<SEC-DOCUMENT>0001140361-21-001312.txt : 20210115
<SEC-HEADER>0001140361-21-001312.hdr.sgml : 20210115
<ACCEPTANCE-DATETIME>20210115165712
ACCESSION NUMBER:		0001140361-21-001312
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		71
FILED AS OF DATE:		20210115
DATE AS OF CHANGE:		20210115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunocore Ltd
		CENTRAL INDEX KEY:			0001671927
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252166
		FILM NUMBER:		21532758

	BUSINESS ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		01235 5430281

	MAIL ADDRESS:	
		STREET 1:		90 PARK DRIVE
		STREET 2:		MILTON PARK, ABINGDON
		CITY:			OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>nt10016217x4_f1.htm
<DESCRIPTION>F-1
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 540pt;"><a name="nt10016217x4_f1_100-regcov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 28pt; text-align: center;">As filed with the United States Securities and Exchange Commission on January 15, 2021.</div><div class="regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: right;">Registration Statement No. 333-&#8195;&#8195;&#8195;</div></div></div><div class="block-frill" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="block-main" style="width: 540pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">UNITED STATES <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 9pt;">Washington, D.C. 20549</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Form F-1<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REGISTRATION STATEMENT<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNDER<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE SECURITIES ACT OF 1933</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 4.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0.5pt; text-align: center;">Immunocore Holdings Limited<font style="font-size: 8pt; font-weight: normal; position: relative; top: -5pt;">1</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 8pt; font-weight: normal;">(Exact name of registrant as specified in its charter)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><table cellspacing="0" cellpadding="0" class="txttab" style="border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 6pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2836</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Not applicable</div></td></tr><tr><td style="width: 31.85%; text-align: center; vertical-align: top; padding-top: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">incorporation or organization)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(Primary Standard Industrial <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Classification Code Number)</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt;">&#8203;</td><td style="width: 31.85%; text-align: center; vertical-align: bottom; padding-top: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">(I.R.S. Employer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: center;">Identification Number)</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">92 Park Drive<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Milton Park<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Abingdon, Oxfordshire OX14 4RY <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">United Kingdom<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tel: +44 1235 438600<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Immunocore, LLC<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Six Tower Bridge, Suite 200<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">181 Washington Street<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conshohocken, Pennsylvania 19428<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">United States<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Tel: +1 484 534 5261<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-weight: normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Copies of all communications, including communications sent to agent for service, should be sent to:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 0.75pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 22.96%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Divakar Gupta <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Eric W. Blanchard<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Peter Byrne <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Courtney T. Thorne <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cooley LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">55 Hudson Yards <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, New York 10001 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+1 212 479 6000</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 22.96%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Nicola Maguire<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Claire Keast-Butler<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Thomas Goodman <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cooley (UK) LLP<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dashwood <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">69 Old Broad Street <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">London EC2M 1QS <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">United Kingdom<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+44 20 7583 4055</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 24.44%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Simon Witty <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Davis Polk &amp; Wardwell London LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">5 Aldermanbury Square <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">London EC2V 7HR <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">United Kingdom <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+44 20 7418 1300</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 22.96%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Richard D. Truesdell, Jr. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Yasin Keshvargar <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Davis Polk &amp; Wardwell LLP <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">450 Lexington Avenue <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">New York, New York 10017 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">+1 212 450 4000</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 1.25pt;"> </div></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2.5pt; text-align: center;">Approximate date of commencement of proposed sale to public:<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As soon as practicable after this registration statement becomes effective.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; text-align: right;">Emerging growth company &#x2611; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B) of the Securities Act. <font style="font-size: 1pt;">&#8201;</font>&#x2610;</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: -2pt; text-align: center;">CALCULATION OF REGISTRATION FEE</div><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 2pt; margin-left: auto; margin-right: auto;"> </div></div><table cellspacing="0" cellpadding="0" class="regtab" style="margin-top: 1.5pt; border-collapse: collapse; width: 540pt; margin-left: auto; margin-right: auto; border-top: 1pt solid #000000; border-bottom: 1pt solid #000000;"><tr class="header"><td style="width: 57.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title of Each Class of Securities to be Registered</div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 20%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Maximum <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Offering Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div></td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.56%; font-size: 2pt; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 20%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6.5pt; padding-bottom: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount of <br></div><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7.5pt; font-weight: bold; margin-top: 0pt; text-align: center;">Registration Fee<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div></td></tr><tr><td style="width: 57.78%; text-align: left; vertical-align: bottom; padding-top: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ordinary shares, nominal value &#163;0.0001 per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)(4)</sup><font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 20%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 32pt; text-align: left;">$100,000,000</div></td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; border-right: 1pt solid #000000; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.56%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 20%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="calc" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 41pt; text-align: left;">$10,910</div></td></tr></table><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 3pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; text-align: left;">Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. Includes the aggregate offering price of additional American Depositary Shares, or ADSs, that the underwriters have the option to purchase.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 2pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; text-align: left;">Calculated pursuant to Rule 457(o) under the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate offering price.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 2pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; text-align: left;">These ordinary shares are represented by ADSs, each of which represents one ordinary share of the Registrant. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 2pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 7pt; text-align: left;">ADSs issuable upon deposit of the ordinary shares registered hereby are being registered pursuant to a separate registration statement on Form F-6 (File No. 333-&#8195;&#8195;&#8195;).</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of&#160;1933, as amended or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), shall determine.<font style="font-weight: normal;"> </font></div></div><div class="block-footnote" style="width: 540pt; margin-left: 0pt;"><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div></div></div><div class="block-footnote" style="width: 540pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 10pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">1</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 8pt;">We intend to alter the legal status of our company under the laws of England and Wales from a private limited company by re-registering as a public limited company </font><font style="font-size: 8pt;">and changing our name from Immunocore Holdings Limited to Immunocore Holdings plc prior to the completion of this offering.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 10pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><font style="position: relative; top: -3.25pt;">&#8224;</font><br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 8pt;">The term &#8220;new or revised financial accounting standards&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards </font><font style="font-size: 8pt;">Codification after April 5, 2012.</font></div></td></tr></table></div><div class="block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 1-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="nt10016217x4_f1_101-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</div>Subject to Completion<br></div><div class="h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preliminary Prospectus dated &#8195;&#8195;&#8195; , 2021</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><u>PRELIMINARY PROSPECTUS</u></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">&#8195;&#8195; American Depositary Shares<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Representing &#8195;&#8195; Ordinary Shares)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.25pt; text-align: center;"><img style="height: 27px; width: 249px;" src="logo_immunocore.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Immunocore Holdings plc<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 20pt; font-weight: bold; margin-top: 0pt; text-align: center;"><font style="font-size: 12pt; font-style: italic; font-weight: normal;">(Incorporated in England and Wales)</font></div><div><div class="rule-partial" style="height: 0pt; width: 144pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are offering &#8195;&#8195;&#8195; American Depositary Shares, or ADSs, in the United States, referred to herein as the U.S. offering. Each ADS represents the right to receive one ordinary share and may be evidenced by American Depositary Receipts, or ADRs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This is our initial public offering and no public market currently exists for our ADSs or ordinary shares. We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#8220;IMCR.&#8221; </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. See &#8220;Prospectus summary&#8212;Implications of being an emerging growth company&#8221; and &#8220;&#8212;Implications of being a foreign private issuer&#8221; for additional information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our ADSs involves a high degree of risk. Before buying any ADSs, you should carefully read the discussion of material risks of investing in our ordinary shares or ADSs in &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">12</a> of this prospectus.<font style="font-weight: normal;"> </font></div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 21.25pt;"> </div></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 73.68%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PER ADS</div></td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TOTAL</div></td></tr><tr><td style="width: 73.68%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Initial public offering price<font style="padding-left: 2.61pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$&#8195;&#8195;&#8195;&#8195;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$&#8195;&#8195;&#8195;&#8195;</div></td></tr><tr><td style="width: 73.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Underwriting discounts and commissions<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 73.68%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds, before expenses, to us<font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See &#8220;Underwriting&#8221; for additional information regarding total underwriter compensation. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters may also exercise their option to purchase up to an additional &#8195;&#8195;&#8195;&#8195; ADSs from us at the initial public offering price, less the underwriting commissions and commissions, for 30 days after the date of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters expect to deliver the ADSs to purchasers on or about &#8195;&#8195;&#8195; , 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 26.5pt; text-align: center;">Joint Book-Running Managers</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 17.25pt; border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 42.11%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Goldman Sachs &amp; Co. LLC</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 26.32%; text-align: center; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">J.P. Morgan</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 26.32%; text-align: center; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jefferies</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 40.5pt; text-align: center;">The date of this prospectus is &#8195;&#8195;&#8195;&#8195; , 2021.</div></div></div></div>
<!--End Page 2-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_102-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS<font style="padding-left: 1.33pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP"><font style="padding-left: 6.66pt;">iii</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPFI">PRESENTATION OF FINANCIAL INFORMATION<font style="padding-left: 3.85pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPFI"><font style="padding-left: 6.66pt;">iii</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSUM">PROSPECTUS SUMMARY<font style="padding-left: 4.84pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSUM"><font style="padding-left: 10pt;">1</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTFG">THE OFFERING<font style="padding-left: 4.85pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTFG"><font style="padding-left: 10pt;">8</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSUMF">SUMMARY CONSOLIDATED FINANCIAL DATA<font style="padding-left: 0.32pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSUMF"><font style="padding-left: 5.37pt;">11</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 1.32pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">12</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSNR">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS<font style="padding-left: 2.19pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSNR"><font style="padding-left: 5pt;">90</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIAM">INDUSTRY AND MARKET DATA<font style="padding-left: 2.89pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIAM"><font style="padding-left: 5pt;">92</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUSE">USE OF PROCEEDS<font style="padding-left: 2.07pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUSE"><font style="padding-left: 5pt;">93</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDPY">DIVIDEND POLICY<font style="padding-left: 3.2pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDPY"><font style="padding-left: 5pt;">94</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCRN">CORPORATE REORGANIZATION<font style="padding-left: 2.09pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCRN"><font style="padding-left: 5pt;">95</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCAP">CAPITALIZATION<font style="padding-left: 0.66pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCAP"><font style="padding-left: 5pt;">97</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDIN">DILUTION<font style="padding-left: 3.74pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDIN"><font style="padding-left: 5pt;">99</font></a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSCDF">SELECTED CONSOLIDATED FINANCIAL DATA<font style="padding-left: 1.06pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSCDF">101</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMDA">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS<font style="padding-left: 0.4pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMDA">102</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBUS">BUSINESS<font style="padding-left: 4.28pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBUS">124</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMGT">MANAGEMENT<font style="padding-left: 4.3pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMGT">186</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRPT">RELATED PARTY TRANSACTIONS<font style="padding-left: 3.6pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRPT">205</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPRS">PRINCIPAL SHAREHOLDERS<font style="padding-left: 3.93pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPRS">208</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOS">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION<font style="padding-left: 1.12pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDOS">210</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDADS">DESCRIPTION OF AMERICAN DEPOSITARY SHARES<font style="padding-left: 3.83pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDADS">228</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOSAA">ORDINARY SHARES AND ADSS ELIGIBLE FOR FUTURE SALE<font style="padding-left: 3.6pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tOSAA">238</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMIT">MATERIAL INCOME TAX CONSIDERATIONS<font style="padding-left: 1.8pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMIT">240</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUDG">UNDERWRITING<font style="padding-left: 4.3pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUDG">248</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tETO">EXPENSES OF THIS OFFERING<font style="padding-left: 3.38pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tETO">254</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLMS">LEGAL MATTERS<font style="padding-left: 0.22pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLMS">255</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tETS">EXPERTS<font style="padding-left: 3.77pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tETS">255</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSOPAEO">SERVICE OF PROCESS AND ENFORCEMENT OF LIABILITIES<font style="padding-left: 4.76pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSOPAEO">256</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWCN">WHERE YOU CAN FIND ADDITIONAL INFORMATION<font style="padding-left: 3.45pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWCN">258</a></div></td></tr><tr><td style="width: 94.87%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tINF">INDEX TO FINANCIAL STATEMENTS<font style="padding-left: 0.86pt;"></font></a></div></td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 3.21%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tINF"><font style="padding-left: 1.11pt;">F-</font>1</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 3-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_102-toc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Neither we nor the underwriters have authorized anyone to provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. Neither we nor the underwriters take any responsibility for, or provide any assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell ADSs and seeking offers to purchase ADSs only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For investors outside the United States: Neither we nor any of the underwriters have taken any action to permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are incorporated under the laws of England and Wales and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a &#8220;foreign private issuer.&#8221; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br></div></div></div>
<!--End Page 4-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_103-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the completion of this offering, we will undertake a corporate reorganization, as described in the section titled &#8220;Corporate Reorganization,&#8221; pursuant to which Immunocore Holdings Limited will acquire all of the issued shares of Immunocore Limited in a share for share exchange, or the Share Exchange, and subsequently will re-register as a public limited company and change its name to Immunocore Holdings plc.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, all references in this prospectus to the terms &#8220;Immunocore,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to (1) prior to the Share Exchange, Immunocore Limited and its subsidiaries, (2) after the Share Exchange and prior to the re-registration and change of name described above, Immunocore Holdings Limited and its subsidiaries and (3) after the Share Exchange, re-registration and change of name, Immunocore Holdings plc and its subsidiaries. See the section titled &#8220;Corporate Reorganization&#8221; for additional information. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus appear without the &#174;, &#8482; and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tPFI"><!--Anchor--></a>PRESENTATION OF FINANCIAL INFORMATION </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our financial statements in this prospectus were prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB. None of our financial statements were prepared in accordance with U.S. GAAP. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our financial information is presented in pounds sterling. For the convenience of the reader, in this prospectus, unless otherwise indicated, translations from pounds sterling into U.S. dollars were made at the rate of &#163;1.00 to $1.2921, which was the noon buying rate of the Federal Reserve Bank of New York on September 30, 2020. Such U.S.&#160;dollar amounts are not necessarily indicative of the amounts of U.S. dollars that could actually have been purchased upon exchange of pounds sterling at the dates indicated or any other date. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All references in this prospectus to &#8220;$&#8221; mean U.S. dollars and all references to &#8220;&#163;&#8221; and &#8220;GBP&#8221; mean pounds sterling. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have historically conducted our business through Immunocore Limited, and therefore, our historical consolidated statements present the consolidated results of operations of Immunocore Limited. Following the completion of the transactions described in the section titled &#8220;Corporate Reorganization,&#8221; our consolidated financial statements will present the consolidated financial results of operations of Immunocore Holdings plc.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">iii<br></div></div></div>
<!--End Page 5-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPSUM"><!--Anchor--></a>PROSPECTUS SUMMARY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This summary highlights, and is qualified in its entirety by, the more detailed information contained elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. Before investing in our ADSs, you should carefully read this entire prospectus, especially the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus. .<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease &#8211; designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our ImmTAX product candidates, which we believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. This primary endpoint was achieved with a hazard ratio of 0.51 (95% CI: 0.36, 0.71; p&lt; 0.0001) at the first pre-planned interim analysis. Based on these results, we are preparing to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for tebentafusp for the treatment of metastatic uveal melanoma in the third quarter of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unlike antibody targeted immunotherapies that have a relatively small target pool, our approach relies on the power of T cell receptors, or TCRs, which are naturally occurring receptors found on the surface of T cells that have the ability to target nearly all of the human proteome. Natural TCRs give T cells the ability to scan for abnormalities in nearly any cell in the body that are presented as protein fragments, or antigens, by human leukocyte antigen, or HLA, on the cell surface. Our ImmTAX platform builds upon these natural TCRs to engineer soluble targeted and high-affinity TCRs. By engineering these TCRs, using our ImmTAX platform, we are developing off-the-shelf, bispecific therapeutics, which are able to precisely target a wide range of proteins uniquely expressed by unhealthy and abnormal cells that cannot be targeted by current antibody-based immunotherapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAX bispecific therapeutics couple the targeting power of these engineered TCRs on one end with the other end displaying pre-optimized effector functions, which have the ability to drive a desired immune response at the site of the disease. This combination is designed to provide us with significant flexibility as we are able to engineer and tailor our ImmTAX therapeutics to target proteins that are specific to the disease we are trying to treat and then modulate the corresponding immune response by either boosting or inhibiting the immune system.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From our strong foundation and expertise in TCR targeting development, we continue to push boundaries to improve the product candidates we can generate from our ImmTAX platform. Our mission is to pursue the development of innovative product candidates designed to benefit the greatest number of patients. For example, we recently developed a universally applicable HLA-E platform for universal patient access, which we have validated in pre-clinical proof-of-concept studies. Using this platform, we believe we may be able to develop product candidates which will allow all patients globally to benefit from a single therapeutic per target rather than requiring several classical HLA programs with their associated development costs. While still early in our development, we believe this advancement to our platform has the potential to further revolutionize the future of TCR-based therapies by expanding the therapeutic reach of our ImmTAX platform. </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 6-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Pipeline</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are currently leveraging our ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. We have named each of these platforms according to their therapeutic area to distinguish the type of target recognized by the TCR targeting system and the selected effector function. We have five clinical stage assets, including one pivotal stage program, as well as numerous pre-clinical programs. While our most advanced clinical programs are focused on developing treatments for oncology, we believe our ImmTAX platform is versatile, and will also allow us to develop therapeutics with significant advantages in the treatment of infectious and autoimmune diseases. Our current pipeline is represented in the diagram below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 258px; width: 579px;" src="nt10016217x4_graphic01x8.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our ImmTAC Platform (Oncology)</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Within our ImmTAC (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>C</u></font>ancer) platform, we have four clinical stage programs and an additional five pre-clinical programs, focusing on the treatment of solid tumors with high unmet medical needs. Our ImmTAC product candidates are bispecific, soluble TCR molecules featuring an antigen-specific targeting module based on our high-affinity, highly specific TCR system and our proprietary cluster of differentiation 3, or CD3, effector module for T cell recruitment, engagement and activation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAC programs include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Tebentafusp</font>, our ImmTAC molecule targeting an HLA-A*02:01 gp100 antigen, demonstrated monotherapy activity and recently achieved the primary endpoint of superior overall survival at the first pre-planned interim analysis of a randomized Phase 3 clinical trial in patients with previously untreated metastatic uveal melanoma. We anticipate submitting a BLA to the FDA in the third quarter of 2021 followed by a Marketing Authorization Application, or MAA, submission to the European Medicines Agency, or EMA. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-C103C</font>, our ImmTAC molecule targeting an HLA-A*02:01 MAGE-A4 antigen, is currently being evaluated in a first-in-human, Phase 1/2 dose escalation trial in patients with solid tumor cancers including non-small-cell lung cancer, or NSCLC, gastric, head and neck, ovarian and synovial sarcoma. We believe this trial will demonstrate clinical activity of IMC-C103C, and we anticipate reporting Phase&#160;1 initial data from this trial in the second half of 2021. We are developing this program under a co-development collaboration with Genentech, Inc., or Genentech, under which we have an option to retain 50% of the economics.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-F106C</font>, our ImmTAC molecule targeting an optimal HLA-A*02:01 PRAME antigen identified with our MassSpec technology, is currently being evaluated in a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers including breast, endometrial, ovarian and small cell lung cancer, or SCLC. We believe this trial will demonstrate clinical activity of IMC-F106C, and we anticipate reporting Phase&#160;1 initial data from this trial in mid-2022.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 7-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">GSK01</font>, our ImmTAC molecule targeting an NY-ESO HLA-A*02:01 antigen, is currently being evaluated in the dose escalation phase of a Phase 1 clinical trial. When an optimal dosing regimen has been identified, a small expansion cohort of synovial sarcoma patients will be recruited to evaluate the clinical benefit of the therapeutic. This program is being developed under a collaboration with GlaxoSmithKline Intellectual Property Development Ltd, or GSK, which has an option to acquire full commercialization and development rights to this product candidate at the end of the ongoing Phase 1 clinical trial. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Our ImmTAV Platform (Infectious Diseases) </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAV (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>V</u></font>irus) platform, we have advanced our first program into the clinic, and we are working to advance a second program from pre-clinical into the clinic during the second half of 2021. Our ImmTAV product candidates are bispecific soluble TCR molecules featuring our ImmTAX TCR-based targeting system with high specificity for low-expression viral antigens, combined with the proprietary CD3 effector module for T cell engagement and activation that has been validated in our clinical oncology pipeline. We are seeking to develop therapeutics that can provide a functional cure to chronic viral disease and are focusing initially on hepatitis B virus, or HBV, and human immunosuppression virus, or HIV.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAV programs include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-I109V</font>, our ImmTAV molecule targeting a conserved HBV envelope antigen, is our most advanced ImmTAV program and is currently being evaluated in a Phase 1/2 clinical trial in patients with chronic HBV who are non-cirrhotic, hepatitis B e-Antigen negative, and virally suppressed on chronic nucleot(s)ide analogue therapy. Our goal is to develop a functional cure for HBV and we anticipate commencing dosing in our Phase 1 single ascending dose, or SAD, trial in mid-2021. We are also developing a next-generation version of this molecule leveraging our research into universal HLA-E molecules which could benefit a much larger patient population as compared to classical-HLA antigens.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-M113V</font>, our ImmTAV molecule targeting an HIV gag antigen bispecific TCR molecule, is currently in pre-clinical development. Our HIV programs are funded by the Bill &amp; Melinda Gates Foundation, or the Gates Foundation, and we are required to make any successfully approved products available at reduced prices in certain developing countries. We retain full development and commercial right in non-developing countries.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Our ImmTAAI Platform (Autoimmune Diseases)</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While our ImmTAC and ImmTAV platforms attempt to provide therapeutic benefit by driving an immune response against targeted cells, our ImmTAAI (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>A</u></font>uto<font style="font-weight: bold;"><u>I</u></font>mmune disease) platform leverages our ImmTAX platform to generate product candidates designed to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Our ImmTAAI product candidates are designed to target organs, tissues or immune cells and deliver an immune suppressive effector function. We have optimized two immune system modulating effector functions to provide local T cell inhibition, which we believe may limit any adverse effects originating from systemic immune suppression. We believe we can use our ImmTAAI platform to develop a portfolio of product candidates to treat autoimmune indications with a high unmet medical need, and provide significant benefit to patients. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Our Company History and Team</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were originally incorporated under the laws of England and Wales in December 2007 as a spin-out company of MediGene AG, with the goal of focusing on the development of soluble, off-the-shelf TCR bispecifics. Since then, we have made substantial progress in developing and expanding our novel platform technology into new therapeutic areas, advancing multiple programs into the clinic and dosing over 600 patients with our ImmTAX product candidates. Since our inception, we have raised an aggregate of $873.2 million (&#163;675.8 million) through private placements of our ordinary and preferred shares, payments from our collaboration partners, and most recently, borrowings under our debt facility with Oxford Finance and the sale of our Series&#160;C preferred shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2020, we had 291 employees, including 129 (44%) who hold a Ph.D. or M.D. degree. Of these employees, two-thirds of our team are primarily focused on research and development activities and </div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 8-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">possess broad and industry-leading expertise in immunology, TCR biology, protein engineering, bioinformatics and clinical development. We have assembled an experienced management team led by our Chief Executive Officer, Bahija Jallal, who previously served as president of MedImmune, LLC (now known as AstraZeneca plc); our Chief Financial Officer and Head of Strategy, Brian Di Donato, who started his career in investment banking at Morgan Stanley and UBS Securities LLC before serving as chief financial officer of Achillion Pharmaceuticals, Inc. where he oversaw its acquisition by Alexion Pharmaceuticals Inc.; and David Berman, our Head of Research and Development, who oversaw the clinical development of Yervoy, Empliciti and Imfinzi during his previous tenures at Bristol-Myers Squibb Company and MedImmune/AstraZeneca, respectively. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Our Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our vision is to build a global immuno-therapy business with a portfolio of therapeutics that have the potential to beneficially impact the clinical outcomes of patients across a broad range of diseases, with a near-term focus on the treatment of cancer, infectious diseases and autoimmune diseases. We are pioneering the field of TCR bispecifics by leveraging the power of TCRs to recognize nearly any cellular target with targeted precision and convert them into potent ImmTAX therapies that can either boost or inhibit the immune system to treat the targeted disease. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to execute our strategy, we are pursuing the following near-term goals:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Secure marketing approval for, and then commercialize, tebentafusp, our lead ImmTAC, for the treatment of metastatic uveal melanoma. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Advance our IMC-C103C program targeting MAGE-A4 for the treatment of solid tumors in collaboration with Genentech. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Advance our IMC-F106C program targeting PRAME for the treatment of solid tumors. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Advance our IMC-I109V program for the treatment of chronic HBV. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Continue to develop our novel universal ImmTAX platform to meaningfully broaden the eligible patient pool. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Continue to invest in our platform to discover and develop novel therapeutics. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Opportunistically pursue strategic partnerships to maximize the full potential of our pipeline and ImmTAX platform.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Risks Associated with Our Business</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our business is subject to a number of risks of which you should be aware before making an investment decision. You should carefully consider all of the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth in the section titled &#8220;Risk Factors&#8221; before deciding whether to invest in our ADSs. Among these important risks are the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We will require substantial additional funding to achieve our business goals. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are heavily dependent on the success of our ImmTAX platform to identify and develop product candidates. If we or our collaborators are unable to successfully develop and commercialize our platforms or experience significant delays in doing so, our business may be harmed.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop after tebentafusp.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our product candidates utilize a novel mechanism of action and involve novel targets which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 9-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The effects of health epidemics, including the ongoing COVID-19 coronavirus pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our pre-clinical studies and clinical trials, as well as the business or operations of our CROs or other third parties with whom we conduct business.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">For a period of four weeks, our IMC-F106C program was put on partial clinical hold in 2018 by the FDA following the death of the second patient dosed in this trial, which was subsequently determined to be unrelated to study drug. The hold has since been lifted and the trial has been resumed.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We are subject to manufacturing risks that could substantially increase our costs and limit supply of our products. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our existing collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If we are unable to adequately protect our proprietary technology or obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products or if the scope of the protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property or proprietary rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The FDA regulatory pathways can be difficult to predict and whether, for example, further unanticipated clinical trials are required, will depend on the data obtained in our ongoing clinical trials. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">As a company based outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We have identified a material weakness in our internal control over financial reporting and may identify material weaknesses in the future or otherwise fail to maintain proper and effective internal controls, which may impair our ability to produce timely and accurate financial statements or prevent fraud. If we are unable to establish and maintain effective internal controls, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being an Emerging Growth Company</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a company with less than $1.07&#160;billion in revenue during our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies in the United States. These provisions include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exemption from compliance with any requirement that the Public Company Accounting Oversight Board may adopt regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduced disclosure about our executive compensation arrangements;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exemption from the non-binding advisory votes on executive compensation, including golden parachute arrangements; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 10-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As a result, we do not know if some investors will find our ADSs less attractive. The result may be a less active trading market for our ADSs, and the price of our ADSs may become more volatile. We may choose to take advantage of some or all these provisions for up to the last day of the fiscal year ending after the fifth anniversary of this offering or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.07&#160;billion in total annual gross revenue, have more than $700&#160;million in market value of our ADSs held by non-affiliates or issue more than $1.0&#160;billion of non-convertible debt over a three-year period. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being a Foreign Private Issuer</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our status as a foreign private issuer also exempts us from compliance with certain laws and regulations of the SEC and certain regulations of The Nasdaq Stock Market, or Nasdaq. Consequently, we are not subject to all of the disclosure requirements applicable to U.S. public companies. For example, we are exempt from certain rules under the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our executive officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning us than there is for U.S. public companies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may take advantage of these exemptions until such time as we no longer qualify as a foreign private issuer. In order to maintain our current status as a foreign private issuer, either a majority of our outstanding voting securities must be directly or indirectly held of record by non-residents of the United States, or, if a majority of our outstanding voting securities are directly or indirectly held of record by residents of the United States, a majority of our executive officers or directors may not be United States citizens or residents, more than 50% of our assets cannot be located in the United States and our business must be administered principally outside the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have taken advantage of certain of these reduced reporting and other requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold equity securities.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immunocore Holdings Limited was incorporated under the laws of England and Wales on January 7, 2021 with company registration number 13119746 to become the holding company of Immunocore Limited.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immunocore Limited was incorporated under the laws of England and Wales in December 2007, with company registration number 06456207. Our registered office is located at 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, and the telephone number of our registered office is +44&#160;(0)1235 438600. Our principal executive offices in the United States are located at Six Tower Bridge, Suite&#160;200, 181 Washington Street, Conshohocken, Pennsylvania 19428, and the telephone number of our U.S. office is +1&#160;484 534 5261. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our website address is www.immunocore.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. Our agent for service of process in the United States is Immunocore, LLC.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 11-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Corporate Reorganization</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the completion of this offering, we will undertake a corporate reorganization whereby all shareholders of Immunocore Limited will exchange each of the shares held by them for 100 newly issued shares of the same class, and with the same rights attaching thereto, of Immunocore Holdings Limited and, as a result, Immunocore Limited will become a wholly-owned subsidiary of Immunocore Holdings Limited. Subsequent to the Share Exchange, Immunocore Holdings Limited will be re-registered as a public limited company and will change its name to Immunocore Holdings plc. Immediately prior to completion of this offering, it is expected that Immunocore Holdings plc&#8217;s share capital will be reorganized such that it consists of a single class of ordinary shares, and potentially also non-voting ordinary shares, as well as deferred shares. Please see the section titled &#8220;Corporate Reorganization&#8221; for additional information.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 12-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tTFG"><!--Anchor--></a>THE OFFERING </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">ADSs offered by us<font style="font-weight: normal; padding-left: 3.27pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8195;&#8195;&#8195;&#8195;ADSs, each representing one ordinary share.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Underwriters&#8217; option to purchase additional ADSs <font style="font-weight: normal; padding-left: 2.29pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to an additional &#8195;&#8195;&#8195;ADSs from us.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Ordinary shares to be outstanding immediately after this offering <font style="font-weight: normal; padding-left: 3.72pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">&#8195;&#8195;&#8195;ordinary shares (or&#8195;&#8195;&#8195; ordinary shares if the underwriters exercise in full their option to purchase an additional &#8195;&#8195;&#8195;ADSs).</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">American Depositary Shares<font style="font-weight: normal; padding-left: 5.28pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">Each ADS represents one ordinary share, nominal value &#163;0.0001 per ordinary share. As a holder of ADSs, you will not be treated as one of our shareholders and you will not have shareholder rights. You will have the rights of an ADS holder or beneficial owner of ADSs (as applicable) as provided in the deposit agreement among us, the depositary and holders and beneficial owners of ADSs from time to time. To better understand the terms of our ADSs, see &#8220;Description of American Depositary Shares.&#8221; We also encourage you to read the deposit agreement, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Depositary<font style="font-weight: normal; padding-left: 4.85pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">Citibank, N.A.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds<font style="font-weight: normal; padding-left: 1.38pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">We estimate that the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, to be approximately $ &#8195;&#8195;&#8195;million, or $ &#8195;&#8195;&#8195;million if the underwriters exercise in full their option to purchase additional &#8195;&#8195;&#8195;ADSs, based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus. We intend to use the net proceeds from this offering, as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to fund tebentafusp, our lead ImmTAC, for the treatment of metastatic uveal melanoma through the completion of our Phase 3 clinical trial as well as preparations for a commercial launch; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to advance the clinical development of IMC-C103C targeting MAGE A4 for the treatment of solid tumors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to advance the clinical development of IMC-F106C targeting PRAME for the treatment of solid tumors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to advance the clinical development of IMC-I109V targeting a functional cure for chronic HBV; </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 13-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to continue to continue to advance our pre-clinical programs and invest in our ImmTAX platform to discover and develop novel therapeutic targets; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 260pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">for working capital and general corporate purposes.</div></td></tr></table><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 240pt; text-align: left;">See &#8220;Use of proceeds&#8221; for a more complete description of the intended use of proceeds from this offering. </div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Risk factors<font style="font-weight: normal; padding-left: 5.3pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">See &#8220;Risk factors&#8221; and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ADSs.</div><div class="sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Proposed Nasdaq Global Market symbol<font style="font-weight: normal; padding-left: 0.5pt;"></font></div><div class="sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -10pt; margin-left: 240pt; text-align: left;">&#8220;IMCR&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of ordinary shares, including ordinary shares represented by ADSs, that will be outstanding after this offering is based on 5,462,453 ordinary shares outstanding as of September 30, 2020 and gives effect to our corporate reoganization as well as the sale of 837,719 series C preferred shares which closed in December&#160;2020, and excludes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">832,904 ordinary shares issuable upon the exercise of options outstanding under our existing equity incentive plans as of September 30, 2020, with a weighted-average exercise price of &#163;63.23 per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares reserved for future issuance under our 2021 Equity Incentive Plan, or the 2021 EIP, which will become effective in connection with this offering, as well as any automatic annual increases in the number of ordinary shares reserved for future issuance under the 2021 EIP, as more fully described in the section titled &#8220;Management&#8212;Equity Incentive Plans;&#8221; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares (assuming an initial public offering price of $&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus) underlying the grants to be issued prior to the closing of this offering to certain of our officers, directors and employees under our 2021 EIP, contingent and effective upon the execution and delivery of the underwriting agreement relating to this offering, with an exercise price that is equal to or greater than the price per ADS at which our ADSs are first sold to the public in this offering.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as otherwise noted, the information in this prospectus assumes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the completion of the transactions described in the section titled &#8220;Corporate Reorganization&#8221; prior to the completion of this offering, including (i)&#160;the approximately &#8195;-for-&#8195; reverse split of all our ordinary shares and non-voting ordinary shares, if any, prior to completion of this offering, (ii)&#160;the re-designation of G1 shares held by our U.K. employees and former employees as &#8195;&#8195;&#8195; deferred shares; (iii)&#160;&#8195;&#8195;&#8195; ordinary shares underlying the grants to be issued prior to the closing of this offering under our 2021 EIP (to our current employees) and under standalone option agreements (to our former employees) to replace the G1 shares that will be re-designated as deferred shares, conditional on and effective immediately prior to closing of this offering, with an exercise price that is equal to or greater than the price per ADS at which our ADSs are first sold to the public in this offering; (iv)&#160;the re-designation of G2 shares held by our U.K. employees into deferred shares and ordinary shares on a &#8195;-for-&#8195; basis, conditional on and effective immediately prior to closing of this offering; and (v)&#160; &#8195;&#8195;&#8195; ordinary shares underlying the grants to be issued prior to the closing of this offering under our 2021 EIP to replace the G2 shares that will be re-designated as a mixture of deferred shares and ordinary shares and ordinary shares, conditional on and effective immediately prior to closing of this offering, with an exercise price that is equal to the price per ADS at which our ADSs are first sold to the public in this offering;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus; and </div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 14-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no exercise by the underwriters of their option to purchase up to &#8195;&#8195;&#8195;additional ADSs in this offering. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the reorganization into a single class of ordinary shares, and if applicable non-voting ordinary shares, as described above, such ordinary shares, and if applicable non-voting ordinary shares, will be consolidated and/or subdivided to reflect an approximately &#8195;-for-&#8195; reverse split of such ordinary shares and. if applicable, non-voting ordinary shares and, if required, re-designated as ordinary shares or non-voting ordinary shares of &#163;&#8195;&#8195; and deferred shares of &#163;&#8195;&#8195; conditional on and immediately prior to closing of this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such reorganization will involve (without limitation) the re-designation of classes of shares, the consolidation and/or the subdivision of shares pursuant to the terms of the articles of association in effect at such time as described above. The number of ordinary shares and non-voting ordinary shares that each shareholder of Immunocore Holdings plc receives will be rounded up or down to the nearest whole share. Therefore, upon consummation of the corporate reorganization and prior to the completion of this offering, assuming an initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover of this prospectus, the current shareholders of Immunocore Holdings plc will hold an aggregate of approximately &#8195;&#8195;&#8195; ordinary shares, and if applicable, non-voting ordinary shares, of Immunocore Holdings plc. In the event of a $1.00 increase in the assumed initial public offering price per ADS to $&#8195;&#8195;&#8195; per ADS, the current shareholders of Immunocore Holdings plc will hold an aggregate of approximately &#8195;&#8195;&#8195; ordinary shares and, if applicable, non-voting ordinary shares of Immunocore Holdings plc. In the event of a $1.00 decrease in the assumed initial public offering price per ADS to $&#8195;&#8195;&#8195; per ADS, the current shareholders of Immunocore Holdings plc will hold an aggregate of approximately &#8195;&#8195;&#8195; ordinary shares, and if applicable, non-voting ordinary shares, of Immunocore Holdings plc.</div></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 15-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 492pt;"><a name="nt10016217x4_f1_104-summary_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="page-content" style="margin-left: 12pt;"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSUMF"><!--Anchor--></a>SUMMARY CONSOLIDATED FINANCIAL DATA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following tables present summary consolidated financial data as of the dates and for the periods indicated. Our audited annual consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB. We derived the summary consolidated statements of loss and other comprehensive income for the years ended December 31, 2018 and 2019 and summary consolidated statement of financial position data as of December 31, 2018 and 2019 from our audited consolidated financial statements included elsewhere in this prospectus. We derived the summary consolidated statements of loss and other comprehensive income for the nine months ended September 30, 2019 and 2020 and summary consolidated statement of financial position data as of September 30, 2020 from our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus. The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34, as issued by the IASB on the same basis as the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our financial position and results of operations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our historical and interim results are not necessarily indicative of the results to be expected for the full year or any other period in the future. You should read the consolidated financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained elsewhere in this prospectus. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 470.45pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine month period ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30,</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.77%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td colspan="4" style="width: 24.61%; text-align: center; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in thousands <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">except for share and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share data)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td colspan="4" style="width: 21.82%; text-align: center; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in thousands <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">except for share and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share data)</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Consolidated statement of loss and other comprehensive income data:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 3.16pt;">22</font>,694</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 3.16pt;">22</font>,027</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt;">25,669</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 3.16pt;">23,654</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 0.83pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 15.04pt;">408</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 15.04pt;">420</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 19.79pt;">185</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 15.04pt;">622</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(57,566)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(75,415)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 4.75pt;">(99,991)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">(83,575)</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administration<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">3</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">1,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">5</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">69</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 0.35pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">35</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">611</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 34.04pt;">(44,183</font><font style="min-width: 34.04pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(34,156</font><font style="min-width: 29.29pt;">)</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 1.7pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(66,033)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(90,579)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 0.35pt;">(118,320)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">(93,455)</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 19.79pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 19.79pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt;">4,979</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 1.42pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 7.91pt;">1,</font>972</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 7.91pt;">1,</font>134</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 12.66pt;">1,510</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt;">1,140</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 0.39pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">2</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">272</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">6</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">5</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">32</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; min-width: 34.04pt;">(9,379</font><font style="min-width: 34.04pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 11.88pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(842</font><font style="min-width: 29.29pt;">)</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating (expense) / income<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 11.88pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">300</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">5,398</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; min-width: 34.04pt;">(7,8</font><font style="border-bottom: 1pt solid #000000; min-width: 34.04pt;">6</font><font style="border-bottom: 1pt solid #000000; min-width: 34.04pt;">9</font><font style="border-bottom: 1pt solid #000000; min-width: 34.04pt;"></font><font style="min-width: 34.04pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">5,277</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before tax<font style="padding-left: 2.49pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(66,333)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;">(95,977)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">(126,189)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;">(88,178)</div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 4.58pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 3.51pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">11</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">120</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 3.51pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">1</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">8</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">011</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; min-width: 34.04pt;">22,258</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">16,548</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 3.25pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">5</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">5,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">213</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">77</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">966</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 34.04pt;">(103,931</font><font style="min-width: 34.04pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(71,630</font><font style="min-width: 29.29pt;">)</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences on translation of foreign operations<font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 15.04pt;">3</font>38</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 19.79pt;">82</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 21.38pt;">(99)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 19.79pt;">72</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Income tax effect relating to the components of other comprehensive income<font style="padding-left: 4.49pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 19.79pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 19.79pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 24.54pt; border-bottom: 1pt solid #000000; min-width: 34.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; min-width: 29.29pt;">3,634</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period, net of tax<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">54,875</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">77</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">,</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">884</font><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;"></font><font style="min-width: 29.29pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 34.04pt;">(104,030</font><font style="min-width: 34.04pt;">)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.29pt;">(67,924</font><font style="min-width: 29.29pt;">)</font></div></td></tr><tr><td style="width: 51.01%; text-align: left; vertical-align: bottom; padding-top: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 0.5pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 9.5pt;">(0.01)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 11.67%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.81pt; text-align: left;"><font style="padding-left: 9.5pt;">(0.0</font>2)</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 10.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 14.25pt;">(0.02)</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt;">&#8203;</td><td style="width: 9.77%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.33pt; text-align: left;"><font style="padding-left: 9.5pt;">(0.02)</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of September 30,</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.55%; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">thousands)</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt;">&#8203;</td><td colspan="4" style="width: 18.36%; text-align: center; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">thousands)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated statement of financial position data:<br></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 4.75pt;">56,</font>687</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 4.75pt;">73,966</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">124,385</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 4.75pt;">29</font>,335</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 4.75pt;">3</font>9,768</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">121,574</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 1.92pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;">130,839</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">185,649</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">195,777</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 21.38pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 21.38pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 21.38pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 3.72pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 0.35pt;">1</font>15,291</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">170,878</div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;">139,195</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 1.51pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 26.13pt;">1</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 21.38pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt; padding-bottom: 2pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 21.38pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 0.33pt;"></font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 19.7pt; text-align: left;"><font style="padding-left: 4.75pt;">15,548</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 4.75pt;">14,771</font></div></td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 2.55%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 6.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.07pt; text-align: left;"><font style="padding-left: 4.75pt;">56,582</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 1pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Note 10 to our audited consolidated financial statements for the year ended December&#160;31, 2019 and year ended December&#160;31, 2018 and Note 6 to our unaudited consolidated financial statements appearing elsewhere in this prospectus for a description of the method used to compute diluted net loss per share.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">We define working capital as current assets less current liabilities.</div></td></tr></table></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 16-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investing in our ADSs involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this prospectus, including our consolidated financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our ADSs. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our ADSs could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.<font style="font-style: normal;"> </font></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Risks Related to Our Financial Position</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have incurred significant losses in every year since our inception. We expect to continue to incur losses over the next several years and may never achieve or maintain profitability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late-stage clinical stage biotechnology company and have incurred net losses in each year since our inception. Our losses were &#163;103.9 million, &#163;71.6 million, &#163;55.2 million and &#163;78.0 million for the years ended December&#160;31, 2019 and 2018 and the nine months ended September 30, 2020 and 2019, respectively. We had an accumulated deficit of &#163;331.0 million as of September 30, 2020. We have funded our operations to date primarily with proceeds from private placements of our ordinary and preferred shares, payments from our collaboration partners, and most recently, debt financing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Since inception, we have focused substantially all of our efforts and financial resources on developing our drug discovery platform and research and development of our product candidates. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These losses will adversely impact our shareholders&#8217; equity and net assets and may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as, we:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue our ongoing and planned development of our five clinical stage programs, including tebentafusp, our lead oncology program, which is being evaluated in a Phase 3 pivotal trial in patients with metastatic uveal melanoma;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">initiate pre-clinical studies and clinical trials for any additional product candidates that we may pursue in the future, including our earlier-stage programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek regulatory approvals for tebentafusp and any future product candidates that successfully complete clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">build a portfolio of product candidates through the discovery, development, or acquisition or in-license of drugs, product candidates or technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish a sales, marketing, manufacturing and distribution capability to commercialize tebentafusp and any future product candidate for which we may obtain marketing approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintain, protect, enforce and expand our intellectual property portfolio;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire or in-license other product candidates, intellectual property and technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hire additional clinical, regulatory and scientific personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">incur additional legal, accounting and other expenses associated with operating as a public company.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 17-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">including completing our Phase 3 clinical trial of tebentafusp and any future product candidates that we may pursue, obtaining regulatory approval, procuring commercial-scale manufacturing, marketing and selling tebentafusp and any future products for which we may obtain regulatory approval, as well as discovering or acquiring and then developing additional product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, or other regulatory authorities to perform studies in addition to those we currently expect, or if there are any delays in the initiation and completion of our clinical trials or the development of tebentafusp or any future product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our ADSs and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our ADSs could also cause you to lose all or part of your investment.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We will require substantial additional funding to achieve our business goals. If we are unable to obtain this funding when needed and on acceptable terms, we could be forced to delay, limit or terminate our product development efforts.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Developing biopharmaceutical products is expensive and time-consuming, and we expect to require substantial additional capital to conduct research, pre-clinical testing and human studies, may establish pilot scale and commercial scale manufacturing processes and facilities, and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support our existing programs and pursue potential additional programs. We are also responsible for the payments to third parties of expenses that may include milestone payments, license maintenance fees and royalties, including in the case of certain of our agreements with academic institutions or other companies from whom intellectual property rights underlying their respective programs have been in-licensed or acquired. Because the outcome of any pre-clinical or clinical development and regulatory approval process is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of any future product candidates we may identify.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 30, 2020, we had working capital (defined as total current assets less total current liabilities) of &#163;29.3&#160;million ($37.9 million) and cash and cash equivalents of &#163;56.7&#160;million ($73.3&#160;million). Subsequent to this date, we drew down $50 million (&#163;38.7 million) pursuant to the first tranche of our debt facility that we entered into with Oxford Finance, and we closed the sale of our Series C preferred shares resulting in gross proceeds of $75.0 million. We estimate that the net proceeds from this offering will be approximately $&#8195;&#8195; million (or&#160;approximately $&#8195;&#8195; million if the underwriters exercise in full their option to purchase additional ADSs), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We expect that the net proceeds from this offering, together with our existing cash will be sufficient to fund our operations through at least the next &#8195;&#8195; months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations or license and development agreements. Any additional fundraising efforts for us may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize product candidates that we may identify and pursue. Moreover, such financing may result in dilution to our shareholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our future funding requirements will depend on many factors, including, but not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical sites, enroll subjects and manufacture soluble bispecific TCR product candidates for our ongoing, </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 18-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">planned and potential future clinical trials, including our Phase 3 clinical trial of tebentafusp in metastatic uveal melanoma, our Phase 1/2 clinical trial of IMC-C103C (MAGE-A4) in multiple solid tumors and our Phase 1/2 clinical trial of IMC-F106C (PRAME) in multiple solid tumors;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">time and costs required to perform research and development to identify and characterize new product candidates from our research programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the time and cost necessary to pursue regulatory authorizations and approvals that may be required by regulatory authorities to execute clinical trials or commercialize our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to successfully commercialize our product candidates, if approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to have clinical and commercial products successfully manufactured consistent with FDA, EMA and other authorities&#8217; regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales and marketing costs associated with commercializing our products, if approved, including the cost and timing of building our marketing and sales capabilities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">terms and timing of any revenue from our existing collaborations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of operating as a public company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">time and cost necessary to respond to technological, regulatory, political and market developments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs, associated with, and terms and timing of, any future any potential acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability of clinical sites to enroll patients as healthcare capacities are required to cope with natural disasters, epidemics or other health system emergencies, such as the COVID-19 pandemic.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development and commercialization of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional funds may not be available when we need them, on terms that are acceptable, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit or terminate one or more research or development programs or the commercialization of any product candidates or be unable to expand operations or otherwise capitalize on business opportunities, as desired, which could materially affect our business, prospects, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our operating history may make it difficult for you to evaluate the success of our business as a commercial organization and to assess our future viability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an organization, we have not demonstrated an ability to successfully complete late-stage clinical trials, obtain regulatory approvals, manufacture our product candidates at commercial scale or arrange for a third party to do so on our behalf, conduct sales and marketing activities necessary for successful commercialization, or obtain reimbursement in the countries of sale. We may encounter unforeseen expenses, difficulties, complications, and delays in achieving our business objectives and our transition to a commercial stage organization. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had commercialized a product.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will need to transition in near future from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We expect </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 19-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Raising additional capital may cause dilution to our shareholders, including purchasers of ADSs in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of ADSs, ordinary shares or securities convertible or exchangeable into ADSs or ordinary shares, your ownership interest will be diluted, and the terms of those securities may include liquidation or other preferences that materially adversely affect your rights as a shareholder. Debt financing in addition to our loan and security agreement with Oxford Finance Luxembourg S.A.R.L., or Oxford Finance, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property and proprietary rights, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Development of Our Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are heavily dependent on the success of our ImmTAX platform to identify and develop product candidates. If we or our collaborators are unable to successfully develop and commercialize our platforms or experience significant delays in doing so, our business may be harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are heavily dependent on the success our ImmTAX platform technology and the product candidates currently in our core programs. Our ImmTAC, ImmTAV and ImmTAAI platforms were developed from the foundation of our ImmTAX platform and are our primary platform technologies. Our commercial prospects will be heavily dependent on product candidates identified and developed using our ImmTAX platform. To date, we have invested substantially all of our efforts and financial resources to identify, acquire intellectual property for, and develop our ImmTAX platform technology and our programs, including conducting pre-clinical studies and early-stage clinical trials, and providing general and administrative support for these operations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not be successful in our efforts to further develop our ImmTAX platform technology and current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates will require significant additional clinical development, management of preclinical, clinical, and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop after tebentafusp. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may be unable to successfully complete additional large-scale, pivotal clinical trials for any product candidates we develop after tebentafusp. In addition, we may be unable to obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. We have three programs, IMC-C103C, IMC-F106C, and GSK01, in Phase 1 clinical development and, in the case of IMC-I109V, we have received clearance to begin a Phase 1 clinical trial in Australia, Belgium, Hong Kong, New Zealand, Poland, South Korea, Spain and the United Kingdom and submitted for Health Authority approvals to begin clinical development in Romania. We may not receive marketing approval by the FDA for tebentafusp. Furthermore, we cannot be sure that issues will not arise that require us to suspend or terminate our Phase 1 clinical trials. Guidance we have </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 20-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">received from the FDA or other regulatory authorities on clinical trial design is subject to change. These regulatory authorities could change their position, including, on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or impose stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting a Biologics License Application, or BLA, to the FDA and a Marketing Authorization Application, or MAA, to the EMA, for each product candidate and, consequently, the ultimate approval and commercial marketing of each product candidate. We do not know whether any of our future clinical trials will begin on time or ever be completed on schedule, if at all. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be delayed in obtaining marketing approval for our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">not obtain marketing approval at all; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtain approval for indications or patient populations that are not as broad as intended or desired; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">be subject to post-marketing testing requirements; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have the product removed from the market after obtaining marketing approval.</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our product candidates utilize a novel mechanism of action and involve novel targets which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates utilize novel mechanisms of action and involve novel targets which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects. Our ImmTAX platform uses advanced computational models in tight integration with our structural biology, protein engineering, affinity maturation and binding efficacy capabilities to predict and design the compounds that will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our abilities to expand our ImmTAX platform, and we cannot predict whether we will continue to have access to these capabilities in the future to support our ImmTAX platform. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of this novel mechanism will not arise in the future, which may cause significant delays or we raise problems we may not be able to resolve. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#8217; lack of experience with them. The novelty of our mechanism of action may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. Because our soluble bispecific TCRs utilize a novel mechanism of action and involve novel targets, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our pre-clinical studies and clinical trials. Any such events could adversely impact our business prospects, financial condition and results of operations. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The incidence and prevalence for target patient populations for some of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have completed a Phase 2 monotherapy trial and a Phase 3 pivotal trial of tebentafusp for the treatment of metastatic uveal melanoma patients who test positive for HLA-A*02:01. We estimate that there are approximately 1,000 metastatic uveal melanoma patients per annum in the United States and Western Europe who test positive for HLA-A*02:01 and might benefit from our tebentafusp monotherapy.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 21-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are evaluating the safety and tolerability of IMC-C103C and IMC-F106C in Phase 1 dose escalation trials in patients with advanced or metastatic solid tumors who express MAGE-A4 and PRAME and test positive for HLA-A*02:01. We estimate that, across all solid tumors, there are over 100,000 patients worldwide who test positive for HLA-A*02:01 and can potentially benefit from our IMC-C103C and IMC-F106C programs. There is no assurance, however, as to what percentage of this population might benefit from these monotherapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will soon be evaluating the safety and tolerability of I109V/HBV in a Phase 1 dose escalation clinical trial in patients with chronic HBV who test positive for HLA-A*02:01. We estimate that there are approximately 16 to 24&#160;million chronic HBV patients who test positive for HLA-A*02:01. There is no assurance however as to what percentage of this population might benefit from this monotherapy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The total addressable market opportunity for our programs will ultimately depend upon, among other things, the diagnosis criteria included in the final label, if our product candidates are approved for sale for these indications, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with cancers, solid tumors and chronic HBV and test positive for HLA-A*02:01 may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and access to capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Although we intend to explore other therapeutic opportunities, in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. For example, we develop various protein models and make predictions as to how molecules might target antigens, with subsequent validation efforts in our labs and labs of our contract research organizations, or CROs. There can be no assurance that we will find potential additional targets using this approach, that any such targets will be tractable, or that such clinical validations will be successful. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the research methodology used may not be successful in identifying potential indications and/or product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 22-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The effects of health epidemics, including the recent COVID-19 coronavirus pandemic, in regions where we, or the third parties on which we rely, have business operations could adversely impact our business, including our pre-clinical studies and clinical trials, as well as the business or operations of our CROs or other third parties with whom we conduct business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our business could be adversely affected by health epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. Since December 2019, a novel strain of coronavirus, COVID-19, has spread to multiple countries, including the United States, Canada and several European countries. Our company headquarters is located in Oxfordshire, United Kingdom, we have U.S. offices in Conshohocken, Pennsylvania and Rockville, Maryland, and our CROs and CMOs are operating in Europe, United States and Asia. In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic, and the U.S. government imposed travel restrictions on travel between the United States, Europe and certain other countries. Further, the President of the United States declared the COVID-19 pandemic a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In response to these public health directives and orders, we have implemented work-from-home policies to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state/provincial or municipal government and health authorities. We implemented a number of measures to ensure employee safety and business continuity. Employees who can work from home have been doing so, while those needing to work in laboratory facilities are divided into shifts to reduce the number of people gathered together at one time. Business travel has been suspended, and online and teleconference technology is used to meet virtually rather than in person. We have taken measures to secure our research and development project activities, while work in laboratories and facilities has been organized to reduce risk of COVID-19 transmission.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The effects of the executive orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines (for example, our timeline for tebentafusp), the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United Kingdom, United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, the COVID-19 pandemic has resulted in a short-term delay of up to six months in progressing our early-stage pipeline programs and specifically, our Phase 1 clinical trial in HBV. The continued effects of the COVID-19 pandemic may also further negatively impact our clinical trials in the future, including potential delays and restrictions on our ability to recruit and retain patients, principal investigators and healthcare employees. The COVID-19 pandemic could also affect the operations of our CROs or CMOs, which may result in delays or disruptions in our clinical trials or in the supply of product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, our planned clinical trials may be affected by the COVID-19 pandemic, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays or difficulties in enrolling and retaining patients in our clinical trials, including patients that may not be able or willing to comply with clinical trial protocols such as weekly dosing regimens if quarantines impede patient movement or interrupt healthcare services;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays or difficulties in clinical site initiation, including difficulties in recruiting and retaining clinical site investigators and clinical site staff;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of risks of exposure to COVID-19, being forced to quarantine or being unable to visit clinical trial locations or otherwise comply with clinical trial protocols;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 23-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">interruption of our clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state/provincial or municipal governments, employers and others; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For our clinical trials that we expect to conduct at sites outside the United States, particularly in countries which are experiencing heightened impact from the COVID-19 coronavirus, in addition to the risks listed above, we may also experience the following adverse impacts:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in federal, state/provincial or municipal regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the refusal of the FDA to accept data from clinical trials in these affected geographies.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United Kingdom, United States, and other countries, business closures or business disruptions and the effectiveness of actions taken in the United Kingdom, United States, and other countries to contain and treat the disease. The ultimate impact of the COVID-19 pandemic or a similar epidemic is highly uncertain and subject to change. We may experience a material impact on our operations, and we continue to monitor the COVID-19 situation closely.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is impossible to predict when or if tebentafusp will receive marketing approval. Furthermore, it is impossible to predict when or if IMC-C103C, IMC-F106C, IMCI109V and GSK01 or any of our future product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete pre-clinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of pre-clinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, pre-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. Our pre-clinical studies and future clinical trials may not be successful. From time to time, we may publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 24-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also expect to rely on outside vendors (for example, independent contractors and CROs) to conduct, supervise or monitor some or all aspects of clinical trials involving our products. We will have less control over the timing and other aspects of these clinical trials than if we conducted them entirely on our own. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as currently planned could be harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently anticipate that we will have to rely on CMOs to manufacture our products for clinical trials. If they fail to commence or complete, or experiences delays in, manufacturing our products and product candidates, our planned clinical trials will be delayed, which will adversely affect our stock price and our ability to conduct our business as currently planned. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize any of our product candidates, we must obtain marketing approval. Currently, all of our product candidates are in development, and we have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have only limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We may also face greater than expected difficulty in manufacturing our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA, EMA or a comparable foreign regulatory authority requires that we perform additional pre-clinical or clinical trials, approval, if obtained at all, may be delayed. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 25-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be unable to demonstrate to the satisfaction of the FDA, EMA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or comparable foreign regulatory authorities for approval;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission a BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA, EMA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Positive results from early pre-clinical studies of our product candidates are not necessarily predictive of the results of later pre-clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier pre-clinical studies of our product candidates in our later pre-clinical studies and future clinical trials, we may be unable to successfully develop, obtain regulatory for and commercialize our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any positive results from our pre-clinical studies of our product candidates may not necessarily be predictive of the results from required later pre-clinical studies and clinical trials. Similarly, even if we are able to complete our planned pre-clinical studies or any future clinical trials of our product candidates according to our current development timeline, the positive results from such pre-clinical studies and clinical trials of our product candidates may not be replicated in subsequent pre-clinical studies or clinical trial results. In addition, positive results in later stage clinical trials of one of our product candidates in an indication may not be predictive of the safety or efficacy of our other product candidates in other indications, even if they employ a similar mechanism of action. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, pre-clinical and other nonclinical findings made while clinical trials were underway, or safety or efficacy observations made in pre-clinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials nonetheless failed to obtain FDA or EMA approval. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 26-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may publish interim, &#8220;top-line&#8221; or preliminary data from our planned clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our ADSs to fluctuate significantly.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may experience delays in completing our pre-clinical studies and initiating or completing clinical trials, and we may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional pre-clinical studies or clinical trials or we may decide to abandon product development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of clinical trials of our product candidates may be greater than we anticipate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from pre-clinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 27-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant delays in pre-clinical studies or clinical trials, including those caused by the COVID-19 pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. Any delays in our pre-clinical or future clinical development programs may harm our business, financial condition and prospects significantly. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, because we will be deploying our drug discovery platform across a broad target space, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Furthermore, our ability to enroll patients may be significantly delayed by the evolving COVID-19 pandemic and we do not know the extent and scope of such delays at this point. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the competitive trial environment, the eligibility criteria of our planned clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of potential products may be delayed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, furthering the difficulty in identifying patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek participation in the FDA&#8217;s expedited review and development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise to seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the severity of the disease under investigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the eligibility criteria for the clinical trial in question; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of an appropriate genomic screening test; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the perceived risks and benefits of the product candidate under study; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efforts to facilitate timely enrollment in clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patient referral practices of physicians; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to monitor patients adequately during and after treatment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proximity and availability of clinical trial sites for prospective patients; and </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 28-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">factors we may not be able to control, such as current or potential pandemics that may limit patients, principal investigators or staff or clinical site availability (<font style="font-style: italic;">e.g.</font>, outbreak of COVID-19).</div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our planned clinical trials or those of our future collaborators may reveal significant adverse events not seen in our pre-clinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive pre-clinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may develop future product candidates, in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As is the case with many treatments for cancer, infectious diseases and autoimmune diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">For a period of four weeks, our IMC-F106C program was put on partial clinical hold in 2018 by the FDA following the death of the second patient dosed in this trial, which was subsequently determined to be unrelated to study drug. The hold has since been lifted and the trial has been resumed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are at risk of a clinical hold at any time based on the evaluation of the data and information submitted to the governing regulatory authorities. In 2018, we received notice from the FDA of a partial clinical hold on our IMC-F106C clinical trial after the second patient (with baseline elevated risk factors for pulmonary embolus) experienced a fatal adverse event of respiratory failure due to multiple pulmonary emboli 24 hours after receiving the first dose (0.3 mcg). In accordance with our own internal guidelines, we put our clinical trial on hold to investigate this unexplained death and informed the FDA. The FDA subsequently put our clinical trial on a partial clinical hold and allowed us the option to continue dosing the first patient. After autopsy, including expert review, and other investigations, the primary investigator concluded that the cause of death was respiratory failure and not related to study drug. We modified the trial protocol to add a lower dose cohort and additional screening and on-treatment precautions. The FDA has accepted our changes and removed the partial clinical hold enabling the trial to continue. However, if in the future we are delayed in addressing, or unable to address, any FDA concerns, we could be delayed, or prevented, from conducting our clinical trials.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 29-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities, including IRBs, to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the drug. Because of our planned dose escalation design for our clinical trials, undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Additionally, results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, which may stem from our therapies specifically or may be due to an illness from which the clinical trial subject is suffering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, our oncology clinical trials include cancer patients who are very sick and whose health is deteriorating, and we expect that additional clinical trials of our other product candidates will include similar patients with deteriorating health. In clinical trials conducted by other companies involving CAR T cells, TCR T or T cell redirecting bispecifics, the most prominent acute toxicities included symptoms thought to be associated with cytokine release syndrome, or CRS, such as fever, low blood pressure and kidney dysfunction. It is possible that some of these patients may experience similar adverse side effects as were observed in clinical trials conducted by other companies and academic institutions, and that additional patients may die during our clinical trials for various reasons, including as a result of receiving our product candidates, because the patient&#8217;s disease is too advanced, or because the patient experiences medical problems that may not be related to our product candidate. Even if the deaths are not related to our product candidate, the deaths could affect perceptions regarding the safety of our product candidate.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patient deaths and severe side effects caused by our product candidates, or by products or product candidates of other companies that are thought to have similarities with our therapeutic candidates, could result in the delay, suspension, clinical hold or termination of clinical trials by us, the FDA, the EMA or other regulatory authorities for a number of reasons. If we elect or are required to delay, suspend or terminate any clinical trial of any product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates would be delayed or eliminated. Serious adverse events observed in clinical trials could hinder or prevent market acceptance of the product candidate at issue. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Our product candidates may have serious and potentially fatal cross-reactivity to other peptides or protein sequences within the body.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates may recognize and bind to a peptide unrelated to the target antigen to which it is designed to bind. If this peptide is expressed within normal tissues, our product candidates may target and kill the normal tissue in a patient, leading to serious and potentially fatal adverse effects. Detection of any cross-reactivity may halt or delay any ongoing clinical trials for any TCR-based product candidate and prevent or delay regulatory approval. Unknown cross-reactivity of the TCR binding domain to related proteins could also occur. We have also developed a pre-clinical screening process to identify cross-reactivity of the TCR binders. Any cross-reactivity that impacts patient safety could materially impact our ability to advance our product candidates into clinical trials or to proceed to marketing approval and commercialization.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">We intend to develop our IMC-C103C and IMC-F106C programs, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to develop our IMC-C103C and IMC-F106C programs, and may develop future product candidates, for use in combination with one or more currently approved cancer therapies. Even if any product candidate we develop was to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to bear the risks that the FDA or similar foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. Combination therapies are commonly </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 30-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also evaluate our IMC-C103C and IMC-F106C programs, or any other future product candidates, in combination with one or more other cancer, infectious disease or autoimmune disease therapies that have not yet been approved for marketing by the FDA or similar foreign regulatory authorities. We will not be able to market and sell our IMC-C103C and IMC-F106C programs, or any product candidate we develop in combination with any such unapproved cancer, infectious disease or autoimmune therapies, that do not ultimately obtain marketing approval. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the FDA, EMA or similar foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with our or any product candidate we develop, we may be unable to obtain approval of or market our IMC-C103C and IMC-F106C programs, or any product candidate we develop. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of our product candidates or any future product candidates may be delayed, and our business will be harmed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For planning purposes, we estimate the timing of achieving various scientific, clinical, regulatory, and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, regulatory submissions or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of clinical trials, receipt of regulatory approval, or the commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions, which may cause the timing of achieving the milestones to vary considerably from our estimates, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our available capital resources or capital constraints we experience; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the rate of progress, costs, and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify and enroll patients who meet clinical trial eligibility criteria;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our receipt of approvals by the FDA, EMA and comparable foreign regulatory authorities, and the timing thereof;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other actions, decisions, or rules issued by regulators;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to access sufficient, reliable, and affordable supplies of materials used in the manufacture of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efforts of our collaborators with respect to the commercialization of our approved products, if any; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the securing of, costs related to, and timing issues associated with, commercial product manufacturing, as well as sales and marketing activities. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of our lead product candidate and any other current or future product candidates may be delayed, and our business, results of operations, financial condition, and prospects may be adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates over other potential product candidates. These decisions may prove to have been wrong and may adversely affect our ability to develop our own programs, our attractiveness as a commercial partner and may ultimately have an impact on our commercial success.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources toward particular proprietary molecules </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 31-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">in our library, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for our lead product candidate, our business, financial condition and results of operations could be materially adversely affected.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We conduct clinical trials for our product candidates outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We conduct clinical trials outside the United States including in Australia, New Zealand, Europe and Asia and are likely to continue to do so in these or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">A variety of risks associated with conducting research and clinical trials in multiple countries and marketing our product candidates internationally could materially adversely affect our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials are currently being conducted in multiple countries throughout the world, and we plan to globally develop our current and future product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing regulatory requirements in foreign countries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing standards for the conduct of clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States or elsewhere and shipping the product candidate to patients in other countries; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">import and export requirements and restrictions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">economic weakness, including inflation, or political instability in foreign economies and markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign taxes, including withholding of payroll taxes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties staffing and managing foreign operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">workforce uncertainty in countries where labor unrest is more common than in the United Kingdom or the United States; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 32-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential liability under the Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or comparable foreign regulations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">challenges enforcing or protecting our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States or the United Kingdom;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impacts Brexit may have with respect to the cross-border acknowledgment of clinical trial results and marketing authorizations as well as recruitment of scientific personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business interruptions resulting from geo-political actions, including war and terrorism.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Commercialization of Our Product Candidates</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are subject to manufacturing risks that could substantially increase our costs and limit supply of our products. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates are biologics and the process of manufacturing our products is complex, highly regulated and subject to multiple risks. We may encounter difficulties in production, particularly with respect to process development, quality control, upscaling or scaling-out of our manufacturing capabilities. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any failure to follow current Good Manufacturing Practice, or cGMP, or other regulatory requirements or any delay, interruption or other issues that arise in the manufacture, fill and finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination of or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our TCR bispecific product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer other quality defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical trials or other development activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even to the extent we use and continue to use CMOs, we are ultimately responsible for the manufacture of our products and product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, suspension, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, or FCA, corporate integrity agreements, consent decrees, or withdrawal of product approval. For example, our IMC-C103C program was placed on partial clinical hold in 2018 due to insufficient specifications on a drug release assay in the corresponding IND. The partial clinical hold was later lifted and the trial has resumed.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 33-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Challenges we may face could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods, cause a lack of patient participation in clinical trials and have an adverse effect on our business, financial condition, results of operations and growth prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We have no internal sales, marketing or distribution capabilities currently and we may not be able to effectively market, sell and distribute tebentafusp, if approved or any of other product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Currently, we have no internal sales, marketing or distribution capabilities. If tebentafusp ultimately receives regulatory approval, we may not be able to effectively market and distribute the product candidate. We will have to invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that tebentafusp will be approved, or engage third parties to provide these services. We have entered into an agreement with Syneos Health, Inc., or Syneos, to build our commercial infrastructure for the potential commercial launch of tebentafusp, including to potentially retain, train and deploy a direct sales force, but we have no experience operating or managing a third-party sales force. There can be no assurance that the capabilities of the Syneos sales organization will be more effective than an internally developed sales organization. In addition, Syneos can terminate our agreement under certain circumstances. If Syneos fails to hire, train, and retain qualified sales personnel, market our product successfully or on a cost effective basis or otherwise terminates our relationship, our ability to generate revenue will be limited and we will need to identify and retain an alternative organization, or develop our own sales and marketing capability. This could involve significant delays and costs, including the diversion of our management&#8217;s attention from other activities. We will also need to retain additional consultants or external service providers to assist us in sales, marketing and distribution functions, and may be unsuccessful in retaining such services on acceptable financial terms or at all.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For our other product candidates, there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a commercial organization is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future product that we may develop;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of complementary treatments to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability to us from these revenue streams is likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties and any of them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we may not be successful in commercializing our product candidates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 34-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we obtain approvals from the FDA, the EMA or other comparable regulatory agencies and are able to initiate commercialization of our clinical stage product candidates or any other product candidates we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the clinical indications for which our product candidates are approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">physicians, hospitals, cancer treatment centers, and patients considering our product candidates as a safe and effective treatment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hospitals and cancer treatment centers establishing the infrastructure required for the administration of the product candidate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential and perceived advantages of our product candidates over alternative treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prevalence and severity of any side effects;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product labeling or product insert requirements of the FDA, the EMA or other regulatory authorities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">limitations or warnings contained in the labeling approved by the FDA or the EMA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of market introduction of our product candidates as well as competitive products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of treatment in relation to alternative treatments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount of upfront costs or training required for physicians to administer our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the pricing of our products and the availability of coverage and adequate reimbursement by third-party payors and government authorities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the willingness of patients to pay out-of-pocket in the absence of comprehensive coverage and adequate reimbursement by third-party payors and government authorities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of our sales and marketing efforts and distribution support.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our products, if approved, may require significant resources and may never be successful. For example, our focus on median overall survival rates for tebentafusp treated patients instead of response evaluation criteria in solid tumor, or RECIST, which has traditionally been used as a standard measure of activity in clinical trials, may inhibit market acceptance. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our product revenue for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The biotechnology industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 35-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to acquire or in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent or other proprietary protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of therapeutics to address unmet needs in cancer, infectious and autoimmune diseases, including Adaptimmune Therapeutics plc, or Adaptimmune, Gritstone Oncology, Inc., Immatics Biotechnologies GmbH, Adaptive Biotechnologies Corporation, or Adaptive, pure MHC, LLC, BioNTech SE, and Genentech, Inc., who are also seeking to identify HLA targets and develop product candidates; Adaptimmune, T-Knife GmbH, Adaptive, 3T Biosciences, Inc., MediGene AG, or MediGene, Regeneron Pharmaceuticals, Inc., Gilead Sciences, Inc., bluebird Bio, Inc., or bluebird bio, and AgenTus Therapeutics, Inc. who are also developing TCR-based approaches; and Takara Bio Inc., Tmunity Therapeutics, Inc., Kuur Therapeutics Limited, Bristol-Myers Squibb Company, GlaxoSmithKline Intellectual Property Development Ltd, or GSK, Adaptimmune, bluebird bio, MediGene, TCR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Therapeutics, and Bellicum Pharmaceuticals, Inc. who are developing novel autologous TCR-T therapeutics; Amgen, Inc., Genmab, Inc. and MorphoSys AG are developing TCR bispecific compounds or TCR mimetic antibodies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We anticipate that we will continue to face intense and increasing competition as new treatments enter the market and advanced technologies become available. There can be no assurance that our competitors are not currently developing, or will not in the future develop, products that are equally or more effective or are more economically attractive than any of our current or future product candidates. Competing products may gain faster or greater market acceptance than our products, if any, and medical advances or rapid technological development by competitors may result in our product candidates becoming non-competitive or obsolete before we are able to recover our research and development and commercialization expenses. If we or our product candidates do not compete effectively, it may have a material adverse effect on our business, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these products and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may incur significant costs to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain FDA approvals. Our product candidates may not be considered medically necessary or cost-effective.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 36-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor&#8217;s formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products, and providers are unlikely to prescribe our products, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products and their administration. Therefore, coverage and adequate reimbursement is critical to new medical product acceptance.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, we are developing a proprietary diagnostic test for use with certain of our product candidates. We will be required to obtain coverage and reimbursement for this test separate and apart from the coverage and reimbursement we seek for our product candidates, if approved. There is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for this proprietary diagnostic test for reasons similar to those applicable to our product candidates.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the impairment of our business reputation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the withdrawal of clinical trial participants;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs due to related litigation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the distraction of management&#8217;s attention from our primary business;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substantial monetary awards to patients or other claimants;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to commercialize our product candidates; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">decreased demand for our product candidates, if approved for commercial sale.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe our product liability insurance coverage is sufficient in light of our current commercial and clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. We intend to expand our insurance coverage each time we commercialize an additional product; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">32<br></div></div></div>
<!--End Page 37-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Patients with the diseases targeted by certain of our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to Our Dependence on Third Parties</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including for example with Genentech, GSK or Eli Lilly and Company, or Lilly. These collaborations have also provided us with important funding for our development programs and technology platforms, and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not perform their obligations as expected; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; this may also happen if the collaborators&#8217; development of competing products is substantially faster than our development timelines; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not further develop product candidates developed by us or co-developed with us under the collaboration; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">33<br></div></div></div>
<!--End Page 38-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators have certain defined rights to change or expand the scope of development programs during the course of the collaboration. This may lead to additional research work for us that may be time-consuming and expensive. Such work may compete with our own development programs and may delay timelines to market or proof-of-concept for our product candidates. If development programs under the collaboration turn out to be more costly and time-consuming, such unanticipated costs and work could likewise compete with our internal development programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not properly maintain, enforce or defend our intellectual property or proprietary information or may use them in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability, and collaborators may also allege that we are liable for potential infringement, misappropriation or other violations of third-party intellectual property or proprietary rights during the research and development work for the collaboration; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, certain of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may discontinue the development of product candidates within the collaboration, for example if they consider the results achieved so far or the product candidates not promising enough or if their development strategies change. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our program collaborators. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, it may find it more difficult to attract new collaborators. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that reduced the number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">34<br></div></div></div>
<!--End Page 39-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Subject to certain specified exceptions, each of our existing therapeutic collaborations contains an exclusivity restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We rely on CROs and other third parties to conduct our Phase 1, Phase 2 and Phase 3 pivotal clinical trials and expect to rely on CROs and other third parties to conduct future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these CROs and other third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We rely and expect to continue to rely on CROs, medical institutions, clinical investigators, contract laboratories and other third parties to conduct or otherwise support clinical trials for our product candidates, including our Phase&#160;2 and Phase 3 pivotal clinical trials of tebentafusp, our Phase 1 clinical trials of IMC-C103C and IMC-F106C, our imminent Phase1 clinical trial of IMC-I109V and GSK&#8217;s Phase 1 clinical trial of GSK01. We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such arrangements will likely provide us certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator-sponsored trials. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We rely and expect to continue to rely heavily on CROs, medical institutions, clinical investigators, contract laboratories and other third parties for execution of clinical trials for our product candidates and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, our principal investigators and our CROs are required to comply with regulations, including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">35<br></div></div></div>
<!--End Page 40-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we designed our Phase 2 and Phase 3 pivotal clinical trials of tebentafusp, our Phase 1 clinical trials of IMC-C103C and IMC-F106C, our imminent Phase 1 clinical trial of IMC-I109V and GSK&#8217;s Phase 1 clinical trial of GSK01 and intend to design the future clinical trials for our product candidates, we expect that CROs will conduct all of our clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">have staffing difficulties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fail to comply with contractual obligations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experience regulatory compliance issues; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">undergo changes in priorities or become financially distressed; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">form relationships with other entities, some of which may be our competitors.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates, or our development program materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">We contract with third parties for the manufacture of our product candidates for pre-clinical development, clinical testing, and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for pre-clinical development and clinical testing, as well as for the commercial manufacture of our </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">36<br></div></div></div>
<!--End Page 41-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">products if any of our product candidates receive marketing approval. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third -party manufacturers entails additional risks, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reliance on the third party for regulatory compliance and quality assurance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible breach of the manufacturing agreement by the third party; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible misappropriation or unauthorized disclosure of our proprietary information, including our trade secrets and know-how; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredient used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The active pharmaceutical ingredients, or API, used in our product candidates are supplied to us from single-source suppliers. Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We do not currently have arrangements in place for a redundant or second-source supply of any such API in the event any of our current suppliers of such API cease their operations for any </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">37<br></div></div></div>
<!--End Page 42-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reason. We are also unable to predict how changing global economic conditions or potential global health concerns such as the COVID-19 pandemic will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API prior to submission of a BLA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Establishing additional or replacement suppliers for the API used in our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">38<br></div></div></div>
<!--End Page 43-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Where we license technology from a third party, the prosecution, maintenance, enforcement and defense of the patent or other intellectual property or proprietary rights licensed from such third party may be controlled by the third party, which may impact the scope of patent or other protection.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where we license patent rights, technology or other intellectual property or proprietary rights from a third party, control of such third-party rights may vest in the licensor, particularly where the license is non-exclusive or field-restricted. This may mean that we are not able to control or affect the scope of the claims of any relevant third-party patent or other intellectual property protection or have control over the preparation, filing, prosecution, maintenance, enforcement and defense of such patents and patent applications. Therefore, we cannot be certain that such patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject to such licensed rights could be adversely affected. Where a licensor brings an enforcement action with respect to licensed patents or other intellectual property, this could negatively impact our business or result in additional restrictions being imposed on the license we have and the scope of such license, or result in invalidation or limitation of the scope of the licensed patents or other intellectual property rights. In addition, should we wish to enforce the relevant patent or other intellectual property rights against a third person, we may be reliant on consent from the relevant licensor or the cooperation of the licensor. The licensor may refuse to bring such action and leave us unable to restrict competitor entry into the market. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, potentially infectious material and genetically modified cells. We and our suppliers are subject to federal, state and local laws and regulations in the United Kingdom and United States governing the use, manufacture, storage, handling and disposal of such hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, and that we and our suppliers have all necessary permits, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from hazardous chemical or biological materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We have insurance in place for liabilities arising from handling biological and hazardous substances, but it may not or may not fully cover all costs from such accidents. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could impact our business, prospects, financial condition or results of operations. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Intellectual Property</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">If we are unable to adequately protect our proprietary technology or obtain, maintain, protect and enforce patent and other intellectual property protection for our technology and products or if the scope of the protection obtained is not sufficiently broad, our competitors and other third parties could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial success will depend in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our product candidates and our core technologies, including our novel target discovery technology, our proprietary compound library and other know-how. We seek </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">39<br></div></div></div>
<!--End Page 44-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the United States and abroad related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our current or future pending patent applications will issue or will mature into issued patents that include claims with a scope sufficient to protect tebentafusp, IMC-C103C, IMC-F106C, IMC-I109V, GSK&#8217;s GSK01 or any other current or future product candidates or technologies, in whole or in part, or effectively prevent others from commercializing competing product candidates and technologies. While we own issued patents relating to tebentafusp and pending patent applications relating to our other product candidates, including IMC-C103C, IMC-F106C, GSK&#8217;s GSK01 and IMC-I109V, we do not own or in-license any issued patents relating to such other product candidates, and we can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage. In addition, the laws of foreign jurisdictions may not protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the United States and countries of the European Union, the natural expiration of a patent is generally twenty years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar or identical to our product candidates, including generic versions of such products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, certain of our patents and technology were funded in part by investments from nonprofit third parties, including the Bill &amp; Melinda Gates Foundation, or the Gates Foundation. We are required to fulfill certain contractual obligations with respect to products created using such grant funding, including making certain products available at an affordable price in a list of clearly defined low and lower-middle income countries. For more information see &#8220;Business &#8212; Collaborations and License Agreements &#8212; Gates Collaboration.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other parties may have developed technologies that are related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive issued patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same methods or formulations or the same subject matter. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our pending patent applications or any patent application we may license, or that we were the first to file for patent protection of such inventions. In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to most of the pending patent applications covering our product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office, or USPTO, or its global equivalents, are often significantly narrowed by the time they issue, if they issue at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">40<br></div></div></div>
<!--End Page 45-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we may license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we acquire patent protection that we expect should enable us to maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents or any patent we may license may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of any of our pending patent applications. We may become involved in opposition, derivation, re-examination, revocation, <font style="font-style: italic;">inter partes </font>review, post-grant review, interference or other proceedings challenging our patent rights or the patent rights of others from whom we have obtained licenses to such rights. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competitors or other third parties may claim that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Third parties may also claim that we are infringing, misappropriating or otherwise violating their patents or other intellectual property rights and that we therefore cannot practice our technology as claimed under our patents, if issued. Competitors and other third parties may also contest our patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In litigation, a competitor or other third party could claim that our patents, if issued, are not valid for a number of reasons. If a patent office or court agrees, we would lose our rights to those challenged patents, in whole or in part. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, without payment to us, or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may also result in our inability to manufacture or commercialize our product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such proceedings also may result in substantial cost and require significant time and attention from our scientists and management.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products or technology similar or identical to ours. Moreover, some of our patents and patent applications are, and may in the future be, co-owned with third parties. In-licensed patents and patent applications may also be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their interest to other parties, including our competitors, who could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if unchallenged, our patent portfolio may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our patents or any patents we may license by developing similar or alternative technologies or products in a non-infringing manner. For example, a third party </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">41<br></div></div></div>
<!--End Page 46-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">may develop a competitive product that provides benefits similar to one or more of our product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance and renewal fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates and technologies, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how, proprietary information and continuing technological innovation to develop and maintain our competitive position. With respect to the building of our ImmTAX platform, we consider trade secrets and know-how to be our primary intellectual property. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our collaborators, scientific advisors, employees, CROs and consultants, and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures of trade secrets and other confidential information is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, CROs and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secret protection as a result. In addition, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, some courts, especially outside the United States, are sometimes less willing to protect trade secrets. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our trade secrets could otherwise become known, obtained or independently discovered by our competitors or other third parties, who could purchase our products and product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate such information, from using that technology or information </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">42<br></div></div></div>
<!--End Page 47-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to compete with us. If our trade secrets are not adequately protected so as to protect our market against competitors&#8217; products, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property or proprietary rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating, or otherwise violating the intellectual property and proprietary rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We are subject to, and may in the future become party to or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including interference, post-grant review, <font style="font-style: italic;">inter partes</font> review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions, such as oppositions before the European Patent Office, or EPO. Our competitors or other third parties may assert infringement claims against us, alleging that our products or technologies are covered by their patents. Given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and continue to file, patent applications related to soluble, bispecific TCRs. Some of these patent applications have already been allowed or issued, and others may issue in the future. Since these areas are competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates, or the practice of our technology. If a patent holder believes our product or product candidate infringes on its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if we believe that such claims are without merit, there is no assurance that a court or patent office would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of a U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe, misappropriate or otherwise violate a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our product candidates and technology. We may also attempt to obtain a license even in the absence of an action or finding of infringement. In either case, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Without such a license, we could be forced, including by court order, to cease developing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such third-party patent rights. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. If we lose a foreign lawsuit alleging our infringement, misappropriation of other violation of a competitor&#8217;s patents or other intellectual property or proprietary rights, we could be prevented from marketing our products in one or more foreign countries. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">43<br></div></div></div>
<!--End Page 48-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets or other confidential information of our competitors or other third parties or are in breach of non-competition or non-solicitation agreements with our competitors or other third parties, or claims asserting ownership of what we regard as our own intellectual property. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers or competitors. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business, and may prevent us from successfully commercializing our product candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competitors and other third parties may infringe, misappropriate or otherwise violate our patents and other intellectual property rights. In addition, four of our patents relating to our ImmTAX platform technology are involved in European patent opposition proceedings challenging the validity of those European patents and our patents or the patents of our licensing or collaboration partners may in the future become, involved in inventorship or priority disputes. Such challenges may result in loss of patent rights, exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the scope and duration of the patent protection of our ImmTAX platform technology and product candidates. To counter infringement or unauthorized use, we or our licensing or collaboration partners may be required to file infringement claims. A court may disagree with such allegations, however, and may refuse to stop the other party from using the technology at issue on the grounds that the applicable patents or other intellectual property do not cover the third-party technology in question. Further, such third parties could counterclaim that we infringe, misappropriate or otherwise violate their intellectual property or that a patent or other intellectual property right asserted against them is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us to assert such challenges to our intellectual property rights. The outcome of any such proceeding is generally unpredictable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. It is possible that prior </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">44<br></div></div></div>
<!--End Page 49-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">art of which we and the patent examiner were unaware during prosecution exists, which could render any patents that may issue invalid. Moreover, it is also possible that prior art may exist that we are aware of but do not believe is relevant to our future patents, should they issue, but that could nevertheless be determined to render our patents invalid. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity or unenforceability of our patents covering one of our product candidates, we would lose at least part, and perhaps all, of the patent protection covering such product candidate. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Intellectual property litigation and proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating, or from successfully challenging, our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may not be able to effectively enforce our intellectual property and proprietary rights throughout the world. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain jurisdictions, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Additionally, the patent laws of some foreign jurisdictions do not afford intellectual property protection to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property rights. This could make it difficult for us to stop the infringement, misappropriation or other violation of our patents and other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business, could put our patents at </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">45<br></div></div></div>
<!--End Page 50-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">risk of being invalidated or interpreted narrowly, or our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in the major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. If we are not able to obtain a license, or not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially. Even if we are able to obtain a license, it may be non-exclusive, which may allow our competitors or other third parties access to the same technologies licensed to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In cases where we are unable to procure sufficient rights to third-party intellectual property rights, we might need to cease use of the compositions or methods covered by such third-party intellectual property rights and/or develop alternative approaches that do not infringe, misappropriate or otherwise violate such intellectual property rights. This could entail additional costs and development delays, and the development of such alternatives may not be feasible. Any of the foregoing could prevent us from developing or commercializing one or more of our product candidates, or force us to modify such product candidates, or to cease some aspect of our business operations, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we fail to comply with our obligations in the agreements under which we collaborate with or license intellectual property rights from third parties, or otherwise experience disruptions to our business relationships with our collaborators or licensors, we could lose rights that are important to our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our current and any future collaboration and license agreements impose, or we expect will impose, various development, diligence, commercialization, payment, and other obligations on us. In spite of our efforts, a </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">46<br></div></div></div>
<!--End Page 51-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">collaborator or licensor might conclude that we have materially breached our obligations under such agreement and seek to terminate the agreement, thereby removing or limiting our ability to develop and commercialize products and technology covered by these agreements. If these agreements are terminated, or if the underlying patent or other intellectual property rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or similar to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, disputes may arise regarding intellectual property subject to a collaboration or licensing agreement, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope of rights granted under the agreement and other interpretation-related issues; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the extent to which our technology and processes infringe on intellectual property of the counterparty that is not subject to the agreement; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sublicensing of patent and other intellectual or proprietary rights under our collaborative development relationships; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our counterparty and us and our partners; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the priority of invention of patented technology.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These agreements may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Recent patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law in 2011, could increase those uncertainties and costs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. For example, the Leahy-Smith Act limits where a patentee may file a patent infringement suit and provides opportunities for third parties to challenge any issued patent with the USPTO. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a patent claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the enforcement or defense of our or our collaboration or licensing partners&#8217; issued patents.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#8220;first to file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">47<br></div></div></div>
<!--End Page 52-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. This will require us to be cognizant of the time from invention to filing of a patent application and be diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. Therefore, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce rights in our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce any existing patents and patents that we may obtain in the future. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Intellectual property rights do not necessarily address all potential threats. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may be able to make products that are similar to our product candidates or utilize similar technology but that are not covered by the claims of the patents that we own or license now or in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we or our licensors or collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license now or in the future;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we or our licensors or collaborators might not have been the first to file patent applications covering certain of our or their inventions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights or any intellectual property rights we may license; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is possible that our present or future pending patent applications (whether owned or licensed) will not lead to issued patents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is possible that there are or will be prior public disclosures that could invalidate our or our licensors&#8217; or collaboration partners&#8217; patents;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issued patents that we hold rights to may fail to provide us with any competitive advantage, or may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may not develop additional proprietary technologies that are patentable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ownership, validity or enforceability of our patents or patent applications may be challenged by third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the patents or pending or future applications of others, if issued, may harm our business; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">48<br></div></div></div>
<!--End Page 53-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Issued patents covering our product candidates or technologies could be found invalid or unenforceable if challenged in court or in administrative proceedings. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or technologies, should such a patent issue, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <font style="font-style: italic;">inter partes</font> review and equivalent proceedings in foreign jurisdictions <font style="font-style: italic;">(e.g.,</font> opposition proceedings). An adverse determination in any of the foregoing proceedings could result in the revocation or cancellation of, or amendment to, our patents in such a way that they no longer cover our product candidates or technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant or third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates or technologies. Such a loss of patent protection could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If our trademarks and trade names are not adequately protected, then this may impede our ability to build and sustain name recognition in our markets of interest and our business may be adversely affected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may rely on trademarks and trade names to protect our business. If our trademarks and trade names are not adequately protected, this may impede our ability to build and sustain name recognition in our markets of interest and our business may be adversely affected. We may not be able to protect our rights to these trademarks and trade names, which we need to support name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark oppositions or infringement claims brought by owners of other registered or unregistered trademarks or trade names that incorporate elements which are identical or similar to our trademarks or trade names. For example, our U.S. trademark application for IMMTAX is currently subject to an opposition filed by Immatics Biotechnologies GmbH. If we are unsuccessful in defending this opposition, we may be required to change our branding for our ImmTAX platform which could cause us to incur substantial costs and impede our ability to build and sustain name recognition for such platform. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on effective use of our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Related to Government Regulation </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA regulatory pathways can be difficult to predict and whether, for example, further unanticipated clinical trials are required, will depend on the data obtained in our ongoing clinical trials. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The regulatory approval pathway and the amount of time it takes us to obtain regulatory approvals for our product candidates will depend on the data that are obtained in our ongoing clinical trials and any future clinical trials, including future registrational or pivotal clinical trials. We may attempt to seek approval on a per indication basis for our product candidates on the basis of a single pivotal trial or on the basis of data from one or more uncontrolled trials. While the FDA requires in most cases two adequate and well-controlled pivotal clinical trials to demonstrate the efficacy of a product candidate, a single trial with strong confirmatory evidence </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">49<br></div></div></div>
<!--End Page 54-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">may be sufficient in instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and if confirmation of the result in a second trial would be practically or ethically impossible. In rare cancer indications with very limited treatment options, a large and/or controlled trial is often not feasible and thus data from smaller and even uncontrolled trials may be sufficient for regulatory approval. Depending on the data we obtain, the FDA or other regulatory authorities may require additional clinical trials to be carried out or further patients to be treated prior to the granting of any regulatory approval for marketing of our product candidates. It is difficult for us to predict with such a novel technology exactly what will be required by the regulatory authorities in order to take our product candidates to market or the timeframes under which the relevant regulatory approvals can be obtained. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. For example, clinical trials may be required in pediatric populations before any marketing approval can be obtained, which can be time-consuming and costly. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and foreign regulatory authorities also have substantial discretion in the drug and biologics approval processes. The number and types of pre-clinical programs and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from pre-clinical programs or clinical trials, either of which may cause delays or limitations in the approval or the decision not to approve an application. In addition, approval of our product candidates could be delayed or refused for many reasons, including the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our or our collaborators&#8217; clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we or our collaborators may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe, pure, potent and have a favorable risk/benefit profile for any of their proposed indications; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical programs or clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">data collected from clinical trials of product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">manufacturing processes or facilities or those of the third-party manufacturers we use may not be adequate to support approval of our product candidates; and </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is possible that no product candidates will ever obtain the appropriate regulatory approvals necessary to be commercialized. Any delay in obtaining, or failure to obtain, required approvals would materially adversely affect our ability to generate revenue from the particular product candidate, which would result in significant harm to our business. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">50<br></div></div></div>
<!--End Page 55-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 56-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trial holds; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, warning letters or other regulatory enforcement action; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about approved prescription drug products. In particular, while the FDA permits the dissemination of truthful and non-misleading information about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA. If we are found to have promoted such off-label uses, we may become subject to significant liability. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of regulated products for off-label uses and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">51<br></div></div></div>
<!--End Page 56-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 57-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">We are subject to stringent and changing privacy laws, regulations and standards as well as contractual obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could harm our reputation, subject us to significant fines and liability, or otherwise adversely affect our business or prospects. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to data privacy and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission, storage, processing and use of personal information or personal data, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with laws, regulations and other obligations governing personal information could result in enforcement actions against us, including fines, imprisonment of company officials and public censure, processing penalties, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The regulatory framework for the collection, use, retention, safeguarding, disclosure, sharing, transfer and other processing of personal information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer or other processing of personal data regarding individuals in the United Kingdom and European Union, including personal health data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member states of the European Union, or EU, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data that requires the adoption of administrative, physical and technical safeguards, providing notification of data breaches to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their personal data and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EU by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Economic Area, or EEA, including the United States and, as a result, increases the scrutiny for transfers of personal data from clinical trial sites located in the EU to the United States. The United Kingdom and Switzerland have adopted similar restrictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although there are legal mechanisms to allow for the transfer of personal data from the EEA, Switzerland and United Kingdom to the United States, uncertainty remains about compliance with such data protection laws and such mechanisms may not be available or applicable with respect to the personal data processing activities necessary to research, develop and market any product candidates we develop. For example, legal challenges in the EU to the mechanisms that allow companies to transfer personal data from the EU to the United States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross-border data transfers, such as the EU-U.S. and Swiss-U.S. Privacy Shield Frameworks. Specifically, on July&#160;16, 2020, in a case known as Schrems II, the Court of Justice of the European Union, or CJEU, invalidated the European Commission&#8217;s Decision 2016/1250 on the adequacy of the protection provided by the EU-U.S. Privacy Shield and raised questions about whether one of the primary alternatives to the EU-U.S. Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from the EU to the United States or most other countries. Use of the Standard Contractual Clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board, or EDPB, would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a GDPR-compliant &#8216;&#8216;transfer mechanism.&#8217;&#8217; However, the aforementioned draft </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">52<br></div></div></div>
<!--End Page 57-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 58-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8216;&#8216;in the clear&#8217;&#8217; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8216;&#8216;necessary and proportionate in a democratic society&#8217;&#8217;, which may, following the CJEU&#8217;s conclusions in Schrems II on relevant powers of United States public authorities and commentary in that draft EDPB guidance, include the United States in certain circumstances (<font style="font-style: italic;">e.g.</font>, where Section 702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any, viable alternatives to the EU-U.S. Privacy Shield and the Standard Contractual Clauses. Inability to transfer personal data from the EU, Switzerland or United Kingdom to the United States may restrict our clinical trial activities in the EU and limit our ability to collaborate with service providers and other companies subject to European data protection laws.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20&#160;million Euros, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data; as well as personal data related to criminal offences or convictions. For example, in the United Kingdom, the Data Protection Act 2018, or DPA 2018, complements the GDPR in this regard. This fact may lead to greater divergence in the laws that apply to the processing of such data types across the EEA and/or United Kingdom, compliance with which, as and where applicable, may increase our costs and could increase our overall compliance risk. Such member state specific regulations could also limit our ability to collect, use and share data in the context of our EEA and/or United Kingdom establishments (regardless of where any processing in question occurs), and/or could cause our compliance costs to increase, ultimately having an adverse impact on our business, and harming our business and financial condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, the United Kingdom&#8217;s decision to leave the EU, often referred to as Brexit, and ongoing developments in the United Kingdom have created uncertainty with regard to data protection regulation in the United Kingdom. Following the United Kingdom&#8217;s withdrawal from the EU on January 31, 2020, pursuant to the transitional arrangements agreed to between the United Kingdom and EU, the GDPR continued to have effect under United Kingdom law, and continued to do so until December 31, 2020 as if the United Kingdom remained a member state of the EU for such purposes. Following December 31, 2020, and the expiry of those transitional arrangements, the data protection obligations of the GDPR continue to apply to United Kingdom-related processing of personal data in substantially unvaried form and fashion under the so-called &#8216;&#8216;UK GDPR&#8217;&#8217; (<font style="font-style: italic;">i.e.</font>, the GDPR as it continues to form part of law in the United Kingdom by virtue of section 3 of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments etc) (EU Exit) Regulations)). However, going forward, there may be increasing scope for divergence in application, interpretation and enforcement of data protection laws as between the United Kingdom and EEA. Furthermore, the relationship between the United Kingdom and the EEA in relation to certain aspects of data protection law remains unclear. For example, it is still unclear whether the transfer of data from the EEA to the United Kingdom will in the future remain lawful under the GDPR. Under the post-Brexit Trade and Cooperation Agreement between the EU and the United Kingdom, or the Trade and Cooperation Agreement, it has been agreed that transfers of personal data to the United Kingdom from EU Member States will not be treated as &#8220;restricted transfers&#8221; to a non-EEA country for a period of up to four months from January 1, 2021 (with a potential two month extension), or the extended adequacy assessment period. This will also apply to transfers to the United Kingdom from EEA member state, assuming those member state accede to the relevant provision of the Trade and Cooperation Agreement. Although the current maximum duration of the extended adequacy assessment period is six months, it may end sooner, for example, in the event that the European Commission adopts an adequacy decision in respect of the United Kingdom, or the United Kingdom amends the UK GDPR and/or makes certain changes regarding data transfers under the UK GDPR/ DPA 2018 without the consent of the EU (unless those amendments or decisions are made simply to keep relevant United Kingdom laws aligned with the EU&#8217;s data protection regime). Unless the European Commission makes an &#8216;&#8216;adequacy finding in respect of the United Kingdom prior to the expiry of the extended adequacy assessment&#8221; period, from that point onwards the United Kingdom will be an inadequate &#8220;third country&#8221; under the GDPR and transfers of data from the EEA to the United Kingdom will require a &#8216;&#8216;transfer mechanism,&#8217;&#8217; such as the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">53<br></div></div></div>
<!--End Page 58-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 59-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">European Commission&#8217;s Standard Contractual Clauses issued and approved from time to time. Additionally, the United Kingdom has transposed the GDPR into domestic law by way of the UK GDPR with effect from January 2021, which could expose us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. In addition to such parallel United Kingdom and EU regimes, following the expiry of the post-Brexit transitional arrangements agreed between the United Kingdom and EU, the United Kingdom Information Commissioner&#8217;s Office is not able to be our &#8216;&#8216;lead supervisory authority&#8217;&#8217; in respect of any &#8216;&#8216;cross border processing&#8217;&#8217; for the purposes of the GDPR. Because we did not designate a lead supervisory authority in an EEA member state with effect from January 1, 2021, we are not able to benefit from the GDPR&#8217;s &#8216;&#8216;one stop shop&#8217;&#8217; mechanism. Among other things, this means that, in the event of a violation of the GDPR affecting data subjects across the United Kingdom and the EEA, we could be investigated, and ultimately fined by, the United Kingdom Information Commissioner&#8217;s Office and the supervisory authority in each and every EEA member state where data subjects have been affected by such violation. Other countries have also passed or are considering passing laws requiring local data residency and/or restricting the international transfer of data. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Privacy and data security requirements are also either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state attorneys general can all be aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on January&#160;1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, provides such individuals with new data privacy rights (including the ability to opt out of certain disclosures of personal information), imposes new operational requirements for covered businesses, provides a private right of action for data breaches and creates a statutory damages framework. Many other states are considering similar legislation, and a broad range of legislative measures also have been introduced at the federal level. Although there are limited exemptions for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, regulations promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions may be applicable to our business or that of our collaborators, service providers, contractors or consultants. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. If we are unable to properly protect the privacy and security of protected health information, we could be found to have violated these privacy and security laws and/or breached certain contracts with our business partners (including as a business associate). Further, if we fail to comply with applicable privacy laws, such as, to the extent applicable, HIPAA privacy and security standards, we could face significant civil and criminal penalties. In the United States, the Department of Health and Human Services&#8217; and state attorney&#8217;s general enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR, CCPA and similar laws&#8217; requirements are rigorous and time-intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data. Changes involving the GDPR, CCPA or other laws or regulations associated with the enhanced protection of certain types of sensitive data, such as </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">54<br></div></div></div>
<!--End Page 59-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 60-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could expose us to government enforcement actions, regulatory investigations, private litigation and significant fines, penalties and remediation costs and could have a material adverse effect on our business, financial condition or results of operations. Additionally, any failure by our third-party collaborators, service providers, contractors or consultants to comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against us by governmental entities or others, fines, reputational harm and other liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed fines, or penalties or orders requiring that we change our practices, which could adversely affect our business. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with federal, state and foreign laws regarding privacy and security of personal information could expose us to government-imposed fines and penalties under such laws, penalties or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement actions, litigation and significant costs for remediation, reputational harm, diminished profits and earnings, additional reporting requirements and/or oversight, any of which could adversely affect our business, our results of operations or prospects. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity. Any of the foregoing could have a materially adverse effect on our reputation and our business, financial condition, results of operations or prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">55<br></div></div></div>
<!--End Page 60-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 61-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or obtain access to <font style="font-style: italic;">in vitro</font> companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics would be used during our clinical trials as well as in connection with the commercialization of our product candidates. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. The FDA and comparable foreign regulatory authorities regulate <font style="font-style: italic;">in vitro</font> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we may develop, which we expect will require separate regulatory clearance or approval prior to commercialization. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from pre-clinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these therapeutics that obtain marketing approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic candidates. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We are subject to the U.K. Bribery Act 2010, or the Bribery Act, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. Violations of such laws and regulations could subject us to liability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The Bribery Act, the FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. In addition, the FCPA requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">56<br></div></div></div>
<!--End Page 61-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 62-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are also subject to other laws and regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union governing our international operations, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As disclosed elsewhere in this prospectus, we conducted an internal investigation in the summer and fall of 2020 as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors between 2018 and 2020. Our audit committee led the investigation utilizing outside counsel, during which the named employee resigned. After the investigation, we terminated the one remaining open contract with the third party vendors and issued proceedings in October 2020 against the involved parties. The amount in question was estimated to be in the range of &#163;1.1 million to &#163;1.8 million, and we recovered &#163;1.8 million from the employee and third-party vendors in December 2020. As a result of this investigation, we identified a material weakness in our internal controls relating to our procurement processes and application of delegation of authority approval limits due to insufficient risk assessment procedures. We have taken and will continue to take steps to remediate the material weakness and to enhance our overall control environment and compliance program. However, we cannot assure you that these measures will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including Trade Control laws, or prevent future material weaknesses or deficiencies. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our activities in the United States subject us to various laws relating to foreign investment and the export of certain technologies, and our failure to comply with these laws or adequately monitor the compliance of our third parties and others we do business with could subject us to substantial fines, penalties and even injunctions, the imposition of which on us could have a material adverse effect on the success of our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because we have a U.S. subsidiary and substantial operations in the United States, we are subject to U.S. laws that regulate foreign investments in U.S. businesses and access by foreign persons to technology developed and produced in the United States. These laws include section 721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts 800 and 801, as amended, administered by the Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part through U.S. Commerce Department rulemakings to impose new export control restrictions on &#8220;emerging and foundational technologies&#8221; yet to be fully identified. Application of these laws, including as they are implemented through regulations being developed, may negatively impact our business in various ways, including by restricting our access to capital and markets; limiting the collaborations we may pursue; regulating the export our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to ensure compliance; and threatening monetary fines and other penalties if we do not. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">57<br></div></div></div>
<!--End Page 62-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 63-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may seek Orphan Drug Designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As part of our business strategy, we have obtained Orphan Drug Designation from the FDA for tebentafusp in both uveal and cutaneous melanoma, and we may also seek Orphan Drug Designation for certain of our other product candidates in the future which could be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Similarly, in Europe, the European Commission, upon the recommendation of the EMA&#8217;s Committee for Orphan Medicinal Products, grants Orphan Drug Designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than 5 in 10,000 persons in the European Union and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in European Union would be sufficient to justify the necessary investment in developing the drug. In the European Union, Orphan Drug Designation entitles a party to financial incentives such as reduction of fees or fee waivers. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">58<br></div></div></div>
<!--End Page 63-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 64-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Generally, if a drug with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in the European Union. The European Union exclusivity period can be reduced to six years if a drug no longer meets the criteria for Orphan Drug Designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even when and if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition or if another drug with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we may seek Orphan Drug Designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 11.5pt; margin-left: 0pt; text-align: left;">A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive marketing approval in the United States. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may seek a breakthrough therapy designation for some of our future product candidates. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 11.5pt; margin-left: 0pt; text-align: left;">A Fast Track designation by the FDA, for tebentafusp or even if granted for any other future product candidate(s), may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have obtained Fast Track designation from the FDA for tebentafusp for uveal melanoma, and we may seek Fast Track designation for some of our other future product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even though we have received Fast Track designation for tebentafusp for uveal melanoma, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">59<br></div></div></div>
<!--End Page 64-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 65-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions, and legislative bodies may enact new policies, including unfavorable pricing restrictions, that may adversely affect the development and commercialization of our product candidates, and such changes can be difficult to predict. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The U.S. and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our current or future product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements, (ii)&#160;additions or modifications to product labeling, (iii)&#160;the recall or discontinuation of our products or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There remain judicial and congressional challenges to certain aspects of the ACA as well as efforts by the current presidential administration to repeal or replace certain aspects of the ACA. While Congress has not passed repeal legislation to date, the TCJA, repealed, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On December&#160;14, 2018, a federal district court in Texas ruled the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The current administration and Centers for Medicare &amp; Medicaid Services, or CMS, have both stated that the ruling will have no immediate effect, and on December&#160;18, 2019, the Fifth Circuit U.S. Court of Appeals held that the individual mandate is unconstitutional, and remanded the case to the lower court to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">60<br></div></div></div>
<!--End Page 65-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 66-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reconsider its earlier invalidation of the full ACA. On March&#160;2, 2020, the Supreme Court of the United States granted the petitions for writ of certiorari, and the case is currently under review by the Supreme Court. Pending review, the ACA remains in effect, but it is unclear what effect this litigation and other efforts to repeal and replace the ACA will have on the status of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, and other COVID-19 pandemic relief legislation suspended the 2% Medicare sequester from May&#160;1, 2020 through March&#160;31, 2021. The American Taxpayer Relief Act of 2012 among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the current administration&#8217;s budget for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the current administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Additionally, the current administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out-of-pocket costs of product candidates paid by consumers. The U.S. Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. This final rule codified CMS&#8217;s policy change that was effective January&#160;1, 2019. More recently, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders that are intended to lower the costs of prescription drug products and seek to implement several of the administration's proposals. As a result, the FDA also released a final rule on September 24, 2020 providing guidance for states to build and submit importation plans for drugs from Canada. The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump's Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. However, on December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. The likelihood of implementation of any of the other Trump administration reform initiatives is uncertain, particularly in light of the recent U.S. presidential election. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">61<br></div></div></div>
<!--End Page 66-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 67-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our current or future product candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. For example, on August&#160;6, 2020, the current president issued another executive order that instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement or significant revisions to the ACA, particularly in light of the recent U.S. presidential election. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the demand for our current or future product candidates, if we obtain regulatory approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to set a price that we believe is fair for our products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to obtain coverage and adequate reimbursement for a product; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to generate revenue and achieve or maintain profitability; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of taxes that we are required to pay; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of capital.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">62<br></div></div></div>
<!--End Page 67-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 68-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false of fraudulent claim for purposes of the False Claims Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal physician payment transparency requirements, sometimes referred to as the &#8220;Sunshine Act&#8221; under the Affordable Care Act, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to the Department of Health and Human Services information related to transfers of value made to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests of such physicians and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers including physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">analogous state laws and regulations, such as state anti-kickback and false claims laws may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Further, many state laws governing the privacy and security of health information in certain circumstances, differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations. If </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">63<br></div></div></div>
<!--End Page 68-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 69-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may not be able to file applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or applicable competent authorities may not permit us to proceed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We plan to submit investigational new drug applications, or INDs, for additional product candidates to the FDA in the future. We also plan to submit applications to start clinical trials of additional product candidates outside the U.S. to the national competent authorities (for example, a clinical trial authorization, or CTA, to Medicines and Healthcare products Regulatory Agency, or MHRA, in the United Kingdom).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The filing of INDs to the FDA and the filing of applications outside the U.S. is dependent on additional data that have to be generated to support such regulatory filings. Hence, these filings may be delayed if the tests to generate those data show unexpected results or if technical issues arise in generating those data in the first place. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We cannot be sure that submission of an IND, IND amendment or CTA will result in the FDA or any other competent authority outside the U.S. allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing and pre-clinical safety and efficacy testing requirements of both ImmTAC&#174; and ImmTAAI&#174; remain emerging and evolving fields. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, as well as pre-clinical safety testing, will be a focus of IND reviews, which may delay the allowance of INDs by the FDA or CTA approval by other competent authorities outside the U.S. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA and other government agencies on which our operations may rely are subject to the political process, which is inherently fluid and unpredictable. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">64<br></div></div></div>
<!--End Page 69-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 70-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations due to insufficient funding of the SEC and other government agencies or due to a government shutdown that affects the SEC. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our failure to obtain regulatory approval in international jurisdictions would prevent us from marketing our lead product candidate or any other current or future product candidates outside the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we succeed in developing any products, we intend to market them in non-U.S. jurisdictions in addition to the United States or we may also apply for non-U.S. regulatory approval at the same time as we apply for U.S. regulatory approval. For example, we anticipate submitting a BLA for tebentafusp to the FDA in the third quarter of 2021 followed by an MAA submission to the EMA; however, the trial protocol provides for event driven interim analyses prior to trial completion, which could allow for an earlier BLA submission. In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. We may not obtain non-U.S. regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. Approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. If we fail to obtain approval of any of our product candidates by regulatory authorities in another country we will be unable to commercialize our product in that country, and the commercial prospects of that product candidate and our business prospects could decline. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, we must secure product reimbursement approvals before regulatory authorities will approve the product for sale in that country. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. Also, regulatory approval for any of our product candidates may be withdrawn if we fail to comply with regulatory requirements, if problems occur after the product candidate reaches the market or for other reasons. If we fail to comply with the regulatory requirements in international markets and fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business will be negatively affected.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Relating to our Business Operations, Employee Matters and Managing Growth </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are highly dependent on the research and development, clinical and business development expertise of Dr. Bahija Jallal, Chief Executive Officer, Brian Di Donato, Chief Financial Officer, Dr. David Berman, Head of Research and Development, as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">65<br></div></div></div>
<!--End Page 70-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 71-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In particular, we have experienced competitive hiring environments in our three locations: Oxfordshire, England where we are headquartered, Pennsylvania and Maryland. We may also experience further competition as a result of Brexit. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2020, we had 291 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Our employees, principal investigators, CROs, partners, vendors and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are exposed to the risk that our employees, principal investigators, CROs, partners, vendors and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our pre-clinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">66<br></div></div></div>
<!--End Page 71-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 72-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For example, in the summer and fall of 2020, we conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors between 2018 and 2020. Our audit committee led the investigation utilizing outside counsel, during which the named employee resigned. After the investigation, we terminated the one remaining open contract with the third party vendors and issued proceedings in October 2020 against the involved parties. The amount in question was estimated to be in the range of &#163;1.1 million to &#163;1.8 million, and we recovered &#163;1.8 million from the employee and third-party vendors in December 2020. As a result of this investigation, we identified a material weakness relating to our procurement processes and application of delegation of authority approval limits due to insufficient risk assessment procedures. We determined that our internal controls did not operate effectively to prevent or timely detect unauthorized contracts and purchase orders. This resulted in the inability to prevent and timely detect these fraudulent activities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to adopt, prior to the completion of this offering, a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, imprisonment, disgorgement, additional reporting obligations and oversight, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have a $100&#160;million loan and security agreement with Oxford Finance, or the Loan Agreement, that is secured by a lien covering substantially all of our assets, including intellectual property. As of November&#160;6, 2020, the outstanding principal balance under the Loan Agreement was $50.0&#160;million. An additional $25.0&#160;million is available to us at our option following a BLA approval for tebentafusp so long as it occurs prior to June&#160;30, 2022 and a further $25.0&#160;million is available at our option and at the discretion of Oxford Finance. The Loan Agreement contains customary covenants and events of default applicable to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the agreement governing the Loan Agreement contains, and any agreements evidencing or governing other future indebtedness may contain, certain covenants that limit our ability to engage in certain transactions that may be in our long-term best interests. Subject to certain limited exceptions, these covenants limit our ability to, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">convey, sell, lease, transfer, assign, dispose of or otherwise make cash payments consisting of all or any part of our business or property;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">effect certain changes in our business, management, ownership or business locations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">merge or consolidate with, or acquire all or substantially all of the capital stock or assets of, any other company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create, incur, assume or be liable for any additional indebtedness, or create, incur, allow or permit to exist any additional liens;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pay cash dividends on, make any other distributions in respect of, or redeem, retire or repurchase, any shares of our capital stock;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make certain investments; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into transactions with our affiliates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While we have not previously breached and are not currently in breach of these or any of the other covenants contained in our credit agreement, there can be no guarantee that we will not breach these covenants in the future. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, our lender may choose to declare an event of default </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">67<br></div></div></div>
<!--End Page 72-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 73-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and require that we immediately repay all amounts outstanding, terminate any commitment to extend further credit and foreclose on the collateral granted to it to collateralize such indebtedness. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Business disruptions could seriously harm our future revenue and financial condition and increase costs and expenses. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our operations and those of our third-party suppliers and collaborators could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes or other extreme weather conditions, medical epidemics, labor disputes or other business interruptions. Although we have limited business interruption insurance policies in place, any interruption could come with high costs for us, as salaries and loan payments would usually continue. Moreover, any interruption could seriously harm our ability to timely proceed with any clinical programs or to supply product candidates for use in our clinical programs or during commercialization. For example, the current COVID-19 pandemic is causing an interruption in our clinical trial activities. Specifically, we had to reduce our business activities including those in the laboratory according to governmental orders in the United States as well as in the United Kingdom. Additionally, supply chains disruptions impact and may continue to impact our research activities. Clinical sites involved may not be able to enroll patients into our trials as they have to keep free or use capacities for the treatment of COVID-19 patients. Any of the sites where we conduct clinical trials may announce that they will not enroll further patients into clinical trials until further notice. We currently do not know, how substantial the delay for the development of our product candidates will be. Even if the situation improves in the United States and/or Europe, the impact on supply chains and patient recruitment may last longer.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Computer system failures, cyber-attacks or deficiencies in our or related parties&#8217; cyber security could result in a material disruption of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations, any of which could potentially expose us to liability or reputational harm or otherwise adversely affect our business and financial results.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have implemented our security measures designed to protect the information (including but not limited to intellectual property, proprietary business information and personal information) in our possession, custody or control. Our internal computer systems and those of current and future third parties (such as vendors, CROs, collaborators or others) on which we rely may fail and are vulnerable to breakdown, breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures or other compromise. Despite our security practices, there is a risk that we may be subject to phishing and other cyberattacks in the future. For example, in 2018 and 2019, we experienced two minor phishing attack incidents. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate use, disclosure of or access to confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates or any future product candidates could be hindered or delayed. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with the investigation, remediation and potential notification of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">68<br></div></div></div>
<!--End Page 73-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 74-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the breach to counterparties, data subjects, regulators or others could be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors, CROs, collaborators or other contractors or consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding clinical trial participants or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, cause us to breach our contractual obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to enhance our protective measures or to remediate any information security vulnerability.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in response to the ongoing COVID-19 pandemic, varying parts of our workforce are currently working remotely on a part or full time basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased operating expenses and cash requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the assumption of additional indebtedness or contingent liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assimilation of operations, intellectual property and products of an acquired company or product, including difficulties associated with integrating new personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Depending on the size and nature of future strategic acquisitions, we may acquire assets or businesses that require us to raise additional capital or to operate or manage businesses in which we have limited experience. Making larger acquisitions that require us to raise additional capital to fund the acquisition will expose us to the risks associated with capital raising activities. Acquiring and thereafter operating larger new businesses will also increase our management, operating and reporting costs and burdens. In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">69<br></div></div></div>
<!--End Page 74-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 75-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our insurance policies are expensive and protect only from some business risks, which leaves us exposed to significant uninsured liabilities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not carry insurance for all categories of risks that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. Required coverage limits for such insurances are difficult to predict and may not be sufficient. If potential losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop. Additionally, operating as a public company will make it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult to attract and retain qualified individuals to serve on our board of directors or the board committees.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our current operations are located in Oxfordshire, England, Pennsylvania and Maryland and we or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our current operations are located in Oxfordshire, England, Pennsylvania and Maryland. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, including any potential effects from the current global spread of COVID-19, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Natural disasters or pandemics such as the COVID-19 outbreak could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. For example, certain staff members presently work from home on a part or full time basis and it is possible that this could have a negative impact on the execution of our business plans and operations. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">70<br></div></div></div>
<!--End Page 75-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 76-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Our International Operations </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a company based outside of the United States, we are subject to economic, political, regulatory and other risks associated with international operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a company based in the United Kingdom, our business is subject to risks associated with conducting business outside of the United States. Many of our suppliers and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing and changing regulatory requirements for product approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potentially reduced protection for intellectual property and proprietary rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties in compliance with different, complex and changing laws, regulations and court systems of multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in non-U.S. regulations and customs, tariffs and trade barriers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in non-U.S. currency exchange rates of the pound sterling, U.S. dollar, euro and currency controls; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in a specific country&#8217;s or region&#8217;s political or economic environment, including the implications of the recent decision of the United Kingdom to withdraw from the European Union; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">trade protection measures, import or export licensing requirements or other restrictive actions by governments; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing reimbursement regimes and price controls in certain non-U.S. markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negative consequences from changes in tax laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment in different jurisdictions of options granted under our share option schemes or equity incentive plans; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">workforce uncertainty in countries where labor unrest is more common than in the United States; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">litigation or administrative actions resulting from claims against us by current or former employees or consultants individually or as part of class actions, including claims of wrongful terminations, discrimination, misclassification or other violations of labor law or other alleged conduct; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties associated with staffing and managing international operations, including differing labor relations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The United Kingdom&#8217;s withdrawal from the European Union may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal office space is located in the United Kingdom. The United Kingdom formally exited the European Union, commonly referred to as Brexit, on January&#160;31, 2020. Under the terms of its departure, the United Kingdom entered a transition period, or the Transition Period, during which it continued to follow all European Union rules. The Transition Period ended on December&#160;31, 2020. On December&#160;30, 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">71<br></div></div></div>
<!--End Page 76-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 77-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is considerable uncertainty resulting from a lack of precedent and the complexity of the United Kingdom and EU&#8217;s intertwined legal regimes as to how Brexit (following the Transition Period) will impact the life sciences industry in Europe, including our company, including with respect to ongoing or future clinical trials. Since a significant proportion of the regulatory framework in the United Kingdom applicable to our business and our product candidates is derived from EU directives and regulations, the withdrawal could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom or the European Union. The impact will largely depend on the model and means by which the United Kingdom&#8217;s relationship with the European Union is governed post-Brexit and the extent to which the United Kingdom chooses to diverge from the EU regulatory framework. For example, following the Transition Period, Great Britain will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorizations and our products will therefore require a separate marketing authorization to allow us to market such products in Great Britain. It is unclear as to whether the relevant authorities in the EU and the United Kingdom are adequately prepared for the additional administrative burden caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from or delay us commercializing our product candidates in the United Kingdom and/or the EEA and restrict our ability to generate revenue and achieve and sustain profitability. In the short term, following the expiry of the Transition Period there is a risk of disrupted import and export processes due to a lack of administrative processing capacity by the respective United Kingdom and EU customs agencies that may delay time-sensitive shipments and may negatively impact our product supply chain. Further, under current plans, orphan designation in the United Kingdom (or Great Britain, depending on whether there is a prior centralized marketing authorization in the EEA) following Brexit is to be based on the prevalence of the condition in Great Britain as opposed to the current position where prevalence in the EU is the determinant. It is therefore possible that conditions that are currently designated as orphan conditions in the United Kingdom will no longer be and that conditions are not currently designated as orphan conditions in the European Union will be designated as such in the United Kingdom.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EEA for our product candidates, which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit will have on (i) the marketing of pharmaceutical products, (ii) the process to obtain regulatory approval in the United Kingdom for product candidates or (iii) the award of exclusivities that are normally part of the EU legal framework (for instance Supplementary Protection Certificates, Pediatric Extensions or Orphan exclusivity).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Brexit may also result in a reduction of funding to the EMA once the United Kingdom no longer makes financial contributions to European institutions, such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the European Union. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the European Union will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Exchange rate fluctuations may materially affect our results of operations and financial condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S. dollar, may adversely affect us. Although we are based in the United Kingdom, we source research and development, manufacturing, consulting and other services from the United States and the European Union. Further, potential future revenue may be derived from abroad, particularly from the United </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">72<br></div></div></div>
<!--End Page 77-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 78-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">States. As a result, our business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the euro, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Related to this Offering and Ownership of Our Securities </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">We do not know whether an active, liquid and orderly trading market will develop for our ADSs or what the market price of our ADSs will be. As a result, it may be difficult for you to sell your ADSs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This offering constitutes the initial public offering of our ADSs, and no public market has previously existed for our ADSs or ordinary shares. We have applied to have our ADSs listed on The Nasdaq Global Market, or Nasdaq, and we expect our ADSs to be quoted on Nasdaq, subject to completion of customary procedures in the United States. Any delay in the commencement of trading of the ADSs on Nasdaq would impair the liquidity of the market for the ADSs and make it more difficult for holders to sell the ADSs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to this offering, there was no public trading market for our ordinary shares or ADSs. If the ADSs are listed and quoted on Nasdaq, there can be no assurance that an active trading market for the ADSs will develop or be sustained after this offering is completed. You may not be able to sell your ADSs quickly or at the market price if trading in our ADSs is not active. The initial offering price will be determined by negotiations among the lead underwriters and us. Among the factors considered in determining the initial public offering price will be our future prospects and the prospects of our industry in general, our revenue, net income and certain other financial and operating information in recent periods, and the market prices of securities and certain financial and operating information of companies engaged in activities similar to ours. However, there can be no assurance that, following the completion of this offering, the ADSs will trade at a price equal to or greater than the public offering price. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Raising additional capital may cause dilution to our existing shareholders, restrict our operations or cause us to relinquish valuable rights.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as holder of ADSs. Any indebtedness we incur would result in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any debt or additional equity financing that we raise may contain terms that are not favorable to us or our shareholders. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ADSs to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through strategic partnerships, collaborations, and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies or our product candidates, or grant licenses on terms unfavorable to us.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The market price of our ADSs may be highly volatile, and you may not be able to resell your ADSs at or above the initial public offering price. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The market price of our ADSs following this offering is likely to be highly volatile. The stock market in general, and the market for biopharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your ADSs at or above the initial public offering price. The market price for our ADSs may be influenced by many factors, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse results or delays in pre-clinical studies or clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reports of adverse events in products similar or perceived to be similar to those we are developing or clinical trials of such products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an inability to obtain additional funding; </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">73<br></div></div></div>
<!--End Page 78-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 79-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg63"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us to successfully develop and commercialize our product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us to maintain our existing strategic collaborations or enter into new collaborations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us to identify additional product candidates for our pipeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us or our licensors and strategic partners to prosecute, maintain, protect or enforce our intellectual property and proprietary rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disputes or other developments relating to intellectual and other proprietary rights, including litigation</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">matters and our ability to obtain patent and other intellectual property protection for our technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws or regulations applicable to future products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse regulatory decisions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the introduction of new products, services or technologies by our competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us to meet or exceed financial projections we may provide to the public; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by us to meet or exceed the financial projections of the investment community; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the structure of healthcare payment systems;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic partner or our competitors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions or departures of key scientific or management personnel; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">significant lawsuits, including patent or shareholder litigation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the market valuations of similar companies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general economic, industry, political and market conditions, including, but not limited to, the ongoing impact of the COVID-19 pandemic;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales of our ADSs or ordinary shares by us or our shareholders in the future; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the trading volume of our ADSs. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, companies trading in the stock market in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant securities price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business. Broad market and industry factors may negatively affect the market price of our ADSs, regardless of our actual operating performance. Further, a decline in the financial markets and related factors beyond our control may cause the price of our ADSs to decline rapidly and unexpectedly. If the market price of our ADSs after the completion of this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our ADS price and trading volume could decline. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The trading market for our ADSs will likely depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We do not currently have research coverage, and there can be no assurance that analysts will cover us, or provide favorable coverage. Securities or industry analysts may elect not to provide research coverage of our ADSs after this offering, and such lack of research coverage may negatively impact the market price of our ADSs. In the event </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">74<br></div></div></div>
<!--End Page 79-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 80-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg64"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">we do have analyst coverage, if one or more analysts downgrade our ADSs or change their opinion of our ADSs, our ADS price would likely decline. In addition, if one or more analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our ADS&#160;price or trading volume to decline. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Concentration of ownership of our ordinary shares (including ordinary shares represented by ADSs) among our existing executive officers, directors and principal shareholders may prevent new investors from influencing significant corporate decisions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon completion of the offering, our executive officers, directors and current beneficial owners of five&#160;percent or more of our ordinary shares and their respective affiliates will, in aggregate, beneficially own approximately % of our outstanding ordinary shares, based on the number of ordinary shares outstanding as of December&#160;31, 2020 and assuming the issuance of ordinary shares (including ordinary shares represented by ADSs) in the offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result, depending on the level of attendance at our general meetings of shareholders, these persons, acting together, would be able to significantly influence all matters requiring approval by our shareholders, including the election, re-election and removal of directors, any merger, scheme of arrangement, or sale of all or substantially all of our assets, or other significant corporate transactions, and amendments to our articles of association. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, these persons, acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our ADSs and ordinary shares by: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delaying, deferring, or preventing a change in control; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">entrenching our management and/or the board of directors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impeding a merger, scheme of arrangement, takeover, or other business combination involving us; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">discouraging a potential acquirer from making a takeover offer or otherwise attempting to obtain control of us.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, some of these persons or entities may have interests different than yours. For example, because many of these shareholders purchased their ordinary shares at prices substantially below the price at which ADSs are being sold in this offering and have held their ordinary shares for a longer period, they may be more interested in selling our company to an acquirer than other investors or they may want us to pursue strategies that deviate from the interests of other shareholders. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">We may be required to redeem for cash all, or to facilitate the purchase by a third party of all, the shares of our company held by the Bill &amp; Melinda Gates Foundation if we default under the Global Access Agreement, which could have an adverse impact on us and limit our ability to make distributions to our shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We entered into a Global Access Agreement with our shareholder, the Bill &amp; Melinda Gates Foundation, or the Gates Foundation, in September 2017 pursuant to which we are required to take certain actions to support the Gates Foundation&#8217;s mission. In the event that we are in breach of certain provisions of the Global Access Agreement, following a cure period, we may be required to redeem for cash all, or to facilitate the purchase by a third party of all, the shares of our company held by the Gates Foundation at certain terms that may not be favorable to us. If this occurs, cash used for this purpose may, adversely affect our liquidity, cause us to reduce expenditures in other areas of our business, or curtail our growth plans. If we do not have sufficient cash on hand to purchase the shares, we could have to seek financing alternatives in order to meet our obligations, and there is no certainty that financing would be available on reasonable terms or at all. For the period that we are unable to redeem the shares held by the Gates Foundation or arrange for a third party to purchase such shares, we would not likely be allowed to pay dividends, redeem the shares of any other shareholder or otherwise make any other distribution to any of our shareholders in connection with their shares. Therefore, meeting this purchase obligation, if necessary, could have a material adverse effect on our business and financial results. For more information on the Gates Foundation&#8217;s withdrawal rights, see &#8220;Business - Our Collaborations and License Agreements - Gates Collaboration.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">75<br></div></div></div>
<!--End Page 80-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 81-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg65"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Future sales, or the possibility of future sales, of a substantial number of our securities could adversely affect the price of the shares and dilute shareholders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Sales of a substantial number of our ADSs in the public market could occur at any time, subject to certain restrictions described below. If our existing shareholders sell, or indicate an intent to sell, substantial amounts of our securities in the public market, the trading price of the ADSs could decline significantly and could decline below the public offering price in this offering. Upon completion of this offering, we will have &#8195;&#8195;outstanding ordinary shares (including ordinary shares represented by ADSs), based on the number of shares outstanding as of &#8195;&#8195;&#8195;&#8195;&#8195;, 2020 (or &#8195;&#8195;&#8195;&#8195;&#8195;ordinary shares if the underwriters exercise in full their option to purchase additional ADSs). Of these shares, only the &#8195;&#8195;ADSs sold in the offering will be freely tradable, and the remaining&#160;&#8195;&#8195;ordinary shares will be available for sale in the public market beginning 180 days after the date of this prospectus following the expiration of lock-up agreements entered into by our directors, executive officers and substantially all of our shareholders in connection with the offering. The representatives of the underwriters may agree to release our directors, executive officers or shareholders from their lock-up agreements at any time and without notice, which would allow for earlier sales of ordinary shares in the public market. See &#8220;Shares and American Depositary Shares Eligible for Future Sale.&#8221; After the lock-up agreements pertaining to this offering expire, these &#8195;&#8195;additional ordinary shares will be eligible for sale in the public market, though shares that are held by directors and executive officers and other affiliates and will be subject to volume limitations under Rule&#160;144 under the Securities Act of 1933, as amended, or the Securities Act, for sales in the United States. In addition, ordinary shares subject to outstanding options under our equity incentive plans and the ordinary shares reserved for future issuance under our equity incentive plans will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Sales of a substantial number of such ADSs or ordinary shares upon expiration of the lock-up agreements, the perception that such sales may occur, or early release of restrictions in the lock-up agreements, could cause the market price of our ADSs to fall or make it more difficult for purchasers of ADSs to sell their ADSs at a time and price that they deem appropriate. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Moreover, after this offering, holders of an aggregate of &#8195;&#8195;ordinary shares will have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other shareholders, as well as to cooperate in certain public offerings of such ordinary shares. In addition, we intend to register all ordinary shares that we may issue under our equity compensation plans. Once we register these ordinary shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the &#8220;Shares and American Depositary Shares Eligible for Future Sale&#8221; section of this prospectus. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Holders of ADSs are not treated as holders of our ordinary shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">By participating in this offering you will become a holder of ADSs with underlying ordinary shares in a company incorporated under English law. Holders of ADSs are not treated as holders of our ordinary shares, unless they withdraw the ordinary shares underlying their ADSs in accordance with the deposit agreement and applicable laws and regulations. The depositary is the holder of the ordinary shares underlying the ADSs. Holders of ADSs therefore do not have any rights as holders of our ordinary shares, other than the rights that they have pursuant to the deposit agreement. See &#8220;Description of American Depositary Shares.&#8221; </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Holders of ADSs may be subject to limitations on the transfer of their ADSs and the withdrawal of the underlying ordinary shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADSs are transferable on the books of the depositary. However, the depositary may close its books at any time or from time to time when it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, government or governmental body, or under any provision of the deposit agreement, or for any other reason, subject to the right of ADS holders to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of your ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares. In addition, ADS holders may not be able to cancel their ADSs and withdraw the underlying </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">76<br></div></div></div>
<!--End Page 81-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 82-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg66"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities. See &#8220;Description of American Depositary Shares.&#8221; </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us or to the depositary. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are materially disadvantageous to ADS holders, ADS holders will only receive 30 days&#8217; advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to direct the depositary to terminate the ADS facility at any time for any reason. For example, terminations may occur when we decide to list our ordinary shares on a non-U.S. securities exchange and determine not to continue to sponsor an ADS facility or when we become the subject of a takeover or a going-private transaction. If the ADS facility will terminate, ADS holders will receive at least 30 days&#8217; prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but will have no right to any compensation whatsoever. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, holders and beneficial owners of ADSs irrevocably waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to the ADSs or the deposit agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of the claims, the judge or justice hearing such claims, and the venue of the hearing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">77<br></div></div></div>
<!--End Page 82-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 83-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg67"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">You will not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise your right to vote. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as described in this prospectus and the deposit agreement, holders of the ADSs will not be able to exercise voting rights attaching to the ordinary shares represented by the ADSs. Under the terms of the deposit agreement, holders of the ADSs may instruct the depositary to vote the ordinary shares underlying their ADSs. Otherwise, holders of ADSs will not be able to exercise their right to vote unless they withdraw the ordinary shares underlying their ADSs to vote them in person or by proxy in accordance with applicable laws and regulations and our articles of association. Even so, ADS holders may not know about a meeting far enough in advance to withdraw those ordinary shares. If we ask for the instructions of holders of the ADSs, the depositary, upon timely notice from us, will notify ADS holders of the upcoming vote and arrange to deliver our voting materials to them. Upon our request, the depositary will mail to holders a shareholder meeting notice that contains, among other things, a statement as to the manner in which voting instructions may be given. We cannot guarantee that ADS holders will receive the voting materials in time to ensure that they can instruct the depositary to vote the ordinary shares underlying their ADSs. A shareholder is only entitled to participate in, and vote at, the meeting of shareholders, provided that it holds our ordinary shares as of the record date set for such meeting and otherwise complies with our articles of association. In addition, the depositary&#8217;s liability to ADS holders for failing to execute voting instructions or for the manner of executing voting instructions is limited by the deposit agreement. As a result, holders of ADSs may not be able to exercise their right to give voting instructions or to vote in person or by proxy and they may not have any recourse against the depositary or us if their ordinary shares are not voted as they have requested or if their shares cannot be voted. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">You may not receive distributions on our ordinary shares represented by the ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on our ordinary shares or other deposited securities after deducting its fees and expenses. You will receive these distributions in proportion to the number of our ordinary shares your ADSs represent. However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit distribution on the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that you may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them available to you. These restrictions may have an adverse effect on the value of your ADSs. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Because we do not anticipate paying any cash dividends on our ADSs in the foreseeable future, capital appreciation, if any, will be your sole source of gains and you may never receive a return on your investment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under current English law, a company&#8217;s accumulated realized profits must exceed its accumulated realized losses (on a non-consolidated basis) before dividends can be declared and paid. Therefore, we must have distributable profits before declaring and paying a dividend. In addition, as a public limited company incorporated in England and Wales, we will only be able to make a distribution if the amount of our net assets is not less than the aggregate of our called-up share capital and undistributable reserves and if, and to the extent that, the distribution does not reduce the amount of those assets to less than that aggregate. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have not paid dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs will be your sole source of gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs at or above the initial public offering price. Investors seeking cash dividends should not purchase our ADSs in this offering. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If you purchase our ADSs in this offering, you will incur immediate and substantial dilution in the book value of your shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Investors purchasing ADSs in this offering will pay a price per ordinary share that substantially exceeds the pro forma book value per share of our tangible assets after subtracting our liabilities. As a result, investors purchasing ADSs in this offering will incur immediate dilution of $&#8195;&#8195; per ADS, based on the assumed initial public offering price of $&#8195;&#8195; per ADS, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, representing the difference between the assumed initial public offering </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">78<br></div></div></div>
<!--End Page 83-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 84-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg68"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">price and our pro forma as adjusted net tangible book value as of September&#160;30, 2020 after giving effect to this offering. Further, investors purchasing ADSs in this offering will contribute approximately &#8195;&#8195;% of the total amount invested by shareholders since our inception, but will own only approximately &#8195;&#8195;% of the ordinary shares outstanding. Furthermore, if the underwriters exercise their option to purchase additional shares or our previously issued options to acquire ordinary shares at prices below the assumed initial public offering price are exercised, you will experience further dilution. For additional information on the dilution that you will experience immediately after this offering, see the section titled &#8220;Dilution.&#8221; </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our shareholders. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Claims of U.S. civil liabilities may not be enforceable against us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are incorporated under English law and have our registered office in England. Certain members of our board of directors and senior management are non-residents of the United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S. courts against them or us based on civil liability provisions of the securities laws of the United States. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The United States and the United Kingdom do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the United Kingdom. In addition, uncertainty exists as to whether U.K. courts would entertain original actions brought in the United Kingdom against us or our directors or senior management predicated upon the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may from time to time distribute rights to our shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless either both the rights and any related securities are registered under the Securities Act, or the distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration statement to be declared effective. Moreover, we may not be able to establish an exemption from registration </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">79<br></div></div></div>
<!--End Page 84-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 85-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg69"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if possible, or allow them to lapse. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than U.S. public companies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a &#8220;foreign private issuer,&#8221; as defined in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable to companies organized within the United States. For example, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a foreign private issuer, we will file an annual report on Form 20-F within four months of the close of each fiscal year ended December 31 and reports on Form 6-K relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions for foreign private issuers, our shareholders will not be afforded the same protections or information generally available to investors holding shares in public companies organized in the United States. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">While we are a foreign private issuer, we are not subject to certain Nasdaq corporate governance rules applicable to public companies organized in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are entitled to rely on a provision in Nasdaq&#8217;s corporate governance rules that allows us to follow English corporate law with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices that differ in significant respects from the corporate governance requirements applicable to domestic issuers listed on Nasdaq.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are not subject to Nasdaq Listing Rule 5605(b)(2) because English law does not require that independent directors regularly have scheduled meetings at which only independent directors are present. Similarly, we have adopted a compensation committee, but English law does not require that we adopt a compensation committee or that such committee be fully independent. As a result, our practice varies from the requirements of Nasdaq Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees. English law requires that we disclose information regarding compensation of our directors for services as a director of an undertaking that is our subsidiary undertaking and as a director of any other undertaking of which a director is appointed by virtue of our nomination (directly or indirectly) but not other third-party compensation of our directors or director nominees. As a result, our practice varies from the third-party compensation disclosure requirements of Nasdaq Listing Rule 5250(b)(3). In addition, while we have a compensation committee, English law does not require that we adopt a compensation committee or that such committee be fully independent. Additionally, we are not subject to Nasdaq Listing Rule 5605(e) because, under English law, director nominees are not required to be selected or recommended for selection by either a majority of the independent directors or a nominations committee comprised solely of independent directors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, English law does not have a regulatory regime for the solicitation of proxies applicable to us, thus our practice varies from the requirement of Nasdaq Listing Rule 5620(b), which sets forth certain requirements regarding the solicitation of proxies. In addition, we have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice will vary from the requirements of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. In addition, while we have adopted a code of business conduct and ethics, English law does not require us to publicly disclose waivers from this code that have been approved by our board within four business days. We expect to report any such waivers in the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">80<br></div></div></div>
<!--End Page 85-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 86-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg70"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">subsequent Annual Report on Form 20-F. Moreover, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information, although we have voluntarily adopted a corporate disclosure policy substantially similar to Regulation FD. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result, our practice varies from the requirements for domestic issuers pursuant to Nasdaq Listing Rule&#160;5610. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with our Nasdaq listing, our audit committee is required to comply with the provisions of Section 301 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and Rule 10A-3 of the Exchange Act, both of which are also applicable to Nasdaq listed U.S. companies. Because we are a foreign private issuer, however, our audit committee is not subject to additional requirements applicable to Nasdaq listed U.S. companies, including an affirmative determination that all members of the audit committee are &#8220;independent,&#8221; using more stringent criteria than those applicable to us as a foreign private issuer, subject to certain phase-in requirements permitted by Rule 10A-3 of the Exchange Act.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">We are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our ADSs less attractive to investors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are an emerging growth company and we will remain an emerging growth company until the earlier to occur of (1) the last day of 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at least $1.07&#160;billion, (3) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer,&#8221; under the rules of the U.S. Securities and Exchange Commission, or SEC, which means the market value of our equity securities that is held by non-affiliates exceeds $700&#160;million as of the prior June 30th, and (4) the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or Section 404; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">not being required to comply with any requirement that has or may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">being permitted to provide only two years of audited financial statements in this initial registration statement, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduced disclosure obligations regarding executive compensation; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exemption from the requirement to seek nonbinding advisory votes on executive compensation or golden parachute arrangements. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have not included all of the executive compensation information that would be required if we were not an EGC. We cannot predict whether investors will find our ADSs less attractive if we rely on certain or all of these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and our ADS price may be more volatile. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, the JOBS Act provides that an EGC may take advantage of an extended transition period for complying with new or revised accounting standards. This allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">81<br></div></div></div>
<!--End Page 86-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 87-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg71"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; if the market value of our ordinary shares held by non-affiliates is below $250&#160;million (or&#160;$700&#160;million if our annual revenue is less than $100&#160;million) as of June 30 in any given year, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We will incur increased costs as a result of operating as a company whose ADSs are publicly traded in the United States, and our management will be required to devote substantial time to new compliance initiatives. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a company whose ADSs are publicly traded in the United States, and particularly after we are no longer an EGC, we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on publicly traded companies of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk we will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We have identified a material weakness in our internal control over financial reporting and may identify material weaknesses in the future or otherwise fail to maintain proper and effective internal controls, which may impair our ability to produce timely and accurate financial statements or prevent fraud. If we are unable to establish and maintain effective internal controls, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Although we are not yet subject to the certification or attestation requirements of Section 404 of the Sarbanes-Oxley Act, in the course of auditing our financial statements for this offering, we and our independent registered public accounting firm identified a material weakness in our internal control over financial reporting. A company&#8217;s internal control over financial reporting is a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with IFRS. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the summer and fall of 2020, we conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors between 2018 and 2020. Our audit committee led the investigation utilizing outside counsel, during which the named employee resigned. After the investigation, we terminated the one remaining open contract with the third party vendors and issued proceedings in October 2020 against the involved parties. The amount in question was estimated to be in the range of &#163;1.1 million to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">82<br></div></div></div>
<!--End Page 87-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 88-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg72"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#163;1.8 million, and we recovered &#163;1.8 million from the employee and third-party vendors in December 2020. As a result of this investigation, we identified a material weakness relating to our procurement processes and application of delegation of authority approval limits due to insufficient risk assessment procedures. We determined that our internal controls did not operate effectively to prevent or timely detect unauthorized contracts and purchase orders. This resulted in the inability to prevent and timely detect these fraudulent activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have taken and continue to take steps to remediate the aforementioned material weakness and to enhance our overall control environment, including adding personnel to drive and implement required additional procurement controls, implementing improvements in software relating to approvals of purchase orders and contracts, adding additional layers of review of contracts and journal entries and delegation of contract authority limits. The actions that we are taking are subject to ongoing executive management review, and will be subject to audit committee oversight. Although we intend to complete this remediation process as quickly as practicable, we cannot at this time estimate how long it will take, and our initiatives may not prove to be successful in remediating the material weakness.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a public company, we will be subject to reporting obligations under U.S. securities laws, including the Sarbanes-Oxley Act of 2002. Section 404(a) of the Sarbanes-Oxley Act, or Section 404(a), will require that, beginning with our second annual report following our initial public offering, management assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses in our internal control over financial reporting. We expect our first Section 404(a) assessment will take place for our annual report for the fiscal year ending December&#160;31, 2021. If we fail to remediate the material weakness identified above, our management may conclude that our internal control over financial reporting is not effective. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over financial reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply with SEC rules that implement Section 404(b) until such time as we are no longer an emerging growth company. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. If we are unable to successfully remediate our identified material weakness, if we discover additional material weaknesses, or if we otherwise are unable to otherwise determine on an ongoing basis that we have effective internal control over financial reporting, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and the price of our ADSs may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities. Our disclosure controls and procedures may not prevent or detect allerrors or acts of fraud.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected. </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we are a controlled foreign corporation, there could be adverse U.S. federal income tax consequences to certain U.S. holders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a U.S. holder is treated as owning, directly, indirectly or constructively, at least 10% of the value or voting power of our ordinary shares or ADSs, such U.S. holder may be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221; in our group, if any. Because our group includes U.S. subsidiaries, our current non-U.S. subsidiaries and any future newly formed or acquired non-U.S. subsidiaries will be treated as controlled foreign corporations, regardless of whether we are treated as a controlled foreign </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">83<br></div></div></div>
<!--End Page 88-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 89-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg73"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">corporation. A United States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S.&#160;taxable income its pro rata share of &#8220;Subpart F income,&#8221; &#8220;global intangible low-taxed income&#8221; and investments in U.S. property by controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with controlled foreign corporation reporting obligations may subject a United States shareholder to significant monetary penalties. We cannot provide any assurances that we will furnish to any United States shareholder information that may be necessary to comply with the reporting and tax paying obligations applicable under the controlled foreign corporation rules of the Internal Revenue Code of 1986, as amended, or the Code. U.S. holders should consult their tax advisors regarding the potential application of these rules to their investment in our ordinary shares or ADSs.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If we are a passive foreign investment company, or PFIC, for any taxable year, there could be adverse U.S. federal income tax consequences to U.S. investors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Code, we will be a PFIC, for any taxable year in which (1) 75% or more of our gross income consists of passive income or (2) 50% or more of the value of our assets (generally determined in the basis of a weighted quarterly average) consists of assets that produce, or are held for the production of, passive income (including cash). For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. Cash and cash-equivalents are passive assets for these purposes. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. investor holds our shares, the U.S. investor may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Based on our analysis of our activities and current estimates (and not fully audited financials) of the composition of our income and assets, we believe that we were not a PFIC for our most recent taxable year. However, the determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year. In addition, for our current and future taxable years, the total value of our assets (including goodwill) for PFIC testing purposes may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Accordingly, if our market capitalization declines while we hold a substantial amount of cash and cash-equivalents for any taxable year we may be a PFIC for that taxable year. Under the income test, our status as a PFIC depends on the composition of our income for the relevant taxable year which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how we spend the cash we raise in any offering, including this offering. We currently do not generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate sufficient amounts of active income to offset our passive financing income. Therefore, we cannot express an expectation regarding our PFIC status for the current or any future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the Internal Revenue Service, or IRS, will agree with our conclusion and that the IRS would not successfully challenge our position. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S. investors, see the section of this prospectus titled &#8220;Material Income Tax Considerations &#8212; Material United States Federal Income Considerations for U.S. Holders.&#8221;</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable U.K. tax legislation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a U.K. incorporated and tax resident entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses since inception and therefore have not paid any U.K. corporation tax. As of December&#160;31, 2019, we had cumulative carryforward tax losses of &#163;127.2 million. Subject to any relevant </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">84<br></div></div></div>
<!--End Page 89-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 90-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg74"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">utilization criteria and restrictions (for example, the use of loss carryforwards in relation to U.K. profits incurred on or after April&#160;1, 2017 will be limited each year to &#163;5.0&#160;million per group plus, broadly, an incremental 50%&#160;of U.K. taxable profits), we expect these to be eligible for carry forward against future operating profits.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a company that carries out extensive research and development activities, we seek to benefit from the U.K. research and development tax relief programs, being the Small and Medium-sized Enterprises R&amp;D tax relief program, or SME Program, and, to the extent that our projects are grant funded or relate to work subcontracted to the company by third parties, the Research and Development Expenditure Credit program, or RDEC Program. The tax reliefs we have obtained under these programs have generated a meaningful proportion of our cash flow, amounting to &#163;13.5 million and &#163;38.9 million in the accounting periods ending December 31, 2019 and September 30, 2020, respectively. Under the SME Program, we may be able to surrender the trading losses that arise from our qualifying research and development activities for a cash rebate of up to 33.35% of such qualifying research and development expenditures. The majority of our pipeline research, clinical trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. We may not be able to continue to claim payable research and development tax credits in the future if we cease to qualify as a SME, based on size criteria concerning employee headcount, turnover and gross assets. On October&#160;29, 2018, the U.K. Government announced its intention to cap the amount of payable credit that a qualifying loss-making SME business can receive through R&amp;D relief in any one year. Although the implementation of this measure has been delayed, the U.K. Government has stated that it remains committed to the reform and, subject to the outcome of further consultation, intends to introduce the cap on payable credit claims in excess of &#163;20,000 with effect from April 2021 by reference to, broadly, three times the total PAYE and NICs liability of the company. If such cap comes into force, this could restrict the amount of payable credit that we claim.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may benefit in the future from the United Kingdom&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable to revenues from patented products (and other qualifying income) to be taxed at an effective rate of 10% by giving an additional tax deduction. We are the owner of several patent applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues and royalties could be eligible for this deduction. When taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term rate of corporation tax lower than the statutory to apply to us. If, however, there are unexpected adverse changes to the U.K. research and development tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. This may impact our ongoing requirement for investment and the timeframes within which additional investment is required.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes and uncertainties in the tax system in the countries in which we have operations, could materially adversely affect our financial condition and results of operations, and reduce net returns to our shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We conduct business globally and file income tax returns in multiple jurisdictions. Our consolidated effective income tax rate, and the tax treatment of our ADSs and ordinary shares, could be materially adversely affected by several factors, including: changing tax laws, regulations and treaties, or the interpretation thereof; tax policy initiatives and reforms under consideration (such as those related to the Organisation for Economic Co-Operation and Development&#8217;s, or OECD, Base Erosion and Profit Shifting, or BEPS, Project, the European Commission&#8217;s state aid investigations and other initiatives); the practices of tax authorities in jurisdictions in which we operate; the resolution of issues arising from tax audits or examinations and any related interest or penalties. Such changes may include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context of withholding tax) dividends paid, or the stamp duty or stamp duty reserve tax treatment of our ADSs or ordinary shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are unable to predict what tax reform may be proposed or enacted in the future or what effect such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies or practices in jurisdictions in which we operate, could increase the estimated tax liability that we have expensed to date and paid or accrued on our statement of financial position, and otherwise affect our financial position, future results of operations, cash flows in a particular period and overall or effective tax rates in the future in countries where we have operations, reduce post-tax returns to our shareholders and increase the complexity, burden and cost of tax compliance.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">85<br></div></div></div>
<!--End Page 90-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 91-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg75"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Tax authorities may disagree with our positions and conclusions regarding certain tax positions, or may apply existing rules in an unforeseen manner, resulting in unanticipated costs, taxes or non-realization of expected benefits.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&#8217;s Revenue &amp; Customs, or HMRC, the IRS or another tax authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to our intellectual property development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">HMRC may decline to grant relief from stamp duty for which we currently intend to apply under section&#160;77 of the Finance Act 1986 in respect of the share for share exchange effected pursuant to our corporate reorganization. See the section titled &#8220;Corporate Reorganization&#8221; elsewhere in this prospectus. If HMRC does decline to grant relief, stamp duty will arise at a rate of 0.5%, chargeable on the greater of the amount or value of the consideration given (being the value of the shares issued by the company to each shareholder of Immunocore Limited) and the market value of the shares in Immunocore Limited at the time of the share for share exchange. Stamp duty reserve tax will also be chargeable on the agreement to enter into the share for share exchange, although such liability would be canceled, or if already paid, repaid, if stamp duty is duly paid on the relevant instruments of transfer within a period of six years from the stamp duty reserve tax charge arising or if the relevant instruments of transfer are otherwise exempt from stamp duty.</div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Shareholder protections found in provisions under the U.K. City Code on Takeovers and Mergers, or the Takeover Code, will not apply if our place of management and control remains outside the United Kingdom. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the consummation of this offering, we will re-register as a public limited company incorporated in England and Wales. We believe that, as of the date of this document, our place of central management and control is not in the United Kingdom (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are currently not subject to the Takeover Code and, as a result, our shareholders are not currently entitled to the benefit of certain takeover offer protections provided under the Takeover Code, including the rules regarding mandatory takeover bids. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event that this changes, or if the interpretation and application of the Takeover Code by the Panel on Takeovers and Mergers, or Takeover Panel, changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside of the United Kingdom), the Takeover Code may apply to us in the future.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Takeover Code provides a framework within which takeovers of companies are regulated and conducted. The following is a brief summary of some of the most important rules of the Takeover Code:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In connection with a potential offer, if following an approach by or on behalf of a potential bidder, the company is &#8220;the subject of rumor or speculation&#8221; or there is an &#8220;untoward movement&#8221; in the company&#8217;s share price, there is a requirement for the potential bidder to make a public announcement about a potential offer for the company, or for the company to make a public announcement about its review of a potential offer.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">When a person or group of persons acting in concert (a) acquires, whether by a series of transactions over a period of time or not, interests in shares carrying 30% or more of the voting rights of a company (which percentage is treated by the Takeover Code as the level at which effective control is obtained) or (b) acquires an interest in any other shares which increases the percentage of shares </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">86<br></div></div></div>
<!--End Page 91-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 92-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg76"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">carrying voting rights in which they are interested when they are already interested in shares which carry not less than 30% of the voting rights but do not hold shares carrying more than 50% of such voting rights, they must make a cash offer to all other shareholders at the highest price paid by them or any person acting in concert with them in the 12 months before the offer was announced.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">When interests in shares carrying 10% or more of the voting rights of a class have been acquired by an offeror (i.e., a bidder) and any person acting in concert with it in the offer period (i.e., before the shares subject to the offer have been acquired) or within the previous 12 months, the offer must be in cash or be accompanied by a cash alternative for all shareholders of that class at the highest price paid by the offeror or any person acting in concert with them in that period. Further, if an offeror or any person acting in concert with them acquires any interest in shares during the offer period, the offer for the shares must be in cash or accompanied by a cash alternative at a price at least equal to the price paid for such shares during the offer period.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If after an announcement is made, the offeror or any person acting in concert with them acquires an interest in shares in an offeree company (i.e., a target) at a price higher than the value of the offer, the offer must be increased to not less than the highest price paid for the interest in shares so acquired.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The board of directors of the offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the shareholders, together with the opinion of the board of directors of the offeree company.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Special or favorable deals for selected shareholders are not permitted, except in certain circumstances where independent shareholder approval is given and the arrangements are regarded as fair and reasonable in the opinion of the financial adviser to the offeree. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All shareholders must be given the same information. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each document published in connection with an offer by or on behalf of the offeror or offeree must state that the directors of the offeror or the offeree, as the case may be, accept responsibility for the information contained therein.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by professional advisers.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve these plans. Frustrating actions would include, for example, lengthening the notice period for directors under their service contract or agreeing to sell off material parts of the target group.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Stringent and detailed requirements are laid down for the disclosure of dealings in relevant securities during an offer, including the prompt disclosure of positions and dealing in relevant securities by the parties to an offer and any person who is interested (directly or indirectly) in 1% or more of any class of relevant securities. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3.5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Employees of both the offeror and the offeree company and the trustees of the offeree company&#8217;s pension scheme must be informed about an offer. In addition, the offeree company&#8217;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#8217; circular or published on a website. </div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs, are governed by English law, including the provisions of the U.K. Companies Act, or the Companies Act, and by our articles of association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See &#8220;Description of Share Capital and Articles of Association &#8212; Differences in Corporate Law&#8221; in this prospectus for a description of the principal differences between the provisions of the Companies Act applicable to us and, for example, the Delaware General Corporation Law relating to shareholders&#8217; rights and protections. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">87<br></div></div></div>
<!--End Page 92-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 93-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg77"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The principal differences include the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">under our articles of association to be effective upon completion of this offering, any resolution put to the vote of a general meeting must be decided exclusively on a poll. Under English law, it would be possible for our articles of association to be amended such that each shareholder present at a meeting has only one vote unless demand is made for a vote on a poll, in which case each holder gets one vote per share owned. Under U.S. law, each shareholder typically is entitled to one vote per share at all meetings;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">under English law, subject to certain exceptions and disapplications, each shareholder generally has preemptive rights to subscribe on a proportionate basis to any issuance of ordinary shares or rights to subscribe for, or to convert securities into, ordinary shares for cash. Under U.S. law, shareholders generally do not have preemptive rights unless specifically granted in the certificate of incorporation or otherwise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">under English law and our articles of association, certain matters require the approval of 75% of the shareholders who vote (in person or by proxy) on the relevant resolution (or on a poll of shareholders representing 75% of the ordinary shares voting (in person or by proxy)), including amendments to the articles of association. This may make it more difficult for us to complete corporate transactions deemed advisable by our board of directors. Under U.S. law, generally only majority shareholder approval is required to amend the certificate of incorporation or to approve other significant transactions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the United Kingdom, takeovers may be structured as takeover offers or as schemes of arrangement. Under English law, a bidder seeking to acquire us by means of a takeover offer would need to make an offer for all of our outstanding ordinary shares/ADSs. If acceptances are not received for 90% or more of the ordinary shares/ADSs under the offer, under English law, the bidder cannot complete a &#8220;squeeze out&#8221; to obtain 100% control of us. Accordingly, acceptances of 90% of our outstanding ordinary shares/ADSs will likely be a condition in any takeover offer to acquire us, not 50% as is more common in tender offers for corporations organized under Delaware law. By contrast, a scheme of arrangement, the successful completion of which would result in a bidder obtaining 100% control of us, requires the approval of a majority of shareholders voting at the meeting and representing 75% of the ordinary shares voting for approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">under English law and our articles of association, shareholders and other persons whom we know or have reasonable cause to believe are, or have been, interested in our shares may be required to disclose information regarding their interests in our shares upon our request, and the failure to provide the required information could result in the loss or restriction of rights attaching to the shares, including prohibitions on certain transfers of the shares, withholding of dividends and loss of voting rights. Comparable provisions generally do not exist under U.S. law; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the quorum requirement for a shareholders&#8217; meeting is a minimum of two shareholders entitled to vote at the meeting and present in person or by proxy or, in the case of a shareholder which is a corporation, represented by a duly authorized representative. Under U.S. law, a majority of the shares eligible to vote must generally be present (in person or by proxy) at a shareholders&#8217; meeting in order to constitute a quorum. The minimum number of shares required for a quorum can be reduced pursuant to a provision in a company&#8217;s certificate of incorporation or bylaws, but typically not below one-third of the shares entitled to vote at the meeting. </div></td></tr></table><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">As an English public limited company, certain capital structure decisions will require shareholder approval, which may limit our flexibility to manage our capital structure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the completion of the Share Exchange and prior to the consummation of this offering, we will alter the legal status of our company under English law from a private limited company by re-registering as a public limited company and changing our name from Immunocore Holdings Limited to Immunocore Holdings plc. English law provides that a board of directors may only allot shares (or&#160;rights to subscribe for or convert any security into shares) with the prior authorization of shareholders, such authorization stating the aggregate nominal amount of shares that it covers and being valid for a maximum period of five years, each as specified in the articles of association or relevant shareholder resolution. We have obtained authority from our shareholders to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">88<br></div></div></div>
<!--End Page 93-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 94-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_105-risk_pg78"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">allot additional shares for a period of five years from &#8195;&#8195;&#8195;, 2021, which authorization will need to be renewed upon expiration (i.e., at least every five years) but may be sought more frequently for additional five-year terms (or any shorter period). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">English law also generally provides shareholders with preemptive rights when new shares are issued for cash. However, it is possible for the articles of association, or for shareholders to pass a special resolution at a general meeting, being a resolution passed by at least 75% of the votes cast, to disapply preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder special resolution, if the disapplication is by shareholder special resolution but not longer than the duration of the authority to allot shares to which the disapplication relates. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (i.e., at least every five years). We have obtained authority from our shareholders to disapply preemptive rights for a period of five years from&#160;&#8195;&#8195;&#8195;,&#160;2021 which disapplication will need to be renewed upon expiration (i.e., at least every five years), but may be sought more frequently for additional five-year terms (or any shorter period). </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">English law also generally prohibits a public company from repurchasing its own shares without the prior approval of shareholders by ordinary resolution, being a resolution passed by a simple majority of votes cast, and other formalities. Such approval may be for a maximum period of up to five years. See &#8220;Description of Share Capital and Articles of Association.&#8221; </div><div class="frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Our articles of association to be effective in connection with this offering will provide that the courts of England and Wales will be the exclusive forum for the resolution of all shareholder complaints other than complaints asserting a cause of action arising under the Securities Act and the Exchange Act, and that the U.S. District Court for the Southern District of New York will be the exclusive forum for the resolution of any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association to be effective in connection with this offering will provide that the courts of England and Wales will be the exclusive forum for resolving all shareholder complaints (i.e., any derivative action or proceeding brought on behalf of us, any action or proceeding asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees, any action or proceeding asserting a claim arising out of any provision of the Companies Act or our articles of association or any action or proceeding asserting a claim or otherwise related to the affairs of our company) other than shareholder complaints asserting a cause of action arising under the Securities Act or the Exchange Act, and that the U.S. District Court for the Southern District of New York will be the exclusive forum for resolving any shareholder complaint asserting a cause of action arising under the Securities Act or the Exchange Act, including applicable claims arising out of this offering. In addition, our articles of association will provide that any person or entity purchasing or otherwise acquiring any interest in our shares is deemed to have notice of and consented to these provisions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This choice of forum provision may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. The enforceability of similar exclusive forum provisions (including exclusive federal forum provisions for actions, suits or proceedings asserting a cause of action arising under the Securities Act) in other companies&#8217; organizational documents has been challenged in legal proceedings, and there is uncertainty as to whether courts would enforce the exclusive forum provisions in our articles of association. Additionally, our shareholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If a court were to find either choice of forum provision contained in our articles of association to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our results of operations and financial condition.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">89<br></div></div></div>
<!--End Page 94-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 95-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_106-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSNR"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this prospectus are based upon information available to us as of the date of this prospectus and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements include, but are not limited to, statements about: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and related preparatory work and the period during which the results of the trials will become available, as well as our research and development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding timing of regulatory filings for, or our ability to obtain regulatory approval of, tebentafusp or any of our other product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify and develop additional product candidates using our ImmTAX platform; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business disruptions affecting the initiation, patient enrollment, development and operation of our clinical trials, including a public health emergency, such as the ongoing the coronavirus 2019, or COVID-19, pandemic; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential benefits of our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the potential market size and the rate and degree of market acceptance for any product candidates that we develop;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our business strategies and goals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our plans to collaborate, or statements regarding our current collaborations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to find future partners and collaborators; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the performance of our third-party suppliers and manufacturers,</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding our ability to obtain, maintain and enforce intellectual property protection for our product candidates and our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effects of competition with respect to tebentafusp or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our financial performance and our ability to effectively manage our anticipated growth;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to identify, recruit and retain key personnel; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expectations regarding the uses of the proceeds from this offering and the sufficiency of such net proceeds together with our existing cash and cash equivalents to fund our operations and capital expenditures. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">90<br></div></div></div>
<!--End Page 95-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 96-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_106-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, applicable regulations or the rules of any stock exchange to which we are subject. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">91<br></div></div></div>
<!--End Page 96-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 97-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_106-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tIAM"><!--Anchor--></a>INDUSTRY AND MARKET DATA </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our diagnostic products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we believe our internal company research as to such matters is reliable and the market definitions are appropriate, neither such research nor these definitions have been verified by any independent source.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, assumptions and estimates of our and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk factors.&#8221; These and other factors could cause our future performance to differ materially from our assumptions and estimates. See &#8220;Special note regarding forward-looking statements.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">92<br></div></div></div>
<!--End Page 97-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 98-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_106-fls_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUSE"><!--Anchor--></a>USE OF PROCEEDS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We estimate that the net proceeds from the sale of &#8195;&#8195;&#8195;ADSs in this offering will be approximately $&#8195;&#8195; million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, based on an assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus. If the underwriters exercise in full their option to purchase additional&#8195;&#8195;&#8195;&#8195; ADSs, we estimate that the net proceeds to us from this offering will be approximately $&#8195;&#8195;&#8195; million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS would increase (decrease) the net proceeds from this offering to us by $ &#8195;&#8195;&#8195;million, assuming that the total number of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, remains the same. Similarly, an increase (decrease) of 1,000,000 in the number of ADSs offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds from this offering to us by $ &#8195;&#8195;&#8195;million, assuming the assumed initial public offering price per ADS remains the same. This as adjusted information is illustrative only and will depend on the actual offering price and other terms of this offering determined at pricing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $ &#8195;&#8195;&#8195;million to $&#8195;&#8195;&#8195; million to fund tebentafusp, our lead ImmTAC, for the treatment of metastatic uveal melanoma through the completion of our Phase 3 clinical trial as well as preparations for a commercial launch; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195;&#8195; million to $ &#8195;&#8195;&#8195;million to advance the clinical development of IMC-C103C targeting MAGE A4 for the treatment of solid tumors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $ &#8195;&#8195;&#8195;million to $&#8195;&#8195;&#8195; million to advance the clinical development of IMC-F106C targeting PRAME for the treatment of solid tumors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $&#8195;&#8195;&#8195; million to $&#8195;&#8195;&#8195; million to advance the clinical development of IMC-I109V targeting a functional cure for chronic HBV; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approximately $ &#8195;&#8195;&#8195;million to $&#8195;&#8195;&#8195; million to continue to advance our pre-clinical programs and invest in our ImmTAX platform to discover and develop novel therapeutics; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the remainder for working capital and general corporate purposes.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We may also use a portion of the net proceeds to in-license, acquire or invest in additional businesses, technologies, products or assets. We cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend on the uses set forth above. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. See &#8220;Risk Factors&#8212;We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on our planned use of the net proceeds from this offering and our existing cash and cash equivalents, we estimate that such funds will be sufficient to fund our operations and capital expenditure requirements through at least&#8195;&#8195;&#8195; . We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We expect that we will require additional funding to successfully commercialize tebentafusp and to complete the clinical development of any of our other current or future product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pending our use of proceeds from this offering, we plan to invest these net proceeds in a variety of capital preservation instruments, including short term, interest bearing obligations and investment grade instruments.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">93<br></div></div></div>
<!--End Page 98-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 99-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_106-fls_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDPY"><!--Anchor--></a>DIVIDEND POLICY</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since our incorporation, we have not declared or paid any dividends on our issued share capital. We intend to retain any earnings for use in our business and do not currently intend to pay dividends on our ordinary shares or ADSs. The declaration and payment of any future dividends will be at the discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions, any future debt agreements or applicable laws and other factors that our board of directors may deem relevant.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the laws of England and Wales, among other things, we may only pay dividends if we have sufficient distributable reserves (on a non-consolidated basis), which are our accumulated realized profits that have not been previously distributed or capitalized less our accumulated realized losses, so far as such losses have not been previously written off in a reduction or reorganization of capital. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">94<br></div></div></div>
<!--End Page 99-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 100-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCRN"><!--Anchor--></a>CORPORATE REORGANIZATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immunocore Holdings Limited was incorporated on January 7, 2021 under the laws of England and Wales with nominal assets and liabilities for the purpose of becoming the holding company of Immunocore Limited and consummating the corporate reorganization described herein. Immunocore Limited was incorporated under the laws of England and Wales in December 2007. Immunocore Holdings Limited is a holding company which will not conduct any operations prior to this offering other than activities incidental to its formation, the corporate reorganization and this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the terms of the Share Exchange described below, as part of our corporate reorganization, all shareholders of Immunocore Limited will exchange each of the shares held by them for 100 newly issued shares of the same class, and with the same rights attaching thereto, of Immunocore Holdings Limited and, as a result, Immunocore Limited will become a wholly-owned subsidiary of Immunocore Holdings Limited. Subsequently, it is intended to re-register Immunocore Holdings Limited as a public limited company and rename it as Immunocore Holdings plc. Immediately prior to completion of this offering, it is expected that Immunocore Holdings plc&#8217;s share capital will be reorganized such that it consists of a single class of ordinary shares, and potentially also non-voting ordinary shares, as well as deferred shares. Therefore, investors in this offering will only acquire, and this prospectus only describes the offering of, ADSs representing ordinary shares of Immunocore Holdings plc. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The corporate reorganization will take place in several steps, all of which will be completed prior to the completion of this offering (apart from the step described below under &#8220;Bonus issue and reduction of capital of Immunocore Holdings plc&#8221;). We refer to these steps, which are discussed below, as our &#8220;corporate reorganization.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Exchange of shares of Immunocore Limited for shares of Immunocore Holdings Limited</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of January&#160;15, 2021, the issued share capital of Immunocore Limited is comprised of 2,679,764 ordinary shares of &#163;0.0001 each, 1,699,576 series A preferred shares of &#163;0.0001 each, 1,148,703 series B preferred shares of &#163;0.0001 each, 823,719 series C preferred shares of &#163;0.0001 each and 62,750 G shares (comprised of 43,490 G1 shares and 19,260 G2 shares) of &#163;0.0001 each. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Share Exchange, the shareholders of Immunocore Limited will agree to exchange each of their shares of Immunocore Limited for 100 newly issued shares of the same class, with the same rights attaching thereto, of Immunocore Holdings Limited. As a result, Immunocore Holdings Limited will become the sole shareholder of Immunocore Limited. Holders of options over ordinary shares in Immunocore Limited will be invited to exchange those options for replacement options over ordinary shares in Immunocore Holdings Limited.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reorganization of share capital of Immunocore Limited</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the Share Exchange, Immunocore Limited will undertake a reorganization of its share capital to re-designate its series A preferred shares, series B preferred shares, series C preferred shares and G shares into a single class of ordinary shares.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reduction of capital of Immunocore Limited</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is expected that subsequent to the Share Exchange Immunocore Limited will reduce its share capital pursuant to Part 17 of the Companies Act in order to create distributable reserves.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Re-registration of Immunocore Holdings Limited as a public limited company</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following completion of the Share Exchange, Immunocore Holdings Limited will be re-registered as a public limited company and will change its name to Immunocore Holdings plc. Such re-registration and change of name will require certain special resolutions to be passed by the shareholders of Immunocore Holdings Limited to approve the re-registration as a public limited company, the name change to Immunocore Holdings plc and adoption of new articles of association for Immunocore Holdings plc appropriate for a public company.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reorganization of share capital of Immunocore Holdings plc</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Conditional on and effective immediately prior to completion of this offering, all of Immunocore Holdings plc&#8217;s outstanding series A preferred shares, series B preferred shares and series C preferred shares will be re-designated as ordinary shares of Immunocore Holdings plc on a one for one basis. Pursuant to our current </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">95<br></div></div></div>
<!--End Page 100-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 101-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">articles of association, certain of our holders of series C preferred shares may have the right to require that some or all of the series C preferred shares held by them be re-designated as a separate class of non-voting ordinary shares. Further details of the rights and restrictions attaching to any such non-voting ordinary shares are set out in the section titled &#8220;Description of Share Capital and Articles of Association&#8221;. All of the G1 shares will be re-designated as deferred shares of Immunocore Holdings plc. The G2 shares will be re-designated as deferred shares and ordinary shares of Immunocore Holdings plc on a &#8195;-for-&#8195; basis, with any fractional entitlements to deferred shares and/or ordinary shares being aggregated and re-designated as a single deferred share that will be transferred to a person nominated by our directors. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immediately following the re-designations referred to above, and conditional upon and effective immediately prior to the completion of this offering, each ordinary share of &#163;0.0001 and non-voting ordinary share of &#163;0.0001 (if any) in Immunocore Holdings plc will be consolidated and/or sub-divided and, if required, re-designated into &#8195;&#8195;&#8195;&#8195;&#8195;&#8195; ordinary shares or non-voting ordinary shares of &#163;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195; deferred shares of &#163;&#8195;&#8195;&#8195;. This will have the effect of an approximately &#8195;-for-&#8195; reverse stock split on such ordinary shares and, if applicable, non-voting ordinary shares. The number of ordinary shares and, if applicable, non-voting ordinary shares that each shareholder of Immunocore Holdings plc receives will be rounded up or down to the nearest whole share and the directors shall be authorized to deal with any fractional entitlements as they see fit. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain further resolutions will be required to be passed by the shareholders of Immunocore Holdings plc prior to the completion of this offering, details of which are set out in the section titled &#8220;Description of Share Capital and Articles of Association.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Therefore, upon consummation of the corporate reorganization and immediately prior to the completion of this offering, the current shareholders of Immunocore Limited will hold an aggregate of &#8195;&#8195;&#8195;ordinary shares and, if applicable, non-voting ordinary shares of Immunocore Holdings plc.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Bonus issue and reduction of capital of Immunocore Holdings plc</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of this offering, Immunocore Holdings plc expects to capitalise the amount standing to the credit of its merger reserve and apply such sums in paying up in full new shares to the holders of its ordinary shares and non-voting ordinary shares (if any), which we refer to as bonus issue shares. Following the issue of the bonus issue shares, it is expected that Immunocore Holdings plc will undertake a reduction of capital, to be approved by the High Court of Justice in England and Wales, to (i) cancel all of the bonus issue shares and (ii) cancel the whole of the amount standing to the credit of its share premium account following closing of this offering. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">96<br></div></div></div>
<!--End Page 101-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 102-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tCAP"><!--Anchor--></a>CAPITALIZATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth our cash and cash equivalents and capitalization as of September 30, 2020 on:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an actual basis; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a pro forma basis to give effect to (i)&#160;the issuance and sale of 832,719 Series C preferred shares for aggregate gross proceeds of $75.0&#160;million in December 2020; and (ii)&#160;the borrowing of $50.0&#160;million in November 2020 under a new debt facility with Oxford Finance Luxembourg S.A.R.L., or Oxford Finance; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a pro forma as adjusted basis to give further effect to (i)&#160;our corporate reorganization and (ii)&#160;the sale of &#8195;&#8195;&#8195;ADSs in this offering at an assumed initial public offering price of $&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read this information together with our audited consolidated financial statements appearing elsewhere in this prospectus and the information set forth under the sections titled &#8220;Selected Consolidated Financial Data,&#8221; &#8220;Use of Proceeds&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 34.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of September 30, 2020 </div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Actual</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma</div></td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.75%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As Adjusted </div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td colspan="7" style="width: 34.96%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands except share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and per share amounts)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">$</font><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">&#8203;</font><font style="border-bottom: 3pt double #000000; min-width: 40.83pt;">73,245</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$&#8195;&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt;">$&#8195;&#8195;&#8195;&#8195;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term debt<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">50,000</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders&#8217; equity:<br></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Ordinary shares, shares authorized, 2,551,624 shares issued and outstanding, actual; &#8195;&#8195; shares authorized, 2,551,624 shares issued and outstanding, pro forma; &#8195;&#8195; shares authorized, &#8195;&#8195; shares issued and outstanding, pro forma as adjusted<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 35.83pt;">1</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">426,897</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other reserves<font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">20,863</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">(427,671</font><font style="min-width: 40.83pt;">)</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 45pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 45pt;"></font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total shareholders&#8217; equity<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 40.83pt;">20,090</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 45pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="border-bottom: 1pt solid #000000; padding-left: 45pt;"></font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total capitalization<font style="padding-left: 2.89pt;"></font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.72%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 3pt double #000000; min-width: 40.83pt;">93,335</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt; padding-right: 40pt;">$</font></div></td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.75%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 45pt; padding-right: 40pt;">$</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS would increase (decrease) the as adjusted amount of each of cash and cash equivalents, total shareholders&#8217; equity and total capitalization by $&#8195;&#8195;&#8195; million, assuming that the total number of ADSs offered by us in this offering, as set forth on the cover page of this prospectus, remains the same. Similarly, an increase (decrease) of 1,000,000 in the number of ADSs offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the as adjusted amount of each of cash and cash equivalents, total shareholders&#8217; equity and total capitalization by $&#8195;&#8195;&#8195; million, assuming the assumed initial public offering price per ADS remains the same. This as adjusted information is illustrative only and will depend on the actual offering price and other terms of this offering determined at pricing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The number of ordinary shares, including ordinary shares represented by ADSs, outstanding on a pro forma as adjusted basis in the table above excludes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">832,904 ordinary shares issuable upon the exercise of options outstanding under our existing equity incentive plans as of September 30, 2020, with a weighted-average exercise price of &#163;63.23 per share; and</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">97<br></div></div></div>
<!--End Page 102-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 103-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares reserved for future issuance under our 2021 EIP which will become effective in connection with this offering, as well as any automatic annual increases in the number of ordinary shares reserved for future issuance under the 2021 EIP, as more fully described in the section titled &#8220;Management&#8212;Equity Incentive Plans;&#8221; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares (assuming an initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus) underlying the grants to be issued prior to the closing of this offering to certain of our officers, directors and employees under our 2021 EIP, contingent and effective upon the execution and delivery of the underwriting agreement relating to this offering, with an exercise price that is equal to or greater than the price per ADS at which our ADSs are first sold to the public in this offering.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">98<br></div></div></div>
<!--End Page 103-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 104-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDIN"><!--Anchor--></a>DILUTION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you invest in our ADSs in this offering, your interest will be immediately diluted to the extent of the difference between the initial public offering price per ADS and the as adjusted net tangible book value per ADS after completion of this offering. Our net tangible book value as of September 30, 2020 was $20.1 million, or $3.68 per ADS. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of ordinary shares outstanding on September 30, 2020. Dilution results from the fact that the initial public offering price per ADS is substantially in excess of the net tangible book value per ADS.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After giving effect to (i)&#160;our corporate reorganization (including the approximately &#8195;-for-&#8195; reverse split of all our ordinary shares prior to completion of this offering); (ii)&#160;the issuance and sale of 832,719 Series C preferred shares for aggregate gross proceeds of $75.0&#160;million in December 2020; and (iii) the borrowing of $50.0&#160;million under a new debt facility with Oxford Finance, our pro forma net tangible book value at September&#160;30, 2020 would have been $&#8195;&#8195;&#8195;&#160;million, or $&#8195;&#8195;&#8195; per ADS. After giving further effect to the sale of &#8195;&#8195;&#8195;ADSs in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195;&#160;per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value at September 30, 2020 would have been $&#8195;&#8195; million, or $ &#8195;&#8195;&#8195;per ADS. This represents an immediate increase in net tangible book value of $&#8195;&#8195;&#8195; per ADS to existing shareholders and immediate dilution of $&#8195;&#8195;&#8195; per ADS to new investors. The following table illustrates this dilution to new investors purchasing ADSs in this offering:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed initial public offering price per ADS<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$&#8195;&#8195;&#8195;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Historical net tangible book value per ADS as of September 30, 2020<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$3.68</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Increase in net tangible book value per ADS attributable to our corporate reorganization and Series C preferred share issuance<font style="padding-left: 2.8pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pro forma net tangible book value per ADS as of September&#160;30, 2020<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in net tangible book value per ADS attributable to this offering<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pro forma as adjusted net tangible book value per ADS after this offering<font style="padding-left: 0.03pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35pt;">&#8195;&#8195;&#8195;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Dilution in as adjusted net tangible book value per ADS to new investors participating in this offering<font style="padding-left: 1.59pt;"></font></div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.7%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$&#8195;&#8195;&#8195;</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each $1.00 increase (decrease) in the assumed initial public offering price of $ &#8195;&#8195;&#8195;per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the as adjusted net tangible book value after this offering by $&#8195;&#8195;&#8195; per ADS and the dilution to new investors in this offering by $&#8195;&#8195;&#8195; per ADS, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, an increase (decrease) of 1,000,000 in the number of ADSs offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the as adjusted net tangible book value after this offering by $&#8195;&#8195;&#8195; per ADS and decrease the dilution to new investors in this offering by $&#8195;&#8195;&#8195; per ADS, assuming no change in the assumed initial public offering price per ADS and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. The as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table shows, as of September 30, 2020, on an as adjusted basis, the number of ADSs offered by us, the total consideration paid to us and the average price paid per ordinary share by existing shareholders and by new investors purchasing ADSs in this offering at an assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the underwriting commission and estimated offering expenses payable by us (in thousands, except share and per share amounts and percentages).</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 28.2%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 17.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ordinary Shares or <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADSs Purchased</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total Consideration</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Per Ordinary Share</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.31%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Per ADS </div></td></tr><tr class="header"><td style="width: 28.2%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.48%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 14.84%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 10.31%; text-align: center; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 28.2%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Existing shareholders<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 37.5pt;">%</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 37.5pt;">%</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.24pt; text-align: left;">$<font style="padding-left: 10pt;">&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.63pt; text-align: left;">$<font style="padding-left: 10pt;">&#8195;&#8195;</font></div></td></tr><tr><td style="width: 28.2%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New investors<font style="padding-left: 1.19pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30pt;">&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 37.5pt; padding-right: 7.5pt;">&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35pt;">$&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 37.5pt; padding-right: 7.5pt;">&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 14.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.24pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35pt;">$&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 10.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.63pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35pt;">$&#8195;&#8195;&#8195;</font></div></td></tr><tr><td style="width: 28.2%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Totals<font style="padding-left: 0.2pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30pt;">&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 3pt double #000000; min-width: 37.5pt;">100.0</font><font style="min-width: 37.5pt;">%</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.48%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35pt;">$&#8195;&#8195;&#8195;</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 3pt double #000000; min-width: 37.5pt;">100.0</font><font style="min-width: 37.5pt;">%</font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.24pt; text-align: left;">$</div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.31%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.63pt; text-align: left;">$</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">99<br></div></div></div>
<!--End Page 104-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 105-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_107-corporate_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $ &#8195;&#8195;&#8195;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &#8195;&#8195;&#8195;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by &#8195;&#8195;&#8195;percentage points, assuming that the number of ADSs offered by us, as set forth on the cover page of this prospectus, remains the same. Similarly, an increase (decrease) of 1,000,000 in the number of ADSs offered by us, as set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $ &#8195;&#8195;&#8195;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by &#8195;&#8195;&#8195;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by percentage points, assuming no change in the assumed initial public offering price per ADS.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the underwriters exercise in full their option to purchase an additional&#8195;&#8195;&#8195; ADSs, the percentage of ordinary shares held by existing shareholders will decrease to&#8195;&#8195;&#8195; % of the total number of ordinary shares outstanding after this offering, and the number of ordinary shares held by new investors will be increased to &#8195;&#8194;, or &#8195;&#8195;% of the total number of ordinary shares outstanding after this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The table and discussion above excludes:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">832,904 ordinary shares issuable upon the exercise of options outstanding under our existing equity incentive plans as of September 30, 2020, with a weighted-average exercise price of &#163;63.23 per share; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares reserved for future issuance under our 2021 EIP which will become effective in connection with this offering, as well as any automatic annual increases in the number of ordinary shares reserved for future issuance under the 2021 EIP, as more fully described in the section titled &#8220;Management&#8212;Equity Incentive Plans;&#8221; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8195;&#8195;&#8195; ordinary shares (assuming an initial public offering price of $&#8195;&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus) underlying the grants to be issued prior to the closing of this offering to certain of our officers, directors and employees under our 2021 EIP, contingent and effective upon the execution and delivery of the underwriting agreement relating to this offering, with an exercise price that is equal to or greater than the price per ADS at which our ADSs are first sold to the public in this offering. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent these outstanding options or any newly issued options are exercised, or we issue additional ADSs or ordinary shares in the future, there will be further dilution to the new investors purchasing ADSs in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">100<br></div></div></div>
<!--End Page 105-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 106-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_108-selected_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSCDF"><!--Anchor--></a>SELECTED CONSOLIDATED FINANCIAL DATA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following tables present selected consolidated financial data as of the dates and for the periods indicated. Our audited consolidated financial statements have been prepared in accordance with IFRS, as issued by the IASB. We derived the summary consolidated statements of loss and other comprehensive income for the years ended December 31, 2018 and 2019 and summary consolidated statement of financial position data as of December 31, 2018 and 2019 from our audited consolidated financial statements included elsewhere in this prospectus. We derived the summary consolidated statements of loss and other comprehensive income for the nine months ended September 30, 2019 and 2020 and summary consolidated statement of financial position data as of September 30, 2020 from our unaudited condensed consolidated interim financial statements included elsewhere in this prospectus. The unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34, as issued by the IASB on the same basis as the annual consolidated financial statements, and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our financial position and results of operations. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our historical and interim results are not necessarily indicative of the results to be expected for the full year or any other period in the future. You should read the consolidated financial data set forth below in conjunction with our consolidated financial statements and the accompanying notes and the information in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contained elsewhere in this prospectus. </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 25.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine-month period ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30,</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 22.44%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the years ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div></td></tr><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.73%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 25.25%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in thousands <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">except for share and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share data)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 22.44%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in thousands <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">except for share and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share data)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; font-weight: bold; margin-top: 0pt; margin-left: 9.8pt; text-indent: -9.8pt; text-align: left;">Consolidated statement of loss and other comprehensive income data:<br></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 3.26pt;">22,6</font>94</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 3.26pt;">20,027</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt;">25,669</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 3.26pt;">23,654</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 15.51pt;">408</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 15.51pt;">420</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 20.4pt;">185</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 15.51pt;">622</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<font style="padding-left: 3.38pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(57,566)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(75,415)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 4.9pt;">(99,991)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;">(83,575)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administration<font style="padding-left: 2.28pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(31,569</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 0.36pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(35,611</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 4.9pt; border-bottom: 1pt solid #000000; min-width: 35.1pt;">(44,183</font><font style="min-width: 35.1pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(34,156</font><font style="min-width: 30.2pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="padding-left: 2.88pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(66,033)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(90,579)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 0.36pt;">(118,320)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;">(93,455)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 1.14pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 20.4pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 20.4pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 25.3pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt;">4,979</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 8.16pt;">1,972</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 8.16pt;">1,134</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 13.06pt;">1,510</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt;">1,140</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 1.68pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 4.9pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(2,272</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 4.9pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(6,532</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 9.8pt; border-bottom: 1pt solid #000000; min-width: 35.1pt;">(9,379</font><font style="min-width: 35.1pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 12.24pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(842</font><font style="min-width: 30.2pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating (expense) / income<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 12.24pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(300</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 4.9pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">(5,398</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 9.8pt; border-bottom: 1pt solid #000000; min-width: 35.1pt;">(7,8</font><font style="border-bottom: 1pt solid #000000; min-width: 35.1pt;">6</font><font style="border-bottom: 1pt solid #000000; min-width: 35.1pt;">9</font><font style="border-bottom: 1pt solid #000000; min-width: 35.1pt;"></font><font style="min-width: 35.1pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">5,277</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before tax<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(66,333)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;">(95,977)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;">(126,189)</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;">(88,178)</div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 3.62pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">11,120</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 3.62pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">18,011</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt; border-bottom: 1pt solid #000000; min-width: 35.1pt;">22,258</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 3.26pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">16,548</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 3.84pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(55,213</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(77,966</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.1pt;">(103,931</font><font style="min-width: 35.1pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(71,630</font><font style="min-width: 30.2pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 9.8pt; text-indent: -9.8pt; text-align: left;">Exchange differences on translation of foreign operations<font style="padding-left: 4.94pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 15.51pt;">338</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 20.4pt;">82</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 22.04pt;">(99)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 20.4pt;">72</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 9.8pt; text-indent: -9.8pt; text-align: left;">Income tax effect relating to the components of other comprehensive income <font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 20.4pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 20.4pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 25.3pt; border-bottom: 1pt solid #000000; min-width: 35.1pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 8.16pt; border-bottom: 1pt solid #000000; min-width: 30.2pt;">3,634</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period, net of tax<font style="padding-left: 1.95pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(54,875</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(77,884</font><font style="min-width: 30.2pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.1pt;">(104,030</font><font style="min-width: 35.1pt;">)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.2pt;">(67,924</font><font style="min-width: 30.2pt;">)</font></div></td></tr><tr><td style="width: 48.72%; text-align: left; vertical-align: bottom; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 9.8pt;">(0.01)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 11.73%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 12.36pt; text-align: left;"><font style="padding-left: 9.8pt;">(0.02)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 10.85%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 14.69pt;">(0.02)</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt;">&#8203;</td><td style="width: 9.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 7.84pt; text-align: left;"><font style="padding-left: 9.8pt;">(0.02)</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of September 30,</div></td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of December&#160;31,</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.5%; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 15.01%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">thousands)</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td colspan="4" style="width: 18.59%; text-align: center; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(pounds sterling in <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">thousands)</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated statement of financial position data:<br></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 4.9pt;">56,687</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.9pt;">73,966</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">124,385</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><font style="padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 4.9pt;">29,335</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.9pt;">3</font>9,768</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">121,574</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;">130,839</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">185,649</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">195,777</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Debt<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 22.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.04pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="padding-left: 1.82pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 0.36pt;">115,291</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">170,878</div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">139,195</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 4.87pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 26.94pt;">1</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt; padding-bottom: 1.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.04pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="padding-left: 3.8pt;"></font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td style="width: 15.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 19.21pt; text-align: left;"><font style="padding-left: 4.9pt;">15,548</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.9pt;">14,771</font></div></td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td class="gutter" style="width: 2.5%; border-bottom: none; font-size: 2pt; padding-top: 1.5pt;">&#8203;</td><td style="width: 6.8%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 1.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.9pt;">56,582</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">See Note 10 to our audited consolidated financial statements for the year ended December&#160;31, 2019 and year ended December&#160;31, 2018 and Note 6 to our unaudited consolidated financial statements appearing elsewhere in this prospectus for a description of the method used to compute diluted net loss per share.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">We define working capital as current assets less current liabilities.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">101<br></div></div></div>
<!--End Page 106-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 107-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMDA"><!--Anchor--></a>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You should read the following discussion and analysis of our financial condition and results of operations together with the section titled &#8220;Selected Consolidated Financial Data&#8221; our consolidated financial statements and the related notes thereto appearing elsewhere in this prospectus. The following discussion is based on our financial information prepared in accordance with the International Financial Reporting Standards, or IFRS, as issued by the IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including U.S. GAAP. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis, as well as the section titled &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the convenience of the reader, we have translated pound sterling amounts as of and for the period ended September 30, 2020 into U.S. dollars at the noon buying rate of the Federal Reserve Bank of New York on September 30, 2020, which was &#163;1.00 to $1.2921. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as of that or any other date.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease &#8211; designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five&#160;clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our ImmTAX product candidates, which we believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase&#160;3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. This primary endpoint was achieved with a hazard ratio of 0.51 (95% CI: 0.36, 0.71; p&lt;&#160;0.0001) at the first pre-planned interim analysis. Based on these results, we are preparing to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for tebentafusp for the treatment of metastatic uveal melanoma in the third quarter of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were incorporated in 2007. Since our inception, we have focused on organizing and staffing our company, raising capital and performing research and development activities to advance our research, development and technology. We have not yet generated revenue from any marketed products. We may never be able to develop or commercialize a marketable product. Our ability to develop product revenue depends on the successful development and regulatory approval of one or more of our product candidates and our ability to finance operations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since inception, we have raised an aggregate of $873.2 million (&#163;675.8 million) through private placements of our ordinary and preferred shares through debt financing, payments from our collaboration partners, and most recently, borrowings under our debt facility with Oxford Finance Luxembourg S.A.R.L., or Oxford Finance, and the sale of our Series&#160;C preferred shares. These funds have and are being used to fund operations and invest in activities for technology creation, drug discovery and clinical development programs, infrastructure, creation of portfolio of intellectual property and administrative support. We have assembled a team of over 250 employees. We have also established relationships with three pharmaceutical collaborators, Genentech, Inc., or Genentech, GlaxoSmithKline Intellectual Property Development Ltd, or GSK, and Eli Lilly and Company, or Lilly.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have incurred significant operating losses and expect to continue to incur significant expenses and operating losses for the near future. Losses were &#163;78.0 million and &#163;55.2 million for the nine months ended September 30, 2019 and 2020, respectively, and &#163;71.6 million and &#163;103.9 million for the years ended December&#160;31, 2018 and 2019, respectively. As of September 30, 2020, our accumulated deficit was </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">102<br></div></div></div>
<!--End Page 107-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 108-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#163;331.0 million. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio, as well as hire additional personnel, pay for accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission, or SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not expect to generate revenue from the sale of our product candidates unless and until we successfully complete clinical development of and obtain regulatory approval for such product candidates. As a result, we will need substantial additional funding to support our continued operations and pursue our clinical development and growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings, government funding arrangements, collaborations and marketing, distribution and licensing arrangements. We may be unable to raise additional funds or enter into such other arrangements on favorable terms, or at all. If we fail to raise capital or enter into such arrangements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our programs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">COVID-19 Business Update</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">With the global spread of the ongoing coronavirus 2019, or COVID-19, pandemic since the first quarter of 2020, we have implemented business continuity plans designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business, including our preclinical studies and clinical trials. Our operations are considered as an essential business and we are continuing to operate during this period. We have taken measures to secure our research and development activities, while work in laboratories and facilities has been organized to reduce risk of COVID-19 transmission. While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, our business, financial condition and results of operations could be materially adversely affected. We continue to closely monitor the COVID-19 pandemic as we evolve our business continuity plans, clinical development plans and response strategy as required or recommended by government authorities or in the best interests of our employees and business partners. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, the COVID-19 pandemic has resulted in a short-term delay of up to six months in progressing our early-stage pipeline programs and specifically, our Phase 1 clinical trial in HBV. In addition, our current and planned clinical trials may also be affected by the COVID-19 pandemic, including (i) delays or difficulties in enrolling and retaining patients in our clinical trials, including patients that may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services; (ii) delays or difficulties in clinical site initiation, including difficulties in recruiting and retaining clinical site investigators and clinical site staff; (iii) diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the COVID-19 pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials and, because as healthcare providers, may also have a heightened exposure to COVID-19 and adversely impact our clinical trial operations; (iv) interruption of our future clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal, state/provincial or municipal governments, employers and others; and (v) limitations in employee resources that would otherwise be focused on the conduct of our planned clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The COVID-19 pandemic remains a rapidly evolving situation and management does not yet know the full extent of its potential impact on our business operations. We will continue to closely monitor, assess and mitigate the effects of the COVID-19 pandemic on our business. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">103<br></div></div></div>
<!--End Page 108-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 109-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Key Collaboration Agreements</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Genentech Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2013, we entered into a research collaboration and license agreement, or the 2013 Genentech Agreement, with Genentech, and F. Hoffmann-La Roche Ltd, or Roche, pursuant to which we along with Genentech and Roche agreed to collaborate in the development, manufacture and ultimately, commercialization of soluble TCR bispecific therapeutic candidate compounds. Under the 2013 Genentech Agreement, Genentech paid us an initial upfront payment of $20&#160;million in exchange for exclusive licenses to two of our targets, MAGE-A4 and as well as an undisclosed target. We refer to these two initial targets as the Negotiated Targets. For each of the Negotiated Targets, we were responsible for developing a soluble TCR bispecific therapeutic pre-clinical candidate compound, and Genentech was responsible for all GMP manufacture, clinical development and commercialization of those compounds, upon which we would be entitled to receive future milestone and royalty payments. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The first pre-clinical program nominated under the 2013 Genentech Agreement was target MAGE-A4, which we refer to as our IMC-C103C program. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September 2016, following achievement of formal nomination of the pre-clinical candidate compound, we and Genentech amended the 2013 Genentech Agreement. We refer to this amendment as the 2016 Genentech Amendment. The 2016 Genentech Amendment provided that the Negotiated Targets, including MAGE-A4, ceased to be considered eligible targets under the 2013 Genentech Agreement. On the same day, we entered into a license agreement with Genentech, or the 2016 Genentech Agreement. Pursuant to the 2016 Genentech Agreement, we regained control of the initial two programs covering the Negotiated Targets in existence at the time of execution, including MAGE-A4, and Genentech granted us an exclusive worldwide license to use its background intellectual property rights to advance such programs. Under the 2016 Genentech Agreement, we had sole responsibility for the development, manufacture and commercialization of the soluble TCR bispecific therapeutic compounds of the Negotiated Targets at our own expense, and are required to use diligent efforts to achieve commercialization of at least one therapeutic compound for each of the programs. In exchange for the rights granted to us under the 2016 Genentech Agreement, Genentech would be able to earn future development and commercial milestones of up to approximately $167&#160;million and tiered royalty payments between a mid-single-digit and low-teens percentage on net sales of such compounds. Genentech also obtained a right of first negotiation in respect of the programs of the Negotiated Targets, should we seek to license the rights to develop and/or commercialize either program to a third party. The 2016 Genentech Agreement is effective on a country-by-country basis, and shall expire on the later of (i)&#160;the expiration of the last to expire patent containing a valid claim which covers the sale of the applicable soluble TCR bispecific therapeutic compounds of the Negotiated Targets and (ii)&#160;the tenth anniversary of the date of the first commercial sale of such compounds. Either party is entitled to terminate the 2016 Genentech Agreement for an uncured material breach of the other party upon 90&#160;days&#8217; written notice, or 30 days&#8217; written notice, in the case of payment defaults, or immediately upon insolvency of the other party. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In November 2018, Genentech exercised its right of first negotiation with respect to our IMC-C103C program. We received an aggregate of $100&#160;million from Genentech, consisting of an initial upfront payment of $50&#160;million and $50&#160;million paid upon an IND filing for the first clinical trial of the product candidate compound, in exchange for granting Genentech rights to co-develop/co-promote our IMC-C103C program. In November 2018, in response to Genentech&#8217;s exercise of its right of first negotiation in regards to our IMC-C103C program, we entered into a new license and collaboration agreement, or the 2018 Genentech Agreement, pursuant to which we and Genentech agreed to collaborate in the development and commercialization of certain compounds targeting MAGE-A4, specifically pHLA-A2. Under the 2018 Genentech Agreement, we granted Genentech a co-exclusive worldwide license to our intellectual property rights in MAGE-A4 soluble TCR bispecific therapeutic candidate compounds to advance the development and commercialization of such compounds as contemplated under the 2018 Genentech Agreement. We are responsible for development of the IMC-C103C program through the completion of the Phase 1 clinical trial, with costs being shared equally with Genentech, and are required to use diligent efforts with respect to our development and commercialization obligations. For more information, please see &#8220;Business &#8212; Collaborations and License Agreements &#8212; Genentech Collaboration.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">104<br></div></div></div>
<!--End Page 109-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 110-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">GSK Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2013, we entered into a collaboration and license agreement, or the GSK Agreement, with GlaxoSmithKline Intellectual Property Development Ltd, or GSK, pursuant to which we and GSK agreed to collaborate in the development of soluble TCR bispecific therapeutic compounds. Under the GSK Agreement, we granted GSK the right to nominate up to four targets as being exclusive to GSK under our collaboration. The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK Agreement. A second target was nominated in July 2017. GSK has no further ability to nominate additional targets under the GSK Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the GSK Agreement, for NY-ESO, we are responsible for the development of the soluble TCR bispecific therapeutic candidate compounds through initial Phase 1 clinical trials. GSK has the option until a certain period following completion of such development work to obtain an exclusive worldwide license to NY-ESO. GSK has an option to obtain an exclusive worldwide license for the therapeutic candidate compounds directed towards the second collaboration target until a certain period following the identification of at least one development candidate or the earlier termination of the applicable development work. During each GSK option period, we are prohibited from directly or indirectly developing or commercializing any soluble TCR bispecific therapeutic products arising under such program other than as provided under the GSK Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event that GSK exercises an option, we have agreed to grant GSK an exclusive worldwide license for intellectual property rights specific to the soluble TCR bispecific therapeutic candidate compounds developed under the relevant collaboration programs and to our background intellectual property rights to the extent they are necessary for GSK to manufacture, use and commercialize the compounds developed under the GSK Agreement. Following the grant of any exclusive license, GSK will be fully responsible for all further development, manufacture and commercialization of the relevant soluble TCR bispecific therapeutic candidate compound, at its sole expense. The licenses, if granted, do not include any right for GSK to develop alternative affinity-enhanced TCRs using our intellectual property rights or to develop other TCR therapeutic candidates directed to different target peptides.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the GSK Agreement, we received an upfront payment upon execution and one additional payment in connection with GSK&#8217;s nomination of the second collaboration target. We are eligible to receive up to an additional &#163;17.6&#160;million in initial payments if GSK nominates the maximum number of additional HLA alleles. Under the GSK&#160;Agreement, we are additionally entitled to various milestone payments based on the achievement of specified development and commercialization milestones by either us or GSK. For each product which reaches the market, we are eligible to receive up to an aggregate of approximately &#163;200&#160;million in development and commercial milestone payments plus royalties. As of September 30, 2020, we have received payments totaling &#163;22.9 million in upfront payments and early development milestones, with the potential to achieve an additional aggregate of &#163;14.0 million through option exercise of the two collaboration targets. For more information, please see &#8220;Business &#8212; Collaborations and License Agreements &#8212; GSK Collaboration.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Lilly Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In July 2014, we entered into a development and license agreement with Lilly, referred to, as subsequently amended, as the Lilly Collaboration, pursuant to which we and Lilly agreed to collaborate in the development, manufacture and commercialization of soluble TCR bispecific therapeutic compounds.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Lilly Collaboration, Lilly paid us an initial upfront fee payment of $45&#160;million in exchange for options to three targets. Lilly no longer has the ability to nominate any further targets under the initial agreement with Lilly. In December 2016, we and Lilly agreed to swap an existing antigen target, selected by Lilly, for a new, well-known neo-antigen target. Lilly has no further obligations with respect to the initial target that was replaced. In September 2017, we and Lilly agreed to swap a second antigen target, selected by Lilly, for a second neo-antigen target. Similarly, Lilly has no further obligations with respect to the initial target that was replaced. From the designation of each selected target until the expiration or termination of any exclusive license Lilly may obtain by exercising its option rights, we are prohibited from directly or indirectly conducting any development or commercialization activities relating to such target selected under the Lilly Collaboration or epitopes derived from such target or any compounds directed to such target, other than as provided under the Lilly Collaboration. For more information, please see &#8220;Business &#8212; Collaborations and License Agreements &#8212; Lilly Collaboration.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">105<br></div></div></div>
<!--End Page 110-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 111-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Components of Results of Operations</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Revenue</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To date, we have not generated any revenue from the sale of marketed pharmaceutical products. If our development efforts for our product candidates are successful and result in regulatory approval of a product candidate, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Revenue from Collaboration Agreements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our revenue has been solely derived from our collaboration agreements with Genentech, GSK and Lilly and previously pursuant to our collaboration agreement with MedImmune plc (now known as AstraZeneca plc), or MedImmune which terminated during 2019. Our revenue from collaboration agreements consists of non-refundable upfront payments, development milestones as well as reimbursement of research and development expenses. To the extent that existing or potential future collaborations generate revenue, such revenue may vary due to many uncertainties in the development of our product candidates and other factors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September 30, 2020, we have received a total of $216.8 million (&#163;167.8 million) in upfront and milestone payments, intended to fund the research and development activities under each contract. As part of the agreements, we contribute our ImmTAC technology and commit to participate in joint research activities. In addition, we agree to license or option certain target rights and the possible product candidates developed under the collaboration. The agreements provide for future payments if development, regulatory or sales milestones are achieved. In addition, we are entitled to future royalties. The uncertainty of achieving these certain milestones significantly impacts our ability to project revenue.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upfront payments and development milestones are initially recorded on our statement of financial position as deferred revenue and are subsequently recognized as revenue as the underlying programs progress through research and development using an estimate of the percentage completion of each program in accordance with our accounting policy as described further in &#8220;Critical Accounting Policies and Significant Judgments and Estimates.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Operating Expenses</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenses consist primarily of costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical knowledge and understanding and consist primarily of personnel-related costs, including salaries, for the various research and development departments, costs associated with clinical trial activities undertaken by contract research organizations, or CROs, and external manufacturing costs undertaken by contract manufacturing organizations, or CMOs, research and development laboratory consumables, internal clinical trial expenses and costs associated with maintaining laboratory equipment. All research and development expenses are expensed as incurred due to scientific uncertainty. Research and development expenses incurred with external organizations typically relate to clinical programs and are assigned to the individual programs, however for pre-clinical programs and other research spend incurred externally, such spend is typically not assigned to individual programs. Internal research and development expenses typically relate to personnel-related costs and research and development laboratory consumables and due to the cross functional expertise of our people it is not possible to provide a breakdown of internal costs by program. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect our research and development expenses to remain significant in the future as we advance existing and future product candidates into and through clinical studies and pursue regulatory approval. The process of conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming. We maintain our headcount at a level required to support our continued research activities and development of our product candidates. Clinical trials generally become larger and more costly to conduct as they advance into later stages. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">106<br></div></div></div>
<!--End Page 111-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 112-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">complete the development of any product candidates that we develop from our programs. As a result, our research and development expenses may vary substantially from period to period based on the timing of our research and development activities. Several of our research and development programs are at an early stage. We must demonstrate the safety and efficacy of our product candidates in humans through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our products, including but not limited to the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">after reviewing trial results, our collaboration partners may abandon projects that might previously have been believed to be promising;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we, our collaboration partners, or regulators may suspend or terminate clinical trials if the participating subjects or patients are being exposed to unacceptable health risks;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our potential products may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">manufacturers may not meet the necessary standards for the production of the product candidates or may not be able to supply the product candidates in a sufficient quantity;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities may find that our clinical trial design or conduct does not meet the applicable approval requirements; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">safety and efficacy results in various human clinical trials reported in scientific and medical literature may not be indicative of results we obtain in our clinical trials.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the FDA, EMA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">General and administrative expenses consist primarily of personnel-related costs, including salaries and share-based compensation expense, for corporate and other administrative and operational functions including finance, legal, human resources, and information technology, as well as facility-related costs. These costs relate to the operation of the business, unrelated to the research and development function or any individual program.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Due to our substantial increase in planned research and development expenses, as explained above, we also expect that our general and administrative expenses will increase proportionally. We expect that we will incur increased accounting, audit, legal, regulatory, compliance, director, and officer insurance costs as well as investor and public relations expenses associated with being a public company. We anticipate that the additional costs for these services will substantially increase our general and administrative expenses. Additionally, if and when we receive regulatory approval of a product candidate we anticipate an increase in payroll and expenses as a result of our preparation for commercial operations. During the year ended December&#160;31, 2019, we adopted IFRS 16 &#8220;Leases&#8221; and a result, lease-related expenses are no longer reflected as general and administrative expenses. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Other Operating Income</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Finance Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Finance income arises primarily from interest income on cash and cash equivalents, short-term deposits and gains on entering into sub-lease arrangements on leasehold properties as recognized under the accounting standard IFRS 16 &#8216;Leases&#8217; as adopted in the year ended December&#160;31, 2019 and gains arising on changes in the fair value of an embedded derivative asset and derivative liability.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">107<br></div></div></div>
<!--End Page 112-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 113-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Finance Costs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Finance costs consist of the movement in fair value of an embedded derivative asset and derivative liability and interest expenses related to financial liabilities and lease liabilities as recognized under the accounting standard IFRS 16 &#8216;Leases&#8217; as adopted in the year ended December&#160;31, 2019.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Income Tax Credit</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our income tax balance largely comprises research and development tax credits. Research and development credits are obtained at a maximum rate of 33.35% of our qualifying research and development.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to corporate taxation in the United Kingdom. Our wholly owned U.S. subsidiaries, Immunocore LLC and Immunocore Commercial LLC, are subject to corporate taxation in the United States. Due to the nature of our business, we have generated losses since inception. Our income tax credit recognized represents the sum of the research and development tax credits recoverable in the United Kingdom and income tax payable in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a company that carries out extensive research and development activities, we benefit from the U.K. research and development tax credit regime and are able to surrender some of our losses for a cash rebate of up to 33.35% of expenditures related to eligible research and development projects. Qualifying expenditures largely comprise clinical trial and manufacturing costs, employment costs for relevant staff and consumables incurred as part of research and development projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.68%. A large portion of costs relating to our research and development, clinical trials and manufacturing activities are eligible for inclusion within these tax credit cash rebate claims.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not be able to continue to claim research and development tax credits in the future under the current research and development tax credit scheme when we become a public company because we may no longer qualify as a small or medium-sized company. However, we may be able to file under a large company scheme.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event we generate revenues in the future, we may benefit from the new &#8220;patent box&#8221; initiative that allows profits attributable to revenues from patents or patented products to be taxed at a lower rate than other revenue. The rate of tax for relevant streams of revenue for companies receiving this relief will be 10%. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Results of Operations</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Comparison of the Nine Months Ended September 30, 2019 and 2020<font style="font-style: normal; font-weight: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our consolidated statement of loss for each period presented:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.27%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Nine months ended September 30, </div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$000</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 0.51pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 1.96pt;">29,323</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 1.96pt;">22,694 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 1.96pt;">20,027</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(74,381<font style="padding-left: 0.2pt;">) </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(57,566<font style="padding-left: 0.2pt;">) </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(75,415<font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(40,790<font style="padding-left: 0.2pt;">)</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(31,569<font style="padding-left: 0.2pt;">)</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 0.37pt;">(35,611</font><font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 15.05pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">527 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 15.05pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">408 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 15.05pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">420</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="font-weight: normal; padding-left: 0.48pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(85,321</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font><font style="min-width: 29.65pt;"> </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(66,033</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font><font style="min-width: 29.65pt;"> </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(90,579</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 2.32pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 19.65pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 19.65pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 19.65pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 7.94pt;">2,548</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 7.94pt;">1,972 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 7.94pt;">1,134</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(2,936</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font><font style="min-width: 29.65pt;"> </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(2,272</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">) </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(6,532</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating (expense) / income<font style="font-weight: normal; padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 11.91pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(388</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">) </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 11.91pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(300</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">) </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 4.8pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">(5,398</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="font-weight: normal; padding-left: 4.05pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(85,709<font style="padding-left: 0.2pt;">)</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(66,333<font style="padding-left: 0.2pt;">)</font> </div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;">(95,977<font style="padding-left: 0.2pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 2.2pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 3.13pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">14,368 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 3.5pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">11,120 </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="padding-left: 3.5pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;">18,011</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="font-weight: normal; padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(71,341</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font><font style="min-width: 29.65pt;"> </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(55,213</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font><font style="min-width: 29.65pt;"> </font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.04pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 29.65pt;">(77,966</font><font style="padding-left: 0.2pt; border-bottom: 1pt solid #000000; min-width: 29.65pt;"></font><font style="min-width: 29.65pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">108<br></div></div></div>
<!--End Page 113-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 114-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Revenue</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 29.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Nine months ended September 30, </div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 </div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$000</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.74%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 29.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GSK<font style="padding-left: 4.51pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">5,613</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">4,344</font> </div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">3,796</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 0.06pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">4,551 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">3,522 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,886</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 1.74pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,159</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,828</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,345</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">29,323 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">22,694 </font></div></td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.74%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">20,027</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, revenue from collaboration agreements increased to &#163;22.7&#160;million from &#163;20.0&#160;million for the nine months ended September&#160;30, 2019. The increase of &#163;2.7&#160;million was primarily related to a change in program focus under the Lilly Collaboration under which a balance of &#163;3.1&#160;million deferred income held at December&#160;31, 2019 was released in full. During the same period, we reviewed and revised the estimated completion of each of the programs under our collaboration agreements, arising from the availability of additional historical data as the programs progress through our research and development activities. The impact of this change in estimate increased revenue recognized in the nine months ended September&#160;30, 2020 by &#163;0.2&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Nine months ended September&#160;30,</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.45%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$000</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 33.27%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External research and development expenses:<br></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tebentafusp<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">34,759</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">26,901</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">42,035</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IMC-F106C (PRAME)<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,620</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,254</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">2,264</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IMC-C103C (MAGE-A4)<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">4,654</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">3,602</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">2,284</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other programs<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">8,471</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">6,556</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">4,653</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research expenses<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">536</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">415</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">567</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total external research and development expenses<font style="font-weight: normal; padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">50,040</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">38,728</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">51,803</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Internal research and development expenses:<br></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Headcount related expenses<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">18,510</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">14,325</div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;">16,895</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory consumables<font style="padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">4,199</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">3,250</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">5,123</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment expenses<font style="padding-left: 1.1pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,552</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,201</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 5pt;">1,231</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 2.73pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">80</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">62</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">363</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total internal research and development expenses<font style="font-weight: normal; padding-left: 4.08pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">24,341</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,838</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">23,612</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="font-weight: normal; padding-left: 1.29pt;"></font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">74,381</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">57,566</font></div></td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.6%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.63%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.11pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">75,415</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, our research and development expenses were &#163;57.6&#160;million compared to &#163;75.4&#160;million for the nine months ended September&#160;30, 2019. This decrease of &#163;17.8&#160;million was primarily attributable to a decrease in external research and development expenses of &#163;13.1&#160;million. External expenses incurred for our tebentafusp program decreased by &#163;15.1&#160;million due to the following: the achievement of full patient enrollment in the pivotal trials for tebentafusp in 2019 and the associated decrease in patient expenses that are incurred during patient enrollment as well as the manufacture of tebentafusp required for regulatory approval being substantially completed in 2019. External expenses incurred for our IMC-F106C program decreased by &#163;1.0&#160;million due to the program being placed on partial clinical hold during the nine months ended September&#160;30, 2020. This amount was partially offset by an increase in external expenses for IMC-C103C of &#163;1.3&#160;million and for other programs of &#163;1.9&#160;million primarily driven by the development of IMC-I109V for HBV due to increased clinical activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, our internal research and development expenses decreased by &#163;4.8&#160;million driven by a decrease in headcount-related expenses and consumables of &#163;2.6&#160;million. The </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">109<br></div></div></div>
<!--End Page 114-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 115-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">decrease in headcount-related expenses was due to a decrease in headcount partially offset by corporate restructuring costs of &#163;1.2&#160;million. As a result of the corporate restructuring, which was completed in the second quarter of 2020, our overall headcount was reduced by 78. The decrease in laboratory consumables required reflects both a decrease in headcount and a slowdown of some internal research and development activities as a result of the COVID-19 pandemic as noted above under &#8220;COVID-19 Business Update.&#8221; The decrease in other expenses relates to reduced travel expenses incurred, again as a result of the COVID-19 pandemic. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, general and administrative expenses were &#163;31.6 million, compared to &#163;35.6&#160;million for the nine months ended September&#160;30, 2019. The decrease of &#163;4.0&#160;million is due to the following: a decrease in pre-commercial spend related to tebentafusp of &#163;3.1&#160;million, favorable foreign exchange movements of &#163;2.4&#160;million, a decrease in the depreciation charge of &#163;0.6 million&#160;following the disposal of our interest in a leasehold property and &#163;0.6 million&#160;relating to reduced travel expenses incurred as a result of the COVID-19 pandemic. This is partially offset by an increase in the share-based compensation charge of &#163;2.7&#160;million. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Finance Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, finance income was &#163;2.0&#160;million compared to &#163;1.1&#160;million for the nine months ended September&#160;30, 2019. This increase of &#163;0.9&#160;million reflects the movement in fair value of the derivative liability for &#163;1.3&#160;million, a foreign exchange call option over certain series B preferred shares which was settled in full on March&#160;2, 2020, partially offset by a decrease of &#163;0.4&#160;million in interest received on cash and cash equivalents.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Finance Costs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, finance costs amounted to &#163;2.3&#160;million, compared to &#163;6.5&#160;million for the nine months ended September&#160;30, 2019. This decrease of &#163;4.2&#160;million reflects primarily the movement in fair value of the derivative liability of &#163;3.1&#160;million representing a foreign exchange call option of certain series B preferred shares. In addition, interest expenses on financial liabilities measured at amortized cost decreased by &#163;0.5&#160;million following conversion of our outstanding loan from the Bill &amp; Melinda Gates Foundation, or Gates Foundation, into series B shares on March&#160;2, 2020 and a decrease in interest on lease liabilities of &#163;0.5&#160;million. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Income Tax Credit</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the nine months ended September&#160;30, 2020, the income tax credit amounted to &#163;11.1&#160;million compared to &#163;18.0&#160;million for the nine months ended September&#160;30, 2019. This decrease of &#163;6.1&#160;million primarily relates to a reduction in loss before taxes of &#163;29.6 million. For interim periods, income tax credit is recognized at an amount determined by multiplying the loss before taxation for the interim reporting period by our best estimate of the weighted-average annual income taxation rate expected for the full financial year adjusted for significant items. As such, the effective tax rate in the interim financial statements may differ from our estimate of the effective tax rate for the annual reporting periods. Our effective tax rate was 18.8% and 16.8% for the nine months ended September&#160;30, 2019 and 2020, respectively.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Comparison of the Years ended December 31, 2018 and 2019</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our results of operations for the years ended December 31, 2018 and 2019:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 3.33pt;">25,669</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 3.33pt;">23,654</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses<font style="padding-left: 3.68pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(99,991)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;">(83,575)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses<font style="padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(44,183)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;">(34,156)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">185</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">622</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"> </font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">110<br></div></div></div>
<!--End Page 115-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 116-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.67%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.61%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.7%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="font-weight: normal; padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(118,320</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(93,455</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 8.33pt;">4,979</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 13.33pt;">1,510</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 8.33pt;">1,140</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(9,379</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(842</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating (expense) / income<font style="font-weight: normal; padding-left: 2pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(7,869</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">5,277</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"> </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxes<font style="font-weight: normal; padding-left: 2.72pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.24pt; text-align: left;">(126,189)</div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.51pt; text-align: left;">(88,178)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">22,258</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">16,548</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"> </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss<font style="font-weight: normal; padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.61%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(103,931</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.7%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.51pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(71,630</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Revenue</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GSK<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">5,753</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">6,079</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 12.5pt;">819</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">8,561</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;">19,097</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">1,461</font> </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">MedImmune<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,553</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,669</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,654</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, revenue from collaboration agreements was &#163;25.7&#160;million, compared to &#163;23.7&#160;million for the year ended December&#160;31, 2018. The increase of &#163;2.0&#160;million was due to the recognition of an additional &#163;17.6&#160;million revenue under the 2018 Genentech Agreement, which was executed in November 2018. This was partially offset by the reduction of revenue recognized under the Lilly Collaboration of &#163;7.7&#160;million reflecting a slowdown in percentage completion as a result of extended program timelines, and the recognition of &#163;7.6&#160;million revenue upon the termination of the last program under our prior collaboration with MedImmune. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">External research and development expenses:<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tebentafusp <font style="padding-left: 0.44pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;">52,406</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;">34,493</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IMC-F106C (PRAME)<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">2,825</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">1,179</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">IMC-C103C (MAGE-A4)<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">3,182</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">2,315</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other programs<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">8,870</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">9,710</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research expenses<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">795</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,025</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total external research and development expenses<font style="font-weight: normal; padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">68,078</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">48,722</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Internal research and development expenses:<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Headcount related expenses<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;">23,320</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;">23,475</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory consumables<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">6,704</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">8,146</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment expenses<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5.37pt;">1,411</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt;">1,589</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other<font style="padding-left: 4.73pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">478</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,643</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total internal research and development expenses<font style="font-weight: normal; padding-left: 1.08pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">31,913</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">34,853</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses<font style="font-weight: normal; padding-left: 3.29pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">99,991</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">83,575</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, our research and development expenses were &#163;100.0&#160;million compared to &#163;83.6&#160;million for the year ended December&#160;31, 2018. This increase of &#163;16.4&#160;million was primarily </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">111<br></div></div></div>
<!--End Page 116-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 117-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">due to increased external research and development expenses of &#163;19.4&#160;million including the increased clinical trial activity during 2019 for our tebentafusp program in the amount of &#163;17.9&#160;million, our IMC-F106C program in the amount of &#163;1.6&#160;million and our IMC-C103C program in the amount of &#163;0.9&#160;million, partially offset by a decrease in external expenses incurred for our other programs of &#163;0.8&#160;million. Internal research and development expenses decreased by &#163;3.0&#160;million driven by a decrease in expenses related to laboratory consumables for &#163;1.4&#160;million equipment and a decrease in travel-related expenditure of &#163;1.1&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, general and administrative expenses increased to &#163;44.2&#160;million from &#163;34.2&#160;million for the year ended December&#160;31, 2018. This increase of &#163;10.0&#160;million was primarily driven by an increase in salary and personnel costs reflecting an increase in headcount during the year, offset by a decrease of &#163;3.9&#160;million which reflects the adoption of IFRS, 16 &#8216;<font style="font-style: italic;">Leases</font>&#8217; which was adopted with effect from January&#160;1, 2019. Please refer to &#8220;Recently Issued and Adopted Accounting Pronouncements&#8221; for further information.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Other Operating Income</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, other operating income totaled &#163;0.2&#160;million, compared to &#163;0.6&#160;million for the year ended December&#160;31, 2018. The decrease of &#163;0.4&#160;million reflects the reclassification of certain sub-lease income received during the year to finance income in accordance with IFRS 16, &#8216;<font style="font-style: italic;">Leases</font>&#8217; which was adopted with effect from January&#160;1, 2019. Please refer to &#8220;Recently Issued and Adopted Accounting Pronouncements&#8221; for further information. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Other Income</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other income received during the year ended December&#160;31, 2018 represents a gain of &#163;5.0&#160;million arising on the disposal of a fixed asset investment in Adaptimmune Therapeutics plc. There was no similar income received in 2019.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Finance Income </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, finance income was &#163;1.5&#160;million compared to &#163;1.1&#160;million for the year ended December&#160;31, 2018, primarily reflecting increased bank interest received on cash and cash equivalent balances of &#163;1.4&#160;million and &#163;0.1&#160;million gain on entering into sub-leases on leasehold properties. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Finance Costs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, finance costs amounted to &#163;9.4&#160;million, compared to &#163;0.8&#160;million during the year ended December&#160;31, 2018. This increase reflects the movement in fair value of a derivative liability of &#163;5.1&#160;million, &#163;2.9&#160;million of interest on lease liabilities and &#163;0.5&#160;million change in the fair value of an embedded derivative asset. The derivative liability represents a foreign exchange call option of certain series B preferred shares which was settled in full in March 2020. The embedded derivative asset is associated with the Gates Foundation convertible loan as the conversion features of the loan are accounted for as an embedded derivative and accounted for separately from the loan. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Income Tax Credit</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2019, the income tax credit amounted to &#163;22.3&#160;million compared to &#163;16.5&#160;million for the year ended December&#160;31, 2018. Our income tax balance largely comprised of research and development tax credits which increased over the year due to an underlying increase in qualifying research and development expenditure. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Sources of Liquidity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September&#160;30, 2020, we have raised an aggregate of $748.2&#160;million (&#163;579.1 million) through private placements of our ordinary and preferred shares, payments from our collaboration partners, and most recently, through debt financing. Subsequent to this date, we drew down $50 million (&#163;38.7 million) pursuant to the first tranche of our debt facility that we entered into with Oxford Finance, and we closed the sale of our Series C preferred shares resulting in gross proceeds of $75.0 million (&#163;58.0&#160;million). </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">112<br></div></div></div>
<!--End Page 117-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 118-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September&#160;30, 2020, and December&#160;31, 2019, we had cash and cash equivalents of &#163;56.7&#160;million and &#163;74.0&#160;million, respectively. Subsequent to September&#160;30, 2020, we drew down an aggregate of $50.0&#160;million under the Loan Agreement (as defined below) with Oxford Finance. See &#8220;&#8212;Loan Agreement with Oxford Finance Luxembourg S.A.R.L.&#8221; Cash and cash equivalents are invested in accordance with our treasury policy, primarily with a view to liquidity and capital preservation placing cash in financial institutions on short-term deposit with an original maturity ranging from one to nine months. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, subsequent to September&#160;30, 2020, we also reached an agreement to exit a lease agreement for a leasehold property. As a result, we will receive &#163;1.4&#160;million lease incentive for exiting the lease early as well as the repayment of &#163;1.8&#160;million security deposit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in December 2020, we closed the sale of 823,719 of our Series C preferred shares which resulted in gross proceeds of $75.0&#160;million (&#163;58.0&#160;million).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes the primary sources and uses of cash for each period presented:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 30.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Nine months ended September&#160;30,</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.37%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31,</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 </div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$000</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.22%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.84%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.82%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(unaudited)</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.86%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.22%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.2%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.49%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Brought forward<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;"><font style="padding-left: 3.33pt;">95,572</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 3.33pt;">73,966</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;">124,385</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;"><font style="padding-left: 3.33pt;">124,385</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="padding-left: 5pt;">82,883</font> </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="padding-left: 0.68pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;">(51,683)</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;">(39,998)</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 1.67pt;">(75,690)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;">(101,376)</div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="padding-left: 1.67pt;">(16,626)</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net cash (used in) / provided by investing activities<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;"><font style="padding-left: 5pt;">(1,739)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 5pt;">(1,346)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,543)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;"><font style="padding-left: 10pt;">(4,137)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="padding-left: 5pt;">58,014</font> </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by financing activities<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;"><font style="padding-left: 3.33pt;">30,983</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 3.33pt;">23,978</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 5pt;">56,172</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;"><font style="padding-left: 8.33pt;">55,127</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="padding-left: 17.5pt;">101</font> </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign exchange on cash held<font style="padding-left: 2.33pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;"><font style="padding-left: 16.2pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">112</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">87</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">74</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(33</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">13</font><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;"> </font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.82%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.22pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">73,245</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">56,687</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.22%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.64pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">102,398</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.6pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">73,966</font></div></td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.84%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.61pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">124,385</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Operating Activities </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities decreased to &#163;40.0&#160;million for the nine months ended September&#160;30, 2020 from &#163;75.7&#160;million for the nine months ended September&#160;30, 2019. The decrease of &#163;35.7&#160;million is driven by lower operating expenses of &#163;22.8 million and increased receipts of the research and development tax credits of &#163;25.1&#160;million partially offset by a decrease in trade payables of &#163;12.0&#160;million.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in operating activities increased to &#163;101.4&#160;million for the year ended December&#160;31, 2019 from &#163;16.6&#160;million for the year ended December&#160;31, 2018. This is driven by both an increase in operating expenses and a decrease in upfront payments received under collaboration agreements during the year ended December&#160;31, 2019 of &#163;80.8&#160;million due to the receipt of an upfront payment from Genentech in the amount of $100.0&#160;million (&#163;77.4&#160;million) during the year ended December&#160;31, 2018. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Investing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in investing activities for the nine months ended September&#160;30, 2020 was &#163;1.3&#160;million compared to &#163;2.5&#160;million for the nine months ended September&#160;30, 2019. The decrease in cash used in investing activities was driven by the receipt of &#163;1.1&#160;million lease capital contribution relating to a leasehold property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash used in investing activities for the year ended December&#160;31, 2019 was &#163;4.1&#160;million primarily related to capital expenditure incurred on leasehold improvements and plant and equipment. Net cash provided by investing activities for the year ended December&#160;31, 2018 of &#163;58.0&#160;million of income, driven by &#163;27.5&#160;million cash consideration for the disposal of the fixed asset investment in Adaptimmune Therapeutics plc and the realization of long-term treasury deposits with a value of &#163;34.1&#160;million.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Financing Activities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash provided by financing activities during the nine months ended September&#160;30, 2020 was &#163;24.0&#160;million, reflecting funding of &#163;47.1&#160;million from the second and final closing of the series B preferred share financing in March 2020. Of this amount, &#163;19.9 million related to non-cash consideration arising from the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">113<br></div></div></div>
<!--End Page 118-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 119-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">conversion of the Gates Foundation loan into series B preferred shares. Net cash provided by financing activities during the nine months ended September&#160;30, 2019 was &#163;56.2 million representing &#163;59.2&#160;million raised from the first closing of the series B preferred share financing partially offset by &#163;3.0&#160;million of lease liability repayments.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Net cash provided by financing activities during the year ended December&#160;31, 2019 was &#163;55.1&#160;million. This amount represents &#163;59.9&#160;million of funding received from the first closing of the series B preferred share financing in August 2019 partially offset by the repayment of lease liabilities of &#163;4.0&#160;million. Net cash provided by financing activities during the year ended December&#160;31, 2018 totaled &#163;0.1&#160;million arising from exercise of share-based compensation awards. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Loan Agreement with Oxford Finance Luxembourg S.A.R.L.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On November&#160;6, 2020, we entered into a loan and security agreement, or the Loan Agreement with Oxford Finance for the provision of up to $100&#160;million (&#163;77.4 million) debt financing to fund our working capital and other general corporate needs. The loan is subject to funding in three tranches, of which the first tranche of $50&#160;million was received on signing the Loan Agreement. The second tranche of $25&#160;million can be drawn down upon tebentafusp receiving BLA approval from the FDA prior to June&#160;30, 2022 and the third and final tranche of $25&#160;million can be drawn down at the sole discretion of Oxford Finance. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Borrowings under the Loan Agreement bear interest at an annual rate equal to LIBOR plus 8.85%, with a minimum rate of 9.01% and a maximum rate of 12.01%. Borrowings under the Loan Agreement are repayable in monthly interest-only payments through November 2023. The interest only period may be extended for an additional twelve months upon tebentafusp receiving BLA approval from the FDA. The ultimate interest-only period will be followed by equal monthly payments of principal and interest to the maturity date in November 2025. Our obligations under the Loan Agreement may be prepaid in part or part at any time; provided that we may prepay in full or in part a minimum of $10&#160;million of our obligations together with accrued interest and a prepayment fee. Our obligations under the Loan Agreement are secured by substantially all our current and future assets, including our intellectual property.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants applicable to us, including limitations on our ability to dispose of assets, enter into merger, consolidation or acquisition transactions and incur additional debt. The Loan Agreement includes customary events of default, including but not limited to the nonpayment of principal or interest, violations of covenants and material adverse changes. Upon an event of default, the lender may, among other things, accelerate the loans and foreclose on the collateral.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Operation and Funding Requirements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since our inception, we have incurred significant losses due to our substantial research and development expenses. We have an accumulated deficit of &#163;331.0 million as of September 30, 2020. We expect to continue to incur significant losses in the foreseeable future and expect our expenses to increase in connection with our ongoing activities, particularly as we continue research and development and clinical activities for our product candidates. In addition, upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Our expenses will also increase if, and as, we:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to advance the development of our clinical trials and pre-clinical programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">continue to invest in our soluble TCR platforms to conduct research to identify novel technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">change or add additional suppliers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to support our operations as we progress product candidates toward commercialization;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek to attract and retain skilled personnel;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create additional infrastructure to support our operations as a public company listed in the United States and our product development and planned future commercialization efforts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek marketing approvals and reimbursement for our product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">114<br></div></div></div>
<!--End Page 119-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 120-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek to identify and validate additional product candidates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquire or in-license other product candidates and technologies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintain, protect, defend, enforce and expand our intellectual property portfolio; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">experience any delays, interruptions or encounter issues with any of the above, including any delays or other impacts as a result of the COVID-19 pandemic.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We held cash and cash equivalents of &#163;56.7 million as at September 30, 2020. Subsequent to this date, we drew down $50&#160;million (&#163;38.7 million) pursuant to the first tranche of our debt facility that we entered into with Oxford Finance, and we closed the sale of our Series C preferred shares resulting in gross proceeds of $75.0 million. We believe that our existing cash and cash equivalents, together with our debt facility, is sufficient to enable us to fund our planned operating expenses and capital expenditure requirements to February 2022. This estimation of funding requirements includes a rigorous assessment of the forecasts and identified reasonable risks and mitigating actions referred to elsewhere in the prospectus, including the ongoing impact of the COVID-19 pandemic. We expect that our existing cash and cash equivalents, including the proceeds of this offering, will fund our operations to &#8195;&#8195;&#8195;. We have based this estimation of capital requirements on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. We are subject to the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Our forecast of sufficient financial runway to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. Our future funding requirements will depend on many factors, including, but not limited to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical sites, enroll subjects and manufacture soluble bispecific TCR product candidates for our ongoing, planned and potential future clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">time and costs required to perform research and development to identify and characterize new product candidates from our research programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">time and cost necessary to obtain regulatory authorizations and approvals that may be required by regulatory authorities to execute clinical trials or commercialize our products;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to successfully commercialize our product candidates, if approved;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to have clinical and commercial products successfully manufactured consistent with FDA, EMA and other authorities&#8217; regulations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">amount of sales and other revenues from product candidates that we may commercialize, if any, including the selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales and marketing costs associated with commercializing our products, if approved, including the cost and timing of building our marketing and sales capabilities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">terms and timing of any revenue from our existing collaborations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of operating as a public company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">time and cost necessary to respond to technological, regulatory, political and market developments;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">costs, associated with, and terms and timing of, any future any potential acquisitions, strategic collaborations, licensing agreements or other arrangements that we may establish; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">inability of clinical sites to enroll patients as healthcare capacities are required to cope with natural disasters, epidemics or other health system emergencies, such as the COVID-19 pandemic.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">115<br></div></div></div>
<!--End Page 120-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 121-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development and commercialization of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements as well as grant funding. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our shareholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our shareholders&#8217; ownership interest will be diluted. If we raise additional capital through debt financing, it would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain additional funding on favorable terms when needed, we may have to delay, reduce the scope of or terminate one or more of our research and development programs or clinical trials.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Internal Control Over Financial Reporting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the summer and fall of 2020, we conducted an internal investigation as a result of receiving a whistle blower complaint alleging employee misconduct and other improper activities related to a kick-back scheme involving an employee and two third-party vendors between 2018 and 2020. Our audit committee led the investigation utilizing outside counsel, during which the named employee resigned. After the investigation, we terminated the one remaining open contract with the third party vendors and issued proceedings in October 2020 against the involved parties. The amount in question was estimated to be in the range of &#163;1.1 million to &#163;1.8 million, and we recovered &#163;1.8 million from the employee and third-party vendors in December 2020. As a result of this investigation, we identified a material weakness relating to our procurement processes and application of delegation of authority approval limits due to insufficient risk assessment procedures. We determined that our internal controls did not operate effectively to prevent or timely detect unauthorized contracts and purchase orders. This resulted in the inability to prevent and timely detect these fraudulent activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have taken and continue to take steps to remediate the aforementioned material weakness and to enhance our overall control environment, including adding personnel to drive and implement required additional procurement controls, implementing improvements in software relating to approvals of purchase orders and contracts, adding additional layers of review of contracts and journal entries and delegation of contract authority limits. However, we cannot assure you that these measures will be sufficient to prevent future material weaknesses or significant deficiencies in our internal control over financial reporting from occurring. See &#8220;Risk Factors&#8212;We have identified a material weakness in our internal control over financial reporting and may identify material weaknesses in the future or otherwise fail to maintain proper and effective internal controls, which may impair our ability to produce timely and accurate financial statements or prevent fraud. If we are unable to establish and maintain effective internal controls, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.&#8221;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">116<br></div></div></div>
<!--End Page 121-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 122-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Commitments </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table summarizes our contractual obligations as of September&#160;30, 2020 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As at September&#160;30, 2020 </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160;year </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1-3&#160;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3-5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than 5&#160;years </div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; existing <font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.92pt; text-align: left;"><font style="padding-left: 5pt;">4,275 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">7,910</font> </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.45pt;">6,548</font> </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">35,657 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">54,390 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; contingent <font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.92pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">2,254 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.45pt;">2,471 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 5pt;">1,841 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,566 </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Manufacturing<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.92pt; text-align: left;"><font style="padding-left: 5pt;">2,021 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">471 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 16.95pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">2,492 </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital commitments <font style="padding-left: 1.52pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.92pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,134 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 16.95pt; border-bottom: 1pt solid #000000; min-width: 26.95pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212; </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,134 </font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contractual obligations (in thousands, pounds)<font style="font-weight: normal; padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.92pt; text-align: left;"><font style="padding-left: 5pt;">8,430 </font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10,635 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.45pt;">9,019</font> </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">37,498 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">65,582 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contractual obligations (in thousands, U.S. dollars)<font style="font-weight: normal; padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.92pt; text-align: left;">10,373 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">13,741 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">11,653 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">48,451 </div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">84,737</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Lease liabilities are for leasehold properties and represent the contractual lease obligations over the expected lease term. Also included are future lease obligations for leasehold properties we do not currently lease but are under contractual obligation to do so should the properties become vacant in the future. Subsequent to September&#160;30, 2020, we reached an agreement to exit a substantial leasehold property obligation prior to the end of 2020. The impact of this agreement reduces our total contractual obligations by &#163;7.7 million. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Manufacturing obligations represent manufacturing of primarily tebentafusp required for regulatory approval. Such manufacturing expenditure are expensed as incurred and where payments are made to the CMOs in excess of the level of services provided, a prepayment is recognized. Capital commitments are contracts for fixed assets which will be received in future periods.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally provide us the option to cancel, reschedule and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. However, it is not possible to predict the maximum potential amount of future payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Off-Balance Sheet Arrangements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the periods presented, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosures about Market Risk </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are exposed to interest rate, currency, credit and liquidity risks. Our executive board oversees the management of these risks supported by a financial risk committee that advises on financial risks and the appropriate financial risk governance framework for us. The financial risk committee provides assurance to our executive board that our financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with our policies and risk objectives. The most significant financial risks to which we are exposed include the risks discussed below.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our principal financial assets include trade and other receivables and cash and security deposits that derive directly from our operations. Our principal financial liabilities comprise our convertible loan from the Gates Foundation, a derivative liability, lease liabilities and trade and other payables. The main purpose of these financial liabilities is to finance our operations. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Interest Rate Risk</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our exposure to changes in interest rates relates to investments in deposits and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. As a result of entering into the Loan Agreement with Oxford Finance, we are exposed to further interest rate risk as a variable rate of interest will be applied within a defined cap and collar over the team of the debt. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">117<br></div></div></div>
<!--End Page 122-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 123-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regarding the liabilities shown in the statement of financial position, we are currently not subject to interest rate risks.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Currency Risk</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Our exposure to the risk of changes in foreign exchange rates relates primarily to our operating activities in the United States and outsourced supplier agreements denominated in currencies other than pound sterling.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our cash and cash equivalents were &#163;56.7 million and &#163;74.0 million as of September 30, 2020 and December 31, 2019, respectively. As of September 30, 2020, 91% of our cash and cash equivalents were held in United Kingdom, of which 76% were denominated in pounds sterling, 17% were denominated in U.S. dollars and 7% were denominated in euros. The remainder of our cash and cash equivalents (9%) are held in the United States and denominated in U.S. dollars. A hypothetical 10% change in exchange rates during any of the periods presented would not have had a material impact on our consolidated financial statements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A one percentage point increase in exchange rates would reduce the carrying value of net financial assets and liabilities held in foreign currencies at September 30, 2020 by &#163;152,000 and as at December 31, 2019 by &#163;131,000. A one percentage point decrease in exchange rates would increase the carrying value of net financial assets and liabilities held in foreign currencies at September 30, 2020 by &#163;152,000 and as at December 31, 2019 by &#163;131,000. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Credit Risk</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are exposed to credit risk from our operating activities, primarily trade receivables, and cash, cash equivalents and deposits held with banks and financial institutions. Cash, cash equivalents and deposits are maintained with high-quality financial institutions in the United Kingdom. We are also potentially subject to concentrations of credit risk in our trade receivables. Concentrations of credit risk are with respect to trade receivables owed by a limited number of companies comprising our customer base. Our exposure to credit losses is low, however, owing largely to the credit quality of our collaboration partners which are significantly larger than us. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We continually monitor our positions with, and the credit quality of, the financial institutions and corporations, which are counterparts to our financial instruments and do not anticipate non-performance. The maximum default risk corresponds to the carrying amount of the financial assets shown in the statement of financial positions. We monitor the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from equity measures.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Liquidity Risk</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We continuously monitor our risk to a shortage of funds. Our objective is to maintain a balance between continuity of funding and flexibility through the use of capital increases. Our financial statements were prepared on a going concern basis, however there is a material uncertainty related to events or conditions that may cast significant doubt on our ability to continue as a going concern and we may therefore be unable to realize our assets and discharge our liabilities in the normal course of business. See &#8220;&#8212;Going Concern&#8221;.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Going Concern</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We held &#163;56.7&#160;million and &#163;129.7 million of cash at September&#160;30, 2020 and December&#160;31, 2020, respectively. We recorded an operating loss of &#163;118.3&#160;million at December&#160;31, 2019 and a further operating loss of &#163;66.0&#160;million for the nine months ended September&#160;30, 2020. We did not generate positive operational cash flow which was largely due to the continuing focus on the research, development and clinical activities to advance the other product candidates within the our pipeline.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In assessing the going concern assumptions, our board of directors has undertaken a rigorous assessment of the forecasts and assessed identified downside risks and mitigating actions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The increase in cash between September 2020 and December 2020 arose following the recent closing of our Series&#160;C preferred share financing under which a total of $75.0&#160;million was raised in December 2020 and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">118<br></div></div></div>
<!--End Page 123-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 124-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">borrowings of $50.0&#160;million under a loan facility with Oxford Finance received in November 2020. We have increased our forecast costs to include those costs required to commercialize tebentafusp, assuming we receive regulatory approval, based on the positive tebentafusp Phase&#160;3 clinical trial data announced in November 2020 and the increased capital raised. Due to our plans to continue to develop and commercialize tebentafusp and other product candidates, we will require additional financing in the form of equity financing or loan financing in the future in order to continue our operations and current capabilities beyond the first quarter of 2022. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The downside risks include a number of severe but plausible scenarios incorporating underperformance against the business plan, and delays in cash inflows. As part of these risks, our board of directors has considered the impact of the ongoing COVID-19 pandemic. While it is difficult to estimate the impact of the COVID-19 pandemic due to the rapidly changing nature of the pandemic, the cash flow forecasts include our current assumptions, taking into account reasonable plausible downsides. The assumptions include no additional receipts from forecasted milestones for the next 12&#160;months, a reduction in related operational costs and lower discretionary capital expenditures. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite the above uncertainties, our board of directors has the confidence that the accounts should be prepared on a going concern basis for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we have key worker status which allows continuity of providing services throughout a prolonged lockdown period;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we have a track record of meeting expectations under its collaboration agreements and meeting expected milestones within the contracted timeframe;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we have a history of being able to access equity and loan financing as and when needed; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we have the ability and history to control capital expenditure costs and lower other operational spend, as necessary.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Therefore, the our board of directors has continued to adopt the going concern basis of preparation in the financial statements. Whilst our board of directors is progressing with its plans to secure additional financing from an initial public offering, it has assessed that should this not proceed that it would be unable to generate sufficient cash flows to support its level of activities beyond February 2022 in downside scenarios. This gives rise to a material uncertainty related to events or conditions that may cast significant doubt on our ability to continue as a going concern and that it may therefore be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Significant Judgments and Estimates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our consolidated financial statements for the years ended December&#160;31, 2018 and 2019, and for the nine months ended September&#160;30, 2019 and 2020, respectively have been prepared in accordance with IFRS. The preparation of the consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the value of assets and liabilities&#8212;as well as contingent assets and liabilities&#8212;as reported on the statement of financial position date, and revenues and expenses arising during the fiscal year. The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Judgements and assumptions are primarily made in relation to revenue recognition to determine whether promises contained within the collaboration agreements are distinct from the other promises in the contract, whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and for performance obligations satisfied over time the appropriate method of measuring progress for the purposes of revenue recognition. Estimates and assumptions are also made in relation to the valuation of ordinary shares, the incremental borrowing rate for leases, and valuation of derivatives. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Hence, our estimates may vary from the actual values.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our significant accounting policies are more fully described in the notes to our consolidated financial statements appearing elsewhere in this prospectus. We believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our consolidated financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">119<br></div></div></div>
<!--End Page 124-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 125-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Revenue Recognition for Collaboration Agreements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our collaboration agreements, we may receive upfront licensing payments, milestone payments and reimbursement of research and development expenses. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Within the collaboration agreements, we grant licensing rights and access to our technology to develop specified targets and commercialize future product candidates for specified targets defined in the respective collaboration agreements, in addition to research and development services and participation on a joint steering committee. In each of our collaboration agreements, these promises represent one combined performance obligation, because the promises are mutually dependent and the collaborator is unable to derive significant benefits from its access to these targets for their intended purpose without receipt of the remaining promises, which are highly specialized and cannot be performed by other organizations. This single combined performance obligation is satisfied over time and deemed fully satisfied when the collaborator is contractually entitled to benefit from the exclusive rights to the associated intellectual property license either through the collaborator exercising an option to do so, or at our election. This occurs at different stages of the research and development process within each of the collaboration agreements. Once the collaborator has obtained exclusive rights to the associated intellectual property, we have no further contractual obligations relating to the performance obligation and accordingly the performance obligation is deemed satisfied and complete at this point. We account for each collaboration agreement and the related targets as having one combined performance obligation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where we receive development milestones at key inflection points specified within the collaboration agreements, these are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. We determine the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applying a constraint to reduce the consideration to the amount which is not probable of being reversed. The determination of whether a milestone is probable includes consideration of the following factors:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies or the customer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether we can reasonably predict that a milestone will be achieved based on previous experience; and.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the complexity and inherent uncertainty underlying the achievement of the milestone.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any development milestone revenue adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No variable consideration was included at December 31, 2018 and 2019 or September&#160;30, 2019 and 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under these collaboration agreements, we may also receive commercialization milestones upon the first commercial sale of a product, the amount of which is based on the territory the sale occurs in, and royalties based on worldwide net sales. These amounts have not been included within the transaction price as of December&#160;31, 2018 and 2019 or September&#160;30, 2019 and 2020 because they are sales-based royalties which will be recognized when the subsequent sale occurs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Revenue is recognized as the programs progress through the various stages of research and development using an estimate of percentage completion which takes into consideration the estimated timelines required to satisfy the performance obligation and the time taken since program nomination. The determination of the percentage of completion requires us to estimate when the performance obligation will be completed, and this is reviewed and re-assessed quarterly, typically by the joint steering committee for the contract, based on the latest project plan and discussions with project teams and will consider progress achieved to date, historical experience on similar programs and other internal factors as may be available. If a change in facts or circumstances occurs, the estimate of percentage completion is adjusted, and revenue recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate is recognized as an adjustment to revenue in the period in which the change in estimate occurs. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">120<br></div></div></div>
<!--End Page 125-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 126-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We recognize deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied, or part satisfied, performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Changes in deferred revenue typically arise due to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustments arising from a change in the estimate of when the performance obligation will have been completed.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustment to revenue that affects deferred revenue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a change in the estimate of the transaction price due to changes in the assessment of whether variable consideration is constrained because it is not considered probable of being received; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the recognition of revenue.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under certain collaboration agreements, research and development costs incurred either in excess of a defined amount, or in accordance with a cost sharing agreement, are reimbursed. These amounts are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. We determine the variable consideration to be included in the transaction price by estimating the expected value that will be received and then applying a constraint to reduce the consideration to the amount which is not probable of being reversed. The determination of whether reimbursed costs are highly probable to not be reversed includes the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">past history and experience with similar contracts.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unexpected fluctuations in planned spend.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes to project timelines.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Research and development expenditure is expensed as incurred. As part of the financial close reporting process, we may be required to estimate accrued research and development expenditure incurred, the most significant of which is that relating to ongoing clinical trials. These estimates are based on reviews of open contracts, reports provided by the CROs and internal reviews to estimate the level of service performed and the associated cost incurred for those services when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our CROs invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each statement of financial position date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the CROs and adjust if necessary. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial terms agreed with the CROs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the CROs will exceed the level of services provided and result in either a prepayment of the research and development expenses or, where the payments are returned back to us at the end of the clinical trial, a non-current financial asset. In accruing clinical trial expenses, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepayment expense accordingly.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We operate equity-settled, share-based compensation plans whereby certain of our employees and directors are granted awards over the shares in our company. The grant date fair value of awards granted under these share-based compensation plans is calculated using both the Black Scholes valuation model and the Back Solve valuation model. The resulting cost is recognized in the profit and loss account over the vesting period of the awards, being the period in which the services are received. The value of the charge is adjusted to reflect actual levels of awards vesting, except where the failure to vest is as a result of not meeting a market condition. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The valuations models used require the input of subjective assumptions, including assumptions about the expected life of share-based awards, share price volatility and as a privately held company the estimated fair </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">121<br></div></div></div>
<!--End Page 126-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 127-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">value of our ordinary shares. These assumptions used represent our best estimates at the time of grant, but the estimates involve inherent uncertainties and the application of our judgment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The various assumptions used in determining the grant date fair value of the awards and the resulting cost recognized in the profit and loss account are set out in the notes to our consolidated financial statements appearing elsewhere in this prospectus. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Valuation of Ordinary Shares </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As there has been no public market for our ordinary shares to date, the estimated fair value of our ordinary shares has been determined by our board of directors as of the date of each grant, with input from management, considering our most recently available third-party valuations of our ordinary shares, and our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Our ordinary share valuations were prepared using a probability weighting expected return and a current value method. The probability weighted expected return method estimates the fair value of the common stock based on an analysis of future values for the enterprise assuming various future outcomes. Share value is based on the probability weighted present value of the expected future investment returns, considering each of the possible outcomes available to the enterprise, as well as the rights of each share class. Common future outcomes considered in the analysis include an initial public offering, merger or sale, continued operation as a private company, and liquidation. The current-value method is based on the assumption that each class of preferred stockholders will exercise its rights and achieve its return based on the enterprise value as of the valuation date and not at some future date. Accordingly, preferred stockholders will participate in enterprise value allocation either as preferred stockholders or, if conversion would provide them with better economic results, as common stockholders. Common shares are assigned a value equal to their pro rata share of the residual amount (if any) that remains after consideration of the liquidation preference of debt and preferred stock. Likewise, any outstanding options will share in the enterprise value only if the implied value of the fully-diluted common share resulting from the analysis indicates that the options are in-the-money. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our ordinary shares as of each grant date, including:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the data generated from our research and development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our future operating performance, prospects and business strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the material risks related to our business and industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of an active public market for our ordinary and convertible preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market performance of publicly traded companies in the life science and biotechnology sectors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prices at which we issued ordinary and preferred shares and the superior rights and preferences of the preferred shares relative to the ordinary shares at the time of each grant; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood of achieving a liquidity events for the holders of our ordinary shares, series A preferred and series B preferred shares and G shares, such as an initial public offering, given prevailing market conditions.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we had made different judgements and estimates, our share-based payment expense, loss for the year and total comprehensive loss, on both an absolute and per-share basis, could have been significantly different.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Estimates by our management board will not be necessary to determine the fair value of ordinary shares once a public trading market for our ordinary shares has been established in connection with the completion of this offering.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Leases</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our right of use assets and lease liabilities associated with leases for leasehold properties are recognized at lease commencement date based on the present value of minimum lease payments over the lease term. Since the rate implicit in the lease is not readily determinable, we use the incremental borrowing rates based on indicative </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">122<br></div></div></div>
<!--End Page 127-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 128-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_109-mda_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">borrowing rates that would be available based on the value, currency and borrowing term provided by financial institutions, adjusted for company and market specific factors. This incremental borrowing rate is the rate of interest that we would have to pay to borrow on a collateralized basis an amount equal to the lease payments over a similar term in a similar economic environment, based on the information available at commencement date in determining the discount rate used to calculate the present value of lease payments. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Valuation of Derivatives</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have both an embedded derivative asset and a derivative liability that are marked to fair valued at each reporting period. The embedded derivative asset is associated with the Gates Foundation convertible loan whereby the conversion features of the loan are accounted for as an embedded derivative and accounted for separately from the loan. This loan was converted into series B preferred shares in March 2020 and the embedded derivative asset derecognized. The derivative liability represents a foreign exchange call option of certain series B preferred shares which was settled in full in March 2020.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The fair value of the embedded derivative asset was determined using an the Back Solve model, discounted and probability weighted for the conversion features within the underlying convertible loan, which includes unobservable inputs supported by little or no market activity. The conversion features within the convertible loan are activated under different circumstances and the resulting fair value may vary based on factors including the date of conversion or the event triggering conversion, such as an initial public offering or the Gates Foundation electing to convert the loan to equity. The option pricing model incorporates input assumptions reflecting the varied circumstances under which the conversion from debt to equity may occur. Significant unobservable inputs used in the fair value measurement of the embedded derivative asset are predominantly regarding the probability of each of the conversion features occurring. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The fair value of the derivative liability was determined using an option pricing model using a range of inputs both observable and unobservable in nature. The unobservable input is the expected final close date of the series B private finance round which was determined based on all relevant internal and external information available and was reviewed and reassessed at each reporting date. The resulting fair value of the derivative liability was not sensitive to changes in the expected close date.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recently Issued and Adopted Accounting Pronouncements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For information on the standards applied for the first time as of January&#160;1, 2019 and 2020, please refer to our consolidated financial statements as of December&#160;31, 2019 elsewhere in this prospectus.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">123<br></div></div></div>
<!--End Page 128-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 129-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tBUS"><!--Anchor--></a>BUSINESS<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease &#8211; designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five&#160;clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. To date, we have dosed over 600 cancer patients with our ImmTAX product candidates, which we believe is the largest clinical data set of any bispecific in a solid tumor and any TCR therapeutic. Our clinical programs are being conducted with patients with a broad range of cancers including lung, bladder, gastric, head and neck and ovarian, among others. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase 3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. This primary endpoint was achieved with a hazard ratio of 0.51 (95% CI: 0.36, 0.71; p&lt;&#160;0.0001) at the first pre-planned interim analysis. Based on these results, we are preparing to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, for tebentafusp for the treatment of metastatic uveal melanoma in the third quarter of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unlike antibody targeted immunotherapies that have a relatively small target pool, our approach relies on the power of T cell receptors, or TCRs, which are naturally occurring receptors found on the surface of T cells that have the ability to target nearly all of the human proteome. Natural TCRs give T cells the ability to scan for abnormalities in nearly any cell in the body that are presented as protein fragments, or antigens, by human leukocyte antigen, or HLA, on the cell surface. Our ImmTAX platform builds upon these natural TCRs to engineer soluble targeted and high-affinity TCRs. By engineering these TCRs, using our ImmTAX platform, we are developing off-the-shelf, bispecific therapeutics, which are able to precisely target a wide range of proteins uniquely expressed by unhealthy and abnormal cells that cannot be targeted by current antibody-based immunotherapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAX bispecific therapeutics couple the targeting power of these engineered TCRs on one end with the other end displaying pre-optimized effector functions, which have the ability to drive a desired immune response at the site of the disease. This combination is designed to provide us with significant flexibility as we are able to engineer and tailor our ImmTAX therapeutics to target proteins that are specific to the disease we are trying to treat and then modulate the corresponding immune response by either boosting or inhibiting the immune system.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From our strong foundation and expertise in TCR targeting development, we continue to push boundaries to improve the product candidates we can generate from our ImmTAX platform. Our mission is to pursue the development of innovative product candidates designed to benefit the greatest number of patients. For example, we recently developed a universally applicable HLA-E platform for universal patient access, which we have validated in pre-clinical proof-of-concept studies. Using this platform, we believe we may be able to develop product candidates which will allow all patients globally to benefit from a single therapeutic per target rather than requiring several classical HLA programs with their associated development costs. While still early in our development, we believe this advancement to our platform has the potential to further revolutionize the future of TCR-based therapies by expanding the therapeutic reach of our ImmTAX platform. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">124<br></div></div></div>
<!--End Page 129-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 130-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Our Pipeline</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are currently leveraging our ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. We have named each of these platforms according to their therapeutic area to distinguish the type of target recognized by the TCR targeting system and the selected effector function. We have five clinical stage assets, including one pivotal stage program, as well as numerous pre-clinical programs. While our most advanced clinical programs are focused on developing treatments for oncology, we believe our ImmTAX platform is versatile, and will also allow us to develop therapeutics with significant advantages in the treatment of infectious and autoimmune diseases. Our current pipeline is represented in the diagram below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 258px; width: 579px;" src="nt10016217x4_graphic01x8.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Our ImmTAC Platform (Oncology)</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Within our ImmTAC (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>C</u></font>ancer) platform, we have four&#160;clinical stage programs and an additional five pre-clinical programs, focusing on the treatment of solid tumors with high unmet medical needs. Our ImmTAC product candidates are bispecific, soluble TCR molecules featuring an antigen-specific targeting module based on our high-affinity highly specific TCR system and our proprietary cluster of differentiation 3, or CD3, effector module for T cell recruitment, engagement and activation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAC programs include:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Tebentafusp</font>, our ImmTAC molecule targeting an HLA-A*02:01 gp100 antigen, demonstrated monotherapy activity and recently achieved the primary endpoint of superior overall survival at the first pre-planned interim analysis of a randomized Phase 3 clinical trial in patients with previously untreated metastatic uveal melanoma. We anticipate submitting a BLA to the FDA in the third quarter of 2021, followed by a Marketing Authorization Application, or MAA, submission to the European Medicines Agency, or EMA.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-C103C</font>, our ImmTAC molecule targeting an HLA-A*02:01 MAGE-A4 antigen, is currently being evaluated in a first-in-human, Phase 1/2 dose escalation trial in patients with solid tumor cancers including non-small-cell lung cancer, or NSCLC, gastric, head and neck, ovarian and synovial sarcoma. We believe this trial will demonstrate clinical activity of IMC-C103C, and we anticipate reporting Phase 1 initial data from this trial in the second half of 2021. We are developing this program under a co-development collaboration with Genentech, Inc., or Genentech, under which we have an option to retain 50% of the economics.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-F106C</font>, our ImmTAC molecule targeting an optimal HLA-A*02:01 PRAME antigen identified with our MassSpec technology, is currently being evaluated in a first-in-human, Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers including breast, endometrial, ovarian and small cell lung cancer, or SCLC. We believe this trial will demonstrate clinical activity of IMC-F106C, and we anticipate reporting Phase&#160;1 initial data from this trial in mid-2022.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">125<br></div></div></div>
<!--End Page 130-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 131-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">GSK01</font>, our ImmTAC molecule targeting an NY-ESO HLA-A*02:01 antigen, is currently being evaluated in the dose escalation phase of a Phase 1 clinical trial. When an optimal dosing regimen has been identified, a small expansion cohort of synovial sarcoma patients will be recruited to evaluate the clinical benefit of the therapeutic. This program is being developed under a collaboration with GlaxoSmithKline Intellectual Property Development Ltd, or GSK, which has an option to acquire full commercialization and development rights to this product candidate at the end of the ongoing Phase 1 clinical trial. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Our ImmTAV Platform (Infectious Diseases) </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAV (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>V</u></font>irus) platform, we have advanced our first program into the clinic, and we are working to advance a second program from pre-clinical into the clinic during the second half of 2021. Our ImmTAV product candidates are bispecific soluble TCR molecules featuring our ImmTAX TCR-based targeting system with high specificity for low-expression viral antigens, combined with the proprietary anti-CD3 effector module for T cell engagement and activation that has been evidenced by our clinical oncology pipeline. We are seeking to develop therapeutics that can provide a functional cure to chronic viral disease and are focusing initially on hepatitis B virus, or HBV, and human immunosuppression virus, or HIV.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAV programs include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-I109V</font>, our ImmTAV molecule targeting a conserved HBV envelope antigen, is our most advanced ImmTAV program and is currently being evaluated in a Phase 1/2 clinical trial in patients with chronic HBV&#160;who are non-cirrhotic, hepatitis B e-Antigen negative, and virally suppressed on chronic nucleot(s)ide analogue therapy. Our goal is to develop a functional cure for HBV and we anticipate commencing dosing in our Phase 1 single ascending dose, or SAD, trial in mid-2021. We are also developing a next-generation version of this molecule leveraging our research into universal HLA-E molecules which could benefit a much larger patient population as compared to classical-HLA antigens.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">IMC-M113V</font>, our ImmTAV molecule targeting an HIV gag antigen bispecific TCR molecule, is currently in pre-clinical development. Our HIV programs are funded by the Bill &amp; Melinda Gates Foundation, or the Gates Foundation, and we are required to make any successfully approved products available at reduced prices in certain developing countries. We retain full development and commercial right in non-developing countries.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 20pt; text-align: left;">Our ImmTAAI Platform (Autoimmune Diseases)</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While our ImmTAC and ImmTAV platforms attempt to provide therapeutic benefit by driving an immune response against targeted cells, our ImmTAAI (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;">m</font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>A</u></font>uto<font style="font-weight: bold;"><u>I</u></font>mmune disease) platform leverages our ImmTAX platform to generate product candidates designed to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Our ImmTAAI product candidates are designed to target organs, tissues or immune cells and deliver an immune suppressive effector function. We have optimized two immune system modulating effector functions to provide local T cell inhibition, which we believe may limit any adverse effects originating from systemic immune suppression. We believe we can use our ImmTAAI platform to develop a portfolio of product candidates to treat autoimmune indications with a high unmet medical need, and provide significant benefit to patients. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">Our Company History and Team</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We were originally incorporated under the laws of England and Wales in December 2007 as a spin-out company of MediGene AG, or MediGene, with the goal of focusing on the development of soluble, off-the-shelf TCR bispecifics. Since then, we have made substantial progress in developing and expanding our novel platform technology into new therapeutic areas, advancing multiple programs into the clinic and dosing over 600 patients with our ImmTAX product candidates. Since our inception, we have raised an aggregate of $873.2 million (&#163;675.8 million) through private placements of our ordinary and preferred shares, payments from our collaboration partners, and most recently, borrowings under our debt facility with Oxford Finance and the sale of our Series&#160;C preferred shares. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">126<br></div></div></div>
<!--End Page 131-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 132-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2020, we had 291&#160;employees, including 129 (44%) who hold a Ph.D. or M.D. degree. Of these employees, two-thirds of our team are primarily focused on research and development activities and possess broad and industry-leading expertise in immunology, TCR biology, protein engineering, bioinformatics and clinical development. We have assembled an experienced management team led by our Chief Executive Officer, Bahija Jallal, who previously served as president of MedImmune, LLC (now known as AstraZeneca plc); our Chief Financial Officer and Head of Strategy, Brian Di Donato, who started his career in investment banking at Morgan Stanley and UBS Securities LLC before serving as chief financial officer of Achillion Pharmaceuticals, Inc. where he oversaw its acquisition by Alexion Pharmaceuticals Inc.; and David Berman, our Head of Research and Development, who oversaw the clinical development of Yervoy, Empliciti and Imfinzi during his previous tenures at Bristol-Myers Squibb Company and MedImmune/AstraZeneca, respectively. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; text-align: center;">Our Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our vision is to build a global immuno-therapy business with a portfolio of therapeutics that have the potential to beneficially impact the clinical outcomes of patients across a broad range of diseases, with a near-term focus on the treatment of cancer, infectious diseases and autoimmune diseases. We are pioneering the field of TCR bispecifics by leveraging the power of TCRs to recognize nearly any cellular target with targeted precision and convert them into potent ImmTAX therapies that can either boost or inhibit the immune system to treat the targeted disease. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to execute our strategy, we are pursuing the following near-term goals:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Secure marketing approval for, and then commercialize, tebentafusp, our lead ImmTAC, for the </font><font style="font-weight: bold;">treatment of metastatic uveal melanoma</font>. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase&#160;3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. This primary endpoint was achieved with a hazard ratio of 0.51 (95% CI: 0.36, 0.71; p&lt;&#160;0.0001) at the first pre-planned interim analysis. We intend to seek regulatory approval for tebentafusp in the United States and Europe. We believe achieving regulatory approval of tebentafusp would provide validation of our entire ImmTAX platform. If tebentafusp is approved, we also believe it will present us with an attractive commercial opportunity, which we intend to pursue using a targeted commercialization strategy that requires minimal internal infrastructure. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Advance our IMC-C103C program targeting MAGE-A4 for the treatment of solid tumors in </font><font style="font-weight: bold;">collaboration with Genentech</font>. We believe IMC-C103C has the potential to treat a wide range of solid tumors, including NSCLC. We are currently evaluating IMC-C103C in a first-in-human, Phase 1/2 dose escalation trial in patients with solid tumor cancers. We believe this trial will demonstrate clinical activity of IMC-C103C, and we anticipate reporting Phase&#160;1 initial data from this trial in the second half of 2021. We are developing this program under a co-development collaboration with Genentech, and are jointly progressing clinical development of IMC-C103C with a partner who possesses deep expertise in clinical development and regulatory strategy. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Advance our IMC-F106C program targeting PRAME for the treatment of solid tumors. </font>IMC-F106C represents a significant commercial opportunity given the prevalence of the PRAME target across various cancers. PRAME is overexpressed in many solid tumors, including NSCLC, SCLC, endometrial, ovarian, esophageal, head and neck squamous cell carcinoma, and urothelial cancers. PRAME is also overexpressed in some hematological malignancies, including acute myeloid leukemia. PRAME expression is generally identified as a poor prognostic feature. We are currently evaluating IMC-F106C in a first-in-human, Phase 1/2 dose escalation trial in patients with solid tumor cancers including NSCLC, gastric, head and neck, ovarian and synovial sarcoma. We believe this trial will demonstrate clinical activity of IMC-F106C, and we anticipate reporting Phase 1 initial data from this trial in mid-2022.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Advance our IMC-I109V program for the treatment of chronic HBV</font>. Current standard-of-care antiviral agents for HBV do not provide a permanent cure in most cases. Therefore, lifelong treatment is necessary to lower the risk of chronic HBV-related complications and there remains a large unmet need for a functional cure. The goal of our IMC-I109V program is to develop a functional cure for chronic HBV. If successful, we believe our therapeutic will allow patients to have a finite period of </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">127<br></div></div></div>
<!--End Page 132-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 133-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">treatment that will also reduce the risks of end-stage liver disease and hepatocellular carcinoma, which are not completely eliminated by currently available treatments. We have begun screening patients for our first-in-human, Phase 1/2 clinical trial of IMC-I109V and anticipate commencing dosing in our Phase 1 SAD trial in mid-2021. </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Continue to develop our novel universal ImmTAX platform to meaningfully broaden the eligible </font><font style="font-weight: bold;">patient pool. </font>We are developing universal TCR therapeutics that are designed to be unrestricted by classical HLA status, which would have the potential to significantly increase the patient pool eligible for our therapeutics. Having pioneered the engineering of TCR bispecifics against classical HLA targets, we believe we are now at the forefront of ushering in a new era of TCR therapies by unlocking universal HLAs, such as HLA-E. This new approach, which we have validated in pre-clinical studies, offers the potential for all patients globally to benefit from a single therapeutic per target rather than requiring several classical HLA programs with their associated development costs. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Continue to invest in our platform to discover and develop novel therapeutics</font>. To remain an industry leader in TCR bispecifics, we intend to continue identifying and validating unique targets as well as optimizing current TCRs to continue to improve outcomes for patients across a broad range of diseases. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Opportunistically pursue strategic partnerships to maximize the full potential of our pipeline and </font><font style="font-weight: bold;">ImmTAX platform</font>. We intend to selectively evaluate partnerships to explore combination therapies and access our partners&#8217; industry-leading capabilities. We plan to assess opportunities to partner with large pharmaceutical companies in the areas of infectious disease and autoimmune diseases to access a broad commercial infrastructure for those indications.</div></td></tr></table><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">Background on Immunotherapy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In recent years, there has been significant focus on scientific and clinical development of a range of therapeutics classes that harness the power of the immune system to recognize tumor and infected cells as foreign and the ability to eradicate them efficiently, to address diseases. Immunotherapy is increasingly deployed to address cancer, with some notable successes. To date, two distinct immunotherapy classes have been successfully advanced to commercial approval:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Antibody-based Therapeutics</font> &#8211; Engineered proteins derived from antibodies are able to recognize and bind cell surface antigens on both tumor and infected cells or modulate regulatory proteins, such as checkpoints, on the surface of immune cells. There are several types/classes of antibody-based therapeutics leveraging the properties of antibodies to treat disease, including for example:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt; font-weight: bold;">Checkpoint Inhibitors</font><font style="font-size: 10pt;"> &#8211; Checkpoint inhibition is an approach by which an antibody, called a </font><font style="font-size: 10pt;">checkpoint inhibitor, binds and blocks receptors on immune cells that function as negative </font><font style="font-size: 10pt;">regulators of the cell, which results in stimulation of T cell function and activation of an immune </font><font style="font-size: 10pt;">response. This approach is known as &#8220;releasing the break&#8221; </font><font style="font-size: 10pt;">on T cells </font><font style="font-size: 10pt;">and has been successfully </font><font style="font-size: 10pt;">employed in oncology where tumor cells often exploit these checkpoint molecules to turn off the </font><font style="font-size: 10pt;">immune response. </font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt; font-weight: bold;">Bispecific T cell Engagers</font><font style="font-size: 10pt;"> &#8211; These therapeutics are engineered antibodies able to recognize two </font><font style="font-size: 10pt;">cell surface </font><font style="font-size: 10pt;">targets, as opposed to one as is the case for a simple antibody, and redirect T cells to </font><font style="font-size: 10pt;">recognize and kill cancer by forming a bridge between the cancer cell and T cell.</font></div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Cell Therapies</font> &#8211; Immune cells, often derived from the patient, engineered to be able to identify and target a specific antigen and disease. T cells are, in particular, the killer arm of the immune system. Because they can scan the body to identify abnormal or infected cells and only be activated once such identification is triggered, they play a critical role in the elimination of infections and tumors. This approach includes, among other therapeutics:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt; font-weight: bold;">Antibody-Targeted CAR-T</font><font style="font-size: 10pt;"> &#8211; These therapeutics are T cells extracted from a patient and </font><font style="font-size: 10pt;">engineered to express a chimeric antigen receptor, or CAR, on the cell surface. CARs are receptors </font><font style="font-size: 10pt;">which have the same binding properties as antibodies and are derived from the same molecular </font><font style="font-size: 10pt;">structure. These engineered T cells thus utilize antibody recognition to identify and target certain </font><font style="font-size: 10pt;">surface proteins/antigens on cancer cells. Upon binding, the T cell activation is triggered and can </font><font style="font-size: 10pt;">result/results in killing of the recognized cell.</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">128<br></div></div></div>
<!--End Page 133-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 134-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt; text-align: left;"><font style="font-size: 10pt; font-weight: bold;">T Cell Receptor (TCR) T cells</font><font style="font-size: 10pt;"> &#8211; T cells extracted from a patient and engineered to express </font><font style="font-size: 10pt;">enhanced TCR molecules. TCRs, unlike antibodies, recognize a protein fragment</font><font style="font-size: 10pt;"> or </font><font style="font-size: 10pt;">antigen </font><font style="font-size: 10pt;">presented on the cell surface in conjunction with a HLA complex. These TCRs can be engineered </font><font style="font-size: 10pt;">to recognize a specific cellular target associated with a tumor or infection. Upon binding, similarly </font><font style="font-size: 10pt;">to the CAR-T approach, the T cell will be activated and able to attack the cell.</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite encouraging efficacy results of these approaches in selected tumor types, a number of limitations still remain. For example, both CAR-T and antibody-based therapeutics are significantly limited in their therapeutic addressability or potential, given the antibody structure is only able to target proteins on the cell surface. These cell surface targets account for only approximately 10% of the entire human proteome, thereby limiting the development of therapeutics based on antibodies to this smaller pool of targets. In contrast, HLA complexes are able to present antigens from proteins expressed or located within the cell, and TCRs are therefore able to identify or recognize a much broader portion of the human proteome. The majority of cancer-specific targets are found inside the cell and not accessible by antibodies.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cell therapies and antibody therapeutics also retain a number of limitations specific to their therapeutic classes. Cell therapies, for example, generally require complex and costly manufacturing processes that take weeks to derive a therapeutic after initial extraction of T cells from a patient, making the strategy unsuitable for a number of aggressive tumors and advanced disease patients. CAR-Ts have, to date, not been successfully developed for any solid tumor. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Our Next-Generation ImmTAX Immunotherapy Platform</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are pioneers in the development of TCR therapeutics and believe our innovative ImmTAX platform will allow us to create novel biological therapies to treat patients with significant unmet need while addressing many of the issues associated with the current immunotherapy therapies described above.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Overview of ImmTAX Platform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our therapeutic platform takes advantage of human TCRs through engineering of novel therapies known as <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease, or ImmTAX. Our ImmTAX product candidates are bispecific therapies that are comprised of two key elements&#8212;a TCR targeting system and an effector function&#8212;that, when combined, are designed to give our platform significant flexibility to treat a range of diseases. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">129<br></div></div></div>
<!--End Page 134-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 135-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Specifically, our optimized ImmTAX bispecifics couple a high-affinity TCR targeting system with a range of effector functions tailored for the specific disease being addressed. TCRs are naturally found on the surface of T&#160;cells and are programmed to scan for abnormalities in the body through binding protein fragments presented by HLA on the surface of other cells. We have been able to build upon the activity of natural TCRs to develop high-affinity TCRs, which allow for a precise targeting by our therapeutics of unhealthy and abnormal cells. Our TCR targeting system can be customized to target almost any protein within the human proteome, thereby increasing the potential for an on-target immune response. We accomplish this by identifying proteins that are specific to a disease, and customizing the TCR domain of our ImmTAX molecules to target the HLA fragment presented by that specific protein. Below is a depiction of how our ImmTAX molecules combine a TCR targeting domain with a range of effector functions that can either activate or turn off the immune system (<font style="font-style: italic;">e.g.</font>, anti-CD3 or PD1 agonist).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 318px; width: 324px;" src="nt10016217x4_graphic02x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The non-targeting component of our ImmTAX molecules is an effector antibody fragment designed to mimic the body&#8217;s natural mechanisms for modulating the immune system, thereby allowing us to develop product candidates which are designed to generate a range of immune responses depending on the disease that is being treated. For example, for diseases such as cancer or infectious disease where an enhanced immune response is required, certain effectors can be applied to drive a potent immune response recruiting any T cell to attack the targeted cell. Alternatively, for certain autoimmune disorders where establishing control of an aberrant immune response is required, certain other effectors can be used to mimic the body&#8217;s natural control mechanisms. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe the flexibility of our approach will allow us to develop therapeutics designed to treat a broad range of diseases. While we have focused our initial efforts on oncology, we are broadening our development efforts to infectious and autoimmune diseases. We have named each of these platforms according to their therapeutic area to distinguish the type of target recognized by the TCR targeting system and the selected effector function:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ImmTAC - <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>C</u></font>ancer </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ImmTAV - <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>V</u></font>iruses </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ImmTAAI - <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>odulating <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>A</u></font>uto<font style="font-weight: bold;"><u>I</u></font>mmune disease </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">130<br></div></div></div>
<!--End Page 135-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 136-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The versatility of our approach across the three therapeutic areas can be seen below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 355px; width: 619px;" src="nt10016217x4_graphic03x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Advantages of our ImmTAX Platform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAX platform enables us to combine a high-affinity TCR targeting system with a range of immune-activating effector domains resulting in what we believe is a highly tailored and flexible approach to treat a broad range of diseases with a number of potential advantages, which are described below:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ability to access significantly larger pool of cellular targets compared to currently approved therapies<font style="font-weight: normal;">. </font><font style="font-weight: normal;">Currently approved antibody-targeted therapies are limited to cell surface protein targets, a subset that makes up </font><font style="font-weight: normal;">approximately 10% of the human proteome. Our ImmTAX platform has the potential to access a significantly </font><font style="font-weight: normal;">larger pool of cellular targets when compared to antibody-targeted therapies, given their ability to target </font><font style="font-weight: normal;">intracellular proteins, thereby expanding the total addressable therapeutic landscape. By using TCRs specific to </font><font style="font-weight: normal;">HLA complexes, our ImmTAX platform allows for the selection of targets expressed by indications for which </font><font style="font-weight: normal;">there are no currently effective antibody targets. Additionally, our platform benefits from the ability to select </font><font style="font-weight: normal;">targets with very high levels of differential expression between healthy and diseased cells, thereby allowing </font><font style="font-weight: normal;">clinical doses to be increased with manageable toxicity. The targeting advantage of our platform versus </font><font style="font-weight: normal;">antibody-targeted therapies is shown below.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">131<br></div></div></div>
<!--End Page 136-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 137-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 253px; width: 563px;" src="nt10016217x4_graphic04x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ability to engineer ImmTAX with million-fold greater affinity and enhanced specificity allows for precise cellular targeting<font style="font-weight: normal;">. Natural TCRs have binding half-lives measured in seconds and broad specificity </font><font style="font-weight: normal;">profiles. Our processes are unique in our ability to consistently engineer TCRs with million-fold improvements in </font><font style="font-weight: normal;">affinity over natural TCRs while simultaneously improving specificity. We believe this proprietary engineering </font><font style="font-weight: normal;">technology will allow us to develop therapeutics that have antibody-like binding properties with high specificity </font><font style="font-weight: normal;">and target binding half-lives measured in hours to days. These properties are designed to enable low doses of </font><font style="font-weight: normal;">drug required and prolonged binding to cell targets. Additionally, the high specificity and affinity of ImmTAX </font><font style="font-weight: normal;">give them the ability to bind to targets that are present with extremely low density across the cell surface.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Ability to address a broad range of disease types by leveraging a variety of precise effector domains to drive a specific immune response<font style="font-weight: normal;">. Affinity enhanced TCRs are coupled in a modular fashion to one of our </font><font style="font-weight: normal;">pre-optimized immune-modulatory effectors to fine tune the characteristics of the therapy specific to the biology </font><font style="font-weight: normal;">factors for a disease indication. By optimizing factors such as potency, therapeutic index and clearance </font><font style="font-weight: normal;">characteristics</font><font style="font-weight: normal;">,</font><font style="font-weight: normal;"> we aim to maximize potential clinical benefit. Using this modular approach, we are developing </font><font style="font-weight: normal;">immune activating therapies for both cancer and infectious diseases which are designed to potently and </font><font style="font-weight: normal;">specifically eliminate TCR targeted cells through redirection of non-exhausted polyclonal T cells. For </font><font style="font-weight: normal;">autoimmune diseases, we employ an effector function that provides potent immunosuppression at the tissue or </font><font style="font-weight: normal;">cellular level, with the goal of minimizing harmful systemic immunosuppression. </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">132<br></div></div></div>
<!--End Page 137-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 138-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Proprietary ImmTAX Development Engine </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To ensure we identify the best targets, isolate the best TCRs and have full understanding and control of specificity throughout TCR affinity maturation we have created a seamless workflow through a suite of proprietary technologies that optimize our drug discovery and development capabilities. The suite of technologies that underpins our ImmTAX platform are reflected below. Our technology platform affords seamless integration from target selection and validation, through TCR cloning and engineering plus de-risking of ImmTAX candidates prior to manufacture and clinical trials.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 378px; width: 563px;" src="nt10016217x4_graphic05.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">1) ImmSPECT identifies the best targets<font style="font-weight: normal;">.</font><font style="font-weight: normal;"> We use mass-spectrometry based target identification, which is </font><font style="font-weight: normal;">often referred to as the gold standard in the field, as it not only informs which peptides are being presented by </font><font style="font-weight: normal;">HLA but also which are presented at effective levels. This approach is significantly more robust than other </font><font style="font-weight: normal;">techniques such as </font><font style="font-style: italic; font-weight: normal;">in silico</font><font style="font-weight: normal;"> or mapping through T cell activation assays, which we believe may have led others </font><font style="font-weight: normal;">to develop therapies targeting sub-optimal peptides. Our ImmSPECT target database has identified peptide targets </font><font style="font-weight: normal;">for every protein in the human and HBV genome, and </font><font style="font-weight: normal;">all but one</font><font style="font-weight: normal;"> protein</font><font style="font-weight: normal;"> in the HIV genome. ImmSPECT is </font><font style="font-weight: normal;">underpinned by a large internal warehouse of tissues and cell lines, comprising over 400 internal tissue samples, </font><font style="font-weight: normal;">including over 250 tumor and healthy tissue samples and over 150 immortalized cell lines, as well as a panel of </font><font style="font-weight: normal;">86 model cell lines representing distinct cell types within normal tissues which we leverage to analyze the parent </font><font style="font-weight: normal;">gene and protein as well as the peptide-human leukocyte antigen, or pHLA to help de-risk our target selection. </font><font style="font-weight: normal;">Our ultra-sensitive mass spectrometry can detect pHLA targets at the 10</font><font style="font-weight: normal;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">-18</sup></font><font style="font-weight: normal;"> molar level and typically provides </font><font style="font-weight: normal;">multiple targeting opportunities for each candidate protein. The cell line dataset contains target gene expression </font><font style="font-weight: normal;">data as well as quantitative information on individual pHLA targets. This facilitates optimal candidate selection </font><font style="font-weight: normal;">based on relative abundance and preliminary safety assessment. This target selection technology has enabled us </font><font style="font-weight: normal;">to frontload our pipeline with more than 60 targets for which we have validated pHLA data.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2) Proprietary Blind Date libraries enable us to create unique and therapeutically relevant ImmTAX<font style="font-weight: normal;">.</font><font style="font-weight: normal;"> </font><font style="font-weight: normal;">The current</font><font style="font-weight: normal;"> industry standard </font><font style="font-weight: normal;">TCR</font><font style="font-weight: normal;"> identification method</font><font style="font-weight: normal;"> relies on cloning T cells from donor's blood. In </font><font style="font-weight: normal;">addition to this approach, we can identify</font><font style="font-weight: normal;"> TCRs </font><font style="font-weight: normal;">using</font><font style="font-weight: normal;"> our proprietary Blind Date TCR phage libraries </font><font style="font-weight: normal;">which </font><font style="font-weight: normal;">allow</font><font style="font-weight: normal;">s</font><font style="font-weight: normal;"> us to create therapeutics with significantly higher specificities than achievable from natural TCRs. This </font><font style="font-weight: normal;">approach identifies TCRs (and TCR chain pairings) that would not be identifiable through </font><font style="font-weight: normal;">screening the T cells </font><font style="font-weight: normal;">from blood of donors</font><font style="font-weight: normal;">, as they would have been removed through thymic selection and thus provides a greater </font><font style="font-weight: normal;">level of diversity than using TCRs cloned from T cells. Blind Date is the only successful library-based approach </font><font style="font-weight: normal;">for </font><font style="font-style: italic; font-weight: normal;">de-novo</font><font style="font-weight: normal;"> TCR discovery for soluble TCR therapeutics.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">133<br></div></div></div>
<!--End Page 138-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 139-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3) TCR quality evaluation platform ensures only the best TCRs enter affinity maturation<font style="font-weight: normal;">.</font><font style="font-weight: normal;"> We have </font><font style="font-weight: normal;">developed a range of TCR specificity mapping tools and routinely generate in-house pHLA/TCR crystal </font><font style="font-weight: normal;">structures to ensure only the best TCRs enter affinity maturation. Our internal database contains in excess of </font><font style="font-weight: normal;">300&#160;TCR crystal structures which we believe is the largest private repository. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">4) Routine million-fold improvement in TCR affinity delivers precision targeting<font style="font-weight: normal;">.</font><font style="font-weight: normal;"> Wild-type TCRs have </font><font style="font-weight: normal;">weak affinities and are not suitable for use as soluble immunotherapies. To ensure stable and durable binding to </font><font style="font-weight: normal;">target pHLA, their affinity needs to be increased to low picomolar, or pM, levels, particularly to observe potency </font><font style="font-weight: normal;">for pHLA targets that have low density on the cell surface. We have developed and use a range of proprietary </font><font style="font-weight: normal;">phage display techniques, enabling the interrogation of very large mutational libraries containing billions of TCR </font><font style="font-weight: normal;">variants with discreet mutations within the six pHLA binding regions, to uniquely engineer TCR affinity up to a </font><font style="font-weight: normal;">million-fold higher while improving specificity. These techniques allow us to deliver antibody-like binding to </font><font style="font-weight: normal;">pHLA targets including those with significant specificity challenges such as neoantigens. Once a high-affinity, </font><font style="font-weight: normal;">soluble TCR is engineered, the bispecific ImmTAX is made by fusing the TCR to an immune modulating </font><font style="font-weight: normal;">effector domain. The effector domain is modular, and we can select different effectors depending on the intended </font><font style="font-weight: normal;">therapeutic goal.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5) In-house developed <font style="font-style: italic;">in vitro</font> toxicity platform has supported five clinical stage programs.<font style="font-weight: normal;"> We have </font><font style="font-weight: normal;">developed a proprietary pre-clinical human </font><font style="font-style: italic; font-weight: normal;">in vitro</font><font style="font-weight: normal;"> screening platform that assesses potential off-target binding or </font><font style="font-weight: normal;">cross-reactivity of our ImmTAX molecules, to identify the therapeutic window and provide a first-in-human </font><font style="font-weight: normal;">starting dose. By testing an extensive panel of normal and cancer cells (over 30 tissue types), blood and tissues, </font><font style="font-weight: normal;">performing both cellular and molecular analyses to provide a robust package with complementary assays, the </font><font style="font-weight: normal;">pre-clinical package not only de-risks the drug candidate appropriately but also informs on clinical protocol </font><font style="font-weight: normal;">design, clinical starting dose and any specific monitoring that may be required. The toxicity packages produced </font><font style="font-weight: normal;">with this platform have supported progression from pre-clinical to clinical stage of five programs and the dosing </font><font style="font-weight: normal;">of ImmTAX in over 600 patients to date and has laid the foundation for successful regulatory submissions in this </font><font style="font-weight: normal;">therapeutic class.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">6) Efficient manufacturing platform successfully scaled to support commercial launch.<font style="font-weight: normal;"> Off-the-shelf </font><font style="font-weight: normal;">ImmTAXs are manufactured via an in-house developed </font><font style="font-style: italic; font-weight: normal;">E. coli</font><font style="font-weight: normal;"> based manufacture platform that is robust, </font><font style="font-weight: normal;">reproducible and has been successfully scaled to produce commercial launch supply of tebentafusp. To date, our </font><font style="font-weight: normal;">manufacturing platform has successfully produced over 40 GMP batches over five clinical stage programs.</font></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Our ImmTAC Platform</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Overview of ImmTAC, Our Oncology-Focused ImmTAX Platform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAC (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>C</u></font>ancer) platform, we have four&#160;clinical stage programs and an additional five pre-clinical programs, focusing on the treatment of solid tumors with high unmet medical needs. Our ImmTAC platform was developed to address the limitations of other immunotherapy-based oncology therapeutics and to optimize treatment for these indications, leveraging our knowledge and know-how of T cells, TCRs and immune responses to cancer.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">134<br></div></div></div>
<!--End Page 139-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 140-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAC product candidates are bispecific, soluble TCR molecules featuring an antigen-specific targeting module/system based on our high-affinity, highly specific TCR system and our proprietary cluster of CD3, effector module for T cell recruitment, engagement and activation. For the development of our ImmTAC product candidates, we fuse an affinity optimized CD3 binding antibody fragment effector domain to the high-affinity TCR-based cell targeting system to drive a broad and robust immune response. This effector allows ImmTACs to redirect all CD3&#160;positive T cells, including CD8+ killer T cells and CD4+ Helper T cells, against the targeted cancer, including those that are not specific to the cancer. ImmTAC&#8217;s ability to recruit a robust immune response regardless of T cell specificity and target intracellular proteins unlike previous generations of immunotherapies is shown below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 269px; width: 594px;" src="nt10016217x4_graphic06.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTACs have a significantly enhanced TCR targeting system that we believe drives highly efficient drug delivery and therapeutic activity at the cancer site, as observed in our most advanced candidate tebentafusp. We believe this enhanced binding affinity leads to the efficient formation of an immune synapse between the T&#160;cell and its target required for activation. Work we published in Nature Medicine demonstrates that ImmTACs can redirect T cell activity through the formation of an immune synapse comprising as few as 7 to 10 ImmTAC molecules providing a significant sensitivity advantage over antibody-based T cell engagers that typically require thousands of molecules per cell. A schematic representation of ImmTAC mediated immune synapse formation and resultant T cell activation and tumor cell destruction is provided below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 314px; width: 593px;" src="nt10016217x4_graphic07x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">135<br></div></div></div>
<!--End Page 140-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 141-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Advantages of our ImmTAC Platform vs. Other Cancer Immunotherapies </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAC platform is highly differentiated and can overcome many of the limitations of previous generations of immunotherapies in oncology. If approved, we believe our products may provide the potential advantages described below. Despite these advantages, none of our product candidates have been approved as of yet, and there is no guarantee that our product candidates will prove to be safe and efficacious for the treatment of our target indications.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Expands the therapeutic landscape by unlocking cellular targets beyond the reach of antibody targeted approaches<font style="font-weight: normal;">. Almost all immunotherapy based therapeutics utilize an antibody-based targeting approach, </font><font style="font-weight: normal;">which typically restricts the universe of targets these therapeutics can access to cell surface proteins. Most </font><font style="font-weight: normal;">cancer-specific proteins are located intracellularly and have thus been able to evade this traditional targeting </font><font style="font-weight: normal;">approach. Additionally, for many tumor types, cell surface targets are also expressed on vital healthy tissues, </font><font style="font-weight: normal;">resulting in killing of healthy cells leading to a restricted therapeutic window and potential safety concerns. </font><font style="font-weight: normal;">These targeting limitations leave a vast unmet need in the field of oncology. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ImmTACs overcome these issues through the use of a high-affinity TCR targeting domain that gives them the ability to target the entire proteome, including intracellular proteins, thereby providing a significantly greater number of targets for which to develop potential therapies against. Additionally, the high specificity and affinity of ImmTACs give them the ability to bind to targets with extremely low density across the cell surface, which can be seen in the below figure. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 250px; width: 523px;" src="nt10016217x4_graphic08x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 3pt; margin-left: 20pt; text-align: left;">ImmTAC target density requirements based on internal studies, target density requirements for CAR-T, Antibody Drug Conjugates and Antibody Targeted T cell Engagers obtained from peer reviewed scientific publications.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">These characteristics provide ImmTACs with a key advantage in that there is a significantly greater pool of targets to choose from, which allows for selection of targets that are highly specific to the disease being treated, which we believe will result in an enhanced efficacy and tolerability profile.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Warming up&#8221; cold solid tumors by recruiting and activating non-cancer-specific T cells<font style="font-weight: normal;">. Most </font><font style="font-weight: normal;">immunotherapy based oncology treatments are unable to harness a full immune response against the disease they </font><font style="font-weight: normal;">are targeting given limitations particular to their mechanism of action and treatment regime. For example, </font><font style="font-weight: normal;">antibody-based therapeutics, such as checkpoint inhibitors, rely on active T cells in the tumor microenvironment </font><font style="font-weight: normal;">having the ability to recognize the tumor and mount an attack once a particular checkpoint is inhibited. However, </font><font style="font-weight: normal;">it is often the case that the tumors being targeted are &#8220;immune-cold&#8221; or &#8220;immune-deserted&#8221;, meaning that they </font><font style="font-weight: normal;">have insufficient numbers of immune cells in the tumor microenvironment that have the ability to recognize the </font><font style="font-weight: normal;">diseased cell even after the targeted checkpoints have been inhibited.</font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">136<br></div></div></div>
<!--End Page 141-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 142-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Typically, cancers that are &#8220;immune-cold&#8221; are those that are not sufficiently immunogenic. Immunogenicity levels vary widely by cancer type and are largely correlated with a factor called tumor mutational burden which is a measure of how many separate mutations the tumor has per million bases of DNA. Specifically, a cancer with a higher number of mutations is more likely to be recognized by the immune system as foreign and thereby targeted for attack. Although highly immunogenic cancer types are typically well treated by checkpoint inhibitors, there are a substantial number of highly prevalent tumor types with significant mortality rates that are typically associated with low immunogenicity, making these therapies largely ineffective. This correlation is evident in the figure below where tumors with low levels of mutational burden have lower levels of objective response to checkpoint inhibitors.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 351px; width: 481px;" src="nt10016217x4_graphic09x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ImmTACs are designed to overcome this limitation and target tumor types with low immunogenicity given their ability to drive an immune response that does not rely on T cells that naturally recognize the targeted tumor. Instead, the bispecific nature of ImmTAC results in a therapeutic candidate that is able to drive a broad immune response against a highly specific target. Specifically, the CD3 effector domain can attract a multitude of T cells regardless of their specificity to the tumor, while the highly specific TCR targeting domain redirects this broad response to the targeted tumor microenvironment. Our most advanced oncology therapeutic candidate, tebentafusp has demonstrated monotherapy activity in both metastatic uveal and cutaneous melanomas which represent the bookends of tumor mutational burden.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to antibody-based approaches, other immunotherapies, including cell therapies, have significant limitations around their ability to drive a natural immune response against the targeted disease. Specifically, cell therapies require an aggressive lymphodepleting regimen prior to infusion. Consequently, the regimen kills pre-existing natural tumor-infiltrating lymphocytes and other effector T cells that may contribute to anti-tumor activity. Therefore, the cell therapy approach relies solely on the engineered T cells to mount the immune response. Variability in the patients&#8217; T cells selected to be engineered, can result in variable potency of manufactured T cells, and this variability may cause unpredictable treatment outcomes. ImmTAC, on the other hand, does not require any form of patient conditioning, such as lymphodepletion, leveraging only the patient&#8217;s own natural immune system to attack the targeted tumor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Manageable and consistent tolerability profile with limited on-target/off-tumor toxicity<font style="font-weight: normal;">. The </font><font style="font-weight: normal;">effectiveness of antibody targeting immunotherapies is also limited by the fact that the targeted proteins are often </font><font style="font-weight: normal;">also expressed to some degree on healthy human tissue. Therefore, these therapies are often associated with </font><font style="font-weight: normal;">tolerability issues, as there can be off-target effects on the healthy human tissue on which these targeted proteins </font><font style="font-weight: normal;">are also present. These&#160;considerations narrow the therapeutic window impacting the potential efficacy of the </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">137<br></div></div></div>
<!--End Page 142-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 143-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">treatments as it limits the potential dosing that can be administered to the patient. However, despite these limitations, antibody-based therapeutics continue to attempt to take advantage of these targets because the pool of targets for which these therapies can be developed remains limited. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Conversely, because ImmTAC has a significantly larger pool of potential targets, it can take advantage of target proteins that either aren&#8217;t expressed on healthy cells or are expressed at minimal levels, enhancing its tolerability profile vs. most other immunotherapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Easy to administer, off-the-shelf treatment with no pre-conditioning required<font style="font-weight: normal;">. Antibody and cell </font><font style="font-weight: normal;">immunotherapies also face a number of limitations related to their manufacturing and engineering processes and </font><font style="font-weight: normal;">ultimately each patient&#8217;s experience in receiving the treatment. Specifically, cell therapy patients beginning a </font><font style="font-weight: normal;">course of treatment have to wait several weeks to commence therapy due to the lengthy &#8220;vein to vein&#8221; time, or </font><font style="font-weight: normal;">the time required for T cell extraction, engineering and reinfusion. The lag time in generating a cell therapy </font><font style="font-weight: normal;">therapeutic may result in disease progression for the patient. In contrast, the off-the-shelf nature of ImmTAC </font><font style="font-weight: normal;">results in immediate treatment attacking the tumor on day one of treatment, preventing delays to treatment and </font><font style="font-weight: normal;">the associated risk of disease progression.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From a patient experience perspective, there are also a number of elements associated with both antibody and cell therapies that result in a more difficult patient experience. For example, cell therapies require an aggressive lymphodepletion pre-conditioning regimen. Lymphodepletion results in hematological toxicity, which is both unpleasant for the patient and restricts the applicability of this approach to those patients healthy enough to tolerate the lymphodepletion. In addition, lymphodepletion also restricts the potential of cell therapies in an adjuvant setting. Alternative therapies, such as antibody directing T cell engagers, also require preconditioning, but with corticosteriods, which can dampen the immune system and increase risk of infection. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ImmTAC&#8217;s favorable tolerability profile means no requirement for patient conditioning, opening up the patient population that can benefit from this next-generation immunotherapy beyond just healthy patients that can tolerate lymphodepletion. The unique characteristics and versatility of ImmTAC molecules make them attractive as monotherapies as well as appealing in an adjuvant setting.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe these differences between ImmTACs and competing therapies provide for a differentiated platform in oncology.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 261px; width: 597px;" src="nt10016217x4_graphic24x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">138<br></div></div></div>
<!--End Page 143-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 144-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Our Oncology Portfolio </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 233px; width: 607px;" src="nt10016217x4_graphic10x4.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our oncology pipeline includes four clinical stage therapeutic programs addressing both high unmet need orphan indications and a broad range of high prevalence solid tumors. Additionally, our early oncology pipeline comprises an additional eight programs that target a range of novel targets. Our most advanced oncology therapeutic candidate, tebentafusp, has demonstrated superior overall survival benefit as a monotherapy in a randomized Phase&#160;3 clinical trial in previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. This primary endpoint was achieved with a hazard ratio of 0.51 (95% CI: 0.36, 0.71; p&lt;&#160;0.0001) at the first pre-planned interim analysis. It has been granted Orphan Drug Designation in both uveal and cutaneous melanoma by the FDA and Promising Innovative Medicine, or PIM, designation under the U.K. Early Access to Medicines Scheme for metastatic uveal melanoma. We anticipate submitting a BLA to the FDA in the third quarter of 2021 followed by an MAA submission to the EMA. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Tebentafusp: Our Most Advanced Oncology Therapeutic Candidate </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tebentafusp, our ImmTAC molecule targeting a HLA-A*02:01 gp100 antigen, has achieved the primary endpoint of superior overall survival in a randomized Phase 3 pivotal trial in previously untreated patients with metastatic uveal melanoma. The melanocyte-lineage protein gp100 is expressed exclusively in melanocytes found in the skin, eye and ear, and overexpressed in melanoma tumors. Tebentafusp is dosed weekly by 15 minute intravenous infusion with no protocol requirement for prophylactic steroid or any type of conditioning regimen. Tebentafusp was the first TCR bispecific to demonstrate solid tumor monotherapy responses in both metastatic cutaneous and metastatic uveal melanomas. Over 500 patients have received tebentafusp making it the most advanced and most extensively evaluated TCR-based therapy to date. Our clinical development of tebentafusp has been focused on metastatic uveal melanoma and has demonstrated an improvement in overall survival in a Phase&#160;3 randomized trial, confirming improved overall survival observed in Phase&#160;2 compared to historical data, which are summarized below:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 1 first-in-human clinical trial (n=84) demonstrated monotherapy activity per RECIST and immune related responses in uveal and cutaneous melanoma patients.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 2 clinical trial (n=127) demonstrated improved overall survival in a cross-trial comparison to a recent metanalysis based on prior clinical trials in a similar previously treated uveal melanoma patient population (n=287). The cross trial overall survival hazard ratio was 0.50 (95% CI 0.38,0.66). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 3 randomized clinical trial (n=378) achieved the primary endpoint of superior overall survival in the intent-to-treat population with a hazard ratio of 0.51 (95% CI: 0.36, 0.71), p&lt;0.0001 favoring tebentafusp over investigators choice. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We anticipate submitting a BLA to the FDA in the third quarter of 2021 followed by an MAA submission to the EMA. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">139<br></div></div></div>
<!--End Page 144-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 145-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA has granted Orphan Drug Designation for tebentafusp in both uveal and cutaneous melanoma, with an additional Fast Track designation for uveal melanoma. We have also received PIM designation under the U.K. Early Access to Medicines Scheme for tebentafusp in metastatic uveal melanoma, which is granted to promising products focused on treating high unmet medical need patient populations. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Tebentafusp for the Treatment of Metastatic Uveal Melanoma </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Uveal melanoma is the most common intraocular malignancy in adults and is often diagnosed as localized disease in the eye. While treatment of localized primary disease has an initial high success rate, up to 50% of patients will subsequently develop metastatic disease, usually involving the liver and less frequently lung, bone and other organs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Metastatic uveal melanoma has a very poor prognosis with a 2019 published systematic review and meta-analysis finding a one-year survival rate of only 52% for first-line treated patients, falling to 10% after three years regardless of treatment modality.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are currently no FDA-approved treatments for metastatic uveal melanoma and the National Comprehensive Cancer Network Clinical Practice Guidelines recommend enrollment in a clinical trial as the preferred option for patients with metastatic disease, illustrating the lack of effective treatment options. When a clinical trial is not available or clinically appropriate, other potential treatment options include anti-PD1 or anti-CTLA4 checkpoint inhibitors, chemotherapy or kinase inhibitors, some of which are approved for cutaneous melanoma. However, none of these other treatment options have advanced into Phase 3 clinical trials for uveal melanoma. Patients with hepatic-only disease may also be treated with liver-directed cancer therapies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Epidemiology of uveal melanoma varies by region and ethnicity. In the United States and Europe, we estimate that there are approximately 5,000 to 6,000 new cases of primary uveal melanoma per annum of which we estimate 1,000 patients per annum have metastatic uveal melanoma that are HLA-A*02:01-positive and will be eligible for treatment with tebentafusp. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Mechanism of Action </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tebentafusp is engineered to recognize a peptide derived from the gp100 protein, expressed exclusively on melanocytes and overexpressed in melanoma, while the anti-CD3 effector domain is engineered to redirect and activate non-specific T cells to attack. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During clinical development, we observed rash and vitiligo, which represent strong evidence of on-target activity as they demonstrate that tebentafusp is successfully binding to gp100-positive melanocytes in skin and driving an immune response to those areas, thus validating the TCR targeting domain of tebentafusp. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">140<br></div></div></div>
<!--End Page 145-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 146-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Because rash is a strong biomarker of tebentafusp&#8217;s binding to gp100-positive melanocytes, we evaluated the association of rash with outcomes in our clinical development. In our Phase 2 clinical trial, we observed that 64% of patients developed a rash within the first week after initial dose, which usually goes away within a week of appearance. The data indicates that this transient rash was associated with better overall survival outcomes, and thus we believe validates rash appearance as a biomarker for better overall survival. Survival for the remaining patients who did not develop a rash was no different from the historical survival in this population as reported by Khoja et al. in <font style="font-style: italic;">Annals of Oncology</font> in August 2019. The relationship between the appearance of a rash and overall survival in our Phase 2 clinical trial is depicted in the figure below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 302px; width: 558px;" src="nt10016217x4_graphic11x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to validation of the targeting mechanism of tebentafusp, there have been clear indications that tebentafusp&#8217;s effector mechanism is stimulating the desired anti-tumor immune response in that it is driving the trafficking of T cells into the targeted tumor microenvironment. In our Phase 2 clinical trial, we observed that the majority of patients had an increase in the number of tumor-infiltrating T cells, with the average increase being 3.2-fold. This data supports our belief that our ImmTAC product candidates will have the potential to overcome the known challenge of cold tumors, where insufficient numbers of T cells in the microenvironment limit the efficacy of current immunotherapy approaches. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Translational studies of tumor and serum samples from the Phase 2 clinical trial confirmed that tebentafusp drives the release of cytokine and chemokine signals that then mobilize CD3 positive T cells (both CD8+ killer T&#160;cells and CD4+ Helper T cells) to migrate from circulation in the bloodstream and infiltrate tumors. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">141<br></div></div></div>
<!--End Page 146-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 147-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tebentafusp&#8217;s impact on driving an immune response is demonstrated across the figure below, which shows tebentafusp driving the release of serum cytokine and chemokine signals which peak around eight hours post-treatment and stay elevated for at least 24 hours. This was then followed by a marked reduction in numbers of CD4+ and CD8+T cells in the blood, but not a significant reduction in B cells, which are CD3 negative and thus would not be expected to be impacted by introduction of tebentafusp. The reduction of CD3+ T cells in circulation illustrates that tebentafusp is driving the migration of these T cells out of the blood. The number of tumor-infiltrating T cells increased in a large majority of patients by day 16 after starting tebentafusp treatment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 315px; width: 551px;" src="nt10016217x4_graphic12x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Phase 1/2 Clinical Trial </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We conducted an open-label Phase 1/2 clinical trial evaluating the safety and efficacy of tebentafusp using an intra-patient dose-escalation regimen in HLA-A*02:01-positive, metastatic uveal melanoma patients previously treated with one or two lines of therapy, which we refer to as IMCgp100-102. The trial was conducted in two phases:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Phase 1 portion (dose escalation)</font>: This portion of the clinical trial defined the intra-patient dose escalation regimen, with a top dose of 68 mcg, which was then advanced as the recommended dose in the Phase 2 portion of the trial and our ongoing Phase 3 clinical trial. Of the 19 patients in the Phase 1 portion, we observed three patients had tumor responses that met the criteria defined by RECIST. An additional four patients did not meet RECIST criteria but had immune-related responses, a category of response previously described for the immune checkpoint therapies, and also suggested improved survival results that supported further studies. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Phase 2 portion (expansion)</font>: This portion of the clinical trial was to evaluate the efficacy of tebentafusp in 127 patients with metastatic uveal melanoma as a second-line or later treatment. The primary endpoint was to estimate the objective response rate, or ORR, under RECIST 1.1 according to an independent central review committee. We believe the observation of immune related responses in the Phase 1 portion of this trial and the Phase 1 first-in-human trial indicates that overall survival, which captures benefit from RECIST and immune related responses, is a better measurement of treatment effect for tebentafusp, and thus was included as a secondary endpoint of this trial. Of the 127 metastatic uveal melanoma patients treated, all had received prior treatments and the majority had received prior immunotherapy regimens (73.2% had prior immunotherapy; 65.4% had prior anti-PD-1).</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the Phase 2 expansion portion of the clinical trial the majority, 73.2% of the 127 patients had previously received checkpoint immunotherapy, most commonly with PD1/PD-L1 targeted agents. There was a very low rate, 3.1%, of treatment related discontinuation and no treatment related deaths.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">142<br></div></div></div>
<!--End Page 147-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 148-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 201px; width: 618px;" src="nt10016217x4_graphic32x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">RECIST is a standard set of guidelines for assessing responses in solid tumors, with definitions for complete response (disappearance of all target lesions), partial response (at least a 30% decrease in the sum of the longest diameter of target lesions from baseline), stable disease (neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease), and progressive disease (at least a 20% increase in the sum of the longest diameter of target lesions from the smallest sum on study or the presence of new lesions). A complete or partial response is considered confirmed if the response criteria are met on a subsequent assessment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary endpoint of objective response rate by RECIST was 4.7% (all partial responses), however 44% of patients with evaluable tumors had shrinkage of their target lesion burden. Notably, we observed that 86% of evaluable patients in the trial with tumor shrinkage had survival of at least 12&#160;months and of which the majority were still alive at primary analysis. In addition, even some patients with tumor growth still had survival of at least 12&#160;months. In the lower chart below, each bar represents the percent change in tumor size from baseline experienced by each patient with corresponding survival for each patient represented directly by the bar above. Patients marked with a plus sign were still alive as of the study analysis cut-off date. As noted above, those patients who experienced tumor shrinkage have experienced higher rates of survival.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 325px; width: 607px;" src="nt10016217x4_graphic13x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">143<br></div></div></div>
<!--End Page 148-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 149-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since the Phase 2 clinical trial was a single arm trial, overall survival was compared in a cross-trial analysis to a recent 2019 meta-analysis by Rantala <font style="font-style: italic;">et al</font>. of previously published trials conducted in a similarly matched uveal melanoma population, which can be seen in the figure below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 368px; width: 547px;" src="nt10016217x4_graphic14x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In this cross-trial comparison, the overall survival curve for tebentafusp demonstrates an improvement relative to the historical population including early separation of the overall survival curves which is maintained for at least several years.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">144<br></div></div></div>
<!--End Page 149-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 150-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In our Phase 2 clinical trial, we reported a low rate (3.1 %) of discontinuation due to drug-related adverse events, or AEs, no drug-related deaths and, consistent with our observations in our first-in-human, Phase 1 clinical trial, the most frequent adverse events in the Phase 2 clinical trial were related to tebentafusp&#8217;s mechanism of action. The two major classes of related AEs were skin-related and cytokine-mediated and due to on-target activity against gp100+ melanocytes and activation of T&#160;cells, respectively. The table below summarizes the AEs recorded for the Phase&#160;2 clinical trial graded according to the Common Terminology Criteria for Adverse Events grading system where Grade&#160;1 indicates a mild AE, Grade&#160;2 indicates a moderate AE, Grade&#160;3 indicates a severe AE, Grade&#160;4 indicates a life-threatening AE and Grade&#160;5 indicates death. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 426px; width: 383px;" src="nt10016217x4_graphic25x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">a.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Investigator assignment of causality;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">b.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">LFT elevation and rash are composites of preferred terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 60pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">c.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">CRS assesed retrospectively by ASTCT (Lee 2019) criteria </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">145<br></div></div></div>
<!--End Page 150-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 151-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As shown in the chart below, the majority of treatment-related adverse events occurred in the first few weeks following the first dose, were predictable and manageable, and decreased in severity and frequency during treatment. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 293px; width: 512px;" src="nt10016217x4_graphic26x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the Phase&#160;2 clinical trial, 27 (21.3%) patients experienced at least one treatment-related serious adverse event, or SAE, per the investigator. In these patients, SAEs included pyrexia in eight (6.3%) patients; cytokine release in four (3.1%) patients; rash maculo-papular and hypotension each in three (2.4%) patients; ALT increase, diarrhea and nausea each in two (1.6%) patients and the following each occurred in one (0.8%) patient, AST increase, atrial fibrillation, atrial flutter, cardiac failure, confusion, embolism, generalized rash, GGT increase, hypophosphataemia, left ventricular dysfunction, multi-organ dysfunction, musculoskeletal pain, pleural effusion and pulmonary oedema. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">Phase 3 Clinical Trial </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tebentafusp achieved the primary endpoint of superior overall survival in a randomized Phase 3 pivotal trial in patients with previously untreated metastatic uveal melanoma. The study was unblinded by an independent data monitoring committee at the first of the trial's pre-planned interim analyses in November 2020. While there is no approved standard of care, common options for these patients typically include chemotherapy or checkpoint therapy which comprised the control arm of investigator's choice. 378 patients were randomized in a 2:1 ratio between tebentafusp and investigator&#8217;s choice of therapy (dacarbazine chemotherapy, ipilimumab, or pembrolizumab) with the two arms stratified to ensure balance for lactate dehydrogenase, or LDH, status, a well-known prognostic factor for overall survival in metastatic uveal melanoma. Randomization was completed in June 2020 with investigators choice in the control arm comprising 82% pembrolizumab, 12% ipilimumab and 6% dacarbazine.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">146<br></div></div></div>
<!--End Page 151-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 152-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 224px; width: 601px;" src="nt10016217x4_graphic15.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The primary endpoint of the randomized Phase 3 clinical trial was overall survival. At the first pre-planned interim analysis conducted by the independent Data Monitoring Committee, tebentafusp demonstrated superior overall survival in the intent-to-treat population with a hazard ratio of 0.51 (95% CI: 0.36, 0.71), p&lt; 0.0001 favoring tebentafusp over investigator&#8217;s choice. Although follow-up in all patients has not yet reached one year, the Kaplan-Meier curve estimates suggest a 1-year OS rate of approximately 73% vs 58%, respectively. The following table provides a comparison of patient population, therapy and hazard ratio for selected Phase&#160;3 clinical trials in uveal and cutaneous melanoma.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 184px; width: 619px;" src="nt10016217x4_graphic33x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe this positive Phase&#160;3 clinical data represents the first positive Phase&#160;3 clinical trial for a TCR therapeutic and the first immune-oncology monotherapy survival benefit in a solid tumor with low tumor mutational burden, and we believe tebentafusp to be the first bispecific immune-oncology therapy with demonstrated overall survival advantage in any solid tumor. The efficacy data also replicate the overall survival observed in the Phase&#160;2 clinical trial IMCgp100-102 in previously treated mUM presented at the ESMO Immuno-Oncology Virtual Congress 2020. We anticipate presenting the Phase&#160;3 clinical data at an academic congress in the first half of 2021.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additional analyses will include response rate, progression free survival, disease control rate and overall survival in patients who develop a rash on tebentafusp. We expect the results from this trial to support global regulatory submissions for approval of tebentafusp for the treatment of previously untreated advanced, metastatic uveal melanoma. Global health authorities consider overall survival in the intention-to-treat population, the primary endpoint for this trial, as the gold standard for cancer trials. We anticipate submitting a BLA to the FDA in the third quarter of 2021 followed by an MAA submission to the EMA.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 20pt; text-align: left;">Commercialization Strategy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Metastatic uveal melanoma is an orphan indication and, in many countries, patients are referred to and treated at specialist centers. The specialists who are responsible for the majority of these patients can be easily and efficiently reached with a small commercial organization. As is typical for other orphan indications, a number of patient advocacy groups have been established to promote research and development and direct patients towards the most promising clinical approaches. If tebentafusp is approved, we will seek to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">147<br></div></div></div>
<!--End Page 152-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 153-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">commercialize tebentafusp using our own small, core team with extensive experience in market access, marketing and sales in oncology in the United States and Europe through a largely outsourced operating model.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have already established our internal core team and external network of providers to support commercialization. In addition, activities such as engagement with key advocacy groups and key opinion leaders, mapping of patient pathways, branding and early engagement with healthcare authorities and payers across the United States and key European territories are ongoing.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Additional ImmTAC Clinical Programs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are developing three additional clinical stage programs targeting three cancer/testis antigens: MAGE-A4, PRAME and NY-ESO. These tumor-associated antigens are highly expressed in several cancer types with relatively high prevalence and in some orphan tumors and therefore represent a significant opportunity to address diseases with unmet medical needs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Cancer/testis antigens are a group of approximately 50 proteins transiently expressed during fetal development which are turned off for the remainder of life in all tissues except the testis, which is an immune-privileged organ ignored by the immune system. Cancer, however, is typically driven by a number of mutations which lead to disregulation of the mechanisms governing protein expression, which in this particular case leads to aberrant expression of cancer/testis antigens in adult tissues. Cancer/testis antigens are widely regarded as ideal oncology targets as they are both frequently expressed across a range of indications and on-target activity of the therapeutic should be restricted to the cancer, enhancing the tolerability profile.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The figure below shows the expression of MAGE-A4, PRAME and NY-ESO across a range of solid and hematological cancers, with MAGE-A4 and PRAME, in particular, having significant expression frequency across a range of cancers with high incidence.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 328px; width: 552px;" src="nt10016217x4_graphic16x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">148<br></div></div></div>
<!--End Page 153-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 154-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">IMC-C103C - Targeting MAGE-A4 </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-C103C is an ImmTAC targeting a MAGE-A4 derived peptide presented by HLA-A*02:01. We have entered into a co-development/co-promotion collaboration with Genentech under which we share program costs and profits equally. IMC-C103C is currently in the Phase 1 portion of a Phase 1/2 clinical trial from which we anticipate reporting initial data in the second half of 2021. MAGE-A4 is an X-chromosome-linked cancer/testis protein that is broadly expressed across a range of cancer indications, including non-small-cell lung cancer amongst others. As with other cancer/testis antigens, its expression is limited to cancerous tissue. We believe IMC-C106C is the first clinical stage bispecific targeting MAGE-A4. We estimate the annual net population addressable with IMC-C103C as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 197px; width: 373px;" src="nt10016217x4_graphic29x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAX discovery engine, we identified an optimal MAGE-A4 specific TCR and engineered the molecule to increase its affinity 1.9 million fold, in order to have a TCR targeting system with affinity levels similar to that used by tebentafusp, and combined it with the same anti-CD3 effector function used in tebentafusp to create IMC-C103C. Pre-clinical evaluation of IMC-C103C across a range of cancer types indicated that it is approximately ten-fold more potent than tebentafusp. The figure below shows the selective elimination of MAGE-A4 positive cancer cells, which are identified by the color red, by IMC-C103C redirected non-cancer-specific T cells, which are identified by the color green, without affecting MAGE-A4 negative cells growing in close proximity. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 260px; width: 523px;" src="nt10016217x4_graphic23x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-C103C is currently in the dose escalation phase of a Phase 1/2 clinical trial. Patient eligibility for the dose escalation phase of the trial are HLA-A*02:01 positivity with either a high expression frequency tumor indication that does not require screening for MAGE-A4 positivity or a lower expression frequency tumor indication where MAGE-A4 positivity has been confirmed by immunohistochemistry staining. As of December 31, 2020, we have dosed 21 patients in the dose escalation phase of the clinical trial. Early pharmacodynamics data indicates that IMC-C103C is now being dosed at levels with biological activity and in patients can produce signals consistent with those observed for tebentafusp; we anticipate presenting this early </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">149<br></div></div></div>
<!--End Page 154-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 155-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">pharmacodynamic data at a future scientific conference. Once an optimal dosing regimen has been identified, the clinical protocol allows for expansion cohorts both as monotherapy and in combination with Genentech&#8217;s anti-PDL1 antibody Tecentriq across multiple indications including non-small-cell lung, ovarian, head and neck and esophageal cancers. We believe the ability to drive T cell infiltration into solid tumors, as demonstrated by tebentafusp, is a characteristic of our platform and will be observed for all ImmTAC programs. On this basis, we believe we may observe additional clinical benefit by combining IMC-C103C with Tecentriq over and above its monotherapy activity. Patients will continue to be dosed weekly until disease progression, discontinuation due to adverse events or withdrawal of consent. We anticipate reporting Phase&#160;1 initial data from this trial in the second half of 2021. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Manufacturing scale up activities are underway in collaboration with Genentech to support late stage clinical development activities. We are also conducting pre-clinical evaluation of a half-life extended version of IMC-C103C, developed using our own intellectual property.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">IMC-F106C - Targeting PRAME</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-F106C is an ImmTAC targeting a PRAME derived peptide presented by HLA-A*02:01 currently in the Phase 1 portion of a Phase 1/2 clinical trial from which we anticipate reporting Phase&#160;1 initial data from this trial in mid-2022. We believe IMC-F106C is the first clinical stage bi-specific targeting PRAME. We retain full rights to IMC-F106C. PRAME has the highest expression frequency of all cancer/testis antigens across a range of solid and hematologic cancers, notably non-small-cell lung cancer, and its expression is generally identified as a poor prognostic feature. PRAME expression is often high as also in ovarian, breast and endometrial cancers. A significant advantage of targeting PRAME over some other cancer/testis antigens, is that its expression within tumors tends to be homogeneous rather than heterogeneous. We estimate the annual net population addressable with IMC-F106C as follows: </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 215px; width: 373px;" src="nt10016217x4_graphic30x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmSPEC target identification technology allowed us to select a PRAME antigen which we believe has high potential to be highly immunogenic. Using the ImmTAX discovery engine we identified an optimal PRAME specific TCR and increased its affinity 3.7 million fold to deliver a TCR targeting system with affinity levels similar to the TCR system in tebentafusp and combined it with the same anti-CD3 effector function to create IMC-F106C. Preclinical evaluation of IMC-F106C across a range of cancer types indicates that it is approximately ten-fold more potent than tebentafusp. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-F106C is currently in the dose escalation phase of a Phase 1/2 clinical trial. Patient eligibility for the dose escalation phase of the trial are HLA-A*02:01 positivity with either a high expression frequency tumor indication that does not require screening for PRAME positivity or a lower expression frequency tumor indication where PRAME positivity has been confirmed by immunohistochemistry staining. As of December&#160;31, 2020, we have dosed nine patients in the dose escalation phase of the clinical trial. Once an optimal dosing regimen has been identified, the clinical protocol allows for expansion cohorts as both monotherapy and in combination either an anti-PD1 or an anti-PD-L1 antibody across multiple indications with an initial focus on non-small-cell lung, ovarian, endometrial and triple-negative breast cancer. Patients will continue to be dosed weekly until disease progression, discontinuation due to adverse events or withdrawal of consent.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">150<br></div></div></div>
<!--End Page 155-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 156-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-F106C was placed on partial clinical hold early in clinical development because of the death of the second patient dosed in the trial who had elevated baseline risk factors for pulmonary emboli. Following investigations, including autopsy, the investigator concluded that the cause of death was respiratory failure and not related to study drug. As a precaution, we modified the protocol to add a lower dose and added additional screening and on-treatment safeguards. The FDA accepted the revised protocol, lifted the partial clinical hold and to date, the trial has subsequently dosed an additional seven patients.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">GSK01 - Targeting NY-ESO </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">NY-ESO was one of the earliest of the cancer family of targets to be identified and as such, has been extensively studied as a target for cancer vaccines and TCR-T cellular therapies. While broadly expressed across a range of both solid and hematological cancers, its frequency of expression is lower than for either MAGE-A4 and PRAME.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our collaboration with GSK, we are responsible for executing a Phase 1 clinical trial of GSK01. GSK has an option to acquire full commercialization and development rights to GSK01 at the end of the ongoing Phase 1 clinical trial. GSK01 is currently in the dose escalation phase of the Phase 1 clinical trial in HLA-A*02:01 positive patients with NY-ESO positive tumors by immunohistochemistry staining. As of December&#160;31, 2020, we have dosed 27 patients in the dose escalation phase of the clinical trial. Once an optimal dosing regimen has been identified, a small expansion cohort of synovial sarcoma patients will be recruited to look for early evidence of clinical benefit. Patients will continue to be dosed weekly until disease progression, discontinuation due to adverse events or withdrawal of consent.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Pre-Clinical Oncology Pipeline</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to our four clinical stage ImmTAC programs, we are progressing an additional eight ImmTAC programs through pre-clinical development. Five of these programs are wholly owned and three are being developed in partnership. Our strategy around our pre-clinical development of ImmTACs is to pursue both well understood, relatively low risk targets, in addition to higher risk novel targets that have the potential to have a significant impact on our ability to treat diseases. Additionally, we continue to look to develop assets that target antigens with high levels of expression on tumors with significant unmet need, as can be seen in the figure below.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"><img style="height: 339px; width: 625px;" src="nt10016217x4_graphic17x1.jpg">&#8201;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">151<br></div></div></div>
<!--End Page 156-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 157-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Our ImmTAV Platform </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview of ImmTAV, Our Infectious Disease-Focused ImmTAX Platform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAV (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>V</u></font>irus) platform, we have advanced our first program into the clinic, and we are working to advance a second program from pre-clinical into the clinic during the second half of 2021. Our ImmTAV product candidates are bispecific soluble TCR molecules featuring our ImmTAX TCR-based targeting system with high specificity for low expression viral antigens, combined with the proprietary anti-CD3 effector module for T cell engagement and activation that has been validated in our clinical oncology pipeline. We are seeking to develop therapeutics which could provide a functional cure to chronic viral disease and are focusing initially on HBV and HIV.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Chronic viral infections can be compared to cancer from an immune system response perspective, in that they arise from an inability of the immune system to eliminate the infection, either because of immune cell exhaustion, viral mediated immune-suppression or because the level of target presented by infected cells is too low for viral specific T cells to recognize them effectively. These represent a high unmet need and are a high burden to society from both a cost and human perspective. Our ImmTAX platform enables us to efficiently target infected cells with low levels of viral antigen and in the case of exhausted immune response to prompt what we believe is an effective immune response against them. We are developing multiple ImmTAV molecules with the goal of providing a functional cure for infectious diseases currently incurable with standard-of-care treatments.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAV platform is designed to overcome the limitations of natural immune responses to chronic infections by using the same anti-CD3 effector function used for our oncology ImmTAC platform. This allows the platform to redirect non-exhausted, non-viral specific T cells against the infected cells using an effector that has been clinically proven to be effective in a highly immunosuppressive environment, such as that found within the liver in the case of metastatic uveal melanoma patients. Our ability to significantly increase the affinity of TCR targeting system as compared to those used by naturally occurring viral-specific T cells makes our ImmTAVs molecules a powerful and sensitive tool to target infected cells with low levels of target viral antigen. This is particularly important for the treatment for viruses that resist elimination through the formation of a reservoir of long-lived cells that present very low levels of target, as is the case for HBV and HIV.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our ImmTAV Portfolio</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 132px; width: 612px;" src="nt10016217x4_graphic18x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our most advanced ImmTAV product candidate is IMC-I109V, the first of our chronic HBV targeted assets, which is currently in Phase 1/2 development. We are also advancing IMC-M113V through GMP manufacturing and IND supporting pre-clinical studies for HIV. Our HIV programs are funded by the Gates Foundation and we are required to make any successfully approved products available at reduced prices in certain developing countries. We retain full development and commercial right in non-developing countries. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">IMC-I109V &#8211; Pursuing a Functional Cure of HBV</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-I109V is an ImmTAV product candidate targeting a conserved HVB envelope antigen called HBsAg (all variants), combined with a an anti-CD3 effector module. We are currently conducting a Phase 1/2 clinical trial in patients with chronic HBV who are non-cirrhotic, hepatitis B e-Antigen negative, and virally suppressed on chronic nucleot(s)ide analogue therapy. Our goal is to develop a functional cure for HBV. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">According to The World Health Organization, or WHO, there are over 250&#160;million people living with chronic HBV infection at risk of end-stage liver disease and hepatocellular carcinoma and which result in approximately 900,000 deaths each year, mostly from cirrhosis and hepatocellular carcinoma. Current standard-of-care antiviral agents do not provide a permanent cure in most cases and lifelong treatment is necessary to lower the risk of HBV-related complications and liver disease progression.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">152<br></div></div></div>
<!--End Page 157-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 158-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Despite recent progress in direct anti-viral approaches such as RNAi and CpAM agents targeting elements of the viral lifecycle, the rate of functional cure, defined as a sustained loss of circulating HBsAg and HBV DNA, remains low even in cases of long term treatment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Current therapies are effective in inhibiting viral replication in HBV infected patients, but the ability of the virus to create long-lived reservoirs in infected hepatocytes means that the infection can reseed once direct viral inhibition is removed. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Most HBV specific T cells are exhausted in chronically infected patients and recently published data suggests that cells forming the viral reservoir express very low levels of HBV antigen, which makes it hard for the immune system to recognize them effectively. Additionally, while most patients possess HBV specific T cells, these T cells are exhausted and attempts to boost their antiviral activity either through use of the general immune stimulator interferon or a checkpoint agent that blocks an inhibitory pathway have to date only produced low rates of functional cure.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAV platform is designed to address both limitations of existing immunotherapeutic approaches through redirecting non-exhausted non-HBV specific T cells against the viral reservoir and increasing their ability to recognize these cells presenting very low levels of target through very high affinity of the ImmTAV targeting. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 359px; width: 620px;" src="nt10016217x4_graphic31x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using ImmSPECT, our mass-spectrometry platform, we identified a large number of HBV derived peptides presented by HLA. Of those that bind HLA-A2, seven met our criterion for acceptability. Of the seven peptides, we selected an optimal HLA-A*02:01 envelope peptide antigen expressed by all cells capable of reseeding the viral infection. Elimination of cells expressing this target also provides a rapid means to track clinical activity through a well-validated HBsAg biomarker used to define functional cure.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">153<br></div></div></div>
<!--End Page 158-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 159-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmTAX discovery engine, we identified an optimal HBV envelope-specific TCR and we subsequently increased its affinity to deliver a TCR targeting system whose affinity is similar to that used by tebentafusp. Our IMC-I109V was created combining this TCR-based targeting module with the same anti-CD3 effector module used in our clinical stage oncology programs. Pre-clinical evaluation of IMC-I109V demonstrated it can eliminate HBV infected cells with both integrated and extra-chromosomal HBV DNA, a characteristic which is critical for effectively targeting the viral reservoir. The figure below shows the selective elimination of HBV positive cells (red) by IMC-I109V redirected non-HBV specific T cells (blue) without affecting HBV negative cells growing in close proximity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 308px; width: 587px;" src="nt10016217x4_graphic22x2.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are currently conducting a Phase 1/2 trial of our IMC-I109V in patients with chronic HBV who are non-cirrhotic, hepatitis B e-Antigen negative, and virally suppressed on chronic nucleot(s)ide analogue therapy. We have activated sites in three countries to initiate patients screening. The development plan includes a Part 1 single ascending dose to identify the clinically active dose, followed by a Part 2 including multiple ascending dose to identify a well-tolerated but efficacious regimen during which patients will be treated for up to 24 weeks to determine preliminary clinical activity. The protocol allows for patients who achieve biomarker-defined evidence of clinical benefit to stop antiviral suppression treatment in order to determine the extent and kinetics of any viral rebound. We anticipate commencing dosing in our Phase 1 SAD trial in mid-2021.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">IMC-M113V &#8211; Pursuing a Functional Cure for HIV</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-M113V is an ImmTAV product candidate targeting a HIV gag antigen, is currently in pre-clinical development. Approximately 38&#160;million people were living with HIV worldwide in 2019, according to UNAIDS, of which an estimated 25&#160;million had access to antiretroviral therapy, or ART. Despite the wide availability of ARTs, no curative therapies or effective vaccines currently exist. Therefore, lifelong anti-viral treatment is necessary to prevent both disease progression and onward transmission. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The goal of our HIV ImmTAV program is to achieve a functional HIV cure, or remission with sustained control of HIV replication and maintenance of normal CD4 T cell count in the absence of anti-viral treatment. As with HBV, the biggest hurdle to delivering a functional HIV cure is the existence of a viral reservoir of long-lived cells harboring latent forms of HIV that reseed infection upon discontinuation of anti-viral treatment. Therapeutic approaches to achieve functional HIV cures have been unsuccessful to date, either because existing HIV specific T cells are exhausted, or because the levels of HIV target presented by latently infected cells are too low to be effectively recognized by HIV specific T cells.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our novel and proprietary ImmTAV platform and lead HIV product candidate IMC-M113V is designed to address the key limitations of existing immunotherapeutic approaches by redirecting non-exhausted non-HIV specific T cells against the viral reservoir and by increasing their ability to recognize reservoir cells presenting very low levels of target, through the enhanced affinity of the ImmTAV targeting system.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">154<br></div></div></div>
<!--End Page 159-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 160-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Using our ImmSPECT mass-spectrometry platform, we have mapped the entire HIV peptidome to identify the best HLA presented peptide targets. From this data, we selected a HLA-A*02:01 presented peptide antigen, derived from the HIV gag protein, as the optimal target since it should be expressed by all cells capable of reseeding the viral infection and has a sequence that is conserved across a number of HIV strains circulating in the population.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We engineered IMC-M113V by leveraging our ImmTAX discovery engine, to identify an optimal HIV envelope specific TCR and increasing its affinity to deliver a TCR targeting system equivalent to that used by tebentafusp; and then combined it with our second generation anti-CD3 effector function for enhanced potency against latently infected cells. Pre-clinical evaluation of IMC-M113V has demonstrated that it can potently redirect non-HIV specific T cells to eliminate HIV-infected resting CD4+ T cells, which represents one of the best models of HIV latency currently available.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">IMC-M113V is currently advancing through GMP manufacturing at an external contract manufacturing organization and we anticipate regulatory submission to enable clinical testing during the second half of 2021. Due to the mutational frequency observed within HIV we anticipate that a cocktail of ImmTAV molecules will be required, therefore additional ImmTAV molecules targeting other HIV epitopes are also currently in development.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our HIV programs are funded by the Gates Foundation, and we are required to make any successfully approved products available at reduced prices in certain developing countries. We retain full development and commercial right in non-developing countries.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">Our ImmTAAI Platform</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Overview of ImmTAAI, Our Autoimmune Disease-Focused ImmTAX Platform</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 103px; width: 620px;" src="nt10016217x4_graphic19x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While our ImmTAC and ImmTAV platforms aim to provide therapeutic benefit by driving an immune response against targeted cells, our ImmTAAI (<font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;">m</font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>A</u></font>uto<font style="font-weight: bold;"><u>I</u></font>mmune disease) platform leverages our ImmTAX technology to generate product candidates designed to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Our ImmTAAI product candidates are designed to selectively target organs, tissues or immune cells and deliver an immunosuppressive effector function. We have optimized two immune system modulating effector functions to provide local T cell inhibition, which we believe may limit any adverse effects originating from systemic immune suppression. We believe we can use our ImmTAAI platform to develop a portfolio of product candidates to treat autoimmune indications with a high unmet medical need, and provide significant benefit to patients. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Similar to our other ImmTAX platforms, ImmTAAI product candidates are highly modular and flexible with two effector domains in development to provide maximum therapeutic impact depending on the underlying biology of the autoimmune disease to be treated. The first effector is an in-house generated PD-1 agonist, which stimulates a immunosuppressive pathway to inhibit the activity of aberrant T effector cells at the site of the disease. The second effector is an IL-2 approach to selectively stimulate the proliferation and activity of regulatory T cells (Treg) whose normal role is to more broadly suppress immune activity against normal tissue. The below graphic depicts our flexible and modular approach using the dual effector domains described above.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">155<br></div></div></div>
<!--End Page 160-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 161-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 250px; width: 485px;" src="nt10016217x4_graphic20x1.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our ImmTAAI platform has the potential to treat a broad range of autoimmune diseases that impact a significant population of patients. In the United States, more than 23&#160;million people suffer from autoimmune or autoimmune diseases, which are often chronic and debilitating conditions that have a significant impact on patients&#8217; quality of life. There are more than 100 separate autoimmune diseases across multiple therapeutic areas, and patients still have significant unmet medical needs as current therapies rarely achieve complete remission, are not universally effective, typically require chronic administration and cause side effects resulting from broad systemic immune suppression.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our initial focus is on validating our ImmTAAI platform by addressing type 1 diabetes. We are also actively working to develop ImmTAAI product candidates against a number of autoimmune skin diseases, such as vitiligo, atopic dermatitis and alopecia. We continue to evaluate other opportunities to apply our ImmTAAI platform for the treatment of a range of autoimmune diseases. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our most advanced ImmTAAI product candidate is being evaluated for the treatment of the disease process underlying type 1 diabetes, and it is currently in lead optimization and pre-clinical evaluation. We retain all rights to the asset, which is being developed in collaboration with, and using resources from, the Juvenile Diabetes Research Foundation and Type 1 Diabetes Fund. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">The Next Generation of the ImmTAX Platform</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are building on our foundations as pioneers of TCR-based therapies to develop the next generation of the ImmTAX platform. Although our current ImmTAX platform has the ability to address a significant group of patients suffering from the targeted diseases, we are pioneering TCRs that are able to target universally found HLAs, and thus maximize the eligible patient population. Additionally, we continue to engineer our ImmTAX technology to improve the patient experience associated with our treatment. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Developing an ImmTAX with Universal Patient Access</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our current ImmTAX platform, like all other TCR therapies, is able to effectively target classical HLAs. Classical HLAs present several genetic variants across individuals. Consequently, only those individuals with the specific classical HLA recognized by the TCR are eligible to receive the treatment. This limits the total addressable population for each product within each indication.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">156<br></div></div></div>
<!--End Page 161-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 162-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Several universal non-classical HLAs such as HLA-E, offer a route to broaden the patient population eligible for each TCR-based therapeutic. We are not aware of any other group that has managed to overcome the significant technical challenges around developing HLA-E targeting TCR therapeutics. We have leveraged our expertise to develop the first HLA-E technology platform that has achieved pre-clinical proof-of-concept for an HLA-E targeted bispecific. In building this new HLA-E platform, we have built a suite of tools to overcome three key technical challenges:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">HLA-E target identification and validation</font>: HLA-E peptide antigens are significantly more unstable than classical HLA peptides and fall apart within minutes rather than hours. Therefore, we have developed a suite of four new HLA-E target identification and validation assays that have allowed us to identify novel HLA-E targets for HBV, HIV, TB and a number of oncology targets.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Antigen stabilization</font>: HLA-E/peptide instability also makes the isolation and engineering of specific TCRs challenging. We developed and patented a new HLA-E stabilization approach that allows highly specific TCRs to be isolated and engineered.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-weight: bold;">Sufficiently high specificity</font>: HLA-E presents peptides that tend to have a high degree of similarity in their sequence, making it challenging to introduce sufficient levels of specificity to support clinical development. We have successfully adapted existing specificity tools to overcome these challenges.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our HLA-E bispecific platform has achieved pre-clinical proof-of-concept. We believe this is the first demonstration of a T cell redirecting bispecific targeting a HLA-E presented peptide. We currently have ongoing HLA-E discovery stage programs as part of our research efforts to find a functional cure for HBV and HIV and to several oncology targets that have extremely high prevalence levels across a range of solid tumors with high unmet medical need.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Improving the Patient Experience</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are leveraging our half-life extension technology with our high-affinity TCR targeting system to enable less frequent dosing intervals than other immunotherapy therapeutics. Due to target binding half-lives that are already in the range of tens of hours, we have observed clinical activity using the same weekly administration regimen employed by our competitors that are already using half-life extension technology. Therefore, we have an opportunity to further improve patient acceptability by applying these half-life extenders to our own products which we believe will significantly increase intervals between dosing while maintaining clinical activity. Half-life extended versions of IMC-C103C and IMC-F106C are in pre-clinical evaluation. We will also explore sub-cutaneous dosing that may ultimately allow patients to treat themselves in their own homes. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">Manufacturing and Drug Supply</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our Chemistry, Manufacturing and Controls, or CMC, group conducts studies in molecular bioengineering, process development, analytical assay development, product characterization, formulation development and stability studies in support of Good Manufacturing Practice, or cGMP, -compliant manufacturing.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We do not currently own or operate cGMP-compliant manufacturing facilities for the production of clinical or commercial ImmTAX product candidates; however, we extensively outsource to microbial contract manufacturing organizations, or CMOs, for both drug substance and drug product production and have a successful cGMP-compliant manufacturing history of production of cGMP batches. We develop the upstream fermentation and downstream purification processes, as well as developing the analytical assays for quality control batch release testing and stability studies in-house and then transfer the technology and know-how to the CMOs to establish, scale-up, validation and manufacturing. This outsourced approach to manufacturing requires the CMOs to establish master and working cell banks, ImmTAX reference standards and produce the cGMP-compliant drug substance, and/or cGMP-compliant drug product. We conduct quality and technical audits of the CMOs to monitor the manufacturing operations and ensure compliance with the mutually agreed process operations and cGMP-regulations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently contract with the following three well-established third-party manufacturers: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Biovian Ltd., headquartered in Turku, Finland, for early-phase clinical drug substance and drug product cGMP manufacturing;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">AGC Biologics A/S, headquartered in Copenhagen, Denmark, for late-phase clinical and commercial scale drug substance cGMP manufacturing; and</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">157<br></div></div></div>
<!--End Page 162-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 163-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg35"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Baxter Oncology GmbH, headquartered in Halle/Westfalen, Germany for late-phase clinical and commercial scale drug product cGMP manufacturing.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Tebentafusp is manufactured by AGC Biologics A/S and Baxter Oncology GmbH. Our manufacturers have recently manufactured triplicate Process Performance Qualification, or PPQ, batches, commercial large-scale manufacturing consistency batches of drug substance and drug product of tebentafusp, and we believe the quantities will be sufficient for commercial launch and initial commercial supply, assuming regulatory approval. AGC Biologics A/S and Baxter Oncology GmbH are positioned to provide longer term commercial manufacture of tebentafusp, with the storage, global distribution, packaging and labeling operations being provided by Deutsche Post DHL Group, or DHL and Integrated Commercialization Solutions, LLC, a division of AmerisourceBergen Corporation.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; text-align: center;">Competition</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies and intense competition. We believe that our approach, strategy, TCR experience and ultimately, our ImmTAX platform provide us with competitive advantages. However, we expect substantial competition from multiple sources, including major pharmaceutical, specialty pharmaceutical, and existing or emerging biotechnology companies, academic research institutions and governmental agencies and public and private research institutions worldwide. Many of our competitors, either alone or with their collaborations, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of therapeutics to address unmet needs in cancer, infectious and autoimmune diseases, including: Adaptimmune Therapeutics plc, or Adaptimmune, Gritstone Oncology, Inc., Immatics Biotechnologies GmbH, or Immatics, Adaptive Biotechnologies Corporation, or Adaptive, pure MHC, LLC, BioNTech SE, and Genentech, who are also seeking to identify HLA targets and develop product candidates; Adaptimmune, T-Knife GmbH, Adaptive, 3T Biosciences, Inc., MediGene, Regeneron Pharmaceuticals, Inc., or Regeneron, Gilead Sciences, Inc., bluebird Bio, Inc., or bluebird bio, and AgenTus Therapeutics, Inc. who are also developing TCR-based approaches; and Takara Bio Inc., Tmunity Therapeutics, Inc., Kuur Therapeutics Limited, Bristol-Myers Squibb Company, GSK, Adaptimmune, bluebird bio, MediGene, TCR<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> Therapeutics Inc., and Bellicum Pharmaceuticals, Inc. who are developing novel autologous TCR-T therapeutics; Amgen, Inc., Genmab, Inc. and MorphoSys AG are developing TCR bispecific compounds or TCR mimetic antibodies. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Competitors targeting pHLA complexes fall primarily into the two groups based on mechanism of action. Specifically, we are aware of various companies and academic institutions that are developing TCR transduced cell therapies against a range of pHLA targets, some of which overlap with those in our pipeline such as MAGE-A4 and PRAME including. Adaptimmune, who is developing a MAGE-A4 directed cellular therapy, which believe to be the most advanced in the field and has entered pivotal testing for various forms of sarcoma. In regard to PRAME, we are aware that Adaptimmune and Immatics both are making advancements in the field and have PRAME directed cellular therapies in Phase 1 clinical trials. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Oncology</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any ImmTAC product candidates that we successfully develop and commercialize for oncology indications may compete with existing products and new products that may become available in the future. There is intense competition in the field of oncology from multiple different treatment modalities and new approaches are continually emerging. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We evaluated tebentafusp in a randomized Phase 3 pivotal trial for patients with metastatic uveal melanoma with tebentafusp demonstrating superior overall survival versus investigators&#8217; choice. There is currently no FDA-approved standard of care for the treatment of this disease. Delcath Systems, Inc. is conducting a single-arm pivotal trial in metastatic uveal melanoma to evaluate a procedure that delivers a high dose of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">158<br></div></div></div>
<!--End Page 163-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 164-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg36"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">melphalan to the liver via percutaneous hepatic perfusion. This system is currently marketed in Europe as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT&#174; Delivery System for Melphalan (CHEMOSAT). We are aware of several other companies with product candidates in clinical development for the treatment of metastatic uveal melanoma, none of which have yet progressed to pivotal trial testing. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 20pt; text-align: left;">Chronic HBV</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are numerous antiviral therapies approved by the FDA for the treatment of chronic HBV infections. These treatments consist of life-long antiviral therapy to suppress virus replication. This can slow the progression of liver cirrhosis and reduce the incidence of liver cancer, but most patients do not achieve functional cure. There are also FDA-approved vaccinations that provide effective prophylaxis against HBV, although they do not reverse or cure the disease in people who have already contracted the virus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are aware of numerous academic institutions and companies that are developing novel therapies with varying mechanisms of action to address chronic HBV. Types of products in development include adoptive cell therapies, antisense oligonucleotides / RNAi therapeutics, capsid assembly modulators, checkpoint inhibitors, cyclophilin inhibitors, farnesoid X receptor agonists, genome editing, innate immune defense / toll-like receptor agonists, nucleic acid polymers, nucleos(t)ide analogues, recombinant monoclonal antibodies, RNA destabilizers, SMAC mimetics / IAP antagonists, therapeutic vaccines, viral entry receptor inhibitors, viral phosphoprotein inhibitors and viral protease inhibitors. We believe that instead of competing with certain of these therapies, our ImmTAV product candidates have the potential to be used as a complementary therapy.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">Intellectual Property</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including by seeking, maintaining, enforcing and defending patent rights for our therapeutics and processes, whether developed internally or licensed from third parties. Our success will depend on our ability to obtain and maintain patent and other protection including data/market exclusivity for our soluble TCR bispecific therapeutic candidates and platform technology, preserve the confidentiality of our know-how and operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and proprietary rights of third parties. For more information, please see &#8220;Risk Factors &#8212; Risks Related to Intellectual Property.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We seek to protect our proprietary position by filing patent applications in territories that are commercially important for our soluble TCR bispecific therapeutic candidates and technology platform, generally including but not limited to the United States, Europe, Australia, Brazil, Canada, China, India, Israel, Japan, Mexico, New Zealand, Russia, South Africa and South Korea. We also intend to rely on data exclusivity, market exclusivity and patent term extensions when available, including any relevant exclusivity through supplementary protection certificates and orphan or pediatric drug designation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, we solely own six issued U.S. patents, 145 issued foreign patents, eight pending U.S. patent applications, 81 pending foreign patent applications and seven pending Patent Cooperation Treaty, or PCT, patent applications. We also co-own with Adaptimmune 11 issued U.S. patents, 152 issued foreign patents, 36 pending U.S. patent applications, and 42 pending foreign patent applications. These patents and patent applications include claims directed to our soluble TCR bispecific therapeutic candidates, required intermediates in the preparation of our soluble TCR bispecific therapeutic candidates, our platform technology used to identify and generate soluble TCR bispecific therapeutic candidates, targets, formulations and methods of treatment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">While we own issued composition of matter patents relating to tebentafusp and pending patent applications relating to our other product candidates, including IMC-C103C, IMC-F106C, IMC-I109V, GSK01 and IMC-I109V, we do not own or in-license any issued patents relating to such other product candidates and we can provide no assurance that any of our current or future patent applications will result in issued patents or that any issued patents will provide us with any competitive advantage.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">ImmTAC platform</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">Tebentafusp, our ImmTAC product candidate</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, we own granted patents and patent applications covering the composition of matter of our lead TCR bispecific therapeutic candidate, tebentafusp, and required intermediates in the preparation of tebentafusp. The patent claims extend to cover additional TCR variants with similar biological properties in </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">159<br></div></div></div>
<!--End Page 164-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 165-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg37"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">addition to the specific candidate sequence. Granted patents have been obtained in major territories including two in the United States and 28 in foreign jurisdictions, including Europe (including United Kingdom, France, Germany, Italy, Spain, Ireland, Denmark and the Netherlands), Australia, Canada, China, Hong Kong, Japan, Mexico, Eurasia and South Africa. These granted patents are expected to expire in 2030, subject to further patent term adjustments, patent term extensions and/or supplementary protection certificates. Further protection may be achieved if further pending patent applications covering the expected label dosing regimen and formulation of tebentafusp are granted. The dosing regimen patent applications include one pending in the United States and nine pending in foreign jurisdictions, including Europe, Australia, Brazil, Canada, China, Japan, Mexico, Russia and South Africa. The formulation patent family currently includes one pending PCT patent application. If granted the dosing regimen patent application family would expire in 2037 and any U.S. non-provisional or foreign patent applications timely filed based on the formulation PCT application family would expire in 2040, each excluding any additional term for patent term adjustments or patent term extensions. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Further soluble TCR bispecific candidates</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, we own pending composition of matter patent applications, including three pending U.S. patent applications and 52 pending foreign patent applications and one PCT application, covering further clinical and pre-clinical stage soluble TCR bispecific therapeutic candidates for oncology, including IMC-C103C, IMC-F106C, GSK01 and IMC-J110C targeting NY-ESO, MAGE-A4, PRAME and MAGE-A1. In each case, claims of the patent application are directed to the engineered soluble TCR bispecific therapeutic candidate and to TCR variants with similar biological properties. If granted, patents derived from these applications or applications that claim priority from these applications would expire in 2036 for GSK01, 2037 for IMC-C103C, 2038 for IMC-F106C and 2041 for IMC-J110C, excluding any additional term for patent term adjustments or patent term extensions. National patent applications for GSK-01, IMC-C103C and IMC-F106C have been filed in the United States and foreign jurisdictions, including Europe, Australia, Canada, China, Japan, Mexico and Russia. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">ImmTAV platform</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 20pt; text-align: left;">IMC-I109V clinical program </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, we own one pending composition of matter PCT patent application relating to our IMC-I109V clinical program. If granted, national applications derived from the PCT application are expected to expire in 2040, excluding any additional term for patent term adjustments or patent term extensions. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Our ImmTAX platform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October 31, 2020, we own a number of patents and patent applications related to our ImmTAX platform. These include platform technology composition-of-matter patents and patent applications that aim to cover a disulphide bond stabilization approach for obtaining soluble TCRs, phage display methodology for the production of TCRs with supraphysiological affinity and specificity for target antigen, and a TCR bispecific format with potent T cell redirection activity. Granted patents for these core platform technologies have been obtained in major territories including nine issued patents in the United States and a 196 patents in a mixture of foreign jurisdictions, including Europe, Australia, Brazil, Canada, China, Eurasia, Hong Kong, Israel, India, Japan, South Korea, Norway, New Zealand, Mexico, Russia, Singapore and South Africa. The earliest of these patents will begin to expire in 2022 and 2023, for soluble TCRs with disulphide bond stabilization and phage display technology, respectively, excluding any additional term for patent term adjustments or patent term extensions. Patents relating to the TCR bispecific format required for enhanced potency will expire starting in 2030, excluding any additional term for patent term adjustments or patent term extensions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October 31, 2020, we own two pending composition-of-matter PCT platform technology patent applications relating to TCR bispecifics with improved therapeutic properties, including formats with extended in vivo half-life and improved anti-CD3 effector functions. We also own a pending composition-of-matter PCT patent application relating to a TCR-PD1 agonist bispecific platform for tissue/organ specific immunosuppression for the treatment of autoimmune and autoimmune indications. Any U.S. non-provisional patent applications or foreign patent applications timely filed based on these applications, if issued, would expire between 2039 and 2040, excluding any additional term for patent term adjustments or patent term extensions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The platform patents and patent applications relating to soluble TCRs with disulphide bond stabilization and phage display methodology, as well as certain other technology patents, are jointly owned in 50% equal share </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">160<br></div></div></div>
<!--End Page 165-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 166-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg38"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with Adaptimmune. We control the prosecution of these jointly owned patents and patent applications. A field restricted cross license limits each company&#8217;s exploitation of the technology to their respective fields. For more information on our assignment and exclusive license agreement with Adaptimmune, see &#8220;Business &#8212; Collaborations and License Agreements &#8212;Assignment and Exclusive License Agreement with Adaptimmune Limited.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Target patent applications</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, we own, in equal share with Adaptimmune, one issued U.S. patent, 32 pending U.S. patent applications, and 25 pending foreign patent applications relating to novel HLA-restricted peptide targets and their use. Such patents and pending patent applications, if granted, are expected to expire between 2036 and 2037, excluding any additional term for patent term adjustments or patent term extensions. In addition, we also own one pending PCT patent application relating to non-classical HLA antigens suitable for the isolation and affinity maturation of non-classically HLA restricted TCRs and methods for production of such antigens. If granted, national applications derived from the PCT application are expected to expire in 2040, excluding any additional term for patent term adjustments or patent term extensions.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Patent term</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Typically, we submit an initial priority application at the U.K. Intellectual Property Office, or UKIPO. This is followed 12 months later by the filing of a patent application under the PCT claiming priority from the initial application(s). Further data can be added to the application during the priority year and the resulting patent term is calculated from the PCT filing date. This strategy allows us to obtain an early priority date while additional experimental data are generated. At the end of the PCT period, generally two and a half years from the priority date, separate patent applications can be pursued in any of the 153 PCT member states. Our PCT patent applications are not eligible to become issued patents until, among other things, we file national stage patent applications within such PCT period in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose any patent protection on the inventions disclosed in such PCT patent applications. For all patent applications, we determine claiming strategy and territory coverage on a case-by-case basis. Advice of counsel and alignment with overarching business objectives is always considered. We regularly reassess the value of the patents and patent applications in our portfolio.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed patent applications, including the U.S., the patent term is 20&#160;years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements are met. For more information on patent term extension, see &#8220;Business &#8212; Government Regulation &#8212; Patent Term Restoration and Extension.&#8221; As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned pending patent applications, and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated, narrowed, held unenforceable, infringed or circumvented. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. See &#8220;Risk Factors &#8212; Risks Related to Intellectual Property.&#8221; </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Trade secrets</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and know-how can be difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">161<br></div></div></div>
<!--End Page 166-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 167-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg39"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and consultants and invention assignment agreements with our employees. We also have confidentiality agreements and invention assignment agreements with our collaborators and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. We cannot guarantee, however, that we have executed such agreements with all applicable counterparties. Furthermore, these agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors and other third parties. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, please see &#8220;Risk Factors &#8212; Risks Related to Intellectual Property.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Third-party rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our product candidates or processes, obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our current or future product candidates may have an adverse impact on us. For more information, please see &#8220;Risk Factors &#8212; Risks Related to Intellectual Property.&#8221; </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Trademarks</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of October&#160;31, 2020, our trademark portfolio contains registrations or registration applications including for Immunocore, ImmTAC, ImmTAX and ImmTAV in the United States and in certain foreign jurisdictions.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; text-align: center;">Our Collaborations and License Agreements</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Genentech Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2013, we entered into a research collaboration and license agreement, or the 2013 Genentech Agreement, with Genentech, Inc., or Genentech, and F. Hoffmann-La Roche Ltd, or Roche, pursuant to which we along with Genentech and Roche agreed to collaborate in the development, manufacture and ultimately, commercialization of soluble TCR bispecific therapeutic candidate compounds. Under the 2013 Genentech Agreement, Genentech paid us an initial upfront payment of $20&#160;million in exchange for exclusive licenses to two of our targets, MAGE-A4 as well as an undisclosed target. We refer to these two initial targets as the Negotiated Targets. For each of the Negotiated Targets, we were responsible for developing a soluble TCR bispecific therapeutic pre-clinical candidate compound, and Genentech was responsible for all GMP manufacture, clinical development and commercialization of those compounds, upon which we would be entitled to receive future milestone and royalty payments. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The first pre-clinical program nominated under the 2013 Genentech Agreement was target MAGE-A4, which we refer to as our IMC-C103C program. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September 2016, following achievement of formal nomination of the pre-clinical candidate compound, we and Genentech amended the 2013 Genentech Agreement. We refer to this amendment as the 2016 Genentech Amendment. The 2016 Genentech Amendment provided that the Negotiated Targets, including MAGE-A4, ceased to be considered eligible targets under the 2013 Genentech Agreement. On the same day, we entered into a license agreement with Genentech, or the 2016 Genentech Agreement. Pursuant to the 2016 Genentech Agreement, we regained control of the initial two programs covering the Negotiated Targets in existence at the time of execution, including MAGE-A4, and Genentech granted us an exclusive worldwide license to use its background intellectual property rights to advance such programs. Under the 2016 Genentech Agreement, we had sole responsibility for the development, manufacture and commercialization of the soluble TCR bispecific therapeutic compounds of the Negotiated Targets at our own expense, and are required to use diligent efforts to achieve commercialization of at least one therapeutic compound for each of the programs. In exchange for the rights granted to us under the 2016 Genentech Agreement, Genentech would be able to earn future development and commercial milestones of up to approximately $167&#160;million and tiered royalty payments between a mid-single-digit and low-teens percentage on net sales of such compounds. Genentech also obtained a right of first negotiation in respect of the programs of the Negotiated Targets, should we seek to license the rights to </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">162<br></div></div></div>
<!--End Page 167-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 168-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg40"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">develop and/or commercialize either program to a third party. The 2016 Genentech Agreement is effective on a country-by-country basis and shall expire on the later of (i)&#160;the expiration of the last to expire patent containing a valid claim which covers the sale of the applicable soluble TCR bispecific therapeutic compounds of the Negotiated Targets and (ii)&#160;the tenth anniversary of the date of the first commercial sale of such compounds. Either party is entitled to terminate the 2016 Genentech Agreement for an uncured material breach of the other party upon 90&#160;days&#8217; written notice, or 30 days&#8217; written notice, in the case of payment defaults, or immediately upon insolvency of the other party. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In November 2018, Genentech exercised its right of first negotiation with respect to our IMC-C103C program. We received an aggregate of $100&#160;million from Genentech, consisting of an initial upfront payment of $50&#160;million and $50&#160;million paid upon an IND filing for the first clinical trial of the product candidate compound, in exchange for granting Genentech rights to co-develop/co-promote our IMC-C103C program. In November 2018, in response to Genentech&#8217;s exercise of its right of first negotiation in regards to our IMC-C103C program, we entered into a new license and collaboration agreement, or the 2018 Genentech Agreement, pursuant to which we and Genentech agreed to collaborate in the development and commercialization of certain compounds targeting MAGE-A4, specifically pHLA-A2. Under the 2018 Genentech Agreement, we granted Genentech a co-exclusive worldwide license to our intellectual property rights in MAGE-A4 soluble TCR bispecific therapeutic candidate compounds to advance the development and commercialization of such compounds as contemplated under the 2018 Genentech Agreement. We are responsible for development of the IMC-C103C program through the completion of the Phase 1 clinical trial, with costs being shared equally with Genentech, and are required to use diligent efforts with respect to our development and commercialization obligations. After completion of the Phase 1 clinical trial, we have a limited time period in which to decide to either continue co-development (including co-funding) of our IMC-C103C program or withdraw from our co-funding commitment and thereby convert our co-exclusive license to a full out-license to Genentech of the program, in exchange for future milestone and royalty payments to us. Unless we decide to withdraw co-funding and co-development of our IMC-C103C program following completion of the Phase 1 clinical trial, we and Genentech would be jointly responsible for further clinical development of the asset, with costs shared equally between us. We would retain co-exclusive rights and joint responsibility for commercialization of our IMC-C103C program; although Genentech would have sole rights to book sales. We have already agreed to an equal sharing of funding and profits in regards to our IMC-C103C program. Within six months of starting the first Phase 3 registrational trial of our IMC-C103C program, we are obligated to negotiate a co-promotion agreement with Genentech to define the remaining co-promotion activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we elect to withdraw from co-funding of our IMC-C103C program after completion of the Phase 1 clinical trial, then Genentech shall acquire an exclusive worldwide license to the MAGE-A4 soluble TCR bispecific therapeutic candidate compounds and shall be fully responsible for all further development and commercialization of such candidate compounds, at its expense. These licenses, if granted, do not include any rights to affinity-enhanced TCRs or TCR therapeutic compounds directed to different target peptides. From the point of co-funding withdrawal, we will be eligible to receive over $700 million in aggregated development and commercial milestone payments plus royalties from Genentech on all sales of products arising from the our IMC-C103C program under the 2018 Genentech Agreement, with a rate varying between a high single-digit percentage and a low-teens percentage of net sales, subject to certain agreed reductions, dependent on the cumulative annual net sales for each calendar year. Royalties are payable while there is a jointly owned or solely owned valid patent claim covering the soluble TCR bispecific therapeutic product in the country in which the relevant TCR therapeutic product is being sold, which, if applicable patent applications are granted, is expected to be at least 2037 for IMC-C103C, and, in each case, for a minimum of 10 years from the first commercial sale of the relevant soluble TCR bispecific therapeutic product. We are required to notify Genentech as soon as reasonably practicable in the event that we experience a change of control prior to the completion of the first Phase 1 clinical trial, and Genentech could treat such a change of control as a co-funding withdrawal notice.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the 2018 Genentech Agreement, Genentech also obtained a right of first negotiation in respect of other TCR therapeutic candidate compounds that target MAGE-A4 by binding to an antigen other than pHLA-A2, should we discover any such therapeutic candidate compounds and seek to license the rights to a third party during the term of the 2018 Genentech Agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2018 Genentech Agreement is effective until all payment obligations expire. Both parties have rights to terminate the 2018 Genentech Agreement for uncured material breach upon 90 days&#8217; written notice or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">163<br></div></div></div>
<!--End Page 168-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 169-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg41"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">immediately upon insolvency of the other party. Genentech has additional rights to terminate the 2018 Genentech Agreement for convenience on provision of 90 days&#8217; notice to us. We also have rights to terminate any license where Genentech ceases development or withdraws from the market any licensed compound in specified circumstances. Following termination of the 2018 Genentech Agreement by either party, a formal negotiation process exists under which we can agree to commercially reasonable terms with Genentech for us to continue development and commercialization of the terminated assets.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">GSK Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In June 2013, we entered into a collaboration and license agreement, or the GSK Agreement, with GlaxoSmithKline Intellectual Property Development Ltd, or GSK, pursuant to which we and GSK agreed to collaborate in the development of soluble TCR bispecific therapeutic compounds.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the GSK Agreement, we granted GSK the right to nominate up to four targets as being exclusive to GSK&#160;under our collaboration. The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK&#160;Agreement. A second target was nominated in July&#160;2017. GSK has no further ability to nominate additional targets under the GSK Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the GSK Agreement, for NY-ESO, we are responsible for the development of the soluble TCR bispecific therapeutic candidate compounds through initial Phase 1 clinical trials. GSK has the option until a certain period following completion of such development work to obtain an exclusive worldwide license to such therapeutic candidate compounds directed at NY-ESO. GSK has an option to obtain an exclusive worldwide license for the therapeutic candidate compounds directed towards the second collaboration target until a certain period following the identification of at least one development candidate or the earlier termination of the applicable development work. During each GSK option period, we are prohibited from directly or indirectly developing or commercializing any soluble TCR&#160;bispecific therapeutic products arising under such program other than as provided under the GSK Agreement. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Until a defined point in clinical development, GSK may additionally request that we initiate development of up to eight additional soluble TCR bispecific therapeutics directed to the collaboration targets that have been nominated but recognizing different HLA alleles to extend patient access. As of December&#160;31, 2020, GSK has not currently exercised its right to nominate additional HLA alleles. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event that GSK exercises an option, we have agreed to grant GSK an exclusive worldwide license for intellectual property rights specific to the soluble TCR bispecific therapeutic candidate compounds developed under the relevant collaboration programs and to our background intellectual property rights to the extent they are necessary for GSK to manufacture, use and commercialize the compounds developed under the GSK Agreement. Following the grant of any exclusive license, GSK will be fully responsible for all further development, manufacture and commercialization of the relevant soluble TCR bispecific therapeutic candidate compound, at its sole expense. The&#160;licenses, if granted, do not include any right for GSK to develop alternative affinity-enhanced TCRs using our intellectual property rights or to develop other TCR therapeutic candidates directed to different target peptides.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the GSK Agreement, we received an upfront payment upon execution and one additional payment in connection with GSK&#8217;s nomination of the second collaboration target. We are eligible to receive up to an additional &#163;17.6&#160;million in initial payments if GSK nominates the maximum number of additional HLA alleles. Under the GSK&#160;Agreement, we are additionally entitled to various milestone payments based on the achievement of specified development and commercialization milestones by either us or GSK. For each product which reaches the market, we are eligible to receive up to an aggregate of approximately &#163;200&#160;million in development and commercial milestone payments plus royalties. As of September&#160;30, 2020, we have received payments totaling &#163;22.9 million in upfront payments and early development milestones, with the potential to achieve an additional aggregate of &#163;14.0 million through option exercise of the two collaboration targets. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the development milestones, we are entitled to tiered royalties from GSK on all GSK sales of TCR therapeutic products licensed under the GSK Agreement, ranging from five to ten percent (dependent on the cumulative annual net sales for each calendar year), subject to certain agreed reductions. Royalties are payable while there is a valid patent claim of certain of our intellectual property covering the soluble TCR bispecific therapeutic product in the country in which the relevant TCR therapeutic product is being sold, which, if applicable patent applications are granted, is expected to be at least 2036 for GSK01, and, in each case, for a minimum of 10&#160;years from the first commercial sale of the relevant soluble TCR bispecific therapeutic product. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">164<br></div></div></div>
<!--End Page 169-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 170-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg42"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The GSK Agreement is effective until all payment obligations expire, including any ongoing royalty payments due in relation to GSK&#8217;s sale of any covered soluble TCR bispecific therapeutic products. The GSK Agreement can be terminated on a program-by-program basis by GSK for lack of feasibility or inability to meet certain agreed requirements. We and GSK can terminate the GSK Agreement or any specific license or collaboration program for uncured material breach of the other party upon 60 days&#8217; written notice, or immediately upon insolvency of the other party. GSK has additional termination rights to terminate either the GSK Agreement or any specific license or collaboration program for convenience on provision of 90 business days&#8217; written notice to us. Where we continue any development of any soluble TCR bispecific therapeutic compound resulting from a terminated collaboration program, depending on the stage of development, we have agreed to pay royalties to GSK at a mid-single-digit percentage rate of net sales. We also have rights to terminate any license where GSK ceases development of or withdraws any licensed compound in specified circumstances.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Lilly Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In July 2014, we entered into a development and license agreement, referred to, as subsequently amended, as the Lilly Collaboration, with Eli Lilly and Company, or Lilly, pursuant to which we and Lilly agreed to collaborate in the development, manufacture and commercialization of soluble TCR bispecific therapeutic compounds.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Lilly Collaboration, Lilly paid us an initial upfront fee payment of $45&#160;million in exchange for options to three targets. Lilly no longer has the ability to nominate any further targets under the initial agreement with Lilly. In December 2016, we and Lilly agreed to swap an existing antigen target, selected by Lilly, for a new, well-known neo-antigen target. Lilly has no further obligations with respect to the initial target that was replaced. In September 2017, we and Lilly agreed to swap a second antigen target, selected by Lilly, for a second neo-antigen target. Similarly, Lilly has no further obligations with respect to the initial target that was replaced. From the designation of each selected target until the expiration or termination of any exclusive license Lilly may obtain by exercising its option rights, we are prohibited from directly or indirectly conducting any development or commercialization activities relating to such target selected under the Lilly Collaboration or epitopes derived from such target or any compounds directed to such target, other than as provided under the Lilly Collaboration.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Lilly Collaboration, we are responsible for developing soluble TCR bispecific therapeutic pre-clinical candidates to each target with Lilly being responsible for GMP manufacture of Phase 1 material at its expense. On a collaboration target-by-collaboration target basis, at the point of clinical candidate nomination, Lilly has the option to pay a $10&#160;million option fee to gain exclusive co-development/co-promotion rights to the target program. Following exercise of its option, Lilly will provide to us a clinical development plan and budget plan for the advancement of the selected candidate through clinical Phase 1 development. Upon receipt of the proposed development plan and Phase 1 budget, we have a limited time period in which to elect to contribute either 25% or 50% costs to reach the next clinical phase or to opt-out of further development. Similar provisions are available at the start of Phase 2 clinical trials and registrational clinical trials. Should we elect to contribute towards registrational trials, then, within six months of the start of the first registrational trial, we would agree with Lilly on the terms of a co-promotion agreement that establishes how co-promotion activities would be divided and receive either a 25:75 or 50:50 profit split that aligns with the funding contributions established in development. Should we opt-out of co-development on a collaboration target-by-collaboration target basis, Lilly would obtain an exclusive worldwide license to develop and commercialize the compound at its sole expense. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are eligible to receive differing development milestones, commercial milestones and royalties dependent on whether we exercise our opt-out right at the time when a product is Phase 1-ready, Phase 2-ready or registrational trial-ready and if we have contributed either 0%, 25% or 50% of clinical expenses prior to the point of opt-out. The maximum aggregate amount of milestone payments we are eligible to receive for a product (in the case of such product treating a single indication) is $336&#160;million and the tiered royalties we are eligible to receive range from a mid-single-digit to a mid-teens percentage. Royalties are payable while there is a jointly owned or solely owned valid patent claim covering the licensed product in the country in which the relevant product is sold, which, if applicable patent application are granted, is expected to be at least 2041 for the first neoantigen program, and, in each case, for a minimum of 10&#160;years from first commercial sale of the relevant licensed product. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Lilly Collaboration is effective until all payment obligations expire, including any ongoing royalty payments due in relation to Lilly&#8217;s sale of any licensed product. The Lilly Collaboration can also be terminated </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">165<br></div></div></div>
<!--End Page 170-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 171-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg43"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">on a program-by-program basis by Lilly if a selected target or any product or selected candidate is not viable or will not otherwise obtain regulatory approval. Both parties have rights to terminate the Lilly Collaboration in whole or in part for uncured material breach upon 90 days&#8217; written notice or immediately upon insolvency of the other party. Lilly has additional rights to terminate either the Lilly Collaboration or any specific program for convenience on provision of 90 days&#8217; notice to us. We also have rights to terminate any license where Lilly ceases development on any compound or withdraws any licensed product in specified circumstances. Where we continue any development of any compound resulting from a terminated collaboration program where Lilly has exercised its option to obtain an exclusive license, we would agree with Lilly on a royalty that reflects the value to the program contributed by Lilly prior to the date of termination.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Gates Collaboration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September 2017, we entered into a $40&#160;million convertible loan agreement and a global access agreement with the Gates Foundation, pursuant to which we agreed to develop, manufacture and commercialize soluble TCR bispecific therapeutic candidates targeted to neglected diseases, primarily tuberculosis and HIV, with the potential to treat people at an affordable price in developing countries. In March 2020, we and the Gates Foundation amended and restated the global access agreement, or the Gates Agreement, pursuant to which we are required to take certain actions to support the mission of the Gates Foundation. The initial tranche of $25&#160;million was directed to the development of product candidates for the treatment of tuberculosis or HIV, and converted into equity as part of our series B preferred share financing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the terms of the Gates Agreement, the Gates Foundation has the ability to request additional product development work for the development of product candidates for the treatment of malaria and human papillomavirus, with the terms of any such work to be negotiated in good faith between us and the Gates Foundation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are required to use diligent efforts to complete agreed upon research plans for tuberculosis and HIV. While we delivered a potential product candidate for the treatment of tuberculosis, under a program within the Gates Agreement, leveraging our universal HLA-E capabilities, the governing committee selected instead a potential HIV product candidate for GMP manufacture and for evaluation in a Phase 1 single ascending dose evaluation clinical trial. We can elect to draw down a second tranche of $15&#160;million in funding if we and the Gates Foundation wish to continue further development following completion of the Phase 1 clinical trial and observation of an accepted safety profile. Following receipt of such additional funding, if requested by the Gates Foundation, we will be required to continue further development of the HIV program through commercialization of a final product with the terms of any such work to be negotiated in good faith between us and the Gates Foundation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of certain defaults by us under the Gates Agreement, the Gates Foundation has a right to sell (or require a buy-back by us of) any of the equity securities held by the Gates Foundation. In such an event, if within 12 months after such redemption or sale, we experience a change in control or an initial public offering at a valuation of more than 150% of the valuation used for the redemption or the sale of the shares, we have agreed to pay the Gates Foundation compensation equal to the excess of what it would have received in such transaction if it still held its shares at the time of such initial public offering or a change of control over what it received in the sale or redemption of its shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the terms of the Gates Agreement, we have full control over the development, commercialization and pricing of the Gates Foundation funded programs in developed countries. Within a defined list of developing countries, we have an obligation to abide by the Gates Foundation global access principles, which includes pricing restrictions and a requirement that we use diligent efforts to make funded products available in such countries. We also grant the Gates Foundation certain non-exclusive, perpetual, royalty-free licenses under our intellectual property and products developed using funds from the Gates Foundation for the benefit of people in identified developing countries. These licenses would only be exercised in certain defined default events, including where we are unwilling or unable to continue with the development of a program or where we are in breach of certain obligations under the Gates Agreement (including the global access commitments). Under the terms of the Gates Agreement, the Gates Foundation can request that we work on further neglected diseases (excluding hepatitis, oncology or autoimmune diseases) provided acceptable terms can be reached. We also have an obligation to make available certain research tools on a royalty-free basis to certain entities supported by the Gates Foundation and other third parties and certain obligations relating to publishing of scientific results of our work. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">166<br></div></div></div>
<!--End Page 171-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 172-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg44"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Assignment and Exclusive License Agreement with Adaptimmune Limited</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In May 2013, we entered into an assignment and exclusive license agreement with Adaptimmune Limited, or Adaptimmune, which relates to the joint ownership and licensing of certain patents, patent applications, rights in know-how and other intellectual property rights, or the Adaptimmune License. Pursuant to the Adaptimmune License, we and Adaptimmune jointly own certain identified patents, patent applications, rights in know-how and other intellectual property rights in equal shares. We each grant the other party an exclusive, royalty-free, irrevocable license, with the right to sub-license, under those jointly owned intellectual property rights in separate fields. Adaptimmune&#8217;s exclusive field relates to treatment of patients with engineered TCR therapeutic candidates and our exclusive field relates to the treatment of patients with soluble TCRs. There is no royalty payable under the Adaptimmune License but we share equally in the costs associated with the filing, maintenance and prosecution of the jointly owned patents and patent applications covered by the Adaptimmune License. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Adaptimmune License is effective until the later of the expiration of the last to expire jointly owned patent under the Adaptimmune License or the jointly owned know-how ceasing to be confidential. The Adaptimmune License cannot be terminated by either party. Upon the insolvency of either party, the other party has the right to take over patent prosecution of the licensed patents and to request assignment of the insolvent party&#8217;s interest in all the licensed patents, know-how and results on commercially reasonable terms.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">Government Regulation </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Government authorities in the United States, at the federal, state and local level, and in the European Union and other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Data Privacy and Security Laws</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We also are or may become subject to privacy laws in the jurisdictions in which we are established, have partners, or sell or market our products or run clinical trials. For example, we are or may become subject to privacy and data protection laws, such as the EU&#8217;s General Data Protection Regulation, or GDPR, and the Health Insurance Portability and Accountability Act, HIPAA in the United States, among many others. Our regulatory obligations in foreign jurisdictions could harm the use or cost of our solution in international locations as data protection and privacy laws and regulations around the world continue to evolve.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain aspects of our business, including those for which we rely upon collaborators, service providers, contractors or others, are or may become subject to HIPAA and its implementing regulations, which establish standards for covered entities (healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information, including, among other requirements, mandatory contractual terms and technical safeguards designed to protect the privacy, security and transmission of protected health information and notification to affected individuals and regulatory authorities in the event of certain breaches of security of protected health information. The American Recovery and Reinvestment Act of 2009, commonly referred to as the economic stimulus package, included sweeping expansion of HIPAA&#8217;s privacy and security standards called the Health Information Technology for Economic and Clinical Health Act, or HITECH, which became effective on February&#160;17, 2010. Among other things, the HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, or independent contractors or agents of covered entities, that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce and be construed as a violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">167<br></div></div></div>
<!--End Page 172-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 173-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg45"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In Europe we are subject to the GDPR (Regulation (EU) 2016/679), in relation to our processing and other use of personal data (i.e. data relating to an identifiable living individual). We may in the future process personal data in relation to participants in our clinical trials in the European Economic Area, including the health and medical information of these participants. The GDPR imposes accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects how their personal information will be used; imposes limitations on retention of personal data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">EU Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase. In addition, the GDPR includes restrictions on cross-border data transfers. Certain aspects of cross-border data transfers under the GDPR are uncertain as the result of legal proceedings in the EU, including a recent decision by the Court of Justice for the European Union that invalidated the EU-U.S. Privacy Shield and, to some extent, called into question the efficacy and legality of using standard contractual clauses. This may increase the complexity of transferring personal data across borders out of the European Union.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20&#160;million or 4% of total global annual turnover. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders change our use of data, enforcement notices, or potential civil claims including class action type litigation. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, Brexit, and ongoing developments in the United Kingdom have created uncertainty with regard to data protection regulation in the United Kingdom. Following the United Kingdom&#8217;s withdrawal from the EU on January 31, 2020, pursuant to the transitional arrangements agreed to between the United Kingdom and EU, the GDPR continued to have effect under law in the United Kingdom, and continued to do so until December&#160;31, 2020 as if the United Kingdom remained a member state of the EU for such purposes. Following December&#160;31, 2020, and the expiry of those transitional arrangements, the data protection obligations of the GDPR continue to apply to United Kingdom-related processing of personal data in substantially unvaried form and fashion under the so-called &#8216;&#8216;UK GDPR&#8217;&#8217; (<font style="font-style: italic;">i.e.</font>, the GDPR as it continues to form part of United Kingdom law by virtue of section&#160;3&#160;of the European Union (Withdrawal) Act 2018, as amended (including by the various Data Protection, Privacy and Electronic Communications (Amendments etc) (EU Exit) Regulations)). However, going forward, there will be increasing scope for divergence in application, interpretation and enforcement of data protection laws as between the United Kingdom and EEA. In addition, the relationship between the United Kingdom and the EEA in relation to certain aspects of data protection law remains unclear. For example, it is still unclear whether the transfer of data from the EEA to the United Kingdom will in the future remain lawful under the GDPR. For the meantime, under the Trade and Cooperation Agreement, it has been agreed that, transfers of personal data to the United Kingdom from EU Member States will not be treated as &#8220;restricted transfers&#8221; to a non-EEA country for a period of up to six months from January 1, 2021, or the extended adequacy assessment period. This will also apply to transfers to the United Kingdom from EEA member states, assuming those member states accede to the relevant provision of the Trade and Cooperation Agreement. Although the current maximum duration of the extended adequacy assessment period is six months, it may end sooner, for example, in the event that the European Commission adopts an adequacy decision in respect of the United Kingdom, or the United Kingdom amends the UK GDPR and/or makes certain changes regarding data transfers under the UK GDPR/ DPA 2018 without the consent of the EU (unless those amendments or decisions are made simply to keep relevant laws in the United Kingdom aligned with the EU&#8217;s data protection regime). Unless the European Commission makes an &#8216;&#8216;adequacy finding&#8217;&#8217; in respect of the United Kingdom prior to the expiry of the extended adequacy assessment period, from that point onwards the United Kingdom will be an inadequate &#8220;third country&#8221; under the GDPR and transfers of data from the EEA to the United Kingdom will require a &#8220;transfer mechanism,&#8221; such as the European Commission&#8217;s Standard Contractual Clauses issued and approved from time to time. Additionally, as noted above, the United Kingdom has transposed the GDPR into domestic law by way of the UK GDPR with effect from January 2021, which could expose us to two parallel regimes, each of which </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">168<br></div></div></div>
<!--End Page 173-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 174-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg46"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. In addition to such parallel United Kingdom and EU regimes, following the expiry of the post-Brexit transitional arrangements agreed between the United Kingdom and EU, the United Kingdom Information Commissioner&#8217;s Office is not able to be our &#8216;lead supervisory authority&#8217; in respect of any &#8216;&#8216;cross border processing&#8217;&#8217; for the purposes of the GDPR. Because we did not designate a lead supervisory authority in an EEA member state with effect from January 1, 2021, we are not able to benefit from the GDPR&#8217;s &#8216;&#8216;one stop shop&#8217;&#8217; mechanism. Among other things, this means that, in the event of a violation of the GDPR affecting data subjects across the United Kingdom and the EEA, we could be investigated and ultimately fined by, the United Kingdom Information Commissioner&#8217;s Office and the supervisory authority in each and every EEA member state where data subjects have been affected by such violation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, state laws may be more stringent, broader in scope or offer greater individual rights with respect to health information than HIPAA, and state laws may differ from each other, which may complicate compliance efforts. By way of example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California residents and places increased privacy and security obligations on entities handling certain personal data of such residents. The CCPA requires covered companies to provide new disclosures to California residents about such companies&#8217; data collection, use and sharing practices and provide such residents new ways to opt out of certain disclosures of personal information and provides such residents with additional causes of action. The CCPA became effective on January&#160;1, 2020, and (a) allows enforcement by the California Attorney General, with fines set at $2,500 per non-intentional violation or $7,500 per intentional violation and (b) authorizes private lawsuits to recover statutory damages for certain data breaches. Additionally, a new privacy law, the California Privacy Rights Act, or CPRA, was recently approved by California voters in November 2020. The CPRA significantly modifies the CCPA, resulting in further uncertainty and requiring us to incur additional costs and expenses to comply.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Patent Term Restoration and Extension</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Depending upon the timing, duration and specifics of FDA approval of product candidates, some of a sponsor&#8217;s U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14&#160;years from the product&#8217;s approval date. The patent term restoration period generally is one-half the time between the effective date of an IND and the submission date of a BLA less any time the sponsor did not act with due diligence during the period, plus the time between the submission date of a BLA and the approval of that application less any time the sponsor did not act with due diligence during the period. Only one patent applicable to an approved biologic product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent. Moreover, a given patent may only be extended once based on a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Licensure and Regulation of Biologics in the United States</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the United States, biological products are subject to regulation under the Federal Food, Drug and Cosmetic Act, or FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Product candidates must be approved by the FDA before they may be legally marketed in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An applicant seeking approval to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">nonclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#8217;s good laboratory practices, or GLP, regulations;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">169<br></div></div></div>
<!--End Page 174-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 175-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg47"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the FDA of an IND application for human clinical testing, which must become effective before human clinical trials may begin;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval by an institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with Good Clinical Practices, or GCP;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preparation and submission to the FDA of a BLA for a biological product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labeling;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review of the product by an FDA advisory committee, if applicable;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FDA audits of the clinical study sites to assure compliance with GCPs, and the integrity of clinical data in support of the BLA;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">payment of user fees and securing FDA approval of the BLA and licensure of the new biological product; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post-approval studies required by the FDA.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Nonclinical Studies and Investigational New Drug Application</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before testing any biological product candidate in humans, the product candidate must undergo nonclinical testing. Nonclinical tests include laboratory evaluations of product formulation and stability, as well as animal studies to evaluate the potential for activity and toxicity. The results of the nonclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trial can begin.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a result, submission of the IND may result in the FDA not allowing the trial to commence or on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND process, it may choose to impose a partial or complete clinical hold. This order issued by the FDA would delay either a proposed clinical study or cause suspension of an ongoing study, or in the case of a partial clinical hold place limitations on the conduct of the study such as duration of treatment, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigation may proceed and then only under terms authorized by the FDA. This could cause significant delays or difficulties in completing planned clinical trials in a timely manner. The FDA may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Human Clinical Trials in Support of a BLA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under study protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">170<br></div></div></div>
<!--End Page 175-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 176-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg48"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the sponsor may submit data from the clinical trial to the FDA in support of the BLA so long as the clinical trial is well-designed and well-conducted in accordance with GCP, including review and approval by an independent ethics committee, and the FDA is able to validate the study data through an onsite inspection, if necessary.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, each clinical trial must be reviewed and approved by an institutional review board, or IRB, either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors and the safety of human subjects. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group may recommend continuation of the study as planned, changes in study conduct, or cessation of the study at designated check points based on access to certain data from the study. Information about certain clinical studies must be submitted within specific timeframes to the National Institutes of Health for public dissemination.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger Phase 3 clinical trials.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Phase 3 clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to gather additional information about safety and effectiveness necessary to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. Failure to exhibit due diligence with regard to conducting required Phase 4 clinical trials could result in withdrawal of approval for products.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Compliance with cGMP Requirements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">171<br></div></div></div>
<!--End Page 176-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 177-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg49"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Manufacturers may have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting or refusing inspection by the FDA may lead to a product being deemed to be adulterated.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 20pt; text-align: left;">Review and Approval of a BLA</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The results of product candidate development, nonclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of a BLA requesting a license to market the product. The BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA has 60 days after submission of the application to conduct an initial review to determine whether the BLA is sufficient to accept for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or the PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of an application. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs. The review process may often be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure and potent. If the application is not approved, the FDA may issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a complete response letter may submit to the FDA information that represents a complete response to the issues identified by the FDA or withdraw the application or request a hearing. The FDA will not approve an application until issues identified in the complete response letter have been addressed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may also refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the FDA approves a new product, it may limit the approved indications for use of the product. It may also require that contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">172<br></div></div></div>
<!--End Page 177-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 178-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg50"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Fast Track, Breakthrough Therapy and Priority Review Designations</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation and priority review designation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may designate a product for fast track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 20pt; text-align: left;">Accelerated Approval Pathway</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">173<br></div></div></div>
<!--End Page 178-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 179-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg51"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 20pt; text-align: left;">Post-Approval Regulation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all post-approval regulatory requirements as well as any post-approval requirements that the FDA has imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A biological product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. FDA also has authority to require post-market studies, in certain circumstances, on reduced effectiveness of a product and may require labeling changes related to new reduced effectiveness information. Other potential consequences for a failure to maintain regulatory compliance include, among other things:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, untitled letters or warning letters or holds on post-approval clinical trials;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Pharmaceutical products may be promoted only for the approved indications and in accordance with the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">174<br></div></div></div>
<!--End Page 179-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 180-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg52"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;">Orphan Drug Designation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Orphan Drug Designation in the United States is designed to encourage sponsors to develop products intended for rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Orphan Drug Designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives Orphan Drug Designation from the Office of Orphan Products Development, or OOPD, at the FDA based on an acceptable confidential request made under the regulatory provisions. The product must then go through the review and approval process like any other product in order to be marketed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A sponsor may request Orphan Drug Designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain Orphan Drug Designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive Orphan Drug Designation for the same product for the same rare disease or condition, but each sponsor seeking Orphan Drug Designation must file a complete request for designation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor or the sponsor is unable to provide sufficient quantities. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;">Pediatric Studies and Exclusivity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Pediatric Research Equity Act of 2003, as amended, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Generally, the pediatric data requirements do not apply to products with orphan designation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">175<br></div></div></div>
<!--End Page 180-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 181-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg53"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 20pt; text-align: left;">Biosimilars and Exclusivity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Biologics Price Competition and Innovation Act, or BPCIA, established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. To date, while biosimilar products have been approved by the FDA for use in the United States, no interchangeable biosimilars have been approved.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; For the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12&#160;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own nonclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. However, to rely on such exclusivities for establishing or protecting a manufacturer&#8217;s market position is not without risk, as such laws are subject to changes by the legislature. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Regulation and Procedures Governing Approval of Medicinal Products in the European Union</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In order to market any product outside of the United States, a company also must comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal product for each proposed indication. It also requires the submission to relevant competent authorities for clinical trials authorization and to the EMA or to competent authorities in European Union Member States for a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 20pt; text-align: left;">Clinical Trial Approval</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the Directive 2005/28/EC on GCP, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted or in multiple member states if the clinical trial is to be conducted in a number of member states. Furthermore, the applicant may only start a clinical trial at a specific study site after the independent ethics committee has issued a favorable opinion. The CTA, must be accompanied by an investigational medicinal product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member states and further detailed in applicable guidance documents.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">176<br></div></div></div>
<!--End Page 181-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 182-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg54"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It is expected that the new Clinical Trials Regulation will enter into force in 2020 with a three-year transition period. It will overhaul the current system of approvals for clinical trials in the European Union. Specifically, the new regulation, which will be directly applicable in all member states, aims at simplifying and streamlining the approval of clinical trials in the European Union. For instance, the new Clinical Trials Regulation provides for a streamlined application procedure via a single-entry point and strictly defined deadlines for the assessment of clinical trial applications.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;">Orphan Drug Designation and Exclusivity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulation (EC) No. 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug has to be of significant benefit compared to products available for the condition.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An Orphan Drug Designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for Orphan Drug Designation because, for example, the product is sufficiently profitable not to justify market exclusivity.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 20pt; text-align: left;">Marketing Authorization</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit an MAA, either to EMA using the centralized procedure or to competent authorities in European Union Member States using the other procedures (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No. 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer and auto-immune diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which the centralized procedure is in the interest of public health, the centralized procedure may be optional.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting the assessment of a product to define its risk/benefit profile. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">177<br></div></div></div>
<!--End Page 182-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 183-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg55"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Periods of Authorization and Renewals</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Regulatory Requirements after Marketing Authorization</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Regulation in the United Kingdom</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Brexit may influence the attractiveness of the United Kingdom as a place to conduct clinical trials. The European Union&#8217;s regulatory environment for clinical trials is being harmonized as part of the Clinical Trial Regulations, which are due to enter into full effect at the end of 2021, but it is currently unclear as to what extent the United Kingdom will seek to align its regulations with the European Union. Failure of the United Kingdom to closely align its regulations with the EU may have an effect on the cost of conducting clinical trials in the United Kingdom as opposed to other countries and/or make it harder to seek a marketing authorization for our product candidates on the basis of clinical trials conducted in the United Kingdom.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the short term there will be few changes to clinical trials that only have sites in the United Kingdom. The MHRA have confirmed that the sponsor of a clinical trial can be based in the EEA for an initial period following Brexit. Further investigational medicinal products can be supplied directly from the EU/EEA to a trial site in Great Britain without further oversight until 1 January 2022, and to Northern Ireland beyond such date. The United Kingdom is now a &#8220;third country&#8221; for the purpose of clinical trials that have sites in the EEA. For such trials the sponsor/legal representative must be based in the EEA, and the trial must be registered on the EU Clinical Trials Register (including data on sites outside of the EEA).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Healthcare Laws and Regulations </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources, including healthcare providers, are subject to broadly applicable fraud and abuse, and these laws and regulations may constrain the business or financial arrangements and relationships through which manufacturers conduct research, market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an individual for, or the purchase, </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">178<br></div></div></div>
<!--End Page 183-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 184-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg56"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">order or recommendation of, any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other individuals and entities on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to commit a violation; </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal civil and criminal false claims, including the civil False Claims Act, or the FCA, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent, or knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease, or conceal an obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA imposes criminal and civil liability, among other things, for executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. Effective January&#160;1, 2022, applicable manufacturers will also be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the transmission, security and privacy of individually identifiable health information on covered entities, such as health plans, health care clearinghouses and certain healthcare providers, and their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, and their subcontractors that use, disclose, access, or otherwise process individually identifiable protected health information; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, drug pricing and/or marketing expenditures; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Violation of the laws described above or any other governmental laws and regulations may result in significant penalties, including administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">179<br></div></div></div>
<!--End Page 184-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 185-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg57"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, and additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Coverage and Reimbursement </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of FDA-approved drugs for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. New metrics frequently are used as the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. In order to obtain coverage and reimbursement for any product that might be approved for sale, it may be necessary to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the products, in addition to the costs required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. Additionally, any companion diagnostic test that we develop will be required to obtain coverage and reimbursement separate and apart from the coverage and reimbursement we seek for our product candidates, if approved. If any companion diagnostic is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions for our product candidates, if approved.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">180<br></div></div></div>
<!--End Page 185-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 186-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg58"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Health Reform </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">By way of example, in March 2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our business are: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for most branded and generic drugs, respectively; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There remain executive, judicial and Congressional challenges to certain aspects of the ACA. Since January&#160;2017, the current president has signed several executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, effective January&#160;1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. In addition, the 2020 federal spending package permanently eliminated, effective January&#160;1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">181<br></div></div></div>
<!--End Page 186-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 187-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg59"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. Further, on December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the United States Supreme Court granted the petitions for writs of certiorari, and the case is currently under review by the United States Supreme Court. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to reach its target goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and other COVID-19 pandemic relief legislation suspended the 2%&#160;Medicare sequester from May&#160;1, 2020 through March&#160;31, 2021. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the current presidential administration&#8217;s budget proposal for fiscal year 2021 includes a $135&#160;billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March&#160;10, 2020, the current president sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the current presidential administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. More recently, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders that are intended to lower the costs of prescription drug products and seek to implement several of the administration's proposals. As a result, the FDA also released a final rule on September 24, 2020 providing guidance for states to build and submit importation plans for drugs from Canada. The FDA also released a final rule, effective November&#160;30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November&#160;20, 2020, CMS issued an interim final rule implementing President Trump's Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. However, on December&#160;28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. The likelihood of implementation of any of the other Trump administration reform initiatives is uncertain, particularly in light of the recent U.S. presidential election. At the state level, individual states in the United States have increasingly passed legislation and implemented regulations designed to control </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">182<br></div></div></div>
<!--End Page 187-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 188-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg60"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on August&#160;6, 2020, the Trump administration issued another executive order that instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. Further, any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Further, additional healthcare reform initiatives may arise from future legislation or administrative action, particularly as a result of the recent U.S. presidential election.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Additional Regulation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to the foregoing, provincial, state and federal U.S. and European Union laws regarding environmental protection and hazardous substances affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Anti-Corruption Laws</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, the UK Bribery Act 2010 and the UK Proceeds of Crime Act 2002 and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities, collectively, Anti-Corruption Laws. Among other matters, such Anti-Corruption Laws prohibit corporations and individuals from directly or indirectly paying, offering to pay or authorizing the payment of money or anything of value to any foreign government official, government staff member, political party or political candidate, or certain other persons, in order to obtain, retain or direct business, regulatory approvals or some other advantage in an improper manner. We can also be held liable for the acts of our third party agents under the FCPA, the UK Bribery Act 2010 and possibly other Anti-Corruption Laws. In the healthcare sector, anti-corruption risk can also arise in the context of improper interactions with doctors, key opinion leaders and other healthcare professionals who work for state-affiliated hospitals, research institutions or other organizations.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Government Regulation Outside of the United States and the European Union</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to regulations in the United States and European Union, we may be subject to a variety of regulations in other jurisdictions governing, among other things, clinical studies and any commercial sales and distribution of their products. Whether or not we obtain FDA or EU approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical studies or marketing of the product in those countries. Certain countries outside of the United States and the European Union have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. The requirements and process governing the conduct of clinical studies, product licensing, coverage, pricing and reimbursement vary from country to country. In all cases, the clinical studies are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">183<br></div></div></div>
<!--End Page 188-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 189-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg61"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Employees and Human Capital Resources</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2020, we had 291&#160;employees, 129 (44%) of whom hold Ph.D. or M.D. degrees. Of these employees, 236 are engaged in research and development activities and 55 are engaged in business development, finance, information systems, facilities, human resources or administrative support. None of our employees are subject to collective bargaining agreements. We consider our relationship with our employees to be good.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At each date shown, we had the following number of employees engaged in either administrative or research and development functions, as indicated below.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 18.8%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At December&#160;31,</div></td></tr><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.14%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Function:<br></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Administrative<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">67</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">67</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">55</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">394</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">392</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">236</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">461</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">459</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">291</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Geography:<br></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">United Kingdom<font style="padding-left: 4.18pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">422</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">409</div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">242</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">European Union<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt;">2</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt;">3</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt;">2</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">United States<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">37</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">47</font></div></td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">47</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of equity-based compensation awards.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; text-align: center;">Facilities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We currently lease a facility containing our research and development, laboratory and office space, which consists of approximately 102,000 square feet located in Oxfordshire, United Kingdom. Our lease expires in 2037. In addition, we lease approximately 5,000 and 4,000 square feet of office space in Rockville, Maryland and Conshocken, Pennsylvania, respectively. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations. </div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; text-align: center;">Legal Proceedings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We consider it in the ordinary course of our business that our patents and trademarks may become subject to interference or opposition proceedings. There are currently four patent opposition proceedings ongoing regarding patents relating to our ImmTAX platform technology challenging the validity of those European patents; however, we do not believe the ultimate resolution of any such existing matters would have a material adverse effect on our business or financial condition and will also have no material adverse effect on our development of our product candidates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In September 2020, an opposition was filed by Immatics Biotechnologies GmbH which challenges our ImmTAX U.S. trademark registration. We do not believe this trademark is material to our business as a whole.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There can be no assurance that pending patent applications will result in the issuance of patents, that patents issued to or licensed by us will not be challenged or circumvented by competitors, or that these patents will be found to be valid or sufficiently broad to protect our technology or to provide us with a competitive advantage. However, we believe that no single patent, technology, trademark, intellectual property asset or license is material in relation to our business as a whole. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the summer and fall of 2020, we conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors between 2018 and 2020. Our audit committee led the investigation utilizing outside counsel, during which the named employee resigned. The investigation led to the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">184<br></div></div></div>
<!--End Page 189-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 190-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_110-bus_pg62"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">identification of a material weakness in our internal control over financial reporting. See &#8220;Risk Factors&#8212;We have identified a material weakness in our internal control over financial reporting and may identify material weaknesses in the future or otherwise fail to maintain proper and effective internal controls, which may impair our ability to produce timely and accurate financial statements or prevent fraud. If we are unable to establish and maintain effective internal controls, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ADSs.&#8221; After the investigation, we terminated the one remaining open contract with the third party vendors and issued proceedings in October 2020 against the involved parties. The amount in question was estimated to be in the range of &#163;1.1 million to &#163;1.8 million, and we recovered &#163;1.8 million from the employee and third-party vendors in December 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">From time to time, we may become involved in other legal proceedings arising in the ordinary course of our business. We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on our results of operations, financial condition or cash flows. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">185<br></div></div></div>
<!--End Page 190-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 191-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMGT"><!--Anchor--></a>MANAGEMENT</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth information regarding our executive officers and directors, including their ages as of December&#160;31, 2020.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 38.46%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Age</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 51.28%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Position(s)</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bahija Jallal, Ph.D. <font style="padding-left: 0.03pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">59</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Director</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Brian Di Donato<font style="padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">54</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer and Head of Strategy</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">David Berman, M.D., Ph.D. <font style="padding-left: 4.21pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">50</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Head of Research and Development </div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Executive Directors:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professor Sir John Bell<font style="padding-left: 2.54pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">68</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board of Directors </div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Travis Coy<font style="padding-left: 2.31pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">40</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Robert Perez<font style="padding-left: 4.75pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">56</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kristine Peterson<font style="padding-left: 2.53pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">61</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professor Sir Peter Ratcliffe<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.69%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">66</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Executive Officers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Bahija Jallal, Ph.D.<font style="font-style: normal;"> has served as our Chief Executive Officer since </font><font style="font-style: normal;">January 2019. Previously, she served as </font><font style="font-style: normal;">President of MedImmune, </font><font style="font-style: normal;">LLC, </font><font style="font-style: normal;">at AstraZeneca plc&#8217;s global biologics research and development unit, and </font><font style="font-style: normal;">Executive Vice&#160;President of AstraZeneca </font><font style="font-style: normal;">plc </font><font style="font-style: normal;">and a member of its senior executive team, where she worked from </font><font style="font-style: normal;">2008 to 2019. Prior to joining MedImmune, Dr. Jallal was </font><font style="font-style: normal;">v</font><font style="font-style: normal;">ice </font><font style="font-style: normal;">p</font><font style="font-style: normal;">resident, drug assessment and development, at </font><font style="font-style: normal;">Chiron Corporation. Previously, she was part of the research team at Sugen, Inc. Dr. Jallal currently serves on the </font><font style="font-style: normal;">board</font><font style="font-style: normal;">s</font><font style="font-style: normal;"> of directors of Anthem, Inc. and Guardant Health, Inc. She is also a member of the Board of Trustees of </font><font style="font-style: normal;">the Johns Hopkins University and the board of directors of the University of Maryland Health Sciences Research </font><font style="font-style: normal;">Park Corporation. Dr.&#160;Jallal is also a Council Member of the Government-University-Industry Research </font><font style="font-style: normal;">Roundtable of the National Academies of Sciences, Engineering and Medicine, and the immediate past president </font><font style="font-style: normal;">of the Association of Women in Science. Dr. Jallal received her Ph</font><font style="font-style: normal;">.</font><font style="font-style: normal;">D</font><font style="font-style: normal;">.</font><font style="font-style: normal;"> in Physiology from Universit&#233; de Paris VI, </font><font style="font-style: normal;">France and conducted her post-doctorate work in molecular biology and oncology at the Max Planck Institute for </font><font style="font-style: normal;">Biochemistry in Germany. We believe that Dr. Jallal&#8217;s extensive experience in the biotechnology industry, leading </font><font style="font-style: normal;">drug research and development efforts, her educational background and her knowledge of </font><font style="font-style: normal;">our company</font><font style="font-style: normal;"> as our </font><font style="font-style: normal;">Chief Executive Officer, qualify her to serve on our board of directors. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Brian Di Donato<font style="font-style: normal;"> has served as our Chief Financial Officer since April 2020. He joined us from Achillion </font><font style="font-style: normal;">Pharmaceuticals, Inc., where he was Senior Vice President and Chief Financial Officer from August 2018 to </font><font style="font-style: normal;">May&#160;2020. Prior to joining Achillion, Mr.&#160;Di Donato was a private investor and </font><font style="font-style: normal;">a </font><font style="font-style: normal;">full-time student at </font><font style="font-style: normal;">Pennsylvania State University from May 2015 to May 2018. Previously, Mr.&#160;Di Donato held positions as </font><font style="font-style: normal;">Managing Director and Co-Portfolio Manager at Sorin Capital Management, where he worked from 2008 to </font><font style="font-style: normal;">2014, and President and Chief Investment Officer at Capmark Investments, where he worked from 2002 to 2008. </font><font style="font-style: normal;">He also previously served as an Executive Director at Morgan Stanley and Vice President at UBS Securities</font><font style="font-style: normal;"> </font><font style="font-style: normal;">LLC</font><font style="font-style: normal;">. Mr.&#160;Di Donato holds an M.B.A. from New York University&#8217;s Stern School of Business and B.S. degrees in </font><font style="font-style: normal;">biology from Penn State University and in mechanical engineering from Villanova University. Prior to business </font><font style="font-style: normal;">school, he was an aerospace engineering officer in the U.S. Navy. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">David Berman, M.D., Ph.D.<font style="font-style: normal;"> has served as our Head of Research and Development since January 2019</font><font style="font-style: normal;">, after </font><font style="font-style: normal;">initially joining us </font><font style="font-style: normal;">in September 2018. Previously, Dr. Berman served as Senior Vice President and Head of </font><font style="font-style: normal;">AstraZeneca plc&#8217;s Immuno-oncology Franchise from 2017 to 2018. Prior to that, from 2015 to 2017, he was </font><font style="font-style: normal;">h</font><font style="font-style: normal;">ead </font><font style="font-style: normal;">of the early stage oncology program at MedImmune</font><font style="font-style: normal;">, LLC (now known as AstraZeneca plc)</font><font style="font-style: normal;">. Dr. Berman has also </font><font style="font-style: normal;">held senior development roles at Bristol-Myers Squibb Company, where he worked from 2005 to 2015, including </font><font style="font-style: normal;">as Head of the Immuno-oncology exploratory development team. Dr. Berman received a B.S. from the </font><font style="font-style: normal;">Massachusetts Institute of Technology and </font><font style="font-style: normal;">a </font><font style="font-style: normal;">M.D. and Ph.D. from the University of Texas Southwestern Medical </font><font style="font-style: normal;">School. He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins </font><font style="font-style: normal;">Hospital.</font><font style="font-style: normal;"> </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">186<br></div></div></div>
<!--End Page 191-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 192-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Non-Executive Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Professor Sir John Bell <font style="font-style: normal;">has served on our board of directors since March 2015. Professor </font><font style="font-style: normal;">Sir John </font><font style="font-style: normal;">Bell has </font><font style="font-style: normal;">been the Regius Professor of Medicine at Oxford University since 2002. He is a distinguished scientist in the </font><font style="font-style: normal;">fields of genomic and genetic research and immunology, and has been a founding director at three biotechnology </font><font style="font-style: normal;">companies: Avidex Ltd (acquired by MediGene AG in 2006), Oxagen Ltd. and PowderJect Pharmaceuticals plc </font><font style="font-style: normal;">(acquired by Chiron Corporation in 2003). He also previously served on the boards of Roche Holding AG, </font><font style="font-style: normal;">Sensyne Health plc, and Genentech, Inc., and the scientific advisory board at AstraZeneca plc. Professor </font><font style="font-style: normal;">Sir John </font><font style="font-style: normal;">Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now </font><font style="font-style: normal;">chairs the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is the Life </font><font style="font-style: normal;">Science Champion for the </font><font style="font-style: normal;">United Kingdom</font><font style="font-style: normal;">, advising the government on the life sciences industry. We believe </font><font style="font-style: normal;">his extensive scientific background and experience in the healthcare industry qualify him to serve on our board </font><font style="font-style: normal;">of directors</font>.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Travis Coy <font style="font-style: normal;">has served on our board of directors since September 2019. Mr.&#160;Coy is currently Vice President, </font><font style="font-style: normal;">Head of Transactions and M&amp;A, Corporate Business Development at Eli Lilly and Company, a position he has </font><font style="font-style: normal;">held since October 2019. Prior to this role, Mr.&#160;Coy had a variety of finance and business development </font><font style="font-style: normal;">experiences at Lilly, where he has worked since 2003, including positions as Vice President, Transactions - </font><font style="font-style: normal;">Oncology and Diagnostics; Vice President, Transactions - Cardiometabolic Diseases, Drug Delivery and Devices; </font><font style="font-style: normal;">Finance Director of the Oncology Business Unit; Director of Investor Relations; Director of Corporate Finance </font><font style="font-style: normal;">and Investment Banking; and other financial controllership roles. Before transitioning to finance and business </font><font style="font-style: normal;">development, he was a chemist in Lilly&#8217;s research laboratories and a production manager for Milliken &amp; </font><font style="font-style: normal;">Company. We believe that Mr.&#160;Coy&#8217;s experience in finance and business development qualify him to serve on </font><font style="font-style: normal;">our board of directors.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Robert Perez <font style="font-style: normal;">has served on our board of directors since September 2019. Mr.&#160;Perez is an Operating Partner </font><font style="font-style: normal;">and part of General Atlantic&#8217;s Operations Group, with a particular focus on the biopharma and life sciences </font><font style="font-style: normal;">sectors. Before joining General Atlantic in 2019, he </font><font style="font-style: normal;">served as</font><font style="font-style: normal;"> Managing Director of Vineyard Sound Advisors, </font><font style="font-style: normal;">LLC, an advisory practice focused on growth companies in the </font><font style="font-style: normal;">biopharmaceutical</font><font style="font-style: normal;"> industry, from March 2015 to </font><font style="font-style: normal;">January 2019. Prior to </font><font style="font-style: normal;">then, Mr. Perez was with</font><font style="font-style: normal;"> Cubist Pharmaceuticals, Inc., where he </font><font style="font-style: normal;">held various positions of </font><font style="font-style: normal;">increasing responsibility, including most recently as its President and Chief Executive Officer</font><font style="font-style: normal;"> from 2003 until its </font><font style="font-style: normal;">sale to Merck &amp; Co. in 2015. Before joining Cubist, he served as Vice President of Biogen, Inc.&#8217;s CNS Business </font><font style="font-style: normal;">Unit. Mr.&#160;Perez currently serves on the board of directors of Vir Biotechnology, Inc. and Akili Interactive Labs, </font><font style="font-style: normal;">Inc., and he previously served on the board of directors of AMAG Pharmaceuticals, Zafgen, Inc., Spark </font><font style="font-style: normal;">Therapeutics, Inc., Unum Therapeutics and Cidara Therapeutics. We believe Mr.&#160;Perez&#8217;s breadth of experience in </font><font style="font-style: normal;">investing and serving on boards of other companies in the biopharma and life sciences industries </font><font style="font-style: normal;">and his </font><font style="font-style: normal;">extensive management experience </font><font style="font-style: normal;">qualify him to serve on our board of directors. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Kristine Peterson <font style="font-style: normal;">has served on our board of directors since November 2017. Ms.&#160;Peterson most recently </font><font style="font-style: normal;">served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms.&#160;Peterson </font><font style="font-style: normal;">was Company Group Chair of the biotechnology group at Johnson &amp; Johnson from 2006 until 2009 and was </font><font style="font-style: normal;">Executive Vice President of Pharmaceutical Group Strategic Marketing from 2001 to 2006. Previously, she </font><font style="font-style: normal;">served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her </font><font style="font-style: normal;">career, Kristine spent 20&#160;years at Bristol-Myers Squibb Company in a variety of senior roles, including running </font><font style="font-style: normal;">their cardiovascular and metabolics business unit. Ms.&#160;Peterson currently serves on the board of directors of </font><font style="font-style: normal;">Amarin Corporation plc, Paratek Pharmaceuticals, Enanta Pharmaceutics</font><font style="font-style: normal;"> and ImmunoGen, Inc. She was also a </font><font style="font-style: normal;">senior advisor to the Healthcare Businesswomen&#8217;s Association and a former Member of the Biotechnology </font><font style="font-style: normal;">Industry Organization Board.</font> <font style="font-style: normal;">Ms.&#160;Peterson has a B.S. and an M.B.A. from the University of Illinois at </font><font style="font-style: normal;">Urbana-Champaign. We believe Ms.&#160;Peterson&#8217;s operational knowledge of, and executive-level experience in, the </font><font style="font-style: normal;">global pharmaceutical and biotech industry qualify her to serve on our board of directors. </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Professor Sir Peter Ratcliffe <font style="font-style: normal;">has served on our board of directors since November 2020. Professor </font><font style="font-style: normal;">Sir Peter </font><font style="font-style: normal;">Ratcliffe currently serves as the Director of Clinical Research at The Francis Crick Institute in London and </font><font style="font-style: normal;">Director for the Target Discovery Institute and Distinguished Scholar of the Ludwig Institute for Cancer Research </font><font style="font-style: normal;">within the Nuffield Department of Medicine at the University of Oxford. Previously, Professor </font><font style="font-style: normal;">Sir Peter </font><font style="font-style: normal;">Ratcliffe </font><font style="font-style: normal;">served as Nuffield Professor and Head of the Nuffield Department of Clinical Medicine from 2004 to 2016. In </font><font style="font-style: normal;">2019, Professor</font><font style="font-style: normal;"> Sir Peter</font><font style="font-style: normal;"> Ratcliffe was awarded the Nobel Prize for Physiology or Medicine alongside William G </font><font style="font-style: normal;">Kaelin, Jr</font><font style="font-style: normal;">.</font><font style="font-style: normal;"> of Harvard University and Gregg L</font><font style="font-style: normal;">.</font><font style="font-style: normal;"> Semenza of Johns Hopkins University. In 2002, Professor</font><font style="font-style: normal;"> Sir </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">187<br></div></div></div>
<!--End Page 192-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 193-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Peter Ratcliffe was elected to the Fellowship of the Royal Society and to the Academy of Medical Sciences. He is also a member of European Molecular Biology Organization, a foreign honorary member of the American Academy of Arts and Sciences and a Fellow of the American Association for Cancer Research Academy. We believe Professor Ratcliffe&#8217;s extensive scientific background qualifies him to serve on our board of directors.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Family Relationships</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are no family relationships among any of our executive officers or directors.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Foreign Private Issuer Exemption </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are a &#8220;foreign private issuer,&#8221; as defined by the SEC. As a result, in accordance with Nasdaq rules, we will comply with home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. While we expect to voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited exemptions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from filing quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form 8-K upon the occurrence of specified significant events; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from Section 16 rules requiring insiders to file public reports of their securities ownership and trading activities and providing for liability for insiders who profit from trades in a short period of time;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from quorum requirements for shareholder meetings. In accordance with usual practice in England and Wales, our articles of association will provide alternative quorum requirements that are generally applicable to shareholder meetings; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of the code of business conduct and ethics to directors and officers;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement that our audit committee have review and oversight responsibilities over all &#8220;related party transactions,&#8221; as defined in Item 7.B of Form 20-F;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirement that our board have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exemption from the requirements that director nominees are selected, or recommended for selection by our board, either by (1) independent directors constituting a majority of our board&#8217;s independent directors in a vote in which only independent directors participate, or (2) a committee comprised solely of independent directors, and that a formal written charter or board resolution, as applicable, addressing the nominations process is adopted.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Furthermore, Nasdaq Rule 5615(a)(3) provides that a foreign private issuer, such as we, may rely on home country corporate governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule&#160;5250(d), provided that we nevertheless comply with Nasdaq&#8217;s Notification of Noncompliance requirement (Rule&#160;5625), the Voting Rights requirement (Rule 5640) and that we have an audit committee that satisfies Rule&#160;5605(c)(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although we are permitted to follow certain corporate governance rules that conform to U.K. requirements in lieu of many of the Nasdaq corporate governance rules, we intend to comply with the Nasdaq corporate governance rules applicable to foreign private issuers. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Accordingly, our shareholders will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq. We may utilize these exemptions for as long as we continue to qualify as a foreign private issuer. See the section titled &#8220;Description of Share Capital and Articles of Association&#8221; for additional information.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">188<br></div></div></div>
<!--End Page 193-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 194-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Composition of our Board of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors will be composed of six members upon the closing of this offering. As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have independent directors on our board of directors, except that our audit committee is required to consist fully of independent directors, subject to certain phase-in schedules. Our board of directors has determined that Mr.&#160;Coy, Mr.&#160;Perez, Ms.&#160;Peterson, Professor Sir John Bell and Professor Sir Peter Ratcliffe, representing five of the six directors who will be serving upon the closing of this offering, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of director and that each of these directors is &#8220;independent&#8221; as that term is defined under Nasdaq rules. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with our articles of association to be in effect upon the completion of this offering, one-third of our directors will retire from office at each annual general meeting of shareholders. See &#8220;Description of Share Capital and Articles of Association&#8212;Board of Directors.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Committees of our Board of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors has three standing committees: an audit committee, a remuneration committee and a nominating and corporate governance committee, each of which will be reconstituted in connection with this offering.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Audit Committee </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of this offering, our audit committee will consist of Mr.&#160;Coy, Mr.&#160;Perez and Professor Sir Peter Ratcliffe, and will assist the board of directors in overseeing our accounting and financial reporting processes and the audits of our financial statements. Mr.&#160;Coy will serve as chairman of the audit committee. The audit committee consists exclusively of members of our board who are financially literate, and Mr.&#160;Coy is considered an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules and regulations. Our board has determined that all of the members of the audit committee satisfy the &#8220;independence&#8221; requirements set forth in Rule 10A-3 under the Exchange Act. The audit committee will be governed by a charter that complies with Nasdaq rules, effective upon the effectiveness of the registration statement of which this prospectus forms a part.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit committee&#8217;s responsibilities will include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">determining whether to appoint, reappoint or remove any auditors, and making recommendations to the board of directors to be put to the shareholders for approval at the annual general meeting; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing audit plans, the adequacy of staffing and fees, whilst overseeing the negotiation and execution of any engagement letters on behalf of the Company; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at least annually, assessing the qualifications, performance, and independence of the auditors, or in the case of prospective auditors, before they are engaged; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the policies and procedures governing how the Company may employ individuals who are or once were employed by the auditors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing results of the annual audit, audited financial statements, periodic and annual reports, earnings announcements, proxy report, accounting principles and policies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating management&#8217;s cooperation with the auditors during their audit examination;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and reporting on policies on financial risk management and assessment;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing the audit plan of any internal audit team;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing the scope, design, adequacy and effectiveness of internal controls;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing correspondence with regulators or governmental agencies that raise material issues regarding the Company&#8217;s financial statements or accounting policies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing procedures for receiving, retaining and investigating complaints; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">monitoring compliance with company&#8217;s Code of Business Conduct and Ethics and related party transactions rules; and</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">189<br></div></div></div>
<!--End Page 194-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 195-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing with management legal and regulatory compliance and any actual, pending, or threatened legal or financial matters that could significantly affect the Company&#8217;s business or financial statements or as otherwise deemed appropriate by the audit committee. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remuneration Committee </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of this offering, our remuneration committee will consist of Mr.&#160;Coy, Ms.&#160;Peterson and Professor Sir John Bell and will assist the board of directors in determining executive officer compensation. Ms. Peterson will serve as chairman of the remuneration committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The remuneration committee&#8217;s responsibilities will include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing, modifying and overseeing the company&#8217;s overall compensation strategy and policies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving the compensation and other terms of employment of the company&#8217;s Chief Executive Officer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving all elements of the compensation and other terms of employment of the executive officers and other senior management reporting directly to the Chief Executive Officer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and recommending to the board of directors for its approval the type and amount of compensation to be paid or awarded to members of the board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">undertaking sole responsibility for the appointment, authority to select, retain, and terminate any compensation and oversight of the work of compensation consultants, legal counsel, or any other advisors engaged for the purpose of advising the remuneration committee;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">exercising full power and authority to adopt, amend, terminate, and administer the Company&#8217;s equity award, pension, and profit sharing plans, incentive plans, bonus plans, executive benefit plans, stock purchase plans, deferred compensation plans and other similar programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and discussing with management the company&#8217;s Compensation Discussion and Analysis section of the company&#8217;s annual reports, registration statements, proxy statements, or information statements filed with the SEC;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and discussing with management any conflicts of interest raised; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the preparation of any report required by applicable U.S. and U.K. rules and regulations to be included in the company&#8217;s public filings relating to compensation policy and practices, including but not limited to the directors&#8217; remuneration report required under the Companies Act. </div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Nominating and Corporate Governance Committee </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Following the completion of this offering, our nominating and corporate governance committee will consist of Mr. Perez, Professor Sir John Bell and Professor Sir Peter Ratcliffe, and will assist our board of directors in identifying individuals qualified to become members of our board and executive officers consistent with criteria established by our board and in developing our corporate governance principles. Mr. Perez will serve as chairman of the nominating and corporate governance committee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The nominating and corporate governance committee&#8217;s responsibilities will include: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying and evaluating candidates, including nomination of incumbent directors for re-election and nominees recommended by shareholders to serve on the board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">making recommendations to the board of directors regarding nominees for directors at the next annual general meeting;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periodically reviewing the performance of the board of directors, including committees of the board of directors and management;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the board of directors' committee structure and operations, including authority to delegate to subcommittees and committee reporting to the board of directors;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing with the Chief Executive Officer the succession plans for the Company&#8217;s executive officers;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">190<br></div></div></div>
<!--End Page 195-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 196-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">instituting plans or programs for the continuing education of directors and orientation of new directors, as it deems appropriate; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">periodically reviewing the processes and procedures to provide information to the board of directors and its committees. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Code of Business Conduct and Ethics</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, we have adopted a Code of Business Conduct and Ethics, or Code of Ethics, applicable to our and our subsidiaries&#8217; employees, independent contractors, senior management and directors, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Following the effectiveness of the registration statement of which this prospectus is a part, a current copy of the Code of Ethics will be posted on our website, which is located at www.immunocore.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Compensation of Executive Officers and Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the year ended December&#160;31, 2020, the aggregate compensation paid to the members of our board of directors and our executive officers for services in all capacities, including retirement and similar benefits, was &#163;1.5 million. Of that aggregate amount, &#163;0.7 million was related to compensation paid to the members of our board of directors. In 2020, our highest paid director was Dr. Bahija Jallal, our Chief Executive Officer, who received compensation of &#163;0.6 million.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We maintain performance-based bonus arrangements with our executives pursuant to the terms of their services agreements (or otherwise pursuant to our discretionary annual bonus arrangements). We do not set aside or accrue any amounts to provide pension, retirement or similar benefits to members of our board of directors or executive officers, although we made defined contribution pension contributions on behalf of our directors or executive officers in an aggregate amount of &#163;26,769 during the year ended December&#160;31, 2020, which amount is included in the foregoing aggregate compensation figure. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards including Restricted G share Awards and Option Grants</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our shareholder agreements, we are authorized to issue G shares, as well as options and other securities exercisable for or convertible into ordinary shares, as incentives to our employees and members of our board of directors. To the extent such incentives are in the form of share options, the options are granted pursuant to the terms of our Legacy Arrangements (as defined below). As of December&#160;31, 2020, we were authorized under the shareholder agreements to issue a total of 1,189,951 ordinary shares, including shares underlying options granted pursuant to the Legacy Arrangements. Awards of restricted G1 or G2 shares, which we refer to herein as employee shares, are subject to vesting. Depending on the circumstances of termination, some or all vested and/or unvested employee shares are forfeited upon termination of employment. The forfeited shares are converted into deferred shares, and/or are subject to a repurchase right in favor of the company or the company&#8217;s designee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">During the year ended December&#160;31, 2020, we granted options to purchase an aggregate of 653,868 ordinary shares to executive officers and directors under the Legacy Arrangements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the share exchange, Immunocore Holdings Limited will grant options over its ordinary shares to replace the released options granted under the Legacy Arrangements. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Equity Awards Relating to the Completion of this Offering</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, we expect that our board of directors will grant awards under the 2021 EIP to certain of our officers, directors and employees, representing an aggregate of &#8195;&#8195;&#8195; ordinary shares, or the IPO Awards. These IPO Awards are one-time grants solely related to this offering and the number of ordinary shares subject to the IPO Awards has been estimated assuming an initial public offering price of $&#8195;&#8195;&#8195; per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Of these IPO Awards, an aggregate of &#8195;&#8195;&#8195; options will be granted to our executive officers, including &#8195;&#8195;&#8195; options to Dr. Bahija Jallal. The IPO Awards to be granted to our executives will vest over a four-year period, with 25% of </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">191<br></div></div></div>
<!--End Page 196-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 197-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the shares subject to the option vesting on the first anniversary of the vesting commencement date, with the remainder vesting in 12 equal installments on the quarterly dates thereafter, subject to each executive&#8217;s continuous service with us as of each vesting date. The actual number of shares subject to the IPO Awards may change.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As further described above in the section titled Corporate Reorganization, certain of our U.K. employees and former employees hold awards of G1 shares, which are proposed to be re-designated as deferred shares, or hold awards of G2 shares, which are proposed to be re-designated as a mixture of deferred shares and ordinary shares, prior to the completion of this offering. In connection with this offering, we expect that our board of directors will grant (i) an aggregate of &#8195;&#8195;&#8195; ordinary shares underlying the grants to be issued prior to the closing of this offering under our 2021 EIP (to our current employees) and under standalone option agreements (to our former employees) to replace the G1 shares that will be re-designated as deferred shares, conditional on and effective immediately prior to the closing of this offering, with an exercise price that is equal to or greater than the price per ADS at which our ADSs are first sold to the public in this offering; and (ii) an aggregate of &#8195;&#8195;&#8195; ordinary shares underlying the grants to be issued prior to the closing of this offering under our 2021 EIP to replace the G2 shares that will be re-designated as a mixture of deferred shares and ordinary shares conditional on and effective immediately prior to the closing of this offering, with an exercise price that is equal to the price per ADS at which our ADSs are first sold to the public in this offering</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All of the IPO Awards described above are expected to be granted prior to the closing of this offering and under the 2021 EIP or under standalone option agreements (options granted to our former employees in respect of options granted to replace re-designated G1 shares only). Each IPO Award will be subject to the terms and conditions of the 2021 EIP and an award agreement that we will enter into with the applicable grantee (to our current employees) and under standalone option agreements (to our former employees, in respect of options granted to replace re-designated G1 shares only). </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Executive Officer Employment Arrangements and Director Service Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The compensation for each member of our executive officers comprises the following elements: base salary, annual performance bonus, personal benefits, pension or 401(k) plan and equity incentives. These equity incentives include participation in certain of the Legacy Arrangements and will include participation in the 2021 EIP. Certain awards granted under the Legacy Arrangements will vest and, to the extent they are in the form of options, become exercisable in whole or in part in connection with the initial public offering or the Corporate Reorganization. We intend to enter into new service agreements with our executive officers prior to the closing of this offering. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Non-Executive Director Appointment Letters</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Non-executive directors are engaged on letters of appointment that set out their duties and responsibilities. The non-executive directors do not receive benefits upon termination or resignation from their respective positions as directors. We intend to enter into new appointment letters with our non-executive directors prior to the closing of this offering, and a new appointment letter with our non-executive chairman, Professor Sir John Bell. Under the non-executive director appointment letters, our non-executive directors are entitled to receive annual fees in accordance with our non-executive director remuneration policy as described below, and in each case inclusive of fees payable for all duties. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Non-Executive Director Remuneration Policy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In January 2021, following advice from its compensation consultant, our board of directors adopted a non-executive director remuneration policy, to be effective upon the execution of the underwriting agreement in connection with this offering.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 20pt; text-align: left;">Cash Compensation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under this policy, effective the first calendar quarter after this offering, we will pay each of our nonexecutive directors a cash retainer for service on our board of directors and committees of our board of directors. The annual cash compensation amount set forth below is payable to eligible directors under the policy in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">192<br></div></div></div>
<!--End Page 197-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 198-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an eligible director joins our board of directors or a committee of our board of directors at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the eligible director provides the service and regular full quarterly payments thereafter.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All annual retainers are vested upon payment. At their election, eligible directors residing in the United Kingdom will be paid the applicable amounts converted from U.S. dollars to pounds sterling at the time of payment.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Directors are eligible to receive cash compensation as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Board of Directors Service Retainer:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All Eligible Directors: $40,000</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Independent Chair of the Board of Directors Service Retainer (in addition to Eligible Director Service Retainer): $30,000</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Committee Member Service Retainer:</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Member of the Audit Committee: $7,500</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Member of the Remuneration Committee: $5,000</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Member of the Nominating and Corporate Governance Committee: $4,000</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Annual Committee Chair Service Retainer (in addition to Annual Committee Member Service Retainer):</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Chair of the Audit Committee: $7,500</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Chair of the Remuneration Committee: $5,000</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 40pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Chair of the Nominating and Corporate Governance Committee: $4,000</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Equity Compensation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to cash compensation, each eligible director is eligible to receive equity compensation set forth below will be granted under the Non-Employee Sub-Plan to our 2021 EIP. All share options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value (as such term is defined in our 2021 EIP) of the underlying Shares on the date of grant, and a term of ten years from the date of grant, subject to earlier termination in connection with a termination of service (as such term is defined in our 2021 EIP).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 20pt; text-align: left;">Initial Grant</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each eligible director who is first elected or appointed to our board of directors following the effective date of this policy, will automatically, and without further action by our board of directors or the Remuneration Committee of our board of directors, upon the date of his or her initial election or appointment to be an eligible director (or, if such date is not a market trading day, the first market trading day thereafter), be granted a share option to purchase &#8195;&#8195;&#8195;&#8195; shares, or the Initial Grant. The shares subject to each Initial Grant will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant; <font style="font-style: italic;">provided</font>, that the eligible director continues to be a service provider (as such term is defined in our 2021 EIP) through each such vesting date.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 20pt; text-align: left;">Annual Grant</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At the close of business on the date of each of our annual general meetings held after this offering, each eligible director who continues to serve as a non-employee member of our board of directors following such meeting will be automatically, and without further action by our board of directors or the Remuneration Committee of our board of directors, be granted a share option to purchase &#8195;&#8195;&#8195;&#8195; shares, or the Annual Grant. The shares subject to the Annual Grant will vest at the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately prior to the date of our next annual general meeting; <font style="font-style: italic;">provided</font>, that the eligible director continues to be a service provider (as defined in the 2021 EIP) through such vesting date.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">193<br></div></div></div>
<!--End Page 198-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 199-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">Vesting; Change of Control</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All vesting is subject to the eligible director continuing to be a service provider (as such term is defined in our 2021 EIP) on each applicable vesting date. Notwithstanding the foregoing vesting schedules, for each eligible director who remains continuously a service provider until immediately prior to the closing of a change in control (as such term is defined in our 2021 EIP), the shares subject to his or her then-outstanding equity awards will become fully vested immediately prior to the closing of such change in control.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 20pt; text-align: left;">Expenses</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will also reimburse our directors for their reasonable out-of-pocket expenses in connection with attending board and committee meetings.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Equity Award to Two Directors Upon the Completion of this Offering</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with this offering, we expect that our board of directors will grant awards under the 2021 EIP to two of our directors, which are included in the IPO Awards described above. Each of these awards is a one-time grant which will be granted contingent and effective upon the execution of the underwriting agreement for this offering, with an exercise price per share equal to the initial public offering price per ADS. Assuming an initial public offering price of $&#8195;&#8195; per ADS, which is the midpoint of the price range set forth on the cover page of this prospectus, an aggregate of &#8195;&#8195; ordinary shares would be granted. The actual number of shares subject to the IPO Awards may change. These IPO Awards will vest in 36 equal monthly installments.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Equity Incentive Plans</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have granted options and equity incentive awards under our: (1) 2020 Company Share Option Plan, or the 2020 CSOP; (2) 2020 Non Tax-Advantaged Share Option Plan, or the 2020 SOP; (3) 2018 Non Tax-Advantaged Share Option Plan, or the 2018 SOP; (4) 2015 Company Share Option Plan, or the 2015 CSOP; (5) 2015 Non Tax-Advantaged Share Option Plan, or the 2015 SOP; (6) Immunocore Limited Share Option Scheme, or the 2008 SOP, and (7) various standalone equity agreements further described below. No further options or awards will be granted under these plans or arrangements, or the Legacy Arrangements, following completion of this offering. We intend to adopt the 2021 EIP prior to the completion of this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The principal features of our equity incentive plans and arrangements are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans or arrangements, which are filed as exhibits to the registration statement of which this prospectus is a part.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">2021 Equity Incentive Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2021 EIP which will be adopted prior to the completion of this offering and become effective upon pricing, allows for the grant of equity-based incentive awards to our employees and directors, including directors who are also our employees. The material terms of the 2021 EIP are summarized below. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Eligibility and administration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our employees and directors, who are also our employees, and employees of our subsidiaries are eligible to receive awards under the 2021 EIP. Our consultants and directors, who are not employees, and those of our subsidiaries, are eligible to receive awards under the Non-Employee Sub-Plan to the 2021 EIP described below. Persons eligible to receive awards under the 2021 EIP (including the Non-Employee Sub-Plan) are together referred to as service providers below. Except as otherwise specified, references below to the 2021 EIP include the Non-Employee Sub-Plan.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2021 EIP is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors and/or officers (referred to as the Plan Administrator below), subject to certain limitations imposed under the 2021 EIP, and other applicable laws and stock exchange rules. The Plan Administrator has the authority to take all actions and make all determinations under the 2021 EIP, to interpret the 2021 EIP and award agreements and to adopt, amend and repeal rules for the administration of the 2021 EIP as it deems advisable. The Plan Administrator also has the authority to determine which eligible service providers receive awards, grant awards, set the terms and conditions of all awards under the 2021 EIP, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2021 EIP.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">194<br></div></div></div>
<!--End Page 199-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 200-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Shares available for awards</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The maximum number of ordinary shares, or the Share Reserve, that may be issued under our 2021 EIP will be confirmed upon pricing but will, subject to adjustment, be a number equal to the sum of (i) 1,145,036 ordinary shares, being 12 per cent. of our expected entire issued share capital immediately prior to completion of the offering, not taking account of any proposed share split and assuming exercising of 100 per cent. of the shoe; plus (ii) &#8195; ordinary shares representing the number of ordinary shares proposed to be subject to options granted under the 2021 EIP to replace holdings of G1 shares which will be re-designated as deferred shares and G2 shares which will be re-designated as a mixture of deferred shares and ordinary shares, in each case immediately prior to completion of this offering, as further described above in the section entitled &#8220;Corporate Reorganization&#8221; plus (iii) &#8195;&#8195;&#8195;&#8195; ordinary shares representing the outstanding authorized option pool in respect of the Legacy Arrangements (each subject to the same assumptions and adjustments as noted at (i) above). No more than a number of ordinary shares equal to the share reserve may be issued under the 2021 EIP upon the exercise of incentive share options. In addition, the number of ordinary shares reserved for issuance under our 2021 EIP will automatically increase on January 1 of each year, commencing on January&#160;1, 2022 and ending on (and including) January&#160;1, 2031, in an amount equal to 5% of the total number of ordinary shares outstanding on December 31 of the preceding calendar year. Our board may act prior to January 1 of a given year to provide that there will be no increase for such year or that the increase for such year will be a lesser (but not greater) number of ordinary shares. Ordinary shares issued under the 2021 EIP may be new shares, shares purchased on the open market or treasury shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an award under the 2021 EIP, expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, cancelled without having been fully exercised or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 EIP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option granted under the Legacy Arrangements prior to the effective date expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, cancelled without having been fully exercised or forfeited on or after the effective date, any unused shares subject to the option will, as applicable, become available for new grants under the 2021 EIP and shall be added to the share reserve.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Awards granted under the 2021 EIP in substitution for any options or other equity or equity-based awards granted by an entity before the entity&#8217;s merger or consolidation with us or our acquisition of the entity&#8217;s property or stock will not reduce the number of ordinary shares available for grant under the 2021 EIP, but will count against the maximum number of ordinary shares that may be issued upon the exercise of incentive stock options. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">References in this summary to ordinary shares include an equivalent number of our ADSs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Awards</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2021 EIP provides for the grant of market value options, market value share appreciation rights, or SARs, restricted shares, restricted share units, or RSUs, and other share-based awards. All awards under the 2021 EIP will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms, change of control provisions and post-termination exercise limitations. A brief description of each award type follows.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options and SARs<font style="font-style: normal;">. Options provide for the purchase of our ordinary shares in the future at an exercise price </font><font style="font-style: normal;">set at no less than the market value of an ordinary share on the grant date. SARs entitle their holder, upon </font><font style="font-style: normal;">exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the </font><font style="font-style: normal;">grant date and the exercise date. The Plan Administrator will determine the number of shares covered by each </font><font style="font-style: normal;">option and SAR, and the conditions and limitations applicable to the exercise of each option and SAR.</font><font style="font-style: normal;"> </font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Restricted shares and RSUs<font style="font-style: normal;">. Restricted shares are an award of non-transferable ordinary shares that remain </font><font style="font-style: normal;">forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs </font><font style="font-style: normal;">are </font><font style="font-style: normal;">contractual promises to deliver our ordinary shares in the future, which may also remain forfeitable unless and </font><font style="font-style: normal;">until specified conditions are met. The Plan Administrator may provide that the delivery of the shares underlying </font><font style="font-style: normal;">RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions </font><font style="font-style: normal;">applicable to restricted shares</font><font style="font-style: normal;"> and</font><font style="font-style: normal;"> RSUs </font><font style="font-style: normal;">will be determined by the Plan Administrator, subject to the conditions </font><font style="font-style: normal;">and limitations contained in the 202</font><font style="font-style: normal;">1</font><font style="font-style: normal;"> EIP.</font></div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Other share-based awards<font style="font-style: normal;">. Other share-based awards are awards of fully vested ordinary shares and other </font><font style="font-style: normal;">awards valued wholly or partially by referring to, or otherwise based on, our ordinary shares or other property. </font></div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">195<br></div></div></div>
<!--End Page 200-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 201-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other share-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The Plan Administrator will determine the terms and conditions of other share-based awards, which may include any purchase price, performance goal, transfer restrictions and vesting conditions.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Performance criteria</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Plan Administrator may set performance goals in respect of any awards in its discretion. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Certain transactions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with certain corporate transactions and events affecting our ordinary shares, including a change of control or another similar corporate transaction or event, the Plan Administrator has broad discretion to take action under the 2021 EIP. This includes cancelling awards for cash or property, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares subject to outstanding awards and/or with respect to which awards may be granted under the 2021 EIP and replacing or terminating awards under the 2021 EIP. In addition, in the event of certain equity restructuring transactions, the Plan Administrator will make equitable adjustments to the limits under the 2021 EIP and outstanding awards as it deems appropriate to reflect the transaction. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Plan amendment and termination</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our board of directors may amend or terminate the 2021 EIP at any time; however, no amendment may be made which materially adversely affects an award outstanding under the 2021 EIP without the consent of the affected participant and shareholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws. The 2021 EIP will remain in effect until the tenth anniversary of its effective date unless earlier terminated by our board of directors. No awards may be granted under the 2021 EIP after its termination.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Transferability and participant payments</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as the Plan Administrator may determine or provide in an award agreement, awards under the 2021 EIP are generally non-transferrable, except to a participant&#8217;s designated beneficiary, as defined in the 2021 EIP. With regard to tax and/or social security withholding obligations arising in connection with awards under the 2021 EIP, and exercise price obligations arising in connection with the exercise of options under the 2021 EIP, the Plan Administrator may, in its discretion, accept cash, wire transfer or check, our ordinary shares that meet specified conditions, a promissory note, a &#8220;market sell order,&#8221; such other consideration as the Plan Administrator deems suitable or any combination of the foregoing.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Non-U.S. and Non-U.K. participants</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Plan Administrator may modify awards granted to participants who are non-U.S. or U.K. nationals or employed outside the U.S. and the U.K. or establish sub-plans or procedures to address differences in laws, rules, regulations or customs of such international jurisdictions with respect to tax, securities, currency, employee benefit or other matters or to enable awards to be granted in compliance with a tax favorable regime that may be available in any jurisdiction.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Non-Employee Sub-Plan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Non-Employee Sub-Plan governs equity awards granted to our non-executive directors, consultants, advisers and other non-employee service providers and provides for awards to be made on identical terms to awards made under our 2021 EIP.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Legacy Arrangements</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2020 Company Share Option Plan </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2020 CSOP was adopted on April 20, 2020 and was intended to qualify as a company share option plan that meets the requirements of Schedule 4 to the Income Tax (Earnings and Pensions) Act 2003, or ITEPA. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">196<br></div></div></div>
<!--End Page 201-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 202-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Options granted under the 2020 CSOP were, subject to certain qualifying conditions being met, potentially U.K. tax favored options up to an individual limit of &#163;30,000 calculated by reference to the market value of the shares under option at the date of grant. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 CSOP must have an exercise price equal to or more than the market value of a share on the date of grant and, where the exercise of an option is to be satisfied by newly issued shares, the exercise price must not be less than the nominal value of a share.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Participation / Eligibility and Administration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 CSOP are granted by the board of directors in its absolute discretion to employees that qualify to be granted an option under Schedule 4 of ITEPA.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Vesting and Exercise of Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 CSOP may be granted subject to a vesting schedule containing one or more time-based conditions and additionally, or in the alternative, specific performance conditions that must be met before all or part of an option can be exercised. The board of directors has discretion to determine the extent to which a performance condition has been satisfied.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may accelerate vesting of an option and/or vary or waive one or more performance conditions attaching to an option, provided that such variation to a performance condition can only be effected by the board of directors if it reasonably considers that the variation is required to ensure that the objective criteria against which the performance condition is measured will be either a fairer measure of performance or a more effective incentive to the option holder and will be no more difficult to satisfy than when the original performance condition was set.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 CSOP may not be exercised after the tenth anniversary of the date of grant and generally may only be exercised on the earliest of (1) the company coming under the control (as defined in section&#160;719 ITEPA) of another person; (2) a court sanctioned scheme of arrangement; (3) the sale of all, or substantially all, of the business assets of the company; (4) the listing of the company&#8217;s shares on the London Stock Exchange or any recognized investment exchange; or (5) 114 months after the date of grant. Options may also be exercised by certain Leavers. See Cessation of Employment below. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Terms Generally Applicable to Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Save for transferring an option to a deceased option holder&#8217;s personal representative on their death, options granted under the 2020 CSOP cannot be transferred, assigned or have any charge or other security created over them.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 CSOP will lapse on the earliest of the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an attempt to transfer, assign or encumber the option (save for a transfer to a personal representative on death);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a performance condition failing to be met that results in the entire option being incapable of exercise;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date stated in the relevant option certificate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the first anniversary of an option holder&#8217;s death; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">90 days after the option holder ceases to be employed by the company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the board of directors uses its discretion to permit early exercise of an option within a defined period determined by the board of directors, the expiry of such period;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">40 days after the completion of a Takeover or an Asset Sale (both as defined below) (or immediately after completion if option holders are given the opportunity to exercise their options by the board of directors prior to completion);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">40 days after a reorganization of the company if a replacement option is offered in the acquirer as part of the reorganization; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the option holder becoming bankrupt.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">197<br></div></div></div>
<!--End Page 202-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 203-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 20pt; text-align: left;">If an option holder becomes a Leaver, their option will lapse and cease to be exercisable unless:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">they are a Good Leaver, in which case they may exercise their vested option and 50% of their unvested option (calculated as at the date the option holder ceased to employed) for a period ending 90 days after becoming a Leaver, or 12 months from the date of death if the reason for leaving is due to an option holder&#8217;s death; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">they are Bad Leaver, in which case they may exercise their vested option (calculated as at the date the option holder ceased to employed) for a period ending 90 days after becoming a Leaver; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the board of directors determines otherwise.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of the 2020 CSOP:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Leaver&#8221; means an option holder that ceases, or has ceased to be, an employee and does not continue as, or become, an employee of the company or one its subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Good Leaver&#8221; means an option holder that becomes a Leaver as a result of their: (a) injury, ill-health or disability (evidenced to the satisfaction of the board of directors); (b) death; (c) redundancy within the meaning of the Employment Rights Act 1996; or (d) employment being solely with a company which is not the company or one of its subsidiaries or their employment being transferred to a person who is not the company or one of its subsidiaries on completion of the sale of the business or part of the business to which their employment relates.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Bad Leaver&#8221; means a Leaver other than a Good Leaver or Very Bad Leaver.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Very Bad Leaver&#8221; means a Leaver (a) as a result of the termination of his or her contract of employment or engagement, whether such termination is by the company or one of its subsidiaries, the option holder or otherwise, in circumstances where the company or subsidiary is entitled to terminate such contract summarily with immediate effect without notice or payment in lieu of notice; or (b) that breaches the terms of any confidentiality, non-competition, good faith, warranty or non-solicitation obligations due by him or her to the company or any subsidiary, whether under his contract of employment or engagement or otherwise.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Corporate Transactions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a person or entity acquires control (as defined in section 719 ITEPA) of the company, or enters into a share sale and purchase agreement which will result in the such person or entity obtaining control of the company upon completion (on its own account or acting together with others), or a Takeover, option holders shall be entitled to exercise their options in whole or in part within the period of 40 days beginning with the date when the person or entity has obtained Control of the company and to the extent that an option is not exercised within such period it shall lapse and cease to be exercisable. However, in anticipation of the completion of a Takeover, the board of directors may in its absolute discretion and by notice in writing to all option holders declare all outstanding options to be exercisable either in whole or in part during a reasonable limited period specified by the board of directors in the notice (which period shall end immediately before the acquirer obtains control of the company if it has not already ended). If options are not exercised within this period, they shall lapse immediately upon expiry of such period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A Takeover will not apply in a scenario in which the acquirer is an entity owned substantially by the same persons as the company prior to completion of the Takeover.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an unconditional agreement is entered into for the sale to a person other than the company or one of its subsidiaries of the whole, or substantially the whole, of the business and assets of the company, or an Asset Sale, options may be exercised in whole or in part within the period of 40 days beginning with the date of completion of the Asset Sale and shall lapse and cease to be exercisable at the end of that period. However, if the board of directors anticipates that an Asset Sale may occur it may invite option holders to exercise their options in respect of shares that would be vested on the date of completion of such Asset Sale within such period preceding the Asset Sale as the board of directors may specify. If an option is not then exercised, it shall, unless the board of directors otherwise determines, lapse and cease to be exercisable at the end of that period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If there is a listing of the company&#8217;s shares on the London Stock Exchange or any recognized investment exchange, or a Listing, options over vested shares may be exercised within one or more periods after the Listing as the board of directors shall determine. If the board of directors makes such a determination, it shall notify as </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">198<br></div></div></div>
<!--End Page 203-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 204-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">such to option holders before the Listing provided that (1) periods cannot be less than seven days long; (2) the first period shall begin within the period of 14 days beginning with the date of the Listing; (3) if no period is specified by the board of directors, vested options can be exercised immediately after the Listing; (4) if the board of directors specifies more than one exercise period, no less than one-third of the vested option can be exercised in the first period; and (5) if there is more than one exercise period, all such periods and dates must be notified to the option holders at the same time as notification of the first exercise period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option becomes exercisable due to a Listing, the company does not have to issue shares unless the option holder has first agreed with the company (in such form as the board of directors shall determine) he or she shall not sell the shares acquired within such lock-up period or periods (not extending beyond the second anniversary of the date of Listing) as the board of directors may specify in a notice in writing to the option holder. However, such lock-up period(s) do not apply and an option holder can immediately sell a number of the shares acquired, for cash, to cover the exercise price and any income tax and national insurance contributions that arise on exercise of their option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The treatment of awards granted in the form of CSOP options is subject to certain additional restrictions under the CSOP regime.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Adjustment of Options, Malus and Clawback</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options are subject to such to adjustments and deductions or recovery as may be required to be made upon reasonable evidence that an option holder contributed to, or was materially responsible for (1) the need for restatement of the company&#8217;s or any subsidiaries&#8217; financial results because of fraud, dishonesty or such other misconduct; (2) misstating or misreporting or fraudulent or dishonest concealment of any clinical or trial data; (3) personally acting fraudulently or dishonestly in a manner that adversely affects the company&#8217;s reputation or which is characterized as gross misconduct; (4) directing an employee, contractor, or advisor to act fraudulently, dishonestly, or to undertake other misconduct; and (5) breaching their material obligations to the company through error, omission, or negligence.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Amendments to 2020 CSOP </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors can amend the 2020 CSOP from time to time save that such amendments (1) cannot be made if it would mean that the 2020 CSOP would no longer qualify under Schedule 4 of ITEPA; (2) cannot be made without option holders&#8217; prior written consent if the amendment would have a material adverse impact on their rights; or (3) require certain investor approvals if the amendment would (a) make existing options grants materially more generous; (b) increase option limits; or (c) expand the class of employees eligible to participate in the 2020 CSOP.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">2020 Non Tax-Advantaged Share Option Plan </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2020 SOP was adopted on April 20, 2020 and provides for the grant of options over ordinary shares in the capital of the company. Options granted under the 2020 SOP must have an exercise price equal to or more than the market value of a share on the date of grant and where the exercise of an option is to be satisfied by newly issued shares, the exercise price shall not be less than the nominal value of a share.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Participation / Eligibility and Administration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 SOP are granted by the board of directors in its absolute discretion to former, current and prospective employees and consultants.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Vesting and Exercise of Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 SOP may be granted subject to a vesting schedule containing one or more time-based conditions and additionally, or in the alternative, specific performance conditions that must be met before all or part (as applicable) of an option can be exercised. The board of directors has discretion to determine the extent to which a performance condition has been satisfied.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">199<br></div></div></div>
<!--End Page 204-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 205-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may accelerate a vesting schedule and/or vary or waive one or more performance conditions attaching to an option, provided that such variation to a performance condition can only be effected by the board of directors if it reasonably considers that the variation is required to ensure that the objective criteria against which the performance condition is measured will be either a fairer measure of performance or a more effective incentive to the option holder and will be no more difficult to satisfy than when the original performance condition was set.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 SOP may not be exercised after the tenth anniversary of the date of grant and generally, may only be exercised on the earliest of the following to occur: (a) the company coming under the control (as defined in section 719 ITEPA) of another person; (b) a court sanctioned scheme of arrangement; (c)&#160;the sale of all, or substantially all, of the business assets of the company; (d) the listing of the company&#8217;s shares on the London Stock Exchange or any recognized investment exchange; or (e) 114 months after the date of grant. Options may also be exercised by certain Leavers. See Cessation of Employment below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Terms Generally Applicable to Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Save for transferring an option to a deceased option holder&#8217;s personal representative on their death, options granted under the 2020 SOP cannot be transferred, assigned or have any charge or other security created over them.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2020 SOP will lapse on the earliest of the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an attempt to transfer, assign or encumber the option (save for a transfer to a personal representative on death);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a performance condition failing to be met that results in the entire option being incapable of exercise;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date stated in the relevant option certificate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the first anniversary of an option holder&#8217;s death;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">90 days after the option holder ceases to be employed or engaged by the company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the board of directors uses its discretion to permit early exercise of an option within a defined period determined by the board of directors, the expiry of such period;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">40 days after the completion of a Takeover or an Asset Sale (or immediately after completion if option holders are given the opportunity to exercise their options by the board of directors prior to completion); or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the option holder becoming bankrupt.</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder becomes a Leaver, their option shall lapse and cease to be exercisable unless:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">they are a Good Leaver, in which case they may exercise their vested option and 50% of their unvested option (calculated as at the date the option holder ceased to employed) for a period ending 90 days after becoming a Leaver, or 12 months from the date of death if the reason for leaving is due to an option holder&#8217;s death; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">they are Bad Leaver, in which case they may exercise their vested option (calculated as at the date the option holder ceased to employed) for a period ending 90 days after becoming a Leaver; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the board of directors determines otherwise.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of the 2020 SOP:</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Leaver&#8221; means an option holder that ceases, or has ceased to be, an employee and does not continue as, or become, an employee of the company or one its subsidiaries.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Good Leaver&#8221; means an option holder that becomes a Leaver as a result of their: (a) injury, ill-health or disability (evidenced to the satisfaction of the board of directors); (b) death; (c) redundancy within the meaning of the Employment Rights Act 1996; or (d) employment being solely with a company which is not the company or one of its subsidiaries or their employment being transferred to a person who is not a member of the company or one of its subsidiaries on completion of the sale of the business or part of the business to which their employment relates.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">200<br></div></div></div>
<!--End Page 205-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 206-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Bad Leaver&#8221; means a Leaver other than a Good Leaver or Very Bad Leaver.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">&#8220;Very Bad Leaver&#8221; means a Leaver (a) as a result of the termination of his or her contract of employment or engagement, whether such termination is by the company or one of its subsidiaries, the option holder or otherwise, in circumstances where the company or subsidiary is entitled to terminate such contract summarily with immediate effect without notice or payment in lieu of notice; or (b) that breaches the terms of any confidentiality, non-competition, good faith, warranty or non-solicitation obligations due by him or her to the company or any subsidiary, whether under his contract of employment or engagement or otherwise.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Corporate Transactions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a Takeover occurs, option holders shall be entitled to exercise their options in whole or in part within the period of 40 days beginning with the date when the person or entity has obtained Control of the company and to the extent that an option is not exercised within such period it shall lapse and cease to be exercisable. However, in anticipation of the completion of a Takeover, the board of directors may in its absolute discretion and by notice in writing to all option holders declare all outstanding options to be exercisable either in whole or in part during a reasonable limited period specified by the board of directors in the notice (which period shall end immediately before the acquirer obtains control of the company if it has not already ended). If options are not exercised within this period, they shall lapse immediately upon expiry of such period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors, in its discretion, may determine that the rights and obligations arising on a Takeover shall not apply if a Takeover takes place in the course of any corporate reconstruction or reorganization under which the ultimate beneficial ownership of the business of the company and its subsidiaries will remain the same, and the arrangements for the corporate reorganization or reconstruction include appropriate provisions for either the replacement of options or other compensation of option holders for which the board of directors, in its reasonable opinion, considers to be fair. If an option holder does not accept the replacement option or other compensation, their option will lapse at the end of the period in which he or she invited to accept such replacement option or compensation.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If there is an Asset Sale, options may be exercised in whole or in part within the period of 40 days beginning with the date of completion of the Asset Sale and shall lapse and cease to be exercisable at the end of that period. However, if the board of directors anticipates that an Asset Sale may occur it may invite option holders to exercise their options in whole or in part within such period preceding the Asset Sale as the board of directors may specify. If an option is not then exercised, it shall, unless the board of directors otherwise determines, lapse and cease to be exercisable at the end of that period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If there is a Listing, options over vested shares may be exercised within one or more periods after the Listing as the board of directors shall determine. If the board of directors makes such a determination, it shall notify as such to option holders before the Listing provided that (a) periods cannot be less than seven (7) days long; (b) the first period shall begin within the period of fourteen (14) days beginning with the date of the Listing; (c) if no period is specified by the board of directors, vested options can be exercised immediately after the Listing; (d) if the board of directors specifies more than one exercise period, no less than one-third of the vested option can be exercised in the first period; and (e) if there is more than one exercise period, all such periods and dates must be notified to the option holders at the same time as notification of the first exercise period.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option becomes exercisable due to a Listing, the company does not have to issue shares unless the option holder has first agreed with the company (in such form as the board of directors shall determine) he or she shall not sell the shares acquired within such lock-up period or periods (not extending beyond the second anniversary of the date of Listing) as the board of directors may specify in a notice in writing to the option holder. However, such lock-up period(s) do not apply and an option holder can immediately sell a number of the shares acquired, for cash, to cover the exercise price and any income tax and national insurance contributions that arise on exercise of their option.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The treatment of awards granted in the form of SOP options is subject to certain additional restrictions under the SOP regime.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Adjustment of Options, Malus and Clawback</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options are subject to such to adjustments and deductions or recovery as may be required to be made upon reasonable evidence that an option holder contributed to, or was materially responsible for (a) the need for </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">201<br></div></div></div>
<!--End Page 206-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 207-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">restatement of the company&#8217;s or any subsidiaries&#8217; financial results because of fraud, dishonesty or such other misconduct; (b) misstating or misreporting or fraudulent or dishonest concealment of any clinical or trial data; (c)&#160;personally acting fraudulently or dishonestly in a manner that adversely affects the company&#8217;s reputation or which is characterized as gross misconduct; (d) directing an employee, contractor, or advisor to act fraudulently, dishonestly, or to undertake other misconduct; and (e) breaching their material obligations to the company through error, omission, or negligence.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Amendments to 2020 SOP </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors can amend the 2020 SOP from time to time though such amendments (a) cannot be made without option holders&#8217; prior written consent if the amendment would have a material adverse impact on their rights; or (b) require certain investor approvals if the amendment would make existing options grants materially more generous.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">2018 Non Tax-Advantaged Share Option Plan </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2018 SOP is operated on the same terms as the 2020 SOP but with the following differences.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder ceases to be employed or engaged with the company or a subsidiary without becoming employed or engaged with the company or a subsidiary, their option will not be exercisable unless permitted by the board of directors (and shall lapse to the extent not so permitted on the earlier of the date of the board of directors&#8217; determination or 90 days after such cessation). If an option is permitted to be exercised, it shall lapse and cease to be exercisable on the date determined by the board of directors (being not later than the normal lapse date of the option, or 12 months after the date of death (if applicable)).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">2015 Company Share Option Plan </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2015 CSOP is operated on the same terms as the 2020 CSOP but with the following differences.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder ceases to be employed or engaged with the company or a subsidiary without becoming employed or engaged with the company or a subsidiary, their option will not be exercisable unless permitted by the board of directors (and shall lapse to the extent not so permitted on the earlier of the date of the board of directors&#8217; determination or 90 days after such cessation). If an option is permitted to be exercised, it shall lapse and cease to be exercisable on the date determined by the board of directors (being not later than the normal lapse date of the option, or 12 months after the date of death (if applicable)).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Malus and Clawback</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No malus or clawback provisions apply to options granted under the 2015 CSOP.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">2015 Non Tax-Advantaged Share Option Plan </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2015 SOP is operated on the same terms as the 2020 SOP but with the following differences:</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder ceases to be employed or engaged with the company or a subsidiary without becoming employed or engaged with the company or a subsidiary, their option will not be exercisable unless permitted by the board of directors (and shall lapse to the extent not so permitted on the earlier of the date of the board of directors&#8217; determination or 90 days after such cessation). If an option is permitted to be exercised, it shall lapse and cease to be exercisable on the date determined by the board of directors (being not later than the normal lapse date of the option, or 12 months after the date of death (if applicable)).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16pt; margin-left: 0pt; text-align: left;">Malus and Clawback</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No malus or clawback provisions apply to options granted under the 2015 SOP.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">202<br></div></div></div>
<!--End Page 207-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 208-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Amendments to 2015 SOP </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors can amend the 2015 SOP from time to time though such amendments (1) cannot be made without option holders&#8217; prior written consent if the amendment would have a material adverse impact on their rights; or (2) require certain shareholder approvals if the amendment would (a) make existing options grants materially more generous; or (b) expand the class of potential option holders.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Immunocore Limited Share Option Scheme</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The 2008 SOP was adopted on August 14, 2008 and is intended to qualify as an enterprise management incentive plan, or EMI plan, that meets the requirements of Schedule 5 to ITEPA. It is also capable of granting non-tax favored options to employees.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Only non-tax favored options remain outstanding under the 2008 SOP.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Participation / Eligibility and Administration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors determine in its absolute discretion who can be granted an option under the 2008 SOP.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the company and option requirements, an individual is eligible to be granted EMI options under the 2008 SOP if they satisfy the employee requirements of Schedule 5 to ITEPA. If the requirements are not satisfied, non-tax favored options may be granted to employees.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Vesting and Exercise of Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may specify that the exercise of any option granted under the 2008 SOP shall be subject to one or more objective conditions, performance targets and/or performance periods as it may think fit. The board of directors may waive such conditions, targets or periods provided that an event or events has occurred that means the condition, target or period is no longer an effective incentive.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the provisions relating to takeovers and changes of control that are set out in the 2008 SOP, options granted under the 2008 SOP may not be exercised earlier than the time or times set out in the individual option agreements.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Terms Generally Applicable to Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2008 SOP must have an exercise price equal to or more than the market value of a share on the date of grant and, where the exercise of an option is to be satisfied by newly issued shares, the exercise price must not be less than the nominal value of a share.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Options granted under the 2008 SOP lapse on the tenth anniversary of the date of grant or such earlier date that is specified in an individual option agreement or the plan rules.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cessation of Employment</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder ceases to employed with a group company due to retirement, injury, ill-health, disability or the company he or she works for is no longer part of the group, his or her option may be exercised to the extent it has vested during the period of six months beginning with the date of cessation of employment after which, it will lapse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder dies whilst he or she is employed with the Company, his or her option may be exercised to the extent vested by the option holder&#8217;s personal representatives for a period of twelve months beginning with the date of death after which, it will lapse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an option holder ceases to be employed with a group company due to any reason other than those set out above, then his or her option may be exercised in relation to such proportion of the shares and within such period as the board of directors determines. If the board of directors do not make such a determination within three months of the date of cessation, the option will lapse.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">203<br></div></div></div>
<!--End Page 208-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 209-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Corporate Transactions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a person obtains control of the Company, option holders may exercise their options to the extent vested within four months of the date on which such person obtains control of the Company, after which, they will lapse.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Notwithstanding the above, the board of directors may in their absolute discretion prior to the obtaining of control give notice to each of the option holders to declare all outstanding options granted under the 2008 SOP exercisable for a limited period. If options are not exercised within this period, they will lapse at the end of such period.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Amendments to 2008 SOP </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors can, in their absolute discretion, amend the 2008 SOP from time to time save that such amendments cannot be made without 75% of the option holders&#8217; prior written consent (either by number shares under option or number of individual option holders) if the amendment would abrogate or adversely alter their existing rights. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other arrangements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As further described above in the section entitled &#8220;Corporate Reorganization&#8221;, certain of our U.K. employees and former employees hold awards of G1 or G2 shares, which are proposed to be re-designated as deferred shares and ordinary shares or G2 shares which are proposed to be re-designated as a mixture of deferred shares and ordinary shares, in each case and ordinary shares immediately prior to completion of this offering. Certain holders of awards of G1 shares were granted nominal cost options over our ordinary shares pursuant to standalone option agreements, the terms of which were linked to the awards of G1 shares such that these options will lapse in connection with the Corporate Reorganization. Certain of our non-executive directors and other service providers were also granted options under standalone option agreements on substantially similar terms to the 2020 SOP.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Insurance and Indemnification </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To the extent permitted by the Companies Act, we are empowered to indemnify our directors against any liability they incur by reason of their directorship. We maintain directors&#8217; and officers&#8217; insurance to insure such persons against certain liabilities. We expect to enter into a deed of indemnity with each of our directors and executive officers prior to the completion of this offering. In addition to such indemnification, we provide our directors and executive officers with directors&#8217; and officers&#8217; liability insurance. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Insofar as indemnification of liabilities arising under the Securities Act may be permitted to our board, executive officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">204<br></div></div></div>
<!--End Page 209-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 210-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRPT"><!--Anchor--></a>RELATED PARTY TRANSACTIONS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since January 1, 2018, we have engaged in the following transactions or loans between us and (a) enterprises that directly or indirectly through one or more intermediaries, control or are controlled by, or are under common control with, our company; (b) associates; (c) individuals owning, directly or indirectly, an interest in the voting power of our company that gives them significant influence over our company, and close members of any such individual&#8217;s family; (d) key management personnel, that is, those persons having authority and responsibility for planning, directing and controlling our activities, including directors and senior management and close members of such individuals&#8217; families; and (e) enterprises in which a substantial interest in the voting power is owned, directly or indirectly, by any person described in (c) or (d) or over which such a person is able to exercise significant influence. We refer to the entities and persons described in (a) through (e) above as &#8220;related parties.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Subscription of our Series C Preferred Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In December 2020, we entered into a subscription agreement with investors to purchase an aggregate of 823,719 series C preferred shares for aggregate proceeds of $75m at a price of $91.05 per share. In addition, 127,893 ordinary shares were issued to existing shareholders by way of capitalisation of our undistributable reserves in satisfaction of pre-existing anti-dilution rights held by holders of our series A preferred shares and series B preferred shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the aggregate number of series C preferred shares and ordinary shares issued to our related parties pursuant to this transaction:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participants</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series C Preferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares (#)</div></td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.14%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ordinary Shares (#)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with General Atlantic<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.02pt; text-align: left;">219,659</div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.27pt; text-align: left;">18,963</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly S.A.<font style="padding-left: 3.95pt;"></font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.02pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.14%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 14.97%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.27pt; text-align: left;">23,238</div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">December 2020 Shareholders&#8217; Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The December 2020 Shareholders&#8217; Agreement, or the Series C Shareholders&#8217; Agreement, amended and restated an agreement entered into between us and our shareholders in August 2019. Among other things, the Series C Shareholders&#8217; Agreement:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">grants our preferred shareholders specified registration rights with respect to our shares held by them;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obligates us to deliver periodic financial statements and other information to certain of the shareholders who are parties to the Series C Shareholders&#8217; Agreement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provides for certain appointment rights with respect to our board of directors and the voting of shares in favor of specified transactions approved by our board of directors and the requisite majority of our shareholders.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The rights granted above will terminate upon the completion of this offering, except for the contemplated registration rights, which survive in the circumstances described in more detail in the agreement. For more information regarding the registration rights to be provided in this agreement, please refer to the section titled &#8220;Description of Share Capital and Articles of Association&#8212; Registration Rights.&#8221;</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Management Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with our series C preferred share financing, we also granted certain investors the right to, among other matters, consult with and advise management on significant business issues, appoint a director and/or an observer to our board, participate up to a certain amount in our offering and have access to our books and records.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Subscriptions of our Series B Preferred Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In July 2019, with subsequent closings in August 2019 and February 2020, we entered into subscription agreements with investors to purchase an aggregate of 1,148,703 series B preferred shares for aggregate proceeds of &#163;109.5 million. Of these shares, 1,105,671 series B preferred shares were purchased at a price of &#163;96.19 per </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">205<br></div></div></div>
<!--End Page 210-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 211-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">share and the remaining 43,032 series B preferred shares were purchased at a price of &#163;73.91 per share. This aggregate amount includes 203,697 series B preferred shares issued to the Gates Foundation in exchange for conversion of our outstanding loan into equity, consisting of $25 million loan plus accrued interest for a total of $25.5 million. In addition, 70,106 ordinary shares were issued to existing shareholders by way of capitalisation of our undistributable reserves in satisfaction of pre-existing anti-dilution rights held by holders of our series A preferred shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth the aggregate number of series B preferred shares issued to our related parties pursuant to these transactions: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participants</div></td><td class="gutter" style="width: 3.96%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.96%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Perferred <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares (#)</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities affiliated with General Atlantic<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 3.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.96%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;">555,893</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly S.A.<font style="padding-left: 2.95pt;"></font></div></td><td class="gutter" style="width: 3.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.96%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><font style="padding-left: 5pt;">71,588</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">These shares were purchased by GA IMC Holding, L.P. </div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">August 2019 Shareholders&#8217; Agreement </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition to providing for the purchase and sale of series B preferred shares, the August 2019 Shareholders&#8217; Agreement, or the Series B Shareholders&#8217; Agreement, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contemplates granting our preferred shareholders specified registration rights with respect to our shares held by them, which is to be memorialized in a registration rights agreement that we intend to enter into prior to the completion of this offering;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obligates us to deliver periodic financial statements to certain of the shareholders who are parties to the Series B Shareholders&#8217; Agreement; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provides for certain appointment rights with respect to our board of directors and the voting of shares in favor of specified transactions approved by our board of directors and the requisite majority of our shareholders.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The rights granted above will terminate upon the completion of this offering, except for the contemplated registration rights, which will be memorialized in a registration rights agreement that we intend to enter into prior to the completion of this offering. For more information regarding the registration rights to be provided in this agreement, please refer to the section titled &#8220;Description of Share Capital and Articles of Association&#8212;Registration Rights.&#8221; </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Management Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with our series B preferred share financing, we also granted certain investors the right to consult with and advise management on significant business issues, appoint an observer to our board and have access to our books and records. These rights will terminate upon the completion of this offering. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research Software Development Agreement</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into a software development agreement with Aigenpulse Limited, or Aigenpulse, where Aigenpulse agreed to develop scientific computing software designed to assist us in our drug development processes. Nicholas Cross, a beneficial holder of more than 5% of our share capital and a member of our board of directors from October 2008 until August 2019, is affiliated with Aigenpulse. During the years ended December 31, 2018, 2019 and 2020, we incurred costs in the amount of &#163;729,000, &#163;500,000 and &#163;0, respectively. We terminated our agreement with Aigenpulse in 2020.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Agreements with Our Executive Officers and Directors </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have entered into service agreements with the executive officers and a direct services agreement with Dr. Bahija Jallal, our executive director. See &#8220;Management&#8212;Compensation of Executive Officers and Directors.&#8221; These agreements contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by our executive officers. However, the enforceability of the non-competition provisions may be limited under applicable law. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">206<br></div></div></div>
<!--End Page 211-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 212-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to enter into a deed of indemnity with each of our directors and executive officers prior to the completion of this offering. Our articles of association to be adopted in connection with the consummation of this offering empower us to indemnify our directors and executive officers to the fullest extent permitted by applicable law. See &#8220;Management&#8212;Insurance and Indemnification.&#8221;</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Related Person Transactions Policy</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the completion of this offering, we expect to adopt a related person transaction policy. Our related person transaction policy will set forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. The policy will become effective immediately upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we or any of our subsidiaries and any related person are, were or will be participants in which the amount involved exceeds $120,000 or which is unusual in its nature or conditions. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent body of our board of directors for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related person transactions and to effectuate the terms of the policy. In addition, under our Code of Business Conduct and Ethics, which we will adopt prior to the completion of this offering, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">207<br></div></div></div>
<!--End Page 212-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 213-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPRS"><!--Anchor--></a>PRINCIPAL SHAREHOLDERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of December&#160;31, 2020 for:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each beneficial owner of 5% or more of our outstanding ordinary shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of our directors and executive officers; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of our directors and executive officers as a group.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares issuable upon the exercise of options that are immediately exercisable or exercisable within 60 days of December&#160;31, 2020. Percentage ownership calculations are based on ordinary shares outstanding as of December&#160;31, 2020. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The percentage of ordinary shares beneficially owned after completion of this offering is based on ordinary shares outstanding after this offering, including &#8195;&#8195;&#8195;&#8195; ordinary shares represented by ADSs issued in connection with this offering. The table assumes no exercise of the underwriters&#8217; option to purchase additional ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed below have sole voting and investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not necessarily indicative of beneficial ownership for any other purpose. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except as otherwise indicated in the table below, addresses of the directors, executive officers and named beneficial owners are care of Immunocore Holdings Limited, 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom. As of December&#160;31, 2020, to our knowledge, &#8195;&#8195;&#8195;&#8195; U.S. record holders held &#8195;&#8195;&#8195;&#8195;&#8195; % of our issued and outstanding ordinary shares.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td rowspan="2" style="width: 12.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ordinary Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div></td><td class="gutter" rowspan="2" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.02%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage of Ordinary Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially Owned </div></td></tr><tr class="header"><td style="width: 58.97%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Before <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering</div></td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.15%; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Offering</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% or Greater Shareholders:<br></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities affiliated with General Atlantic<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">794,515</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;">12.4%</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Eli Lilly S.A.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">.</sub><font style="padding-left: 2.33pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">509,629</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">7.9%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Nicholas John Cross<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><font style="padding-left: 0.9pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">473,922</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">7.4%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Ian Laing<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup><font style="padding-left: 0.33pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">384,066</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">6.0%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Malin Life Sciences Holdings Limited<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup><font style="padding-left: 2.59pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">471,885</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">7.4%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">George Edward Silvanus Robinson<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup><font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">431,742</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">6.7%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities affiliated with Baker Brothers<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup> <font style="padding-left: 0.56pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;">332,651</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">5.2%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Schroders UK Public Private Trust plc<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup><font style="padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 0.37pt;">319,117</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 5pt;">5.0%</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors:<font style="font-style: normal;"> </font><br></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Bahija Jallal, Ph.D.<font style="padding-left: 4.36pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Brian Di Donato<font style="padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">David Berman, M.D., Ph.D.<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Professor Sir John Bell<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup><font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 10pt;">6,712</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 17.5pt;">*</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Travis Coy<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Robert Perez<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Kristine Peterson<font style="padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Professor Sir Peter Ratcliffe<font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 7.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">All current directors and executive officers as a group <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">(8 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup><font style="padding-left: 0.47pt;"></font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.78pt; text-align: left;"><font style="padding-left: 10pt;">6,712</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.66pt; text-align: left;"><font style="padding-left: 17.5pt;">*</font></div></td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.15%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.86%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.75pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of series B preferred shares, series C preferred shares and ordinary shares held by GA IMC Holding, L.P. The limited partners that share beneficial ownership of the shares held by GA IMC Holding are the following General Atlantic investment funds: General Atlantic Partners (Bermuda) EU, L.P. (&#8220;GAP EU&#8221;), General Atlantic Partners (Bermuda) IV, L.P. (&#8220;GAP IV&#8221;) , GAP Coinvestments III, LLC (&#8220;GAPCO III&#8221;), GAP Coinvestments IV, LLC (&#8220;GAPCO IV&#8221;), GAP Coinvestments V, LLC (&#8220;GAPCO V&#8221;) and GAP </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">208<br></div></div></div>
<!--End Page 213-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 214-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_111-management_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">Coinvestments CDA, LLC (&#8220;GAPCO CDA&#8221;). The general partner of GAP EU and GAP IV is General Atlantic GenPar (Bermuda), L.P. (&#8220;GenPar Bermuda&#8221;). GAP (Bermuda) Limited (&#8220;GAP (Bermuda) Limited&#8221;) is the general partner of GenPar Bermuda. General Atlantic&#8217;s address is c/o Conyers Client Services (Bermuda) Limited, Clarendon House, 2 Church Street, Hamilton MM II, Bermuda.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 39,703 ordinary shares held by Eli Lilly S.A., (b) 398,338 series A preferred shares held by Eli Lilly S.A (c)&#160;71,588 series B preferred shares and (d) 39,703 ordinary shares held by Eli Lilly S.A. Eli Lilly S.A.&#8217;s address is 16, Chemin des Coquelicots, 12 Geneva, Switzerland.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 467,458 ordinary shares held by Mr.&#160;Cross (b) 6,462 series A preferred shares and (c) 2 series B preferred shares held by Mr.&#160;Cross.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 377,792 ordinary shares held by Mr.&#160;Laing, (b) 5,234 series A preferred shares held by Mr.&#160;Laing, (c) 2 series B preferred shares and (d) 1,038 ordinary shares underlying options exercisable within 60 days of December&#160;31, 2020 held by Mr.&#160;Laing.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 46,991 ordinary shares held by Malin Life Sciences Holdings Limited and (b) 424,894 series A preferred shares held by Malin Life Sciences Holdings Limited. Malin Life Sciences Holdings Limited&#8217;s address is The Lennox Building, 50 Richmond Street South, Dublin D02 FK02, Ireland.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 424,255 ordinary shares held by Mr.&#160;Robinson, (b) 6,447 series A preferred shares held by Mr.&#160;Robinson, (c)&#160;2 series B preferred shares held by Mr.&#160;Robinson and (d)&#160;1,038 ordinary shares underlying options exercisable within 60 days of December&#160;31, 2020 held by Mr.&#160;Robinson.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a)&#160;307,816 ordinary shares held by Baker Brothers Life Sciences L.P. and (b)&#160;24,835 ordinary shares held by 667, L.P. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of 27,303 ordinary shares held by Schroders UK Public Private Trust plc and 291,814 series A preferred shares held by Schroders UK Public Private Trust plc.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 1,152 ordinary shares held by Professor Sir John Bell and (b)&#160;5,560 ordinary shares underlying options exercisable within 60&#160;days of December&#160;31, 2020 held by Professor Sir John Bell.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Consists of (a) 1,152 ordinary shares and (b) 5,560 ordinary shares underlying options exercisable within 60 days of December 31, 2020. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">209<br></div></div></div>
<!--End Page 214-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 215-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDOS"><!--Anchor--></a>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Introduction</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of association and relevant provisions of the Companies Act. The summary below contains only material information concerning our share capital and corporate status and does not purport to be complete and is qualified in its entirety by reference to our articles of association to be in effect upon completion of this offering and applicable English law. Further, please note that holders of ADSs to be in effect upon completion of this offering will not be treated as one of our shareholders and will not have any shareholder rights. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Immunocore Holdings Limited was incorporated on January&#160;7, 2021 under the laws of England and Wales with nominal assets and liabilities for the purpose of becoming the holding company of Immunocore Limited and consummating the corporate reorganization described herein. Immunocore Limited was incorporated under the laws of England and Wales in December 2007. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the completion of this offering, we will undertake a corporate reorganization whereby all shareholders of Immunocore Limited will exchange each of the shares held by them for 100 newly issued shares of the same class, and with the same rights attaching thereto, of Immunocore Holdings Limited and, as a result, Immunocore Limited will become a wholly-owned subsidiary of Immunocore Holdings Limited. Subsequent to the Share Exchange, Immunocore Holdings Limited will be re-registered as a public limited company and will change its name to Immunocore Holdings plc. Immediately prior to completion of this offering, Immunocore Holdings plc&#8217;s share capital will be reorganized such that it consists of a single class of ordinary shares, and potentially also non-voting ordinary shares, as well as deferred shares. See the section titled &#8220;Corporate Reorganization&#8221; for more information.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our registered office in the United Kingdom is located at 92 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, United Kingdom, and the telephone number of our registered office is +44 (0)1235 438600.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of September&#160;30, 2020, the issued and outstanding share capital of Immunocore Limited was 2,551,624 ordinary shares, 1,699,576 series A preferred shares, 1,148,703 series B preferred shares and 29,748 G1 shares. The nominal value of each class of shares is &#163;0.0001 per share and each issued share is fully paid. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon the closing of this offering, Immunocore Holdings plc will have &#8195;&#8195;&#8195; ordinary shares and, if applicable, non-voting ordinary shares outstanding, including ordinary shares represented by ADSs. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Ordinary Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with our articles of association to be in effect upon the completion of this offering, the following summarizes the rights of holders of our ordinary shares:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each holder of our ordinary shares is entitled to one vote per ordinary share on all matters to be voted on by shareholders generally; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holders of the ordinary shares shall be entitled to receive notice of, attend, speak and vote at our general meetings; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holders of our ordinary shares are entitled to receive such dividends as are recommended by our directors and declared by our shareholders.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">See also &#8220;&#8212;Articles of Association&#8221; below.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Deferred Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with our articles of association to be in effect upon the completion of this offering, the following summarizes the rights of holders of our deferred shares:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the deferred shares shall not be entitled to any dividends or to any other right of participation in the income or profits of the Company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">on the return of assets on a winding-up of the Company, the deferred shares shall confer on the holders thereof an entitlement to receive out of the assets of the Company available for distribution amongst </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">210<br></div></div></div>
<!--End Page 215-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 216-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">the members (subject to the rights of any new class of shares with preferred rights) the amount paid up or credited as paid up on the deferred shares held by them respectively after (but only after) payment shall have been made to the holders of the ordinary shares and non-voting ordinary shares (if any) of the amounts paid up or credited as paid up on such shares and the sum of &#163;1,000,000 in respect of each ordinary share or non-voting ordinary share held by them respectively. The deferred shares shall confer on the holders thereof no further right to participate in the assets of the Company;</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the deferred shares do not entitle the holder thereof to vote upon any resolution or to receive notice of, attend any general meeting, or be part of the quorum thereof as the holders of the deferred shares; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Company shall have irrevocable authority from each holder of deferred shares to either (i) appoint any person to execute on behalf of any holder of deferred shares a transfer of all or any of those shares and/or an agreement to transfer the same (without making any payment for them) to such person or persons as the Company may determine and to execute any other documents which such person may consider necessary or desirable to effect such transfer, in each case without obtaining the sanction of the holder(s) and without any payment being made in respect of such acquisition; and (ii) to purchase all or any of the deferred shares without obtaining the consent of the holders of those shares in consideration for an amount not exceeding &#163;1.00 in respect of all the deferred shares then being purchased.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Non-Voting Ordinary Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association to be in effect upon the completion of this offering will provide for any non-voting ordinary shares to have the same rights and restrictions as the ordinary shares and otherwise rank <font style="font-style: italic;">pari </font><font style="font-style: italic;">passu</font> in all respects with the ordinary shares save as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a holder of non-voting ordinary shares shall, in relation to the non-voting ordinary shares held by him or her, have no right to receive notice of, or to attend or vote at, any general meeting of shareholders save in relation to a variation of class rights of the non-voting ordinary shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the non-voting ordinary shares shall be re-designated as ordinary shares by our board of directors, or a duly authorised committee or representative thereof, upon receipt of a re-designation notice and otherwise subject to the terms and conditions set out therein. A holder of non-voting ordinary shares shall not be entitled to have any non-voting ordinary shares re-designated as ordinary shares where such re-designation would result in such holder thereof beneficially owning (for purposes of section 13(d) of the Exchange Act), when aggregated with &#8220;affiliates&#8221; and &#8220;group&#8221; members with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act, in excess of 9.99 per cent. of any class of securities of the Company registered under the Exchange Act (which percentage may be increased or decreased on a holder-by-holder basis subject to the provisions set out therein); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the non-voting ordinary shares shall be re-designated as ordinary shares automatically upon transfer of a non-voting ordinary share by its holder to any person that is not an &#8220;affiliate&#8221; or &#8220;group member&#8221; with whom such holder is required to aggregate beneficial ownership for purposes of section 13(d) of the Exchange Act. This automatic re-designation shall only be in respect of the non-voting ordinary shares that are subject to such transfer.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Options</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As of December&#160;31, 2020, there were options to purchase 910,272 ordinary shares outstanding with a weighted average exercise price of &#163;62.90 per ordinary share. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Register of Members</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are required by the Companies Act to keep a register of our shareholders. Under the laws of England and Wales, the ordinary shares are deemed to be issued when the name of the shareholder is entered in our register of members. The register of members therefore is prima facie evidence of the identity of our shareholders, and the shares that they hold. The register of members generally provides limited, or no, information regarding the ultimate beneficial owners of our ordinary shares. Our register of members is maintained by our registrar, Computershare Investor Services plc.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">211<br></div></div></div>
<!--End Page 216-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 217-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Holders of our ADSs will not be treated as one of our shareholders and their names will therefore not be entered in our register of members. The depositary, the custodian or their nominees will be the holder of the ordinary shares underlying our ADSs. Holders of our ADSs have a right to receive the ordinary shares underlying their ADSs. For discussion on our ADSs and ADS holder rights, see the section titled &#8220;Description of American Depositary Shares&#8221; in this prospectus. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Companies Act, we must enter an allotment of shares in our register of members as soon as practicable and in any event within two months of the allotment. We will perform all procedures necessary to update the register of members to reflect the ordinary shares being sold in this offering, including updating the share register with the number of ordinary shares to be issued to the depositary upon the closing of this offering. We also are required by the Companies Act to register a transfer of shares (or give the transferee notice of and reasons for refusal) as soon as practicable and in any event within two months of receiving notice of the transfer. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, any of our shareholders or any other affected person, may apply to the court for rectification of the register of members if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the name of any person, without sufficient cause, is wrongly entered in or omitted from our register of members; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">there is a default or unnecessary delay in entering on the register the fact of any person having ceased to be a member or on which we have a lien, provided that such refusal does not prevent dealings in the shares taking place on an open and proper basis.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Registration Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We, the holders of our series A preferred shares, the holders of our series B preferred shares, the holders of our series C preferred shares and certain holders of our ordinary shares entered into the Series C Shareholders&#8217; Agreement which provided that, among other things, certain holders of our series A preferred shares, series B preferred shares and series C preferred shares would benefit from registration rights in the event of an initial public offering. We have granted the following registration rights to such shareholders, subject to customary terms and conditions:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Demand Registration on Form F-1</font> &#8211; following this offering, each holder shall be entitled to demand registration on Form F-1, provided that these demand registration rights may only be exercised by holders who hold, in the aggregate, not less than 30% of the aggregate number of shares held, immediately prior to the completion of this offering, by all holders who are party to the agreement. These demand registration rights may not be exercised more than twice.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Demand Registration on Form F-3</font> &#8211; each holder shall be entitled to demand registration on Form F-3, if we are eligible to register shares on Form F-3, provided that these demand registration rights may only be exercised by holders who hold, in the aggregate, not less than 20% of the aggregate number of shares held, immediately prior to the completion of this offering, by all holders who are party to the agreement. These demand registration rights may not be exercised more than twice in any calendar year.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Piggyback Registration</font> &#8211; each holder shall be entitled to piggyback registration rights, subject, in the case of an underwritten offering, to customary reductions by the underwriter.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">Expenses</font> &#8211; We will pay all registration expenses relating to the exercise of the registration rights above, including the reasonable fees and expenses of one legal counsel to the participating holders up to a maximum of $50,000 in the aggregate.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Preemptive Rights </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The laws of England and Wales generally provide shareholders with preemptive rights when new shares are issued for cash; however, it is possible for the articles of association, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and voting at that general meeting, to disapply these preemptive rights. Such a disapplication of preemptive rights may be for a maximum period of up to five years from the date of adoption of the articles of association, if the disapplication is contained in the articles of association, or from the date of the shareholder resolution, if the disapplication is by shareholder resolution. In either case, this disapplication would need to be renewed by our shareholders upon its expiration (<font style="font-style: italic;">i.e.</font>, at least every five years) to be effective. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">212<br></div></div></div>
<!--End Page 217-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 218-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On &#8195;&#8195;&#8195; 2021, our shareholders approved the disapplication of preemptive rights for the allotment of ordinary shares up to an aggregate nominal amount of &#163;&#8195;&#8195;&#8195;&#8195;&#8195;, including in connection with this offering. This disapplication is effective until &#8195;&#8195;&#8195; 2026. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Articles of Association</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association were approved by a special resolution of our shareholders passed on &#8195;&#8195;&#8195;&#160;2021 and will be effective subject to and conditional upon completion of this offering and listing of ADSs representing our ordinary shares on the Nasdaq. A summary of the terms of the articles of association is set out below. The summary below is not a complete copy of the terms of the articles of association. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The articles of association contain, among other things, provisions to the following effect:</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Objects</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The objects of the Company are unrestricted.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Share Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the Companies Act and any rights attaching to shares already in issue, our shares may be issued with or have attached to them any rights and restrictions as we may by ordinary resolution of the shareholders determine or, in the absence of any such determination, as our board of directors may determine.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to any rights or restrictions attached to any shares from time to time, the general voting rights attaching to shares are as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any resolution put to the vote of a general meeting must be decided exclusively on a poll; on a poll, every shareholder who is present in person or by proxy or corporate representative shall have one vote for each share of which they are the holder. A shareholder entitled to more than one vote need not, if they vote, use all their votes or cast all the votes in the same way; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if two or more persons are joint holders of a share, then in voting on any question the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose seniority shall be determined by the order in which the names of the holders stand in the share register.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Restrictions on Voting</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No shareholder shall be entitled to vote at any general meeting or at any separate class meeting in respect of any share held by him unless all calls or other sums payable by him in respect of that share have been paid.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board may from time to time make calls upon the shareholders in respect of any money unpaid on their shares and each shareholder shall (subject to at least 14 clear days&#8217; notice specifying the time or times and place of payment) pay at the time or times so specified the amount called on their shares.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Dividends</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may, subject to the provisions of the Companies Act and the articles of association, by ordinary resolution of shareholders declare dividends out of profits available for distribution in accordance with the respective rights of shareholders, but no such dividend shall exceed the amount recommended by the board of directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may from time to time pay shareholders such interim dividends as appears to the board to be justified by the profits available for distribution (including any dividends at a fixed rate). If the share capital is divided into different classes, the board of directors may pay interim dividends on shares which confer deferred or non-preferred rights with regard to dividend as well as on shares which confer preferential rights with regard to dividend, but no interim dividend shall be paid on shares carrying deferred or non-preferred rights if, at the time of payment, any preferential dividend is in arrears.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">213<br></div></div></div>
<!--End Page 218-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 219-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may deduct from any dividend or other money payable to any person on or in respect of a share all such sums as may be due from such shareholder to the Company on account of calls or otherwise in relation to the shares of the Company. Sums so deducted can be used to pay amounts owing to the Company in respect of the shares. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to any special rights attaching to or the terms of issue of any share, no dividend or other moneys payable by us on or in respect of any share shall bear interest against us. Any dividend unclaimed after a period of 12&#160;years from the date such dividend became due for payment shall be forfeited and shall revert to us.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividends may be declared or paid in any currency and the board may decide the rate of exchange for any currency conversions that may be required, and how any costs involved are to be met.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may, by ordinary resolution of the Company, direct (or in the case of an interim dividend may without the authority of an ordinary resolution direct) that payment of any dividend declared may be satisfied wholly or partly by the distribution of assets, and in particular of paid up shares or debentures of any other company, or in any one or more of such ways.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Change of Control</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There is no specific provision in our articles of association that would have the effect of delaying, deferring or preventing a change of control.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Distributions on Winding Up</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On a winding up, the liquidator may, with the sanction of a special resolution of shareholders and any other sanction required by law, divide amongst the shareholders in specie the whole or any part of the assets of the Company and may, for that purpose, value any assets and determine how the division shall be carried out as between the shareholders or different classes of shareholders. The liquidator may, with the like sanction, vest the whole or any part of the assets in trustees upon such trusts for the benefit of the shareholders as he may with the like sanction determine, but no shareholder shall be compelled to accept any assets upon which there is a liability.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Variation of Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All or any of the rights and restrictions attached to any class of shares issued may be varied or abrogated with the consent in writing of the holders of not less than three-fourths in nominal value of the issued shares of that class (excluding any shares held as treasury shares) or by special resolution passed at a separate general meeting of the holders of such shares, subject to the Companies Act and the terms of their issue. The Companies Act provides a right to object to the variation of the share capital by the shareholders who did not vote in favor of the variation. Should an aggregate of not less than 15% of the shareholders of the issued shares in question apply to the court to have the variation cancelled, the variation shall have no effect unless and until it is confirmed by the court.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Alteration to Share Capital</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may, by ordinary resolution of shareholders, consolidate all or any of our share capital into shares of larger amount than our existing shares, or sub-divide our shares or any of them into shares of a smaller amount. We may, by special resolution of shareholders, confirmed by the court, reduce our share capital or any capital redemption reserve or any share premium account in any manner authorized by the Companies Act. We may redeem or purchase all or any of our shares as described in &#8220;&#8212;Other English Law Considerations&#8212;Purchase of Own Shares.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association to be in effect upon completion of this offering will provide for non-voting ordinary shares (if any) to be re-designated as ordinary shares in certain circumstances as set out under &#8220;Non-Voting Ordinary Shares&#8221;above. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Allotment of Shares and Preemption Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the Companies Act 2006 and to any rights attached to existing shares, any share may be issued with or have attached to it such rights and restrictions as we may by ordinary resolution determine, or if no ordinary resolution has been passed or so far as the resolution does not make specific provision, as our board of directors may determine (including shares which are to be redeemed, or are liable to be redeemed at our option or the holder of such shares). </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">214<br></div></div></div>
<!--End Page 219-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 220-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Companies Act, the board of directors may be generally and unconditionally authorized to exercise for each prescribed period of up to five years all the powers of the Company to allot shares or grant rights to subscribe for or to convert any security into shares up to an aggregate nominal amount equal to the amount stated in the relevant ordinary resolution authorizing such allotment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">On &#8195;&#8195;&#8195; 2021, our shareholders authorized our board of directors to allot ordinary shares up to an aggregate nominal value of &#163;&#8195;&#8195;&#8195;, including in connection with this offering. This authority is effective until 2026. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In certain circumstances, our shareholders may have statutory preemptive rights under the Companies Act in respect of the allotment of new shares as described in &#8220;&#8212;Preemptive Rights&#8221; and &#8220;&#8212;Differences in Corporate Law &#8212; Preemptive Rights&#8221; in this prospectus.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Transfer of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any shareholder holding shares in certificated form may transfer all or any of his shares by an instrument of transfer in any usual or common form or in any other manner which is permitted by the Companies Act and approved by the board. Any written instrument of transfer shall be signed by or on behalf of the transferor and (in the case of a share which is not fully paid up) the transferee.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All transfers of uncertificated shares shall be made in accordance with and subject to the provisions of the Uncertificated Securities Regulations 2001 and the facilities and requirements of its relevant system. The Uncertificated Securities Regulations 2001 permit shares to be issued and held in uncertificated form and transferred by means of a computer-based system.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may, in its absolute discretion, decline to register any transfer of any share in certificated form unless:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is for a share which is fully paid up;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is for a share upon which the Company has no lien;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is only for one class of share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is in favor of a single transferee or no more than four joint transferees;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is duly stamped or is duly certificated or otherwise shown to the satisfaction of the board to be exempt from stamp duty (if this is required); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is delivered for registration to our registered office (or such other place as the board may determine), accompanied (except in the case of a transfer by a person to whom the Company is not required by law to issue a certificate and to whom a certificate has not been issued or in the case of a renunciation) by the certificate for the shares to which it relates and such other evidence as the board may reasonably require to prove the title of the transferor (or person renouncing) and the due execution of the transfer or renunciation by him or, if the transfer or renunciation is executed by some other person on his behalf, the authority of that person to do so.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may decline to register a transfer of uncertificated shares in any circumstances that are allowed or required by the Uncertificated Securities Regulations 2001 and the requirements of its relevant system.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the board of directors declines to register a transfer it shall, as soon as practicable and in any event within two months after the date on which the transfer is lodged, send to the transferee notice of the refusal, together with reasons for the refusal or, in the case of uncertified shares, notify such persons as may be required by the Uncertified Securities Regulations 2001 and the requirements of the relevant system concerned.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Annual General Meetings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In accordance with the Companies Act, we are required in each year to hold an annual general meeting in addition to any other general meetings in that year and to specify the meeting as such in the notice convening it. The annual general meeting shall be convened whenever and wherever the board sees fit, subject to the requirements of the Companies Act, as described in &#8220;&#8212;Differences in Corporate Law&#8212;Annual General Meeting&#8221; and &#8220;&#8212;Differences in Corporate Law&#8212;Notice of General Meetings&#8221; in this prospectus.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">215<br></div></div></div>
<!--End Page 220-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 221-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Notice of General Meetings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The arrangements for the calling of general meetings are described in &#8220;&#8212;Differences in Corporate Law&#8212;Notice of General Meetings&#8221; in this prospectus.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Quorum of General Meetings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No business shall be transacted at any general meeting unless a quorum is present. At least two shareholders present in person or by proxy and entitled to vote shall be a quorum for all purposes.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Class&#160;Meetings</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The provisions in our articles of association relating to general meetings apply to every separate general meeting of the holders of a class of shares except that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the quorum for such class meeting shall be two holders in person or by proxy representing not less than one-third in nominal value of the issued shares of the class (excluding any shares held in treasury); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if at any adjourned meeting of such holders a quorum is not present at the meeting, one holder of shares of the class present in person or by proxy at an adjourned meeting constitutes a quorum.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Number of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may not have less than two directors or more than fifteen directors on the board of directors. We may, by ordinary resolution of the shareholders, vary the minimum and/or maximum number of directors from time to time. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Appointment of Directors, Classification and Reappointment of Directors</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to our articles of association and the Companies Act, the company may by ordinary resolution appoint a person who is willing to act as a director and the board of directors shall have power at any time to appoint any person who is willing to act as a director, in both cases either to fill a vacancy or as an addition to the existing board of directors, provided the total number of directors shall not exceed the maximum number of fifteen. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our articles of association provide that our board of directors will be divided into three classes, each of which will consist, as nearly as possible, of one-third of the total number of directors constituting our entire board and which will serve staggered three-year terms. At each annual general meeting, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual general meeting following election. Directors of the class retiring at the annual general meeting shall be eligible for re-appointment by ordinary resolution at such annual general meeting.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At every subsequent annual general meeting, any director who has been appointed by the board of directors since the last annual general meeting, must retire from office and may offer themselves for reappointment by the shareholders by ordinary resolution.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Directors&#8217; Interests</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The directors may authorize, to the fullest extent permitted by law, any matter or situation proposed to them which would otherwise result in a director infringing his duty to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with our interests. A director shall not, save as otherwise agreed by him, be accountable to us for any remuneration, profit or other benefit which he derives from any matter authorized by the directors or by the shareholders in general meeting and no contract shall be liable to be avoided on any such grounds.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the requirements under sections 175, 177 and 182 of the Companies Act, a director who is any way, whether directly or indirectly, interested in a proposed or existing transaction or arrangement with us shall declare the nature of his interest at a meeting of the directors.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A director shall not vote in respect of any transactions or, arrangement with the Company in which he has an interest and which may reasonably be regarded as likely to give rise to a conflict of interest. A director shall not be counted in the quorum at a meeting in relation to any resolution on which he is debarred from voting.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">216<br></div></div></div>
<!--End Page 221-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 222-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A director shall be entitled to vote (and be counted in the quorum) in respect of any resolution concerning any of the following matters:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the giving of any guarantee, security or indemnity in respect of money lent or obligations incurred by him or by any other person at the request of or for the benefit of our company or any of our subsidiary undertakings;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the giving of any guarantee, security or indemnity in respect of a debt or obligation of our company or any of our subsidiary undertakings for which he himself has assumed responsibility in whole or in part under a guarantee or indemnity or by the giving of security;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any proposal or contract relating to an offer of securities of or by our company or any of our subsidiary undertakings in which offer he is or may be entitled to participate as a holder of securities or in the underwriting or sub-underwriting of which he is to participate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any arrangement involving any other company if the director (together with any person connected with him) has an interest of any kind in that company (including an interest by holding any position in that company or by being a member of that company), unless he is to his knowledge (either directly or indirectly) the holder of or beneficially interested in one per cent or more of any class of the equity share capital of that company (calculated exclusive of any shares of that class in that company held as treasury shares) or of the voting rights available to members of that company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any arrangement for the benefit of employees of our company or any of our subsidiary undertakings which only gives him benefits which are also generally given to employees to whom the arrangement relates;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any contract relating to insurance which our company is to buy or renew for the benefit of the directors or a group of people which includes directors; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a contract relating to a pension, superannuation or similar scheme or a retirement, death, disability benefits scheme or employees&#8217; share scheme which gives the director benefits which are also generally given to the employees to whom the scheme relates.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a question arises at a meeting of the board or of a committee of the board as to the right of a director to vote or be counted in the quorum, and such question is not resolved by his voluntarily agreeing to abstain from voting or not to be counted in the quorum, the question shall be determined by the Chairman and his ruling in relation to any director other than himself shall be final and conclusive except in a case where the nature or extent of the interest of the director concerned has not been fairly disclosed. If the question arises about the Chairman, the question must be directed to the directors. The Chairman cannot vote on the question but can be counted in the quorum. The directors&#8217; resolution about the chairman is final and conclusive, unless the nature and extent of the Chairman&#8217;s interests have not been fairly disclosed to the directors.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Directors&#8217; Fees and Remuneration</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each of the directors shall be paid a fee at such rate as may from time to time be determined by the board (or for the avoidance of doubt any duly authorized committee of the board) provided that the aggregate of all such fees so paid to directors shall not exceed $&#8195;&#8195;&#8195; per annum, or such higher amount as may from time to time be determined by ordinary resolution of the shareholders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each director may be paid his reasonable traveling, hotel and other expenses of attending and returning from meetings of the board or committees of the board or general meetings or separate meetings of the holders of any class of shares or of debentures and shall be paid all expenses properly incurred by him in the conduct of the Company&#8217;s business. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any director who is appointed to any executive office or who serves on any committee or who devotes special attention to the business of our company, or who otherwise performs services which in the opinion of the directors are outside the scope of the ordinary duties of a director, may be paid such extra remuneration by way of salary, commissions, participation in profits or otherwise as the directors may determine.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Borrowing Powers</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The board of directors may exercise all the powers to borrow money, provide any indemnity or guarantee, and to mortgage or charge our undertaking, property and assets (present or future) and uncalled capital or any </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">217<br></div></div></div>
<!--End Page 222-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 223-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">part thereof, to create and issue debentures and other securities and to give security, whether outright or as collateral security for any debt, liability or obligation of us or of any third party.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Indemnity</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Every director or other office of our group may be indemnified against all costs, charges, expenses, losses and liabilities sustained or incurred by them in connection with that director&#8217;s or officer&#8217;s duties or powers in relation to the Company or other members of our group. See also &#8220;Indemnification of directors and officers&#8221; in Part II below.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Relevant English Law Considerations</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Mandatory Bid</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We believe that, at the date of this prospectus, our place of central management and control is not in the United Kingdom (or the Channel Islands or the Isle of Man) for the purposes of the jurisdictional criteria of the Takeover Code. Accordingly, we believe that we are currently not subject to the Takeover Code and, as a result, our shareholders are not currently entitled to benefit from certain takeover offer protections provided under the Takeover Code, including the rules regarding mandatory takeover bids (a summary of which is set out below). In the event that this changes, or if the interpretation or application of the Takeover Code by the Takeover Panel changes (including changes to the way in which the Takeover Panel assesses the application of the Takeover Code to English companies whose shares are listed outside the United Kingdom), the Takeover Code may apply to us in the future. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Under the Takeover Code, where:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any person, together with persons acting in concert with him, acquires, whether by a series of transactions over a period of time or not, an interest in shares which (taken together with shares in which he is already interested, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any person who, together with persons acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights and such person, or any person acting in concert with him, acquires an interest in any other shares which increases the percentage of shares carrying voting rights in which he is interested,</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">such person shall, except in limited circumstances, be obliged to extend offers, on the basis set out in Rules 9.3, 9.4 and 9.5 of the Takeover Code, to the holders of any class of equity share capital, whether voting or non-voting, and also to the holders of any other class of transferable securities carrying voting rights. Offers for different classes of equity share capital must be comparable; the Takeover Panel should be consulted in advance in such cases. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An offer under Rule 9 of the Takeover Code must be in cash and at the highest price paid for any interest in the shares by the person required to make an offer or any person acting in concert with him during the 12&#160;months prior to the announcement of the offer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Takeover Code, a &#8220;concert party&#8221; arises where persons acting together pursuant to an agreement or understanding (whether formal or informal and whether or not in writing) actively cooperate, through the acquisition by them of an interest in shares in a company, to obtain or consolidate control of the company. &#8220;Control&#8221; means holding, or aggregate holdings, of an interest in shares carrying 30% or more of the voting rights of the company, irrespective of whether the holding or holdings give de facto control.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Mandatory Purchases and Acquisitions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Sections 979 to 991 of the Companies Act, where a takeover offer has been made for us and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the shares to which the offer relates and not less than 90% of the voting rights carried by those shares, the offeror may give notice to the holder of any shares to which the offer relates which the offeror has not acquired or unconditionally contracted to acquire that he wishes to acquire, and is entitled to so acquire, those shares on the same terms as the general offer. The offeror would do so by sending a notice to the outstanding minority shareholders telling them that it will compulsorily acquire their shares.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">218<br></div></div></div>
<!--End Page 223-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 224-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Such notice must be sent within three months of the last day on which the offer can be accepted in the prescribed manner or if earlier, and the offer is not one to which section 943(1) of the Companies Act 2006 applies, within the period of six months beginning with the date of the offer. The squeeze out of the minority shareholders can be completed at the end of six weeks from the date the notice has been given, subject to the minority shareholders failing to successfully lodge an application to the court to prevent such squeeze out any time prior to the end of those six weeks following which the offeror can execute a transfer of the outstanding shares in its favor and pay the consideration to us, which would hold the consideration on trust for the outstanding minority shareholders. The consideration offered to the outstanding minority shareholders whose shares are compulsorily acquired under the Companies Act must, in general, be the same as the consideration that was available under the takeover offer.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Sell Out</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The Companies Act also gives our minority shareholders a right to be bought out in certain circumstances by an offeror who has made a takeover offer for all of our shares. The holder of shares to which the offer relates, and who has not otherwise accepted the offer, may require the offeror to acquire his shares if, prior to the expiry of the acceptance period for such offer, (1) the offeror has acquired or unconditionally agreed to acquire not less than 90% in value of the voting shares, and (2) not less than 90% of the voting rights carried by those shares. The offeror may impose a time limit on the rights of minority shareholders to be bought out that is not less than three months after the end of the acceptance period. If a shareholder exercises his rights to be bought out, the offeror is required to acquire those shares on the terms of this offer or on such other terms as may be agreed.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Disclosure of Interest in Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to Part 22 of the Companies Act and our articles of association, we are empowered by notice in writing to any person whom we know or have reasonable cause to believe to be interested in our shares, or at any time during the three years immediately preceding the date on which the notice is issued has been so interested, within a reasonable time to disclose to us particulars of that person&#8217;s interest and (so far as is within his knowledge) particulars of any other interest that subsists or subsisted in those shares.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under our articles of association, if a person defaults in supplying us with the required particulars in relation to the shares in question, or default shares, within the prescribed period, the directors may by notice direct that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in respect of the default shares, the relevant shareholder shall not be entitled to vote (either in person or by representative or proxy) at any general meeting or to exercise any other right conferred by a shareholding in relation to general meetings; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">where the default shares represent at least 0.25% in nominal value of the issued shares of their class, (a)&#160;any dividend or other money payable in respect of the default shares shall be retained by us without liability to pay interest and/or (b) no transfers by the relevant shareholder of any default shares may be registered (unless the shareholder himself is not in default and the shareholder provides a certificate, in a form satisfactory to the directors, to the effect that after due and careful enquiry the shareholder is satisfied that none of the shares to be transferred are default shares).</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Purchase of Own Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the laws of England and Wales, a limited company may only purchase its own shares out of the distributable profits of the Company or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, subject to complying with procedural requirements under the Companies Act and provided that they are not restricted from doing so by their articles of association. A limited company may not purchase its own shares if, as a result of the purchase, there would no longer be any issued shares of the Company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any such purchase will be either a &#8220;market purchase&#8221; or &#8220;off market purchase,&#8221; each as defined in the Companies Act. A &#8220;market purchase&#8221; is a purchase made on a &#8220;recognized investment exchange&#8221; (other than an overseas exchange) as defined in the U.K. Financial Services and Markets Act 2000, as amended, or FSMA. An &#8220;off market purchase&#8221; is a purchase that is not made on a &#8220;recognized investment exchange.&#8221; Both &#8220;market purchases&#8221; and &#8220;off market purchases&#8221; require prior shareholder approval by way of an ordinary resolution. In the case of an &#8220;off market purchase,&#8221; a company&#8217;s shareholders, other than the shareholders from whom the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">219<br></div></div></div>
<!--End Page 224-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 225-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">company is purchasing shares, must approve the terms of the contract to purchase shares and in the case of a &#8220;market purchase,&#8221; the shareholders must approve the maximum number of shares that can be purchased and the maximum and minimum prices to be paid by the company. Both resolutions authorizing &#8220;market purchases&#8221; and &#8220;off-market purchases&#8221; must specify a date, not later than five years after the passing of the resolution, on which the authority to purchase is to expire.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A share buy-back by a company of its shares will give rise to U.K. stamp duty reserve tax and stamp duty at the rate of 0.5% of the amount or value of the consideration payable by the company (rounded up to the next &#163;5.00), and such stamp duty reserve tax or stamp duty will be paid by the company. The charge to stamp duty reserve tax will be cancelled or, if already paid, repaid (generally with interest), where a transfer instrument for stamp duty purposes has been duly stamped within six years of the charge arising (either by paying the stamp duty or by claiming an appropriate relief) or if the instrument is otherwise exempt from stamp duty.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Nasdaq is an &#8220;overseas exchange&#8221; for the purposes of the Companies Act and does not fall within the definition of a &#8220;recognized investment exchange&#8221; for the purposes of FSMA and any purchase made by us would need to comply with the procedural requirements under the Companies Act that regulate &#8220;off market purchases.&#8221; </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Distributions and Dividends</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Companies Act, before a company can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves (on a non consolidated basis). The basic rule is that a company&#8217;s profits available for the purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under the laws of England and Wales.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">It is not sufficient that we, as a public company, have made a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the Company is at least equal to the amount of its capital. A public company can only make a distribution:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if, at the time that the distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if, and to the extent that, the distribution itself, at the time that it is made, does not reduce the amount of the net assets to less than that total.</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Shareholder Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain rights granted under the Companies Act, including the right to requisition a general meeting or require a resolution to be put to shareholders at the annual general meeting, are only available to our shareholders. For English law purposes, our shareholders are the persons who are registered as the owners of the legal title to the shares and whose names are recorded in our share register. If a person who holds their ADSs in DTC wishes to exercise certain of the rights granted under the Companies Act, they may be required to first take steps to withdraw their ADSs from the settlement system operated by DTC and become the registered holder of the shares in our share register. A withdrawal of shares from DTC may have tax implications. </div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Exchange Controls</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by us to non resident holders of our ordinary shares or ADSs representing our ordinary shares, other than withholding tax requirements. There is no limitation imposed by the laws of England and Wales or in the articles of association on the right of non residents to hold or vote shares.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Differences in Corporate Law</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The applicable provisions of the Companies Act differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">220<br></div></div></div>
<!--End Page 225-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 226-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and the laws of England and Wales.<font style="font-style: normal;"> </font></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#8217;s articles of association.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Removal of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy at a general meeting) irrespective of any provisions of any service contract the director has with the Company, provided 28 clear days&#8217; notice of the resolution has been given to the Company and its shareholders. On receipt of notice of an intended resolution to remove a director, the Company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the. Companies Act must also be followed such as allowing the director to make representations against his or her removal either at the meeting or in writing.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (a)&#160;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, shareholders may effect such removal only for cause, or (b) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vacancies on the Board of Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the laws of England and Wales, the procedure by which directors, other than a company&#8217;s initial directors, are appointed is generally set out in a company&#8217;s articles of association, provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders, resolutions appointing each director must be voted on individually.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (a) otherwise provided in the certificate of incorporation or by-laws of the corporation or (b) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">221<br></div></div></div>
<!--End Page 226-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 227-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Annual General Meeting</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, a public limited company must hold an annual general meeting in each six-month period following its annual accounting reference date.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General Meeting</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, a general meeting of the shareholders of a public limited company may be called by the directors. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholders holding at least 5% of the paid-up capital of the Company carrying voting rights at general meetings (excluding any paid up capital held as treasury shares) can require the directors to call a general meeting and, if the directors fail to do so within a certain period, may themselves (or any of them representing more than one half of the total voting rights of all of them) convene a general meeting.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notice of General Meetings</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subject to a company&#8217;s articles of association providing for a longer period, under the Companies Act, 21 clear days&#8217; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company&#8217;s articles of association providing for a longer period, at least 14&#160;clear days&#8217; notice is required for any other general meeting. In addition, certain matters, such as the removal of directors or auditors, require special notice, which is 28 clear days&#8217; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#8217; consent required being 100% of those entitled to attend and vote in the case of an annual general meeting and, in the case of any other general meeting, a majority in number of the members having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to attend and vote at the meeting.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">222<br></div></div></div>
<!--End Page 227-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 228-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Quorum</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subject to the provisions of a company&#8217;s articles of association, the Companies Act provides that two shareholders present at a meeting (in person, by proxy or authorized representative under the Companies Act) shall constitute a quorum for companies with more than one member.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one third of the shares entitled to vote at the meeting. In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by proxy.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preemptive Rights</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, &#8220;equity securities,&#8221; being (1) shares in the Company other than shares that, with respect to dividends and capital, carry a right to participate only up to a specified amount in a distribution, referred to as &#8220;ordinary shares,&#8221; or (2)&#160;rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing equity shareholders in the Company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise in each case in accordance with the provisions of the Companies Act.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Authority to Allot</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, the directors of a company must not allot shares or grant of rights to subscribe for or to convert any security into shares unless an exception applies or an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, if the corporation&#8217;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">223<br></div></div></div>
<!--End Page 228-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 229-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">otherwise in each case in accordance with the provisions of the Companies Act.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">combination thereof. It may determine the amount of such consideration by approving a formula. In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liability of Directors and Officers</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the Companies Act, any provision, whether contained in a company&#8217;s articles of association or any contract or otherwise, that purports to exempt a director of a company, to any extent, from any liability that would otherwise attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the Company is void.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the Company or of an associated company against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the Company of which he is a director is also void except as permitted by the Companies Act, which provides exceptions for the Company to (a) purchase and maintain insurance against such liability; (b) provide a &#8220;qualifying third party indemnity&#8221; (being an indemnity against liability incurred by the director to a person other than the Company or an associated company or criminal proceedings in which he is convicted); and (c) provide a &#8220;qualifying pension scheme indemnity&#8221; (being an indemnity against liability incurred in connection with our activities as trustee of an occupational pension plan). </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for: <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders; <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;intentional or negligent payment of unlawful dividends or stock purchases or redemptions; or<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;any transaction from which the director derives an improper personal benefit. </div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Voting Rights</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">For a company incorporated under the laws of England and Wales, it is usual for the articles of association to provide that, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or our articles of association, shareholders shall vote on all resolutions on a show of hands. Under the Companies Act, a poll may be demanded by (a) not fewer than five shareholders having the right to vote on the resolution; (b) any</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">224<br></div></div></div>
<!--End Page 229-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 230-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">shareholder(s) representing not less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution (excluding any voting rights attaching to treasury shares); or (c) any shareholder(s) holding shares in the Company conferring a right to vote on the resolution (excluding any voting rights attaching to treasury shares) being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares conferring that right. A company&#8217;s articles of association may provide more extensive rights for shareholders to call a poll.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the laws of England and Wales, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or by proxy, who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting. If a poll is demanded, a special resolution is passed if it is approved by holders representing not less than 75% of the total voting rights of shareholders in person or by proxy who, being entitled to vote, vote on the resolution.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholder Vote on Certain Transactions</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Companies Act provides for schemes of arrangement, which are arrangements or compromises between a company and any class of shareholders or creditors and used in certain types of reconstructions, amalgamations, capital reorganizations, or takeovers. These arrangements require: <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;the approval at a shareholders&#8217; or creditors&#8217; meeting convened by order of the court, of a majority in number of shareholders or creditors or a class thereof representing 75% in value of the capital held by, or debt owed to, the </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-align: left;">class of shareholders or creditors, or </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires:<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;the approval of the board of directors; and<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">225<br></div></div></div>
<!--End Page 230-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 231-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-align: left;">class thereof present and voting, either in person or by proxy; and<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8226;&#8195;the approval of the court. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-align: left;">a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Standard of Conduct for Directors</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the laws of England and Wales, a director owes various statutory and fiduciary duties to the Company, including: <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;to act in the way he considers, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole, and in doing so have regard (amongst other matters) to: (i)&#160;the likely consequences of any decision in the long-term, (ii)&#160;the interests of the company&#8217;s employees, (iii)&#160;the need to foster the company&#8217;s business relationships with suppliers, customers and others, (iv)&#160;the impact of the company&#8217;s operations on the community and the environment, (v)&#160;the desirability to maintain a reputation for high standards of business conduct, and (vi)&#160;the need to act fairly as between members of the company;<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;to avoid a situation in which he has, or can have, a direct or indirect interest that conflicts, or possibly conflicts, with the interests of the Company;<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;to act in accordance with our constitution and only exercise his powers for the purposes for which they are conferred;<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;to exercise independent judgment;<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;to exercise reasonable care, skill, and diligence; <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;not to accept benefits from a third party conferred by reason of his being a director or doing, or not doing, anything as a director; and <br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.21pt; text-indent: -14.21pt; text-align: left;">&#8226;&#8195;a duty to declare any interest that he has, whether directly or indirectly, in a proposed or existing transaction or arrangement with the Company. </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders. <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders. </div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">226<br></div></div></div>
<!--End Page 231-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 232-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 4pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">England and Wales</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 37.18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: top; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shareholder Litigation</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under the laws of England and Wales, generally, the Company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the Company or where there is an irregularity in the Company&#8217;s internal management. Notwithstanding this general position, the Companies Act provides that (1) a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf of the Company) in respect of a cause of action arising from a director&#8217;s negligence, default, breach of duty or breach of trust and (2)&#160;a shareholder may bring a claim for a court order where our affairs have been or are being conducted in a manner that is unfairly prejudicial to some of its shareholders.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt;">&#8203;</td><td style="width: 37.18%; text-align: left; vertical-align: top; padding-top: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must:<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action; or<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.6pt; text-indent: -14.6pt; text-align: left;">&#8226;&#8195;state the reasons for not making the effort.<br>&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stock Exchange Listing</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#8220;IMCR.&#8221; </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Registrar of Shares, Depositary for ADSs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Our register of members is maintained by Computershare Investor Services plc. The share register reflects only registered holders of our ordinary shares. Holders of ADSs representing our ordinary shares are not treated as our shareholders and their names will therefore not be entered in our share register. Citibank, N.A., has agreed to act as the depositary for the ADSs representing our ordinary shares and the custodian for ordinary shares represented by ADSs will be Citibank, N.A., London Branch. Holders of ADSs representing our ordinary shares have a right to receive the ordinary shares underlying such ADSs. For discussion on ADSs representing our ordinary shares and rights of ADS holders, see the section titled &#8220;Description of American Depositary Shares.&#8221; </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">227<br></div></div></div>
<!--End Page 232-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 233-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDADS"><!--Anchor--></a>DESCRIPTION OF AMERICAN DEPOSITARY SHARES</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">American Depositary Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Citibank, N.A., or Citibank, has agreed to act as the depositary for the ADSs representing our ordinary shares. Citibank&#8217;s depositary offices are located at 388 Greenwich Street, New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A., London Branch, located at 25&#160;Canada Square, Canary Wharf, London, E14 5LB, United Kingdom.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have appointed Citibank as depositary pursuant to a deposit agreement. The form of the deposit agreement is on file with the SEC under cover of a registration statement on Form F-6. You may obtain a copy of the deposit agreement from the SEC&#8217;s website (<font style="font-style: italic;">www.sec.gov</font>). Please refer to registration number 333-&#8195;&#8195;&#8195;&#8195;when retrieving such copy.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit with the depositary or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the ADS-to-share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your behalf in certain circumstances. The deposit agreement and the ADRs and ADSs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of England and Wales, which may be different from the laws in the United States.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. None of the depositary, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. You agree to comply with information requests from us pursuant to applicable laws, stock exchange rules and our articles of association. We may restrict transfers of ADSs and take other actions necessary to comply with any applicable ownership restrictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the ordinary </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">228<br></div></div></div>
<!--End Page 233-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 234-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The manner in which you own the ADSs (<font style="font-style: italic;">e.g.</font>, in a brokerage account versus as a registered holder, or as a holder of certificated versus uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary&#8217;s services are made available to you.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs, you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary (commonly referred to as the direct registration system or DRS). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary to the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC, which nominee will be the only &#8220;holder&#8221; of such ADSs for purposes of the deposit agreement and any applicable ADR. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#8220;holder.&#8221; When we refer to &#8220;you,&#8221; we assume the reader owns ADSs and will own ADSs at the relevant time.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The registration of the ordinary shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Dividends and Other Distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deduction the applicable fees, taxes and expenses.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Distributions of Cash</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of England and Wales. The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">229<br></div></div></div>
<!--End Page 234-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 235-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Distributions of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs representing the ordinary shares deposited or modify the ADS-to-ordinary shares ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The distribution of new ADSs or the modification of the ADS-to-ordinary shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No such distribution of new ADSs will be made if it would violate a law (<font style="font-style: italic;">e.g.</font>, the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Distributions of Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to purchase additional ADSs to holders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other represented by ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will <font style="font-style: italic;">not</font> distribute the rights to you if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we fail to deliver satisfactory documents to the depositary; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is not reasonably practicable to distribute the rights.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Elective Distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">230<br></div></div></div>
<!--End Page 235-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 236-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in England and Wales would receive upon failing to make an election, as more fully described in the deposit agreement.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Other Distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will <font style="font-style: italic;">not</font> distribute the property to you and will sell the property if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we do not request that the property be distributed to you or if we ask that the property not be distributed to you; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we do not deliver satisfactory documents to the depositary; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the depositary determines that all or a portion of the distribution to you is not reasonably practicable.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Redemption</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a <font style="font-style: italic;">pro rata</font> basis, as the depositary may determine.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Changes Affecting Ordinary Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal value, sub-division, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of our company.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable registration statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Issuance of ADSs upon Deposit of Ordinary Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the completion of the U.S. offering, the ordinary shares being offered pursuant to this prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the underwriters named in this prospectus.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">231<br></div></div></div>
<!--End Page 236-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 237-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After the completion of this offering, the depositary may also create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian and provide such documentation as may be required pursuant to the deposit agreement. Your ability to deposit ordinary shares and receive ADSs may be limited by legal considerations under the laws of the United States and England and Wales applicable at the time of deposit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The issuance of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ordinary shares are duly authorized, validly allotted and issued, fully paid, not subject to any call for the payment of further capital and legally obtained;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived, disapplied or exercised;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">you are duly authorized to deposit the ordinary shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the deposit agreement); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ordinary shares presented for deposit have not been stripped of any rights or entitlements.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Transfer, Combination and Split Up of ADRs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary and also must:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide such proof of identity and genuineness of signatures, and of such other matters contemplated in the deposit agreement, as the depositary deems appropriate;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">comply with applicable laws and regulations, including regulations imposed by us and the depositary consistent with the deposit agreement, the ADR and applicable law;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide any transfer stamps required by the State of New York or the United States; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Withdrawal of Ordinary Shares Upon Cancellation of ADSs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a holder of ADSs, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian&#8217;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by legal considerations under the laws of the United States and England and Wales applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">232<br></div></div></div>
<!--End Page 237-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 238-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You will have the right to withdraw the securities represented by your ADSs at any time except as a result of:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">temporary delays that may arise because (1) the transfer books for the ordinary shares or ADSs are closed, or (2) ordinary shares are immobilized on account of a shareholders&#8217; meeting or a payment of dividends;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obligations to pay fees, taxes and similar charges; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in the section titled &#8220;Description of Share Capital and Articles of Association&#8221; in this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">At our request, the depositary will distribute to you any notice of shareholders&#8217; meeting received from us together with information explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#8217;s ADSs as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">In the event of voting by show of hands</font>, the depositary will vote (or cause the custodian to vote) all ordinary shares held on deposit at that time in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-style: italic;">In the event of voting by poll</font>, the depositary will vote (or cause the custodian to vote) the ordinary shares held on deposit in accordance with the voting instructions received from the holders of ADSs.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Note that our articles of association currently provide for all resolutions to be decided as a poll, not a show of hands. The depositary will not join in demanding a vote by poll.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Securities for which no voting instructions have been received will not be voted (except (a) if voting is by show of hands, in which case the depositary will vote all deposited securities in accordance with voting instructions received from a majority of holders who provided voting instructions, and (b) as otherwise contemplated herein). Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">233<br></div></div></div>
<!--End Page 238-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 239-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Fees and Charges</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement:</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 64.1%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Service</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fee</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance of ADSs (<font style="font-style: italic;">e.g.</font>, an issuance of ADS upon a deposit of ordinary shares or upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS issued</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cancellation of ADSs (<font style="font-style: italic;">e.g.</font>, a cancellation of ADSs for delivery of deposited property or upon a change in the ADS(s)-to-ordinary shares ratio, or for any other reason)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS cancelled</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Distribution of cash dividends or other cash distributions (<font style="font-style: italic;">e.g.</font>, upon a sale of rights and other entitlements)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS held</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Distribution of ADSs pursuant to (i)&#160;share dividends or other distributions, or (ii)&#160;exercise of rights to purchase additional ADSs</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS held</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Distribution of securities other than ADSs or rights to purchase additional ADSs (<font style="font-style: italic;">e.g.</font>, upon a spin-off)</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS held</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ADS services</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 33.33%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Up to $0.05 per ADS held on the applicable record date(s) established by the depositary</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an ADS holder, you will also be responsible to pay certain charges such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">taxes (including applicable interest and penalties) and other governmental charges;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">certain cable, telex and facsimile transmission and delivery expenses;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expenses and charges incurred by the depositary in the conversion of foreign currency;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fees and expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fees and expenses incurred by the depositary, the custodian, or any nominee in connection with the servicing or delivery of deposited property.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADS fees and charges payable upon (i)&#160;the issuance of ADSs, and (ii)&#160;the cancellation of ADSs are charged to the person to whom the ADSs are issued (in the case of ADS issuances) and to the person whose ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&#160;distributions other than cash and (ii)&#160;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">234<br></div></div></div>
<!--End Page 239-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 240-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the event of refusal to pay the depositary fees or charges, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees and charges from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of this offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of such changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADSs, by making available a portion of the ADS fees charged in respect of the ADSs or otherwise, upon such terms and conditions as we and the depositary agree from time to time.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Amendments and Termination</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give holders of ADSs 30 days&#8217; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have the right to direct the depositary to terminate the deposit agreement subject to certain conditions. Similarly, the depositary may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary will have no further obligations to ADS holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses).</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the termination of the deposit agreement, the depositary may, but shall not be obligated to, independently and without the need for any action by us, make available to holders of ADSs a means to withdraw the ordinary shares and other deposited securities represented by their ADSs and to direct the deposit of such ordinary shares and other deposited securities into an unsponsored American depositary shares program established by the depositary, upon such terms and conditions as the depositary may deem reasonably appropriate, subject however, in each case, to satisfaction of the applicable registration requirements by the unsponsored American depositary shares program under the Securities Act, and to receipt by the depositary of payment of the applicable fees and charges of, and reimbursement of the applicable expenses incurred by, the depositary.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Books of Depositary</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary maintains ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary maintains in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Transmission of Notices, Reports and Proxy Soliciting Material</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. Subject </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">235<br></div></div></div>
<!--End Page 240-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 241-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to the terms of the deposit agreement, the depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Limitations on Obligations and Liabilities</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The deposit agreement limits our obligations and the depositary&#8217;s obligations to you. Please note the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The depositary disclaims any liability for any failure to accurately determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs or other deposited property, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice or for any act or omission of or information provided by DTC or any DTC participant.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The depositary shall not be liable for acts or omissions of any successor depositary in connection with any matter arising wholly after the resignation or removal of the depositary.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, including regulations of any stock exchange or by reason of present or future provisions of our articles of association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our or the depositary&#8217;s control.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our articles of association or in any provisions of or governing the securities on deposit.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary also disclaim liability for the inability by any ADS holder or beneficiary owner to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">We and the depositary disclaim liability arising out of losses, liabilities, taxes, charges or expenses resulting from the manner in which a holder or beneficial owner of ADSs holds ADSs, including resulting from holding ADSs through a brokerage account.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary and you as ADS holder.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">236<br></div></div></div>
<!--End Page 241-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 242-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Taxes</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11pt;">As a Holder or Beneficial Owner of ADSs, you will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs as provided for in the deposit agreement. We, the depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by Holders and Beneficial Owners (as defined in the deposit agreement) of ADSs and may sell any and all property on deposit to pay the taxes and governmental charges payable by ADS holders. As a Holder or Beneficial Owner of ADSs, you will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. Notwithstanding the foregoing, we expect to bear the cost of stamp duty or stamp duty reserve tax, if any, payable in respect of the issue of ordinary shares to the depositary in this offering.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left; line-height: 11pt;">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable Holder or Beneficial Owner (as defined in the deposit agreement) of ADSs. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Foreign Currency Conversion</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary may take any of the following actions in its discretion:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the ADS holders for whom the conversion and distribution is lawful and practical.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Distribute the foreign currency to ADS holders for whom the distribution is lawful and practical.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Hold the foreign currency (without liability for interest) for the applicable ADS holders.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Governing Law / Waiver of Jury Trial</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The deposit agreement and the ADRs and ADSs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of England and Wales.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As an owner of ADSs, you irrevocably agree that any legal action arising out of the Deposit Agreement, the ADSs or the ADRs, involving the Company or the Depositary, may only be instituted in a state or federal court in the city of New York.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU WAIVE IRREVOCABLY YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADSs AGAINST US AND/OR THE DEPOSITARY.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">237<br></div></div></div>
<!--End Page 242-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 243-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tOSAA"><!--Anchor--></a>ORDINARY SHARES AND ADSs ELIGIBLE FOR FUTURE SALE</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Future sales of ordinary shares ADSs in the public market after this offering, and the availability of ordinary shares and ADSs for future sale, could adversely affect the market price of the ordinary shares and ADSs prevailing from time to time. As described below, a significant number of currently outstanding ordinary shares will not be available for sale shortly after this offering due to contractual restrictions on transfers. There may be sales of substantial amounts of our ADSs in the public market after such restrictions lapse. Sales of substantial amounts of ADSs, or the perception that these sales could occur, could adversely affect prevailing market prices for ordinary shares and ADSs and could impair our ability to raise equity capital in the future.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on the number of ordinary shares outstanding as of December&#160;31, 2020, and assuming (1) no exercise of the underwriters&#8217; option to purchase additional ADSs, and (2) no exercise of any of our outstanding options, we will have outstanding an aggregate of&#8195;&#8195;&#8195;ordinary shares, including ordinary shares represented by ADSs, following this offering. All of the ADSs to be sold in this offering and any ADSs sold upon exercise of the underwriters&#8217; option to purchase additional ADSs, will be freely tradable in the U.S. public market without restriction or further registration under the Securities Act, unless the ADSs are held by any of our &#8220;affiliates&#8221; as such term is defined in Rule 144 of the Securities Act, subject, in each case, to the terms of the lock-up agreements referred to below, as applicable. The number of ADSs available for sale immediately after this offering will be the number sold in this offering less any ADSs held by our directors, officers and certain shareholders are subject to lock-up agreements through 180 days after the date of this prospectus.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Lock-up Agreements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We expect that all of our directors and executive officers and certain of our existing shareholders will agree, subject to limited exceptions, with the underwriters not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of our ADSs, ordinary shares or such other securities for a period of 180 days after the date of this prospectus, without the prior written consent of Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC. See &#8220;Underwriting.&#8221; Following the lock-up periods set forth in the agreements described above, and assuming that the representatives of the underwriters do not release any parties from these agreements, all of the ADSs and ordinary shares that are held by these parties as of the date of this prospectus will be eligible for sale in the public market in compliance with Rule 144 under the Securities Act.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Rule 144</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In general, persons who have beneficially owned restricted ordinary shares for at least six months, and any affiliate of the Company who owns either restricted or unrestricted ordinary shares, are entitled to sell their securities without registration with the SEC under an exemption from registration provided by Rule 144 under the Securities Act.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Non-Affiliates </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any person who is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale may sell an unlimited number of restricted securities under Rule 144 if:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the restricted securities have been held for at least six months, including the holding period of any prior owner other than one of our affiliates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we have been subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we are current in our Exchange Act reporting at the time of sale. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any person who is not deemed to have been an affiliate of ours at the time of, or at any time during the three months preceding, a sale and has held the restricted securities for at least one year, including the holding period of any prior owner other than one of our affiliates, will be entitled to sell an unlimited number of restricted securities without regard to the length of time we have been subject to Exchange Act periodic reporting or whether we are current in our Exchange Act reporting. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">238<br></div></div></div>
<!--End Page 243-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 244-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_112-desc_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Affiliates </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Persons seeking to sell restricted securities who are our affiliates at the time of, or any time during the three months preceding, a sale, would be subject to the restrictions described above. They are also subject to additional restrictions, by which such person would be required to comply with the manner of sale and notice provisions of Rule 144 and would be entitled to sell within any three-month period only that number of securities that does not exceed the greater of either of the following:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">1% of the number of ordinary shares then outstanding, being represented by ADSs or otherwise, which will equal approximately&#8195;&#8195;&#8195;ordinary shares immediately after the closing of this offering based on the number of ordinary shares outstanding as of&#8195;&#8195;&#8195;, 2020; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the average weekly trading volume of our ADSs on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Additionally, persons who are our affiliates at the time of, or any time during the three months preceding, a sale may sell unrestricted securities under the requirements of Rule 144 described above, without regard to the six-month holding period of Rule 144, which does not apply to sales of unrestricted securities. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Rule 701</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Rule 701 under the Securities Act, as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule 144 but without compliance with certain restrictions of Rule 144, including the holding period requirement. Most of our employees, executive officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule 701, but all holders of Rule&#160;701 shares are required to wait until 90 days after the date of this prospectus before selling their shares. However, substantially all Rule 701 shares are subject to lock-up agreements as described below and in the section of this prospectus titled &#8220;Underwriting&#8221; and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Form S-8 Registration Statements</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As soon as practicable after the closing of this offering, we intend to file with the SEC one or more registration statements on Form S-8 under the Securities Act to register the ordinary shares subject to outstanding stock options or reserved for issuance under our equity incentive plans. These registration statements will become effective immediately upon filing. Shares covered by these registration statements will then be eligible for sale in the open market, subject to vesting restrictions, any applicable lock-up agreements described below and Rule 144 limitations applicable to affiliates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Regulation S </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Regulation S under the Securities Act, or Regulation S, provides that ordinary shares owned by any person may be sold without registration in the United States, provided that the sale is effected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our ordinary shares may be sold outside the United States without registration in the United States being required.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, Regulation S provides that any shares sold by us outside the United States pursuant thereto may be freely resold into the United States as long as we were a foreign private issuer at the time of the issuance, subject to limitations on affiliate resales and contractual lock-up agreements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">239<br></div></div></div>
<!--End Page 244-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 245-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tMIT"><!--Anchor--></a>MATERIAL INCOME TAX CONSIDERATIONS</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Considerations for U.S. Holders</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of our ordinary shares or ADSs. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#8217;s decision to acquire securities. This discussion applies only to a U.S. Holder that holds our ordinary shares or ADSs as a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including state, local and non-U.S. tax consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special rules, such as:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">banks, insurance companies, and certain other financial institutions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">U.S. expatriates and certain former citizens or long-term residents of the United States;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">dealers or traders in securities who use a mark-to-market method of tax accounting;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding ordinary shares or ADSs as part of a hedging transaction, &#8220;straddle,&#8221; wash sale, conversion transaction or integrated transaction or persons entering into a constructive sale with respect to ordinary shares or ADSs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons whose &#8220;functional currency&#8221; for U.S. federal income tax purposes is not the U.S. dollar;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities, commodities or currencies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt entities or government organizations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal income tax purposes (and investors therein);</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulated investment companies or real estate investment trusts;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired our ordinary shares or ADSs pursuant to the exercise of any employee stock option or otherwise as compensation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding shares or ADSs in connection with a trade or business outside the United States; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons that own or are deemed to own ten percent or more of our shares (by vote or value); and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding our ordinary shares or ADSs in connection with a trade or business, permanent establishment, or fixed base outside the United States.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares or ADSs, the U.S. federal income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary shares or ADSs and partners in such partnerships are encouraged to consult their tax advisors as to the particular U.S. federal income tax consequences of holding and disposing of ordinary shares or ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The discussion is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury Regulations, and the income tax treaty between the United Kingdom and the United States, the Treaty, all as of the date hereof, changes to any of which may affect the tax consequences described herein &#8212; possibly with retroactive effect.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A &#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares or ADSs who is:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an individual who is a citizen or resident of the United States;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">240<br></div></div></div>
<!--End Page 245-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 246-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a trust if (1) a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial decisions of the trust or (2) the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">U.S. Holders are encouraged to consult their tax advisors concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of ordinary shares or ADSs in their particular circumstances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for U.S. federal income tax purposes as holding the ordinary shares represented by the ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Passive Foreign Investment Company rules</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Under the Code, we will be a PFIC for any taxable year in which (1) 75% or more of our gross income consists of passive income or (2) 50% or more of the value of our assets (generally determined on the basis of a weighted quarterly average) consists of assets that produce, or are held for the production of, passive income (including cash). For purposes of these tests, passive income includes dividends, interest, gains from the sale or exchange of investment property and certain rents and royalties. Cash and cash-equivalents are passive assets for these purposes. In addition, for purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation. If we are a PFIC for any taxable year during which a U.S. Holder holds our shares, the U.S. Holder may be subject to adverse tax consequences regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Based on our analysis of our activities and current estimates (and not fully audited financials) of our income and assets, we believe that we were not a PFIC for our most recently completed taxable year. However, the determination of whether we are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. As a result, there can be no assurance that we will not be treated as a PFIC for the current or any future taxable year. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes (including goodwill) may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably. Accordingly, if our market capitalization declines while we hold a substantial amount of cash and cash-equivalents for any taxable year we may be a PFIC for that taxable year. Under the income test, our status as a PFIC depends on the composition of our income for the relevant taxable year which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by how we spend the cash we raise in any offering, including this offering. We currently do not generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate sufficient amounts of active income to offset our passive financing income. Therefore, we cannot express an expectation regarding our PFIC status for the current or any future taxable year. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with our conclusion and that the IRS would not successfully challenge our position. Accordingly, our U.S. counsel expresses no opinion with respect to our PFIC status for any prior, current or future taxable year.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are classified as a PFIC in any year with respect to which a U.S. Holder owns the ordinary shares or ADSs, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the ordinary shares or ADSs, regardless of whether we continue to meet the tests described above unless we cease to be a PFIC and the U.S. Holder has made a &#8220;deemed sale&#8221; election under the PFIC rules. If such a deemed sale election is made, a U.S. Holder will be deemed to have sold the ordinary shares or ADSs the U.S. Holder holds at their fair market value and any gain from such deemed sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. Holder&#8217;s ordinary shares or ADSs with respect to which such election was made will not be treated as shares in a PFIC and the U.S. Holder will not be subject to the rules described below with respect to any &#8220;excess distribution&#8221; the U.S. Holder receives from us or any gain from an actual sale or </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">241<br></div></div></div>
<!--End Page 246-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 247-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">other disposition of the ordinary shares or ADSs. U.S. Holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if we are a PFIC and cease to be a PFIC and such election becomes available.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For each taxable year that we are treated as a PFIC with respect to U.S. Holders, U.S. Holders will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; such U.S. Holder receives and any gain such U.S. Holder recognizes from a sale or other disposition (including a pledge) of ordinary shares or ADSs, unless (i)&#160;such U.S. Holder makes a &#8220;qualified electing fund&#8221; election, or QEF Election, with respect to all taxable years during such U.S. Holder's holding period in which we are a PFIC, or (ii)&#160;our ordinary shares or ADSs constitute &#8220;marketable stock&#8221; and such U.S. Holder makes a mark-to-market election (as discussed below). Distributions a U.S. Holder receives in a taxable year that are greater than 125% of the average annual distributions a U.S. Holder received during the shorter of the three preceding taxable years or the U.S. Holder&#8217;s holding period for the ordinary shares or ADSs will be treated as an excess distribution. Under these special tax rules:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the excess distribution or gain will be allocated ratably over a U.S. Holder&#8217;s holding period for the ordinary shares or ADSs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount allocated to the taxable year of the disposition or distribution (as applicable), and any taxable year prior to the first taxable year in which we became a PFIC, will be treated as ordinary income; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The tax liability for amounts allocated to years prior to the year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the ordinary shares or ADSs cannot be treated as capital, even if a U.S. Holder holds the ordinary shares or ADSs as capital assets.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If we are a PFIC, a U.S. Holder will generally be subject to similar rules with respect to distributions we receive from, and our dispositions of the stock of, any of our direct or indirect subsidiaries or any other entities in which we hold equity interests that also are PFICs (&#8220;lower-tier PFICs&#8221;), as if such distributions were indirectly received by, and/or dispositions were indirectly carried out by, such U.S. Holder. U.S. Holders should consult their tax advisors regarding the application of the PFIC rules to lower-tier PFICs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a U.S. Holder makes an effective QEF election, the U.S. Holder will be required to include in gross income for each year in which we are a PFIC, whether or not we make distributions, as capital gains, such U.S. Holder's pro rata share of our net capital gains and, as ordinary income, such U.S. Holder's pro rata share of our earnings in excess of our net capital gains. An electing U.S. Holder's basis in our ordinary shares or ADSs will be increased to reflect the amount of any taxed but undistributed income. Distributions of income that had previously been taxed will result in a corresponding reduction of basis in the ordinary shares or ADSs and generally will not be taxed again as distributions to the U.S. Holder. In addition, a U.S. Holder that makes a QEF election will be taxed on the disposition of ordinary shares or ADSs as described in &#8220;Sale or other taxable disposition of ordinary shares and ADSs&#8221; below. In order to apply the QEF regime in lieu of the general PFIC rules described above, a U.S. Holder generally must make the QEF election for the first taxable year during a U.S. Holder&#8217;s holding period in which we are treated as a PFIC.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. Holder can only make a QEF election with respect to ordinary shares or ADSs in a PFIC if the Company agrees to furnish such U.S. Holder with certain information annually. If we determine that the Company is a PFIC in any taxable year, we intend to make available to U.S. Holders, upon request and in accordance with applicable procedures and confidentiality requirements, a &#8220;PFIC Annual Information Statement&#8221; with respect to the Company for such taxable year. The &#8220;PFIC Annual Information Statement&#8221; may be used by U.S. Holders for purposes of complying with the reporting requirements applicable to a QEF election with respect to the Company. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">242<br></div></div></div>
<!--End Page 247-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 248-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A QEF election with respect to the Company will not apply to any of our lower-tier PFICs. If we determine that any of our current subsidiaries is a lower-tier PFIC for any taxable year in which the Company is a PFIC, we currently expect that we will provide the information necessary for U.S. Holders to make a QEF election with respect to such lower-tier PFIC, but there can be no assurance that we will be able to provide such information. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">U.S. Holders should note that if they make a QEF election with respect to us, they may be required to pay U.S. federal income tax with respect to their ordinary shares or ADSs for any taxable year significantly in excess of any cash distributions (which are currently expected to be zero) received on the ordinary shares or ADSs for such taxable year. U.S. Holders should consult their tax advisors regarding PFIC investments and making QEF elections based on their particular circumstances.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">U.S. Holders can avoid the interest charge on excess distributions or gain relating to the ordinary shares or ADSs by making a mark-to-market election with respect to the ordinary shares or ADSs, provided that the ordinary shares or ADSs are &#8220;marketable stock.&#8221; Ordinary shares or ADSs will be marketable stock if they are &#8220;regularly traded&#8221; on certain U.S. stock exchanges or on a non-U.S. stock exchange that meets certain conditions. For these purposes, the ordinary shares or ADSs will be considered regularly traded during any calendar year during which they are traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded. Our ADSs (but not ordinary shares) will be listed on the Nasdaq, which is a qualified exchange for these purposes. Consequently, if our ADSs remain listed on the Nasdaq and are regularly traded, of our ADSs we expect the mark-to-market election would be available to U.S. Holders if we are a PFIC. Each U.S. Holder should consult its tax advisor as to the whether a mark-to-market election is available or advisable with respect to the ordinary shares or ADSs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. Holder that makes a mark-to-market election must include in ordinary income for each year an amount equal to the excess, if any, of the fair market value of the ordinary shares or ADSs at the close of the taxable year over the U.S. Holder&#8217;s adjusted tax basis in the ordinary shares or ADSs. An electing U.S. Holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder&#8217;s adjusted basis in the ordinary shares or ADSs over the fair market value of the ordinary shares or ADSs at the close of the taxable year, but this deduction is allowable only to the extent of any net mark-to-market gains for prior years. Gains from an actual sale or other disposition of the ordinary shares or ADSs in any year in which we are a PFIC will be treated as ordinary income, and any losses incurred on a sale or other disposition of the shares will be treated as an ordinary loss to the extent of any net mark-to-market gains for prior years. Once made, the election cannot be revoked without the consent of the IRS unless the ordinary shares or ADSs cease to be marketable stock.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">However, a mark-to-market election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves &#8220;marketable stock.&#8221; As a result, even if a U.S. Holder validly makes a mark-to-market election with respect to our ordinary shares or ADSs, the U.S. Holder may continue to be subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. Holders should consult their tax advisors as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an annual report containing such information as the U.S. Treasury may require. A U.S. Holder&#8217;s failure to file the annual report may result in substantial penalties and extend the statute of limitations with respect to the U.S. Holder&#8217;s federal income tax return. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">WE STRONGLY URGE YOU TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT OF OUR PFIC STATUS ON YOUR INVESTMENT IN THE ORDINARY SHARES OR ADSs AS WELL AS THE APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT IN THE ORDINARY SHARES OR ADSs.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Taxation of distributions</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the discussion above under &#8220;Passive Foreign Investment Company rules,&#8221; distributions paid on ordinary shares or ADSs, other than certain pro rata distributions of ordinary shares or ADSs, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">243<br></div></div></div>
<!--End Page 248-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 249-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">under U.S. federal income tax principles). Because we may not calculate our earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid to certain non-corporate U.S. Holders may be taxable at preferential rates applicable to &#8220;qualified dividend income.&#8221; However, the qualified dividend income treatment will not apply if we are treated as a PFIC with respect to the U.S. Holder for our taxable year of the distribution or the preceding taxable year. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other than cash (and other than certain pro rata distributions of ordinary shares or ADSs or rights to acquire ordinary shares or ADSs) will be the fair market value of such property on the date of distribution. For foreign tax credit purposes, our dividends will generally be treated as passive category income.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Sale or other taxable disposition of ordinary shares and ADSs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the discussion above under &#8220;Passive Foreign Investment Company rules,&#8221; gain or loss realized on the sale or other taxable disposition of ordinary shares or ADSs will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares or ADSs for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the ordinary shares or ADSs disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If the consideration received by a U.S. Holder is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if the ordinary shares or ADSs are treated as traded on an &#8220;established securities market&#8221; and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), you will determine the U.S. dollar value of the amount realized in a non-U.S. dollar currency by translating the amount received at the spot rate of exchange on the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss to the extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Information reporting and backup withholding</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Information with respect to foreign financial assets</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Certain U.S. Holders who are individuals and certain closely-held entities may be required to report information relating to the ordinary shares or ADSs, subject to certain exceptions (including an exception for ordinary shares or ADSs held in accounts maintained by financial institutions, in which case the accounts </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">244<br></div></div></div>
<!--End Page 249-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 250-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">themselves may have to be reported if maintained by non-U.S. financial institutions). U.S. Holders should consult their tax advisors regarding their reporting obligations with respect to their ownership and disposition of the ordinary shares or ADSs.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Transfer Reporting Requirements </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A U.S. Holder may be required to file an IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) if the amount paid by the U.S. Holder in connection with the purchase of ordinary shares or ADSs in this offering, when aggregated with all transfers of cash made by the U.S. Holder (or any related person) to the Company within the preceding twelve-month period, exceeds $100,000 (or its foreign currency equivalent). U.S. Holders that are required to file IRS Form 926, but fail to do so, could be subject to substantial penalties. U.S. Holders should consult their tax advisors to determine whether they are subject to any Form&#160;926 filing requirements.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">U.K. Taxation</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following is intended as a general guide to current U.K. tax law and HM Revenue &amp; Customs, or HMRC, practice applying as at the date of this prospectus (both of which are subject to change at any time, possibly with retrospective effect) relating to the holding of ADSs. It does not constitute legal or tax advice and does not purport to be a complete analysis of all U.K. tax considerations relating to the holding of ADSs, or all of the circumstances in which holders of ADSs may benefit from an exemption or relief from U.K. taxation. It is written on the basis that the company does not (and will not) directly or indirectly derive 75% or more of its qualifying asset value from U.K. land, and that the company is and remains solely resident in the United Kingdom for tax purposes and will therefore be subject to the U.K. tax regime and not the U.S. tax regime save as set out above under &#8220;U.S. Federal Income Taxation.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Except to the extent that the position of non-U.K. resident persons is expressly referred to, this guide relates only to persons who are resident (and, in the case of individuals, domiciled or deemed domiciled) for tax purposes solely in the United Kingdom and do not have a permanent establishment, branch, agency (or equivalent) or fixed base in any other jurisdiction with which the holding of the ADSs is connected, or U.K. Holders, who are absolute beneficial owners of the ADSs (where the ADSs are not held through an Individual Savings Account or a Self-Invested Personal Pension) and who hold the ADSs as investments.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This guide may not relate to certain classes of U.K. Holders, such as (but not limited to):</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who are connected with the company;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">financial institutions;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">insurance companies;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">charities or tax-exempt organizations;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collective investment schemes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pension schemes;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">market makers, intermediaries, brokers or dealers in securities;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who have (or are deemed to have) acquired their ADSs by virtue of an office or employment or who are or have been officers or employees of the company or any of its affiliates; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">individuals who are subject to U.K. taxation on a remittance basis.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The decision of the First-tier Tribunal (Tax Chamber) in HSBC Holdings PLC and The Bank of New York Mellon Corporation v HMRC (2012) cast some doubt on whether a holder of a depositary receipt is the beneficial owner of the underlying shares. However, based on published HMRC guidance we would expect that HMRC will regard a holder of ADSs as holding the beneficial interest in the underlying shares and therefore these paragraphs assume that a holder of ADSs is the beneficial owner of the underlying ordinary shares and any dividends paid in respect of the underlying ordinary shares (where the dividends are regarded for U.K. purposes as that person&#8217;s own income) for U.K. direct tax purposes.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">THESE PARAGRAPHS ARE A SUMMARY OF CERTAIN U.K. TAX CONSIDERATIONS AND ARE INTENDED AS A GENERAL GUIDE ONLY. IT IS RECOMMENDED THAT ALL HOLDERS OF </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">245<br></div></div></div>
<!--End Page 250-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 251-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ADSs OBTAIN ADVICE AS TO THE CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSAL OF THE ADSs IN THEIR OWN SPECIFIC CIRCUMSTANCES FROM THEIR OWN TAX ADVISORS. IN PARTICULAR, NON-U.K. RESIDENT OR DOMICILED PERSONS ARE ADVISED TO CONSIDER THE POTENTIAL IMPACT OF ANY RELEVANT DOUBLE TAXATION AGREEMENTS.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Dividends</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Withholding Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Dividends paid by the company will not be subject to any withholding or deduction for or on account of U.K. tax.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Income Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An individual U.K. Holder may, depending on his or her particular circumstances, be subject to U.K. tax on dividends received from the company. An individual holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. income tax on dividends received from the company unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in the United Kingdom through a branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the UK through independent agents, such as some brokers and investment managers.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">All dividends received by an individual U.K. Holder from us or from other sources will form part of that U.K. Holder&#8217;s total income for income tax purposes and will constitute the top slice of that income. A nil rate of income tax will apply to the first &#163;2,000 of taxable dividend income received by the individual U.K. Holder in a tax year. Income within the nil rate band will be taken into account in determining whether income in excess of the &#163;2,000 tax-free allowance falls within the basic rate, higher rate or additional rate tax bands. Dividend income in excess of the tax-free allowance will (subject to the availability of any income tax personal allowance) be taxed at 7.5% to the extent that the excess amount falls within the basic rate tax band, 32.5% to the extent that the excess amount falls within the higher rate tax band and 38.1% to the extent that the excess amount falls within the additional rate tax band.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Corporation Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A corporate holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. corporation tax on dividends received from the company unless it carries on (whether solely or in partnership) a trade in the United Kingdom through a permanent establishment to which the ADSs are attributable.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Corporate U.K. Holders should not be subject to U.K. corporation tax on any dividend received from the company so long as the dividends qualify for exemption, which should be the case, although certain conditions must be met. If the conditions for the exemption are not satisfied, or such U.K. Holder elects for an otherwise exempt dividend to be taxable, U.K. corporation tax will be chargeable on the amount of any dividends (at the current rate of 19%).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Chargeable Gains</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A disposal or deemed disposal of ADSs by a U.K. Holder may, depending on the U.K. Holder&#8217;s circumstances and subject to any available exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of U.K. capital gains tax and corporation tax on chargeable gains.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an individual U.K. Holder who is subject to U.K. income tax at either the higher or the additional rate is liable to U.K. capital gains tax on the disposal of ADSs, the current applicable rate will be 20%. For an individual U.K. Holder who is subject to U.K. income tax at the basic rate and liable to U.K. capital gains tax on such disposal, the current applicable rate would be 10%, save to the extent that any capital gains when aggregated with the U.K. Holder&#8217;s other taxable income and gains in the relevant tax year exceed the unused basic rate tax band. In that case, the rate currently applicable to the excess would be 20%.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If a corporate U.K. Holder becomes liable to U.K. corporation tax on the disposal (or deemed disposal) of ADSs, the main rate of U.K. corporation tax (currently 19%) would apply.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">246<br></div></div></div>
<!--End Page 251-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 252-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">A holder of ADSs which is not resident for tax purposes in the United Kingdom should not normally be liable to U.K. capital gains tax or corporation tax on chargeable gains on a disposal (or deemed disposal) of ADSs unless the person is carrying on (whether solely or in partnership) a trade, profession or vocation in the United Kingdom through a branch or agency (or, in the case of a corporate holder of ADSs, through a permanent establishment) to which the ADSs are attributable. However, an individual holder of ADSs who has ceased to be resident for tax purposes in the United Kingdom for a period of less than five years and who disposes of ADSs during that period may be liable on his or her return to the United Kingdom to U.K. tax on any capital gain realized (subject to any available exemption or relief).</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Stamp Duty and Stamp Duty Reserve Tax</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that special rules may apply to certain persons such as market makers, brokers, dealers or intermediaries.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Issue of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No U.K. stamp duty or stamp duty reserve tax, or SDRT, is payable on the issue of the underlying ordinary shares in the company.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfers of Shares</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An unconditional agreement to transfer ordinary shares in certificated form will normally give rise to a charge to SDRT at the rate of 0.5% of the amount or value of the consideration payable for the transfer. The purchaser of the shares is liable for the SDRT. Transfers of ordinary shares in certificated form are generally also subject to stamp duty at the rate of 0.5% of the amount or value of the consideration given for the transfer (rounded up to the next &#163;5.00). Stamp duty is normally paid by the purchaser. The charge to SDRT will be canceled or, if already paid, repaid (generally with interest), where a transfer instrument has been duly stamped within six years of the charge arising (either by paying the stamp duty or by claiming an appropriate relief) or if the instrument is otherwise exempt from stamp duty.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">An unconditional agreement to transfer ordinary shares to, or to a nominee or agent for, a person whose business is or includes the issue of depositary receipts or the provision of clearance services will generally be subject to SDRT (or, where the transfer is effected by a written instrument, stamp duty) at a higher rate of 1.5% of the amount or value of the consideration given for the transfer unless the clearance service has made and maintained an election under section 97A of the U.K. Finance Act 1986, or a section 97A election. It is understood that HMRC regards the facilities of DTC as a clearance service for these purposes and we are not aware of any section 97A election having been made by DTC. However, no SDRT is generally payable where the transfer of ordinary shares to a clearance service or depositary receipt system is an integral part of an issue of share capital.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Any stamp duty or SDRT payable on a transfer of ordinary shares to a depositary receipt system or clearance service will in practice generally be paid by the participants in the clearance service or depositary receipt system.</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfers of ADSs</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No SDRT should be required to be paid on a paperless transfer of ADSs through the clearance service facilities of DTC, provided that no section 97A election has been made by DTC, and such ADSs are held through DTC at the time of any agreement for their transfer.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No U.K. stamp duty will in practice be payable on a written instrument transferring an ADS provided that the instrument of transfer is executed and remains at all times outside the United Kingdom. Where these conditions are not met, the transfer of, or agreement to transfer, an ADS could, depending on the circumstances, attract a charge to U.K. stamp duty at the rate of 0.5% of the amount or value of the consideration. If it is necessary to pay stamp duty, it may also be necessary to pay interest and penalties.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">247<br></div></div></div>
<!--End Page 252-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 253-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUDG"><!--Anchor--></a>UNDERWRITING</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The company and the underwriters named below will enter into an underwriting agreement with respect to the ADSs being offered. Subject to certain conditions, each underwriter shall severally agree to purchase the number of ADSs indicated in the following table. Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC are the representatives of the underwriters.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 84.62%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Underwriters</div></td><td class="gutter" style="width: 1.4%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.4%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of ADSs</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Goldman Sachs &amp; Co. LLC <font style="padding-left: 0.48pt;"></font></div></td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.47pt; text-align: left;">&#8195;&#8195;&#8195;&#8195;</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">J.P. Morgan Securities LLC <font style="padding-left: 2.05pt;"></font></div></td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jefferies LLC<font style="padding-left: 2.6pt;"></font></div></td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.47pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">&#8195;&#8195;&#8195;&#8195;</font></div></td></tr><tr><td style="width: 84.62%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Total<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.4%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 12.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.47pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 40pt;">&#8195;&#8195;&#8195;</font></div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters will be committed to take and pay for all of the ADSs being offered, if any are taken, other than the ADSs covered by the option described below unless and until this option is exercised.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters have an option to buy up to an additional&#8195;&#8195; ADSs from the company to cover sales by the underwriters of a greater number of ADSs than the total number set forth in the table above. They may exercise that option for 30 days after the date of the final prospectus. If any ADSs are purchased pursuant to this option, the underwriters will severally purchase ADSs in approximately the same proportion as set forth in the table above.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table shows the per ADS and total underwriting discounts and commissions to be paid to the underwriters by the company. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase&#8195;&#8195;&#8195; additional ADSs.</div><div class="h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; text-align: center;"><u>Paid by the Company</u></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.62%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">No Exercise</div></td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.95%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Full Exercise</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Per ADS<font style="padding-left: 1.4pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$&#8195;&#8195;&#8195;&#8195;</div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;">$&#8195;&#8195;&#8195;&#8195;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.62%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$</div></td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 0.95%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.09pt; text-align: left;">$</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">ADSs sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any ADSs sold by the underwriters to securities dealers may be sold at a discount of up to $ &#8195;&#8195;per ADS from the initial public offering price. After the initial offering of the ADSs, the representatives may change the offering price and the other selling terms. The offering of the ADSs by the underwriters is subject to receipt and acceptance and subject to the underwriters&#8217; right to reject any order in whole or in part.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The company and its officers, directors, and holders of substantially all of the company&#8217;s equity interests have agreed with the underwriters not to dispose of or hedge any of their ordinary shares, ADSs or securities convertible into or exchangeable for ordinary shares or ADSs during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of Goldman Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Jefferies LLC. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The restrictions described in the paragraph above relating to the officers, directors and our shareholders do not apply, subject in certain cases to various conditions, to certain transactions, including transfers:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as a bona fide gift or gifts or charitable contribution; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to any trust for the direct or indirect benefit of the lock-up party or the immediate family of the lock-up party;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">with the prior written consent of the representatives on behalf of the underwriters;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by will or intestacy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to any corporation, partnership limited liability company or other business entity, all of the beneficial ownership interests of which, in each such case, are held by the lock-up party or any member of the lock-up party&#8217;s immediate family;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by operation of law, including pursuant to a domestic order or negotiated divorce settlement;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">248<br></div></div></div>
<!--End Page 253-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 254-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">(i)&#160;the exercise of options or other similar awards or the vesting or settlement of awards granted pursuant to the our equity incentive plans as described herein (including the delivery and receipt of ordinary shares or ADSs, other awards or any securities convertible into or exercisable or exchangeable for ordinary shares or ADSs in connection with such exercise, vesting or settlement), or (ii)&#160;the transfer or disposition of ordinary shares or ADSs or any securities convertible into ordinary shares or ADSs by the lock-up party to us (or the purchase and cancellation of same by us) upon a vesting or settlement event of the our securities or upon the exercise of options to purchase the our securities on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis to the extent permitted by the instruments representing such options pursuant to our share option plan, equity incentive plan, share purchase plan or other equity incentive arrangement as described herein;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to us to the extent required to realize sufficient funds to satisfy the exercise price and/or any income, employment tax and/or social security withholding and remittance obligations upon the vesting or exercise of an option or other award granted under a share option plan, equity incentive plan, share purchase plan or other equity incentive arrangement by us described herein or the conversion or exercise of a warrant described herein;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to us pursuant to any contractual arrangement in effect on the date the lock-up party entered into the lock-up agreement and described herein that provides for the repurchase of the lock-up party&#8217;s ordinary shares or ADSs by the us in connection with the termination of the lock-up party&#8217;s employment or other service relationship with us or the lock-up party&#8217;s failure to meet certain conditions set out upon receipt of such ordinary shares or ADSs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in connection with the corporate reorganization as described herein and consummated before, or at the same time as, the closing of this offering;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acquired in the offering, or in open market transactions following the offering;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as part of a distribution, transfer or disposition without consideration by the lock-up party to its limited or general partners, members, stockholders or affiliates (as defined under Rule 12b-2 of the Exchange Act); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in connection with the establishment or amendment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act, provided that (A) the lock-up party does not otherwise voluntarily effect any public filing or report regarding the establishment of such plan during the lock-up period and (B) no sale or other transfer of ordinary shares or ADSs pursuant to such plan may occur during the lock-up period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pursuant to a bona fide third-party tender offer, merger, takeover offer consolidation, scheme of arrangement or other similar transaction approved by the our board of directors and made with or offered to all holders of the our ordinary shares and ADSs resulting in a change in the ownership of 90% of our voting capital stock that is made or offered after the offering, provided that, in the event that such change of control is not completed, the lock-up party&#8217;s ordinary shares and ADSs shall remain subject to the restrictions contained in the lock-up agreement and title to the lock-up party&#8217;s ordinary shares and ADSs shall remain with the lock-up party; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through the deposit of ordinary shares with our ADS depositary in exchange for the issuance of ADSs, or the cancellation of ADSs and withdrawal of underlying ordinary shares.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">See &#8220;Ordinary Shares and ADSs Eligible for Future Sale&#8221; for a discussion of certain transfer restrictions.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Prior to the offering, there has been no public market for the ADSs. The initial public offering price has been negotiated among the company and the representatives. Among the factors to be considered in determining the initial public offering price of the ADSs, in addition to prevailing market conditions, will be the company&#8217;s historical performance, estimates of the business potential and earnings prospects of the company, an assessment of the company&#8217;s management and the consideration of the above factors in relation to market valuation of companies in related businesses.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We intend to apply to list our ADSs on the Nasdaq Global Market under the symbol &#8220;IMCR.&#8221;</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In connection with the offering, the underwriters may purchase and sell ADSs in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">249<br></div></div></div>
<!--End Page 254-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 255-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">sales. Short sales involve the sale by the underwriters of a greater number of ADSs than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#8220;covered short position&#8221; is a short position that is not greater than the amount of additional ADSs for which the underwriters&#8217; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional ADSs or purchasing ADSs in the open market. In determining the source of ADSs to cover the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase additional ADSs pursuant to the option described above. &#8220;Naked&#8221; short sales are any short sales that create a short position greater than the amount of additional ADSs for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing ADSs in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the ADSs made by the underwriters in the open market prior to the completion of the offering. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased ADSs sold by or for the account of such underwriter in stabilizing or short covering transactions. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the company&#8217;s ADSs, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the ADSs. As a result, the price of the ADSs may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the Nasdaq Global Market, in the over-the-counter market or otherwise.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $&#8199;&#8199;&#8199;&#8199; million. We have also agreed to reimburse the underwriters for certain FINRA-related expenses incurred by them in connection with the offering in an amount up to $ &#8195;&#8195;.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act of 1933.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they received or will receive customary fees and expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively traded securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">European Economic Area </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In relation to each Member State of the European Economic Area (each a &#8220;Relevant State&#8221;), no ADSs have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the ADSs which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of ADSs may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation:</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">250<br></div></div></div>
<!--End Page 255-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 256-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the Representatives for any such offer; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">provided that no such offer of ADSs shall require the Issuer or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any ADSs or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and the Issuer that it is a &#8220;qualified investor&#8221; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any ADSs being offered to a financial intermediary as that term is used in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the ADSs acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any ADSs to the public other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has been obtained to each such proposed offer or resale.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the ADSs in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">United Kingdom</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">No ADSs have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the ADSs which has been approved by the Financial Conduct Authority, except that the ADSs may be offered to the public in the United Kingdom at any time:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus Regulation;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the U.K. Prospectus Regulation), subject to obtaining the prior consent of the Representatives for any such offer; or</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in any other circumstances falling within Section 86 of the FSMA.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">provided that no such offer of the ADSs shall require the Issuer or any underwriter to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to the ADSs in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any ADSs to be offered so as to enable an investor to decide to purchase or subscribe for any ADSs and the expression &#8220;U.K. Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; (as defined in the U.K. Prospectus Regulation) (i)&#160;who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the &#8220;Order,&#8221; and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (e) of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the ADSs in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. Any person in the UK who is not a relevant person must not act on or rely upon this document or any of its contents.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">251<br></div></div></div>
<!--End Page 256-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 257-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Canada</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ADSs may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the ADSs must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment hereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory of these rights or consult with a legal advisor.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Hong Kong</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The ADSs may not be offered or sold in Hong Kong by means of any document other than (i)&#160;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (&#8220;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#8221;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#8220;Securities and Futures Ordinance&#8221;), or (ii)&#160;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Singapore</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&#160;to an institutional investor (as defined under Section 4A of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA) under Section 274 of the SFA, (ii)&#160;to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii)&#160;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where the ADSs are subscribed or purchased under Section 275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the ADSs under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#8217;s securities pursuant </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">252<br></div></div></div>
<!--End Page 257-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 258-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore, or Regulation 32. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Where the ADSs are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the ADSs under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Solely for the purposes of our obligations pursuant to Section 309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018, or CMP Regulations) that the ADSs are &#8220;prescribed capital markets products&#8221; (as defined in the CMP Regulations) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Japan</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">253<br></div></div></div>
<!--End Page 258-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 259-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tETO"><!--Anchor--></a>EXPENSES OF THIS OFFERING</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Set forth below is an itemization of the total expenses, excluding the underwriting discounts and commissions, which are expected to be incurred in connection with the sale of ADSs in this offering. With the exception of the registration fee payable to the SEC, the Nasdaq listing fee and the filing fee payable to Financial Industry Regulatory Authority, Inc., or FINRA, all amounts are estimates.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 90.81%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expense</div></td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.41%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">SEC registration fee<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;&#8195;&#8195;*</div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nasdaq initial listing fee<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FINRA filing fee<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Printing expenses<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legal fees and expenses<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting fees and expenses<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Miscellaneous fees and expenses<font style="padding-left: 3.13pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr><tr><td style="width: 90.81%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 6.41%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 30pt;">*</font></div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be completed by amendment.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">254<br></div></div></div>
<!--End Page 259-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 260-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLMS"><!--Anchor--></a>LEGAL MATTERS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The validity of the ADSs being offered by this prospectus and certain other matters of English law will be passed upon for us by Cooley (UK) LLP and certain other matters of U.S. federal law will be passed upon for us by Cooley LLP. Certain legal matters related to this offering will be passed upon for the underwriters by Davis&#160;Polk &amp; Wardwell LLP, with respect to U.S. federal law, and Davis Polk &amp; Wardwell London LLP, with respect to English law.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tETS"><!--Anchor--></a>EXPERTS</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The consolidated financial statements of Immunocore Limited as of December&#160;31, 2019 and 2018, and for each of the years in the two-year period ended December&#160;31, 2019 have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit report covering the December&#160;31, 2019 consolidated financial statements contains an explanatory paragraph that states that the Company&#8217;s recurring losses from operations raise significant doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The audit report covering the December&#160;31, 2019 consolidated financial statements refers to a change to the method of accounting for leases as of January&#160;1, 2019 due to the adoption of IFRS&#160;16, Leases. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The financial statement of Immunocure Holdings Limited as of January&#160;7, 2021, has been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The offices of KPMG LLP are located at 15 Canada Square, Canary Wharf, London, E14 5GL, United Kingdom.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">255<br></div></div></div>
<!--End Page 260-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 261-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSOPAEO"><!--Anchor--></a>SERVICE OF PROCESS AND ENFORCEMENT OF LIABILITIES</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We are incorporated and currently existing under the laws of England and Wales. In addition, certain of our directors and officers reside outside of the United States and most of the assets of our non-U.S. subsidiaries are located outside of the United States. As a result, it may be difficult for investors to effect service of process on us or those persons in the United States or to enforce in the United States judgments obtained in U.S. courts against us or those persons based on the civil liability or other provisions of the U.S. securities laws or other laws. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In addition, uncertainty exists as to whether the courts of England and Wales would:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recognize or enforce judgments of U.S. courts obtained against us or our directors or officers predicated upon the civil liabilities provisions of the securities laws of the United States or any state in the United States; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">entertain original actions brought in England and Wales against us or our directors or officers predicated upon the securities laws of the United States or any state in the United States.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have been advised by Cooley (UK) LLP and Cooley LLP that there is currently no treaty between (i)&#160;the United States and (ii)&#160;England and Wales providing for reciprocal recognition and enforcement of judgments of U.S. courts in civil and commercial matters (although the United States and the United Kingdom are both parties to the New York Convention on the Recognition and Enforcement of Foreign Arbitral Awards) and that a final judgment for the payment of money rendered by any general or state court in the United States based on civil liability, whether or not predicated solely upon the United States securities laws, would not be automatically enforceable in England and Wales. We have also been advised by Cooley (UK) LLP and Cooley LLP that any final and conclusive monetary judgment for a definite sum obtained against us in United States courts would be treated by the courts of England and Wales as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the relevant U.S. court had jurisdiction over the original proceedings according to English conflicts of laws principles at the time when proceedings were initiated; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">England and Wales courts had jurisdiction over the matter on enforcement and we either submitted to such jurisdiction or were resident or carrying on business within such jurisdiction and were duly served with process; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the U.S. judgment was final and conclusive on the merits in the sense of being final and unalterable in the court that pronounced it and being for a definite sum of money; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment given by the courts was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations (or otherwise based on a U.S. law that an English court considers to relate to a penal, revenue or other public law); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment was not procured by fraud; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the judgment was not obtained following a breach of a jurisdictional or arbitrational clause, unless with the agreement of the defendant as the defendant&#8217;s subsequent submission to the jurisdiction of the court;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recognition or enforcement of the judgment in England and Wales would not be contrary to public policy or the Human Rights Act 1998; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proceedings pursuant to which judgment was obtained were not contrary to natural justice; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the U.S. judgment was not arrived at by doubling, trebling or otherwise multiplying a sum assessed as compensation for the loss or damages sustained and not being otherwise in breach of Section 5 of the U.K. Protection of Trading Interests Act 1980, or is a judgment based on measures designated by the Secretary of State under Section 1 of that Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">there is not a prior decision of an English court or the court of another jurisdiction on the issues in question between the same parties; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the English enforcement proceedings were commenced within the limitation period.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">256<br></div></div></div>
<!--End Page 261-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 262-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the United States securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the foregoing, investors may be able to enforce in England and Wales judgments in civil and commercial matters that have been obtained from U.S. federal or state courts. Nevertheless, we cannot assure you that those judgments will be recognized or enforceable in England and Wales. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement. In addition, it may not be possible to obtain an English judgment or to enforce that judgment if the judgment debtor is or becomes subject to any insolvency or similar proceedings, or if the judgment debtor has any set-off or counterclaim against the judgment creditor. Also note that, in any enforcement proceedings, the judgment debtor may raise any counterclaim that could have been brought if the action had been originally brought in England unless the subject of the counterclaim was in issue and denied in the U.S. proceedings.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">257<br></div></div></div>
<!--End Page 262-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 263-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_113-tax_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tWCN"><!--Anchor--></a>WHERE YOU CAN FIND ADDITIONAL INFORMATION</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form F-1 under the Securities Act with respect to the ADSs offered in this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to us and the ADSs offered hereby, reference is made to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is www.sec.gov. We currently make available to the public our annual and interim reports, as well as certain information regarding our corporate governance and other matters, on the Investors page of our website, www.immunocore.com. The reference to our website address does not constitute incorporation by reference of the information contained on or available through our website, and you should not consider it to be a part of this prospectus.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers. Accordingly, we will be required to file reports and other information with the SEC, including annual reports on Form 20-F and current reports on Form 6-K. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">We will send the depositary a copy of all notices of shareholders meetings and other reports, communications and information that are made generally available to shareholders. The depositary will, if we so request, mail to all registered holders of ADSs a notice containing the information (or a summary of the information) contained in any notice of a meeting of our shareholders received by the depositary from us or will make available to all registered holders of ADSs such notices and all such other reports and communications received by the depositary from us.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">258<br></div></div></div>
<!--End Page 263-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 264-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_200-fintoc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tINF"><!--Anchor--></a>INDEX TO FINANCIAL STATEMENTS</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">page</div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audited Financial Statement of Immunocore Holdings Limited<font style="font-weight: normal;"> </font><br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tROI">Report of Independent Registered Public Accounting Firm<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tROI"><font style="padding-left: 5pt;">F-</font>2</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBS">Statement of Financial Position as of January 7, 2021<font style="padding-left: 4.3pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tBS"><font style="padding-left: 5pt;">F-</font>3</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNTF">Notes to the Financial Statement<font style="padding-left: 0.66pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNTF"><font style="padding-left: 5pt;">F</font>-4</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Audited Consolidated Financial Statements of Immunocore Limited<br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tREPORT">Report of Independent Registered Public Accounting Firm<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tREPORT"><font style="padding-left: 5pt;">F-</font>5</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#fCSLOC">Consolidated Statement of Loss and Other Comprehensive Income for the Years Ended December&#160;31, 2018 and 2019<font style="padding-left: 3.4pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fCSLOC"><font style="padding-left: 5pt;">F-</font>6</a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fCSFP">Consolidated Statement of Financial Position as at December 31, 2019<font style="padding-left: 4.32pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fCSFP"><font style="padding-left: 5pt;">F-</font>7 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fCSCE">Consolidated Statement of Changes in Equity for the Years Ended December 31, 2018 and 2019<font style="padding-left: 3.51pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fCSCE"><font style="padding-left: 5pt;">F-</font>8 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fCGSCF">Consolidated Statement of Cash Flows for the Years Ended December 31, 2018 and 2019<font style="padding-left: 1.29pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fCGSCF"><font style="padding-left: 5pt;">F-</font>9 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fCNFS">Consolidated Notes to the Financial Statements<font style="padding-left: 0.67pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fCNFS">F-10 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unaudited Condensed Consolidated Interim Financial Statements of Immunocore Limited<br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#fUCCSL">Unaudited Condensed Consolidated Statement of Loss and Other Comprehensive Income for the Nine Months Ended September 30, 2019 and 2020<font style="padding-left: 3.72pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fUCCSL">F-44 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fUCCSFP">Unaudited Condensed Consolidated Statement of Financial Position as at September 30, 2020<font style="padding-left: 4.89pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fUCCSFP">F-45 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#fUCCSCE">Unaudited Condensed Consolidated Statement of Changes in Equity for the Nine Months Ended September 30, 2019 and 2020<font style="padding-left: 1.48pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fUCCSCE">F-46 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#fUCCGSCF">Unaudited Condensed Consolidated Statement of Cash Flows for the Nine Months Ended September 30, 2019 and 2020<font style="padding-left: 3.4pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fUCCGSCF">F-47 </a></div></td></tr><tr><td style="width: 93.38%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fUCNFS">Unaudited Consolidated Notes to the Financial Statements<font style="padding-left: 0.68pt;"></font></a></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 4.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#fUCNFS">F-48</a></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br></div></div></div>
<!--End Page 264-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 265-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tROI"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">To the Shareholder and Board of Directors of Immunocore Holdings Limited:</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statement</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have audited the accompanying statement of financial position of Immunocore Holdings Limited (the Company) as of January 7, 2021, and the related note (collectively, the financial statement). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company as of January 7, 2021, in conformity with International Financial Reporting Standards, as issued by the International Accounting Standards Board.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on this financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement. We believe that our audit provides a reasonable basis for our opinion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">/s/ KPMG LLP</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">London, United Kingdom<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br></div></div></div>
<!--End Page 265-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 266-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Holdings Limited <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial Statement<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">January 7, 2021 </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><a name="tBS"><!--Anchor--></a>Statement of Financial Position as at January 7, 2021 (date of inception)</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.45%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January 7, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2021 </div></td></tr><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.45%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163; </div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity<br></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital [&#163;0.0001 par value, one share authorized, called up and fully paid]<font style="padding-left: 0.37pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share premium<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;">&#8212;</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity and liabilities<font style="font-weight: normal; padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.45%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br></div></div></div>
<!--End Page 266-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 267-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Holdings Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financial Statement<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">January 7, 2021 <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="tNTF"><!--Anchor--></a>Notes to the Financial Statements</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">1.&#8195;Significant accounting policies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">General information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Immunocore Holdings Limited (the &#8220;Company&#8221;) is a private company incorporated in England and Wales on January 7, 2021.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The authorized share capital of the Company consists of one ordinary share, par value &#163;0.0001 per share, which has been issued. The Company was incorporated with nominal assets and liabilities for the purpose of becoming a holding company for Immunocore Limited and for the purposes of consummating a corporate reorganization.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Company&#8217;s proposed initial public offering, the Company will undertake a corporate reorganization pursuant to which (i) the Company will ultimately become the direct holding company of Immunocore Limited and the Company will re-register as a public limited company and change its name to Immunocore Holdings plc.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis of preparation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial statements have been prepared in accordance with International Financial Reporting Standards (collectively, &#8220;IFRS&#8221;) as issued by the International Accounting Standards Board. Separate statements of income, changes in equity and cash flows have not been presented in the financial statements as there have been no operations in the Company at the balance sheet date.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Date of authorization</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These financial statements were prepared at the request of the Group&#8217;s Board of Directors (the &#8220;Board&#8221;) to meet regulatory and contractual commitments and were approved by the Board on January 15, 2021 and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Subsequent events</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">There have been no subsequent events at the date of issue of this balance sheet.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br></div></div></div>
<!--End Page 267-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 268-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><a name="tREPORT"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">To the Shareholders and Board of Directors of Immunocore Limited<font style="font-weight: normal;"> </font></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Opinion on the Consolidated Financial Statements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have audited the accompanying consolidated statement of financial position of Immunocore Limited and subsidiaries (the Company) as of December&#160;31, 2019 and 2018, the related consolidated statements of loss and other comprehensive income, changes in equity, and cash flows for each of the years in the two year period ended December&#160;31, 2019, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the two year period ended December&#160;31, 2019, in conformity with International Financial reporting Standards as adopted by the International Accounting Standards Board.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Going Concern</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations that raise significant doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Change in Accounting Principles</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases as of January&#160;1, 2019 due to the adoption of IFRS 16, Leases.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">/s/ KPMG LLP</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2009. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">London, United Kingdom<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November 17, 2020 </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br></div></div></div>
<!--End Page 268-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 269-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Immunocore Limited <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><a name="fCSLOC"><!--Anchor--></a>Consolidated Statement of Loss and Other Comprehensive Income<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">for the years ended December&#160;31, </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.65%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.65%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 3.51pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">25,669</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">23,654</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total revenue<font style="font-weight: normal; padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">25,669</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">23,654</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 1.87pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">185</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">622</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development costs<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(99,991)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(83,575)</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Administrative expenses<font style="padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(44,183</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(34,156</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="font-weight: normal; padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.55pt;">(118,320)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(93,455)</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">4,979</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 4.08pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,510</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">1,140</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 3.52pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(9,379</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(842</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating (expense) / income<font style="font-weight: normal; padding-left: 3pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(7,869</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">5,277</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxation<font style="font-weight: normal; padding-left: 0.38pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(126,189)</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(88,178)</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 1.87pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">22,258</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">16,548</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(103,931</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(71,630</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive (expense) / income<br></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Other comprehensive (expense) / income that are or may be reclassified to profit or loss in subsequent periods (net of tax):<br></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences on translation of foreign operations<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(99)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">72</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax effect relating to the components of other comprehensive income<font style="padding-left: 2.7pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">3,634</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other comprehensive (expense) / income for the year, net of tax<font style="font-weight: normal; padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(99</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">3,706</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the year, net of tax<font style="font-weight: normal; padding-left: 4.4pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(104,030</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(67,924</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<font style="font-weight: normal; padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 15pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(0.02</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.65%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">(0.02</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br></div></div></div>
<!--End Page 269-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 270-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fCSFP"><!--Anchor--></a>Consolidated Statement of Financial Position as at December&#160;31, </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intangible assets<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">318</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment<font style="padding-left: 0.57pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">54,880</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">20,874</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment in sub-lease<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">591</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other non-current financial assets<font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">4,390</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">2,532</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax asset<font style="padding-left: 4.66pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,507</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">872</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current assets<font style="font-weight: normal; padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">61,368</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">24,596</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade and other receivables<font style="padding-left: 0.58pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">9,639</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">13,738</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax receivable<font style="padding-left: 4.23pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">40,410</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">32,339</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Embedded derivative assets<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">266</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">719</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 0.77pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">17</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">73,966</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">124,385</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="font-weight: normal; padding-left: 3.53pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">124,281</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">171,181</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">185,649</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">195,777</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share premium<font style="padding-left: 1.3pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">283,250</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">224,087</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign currency translation reserve<font style="padding-left: 1.35pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">(32)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">67</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based payment reserve<font style="padding-left: 4.67pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18, 22</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">10,659</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">7,603</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated deficit<font style="padding-left: 1.31pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(279,106</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(175,175</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">14,771</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">56,582</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings<font style="padding-left: 4.12pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">18,878</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred liabilities<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">47,961</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">70,665</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">38,299</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provisions<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">20</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">105</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">45</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current liabilities<font style="font-weight: normal; padding-left: 4.63pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">86,365</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">89,588</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings<font style="padding-left: 4.12pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">19,157</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade and other payables<font style="padding-left: 0.57pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">29,501</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">19,555</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred liabilities<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">28,522</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">29,741</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax payable<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">72</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">139</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 4.64pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">1,951</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derivative liabilities<font style="padding-left: 0.75pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">23</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt;">5,127</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provisions<font style="padding-left: 1.28pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">20</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">183</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">172</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="font-weight: normal; padding-left: 4.07pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">84,513</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">49,607</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">170,878</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">139,195</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity and liabilities<font style="font-weight: normal; padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">185,649</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">195,777</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br></div></div></div>
<!--End Page 270-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 271-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fCSCE"><!--Anchor--></a>Consolidated Statement of Changes in Equity for the years ending December&#160;31, </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 473.19pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.87%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">premium <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Foreign <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">currency <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">translation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Available-<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">for-sale <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.29%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share-<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">based <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">payment <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 4.91pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">223,986</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 5pt;">(5)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 3.33pt;">14,962</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt;">6,812</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(122,016)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">123,739</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(71,630)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(71,630)</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Reclassification on sale of asset held for sale<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">15</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;">(18,471)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 8.33pt;">18,471</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income<font style="padding-left: 4.1pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">72</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">3,509</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">125</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,706</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the year<font style="font-weight: normal; padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">72</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.85pt; text-align: left;">(14,962)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 12.5pt;">125</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(53,159)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(67,924)</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issue of share capital<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">101</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">101</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity-settled share-based payment transactions<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18, 22</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">666</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">666</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">224,087</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 13.33pt;">67</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">7,603</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(175,175</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">56,582</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(103,931)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(103,931)</div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive loss<font style="padding-left: 2.99pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 13.33pt;">(99</font><font style="min-width: 13.33pt;">)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(99</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total comprehensive loss for the year<font style="font-weight: normal; padding-left: 4.62pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.99pt; text-align: left;">(99)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(103,931)</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(104,030)</div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issue of share capital<font style="padding-left: 1.89pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">59,163</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">59,163</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity-settled share-based payment transactions<font style="padding-left: 0.74pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18, 22</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 13.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3,056</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">3,056</font></div></td></tr><tr><td style="width: 34.02%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.34pt;"></font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.46%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.88%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.87%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">283,250</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.89%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.99pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 13.33pt;">(32</font><font style="min-width: 13.33pt;">)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.85pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.29%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,659</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(279,106</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.63%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">14,771</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br></div></div></div>
<!--End Page 271-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 272-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_201-fintab01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fCGSCF"><!--Anchor--></a>Consolidated Statement of Cash Flows for the years ended December&#160;31, </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.35%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.95%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from operating activities<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="padding-left: 3.54pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">(103,931)</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(71,630)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments for:<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 4.49pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">9,003</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">6,410</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">210</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">297</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Write-off of intangible assets<font style="padding-left: 4.69pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">306</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">170</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss on disposal of property, plant and equipment<font style="padding-left: 2.83pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 30.83pt;">3</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">135</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross gain from sale of equity investment<font style="padding-left: 0.79pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(5,204)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net finance costs / (income)<font style="padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">7,867</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 14.17pt;">(298)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Movement in provisions and other charges<font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">20</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">71</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(50)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign exchange translation differences<font style="padding-left: 3.2pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(618)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">1,157</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity settled share-based payment expenses<font style="padding-left: 4.69pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">3,056</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">666</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Taxation charge<font style="padding-left: 3.85pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(22,258)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(16,548)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital adjustments:<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decrease/(increase) in trade and other receivables<font style="padding-left: 0.29pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">16</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,828</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(1,522)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase in trade and other payables<font style="padding-left: 0.8pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">21</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">9,946</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">5,300</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(Decrease)/increase in deferred liabilities<font style="padding-left: 1.38pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">19, 21</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(21,866</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">63,797</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operations<font style="font-weight: normal; padding-left: 4.09pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 0.55pt;">(116,383)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(17,320)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank interest received on cash and cash equivalents <font style="padding-left: 1.94pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.33pt;">1,525</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">760</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net taxation received<font style="padding-left: 1.32pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">13,482</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(66</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="font-weight: normal; padding-left: 1.34pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(101,376</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">(16,626</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from investing activities<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from sale of property, plant and equipment<font style="padding-left: 3.4pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">82</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds from disposal of equity investment<font style="padding-left: 0.25pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">15</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">27,451</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of property, plant and equipment<font style="padding-left: 0.05pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt;">(4,078)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 6.67pt;">(3,486)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchase of intangible assets<font style="padding-left: 0.78pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(198)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 19.17pt;">(51)</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from sub-leases<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">57</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment in short and long-term treasury deposits<font style="padding-left: 2.47pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">34,100</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows used in investing activities<font style="font-weight: normal; padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(4,137</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">58,014</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from financing activities<br></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from exercise of share options<font style="padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">22</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">27</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">101</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gross proceeds from issue of share capital<font style="padding-left: 4.15pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">18</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">59,874</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Costs from issue of share capital<font style="padding-left: 4.12pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(738)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Repayment of lease liabilities<font style="padding-left: 2.43pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">13</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">(4,036</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows from financing activities<font style="font-weight: normal; padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">55,127</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">101</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Increase/(decrease) in net cash and cash equivalents <font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">(50,386)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">41,489</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net foreign exchange difference on cash held<font style="padding-left: 2.11pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(33)</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">13</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of the year<font style="padding-left: 4.14pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">124,385</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">82,883</font></div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of the year<font style="font-weight: normal; padding-left: 2.46pt;"></font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">73,966</font></div></td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.35%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.95%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">124,385</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br></div></div></div>
<!--End Page 272-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 273-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="fCNFS"><!--Anchor--></a>Immunocore Limited <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">General information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Immunocore Limited (the &#8220;Company&#8221;) is a private company incorporated in England and Wales and has the following wholly owned subsidiaries, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited and Immunocore Nominees Limited (the &#8220;Group&#8221;). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The principal activity of the Group is pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease &#8211; designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Basis of preparation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated Group financial statements for the years ended December&#160;31, 2019 and 2018 have been prepared in accordance with International Financial Reporting Standards (collectively, &#8220;IFRS&#8221;) as issued by the International Accounting Standards Board. The Group has historically prepared the financial statements in accordance with IFRS&#160;as adopted by the European Union, however the Group could have asserted it was in compliance with IFRS as adopted by the International Accounting Standards Board for the previous period. There is no material difference noted on adoption and therefore, the Group is not considered a first-time adopter.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated Group financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in sterling which is the Group&#8217;s presentation currency. All values are rounded to the nearest thousands, except where otherwise indicated.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Date of authorization</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These consolidated financial statements were prepared at the request of the Board to meet regulatory and contractual commitments and were approved by the Board on November&#160;16, 2020 and signed on its behalf by Dr.&#160;Bahija Jallal, Chief Executive Officer of the Group. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Going concern</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial position of the Group, its cash flows and liquidity position are described in the primary statements and notes to these financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group held &#163;56,809,000 and &#163;49,310,00 of cash at the end of June 2020 and October 2020, respectively. The&#160;Group has recorded an operating loss of &#163;118,320,000 at December&#160;31, 2019 and a further operating loss of &#163;42,614,000 for the interim period to June&#160;30, 2020. The Group did not generate positive operational cash flow which was largely due to the continuing focus on the research, development and clinical activities to advance the programs within the Group&#8217;s pipeline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In assessing the going concern assumptions, the Board has undertaken a rigorous assessment of the forecasts and assessed identi&#64257;ed downside risks and mitigating actions. The downside risks include a number of severe but plausible scenarios incorporating underperformance against the business plan, and delays in cash inflows. Due to the Board&#8217;s plans to continue to develop and ultimately, commercialize the product candidates, the Group requires additional financing in the form of equity financing or loan financing in order to continue its operations and current capabilities. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As part of considering the downside risks, the Board has considered the impact of the ongoing coronavirus 2019 (&#8220;COVID-19&#8221;) pandemic. Whilst it is difficult to estimate the impact of COVID-19 pandemic due to the rapidly changing nature of the pandemic, the cash flow forecasts include the Group&#8217;s current assumptions, taking into account reasonable plausible downsides. The assumptions include no additional receipts from forecasted milestones for the next 12 months, a reduction in related operational costs and lower discretionary capital expenditures. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br></div></div></div>
<!--End Page 273-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 274-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Despite the above uncertainties, the Board has the confidence that the accounts should be prepared on a going concern basis for the following reasons: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group has key worker status which allows continuity of providing services throughout a prolonged lockdown period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group has a track record of meeting expectations under its collaboration agreements and meeting expected milestones within the contracted timeframe; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group&#8217;s history of being able to access equity and loan financing as and when needed; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group&#8217;s ability and history to control capital expenditure costs and lower other operational spend, as necessary.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Therefore, the Board has continued to adopt the going concern basis of preparation in the financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Whilst the Board is progressing with its plans to secure external financing these still require approval by third parties and if the Group is unable to the secure the external financing as discussed above, it has assessed that it would not be able to generate sufficient cash flows to support its level of activities beyond the third quarter 2021, in downside scenarios, or the fourth quarter 2021 in base case scenarios. This gives rise to a material uncertainty related to events or conditions that may cast signi&#64257;cant doubt on the Group&#8217;s ability to continue as a going concern and that it may therefore be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Estimates and judgments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as income and expenses in the financial period.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Judgements and assumptions are primarily made in relation to revenue recognition to determine whether promises contained within the collaboration agreements are distinct from the other promises in the contract, whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and for performance obligations satisfied over time the appropriate method of measuring progress for the purposes of revenue recognition. Estimates and assumptions are also made in relation to the valuation of ordinary shares, the incremental borrowing rate for leases, and valuation of derivatives. Details of the estimates and judgements made are included in the accounting policies set out below. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the Group&#8217;s control. Hence, estimates may vary from the actual values. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or the period of revision and future periods if this revision affects both current and future periods. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Basis of consolidation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated financial statements comprise the financial statements of the Company and its subsidiaries as at December&#160;31, 2019 and 2018. A subsidiary is an entity controlled, directly or indirectly, by Immunocore Limited. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br></div></div></div>
<!--End Page 274-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 275-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Control is regarded as the exposure or rights to the variable returns of the entity when combined with the power to affect those returns. The financial results of subsidiaries are consolidated from the date control is obtained until the date that control ceases.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Segment reporting</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group operates in one operating segment. The Group&#8217;s chief operating decision maker (the &#8220;CODM&#8221;), its Chief&#160;Executive Officer, manages the Group&#8217;s operations on an integrated basis for the purposes of allocating resources. The Group is registered in three geographic regions: the United Kingdom, the Republic of Ireland and the United&#160;States. Substantially all of the Group&#8217;s assets are held in the United Kingdom.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Foreign currencies</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Transactions in foreign currencies are translated to the Group companies&#8217; functional currency at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the statement of financial position date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are retranslated to the functional currency at foreign exchange rates ruling at the dates the fair value was determined. Foreign exchange differences arising on translation are recognized in the profit and loss account.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On consolidation, the assets and liabilities of foreign operations, are translated to the Group&#8217;s presentational currency, sterling, at foreign exchange rates ruling at the reporting date. The revenues and expenses of foreign operations are translated at an average rate for the year where this rate approximates to the foreign exchange rates ruling at the dates of the transactions. Foreign exchange differences arising on retranslation are recognized in other comprehensive income.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Revenue recognition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue arises from the supply of services under the Group&#8217;s collaboration agreements, which are reviewed and assessed in line with the five-step framework established by IFRS 15 &#8220;<font style="font-style: italic;">Revenue from Contracts with Customers</font>&#8221;. In doing so, the Group will consider the promises contained within the collaboration agreements and uses judgment to determine whether those promises are distinct from the other promises in the contract. In addition, the Group uses judgment to determine whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and for performance obligations satisfied over time the appropriate method of measuring progress for the purposes of revenue recognition. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Within these collaboration agreements, the Group grants licensing rights and access to the Group's technology to develop specified targets and commercialize future product candidates for specified targets defined in the respective collaboration agreements, in addition to research and development services and participation on a joint steering committee. In each of the collaboration agreements, these promises represent one combined performance obligation, because the promises are mutually dependent and the collaborator is unable to derive significant benefits from its access to these targets for their intended purpose without receipt of the remaining promises, which are highly specialized and cannot be performed by other organizations. This performance obligation is deemed satisfied when the collaborator is contractually entitled to exercise an option to obtain either exclusive rights or benefit from co-exclusive rights to the intellectual property license. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br></div></div></div>
<!--End Page 275-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 276-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Where the Group receives development milestones at key inflection points specified within the collaboration agreements, these are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. The Group determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applying a constraint to reduce the consideration to the amount which is not probable of being reversed. The determination of whether a milestone is probable includes consideration of the following factors:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies or the customer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the complexity and inherent uncertainty underlying the achievement of the milestone.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any development milestone revenue adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under these collaboration agreements, depending on the terms, the Group may also receive commercialization milestones upon the first commercial sale of a product, the amount of which is based on the territory the sale occurs in, and royalties based on worldwide net sales. These amounts have not been included within the transaction price as of December&#160;31, 2019 and 2018 because they are sales-based royalties which will be recognized when the subsequent sale occurs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue is recognized as the programs progress through the various stages of research and development using an estimate of percentage completion which takes into consideration the estimated timelines required to satisfy the performance obligation and the time taken since program nomination. The determination of the percentage of completion requires the estimation of when the performance obligation will be completed, and this is reviewed and re-assessed quarterly, typically by the joint steering committee for the contract, based on the latest project plan and discussions with project teams and will consider progress achieved to date, historical experience on similar programs and other internal factors as may be available. If a change in facts or circumstances occurs, the estimate of percentage completion is adjusted, and revenue recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate is recognized as an adjustment to revenue in the period in which the change in estimate occurs. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group recognizes deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied, or part satisfied, performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Changes in deferred revenue typically arise due to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustments arising from a change in the estimate of when the performance obligation will have been completed;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustment to revenue that affects deferred revenue;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a change in the estimate of the transaction price due to changes in the assessment of whether variable consideration is constrained because it is not considered probable of being received; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the recognition of revenue.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br></div></div></div>
<!--End Page 276-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 277-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Under certain collaboration agreements, research and development costs incurred in excess of a defined amount are reimbursed and such revenue is recognized in full when the reimbursements fall due. Reimbursements from the collaboration partner are evaluated as to whether the Group acts as a principal or an agent in such relationships. The Group evaluates whether control over the underlying goods or services were obtained prior to transferring these goods or services to the collaboration partner. Where the Group does not control the goods or services prior to transferring these goods or services to the collaboration partner, such reimbursements are presented net of costs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Research and development costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenditure is expensed as incurred. In preparing the financial statements, the Group may be required to estimate accrued research and development expenditure incurred, the most significant of which is that relating to ongoing clinical trials. These estimates are based on reviews of open contracts, reports provided by the contract research organizations (CROs) and internal reviews to estimate the level of service performed and the associated cost incurred for those services when the Group has not yet been invoiced or otherwise notified of the actual cost. The majority of CROs invoice the Group monthly in arrears for services performed or when contractual milestones are met. The Group makes estimates of accrued expenses as of each statement of financial position date in our financial statements based on facts and circumstances known at that time. The Group periodically confirms the accuracy of estimates with the CROs and adjust if necessary. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial terms agreed with the CROs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to the CROs will exceed the level of services provided and result in either a prepayment of the research and development expenses or, where the payments are repaid back to the Group at the end of the clinical trial, a non-current financial asset. In accruing clinical trial expenses, the Group estimates the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate made, the accrual or prepayment expense is adjusted accordingly.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Share-based payments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group operates equity-settled, share-based compensation plans whereby certain employees of the Group are granted equity awards in the Company. The grant date fair value of these employee share plan awards are calculated using both the Black Scholes valuation model and the Back Solve valuation model. The resulting cost is recognized in the profit and loss account over the vesting period of the awards, in line with the vesting schedule of the awards, being the period in which the services are received. The value of the charge is adjusted to reflect actual levels of awards vesting, except where the failure to vest is as a result of not meeting a market condition. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The valuations models used require the input of subjective assumptions, including assumptions about the expected life of share-based awards, share price volatility and as a privately held company, the estimated fair value of the Company&#8217;s ordinary shares. These assumptions used represent the Group&#8217;s best estimates at the time of grant, but the estimates involve inherent uncertainties and the application of its judgment.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Valuation of ordinary shares</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As there has been no public market for the Group&#8217;s ordinary shares to date, the estimated fair value of the ordinary shares has been determined by the board of directors as of the date of each grant, with input from management, considering the most recently available third-party valuations of the Group&#8217;s ordinary shares, and the assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. The ordinary share valuations were prepared using a probability weighting expected return and a current value method. The probability weighted expected return method estimates the fair value of the common stock based on an analysis of future </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br></div></div></div>
<!--End Page 277-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 278-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">values for the enterprise assuming various future outcomes. Share value is based on the probability-weighted present value of the expected future investment returns, considering each of the possible outcomes available to the enterprise, as well as the rights of each share class. Common future outcomes considered in the analysis include an initial public offering (&#8220;IPO&#8221;), merger or sale, continued operation as a private company, and liquidation. The current-value method is based on the assumption that each class of preferred shareholders will exercise its rights and achieve its return based on the enterprise value as of the valuation date and not at some future date. Accordingly, preferred shareholders will participate in enterprise value allocation either as preferred shareholders or, if conversion would provide them with better economic results, as common shareholders. Common shares are assigned a value equal to their pro rata share of the residual amount (if any) that remains after consideration of the liquidation preference of debt and preferred stock. Likewise, any outstanding options will share in the enterprise value only if the implied value of the fully-diluted common share resulting from the analysis indicates that the options are in-the-money. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to considering the results of these third-party valuations, the Board and the remuneration committee considered various objective and subjective factors to determine the fair value of our ordinary shares as of each grant date, including</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the data generated from the Group&#8217;s research and development programs;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the future operating performance, prospects and business strategy;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the material risks related to the Group&#8217;s business and industry;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of an active public market for the Group&#8217;s ordinary and convertible preferred shares;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market performance of publicly traded companies in the life science and biotechnology sectors; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prices at which the Group issued ordinary and preferred shares and the superior rights and preferences of the preferred shares relative to the ordinary shares at the time of each grant; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood of achieving a liquidity events for the holders of our ordinary shares, series A and B shares and Growth Shares, such as an IPO, given prevailing market conditions.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If different judgements and estimates had been made, the share-based payment expense, loss for the year and total comprehensive loss, on both an absolute and per-share basis, could have been significantly different.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Estimates by the Group&#8217;s management board will not be necessary to determine the fair value of ordinary shares once a public trading market for the ordinary shares has been established.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The various assumptions used in determining the grant date fair value of the awards and the resulting cost recognized in the profit and loss account are set out in the Note 22. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Taxation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. The U.K. Research and Development Tax Credit calculation incorporates an estimate of employee time spent on qualifying research and development activities which are reviewed and updated annually.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Tax on the loss for the year comprises current and deferred tax. Tax is recognized in the profit and loss account except to the extent that it relates to items recognized directly in equity, in which case it is recognized directly in equity. Current tax is provided at the amounts expected to be paid applying tax rates that have been enacted or substantively enacted by the statement of financial position date. Current tax includes tax credits, which are accrued for the period based on calculations that conform to the U.K. Research and Development Tax Credit </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br></div></div></div>
<!--End Page 278-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 279-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">scheme applicable to small and medium sized companies. Research and development costs which are not eligible for reimbursement under this scheme, such as expenditure incurred on research projects for which we receive income, may be reimbursed under the U.K. R&amp;D expenditure credit (&#8220;RDEC&#8221;) scheme.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred tax is provided in full, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets are recognized to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilized. Deferred tax is provided on temporary differences arising on investment in subsidiaries, associates and joint ventures, except where the timing of the reversal of the temporary difference can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is provided using rates of tax that have been enacted or substantively enacted by the statement of financial position date.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Leases &#8211; after the adoption of IFRS 16</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group&#8217;s right of use assets and lease liabilities associated with leases for leasehold properties are recognized at lease commencement date based on the present value of minimum lease payments over the lease term. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognizes a right of use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The right-of-use assets comprise leasehold property and reflect the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day and any initial direct costs less lease incentives that may have been received. They are subsequently measured at cost less accumulated depreciation, impairment losses and remeasurements of the underlying lease liability. Depreciation is charged to the profit and loss account on a straight-line basis over the expected life of each lease agreement. The Group assesses at each reporting date whether the right-of-use asset is impaired.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The lease liability is initially measured at the present value of the lease payments that are not paid at commencement date. Where the terms of the lease agreement include increases to the rent charge, the minimum guaranteed increase is included in the lease liability. They are subsequently measured by increasing the carrying amount to reflect interest of the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The lease liability will also be remeasured to reflect changes in the underlying lease agreement such as the expected lease length.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since the rate implicit in the lease is not readily determinable the Group uses incremental borrowing rates based on indicative borrowing rates that would be available based on the value, currency and borrowing term provided by financial institutions, adjusted for company and market specific factors. This incremental borrowing rate is the rate of interest that would have to be paid to borrow on a collateralized basis on an amount equal to the lease payments over a similar term in a similar economic environment, based on the information available at commencement date in determining the discount rate used to calculate the present value of lease payments. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group on occasion enters into sub-lease arrangements which are assessed at inception. For operating leases, the associated income is recognized in the profit and loss account on a straight-line basis over the term of the lease.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Leases &#8211; before the adoption of IFRS 16</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under IAS 17 &#8216;&#8216;<font style="font-style: italic;">Leases</font>&#8217;&#8217; (&#8220;IAS 17&#8221;), the Group classified leases as finance leases if they transferred substantially all the risks and rewards incidental to ownership, otherwise they were classified as operating leases.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Operating lease payments, under IAS 17, were recognized as an operating expense in the profit and loss account on a straight-line basis over the lease term. Lease incentives received were recognized in the profit and loss </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br></div></div></div>
<!--End Page 279-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 280-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">account over the term of the lease as part of the lease expense. Where the terms of the lease agreement include increases to the rent charge, the minimum guaranteed increase was recognized in the profit and loss account over the term of the lease. Where such increases are variable in nature these were recognized in the profit and loss account as incurred. Where the Group enters into sub-lease arrangements, the risks and rewards incidental to ownership of the asset are not substantially transferred and such operating lease income was recognized in the profit and loss account over the term of the lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019 and 2018, there were no assets held under finance leases.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents comprise cash balances and call deposits with original maturities of three months or less.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Loans and borrowings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All loans and borrowings are classified as financial liabilities and are initially recorded at fair value less the value attributable to any separately accounted for embedded derivative. After initial recognition, any such loans and borrowings are measured at amortized cost using the effective interest method, with the amortization recognized in finance costs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group has a convertible loan, evidenced by loan notes, which is classified as a current liability, as at December&#160;31, 2019, and accounted for under the amortized cost method and the embedded derivative, the conversion features, is accounted for separately. The convertible loan was initially recognized at fair value less the value attributable to the separated embedded derivative. The fair value of the embedded derivative is updated at each reporting period, with any changes in fair value recognized in finance income or finance costs as appropriate.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The fair value of the convertible loan is calculated based on the present value of the future principal and interest cash flows, discounted at the market rate at the statement of financial position date. The loan notes are subsequently measured at amortized cost, with the unwinding of the discount recorded in finance costs over the life of the loan. The initial difference between proceeds received, net of transaction costs, and fair value was recognized in finance income.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Derivatives</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Derivatives are initially measured at fair value and are subsequently remeasured to fair value at each reporting date. Changes in fair value are recognized in finance income or finance costs as appropriate.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Equity conversion features within host instruments that meet the definition of a derivative and have economic and risk characteristics that are not closely related to the host are considered embedded derivatives and are separated from the host instrument and accounted for separately.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group has a recognized embedded derivative asset related to the conversion features within the $40&#160;million convertible loan it received from the Bill and Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;). This derivative financial asset was initially recorded at fair value and re-measured to fair value at each reporting period, while the convertible loan is outstanding, with gains and losses arising from changes in the fair value recognized in finance income or finance costs as appropriate. The initial tranche of the Gates Foundation convertible loan in the amount of $25&#160;million was converted into equity as part of the Group&#8217;s series B preferred share financing in March 2020 and the embedded derivative asset derecognized.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The fair value of the embedded derivative asset was determined using the Back Solve model, discounted and probability weighted for the conversion features within the underlying convertible loan, which includes unobservable inputs supported by little or no market activity. The conversion features within the convertible loan </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br></div></div></div>
<!--End Page 280-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 281-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Accounting policies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">are activated under different circumstances and the resulting fair value may vary based on factors including the date of conversion or the event triggering conversion, such as an IPO or the Gates Foundation electing to convert its loan to the Group into equity, under certain specified circumstances. The option pricing model incorporates input assumptions reflecting the varied circumstances under which the conversion from debt to equity may occur. Significant unobservable inputs used in the fair value measurement of the embedded derivative asset are predominantly regarding the probability of each of the conversion features occurring. The probabilities are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date. The Group will de-recognize the embedded derivative asset when the convertible loan is settled or converted.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group also has a derivative liability that is marked to fair valued at each reporting period. The derivative liability represents a foreign exchange call option over certain series B shares which was settled in full in March 2020.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The fair value of the derivative liability was determined using an option pricing model using a range of inputs both observable and unobservable in nature. The unobservable input was the expected final close date of the series B private finance round which was determined based on all relevant internal and external information available and was reviewed and reassessed at each reporting date. The resulting fair value of the derivative liability was not sensitive to changes in the expected close date.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Fair value measurements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Where financial and non-financial assets and liabilities are measured at fair value, the Group uses appropriate valuation techniques for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the changes have occurred.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The carrying amount of cash and cash equivalents, trade receivables, short and long-term deposits, trade payables, accruals and other current liabilities in the Group&#8217;s consolidated statement of financial position approximates their fair value because of the short maturities of these instruments. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">2. New accounting standards</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">IFRS 16 Leases</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">IFRS 16 &#8220;<font style="font-style: italic;">Leases</font>&#8221; (&#8220;IFRS 16&#8221;) supersedes IAS 17 and requires lease liabilities and right of use assets to be recognized on the statement of financial position for those leases which conveys the right to control the use of an asset. In applying IFRS 16, the Group is required to exercise judgement and to take into consideration all the relevant facts and circumstances relating to each contract.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group adopted IFRS 16 using the modified transition approach with the date of initial application of January&#160;1, 2019. Under this method, the Group has elected to apply the standard to all leases at the date of initial </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br></div></div></div>
<!--End Page 281-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 282-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2. New accounting standards<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">application. The cumulative effect of initially applying IFRS 16 is recognized at January&#160;1, 2019 as an adjustment to the opening balance of the accumulated deficit. Therefore, the comparative information is not restated and continues to be reported under IAS 17.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group recognized right of use assets and lease liabilities for all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Previously, the Group recognized operating lease expenses on a straight-line basis over the term of the lease and recognized assets and liabilities only to the extent that there was a timing difference between actual lease payments and the expense recognized.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Lease liabilities are measured at the present value of the lease payments that are not paid at commencement date. Where the terms of the lease agreement include increases to the rent charge, the minimum guaranteed increase is included in the lease liability. Similarly, lease liabilities also include contractual penalties for early termination where the Group is reasonably certain that a lease agreement containing such provisions will be terminated early. The&#160;discount rate applied is the Group&#8217;s incremental borrowing rate. Such liabilities are subsequently measured at amortized cost, using the effective interest method, and recognizing lease payments made.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Right-of-use assets reflect the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day and any initial direct costs less lease incentives that may have been received. They&#160;are subsequently measured at cost less accumulated depreciation and impairment losses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The most significant judgements in applying IFRS 16 relate to the determination of the discount rate and the lease term. The lease terms for leasehold properties may include a non-cancellable period, the right to extend and the option to terminate the lease early. When determining the lease term, the Group will assess all relevant facts relating to each leasehold property and will reassess the lease term annually.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Leases in which the Group is a Lessor</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Where the Group enters into sub-lease arrangements, the Group has assessed the sub-lease under IFRS 16 with reference to the right of use asset to determine the classification as either a finance lease or operating lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For those sub-lease arrangements assessed as a finance lease, the Group recognizes the net investment in the sub-lease and derecognizes the right of use asset associated with the head lease with the difference recognized in the profit and loss account.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For those sub-lease arrangements classified as an operating lease, the associated sub-lease income is recognized in the profit and loss account on a straight-line basis over the term of the lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The adjustment made on the transition date of January&#160;1, 2019 to each statement of financial position item is as follows,</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">as previously <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reported <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.92%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">IFRS 16 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">adjustments <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">as adjusted <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<font style="padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.34pt; text-align: left;"><font style="padding-left: 5pt;">24,596</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.47pt; text-align: left;"><font style="padding-left: 3.33pt;">44,984</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.64pt; text-align: left;"><font style="padding-left: 8.33pt;">69,580</font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<font style="padding-left: 0.31pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.34pt; text-align: left;">171,181</div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.47pt; text-align: left;"><font style="padding-left: 12.5pt;">(486)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.64pt; text-align: left;"><font style="padding-left: 3.33pt;">170,695</font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<font style="padding-left: 1.41pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.34pt; text-align: left;"><font style="padding-left: 1.67pt;">(49,607)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.47pt; text-align: left;"><font style="padding-left: 12.5pt;">(828)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.64pt; text-align: left;"><font style="padding-left: 5pt;">(50,435)</font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.34pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(89,588</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.47pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(43,670</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.64pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(133,258</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 64.1%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total net assets<font style="font-weight: normal; padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.34pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">56,582</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.92%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.47pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.42%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.64pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">56,582</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br></div></div></div>
<!--End Page 282-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 283-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The adoption of IFRS 16 did not have an impact on the Group&#8217;s accumulated deficit.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group used the following practical expedients when applying IFRS 16 to leases previously classified as operating leases under IAS 17.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Applied a single discount rate to a portfolio of leases with similar characteristics.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Applied the exemption not to recognize right of use assets and liabilities for assets with less than 12&#160;months of lease term.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Excluded initial direct costs from measuring the right of use asset at the date of initial application.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">When measuring lease liabilities at January&#160;1, 2019, the date of initial application, the Group discounted lease payments applying an incremental borrowing rate to lease agreement grouped by expected length of lease term. The Group&#8217;s weighted average incremental borrowing rate at the date of initial application was 6%.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The difference between operating lease commitments under IAS 17 at December&#160;31, 2018, discounted using the weighted average incremental borrowing rate of 6%, and lease liabilities recognized at the date of initial application of IFRS 16 is immaterial. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">3. Revenue &amp; segmental reporting</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue recognized during 2019 and 2018 was from collaboration agreements with GlaxoSmithKline Intellectual Property Development Ltd (&#8220;GlaxoSmithKline&#8221;), Eli Lilly and Company (&#8220;Eli Lilly&#8221;), Genentech, Inc. (&#8220;Genentech&#8221;) and MedImmune LLC, a wholly owned subsidiary of AstraZeneca plc (&#8220;MedImmune&#8221; ).</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GlaxoSmithKline<font style="padding-left: 0.95pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">5,753</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,079</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.65pt; padding-bottom: 2.65pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 2.06pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 2.65pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">819</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 2.65pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">8,561</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 3.74pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">19,097</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,461</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">MedImmune<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,553</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,669</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,654</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">5,753</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 6pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,079</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States<font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,916</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">17,575</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,669</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,654</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.9pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current deferred income (see Note 21)<font style="padding-left: 2.7pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">28,457</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 2.65pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">29,437</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current deferred income (see Note 19)<font style="padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">47,961</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.65pt; padding-bottom: 3.9pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.65pt; padding-bottom: 3.9pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">68,795</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">76,418</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.9pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">98,232</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred revenue is in respect of the upfront fee and development milestone consideration received from the various collaboration agreements in advance of services performed by the Group. Included in the current deferred revenue balance of &#163;28,457,000 at December&#160;31, 2019 is &#163;3,132,000 of deferred revenue that will be held whilst a further program is nominated into an existing collaboration in accordance with the underlying collaboration agreement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue recognized during 2019 that was included in the deferred revenue balance as at December&#160;31, 2018 totaled &#163;21,814,000 (2018: &#163;16,071,000). No revenue was recognized in 2019 relating to performance obligations satisfied in previous years (2018: &#163;nil). </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-20<br></div></div></div>
<!--End Page 283-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 284-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">4. Operating loss is stated after charging:</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following items have been included in operating loss:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development costs<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">99,991</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">83,575</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss on disposal of property, plant and equipment<font style="padding-left: 0.83pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">3</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">135</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss on write-offs of intangible fixed assets<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">306</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">170</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation of property, plant and equipment (see Note 12)<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">9,003</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,410</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization of intangible assets (see Note 11)<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">210</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">297</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease expense (see Note 13)<font style="padding-left: 3.81pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">486</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4,205</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease income (see Note 6)<font style="padding-left: 1.58pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">185</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 9.17pt;">(622)</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Realized foreign exchange (gains)/loss<font style="padding-left: 3.79pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">189</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(1,341)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development costs are stated net of the research and development expenditure credit, totaling &#163;396,000 for 2019 (2018: &#163;237,000).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">5. Staff numbers and costs</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The average number of persons employed by the Group (including the Board) during the year, analyzed by category, was as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 No. of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">employees</div></td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.52%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 No. of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">employees</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research<font style="padding-left: 0.86pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;">284</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;">299</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Development<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;">108</div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="padding-left: 5pt;">95</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Corporate<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">67</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">67</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total<font style="font-weight: normal; padding-left: 0.64pt;"></font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">459</font></div></td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.52%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.38pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">461</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Group</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The aggregate staff costs of these persons were as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.83%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.83%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.83%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wages and salaries<font style="padding-left: 0.01pt;"></font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">31,920</div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">29,501</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Social security costs<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">2,767</font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">2,731</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based payments (see Note 22)<font style="padding-left: 3.13pt;"></font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">3,056</font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">666</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contributions to defined contribution plans (see Note 24)<font style="padding-left: 2.58pt;"></font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,213</font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">981</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">38,956</font></div></td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.83%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">33,879</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">6. Other operating income</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 3.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rental income<font style="padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">185</font></div></td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">622</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">185</font></div></td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">622</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other income comprises income from sub-lease arrangements on operating leases for certain leasehold properties. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-21<br></div></div></div>
<!--End Page 284-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 285-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">7. Finance income</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 3.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 3.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.37%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bank interest on cash and cash equivalents<font style="padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,386</div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">550</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on short-term deposits<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">272</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gain on entering into sub-leases on leasehold properties<font style="padding-left: 2.6pt;"></font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.87pt;">115</font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease interest income<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">9</font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gain from change in fair value of embedded derivative asset<font style="padding-left: 3.18pt;"></font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">318</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,510</font></div></td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.37%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,140</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group received a convertible loan in September 2017 from the Gates Foundation which contains conversion features which are accounted for as an embedded derivative and separated from the convertible loan. The gain from the change in fair value of the embedded derivative asset represents the movement in fair value of this embedded derivative during 2018 (see Note 23). During 2019, a loss of &#163;454,000 arose from the change in fair value of the embedded derivative asset (see Note 8).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">8. Finance costs</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 3.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 3.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.57%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on lease liabilities<font style="padding-left: 0.33pt;"></font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,947</div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest expenses on financial liabilities measured at amortized cost<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">849</font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;">842</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from change in fair value of embedded derivative asset<font style="padding-left: 3.73pt;"></font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">454</font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from change in fair value of derivative liability<font style="padding-left: 1.48pt;"></font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5,127</div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other finance costs<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">2</font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">9,379</font></div></td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.57%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">842</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest expenses relate to the convertible loan received from the Gates Foundation (see Note 23).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The derivative liability represents a foreign exchange call option over series B shares. The loss from the change in fair value of the derivative liability represents the movement in fair value of this derivative from inception, during 2019, to December&#160;31, 2019.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Income tax</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The major components of the income tax expenses for the years ended December&#160;31, 2019 and 2018 are:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Profit or loss<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current tax:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D tax credit for the year<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(21,767)</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(18,486)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax related to share-based compensation plans<font style="padding-left: 2.17pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">125</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign corporation tax on profits for the year<font style="padding-left: 2.58pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">152</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">139</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments in respect of prior years<font style="padding-left: 0.35pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">43</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current tax<font style="font-weight: normal; padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(21,572)</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(18,222)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Originating and reversal of timing differences, including adjustments in respect of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">prior years<font style="padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(686</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">1,674</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total deferred tax<font style="font-weight: normal; padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(686</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">1,674</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total income tax credit<font style="font-weight: normal; padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(22,258</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(16,548</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-22<br></div></div></div>
<!--End Page 285-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 286-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Income tax<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Other comprehensive income</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax related to items recognized in other comprehensive income during the year:<br></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current tax related to share-based compensation plans<font style="padding-left: 0.93pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(125)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax on fair value movements of available-for-sale financial assets<font style="padding-left: 1.75pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,509</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax charged to other comprehensive income<font style="font-weight: normal; padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(3,634</font><font style="min-width: 25.83pt;">)</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reconciliation of tax expense and accounting profit for 2019 and 2018:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.66%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before tax<font style="font-weight: normal; padding-left: 1.04pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(126,189</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(88,178</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax credit using the UK Corporation tax rate of 19% (2018: 19%)<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(23,976)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(16,754)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of:<br></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-deductible expenses<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">13,148</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">629</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income not taxable for tax purposes<font style="padding-left: 4.79pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(954)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chargeable gain on sale of assets held for sale<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">4,359</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other permanent differences<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 27.5pt;">(1)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(38)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additional deduction for R&amp;D expenditure<font style="padding-left: 1.44pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(29,365)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(13,691)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surrender of tax losses for R&amp;D tax credit refund<font style="padding-left: 2.6pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">28,523</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">24,223</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">R&amp;D expenditure credits<font style="padding-left: 0.32pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">(22,602)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(19,215)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Credit to other comprehensive income for share-based compensation plans<font style="padding-left: 2.07pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">125</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Movement in deferred tax not recognized<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">12,413</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">4,746</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to tax charge in respect of previous periods - deferred tax<font style="padding-left: 1.71pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(500)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to tax charge in respect of previous periods<font style="padding-left: 0.56pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">43</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effects of tax rates in foreign jurisdictions<font style="padding-left: 3.87pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">59</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">22</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total tax credit included in loss for the year<font style="font-weight: normal; padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.66%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">(22,258</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.21%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(16,548</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The components of income tax are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt;">&#8203;</td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.48%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current tax:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Federal<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">100</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">137</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">State<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">15</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 25.83pt;">2</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom<font style="padding-left: 4.18pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(21,687</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(18,361</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current tax<font style="font-weight: normal; padding-left: 3.63pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(21,572)</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(18,222)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States:<br></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Federal<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(644)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(516)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">State<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">(42)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">(1)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom<font style="padding-left: 4.18pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 4pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">2,191</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total deferred tax<font style="font-weight: normal; padding-left: 4.19pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(686)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">1,674</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total income tax credit<font style="font-weight: normal; padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(22,258</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.48%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(16,548</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-23<br></div></div></div>
<!--End Page 286-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 287-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Income tax<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Other comprehensive income</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Tax related to items recognized in other comprehensive income during the year:<font style="font-style: normal;"> </font></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States<font style="padding-left: 3.07pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom &#8211; current tax<font style="padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">(125)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom &#8211; deferred tax<font style="padding-left: 3.66pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(3,509</font><font style="min-width: 25.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax charged to other comprehensive income<font style="font-weight: normal; padding-left: 0.52pt;"></font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(3,634</font><font style="min-width: 25.83pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September 2016, the U.K. substantively enacted legislation to reduce the main rate of corporation tax from 20% to 19% effective April 1, 2017 and then a further reduction to 17% effective April 1, 2020. On March&#160;11, 2020, the Chancellor of the Exchequer announced that the rate would not reduce on April&#160;1, 2020 and would remain at 19%.&#160;As this was not substantively enacted at the statement of financial position date, the 17% rate has been used for the purposes of measuring unrecognized U.K. deferred tax asset.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A deferred tax asset of &#163;1,507,000 has been recognized in 2019 (2018: &#163;872,000) representing unused tax credits carried forward for the Group's U.S. subsidiary, Immunocore LLC.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to the deferred tax asset above, the Group has unrecognized deferred tax assets on gross tax losses of &#163;20,820,000 (2018: &#163;12,239,000) which do not expire. Deferred tax assets have not been recognized in respect of these losses as they may not be used to offset taxable profits elsewhere in the Group and there are no other tax planning opportunities or other evidence of recoverability in the near future. If the Group were able to recognize all unrecognized deferred tax assets, the income tax credit would increase by &#163;23,007,000 (2018: &#163;14,430,000).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">10. Basic and diluted loss per share</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.51%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.47%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the year<font style="font-weight: normal; padding-left: 3.27pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 4.17pt;">(103,931)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.8pt;">(71,630)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted weighted average number of shares<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">4,459,587</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 39.63pt;">4,311,778</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<font style="font-weight: normal; padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 3pt double #000000; min-width: 40pt;">(0.02</font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.51%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.47%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 18.8pt; border-bottom: 3pt double #000000; min-width: 39.63pt;">(0.02</font><font style="min-width: 39.63pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Basic loss per share is calculated by dividing the loss for the period attributable to the equity holders of the Group by the weighted average number of shares outstanding during the period. The dilutive effect of potential shares through share options are considered to be anti-dilutive as they would decrease the loss per share and are therefore excluded from the calculation of diluted loss per share.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">11. Intangible assets</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Patent and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">trademarks <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Computer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">software <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Assets under <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">construction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost:<br></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;">516</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.42pt; text-align: left;">828</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.51pt; text-align: left;"><font style="padding-left: 3.16pt;">170</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,514</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.42pt; text-align: left;"><font style="padding-left: 4.75pt;">38</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.51pt; text-align: left;"><font style="padding-left: 7.91pt;">13</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 11.88pt;">51</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Write-offs<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.42pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.51pt; text-align: left;">(170)</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.96pt;">(170)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign currency translation<font style="padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 14.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 10.42pt; text-align: left;"><font style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; min-width: 14.25pt;">1</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.51pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 1pt solid #000000; min-width: 17.41pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 16.63pt; border-bottom: 1pt solid #000000; min-width: 21.38pt;">1</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.87pt; text-align: left;">516</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 10.42pt; text-align: left;">867</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 13.51pt; text-align: left;"><font style="padding-left: 7.91pt;">13</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,396</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-24<br></div></div></div>
<!--End Page 287-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 288-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">11. Intangible assets<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Patent and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">trademarks <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Computer <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">software <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Assets under <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">construction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.04%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 3.16pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 7.91pt;">76</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 2.46pt;">122</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt;">198</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transferred<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 7.91pt;">24</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 4.05pt;">(24)</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Write-offs<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 14.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 17.41pt;">(967</font><font style="min-width: 17.41pt;">)</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 16.71pt;">(111</font><font style="min-width: 16.71pt;">)</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: justify;"><font style="border-bottom: 1pt solid #000000; min-width: 24.54pt;">(1,078</font><font style="min-width: 24.54pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.87pt; text-align: left;">516</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 7.91pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt;">516</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization and impairment:<br></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;">477</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt;">304</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt;">781</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization for the year<font style="padding-left: 1.45pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 14.25pt;">39</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 1pt solid #000000; min-width: 17.41pt;">258</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt; border-bottom: 1pt solid #000000; min-width: 16.71pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">297</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.87pt; text-align: left;">516</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt;">562</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: justify;"><font style="padding-left: 3.16pt;">1,078</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Write-offs<font style="padding-left: 1.62pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;">(772)</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 7.13pt;">(772)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amortization for the year<font style="padding-left: 1.45pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; min-width: 14.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 1pt solid #000000; min-width: 17.41pt;">210</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt; border-bottom: 1pt solid #000000; min-width: 16.71pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">210</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 14.25pt;">516</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 3pt double #000000; min-width: 17.41pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt; border-bottom: 3pt double #000000; min-width: 16.71pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">516</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Carrying value:<br></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 14.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 7.91pt; border-bottom: 3pt double #000000; min-width: 17.41pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt; border-bottom: 3pt double #000000; min-width: 16.71pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="padding-left: 1.73pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 14.25pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 3pt double #000000; min-width: 17.41pt;">305</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 7.21pt; border-bottom: 3pt double #000000; min-width: 16.71pt;">13</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">318</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.87pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 14.25pt;">39</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 8.84pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 3pt double #000000; min-width: 17.41pt;">524</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 13.86pt; text-align: left;"><font style="padding-left: 2.46pt; border-bottom: 3pt double #000000; min-width: 16.71pt;">170</font></div></td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.04%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: -3.17pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">733</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Patent and trademarks comprise the purchase of intellectual property from the Company&#8217;s predecessor on January&#160;1, 2016. Assets under construction represents the development of bespoke software.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following a review undertaken during the year ended December 31, 2019, a total of &#163;306,000 intangible assets were written-off comprising, &#163;195,000 of computer software and &#163;111,000 of assets under construction.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-25<br></div></div></div>
<!--End Page 288-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 289-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg17"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">12. Property, plant and equipment</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.01%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leasehold <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">properties and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">improvements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">including right <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of use assets <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.78%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Plant and <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equipment <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Assets under <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">construction <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.58%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cost:<br></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">7,650</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;">22,943</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt;">3,934</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">34,527</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 11.88pt;">146</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">1,571</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt;">1,769</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.75pt;">3,486</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfers<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">3,558</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">1,156</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;">(4,714)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign currency translation<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 16.63pt;">10</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 21.38pt;">7</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 16.63pt;">17</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(227</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 13.46pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(38</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(265</font><font style="min-width: 26.13pt;">)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 0.52pt;">11,137</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;">25,639</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 10.29pt;">989</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">37,765</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of adopting new accounting standards<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">44,984</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">44,984</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 5.1pt;">1,112</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">1,150</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt;">2,713</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.75pt;">4,975</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfers<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">1,090</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 16.63pt;">41</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;">(1,131)</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign currency translation<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 13.46pt;">(17)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 18.21pt;">(4)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 13.46pt;">(21)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements<font style="padding-left: 3.73pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 1.59pt;">(6,849)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 1.59pt;">(6,849)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(185</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(500</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(685</font><font style="min-width: 26.13pt;">)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">51,272</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">26,326</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">2,571</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">80,169</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation and impairment:<br></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">1,821</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">8,787</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">10,608</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge for the year<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">2,023</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">4,387</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.75pt;">6,410</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign currency translation<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 21.38pt;">3</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 21.38pt;">3</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 13.46pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(92</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 13.46pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(38</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(130</font><font style="min-width: 26.13pt;">)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">3,752</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;">13,139</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">16,891</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in accounting policies<font style="padding-left: 1.49pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 16.63pt;">&#8212;</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge for the year<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt;">4,501</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt;">4,502</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 4.75pt;">9,003</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of foreign currency translation<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 18.21pt;">(2)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 18.21pt;">(3)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 18.21pt;">(5)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disposals<font style="padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(155</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(445</font><font style="min-width: 26.13pt;">)</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 1pt solid #000000; min-width: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 8.71pt; border-bottom: 1pt solid #000000; min-width: 26.13pt;">(600</font><font style="min-width: 26.13pt;">)</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 26.13pt;">8,096</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">17,193</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 15.04pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">25,289</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Carrying value:<br></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt;">&#160;</div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">43,176</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 26.13pt;">9,133</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">2,571</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">54,880</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 2.27pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 26.13pt;">7,385</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">12,500</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 10.29pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">989</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">20,874</font></div></td></tr><tr><td style="width: 58.97%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.01%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><font style="padding-left: 4.75pt; border-bottom: 3pt double #000000; min-width: 26.13pt;">5,829</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.78%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 5.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">14,156</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.49%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.94pt; text-align: left;"><font style="padding-left: 3.16pt; border-bottom: 3pt double #000000; min-width: 24.54pt;">3,934</font></div></td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.58%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 26.13pt;">23,919</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019, none of the Group&#8217;s property, plant and equipment was held under finance leases or similar hire purchase agreements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Right-of-use assets represent leasehold properties recognized in accordance with IFRS 16 (see Note 13). The remeasurement of during the year ended December&#160;31, 2019 of &#163;6,849,000 relates to the reduction to the lease term for a leasehold property. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-26<br></div></div></div>
<!--End Page 289-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 290-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg18"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">13. Leases</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group leases leasehold properties, some of which are subject to sub-lease arrangements. Information about leases for which the Group is a lessee and a lessor is presented below. The lease payments for short-term leases and leases of low value assets are recognized in the profit and loss account on a straight-line basis over the term of the lease.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">These leases have terms that may include,</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Options to terminate the lease early at the right of the tenant</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Variable lease payments with a guaranteed minimum increase and capped maximum increase</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, there are leasehold properties to which the Group is committed to assume the leases should the properties become vacant. The future contingent liabilities associated with these leases are set out in Note 25.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Leases in which the Group is a Lessee</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Right-of-use assets</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at January&#160;1, 2019<font style="padding-left: 4.16pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effect of adopting new accounting standards<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">44,984</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Additions<font style="padding-left: 1.06pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">897</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remeasurements<font style="padding-left: 2.19pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(6,849)</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Depreciation charge for the year<font style="padding-left: 2.98pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">(2,454</font><font style="min-width: 27.5pt;">)</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">36,578</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon implementation of IFRS 16, current deferred liabilities of &#163;187,000 and non-current deferred liabilities of &#163;1,870,000 were reclassified to right of use assets reflecting primarily lease incentives previously recognized under IAS 17.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Lease liabilities</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Maturity analysis &#8211; contractual undiscounted cash flows</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than one year<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4,469</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">One to five years<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,834</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than five years<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">45,288</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease liabilities at December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.73pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">66,591</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">All operating leases, excepting those of small value, terminate within one year.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-27<br></div></div></div>
<!--End Page 290-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 291-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg19"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">13. Leases<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Lease liabilities included in the consolidated statement of financial position</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 3.47%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current<font style="padding-left: 4.95pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,951</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current<font style="padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">38,299</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities at December&#160;31, 2019<font style="padding-left: 2.11pt;"></font></div></td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.47%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">40,250</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts recognized in the Consolidated Statement of Loss</div></td><td class="gutter" style="width: 4.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on lease liabilities<font style="padding-left: 3.33pt;"></font></div></td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,947</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expenses relating to short-term leases<font style="padding-left: 0.57pt;"></font></div></td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt;">486</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expenses relating to leases of low-value assets<font style="padding-left: 3.93pt;"></font></div></td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">33</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income from sub-leasing right-of-use-asset<font style="padding-left: 0.58pt;"></font></div></td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">(9</font><font style="min-width: 22.5pt;">)</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Operating lease rentals payable</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group has operating leases on leasehold properties. All such operating leases are for less than fifty years. Future minimum rentals payable under non-cancellable operating leases as at December&#160;31 are, as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Within one year<font style="padding-left: 0.81pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">73</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4,329</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">After one year but not more than five years<font style="padding-left: 2.15pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,566</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than five years<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">60,691</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">73</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">81,586</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year, &#163;486,000 was recognized as an expense in the income statement in respect of operating leases (2018: &#163;4,205,000).</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amounts recognized in the Consolidated Statement of Cash Flows</div></td><td class="gutter" style="width: 4.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.01%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total cash outflow for leases<font style="padding-left: 2.37pt;"></font></div></td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.01%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,036</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Leases in which the Group is a lessor</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease income</div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 4.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease income<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;">185</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance lease income on the net investment in the lease<font style="padding-left: 1.15pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">9</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maturity analysis &#8211; undiscounted finance lease income</div></td><td class="gutter" style="width: 4.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 4.42%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than one year<font style="padding-left: 3.32pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;">317</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">One to two years<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;">317</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Two to three years<font style="padding-left: 4.02pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">12</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Three to four years<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Four to five years<font style="padding-left: 2.2pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than five years<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted finance lease income<font style="padding-left: 4.6pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">646</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unearned finance income<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 15pt;">(39</font><font style="min-width: 15pt;">)</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net investment in the lease<font style="padding-left: 3.88pt;"></font></div></td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 4.42%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">607</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-28<br></div></div></div>
<!--End Page 291-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 292-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg20"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">13. Leases<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 3.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maturity analysis &#8211; undiscounted operating lease income</div></td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less than one year<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">96</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;">176</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">One to two years<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">50</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5.37pt;">11</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Two to three years<font style="padding-left: 0.02pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">12</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5.37pt;">11</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Three to four years<font style="padding-left: 2.66pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5.37pt;">11</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Four to five years<font style="padding-left: 3.2pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5.37pt;">11</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">More than five years<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted operating lease income<font style="font-weight: normal; padding-left: 1.91pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">158</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">220</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">14. Other non-current financial assets</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 1.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Security deposits</div></td><td class="gutter" style="width: 2.08%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.08%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.08%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.08%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term security deposits<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,532</div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,532</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,858</font></div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,390</font></div></td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,532</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The long-term security deposits represent lease security deposits for buildings.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income are those amounts paid in advance for clinical trials that will be repaid at the end of the associated clinical trials.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">15. Available for sale assets</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group previously held an investment in Adaptimmune Therapeutics plc which was classified as available for sale as at the year ended December&#160;31, 2017. The investment was sold during the year ended December&#160;31, 2018 for cash consideration of &#163;27,451,000, giving rise to a gain on disposal of &#163;4,979,000 recognized in Other income. Prior to disposal, unrealized gains and losses relating to prior financial reporting periods were recognized in other comprehensive income, as reflected in the available for sale reserve in the consolidated statement of equity, totaling &#163;18,471,000. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">16. Trade and other receivables</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 1.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,471</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">4,374</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other receivables<font style="padding-left: 0.43pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3,667</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">1,631</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivable<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">28</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">167</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,473</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">7,566</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">9,639</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">13,738</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">17. Cash and cash equivalents </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 1.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash at bank and in hand<font style="padding-left: 1.54pt;"></font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-29<br></div></div></div>
<!--End Page 292-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 293-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg21"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">18. Capital and reserves</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issued share capital<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">(0.01p per share)</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series A <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.58%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ordinary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 2.91pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">155,246</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,699,576</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,459,363</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 4.9pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">10,950</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Repurchased and cancelled<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt;">(36,800)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 0.34pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">118,446</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">1,699,576</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">2,470,313</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 4.9pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">621,556</div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">45,581</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Repurchased and cancelled<font style="padding-left: 1pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(60,240</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.34pt;"></font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">58,206</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,699,576</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">621,556</font></div></td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.58%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,515,894</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;</div></td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allotted, called up and fully paid<br></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ordinary shares<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">252</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">247</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series A shares<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">170</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">170</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series B shares<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">62</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Growth shares<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">6</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">12</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">490</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">429</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On August 13, 2019, the Group completed the first closing of the series B preferred share private financing. A total of 621,556 series B shares were issued to new and existing investors totaling proceeds of $72.25&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the period to December 31, 2019, 45,581 ordinary shares of 0.01p each with a nominal value of &#163;5 were issued fully paid for cash consideration of &#163;27,000 of which 37,007 were issued as anti-dilution shares at nominal value. Growth Shares of 0.01p each totaling 60,240 with a nominal value of &#163;6 repurchased and cancelled.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Growth Shares were issued in respect of the Growth Share Plan (see Note 22) and the awards granted to certain employees and members of the Board during 2017. These Growth Shares are held by Immunocore Nominees Limited on behalf of the individuals who received these awards. In accordance with the Growth Share Plan rules, the shares held by Immunocore Nominees Limited are considered treasury shares until all vesting conditions have been achieved and the awards vested.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-30<br></div></div></div>
<!--End Page 293-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 294-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg22"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Share premium</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="font-weight: normal; padding-left: 1.91pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">223,986</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">101 </font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018<font style="font-weight: normal; padding-left: 4.34pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">224,087</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">59,163 </font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.34pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">283,250</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">New shares issued during the year ended December 31, 2019 gave rise to net proceeds of &#163;59,163,000. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Nature and purpose of reserves</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The share-based payments reserve is used to recognize the value of equity-settled share-based payments provided to employees. All other reserves are as stated in the consolidated statement of changes in equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The treasury reserve represents those unvested awards granted to certain employees and members of the Board under the Growth Share Plan (see Note 22). As at December 31, 2019, the treasury reserve totaled &#163;4.42 (2018: &#163;10.19).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">No dividends were paid or declared in the years ended December&#160;31, 2019 and December&#160;31, 2018. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Capital management</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The capital structure of the Group consists of shareholders&#8217; equity, debt, cash and fixed notice long- and short-term deposits. For the foreseeable future, the Board will maintain a capital structure that supports the Group&#8217;s strategic objectives through:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">managing the budgeting process;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">managing funding and liquidity risk; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintaining strong investor relations.</div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">19. Interest-bearing loans and borrowing and deferred liabilities</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term convertible loan (see Note 23)<font style="padding-left: 1.02pt;"></font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,878</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">18,878</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The contractual maturity for the first tranche of the Gates Foundation long term convertible loan is September&#160;12, 2020, being three years after the September&#160;13, 2017 issue date. Accordingly, as at December&#160;31, 2019, the long-term convertible loan was reclassified from a non-current liability to a current liability (see Note&#160;21).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-31<br></div></div></div>
<!--End Page 294-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 295-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg23"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Deferred liabilities</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">47,961</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">68,795</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred rent<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,870</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">47,961</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">70,665</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred revenue is in respect of the upfront fee and development milestones payments received from collaboration agreements in advance of services performed by the Group (see Note 3).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On implementation of IFRS 16, previously recognized deferred rent balances were reclassified to right-of-use assets (see Note 13).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">20. Provisions</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2018<font style="padding-left: 0.92pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt;">267</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arising during the year<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 8.33pt;">50</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Utilized<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 18.33pt;">(100</font><font style="min-width: 18.33pt;">)</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December 31, 2018<font style="font-weight: normal; padding-left: 3.34pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt;">217</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Arising during the year<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt;">150</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Utilized<font style="padding-left: 2.29pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">(79</font><font style="min-width: 18.33pt;">)</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019<font style="font-weight: normal; padding-left: 3.34pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 4.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">288</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current<font style="font-weight: normal; padding-left: 4.7pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 4.75pt;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 4.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">183</font></div></td></tr><tr><td style="width: 92.31%; text-align: left; vertical-align: bottom; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current<font style="font-weight: normal; padding-left: 1.37pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.16pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 18.33pt;">105</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The provision represents the contractual liability that will arise on termination of lease agreements on leasehold properties.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">21. Current liabilities</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Short-term convertible loan (see Note 23)<font style="padding-left: 0.46pt;"></font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,157</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.59%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 3.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.74pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">19,157</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.59%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September 2017, the Company entered into a $40&#160;million convertible loan agreement and a global access agreement with the Gates Foundation, pursuant to which the Company agreed to develop, manufacture and commercialize soluble TCR bispecific therapeutic candidates targeted to neglected diseases, primarily tuberculosis and human immunodeficiency virus (&#8220;HIV&#8221;), with the potential to treat people at an affordable price in developing countries. The initial tranche of the convertible loan in the amount of $25&#160;million was directed to the development of product candidates for the treatment of tuberculosis or HIV, and converted into equity as part of the Group&#8217;s series B preferred share financing (see Note 23). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The loan notes issued by the Company to the Gates Foundation are accounted for as financial liabilities in these financial statements. The equity conversion feature in the loan note meet the definition of an embedded derivative and are separated from the convertible loan and accounted for separately (see Note 23).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-32<br></div></div></div>
<!--End Page 295-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 296-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg24"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">21. Current liabilities<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The contractual maturity for the first tranche of the Gates Foundation long term convertible loan note of $25&#160;million is September&#160;12, 2020, being three years after the September&#160;13, 2017 issue date. Accordingly, as at December&#160;31, 2019, the long-term convertible loan was reclassified from a non-current liability (see Note 19) to a current liability (see Note 19).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Trade and other payables</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">15,729</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,444</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other taxation and social security<font style="padding-left: 3.78pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">522</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">640</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accruals<font style="padding-left: 0.97pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">13,250</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">12,471</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,501</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">19,555</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Deferred liabilities </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.55%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.75pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">28,457</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 2.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">29,437</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred rent<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">65</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 2.5pt; padding-bottom: 3.75pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.5pt; padding-bottom: 3.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">304</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">28,522</font></div></td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.55%; border-bottom: none; font-size: 2pt; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.75pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,741</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred revenue is in respect of the upfront fee and development milestones payments received from collaboration agreements in advance of services performed by the Group (see Note 3).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On implementation of IFRS 16, previously recognized deferred rent balances were reclassified to right-of-use assets (see Note 13). The remaining deferred rent balances represent lease incentives granted on certain short-term leasehold property agreements and rentals paid in advance for associated sub-leases arrangements.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Tax payable</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.49%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax payable<font style="padding-left: 2.22pt;"></font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">72</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 3.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">139</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.33pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">72</font></div></td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.49%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.99%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">139</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">22. Share-based payments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group operates various employee share schemes that grant awards to certain employees and members of the Board. The Share Option Plan, whereby options are granted to acquire shares in the Company at a specified exercise price and the Growth Share Plan, whereby Growth shares of the Company are awarded with an associated hurdle rate as set at the time of award. For defined employees, awards made under the Growth Share Plan are subject to the achievement by the Group of additional specified performance targets.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Grants under both plans are normally exercisable over a four-year period with 25% vesting at the end of the first year and the remaining award vesting quarterly over the following three years. For defined employees, awards made under the Growth Share Plan are normally exercisable over an eight-year period with 12.5% vesting at the end of the first year and the remaining award vesting quarterly over the following seven years. All awards lapse on the tenth anniversary from the date of grant and are not entitled to dividends.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The total charge for such share-based payment plans in 2019 was &#163;3,056,000 (2018 &#8211; &#163;666,000), all of which relate to equity settled awards.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-33<br></div></div></div>
<!--End Page 296-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 297-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg25"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">22. Share-based payments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Share Option Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Share Option Plan, awards are granted to certain employees and members of the Board to acquire shares in the Company at a specified exercise price. Those awards granted from 2017 normally vest over a four-year period with 25% of the award vesting at the end of the first year and the remaining award vesting quarterly over the following three years. Awards granted prior to 2017 normally vest over a four-year period with 25% of the award vesting after each complete year.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The number and weighted average exercise prices of share options are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of shares issuable</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options (#)</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price (&#163;)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2018<font style="font-weight: normal; padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;">227,608</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">54.01</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 1.67pt;">(10,950)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 10pt;">9.26</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(67,935</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">53.57</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2018<font style="font-weight: normal; padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">148,723</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">57.50</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;">582,252</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">150.00</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 6.67pt;">(8,574)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 10pt;">2.71</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(6,578</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">103.17</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2019<font style="font-weight: normal; padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">715,823</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">132.89</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at December 31, 2019<font style="font-weight: normal; padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 12.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">125,305</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">53.09</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The weighted average fair value of options granted in 2019 was &#163;11.95 (2018: &#163;nil). The weighted average share price at the date of exercise of the options during 2019 was &#163;64.00 (2018: &#163;144.14).</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Growth Share Plan</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Growth Share Plan, awards are granted to certain employees and members of the Board to acquire shares in the Company at the nominal value provided the share price exceeds a hurdle rate, as set at the time of award. Awards vest over a four-year period with 25% of the award vesting at the end of the first year and the remaining award vesting quarterly over the following three years. For a defined number of employees, their awards vest over an eight-year period with 12.5% vesting at the end of the first year and the remaining vesting quarterly over the following seven years. These awards are also subject to the achievement by the Group of additional specified performance targets. These performance targets are based primarily on the progression of the Company&#8217;s pipeline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The number and weighted average hurdle rate of growth shares are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of shares issuable</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">growth shares</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">hurdle rate &#163;</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2018<font style="font-weight: normal; padding-left: 3.47pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.04pt; text-align: left;">155,246</div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.04pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.04pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.04pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(36,800</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00 </div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2018<font style="font-weight: normal; padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.04pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">118,446</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-34<br></div></div></div>
<!--End Page 297-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 298-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg26"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">22. Share-based payments<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 69.23%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of shares issuable</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.38%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">growth shares</div></td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.8%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">hurdle rate &#163;</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 3.01pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 0.24pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 3.57pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.88pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(60,240</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2019<font style="font-weight: normal; padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.88pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">58,206</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr><tr><td style="width: 69.23%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at December&#160;31, 2019<font style="font-weight: normal; padding-left: 4.97pt;"></font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.38%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.88pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">14,004</font></div></td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.8%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For share options and growth share awards outstanding at the end of the year, the range of exercise prices and weighted average remaining contractual life are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 36.4%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth Shares</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 38.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options</div></td></tr><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hurdle rate &#163;</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual life</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise price &#163;</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual life</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;">170.00</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;">58,206</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">7.3</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;"><font style="padding-left: 10pt;">1.99</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 10pt;">1,563</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">1.7</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;"><font style="padding-left: 5pt;">43.37</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 0.74pt;">111,319</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">5.2</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;"><font style="padding-left: 2.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;">120.87</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 10pt;">3,309</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">6.0</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;"><font style="padding-left: 2.5pt; border-bottom: 3pt double #000000; min-width: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.84%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">150.00</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">599,632</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">9.3</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Awards granted under the Share Option Plan have been valued using the Black-Scholes option pricing model, those awards granted under the Growth Share Plan have been valued using the Back Solve model, reflecting the different rights available to holders of Growth Shares. The assumptions used in the models are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.85%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">April 2017</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.17%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">May 2019</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">April 2017</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.96%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2016</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share price at grant date<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;150.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;64.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;150.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;140.00</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise price<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;150.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;150.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;43.37 - &#163;150.00 </div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hurdle rate<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;170.00</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">65%</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">67%</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">65%</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">60%</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected life (years)<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">2.7 yrs</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1.9 yrs - 3 yrs</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">5 yrs</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">5 yrs</div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk free rate<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">0.15%</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">0.69% - 0.71%</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">0.42%</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">0.62% - 1.41%</font></div></td></tr><tr><td style="width: 41.03%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.85%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">&#163;</font><font style="border-bottom: 1pt solid #000000;">58.55</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.17%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">&#163;</font><font style="border-bottom: 1pt solid #000000;">11.95</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.13%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">&#163;</font><font style="border-bottom: 1pt solid #000000;">80.63</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.96%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 1pt solid #000000;">&#163;</font><font style="border-bottom: 1pt solid #000000;">77.16 - </font><font style="border-bottom: 1pt solid #000000;">&#163;</font><font style="border-bottom: 1pt solid #000000;">107.94</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">Share options and growth shares are not entitled to dividends.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the awards is indicative of future trends, which may not necessarily be the actual outcome. The expected life of the share options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The risk-free rate is based on the Bank of England&#8217;s estimates of gilt yield curve as at the respective grant dates.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">23. Financial instruments</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Financial instruments risk management objectives and policies</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group&#8217;s principal financial assets include trade and other receivables and cash and security deposits that derive directly from its operations.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-35<br></div></div></div>
<!--End Page 298-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 299-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg27"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Group&#8217;s principal financial liabilities comprised of the convertible loan from the Gates Foundation, a derivative liability and trade and other payables. The main purpose of these financial liabilities is to finance the Group&#8217;s operations.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group is exposed to liquidity risk, credit risk and market risk. The Group&#8217;s senior management oversees the management of these risks. The Group&#8217;s senior management is supported by a financial risk committee that advises on financial risks and the appropriate financial risk governance framework for the Group. The financial risk committee provides assurance to the Group&#8217;s senior management that the Group&#8217;s financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with the Group&#8217;s policies and risk objectives. The Board reviews and approves policies for managing each of these risks, which are summarized below.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Liquidity risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The cash utilization is constantly monitored to provide an appropriate lead time for raising further funding. The Group&#8217;s treasury policy gives guidance on how significant cash balances should be distributed across a range of highly rated counterparties at maturities to meet its requirements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following are the contractual maturities of financial assets and liabilities, including estimated interest payments:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2019</div></td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cash flows <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">One year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or less <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets<br></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivable<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="padding-left: 17.5pt;">28</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="padding-left: 17.5pt;">28</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="padding-left: 17.5pt;">28</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 2.89pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="padding-left: 5pt;">2,282</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="padding-left: 5pt;">2,282</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="padding-left: 12.5pt;">424</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term security deposits<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="padding-left: 5pt;">2,532</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="padding-left: 5pt;">2,532</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="font-weight: normal; padding-left: 4.34pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">80,279</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">80,279</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">75,889</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities<br></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;">15,579</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;">15,579</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;">15,579</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings (see Note 21)<font style="padding-left: 1.27pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;">19,157</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;">19,426</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;">19,157</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derivative liability<font style="padding-left: 2.86pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,127</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,127</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,863</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.91pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">35,005</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,863</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The maturity of contractual cashflows for the majority of financial assets and liabilities is one year or less in except for the following balances. Prepayments and accrued income related to amounts paid in advance for clinical trials to be repaid at the end of the associated clinical trials are estimated to be received in one to three years as at December&#160;31, 2019. Long-term security deposits are estimated to be received in more than five years, as at December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The carrying amount of interest-bearing loans and borrowings has been calculated in accordance with the Group&#8217;s loans and borrowings accounting policy which states that all such balances are classified as financial liabilities and are initially recorded at the amount of proceeds received, net of transaction costs. Loans and borrowings are subsequently measured at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as an expense to the profit and loss account over the period of the relevant loan and borrowings.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-36<br></div></div></div>
<!--End Page 299-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 300-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg28"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Gates Foundation convertible loan, evidenced by subordinated loan notes, is accounted for as a financial liability and initially recognized at fair value. The difference between proceeds received, net of transaction costs, and fair value is recognized in finance income. Fair value is calculated based on the present value of the future principal and interest cash flows, discounted at the market rate at the statement of financial position balance sheet date. The loan notes are subsequently measured at amortized cost, with the unwinding of the discount recorded in finance costs over the life of the loan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The convertible loan contains conversion features which are accounted for as an embedded derivative and separated from the convertible loan.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The contractual cash flows represent the cash contractually due to the Gates Foundation in accordance with the agreement. The contractual maturity for the first tranche of the Gates Foundation convertible loan note of $25&#160;million is September&#160;12, 2020, being three years after the September&#160;13, 2017 issue date.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For series B shares issued during 2019, a foreign exchange call option was established whereby additional series&#160;B shares will be issued at nominal value should the U.S. dollar exchange rate weaken against pound Sterling in the period between the first closing of the series B preferred share financing in August 2019 and any subsequent closings during 2020. This foreign exchange call option is a derivative financial liability not designated as an accounting hedge and is measured at fair value both at inception and at subsequent reporting dates.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At December&#160;31, 2018</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.83%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">cash flows <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.77%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">One year <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or less <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets<br></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 3.22pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,374</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 10pt;">4,374</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">4,374</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivable<font style="padding-left: 0.1pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">167</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 17.5pt;">167</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">167</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 2.89pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,660</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 10pt;">2,660</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,660</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term security deposits<font style="padding-left: 0.65pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,532</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 10pt;">2,532</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 1.77pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets<font style="font-weight: normal; padding-left: 4.34pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">134,118</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 0.55pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">134,118</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">131,586</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities<br></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 3.21pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6,444</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 10pt;">6,444</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6,444</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings (Note 19)<font style="padding-left: 2.37pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">18,878</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">20,096</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="padding-left: 0.23pt;"></font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">25,322</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.83%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.41pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">26,540</font></div></td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.77%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">6,444</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Credit risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade receivables), including deposits with banks and financial institutions. The Group has assessed the expected credit loss by considering a number of factors including the credit quality of the Group&#8217;s counter-parties and the short term nature of the receivables and based on these factors the expected credit loss is not significant. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group&#8217;s material receivables are from large pharmaceutical companies and sub-tenants. Appropriate due diligence is performed on these organizations before agreements are entered into. There are no significant amounts which are past due at December&#160;31, 2019 or December&#160;31, 2018.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group held cash and cash equivalents of &#163;73,966,000 at December&#160;31, 2019 (2018: &#163;124,385,000) which are held with multiple highly rated banks. The Group monitors the credit rating of those banks.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-37<br></div></div></div>
<!--End Page 300-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 301-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg29"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">An impairment analysis is performed at each reporting date on an individual basis for major clients. In addition, minor receivables are grouped into homogenous groups and assessed for impairment collectively. The calculation is based on actual incurred historical data. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in this Note 23.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Market risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: interest rate risk, currency risk and other price risk, such as equity price risk and commodity risk.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interest risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The group&#8217;s interest-bearing assets include cash balances, which earn interest at variable rates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Financial assets subject to variable interest rates are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.02pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">124,385</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">An increase in Bank of England base rates by 0.5 percentage points would increase the net annual interest income to all the deposit accounts as of December&#160;31, 2019 by &#163;370,000 (2018: &#163;573,000). A decrease in Bank of England base rates by 0.5 percentage points would reduce the net annual interest income to all the deposit accounts as of December&#160;31, 2019 by &#163;370,000 (2018: &#163;549,000) </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Foreign currency risk</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Group&#8217;s exposure to the risk of changes in foreign exchange rates relates primarily to the Group&#8217;s operating activities in the United States and outsourced supplier agreements denominated in currencies other than pound sterling.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Financial assets and liabilities in foreign currencies are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets at amortized cost:<br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivable<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 17.5pt;">15</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 12.5pt;">137</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">1,858</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">2,405</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">12,518</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">86,251</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">14,391</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">88,793</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-38<br></div></div></div>
<!--End Page 301-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 302-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg30"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><table cellspacing="0" cellpadding="0" class="fintab" style="border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.12%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities at amortized cost:<br></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">4,374</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">2,637</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings (see Note 21)<font style="padding-left: 3.27pt;"></font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,157</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,878</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,531</font></div></td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.12%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">21,515</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A 1 percentage point increase in exchange rates would reduce the carrying value of net financial assets and liabilities held in foreign currencies at December&#160;31, 2019 by &#163;131,000 (2018: &#163;666,000 increase). A&#160;1&#160;percentage point decrease in exchange rates would increase the carrying value of net financial assets and liabilities held in foreign currencies at December&#160;31, 2019 by &#163;131,000 (2018: &#163;680,000 decrease). </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Disclosure of financial assets and liabilities</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Fair value of financial assets</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.85%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.57%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial assets at amortized cost:<br></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 0.22pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 5pt;">1,471</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">4,374</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 10pt;">4,374</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivable<font style="padding-left: 2.1pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 17.5pt;">28</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 17.5pt;">28</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">167</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 17.5pt;">167</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 4.89pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">2,282</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 5pt;">2,282</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,660</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 10pt;">2,660</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term security deposits<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">2,532</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 5pt;">2,532</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 10pt;">2,532</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 10pt;">2,532</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Embedded derivative asset<font style="padding-left: 2.65pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 12.5pt;">266</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 12.5pt;">266</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">719</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="padding-left: 17.5pt;">719</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 3.77pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial assets at amortized cost<font style="font-weight: normal; padding-left: 3.05pt;"></font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">80,545</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">80,545</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">134,837</font></div></td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.85%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.57%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">134,837</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Fair value of financial liabilities</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 18.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.74%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">amount<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.87%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial liabilities at amortized cost<br></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 0.21pt;"></font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">15,579</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;">15,579</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt;">6,444</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 5pt;">6,444</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings (Note 21)<font style="padding-left: 4.37pt;"></font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">19,157</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;">19,157</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;">18,878</div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;">18,878</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derivative liability<font style="padding-left: 4.86pt;"></font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,127</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,127</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total financial liabilities<font style="font-weight: normal; padding-left: 1.88pt;"></font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,863</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">39,863</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.74%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.03pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,322</font></div></td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.87%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.56%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">25,322</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The carrying amount of all financial assets and financial liabilities, excluding the embedded derivative asset and the derivative liability, approximates their fair value because of the short maturities of these instruments.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The embedded derivative associated with the conversion features within the Gates Foundation convertible loan are accounted for as an asset and are marked to fair value at each reporting period. The fair value of this embedded derivative asset, measured at December&#160;31, 2018 and December&#160;31, 2019, was determined using an option pricing model, discounted and probability weighted for the conversion features within the underlying convertible loan, which includes unobservable (Level 3) inputs supported by little or no market activity.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-39<br></div></div></div>
<!--End Page 302-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 303-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg31"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The embedded derivative asset measured at fair value using significant Level 3 inputs was &#163;266,000 on December&#160;31, 2019 and &#163;719,000 on December&#160;31, 2018. Changes in the embedded derivative asset are recognized in finance income, or finance costs accordingly.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The conversion features within the convertible loan are activated under different circumstances and the resulting equity value may vary based on factors including the date of conversion or the event triggering conversion, such as an IPO or the Gates Foundation electing to convert the loan into equity. The option pricing model incorporates input assumptions reflecting the varied circumstances under which the conversion from debt to equity may occur. Significant unobservable inputs used in the fair value measurement of the embedded derivative asset are predominantly regarding the probability of each of the conversion features occurring.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The resulting embedded derivative asset is sensitive to changes in this significant unobservable input used in the fair value measurement. In respect of the probabilities ascribed to each of the conversion events, should any one of the conversion events be considered an absolute certainty the resulting embedded derivative fair value would range from &#163;nil to an embedded derivative asset of &#163;8,855,000. The valuation of the embedded derivative is not sensitive to changes in other inputs including the expected date of conversion and share price used in the valuation.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The derivative liability comprises a foreign exchange call option over series B shares and is a financial liability not designated as an accounting hedge marked to fair value at each reporting period. This derivative liability has the effect of issuing additional series B shares to certain series B investors in the event of the U.S. dollar exchange rate weakening relative to the pound sterling over the period of time from the first closing of the series B preferred share financing in August 2019 through to the second and final closing in March 2020. The fair value of this derivative liability, measured at December&#160;31, 2019, was determined using an option pricing model using a range of inputs both quoted, observable and unobservable in nature. The unobservable input is the expected final closing of the series B preferred share financing. The resulting derivative liability is not sensitive to changes in the expected close date nor in changes to other underlying input assumptions.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Financial liabilities: interest-bearing loans and borrowings</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Interest <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">rate %</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 17.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Maturity date <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 53.85%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gates Foundation convertible loan<font style="padding-left: 3.99pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 33.32pt;">Variable</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 17.5%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000;">September&#160;12, 2020</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">19,157</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,878</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Interest bearing loans and borrowings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group has a convertible loan agreement with the Gates Foundation in which the Foundation has agreed to lend the Group an amount not to exceed $40&#160;million in two tranches, of which the first tranche of $25&#160;million was received on September&#160;13, 2017. Interest is payable at a rate of 2% per annum for the first year and 0% thereafter until either repayment or conversion of the loan. The loans are evidenced by convertible loan notes. Each loan note is convertible into ordinary shares of the Group based on a series of specific conversion criteria.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Trade and other receivables, cash and cash equivalents and trade and other payables</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For trade and other receivables, cash and cash equivalents and trade and other payables with a remaining life of less than one year, the nominal amount is deemed to reflect fair value.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Long-term security deposit</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The long-term deposits represent lease security deposits for buildings, the balance at December&#160;31, 2019 is &#163;2,532,000 (2018: &#163;2,532,000).</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-40<br></div></div></div>
<!--End Page 303-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 304-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg32"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">23. Financial instruments<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Included within prepayments and accrued income are amounts paid in advance for clinical trials. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes in liabilities arising from financing activities</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.5%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January 1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cash <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">flows <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Foreign <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exchange <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">movement <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Net <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">finance <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(income) <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">/ costs <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leases <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.07%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings<font style="padding-left: 2.12pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.14pt; text-align: left;">18,878</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.6pt; text-align: left;">(563)</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="padding-left: 7.5pt;">842</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;">19,157</div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derivative liability<font style="padding-left: 4.86pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.14pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.6pt; text-align: left;"><font style="padding-left: 8.33pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;">5,127</div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">5,127</font></div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.14pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">46,555</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(4,036</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.6pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 18.33pt;">9</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,938</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 25.83pt;">(5,216</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">40,250</font></div></td></tr><tr><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities from financing activities<font style="font-weight: normal; padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.5%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.14pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">65,433</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(4,036</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 8.6pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 18.33pt;">(554</font><font style="min-width: 18.33pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.62pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,907</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 25.83pt;">(5,216</font><font style="min-width: 25.83pt;">)</font></div></td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.07%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">64,534</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Foreign <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exchange <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">movement <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.69%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Interest <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">expense <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.9%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings<font style="padding-left: 1.12pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">16,940</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.52pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,096</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">842</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,878</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities from financing activities<font style="font-weight: normal; padding-left: 2.76pt;"></font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">16,940</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.59%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.52pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,096</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.69%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">842</font></div></td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.9%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">18,878</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Balances as at January&#160;1, 2019 for lease liabilities and deferred rent reflect the adoption of IFRS 16 &#8216;Leases&#8217;. Lease movements during the year ended December&#160;31, 2019 represent lease remeasurements of &#163;6,113,000 partially offset by the addition of new leases of &#163;897,000. Movements relating to finance income and costs are set out in Note 7 and Note 8. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">24. Post-employment benefit plans</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group operates a defined contribution pension scheme for its directors and employees. The assets of the scheme are held separately from those of the Group in an independently administered fund.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unpaid contributions outstanding at December&#160;31, 2019 were &#163;1,000 (2018: &#163;150,000). The total expense relating to these plans in the current period was &#163;1,213,000 (2018: &#163;981,000).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">25. Commitments and contingencies</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2019</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160; year</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1-3 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3-5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">5&#160; years</div></td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.02%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; existing<font style="padding-left: 4.32pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;">4,469</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.45pt;">8,958</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">7,876</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">45,288</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">66,591</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; contingent<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 12.5pt;">68</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 4.45pt;">1,604</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">2,685</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 5pt;">2,688</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7,045</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Manufacturing<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;">3,669</div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 11.95pt;">642</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5.37pt;">4,311</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital commitments<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,460</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 16.95pt; border-bottom: 1pt solid #000000; min-width: 26.95pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,460</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contractual obligations<font style="font-weight: normal; padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">9,666</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 26.95pt;">11,204</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">10,561</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">47,976</font></div></td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.02%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">79,407</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2018</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1&#160; year</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1-3 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3-5 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">5 years</div></td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.22%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease payables<font style="padding-left: 4.88pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 5pt;">4,329</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">8,467</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">8,099</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;">60,691</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">81,586</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Manufacturing<font style="padding-left: 2.08pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;">10,544</div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">55</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">10,599</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital commitments<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">347</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">347</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contractual obligations<font style="font-weight: normal; padding-left: 2.45pt;"></font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 2.91pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">15,220</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">8,522</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">8,099</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.76pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">60,691</font></div></td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.22%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">92,532</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-41<br></div></div></div>
<!--End Page 304-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 305-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg33"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">25. Commitments and contingencies<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Group has contractual obligations for two leasehold properties under which it is obligated to take on the leases should the properties become vacant at specified dates in the future. For both properties, the Group has assessed these contingent events as highly probable as at December&#160;31, 2019 and has recognized an additional contingent commitment totaling &#163;7,046,000.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As at December&#160;31, 2018, prior to the adoption of IFRS 16, the Group&#8217;s future lease commitments are reflected as future minimum operating lease payables. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">26. Related party disclosures</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group entered into transactions, in the ordinary course of business, with other related parties. Transactions entered into and trading balances outstanding at December&#160;31 are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 20.34%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchases <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">from related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">party &#163;000&#8217;s</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.73%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchases <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">from related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">party &#163;000&#8217;s</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adaptimmune Limited<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">69</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aigenpulse Limited<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;">500</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;">729</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Malin Life Sciences Holdings Limited<font style="padding-left: 4.33pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 10pt;">2</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oxford Nanosystems Limited<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="padding-left: 5pt;">2</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oxford Innovation Ltd<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">30</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">13</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">530</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">71</font></div></td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.73%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 9.24%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 14.12pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">744</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 19.72%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019</div></td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 21.21%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018</div></td></tr><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Receivables <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">from related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">party &#163;000&#8217;s</div></td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Payables <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">to related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">party &#163;000&#8217;s</div></td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Receivables <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">from related <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">party &#163;000&#8217;s</div></td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.67%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Payables <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">outstanding to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aigenpulse Limited<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.4pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.39pt; text-align: left;">345</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adaptimmune Limited<font style="padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.4pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="padding-left: 0.37pt;">11</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.39pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oxford Nanosystems Limited<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.4pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="padding-left: 5pt;">2</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.39pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oxford Innovation Ltd<font style="padding-left: 3.75pt;"></font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.4pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.39pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">1</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.15%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.4pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.24%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.62pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">13</font></div></td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.67%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.63%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.39pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">346</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group&#8217;s investment in Adaptimmune Therapeutics plc, the parent of Adaptimmune Limited, was sold during 2018. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Remuneration of key management personnel</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The remuneration of the executive directors and executive officers, who are the key management personnel of the Group, is set out below in aggregate for each of the categories specified in IAS 24, &#8220;<font style="font-style: italic;">Related Party </font><font style="font-style: italic;">Disclosures</font>&#8221;.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.82%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2018 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000&#8217;s</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Short-term employee benefits<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">6,502</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4,435</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based payments<font style="padding-left: 0.98pt;"></font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3,667</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">270</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,169</font></div></td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.82%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">4,705</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-42<br></div></div></div>
<!--End Page 305-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 306-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_202-finnotes01_pg34"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Annual report and consolidated financial statements <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">December 31, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consolidated Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">27. Events after the reporting period</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subsequent to the period to June 30, 2020, management conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors. After the investigation, the one remaining open contract with the third party vendors was terminated and the Group has undertaken proceedings against the involved parties but is not yet in the position to verify or validate any information relating to this matter due to the very recent timing of the issue. As at June 30, 2020, the Group estimates the amounts in question to be in the range of &#163;1.1&#160;million to &#163;1.8 million. However, in management's opinion, it is too early to consider the estimate to be sufficiently reliable to recognize an asset in respect of this matter. The assessment in inherently judgmental and there is a risk that the final amounts are materially different to the amount provided above or do not include all factors and therefore, management cannot currently predict the outcome of this matter.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;6, 2020, the Group entered into an loan and security agreement with Oxford Finance Luxembourg S.A.R.L. (Oxford Finance) for the provision of up to $100&#160;million debt financing to be provided under three tranches, of which the first tranche of $50&#160;million was received on signing the agreement. The second tranche of $25&#160;million can be drawn down upon tebentafusp receiving Biologics License Application approval prior to June&#160;30, 2022 and the third and final tranche of $25&#160;million can be drawn down at the sole discretion of Oxford Finance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March&#160;2, 2020, the Group completed the second close of the series B preferred share financing. A total of $133&#160;million was raised with a number of new and existing investors. The total raised comprises $72&#160;million in the first close in August 2019 and $61&#160;million in the second close of which $25.5&#160;million arose on the conversion of the Gates Foundation convertible loan. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December 2019, a novel strain of coronavirus (COVID-19) was identified in China and subsequently has spread globally. The Group is continuing to monitor the global outbreak and spread of the novel strain of COVID-19 pandemic and has taken steps to identify and mitigate the adverse effects and risks to the Group as a result of the pandemic. The Group has modified its business practices, including sustaining ongoing enrolment and treatment of patients in clinical trials, clinical site interactions and maintaining the clinical supply chain. Substantially all laboratory-based work has been maintained whilst ensuring social distancing and employee safety. Management expects to continue to take actions as may be required or recommended by government authorities or in the best interests of the Group&#8217; employees and business partners. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">To date, the COVID-19 pandemic has resulted in a short-term delay of up to six months in progressing the early stage pipeline related to the Phase 1 clinical trial in HBV. The ongoing spread of COVID-19 may further negatively impact the Group&#8217;s clinical trials in the future, including potential delays and restrictions on the ability to recruit and retain patients, principal investigators and healthcare employees. COVID-19 pandemic could also affect the operations of the CROs used by the Group, which may result in delays or disruptions in the supply of product candidates.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The COVID-19 pandemic remains a rapidly evolving situation and management does not yet know the full extent of its potential impact on business operations. The Group will continue to closely monitor, assess and mitigate the effects of the COVID-19 pandemic on the business. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-43<br></div></div></div>
<!--End Page 306-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 307-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_203-fintab02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, 2020</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"><a name="fUCCSL"><!--Anchor--></a>Unaudited Condensed Consolidated Statement of Loss and Other Comprehensive Income <br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">for the Nine Months ended September&#160;30,</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Revenue<font style="padding-left: 2.51pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">2</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">22,694</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">20,027</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total revenue<font style="font-weight: normal; padding-left: 3.62pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">22,694</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">20,027</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other operating income<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">408</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">420</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development costs<font style="padding-left: 4.78pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(57,566)</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(75,415)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Administrative expenses<font style="padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(31,569</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(35,611</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating loss<font style="font-weight: normal; padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(66,033)</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(90,579)</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance income<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">1,972</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">1,134</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Finance costs<font style="padding-left: 2.52pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(2,272</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(6,532</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-operating expense<font style="font-weight: normal; padding-left: 3.64pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(300</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(5,398</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before taxation<font style="font-weight: normal; padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(66,333</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(95,977</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax credit<font style="padding-left: 0.87pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">11,120</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.7pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">18,011</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="font-weight: normal; padding-left: 4.38pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(55,213</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(77,966</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income<br></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income that are or may be reclassified to<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 10pt; text-align: left;">profit or loss in subsequent periods (net of tax):<br></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange differences on translation of foreign operations<font style="font-weight: normal; padding-left: 3.5pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">338</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">82</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total other comprehensive income for the period, net of tax<font style="font-weight: normal; padding-left: 2.68pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">338</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">82</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period, net of tax<font style="font-weight: normal; padding-left: 3.59pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(54,875</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(77,884</font><font style="min-width: 30.83pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<font style="font-weight: normal; padding-left: 4.01pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.08%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">(0.01</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">(0.02</font><font style="min-width: 30.83pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these unaudited condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-44<br></div></div></div>
<!--End Page 307-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 308-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_203-fintab02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fUCCSFP"><!--Anchor--></a>Unaudited Condensed Consolidated Statement of Financial Position as at </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.05%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current assets<br></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property, plant and equipment<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">7</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">45,068</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">54,880 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investment in sub-lease<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 20.83pt;">384</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">591 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other non-current financial assets<font style="padding-left: 2.79pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 13.33pt;">7,003</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">4,390 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax asset<font style="padding-left: 1.66pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,539</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">1,507 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current assets<font style="font-weight: normal; padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">53,994</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">61,368</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets<br></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade and other receivables<font style="padding-left: 2.58pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 13.33pt;">7,479</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">9,639 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax receivable<font style="padding-left: 1.23pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">12,679</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">40,410 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Embedded derivative assets<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt;">266 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents<font style="padding-left: 2.77pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">11</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">56,687</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">73,966 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current assets<font style="font-weight: normal; padding-left: 0.53pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">76,845</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">124,281 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total assets<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">130,839</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">185,649</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Equity<br></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share capital<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 30.83pt;">1</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share premium<font style="padding-left: 3.3pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 3.33pt;">330,390</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt;">283,250</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign currency translation reserve<font style="padding-left: 3.35pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 20.83pt;">306</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 22.5pt;">(32)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based payment reserve<font style="padding-left: 1.67pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12, 13</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">15,840</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">10,659</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated deficit<font style="padding-left: 3.31pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(330,989</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 35.83pt;">(279,106</font><font style="min-width: 35.83pt;">)</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity<font style="font-weight: normal; padding-left: 3.65pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">15,548</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">14,771</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current liabilities<br></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred liabilities<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">35,682</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">47,961</font> </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">31,861</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">38,299 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provisions<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">238</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">105 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total non-current liabilities<font style="font-weight: normal; padding-left: 1.63pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">67,781</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">86,365</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities<br></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest-bearing loans and borrowings<font style="padding-left: 1.12pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">19,157 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade and other payables<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">15</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">23,280</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">29,501</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred liabilities<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt;">22,132</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt;">28,522</font> </div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax payable<font style="padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 25.83pt;">72</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities<font style="padding-left: 1.64pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">14</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 13.33pt;">2,098</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">1,951</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derivative liabilities<font style="padding-left: 2.75pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 13.33pt;">5,127</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Provisions<font style="padding-left: 3.28pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">183 </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total current liabilities<font style="font-weight: normal; padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">47,510</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">84,513</font><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;"> </font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities<font style="font-weight: normal; padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 3.88pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">115,291</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">170,878</font></div></td></tr><tr><td style="width: 61.54%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total equity and liabilities<font style="font-weight: normal; padding-left: 1.99pt;"></font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.79pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">130,839</font></div></td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.05%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.67pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 35.83pt;">185,649</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these unaudited condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-45<br></div></div></div>
<!--End Page 308-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 309-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_203-fintab02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fUCCSCE"><!--Anchor--></a>Unaudited Condensed Consolidated Statement of Changes in Equity for the Nine Months ending September&#160;30,&#160;2020</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">capital <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">premium <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.97%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Foreign <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">currency <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">translation <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.36%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share-<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">based <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">payment <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reserve <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.68%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">equity <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2019<font style="font-weight: normal; padding-left: 3.91pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">224,087</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">67</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt;">7,603</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(175,175)</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">56,582</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(77,966)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(77,966)</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">82</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">82</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">82</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(77,966)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(77,884)</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issue of share capital<font style="padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">59,162</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">59,162</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity-settled share-based payment transactions<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12, 13</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,501</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">2,501</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At September&#160;30, 2019<font style="font-weight: normal; padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">283,249</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">149</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,104</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(253,141</font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">40,361</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">As at January&#160;1, 2020<font style="font-weight: normal; padding-left: 1.69pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">283,250</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 1.67pt;">(32)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">10,659</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;">(279,106)</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">14,771</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(55,213)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(55,213)</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other comprehensive income<font style="padding-left: 3.1pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 15pt;">338</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">338</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total comprehensive loss for the period<font style="font-weight: normal; padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;">338</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 5pt;">(55,213)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">(54,875)</div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conversion of interest-bearing loan<font style="padding-left: 3.11pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">10</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 17.5pt;">(510)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">(510)</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derecognition of derivative liability<font style="padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 13.33pt;">3,840</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt;">3,840</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issue of share capital<font style="padding-left: 0.89pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="padding-left: 5pt;">1</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 5pt;">47,140</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">47,141</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity-settled share-based payment transactions<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">12, 13</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">5,181</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; min-width: 35.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">5,181</font></div></td></tr><tr><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At September&#160;30, 2020<font style="font-weight: normal; padding-left: 3.55pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.52%; text-align: center; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.56pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 10pt;">1</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">330,390</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.97%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.16pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">306</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.36%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">15,840</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.68%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.74pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;">(330,989</font><font style="border-bottom: 3pt double #000000; min-width: 35.83pt;"></font><font style="min-width: 35.83pt;">)</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">15,548</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these unaudited condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-46<br></div></div></div>
<!--End Page 309-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 310-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_203-fintab02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"><a name="fUCCGSCF"><!--Anchor--></a>Unaudited Condensed Consolidated Group Statement of Cash Flows for the Nine Months ended September 30,</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 2.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.39%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from operating activities<br></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss for the period<font style="padding-left: 4.2pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(55,213)</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(77,966)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments for:<br></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation of property, plant and equipment<font style="padding-left: 3.49pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">6,652</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">6,691 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of intangible assets<font style="padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">210</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Write-off of intangible assets<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">306</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss on disposal of property, plant and equipment<font style="padding-left: 1.83pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">(148)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 19.17pt;">(26)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net finance costs<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">300</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,398</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Movement in provisions and other charges<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">(50)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,392</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Foreign exchange translation differences<font style="padding-left: 2.2pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">326</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">608 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Equity settled share-based payment expenses<font style="padding-left: 3.69pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">5,181</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">2,501 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Taxation charge<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 0.37pt;">(11,120)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 2.04pt;">(18,011)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Working capital adjustments<font style="font-weight: normal;">:</font><br></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">(Increase)/decrease in trade and other receivables<font style="padding-left: 0.96pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">(612)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(857)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">(Decrease)/increase in trade and other payables<font style="padding-left: 4.28pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(6,224)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">5,784 </font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Decrease in deferred liabilities<font style="padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(18,670</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(17,747</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash used in operations<font style="font-weight: normal; padding-left: 3.09pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(79,578)</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(90,717)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Bank interest received on cash and cash equivalents<font style="padding-left: 4.27pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt;">676</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 10pt;">1,202</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net taxation received<font style="padding-left: 0.32pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">38,904</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">13,825</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities<font style="font-weight: normal; padding-left: 0.34pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(39,998</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">(75,690</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from investing activities<br></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from sale of property, plant and equipment<font style="padding-left: 2.4pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">52</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">82</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchase of property, plant and equipment<font style="padding-left: 4.05pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">(2,727)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,449)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease capital contribution<font style="padding-left: 1.98pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 8.33pt;">1,088</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchase of intangible assets<font style="padding-left: 4.78pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(198)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from sub-leases<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">241</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">22</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows used in investing activities<font style="font-weight: normal; padding-left: 2.57pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">(1,346</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">(2,543</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from financing activities<br></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from exercise of share options<font style="padding-left: 3.7pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">45</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gross proceeds from issue of share capital<font style="padding-left: 3.15pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt;">27,288</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">59,901</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Costs from issue of share capital<font style="padding-left: 3.12pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt;">(58)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 14.17pt;">(738)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Repayment of lease liabilities<font style="padding-left: 1.43pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(3,297</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(2,991</font><font style="min-width: 32.5pt;">)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash flows from financing activities<font style="font-weight: normal; padding-left: 1.09pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">23,978</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 32.5pt;">56,172</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Increase/(decrease) in net cash and cash equivalents<font style="padding-left: 4.85pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(17,366)</div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 1.67pt;">(22,061)</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net foreign exchange difference on cash held<font style="padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 20.83pt;">87</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 22.5pt;">74</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents at beginning of the year<font style="padding-left: 3.14pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">73,966</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 32.5pt;">124,385</font></div></td></tr><tr><td style="width: 76.92%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of the year<font style="font-weight: normal; padding-left: 1.46pt;"></font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">56,687</font></div></td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.39%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">102,398</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes form part of these unaudited condensed consolidated financial statements.<br></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-47<br></div></div></div>
<!--End Page 310-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 311-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="fUCNFS"><!--Anchor--></a>Immunocore Limited<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, 2020</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">1. Significant accounting policies</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">General information</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Immunocore Limited (the &#8220;Company&#8221;) is a private company incorporated in England and Wales and has the following wholly owned subsidiaries, Immunocore LLC, Immunocore Commercial LLC, Immunocore Ireland Limited and Immunocore Nominees Limited (collectively referred to as the &#8220;Group&#8221;).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The principal activity of the Group is pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX &#8211; <font style="font-weight: bold;"><u>I</u></font>mmune <font style="font-weight: bold;"><u>m</u></font>obilizing <font style="font-weight: bold;"><u>m</u></font>onoclonal <font style="font-weight: bold;"><u>T</u></font>CRs <font style="font-weight: bold;"><u>A</u></font>gainst <font style="font-weight: bold;"><u>X</u></font> disease &#8211; designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, the Group is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Basis of preparation</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The interim condensed consolidated financial statements for the nine months ended September&#160;30, 2020 have been prepared in accordance with International Accounting Standard 34, &#8220;<font style="font-style: italic;">Interim Financial Reporting&#8221;</font> (&#8220;IAS 34&#8221;) as issued by the International Accounting Standards Board. The accounting policies and methods of computation applied in the preparation of the interim financial statements are consistent with those applied in the Group&#8217;s annual financial statements for the year ended December 31, 2019. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The interim financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the consolidated financial statements of the Group for the year ended December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated Group financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in pounds sterling which is the Group&#8217;s and parent&#8217;s presentation currency. All values are rounded to the nearest thousands, except where otherwise indicated.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Date of authorization</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These condensed consolidated interim financial statements were prepared at the request of the Group&#8217;s Board of Directors (the &#8220;Board&#8221;) to meet regulatory and contractual commitments and were approved by the Board on January&#160;15, 2021and signed on its behalf by Dr. Bahija Jallal, Chief Executive Officer of the Group.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Adoption of New Accounting Standards</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There have been no recent new accounting standards that have had an impact on these condensed consolidated interim financial statements. New accounting standards not listed below were assessed and determined to be either not applicable or did not have a material impact on the interim financial statements or processes.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group adopted the amendments to IAS 1, &#8220;<font style="font-style: italic;">Presentation of Financial Statements,</font>&#8221; and IAS 8, &#8220;<font style="font-style: italic;">Accounting </font><font style="font-style: italic;">Policies, Changes in Accounting Estimates and Errors</font>&#8221; which clarified the definition of &#8216;materiality&#8217; and how it should be applied. The amendments also improve the explanations of the definition and ensure consistency across all International Financial Reporting Standards (&#8220;IFRS&#8221;). There was no impact on the interim financial statements from the adoption of these new standards.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Going concern</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial position of the Group, its cash flows and liquidity position are described in the primary statements and notes to these financial statements.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-48<br></div></div></div>
<!--End Page 311-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 312-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Group held &#163;56,687,000 and &#163;129,717,000 of cash at the end of September 2020 and December 2020, respectively. The Group has recorded an operating loss of &#163;118,320,000 at December&#160;31, 2019 and a further operating loss of &#163;66,033,000 for the nine months ended September&#160;30, 2020. The Group did not generate positive operational cash flow which was largely due to the continuing focus on the research, development and clinical activities to advance the product candidates and programs within the Group&#8217;s pipeline.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In assessing the going concern assumptions, the Board has undertaken a rigorous assessment of the forecasts and assessed identified downside risks and mitigating actions. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The increase in cash between September and December 2020 arose following the Group&#8217;s recent series C preferred share financing under which a total of $75.0&#160;million was raised in December 2020 and an additional $50.0&#160;million under a loan facility with Oxford Finance Luxembourg S.A.R.L received in November 2020. Based on the positive tebentafusp Phase&#160;3 clinical trial data announced in November 2020 and the increased capital raised, the Group has increased its forecast costs to include those costs required to commercialize tebentafusp. Due to plans to continue to develop and commercialize tebentafusp and other product candidates, the Group will require additional financing in the form of equity financing or loan financing in the future in order to continue its operations and current capabilities beyond the first quarter of 2022. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The downside risks include a number of severe but plausible scenarios incorporating underperformance against the business plan, and delays in cash inflows. As part of these risks, the Board has considered the impact of the ongoing coronavirus 2019 (&#8220;COVID-19&#8221;) pandemic. While it is difficult to estimate the impact of the COVID-19 pandemic due to the rapidly changing nature of the pandemic, the cash flow forecasts include the Group&#8217;s current assumptions, taking into account reasonable plausible downsides. The assumptions include no additional receipts from forecasted milestones for the next 12 months, a reduction in related operational costs and lower discretionary capital expenditures. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Despite the above uncertainties, the Board has the confidence that the accounts should be prepared on a going concern basis for the following reasons:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group has key worker status which allows continuity of providing services throughout a prolonged lockdown period;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group has a track record of meeting expectations under its collaboration agreements and meeting expected milestones within the contracted timeframe;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group&#8217;s history of being able to access equity and loan financing as and when needed; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Group&#8217;s ability and history to control capital expenditure costs and lower other operational spend, as necessary.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Therefore, the Board has continued to adopt the going concern basis of preparation in the financial statements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Whilst the Board is progressing with its plans to secure additional financing from an Initial Public Offering, it has assessed that should this not proceed that it would be unable to generate sufficient cash flows to support its level of activities beyond February 2022 in downside scenarios. This gives rise to a material uncertainty related to events or conditions that may cast significant doubt on the Group&#8217;s ability to continue as a going concern and that it may therefore be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. </div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Estimates and judgements</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions. These judgments, estimates and assumptions affect the reported assets and liabilities as well as income and expenses in the financial period.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-49<br></div></div></div>
<!--End Page 312-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 313-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The estimates and associated assumptions are based on information available when the consolidated financial statements are prepared, historical experience and various other factors which are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Judgements and assumptions are primarily made in relation to revenue recognition to determine whether promises contained within the collaboration agreements are distinct from the other promises in the contract, whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and for performance obligations satisfied over time the appropriate method of measuring progress for the purposes of revenue recognition. Estimates and assumptions are also made in relation to the valuation of ordinary shares, the incremental borrowing rate for leases, and valuation of derivatives. Details of the estimates and judgements made are included in the accounting policies set out in the consolidated financial statements of the Group for the year ended December&#160;31, 2019.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the Group&#8217;s control. Hence, estimates may vary from the actual values.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or the period of revision and future periods if this revision affects both current and future periods. The significant judgements made by management in applying the Group&#8217;s accounting policies and the key sources of estimation uncertainty are the same as those applied in the annual consolidated financial statements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The significant accounting policies are set out in the consolidated financial statements of the Group for the year ended December&#160;31, 2019. There have been no changes to these accounting policies for the nine months ended September&#160;30, 2020 with the exception of that for revenue recognition which has been amended to provide further clarification regarding the policy and the method of computation. These clarifications do not amend the method of computation for revenue recognition as applied in the Group&#8217;s financial statements. Accordingly, the policy for revenue recognition is set out below in full.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Revenue recognition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue arises from the supply of services under the Group&#8217;s collaboration agreements, which are reviewed and assessed in line with the five-step framework established by IFRS 15 &#8220;<font style="font-style: italic;">Revenue from Contracts with Customers</font>&#8221;. In doing so, the Group will consider the promises contained within the collaboration agreements and uses judgment to determine whether those promises are distinct from the other promises in the contract. In addition, the Group uses judgment to determine whether milestones or other variable consideration should be included in the transaction price, whether performance obligations are satisfied at a point in time or over time, and for performance obligations satisfied over time the appropriate method of measuring progress for the purposes of revenue recognition</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Within these collaboration agreements, the Group grants licensing rights and access to the Group&#8217;s technology to develop specified targets and commercialize future product candidates for specified targets defined in the respective collaboration agreements, in addition to research and development services, participation on a joint steering committee and the option to obtain exclusive rights to the associated intellectual property license either through the collaborator exercising an option to do so, or at the Group&#8217;s election. In each of the collaboration agreements, these promises represent one combined performance obligation, because the promises are mutually dependent and the collaborator is unable to derive significant benefits from its access to these targets for their intended purpose without receipt of the remaining promises, which are highly specialized and cannot be performed by other organizations. This single combined performance obligation is satisfied over time and deemed fully satisfied when the collaborator is contractually entitled to benefit from the exclusive rights to the associated intellectual property license either through the collaborator exercising an option to do so or at the Group&#8217;s election. This occurs at different stages of the research and development process within each of the collaboration agreements and is set out in Note 2. Once the collaborator has obtained exclusive rights to the associated intellectual property, the Group has no further contractual obligations relating to the performance </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-50<br></div></div></div>
<!--End Page 313-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 314-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">obligation and accordingly the performance obligation is deemed satisfied and complete at this point. The Group accounts for each collaboration agreement and the related targets as having one combined performance obligation. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Where the Group receives development milestones at key inflection points specified within the collaborationagreements, these are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. The Group determines the variable consideration to be included in the transaction price by estimating the most likely amount that will be received and then applying a constraint to reduce the consideration to the amount which is not probable of being reversed. The determination of whether a milestone is probable includes consideration of the following factors:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether achievement of a development milestone is highly susceptible to factors outside the entity&#8217;s influence, such as milestones involving the judgment or actions of third parties, including regulatory bodies or the customer;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the uncertainty about the achievement of the milestone is not expected to be resolved for a long period of time;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the Company can reasonably predict that a milestone will be achieved based on previous experience; and.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the complexity and inherent uncertainty underlying the achievement of the milestone.</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any development milestone revenue adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under these collaboration agreements, depending on the terms, the Group may also receive commercialization milestones upon the first commercial sale of a product, the amount of which is based on the territory the sale occurs in, and royalties based on worldwide net sales. These amounts have not been included within the transaction price as of December 31, 2019 and 2018 because they are sales-based royalties which will be recognized when the subsequent sale occurs.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue is recognized as the programs progress through the various stages of research and development using an estimate of percentage completion which takes into consideration the estimated timelines required to satisfy the performance obligation and the time taken since program nomination. The determination of the percentage of completion requires the estimation of when the performance obligation will be completed, and this is reviewed and re-assessed quarterly, typically by the joint steering committee for the contract, based on the latest project plan and discussions with project teams and will consider progress achieved to date, historical experience on similar programs and other internal factors as may be available. If a change in facts or circumstances occurs, the estimate of percentage completion is adjusted, and revenue recognized based on the revised estimate. The difference between the cumulative revenue recognized based on the previous estimate and the revenue recognized based on the revised estimate is recognized as an adjustment to revenue in the period in which the change in estimate occurs. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group recognizes deferred revenue when the amount of unconditional consideration is in excess of the value of satisfied, or part satisfied, performance obligations. Once a right to receive consideration is unconditional, that amount is presented as a receivable.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Changes in deferred revenue typically arise due to:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustments arising from a change in the estimate of when the performance obligation will have been completed.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adjustment to revenue that affects deferred revenue;</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-51<br></div></div></div>
<!--End Page 314-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 315-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 0pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a change in the estimate of the transaction price due to changes in the assessment of whether variable consideration is constrained because it is not considered probable of being received; and</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the recognition of revenue. </div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under certain collaboration agreements, research and development costs incurred either in excess of a defined amount, or in accordance with a cost sharing agreement, are reimbursed. These amounts are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. The Group determines the variable consideration to be included in the transaction price by estimating the expected value that will be received and then applying a constraint to reduce the consideration to the amount which is not probable of being reversed. The determination of whether reimbursed costs are highly probable to not be reversed includes the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">past history and experience with similar contracts. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unexpected fluctuations in planned spend. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes to project timelines. </div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">2. Revenue</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Revenue recognized during the nine months ended September&#160;30, 2020 and 2019 was from collaboration agreements with GlaxoSmithKline Intellectual Property Development Ltd (&#8220;GlaxoSmithKline&#8221;), Eli Lilly and Company (&#8220;Eli Lilly&#8221;) and Genentech, Inc. (&#8220;Genentech&#8221;). </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">30, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GlaxoSmithKline<font style="padding-left: 4.95pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 5pt;">4,344</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="padding-left: 5pt;">3,796</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 1.06pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 5pt;">3,522</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="padding-left: 5pt;">1,886</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 2.74pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,828</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">14,345</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">22,694</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,027</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United Kingdom<font style="padding-left: 2.18pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 5pt;">4,</font>344</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="padding-left: 5pt;">3,796</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">United States<font style="padding-left: 1.07pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">18,350</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">16,231</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">22,694</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">20,027</font></div></td></tr></table><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Genentech Collaboration.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Genentech agreement signed in November 2018 (the &#8220;2018 Genentech Agreement&#8221;), the Group received an aggregate non-refundable payments totaling $100 million consisting of an initial upfront payment of $50 million and $50 million paid upon an investigational new drug filing for the first clinical trial of the product candidate compound, in exchange for granting Genentech rights to co-develop/co-promote the Group&#8217;s IMC-C103C program and the co-exclusive worldwide license to the Group&#8217;s intellectual property rights in MAGE A4 soluble TCR bispecific therapeutic candidate compounds. The Group is responsible for development of the IMC-C103C program over the period of time to estimated completion of the Phase 1 clinical trial, with costs being shared equally with Genentech. After completion of the Phase 1 clinical trial, the Group has a limited time period in which to decide to either continue co-development (including co-funding) of the IMC-C103C program or withdraw from the co-funding commitment and convert the co-exclusive license to a full out-license to Genentech of the IMC-C103C program, in exchange for future milestone and royalty payments to the Group. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-52<br></div></div></div>
<!--End Page 315-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 316-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The total payments of $100 million (&#163;77.4 million) upfront payment was recorded as deferred revenue on receipt in November 2018 and allocated to a single combined performance obligation covering the granting of the co-exclusive worldwide license, the provision of development services and participation on a joint steering committee. This deferred revenue is recognized as the Group satisfies the combined performance obligation over the estimated period of time to when the Group may decide to withdraw from the co-funding commitments and convert the co-exclusive license to a full out-license to Genentech. This occurs after completion of the Phase I clinical trial and should the Group withdraw from the co-funding commitment, the Group has no further contractual obligations relating to the performance obligation and accordingly the performance obligation is deemed satisfied and complete at this point in time. Research and development costs reimbursed under the 2018 Genentech Agreement are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September 30, 2020, the Group recognized &#163;14,828,000 revenue relating to the 2018 Genentech Agreement (for the nine months ended September 30, 2019: &#163;14,345,000 and for the years ended December 31, 2019 and 2018: &#163;19,097,000 and &#163;1,461,000 respectively). Of this, &#163;1,648,000 represented research and development cost reimbursements (for the nine months ended September 30, 2019: &#163;1,272,000 and for the years ended December 31, 2019 and 2018: &#163;1,696,000 and &#163;nil respectively). Such reimbursements arise in order to ensure that research and development costs are shared equally in-line with the collaboration agreement. As at September 30, 2020, it was estimated that the performance obligation would be satisfied within two to three years.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">GlaxoSmithKline Collaboration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June 2013, the Group entered into a collaboration and license agreement with GlaxoSmithKline pursuant to which the Group and GlaxoSmithKline agreed to collaborate in the development of soluble TCR bispecific therapeutic compounds (the &#8220;GSK Agreement&#8221;). Under the GSK Agreement, the Group granted GSK the right to nominate up to four targets as being exclusive to GSK under the GSK Agreement. The first target, GSK01/NY-ESO, was nominated at the time of execution of the GSK Agreement. A second target was nominated in July 2017. GlaxoSmithKline has no further ability to nominate additional targets under the GSK Agreement. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the GSK Agreement, for NY-ESO, the Group is responsible for the development of the soluble TCR bispecific therapeutic candidate compounds over the period of time to estimated completion of the initial Phase 1 clinical trials. GlaxoSmithKline has the option until a certain period following completion of such development work to obtain an exclusive worldwide license to NY-ESO. For the second collaboration target, GlaxoSmithKline has an option to obtain an exclusive worldwide license for the therapeutic candidate compounds until a certain period following the identification of at least one development candidate or the earlier termination of the applicable development work.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group received non-refundable upfront payments upon execution of the agreement and nomination of the second collaboration target. Further non-refundable milestone payments have been received based on the achievement of specified development milestones. These development milestone payments are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. In respect of the first target, development costs incurred over a specified amount are reimbursed to the Group.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As at September 30, 2020, the Group has received a total of &#163;22,900,000 in non-refundable payments of which &#163;nil were received nine months ended September 30, 2020 and 2019, and the year ended December 31, 2019, and &#163;9,500,000 were received in the year ended December 31, 2018. These payments have been recorded as deferred revenue on receipt and allocated to a single combined performance obligation for each target covering the provision of research and development services and participation on a joint steering committee. This deferred revenue is recognized as the Group satisfies the combined performance obligation over the estimated period of time to when GlaxoSmithKline can exercise the option to obtain an exclusive worldwide license for the </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-53<br></div></div></div>
<!--End Page 316-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 317-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">therapeutic candidate compounds. Should GlaxoSmithKline exercise the option to obtain an exclusive worldwide license, the Group has no further contractual obligations relating to the associated performance obligation and accordingly the associated performance obligation is deemed satisfied and complete at this point in time. Research and development costs reimbursed under the GSK Agreement are considered variable consideration and are assessed at contract inception and each subsequent reporting period and not recognized in the transaction price until it is highly probable that the recognition of such revenue will not be reversed. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September 30, 2020, the Group recognized &#163;4,344,000 revenue relating to the GSK Agreement (for the nine months ended September 30, 2019: &#163;3,796,000 and for the years ended December 31, 2019 and 2018: &#163;5,753,000 and &#163;6,079,000 respectively). Of this, &#163;2,348,000 represented research and development cost reimbursement (for the nine months ended September 30, 2019: &#163;1,173,000 and the years ended December 31, 2019 and 2018: &#163;2,159,000 and &#163;nil respectively). Such reimbursements arise where research and development costs in excess of a defined amount are incurred on one specified program. As at September 30, 2020, it was estimated that the performance conditions across the two targets would be satisfied in timeframes ranging from up to eighteen months for the first target and four to five years for the second target.</div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Lilly Collaboration</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July 2014, the Group entered into a development and license agreement with Eli Lilly pursuant to which the Group and Eli Lilly, or the Lilly Agreement, agreed to collaborate in the development, manufacture and commercialization of soluble TCR bispecific therapeutic compounds. Under the Lilly Agreement, Eli Lilly paid an initial non-refundable upfront fee payment of $45 million in exchange for options to three targets. Eli Lilly no longer has the ability to nominate any further targets under the initial agreement with Lilly. In December 2016, the Group and Eli Lilly agreed to swap an existing antigen target, selected by Lilly, for a new, well-known neo-antigen target. Lilly has no further obligations with respect to the initial target that was replaced. In September 2017, the Group and Eli Lilly agreed to swap a second antigen target, selected by Lilly, for a second neo-antigen target. Similarly, Eli Lilly has no further obligations with respect to the initial target that was replaced.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Lilly Agreement, the Group is responsible for developing soluble TCR bispecific therapeutic pre-clinical candidates to each target with Eli Lilly responsible for GMP manufacture of Phase 1 material at its expense. On a collaboration target-by-collaboration target basis, at the point of clinical candidate nomination, Lilly has the right to opt in to gain exclusive co-development/co-promotion rights to the target program. Upon receipt of the proposed development plan and Phase 1 budget, the Group has a limited time period in which to elect to contribute either 25% or 50% costs to reach the next clinical phase or to opt-out of further development. Similar provisions are available at the start of Phase 2 clinical trials and registrational clinical trials. Should the Group opt-out of co-development on a collaboration target-by-collaboration target basis, Eli Lilly would obtain an exclusive worldwide license to develop and commercialize the compound at its sole expense. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The $45 million upfront payment was recorded as deferred revenue on receipt and allocated to a single combined performance obligation for each target covering the provision of research and development services and participation on a joint steering committee. This deferred revenue is recognized as the Group satisfies the combined performance obligations over the estimated period of time to when Eli Lilly can exercise the option to obtain exclusive co-development/co-promotion rights to the target and the Group can opt-out of the co-development of the target. Should this occur, the Group has no further contractual obligations relating to the associated performance obligation and accordingly the associated performance obligation is deemed satisfied and complete at this point in time. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September 30, 2020, the Group recognized &#163;3,522,000 revenue relating to the Lilly Agreement (for the nine months ended September 30, 2019: &#163;1,886,000 and for the years ended December 31, 2019 and 2018: &#163;819,000 and &#163;8,561,000 respectively). Following termination of one of the programs under the Eli Lilly collaboration during 2019, a balance of &#163;3,132,000 was held as deferred revenue at December 31, 2019. During the nine months ended September 30, 2020, after a change in program focus under the Eli Lilly collaboration, the &#163;3,132,000 balance of deferred revenue was released in full. No further revenue </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-54<br></div></div></div>
<!--End Page 317-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 318-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">was recognized for a second program under the Eli Lilly collaboration while the lead program is prioritized. For the remaining target the estimated timeframe to satisfy the performance conditions is one to two years. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the period, the Group has reviewed and revised the estimated completion of each of the programs under the collaboration agreements, arising from the availability of additional historical data as programs progress through research and development activities within the Group. The impact of this revision is on current and future reporting periods only and increased revenue recognized in the nine months ended September 30, 2020 by &#163;218,000. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following tables presents changes in the Group&#8217;s trade receivables, contract assets and contract liabilities during the nine months ended September 30, 2020 and the year ended December 31, 2019.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additions <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deductions<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables:<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration agreement trade receivables<font style="padding-left: 4.91pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,186</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,076</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">4,262</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"></font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total receivables<font style="font-weight: normal; padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,186</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,076</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">4,262</font><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;"></font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract assets:<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract assets<font style="padding-left: 0.42pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">424</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">920</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(424</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">920</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contract assets<font style="font-weight: normal; padding-left: 3.02pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">424</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">920</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(424</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">920</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liabilities:<br></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">76,418</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(18,698</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">57,720</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contract liabilities<font style="font-weight: normal; padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">76,418</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.69pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(18,698</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.95pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">57,720</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.93%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">January&#160;1,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additions<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deductions <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.29%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000 </div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables:<br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration agreement trade receivables<font style="padding-left: 4.91pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3,600</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,431</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(5,845</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,186</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total receivables<font style="font-weight: normal; padding-left: 4.29pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">3,600</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,431</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">(5,845</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">1,186</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract assets:<br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract assets<font style="padding-left: 0.42pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">424</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">424</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contract assets<font style="font-weight: normal; padding-left: 3.02pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">424</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; min-width: 30.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">424</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contract liabilities:<br></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue<font style="padding-left: 0.99pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">98,232</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(21,814</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">76,418</font></div></td></tr><tr><td style="width: 56.41%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contract liabilities<font style="font-weight: normal; padding-left: 3.56pt;"></font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.93%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.8pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">98,232</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.42pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 3pt double #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.7pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 30.83pt;">(21,814</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.29%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">76,418</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the nine months ended September 30, 2020 and the years ended December 31, 2019 and 2018, deductions from deferred revenue represent revenue recognized during the year. During the nine months ended September 30, 2020 and the year ended December 31, 2019 there were no additions to deferred revenue. For the year ended December 31, 2018 there were additions of &#163;86,400,000 to deferred revenue representing &#163;76,900,000 received under the 2018 Genentech Agreement and &#163;9,500,000 received under the GSK Agreement. Trade receivables and contract assets relate to the reimbursement of research and developments costs under the 2018 Genentech Agreement and GSK Agreement. No such reimbursements were received during the year ended December 31, 2018. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The total revenue recognized during the nine months ended September 30, 2020 was &#163;22,694,000 of which &#163;18,698,000 was included in deferred revenue at January 1, 2020 and the balance &#163;3,996,000 relates to reimbursed </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-55<br></div></div></div>
<!--End Page 318-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 319-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">research and development costs. The total revenue recognized during the year ended December 31, 2019 was &#163;25,669,000, of which &#163;21,814,000 was included in deferred revenue at January 1, 2019 and the balance &#163;3,855,000 relates to reimbursed research and development costs. The total revenue recognized during the year ended December&#160;31, 2018 was &#163;23,654,000 which was all included in deferred revenue at January 1, 2018. Reimbursed research and development costs are recognized gross as revenue. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">No revenue was recognized in the nine months ended September 30, 2020 relating to performance obligations satisfied in previous years (nine months ended September 30, 2019: &#163;nil).</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468.54pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">At <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current deferred revenue:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GlaxoSmithKline<font style="padding-left: 1.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">3,253</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">3,895</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">1,696</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">7,151</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">17,089</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">17,411</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current deferred revenue<font style="font-weight: normal; padding-left: 0.88pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">22,038</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">28,457</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current deferred revenue:<br></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GlaxoSmithKline<font style="padding-left: 1.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">2,247</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">3,603</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly<font style="padding-left: 3.06pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">5,665</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">3,732</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Genentech<font style="padding-left: 4.74pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">27,770</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">40,626</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current deferred revenue<font style="font-weight: normal; padding-left: 2.55pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">35,682</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">47,961</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total deferred revenue<font style="font-weight: normal; padding-left: 3.82pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">57,720</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">76,418</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred revenue is in respect of the upfront fee and development milestone consideration received from the various collaboration agreements in advance of services performed by the Group. Included in the current deferred revenue balance of &#163;28,457,000 at December 31, 2019 is &#163;3,132,000 that was held following termination of one of the programs under the Eli Lilly collaboration during 2019. During the nine months ended September 30, 2020, after a change in program focus under the Eli Lilly collaboration, the &#163;3,132,000 balance of deferred income was released in full. As at December 31, 2018, current deferred revenue balances totaled &#163;29,437,000 comprising: GlaxoSmithKline &#163;4,163,000; Eli Lilly &#163;7,524,000 and Genentech &#163;17,750,000 and non-current deferred revenue balances totaled &#163;68,795,000 comprising: GlaxoSmithKline &#163;6,929,000; Eli Lilly &#163;4,178,000 and Genentech &#163;57,688,000.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">3. Finance income</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">30, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on cash and cash equivalents<font style="padding-left: 3.35pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="padding-left: 7.5pt;">660</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;">1,107</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease interest income<font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="padding-left: 12.5pt;">25</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="padding-left: 12.5pt;">27</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gain from change in fair value of derivative liability<font style="padding-left: 3.93pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,287</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,972</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.35%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">1,134</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The derivative liability represents a foreign exchange call option over certain series B shares which was settled in full in March 2020, resulting in a gain of &#163;1,287,000 based on the fair value as at derecognition, and a credit to equity of &#163;3,840,000. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-56<br></div></div></div>
<!--End Page 319-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 320-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">4. Finance costs</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.18%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">30, 2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest on lease liabilities<font style="padding-left: 3.33pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;">1,847</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;">2,283</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest expenses on financial liabilities measured at amortized cost<font style="padding-left: 3.96pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="padding-left: 7.5pt;">159</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="padding-left: 7.5pt;">694</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from change in fair value of embedded derivative asset<font style="padding-left: 1.73pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="padding-left: 7.5pt;">266</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="padding-left: 7.5pt;">438</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from change in fair value of derivative liability<font style="padding-left: 4.48pt;"></font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,117</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">2,272</font></div></td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.18%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.35%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 12.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">6,532</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest expenses related to the Bill &amp; Melinda Gates Foundation (the &#8220;Gates Foundation&#8221;) convertible loan, which was partially converted into series B shares in March 2020 (see Note 10).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The convertible loan received from the Gates Foundation contains conversion features which are accounted for as an embedded derivative and separated from the convertible loan. During the nine months ended September&#160;30, 2020, the loss from the change in fair value of the embedded derivative asset represents the movement in fair value of this embedded derivative asset on derecognition arising from the conversion of the loan into series B shares and during the nine months ended September&#160;30, 2019, this also represents the movement in fair value of this embedded derivative asset. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The derivative liability represents a foreign exchange call option over certain series B shares. The loss of &#163;3,117,000 from the change in fair value of the derivative liability represents the movement in fair value of this derivative from inception, during 2019, to September&#160;30, 2019. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">5. Income tax</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Income tax credit is recognized at an amount determined by multiplying the loss before taxation for the interim reporting period by the Group&#8217;s best estimate of the weighted-average annual income taxation rate expected for the full financial year, adjusted for the tax effect of certain items recognized in full in the interim period. As such, the effective tax rate in the interim financial statements may differ from the Group&#8217;s estimate of the effective tax rate for the annual financial statements. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group&#8217;s consolidated effective tax rate in respect of continuing operations for the nine months ended September&#160;30, 2020 was 16.8% (nine months ended September&#160;30, 2019: 18.8%). </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">6. Basic and diluted loss per share</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss for the period<font style="font-weight: normal; padding-left: 2.38pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="padding-left: 9.17pt;">(55,213)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="padding-left: 9.17pt;">(77,966)</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted weighted average number of shares<font style="padding-left: 1.16pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">5,458,712</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 40pt;">4,315,976</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Basic and diluted loss per share<font style="font-weight: normal; padding-left: 2.01pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 3pt double #000000; min-width: 40pt;">(0.01</font><font style="min-width: 40pt;">)</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.7pt; text-align: left;"><font style="padding-left: 19.17pt; border-bottom: 3pt double #000000; min-width: 40pt;">(0.02</font><font style="min-width: 40pt;">)</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Basic loss per share is calculated by dividing the loss for the period attributable to the equity holders of the Group by the weighted average number of shares outstanding during the period. The dilutive effect of potential shares through equity settled transactions are considered to be anti-dilutive as they would decrease the loss per share and are, therefore, excluded from the calculation of diluted loss per share.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-57<br></div></div></div>
<!--End Page 320-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 321-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">7. Property, plant and equipment</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September&#160;30, 2020, the Group acquired assets at a cost of &#163;3,179,000, of which &#163;2,080,000 were additions to leasehold improvements and &#163;557,000 were additions to plant and equipment, primarily laboratory equipment. During the year ended December&#160;31, 2019, the Group acquired assets at a cost of &#163;4,975,000, of which &#163;897,000 were additions to right of use assets relating to the Group entering into a new lease for leasehold property, &#163;1,150,000 plant and equipment, primarily laboratory equipment and &#163;2,713,000 assets under construction primarily related to leasehold improvements.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September&#160;30, 2020, the Group terminated the lease for a leasehold property with an associated reduction in right of use assets of &#163;4,104,000. The Group also received a leasehold incentive in respect of another leasehold property for &#163;1,088,000 and remeasured the right of use assets associated with four leasehold properties for &#163;876,000 which both reduced the carrying value of the right of use assets. During the year ended December&#160;31, 2019, there was a separate reduction to the lease term for a leasehold property and the associated right of use asset reduced by &#163;6,849,000. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">8. Other non-current financial assets</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160; 30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160; 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Long-term security deposits<font style="padding-left: 1.65pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;">2,532</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">2,532</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,471</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 10.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">1,858</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">7,003</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.64%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,390</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income include those amounts paid in advance for clinical trials that will be repaid at the end of the associated clinical trials. Subsequent to September&#160;30, 2020, the Group reached an agreement to exit the lease for a leasehold property. Under the terms of the agreement the Group will receive &#163;1.8&#160;million security deposit associated with the lease (see Note 18).</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">9. Trade and other receivables</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160; 30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.97%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.64%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160; 31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade receivables<font style="padding-left: 4.22pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="padding-left: 7.5pt;">136</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">1,471</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 2.05pt; padding-bottom: 2.05pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other receivables<font style="padding-left: 4.43pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt;">&#8203;</td><td style="width: 11.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 2.05pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;">1,861</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt;">&#8203;</td><td style="width: 10.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 2.05pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;">3,667</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interest receivables<font style="padding-left: 2.21pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 2.05pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;"><font style="padding-left: 12.5pt;">28</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepayments and accrued income<font style="padding-left: 3.89pt;"></font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 11.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">5,482</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 2.05pt; padding-bottom: 3.3pt;">&#8203;</td><td style="width: 10.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.05pt; padding-bottom: 3.3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.66pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">4,473</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 14.78pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">7,479</font></div></td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.97%; border-bottom: none; font-size: 2pt; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.64%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.66pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">9,639</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">10. Interest-bearing loans and borrowings</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The initial tranche of the Gates Foundation loan in the amount of $25&#160;million was converted into 203,697 series B shares as part of the Group&#8217;s second closing of the series B preferred share financing in March 2020. Following conversion of the loan, the associated embedded derivative asset of &#163;266,000 as at December&#160;31, 2019 was derecognized and &#163;510,000 recognized in the accumulated deficit representing the difference between the amortized cost carrying value of the loan of &#163;19,356,000 and the outstanding loan value of $25.5&#160;million as at the date of conversion.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-58<br></div></div></div>
<!--End Page 321-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 322-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">11. Cash and cash equivalents </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160; 30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.11%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash at bank and in hand<font style="padding-left: 0.54pt;"></font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.27pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">56,687</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">73,966</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.12%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.27pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">56,687</font></div></td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.11%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.08%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.83pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">73,966</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">12. Capital and reserves</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 58.98%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issued share capital (0.01p per share)</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.59%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series A <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series B <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.1%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ordinary <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td></tr><tr><td style="width: 58.98%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2020<font style="font-weight: normal; padding-left: 4.91pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">58,206</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">1,699,576</div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">621,556</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2,515,894</div></td></tr><tr><td style="width: 58.98%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 1.9pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt;">34,260</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">323,450</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 12.5pt;">35,730</font></div></td></tr><tr><td style="width: 58.98%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for non-cash consideration<font style="padding-left: 1.37pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 7.5pt;">203,697</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt;">&#8212;</font></div></td></tr><tr><td style="width: 58.98%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Repurchased and cancelled<font style="padding-left: 3pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(29,916</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 30pt; border-bottom: 1pt solid #000000; min-width: 40pt;">&#8212;</font></div></td></tr><tr><td style="width: 58.98%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At September&#160;30, 2020<font style="font-weight: normal; padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.59%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">62,550</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,699,576</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">1,148,703</font></div></td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.1%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.55%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 40pt;">2,551,624</font></div></td></tr></table><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 6pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;</div></td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 2.78%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 3.42%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allotted, called up and fully paid<font style="padding-left: 0.16pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ordinary shares<font style="padding-left: 2.09pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">255</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">252</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series A shares<font style="padding-left: 4.3pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">170</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;">170</div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series B shares<font style="padding-left: 3.76pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 0.37pt;">115</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 5pt;">62</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Growth shares<font style="padding-left: 2.64pt;"></font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">6</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="padding-left: 10pt; border-bottom: 1pt solid #000000; min-width: 15pt;">6</font></div></td></tr><tr><td style="width: 82.05%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">546</font></div></td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.78%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 3.42%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.5pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">490</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March&#160;2, 2020, the Group completed the second and final closing of the series B preferred share financing. A total of 527,147 series B shares were issued, of which 280,418 series B shares were issued to new and existing investors for net cash consideration totaling &#163;27,230,000. The initial tranche of the Gates Foundation loan in the amount of $25&#160;million was converted into 203,697 series B shares as part of the Group&#8217;s second closing of the series B preferred share financing in March 2020 (Note 10) and 43,032 series B shares were issued at nominal value to certain series B investors on derecognition of the derivative liability of &#163;3,184,000 represented by a foreign exchange call option over series B shares.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the period to September&#160;30, 2020, a total of 35,730 ordinary shares of 0.01p each with a total nominal value of &#163;4 were issued for cash consideration of &#163;45,000, of which 33,201 were issued as anti-dilution shares at nominal value. Growth shares of 0.01p each totaling 34,260 were issued during the nine months ended September&#160;30, 2020 for cash consideration totaling &#163;3 and 29,916 Growth shares with a total nominal value of &#163;3 were repurchased and cancelled.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Share premium</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 2.94%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 6.94%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At January&#160;1, 2020<font style="font-weight: normal; padding-left: 1.91pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">283,250</div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for cash<font style="padding-left: 3.9pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">27,275</font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">New shares issued for non-cash consideration<font style="padding-left: 3.37pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">19,865 </font></div></td></tr><tr><td style="width: 87.18%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">At September&#160;30, 2020<font style="font-weight: normal; padding-left: 1.55pt;"></font></div></td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 2.94%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 6.94%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">330,390</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">New shares issued during the year gave rise to net proceeds of &#163;27,275,000. Non-cash proceeds of &#163;19,865,000 arose upon the conversion of the first tranche of the Gates Foundation loan into series B shares.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-59<br></div></div></div>
<!--End Page 322-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 323-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg13"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Nature and purpose of reserves</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The share-based payments reserve is used to recognize the value of equity-settled share-based payments provided to employees. All other reserves are as stated in the consolidated statement of changes in equity.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The treasury reserve represents those unvested awards granted to certain employees and directors under the Growth Share Plan (see Note 13). As at September&#160;30, 2020, the treasury reserve totaled &#163;2.52 (December&#160;31, 2019: &#163;4.42).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">No dividends were paid or declared in the nine months ended September&#160;30, 2020. </div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">13. Share-based payments</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group operates various employee share schemes that grant awards to certain employees and directors. The total charge for such share-based payment plans during the nine months ended September&#160;30, 2020 was &#163;5,181,000 (nine months ended September&#160;30, 2019 &#8211; &#163;2,501,000), all of which relate to equity settled awards and are charged to administrative expenses.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A total of 144,370 share options and 34,260 Growth Shares were awarded during the nine months to September&#160;30, 2020 (nine months September&#160;30, 2019 &#8211; 582,252 share options) which will vest over a four-year period from the date of grant and are not entitled to dividends. Those share options awarded in 2019 were modified during the nine months ended September&#160;30, 2020 through a reduction in the associated exercise price from &#163;150 to &#163;64 per share. The incremental fair value granted was valued on a consistent basis to other awards made within the Group and was valued at &#163;14.06 per share and has been applied to those unvested awards as at the date of modification.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The number and weighted average exercise prices of share options are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of shares issuable </div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options (#)</div></td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.89%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price (&#163;)</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2020<font style="font-weight: normal; padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;">715,823</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">132.89</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;">144,370</div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 6.67pt;">(2,529)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">17.80</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; min-width: 32.5pt;">(24,760</font><font style="min-width: 32.5pt;">)</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">67.43</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at September&#160;30, 2020<font style="font-weight: normal; padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">832,904</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 5.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">63.</font>23</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at September&#160;30, 2020<font style="font-weight: normal; padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 12.56%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 13.15pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">220,519</font></div></td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.89%; border-bottom: none; font-size: 2pt; padding-top: 5.25pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 5.25pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">59.44</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The weighted average fair value of options granted in the nine months ended September&#160;30, 2020 was &#163;32.46 (for the year ended December&#160;31, 2019: &#163;11.95). The weighted average share price at the date of exercise of the options during the nine months ended September&#160;30, 2020 was &#163;64.00 (for the year ended December&#160;31, 2019: &#163;64.00).</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The number and weighted average hurdle rate of Growth Shares are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of shares issuable </div></td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.79%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of growth <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div></td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.59%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">hurdle rate &#163;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2020<font style="font-weight: normal; padding-left: 1.47pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="padding-left: 3.33pt;">58,206</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards granted<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="padding-left: 3.33pt;">34,260</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards exercised<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="padding-left: 20.83pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Awards forfeited<font style="padding-left: 1.57pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 30.83pt;">(29,916</font><font style="min-width: 30.83pt;">)</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">170.00</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at September&#160;30, 2020<font style="font-weight: normal; padding-left: 1.11pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">62,550</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 4.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">137.36</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at September&#160;30, 2020<font style="font-weight: normal; padding-left: 0.19pt;"></font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.79%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 16.87pt; text-align: left;"><font style="padding-left: 3.33pt; border-bottom: 3pt double #000000; min-width: 30.83pt;">36,761</font></div></td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.59%; border-bottom: none; font-size: 2pt; padding-top: 4.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 17.13pt; text-align: left;">156.78</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-60<br></div></div></div>
<!--End Page 323-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 324-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg14"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The weighted average fair value of growth shares granted in the nine months ended September&#160;30, 2020 was &#163;4.93 (for the year ended December&#160;31, 2019: nil). </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For share options and Growth Share awards outstanding at September&#160;30, 2020, the range of exercise prices and weighted average remaining contractual life are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 4.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 36.4%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth Shares</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="7" style="width: 38.08%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options</div></td></tr><tr class="header"><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.16%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hurdle rate &#163;</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual life</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise price &#163;</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options</div></td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.25%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual life</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;">170.00</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;">43,290</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">7.6</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;"><font style="padding-left: 5pt;">43.37</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 5pt;">92,544</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">4.4</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;"><font style="padding-left: 5pt;">64.00</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;">19,260</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="padding-left: 5pt;">9.6</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;">120.87</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 10pt;">3,309</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">5.3</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;">150.00</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 5pt;">12,585</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;">6.5</div></td></tr><tr><td style="width: 20.51%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.16%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.02pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8195;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.06pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">&#8195;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.13pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 17.5pt; padding-right: 7.5pt;">&#8195;</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 11.84%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.94pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 3pt double #000000; min-width: 27.5pt;">64.00</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 32.5pt;">724,466</font></div></td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 1.25%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 13.2%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.63pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 12.5pt;">8.5</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Awards granted under the Share Option Plan have been valued using the Black-Scholes option pricing model, those awards granted under the Growth Share Plan have been valued using the Back Solve model, reflecting the different rights available to holders of Growth Shares. The assumptions used in the models for awards granted during the nine months ended September&#160;30, 2020, are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 13.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Growth shares</div></td><td class="gutter" style="width: 1.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.21%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 14.6%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share options </div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share price at grant date<font style="padding-left: 4pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;64.00</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;64.00</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise price<font style="padding-left: 1.76pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;64.00</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hurdle rate<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#163;64.00</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">&#8212;</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility<font style="padding-left: 2.85pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">91% - 102%</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">78% - 93%</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected life (years)<font style="padding-left: 4.55pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1 yrs</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">1.6 - 3 yrs</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free rate<font style="padding-left: 3.98pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(0.02%) -0.03%</div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">(0.03%) - 0.13%</div></td></tr><tr><td style="width: 66.67%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fair value<font style="padding-left: 3.41pt;"></font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 13.88%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 3pt double #000000;">&#163;</font><font style="border-bottom: 3pt double #000000;">2.12 - </font><font style="border-bottom: 3pt double #000000;">&#163;</font><font style="border-bottom: 3pt double #000000;">7.71</font></div></td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.21%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 14.6%; text-align: right; vertical-align: bottom; padding-top: 3pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;"><font style="border-bottom: 3pt double #000000;">&#163;</font><font style="border-bottom: 3pt double #000000;">28.44 - </font><font style="border-bottom: 3pt double #000000;">&#163;</font><font style="border-bottom: 3pt double #000000;">34.30</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">14. Leases liabilities</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468.54pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current<font style="padding-left: 1.95pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">2,098 </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 5pt;">1,951</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-current <font style="padding-left: 0.3pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">31,861</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">38,299</font><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;"> </font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities <font style="font-weight: normal; padding-left: 1.22pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">33,959</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">40,250</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the nine months ended September&#160;30, 2020, the lease term for one leasehold property was terminated and the lease liability for four leasehold properties were remeasured reducing the associated lease liability by &#163;4,351,000 and &#163;1,075,000 respectively. The Group also entered into a new lease for a leasehold property with an associated lease liability of &#163;422,000 as at September&#160;30, 2020. The maturity of undiscounted lease commitments is set out in Note 16.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">15. Trade and other payables</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468.54pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.54%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;&#8217;000</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.07%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Trade payables<font style="padding-left: 1.21pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 5pt;">5,829</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;">15,729</div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other taxation and social security<font style="padding-left: 4.78pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="padding-left: 12.5pt;">607</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="padding-left: 12.5pt;">522</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accruals<font style="padding-left: 1.97pt;"></font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">16,844</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 27.5pt;">13,250</font></div></td></tr><tr><td style="width: 76.83%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.54%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">23,280</font></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt;">&#8203;</td><td style="width: 10.07%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 9.82pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">29,501</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-61<br></div></div></div>
<!--End Page 324-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 325-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg15"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">16. Commitments and contingencies</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following table summarizes the Group&#8217;s contractual obligations as of September&#160;30, 2020: </div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 51.28%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#163;000s</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.12%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Less than <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1 year</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">1-3<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">years</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 4.81%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">3-5<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.76%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">More than<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">5&#160;years</div></td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.63%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 5.88%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; existing<font style="padding-left: 0.32pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;">4,275</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">7,910</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6,548</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.75pt; text-align: left;">35,657</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">54,390</div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease liabilities &#8211; contingent<font style="padding-left: 4.76pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 5pt;">2,254</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2,471</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.75pt; text-align: left;"><font style="padding-left: 5pt;">1,841</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">6,566</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Manufacturing<font style="padding-left: 3.08pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;">2,021</div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">471</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.75pt; text-align: left;"><font style="padding-left: 17.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt;">2,492</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capital commitments<font style="padding-left: 0.85pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,134</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; min-width: 22.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.75pt; text-align: left;"><font style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 27.5pt;">2,134</font></div></td></tr><tr><td style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total contractual obligations<font style="font-weight: normal; padding-left: 3.45pt;"></font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.12%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 5.41pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,430</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">10,635</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 4.81%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">9,019</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.76%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 6.75pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">37,498</font></div></td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.63%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 5.88%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 27.5pt;">65,582</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Significant changes to contractual obligations and commitments as presented at December&#160;31, 2019, have arisen from the termination of a leasehold property during the nine months ended September&#160;30, 2020 reducing the undiscounted contractual liability by &#163;8,047,000. In addition, the Group entered into a new lease for a leasehold property with undiscounted contractual payments of &#163;457,000. The Group has contractual obligations for two leasehold properties under which it is obligated to take on the leases should the properties become vacant at specified dates in the future. For both properties, the Group has assessed these contingent events as highly probable as at September&#160;30, 2020 and has recognized an additional contingent commitment totaling &#163;6,566,000. Subsequent to September&#160;30, 2020, the Group reached an agreement to exit a leasehold property obligation prior to the end of 2020. The impact of this agreement reduces the Group&#8217;s total contractual obligations by &#163;7.7&#160;million.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subsequent to the period to September 30, 2020, management of the Group conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors. After the investigation, the one remaining open contract with the third-party vendors was terminated and the Group has undertaken proceedings against the involved parties but is not yet in the position to verify or validate any information relating to this matter due to the very recent timing of the issue. As at September&#160;30, 2020, the Group estimated the amount in question to be in the range of &#163;1.1&#160;million to &#163;1.8&#160;million and recovered &#163;1.8&#160;million from the employee and third-party vendors in December 2020.</div><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">17. Related Party Disclosures</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Group entered into transactions with related parties in the ordinary course of business. Transactions and trading balances outstanding as at September&#160;30, 2020 and December&#160;31, 2019 are as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, 2020</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 24.05%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2019</div></td></tr><tr class="header"><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchases from <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Sales to <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.44%; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 3.5pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3.5pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Purchases from <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">related party <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aigenpulse Limited<font style="padding-left: 2.96pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.59pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.96pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;">&#8212;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 2.25pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.46pt; text-align: left;">500</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oxford Innovation Limited<font style="padding-left: 2.97pt;"></font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.59pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.96pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 2.25pt; padding-bottom: 3.5pt;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 2.25pt; padding-bottom: 3.5pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.46pt; text-align: left;"><font style="padding-left: 5pt; border-bottom: 1pt solid #000000; min-width: 15pt;">30</font></div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: bottom; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.59pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.96pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 9.65%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.58pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 10pt;">&#8212;</font></div></td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.44%; border-bottom: none; font-size: 2pt; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 11.52%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3.5pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.46pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 15pt;">530</font></div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">There were no trading balances outstanding with related parties as at September&#160;30, 2020 or December&#160;31, 2019.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-62<br></div></div></div>
<!--End Page 325-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 326-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_204-finnotes02_pg16"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Immunocore Limited<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unaudited condensed consolidated interim financial statements<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">September 30, 2020<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Notes to the Financial Statements<font style="padding-left: 4pt;">(continued)</font><br></div><div class="h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remuneration of key management personnel</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The remuneration of the directors and executive officers (excluding non-executive directors), who are the key management personnel of the Group, is set out below in aggregate for each of the categories specified in IAS 24, &#8220;<font style="font-style: italic;">Related Party Disclosures</font>&#8221;.</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2020 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.13%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the nine <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">months ended <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">September&#160;30, <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2019 <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#163;000</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Short-term employee benefits<font style="padding-left: 4.99pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;">2,084</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;">5,827</div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based payments<font style="padding-left: 4.98pt;"></font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">3,</font><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">416</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 1pt solid #000000; min-width: 22.5pt;">2,874</font></div></td></tr><tr><td style="width: 74.36%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">5,</font><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">500</font></div></td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 1.13%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 10.55%; text-align: center; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 6pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.45pt; text-align: left;"><font style="border-bottom: 3pt double #000000; min-width: 22.5pt;">8,701</font></div></td></tr></table><div class="h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">18. Events after the reporting period</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subsequent to the period to September&#160;30, 2020, management of the Group conducted an internal investigation as a result of receiving a whistleblower complaint alleging employee misconduct and other improper activities related to a kickback scheme involving an employee and two third-party vendors. After the investigation, the one remaining open contract with the third party vendors was terminated and the Group has undertaken proceedings against the involved parties but is not yet in the position to verify or validate any information relating to this matter due to the very recent timing of the issue. As at September&#160;30, 2020, the Group estimated the amount in question to be in the range of &#163;1.1&#160;million to &#163;1.8&#160;million, and recovered &#163;1.8 million from the employee and third-party vendors in December 2020. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;6, 2020, the Group entered into a loan and security agreement with Oxford Finance Luxembourg S.A.R.L. (&#8220;Oxford Finance&#8221;) for the provision of up to $100&#160;million debt financing to be provided under three tranches, of which the first tranche of $50&#160;million was received on signing the agreement. The second tranche of $25&#160;million can be drawn down upon tebentafusp receiving Biologics License Application approval prior to June&#160;30, 2022 and the third and final tranche of $25&#160;million can be drawn down at the sole discretion of Oxford Finance.</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On December&#160;21, 2020, the Group completed the series C preferred share financing. A total of $75.0&#160;million was raised with a number of new and existing investors. </div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On December&#160;23, 2020, the Group reached an agreement to exit the lease on a leasehold property. Under the terms of the agreement, the Group will be repaid the security deposit of &#163;1.8&#160;million for the property together with &#163;1.4&#160;million incentive for exiting the lease early. The associated reduction in total contingent lease liabilities was &#163;7.7&#160;million.</div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-63<br></div></div></div>
<!--End Page 326-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 327-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 456pt;"><a name="nt10016217x4_f1_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="page-content"><div class="block-main" style="width: 456pt; margin-left: 0pt;"><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Through and including &#8195;&#8195;&#8195;, 2021, (the 25th day after the date of this prospectus), all dealers effecting transactions in the ADSs, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&#8217;s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 164.5pt; text-align: center;">&#8195;&#8195; American Depositary Shares<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Representing &#8195;&#8195; Ordinary Shares)</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 31.25pt; text-align: center;"><img style="height: 27px; width: 249px;" src="logo_immunocore.jpg"><br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 57.25pt;"> </div></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">PRELIMINARY PROSPECTUS</div><div><div class="rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 31.25pt;"> </div></div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 125.25pt; border-collapse: collapse; width: 456pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 42.11%; text-align: center; vertical-align: top; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Goldman Sachs &amp; Co. LLC</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 26.32%; text-align: center; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">J.P. Morgan</div></td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td class="gutter" style="width: 1.32%; border-bottom: none; font-size: 2pt; padding-top: 6pt;">&#8203;</td><td style="width: 26.32%; text-align: center; vertical-align: bottom; padding-top: 6pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Jefferies</div></td></tr></table><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 60.5pt; text-align: center;">&#8195;&#8195;&#8195;&#8195;, 2021</div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 29.5pt; margin-left: 0pt; text-align: left;">&#8195;</div></div></div><div class="block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 327-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 328-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_301-part2_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br></div><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Information Not Required in Prospectus</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 6.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Subject to the Companies Act 2006, members of the registrant&#8217;s board of directors and its officers have the benefit of the following indemnification provisions in the registrant&#8217;s articles of association: </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Current and former members of the registrant&#8217;s board of directors or officers shall be indemnified for all costs, charges, losses, expenses and liabilities sustained or incurred, including any liability incurred in defending any criminal or civil proceedings in which judgement is given is his favor or in which he is acquitted or the proceedings are otherwise disposed of without any finding or admission of any material breach of duty on his behalf or in connection with any application in which the court grants him relief from liability for negligence, default, breach of duty or breach of trust in relation to the registrant&#8217;s or its group&#8217;s affairs. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">In the case of current or former members of the registrant&#8217;s board of directors, in compliance with the&#160;Companies Act, there shall be no entitlement to indemnification as referred to above for (i)&#160;any liability incurred to the registrant or any associated company, (ii)&#160;the payment of a fine imposed in any criminal proceeding or a penalty imposed by a regulatory authority for non-compliance with any requirement of a regulatory nature, (iii)&#160;the defense of any criminal proceeding if the member of the registrant&#8217;s board of directors is convicted, (iv)&#160;the defense of any civil proceeding brought by the registrant or an associated company in which judgment is given against the director, and (v)&#160;any application for relief under the Companies Act in which the court refuses to grant relief to the director. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The registrant may provide any current or former director or officer with funds to meet expenditure incurred or to be incurred by them in connection with any proceedings or application referred to above and otherwise may take any action to enable any such relevant officer to avoid incurring such expenditure. Members of the registrant&#8217;s board of directors and its officers who have received payment from the registrant under the relevant indemnification provisions must repay the amount they received in accordance with the Companies Act or in any other circumstances that the registrant may prescribe or where the registrant has reserved the right to require repayment. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The underwriting agreement the registrant will enter into in connection with the offering of ADSs being registered hereby provides that the underwriters will indemnify, under certain conditions, the registrant&#8217;s board of directors and its officers against certain liabilities arising in connection with this offering.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 45pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Recent Sales of Unregistered Securities.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Set forth below is information regarding share capital issued by us since January&#160;1, 2017. Some of the transactions described below involved directors, officers and 5% shareholders and are more fully described under the&#160;section titled &#8220;Related Party Transactions.&#8221;</div><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Issuances of Share Capital </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 19, 2017, we issued 155,246 G1 shares to Immunocore Nominees Limited at a purchase price of &#163;0.0001 per share for an aggregate consideration of &#163;15.52.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 19, 2017, we issued 10,000 ordinary shares to an option holder upon the exercise of share options at an exercise price of &#163;43.37 per share for an aggregate consideration of &#163;433,700.00. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In August 2018, September 2018, October 2018, November 2018 and December 2018, we issued an aggregate of 10,960 ordinary shares to Immunocore Nominees Limited at purchase prices ranging from &#163;0.74 to &#163;150 per share for an aggregate consideration of &#163;101,409.74.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In January 2019, February 2019, and March 2019, we issued an aggregate of 4,267 ordinary shares to Immunocore Nominees Limited at purchase prices ranging from &#163;0.74 to &#163;1.99 per share for an aggregate consideration of &#163;4,020.08.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In April 2019 and June 2019, we issued an aggregate of 3,043 ordinary shares to Immunocore Nominees&#160;Limited at purchase prices ranging from &#163;0.74 to &#163;1.99 per share for an aggregate consideration of &#163;5,373.10. </div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br></div></div></div>
<!--End Page 328-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 329-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_301-part2_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In July 2019 and September 2019, we issued an aggregate of 345 ordinary shares to Immunocore Nominees&#160;Limited at purchase prices ranging from &#163;1.99 to &#163;43.37 per share for an aggregate consideration of &#163;11,155.69.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On November&#160;4, 2019, we issued 919 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for aggregate consideration of &#163;1,828.81.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On December&#160;19, 2019, we issued an aggregate of 37,007 ordinary shares to 30 accredited investors and insiders at a purchase price of &#163;0.0001 per share for aggregate consideration of &#163;3.70.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On January&#160;9, 2020, we issued 360 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for aggregate consideration of &#163;714.60.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On February&#160;17, 2020, we issued 184 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for aggregate consideration of &#163;366.16.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On February&#160;24, 2020, we issued 25 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;43.37 per share for aggregate consideration of &#163;1,084.25.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On March 2, 2020, we issued an aggregate of 33,201 ordinary shares to 30 insiders and accredited investors at a purchase price of &#163;0.0001 per share for an aggregate consideration of &#163;3.32. </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On March 9, 2020, we issued 500 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for an aggregate consideration of &#163;995.00.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On March&#160;19, 2020, we issued 289 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for aggregate consideration of &#163;575.11.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In June 2020, we issued 941 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;43.37 per share for aggregate consideration of &#163;40,811.17.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On September&#160;3, 2020, we issued 230 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;1.99 per share for aggregate consideration of &#163;457.70.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On October&#160;19, 2020, we issued 247 ordinary shares to Immunocore Nominees Limited at a purchase price of &#163;64 per share for aggregate consideration of &#163;15,808.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In August 2019, we issued an aggregate of 621,556 series B preferred shares to 5 insiders and accredited investors at a purchase price of &#163;96.19 per share for an aggregate consideration of &#163;59,787,471.64.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In March 2020, we issued an aggregate of 527,147 series B preferred shares to 10 insiders and accredited investors at purchase prices ranging from &#163;73.91 to &#163;96.19 per share for an aggregate consideration of &#163;49,747,271.89.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In December 2020, we issued an aggregate of 832,719 series C preferred shares to four insiders and accredited investors and third party accredited investors at a purchase price of $91.05 per share for an aggregate consideration of $74,999,614.95. At the same time, we issued 127,893 ordinary shares to insiders by way of capitalization of our undistributable reserves pursuant to their pre-existing anti-dilution rights.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The offers, sales and issuances of the securities described in the preceding paragraph were exempt from registration either (1) under Section 4(a)(2) of the Securities Act in that the transactions were between an issuer and members of its senior executive management and did not involve any public offering within the meaning of Section&#160;4(a)(2), (2) under Rule 701 promulgated under the Securities Act in that the transactions were under compensatory benefit plans and contracts relating to compensation or (3) under Regulation S promulgated under the Securities Act in that offers, sales and issuances were not made to persons in the United States and no directed selling efforts were made in the United States. </div></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br></div></div></div>
<!--End Page 329-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 330-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_301-part2_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Share Option Grants</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since January&#160;1, 2018 through the date of the prospectus that forms a part of this registration statement, we have granted share options to employees, directors, consultants and service providers covering an aggregate of 806,788 ordinary shares with exercise prices ranging from &#163;64.00 to &#163;150.00 per share, as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Date</div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 3.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Share <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options</div></td><td class="gutter" style="width: 3.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 3.23%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 7.25%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per Share</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;13, 2019<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;">582,252</div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;150.00</div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;30, 2020<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;">138,620</div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;4, 2020<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 17.5pt;">450</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;3, 2020<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 10pt;">5,100</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;10, 2020<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 17.5pt;">200</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;30, 2020<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 5pt;">51,519</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November&#160;10, 2020<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 5pt;">22,700</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr><tr><td style="width: 71.79%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November&#160;16, 2020<font style="padding-left: 2.13pt;"></font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.55pt; text-align: left;"><font style="padding-left: 10pt;">5,947</font></div></td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 3.23%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 7.25%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.72pt; text-align: left;">&#163;<font style="padding-left: 5pt;">64.00</font></div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">G Share Grants</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Since January&#160;1, 2018 through the date of the prospectus that forms a part of this registration statement, we has granted G shares to employees, directors and consultants covering an aggregate of 34,260 ordinary shares issuable upon conversion of the G shares, as follows:</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Date</div></td><td class="gutter" style="width: 10.08%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 10.08%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 8.04%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">G <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Granted</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April&#160;30, 2020<font style="padding-left: 3.24pt;"></font></div></td><td class="gutter" style="width: 10.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 10.08%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 4.25pt; padding-bottom: 3pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.05pt; text-align: left;">32,260</div></td></tr><tr><td style="width: 71.8%; text-align: left; vertical-align: bottom; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;10, 2020<font style="padding-left: 1.01pt;"></font></div></td><td class="gutter" style="width: 10.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 10.08%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 8.04%; text-align: left; vertical-align: bottom; white-space: nowrap; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.05pt; text-align: left;"><font style="padding-left: 5pt;">2,000</font></div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br></div></div></div>
<!--End Page 330-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 331-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_301-part2_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 0pt;"><tr><td style="width: 45pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statement Schedules</div></td></tr></table><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Exhibits</div><table cellspacing="0" cellpadding="0" class="fintab" style="margin-top: 10.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 12.82%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exhibit <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number</div></td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 0.64%; font-size: 2pt; padding-top: 6pt; padding-bottom: 4pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 85.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 4pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Description of Exhibit</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.1*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 4pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Underwriting Agreement.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.1*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Articles of Association, as amended and as currently in effect.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.2*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Articles of Association to become effective upon the closing of this offering.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.1*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Deposit Agreement.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.2*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of American Depositary Receipt (included in Exhibit 4.1).</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Cooley (UK) LLP.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-1.htm">10.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Deed of Indemnity between the Registrant and each of its directors.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-2.htm">10.2#</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Deed of Indemnity between the Registrant and each of its executive officers.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.3*#</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Immunocore Holdings plc 2021 Equity Incentive Plan.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.4*#</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Sub Plan to the Immunocore Holdings plc 2021 Equity Incentive Plan.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-5.htm">10.</a><a href="nt10016217x4_ex10-5.htm">5</a><a href="nt10016217x4_ex10-5.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research Collaboration and License Agreement, dated as of June&#160;14, 2013, by and among the Registrant, Genentech, Inc. and F. Hoffman-La Roche Ltd, as amended on September 27, 2016.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-6.htm">10.</a><a href="nt10016217x4_ex10-6.htm">6</a><a href="nt10016217x4_ex10-6.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration and License Agreement, dated as of June&#160;29, 2013, between the Registrant and GlaxoSmithKline Intellectual Property Development Ltd.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-7.htm">10.</a><a href="nt10016217x4_ex10-7.htm">7</a><a href="nt10016217x4_ex10-7.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Development and License Agreement, dated as of July&#160;11, 2014, between the Registrant and Eli&#160;Lilly and Company, as amended on December 21, 2016, September&#160;20, 2017 and December 19, 2018.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-8.htm">10.</a><a href="nt10016217x4_ex10-8.htm">8</a><a href="nt10016217x4_ex10-8.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License Agreement, dated as of September&#160;27, 2016, between the Registrant and Genentech, Inc.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-9.htm">10.</a><a href="nt10016217x4_ex10-9.htm">9</a><a href="nt10016217x4_ex10-9.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">License and Collaboration Agreement, dated as of November&#160;15, 2018, by and among the Registrant, Genentech, Inc. and F. Hoffman-La Roche Ltd.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-10.htm">10.</a><a href="nt10016217x4_ex10-10.htm">10</a><a href="nt10016217x4_ex10-10.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible Loan Note Purchase Agreement, dated as of September&#160;13, 2017, between the Registrant and the Bill and Melinda Gates Foundation.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-11.htm">10.</a><a href="nt10016217x4_ex10-11.htm">1</a><a href="nt10016217x4_ex10-11.htm">1</a><a href="nt10016217x4_ex10-11.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Global Access Commitments Agreement, dated as of March&#160;2, 2020, between the Registrant and the Bill and Melinda Gates Foundation.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.12*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Registration Rights Agreement between the Registrant and the shareholders listed therein.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-13.htm">10.1</a><a href="nt10016217x4_ex10-13.htm">3</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP. </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-14.htm">10.1</a><a href="nt10016217x4_ex10-14.htm">4</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease, dated as of December 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-15.htm">10.1</a><a href="nt10016217x4_ex10-15.htm">5</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease, dated as of March 28, 2017, between the Registrant and MEPC MILTON PARK NO. 1 LIMITED and MEPC MILTON PARK NO. 2 LIMITED, on behalf of MEPC Milton LP. </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-16.htm">10.1</a><a href="nt10016217x4_ex10-16.htm">6</a><a href="nt10016217x4_ex10-16.htm">&#8224;</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assignment and Exclusive License, dated as of January 28, 2015, between the Registrant and Adaptimmune Limited. </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex10-17.htm">10.1</a><a href="nt10016217x4_ex10-17.htm">7</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loan and Security Agreement, dated as of November 6, 2020, among the Registrant, Oxford Finance Luxembourg S.&#224; r.l., and the lenders listed on Schedule 1.1 thereof.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10.18*#</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employment Agreement between the Registrant and Bahija Jallal, Ph.D, dated January&#160;&#8199;&#8199;, 2021. </div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex21-1.htm">21.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subsidiaries of the Registrant.</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex23-1.htm">23.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of KPMG LLP, the Registrant&#8217;s independent registered public accounting firm (Immunocore Holdings Limited).</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="nt10016217x4_ex23-2.htm">23.2</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of KPMG LLP, the Registrant&#8217;s independent registered public accounting firm (Immunocore Limited).</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.3*</div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; padding-bottom: 2.75pt;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; padding-bottom: 2.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Cooley (UK) LLP (included in Exhibit 5.1).</div></td></tr><tr><td style="width: 12.82%; text-align: left; vertical-align: top; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSIG">24.1</a></div></td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td class="gutter" style="width: 0.64%; border-bottom: none; font-size: 2pt; padding-top: 2.75pt; background-color: #CCEEFF;">&#8203;</td><td style="width: 85.9%; text-align: left; vertical-align: bottom; padding-top: 2.75pt; background-color: #CCEEFF;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on signature page to this registration statement).</div></td></tr></table><div><div class="rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Certain portions of this exhibit (indicated by asterisks) have been redacted in accordance with Regulation S-K, Item 601(b)(10). </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed by amendment.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">#<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Indicates a management contract or any compensatory plan, contract or arrangement.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br></div></div></div>
<!--End Page 331-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 332-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_301-part2_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Financial Statement Schedules</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">None. All schedules have been omitted because the information required to be set forth therein is not applicable or has been included in the consolidated financial statements and notes thereto.</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 12pt; margin-left: 0pt;"><tr><td style="width: 40pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings.</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities&#160;Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The undersigned Registrant hereby undertakes that:</div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities&#160;Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br></div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div></td></tr></table></div></div><div class="block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br></div></div></div>
<!--End Page 332-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 333-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_302-sig_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tSIG"><!--Anchor--></a>SIGNATURES</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city Oxford, United Kingdom, on January&#160;15, 2021.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 2pt;">&#8203;</td><td colspan="7" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">IMMUNOCORE HOLDINGS LIMITED</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 2pt; padding-bottom: 3.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td colspan="4" style="width: 46.15%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 2pt; padding-bottom: 3.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Bahija Jallal, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3.25pt; padding-bottom: 2pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 3.25pt; padding-bottom: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bahija Jallal, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 2.56%; text-align: left; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 2pt;">&#8203;</td><td style="width: 38.46%; text-align: left; vertical-align: bottom; padding-top: 2pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div></td></tr></table><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Bahija Jallal, Ph.D. and Brian Di Donato, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for and in his or her name, place and stead, in any and all capacities, to (1) act on, sign and file with the Securities and Exchange Commission any and all amendments (including post-effective amendments) to this Registration Statement together with all schedules and exhibits thereto and any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, together with all schedules and exhibits thereto, (2) act on, sign and file such certificates, instruments, agreements and other documents as may be necessary or appropriate in connection therewith, (3) act on and file any supplement to any prospectus included in this Registration Statement or any such amendment or any subsequent registration statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and (4) take any and all actions which may be necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue thereof. </div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 5.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="header"><td style="width: 29.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Signature</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 35.9%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Title</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 29.49%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div></td></tr><tr><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Bahija Jallal, Ph.D.</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer and Director <br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(<font style="font-style: italic;">Principal Executive Officer</font>)</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Bahija Jallal, Ph.D.</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Brian Di Donato</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer<br></div><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(<font style="font-style: italic;">Principal Financial Officer and </font><font style="font-style: italic;">Principal Accounting Officer)</font> </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Brian Di Donato </div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Professor Sir John Bell</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman of the Board of Directors</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Professor Sir John Bell</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Travis Coy</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Travis Coy</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Robert Perez</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Robert Perez</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Kristine Peterson</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Kristine Peterson</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 1.75pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 1.75pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; border-bottom: 1pt solid #000000; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Professor Sir Peter Ratcliffe</div></td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td rowspan="2" style="width: 35.9%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div></td><td class="gutter" rowspan="2" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 1.75pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 1.75pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 29.49%; text-align: center; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Professor Sir Peter Ratcliffe</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt;">&#8203;</td><td style="width: 29.49%; text-align: left; vertical-align: top; padding-top: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January 15, 2021</div></td></tr></table></div></div></div>
<!--End Page 333-->
<div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div id="DSPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 334-->
<div class="page" style="text-align: left; margin: auto; position: relative; width: 468pt;"><a name="nt10016217x4_f1_302-sig_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="page-content"><div class="block-main" style="width: 468pt; margin-left: 0pt;"><div class="h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF THE REGISTRANT</div><div class="para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Immunocore Holdings Limited has signed this registration statement or amendment thereto on January 15, 2021.</div><table cellspacing="0" cellpadding="0" class="txttab" style="margin-top: 11.25pt; border-collapse: collapse; width: 468pt; margin-left: auto; margin-right: auto;"><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 6pt; padding-bottom: 3pt;">&#8203;</td><td colspan="4" style="width: 51.28%; text-align: left; vertical-align: bottom; padding-top: 6pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Immunocore, LLC</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 3pt;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 3pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 3pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 3pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Bahija Jallal, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 4.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 4.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bahija Jallal, Ph.D.</div></td></tr><tr><td style="width: 46.15%; text-align: left; vertical-align: top; padding-top: 4.25pt; padding-bottom: 1.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 1.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 1.25pt;">&#8203;</td><td style="width: 5.13%; text-align: left; vertical-align: bottom; padding-top: 4.25pt; padding-bottom: 1.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div></td><td class="gutter" style="width: 1.28%; border-bottom: none; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 1.25pt;">&#8203;</td><td class="gutter" style="width: 1.28%; font-size: 2pt; padding-top: 4.25pt; padding-bottom: 1.25pt; border-bottom: 1px solid #ffffff;">&#8203;</td><td style="width: 43.59%; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; padding-top: 4.25pt; padding-bottom: 1.25pt;"><div class="fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Authorized Signatory</div></td></tr></table></div></div></div>
<!--End Page 334-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>nt10016217x4_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div style="text-align: right; font-weight: bold;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">EXHIBIT 10.1</div>
  <div><br>
  </div>
  <div style="text-align: center; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
  <div><br>
  </div>
  <div>[<font style="font-style: italic;">Name of Director</font>]</div>
  <div>[<font style="font-style: italic;">Address</font>]</div>
  <div><br>
  </div>
  <div style="text-align: right;">&#160;[<font style="font-style: italic;">Date</font>]</div>
  <div><br>
  </div>
  <div>Dear [<font style="font-style: italic;">Name of Director</font>],</div>
  <div><br>
  </div>
  <div style="font-weight: bold;">Immunocore Holdings plc (the &#8220;Company&#8221;) and your role as a director of the Company</div>
  <div><br>
  </div>
  <div style="text-align: justify;">As you are aware, the articles of association of the Company (the &#8220;<font style="font-weight: bold;">Articles</font>&#8221;), at Article 150, contemplate that the Company will indemnify the Company&#8217;s directors in relation to specific liabilities incurred by them in the performance of their duties. We are taking this opportunity to afford you the
    direct benefit of this indemnity in the form of a deed for your benefit (this &#8220;<font style="font-weight: bold;">Deed</font>&#8221;). The arrangements contemplated by this Deed are within the
    scope of permitted directors&#8217; indemnities under the Companies Act 2006 (the &#8220;<font style="font-weight: bold;">Act</font>&#8221;).</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4421cae059fa4143a2a05d51b745d4d9" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Interpretation</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9f3afd9755154c108adb2df53f0cf9ee" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>In this Deed:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94b9f94f3c4744e6b747bcb37c63c259" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any defined terms (to the extent undefined herein) shall have the meanings given to them in the Articles;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb0d027a9481a421a9744ff3efee015f2" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z110283f82e3b4264ac22606153ecf662" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>unless the context otherwise requires, reference to paragraphs are to paragraphs of this Deed;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z13b20f292a264c16a1988c67be96f05c" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any words following the terms including, include, in particular, for example or any similar expression shall be construed as illustrative and shall not limit the sense of
            the words, description, definition, phrase or term preceding those terms; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdf953619d6cf4b02b9fd137fdef49ce8" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>other and otherwise are illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding them.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a23c7e176e149c597b44aa7f1de7160" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Indemnity</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z62cef64c30464941b17a0fe0cfa44682" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Subject to paragraph 2.2, without prejudice to any indemnity to which you may otherwise be entitled pursuant to Article 150 of the Articles or otherwise and subject to
            the terms of this Deed, you shall be indemnified and held harmless by the Company to the fullest extent permitted by law against all costs, charges, expenses, losses and liabilities (&#8220;<font style="font-weight: bold;">Liabilities</font>&#8221;) arising out of or in connection with any civil, criminal, regulatory or other proceeding connected with any application under section 144(3) or (4) or section 727 of the Act
            whether instigated, imposed or incurred under the laws of England and Wales or the laws of any other jurisdiction (&#8220;<font style="font-weight: bold;">Proceedings</font>&#8221;) which
            relate to any act done or omitted or alleged to be done or omitted by you whilst in the course of acting or purporting to act as a director or officer (or equivalent position under the laws of any relevant jurisdiction) of the Company and/or
            any associated company of the Company (as defined in section 256(b) of the Act for these purposes) (an &#8220;<font style="font-weight: bold;">Associated</font>&#160;<font style="font-weight: bold;">Company</font>&#8221;) or which arises by virtue of you holding or having held such a position (&#8220;<font style="font-weight: bold;">Claim</font>&#8221;).</div>
        </td>
      </tr>

  </table>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0140703913f54214a008a8814e5e1bef" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The indemnity in paragraph 2.1 shall not apply to:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ab2677eec21482c9925b92c7d9e59a5" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>the extent prohibited by the Act or otherwise prohibited by law;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ea1b7cdac2e4f168f93cb222e626356" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any Liability incurred by you:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ba8fa1bbfc14600a0bcf942bbcb987e" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">2.2.2.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in defending any criminal Proceedings in which you are convicted;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb68b2fb95d5a4c1e99f3237ab328fcea" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">2.2.2.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in defending any civil Proceedings brought by the Company or any Associated Company in which judgement is given against you; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc3d006dc21924f08ac259f5102007de1" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">2.2.2.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in connection with any application under section 661(3) or (4) or section 1157 of the Act (a &#8220;<font style="font-weight: bold;">Relevant Application</font>&#8221;) in which the court refuses to grant you relief on the application,</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 72pt;">where, in any such case, any such conviction, judgement or refusal of relief has become final (reference in this paragraph 2.2.2 to a
    conviction, judgement or refusal of relief being &#8220;final&#8221; shall be construed in accordance with section 234(4) and (5) of the Act);</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcaa864cdd91e425a97e7c355093622a6" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any Liability incurred by you to the Company or any Associated Company;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z484136e6bdd24300bb4b383cd4e89dbd" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any fine imposed in any criminal Proceedings;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze9938488fff34b7c9de3195389faeeec" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (howsoever arising);</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zddb8633904af446fb6b3f362ce78ea2f" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.6</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any Liability relating to any taxation or national insurance payable by you in connection with your remuneration or other benefits received from the Company or any
            Associated Company;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z246a4be40abc40c9ac16dd52de56e832" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.7</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>the extent you are entitled to recover from any other person (including under any policy of insurance) any amount in relation to a Claim; or</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8c1e3ab4c1e4fc79b9510d5cb0f82c9" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.8</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any Liability incurred by, or Claim made against, you which the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) reasonably determines arises out of your fraud, wilful deceit, wilful misconduct, reckless conduct, dishonesty or act of bad faith (&#8220;<font style="font-weight: bold;">Misconduct</font>&#8221;), save that if a court, tribunal or regulatory authority thereafter finally determines that the relevant Liability or Claim did not arise as a result of your Misconduct, you may, by
            notice to the Company, request payment of such amount from the Company as the Company would have been liable to pay under this Deed had the Board not made such a determination and the Company shall make a payment to you upon satisfaction of the
            obligation in paragraph 2.5.</div>
        </td>
      </tr>

  </table>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z312fb3bda45d4386bcb614ff036e87fe" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Without prejudice and in addition to any indemnity to which you may otherwise be entitled pursuant to Article 150 of the Articles or otherwise and subject to the terms of
            this Deed, you shall be indemnified and held harmless by the Company to the fullest extent permitted by law against all Liabilities incurred by you and Claims in connection with the Company&#8217;s activities as a trustee of an occupational pension
            scheme (as defined by section 235(6) of the Act) established under a trust provided that no such indemnity shall extend to any Liability arising out of your fraud or dishonesty or the obtaining by you of any personal profit or advantage to
            which you were not entitled and you shall not be entitled to be indemnified for:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z603715f13b8a47648c203dc1be1efc54" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.3.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any fine imposed in any criminal Proceedings;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb4f743e994f241679f231c57004750bc" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.3.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any sum payable to a regulatory authority by way of a penalty in respect of non-compliance with any requirement of a regulatory nature (howsoever arising); and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z089005ebbe704fa09921e2fbc5651ff5" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.3.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any Liability incurred by you in defending any criminal Proceedings in which you are convicted where such conviction has become final (reference in this paragraph 2.3.3
            to a conviction becoming &#8220;final&#8221; shall be construed in accordance with section 235(4) and (5) of the Act).</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfd3c06c958644b2eb62155fef165d221" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>References in paragraphs 2.1 and 2.3 to acts or omissions are to acts or omissions made or omitted to be made before, on or after the date of this Deed, however:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf9cbbc4e88884c659052d23d75814e6e" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.4.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>if a company ceases to be an Associated Company after the date of this Deed, the Company shall only be liable to indemnify you in respect of Liabilities arising from acts
            done or omitted or alleged to be done or omitted in relation to that company before the date on which the company ceased to be an Associated Company; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18c21ef45d494165b401d4d106f6772e" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.4.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>you, as director or officer (or equivalent position under the laws of any relevant jurisdiction) of any company which becomes an Associated Company after the date of this
            Deed, shall be indemnified only in respect of Liabilities arising from acts done or omitted or alleged to be done or omitted after the date on which that company becomes an Associated Company.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4055b6ca0d14dcf8f1719a6e1b240f8" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The Company&#8217;s obligation to make any payment to you under paragraphs 2.1 and/or 2.3 is conditional upon you having made an application in writing to the Company supported
            by such documentation and evidence which, in the reasonable opinion of the Board, is satisfactory to prove that:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6e6796d11de443ca95bb75539c0a64f3" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.5.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>the Liability suffered or incurred by you and of the date(s) on which it was suffered or incurred and that it falls within the scope of the indemnities given in
            paragraphs 2.1 and/or 2.3; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94737727997147b5b62ddf2155e3b810" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.5.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>any costs and expenses of any third party (including legal costs) which are to be reimbursed by the Company in accordance with paragraphs 2.1 and/or 2.3 were properly
            incurred and reasonable in amount,</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">and where the Company is satisfied that these conditions have been fulfilled, the Company shall make payment to you within 20 Business
    Days (being a day that is not a Saturday or Sunday or a public holiday in England) of receipt of such application.</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcef614f05cf84b8490b571e23aa4fe2b" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Defence Costs</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf5d8a2d1a16a452c858ecd7713b4a7e8" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Subject to the Act and the provisions of this Deed, the Company will advance to you (subject to repayment in accordance with paragraph 3.3) such amounts as are required
            to meet the legal and other reasonable costs, charges and expenses incurred or to be incurred by you:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb12852681164cc1a97eb9321b662504" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">3.1.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in defending any criminal or civil Proceedings in connection with any alleged negligence, default, breach of duty or breach of trust by you in relation to the Company or
            an Associated Company; or</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11d74bb930ad4158a22eb2a2debb3a73" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">3.1.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in connection with any Relevant Application.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72f7658cde68417e9e7b03cf31b3295d" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The Company shall advance any such amount as provided for in paragraph 3.1 (&#8220;<font style="font-weight: bold;">Advance Amounts</font>&#8221;) to you within fourteen days of receiving a notice in writing from you of the amount required, together with such evidence of the costs as the Company may reasonably require.&#160; No interest shall accrue on the
            Advance Amounts.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z41dd29d78951442391619d71acc3e389" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>All Advance Amounts outstanding to you in respect of particular Proceedings shall be repaid by you if:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z056c05af438f4d14b23ca2173cf03066" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in respect of criminal Proceedings, you are convicted;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za75788cf66ce47c0977ed636291f0d5d" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in respect of civil Proceedings, judgement is given against you; or</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7798c886628845dbb5660bf4644c593b" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>in respect of any Relevant Application, the court refuses to grant you relief on the application,</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 0.55pt; margin-left: 35.45pt;">and such outstanding Advance Amounts shall be repaid no later than the date when the conviction, judgement or
    refusal of relief becomes final (reference in this paragraph 3.3 to a conviction, judgement or refusal of relief being &#8220;final&#8221; shall be construed in accordance with section 205(3) and (4) of the Act).</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4b8770d3cd014a52a90a717f85ceead5" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The Company shall not be required to advance any amount under paragraph 3.1, and any amounts advanced shall become immediately repayable upon demand from the Company, to
            the extent that the Board reasonably determines that the relevant Proceedings arose out of your Misconduct.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z26014d96d5f8410797f0f0655d7b2770" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>In the event that the relevant Proceedings are either (i) abandoned, withdrawn or discontinued, (ii) settled, (iii) a permanent stay is granted, or (iv) a final
            determination of the court is made (or Proceedings otherwise finally conclude) without any of the events referred to in paragraph 3.3 (as applicable) occurring (each such conclusion of Proceedings being referred to hereafter as a &#8220;<font style="font-weight: bold;">Favourable Conclusion</font>&#8221;) then the indemnity provided under paragraph 2.1 shall thereafter apply with respect to all legal and other reasonable
            costs, charges and expenses of those Proceedings as were incurred by you.&#160; Any liability of the Company to so indemnify you shall be set-off against any liability of you to repay to the Company any Advance Amounts outstanding in respect of
            those Proceedings and shall be subject to the exclusions and limitations contained in paragraph 2.2, and paragraph 5 shall be applied (with such changes as are appropriate).</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf8410382c53b45489fecf68bb8aaec26" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.6</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>In the event that a Favourable Conclusion is reached in relation to particular Proceedings but any Advance Amount advanced to you in relation to those Proceedings remains
            outstanding in circumstances where the Company is (for any reason) not liable or is no longer liable to indemnify you in relation to those Proceedings, then all such Advance Amounts which remain outstanding shall be repayable upon demand from
            the Company.</div>
        </td>
      </tr>

  </table>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71ca3cedc5114e189afd03e7fd82c9a6" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">4.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Directors&#8217; and Officers&#8217; Liability Insurance</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 35.45pt;">The Company shall use all reasonable endeavours to provide and maintain appropriate directors&#8217; and officers&#8217; liability insurance
    (including ensuring that premiums are properly paid) for your benefit for so long as any Claims may lawfully be brought against you.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za34ff8ff0f9c471fabd1c292948e55d3" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Notification and Conduct</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z124354dcaa1d4b37bf563a29f1568d87" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>If you receive any demand relating to a Claim or become aware of any circumstances which might or may be reasonably expected to give rise to the Company being required to
            indemnify you pursuant to this Deed and before incurring any costs, charges or expenses in respect of any Claim (including securing legal representation), you shall:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3b936e09db56487db04e2c0a8c964a89" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>as soon as reasonably practicable, give written notice of the circumstances to the Company, as well as any other information which the Company may reasonably request from
            time to time;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23bcc46afbd84dc4882055a8423d3aa0" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>take all reasonable actions to mitigate any Liability you suffer in respect of the circumstances giving rise to the Claim (including any action that the Company may
            reasonably request to avoid, dispute, resist, appeal or defend any Claim and shall not make any admission of liability, agreement or compromise with any person in relation to any Claim without the prior written consent of the Company);</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb311db1e229c45c998ef0a942c5fdbca" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>forward all documents you receive in respect of such Claim to the Company as soon as reasonably practical following receipt;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4fdd74deec974e4ca543963c944db823" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>assist the Company as it may reasonably require in resisting, defending or settling the Claim; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd690b1fa2c5b416fb84b860b781d30da" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>provide to the Company all such information in relation to any Claim or Liabilities as the Company may reasonably request, and take all such action as the Company may
            reasonably request.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7e752329dc1740b8a7faaa60cffd86b3" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Notwithstanding the provisions of paragraph 5.1, you shall not be required to provide any document or information to the Company where doing so would result in a loss of
            privilege in that document or information.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf567971d635941de8651aaaf04f3a36c" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The Company or an Associated Company (as the case may be) will be entitled to take over, negotiate and conduct in your name the defence to or settlement of any Claim or
            to prosecute in your name for its own behalf any proceedings relating to a Claim.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z497fca0209134d8c8561507ecb68fb71" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>If the Company or an Associated Company exercises its right pursuant to paragraph 5.3, the Company or relevant Associated Company shall:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f52716ec8e74e72ae6ebddf6f3978ad" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>consult with you in relation to the conduct of the Claim or Proceedings on aspects of the Claim or Proceedings materially relevant to you and keep you reasonably informed
            of material developments in the Claim or Proceedings, provided that the Company or Associated Company shall be under no obligation to provide any information the provision of which is reasonably likely to adversely affect the ability of the
            Company or an Associated Company to claim in respect of the relevant loss under any applicable policy of insurance;</div>
        </td>
      </tr>

  </table>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a94f7f1ff8a4aa2ba648489cd484a4a" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>take into account your reasonable requests relating to the Claim or Proceedings (including any settlement) on issues which may be reasonably likely to result in material
            damage to your reputation; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81924a546d2346c8bb5dd7b251d49d75" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>have full discretion in the conduct or settlement of the Claim or Proceedings relating to such Claim provided you are not required to make any contribution to the
            settlement and the settlement contains no admission of liability by you.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf50bd834a765433a9ec9b181f157c063" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>The Company&#8217;s obligations owed to you under this Deed (including the obligation to indemnify you in paragraphs 2.1 and 2.3) are conditional upon your compliance with the
            provisions of this paragraph 5.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83b54653f79c4790915e43ec5305fdc8" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>[<font style="font-weight: bold;">Fund Director Indemnity</font></div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 35.45pt;">The Company hereby acknowledges that you may have certain rights to indemnification, advancement of expenses and/or insurance provided
    by [<font style="font-style: italic;">Name of Fund</font>] and certain of its affiliates from time to time (collectively, the &#8220;<font style="font-weight: bold;">Fund Indemnitors</font>&#8221;). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to you are primary and any obligation of the Fund Indemnitors to advance expenses or to
    provide indemnification for the same expenses or liabilities incurred by you are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by you and shall be liable for the full amount of all expenses, judgments,
    penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Deed and the Articles (or any other agreement between you and the Company), without regard to any rights you may have against the Fund
    Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.&#160; The Company
    further agrees that no advancement or payment by the Fund Indemnitors on your behalf with respect to any claim for which you have sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of
    contribution and/or be subrogated to the extent of such advancement or payment to all of your rights of recovery against the Company. You and the Company agree that the Fund Indemnitors are express third party beneficiaries of the terms of this
    paragraph 6.]</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4275dcc94b4f45f3a37ad242a5bc05f8" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-weight: bold;">Miscellaneous</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2c3e27679726485ba13e02c56d8c7546" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div><font style="font-style: italic;">Effect of </font><font style="font-style: italic;">Ceasing to be a Director or Officer of the Company or any Associated Company</font></div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">In the event that you cease to be a director or officer (or equivalent position under the laws of any relevant jurisdiction) of the
    Company or any Associated Company, this Deed shall remain in force and you will continue to be indemnified in accordance with the terms and conditions of this Deed, until such time as any relevant limitation periods for bringing Claims against you have
    expired, or for so long as you remain liable for any Liabilities, notwithstanding that you may have ceased to be a director or officer (or equivalent position under the laws of any relevant jurisdiction) of the Company or any Associated Company.</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb039734a96c845d9978378ae13a96abd" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Payments</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">The Company shall, in the event that a payment is made to you under this Deed in respect of a particular Liability, be entitled to recover
    from you an amount equal to any payment received by you under any policy of insurance or from any other third party source to the extent that such payment relates to the Liability, or if the payment received by you is greater than the payment made
    under this Deed, a sum equal to the payment made under this Deed. You shall pay over such sum promptly on the Company&#8217;s request.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcd3cbba2dc3d465396fb3dc0bb10fe8d" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Taxation</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; text-indent: 0.7pt; margin-left: 35.3pt;">The Company shall pay such amount to you as shall after the payment of any tax thereon leave you with sufficient
    funds to meet any Liability to which this Deed applies.&#160; For the avoidance of doubt, when calculating the amount of any such tax the amount of any tax deductions, credits or reliefs which are or may be available to you in respect of the relevant
    payment under this Deed received by you or any payment made by you to a third party in respect of the relevant Liability will be taken into account.&#160; In the event that any amount is paid to you under this Deed but a tax deduction, credit or relief is
    or becomes available to you in respect of the relevant payment or any payment made by you to a third party in respect of the relevant Liability which was not taken into account in calculating the amount payable in respect of the relevant payment under
    this Deed, you shall make a payment to the Company of such an amount as is equal to the benefit of such deduction, credit or relief which was not taken into account.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z59975eebe6b446a5b026249e2ae271b9" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">No Double Recovery</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">You shall not be entitled to recover any Liability more than once and in the event that the Company makes payment under this Deed, the
    Company shall be subrogated to the extent of such payment to all of your rights of recovery against third parties (including any claim under any applicable directors&#8217; and officer&#8217;s insurance policy) in respect of the payment and you shall do everything
    that may be necessary to secure any such rights including:</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02e0bed692f44172aec8f1a98ed83d7b" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.4.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>the execution of any documents necessary to enable the Company effectively to bring an action in your name; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17c4b3cd916b4973a2c04b902ef91786" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.4.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>the provision of assistance as a witness.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zda925578ccb5493b83338d974b2290ce" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.5</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Assignment</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">The Company may at any time assign, mortgage, charge, subcontract, delegate, declare a trust over or deal in any other manner with any or
    all of its rights under this Deed, provided that it gives notice of such dealing to you. You shall not assign, transfer, mortgage, charge, subcontract, declare a trust over or deal in any other manner with any of your rights and obligations under this
    Deed.</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcbdb6ce7ccc741069cf9a6888aefe3a9" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.6</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Entire Agreement</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">This Deed constitutes the entire agreement between the parties and supersedes and extinguishes all previous agreements, promises,
    assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69b317bd77d54f98aad7d14d5387d415" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.7</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Severance</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">If any provision or part-provision of this Deed is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the
    minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this
    paragraph 6.7 shall not affect the validity and enforceability of the rest of this Deed. If one party gives notice to the other of the possibility that any provision or part-provision of this Deed is invalid, illegal or unenforceable, the parties shall
    negotiate in good faith to amend such provision so that, as amended, it is legal, valid and enforceable, and, to the greatest extent possible, achieves the intended commercial result of the original provision.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze0a262a1908a49b4a9aae755859b95ea" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.8</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Notices and Demands</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z40f1ac6997db435ebbe3d507c97e596a" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.8.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Any notice or demand given to a party under or in connection with this Deed:</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25d9104ab3ee411dafd3f802200bba9f" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">7.8.1.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>shall be in writing and in English;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3997bb7e8be64c4dbf146a3e2f58d135" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">7.8.1.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>shall be signed by or on behalf of the party giving it;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7574599ee76402694d4de59aedbb92d" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">7.8.1.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>shall be sent by a method listed in paragraph 7.8.2; and</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf698206d6ad8490da075f619a7284226" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 72.55pt;"><br>
        </td>
        <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">7.8.1.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>is deemed received as set out in paragraph 7.8.2 if prepared and sent in accordance with this paragraph.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd5ff4d9048a4d1680a4c61e889278ad" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.8.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>This paragraph 7.8.2 sets out the delivery methods for sending a notice to a party under this Deed and, for each delivery method, the date and time when the notice is
            deemed to have been received (provided that all other requirements of this paragraph have been satisfied and subject to the provisions in paragraph 7.8.3):</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9aa9c501e95a44ccac7249250300a4ee" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 70.9pt;"><br>
        </td>
        <td style="width: 35.45pt; vertical-align: top; align: right;">(a)</td>
        <td style="width: auto; vertical-align: top;">
          <div>if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the address;</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3d8a9a1cc00f4b0ba730aa5df2948c9f" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 70.9pt;"><br>
        </td>
        <td style="width: 35.45pt; vertical-align: top; align: right;">(b)</td>
        <td style="width: auto; vertical-align: top;">
          <div>if sent by pre-paid first class post or other next working day delivery service, at the time recorded by the delivery service; or</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd930871eb051453db748b2136bfee14b" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 70.9pt;"><br>
        </td>
        <td style="width: 35.45pt; vertical-align: top; align: right;">(c)</td>
        <td style="width: auto; vertical-align: top;">
          <div>if sent by pre-paid airmail, at the time recorded by the delivery service.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc510fd48d1af4541a05d20c8a607c6a1" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.8.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>If deemed receipt under paragraph 7.8.2 would occur outside business hours in the place of receipt, it shall be deferred until business hours resume. In this paragraph,
            business hours means 9.00 a.m. to 5.00 p.m. Monday to Friday on a day that is not a public holiday in the place of receipt.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z100f93d6d176481391b7ae2e66b2514c" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.8.4</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>This paragraph 7.8 does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of
            dispute resolution.</div>
        </td>
      </tr>

  </table>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za95e3e0089574442b06b38343e28b83f" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.9</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Variation</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d6b30d141194dde9f2da2154cf5db56" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.9.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>No variation of this Deed shall be effective unless it is in writing and signed by the parties (or their authorised representatives).</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2c0a4996cd2d4c73aed71757e0f5d507" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">7.9.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>No failure or delay by a party to exercise any right or remedy provided under this Deed or by law shall constitute a waiver of that or any other right or remedy, nor
            shall it prevent or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall prevent or restrict the further exercise of that or any other right or remedy.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0519c8067fd428fba27283a63d5d502" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.10</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Counterparts</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d0db2f97e4f41889adb666a3d8e1ccc" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">7.10.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>This Deed may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall
            together constitute the one deed.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51b7f2789a494048a3fb1458dd097d57" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">7.10.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>Transmission of an executed counterpart of this Deed (but for the avoidance of doubt not just a signature page) by email (in PDF, JPEG or other agreed format), shall take
            effect as delivery of an executed counterpart of this Deed.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39fa9639a514446884be406e98d46b7e" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">7.10.3</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>No counterpart shall be effective until each party has executed and delivered at least one counterpart.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfbad1fe6d3cf4d46b87a3e69d007dcb3" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.11</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Third Party Rights</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: justify; margin-left: 36pt;">Unless this Deed expressly states otherwise, this Deed does not confer any rights on any person or party (other than the parties to this
    Deed and any Associated Company) pursuant to the Contracts (Rights of Third Parties) Act 1999.</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za929e868383b414d832824cfbdf816e2" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.12</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div style="font-style: italic;">Governing Law and Jurisdiction</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z713da3906f5a435b8e8e8a9b2d70a3aa" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">7.12.1</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>This Deed and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual disputes or claims) shall be governed
            by and construed in accordance with the law of England and Wales.</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08d3e9bf029c4e529e3261afd6bb54c2" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 36pt;"><br>
        </td>
        <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">7.12.2</td>
        <td style="width: auto; vertical-align: top; text-align: justify;">
          <div>You and the Company irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in
            connection with this Deed or its subject matter or formation (including non-contractual disputes or claims).</div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <div style="text-align: center; margin-left: 36pt;">[<font style="font-style: italic;">Deliberately left blank, signature page
      to follow.</font>]</div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div><font style="font-weight: bold;">IN WITNESS WHEREOF, </font>this Deed has been executed as a
    deed by the Company and you on the day and year first above written.</div>
  <div><br>
  </div>
  <div>
    <table id="z4a741735441d49b1bc0269713639b7df" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td rowspan="2" style="width: 50.00%;">
            <div style="text-align: left;"><font style="font-weight: bold;">EXECUTED </font>as a<font style="font-weight: bold;"> DEED </font>by <font style="font-weight: bold;">IMMUNOCORE HOLDINGS PLC </font>acting by [<font style="font-style: italic;">Name of</font>&#160;<font style="font-style: italic;">Director</font>], a
              director and [<font style="font-style: italic;">Name of Director</font>], a director</div>
          </td>
          <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">Director<br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%;">&#160;</td>
          <td rowspan="1" style="width: 50%;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">Director <br>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div style="text-align: left;"><font style="font-weight: bold;">EXECUTED </font>as a<font style="font-weight: bold;">&#160;</font><font style="font-weight: bold;">DEED </font>and delivered by</div>
          </td>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; padding-bottom: 2px;">
            <div style="text-align: left; font-weight: bold;">[<font style="font-style: italic;">Name of Director</font>]</div>
          </td>
          <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div style="text-align: left;">In the presence of:</div>
          </td>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
          <td style="width: 50.00%;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; padding-bottom: 2px;">
            <div style="text-align: left;">Witness signature:</div>
          </td>
          <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
            <div style="text-align: left;">Name:</div>
          </td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
            <div style="text-align: left;">Address:</div>
          </td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
          <td rowspan="1" style="width: 50.00%;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
            <div style="text-align: left;">Occupation:</div>
          </td>
          <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
  </div>
  <div><br>
  </div>
  <div>
    <div><font style="font-weight: bold;">Adopted by the Board of Directors:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">[<font style="font-style: italic;">Date</font>]</font></div>
    <div><font style="font-weight: bold;">Effective:</font>&#160;&#160;&#160;&#160;&#160;&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> </font>&#160;&#160;&#160; <font style="font-weight: bold;">[<font style="font-style: italic;">Date</font>]</font></div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>nt10016217x4_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">EXHIBIT 10.2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">IMMUNOCORE HOLDINGS PLC</div>
    <div><br>
    </div>
    <div>[<font style="font-style: italic;">Name of Officer</font>]</div>
    <div>[<font style="font-style: italic;">Address</font>]</div>
    <div><br>
    </div>
    <div style="text-align: right;">&#160;[<font style="font-style: italic;">Date</font>]</div>
    <div><br>
    </div>
    <div>Dear [<font style="font-style: italic;">Name of Officer</font>],</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Immunocore Holdings plc (the &#8220;Company&#8221;) and your role as an officer of the Company</div>
    <div><br>
    </div>
    <div style="text-align: justify;">You are [<font style="font-style: italic;">describe nature of the office</font>] at the
      Company.&#160; The Company has agreed to indemnify you on the terms and conditions set out in this deed of indemnity (this &#8220;<font style="font-weight: bold;">Deed</font>&#8221;).</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z104930db2bf04145802fc170063d7a0f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Interpretation</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8443f6ee97844209a2f20718311d89eb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In this Deed:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6144c4d481464a398190675bc7f50e73" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any defined terms (to the extent undefined herein) shall have the meanings given to them in the articles of association (&#8220;the <font style="font-weight: bold;">Articles</font>&#8221;) of the Company;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf4334ca9769d4f498f6b46f11c67e23f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze8563ad9f682438a805854aa30389fe8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>unless the context otherwise requires, reference to paragraphs are to paragraphs of this Deed;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb91c5817e24f4c4c97a5dac1007e2616" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any words following the terms including, include, in particular, for example or any similar expression shall be construed as illustrative and shall not limit the sense
              of the words, description, definition, phrase or term preceding those terms; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a62db7b03fa4e0f9ba2b42c8c6abc5f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">1.1.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>other and otherwise are illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding them.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5bc4c65b26014ba682e5005248a4fc7f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Indemnity</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2eba615d12924f66942facd2a4094a8e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Subject to paragraph 2.2, without prejudice to any indemnity to which you may otherwise be entitled pursuant to Article 150 of the Articles or otherwise and subject to
              the terms of this Deed, you shall be indemnified and held harmless by the Company to the fullest extent permitted by law against all costs, charges, expenses, losses and liabilities (&#8220;<font style="font-weight: bold;">Liabilities</font>&#8221;) arising out of or in connection with any civil, criminal, regulatory or other proceeding connected with any application under section 144(3) or (4) or section 727 of the Act
              whether instigated, imposed or incurred under the laws of England and Wales or the laws of any other jurisdiction (&#8220;<font style="font-weight: bold;">Proceedings</font>&#8221;) which
              relate to any act done or omitted or alleged to be done or omitted by you whilst in the course of acting or purporting to act as a director or officer (or equivalent position under the laws of any relevant jurisdiction) of the Company and/or
              any associated company of the Company (as defined in section 256(b) of the Act for these purposes) (an &#8220;<font style="font-weight: bold;">Associated</font>&#160;<font style="font-weight: bold;">Company</font>&#8221;) or which arises by virtue of you holding or having held such a position (&#8220;<font style="font-weight: bold;">Claim</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaee57b500c7149858e607fe891442670" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The indemnity in paragraph 2.1 shall not apply to:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9bd29aa76a20442db556cf0c0ddcc6d5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any Liability relating to any taxation or national insurance payable by you in connection with your remuneration or other benefits received from the Company or any
              Associated Company;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93e28e1002364c8a9f85e11f79eab8f9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the extent you are entitled to recover from any other person (including under any policy of insurance) any amount in relation to a Claim;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ed660ddece849228a4eb35427932248" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any Liability incurred by, or Claim made against, you which the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) reasonably determines arises out of your fraud, wilful deceit, wilful misconduct, reckless conduct, dishonesty or act of bad faith (&#8220;<font style="font-weight: bold;">Misconduct</font>&#8221;), save that if a court, tribunal or regulatory authority thereafter finally determines that the relevant Liability or Claim did not arise as a result of your Misconduct, you may,
              by notice to the Company, request payment of such amount from the Company as the Company would have been liable to pay under this Deed had the Board not made such a determination and the Company shall make a payment to you upon satisfaction
              of the obligation in paragraph 2.4; or</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc47e65517cfa4d368f94064487364484" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.7pt; vertical-align: top; align: right; font-weight: bold;">2.2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any Claim initiated by you, including any Claim initiated by you against the Company or an Associated Company or any of their respective directors, officers, employees
              or other indemnified persons, unless the Board has authorised the Claim prior to its initiation.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8ed23086e6bd43f2b38810d2a07cc5b5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>References in paragraph 2.1 to acts or omissions are to acts or omissions made or omitted to be made before, on or after the date of this Deed, however:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z875c0e43892a48079e436cc19a64d597" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>if a company ceases to be an Associated Company after the date of this Deed, the Company shall only be liable to indemnify you in respect of Liabilities arising from
              acts done or omitted or alleged to be done or omitted in relation to that company before the date on which the company ceased to be an Associated Company; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7bbe394b8864aa893287d1ebabfc45d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>you, as an officer (or equivalent position under the laws of any relevant jurisdiction) of any company which becomes an Associated Company after the date of this Deed,
              shall be indemnified only in respect of Liabilities arising from acts done or omitted or alleged to be done or omitted after the date on which that company becomes an Associated Company.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc2b1af52b34411784997bb983c382b6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s obligation to make any payment to you under paragraph 2.1 depends on you having made an application in writing to the Company supported by such
              documentation and evidence which, in the reasonable opinion of the Board, is satisfactory to prove that:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc695aef381a34251b17be95dc637c9bc" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Liability suffered or incurred by you and of the date(s) on which it was suffered or incurred and that it falls within the scope of the indemnity given in paragraph
              2.1; and</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z14a631671c814608b25175ebc837594f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">2.4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any costs and expenses of any third party (including legal costs) which are to be reimbursed by the Company in accordance with paragraph 2.1 were properly incurred and
              reasonable in amount,</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">and to the extent that the Company is satisfied that these conditions have been fulfilled, the Company shall make payment to you within
      20 Business Days (being a day that is not a Saturday or Sunday or a public holiday in England) of receipt of such application.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9b188d2ea8d44419c58384b88981df4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Defence Costs</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7510345f64d44a9d99382f7ca670b2ff" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Without prejudice to the generality of the indemnity set out in paragraph 2.1 of this Deed, and subject to the remainder of this paragraph 3, the Company agrees to fund
              such amounts as are required to meet such legal and other reasonable costs and expenses incurred by you in connection with any Claims.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze48dcaed03a54db6ad032cb4eb30b81a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any request for funding under this paragraph shall be made by you to the Company and made subject to such conditions as the Board thinks fit.&#160; The Company shall provide
              the relevant funding within fourteen days of receipt of any such written request.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za99bd5154de948a2afb7f312c3fdda92" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company shall not be required to pay any amounts due under paragraph 3.1, and any amounts paid shall become immediately repayable upon demand from the Company, to
              the extent that the Board reasonably determines that the relevant Proceedings arose out of your Misconduct.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9763091f8b5d41579a639c5798249419" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company shall not be required to fund any legal or other costs and expenses incurred by you in respect of any Claims initiated by you, including any Claim initiated
              by you against the Company or an Associated Company or any of their respective directors, officers, employees or other indemnified persons, unless the Board has authorised the Claim prior to its initiation.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za2ea4401bcb44b0f8742920f814b65ae" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Directors&#8217; and Officers&#8217; Liability Insurance</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 35.45pt;">The Company shall use all reasonable endeavours to provide and maintain appropriate directors&#8217; and officers&#8217; liability insurance
      (including ensuring that premiums are properly paid) for your benefit for so long as any Claims may lawfully be brought against you.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za69b53775f2a4864ae0b97504958b0ba" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Notification and Conduct</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd64b1706f564fda96bccc34350dad12" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If you receive any demand relating to a Claim or become aware of any circumstances which might or may be reasonably expected to give rise to the Company being required
              to indemnify you pursuant to this Deed and before incurring any costs, charges or expenses in respect of any Claim (including securing legal representation), you shall:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z404ae1ff5a7e4d4c9518a1f3b11f4065" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>as soon as reasonably practicable, give written notice of the circumstances to the Company, as well as any other information which the Company may reasonably request
              from time to time;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1deb637ad854ad09ec235f31131f457" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>take all reasonable actions to mitigate any Liability you suffer in respect of the circumstances giving rise to the Claim (including any action that the Company may
              reasonably request to avoid, dispute, resist, appeal or defend any Claim and shall not make any admission of liability, agreement or compromise with any person in relation to any Claim without the prior written consent of the Company);</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z079b8c74aeb14798b2612522cfe46383" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>forward all documents you receive in respect of such Claim to the Company as soon as reasonably practical following receipt;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf58ba0b5837b4bcd97176751e8fbd1cb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>assist the Company as it may reasonably require in resisting, defending or settling the Claim; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6559c2a0a0674eea8c069b109c39fdf1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.1.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>provide to the Company all such information in relation to any Claim or Liabilities as the Company may reasonably request, and take all such action as the Company may
              reasonably request.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48dad809e30b4c84b1aac35d8c539bf8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Notwithstanding the provisions of paragraph 5.1, you shall not be required to provide any document or information to the Company where doing so would result in a loss
              of privilege in that document or information.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c655adfc70e4aca8bc39844e496e157" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company or an Associated Company (as the case may be) will be entitled to take over, negotiate and conduct in your name the defence to or settlement of any Claim or
              to prosecute in your name for its own behalf any proceedings relating to a Claim.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48347efdadd349e08b44d7e90800eb5c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If the Company or an Associated Company exercises its right pursuant to paragraph 5.3, the Company or relevant Associated Company shall:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4002af401a8043dbad271d95364ef7ce" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>consult with you in relation to the conduct of the Claim or Proceedings on aspects of the Claim or Proceedings materially relevant to you and keep you reasonably
              informed of material developments in the Claim or Proceedings, provided that the Company or Associated Company shall be under no obligation to provide any information the provision of which is reasonably likely to adversely affect the ability
              of the Company or an Associated Company to claim in respect of the relevant loss under any applicable policy of insurance;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z532b9e8faf2548dda945cb91ace80863" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>take into account your reasonable requests relating to the Claim or Proceedings (including any settlement) on issues which may be reasonably likely to result in
              material damage to your reputation; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z09f0385c71a348d199b0ad6b9da3a0db" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">5.4.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>have full discretion in the conduct or settlement of the Claim or Proceedings relating to such Claim provided you are not required to make any contribution to the
              settlement and the settlement contains no admission of liability by you.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff147e9fb8e147e6908a941a5ed01aa7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Company&#8217;s obligations owed to you under this Deed (including the obligation to indemnify you in paragraph 2.1) is conditional upon your compliance with the
              provisions of this paragraph 5.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6b05bc990324dd6937ad7b3361035af" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-weight: bold;">Miscellaneous</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaee6276748774e6bbac15e2bb4a106d0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-style: italic;">Effect of </font><font style="font-style: italic;">Ceasing to be an Officer of the Company or any Associated Company</font></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">In the event that you cease to be an officer (or equivalent position under the laws of any relevant jurisdiction) of the Company or any
      Associated Company, this Deed shall remain in force and you will continue to be indemnified in accordance with the terms and conditions of this Deed, until such time as any relevant limitation periods for bringing Claims against you have expired, or
      for so long as you remain liable for any Liabilities, notwithstanding that you may have ceased to be an officer (or equivalent position under the laws of any relevant jurisdiction) of the Company or any Associated Company.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze26488baaf014993a17718d5cfe73106" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Payments</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">The Company shall, in the event that a payment is made to you under this Deed in respect of a particular Liability, be entitled to
      recover from you an amount equal to any payment received by you under any policy of insurance or from any other third party source to the extent that such payment relates to the Liability, or if the payment received by you is greater than the payment
      made under this Deed, a sum equal to the payment made under this Deed. You shall pay over such sum promptly on the Company&#8217;s request.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z341cb7f807f041069a91c1b3e6937ea1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Taxation</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 0.7pt; margin-left: 35.3pt;">The Company shall pay such amount to you as shall after the payment of any tax thereon leave you with sufficient
      funds to meet any Liability to which this Deed applies.&#160; For the avoidance of doubt, when calculating the amount of any such tax the amount of any tax deductions, credits or reliefs which are or may be available to you in respect of the relevant
      payment under this Deed received by you or any payment made by you to a third party in respect of the relevant Liability will be taken into account.&#160; In the event that any amount is paid to you under this Deed but a tax deduction, credit or relief is
      or becomes available to you in respect of the relevant payment or any payment made by you to a third party in respect of the relevant Liability which was not taken into account in calculating the amount payable in respect of the relevant payment
      under this Deed, you shall make a payment to the Company of such an amount as is equal to the benefit of such deduction, credit or relief which was not taken into account.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a3cdde8188e4dcc93a649a3818cd709" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">No Double Recovery</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">You shall not be entitled to recover any Liability more than once and in the event that the Company makes payment under this Deed, the
      Company shall be subrogated to the extent of such payment to all of your rights of recovery against third parties (including any claim under any applicable directors&#8217; and officers&#8217; insurance policy) in respect of the payment and you shall do
      everything that may be necessary to secure any such rights including:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z806f415c47cd443abe0c68f580335f40" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.4.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the execution of any documents necessary to enable the Company effectively to bring an action in your name; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6cf7f1a73b94b8796284990fd8abe19" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.4.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the provision of assistance as a witness.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd473aeebf3a3498ebe3ef7ecbfc92977" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.5</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Assignment</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">The Company may at any time assign, mortgage, charge, subcontract, delegate, declare a trust over or deal in any other manner with any
      or all of its rights under this Deed, provided that it gives notice of such dealing to you. You shall not assign, transfer, mortgage, charge, subcontract, declare a trust over or deal in any other manner with any of your rights and obligations under
      this Deed.</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z12ca45b30f9442738e1f74fe48df4872" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.6</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Entire Agreement</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">This Deed constitutes the entire agreement between the parties and supersedes and extinguishes all previous agreements, promises,
      assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e13981057b0412b8cd6919eb549a3c4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.7</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Severance</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">If any provision or part-provision of this Deed is or becomes invalid, illegal or unenforceable, it shall be deemed modified to the
      minimum extent necessary to make it valid, legal and enforceable. If such modification is not possible, the relevant provision or part-provision shall be deemed deleted. Any modification to or deletion of a provision or part-provision under this
      paragraph 6.7 shall not affect the validity and enforceability of the rest of this Deed. If one party gives notice to the other of the possibility that any provision or part-provision of this Deed is invalid, illegal or unenforceable, the parties
      shall negotiate in good faith to amend such provision so that, as amended, it is legal, valid and enforceable, and, to the greatest extent possible, achieves the intended commercial result of the original provision.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6bd2c3001e434aa5891344a149c9b0d5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.8</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Notices and Demands</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z41e68c99c1424ac9b2f456b9ee82fe90" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.8.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Any notice or demand given to a party under or in connection with this Deed:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f1449c7a0c7407bac2d5167ef6e06c3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72.55pt;"><br>
          </td>
          <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">6.8.1.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>shall be in writing and in English;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze16a3f19a08040aabfd0898f5d00b241" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72.55pt;"><br>
          </td>
          <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">6.8.1.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>shall be signed by or on behalf of the party giving it;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z691beb85f53a4543bb7d7b1b74885efb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72.55pt;"><br>
          </td>
          <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">6.8.1.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>shall be sent by a method listed in paragraph 6.8.2; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zead058af229342cd904b975f575f2fa8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 72.55pt;"><br>
          </td>
          <td style="width: 71.45pt; vertical-align: top; align: right; font-weight: bold;">6.8.1.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>is deemed received as set out in paragraph 6.8.2 if prepared and sent in accordance with this paragraph.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfae454e72a424235a0be7316da251521" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.8.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This paragraph 6.8.2 sets out the delivery methods for sending a notice to a party under this Deed and, for each delivery method, the date and time when the notice is
              deemed to have been received (provided that all other requirements of this paragraph have been satisfied and subject to the provisions in paragraph 6.8.3):</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f9882170bc343b7b5ee043c5392fc63" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 70.9pt;"><br>
          </td>
          <td style="width: 35.45pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the address;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b5b4da6da1246b2906b6fc59c74ffdf" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 70.9pt;"><br>
          </td>
          <td style="width: 35.45pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if sent by pre-paid first class post or other next working day delivery service, at the time recorded by the delivery service; or</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z56ab9021d5e44019b5c0e7f7966a6188" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 70.9pt;"><br>
          </td>
          <td style="width: 35.45pt; vertical-align: top; align: right;">(c)</td>
          <td style="width: auto; vertical-align: top;">
            <div>if sent by pre-paid airmail, at the time recorded by the delivery service.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z102e6bcd0dad4d53ace9953c589ca5cd" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.8.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>If deemed receipt under paragraph 6.8.2 would occur outside business hours in the place of receipt, it shall be deferred until business hours resume. In this paragraph,
              business hours means 9.00 a.m. to 5.00 p.m. Monday to Friday on a day that is not a public holiday in the place of receipt.</div>
          </td>
        </tr>

    </table>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z736452b76f12442bb329611eb3de91b7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.8.4</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This paragraph 6.8 does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of
              dispute resolution.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8778852e924475482c3a16a222ca2c6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.9</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Variation</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8235d555107d40b3a1d7285c6addf4b6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.9.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No variation of this Deed shall be effective unless it is in writing and signed by the parties (or their authorised representatives).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z09b02fe788654695a25d2afb23c33ebf" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36.55pt; vertical-align: top; align: right; font-weight: bold;">6.9.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No failure or delay by a party to exercise any right or remedy provided under this Deed or by law shall constitute a waiver of that or any other right or remedy, nor
              shall it prevent or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall prevent or restrict the further exercise of that or any other right or remedy.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d018e67191843d59d72f26353a969a8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.10</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Counterparts</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z437641950ef44f93878082994a6b636c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">6.10.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Deed may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall
              together constitute the one deed.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9e3b385d773455b9985d9339185acd4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">6.10.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Transmission of an executed counterpart of this Deed (but for the avoidance of doubt not just a signature page) by email (in PDF, JPEG or other agreed format), shall
              take effect as delivery of an executed counterpart of this Deed.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5737440746de4f98bc50a1a6d1e83d6a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">6.10.3</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>No counterpart shall be effective until each party has executed and delivered at least one counterpart.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zebbf2b452afb4b64ac118b72aac9d545" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.11</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Third Party Rights</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">Unless this Deed expressly states otherwise, this Deed does not confer any rights on any person or party (other than the parties to this
      Deed and any Associated Company) pursuant to the Contracts (Rights of Third Parties) Act 1999.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z724b2ae252e44a458f0881cabcc92090" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.12</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-style: italic;">Governing Law and Jurisdiction</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5b94445ace2440097536ea219569684" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">6.12.1</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This Deed and any dispute or claim arising out of or in connection with its subject matter or formation (including non-contractual disputes or claims) shall be governed
              by and construed in accordance with the law of England and Wales.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff082bd4aa1f4677b447a375091efd55" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">6.12.2</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>You and the Company irrevocably agree that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim that arises out of or in
              connection with this Deed or its subject matter or formation (including non-contractual disputes or claims).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; margin-left: 36pt;">[<font style="font-style: italic;">Deliberately left blank, signature page
        to follow.</font>]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div><font style="font-weight: bold;">IN WITNESS WHEREOF, </font>this Deed has been executed as a
      deed by the Company and you on the day and year first above written.</div>
    <div> <br>
    </div>
    <div>
      <div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td rowspan="2" style="width: 50.00%;">
                <div style="text-align: left;"><font style="font-weight: bold;">EXECUTED </font>as a<font style="font-weight: bold;"> DEED </font>by <font style="font-weight: bold;">IMMUNOCORE HOLDINGS PLC </font>acting by [<font style="font-style: italic;">Name of</font>&#160;<font style="font-style: italic;">Director</font>],
                  a director and [<font style="font-style: italic;">Name of Director</font>], a director</div>
              </td>
              <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">Director<br>
              </td>
            </tr>
            <tr>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%;">&#160;</td>
              <td rowspan="1" style="width: 50%;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">Director <br>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div style="text-align: left;"><font style="font-weight: bold;">EXECUTED </font>as a<font style="font-weight: bold;">&#160;</font><font style="font-weight: bold;">DEED </font>and delivered by</div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; padding-bottom: 2px;">
                <div style="text-align: left; font-weight: bold;">[<font style="font-style: italic;">Name of Director</font>]</div>
              </td>
              <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div style="text-align: left;">In the presence of:</div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; padding-bottom: 2px;">
                <div style="text-align: left;">Witness signature:</div>
              </td>
              <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
                <div style="text-align: left;">Name:</div>
              </td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
                <div style="text-align: left;">Address:</div>
              </td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">&#160;</td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
              <td rowspan="1" style="width: 50.00%;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; padding-bottom: 2px;">
                <div style="text-align: left;">Occupation:</div>
              </td>
              <td rowspan="1" style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div>
        <div><font style="font-weight: bold;">Adopted by the Board of Directors:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">[<font style="font-style: italic;">Date</font>]</font></div>
        <div><font style="font-weight: bold;">Effective:</font>&#160;&#160;&#160;&#160;&#160;&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;</font>&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font>&#160;&#160;&#160; <font style="font-weight: bold;">[<font style="font-style: italic;">Date</font>]</font></div>
      </div>
    </div>
    <div><br>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>nt10016217x4_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <br>
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS
        BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: right;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit 10.5</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BETWEEN</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMUNOCORE LIMITED.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on the one hand,</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENENTECH, INC</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AND</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. HOFFMANN-LA ROCHE LTD.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>on the other hand,</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AS OF JUNE 14, 2013</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE OF CONTENTS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%" cellpadding="0" cellspacing="0">

      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="width: 90%; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article </font>1 DEFINITIONS</font></td>
        <td style="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 2 GOVERNANCE</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 3 RESEARCH PROGRAM</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 4 LICENSES AND OPTIONS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 5 MATERIALS AND TECHNOLOGY TRANSFER</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 6 DILIGENCE</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 7 FINANCIAL TERMS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 8 FINANCIAL TERMS; REPORTS; AUDITS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 9 INTELLECTUAL PROPERTY; OWNERSHIP</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article </font>10 CONFIDENTIALITY</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 11 PUBLICITY; PUBLICATIONS; USE OF NAME</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 12 REPRESENTATIONS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="color: rgb(0, 0, 0); text-transform: uppercase;">Article</font> 13 INDEMNIFICATION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 14 TERM; TERMINATION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 15 DISPUTE RESOLUTION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 12pt Times New Roman, Times, Serif">
        <td style="padding-top: 0in; padding-bottom: 5pt; padding-left: 0in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><font style="text-transform: uppercase;">Article</font> 16 MISCELLANEOUS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
  <div><br>
  </div>
  <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit A</font><font style="font-size: 10pt;"> &#8211; Immunocore Background IP Patents (Section 1.45)</font>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit B</b> &#8211; Nomination Notice (Section 4.3.2)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit C</b> &#8211; Research Plan Template (Section 3.2)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit D</b> &#8211; Materials required at Effective Date (Section 5)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit E</b> &#8211; Press Release (Section 11.1)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit F</b> &#8211; Immunocore sub-contractors (Section 3.3)</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Certain confidential information contained in this document, marked by <font style="font-family: Times New Roman, Times, Serif Bold,serif; text-transform: uppercase">[***]</font>, has
      been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RESEARCH COLLABORATION AND LICENSE AGREEMENT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>This Research Collaboration and License Agreement</b></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&#8220;<b>Agreement</b>&#8221;) is made and entered into, effective as of June 14, 2013 (&#8220;<b>Effective Date</b>&#8221;), by and between <font style="font-variant: small-caps"><b>Immunocore Limited</b></font>,
      having its principal place of business at 57 Jubilee Avenue, Milton Park, Abingdon, Oxon, United Kingdom OX14 4RX (&#8220;<b>Immunocore</b>&#8221;), on the other hand, <font style="font-variant: small-caps"><b>Genentech, Inc.</b></font>, a Delaware corporation,
      having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (&#8220;<b>GNE</b>&#8221;) and <font style="font-variant: small-caps"><b>F. Hoffmann-La Roche Ltd</b></font>, with its principal place of business at Grenzacherstrasse
      124, CH 4070 Basel, Switzerland (&#8220;<b>Roche</b>&#8221;), on the other hand. GNE and Immunocore are sometimes referred to herein individually as a &#8220;<b>Party</b>&#8221; and collectively as the &#8220;<b>Parties.</b>&#8221; The term &#8220;<b>Party</b>&#8221; or &#8220;<b>Parties</b>&#8221; shall not
      include Roche unless explicitly stated below.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Background</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, Immunocore is a biotechnology company that is engaged in research and
      development of TCR technology for use in pharmaceutical products.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, GNE and Roche are biopharmaceutical companies that are engaged in the
      research, development, manufacture and sale of pharmaceutical products.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, GNE and Immunocore desire to collaborate in the discovery and development of
      TCR technology for use in pharmaceutical products; and WHEREAS, GNE and Roche desire to obtain an exclusive license and other rights from Immunocore to develop and commercialize products that contain the developed TCRs, and Immunocore agrees to grant
      GNE and Roche such an exclusive license and other rights in exchange for certain agreed to upfront and other payments.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW THEREFORE</b>, for good and valuable consideration, the receipt and sufficiency of
      which is hereby acknowledged, GNE, Roche and Immunocore agree as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 1</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>DEFINITIONS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used in this Agreement, whether used in the singular or plural, shall have
      the meanings set forth below, unless otherwise specifically indicated herein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Acceptance</b>&#8221; or &#8220;<b>Accepted</b>&#8221; is defined in
      Section 4.3.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Accounting Standard</b>&#8221; means, either (a)
      International Financial Reporting Standards (&#8220;<b>IFRS</b>&#8221;) or (b) United States generally accepted accounting principles (&#8220;<b>GAAP</b>&#8221;), in either case, which standards or principles (as applicable) are currently used at the applicable time by, and
      as consistently applied by GNE and Roche.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Affiliate</b>&#8221; means any person that, directly or
      indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of this Section 1.3, &#8220;control&#8221; means (i) the direct or indirect ownership of fifty percent (50%) or more of the voting
      stock or other voting interests or interest in the profits of the Party, or (ii) the ability to otherwise control or direct the decisions of the board of directors or equivalent governing body thereof. [***].</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Alliance Manager</b>&#8221; is defined in Section 2.5.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Applicable Laws</b>&#8221; means all laws, rules and
      regulations and guidelines which are in force during the term of this Agreement and in any jurisdiction in which the Research Program or any Clinical Trial is performed or in which any Licensed Product is manufactured, sold or supplier to the extent
      in each case applicable to any Party to this Agreement or any Sublicensee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Available Target</b>&#8221; is defined in Section 4.3.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Background IP</b>&#8221; means Background Know-How and
      Background Patents.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Background Know-How</b>&#8221; means any Know-How existing
      as of the Effective Date, or created after the Effective Date and outside the course of the activities conducted under any Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Background Patents</b>&#8221; means any Patents filed
      prior to the Effective Date, or any Patents which Cover the Background Know-How.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Biosimilar</b>&#8221; is defined in Section 7.6.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Clinical Trial</b>&#8221; shall mean a Phase I Clinical
      Trial, Phase II Clinical Trial or Phase III Clinical Trial or any other equivalent, combined or other trial in which any Licensed Product is administered to a human subject.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>CMO</b>&#8221; is defined in Section 5.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Combination</b>&#8221; is defined in Section 1.65(c).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Companion Diagnostic</b>&#8221; means any product or service
      that: [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Compound</b>&#8221; means a product that comprises (a) a TCR
      or a portion of a TCR that comprises a TCR alpha chain variable domain and a TCR beta chain variable domain wherein the TCR or portion of the TCR binds to an HLA-presented antigen derived from a Target; and (b) an Effector.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Compulsory Sublicense</b>&#8221; means a sublicense granted to
      a Third Party, through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sale, offer for sale, import or export a Product in any country in the Territory [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Compulsory Sublicensee</b>&#8221; means a Third Party that was
      granted a Compulsory Sublicense.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Confidential Information</b>&#8221; means proprietary Know-How
      (of whatever kind and in whatever form or medium, including copies thereof), tangible materials or other deliverables (a) disclosed by or on behalf of a Party in connection with this Agreement, whether prior to or during the Term and whether
      disclosed orally, electronically, by observation or in writing, or (b) created by, or on behalf of, either Party and provided to the other Party, or created jointly by the Parties,</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">2</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">in the course of this Agreement. For the avoidance of doubt, &#8220;Confidential Information&#8221;
      includes (i) Know-How regarding such Party&#8217;s research, development plans, clinical trial designs, preclinical and clinical data, technology, products, business information or objectives and other information of the type that is customarily considered
      to be confidential information by entities engaged in activities that are substantially similar to the activities being engaged in by the Parties pursuant to this Agreement and (ii) any tangible materials or other deliverables provided by one Party
      to the other Party pursuant to Article 5.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Control</b>&#8221; or &#8220;<b>Controlled by</b>&#8221; means the
      rightful possession by a Party, whether directly or indirectly and whether by ownership, license (other than pursuant to this Agreement) or otherwise as of the Effective Date or throughout the Term, of the unfettered right (excluding where any
      required Third Party consent can not be obtained) to grant a license, sublicense or other right to exploit, as provided herein, without violating the terms of any agreement with any Third Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Covers</b>&#8221; (including variations such as &#8220;<b>Covered</b>&#8221;,













      &#8220;<b>Covering</b>&#8221; and the like), means, with respect to a particular Patent and in reference to a particular compound or product (whether alone or in combination with one or more other ingredients) that the use, manufacture, sale, supply, import,
      offer for sale of such compound or product would infringe a Valid Claim of such Patent in the absence of any license granted under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>CPA Firm</b>&#8221; is defined in Section 8.7.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Create Act</b>&#8221; is defined in Section 9.2.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Diligent Efforts</b>&#8221; means carrying out obligations or
      tasks using commercially reasonable efforts and resources comparable with standard practices of pharmaceutical companies [***] to the Party concerned and exercising decisions in good faith and using prudent, scientific and business judgment.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Disclosing Party</b>&#8221; is defined in Section 11.6.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Dispute(s)</b>&#8221; is defined in Section 15.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Early Development</b>&#8221;&#183; is defined in Section 4.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Effector</b>&#8221; means any protein or polypeptide having
      the ability to modulate immune cell function such as anti-CD3 scFv or a diagnostic label, including derivatives or variants thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Entity</b>&#8221; is defined in Section 4.3.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Exclusive License</b>&#8221; is defined in Section 4.2.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Exclusive Target</b>&#8221; is defined in Section 4.3.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Exclusive Target Payment</b>&#8221; is defined in Section 7.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>EU</b>&#8221; means the member states of the European Union,
      or any successor entity thereto performing similar functions.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Event</b>&#8221; means the events listed in 7.3.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Event Payment</b>&#8221; means the payments on achieving an
      Event and as set out in Section 7.3.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>FDA</b>&#8221; means the United States Food and Drug
      Administration, or any successor entity thereto performing similar functions.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Field</b>&#8221; means any and all uses, excluding any product
      that contains cells transfected with genes encoding TCRs or modified TCRs [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>First Commercial Sale</b>&#8221; means, with respect to a
      particular Licensed Product in a given country, the first commercial sale of such Licensed Product following Marketing Approval in such country by or under authority of GNE or any of its Sublicensees. As used herein, &#8220;<b>Marketing Approval</b>&#8221; means
      all approvals, licenses, registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale of Licensed Products
      in a country or regulatory jurisdiction. For countries where governmental approval is required for pricing or reimbursement for the Licensed Product, &#8220;<b>Marketing Approval</b>&#8221; shall not be deemed to occur until such pricing or reimbursement
      approval is obtained; provided, to the extent GNE or any of its Sublicensees sell a Licensed Product prior to obtaining such pricing or reimbursement approval, such sales shall be accrued at the time of sale and any royalties thereon shall be paid in
      the quarter following the obtaining of such pricing or reimbursement approval. For the purpose of clarity and subject to Section l .65(a), sales of Licensed Products between or among any of GNE, Roche and their Sublicensees shall be excluded from
      &#8220;First Commercial Sales&#8221;.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Foreground IP</b>&#8221; means the Immunocore Foreground IP
      and the GNE Foreground IP.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>FTE</b>&#8221; means the equivalent of the work of one
      employee full time on (equivalent to a twelve month period of work directly related to) any Research Program, including [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GMP</b>&#8221; means all current good manufacturing practices
      applicable to biopharmaceuticals in the United States and/or in the European Union, as are in effect from time to time during the Term.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE</b>&#8221; is defined in the introduction.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Foreground IP</b>&#8221; means (a) any Know-How
      discovered, conceived or reduced to practice solely by or on behalf of GNE after the Effective Date in the course of performing activities under any Research Program: and (b) any Patents derived from or claiming the Know-How in Section 1.40(a), which
      Patents have an earliest priority date after the Effective Date. GNE Foreground IP will exclude (i) any Patents or Know-How that [***] and (ii) any Patents or Know-How [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Improvement IP</b>&#8221; means (a) any Know-How
      discovered, conceived or reduced to practice solely by or on behalf of GNE after the Effective Date in the course of performing any activities covered by the Research License (and not in the course of performing activities under any Research Program)
      and which directly relates to improvements to ImmTACs or the</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Immunocore Background IP; and (b) any Patents derived from or claiming the Know-How in
      Section 1.4l(a). GNE Improvement IP excludes (i) any GNE Foreground IP; (ii) any Joint IP; (iii) any Patents or Know-How [***]; or (iv) any Patents or Know-How [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Grantback License</b>&#8221; is defined in Section 4.5.1(a).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>HLA</b>&#8221; means human leukocyte antigen and &#8220;<b>HLA Type</b>&#8221;
      means human leukocyte antigent type.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>ImmTAC</b>&#8221; means a bifunctional protein that combines a
      high affinity TCR with an anti-CD3 scFv domain or other Effector.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Immunocore Background IP</b>&#8221; means the Background IP
      owned or Controlled by Immunocore as of the Effective Date or during the Term including but not limited to the Patents listed in Exhibit A.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Immunocore Foreground IP</b>&#8221; means (a) any Know-How
      discovered, conceived or reduced to practice solely by or on behalf of Immunocore in the course of performing activities under any of the Research Programs; and (b) any Patents derived from or claiming the Know-How in Section 1.46(a).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>IND</b>&#8221; means an investigational new drug application
      filed with the FDA pursuant to 21 CFR Part 312 before the commencement of clinical trials of a product, or any comparable or equivalent filing with any relevant regulatory authority in any other jurisdiction required before the commencement of any
      Clinical Trial.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Indemnitee</b>&#8221; is defined in Section 13.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Indemnitor</b>&#8221; is defined in Section 13.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Infringement</b>&#8221; is defined in Section 9.4.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Initial License Fee</b>&#8221; is defined in Section 7.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Immunocore</b>&#8221; is defined in the introduction.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Joint IP</b>&#8221; means (a) any Know-How discovered,
      conceived or reduced to practice by one or more employees of or on behalf of GNE and one or more employees of or on behalf of Immunocore in the course of performing activities under the any of the Research Programs; and (b) any Patents derived from
      or claiming the Know-How in Section 1.53(a)), which Patents have an earliest priority date after the Effective Date. Joint IP excludes any Immunocore Foreground IP, GNE Foreground IP, and GNE Improvement IP.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Joint Project Team</b>&#8221; or &#8220;<b>JPT</b>&#8221; is defined in
      Section 2.2.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Joint Research Committee</b>&#8221; or &#8220;<b>JRC</b>&#8221; is defined
      in 2.1.1.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.56&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Know-How</b>&#8221; means all information, inventions (whether
      or not patentable), improvements, practices, formula, trade secrets, techniques, methods, procedures, knowledge, results, test data (including pharmacological, toxicological, pharmacokinetic and pre-clinical and clinical information and test data,
      related reports, structure-activity relationship data and statistical analysis), analytical and quality control data, protocols, processes, models, designs, and other information regarding discovery, development, marketing, pricing, distribution,
      cost, sales and manufacturing. Know-How shall not include any Patents.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Licensed Intellectual Property</b>&#8221; means the Licensed
      Know-How and Licensed Patents.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57.1&#160;&#160;&#160; &#8220;<b>Licensed Know-How</b>&#8221; means, as owned or Controlled by
      Immunocore as of the Effective Date or during the Term, any (a) Background Know-How specific to the relevant Exclusive Target; and (b) any Background Know-How specific to any Compound developed during the Research Program relating to such Exclusive
      Target and selected for use in any Clinical Trial, including to the extent such Background Know-How relates to the manufacture, use, import, offer to sell or sale of such Compound.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57.2&#160;&#160;&#160; &#8220;<b>Licensed Patents</b>&#8221; means any Patents owned or
      Controlled by Immunocore as of the Effective Date or during the Term and which Cover a Licensed Product. Licensed Patents does not include any Patents within the Joint IP or Immunocore Foreground IP.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.58&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Licensed Product</b>&#8221; means any product (other than a
      Companion Diagnostic) containing a Compound derived from an Exclusive Target, which Compound:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is owned or Controlled by Immunocore as of the Effective
      Date;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is generated solely by Immunocore or jointly by the
      Parties during the Term;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is generated solely by GNE in the course of performing
      activities under any Research Program;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is generated solely by GNE after the Research Term for a
      given HLA-presented antigen derived from an Exclusive Target, which generation resulted from the direct modification of the Compounds in (a), (b) or (c); or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE elects to bring under this Agreement by providing
      written notice to Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.59&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Licensed Product/Different HLA Type</b>&#8221; is defined in
      Section 4.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.60&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221; is defined in Section 13.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Major European Market</b>&#8221; means [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.62&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>MAA</b>&#8221; or &#8220;<b>Marketing Approval Application</b>&#8221;
      means BLA, sBLA, NDA, sNDA and any equivalent thereof in the United States or any other country or jurisdiction in the Territory. As used herein: &#8220;<b>BLA</b>&#8221; means a Biologics License Application and amendments thereto filed pursuant to the
      requirements of the FDA, as defined in 21 C.F.R. &#167; 600 et seq., for FDA approval</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">of a Licensed Product and &#8220;<b>sBLA</b>&#8221; means a supplemental BLA; and &#8220;<b>NDA</b>&#8221; means a
      New Drug Application and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. &#167; 314 et seq., for FDA approval of a Licensed Product and &#8220;<b>sNDA</b>&#8221; means a supplemental NDA.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.63&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Materials</b>&#8221; is defined in Section 5.1.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.64&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Milestone Payment</b>&#8221; shall mean the payments to be
      made on the Net Sales Events and as set out in Section 7.5.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Net Sales</b>&#8221; with respect to a Licensed Product shall
      mean an amount calculated by subtracting from the amount of Sales of such Licensed Product by Roche, GNE or their Sublicensees to Third Parties (including distributors): (i) a lump sum deduction of [***] of Sales in lieu of those deductions which are
      not accounted for within Roche or ONE on a Licensed Product-by-Licensed Product basis [***]. The deductions under this Section will be those deductions as consistently applied by GNE, Roche or their Sublicensees in accordance with internal practices.
      As used herein this Section 1.65:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Sales Among Affiliates and Sublicensees</b>. Sales
      between or among a Party and its Sublicensees shall be excluded from the computation of Net Sales provided (a) there is an arms length sale or supply to a Third Party in relation to such Licensed Product; and (b) any sale between a Party and its
      Sublicensee is made on an arms length basis.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Supply as Samples/Test Materials</b>. Notwithstanding
      anything to the contrary in the definition of Net Sales, the supply or other disposition of Licensed Products (i) as samples provided free of charge to any Third Party and in accordance with standard industry practice (but not in circumstances where
      such Third Party is able to pass samples to any other Third Party other than free of charge); (ii) for use in non-clinical or clinical studies (provided such samples are provided to any Third Party in exchange for data from such study, at cost, or
      free of charge); (iii) for use in any tests or studies reasonably necessary to comply with any applicable law, regulation or request by a regulatory or governmental authority (provided such samples are provided to any Third Party in exchange for data
      from such test or study, at cost, or free of charge) or (iv) as is otherwise reasonable and customary in the industry (but not in circumstances where such Third Party is able to pass samples to any other Third Party other than free of charge), in
      each case of (i) through (iv) shall not be included in the computation of Net Sales.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Licensed Products Sold in Combinations</b>. In the event
      that a Licensed Product is sold or supplied in combination (in the same package, including as a co-formulation) with one or more other active ingredients or other products that are not the subject of this Agreement (for purposes of this Section
      1.65(c), a &#8220;<b>Combination</b>&#8221;), the following shall apply:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Sales from Compulsory Sublicensees</b>. The Parties shall
      discuss in good faith and agree the reasonable treatment to be used on a consistent basis to fairly share Compulsory Sublicense payments between the Parties. For the purpose of clarity, any Party will not be</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">penalized or be subject to Material Breach for delayed or deferred payments during the period
      of discussion.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.66&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Net Sales Event(s)</b>&#8221; is defined in Section 7.5.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.67&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Net Sales Report</b>&#8221; is defined in Section 8.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.68&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Nomination Notice</b>&#8221; is defined in Section 4.3.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.69&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Non-Disclosing Party</b>&#8221; is defined in Section 11.6.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.70&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Non-Exclusive License</b>&#8221; is defined in Section 4.2.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.71&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Option Period</b>&#8221; is defined in Section 4.2.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.72&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Patent(s)</b>&#8221; means any and all patents and patent
      applications and any patents issuing therefrom or claiming priority to, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, reexaminations,
      substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Party Vote</b>&#8221; is defined in Section 2.4.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Phase I Clinical Trial</b>&#8221; means a human clinical
      trial, the principal purpose of which is preliminary determination of safety of a Licensed Product in healthy individuals or patients as described in 21 C.F.R. &#167;312.21, or similar clinical study in a country other than the United States.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Phase II Clinical Trial</b>&#8221; means a human clinical
      trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy of a Licensed Product in patients being studied as described in 21 C.F.R. &#167;312.21, or similar clinical study in a country
      other than the United States. Phase II Clinical Trials shall include Phase IIa and Phase IIb Clinical Trials.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.76&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Phase III Clinical Trial</b>&#8221; means a human clinical
      trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Licensed Product for one or more indications in order to obtain Marketing Approval of such Licensed Product for such indication(s), as
      further defined in 21 C.F.R. &#167;312.21 or a similar clinical study in a country other than the United States.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Pivotal Trial</b>&#8221; is defined in Section 7.3.2(f).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.78&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Project Co-Leader</b>&#8221; is defined in Section 2.2.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.79&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Proposed Target</b>&#8221; is defined in Section 4.3.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Prosecute and Maintain</b>&#8221; or &#8220;<b>Prosecution and
        Maintenance</b>&#8221; is defined in Section 9.1.1.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.81&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Regulatory Approval</b>&#8221; means the technical, medical
      and scientific licenses, registrations, authorizations and approvals required for marketing or use of a Licensed Product (including, without limitation, approvals of, BLAs (as defined in Section 1.62), investigational new drug applications, pre- and
      post- approvals, and labeling approvals and any supplements and amendments to any of such approvals) of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity,
      necessary for the development, manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Licensed Products in a regulatory jurisdiction. In the United States, its territories and possessions, Regulatory Approval
      means approval of any Marketing Approval Application or equivalent by the FDA.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Release</b>&#8221; is defined in Section 11.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.83&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Research License</b>&#8221; is defined in Section 4.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.84&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Research Plan</b>&#8221; is defined in Section 3.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Research Program</b>&#8221; means the activities conducted by
      the Parties pursuant to Article 3 and the Research Plan and comprising the Stages.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.86&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Research Term</b>&#8221; is defined in Section 3.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.87&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Roche</b>&#8221; is defined in the introduction.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Rules</b>&#8221; is defined in Section 15.2.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.89&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Section 9.4.2 Enforcement</b>&#8221; is defined in Section
      9.4.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.90&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Sales</b>&#8221; of a Licensed Product shall mean, for any
      period, the amount stated in Roche&#8217;s &#8220;<b>Sales</b>&#8221; line of its quarterly produced and reviewed financial statements with respect to such Licensed Product for such period, which amount reflects the gross invoice price such Licensed Product sold or
      otherwise disposed of (other than for use as clinical supplies or free samples) by Roche, GNE and their Sublicensees reduced by gross-to-net deductions (to the extent applied consistently by Roche, GNE and their Sublicensees with respect to sales of
      their respective other products) if not previously deducted from the amount invoiced, taken in accordance with the then currently used Accounting Standard. By way of example, the gross-to-net deductions taken in accordance with Accounting Standard as
      of the Effective Date are the following: [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of clarity and subject to Section 1.65(a), sales of Licensed Products
      between or among any of GNE, Roche or their Sublicensees shall be excluded from &#8220;Sales&#8221;.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Stage</b>&#8221; or &#8220;<b>Stages</b>&#8221; means one of each of the
      following stages of the Research Program: TCR isolation (&#8220;Stage 1&#8221;), affinity maturation (&#8220;Stage 2&#8221;) and pre-clinical biology (&#8220;Stage 3&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Sublicensee</b>&#8221; shall mean a Third Party or Affiliate
      who has been granted a sublicense under either of the Exclusive License or Non-Exclusive License and where such sub-license is in compliance with Section 4.2.5.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.93&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Subsequent Licensed Product</b>&#8221; is defined in Section
      7.3.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.94&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Target</b>&#8221; means the protein or biological molecule
      from which an HLA-presented antigen is derived (including all HLA alleles).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.95&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Target Database</b>&#8221; is defined in Section 4.3.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.96&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>TCR</b>&#8221; means T-cell receptor.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.97&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Term</b>&#8221; is defined in Section 14.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.98&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Territory</b>&#8221; means all the countries of the world.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.99&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party</b>&#8221; means any entity other than Immunocore,
      GNE, Roche or an Affiliate of any of the foregoing.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.100&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party Claims</b>&#8221; is defined in Section 13.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.101&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party Infringement Claim</b>&#8221; is defined in Section
      9.5.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.102&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party Licensee</b>&#8221; is defined in Section 4.5.3(b).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.103&#160;&#160;&#160;&#160;&#160; &#8220;<b>Title 11</b>&#8221; is defined in Section 14.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.104&#160;&#160;&#160;&#160;&#160; &#8220;<b>Tractable</b>&#8221; including variations such as &#8220;<b>Tractability</b>&#8221;
      means that a target derived peptide is detectable by mass-spectrometry at levels supportive of achieving biological activity using an ImmTAC and the expression profile of the target by qRT-PCR suggests that a viable therapeutic window may be
      achievable.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.105&#160;&#160;&#160;&#160;&#160; &#8220;<b>Unavailable Target</b>&#8221; is defined in Section 4.3.4</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.106&#160;&#160;&#160;&#160;&#160; &#8220;<b>US</b>&#8221; means the United States of America and its
      territories and possessions.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.107&#160;&#160;&#160;&#160;&#160; &#8220;<b>Valid Claim</b>&#8221; means, with respect to a particular
      country, (a) a claim in an issued and unexpired Patent within the Licensed Intellectual Property, Foreground IP or Joint IP; or (b) claim in an issued and unexpired Patent within the GNE Improvement IP and which Covers a Compound which has not
      resulted from a Research Program but GNE has elected to designate as a Licensed Product under Section 1.58(e); in each case in such country that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of
      a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or otherwise, or
      lost in an interference proceeding.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.108&#160;&#160;&#160;&#160;&#160; &#8220;<b>VAT</b>&#8221; means, in the EU, value added tax calculated in
      accordance with Council Directive 2006/112/EC and, in a jurisdiction outside the EU, any equivalent tax.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.109&#160;&#160;&#160;&#160;&#160; &#8220;<b>Working Group</b>&#8221; is defined in Section 2.1.3.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 2</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>GOVERNANCE</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Joint Research Committee.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Formation and Composition</b>. As soon as reasonably
      possible and in any event within thirty (30) days after the Effective Date, Immunocore and GNE shall establish a joint research committee (the &#8220;<b>JRC</b>&#8221;) to monitor and coordinate the activities under the Research Programs. The JRC shall be
      composed of at least [***] but no more than [***] representatives designated by each Party and in each case an equal number of representatives from each Party. Representatives must be appropriate for the tasks then being undertaken and the stage of
      research or pre-clinical development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JRC contact. Each Party may
      replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing notification
      in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers may attend meetings of the JRC but shall have
      no right to vote on any decisions of the JRC.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JRC Responsibilities</b>. In addition to its overall
      responsibility for monitoring the Research Programs, the JRC shall, in particular:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; work with the Project Co-Leaders to coordinate the
      activities of the Parties hereunder;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; review progress reports submitted by each JPT or Working
      Group with respect to its respective Research Program activities;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; review and approve Research Plans for a Research
      Program, reviewing and approving amendments to the Research Plans for its respective Research Program;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; discuss new Targets validated by Immunocore or added to
      the database of Targets that may be available for nomination as an Exclusive Target;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; review proposals for nomination of any Targets as a
      subsequent or additional Exclusive Target;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; work to resolve any disputes, controversy or claim
      related to the matters and authority of the JRC;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; perform such other functions as appropriate to further
      the purposes of this Agreement as determined by the Parties;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; review and approve the allocation of resources and
      efforts for the Research Programs;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; discuss the results of GNE&#8217;s research activities, if
      any, under the Research License; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; discuss Immunocore&#8217;s progress in conducting any
      Clinical Trials with a Compound, where the Compound is not subject to any Third Party confidentiality restrictions.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Working Groups</b>. From time to time, the JRC may also
      establish and delegate duties to directed teams on an &#8220;as-needed&#8221; basis to oversee particular projects or activities, and such teams shall be constituted and shall operate as the JRC determines (&#8220;<b>Working Group(s)</b>&#8221;). Each such Working Group and
      its activities shall be subject to the oversight, review and approval of, and shall report to, the JRC. In no event shall the authority of a Working Group exceed that specified for the JRC in this Article 2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Joint Project Team</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Formation and Composition</b>. On an Exclusive
      Target-by-Exclusive Target basis, within [***] after designation of a Target as an Exclusive Target, the Parties shall establish a joint project team (the &#8220;<b>JPT</b>&#8221;) to manage the activities under, and facilitate communications between the
      Parties, with respect to the Research Program for such Exclusive Target. The JPT shall be composed of representatives designated by each Party. Representatives must be appropriate for the tasks then being undertaken and the stage of research or
      pre-clinical development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JPT contact (each, a &#8220;<b>Project Co-Leader</b>&#8221;).













      Each Party may replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate a knowledgeable alternate to attend such
      meeting and perform the functions of such representative. The JPT shall be subject to the oversight, review and approval of the JRC.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JPT Responsibilities</b>. In addition to its overall
      responsibility for managing its respective Research Program, each JPT shall, in particular:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; prepare any amendments to its respective Research Plan
      in accordance with Section 3.2, and submit amended Research Plans to the JRC for approval;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; implement its respective Research Plan, ensuring that
      activities thereunder are performed in accordance with the approved timelines and budgets;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ensure that each Party keeps the JPT informed regarding
      all material activities performed by such Party under this Agreement that are within the purview of the JPT;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; generate and maintain a list of all Compounds identified
      under its respective Research Program; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; perform such other functions as agreed to by the JRC
      (in each case subject to Section 2.4.2) or as specified in this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Meetings.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JRC</b>. The JRC shall meet in person [***] at
      Immunocore&#8217;s facilities in Abingdon, Oxfordshire, England or GNE&#8217;s facilities in South San Francisco, California, or via telecon or otherwise, in each case as agreed by the JRC. Where possible meetings will be held by telephone conference with only
      [***] and at either Immunocore&#8217;s or GNE&#8217;s facility. Where necessary, for example to resolve any dispute, the JRC shall meet more frequently.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JPT</b>. The JPT shall meet at least [***] by audio or
      video teleconference or as otherwise agreed by the JPT.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Meeting Agendas and Minutes</b>. Not later than [***]
      after the JRC and each JPT are formed, the respective committee&#8217;s shall each hold an organizational meeting by video- or tele- conference to establish their respective operating procedures, including establishment of agendas, and preparation and
      approvals of minutes. The Parties shall alternate responsibility for taking the meeting minutes, GNE shall be responsible for taking the meeting minutes at the first JRC meeting. Meeting minutes shall be sent to both Parties promptly (and in any
      event within [***]) after a meeting for review, comment and approval by each Party. Where minutes are not approved by both Parties, the dispute shall be resolved at the next JRC or JPT meeting. A decision that is made at the JRC or a JPT meeting
      shall be recorded in minutes, and decisions that are made by the JRC or a JPT outside of a meeting shall be documented in writing and be shown to be clearly agreed by all representatives of the JRC or JPT as relevant.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>General</b>. Employees of each Party other than its JRC
      or JPT representatives may attend meetings of the JRC or JPT as nonvoting participants, and, with the consent of the other Party, a Party&#8217;s consultants and advisors involved in a Research Program may attend meetings of the JRC or the respective JPT
      as nonvoting observers; provided, that such consultants and advisors are under obligations of confidentiality and non-use applicable to the Confidential Information of the other Party as required by Section 10.3(e). Each Party shall be responsible
      for all of its own expenses of participating in the JRC or JPT. A Project Co-Leader may be responsible for more than one Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Decision-Making</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JPT</b>. Each Party will discuss and attempt to resolve
      any potential or evolving disagreement related to a Research Program through its respective Project Co-Leaders before it is brought before its respective JPT. With respect to the responsibilities of each JPT, each Party shall have [***] on all
      matters brought before the JPT. Each JPT shall operate as to matters within its responsibility by [***] Party Vote. If a JPT is unable to achieve [***] Party Vote within [***] after the dispute matter is brought to a vote before the JPT, such matter
      shall be referred to [***] for resolution.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>JRC</b>. Each Party will discuss and attempt to resolve
      any potential or evolving disagreement related to the Research Programs through their respective [***] before it is brought before [***]. Each Party&#8217;s designees on the JRC shall, collectively, have [***] (the &#8220;<b>Party Vote</b>&#8221;) on all matters
      brought before the JRC. Except as expressly provided in this Section 2.4.2, the JRC shall operate as to matters within its responsibility by [***] Party Vote. If the JRC is unable to achieve [***] Party Vote, [***] shall have the final
      decision-making authority; provided, that (i) neither the JRC nor either Party shall have the authority to amend or modify, or waive its own</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">compliance with, this Agreement; and (ii) [***] shall not be entitled to materially vary the
      scope of work covered by any Stage of a Research Program beyond that which can be resourced by [***] using commercially reasonably efforts and in accordance with Section 3.7.1 and in any event not exceeding the [***] agreed under any Research
      Program; and (iii) [***] shall not have the right to increase or decrease the level of [***]&#8217;s FTEs dedicated to conducting research under any Research Plan or modify the terms of the FTE rate; and (iv) [***] shall not be entitled to materially
      increase any expenditure or costs to be incurred by [***]e in relation to any initial Research Plan, in each case without the mutual consent of both Parties.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Dissolution of the JPT and JRC</b>. Upon the earlier of
      expiration or termination of a Research Program with respect to a particular Exclusive Target, the respective JPT will have no further responsibilities or authority under this Agreement and such JPT will be deemed dissolved by the Parties. Upon the
      earlier of expiration or termination of the last Research Program with respect to a particular Exclusive Target, the JRC and the respective JPT will have no further responsibilities or authority under this Agreement and the JRC and such JPT will be
      deemed dissolved by the Parties. Notwithstanding the foregoing, each time GNE subsequently elects by written notice to Immunocore pursuant to Section 4.4 to develop any additional HLA Type to any Exclusive Target, within [***] of such notice, the
      Parties shall re-establish a JPT and the JRC shall resume its previous responsibility under Section 2.1.2 until the earlier of expiration or termination of such Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Alliance Managers</b>. Promptly following the Effective
      Date, each Party shall designate an individual to act as the primary business contact for such Party for matters related to this Agreement (such Party&#8217;s &#8220;<b>Alliance Manager</b>&#8221;), unless another contact is expressly specified in the Agreement or
      designated by the JRC for a particular purpose. The Alliance Managers shall facilitate the flow of information and collaboration between the Parties and assist in the resolution of potential and pending issues and potential disputes in a timely
      manner to enable the JRC (during the Research Programs) and the Parties (during the term of the Agreement) to reach consensus and avert escalation of such issues or potential disputes. Either Party may replace its Alliance Manager at any time upon
      prior written notice (including by email) to the other Party&#8217;s Alliance Manager. Each Party shall ensure that its Alliance Manager is capable of performing the obligations required of an Alliance Manager under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 3</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>RESEARCH PROGRAM</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>General</b>. Following designation of each new Proposed
      Target as an Exclusive Target, the Parties shall conduct a Research Program in accordance with the Research Plan for such Exclusive Target. Each Party shall comply with all laws, rules and regulations applicable to the conduct and documentation of
      its Research Program activities. Each Party shall, in performing its obligations under any Research Program, assign responsibilities to those portions of its organization that have the appropriate resources, expertise and responsibility for such
      obligations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Research Plan</b>. Within [***] after the designation of
      a Proposed Target as an Exclusive Target (or such longer time as mutually agreed), the Parties shall draft and agree upon a research plan (&#8220;<b>Research Plan</b>&#8221;) for the Research Program to such Exclusive Target. The Research Plan shall unless
      otherwise agreed include the information and be in the form of the template Research</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Plan set out in Exhibit C. The JRC may amend in writing the Research Plans from time to time.
      Without limiting the foregoing, it is envisioned that after the nomination and acceptance of the Exclusive Target, Immunocore will initially focus on [***], and GNE will focus on [***]. Once a clinical candidate has been selected, Immunocore will
      work with GNE [***]. If appropriate, GNE shall conduct [***] experiments. In addition, the parties will collaborate on IND preparations and the regulatory filings, [***]. GNE shall be responsible for IND filings and other regulatory filings.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Subcontractors</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE Subcontracting</b>. GNE may subcontract portions of
      its work under the Research Program to (i) any Affiliate directly or indirectly controlled by GNE, (ii) any Roche Affiliate whose primary business is to develop and commercialize equipment and reagents for research tools and medical diagnostic
      applications and in each case only for such development or commercialization of equipment and reagents for research tools and medical diagnostic applications, or (iii) Third Parties; <i>provided</i>, such subcontract is in writing and is consistent
      with the terms and conditions of this Agreement including the confidentiality provisions of Article 10 and any rights granted to such subcontractor are restricted to only those rights necessary for performance by subcontractor of the portions of work
      on behalf of GNE. GNE will remain responsible (at its cost) for all acts or omissions of any subcontractor it appoints (including any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor
      complies with the terms and conditions of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore Subcontracting</b>. Immunocore may not
      subcontract portions of its work under the Research Program (including without limitation those quantities to be supplied under the Research Program, as further specified in the Research Plan) to Affiliates or Third Parties without GNE&#8217;s prior
      written consent, such consent not to be unreasonably withheld. Any approved subcontract shall be in writing and consistent with the terms and conditions of this Agreement including the confidentiality provisions of Article 10 and any rights granted
      to such subcontractor are restricted to only those rights necessary for performance by subcontractor of the portions of work on behalf of Immunocore. Immunocore shall remain responsible (at its cost) for all acts or omissions of any subcontractor it
      appoints (including any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement. As of the Effective Date, GNE has consented to
      Immunocore subcontracting with the subcontractors listed in Exhibit F.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Research Term</b>. The Research Program for a particular
      Exclusive Target shall commence on Acceptance, and shall continue, unless earlier terminated in accordance with Article 14, until the earlier of completion of all the tasks set out in the Research Plan for such Research Program or filing of an IND by
      or on behalf of GNE or any of its Sublicensees for a Compound directed to an HLA-presented antigen derived from the Exclusive Target relating to the Research Program (the &#8220;<b>Research Term</b>&#8221;). During the Research Term, each Party shall be
      responsible for its own costs associated with the activities it conducts under the Research Program. For the avoidance of doubt, any materials to be used in any Clinical Trial will be at GNE&#8217;s cost.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Multiple Exclusive Targets</b>. At any time Immunocore
      shall not be obliged to perform more than [***] Research Programs at the same time and in the same Stage. In addition, Immunocore will not be obligated to commence work on any Research Programs until the earlier</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">of either: (i) [***] after starting work on any preceding Research Program or (ii) the date
      on which Immunocore is adequately staffed to perform the additional Research Program, such adequate staffing being determined by Immunocore in its absolute discretion. [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Reports; Records; and Inspections.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Progress Reports</b>. Each Party shall use Diligent
      Efforts to keep the other Party informed of its activities under the Research Program and shall provide to the other Party&#8217;s representatives on the JRC regular written summary updates at each JRC meeting. If reasonably necessary for a Party to
      perform its work under the Research Program, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party shall promptly provide the requesting Party with
      information and data as is reasonably available and reasonably necessary to conduct the Research Program, and such other information as the Parties agree. Neither Party is required to generate additional data or prepare additional reports to comply
      with the foregoing obligation. Subject to Section 10.2, all such reports, information and data provided by a Party shall be considered the providing Party&#8217;s Confidential Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Research Records</b>. Each Party shall maintain records
      of the Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of the Research Program.
      All laboratory notebooks shall be maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the Research Term and for [***] thereafter. All such records of a Party shall be
      considered such Party&#8217;s Confidential Information.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Research Efforts</b>. The Parties shall use Diligent
      Efforts to conduct their respective tasks under the Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore Research Efforts</b>. Immunocore shall
      devote such numbers of scientists, with the requisite qualifications, as the Research Program may require [***]. During the Research Term, such Immunocore FTE&#8217;s shall be provided by Immunocore at its cost.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE Research Efforts</b>. Notwithstanding any Diligent
      Efforts applied by Immunocore to the Research Program, GNE shall have the right, at its sole discretion and cost, to apply additional GNE&#8217;s FTEs to conduct activities under the Research Program, including those activities for which Immunocore has
      primary responsibility under the Research Program. If GNE elects to take over any activities under a Research Program for which Immunocore has primary responsibility, GNE shall provide written notice via email to Immunocore thereof, and following
      such written notice Immunocore shall have no further responsibility for such activities under such Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 4</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>LICENSES AND OPTIONS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Research License.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Original Research License</b>. Commencing on the
      Effective Date and continuing in full force and effect conterminously with each Exclusive License and Non-Exclusive License to an Exclusive Target, Immunocore hereby grants to GNE:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a royalty-free, non-transferable, non-sublicenseable,
      non-exclusive research license under Immunocore&#8217;s rights in the Immunocore Background IP, the Immunocore Foreground IP, and the Joint IP to use and evaluate the Materials supplied by Immunocore under Section 5.1.2(a) for the purposes of process
      development and CMC related to the manufacture, use, sale or supply of Licensed Products; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a royalty-free, non-transferable, non-sublicenseable,
      non-exclusive research license under Immunocore&#8217;s rights in the Licensed Intellectual Property, the Immunocore Foreground IP, and the Joint IP for the purposes of manufacturing or testing of a Licensed Product arising from performance of a Research
      Program, development of Companion Diagnostics for such Licensed Product or other research and development in each case as necessary to enable manufacture, sale or supply of or obtaining Marketing Approval for such Licensed Product including PK
      modification, optimisation for chemical stability and manufacturability, assay development, drug resistance analysis and formulation and in each case to the extent such activities do not form part of any Research Program.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The licences under Sections 4.1.1(a) and (b) shall together be referred to as the &#8220;<b>Research













        License</b>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, upon the termination of an Exclusive License and Non-Exclusive
      License to a particular Exclusive Target, the Research License to such Exclusive Target shall also terminate.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In performing the Research License under Section 4.1.1, GNE agrees that it shall not file
      any Patents over any modifications to or derivatives of the Materials provided under Section 5.1.2(a).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; Alternative Research License. Commencing upon GNE having
      paid to Immunocore an amount equal to or greater than [***]:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Research License as set forth in Section 4.1.1 shall
      terminate in its entirety; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore hereby grants to GNE a royalty-free,
      non-transferable, non-sublicenseable, non-exclusive research license under Immunocore&#8217;s rights in the Immunocore Background IP, the Immunocore Foreground IP, and the Joint IP to conduct research related to all Targets (upon such grant, such license
      shall hereinafter be referred to as the &#8220;<b>Research License</b>&#8221;):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any Compounds generated by or on behalf of
      GNE under the Research License in Section 4.1.2(b), GNE shall not advance into Early Development such Compounds to any Target unless and until such Target is designated as an Exclusive Target. GNE shall have the right to enter into subcontracts under
      the Research License as provided in Section 3.3. As used herein, &#8220;<b>Early Development</b>&#8221; means [***]. For the avoidance of doubt, the foregoing</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">restriction on advancing into Early Development a Compound to any Target shall not apply to:
      (i) Compound generated, researched and/or developed by GNE other than in the course of performing any activities under the Research License, (ii) Compounds in-licensed or acquired by GNE from a Third Party (unless following such in-license or
      acquisition, GNE conducts research on such Compound in the course of performing any activities under the Research License), or (iii) Compounds generated, researched and/or developed by GNE with a Third Party other than in the course of performing any
      activities under the Research License. and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall have the right to terminate the Research License
      in Section 4.1.2(b), in its sole discretion, at any time by providing written notice to Immunocore; such termination to be effective [***] after such notice.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of determining whether GNE has paid to Immunocore an amount equal to or greater
      than [***], the amounts received by Immunocore from GNE for (i) under Sections 7.1, 7.2, 7.3, 7.5, 7.6 and 7.7 shall be included; and (ii) funding or reimbursement of Immunocore FTEs or reimbursement of expenses, in each case under Article 5 or
      Section 7.4, shall be excluded.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, upon termination of the Research License in Section 4.1.1, it is
      understood and agreed by Immunocore and GNE that the Exclusive License and Non-Exclusive License to an Exclusive Target includes the right of GNE to conduct research on Licensed Products and Companion Diagnostics which bind to antigens derived from
      the same Exclusive Target; provided that such research is subject to the same terms and conditions as set forth in Sections 3.3 and 4.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Option Grant/Exclusive License Grant from Immunocore.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Option Grant</b>. Upon receipt of the Initial License
      Fee, Immunocore hereby grants to GNE an option to obtain up to [***] Exclusive Licenses, on an Exclusive Target-by-Exclusive Target basis.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2&#160;&#160;&#160;&#160;&#160;&#160; <b>Option Exercise</b>. GNE may exercise its option to
      obtain individual Exclusive Licenses in accordance with the procedure set forth in Section 4.3 at any time commencing on receipt of Initial License Fee and continuing until the [***] anniversary of the Effective Date (the &#8220;<b>Option Period</b>&#8221;). For
      the avoidance of doubt, GNE may exercise such option repeatedly during the Option Period for up to a maximum of [***] Exclusive Targets, including permitted replacements of Targets in accordance with Section 4.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exclusive License Grant</b>. Upon Acceptance of a
      Proposed Target and payment by GNE of the Exclusive Target Payment (if any) set forth in Section 7.2, Immunocore hereby grants to GNE and Roche an exclusive (even as to Immunocore and its Affiliates), royalty-bearing, right and license, with the
      right to grant sublicenses, under its rights in the (a) Licensed Intellectual Property; (b) Immunocore Foreground IP; and (c) Joint IP, in each case of (a), (b) and (c), to make, use, import, sell and offer for sale Licensed Products and Companion
      Diagnostics (to the extent in each case that such Companion Diagnostics are specific to the Licensed Product) in the Field in the Territory (each, an &#8220;<b>Exclusive License</b>&#8221;).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Non-Exclusive License Grant.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon Acceptance of a Proposed Target, Immunocore hereby
      grants to GNE and Roche a non-exclusive, royalty-bearing, right and license, with the right to grant sublicenses, under its rights in the Background IP (excluding Licensed Intellectual Property) to the extent necessary to make, use, import, sell and
      offer for sale Licensed Products and Companion Diagnostics (to the extent such Companion Diagnostics are not specific to the Licensed Product) in the Field in the Territory (each a &#8220;<b>Non-Exclusive License</b>&#8221;). For clarity, such non-exclusive
      license shall not prevent Immunocore from offering and granting to Third Parties an exclusive license under that portion of the Immunocore Background IP that is specific to a Target (other than the Exclusive Targets).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon Acceptance of a Proposed Target, Immunocore hereby
      grants to GNE and Roche a non-exclusive royalty-bearing, right and license, with the right to grant sublicenses, under its rights in the Background IP to GNE to use the Background IP outside of the Field and to the extent necessary for research,
      development and manufacture of Licensed Products (including transfection of cells with genes encoding TCRs or modified TCRs). For clarity such non-exclusive license shall not include any right to sell any products outside of the Field.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Sublicenses</b>. GNE and Roche shall have the right to
      sublicense the rights granted under Section 4.2.3 and 4.2.4 to its Affiliates or Third Parties; provided that in each case such sublicense:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is consistent with the terms and conditions of this
      Agreement;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is in writing;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; contains obligations on the Sublicensee equivalent to those
      applicable to GNE under Sections 7.3.2(b), 7.5.2, 8.7.1 and 10; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; is granted on an arms length basis for monetary
      consideration and requires the Sublicensee to sell or supply Licensed Products to any Third Party on an arms-length basis.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GNE and Roche shall continue to remain responsible for all reporting obligations under this
      Agreement during the Term. GNE and Roche shall be responsible for all actions and omissions of any Sublicensee including where such actions and omissions result in a breach of the terms of this Agreement. Following the grant of any sublicense to a
      Third Party, GNE or Roche shall notify Immunocore of the identity of such Third Party Sublicensee. For clarity, no grant of any sublicense to a Third Party or an Affiliate shall relieve GNE and Roche of its obligations hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Subcontracting</b>. GNE and Roche shall have right to
      enter into subcontracts with the Third Parties and Affiliates to enable such Third Parties and Affiliates to provide services to or on behalf of GNE and Roche in relation to Licensed Products and Companion Diagnostics. Any subcontract agreement must
      be in writing, consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article 10, and any rights granted to such subcontractor are restricted to only those rights necessary for performance by
      subcontractor of the portions of work on behalf of GNE or Roche. In addition, to the extent such subcontract involves any research under a Research Program or the Research License, such subcontract shall be subject to and granted in accordance with
      Section 3.3. GNE and Roche will remain responsible (at its cost)</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">for all acts or omissions of any subcontractor it appoints (including any acts or omissions
      which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exclusive Targets.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Target Database</b>. Following receipt of the Initial
      License Fee under Section 7.1 and continuing during the Option Period, Immunocore will provide GNE access to an electronic data-room with information on all Targets evaluated by Immunocore and available for nomination as an Exclusive Target from time
      to time (&#8220;<b>Target Database</b>&#8221;). GNE understands and accepts that the same Target Database will be made available to all relevant partners, licensees and potential licensees of Immunocore (each an &#8220;<b>Entity</b>&#8221;). Immunocore and GNE shall work
      together after the Effective Date to provide access to the Target Database, to agree the terms of relevant Research Plans and to provide the Materials under Section 5.1 promptly so as to enable the nomination and Acceptance of the first two (2)
      Exclusive Targets (and the agreed upon written Research Plan for such Exclusive Targets) within [***] after the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exclusive Target Identification</b>. At any time during
      the Option Period, GNE may notify Immunocore in writing in the form set out in Exhibit B that GNE wishes to nominate a particular Target (the &#8220;<b>Proposed Target</b>&#8221;) as an Exclusive Target (&#8220;<b>Nomination Notice</b>&#8221;). The Nomination Notice shall
      become effective on Immunocore on the date Immunocore receives the Nomination Notice.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Proposed Target Available as an Exclusive Target</b>.
      Immunocore shall have a period of [***] within which to accept or reject the Nomination Notice by returning a signed version of the relevant Nomination Notice to GNE specifying whether accepted or rejected, and if rejected, the reasons therefor.
      Immunocore will accept the Nomination Notice (&#8220;<b>Acceptance</b>&#8221;) unless [***], in which case it will reject the Nomination Notice by written notice to GNE. Acceptance shall be deemed to occur on the date of Immunocore&#8217;s signature on the Nomination
      Notice. On Acceptance the Proposed Target shall thereafter be designated as an &#8220;<b>Exclusive Target</b>&#8221;. Upon designation of an Exclusive Target hereunder, Immunocore shall be prohibited from granting any Immunocore Affiliate or any Third Party any
      rights under the Licensed Intellectual Property, Immunocore Foreground IP, Immunocore Background IP and/or Joint IP that would breach the grant of the Exclusive License and/or Non-Exclusive License to such Exclusive Target.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Proposed Target Not Available as an Exclusive Target.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Unavailable Target</b>. If GNE nominated a Proposed
      Target as an Exclusive Target during the Option Period, then Immunocore shall have the right to reject such request if and only if: [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where Immunocore rejects the Nomination Notice, the Proposed Target shall be designated as
      an &#8220;<b>Unavailable Target</b>&#8221;.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Subsequently Available Target.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Unavailable Targets under Section 4.3.4(a)(i)
        and (ii).</b> If an Unavailable Target that was the subject of Section 4.3.4(a)(i) or (ii) above subsequently becomes available for license, Immunocore shall provide prompt written notice to the first Entity in time that (a) previously requested
      such Unavailable Target as a Proposed Target for license by such Entity (each, an &#8220;<b>Available Target</b>&#8221;); and (b) has any further right to request a license to the Available Target. That Entity shall then have a [***] period to nominate the
      Available Target in accordance with the terms for nomination agreed between Immunocore and the relevant Entity. After expiration of the [***] period, if such entity has not provided Immunocore with a relevant Nomination Notice for the Available
      Target, Immunocore shall offer the Available Target to the next Entity in time that previously requested such Available Target and that Entity shall then have a [***] period to nominate the Available Target. This procedure shall continue for the next
      Entity in time using the same procedure as set forth in this Section 4.3.4(b)(i) until the earlier of an Entity taking a license to such Available Target or all Entities reject such Available Target.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Unavailable Targets under Section 4.3.4(a)(iii).</b>
      With respect to an Unavailable Target that was rejected under Section 4.3.4(a)(iii) above, Immunocore hereby agrees that it will not work on such Unavailable Target during the Term, either by itself or in collaboration with a Third Party or
      Immunocore Affiliate, without first offering GNE the opportunity to re-nominate such Target as an Exclusive Target and provided six (6) Exclusive Targets have not previously been Accepted and GNE has no further right to nominate a replacement Target.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Target substitutions</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For Exclusive Targets that have not been previously
      validated by Immunocore, Immunocore shall assess the Tractability of the Exclusive Target following Acceptance. Should Immunocore determine that such Exclusive Target is non-Tractable, ONE may nominate a replacement Target utilizing the same Target
      nomination process as in Section 4.3.2. GNE shall be entitled to nominate such replacement Target, in accordance with Section 4.3.2, for any Target which is found to be non-Tractable without restriction until [***], at which point GNE shall only be
      entitled to nominate one further replacement Target. Should such final replacement Target also be found to be non-Tractable, GNE shall have no further right to nominate any replacement Targets and the number of Exclusive Licenses shall be reduced by
      one.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In addition, if prior to Immunocore&#8217;s initiation of work on
      an Exclusive Target (whether as part of validation under Section 4.3.5(a) or as part of the performance of the Research Plan) GNE provides [***] such Exclusive Target is non-Tractable, then GNE shall [***] have the right to nominate a replacement
      Target utilizing the same Target nomination process as in Section 4.3.2. For the avoidance of doubt, GNE may nominate a replacement Target in accordance with Section 4.3.2 [***]. With respect to any such Exclusive Target for which GNE provides [***]
      such Exclusive Target is technically non-Tractable, Immunocore shall have a royalty-free, non-transferable (subject to Section 16.3), non-sublicenseable, non-exclusive license to use the data provided by GNE to facilitate Immunocore&#8217;s selection and
      determination of which Targets to develop with an Entity. For the avoidance of doubt, Immunocore may not disclose such data to such Entity.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Finally, if, following [***] from Immunocore&#8217;s initiation
      of work on an Exclusive Target (whether as part of validation under Section 4.3.5(a) or as part of the performance of a Research Plan), Immunocore fails to [***], then GNE shall have the right to nominate a replacement Target using Diligent Efforts
      and in accordance with the process as in Section 4.3.2. Such ability to nominate a replacement Target shall apply once [***] no further replacement Target shall be capable of nomination by GNE and the number of Exclusive Licenses shall reduce by one.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For the avoidance of doubt, the Exclusive Target Fee payable
      on Acceptance of an Exclusive Target shall not be payable for any replacement Target nominated in accordance with Sections 4.3.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Additional HLA Types to an Exclusive Target.</b> On an
      Exclusive Target-by-Exclusive Target basis, commencing on initiation of a Research Program to an Exclusive Target and continuing until [***], GNE shall have the right to request Immunocore&#8217;s assistance in developing up to [***] additional Licensed
      Products that bind to antigens derived from the same Exclusive Target but to different HLA-presented antigens derived from the same Exclusive Target by providing a written notification to Immunocore (each a &#8220;<b>Licensed Product/Different HLA Type</b>&#8221;).













      Upon receipt of the written notification, Immunocore and GNE shall in good faith agree upon an additional Research Plan that defines the resources and costs associated with activities for the development of the Licensed Product/Different HLA Type,
      including an agreed upon Immunocore FTE rate. Performance of the agreed additional Research Plan by Immunocore shall be subject to GNE paying for all Immunocore time and effort incurred in performance of the agreed additional Research Plan at the
      agreed FTE rate together with reimbursement of all costs and expenses directly incurred in performance of the agreed additional Research Plan by Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE License.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>License to Immunocore.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE hereby grants to Immunocore a non-exclusive,
      royalty-free, fully paid-up, worldwide license, with the right to sublicense to Third Party Sublicensees, under GNE&#8217;s rights in the GNE Improvement IP and GNE Foreground IP for the purpose of making, having made, selling, supplying, using and
      importing ImmTACs (or products comprising ImmTACs) to any Target other than the Exclusive Targets (the &#8220;<b>Grantback License</b>&#8221;). For clarity, such license does not include any right to manufacture, sell, supply, use or import any products which
      contain GNE&#8217;s CD3 Effector (including anti-CD3 antibodies, antigen-binding fragments thereof and other derivatives and variants).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE hereby also grants to Immunocore and its Third Party
      Sublicensees the right to negotiate with GNE the terms under which GNE may grant Immunocore or its Third Party Sublicensees (as applicable) a non-exclusive, non-sublicensable, royalty bearing, license under the issued Patents within the Manufacturing
      IP, such license to be limited to only those rights necessary to make and use a Compound incorporated in a product comprising an ImmTac (the &#8220;<b>Manufacturing License</b>&#8221;). Immunocore and its Third Party Sublicensees may exercise such right to
      negotiate at any time during the Term, by providing written notice to GNE thereof, such notice to identify (i) the Compounds to be covered; (ii) the Manufacturing IP to be licensed; and (iii) the countries in which such Compound is to be manufactured
      and/or sold.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore or its Third Party Sublicensee (as applicable)
      will have the right for [***] (or such longer period as mutually agreed) following Immunocore&#8217;s or its Third Party Sublicensee&#8217;s (as applicable) written notice to GNE under Section 4.5.1(b) to negotiate in good faith with GNE the commercially
      reasonable terms under which GNE may grant to Immunocore a Manufacturing License.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As used herein, &#8220;<b>Manufacturing IP</b>&#8221; means any issued
      Patents that Cover the manufacture (including without limitation, processes, expression technology, formulations and assays developed for clinical or commercial manufacturing) of a Compound and which inventions claimed by any such Patent were
      conceived or reduced to practice solely by GNE in the course of performance by GNE under the Research License or any Research Program. Where reasonably possible, GNE agrees to notify Immunocore of any Manufacturing IP within [***] of issue of any
      Patent within the Manufacturing IP.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The right to negotiate granted to Immunocore and its Third
      Party Sublicensees under this Section 4.5.1, including without limitation any dispute as to GNE&#8217;s election to grant or not grant Immunocore or its Third Party Sublicensees (as applicable) any rights under the issued Patents within the Manufacturing
      IP, including the scope and/or terms thereof, shall expire at the end of such [***] period from the receipt of the written notice given in accordance to Section 4.5.1(b) (or such longer period as mutually agreed) [***]. Without limiting the
      foregoing, GNE shall have no obligation to grant, and Immunocore and its Third Party Sublicensees shall have no rights to obtain, a license to the issued Patents within the Manufacturing IP if a written agreement on commercially reasonable terms is
      not concluded within such [***] period (or such longer period as mutually agreed). For clarity, such right to negotiate does not include any right to negotiate a licence for the manufacture, sale, supply, use or import of any products which contain
      GNE&#8217;s CD3 Effector (including anti-CD3 antibodies, antigen-binding fragments thereof and other derivatives and variants).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Restrictions on Immunocore Sublicensing.</b> Immunocore
      may sublicense a Third Party Licensee under the Grantback License if and only when such Third Party Licensee grants to Immunocore a license, with the right to sublicense Immunocore licensees (including GNE and Roche) on a non-exclusive basis, under
      its Third Party Improvements, wherein such license contains terms and confers upon Immunocore and its licensees rights thereto substantially similar to the rights granted by GNE to Immunocore under the Grantback License. Immunocore shall use [***]
      efforts to contractually require all of its Third Party Licensees to grant such a license to Immunocore and its other licensees. For clarity, GNE shall have no obligation to disclose any GNE Foreground IP, GNE Improvement IP or Joint IP to any Third
      Party Licensee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Certain Terms.</b> As used herein this Section 4.5:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party Improvements</b>&#8221; means claims within any
      issued patent owned or Controlled by a Third Party Licensee, to the extent such claims (i) cover improvements to ImmTACs or the Immunocore Background IP; and (ii) define an invention conceived or reduced to practice by such Third Party Licensee after
      the effective date of the first agreement granting such Third Party Licensee a license to the Immunocore Background IP; and (iii) to the extent such claims arise from the performance of a license similar to the Research License or from a joint
      research program with Immunocore. Immunocore shall have no obligation to disclose any Third</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Party Improvement to GNE; however, Immunocore shall provide to GNE a confidential list of Third
      Party Licensees, with the date each such Third Party became a Third Party Licensee, for use by GNE to facilitate GNE&#8217;s identification of Third Party Improvements. Such confidential list shall be held by GNE legal department and only accessed by such
      legal department or external legal advisors. Third Party Improvements shall also not cover any improvements to Third Party intellectual property rights where such intellectual property rights are created outside the performance of any agreement
      between the Third Party and Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Third Party Licensee</b>&#8221; means a Third Party to which
      Immunocore has granted a license under the Immunocore Background IP in the Field.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>No Additional Licenses.</b> Except as expressly provided
      in this Agreement, nothing in this Agreement shall grant either Party any right, title or interest in and to the Know-How, Patents or other intellectual property rights of the other Party (either expressly or by implication or estoppel).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 5</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>MATERIALS AND TECHNOLOGY TRANSFER</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Materials.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.1&#160;&#160;&#160;&#160;&#160;&#160; <b>Generally.</b> Each Party shall use Diligent Efforts to
      provide the other Party with the tangible materials and other deliverables specified under the Research Plan (collectively, the &#8220;<b>Materials</b>&#8221;). The JRC shall determine the specific format and timeline for the transfer of such Materials.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Certain Transfers.</b> Without limiting Section 5.1.1:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160; &#160; &#160;&#160;&#160;&#160; Within [***] of the Effective Date, Immunocore shall (at its
      cost) provide to GNE the Materials listed in Exhibit D. GNE shall only use such Materials for internal evaluation purposes only and in accordance with the licences granted under clauses 4.1 and 4.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the Research Term and to the extent not already
      covered by the Research Plan, Immunocore (at its cost and save as provided below) shall provide GNE with ongoing technical assistance related to the research, development and manufacturing of Licensed Products as reasonably requested by GNE. Such
      technical assistance will be limited to no more than [***] of Immunocore time and effort per quarter per Exclusive Target. GNE shall also reimburse Immunocore direct Third Party costs and expenses incurred in providing such assistance. Where
      technical assistance exceeds this maximum number of hours GNE shall reimburse Immunocore its direct costs and expenses and pay Immunocore for its FTE time and effort incurred in providing such technical assistance at Immunocore&#8217;s FTE rate applicable
      at the time of provision. Immunocore shall use reasonable efforts to provide the assistance under this Section 5.1.2(b) as reasonably requested by GNE and in any event as soon &#8216;as such resource can reasonably be made available.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In addition outside of the Research Term, Immunocore shall
      provide GNE with ongoing technical assistance related to the research, development and manufacturing of Licensed Products as reasonably requested by GNE. ONE shall reimburse Immunocore its direct costs and expenses and pay Immunocore for its FTE time
      and effort incurred in providing such</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">technical assistance at Immunocore&#8217;s FTE rate applicable at the time of provision. Immunocore
      shall use reasonable efforts to provide the assistance under this Section 5.1.2(b) as reasonably requested by GNE and in any event as soon as such resource can reasonably be made available.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights of Use.</b> With respect to the Materials
      provided by one Party to another Party pursuant to this Section 5.1, each Party shall have the right to use such Materials for the activities under the Research Program and to exercise the rights granted to such Party pursuant to Article 4. Subject
      to the foregoing, all such Materials (i) shall be used by a Party only in accordance with the terms and conditions of this Agreement; (ii) shall not be used or delivered by a Party to or for the benefit of any Third Party except as expressly provided
      for herein; and (iii) shall be used by a Party in compliance with all Applicable Laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2 &#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Technology Transfer.</b> As part of the research,
      development and manufacturing of Licensed Products, Immunocore will (at its cost) assist GNE in establishing a CMC supply chain and will allow and enable GNE to work with Immunocore&#8217;s designated CMOs. Unless requested otherwise, Immunocore will (at
      its cost and save as provided below) transfer the assay development, manufacturing know-how and GMP manufacture to GNE (or its designated CMO) and will provide technical training sufficient to enable GNE (or its designated CMO) to use such
      manufacturing know-how to make Compounds. GNE shall be responsible for GMP manufacture via GNE&#8217;s internal facilities or Immunocore&#8217;s CMOs. As used herein, &#8220;<b>CMO</b>&#8221; means a Third Party with which a Party has contracted to conduct manufacturing
      (including without limitation, process development and scale-up) of Compounds on behalf of such Party. It is understood and agreed that any such transfer and technical training provided by Immunocore (at its cost) to be limited to no more than [***]
      of Immunocore FTEs per Exclusive Target, with the reasonable direct costs of any such transfer to be fully reimbursed by GNE. Where such allocation has been exceeded, any further assistance by Immunocore shall be subject to agreement between GNE and
      Immunocore as to reimbursement and/or payment for such technical assistance by GNE. Immunocore shall use reasonable efforts to provide the assistance under this Section 5.2 as reasonably requested by GNE and in any event as soon as such resource can
      reasonably be made available.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 6</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>DILIGENCE</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Development and Commercialization of Licensed Products.</b>
      Except with respect to the activities being conducted by the Parties under the Research Programs, as between GNE and Immunocore (i) GNE shall have sole responsibility for and bear all costs for, researching, developing and commercializing Licensed
      Products; and (ii) GNE shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. On an Exclusive Target-by-Exclusive Target basis, GNE agrees to use Diligent
      Efforts to research, develop and commercialize at least one Licensed Product that binds to an HLA-presented antigen derived from each Exclusive Target within the Field in the Territory.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Additional Compounds that bind to HLA-presented antigen
        derived from the same Exclusive Target.</b> Following [***], Immunocore can request in writing to GNE that it desires to discuss the development and commercialization of Subsequent Licensed Products. GNE will respond to Immunocore&#8217;s request within
      a period of [***] with either (a) a plan for when it expects</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">to start development of a Subsequent Licensed Product and which Subsequent Licensed Product
      it is considering; or (b) a schedule to meet and discuss the reasons why it is not intending to develop any further Subsequent Licensed Product.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Progress Reports.</b> Commencing on the dissolution of
      the JRC and continuing thereafter during the Term, GNE shall provide to Immunocore, on or before [***] of such dissolution, [***] written report summarizing GNE&#8217;s progress in the development of the Licensed Products in the [***], [***]; such [***]
      written report to provide Immunocore during the Term with information reasonably necessary to determine GNE&#8217;s progress in developing and commercializing a Licensed Product to such Exclusive Target, including [***]. Immunocore may address questions on
      the [***] reports to the Alliance Managers following receipt of such written reports. Additionally, GNE shall provide to Immunocore[***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 7</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>FINANCIAL TERMS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1&#160; &#160; &#160;&#160; &#160;&#160; <b>Initial License Fee.</b> In consideration of the rights
      granted by Immunocore to GNE and Roche under Article 4 to the Licensed Intellectual Property, Immunocore Background IP, Immunocore Foreground IP and Immunocore&#8217;s interest in Joint IP and the technology transferred by Immunocore to GNE under Article 5
      with respect to the Research Programs, GNE shall pay to Immunocore a one-time-license-fee in the amount of Twenty Million US Dollars ($20,000,000) (&#8220;<b>Initial License Fee</b>&#8221;). Such payment is due as of the Effective Date and shall be made no later
      than fifteen (15) days of the Effective Date, and shall be non-refundable. Such payment shall include the Exclusive Target Payments payable for the first two (2) Exclusive Targets.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exclusive Target Payment.</b> On an Exclusive
      Target-by-Exclusive Target basis, GNE will pay Immunocore the following one-time payments (&#8220;<b>Exclusive Target Payments</b>&#8221;):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 70%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>Exclusive Target</b></td>
        <td style="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>Exclusive Target <br>
            Payment (US$)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GNE shall pay Immunocore the respective Exclusive Target Payment within [***] of Acceptance
      of the relevant Exclusive Target and following receipt of an invoice from Immunocore with respect thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Development and Commercial Event Payments.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>First Licensed Product Events.</b> GNE will pay
      Immunocore the following one-time Event Payments upon each Licensed Product achieving the following Events:</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">26</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td rowspan="2" style="border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>Event</b></td>
        <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>Event Payment (US$)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st </sup>Indication</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd </sup>Indication</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd </sup>Indication</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 43%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="width: 20%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-indent: 21.25pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt"><b>&#160;&#160;[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt"><b>[***]</b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">For the avoidance of doubt, with respect to this Article 7, each Licensed Product [***] Licensed Product. In
      this Section 7.3, &#8220;<b>Indication</b>&#8221; means the intended use of a Licensed Product for either therapeutic treatment or for the prevention of a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function, system,
      tissue type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval is being sought and which
      will be referenced on any Licensed Product labeling in any country. For clarity, label extensions (including without limitation front-line, metastatic, adjuvant, etc.) shall not be deemed to be separate Indications.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Certain Terms.</b> It is understood and agreed that the
      following terms shall apply to the Events achieved under Section 7.3.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payments under Section 7.3.1 shall be due only once for
      each Licensed Product in the first three Indications to achieve such Event for such Indication.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Payments shall be due under Section 7.3.1 by GNE and Roche
      regardless of whether it is GNE or Roche itself that meets the Event (as defined in the table in Section 7.3.1) or where such Event is met through the actions of any Sublicensee. GNE and Roche shall procure that any Sublicensee agrees to notify GNE
      or Roche, as applicable, immediately on any Event being met by such Sublicensee.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; For the avoidance of doubt, GNE and Roche&#8217;s (including where
      such obligation arises as a result of actions by any Sublicensee) cumulative obligation under Section 7.3.1 with respect to the: (i) first Licensed Product binding to a particular HLA-presented antigen derived </font><font style="font: 10pt Times New Roman, Times, Serif">from an Exclusive Target in the first Indication shall in no event exceed [***] per Exclusive Target; (ii) first Licensed Product binding to a particular HLA-presented antigen derived </font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">from an Exclusive Target in the second Indication shall in no event exceed [***] per Exclusive
      Target; and (iii) first Licensed Product binding to a particular HLA-presented antigen derived from an Exclusive Target in the third Indication shall in no event exceed [***] per Exclusive Target. By way of example, if [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If GNE, Roche or a Sublicensee develops a Licensed Product
      binding to a particular HLA -presented antigen derived from an Exclusive Target, after having paid the Event Payment in Section 7.3.1(a) with respect to a Licensed Product binding to a different HLA-presented antigen derived from the same Exclusive
      Target (each a &#8220;<b>Subsequent Licensed Product</b>&#8221;) all of the Event Payments set out above shall remain payable and on such Subsequent Licensed Product achieving the Event set out in Section 7.3.1(a) above, GNE or Roche shall pay to Immunocore
      [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If, for any reason, a particular Event specified in Section
      7.3.1 is achieved without one or more preceding Events having been achieved, then upon the achievement of such Event, both the Event Payment applicable to such achieved Event and the Event Payment(s) applicable to such preceding unachieved Event(s)
      shall be due and payable. For example [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If any Event is merged or combined with any other Event,
      for example a [***] is combined with a [***], the Event shall be achieved when the second Event starts or could reasonably be assumed to have been achieved. For example, [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the payment obligations set forth in Section
      7.3.1 above, Event Payments shall only be due under:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 7.3.1(c), if the Licensed Product that
      achieves such Event is Covered by a Valid Claim [***] at the time of achievement of such Event; provided, if no Valid Claim [***] Covers the Event in Section 7.3.1(c) at the time of achievement of such Event, such Event Payment shall be accrued at
      the time of such achievement, but shall not be due and payable unless and until such time as a Valid Claim [***] Covering such Event occurs. Any obligation to accrue payments under this Section shall cease once all patent applications Covering the
      relevant Licensed Product existing at the date of the Event in Section 7.3.1(c) and which if issued would constitute a Valid Claim have either lapsed, been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or
      other governmental agency of competent jurisdiction, unappealed or appealed within the time allowed for appeal.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Section 7.3.1(d), (e) (f), (g), (h) or (i), if the
      Licensed Product that achieves such event is Covered by a Valid Claim [***] at the time of achievement of such Event.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notice of Achievement; Timing of Payment.</b> With
      respect to each Event referred to in Section 7.3.1, GNE shall inform Immunocore within [***] of the achievement of such Event (whether such Event is achieved by GNE, Roche or its Sublicensees). GNE shall pay Immunocore the respective accrued and
      payable Event Payment within [***] of receipt of an invoice from Immunocore with respect thereto.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore FTE&#8217;s for a Research Program directed to a
        Different HLA Type.</b> With respect to each Research Program for the development of a Licensed Product/Different HLA Type,</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Immunocore shall submit a written invoice to GNE on the first day of each quarter in an
      amount equal to the Immunocore FTEs agreed to under such Research Program. GNE shall pay such invoice within [***] thereof. All Research Program funding shall be used only to conduct the Research Program. At the end of each quarter and on completion
      of the Research Program, GNE and Immunocore shall reconcile that amount of payment made by GNE as against actual number of Immunocore FTEs dedicated to conducting activities under such Research Program. Any unused amount following such reconciliation
      shall be either rolled over to the next quarter (where the Research Program remains ongoing) or repaid to GNE where the relevant Research Program has completed. Any underpayment following such reconciliation shall be paid in addition with the advance
      due for the next quarter under the Research Program. Any expenses incurred by Immunocore and reimbursable under Section 4.4 shall be paid quarterly in arrears and within [***] of receipt of an invoice from Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Net Sales Event Payments.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Net Sales Events.</b> Subject to the terms of Section
      7.5.2, GNE shall pay Immunocore the following one-time Milestone Payments per Licensed Product upon each Licensed Product achieving the following Net Sales Events (whether such achievement is by GNE, Roche or their Sublicensees):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 71%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt"><b>Net Sales Event</b></td>
        <td style="width: 29%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt"><b>Milestone Payment </b><br>
          <b>(in US dollars)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">(a) When annual worldwide Net Sales for such Licensed
          Product first exceeds [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">(b) When annual Net Sales for such Licensed Product first
          exceeds [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">(c) When annual Net Sales for such Licensed Product first
          exceeds [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt"><b>Total Potential Net Sales Event Payments for each
            Licensed Product:</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt"><b>[***]</b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Milestone Payments under this Section 7.5.1 shall be due only once for the first Licensed Product to any
      specific HLA-presented antigen derived from an Exclusive Target. For the avoidance of doubt, GNE, Roche and their Sublicensees cumulative obligation under Section 7.5.1 shall in no event exceed [***] per Licensed Product.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notice of Achievement; Payment.</b> With respect to
      each event listed in Section 7.5.1 above, GNE shall promptly (and in any event within [***] of such Net Sales Event being met) inform Immunocore following the achievement of such event by either GNE, Roche or their Sublicensees. On or after
      Immunocore&#8217;s receipt of such notice of achievement, Immunocore shall submit a written invoice to GNE for the corresponding Milestone Payment. Each such invoice shall specify the applicable Net Sales Event, and shall be payable within [***] of receipt
      of an invoice from Immunocore with respect thereto. To the extent GNE elects to have Immunocore</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">send an invoice to an address other than that specified in Section 16.2, GNE shall provide
      written notice to Immunocore thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Royalty Payments for Licensed Products.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Valid Claim Products.</b> GNE or Roche shall pay
      Immunocore, on a Licensed Product-by-Licensed Product and country-by-country basis, and subject to the terms of Section 7.6.3 through 7.6.6, the following royalties on annual worldwide Net Sales of Licensed Products by GNE, Roche or their
      Sublicensees, which at the time of sale or supply, are Covered by a Valid Claim in the country in which such Licensed Product is sold:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 78%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt"><b>Annual Worldwide Net Sales (in US Dollars)</b></td>
        <td style="width: 22%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt"><b>Royalty Rate Percentage</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt">Up to [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt; padding-left: 5pt">Portion greater than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Know-How Products.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If in any calendar quarter, the sale of a Licensed Product is
      not Covered by a Valid Claim in the country in which such Licensed Product is sold, then GNE or Roche shall pay to Immunocore, on a Licensed Product-by-Licensed Product and country-by-country basis, and subject to the terms of Section 7.6.3 through
      7.6.6, a royalty equivalent to [***] of the amounts specified in Section 7.6.1 on annual worldwide Net Sales of such Licensed Product.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the foregoing, in no event shall GNE, Roche
      or their Sublicensee be obligated to make any royalty payment on the Net Sales of a Licensed Product, where the sale or manufacture of such Licensed Product is not Covered by a Valid Claim in the country in which such Licensed Product was sold, and:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Licensed Product [***]; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Licensed Product was [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For clarity, where notice under Section 1.58(e) is provided more than [***] after the
      Research Term for a given HLA-presented antigen derived from an Exclusive Target, the Parties agree that [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Payment Offsets.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Third Party Payments.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore</b>. Immunocore shall continue to
      have the obligation to make payments owed under written agreements entered into by Immunocore with Third Parties which relate to any Licensed Product, as of the Effective Date or during the Term.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE</b>. If, after the Effective Date, GNE,
      Roche or their Sublicensees obtains a right or license under any intellectual property of a Third Party, where the making, using, selling, offering for sale, or importing of a Licensed Product by GNE, Roche or the relevant Sublicensee would in the
      absence of such right or license infringe the intellectual property of a Third Party, then GNE or Roche may offset the payments due and payable to Immunocore with respect to such Licensed Product by the amount of payments paid by GNE, Roche or its
      Sublicensee to such Third Party for such right or license; provided that in no event shall such reductions reduce the payments owed to Immunocore for such Licensed Product by [***] of what would otherwise be owed by GNE, Roche or their Sublicensee to
      Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Biosimilar</b>. Following the first commercial sale of a
      Biosimilar in a country and:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Biosimilar is Covered by a Valid Claim [***],
      no royalty reduction may be made under this Section 7.6.3(b);</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Biosimilar is Covered by a Valid Claim [***] in
      such country, and such country is [***], and where [***], the royalties due and payable by GNE hereunder shall be reduced by [***] in such country;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Biosimilar is Covered by a Valid Claim in such
      country, [***], and where [***], the royalties due and payable by GNE hereunder shall be reduced by [***] in such country; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Biosimilar is not Covered by a Valid Claim in
      such country, the royalties due and payable by GNE, Roche or their Sublicensee hereunder shall be reduced by [***] in such country [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reduction in royalties under Section 7.6.3(b)(ii) and (iii) shall only apply during the
      period of time that [***] in such country. For the purpose of this Section 7.6.3(b) [***]. As used herein, &#8220;<b>Biosimilar</b>&#8221; means any drug or biological product that is interchangeable directly with any Licensed Product and which is subject to
      review under an abbreviated approval pathway as a biosimilar, follow-on biologic or generic biological product, as those terms are commonly understood under the FD&amp;C Act or the PHS Act and related rules and regulations, or the corresponding or
      similar laws, rules and regulations of any other jurisdiction and (1) where such Biosimilar obtains Regulatory Approval or is otherwise sold by a Third Party that is not GNE, Roche or a Sublicensee; and (2) where GNE, Roche or their Sublicensees have
      not directly authorised or permitted such Third Party to market, manufacture and sell such product in the market in question.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The cumulative reduction made under Sections 7.6.3 (a),
      (b)(ii) and (b)(iii) in a country shall not exceed a total of more than [***] of what would otherwise be owed by GNE to Immunocore in accordance with Sections 7.6.1 and 7.6.2 in such country.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Single Royalty.</b> No more than one royalty payment
      shall be due under this Section 7.6 with respect to a sale of a particular Licensed Product. For the avoidance of doubt: (a) multiple royalties shall not be payable because the sale of a particular Licensed Product is Covered by more than one (1)
      Valid Claim in the country in which such Licensed Product is sold; or (b) in no event shall GNE and/or its Sublicensees be obligated to simultaneously pay a royalty under Section 7.6.1 with respect to a sale of a particular Licensed Product that is
      subject to Section 7.6.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Royalty Term.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The royalty obligations set forth in Section 7.6.1 above
      will commence on a country-by-country basis upon the First Commercial Sale of any Licensed Product, and expire on a country-by-country basis upon the expiration of the last to expire Patent containing a Valid Claim which Covers the sale of such
      Licensed Product in such country. For clarity, if the last Valid Claim Covering the sale of a Licensed Product in a particular country expires prior to [***] anniversary of the date of First Commercial Sale of such Licensed Product in such country,
      royalties shall continue to be payable on the sales of such Licensed Product in such country pursuant to Section 7.6.2 at the rates set forth therein, as applicable, until the [***] anniversary of the date of First Commercial Sale of such Licensed
      Product in such country.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The royalty obligations set forth in Section 7.6.2 above
      will commence on a country-by-country basis upon the First Commercial Sale of any Licensed Product, and expire on a country-by-country basis upon the earlier of (i) [***] anniversary of the date of First Commercial Sale of such Licensed Product in
      such country; or (ii) such time as such Licensed Product is Covered by a Valid Claim in such country, in which case such Licensed Product shall be subject to the royalty term set forth in Section 7.6.1 above. For clarity, in the case of a Licensed
      Product for which a Valid Claim first comes into existence in a particular country after the date of First Commercial Sale in such country, on the date of issuance of such Valid Claim royalties shall continue to be payable on the sales of such
      Licensed Product pursuant to Section 7.6.1 at the rates set forth therein, and expire upon the expiration of such Valid Claim in such country. For the purposes of calculating the [***] period above for each Licensed Product in any country within the
      EU, the [***] period shall start [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6.6&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Rights Following Expiration of Royalty Term</b>. Upon
      expiry of GNE&#8217;s payment obligation hereunder with respect to a Licensed Product in a country, the license in Sections 4.2.3 and 4.2.4 shall be fully paid-up in respect of that Licensed Product in that country.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Companion Diagnostic Sublicensing Revenue.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Revenue Share.</b> GNE or Roche shall pay lmmunocore,
      on a Companion Diagnostic -by- Companion Diagnostic and country-by-country basis, and subject to the terms of Section 7.7.2, a royalty of [***] of the Sublicensing Revenue that Genentech receives from a Companion Diagnostic Sublicensee from the sale
      of a Companion Diagnostic in such country. Notwithstanding the foregoing, in no event shall GNE or Roche be obligated to make any royalty payment on the Sublicensing Revenue of a Companion Diagnostic, where the sale of such Companion Product is not
      Covered by a Valid Claim in the country in which such Companion Product was sold, and:</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Companion Diagnostic was not generated from the direct
      modification of the Compounds described in Section 1.58 (a), (b) or (c) or (e); or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; such Companion Diagnostic was generated solely by GNE,
      Roche or their Sublicensees more than [***] after the Research Term for a given HLA-presented antigen derived from an Exclusive Target.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Certain Terms.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Sublicensing Revenue.</b> &#8220;<b>Sublicensing Revenue</b>&#8221;
      shall mean [***]. Sublicensing Revenues shall exclude: [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Companion Diagnostic Sublicensee</b>&#8221; means a Third
      Party or Affiliate who has been granted a sub-license under either of the Exclusive License or Non-Exclusive License to research, develop and commercialize a Companion Diagnostic, and where such sublicense is in compliance with Section 4.2.5.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Royalty Term for Companion Diagnostics.</b> The royalty
      obligations set forth in Section 7.7.1 above will commence upon the effective date that GNE, Roche or its Sublicensee (as applicable) enters into a written agreement with a Companion Diagnostic Sublicensee, and expire, on a country by country basis,
      upon the later of (i) the expiration of the last to expire Patent containing a Valid Claim which Covers the sale of such Companion Diagnostic in such country, or (ii) [***] anniversary of the date of First Commercial Sale of such Companion Diagnostic
      in such country. For the purposes of calculating the [***] period above for each Licensed Product in any country within the EU, the [***] period shall start [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 8</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>FINANCIAL TERMS; REPORTS; AUDITS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Timing of Royalty Payment.</b> All royalty payments
      shall be made within [***] of the end of each calendar quarter in which the sale was made.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Royalty Report.</b> For each calendar quarter for which
      GNE has an obligation to make royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the following information (&#8220;<b>Net Sales Report</b>&#8221;):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; total Net Sales of all Licensed Products sold in the
      Territory;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Net Sales on a country-by-country basis for all
      Licensed Products sold;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the exchange rate used to convert Net Sales from the
      currency in which they are earned to United States dollars; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the total royalties due to Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If GNE is reporting Net Sales for more than one Licensed Product, the foregoing information
      shall be reported on a Licensed Product-by-Licensed Product basis.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Mode of Payment.</b> All payments hereunder shall be
      made in immediately available funds to the account listed below (or such other account as Immunocore shall designate before such payment is due):</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Currency of Payments.</b> All payments under this
      Agreement shall be made in United States dollars, unless otherwise expressly provided in this Agreement. Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then be converted into an
      amount in United States dollars as follows: (i) with respect to sales by or on behalf of Roche or GNE, use Roche and GNE&#8217;s customary and usual conversion procedures, consistently applied in preparing its audited financial statements; and (ii) with
      respect to sales by or on behalf of a given Sublicensee, using the conversion procedures applicable to payments by such Sublicensee to Roche or GNE for such sales and where such procedures have been agreed prior to the Effective Date or as modified
      by GNE, Roche and its Affiliates ([***]) after the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Blocked Currency.</b> If, at any time, legal
      restrictions prevent Roche, GNE or a Sublicensee from remitting part or all of royalty payments when due with respect to any country in. the Territory where Licensed Products are sold, Roche shall continue to provide Net Sales Reports for such
      royalty payments, and such royalty payments shall continue to accrue in such country, but Roche shall not be obligated to make such royalty payments until such time as payment may be made through reasonable, lawful means or methods that may be
      available, as Roche shall determine.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Taxes.</b> Each Party shall comply with applicable
      laws and regulations regarding filing and reporting for income tax purposes. Neither Party shall treat their relationship under this Agreement as a pass through entity for tax purposes. All payments made under this Agreement shall be made free and
      clear of any and all taxes, duties, levies, fees or other, except for withholding taxes and VAT (if applicable). Any payments subject to withholding or other similar tax shall be subject to the following:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to extent Immunocore is (i) not a publicly held company,
      (ii) has not been acquired, and (iii) has not moved its principal place of business from the United Kingdom to another country, at the time of the payment, GNE, Roche and their Sublicensees shall be entitled to deduct from payments made to Immunocore
      under this Agreement [***] of the amount of any withholding taxes required to be withheld, to the extent paid to the appropriate governmental authority on behalf of Immunocore (and not refunded or reimbursed); and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent Immunocore is (i) a publicly held company
      (including without limitation if Immunocore is under the control of a publicly held company) (ii) has been acquired by another entity, or (iii) has moved its principal place of business from the United Kingdom to another country, at the time of the
      payment, GNE, Roche and their Sublicensees shall be entitled to deduct from payments made to Immunocore under this Agreement the amount of any withholding taxes required to be withheld, to the extent paid to the appropriate governmental authority on
      behalf of Immunocore (and not refunded or reimbursed). GNE or Roche shall deliver to Immunocore, upon request, proof of payment of all such withholding taxes. GNE and Roche (on the one hand) and Immunocore (on the other hand) shall provide reasonable
      assistance to other</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">Party in seeking any benefits available to either Party with respect to government tax
      withholdings by any relevant law, regulation or double tax treaty. All payments made under this Agreement shall be exclusive of VAT (if applicable) and such VAT shall be paid promptly on receipt of a valid VAT invoice.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Records; Inspection.</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Records</b>. GNE and Roche agrees to keep, for [***]
      from the year of creation, records of all sales of Licensed Products for each reporting period in which royalty payments are due, showing sales of Licensed Products for each of GNE, Roche and their Sublicensees and applicable deductions in sufficient
      detail to enable the report provided under Section 8.2 to be verified. GNE and Roche shall procure that its Sublicensees keep records in accordance with this Section.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Audits</b>. Immunocore shall have the right to request
      that such report be verified by an independent, certified and internationally recognized public accounting firm selected by Immunocore and acceptable to GNE (the &#8220;<b>CPA Firm</b>&#8221;). Such right to request a verified report shall (i) be limited to a
      [***] period immediately preceding such request for a verified report; (ii) not be exercised more than once in any calendar year; and (iii) not more frequently than once with respect to records covering any specific period of time. Subject to Section
      8.7.3, GNE shall, upon timely request and at least [***] advance notice from Immunocore and at a mutually agreeable time during its regular business hours, make its records available for inspection by such CPA Firm at such place or places where such
      records are customarily kept, solely to verify the accuracy of the reports provided under Section 8.2 and related payments due under this Agreement. The CPA Firm shall only state factual findings in the audit reports. The draft audit report shall be
      shared with GNE at the same time that it is shared with Immunocore. Following review and approval by all Parties of the draft audit, the final audit report shall be shared with GNE. Roche and Immunocore. GNE and Roche shall procure access to
      Sublicensee records relevant to verify the accuracy of repo1is under section 8.2. relating to such Sublicensee and in accordance with this Section 8.7.2 and shall make such Sublicensee records available to the CPA Firm at the same time and location
      as GNE and Roche&#8217;s own records are made available to the CPA Firm.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Confidentiality</b>. Prior to any audit under Section
      8.7.2, the CPA Firm shall enter into a written confidentiality agreement with GNE and Roche that (i) limits the CPA Firm&#8217;s use of GNE. Roche and their Sublicensee&#8217;s records to the verification purpose described in Section 8.7.2; (ii) limits the
      information that the CPA Finn may disclose to the Immunocore to the numerical summary of payments due and paid; and (iii) prohibits the disclosure of any information contained in such records to any Third Party for any purpose. The Parties agree that
      all information subject to review under Section 8.7.2 and/or provided by the CPA Firm to Immunocore is GNE and Roche&#8217;s Confidential Information, and Immunocore shall not use any such information for any purpose that is not germane to Section 8.7.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Underpayment; Overpayment</b>. After reviewing the CPA
      Firm&#8217;s audit report, GNE shall promptly pay any uncontested, understated amounts due to Immunocore. Any overpayment made by GNE, Roche or any Sublicensee shall be promptly refunded or fully creditable against amounts payable in subsequent payment
      periods, at GNE&#8217;s election. Any audit under Section 8.7.2 shall be at Immunocore&#8217;s expense; provided, however, GNE shall reimburse</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">reasonable audit fees for a given audit if the results of such audit reveal that GNE, Roche and
      any Sublicensee underpaid Immunocore [***] for the audited period [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 9</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <b>INTELLECTUAL PROPERTY; OWNERSHIP</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Definitions</b>. As used herein this Article 9:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Prosecution and Maintenance</b>&#8221; or &#8220;<b>Prosecute and
        Maintain</b>&#8221;, with respect to a particular Patent, means all activities associated with the preparation, filing, prosecution and maintenance of such Patent (and patent application(s) derived from such Patent), as well as re-examinations, reissues,
      applications for patent tem1 adjustments and extensions, supplementary protection certificates and the like with respect to that Patent, together with the conduct of interferences, derivation proceedings, pre- and post-grant proceedings, the defense
      of oppositions and other similar proceedings with respect to that Patent.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Disclosure; Ownership; Inventorship; Assignment and
        Cooperation</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Disclosure</b>. During the Term, each Party shall
      promptly disclose to the other any Foreground IP or Joint IP or GNE Improvement IP conceived, or reduced to practice by or for the disclosing Party. Disclosure will be made via designated patent practitioners representing each Party. Such disclosure
      obligation continues beyond the Term to the extent necessary to obtain patent protection for all inventions within the Foreground IP or Joint IP, and to establish inventorship thereof. In addition, during the Research Term and for the remainder of
      the Term, Immunocore shall promptly following filing by Immunocore disclose to GNE all other Patents within Licensed Intellectual Property in each case to the extent licensed under the Exclusive License.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Ownership</b>. As between the Parties:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore shall solely own the Immunocore Background IP and
      the Immunocore Foreground IP;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore and GNE shall jointly own the Joint IP; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall solely own the GNE Foreground IP and the GNE
      Improvement IP.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Without limiting the foregoing, each Party retains an undivided one-half interest in and to
      the Joint IP (including Patents and Know-How therein). Subject to the licenses granted in Article 4, each Party may exploit fully the Joint IP, in any field, and may grant licenses and sublicenses of the Joint IP without accounting to the other
      Party. Each Party hereby consents explicitly to the granting of sublicenses by the other Party in accordance with this Section 9.2.2. Further, each Party may transfer or encumber its ownership interest, without the need to obtain the consent of
      (consent for such shall be deemed given) and without accounting to the other Party, subject to the licenses granted under Article 4.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Assignment; Cooperation</b>. The assignments necessary
      to accomplish the ownership provisions set forth in this Article 9 are hereby made, and each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation, to implement the
      provisions of this Article 9. Each Party shall to the extent legally possible under relevant national or local laws require all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on its behalf, to assign (or
      otherwise convey rights) to such Party any Patents and Know-How discovered, conceived or reduced to practice by such employee, Affiliate or Third Party, and to cooperate with such Party in connection with obtaining patent protection therefore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>CREATE Act</b>. It is the intention of the Parties that
      this Agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in Public Law 108-53 (the &#8220;<b>Create Act</b>&#8221;). In the event that either Party to this Agreement intends to overcome a rejection of a claimed invention within the Immunocore
      Background IP, the Foreground IP, GNE Improvement IP and/or Joint IP pursuant to the provisions of the Create Act, such Party shall first obtain the prior written consent of the other Party and the Parties shall work together in good faith to agree
      how any rejection should be overcome. To the extent that the Parties agree that, in order to overcome a rejection of a claimed invention within Immunocore Background IP, the Foreground IP, GNE Improvement IP and/or Joint IP pursuant to the provisions
      of the Create Act, the filing of a terminal disclaimer is required or advisable, the Parties shall first agree on terms and conditions under which the patent application subject to such terminal disclaimer and the patent or application over which
      such application is disclaimed shall be jointly enforced, to the extent that the Parties have not previously agreed to such terms and conditions. To the extent that this Section 9.2.4 applies to Licensed Intellectual Property, any obligation under
      this Section will be subject to any Third Party agreements entered into with Immunocore prior to the Effective Date relating to the prosecution or maintenance of such Licensed Intellectual Property and any co-operation or consultation by Immunocore
      under this Section 9.2.4 shall be subject to such Third Party agreements. To the extent that this Section 9.2.4 applies to Immunocore Background IP (excluding Licensed Intellectual Property), any obligation under this Section will be subject to any
      Third Party agreements entered into with Immunocore prior to or after the Effective Date relating to the prosecution or maintenance of such Immunocore Background IP and any co-operation or consultation by Immunocore under this Section 9.2.4 shall be
      subject to such Third Party agreements. In the event that GNE, Roche or their Sublicensee intends to enter into an agreement with a Third Party with respect to the further research, development or commercialization of a Licensed Product and such
      agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in the Create Act, the Parties shall in good faith discuss whether Immunocore shall similarly enter into such agreement with such Third Party purely for the purposes of agreeing
      similar consultation rights in relation to any rejection under the Create Act as contained under this Section 9.2.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Patent Prosecution</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore Controlled Prosecution and Maintenance</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore shall, at its sole discretion and expense, have
      the right (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Background IP. Immunocore shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the
      Immunocore Foreground IP, to the extent it any Patent</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">is not specific to a Licensed Product. Immunocore will provide GNE with copies of any filed
      patent application, filings and other material correspondence with applicable governmental authorities relating to such Immunocore Background IP and such Immunocore Foreground IP, and will keep GNE reasonably informed of the status of such
      Prosecution and Maintenance, including providing GNE copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Immunocore.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE Controlled Prosecution and Maintenance</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall, at its sole discretion and expense, have the right
      (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Foreground IP to the extent such Patents are specific to Licensed Products (excluding Joint IP, which is addressed below in Section 9.3.2(b)), and GNE Foreground IP and
      GNE Improvement IP. GNE will provide Immunocore with copies of any filed patent application, filings and other material correspondence with applicable governmental authorities relating to such Immunocore Foreground IP, GNE Foreground IP and GNE
      Improvement IP and will keep Immunocore reasonably informed of the status of such Prosecution and Maintenance, including providing Immunocore copies of all communications received from or filed in patent offices within a reasonable period of time
      after receipt by GNE. Immunocore will provide all reasonable cooperation and assistance to GNE at GNE&#8217;s reasonable request and at GNE&#8217;s expense in Prosecution and Maintenance of such Patents, including making data, reports, and scientific personnel
      reasonably available to prepare and prosecute patent applications.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall, at its sole discretion and expense, have the right
      (but not the obligation) to Prosecute and Maintain Patents within the Joint IP. GNE will provide Immunocore with a draft copy of any proposed patent application, filings and other material correspondence with applicable governmental authorities
      covering the Joint IP for review and comment prior to filing or prior to submission of any response or communication with applicable governmental authorities and will keep Immunocore reasonably informed of the status of such Prosecution and
      Maintenance, including providing Immunocore copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by GNE. GNE will provide any filings or correspondence for comment by Immunocore where
      possible at least [***] prior to any due date or required response date. GNE will consider all comments provided by Immunocore to GNE prior to any due date or required response date as reasonably possible unless it determines in good faith and on
      advice from its patent attorney that such comments are not appropriate or would materially impact on the ability to obtain a granted patent. Immunocore will provide all reasonable cooperation and assistance to GNE at GNE&#8217;s reasonable request and at
      GNE&#8217;s expense in Prosecution and Maintenance of the Joint IP, including making data, reports, and scientific personnel reasonably available to prepare and prosecute patent applications.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Transfer of Prosecution and Maintenance by GNE</b>. If
      GNE elects not to Prosecute and Maintain any Patents under Section 9.3.2, GNE shall provide at least [***] written notice to Immunocore. Thereafter, Immunocore shall have the right, but not the obligation, to Prosecute and Maintain any notified
      Patents, at its sole expense and in its sole discretion. GNE will provide all cooperation and assistance to Immunocore in relation to such Prosecution and Maintenance. The Party assuming responsibility to Prosecute and Maintain said Patents may elect
      to require transfer of ownership or rights of said Patents at their sole discretion.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Transfer of Prosecution and Maintenance by Immunocore</b>.
      If Immunocore elects not to Prosecute and Maintain any Patents under Section 9.3.1 Immunocore shall provide at least [***] written notice to GNE. Thereafter, GNE shall have the right, but not the obligation, to Prosecute and Maintain any notified
      Patents, at its sole expense and in its sole discretion. Immunocore will provide all cooperation and assistance to GNE in relation to such Prosecution and Maintenance. To the extent this Section relates to Immunocore Background IP, the obligations
      under this Section will be subject to any Third Party agreement entered into by Immunocore whether before or after the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Interferences Between the Parties</b>. If an
      interference or derivation proceeding is declared by the US Patent and Trademark Office between one or more of the Patents within the Immunocore Background IP, Foreground IP, GNE Improvement IP or Joint IP, to the extent directed to a Licensed
      Product and such declared interference or derivation proceeding does not involve any Patents owned by a Third Party, then the Parties shall in good faith establish a mutually agreeable process to resolve such interference or derivation proceeding in
      a reasonable manner in conformance with all applicable legal standards, but which prejudices neither Party nor diminishes the value of such Patents at issue.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Enforcement Rights for Infringement by Third Parties</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notice</b>. Each Party shall promptly notify, in
      writing, the other Party upon learning of any actual or suspected infringement of the Patents within the Immunocore Background IP, Foreground IP, GNE Improvement IP or Joint IP to the extent such actual or suspected infringement is relevant to any
      Exclusive Target or a Licensed Product, or, except for the matters that are subject to Section 9.3.4, of any claim of invalidity, unenforceability, or non-infringement of any Patents within the Background IP (to the extent relevant to any Exclusive
      Target or Licensed Product), Foreground IP, GNE Improvement IP or Joint IP (each an &#8220;<b>Infringement</b>&#8221;). At the request of the Party receiving such notice, the other Party shall use Diligent Efforts to provide all evidence in its possession
      pertaining to the actual or suspected Infringement that it can disclose without breach of a pre-existing obligation to a Third Party or waiver of privilege. In addition each Party shall also use reasonable efforts to notify the other Party upon
      learning of any actual or suspected infringement of the Patents within the Immunocore Background IP, Foreground IP, GNE Improvement IP or Joint IP to the extent such actual or suspected infringement is relevant to any Compound.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Enforcement Actions</b>. The Parties shall consult as
      to potential strategies to terminate suspected or potential Infringement, consistent with the overall goals of this Agreement. If the Parties fail to agree on such strategies:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall have the first right, but not the obligation, to
      seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Section 9.3.2(a) and 9.3.2(b). If GNE does not, within [***] of receipt of a notice under
      Section 9.4.1, take steps to abate the Infringement, then GNE shall provide written notice to Immunocore thereof, and GNE and Immunocore shall discuss the strategy thereof.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore shall have the first right, but not the
      obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Section 9.3.1. If Immunocore does not, within [***] of receipt of a notice
      under Section 9.4.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then GNE shall have the right, but not the obligation, to take action to enforce against such Infringement; provided that if Immunocore
      is diligently pursuing ongoing settlement discussions at the end of such [***] period then GNE shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or Immunocore ceases to pursue such
      discussions diligently. To the extent this Section relates to Immunocore Background IP, the obligations under this Section will be subject to any Third Party agreement entered into by Immunocore whether before or after the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The non-controlling Party shall cooperate with the Party
      controlling any such action to abate or enforce (as may be reasonably requested by the controlling Party and at the controlling Party&#8217;s expense), including, if necessary, by being joined as a party provided that the non-controlling Party shall be
      indemnified by the controlling Party as to any costs or expenses, and shall have the right to be represented by its own counsel at its own expense. The Party controlling any such action shall keep the other Party updated with respect to any such
      action, including providing copies of all documents received or filed in connection with any such action.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Settlement</b>. The Party controlling any such
      enforcement action described in Section 9.4.2 (a &#8220;<b>Section 9.4.2 Enforcement</b>&#8221;), at its sole discretion, may take reasonable actions to terminate any alleged Infringement without litigation; provided, that if any such arrangement would adversely
      affect the non-controlling Party&#8217;s rights under this Agreement, then that arrangement is subject to the non-controlling Party&#8217;s prior written consent. The Party controlling any Section 9.4.2 Enforcement may not settle or consent to an adverse
      judgment without the express written consent of the non-controlling Party (such consent not to be unreasonably withheld or delayed).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Costs and expenses</b>. The Party controlling any
      Section 9.4.2 Enforcement shall bear [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Damages</b>. Unless otherwise mutually agreed by the
      Parties, and subject to the respective indemnity obligations of the Parties set forth in Article 13, all damages, amounts received in settlement, judgment or other monetary awards recovered in Section 9.4.2 Enforcement with respect to activities of
      the Third Party that occurred prior to the effective date of such award shall be shared as follows: [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, if any settlement results in the granting to the alleged
      infringer of a sublicense of any of the Licensed Intellectual Property, Foreground IP or Joint IP with running royalties payable on post-settlement sales by the alleged infringer, such alleged infringer shall be deemed to be a Sublicensee and such
      royalties on post-settlement sales (i) shall be subject to all applicable royalty obligations hereunder, and (ii) shall not be subject to this Section 9.4.5; [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Third Party Infringement Claims.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">40</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notice</b>. In the event that a Third Party shall make
      any claim, give notice, or bring any suit or other inter parties proceeding against GNE or Immunocore, or any of their respective Affiliates or licensees or customers, for infringement or misappropriation of any intellectual property rights with
      respect to the research, development, making, using, selling, offering for sale, import or export of any Licensed Product (&#8220;<b>Third Party Infringement Claim</b>&#8221;), in each case, the Party receiving notice of a Third Party Infringement Claim shall
      promptly notify the other Party and use Diligent Efforts to provide all evidence in its possession pertaining to the claim or suit that it can disclose without breach of a pre-existing obligation to a Third Party or waiver of privilege.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Defense</b>. The Parties shall consult as to potential
      strategies to defend against any Third Party Infringement Claim, consistent with the overall goals of this Agreement, including by being joined as a party. The Parties shall cooperate with each other in all reasonable respects in the defense of any
      Third Party Infringement Claim or raising of any counterclaim related thereto. If the Parties fail to agree on such strategies, and subject to the respective indemnity obligations of the Parties set forth in Article 13, GNE shall be solely
      responsible for defending such Third Party Infringement Claim including but not limited to selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation. If GNE does not, within [***] of receipt of a notice
      under Section 9.5.1, take steps to defend the Third Party Infringement Claim, then to the extent that such Third Party Infringement Claim is brought against Immunocore, Immunocore shall have the right, but not the obligation, to take action to
      enforce or defend against such Third Party Infringement Claim provided that if GNE is diligently pursuing ongoing settlement discussions at the end of such [***] period then Immunocore shall not be permitted to exercise such right unless such
      settlement discussions cease without reaching settlement or GNE ceases to pursue such discussions diligently. At the controlling Party&#8217;s request and expense, the non-controlling Party shall cooperate with the controlling Party in connection with any
      such defense and counterclaim, provided that the non-controlling Party shall be indemnified by the controlling Party as to any costs or expenses, and shall have the right to be represented by its own counsel at its own expense. Any counterclaim or
      other similar action by a Party, to the extent such action involves any enforcement of rights under the Licensed Intellectual Property, Foreground IP or Joint IP, will be treated as an enforcement action subject to Section 9.4. Nothing in this
      Section shall prevent Immunocore from complying with the terms of any court order relating to or arising out of any Third Party Infringement Claim.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Settlement</b>. If any such defense under Section 9.5.2
      would adversely affect the other Party&#8217;s rights under this Agreement or impose a financial obligation upon the other Party or grant rights hi respect, or affect the validity or enforceability, of the other Party&#8217;s Patents or any Joint IP, then any
      settlement, consent judgment or other voluntary final disposition of such Third Party Infringement Claim shall not be entered into without the consent of the other Party (such consent not to be unreasonably withheld).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Costs and expenses</b>. The Party controlling the
      defense of any Third Party Infringement Claim shall bear all costs and expenses, including but not limited to litigation expenses, to defend against any Third Party Infringement Claim.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 10</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>CONFIDENTIALITY</b></font></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Non-use and Non-disclosure of Confidential Information</b>.
      During the Term, and for a period of [***] thereafter, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any Third Party any Confidential Information of the
      other Party; (ii) except in connection with activities contemplated by, the exercise of rights permitted by, in order to further the purposes of this Agreement or otherwise agreed to in writing, not use for any purpose any Confidential Information of
      the other Party; and (iii) take all reasonable precautions to protect the Confidential Information of the other Party (including all precautions a Party employs with respect to its own confidential information of a similar nature).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Exclusions Regarding Confidential Information</b>.
      Notwithstanding anything set forth in this Article 10 to the contrary, the obligations of Section 10.1 above shall not apply to the extent that the Party seeking the benefit of the exclusion can demonstrate that the Confidential Information of the
      other Party:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was already known to the receiving Party, other than under
      an obligation of confidentiality, at the time of receipt by the receiving Party;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was generally available to the public or otherwise part of
      the public domain at the time of its receipt by the receiving Party;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; became generally available to the public or otherwise part
      of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was received by the receiving Party without an obligation of
      confidentiality from a Third Party having the right to disclose such information without restriction;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was independently developed by or for the receiving Party
      without use of or reference to the Confidential Information of the other Party; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; was released from the restrictions set forth in this
      Agreement by express prior written consent of the Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Authorized Disclosures of Confidential Information</b>.
      Notwithstanding the foregoing, a Party may use and disclose the Confidential Information of the other Party as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; if required by law, rule or governmental regulation,
      including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the Party seeking to disclose the Confidential Information of the other Party (i) uses all reasonable
      efforts to inform the other Party prior to making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible, requests confidential treatment of
      such information;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent such use and disclosure is reasonably required
      in the Prosecution and Maintenance of a Patent within the Licensed Intellectual Property, Joint IP or GNE Improvement IP, Foreground IP in accordance with this Agreement;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">42</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; as reasonably necessary to obtain or maintain any Regulatory
      Approval, including to conduct preclinical studies and clinical trials and for pricing approvals, for any Licensed Products, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information
      outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to take any lawful action that it deems necessary to protect
      its interest under, or to enforce compliance with the terms and conditions of, this Agreement; or</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent necessary, to Sublicensees, collaborators,
      vendors, consultants, agents, attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such information in connection with such Party
      performing its obligations or exercising its rights under this Agreement. Further, the receiving Party may disclose Confidential Information to existing or potential acquirers, merger partners, permitted collaborators, Sublicensees and sources of
      financing or to professional advisors (e.g. attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such transaction, collaboration or license and under appropriate conditions of
      confidentiality, only to the extent necessary and with the agreement by those permitted individuals to maintain such Confidential Information in strict confidence.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Return of Confidential Information</b>. Except as
      expressly permitted under this Agreement, following any termination of this Agreement each Party shall upon written request by the other Party promptly destroy all Confidential Information received from the disclosing Party, including any copies
      thereof, (except one copy of which may be retained for archival purposes solely to ensure compliance with the terms of this Agreement).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Terms of this Agreement</b>. The Parties agree that this
      Agreement and the terms hereof will be considered Confidential Information of both Parties.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Prior Agreements</b>. As of the Effective
      Date, as between the Parties, this Agreement supersedes: (i) the Mutual Confidentiality Agreement, effective as of 23 February 2013, by and between GNE and Immunocore, but only insofar as each relates to the subject matter of this Agreement. All &#8220;<b>Confidential













        Information</b>&#8221; or &#8220;<b>Information</b>&#8221; (as defined in such agreements) exchanged between the Parties thereunder relating to the subject matter of this Agreement shall be deemed Confidential Information hereunder and shall be subject to the
      provisions of this Article 10.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>No License</b>. As between the Parties, Confidential
      Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses expressly granted
      under Article 4, under any patent, trade secret or other rights now or hereinafter held by the disclosing Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 11</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>PUBLICITY; PUBLICATIONS; USE OF NAME</b></font></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">43</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Publicity</b>. GNE hereby agrees to Immunocore issuing a
      press release, as set out in Appendix E, concerning the execution of this Agreement upon Acceptance of the first Proposed Target or within [***] from the Effective Date whichever is earlier. The text of any other press releases, public announcements
      and powerpoint presentations concerning this Agreement, the subject matter hereof, or the research, development or commercial results of products hereunder (a &#8220;<b>Release</b>&#8221;) shall be addressed pursuant to Sections 11.2 to 11.5. Any such Release
      shall not include any financial terms of this transaction save in the case of Immunocore for making any announcement in relation to any Event Payment, Milestone or other payment made by GNE to Immunocore under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Releases during the Research Term</b>. Subject to
      Sections 10.2 and 11.5, during the Research Term neither Party may issue a Release without the prior written consent of the other, which consent shall not be unreasonably withheld, conditioned or delayed and any consent or refusal shall be provided
      within [***] of request for such consent. In the absence of any reply to a request for consent within such [***] period, consent shall be deemed given.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Releases after the Research Term</b>. Subject to Sections
      10.2. 11.4 and 11.5, after the Research Term:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.1&#160;&#160;&#160; Immunocore may not issue a Release without GNE&#8217;s prior written
      consent; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3.2&#160;&#160;&#160; GNE may not issue a Release without Immunocore&#8217;s prior written
      consent if it includes reference to Immunocore by name.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In each case, consent shall not be unreasonably withheld, conditioned or delayed and shall
      be provided within [***] of request for such consent.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Approved Releases</b>. If a Release requires consent
      pursuant to Sections 10.3, 11.2 or 11.3, once consent has been given both Parties may make subsequent public disclosure of the contents of such statement without the further approval of the Party whose consent was required; provided, such content is
      not presented with any new data or information or conclusions and/or in a form or manner that materially alters the subject matter therein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Releases required by law or regulation</b>. Each Party may
      issue any Release it is required to issue by applicable law or regulation (including, in the case of Immunocore, any announcements required to satisfy the UK Takeover Panel or the UKLA listing rules).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Publications</b>. Notwithstanding Sections 11.1 to 11.5,
      both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the Compounds or Licensed Products may be beneficial to both
      Parties, provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of inventions and other commercial considerations. Accordingly, the following shall apply with respect
      to papers and presentations proposed for disclosure by either Party:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any paper or presentation proposed for
      disclosure by GNE which utilizes information generated by or on behalf of GNE, so long as such paper or presentation does not contain any Confidential Information of Immunocore, GNE shall be free to make, publish</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">44</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">and disclose such papers and presentations at its discretion. GNE shall acknowledge Immunocore,
      as appropriate, in any publication that discloses GNE&#8217;s use of the Licensed Products or the results of any Research Program. For clarity, GNE shall not be permitted to publish or otherwise disclose any Confidential Information of Immunocore except as
      may be expressly permitted pursuant to Section 10.2, 10.3 or 11.6(b); and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any paper or presentation proposed for
      disclosure by (i) GNE which includes Confidential Information of Immunocore, or (ii) Immunocore which utilizes information generated by or on behalf of Immunocore relating to the Licensed Products, including without limitation any publications
      containing Confidential Information of GNE, (in each case, the &#8220;<b>Disclosing Party</b>&#8221;), the other Party shall have the right to review and approve any such proposed paper or presentation (the &#8220;<b>Non-Disclosing Party</b>&#8221;). The Disclosing Party
      shall submit to the Non-Disclosing Party the proposed publication or presentation (including, without limitation, posters, slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) at least [***] prior to the
      date of submission for publication or the date of presentation, whichever is earlier, of any of such submitted materials. The Non-Disclosing Party shall review such submitted materials and respond to the Disclosing Party as soon as reasonably
      possible, but in any case within [***] for abstracts) of receipt thereof. At the option of the Non-Disclosing Party, the Disclosing Party shall (a) delete from such proposed publication or presentation any Confidential Information of the
      Non-Disclosing Party and/or (b) delay the date of such submission for publication or the date of such presentation for a period of time sufficiently long (but in no event longer than [***] to permit the Non-Disclosing Party to seek appropriate patent
      protection. Once a publication has been approved by the Non-Disclosing Party, the Disclosing Party may make subsequent public disclosure of the contents of such publication without the further approval of the Non-Disclosing Party; provided, such
      content is not presented with any new data or information or conclusions and/or in a form or manner that materially alters the subject matter therein.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>No Right to Use Names</b>. Except as expressly provided
      herein, no right, express or implied, is granted by the Agreement to use in any manner the name of &#8220;<b>Immunocore</b>&#8221;, &#8220;<b>Genentech</b>&#8221;, &#8220;<b>Roche</b>&#8221; or any other trade name, symbol, logo or trademark of the other Party in connection with the
      performance of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 12</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>REPRESENTATIONS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Mutual Representations and Warranties</b>. In this
      Article 12, references to Party or Parties shall mean GNE, Roche and Immunocore. Each Party represents and warrants to the other Party that as of the Effective Date:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it is validly organized under the laws of its jurisdiction
      of incorporation;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it has obtained all necessary consents, approvals and
      authorizations of all governmental authorities and other persons or entities required to be obtained by it in connection with this Agreement;</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the execution, delivery and performance of this Agreement
      have been duly authorized by all necessary corporate action on its part;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it has the legal right and power to enter into this
      Agreement and to fully perform its obligations hereunder;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the performance of its obligations under this Agreement will
      not conflict with such Party&#8217;s charter documents or any Third Party agreement, contract or other arrangement to which such Party is a party; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent relevant to this Agreement it follows
      reasonable commercial practices common in the industry to protect its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and
      to the extent permissable under national or local, laws requiring its employees, consultants and agents to assign to it any and all inventions and discoveries discovered by such employees, consultants or agents made within the scope of, and during
      their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written confidentiality and non-disclosure agreements.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Immunocore Additional Warranty</b>. Immunocore also
      represents and warrants to GNE that:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it has the legal right and power to extend the rights and
      licenses granted to GNE and Roche hereunder;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it will not grant during the term of this Agreement, any
      right, license or interest in or to the Licensed Intellectual Property, Immunocore Foreground IP or Joint IP, or any portion thereof, inconsistent with the rights granted to GNE and Roche herein;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in developing, testing, manufacturing, selling and
      supplying any products being manufacture, developed and/or commercialized under the rights granted by GNE to Immunocore in Section 4.5, it will, and it will procure that its Sublicensees will, comply with all Applicable Laws; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; as of the Effective Date, it has no knowledge of any
      threatened or pending actions, lawsuits, claims or arbitration proceedings in any way relating to the Immunocore Background IP (to the extent relevant to the Licensed Product or Exclusive Target or to performance by GNE of the Research License);
      provided, however, that nothing in this Section 12.2 shall be interpreted as requiring Immunocore to have undertaken any inquiries or to have obtained any freedom to operate opinion.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>GNE and Roche Additional Warranty</b>. GNE and Roche
      also represents and warrants to Immunocore that:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it has the legal right and power to extend the rights and
      licenses granted to Immunocore hereunder; and</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; it will not grant during the term of this Agreement, any
      right, license or interest in or to the GNE Foreground IP, GNE Improvement IP or Joint IP, or any portion thereof, inconsistent with the rights granted to Immunocore herein; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in developing, testing, manufacturing, selling and supplying
      any Licensed Product it will, and it will procure that its Sublicensees will, comply with all Applicable Laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Disclaimers</b>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN
      THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, KNOW-HOW, MATERIALS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR
      IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. NOTHING IN THIS SECTION SHALL PREVENT IMMUNOCORE CLAIMING DAMAGES FOR LOSS OF ROYALTIES ARISING AS A RESULT OF A BREACH OF
      THIS AGREEMENT BY GNE.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 13</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>INDEMNIFICATION</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Indemnification</b>. Under this Article 13, &#8220;<b>Party</b>&#8221;
      and &#8220;<b>Parties</b>&#8221; shall mean GNE, Roche and Immunocore. Subject to Section 13.3, Immunocore shall indemnify, defend and hold GNE, Roche, their Affiliates, their Sublicensees and their respective directors, officers, and employees and the
      successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including, without limitation, reasonable attorneys&#8217; fees and other reasonable expenses of
      litigation) (collectively, &#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221;) arising, directly or indirectly out of or in connection with any Third Party claims, suits, actions, demands or judgments (&#8220;<b>Third Party Claims</b>&#8221;) relating to (a) the activities
      performed by or on behalf of such Party under this Agreement, (b) the activities performed by or on behalf of Immunocore to the extent Covered by any GNE Improvement IP or GNE Foreground IP, including, in the case of Immunocore and its Third Party
      Licensees and subcontractors hereunder, product liability and infringement claims to the extent relating to any products Covered by the GNE Improvement IP or GNE Foreground IP and (c) breach by Immunocore of the representations and warranties under
      Article 12, except, in each case, to the extent caused by the negligence or willful misconduct of GNE, Roche or their Affiliates or Sublicensees or any breach of this Agreement by GNE, Roche or its Affiliates or Sublicensees.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Indemnification</b>. Subject to Section 13.3, GNE and
      Roche shall indemnify, defend and hold Immunocore, its Affiliates and its Third Party licensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all
      Losses arising, directly or indirectly out of or in connection with any Third Party Claims relating to (a) the activities performed by or on behalf of GNE, Roche or any Sublicensee under this Agreement, (b) the activities performed by or on behalf of
      GNE, Roche or any Sublicensee to the extent Covered by any of the Immunocore Background IP, Foreground IP and Joint IP, including, in the case of GNE, Roche and its Affiliates and its and their Sublicensees and subcontractors hereunder, product
      liability and infringement claims to the extent relating to the Licensed Products, (c) breach by GNE, Roche, its Sublicensees or subcontractors of the</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">representations and warranties under Article 12, except, in each case, to the extent caused
      by the negligence or willful misconduct of Immunocore or its Affiliates or breach of this Agreement by Immunocore or its Affiliates.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Procedure</b>. If a Party intends to claim
      indemnification under this Agreement (the &#8220;<b>Indemnitee</b>&#8221;), it shall promptly notify the other Party (the &#8220;<b>Indemnitor</b>&#8221;) in writing of such alleged Loss and the Third Party Claim. The Indemnitor shall have the right to control the defense
      thereof with counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee. Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason, provided, however, that if the Indemnitee shall have
      reasonably concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action, in each of which cases the Indemnitor shall pay the fees and
      expenses of one law firm serving as counsel for the Indemnitee) in relation to such Third Party Claim. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any
      Third Party Claims covered by this Agreement. The obligations of this Article 13 shall not apply to any settlement of any Third Party Claims if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld
      or delayed. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to
      the Indemnitee under this Section 13.2. It is understood that only GNE, Roche and Immunocore may claim indemnity under this Agreement (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity
      hereunder.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Insurance</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.1&#160;&#160;&#160; <b>Insurance Coverage</b>. Subject to Section 13.4.4, each
      Party shall obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business, and in any case sufficient to cover its obligations.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.2&#160;&#160;&#160; <b>Evidence of Insurance</b>. Within [***] of signing this
      Agreement, each Party shall provide the other Party with its certificate of insurance evidencing the insurance coverage set forth Section 13.4.1. Each Party shall provide to the other Party at least [***] prior written notice of any cancellation,
      non-renewal or material change in any of such insurance coverage.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.3&#160;&#160;&#160; <b>Product / Clinical Trial Liability Insurance</b>:
      Commencing not later than [***] prior to the first use in humans of the first Licensed Product by GNE, Roche or any of its Sublicensees, GNE and Roche shall have and maintain such type and amounts of products / clinical trial liability insurance
      covering the development, manufacture, use and sale of Licensed Products as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit per occurrence for products /
      clinical trials liability as follows: (a) a minimum limit of [***] for any period during which GNE, Roche or any of its Sublicensees is conducting a clinical trial(s) with any Licensed Product(s); and (b) a minimum limit of [***] for any period
      during which GNE, Roche or any of its Sublicensees is selling any Licensed Product(s). Each of the above insurance policies shall be primary insurance.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">48</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4.4&#160;&#160;&#160; <b>Election to Self-Insure</b>. In the event that either
      Party is an entity which, together with its Affiliates, has worldwide revenues from pharmaceutical sales in excess of [***], the obligations set forth in Section 13.4.3 (in respect of GNE and Roche only), Section 13.3.1 and Section 13.3.2 above shall
      not apply with respect to such Party, if such Party notifies the other Party in writing that it elects to provide coverage through a commercially reasonable program of self-insurance and such self-insurance in the case of Section 13.4.3 is permitted
      under Applicable Laws; provided, however, that the obligations set forth in Section 13.4.3 (in respect of GNE and Roche only), Section 13.4.1 and Section 13.4.2 above shall resume with respect to such Party and its Affiliates, or
      successor-in-interest and its Affiliates, if such program of self-insurance is terminated or discontinued for any reason.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Limitation of Damages</b>. NEITHER PARTY HERETO WILL BE
      LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF A PARTY&#8217;S
      OBLIGATIONS UNDER ARTICLE 10 OR INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 13 FOR CLAIMS OF THIRD PARTIES. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY OR ANY
      LIABILITY ARISING AS A RESULT OF PERSONAL INJURY OR DEATH CAUSED BY NEGLIGENCE OF ANY PARTY.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 14</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>TERM; TERMINATION</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Term</b>. The term of this Agreement (the &#8220;<b>Term</b>&#8221;)
      shall commence on the Effective Date and, unless sooner terminated as provided in this Article 14, shall continue in full force and effect, on a country-by-country and Licensed Product-by-Licensed Product basis until there is no remaining royalty
      payment or other payment obligation in such country with respect to such Licensed Product, at which time this Agreement shall expire with respect to such Licensed Product in such country. The Term shall expire on the date this Agreement has expired
      in its entirety with respect to all Licensed Products in all countries in the Territory.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination by Either Party for Material Breach</b>.
      Either Party may terminate this Agreement or any Exclusive License by written notice to the other Party for any material breach of this Agreement by the other Party if, in the case of remediable breach, such material breach is not cured within [***]
      ([***] for payment defaults) after the breaching Party receives written notice of such breach from the non-breaching Party; provided, that if such breach is not capable of being cured within such [***] (or [***]) period, the cure period shall be
      extended for such amount of time that the Parties may agree in writing is reasonably necessary to cure such breach, so long as (1) the breaching Party is making Diligent Efforts to do so, and (2) the Parties agree on an extension within such [***]
      (or [***]) period. Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i) whether a breach is material or has occurred or (ii) the alleged failure to cure or remedy such material breach,
      and provides written notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in Article 15, and the notifying Party may not so terminate this Agreement until
      it has been determined under Article 15 that the allegedly breaching</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Party is in material breach of this Agreement, and such breaching Party further fails to cure
      such breach within [***] (or such longer period as determined by the arbiter of such dispute resolution) after the conclusion of that dispute resolution procedure.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination by Either Party for Insolvency or Bankruptcy</b>.
      Either Party may terminate this Agreement effective on written notice to the other Party upon the liquidation, dissolution, winding-up, insolvency, bankruptcy, or filing of any petition therefor, appointment of a receiver, custodian or trustee, or
      any other similar proceeding, by or of the other Party where such petition, appointment or similar proceeding is not dismissed or vacated within [***] an where such petition, appointment or similar proceeding is not a part of any bona fide
      reorganisation of a Party or its Affiliates. All rights and licenses granted pursuant to this Agreement are, for purposes of Section 365(n) of Title 11 of the United States Code or any foreign equivalents thereof (as used in this Section 14.3, &#8220;<b>Title













        11</b>&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Title 11. Each Party in its capacity as a licensor hereunder agrees that, in the event of the commencement of bankruptcy proceedings by or against such bankrupt Party under Title
      11, (a) the other Party, in its capacity as a licensee of rights under this Agreement, shall retain and may fully exercise all of such licensed rights under this Agreement (including as provided in this Section 14.3) and all of its rights and
      elections under Title 11 and (b) the other Party shall be entitled to a complete duplicate of all embodiments of such intellectual property, and such embodiments, if not already in its possession, shall be promptly delivered to the other Party (i)
      upon any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i), immediately upon the rejection of this Agreement by or on
      behalf of the bankrupt Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Permissive Termination</b>. GNE shall also have the
      right to terminate this Agreement in its entirety, or an Exclusive License, in its sole discretion, at any time by providing written notice to Immunocore; such termination to be effective [***] after such notice. Any payments (whether royalties or
      otherwise) which have become due or relate to any Net Sales made prior to date of termination, shall remain due and owing following termination and become immediately payable on termination.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination for [***]</b>. If GNE, Roche or their
      Sublicensees [***], then either (i) GNE, Roche or their Sublicensee shall [***], or (ii) [***], Immunocore shall have the right to terminate the Exclusive License [***] on written notice to GNE; [***]. For the avoidance of doubt, [***]. In addition,
      notwithstanding the foregoing, in the event that [***], then [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Effects of Termination</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Accrued Rights and Obligations</b>. Expiration or
      termination of this Agreement in its entirety, or with respect to a particular Exclusive License, for any reason shall not release either Party hereto from any liability which, as of the effective date of such expiration or termination, had already
      accrued to the other Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event
      occurring prior to the effective date of such expiration or termination.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'imes New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Licenses</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon termination of a particular Exclusive License
      pursuant to Section 14.2, or by GNE pursuant to Section 14.4, such Exclusive License and any other license (including the Non-Exclusive License and Research License) to any Licensed Product or Compound covered by such Exclusive License or binding to
      an HLA-presented antigen derived from the same Exclusive Target (other than the licenses set forth in Section 4.5) shall terminate as of the effective date of such termination;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon termination of the Agreement in its entirety by
      Immunocore pursuant to Section 14.3, all licenses under this Agreement (other than the licenses set forth in Section 4.5) shall terminate as of the effective date of such termination; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon termination of Agreement by GNE in accordance
      with Section 14.2 or 14.3, the licenses set forth in Section 4.5 shall terminate as of the effective date of such termination.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Continuation of Sublicenses</b>. Upon termination by
      Immunocore of this Agreement or any specific Exclusive License, Immunocore agrees that on request from any Sublicensee it will grant to such Sublicensee a license on the same terms as set out in this Agreement (including all event payments and
      royalty payments) in relation to any Immunocore rights previously licensed to such Sublicensee. Unless otherwise explicitly agreed in writing, Immunocore shall not agree to vary or amend the terms of the licenses granted hereunder or take on any
      additional or further obligations or burdens.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Clinical Trials</b>. GNE shall ensure that where
      termination of any Exclusive License occurs during any Clinical Trial, that any Clinical Trial shall be wound down in accordance with the protocol for such Clinical Trial and in such a way as to minimise any patient harm and at all times in
      accordance with all Applicable Laws.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Return of Confidential Information</b>. It is understood
      and agreed, that each Party shall have a continuing right to use Confidential Information of the other Party under any surviving licenses pursuant to Article 4 and/or this Section 14.6 or 14.7. Subject to the foregoing, following expiry or any early
      termination of this Agreement, the Party that has Confidential Information of the other Party shall destroy (at such. Party&#8217;s written request) all such Confidential Information in its possession as of the effective date of expiration (with the
      exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information to confirm compliance with the non-use and non-disclosure provisions of this Agreement),
      and any Confidential Information of the other Party contained in its laboratory notebooks or databases, provided that each Party may retain and continue to use such Confidential Information of the other Party to the extent necessary to exercise any
      surviving rights, licenses or obligations under this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Inventory at Termination</b>. Upon termination of this
      Agreement and for a period of [***] following such termination, GNE and its permitted Sublicensee shall have the right to sell or otherwise dispose of all inventory of Licensed Products in all countries then in its stock, subject to the applicable
      royalty payments due under this Agreement, and any other applicable</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><font style="font: 10pt Times New Roman, Times, Serif">provisions of this Agreement, and Immunocore covenants not to sue GNE or its permitted
      Sublicensee for infringement under any of the Patents that were licensed by Immunocore to GNE immediately prior to such termination with respect to such activities conducted by GNE or its permitted Sublicensee pursuant to this Section 14.5.1(e).
      Following expiry of such [***], GNE shall provide any remaining stock to Immunocore and Immunocore shall be entitled to sell, supply such stock in its absolute discretion either directly or through any Third Party. Save where termination results from
      a material breach by GNE (in which case any stock shall be provided free of charge to Immnunocore), [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Survival</b>. In addition to any provisions specified in
      this Agreement as surviving under the applicable circumstances, the provisions of Articles 1, 9, 10, 11, 12, 13 (provided with respect to Article 12 and 13, only with respect to those claims that arise from the acts or omissions of a Party prior to
      the effective date of termination or expiration) 15 and 16 and Sections 3.6.2, 4.5.1(a), 4.5.2, 4.5.3, 4.6, 5.1.3, 7.6.6, 8.7, 14.1, 14.6, 14.7 shall survive any termination or expiration of this Agreement. In addition, Article 7 and 8 shall survive
      with respect to any outstanding unpaid amounts that accrued prior to any termination or expiration of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of this Agreement or an Exclusive License by
        Immunocore pursuant to Section 14.2 or 14.5, or by GNE pursuant to Section 14.4</b>. In the event of termination of this Agreement or an Exclusive License by Immunocore pursuant to Section 14.2 or 14.5, or GNE pursuant to Section 14.4, GNE shall
      grant to Immunocore a right to negotiate for a license under the Reversion Technology (the &#8220;<b>RFN</b>&#8221;). Immunocore shall have [***] following the effective date of such termination, to notify GNE in writing as to whether Immunocore elects to
      exercise its RFN.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7.1&#160;&#160;&#160; If written notice is given that Immunocore does not want to
      exercise such right to negotiate, or written notice is not given by Immunocore to GNE within said [***], the rights to discuss and/or negotiate granted to Immunocore under this Section 14.7, including without limitation any dispute as to GNE&#8217;s
      election to grant or not grant Immunocore any rights under the Reversion Technology, including the scope and/or terms thereof, shall expire at the end of such [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7.2&#160;&#160;&#160; If GNE receives written notice from Immunocore within such
      [***] that Immunocore elects to exercise such RFN,</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall, within [***] following the date of such
      Immunocore notice, provide copies to Immunocore (at GNE&#8217;s expense): [***], (collectively, the &#8220;<b>Data Package</b>&#8221;). GNE is not required to generate additional data or prepare additional reports to comply with the foregoing obligation;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore will have the right for [***] (or such longer
      period as mutually agreed) following the later of Immunocore&#8217;s election to exercise such RFN or delivery of the Data Package to Immunocore (as applicable) to negotiate in good faith with GNE the commercially reasonable terms under which GNE may grant
      to Immunocore a worldwide, sublicensable license under the Reversion Technology to make, have made, use, sell, offer for sale and import Licensed Products. It is understood and agreed that the grant of such license may be:</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">52</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; exclusive or non-exclusive with respect to one or
      more of the Patents or Know-How within the Reversion Technology (other than the GNE Background Patents) [***]; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; only non-exclusive with respect to one or more of the
      Patents within the GNE Background Patents;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to any license granted by GNE to Immunocore
      under this Section 14.7, Immunocore shall be responsible for manufacturing the products thereunder for clinical use and commercial sale, provided, however, that manufacture of the product [***] by a Third Party contract manufacturing organization
      [***] (the &#8220;<b>Authorized CMO</b>&#8221;). [***]. Immunocore shall enter into a manufacturing supply agreement with the Authorized CMO and shall be responsible for all costs and other obligations related to the manufacture and supply of the products by the
      Authorized CMO to Immunocore;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the Parties are unable to agree on the term of the
      license under Section 14.7(b)(i) within such period, Immunocore may submit such dispute to arbitration for resolution as provided in Section 15.2, as modified by Section 14.7.4 below; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The rights to discuss and/or negotiate granted to
      Immunocore under Section 14.7(b)(ii), including without limitation any dispute as to GNE&#8217;s election to grant or not grant Immunocore any rights under the GNE Background Patents, including the scope and/or terms thereof, shall expire at the end of
      such [***] period (or such longer term as mutually agreed) [***]. Without limiting the foregoing, GNE shall have no obligation to grant, and Immunocore shall have no rights to obtain, a license to the GNE Background Patents if a written agreement on
      commercially reasonable terms is not concluded within such [***] period (or such longer term as mutually agreed).</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7.3&#160;&#160;&#160;&#160;&#160; <b>Certain Terms</b>. In this section 14.7:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>Reversion Technology</b>&#8221; means the GNE Foreground IP,
      Joint IP, GNE Improvement IP, GNE Patents, GNE Know-How, GNE Regulatory Information and GNE Background Patents, that are owned and Controlled by GNE as of the effective date of termination of this Agreement or the Exclusive License, as applicable;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Patents</b>&#8221; means those claims within a Patent in
      which the invention(s) [***];</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Know-How</b>&#8221; means Know-How [***];</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Regulatory Information</b>&#8221; means documents [***];
      and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<b>GNE Background Patents</b>&#8221; means those claims within
      Patents [***].</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.7.4&#160;&#160;&#160; <b>Baseball Arbitration</b>. With respect to any dispute
      under Section 14.7.2(b)(i), which dispute is submitted by Immunocore to arbitration for resolution as provided in Section 15.2, such arbitration shall be modified by as follows:</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">53</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; within [***] following the final selection of the
      arbitrator, the Parties, in consultation with the arbitrator, shall set a date for the arbitration, which date shall be no more than [***] after the date the arbitration is demanded under Section 15.2;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the arbitration shall be &#8220;baseball&#8221; style arbitration;
      accordingly, notwithstanding the Rules, and at least [***] prior to the arbitration, each Party shall provide the arbitrator with a brief outlining its position. Briefs may be no more than [***], and must clearly provide and identify the Party&#8217;s
      position with respect to the disputed matter;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; after receiving both Parties&#8217; opening briefs, the arbitrator
      will distribute each Party&#8217;s brief to the other Party. [***] in advance of the arbitration, the Parties shall submit and exchange response briefs of no more than [***]. The Parties&#8217; briefs may include or attach relevant exhibits in the form of
      documentary evidence, any other material voluntarily disclosed to the other Party in advance, or publicly available information. The Parties&#8217; briefs may also include or attach demonstratives and/or expert opinion based on the permitted documentary
      evidence;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the arbitration shall consist of a [***] hearing of not
      longer than [***], such time to be split equally between the Parties, in the form of presentations by counsel and/or employees and officers of the Parties. No live witnesses shall be permitted except expert witnesses whose opinions were provided with
      the Parties&#8217; briefs; and</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; no later than [***] following the arbitration, the
      arbitrator shall issue his/her written decision. The arbitrator shall select one Party&#8217;s proposed positions as his or her decision, and shall not have the authority to render any substantive decision other than to select the proposal submitted by
      either GNE or Immunocore. The arbitrator shall have no discretion or authority with respect to modifying the positions of the Parties. The arbitrator&#8217;s decision shall be final and binding on the Parties and may be enforced in any court of competent
      jurisdiction. Each Party shall bear its own costs and expenses in connection with such arbitration, and shall share equally the arbitrator&#8217;s fees and expenses.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 15</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>DISPUTE RESOLUTION</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Disputes</b>. &#8220;Party&#8221; or &#8220;Parties&#8221; in this Article 15
      shall mean Roche, GNE and Immunocore. Immunocore and GNE recognize that a dispute, controversy or claim of any nature whatsoever arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, (each, a &#8220;<b>Dispute</b>&#8221;)













      may from time to time arise during the Term. Unless otherwise specifically recited in this Agreement (including without limitation, Section 2.4), such Disputes between Immunocore and GNE will be resolved as recited in this Article 15. In the event of
      the occurrence of such a Dispute, the Parties shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral. If such Dispute is not resolved within such [***]
      period, either Immunocore and GNE may, by written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for attempted resolution within [***] after such notice is received. Such
      designated officers are as follows:</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For GNE &#8211;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [***]</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center">54</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For Immunocore &#8211;&#160;&#160;&#160;&#160;&#160; [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the designated officers, or their respective designees, are not able to resolve
      such dispute within [***] of such other Party&#8217;s receipt of such written notice, either Party may initiate the dispute resolution procedures set forth in Section 15.2.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Arbitration</b>.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.1&#160;&#160;&#160; <b>Rules</b>. Except as otherwise expressly provided in this
      Agreement (including under Section 15.3), the Parties agree that any Dispute not resolved internally by the Parties pursuant to Section 15.1 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in
      accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce (for purposes of this Article 15, the &#8220;<b>Rules</b>&#8221;), except as modified in this Agreement, applying the substantive law specified in Sections 16.1.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.2&#160;&#160;&#160; <b>Arbitrators; Location</b>. Each Party shall select one (1)
      arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator. All three (3) arbitrators shall serve as neutrals and have at least [***] of (a) dispute resolution experience (including judicial experience) and/or (b) legal or
      business experience in the biotech or pharmaceutical industry. In any event, at least one (1) arbitrator shall satisfy the foregoing experience requirement under Section (b). If a Party fails to nominate its arbitrator, or if the Parties&#8217; arbitrators
      cannot agree on the third, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings shall be conducted
      in London, England. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in another language shall be translated into English and accompanied by the original or a true
      copy thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.3&#160;&#160;&#160; <b>Procedures; Awards</b>. Each Party agrees to use
      reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may determine any person as necessary. The arbitrators shall be instructed and required to render a written, binding,
      non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than
      [***] after conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for
      enforcement. Each Party agrees that, notwithstanding any provision of applicable law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.4&#160;&#160;&#160; <b>Costs</b>. The prevailing Party, as determined by the
      arbitrators, shall be entitled to [***]. In determining which Party &#8220;prevailed,&#8221; the arbitrators shall consider (i) the significance, including the financial impact, of the claims prevailed upon and (ii) the scope of claims prevailed upon, in
      comparison to the total scope of the claims at issue. If the arbitrators determine that, given the scope of the arbitration, neither Party &#8220;prevailed,&#8221; the arbitrators shall order that the Parties (1) share equally the fees and expenses of the
      arbitrators and (2) bear their own attorneys&#8217; fees and associated costs and expenses.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.5&#160;&#160;&#160; <b>Interim Equitable Relief</b>. Notwithstanding anything to
      the contrary in this Section 15.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this Article 15, such Party may seek a temporary injunction or other
      interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this Section 15.2. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of
      temporary injunction or other interim equitable relief.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2.6&#160;&#160;&#160; <b>Protective Orders; Arbitrability</b>. At the request of
      either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. The arbitrators shall have the power to decide all questions
      of arbitrability.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Subject Matter Exclusions</b>. Notwithstanding the
      provisions of Section 15.2, any Dispute not resolved internally by the Parties pursuant to Section 15.1 that involves the validity or infringement of a Patent Covering a Licensed Product (a) that is issued in the United States shall be subject to
      actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants resides; and (b) that is issued in any other country shall be
      brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Continued Performance</b>. Provided that this Agreement
      has not terminated, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Article 16</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
      <font style="text-transform: uppercase"><b>MISCELLANEOUS</b></font></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Applicable Law</b>. &#8220;Party&#8221; or &#8220;Parties&#8221; in this Article
      16 shall mean Roche, GNE and Immunocore. This Agreement (including the arbitration provisions of Article 15.2) shall be governed by and interpreted in accordance with the laws of England and Wales, without reference to the principles of conflicts of
      laws. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions contemplated by this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Notices</b>. Except as otherwise expressly provided in
      the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in
      person; (b) on the date of receipt, if sent by a facsimile (with delivery confirmed); or (c) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested. Any notice sent via facsimile shall be
      followed by a copy of such notice by private express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Section 16.2 by sending written
      notice to the other Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If to GNE:</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Genentech, Inc.<br>
    </font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: [***]</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>with required copies (which shall not constitute notice) to:</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genentech, Inc.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If to Immunocore:</b> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore Limited</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Chief Executive Officer</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57 Jubilee Avenue</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abingdon, Oxfordshire, UK</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OX14 4RX</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If to Roche:</b> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;F. Hoffmann-La Roche Ltd</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F. Hoffmann-La Roche Ltd</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: [***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Assignment</b>. Neither Party may assign or otherwise
      transfer, in whole or in part, this Agreement without the prior written consent of the non-assigning Party, such approval not to be unreasonably withheld or delayed. Notwithstanding the foregoing, either Party may assign this Agreement to (i) an
      Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation or re-organisation of such Party with or
      into such corporation or entity, provided that the Party to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement. Immunocore may also transfer the
      Immunocore Background IP and Immunocore Foreground IP to any Affiliate that controls Immunocore and provided that any transfer is explicitly subject to this Agreement. A copy of such written agreement by such assignee shall be provided to the
      non-assigning Party within [***] of execution of such written agreement, subject in each case to any confidentiality restrictions. Subject to the foregoing, this Agreement will benefit and bind the Parties&#8217; successors and assigns.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Non-solicit</b>. Neither Party shall (except with the
      prior written consent of the other Party) knowingly solicit or entice away (or attempt to solicit or entice away) from the employment of the other Party any person employed or engaged by such other Party in the provision of its obligations under any
      Research Program during the course of any Research Program and for a further period of [***] from expiry, termination or completion of such. Research Program; provided that this Section 16.4 shall not apply to advertisements of a general nature
      placed in newspapers, trade publications or online. If either Party does breach this Section 16.4 it agrees and accepts that the other Party will suffer damage and as a minimum it agrees to pay liquidated damages equivalent</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">to two year&#8217;s basic salary or the annual fee that was paid by the other Party to the relevant
      employee. The liquidated damages set out in this Section does not prevent the other Party claiming damages in the ordinary course in relation to a breach of this Section 16.4.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Independent Contractors</b>. The Parties hereto are
      independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Integration</b>. Except to the extent expressly provided
      herein, this Agreement constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the Parties with respect to the subject matter of this
      Agreement (including the Mutual Confidentiality Agreement by and between Immunocore and GNE of 23 February 2012 and term sheets exchanged by and between Immunocore and GNE. Nothing in this Section 16.6 shall exclude any liability for fraud or
      fraudulent misrepresentation. Both Parties confirm that save as explicitly stated in this Agreement they have not relied upon or been induced to enter into this Agreement in reliance upon any warranty or representation made by the other Party, save
      to the extent explicitly set out in this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Amendment; Waiver</b>. Except as otherwise expressly
      provided herein, no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorized representative of both Parties. No course of dealing or failing of either Party to strictly enforce any term,
      right or condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition. The observance of any provision of this Agreement may be waived (either generally or any given instance
      and either retroactively or prospectively) only with the written consent of the Party granting such waiver.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.8&#160;&#160;&#160; &#160; &#160;&#160; <b>Further assurance</b>. Each Party shall and shall use all
      reasonable endeavors to procure that any necessary Third Party shall promptly execute and deliver such further documents and do such further acts as may be required for the purpose of giving full effect to this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Severability</b>. The Parties do not intend to violate
      any public policy or statutory or common law. However, if any sentence, paragraph, section, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph,
      section, clause or combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic purpose and structure of this Agreement.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.10&#160;&#160; &#160; &#160; <b>No Third Party Rights</b>. The Parties do not intend that
      any term of this Agreement should be enforceable by any person who is not a Party.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.11&#160;&#160; &#160;&#160; <b>Construction</b>. The Parties mutually acknowledge that
      they and their attorneys have participated in the negotiation and preparation of this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have drafted this Agreement
      or authorized the ambiguous provision.</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.12&#160;&#160;&#160;&#160;&#160; <b>Interpretation</b>. The captions and headings to this
      Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words &#8220;include&#8221; or
      &#8220;including&#8221; shall be construed as incorporating &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;; (b) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement, including the Exhibits; (c) the word &#8220;law&#8221; or &#8220;laws&#8221;
      means any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal,
      agency, legislative body or other instrumentality of any (i) government or country or territory, (ii) any state, province, county, city or other political subdivision thereof, or (iii) any supranational body); (d) all references to the word &#8220;will&#8221;
      are interchangeable with the word &#8220;shall&#8221; and shall be understood to be imperative or mandatory in nature; (f) the singular shall include the plural and vice versa; and (g) the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;.
      All references to days, months, quarters or years are references to calendar days, calendar months, calendar quarters, or calendar years.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.13&#160;&#160;&#160;&#160;&#160; <b>Counterparts</b>. This Agreement may be executed in two or
      more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. For purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the signature
      pages hereto, will be deemed to be an original. Notwithstanding the foregoing, the Parties shall deliver original execution copies of this Agreement to one another as soon as practicable following execution thereof.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Signature page follows &#8211; the rest of this page intentionally left blank.]</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>. Immunocore, Roche and GNE have executed this Agreement by their
      respective officers hereunto duly authorized, on the Effective Date.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;"><b>IMMUNOCORE LIMITED</b></font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black;"><font style="font-style: normal;">/s/ James Noble</font><br>
        </td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; width: 42%;"><font style="font-family: Times New Roman, Times, Serif;">James Noble<br>
          </font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black;">CEO<br>
        </td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 52%">&#160;</td>
      </tr>

  </table>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;"><b>GENENTECH, INC.</b></font></td>
        <td style="width: 2%;">&#160;</td>
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;"><b>Acknowledged and Accepted</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="width: 2%;">&#160;</td>
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black;"><font style="font-style: normal;">/s/ Robert Andreatta</font><br>
        </td>
        <td style="width: 2%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; font-style: normal;"><font style="font-family: Times New Roman,Times,serif; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">/s/ Richard Scherer</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td style="width: 2%;" rowspan="1">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 44%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; width: 42%;">Robert Andreatta<br>
        </td>
        <td style="width: 2%;">&#160;</td>
        <td colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; width: 44%;"><font style="font-family: Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif">Richard Scherer</font></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td style="width: 2%;" rowspan="1">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black;"><font style="font: 10pt Times New Roman, Times, Serif">VP, Controller &amp; CAO</font></td>
        <td style="width: 2%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; font-style: normal;"><font style="font-family: Times New Roman,Times,serif; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">EVP, Genentech</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td style="width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 44%;">&#160;</td>
      </tr>

  </table>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;"><b>F. HOFFMANN-LA ROCHE LTD</b></font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; font-style: normal;"><font style="font-family: Times New Roman,Times,serif; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">/s/ Christophe Carissimo</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; width: 42%; font-style: normal;"><font style="font-family: Times New Roman, Times, Serif;">Christophe Carissimo</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; font-style: normal;"><font style="font-family: Times New Roman,Times,serif; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">Global Head Transaction Excellence</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 52%">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;"><b>and</b></font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; font-style: normal;"><font style="font-family: Times New Roman,Times,serif; font-weight: normal; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">/s/ Stefan Arnold</font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black; width: 42%;"><font style="font-family: Times New Roman, Times, Serif;"><i><font style="font-style: normal;">Stefan Arnold </font><br>
            </i></font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;"><font style="font-family: Times New Roman, Times, Serif;">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: 1pt solid Black;"><font style="font: 10pt Times New Roman, Times, Serif">Head Legal Pharma<br>
          </font></td>
        <td style="font-family: Times New Roman,serif; width: 52%;"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 4%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 42%;">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 52%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit A </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LICENSED PATENTS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 11%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 24%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 41%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Immunocore-GNE Research Collaboration and License Agreement</font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt; width: 11%">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt; width: 24%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt; width: 24%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt; width: 41%; border-top: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; width: 11%; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; width: 24%; border-top: Black 1pt solid; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; width: 24%; border-top: Black 1pt solid; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; width: 41%; border-top: Black 1pt solid; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt; padding-bottom: 3pt">[***]</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit B </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; Nomination Notice</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the agreement executed on 14<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> June 2013 Genentech hereby nominates the following as an Exclusive Target.</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 33%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-left: 5pt">Date Nominated:</td>
        <td style="width: 67%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-left: 5pt">Target name:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-left: 5pt">Protein identification number:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-left: 5pt; padding-bottom: 80pt">Target protein sequence:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 80pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; padding-left: 5pt">Date received by Immunocore:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><b>Authorized for nomination on behalf of Genentech, Inc</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="width: 35%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 60%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accepted as an Exclusive Target on behalf of Immunocore Limited</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="width: 35%; border-bottom: Black 1pt solid">&#160;</td>
        <td style="width: 60%">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td colspan="2">&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</font></td>
        <td style="border-bottom: Black 1pt solid">&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Immunocore-GNE Research Collaboration and License Agreement</font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit C </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; Research Plan Template</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; background-color: #BFBFBF">
        <td style="width: 49%; border: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center; padding-left: 5pt"><b>Activity</b></td>
        <td style="width: 32%; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b>Immunocore</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b>[***]</b></td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt"><i>[***]</i></td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt"><i>[***]</i></td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: #E7E6E6 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center">[***]</td>
      </tr>

  </table>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: Yellow">[***]</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit D </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; Materials required at Effective Date</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Immunocore-GNE Research Collaboration and License Agreement</font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit E </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; Press Release</font>&#160;</p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Immunocore-GNE Research Collaboration and License Agreement</font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Exhibit F </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8211; Immunocore Sub-contractors</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 47%; font-family: Times New Roman, Times, Serif; text-align: justify; padding-bottom: 3pt"><b>CRO and CMO</b></td>
        <td style="width: 53%; font-family: Times New Roman, Times, Serif; padding-bottom: 3pt"><b>SERVICE</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
        <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 3pt">[***]</td>
      </tr>

  </table>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  &#160;
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: left">
        <td style="width: 100%">
          <p style="font: 10pt Times New Roman,serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Immunocore-GNE Research Collaboration and License Agreement</font></p>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS
          BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font> </p>
    <br>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FIRST AMENDMENT TO THE LICENSE AGREEMENT</b></font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>([***] MAGE-A4)</b></font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>This First Amendment to the License Agreement</b></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&#8220;<b>First Amendment</b>&#8221;) is made and entered into, effective as of September 27, 2016 (&#8220;<b>Amendment Effective Date</b>&#8221;), by and between <font style="font-variant: small-caps"><b>Immunocore










            Limited</b></font>, having its principal place of business at 101 Park Drive, Milton Park, Abingdon, Oxon, United Kingdom OX14 4RY (&#8220;<b>Immunocore</b>&#8221;), on the one hand and, <font style="font-variant: small-caps"><b>Genentech, Inc.</b></font>,
        a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (&#8220;<b>GNE</b>&#8221;) and <font style="font-variant: small-caps"><b>F. Hoffmann-La Roche Ltd</b></font>, with its principal place of
        business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (&#8220;<b>Roche</b>&#8221;), on the other hand.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Background</b></font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Parties entered into a Research, Collaboration and License Agreement
        dated as of June 14 2013 pursuant to which Immunocore and GNE agreed to collaborate in the discovery and development of TCR technology for use in pharmaceutical products (the &#8220;<b>Agreement</b>&#8221;);</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Parties have agreed to amend the Agreement to exclude certain
        compounds and targets; and</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Parties also intend to enter into a separate written agreement
        regarding the rights and obligations of the Parties and the development to be undertaken by Immunocore concerning such excluded compounds and targets.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW THEREFORE</b>, for good and valuable consideration, the receipt and sufficiency of
        which is hereby acknowledged, GNE, Roche and Immunocore agree as follows:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>New Definitions</b>. The following new definition are
        hereby added to the end of Article 1:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.110&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>MAGE-A 4</b>&#8221; means the protein known as
        Melanoma Associated Antigen 4 which has UNIPROT number P43358 and the gene that encodes for such protein.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.111&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Section 1.3 Affiliate</b>. Section 1.3 shall be
        deleted and replaced in its entirety with the following:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;<b>Affiliate</b>&#8221; of a Party, means any company, corporation or other
        business entity that is controlled by, controlling, or under common control with such Party. For purposes of this definition, &#8220;control&#8221; of a business entity (including &#8220;controlled by,&#8221; &#8220;under common control with&#8221; or the like) means direct or
        indirect beneficial ownership of more than fifty percent (50%) interest in the voting stock (or the equivalent) of such business entity or having the right to direct, appoint or remove a majority of members of its board of directors (or their
        equivalents) or having the power to control the general management of such business entity, by law or contract. [***].</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
      <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
        <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Section 1.30 &#8220;EU&#8221;</b>. Section 1.30 shall be deleted
        and replaced in in its entirety with the following:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;&#8220;<b>EU</b>&#8221; means the member states of the European Union
        from time to time, or any successor entity thereto performing similar functions together with, should it cease to be a member state of the European Union, the United Kingdom.&#8221;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Targets</b>. The Targets [***] and/or MAGE-A4 shall
        cease to be considered eligible Targets under the Agreement. For the avoidance of doubt, as of the Amendment Effective Date:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; [***] and MAGE-A4 shall cease to be considered
        Exclusive Targets under the Agreement;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall have no right to nominate [***] and/or
        MAGE-A4 as Proposed Targets, and Immunocore shall have no obligation to Accept [***] and MAGE-A4 as Exclusive Targets, pursuant to Section 4.3;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; GNE shall have no right to nominate [***] and/or
        MAGE-A4 as a replacement Target pursuant to Section 4.3.5; and</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; except as provided in paragraph 7 of this First
        Amendment below, the Research Licenses and Exclusive Licenses granted by Immunocore to GNE and Roche to Compounds to [***] and/or MAGE-A4 pursuant to Sections 4.1.1 and 4.2.3 are hereby terminated. The Parties further agree, that notwithstanding
        the terms of the Agreement, any sublicenses granted by GNE and/or Roche under Section 4.2.3 to Compounds to [***] and/or MAGE-A4 are hereby also terminated.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Section 4.2.1 Option Grant</b>. Section 4.2.1 is
        hereby deleted and replaced in its entirety with the following:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;4.2.1 <b>Option Grant</b>. Immunocore hereby grants to GNE
        an option to obtain up to [***] Exclusive Licenses, on an Exclusive Target-by-Exclusive Target basis. For the avoidance of doubt, the Exclusive Licenses granted by Immunocore to GNE and Roche prior to the Amendment Effective Date shall not be
        considered as an exercise of an option by GNE pursuant to this Section 4.2.1.&#8221;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Section 4.6</b>. The following is added to the end of
        Section 4.6:</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;For the avoidance of doubt, Immunocore and its Sublicensees shall not
        during the Term or subsequently, have any right or license under: (i) the GNE Improvement IP to make, have made, sell, offer for sale, supply, use and import ImmTACs (or products comprising ImmTACs) to MAGE-A4 or [***], and (ii) the Manufacturing
        IP to make and use a Compound incorporated in a product comprising an ImmTac to either [***] or [***]; in each case of (i) and (ii), unless and until Immunocore exercises it right of negotiation and obtains a license to such intellectual property
        pursuant to Section 4.5.&#8221;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" id="z42296507580e4575b55528f6b9cedbf3" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top">
          <td style="width: 100%; padding-right: 0; padding-left: 0; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked
                by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></td>
        </tr>

    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
    <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
      <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
        <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Exclusive Targets Payments</b>. The payments set out
        in Section 7.2 of the Existing Agreement shall apply to each Exclusive Target Acceptance after the Amendment Effective Date, taking into account that the MAGE-A4 and [***] Targets were the [***].</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Research Licence</b>. Commencing on the Amendment
        Effective Date and continuing until the date [***] from the Amendment Effective Date, Immunocore hereby grants to GNE a royalty-free, non-transferable, non-sublicenseable, non-exclusive research license under Immunocore&#8217;s rights in the Immunocore
        Background IP, the Immunocore Foreground IP, and the Joint IP solely for the purposes of completing any research related to MAGE-A4 and [***] being undertaken by GNE as at the Amendment Effective Date pursuant to the licence set out in Section
        4.1.1(a) of the Existing Agreement for the purpose of jointly publishing the results. The Alliance Managers will be responsible for jointly agreeing any research and publication to be undertaken pursuant to this licence. Section 11.6 of the
        Agreement shall apply to any publication or disclosure of papers, presentations, abstracts or other written or oral presentation regarding results of and other information generated by GNE as a result of the exercise of its rights pursuant to this
        paragraph 7 except that in the event that of any disagreement by the Parties concerning such publication, the matter shall be referred for determination by the Alliance Managers.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Indemnification</b>. It is understood and agreed, that
        the indemnification obligations of the Parties pursuant to Article 13 shall continue to survive in full force and effect with respect to any acts or omissions of a Party that occurred prior to the Amendment Effective Date, including without
        limitation and acts or omissions that occurred prior to Amendment Effective Date relating to [***] and/or MAGE-A4.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Survival of Agreement Terms</b>. All terms and
        conditions of the Agreement not modified by this First Amendment shall continue in full force and effect in accordance with their terms. All capitalized terms not otherwise defined herein shall have the same definition as in the Agreement. In the
        event of any conflict between the terms and conditions of this First Amendment and the Agreement, the terms and conditions set forth in this First Amendment shall control with respect to the subject matter hereof.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Signature page follows &#8211; the rest of this page intentionally left
          blank]</b></font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
    <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" id="z73fd5b28982b4047abf07c7fdebb76b3" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top">
          <td style="width: 100%; padding-right: 0; padding-left: 0; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked
                by <font style="text-transform: uppercase">[***]</font>, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></td>
        </tr>

    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
      <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
        <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Execution Version&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, Immunocore, Roche and GNE have executed this First Amendment by
        their respective officers hereunto duly authorized, on the Amendment Effective Date.</font></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z7951992ff15e45be9493a43e513050d8" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 100%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMUNOCORE LIMITED</b></font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="ze1f61f37020840ce868ce1ee359fca15" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
            </font></td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z676589ddb7154079aa155a243013ca81" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</font></td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
            </font></td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z0428e85edbf94c0b93ecf9cc1c0ec51d" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#160;</font></td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br>
            </font></td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z9205cb42f46e4ad6ba9154544529f4e6" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 100%; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENENTECH, INC.</b></font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z3c7d4200afb54d1db907c3ec24d22733" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </font></td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Edward Harrington</font></td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z4fcda6f3d0644d22a543b31126973dbb" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: <br>
            </font></td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Edward Harrington</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="zc66031b883a54e2d96ce052798098ebd" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0">
            <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
              </font></div>
            <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &#160;</font></div>
          </td>
          <td style="width: 47%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0">
            <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
              </font></div>
            <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></div>
          </td>
          <td style="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z39f9cbe379804183b70dfe0de3a26334" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 100%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F. HOFFMANN-LA ROCHE LTD</b></font></td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="z4bd129ad22864699885bd6b630676e4a" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Melanie Wick<br>
            </font></td>
          <td style="width: 4%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0">/s/ Stefan Arnold<br>
          </td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="zf8ffe56a37094b27915db090364f2a14" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Melanie Wick<br>
            </font></td>
          <td style="width: 4%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0">Stefan Arnold<br>
          </td>
        </tr>

    </table>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
    <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" id="zcafa43e807844a8f8d5aa495d52a7513" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#160;</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory<br>
            </font></td>
          <td style="width: 4%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
          <td style="width: 3%; font: 10pt Times New Roman, Times, Serif; padding-top: 0; padding-bottom: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&#160;</font></td>
          <td style="width: 45%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-top: 0; padding-bottom: 0">Head Legal Pharma<br>
          </td>
        </tr>

    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>5
<FILENAME>nt10016217x4_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;"><a name="z_mps776490560000000000000007363000000000"></a>Exhibit 10.6</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR
        CONFIDENTIAL.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Dated June 29, 2013</div>
      <div>&#160;</div>
      <div style="text-align: center;"><font style="font-weight: bold;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">IMMUNOCORE LIMITED</font></div>
      <div>&#160;</div>
      <div style="text-align: center;">and</div>
      <div>&#160;</div>
      <div style="text-align: center;"><font style="font-weight: bold;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">GlaxoSmithKline Intellectual Property Development Ltd</font></div>
      <div>&#160;</div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 60%; color: #000000; text-align: center;" align="center" noshade="noshade">
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">COLLABORATION AND LICENSE AGREEMENT</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 60%; color: #000000; text-align: center;" align="center" noshade="noshade"></div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: justify;"><font style="font-weight: bold;">THIS AGREEMENT </font>is made and effective as of June 29, 2013 (the <font style="font-weight: bold;">&#8220;Effective Date</font><font style="color: rgb(31, 31, 38);">&#8221;</font>)</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">BETWEEN</div>
      <div>&#160;</div>
      <table id="z73a57b15420a4c3db5211c46144cf643" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">IMMUNOCORE LIMITED </font>(registered number 6456207<font style="color: rgb(31, 31, 38);">) </font>wh<font style="color: rgb(31, 31, 38);">o</font>se registered office is at 57c Milton Park, Abingdon,
                Oxfordshire, OX14 4RX, U<font style="color: rgb(31, 31, 38);">n</font>ited <font style="color: rgb(54, 54, 66);">K</font>ingdom (&#8220;<font style="font-weight: bold;">Im</font><font style="font-weight: bold; color: rgb(54, 54, 66);">m</font><font style="font-weight: bold;">unocore</font>&#8221;)<font style="color: rgb(31, 31, 38);">;</font><font style="font-weight: bold;">&#160;</font>and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z474ab5cd7abc4c309dcabbf919222cb0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">GlaxoSmithKline Intellectual Property Devel</font><font style="font-weight: bold; color: #1F1F26;">op</font><font style="font-weight: bold;">ment Ltd </font>whose r<font style="color: rgb(31, 31, 38);">e</font>g<font style="color: rgb(31, 31, 38);">is</font>tered office is at 980 Great West Road, Middlesex, TW8 9GS, <font style="color: rgb(31, 31, 38);">U</font><font style="color: rgb(54, 54, 66);">n</font>ited Kingdom (&#8220;<font style="font-weight: bold;">G</font><font style="font-weight: bold; color: rgb(31, 31, 38);">S</font><font style="font-weight: bold;">K</font><font style="color: rgb(31, 31, 38);">&#8221;</font>)</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; color: #070707; font-weight: bold;">BACKGROUND</div>
      <div>&#160;</div>
      <table id="zaaba50974d7c4978af16ad03be4532aa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; color: #070707;">A.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">GSK and its Affiliates are a global pharmaceutical company with expertise in the research, development, manufacturing and commercialization of human pharmaceuticals.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z664cfa53a04543c195281f325d91ba6c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; color: #070707;">B.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Immunocore has extensive experience and intellectual property rights relating to the development of specifically targeted Compounds (as defined further below).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z928499822ff24eb98ab24322b0c2d417" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; color: #070707;">C.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">GSK and Immunocore wish to collaborate to develop further Compounds and Immunocore desires to grant to GSK exclusive options to obtain exclusive licenses to Immunocore&#8217;s intellectual property rights to
                further develop and commercialize Licensed Products (as defined below), in each case on the terms and conditions set out below.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">OPERATIVE PROVI</font><font style="color: #1F1F26;">S</font><font style="color: #070707;">I</font><font style="color: #1F1F26;">ON</font><font style="color: #070707;">S</font></div>
      <div>&#160;</div>
      <table id="z4f69ccbb771e47cab68267f7e230f7a6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Definitio<font style="color: rgb(31, 31, 38);">n</font>s <font style="color: rgb(31, 31, 38);">a</font>n<font style="color: rgb(31, 31, 38);">d </font>Int<font style="color: rgb(31, 31, 38);">er</font>p<font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">e</font>tat<font style="color: rgb(31, 31, 38);">ion</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8c507dbfcc1346489ffb0eae8b7465d1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In this <font style="color: rgb(54, 54, 66);">A</font><font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(54, 54, 66);">ree</font><font style="color: rgb(31, 31, 38);">m</font>en<font style="color: rgb(31, 31, 38);">t
                </font>th<font style="color: rgb(54, 54, 66);">e </font>fo<font style="color: rgb(31, 31, 38);">ll</font>o<font style="color: rgb(31, 31, 38);">wing </font>word<font style="color: rgb(31, 31, 38);">s </font>a<font style="color: rgb(54, 54, 66);">n</font>d expr<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(54, 54, 66);">ss</font>io<font style="color: rgb(31, 31, 38);">ns </font>hav<font style="color: rgb(31, 31, 38);">e </font>the meaning set
                opposite:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="margin-left: 36pt;">
        <table id="z07402255ecc14d08a38272456d92c4b0" style="border-collapse: collapse; width: 70%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Act</font><font style="color: #1F1F26;">i</font><font style="color: #070707;">on</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1F1F26;">h</font><font style="color: #363642;">as </font><font style="color: #070707;">th</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">meani</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">g set forth in Section 7.4.2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Affi</font><font style="color: #1F1F26;">li</font><font style="color: #070707;">ate</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">means any company or other entity which directly or indirectly controls, is controlled by or is under common control with either Party, where &#8216;control&#8217; means the ownership of more than 50% of the issued
                  share capital or other equity interest (or such lesser percentage which is the maximum allowed to be owned by an entity in a particular jurisdiction) or the legal power to direct or cause the direction of the general management and
                  policies of the relevant Party or such company or other entity; Adaptimmune shall not be considered to be an Affiliate of Immunocore for the purposes of this Agreement.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Alliance Manager</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has the meaning set forth in Section 4.11;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Applicable Laws</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 7);">means all laws, rules and regulations and guidelines which are in force during the term of this Agreement and in any jurisdiction in which the Collaboration Program is performed or in</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="zfc74632109ab467ba4044ee51d3004ce" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">which any Licensed Pro</font><font style="color: #1F1F26;">du</font><font style="color: #070707;">ct i</font><font style="color: #1F1F26;">s </font><font style="color: #070707;">manufactured, sold or supplied to the ext</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">nt </font><font style="color: #1F1F26;">i</font><font style="color: #363642;">n </font><font style="color: #070707;">each case a</font><font style="color: #1F1F26;">ppl</font><font style="color: #070707;">icable to any Party to this Ag</font><font style="color: #1F1F26;">reem</font><font style="color: #070707;">ent;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Assignment Agreement</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the As</font><font style="color: #1F1F26;">sig</font><font style="color: #363642;">n</font><font style="color: #070707;">ment and Exclu</font><font style="color: #363642;">s</font><font style="color: #070707;">iv</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">License between Immunocore and Ad</font><font style="color: #1F1F26;">apt</font><font style="color: #070707;">immune






                    Ltd (&#8220;</font><font style="font-weight: bold; color: #070707;">Adaptimm</font><font style="font-weight: bold; color: #1F1F26;">u</font><font style="font-weight: bold; color: #363642;">n</font><font style="font-weight: bold; color: #1F1F26;">e</font><font style="color: #1F1F26;">&#8221;) </font><font style="color: #070707;">d</font><font style="color: #1F1F26;">ate</font><font style="color: #070707;">d May 20</font><font style="color: #1F1F26;">, 201</font><font style="color: #070707;">3;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Background</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means any </font><font style="color: #1F1F26;">I</font><font style="color: #363642;">n</font><font style="color: #070707;">t</font><font style="color: #1F1F26;">ell</font><font style="color: #070707;">ect</font><font style="color: #1F1F26;">u</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">l Pr</font><font style="color: #070707;">ope</font><font style="color: #1F1F26;">rt</font><font style="color: #363642;">y </font><font style="color: #070707;">Ri</font><font style="color: #363642;">g</font><font style="color: #070707;">hts </font><font style="color: #363642;">e</font><font style="color: #1F1F26;">x</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">s</font><font style="color: #070707;">t</font><font style="color: #1F1F26;">in</font><font style="color: #070707;">g at the Effe</font><font style="color: #363642;">c</font><font style="color: #1F1F26;">t</font><font style="color: #070707;">iv</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">Dat</font><font style="color: #1F1F26;">e of </font><font style="color: #363642;">t</font><font style="color: #1F1F26;">h</font><font style="color: #363642;">i</font><font style="color: #070707;">s A</font><font style="color: #1F1F26;">gre</font><font style="color: #363642;">e</font><font style="color: #1F1F26;">m</font><font style="color: #070707;">ent;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Biosimilar Application</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">has </font><font style="color: #363642;">t</font><font style="color: #070707;">h</font><font style="color: #1F1F26;">e me</font><font style="color: #070707;">ani</font><font style="color: #1F1F26;">ng set </font><font style="color: #070707;">fort</font><font style="color: #1F1F26;">h in </font><font style="color: #070707;">Sectio</font><font style="color: #1F1F26;">n 7.4</font><font style="color: #363642;">.</font><font style="color: #070707;">1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Biosimilar Product</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1F1F26;">me</font><font style="color: #363642;">an</font><font style="color: #1F1F26;">s </font><font style="color: #070707;">any </font><font style="color: #1F1F26;">prod</font><font style="color: #070707;">uct </font><font style="color: #363642;">w</font><font style="color: #070707;">h</font><font style="color: #1F1F26;">ich </font><font style="color: #070707;">is fou</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">d </font><font style="color: #1F1F26;">in </font><font style="color: #070707;">any country t</font><font style="color: #1F1F26;">o </font><font style="color: #070707;">be i</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">terchangea</font><font style="color: #1F1F26;">ble </font><font style="color: #070707;">with </font><font style="color: #1F1F26;">or </font><font style="color: #070707;">bi</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">similar to any </font><font style="color: #1F1F26;">Li</font><font style="color: #363642;">c</font><font style="color: #070707;">ensed </font><font style="color: #1F1F26;">Product a</font><font style="color: #070707;">nd whi</font><font style="color: #1F1F26;">c</font><font style="color: #363642;">h </font><font style="color: #070707;">as </font><font style="color: #363642;">a </font><font style="color: #070707;">resu</font><font style="color: #1F1F26;">lt </font><font style="color: #070707;">is subject </font><font style="color: #363642;">t</font><font style="color: #1F1F26;">o </font><font style="color: #070707;">an </font><font style="color: #363642;">a</font><font style="color: #1F1F26;">b</font><font style="color: #070707;">brevi</font><font style="color: #1F1F26;">at</font><font style="color: #070707;">e</font><font style="color: #1F1F26;">d ma</font><font style="color: #070707;">rketing </font><font style="color: #1F1F26;">au</font><font style="color: #070707;">thoris</font><font style="color: #1F1F26;">ation, </font><font style="color: #070707;">or any pro</font><font style="color: #1F1F26;">du</font><font style="color: #363642;">c</font><font style="color: #1F1F26;">t </font><font style="color: #070707;">which </font><font style="color: #1F1F26;">con</font><font style="color: #070707;">t</font><font style="color: #363642;">a</font><font style="color: #070707;">in</font><font style="color: #1F1F26;">s th</font><font style="color: #070707;">e </font><font style="color: #1F1F26;">s</font><font style="color: #070707;">ame </font><font style="color: #1F1F26;">ac</font><font style="color: #070707;">tive
                    ingredient as t</font><font style="color: #1F1F26;">he </font><font style="color: #070707;">activ</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">ingredie</font><font style="color: #1F1F26;">n</font><font style="color: #363642;">t </font><font style="color: #070707;">i</font><font style="color: #1F1F26;">n t</font><font style="color: #070707;">he Lice</font><font style="color: #1F1F26;">nse</font><font style="color: #363642;">d </font><font style="color: #070707;">Produ</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">t;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">BPC&amp;I Act</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means </font><font style="color: #1F1F26;">t</font><font style="color: #363642;">h</font><font style="color: #070707;">e Biolo</font><font style="color: #1F1F26;">gi</font><font style="color: #363642;">c</font><font style="color: #1F1F26;">s </font><font style="color: #070707;">Price </font><font style="color: #1F1F26;">C</font><font style="color: #363642;">o</font><font style="color: #1F1F26;">m</font><font style="color: #070707;">petition and </font><font style="color: #1F1F26;">In</font><font style="color: #070707;">no</font><font style="color: #1F1F26;">va</font><font style="color: #070707;">t</font><font style="color: #1F1F26;">i</font><font style="color: #363642;">o</font><font style="color: #1F1F26;">n </font><font style="color: #070707;">Act of </font><font style="color: #1F1F26;">20</font><font style="color: #363642;">0</font><font style="color: #070707;">9, an</font><font style="color: #1F1F26;">d a</font><font style="color: #363642;">p</font><font style="color: #1F1F26;">p</font><font style="color: #070707;">l</font><font style="color: #1F1F26;">ic</font><font style="color: #070707;">able regulations
                    pro</font><font style="color: #1F1F26;">mu</font><font style="color: #070707;">lg</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">ted </font><font style="color: #1F1F26;">the</font><font style="color: #070707;">reunder, </font><font style="color: #363642;">as </font><font style="color: #1F1F26;">a</font><font style="color: #363642;">me</font><font style="color: #070707;">nded from time to ti</font><font style="color: #1F1F26;">m</font><font style="color: #363642;">e;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Business D</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">y</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1F1F26;">me</font><font style="color: #070707;">ans </font><font style="color: #363642;">a </font><font style="color: #1F1F26;">d</font><font style="color: #070707;">a</font><font style="color: #363642;">y </font><font style="color: #070707;">on w</font><font style="color: #363642;">h</font><font style="color: #1F1F26;">i</font><font style="color: #363642;">c</font><font style="color: #070707;">h banking
                    institutions in Londo</font><font style="color: #1F1F26;">n</font><font style="color: #363642;">, </font><font style="color: #1F1F26;">Eng</font><font style="color: #070707;">land </font><font style="color: #363642;">are </font><font style="color: #070707;">open for business</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">but exclu</font><font style="color: #363642;">d</font><font style="color: #070707;">i</font><font style="color: #1F1F26;">ng </font><font style="color: #070707;">the ni</font><font style="color: #363642;">n</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">(</font><font style="color: #363642;">9</font><font style="color: #070707;">) consecutive calendar days beginnin</font><font style="color: #363642;">g </font><font style="color: #070707;">on Dec</font><font style="color: #363642;">e</font><font style="color: #070707;">mber 24th and
                    continuing t</font><font style="color: #1F1F26;">hro</font><font style="color: #070707;">u</font><font style="color: #1F1F26;">g</font><font style="color: #070707;">h Janua</font><font style="color: #363642;">r</font><font style="color: #070707;">y 1st of each calendar year during t</font><font style="color: #363642;">he T</font><font style="color: #070707;">erm, </font><font style="color: #4D4D59;">a</font><font style="color: #1F1F26;">n</font><font style="color: #363642;">d </font><font style="color: #070707;">all Saturday</font><font style="color: #1F1F26;">s </font><font style="color: #070707;">and Sundays;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">CDA</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">has the m</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">ing </font><font style="color: #1F1F26;">s</font><font style="color: #070707;">et forth in Section 10.7;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Claims</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means all suits, demands</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">claims, actions, proceedings, or liabilities (whether criminal or civil and
                    whether arising under cont</font><font style="color: #1F1F26;">r</font><font style="color: #070707;">a</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">t, tort or under statute </font><font style="color: #1F1F26;">o</font><font style="color: #070707;">r otherwise) made by </font><font style="color: #1F1F26;">a </font><font style="color: #070707;">Th</font><font style="color: #1F1F26;">i</font><font style="color: #070707;">rd Party;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Clari</font><font style="color: #1F1F26;">fic</font><font style="color: #070707;">ation A</font><font style="color: #1F1F26;">gr</font><font style="color: #070707;">e</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">ment</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the Amendment and Clarification Agreement between Immunocore and Adaptimmune</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">dated May 20,
                    2013;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #1F1F26;">C</font><font style="color: #070707;">linical Trial</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">m</font><font style="color: #1F1F26;">ea</font><font style="color: #070707;">ns any human </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">lini</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">al tri</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">l or in</font><font style="color: #1F1F26;">ves</font><font style="color: #070707;">tigati</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">n in which </font><font style="color: #1F1F26;">a </font><font style="color: #070707;">ph</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">rm</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">ceuti</font><font style="color: #1F1F26;">ca</font><font style="color: #070707;">l product is administe</font><font style="color: #1F1F26;">r</font><font style="color: #070707;">ed to a per</font><font style="color: #1F1F26;">s</font><font style="color: #070707;">on or patient including </font><font style="color: #1F1F26;">a</font><font style="color: #070707;">ny Ph</font><font style="color: #1F1F26;">as</font><font style="color: #070707;">e 1 Trial, Phase </font><font style="color: #1F1F26;">2 </font><font style="color: #070707;">Trial or Phase </font><font style="color: #1F1F26;">3 </font><font style="color: #070707;">Trial</font><font style="color: #1F1F26;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Collaboration Program</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">m</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">ans </font><font style="color: #1F1F26;">a </font><font style="color: #070707;">progr</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">m of r</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">s</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">arch to discov</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">r</font><font style="color: #1F1F26;">, </font><font style="color: #080808;">optimize and develop a Compound through</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z92698799b13d4ed0accdf9b2b3e33149" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(8, 8, 8);">Completion of all Project Phases in the applicable agreed Research Plan in accordance with the terms of this Agreement. Collaboration Programs include Initial Programs;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Collaboration Program Option</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">has the meaning set fo</font><font style="color: #2D2D38;">r</font><font style="color: #080808;">t</font><font style="color: #2D2D38;">h </font><font style="color: #1A1A1F;">in






                  </font><font style="color: #080808;">Section 6.2</font><font style="color: #2D2D38;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Collaboration Program Option Period</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">has the meaning </font><font style="color: #1A1A1F;">set forth </font><font style="color: #080808;">in Section</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">6</font><font style="color: #2D2D38;">.</font><font style="color: #080808;">2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Commercially Reasonable Efforts</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means, wit</font><font style="color: #2D2D38;">h </font><font style="color: #080808;">re</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">pect </font><font style="color: #2D2D38;">t</font><font style="color: #1A1A1F;">o </font><font style="color: #080808;">a Pa</font><font style="color: #2D2D38;">rty,</font><font style="color: #1A1A1F;">&#160;</font><font style="color: #080808;">s</font><font style="color: #2D2D38;">u</font><font style="color: #080808;">ch </font><font style="color: #2D2D38;">effo</font><font style="color: #080808;">rt</font><font style="color: #2D2D38;">s </font><font style="color: #080808;">that are co</font><font style="color: #2D2D38;">n</font><font style="color: #1A1A1F;">sist</font><font style="color: #2D2D38;">e</font><font style="color: #080808;">nt </font><font style="color: #2D2D38;">w</font><font style="color: #1A1A1F;">it</font><font style="color: #2D2D38;">h t</font><font style="color: #080808;">he </font><font style="color: #2D2D38;">e</font><font style="color: #080808;">f</font><font style="color: #2D2D38;">fort</font><font style="color: #080808;">s and </font><font style="color: #2D2D38;">r</font><font style="color: #080808;">esources norma</font><font style="color: #2D2D38;">ll</font><font style="color: #080808;">y </font><font style="color: #2D2D38;">use</font><font style="color: #080808;">d b</font><font style="color: #2D2D38;">y </font><font style="color: #080808;">s</font><font style="color: #2D2D38;">uc</font><font style="color: #080808;">h P</font><font style="color: #2D2D38;">arty i</font><font style="color: #080808;">n the </font><font style="color: #2D2D38;">e</font><font style="color: #080808;">xercise of its reas</font><font style="color: #2D2D38;">o</font><font style="color: #080808;">nab</font><font style="color: #2D2D38;">le </font><font style="color: #080808;">bu</font><font style="color: #2D2D38;">sin</font><font style="color: #080808;">e</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">s di</font><font style="color: #2D2D38;">sc</font><font style="color: #1A1A1F;">r</font><font style="color: #2D2D38;">e</font><font style="color: #080808;">tion rela</font><font style="color: #2D2D38;">t</font><font style="color: #080808;">i</font><font style="color: #2D2D38;">n</font><font style="color: #080808;">g to the re</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">e</font><font style="color: #2D2D38;">ar</font><font style="color: #1A1A1F;">ch, </font><font style="color: #080808;">de</font><font style="color: #2D2D38;">v</font><font style="color: #1A1A1F;">el</font><font style="color: #2D2D38;">o</font><font style="color: #1A1A1F;">pmen</font><font style="color: #2D2D38;">t </font><font style="color: #080808;">a</font><font style="color: #2D2D38;">n</font><font style="color: #080808;">d comme</font><font style="color: #2D2D38;">rc</font><font style="color: #080808;">ialization of a </font><font style="color: #2D2D38;">p</font><font style="color: #1A1A1F;">ha</font><font style="color: #2D2D38;">rm</font><font style="color: #080808;">aceut</font><font style="color: #2D2D38;">ic</font><font style="color: #1A1A1F;">a</font><font style="color: #2D2D38;">l </font><font style="color: #080808;">prod</font><font style="color: #2D2D38;">u</font><font style="color: #080808;">ct </font><font style="color: #1A1A1F;">owned </font><font style="color: #2D2D38;">b</font><font style="color: #080808;">y </font><font style="color: #2D2D38;">it </font><font style="color: #080808;">or to which it h</font><font style="color: #2D2D38;">as </font><font style="color: #080808;">e</font><font style="color: #2D2D38;">x</font><font style="color: #080808;">clusive rig</font><font style="color: #2D2D38;">h</font><font style="color: #1A1A1F;">t</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">, w</font><font style="color: #2D2D38;">it</font><font style="color: #1A1A1F;">h </font><font style="color: #080808;">similar product c</font><font style="color: #2D2D38;">h</font><font style="color: #080808;">aracteri</font><font style="color: #2D2D38;">sti</font><font style="color: #1A1A1F;">cs </font><font style="color: #2D2D38;">(</font><font style="color: #1A1A1F;">s</font><font style="color: #2D2D38;">u</font><font style="color: #080808;">ch as t</font><font style="color: #2D2D38;">re</font><font style="color: #080808;">atin</font><font style="color: #2D2D38;">g </font><font style="color: #080808;">the </font><font style="color: #2D2D38;">s</font><font style="color: #1A1A1F;">ame </font><font style="color: #080808;">or a </font><font style="color: #2D2D38;">si</font><font style="color: #080808;">mila</font><font style="color: #2D2D38;">r </font><font style="color: #080808;">Indic</font><font style="color: #2D2D38;">a</font><font style="color: #080808;">t</font><font style="color: #2D2D38;">i</font><font style="color: #080808;">o</font><font style="color: #2D2D38;">n</font><font style="color: #1A1A1F;">), </font><font style="color: #080808;">which is of si</font><font style="color: #2D2D38;">mi</font><font style="color: #080808;">l</font><font style="color: #2D2D38;">ar </font><font style="color: #080808;">market pot</font><font style="color: #2D2D38;">e</font><font style="color: #1A1A1F;">n</font><font style="color: #2D2D38;">tial </font><font style="color: #080808;">at a </font><font style="color: #1A1A1F;">s</font><font style="color: #2D2D38;">im</font><font style="color: #080808;">i</font><font style="color: #2D2D38;">l</font><font style="color: #1A1A1F;">ar </font><font style="color: #2D2D38;">s</font><font style="color: #1A1A1F;">tage </font><font style="color: #080808;">in its </font><font style="color: #2D2D38;">d</font><font style="color: #080808;">evelopment or prod</font><font style="color: #2D2D38;">uc</font><font style="color: #080808;">t life</font><font style="color: #2D2D38;">, </font><font style="color: #080808;">taking in</font><font style="color: #2D2D38;">t</font><font style="color: #080808;">o a</font><font style="color: #2D2D38;">c</font><font style="color: #080808;">count </font><font style="color: #1A1A1F;">is</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">u</font><font style="color: #2D2D38;">e</font><font style="color: #080808;">s of patent </font><font style="color: #2D2D38;">co</font><font style="color: #080808;">v</font><font style="color: #2D2D38;">e</font><font style="color: #080808;">rage, </font><font style="color: #2D2D38;">s</font><font style="color: #080808;">a</font><font style="color: #2D2D38;">f</font><font style="color: #1A1A1F;">ety </font><font style="color: #080808;">and effi</font><font style="color: #2D2D38;">c</font><font style="color: #080808;">acy, </font><font style="color: #2D2D38;">p</font><font style="color: #1A1A1F;">rodu</font><font style="color: #2D2D38;">c</font><font style="color: #080808;">t profile, the compet</font><font style="color: #2D2D38;">i</font><font style="color: #1A1A1F;">ti</font><font style="color: #2D2D38;">ve</font><font style="color: #080808;">ness






                  </font><font style="color: #1A1A1F;">o</font><font style="color: #2D2D38;">f </font><font style="color: #080808;">the m</font><font style="color: #2D2D38;">ark</font><font style="color: #080808;">etplace, the </font><font style="color: #2D2D38;">p</font><font style="color: #080808;">ropriet</font><font style="color: #2D2D38;">ary </font><font style="color: #080808;">positi</font><font style="color: #2D2D38;">o</font><font style="color: #1A1A1F;">n </font><font style="color: #2D2D38;">o</font><font style="color: #080808;">f the </font><font style="color: #2D2D38;">c</font><font style="color: #1A1A1F;">o</font><font style="color: #2D2D38;">m</font><font style="color: #080808;">p</font><font style="color: #2D2D38;">o</font><font style="color: #080808;">und or product, the </font><font style="color: #2D2D38;">re</font><font style="color: #080808;">gulator</font><font style="color: #2D2D38;">y </font><font style="color: #1A1A1F;">structure i</font><font style="color: #2D2D38;">nvolve</font><font style="color: #080808;">d, the potential or ac</font><font style="color: #2D2D38;">tua</font><font style="color: #080808;">l profit</font><font style="color: #2D2D38;">a</font><font style="color: #080808;">bil</font><font style="color: #2D2D38;">it</font><font style="color: #080808;">y of </font><font style="color: #2D2D38;">the </font><font style="color: #080808;">applicable products </font><font style="color: #2D2D38;">(i</font><font style="color: #080808;">n</font><font style="color: #2D2D38;">cl</font><font style="color: #1A1A1F;">uding pricing </font><font style="color: #2D2D38;">an</font><font style="color: #080808;">d
                    reimbursement status </font><font style="color: #1A1A1F;">achieved </font><font style="color: #2D2D38;">o</font><font style="color: #080808;">r </font><font style="color: #2D2D38;">to </font><font style="color: #080808;">be ac</font><font style="color: #2D2D38;">h</font><font style="color: #1A1A1F;">ie</font><font style="color: #2D2D38;">v</font><font style="color: #080808;">ed), and other relevant factors</font><font style="color: #2D2D38;">, in</font><font style="color: #1A1A1F;">cl</font><font style="color: #2D2D38;">u</font><font style="color: #080808;">ding te</font><font style="color: #2D2D38;">chn</font><font style="color: #080808;">ical, legal, scientific and/or medical </font><font style="color: #2D2D38;">f</font><font style="color: #080808;">actors</font><font style="color: #2D2D38;">. </font><font style="color: #080808;">For purposes </font><font style="color: #1A1A1F;">of clarity, </font><font style="color: #080808;">Commer</font><font style="color: #2D2D38;">c</font><font style="color: #080808;">ially Rea</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">onable Efforts would be </font><font style="color: #1A1A1F;">d</font><font style="color: #2D2D38;">ete</font><font style="color: #080808;">rmined </font><font style="color: #1A1A1F;">on </font><font style="color: #080808;">a market-by-market and </font><font style="color: #1A1A1F;">I</font><font style="color: #2D2D38;">nd</font><font style="color: #080808;">i</font><font style="color: #2D2D38;">c</font><font style="color: #1A1A1F;">ation-</font><font style="color: #2D2D38;">b</font><font style="color: #080808;">y</font><font style="color: #2D2D38;">-</font><font style="color: #080808;">Indication basis for a particular </font><font style="color: #2D2D38;">p</font><font style="color: #1A1A1F;">roduct </font><font style="color: #2D2D38;">a</font><font style="color: #1A1A1F;">nd </font><font style="color: #2D2D38;">i</font><font style="color: #1A1A1F;">t </font><font style="color: #080808;">is anticipated that the level of effort may be di</font><font style="color: #2D2D38;">ffe</font><font style="color: #080808;">rent for different markets and may change over time, reflecting changes in the status of the product and the market(s) involved;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Completion</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means in relation to any Project Phase, the earlier of either completion of all activities agreed for such Project Phase or commencement of activities under the next Project
                    Phase.</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">In relation to a </font><font style="color: #1A1A1F;">Collaboration </font><font style="color: #080808;">Program, &#8220;Completion&#8221; means the earlier of (i)
                    completion </font><font style="color: #1A1A1F;">of </font><font style="color: #080808;">all </font><font style="color: #1A1A1F;">activities of the </font><font style="color: #080808;">final Project Phase or (ii) either commencement
                    of a Phase 1 </font><font style="color: #2D2D38;">T</font><font style="color: #080808;">rial if the </font><font style="color: #1A1A1F;">Collaboration </font><font style="color: #080808;">Program is not an Initial Program, or
                    commencement of a Phase 2 Trial if the Collaboration Program is an Initial Program. In relation to </font><font style="color: #1A1A1F;">a </font><font style="color: #080808;">Clinical Trial &#8220;Completion&#8221; means the </font><font style="color: #1A1A1F;">completion </font><font style="color: #080808;">of the Clinical Trial and</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="zcac19803bf1844e681b97be752a03762" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">production of final report from Clinical </font><font style="color: #070707;">Trial in accordance with Clinical Trial protocol;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Compound</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means a product that comprises (a) a TCR or a portion of a TCR that comprises a TCR alpha chain variable domain and a TCR beta chain variable domain wherein the TCR </font><font style="color: #363642;">o</font><font style="color: #1D1D23;">r </font><font style="color: #070707;">portion of </font><font style="color: #1D1D23;">the </font><font style="color: #070707;">TCR binds to an HLA-prese</font><font style="color: #363642;">n</font><font style="color: #070707;">t</font><font style="color: #363642;">e</font><font style="color: #1D1D23;">d </font><font style="color: #070707;">antigen deriv</font><font style="color: #363642;">e</font><font style="color: #1D1D23;">d </font><font style="color: #070707;">from a Target; and (b) an </font><font style="color: #1D1D23;">Ef</font><font style="color: #363642;">f</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">c</font><font style="color: #363642;">t</font><font style="color: #1D1D23;">o</font><font style="color: #070707;">r;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Confidential Information</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means (a) th</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">Results; and (b</font><font style="color: #363642;">) </font><font style="color: #1D1D23;">all </font><font style="color: #070707;">technic</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">scientific or </font><font style="color: #1D1D23;">co</font><font style="color: #363642;">m</font><font style="color: #1D1D23;">m</font><font style="color: #363642;">e</font><font style="color: #070707;">rci</font><font style="color: #363642;">a</font><font style="color: #1D1D23;">l </font><font style="color: #070707;">informatio</font><font style="color: #1D1D23;">n (</font><font style="color: #070707;">in an</font><font style="color: #1D1D23;">y fo</font><font style="color: #070707;">rm
                    or medium </font><font style="color: #1D1D23;">an</font><font style="color: #070707;">d </font><font style="color: #363642;">i</font><font style="color: #1D1D23;">n</font><font style="color: #070707;">clud</font><font style="color: #363642;">i</font><font style="color: #070707;">n</font><font style="color: #1D1D23;">g </font><font style="color: #070707;">all c</font><font style="color: #1D1D23;">op</font><font style="color: #363642;">i</font><font style="color: #1D1D23;">es </font><font style="color: #070707;">of th</font><font style="color: #363642;">e sa</font><font style="color: #1D1D23;">m</font><font style="color: #070707;">e) concerning </font><font style="color: #1D1D23;">pa</font><font style="color: #070707;">st,&#160; </font><font style="color: #1D1D23;">pre </font><font style="color: #070707;">sen</font><font style="color: #1D1D23;">t</font><font style="color: #070707;">,</font><font style="color: #070707;">&#160; </font><font style="color: #363642;">a</font><font style="color: #070707;">nd</font><font style="color: #1D1D23;">/ or fu</font><font style="color: #070707;">ture transac</font><font style="color: #1D1D23;">t</font><font style="color: #363642;">i</font><font style="color: #070707;">on</font><font style="color: #1D1D23;">s</font><font style="color: #363642;">, </font><font style="color: #070707;">dea</font><font style="color: #1D1D23;">ling</font><font style="color: #363642;">s, </font><font style="color: #070707;">p</font><font style="color: #1D1D23;">rojec</font><font style="color: #363642;">t</font><font style="color: #1D1D23;">s, </font><font style="color: #070707;">plans, </font><font style="color: #363642;">p</font><font style="color: #070707;">roposals, and o</font><font style="color: #363642;">t</font><font style="color: #1D1D23;">he</font><font style="color: #363642;">r </font><font style="color: #1D1D23;">b</font><font style="color: #070707;">usi</font><font style="color: #1D1D23;">n</font><font style="color: #363642;">e</font><font style="color: #1D1D23;">ss a</font><font style="color: #070707;">ffai</font><font style="color: #1D1D23;">r</font><font style="color: #363642;">s </font><font style="color: #070707;">t</font><font style="color: #363642;">h</font><font style="color: #070707;">at (i</font><font style="color: #1D1D23;">) a</font><font style="color: #070707;">re </font><font style="color: #1D1D23;">d</font><font style="color: #070707;">isclosed dire</font><font style="color: #363642;">c</font><font style="color: #1D1D23;">t</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">y o</font><font style="color: #363642;">r </font><font style="color: #070707;">indir</font><font style="color: #363642;">ec</font><font style="color: #1D1D23;">t</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">y </font><font style="color: #070707;">by o</font><font style="color: #363642;">n</font><font style="color: #1D1D23;">e </font><font style="color: #363642;">P</font><font style="color: #070707;">arty </font><font style="color: #1D1D23;">(</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">h</font><font style="color: #070707;">e &#8220;</font><font style="font-weight: bold; color: #1D1D23;">d</font><font style="font-weight: bold; color: #070707;">isclosing P</font><font style="font-weight: bold; color: #1D1D23;">a</font><font style="font-weight: bold; color: #070707;">r</font><font style="font-weight: bold; color: #1D1D23;">t</font><font style="font-weight: bold; color: #363642;">y</font><font style="color: #1D1D23;">&#8221;</font><font style="color: #070707;">) to t</font><font style="color: #1D1D23;">he o</font><font style="color: #070707;">ther </font><font style="color: #363642;">(</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">h</font><font style="color: #363642;">e </font><font style="color: #070707;">&#8220;</font><font style="font-weight: bold; color: #070707;">rec</font><font style="font-weight: bold; color: #1D1D23;">ei</font><font style="font-weight: bold; color: #070707;">v</font><font style="font-weight: bold; color: #1D1D23;">i</font><font style="font-weight: bold; color: #363642;">n</font><font style="font-weight: bold; color: #070707;">g Party</font><font style="color: #070707;">&#8221;)</font><font style="font-weight: bold; color: #070707;">&#160;</font><font style="color: #070707;">at </font><font style="color: #1D1D23;">any </font><font style="color: #363642;">t</font><font style="color: #1D1D23;">i</font><font style="color: #070707;">me in </font><font style="color: #1D1D23;">con</font><font style="color: #070707;">tem</font><font style="color: #1D1D23;">pla</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">io</font><font style="color: #070707;">n of or </font><font style="color: #1D1D23;">i</font><font style="color: #070707;">n </font><font style="color: #1D1D23;">c</font><font style="color: #363642;">o</font><font style="color: #070707;">nnection
                    with t</font><font style="color: #1D1D23;">h</font><font style="color: #363642;">is </font><font style="color: #070707;">A</font><font style="color: #1D1D23;">gr</font><font style="color: #070707;">eem</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">nt. F</font><font style="color: #363642;">o</font><font style="color: #1D1D23;">r </font><font style="color: #070707;">the </font><font style="color: #1D1D23;">av</font><font style="color: #363642;">o</font><font style="color: #070707;">id</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">nce of doubt </font><font style="color: #1D1D23;">C</font><font style="color: #363642;">o</font><font style="color: #070707;">nfident</font><font style="color: #1D1D23;">i</font><font style="color: #363642;">a</font><font style="color: #1D1D23;">l </font><font style="color: #070707;">I</font><font style="color: #1D1D23;">nfo</font><font style="color: #363642;">r</font><font style="color: #070707;">mation </font><font style="color: #363642;">s</font><font style="color: #070707;">h</font><font style="color: #1D1D23;">all </font><font style="color: #070707;">incl</font><font style="color: #1D1D23;">ude </font><font style="color: #070707;">resuIts</font><font style="color: #1D1D23;">, </font><font style="color: #363642;">d</font><font style="color: #070707;">ata, </font><font style="color: #1D1D23;">da</font><font style="color: #070707;">taba</font><font style="color: #1D1D23;">ses</font><font style="color: #070707;">, </font><font style="color: #1D1D23;">p</font><font style="color: #070707;">r</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">ctices, </font><font style="color: #1D1D23;">m</font><font style="color: #070707;">ethods, </font><font style="color: #1D1D23;">te</font><font style="color: #363642;">c</font><font style="color: #070707;">hniques,






                    spe</font><font style="color: #1D1D23;">cifi</font><font style="color: #363642;">ca</font><font style="color: #1D1D23;">t</font><font style="color: #070707;">ions, </font><font style="color: #1D1D23;">fo</font><font style="color: #070707;">r</font><font style="color: #1D1D23;">m</font><font style="color: #070707;">ul</font><font style="color: #363642;">a</font><font style="color: #1D1D23;">t</font><font style="color: #070707;">i</font><font style="color: #1D1D23;">o</font><font style="color: #070707;">n</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">, for</font><font style="color: #1D1D23;">m</font><font style="color: #070707;">ulae, protein s</font><font style="color: #1D1D23;">equ</font><font style="color: #363642;">e</font><font style="color: #070707;">n</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">es</font><font style="color: #363642;">, </font><font style="color: #1D1D23;">D</font><font style="color: #070707;">NA sequ</font><font style="color: #363642;">e</font><font style="color: #070707;">n</font><font style="color: #363642;">c</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">, kno</font><font style="color: #1D1D23;">w</font><font style="color: #070707;">-</font><font style="color: #1D1D23;">how</font><font style="color: #070707;">, skill, test </font><font style="color: #1D1D23;">da</font><font style="color: #070707;">t</font><font style="color: #363642;">a</font><font style="color: #070707;">, p</font><font style="color: #1D1D23;">r</font><font style="color: #070707;">oc</font><font style="color: #363642;">e</font><font style="color: #070707;">d</font><font style="color: #1D1D23;">u</font><font style="color: #070707;">res</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">p</font><font style="color: #1D1D23;">ro</font><font style="color: #070707;">ces</font><font style="color: #363642;">s </font><font style="color: #070707;">infor</font><font style="color: #1D1D23;">ma</font><font style="color: #363642;">t</font><font style="color: #070707;">io</font><font style="color: #1D1D23;">n</font><font style="color: #070707;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Controlled</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1D1D23;">m</font><font style="color: #070707;">ean</font><font style="color: #1D1D23;">s t</font><font style="color: #363642;">ha</font><font style="color: #070707;">t any </font><font style="color: #1D1D23;">Pa</font><font style="color: #363642;">r</font><font style="color: #1D1D23;">t</font><font style="color: #363642;">y </font><font style="color: #070707;">has </font><font style="color: #363642;">t</font><font style="color: #1D1D23;">he </font><font style="color: #070707;">ri</font><font style="color: #1D1D23;">g</font><font style="color: #070707;">ht to grant any lice</font><font style="color: #1D1D23;">n</font><font style="color: #363642;">c</font><font style="color: #1D1D23;">e i</font><font style="color: #070707;">n re</font><font style="color: #1D1D23;">la</font><font style="color: #070707;">tion to </font><font style="color: #1D1D23;">an</font><font style="color: #363642;">y </font><font style="color: #1D1D23;">In</font><font style="color: #363642;">t</font><font style="color: #070707;">ellectual Pr</font><font style="color: #1D1D23;">o</font><font style="color: #070707;">perty R</font><font style="color: #1D1D23;">ig</font><font style="color: #363642;">h</font><font style="color: #1D1D23;">t </font><font style="color: #070707;">witho</font><font style="color: #363642;">u</font><font style="color: #1D1D23;">t </font><font style="color: #070707;">violatin</font><font style="color: #1D1D23;">g th</font><font style="color: #070707;">e terms of any </font><font style="color: #1D1D23;">ag</font><font style="color: #070707;">r</font><font style="color: #363642;">e</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">men</font><font style="color: #1D1D23;">t o</font><font style="color: #363642;">r </font><font style="color: #1D1D23;">ot</font><font style="color: #070707;">her </font><font style="color: #363642;">a</font><font style="color: #1D1D23;">r</font><font style="color: #070707;">ran</font><font style="color: #1D1D23;">g</font><font style="color: #070707;">ement with any Third </font><font style="color: #1D1D23;">P</font><font style="color: #070707;">a</font><font style="color: #1D1D23;">rt</font><font style="color: #070707;">y </font><font style="color: #1D1D23;">a</font><font style="color: #363642;">nd &#8220;</font><font style="color: #1D1D23;">C</font><font style="color: #070707;">ontrol</font><font style="color: #363642;">&#8221; </font><font style="color: #1D1D23;">o</font><font style="color: #363642;">r </font><font style="color: #070707;">&#8220;Control</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">&#8221; shall be
                    interpr</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">t</font><font style="color: #363642;">e</font><font style="color: #1D1D23;">d </font><font style="color: #363642;">a</font><font style="color: #070707;">ccordi</font><font style="color: #1D1D23;">n</font><font style="color: #363642;">gly</font><font style="color: #1D1D23;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Cov</font><font style="color: #1D1D23;">er</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means </font><font style="color: #1D1D23;">w</font><font style="color: #070707;">ith resp</font><font style="color: #1D1D23;">ect </font><font style="color: #070707;">to a
                    particular patent or </font><font style="color: #1D1D23;">p</font><font style="color: #363642;">a</font><font style="color: #1D1D23;">te</font><font style="color: #070707;">nt applic</font><font style="color: #363642;">a</font><font style="color: #070707;">tion and with reference to a </font><font style="color: #1D1D23;">p</font><font style="color: #363642;">a</font><font style="color: #1D1D23;">rti</font><font style="color: #363642;">c</font><font style="color: #070707;">ular </font><font style="color: #1D1D23;">pro</font><font style="color: #070707;">d</font><font style="color: #1D1D23;">uc</font><font style="color: #070707;">t or pr</font><font style="color: #1D1D23;">oc</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">s that th</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">u</font><font style="color: #1D1D23;">se</font><font style="color: #070707;">, </font><font style="color: #1D1D23;">ma</font><font style="color: #070707;">nufac</font><font style="color: #1D1D23;">ture,</font><font style="color: #363642;">&#160;</font><font style="color: #070707;">sale</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">offer to sell, supply or import of </font><font style="color: #1D1D23;">s</font><font style="color: #070707;">uch pr</font><font style="color: #1D1D23;">o</font><font style="color: #363642;">d</font><font style="color: #1D1D23;">u</font><font style="color: #070707;">ct or process would infringe a Valid Claim of su</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">h patent or
                    patent application (or a claim of the Joint Foreground),</font><font style="color: #1D1D23;">&#160;</font><font style="color: #070707;">in the absence of th</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">lic</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">nc</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">s under thi</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">Agre</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">ment;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">CPR</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 7);">has the meaning set forth in Section 15.3;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Data </font><font style="color: #1D1D23;">S</font><font style="color: #070707;">haring I</font><font style="color: #363642;">n</font><font style="color: #1D1D23;">i</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">i</font><font style="color: #363642;">a</font><font style="color: #070707;">tive</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means GSK</font><font style="color: #1D1D23;">&#8217;</font><font style="color: #070707;">s policy initiative, known </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">t the Effective Date </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">s the &#8220;SHARE Initi</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">tive&#8221;, to p</font><font style="color: #1D1D23;">ro</font><font style="color: #070707;">vide researchers with access to Clinical Trial and study information</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">including anonymised patient
                    level d</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">a </font><font style="color: #070707;">and </font><font style="color: #1D1D23;">as co</font><font style="color: #070707;">mmuni</font><font style="color: #1D1D23;">ca</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">ed </font><font style="color: #070707;">to Immu</font><font style="color: #1D1D23;">noco</font><font style="color: #070707;">r</font><font style="color: #1D1D23;">e fro</font><font style="color: #070707;">m time t</font><font style="color: #1D1D23;">o </font><font style="color: #070707;">tim</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">and </font><font style="color: #1D1D23;">e</font><font style="color: #070707;">a</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">h </font><font style="color: #1D1D23;">c</font><font style="color: #070707;">ase provided such initiative does not require any</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z3698467808ec40148b1e838b8936bd93" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">materi</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">l </font><font style="color: #1D1D23;">c</font><font style="color: #070707;">h</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">nge</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">to any </font><font style="color: #1D1D23;">Immunocore</font><font style="color: #070707;">
                    polici</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">s or op</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">rational pra</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">ti</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Dataroom</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">m</font><font style="color: #1D1D23;">ea</font><font style="color: #070707;">n</font><font style="color: #1D1D23;">s a</font><font style="color: #070707;">n </font><font style="color: #1D1D23;">e</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">ec</font><font style="color: #070707;">tronic d</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">room </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">cc</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">s</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">ibl</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">by GSK and other existing or potential licensees of Immunocore which contains Confidential
                    Information in relation to Targets and in particular the following information relevant to each Target: [***];</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Dataroom Period</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">has the me</font><font style="color: #2D2D36;">a</font><font style="color: #070707;">ning </font><font style="color: #2D2D36;">s</font><font style="color: #070707;">et fo</font><font style="color: #2D2D36;">r</font><font style="color: #070707;">t</font><font style="color: #2D2D36;">h i</font><font style="color: #070707;">n Section 5.3.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Deed</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means th</font><font style="color: #2D2D36;">e </font><font style="color: #070707;">D</font><font style="color: #2D2D36;">eed </font><font style="color: #1A1A1F;">of
                    Assignment between </font><font style="color: #070707;">Immu</font><font style="color: #2D2D36;">nocore </font><font style="color: #070707;">an</font><font style="color: #2D2D36;">d Ad</font><font style="color: #070707;">apti</font><font style="color: #2D2D36;">mmu</font><font style="color: #070707;">ne d</font><font style="color: #2D2D36;">ate</font><font style="color: #070707;">d </font><font style="color: #1A1A1F;">May </font><font style="color: #070707;">20, 201</font><font style="color: #2D2D36;">3</font><font style="color: #070707;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Defending Party</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1A1A1F;">has </font><font style="color: #2D2D36;">th</font><font style="color: #070707;">e me</font><font style="color: #2D2D36;">an</font><font style="color: #070707;">i</font><font style="color: #2D2D36;">n</font><font style="color: #070707;">g set </font><font style="color: #2D2D36;">forth </font><font style="color: #070707;">in Sec</font><font style="color: #2D2D36;">t</font><font style="color: #070707;">io</font><font style="color: #2D2D36;">n </font><font style="color: #070707;">7.7.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Development Additiona</font><font style="color: #2D2D36;">l Work</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">h</font><font style="color: #2D2D36;">a</font><font style="color: #070707;">s the m</font><font style="color: #2D2D36;">ea</font><font style="color: #070707;">ni</font><font style="color: #2D2D36;">ng se</font><font style="color: #070707;">t forth </font><font style="color: #1A1A1F;">i</font><font style="color: #42424D;">n </font><font style="color: #1A1A1F;">Section </font><font style="color: #070707;">3</font><font style="color: #2D2D36;">.6.</font><font style="color: #070707;">1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Development Candidate</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">me</font><font style="color: #2D2D36;">ans </font><font style="color: #070707;">a </font><font style="color: #1A1A1F;">Compound meeting </font><font style="color: #070707;">the






                  </font><font style="color: #2D2D36;">D</font><font style="color: #070707;">evelopment </font><font style="color: #2D2D36;">C</font><font style="color: #070707;">andid</font><font style="color: #2D2D36;">a</font><font style="color: #070707;">te </font><font style="color: #2D2D36;">C</font><font style="color: #070707;">riteria o</font><font style="color: #42424D;">r </font><font style="color: #070707;">de</font><font style="color: #2D2D36;">s</font><font style="color: #070707;">i</font><font style="color: #2D2D36;">g</font><font style="color: #070707;">nated as a Develo</font><font style="color: #2D2D36;">pme</font><font style="color: #070707;">nt Candid</font><font style="color: #2D2D36;">ate </font><font style="color: #070707;">by the JS</font><font style="color: #2D2D36;">C </font><font style="color: #070707;">in accordance </font><font style="color: #2D2D36;">w</font><font style="color: #070707;">ith </font><font style="color: #1A1A1F;">Section </font><font style="color: #070707;">3.6;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Development C</font><font style="color: #2D2D36;">an</font><font style="color: #070707;">didate Criteria</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">m</font><font style="color: #2D2D36;">eans </font><font style="color: #070707;">the </font><font style="color: #2D2D36;">c</font><font style="color: #070707;">ri</font><font style="color: #2D2D36;">te</font><font style="color: #070707;">ria to </font><font style="color: #2D2D36;">be </font><font style="color: #070707;">achieved by any </font><font style="color: #2D2D36;">Com</font><font style="color: #070707;">pound </font><font style="color: #1A1A1F;">during Project </font><font style="color: #070707;">Phase 2 of any </font><font style="color: #2D2D36;">C</font><font style="color: #070707;">ollabor</font><font style="color: #2D2D36;">atio</font><font style="color: #070707;">n Progra</font><font style="color: #2D2D36;">m a</font><font style="color: #070707;">s initially set forth in Section </font><font style="color: #2D2D36;">B </font><font style="color: #42424D;">o</font><font style="color: #070707;">f Exhi</font><font style="color: #2D2D36;">bit </font><font style="color: #070707;">A, which criteria may be modi</font><font style="color: #2D2D36;">fi</font><font style="color: #070707;">e</font><font style="color: #2D2D36;">d </font><font style="color: #1A1A1F;">for each </font><font style="color: #2D2D36;">a</font><font style="color: #070707;">p</font><font style="color: #2D2D36;">p</font><font style="color: #070707;">licable </font><font style="color: #1A1A1F;">Collaboration </font><font style="color: #070707;">Program by the J</font><font style="color: #2D2D36;">S</font><font style="color: #070707;">C.</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">Eff</font><font style="color: #2D2D36;">ect</font><font style="color: #070707;">ive </font><font style="color: #1A1A1F;">Date</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1A1A1F;">h</font><font style="color: #42424D;">as </font><font style="color: #2D2D36;">the </font><font style="color: #070707;">m</font><font style="color: #2D2D36;">eani</font><font style="color: #070707;">ng </font><font style="color: #2D2D36;">s</font><font style="color: #070707;">et forth in the preamble;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Effector</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 7);">means any protein or polypeptide having the ability to modulate cell function, a cytotoxic moiety or a diagnostic label, including derivatives or variants thereof;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">EMA</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the </font><font style="color: #1A1A1F;">European </font><font style="color: #070707;">Medicines Agency, and any successor entity thereto;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070707;">En</font><font style="color: #2D2D36;">tity</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">has the meaning </font><font style="color: #1A1A1F;">set </font><font style="color: #070707;">forth in Section 5.3.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #2D2D36;">Exe</font><font style="color: #070707;">cutive Officers</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 7);">has the meaning set forth in Section 4.5;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">FDA</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">Means the United States Food and Drug Administration, and any successor </font><font style="color: #1A1A1F;">entity </font><font style="color: #070707;">thereto;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z8be0ed4a1fc24fb88277ed113773f2f9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Field</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means </font><font style="color: #1A1A1F;">any </font><font style="color: #070707;">use or purpose, including the treatment, palliation, diagnosis or prevention of </font><font style="color: #070708;">any human disease;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">First Commercial Sale</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means, with respect to any Licensed Product, the first sale in any country in the Territory by GSK, its Affiliates or their sub</font><font style="color: #1C1C21;">lic</font><font style="color: #070708;">ens</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">es after all required Regulatory Approvals hav</font><font style="color: #1C1C21;">e </font><font style="color: #2D2D38;">b</font><font style="color: #070708;">een granted </font><font style="color: #2D2D38;">in </font><font style="color: #070708;">such country;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Foreground</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means any Int</font><font style="color: #1C1C21;">ellec</font><font style="color: #070708;">tual Property Rights</font><font style="color: #2D2D38;">&#160;</font><font style="color: #070708;">in any Results or any </font><font style="color: #1C1C21;">In</font><font style="color: #070708;">tell</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">ctual Propert</font><font style="color: #2D2D38;">y </font><font style="color: #070708;">R</font><font style="color: #2D2D38;">ig</font><font style="color: #070708;">hts arising as a result </font><font style="color: #2D2D38;">of th</font><font style="color: #070708;">e </font><font style="color: #2D2D38;">p</font><font style="color: #070708;">erformance </font><font style="color: #2D2D38;">of </font><font style="color: #070708;">a </font><font style="color: #1C1C21;">Party&#8217;</font><font style="color: #070708;">s
                    obligations </font><font style="color: #1C1C21;">o</font><font style="color: #070708;">r e</font><font style="color: #1C1C21;">xe</font><font style="color: #070708;">rcis</font><font style="color: #2D2D38;">e </font><font style="color: #1C1C21;">of </font><font style="color: #070708;">a P</font><font style="color: #1C1C21;">a</font><font style="color: #070708;">r</font><font style="color: #1C1C21;">ty</font><font style="color: #070708;">&#8217;</font><font style="color: #1C1C21;">s </font><font style="color: #070708;">righ</font><font style="color: #1C1C21;">ts </font><font style="color: #2D2D38;">und</font><font style="color: #070708;">er this Agreem</font><font style="color: #2D2D38;">en</font><font style="color: #070708;">t</font><font style="color: #2D2D38;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">FTE</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">mean</font><font style="color: #2D2D38;">s </font><font style="color: #1C1C21;">the </font><font style="color: #070708;">eq</font><font style="color: #2D2D38;">ui</font><font style="color: #070708;">v</font><font style="color: #2D2D38;">ale</font><font style="color: #070708;">nt </font><font style="color: #2D2D38;">of </font><font style="color: #1C1C21;">t</font><font style="color: #070708;">he </font><font style="color: #2D2D38;">wo</font><font style="color: #070708;">rk of one em</font><font style="color: #1C1C21;">ploy</font><font style="color: #070708;">e</font><font style="color: #2D2D38;">e </font><font style="color: #070708;">full
                  </font><font style="color: #1C1C21;">tim</font><font style="color: #070708;">e on th</font><font style="color: #2D2D38;">e C</font><font style="color: #070708;">ollabo</font><font style="color: #1C1C21;">r</font><font style="color: #070708;">at</font><font style="color: #2D2D38;">ion </font><font style="color: #070708;">Program an</font><font style="color: #1C1C21;">d </font><font style="color: #2D2D38;">pe</font><font style="color: #070708;">rformi</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">g </font><font style="color: #2D2D38;">a</font><font style="color: #070708;">ny fu</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">ct</font><font style="color: #2D2D38;">io</font><font style="color: #070708;">n dire</font><font style="color: #2D2D38;">ct</font><font style="color: #070708;">l</font><font style="color: #1C1C21;">y re</font><font style="color: #070708;">lated to the
                  </font><font style="color: #2D2D38;">condu</font><font style="color: #070708;">ct of t</font><font style="color: #2D2D38;">h</font><font style="color: #070708;">e </font><font style="color: #2D2D38;">a</font><font style="color: #070708;">ppli</font><font style="color: #1C1C21;">ca</font><font style="color: #070708;">b</font><font style="color: #1C1C21;">le </font><font style="color: #070708;">Resear</font><font style="color: #2D2D38;">c</font><font style="color: #070708;">h </font><font style="color: #2D2D38;">Pl</font><font style="color: #070708;">an;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">GAAP</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1C1C21;">me</font><font style="color: #070708;">ans Ge</font><font style="color: #2D2D38;">ne</font><font style="color: #070708;">ra</font><font style="color: #1C1C21;">lly </font><font style="color: #2D2D38;">A</font><font style="color: #070708;">ccepted </font><font style="color: #2D2D38;">Acc</font><font style="color: #070708;">o</font><font style="color: #2D2D38;">un</font><font style="color: #070708;">ting </font><font style="color: #1C1C21;">Pr</font><font style="color: #070708;">inciples;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">GSK</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has </font><font style="color: #2D2D38;">the </font><font style="color: #1C1C21;">m</font><font style="color: #070708;">eani</font><font style="color: #2D2D38;">ng set </font><font style="color: #070708;">forth in the pr</font><font style="color: #2D2D38;">ea</font><font style="color: #070708;">mb</font><font style="color: #1C1C21;">l</font><font style="color: #070708;">e;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">GSK Background</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1C1C21;">m</font><font style="color: #070708;">e</font><font style="color: #2D2D38;">a</font><font style="color: #070708;">ns B</font><font style="color: #1C1C21;">ac</font><font style="color: #070708;">k</font><font style="color: #2D2D38;">g</font><font style="color: #070708;">round own</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">d or </font><font style="color: #2D2D38;">Con</font><font style="color: #070708;">trolled by GSK o</font><font style="color: #1C1C21;">r </font><font style="color: #070708;">its A</font><font style="color: #2D2D38;">ffilia</font><font style="color: #070708;">tes;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">GSK Foregrou</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">d</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">mea</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">s </font><font style="color: #2D2D38;">F</font><font style="color: #070708;">oreg</font><font style="color: #1C1C21;">ro</font><font style="color: #070708;">und whic</font><font style="color: #1C1C21;">h </font><font style="color: #2D2D38;">is so</font><font style="color: #070708;">lely conceived or re</font><font style="color: #2D2D38;">duce</font><font style="color: #070708;">d to p</font><font style="color: #2D2D38;">ra</font><font style="color: #070708;">c</font><font style="color: #1C1C21;">tic</font><font style="color: #070708;">e by G</font><font style="color: #2D2D38;">SK, </font><font style="color: #070708;">its Affiliates or their </font><font style="color: #2D2D38;">sublic</font><font style="color: #070708;">ense</font><font style="color: #2D2D38;">e</font><font style="color: #070708;">s </font><font style="color: #1C1C21;">o</font><font style="color: #070708;">r any of </font><font style="color: #2D2D38;">the</font><font style="color: #070708;">ir sub-contractors</font><font style="color: #1C1C21;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">GSK In</font><font style="color: #1C1C21;">de</font><font style="color: #070708;">m</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">ified </font><font style="color: #2D2D38;">Par</font><font style="color: #070708;">ties</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has th</font><font style="color: #1C1C21;">e </font><font style="color: #2D2D38;">mean</font><font style="color: #070708;">ing se</font><font style="color: #2D2D38;">t for</font><font style="color: #070708;">th in Section 11.9;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">GSK </font><font style="color: #1C1C21;">P</font><font style="color: #070708;">at</font><font style="color: #2D2D38;">en</font><font style="color: #070708;">t Ch</font><font style="color: #2D2D38;">all</font><font style="color: #070708;">enge</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has the </font><font style="color: #2D2D38;">m</font><font style="color: #070708;">eaning se</font><font style="color: #2D2D38;">t </font><font style="color: #070708;">forth
                    in Section 13.8;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(28, 28, 33); font-weight: bold;">HLA</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1C1C21;">me</font><font style="color: #070708;">a</font><font style="color: #2D2D38;">n</font><font style="color: #070708;">s Hu</font><font style="color: #1C1C21;">m</font><font style="color: #070708;">a</font><font style="color: #2D2D38;">n </font><font style="color: #070708;">L</font><font style="color: #2D2D38;">eu</font><font style="color: #070708;">kocyte Antigen;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">HLA Program</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">h</font><font style="color: #1C1C21;">a</font><font style="color: #070708;">s the m</font><font style="color: #1C1C21;">ean</font><font style="color: #070708;">ing set forth in
                    Section 5.2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">ICC</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has the meaning set forth in Section 15.4</font><font style="color: #1C1C21;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">IFRS</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 8);">means International Financial Reporting Standards;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Immunocore</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has the meaning </font><font style="color: #1C1C21;">s</font><font style="color: #070708;">et forth in the preamble;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #1C1C21;">Immunocore</font><font style="color: #070708;"> Background</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">me</font><font style="color: #1C1C21;">a</font><font style="color: #070708;">ns Background </font><font style="color: #1C1C21;">o</font><font style="color: #070708;">wned or C</font><font style="color: #1C1C21;">o</font><font style="color: #070708;">ntrolled by Immunocor</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">, including th</font><font style="color: #1C1C21;">e </font><font style="color: #070708;">p</font><font style="color: #1C1C21;">a</font><font style="color: #070708;">t</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">nts and pat</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">nt applications listed on Schedule 3 but e</font><font style="color: #1C1C21;">x</font><font style="color: #070708;">cluding any Third Party Platform Rights;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z06935d6561084d99a657d990ecb8aa4d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Immunocore Foreground</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means Foreground solely con</font><font style="color: #1C1C21;">c</font><font style="color: #070708;">eiv</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">d </font><font style="color: #1C1C21;">o</font><font style="color: #070708;">r </font><font style="color: #1C1C21;">r</font><font style="color: #070708;">edu</font><font style="color: #1C1C21;">c</font><font style="color: #070708;">ed to practi</font><font style="color: #1C1C21;">c</font><font style="color: #070708;">e by Immunocore or its sub-c</font><font style="color: #1C1C21;">o</font><font style="color: #070708;">ntra</font><font style="color: #1C1C21;">c</font><font style="color: #070708;">tors;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Immunocore Indemnified Parties</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 8);">has the meaning set forth in Section 11.8;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Immunocore Patent Challenge</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 8);">has the meaning set forth in Section 13.9;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Indication</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means a disease, tre</font><font style="color: #212126;">atme</font><font style="color: #070708;">nt area or t</font><font style="color: #212126;">he</font><font style="color: #363644;">r</font><font style="color: #212126;">a</font><font style="color: #070708;">peutic indication in rela</font><font style="color: #212126;">t</font><font style="color: #070708;">i</font><font style="color: #212126;">on t</font><font style="color: #070708;">o which an</font><font style="color: #212126;">y Li</font><font style="color: #070708;">censed Product has obta</font><font style="color: #212126;">in</font><font style="color: #363644;">e</font><font style="color: #212126;">d </font><font style="color: #070708;">Regulatory App</font><font style="color: #212126;">ro</font><font style="color: #070708;">v</font><font style="color: #212126;">al. </font><font style="color: #070708;">By
                    way of example a s</font><font style="color: #212126;">pe</font><font style="color: #070708;">cifi</font><font style="color: #212126;">c </font><font style="color: #070708;">type or sub</font><font style="color: #212126;">-t</font><font style="color: #070708;">y</font><font style="color: #212126;">p</font><font style="color: #070708;">e of cancer will be an Ind</font><font style="color: #212126;">i</font><font style="color: #363644;">ca</font><font style="color: #212126;">tion</font><font style="color: #070708;">. F</font><font style="color: #363644;">o</font><font style="color: #212126;">r </font><font style="color: #070708;">the pur</font><font style="color: #212126;">p</font><font style="color: #070708;">os</font><font style="color: #212126;">es </font><font style="color: #070708;">of pa</font><font style="color: #212126;">y</font><font style="color: #363644;">m</font><font style="color: #212126;">e</font><font style="color: #070708;">nt of Mileston</font><font style="color: #212126;">e </font><font style="color: #070708;">F</font><font style="color: #212126;">e</font><font style="color: #070708;">e</font><font style="color: #212126;">s </font><font style="color: #070708;">an I</font><font style="color: #363644;">n</font><font style="color: #070708;">d</font><font style="color: #212126;">i</font><font style="color: #363644;">c</font><font style="color: #212126;">a</font><font style="color: #070708;">tion w</font><font style="color: #363644;">i</font><font style="color: #070708;">ll </font><font style="color: #212126;">n</font><font style="color: #070708;">ot in</font><font style="color: #212126;">c</font><font style="color: #363644;">l</font><font style="color: #212126;">u</font><font style="color: #363644;">de </font><font style="color: #070708;">an extension,</font><font style="color: #212126;">&#160;</font><font style="color: #363644;">a</font><font style="color: #070708;">m</font><font style="color: #212126;">e</font><font style="color: #070708;">ndm</font><font style="color: #363644;">e</font><font style="color: #212126;">nt </font><font style="color: #070708;">or </font><font style="color: #363644;">s</font><font style="color: #212126;">u</font><font style="color: #070708;">pp</font><font style="color: #363644;">l</font><font style="color: #212126;">e</font><font style="color: #070708;">me</font><font style="color: #212126;">nt </font><font style="color: #070708;">t</font><font style="color: #212126;">o </font><font style="color: #070708;">an existing </font><font style="color: #212126;">R</font><font style="color: #070708;">e</font><font style="color: #212126;">gu</font><font style="color: #070708;">lato</font><font style="color: #363644;">r</font><font style="color: #212126;">y </font><font style="color: #363644;">A</font><font style="color: #212126;">pp</font><font style="color: #070708;">ro</font><font style="color: #212126;">v</font><font style="color: #363644;">a</font><font style="color: #070708;">l </font><font style="color: #363644;">for </font><font style="color: #070708;">treatm</font><font style="color: #363644;">e</font><font style="color: #212126;">n</font><font style="color: #070708;">t of the same </font><font style="color: #212126;">d</font><font style="color: #070708;">i</font><font style="color: #212126;">s</font><font style="color: #363644;">e</font><font style="color: #212126;">as</font><font style="color: #070708;">e o</font><font style="color: #363644;">r </font><font style="color: #212126;">d</font><font style="color: #363644;">i</font><font style="color: #212126;">ff</font><font style="color: #070708;">ere</font><font style="color: #212126;">nt pa</font><font style="color: #070708;">tient </font><font style="color: #363644;">s</font><font style="color: #070708;">tratifications






                    with</font><font style="color: #363644;">i</font><font style="color: #212126;">n </font><font style="color: #070708;">th</font><font style="color: #212126;">e </font><font style="color: #070708;">sam</font><font style="color: #212126;">e d</font><font style="color: #070708;">is</font><font style="color: #212126;">e</font><font style="color: #070708;">ase </font><font style="color: #212126;">s</font><font style="color: #363644;">t</font><font style="color: #212126;">ate</font><font style="color: #070708;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Infringement</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">has </font><font style="color: #363644;">t</font><font style="color: #212126;">h</font><font style="color: #070708;">e me</font><font style="color: #212126;">an</font><font style="color: #070708;">i</font><font style="color: #212126;">n</font><font style="color: #070708;">g set </font><font style="color: #212126;">forth </font><font style="color: #070708;">in Section</font><font style="color: #212126;">&#160;</font><font style="color: #070708;">7.4.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Infringement Notice</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">h</font><font style="color: #363644;">a</font><font style="color: #070708;">s the m</font><font style="color: #363644;">ea</font><font style="color: #070708;">ni</font><font style="color: #212126;">ng se</font><font style="color: #070708;">t forth </font><font style="color: #212126;">i</font><font style="color: #363644;">n </font><font style="color: #212126;">Section</font><font style="color: #070708;"> 7</font><font style="color: #212126;">.4</font><font style="color: #363644;">.</font><font style="color: #070708;">1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Initial HLA Program</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has </font><font style="color: #212126;">th</font><font style="color: #363644;">e </font><font style="color: #212126;">m</font><font style="color: #070708;">eani</font><font style="color: #212126;">ng set </font><font style="color: #070708;">forth in Section</font><font style="color: #212126;">&#160;</font><font style="color: #070708;">5.2</font><font style="color: #212126;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Initial Program Opt</font><font style="color: #363644;">i</font><font style="color: #070708;">on</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">ha</font><font style="color: #070708;">s </font><font style="color: #212126;">t</font><font style="color: #070708;">he m</font><font style="color: #363644;">e</font><font style="color: #070708;">a</font><font style="color: #212126;">n</font><font style="color: #363644;">i</font><font style="color: #070708;">ng set forth</font><font style="color: #212126;">&#160;</font><font style="color: #070708;">in Section
                  </font><font style="color: #212126;">6</font><font style="color: #070708;">.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Initial Program Option Period</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">ha</font><font style="color: #070708;">s </font><font style="color: #212126;">t</font><font style="color: #070708;">he m</font><font style="color: #363644;">e</font><font style="color: #070708;">a</font><font style="color: #212126;">n</font><font style="color: #363644;">i</font><font style="color: #070708;">ng set forth</font><font style="color: #212126;">&#160;</font><font style="color: #070708;">in Section
                  </font><font style="color: #212126;">6</font><font style="color: #070708;">.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Initial Pro</font><font style="color: #212126;">gr</font><font style="color: #070708;">ams</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">m</font><font style="color: #070708;">e</font><font style="color: #363644;">a</font><font style="color: #212126;">n</font><font style="color: #070708;">s th</font><font style="color: #212126;">e </font><font style="color: #070708;">I</font><font style="color: #212126;">n</font><font style="color: #070708;">it</font><font style="color: #212126;">i</font><font style="color: #070708;">al Tar</font><font style="color: #212126;">ge</font><font style="color: #070708;">t Programs and the Initial HLA Pro</font><font style="color: #363644;">g</font><font style="color: #212126;">r</font><font style="color: #363644;">a</font><font style="color: #070708;">m</font><font style="color: #363644;">s, </font><font style="color: #070708;">collect</font><font style="color: #363644;">iv</font><font style="color: #070708;">el</font><font style="color: #363644;">y</font><font style="color: #070708;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Initia</font><font style="color: #212126;">l T</font><font style="color: #363644;">a</font><font style="color: #212126;">rge</font><font style="color: #070708;">t</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">h</font><font style="color: #212126;">as </font><font style="color: #070708;">t</font><font style="color: #363644;">h</font><font style="color: #212126;">e me</font><font style="color: #070708;">aning </font><font style="color: #363644;">s</font><font style="color: #212126;">e</font><font style="color: #070708;">t </font><font style="color: #212126;">fo</font><font style="color: #070708;">rth in Se</font><font style="color: #212126;">c</font><font style="color: #070708;">tion 5.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Ini</font><font style="color: #212126;">t</font><font style="color: #070708;">ia</font><font style="color: #212126;">l T</font><font style="color: #070708;">arge</font><font style="color: #363644;">t </font><font style="color: #212126;">Pr</font><font style="color: #070708;">ogra</font><font style="color: #212126;">m</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">h</font><font style="color: #363644;">as </font><font style="color: #070708;">th</font><font style="color: #212126;">e </font><font style="color: #070708;">meani</font><font style="color: #212126;">n</font><font style="color: #070708;">g set forth i</font><font style="color: #212126;">n </font><font style="color: #070708;">Section 5.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Ini</font><font style="color: #212126;">tia</font><font style="color: #070708;">tion Fee</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #212126;">m</font><font style="color: #070708;">eans t</font><font style="color: #212126;">h</font><font style="color: #070708;">e </font><font style="color: #363644;">a</font><font style="color: #070708;">mount of either [***] per Collaboration Program, as applicable</font><font style="color: #212126;">, </font><font style="color: #070708;">as set forth in Schedule 2</font><font style="color: #212126;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Intelle</font><font style="color: #212126;">ctua</font><font style="color: #070708;">l Property Right</font><font style="color: #363644;">s</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means patents, rights to inventions, copyright and related rights, tradem</font><font style="color: #212126;">a</font><font style="color: #070708;">rks, trade names and domain
                    names, right</font><font style="color: #212126;">s </font><font style="color: #070708;">in d</font><font style="color: #212126;">es</font><font style="color: #070708;">igns, rights in </font><font style="color: #212126;">c</font><font style="color: #070708;">omputer </font><font style="color: #212126;">so</font><font style="color: #070708;">ftware, databa</font><font style="color: #212126;">se </font><font style="color: #070708;">right</font><font style="color: #212126;">s, </font><font style="color: #070708;">right</font><font style="color: #212126;">s </font><font style="color: #070708;">in Confidenti</font><font style="color: #212126;">a</font><font style="color: #070708;">l Information </font><font style="color: #212126;">(</font><font style="color: #070708;">includin</font><font style="color: #212126;">g </font><font style="color: #070708;">know-how) and </font><font style="color: #212126;">a</font><font style="color: #070708;">ny






                    oth</font><font style="color: #212126;">e</font><font style="color: #070708;">r intell</font><font style="color: #212126;">e</font><font style="color: #070708;">ctual prop</font><font style="color: #212126;">e</font><font style="color: #070708;">rty rights, in </font><font style="color: #212126;">ea</font><font style="color: #070708;">ch ca</font><font style="color: #212126;">s</font><font style="color: #070708;">e whether regi</font><font style="color: #212126;">s</font><font style="color: #070708;">tered </font><font style="color: #212126;">o</font><font style="color: #070708;">r unregi</font><font style="color: #212126;">s</font><font style="color: #070708;">tered and including all applications (or rights
                    to apply) for</font><font style="color: #212126;">, a</font><font style="color: #070708;">nd renewals </font><font style="color: #212126;">o</font><font style="color: #070708;">r exten</font><font style="color: #212126;">s</font><font style="color: #070708;">ions of, such rights and all similar or equiv</font><font style="color: #212126;">a</font><font style="color: #070708;">lent rights or form</font><font style="color: #212126;">s </font><font style="color: #070708;">of</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z2ce45e5a8b724a0ba48647695b7bdf0d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">prot</font><font style="color: #212126;">ec</font><font style="color: #070708;">tion which subsist or will subsist now or in the future in any part of the world;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 10); font-weight: bold;">Joint Foreground</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #08080A;">means any Foreground conceived or reduced to practice jointly by any of Immunocore or its sub- contractors on the one hand and any of GSK, its Affiliates or their sublice</font><font style="color: #363642;">n</font><font style="color: #08080A;">sees or any of their sub- contractors on the other ha</font><font style="color: #363642;">nd</font><font style="color: #08080A;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">JPT</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has the meaning s<font style="color: rgb(40, 40, 49);">e</font>t <font style="color: rgb(40, 40, 49);">fo</font>r<font style="color: rgb(40, 40, 49);">t</font>h in Section 4.6<font style="color: rgb(54, 54, 66);">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">JSC</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has the meaning <font style="color: rgb(40, 40, 49);">g</font>iven in Section 4<font style="color: rgb(54, 54, 66);">.</font>1;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Lapse Notice</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has the me<font style="color: rgb(54, 54, 66);">a</font>ning <font style="color: rgb(40, 40, 49);">g</font>iven in <font style="color: rgb(40, 40, 49);">S</font>ection <font style="color: rgb(40, 40, 49);">7</font>.<font style="color: rgb(40, 40, 49);">3</font>.5;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Lead Additional Work</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has the me<font style="color: rgb(40, 40, 49);">a</font>ning <font style="color: rgb(40, 40, 49);">se</font>t <font style="color: rgb(40, 40, 49);">for</font>th <font style="color: rgb(40, 40, 49);">in
                    Section</font> 3.5.<font style="color: rgb(54, 54, 66);">1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Lead Candidate</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">me<font style="color: rgb(40, 40, 49);">an</font>s <font style="color: rgb(54, 54, 66);">a</font>ny <font style="color: rgb(40, 40, 49);">Co</font>mpoun<font style="color: rgb(54, 54, 66);">d </font>resulting






                  <font style="color: rgb(54, 54, 66);">f</font>rom the perf<font style="color: rgb(40, 40, 49);">or</font>mance o<font style="color: rgb(40, 40, 49);">f </font>a Proje<font style="color: rgb(54, 54, 66);">c</font>t Pha<font style="color: rgb(54, 54, 66);">s</font>e <font style="color: rgb(40, 40, 49);">1 </font>and which <font style="color: rgb(40, 40, 49);">m</font>e<font style="color: rgb(40, 40, 49);">ets </font>or i<font style="color: rgb(40, 40, 49);">s </font>a<font style="color: rgb(40, 40, 49);">gr</font>eed <font style="color: rgb(40, 40, 49);">t</font>o meet th<font style="color: rgb(40, 40, 49);">e </font>L<font style="color: rgb(40, 40, 49);">e</font>ad Candidate <font style="color: rgb(40, 40, 49);">C</font>r<font style="color: rgb(54, 54, 66);">it</font>eria <font style="color: rgb(40, 40, 49);">o</font>r in relatio<font style="color: rgb(40, 40, 49);">n </font>t<font style="color: rgb(54, 54, 66);">o </font>whic<font style="color: rgb(40, 40, 49);">h </font>t<font style="color: rgb(54, 54, 66);">h</font>e <font style="color: rgb(40, 40, 49);">P</font>arties agree to p<font style="color: rgb(40, 40, 49);">ro</font>ceed t<font style="color: rgb(40, 40, 49);">o P</font>ro<font style="color: rgb(40, 40, 49);">ject </font>Phase 2<font style="color: rgb(54, 54, 66);">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Lead Candidate Criteria</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">me<font style="color: rgb(40, 40, 49);">a</font>n<font style="color: rgb(54, 54, 66);">s </font>the cri<font style="color: rgb(54, 54, 66);">t</font>e<font style="color: rgb(40, 40, 49);">ri</font>a <font style="color: rgb(40, 40, 49);">t</font>o b<font style="color: rgb(40, 40, 49);">e </font>achieved by Compounds as <font style="color: rgb(40, 40, 49);">se</font>t forth in Sect<font style="color: rgb(40, 40, 49);">io</font>n A of
                  Exhi<font style="color: rgb(40, 40, 49);">bi</font>t A, which <font style="color: rgb(40, 40, 49);">cr</font>it<font style="color: rgb(40, 40, 49);">e</font>ria m<font style="color: rgb(54, 54, 66);">a</font>y be modifie<font style="color: rgb(54, 54, 66);">d </font>for <font style="color: rgb(54, 54, 66);">e</font>a<font style="color: rgb(54, 54, 66);">c</font>h Collaboration Program <font style="color: rgb(40, 40, 49);">by </font>the JSC<font style="color: rgb(54, 54, 66);">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Licensed GSK <font style="color: rgb(54, 54, 66);">F</font>or<font style="color: rgb(40, 40, 49);">eg</font>roun<font style="color: rgb(54, 54, 66);">d</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">has <font style="color: rgb(54, 54, 66);">th</font>e meani<font style="color: rgb(40, 40, 49);">n</font>g set forth <font style="color: rgb(54, 54, 66);">in </font><font style="color: rgb(40, 40, 49);">Section</font>
                  6.13;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Licensed P<font style="color: rgb(54, 54, 66);">r</font>oduct</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #282831;">m</font>e<font style="color: rgb(54, 54, 66);">a</font>ns an<font style="color: rgb(40, 40, 49);">y </font>pharmace<font style="color: rgb(54, 54, 66);">u</font>tical product
                  comprising or <font style="color: rgb(54, 54, 66);">c</font>ontaini<font style="color: rgb(54, 54, 66);">ng a </font>Com<font style="color: rgb(54, 54, 66);">p</font>ound arising from a Collabor<font style="color: rgb(40, 40, 49);">at</font>io<font style="color: rgb(54, 54, 66);">n </font>Progr<font style="color: rgb(40, 40, 49);">am </font>whether or not as the sole activ<font style="color: rgb(40, 40, 49);">e </font><font style="color: rgb(54, 54, 66);">ing</font>redien<font style="color: rgb(54, 54, 66);">t </font>a<font style="color: rgb(54, 54, 66);">n</font>d in any dosage form or formulat<font style="color: rgb(54, 54, 66);">i</font>on. Licen<font style="color: rgb(54, 54, 66);">s</font>ed Product
                  excludes any p<font style="color: rgb(40, 40, 49);">ha</font>rmaceutica<font style="color: rgb(40, 40, 49);">l </font>product in which the relevant C<font style="color: rgb(54, 54, 66);">o</font>m<font style="color: rgb(40, 40, 49);">p</font>ound






                  w<font style="color: rgb(40, 40, 49);">h</font>en administered to any patient or <font style="color: rgb(40, 40, 49);">in</font>dividua<font style="color: rgb(40, 40, 49);">l </font>i<font style="color: rgb(54, 54, 66);">s </font>comprised







                  within or attached to (including <font style="color: rgb(40, 40, 49);">via </font>transfection) any cell;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Losses</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">means losses, damages, legal costs and other expenses arising out of or relating to a Claim;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Milesto<font style="color: rgb(40, 40, 49);">ne </font>Fee</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">means the amounts set out in Schedule 2 in relation to each milestone;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;">Ne<font style="color: rgb(40, 40, 49);">t S</font>ales</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">means, with respect to each Licensed Product, the amount for all sales reported (either publicly, or internally if public reporting is not applicable) by GSK, its Affiliates or their sublicensees in each of
                  their respective accounts on a calendar quarterly basis and in each case based on the</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z6ccdaf08799f42d0984a30daf638c8f0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;">accounting rules applicable to production of such accounts (&#8220;<font style="font-weight: bold;">Accounting Rules</font><font style="color: rgb(40, 40, 49);">&#8221;</font>). Such sales figures shall be the gross
                  amount billed by GSK<font style="color: rgb(40, 40, 49);">, </font>GSK&#8217;s <font style="color: rgb(8, 8, 8);">Affiliates or its sublicensees or where not billed, received by GSK, GSK&#8217;s Affiliates or its sublicensees in relation to any
                    Licensed Product less gross to net deductions typically and consistently applied to such receipts by either GSK, GSK&#8217;s Affiliates o</font><font style="color: rgb(38, 38, 45);">r </font><font style="color: rgb(8, 8, 8);">its sublicen</font><font style="color: rgb(38, 38, 45);">se</font><font style="color: rgb(8, 8, 8);">es in accordance with the </font><font style="color: rgb(38, 38, 45);">app</font><font style="color: rgb(8, 8, 8);">licable Account</font><font style="color: rgb(52, 52, 65);">ing </font><font style="color: rgb(8, 8, 8);">Rules and in each case </font><font style="color: rgb(52, 52, 65);">w</font><font style="color: rgb(8, 8, 8);">hi</font><font style="color: rgb(52, 52, 65);">c</font><font style="color: rgb(8, 8, 8);">h are actuall</font><font style="color: rgb(38, 38, 45);">y in</font><font style="color: rgb(8, 8, 8);">curred, allowed, paid, a</font><font style="color: rgb(52, 52, 65);">cc</font><font style="color: rgb(8, 8, 8);">rued or specifical</font><font style="color: rgb(52, 52, 65);">ly a</font><font style="color: rgb(8, 8, 8);">llocated. An illustration </font><font style="color: rgb(52, 52, 65);">o</font><font style="color: rgb(8, 8, 8);">f the gross to </font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(8, 8, 8);">et deductions applied by GS</font><font style="color: rgb(52, 52, 65);">K </font><font style="color: rgb(38, 38, 45);">as a</font><font style="color: rgb(8, 8, 8);">t t</font><font style="color: rgb(38, 38, 45);">h</font><font style="color: rgb(8, 8, 8);">e Effective D</font><font style="color: rgb(38, 38, 45);">a</font><font style="color: rgb(8, 8, 8);">te is s</font><font style="color: rgb(52, 52, 65);">et </font><font style="color: rgb(38, 38, 45);">o</font><font style="color: rgb(8, 8, 8);">ut in Schedul</font><font style="color: rgb(52, 52, 65);">e </font><font style="color: rgb(8, 8, 8);">10. As </font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(8, 8, 8);">t </font><font style="color: rgb(52, 52, 65);">the</font><font style="color: rgb(8, 8, 8);"> Eff</font><font style="color: rgb(52, 52, 65);">ec</font><font style="color: rgb(8, 8, 8);">t</font><font style="color: rgb(38, 38, 45);">i</font><font style="color: rgb(8, 8, 8);">ve D</font><font style="color: rgb(52, 52, 65);">ate, </font><font style="color: rgb(8, 8, 8);">the applicable A</font><font style="color: rgb(52, 52, 65);">ccou</font><font style="color: rgb(8, 8, 8);">ntin</font><font style="color: rgb(38, 38, 45);">g </font><font style="color: rgb(8, 8, 8);">Rules </font><font style="color: rgb(38, 38, 45);">are </font><font style="color: rgb(8, 8, 8);">IF</font><font style="color: rgb(38, 38, 45);">R</font><font style="color: rgb(8, 8, 8);">S b</font><font style="color: rgb(38, 38, 45);">u</font><font style="color: rgb(8, 8, 8);">t th</font><font style="color: rgb(38, 38, 45);">e </font><font style="color: rgb(8, 8, 8);">Net Sales d</font><font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(8, 8, 8);">fini</font><font style="color: rgb(52, 52, 65);">ti</font><font style="color: rgb(8, 8, 8);">on w</font><font style="color: rgb(38, 38, 45);">i</font><font style="color: rgb(8, 8, 8);">ll </font><font style="color: rgb(52, 52, 65);">be </font><font style="color: rgb(8, 8, 8);">am</font><font style="color: rgb(52, 52, 65);">en</font><font style="color: rgb(8, 8, 8);">d</font><font style="color: rgb(52, 52, 65);">ed </font><font style="color: rgb(8, 8, 8);">as app</font><font style="color: rgb(52, 52, 65);">rop</font><font style="color: rgb(8, 8, 8);">riate to reflect c</font><font style="color: rgb(52, 52, 65);">ha</font><font style="color: rgb(8, 8, 8);">nges t</font><font style="color: rgb(52, 52, 65);">o </font><font style="color: rgb(8, 8, 8);">G</font><font style="color: rgb(38, 38, 45);">SK</font><font style="color: rgb(8, 8, 8);">&#8217;s, its Affiliates or Sub</font><font style="color: rgb(38, 38, 45);">li</font><font style="color: rgb(8, 8, 8);">cen</font><font style="color: rgb(52, 52, 65);">se</font><font style="color: rgb(8, 8, 8);">es </font><font style="color: rgb(38, 38, 45);">acc</font><font style="color: rgb(8, 8, 8);">ounting </font><font style="color: rgb(52, 52, 65);">r</font><font style="color: rgb(8, 8, 8);">ules </font><font style="color: rgb(38, 38, 45);">(</font><font style="color: rgb(8, 8, 8);">fo</font><font style="color: rgb(52, 52, 65);">r </font><font style="color: rgb(8, 8, 8);">example, chan</font><font style="color: rgb(52, 52, 65);">g</font><font style="color: rgb(8, 8, 8);">e from </font><font style="color: rgb(38, 38, 45);">IFR</font><font style="color: rgb(8, 8, 8);">S to </font><font style="color: rgb(38, 38, 45);">U</font><font style="color: rgb(8, 8, 8);">K GAAP) </font><font style="color: rgb(52, 52, 65);">b</font><font style="color: rgb(8, 8, 8);">ro</font><font style="color: rgb(52, 52, 65);">u</font><font style="color: rgb(8, 8, 8);">ght about by </font><font style="color: rgb(38, 38, 45);">m</font><font style="color: rgb(8, 8, 8);">e</font><font style="color: rgb(38, 38, 45);">rge</font><font style="color: rgb(8, 8, 8);">r, ta</font><font style="color: rgb(38, 38, 45);">ke</font><font style="color: rgb(8, 8, 8);">-o</font><font style="color: rgb(52, 52, 65);">v</font><font style="color: rgb(8, 8, 8);">er o</font><font style="color: rgb(38, 38, 45);">r </font><font style="color: rgb(8, 8, 8);">la</font><font style="color: rgb(38, 38, 45);">w</font><font style="color: rgb(8, 8, 8);">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Nominated HLA</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">h</font><font style="color: #343441;">a</font><font style="color: #080808;">s the m</font><font style="color: #343441;">ea</font><font style="color: #080808;">ni</font><font style="color: #26262D;">ng s</font><font style="color: #080808;">et forth </font><font style="color: #26262D;">in </font><font style="color: #080808;">Section 5</font><font style="color: #343441;">.2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Nominated Target</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">has </font><font style="color: #26262D;">the </font><font style="color: #080808;">meani</font><font style="color: #26262D;">ng set </font><font style="color: #080808;">forth
                    in Section</font><font style="color: #26262D;">&#160;</font><font style="color: #080808;">5.1</font><font style="color: #26262D;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Nomination Date</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">me</font><font style="color: #26262D;">a</font><font style="color: #080808;">ns th</font><font style="color: #26262D;">e </font><font style="color: #080808;">date of r</font><font style="color: #26262D;">e</font><font style="color: #080808;">ceipt b</font><font style="color: #343441;">y </font><font style="color: #080808;">GSK of the accepta</font><font style="color: #26262D;">nce </font><font style="color: #080808;">in wri</font><font style="color: #26262D;">t</font><font style="color: #080808;">i</font><font style="color: #26262D;">ng </font><font style="color: #080808;">by Immunocore of the </font><font style="color: #26262D;">N</font><font style="color: #080808;">omina</font><font style="color: #26262D;">tio</font><font style="color: #080808;">n Notice;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Nomination No</font><font style="color: #26262D;">tic</font><font style="color: #080808;">e</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">h</font><font style="color: #26262D;">as </font><font style="color: #343441;">t</font><font style="color: #080808;">he mean</font><font style="color: #343441;">i</font><font style="color: #080808;">ng </font><font style="color: #26262D;">g</font><font style="color: #080808;">iven in </font><font style="color: #343441;">Section</font><font style="color: #080808;"> 5.3.2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Non-valida</font><font style="color: #343441;">te</font><font style="color: #080808;">d Targ</font><font style="color: #343441;">e</font><font style="color: #080808;">t</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">has the </font><font style="color: #343441;">me</font><font style="color: #080808;">a</font><font style="color: #26262D;">nin</font><font style="color: #080808;">g set </font><font style="color: #26262D;">forth </font><font style="color: #080808;">in Section 5.3.8;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Optio</font><font style="color: #26262D;">n </font><font style="color: #080808;">N</font><font style="color: #26262D;">oti</font><font style="color: #080808;">ce</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">has t</font><font style="color: #343441;">h</font><font style="color: #080808;">e </font><font style="color: #26262D;">me</font><font style="color: #080808;">aning </font><font style="color: #343441;">se</font><font style="color: #080808;">t </font><font style="color: #26262D;">forth</font><font style="color: #080808;"> in Section 6.3;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Party</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #26262D;">mea</font><font style="color: #080808;">n</font><font style="color: #26262D;">s </font><font style="color: #080808;">either </font><font style="color: #26262D;">G</font><font style="color: #080808;">SK or Immunocore as the context r</font><font style="color: #343441;">eq</font><font style="color: #080808;">u</font><font style="color: #343441;">i</font><font style="color: #080808;">res </font><font style="color: #343441;">a</font><font style="color: #080808;">n</font><font style="color: #343441;">d &#8220;</font><font style="color: #080808;">Parties&#8221; shall be construed </font><font style="color: #343441;">ac</font><font style="color: #080808;">cordingly;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Patent Liaison</font><font style="color: #343441;">s</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(8, 8, 8);">has the meaning set forth in Section 4.12;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Phase 1 D</font><font style="color: #343441;">at</font><font style="color: #080808;">a Package</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">[***] of each Phase 1 Trial conducted by Immunocore in connection with the Initial Programs</font><font style="color: #26262D;">&#160;</font><font style="color: #080808;">to all</font><font style="color: #26262D;">o</font><font style="color: #080808;">w GSK to determine whether it will exercise any Initial Program Option;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Phase 1 Trial</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means a clinical trial of a pharmaceutical product on human subjects or patients designed with the primary purpose of determining safety</font><font style="color: #26262D;">, </font><font style="color: #080808;">metabolism and pharmacokinetic properties and clinical pharmacology of </font><font style="color: #26262D;">s</font><font style="color: #080808;">uch product as and to</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z4d12f8a507614f0981bf362a8b6ff3dc" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">the extent defined for the United States in 21 C.F.R. &#167; 312.21(a), or its successor regulation</font><font style="color: #21212A;">, </font><font style="color: #080808;">or
                    the equivalent regulation in any other country, including the Phase 1 part of any Clinical Trial that is a combination Phase </font><font style="color: #21212A;">1 </font><font style="color: #080808;">Trial and Phase 2 Trial;
                    provided, that multiple coh</font><font style="color: #31333D;">or</font><font style="color: #080808;">ts in a single </font><font style="color: #31333D;">Phase</font><font style="color: #080808;"> 1 Trial, such as multip</font><font style="color: #31333D;">le </font><font style="color: #21212A;">d</font><font style="color: #080808;">ose-escalation </font><font style="color: #31333D;">co</font><font style="color: #080808;">horts, shall constitute a s</font><font style="color: #21212A;">i</font><font style="color: #080808;">n</font><font style="color: #21212A;">gl</font><font style="color: #080808;">e </font><font style="color: #31333D;">P</font><font style="color: #080808;">hase 1 Trial;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Phase 2 Trial</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means a clinica</font><font style="color: #21212A;">l t</font><font style="color: #080808;">rial of a pharmaceutical product on human p</font><font style="color: #31333D;">atient</font><font style="color: #080808;">s </font><font style="color: #31333D;">d</font><font style="color: #080808;">esigned to </font><font style="color: #21212A;">determine</font><font style="color: #31333D;">&#160;</font><font style="color: #080808;">a
                    variety of </font><font style="color: #21212A;">do</font><font style="color: #080808;">s</font><font style="color: #21212A;">e</font><font style="color: #080808;">s, dose r</font><font style="color: #31333D;">es</font><font style="color: #080808;">pon</font><font style="color: #21212A;">s</font><font style="color: #080808;">e</font><font style="color: #31333D;">, </font><font style="color: #080808;">and du</font><font style="color: #21212A;">ration </font><font style="color: #080808;">of effect, and </font><font style="color: #31333D;">to g</font><font style="color: #080808;">ener</font><font style="color: #31333D;">at</font><font style="color: #080808;">e </font><font style="color: #21212A;">initial </font><font style="color: #31333D;">e</font><font style="color: #080808;">vi</font><font style="color: #21212A;">de</font><font style="color: #080808;">nce o</font><font style="color: #31333D;">f </font><font style="color: #080808;">c</font><font style="color: #21212A;">li</font><font style="color: #080808;">nical safety </font><font style="color: #21212A;">an</font><font style="color: #080808;">d </font><font style="color: #31333D;">activity</font><font style="color: #21212A;">&#160;</font><font style="color: #080808;">i</font><font style="color: #31333D;">n a </font><font style="color: #080808;">ta</font><font style="color: #21212A;">rg</font><font style="color: #080808;">e</font><font style="color: #31333D;">t patient</font><font style="color: #080808;"> population, as an</font><font style="color: #21212A;">d </font><font style="color: #080808;">to </font><font style="color: #21212A;">th</font><font style="color: #080808;">e extent</font><font style="color: #31333D;">&#160;</font><font style="color: #080808;">defin</font><font style="color: #31333D;">ed </font><font style="color: #21212A;">fo</font><font style="color: #080808;">r the </font><font style="color: #21212A;">U</font><font style="color: #080808;">nited States in </font><font style="color: #31333D;">2</font><font style="color: #080808;">1 </font><font style="color: #21212A;">C.</font><font style="color: #080808;">F.R.






                  </font><font style="color: #31333D;">&#167; </font><font style="color: #080808;">312.2</font><font style="color: #31333D;">1</font><font style="color: #080808;">(</font><font style="color: #31333D;">b</font><font style="color: #080808;">), or
                    its</font><font style="color: #31333D;">&#160;</font><font style="color: #080808;">successor regulation, o</font><font style="color: #31333D;">r t</font><font style="color: #080808;">he equivalent regulation in any </font><font style="color: #21212A;">o</font><font style="color: #080808;">th</font><font style="color: #21212A;">er </font><font style="color: #080808;">count</font><font style="color: #31333D;">ry</font><font style="color: #080808;">, </font><font style="color: #21212A;">e</font><font style="color: #080808;">xclu</font><font style="color: #31333D;">d</font><font style="color: #080808;">ing the Phase</font><font style="color: #21212A;">&#160;</font><font style="color: #080808;">1 part
                    of any </font><font style="color: #21212A;">clin</font><font style="color: #080808;">ical </font><font style="color: #21212A;">t</font><font style="color: #080808;">rial that is </font><font style="color: #31333D;">a </font><font style="color: #080808;">comb</font><font style="color: #31333D;">inati</font><font style="color: #080808;">o</font><font style="color: #21212A;">n </font><font style="color: #080808;">Phase 1 Trial a</font><font style="color: #31333D;">n</font><font style="color: #080808;">d Phase </font><font style="color: #31333D;">2 </font><font style="color: #080808;">Trial;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Phase 3 Trial</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means</font><font style="color: #31333D;"> a </font><font style="color: #080808;">clinical</font><font style="color: #21212A;"> t</font><font style="color: #080808;">r</font><font style="color: #21212A;">ia</font><font style="color: #080808;">l of a pharmaceutical</font><font style="color: #21212A;">&#160;</font><font style="color: #080808;">product on </font><font style="color: #21212A;">pa</font><font style="color: #080808;">tient</font><font style="color: #21212A;">s </font><font style="color: #080808;">designed </font><font style="color: #31333D;">t</font><font style="color: #080808;">o </font><font style="color: #31333D;">(a</font><font style="color: #080808;">) estab</font><font style="color: #21212A;">l</font><font style="color: #080808;">i</font><font style="color: #21212A;">sh </font><font style="color: #080808;">that a drug i</font><font style="color: #31333D;">s
                  </font><font style="color: #080808;">s</font><font style="color: #21212A;">a</font><font style="color: #080808;">fe an</font><font style="color: #21212A;">d </font><font style="color: #31333D;">e</font><font style="color: #080808;">fficac</font><font style="color: #21212A;">i</font><font style="color: #080808;">ous f</font><font style="color: #31333D;">o</font><font style="color: #080808;">r its </font><font style="color: #21212A;">i</font><font style="color: #080808;">n</font><font style="color: #31333D;">t</font><font style="color: #080808;">ended use; (b) define </font><font style="color: #31333D;">wa</font><font style="color: #080808;">rnings, </font><font style="color: #31333D;">pr</font><font style="color: #080808;">ecautions and adverse </font><font style="color: #31333D;">r</font><font style="color: #080808;">eacti</font><font style="color: #21212A;">o</font><font style="color: #080808;">n</font><font style="color: #31333D;">s t</font><font style="color: #080808;">hat are </font><font style="color: #21212A;">ass</font><font style="color: #080808;">ociate</font><font style="color: #21212A;">d </font><font style="color: #31333D;">w</font><font style="color: #080808;">it</font><font style="color: #21212A;">h </font><font style="color: #080808;">the drug in the dos</font><font style="color: #21212A;">ag</font><font style="color: #080808;">e </font><font style="color: #31333D;">r</font><font style="color: #080808;">ange






                  </font><font style="color: #21212A;">to </font><font style="color: #080808;">be pres</font><font style="color: #21212A;">cribed; </font><font style="color: #080808;">and (c) support a Regulatory A</font><font style="color: #31333D;">ppro</font><font style="color: #080808;">val of s</font><font style="color: #31333D;">uch </font><font style="color: #080808;">drug, as and to the </font><font style="color: #31333D;">ex</font><font style="color: #080808;">t</font><font style="color: #31333D;">en</font><font style="color: #080808;">t defi</font><font style="color: #21212A;">n</font><font style="color: #080808;">ed for the United States in 21 C.F.R. &#167; </font>312.21 (<font style="color: rgb(49, 51, 61);">c), </font>o<font style="color: rgb(49, 51, 61);">r </font>its s<font style="color: rgb(33, 33, 42);">ucc</font>e<font style="color: rgb(49, 51, 61);">s</font>sor regulation, or the equival<font style="color: rgb(33, 33, 42);">ent </font>regulation<font style="color: rgb(49, 51, 61);"> in </font>any other country;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Pivo</font><font style="color: #31333D;">t</font><font style="color: #080808;">al </font><font style="color: #21212A;">Tr</font><font style="color: #080808;">ial</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means (</font><font style="color: #31333D;">a</font><font style="color: #080808;">) any Ph</font><font style="color: #21212A;">as</font><font style="color: #080808;">e 3 Trial,
                    or (b) a Phase 2 Trial; </font><font style="color: #21212A;">o</font><font style="color: #080808;">r (c) a</font><font style="color: #21212A;">n</font><font style="color: #080808;">y Clinical Trial, the results of which a</font><font style="color: #31333D;">re </font><font style="color: #080808;">deter</font><font style="color: #21212A;">m</font><font style="color: #080808;">i</font><font style="color: #21212A;">ne</font><font style="color: #080808;">d by a
                    Regulatory Authority to </font><font style="color: #31333D;">en</font><font style="color: #080808;">able g</font><font style="color: #31333D;">ra</font><font style="color: #080808;">n</font><font style="color: #31333D;">t </font><font style="color: #080808;">of Regulatory Approval or in relation to which </font><font style="color: #21212A;">a </font><font style="color: #080808;">R</font><font style="color: #21212A;">e</font><font style="color: #080808;">gulatory
                    Authority has found that the results may be sufficient to support an application for Regulatory Approval;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #080808;">Platform </font><font style="color: #31333D;">R</font><font style="color: #080808;">i</font><font style="color: #21212A;">g</font><font style="color: #080808;">hts</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means any Intellectual Property Rights owned or Controlled by Immunocore arising outside of this Agreement (in</font><font style="color: #21212A;">c</font><font style="color: #080808;">luding Third Party Platform Rights) but excluding Immunocore Background. For </font><font style="color: #21212A;">c</font><font style="color: #080808;">larity, Platform Right</font><font style="color: #21212A;">s </font><font style="color: #080808;">do not in</font><font style="color: #21212A;">c</font><font style="color: #080808;">lude Foreground;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #31333D;">Pro</font><font style="color: #080808;">ject Phase</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(8, 8, 8);">means a phase of a Collaboration Program set forth in the applicable Research Plan agreed between the Parties from time to time during the term of this Agreement;</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z0ca058b676be4d49824a75357c4165cd" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Project Phase 1</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means the first phase of any Collaboration Program to identify one or more Compounds to </font><font style="color: #070707;">the Target that meet the Lead Candidate Criteria;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Project Phase 2</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means Project Phase 2A and Project Phase 2B of any Collaboration Program in which any Compounds developed </font><font style="color: #1A1A1D;">o</font><font style="color: #2D2F38;">r </font><font style="color: #070707;">identified during Project Phase 1 are further </font><font style="color: #1A1A1D;">dev</font><font style="color: #2D2F38;">elo</font><font style="color: #070707;">ped with a </font><font style="color: #2D2F38;">go</font><font style="color: #070707;">al of meeting the Development</font><font style="color: #2D2F38;">&#160;</font><font style="color: #1A1A1D;">Candidate </font><font style="color: #070707;">Crit</font><font style="color: #2D2F38;">e</font><font style="color: #1A1A1D;">r</font><font style="color: #2D2F38;">ia</font><font style="color: #070707;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Project Phase 2A</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the first </font><font style="color: #2D2F38;">par</font><font style="color: #1A1A1D;">t </font><font style="color: #070707;">of Project Phase</font><font style="color: #2D2F38;">&#160;</font><font style="color: #070707;">2 in which any Compound </font><font style="color: #2D2F38;">f</font><font style="color: #070707;">rom Project Phase</font><font style="color: #2D2F38;">&#160;</font><font style="color: #1A1A1D;">1 </font><font style="color: #070707;">undergoes [***]</font><font style="color: #2D2F38;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Project Phase 2B</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the </font><font style="color: #1A1A1D;">s</font><font style="color: #2D2F38;">e</font><font style="color: #1A1A1D;">c</font><font style="color: #2D2F38;">o</font><font style="color: #1A1A1D;">nd </font><font style="color: #070707;">p</font><font style="color: #2D2F38;">art of </font><font style="color: #070707;">Project </font><font style="color: #1A1A1D;">P</font><font style="color: #2D2F38;">h</font><font style="color: #070707;">ase </font><font style="color: #1A1A1D;">2 </font><font style="color: #2D2F38;">i</font><font style="color: #1A1A1D;">n which</font><font style="color: #2D2F38;"> [***]</font><font style="color: #1A1A1D;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Prosecuting Party</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">has </font><font style="color: #2D2F38;">the</font><font style="color: #070707;"> mean</font><font style="color: #2D2F38;">i</font><font style="color: #070707;">n</font><font style="color: #2D2F38;">g </font><font style="color: #070707;">set fo</font><font style="color: #2D2F38;">r</font><font style="color: #070707;">t</font><font style="color: #2D2F38;">h </font><font style="color: #070707;">in Section</font><font style="color: #1A1A1D;"> 7.3.5;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Regulatory Approval</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1A1A1D;">m</font><font style="color: #2D2F38;">e</font><font style="color: #1A1A1D;">ans </font><font style="color: #2D2F38;">r</font><font style="color: #070707;">egulatory </font><font style="color: #1A1A1D;">approval</font><font style="color: #070707;">&#160;</font><font style="color: #2D2F38;">(</font><font style="color: #070707;">i</font><font style="color: #2D2F38;">ncl</font><font style="color: #070707;">uding pricing
                    or </font><font style="color: #1A1A1D;">[***]</font><font style="color: #070707;"> to the exte</font><font style="color: #2D2F38;">n</font><font style="color: #1A1A1D;">t </font><font style="color: #070707;">the </font><font style="color: #1A1A1D;">applicable </font><font style="color: #2D2F38;">r</font><font style="color: #1A1A1D;">e</font><font style="color: #2D2F38;">g</font><font style="color: #070707;">ulatory </font><font style="color: #1A1A1D;">authorities</font><font style="color: #070707;"> in </font><font style="color: #2D2F38;">s</font><font style="color: #1A1A1D;">uc</font><font style="color: #2D2F38;">h </font><font style="color: #070707;">country</font><font style="color: #1A1A1D;">&#160;</font><font style="color: #070707;">require a </font><font style="color: #1A1A1D;">pricing </font><font style="color: #070707;">o</font><font style="color: #2D2F38;">r </font><font style="color: #070707;">reimbursement approv</font><font style="color: #2D2F38;">a</font><font style="color: #1A1A1D;">l </font><font style="color: #2D2F38;">pr</font><font style="color: #070707;">ior to commercialization</font><font style="color: #2D2F38;">&#160;</font><font style="color: #070707;">of a product in </font><font style="color: #2D2F38;">s</font><font style="color: #070707;">uch </font><font style="color: #2D2F38;">c</font><font style="color: #1A1A1D;">o</font><font style="color: #2D2F38;">un</font><font style="color: #070707;">try) r</font><font style="color: #2D2F38;">e</font><font style="color: #1A1A1D;">qu</font><font style="color: #2D2F38;">ir</font><font style="color: #070707;">ed t</font><font style="color: #2D2F38;">o m</font><font style="color: #070707;">a</font><font style="color: #2D2F38;">r</font><font style="color: #070707;">ket a Licensed Product</font><font style="color: #1A1A1D;">&#160;</font><font style="color: #070707;">for a</font><font style="color: #2D2F38;">n </font><font style="color: #070707;">Indication </font><font style="color: #2D2F38;">in acc</font><font style="color: #070707;">ordance with the A</font><font style="color: #2D2F38;">p</font><font style="color: #1A1A1D;">p</font><font style="color: #2D2F38;">lic</font><font style="color: #1A1A1D;">able L</font><font style="color: #2D2F38;">a</font><font style="color: #070707;">ws and </font><font style="color: #1A1A1D;">regulation</font><font style="color: #070707;">s
                    of a given </font><font style="color: #2D2F38;">co</font><font style="color: #070707;">u</font><font style="color: #2D2F38;">n</font><font style="color: #1A1A1D;">try, </font><font style="color: #2D2F38;">o</font><font style="color: #070707;">r similar </font><font style="color: #2D2F38;">a</font><font style="color: #1A1A1D;">pprovals </font><font style="color: #070707;">in other foreign </font><font style="color: #2D2F38;">j</font><font style="color: #070707;">urisdict</font><font style="color: #2D2F38;">ion</font><font style="color: #1A1A1D;">s. </font><font style="color: #070707;">In the </font><font style="color: #1A1A1D;">U</font><font style="color: #2D2F38;">n</font><font style="color: #070707;">ited
                    States, Regulatory Approval </font><font style="color: #2D2F38;">m</font><font style="color: #070707;">eans </font><font style="color: #2D2F38;">app</font><font style="color: #070707;">roval of a New Drug Application</font><font style="color: #2D2F38;">&#160;</font><font style="color: #070707;">(&#8220;</font><font style="font-weight: bold; color: #070707;">ND</font><font style="font-weight: bold; color: #2D2F38;">A</font><font style="color: #1A1A1D;">&#8221;),</font><font style="color: #070707;"> Biologics License Application (&#8220;</font><font style="font-weight: bold; color: #070707;">BLA</font><font style="color: #070707;">&#8221;) </font><font style="color: #1A1A1D;">or </font><font style="color: #070707;">an






                    equi</font><font style="color: #2D2F38;">v</font><font style="color: #1A1A1D;">alent </font><font style="color: #070707;">by the FDA, and in the </font><font style="color: #1A1A1D;">European</font><font style="color: #070707;"> Union</font><font style="color: #1A1A1D;">, </font><font style="color: #070707;">Regulatory Approval means </font><font style="color: #1A1A1D;">a</font><font style="color: #2D2F38;">p</font><font style="color: #1A1A1D;">p</font><font style="color: #2D2F38;">ro</font><font style="color: #070707;">val </font><font style="color: #1A1A1D;">o</font><font style="color: #2D2F38;">f </font><font style="color: #1A1A1D;">a </font><font style="color: #070707;">Marketing Authorization
                    Application </font><font style="color: #2D2F38;">(</font><font style="color: #070707;">&#8220;</font><font style="font-weight: bold; color: #070707;">MAA</font><font style="color: #070707;">&#8221;)</font><font style="font-weight: bold; color: #070707;">&#160;</font><font style="color: #2D2F38;">o</font><font style="color: #070707;">r </font><font style="color: #2D2F38;">a</font><font style="color: #070707;">n equivalent by the EMA. [***]</font><font style="color: #1A1A1D;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #1A1A1D;">R</font><font style="color: #2D2F38;">e</font><font style="color: #1A1A1D;">gulatory </font><font style="color: #070707;">Authority</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070707;">means the FDA in the U.S. </font><font style="color: #1A1A1D;">or any </font><font style="color: #070707;">health regulatory </font><font style="color: #1A1A1D;">authority </font><font style="color: #070707;">in </font><font style="color: #1A1A1D;">another </font><font style="color: #070707;">country in the Territory that is a counterpart to the FDA </font><font style="color: #1A1A1D;">and </font><font style="color: #070707;">holds responsibility for granting Regulatory Approval for a product in such country, including the EMA, </font><font style="color: #1A1A1D;">and </font><font style="color: #070707;">any successor(s) thereto;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 7); font-weight: bold;">Replacement Target</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 7);">has the meaning set forth in Section 5.3.4;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Research Plan</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 8);">has the meaning set forth in Section 2.1;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Results</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means any data, know-how, output, mutations, sequences, produ</font><font style="color: #2A2A34;">c</font><font style="color: #070708;">ts, modifications, developments, assay</font><font style="color: #2A2A34;">s, </font><font style="color: #1C1C1F;">c</font><font style="color: #3B3B48;">o</font><font style="color: #1C1C1F;">mpounds, </font><font style="color: #070708;">m</font><font style="color: #2A2A34;">ate</font><font style="color: #070708;">rials, documentation or oth</font><font style="color: #2A2A34;">er r</font><font style="color: #070708;">esults arisin</font><font style="color: #2A2A34;">g directly</font><font style="color: #070708;"> from the
                    performanc</font><font style="color: #3B3B48;">e </font><font style="color: #1C1C1F;">of </font><font style="color: #070708;">a Collaboration </font><font style="color: #2A2A34;">P</font><font style="color: #070708;">rogram</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="z4800f76e0d9c4a12b505723b322f4324" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">&#160;</td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">by either Pa</font><font style="color: #2A2A34;">rty, </font><font style="color: #1C1C1F;">its </font><font style="color: #070708;">Affiliates </font><font style="color: #3B3B48;">o</font><font style="color: #070708;">r their subcontractors;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Royalty</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means the </font><font style="color: #2A2A34;">roya</font><font style="color: #070708;">lt</font><font style="color: #2A2A34;">y </font><font style="color: #070708;">set </font><font style="color: #2A2A34;">o</font><font style="color: #070708;">u</font><font style="color: #2A2A34;">t i</font><font style="color: #070708;">n Section 9.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Royalty Report</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has the </font><font style="color: #1C1C1F;">meaning </font><font style="color: #2A2A34;">given </font><font style="color: #1C1C1F;">in Section</font><font style="color: #3B3B48;">&#160;</font><font style="color: #070708;">9.8;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Royalty Term</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has </font><font style="color: #2A2A34;">t</font><font style="color: #070708;">he </font><font style="color: #2A2A34;">me</font><font style="color: #070708;">aning </font><font style="color: #1C1C1F;">set </font><font style="color: #070708;">forth </font><font style="color: #1C1C1F;">in </font><font style="color: #070708;">Section </font><font style="color: #1C1C1F;">9</font><font style="color: #3B3B48;">.</font><font style="color: #070708;">2;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Subcommittee</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1C1C1F;">has </font><font style="color: #3B3B48;">t</font><font style="color: #1C1C1F;">he </font><font style="color: #070708;">me</font><font style="color: #2A2A34;">an</font><font style="color: #070708;">i</font><font style="color: #2A2A34;">n</font><font style="color: #070708;">g set </font><font style="color: #2A2A34;">forth </font><font style="color: #070708;">in Section</font><font style="color: #2A2A34;">&#160;</font><font style="color: #1C1C1F;">4.</font><font style="color: #070708;">9;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Target</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #1C1C1F;">means </font><font style="color: #070708;">th</font><font style="color: #2A2A34;">e </font><font style="color: #070708;">protein or bi</font><font style="color: #2A2A34;">ologica</font><font style="color: #070708;">l mol</font><font style="color: #2A2A34;">ec</font><font style="color: #070708;">ule from </font><font style="color: #2A2A34;">w</font><font style="color: #070708;">hich </font><font style="color: #2A2A34;">an
                  </font><font style="color: #070708;">HLA</font><font style="color: #2A2A34;">-presented</font><font style="color: #070708;"> antigen is derived</font><font style="color: #2A2A34;">;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">Target Program</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has </font><font style="color: #2A2A34;">the</font><font style="color: #070708;"> me</font><font style="color: #2A2A34;">a</font><font style="color: #070708;">ning set forth</font><font style="color: #3B3B48;">&#160;</font><font style="color: #1C1C1F;">in </font><font style="color: #070708;">Section </font><font style="color: #2A2A34;">5.</font><font style="color: #070708;">1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(7, 7, 8); font-weight: bold;">TCR</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means </font><font style="color: #2A2A34;">a </font><font style="color: #3B3B48;">T-</font><font style="color: #070708;">cell recept</font><font style="color: #3B3B48;">or </font><font style="color: #070708;">in any for</font><font style="color: #2A2A34;">m;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Terminated Produ</font><font style="color: #2A2A34;">ct</font><font style="color: #070708;">s</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">has </font><font style="color: #2A2A34;">the</font><font style="color: #070708;"> meani</font><font style="color: #2A2A34;">ng </font><font style="color: #070708;">set forth
                  </font><font style="color: #2A2A34;">in Section</font><font style="color: #070708;"> 13.6.7;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Terminate</font><font style="color: #2A2A34;">d </font><font style="color: #070708;">Projects</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #2A2A34;">has t</font><font style="color: #070708;">he m</font><font style="color: #2A2A34;">ean</font><font style="color: #070708;">ing set forth in Section 13.6;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Territo</font><font style="color: #2A2A34;">ry</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">mean</font><font style="color: #2A2A34;">s </font><font style="color: #1C1C1F;">w</font><font style="color: #3B3B48;">o</font><font style="color: #1C1C1F;">rldwide;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Thir</font><font style="color: #3B3B48;">d </font><font style="color: #070708;">Pa</font><font style="color: #2A2A34;">rt</font><font style="color: #070708;">y</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means </font><font style="color: #3B3B48;">a</font><font style="color: #070708;">ny entity </font><font style="color: #2A2A34;">o</font><font style="color: #070708;">r
                    individual which is not a </font><font style="color: #1C1C1F;">Party</font><font style="color: #070708;">&#160;</font><font style="color: #1C1C1F;">to </font><font style="color: #070708;">this A</font><font style="color: #2A2A34;">g</font><font style="color: #070708;">reement or an Affiliate of GSK;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Thi</font><font style="color: #2A2A34;">rd </font><font style="color: #070708;">Party Infringement Claim</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #2A2A34;">ha</font><font style="color: #070708;">s the </font><font style="color: #1C1C1F;">mea</font><font style="color: #3B3B48;">n</font><font style="color: #070708;">ing set forth
                    in Section 7.7.1;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Third Part</font><font style="color: #2A2A34;">y Platform </font><font style="color: #070708;">Rights</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify; color: rgb(7, 7, 8);">means any patents or patent applications Controlled by Immunocore and arising under an agreement between Immunocore and a Third Party, which agreement is for the development or research
                  of Compounds;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="font-weight: bold;"><font style="color: #070708;">Va</font><font style="color: #3B3B48;">l</font><font style="color: #070708;">i</font><font style="color: #2A2A34;">d </font><font style="color: #070708;">Claim</font></div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #070708;">means a </font><font style="color: #1C1C1F;">claim of </font><font style="color: #070708;">any issued and unexpired pat</font><font style="color: #2A2A34;">e</font><font style="color: #070708;">nt or patent application within the Immunocore Foreground, Immunocore Background or Platform Rights, to the extent that </font><font style="color: #1C1C1F;">such </font><font style="color: #070708;">claim in
                    any patent or patent application has not lapsed, been withdrawn or been disclaimed, denied or admitted to be invalid by any </font><font style="color: #1C1C1F;">court </font><font style="color: #070708;">of competent jurisdiction in a
                    non-appealable judgment or otherwise rendered invalid or unenforceable </font><font style="color: #080808;">through reissue, disclaimer or otherwise through re-examination, opposition, post-grant review or </font><font style="font-style: italic; color: #080808;">inter partes </font><font style="color: #080808;">review, or lost through interference proceeding, or been cancelled or abandoned or dedicated to the public;</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table id="zb6fd5b2f87284cdb8de827ffd1d79e18" style="font-family: 'Times New Roman'; font-size: 10pt; width: 70%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">VAT</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means value added t</font><font style="color: #2D2D38;">ax </font><font style="color: #1C1C1F;">as </font><font style="color: #080808;">provided f</font><font style="color: #2D2D38;">or </font><font style="color: #080808;">in the Value Added Tax A</font><font style="color: #2D2D38;">ct </font><font style="color: #080808;">1994 togeth</font><font style="color: #2D2D38;">er </font><font style="color: #080808;">with legislation supple</font><font style="color: #2D2D38;">me</font><font style="color: #080808;">ntal thereto or othe</font><font style="color: #2D2D38;">r </font><font style="color: #080808;">tax or a similar nature in </font><font style="color: #2D2D38;">s</font><font style="color: #080808;">ubstitution for it;</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="width: 40%; vertical-align: top;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="color: rgb(8, 8, 8); font-weight: bold;">Year</div>
              </td>
              <td style="width: 40%; vertical-align: top;">
                <div style="text-align: justify;"><font style="color: #080808;">means a pe</font><font style="color: #2D2D38;">riod </font><font style="color: #1C1C1F;">of </font><font style="color: #080808;">12 </font><font style="color: #1C1C1F;">calendar






                  </font><font style="color: #080808;">months.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <table id="z64a446094b84432fa17047b56e0b77fa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In this Agreement:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zac80bfaafb99424ab37440fffdddfff9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">1.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>references to Sections <font style="color: rgb(45, 45, 56);">and </font><font style="color: rgb(28, 28, 31);">Articles a</font><font style="color: rgb(61, 63, 73);">r</font>e to <font style="color: rgb(28, 28, 31);">the </font>Sections






                <font style="color: rgb(45, 45, 56);">an</font>d Articles of this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z188f0b0dd2f343a88a6ee02f2cf242fc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">1.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>headings are used f<font style="color: rgb(45, 45, 56);">or </font><font style="color: rgb(28, 28, 31);">convenience</font> onl<font style="color: rgb(45, 45, 56);">y and </font><font style="color: rgb(28, 28, 31);">do </font>not affe<font style="color: rgb(61, 63, 73);">c</font>t its int<font style="color: rgb(45, 45, 56);">erpre</font>tation;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze7a5fbe2994f48809d6ff521091c1bf9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">1.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">(a) the word &#8220;includi</font><font style="color: #2D2D38;">n</font><font style="color: #080808;">g&#8221; sha</font><font style="color: #2D2D38;">ll </font><font style="color: #080808;">be deemed to be </font><font style="color: #1C1C1F;">followed </font><font style="color: #080808;">b</font><font style="color: #2D2D38;">y the </font><font style="color: #080808;">phrase &#8220;without limitation&#8221; or </font><font style="color: #2D2D38;">li</font><font style="color: #080808;">ke expres</font><font style="color: #2D2D38;">si</font><font style="color: #080808;">on; (b) </font><font style="color: #2D2D38;">t</font><font style="color: #080808;">he singular sh</font><font style="color: #2D2D38;">a</font><font style="color: #080808;">ll inclu</font><font style="color: #2D2D38;">d</font><font style="color: #080808;">e </font><font style="color: #1C1C1F;">the </font><font style="color: #080808;">plural and vice versa;
                  and </font><font style="color: #1C1C1F;">(c) </font><font style="color: #080808;">masculi</font><font style="color: #2D2D38;">ne, </font><font style="color: #1C1C1F;">feminine </font><font style="color: #080808;">and neut</font><font style="color: #2D2D38;">er </font><font style="color: #080808;">pronouns </font><font style="color: #3D3F49;">a</font><font style="color: #1C1C1F;">nd </font><font style="color: #080808;">expressions shall be interchangeable; </font><font style="color: #1C1C1F;">and</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z458cbb9c510c49b8a43f801c2d2989c6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">1.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>referen<font style="color: rgb(45, 45, 56);">c</font>e<font style="color: rgb(45, 45, 56);">s </font><font style="color: rgb(28, 28, 31);">to </font>a st<font style="color: rgb(45, 45, 56);">atu</font>tory <font style="color: rgb(28, 28, 31);">provision </font>includ<font style="color: rgb(45, 45, 56);">e </font>refere<font style="color: rgb(45, 45, 56);">nces </font>to the statutory provision as m<font style="color: rgb(45, 45, 56);">o</font>dified or <font style="color: rgb(28, 28, 31);">re</font><font style="color: rgb(61, 63, 73);">-e</font>nact<font style="color: rgb(45, 45, 56);">ed </font><font style="color: rgb(61, 63, 73);">or </font>both from time to time and to any subordinate
                legislation<font style="color: rgb(28, 28, 31);">&#160;</font>made <font style="color: rgb(28, 28, 31);">under the statutory </font>p<font style="color: rgb(45, 45, 56);">ro</font>vision.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1e710a1482d4487eb4674a483210ff4b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Gener</font><font style="font-weight: bold; color: #2D2D38;">a</font><font style="font-weight: bold;">l </font><font style="font-weight: bold; color: #2D2D38;">Bac</font><font style="font-weight: bold;">kground






                  - Collaboration </font><font style="font-weight: bold; color: #1C1C1F;">Programs</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z212aa4d3835149c3b3b60db64dbad574" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties sha<font style="color: rgb(45, 45, 56);">ll </font>collaborate on <font style="color: rgb(45, 45, 56);">a s</font>eries of C<font style="color: rgb(45, 45, 56);">o</font>llaboration Programs in accordance with t<font style="color: rgb(45, 45, 56);">he ter</font>ms <font style="color: rgb(28, 28, 31);">a</font><font style="color: rgb(61, 63, 73);">n</font><font style="color: rgb(28, 28, 31);">d conditions </font>set forth<font style="color: rgb(45, 45, 56);"> in </font>this A<font style="color: rgb(45, 45, 56);">gree</font>ment, and in accordance with a research plan <font style="color: rgb(61, 63, 73);">e</font>stablished by the JSC, as <font style="color: rgb(45, 45, 56);">am</font>ended






                <font style="color: rgb(28, 28, 31);">from </font>time to time (each, a &#8220;<font style="font-weight: bold;">Research Plan</font>&#8221;). The Research Plan <font style="color: rgb(28, 28, 31);">agreed </font>to by the Parties<font style="color: rgb(45, 45, 56);">&#160;</font>prior to the Effective Date governing the first Initial <font style="color: rgb(28, 28, 31);">Targ</font><font style="color: rgb(61, 63, 73);">et </font><font style="color: rgb(28, 28, 31);">Program is </font><font style="color: rgb(45, 45, 56);">se</font>t forth in Schedule 1; provided, that such Research Plan shall be updat<font style="color: rgb(45, 45, 56);">ed b</font>y the J<font style="color: rgb(45, 45, 56);">S</font>C within [***] of the
                establishment of the JSC to include additional <font style="color: rgb(45, 45, 56);">de</font>tails of <font style="color: rgb(45, 45, 56);">specific </font>activities and timelines required to achieve the Lead Candidate <font style="color: rgb(61, 63, 73);">Criteria</font> an<font style="color: rgb(61, 63, 73);">d </font>D<font style="color: rgb(45, 45, 56);">ev</font>elopment Candidate Criteria. Thereafter, the Research Plan for the <font style="color: rgb(28, 28, 31);">first </font>Initial Target Program shall be further updated when reasonable, to include detaile<font style="color: rgb(45, 45, 56);">d Clinical</font> Trial<font style="color: rgb(45, 45, 56);"> de</font>sign and other
                matters that cannot reasonably be <font style="color: rgb(28, 28, 31);">addressed as </font>of th<font style="color: rgb(45, 45, 56);">e </font><font style="color: rgb(28, 28, 31);">Effective Date </font>or the [***] period referred to
                above. It is anticipated that Im<font style="color: rgb(45, 45, 56);">mu</font>nocore w<font style="color: rgb(45, 45, 56);">il</font>l <font style="color: rgb(61, 63, 73);">b</font>e primarily responsible for the conduct of the Research
                Plans as<font style="color: rgb(28, 28, 31);"> p</font><font style="color: rgb(61, 63, 73);">ro</font>v<font style="color: rgb(45, 45, 56);">id</font>ed further in this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9e7e3317ca59413e96febdd3f1fec35e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2D2D38;">In </font><font style="color: #1C1C1F;">general, </font>each Research Plan for each Collaboration Program shall include equivalent details to those agreed in the Research Plan for the first Initial Target
                Program set forth in Schedule 1, [***]<font style="color: rgb(7, 7, 8);">. The Research Plan for each Collaboration Program shall be developed and agreed in accordance with Section 5.3.7</font><font style="color: rgb(29, 29, 35);">, </font><font style="color: rgb(7, 7, 8);">and once agreed and finally approved by the JSC</font><font style="color: rgb(29, 29, 35);">, </font><font style="color: rgb(7, 7, 8);">the Research Plan for each Collaboration Program shall form a schedule
                  to this Agreement; provided, that with respect to the Initial Programs, each such Research Plan </font><font style="color: rgb(29, 29, 35);">s</font><font style="color: rgb(7, 7, 8);">hall be updated by the JSC to include detailed
                  Clinical Trial design and other matters </font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">h</font><font style="color: rgb(7, 7, 8);">at cannot r</font><font style="color: rgb(52, 52, 63);">ea</font><font style="color: rgb(29, 29, 35);">s</font><font style="color: rgb(7, 7, 8);">onably be addressed at the time the initial Research Plan is agree</font><font style="color: rgb(52, 52, 63);">d.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zadb4d6b821b541cd9ce784a9314527b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Performance and Funding of Collaboration Programs</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze3c9479f366e4555a1fff9868a5f4af8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall commence work under th<font style="color: rgb(29, 29, 35);">e </font><font style="color: rgb(52, 52, 63);">R</font><font style="color: rgb(29, 29, 35);">es</font><font style="color: rgb(52, 52, 63);">e</font>arc<font style="color: rgb(29, 29, 35);">h </font>Plan for th<font style="color: rgb(29, 29, 35);">e fi</font>rst Collaboration Program upon completion by the JSC of <font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">he </font>u<font style="color: rgb(29, 29, 35);">p</font>date<font style="color: rgb(29, 29, 35);">d </font><font style="color: rgb(52, 52, 63);">R</font><font style="color: rgb(29, 29, 35);">e</font>searc<font style="color: rgb(29, 29, 35);">h P</font>lan a<font style="color: rgb(52, 52, 63);">s set </font>forth in Section 2.1. All other Collaboration <font style="color: rgb(29, 29, 35);">Program</font>s <font style="color: rgb(52, 52, 63);">s</font><font style="color: rgb(29, 29, 35);">hal</font>l c<font style="color: rgb(52, 52, 63);">om</font>m<font style="color: rgb(29, 29, 35);">en</font>ce <font style="color: rgb(29, 29, 35);">prom</font>ptly after agreement of the Research Plan, in
                acc<font style="color: rgb(29, 29, 35);">o</font><font style="color: rgb(52, 52, 63);">r</font>da<font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(29, 29, 35);">c</font>e w<font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(29, 29, 35);">th </font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(29, 29, 35);">n</font><font style="color: rgb(52, 52, 63);">d </font>su<font style="color: rgb(52, 52, 63);">b</font><font style="color: rgb(29, 29, 35);">je</font><font style="color: rgb(52, 52, 63);">c</font><font style="color: rgb(29, 29, 35);">t t</font>o Sect<font style="color: rgb(29, 29, 35);">i</font><font style="color: rgb(52, 52, 63);">on </font>5.3.7.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z5ec63dc17c38444d849263faa2daf99e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore (or its subcontractors) <font style="color: rgb(52, 52, 63);">s</font>h<font style="color: rgb(29, 29, 35);">all b</font>e re<font style="color: rgb(52, 52, 63);">s</font><font style="color: rgb(29, 29, 35);">po</font>n<font style="color: rgb(29, 29, 35);">s</font>ible f<font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(29, 29, 35);">r </font><font style="color: rgb(52, 52, 63);">c</font>onduc<font style="color: rgb(29, 29, 35);">ti</font>n<font style="color: rgb(52, 52, 63);">g </font><font style="color: rgb(29, 29, 35);">th</font>e activities set forth in each Research Plan, in ac<font style="color: rgb(29, 29, 35);">c</font>o<font style="color: rgb(29, 29, 35);">r</font><font style="color: rgb(52, 52, 63);">d</font><font style="color: rgb(29, 29, 35);">a</font>nce w<font style="color: rgb(29, 29, 35);">i</font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">h t</font>he te<font style="color: rgb(52, 52, 63);">r</font>m<font style="color: rgb(52, 52, 63);">s </font>of suc<font style="color: rgb(52, 52, 63);">h </font><font style="color: rgb(29, 29, 35);">R</font><font style="color: rgb(52, 52, 63);">e</font>s<font style="color: rgb(29, 29, 35);">e</font>arch Plan, using Commercially Reasonable Effor<font style="color: rgb(29, 29, 35);">ts </font><font style="color: rgb(52, 52, 63);">an</font><font style="color: rgb(29, 29, 35);">d </font>in <font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(29, 29, 35);">cc</font><font style="color: rgb(52, 52, 63);">o</font>rda<font style="color: rgb(29, 29, 35);">n</font><font style="color: rgb(52, 52, 63);">c</font>e <font style="color: rgb(29, 29, 35);">w</font>ith all A<font style="color: rgb(29, 29, 35);">pp</font>licable Laws<font style="color: rgb(29, 29, 35);">. </font>In addition, Immunocore (or its s<font style="color: rgb(29, 29, 35);">ubc</font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(29, 29, 35);">n</font>tra<font style="color: rgb(29, 29, 35);">ct</font>ors) <font style="color: rgb(29, 29, 35);">s</font>hall p<font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">rfo</font>rm t<font style="color: rgb(29, 29, 35);">he </font><font style="color: rgb(52, 52, 63);">Collaboration</font> Program in good scientific manner, and <font style="color: rgb(52, 52, 63);">i</font>n
                <font style="color: rgb(29, 29, 35);">a</font><font style="color: rgb(52, 52, 63);">c</font>cordan<font style="color: rgb(29, 29, 35);">c</font><font style="color: rgb(52, 52, 63);">e </font>wi<font style="color: rgb(29, 29, 35);">th t</font>he






                poli<font style="color: rgb(29, 29, 35);">ci</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">s se</font><font style="color: rgb(52, 52, 63);">t </font>forth in the attached Schedule 5 (to the
                extent <font style="color: rgb(29, 29, 35);">s</font><font style="color: rgb(52, 52, 63);">u</font>c<font style="color: rgb(29, 29, 35);">h </font><font style="color: rgb(52, 52, 63);">p</font><font style="color: rgb(29, 29, 35);">o</font>lici<font style="color: rgb(29, 29, 35);">e</font><font style="color: rgb(52, 52, 63);">s </font><font style="color: rgb(29, 29, 35);">a</font>re a<font style="color: rgb(29, 29, 35);">ppl</font>i<font style="color: rgb(29, 29, 35);">c</font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(29, 29, 35);">b</font><font style="color: rgb(52, 52, 63);">l</font><font style="color: rgb(29, 29, 35);">e </font>to the activities <font style="color: rgb(29, 29, 35);">b</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">i</font><font style="color: rgb(52, 52, 63);">n</font>g conducted) and, to the extent applica<font style="color: rgb(52, 52, 63);">b</font>le, <font style="color: rgb(52, 52, 63);">a</font>ll oth<font style="color: rgb(29, 29, 35);">er r</font><font style="color: rgb(52, 52, 63);">e</font>quire<font style="color: rgb(29, 29, 35);">men</font>ts of <font style="color: rgb(29, 29, 35);">G</font>L<font style="color: rgb(29, 29, 35);">P</font>, <font style="color: rgb(29, 29, 35);">G</font>CP a<font style="color: rgb(29, 29, 35);">nd </font>GM<font style="color: rgb(29, 29, 35);">P</font>. All activities that are required to be <font style="color: rgb(29, 29, 35);">pe</font>rform<font style="color: rgb(29, 29, 35);">e</font><font style="color: rgb(52, 52, 63);">d </font>to <font style="color: rgb(29, 29, 35);">GL</font>P, GCP <font style="color: rgb(52, 52, 63);">o</font>r
                <font style="color: rgb(29, 29, 35);">G</font>MP sh<font style="color: rgb(29, 29, 35);">a</font>l<font style="color: rgb(29, 29, 35);">l </font><font style="color: rgb(52, 52, 63);">b</font>e performed by [***].&#160; [***] Commercially
                Reasonable Eff<font style="color: rgb(29, 29, 35);">o</font><font style="color: rgb(52, 52, 63);">r</font>ts <font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">o </font>ensu<font style="color: rgb(52, 52, 63);">r</font><font style="color: rgb(29, 29, 35);">e th</font>e fo<font style="color: rgb(52, 52, 63);">ll</font><font style="color: rgb(29, 29, 35);">o</font>w<font style="color: rgb(52, 52, 63);">i</font>ng: <font style="color: rgb(29, 29, 35);">(i) </font>da<font style="color: rgb(29, 29, 35);">t</font>a are <font style="color: rgb(29, 29, 35);">bei</font><font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(29, 29, 35);">g </font>generated
                using sound scientific tech<font style="color: rgb(29, 29, 35);">n</font>i<font style="color: rgb(29, 29, 35);">q</font><font style="color: rgb(52, 52, 63);">u</font><font style="color: rgb(29, 29, 35);">e</font>s an<font style="color: rgb(29, 29, 35);">d </font><font style="color: rgb(52, 52, 63);">p</font>roces<font style="color: rgb(29, 29, 35);">se</font><font style="color: rgb(52, 52, 63);">s; </font>(ii) d<font style="color: rgb(29, 29, 35);">a</font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">a a</font>re bei<font style="color: rgb(29, 29, 35);">ng </font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(29, 29, 35);">c</font>curately






                and reasonably contemporaneously re<font style="color: rgb(29, 29, 35);">co</font>r<font style="color: rgb(52, 52, 63);">d</font><font style="color: rgb(29, 29, 35);">e</font>d in <font style="color: rgb(52, 52, 63);">a</font>c<font style="color: rgb(52, 52, 63);">co</font>rdanc<font style="color: rgb(52, 52, 63);">e with</font> goo<font style="color: rgb(29, 29, 35);">d </font>scientific practices by personnel conductin<font style="color: rgb(29, 29, 35);">g </font><font style="color: rgb(52, 52, 63);">r</font><font style="color: rgb(29, 29, 35);">e</font>s<font style="color: rgb(52, 52, 63);">e</font>arch or d<font style="color: rgb(29, 29, 35);">ev</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">lo</font>pment <font style="color: rgb(52, 52, 63);">h</font><font style="color: rgb(29, 29, 35);">e</font>r<font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">u</font>nder<font style="color: rgb(29, 29, 35);">; </font><font style="color: rgb(52, 52, 63);">(</font>iii<font style="color: rgb(52, 52, 63);">) </font>data are being analyzed appropriately<font style="color: rgb(52, 52, 63);">&#160;</font>witho<font style="color: rgb(29, 29, 35);">ut </font>bias i<font style="color: rgb(29, 29, 35);">n a</font>ccorda<font style="color: rgb(29, 29, 35);">nc</font><font style="color: rgb(52, 52, 63);">e </font><font style="color: rgb(29, 29, 35);">w</font><font style="color: rgb(52, 52, 63);">i</font>th goo<font style="color: rgb(52, 52, 63);">d s</font><font style="color: rgb(29, 29, 35);">c</font>ientific practices; and (iv) data and r<font style="color: rgb(29, 29, 35);">e</font><font style="color: rgb(52, 52, 63);">s</font><font style="color: rgb(29, 29, 35);">ul</font><font style="color: rgb(52, 52, 63);">ts </font><font style="color: rgb(29, 29, 35);">a</font>re <font style="color: rgb(29, 29, 35);">be</font>i<font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(29, 29, 35);">g s</font>t<font style="color: rgb(29, 29, 35);">o</font><font style="color: rgb(52, 52, 63);">r</font><font style="color: rgb(29, 29, 35);">ed </font>secur<font style="color: rgb(29, 29, 35);">e</font><font style="color: rgb(52, 52, 63);">l</font>y a<font style="color: rgb(29, 29, 35);">n</font>d ca<font style="color: rgb(29, 29, 35);">n </font>b<font style="color: rgb(29, 29, 35);">e </font>easily






                retrieved. Notwithstanding Immunocore&#8217;s responsibility<font style="color: rgb(29, 29, 35);"> t</font>o carry ou<font style="color: rgb(52, 52, 63);">t </font>the act<font style="color: rgb(29, 29, 35);">i</font>vi<font style="color: rgb(29, 29, 35);">t</font><font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(29, 29, 35);">e</font>s set forth in the Research Plans, GSK (<font style="color: rgb(29, 29, 35);">or its</font> su<font style="color: rgb(29, 29, 35);">b</font>c<font style="color: rgb(52, 52, 63);">o</font>ntract<font style="color: rgb(29, 29, 35);">or</font><font style="color: rgb(52, 52, 63);">s </font><font style="color: rgb(29, 29, 35);">o</font>r Affiliates<font style="color: rgb(29, 29, 35);">) </font>may c<font style="color: rgb(29, 29, 35);">on</font>duct certain activities as set forth in the a<font style="color: rgb(52, 52, 63);">p</font><font style="color: rgb(29, 29, 35);">p</font><font style="color: rgb(52, 52, 63);">lic</font><font style="color: rgb(29, 29, 35);">a</font>ble <font style="color: rgb(29, 29, 35);">R</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(29, 29, 35);">se</font><font style="color: rgb(52, 52, 63);">a</font>r<font style="color: rgb(29, 29, 35);">c</font>h <font style="color: rgb(29, 29, 35);">P</font><font style="color: rgb(52, 52, 63);">l</font><font style="color: rgb(29, 29, 35);">a</font><font style="color: rgb(52, 52, 63);">n </font>[***]; pro<font style="color: rgb(29, 29, 35);">v</font>id<font style="color: rgb(29, 29, 35);">e</font>d that <font style="color: rgb(29, 29, 35);">G</font>SK will <font style="color: rgb(29, 29, 35);">c</font>omply (<font style="color: rgb(52, 52, 63);">a</font>nd en<font style="color: rgb(29, 29, 35);">su</font><font style="color: rgb(52, 52, 63);">re </font>its su<font style="color: rgb(29, 29, 35);">bc</font>o<font style="color: rgb(52, 52, 63);">nt</font>ractors or Affiliates comply) with Sections 3.2, 3.3 and 3.4 wi<font style="color: rgb(29, 29, 35);">th </font>respect to such condu<font style="color: rgb(52, 52, 63);">ct.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3adc5e8d22674108957d40a2419e124f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to the <font style="color: rgb(52, 52, 63);">requirements</font>&#160;<font style="color: rgb(29, 29, 35);">s</font>et forth abov<font style="color: rgb(29, 29, 35);">e </font>in Section 3.2<font style="color: rgb(29, 29, 35);">, </font>including






                the obligation to use Comm<font style="color: rgb(52, 52, 63);">er</font><font style="color: rgb(29, 29, 35);">c</font>ially Re<font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(29, 29, 35);">so</font><font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(29, 29, 35);">ab</font>l<font style="color: rgb(29, 29, 35);">e </font>Efforts, Immunocore shall perform (or en<font style="color: rgb(29, 29, 35);">s</font>ur<font style="color: rgb(29, 29, 35);">e </font>that its subcontrac<font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(29, 29, 35);">o</font>r<font style="color: rgb(52, 52, 63);">s </font>perform) <font style="color: rgb(29, 29, 35);">the</font>
                Collaboration Program using personnel which are suitably qualified <font style="color: rgb(29, 29, 35);">a</font><font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(29, 29, 35);">d </font>experienced to perform the
                activities set out in the Collaboration Program. Immunocore shal<font style="color: rgb(29, 29, 35);">l </font>(<font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(29, 29, 35);">) </font>within a reasonable period of
                time after agreement of the Rese<font style="color: rgb(52, 52, 63);">ar</font><font style="color: rgb(29, 29, 35);">c</font>h Plan [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0a3860363b5d42eebda27c480f427443" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Ea<font style="color: rgb(29, 29, 35);">c</font>h Party shall provide <font style="color: rgb(29, 29, 35);">c</font>ooperation and information as reasonably ne<font style="color: rgb(29, 29, 35);">c</font>essary to assist the oth<font style="color: rgb(29, 29, 35);">e</font>r Party in performing the Collaboration Program. A P<font style="color: rgb(29, 29, 35);">a</font>rty <font style="color: rgb(29, 29, 35);">s</font>hall not be <font style="color: rgb(7, 7, 8);">responsible






                  for any delay or suspension of any Collaboration Program where such delay or suspension is caused by any failure of the other Party to provide any information</font><font style="color: rgb(28, 28, 33);">, </font><font style="color: rgb(7, 7, 8);">assistance or cooperation.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8b85dee3b8f4424aab13e890dbd6d32e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On a Collaboration Program-by-Collaboration Program <font style="color: rgb(28, 28, 33);">b</font>asis<font style="color: rgb(49, 49, 59);">, </font>at any time during the conduct of Project Phase 1 of such Collaboration Program <font style="color: rgb(49, 49, 59);">through</font> the [***] period following Completion of Project<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(49, 49, 59);">Phase</font> 1 of suc<font style="color: rgb(28, 28, 33);">h
                </font><font style="color: rgb(49, 49, 59);">Collaboration</font> Program, Immunocore shall either (i) make a <font style="color: rgb(28, 28, 33);">r</font>e<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(49, 49, 59);">o</font><font style="color: rgb(28, 28, 33);">mm</font>endation to <font style="color: rgb(28, 28, 33);">th</font><font style="color: rgb(49, 49, 59);">e </font>JSC that a Compound satisfies the applicable Lead Candidate<font style="color: rgb(49, 49, 59);"> Criteria</font>, or (ii) advi<font style="color: rgb(49, 49, 59);">s</font><font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">h</font>e JSC that no Compound satisfies the applicable Lead Candid<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">e </font>Criteria, but tha<font style="color: rgb(49, 49, 59);">t </font>a<font style="color: rgb(28, 28, 33);">d</font>ditional research is likely to result in a Lead Candidate; or (iii) <font style="color: rgb(49, 49, 59);">advise </font>th<font style="color: rgb(49, 49, 59);">e </font>JSC that no <font style="color: rgb(28, 28, 33);">Compound</font><font style="color: rgb(49, 49, 59);">&#160;</font>satisfies the applicable Lead Candidate Criteria and <font style="color: rgb(49, 49, 59);">t</font>h<font style="color: rgb(49, 49, 59);">a</font>t <font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(49, 49, 59);">n </font>Immunocore&#8217;s<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(49, 49, 59);">r</font>easona<font style="color: rgb(49, 49, 59);">ble di</font>scretion, it is not technically feasible to develo<font style="color: rgb(28, 28, 33);">p a L</font>ead <font style="color: rgb(49, 49, 59);">C</font><font style="color: rgb(28, 28, 33);">an</font>did<font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(49, 49, 59);">e </font>u<font style="color: rgb(28, 28, 33);">n</font>der <font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(49, 49, 59);">h</font>e applicable Collaboration Program.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4213e24332b643f9a0fd65ff287e1d1c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Within [***]<font style="color: rgb(49, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">aft</font>er re<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(49, 49, 59);">om</font>menda<font style="color: rgb(28, 28, 33);">t</font>i<font style="color: rgb(28, 28, 33);">on b</font>y Immunocore of the potential Lead Ca<font style="color: rgb(28, 28, 33);">n</font>d<font style="color: rgb(49, 49, 59);">id</font><font style="color: rgb(28, 28, 33);">a</font>te






                in <font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">c</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(49, 49, 59);">o</font><font style="color: rgb(28, 28, 33);">r</font>danc<font style="color: rgb(49, 49, 59);">e </font><font style="color: rgb(28, 28, 33);">with</font> Sec<font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">i</font>o<font style="color: rgb(49, 49, 59);">n </font><font style="color: rgb(28, 28, 33);">3</font>.5(i), the JSC will decide on the nomina<font style="color: rgb(28, 28, 33);">tion </font><font style="color: rgb(49, 49, 59);">o</font>f one <font style="color: rgb(28, 28, 33);">or </font>mor<font style="color: rgb(28, 28, 33);">e </font>L<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">a</font>d Can<font style="color: rgb(28, 28, 33);">d</font><font style="color: rgb(49, 49, 59);">i</font>d<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">te</font>(s) to progress to Project Phase 2. U<font style="color: rgb(28, 28, 33);">po</font>n <font style="color: rgb(49, 49, 59);">the</font> J<font style="color: rgb(49, 49, 59);">S</font>C&#8217;s <font style="color: rgb(28, 28, 33);">determination</font> t<font style="color: rgb(28, 28, 33);">h</font>a<font style="color: rgb(28, 28, 33);">t a</font>t <font style="color: rgb(28, 28, 33);">l</font>east one Compound satisfies the appli<font style="color: rgb(28, 28, 33);">ca</font>ble Lead <font style="color: rgb(28, 28, 33);">Candidate</font><font style="color: rgb(49, 49, 59);">&#160;</font>Criteria, s<font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(49, 49, 59);">c</font><font style="color: rgb(28, 28, 33);">h </font>Co<font style="color: rgb(28, 28, 33);">mp</font>ound shall be deemed a Lead <font style="color: rgb(28, 28, 33);">C</font>a<font style="color: rgb(49, 49, 59);">ndi</font><font style="color: rgb(28, 28, 33);">d</font>ate <font style="color: rgb(49, 49, 59);">a</font>nd sh<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">ll be </font>progres<font style="color: rgb(28, 28, 33);">sed </font>into <font style="color: rgb(49, 49, 59);">Project</font> Phase 2A development. If the <font style="color: rgb(49, 49, 59);">J</font><font style="color: rgb(28, 28, 33);">S</font><font style="color: rgb(49, 49, 59);">C </font>does <font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(49, 49, 59);">o</font><font style="color: rgb(28, 28, 33);">t </font>sel<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">c</font>t any of <font style="color: rgb(28, 28, 33);">the</font>&#160;<font style="color: rgb(28, 28, 33);">p</font>roposed Lead Candidates with <font style="color: rgb(28, 28, 33);">in [***]</font>&#160;<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(49, 49, 59);">f </font>submission by Immunocore, then th<font style="color: rgb(28, 28, 33);">e </font>J<font style="color: rgb(49, 49, 59);">S</font>C m<font style="color: rgb(49, 49, 59);">ay s</font>pecify with<font style="color: rgb(49, 49, 59);">i</font>n a f<font style="color: rgb(49, 49, 59);">u</font><font style="color: rgb(28, 28, 33);">rther [***]</font> wha<font style="color: rgb(49, 49, 59);">t </font><font style="color: rgb(28, 28, 33);">ad</font>ditio<font style="color: rgb(49, 49, 59);">nal </font>resear<font style="color: rgb(28, 28, 33);">c</font>h <font style="color: rgb(49, 49, 59);">activities</font>, if <font style="color: rgb(49, 49, 59);">a</font>ny, that were not include<font style="color: rgb(28, 28, 33);">d </font>in the ap<font style="color: rgb(28, 28, 33);">p</font>li<font style="color: rgb(49, 49, 59);">ca</font><font style="color: rgb(28, 28, 33);">b</font>le R<font style="color: rgb(28, 28, 33);">es</font><font style="color: rgb(49, 49, 59);">ea</font>rch Plan<font style="color: rgb(49, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">r</font><font style="color: rgb(28, 28, 33);">e </font>req<font style="color: rgb(28, 28, 33);">u</font>i<font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(49, 49, 59);">ed t</font><font style="color: rgb(28, 28, 33);">o </font>enable at least one (1) Compound t<font style="color: rgb(49, 49, 59);">o </font>achieve<font style="color: rgb(28, 28, 33);">&#160;</font>th<font style="color: rgb(28, 28, 33);">e </font>Le<font style="color: rgb(28, 28, 33);">ad </font>Can<font style="color: rgb(28, 28, 33);">d</font>idat<font style="color: rgb(49, 49, 59);">e Criteria</font> (&#8220;<font style="font-weight: bold;">Lead Additional Wor</font><font style="font-weight: bold; color: rgb(28, 28, 33);">k</font><font style="color: rgb(49, 49, 59);">&#8221;</font><font style="color: rgb(28, 28, 33);">)</font><font style="color: rgb(49, 49, 59);">.</font><font style="font-weight: bold; color: rgb(49, 49, 59);">&#160;</font>Prom<font style="color: rgb(28, 28, 33);">p</font><font style="color: rgb(49, 49, 59);">tl</font><font style="color: rgb(28, 28, 33);">y </font>ther<font style="color: rgb(49, 49, 59);">eaf</font><font style="color: rgb(28, 28, 33);">te</font>r,
                the <font style="color: rgb(49, 49, 59);">Parties</font> will <font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">m</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">n</font>d
                the applicable Research Plan<font style="color: rgb(28, 28, 33);">&#160;</font>to reflect<font style="color: rgb(49, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">n</font>y su<font style="color: rgb(28, 28, 33);">ch L</font><font style="color: rgb(49, 49, 59);">e</font>ad A<font style="color: rgb(28, 28, 33);">d</font><font style="color: rgb(49, 49, 59);">d</font>i<font style="color: rgb(49, 49, 59);">ti</font>onal
                Wo<font style="color: rgb(49, 49, 59);">r</font><font style="color: rgb(28, 28, 33);">k </font>an<font style="color: rgb(28, 28, 33);">d </font>Immunocore shall conduct<font style="color: rgb(49, 49, 59);"> s</font>u<font style="color: rgb(49, 49, 59);">c</font><font style="color: rgb(28, 28, 33);">h Le</font>ad <font style="color: rgb(28, 28, 33);">Additional</font>&#160;<font style="color: rgb(28, 28, 33);">W</font>o<font style="color: rgb(28, 28, 33);">r</font>k. If<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(49, 49, 59);">no </font><font style="color: rgb(28, 28, 33);">L</font><font style="color: rgb(49, 49, 59);">e</font>ad Additional Work is agreed or no Lead<font style="color: rgb(28, 28, 33);"> Candidate i</font><font style="color: rgb(49, 49, 59);">s </font>nominated by <font style="color: rgb(28, 28, 33);">t</font>h<font style="color: rgb(49, 49, 59);">e </font><font style="color: rgb(28, 28, 33);">J</font><font style="color: rgb(49, 49, 59);">S</font>C wit<font style="color: rgb(28, 28, 33);">h</font><font style="color: rgb(49, 49, 59);">in [***] after</font> Completion <font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(49, 49, 59);">f </font><font style="color: rgb(28, 28, 33);">s</font>uch L<font style="color: rgb(28, 28, 33);">ead </font>Additional <font style="color: rgb(28, 28, 33);">W</font>ork, then GSK shall terminate th<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);"> C</font>ollab<font style="color: rgb(49, 49, 59);">or</font><font style="color: rgb(28, 28, 33);">at</font><font style="color: rgb(49, 49, 59);">i</font>on
                Program and Sec<font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">i</font>on 13.6 s<font style="color: rgb(28, 28, 33);">ha</font>ll apply.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z8c15e425fc95455ca669d70529d5cf82" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top; align: right;">3.5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>W<font style="color: rgb(49, 49, 59);">it</font><font style="color: rgb(28, 28, 33);">hi</font><font style="color: rgb(49, 49, 59);">n [***]</font><font style="color: rgb(28, 28, 33);">&#160;</font>aft<font style="color: rgb(28, 28, 33);">e</font>r
                a<font style="color: rgb(28, 28, 33);">d</font>vising the JSC that no Com<font style="color: rgb(28, 28, 33);">p</font>ound satisfies <font style="color: rgb(49, 49, 59);">the </font>Lead <font style="color: rgb(28, 28, 33);">C</font>a<font style="color: rgb(49, 49, 59);">nd</font>idate Criteria in accordance with Section 3.5(ii) <font style="color: rgb(28, 28, 33);">o</font>r <font style="color: rgb(28, 28, 33);">3</font>.5(iii), then the JSC s<font style="color: rgb(49, 49, 59);">ha</font>ll either (i) specify within a further [***] what Lead Additional Work, if any, is required to enab<font style="color: rgb(49, 49, 59);">le a</font><font style="color: rgb(28, 28, 33);">t </font>least <font style="color: rgb(49, 49, 59);">o</font>n<font style="color: rgb(28, 28, 33);">e </font>(1) Compound to achieve the Lead Candidate Criteria, or (<font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(49, 49, 59);">i) </font>decide






                t<font style="color: rgb(49, 49, 59);">o </font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">rm</font>inat<font style="color: rgb(28, 28, 33);">e </font>the






                applicable Collaboration Program. In the<font style="color: rgb(28, 28, 33);"> e</font>v<font style="color: rgb(28, 28, 33);">e</font>nt that<font style="color: rgb(28, 28, 33);">&#160;</font>Section<font style="color: rgb(28, 28, 33);">&#160;</font>3.5.2(i)






                occurs, the Parties will amend the applicable Resear<font style="color: rgb(28, 28, 33);">c</font>h<font style="color: rgb(49, 49, 59);"> Plan</font> to reflect any such Lead Additional Wo<font style="color: rgb(28, 28, 33);">r</font>k and
                Immunocore <font style="color: rgb(28, 28, 33);">s</font>h<font style="color: rgb(28, 28, 33);">a</font>ll conduct<font style="color: rgb(49, 49, 59);"> s</font>uch Le<font style="color: rgb(49, 49, 59);">a</font>d <font style="color: rgb(49, 49, 59);">Additional</font> Work. If no Lead Candidate is nominated by the JSC within [***] after Completion of the Lead Additional Work, <font style="color: rgb(28, 28, 33);">th</font><font style="color: rgb(49, 49, 59);">e</font>n
                the <font style="color: rgb(28, 28, 33);">Collaboration</font> Program shall terminate and thereafter, or in the event Secti<font style="color: rgb(28, 28, 33);">o</font>n 3.5.2(ii) occurs<font style="color: rgb(28, 28, 33);">, </font>Section






                13.6 shall apply.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z99ab724226a54ef58199b48c6b4b91ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #31313B;">O</font>n <font style="color: rgb(28, 28, 33);">a Collaboration</font> Program-by-<font style="color: rgb(28, 28, 33);">Collaboration</font> P<font style="color: rgb(28, 28, 33);">ro</font>gram basis, at <font style="color: rgb(28, 28, 33);">a</font>ny time during th<font style="color: rgb(28, 28, 33);">e co</font>ndu<font style="color: rgb(28, 28, 33);">ct </font>of Project Phase 2 of such Collaboration Program through <font style="color: rgb(28, 28, 33);">the</font> [***] p<font style="color: rgb(28, 28, 33);">e</font>riod following Completion of Project Phase<font style="color: rgb(28, 28, 33);">&#160;</font>2 of such <font style="color: rgb(28, 28, 33);">Collaboration</font>
                Program, Immunocore<font style="color: rgb(28, 28, 33);">&#160;</font>shall <font style="color: rgb(28, 28, 33);">e</font>ither (i) mak<font style="color: rgb(28, 28, 33);">e </font>a re<font style="color: rgb(28, 28, 33);">co</font>mmend <font style="color: rgb(28, 28, 33);">a</font>t ion to the J<font style="color: rgb(28, 28, 33);">SC </font>that <font style="color: rgb(28, 28, 33);">a </font>Lead Candidate satisfies the applicable Development Candidate Criteria, or (ii)
                advise the JSC that no Lead C<font style="color: rgb(28, 28, 33);">a</font>ndidate <font style="color: rgb(28, 28, 33);">s</font>atisfie<font style="color: rgb(28, 28, 33);">s </font>the appli<font style="color: rgb(28, 28, 33);">c</font>able






                Development Candidate Criteria, but that <font style="color: rgb(7, 7, 8);">in Immunocore&#8217;s reasonable discretion, additional research is likely to result in a Development Candidate; or (iii) advise the JSC that no Lead Candidate satisfies
                  the applicable Development Candidate Criteria and that in Immunocore&#8217;s reasonable discretion, there is no additional research that will result in a Development Candidate because it is not technically feasible to develop a Dev</font><font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(7, 7, 8);">lopment Candidate under the applicable Collaboration Program.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2c96bb1c1f1240c990da34b4d2c7df62" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top; align: right;">3.6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Within [***] after<font style="color: rgb(47, 49, 59);">&#160;</font>recommendation <font style="color: rgb(28, 28, 31);">b</font><font style="color: rgb(47, 49, 59);">y </font>Immunocore of the potential Development Candidate <font style="color: rgb(47, 49, 59);">in </font>accordance with <font style="color: rgb(47, 49, 59);">S</font>ec<font style="color: rgb(47, 49, 59);">t</font>ion 3.6(i), the JSC will decide on the nomination of <font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 49, 59);">n</font>e or more Develo<font style="color: rgb(47, 49, 59);">p</font>ment Candidate(s). Upon the JSC&#8217;s determination that <font style="color: rgb(47, 49, 59);">at lea</font>st <font style="color: rgb(47, 49, 59);">o</font>ne Lead <font style="color: rgb(28, 28, 31);">Can</font><font style="color: rgb(47, 49, 59);">d</font><font style="color: rgb(28, 28, 31);">idate s</font><font style="color: rgb(47, 49, 59);">ati</font><font style="color: rgb(28, 28, 31);">sfies </font>the applicable Development Candidate Cr<font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 31);">teria,</font><font style="color: rgb(47, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(47, 49, 59);">u</font><font style="color: rgb(28, 28, 31);">ch </font>Lea<font style="color: rgb(47, 49, 59);">d </font>Candi<font style="color: rgb(47, 49, 59);">date </font><font style="color: rgb(28, 28, 31);">shall </font>be deemed a Development Candida<font style="color: rgb(47, 49, 59);">te a</font>nd <font style="color: rgb(28, 28, 31);">if the </font>Collaboration <font style="color: rgb(47, 49, 59);">Program</font>
                is an Initial Program, it shall be p<font style="color: rgb(47, 49, 59);">ro</font>gr<font style="color: rgb(47, 49, 59);">e</font>ssed <font style="color: rgb(28, 28, 31);">in</font><font style="color: rgb(47, 49, 59);">to f</font>urthe<font style="color: rgb(47, 49, 59);">r p</font><font style="color: rgb(28, 28, 31);">re-clinic</font><font style="color: rgb(47, 49, 59);">al </font>development and/or Clinical Trial develop<font style="color: rgb(47, 49, 59);">m</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 49, 59);">n</font><font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 49, 59);">, </font>and <font style="color: rgb(28, 28, 31);">if </font><font style="color: rgb(47, 49, 59);">the</font> Collaboration<font style="color: rgb(47, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 31);">Program </font>is not an Initial Program, then the <font style="color: rgb(28, 28, 31);">provis</font><font style="color: rgb(47, 49, 59);">io</font>ns of <font style="color: rgb(47, 49, 59);">S</font><font style="color: rgb(28, 28, 31);">ection 6</font><font style="color: rgb(47, 49, 59);">.2</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(47, 49, 59);">s</font>hall appl<font style="color: rgb(47, 49, 59);">y</font>. If the JSC does not select any of the prop<font style="color: rgb(47, 49, 59);">o</font>sed Development <font style="color: rgb(47, 49, 59);">Candidates</font>&#160;<font style="color: rgb(28, 28, 31);">within [***]</font> of <font style="color: rgb(28, 28, 31);">su</font><font style="color: rgb(47, 49, 59);">bm</font>ission by Immunocore, th<font style="color: rgb(47, 49, 59);">e</font>n <font style="color: rgb(47, 49, 59);">th</font>e JSC may specify within a further [***] <font style="color: rgb(47, 49, 59);">wh</font>at additional research activities, if any, that <font style="color: rgb(47, 49, 59);">w</font>ere not <font style="color: rgb(47, 49, 59);">in</font>cluded in the <font style="color: rgb(47, 49, 59);">ap</font><font style="color: rgb(28, 28, 31);">plic</font><font style="color: rgb(47, 49, 59);">a</font>ble R<font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(28, 28, 31);">search </font>Plan are required to en<font style="color: rgb(47, 49, 59);">ab</font>le <font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 31);">t </font>le<font style="color: rgb(47, 49, 59);">as</font>t on<font style="color: rgb(47, 49, 59);">e </font>(<font style="color: rgb(47, 49, 59);">1) </font>Lead <font style="color: rgb(28, 28, 31);">Ca</font><font style="color: rgb(47, 49, 59);">n</font>didate <font style="color: rgb(28, 28, 31);">to </font>achieve the Development C<font style="color: rgb(47, 49, 59);">a</font>ndi<font style="color: rgb(47, 49, 59);">d</font>ate <font style="color: rgb(28, 28, 31);">Criteria</font> (the<font style="color: rgb(28, 28, 31);"> &#8220;</font><font style="font-weight: bold; color: rgb(28, 28, 31);">Development Additional </font><font style="font-weight: bold;">Work</font>&#8221;).
                Promptly thereafter, the <font style="color: rgb(47, 49, 59);">Parties</font>&#160;<font style="color: rgb(28, 28, 31);">will </font>amend t<font style="color: rgb(47, 49, 59);">h</font>e applicab<font style="color: rgb(47, 49, 59);">l</font><font style="color: rgb(28, 28, 31);">e </font>Research Plan to reflect any <font style="color: rgb(47, 49, 59);">s</font>uch Development Additional Work <font style="color: rgb(28, 28, 31);">and </font>Immunocore shall conduct such Dev<font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(28, 28, 31);">l</font><font style="color: rgb(47, 49, 59);">op</font>ment <font style="color: rgb(28, 28, 31);">Additional </font><font style="color: rgb(47, 49, 59);">W</font><font style="color: rgb(28, 28, 31);">ork. </font>If <font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 49, 59);">o </font>Developme<font style="color: rgb(47, 49, 59);">nt </font>Additional Work is agreed or no Deve<font style="color: rgb(47, 49, 59);">lo</font>pment <font style="color: rgb(47, 49, 59);">C</font>andidate <font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 31);">s </font>nomin<font style="color: rgb(47, 49, 59);">a</font>ted by the JSC after Completion<font style="color: rgb(47, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 31);">of </font>su<font style="color: rgb(47, 49, 59);">c</font>h <font style="color: rgb(47, 49, 59);">D</font>evel<font style="color: rgb(47, 49, 59);">op</font>ment Additional W<font style="color: rgb(47, 49, 59);">ork, the</font><font style="color: rgb(28, 28, 31);">n </font>GSK shall terminate the Collaboration<font style="color: rgb(28, 28, 31);">
                  Program</font><font style="color: rgb(47, 49, 59);"> a</font>nd Section <font style="color: rgb(47, 49, 59);">1</font>3.6 sha<font style="color: rgb(47, 49, 59);">ll a</font><font style="color: rgb(28, 28, 31);">pply.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1c573e9a3e3d46b7b083448d541c0c89" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top; align: right;">3.6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Wi<font style="color: rgb(47, 49, 59);">t</font><font style="color: rgb(28, 28, 31);">hin [***]</font>&#160;<font style="color: rgb(28, 28, 31);">aft</font><font style="color: rgb(47, 49, 59);">er </font><font style="color: rgb(28, 28, 31);">a</font><font style="color: rgb(47, 49, 59);">d</font>vising the JSC that no Lead<font style="color: rgb(28, 28, 31);"> C</font><font style="color: rgb(47, 49, 59);">an </font>did ate <font style="color: rgb(47, 49, 59);">sa</font>tisfies <font style="color: rgb(47, 49, 59);">t</font>he Develo<font style="color: rgb(47, 49, 59);">p</font><font style="color: rgb(28, 28, 31);">ment </font>Ca<font style="color: rgb(47, 49, 59);">ndid </font>ate Criteria in accordance with<font style="color: rgb(47, 49, 59);"> Section</font>&#160;<font style="color: rgb(47, 49, 59);">3</font>.<font style="color: rgb(47, 49, 59);">6(</font>ii) <font style="color: rgb(28, 28, 31);">or </font><font style="color: rgb(47, 49, 59);">3</font>.<font style="color: rgb(47, 49, 59);">6</font>(iii), then the JSC <font style="color: rgb(28, 28, 31);">ma</font><font style="color: rgb(47, 49, 59);">y </font>either (i) specify within a further<font style="color: rgb(47, 49, 59);"> [***] </font>what






                Deve<font style="color: rgb(47, 49, 59);">l</font><font style="color: rgb(28, 28, 31);">opment </font>Additional Work is required to <font style="color: rgb(28, 28, 31);">en</font><font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 31);">ble </font>at <font style="color: rgb(47, 49, 59);">le</font>ast on<font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(28, 28, 31);">(1</font><font style="color: rgb(47, 49, 59);">) </font>Lead






                <font style="color: rgb(28, 28, 31);">Candidate </font>to achieve the Development Candidate <font style="color: rgb(47, 49, 59);">Criteria</font>, <font style="color: rgb(28, 28, 31);">or (</font><font style="color: rgb(47, 49, 59);">ii</font>)
                decid<font style="color: rgb(47, 49, 59);">e t</font><font style="color: rgb(28, 28, 31);">o terminate </font>the applicable Collaboration Program. In <font style="color: rgb(47, 49, 59);">the</font> eve<font style="color: rgb(47, 49, 59);">nt that</font> Section<font style="color: rgb(47, 49, 59);">&#160;</font>3.6.2(i) occurs, the Parties will amend the applicable Research Plan to reflect <font style="color: rgb(28, 28, 31);">any </font>such Development Additional Work
                and Immunocore<font style="color: rgb(28, 28, 31);">&#160;</font>sha<font style="color: rgb(47, 49, 59);">ll </font><font style="color: rgb(28, 28, 31);">conduct </font>such Development Additional Work. If no Deve<font style="color: rgb(47, 49, 59);">lop</font><font style="color: rgb(28, 28, 31);">ment </font>C<font style="color: rgb(47, 49, 59);">a</font>nd<font style="color: rgb(47, 49, 59);">i</font>date is nominated by the JSC after Completion of the D<font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(28, 28, 31);">velopmen</font><font style="color: rgb(47, 49, 59);">t </font><font style="color: rgb(28, 28, 31);">A</font><font style="color: rgb(47, 49, 59);">d</font><font style="color: rgb(28, 28, 31);">ditional </font>Work, then the Collaboration Program shall terminate<font style="color: rgb(47, 49, 59);"> an</font>d <font style="color: rgb(28, 28, 31);">thereaf</font><font style="color: rgb(47, 49, 59);">te</font>r, <font style="color: rgb(28, 28, 31);">or </font>in the event Section 3.6.2(ii) <font style="color: rgb(28, 28, 31);">occurs, </font>if the Collaboration<font style="color: rgb(47, 49, 59);"> P</font>rogram is an
                Initial Target Program, Sections 8.3 and 13.6 shall apply and in<font style="color: rgb(47, 49, 59);"> a</font><font style="color: rgb(28, 28, 31);">ll </font>other <font style="color: rgb(47, 49, 59);">c</font>ir<font style="color: rgb(47, 49, 59);">c</font>umstances, Section and 13.6 shall apply.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z4bf258fc6b5d48d59d6d8944f39d8d53" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In <font style="color: rgb(47, 49, 59);">r</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 49, 59);">la</font>tion to a<font style="color: rgb(47, 49, 59);">n</font><font style="color: rgb(28, 28, 31);">y
                </font><font style="color: rgb(47, 49, 59);">L</font>ead Additional Work <font style="color: rgb(28, 28, 31);">or </font>Development Additional Work <font style="color: rgb(28, 28, 31);">agreed </font>by the<font style="color: rgb(28, 28, 31);"> J</font><font style="color: rgb(47, 49, 59);">SC </font><font style="color: rgb(28, 28, 31);">under </font>Sections 3.5.1, 3.5.2, <font style="color: rgb(28, 28, 31);">3.6.1 or </font>3.6.2, any additional time and effort
                incurred<font style="color: rgb(47, 49, 59);">&#160;</font>[***] <font style="color: rgb(28, 28, 31);">of such Collaboration</font> Program, together with the Lead Additional Work or Development Additional Work, <font style="color: rgb(28, 28, 31);">as</font> applicable, [***]<font style="color: rgb(7, 7, 8);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zcd6de4606e0d4bd1ab3bc99a8a85258a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore&#8217;s FTE rate as at the Effective Date is [***] per Year.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1c88c961540f4f31a5b523cd0dfae158" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to the terms of this Agreement,<font style="color: rgb(31, 31, 38);">&#160;</font>GSK shall h<font style="color: rgb(31, 31, 38);">ave t</font>he right to e<font style="color: rgb(31, 31, 38);">ng</font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 38);">g</font>e Affiliates and both Parties shall have the right to engage T<font style="color: rgb(31, 31, 38);">h</font>i<font style="color: rgb(52, 52, 65);">rd </font><font style="color: rgb(31, 31, 38);">Party</font> subcontr<font style="color: rgb(31, 31, 38);">act</font><font style="color: rgb(52, 52, 65);">o</font><font style="color: rgb(31, 31, 38);">r</font>s to perform certain of its obligations under the
                Collaboration<font style="color: rgb(52, 52, 65);">&#160;</font>Programs, and <font style="color: rgb(31, 31, 38);">s</font>u<font style="color: rgb(31, 31, 38);">c</font>h Affiliates or subcontractors shall be assigned the applicable<font style="color: rgb(31, 31, 38);">&#160;</font>obl<font style="color: rgb(31, 31, 38);">ig</font>ation as set <font style="color: rgb(31, 31, 38);">forth</font> in the agreed Research Plans; [***]. Any Affiliate or subcontractor to be engag<font style="color: rgb(31, 31, 38);">ed by </font>a Party<font style="color: rgb(52, 52, 65);"> t</font>o <font style="color: rgb(31, 31, 38);">perform </font>a Pa<font style="color: rgb(52, 52, 65);">rty</font><font style="color: rgb(31, 31, 38);">&#8216;</font>s obligations under a Collaboration Program shall <font style="color: rgb(31, 31, 38);">m</font>e<font style="color: rgb(31, 31, 38);">et </font><font style="color: rgb(52, 52, 65);">t</font><font style="color: rgb(31, 31, 38);">h</font>e <font style="color: rgb(31, 31, 38);">qu</font>a<font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">f</font><font style="color: rgb(52, 52, 65);">i</font>cati<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 65);">ns </font><font style="color: rgb(31, 31, 38);">t</font>ypica<font style="color: rgb(31, 31, 38);">ll</font><font style="color: rgb(52, 52, 65);">y </font>required by such Party for the performance of work s<font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">mi</font>la<font style="color: rgb(31, 31, 38);">r </font>in sc<font style="color: rgb(52, 52, 65);">o</font><font style="color: rgb(31, 31, 38);">pe a</font>nd c<font style="color: rgb(31, 31, 38);">om</font><font style="color: rgb(52, 52, 65);">p</font>lexity <font style="color: rgb(31, 31, 38);">to</font>&#160;<font style="color: rgb(52, 52, 65);">t</font>h<font style="color: rgb(31, 31, 38);">e </font>subcontracted activity and shall agree in writing <font style="color: rgb(31, 31, 38);">t</font>o <font style="color: rgb(52, 52, 65);">c</font><font style="color: rgb(31, 31, 38);">o</font>mply <font style="color: rgb(31, 31, 38);">with</font><font style="color: rgb(52, 52, 65);">&#160;</font>the a<font style="color: rgb(52, 52, 65);">p</font>p<font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">c</font>able t<font style="color: rgb(31, 31, 38);">erm</font><font style="color: rgb(52, 52, 65);">s </font><font style="color: rgb(31, 31, 38);">o</font>f
                this Agreement (including confidentiality terms<font style="color: rgb(31, 31, 38);">); provided</font><font style="color: rgb(52, 52, 65);">, </font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 52, 65);">h</font>at






                a<font style="color: rgb(52, 52, 65);">n</font>y <font style="color: rgb(52, 52, 65);">P</font>arty e<font style="color: rgb(52, 52, 65);">n</font>g<font style="color: rgb(31, 31, 38);">agi</font>ng an Affiliate or subcontractor hereunder
                will r<font style="color: rgb(31, 31, 38);">e</font>m<font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 38);">i</font>n r<font style="color: rgb(31, 31, 38);">es</font>pons<font style="color: rgb(31, 31, 38);">i</font>ble







                fo<font style="color: rgb(52, 52, 65);">r </font><font style="color: rgb(31, 31, 38);">th</font>e ac<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 38);">s a</font>nd omissions of any subcontractor to whom it del<font style="color: rgb(31, 31, 38);">e</font>gat<font style="color: rgb(31, 31, 38);">es </font>its
                obligations<font style="color: rgb(31, 31, 38);"> u</font>nder th<font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(52, 52, 65);">s </font>Agreement<font style="color: rgb(31, 31, 38);">&#160;</font>including to the extent
                such actions or omi<font style="color: rgb(31, 31, 38);">ss</font>i<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 65);">ns </font>result<font style="color: rgb(31, 31, 38);">&#160;</font>in a <font style="color: rgb(31, 31, 38);">b</font>r<font style="color: rgb(52, 52, 65);">e</font>a<font style="color: rgb(52, 52, 65);">c</font><font style="color: rgb(31, 31, 38);">h o</font>f the terms of t<font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">s </font><font style="color: rgb(52, 52, 65);">Agreement</font>. In addition, any Party eng<font style="color: rgb(52, 52, 65);">a</font>gin<font style="color: rgb(52, 52, 65);">g </font>a <font style="color: rgb(31, 31, 38);">subcontractor sh</font>all in all ca<font style="color: rgb(31, 31, 38);">se</font>s r<font style="color: rgb(31, 31, 38);">et</font>ain or obtain ownership of any and
                all Intellectual<font style="color: rgb(31, 31, 38);">&#160;</font>Property Rights <font style="color: rgb(31, 31, 38);">a</font>ri<font style="color: rgb(52, 52, 65);">s</font>i<font style="color: rgb(31, 31, 38);">n</font>g as a <font style="color: rgb(52, 52, 65);">r</font>e<font style="color: rgb(31, 31, 38);">sul</font>t of performan<font style="color: rgb(31, 31, 38);">c</font>e of any sub-contracte<font style="color: rgb(31, 31, 38);">d </font>activity u<font style="color: rgb(31, 31, 38);">nd</font>e<font style="color: rgb(31, 31, 38);">r </font>th<font style="color: rgb(31, 31, 38);">e </font>R<font style="color: rgb(52, 52, 65);">e</font>s<font style="color: rgb(31, 31, 38);">ea</font>rch
                Plan a<font style="color: rgb(31, 31, 38);">n</font>d any <font style="color: rgb(31, 31, 38);">su</font>b-<font style="color: rgb(31, 31, 38);">c</font>ontract agreement shall state that suc<font style="color: rgb(31, 31, 38);">h </font><font style="color: rgb(52, 52, 65);">su</font>b-contr<font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 38);">c</font>tor has <font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(52, 52, 65);">o </font>rights






                to <font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 38);">e </font>any Intellectual Property Rights owned or Controlled by <font style="color: rgb(31, 31, 38);">the</font>&#160;<font style="color: rgb(31, 31, 38);">othe</font><font style="color: rgb(52, 52, 65);">r </font>Part<font style="color: rgb(31, 31, 38);">y s</font><font style="color: rgb(52, 52, 65);">av</font>e as str<font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 38);">ctl</font><font style="color: rgb(52, 52, 65);">y </font>nece<font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(52, 52, 65);">ar</font>y <font style="color: rgb(52, 52, 65);">f</font>or performance of the sub<font style="color: rgb(31, 31, 38);">-</font>contracted <font style="color: rgb(31, 31, 38);">a</font>c<font style="color: rgb(31, 31, 38);">ti</font><font style="color: rgb(52, 52, 65);">v</font><font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(52, 52, 65);">t</font>ies. <font style="color: rgb(52, 52, 65);">A</font>n<font style="color: rgb(31, 31, 38);">y </font>sub<font style="color: rgb(52, 52, 65);">-contractor</font><font style="color: rgb(31, 31, 38);">&#160;</font>shall not <font style="color: rgb(31, 31, 38);">be </font><font style="color: rgb(52, 52, 65);">entitled</font> to further sub<font style="color: rgb(31, 31, 38);">-</font>contract its ob<font style="color: rgb(31, 31, 38);">l</font>ig<font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 38);">t</font>ions u<font style="color: rgb(31, 31, 38);">nd</font><font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(31, 31, 38);">r </font>this <font style="color: rgb(31, 31, 38);">Agre</font>ement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zbdf16ac4c7c64d71b28c87099a80fe92" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Except as p<font style="color: rgb(31, 31, 38);">ro</font>v<font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(52, 52, 65);">d</font>ed i<font style="color: rgb(31, 31, 38);">n </font>Section <font style="color: rgb(52, 52, 65);">3.</font>7, Immunocore sha<font style="color: rgb(31, 31, 38);">ll be </font>r<font style="color: rgb(31, 31, 38);">e</font>sponsible for its own costs and ex<font style="color: rgb(31, 31, 38);">p</font><font style="color: rgb(52, 52, 65);">e</font>n<font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(52, 52, 65);">e</font>s incurred<font style="color: rgb(31, 31, 38);">&#160;</font>in <font style="color: rgb(31, 31, 38);">pe</font>rformin<font style="color: rgb(31, 31, 38);">g </font><font style="color: rgb(52, 52, 65);">a</font>n<font style="color: rgb(52, 52, 65);">y </font>Collaboration Program. If either Party believ<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(52, 52, 65);">s a </font><font style="color: rgb(31, 31, 38);">Research </font>Plan <font style="color: rgb(31, 31, 38);">for </font>any <font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 65);">f the</font><font style="color: rgb(31, 31, 38);">&#160;</font>Initial<font style="color: rgb(52, 52, 65);">&#160;</font>Programs should b<font style="color: rgb(31, 31, 38);">e </font>amended with resp<font style="color: rgb(52, 52, 65);">ec</font>t
                t<font style="color: rgb(31, 31, 38);">o </font>the a<font style="color: rgb(52, 52, 65);">pp</font>li<font style="color: rgb(31, 31, 38);">c</font>able <font style="color: rgb(52, 52, 65);">P</font>h<font style="color: rgb(31, 31, 38);">as</font>e
                1 Trial in a manner <font style="color: rgb(31, 31, 38);">th</font>at is reasonably expected to cause [***]. If the JSC <font style="color: rgb(31, 31, 38);">a</font>pprov<font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(31, 31, 38);">s s</font>uch a<font style="color: rgb(31, 31, 38);">m</font>e<font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(52, 52, 65);">d</font>ment to the Phase 1 Trial, then [***]. [***] or liable under <font style="color: rgb(52, 52, 65);">t</font><font style="color: rgb(31, 31, 38);">his </font>Agree<font style="color: rgb(31, 31, 38);">m</font>e<font style="color: rgb(52, 52, 65);">n</font>t for any delay to a Collaboration Program or
                delay to the developme<font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 38);">t </font>of any <font style="color: rgb(31, 31, 38);">Lice</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 38);">se</font>d Product to the extent caus<font style="color: rgb(31, 31, 38);">e</font>d by a failure of the JSC or GSK to agree<font style="color: rgb(31, 31, 38);">&#160;</font>to amend the applicable Research Plan as described
                in the foregoing sentenc<font style="color: rgb(52, 52, 65);">e.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z504ec4c29ab1408dbfd8466ecc451a3d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Governance; Collaboration Program Management</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z12289eb909dc459f80a5c79a79c502a6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1F1F26;">W</font><font style="color: #343441;">i</font><font style="color: #1F1F26;">thin [***]</font> of the Effective Date, the Parties will establish a joint steering<font style="color: rgb(31, 31, 38);">
                  committee</font> (the &#8220;<font style="font-weight: bold;">JSC</font>&#8221;). The JSC sh<font style="color: rgb(31, 31, 38);">a</font>ll be responsible for overseeing the conduct of all<font style="color: rgb(52, 52, 65);"> Collaboration</font>
                Program<font style="color: rgb(31, 31, 38);">s</font>, <font style="color: rgb(31, 31, 38);">a</font>nd approving th<font style="color: rgb(31, 31, 38);">e de</font>t<font style="color: rgb(31, 31, 38);">a</font>iled requirem<font style="color: rgb(31, 31, 38);">e</font>nt<font style="color: rgb(31, 31, 38);">s a</font>nd d<font style="color: rgb(31, 31, 38);">e</font>liv<font style="color: rgb(31, 31, 38);">e</font>rabl<font style="color: rgb(31, 31, 38);">es f</font>or<font style="color: rgb(31, 31, 38);"> a</font>ny Collaboration Program <font style="color: rgb(31, 31, 38);">a</font>s developed by the JPT. The JSC sh<font style="color: rgb(31, 31, 38);">a</font>ll have <font style="color: rgb(31, 31, 38);">o</font>versigh<font style="color: rgb(31, 31, 38);">t </font>and decision-making respon<font style="color: rgb(31, 31, 38);">s</font>ibilities for activities<font style="color: rgb(31, 31, 38);">&#160;</font>performed for each
                Collaboration Program and shall resolv<font style="color: rgb(31, 31, 38);">e </font>disputes at the JPT. The JPT shall keep the JS<font style="color: rgb(31, 31, 38);">C </font>informed of th<font style="color: rgb(31, 31, 38);">e</font>
                progress and activities under each Collaboration Program. The JSC shall be comprised of [***] representatives<font style="color: rgb(31, 31, 38);">&#160;</font>(or <font style="color: rgb(31, 31, 38);">s</font>u<font style="color: rgb(31, 31, 38);">c</font>h other number of representatives<font style="color: rgb(31, 31, 38);">&#160;</font>a<font style="color: rgb(31, 31, 38);">s </font>the Parties<font style="color: rgb(31, 31, 38);">&#160;</font><font style="color: rgb(7, 7, 7);">may
                  agree) from each of GSK and Immunocore. Each Party may replace any or all of its representatives on the JSC at any time upon written notice to the other Party in accordance with Section 16.1 or by e-mail to the other Party&#8217;s Alliance
                  Manager. Each representative of a Party shall have sufficient seniority and appropriate expertise in biotechnology and pharmaceutical drug discovery and de</font><font style="color: rgb(42, 42, 51);">v</font><font style="color: rgb(7, 7, 7);">elopment to participate on the JSC. Each Party may, subject to the other Party&#8217;s prior </font><font style="color: rgb(42, 42, 51);">ap</font><font style="color: rgb(7, 7, 7);">proval, invite </font><font style="color: rgb(56, 56, 68);">n</font><font style="color: rgb(26, 26, 29);">on-member </font><font style="color: rgb(7, 7, 7);">representatives of such Party to attend meetings of th</font><font style="color: rgb(56, 56, 68);">e JS</font><font style="color: rgb(26, 26, 29);">C </font><font style="color: rgb(7, 7, 7);">as non-voting </font><font style="color: rgb(26, 26, 29);">participants, </font><font style="color: rgb(7, 7, 7);">subject to the confidentiality obligations of Article 1</font><font style="color: rgb(42, 42, 51);">0. </font><font style="color: rgb(26, 26, 29);">The </font><font style="color: rgb(7, 7, 7);">Alliance Managers shall also participate as non-voting members in JSC meetings</font><font style="color: rgb(42, 42, 51);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z0f04516eeb774584b5eb8a342b5cd3ea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In addition to the responsibilities set forth i<font style="color: rgb(42, 42, 51);">n Section</font> 4.1,<font style="font-weight: bold;">&#160;</font>the JS<font style="color: rgb(42, 42, 51);">C </font><font style="color: rgb(26, 26, 29);">shall p</font><font style="color: rgb(56, 56, 68);">e</font><font style="color: rgb(26, 26, 29);">rform </font>the following functions, subject to the final <font style="color: rgb(26, 26, 29);">decision-makin</font><font style="color: rgb(56, 56, 68);">g </font>authority of t<font style="color: rgb(42, 42, 51);">he </font><font style="color: rgb(56, 56, 68);">re</font><font style="color: rgb(26, 26, 29);">spective</font> Parties as set forth in Section
                4.5:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4c24c15ef2c6475395bcf381da97c4ba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve a Research<font style="color: rgb(42, 42, 51);">&#160;</font>Plan<font style="color: rgb(42, 42, 51);"> for </font>each<font style="color: rgb(42, 42, 51);"> Collaboration</font> Program in accordance with the timeli<font style="color: rgb(42, 42, 51);">n</font>es s<font style="color: rgb(56, 56, 68);">e</font>t fort<font style="color: rgb(42, 42, 51);">h i</font>n Article 5<font style="color: rgb(42, 42, 51);">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zcabbd6882a754b77b7aa842b06de98ba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve <font style="color: rgb(42, 42, 51);">any c</font>hang<font style="color: rgb(42, 42, 51);">es re</font>quir<font style="color: rgb(56, 56, 68);">e</font>d <font style="color: rgb(42, 42, 51);">t</font>o the <font style="color: rgb(26, 26, 29);">Research </font>Plan for any Collaboration Program i<font style="color: rgb(42, 42, 51);">n </font><font style="color: rgb(26, 26, 29);">accordance </font>with <font style="color: rgb(42, 42, 51);">Section</font>
                4<font style="color: rgb(56, 56, 68);">.7</font><font style="color: rgb(42, 42, 51);">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z84d1c5be4e64401dbb81ad1196e15ea4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and monitor <font style="color: rgb(42, 42, 51);">pro</font>gre<font style="color: rgb(42, 42, 51);">ss </font>of ea<font style="color: rgb(56, 56, 68);">c</font><font style="color: rgb(26, 26, 29);">h </font><font style="color: rgb(42, 42, 51);">Collaboration</font>&#160;<font style="color: rgb(26, 26, 29);">Program </font><font style="color: rgb(42, 42, 51);">wit</font>h input from the JPT;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4d21284a4c684000911efb465e804087" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>confirm wh<font style="color: rgb(42, 42, 51);">e</font>ther the <font style="color: rgb(42, 42, 51);">L</font>e<font style="color: rgb(42, 42, 51);">a</font>d <font style="color: rgb(26, 26, 29);">Candi</font><font style="color: rgb(56, 56, 68);">d</font>ate <font style="color: rgb(26, 26, 29);">Criteria </font>hav<font style="color: rgb(56, 56, 68);">e </font><font style="color: rgb(42, 42, 51);">b</font>e<font style="color: rgb(42, 42, 51);">e</font>n
                achieved by a Compound;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zbe50da37ec7d41dfb4e64d7cc780fe73" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review a<font style="color: rgb(56, 56, 68);">nd </font>app<font style="color: rgb(42, 42, 51);">ro</font>v<font style="color: rgb(56, 56, 68);">e </font>ch<font style="color: rgb(42, 42, 51);">an</font>ges to <font style="color: rgb(26, 26, 29);">the Lead </font><font style="color: rgb(42, 42, 51);">Candid</font>ate Criteria for each Collaboration Program<font style="color: rgb(26, 26, 29);">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zed12d6c87c1d46458542f49b0b71b262" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2A2A33;">c</font>o<font style="color: rgb(56, 56, 68);">n</font><font style="color: rgb(26, 26, 29);">firm </font>wh<font style="color: rgb(56, 56, 68);">e</font><font style="color: rgb(26, 26, 29);">ther </font>the






                Develop<font style="color: rgb(42, 42, 51);">me</font>nt <font style="color: rgb(42, 42, 51);">C</font>andid <font style="color: rgb(42, 42, 51);">ate C</font>riteria have been met by a<font style="color: rgb(26, 26, 29);"> Compound;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9ee148d199a540b7b39e938f33589fbf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2A2A33;">re</font><font style="color: #070707;">view </font><font style="color: #2A2A33;">a</font><font style="color: #070707;">n</font><font style="color: #2A2A33;">d </font><font style="color: #070707;">ap</font><font style="color: #2A2A33;">prove </font><font style="color: #070707;">changes </font><font style="color: #1A1A1D;">to </font><font style="color: #070707;">the Deve</font><font style="color: #383844;">lo</font><font style="color: #070707;">pment






                  Candidate Criteria for each Collaboration</font><font style="color: #1A1A1D;">&#160;</font><font style="color: #383844;">Program</font><font style="color: #070707;">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z76ac9e5fe98d4dbd98776bdb98a5369c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and <font style="color: rgb(26, 26, 29);">d</font><font style="color: rgb(56, 56, 68);">i</font><font style="color: rgb(26, 26, 29);">scuss </font><font style="color: rgb(42, 42, 51);">data </font>arisin<font style="color: rgb(42, 42, 51);">g fro</font>m the Phase I Trials conducted under the Initial Programs;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1467d5eed2274643843e14bcfdb028d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>gene<font style="color: rgb(42, 42, 51);">ra</font>ll<font style="color: rgb(42, 42, 51);">y </font>serve a<font style="color: rgb(42, 42, 51);">s </font>a forum for exchange of information and to facilitate<font style="color: rgb(26, 26, 29);"> di</font><font style="color: rgb(56, 56, 68);">sc</font>ussions <font style="color: rgb(56, 56, 68);">re</font><font style="color: rgb(26, 26, 29);">g</font><font style="color: rgb(56, 56, 68);">ard</font><font style="color: rgb(26, 26, 29);">ing </font>the conduct of the Collaboration Programs hereunder;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf6836b8edc5b43e48cbd653761245abc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top;">4.2.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #464854;">r</font><font style="color: #2A2A33;">e</font><font style="color: #070707;">solve disputes referred from the JPT;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3847b4ffa5094d1d924ce300efc94af3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top;">4.2.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">review </font><font style="color: #2A2A33;">and </font><font style="color: #070707;">determine the requirement for </font><font style="color: #1A1A1D;">any </font><font style="color: #070707;">additional
                  documentation under Section 6.11 below;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze4b3b1dbd9b044a9be87b00a0fcf1fa1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top;">4.2.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and determine the amount of initial training and te<font style="color: rgb(42, 42, 51);">c</font>hnical assistance required from Immunocore to GSK under Section 6.11 together with the time for provision of such initial training
                and t<font style="color: rgb(42, 42, 51);">e</font>chnical assistance; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z996dab97bfba4dafb0bbee53aaecf486" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 32.4pt; vertical-align: top;">4.2.13</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>such other responsibilities as may be assigned to the JSC pursuant to this Agreement or as may be mutually agreed by the Parties from time to time.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5af5431558c5488dbdd7d9bb0876a147" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1A1A1D;">Save </font>as provided under <font style="color: rgb(26, 26, 29);">Section </font>4.7, the <font style="color: rgb(26, 26, 29);">JSC shall </font>meet qu<font style="color: rgb(42, 42, 51);">a</font>rterly






                and <font style="color: rgb(26, 26, 29);">chairing of </font>the <font style="color: rgb(7, 7, 7);">meetings shall be alternated between each Party&#8217;s designated representative, unless otherwise agreed. The meetings shall be held at the
                  premises of the Party chairing the meeting unless otherwise agreed. The Parties may also agree to hold such meeting by telephone or video conference or webinar although at least [***] in any Year shall be in person to the extent possible.
                  The first mee</font><font style="color: rgb(31, 31, 36);">t</font><font style="color: rgb(7, 7, 7);">ing shall be chaired by [***] and shall be held within [***] </font><font style="color: rgb(52, 52, 65);">o</font><font style="color: rgb(31, 31, 36);">f </font><font style="color: rgb(7, 7, 7);">the Effectiv</font><font style="color: rgb(31, 31, 36);">e </font><font style="color: rgb(7, 7, 7);">Date. The Alliance Manager for the Party chairing each meeting </font><font style="color: rgb(31, 31, 36);">sh</font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">ll </font><font style="color: rgb(7, 7, 7);">be responsibl</font><font style="color: rgb(52, 52, 65);">e f</font><font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(7, 7, 7);">r [***] to comment on and add items to the agenda a</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 36);">d </font><font style="color: rgb(7, 7, 7);">re</font><font style="color: rgb(31, 31, 36);">-</font><font style="color: rgb(7, 7, 7);">circulate the </font><font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(7, 7, 7);">g</font><font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(7, 7, 7);">nda at lea</font><font style="color: rgb(31, 31, 36);">s</font><font style="color: rgb(7, 7, 7);">t [***] ahead of the agreed date </font><font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(52, 52, 65);">f </font><font style="color: rgb(31, 31, 36);">the </font><font style="color: rgb(7, 7, 7);">m</font><font style="color: rgb(31, 31, 36);">ee</font><font style="color: rgb(7, 7, 7);">ting. Th</font><font style="color: rgb(31, 31, 36);">e Parties</font><font style="color: rgb(7, 7, 7);"> s</font><font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">ll </font><font style="color: rgb(7, 7, 7);">each be responsible for their own costs and expense</font><font style="color: rgb(52, 52, 65);">s </font><font style="color: rgb(7, 7, 7);">i</font><font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(7, 7, 7);">c</font><font style="color: rgb(31, 31, 36);">u</font><font style="color: rgb(52, 52, 65);">r</font><font style="color: rgb(7, 7, 7);">red </font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 36);">n participating</font><font style="color: rgb(7, 7, 7);"> and </font><font style="color: rgb(52, 52, 65);">attending</font><font style="color: rgb(7, 7, 7);">
                  JSC meetings. Copies of data and proposals t</font><font style="color: rgb(52, 52, 65);">o </font><font style="color: rgb(7, 7, 7);">b</font><font style="color: rgb(52, 52, 65);">e </font><font style="color: rgb(7, 7, 7);">dis</font><font style="color: rgb(31, 31, 36);">c</font><font style="color: rgb(52, 52, 65);">u</font><font style="color: rgb(31, 31, 36);">sse</font><font style="color: rgb(7, 7, 7);">d s</font><font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">l</font><font style="color: rgb(7, 7, 7);">l b</font><font style="color: rgb(52, 52, 65);">e </font><font style="color: rgb(7, 7, 7);">cir</font><font style="color: rgb(52, 52, 65);">c</font><font style="color: rgb(31, 31, 36);">u</font><font style="color: rgb(52, 52, 65);">l</font><font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(7, 7, 7);">t</font><font style="color: rgb(31, 31, 36);">ed </font><font style="color: rgb(7, 7, 7);">by each Party at least [***] </font><font style="color: rgb(31, 31, 36);">p</font><font style="color: rgb(7, 7, 7);">ri</font><font style="color: rgb(31, 31, 36);">or t</font><font style="color: rgb(7, 7, 7);">o </font><font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(31, 31, 36);">ach </font><font style="color: rgb(7, 7, 7);">JSC </font><font style="color: rgb(31, 31, 36);">m</font><font style="color: rgb(52, 52, 65);">ee</font><font style="color: rgb(7, 7, 7);">ting w</font><font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(31, 31, 36);">r</font><font style="color: rgb(7, 7, 7);">e reasonably possible.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z6a6b6058191c4eb0ba14a6e169f6a203" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Alliance Manager from the Party<font style="color: rgb(31, 31, 36);">&#160;</font><font style="color: rgb(52, 52, 65);">that</font> is <font style="color: rgb(31, 31, 36);">not</font><font style="color: rgb(72, 73, 84);">&#160;</font>the c<font style="color: rgb(31, 31, 36);">h</font>a<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">r</font>ing Party <font style="color: rgb(52, 52, 65);">shall</font> be responsible for preparing and
                circulating min<font style="color: rgb(31, 31, 36);">ute</font><font style="color: rgb(52, 52, 65);">s, </font>withi<font style="color: rgb(31, 31, 36);">n [***]</font> of each<font style="font-weight: bold;">&#160;</font>meeting of the JSC,
                setting forth, <font style="font-style: italic;">inter </font><font style="font-style: italic; color: rgb(31, 31, 36);">alia</font><font style="font-style: italic;">, </font><font style="color: rgb(31, 31, 36);">a</font>n <font style="color: rgb(31, 31, 36);">ov</font>ervi<font style="color: rgb(31, 31, 36);">e</font>w of t<font style="color: rgb(52, 52, 65);">he </font><font style="color: rgb(31, 31, 36);">d</font>iscu<font style="color: rgb(31, 31, 36);">ss</font>i<font style="color: rgb(31, 31, 36);">on</font>s at the meeting and a list of any actions and deci<font style="color: rgb(31, 31, 36);">s</font><font style="color: rgb(52, 52, 65);">i</font>on<font style="color: rgb(31, 31, 36);">s </font>approv<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(52, 52, 65);">d </font>b<font style="color: rgb(31, 31, 36);">y the </font>JSC a<font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(52, 52, 65);">d </font>a
                <font style="color: rgb(31, 31, 36);">l</font><font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 36);">s</font>t of <font style="color: rgb(31, 31, 36);">an</font>y issues to be resolved by the Executive<font style="color: rgb(31, 31, 36);"> Officers</font>&#160;<font style="color: rgb(31, 31, 36);">pursuant</font>&#160;<font style="color: rgb(52, 52, 65);">t</font>o <font style="color: rgb(31, 31, 36);">Se</font>ction <font style="color: rgb(31, 31, 36);">4.5</font>. Such <font style="color: rgb(31, 31, 36);">min</font>utes shall be effective only after app<font style="color: rgb(31, 31, 36);">rov</font>ed by b<font style="color: rgb(52, 52, 65);">o</font>t<font style="color: rgb(52, 52, 65);">h Parties </font><font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">n </font><font style="color: rgb(31, 31, 36);">writing</font>. With t<font style="color: rgb(31, 31, 36);">he </font>so<font style="color: rgb(31, 31, 36);">l</font>e exception of specific items of the meetin<font style="color: rgb(31, 31, 36);">g </font>minut<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(52, 52, 65);">s </font>to w<font style="color: rgb(31, 31, 36);">hic</font>h the m<font style="color: rgb(31, 31, 36);">e</font>m<font style="color: rgb(52, 52, 65);">b</font><font style="color: rgb(31, 31, 36);">er</font>s cann<font style="color: rgb(31, 31, 36);">ot ag</font>ree






                and that are escalated to the Executive Officers <font style="color: rgb(31, 31, 36);">a</font>s <font style="color: rgb(31, 31, 36);">p</font>ro<font style="color: rgb(31, 31, 36);">v</font>id<font style="color: rgb(31, 31, 36);">e</font>d
                in <font style="color: rgb(31, 31, 36);">Section </font>4.5<font style="color: rgb(31, 31, 36);">, </font>definitive minutes of all JSC meetings shall <font style="color: rgb(52, 52, 65);">be </font>finalize<font style="color: rgb(52, 52, 65);">d </font>no late<font style="color: rgb(52, 52, 65);">r </font><font style="color: rgb(31, 31, 36);">t</font><font style="color: rgb(52, 52, 65);">h</font>an [***] after the meeting to whic<font style="color: rgb(31, 31, 36);">h
                </font>the minu<font style="color: rgb(31, 31, 36);">te</font><font style="color: rgb(52, 52, 65);">s </font><font style="color: rgb(31, 31, 36);">p</font>ert<font style="color: rgb(31, 31, 36);">ai</font>n. If, at <font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">ny </font>time <font style="color: rgb(52, 52, 65);">d</font>u<font style="color: rgb(52, 52, 65);">r</font><font style="color: rgb(31, 31, 36);">i</font>n<font style="color: rgb(31, 31, 36);">g </font>the preparation and finalization of t<font style="color: rgb(31, 31, 36);">h</font>e <font style="color: rgb(52, 52, 65);">JS</font><font style="color: rgb(31, 31, 36);">C </font>minutes, the <font style="color: rgb(31, 31, 36);">Parties</font> do<font style="color: rgb(31, 31, 36);">&#160;</font>not agre<font style="color: rgb(31, 31, 36);">e </font><font style="color: rgb(52, 52, 65);">o</font><font style="color: rgb(31, 31, 36);">n </font><font style="color: rgb(52, 52, 65);">an</font>y issue with respect to the minutes, su<font style="color: rgb(52, 52, 65);">c</font><font style="color: rgb(31, 31, 36);">h </font>issu<font style="color: rgb(31, 31, 36);">e </font><font style="color: rgb(52, 52, 65);">s</font>hall <font style="color: rgb(31, 31, 36);">be re</font>solved by the es<font style="color: rgb(52, 52, 65);">ca</font><font style="color: rgb(31, 31, 36);">la</font><font style="color: rgb(52, 52, 65);">t</font>ion process set forth in Section 4.5. <font style="color: rgb(31, 31, 36);">T</font>he decis<font style="color: rgb(31, 31, 36);">io</font>n <font style="color: rgb(52, 52, 65);">r</font>esult<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 36);">g </font><font style="color: rgb(52, 52, 65);">fr</font>om t<font style="color: rgb(31, 31, 36);">h</font>e <font style="color: rgb(31, 31, 36);">escalation</font><font style="color: rgb(52, 52, 65);">&#160;</font>process shall be recorded by the Alliance Manager<font style="color: rgb(52, 52, 65);">&#160;</font>in a<font style="color: rgb(31, 31, 36);">m</font>e<font style="color: rgb(31, 31, 36);">nd</font>ed f<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 36);">a</font>li<font style="color: rgb(31, 31, 36);">z</font>ed m<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 36);">u</font>t<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(52, 52, 65);">s </font>for su<font style="color: rgb(31, 31, 36);">c</font><font style="color: rgb(52, 52, 65);">h </font>m<font style="color: rgb(31, 31, 36);">e</font>eting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc90379cd92fb4ddabc20628904ee3a0b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Decisi<font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(52, 52, 65);">n</font><font style="color: rgb(31, 31, 36);">s </font><font style="color: rgb(52, 52, 65);">of </font><font style="color: rgb(31, 31, 36);">t</font>he






                <font style="color: rgb(31, 31, 36);">J</font><font style="color: rgb(52, 52, 65);">S</font><font style="color: rgb(31, 31, 36);">C s</font>h<font style="color: rgb(31, 31, 36);">a</font>ll <font style="color: rgb(31, 31, 36);">b</font><font style="color: rgb(52, 52, 65);">e </font>mad<font style="color: rgb(31, 31, 36);">e </font><font style="color: rgb(52, 52, 65);">o</font>n <font style="color: rgb(31, 31, 36);">a u</font>nani<font style="color: rgb(31, 31, 36);">mo</font>u<font style="color: rgb(31, 31, 36);">s </font>basis with each Party having <font style="color: rgb(31, 31, 36);">o</font>n<font style="color: rgb(31, 31, 36);">e</font> vote <font style="color: rgb(52, 52, 65);">o</font>n t<font style="color: rgb(52, 52, 65);">h</font><font style="color: rgb(31, 31, 36);">e </font>JSC. <font style="color: rgb(31, 31, 36);">I</font>n <font style="color: rgb(31, 31, 36);">the</font>&#160;<font style="color: rgb(52, 52, 65);">event</font><font style="color: rgb(31, 31, 36);">&#160;</font>of any inability to <font style="color: rgb(31, 31, 36);">r</font>e<font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(52, 52, 65);">c</font>h a decision at a JSC meeting, the
                [***] (the<font style="color: rgb(31, 31, 36);">&#160;</font>&#8220;<font style="font-weight: bold;">Executive Offi</font><font style="font-weight: bold; color: rgb(52, 52, 65);">c</font><font style="font-weight: bold; color: rgb(31, 31, 36);">e</font><font style="font-weight: bold;">rs</font>&#8221;). W<font style="color: rgb(31, 31, 36);">h</font>ere res<font style="color: rgb(31, 31, 36);">o</font>lution <font style="color: rgb(52, 52, 65);">i</font><font style="color: rgb(31, 31, 36);">s </font><font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 36);">t</font>ill not <font style="color: rgb(31, 31, 36);">po</font><font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 36);">s</font>ible
                within [***] of referral to the Executive Officers<font style="color: rgb(31, 31, 36);">, </font>GSK sh<font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">ll </font>have the final decision-making authority
                save that GSK <font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 36);">ha</font>l<font style="color: rgb(31, 31, 36);">l n</font>ot be <font style="color: rgb(52, 52, 65);">entitled</font> to resolve any dispute
                in a way which would (a) require amend<font style="color: rgb(52, 52, 65);">m</font><font style="color: rgb(31, 31, 36);">en</font>t of th<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 52, 65);">s </font>A<font style="color: rgb(31, 31, 36);">g</font>reement; or (b) materially increase or change the scope of work, c<font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(52, 52, 65);">s</font><font style="color: rgb(31, 31, 36);">t
                </font>or exp<font style="color: rgb(52, 52, 65);">e</font><font style="color: rgb(31, 31, 36);">ns</font><font style="color: rgb(52, 52, 65);">e</font>s of Immunocore under any agreed Research Plan for any Collaboration <font style="color: rgb(52, 52, 65);">Program</font><font style="color: rgb(31, 31, 36);"> o</font>r <font style="color: rgb(52, 52, 65);">r</font>esult in a material delay to the Collaboration Program; o<font style="color: rgb(31, 31, 36);">r
                </font>(c) result i<font style="color: rgb(31, 31, 36);">n </font><font style="color: rgb(52, 52, 65);">I</font><font style="color: rgb(31, 31, 36);">m</font>munoco<font style="color: rgb(31, 31, 36);">r</font>e <font style="color: rgb(31, 31, 36);">l</font>osing any ownership <font style="color: rgb(31, 31, 36);">i</font>nterest in any Foreground; or (d) place patien<font style="color: rgb(31, 31, 36);">t</font><font style="color: rgb(52, 52, 65);">s </font><font style="color: rgb(31, 31, 36);">at </font>exces<font style="color: rgb(52, 52, 65);">si</font>v<font style="color: rgb(52, 52, 65);">e </font>risk or which might be reasonably considered to place patient healt<font style="color: rgb(31, 31, 36);">h a</font>nd safet<font style="color: rgb(31, 31, 36);">y </font><font style="color: rgb(52, 52, 65);">a</font><font style="color: rgb(31, 31, 36);">t r</font>isk in a Clinical Trial conducted by Immunocore in accordance with a
                <font style="color: rgb(52, 52, 65);">Research</font> Plan<font style="color: rgb(114, 114, 119);">. </font>For the<font style="color: rgb(31, 31, 36);">&#160;</font>avoidance<font style="color: rgb(31, 31, 36);">&#160;</font>of d<font style="color: rgb(31, 31, 36);">o</font>ubt, a &#8220;material d<font style="color: rgb(31, 31, 36);">e</font>lay&#8221; <font style="color: rgb(31, 31, 36);">s</font>hall m<font style="color: rgb(31, 31, 36);">e</font>an an <font style="color: rgb(31, 31, 36);">ad</font><font style="color: rgb(52, 52, 65);">d</font>i<font style="color: rgb(31, 31, 36);">tio</font>nal period of time adde<font style="color: rgb(31, 31, 36);">d </font>to any Program Phase of at [***] of the timelines<font style="color: rgb(52, 52, 65);"> se</font><font style="color: rgb(31, 31, 36);">t </font>forth in the Re<font style="color: rgb(31, 31, 36);">s</font>earch Plan. By way of <font style="color: rgb(31, 31, 36);">e</font>xample, if Project Phase 1 i<font style="color: rgb(31, 31, 36);">s </font>scheduled to<font style="color: rgb(52, 52, 65);"> t</font><font style="color: rgb(31, 31, 36);">a</font>k<font style="color: rgb(31, 31, 36);">e [***]</font> for <font style="color: rgb(31, 31, 36);">Completion</font>, then a materi<font style="color: rgb(31, 31, 36);">a</font>l delay in that case shall be a suspension of work under Project Phase 1 for a period of [***]. Solely in the ca<font style="color: rgb(31, 31, 36);">s</font>e
                wh<font style="color: rgb(31, 31, 36);">e</font>r<font style="color: rgb(31, 31, 36);">e </font>Immunocore r<font style="color: rgb(31, 31, 36);">e</font>asonably b<font style="color: rgb(31, 31, 36);">e</font>lieves GSK&#8217;s final d<font style="color: rgb(31, 31, 36);">e</font>ci<font style="color: rgb(31, 31, 36);">s</font>ion will h<font style="color: rgb(31, 31, 36);">a</font>ve on<font style="color: rgb(31, 31, 36);">e </font>or mor<font style="color: rgb(31, 31, 36);">e</font> of the <font style="color: rgb(31, 31, 36);">co</font>n<font style="color: rgb(31, 31, 36);">s</font>equen<font style="color: rgb(31, 31, 36);">c</font>e<font style="color: rgb(31, 31, 36);">s </font>set forth in (<font style="color: rgb(31, 31, 36);">a</font>) - (d) above, Immunocore m<font style="color: rgb(31, 31, 36);">a</font>y refer the matter t<font style="color: rgb(31, 31, 36);">o</font> the dispute resolution process set forth in Article 15.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zb2d769c6113b4118855419707d72837a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Joint Project Team</u>. As soon as possible after the Effective Date, the Parties shall establish a joint project team (the &#8220;<font style="font-weight: bold;">JPT</font>&#8221;)<font style="font-weight: bold;">&#160;</font>which shall be
                initially responsible for the day-to-day operations of the Initial Target Program. The JPT shall also be responsible for the day-to-day operations of all other Collaboration Programs when they become effective; provided, that if multiple
                JPTs are needed due <font style="color: rgb(26, 26, 31);">to </font>different Targets or disease areas, then the Parties may establish separate <font style="color: rgb(26, 26, 31);">JPTs </font><font style="color: rgb(42, 42, 51);">for</font>
                different <font style="color: rgb(42, 42, 51);">Collaboration</font> Programs. The JPT shall be comprised of representatives from eac<font style="color: rgb(42, 42, 51);">h o</font>f GSK and Immunocore with the appropriate scientific
                expertise<font style="color: rgb(42, 42, 51);"> w</font>i<font style="color: rgb(59, 59, 72);">t</font><font style="color: rgb(26, 26, 31);">h </font>respect to the <font style="color: rgb(59, 59, 72);">c</font><font style="color: rgb(26, 26, 31);">onduct </font>of the Research Plans (and such representatives may <font style="color: rgb(42, 42, 51);">vary </font>depending on th<font style="color: rgb(42, 42, 51);">e </font>r<font style="color: rgb(42, 42, 51);">e</font>levant






                Project Phase) and shall meet on a [***] basis (or <font style="color: rgb(26, 26, 31);">more </font><font style="color: rgb(42, 42, 51);">o</font>r less frequently as agreed by the Parties) at Immunocore&#8217;s facilities or via telec<font style="color: rgb(42, 42, 51);">onfere</font>nc<font style="color: rgb(42, 42, 51);">e </font>at such times as ma<font style="color: rgb(42, 42, 51);">y </font><font style="color: rgb(59, 59, 72);">b</font><font style="color: rgb(26, 26, 31);">e </font>agreed by the Parties during the Research Term. The <font style="color: rgb(42, 42, 51);">J</font>PT <font style="color: rgb(42, 42, 51);">w</font>ill <font style="color: rgb(42, 42, 51);">r</font>eport t<font style="color: rgb(42, 42, 51);">o t</font>he JS<font style="color: rgb(59, 59, 72);">C an</font><font style="color: rgb(26, 26, 31);">d </font>will be responsible for the day-to-day managem<font style="color: rgb(42, 42, 51);">en</font>t
                <font style="color: rgb(26, 26, 31);">of </font>th<font style="color: rgb(59, 59, 72);">e </font><font style="color: rgb(42, 42, 51);">co</font>ndu<font style="color: rgb(42, 42, 51);">ct </font>of the <font style="color: rgb(42, 42, 51);">Re</font>se<font style="color: rgb(42, 42, 51);">a</font>rch Plans including overseeing the conduct of experiments <font style="color: rgb(42, 42, 51);">and reviewing </font><font style="color: rgb(59, 59, 72);">d</font>ata res<font style="color: rgb(42, 42, 51);">ult</font>ing from such experiments as set forth in the Resear<font style="color: rgb(59, 59, 72);">c</font>h <font style="color: rgb(42, 42, 51);">Plan</font>s, <font style="color: rgb(26, 26, 31);">prop</font><font style="color: rgb(59, 59, 72);">o</font>sing <font style="color: rgb(59, 59, 72);">a</font><font style="color: rgb(26, 26, 31);">mendments </font>to the Research Plans, proposing new Research Plan<font style="color: rgb(59, 59, 72);">s
                </font>to <font style="color: rgb(26, 26, 31);">t</font><font style="color: rgb(59, 59, 72);">h</font>e JSC <font style="color: rgb(42, 42, 51);">for </font>new <font style="color: rgb(42, 42, 51);">Co</font>l<font style="color: rgb(42, 42, 51);">la</font>borati<font style="color: rgb(42, 42, 51);">o</font>n P<font style="color: rgb(42, 42, 51);">ro</font>grams for JSC approval, discussing potential Lea<font style="color: rgb(59, 59, 72);">d </font>Candi<font style="color: rgb(42, 42, 51);">da</font><font style="color: rgb(77, 77, 89);">t</font><font style="color: rgb(42, 42, 51);">e</font>s an<font style="color: rgb(42, 42, 51);">d </font><font style="color: rgb(26, 26, 31);">Development </font>Candidates






                for proposal to the JSC. All decisions<font style="color: rgb(42, 42, 51);"> of </font>the <font style="color: rgb(26, 26, 31);">JPT </font><font style="color: rgb(42, 42, 51);">o</font>n matters<font style="color: rgb(42, 42, 51);">&#160;</font>for






                wh<font style="color: rgb(42, 42, 51);">ich it </font>has responsibility shall be made unanimously. In<font style="color: rgb(42, 42, 51);">&#160;</font>t<font style="color: rgb(42, 42, 51);">he </font>ev<font style="color: rgb(42, 42, 51);">e</font>nt






                that the <font style="color: rgb(42, 42, 51);">JPT </font>is un<font style="color: rgb(42, 42, 51);">able </font>to reach a unanimous decision within [***]<font style="color: rgb(26, 26, 31);">&#160;</font><font style="color: rgb(42, 42, 51);">a</font>fter it <font style="color: rgb(26, 26, 31);">h</font><font style="color: rgb(59, 59, 72);">as </font>m<font style="color: rgb(42, 42, 51);">et a</font>nd attempted <font style="color: rgb(42, 42, 51);">t</font>o rea<font style="color: rgb(42, 42, 51);">c</font>h such decision, then either Party may, by <font style="color: rgb(42, 42, 51);">written </font>not<font style="color: rgb(42, 42, 51);">ice </font>to the o<font style="color: rgb(42, 42, 51);">ther</font>,
                have su<font style="color: rgb(42, 42, 51);">c</font>h issu<font style="color: rgb(42, 42, 51);">e submitted</font> to the JSC for resolution in acco<font style="color: rgb(59, 59, 72);">r</font>dan<font style="color: rgb(42, 42, 51);">c</font>e
                wi<font style="color: rgb(42, 42, 51);">t</font>h <font style="color: rgb(42, 42, 51);">Se</font>ction <font style="color: rgb(26, 26, 31);">4.5. </font>Ea<font style="color: rgb(42, 42, 51);">ch </font>Party will bear all expenses it
                incurs in regard to participating in a<font style="color: rgb(42, 42, 51);">ll </font>meeti<font style="color: rgb(42, 42, 51);">ng</font>s of the <font style="color: rgb(42, 42, 51);">J</font>P<font style="color: rgb(42, 42, 51);">T</font>,
                <font style="color: rgb(26, 26, 31);">including all </font>travel and living expenses.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z04bfde8a105a417da7cfcb132a4f9276" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Where any Party wants to </font><font style="color: #1A1A1F;">amend </font><font style="color: #070707;">th</font><font style="color: #2A2A33;">e serv </font><font style="color: #070707;">ices o</font><font style="color: #3B3B48;">r </font><font style="color: #2A2A33;">tas</font><font style="color: #070707;">ks all</font><font style="color: #2A2A33;">ocat</font><font style="color: #070707;">ed under any Research Plan it shall not</font><font style="color: #2A2A33;">if</font><font style="color: #070707;">y the</font><font style="color: #2A2A33;">&#160;</font><font style="color: #070707;">JSC </font><font style="color: #2A2A33;">of </font><font style="color: #070707;">such d</font><font style="color: #2A2A33;">es</font><font style="color: #070707;">ir</font><font style="color: #2A2A33;">e </font><font style="color: #070707;">to amend. </font><font style="color: #1A1A1F;">The notification</font><font style="color: #070707;"> shall include details of the chang</font><font style="color: #2A2A33;">e</font><font style="color: #070707;">s </font><font style="color: #2A2A33;">b</font><font style="color: #070707;">eing </font><font style="color: #2A2A33;">requ</font><font style="color: #070707;">este</font><font style="color: #2A2A33;">d </font><font style="color: #3B3B48;">a</font><font style="color: #070707;">nd the </font><font style="color: #2A2A33;">i</font><font style="color: #070707;">m</font><font style="color: #2A2A33;">pa</font><font style="color: #070707;">ct suc</font><font style="color: #2A2A33;">h </font><font style="color: #070707;">changes will have on the remainder o</font><font style="color: #2A2A33;">f </font><font style="color: #1A1A1F;">the </font><font style="color: #070707;">Rese</font><font style="color: #2A2A33;">ar</font><font style="color: #070707;">c</font><font style="color: #2A2A33;">h </font><font style="color: #070707;">Plan </font><font style="color: #2A2A33;">inclu</font><font style="color: #070707;">ding </font><font style="color: #3B3B48;">a</font><font style="color: #070707;">n</font><font style="color: #3B3B48;">y </font><font style="color: #070707;">impact </font><font style="color: #2A2A33;">o</font><font style="color: #070707;">n timescales. Unless the request needs to be determine</font><font style="color: #2A2A33;">d </font><font style="color: #070707;">ahe</font><font style="color: #2A2A33;">ad </font><font style="color: #1A1A1F;">of </font><font style="color: #070707;">th</font><font style="color: #2A2A33;">e n</font><font style="color: #070707;">e</font><font style="color: #2A2A33;">xt </font><font style="color: #070707;">JSC </font><font style="color: #2A2A33;">meeting</font><font style="color: #070707;">, any amendment to the Research </font><font style="color: #1A1A1F;">Plan </font><font style="color: #070707;">will </font><font style="color: #1A1A1F;">be </font><font style="color: #2A2A33;">d</font><font style="color: #070707;">iscuss</font><font style="color: #2A2A33;">ed </font><font style="color: #070707;">at the </font><font style="color: #1A1A1F;">next </font><font style="color: #3B3B48;">J</font><font style="color: #070707;">SC me</font><font style="color: #2A2A33;">eting </font><font style="color: #070707;">and the request for change will be add</font><font style="color: #3B3B48;">e</font><font style="color: #070707;">d </font><font style="color: #2A2A33;">to the</font><font style="color: #070707;">&#160;</font><font style="color: #2A2A33;">agend</font><font style="color: #070707;">a fo</font><font style="color: #3B3B48;">r </font><font style="color: #1A1A1F;">the </font><font style="color: #070707;">next </font><font style="color: #2A2A33;">mee</font><font style="color: #070707;">ting. W</font><font style="color: #3B3B48;">h</font><font style="color: #1A1A1F;">ere </font><font style="color: #070707;">a request needs to be determined mor</font><font style="color: #2A2A33;">e </font><font style="color: #070707;">qui</font><font style="color: #2A2A33;">ck</font><font style="color: #070707;">ly, t</font><font style="color: #2A2A33;">he </font><font style="color: #1A1A1F;">JSC m</font><font style="color: #3B3B48;">a</font><font style="color: #1A1A1F;">y </font><font style="color: #2A2A33;">c</font><font style="color: #070707;">all a speci</font><font style="color: #2A2A33;">a</font><font style="color: #070707;">l meeting </font><font style="color: #2A2A33;">to </font><font style="color: #070707;">resolve the matter ahead of the next scheduled</font><font style="color: #2A2A33;"> JS</font><font style="color: #070707;">C meeting. Th</font><font style="color: #2A2A33;">e </font><font style="color: #3B3B48;">c</font><font style="color: #070707;">hai</font><font style="color: #2A2A33;">r </font><font style="color: #070707;">of
                  such special meeting shall be the same chair a</font><font style="color: #3B3B48;">s </font><font style="color: #2A2A33;">for </font><font style="color: #070707;">the </font><font style="color: #2A2A33;">next </font><font style="color: #070707;">JSC meeting</font><font style="color: #1A1A1F;">.</font><font style="color: #3B3B48;">&#160;</font><font style="color: #1A1A1F;">M</font><font style="color: #3B3B48;">in</font><font style="color: #070707;">u</font><font style="color: #3B3B48;">t</font><font style="color: #070707;">es of </font><font style="color: #1A1A1F;">the </font><font style="color: #2A2A33;">s</font><font style="color: #070707;">pecial meeting will be </font><font style="color: #1A1A1F;">circulated </font><font style="color: #070707;">and pre</font><font style="color: #2A2A33;">par</font><font style="color: #070707;">ed in </font><font style="color: #1A1A1F;">accordance </font><font style="color: #070707;">with</font><font style="font-weight: bold; color: #070707;">&#160;</font><font style="color: #070707;">Section 4.4.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z15c6b48ef1ba41839a1a2b655830a34b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The JSC shall n<font style="color: rgb(42, 42, 51);">ot </font>h<font style="color: rgb(42, 42, 51);">av</font>e any <font style="color: rgb(42, 42, 51);">authority</font> to amend the terms of this Agreement or to add Collaboration <font style="color: rgb(26, 26, 31);">Programs </font>in e<font style="color: rgb(42, 42, 51);">xc</font>ess of the [***] Collaboration Programs permitted under this <font style="color: rgb(42, 42, 51);">Ag</font>reeme<font style="color: rgb(42, 42, 51);">nt. </font><font style="color: rgb(26, 26, 31);">The </font>foregoing provisions of this Article 4 notwithstanding, neither Party shall h<font style="color: rgb(59, 59, 72);">a</font>ve the right to exercise its final
                decision-making authority to unilater<font style="color: rgb(42, 42, 51);">ally: </font>(a) determine that it has fulfilled any obligations under this Agreement or that t<font style="color: rgb(42, 42, 51);">he ot</font>her Party <font style="color: rgb(26, 26, 31);">has </font>breached any obligation under this Agreement; (b) make a decisi<font style="color: rgb(59, 59, 72);">o</font>n <font style="color: rgb(26, 26, 31);">that </font>is <font style="color: rgb(42, 42, 51);">expres</font>sly stated to require the mutual agreement of the Parties; or (c) othe<font style="color: rgb(77, 77, 89);">r</font><font style="color: rgb(42, 42, 51);">w</font>ise <font style="color: rgb(26, 26, 31);">expand </font><font style="color: rgb(59, 59, 72);">its</font><font style="color: rgb(26, 26, 31);">&#160;</font>rights or reduce its <font style="color: rgb(26, 26, 31);">obligations </font>under thi<font style="color: rgb(42, 42, 51);">s </font>Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze2eb5115a006465e92181d8f9020449f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2A2A33;">From </font>time to time, the JSC may establish <font style="color: rgb(26, 26, 31);">subcommittees </font>to oversee particular projects<font style="color: rgb(59, 59, 72);"> o</font>r <font style="color: rgb(42, 42, 51);">ac</font>tivities, <font style="color: rgb(26, 26, 31);">as </font>it deem<font style="color: rgb(42, 42, 51);">s </font>necessary or <font style="color: rgb(26, 26, 31);">advisable </font>(each, <font style="color: rgb(26, 26, 31);">a </font>&#8220;<font style="font-weight: bold;">Subcommittee</font><font style="color: rgb(42, 42, 51);">&#8221;</font>).<font style="font-weight: bold;">&#160;</font><font style="color: rgb(26, 26, 31);">Each
                  Subcommittee shall </font>consist of <font style="color: rgb(26, 26, 31);">such </font>number of members <font style="color: rgb(26, 26, 31);">as </font>the JSC determines is appropriate from time to time. Such members shall be
                individuals with <font style="color: rgb(26, 26, 31);">expertise </font>and responsibilities in the relevant area<font style="color: rgb(42, 42, 51);">s </font><font style="color: rgb(26, 26, 31);">over </font>which <font style="color: rgb(26, 26, 31);">such </font>Subcommittee <font style="color: rgb(26, 26, 31);">shall </font>have oversight and/or decision-making authority.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf7b97cb5cdd04c71920c0be39cb365eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The JSC shall automatically cease to exist on completion of all Collaboration Programs. The JSC&#8217;s involvement in relation to any particular Collaboration Program shall <font style="color: rgb(31, 31, 38);">c</font>ease on the earlier of
                termination of such Collaboration Program in accordance with Article 13 or Completion of such Collaboration Program.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0245dfa4ca8a41ba83c2bb1a5211ab19" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Promptly after the Effective Date, each Party shall app<font style="color: rgb(31, 31, 38);">oin</font>t an individ<font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(52, 54, 66);">a</font>l to act as alliance manager
                for such Party (each, an &#8220;<font style="font-weight: bold;">Allia</font><font style="font-weight: bold; color: rgb(31, 31, 38);">nce M</font><font style="font-weight: bold;">anager</font>&#8221;). <font style="color: rgb(31, 31, 38);">Ea</font>ch
                Alliance Manager shall thereafter be permitted to attend <font style="color: rgb(31, 31, 38);">me</font><font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">t</font>i<font style="color: rgb(52, 54, 66);">n</font>gs






                of the JSC <font style="color: rgb(31, 31, 38);">as </font>a non-voting observer, subject to the confidentiality provision<font style="color: rgb(52, 54, 66);">s o</font><font style="color: rgb(31, 31, 38);">f </font>Article 10. The <font style="color: rgb(31, 31, 38);">A</font>ll<font style="color: rgb(31, 31, 38);">ia</font>nc<font style="color: rgb(31, 31, 38);">e </font>Managers shall be the primary point of contact for the Parties r<font style="color: rgb(31, 31, 38);">e</font>garding the c<font style="color: rgb(31, 31, 38);">oll</font>a<font style="color: rgb(31, 31, 38);">b</font>oration activities contemplated by this Agreement or other re<font style="color: rgb(31, 31, 38);">p</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">rti</font><font style="color: rgb(52, 54, 66);">n</font>g <font style="color: rgb(31, 31, 38);">ob</font>ligations un<font style="color: rgb(31, 31, 38);">d</font><font style="color: rgb(52, 54, 66);">e</font>r this <font style="color: rgb(52, 54, 66);">A</font><font style="color: rgb(31, 31, 38);">g</font>reement and shall facilitate all such activities here<font style="color: rgb(31, 31, 38);">unde</font>r.






                Th<font style="color: rgb(31, 31, 38);">e </font>A<font style="color: rgb(52, 54, 66);">ll</font><font style="color: rgb(31, 31, 38);">i</font>ance <font style="color: rgb(31, 31, 38);">Ma</font>nagers <font style="color: rgb(52, 54, 66);">sha</font><font style="color: rgb(31, 31, 38);">ll </font>also be responsible for assisting the JSC in performing<font style="color: rgb(31, 31, 38);">&#160;</font><font style="color: rgb(52, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">t</font>s o<font style="color: rgb(31, 31, 38);">v</font><font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">r</font>s<font style="color: rgb(31, 31, 38);">ig</font>ht r<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">p</font>on<font style="color: rgb(52, 54, 66);">s</font>ibili<font style="color: rgb(31, 31, 38);">tie</font><font style="color: rgb(52, 54, 66);">s </font>w<font style="color: rgb(52, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">t</font>h respect to the activities of the JPT, as well a<font style="color: rgb(31, 31, 38);">s </font>by prep<font style="color: rgb(52, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">r</font>i<font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(52, 54, 66);">g </font>an<font style="color: rgb(31, 31, 38);">d </font>fi<font style="color: rgb(52, 54, 66);">na</font><font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(52, 54, 66);">i</font>zing th<font style="color: rgb(52, 54, 66);">e </font>minutes from meetings of the JSC. The name and c<font style="color: rgb(52, 54, 66);">o</font>n<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(52, 54, 66);">t </font>in<font style="color: rgb(31, 31, 38);">for</font>m<font style="color: rgb(52, 54, 66);">at</font>ion <font style="color: rgb(31, 31, 38);">f</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">r su</font>ch
                A<font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(52, 54, 66);">li</font><font style="color: rgb(31, 31, 38);">a</font>nce Managers, as well as any replacement(s) chosen <font style="color: rgb(31, 31, 38);">by I</font>m<font style="color: rgb(31, 31, 38);">m</font>uno<font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">r</font>e <font style="color: rgb(31, 31, 38);">o</font>r GS<font style="color: rgb(52, 54, 66);">K, </font><font style="color: rgb(31, 31, 38);">in </font>their <font style="color: rgb(31, 31, 38);">s</font>o<font style="color: rgb(52, 54, 66);">l</font><font style="color: rgb(31, 31, 38);">e d</font>iscretion,






                from time to time, shall be promptly p<font style="color: rgb(31, 31, 38);">rov</font><font style="color: rgb(52, 54, 66);">id</font>ed to <font style="color: rgb(31, 31, 38);">the o</font>ther <font style="color: rgb(31, 31, 38);">Party</font>
                in accordance with Section 16.1 of this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze25656b980964e7894ed9f7b433e4935" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Within [***] after t<font style="color: rgb(52, 54, 66);">h</font>e Effective<font style="color: rgb(31, 31, 38);"> Date</font>, the <font style="color: rgb(31, 31, 38);">Parties </font>shall <font style="color: rgb(31, 31, 38);">e</font>ach







                designate representative(s) to cons<font style="color: rgb(31, 31, 38);">ult </font><font style="color: rgb(52, 54, 66);">with</font><font style="color: rgb(31, 31, 38);">&#160;</font>th<font style="color: rgb(31, 31, 38);">e o</font>ther <font style="color: rgb(31, 31, 38);">Pa</font>r<font style="color: rgb(52, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">y</font><font style="color: rgb(52, 54, 66);">&#8217;</font><font style="color: rgb(31, 31, 38);">s </font>represe<font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(52, 54, 66);">t</font>ative(s<font style="color: rgb(52, 54, 66);">) wi</font><font style="color: rgb(31, 31, 38);">t</font>h respect to patent prosecution, defen<font style="color: rgb(52, 54, 66);">s</font>e a<font style="color: rgb(52, 54, 66);">n</font>d en<font style="color: rgb(31, 31, 38);">for</font><font style="color: rgb(52, 54, 66);">c</font><font style="color: rgb(31, 31, 38);">em</font>ent
                <font style="color: rgb(31, 31, 38);">matters</font>&#160;<font style="color: rgb(31, 31, 38);">(the</font> &#8220;<font style="font-weight: bold;">Paten</font><font style="font-weight: bold; color: rgb(31, 31, 38);">t </font><font style="font-weight: bold;">Liaisons</font><font style="color: rgb(31, 31, 38);">&#8221;</font>) as m<font style="color: rgb(31, 31, 38);">o</font>re fully described in this Section<font style="color: rgb(31, 31, 38);">&#160;</font>4.1 <font style="color: rgb(31, 31, 38);">2</font>. The P<font style="color: rgb(31, 31, 38);">a</font>tent Liai<font style="color: rgb(31, 31, 38);">sons s</font>hall d<font style="color: rgb(31, 31, 38);">is</font>cu<font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">s</font>, at such times, places and frequencie<font style="color: rgb(52, 54, 66);">s </font>as either <font style="color: rgb(31, 31, 38);">Patent</font> Li<font style="color: rgb(31, 31, 38);">ai</font>s<font style="color: rgb(31, 31, 38);">on </font>determine<font style="color: rgb(31, 31, 38);">s </font>is n<font style="color: rgb(31, 31, 38);">eces</font>s<font style="color: rgb(31, 31, 38);">a</font>ry<font style="color: rgb(31, 31, 38);">, </font>material issues and provide input t<font style="color: rgb(52, 54, 66);">o e</font><font style="color: rgb(31, 31, 38);">a</font>ch oth<font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">r r</font>egar<font style="color: rgb(31, 31, 38);">din</font><font style="color: rgb(52, 54, 66);">g </font>the pro<font style="color: rgb(31, 31, 38);">se</font><font style="color: rgb(52, 54, 66);">cu</font>tion,






                main<font style="color: rgb(52, 54, 66);">te</font>nance, enforcement or defense of Platform Rights<font style="color: rgb(31, 31, 38);"> (t</font><font style="color: rgb(52, 54, 66);">o </font><font style="color: rgb(31, 31, 38);">the</font>&#160;<font style="color: rgb(31, 31, 38);">ext</font><font style="color: rgb(52, 54, 66);">en</font>t Immunocore h<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(52, 54, 66);">s </font><font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">ch </font>rights with respect to Third Party Plat<font style="color: rgb(31, 31, 38);">fo</font>r<font style="color: rgb(31, 31, 38);">m Rights</font><font style="color: rgb(52, 54, 66);">), Immunocore</font> B<font style="color: rgb(31, 31, 38);">ack</font>gro<font style="color: rgb(31, 31, 38);">u</font>nd, I<font style="color: rgb(52, 54, 66);">m</font><font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">no</font>core Foreground, Joint Foreground an<font style="color: rgb(31, 31, 38);">d t</font><font style="color: rgb(52, 54, 66);">h</font><font style="color: rgb(31, 31, 38);">e </font>Lice<font style="color: rgb(31, 31, 38);">ns</font><font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">d </font>GSK <font style="color: rgb(31, 31, 38);">Foreground</font><font style="color: rgb(52, 54, 66);">&#160;</font>a<font style="color: rgb(31, 31, 38);">n</font>d in ea<font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(52, 54, 66);">h </font><font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(52, 54, 66);">a</font>se in accordance with the rights grant<font style="color: rgb(31, 31, 38);">ed </font>under Article<font style="color: rgb(31, 31, 38);">&#160;</font>7. The <font style="color: rgb(52, 54, 66);">P</font>atent






                Li<font style="color: rgb(52, 54, 66);">a</font>is<font style="color: rgb(31, 31, 38);">o</font>ns sh<font style="color: rgb(52, 54, 66);">a</font>ll be responsible for coordinating the implem<font style="color: rgb(31, 31, 38);">enta</font><font style="color: rgb(52, 54, 66);">t</font>ion <font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">f </font><font style="color: rgb(52, 54, 66);">e</font>ach <font style="color: rgb(52, 54, 66);">P</font><font style="color: rgb(31, 31, 38);">a</font>rty&#8217;s s<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 54, 66);">ra</font><font style="color: rgb(31, 31, 38);">t</font>e<font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(52, 54, 66);">i</font>es for <font style="color: rgb(31, 31, 38);">the </font>protection of the foregoing Intellect<font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(52, 54, 66);">a</font>l <font style="color: rgb(52, 54, 66);">P</font><font style="color: rgb(31, 31, 38);">r</font>opert<font style="color: rgb(52, 54, 66);">y </font><font style="color: rgb(31, 31, 38);">Ri</font>ghts i<font style="color: rgb(52, 54, 66);">n </font><font style="color: rgb(31, 31, 38);">a</font>ccord<font style="color: rgb(31, 31, 38);">anc</font><font style="color: rgb(52, 54, 66);">e </font><font style="color: rgb(31, 31, 38);">with</font> the <font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 54, 66);">er</font>ms of this Agreement. All final decisio<font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">s </font><font style="color: rgb(52, 54, 66);">re</font><font style="color: rgb(31, 31, 38);">la</font>ted t<font style="color: rgb(31, 31, 38);">o </font>th<font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(52, 54, 66);">p</font><font style="color: rgb(31, 31, 38);">ro</font><font style="color: rgb(52, 54, 66);">s</font>ecutio<font style="color: rgb(31, 31, 38);">n</font>,</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #1F1F26;">ma</font>inten<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">c</font>e, enforcement
        or defense of any Immunocore B<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(52, 54, 66);">ck</font><font style="color: rgb(31, 31, 38);">gro</font>un<font style="color: rgb(31, 31, 38);">d, Platform</font> Rights, Joint
        Foreground, Immunocore Foreground and Lic<font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">n</font>sed <font style="color: rgb(31, 31, 38);">GSK </font>Fore<font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(52, 54, 66);">ro</font>und sh<font style="color: rgb(52, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">ll </font>be made b<font style="color: rgb(31, 31, 38);">y </font>the Prosecuting Party.</div>
      <div>&#160;</div>
      <table id="z97ba87cd5ce5432f86713e3752cd3db3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Collaboration Programs - R</font><font style="font-weight: bold; color: #1F1F26;">ese</font><font style="font-weight: bold;">arch P</font><font style="font-weight: bold; color: #1F1F26;">l</font><font style="font-weight: bold;">a</font><font style="font-weight: bold; color: #1F1F26;">n</font><font style="font-weight: bold; color: #343642;">s</font><font style="font-weight: bold; color: #1F1F26;">; </font><font style="font-weight: bold;">Target Nomination</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z32099f1879ff4367bc8950766316e69d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Targ</u><font style="color: #1F1F26;"><u>e</u></font><u>t Program</u><font style="color: #343642;"><u>s</u></font><font style="color: #343642;">. G</font>SK h<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(52, 54, 66);">s </font>the right to nominat<font style="color: rgb(31, 31, 38);">e </font>up to four (4) Target<font style="color: rgb(31, 31, 38);">s </font>(ea<font style="color: rgb(31, 31, 38);">c</font>h, a &#8220;<font style="font-weight: bold;">Nominated </font><font style="font-weight: bold; color: rgb(31, 31, 38);">T</font><font style="font-weight: bold; color: rgb(52, 54, 66);">a</font><font style="font-weight: bold;">r</font><font style="font-weight: bold; color: rgb(31, 31, 38);">g</font><font style="font-weight: bold;">et</font>&#8221;) t<font style="color: rgb(31, 31, 38);">o </font>b<font style="color: rgb(31, 31, 38);">e </font>the subject of Collaboration Programs as <font style="color: rgb(31, 31, 38);">s</font>et forth bel<font style="color: rgb(31, 31, 38);">o</font>w (<font style="color: rgb(31, 31, 38);">e</font>ach Collaboration <font style="color: rgb(52, 54, 66);">Program</font> directed to a Nominated Targ<font style="color: rgb(31, 31, 38);">e</font>t<font style="color: rgb(31, 31, 38);">, </font>b<font style="color: rgb(31, 31, 38);">e</font>ing a &#8220;<font style="font-weight: bold;">Target Program</font>&#8221;<font style="color: rgb(52, 54, 66);">).
                </font><font style="color: rgb(31, 31, 38);">E</font>ach s<font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(52, 54, 66);">c</font>h <font style="color: rgb(52, 54, 66);">T</font>arget Program shall relate to a different
                Nominated Target. The No<font style="color: rgb(31, 31, 38);">m</font>i<font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">a</font>ted Target and its HLA allele for the first Target Program are specified in
                Sched<font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">le 1 </font>to this<font style="color: rgb(52, 54, 66);">&#160;</font>Agreement (the &#8220;<font style="font-weight: bold;">Initial Target</font><font style="color: rgb(31, 31, 38);">&#8221;</font>). GSK has the right to nominate the s<font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">c</font>ond No<font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(52, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">nate</font>d T<font style="color: rgb(31, 31, 38);">a</font>rget no later than [***] after the Effective Da<font style="color: rgb(52, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">e o</font>f the Ag<font style="color: rgb(31, 31, 38);">r</font><font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">em</font>ent, and thereafter shall have the right to
                nominate the third and<font style="color: rgb(31, 31, 38);"> fo</font><font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">rth </font>Nominated Targets no later than the [***] of the Effective Date<font style="color: rgb(31, 31, 38);">,</font><font style="color: rgb(52, 54, 66);"> e</font><font style="color: rgb(31, 31, 38);">xce</font>pt as otherwise provided in this Agreement. The first two (2) Target Programs are<font style="color: rgb(52, 54, 66);"> r</font><font style="color: rgb(31, 31, 38);">efe</font>rred to her<font style="color: rgb(31, 31, 38);">e</font>in a<font style="color: rgb(31, 31, 38);">s </font>th<font style="color: rgb(31, 31, 38);">e </font>&#8220;<font style="font-weight: bold;">Initial Target Programs</font><font style="color: rgb(31, 31, 38);">.</font>&#8221;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za08bca586d724f32973e96108ca13e6a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>HLA Programs</u>. Each Target Program under Section 5.1 above <font style="color: rgb(31, 31, 38);">s</font>h<font style="color: rgb(31, 31, 38);">a</font>ll be <font style="color: rgb(31, 31, 38);">s</font>pecific to <font style="color: rgb(31, 31, 38);">a</font> designated HLA all<font style="color: rgb(31, 31, 38);">e</font>le. GSK also has the right to nominat<font style="color: rgb(31, 31, 38);">e </font>up to [***] HLA alleles (each, a &#8220;<font style="font-weight: bold;">Nominated HLA</font><font style="color: rgb(31, 31, 38);">&#8221;</font>)<font style="font-weight: bold;">&#160;</font>to be the subject of further Collaboration Programs as s<font style="color: rgb(31, 31, 38);">e</font>t
                forth in this Section 5.2 (<font style="color: rgb(31, 31, 38);">e</font>ach Collaboration Program dire<font style="color: rgb(31, 31, 38);">c</font>t <font style="color: rgb(31, 31, 38);">e</font>d to a Nominat<font style="color: rgb(31, 31, 38);">e</font>d <font style="color: rgb(7, 7, 7);">HLA, an &#8220;</font><font style="font-weight: bold; color: rgb(7, 7, 7);">HLA Program</font><font style="color: rgb(7, 7, 7);">&#8221;). Each Nominated HLA shall be associated with a Nominated
                  Target; provided, that GSK may nominate any number of Nominated HLAs related to a specific Nominated Target at GSK&#8217;s discretion subject to the overall maximum of [***]. GSK may exercise its right to nominate a Nominated HLA associated
                  with a Nominated Target at any time beginning on the d</font><font style="color: rgb(28, 28, 31);">at</font><font style="color: rgb(7, 7, 7);">e of commencement of the applicable Target Program for such Nominated Target and </font><font style="color: rgb(45, 45, 56);">ex</font><font style="color: rgb(7, 7, 7);">piring on th</font><font style="color: rgb(28, 28, 31);">e [***]</font><font style="color: rgb(7, 7, 7);"> anniversary of Completion of the Phase I Trial conduct</font><font style="color: rgb(45, 45, 56);">ed </font><font style="color: rgb(28, 28, 31);">w</font><font style="color: rgb(7, 7, 7);">ith respect to </font><font style="color: rgb(28, 28, 31);">the </font><font style="color: rgb(7, 7, 7);">Compound






                  arising from such Target Program, whether su</font><font style="color: rgb(45, 45, 56);">ch </font><font style="color: rgb(7, 7, 7);">P</font><font style="color: rgb(45, 45, 56);">h</font><font style="color: rgb(7, 7, 7);">ase 1 Trial i</font><font style="color: rgb(28, 28, 31);">s </font><font style="color: rgb(45, 45, 56);">co</font><font style="color: rgb(7, 7, 7);">nducted by Immunocore or GSK. The first [***] HLA Programs are referred to herein as the &#8220;</font><font style="font-weight: bold; color: rgb(7, 7, 7);">Initial HLA Programs</font><font style="color: rgb(7, 7, 7);">.&#8221;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z76084797958d499f87547634a7cf9d79" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Nomination Process</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf123d80c7d33430889ee3e787ebc90ea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Dataroom shall be availa<font style="color: rgb(28, 28, 31);">bl</font>e t<font style="color: rgb(45, 45, 56);">o </font>GSK f<font style="color: rgb(28, 28, 31);">or a </font>pe<font style="color: rgb(28, 28, 31);">rio</font>d <font style="color: rgb(45, 45, 56);">of [***]</font> from the Effective Date, except as ma<font style="color: rgb(45, 45, 56);">y </font><font style="color: rgb(28, 28, 31);">be </font><font style="color: rgb(45, 45, 56);">e</font>xte<font style="color: rgb(28, 28, 31);">nd</font>e<font style="color: rgb(45, 45, 56);">d </font><font style="color: rgb(28, 28, 31);">a</font>s p<font style="color: rgb(45, 45, 56);">rov</font>i<font style="color: rgb(45, 45, 56);">de</font>d
                in <font style="color: rgb(45, 45, 56);">thi</font>s Agreement (the &#8220;<font style="font-weight: bold;">Dataroom Period</font>&#8221;).<font style="font-weight: bold;">&#160;</font>T<font style="color: rgb(45, 45, 56);">h</font>e s<font style="color: rgb(45, 45, 56);">am</font>e in<font style="color: rgb(45, 45, 56);">form</font>ation <font style="color: rgb(45, 45, 56);">as </font>provid<font style="color: rgb(28, 28, 31);">e</font>d i<font style="color: rgb(45, 45, 56);">n </font>the






                Dataroom shall also be available <font style="color: rgb(28, 28, 31);">t</font>o <font style="color: rgb(45, 45, 56);">a</font>ll part<font style="color: rgb(45, 45, 56);">ners, </font>lice<font style="color: rgb(45, 45, 56);">n</font>s<font style="color: rgb(45, 45, 56);">ee</font>s and p<font style="color: rgb(45, 45, 56);">ot</font>e<font style="color: rgb(28, 28, 31);">n</font>tial licensees of Immunocore. Immunocore<font style="color: rgb(61, 61, 75);">&#160;</font>warr<font style="color: rgb(45, 45, 56);">an</font>ts that<font style="color: rgb(61, 61, 75);">, </font><font style="color: rgb(28, 28, 31);">as o</font>f the Effective Date the same information has been<font style="color: rgb(45, 45, 56);">, </font>a<font style="color: rgb(45, 45, 56);">nd </font>for <font style="color: rgb(28, 28, 31);">the</font> Dataroom<font style="color: rgb(45, 45, 56);"> P</font>eriod w<font style="color: rgb(45, 45, 56);">ill </font>b<font style="color: rgb(28, 28, 31);">e</font>, provided to GSK in the Dataroom in r<font style="color: rgb(28, 28, 31);">el</font>ati<font style="color: rgb(28, 28, 31);">on </font>to Tar<font style="color: rgb(28, 28, 31);">get</font>s <font style="color: rgb(45, 45, 56);">as </font><font style="color: rgb(28, 28, 31);">h</font>as bee<font style="color: rgb(28, 28, 31);">n o</font>r <font style="color: rgb(28, 28, 31);">will </font>be <font style="color: rgb(45, 45, 56);">pro</font>vided






                to other potential license<font style="color: rgb(28, 28, 31);">es </font>a<font style="color: rgb(45, 45, 56);">nd </font>partners of <font style="color: rgb(45, 45, 56);">Immunocore</font><font style="color: rgb(28, 28, 31);">&#160;</font>(ea<font style="color: rgb(45, 45, 56);">c</font>h an &#8220;<font style="font-weight: bold; color: rgb(28, 28, 31);">Ent</font><font style="font-weight: bold;">i</font><font style="font-weight: bold; color: rgb(45, 45, 56);">t</font><font style="font-weight: bold;">y</font>&#8221;)<font style="font-weight: bold;">&#160;</font>who have been granted a<font style="color: rgb(61, 61, 75);">c</font>ces<font style="color: rgb(45, 45, 56);">s </font>or <font style="color: rgb(45, 45, 56);">will b</font>e gr<font style="color: rgb(45, 45, 56);">ante</font>d ac<font style="color: rgb(28, 28, 31);">ce</font>s<font style="color: rgb(28, 28, 31);">s </font>to the <font style="color: rgb(28, 28, 31);">D</font>ata<font style="color: rgb(28, 28, 31);">ro</font>om as of the Effective Date o<font style="color: rgb(28, 28, 31);">r d</font>urin<font style="color: rgb(28, 28, 31);">g </font><font style="color: rgb(45, 45, 56);">t</font>he D<font style="color: rgb(28, 28, 31);">at</font>aroom Period (excluding<font style="color: rgb(28, 28, 31);">&#160;</font>any information relating to <font style="color: rgb(45, 45, 56);">T</font>argets which ha<font style="color: rgb(28, 28, 31);">v</font>e
                <font style="color: rgb(45, 45, 56);">b</font>e<font style="color: rgb(45, 45, 56);">e</font>n exclusively lice<font style="color: rgb(45, 45, 56);">n</font>s<font style="color: rgb(28, 28, 31);">ed t</font>o any 5.3.4). Immunocore may <font style="color: rgb(28, 28, 31);">add </font>fu<font style="color: rgb(28, 28, 31);">rthe</font><font style="color: rgb(45, 45, 56);">r </font>Target<font style="color: rgb(45, 45, 56);">s to </font>the <font style="color: rgb(28, 28, 31);">D</font><font style="color: rgb(61, 61, 75);">a</font><font style="color: rgb(28, 28, 31);">t</font>a<font style="color: rgb(28, 28, 31);">ro</font>om in its absolute discretion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5fc675556c3b414895300f1eb9f2e736" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Ex<font style="color: rgb(45, 45, 56);">c</font>ept for the<font style="color: rgb(45, 45, 56);">&#160;</font>Initial T<font style="color: rgb(45, 45, 56);">ar</font>g<font style="color: rgb(45, 45, 56);">et</font>, GS<font style="color: rgb(28, 28, 31);">K </font>s<font style="color: rgb(45, 45, 56);">h</font>all nominate a Target or HLA by providing<font style="color: rgb(28, 28, 31);"> no</font><font style="color: rgb(61, 61, 75);">tic</font><font style="color: rgb(28, 28, 31);">e </font>in <font style="color: rgb(28, 28, 31);">writing</font> in <font style="color: rgb(61, 61, 75);">t</font><font style="color: rgb(28, 28, 31);">h</font>e form <font style="color: rgb(61, 61, 75);">s</font><font style="color: rgb(28, 28, 31);">e</font>t <font style="color: rgb(45, 45, 56);">o</font>ut in <font style="color: rgb(45, 45, 56);">Sc</font>h<font style="color: rgb(45, 45, 56);">e</font>dule 8 to Immunocore (the &#8220;<font style="font-weight: bold; color: rgb(28, 28, 31);">No</font><font style="font-weight: bold;">mina</font><font style="font-weight: bold; color: rgb(45, 45, 56);">tion </font><font style="font-weight: bold;">Not</font><font style="font-weight: bold; color: rgb(45, 45, 56);">ice</font>&#8221;). The <font style="color: rgb(45, 45, 56);">Nom</font>ination <font style="color: rgb(45, 45, 56);">No</font>tice shall specify either (a) the<font style="color: rgb(45, 45, 56);"> Tar</font>get <font style="color: rgb(45, 45, 56);">be</font>i<font style="color: rgb(45, 45, 56);">ng </font>n<font style="color: rgb(28, 28, 31);">om</font>i<font style="color: rgb(45, 45, 56);">na</font>ted together<font style="color: rgb(28, 28, 31);">&#160;</font>with <font style="color: rgb(45, 45, 56);">th</font>e <font style="color: rgb(45, 45, 56);">H</font>LA allele to which any Compound<font style="color: rgb(45, 45, 56);"> d</font>irect <font style="color: rgb(45, 45, 56);">ed </font><font style="color: rgb(28, 28, 31);">at </font>the <font style="color: rgb(45, 45, 56);">Targ</font>et should <font style="color: rgb(45, 45, 56);">fi</font>rst be d<font style="color: rgb(28, 28, 31);">e</font>v<font style="color: rgb(45, 45, 56);">el</font>oped; or (b) the new HLA allele to whi<font style="color: rgb(45, 45, 56);">ch a</font>ny C<font style="color: rgb(28, 28, 31);">omp</font>ound <font style="color: rgb(45, 45, 56);">sho</font>ul<font style="color: rgb(28, 28, 31);">d </font>be dir<font style="color: rgb(28, 28, 31);">ec</font>ted for a Nominated Target that is the subject <font style="color: rgb(28, 28, 31);">o</font>f <font style="color: rgb(61, 61, 75);">a </font><font style="color: rgb(45, 45, 56);">pre</font>-existing<font style="color: rgb(45, 45, 56);"> T</font>arget <font style="color: rgb(28, 28, 31);">Pro</font>g<font style="color: rgb(28, 28, 31);">ra</font>m. Immunocore <font style="color: rgb(28, 28, 31);">s</font>hall hav<font style="color: rgb(28, 28, 31);">e [***]</font> from <font style="color: rgb(45, 45, 56);">re</font>ceipt <font style="color: rgb(28, 28, 31);">of
                </font><font style="color: rgb(45, 45, 56);">Nomination</font> Notice to accept or reject the Nomination<font style="color: rgb(45, 45, 56);">&#160;</font>Notice by signing an<font style="color: rgb(45, 45, 56);">d returning</font> a completed
                Nomination Notice to<font style="color: rgb(28, 28, 31);"> G</font>SK<font style="color: rgb(28, 28, 31);">; </font><font style="color: rgb(45, 45, 56);">pro</font>v<font style="color: rgb(28, 28, 31);">id</font>ed that<font style="color: rgb(45, 45, 56);">&#160;</font><font style="color: rgb(28, 28, 31);">a </font>Nomination Notice may only be rejected in a<font style="color: rgb(28, 28, 31);">c</font>cordance with <font style="color: rgb(45, 45, 56);">Sec</font>tion 5.<font style="color: rgb(45, 45, 56);">3</font>.4 below and shall be accepted by Immunocore under all o<font style="color: rgb(45, 45, 56);">th</font>er circu<font style="color: rgb(28, 28, 31);">mst</font><font style="color: rgb(61, 61, 75);">a</font><font style="color: rgb(28, 28, 31);">nce</font>s. Th<font style="color: rgb(28, 28, 31);">e </font>Nomination Date for th<font style="color: rgb(28, 28, 31);">e</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 90pt;">first T<font style="color: rgb(28, 28, 31);">a</font>rget <font style="color: rgb(28, 28, 31);">a</font>nd HLA type<font style="color: rgb(28, 28, 31);"> sp</font>e<font style="color: rgb(45, 45, 56);">ci</font>fied in <font style="color: rgb(45, 45, 56);">S</font>c<font style="color: rgb(45, 45, 56);">he</font>dule 1 shall be the Effective Date. Date of acceptan<font style="color: rgb(28, 28, 31);">c</font>e of a<font style="color: rgb(45, 45, 56);"> Nomination</font> Notice by Immunocore under this Section 5<font style="color: rgb(28, 28, 31);">.3</font>.2 shall <font style="color: rgb(28, 28, 31);">constitute</font><font style="color: rgb(45, 45, 56);"> th</font>e
        Nomination Date in relation to all other <font style="color: rgb(28, 28, 31);">T</font>argets and HLAs notified under this <font style="color: rgb(28, 28, 31);">S</font><font style="color: rgb(61, 61, 75);">ec</font>ti<font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(61, 61, 75);">n</font> 5.3.2. Where the Target is not a Target provided in the Data<font style="color: rgb(45, 45, 56);">room</font>, then prior to any nomination of such <font style="color: rgb(45, 45, 56);">T</font>arget the provisions of Section 5.3.8 shall apply and GSK <font style="color: rgb(28, 28, 31);">s</font>hall not be entitled to nominate a Target which i<font style="color: rgb(28, 28, 31);">s </font>not provid<font style="color: rgb(28, 28, 31);">e</font>d in the Dat<font style="color: rgb(28, 28, 31);">a</font>room unle<font style="color: rgb(28, 28, 31);">s</font>s the <font style="color: rgb(28, 28, 31);">s</font>teps <font style="color: rgb(28, 28, 31);">s</font>et
        out in Section 5.3.8 h<font style="color: rgb(28, 28, 31);">a</font>v<font style="color: rgb(28, 28, 31);">e </font>b<font style="color: rgb(28, 28, 31);">ee</font>n t<font style="color: rgb(28, 28, 31);">a</font>k<font style="color: rgb(28, 28, 31);">e</font>n. <font style="color: rgb(28, 28, 31);">G</font>SK und<font style="color: rgb(28, 28, 31);">e</font>r<font style="color: rgb(28, 28, 31);">s</font>tand<font style="color: rgb(28, 28, 31);">s a</font>nd a<font style="color: rgb(28, 28, 31);">cce</font>pts <font style="color: rgb(28, 28, 31);">t</font>h<font style="color: rgb(28, 28, 31);">a</font>t prior to n<font style="color: rgb(28, 28, 31);">o</font>min<font style="color: rgb(28, 28, 31);">a</font>tion o<font style="color: rgb(28, 28, 31);">f a </font>Non-validated T<font style="color: rgb(28, 28, 31);">a</font>r<font style="color: rgb(28, 28, 31);">g</font>et (<font style="color: rgb(28, 28, 31);">as </font>defined in Section 5.3.8)<font style="color: rgb(45, 45, 56);">, </font>GSK h<font style="color: rgb(28, 28, 31);">a</font>s n<font style="color: rgb(28, 28, 31);">o </font>ex<font style="color: rgb(28, 28, 31);">c</font>lusive option under Section 6.1 or 6.2 and th<font style="color: rgb(28, 28, 31);">a</font>t Immunocore<font style="color: rgb(28, 28, 31);">&#160;</font>will still be <font style="color: rgb(28, 28, 31);">entitled</font> to reje<font style="color: rgb(28, 28, 31);">c</font>t any Nomination N<font style="color: rgb(28, 28, 31);">o</font>ti<font style="color: rgb(28, 28, 31);">ce </font>naming <font style="color: rgb(28, 28, 31);">a </font>Non-v<font style="color: rgb(28, 28, 31);">a</font>li<font style="color: rgb(28, 28, 31);">da</font>ted






        T<font style="color: rgb(28, 28, 31);">a</font>rg<font style="color: rgb(28, 28, 31);">e</font>t for th<font style="color: rgb(28, 28, 31);">e </font>rea<font style="color: rgb(28, 28, 31);">s</font>on<font style="color: rgb(28, 28, 31);">s</font>
        given in Section 5.3.4.</div>
      <div>&#160;</div>
      <table id="zde3111d514b7446e9dacc1e417b0bbc6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon the Nomination Date, Immunocore shall immediately remove the Nominated Target from the Dataroom<font style="color: rgb(31, 31, 38);">, </font>and thereafter,<font style="color: rgb(31, 31, 38);">&#160;</font>Immunocore shall not <font style="color: rgb(8, 8, 8);">(a) work on or further develop any Compound to the Nominated Target</font><font style="color: rgb(31, 31, 38);">, </font><font style="color: rgb(8, 8, 8);">including any HLA alleles associated with such
                  Nominated Target except as provided in this Agreement; (b) license or coll</font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(8, 8, 8);">borate with any Third Party in relation to the development of any Compoun</font><font style="color: rgb(31, 31, 38);">d </font><font style="color: rgb(8, 8, 8);">to </font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(8, 8, 8);">e Nominated </font><font style="color: rgb(31, 31, 38);">Ta</font><font style="color: rgb(8, 8, 8);">rget; or (c) otherwise make available such Nominated </font><font style="color: rgb(31, 31, 38);">Tar</font><font style="color: rgb(8, 8, 8);">get to any T</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(52, 52, 63);">ir</font><font style="color: rgb(8, 8, 8);">d Party for development of a Compound to such </font><font style="color: rgb(31, 31, 38);">Nominated</font><font style="color: rgb(8, 8, 8);"> Target</font><font style="color: rgb(31, 31, 38);">. </font><font style="color: rgb(8, 8, 8);">Immunocore warrants that all information regardin</font><font style="color: rgb(31, 31, 38);">g </font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(8, 8, 8);">e Initial Target h</font><font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(8, 8, 8);">s been
                  removed from the Dataroom on or before the Effective Date, and t</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(8, 8, 8);">e </font><font style="color: rgb(31, 31, 38);">Parties</font><font style="color: rgb(8, 8, 8);"> agree that the foregoing sentence applies to th</font><font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(52, 52, 63);">In</font><font style="color: rgb(31, 31, 38);">itia</font><font style="color: rgb(8, 8, 8);">l T</font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(31, 31, 38);">r</font><font style="color: rgb(8, 8, 8);">get as of th</font><font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(8, 8, 8);">Effective</font><font style="color: rgb(52, 52, 63);">&#160;</font><font style="color: rgb(8, 8, 8);">Date.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf2c81cae89be4b29b3ab90a0340775cd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore may remove Target<font style="color: rgb(31, 31, 38);">s </font><font style="color: rgb(52, 52, 63);">f</font>r<font style="color: rgb(31, 31, 38);">om </font>th<font style="color: rgb(52, 52, 63);">e </font><font style="color: rgb(31, 31, 38);">Dat</font>aro<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 63);">m </font>in <font style="color: rgb(31, 31, 38);">i</font>ts <font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(52, 52, 63);">e </font>discretion at any time prior to receipt of a <font style="color: rgb(31, 31, 38);">Nomination N</font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(31, 31, 38);">c</font>e, <font style="color: rgb(52, 52, 63);">a</font>n<font style="color: rgb(31, 31, 38);">d may</font> reject<font style="color: rgb(52, 52, 63);">&#160;</font>a Nomination Notice <font style="color: rgb(31, 31, 38);">[***]</font><font style="color: rgb(8, 8, 8);"> Nomination N</font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 63);">t</font><font style="color: rgb(8, 8, 8);">ice reject</font><font style="color: rgb(31, 31, 38);">ed </font><font style="color: rgb(52, 52, 63);">b</font><font style="color: rgb(8, 8, 8);">y Immunocore </font><font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(31, 31, 38);">n </font><font style="color: rgb(52, 52, 63);">accordance</font><font style="color: rgb(31, 31, 38);">&#160;</font><font style="color: rgb(8, 8, 8);">wi</font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(8, 8, 8);">h this Section 5.3.4 shall be</font><font style="color: rgb(31, 31, 38);"> d</font><font style="color: rgb(8, 8, 8);">e</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(31, 31, 38);">med </font><font style="color: rgb(8, 8, 8);">an &#8220;</font><font style="font-weight: bold; color: rgb(8, 8, 8);">Invalid</font><font style="font-weight: bold; color: rgb(31, 31, 38);"> T</font><font style="font-weight: bold; color: rgb(8, 8, 8);">a</font><font style="font-weight: bold; color: rgb(31, 31, 38);">r</font><font style="font-weight: bold; color: rgb(8, 8, 8);">get</font><font style="color: rgb(8, 8, 8);">&#8221;.</font><font style="font-weight: bold; color: rgb(52, 52, 63);">&#160;</font><font style="color: rgb(31, 31, 38);">Immunocore sha</font><font style="color: rgb(8, 8, 8);">ll not be liable for any claim</font><font style="color: rgb(31, 31, 38);"> b</font><font style="color: rgb(8, 8, 8);">y </font><font style="color: rgb(31, 31, 38);">G</font><font style="color: rgb(8, 8, 8);">SK a</font><font style="color: rgb(52, 52, 63);">r</font><font style="color: rgb(31, 31, 38);">is</font><font style="color: rgb(52, 52, 63);">i</font><font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(8, 8, 8);">g out </font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(31, 31, 38);">f </font><font style="color: rgb(8, 8, 8);">remov</font><font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(8, 8, 8);">l </font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(31, 31, 38);">f a </font><font style="color: rgb(8, 8, 8);">Targ</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">t </font><font style="color: rgb(52, 52, 63);">fro</font><font style="color: rgb(31, 31, 38);">m </font><font style="color: rgb(8, 8, 8);">the Dataroom by Immunocore</font><font style="color: rgb(31, 31, 38);"> p</font><font style="color: rgb(52, 52, 63);">ri</font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(8, 8, 8);">r to r</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(52, 52, 63);">c</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">ip</font><font style="color: rgb(31, 31, 38);">t of a </font><font style="color: rgb(8, 8, 8);">Nomination</font><font style="color: rgb(31, 31, 38);">&#160;</font><font style="color: rgb(8, 8, 8);">Notic</font><font style="color: rgb(52, 52, 63);">e. </font><font style="color: rgb(31, 31, 38);">A</font><font style="color: rgb(8, 8, 8);">ny Nomination Notice r</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">ceived in</font><font style="color: rgb(52, 52, 63);">
                  r</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">lati</font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 63);">n </font><font style="color: rgb(31, 31, 38);">to </font><font style="color: rgb(8, 8, 8);">an </font><font style="color: rgb(52, 52, 63);">In</font><font style="color: rgb(31, 31, 38);">vali</font><font style="color: rgb(8, 8, 8);">d Target s</font><font style="color: rgb(52, 52, 63);">h</font><font style="color: rgb(8, 8, 8);">all be dee</font><font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(8, 8, 8);">ed rejected and Immunocore shall rem</font><font style="color: rgb(31, 31, 38);">ov</font><font style="color: rgb(52, 52, 63);">e </font><font style="color: rgb(8, 8, 8);">the In</font><font style="color: rgb(31, 31, 38);">v</font><font style="color: rgb(52, 52, 63);">a</font><font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(8, 8, 8);">id Tar</font><font style="color: rgb(52, 52, 63);">ge</font><font style="color: rgb(31, 31, 38);">t </font><font style="color: rgb(8, 8, 8);">f</font><font style="color: rgb(31, 31, 38);">ro</font><font style="color: rgb(8, 8, 8);">m the </font><font style="color: rgb(31, 31, 38);">D</font><font style="color: rgb(8, 8, 8);">atabase if not previously removed. GSK s</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(70, 72, 84);">a</font><font style="color: rgb(31, 31, 38);">ll </font><font style="color: rgb(8, 8, 8);">hav</font><font style="color: rgb(31, 31, 38);">e t</font><font style="color: rgb(52, 52, 63);">h</font><font style="color: rgb(8, 8, 8);">e
                  ri</font><font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(8, 8, 8);">h</font><font style="color: rgb(31, 31, 38);">t to </font><font style="color: rgb(8, 8, 8);">no</font><font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(8, 8, 8);">i</font><font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(8, 8, 8);">at</font><font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(8, 8, 8);">a replacement Target (</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">ach, a &#8220;</font><font style="font-weight: bold; color: rgb(8, 8, 8);">Replacement Target</font><font style="color: rgb(8, 8, 8);">&#8221;</font><font style="color: rgb(31, 31, 38);">) </font><font style="color: rgb(8, 8, 8);">in lie</font><font style="color: rgb(52, 52, 63);">u </font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(52, 52, 63);">f </font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(8, 8, 8);">he Invali</font><font style="color: rgb(31, 31, 38);">d </font><font style="color: rgb(8, 8, 8);">Target in the s</font><font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(8, 8, 8);">me manner </font><font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(8, 8, 8);">s d</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">scrib</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">d </font><font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(8, 8, 8);">n Section 5.3.2 until t</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(70, 72, 84);">e </font><font style="color: rgb(8, 8, 8);">later of either the </font>[***]<font style="color: rgb(8, 8, 8);"> anniv</font><font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(8, 8, 8);">rsary






                  of the Effective Dat</font><font style="color: rgb(31, 31, 38);">e or [***]</font><font style="color: rgb(8, 8, 8);"> from GSK&#8217;s receipt of notice that a Nom</font><font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(52, 52, 63);">n</font><font style="color: rgb(31, 31, 38);">ated </font><font style="color: rgb(8, 8, 8);">Tar</font><font style="color: rgb(31, 31, 38);">ge</font><font style="color: rgb(8, 8, 8);">t </font><font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(8, 8, 8);">s an Invalid Target. For clarity</font><font style="color: rgb(31, 31, 38);">, </font><font style="color: rgb(8, 8, 8);">GSK may continue to n</font><font style="color: rgb(52, 52, 63);">o</font><font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(8, 8, 8);">inate R</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(31, 31, 38);">pla</font><font style="color: rgb(52, 52, 63);">c</font><font style="color: rgb(8, 8, 8);">ement Targets under the terms of this Agreement when and i</font><font style="color: rgb(52, 52, 63);">f </font><font style="color: rgb(31, 31, 38);">p</font><font style="color: rgb(8, 8, 8);">r</font><font style="color: rgb(52, 52, 63);">e</font><font style="color: rgb(8, 8, 8);">viously no</font><font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(8, 8, 8);">inated Replacement Targets are deemed Invalid Targets and</font><font style="color: rgb(52, 52, 63);"> subject</font><font style="color: rgb(8, 8, 8);"> to the maximum of four (4) </font><font style="color: rgb(31, 31, 38);">T</font><font style="color: rgb(8, 8, 8);">arget Programs under </font><font style="color: rgb(31, 31, 38);">Section</font><font style="color: rgb(8, 8, 8);"> 5.1.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za9cf8eedbed748e1958c407719a65a65" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">With r</font><font style="color: #1F1F26;">e</font><font style="color: #34343F;">s</font><font style="color: #1F1F26;">pec</font><font style="color: #080808;">t to any Invalid Target, Immunocore agrees not
                  to (a) work on or furthe</font><font style="color: #464854;">r </font><font style="color: #1F1F26;">d</font><font style="color: #34343F;">e</font><font style="color: #080808;">v</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">lop any </font><font style="color: #1F1F26;">C</font><font style="color: #080808;">ompound to the</font><font style="color: #1F1F26;">&#160;</font><font style="color: #080808;">Inv</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">lid Targ</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">t, including any </font><font style="color: #1F1F26;">o</font><font style="color: #080808;">f its</font><font style="color: #1F1F26;">&#160;</font><font style="color: #080808;">HLA alleles associated with such Invalid Target; or (b) licence or </font><font style="color: #1F1F26;">c</font><font style="color: #080808;">ollaborate with any Third Party in relation to
                  the development of any Compound to the Invalid</font><font style="color: #1F1F26;"> T</font><font style="color: #080808;">arget, including any HLA alleles associated with such Invalid Target, in each case</font><font style="color: #1F1F26;">, </font><font style="color: #080808;">for a period commencing on the date that the Nomination Notice sp</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">cifying such Invalid Targ</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">t was d</font><font style="color: #1F1F26;">ee</font><font style="color: #080808;">m</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">d invalid (or as
                  r</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">l</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">v</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">nt th</font><font style="color: #1F1F26;">e </font><font style="color: #080808;">dat</font><font style="color: #1F1F26;">e a</font><font style="color: #080808;"> T</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">rg</font><font style="color: #1F1F26;">e</font><font style="color: #080808;">t is rem</font><font style="color: #1F1F26;">o</font><font style="color: #080808;">ved from the Dat</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">room),






                  and </font><font style="color: #1F1F26;">e</font><font style="color: #080808;">nding </font><font style="color: #1F1F26;">o</font><font style="color: #080808;">n the</font><font style="color: #1F1F26;">&#160;</font><font style="color: #080808;">l</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">t</font><font style="color: #1F1F26;">es</font><font style="color: #080808;">t to </font><font style="color: #1F1F26;">o</font><font style="color: #080808;">c</font><font style="color: #1F1F26;">c</font><font style="color: #080808;">ur </font><font style="color: #1F1F26;">o</font><font style="color: #080808;">f either (i) [***] from su</font><font style="color: #1F1F26;">c</font><font style="color: #080808;">h d</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">te</font><font style="color: #1F1F26;">; </font><font style="color: #080808;">or (ii) the [***] </font><font style="color: #1F1F26;">a</font><font style="color: #080808;">nnivers</font><font style="color: #1F1F26;">a</font><font style="color: #080808;">ry of the Effective Date, in </font><font style="color: #1F1F26;">e</font><font style="color: #080808;">ach case subject to Section
                  5.</font><font style="color: #1F1F26;">3</font><font style="color: #080808;">.6 below</font><font style="color: #1F1F26;">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z89208845e6ce41bf8f7b7d0b144b31a8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any Invalid Target, with respect to which Immunocore rejected a Nomination Notice from GSK, subsequently becomes available for licence [***]<font style="color: rgb(7, 7, 8);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z3c0c01b11791435b8641851042b6a432" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any Nominated Tar<font style="color: rgb(47, 47, 59);">g</font>e<font style="color: rgb(28, 28, 33);">t i</font><font style="color: rgb(47, 47, 59);">s </font>acce<font style="color: rgb(47, 47, 59);">pt</font><font style="color: rgb(28, 28, 33);">ed </font>by Immunocore, t<font style="color: rgb(47, 47, 59);">he </font>JSC shall have [***] (or suc<font style="color: rgb(28, 28, 33);">h o</font><font style="color: rgb(47, 47, 59);">th</font>er rea<font style="color: rgb(47, 47, 59);">s</font><font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(47, 47, 59);">na</font>ble p<font style="color: rgb(47, 47, 59);">e</font>r<font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(47, 47, 59);">o</font>d as <font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 47, 59);">a</font>y <font style="color: rgb(47, 47, 59);">b</font>e necessary) after the Nomination Date <font style="color: rgb(28, 28, 33);">to </font><font style="color: rgb(47, 47, 59);">d</font>evelo<font style="color: rgb(28, 28, 33);">p a</font><font style="color: rgb(47, 47, 59);">n</font>d a<font style="color: rgb(47, 47, 59);">p</font><font style="color: rgb(28, 28, 33);">pro</font><font style="color: rgb(47, 47, 59);">v</font>e the <font style="color: rgb(28, 28, 33);">Re</font><font style="color: rgb(47, 47, 59);">se</font>arch Plan for the applicable Target Program <font style="color: rgb(28, 28, 33);">o</font>r HLA Program, and<font style="color: rgb(47, 47, 59);">&#160;</font>promptly thereafter Immunocore shall co<font style="color: rgb(28, 28, 33);">m</font>mence <font style="color: rgb(47, 47, 59);">th</font>e
                <font style="color: rgb(28, 28, 33);">wor</font>k set <font style="color: rgb(28, 28, 33);">forth in </font>th<font style="color: rgb(28, 28, 33);">e </font>Research Plan; provided, that Immunocore <font style="color: rgb(47, 47, 59);">sh</font>all






                ha<font style="color: rgb(28, 28, 33);">v</font><font style="color: rgb(47, 47, 59);">e no o</font>bligation <font style="color: rgb(47, 47, 59);">t</font>o com<font style="color: rgb(47, 47, 59);">menc</font>e work under an agreed
                Research Plan <font style="color: rgb(28, 28, 33);">until </font>the <font style="color: rgb(28, 28, 33);">earlier</font><font style="color: rgb(47, 47, 59);">&#160;</font>of <font style="color: rgb(28, 28, 33);">(a) </font>the expiry of a
                period of [***]<font style="color: rgb(7, 7, 8);"> after </font><font style="color: rgb(28, 28, 33);">co</font><font style="color: rgb(7, 7, 8);">mmen</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(7, 7, 8);">ment </font><font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(7, 7, 8);">f work u</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(7, 7, 8);">d</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 47, 59);">r a </font><font style="color: rgb(7, 7, 8);">Research</font><font style="color: rgb(28, 28, 33);"> P</font><font style="color: rgb(7, 7, 8);">lan for the most
                  recently ag</font><font style="color: rgb(47, 47, 59);">r</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(7, 7, 8);">ed and active</font><font style="color: rgb(47, 47, 59);">&#160;</font><font style="color: rgb(7, 7, 8);">Collaboration Program; o</font><font style="color: rgb(47, 47, 59);">r </font><font style="color: rgb(28, 28, 33);">(b</font><font style="color: rgb(7, 7, 8);">) </font><font style="color: rgb(28, 28, 33);">the</font><font style="color: rgb(7, 7, 8);"> date on which </font><font style="color: rgb(47, 47, 59);">[***]</font><font style="color: rgb(7, 7, 8);"> to com</font><font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 47, 59);">en</font><font style="color: rgb(7, 7, 8);">ce </font><font style="color: rgb(28, 28, 33);">wo</font><font style="color: rgb(47, 47, 59);">rk </font><font style="color: rgb(7, 7, 8);">under t</font><font style="color: rgb(28, 28, 33);">h</font><font style="color: rgb(47, 47, 59);">e </font><font style="color: rgb(7, 7, 8);">app</font><font style="color: rgb(28, 28, 33);">li</font><font style="color: rgb(47, 47, 59);">c</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 59);">b</font><font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(7, 7, 8);">e Research Plan. For clarity</font><font style="color: rgb(47, 47, 59);">, </font><font style="color: rgb(7, 7, 8);">w</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(47, 47, 59);">t</font><font style="color: rgb(28, 28, 33);">h </font><font style="color: rgb(7, 7, 8);">resp</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 47, 59);">c</font><font style="color: rgb(7, 7, 8);">t </font><font style="color: rgb(47, 47, 59);">t</font><font style="color: rgb(7, 7, 8);">o th</font><font style="color: rgb(28, 28, 33);">e In</font><font style="color: rgb(7, 7, 8);">i</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(7, 7, 8);">ial Programs, ea</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 59);">h </font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(47, 47, 59);">uch </font><font style="color: rgb(7, 7, 8);">Research Plan shall be upd</font><font style="color: rgb(28, 28, 33);">at</font><font style="color: rgb(7, 7, 8);">e</font><font style="color: rgb(47, 47, 59);">d </font><font style="color: rgb(7, 7, 8);">by the </font><font style="color: rgb(28, 28, 33);">J</font><font style="color: rgb(47, 47, 59);">S</font><font style="color: rgb(28, 28, 33);">C </font><font style="color: rgb(7, 7, 8);">to i</font><font style="color: rgb(47, 47, 59);">nclu</font><font style="color: rgb(28, 28, 33);">d</font><font style="color: rgb(7, 7, 8);">e detailed </font><font style="color: rgb(28, 28, 33);">C</font><font style="color: rgb(7, 7, 8);">linical </font><font style="color: rgb(47, 47, 59);">T</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(47, 47, 59);">i</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 59);">l </font><font style="color: rgb(7, 7, 8);">design and other matters th</font><font style="color: rgb(47, 47, 59);">a</font><font style="color: rgb(28, 28, 33);">t </font><font style="color: rgb(7, 7, 8);">c</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(7, 7, 8);">nnot r</font><font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(47, 47, 59);">so</font><font style="color: rgb(7, 7, 8);">nabl</font><font style="color: rgb(47, 47, 59);">y </font><font style="color: rgb(7, 7, 8);">b</font><font style="color: rgb(47, 47, 59);">e </font><font style="color: rgb(7, 7, 8);">addr</font><font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(28, 28, 33);">ss</font><font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(7, 7, 8);">d at th</font><font style="color: rgb(47, 47, 59);">e </font><font style="color: rgb(7, 7, 8);">tim</font><font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(7, 7, 8);">the initial Research Plan is</font><font style="color: rgb(28, 28, 33);"> a</font><font style="color: rgb(7, 7, 8);">g</font><font style="color: rgb(47, 47, 59);">re</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 47, 59);">d</font><font style="color: rgb(7, 7, 8);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z846c8f7e3a0c4dc5a3325562e6a26a98" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2F2F3B;">At </font>any <font style="color: rgb(47, 47, 59);">time </font>c<font style="color: rgb(28, 28, 33);">o</font>m<font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 47, 59);">e</font>ncing






                <font style="color: rgb(47, 47, 59);">o</font><font style="color: rgb(28, 28, 33);">n </font><font style="color: rgb(47, 47, 59);">t</font>h<font style="color: rgb(28, 28, 33);">e </font>Effective<font style="color: rgb(28, 28, 33);">&#160;</font>Date






                and <font style="color: rgb(28, 28, 33);">e</font>nding [***]<font style="color: rgb(28, 28, 33);">&#160;</font>fro<font style="color: rgb(47, 47, 59);">m </font>t<font style="color: rgb(28, 28, 33);">h</font>e Effective <font style="color: rgb(28, 28, 33);">D</font>ate<font style="color: rgb(28, 28, 33);">, </font>and <font style="color: rgb(47, 47, 59);">a</font><font style="color: rgb(28, 28, 33);">s </font>long as GSK has at least one (1) targ<font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(28, 28, 33);">t </font><font style="color: rgb(47, 47, 59);">n</font>omin<font style="color: rgb(47, 47, 59);">a</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 47, 59);">io</font>n avai<font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 59);">ab</font>le, GSK may<font style="color: rgb(47, 47, 59);">&#160;</font>notify Immunocore in writing up to [***]<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(47, 47, 59);">during su</font><font style="color: rgb(28, 28, 33);">c</font>h p<font style="color: rgb(28, 28, 33);">e</font>ri<font style="color: rgb(47, 47, 59);">od</font>,
                <font style="color: rgb(47, 47, 59);">t</font><font style="color: rgb(28, 28, 33);">h</font>at it <font style="color: rgb(47, 47, 59);">w</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(70, 70, 82);">s</font>he<font style="color: rgb(47, 47, 59);">s </font>to evaluat<font style="color: rgb(28, 28, 33);">e </font>a Target other than those set <font style="color: rgb(47, 47, 59);">o</font>ut in t<font style="color: rgb(28, 28, 33);">h</font><font style="color: rgb(47, 47, 59);">e </font>Data<font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(47, 47, 59);">oo</font><font style="color: rgb(28, 28, 33);">m </font>(&#8220;<font style="font-weight: bold;">No</font><font style="font-weight: bold; color: rgb(47, 47, 59);">n</font><font style="font-weight: bold;">-</font><font style="font-weight: bold; color: rgb(47, 47, 59);">va</font><font style="font-weight: bold;">lidated Target</font>&#8221;). The
                notification from GSK sh<font style="color: rgb(28, 28, 33);">all i</font>nclude the following [***] shall be<font style="color: rgb(47, 47, 59);"> d</font><font style="color: rgb(28, 28, 33);">is</font>cussed at the ne<font style="color: rgb(28, 28, 33);">x</font>t meeting of the JSC (o<font style="color: rgb(28, 28, 33);">r </font>as otherwise provided by the<font style="color: rgb(47, 47, 59);"> JS</font>C). <font style="color: rgb(47, 47, 59);">If </font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 47, 59);">h</font><font style="color: rgb(28, 28, 33);">e </font>JSC determines that further investigation of a Non-<font style="color: rgb(28, 28, 33);">v</font>alidated






                Target <font style="color: rgb(47, 47, 59);">is </font><font style="color: rgb(28, 28, 33);">re</font>quired in order to determine its technical feasibility as a tractable Targe<font style="color: rgb(47, 47, 59);">t,</font> [***]
                Immunocore of [***] in which <font style="color: rgb(28, 28, 33);">GS</font>K is interested. <font style="color: rgb(28, 28, 33);">T</font>he J<font style="color: rgb(28, 28, 33);">SC </font>shall agree [***], but as of the Effective
                Date, it is <font style="color: rgb(28, 28, 33);">a</font>nticipat<font style="color: rgb(28, 28, 33);">e</font>d that Immunocor<font style="color: rgb(28, 28, 33);">e </font>shall r<font style="color: rgb(28, 28, 33);">e</font>quire
                [***]. Immunocore shall th<font style="color: rgb(28, 28, 33);">e</font>n <font style="color: rgb(28, 28, 33);">a</font>s <font style="color: rgb(28, 28, 33);">s</font>oon <font style="color: rgb(28, 28, 33);">a</font>s r<font style="color: rgb(28, 28, 33);">e</font>as<font style="color: rgb(28, 28, 33);">o</font>n<font style="color: rgb(28, 28, 33);">a</font>bly p<font style="color: rgb(28, 28, 33);">oss</font>ible <font style="color: rgb(28, 28, 33);">a</font>nd







                in any ev<font style="color: rgb(28, 28, 33);">e</font>nt <font style="color: rgb(28, 28, 33);">o</font>nly on<font style="color: rgb(28, 28, 33);">c</font>e it h<font style="color: rgb(28, 28, 33);">a</font>s resources <font style="color: rgb(28, 28, 33);">a</font>vailable (<font style="color: rgb(28, 28, 33);">as </font>determined by Immunocore in its<font style="color: rgb(28, 28, 33);">&#160;</font>sole discretion), attempt to identify [***] from the
                Non-validated [***]<font style="color: rgb(7, 7, 8);">. The validation work shall not extend beyond validation work typically carried out by Immunocore for Targets within the Dataroom. Immunocore shall report to the JSC on the progress of
                  the validation work and on completion shall notify the JS</font><font style="color: rgb(28, 28, 33);">C </font><font style="color: rgb(7, 7, 8);">either that (a) in its view, the validation work sugge</font><font style="color: rgb(49, 49, 59);">s</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(7, 7, 8);">s that it would be possible or technically feasible to identify a Compound t</font><font style="color: rgb(28, 28, 33);">o </font><font style="color: rgb(7, 7, 8);">the</font><font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(49, 49, 59);">N</font><font style="color: rgb(7, 7, 8);">on-validated </font><font style="color: rgb(28, 28, 33);">T</font><font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(7, 7, 8);">get; or (b) in its view, the validation work does not sug</font><font style="color: rgb(49, 49, 59);">g</font><font style="color: rgb(28, 28, 33);">est </font><font style="color: rgb(7, 7, 8);">that it would </font><font style="color: rgb(28, 28, 33);">b</font><font style="color: rgb(49, 49, 59);">e </font><font style="color: rgb(7, 7, 8);">possible
                  or technically feasible to identify a Compound to the Non-</font><font style="color: rgb(28, 28, 33);">vali</font><font style="color: rgb(49, 49, 59);">d</font><font style="color: rgb(7, 7, 8);">ated Target. Following completion of the
                  validation </font><font style="color: rgb(49, 49, 59);">wo</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(7, 7, 8);">k and notificatio</font><font style="color: rgb(28, 28, 33);">n </font><font style="color: rgb(7, 7, 8);">t</font><font style="color: rgb(28, 28, 33);">o </font><font style="color: rgb(7, 7, 8);">the JSC as to the technical feasibility of identifyin</font><font style="color: rgb(28, 28, 33);">g </font><font style="color: rgb(7, 7, 8);">the Compound t</font><font style="color: rgb(49, 49, 59);">o </font><font style="color: rgb(7, 7, 8);">the Non-validated Target, GSK shall be entitled to </font><font style="color: rgb(49, 49, 59);">nominate</font><font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(7, 7, 8);">the Non-</font><font style="color: rgb(28, 28, 33);">val</font><font style="color: rgb(7, 7, 8);">idate</font><font style="color: rgb(28, 28, 33);">d T</font><font style="color: rgb(7, 7, 8);">arget in accordance with Section 5.3.2 a</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(7, 7, 8);">d </font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(7, 7, 8);">uch N</font><font style="color: rgb(49, 49, 59);">o</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(7, 7, 8);">-valid</font><font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(7, 7, 8);">ed Ta</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(49, 49, 59);">get </font><font style="color: rgb(7, 7, 8);">shall be thereafter treated in the
                  same </font><font style="color: rgb(49, 49, 59);">w</font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(49, 49, 59);">y </font><font style="color: rgb(7, 7, 8);">as </font><font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">ny </font><font style="color: rgb(7, 7, 8);">No</font><font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(49, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(7, 7, 8);">d T</font><font style="color: rgb(28, 28, 33);">ar</font><font style="color: rgb(49, 49, 59);">g</font><font style="color: rgb(7, 7, 8);">e</font><font style="color: rgb(28, 28, 33);">t </font><font style="color: rgb(7, 7, 8);">from the Dataroom.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2bf708f0f14f47ee94e6056f8a0864e5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Should GSK wish to asses<font style="color: rgb(49, 49, 59);">s </font>any <font style="color: rgb(28, 28, 33);">a</font>ddit<font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(49, 49, 59);">on</font>a<font style="color: rgb(28, 28, 33);">l </font>Non-<font style="color: rgb(49, 49, 59);">v</font><font style="color: rgb(28, 28, 33);">a</font>l<font style="color: rgb(49, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">d</font>ated
                Tar<font style="color: rgb(49, 49, 59);">ge</font><font style="color: rgb(28, 28, 33);">ts </font>other than in accordance with Section 5.<font style="color: rgb(49, 49, 59);">3.8</font>, the<font style="color: rgb(28, 28, 33);">n th</font>e
                Par<font style="color: rgb(49, 49, 59);">t</font>ie<font style="color: rgb(49, 49, 59);">s </font>shall <font style="color: rgb(28, 28, 33);">d</font><font style="color: rgb(49, 49, 59);">i</font>s<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(49, 49, 59);">u</font>s<font style="color: rgb(28, 28, 33);">s </font>the assessment of such Non-validated T<font style="color: rgb(28, 28, 33);">ar</font><font style="color: rgb(49, 49, 59);">ge</font>ts. W<font style="color: rgb(49, 49, 59);">h</font><font style="color: rgb(28, 28, 33);">er</font><font style="color: rgb(49, 49, 59);">e </font>the <font style="color: rgb(28, 28, 33);">Parties</font> agr<font style="color: rgb(28, 28, 33);">ee t</font><font style="color: rgb(49, 49, 59);">o </font>proceed with such assessment, the Parties<font style="color: rgb(28, 28, 33);">&#160;</font>will <font style="color: rgb(49, 49, 59);">n</font>egot<font style="color: rgb(28, 28, 33);">i</font>ate in
                <font style="color: rgb(49, 49, 59);">go</font><font style="color: rgb(28, 28, 33);">o</font>d fa<font style="color: rgb(49, 49, 59);">it</font><font style="color: rgb(28, 28, 33);">h t</font>h<font style="color: rgb(28, 28, 33);">e </font>terms






                which would apply to such ass<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">s</font>sm<font style="color: rgb(49, 49, 59);">e</font>nt inclu<font style="color: rgb(49, 49, 59);">di</font><font style="color: rgb(28, 28, 33);">n</font>g <font style="color: rgb(49, 49, 59);">responsibilities</font>&#160;<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(49, 49, 59);">f </font>each Party and time, cost and resourc<font style="color: rgb(28, 28, 33);">e all</font><font style="color: rgb(49, 49, 59);">oca</font>tion<font style="color: rgb(49, 49, 59);">s r</font>equir<font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">d </font>o<font style="color: rgb(49, 49, 59);">f </font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">a</font>ch Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zba2761f67e984917ba8ab0f46b730df3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Research Licence</u>. Commencing<font style="color: rgb(28, 28, 33);"> o</font><font style="color: rgb(49, 49, 59);">n </font>each<font style="color: rgb(28, 28, 33);">&#160;</font>Nomination<font style="color: rgb(28, 28, 33);"> D</font>ate






                for <font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">a</font>ch Collaboration Program,<font style="color: rgb(28, 28, 33);">&#160;</font>and solely <font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">o </font>the exte<font style="color: rgb(49, 49, 59);">n</font>t <font style="color: rgb(49, 49, 59);">that</font> it is <font style="color: rgb(28, 28, 33);">a</font>gree<font style="color: rgb(28, 28, 33);">d </font>in a<font style="color: rgb(49, 49, 59);">n</font>y Collaboration Program that GSK should conduc<font style="color: rgb(49, 49, 59);">t w</font><font style="color: rgb(28, 28, 33);">o</font>rk und<font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">r the</font> a<font style="color: rgb(28, 28, 33);">ppl</font><font style="color: rgb(49, 49, 59);">ic</font>able Research Plan, I<font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(49, 49, 59);">m</font>unocore shall grant and hereby grants to GS<font style="color: rgb(28, 28, 33);">K </font><font style="color: rgb(49, 49, 59);">a </font>non-<font style="color: rgb(28, 28, 33);">exclusive</font>&#160;<font style="color: rgb(49, 49, 59);">l</font>i<font style="color: rgb(28, 28, 33);">ce</font><font style="color: rgb(49, 49, 59);">n</font>ce i<font style="color: rgb(28, 28, 33);">n </font><font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">h</font>e Territory under the Immunocore B<font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">c</font>k<font style="color: rgb(28, 28, 33);">g</font><font style="color: rgb(49, 49, 59);">ro</font><font style="color: rgb(28, 28, 33);">u</font>nd, <font style="color: rgb(49, 49, 59);">Immunocore</font><font style="color: rgb(28, 28, 33);">&#160;</font>Foreground, J<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(49, 49, 59);">in</font><font style="color: rgb(28, 28, 33);">t </font><font style="color: rgb(49, 49, 59);">Fo</font><font style="color: rgb(28, 28, 33);">r</font>eground and Platform Rights to the extent nece<font style="color: rgb(49, 49, 59);">ssa</font>ry for <font style="color: rgb(49, 49, 59);">GS</font>K<font style="color: rgb(49, 49, 59);">&#8217;</font>s performance of the<font style="color: rgb(49, 49, 59);"> Collaboration</font> Program. The
                licence und<font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">r </font>this Section<font style="color: rgb(49, 49, 59);">&#160;</font>5.4 <font style="color: rgb(49, 49, 59);">s</font>h<font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(49, 49, 59);">l </font>expire on the <font style="color: rgb(49, 49, 59);">earlier</font><font style="color: rgb(28, 28, 33);">&#160;</font>of
                (a) the date on whi<font style="color: rgb(28, 28, 33);">c</font>h Immunoc<font style="color: rgb(28, 28, 33);">or</font>e <font style="color: rgb(28, 28, 33);">reje</font>cts <font style="color: rgb(49, 49, 59);">a </font>Nomination
                Noti<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(49, 49, 59);">e </font><font style="color: rgb(28, 28, 33);">i</font>n <font style="color: rgb(68, 70, 82);">accordance</font>&#160;<font style="color: rgb(28, 28, 33);">w</font>ith






                Section 5.3.2; or (b) an exclusiv<font style="color: rgb(49, 49, 59);">e </font>li<font style="color: rgb(49, 49, 59);">ce</font>nce b<font style="color: rgb(49, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(49, 49, 59);">ng </font>gra<font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(49, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">e</font>d follo<font style="color: rgb(28, 28, 33);">w</font>i<font style="color: rgb(49, 49, 59);">ng e</font>xerci<font style="color: rgb(28, 28, 33);">se </font><font style="color: rgb(49, 49, 59);">of </font>the Initial Program Option or Collaboration<font style="color: rgb(49, 49, 59);">&#160;</font>Pro<font style="color: rgb(49, 49, 59);">g</font><font style="color: rgb(28, 28, 33);">r</font>a<font style="color: rgb(49, 49, 59);">m </font><font style="color: rgb(28, 28, 33);">Option</font><font style="color: rgb(49, 49, 59);">, </font>as
                ap<font style="color: rgb(49, 49, 59);">p</font>li<font style="color: rgb(28, 28, 33);">cab</font>le; or <font style="color: rgb(49, 49, 59);">(</font>c) <font style="color: rgb(28, 28, 33);">e</font>xpiration of the applicable Initial
                Program <font style="color: rgb(49, 49, 59);">Option</font><font style="color: rgb(28, 28, 33);"> Period</font>&#160;<font style="color: rgb(49, 49, 59);">or</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #1C1C21;">Co</font>llabo<font style="color: rgb(28, 28, 33);">r</font>atio<font style="color: rgb(28, 28, 33);">n </font>Option P<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(49, 49, 59);">r</font>iod without exercise of the Initial Program<font style="color: rgb(49, 49, 59);">&#160;</font>Option<font style="color: rgb(28, 28, 33);"> o</font>r Collaboration <font style="color: rgb(28, 28, 33);">Program</font>
        Option,<font style="color: rgb(28, 28, 33);">&#160;</font>as applicable; or (d) Completion of t<font style="color: rgb(49, 49, 59);">h</font><font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(49, 49, 59);">Co</font>llabo<font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(68, 70, 82);">a</font><font style="color: rgb(28, 28, 33);">t</font>i<font style="color: rgb(49, 49, 59);">on </font>Pro<font style="color: rgb(49, 49, 59);">g</font>r<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(49, 49, 59);">m</font>. Th<font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(49, 49, 59);">lice</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(49, 49, 59);">c</font>e un<font style="color: rgb(49, 49, 59);">d</font><font style="color: rgb(28, 28, 33);">er </font>thi<font style="color: rgb(49, 49, 59);">s </font>Section 5.4 <font style="color: rgb(28, 28, 33);">s</font>hall






        be <font style="color: rgb(28, 28, 33);">s</font>ubli<font style="color: rgb(28, 28, 33);">c</font>en<font style="color: rgb(28, 28, 33);">s</font>eable t<font style="color: rgb(28, 28, 33);">o</font> GSK&#8217;<font style="color: rgb(68, 70, 82);">s </font>Affiliates






        to the <font style="color: rgb(49, 49, 59);">e</font>xtent <font style="color: rgb(49, 49, 59);">s</font><font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(68, 70, 82);">c</font>h Affiliates<font style="color: rgb(49, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">are</font> performing <font style="color: rgb(28, 28, 33);">a</font>ny obligations under any Collaboration Program.</div>
      <div>&#160;</div>
      <table id="z0f760e72505947d782cc7c9b7788a6b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Options; Lice</font><font style="font-weight: bold; color: #31313B;">n</font><font style="font-weight: bold; color: #1C1C21;">ce</font><font style="font-weight: bold;">s</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3122b2d1933144d587cb7d8d0d085c23" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On an Initial Program-b<font style="color: rgb(49, 49, 59);">y</font><font style="color: rgb(28, 28, 33);">-</font>Initial Program basis, Immunocore shall grant and hereby grants t<font style="color: rgb(49, 49, 59);">o </font><font style="color: rgb(28, 28, 33);">G</font>SK, an exclusive option to obtain the exclusive licences on the terms set out in Section<font style="color: rgb(49, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">6</font>.7 (e<font style="color: rgb(49, 49, 59);">ac</font>h, an &#8220;<font style="font-weight: bold;">Initial Program Option</font>&#8221;).<font style="font-weight: bold;">&#160;</font>With respect to the first Initial Targ<font style="color: rgb(49, 49, 59);">et </font>Program






                <font style="color: rgb(49, 49, 59);">de</font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(49, 49, 59);">c</font><font style="color: rgb(28, 28, 33);">r</font>ibed on Schedule 1, the Initial Program Option shall c<font style="color: rgb(28, 28, 33);">o</font>mmen<font style="color: rgb(28, 28, 33);">c</font>e on th<font style="color: rgb(49, 49, 59);">e Effective</font> D<font style="color: rgb(49, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">te






                  [***]</font>.<font style="color: rgb(28, 28, 33);"> W</font><font style="color: rgb(49, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">th </font>respect to the additional Initial Programs, the Initial Program Option shall<font style="color: rgb(49, 49, 59);"> com</font>mence on the Nomination Date, and each Initial Program Option <font style="color: rgb(28, 28, 33);">s</font>hall expire on an<font style="color: rgb(49, 49, 59);"> Initial</font>
                Program-by-Initial Program b<font style="color: rgb(28, 28, 33);">as</font>i<font style="color: rgb(28, 28, 33);">s o</font>n th<font style="color: rgb(28, 28, 33);">e </font>e<font style="color: rgb(28, 28, 33);">a</font>rlier of eith<font style="color: rgb(28, 28, 33);">e</font>r (i) th<font style="color: rgb(28, 28, 33);">e d</font>ate th<font style="color: rgb(28, 28, 33);">a</font>t i<font style="color: rgb(28, 28, 33);">s [***]</font><font style="color: rgb(7, 7, 8);">
                  foll</font><font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(7, 7, 8);">wing receipt by GSK </font><font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(7, 7, 8);">f the</font><font style="color: rgb(28, 28, 33);"> a</font><font style="color: rgb(7, 7, 8);">pplicable Phase 1 Dat</font><font style="color: rgb(28, 28, 33);">a </font><font style="color: rgb(7, 7, 8);">P</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(7, 7, 8);">ckage; </font><font style="color: rgb(28, 28, 33);">or </font><font style="color: rgb(7, 7, 8);">(ii) termination of the appli</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(7, 7, 8);">able Coll</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(7, 7, 8);">bor</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(7, 7, 8);">tion Program in ac</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(7, 7, 8);">o</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(7, 7, 8);">dance with Sections 3.5.1, </font><font style="color: rgb(28, 28, 33);">3</font>.5.2,






                3.6.1 and <font style="color: rgb(28, 28, 33);">3</font>.6.2, including if such termination occurs after Completion of any Lead Additional Work or Development Additional Work without nomination of a Lead C<font style="color: rgb(28, 28, 33);">a</font>ndidate or Developm<font style="color: rgb(28, 28, 33);">e</font>nt Candidate, re<font style="color: rgb(28, 28, 33);">s</font>pectively (the &#8220;<font style="font-weight: bold;">Initial Program Option </font><font style="font-weight: bold; color: rgb(7, 7, 8);">Period</font><font style="color: rgb(7, 7, 8);">&#8221;).</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8eaa642088a24f7ab46a6b7c50eeb6bb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>With respect to all Collaboration Programs other than as provided in Section 6.1, on a Collaboration Program-by-Collaboration Program basis, Immunocore shall grant and hereby grants to GSK, an exclusive option to obtain the <font style="color: rgb(47, 47, 59);">e</font>xclusive licenses on the terms set out in Section 6.8 (each, a &#8220;<font style="font-weight: bold;">Collaboration Prog</font><font style="font-weight: bold; color: rgb(29, 29, 35);">ra</font><font style="font-weight: bold;">m Option</font>&#8221;). Each such [***]<font style="color: rgb(29, 29, 35);">&#160;</font>Collaboration Program-by-Collaboration Program basis on the <font style="color: rgb(47, 47, 59);">earl</font>ier of either (i) th<font style="color: rgb(47, 47, 59);">e </font>d<font style="color: rgb(29, 29, 35);">a</font>te that is [***]<font style="color: rgb(7, 7, 8);"> following determination by the JSC </font><font style="color: rgb(29, 29, 35);">that</font><font style="color: rgb(7, 7, 8);"> at least one </font><font style="color: rgb(29, 29, 35);">Le</font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(29, 29, 35);">d </font><font style="color: rgb(7, 7, 8);">Candidate from
                  such Collaboration Program satisfies the appli</font><font style="color: rgb(29, 29, 35);">cable </font><font style="color: rgb(7, 7, 8);">Development Ca</font><font style="color: rgb(29, 29, 35);">nd</font><font style="color: rgb(7, 7, 8);">idate </font><font style="color: rgb(47, 47, 59);">Crit</font><font style="color: rgb(7, 7, 8);">eria and is deemed a Development Candidate; or (i</font><font style="color: rgb(29, 29, 35);">i) </font><font style="color: rgb(7, 7, 8);">termination </font><font style="color: rgb(47, 47, 59);">of </font><font style="color: rgb(7, 7, 8);">the a</font><font style="color: rgb(47, 47, 59);">p</font><font style="color: rgb(7, 7, 8);">p</font><font style="color: rgb(29, 29, 35);">l</font><font style="color: rgb(7, 7, 8);">icabl</font><font style="color: rgb(29, 29, 35);">e </font><font style="color: rgb(47, 47, 59);">Collaboration</font><font style="color: rgb(7, 7, 8);"> Program in accordance with
                  Sections 3.5.1</font><font style="color: rgb(29, 29, 35);">, 3.</font><font style="color: rgb(7, 7, 8);">5.2, </font><font style="color: rgb(29, 29, 35);">3.6</font><font style="color: rgb(7, 7, 8);">.</font><font style="color: rgb(29, 29, 35);">1 </font><font style="color: rgb(7, 7, 8);">an</font><font style="color: rgb(47, 47, 59);">d </font><font style="color: rgb(7, 7, 8);">3.</font><font style="color: rgb(47, 47, 59);">6.2</font><font style="color: rgb(7, 7, 8);">,
                  i</font><font style="color: rgb(47, 47, 59);">nclu</font><font style="color: rgb(7, 7, 8);">d</font><font style="color: rgb(29, 29, 35);">in</font><font style="color: rgb(7, 7, 8);">g if such termination occurs after Completion </font><font style="color: rgb(47, 47, 59);">of </font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(47, 47, 59);">n</font><font style="color: rgb(7, 7, 8);">y L</font><font style="color: rgb(29, 29, 35);">ea</font><font style="color: rgb(7, 7, 8);">d </font><font style="color: rgb(29, 29, 35);">Additional</font><font style="color: rgb(47, 47, 59);">&#160;</font><font style="color: rgb(7, 7, 8);">Work </font><font style="color: rgb(29, 29, 35);">or </font><font style="color: rgb(7, 7, 8);">Development Additional Work without nomination </font><font style="color: rgb(47, 47, 59);">of a </font><font style="color: rgb(29, 29, 35);">Le</font><font style="color: rgb(7, 7, 8);">ad </font><font style="color: rgb(47, 47, 59);">Candidate </font><font style="color: rgb(29, 29, 35);">or </font><font style="color: rgb(7, 7, 8);">Deve</font><font style="color: rgb(29, 29, 35);">lop</font><font style="color: rgb(7, 7, 8);">ment
                  Candidate, respectively (the &#8220;</font><font style="font-weight: bold; color: rgb(7, 7, 8);">Collaboration Pr</font><font style="font-weight: bold; color: rgb(29, 29, 35);">og</font><font style="font-weight: bold; color: rgb(7, 7, 8);">ra</font><font style="font-weight: bold; color: rgb(29, 29, 35);">m </font><font style="font-weight: bold; color: rgb(7, 7, 8);">Op</font><font style="font-weight: bold; color: rgb(47, 47, 59);">tio</font><font style="font-weight: bold; color: rgb(7, 7, 8);">n Perio</font><font style="font-weight: bold; color: rgb(29, 29, 35);">d</font><font style="color: rgb(29, 29, 35);">&#8221;)</font><font style="color: rgb(7, 7, 8);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zecbed850f1604e2e81802496ae581cfc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK may exercise an Initial Pro<font style="color: rgb(29, 29, 35);">g</font>r<font style="color: rgb(47, 47, 59);">am </font>Opti<font style="color: rgb(47, 47, 59);">o</font>n <font style="color: rgb(47, 47, 59);">o</font>r
                Collaboration <font style="color: rgb(29, 29, 35);">Program</font> Option at any time during the Initial Program <font style="color: rgb(29, 29, 35);">Option</font> Period<font style="color: rgb(29, 29, 35);">&#160;</font>or Collaboration<font style="color: rgb(47, 47, 59);">&#160;</font><font style="color: rgb(29, 29, 35);">P</font>rogram Option Period, respectively, by provision of <font style="color: rgb(47, 47, 59);">written</font> notice <font style="color: rgb(47, 47, 59);">to






                </font>Immunocore <font style="color: rgb(47, 47, 59);">sp</font>ecif<font style="color: rgb(47, 47, 59);">y</font>ing the<font style="color: rgb(29, 29, 35);">&#160;</font>Initial Program or Collaboration Program i<font style="color: rgb(29, 29, 35);">n r</font>e<font style="color: rgb(47, 47, 59);">latio</font>n t<font style="color: rgb(29, 29, 35);">o </font><font style="color: rgb(47, 47, 59);">w</font>hich <font style="color: rgb(47, 47, 59);">the In</font>i<font style="color: rgb(47, 47, 59);">t</font>ial Program<font style="color: rgb(29, 29, 35);">&#160;</font>Option<font style="color: rgb(47, 47, 59);"> or </font>Collaboration Program Option is being <font style="color: rgb(29, 29, 35);">e</font>xer<font style="color: rgb(47, 47, 59);">ci</font>sed (&#8220;<font style="font-weight: bold; color: rgb(47, 47, 59);">Opt</font><font style="font-weight: bold;">ion </font><font style="font-weight: bold; color: rgb(29, 29, 35);">Noti</font><font style="font-weight: bold;">c</font><font style="font-weight: bold; color: rgb(47, 47, 59);">e</font>&#8221;). <font style="color: rgb(29, 29, 35);">O</font>n receipt <font style="color: rgb(29, 29, 35);">o</font>f th<font style="color: rgb(29, 29, 35);">e </font>Option Notice by Immunocore, Immuno<font style="color: rgb(29, 29, 35);">cor</font>e sh<font style="color: rgb(29, 29, 35);">a</font>l<font style="color: rgb(29, 29, 35);">l g</font>rant<font style="color: rgb(47, 47, 59);">, </font>and here<font style="color: rgb(47, 47, 59);">b</font>y <font style="color: rgb(29, 29, 35);">grants</font>, <font style="color: rgb(47, 47, 59);">t</font>o <font style="color: rgb(47, 47, 59);">G</font>SK
                the exclusive licence on the terms <font style="color: rgb(47, 47, 59);">s</font>et out in <font style="color: rgb(47, 47, 59);">Section</font> 6.<font style="color: rgb(47, 47, 59);">7 </font><font style="color: rgb(29, 29, 35);">with</font>
                re<font style="color: rgb(29, 29, 35);">s</font>pect <font style="color: rgb(47, 47, 59);">t</font>o suc<font style="color: rgb(47, 47, 59);">h Initial</font> Program Option or Collaboration Program Option.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze568f10880154057b045e79dd098a2f4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On a Collaboration <font style="color: rgb(47, 47, 59);">Program-</font>b<font style="color: rgb(47, 47, 59);">y</font>-Collaboration <font style="color: rgb(29, 29, 35);">P</font>rogram ba<font style="color: rgb(47, 47, 59);">sis and
                </font>Target-by-Target basis and during th<font style="color: rgb(29, 29, 35);">e </font>In<font style="color: rgb(47, 47, 59);">it</font>ial Program Option<font style="color: rgb(47, 47, 59);">&#160;</font><font style="color: rgb(29, 29, 35);">P</font>eriod <font style="color: rgb(47, 47, 59);">or </font><font style="color: rgb(29, 29, 35);">Collaboration</font><font style="color: rgb(47, 47, 59);">&#160;</font>Program Option Period, as applicable, <font style="color: rgb(29, 29, 35);">Immunocore</font><font style="color: rgb(47, 47, 59);"> sh</font>all n<font style="color: rgb(47, 47, 59);">ot (a</font>) ind<font style="color: rgb(47, 47, 59);">e</font>p<font style="color: rgb(47, 47, 59);">e</font>n<font style="color: rgb(29, 29, 35);">d</font>ently <font style="color: rgb(47, 47, 59);">o</font>r with, or on behalf of<font style="color: rgb(29, 29, 35);">, </font>a Third Party, co<font style="color: rgb(29, 29, 35);">n</font>d<font style="color: rgb(47, 47, 59);">uc</font>t any <font style="color: rgb(47, 47, 59);">rese</font>arch<font style="color: rgb(29, 29, 35);">, de</font>velop<font style="color: rgb(47, 47, 59);">me</font>n<font style="color: rgb(29, 29, 35);">t </font>or co<font style="color: rgb(29, 29, 35);">mmer</font>cialisation activities on any Licensed Product; <font style="color: rgb(47, 47, 59);">or (</font>b) licence any Third Party <font style="color: rgb(29, 29, 35);">unde</font>r
                its rights in the Immunocore Foreg<font style="color: rgb(47, 47, 59);">round, </font>Im<font style="color: rgb(47, 47, 59);">m</font>u<font style="color: rgb(47, 47, 59);">no</font>co<font style="color: rgb(47, 47, 59);">r</font>e <font style="color: rgb(47, 47, 59);">B</font>ackgro<font style="color: rgb(29, 29, 35);">und, </font>Joint Foreground or Platform Rights to man<font style="color: rgb(47, 47, 59);">uf</font>ac<font style="color: rgb(29, 29, 35);">tur</font>e,
                u<font style="color: rgb(47, 47, 59);">se, </font><font style="color: rgb(29, 29, 35);">se</font>ll o<font style="color: rgb(47, 47, 59);">r s</font>u<font style="color: rgb(29, 29, 35);">p</font>ply any Lic<font style="color: rgb(47, 47, 59);">e</font>nsed Product. There shall be no breach of this [***] (ii) Immunocore licen<font style="color: rgb(29, 29, 35);">s</font>es its Intellectual Proper<font style="color: rgb(47, 47, 59);">t</font>y Rights to a Third <font style="color: rgb(47, 47, 59);">Pa</font>rty in relation to the development of Compounds <font style="color: rgb(29, 29, 35);">o</font>r <font style="color: rgb(47, 47, 59);">TCRs </font>to Tar<font style="color: rgb(29, 29, 35);">gets
                </font>other than the Nominated Target; or (iii) Immunocore licenses its Intellectual Property Rights to a Third Party to enable such Third Party to c<font style="color: rgb(29, 29, 35);">a</font>rry out <font style="color: rgb(29, 29, 35);">spe</font>cific r<font style="color: rgb(29, 29, 35);">e</font>s<font style="color: rgb(47, 47, 59);">earc</font>h projects intended to improve or enhance the Immunocore Backgroun<font style="color: rgb(47, 47, 59);">d an</font>d wh<font style="color: rgb(29, 29, 35);">ic</font>h <font style="color: rgb(47, 47, 59);">ar</font>e not specific<font style="color: rgb(29, 29, 35);">&#160;</font>to any Target. For clarity any research or development licence agreement with a Third
                Party under Section 6.4(iii) shall not includ<font style="color: rgb(47, 47, 59);">e </font><font style="color: rgb(29, 29, 35);">any </font>licen<font style="color: rgb(29, 29, 35);">ce </font><font style="color: rgb(47, 47, 59);">un</font>der






                Immunocore Background, Platform Rights or Immunocore Fore<font style="color: rgb(29, 29, 35);">gro</font>und to <font style="color: rgb(47, 47, 59);">manufacture</font>, sell, supply, use, import or commercialise any Licensed Product.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z8641564765494576a33613f52ccf260d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2F2F3B;">For </font><font style="color: #070708;">the avoidance of any doubt and save as explicitly otherwise provided in Section 6.7</font><font style="color: #2F2F3B;">, n</font><font style="color: #070708;">o </font><font style="color: #2F2F3B;">l</font><font style="color: #070708;">icen</font><font style="color: #1D1D23;">c</font><font style="color: #070708;">e i</font><font style="color: #1D1D23;">s </font><font style="color: #070708;">grant</font><font style="color: #1D1D23;">e</font><font style="color: #070708;">d und</font><font style="color: #1D1D23;">e</font><font style="color: #070708;">r thi</font><font style="color: #1D1D23;">s </font><font style="color: #070708;">Agreement
                  (including under any ex</font><font style="color: #1D1D23;">e</font><font style="color: #070708;">r</font><font style="color: #1D1D23;">c</font><font style="color: #070708;">i</font><font style="color: #1D1D23;">se o</font><font style="color: #070708;">f </font><font style="color: #1D1D23;">a</font><font style="color: #070708;">n Initial Program Option, Collaboration Program Option or </font><font style="color: #1D1D23;">t</font><font style="color: #070708;">he
                  licen</font><font style="color: #1D1D23;">s</font><font style="color: #070708;">es gr</font><font style="color: #1D1D23;">a</font><font style="color: #070708;">nted under Secti</font><font style="color: #1D1D23;">o</font><font style="color: #070708;">n 6.7) </font>to GSK under Immunocore Background, Immunocore For<font style="color: rgb(29, 29, 35);">e</font>ground or Platform Rights<font style="color: rgb(29, 29, 35);">&#160;</font>in relation t<font style="color: rgb(29, 29, 35);">o </font>any product that <font style="color: rgb(29, 29, 35);">co</font>nt<font style="color: rgb(29, 29, 35);">a</font>in<font style="color: rgb(29, 29, 35);">s c</font>ell<font style="color: rgb(47, 47, 59);">s </font>th<font style="color: rgb(29, 29, 35);">a</font>t <font style="color: rgb(29, 29, 35);">a</font>re tran<font style="color: rgb(29, 29, 35);">s</font>fe<font style="color: rgb(29, 29, 35);">c</font>ted with g<font style="color: rgb(29, 29, 35);">e</font>ne<font style="color: rgb(29, 29, 35);">s</font> en<font style="color: rgb(29, 29, 35);">c</font>oding TCRs or modified TCRs including any produ<font style="color: rgb(29, 29, 35);">c</font>t containing cells that may also be transfected with one
                or mo<font style="color: rgb(29, 29, 35);">r</font>e additional other molecule<font style="color: rgb(29, 29, 35);">s </font>(whether or not tran<font style="color: rgb(29, 29, 35);">s</font>fe<font style="color: rgb(29, 29, 35);">c</font>ted






                at <font style="color: rgb(8, 8, 8);">the same time or by the same means as the genes encoding TCRs or modified TCRs).</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zacd1c3203799486ebcf5d836cf022ca5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>During the term of this Agreement, Immunocore shall inform GSK where it reasonably [***] within the timescales agreed in the relevan<font style="color: rgb(45, 45, 56);">t R</font>e<font style="color: rgb(45, 45, 56);">s</font>earch Plan
                th<font style="color: rgb(45, 45, 56);">at </font>were to be conducted in the next [***]. Such determination shall [***]. In particular, Immunocore&#8217;s Alliance Manager shall report t<font style="color: rgb(45, 45, 56);">o </font>the JSC at
                each JS<font style="color: rgb(45, 45, 56);">C </font>meeting as to whether, [***]. <font style="color: rgb(45, 45, 56);">F</font>ollo<font style="color: rgb(45, 45, 56);">w</font>ing <font style="color: rgb(45, 45, 56);">d</font>is<font style="color: rgb(45, 45, 56);">cl</font>osure o<font style="color: rgb(45, 45, 56);">f </font>such c<font style="color: rgb(45, 45, 56);">once</font>rns, GSK may request a meeting [***]. An<font style="color: rgb(45, 45, 56);">y meeting</font>
                [***] shall be held promptly and <font style="color: rgb(45, 45, 56);">Immunocore</font> will answ<font style="color: rgb(45, 45, 56);">e</font>r any reasonable questions raised in such meeting<font style="color: rgb(45, 45, 56);">. N</font>othing






                in this S<font style="color: rgb(45, 45, 56);">e</font>c<font style="color: rgb(45, 45, 56);">ti</font>on 6.6 sh<font style="color: rgb(45, 45, 56);">a</font>ll be construed to require Immunocore to breach <font style="color: rgb(45, 45, 56);">a</font>n<font style="color: rgb(45, 45, 56);">y </font>regula<font style="color: rgb(45, 45, 56);">to</font>r<font style="color: rgb(45, 45, 56);">y </font>req<font style="color: rgb(45, 45, 56);">ui</font>re<font style="color: rgb(45, 45, 56);">m</font>ents o<font style="color: rgb(45, 45, 56);">r </font>r<font style="color: rgb(45, 45, 56);">ul</font>es of any relevant stock exchange on which Immunocore may at any ti<font style="color: rgb(45, 45, 56);">me </font>be






                lis<font style="color: rgb(45, 45, 56);">t</font>e<font style="color: rgb(45, 45, 56);">d.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc6c9bb73579647ba86209e751709d448" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Licence Terms</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2c27fb3227184d1aabed6a5c6c3f9ba9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">6.7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Commencing upo<font style="color: rgb(45, 45, 56);">n </font>GSK&#8217;s <font style="color: rgb(45, 45, 56);">ex</font>ercise of an Initi<font style="color: rgb(45, 45, 56);">a</font>l <font style="color: rgb(45, 45, 56);">P</font>rogram
                Option as described in Section 6.1 or a Collaboration <font style="color: rgb(45, 45, 56);">Program</font> Option<font style="color: rgb(45, 45, 56);">&#160;</font>as d<font style="color: rgb(45, 45, 56);">e</font>s<font style="color: rgb(45, 45, 56);">c</font>ribed in Section 6.2, Immunoc<font style="color: rgb(45, 45, 56);">ore </font>shall gr<font style="color: rgb(45, 45, 56);">a</font>nt and h<font style="color: rgb(45, 45, 56);">ere</font>by grants <font style="color: rgb(45, 45, 56);">to </font>GSK the following licenses:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7bc95113690945a2b509ce409bc7e6c6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>a<font style="color: rgb(45, 45, 56);">n </font>exclusive<font style="color: rgb(45, 45, 56);">&#160;</font>licen<font style="color: rgb(45, 45, 56);">s</font>e under Immunocore<font style="color: rgb(45, 45, 56);"> righ</font>ts in the
                Immunocore Foregrou<font style="color: rgb(45, 45, 56);">n</font>d and <font style="color: rgb(45, 45, 56);">Jo</font>int Foreground to make<font style="color: rgb(68, 68, 84);">, </font>have made, import, use, offer fo<font style="color: rgb(45, 45, 56);">r </font>sale<font style="color: rgb(45, 45, 56);">, </font>an<font style="color: rgb(45, 45, 56);">d </font>sell Lic<font style="color: rgb(45, 45, 56);">e</font>nsed Products arising from the applicable
                Collaboration<font style="color: rgb(45, 45, 56);">&#160;</font>Program <font style="color: rgb(45, 45, 56);">in </font>the<font style="color: rgb(45, 45, 56);">&#160;</font>Field i<font style="color: rgb(45, 45, 56);">n </font>th<font style="color: rgb(45, 45, 56);">e </font>Territory. Each such license s<font style="color: rgb(45, 45, 56);">hall </font>continue for the<font style="color: rgb(45, 45, 56);">&#160;</font>applica<font style="color: rgb(45, 45, 56);">ble </font>Royalty






                Term, unless earlier<font style="color: rgb(45, 45, 56);"> t</font>e<font style="color: rgb(45, 45, 56);">rm</font>inat<font style="color: rgb(45, 45, 56);">ed </font>pursuan<font style="color: rgb(45, 45, 56);">t </font>t<font style="color: rgb(45, 45, 56);">o </font>Article <font style="color: rgb(45, 45, 56);">1</font>3;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z13f688199f4e4f2c99dfc6b13e6ee844" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 99pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right; color: #080808;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">an e</font><font style="color: #2D2D38;">xclu</font><font style="color: #080808;">sive li</font><font style="color: #2D2D38;">cen</font><font style="color: #080808;">se under the Immunocore Background and
                  Platform Rights</font><font style="color: #2D2D38;">, </font><font style="color: #080808;">in e</font><font style="color: #2D2D38;">a</font><font style="color: #080808;">c</font><font style="color: #2D2D38;">h cas</font><font style="color: #080808;">e, so</font><font style="color: #2D2D38;">le</font><font style="color: #080808;">l</font><font style="color: #2D2D38;">y </font><font style="color: #080808;">to the extent it is necessary for GSK to make, have </font><font style="color: #2D2D38;">m</font><font style="color: #080808;">ade, imp</font><font style="color: #2D2D38;">ort</font><font style="color: #080808;">, use, offer for sale, and sell Licensed Products arising from t</font><font style="color: #2D2D38;">he </font><font style="color: #080808;">applicable Collaboration Program in the Fi</font><font style="color: #2D2D38;">el</font><font style="color: #080808;">d in the</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">Territory. Each such license shall continue until the</font><font style="color: #2D2D38;"> e</font><font style="color: #080808;">arlier </font><font style="color: #2D2D38;">t</font><font style="color: #080808;">o
                </font><font style="color: #2D2D38;">o</font><font style="color: #080808;">ccur of (i) the date on which such license is no longer necessary for GSK to make, have made, import, use, offer for sale, an</font><font style="color: #2D2D38;">d </font><font style="color: #080808;">sell such Licensed Products in the Field in the Territory; (ii) the expiration of the applicable Royalty Term; or (iii) termination of the</font><font style="color: #2D2D38;"> a</font><font style="color: #080808;">p</font><font style="color: #2D2D38;">pl</font><font style="color: #080808;">icable license or the Agreement in its entirety pursuant to Article 1</font><font style="color: #2D2D38;">3</font><font style="color: #080808;">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0fd3628f038746c4b576042fa828a4f1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each licence granted in accordance with Section 6.7 is separate and independent from any other exclusive licence granted in accordance with this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zbb67218838bf4af09502e751b8eb1aa6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The licences under Section 6.7 include the right to sub-licence with the prior written consent of Immunocore, such consent not to be unreasonably withheld, ex<font style="color: rgb(45, 45, 56);">c</font>ept, that consent shall not be
                required <font style="color: rgb(45, 45, 56);">a</font>s follows:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za74c6709bf6145bda67bcdb73f70a4e4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK may use contract research organizations to perform portions of the <font style="color: rgb(8, 8, 8);">development of the Licensed Products to the extent consistent with its normal business practices and in all cases consistent with
                  Section 3.8 above;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">24</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="zfa52f8c92ea044ad89adea201f11ee59" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK may engage reasonably qualified third parties to assist with the distribution and sales of the Licensed Products to the extent such arrangements are commercially reasonable throughout the Territ<font style="color: rgb(45, 45, 56);">or</font>y
                and in all cases consistent with Section 3.8 above;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za4219b75df77442f837a44fa5077fdf1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK may use Third Parties, including contract manufacturers,<font style="color: rgb(45, 45, 56);">&#160;</font>t<font style="color: rgb(45, 45, 56);">o </font>manufacture, label and package the Licensed Products provided such u<font style="color: rgb(45, 45, 56);">s</font>e is in all cases consistent with Section 3.8 above;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf0d9878bfaf04bf99d936e69b8878626" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.8.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK may sub-license any of its rig<font style="color: rgb(45, 45, 56);">ht</font>s <font style="color: rgb(45, 45, 56);">t</font>o Affiliates.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 54pt;">GSK shall notify Immunocore within [***] of <font style="color: rgb(45, 45, 56);">e</font>x<font style="color: rgb(45, 45, 56);">e</font>cution of any sub-licence agreement and, except with res<font style="color: rgb(45, 45, 56);">p</font>ect to s<font style="color: rgb(45, 45, 56);">ub </font>lic<font style="color: rgb(45, 45, 56);">e</font>nses <font style="color: rgb(45, 45, 56);">t</font>o Affiliates,<font style="color: rgb(45, 45, 56);"> s</font>hall provide a redacted copy (in which commerc<font style="color: rgb(45, 45, 56);">ial </font>terms o<font style="color: rgb(45, 45, 56);">r </font>terms n<font style="color: rgb(45, 45, 56);">o</font>t relev<font style="color: rgb(45, 45, 56);">a</font>nt <font style="color: rgb(45, 45, 56);">t</font>o compliance with the terms of this Agreement sh<font style="color: rgb(45, 45, 56);">al</font>l be r<font style="color: rgb(45, 45, 56);">e</font>da<font style="color: rgb(45, 45, 56);">c</font>ted) <font style="color: rgb(45, 45, 56);">o</font>f <font style="color: rgb(45, 45, 56);">s</font>uch su<font style="color: rgb(45, 45, 56);">b</font>-li<font style="color: rgb(45, 45, 56);">ce</font>nce agreement to
        Immunocore. Where any Affiliate<font style="color: rgb(45, 45, 56);">&#160;</font>is s<font style="color: rgb(45, 45, 56);">u</font>b-licensed <font style="color: rgb(45, 45, 56);">by G</font>SK, <font style="color: rgb(45, 45, 56);">G</font>S<font style="color: rgb(45, 45, 56);">K </font>shall procure that such Affiliate agrees to comply wit<font style="color: rgb(45, 45, 56);">h </font>the a<font style="color: rgb(45, 45, 56);">ppl</font>ic<font style="color: rgb(45, 45, 56);">ab</font>l<font style="color: rgb(45, 45, 56);">e </font>terms <font style="color: rgb(45, 45, 56);">of </font>thi<font style="color: rgb(45, 45, 56);">s </font>Agreement including Sections 6.8, 6.9, 13.6.5 a<font style="color: rgb(45, 45, 56);">nd </font>13.8






        <font style="color: rgb(45, 45, 56);">a</font>nd Article<font style="color: rgb(45, 45, 56);">s </font>7, 9, 10, <font style="color: rgb(45, 45, 56);">a</font>nd 14. <font style="color: rgb(45, 45, 56);">GSK </font>shall remain responsible for
        any act<font style="color: rgb(45, 45, 56);">s </font>or <font style="color: rgb(45, 45, 56);">o</font>miss<font style="color: rgb(45, 45, 56);">ions </font>of its s<font style="color: rgb(45, 45, 56);">u</font>b<font style="color: rgb(45, 45, 56);">li</font>cen<font style="color: rgb(45, 45, 56);">s</font>ees and shall be liable for any breach of the terms of <font style="color: rgb(45, 45, 56);">thi</font>s Agreement as a resu<font style="color: rgb(45, 45, 56);">l</font>t <font style="color: rgb(45, 45, 56);">o</font>f any a<font style="color: rgb(45, 45, 56);">c</font>t <font style="color: rgb(45, 45, 56);">or </font>omission by its sublicensees.</div>
      <div>&#160;</div>
      <table id="zdbf1849eadad4508bf38db52ddfd7c94" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK will include binding provisions in <font style="color: rgb(45, 45, 56);">a</font>ll sub-<font style="color: rgb(45, 45, 56);">li</font>c<font style="color: rgb(45, 45, 56);">en</font>ses <font style="color: rgb(45, 45, 56);">gr</font>a<font style="color: rgb(45, 45, 56);">n</font>ted in accordance with Section 6.8 pro<font style="color: rgb(45, 45, 56);">vi</font>di<font style="color: rgb(45, 45, 56);">ng t</font>hat i<font style="color: rgb(45, 45, 56);">f </font>th<font style="color: rgb(45, 45, 56);">e </font>subl<font style="color: rgb(45, 45, 56);">ic</font>ensee or any of subl<font style="color: rgb(45, 45, 56);">ic</font>e<font style="color: rgb(45, 45, 56);">nse</font>es&#8217; Affiliates undertakes a
                Patent Cha<font style="color: rgb(45, 45, 56);">ll</font>e<font style="color: rgb(45, 45, 56);">ng</font>e with <font style="color: rgb(45, 45, 56);">re</font>spect <font style="color: rgb(45, 45, 56);">to </font>any p<font style="color: rgb(45, 45, 56);">at</font>e<font style="color: rgb(45, 45, 56);">nt </font>or pa<font style="color: rgb(45, 45, 56);">ten</font>t application to which the sublicensee <font style="color: rgb(45, 45, 56);">i</font>s granted a <font style="color: rgb(45, 45, 56);">lic</font>ense<font style="color: rgb(45, 45, 56);">, </font>G<font style="color: rgb(45, 45, 56);">S</font>K will b<font style="color: rgb(45, 45, 56);">e </font>permitt<font style="color: rgb(45, 45, 56);">e</font>d, subject to Applicable Laws, to terminate s<font style="color: rgb(45, 45, 56);">uc</font>h <font style="color: rgb(45, 45, 56);">s</font>ublic<font style="color: rgb(45, 45, 56);">e</font>n<font style="color: rgb(45, 45, 56);">se </font>agr<font style="color: rgb(45, 45, 56);">ee</font>m<font style="color: rgb(45, 45, 56);">e</font>nt. <font style="color: rgb(45, 45, 56);">If a su</font>blicens<font style="color: rgb(45, 45, 56);">ee o</font>f GSK or
                any Affiliate of such sublicen<font style="color: rgb(45, 45, 56);">se</font>e <font style="color: rgb(45, 45, 56);">u</font>ndert<font style="color: rgb(45, 45, 56);">a</font>k<font style="color: rgb(45, 45, 56);">e</font>s a Patent
                Challe<font style="color: rgb(45, 45, 56);">ng</font>e of any <font style="color: rgb(45, 45, 56);">suc</font>h patent or patent application, then u<font style="color: rgb(45, 45, 56);">p</font>o<font style="color: rgb(45, 45, 56);">n re</font>ceipt






                of notice <font style="color: rgb(45, 45, 56);">fro</font>m Immunocore of <font style="color: rgb(45, 45, 56);">s</font>uc<font style="color: rgb(45, 45, 56);">h </font>Patent Challenge, GSK will either caus<font style="color: rgb(45, 45, 56);">e </font>the<font style="color: rgb(45, 45, 56);">&#160;</font>subli<font style="color: rgb(45, 45, 56);">ce</font>ns<font style="color: rgb(45, 45, 56);">e</font>e t<font style="color: rgb(45, 45, 56);">o c</font>e<font style="color: rgb(45, 45, 56);">as</font>e involvement in suc<font style="color: rgb(45, 45, 56);">h </font>Patent Challenge within [***] o<font style="color: rgb(45, 45, 56);">f </font>recei<font style="color: rgb(45, 45, 56);">p</font>t
                <font style="color: rgb(45, 45, 56);">o</font>f not<font style="color: rgb(45, 45, 56);">ice</font><font style="color: rgb(75, 77, 91);">, </font><font style="color: rgb(45, 45, 56);">t</font>ermi<font style="color: rgb(45, 45, 56);">n</font><font style="color: rgb(75, 77, 91);">a</font><font style="color: rgb(45, 45, 56);">t</font>e the appli<font style="color: rgb(45, 45, 56);">c</font>able sublicense agreement within [***]<font style="color: rgb(8, 8, 8);">&#160;</font><font style="color: rgb(45, 45, 56);">of </font><font style="color: rgb(8, 8, 8);">r</font><font style="color: rgb(45, 45, 56);">ec</font><font style="color: rgb(8, 8, 8);">eipt o</font><font style="color: rgb(45, 45, 56);">f </font><font style="color: rgb(8, 8, 8);">notice i</font><font style="color: rgb(45, 45, 56);">f p</font><font style="color: rgb(8, 8, 8);">e</font><font style="color: rgb(45, 45, 56);">r</font><font style="color: rgb(8, 8, 8);">mitte</font><font style="color: rgb(45, 45, 56);">d b</font><font style="color: rgb(8, 8, 8);">y </font><font style="color: rgb(45, 45, 56);">A</font><font style="color: rgb(8, 8, 8);">pplicable Laws, or Section 13.8 shall appl</font><font style="color: rgb(45, 45, 56);">y </font><font style="color: rgb(8, 8, 8);">with respect to s</font><font style="color: rgb(45, 45, 56);">u</font><font style="color: rgb(8, 8, 8);">ch pat</font><font style="color: rgb(45, 45, 56);">ent </font><font style="color: rgb(8, 8, 8);">or pate</font><font style="color: rgb(45, 45, 56);">n</font><font style="color: rgb(8, 8, 8);">t </font><font style="color: rgb(45, 45, 56);">ap</font><font style="color: rgb(8, 8, 8);">plication on expiry of
                  [***] from receipt of notice.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5c14d5604bf940049104fbcfa0a72572" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Post-Option Ex</u><font style="color: #2D2D38;"><u>erci</u></font><u>se Resp</u><font style="color: #2D2D38;"><u>o</u></font><u>n</u><font style="color: #2D2D38;"><u>s</u></font><u>ibilities</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z94f4ec16955a4236a10071b1964ea7b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.10.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>F<font style="color: rgb(45, 45, 56);">o</font>ll<font style="color: rgb(45, 45, 56);">o</font>wing commencement of each licence as provided in Section 6.7, GSK<font style="color: rgb(45, 45, 56);"> s</font>hall use all Commercially
                Reasonable Efforts to further develop, manufacture<font style="color: rgb(45, 45, 56);">, s</font>ell and <font style="color: rgb(45, 45, 56);">s</font>u<font style="color: rgb(45, 45, 56);">pp</font>ly Licensed Products within the
                Territory with a view to obtaining Regulatory<font style="color: rgb(45, 45, 56);">&#160;</font>Approval for at least one Licensed Product from each Collaboration Program as soon as reasonably possible. GSK shall comply with all Applicable Laws
                including requirements of GMP and GCP in relation to any manufacture<font style="color: rgb(45, 45, 56);">,</font> development, sale or supply of Licensed Products. GSK shall be solely responsible for all activities relating to the
                manufacture, development, sale and supply of Licensed Products and shall have sole and final decision-making authority with respect thereto.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3774560af89a4c63b43ae90c40cc5d32" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">6.10.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK will submit reports to Immunocore on a [***], commencing [***] after GSK exercises the first Initial Program Option or Collaboration Program Option, as applicable, to update Immunocore, in reasonable detail, <font style="color: rgb(7, 7, 8);">on the current progress and status of the conduct of material development activities with respect to the Licensed Products. All such reports will be considered Confidential Information of GSK. Nothing in this Section 6.10.2
                  will obligate GSK to disclose confidential information to Immunocore regarding a proprietary compound or product of GSK or </font><font style="color: rgb(47, 49, 59);">a </font><font style="color: rgb(7, 7, 8);">Third</font><font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(7, 7, 8);">Party. Immunocore may ask clarification questions following receipt of rep</font><font style="color: rgb(47, 49, 59);">or</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(7, 7, 8);">s and GSK (</font><font style="color: rgb(28, 28, 33);">via</font><font style="color: rgb(47, 49, 59);">&#160;</font><font style="color: rgb(7, 7, 8);">its Alliance Manager or otherwise) will
                  provide answers </font><font style="color: rgb(28, 28, 33);">w</font><font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">th</font><font style="color: rgb(7, 7, 8);">in reasonabl</font><font style="color: rgb(47, 49, 59);">e t</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(7, 7, 8);">me</font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(7, 7, 8);">cales to such clarification questions.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">25</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z8f3939fd6af04ab7b96614722ef1aac9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Within a period of [***] after GSK <font style="color: rgb(28, 28, 33);">exercises</font> an Initi<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 49, 59);">l </font>Program Option or Collaboration Program
                Option, Immunoco<font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(47, 49, 59);">e sha</font>ll <font style="color: rgb(47, 49, 59);">tr</font>ansfer and <font style="color: rgb(47, 49, 59);">d</font><font style="color: rgb(28, 28, 33);">e</font>liver <font style="color: rgb(47, 49, 59);">(or </font>provide access) to GSK all ResuIts arising out <font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(47, 49, 59);">f </font><font style="color: rgb(28, 28, 33);">suc</font><font style="color: rgb(47, 49, 59);">h </font>Collaboration <font style="color: rgb(28, 28, 33);">Pro</font>gram <font style="color: rgb(47, 49, 59);">to the</font><font style="color: rgb(28, 28, 33);">&#160;</font>extent GSK does not already have access to suc<font style="color: rgb(47, 49, 59);">h </font>R<font style="color: rgb(47, 49, 59);">e</font>sult<font style="color: rgb(28, 28, 33);">s </font><font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">nd </font>to t<font style="color: rgb(28, 28, 33);">h</font><font style="color: rgb(47, 49, 59);">e </font>ex<font style="color: rgb(47, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">e</font>nt <font style="color: rgb(47, 49, 59);">s</font><font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(47, 49, 59);">c</font>h <font style="color: rgb(47, 49, 59);">R</font>esults are in a
                tangible form<font style="color: rgb(28, 28, 33);">, </font>together with all <font style="color: rgb(28, 28, 33);">m</font>a<font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 49, 59);">e</font>rials <font style="color: rgb(28, 28, 33);">se</font><font style="color: rgb(47, 49, 59);">t </font><font style="color: rgb(28, 28, 33);">fo</font>rt<font style="color: rgb(28, 28, 33);">h o</font><font style="color: rgb(47, 49, 59);">n S</font><font style="color: rgb(28, 28, 33);">c</font>hedul<font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(47, 49, 59);">7 </font>in a manner that allows for the orderly transitio<font style="color: rgb(47, 49, 59);">n </font>o<font style="color: rgb(47, 49, 59);">f Lic</font>en<font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(47, 49, 59);">e</font>d <font style="color: rgb(47, 49, 59);">Pr</font>odu<font style="color: rgb(47, 49, 59);">cts </font><font style="color: rgb(28, 28, 33);">to </font>GSK<font style="color: rgb(47, 49, 59);">. </font>Immunocore shall use Commercially Reasonable Efforts<font style="color: rgb(47, 49, 59);">&#160;</font>to <font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 49, 59);">ra</font>n<font style="color: rgb(28, 28, 33);">s</font>fer t<font style="color: rgb(47, 49, 59);">he </font>Results <font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">nd
                </font>materials on Schedule 7 in a format that is <font style="color: rgb(28, 28, 33);">com</font><font style="color: rgb(47, 49, 59);">p</font>liant w<font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 49, 59);">h </font>Applicable<font style="color: rgb(28, 28, 33);">&#160;</font>Laws<font style="color: rgb(47, 49, 59);">; </font>p<font style="color: rgb(47, 49, 59);">ro</font>v<font style="color: rgb(28, 28, 33);">i</font>ded,






                that if such format is not compliant with <font style="color: rgb(28, 28, 33);">App</font><font style="color: rgb(47, 49, 59);">lic</font><font style="color: rgb(28, 28, 33);">a</font>ble L<font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">w</font><font style="color: rgb(47, 49, 59);">s</font>, the<font style="color: rgb(47, 49, 59);">n </font><font style="color: rgb(28, 28, 33);">GS</font>K shall in<font style="color: rgb(47, 49, 59);">fo</font><font style="color: rgb(28, 28, 33);">r</font>m Immunocore of such insufficiency and Immunocore shall use Commercially<font style="color: rgb(47, 49, 59);">&#160;</font>R<font style="color: rgb(28, 28, 33);">e</font>asonable Efforts to correct such
                insufficiency re<font style="color: rgb(28, 28, 33);">as</font>onably <font style="color: rgb(47, 49, 59);">promptly</font> there<font style="color: rgb(47, 49, 59);">a</font>ft<font style="color: rgb(28, 28, 33);">e</font>r. Th<font style="color: rgb(28, 28, 33);">e </font>details of any additional materials or <font style="color: rgb(47, 49, 59);">documentation</font> tha<font style="color: rgb(47, 49, 59);">t </font><font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 49, 59);">ay </font>be reaso<font style="color: rgb(28, 28, 33);">na</font>bly re<font style="color: rgb(47, 49, 59);">qui</font><font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(47, 49, 59);">e</font>d
                by GSK to further develop, manufacture, re<font style="color: rgb(47, 49, 59);">g</font>i<font style="color: rgb(47, 49, 59);">ster </font>or s<font style="color: rgb(47, 49, 59);">e</font>l<font style="color: rgb(28, 28, 33);">l Lice</font>ns<font style="color: rgb(28, 28, 33);">ed Products</font><font style="color: rgb(47, 49, 59);">, </font>shall be determined by the JSC including a<font style="color: rgb(28, 28, 33);">s relevant</font><font style="color: rgb(47, 49, 59);">&#160;</font>the






                <font style="color: rgb(28, 28, 33);">timing</font> of <font style="color: rgb(47, 49, 59);">provision</font> of <font style="color: rgb(28, 28, 33);">a</font>n<font style="color: rgb(47, 49, 59);">y </font>su<font style="color: rgb(28, 28, 33);">c</font>h additional documentation. Th<font style="color: rgb(47, 49, 59);">e </font>JSC sha<font style="color: rgb(28, 28, 33);">ll </font>a<font style="color: rgb(47, 49, 59);">l</font><font style="color: rgb(28, 28, 33);">s</font>o
                <font style="color: rgb(28, 28, 33);">determine</font> the amount <font style="color: rgb(28, 28, 33);">of </font>r<font style="color: rgb(28, 28, 33);">ea</font>sonable technical assistance and training initially<font style="color: rgb(28, 28, 33);">&#160;</font>requ<font style="color: rgb(47, 49, 59);">ir</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 49, 59);">d </font>from Im<font style="color: rgb(47, 49, 59);">mu</font>nocore to <font style="color: rgb(47, 49, 59);">G</font><font style="color: rgb(28, 28, 33);">S</font>K<font style="color: rgb(28, 28, 33);">&#8217;</font>s personnel with respect to Res<font style="color: rgb(28, 28, 33);">u</font>lts and the <font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 49, 59);">at</font>erial<font style="color: rgb(47, 49, 59);">s </font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(47, 49, 59);">et </font>forth






                i<font style="color: rgb(28, 28, 33);">n Schedule </font><font style="color: rgb(47, 49, 59);">7 to </font>enable GSK to comply with its dilige<font style="color: rgb(47, 49, 59);">n</font>ce <font style="color: rgb(47, 49, 59);">obl</font>igati<font style="color: rgb(47, 49, 59);">o</font>ns <font style="color: rgb(28, 28, 33);">u</font>nde<font style="color: rgb(47, 49, 59);">r </font><font style="color: rgb(28, 28, 33);">Section</font>&#160;<font style="color: rgb(28, 28, 33);">6</font><font style="color: rgb(47, 49, 59);">.</font>10.1. Suc<font style="color: rgb(28, 28, 33);">h </font><font style="color: rgb(47, 49, 59);">initial </font>assistance and training shall be pro<font style="color: rgb(47, 49, 59);">v</font>id<font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(28, 28, 33);">d </font>as a<font style="color: rgb(47, 49, 59);">n</font><font style="color: rgb(28, 28, 33);">d w</font>hen <font style="color: rgb(47, 49, 59);">reas</font><font style="color: rgb(28, 28, 33);">o</font>nably <font style="color: rgb(28, 28, 33);">r</font><font style="color: rgb(47, 49, 59);">e</font>q<font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(47, 49, 59);">i</font>red
                and <font style="color: rgb(47, 49, 59);">determine</font>d by the JSC and in any eve<font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(47, 49, 59);">t </font>s<font style="color: rgb(28, 28, 33);">u</font>bject <font style="color: rgb(28, 28, 33);">t</font>o Immunocore h<font style="color: rgb(47, 49, 59);">a</font>v<font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">ng </font>avai<font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 49, 59);">a</font>ble resources to provide such technic<font style="color: rgb(28, 28, 33);">a</font>l <font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">ss</font><font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 33);">s</font>tanc<font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(28, 28, 33);">an</font>d tr<font style="color: rgb(47, 49, 59);">ai</font>ning. <font style="color: rgb(28, 28, 33);">T</font><font style="color: rgb(47, 49, 59);">he</font>r<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">f</font>ter, G<font style="color: rgb(47, 49, 59);">S</font><font style="color: rgb(28, 28, 33);">K </font>may request up to [***] meeti<font style="color: rgb(47, 49, 59);">ng</font>s <font style="color: rgb(47, 49, 59);">p</font><font style="color: rgb(28, 28, 33);">e</font>r ye<font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 33);">r (</font>whi<font style="color: rgb(28, 28, 33);">c</font>h <font style="color: rgb(47, 49, 59);">m</font>ay be h<font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 49, 59);">ld b</font>y telec<font style="color: rgb(47, 49, 59);">onfe</font>rence or video conference) and [***]<font style="color: rgb(28, 28, 33);"> w</font><font style="color: rgb(47, 49, 59);">ith [***] </font>documentation <font style="color: rgb(47, 49, 59);">s</font><font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(47, 49, 59);">p</font>porti<font style="color: rgb(28, 28, 33);">ng </font><font style="color: rgb(47, 49, 59);">t</font>he <font style="color: rgb(28, 28, 33);">a</font>mount [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0129fe6a33ff478ba5d955c708660142" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On a Co<font style="color: rgb(47, 49, 59);">lla</font>b<font style="color: rgb(47, 49, 59);">o</font>ration <font style="color: rgb(47, 49, 59);">P</font><font style="color: rgb(28, 28, 33);">ro</font><font style="color: rgb(47, 49, 59);">gr</font>am-by-Collaboration Program basis<font style="color: rgb(28, 28, 33);">, </font>c<font style="color: rgb(28, 28, 33);">o</font>mmencing on the date such <font style="color: rgb(47, 49, 59);">Col</font><font style="color: rgb(28, 28, 33);">la</font>boration Program commences and expiring upon the earlier of term<font style="color: rgb(28, 28, 33);">i</font>nation of <font style="color: rgb(47, 49, 59);">t</font><font style="color: rgb(28, 28, 33);">he </font>Collaboration






                Program,<font style="color: rgb(28, 28, 33);">&#160;</font>Completion of the Collaboration Program,<font style="color: rgb(47, 49, 59);">&#160;</font>or termination o<font style="color: rgb(28, 28, 33);">f </font><font style="color: rgb(47, 49, 59);">this </font>Agreement, GSK hereby grants to Immunocore a non-exclusive,<font style="color: rgb(47, 49, 59);"> ro</font><font style="color: rgb(28, 28, 33);">y</font><font style="color: rgb(47, 49, 59);">a</font>lty-free <font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(75, 77, 84);">i</font><font style="color: rgb(47, 49, 59);">cen</font>s<font style="color: rgb(28, 28, 33);">e </font>in the Territory, with th<font style="color: rgb(28, 28, 33);">e </font>right t<font style="color: rgb(28, 28, 33);">o </font>grant <font style="color: rgb(28, 28, 33);">s</font>ublic<font style="color: rgb(28, 28, 33);">e</font>n<font style="color: rgb(28, 28, 33);">ses </font>(<font style="color: rgb(28, 28, 33);">s</font>ubj<font style="color: rgb(28, 28, 33);">ec</font>t t<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(47, 49, 59);"> Section</font> 3.7), under (a) GSK Background that GSK
                determines in its sole discretion is<font style="color: rgb(47, 49, 59);"> n</font>eces<font style="color: rgb(28, 28, 33);">s</font>ary for th<font style="color: rgb(28, 28, 33);">e </font>condu<font style="color: rgb(28, 28, 33);">c</font>t
                of the Collaboration Program, and (b) GSK Foreground and<font style="color: rgb(47, 49, 59);"> G</font>SK<font style="color: rgb(28, 28, 33);">&#8217;</font>s interest in the Joint Foreground, in each case of (a) and (b) solely to permit
                Immunocore to conduct its activities with respect to such Collaboration Program as contemplated und<font style="color: rgb(28, 28, 33);">e</font>r th<font style="color: rgb(28, 28, 33);">e </font>applicabl<font style="color: rgb(28, 28, 33);">e </font>Res<font style="color: rgb(28, 28, 33);">e</font>arch Plans in accordance<font style="color: rgb(28, 28, 33);">&#160;</font>with the t<font style="color: rgb(28, 28, 33);">e</font>rm<font style="color: rgb(28, 28, 33);">s </font>of






                this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zb16dbd75df7449dca66d13c62237ad4b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.13</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">In addition to the licenc</font><font style="color: #1C1C21;">e </font><font style="color: #070708;">under Section 6.12</font><font style="color: #1C1C21;">, </font><font style="color: #070708;">GSK hereby
                  grants to Immunocor</font><font style="color: #1C1C21;">e </font><font style="color: #070708;">a non-exclusive, worldwide, fully paid-up license under its rights in (i) GSK&#8217;s interest in Joint Foreground and (ii) the GSK Foreground,
                  solely to the extent such GSK Foreground or Joint Foreground [***] (the GS</font><font style="color: #2F2F3A;">K </font><font style="color: #070708;">Foreground included in this license grant is referred to as &#8220;</font><font style="font-weight: bold; color: #070708;">Licensed GSK Foregrou</font><font style="font-weight: bold; color: #2F2F3A;">n</font><font style="font-weight: bold; color: #070708;">d</font><font style="color: #070708;">&#8221;). Such lic</font><font style="color: #2F2F3A;">e</font><font style="color: #1C1C1F;">nse </font><font style="color: #070708;">shall be freely sublicenseable through multiple tiers by Immunocore without </font><font style="color: #1C1C1F;">the </font><font style="color: #070708;">need to [***] </font><font style="font-weight: bold; color: #070708;">Agreement</font><font style="color: #070708;">&#8221;); [***] (i) the date on which such license is </font><font style="color: #2F2F3A;">n</font><font style="color: #1C1C1F;">o </font><font style="color: #070708;">longer </font><font style="color: #2F2F3A;">n</font><font style="color: #1C1C1F;">ec</font><font style="color: #2F2F3A;">es</font><font style="color: #1C1C1F;">sary for</font><font style="color: #2F2F3A;"> Immunocore</font><font style="color: #070708;"> or its Third Party sublicensees to make, hav</font><font style="color: #2F2F3A;">e mad</font><font style="color: #070708;">e, imp</font><font style="color: #2F2F3A;">o</font><font style="color: #070708;">rt, </font><font style="color: #1C1C1F;">u</font><font style="color: #2F2F3A;">se, </font><font style="color: #070708;">offer </font><font style="color: #2F2F3A;">fo</font><font style="color: #070708;">r sale,
                  and sell Compounds other than License</font><font style="color: #2F2F3A;">d </font><font style="color: #070708;">Products;</font><font style="color: #2F2F3A;">&#160;</font><font style="color: #070708;">o</font><font style="color: #2F2F3A;">r
                </font><font style="color: #070708;">(ii) </font><font style="color: #1C1C1F;">in </font><font style="color: #070708;">the cas</font><font style="color: #2F2F3A;">e </font><font style="color: #070708;">of Third Party sublicensees, the
                  date of termin</font><font style="color: #2F2F3A;">at</font><font style="color: #070708;">ion of </font><font style="color: #1C1C1F;">t</font><font style="color: #2F2F3A;">h</font><font style="color: #1C1C1F;">e </font><font style="color: #070708;">app</font><font style="color: #2F2F3A;">l</font><font style="color: #070708;">ic</font><font style="color: #2F2F3A;">a</font><font style="color: #1C1C1F;">ble </font><font style="color: #070708;">su</font><font style="color: #2F2F3A;">b</font><font style="color: #070708;">lic</font><font style="color: #2F2F3A;">e</font><font style="color: #070708;">nse or agreement granting such sublicense to su</font><font style="color: #2F2F3A;">c</font><font style="color: #1C1C1F;">h </font><font style="color: #2F2F3A;">Th</font><font style="color: #070708;">ird Party.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6227218a67894578b4a3c7eacba1e568" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.14</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where Immunocore beco<font style="color: rgb(47, 47, 58);">m</font>es aware <font style="color: rgb(47, 47, 58);">of </font>a<font style="color: rgb(47, 47, 58);">ny </font>Licensed GSK Foreground which is [***] legal department <font style="color: rgb(47, 47, 58);">an</font>d only a<font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">cesse</font><font style="color: rgb(47, 47, 58);">d b</font>y such <font style="color: rgb(28, 28, 31);">le</font><font style="color: rgb(47, 47, 58);">ga</font>l department or external legal advisors. As s<font style="color: rgb(47, 47, 58);">o</font>on as re<font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(47, 47, 58);">on</font><font style="color: rgb(28, 28, 31);">ably p</font><font style="color: rgb(47, 47, 58);">os</font><font style="color: rgb(28, 28, 31);">sible </font>af<font style="color: rgb(47, 47, 58);">t</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 47, 58);">r </font>the d<font style="color: rgb(47, 47, 58);">a</font>t<font style="color: rgb(47, 47, 58);">e </font><font style="color: rgb(28, 28, 31);">on </font>which






                Immunocore [***] to Im<font style="color: rgb(47, 47, 58);">m</font>u<font style="color: rgb(47, 47, 58);">no</font>core <font style="color: rgb(28, 28, 31);">within </font>a <font style="color: rgb(47, 47, 58);">p</font><font style="color: rgb(28, 28, 31);">eriod </font>of [***] stating whether it [***] has agreed t<font style="color: rgb(47, 47, 58);">o k</font>ee<font style="color: rgb(47, 47, 58);">p </font>the notification confidential and that such
                notification will be held by the Third <font style="color: rgb(47, 47, 58);">Party&#8217;</font>s leg<font style="color: rgb(47, 47, 58);">a</font>l <font style="color: rgb(47, 47, 58);">department</font> and only accessed by such legal
                department or external <font style="color: rgb(47, 47, 58);">le</font><font style="color: rgb(28, 28, 31);">gal </font>advisors<font style="color: rgb(28, 28, 31);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0768898c9aae497aab6b60c0e46262a9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Intellect</font><font style="font-weight: bold; color: #2F2F3A;">u</font><font style="font-weight: bold; color: #1C1C1F;">al </font><font style="font-weight: bold;">Property Ownership and Prosecution</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc4a76a3d841f4439a5d20a80f347715c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immu<font style="color: rgb(47, 47, 58);">n</font>o<font style="color: rgb(47, 47, 58);">c</font>ore sh<font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(28, 28, 31);">ll </font><font style="color: rgb(47, 47, 58);">re</font>tain






                all of its right, title and interest in and to the Immunocore Ba<font style="color: rgb(47, 47, 58);">ck</font><font style="color: rgb(28, 28, 31);">ground </font>an<font style="color: rgb(47, 47, 58);">d </font>P<font style="color: rgb(47, 47, 58);">la</font>tform Rights, and GSK shall retain all of its rights, title and interest i<font style="color: rgb(47, 47, 58);">n a</font><font style="color: rgb(28, 28, 31);">nd </font>to the GSK Background, except to the
                extent that any such rights are expressly<font style="color: rgb(47, 47, 58);"> lice</font><font style="color: rgb(28, 28, 31);">nsed </font>by one Party to the other Party under this Agreement. Immunocore&#8217;s Patent<font style="color: rgb(47, 47, 58);"> Li</font><font style="color: rgb(28, 28, 31);">a</font><font style="color: rgb(47, 47, 58);">is</font><font style="color: rgb(28, 28, 31);">on shall </font>promptly disclose to GSK&#8217;s</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">26</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">Patent Liaison, any Immunocore Foreground made by it solely (or jointly with <font style="color: rgb(28, 28, 31);">a </font>Third Party) or by <font style="color: rgb(28, 28, 31);">a </font>Third






        Party <font style="color: rgb(28, 28, 31);">on </font>its behalf. Immunocore <font style="color: rgb(28, 28, 31);">shall </font>be the sole owner of Immunocore Foreground <font style="color: rgb(28, 28, 31);">and </font>shall retain all of
        its right, title and interest thereto, <font style="color: rgb(28, 28, 31);">except </font>to the extent that <font style="color: rgb(28, 28, 31);">any </font>rights <font style="color: rgb(28, 28, 31);">or </font>li<font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">enses </font>are expressly granted hereunder by Immunocore to GSK. GSK shall be the sole owner of GSK Foreground and shall retain <font style="color: rgb(28, 28, 31);">all </font>of






        its right, title and interest thereto, except to the <font style="color: rgb(8, 8, 8);">extent that any rights or licenses are expressly granted hereunder by GSK to Immunocore.</font></div>
      <div>&#160;</div>
      <table id="zf0e738de4d20498ba6e19527836b687c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Notwithstanding anything to the contrary contained herein or under Applicable Laws<font style="color: rgb(28, 28, 35);">,</font> and subject to the rights and licenses granted under S<font style="color: rgb(47, 49, 59);">ec</font>tions
                6.7, 6.12 and 6.13, the Parties hereby agree that each Party will be entitled to <font style="color: rgb(28, 28, 35);">practice</font> and su<font style="color: rgb(28, 28, 35);">blic</font>ense Joint Foreground without restriction or
                consent of the other <font style="color: rgb(47, 49, 59);">o</font>r <font style="color: rgb(28, 28, 35);">an </font>obligation to <font style="color: rgb(47, 49, 59);">ac</font><font style="color: rgb(28, 28, 35);">co</font>unt to the
                other Party, and each Party hereby waives any rig<font style="color: rgb(28, 28, 35);">h</font>t <font style="color: rgb(47, 49, 59);">i</font><font style="color: rgb(28, 28, 35);">t </font><font style="color: rgb(47, 49, 59);">m</font>ay
                have unde<font style="color: rgb(28, 28, 35);">r t</font><font style="color: rgb(47, 49, 59);">h</font><font style="color: rgb(28, 28, 35);">e </font>laws of any jurisdiction to require any such consent or accou<font style="color: rgb(47, 49, 59);">nt</font><font style="color: rgb(28, 28, 35);">i</font><font style="color: rgb(47, 49, 59);">n</font><font style="color: rgb(28, 28, 35);">g</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z584ccb1c304e4149bc5b97f59c11fab7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Prosecution</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6431ef4e6d074eb0b9d332befeb6ce02" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Background; Platform Rights</font>. <font style="color: rgb(28, 28, 35);">Im</font>mun<font style="color: rgb(47, 49, 59);">oc</font><font style="color: rgb(28, 28, 35);">ore </font>w<font style="color: rgb(28, 28, 35);">ill r</font>et<font style="color: rgb(47, 49, 59);">a</font>in <font style="color: rgb(47, 49, 59);">control </font>of filing<font style="color: rgb(28, 28, 35);">,</font> prosecution and maintenance<font style="color: rgb(28, 28, 35);">&#160;</font>o<font style="color: rgb(28, 28, 35);">f a</font>ll Immunocore<font style="color: rgb(47, 49, 59);"> Ba</font><font style="color: rgb(28, 28, 35);">c</font>kgrou<font style="color: rgb(28, 28, 35);">n</font><font style="color: rgb(47, 49, 59);">d </font>and Platform Rights (to the extent it has <font style="color: rgb(28, 28, 35);">s</font>u<font style="color: rgb(47, 49, 59);">c</font><font style="color: rgb(28, 28, 35);">h control </font><font style="color: rgb(47, 49, 59);">in </font>the <font style="color: rgb(47, 49, 59);">c</font><font style="color: rgb(28, 28, 35);">a</font><font style="color: rgb(47, 49, 59);">s</font><font style="color: rgb(28, 28, 35);">e </font>of T<font style="color: rgb(47, 49, 59);">h</font>ird Party Platform Rights) at Immunocore&#8217;s <font style="color: rgb(47, 49, 59);">s</font>ole <font style="color: rgb(47, 49, 59);">c</font>ost <font style="color: rgb(28, 28, 35);">d</font><font style="color: rgb(47, 49, 59);">u</font><font style="color: rgb(28, 28, 35);">r</font>i<font style="color: rgb(28, 28, 35);">n</font>g the T<font style="color: rgb(28, 28, 35);">e</font><font style="color: rgb(47, 49, 59);">r</font>m. To
                the<font style="color: rgb(28, 28, 35);">&#160;</font>extent in each case that any Immuno<font style="color: rgb(28, 28, 35);">co</font>r<font style="color: rgb(47, 49, 59);">e </font>Backg<font style="color: rgb(28, 28, 35);">rou</font><font style="color: rgb(47, 49, 59);">n</font>d or <font style="color: rgb(47, 49, 59);">Platform</font>&#160;<font style="color: rgb(28, 28, 35);">Rights</font> (excluding Third Party Platform Rights) <font style="color: rgb(28, 28, 35);">Covers</font>
                an<font style="color: rgb(47, 49, 59);">y </font><font style="color: rgb(28, 28, 35);">Lic</font>ens<font style="color: rgb(28, 28, 35);">ed </font><font style="color: rgb(47, 49, 59);">Product</font>&#160;<font style="color: rgb(28, 28, 35);">or






                </font><font style="color: rgb(47, 49, 59);">No</font>minated Target or Nominated HLA, Immunocore<font style="color: rgb(47, 49, 59);">&#160;</font>sha<font style="color: rgb(28, 28, 35);">ll </font>promptly provide<font style="color: rgb(28, 28, 35);">&#160;</font>GSK via the Patent Liaisons with copie<font style="color: rgb(47, 49, 59);">s </font>of <font style="color: rgb(47, 49, 59);">a</font>ll material<font style="color: rgb(47, 49, 59);">&#160;</font>communications<font style="color: rgb(47, 49, 59);"> f</font><font style="color: rgb(28, 28, 35);">rom </font>an<font style="color: rgb(28, 28, 35);">y p</font>atent authority regarding the Immunocore <font style="color: rgb(28, 28, 35);">B</font>ackgr<font style="color: rgb(28, 28, 35);">ound a</font>nd Platform Rights<font style="color: rgb(47, 49, 59);">&#160;</font>(excluding in relation to Thir<font style="color: rgb(28, 28, 35);">d </font>Party Platform<font style="color: rgb(28, 28, 35);">&#160;</font>Rig<font style="color: rgb(47, 49, 59);">h</font><font style="color: rgb(28, 28, 35);">t</font><font style="color: rgb(47, 49, 59);">s</font><font style="color: rgb(28, 28, 35);">)</font><font style="color: rgb(47, 49, 59);">, </font><font style="color: rgb(28, 28, 35);">a</font>nd <font style="color: rgb(28, 28, 35);">d</font>rafts of a<font style="color: rgb(28, 28, 35);">n</font>y m<font style="color: rgb(28, 28, 35);">at</font>erial filings or responses in relation to
                <font style="color: rgb(47, 49, 59);">a</font>ny Immunocore Background<font style="color: rgb(28, 28, 35);"> o</font><font style="color: rgb(47, 49, 59);">r </font>Platform Rights (excluding <font style="color: rgb(28, 28, 35);">T</font>hird






                Party <font style="color: rgb(47, 49, 59);">Platform</font>&#160;<font style="color: rgb(28, 28, 35);">Rights</font>) to be m<font style="color: rgb(47, 49, 59);">a</font>de to s<font style="color: rgb(47, 49, 59);">u</font>ch patent
                authorities, where re<font style="color: rgb(28, 28, 35);">a</font><font style="color: rgb(47, 49, 59);">son</font><font style="color: rgb(28, 28, 35);">a</font>bly p<font style="color: rgb(28, 28, 35);">o</font><font style="color: rgb(47, 49, 59);">s</font>si<font style="color: rgb(28, 28, 35);">bl</font>e at <font style="color: rgb(28, 28, 35);">le</font><font style="color: rgb(47, 49, 59);">a</font><font style="color: rgb(28, 28, 35);">s</font>t [***] in <font style="color: rgb(47, 49, 59);">ad</font>vance of submitting such filings or r<font style="color: rgb(28, 28, 35);">esp</font><font style="color: rgb(47, 49, 59);">on</font>ses t<font style="color: rgb(47, 49, 59);">o </font><font style="color: rgb(28, 28, 35);">a</font>llow <font style="color: rgb(28, 28, 35);">GSK </font>the <font style="color: rgb(47, 49, 59);">opportunity</font> to review and [***] su<font style="color: rgb(47, 49, 59);">c</font><font style="color: rgb(28, 28, 35);">h </font>prosecution<font style="color: rgb(47, 49, 59);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z338457e7ce3c48eda608c856d29743de" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">F</font><font style="font-weight: bold; color: #1C1C23;">o</font><font style="font-weight: bold; color: #2F313B;">r</font><font style="font-weight: bold;">egrou</font><font style="font-weight: bold; color: #1C1C23;">n</font><font style="font-weight: bold; color: #2F313B;">d</font><font style="font-weight: bold; color: #4B4B5B;">. </font>Prior <font style="color: rgb(47, 49, 59);">t</font><font style="color: rgb(28, 28, 35);">o </font>exerc<font style="color: rgb(28, 28, 35);">ise of </font>an Initial<font style="color: rgb(47, 49, 59);">&#160;</font><font style="color: rgb(28, 28, 35);">P</font>rogram Option or Collaboration<font style="color: rgb(47, 49, 59);"> Program</font><font style="color: rgb(28, 28, 35);"> Option</font>, <font style="color: rgb(28, 28, 35);">Immunocore s</font>hall fil<font style="color: rgb(47, 49, 59);">e</font><font style="color: rgb(75, 75, 91);">, </font><font style="color: rgb(28, 28, 35);">m</font>aintain and prosecute any patent<font style="color: rgb(47, 49, 59);"> a</font>pplic<font style="color: rgb(47, 49, 59);">at</font><font style="color: rgb(28, 28, 35);">io</font><font style="color: rgb(47, 49, 59);">n</font>s
                a<font style="color: rgb(47, 49, 59);">n</font><font style="color: rgb(28, 28, 35);">d </font>patents c<font style="color: rgb(28, 28, 35);">om</font>prising <font style="color: rgb(28, 28, 35);">Immunocore</font> Foreground or Joint For<font style="color: rgb(28, 28, 35);">e</font><font style="color: rgb(47, 49, 59);">gro</font>und <font style="color: rgb(47, 49, 59);">arising</font> f<font style="color: rgb(47, 49, 59);">rom s</font>uch C<font style="color: rgb(28, 28, 35);">oll</font>aboration Program, at its sole <font style="color: rgb(28, 28, 35);">c</font>ost. Immunocore<font style="color: rgb(47, 49, 59);"> sh</font>all pro<font style="color: rgb(28, 28, 35);">m</font><font style="color: rgb(47, 49, 59);">pt</font>l<font style="color: rgb(47, 49, 59);">y </font>prov<font style="color: rgb(28, 28, 35);">i</font><font style="color: rgb(47, 49, 59);">d</font><font style="color: rgb(28, 28, 35);">e G</font>S<font style="color: rgb(28, 28, 35);">K </font>via the Patent Liaisons with copies of all <font style="color: rgb(28, 28, 35);">d</font>raft pa<font style="color: rgb(28, 28, 35);">t</font><font style="color: rgb(47, 49, 59);">e</font>nt ap<font style="color: rgb(47, 49, 59);">plic</font><font style="color: rgb(28, 28, 35);">a</font>tions, <font style="color: rgb(28, 28, 35);">material</font> communications from any patent authori<font style="color: rgb(28, 28, 35);">t</font>y <font style="color: rgb(47, 49, 59);">r</font>egarding Immunocore <font style="color: rgb(47, 49, 59);">Fo</font>reground and Joint Foreground, and drafts of <font style="color: rgb(28, 28, 35);">a</font>n<font style="color: rgb(47, 49, 59);">y
                </font><font style="color: rgb(28, 28, 35);">ma</font><font style="color: rgb(47, 49, 59);">t</font><font style="color: rgb(28, 28, 35);">e</font>rial <font style="color: rgb(28, 28, 35);">fi</font><font style="color: rgb(47, 49, 59);">lin</font><font style="color: rgb(28, 28, 35);">gs </font>or respons<font style="color: rgb(28, 28, 35);">e</font>s to be made t<font style="color: rgb(28, 28, 35);">o </font>su<font style="color: rgb(28, 28, 35);">c</font>h pat<font style="color: rgb(28, 28, 35);">e</font>nt authorities whe<font style="color: rgb(28, 28, 35);">r</font><font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(28, 28, 35);">r</font><font style="color: rgb(47, 49, 59);">e</font>ason<font style="color: rgb(28, 28, 35);">a</font>b<font style="color: rgb(47, 49, 59);">l</font><font style="color: rgb(28, 28, 35);">y po</font>ssible at least [***] in advance of submitting<font style="color: rgb(28, 28, 35);"> s</font><font style="color: rgb(47, 49, 59);">uc</font>h filings<font style="color: rgb(28, 28, 35);"> o</font><font style="color: rgb(47, 49, 59);">r </font><font style="color: rgb(28, 28, 35);">r</font>esponses to allow GSK the opportunity to review
                and<font style="color: rgb(28, 28, 35);"> [***]</font><font style="color: rgb(47, 49, 59);"> p</font><font style="color: rgb(28, 28, 35);">r</font>osecuti<font style="color: rgb(28, 28, 35);">on </font>of Immunocore Foreground and Joint
                Foreground. Unle<font style="color: rgb(28, 28, 35);">s</font>s otherw<font style="color: rgb(47, 49, 59);">is</font><font style="color: rgb(28, 28, 35);">e </font><font style="color: rgb(47, 49, 59);">a</font>greed by the Patent Liaisons<font style="color: rgb(28, 28, 35);">, </font>Immunocore Foreground and Joint Foreg<font style="color: rgb(47, 49, 59);">ro</font><font style="color: rgb(28, 28, 35);">un</font>d shall initially be filed, at a minimum, as an international
                application under the Patent Cooperation Treaty designating all available countries. Thereafter on national phase entry and where the relevant Initial Prog<font style="color: rgb(28, 28, 35);">r</font>am Option <font style="color: rgb(28, 28, 35);">or </font>Collaboration Program Option ha<font style="color: rgb(28, 28, 35);">s ex</font>pir<font style="color: rgb(28, 28, 35);">e</font>d without exerci<font style="color: rgb(28, 28, 35);">s</font>e, Immunocore sh<font style="color: rgb(28, 28, 35);">a</font>ll h<font style="color: rgb(28, 28, 35);">a</font>ve sole discretion as t<font style="color: rgb(28, 28, 35);">o </font>any fin<font style="color: rgb(28, 28, 35);">a</font>l decision <font style="color: rgb(28, 28, 35);">o</font>n which countries any national p<font style="color: rgb(28, 28, 35);">a</font>tent applications [***]<font style="color: rgb(8, 8, 8);"> shall discuss with GSK and agree with GSK what patent
                  application filing [***].</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7408d4b0f6e9414f84b99ba29ab00b5e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Following exercise of an Initial P<font style="color: rgb(47, 49, 59);">rogram </font>Option or Collaboration<font style="color: rgb(31, 31, 35);">&#160;</font>Program Option, GSK shall assume responsibility for a<font style="color: rgb(47, 49, 59);">nd </font>ha<font style="color: rgb(31, 31, 35);">v</font>e <font style="color: rgb(31, 31, 35);">t</font>he firs<font style="color: rgb(31, 31, 35);">t </font><font style="color: rgb(47, 49, 59);">righ</font>t to file,
                maintain and prosecute any pate<font style="color: rgb(47, 49, 59);">nt a</font>ppli<font style="color: rgb(31, 31, 35);">cation</font>s a<font style="color: rgb(47, 49, 59);">nd </font>pa<font style="color: rgb(47, 49, 59);">te</font>nt<font style="color: rgb(47, 49, 59);">s </font><font style="color: rgb(31, 31, 35);">co</font>m<font style="color: rgb(47, 49, 59);">p</font>rising the Immunocore Foreground or Joint Foreground<font style="color: rgb(47, 49, 59);">&#160;</font>arising<font style="color: rgb(47, 49, 59);">&#160;</font>from t<font style="color: rgb(31, 31, 35);">he </font>Collaboration Program in relation to whi<font style="color: rgb(47, 49, 59);">ch suc</font>h Initial<font style="color: rgb(31, 31, 35);">&#160;</font>Program<font style="color: rgb(47, 49, 59);">&#160;</font>Option<font style="color: rgb(31, 31, 35);">&#160;</font>or Collaboration Program Option was exe<font style="color: rgb(31, 31, 35);">rc</font>ise<font style="color: rgb(31, 31, 35);">d </font>and <font style="color: rgb(47, 49, 59);">in </font>each c<font style="color: rgb(47, 49, 59);">ase </font>that Co<font style="color: rgb(47, 49, 59);">ver</font>s the Licensed Product or any part of t<font style="color: rgb(31, 31, 35);">he </font>Licens<font style="color: rgb(47, 49, 59);">ed </font>Product <font style="color: rgb(47, 49, 59);">or</font> any <font style="color: rgb(31, 31, 35);">u</font>s<font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(31, 31, 35);">o</font>f
                or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">27</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 90pt;">process for manufacture of the Lic<font style="color: rgb(31, 31, 35);">ensed </font>Prod<font style="color: rgb(47, 49, 59);">uc</font>t <font style="color: rgb(47, 49, 59);">a</font>risi<font style="color: rgb(31, 31, 35);">ng </font>f<font style="color: rgb(31, 31, 35);">ro</font>m such Collaboration Program. GSK shall promptly <font style="color: rgb(31, 31, 35);">pro</font>v<font style="color: rgb(47, 49, 59);">id</font>e I<font style="color: rgb(31, 31, 35);">m</font>mun<font style="color: rgb(31, 31, 35);">oc</font>ore v<font style="color: rgb(47, 49, 59);">ia t</font>he Pa<font style="color: rgb(47, 49, 59);">t</font>e<font style="color: rgb(47, 49, 59);">nt </font>L<font style="color: rgb(47, 49, 59);">i</font>aisons with copies of all draft patent <font style="color: rgb(31, 31, 35);">ap</font>pli<font style="color: rgb(31, 31, 35);">ca</font>tions, <font style="color: rgb(47, 49, 59);">m</font>at<font style="color: rgb(31, 31, 35);">erial </font>communications f<font style="color: rgb(31, 31, 35);">ro</font>m any patent authority regardi<font style="color: rgb(47, 49, 59);">ng </font><font style="color: rgb(31, 31, 35);">Immunocore</font>
        Foreground and Joint Foreg<font style="color: rgb(47, 49, 59);">roun</font>d, and drafts of any material fili<font style="color: rgb(31, 31, 35);">ng</font>s or r<font style="color: rgb(47, 49, 59);">esp</font>onse<font style="color: rgb(47, 49, 59);">s </font><font style="color: rgb(31, 31, 35);">to b</font>e <font style="color: rgb(31, 31, 35);">ma</font>de to su<font style="color: rgb(31, 31, 35);">ch </font>p<font style="color: rgb(31, 31, 35);">at</font>ent authorities where
        reasonably <font style="color: rgb(31, 31, 35);">p</font>ossible <font style="color: rgb(47, 49, 59);">a</font>t lea<font style="color: rgb(31, 31, 35);">s</font>t [***] in <font style="color: rgb(47, 49, 59);">a</font>d<font style="color: rgb(31, 31, 35);">van</font>ce of submitting such filings <font style="color: rgb(31, 31, 35);">o</font>r respons<font style="color: rgb(47, 49, 59);">e</font>s <font style="color: rgb(47, 49, 59);">to </font>allo<font style="color: rgb(47, 49, 59);">w </font>I<font style="color: rgb(31, 31, 35);">m</font>mun<font style="color: rgb(31, 31, 35);">oc</font>ore <font style="color: rgb(31, 31, 35);">t</font>he opportunity to review and comment. GSK shall<font style="color: rgb(31, 31, 35);"> [***]</font> any re<font style="color: rgb(47, 49, 59);">asona</font>ble <font style="color: rgb(31, 31, 35);">com</font>ments p<font style="color: rgb(47, 49, 59);">rovi</font>ded b<font style="color: rgb(47, 49, 59);">y </font><font style="color: rgb(31, 31, 35);">Immunocore</font> in connection with t<font style="color: rgb(47, 49, 59);">h</font>e <font style="color: rgb(31, 31, 35);">pro</font>secut<font style="color: rgb(47, 49, 59);">io</font>n of Im<font style="color: rgb(31, 31, 35);">m</font>u<font style="color: rgb(31, 31, 35);">n</font>ocor<font style="color: rgb(47, 49, 59);">e </font>Foregroun<font style="color: rgb(47, 49, 59);">d </font><font style="color: rgb(31, 31, 35);">and J</font>oint
        Foreground. The Immunocore Foreground<font style="color: rgb(31, 31, 35);"> s</font>hall continue to <font style="color: rgb(47, 49, 59);">be </font>filed in the name of Im<font style="color: rgb(31, 31, 35);">m</font>unocore<font style="color: rgb(31, 31, 35);">.</font></div>
      <div>&#160;</div>
      <table id="z30b3ab94f7b447f3be2a8c7acd46381f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1F1F23;">GSK </font>shal<font style="color: rgb(47, 49, 59);">l ha</font>ve th<font style="color: rgb(47, 49, 59);">e </font>first ri<font style="color: rgb(47, 49, 59);">g</font>h<font style="color: rgb(47, 49, 59);">t </font>t<font style="color: rgb(47, 49, 59);">o </font>file, <font style="color: rgb(47, 49, 59);">main</font>tain and prosecute any patent<font style="color: rgb(47, 49, 59);"> app</font>licat<font style="color: rgb(47, 49, 59);">io</font>n<font style="color: rgb(47, 49, 59);">s </font>an<font style="color: rgb(31, 31, 35);">d </font><font style="color: rgb(47, 49, 59);">pate</font>nts co<font style="color: rgb(31, 31, 35);">m</font>p<font style="color: rgb(47, 49, 59);">r</font>i<font style="color: rgb(47, 49, 59);">s</font>ing th<font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(31, 31, 35);">GSK </font>Foreground. GSK shall promptly<font style="color: rgb(47, 49, 59);"> p</font>rovid<font style="color: rgb(47, 49, 59);">e </font><font style="color: rgb(31, 31, 35);">Immunocore</font> via the <font style="color: rgb(47, 49, 59);">P</font>atent Liai<font style="color: rgb(31, 31, 35);">so</font>ns
                with copies of all draft patent appl<font style="color: rgb(47, 49, 59);">icat</font>ions, <font style="color: rgb(47, 49, 59);">ma</font>terial <font style="color: rgb(47, 49, 59);">communications</font> from any patent authority
                regarding Li<font style="color: rgb(31, 31, 35);">ce</font>n<font style="color: rgb(47, 49, 59);">se</font>d G<font style="color: rgb(47, 49, 59);">SK </font><font style="color: rgb(31, 31, 35);">Foreground, </font>and <font style="color: rgb(47, 49, 59);">drafts </font><font style="color: rgb(31, 31, 35);">o</font>f any material filings or respon<font style="color: rgb(31, 31, 35);">s</font>es to be <font style="color: rgb(31, 31, 35);">m</font>ade to s<font style="color: rgb(31, 31, 35);">u</font>ch pat<font style="color: rgb(47, 49, 59);">ent </font>authorities<font style="color: rgb(73, 73, 86);">&#160;</font>where reasonably possible at least [***]<font style="color: rgb(47, 49, 59);">&#160;</font>in






                advance of submitting such filings or responses to allow [***] p<font style="color: rgb(47, 49, 59);">ro</font>vided by <font style="color: rgb(31, 31, 35);">Immunocore</font> in connection with the prosecution of Licensed GSK F<font style="color: rgb(47, 49, 59);">o</font>r<font style="color: rgb(47, 49, 59);">e</font>ground.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zaea9f4eaf246457eb831904b7dbd8cac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2F313B;">Pr</font>ior t<font style="color: rgb(31, 31, 35);">o permitting</font> any patent application or patent relating to any Immunocore Foreground, Licensed GSK Foreground or Joint Foreground to lapse, <font style="color: rgb(31, 31, 35);">t</font>h<font style="color: rgb(47, 49, 59);">e </font>Party that is first responsible for prosecution under this Section <font style="color: rgb(47, 49, 59);">7</font>.3 (the &#8220;<font style="font-weight: bold;">Prosecuting Party</font>&#8221;)<font style="font-weight: bold;">&#160;</font>will provide [***] written noti<font style="color: rgb(31, 31, 35);">c</font>e to the non-Prosecuting Party (&#8220;<font style="font-weight: bold;">Lapse Notice</font>&#8221;).







                The non-Pro<font style="color: rgb(31, 31, 35);">s</font>e<font style="color: rgb(31, 31, 35);">c</font>uting Party shall be entitl<font style="color: rgb(31, 31, 35);">e</font>d to tak<font style="color: rgb(31, 31, 35);">e </font>over th<font style="color: rgb(31, 31, 35);">e </font>filing, maint<font style="color: rgb(31, 31, 35);">e</font>nan<font style="color: rgb(31, 31, 35);">ce </font>and pro<font style="color: rgb(31, 31, 35);">sec</font>ution <font style="color: rgb(31, 31, 35);">o</font>f <font style="color: rgb(31, 31, 35);">s</font>u<font style="color: rgb(31, 31, 35);">c</font>h notifi<font style="color: rgb(31, 31, 35);">e</font>d patent or p<font style="color: rgb(31, 31, 35);">a</font>tent






                <font style="color: rgb(31, 31, 35);">a</font>pplicati<font style="color: rgb(31, 31, 35);">o</font>n on providing written notice <font style="color: rgb(31, 31, 35);">t</font>o the Prosecutin<font style="color: rgb(31, 31, 35);">g</font>
                Party within a period of [***] from r<font style="color: rgb(31, 31, 35);">e</font>c<font style="color: rgb(31, 31, 35);">e</font>ipt of Laps<font style="color: rgb(31, 31, 35);">e </font>Notice<font style="color: rgb(31, 31, 35);">, a</font>t
                th<font style="color: rgb(31, 31, 35);">e</font> non-Prosecuting Party&#8217;s sole dis<font style="color: rgb(31, 31, 35);">c</font>retion; for the avoidanc<font style="color: rgb(31, 31, 35);">e </font>of <font style="color: rgb(31, 31, 35);">do</font>ubt,






                the cooperation <font style="color: rgb(31, 31, 35);">a</font>n<font style="color: rgb(31, 31, 35);">d </font>review provisions of Section 7.3.2 or 7.3.3 will no lon<font style="color: rgb(31, 31, 35);">g</font>er apply to the filing,
                maintenance and prosecution of the applicable patents and <font style="color: rgb(8, 8, 8);">patent applications. Where such notice is provided, the Prosecuting Party shall provide all reasonable assistance as soon as possible following
                  receipt of notice from the non-Prosecuting Party to transition the filing, maintenance and prosecution of such notified patent or patent application to the non-Prosecuting Party. If GSK delivers a Lapse Not</font><font style="color: rgb(38, 38, 47);">ic</font><font style="color: rgb(8, 8, 8);">e to Immunocore with respect to Immunocore Foreground, then, on the dat</font><font style="color: rgb(52, 54, 66);">e </font><font style="color: rgb(8, 8, 8);">of receipt of </font><font style="color: rgb(38, 38, 47);">n</font><font style="color: rgb(8, 8, 8);">otice from [***] non-Prosecuting Party indicates it do</font><font style="color: rgb(52, 54, 66);">es </font><font style="color: rgb(38, 38, 47);">n</font><font style="color: rgb(8, 8, 8);">ot </font><font style="color: rgb(38, 38, 47);">w</font><font style="color: rgb(8, 8, 8);">ish to tak</font><font style="color: rgb(38, 38, 47);">e </font><font style="color: rgb(8, 8, 8);">over </font><font style="color: rgb(38, 38, 47);">th</font><font style="color: rgb(8, 8, 8);">e filing, maintenance or prosecution of </font><font style="color: rgb(38, 38, 47);">an</font><font style="color: rgb(8, 8, 8);">y n</font><font style="color: rgb(38, 38, 47);">o</font><font style="color: rgb(8, 8, 8);">tified p</font><font style="color: rgb(52, 54, 66);">at</font><font style="color: rgb(8, 8, 8);">ent or patent </font><font style="color: rgb(52, 54, 66);">applic</font><font style="color: rgb(8, 8, 8);">ation or fails to respond within a period </font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(8, 8, 8);">f [***]</font><font style="color: rgb(38, 38, 47);">&#160;</font><font style="color: rgb(8, 8, 8);">fr</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(8, 8, 8);">m r</font><font style="color: rgb(52, 54, 66);">ece</font><font style="color: rgb(8, 8, 8);">ip</font><font style="color: rgb(52, 54, 66);">t </font><font style="color: rgb(8, 8, 8);">of Lapse Notice, the Prosecuting Party </font><font style="color: rgb(38, 38, 47);">s</font><font style="color: rgb(8, 8, 8);">ha</font><font style="color: rgb(52, 54, 66);">ll </font><font style="color: rgb(8, 8, 8);">be </font><font style="color: rgb(38, 38, 47);">entitled</font><font style="color: rgb(8, 8, 8);"> to </font><font style="color: rgb(38, 38, 47);">perm</font><font style="color: rgb(8, 8, 8);">it the p</font><font style="color: rgb(52, 54, 66);">at</font><font style="color: rgb(8, 8, 8);">ent or patent application to lapse. For </font><font style="color: rgb(52, 54, 66);">t</font><font style="color: rgb(8, 8, 8);">he </font><font style="color: rgb(38, 38, 47);">av</font><font style="color: rgb(8, 8, 8);">oida</font><font style="color: rgb(38, 38, 47);">n</font><font style="color: rgb(8, 8, 8);">c</font><font style="color: rgb(38, 38, 47);">e </font><font style="color: rgb(8, 8, 8);">of d</font><font style="color: rgb(52, 54, 66);">ou</font><font style="color: rgb(8, 8, 8);">b</font><font style="color: rgb(38, 38, 47);">t</font><font style="color: rgb(8, 8, 8);">, the foregoing right to assume responsibility for </font><font style="color: rgb(52, 54, 66);">fi</font><font style="color: rgb(8, 8, 8);">ling, main</font><font style="color: rgb(38, 38, 47);">te</font><font style="color: rgb(8, 8, 8);">n</font><font style="color: rgb(38, 38, 47);">a</font><font style="color: rgb(8, 8, 8);">nce a</font><font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(8, 8, 8);">d prosecuti</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(8, 8, 8);">n of any notified patent or patent applic</font><font style="color: rgb(38, 38, 47);">a</font><font style="color: rgb(8, 8, 8);">ti</font><font style="color: rgb(38, 38, 47);">on </font><font style="color: rgb(8, 8, 8);">in a L</font><font style="color: rgb(38, 38, 47);">a</font><font style="color: rgb(8, 8, 8);">p</font><font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(8, 8, 8);">e Not</font><font style="color: rgb(52, 54, 66);">ic</font><font style="color: rgb(8, 8, 8);">e includes</font><font style="color: rgb(52, 54, 66);">&#160;</font><font style="color: rgb(8, 8, 8);">the right for GSK to assume
                  responsibility f</font><font style="color: rgb(38, 38, 47);">or </font><font style="color: rgb(52, 54, 66);">fil</font><font style="color: rgb(8, 8, 8);">ing, m</font><font style="color: rgb(38, 38, 47);">a</font><font style="color: rgb(8, 8, 8);">in</font><font style="color: rgb(52, 54, 66);">t</font><font style="color: rgb(8, 8, 8);">enan</font><font style="color: rgb(52, 54, 66);">c</font><font style="color: rgb(8, 8, 8);">e </font><font style="color: rgb(38, 38, 47);">a</font><font style="color: rgb(8, 8, 8);">nd prosecution of Immunocore Foreground and Joint Fo</font><font style="color: rgb(52, 54, 66);">re</font><font style="color: rgb(8, 8, 8);">gro</font><font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(8, 8, 8);">nd prior to </font><font style="color: rgb(52, 54, 66);">G</font><font style="color: rgb(8, 8, 8);">SK&#8217;s ex</font><font style="color: rgb(38, 38, 47);">e</font><font style="color: rgb(8, 8, 8);">r</font><font style="color: rgb(52, 54, 66);">ci</font><font style="color: rgb(8, 8, 8);">se the applicable Initial Program Option or </font><font style="color: rgb(52, 54, 66);">Collaboration</font><font style="color: rgb(8, 8, 8);">&#160;</font><font style="color: rgb(52, 54, 66);">Program </font><font style="color: rgb(8, 8, 8);">Option.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6ae485c6c60948a3805ca5346be17674" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party agr<font style="color: rgb(52, 54, 66);">e</font>es <font style="color: rgb(52, 54, 66);">t</font>o re<font style="color: rgb(52, 54, 66);">a</font>s<font style="color: rgb(52, 54, 66);">ona</font>bly <font style="color: rgb(38, 38, 47);">coo</font>p<font style="color: rgb(38, 38, 47);">er</font>ate with the <font style="color: rgb(38, 38, 47);">o</font>ther Party, via the Patent Liaisons, <font style="color: rgb(38, 38, 47);">to </font>exe<font style="color: rgb(38, 38, 47);">cut</font>e all lawful pa<font style="color: rgb(38, 38, 47);">p</font>e<font style="color: rgb(52, 54, 66);">r</font>s and ins<font style="color: rgb(38, 38, 47);">t</font>r<font style="color: rgb(38, 38, 47);">u</font>ments, including obtaining a<font style="color: rgb(38, 38, 47);">n</font>d executin<font style="color: rgb(52, 54, 66);">g </font>n<font style="color: rgb(52, 54, 66);">e</font>ce<font style="color: rgb(38, 38, 47);">s</font>sa<font style="color: rgb(52, 54, 66);">r</font>y <font style="color: rgb(52, 54, 66);">p</font>ower<font style="color: rgb(38, 38, 47);">s </font>of a<font style="color: rgb(38, 38, 47);">tt</font>orney a<font style="color: rgb(38, 38, 47);">n</font>d
                assignments by the named in<font style="color: rgb(52, 54, 66);">vent</font>ors, to make all <font style="color: rgb(38, 38, 47);">rig</font>htful oath<font style="color: rgb(52, 54, 66);">s a</font>nd declar<font style="color: rgb(38, 38, 47);">ati</font>ons, and to provide consult<font style="color: rgb(38, 38, 47);">a</font>tion and a<font style="color: rgb(38, 38, 47);">ssist</font>anc<font style="color: rgb(38, 38, 47);">e as </font>may b<font style="color: rgb(38, 38, 47);">e </font>r<font style="color: rgb(52, 54, 66);">e</font>asona<font style="color: rgb(38, 38, 47);">b</font>ly n<font style="color: rgb(38, 38, 47);">e</font>cessary in the filing, prose<font style="color: rgb(38, 38, 47);">c</font>uti<font style="color: rgb(38, 38, 47);">on</font><font style="color: rgb(86, 87, 102);">, </font>an<font style="color: rgb(38, 38, 47);">d </font>maint<font style="color: rgb(52, 54, 66);">e</font>na<font style="color: rgb(38, 38, 47);">n</font>ce






                <font style="color: rgb(38, 38, 47);">o</font>f all Immunocore Foreground, GSK Foregro<font style="color: rgb(52, 54, 66);">u</font>nd, a<font style="color: rgb(38, 38, 47);">nd </font>Joint <font style="color: rgb(38, 38, 47);">Fore</font>ground






                <font style="color: rgb(38, 38, 47);">u</font>n<font style="color: rgb(52, 54, 66);">d</font>ertaken <font style="color: rgb(38, 38, 47);">in </font>a manner consistent with th<font style="color: rgb(38, 38, 47);">is </font>Section 7<font style="color: rgb(52, 54, 66);">.</font>3.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">28</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z1357dd5270104772840ef7c7f25ff6cd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Enfor<font style="color: rgb(38, 38, 47);">ce</font>m<font style="color: rgb(38, 38, 47);">en</font>t.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc39073c1b8b04e90b6ed0882d26b4d33" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If eithe<font style="color: rgb(52, 54, 66);">r </font><font style="color: rgb(38, 38, 47);">P</font>arty <font style="color: rgb(52, 54, 66);">le</font>arns of (a) a<font style="color: rgb(52, 54, 66);">n</font>y infringe<font style="color: rgb(38, 38, 47);">m</font>ent or threatened infringement, or mis<font style="color: rgb(52, 54, 66);">a</font>p<font style="color: rgb(38, 38, 47);">p</font>ropria<font style="color: rgb(38, 38, 47);">tion </font>or <font style="color: rgb(38, 38, 47);">thr</font>eatened misappropriation, of any Foreground, I<font style="color: rgb(38, 38, 47);">mmun</font>ocor<font style="color: rgb(52, 54, 66);">e </font><font style="color: rgb(38, 38, 47);">Ba</font>ckgrou<font style="color: rgb(38, 38, 47);">nd</font>, <font style="color: rgb(52, 54, 66);">o</font>r Plat <font style="color: rgb(52, 54, 66);">form </font>Rights by a Third Party in the Territory, (b) <font style="color: rgb(8, 8, 8);">(b) any
                  claim made </font><font style="color: rgb(52, 54, 66);">by </font><font style="color: rgb(8, 8, 8);">any Th</font><font style="color: rgb(38, 38, 47);">ir</font><font style="color: rgb(8, 8, 8);">d </font><font style="color: rgb(52, 54, 66);">Party</font><font style="color: rgb(8, 8, 8);"> that any patent or patent application comprisin</font><font style="color: rgb(52, 54, 66);">g </font><font style="color: rgb(8, 8, 8);">the Foreground, Immunocore Background or
                  Platform Rights is invali</font><font style="color: rgb(38, 38, 47);">d o</font><font style="color: rgb(8, 8, 8);">r </font><font style="color: rgb(38, 38, 47);">s</font><font style="color: rgb(8, 8, 8);">hould </font><font style="color: rgb(38, 38, 47);">be </font><font style="color: rgb(8, 8, 8);">revoked, or (c) the submission by any Third Party of an appli</font><font style="color: rgb(38, 38, 47);">ca</font><font style="color: rgb(8, 8, 8);">t</font><font style="color: rgb(52, 54, 66);">io</font><font style="color: rgb(8, 8, 8);">n to the FDA, whether or not in accordance with the BPC&amp;I Act, for a</font><font style="color: rgb(38, 38, 47);">pp</font><font style="color: rgb(8, 8, 8);">roval






                  of </font><font style="color: rgb(38, 38, 47);">a B</font><font style="color: rgb(8, 8, 8);">i</font><font style="color: rgb(38, 38, 47);">o</font><font style="color: rgb(8, 8, 8);">similar Product (a &#8220;</font><font style="font-weight: bold; color: rgb(8, 8, 8);">Biosimilar Application</font><font style="color: rgb(8, 8, 8);">&#8221;), then that Party</font><font style="color: rgb(38, 38, 47);">&#160;</font><font style="color: rgb(8, 8, 8);">shall </font><font style="color: rgb(38, 38, 47);">promptly </font><font style="color: rgb(8, 8, 8);">notify the other Party via the Patent Liaisons and provide</font><font style="color: rgb(52, 54, 66);"> it </font><font style="color: rgb(8, 8, 8);">with all details
                  of such activities (each, an &#8220;</font><font style="font-weight: bold; color: rgb(8, 8, 8);">Infringement</font><font style="color: rgb(8, 8, 8);">&#8221;) of which it is</font><font style="color: rgb(38, 38, 47);"> a</font><font style="color: rgb(8, 8, 8);">ware (</font><font style="color: rgb(38, 38, 47);">ea</font><font style="color: rgb(8, 8, 8);">c</font><font style="color: rgb(52, 54, 66);">h</font><font style="color: rgb(8, 8, 8);">, an &#8220;</font><font style="font-weight: bold; color: rgb(8, 8, 8);">Infringement Notice</font><font style="color: rgb(8, 8, 8);">&#8221;). The Patent Liaisons shall discuss such In</font><font style="color: rgb(52, 54, 66);">f</font><font style="color: rgb(8, 8, 8);">ringement and
                  appropriate steps to be taken with regard to such Infrin</font><font style="color: rgb(52, 54, 66);">gem</font><font style="color: rgb(8, 8, 8);">ent, subject to the provisions set forth in this Section </font><font style="color: rgb(38, 38, 47);">7</font><font style="color: rgb(8, 8, 8);">.4 below. </font><font style="color: rgb(38, 38, 47);">T</font><font style="color: rgb(8, 8, 8);">he Party responsible for bringing an Action (as defined below) against such
                  Infringement shall keep the other Party informed of the progress thereof via the Patent Liaisons.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zb6d1efc540d346cdb7316b620369ca3e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK shall have the first right, but not the obligation, to address Infringement with respect to Foreground in relation to which it i<font style="color: rgb(38, 38, 47);">s </font>the Prose<font style="color: rgb(38, 38, 47);">c</font>uting






                Party, and Immunocore Background or Platform Rights (only including Third Party Platform Rights to the extent that Immunocore is able to enforce such rights <font style="color: rgb(7, 7, 7);">and grant such right of enforcement to GSK in
                  accordance with this Section 7.4.2) solely in the event that patents contained within such Immunocore Background or Platform Rights [***]. GSK shall address such Infringement by taking reasonable steps</font><font style="color: rgb(28, 28, 31);">,</font><font style="color: rgb(7, 7, 7);"> which may include the exchange of patent listi</font><font style="color: rgb(47, 47, 58);">n</font><font style="color: rgb(28, 28, 31);">g </font><font style="color: rgb(7, 7, 7);">information






                  and negotiations regarding such patent lists with a Third Party</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(7, 7, 7);">filin</font><font style="color: rgb(47, 47, 58);">g </font><font style="color: rgb(7, 7, 7);">a Biosimilar </font><font style="color: rgb(28, 28, 31);">A</font><font style="color: rgb(47, 47, 58);">p</font><font style="color: rgb(28, 28, 31);">p</font><font style="color: rgb(7, 7, 7);">lication as required by the
                  BPC&amp;I Act, institution of le</font><font style="color: rgb(28, 28, 31);">ga</font><font style="color: rgb(47, 47, 58);">l </font><font style="color: rgb(7, 7, 7);">proceedings</font><font style="color: rgb(28, 28, 31);">, </font><font style="color: rgb(7, 7, 7);">o</font><font style="color: rgb(47, 47, 58);">r o</font><font style="color: rgb(7, 7, 7);">ther actions (an &#8220;</font><font style="font-weight: bold; color: rgb(7, 7, 7);">Action</font><font style="color: rgb(7, 7, 7);">&#8221;), and to compromise or s</font><font style="color: rgb(28, 28, 31);">ett </font><font style="color: rgb(47, 47, 58);">le s</font><font style="color: rgb(7, 7, 7);">uch Action; p</font><font style="color: rgb(28, 28, 31);">rov</font><font style="color: rgb(47, 47, 58);">i</font><font style="color: rgb(28, 28, 31);">d</font><font style="color: rgb(7, 7, 7);">ed</font><font style="color: rgb(28, 28, 31);">, </font><font style="color: rgb(7, 7, 7);">that: (i) GSK shall keep
                  Immunocore fully infor</font><font style="color: rgb(47, 47, 58);">me</font><font style="color: rgb(7, 7, 7);">d about such Act</font><font style="color: rgb(47, 47, 58);">i</font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(7, 7, 7);">n</font><font style="color: rgb(47, 47, 58);">; </font><font style="color: rgb(7, 7, 7);">(ii) GSK shall not take any position with respect </font><font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(7, 7, 7);">o </font><font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(7, 7, 7);">uch Action </font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">n a</font><font style="color: rgb(7, 7, 7);">ny way that is reasonably likely to directly and </font><font style="color: rgb(47, 47, 58);">adver</font><font style="color: rgb(7, 7, 7);">sel</font><font style="color: rgb(47, 47, 58);">y </font><font style="color: rgb(7, 7, 7);">affect the </font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(7, 7, 7);">cope, </font><font style="color: rgb(47, 47, 58);">va</font><font style="color: rgb(7, 7, 7);">lidity or
                  enforceability of the Foreground, </font><font style="color: rgb(47, 47, 58);">Immunocore</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(47, 47, 58);">B</font><font style="color: rgb(28, 28, 31);">a</font><font style="color: rgb(7, 7, 7);">ckg</font><font style="color: rgb(28, 28, 31);">round </font><font style="color: rgb(7, 7, 7);">or Platform</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(7, 7, 7);">Rights or
                  compromise or settle any s</font><font style="color: rgb(47, 47, 58);">uc</font><font style="color: rgb(7, 7, 7);">h Acti</font><font style="color: rgb(47, 47, 58);">on</font><font style="color: rgb(28, 28, 31);">, </font><font style="color: rgb(7, 7, 7);">with</font><font style="color: rgb(47, 47, 58);">ou</font><font style="color: rgb(28, 28, 31);">t </font><font style="color: rgb(7, 7, 7);">t</font><font style="color: rgb(47, 47, 58);">h</font><font style="color: rgb(7, 7, 7);">e </font><font style="color: rgb(28, 28, 31);">p</font><font style="color: rgb(47, 47, 58);">r</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">or c</font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(7, 7, 7);">nsent of Immunocore, which consent </font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">h</font><font style="color: rgb(7, 7, 7);">a</font><font style="color: rgb(47, 47, 58);">ll </font><font style="color: rgb(7, 7, 7);">not </font><font style="color: rgb(47, 47, 58);">be un </font><font style="color: rgb(7, 7, 7);">rea</font><font style="color: rgb(47, 47, 58);">so</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 58);">abl</font><font style="color: rgb(7, 7, 7);">y with</font><font style="color: rgb(28, 28, 31);">h</font><font style="color: rgb(47, 47, 58);">el</font><font style="color: rgb(7, 7, 7);">d; and (iii) if GSK does not intend to pro</font><font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(28, 28, 31);">cu</font><font style="color: rgb(47, 47, 58);">te </font><font style="color: rgb(7, 7, 7);">or </font><font style="color: rgb(28, 28, 31);">d</font><font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(28, 28, 31);">f</font><font style="color: rgb(7, 7, 7);">e</font><font style="color: rgb(47, 47, 58);">nd </font><font style="color: rgb(7, 7, 7);">an </font><font style="color: rgb(47, 47, 58);">Ac</font><font style="color: rgb(7, 7, 7);">t</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(7, 7, 7);">n, or </font><font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(7, 7, 7);">ases to diligently pursue such an Action, it </font><font style="color: rgb(47, 47, 58);">sh</font><font style="color: rgb(7, 7, 7);">all </font><font style="color: rgb(47, 47, 58);">promptly </font><font style="color: rgb(7, 7, 7);">i</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(7, 7, 7);">form </font><font style="color: rgb(47, 47, 58);">Immunocore</font><font style="color: rgb(7, 7, 7);"> i</font><font style="color: rgb(47, 47, 58);">n </font><font style="color: rgb(7, 7, 7);">such a manner that such Action will not b</font><font style="color: rgb(47, 47, 58);">e </font><font style="color: rgb(28, 28, 31);">p</font><font style="color: rgb(7, 7, 7);">rejud</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 47, 58);">d </font><font style="color: rgb(7, 7, 7);">and </font><font style="color: rgb(47, 47, 58);">Section</font><font style="color: rgb(7, 7, 7);"> 7</font><font style="color: rgb(28, 28, 31);">.4.</font><font style="color: rgb(7, 7, 7);">4 </font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(7, 7, 7);">h</font><font style="color: rgb(28, 28, 31);">a</font><font style="color: rgb(7, 7, 7);">ll apply solely in the event that the Infr</font><font style="color: rgb(47, 47, 58);">ingem</font><font style="color: rgb(7, 7, 7);">ent is </font><font style="color: rgb(28, 28, 31);">re</font><font style="color: rgb(47, 47, 58);">la</font><font style="color: rgb(7, 7, 7);">ted </font><font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 47, 58);">o </font><font style="color: rgb(7, 7, 7);">a License</font><font style="color: rgb(28, 28, 31);">d Pr</font><font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(7, 7, 7);">duct.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z17b6a5b50d2640e99967d783d58db82f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore (or a<font style="color: rgb(28, 28, 31);">s </font>rel<font style="color: rgb(47, 47, 58);">e</font>vant an<font style="color: rgb(47, 47, 58);">y T</font>h<font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">rd </font><font style="color: rgb(28, 28, 31);">P</font>arty ha<font style="color: rgb(47, 47, 58);">vi</font><font style="color: rgb(28, 28, 31);">ng </font><font style="color: rgb(47, 47, 58);">control</font>&#160;<font style="color: rgb(28, 28, 31);">o</font>ver Third Party Platform Rights) <font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">h</font>a<font style="color: rgb(47, 47, 58);">ll h</font>ave <font style="color: rgb(47, 47, 58);">th</font><font style="color: rgb(28, 28, 31);">e </font>first r<font style="color: rgb(47, 47, 58);">i</font>g<font style="color: rgb(47, 47, 58);">ht, </font><font style="color: rgb(28, 28, 31);">b</font>ut






                not <font style="color: rgb(28, 28, 31);">t</font>h<font style="color: rgb(47, 47, 58);">e </font>obliga<font style="color: rgb(47, 47, 58);">t</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 58);">, </font>to prosecute an Action to ad<font style="color: rgb(47, 47, 58);">d</font>res<font style="color: rgb(47, 47, 58);">s </font>Infringement w<font style="color: rgb(28, 28, 31);">it</font><font style="color: rgb(47, 47, 58);">h </font>r<font style="color: rgb(47, 47, 58);">e</font>sp<font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 47, 58);">c</font>t to any
                F<font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(28, 28, 31);">r</font>eg<font style="color: rgb(28, 28, 31);">o</font>und for which it is the Prosecutin<font style="color: rgb(28, 28, 31);">g </font>Party<font style="color: rgb(28, 28, 31);">, </font>Immunocore B<font style="color: rgb(47, 47, 58);">a</font>c<font style="color: rgb(47, 47, 58);">k</font><font style="color: rgb(28, 28, 31);">gro</font>und <font style="color: rgb(28, 28, 31);">and






                </font>Platform Rights (subject to <font style="color: rgb(47, 47, 58);">G</font>SK&#8217;s right<font style="color: rgb(47, 47, 58);">s </font>in Section<font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(47, 47, 58);">7</font>.4.2)






                <font style="color: rgb(28, 28, 31);">a</font>nd: <font style="color: rgb(28, 28, 31);">(</font><font style="color: rgb(47, 47, 58);">i</font>) Immunocore shall keep GSK fully infor<font style="color: rgb(47, 47, 58);">med </font>about <font style="color: rgb(28, 28, 31);">s</font>u<font style="color: rgb(28, 28, 31);">c</font>h Act<font style="color: rgb(47, 47, 58);">ion; </font>(ii) Imm<font style="color: rgb(47, 47, 58);">uno</font>core shall <font style="color: rgb(47, 47, 58);">n</font><font style="color: rgb(28, 28, 31);">o</font>t take any position with re<font style="color: rgb(28, 28, 31);">sp</font>ect to su<font style="color: rgb(28, 28, 31);">ch </font><font style="color: rgb(47, 47, 58);">Act
                </font>ion <font style="color: rgb(28, 28, 31);">i</font>n <font style="color: rgb(47, 47, 58);">an</font>y way t<font style="color: rgb(47, 47, 58);">hat </font><font style="color: rgb(28, 28, 31);">i</font>s rea<font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 58);">na</font>b<font style="color: rgb(47, 47, 58);">l</font><font style="color: rgb(28, 28, 31);">y </font>likely to dire<font style="color: rgb(28, 28, 31);">c</font>tly and adver<font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">e</font>ly <font style="color: rgb(47, 47, 58);">aff</font>ect t<font style="color: rgb(47, 47, 58);">h</font>e <font style="color: rgb(28, 28, 31);">v</font>alidi<font style="color: rgb(47, 47, 58);">ty </font>o<font style="color: rgb(47, 47, 58);">r </font>enfo<font style="color: rgb(28, 28, 31);">r</font><font style="color: rgb(47, 47, 58);">c</font>eab<font style="color: rgb(28, 28, 31);">il</font>ity of <font style="color: rgb(47, 47, 58);">the Immunocore</font> Background or Platform Rights<font style="color: rgb(47, 47, 58);">&#160;</font>(excluding<font style="color: rgb(28, 28, 31);">&#160;</font>Third <font style="color: rgb(47, 47, 58);">P</font><font style="color: rgb(28, 28, 31);">a</font>r<font style="color: rgb(47, 47, 58);">t</font><font style="color: rgb(28, 28, 31);">y </font>Platform<font style="color: rgb(47, 47, 58);"> R</font>ights) that Cover Licensed Products<font style="color: rgb(28, 28, 31);">, </font>or <font style="color: rgb(28, 28, 31);">c</font><font style="color: rgb(47, 47, 58);">o</font>mpro<font style="color: rgb(47, 47, 58);">m</font>i<font style="color: rgb(47, 47, 58);">se </font>or <font style="color: rgb(47, 47, 58);">s</font>e<font style="color: rgb(28, 28, 31);">tt </font>l<font style="color: rgb(28, 28, 31);">e </font>any






                such Action as it relates to<font style="color: rgb(28, 28, 31);"> I</font>m<font style="color: rgb(47, 47, 58);">m</font><font style="color: rgb(28, 28, 31);">u</font><font style="color: rgb(47, 47, 58);">n</font>ocor<font style="color: rgb(47, 47, 58);">e </font>B<font style="color: rgb(47, 47, 58);">a</font>ckg<font style="color: rgb(28, 28, 31);">ro</font><font style="color: rgb(47, 47, 58);">u</font>n<font style="color: rgb(28, 28, 31);">d </font>or P<font style="color: rgb(47, 47, 58);">lat </font>fo<font style="color: rgb(47, 47, 58);">rm </font>Rights<font style="color: rgb(47, 47, 58);">&#160;</font><font style="color: rgb(28, 28, 31);">(</font><font style="color: rgb(47, 47, 58);">e</font>xcluding






                Third Party Platform Rights) that<font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(47, 47, 58);">C</font>over <font style="color: rgb(47, 47, 58);">Lic</font>ensed Products, wit<font style="color: rgb(28, 28, 31);">h</font><font style="color: rgb(47, 47, 58);">out </font>the prior consent of GSK, which<font style="color: rgb(47, 47, 58);"> con</font>sent <font style="color: rgb(28, 28, 31);">sh</font><font style="color: rgb(47, 47, 58);">a</font>ll not <font style="color: rgb(28, 28, 31);">b</font><font style="color: rgb(47, 47, 58);">e </font>unrea<font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(28, 28, 31);">b</font>ly with<font style="color: rgb(47, 47, 58);">h</font><font style="color: rgb(28, 28, 31);">e</font>l<font style="color: rgb(47, 47, 58);">d</font><font style="color: rgb(28, 28, 31);">; </font>and (iii) if Immuno<font style="color: rgb(28, 28, 31);">c</font>or<font style="color: rgb(28, 28, 31);">e </font>does not <font style="color: rgb(47, 47, 58);">i</font><font style="color: rgb(28, 28, 31);">n</font>ten<font style="color: rgb(28, 28, 31);">d </font><font style="color: rgb(47, 47, 58);">t</font><font style="color: rgb(28, 28, 31);">o p</font>ros<font style="color: rgb(47, 47, 58);">ec</font><font style="color: rgb(28, 28, 31);">ut</font><font style="color: rgb(47, 47, 58);">e </font>or defend an Action, <font style="color: rgb(28, 28, 31);">o</font>r ceases to diligently pursue such an A<font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 47, 58);">io</font>n, to <font style="color: rgb(47, 47, 58);">the </font>exten<font style="color: rgb(47, 47, 58);">t n</font><font style="color: rgb(28, 28, 31);">o</font>t
                <font style="color: rgb(47, 47, 58);">i</font>n conflic<font style="color: rgb(28, 28, 31);">t </font>with any Third Party agreement, it shall promptly i<font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 58);">f</font><font style="color: rgb(28, 28, 31);">or</font><font style="color: rgb(47, 47, 58);">m </font>GSK i<font style="color: rgb(28, 28, 31);">n </font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">u</font><font style="color: rgb(47, 47, 58);">c</font>h a <font style="color: rgb(28, 28, 31);">ma</font><font style="color: rgb(47, 47, 58);">n</font><font style="color: rgb(28, 28, 31);">n</font>er that su<font style="color: rgb(28, 28, 31);">c</font>h
                Action will not be prejudice<font style="color: rgb(28, 28, 31);">d</font> and <font style="color: rgb(28, 28, 31);">Section</font>&#160;<font style="color: rgb(47, 47, 58);">7</font>.4.4 sh<font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(28, 28, 31);">l</font><font style="color: rgb(47, 47, 58);">l a</font>pply.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">29</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z5dbef762c9b44a819a64467aea30d25f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In th<font style="color: rgb(47, 47, 58);">e </font><font style="color: rgb(28, 28, 31);">e</font>v<font style="color: rgb(47, 47, 58);">e</font>nt of <font style="color: rgb(47, 47, 58);">an </font>Infringement, if (i) the Party with
                the first right to pros<font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(28, 28, 31);">u</font><font style="color: rgb(47, 47, 58);">t</font>e an Ac<font style="color: rgb(47, 47, 58);">t </font>io<font style="color: rgb(47, 47, 58);">n </font>(the &#8220;<font style="font-weight: bold;">Enforcing Party</font>&#8221;)<font style="font-weight: bold;">&#160;</font>informs the non-Enfor<font style="color: rgb(28, 28, 31);">c</font>ing Party that it does <font style="color: rgb(28, 28, 31);">no</font><font style="color: rgb(47, 47, 58);">t </font>intend to prosecute a particular Action, (ii) within [***]<font style="color: rgb(47, 47, 58);">&#160;</font>after






                <font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 58);">o</font>ti<font style="color: rgb(28, 28, 31);">c</font><font style="color: rgb(47, 47, 58);">e </font>of Infringement the Enforcing Party has not <font style="color: rgb(28, 28, 31);">c</font>ommen<font style="color: rgb(28, 28, 31);">c</font>ed any<font style="color: rgb(47, 47, 58);"> su</font>ch Action, or (iii) if the Enforcing Party the<font style="color: rgb(28, 28, 31);">r</font>eafter






                ceases diligently to<font style="color: rgb(47, 47, 58);"> p</font>ursue <font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(28, 28, 31);">uc</font><font style="color: rgb(47, 47, 58);">h </font>Action, then the non<font style="color: rgb(28, 28, 31);">-</font>Enforcing Party shall have the right<font style="color: rgb(28, 28, 31);">, </font>at its own e<font style="color: rgb(47, 47, 58);">xp</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(47, 47, 58);">n</font><font style="color: rgb(28, 28, 31);">s</font>e, upon notice to the Enforcing Party to take appropriate action to<font style="color: rgb(28, 28, 31);"> ad</font>dre<font style="color: rgb(82, 84, 96);">s</font><font style="color: rgb(47, 47, 58);">s s</font>u<font style="color: rgb(28, 28, 31);">c</font>h Infring<font style="color: rgb(28, 28, 31);">e</font>ment, including by initiating it<font style="color: rgb(28, 28, 31);">s </font>own






                A<font style="color: rgb(28, 28, 31);">c</font>t ion <font style="color: rgb(28, 28, 31);">o</font>r taking over pro<font style="color: rgb(28, 28, 31);">s</font>ecution of any A<font style="color: rgb(28, 28, 31);">c</font>tion initiated
                by the Enfor<font style="color: rgb(28, 28, 31);">c</font>ing Party. In <font style="color: rgb(28, 28, 31);">s</font>uch event<font style="color: rgb(47, 47, 58);">,</font> the non-Enfor<font style="color: rgb(28, 28, 31);">c</font>ing
                Party shall keep the Enforcing P<font style="color: rgb(28, 28, 31);">a</font>rty fully informed about such A<font style="color: rgb(28, 28, 31);">c</font>t ion. <font style="color: rgb(28, 28, 31);">T</font>he non-Enforcing Party shall
                not take any position with respect to such Action in any way that is reasonably likely to directly and adversely<font style="color: rgb(28, 28, 31);"> a</font>ff<font style="color: rgb(28, 28, 31);">e</font>ct th<font style="color: rgb(28, 28, 31);">e </font>scop<font style="color: rgb(28, 28, 31);">e</font>, validity or <font style="color: rgb(28, 28, 31);">e</font>nforc<font style="color: rgb(28, 28, 31);">e</font>ability of th<font style="color: rgb(28, 28, 31);">e </font>Intellectual






                Prop<font style="color: rgb(28, 28, 31);">e</font>rty Rights th<font style="color: rgb(28, 28, 31);">a</font>t are the subje<font style="color: rgb(28, 28, 31);">c</font>t of <font style="color: rgb(28, 28, 31);">s</font>u<font style="color: rgb(28, 28, 31);">c</font>h Action, <font style="color: rgb(28, 28, 31);">o</font>r <font style="color: rgb(28, 28, 31);">co</font>mpr<font style="color: rgb(28, 28, 31);">o</font>mi<font style="color: rgb(28, 28, 31);">se
                  o</font>r s<font style="color: rgb(28, 28, 31);">e</font>ttle <font style="color: rgb(28, 28, 31);">s</font>u<font style="color: rgb(28, 28, 31);">c</font>h A<font style="color: rgb(28, 28, 31);">c</font>tion, without the Enforcing
                Party&#8217;s prior written consent, wh<font style="color: rgb(28, 28, 31);">i</font>ch <font style="color: rgb(28, 28, 31);">c</font>onsent sh<font style="color: rgb(28, 28, 31);">a</font>ll not be unr<font style="color: rgb(28, 28, 31);">e</font>asonably






                withh<font style="color: rgb(28, 28, 31);">e</font>ld. The non-Enforcing Party&#8217;s right to enforcem<font style="color: rgb(28, 28, 31);">e</font>nt <font style="color: rgb(28, 28, 31);">a</font>s <font style="color: rgb(8, 8, 8);">described






                  in this Section 7.4.4 with respect to an Infringement described in Section 7.4.1(c) is applicable solely to the extent permitted by Applicable Law</font><font style="font-weight: bold; color: rgb(8, 8, 8);">. </font><font style="color: rgb(8, 8, 8);">In the event that the Enforcing Party has informed the non-Enforcing Party that it is not proceeding with an Action on the advice of competent counsel, and the non-Enforcing Party opts to proceed </font><font style="color: rgb(47, 47, 58);">with</font><font style="color: rgb(26, 26, 31);"> such </font><font style="color: rgb(8, 8, 8);">Action, then the non-Enforcing Party will, at the Enforcing Party&#8217;s req</font><font style="color: rgb(47, 47, 58);">ue</font><font style="color: rgb(8, 8, 8);">st, execute </font><font style="color: rgb(26, 26, 31);">a</font><font style="color: rgb(47, 47, 58);">n </font><font style="color: rgb(8, 8, 8);">agreement confirming that the decision to sue was ma</font><font style="color: rgb(47, 47, 58);">de </font><font style="color: rgb(26, 26, 31);">despite </font><font style="color: rgb(8, 8, 8);">the E</font><font style="color: rgb(47, 47, 58);">nfor</font><font style="color: rgb(26, 26, 31);">cing </font><font style="color: rgb(8, 8, 8);">Party&#8217;s objection and the non-Enforcing Party </font><font style="color: rgb(47, 47, 58);">sh</font><font style="color: rgb(8, 8, 8);">al</font><font style="color: rgb(47, 47, 58);">l </font><font style="color: rgb(8, 8, 8);">indemnify, def</font><font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(26, 26, 31);">nd </font><font style="color: rgb(8, 8, 8);">and hold harmless the Enforcing Party and its </font><font style="color: rgb(47, 47, 58);">Affiliates</font><font style="color: rgb(8, 8, 8);"> for all Los</font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(26, 26, 31);">es </font><font style="color: rgb(8, 8, 8);">arising






                  out of Claims suffered by the Enforcing Party</font><font style="color: rgb(47, 47, 58);">&#160;</font><font style="color: rgb(8, 8, 8);">as </font><font style="color: rgb(26, 26, 31);">a </font><font style="color: rgb(8, 8, 8);">result of
                  su</font><font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(8, 8, 8);">h </font><font style="color: rgb(26, 26, 31);">suit. </font><font style="color: rgb(8, 8, 8);">This Section 7.4.4 </font>shall not apply to (a)
                any Thir<font style="color: rgb(47, 47, 58);">d Party</font> Platform Rights<font style="color: rgb(47, 47, 58);">&#160;</font><font style="color: rgb(26, 26, 31);">or </font>Platform Rights where Immunocore has in place any agre<font style="color: rgb(47, 47, 58);">e</font>m<font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(26, 26, 31);">nt </font>with <font style="color: rgb(26, 26, 31);">a </font>Third <font style="color: rgb(47, 47, 58);">Party</font>
                which would conflict or which would not <font style="color: rgb(47, 47, 58);">p</font>e<font style="color: rgb(47, 47, 58);">r</font>m it <font style="color: rgb(26, 26, 31);">transfer </font><font style="color: rgb(47, 47, 58);">of </font><font style="color: rgb(26, 26, 31);">an </font><font style="color: rgb(47, 47, 58);">A</font>ctio<font style="color: rgb(47, 47, 58);">n i</font><font style="color: rgb(26, 26, 31);">n </font><font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(26, 26, 31);">ccordance </font>with this Section 7.4.4 or (b) <font style="color: rgb(47, 47, 58);">G</font>SK <font style="color: rgb(26, 26, 31);">Foreg</font><font style="color: rgb(47, 47, 58);">ro</font><font style="color: rgb(26, 26, 31);">u</font><font style="color: rgb(47, 47, 58);">nd</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z78c686af985f436cabae5d7702e49a24" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any recovery obtained by <font style="color: rgb(26, 26, 31);">GSK </font><font style="color: rgb(47, 47, 58);">i</font>n con<font style="color: rgb(47, 47, 58);">ne</font>c<font style="color: rgb(47, 47, 58);">t</font>ion w<font style="color: rgb(47, 47, 58);">it</font>h or as a r<font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(26, 26, 31);">s</font><font style="color: rgb(47, 47, 58);">u</font>lt of an Action, [***] the relevan<font style="color: rgb(47, 47, 58);">t </font>court proceeding<font style="color: rgb(47, 47, 58);">s </font><font style="color: rgb(26, 26, 31);">o</font><font style="color: rgb(47, 47, 58);">r </font>enforcem<font style="color: rgb(47, 47, 58);">e</font>nt h<font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(26, 26, 31);">s </font>been finally decided between <font style="color: rgb(47, 47, 58);">GS</font><font style="color: rgb(26, 26, 31);">K </font>and






                <font style="color: rgb(26, 26, 31);">the </font>rele<font style="color: rgb(47, 47, 58);">van</font>t third <font style="color: rgb(47, 47, 58);">Pa</font><font style="color: rgb(26, 26, 31);">rty. </font>Any r<font style="color: rgb(47, 47, 58);">ec</font>overy obtained by Immunocore in con<font style="color: rgb(47, 47, 58);">nec</font>tion <font style="color: rgb(26, 26, 31);">with </font>or as <font style="color: rgb(47, 47, 58);">a </font><font style="color: rgb(26, 26, 31);">result o</font><font style="color: rgb(47, 47, 58);">f </font>a<font style="color: rgb(47, 47, 58);">n </font>Action, whether by [***] ap<font style="color: rgb(47, 47, 58);">p</font><font style="color: rgb(26, 26, 31);">o</font><font style="color: rgb(47, 47, 58);">rt</font><font style="color: rgb(26, 26, 31);">ionm</font><font style="color: rgb(47, 47, 58);">e</font>n<font style="color: rgb(47, 47, 58);">t </font>shall <font style="color: rgb(47, 47, 58);">onl</font><font style="color: rgb(26, 26, 31);">y </font>occu<font style="color: rgb(47, 47, 58);">r o</font><font style="color: rgb(26, 26, 31);">nc</font><font style="color: rgb(47, 47, 58);">e </font>the






                relevant court proceedings or enforcement <font style="color: rgb(47, 47, 58);">h</font>as be<font style="color: rgb(47, 47, 58);">en </font><font style="color: rgb(26, 26, 31);">finally d</font><font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(26, 26, 31);">ci</font><font style="color: rgb(47, 47, 58);">de</font>d between Immunocore <font style="color: rgb(26, 26, 31);">and </font>the relevant Third Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z407b80c03dad4c37bae8cfac778ad4e0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Party resp<font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(26, 26, 31);">nsible </font>fo<font style="color: rgb(47, 47, 58);">r </font>any Action under Sections 7.4.2 and 7.4.3 shall also be entitled to <font style="color: rgb(47, 47, 58);">d</font>efend a<font style="color: rgb(47, 47, 58);">n</font>y <font style="color: rgb(47, 47, 58);">c</font><font style="color: rgb(26, 26, 31);">ounterclaim </font>proceedings for invalidity or
                revocation of the relevant p<font style="color: rgb(47, 47, 58);">a</font>te<font style="color: rgb(47, 47, 58);">n</font>t in a<font style="color: rgb(47, 47, 58);">n</font><font style="color: rgb(26, 26, 31);">y </font><font style="color: rgb(47, 47, 58);">A</font>ction. The <font style="color: rgb(26, 26, 31);">other </font>Party shall be entitled to its own legal represe<font style="color: rgb(47, 47, 58);">ntati</font>on in relation to such Action and
                any counterclaim and the Party <font style="color: rgb(26, 26, 31);">responsible</font> for the Ac<font style="color: rgb(47, 47, 58);">t i</font>on shal<font style="color: rgb(47, 47, 58);">l </font><font style="color: rgb(26, 26, 31);">w</font><font style="color: rgb(47, 47, 58);">h</font>ere possible take into account reasonable comments or requests made <font style="color: rgb(47, 47, 58);">b</font>y the othe<font style="color: rgb(47, 47, 58);">r P</font>arty in relation to the
                defence of any counterclaim for invalidity or rev<font style="color: rgb(47, 47, 58);">oca</font>tion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3929216286564c3e98ef9af880656e17" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2F2F3A;">T</font><font style="color: #1A1A1F;">h</font><font style="color: #2F2F3A;">e </font>Parties shall cooperate and provide all reasonable assistance, <font style="color: rgb(26, 26, 31);">subject </font>to
                the<font style="color: rgb(47, 47, 58);"> p</font>ayment of all reasonable <font style="color: rgb(26, 26, 31);">expenses </font>and costs<font style="color: rgb(47, 47, 58);">, </font>to <font style="color: rgb(26, 26, 31);">each other
                </font>with respect to any Action described in Section 7.4 <font style="color: rgb(26, 26, 31);">above. </font>Upon the reasonable request of the Party instituting such Action, the other Party shall join <font style="color: rgb(26, 26, 31);">such </font>Action <font style="color: rgb(26, 26, 31);">and </font>shall be represented using<font style="color: rgb(26, 26, 31);"> coun</font><font style="color: rgb(47, 47, 58);">s</font><font style="color: rgb(26, 26, 31);">el






                </font>of its own <font style="color: rgb(26, 26, 31);">choice, </font>at the requesting Party&#8217;s expense; provided, that if GSK <font style="color: rgb(26, 26, 31);">or</font> Immunocore has informed the other Party that it would not
                proceed with <font style="color: rgb(26, 26, 31);">such </font>Action <font style="color: rgb(26, 26, 31);">on</font> the opinion of competent counsel, as provided in Sections 7.4.2 and 7.4.3<font style="color: rgb(47, 47, 58);">, </font>the






                other <font style="color: rgb(8, 8, 8);">Party may not require GSK or Immunocore to join such Action unless legally required to do so. The provision of assistance under this Section 7.6 shall include reasonable assistance as may be
                  required by either Party to determine which patent applications or patents should be used in any Action or should be submitted to a Third Party that files a Biosimilar Application as required by the BPC&amp;I Act. Once any patent
                  application or patent has been identified</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">30</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #080808;">or agreed to be litigated wit</font><font style="color: #2D2D38;">h </font><font style="color: #080808;">the Third Party</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">filing the Biosimilar Application, the Prosecuting Party for such </font><font style="color: #2D2D38;">p</font><font style="color: #080808;">a</font><font style="color: #2D2D38;">t</font><font style="color: #080808;">ent
          application </font><font style="color: #2D2D38;">or </font><font style="color: #080808;">patent shall provide all reasonable assistance (including ac</font><font style="color: #2D2D38;">c</font><font style="color: #080808;">e</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">s to its internal files such as prosecution files and laboratory notebooks) as </font><font style="color: #2D2D38;">ma</font><font style="color: #080808;">y be required to en</font><font style="color: #2D2D38;">s</font><font style="color: #080808;">ure that such patent application or patent is valid, has been filed in accordanc</font><font style="color: #2D2D38;">e </font><font style="color: #080808;">with the rules and
          regulations of the relevant patent office an</font><font style="color: #2D2D38;">d tha</font><font style="color: #080808;">t t</font><font style="color: #2D2D38;">h</font><font style="color: #080808;">ere is no r</font><font style="color: #2D2D38;">ea</font><font style="color: #080808;">son w</font><font style="color: #2D2D38;">hic</font><font style="color: #080808;">h might suggest that any identified patent or paten</font><font style="color: #2D2D38;">t </font><font style="color: #080808;">a</font><font style="color: #2D2D38;">p</font><font style="color: #080808;">pl</font><font style="color: #2D2D38;">ic</font><font style="color: #080808;">atio</font><font style="color: #2D2D38;">n </font><font style="color: #080808;">c</font><font style="color: #2D2D38;">o</font><font style="color: #080808;">uld not </font><font style="color: #2D2D38;">o</font><font style="color: #080808;">r shoul</font><font style="color: #2D2D38;">d not </font><font style="color: #080808;">be used in any Action. Access to internal Immunocore</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">files </font><font style="color: #2D2D38;">s</font><font style="color: #080808;">hall onl</font><font style="color: #2D2D38;">y </font><font style="color: #080808;">be </font><font style="color: #2D2D38;">p</font><font style="color: #080808;">rov</font><font style="color: #2D2D38;">i</font><font style="color: #080808;">d</font><font style="color: #2D2D38;">e</font><font style="color: #080808;">d </font><font style="color: #2D2D38;">t</font><font style="color: #080808;">o external counsel of GSK and nothing in this Section </font><font style="color: #2D2D38;">7</font><font style="color: #080808;">.6 sh</font><font style="color: #2D2D38;">a</font><font style="color: #080808;">ll </font><font style="color: #2D2D38;">re</font><font style="color: #080808;">quir</font><font style="color: #2D2D38;">e </font><font style="color: #080808;">Immunocore</font><font style="color: #2D2D38;">&#160;</font><font style="color: #080808;">to breach any obligation it has to any Third Party.</font></div>
      <div>&#160;</div>
      <table id="ze4a6e92c52174a32b6769d6c0b510a34" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Defense of Infringement Claims</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z16f4938b80c24a059f94f6c64feff224" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party shall promptly noti<font style="color: rgb(45, 45, 56);">f</font>y the other <font style="color: rgb(45, 45, 56);">Par</font>ty in <font style="color: rgb(45, 45, 56);">writing</font> of any allegation by a Third Party in
                the Ter<font style="color: rgb(45, 45, 56);">r</font>itory th<font style="color: rgb(45, 45, 56);">at </font>the<font style="color: rgb(45, 45, 56);"> m</font>aking, h<font style="color: rgb(45, 45, 56);">av</font>ing made<font style="color: rgb(45, 45, 56);">, </font>using, selling or offering for sale <font style="color: rgb(45, 45, 56);">or </font>i<font style="color: rgb(45, 45, 56);">mp</font>ortin<font style="color: rgb(45, 45, 56);">g </font>of an<font style="color: rgb(45, 45, 56);">y Licen</font>sed Product, or the<font style="color: rgb(45, 45, 56);">&#160;</font>c<font style="color: rgb(45, 45, 56);">o</font>nduct of any activities under <font style="color: rgb(45, 45, 56);">t</font>his
                Agree<font style="color: rgb(45, 45, 56);">men</font>t infring<font style="color: rgb(45, 45, 56);">e o</font>r misappropriate or may infringe or misappropriate th<font style="color: rgb(45, 45, 56);">e </font>Intellectual Property Rights<font style="color: rgb(45, 45, 56);"> o</font>f such Thir<font style="color: rgb(45, 45, 56);">d </font>Party (a &#8220;<font style="font-weight: bold;">Third Party Infringement Cla</font><font style="font-weight: bold; color: rgb(45, 45, 56);">i</font><font style="font-weight: bold;">m</font>&#8221;<font style="color: rgb(45, 45, 56);">).</font><font style="font-weight: bold; color: rgb(45, 45, 56);">&#160;</font>Th<font style="color: rgb(45, 45, 56);">e </font>Patent Lia<font style="color: rgb(45, 45, 56);">i</font>sons <font style="color: rgb(45, 45, 56);">s</font>h<font style="color: rgb(45, 45, 56);">a</font>ll discuss which Party shall def<font style="color: rgb(45, 45, 56);">end </font>the Third Party<font style="color: rgb(45, 45, 56);">&#160;</font>Infringem<font style="color: rgb(45, 45, 56);">e</font>nt Claim, <font style="color: rgb(45, 45, 56);">a</font>nd absent mutual agreement otherwi<font style="color: rgb(45, 45, 56);">se</font>, <font style="color: rgb(45, 45, 56);">e</font>ach Pa<font style="color: rgb(45, 45, 56);">rty </font>shall h<font style="color: rgb(45, 45, 56);">ave </font>the ri<font style="color: rgb(45, 45, 56);">g</font>h<font style="color: rgb(45, 45, 56);">t </font>to control the defense of any s<font style="color: rgb(45, 45, 56);">uc</font>h <font style="color: rgb(45, 45, 56);">Thi</font>rd Party Infrin<font style="color: rgb(45, 45, 56);">g</font>ement Cl<font style="color: rgb(45, 45, 56);">a</font>im brought <font style="color: rgb(45, 45, 56);">aga</font>i<font style="color: rgb(45, 45, 56);">n</font>st it in the Territory, by coun<font style="color: rgb(45, 45, 56);">s</font>e<font style="color: rgb(45, 45, 56);">l </font>of its <font style="color: rgb(45, 45, 56);">ow</font>n choi<font style="color: rgb(45, 45, 56);">ce. </font>If a T<font style="color: rgb(45, 45, 56);">h</font>ird Party In<font style="color: rgb(45, 45, 56);">fr</font>i<font style="color: rgb(45, 45, 56);">n</font>gement Claim is brought ag<font style="color: rgb(45, 45, 56);">a</font>inst one Party<font style="color: rgb(45, 45, 56);">&#160;</font>(the &#8220;<font style="font-weight: bold;">D</font><font style="font-weight: bold; color: rgb(45, 45, 56);">e</font><font style="font-weight: bold;">fendi</font><font style="font-weight: bold; color: rgb(45, 45, 56);">n</font><font style="font-weight: bold;">g Party</font>&#8221;)<font style="font-weight: bold;">&#160;</font>but not the other Party, the non-De<font style="color: rgb(45, 45, 56);">fe</font>n<font style="color: rgb(45, 45, 56);">d</font>ing Party<font style="color: rgb(45, 45, 56);">&#160;</font>shall <font style="color: rgb(45, 45, 56);">h</font>ave the <font style="color: rgb(45, 45, 56);">rig</font>h<font style="color: rgb(45, 45, 56);">t, </font>at its <font style="color: rgb(45, 45, 56);">ow</font>n expense, to be represented in su<font style="color: rgb(45, 45, 56);">c</font>h Third<font style="color: rgb(45, 45, 56);"> Pa</font>rty In<font style="color: rgb(45, 45, 56);">fr</font>ingement <font style="color: rgb(45, 45, 56);">C</font>la<font style="color: rgb(45, 45, 56);">i</font>m by c<font style="color: rgb(45, 45, 56);">oun</font>sel of its own choice, at its own<font style="color: rgb(45, 45, 56);"> exp</font>ens<font style="color: rgb(45, 45, 56);">e.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf880e027499d4e0bb5e96343c6165a5f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The P<font style="color: rgb(45, 45, 56);">at</font>ent Li<font style="color: rgb(45, 45, 56);">ais</font>on for <font style="color: rgb(45, 45, 56);">th</font>e Defendin<font style="color: rgb(45, 45, 56);">g </font>Party shall keep
                the Patent Liaison for th<font style="color: rgb(45, 45, 56);">e o</font>ther Party reas<font style="color: rgb(45, 45, 56);">onab</font>ly i<font style="color: rgb(45, 45, 56);">nfo</font>rm<font style="color: rgb(45, 45, 56);">e</font>d
                of all material developments in connection w<font style="color: rgb(45, 45, 56);">i</font>th any <font style="color: rgb(45, 45, 56);">Th</font>ird Party<font style="color: rgb(45, 45, 56);"> Infringement </font>Claim. Each Defending
                Party agrees to provide the other Party <font style="color: rgb(45, 45, 56);">&#8216;s </font>Patent Liaison with copies of all pleadings filed i<font style="color: rgb(45, 45, 56);">n a</font>ny suit or <font style="color: rgb(45, 45, 56);">p</font>roceeding






                relating to such Third Party Infringement Claim. The <font style="color: rgb(45, 45, 56);">De</font>f<font style="color: rgb(45, 45, 56);">e</font>nding Part<font style="color: rgb(45, 45, 56);">y </font>may enter into a settlement or
                compromise of any Third<font style="color: rgb(45, 45, 56);"> Party</font> Infrin<font style="color: rgb(45, 45, 56);">g</font>e<font style="color: rgb(45, 45, 56);">me</font>nt Claim; provided, that if such settlement or compromise<font style="color: rgb(45, 45, 56);"> w</font>ou<font style="color: rgb(45, 45, 56);">l</font>d admi<font style="color: rgb(45, 45, 56);">t </font>lia<font style="color: rgb(45, 45, 56);">b</font>ility on the part of the non-Defending Party
                or any of its<font style="color: rgb(45, 45, 56);"> Affiliates</font> or would otherwise have a material adverse effect on the rights or<font style="color: rgb(45, 45, 56);"> i</font>nterests o<font style="color: rgb(45, 45, 56);">f the</font>
                non-Defending Party or its Affiliates, the Defending Party shall not e<font style="color: rgb(45, 45, 56);">nte</font>r into such settlement or compromise without the prior written conse<font style="color: rgb(45, 45, 56);">n</font>t <font style="color: rgb(45, 45, 56);">o</font>f the non-Defending Party. In the event a proposed settlement involves obtaining a license under Third Party Intellectual Property Rights, the provisions of Section 9.6 <font style="color: rgb(45, 45, 56);">s</font>hall apply. Notwithstanding the foregoing, as between the Parties, solely to the extent permitted under Section 7.4 and 7<font style="color: rgb(45, 45, 56);">.</font>5 above, the Parties shall have the right to
                determine whether to assert any counterclaim under any patent applications or patents comprising Joint Foreground or Immunocore Foreground and to control any such <font style="color: rgb(45, 45, 56);">c</font>ounterclaim, and to control
                the defence of any matters involving the validity or enforceability of any such patent applications or patents, including the right to <font style="color: rgb(7, 7, 8);">make substantive and procedural decisions relating to any such
                  counterclaim or defence and settle, compromise or dispose of any such counterclaim or defence.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z801e25a1f89f4977839081d0b50b74db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK will retain control and all decision-making reg<font style="color: rgb(47, 47, 58);">a</font>rdin<font style="color: rgb(28, 28, 33);">g </font>filing, prosecution and maintenance of all GSK Background and GSK Foregro<font style="color: rgb(28, 28, 33);">u</font>nd, <font style="color: rgb(47, 47, 58);">at </font>GSK&#8217;s sole c<font style="color: rgb(28, 28, 33);">ost </font>during the Term. GSK shall have sole discretion in relation to an<font style="color: rgb(47, 47, 58);">y Act</font>ion against a<font style="color: rgb(28, 28, 33);">n Inf</font>ringement of GSK Background or GSK Foreground by a Third Pa<font style="color: rgb(28, 28, 33);">rty.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z82e74cf564624ccebb09fbcfdc60e62e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Nothing in this Agreement shall assign any Immunocore Backgrou<font style="color: rgb(28, 28, 33);">nd </font><font style="color: rgb(47, 47, 58);">o</font>r Platform Rights to GSK. Nothing in this Agreement shal<font style="color: rgb(47, 47, 58);">l assi</font>gn any GSK B<font style="color: rgb(47, 47, 58);">ac</font>kgrou<font style="color: rgb(47, 47, 58);">nd </font>or GSK Foreground to Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">31</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z2ae75983a0de4ffbb82a2102d21b522d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>CREATE Act</u>. It is the intention of the <font style="color: rgb(47, 47, 58);">Parties</font> that<font style="color: rgb(47, 47, 58);"> this </font>A<font style="color: rgb(28, 28, 33);">gr</font>e<font style="color: rgb(47, 47, 58);">em</font>ent is <font style="color: rgb(28, 28, 33);">a </font><font style="color: rgb(47, 47, 58);">&#8220;j</font>oint research agreement&#8221; as that phrase is defined <font style="color: rgb(47, 47, 58);">in Publ</font>ic <font style="color: rgb(28, 28, 33);">La</font>w <font style="color: rgb(28, 28, 33);">10</font>8-5<font style="color: rgb(28, 28, 33);">3 (th</font>e &#8220;<font style="font-weight: bold;">Cr</font><font style="font-weight: bold; color: rgb(47, 47, 58);">e</font><font style="font-weight: bold;">ate Act</font>&#8221;).<font style="font-weight: bold;">&#160;</font>In the event that either Party to this Agreement<font style="color: rgb(47, 47, 58);">&#160;</font>inte<font style="color: rgb(28, 28, 33);">nds to </font>ove<font style="color: rgb(47, 47, 58);">rcom</font>e a r<font style="color: rgb(28, 28, 33);">e</font>je<font style="color: rgb(47, 47, 58);">c</font>t <font style="color: rgb(47, 47, 58);">io</font>n of a claimed
                invention within the Immunoc<font style="color: rgb(28, 28, 33);">o</font>re Backg<font style="color: rgb(28, 28, 33);">roun</font>d (to<font style="color: rgb(47, 47, 58);"> th</font>e extent<font style="color: rgb(47, 47, 58);"> r</font>elevant






                to any Collaboration Program or Licen<font style="color: rgb(28, 28, 33);">sed </font><font style="color: rgb(47, 47, 58);">P</font>roduct<font style="color: rgb(28, 28, 33);">),</font><font style="color: rgb(66, 66, 80);">&#160;</font><font style="color: rgb(47, 47, 58);">the</font> F<font style="color: rgb(47, 47, 58);">or</font>e<font style="color: rgb(28, 28, 33);">g</font>round, <font style="color: rgb(28, 28, 33);">P</font>la<font style="color: rgb(28, 28, 33);">t fo</font>rm






                Rights (to the extent relevant to any Coll<font style="color: rgb(28, 28, 33);">abora</font>tion Program <font style="color: rgb(28, 28, 33);">or Li</font>cen<font style="color: rgb(28, 28, 33);">sed </font>Product) and/or Joint
                Foreground pursuant to the p<font style="color: rgb(28, 28, 33);">ro</font>vi<font style="color: rgb(47, 47, 58);">si</font>ons of <font style="color: rgb(28, 28, 33);">the </font>C<font style="color: rgb(28, 28, 33);">reat</font>e Act, s<font style="color: rgb(28, 28, 33);">uch Party</font> shall first obtain the prior written consent of the<font style="color: rgb(28, 28, 33);"> o</font>the<font style="color: rgb(47, 47, 58);">r </font>Party<font style="color: rgb(47, 47, 58);">&#160;</font>and t<font style="color: rgb(28, 28, 33);">he Parties</font> shall w<font style="color: rgb(47, 47, 58);">o</font>rk tog<font style="color: rgb(47, 47, 58);">ether </font>in good faith to agree how any rejecti<font style="color: rgb(28, 28, 33);">on </font>s<font style="color: rgb(28, 28, 33);">ho</font>uld <font style="color: rgb(47, 47, 58);">be overcome</font><font style="color: rgb(28, 28, 33);">. </font><font style="color: rgb(47, 47, 58);">T</font>o
                t<font style="color: rgb(28, 28, 33);">h</font>e e<font style="color: rgb(28, 28, 33);">x</font>tent that th<font style="color: rgb(28, 28, 33);">e </font>Parties agree that, in order to overcome <font style="color: rgb(47, 47, 58);">a </font>reje<font style="color: rgb(28, 28, 33);">ctio</font>n of <font style="color: rgb(28, 28, 33);">a </font>claimed <font style="color: rgb(47, 47, 58);">inven</font>tion with<font style="color: rgb(28, 28, 33);">in </font>the Immunocore
                Background (to the extent relev<font style="color: rgb(47, 47, 58);">a</font>nt <font style="color: rgb(47, 47, 58);">t</font>o <font style="color: rgb(28, 28, 33);">a</font>n<font style="color: rgb(28, 28, 33);">y </font>Collaboration <font style="color: rgb(47, 47, 58);">Program </font>or Licensed Product), the Foreground, Platform Righ<font style="color: rgb(47, 47, 58);">ts </font>(<font style="color: rgb(28, 28, 33);">t</font>o the <font style="color: rgb(47, 47, 58);">ext</font>ent rele<font style="color: rgb(28, 28, 33);">vant </font>to any Collaboration Program or Licensed Product) and/ o<font style="color: rgb(28, 28, 33);">r </font>Joi<font style="color: rgb(28, 28, 33);">n</font>t <font style="color: rgb(47, 47, 58);">For</font>eg<font style="color: rgb(28, 28, 33);">ro</font>u<font style="color: rgb(47, 47, 58);">nd </font>pursua<font style="color: rgb(28, 28, 33);">nt </font><font style="color: rgb(47, 47, 58);">to </font>the






                <font style="color: rgb(47, 47, 58);">prov</font>is<font style="color: rgb(47, 47, 58);">io</font>ns of the Create Act, the filing of a te<font style="color: rgb(47, 47, 58);">r</font>mi<font style="color: rgb(47, 47, 58);">nal </font>discl<font style="color: rgb(47, 47, 58);">a</font>im<font style="color: rgb(47, 47, 58);">e</font>r is <font style="color: rgb(28, 28, 33);">re</font>qu<font style="color: rgb(47, 47, 58);">i</font>red <font style="color: rgb(28, 28, 33);">or </font>advi<font style="color: rgb(28, 28, 33);">s</font>able, <font style="color: rgb(28, 28, 33);">the Parties</font> shall first agree on terms and co<font style="color: rgb(28, 28, 33);">n</font>d<font style="color: rgb(47, 47, 58);">itio</font>ns u<font style="color: rgb(47, 47, 58);">nde</font>r whi<font style="color: rgb(47, 47, 58);">ch </font>the pat<font style="color: rgb(66, 66, 80);">e</font>nt applica<font style="color: rgb(28, 28, 33);">tion </font>subject to such terminal
                disclaimer a<font style="color: rgb(47, 47, 58);">nd </font>the pat<font style="color: rgb(28, 28, 33);">e</font>n<font style="color: rgb(28, 28, 33);">t </font><font style="color: rgb(47, 47, 58);">o</font>r ap<font style="color: rgb(47, 47, 58);">pl</font>ic<font style="color: rgb(47, 47, 58);">at</font>ion o<font style="color: rgb(47, 47, 58);">v</font>e<font style="color: rgb(47, 47, 58);">r </font>w<font style="color: rgb(28, 28, 33);">h</font>ich s<font style="color: rgb(47, 47, 58);">uc</font>h application is disclaimed shall be jointly <font style="color: rgb(28, 28, 33);">enfo</font>r<font style="color: rgb(47, 47, 58);">ce</font>d, t<font style="color: rgb(66, 66, 80);">o </font>t<font style="color: rgb(47, 47, 58);">he </font>ex<font style="color: rgb(28, 28, 33);">ten</font>t <font style="color: rgb(28, 28, 33);">t</font>hat <font style="color: rgb(28, 28, 33);">the </font>Parties h<font style="color: rgb(47, 47, 58);">ave n</font>ot previously agreed to such terms a<font style="color: rgb(47, 47, 58);">nd conditions. </font>To <font style="color: rgb(28, 28, 33);">the</font> extent<font style="color: rgb(28, 28, 33);"> that</font> this<font style="color: rgb(47, 47, 58);"> S</font>ection applies to Immunocore Backgr<font style="color: rgb(47, 47, 58);">ound </font><font style="color: rgb(28, 28, 33);">o</font>r Pl<font style="color: rgb(47, 47, 58);">atfor</font>m <font style="color: rgb(28, 28, 33);">Rights</font>, any <font style="color: rgb(28, 28, 33);">ob</font>l<font style="color: rgb(66, 66, 80);">i</font><font style="color: rgb(28, 28, 33);">ga</font>tion u<font style="color: rgb(47, 47, 58);">nd</font>e<font style="color: rgb(28, 28, 33);">r </font>this Section will be subject to any Third Pa<font style="color: rgb(28, 28, 33);">rty </font>agr<font style="color: rgb(47, 47, 58);">ee</font>m<font style="color: rgb(47, 47, 58);">e</font>nts <font style="color: rgb(47, 47, 58);">e</font>n<font style="color: rgb(28, 28, 33);">ter</font>ed into with Immunocore prior to the Effective Date o<font style="color: rgb(28, 28, 33);">r</font> after t<font style="color: rgb(28, 28, 33);">he </font>Effective<font style="color: rgb(47, 47, 58);">&#160;</font>Date <font style="color: rgb(28, 28, 33);">relating</font> t<font style="color: rgb(47, 47, 58);">o the</font>&#160;<font style="color: rgb(28, 28, 33);">prosecution</font> or maintenance of such
                Immunocore B<font style="color: rgb(47, 47, 58);">ackgr</font>ound <font style="color: rgb(47, 47, 58);">o</font>r <font style="color: rgb(28, 28, 33);">P</font>lat f<font style="color: rgb(47, 47, 58);">orm </font>Rights<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(47, 47, 58);">and </font><font style="color: rgb(28, 28, 33);">a</font>ny <font style="color: rgb(47, 47, 58);">co</font>-<font style="color: rgb(66, 66, 80);">operation</font>
                or <font style="color: rgb(28, 28, 33);">c</font>onsultation by Immunocore und<font style="color: rgb(47, 47, 58);">er </font>this Section shall<font style="color: rgb(28, 28, 33);">&#160;</font>be subject<font style="color: rgb(47, 47, 58);">&#160;</font>to






                suc<font style="color: rgb(47, 47, 58);">h </font><font style="color: rgb(28, 28, 33);">Thi</font>rd Party agreements<font style="color: rgb(47, 47, 58);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4fd53f1b37f348218c71f2ab673da655" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Consideration</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5d06108cd4f940cea689eacc9f1d3fa7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In partial <font style="color: rgb(28, 28, 33);">con</font>siderati<font style="color: rgb(28, 28, 33);">on </font><font style="color: rgb(47, 47, 58);">for </font><font style="color: rgb(28, 28, 33);">t</font>he rights granted to GSK
                under this Agreement, GSK shall pay to <font style="color: rgb(66, 66, 80);">Immunocore</font><font style="color: rgb(47, 47, 58);">&#160;</font><font style="color: rgb(28, 28, 33);">a </font>non-refundable<font style="color: rgb(28, 28, 33);">,
                </font>non-creditable upfront payment of <font style="color: rgb(7, 7, 8);">&#163;4</font><font style="color: rgb(28, 28, 33);">,</font><font style="color: rgb(7, 7, 8);">000,</font><font style="color: rgb(47, 47, 58);">000.</font><font style="color: rgb(7, 7, 8);">00 (four million pounds sterling). Such payment shall be payable by wire transf</font><font style="color: rgb(47, 47, 58);">er of </font><font style="color: rgb(7, 7, 8);">immediately available funds in
                  accordance with wire tran</font><font style="color: rgb(28, 28, 33);">s</font><font style="color: rgb(7, 7, 8);">fer instructions of Immunocore pr</font><font style="color: rgb(47, 47, 58);">ovide</font><font style="color: rgb(7, 7, 8);">d
                  in writing to GSK on or prior to the Effective Date. Such pa</font><font style="color: rgb(47, 47, 58);">yme</font><font style="color: rgb(7, 7, 8);">nt shall </font><font style="color: rgb(28, 28, 33);">be </font><font style="color: rgb(47, 47, 58);">m</font><font style="color: rgb(7, 7, 8);">ade within [***]</font><font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(7, 7, 8);">after GSK&#8217;s receipt of an invoice f</font><font style="color: rgb(47, 47, 58);">rom </font><font style="color: rgb(28, 28, 33);">Immunocore</font><font style="color: rgb(7, 7, 8);"> provided on or after the Effective Date, which invoice shall be s</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(7, 7, 8);">nt in </font><font style="color: rgb(47, 47, 58);">acco</font><font style="color: rgb(7, 7, 8);">rdance with the instructions on Schedule 6.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z43258dc2eba344e4bffe88b60da7a25e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>G<font style="color: rgb(28, 28, 33);">S</font>K shall pay to Immunocore a non-refundable, non-creditable Initiation Fee in the amounts and on the term<font style="color: rgb(28, 28, 33);">s </font>provided in Schedule 2. Each
                Initiation Fee shall be due within [***]<font style="color: rgb(28, 28, 33);">&#160;</font>after GSK<font style="color: rgb(28, 28, 33);">&#8217;s </font>re<font style="color: rgb(28, 28, 33);">c</font>eipt of an inv<font style="color: rgb(28, 28, 33);">o</font>i<font style="color: rgb(28, 28, 33);">ce </font>from Immun<font style="color: rgb(28, 28, 33);">oco</font>r<font style="color: rgb(28, 28, 33);">e</font>, whi<font style="color: rgb(28, 28, 33);">c</font>h will be provided
                on or after th<font style="color: rgb(28, 28, 33);">e a</font>pplic<font style="color: rgb(28, 28, 33);">a</font>ble Nomination Date. Immunocore sh<font style="color: rgb(28, 28, 33);">a</font>ll h<font style="color: rgb(28, 28, 33);">a</font>ve






                no oblig<font style="color: rgb(28, 28, 33);">a</font>tion to start any work on a Coll<font style="color: rgb(28, 28, 33);">a</font>boration Program until it has r<font style="color: rgb(28, 28, 33);">e</font>c<font style="color: rgb(28, 28, 33);">e</font>ived the <font style="color: rgb(7, 7, 8);">relevant Initiation Fee.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc95f76fab3bb4a51bbfdbe361d12ff38" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to the terms and conditions set forth in Schedule 2 and this Section 8.3, GSK shall pay to Immunocore the Milestone Fees. Such Milestone Fees shall be payable by GSK whether the relevant milestone is achieved by GSK<font style="color: rgb(33, 33, 40);">, </font>GSK&#8217;s Affiliates or GSK&#8217;<font style="color: rgb(33, 33, 40);">s </font>or its Affiliates&#8217; sublicensees. GSK shall procure it has adeq<font style="color: rgb(33, 33, 40);">ua</font>te <font style="color: rgb(33, 33, 40);">reporting</font> obligations in place between Affiliates and sublicensees to ensure complia<font style="color: rgb(33, 33, 40);">nce with</font> this Section<font style="color: rgb(33, 33, 40);">&#160;</font>8.3.






                A Party achieving a milestone as set forth in Schedule 2 <font style="color: rgb(33, 33, 40);">s</font>h<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">ll notify</font> the other <font style="color: rgb(33, 33, 40);">Party</font> in writing promptly, but in no event later than [***] after ea<font style="color: rgb(33, 33, 40);">c</font>h <font style="color: rgb(54, 54, 66);">a</font>chievement of each milestone that triggers a
                payment. Each <font style="color: rgb(33, 33, 40);">M</font>iles<font style="color: rgb(33, 33, 40);">t</font>one Fee pay<font style="color: rgb(54, 54, 66);">a</font>bl<font style="color: rgb(33, 33, 40);">e </font>for an achieved
                Milestone as set forth in Schedule 2 will be du<font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(33, 33, 40);">with</font>in [***] fr<font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">m
                </font>the date of receipt of an invoice from Immunocore<font style="color: rgb(33, 33, 40);">, </font>w<font style="color: rgb(33, 33, 40);">h</font>i<font style="color: rgb(33, 33, 40);">ch </font>inv<font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">i</font>c<font style="color: rgb(33, 33, 40);">e </font>shall b<font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(33, 33, 40);">p</font>rovid<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">d on </font>or after the date that GSK notifies Immunocore, in <font style="color: rgb(33, 33, 40);">w</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">i</font>t<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">n</font>g, <font style="color: rgb(33, 33, 40);">of </font><font style="color: rgb(54, 54, 66);">s</font>u<font style="color: rgb(33, 33, 40);">c</font>h ac<font style="color: rgb(33, 33, 40);">hie</font>ve<font style="color: rgb(33, 33, 40);">m</font>en<font style="color: rgb(33, 33, 40);">t o</font><font style="color: rgb(54, 54, 66);">r </font>I<font style="color: rgb(33, 33, 40);">m</font>munocore otherwise becomes aware of such achi<font style="color: rgb(54, 54, 66);">e</font>ve<font style="color: rgb(33, 33, 40);">m</font>ent <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">nd su</font>ch <font style="color: rgb(54, 54, 66);">a</font>c<font style="color: rgb(54, 54, 66);">hi</font><font style="color: rgb(33, 33, 40);">ev</font>ement <font style="color: rgb(54, 54, 66);">is </font>not






                disputed by GSK. If an Initial Target Program <font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">s </font>t<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">m</font>ina<font style="color: rgb(33, 33, 40);">ted </font><font style="color: rgb(54, 54, 66);">in </font>acc<font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">d</font>a<font style="color: rgb(33, 33, 40);">n</font>ce w<font style="color: rgb(33, 33, 40);">ith </font>Section 3.6.2(ii), then the level of Milestone Fees pay <font style="color: rgb(33, 33, 40);">a</font>b<font style="color: rgb(33, 33, 40);">l</font>e <font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">n </font>rel<font style="color: rgb(33, 33, 40);">at</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">o</font>n to th<font style="color: rgb(33, 33, 40);">e </font>fi<font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">s</font>t Targ<font style="color: rgb(33, 33, 40);">e</font>t
                <font style="color: rgb(33, 33, 40);">Pro</font>gram and first Initial HLA Program that commen<font style="color: rgb(33, 33, 40);">ce</font><font style="color: rgb(54, 54, 66);">d </font>or will <font style="color: rgb(33, 33, 40);">co</font>mmen<font style="color: rgb(54, 54, 66);">c</font>e <font style="color: rgb(33, 33, 40);">s</font>ubseq<font style="color: rgb(54, 54, 66);">u</font>e<font style="color: rgb(33, 33, 40);">n</font><font style="color: rgb(54, 54, 66);">t </font>t<font style="color: rgb(33, 33, 40);">o </font>the terminated Initial Target Program shall be <font style="color: rgb(33, 33, 40);">adju</font><font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(33, 33, 40);">t</font>ed in <font style="color: rgb(33, 33, 40);">a</font>c<font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(33, 33, 40);">o</font>rda<font style="color: rgb(33, 33, 40);">nc</font>e <font style="color: rgb(33, 33, 40);">with</font>
                Schedule</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">32</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">2. In relation to the [***] Milestone F<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">e</font>s [***], ther<font style="color: rgb(33, 33, 40);">e </font>s<font style="color: rgb(33, 33, 40);">hall </font>be <font style="color: rgb(33, 33, 40);">no </font>obligation on Immunocore to proceed t<font style="color: rgb(33, 33, 40);">o t</font>h<font style="color: rgb(33, 33, 40);">e </font><font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(33, 33, 40);">e</font>xt <font style="color: rgb(33, 33, 40);">Pro</font>ject <font style="color: rgb(33, 33, 40);">Phase until</font> it ha<font style="color: rgb(33, 33, 40);">s
        </font>receiv<font style="color: rgb(33, 33, 40);">ed p</font><font style="color: rgb(54, 54, 66);">a</font>yment of the relevant Milestone Fee.</div>
      <div>&#160;</div>
      <table id="z04cab2cd9296440989e13dae82fee59d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to the terms <font style="color: rgb(33, 33, 40);">a</font>nd condit<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">o</font>n<font style="color: rgb(54, 54, 66);">s </font>se<font style="color: rgb(33, 33, 40);">t </font>f<font style="color: rgb(54, 54, 66);">o</font>rt<font style="color: rgb(54, 54, 66);">h </font>in Schedule<font style="color: rgb(33, 33, 40);">&#160;</font>2 a<font style="color: rgb(33, 33, 40);">nd






                  this </font>Section 8.4, GSK shall pay to Immunocore the <font style="color: rgb(33, 33, 40);">Sa</font>les M<font style="color: rgb(33, 33, 40);">ile</font><font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(33, 33, 40);">t</font>one Fee<font style="color: rgb(33, 33, 40);">s </font><font style="color: rgb(54, 54, 66);">(a</font>s defined <font style="color: rgb(54, 54, 66);">in </font>Schedule 2). Such Sales Milestone F<font style="color: rgb(33, 33, 40);">e</font>es shall b<font style="color: rgb(33, 33, 40);">e p</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">y</font>able <font style="color: rgb(33, 33, 40);">b</font><font style="color: rgb(54, 54, 66);">y </font><font style="color: rgb(33, 33, 40);">G</font>SK ba<font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(33, 33, 40);">ed o</font>n th<font style="color: rgb(33, 33, 40);">e a</font><font style="color: rgb(54, 54, 66);">g</font><font style="color: rgb(33, 33, 40);">gre</font>gate Net Sales made by GSK, GSK&#8217;s <font style="color: rgb(33, 33, 40);">Affiliates</font> or G<font style="color: rgb(54, 54, 66);">S</font>K<font style="color: rgb(33, 33, 40);">&#8217;</font>s <font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">r </font>its<font style="color: rgb(33, 33, 40);">&#160;</font>Affil<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">t</font>es&#8217; <font style="color: rgb(33, 33, 40);">s</font>ublic<font style="color: rgb(54, 54, 66);">en</font><font style="color: rgb(33, 33, 40);">se</font><font style="color: rgb(54, 54, 66);">es </font>and GSK shall procure that it has reporting obligations i<font style="color: rgb(33, 33, 40);">n </font><font style="color: rgb(54, 54, 66);">p</font><font style="color: rgb(33, 33, 40);">la</font>ce






                bet <font style="color: rgb(33, 33, 40);">we</font>e<font style="color: rgb(54, 54, 66);">n </font>Affiliates<font style="color: rgb(54, 54, 66);">&#160;</font><font style="color: rgb(33, 33, 40);">an</font>d sublicensees (including
                Affiliates&#8217; s<font style="color: rgb(54, 54, 66);">u</font><font style="color: rgb(33, 33, 40);">b</font>licensees<font style="color: rgb(33, 33, 40);">) </font><font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">o </font>en<font style="color: rgb(33, 33, 40);">su</font>r<font style="color: rgb(54, 54, 66);">e </font>com<font style="color: rgb(33, 33, 40);">pl</font>i<font style="color: rgb(54, 54, 66);">a</font>n<font style="color: rgb(33, 33, 40);">c</font>e with<font style="color: rgb(33, 33, 40);">&#160;</font>this Section 8.4. Each Sales Milestone F<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(33, 33, 40);">p</font><font style="color: rgb(54, 54, 66);">a</font>yabl<font style="color: rgb(33, 33, 40);">e </font>fo<font style="color: rgb(54, 54, 66);">r </font>an <font style="color: rgb(33, 33, 40);">ach</font>ieved S<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">l</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">s </font><font style="color: rgb(54, 54, 66);">M</font><font style="color: rgb(33, 33, 40);">i</font>leston<font style="color: rgb(33, 33, 40);">e a</font>s set forth in Schedule 2 will be due with<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">n [***]</font> day<font style="color: rgb(54, 54, 66);">s </font>from th<font style="color: rgb(33, 33, 40);">e </font><font style="color: rgb(54, 54, 66);">d</font><font style="color: rgb(33, 33, 40);">a</font>t<font style="color: rgb(54, 54, 66);">e </font>of






                rec<font style="color: rgb(33, 33, 40);">ei</font><font style="color: rgb(54, 54, 66);">p</font><font style="color: rgb(33, 33, 40);">t </font>of an invoi<font style="color: rgb(33, 33, 40);">c</font>e from Immunoco<font style="color: rgb(33, 33, 40);">r</font>e<font style="color: rgb(33, 33, 40);">,</font> which <font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">nv</font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">ce </font>sh<font style="color: rgb(33, 33, 40);">a</font><font style="color: rgb(54, 54, 66);">l</font><font style="color: rgb(33, 33, 40);">l b</font><font style="color: rgb(54, 54, 66);">e </font>pro<font style="color: rgb(54, 54, 66);">v</font>i<font style="color: rgb(54, 54, 66);">d</font><font style="color: rgb(33, 33, 40);">e</font>d on o<font style="color: rgb(54, 54, 66);">r </font><font style="color: rgb(33, 33, 40);">afte</font>r the <font style="color: rgb(54, 54, 66);">d</font><font style="color: rgb(33, 33, 40);">a</font>t<font style="color: rgb(33, 33, 40);">e </font>that GSK notifies Immunocore<font style="color: rgb(33, 33, 40);">, </font>in writing, <font style="color: rgb(33, 33, 40);">of </font>su<font style="color: rgb(33, 33, 40);">c</font><font style="color: rgb(54, 54, 66);">h </font><font style="color: rgb(33, 33, 40);">ac</font>hie<font style="color: rgb(33, 33, 40);">v</font><font style="color: rgb(54, 54, 66);">e</font>m<font style="color: rgb(33, 33, 40);">e</font>nt or Im<font style="color: rgb(33, 33, 40);">m</font>unocore <font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">t</font>herwise becomes aware of such achie<font style="color: rgb(33, 33, 40);">vem</font>ent <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">n</font><font style="color: rgb(54, 54, 66);">d </font>such <font style="color: rgb(33, 33, 40);">ach</font>ievem<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(33, 33, 40);">t </font>is






                not in di<font style="color: rgb(54, 54, 66);">s</font>pute by GSK.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0db4f01509e949fc8c85da10f91c117d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Su<font style="color: rgb(33, 33, 40);">bj</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">c</font>t to the terms a<font style="color: rgb(33, 33, 40);">n</font>d cond<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">ti</font><font style="color: rgb(54, 54, 66);">o</font>ns set <font style="color: rgb(33, 33, 40);">forth</font><font style="color: rgb(54, 54, 66);">&#160;</font>in Article 9<font style="color: rgb(33, 33, 40);">, </font>GSK shall pay to Immunocore the Royalty on Net <font style="color: rgb(33, 33, 40);">S</font>ales of Licensed Products.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zff6eee75baff46819f1e24a89e3ed672" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any tax paid <font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">r r</font>equired t<font style="color: rgb(33, 33, 40);">o </font>be withheld by GSK for the benefit of Immunocore on account o<font style="color: rgb(33, 33, 40);">f a</font>ny Ro<font style="color: rgb(33, 33, 40);">y</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">lt</font><font style="color: rgb(54, 54, 66);">y </font><font style="color: rgb(33, 33, 40);">o</font>r other payments payable to Immunocore under this Agreemen<font style="color: rgb(33, 33, 40);">t </font>s<font style="color: rgb(33, 33, 40);">ha</font>ll be d<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">d</font>u<font style="color: rgb(33, 33, 40);">ct</font>ed from the amount of Royalty or other payments otherwise due. G<font style="color: rgb(33, 33, 40);">SK s</font>hall secure and send to Immunocore
                proof of any such taxes withheld and paid <font style="color: rgb(33, 33, 40);">by </font><font style="color: rgb(54, 54, 66);">G</font><font style="color: rgb(33, 33, 40);">S</font>K for the<font style="color: rgb(54, 54, 66);">&#160;</font>benefit






                of Immunocore, and shall<font style="color: rgb(33, 33, 40);">, </font>at Immunocore<font style="color: rgb(33, 33, 40);">&#8217;s</font> request, provi<font style="color: rgb(33, 33, 40);">d</font><font style="color: rgb(54, 54, 66);">e </font>r<font style="color: rgb(33, 33, 40);">e</font>asona<font style="color: rgb(33, 33, 40);">ble </font><font style="color: rgb(54, 54, 66);">a</font>nd prompt assistan<font style="color: rgb(33, 33, 40);">c</font>e to Immunocore in recovering
                such taxes.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf31238b2f92b4c1d9b5098b3aeb42ded" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #212128;">If any </font>payment due by GSK to Immunocore pursuant to this Agreement is overdue then<font style="color: rgb(33, 33, 40);"> [***]</font> pro-rated for the number of d<font style="color: rgb(33, 33, 40);">a</font>ys from the date upon which p<font style="color: rgb(33, 33, 40);">a</font>ym<font style="color: rgb(33, 33, 40);">e</font>nt of such <font style="color: rgb(33, 33, 40);">s</font>um became due until payment thereof in full
                tog<font style="color: rgb(33, 33, 40);">e</font>ther with such interest; provided, that in no event shall such rate exceed the maximum legal annual interest rate. The payment of <font style="color: rgb(33, 33, 40);">s</font>u<font style="color: rgb(33, 33, 40);">c</font>h interest <font style="color: rgb(33, 33, 40);">s</font>hall n<font style="color: rgb(33, 33, 40);">o</font>t limit Immunocore from exerci<font style="color: rgb(33, 33, 40);">s</font>ing any
                other right<font style="color: rgb(33, 33, 40);">s </font>it may have <font style="color: rgb(5, 5, 5);">as a consequence of the lateness of any payment. Where the late payment is caused by Immunocore, including for reasons such as
                  failure to communicate in a timely manner changes to bank details, or failure to respond to communications from GSK regarding the interpretation or dispute of the terms of such payment,</font><font style="color: rgb(45, 45, 56);">&#160;</font><font style="color: rgb(5, 5, 5);">then no interest will be payable by GSK.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zd8686581538941299986cc07cd19ed31" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All payments to be made by GSK to Immunocore unde<font style="color: rgb(45, 45, 56);">r </font><font style="color: rgb(28, 28, 33);">this </font>Agreement <font style="color: rgb(28, 28, 33);">sh</font><font style="color: rgb(66, 68, 79);">a</font>ll <font style="color: rgb(28, 28, 33);">b</font>e paid by bank wire transfer of immediately available funds <font style="color: rgb(28, 28, 33);">i</font>n <font style="color: rgb(28, 28, 33);">a</font>c<font style="color: rgb(45, 45, 56);">c</font>ordance with <font style="color: rgb(28, 28, 33);">t</font>h<font style="color: rgb(28, 28, 33);">e </font>wire transfer instructions set forth on Schedule 6. Immunocore<font style="color: rgb(28, 28, 33);">&#160;</font>shall issue any i<font style="color: rgb(28, 28, 33);">nv</font>o<font style="color: rgb(45, 45, 56);">ic</font>es under this Agreement in accordance with the instructions s<font style="color: rgb(45, 45, 56);">et </font>ou<font style="color: rgb(28, 28, 33);">t </font>in Schedule <font style="color: rgb(28, 28, 33);">6</font><font style="color: rgb(66, 68, 79);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze35d660b587e4ba6b0961f90807a3d21" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Notification and Royalty Payments</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9a487d37f71b4113b72931411266ca29" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>As further consideration for the rights <font style="color: rgb(28, 28, 33);">gr</font>an<font style="color: rgb(28, 28, 33);">te</font>d to <font style="color: rgb(28, 28, 33);">GSK u</font>nd<font style="color: rgb(45, 45, 56);">er
                  this </font>Agree<font style="color: rgb(45, 45, 56);">me</font>nt, GSK shall pay Immunocore the Royalty set forth<font style="color: rgb(45, 45, 56);">&#160;</font><font style="color: rgb(28, 28, 33);">belo</font>w o<font style="color: rgb(28, 28, 33);">n </font>a <font style="color: rgb(45, 45, 56);">ca</font>len<font style="color: rgb(28, 28, 33);">dar </font><font style="color: rgb(45, 45, 56);">q</font>uarte<font style="color: rgb(45, 45, 56);">rly </font>ba<font style="color: rgb(28, 28, 33);">s</font>is during the Royalty Term, and otherwise in acco<font style="color: rgb(45, 45, 56);">rd</font>an<font style="color: rgb(45, 45, 56);">ce </font>with<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(45, 45, 56);">the </font>provi<font style="color: rgb(45, 45, 56);">sion</font>s of th<font style="color: rgb(45, 45, 56);">i</font>s <font style="color: rgb(45, 45, 56);">Article</font> 9:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table id="zd788bc659fb4445eadda51860cee2038" style="border-collapse: collapse; width: 60%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" align="center" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;"><font style="color: rgb(5, 5, 5);">Cumulative Annual N</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(5, 5, 5);">t S</font><font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(5, 5, 5);">les</font></div>
              <div style="font-weight: bold;"><font style="color: rgb(5, 5, 5);"> <br>
                </font></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(5, 5, 5);">Am</font><font style="font-weight: bold; color: rgb(28, 28, 33);">oun</font><font style="font-weight: bold; color: rgb(5, 5, 5);">t of </font><font style="font-weight: bold; color: rgb(45, 45, 56);">Ro</font><font style="font-weight: bold; color: rgb(5, 5, 5);">y</font><font style="font-weight: bold; color: rgb(45, 45, 56);">a</font><font style="font-weight: bold; color: rgb(5, 5, 5);">lty </font><font style="font-weight: bold; color: rgb(28, 28, 33);"></font></div>
              <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(28, 28, 33);">pa</font><font style="font-weight: bold; color: rgb(5, 5, 5);">yable </font><font style="color: rgb(45, 45, 56);">(% </font><font style="font-weight: bold; color: rgb(45, 45, 56);">of </font><font style="font-weight: bold; color: rgb(5, 5, 5);">Ne</font><font style="font-weight: bold; color: rgb(45, 45, 56);">t </font><font style="font-weight: bold; color: rgb(28, 28, 33);"></font></div>
              <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(28, 28, 33);">S</font><font style="font-weight: bold; color: rgb(5, 5, 5);">a</font><font style="font-weight: bold; color: rgb(45, 45, 56);">l</font><font style="font-weight: bold; color: rgb(5, 5, 5);">es</font><font style="font-weight: bold; color: rgb(28, 28, 33);">)</font></div>
              <div style="text-align: justify;"><font style="font-weight: bold; color: rgb(28, 28, 33);"> <br>
                </font></div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);">On annual aggregate Net </font><font style="color: rgb(45, 45, 56);">Sa</font><font style="color: rgb(5, 5, 5);">l</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(5, 5, 5);">s u</font><font style="color: rgb(45, 45, 56);">p to </font><font style="color: rgb(5, 5, 5);">and </font></div>
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);">including [***]</font></div>
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);"> <br>
                </font></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(5, 5, 5);">[***]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">33</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z6d5600e8650b4fce934da58676426f1f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 60%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" align="center" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);">On annual </font><font style="color: rgb(45, 45, 56);">ag</font><font style="color: rgb(5, 5, 5);">gregate </font><font style="color: rgb(45, 45, 56);">Net S</font><font style="color: rgb(5, 5, 5);">ale</font><font style="color: rgb(28, 28, 33);">s </font><font style="color: rgb(45, 45, 56);">&gt; [***]</font><font style="color: rgb(5, 5, 5);"> up to an</font><font style="color: rgb(28, 28, 33);">d </font></div>
              <div style="text-align: justify;"><font style="color: rgb(28, 28, 33);"></font><font style="color: rgb(5, 5, 5);">incl</font><font style="color: rgb(45, 45, 56);">ud</font><font style="color: rgb(5, 5, 5);">ing [***]</font></div>
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);"> <br>
                </font></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(5, 5, 5);">[***]</div>
              <div style="color: rgb(5, 5, 5);"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify;"><font style="color: rgb(5, 5, 5);">On an</font><font style="color: rgb(45, 45, 56);">n</font><font style="color: rgb(5, 5, 5);">ual aggre</font><font style="color: rgb(28, 28, 33);">gate </font><font style="color: rgb(5, 5, 5);">Net </font><font style="color: rgb(28, 28, 33);">S</font><font style="color: rgb(5, 5, 5);">a</font><font style="color: rgb(66, 68, 79);">les </font><font style="color: rgb(5, 5, 5);">&gt; [***]</font><font style="color: rgb(45, 45, 56);">&#160;</font><font style="color: rgb(5, 5, 5);">up to </font><font style="color: rgb(45, 45, 56);">a</font><font style="color: rgb(5, 5, 5);">nd<br>
                  &#160;</font><font style="color: rgb(45, 45, 56);">i</font><font style="color: rgb(5, 5, 5);">nclu</font><font style="color: rgb(45, 45, 56);">di</font><font style="color: rgb(5, 5, 5);">n</font><font style="color: rgb(45, 45, 56);">g [***]</font></div>
              <div style="text-align: justify;"><font style="color: rgb(45, 45, 56);"> <br>
                </font></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(5, 5, 5);">[***]</div>
              <div style="color: rgb(5, 5, 5);"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="color: rgb(28, 28, 33);">On </font><font style="color: rgb(45, 45, 56);">a</font><font style="color: rgb(5, 5, 5);">nnual </font><font style="color: rgb(45, 45, 56);">agg</font><font style="color: rgb(5, 5, 5);">r</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(5, 5, 5);">gat</font><font style="color: rgb(45, 45, 56);">e </font><font style="color: rgb(28, 28, 33);">Net </font><font style="color: rgb(5, 5, 5);">Sal</font><font style="color: rgb(28, 28, 33);">es </font><font style="color: rgb(66, 68, 79);">&gt; [***]</font><font style="color: rgb(5, 5, 5);"> u</font><font style="color: rgb(28, 28, 33);">p t</font><font style="color: rgb(5, 5, 5);">o and<br>
                  &#160;</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(5, 5, 5);">n</font><font style="color: rgb(45, 45, 56);">clu</font><font style="color: rgb(5, 5, 5);">din</font><font style="color: rgb(45, 45, 56);">g [***]</font></div>
              <div><font style="color: rgb(45, 45, 56);"> <br>
                </font></div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(45, 45, 56);">[***]</div>
              <div style="color: rgb(45, 45, 56);"> <br>
              </div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 33%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="color: rgb(28, 28, 33);">On </font><font style="color: rgb(5, 5, 5);">a</font><font style="color: rgb(45, 45, 56);">n</font><font style="color: rgb(5, 5, 5);">nu</font><font style="color: rgb(45, 45, 56);">a</font><font style="color: rgb(5, 5, 5);">l </font><font style="color: rgb(28, 28, 33);">ag</font><font style="color: rgb(5, 5, 5);">g</font><font style="color: rgb(45, 45, 56);">re</font><font style="color: rgb(5, 5, 5);">gate </font><font style="color: rgb(45, 45, 56);">N</font><font style="color: rgb(5, 5, 5);">et Sal</font><font style="color: rgb(28, 28, 33);">es &gt;</font></div>
              <div style="color: rgb(45, 45, 56);">[***]</div>
              <div style="color: rgb(45, 45, 56);"> <br>
              </div>
            </td>
            <td colspan="1" style="width: 1%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); border-left: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 25%; vertical-align: middle; border-top: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(5, 5, 5);">[***]</div>
              <div style="color: rgb(5, 5, 5);"> <br>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #050505;">For clarity, th</font><font style="color: #2D2D38;">ree ex</font><font style="color: #050505;">a</font><font style="color: #1C1C21;">m</font><font style="color: #050505;">ple</font><font style="color: #2D2D38;">s </font><font style="color: #050505;">ar</font><font style="color: #1C1C21;">e </font><font style="color: #050505;">outlined below:</font></div>
      <div>&#160;</div>
      <div style="margin-left: 36pt;">
        <table id="zedab589272354ffd8546141af00a897e" style="border-collapse: collapse; width: 90%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="color: rgb(5, 5, 5); margin-left: 9pt;">Royalties</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center;"><font style="color: rgb(45, 45, 56);">A</font><font style="color: rgb(5, 5, 5);">nnual w</font><font style="color: rgb(45, 45, 56);">orld</font><font style="color: rgb(5, 5, 5);">wide Net </font></div>
                <div style="text-align: center;"><font style="color: rgb(5, 5, 5);">S</font><font style="color: rgb(28, 28, 33);">ales </font><font style="color: rgb(5, 5, 5);">of </font><font style="color: rgb(28, 28, 33);">[***]</font></div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center;"><font style="color: rgb(5, 5, 5);">Annual worldwide Net </font></div>
                <div style="text-align: center;"><font style="color: rgb(5, 5, 5);">Sal</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(5, 5, 5);">s of </font><font style="color: rgb(28, 28, 33);">[***]</font></div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center;"><font style="color: rgb(5, 5, 5);">Annual worldwide Net </font></div>
                <div style="text-align: center;"><font style="color: rgb(5, 5, 5);">Sales of </font><font style="color: rgb(28, 28, 33);">[***]</font></div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 23%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
              <td style="width: 24%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(28, 28, 33);">[***]</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <table id="zef98dcad3fe04f9b901dfc50acc3eefa" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Royalty Term</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zba07bebe8cff4dc19de592f86086e5ce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to the provisions of this Article 9, G<font style="color: rgb(33, 33, 40);">S</font>K<font style="color: rgb(51, 51, 63);">&#8217;s </font>obligation to <font style="color: rgb(33, 33, 40);">p</font>a<font style="color: rgb(51, 51, 63);">y </font>the Royalty shall be calculated on a country-by-coun<font style="color: rgb(33, 33, 40);">t</font>ry <font style="color: rgb(33, 33, 40);">a</font>n<font style="color: rgb(33, 33, 40);">d </font>Licensed Pro<font style="color: rgb(33, 33, 40);">d</font>u<font style="color: rgb(33, 33, 40);">ct</font>-by-Licensed Product basis, in those countries of t<font style="color: rgb(51, 51, 63);">he </font>Territory in whic<font style="color: rgb(51, 51, 63);">h </font>t<font style="color: rgb(51, 51, 63);">h</font>ere is a Valid Claim that, but for the licenses gran <font style="color: rgb(33, 33, 40);">te</font>d to GSK, would be infringed [***] Royalty with respect to any <font style="color: rgb(33, 33, 40);">Li</font>cen<font style="color: rgb(51, 51, 63);">s</font>ed P<font style="color: rgb(51, 51, 63);">roduct </font>sh<font style="color: rgb(51, 51, 63);">a</font>ll <font style="color: rgb(51, 51, 63);">co</font>mmenc<font style="color: rgb(33, 33, 40);">e u</font>pon the First Commercial Sale of such Li<font style="color: rgb(51, 51, 63);">ce</font>n<font style="color: rgb(51, 51, 63);">sed </font>Product<font style="color: rgb(33, 33, 40);">&#160;</font>in a
                <font style="color: rgb(51, 51, 63);">cou</font>ntry, <font style="color: rgb(51, 51, 63);">an</font>d shall expire on [***] Commercial Sale of <font style="color: rgb(33, 33, 40);">s</font>uc<font style="color: rgb(33, 33, 40);">h </font>Lic<font style="color: rgb(51, 51, 63);">e</font>nsed Product<font style="color: rgb(51, 51, 63);">&#160;</font>in su<font style="color: rgb(51, 51, 63);">c</font>h <font style="color: rgb(51, 51, 63);">c</font>ountry (the &#8220;<font style="font-weight: bold;">Royalty Term</font>&#8221;). To the ext<font style="color: rgb(33, 33, 40);">e</font>nt <font style="color: rgb(51, 51, 63);">that</font> any <font style="color: rgb(51, 51, 63);">Li</font>ce<font style="color: rgb(51, 51, 63);">ns</font>e<font style="color: rgb(33, 33, 40);">d </font>Produ<font style="color: rgb(33, 33, 40);">ct i</font>s s<font style="color: rgb(51, 51, 63);">ol</font>d in <font style="color: rgb(51, 51, 63);">an</font>y country prior to First Commer<font style="color: rgb(33, 33, 40);">cia</font>l <font style="color: rgb(51, 51, 63);">Sal</font>e, N<font style="color: rgb(51, 51, 63);">et </font>Sales fro<font style="color: rgb(51, 51, 63);">m s</font>uch sales shall b<font style="color: rgb(33, 33, 40);">e </font><font style="color: rgb(51, 51, 63);">a</font>c<font style="color: rgb(51, 51, 63);">c</font>rued as from the time of sal<font style="color: rgb(51, 51, 63);">e </font>an<font style="color: rgb(51, 51, 63);">d </font>Roy<font style="color: rgb(33, 33, 40);">alties </font>on <font style="color: rgb(51, 51, 63);">s</font>u<font style="color: rgb(51, 51, 63);">ch </font>Net Sales shall become due in the quarter after First
                <font style="color: rgb(33, 33, 40);">C</font>omme<font style="color: rgb(33, 33, 40);">rci</font>al Sal<font style="color: rgb(33, 33, 40);">e.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z22c61d8b48074cfa985bc1fab06bfec1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If, on a country-by-<font style="color: rgb(51, 51, 63);">c</font>ountry <font style="color: rgb(33, 33, 40);">and </font>Licensed <font style="color: rgb(51, 51, 63);">Pro</font>duct -by-Li<font style="color: rgb(51, 51, 63);">ce</font>nsed






                Product basis, the onl<font style="color: rgb(33, 33, 40);">y </font>Valid Clai<font style="color: rgb(33, 33, 40);">m Co</font>ver<font style="color: rgb(33, 33, 40);">ing </font><font style="color: rgb(51, 51, 63);">a </font>Licens<font style="color: rgb(51, 51, 63);">ed Product </font>i<font style="color: rgb(51, 51, 63);">s </font>a claim of any pending paten<font style="color: rgb(51, 51, 63);">t </font><font style="color: rgb(33, 33, 40);">app</font>licati<font style="color: rgb(51, 51, 63);">o</font>n with<font style="color: rgb(33, 33, 40);">in the</font>&#160;<font style="color: rgb(33, 33, 40);">Immunocore</font><font style="color: rgb(51, 51, 63);">&#160;</font><font style="color: rgb(33, 33, 40);">For</font>eground,






                Immunocore Backgro<font style="color: rgb(51, 51, 63);">u</font>nd or <font style="color: rgb(51, 51, 63);">Plat </font>form <font style="color: rgb(33, 33, 40);">Rig</font>hts cove<font style="color: rgb(51, 51, 63);">ri</font>n<font style="color: rgb(33, 33, 40);">g </font>the co<font style="color: rgb(33, 33, 40);">mp</font>o<font style="color: rgb(51, 51, 63);">s</font>ition of matter, or the use of a process <font style="color: rgb(33, 33, 40);">t</font>o <font style="color: rgb(33, 33, 40);">manufacture</font>, o<font style="color: rgb(33, 33, 40);">r </font>method of <font style="color: rgb(33, 33, 40);">u</font>se of such Licensed Product (a &#8220;<font style="font-weight: bold;">P</font><font style="font-weight: bold; color: rgb(51, 51, 63);">endin</font><font style="font-weight: bold;">g C</font><font style="font-weight: bold; color: rgb(51, 51, 63);">l</font><font style="font-weight: bold;">ai</font><font style="font-weight: bold; color: rgb(33, 33, 40);">m</font>&#8221;, <font style="color: rgb(33, 33, 40);">the</font>n the <font style="color: rgb(33, 33, 40);">follo</font>w<font style="color: rgb(51, 51, 63);">in</font>g sh<font style="color: rgb(33, 33, 40);">a</font>ll






                <font style="color: rgb(51, 51, 63);">app</font>ly with respect to payment of<font style="color: rgb(33, 33, 40);"> t</font>h<font style="color: rgb(51, 51, 63);">e </font>Royal<font style="color: rgb(33, 33, 40);">t</font>y <font style="color: rgb(51, 51, 63);">o</font>n Net <font style="color: rgb(51, 51, 63);">Sa</font>les of <font style="color: rgb(33, 33, 40);">such Lic</font>ensed <font style="color: rgb(51, 51, 63);">Product</font> :</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zfa9c6455eb8c481eb48a0d96a903ca46" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54.35pt;"><br>
            </td>
            <td style="width: 35.65pt; vertical-align: top; align: right; color: #080808;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">If </font><font style="color: #33333F;">G</font><font style="color: #080808;">SK i</font><font style="color: #33333F;">s t</font><font style="color: #080808;">h</font><font style="color: #212128;">e </font><font style="color: #080808;">Party</font><font style="color: #33333F;">&#160;</font><font style="color: #212128;">co</font><font style="color: #080808;">ntrolling p</font><font style="color: #33333F;">ro</font><font style="color: #080808;">secution
                </font><font style="color: #212128;">of </font><font style="color: #080808;">the Pending Claim, then GSK will</font><font style="color: #33333F;"> pa</font><font style="color: #080808;">y [***] </font><font style="color: #33333F;">of </font><font style="color: #212128;">the</font><font style="color: #080808;"> applica</font><font style="color: #33333F;">b</font><font style="color: #080808;">le Royalty that would otherwise be due und</font><font style="color: #212128;">er Section</font><font style="color: #080808;">&#160;</font><font style="color: #212128;">9.</font><font style="color: #080808;">1 to Immunocore </font><font style="color: #33333F;">fo</font><font style="color: #080808;">r </font><font style="color: #212128;">s</font><font style="color: #080808;">o long as there is a Pending Claim [***] Immunocore </font><font style="color: #33333F;">s</font><font style="color: #080808;">hall r</font><font style="color: #212128;">evert </font><font style="color: #080808;">to






                  the full Royalty as set out in Section 9.1 with effect from th</font><font style="color: #33333F;">e d</font><font style="color: #080808;">ate of </font><font style="color: #33333F;">i</font><font style="color: #080808;">ss</font><font style="color: #33333F;">u</font><font style="color: #080808;">e of the Pending Claim until the end of the applicable Roy</font><font style="color: #33333F;">alt</font><font style="color: #080808;">y Term, </font><font style="color: #33333F;">subject</font><font style="color: #080808;"> to any reductions as set forth in Sections 9.</font><font style="color: #212128;">3</font><font style="color: #080808;">, 9.5 or 9.6</font><font style="color: #33333F;">,</font><font style="color: #080808;"> as </font><font style="color: #212128;">a</font><font style="color: #080808;">p</font><font style="color: #33333F;">p</font><font style="color: #080808;">licable du</font><font style="color: #33333F;">rin</font><font style="color: #080808;">g such Royalty Term. In addition,</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">34</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 90pt;"><font style="color: #080808;">GSK will pay to Immunocore</font><font style="color: #212128;">&#160;</font><font style="color: #080808;">within [***]</font><font style="color: #212128;">&#160;</font><font style="color: #080808;">of r</font><font style="color: #212128;">e</font><font style="color: #080808;">ceipt of </font><font style="color: #212128;">a</font><font style="color: #080808;">n invoic</font><font style="color: #212128;">e </font><font style="color: #080808;">from</font><font style="color: #212128;"> Imm</font><font style="color: #080808;">unoco</font><font style="color: #33333F;">re fo</font><font style="color: #080808;">llowing the d</font><font style="color: #212128;">a</font><font style="color: #080808;">te of i</font><font style="color: #212128;">s</font><font style="color: #080808;">sue of the Pending Cl</font><font style="color: #212128;">a</font><font style="color: #080808;">im an amount equal to the addit</font><font style="color: #33333F;">ional [***]</font><font style="color: #080808;"> of the Royalty that would have been payable in respe</font><font style="color: #33333F;">ct o</font><font style="color: #080808;">f Net Sales made before the issue of the
          Pending Claim as if the Pending Claim had been issued on the date of the First Commercial Sale.</font></div>
      <div>&#160;</div>
      <table id="z7debce5c4488424291e94b09d4640ee6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 54.15pt;"><br>
            </td>
            <td style="width: 35.85pt; vertical-align: top; align: right; color: #33333F;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">If Immunocore i</font><font style="color: #212128;">s </font><font style="color: #080808;">the Party controlling prose</font><font style="color: #212128;">c</font><font style="color: #080808;">ution of the
                  Pending Claim, then the term</font><font style="color: #212128;">s </font><font style="color: #080808;">of Section 9.2(</font><font style="color: #212128;">a</font><font style="color: #080808;">) shall apply, except that if the Pending
                  Claim does not issue during the period of [***] from the filing date of the first PCT patent application that supports such P</font><font style="color: #212128;">e</font><font style="color: #080808;">nding Claim, then GSK shall be
                  entitled to continue to pay the Royalty at the rate that is [***] of what would otherwise be due under Section 9.1 during the remainder of the Royalty </font><font style="color: #070707;">Term, even if such Pending Claim issues after
                  such [***] period during the Royalty Term, subject to any reductions as set forth in Section 9.5 and 9.6 as applicable during such Royalty Term.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zed32463c5caa469caf465eb605216243" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On a country-by-country and Licensed Product - by- Lice<font style="color: rgb(47, 47, 58);">n</font>sed Product basis, if, at any time during the Royalty Term, either no Valid Claim e<font style="color: rgb(28, 28, 33);">x</font>ist<font style="color: rgb(28, 28, 33);">s </font><font style="color: rgb(47, 47, 58);">o</font>r all Valid Claims Covering the composition of matter or the use of a process to <font style="color: rgb(47, 47, 58);">m</font><font style="color: rgb(28, 28, 33);">anu</font>facture or ap<font style="color: rgb(47, 47, 58);">pro</font>ved method of use have expired<font style="color: rgb(28, 28, 33);">, </font>and Immunocore has mai<font style="color: rgb(47, 47, 58);">n</font>t<font style="color: rgb(47, 47, 58);">ai</font><font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(28, 28, 33);">d, </font>at the time<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(47, 47, 58);">o</font><font style="color: rgb(28, 28, 33);">f </font>sale of the applicable Licensed Product, Confidential Inform<font style="color: rgb(47, 47, 58);">atio</font>n as documented <font style="color: rgb(47, 47, 58);">i</font>n <font style="color: rgb(47, 47, 58);">written</font> records that covers the composition of matter, or th<font style="color: rgb(28, 28, 33);">e </font>use of a proces<font style="color: rgb(28, 28, 33);">s </font>t<font style="color: rgb(28, 28, 33);">o </font>manufacture or approved method of use of the Licensed Product<font style="color: rgb(47, 47, 58);">,</font><font style="color: rgb(28, 28, 33);">&#160;</font>the<font style="color: rgb(28, 28, 33);">n
                </font>GSK shall <font style="color: rgb(28, 28, 33);">pa</font>y Im<font style="color: rgb(47, 47, 58);">mu</font>nocore a Royalty on Net Sales of such Licensed Product<font style="color: rgb(28, 28, 33);">&#160;</font>a<font style="color: rgb(28, 28, 33);">t </font>a ra<font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 47, 58);">e </font><font style="color: rgb(28, 28, 33);">that</font> is [***] of the applicable Royalty rates set forth<font style="color: rgb(47, 47, 58);">&#160;</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(47, 47, 58);">n </font>Se<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 58);">tio</font><font style="color: rgb(28, 28, 33);">n 9</font>.1.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7ce85875c1294f39ad5c570c7f29956c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon expiration of the applicable R<font style="color: rgb(47, 47, 58);">oy</font>a<font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 58);">ty </font>Ter <font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 47, 58);">, th</font><font style="color: rgb(28, 28, 33);">e </font>li<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 58);">en</font>s<font style="color: rgb(47, 47, 58);">e</font><font style="color: rgb(28, 28, 33);">s </font>gra<font style="color: rgb(47, 47, 58);">nt</font>ed to GSK under Section 6.7 shall become fully paid<font style="color: rgb(96, 96, 110);">-</font>u<font style="color: rgb(28, 28, 33);">p</font>,
                <font style="color: rgb(47, 47, 58);">ro</font>yalt<font style="color: rgb(47, 47, 58);">y</font><font style="color: rgb(96, 96, 110);">-</font><font style="color: rgb(47, 47, 58);">fr</font>e<font style="color: rgb(28, 28, 33);">e</font>,
                per<font style="color: rgb(47, 47, 58);">p</font><font style="color: rgb(28, 28, 33);">etu</font>al licens<font style="color: rgb(47, 47, 58);">es </font>to make, have made, use, sell, offer for sale and i<font style="color: rgb(28, 28, 33);">m</font><font style="color: rgb(47, 47, 58);">p</font>ort the <font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 58);">p</font><font style="color: rgb(28, 28, 33);">p</font>licab<font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 58);">e </font><font style="color: rgb(28, 28, 33);">Li</font>censed Product in the Field in the applicable country of the Ter<font style="color: rgb(28, 28, 33);">rito</font><font style="color: rgb(47, 47, 58);">ry.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z075f5bbd998041bbb916fb8babce401c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Royalty (as adjusted in acc<font style="color: rgb(47, 47, 58);">o</font>rdance <font style="color: rgb(47, 47, 58);">wi</font><font style="color: rgb(28, 28, 33);">t</font>h <font style="color: rgb(28, 28, 33);">Section</font> 9.<font style="color: rgb(28, 28, 33);">3) </font>p<font style="color: rgb(28, 28, 33);">ay</font><font style="color: rgb(47, 47, 58);">a</font>ble i<font style="color: rgb(28, 28, 33);">n </font>relation to any Licensed Product on a country<font style="color: rgb(47, 47, 58);">-by</font>-co<font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(47, 47, 58);">nt</font>ry ba<font style="color: rgb(47, 47, 58);">s</font>i<font style="color: rgb(47, 47, 58);">s s</font><font style="color: rgb(28, 28, 33);">hall </font>also be <font style="color: rgb(47, 47, 58);">r</font>educe<font style="color: rgb(28, 28, 33);">d b</font><font style="color: rgb(47, 47, 58);">y </font>a [***] where an<font style="color: rgb(28, 28, 33);">y </font>Bio<font style="color: rgb(47, 47, 58);">s</font>imila<font style="color: rgb(47, 47, 58);">r Pro</font>duct <font style="color: rgb(47, 47, 58);">is s</font><font style="color: rgb(28, 28, 33);">o</font>l<font style="color: rgb(47, 47, 58);">d </font>in <font style="color: rgb(28, 28, 33);">the relevant </font>cou<font style="color: rgb(28, 28, 33);">n</font>try and where entry of such Biosimilar Product ha<font style="color: rgb(47, 47, 58);">s </font><font style="color: rgb(28, 28, 33);">r</font>educ<font style="color: rgb(28, 28, 33);">e</font>d GSK<font style="color: rgb(28, 28, 33);">&#8217;</font>s <font style="color: rgb(28, 28, 33);">m</font>a<font style="color: rgb(28, 28, 33);">rke</font>t shar<font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(47, 47, 58);">[***] </font>Section 9.5 shall only apply whilst such Biosimilar Product continues to be sold in the [***]<font style="color: rgb(47, 47, 58);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zba3c2a1509e343688310192052070c9e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK <font style="color: rgb(47, 47, 58);">s</font>hall be entitled <font style="color: rgb(47, 47, 58);">t</font>o cre<font style="color: rgb(28, 28, 33);">d</font><font style="color: rgb(47, 47, 58);">i</font><font style="color: rgb(28, 28, 33);">t a</font>gainst <font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 58);">ny </font>milestones or Royalty owed by GSK to Immunocore in r<font style="color: rgb(28, 28, 33);">el</font><font style="color: rgb(47, 47, 58);">a</font>tion to any Licensed <font style="color: rgb(47, 47, 58);">Pr</font><font style="color: rgb(28, 28, 33);">o</font>duct, [***] of any and all payments ma<font style="color: rgb(28, 28, 33);">de </font><font style="color: rgb(47, 47, 58);">to </font><font style="color: rgb(28, 28, 33);">T</font><font style="color: rgb(47, 47, 58);">h</font>ird Parties<font style="color: rgb(47, 47, 58);">&#160;</font>wh<font style="color: rgb(28, 28, 33);">e</font>re






                su<font style="color: rgb(28, 28, 33);">c</font>h paym<font style="color: rgb(28, 28, 33);">e</font>nt<font style="color: rgb(28, 28, 33);">s a</font>re made to <font style="color: rgb(28, 28, 33);">s</font>u<font style="color: rgb(28, 28, 33);">c</font>h Third Parties in accordance wi<font style="color: rgb(28, 28, 33);">t</font><font style="color: rgb(47, 47, 58);">h a </font>licen<font style="color: rgb(28, 28, 33);">c</font>e <font style="color: rgb(47, 47, 58);">t</font>o
                <font style="color: rgb(47, 47, 58);">a </font>patent that <font style="color: rgb(28, 28, 33);">c</font>overs the Li<font style="color: rgb(28, 28, 33);">c</font>ensed Product (<font style="color: rgb(28, 28, 33);">a</font>nd where such
                Lic<font style="color: rgb(28, 28, 33);">e</font>nsed Product wo<font style="color: rgb(47, 47, 58);">ul</font><font style="color: rgb(28, 28, 33);">d </font><font style="color: rgb(47, 47, 58);">b</font><font style="color: rgb(28, 28, 33);">e </font>infringing such Third Party right in th<font style="color: rgb(28, 28, 33);">e </font>abs<font style="color: rgb(28, 28, 33);">e</font>nce of <font style="color: rgb(28, 28, 33);">s</font>uch licence) a<font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(47, 47, 58);">d is </font>owne<font style="color: rgb(47, 47, 58);">d </font>or Controlled by such Third Party; provided, that the Royalty payable <font style="color: rgb(47, 47, 58);">to </font>Immunocore would never be less than [***] of the amount other<font style="color: rgb(28, 28, 33);">w</font><font style="color: rgb(47, 47, 58);">is</font><font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(47, 47, 58);">d</font>ue in <font style="color: rgb(47, 47, 58);">a</font>c<font style="color: rgb(47, 47, 58);">co</font><font style="color: rgb(28, 28, 33);">r</font>d<font style="color: rgb(28, 28, 33);">a</font>nce
                with Section 9.1, as adjusted by Sections 9.3 and 9.5 in any <font style="color: rgb(28, 28, 33);">p</font><font style="color: rgb(47, 47, 58);">a</font>rticular <font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 58);">a</font><font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 58);">end</font>ar quarter. If the amount to be credited exceeds [***]<font style="color: rgb(47, 47, 58);">&#160;</font>of th<font style="color: rgb(28, 28, 33);">e </font>a<font style="color: rgb(47, 47, 58);">m</font><font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(47, 47, 58);">u</font>nt otherwise due to Immunocore in any <font style="color: rgb(28, 28, 33);">c</font>alendar quarter, then <font style="color: rgb(28, 28, 33);">G</font>SK<font style="color: rgb(47, 47, 58);"> sha</font><font style="color: rgb(28, 28, 33);">ll b</font>e entitled to carry forward the excess to offset
                against milestones or Royalty paid<font style="color: rgb(28, 28, 33);"> i</font><font style="color: rgb(47, 47, 58);">n relation</font> to the relevant Licen<font style="color: rgb(28, 28, 33);">s</font>ed Product in future calendar
                quarters but in each case<font style="color: rgb(47, 47, 58);"> in co</font>mpli<font style="color: rgb(28, 28, 33);">a</font>n<font style="color: rgb(28, 28, 33);">ce </font>with thi<font style="color: rgb(28, 28, 33);">s </font>Section
                9.<font style="color: rgb(28, 28, 33);">6</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7e5f6b2cfae34f4a936381f14fa4dde0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>With re<font style="color: rgb(28, 28, 33);">s</font>pe<font style="color: rgb(28, 28, 33);">c</font>t to <font style="color: rgb(28, 28, 33);">sa</font>les of the Licen<font style="color: rgb(28, 28, 33);">s</font>ed Product invoiced
                in pounds <font style="color: rgb(28, 28, 33);">s</font>terling, the Net Sale<font style="color: rgb(28, 28, 33);">s</font> and the amounts due hereunder will be expr<font style="color: rgb(28, 28, 33);">e</font>ssed in pounds st<font style="color: rgb(28, 28, 33);">e</font>rling. With r<font style="color: rgb(28, 28, 33);">e</font>sp<font style="color: rgb(28, 28, 33);">ec</font>t to sales of the Licensed Product invoiced in a <font style="color: rgb(28, 28, 33);">c</font>urrency






                other than pounds sterling, the Net Sale<font style="color: rgb(28, 28, 33);">s </font>and amounts due hereunder will be reported in pound<font style="color: rgb(28, 28, 33);">s s</font>terling, c<font style="color: rgb(28, 28, 33);">a</font>lculated






                u<font style="color: rgb(28, 28, 33);">s</font>ing <font style="color: rgb(7, 7, 8);">the average exchange rates as calculated and utilized by GSK&#8217;s group reporting system on a customary basis and published accounts for its own purposes.
                  As of the Effective Date, the method utilized by GSK&#8217;s group</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">35</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #070708;">reporting system uses spot exchange rates sourced from Reuters/Bloomberg. Such conversion shall be made as part of the quarterly reporting of Net Sales in the relevant
          a</font><font style="color: #212126;">c</font><font style="color: #070708;">counts </font><font style="color: #212126;">o</font><font style="color: #070708;">f GSK, GSK&#8217;s Affiliates or their sublicensees.</font></div>
      <div>&#160;</div>
      <table id="zf93b71a4fbd149b2bb052ac1bcdb023d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Until the expiration of all applicable Royalty Te<font style="color: rgb(33, 33, 38);">rms,</font><font style="color: rgb(54, 56, 68);">&#160;</font>GSK will pro<font style="color: rgb(33, 33, 38);">vide </font>a report to Immunocore within
                [***] after each <font style="color: rgb(54, 56, 68);">c</font><font style="color: rgb(33, 33, 38);">ale</font>ndar quarter <font style="font-weight: bold;">(&#8220;R</font><font style="font-weight: bold; color: rgb(33, 33, 38);">o</font><font style="font-weight: bold;">y</font><font style="font-weight: bold; color: rgb(33, 33, 38);">a</font><font style="font-weight: bold;">lty Report&#8221;)</font><font style="font-weight: bold; color: rgb(33, 33, 38);">,</font><font style="font-weight: bold;">&#160;</font>with the first report due within [***] <font style="color: rgb(33, 33, 38);">a</font>fter <font style="color: rgb(33, 33, 38);">t</font>he expiry of <font style="color: rgb(54, 56, 68);">t</font><font style="color: rgb(33, 33, 38);">h</font>e calendar quarter in which the First Commercial Sale of any Li<font style="color: rgb(33, 33, 38);">c</font><font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">ns</font><font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">d </font>Product by GS<font style="color: rgb(33, 33, 38);">K </font>or its <font style="color: rgb(54, 56, 68);">Affiliates</font> or their sublicensees
                occurs. The Royalty Rep<font style="color: rgb(33, 33, 38);">ort s</font>ha<font style="color: rgb(54, 56, 68);">l</font><font style="color: rgb(33, 33, 38);">l </font>incl<font style="color: rgb(54, 56, 68);">u</font>d<font style="color: rgb(33, 33, 38);">e r</font>eas<font style="color: rgb(33, 33, 38);">o</font>n<font style="color: rgb(54, 56, 68);">a</font>b<font style="color: rgb(33, 33, 38);">l</font>e det<font style="color: rgb(33, 33, 38);">a</font><font style="color: rgb(54, 56, 68);">il as </font><font style="color: rgb(33, 33, 38);">a</font>vailable including: (i) the total Net Sales for ea<font style="color: rgb(33, 33, 38);">c</font>h <font style="color: rgb(33, 33, 38);">Lic</font><font style="color: rgb(54, 56, 68);">e</font>nse<font style="color: rgb(33, 33, 38);">d Product</font>&#160;<font style="color: rgb(54, 56, 68);">o</font>n <font style="color: rgb(54, 56, 68);">a </font>co<font style="color: rgb(33, 33, 38);">unt</font><font style="color: rgb(54, 56, 68);">r</font>y-<font style="color: rgb(33, 33, 38);">b</font>y-country basis; and (ii) a calculation of the am<font style="color: rgb(33, 33, 38);">ou</font>n<font style="color: rgb(33, 33, 38);">t o</font>f R<font style="color: rgb(33, 33, 38);">oyal</font><font style="color: rgb(54, 56, 68);">t</font><font style="color: rgb(33, 33, 38);">y </font>du<font style="color: rgb(33, 33, 38);">e on </font><font style="color: rgb(54, 56, 68);">s</font>uch






                Ne<font style="color: rgb(33, 33, 38);">t S</font>ales for each Licensed Product on a country-by-cou<font style="color: rgb(54, 56, 68);">n</font>t<font style="color: rgb(33, 33, 38);">ry b</font>asis. <font style="color: rgb(33, 33, 38);">Concurrent</font>
                with <font style="color: rgb(33, 33, 38);">the </font>delivery of each such Royalty Report, GSK shall ma<font style="color: rgb(33, 33, 38);">ke t</font>h<font style="color: rgb(33, 33, 38);">e </font>Roy<font style="color: rgb(33, 33, 38);">alty p</font>ayme<font style="color: rgb(54, 56, 68);">n</font><font style="color: rgb(33, 33, 38);">t d</font>ue to <font style="color: rgb(33, 33, 38);">I</font>m<font style="color: rgb(33, 33, 38);">m</font>unocore for the
                calendar quarter covered by such <font style="color: rgb(33, 33, 38);">R</font>o<font style="color: rgb(33, 33, 38);">y</font><font style="color: rgb(54, 56, 68);">a</font>lty Report<font style="color: rgb(54, 56, 68);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zef1122d033274409bf6dae3cef8cc80b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK or its Affiliates and their <font style="color: rgb(33, 33, 38);">sub</font><font style="color: rgb(54, 56, 68);">li</font><font style="color: rgb(33, 33, 38);">c</font>ens<font style="color: rgb(33, 33, 38);">e</font>es shall ke<font style="color: rgb(33, 33, 38);">ep a</font>nd <font style="color: rgb(33, 33, 38);">ma</font>i<font style="color: rgb(54, 56, 68);">n</font><font style="color: rgb(33, 33, 38);">t</font>a<font style="color: rgb(33, 33, 38);">i</font>n
                for [***] (or such longer period allow<font style="color: rgb(33, 33, 38);">ed </font>by GSK&#8217;s record<font style="color: rgb(33, 33, 38);"> retention</font>&#160;<font style="color: rgb(33, 33, 38);">p</font><font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">l</font>i<font style="color: rgb(33, 33, 38);">cie</font><font style="color: rgb(54, 56, 68);">s</font><font style="color: rgb(33, 33, 38);">, </font>not <font style="color: rgb(33, 33, 38);">to </font>exceed [***]) complete and accur<font style="color: rgb(33, 33, 38);">at</font>e <font style="color: rgb(33, 33, 38);">r</font><font style="color: rgb(54, 56, 68);">ec</font><font style="color: rgb(33, 33, 38);">o</font>rds






                <font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">f </font>sale<font style="color: rgb(33, 33, 38);">s o</font>f <font style="color: rgb(33, 33, 38);">Lice</font>nsed <font style="color: rgb(33, 33, 38);">Products</font> in <font style="color: rgb(54, 56, 68);">sufficient</font> detail to allow Immunocore to con<font style="color: rgb(33, 33, 38);">fir</font>m <font style="color: rgb(54, 56, 68);">t</font><font style="color: rgb(33, 33, 38);">h</font>e ac<font style="color: rgb(54, 56, 68);">c</font><font style="color: rgb(33, 33, 38);">u</font><font style="color: rgb(54, 56, 68);">r</font><font style="color: rgb(33, 33, 38);">ac</font>y of <font style="color: rgb(33, 33, 38);">Ro</font><font style="color: rgb(54, 56, 68);">y</font><font style="color: rgb(33, 33, 38);">a</font>l<font style="color: rgb(33, 33, 38);">t</font>ies <font style="color: rgb(54, 56, 68);">a</font>nd
                Sales M<font style="color: rgb(33, 33, 38);">il</font>estones (as defined in Schedule 2) paid hereun<font style="color: rgb(33, 33, 38);">der. </font>Immunocore<font style="color: rgb(33, 33, 38);">&#160;</font>shall ha<font style="color: rgb(33, 33, 38);">v</font>e <font style="color: rgb(54, 56, 68);">t</font>h<font style="color: rgb(33, 33, 38);">e </font>right d<font style="color: rgb(33, 33, 38);">ur</font><font style="color: rgb(54, 56, 68);">i</font><font style="color: rgb(33, 33, 38);">n</font>g such [***] period to appoi<font style="color: rgb(33, 33, 38);">nt </font>an indep<font style="color: rgb(54, 56, 68);">e</font>n<font style="color: rgb(33, 33, 38);">de</font>nt a<font style="color: rgb(33, 33, 38);">u</font>di<font style="color: rgb(33, 33, 38);">to</font>r re<font style="color: rgb(33, 33, 38);">as</font>ona<font style="color: rgb(33, 33, 38);">bl</font>y acc<font style="color: rgb(54, 56, 68);">e</font>p<font style="color: rgb(54, 56, 68);">t</font>a<font style="color: rgb(33, 33, 38);">bl</font>e to GSK to audit the records of GSK <font style="color: rgb(54, 56, 68);">an</font>d/ or a<font style="color: rgb(33, 33, 38);">ny </font>Affiliates<font style="color: rgb(33, 33, 38);"> a</font>nd<font style="color: rgb(33, 33, 38);">/ </font>or th<font style="color: rgb(33, 33, 38);">e</font><font style="color: rgb(54, 56, 68);">ir </font>sublicense<font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">s </font>for the purpose of verifying Royalty Reports pr<font style="color: rgb(33, 33, 38);">o</font>v<font style="color: rgb(33, 33, 38);">id</font><font style="color: rgb(54, 56, 68);">e</font>d b<font style="color: rgb(33, 33, 38);">y GSK</font>. Suc<font style="color: rgb(33, 33, 38);">h aud</font>it rig<font style="color: rgb(33, 33, 38);">ht </font><font style="color: rgb(54, 56, 68);">s</font>h<font style="color: rgb(33, 33, 38);">a</font>ll






                not be exercised by Immunocore m<font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">r</font>e <font style="color: rgb(54, 56, 68);">t</font><font style="color: rgb(33, 33, 38);">ha</font>n on<font style="color: rgb(54, 56, 68);">c</font>e <font style="color: rgb(54, 56, 68);">i</font>n an<font style="color: rgb(54, 56, 68);">y </font>c<font style="color: rgb(33, 33, 38);">al</font>enda<font style="color: rgb(33, 33, 38);">r y</font>ear






                and <font style="color: rgb(33, 33, 38);">the </font><font style="color: rgb(54, 56, 68);">re</font><font style="color: rgb(33, 33, 38);">c</font>ords for a [***] period <font style="color: rgb(33, 33, 38);">may </font>not b<font style="color: rgb(33, 33, 38);">e a</font><font style="color: rgb(54, 56, 68);">u</font>dited <font style="color: rgb(54, 56, 68);">mo</font><font style="color: rgb(33, 33, 38);">r</font>e than <font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">n</font>c<font style="color: rgb(33, 33, 38);">e</font><font style="color: rgb(54, 56, 68);">. </font>GSK <font style="color: rgb(33, 33, 38);">shall </font>make its records available for audit by <font style="color: rgb(33, 33, 38);">s</font>uch inde<font style="color: rgb(33, 33, 38);">p</font>e<font style="color: rgb(33, 33, 38);">nd</font>ent <font style="color: rgb(54, 56, 68);">a</font><font style="color: rgb(33, 33, 38);">ud</font><font style="color: rgb(54, 56, 68);">i</font><font style="color: rgb(33, 33, 38);">t</font>or du<font style="color: rgb(54, 56, 68);">r</font><font style="color: rgb(33, 33, 38);">i</font>n<font style="color: rgb(54, 56, 68);">g </font>regula<font style="color: rgb(33, 33, 38);">r </font>business hours at such place or places wh<font style="color: rgb(33, 33, 38);">e</font>r<font style="color: rgb(54, 56, 68);">e </font><font style="color: rgb(33, 33, 38);">suc</font>h r<font style="color: rgb(33, 33, 38);">e</font><font style="color: rgb(54, 56, 68);">c</font><font style="color: rgb(33, 33, 38);">o</font>r<font style="color: rgb(54, 56, 68);">d</font>s ar<font style="color: rgb(33, 33, 38);">e c</font>u<font style="color: rgb(33, 33, 38);">s</font>tom<font style="color: rgb(54, 56, 68);">ari</font><font style="color: rgb(33, 33, 38);">ly </font><font style="color: rgb(54, 56, 68);">k</font><font style="color: rgb(33, 33, 38);">e</font>pt, up<font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">n [***] </font>written notice from Im<font style="color: rgb(33, 33, 38);">m</font>u<font style="color: rgb(54, 56, 68);">n</font><font style="color: rgb(33, 33, 38);">o</font>core. <font style="color: rgb(33, 33, 38);">A</font>ll rec<font style="color: rgb(54, 56, 68);">or</font>ds ma<font style="color: rgb(33, 33, 38);">de ava</font>ilable <font style="color: rgb(54, 56, 68);">for </font>audit







                shall be deemed to be Confid<font style="color: rgb(33, 33, 38);">en</font>t<font style="color: rgb(54, 56, 68);">ia</font><font style="color: rgb(33, 33, 38);">l In</font>for<font style="color: rgb(33, 33, 38);">m</font>a<font style="color: rgb(33, 33, 38);">tio</font>n <font style="color: rgb(33, 33, 38);">o</font>f <font style="color: rgb(54, 56, 68);">G</font><font style="color: rgb(33, 33, 38);">S</font>K. Th<font style="color: rgb(33, 33, 38);">e </font>r<font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">su</font>lts of <font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">ach </font>audit<font style="color: rgb(33, 33, 38);">, </font>if






                any, shall be binding on both <font style="color: rgb(33, 33, 38);">Parties</font> ab<font style="color: rgb(33, 33, 38);">s</font><font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">n</font>t man<font style="color: rgb(33, 33, 38);">i</font><font style="color: rgb(54, 56, 68);">f</font><font style="color: rgb(33, 33, 38);">e</font>s<font style="color: rgb(33, 33, 38);">t e</font>rror or fra<font style="color: rgb(54, 56, 68);">u</font>d.






                GSK s<font style="color: rgb(33, 33, 38);">ha</font>ll use reasonable efforts to require its <font style="color: rgb(33, 33, 38);">Affiliates</font> a<font style="color: rgb(33, 33, 38);">nd a</font>ny s<font style="color: rgb(33, 33, 38);">ub</font><font style="color: rgb(54, 56, 68);">l</font><font style="color: rgb(33, 33, 38);">ic</font>ensee<font style="color: rgb(33, 33, 38);">s </font><font style="color: rgb(54, 56, 68);">o</font>f Affiliates <font style="color: rgb(54, 56, 68);">o</font>r GSK that sell the Licensed Products to p<font style="color: rgb(54, 56, 68);">e</font>r<font style="color: rgb(54, 56, 68);">mi</font><font style="color: rgb(33, 33, 38);">t </font>Immunocore&#8217;<font style="color: rgb(33, 33, 38);">s au</font><font style="color: rgb(54, 56, 68);">d</font>it or <font style="color: rgb(33, 33, 38);">acc</font><font style="color: rgb(54, 56, 68);">es</font><font style="color: rgb(33, 33, 38);">s </font><font style="color: rgb(54, 56, 68);">t</font>o r<font style="color: rgb(33, 33, 38);">ec</font><font style="color: rgb(54, 56, 68);">o</font><font style="color: rgb(33, 33, 38);">rds </font>o<font style="color: rgb(33, 33, 38);">f s</font>uch
                Affiliates an<font style="color: rgb(33, 33, 38);">d s</font>ubli<font style="color: rgb(33, 33, 38);">c</font>ens<font style="color: rgb(33, 33, 38);">e</font>e<font style="color: rgb(33, 33, 38);">s </font>at the s<font style="color: rgb(33, 33, 38);">am</font><font style="color: rgb(54, 56, 68);">e </font>time an<font style="color: rgb(33, 33, 38);">d </font>pla<font style="color: rgb(33, 33, 38);">c</font>e a<font style="color: rgb(54, 56, 68);">s </font>any a<font style="color: rgb(33, 33, 38);">ud</font><font style="color: rgb(54, 56, 68);">i</font><font style="color: rgb(33, 33, 38);">t </font>of GSK <font style="color: rgb(33, 33, 38);">re</font><font style="color: rgb(54, 56, 68);">c</font><font style="color: rgb(33, 33, 38);">o</font>rds under this Section 9.9. GSK sh<font style="color: rgb(33, 33, 38);">a</font>ll p<font style="color: rgb(33, 33, 38);">a</font>y any underpayment <font style="color: rgb(33, 33, 38);">o</font>f
                Royalty identified b<font style="color: rgb(33, 33, 38);">y </font>the auditor following an audit under this Section 9.9 with<font style="color: rgb(33, 33, 38);">i</font><font style="color: rgb(54, 56, 68);">n [***]</font> after receipt
                of an invoice from Immunocore for such underpaid <font style="color: rgb(54, 56, 68);">a</font><font style="color: rgb(33, 33, 38);">m</font>ount.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zd8c4d5baaa324beab6b84697b05cedd5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">Immunocore</font><font style="color: #212126;"> sh</font><font style="color: #070708;">all be</font><font style="color: #212126;">a</font><font style="color: #363844;">r </font><font style="color: #070708;">th</font><font style="color: #363844;">e </font><font style="color: #070708;">costs of an audit performed under Section 9.9, except where the audi</font><font style="color: #363844;">t r</font><font style="color: #212126;">e</font><font style="color: #070708;">port ident</font><font style="color: #212126;">i</font><font style="color: #070708;">fies an underp</font><font style="color: #212126;">a</font><font style="color: #070708;">yment of Royalty of more than [***], </font><font style="color: #363844;">i</font><font style="color: #212126;">n </font><font style="color: #070708;">which case, all documented and reasonable audit fees shall be paid </font><font style="color: #212126;">b</font><font style="color: #363844;">y </font><font style="color: #070708;">GSK.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z25d1f44efbc34bf282b0b000d2286f58" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #212126;">I</font><font style="color: #363844;">n </font><font style="color: #212126;">th</font>e event that non<font style="color: rgb(33, 33, 38);">-</font>monetary consideration or no ascertainable consideration
                is<font style="color: rgb(33, 33, 38);"> r</font><font style="color: rgb(54, 56, 68);">e</font><font style="color: rgb(33, 33, 38);">c</font><font style="color: rgb(54, 56, 68);">e</font>ived for any Licensed Product,<font style="color: rgb(33, 33, 38);">&#160;</font>Net Sales will be calculated based on the average<font style="color: rgb(54, 56, 68);"> p</font>ri<font style="color: rgb(33, 33, 38);">ce c</font>h<font style="color: rgb(33, 33, 38);">a</font>rg<font style="color: rgb(33, 33, 38);">e</font>d for <font style="color: rgb(33, 33, 38);">s</font>u<font style="color: rgb(33, 33, 38);">c</font>h Li<font style="color: rgb(33, 33, 38);">ce</font>n<font style="color: rgb(33, 33, 38);">s</font>ed






                Product <font style="color: rgb(33, 33, 38);">d</font>uring the pre<font style="color: rgb(33, 33, 38);">ce</font>ding royalty p<font style="color: rgb(33, 33, 38);">e</font>riod, or in th<font style="color: rgb(33, 33, 38);">e a</font>bsenc<font style="color: rgb(33, 33, 38);">e </font>of su<font style="color: rgb(33, 33, 38);">c</font>h sale<font style="color: rgb(33, 33, 38);">s, </font>the fair m<font style="color: rgb(33, 33, 38);">a</font>rket value of the Li<font style="color: rgb(33, 33, 38);">c</font>en<font style="color: rgb(33, 33, 38);">s</font>ed Product, <font style="color: rgb(33, 33, 38);">a</font>s determined by the Parties in good faith. Wh<font style="color: rgb(33, 33, 38);">e</font>re






                the r<font style="color: rgb(33, 33, 38);">e</font>levant mon<font style="color: rgb(33, 33, 38);">e</font>tary con<font style="color: rgb(33, 33, 38);">s</font>id<font style="color: rgb(33, 33, 38);">e</font>ration cannot b<font style="color: rgb(33, 33, 38);">e </font>agr<font style="color: rgb(33, 33, 38);">e</font>ed b<font style="color: rgb(33, 33, 38);">e</font>tw<font style="color: rgb(33, 33, 38);">ee</font>n th<font style="color: rgb(33, 33, 38);">e </font>Parties,






                eith<font style="color: rgb(33, 33, 38);">e</font>r Party <font style="color: rgb(33, 33, 38);">s</font>hall be <font style="color: rgb(33, 33, 38);">entitled</font> t<font style="color: rgb(33, 33, 38);">o </font>r<font style="color: rgb(33, 33, 38);">e</font>f<font style="color: rgb(33, 33, 38);">e</font>r the determination to <font style="color: rgb(33, 33, 38);">a</font>n independent expert located in [***] and appointed by mutual agreement between the Parties <font style="color: rgb(33, 33, 38);">o</font>r in the <font style="color: rgb(33, 33, 38);">a</font>bsence of any agreement within [***]<font style="color: rgb(33, 33, 38);">&#160;</font>of <font style="color: rgb(8, 8, 8);">written request for
                  referral, by [***]. The independent expert shall act as an expert and not an arbitrator, and reach a decision as quickly as possible and in any event within [***] of appointment. The expert&#8217;s decision shall be final and binding on the
                  Parties in the absence of any manifest error and the Parties shall share equally in the costs of th</font><font style="color: rgb(36, 38, 45);">e </font><font style="color: rgb(8, 8, 8);">expert</font><font style="color: rgb(36, 38, 45);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z77a8a274fd5c479abe7ba9615dbe3f79" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In addition to Section 9.11, If a Licensed Product i<font style="color: rgb(52, 52, 63);">s sol</font>d as part of <font style="color: rgb(52, 52, 63);">a m</font>ulti-product sale (whether physically combined or sold or su<font style="color: rgb(36, 38, 45);">p</font>p<font style="color: rgb(52, 52, 63);">li</font>e<font style="color: rgb(36, 38, 45);">d </font>together) wheth<font style="color: rgb(52, 52, 63);">e</font>r by GSK, its Affiliates or their
                sublicensees, then for pu<font style="color: rgb(36, 38, 45);">rpo</font>ses of determining <font style="color: rgb(36, 38, 45);">p</font>ayments due hereunder, Net Sales of such Licensed Product s<font style="color: rgb(36, 38, 45);">h</font>all






                be deem<font style="color: rgb(52, 52, 63);">e</font>d <font style="color: rgb(36, 38, 45);">t</font>o be an amount equal to the following:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">36</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 72pt; color: #080808;">(X divided by Y) multiplied by Z,</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.35pt; margin-left: 36pt;"><font style="color: #080808;">where &#8220;</font><font style="font-weight: bold; color: #080808;">X</font><font style="color: #080808;">&#8221; is the average sales price du</font><font style="color: #34343F;">rin</font><font style="color: #080808;">g th</font><font style="color: #34343F;">e </font><font style="color: #080808;">a</font><font style="color: #34343F;">pp</font><font style="color: #080808;">lica</font><font style="color: #24262D;">ble </font><font style="color: #34343F;">r</font><font style="color: #080808;">eporti</font><font style="color: #34343F;">ng </font><font style="color: #080808;">period generally achieved for the relevant Licensed </font><font style="color: #34343F;">Product</font><font style="color: #080808;"> in </font><font style="color: #34343F;">the </font><font style="color: #24262D;">country</font><font style="color: #080808;"> i</font><font style="color: #24262D;">n </font><font style="color: #080808;">which s</font><font style="color: #24262D;">uc</font><font style="color: #080808;">h sale occurred when the Licensed Product is sold a</font><font style="color: #24262D;">lo</font><font style="color: #080808;">ne on a</font><font style="color: #24262D;">n </font><font style="color: #34343F;">a</font><font style="color: #080808;">rms l</font><font style="color: #34343F;">e</font><font style="color: #080808;">ng</font><font style="color: #34343F;">t</font><font style="color: #080808;">h basi</font><font style="color: #24262D;">s </font><font style="color: #080808;">(i</font><font style="color: #34343F;">n</font><font style="color: #080808;">cluding as relevant such Licensed Product being sol</font><font style="color: #24262D;">d </font><font style="color: #34343F;">at </font><font style="color: #080808;">full m</font><font style="color: #24262D;">a</font><font style="color: #080808;">r</font><font style="color: #34343F;">k</font><font style="color: #080808;">et v</font><font style="color: #24262D;">al</font><font style="color: #080808;">ue </font><font style="color: #24262D;">r</font><font style="color: #080808;">ather tha</font><font style="color: #24262D;">n </font><font style="color: #080808;">at reduced or low cost) and not as part of a multi-p</font><font style="color: #34343F;">ro</font><font style="color: #080808;">duct </font><font style="color: #24262D;">s</font><font style="color: #080808;">ale;</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: -0.35pt; margin-left: 36pt;"><font style="color: #080808;">&#8220;</font><font style="font-weight: bold; color: #080808;">Y</font><font style="color: #080808;">&#8221; is the sum of the a</font><font style="color: #34343F;">v</font><font style="color: #080808;">er</font><font style="color: #34343F;">age </font><font style="color: #080808;">sal</font><font style="color: #34343F;">es </font><font style="color: #080808;">pric</font><font style="color: #24262D;">e </font><font style="color: #080808;">d</font><font style="color: #24262D;">u</font><font style="color: #080808;">r</font><font style="color: #34343F;">i</font><font style="color: #080808;">ng the ap</font><font style="color: #24262D;">p</font><font style="color: #080808;">licable reporting period generally achieved in that cou</font><font style="color: #34343F;">n</font><font style="color: #080808;">try (</font><font style="color: #34343F;">a</font><font style="color: #080808;">s </font><font style="color: #24262D;">ap</font><font style="color: #080808;">plica</font><font style="color: #34343F;">b</font><font style="color: #080808;">l</font><font style="color: #24262D;">e) </font><font style="color: #080808;">o</font><font style="color: #34343F;">f </font><font style="color: #080808;">ea</font><font style="color: #24262D;">c</font><font style="color: #080808;">h product included in the multi- product when such product </font><font style="color: #24262D;">is </font><font style="color: #080808;">sold s</font><font style="color: #24262D;">ep</font><font style="color: #080808;">arately for a single p</font><font style="color: #34343F;">r</font><font style="color: #080808;">ice;






          and</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #080808;">&#8220;</font><font style="font-weight: bold; color: #080808;">Z</font><font style="color: #080808;">&#8221; is the single pri</font><font style="color: #24262D;">ce </font><font style="color: #34343F;">a</font><font style="color: #080808;">t which </font><font style="color: #24262D;">the</font><font style="color: #080808;"> relev</font><font style="color: #24262D;">ant </font><font style="color: #080808;">multi-pro</font><font style="color: #24262D;">duc</font><font style="color: #080808;">t sale was </font><font style="color: #24262D;">m</font><font style="color: #080808;">ade.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.15pt; margin-left: 36pt;"><font style="color: #080808;">In the event th</font><font style="color: #34343F;">a</font><font style="color: #080808;">t n</font><font style="color: #34343F;">o s</font><font style="color: #080808;">epar</font><font style="color: #34343F;">a</font><font style="color: #080808;">te sale </font><font style="color: #34343F;">of </font><font style="color: #080808;">e</font><font style="color: #24262D;">it</font><font style="color: #080808;">her the Licensed Product or any other product contained in </font><font style="color: #24262D;">a m</font><font style="color: #080808;">ulti-pro</font><font style="color: #24262D;">du</font><font style="color: #080808;">ct






          sal</font><font style="color: #34343F;">e are </font><font style="color: #080808;">mad</font><font style="color: #34343F;">e </font><font style="color: #080808;">o</font><font style="color: #34343F;">n </font><font style="color: #080808;">an
          ar</font><font style="color: #34343F;">ms l</font><font style="color: #080808;">ength basis (and not for example sol</font><font style="color: #34343F;">d </font><font style="color: #080808;">at zero price</font><font style="color: #24262D;">&#160;</font><font style="color: #080808;">or a lo</font><font style="color: #34343F;">w </font><font style="color: #080808;">or re</font><font style="color: #34343F;">d</font><font style="color: #080808;">u</font><font style="color: #34343F;">c</font><font style="color: #080808;">ed price) during the accounting period in which the s</font><font style="color: #34343F;">a</font><font style="color: #080808;">le </font><font style="color: #24262D;">w</font><font style="color: #080808;">as </font><font style="color: #24262D;">m</font><font style="color: #080808;">ade or i</font><font style="color: #24262D;">f </font><font style="color: #080808;">the pric</font><font style="color: #34343F;">e </font><font style="color: #24262D;">f</font><font style="color: #080808;">or </font><font style="color: #34343F;">a </font><font style="color: #080808;">particular product cannot otherwise be determin</font><font style="color: #24262D;">e</font><font style="color: #080808;">d </font><font style="color: #24262D;">fo</font><font style="color: #080808;">r an </font><font style="color: #34343F;">acc</font><font style="color: #080808;">ountin</font><font style="color: #24262D;">g </font><font style="color: #080808;">period, N</font><font style="color: #34343F;">e</font><font style="color: #080808;">t </font><font style="color: #34343F;">S</font><font style="color: #080808;">ales all</font><font style="color: #34343F;">oca</font><font style="color: #080808;">ble to the Licensed
          Product and multi-pro</font><font style="color: #34343F;">duc</font><font style="color: #080808;">t sal</font><font style="color: #24262D;">e </font><font style="color: #080808;">s</font><font style="color: #34343F;">h</font><font style="color: #080808;">all be </font><font style="color: #24262D;">determine</font><font style="color: #080808;">d b</font><font style="color: #24262D;">y </font><font style="color: #080808;">mutu</font><font style="color: #34343F;">a</font><font style="color: #080808;">l a</font><font style="color: #34343F;">g</font><font style="color: #080808;">reement reached in good faith by the Parties</font><font style="color: #24262D;">&#160;</font><font style="color: #080808;">prio</font><font style="color: #34343F;">r to </font><font style="color: #24262D;">the</font><font style="color: #080808;">&#160;</font><font style="color: #24262D;">en</font><font style="color: #080808;">d </font><font style="color: #24262D;">of </font><font style="color: #080808;">the accou</font><font style="color: #24262D;">n</font><font style="color: #080808;">ting perio</font><font style="color: #34343F;">d </font><font style="color: #080808;">in question based on an equitable [***] cannot be
          agreed between the Parties, </font><font style="color: #34343F;">ei</font><font style="color: #080808;">ther Party shall be entitled to refer the determination t</font><font style="color: #34343F;">o </font><font style="color: #080808;">an </font><font style="color: #34343F;">i</font><font style="color: #080808;">ndepe</font><font style="color: #34343F;">nde</font><font style="color: #080808;">nt expert located in [***] and appointed by mutual agree</font><font style="color: #24262D;">ment </font><font style="color: #080808;">betwe</font><font style="color: #24262D;">e</font><font style="color: #080808;">n the Parties or in the absence of any agreement within [***] reach a </font><font style="color: #24262D;">dec</font><font style="color: #080808;">ision as quickly as possible and in any event [***] of appoin</font><font style="color: #24262D;">t</font><font style="color: #080808;">m</font><font style="color: #34343F;">e</font><font style="color: #080808;">nt. The e</font><font style="color: #34343F;">xp</font><font style="color: #080808;">ert &#8216;s decision shall be final and binding on the Parties in the abse</font><font style="color: #24262D;">nc</font><font style="color: #080808;">e of any </font><font style="color: #24262D;">m</font><font style="color: #080808;">a</font><font style="color: #34343F;">n</font><font style="color: #080808;">ifest error and the Parties shall share equally in the costs of the ex</font><font style="color: #34343F;">p</font><font style="color: #080808;">e</font><font style="color: #24262D;">rt.</font></div>
      <div>&#160;</div>
      <div>
        <table class="DSPFListTable" id="zd4edc9dbdee24d41a2ebe101aed7b4e3" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 36pt;">
                <div style="text-align: justify;">9.13</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify;"><font style="color: rgb(52, 52, 63);">Sa</font>l<font style="color: rgb(52, 52, 63);">e</font>s of Licensed Product between GSK and its Affiliates or between GSK or its Affiliates<font style="color: rgb(52, 52, 63);"> a</font>nd their sublicensees shall be excluded from the computation of Net Sales and no payments shall be payable on such sales except where such Affiliates or sublicensees are end users. Further, sales of Licen<font style="color: rgb(36, 38, 45);">s</font>ed Product by GSK or its Affiliates or their sublicensees that are for compassionate u<font style="color: rgb(36, 38, 45);">s</font>e or on a named patient <font style="color: rgb(52, 52, 63);">/
                  </font>named hospital basis shall be excluded from the computation of Net Sales and no payments shall be payable on such sales provided in each case that such supplies are at cost or for free<font style="color: rgb(52, 52, 63);">. </font><font style="color: rgb(8, 8, 8);">Where any sales for compassionate use or on a named patient</font><font style="color: rgb(33, 33, 40);">/ </font><font style="color: rgb(8, 8, 8);">named hospital basis are provided for consideration, such
                    sales shall be treated as Net Sales and royalties shall be payable to Immunocore on such Net Sales.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <table id="ze57b6740646e470d9c83147955ab48eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Confidentiality</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1ff2055b0de841949203c2dd45acbe8e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party agrees to keep the Confidential Information<font style="color: rgb(33, 33, 40);"> of </font>the disclosin<font style="color: rgb(33, 33, 40);">g Pa</font>rty in strict confidence and not to use, or disclose such Confidential<font style="color: rgb(33, 33, 40);">&#160;</font>Information t<font style="color: rgb(33, 33, 40);">o any </font>third Party, save as explicitly permitted in this Agreement. <font style="color: rgb(33, 33, 40);">Th</font>e <font style="color: rgb(33, 33, 40);">P</font>arty owning t<font style="color: rgb(33, 33, 40);">h</font>e <font style="color: rgb(33, 33, 40);">R</font>esults or the Foreground in Results shall be deemed to be the<font style="color: rgb(33, 33, 40);">&#160;</font>di<font style="color: rgb(33, 33, 40);">s</font>closing Party <font style="color: rgb(33, 33, 40);">a</font>n<font style="color: rgb(33, 33, 40);">d </font>the other Party shall be obliged to keep such Results confide<font style="color: rgb(33, 33, 40);">n</font><font style="color: rgb(56, 58, 70);">t</font><font style="color: rgb(33, 33, 40);">ial in </font>a<font style="color: rgb(56, 58, 70);">c</font>cordance with<font style="color: rgb(33, 33, 40);"> t</font>his S<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(56, 58, 70);">ct</font><font style="color: rgb(33, 33, 40);">io</font>n 10.1. The foregoing obligations of confidentiality w<font style="color: rgb(33, 33, 40);">i</font>ll <font style="color: rgb(33, 33, 40);">no</font>t a<font style="color: rgb(33, 33, 40);">p</font>p<font style="color: rgb(33, 33, 40);">l</font><font style="color: rgb(56, 58, 70);">y </font>to the <font style="color: rgb(33, 33, 40);">ex</font>tent






                <font style="color: rgb(33, 33, 40);">t</font><font style="color: rgb(56, 58, 70);">h</font><font style="color: rgb(33, 33, 40);">at i</font>t can be established by the receiving Party that such <font style="color: rgb(56, 58, 70);">C</font><font style="color: rgb(33, 33, 40);">onfi</font>den<font style="color: rgb(33, 33, 40);">tial In</font>for<font style="color: rgb(33, 33, 40);">ma</font>tio<font style="color: rgb(56, 58, 70);">n</font>:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z04d537bdfc6147f6b02c42f40d78878a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;">&#160;</td>
            <td style="width: 36pt; vertical-align: top;">10.1.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>was in the lawful knowledge <font style="color: rgb(33, 33, 40);">a</font>n<font style="color: rgb(33, 33, 40);">d po</font>ss<font style="color: rgb(33, 33, 40);">es</font>si<font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(56, 58, 70);">n </font>of t<font style="color: rgb(33, 33, 40);">he re</font>ceivi<font style="color: rgb(33, 33, 40);">ng </font>Party prior to the time it was disclosed to<font style="color: rgb(33, 33, 40);">, o</font><font style="color: rgb(56, 58, 70);">r </font>le<font style="color: rgb(33, 33, 40);">arn</font>ed <font style="color: rgb(33, 33, 40);">by, </font>the re<font style="color: rgb(33, 33, 40);">c</font><font style="color: rgb(56, 58, 70);">e</font>iv<font style="color: rgb(56, 58, 70);">i</font>ng Party, <font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(56, 58, 70);">r </font>was otherwise developed independentl<font style="color: rgb(33, 33, 40);">y by </font>the <font style="color: rgb(33, 33, 40);">rece</font>iving <font style="color: rgb(33, 33, 40);">Pa</font><font style="color: rgb(56, 58, 70);">r</font>ty,<font style="color: rgb(33, 33, 40);">&#160;</font>as e<font style="color: rgb(33, 33, 40);">vide</font>nced






                by written records kept in the ord<font style="color: rgb(33, 33, 40);">inar</font><font style="color: rgb(56, 58, 70);">y </font>cour<font style="color: rgb(33, 33, 40);">s</font><font style="color: rgb(56, 58, 70);">e </font><font style="color: rgb(33, 33, 40);">of </font>busin<font style="color: rgb(33, 33, 40);">e</font>s<font style="color: rgb(33, 33, 40);">s</font>, or oth<font style="color: rgb(33, 33, 40);">er doc</font>umentary proof of actual knowledge by
                <font style="color: rgb(33, 33, 40);">the</font>&#160;<font style="color: rgb(33, 33, 40);">r</font>ecei<font style="color: rgb(33, 33, 40);">v</font>ing P<font style="color: rgb(33, 33, 40);">a</font>rty;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf35f6ac033ba41a3958d5f122f523755" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.1.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>was generally av<font style="color: rgb(33, 33, 40);">ai</font>la<font style="color: rgb(33, 33, 40);">ble t</font>o t<font style="color: rgb(33, 33, 40);">h</font><font style="color: rgb(56, 58, 70);">e </font>publi<font style="color: rgb(33, 33, 40);">c </font><font style="color: rgb(56, 58, 70);">o</font>r <font style="color: rgb(33, 33, 40);">othe</font>rwis<font style="color: rgb(33, 33, 40);">e </font>pa<font style="color: rgb(56, 58, 70);">r</font>t of th<font style="color: rgb(33, 33, 40);">e pub</font>lic domain at the time of its d<font style="color: rgb(56, 58, 70);">i</font><font style="color: rgb(33, 33, 40);">s</font>clo<font style="color: rgb(56, 58, 70);">s</font>ure t<font style="color: rgb(33, 33, 40);">o t</font><font style="color: rgb(56, 58, 70);">h</font><font style="color: rgb(33, 33, 40);">e </font>rece<font style="color: rgb(33, 33, 40);">ivi</font><font style="color: rgb(56, 58, 70);">n</font><font style="color: rgb(33, 33, 40);">g Party</font><font style="color: rgb(56, 58, 70);">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">37</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="zfb03b09ccf2c4dc28d722c55b191b89e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.1.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>became ge<font style="color: rgb(56, 58, 70);">n</font>erally av<font style="color: rgb(33, 33, 40);">a</font><font style="color: rgb(56, 58, 70);">i</font><font style="color: rgb(33, 33, 40);">l</font>a<font style="color: rgb(33, 33, 40);">bl</font>e <font style="color: rgb(33, 33, 40);">t</font>o <font style="color: rgb(33, 33, 40);">t</font>h<font style="color: rgb(33, 33, 40);">e </font>public or <font style="color: rgb(33, 33, 40);">o</font>ther<font style="color: rgb(33, 33, 40);">w</font>i<font style="color: rgb(56, 58, 70);">s</font><font style="color: rgb(33, 33, 40);">e p</font>art of the public domain a<font style="color: rgb(33, 33, 40);">fte</font><font style="color: rgb(56, 58, 70);">r </font>its dis<font style="color: rgb(33, 33, 40);">clo</font>sure an<font style="color: rgb(33, 33, 40);">d </font><font style="color: rgb(56, 58, 70);">o</font><font style="color: rgb(33, 33, 40);">t</font>her than <font style="color: rgb(33, 33, 40);">through</font> any <font style="color: rgb(56, 58, 70);">ac</font>t or omission of the receivin<font style="color: rgb(33, 33, 40);">g </font>Party in br<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(56, 58, 70);">ac</font><font style="color: rgb(33, 33, 40);">h </font>of <font style="color: rgb(33, 33, 40);">t</font>h<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(56, 58, 70);">s </font><font style="color: rgb(33, 33, 40);">A</font>greem<font style="color: rgb(56, 58, 70);">e</font><font style="color: rgb(33, 33, 40);">nt;</font><font style="color: rgb(56, 58, 70);">&#160;</font>or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za92163751889414a8d8eee19c367a391" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.1.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>was d<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(56, 58, 70);">s</font><font style="color: rgb(33, 33, 40);">cl</font>osed <font style="color: rgb(33, 33, 40);">to </font>the <font style="color: rgb(33, 33, 40);">re</font><font style="color: rgb(56, 58, 70);">c</font><font style="color: rgb(33, 33, 40);">e</font>i<font style="color: rgb(33, 33, 40);">v</font>ing P<font style="color: rgb(56, 58, 70);">a</font><font style="color: rgb(33, 33, 40);">r</font>t<font style="color: rgb(33, 33, 40);">y</font><font style="color: rgb(56, 58, 70);">, </font>other <font style="color: rgb(33, 33, 40);">than </font>under an obligation of c<font style="color: rgb(33, 33, 40);">onfi</font>dentialit<font style="color: rgb(33, 33, 40);">y</font><font style="color: rgb(56, 58, 70);">, </font><font style="color: rgb(33, 33, 40);">by </font>a T<font style="color: rgb(33, 33, 40);">hi</font>r<font style="color: rgb(33, 33, 40);">d Party</font>&#160;<font style="color: rgb(33, 33, 40);">who h</font>ad n<font style="color: rgb(33, 33, 40);">o obligation</font> to the disclosing Party no<font style="color: rgb(56, 58, 70);">t </font>to <font style="color: rgb(33, 33, 40);">d</font>iscl<font style="color: rgb(33, 33, 40);">os</font>e <font style="color: rgb(33, 33, 40);">s</font>uch information<font style="color: rgb(56, 58, 70);">&#160;</font><font style="color: rgb(33, 33, 40);">to o</font><font style="color: rgb(56, 58, 70);">t</font><font style="color: rgb(33, 33, 40);">h</font>ers.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z57479021b26d4b1faca3bb3bd3c41e87" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties<font style="color: rgb(56, 58, 70);">&#160;</font><font style="color: rgb(33, 33, 40);">m</font>ay <font style="color: rgb(33, 33, 40);">provide</font> t<font style="color: rgb(33, 33, 40);">he Confidential</font><font style="color: rgb(56, 58, 70);">&#160;</font>Information<font style="color: rgb(33, 33, 40);">&#160;</font>to such of its officers, employees, representatives <font style="color: rgb(56, 58, 70);">a</font><font style="color: rgb(33, 33, 40);">nd </font>subcontractors






                who <font style="color: rgb(56, 58, 70);">r</font>easona<font style="color: rgb(33, 33, 40);">b</font>ly <font style="color: rgb(33, 33, 40);">r</font>equire access to it for the purpose of fulfi<font style="color: rgb(33, 33, 40);">llin</font>g
                th<font style="color: rgb(33, 33, 40);">e r</font><font style="color: rgb(56, 58, 70);">e</font><font style="color: rgb(33, 33, 40);">c</font>eivin<font style="color: rgb(33, 33, 40);">g Par</font>ty&#8217;s <font style="color: rgb(33, 33, 40);">oblig</font>ations






                or <font style="color: rgb(33, 33, 40);">e</font>xercising its rights under thi<font style="color: rgb(33, 33, 40);">s </font>Agreement p<font style="color: rgb(56, 58, 70);">r</font>o<font style="color: rgb(56, 58, 70);">vid</font>ed
                that<font style="color: rgb(33, 33, 40);"> b</font><font style="color: rgb(56, 58, 70);">e</font>fore <font style="color: rgb(56, 58, 70);">a</font>n<font style="color: rgb(33, 33, 40);">y </font>of the d<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(56, 58, 70);">s</font><font style="color: rgb(33, 33, 40);">cl</font><font style="color: rgb(56, 58, 70);">o</font>sing Party&#8217;s <font style="color: rgb(33, 33, 40);">Confidential</font> Information
                is disclosed to the<font style="color: rgb(33, 33, 40);">m, </font>they ar<font style="color: rgb(33, 33, 40);">e </font>made <font style="color: rgb(33, 33, 40);">aw</font>are of <font style="color: rgb(33, 33, 40);">its </font>confid<font style="color: rgb(33, 33, 40);">e</font>n<font style="color: rgb(33, 33, 40);">ti</font><font style="color: rgb(56, 58, 70);">a</font><font style="color: rgb(33, 33, 40);">l </font>nature and that they are under a legally <font style="color: rgb(33, 33, 40);">-</font> binding obligation <font style="color: rgb(56, 58, 70);">t</font><font style="color: rgb(33, 33, 40);">o </font>the receiving Party <font style="color: rgb(33, 33, 40);">t</font><font style="color: rgb(56, 58, 70);">o </font>treat that Confidential Information in the strictest confid<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(56, 58, 70);">n</font><font style="color: rgb(33, 33, 40);">c</font>e
                <font style="color: rgb(33, 33, 40);">in </font>acco<font style="color: rgb(33, 33, 40);">rda</font>nce with the terms of this Agreement. For clarity, such disclosures ma<font style="color: rgb(33, 33, 40);">y b</font>e mad<font style="color: rgb(33, 33, 40);">e </font>in the furtherance of, <font style="font-style: italic;">inter alia</font><font style="font-style: italic; color: rgb(33, 33, 40);">, </font>(i) the performance of its obligations <font style="color: rgb(56, 58, 70);">o</font><font style="color: rgb(33, 33, 40);">r </font>exerci<font style="color: rgb(33, 33, 40);">se of r</font>ig<font style="color: rgb(33, 33, 40);">h</font>ts granted or reserved in this Agreement;
                (ii) to the extent such discl<font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(56, 58, 70);">s</font>u<font style="color: rgb(33, 33, 40);">re </font>is reasonably necessary in filing or prosecuting patent<font style="color: rgb(33, 33, 40);">, </font>copyright and trademark<font style="color: rgb(33, 33, 40);">&#160;</font>appli<font style="color: rgb(33, 33, 40);">ca</font>tions, prosecuting <font style="color: rgb(33, 33, 40);">o</font>r
                defending litigation, obtaining Regulat<font style="color: rgb(33, 33, 40);">o</font>ry Appro<font style="color: rgb(33, 33, 40);">v</font><font style="color: rgb(56, 58, 70);">a</font><font style="color: rgb(33, 33, 40);">ls</font>, condu<font style="color: rgb(33, 33, 40);">c</font>ti<font style="color: rgb(33, 33, 40);">ng </font>pre-clinical activities or clinical trials, marketing Licens<font style="color: rgb(33, 33, 40);">e</font>d Products, or oth<font style="color: rgb(33, 33, 40);">erwi</font><font style="color: rgb(56, 58, 70);">s</font>e required by Applicable Laws; provided, that if a receiving Party is re<font style="color: rgb(33, 33, 40);">qui</font><font style="color: rgb(56, 58, 70);">r</font><font style="color: rgb(33, 33, 40);">e</font>d by Applicable Law to make any such disclosure of a disclosing Party&#8217;s<font style="color: rgb(33, 33, 40);"> Confidential</font> Information it shall, except where impracticable for ne<font style="color: rgb(33, 33, 40);">c</font>essary disclosures<font style="color: rgb(33, 33, 40);">,</font><font style="color: rgb(56, 58, 70);"> fo</font><font style="color: rgb(33, 33, 40);">r e</font>xample in the event of medical
                emergency, give re<font style="color: rgb(33, 33, 40);">a</font>s<font style="color: rgb(33, 33, 40);">o</font>nable advance notice to the<font style="color: rgb(56, 58, 70);"> d</font>is<font style="color: rgb(33, 33, 40);">cl</font>osing
                Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applic<font style="color: rgb(33, 33, 40);">a</font>tion<font style="color: rgb(33, 33, 40);">s</font>, shall use its rea<font style="color: rgb(33, 33, 40);">s</font>onabl<font style="color: rgb(33, 33, 40);">e </font>efforts<font style="color: rgb(33, 33, 40);">&#160;</font>to secure <font style="color: rgb(33, 33, 40);">c</font>onfidential treatment of <font style="color: rgb(33, 33, 40);">s</font>uch Confidential Information required to be disclosed.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0ae64820bc7b4176b46905f0bbef2a07" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties may disclose the Confidenti<font style="color: rgb(33, 33, 40);">a</font>l Information to Affiliates<font style="color: rgb(33, 33, 40);">, </font>exis<font style="color: rgb(33, 33, 40);">t</font>in<font style="color: rgb(33, 33, 40);">g or</font> prospective advisors, sh<font style="color: rgb(33, 33, 40);">a</font>reholder<font style="color: rgb(33, 33, 40);">s, </font>inve<font style="color: rgb(33, 33, 40);">s</font>t<font style="color: rgb(33, 33, 40);">o</font>rs<font style="color: rgb(33, 33, 40);">, collaborators</font>, sublicensees, partners<font style="color: rgb(33, 33, 40);">&#160;</font>or joint venturers, in each case und<font style="color: rgb(33, 33, 40);">e</font>r
                appropriate confidenti<font style="color: rgb(33, 33, 40);">a</font>lity provisions substantially <font style="color: rgb(7, 7, 8);">[***] Confidential Information to Third Parties in connection with (i) a merger, consolidation or similar
                  transaction by such Party, (ii) the sale of all </font><font style="color: rgb(33, 33, 38);">or </font><font style="color: rgb(7, 7, 8);">substantially all of the assets of such Party to which this Agreement relates, or (iii) </font><font style="color: rgb(33, 33, 38);">a</font><font style="color: rgb(7, 7, 8);">s r</font><font style="color: rgb(33, 33, 38);">e</font><font style="color: rgb(54, 54, 66);">q</font><font style="color: rgb(7, 7, 8);">uired by rule</font><font style="color: rgb(33, 33, 38);">s o</font><font style="color: rgb(7, 7, 8);">f any stock exchange on which the secur</font><font style="color: rgb(33, 33, 38);">i</font><font style="color: rgb(7, 7, 8);">ties of a Party are trade</font><font style="color: rgb(33, 33, 38);">d</font><font style="color: rgb(84, 86, 100);">, </font><font style="color: rgb(33, 33, 38);">in the</font><font style="color: rgb(7, 7, 8);"> case of (i</font><font style="color: rgb(33, 33, 38);">) an</font><font style="color: rgb(7, 7, 8);">d (ii) under appropriate confidentiality provisions substanti</font><font style="color: rgb(33, 33, 38);">all</font><font style="color: rgb(54, 54, 66);">y e</font><font style="color: rgb(7, 7, 8);">quivalent
                  t</font><font style="color: rgb(33, 33, 38);">o t</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(33, 33, 38);">o</font><font style="color: rgb(7, 7, 8);">se of this Agreement. In each of the above authorized </font><font style="color: rgb(33, 33, 38);">d</font><font style="color: rgb(54, 54, 66);">is</font><font style="color: rgb(7, 7, 8);">closures, the Receiving Party shall remain responsible for any failure by any </font><font style="color: rgb(33, 33, 38);">pe</font><font style="color: rgb(7, 7, 8);">rso</font><font style="color: rgb(33, 33, 38);">n </font><font style="color: rgb(7, 7, 8);">who recei</font><font style="color: rgb(33, 33, 38);">ve</font><font style="color: rgb(7, 7, 8);">s the </font><font style="color: rgb(33, 33, 38);">Confidential</font><font style="color: rgb(7, 7, 8);"> Information pursuant to this Section 10.3 t</font><font style="color: rgb(33, 33, 38);">o trea</font><font style="color: rgb(7, 7, 8);">t </font><font style="color: rgb(33, 33, 38);">su</font><font style="color: rgb(7, 7, 8);">ch Confidential Information as required under this Article 10.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0e738ad0d93341cbb1ce7e27f0f14bef" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Both Parties shall keep the terms of this <font style="color: rgb(33, 33, 38);">Agreement </font><font style="color: rgb(54, 54, 66);">confidential</font><font style="color: rgb(33, 33, 38);"> a</font>nd su<font style="color: rgb(33, 33, 38);">ch t</font>erms shall be treated as Confidential Information <font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 38);">n </font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 38);">c</font><font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(33, 33, 38);">o</font>rd<font style="color: rgb(33, 33, 38);">an</font>c<font style="color: rgb(33, 33, 38);">e </font>with <font style="color: rgb(33, 33, 38);">thi</font><font style="color: rgb(54, 54, 66);">s </font>Article<font style="color: rgb(54, 54, 66);">&#160;</font>10, except that Immunocore may issue a public an<font style="color: rgb(33, 33, 38);">n</font>o<font style="color: rgb(33, 33, 38);">u</font>n<font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(33, 33, 38);">e</font>me<font style="color: rgb(33, 33, 38);">nt of </font>the e<font style="color: rgb(54, 54, 66);">x</font><font style="color: rgb(33, 33, 38);">e</font><font style="color: rgb(54, 54, 66);">c</font>ution <font style="color: rgb(33, 33, 38);">o</font>f <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 38);">h</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 38);">s </font>Agreement in the form mutually agreed by the Parties and <font style="color: rgb(54, 54, 66);">a</font>s <font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(33, 33, 38);">e</font>t out in Schedule <font style="color: rgb(54, 54, 66);">9. </font><font style="color: rgb(33, 33, 38);">Immunocore</font> may also issue public announceme<font style="color: rgb(33, 33, 38);">nts
                </font><font style="color: rgb(54, 54, 66);">o</font>f the <font style="color: rgb(33, 33, 38);">ac</font><font style="color: rgb(54, 54, 66);">h</font>ieve<font style="color: rgb(33, 33, 38);">m</font>e<font style="color: rgb(33, 33, 38);">nt </font>of e<font style="color: rgb(33, 33, 38);">ac</font>h <font style="color: rgb(33, 33, 38);">M</font>ilestone for each Licensed Product as set out in <font style="color: rgb(33, 33, 38);">Sc</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(33, 33, 38);">e</font>dule 2<font style="color: rgb(33, 33, 38);">, </font>with the <font style="color: rgb(33, 33, 38);">pr</font><font style="color: rgb(54, 54, 66);">i</font>or re<font style="color: rgb(33, 33, 38);">vie</font><font style="color: rgb(54, 54, 66);">w </font>o<font style="color: rgb(33, 33, 38);">f </font>GSK. Neither Party will use the other&#8217;s name or <font style="color: rgb(33, 33, 38);">lo</font>go
                <font style="color: rgb(54, 54, 66);">i</font>n any p<font style="color: rgb(33, 33, 38);">r</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 38);">s</font>s <font style="color: rgb(33, 33, 38);">relea</font>se






                or p<font style="color: rgb(54, 54, 66);">ro</font>duc<font style="color: rgb(33, 33, 38);">t </font>advertising, or for any other promotional purpos<font style="color: rgb(33, 33, 38);">e, with</font>out <font style="color: rgb(33, 33, 38);">fir</font>st o<font style="color: rgb(33, 33, 38);">b</font>t<font style="color: rgb(33, 33, 38);">a</font>i<font style="color: rgb(33, 33, 38);">n</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 38);">ng </font>the o<font style="color: rgb(33, 33, 38);">t</font>h<font style="color: rgb(54, 54, 66);">e</font>r&#8217;s written<font style="color: rgb(33, 33, 38);">&#160;</font>consent and entering into appropriate trademark<font style="color: rgb(33, 33, 38);">&#160;</font><font style="color: rgb(54, 54, 66);">or </font>housemark l<font style="color: rgb(33, 33, 38);">ice</font>nses, as <font style="color: rgb(33, 33, 38);">a</font>ppr<font style="color: rgb(33, 33, 38);">o</font>priate.






                Neither Party will, without the pr<font style="color: rgb(33, 33, 38);">ior </font>written<font style="color: rgb(33, 33, 38);">&#160;</font>con<font style="color: rgb(33, 33, 38);">se</font>nt of the<font style="color: rgb(54, 54, 66);">&#160;</font><font style="color: rgb(33, 33, 38);">o</font>t<font style="color: rgb(33, 33, 38);">h</font>er Party<font style="color: rgb(33, 33, 38);">, i</font>ssue any public announcement or pr<font style="color: rgb(33, 33, 38);">e</font>ss releas<font style="color: rgb(54, 54, 66);">e </font>r<font style="color: rgb(33, 33, 38);">e</font>lat<font style="color: rgb(33, 33, 38);">i</font>n<font style="color: rgb(33, 33, 38);">g </font>t<font style="color: rgb(54, 54, 66);">o </font>this






                Agre<font style="color: rgb(33, 33, 38);">e</font>ment <font style="color: rgb(33, 33, 38);">or the</font> terms of this Agreement. Each Party<font style="color: rgb(54, 54, 66);">&#160;</font>shall <font style="color: rgb(33, 33, 38);">prov</font>ide






                th<font style="color: rgb(54, 54, 66);">e o</font><font style="color: rgb(33, 33, 38);">t</font>her with <font style="color: rgb(33, 33, 38);">an </font>advance c<font style="color: rgb(33, 33, 38);">o</font><font style="color: rgb(54, 54, 66);">p</font>y of any such public announcement at least [***]<font style="color: rgb(33, 33, 38);"> p</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 38);">i</font>or to its<font style="color: rgb(54, 54, 66);">&#160;</font><font style="color: rgb(33, 33, 38);">scheduled</font>&#160;<font style="color: rgb(54, 54, 66);">r</font>el<font style="color: rgb(33, 33, 38);">e</font>ase; provided,<font style="color: rgb(33, 33, 38);">&#160;</font>that






                if the Party propo<font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(33, 33, 38);">i</font>ng <font style="color: rgb(54, 54, 66);">su</font>ch p<font style="color: rgb(33, 33, 38);">u</font>bli<font style="color: rgb(54, 54, 66);">c </font>ann<font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 38);">u</font>n<font style="color: rgb(33, 33, 38);">c</font>emen<font style="color: rgb(33, 33, 38);">t </font>cannot p<font style="color: rgb(33, 33, 38);">ro</font><font style="color: rgb(54, 54, 66);">v</font><font style="color: rgb(33, 33, 38);">id</font><font style="color: rgb(54, 54, 66);">e t</font>he reviewing Pa<font style="color: rgb(33, 33, 38);">r</font>ty






                with [***] <font style="color: rgb(33, 33, 38);">notice</font>&#160;<font style="color: rgb(33, 33, 38);">d</font><font style="color: rgb(54, 54, 66);">u</font><font style="color: rgb(33, 33, 38);">e </font>to <font style="color: rgb(33, 33, 38);">extraordinary</font> circumstances, such Party will use reasonable <font style="color: rgb(33, 33, 38);">efforts</font> to p<font style="color: rgb(33, 33, 38);">ro</font>v<font style="color: rgb(33, 33, 38);">id</font>e th<font style="color: rgb(33, 33, 38);">e r</font>e<font style="color: rgb(54, 54, 66);">vi</font>ewing P<font style="color: rgb(54, 54, 66);">a</font>rty with <font style="color: rgb(33, 33, 38);">th</font>e proposed public statement for
                comment <font style="color: rgb(33, 33, 38);">a</font>t <font style="color: rgb(33, 33, 38);">lea</font><font style="color: rgb(54, 54, 66);">s</font>t [***]<font style="color: rgb(33, 33, 38);"> b</font>e<font style="color: rgb(54, 54, 66);">fo</font>re rele<font style="color: rgb(54, 54, 66);">as</font>e<font style="color: rgb(33, 33, 38);">. </font>Nothing in this Section shall prevent <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 38);">n</font>y <font style="color: rgb(54, 54, 66);">p</font>ress r<font style="color: rgb(33, 33, 38);">el</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 38);">a</font>se or <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 38);">n</font>noun<font style="color: rgb(33, 33, 38);">c</font>e<font style="color: rgb(33, 33, 38);">m</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 38);">nt </font>require<font style="color: rgb(54, 54, 66);">d </font><font style="color: rgb(33, 33, 38);">in </font>accordance with any regulatory r<font style="color: rgb(33, 33, 38);">e</font>quir<font style="color: rgb(33, 33, 38);">em</font><font style="color: rgb(54, 54, 66);">en</font><font style="color: rgb(33, 33, 38);">t o</font>r st<font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 38);">c</font>k <font style="color: rgb(33, 33, 38);">e</font>x<font style="color: rgb(33, 33, 38);">c</font>h<font style="color: rgb(33, 33, 38);">ange </font>requir<font style="color: rgb(54, 54, 66);">e</font>m<font style="color: rgb(33, 33, 38);">en</font>t.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">38</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="zcbd5499d3c5f4c7bbee8d2a5faef1ece" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Aft<font style="color: rgb(33, 33, 38);">e</font>r e<font style="color: rgb(54, 54, 66);">x</font><font style="color: rgb(33, 33, 38);">e</font>rcise <font style="color: rgb(33, 33, 38);">of the</font> applicable Initial Program Option
                or Collaboration Program Option,<font style="color: rgb(33, 33, 38);"> G</font><font style="color: rgb(54, 54, 66);">S</font><font style="color: rgb(33, 33, 38);">K </font><font style="color: rgb(54, 54, 66);">o</font>r its<font style="color: rgb(33, 33, 38);"> Affiliates sh</font><font style="color: rgb(54, 54, 66);">a</font>ll have <font style="color: rgb(33, 33, 38);">t</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(33, 33, 38);">e
                </font>right <font style="color: rgb(33, 33, 38);">to </font>m<font style="color: rgb(33, 33, 38);">a</font>ke dis<font style="color: rgb(33, 33, 38);">c</font>losure<font style="color: rgb(33, 33, 38);">s </font>pertaining t<font style="color: rgb(33, 33, 38);">o </font>Li<font style="color: rgb(33, 33, 38);">ce</font>n<font style="color: rgb(33, 33, 38);">se</font>d Products arising f<font style="color: rgb(33, 33, 38);">ro</font>m t<font style="color: rgb(54, 54, 66);">h</font>e appl<font style="color: rgb(33, 33, 38);">i</font><font style="color: rgb(54, 54, 66);">ca</font><font style="color: rgb(33, 33, 38);">b</font>le Collaboration Program in scientifi<font style="color: rgb(33, 33, 38);">c
                </font>journ<font style="color: rgb(33, 33, 38);">a</font>ls or other publication<font style="color: rgb(33, 33, 38);">s</font>, and a<font style="color: rgb(33, 33, 38);">t </font>scientific conferences i<font style="color: rgb(33, 33, 38);">n </font>each case subject to prior written notice to Immunocore. <font style="color: rgb(33, 33, 38);">Pr</font>ior written<font style="color: rgb(33, 33, 38);"> c</font>onsent from Immunocore will be required where any
                disclosure in <font style="color: rgb(54, 54, 66);">scientific</font>&#160;<font style="color: rgb(54, 54, 66);">j</font>o<font style="color: rgb(33, 33, 38);">u</font>rnals or other publications includes any Confidential Information<font style="color: rgb(33, 33, 38);"> c</font>omprise<font style="color: rgb(54, 54, 66);">d </font><font style="color: rgb(33, 33, 38);">w</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 38);">th</font>in
                Immunocore Background or Platform Rights and which is not specif<font style="color: rgb(54, 54, 66);">ic t</font><font style="color: rgb(33, 33, 38);">o </font>the <font style="color: rgb(33, 33, 38);">Li</font>c<font style="color: rgb(33, 33, 38);">en</font>sed Product. GSK will reason<font style="color: rgb(33, 33, 38);">a</font>bly endeavour to provide Immunocore<font style="color: rgb(33, 33, 38);">&#160;</font>with no less than [***] to rev<font style="color: rgb(33, 33, 38);">i</font>ew the contents of any propo<font style="color: rgb(33, 33, 38);">s</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 38);">d disclosure</font>. <font style="color: rgb(33, 33, 38);">W</font>ithin such [***], Immunocore may request that any such <font style="color: rgb(54, 54, 66);">Confidential</font><font style="color: rgb(33, 33, 38);"> Information</font> is removed from the proposed disclosure and GSK shall
                r<font style="color: rgb(33, 33, 38);">em</font><font style="color: rgb(54, 54, 66);">ov</font><font style="color: rgb(33, 33, 38);">e s</font>u<font style="color: rgb(33, 33, 38);">c</font>h <font style="color: rgb(33, 33, 38);">Confidential</font>
                Informati<font style="color: rgb(33, 33, 38);">o</font>n prior to any di<font style="color: rgb(33, 33, 38);">s</font>closure. Immunocore <font style="color: rgb(33, 33, 38);">s</font>hall n<font style="color: rgb(33, 33, 38);">o</font>t<font style="color: rgb(33, 33, 38);"> m</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 38);">ke </font>disclosures pertaining to Licen<font style="color: rgb(33, 33, 38);">s</font>ed Products or Results
                arising from a Collaboration<font style="color: rgb(54, 54, 66);"> Program</font> unle<font style="color: rgb(33, 33, 38);">s</font>s <font style="color: rgb(33, 33, 38);">s</font>olely related to the Immunocore Ba<font style="color: rgb(33, 33, 38);">c</font>kground or Platform Rights<font style="color: rgb(33, 33, 38);">&#160;</font>in<font style="color: rgb(54, 54, 66);"> scientific</font> journals or other publi<font style="color: rgb(33, 33, 38);">c</font>ations, or
                at scientific conferences<font style="color: rgb(33, 33, 38);">, </font>without the p<font style="color: rgb(33, 33, 38);">r</font>ior written consent of GSK<font style="color: rgb(33, 33, 38);">, </font>which may be withheld in GSK<font style="color: rgb(33, 33, 38);">&#8217;</font>s discretion. Immunocore shall provid<font style="color: rgb(33, 33, 38);">e </font>a copy of such propos<font style="color: rgb(33, 33, 38);">e</font>d disclosur<font style="color: rgb(33, 33, 38);">e </font>or pr<font style="color: rgb(33, 33, 38);">e</font>s<font style="color: rgb(33, 33, 38);">e</font>ntation to GSK no l<font style="color: rgb(33, 33, 38);">e</font>ss th<font style="color: rgb(33, 33, 38);">a</font>n [***]
                prior to Immunoc<font style="color: rgb(33, 33, 38);">o</font>re&#8217;<font style="color: rgb(33, 33, 38);">s </font>int<font style="color: rgb(33, 33, 38);">e</font>nded <font style="color: rgb(33, 33, 38);">s</font>ubmi<font style="color: rgb(33, 33, 38);">ss</font>ion for publi<font style="color: rgb(33, 33, 38);">ca</font>ti<font style="color: rgb(33, 33, 38);">o</font>n<font style="color: rgb(54, 54, 66);">. </font>GSK sh<font style="color: rgb(33, 33, 38);">a</font>ll
                respond in writing promptly <font style="color: rgb(33, 33, 38);">a</font>nd in no event l<font style="color: rgb(33, 33, 38);">a</font>ter th<font style="color: rgb(33, 33, 38);">a</font>n [***] after receipt of the proposed material,
                with one or more of the following: (a) comments <font style="color: rgb(8, 8, 8);">on the proposed material, [***], (b) a specific statement of concern, based upon the need to seek patent protection of GSK</font><font style="color: rgb(40, 40, 49);">&#8217;</font><font style="color: rgb(8, 8, 8);">s Confidential Information, or (c) an identification of GSK&#8217;s Confidential Information that is contained in the material reviewed. In the event of concern over patent protection,
                  Immunocore agrees not to submit such publication or t</font><font style="color: rgb(40, 40, 49);">o </font><font style="color: rgb(8, 8, 8);">make such presentation that contains such information until GSK is given a reasonable </font><font style="color: rgb(40, 40, 49);">per</font><font style="color: rgb(8, 8, 8);">iod of time (</font><font style="color: rgb(40, 40, 49);">no</font><font style="color: rgb(8, 8, 8);">t to exceed [***]</font><font style="color: rgb(8, 8, 8);">)</font><font style="color: rgb(8, 8, 8);"> to seek patent protect</font><font style="color: rgb(40, 40, 49);">ion f</font><font style="color: rgb(8, 8, 8);">or any of i</font><font style="color: rgb(40, 40, 49);">ts </font><font style="color: rgb(8, 8, 8);">Confidential Information in such publication or presentation </font><font style="color: rgb(40, 40, 49);">w</font><font style="color: rgb(8, 8, 8);">h</font><font style="color: rgb(40, 40, 49);">ic</font><font style="color: rgb(8, 8, 8);">h </font><font style="color: rgb(40, 40, 49);">i</font><font style="color: rgb(8, 8, 8);">t believes is </font><font style="color: rgb(40, 40, 49);">pate</font><font style="color: rgb(8, 8, 8);">ntable. With</font><font style="font-weight: bold; color: rgb(8, 8, 8);">&#160;</font><font style="color: rgb(8, 8, 8);">respect to all other non-patentable Confidential </font><font style="color: rgb(40, 40, 49);">Information</font><font style="color: rgb(8, 8, 8);">
                  of GSK, su</font><font style="color: rgb(58, 59, 72);">c</font><font style="color: rgb(8, 8, 8);">h Confidential Information shall be deleted from the proposed </font><font style="color: rgb(40, 40, 49);">p</font><font style="color: rgb(8, 8, 8);">ublication. In the</font><font style="color: rgb(40, 40, 49);">&#160;</font><font style="color: rgb(8, 8, 8);">c</font><font style="color: rgb(40, 40, 49);">a</font><font style="color: rgb(8, 8, 8);">se of conference abstracts
                  and other rapid scientific communic</font><font style="color: rgb(40, 40, 49);">ations</font><font style="color: rgb(8, 8, 8);">, th</font><font style="color: rgb(58, 59, 72);">e </font><font style="color: rgb(8, 8, 8);">Parties will </font><font style="color: rgb(40, 40, 49);">co</font><font style="color: rgb(8, 8, 8);">mplete </font><font style="color: rgb(40, 40, 49);">th</font><font style="color: rgb(8, 8, 8);">e review process in [***] or less.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4c88f21c5d674a19a43def8de3ed122e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall have the right to ma<font style="color: rgb(40, 40, 49);">k</font>e <font style="color: rgb(40, 40, 49);">di</font>sclo<font style="color: rgb(40, 40, 49);">sures p</font>ert<font style="color: rgb(58, 59, 72);">a</font>in<font style="color: rgb(58, 59, 72);">ing </font>to the <font style="color: rgb(40, 40, 49);">Pl</font>at form Rights and Immunocore Background; provid<font style="color: rgb(58, 59, 72);">e</font>d <font style="color: rgb(58, 59, 72);">tha</font>t
                su<font style="color: rgb(40, 40, 49);">c</font>h <font style="color: rgb(40, 40, 49);">d</font><font style="color: rgb(77, 77, 91);">i</font>sclo<font style="color: rgb(40, 40, 49);">sur</font>e or pr<font style="color: rgb(58, 59, 72);">es</font>entation






                shall not contain any Confidential Informatio<font style="color: rgb(40, 40, 49);">n </font>of <font style="color: rgb(40, 40, 49);">G</font>SK or <font style="color: rgb(40, 40, 49);">a</font>ny infor<font style="color: rgb(40, 40, 49);">m</font>a<font style="color: rgb(58, 59, 72);">t</font>ion regar<font style="color: rgb(58, 59, 72);">d</font>i<font style="color: rgb(58, 59, 72);">n</font>g any Licensed Product, whether prior to or after e<font style="color: rgb(58, 59, 72);">xe</font>rcise <font style="color: rgb(40, 40, 49);">of </font><font style="color: rgb(58, 59, 72);">the</font> ap<font style="color: rgb(40, 40, 49);">p</font>lic<font style="color: rgb(58, 59, 72);">a</font>ble Ini<font style="color: rgb(58, 59, 72);">t</font>ial Program Option or Collaboration Program Option.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zcf1ec0bbd4234606af9bb82373501607" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>This Agreement supersedes the Confidential <font style="color: rgb(40, 40, 49);">D</font>i<font style="color: rgb(40, 40, 49);">s</font>closure <font style="color: rgb(40, 40, 49);">Ag</font>ree<font style="color: rgb(40, 40, 49);">m</font>ent






                <font style="color: rgb(40, 40, 49);">e</font>xecuted by the Parties dated 22 April 20<font style="color: rgb(40, 40, 49);">1</font>0 <font style="color: rgb(40, 40, 49);">(th</font>e <font style="font-weight: bold;">&#8220;C</font><font style="font-weight: bold; color: rgb(40, 40, 49);">D</font><font style="font-weight: bold;">A&#8221;). </font><font style="color: rgb(40, 40, 49);">A</font>ll <font style="color: rgb(40, 40, 49);">i</font>n<font style="color: rgb(40, 40, 49);">f</font>ormation exchan<font style="color: rgb(40, 40, 49);">ged </font>between the Parties under the CDA sh<font style="color: rgb(58, 59, 72);">a</font>ll b<font style="color: rgb(58, 59, 72);">e </font>deem<font style="color: rgb(40, 40, 49);">ed C</font>onfi<font style="color: rgb(40, 40, 49);">dent</font>i<font style="color: rgb(40, 40, 49);">al </font>Information of the Party disclosing it under the CDA and shall b<font style="color: rgb(40, 40, 49);">e </font>subje<font style="color: rgb(40, 40, 49);">ct </font>to the terms of t<font style="color: rgb(40, 40, 49);">h</font>is Article 10.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z248a43a24f094d8fbb3371c34d413d1c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon termination <font style="color: rgb(40, 40, 49);">of </font><font style="color: rgb(58, 59, 72);">t</font>his Agreement, <font style="color: rgb(40, 40, 49);">eac</font>h Party <font style="color: rgb(40, 40, 49);">he</font>reto
                and it<font style="color: rgb(58, 59, 72);">s </font>Affiliates shall use Commercially Re<font style="color: rgb(40, 40, 49);">a</font>sonable Eff <font style="color: rgb(40, 40, 49);">orts </font>to <font style="color: rgb(40, 40, 49);">r</font>e<font style="color: rgb(58, 59, 72);">tu</font>rn all C<font style="color: rgb(40, 40, 49);">onfi</font>denti<font style="color: rgb(40, 40, 49);">a</font>l <font style="color: rgb(40, 40, 49);">Information</font> of the
                other Party in its pos<font style="color: rgb(58, 59, 72);">s</font>es<font style="color: rgb(40, 40, 49);">sion </font>to t<font style="color: rgb(40, 40, 49);">h</font>e <font style="color: rgb(40, 40, 49);">o</font>ther <font style="color: rgb(40, 40, 49);">Party</font>; provided, that <font style="color: rgb(40, 40, 49);">eac</font>h Party may retain: (i) a single archival c<font style="color: rgb(40, 40, 49);">op</font>y of th<font style="color: rgb(40, 40, 49);">e Confidential</font> Infor<font style="color: rgb(40, 40, 49);">m</font>at<font style="color: rgb(58, 59, 72);">i</font>on of th<font style="color: rgb(58, 59, 72);">e </font>o<font style="color: rgb(58, 59, 72);">the</font>r
                Party; (ii) any portion of the Confidential Information<font style="color: rgb(40, 40, 49);">&#160;</font><font style="color: rgb(58, 59, 72);">of </font>the o<font style="color: rgb(40, 40, 49);">the</font>r Party<font style="color: rgb(40, 40, 49);">&#160;</font>which is contained in senior managem<font style="color: rgb(40, 40, 49);">e</font>n<font style="color: rgb(58, 59, 72);">t </font>br<font style="color: rgb(58, 59, 72);">i</font>efing <font style="color: rgb(40, 40, 49);">d</font>o<font style="color: rgb(40, 40, 49);">c</font>umen<font style="color: rgb(58, 59, 72);">ts, </font>labor<font style="color: rgb(40, 40, 49);">ator</font>y <font style="color: rgb(58, 59, 72);">no</font>teboo<font style="color: rgb(40, 40, 49);">ks </font>o<font style="color: rgb(58, 59, 72);">r </font>other electronic systems, the deletion f<font style="color: rgb(40, 40, 49);">r</font>o<font style="color: rgb(40, 40, 49);">m </font>which <font style="color: rgb(40, 40, 49);">w</font>ould n<font style="color: rgb(40, 40, 49);">ot </font>be pra<font style="color: rgb(40, 40, 49);">c</font>ti<font style="color: rgb(58, 59, 72);">ca</font>b<font style="color: rgb(58, 59, 72);">l</font>e;






                in e<font style="color: rgb(40, 40, 49);">ithe</font>r case, solely for the purpose of determ<font style="color: rgb(58, 59, 72);">i</font>n<font style="color: rgb(40, 40, 49);">ing </font>the <font style="color: rgb(58, 59, 72);">e</font>xt<font style="color: rgb(58, 59, 72);">e</font>nt of <font style="color: rgb(40, 40, 49);">dis</font>closure o<font style="color: rgb(58, 59, 72);">f </font><font style="color: rgb(40, 40, 49);">Confidential </font>Information hereunder,
                assuring com<font style="color: rgb(40, 40, 49);">pl</font>ian<font style="color: rgb(40, 40, 49);">ce </font>with<font style="color: rgb(40, 40, 49);">&#160;</font>t<font style="color: rgb(40, 40, 49);">h</font>e s<font style="color: rgb(58, 59, 72);">ur</font>vi<font style="color: rgb(40, 40, 49);">v</font>ing provis<font style="color: rgb(58, 59, 72);">io</font>ns of th<font style="color: rgb(58, 59, 72);">is </font>Agreement, relevant document retenti<font style="color: rgb(40, 40, 49);">on </font>policie<font style="color: rgb(58, 59, 72);">s </font>of the<font style="color: rgb(40, 40, 49);"> P</font>arty and<font style="color: rgb(40, 40, 49);"> A</font>pplicable L<font style="color: rgb(40, 40, 49);">a</font>ws. A Party may also retain Confidential Information <font style="color: rgb(40, 40, 49);">w</font>h<font style="color: rgb(58, 59, 72);">e</font>re n<font style="color: rgb(40, 40, 49);">ec</font>e<font style="color: rgb(40, 40, 49);">ss</font>ary for <font style="color: rgb(40, 40, 49);">the</font> perform<font style="color: rgb(40, 40, 49);">an</font>c<font style="color: rgb(40, 40, 49);">e </font>of any surviving licence or obligation<font style="color: rgb(40, 40, 49);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z699c95b849d24ba4866e7f781c292429" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK shall have th<font style="color: rgb(40, 40, 49);">e </font>right at any time aft<font style="color: rgb(40, 40, 49);">er </font>exercise of an Initial Program Option or Collaboration Program<font style="color: rgb(40, 40, 49);">&#160;</font>Option<font style="color: rgb(40, 40, 49);">,</font><font style="color: rgb(77, 77, 91);">&#160;</font>during and after the Term, to (i) publish the result<font style="color: rgb(40, 40, 49);">s </font>or summaries of <font style="color: rgb(58, 59, 72);">res</font>ults of <font style="color: rgb(40, 40, 49);">a</font>ll GSK sponsored or supported clinical trials (which after exercise of <font style="color: rgb(40, 40, 49);">the</font> applic<font style="color: rgb(40, 40, 49);">a</font>b<font style="color: rgb(40, 40, 49);">le </font>Initial Program Option or Collaboration Option shall include any Phase <font style="color: rgb(40, 40, 49);">1 Tr</font>ial res<font style="color: rgb(40, 40, 49);">ul</font>ts <font style="color: rgb(58, 59, 72);">o</font>f Immunocore),</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">39</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">observational studies and other studies such as meta <font style="color: rgb(40, 40, 49);">an</font>alyses, conducted with respect to a Licensed Product in any clinical trial registe<font style="color: rgb(40, 40, 49);">r ma</font>intaine<font style="color: rgb(58, 59, 72);">d </font><font style="color: rgb(40, 40, 49);">by </font>GSK or its Affiliates and the protocols of clinical trials relating to such <font style="color: rgb(40, 40, 49);">Lic</font>ensed P<font style="color: rgb(40, 40, 49);">rod</font>u<font style="color: rgb(58, 59, 72);">c</font>t on<font style="color: rgb(15, 10, 186);">&#160;</font><u>www.ClinicalTrials.gov</u> and/or in each case publish the
        results, sum<font style="color: rgb(40, 40, 49);">ma</font>ries and<font style="color: rgb(58, 59, 72);">/o</font>r protocols of such <font style="color: rgb(40, 40, 49);">C</font>linical <font style="color: rgb(40, 40, 49);">T</font>rials or
        studies on such other websites a<font style="color: rgb(58, 59, 72);">nd/ </font>or repositories and/or at scientific congresses and in a peer<font style="color: rgb(40, 40, 49);">-</font>reviewed journal within<font style="color: rgb(58, 59, 72);"> such </font>timescales as required by law or GSK&#8217;s or its Affiliates&#8217; standard operating<font style="color: rgb(58, 59, 72);"> p</font>ro<font style="color: rgb(58, 59, 72);">c</font>edures, irrespective of the outcome of such Clinical
        Trials; (ii) make information<font style="color: rgb(40, 40, 49);"> f</font>rom Clinical Trials and studies conducted with respect to a Licensed Product available under its Data Sharing Initiative; and (iii) publish the <font style="color: rgb(40, 40, 49);">s</font>tatus of each Licen<font style="color: rgb(40, 40, 49);">s</font>ed Product in its annual and quarterly reports and updates regarding GSK&#8217;s research and development pipeline. Each such publication or disclosure made in
        accordance with this Section 10.9 shall not be a breach of the confidentiality obligations provided in this <font style="color: rgb(7, 7, 7);">Article 10 and GSK shall be entitled to maintain or effect such publication or disclosure even following
          any termination of GSK</font><font style="color: rgb(31, 31, 38);">&#8217;</font><font style="color: rgb(7, 7, 7);">s rights in respect of the relevant Licensed Product. Any disclosure made under this Section 10.9 shall not include any Confidential
          Information of Immunocore comprised within Immunocore Background or Platform Rights where such Confidential Information does not r</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(7, 7, 7);">late explicitly to the
          Licensed Product and without the prior written consent of Immunocore, unless </font><font style="color: rgb(31, 31, 38);">r</font><font style="color: rgb(7, 7, 7);">equired by Applicable Law.</font></div>
      <div>&#160;</div>
      <table id="z0f19633641224462aa9b01fb5b5a1554" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Warranties and Indemnity</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z39e8656b76944c3cb28e0386002197bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore warrants to GSK that as of the E<font style="color: rgb(31, 31, 38);">f</font><font style="color: rgb(54, 54, 66);">fe</font><font style="color: rgb(31, 31, 38);">cti</font><font style="color: rgb(54, 54, 66);">v</font><font style="color: rgb(31, 31, 38);">e </font>D<font style="color: rgb(54, 54, 66);">a</font>te :</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z11ca29b08b044886ac4eb20091988cca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>it has the right to grant the licenc<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(54, 54, 66);">s </font>i<font style="color: rgb(31, 31, 38);">n </font>ac<font style="color: rgb(31, 31, 38);">co</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">danc</font>e <font style="color: rgb(31, 31, 38);">with </font>S<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">c</font>tio<font style="color: rgb(54, 54, 66);">n </font><font style="color: rgb(31, 31, 38);">6.7;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zbbc4979a5cf14ffcbda1c224f073541e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>it has in place contracts wit<font style="color: rgb(31, 31, 38);">h </font>it<font style="color: rgb(54, 54, 66);">s </font><font style="color: rgb(31, 31, 38);">em</font>plo<font style="color: rgb(31, 31, 38);">yee</font><font style="color: rgb(54, 54, 66);">s </font>and <font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">the</font>r per<font style="color: rgb(54, 54, 66);">so</font><font style="color: rgb(31, 31, 38);">n</font>nel






                <font style="color: rgb(31, 31, 38);">i</font>t appoints to perform the Collaboratio<font style="color: rgb(31, 31, 38);">n </font>Program <font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">uffi</font>cient






                <font style="color: rgb(31, 31, 38);">to </font>ensur<font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">ll </font>Foreground is owned in accordance with <font style="color: rgb(31, 31, 38);">Article</font> 7 <font style="color: rgb(31, 31, 38);">ab</font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">v</font>e;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z41ca88c5eb0047c8b4e416f6d6ad4161" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>all of Immunocore&#8217;s <font style="color: rgb(31, 31, 38);">ag</font>r<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(54, 54, 66);">e</font>me<font style="color: rgb(31, 31, 38);">nt</font>s wi<font style="color: rgb(31, 31, 38);">th </font>the <font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(54, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">b</font><font style="color: rgb(54, 54, 66);">c</font>ontr<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">r</font>s <font style="color: rgb(31, 31, 38);">s</font>et forth on Schedule 10 to the extent a<font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(54, 54, 66);">r</font>ee<font style="color: rgb(31, 31, 38);">m</font>ents al<font style="color: rgb(31, 31, 38);">r</font><font style="color: rgb(54, 54, 66);">ea</font>dy <font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">xi</font>st under <font style="color: rgb(31, 31, 38);">which
                </font>subcontractors will be conducting work <font style="color: rgb(31, 31, 38);">u</font>n<font style="color: rgb(31, 31, 38);">d</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">r the</font>&#160;<font style="color: rgb(31, 31, 38);">Re</font>searc<font style="color: rgb(31, 31, 38);">h Plans </font>provide <font style="color: rgb(31, 31, 38);">(</font><font style="color: rgb(54, 54, 66);">i</font>) that I<font style="color: rgb(31, 31, 38);">mmu</font>nocore shall, in all cases, re<font style="color: rgb(31, 31, 38);">ta</font>in <font style="color: rgb(31, 31, 38);">o</font>r ob<font style="color: rgb(31, 31, 38);">ta</font><font style="color: rgb(54, 54, 66);">in
                </font><font style="color: rgb(31, 31, 38);">o</font>wne<font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">ship o</font>f <font style="color: rgb(31, 31, 38);">an</font>y and all <font style="color: rgb(31, 31, 38);">Intellectual</font> Property arising as a resu<font style="color: rgb(31, 31, 38);">lt </font>of per<font style="color: rgb(54, 54, 66);">fo</font>rman<font style="color: rgb(31, 31, 38);">ce </font>of any <font style="color: rgb(31, 31, 38);">sub</font>-contract<font style="color: rgb(31, 31, 38);">ed </font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">c</font>tivity under the Research P<font style="color: rgb(54, 54, 66);">l</font>an, (ii) t<font style="color: rgb(31, 31, 38);">h</font>at su<font style="color: rgb(31, 31, 38);">c</font>h s<font style="color: rgb(31, 31, 38);">ub</font>-contractor<font style="color: rgb(54, 54, 66);">&#160;</font>has






                n<font style="color: rgb(54, 54, 66);">o </font><font style="color: rgb(31, 31, 38);">ri</font>ghts to use any Intellectual<font style="color: rgb(31, 31, 38);"> P</font>roperty R<font style="color: rgb(31, 31, 38);">i</font>ghts <font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">w</font><font style="color: rgb(31, 31, 38);">n</font>ed or <font style="color: rgb(31, 31, 38);">Control</font>led by <font style="color: rgb(54, 54, 66);">Immunocore</font>
                save as strictly necessary fo<font style="color: rgb(31, 31, 38);">r perform</font><font style="color: rgb(54, 54, 66);">an</font>ce of t<font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(31, 31, 38);">s</font>ub-contracted a<font style="color: rgb(31, 31, 38);">c</font>tivities and (iii) that <font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">u</font>c<font style="color: rgb(31, 31, 38);">h </font><font style="color: rgb(54, 54, 66);">s</font>ub-contractor <font style="color: rgb(31, 31, 38);">s</font>h<font style="color: rgb(31, 31, 38);">a</font>ll not be <font style="color: rgb(31, 31, 38);">e</font>ntitle<font style="color: rgb(31, 31, 38);">d t</font><font style="color: rgb(54, 54, 66);">o f</font>urther sub-contract its obligations as t<font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">y </font>rela<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(31, 31, 38);">to </font>the c<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">n</font>du<font style="color: rgb(54, 54, 66);">c</font>t of an<font style="color: rgb(31, 31, 38);">y Collaboration</font> Program under th<font style="color: rgb(31, 31, 38);">is </font>A<font style="color: rgb(31, 31, 38);">g</font>reeme<font style="color: rgb(31, 31, 38);">n</font>t.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4660adf2195a46dbb37bff4488f48699" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>It <font style="color: rgb(31, 31, 38);">h</font>as n<font style="color: rgb(31, 31, 38);">ot re</font>ceive<font style="color: rgb(54, 54, 66);">d </font>any written notice <font style="color: rgb(54, 54, 66);">fro</font><font style="color: rgb(31, 31, 38);">m </font>any Third Party asserting or<font style="color: rgb(54, 54, 66);"> a</font><font style="color: rgb(31, 31, 38);">ll</font><font style="color: rgb(54, 54, 66);">e</font>ging that th<font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">e</font>search<font style="color: rgb(31, 31, 38);">, </font><font style="color: rgb(54, 54, 66);">d</font>e<font style="color: rgb(31, 31, 38);">v</font>elopm<font style="color: rgb(54, 54, 66);">e</font>nt or manufacturing of Compounds<font style="color: rgb(54, 54, 66);"> i</font>nfrin<font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(54, 54, 66);">es </font><font style="color: rgb(31, 31, 38);">o</font>r <font style="color: rgb(31, 31, 38);">m</font><font style="color: rgb(54, 54, 66);">is</font><font style="color: rgb(31, 31, 38);">app</font>ropriates







                <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">h</font>e inte<font style="color: rgb(31, 31, 38);">ll</font>e<font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">u</font>al property rights of such Third Party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zcbb3815bc379460dbd9df49f63c0b5ba" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Schedule 3 </font><font style="color: #1F1F26;">s</font><font style="color: #363642;">e</font><font style="color: #070707;">ts forth</font><font style="color: #363642;"> a </font><font style="color: #070707;">compl</font><font style="color: #1F1F26;">et</font><font style="color: #070707;">e </font><font style="color: #363642;">a</font><font style="color: #070707;">nd accurate list of the patents comprising the Immunocore Background
                  rel</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">v</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">nt to the Targets within the Dataroom as of th</font><font style="color: #1F1F26;">e
                  Effective</font><font style="color: #070707;"> D</font><font style="color: #1F1F26;">at</font><font style="color: #363642;">e</font><font style="color: #1F1F26;">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0cdf01f2d40a492ab6fedaf0070c89be" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.6</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>I<font style="color: rgb(54, 54, 66);">m</font>munocor<font style="color: rgb(31, 31, 38);">e h</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">s </font>provided GSK with a complete and accurate
                copy of the<font style="color: rgb(31, 31, 38);"> As</font>s<font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(54, 54, 66);">g</font>nment Ag<font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">e</font>ement, Deed and Clarification Agreement, as e<font style="color: rgb(31, 31, 38);">a</font>ch <font style="color: rgb(31, 31, 38);">s</font>uch<font style="color: rgb(54, 54, 66);"> a</font><font style="color: rgb(31, 31, 38);">g</font>reement is in effect as of the Effective<font style="color: rgb(31, 31, 38);">&#160;</font>D<font style="color: rgb(31, 31, 38);">a</font>te, <font style="color: rgb(31, 31, 38);">a</font>nd Immunocore<font style="color: rgb(31, 31, 38);">&#160;</font>is not <font style="color: rgb(31, 31, 38);">a</font>ware<font style="color: rgb(54, 54, 66);"> o</font><font style="color: rgb(31, 31, 38);">f </font>any <font style="color: rgb(54, 54, 66);">c</font>u<font style="color: rgb(54, 54, 66);">rr</font><font style="color: rgb(31, 31, 38);">e</font>nt material breach of the Assignment Agreement, Deed and Clarifi<font style="color: rgb(31, 31, 38);">cat</font>i<font style="color: rgb(31, 31, 38);">on






                </font>Agreement that would give Adaptimmune the right to terminate the s<font style="color: rgb(31, 31, 38);">ame</font>;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">40</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z477c6695abf84dd69fb51b09f69399c2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.7</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Immunocore represents and w<font style="color: rgb(31, 31, 38);">a</font>rrants to GSK that it has not intentionally omitted to furnish GSK with any material <font style="color: rgb(31, 31, 38);">i</font>nformat<font style="color: rgb(31, 31, 38);">i</font>on known to Immunocore in response to GSK&#8217;s requests for information, at the time of such response, during the due diligence and negotiation process with re<font style="color: rgb(31, 31, 38);">s</font>pect to
                this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zf94c5100a0134522adacb8b5f54cf527" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.8</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>the inform<font style="color: rgb(31, 31, 38);">a</font>tion in the Dataroom i<font style="color: rgb(31, 31, 38);">s </font>a<font style="color: rgb(31, 31, 38);">c</font>curate in <font style="color: rgb(31, 31, 38);">a</font>ll
                materi<font style="color: rgb(31, 31, 38);">a</font>l respe<font style="color: rgb(31, 31, 38);">c</font>t<font style="color: rgb(31, 31, 38);">s</font>; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0cfa679384fb49e2a58ce74fedee99a3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.1.9</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>the following patents and patent applications are owned by Immunocore<font style="color: rgb(28, 28, 31);">:</font> patents and patent applications derived from [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9d859218bb53483abd43db4814702924" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK warrants to Immunocore that it has in place co<font style="color: rgb(47, 47, 56);">n</font>trac<font style="color: rgb(28, 28, 31);">ts </font>with its employees and other personnel it appoints to perform the Collaboration <font style="color: rgb(47, 47, 56);">P</font><font style="color: rgb(28, 28, 31);">ro</font>gram suffici<font style="color: rgb(47, 47, 56);">en</font>t to ensure all Foreground is owned in accordance with Article 7 <font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(28, 28, 31);">bov</font>e.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6359595e509745959351abaca6a206f4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party warrants to the other that:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za32f5c7c6e604b189a3ffaf1fe5adea3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.3.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>As of the Effective Date, it is a com<font style="color: rgb(28, 28, 31);">p</font><font style="color: rgb(47, 47, 56);">any o</font>r c<font style="color: rgb(47, 47, 56);">o</font><font style="color: rgb(28, 28, 31);">r</font>poration
                du<font style="color: rgb(28, 28, 31);">l</font><font style="color: rgb(47, 47, 56);">y </font>organ<font style="color: rgb(47, 47, 56);">ize</font><font style="color: rgb(28, 28, 31);">d</font>, validly existing, and in good standing un<font style="color: rgb(47, 47, 56);">d</font>e<font style="color: rgb(47, 47, 56);">r </font>the<font style="color: rgb(47, 47, 56);">&#160;</font>Ap<font style="color: rgb(28, 28, 31);">pl</font>i<font style="color: rgb(28, 28, 31);">c</font><font style="color: rgb(47, 47, 56);">a</font>ble L<font style="color: rgb(28, 28, 31);">aws </font>of the <font style="color: rgb(47, 47, 56);">jurisd</font><font style="color: rgb(28, 28, 31);">i</font>ction in which it is incorporated.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z85485a6c1f19486695d5e867bb1ecacf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.3.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>As of the Effective Date, (i) <font style="color: rgb(47, 47, 56);">i</font><font style="color: rgb(28, 28, 31);">t </font><font style="color: rgb(47, 47, 56);">ha</font><font style="color: rgb(28, 28, 31);">s </font>the <font style="color: rgb(47, 47, 56);">c</font><font style="color: rgb(28, 28, 31);">or</font><font style="color: rgb(47, 47, 56);">p</font><font style="color: rgb(28, 28, 31);">o</font>rat<font style="color: rgb(28, 28, 31);">e </font><font style="color: rgb(47, 47, 56);">p</font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 56);">w</font>er a<font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 56);">d </font>authority






                and the legal right to enter into th<font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 56);">s </font>Ag<font style="color: rgb(28, 28, 31);">r</font><font style="color: rgb(47, 47, 56);">e</font>eme<font style="color: rgb(47, 47, 56);">nt </font>a<font style="color: rgb(28, 28, 31);">n</font>d per<font style="color: rgb(47, 47, 56);">fo</font>r<font style="color: rgb(28, 28, 31);">m </font>its o<font style="color: rgb(28, 28, 31);">b</font>lig<font style="color: rgb(28, 28, 31);">at</font><font style="color: rgb(47, 47, 56);">i</font>ons hereunder; <font style="color: rgb(7, 7, 7);">(ii) it has taken all nece</font><font style="color: rgb(28, 28, 31);">ssa</font><font style="color: rgb(47, 47, 56);">ry </font><font style="color: rgb(7, 7, 7);">corpo</font><font style="color: rgb(28, 28, 31);">rat</font><font style="color: rgb(47, 47, 56);">e </font><font style="color: rgb(7, 7, 7);">act io</font><font style="color: rgb(47, 47, 56);">n </font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 56);">n </font><font style="color: rgb(7, 7, 7);">its pa</font><font style="color: rgb(47, 47, 56);">r</font><font style="color: rgb(28, 28, 31);">t r</font><font style="color: rgb(66, 68, 79);">e</font><font style="color: rgb(28, 28, 31);">qu</font><font style="color: rgb(7, 7, 7);">ired to authorize the execution and de</font><font style="color: rgb(28, 28, 31);">live</font><font style="color: rgb(47, 47, 56);">ry </font><font style="color: rgb(7, 7, 7);">of </font><font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 47, 56);">h</font><font style="color: rgb(28, 28, 31);">is A</font><font style="color: rgb(7, 7, 7);">gre</font><font style="color: rgb(28, 28, 31);">eme</font><font style="color: rgb(47, 47, 56);">n</font><font style="color: rgb(28, 28, 31);">t </font><font style="color: rgb(7, 7, 7);">and </font><font style="color: rgb(47, 47, 56);">t</font><font style="color: rgb(7, 7, 7);">h</font><font style="color: rgb(28, 28, 31);">e p</font><font style="color: rgb(7, 7, 7);">erformance of its obligations hereunde</font><font style="color: rgb(28, 28, 31);">r</font><font style="color: rgb(47, 47, 56);">; a</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(7, 7, 7);">d (i</font><font style="color: rgb(47, 47, 56);">i</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(7, 7, 7);">) this</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(7, 7, 7);">Agreement h</font><font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(28, 28, 31);">s </font><font style="color: rgb(47, 47, 56);">b</font><font style="color: rgb(7, 7, 7);">e</font><font style="color: rgb(28, 28, 31);">e</font><font style="color: rgb(7, 7, 7);">n duly executed and
                  delivered on behalf of </font><font style="color: rgb(47, 47, 56);">s</font><font style="color: rgb(28, 28, 31);">u</font><font style="color: rgb(7, 7, 7);">ch Party</font><font style="color: rgb(47, 47, 56);">, </font><font style="color: rgb(7, 7, 7);">a</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 56);">d c</font><font style="color: rgb(7, 7, 7);">onstitut</font><font style="color: rgb(47, 47, 56);">es </font><font style="color: rgb(28, 28, 31);">a l</font><font style="color: rgb(47, 47, 56);">e</font><font style="color: rgb(7, 7, 7);">gal</font><font style="color: rgb(28, 28, 31);">, v</font><font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(7, 7, 7);">lid, and binding obligation of su</font><font style="color: rgb(28, 28, 31);">ch Party </font><font style="color: rgb(7, 7, 7);">that</font><font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(7, 7, 7);">is en</font><font style="color: rgb(28, 28, 31);">fo</font><font style="color: rgb(66, 68, 79);">r</font><font style="color: rgb(28, 28, 31);">c</font><font style="color: rgb(47, 47, 56);">ea</font><font style="color: rgb(28, 28, 31);">b</font><font style="color: rgb(47, 47, 56);">l</font><font style="color: rgb(7, 7, 7);">e aga</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(7, 7, 7);">nst it in a</font><font style="color: rgb(47, 47, 56);">cco</font><font style="color: rgb(28, 28, 31);">r</font><font style="color: rgb(47, 47, 56);">d</font><font style="color: rgb(7, 7, 7);">ance with its terms.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z172e02970de44cd3938751fba6b062f3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.3.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Nothing co<font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 56);">t</font>ained in t<font style="color: rgb(28, 28, 31);">h</font>is <font style="color: rgb(28, 28, 31);">A</font>gr<font style="color: rgb(28, 28, 31);">e</font>e<font style="color: rgb(28, 28, 31);">m</font>e<font style="color: rgb(28, 28, 31);">n</font>t shall be c<font style="color: rgb(47, 47, 56);">o</font>nstru<font style="color: rgb(47, 47, 56);">e</font>d as a warranty,<font style="color: rgb(28, 28, 31);">&#160;</font>either express <font style="color: rgb(47, 47, 56);">o</font><font style="color: rgb(28, 28, 31);">r </font><font style="color: rgb(47, 47, 56);">i</font><font style="color: rgb(28, 28, 31);">m</font>plied,






                <font style="color: rgb(47, 47, 56);">o</font>n <font style="color: rgb(28, 28, 31);">the</font>&#160;<font style="color: rgb(7, 7, 7);">part</font><font style="color: rgb(47, 47, 56);">&#160;</font>of eithe<font style="color: rgb(28, 28, 31);">r P</font>arty






                that <font style="color: rgb(47, 47, 56);">(i</font>) any Collaboration Program will yield <font style="color: rgb(28, 28, 31);">a </font><font style="color: rgb(47, 47, 56);">Lic</font>ens<font style="color: rgb(28, 28, 31);">ed </font><font style="color: rgb(47, 47, 56);">Product</font>&#160;<font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 56);">r othe</font>rwi<font style="color: rgb(47, 47, 56);">s</font><font style="color: rgb(28, 28, 31);">e </font><font style="color: rgb(47, 47, 56);">b</font>e <font style="color: rgb(28, 28, 31);">s</font>uc<font style="color: rgb(28, 28, 31);">c</font>essful or meet its goals<font style="color: rgb(66, 68, 79);">, </font>or <font style="color: rgb(47, 47, 56);">(i</font><font style="color: rgb(28, 28, 31);">i</font><font style="color: rgb(47, 47, 56);">) </font>the <font style="color: rgb(28, 28, 31);">ou</font>t<font style="color: rgb(47, 47, 56);">c</font><font style="color: rgb(28, 28, 31);">o</font>me<font style="color: rgb(28, 28, 31);">s </font><font style="color: rgb(47, 47, 56);">o</font>f <font style="color: rgb(28, 28, 31);">the</font> Collaboration <font style="color: rgb(28, 28, 31);">Programs</font> will be commercially expl<font style="color: rgb(47, 47, 56);">o</font>it<font style="color: rgb(47, 47, 56);">ab</font>le in a<font style="color: rgb(47, 47, 56);">ny </font><font style="color: rgb(28, 28, 31);">r</font>espe<font style="color: rgb(47, 47, 56);">ct.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z36ea34a89e08401e99380a3021084d80" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the cou<font style="color: rgb(28, 28, 31);">r</font>s<font style="color: rgb(47, 47, 56);">e </font><font style="color: rgb(28, 28, 31);">o</font>f <font style="color: rgb(28, 28, 31);">t</font>he r<font style="color: rgb(47, 47, 56);">e</font>se<font style="color: rgb(47, 47, 56);">a</font>rch <font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(66, 68, 79);">r </font>develop<font style="color: rgb(47, 47, 56);">me</font>nt <font style="color: rgb(47, 47, 56);">o</font>f the Compounds and Licensed Products<font style="color: rgb(28, 28, 31);">,</font> each Party<font style="color: rgb(28, 28, 31);">&#160;</font><font style="color: rgb(47, 47, 56);">(</font><font style="color: rgb(28, 28, 31);">and</font> in <font style="color: rgb(28, 28, 31);">the </font>case <font style="color: rgb(47, 47, 56);">o</font>f GSK, <font style="color: rgb(28, 28, 31);">G</font><font style="color: rgb(47, 47, 56);">S</font>K<font style="color: rgb(47, 47, 56);">&#8217;s </font>Affilia<font style="color: rgb(47, 47, 56);">tes) </font><font style="color: rgb(28, 28, 31);">s</font>hall not use any employee or consul<font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 56);">t w</font>ho h<font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(28, 28, 31);">s b</font>een <font style="color: rgb(47, 47, 56);">de</font><font style="color: rgb(28, 28, 31);">b</font>arred <font style="color: rgb(47, 47, 56);">b</font>y any Re<font style="color: rgb(47, 47, 56);">gu</font>la<font style="color: rgb(47, 47, 56);">to</font>ry






                Authority, or, to such Party <font style="color: rgb(47, 47, 56);">&#8216;</font>s kno<font style="color: rgb(28, 28, 31);">w</font><font style="color: rgb(47, 47, 56);">l</font><font style="color: rgb(28, 28, 31);">e</font>dg<font style="color: rgb(66, 68, 79);">e</font><font style="color: rgb(28, 28, 31);">, </font>is t<font style="color: rgb(47, 47, 56);">he </font><font style="color: rgb(28, 28, 31);">su</font>bje<font style="color: rgb(47, 47, 56);">ct </font><font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 56);">f </font>debarmen<font style="color: rgb(28, 28, 31);">t </font>proceedin<font style="color: rgb(47, 47, 56);">gs </font>by <font style="color: rgb(28, 28, 31);">a </font>Regulatory Authority. Each Party <font style="color: rgb(47, 47, 56);">sh</font>all notify<font style="color: rgb(28, 28, 31);">&#160;</font>the <font style="color: rgb(47, 47, 56);">ot</font>h<font style="color: rgb(28, 28, 31);">e</font>r Party<font style="color: rgb(47, 47, 56);">&#160;</font>promptly upon becoming aware that any of its e<font style="color: rgb(47, 47, 56);">mplo</font>yees <font style="color: rgb(47, 47, 56);">or </font><font style="color: rgb(28, 28, 31);">c</font><font style="color: rgb(47, 47, 56);">o</font>nsul<font style="color: rgb(28, 28, 31);">t</font><font style="color: rgb(47, 47, 56);">a</font><font style="color: rgb(28, 28, 31);">n</font><font style="color: rgb(47, 47, 56);">ts </font>(or em<font style="color: rgb(47, 47, 56);">pl</font>o<font style="color: rgb(47, 47, 56);">y</font>ees <font style="color: rgb(28, 28, 31);">o</font><font style="color: rgb(47, 47, 56);">r c</font><font style="color: rgb(28, 28, 31);">o</font>n<font style="color: rgb(47, 47, 56);">s</font>ultants of GSK&#8217;s Affiliates as relevant) ha<font style="color: rgb(28, 28, 31);">s </font><font style="color: rgb(47, 47, 56);">b</font>een deb<font style="color: rgb(28, 28, 31);">a</font>rred o<font style="color: rgb(47, 47, 56);">r </font>is the <font style="color: rgb(47, 47, 56);">su</font>bject <font style="color: rgb(28, 28, 31);">of </font><font style="color: rgb(47, 47, 56);">de</font>barment proceedings by any Regulatory Authority.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zed6039480f3f4b60a1e365fd5d8e88bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party s<font style="color: rgb(28, 28, 31);">h</font><font style="color: rgb(66, 68, 79);">a</font>ll compl<font style="color: rgb(28, 28, 31);">y </font>i<font style="color: rgb(28, 28, 31);">n </font>all material respects with
                all Applicable Laws in the performance<font style="color: rgb(47, 47, 56);">&#160;</font>of its obligations and exercise of its rights under this Agreement to the extent in <font style="color: rgb(47, 47, 56);">each </font>case <font style="color: rgb(47, 47, 56);">th</font>at <font style="color: rgb(47, 47, 56);">s</font>uch Applicable Law<font style="color: rgb(28, 28, 31);">s </font>cover the performance of the relevant obligati<font style="color: rgb(47, 47, 56);">ons </font>or exercise of right<font style="color: rgb(28, 28, 31);">s</font>, includin<font style="color: rgb(28, 28, 31);">g </font>the statutes, regulations <font style="color: rgb(28, 28, 31);">a</font>nd written dir<font style="color: rgb(28, 28, 31);">e</font>cti<font style="color: rgb(47, 47, 56);">ves o</font>f the F<font style="color: rgb(47, 47, 56);">D</font><font style="color: rgb(28, 28, 31);">A</font><font style="color: rgb(47, 47, 56);">, </font>the






                EMA and any other applic<font style="color: rgb(28, 28, 31);">a</font>bl<font style="color: rgb(28, 28, 31);">e </font>R<font style="color: rgb(28, 28, 31);">e</font>gul<font style="color: rgb(28, 28, 31);">a</font>tory Authority, <font style="color: rgb(28, 28, 31);">a</font>nd th<font style="color: rgb(28, 28, 31);">e</font> provision<font style="color: rgb(28, 28, 31);">s </font>of Section<font style="color: rgb(47, 47, 56);">&#160;</font>14, each as may be amended from
                time to time<font style="color: rgb(103, 103, 103);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5920e0036e3641b39d50306d06066e91" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1C1C1F;">S</font><font style="color: #2F2F38;">hould </font>Immunocore propose to amend the Amendment Agreement or Deed and<font style="color: rgb(47, 47, 56);"> C</font><font style="color: rgb(28, 28, 31);">l</font><font style="color: rgb(47, 47, 56);">ar</font>ificati<font style="color: rgb(28, 28, 31);">o</font>n Agreement in a manner that would prevent <font style="color: rgb(28, 28, 31);">o</font>r restrict the grant of any <font style="color: rgb(28, 28, 31);">o</font>f<font style="color: rgb(47, 47, 56);"> t</font>h<font style="color: rgb(28, 28, 31);">e </font>licences under this Agreement to GSK, or provide the right t<font style="color: rgb(28, 28, 31);">o </font>Adaptimmune






                to prosecute any Licensed Patents that it does not have the right to prosecute as of the Effective Date, it will obtain the prior written consent of GSK. Such consent will not be unr<font style="color: rgb(28, 28, 31);">e</font>a<font style="color: rgb(28, 28, 31);">s</font>onably withheld and will be pr<font style="color: rgb(28, 28, 31);">o</font>vi<font style="color: rgb(28, 28, 31);">de</font>d promptly.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">41</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z3290a9e5ad54476695758fd1600b8172" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-variant: small-caps;">11.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-variant: small-caps;">the e<font style="color: rgb(28, 28, 31);">x</font>pre<font style="color: rgb(28, 28, 31);">s</font><font style="color: rgb(47, 47, 56);">s </font>undertaking<font style="color: rgb(47, 47, 56);">s </font>and






                w<font style="color: rgb(28, 28, 31);">a</font>rran<font style="color: rgb(28, 28, 31);">t</font>ie<font style="color: rgb(28, 28, 31);">s g</font>iven b<font style="color: rgb(28, 28, 31);">y t</font>he p<font style="color: rgb(28, 28, 31);">a</font>rtie<font style="color: rgb(47, 47, 56);">s </font>in <font style="color: rgb(28, 28, 31);">t</font>hi<font style="color: rgb(28, 28, 31);">s </font>agree<font style="color: rgb(28, 28, 31);">m</font>e<font style="color: rgb(28, 28, 31);">nt a</font>re in lieu<font style="color: rgb(28, 28, 31);"> o</font>f a<font style="color: rgb(28, 28, 31);">ll o</font>the<font style="color: rgb(28, 28, 31);">r </font>war<font style="color: rgb(28, 28, 31);">r</font>antie<font style="color: rgb(28, 28, 31);">s</font>, <font style="color: rgb(47, 47, 56);">c</font><font style="color: rgb(28, 28, 31);">o</font>nditi<font style="color: rgb(47, 47, 56);">o</font>n<font style="color: rgb(47, 47, 56);">s</font>, te<font style="color: rgb(28, 28, 31);">r</font>m<font style="color: rgb(47, 47, 56);">s</font>, <font style="color: rgb(28, 28, 31);">u</font>nd<font style="color: rgb(28, 28, 31);">er</font>t<font style="color: rgb(28, 28, 31);">a</font>kin<font style="color: rgb(28, 28, 31);">gs </font>an<font style="color: rgb(28, 28, 31);">d ob</font><font style="color: rgb(47, 47, 56);">li</font><font style="color: rgb(28, 28, 31);">ga</font>ti<font style="color: rgb(47, 47, 56);">o</font>n<font style="color: rgb(28, 28, 31);">s </font>wheth<font style="color: rgb(28, 28, 31);">er </font>e<font style="color: rgb(47, 47, 56);">x</font>p<font style="color: rgb(28, 28, 31);">r</font>e<font style="color: rgb(47, 47, 56);">s</font><font style="color: rgb(28, 28, 31);">s </font><font style="color: rgb(7, 7, 7);">or </font>implied<font style="color: rgb(7, 7, 7);"> by statute, common la</font><font style="color: rgb(31, 31, 36);">w</font><font style="color: rgb(7, 7, 7);">, custom, trade usage, course </font><font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(7, 7, 7);">f dealing or in any </font><font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(7, 7, 7);">ther
                  way. all of these are expressly excluded from this agreement to the full e</font><font style="color: rgb(31, 31, 36);">x</font><font style="color: rgb(7, 7, 7);">tent </font><font style="color: rgb(51, 51, 61);">p</font><font style="color: rgb(7, 7, 7);">ermitted by law. no</font><font style="font-weight: bold; color: rgb(7, 7, 7);">&#160;</font><font style="color: rgb(7, 7, 7);">warranty is given by immunocore that any use of immunocore backgrou</font><font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(7, 7, 7);">d will result in any commercially useful licensed products or licensed products w</font><font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(7, 7, 7);">ich </font><font style="color: rgb(31, 31, 36);">w</font><font style="color: rgb(7, 7, 7);">ill successfully treat any specific indication.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z32466a55795b4b1e94fc8969d0767c1d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>GSK will indemnify, defend and hold harmless Immunocore and its dir<font style="color: rgb(31, 31, 36);">ec</font><font style="color: rgb(51, 51, 61);">t</font><font style="color: rgb(31, 31, 36);">o</font>rs, offi<font style="color: rgb(31, 31, 36);">c</font>ers<font style="color: rgb(31, 31, 36);">,</font> employees and representatives (the <font style="font-weight: bold;">&#8220;Immunocore </font><font style="font-weight: bold; color: rgb(31, 31, 36);">Ind</font><font style="font-weight: bold;">emnified Parties</font><font style="font-weight: bold; color: rgb(31, 31, 36);">&#8221;</font><font style="font-weight: bold;">) </font>from and against all Losses arising out of or resulting from <font style="color: rgb(51, 51, 61);">Claims</font> based upon:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za5452bac35ea4db799ef342b594a4f37" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.8.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any negligence or wilful misconduc<font style="color: rgb(31, 31, 36);">t </font><font style="color: rgb(51, 51, 61);">b</font><font style="color: rgb(31, 31, 36);">y </font><font style="color: rgb(51, 51, 61);">a</font>ny <font style="color: rgb(31, 31, 36);">G</font>SK Indemn<font style="color: rgb(31, 31, 36);">ifie</font>d Party<font style="color: rgb(51, 51, 61);">&#160;</font><font style="color: rgb(31, 31, 36);">o</font>r GSK&#8217;s sublicensees in connection with <font style="color: rgb(31, 31, 36);">G</font>S<font style="color: rgb(31, 31, 36);">K</font><font style="color: rgb(51, 51, 61);">&#8217;</font>s pe<font style="color: rgb(51, 51, 61);">r</font><font style="color: rgb(31, 31, 36);">fo</font><font style="color: rgb(51, 51, 61);">r</font>man<font style="color: rgb(31, 31, 36);">ce of </font>its <font style="color: rgb(51, 51, 61);">obligation</font>s or exercise of its rights under this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z402d2fced19f402ab1d467dfe14b812e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.8.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any non-compliance by any <font style="color: rgb(31, 31, 36);">GS</font><font style="color: rgb(51, 51, 61);">K </font><font style="color: rgb(31, 31, 36);">In</font>d<font style="color: rgb(31, 31, 36);">em</font>n<font style="color: rgb(51, 51, 61);">ifi</font><font style="color: rgb(31, 31, 36);">e</font>d P<font style="color: rgb(51, 51, 61);">a</font><font style="color: rgb(31, 31, 36);">rty </font>or G<font style="color: rgb(31, 31, 36);">SK</font>&#8217;s
                sublicensees or their sub-contractors with any Applicable Laws;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8f68129b41e94195832c28dea3a1bba6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.8.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any death or injury or product liability claim resulting from sale or supply of any Licensed Product by GSK or its Affiliates or their sublicensees;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zd150251c08114aad91f9c457409f7f30" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.8.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any death or injury or product liability claim resulting from the conduct of Clinical Trials by any GSK Indemnified Party or GSK&#8217;s sublicensees, and the storage, handling, use, manufacture, marketing, commercialization, importation or
                sale of any Compounds by GSK, its Affiliates, their subcontractors or their sublicensees; and/or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zdc3ba638536d478f80201ebbc9a972ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.8.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>GSK proceed<font style="color: rgb(7, 7, 7);">ing wi</font><font style="color: rgb(51, 51, 61);">t</font><font style="color: rgb(7, 7, 7);">h an A</font><font style="color: rgb(31, 31, 36);">ct </font><font style="color: rgb(7, 7, 7);">ion






                </font><font style="color: rgb(31, 31, 36);">in </font><font style="color: rgb(7, 7, 7);">accordance</font><font style="color: rgb(31, 31, 36);">&#160;</font><font style="color: rgb(51, 51, 61);">with</font><font style="color: rgb(7, 7, 7);">
                  Section 7.4.4 after Imm</font><font style="color: rgb(31, 31, 36);">un</font><font style="color: rgb(51, 51, 61);">oc</font><font style="color: rgb(7, 7, 7);">ore i</font><font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(51, 51, 61);">for</font><font style="color: rgb(7, 7, 7);">ms G</font><font style="color: rgb(31, 31, 36);">SK </font><font style="color: rgb(7, 7, 7);">that it i</font><font style="color: rgb(51, 51, 61);">s </font><font style="color: rgb(7, 7, 7);">n</font><font style="color: rgb(51, 51, 61);">o</font><font style="color: rgb(7, 7, 7);">t proce</font><font style="color: rgb(31, 31, 36);">ed</font><font style="color: rgb(51, 51, 61);">i</font><font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(51, 51, 61);">g </font><font style="color: rgb(7, 7, 7);">with such Action on the ad</font><font style="color: rgb(51, 51, 61);">v</font><font style="color: rgb(7, 7, 7);">i</font><font style="color: rgb(31, 31, 36);">c</font><font style="color: rgb(7, 7, 7);">e of co</font><font style="color: rgb(31, 31, 36);">m</font><font style="color: rgb(7, 7, 7);">p</font><font style="color: rgb(31, 31, 36);">et</font><font style="color: rgb(7, 7, 7);">ent c</font><font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(7, 7, 7);">u</font><font style="color: rgb(51, 51, 61);">ns</font><font style="color: rgb(7, 7, 7);">el</font><font style="color: rgb(31, 31, 36);">, </font><font style="color: rgb(7, 7, 7);">a</font><font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(51, 51, 61);">d</font><font style="color: rgb(7, 7, 7);">, </font><font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(7, 7, 7);">f </font><font style="color: rgb(31, 31, 36);">G</font><font style="color: rgb(7, 7, 7);">SK r</font><font style="color: rgb(31, 31, 36);">eq</font><font style="color: rgb(7, 7, 7);">uire</font><font style="color: rgb(31, 31, 36);">s </font><font style="color: rgb(7, 7, 7);">Immunocore to initiate an</font><font style="color: rgb(31, 31, 36);"> A</font><font style="color: rgb(7, 7, 7);">c</font><font style="color: rgb(51, 51, 61);">t</font><font style="color: rgb(31, 31, 36);">io</font><font style="color: rgb(7, 7, 7);">n</font><font style="color: rgb(51, 51, 61);">, </font><font style="color: rgb(7, 7, 7);">such </font><font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(7, 7, 7);">c</font><font style="color: rgb(51, 51, 61);">ti</font><font style="color: rgb(7, 7, 7);">ons t</font><font style="color: rgb(51, 51, 61);">a</font><font style="color: rgb(7, 7, 7);">ke</font><font style="color: rgb(31, 31, 36);">n </font><font style="color: rgb(7, 7, 7);">by </font><font style="color: rgb(31, 31, 36);">Immunocore</font><font style="color: rgb(7, 7, 7);">&#160;</font><font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(51, 51, 61);">s </font><font style="color: rgb(7, 7, 7);">d</font><font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(51, 51, 61);">r</font><font style="color: rgb(7, 7, 7);">ected by GSK;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="font-style: italic;">except</font><font style="font-style: italic; color: #33333D;">, </font>t<font style="color: rgb(51, 51, 61);">o </font><font style="color: rgb(31, 31, 36);">the</font>&#160;<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(51, 51, 61);">x</font>t<font style="color: rgb(31, 31, 36);">en</font>t su<font style="color: rgb(51, 51, 61);">c</font><font style="color: rgb(31, 31, 36);">h C</font>laim <font style="color: rgb(31, 31, 36);">aro</font>s<font style="color: rgb(31, 31, 36);">e </font>out <font style="color: rgb(51, 51, 61);">o</font>f <font style="color: rgb(51, 51, 61);">o</font>r resulted from any negligence, misc<font style="color: rgb(51, 51, 61);">o</font>ndu<font style="color: rgb(51, 51, 61);">c</font><font style="color: rgb(31, 31, 36);">t </font>or <font style="color: rgb(51, 51, 61);">m</font><font style="color: rgb(31, 31, 36);">at</font><font style="color: rgb(51, 51, 61);">e</font>rial <font style="color: rgb(51, 51, 61);">b</font><font style="color: rgb(31, 31, 36);">re</font><font style="color: rgb(51, 51, 61);">a</font>ch of this Agreement<font style="color: rgb(51, 51, 61);">&#160;</font>by any
        Immunocore Ind<font style="color: rgb(31, 31, 36);">e</font>mnified Party. The <font style="color: rgb(31, 31, 36);">indemnities</font><font style="color: rgb(51, 51, 61);">&#160;</font>given <font style="color: rgb(31, 31, 36);">i</font>n Section
        11.8 are subject to the Immunocore I<font style="color: rgb(51, 51, 61);">n</font>d<font style="color: rgb(51, 51, 61);">em</font>nifie<font style="color: rgb(31, 31, 36);">d Parties</font> promptly notifying GS<font style="color: rgb(31, 31, 36);">K
        </font>i<font style="color: rgb(51, 51, 61);">n </font>writing with details of the Claim and not ma<font style="color: rgb(31, 31, 36);">ki</font><font style="color: rgb(51, 51, 61);">n</font>g any admission <font style="color: rgb(51, 51, 61);">i</font><font style="color: rgb(31, 31, 36);">n </font>relati<font style="color: rgb(51, 51, 61);">on </font>to the <font style="color: rgb(31, 31, 36);">Cl</font>a<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(51, 51, 61);">m</font><font style="color: rgb(31, 31, 36);">.</font></div>
      <div>&#160;</div>
      <table id="z6f7c51986b82402b87b79b8c19d61ff4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">11.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore <font style="color: rgb(51, 51, 61);">s</font><font style="color: rgb(31, 31, 36);">ha</font>l<font style="color: rgb(31, 31, 36);">l </font><font style="color: rgb(51, 51, 61);">i</font>ndem<font style="color: rgb(31, 31, 36);">ni</font><font style="color: rgb(51, 51, 61);">f</font><font style="color: rgb(31, 31, 36);">y</font><font style="color: rgb(51, 51, 61);">, </font>defend and hold harmless GSK and its Affiliates, and its or their res<font style="color: rgb(51, 51, 61);">p</font><font style="color: rgb(31, 31, 36);">ec</font><font style="color: rgb(51, 51, 61);">t</font>ive dir<font style="color: rgb(51, 51, 61);">e</font>ct<font style="color: rgb(51, 51, 61);">o</font>rs,
                officers<font style="color: rgb(31, 31, 36);">, </font>employees and representatives (the <font style="font-weight: bold;">&#8220;GSK Indemn</font><font style="font-weight: bold; color: rgb(31, 31, 36);">ifi</font><font style="font-weight: bold;">ed Parties</font><font style="font-weight: bold; color: rgb(31, 31, 36);">&#8221;)</font><font style="font-weight: bold;">, </font>from and against any and all Losses arising out of or resultin<font style="color: rgb(31, 31, 36);">g </font>fr<font style="color: rgb(51, 51, 61);">o</font><font style="color: rgb(31, 31, 36);">m </font>any <font style="color: rgb(70, 70, 84);">Claims</font> ba<font style="color: rgb(31, 31, 36);">s</font>ed upon:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4afbe843b8574e149260f9400a5717ca" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div><font style="color: #33333D;">A</font>ny neg<font style="color: rgb(31, 31, 36);">li</font>g<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(51, 51, 61);">n</font>ce or wilful misconduct by any Immunocore<font style="color: rgb(31, 31, 36);">&#160;</font>Indemnified Party, in conne<font style="color: rgb(31, 31, 36);">ct io</font><font style="color: rgb(51, 51, 61);">n </font>with Immunocore<font style="color: rgb(31, 31, 36);">&#8217;</font>s
                performance of its obligations or exercise of its rights <font style="color: rgb(31, 31, 36);">und</font>er this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6300cee5ca92494997d3a9e1eef4b1d9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Any non-compliance by any Immunocore Indemnified Party or Immunocore&#8217;s sublicensees or subcontractors with any Applicable Laws;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z729f7a66709e4d9a8381c1c1d0e83403" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any death or injury or product liability claim resulting from sale or supply of any Terminated Product by Immunocore or its Affiliates or their sublicensees;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">42</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="za7fb27ad58984ca1b2bae30f2c23b9ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any death or injury or product liability claim resulting from the conduct of Clinical Trials under any Research Plan by any Immunocore Indemnified Party, and the storage, handling, use, manufacture, marketing, commercialization,
                importation or sale of any Licensed Products by Immunocore<font style="color: rgb(8, 8, 8);">, its Affiliates, or their subcontractors;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4ebefd90f2b447f5a2defef24d539922" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>any breach by Immunocore of the Assignment Agreement, Deed and Clarification Agreement and any claim to I<font style="color: rgb(49, 49, 61);">m</font>munocore Background or Foreground arising under this Agreement <font style="color: rgb(31, 31, 36);">by Ad</font>apt immune <font style="color: rgb(31, 31, 36);">tha</font>t conflict or interfere with the rights and licenses gr<font style="color: rgb(49, 49, 61);">a</font>n<font style="color: rgb(49, 49, 61);">te</font>d
                to GSK by Immunocore under this Agreement; and/or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z29f7f79fa23b4a4db802e445d6272655" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">11.9.6</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Immunocore proceeding with an Act <font style="color: rgb(68, 70, 82);">ion </font><font style="color: rgb(49, 49, 61);">in </font>ac<font style="color: rgb(49, 49, 61);">co</font>rdance with<font style="font-weight: bold;">&#160;</font><font style="color: rgb(31, 31, 36);">Section</font>&#160;<font style="color: rgb(49, 49, 61);">7</font>.4.4 after GSK informs Immunocore that it is n<font style="color: rgb(31, 31, 36);">ot </font>pro<font style="color: rgb(49, 49, 61);">c</font>e<font style="color: rgb(49, 49, 61);">ed</font>ing wi<font style="color: rgb(49, 49, 61);">t</font>h such <font style="color: rgb(49, 49, 61);">Actio</font>n on the advice of competent counsel, and, if <font style="color: rgb(49, 49, 61);">I</font>mm<font style="color: rgb(49, 49, 61);">unoco</font>re r<font style="color: rgb(49, 49, 61);">eq</font>uir<font style="color: rgb(49, 49, 61);">e</font>s G<font style="color: rgb(49, 49, 61);">SK </font>to <font style="color: rgb(31, 31, 36);">i</font>nitiate






                an Action, such actions taken by <font style="color: rgb(49, 49, 61);">G</font>SK as di<font style="color: rgb(49, 49, 61);">rected </font>by <font style="color: rgb(49, 49, 61);">I</font>m<font style="color: rgb(49, 49, 61);">mu</font>nocore<font style="color: rgb(31, 31, 36);">;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="font-style: italic;">except, </font>to the extent such Claim aro<font style="color: rgb(49, 49, 61);">se </font>ou<font style="color: rgb(49, 49, 61);">t </font><font style="color: rgb(31, 31, 36);">of </font>or r<font style="color: rgb(49, 49, 61);">esul</font>ted fr<font style="color: rgb(31, 31, 36);">o</font>m <font style="color: rgb(49, 49, 61);">a</font>ny negligence, misconduct or material breach of th<font style="color: rgb(49, 49, 61);">is </font>Agree<font style="color: rgb(31, 31, 36);">men</font>t by <font style="color: rgb(49, 49, 61);">a</font>ny GSK Ind<font style="color: rgb(31, 31, 36);">emn</font>ified Party. The indemnities given in
        Section 11.9 <font style="color: rgb(31, 31, 36);">are </font>subj<font style="color: rgb(31, 31, 36);">ec</font>t <font style="color: rgb(49, 49, 61);">to </font>th<font style="color: rgb(31, 31, 36);">e </font>G<font style="color: rgb(31, 31, 36);">SK </font>Inde<font style="color: rgb(31, 31, 36);">m</font>ni<font style="color: rgb(49, 49, 61);">fie</font>d Parties promptly notifying Immunocore in writin<font style="color: rgb(31, 31, 36);">g with</font> d<font style="color: rgb(31, 31, 36);">et</font>ails <font style="color: rgb(31, 31, 36);">of </font>the <font style="color: rgb(31, 31, 36);">cla</font>im and n<font style="color: rgb(49, 49, 61);">ot </font>making any admission in relation to the claim.</div>
      <div>&#160;</div>
      <table id="zec2527c8b5cf4e2d91b52a285954c80a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Limitation of Liability</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9d9d7c42b8f5439ea99fe58bfab39254" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to Section 1<font style="color: rgb(49, 49, 61);">2</font>.3, neither Party sh<font style="color: rgb(49, 49, 61);">a</font>ll <font style="color: rgb(31, 31, 36);">b</font>e liable un<font style="color: rgb(49, 49, 61);">d</font>er






                th<font style="color: rgb(49, 49, 61);">is A</font>gr<font style="color: rgb(31, 31, 36);">e</font>ement whether in contract, tort (in<font style="color: rgb(31, 31, 36);">clud</font>ing ne<font style="color: rgb(49, 49, 61);">gl</font>ig<font style="color: rgb(31, 31, 36);">e</font>nce) <font style="color: rgb(49, 49, 61);">or </font>otherwi<font style="color: rgb(31, 31, 36);">se </font>in respect of any indirect or consequential lo<font style="color: rgb(31, 31, 36);">s</font>s
                or dama<font style="color: rgb(31, 31, 36);">ge </font><font style="color: rgb(49, 49, 61);">in</font>cludin<font style="color: rgb(31, 31, 36);">g </font><font style="color: rgb(49, 49, 61);">a</font>ny los<font style="color: rgb(31, 31, 36);">s of </font>prof it<font style="color: rgb(49, 49, 61);">, </font><font style="color: rgb(31, 31, 36);">los</font>s <font style="color: rgb(31, 31, 36);">o</font>f business or loss of goodwill.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zfb7346adf83a43f6b456d3463abc8f14" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to <font style="color: rgb(49, 49, 61);">Section</font> 12.<font style="color: rgb(49, 49, 61);">3</font>, <font style="color: rgb(31, 31, 36);">Immunocore</font>&#8217;s t<font style="color: rgb(49, 49, 61);">o</font>t<font style="color: rgb(31, 31, 36);">al a</font>ggreg<font style="color: rgb(49, 49, 61);">at</font>e liability for any and all claims under thi<font style="color: rgb(49, 49, 61);">s Ag</font>r<font style="color: rgb(49, 49, 61);">e</font>eme<font style="color: rgb(31, 31, 36);">nt or </font>aris<font style="color: rgb(31, 31, 36);">ing i</font>n rel<font style="color: rgb(49, 49, 61);">atio</font>n <font style="color: rgb(49, 49, 61);">to </font>this <font style="color: rgb(49, 49, 61);">Ag</font>r<font style="color: rgb(31, 31, 36);">e</font>ement whether to GSK or its Affiliates<font style="color: rgb(49, 49, 61);">&#160;</font>o<font style="color: rgb(31, 31, 36);">r t</font>heir s<font style="color: rgb(31, 31, 36);">ublic</font>ense<font style="color: rgb(31, 31, 36);">es </font>shall in n<font style="color: rgb(49, 49, 61);">o </font>e<font style="color: rgb(49, 49, 61);">v</font>ent ex<font style="color: rgb(31, 31, 36);">ceed
                  [***]</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zabda8e5c95b94bc8ac129c36da58a639" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-variant: small-caps;">12.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-variant: small-caps;">no<font style="color: rgb(31, 31, 36);">t</font>hi<font style="color: rgb(49, 49, 61);">ng </font>in t<font style="color: rgb(31, 31, 36);">his </font>agre<font style="color: rgb(31, 31, 36);">eme</font>n<font style="color: rgb(31, 31, 36);">t </font>limit<font style="color: rgb(49, 49, 61);">s </font>or exclude<font style="color: rgb(49, 49, 61);">s </font>any party&#8217;s liability for (a) death or<font style="color: rgb(31, 31, 36);"> pers</font><font style="color: rgb(68, 70, 82);">o</font>nal in<font style="color: rgb(49, 49, 61);">jury </font>cau<font style="color: rgb(31, 31, 36);">se</font>d <font style="color: rgb(49, 49, 61);">b</font>y its ne<font style="color: rgb(49, 49, 61);">glig</font>ence; <font style="color: rgb(31, 31, 36);">(b) </font>f<font style="color: rgb(49, 49, 61);">ra</font>ud; (c) any indemnity under se<font style="color: rgb(31, 31, 36);">c</font>tions 11.<font style="color: rgb(31, 31, 36);">8.</font>3, 11.8<font style="color: rgb(31, 31, 36);">.4, </font>11.9.3 <font style="color: rgb(49, 49, 61);">a</font>nd 11.<font style="color: rgb(49, 49, 61);">9.4; </font><font style="color: rgb(31, 31, 36);">(</font>d) gr<font style="color: rgb(31, 31, 36);">oss </font>negligence or wilful mi<font style="color: rgb(31, 31, 36);">s</font>conduct<font style="color: rgb(31, 31, 36);">; </font>or (e) any <font style="color: rgb(8, 8, 8);">sor</font><font style="color: rgb(31, 31, 36);">t </font><font style="color: rgb(8, 8, 8);">of liability th</font><font style="color: rgb(49, 49, 61);">a</font><font style="color: rgb(8, 8, 8);">t, by law</font><font style="color: rgb(31, 31, 36);">, </font><font style="color: rgb(8, 8, 8);">cannot be lim</font><font style="color: rgb(49, 49, 61);">it e</font><font style="color: rgb(8, 8, 8);">d or excluded.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zb19f8801675840979e99054d4dc0125e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore <font style="color: rgb(49, 49, 61);">shal</font>l maint<font style="color: rgb(31, 31, 36);">a</font>i<font style="color: rgb(31, 31, 36);">n, </font>at its cost<font style="color: rgb(49, 49, 61);">, </font>insurance
                against liability and other risks associated with its <font style="color: rgb(49, 49, 61);">activ</font>i<font style="color: rgb(31, 31, 36);">ti</font>es and obligations under this Agreement, including the conduct <font style="color: rgb(31, 31, 36);">of </font><font style="color: rgb(68, 70, 82);">C</font>linical <font style="color: rgb(31, 31, 36);">T</font>ri<font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(68, 70, 82);">l</font>s and its
                indemnification obligations hereunder, in such amount<font style="color: rgb(49, 49, 61);">s</font>, <font style="color: rgb(31, 31, 36);">subject</font> to such deductibles and on such t<font style="color: rgb(31, 31, 36);">e</font>rms as
                <font style="color: rgb(31, 31, 36);">a</font>re <font style="color: rgb(31, 31, 36);">c</font>ustomary for a comp<font style="color: rgb(49, 49, 61);">any </font><font style="color: rgb(31, 31, 36);">s</font>uch a<font style="color: rgb(31, 31, 36);">s Immunocore</font> for the activities to be conducted by it under this Agre<font style="color: rgb(49, 49, 61);">e</font>m<font style="color: rgb(31, 31, 36);">e</font>nt. Immunocore shall furnish to GSK evidence of
                such insurance upon re<font style="color: rgb(49, 49, 61);">que</font>st.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za68d689c633a4677bd41c24d7c3c6526" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; color: #31313D;">Ter</font><font style="font-weight: bold;">m and Termination</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z47d027288f8d435f9d440e0ac498f2f3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1F1F24;">T</font>his Agreement will come into force on the Effective Date and will remain in force until the last financial obligation under this Agreement has been satisfied, unless earlier terminated in accordance
                with this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z3a8e171211274be5b58396e6cf80dac5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>GSK Right to T</u><font style="color: #1F1F24;"><u>e</u></font><u>rmin</u><font style="color: #1F1F24;"><u>a</u></font><u>t</u>e. GSK may terminate<font style="color: rgb(31, 31, 36);">&#160;</font>(a) this Agr<font style="color: rgb(31, 31, 36);">ee</font>ment; or (b) any<font style="color: rgb(31, 31, 36);"> Collaboration</font> Program or (<font style="color: rgb(31, 31, 36);">c</font>) any lic<font style="color: rgb(31, 31, 36);">e</font>n<font style="color: rgb(31, 31, 36);">c</font>e gr<font style="color: rgb(31, 31, 36);">a</font>nt<font style="color: rgb(31, 31, 36);">e</font>d following e<font style="color: rgb(31, 31, 36);">xe</font>r<font style="color: rgb(31, 31, 36);">c</font>i<font style="color: rgb(31, 31, 36);">s</font>e <font style="color: rgb(31, 31, 36);">o</font>f <font style="color: rgb(31, 31, 36);">a</font>n Initial Program <font style="color: rgb(7, 7, 7);">Option or Collaboration Program Option at any
                  time on provision of [***] written notice to Immunocore. The notice shall specify whether GSK is terminating the Agreement or any Collaboration Program or any licence. Where GSK terminates for convenience under this clause 13.2, GSK will
                  reimburse Immunocore for any Third Party expenses incurred or committed to by Immunocore as </font><font style="color: rgb(31, 31, 36);">a</font><font style="color: rgb(7, 7, 7);">t time of receipt of notice of</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">43</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #070707;">termination and where such Third Party expenses c</font><font style="color: #1F1F24;">an</font><font style="color: #070707;">no</font><font style="color: #1F1F24;">t </font><font style="color: #343641;">r</font><font style="color: #1F1F24;">e</font><font style="color: #070707;">asonably be </font><font style="color: #343641;">c</font><font style="color: #1F1F24;">a</font><font style="color: #070707;">ncelled by
          Immunocore using Commercially Reasonable Efforts </font><font style="color: #1F1F24;">(incl</font><font style="color: #070707;">uding costs </font><font style="color: #1F1F24;">o</font><font style="color: #343641;">f </font><font style="color: #1F1F24;">a</font><font style="color: #070707;">ny Clinical Trial</font><font style="color: #1F1F24;">, </font><font style="color: #070707;">sub-contractor costs, CRO costs, CMO costs a</font><font style="color: #1F1F24;">nd </font><font style="color: #070707;">m</font><font style="color: #343641;">a</font><font style="color: #070707;">nufacturing co</font><font style="color: #1F1F24;">sts)</font><font style="color: #343641;">.</font></div>
      <div>&#160;</div>
      <table id="zce7e048185534f9f9c66d7cc183b72d0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Termination for Lack of Feasibility.</u> Where eithe<font style="color: rgb(31, 31, 36);">r the</font>&#160;<font style="color: rgb(31, 31, 36);">J</font>SC or GSK d<font style="color: rgb(52, 54, 65);">e</font><font style="color: rgb(31, 31, 36);">c</font>i<font style="color: rgb(31, 31, 36);">d</font>es to terminate a Collaboration Program in accordance with Section<font style="color: rgb(31, 31, 36);">s </font>3<font style="color: rgb(31, 31, 36);">.5</font>.1, 3.5.2<font style="color: rgb(31, 31, 36);">, 3</font>.6.1 or <font style="color: rgb(52, 54, 65);">3</font>.<font style="color: rgb(31, 31, 36);">6.</font>2, then GSK shall serve [***] written notice<font style="color: rgb(31, 31, 36);">&#160;</font>t<font style="color: rgb(31, 31, 36);">o </font>Imm<font style="color: rgb(31, 31, 36);">un</font><font style="color: rgb(52, 54, 65);">o</font><font style="color: rgb(31, 31, 36);">c</font>ore <font style="color: rgb(31, 31, 36);">t</font>e<font style="color: rgb(52, 54, 65);">r</font><font style="color: rgb(31, 31, 36);">m</font>inatin<font style="color: rgb(31, 31, 36);">g t</font><font style="color: rgb(52, 54, 65);">he </font>relevant Collaboration Program. Where a
                Collaboration<font style="color: rgb(31, 31, 36);">&#160;</font>Program<font style="color: rgb(31, 31, 36);">&#160;</font>is <font style="color: rgb(31, 31, 36);">te</font><font style="color: rgb(52, 54, 65);">r</font>mi<font style="color: rgb(52, 54, 65);">n</font>ated <font style="color: rgb(31, 31, 36);">u</font>n<font style="color: rgb(31, 31, 36);">d</font><font style="color: rgb(52, 54, 65);">e</font>r Section 3.5.2(ii) or 3.6.2(ii), in addition to the <font style="color: rgb(52, 54, 65);">p</font>ro<font style="color: rgb(31, 31, 36);">v</font><font style="color: rgb(52, 54, 65);">i</font><font style="color: rgb(31, 31, 36);">s</font>ions <font style="color: rgb(31, 31, 36);">of </font><font style="color: rgb(52, 54, 65);">Se</font>cti<font style="color: rgb(31, 31, 36);">o</font><font style="color: rgb(52, 54, 65);">n </font><font style="color: rgb(31, 31, 36);">1</font><font style="color: rgb(52, 54, 65);">3.</font><font style="color: rgb(31, 31, 36);">6 </font>belo<font style="color: rgb(31, 31, 36);">w, t</font>he provisions of Section 5.3.5 shall apply.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z943d31c1de3c410c9140c535a889bdd0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><u>Breach</u>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7619137e59b544859af82e2d6ec368ce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Either Party may (with<font style="color: rgb(31, 31, 36);">out </font>lim<font style="color: rgb(31, 31, 36);">it</font>ing a<font style="color: rgb(31, 31, 36);">n</font>y oth<font style="color: rgb(52, 54, 65);">e</font><font style="color: rgb(31, 31, 36);">r </font><font style="color: rgb(52, 54, 65);">r</font>eme<font style="color: rgb(31, 31, 36);">dy i</font><font style="color: rgb(52, 54, 65);">t </font>may have) at any time terminate this Agr<font style="color: rgb(31, 31, 36);">e</font>em<font style="color: rgb(31, 31, 36);">en</font>t in its<font style="color: rgb(31, 31, 36);">&#160;</font><font style="color: rgb(52, 54, 65);">e</font>nt<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 54, 65);">r</font><font style="color: rgb(31, 31, 36);">ety </font>or on <font style="color: rgb(52, 54, 65);">a </font><font style="color: rgb(31, 31, 36);">Colla</font>bor<font style="color: rgb(31, 31, 36);">atio</font>n
                Program-by-Collaboration Program<font style="color: rgb(52, 54, 65);">&#160;</font>or l<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 54, 65);">ce</font>nse-b <font style="color: rgb(31, 31, 36);">y</font><font style="color: rgb(52, 54, 65);">-</font>li<font style="color: rgb(31, 31, 36);">cens</font>e basis <font style="color: rgb(52, 54, 65);">w</font>ith im<font style="color: rgb(31, 31, 36);">med</font><font style="color: rgb(52, 54, 65);">i</font>ate






                effect by giving written <font style="color: rgb(31, 31, 36);">no</font>ti<font style="color: rgb(31, 31, 36);">c</font><font style="color: rgb(52, 54, 65);">e </font>to t<font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(52, 54, 65);">e o</font>ther <font style="color: rgb(52, 54, 65);">i</font><font style="color: rgb(31, 31, 36);">f the </font>ot<font style="color: rgb(31, 31, 36);">her </font>(or in <font style="color: rgb(31, 31, 36);">th</font>e
                ca<font style="color: rgb(31, 31, 36);">s</font>e of GSK<font style="color: rgb(31, 31, 36);">, </font>its Affiliates) is in m<font style="color: rgb(31, 31, 36);">at</font>erial <font style="color: rgb(31, 31, 36);">bre</font>ach <font style="color: rgb(31, 31, 36);">o</font>f any mat<font style="color: rgb(52, 54, 65);">e</font>ri<font style="color: rgb(31, 31, 36);">a</font>l provisi<font style="color: rgb(31, 31, 36);">on </font><font style="color: rgb(52, 54, 65);">o</font>f
                this Agreement and the bre<font style="color: rgb(31, 31, 36);">a</font>ch has no<font style="color: rgb(52, 54, 65);">t </font>b<font style="color: rgb(52, 54, 65);">e</font>en re<font style="color: rgb(31, 31, 36);">m</font>e<font style="color: rgb(52, 54, 65);">d</font>ied w<font style="color: rgb(31, 31, 36);">i</font>thin [***] after receipt of written n<font style="color: rgb(31, 31, 36);">oti</font><font style="color: rgb(52, 54, 65);">ce </font>specif<font style="color: rgb(52, 54, 65);">y</font><font style="color: rgb(31, 31, 36);">i</font>n<font style="color: rgb(31, 31, 36);">g </font>the <font style="color: rgb(52, 54, 65);">b</font><font style="color: rgb(31, 31, 36);">r</font><font style="color: rgb(52, 54, 65);">e</font><font style="color: rgb(31, 31, 36);">a</font>ch and <font style="color: rgb(31, 31, 36);">re</font><font style="color: rgb(52, 54, 65);">q</font><font style="color: rgb(31, 31, 36);">u</font>iring
                its re<font style="color: rgb(52, 54, 65);">m</font>edy (if such breach is capa<font style="color: rgb(31, 31, 36);">b</font>le of reme<font style="color: rgb(31, 31, 36);">dy</font><font style="color: rgb(52, 54, 65);">). </font>If <font style="color: rgb(31, 31, 36);">suc</font><font style="color: rgb(52, 54, 65);">h </font><font style="color: rgb(31, 31, 36);">b</font>reach <font style="color: rgb(52, 54, 65);">i</font><font style="color: rgb(31, 31, 36);">s no</font>t
                su<font style="color: rgb(31, 31, 36);">s</font><font style="color: rgb(52, 54, 65);">c</font><font style="color: rgb(31, 31, 36);">ept</font>ib<font style="color: rgb(31, 31, 36);">l</font>e to cure within such [***] p<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(52, 54, 65);">r</font>io<font style="color: rgb(52, 54, 65);">d</font>, th<font style="color: rgb(31, 31, 36);">e b</font>r<font style="color: rgb(31, 31, 36);">e</font>achin<font style="color: rgb(31, 31, 36);">g </font>Party sh<font style="color: rgb(31, 31, 36);">all,</font><font style="color: rgb(75, 73, 87);">&#160;</font><font style="color: rgb(52, 54, 65);">w</font><font style="color: rgb(31, 31, 36);">ith</font>in






                such [***] peri<font style="color: rgb(31, 31, 36);">o</font>d, <font style="color: rgb(31, 31, 36);">p</font>rovid<font style="color: rgb(31, 31, 36);">ed </font>to th<font style="color: rgb(52, 54, 65);">e </font><font style="color: rgb(31, 31, 36);">no</font>n-bre<font style="color: rgb(52, 54, 65);">ac</font>h<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 54, 65);">n</font>g Party<font style="color: rgb(31, 31, 36);">&#160;</font>a written
                plan reasonably ac<font style="color: rgb(52, 54, 65);">c</font>eptable t<font style="color: rgb(31, 31, 36);">o </font>t<font style="color: rgb(31, 31, 36);">h</font><font style="color: rgb(52, 54, 65);">e </font>non<font style="color: rgb(52, 54, 65);">- </font><font style="color: rgb(31, 31, 36);">b</font>r<font style="color: rgb(52, 54, 65);">ea</font>ching Party, that <font style="color: rgb(31, 31, 36);">i</font>s reasonably cal<font style="color: rgb(31, 31, 36);">c</font>ulated to effect<font style="font-style: italic; color: rgb(31, 31, 36);">&#160;</font><font style="color: rgb(31, 31, 36);">a </font><font style="color: rgb(52, 54, 65);">c</font><font style="color: rgb(31, 31, 36);">u</font>r<font style="color: rgb(52, 54, 65);">e</font>. <font style="color: rgb(31, 31, 36);">Wh</font>e<font style="color: rgb(52, 54, 65);">r</font><font style="color: rgb(31, 31, 36);">e </font>the<font style="color: rgb(31, 31, 36);">&#160;</font>n<font style="color: rgb(31, 31, 36);">o</font>n-bre<font style="color: rgb(52, 54, 65);">ac</font><font style="color: rgb(31, 31, 36);">h</font>i<font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(52, 54, 65);">g </font>Party
                <font style="color: rgb(31, 31, 36);">h</font>a<font style="color: rgb(52, 54, 65);">s </font>accepted any <font style="color: rgb(31, 31, 36);">s</font>uch plan in<font style="color: rgb(31, 31, 36);"> ac</font><font style="color: rgb(52, 54, 65);">co</font>rdan<font style="color: rgb(31, 31, 36);">ce with</font> t<font style="color: rgb(52, 54, 65);">h</font><font style="color: rgb(31, 31, 36);">e </font>prece<font style="color: rgb(31, 31, 36);">d</font>i<font style="color: rgb(52, 54, 65);">n</font><font style="color: rgb(31, 31, 36);">g </font>senten<font style="color: rgb(52, 54, 65);">c</font><font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(75, 73, 87);">, </font>the
                non-breaching Party may<font style="color: rgb(52, 54, 65);"> ter</font><font style="color: rgb(31, 31, 36);">m</font>in<font style="color: rgb(31, 31, 36);">ate </font><font style="color: rgb(52, 54, 65);">this</font> Agreement
                immediately up <font style="color: rgb(52, 54, 65);">o</font>n written notice to the breaching<font style="color: rgb(31, 31, 36);"> P</font>arty <font style="color: rgb(31, 31, 36);">if </font>the<font style="color: rgb(31, 31, 36);">&#160;</font>br<font style="color: rgb(52, 54, 65);">ea</font>c<font style="color: rgb(31, 31, 36);">hi</font>ng Party s<font style="color: rgb(52, 54, 65);">u</font>bsequentl<font style="color: rgb(52, 54, 65);">y </font>fails to carry out such plan<font style="color: rgb(52, 54, 65);">. </font>The righ<font style="color: rgb(31, 31, 36);">t of </font>eithe<font style="color: rgb(52, 54, 65);">r </font><font style="color: rgb(31, 31, 36);">Par</font>ty t<font style="color: rgb(31, 31, 36);">o te</font>rm<font style="color: rgb(31, 31, 36);">i</font>nate th<font style="color: rgb(31, 31, 36);">is </font>Agreement as provided in this Section 13.4 <font style="color: rgb(52, 54, 65);">s</font><font style="color: rgb(31, 31, 36);">h</font>all <font style="color: rgb(31, 31, 36);">n</font><font style="color: rgb(52, 54, 65);">o</font>t <font style="color: rgb(52, 54, 65);">b</font>e aff<font style="color: rgb(31, 31, 36);">ec</font>t<font style="color: rgb(52, 54, 65);">ed i</font><font style="color: rgb(31, 31, 36);">n a</font>ny <font style="color: rgb(31, 31, 36);">w</font><font style="color: rgb(52, 54, 65);">a</font><font style="color: rgb(31, 31, 36);">y b</font>y <font style="color: rgb(31, 31, 36);">s</font>uch Party&#8217;s waiver or failur<font style="color: rgb(31, 31, 36);">e </font>to take actio<font style="color: rgb(31, 31, 36);">n </font>with r<font style="color: rgb(31, 31, 36);">es</font>pect t<font style="color: rgb(31, 31, 36);">o </font><font style="color: rgb(52, 54, 65);">a</font><font style="color: rgb(31, 31, 36);">n</font>y prev<font style="color: rgb(31, 31, 36);">io</font>u<font style="color: rgb(52, 54, 65);">s </font>default.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zd15f54e452374e39bfe22d1e4b9f0fe2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>M<font style="color: rgb(31, 31, 36);">a</font>ter<font style="color: rgb(31, 31, 36);">i</font><font style="color: rgb(52, 54, 65);">a</font><font style="color: rgb(31, 31, 36);">l br</font><font style="color: rgb(52, 54, 65);">e</font>a<font style="color: rgb(31, 31, 36);">c</font>h <font style="color: rgb(31, 31, 36);">sh</font><font style="color: rgb(52, 54, 65);">a</font><font style="color: rgb(31, 31, 36);">ll </font>include non-paym<font style="color: rgb(31, 31, 36);">e</font>nt






                of sums du<font style="color: rgb(31, 31, 36);">e </font>and owing from <font style="color: rgb(31, 31, 36);">G</font>SK. M<font style="color: rgb(31, 31, 36);">a</font>t<font style="color: rgb(31, 31, 36);">e</font><font style="color: rgb(52, 54, 65);">ri</font><font style="color: rgb(31, 31, 36);">a</font>l breach <font style="color: rgb(31, 31, 36);">s</font>h<font style="color: rgb(75, 73, 87);">a</font>ll include f<font style="color: rgb(31, 31, 36);">a</font>ilure






                of Immunocore to c<font style="color: rgb(31, 31, 36);">o</font>mmunicate to GSK [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z58ff2454effd4ae5a400b1d499c4f43d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>If the Parties reasonably and in good faith disagree as to whether there has been a material breach, the Party which seeks to dispute that there has been a mat<font style="color: rgb(31, 31, 36);">er</font>i<font style="color: rgb(31, 31, 36);">a</font>l br<font style="color: rgb(31, 31, 36);">eac</font>h may <font style="color: rgb(31, 31, 36);">c</font>ont<font style="color: rgb(31, 31, 36);">es</font>t the<font style="color: rgb(31, 31, 36);">&#160;</font>all<font style="color: rgb(31, 31, 36);">e</font>gation in <font style="color: rgb(31, 31, 36);">acc</font>ordan<font style="color: rgb(31, 31, 36);">c</font>e with Arti<font style="color: rgb(31, 31, 36);">c</font>l<font style="color: rgb(31, 31, 36);">e </font>1<font style="color: rgb(31, 31, 36);">5</font><font style="color: rgb(52, 54, 65);">.</font> From the date that any claim of material breach i<font style="color: rgb(31, 31, 36);">s </font>referred to the Executive
                Offi<font style="color: rgb(31, 31, 36);">c</font>ers in <font style="color: rgb(31, 31, 36);">a</font>ccord<font style="color: rgb(31, 31, 36);">a</font>nce with Section 15.1 until <font style="color: rgb(31, 31, 36);">s</font>uch time
                as the di<font style="color: rgb(31, 31, 36);">s</font>pute regarding such claimed material br<font style="color: rgb(31, 31, 36);">e</font>ach has b<font style="color: rgb(31, 31, 36);">e</font>come finally settled, th<font style="color: rgb(31, 31, 36);">e </font>time period during which the breaching Party must cure an alleged brea<font style="color: rgb(31, 31, 36);">c</font>h that is the subject matter of th<font style="color: rgb(31, 31, 36);">e </font>di<font style="color: rgb(31, 31, 36);">s</font>put<font style="color: rgb(31, 31, 36);">e </font>shall b<font style="color: rgb(31, 31, 36);">e </font>su<font style="color: rgb(31, 31, 36);">s</font>p<font style="color: rgb(31, 31, 36);">e</font>nd<font style="color: rgb(31, 31, 36);">e</font>d <font style="color: rgb(31, 31, 36);">a</font>nd no termination <font style="color: rgb(7, 7, 8);">under this Section 13.4 shall become effective.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1d63486110184313a24e37bcf226c23b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Either Party may (without limiting any other remedy it may have) at any time terminate this Agreement or a specified Collaboration Program (which may include exercising the applicable Initial Program Option or Collaboration Program) w<font style="color: rgb(47, 47, 59);">i</font>th immediate effect if the other Party becomes insolvent, or if an order is made or <font style="color: rgb(47, 47, 59);">a </font><font style="color: rgb(28, 28, 33);">r</font>esolution is <font style="color: rgb(47, 47, 59);">pa</font>ssed for its<font style="font-weight: bold;">&#160;</font>winding up (except voluntarily for the purpose <font style="color: rgb(47, 47, 59);">o</font><font style="color: rgb(28, 28, 33);">f </font>solvent






                am<font style="color: rgb(47, 47, 59);">alg</font><font style="color: rgb(28, 28, 33);">a</font>mation or reconstruction), or if an administrator, administra<font style="color: rgb(28, 28, 33);">ti</font>v<font style="color: rgb(47, 47, 59);">e </font>r<font style="color: rgb(47, 47, 59);">e</font><font style="color: rgb(28, 28, 33);">c</font>eiver or rece<font style="color: rgb(28, 28, 33);">ive</font><font style="color: rgb(47, 47, 59);">r </font>is appointed over
                the whole or any part of the other Party&#8217;s <font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 59);">sse</font>ts, or if the othe<font style="color: rgb(47, 47, 59);">r </font>Party makes any arrangement with its
                creditors or ceases to ca<font style="color: rgb(47, 47, 59);">rr</font>y o<font style="color: rgb(28, 28, 33);">n </font>business or <font style="color: rgb(28, 28, 33);">d</font>o<font style="color: rgb(47, 47, 59);">e</font>s or
                suffers any similar or analogous act existing under the law<font style="color: rgb(47, 47, 59);">s of a</font>ny <font style="color: rgb(47, 47, 59);">c</font>ountry.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1aefbf1fc8044974b5706fd460ba034d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where GSK terminates any Collaboration Program or <font style="color: rgb(28, 28, 33);">licen</font>ce <font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(47, 47, 59);">n </font>acc<font style="color: rgb(47, 47, 59);">o</font>rda<font style="color: rgb(47, 47, 59);">n</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 59);">e </font><font style="color: rgb(28, 28, 33);">w</font><font style="color: rgb(47, 47, 59);">i</font><font style="color: rgb(28, 28, 33);">t</font>h Section 13.2, a Collaboration Program is ter<font style="color: rgb(47, 47, 59);">m</font>in<font style="color: rgb(28, 28, 33);">a</font><font style="color: rgb(47, 47, 59);">t</font>ed






                i<font style="color: rgb(47, 47, 59);">n acc</font>ord<font style="color: rgb(47, 47, 59);">a</font><font style="color: rgb(28, 28, 33);">nc</font><font style="color: rgb(47, 47, 59);">e </font>with S<font style="color: rgb(47, 47, 59);">ec</font><font style="color: rgb(28, 28, 33);">t</font>ion 13.3, or Immunocore terminates a Collaboration<font style="color: rgb(47, 47, 59);">&#160;</font>Program<font style="color: rgb(47, 47, 59);">&#160;</font>or <font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 59);">ic</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 47, 59);">n</font>ce f<font style="color: rgb(47, 47, 59);">or </font>GSK breach in accordance with Section 13.4 (in ea<font style="color: rgb(47, 47, 59);">c</font><font style="color: rgb(28, 28, 33);">h c</font>a<font style="color: rgb(47, 47, 59);">se </font>a <font style="font-weight: bold;">&#8220;</font><font style="font-weight: bold; color: rgb(28, 28, 33);">T</font><font style="font-weight: bold; color: rgb(47, 47, 59);">er</font><font style="font-weight: bold; color: rgb(28, 28, 33);">m</font><font style="font-weight: bold;">inated </font><font style="font-weight: bold; color: rgb(47, 47, 59);">P</font><font style="font-weight: bold;">roject</font><font style="font-weight: bold; color: rgb(47, 47, 59);">&#8221;</font><font style="font-weight: bold;">)</font><font style="font-weight: bold; color: rgb(47, 47, 59);">:</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">44</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="zc93a2aa549274c1c9c0f7c776c074e2d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The restrictions unde<font style="color: rgb(28, 28, 33);">r Section</font>&#160;<font style="color: rgb(28, 28, 33);">6.4 </font><font style="color: rgb(47, 47, 59);">s</font>hall <font style="color: rgb(47, 47, 59);">c</font>e<font style="color: rgb(47, 47, 59);">as</font>e to a<font style="color: rgb(47, 47, 59);">p</font>p<font style="color: rgb(28, 28, 33);">l</font><font style="color: rgb(47, 47, 59);">y </font>in relation to any Target or Licensed Product re<font style="color: rgb(47, 47, 59);">s</font>ultin<font style="color: rgb(47, 47, 59);">g </font>from <font style="color: rgb(47, 47, 59);">a T</font>ermi<font style="color: rgb(28, 28, 33);">na</font><font style="color: rgb(47, 47, 59);">te</font><font style="color: rgb(28, 28, 33);">d </font><font style="color: rgb(47, 47, 59);">Project</font> from the date of termination of s<font style="color: rgb(28, 28, 33);">u</font><font style="color: rgb(47, 47, 59);">c</font>h Terminated<font style="color: rgb(47, 47, 59);">&#160;</font><font style="color: rgb(28, 28, 33);">Project;</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zb4034cc9bfe24f428f4848b5b550e43f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>All sums due a<font style="color: rgb(47, 47, 59);">n</font>d <font style="color: rgb(28, 28, 33);">ow</font>ing <font style="color: rgb(28, 28, 33);">p</font><font style="color: rgb(47, 47, 59);">rior </font>to t<font style="color: rgb(47, 47, 59);">h</font><font style="color: rgb(28, 28, 33);">e </font><font style="color: rgb(47, 47, 59);">dat</font>e <font style="color: rgb(47, 47, 59);">o</font><font style="color: rgb(28, 28, 33);">f t</font>erminati<font style="color: rgb(28, 28, 33);">o</font>n in <font style="color: rgb(28, 28, 33);">r</font>elation to the Terminated Proje<font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(47, 47, 59);">t </font>shall remain due and
                owing and Immunocore shall have no obligation to reimburse any payment previously made by GSK;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zd196a8bb64b140f0bb5fbd1a6eac7273" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The licences Granted to GSK as set forth in Section 6.7 shall terminate with respect to the particular Terminated Project from date of termination of the Terminated Project. This Agreement shall remain in full force and effect in
                relation to other Collaboration Programs and licences granted to GSK;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zfc2eabceed134e3bbc018ee696b52c02" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Save as provided in Sections 13.3 and 5.3.5 above, Immunocore shall be entitled to license the Immunocore Foreground arising from the performance of the Terminated Project to Third Parties; provided that such licenses are not in breach
                of any other licenses to GSK remaining in effect under this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z577c4e9135e64fae9bd1b1cfe369853d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>[***]<font style="color: rgb(47, 47, 59);"> a</font><font style="color: rgb(28, 28, 33);">s </font>ap<font style="color: rgb(28, 28, 33);">p</font>licable (<font style="color: rgb(28, 28, 33);">s</font>ave as provided in Section 13.7
                below), with the right to g<font style="color: rgb(28, 28, 33);">r</font>ant<font style="color: rgb(47, 47, 59);"> s</font><font style="color: rgb(28, 28, 33);">u</font>b<font style="color: rgb(47, 47, 59);">- </font>lice<font style="color: rgb(28, 28, 33);">n</font><font style="color: rgb(47, 47, 59);">c</font><font style="color: rgb(28, 28, 33);">e</font><font style="color: rgb(47, 47, 59);">s </font>(through multiple tiers) sol<font style="color: rgb(28, 28, 33);">e</font>ly for th<font style="color: rgb(28, 28, 33);">e </font>further d<font style="color: rgb(28, 28, 33);">e</font>v<font style="color: rgb(28, 28, 33);">e</font>lopment and comm<font style="color: rgb(47, 47, 59);">erc</font><font style="color: rgb(28, 28, 33);">i</font><font style="color: rgb(47, 47, 59);">a</font><font style="color: rgb(28, 28, 33);">l</font>ization of the Terminated Products; provided that the foregoing [***] termination in accord<font style="color: rgb(28, 28, 33);">a</font>nce with Section 13.3;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z484f21135c4e457eaeca78030efe7423" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.6</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Prose<font style="color: rgb(28, 28, 33);">c</font>ution of any patents or patent applications covering any Immunocore Foreground that arose out of the performance of the Terminated Project,<font style="color: rgb(28, 28, 33);">&#160;</font>and






                solely appli<font style="color: rgb(28, 28, 33);">c</font>abl<font style="color: rgb(28, 28, 33);">e </font>to <font style="color: rgb(28, 28, 33);">s</font>u<font style="color: rgb(28, 28, 33);">c</font>h Termin<font style="color: rgb(28, 28, 33);">a</font>t<font style="color: rgb(28, 28, 33);">e</font>d Proj<font style="color: rgb(28, 28, 33);">ec</font>t (i.<font style="color: rgb(28, 28, 33);">e</font>. <font style="color: rgb(28, 28, 33);">s</font>u<font style="color: rgb(47, 47, 59);">c</font>h Immun<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(47, 47, 59);">c</font>ore Foreground is not the subject of on-goin<font style="color: rgb(28, 28, 33);">g </font>licenses






                to GSK under the Agreement) sh<font style="color: rgb(28, 28, 33);">a</font>ll revert to Immunocore <font style="color: rgb(28, 28, 33);">a</font>nd GSK shall provide all re<font style="color: rgb(28, 28, 33);">as</font>onable assistance
                at its cost to transition the filing, maintenance and pros<font style="color: rgb(28, 28, 33);">e</font>cution of <font style="color: rgb(8, 8, 10);">such Immunocore Foreground to Immunocore as soon as possible </font>after the date of
                termination.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zdf692b744c8a47008cd437392adcc1af" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.7</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The Parties shall discuss and agree a plan to either transfer responsibility for Clinical Trials of Licensed Products arising from the Terminated Project <font style="font-weight: bold;">(&#8220;Terminated Products&#8221;) </font>in which any pat<font style="color: rgb(38, 38, 47);">ien</font>t has been <font style="color: rgb(38, 38, 47);">enrolled</font>, to Immunocore or Immunocore&#8217;s nominated T<font style="color: rgb(52, 52, 65);">h</font>i<font style="color: rgb(38, 38, 47);">rd
                </font>Party, or per<font style="color: rgb(38, 38, 47);">mit </font>GSK or its Affiliates to complete and/or wind dow<font style="color: rgb(38, 38, 47);">n </font><font style="color: rgb(52, 52, 65);">su</font>c<font style="color: rgb(38, 38, 47);">h </font>Clinical Trial<font style="color: rgb(38, 38, 47);">s</font><font style="color: rgb(68, 68, 80);">. </font><font style="color: rgb(38, 38, 47);">G</font>SK shall be responsible for such costs of com<font style="color: rgb(38, 38, 47);">plet</font>ion and/or wind<font style="color: rgb(52, 52, 65);">i</font>ng down unless otherwise agreed by Parties;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1d584752e9f44e4bab78e5c003d4d727" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.8</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>GSK shall deliver to Immunocore <font style="color: rgb(38, 38, 47);">[***]</font><font style="color: rgb(52, 52, 65);">&#160;</font>within [***] of the date of termination, or as soon a<font style="color: rgb(38, 38, 47);">s </font><font style="color: rgb(52, 52, 65);">r</font>e<font style="color: rgb(52, 52, 65);">a</font>son<font style="color: rgb(38, 38, 47);">abl</font>y possi<font style="color: rgb(38, 38, 47);">ble </font>t<font style="color: rgb(38, 38, 47);">h</font>ere<font style="color: rgb(38, 38, 47);">after</font>, <font style="color: rgb(52, 52, 65);">a</font>ll Results, data, materials, drug, sub<font style="color: rgb(38, 38, 47);">m</font>is<font style="color: rgb(52, 52, 65);">si</font>ons, r<font style="color: rgb(52, 52, 65);">egu</font>lat<font style="color: rgb(38, 38, 47);">or</font>y <font style="color: rgb(52, 52, 65);">documentation</font>, clinical materials, details of Third <font style="color: rgb(38, 38, 47);">Party s</font>ub-<font style="color: rgb(38, 38, 47);">c</font>o<font style="color: rgb(38, 38, 47);">ntr</font>acto<font style="color: rgb(38, 38, 47);">rs </font>(<font style="color: rgb(52, 52, 65);">i</font>nclud<font style="color: rgb(38, 38, 47);">ing </font>manufacturers),






                process details and all o<font style="color: rgb(52, 52, 65);">the</font>r mate<font style="color: rgb(38, 38, 47);">ria</font>ls in its p<font style="color: rgb(38, 38, 47);">o</font>ssession o<font style="color: rgb(52, 52, 65);">r </font>control







                solely related to the applicabl<font style="color: rgb(38, 38, 47);">e </font><font style="color: rgb(52, 52, 65);">Te</font>rminat<font style="color: rgb(38, 38, 47);">e</font>d Product <font style="color: rgb(52, 52, 65);">o</font>r
                Terminated Project, and in each case as reasonably necessary solely for the purpose of permitting Immunocore (or as relevant its nominated Third Party) to continue with the research and development, sale, supply and manufacture of the
                Terminated Products.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z30cef62914d9406ca4ffee36ca9ae41e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.9</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>For the avoidance of doubt, in connect ion with the termination of a Collaboration Program in accordance with Section 13.3, the foregoing provisions of this Section 13.6 that are not relevant to such termination shall not apply. By way
                of illustration only, if a Collaboration Program is terminated prior to exercise of a Collaboration Program Option, then GSK are unlikely to be prosecuting any Immunocore Foreground or conducting Clinical Trials of</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">45</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">Licensed Products at the time of termination, and therefore, Sections 13.6.6 and <font style="color: rgb(38, 38, 47);">13</font>.<font style="color: rgb(52, 52, 65);">6</font>.7 w<font style="color: rgb(38, 38, 47);">ou</font>ld be irr<font style="color: rgb(52, 52, 65);">ele</font>va<font style="color: rgb(52, 52, 65);">n</font>t.</div>
      <div>&#160;</div>
      <table id="z4f44bc5fec154dfea44309d476462bc9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***] c<font style="color: rgb(52, 52, 65);">o</font>m<font style="color: rgb(52, 52, 65);">m</font>erciali<font style="color: rgb(52, 52, 65);">ze</font>s <font style="color: rgb(38, 38, 47);">t</font>he T<font style="color: rgb(52, 52, 65);">e</font>r<font style="color: rgb(52, 52, 65);">mi</font>nated <font style="color: rgb(38, 38, 47);">Product</font>, Immunocore shall pay to GSK a royalty of [***] of the N<font style="color: rgb(52, 52, 65);">e</font>t Sale<font style="color: rgb(38, 38, 47);">s </font><font style="color: rgb(52, 52, 65);">o</font>f such T<font style="color: rgb(52, 52, 65);">e</font>r<font style="color: rgb(52, 52, 65);">mi</font>nated Product. The provisions of Sections 9.4,
                9.7, 9.8, 9.9<font style="color: rgb(68, 68, 80);">, </font><font style="color: rgb(52, 52, 65);">9.</font>10, 9.11 and 9.12 sha<font style="color: rgb(52, 52, 65);">ll </font>apply, <font style="font-style: italic;">mutatis mutandis, </font>to






                Immunocore <font style="color: rgb(38, 38, 47);">&#8216;</font>s obligations to <font style="color: rgb(52, 52, 65);">pa</font>y <font style="color: rgb(38, 38, 47);">ro</font>yalti<font style="color: rgb(38, 38, 47);">es </font>hereunder,
                with all references to &#8220;GSK&#8221; replaced by &#8220;lmmunocore,<font style="color: rgb(68, 68, 80);">&#8220; </font><font style="color: rgb(38, 38, 47);">a</font>ll referen<font style="color: rgb(52, 52, 65);">c</font>e<font style="color: rgb(38, 38, 47);">s </font>to &#8220;lmmunocore&#8221; replaced by &#8220;GSK&#8221; and all references to &#8220;Licensed <font style="color: rgb(38, 38, 47);">Product</font>&#8221; re<font style="color: rgb(38, 38, 47);">plac</font><font style="color: rgb(68, 68, 80);">e</font>d
                with &#8220;Terminated Product.&#8221;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z367816570dd049a0901aa198c9edfb2a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If (a) G<font style="color: rgb(52, 52, 65);">SK </font>or any of its Affiliates directly or indirectly commences any interference or opposi<font style="color: rgb(38, 38, 47);">tion </font>procee<font style="color: rgb(52, 52, 65);">d</font>in<font style="color: rgb(38, 38, 47);">g </font>or challenges the validity or enforceability of, or opposes any exten<font style="color: rgb(68, 68, 80);">s</font>ion of or the<font style="color: rgb(38, 38, 47);"> gr</font>ant of any
                supplementary protection certificate with respect to any pa<font style="color: rgb(38, 38, 47);">ten</font>t or pat<font style="color: rgb(52, 52, 65);">e</font>nt application within the Immunocore Background, Immunocore F<font style="color: rgb(52, 52, 65);">ore</font>ground or Platform Rights licensed to it under Section 6.7 (each such action a &#8220;<font style="font-weight: bold;">GSK</font><font style="font-weight: bold; color: rgb(52, 52, 65);"> Pat</font><font style="font-weight: bold;">ent Challenge</font>&#8221;);<font style="font-weight: bold;">&#160;</font>or (b) GSK uses the Immunocore Background or Immunocore<font style="color: rgb(68, 68, 80);"> F</font>or<font style="color: rgb(38, 38, 47);">e</font>ground






                other than as licensed under Section 6.7.1, then Immunocore shall have the right to terminate the license to such patent granted to GSK under Section 6.7.1 to which the Patent Challenge relates or that GSK uses outside the scope of its
                licenses hereunder (and all Compounds, Targets and Licensed Products covered by such patent), upon [***] written notice to GSK; provided, that Immunocore&#8217;s right to terminate this Agreement under this Section 13.8 shall not apply to any
                Affiliate of GSK <font style="color: rgb(8, 8, 8);">that first becomes an Affiliate of GSK after the Effective Date of this Agreement in connection with a merger or acquisition event, where such Affiliate of GSK was undertaking activities
                  in connection with a Patent Challenge prior to such merger or acquisition event and GSK ceases involvement in such Patent Challenge within [***] after such merger or acquisition event.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z7ed6f9f6e56b49f1b52805ce25eb1142" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If (a) Immunocore or any of its Affiliates or their s<font style="color: rgb(38, 38, 47);">ubl</font>i<font style="color: rgb(38, 38, 47);">c</font>ensees (to the<font style="color: rgb(38, 38, 47);">&#160;</font>extent such sublicensees are
                sublicensed under the relevant <font style="color: rgb(38, 38, 47);">G</font>S<font style="color: rgb(38, 38, 47);">K B</font>ackground or G<font style="color: rgb(38, 38, 47);">SK </font>Foreground which is subject to the Immunocore
                Patent Chall<font style="color: rgb(38, 38, 47);">eng</font>e) directly or indir<font style="color: rgb(38, 38, 47);">e</font>ct<font style="color: rgb(54, 54, 66);">l</font>y commences any interference or opposition proceeding or ch<font style="color: rgb(38, 38, 47);">a</font>llenges the validity or enforceability of, or opposes any extension of or the grant of <font style="color: rgb(54, 54, 66);">any </font><font style="color: rgb(38, 38, 47);">s</font>up<font style="color: rgb(38, 38, 47);">p</font>lementary p<font style="color: rgb(38, 38, 47);">ro</font>tectio<font style="color: rgb(38, 38, 47);">n </font><font style="color: rgb(54, 54, 66);">c</font>ertificate with respect to any patent or
                patent appl<font style="color: rgb(54, 54, 66);">ic</font>a<font style="color: rgb(38, 38, 47);">t</font>io<font style="color: rgb(38, 38, 47);">n </font>wit<font style="color: rgb(38, 38, 47);">h</font>in <font style="color: rgb(38, 38, 47);">t</font>he GS<font style="color: rgb(38, 38, 47);">K </font>Backg<font style="color: rgb(54, 54, 66);">round </font>or GSK Foreground licensed to it under Section<font style="color: rgb(38, 38, 47);">s </font>6<font style="color: rgb(54, 54, 66);">.</font>12 <font style="color: rgb(38, 38, 47);">an</font>d 6.13 (e<font style="color: rgb(54, 54, 66);">a</font>ch <font style="color: rgb(38, 38, 47);">s</font>u<font style="color: rgb(54, 54, 66);">c</font>h action
                an <font style="font-weight: bold;">&#8220;Immunocore Patent Challenge&#8221;); </font>o<font style="color: rgb(54, 54, 66);">r </font>(b<font style="color: rgb(54, 54, 66);">) </font>Imm<font style="color: rgb(38, 38, 47);">u</font>n<font style="color: rgb(54, 54, 66);">oco</font>re <font style="color: rgb(54, 54, 66);">u</font>s<font style="color: rgb(38, 38, 47);">es the</font> GSK <font style="color: rgb(54, 54, 66);">B</font>ackground or GSK Foreground other than as
                licens<font style="color: rgb(54, 54, 66);">e</font>d <font style="color: rgb(54, 54, 66);">un</font>der <font style="color: rgb(38, 38, 47);">Se</font>c<font style="color: rgb(54, 54, 66);">tio</font>ns <font style="color: rgb(38, 38, 47);">6.</font>1<font style="color: rgb(38, 38, 47);">2 </font>or 6<font style="color: rgb(54, 54, 66);">.1</font>3, then GSK shall have the right to terminate the lic<font style="color: rgb(38, 38, 47);">e</font>nse <font style="color: rgb(54, 54, 66);">to </font>suc<font style="color: rgb(38, 38, 47);">h </font>patent gr <font style="color: rgb(38, 38, 47);">an</font>ted to Immunocore under Sections 6.12 or 6.13 to which t<font style="color: rgb(38, 38, 47);">he </font>Immunocore






                Pat<font style="color: rgb(38, 38, 47);">e</font>nt Cha<font style="color: rgb(54, 54, 66);">l</font>le<font style="color: rgb(38, 38, 47);">ng</font>e relates or that Immunocore uses outside the <font style="color: rgb(38, 38, 47);">s</font>co<font style="color: rgb(54, 54, 66);">pe </font>of it<font style="color: rgb(54, 54, 66);">s </font>l<font style="color: rgb(38, 38, 47);">ic</font>ense<font style="color: rgb(54, 54, 66);">s </font>h<font style="color: rgb(38, 38, 47);">e</font>reunde<font style="color: rgb(54, 54, 66);">r </font>(<font style="color: rgb(38, 38, 47);">a</font>nd all Compounds, Targets and products comprisin<font style="color: rgb(38, 38, 47);">g Compound</font>s Cover <font style="color: rgb(38, 38, 47);">ed






                  b</font>y suc<font style="color: rgb(38, 38, 47);">h </font><font style="color: rgb(54, 54, 66);">pa</font>t<font style="color: rgb(38, 38, 47);">e</font>nt),<font style="color: rgb(38, 38, 47);">&#160;</font>upon [***]&#8217; written notice to
                Immu<font style="color: rgb(54, 54, 66);">n</font>oco<font style="color: rgb(54, 54, 66);">r</font>e; prov<font style="color: rgb(38, 38, 47);">ide</font>d<font style="color: rgb(54, 54, 66);">, </font><font style="color: rgb(38, 38, 47);">tha</font>t
                GSK&#8217;s <font style="color: rgb(54, 54, 66);">rig</font>ht <font style="color: rgb(38, 38, 47);">to </font>term<font style="color: rgb(54, 54, 66);">i</font>nate the licence under this Section 13.9 s<font style="color: rgb(38, 38, 47);">ha</font>l<font style="color: rgb(38, 38, 47);">l (i) </font>not <font style="color: rgb(38, 38, 47);">a</font>pply <font style="color: rgb(54, 54, 66);">to </font><font style="color: rgb(38, 38, 47);">an</font>y Affiliate <font style="color: rgb(54, 54, 66);">o</font>f Imm<font style="color: rgb(54, 54, 66);">u</font>n<font style="color: rgb(54, 54, 66);">oc</font>ore that first becomes an Affiliate of <font style="color: rgb(54, 54, 66);">I</font>mm<font style="color: rgb(38, 38, 47);">u</font>noc<font style="color: rgb(38, 38, 47);">ore </font><font style="color: rgb(54, 54, 66);">a</font>fter t<font style="color: rgb(38, 38, 47);">h</font>e Effect<font style="color: rgb(38, 38, 47);">i</font>ve Date
                of this Agreement in connection with a merger o<font style="color: rgb(38, 38, 47);">r </font>acquisi<font style="color: rgb(38, 38, 47);">tio</font>n event, where <font style="color: rgb(38, 38, 47);">s</font>u<font style="color: rgb(54, 54, 66);">c</font>h Affiliate <font style="color: rgb(38, 38, 47);">of </font>Immunocore was undertaking activities <font style="color: rgb(38, 38, 47);">i</font>n connect<font style="color: rgb(38, 38, 47);">io</font>n with a<font style="color: rgb(38, 38, 47);">n </font>Immunocore Patent C<font style="color: rgb(38, 38, 47);">h</font>allenge prior to such merger or acquis<font style="color: rgb(38, 38, 47);">ition </font>event and Immunocore c<font style="color: rgb(54, 54, 66);">au</font>ses such <font style="color: rgb(54, 54, 66);">Immunocore</font> Patent Challenge to terminate within [***] after <font style="color: rgb(38, 38, 47);">s</font>u<font style="color: rgb(54, 54, 66);">c</font>h
                merger or acquisition event; (ii) only app<font style="color: rgb(38, 38, 47);">ly </font>in t<font style="color: rgb(38, 38, 47);">he c</font>ase o<font style="color: rgb(54, 54, 66);">f </font>sublicensees wher<font style="color: rgb(38, 38, 47);">e </font><font style="color: rgb(54, 54, 66);">GSK </font>has given Immunocore notice of any Im<font style="color: rgb(38, 38, 47);">m</font>unocor<font style="color: rgb(38, 38, 47);">e P</font>atent <font style="color: rgb(38, 38, 47);">Cha</font>llenge <font style="color: rgb(38, 38, 47);">an</font>d <font style="color: rgb(38, 38, 47);">a</font>t least [***] to procure the terminat<font style="color: rgb(54, 54, 66);">i</font>on of
                such I<font style="color: rgb(38, 38, 47);">m</font>mun<font style="color: rgb(38, 38, 47);">oc</font>o<font style="color: rgb(38, 38, 47);">re </font>Patent <font style="color: rgb(54, 54, 66);">C</font>halleng<font style="color: rgb(38, 38, 47);">e</font>. This Section 13.9 and the right to termin<font style="color: rgb(38, 38, 47);">a</font>te <font style="color: rgb(38, 38, 47);">a</font>n<font style="color: rgb(54, 54, 66);">y </font>lice<font style="color: rgb(38, 38, 47);">nc</font>e unde<font style="color: rgb(38, 38, 47);">r t</font>his Section<font style="color: rgb(38, 38, 47);">&#160;</font><font style="color: rgb(54, 54, 66);">13</font>.9 sha<font style="color: rgb(38, 38, 47);">ll not </font>apply






                in relation to any pre- existing <font style="color: rgb(54, 54, 66);">su</font>b<font style="color: rgb(54, 54, 66);">-lic</font>ense<font style="color: rgb(54, 54, 66);">e o</font>f Immu<font style="color: rgb(54, 54, 66);">n</font>ocore
                u<font style="color: rgb(38, 38, 47);">n</font>d<font style="color: rgb(54, 54, 66);">e</font>r <font style="color: rgb(54, 54, 66);">t</font>he Immunocore Background and relating to Compound<font style="color: rgb(54, 54, 66);">s a</font>s
                at <font style="color: rgb(54, 54, 66);">t</font>he Effective<font style="color: rgb(38, 38, 47);">&#160;</font>Date.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8ce31b9f41424371b49a4fdfa9288704" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where <font style="color: rgb(38, 38, 47);">Immunocore</font> is <font style="color: rgb(54, 54, 66);">in </font>material breach o<font style="color: rgb(38, 38, 47);">f </font>this Agreement in connection with a C<font style="color: rgb(54, 54, 66);">o</font>ll<font style="color: rgb(54, 54, 66);">abo </font>rat io<font style="color: rgb(54, 54, 66);">n </font>Program<font style="color: rgb(38, 38, 47);">&#160;</font>i<font style="color: rgb(54, 54, 66);">n </font><font style="color: rgb(38, 38, 47);">a</font>ccorda<font style="color: rgb(54, 54, 66);">nce </font>with Section 13.4, the following shall apply:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9b5f5bb936b74b3db6610beb79ab400a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.10.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>GSK shall<font style="color: rgb(38, 38, 47);">&#160;</font>have the right in its <font style="color: rgb(38, 38, 47);">so</font>le discretion to exercise any or all of the Initial <font style="color: rgb(38, 38, 47);">Program</font>
                Options or Collaboration Program Options for all then on-going Collaboration Programs,</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">46</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">and GSK&#8217;s obligation to pay Immunocore the M<font style="color: rgb(54, 54, 66);">ile</font>stone F<font style="color: rgb(54, 54, 66);">e</font>e<font style="color: rgb(38, 38, 47);">s a</font>ssociated






        with the development milestones set forth on <font style="color: rgb(38, 38, 47);">Sc</font>h<font style="color: rgb(38, 38, 47);">e</font>dule 2 <font style="color: rgb(54, 54, 66);">s</font>hall be modified as set forth in Schedule 2;</div>
      <div>&#160;</div>
      <table id="z49358520956a4150aceeff89f0cf275d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.10.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div><font style="color: #26262F;">T</font>he re<font style="color: rgb(38, 38, 47);">st</font>ri<font style="color: rgb(38, 38, 47);">ct</font>ions set forth in Section 6.4 shall continue to apply to Immunocore;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1eac75489b984dff89ec2a0094d27ddb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.10.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The licences granted to Immunocore as set forth in Section 6.12 and 6.13 shall terminate with respect to the particular Collaboration Program from date of termination or exercise of the applicable Initial Program Option or Collaboration
                Program Option thereof. This Agreement shall remain in full force and effect in relation to other Collaboration Programs and licences granted to GSK;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z98c66057aecd47139f5305e288cb9706" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.10.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The Parties shall discuss and agree a plan to transfer responsibility for on<font style="color: rgb(119, 119, 119);">-</font><font style="color: rgb(7, 7, 8);">going Clinical Trials of Licensed Products arising from the terminated
                  Collaboration Program to GSK including which Party shall be responsible for costs associated with transfer, completion or winding down</font><font style="color: rgb(31, 33, 38);">; </font><font style="color: rgb(7, 7, 8);">and</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zca1d87ec10af4c45b0eadb687b1888a6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.10.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Immunocore shall deliver to GSK [***]<font style="color: rgb(31, 33, 38);">&#160;</font>within [***] of the date of termination all Results, data, materi<font style="color: rgb(31, 33, 38);">a</font>ls, <font style="color: rgb(31, 33, 38);">d</font><font style="color: rgb(52, 54, 66);">r</font><font style="color: rgb(31, 33, 38);">u</font>g, submissio<font style="color: rgb(31, 33, 38);">ns,</font><font style="color: rgb(52, 54, 66);">&#160;</font>regulatory documentation, clinical materials,
                details <font style="color: rgb(31, 33, 38);">of T</font>hird Party <font style="color: rgb(31, 33, 38);">sub</font>-<font style="color: rgb(31, 33, 38);">contractor</font>s (including manufacturers), process det<font style="color: rgb(31, 33, 38);">ails a</font>nd all other <font style="color: rgb(31, 33, 38);">m</font><font style="color: rgb(52, 54, 66);">a</font><font style="color: rgb(31, 33, 38);">t</font>erials in its possession or control solely related to <font style="color: rgb(31, 33, 38);">th</font><font style="color: rgb(52, 54, 66);">e </font>applicable Licens<font style="color: rgb(52, 54, 66);">e</font>d <font style="color: rgb(31, 33, 38);">P</font>roduct arising in the course of the
                terminated Collaboration Program,<font style="color: rgb(31, 33, 38);"> a</font>n<font style="color: rgb(31, 33, 38);">d </font>in each case as reasonably necessary solely for the <font style="color: rgb(31, 33, 38);">p</font><font style="color: rgb(52, 54, 66);">u</font><font style="color: rgb(31, 33, 38);">rp</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 33, 38);">s</font>e <font style="color: rgb(52, 54, 66);">o</font>f
                permitting <font style="color: rgb(31, 33, 38);">GS</font>K (or <font style="color: rgb(52, 54, 66);">as </font>relevant its Affiliates or sub-licensee) to c<font style="color: rgb(52, 54, 66);">o</font>n<font style="color: rgb(31, 33, 38);">ti</font>n<font style="color: rgb(31, 33, 38);">ue </font>wit<font style="color: rgb(31, 33, 38);">h t</font><font style="color: rgb(52, 54, 66);">h</font><font style="color: rgb(31, 33, 38);">e </font>res<font style="color: rgb(31, 33, 38);">ea</font><font style="color: rgb(52, 54, 66);">r</font>c<font style="color: rgb(31, 33, 38);">h </font>and <font style="color: rgb(52, 54, 66);">deve</font><font style="color: rgb(31, 33, 38);">l</font>opment, sale,
                supply and manufacture of s<font style="color: rgb(31, 33, 38);">u</font><font style="color: rgb(52, 54, 66);">c</font>h <font style="color: rgb(31, 33, 38);">Li</font>cen<font style="color: rgb(31, 33, 38);">s</font><font style="color: rgb(52, 54, 66);">e</font><font style="color: rgb(31, 33, 38);">d Product</font>s.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z293c9577d5e148c4a34df657bc8ec840" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where GSK terminates this Agreeme<font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 33, 38);">t or a</font>ny <font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(31, 33, 38);">pe</font><font style="color: rgb(52, 54, 66);">ci</font>fied <font style="color: rgb(31, 33, 38);">Collaboration</font> Program under Section 13.5, the following shall app<font style="color: rgb(31, 33, 38);">ly</font>:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6d7f10ac5e0d481d8e4685be5bf7475d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.11.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>GSK shall have the ri<font style="color: rgb(31, 33, 38);">ght </font><font style="color: rgb(52, 54, 66);">i</font><font style="color: rgb(31, 33, 38);">n </font>its <font style="color: rgb(31, 33, 38);">s</font><font style="color: rgb(52, 54, 66);">o</font>l<font style="color: rgb(31, 33, 38);">e </font>discretion<font style="color: rgb(31, 33, 38);">&#160;</font>to ex<font style="color: rgb(31, 33, 38);">e</font>rc<font style="color: rgb(31, 33, 38);">i</font><font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(31, 33, 38);">e </font>any or all of the Initial Program Options <font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 33, 38);">r </font>Coll<font style="color: rgb(31, 33, 38);">a</font>bora<font style="color: rgb(31, 33, 38);">t</font>ion Program O<font style="color: rgb(31, 33, 38);">pti</font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 33, 38);">n</font>s
                for all then on-going Collaboration Programs<font style="color: rgb(31, 33, 38);">&#160;</font>where <font style="color: rgb(31, 33, 38);">th</font>e <font style="color: rgb(31, 33, 38);">Agr</font>eement <font style="color: rgb(52, 54, 66);">i</font>s
                <font style="color: rgb(31, 33, 38);">b</font><font style="color: rgb(52, 54, 66);">e</font>ing t<font style="color: rgb(31, 33, 38);">er</font>minated in its entirety or the <font style="color: rgb(31, 33, 38);">In</font>i<font style="color: rgb(31, 33, 38);">t</font><font style="color: rgb(52, 54, 66);">ia</font><font style="color: rgb(31, 33, 38);">l </font>Program Option<font style="color: rgb(52, 54, 66);">s </font>or Collaboration <font style="color: rgb(31, 33, 38);">Pro</font><font style="color: rgb(52, 54, 66);">g</font>ram Options relevant to a p<font style="color: rgb(52, 54, 66);">a</font>rti<font style="color: rgb(31, 33, 38);">c</font><font style="color: rgb(52, 54, 66);">u</font>lar






                Collaboration<font style="color: rgb(31, 33, 38);"> Program </font>being te<font style="color: rgb(31, 33, 38);">r</font>mina<font style="color: rgb(31, 33, 38);">t</font>ed, and GSK&#8217;s obligation to pay Immunocore the Milestone Fees
                associated with the development milestones set fort h on Schedule 2 shall be modified as set forth in Schedule 2;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z633bb0e8617f4c1086724a58801c09e0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.11.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The licences granted to Immunocore as set forth in Section 6.12 and 6.13 shall terminate with respect to the particular Collaboration Program from date of termination thereof. This Agreement shall remain in full force and effect in
                relation to other Collaboration Programs and licences granted to GSK;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc9699677d1d44315aa803d55f1b5d5db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.11.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>The Parties shall discuss and agree a plan to transfer responsibility for on- going Clinical Trials of Licensed Products arising from any terminated Collaboration Program to GSK. GSK shall pay for any costs or expenses associated with
                transfer, completion or winding down of such Clinical Trials;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z193d86c6909d47ed8defbf1c02e64a50" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.11.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>Immunocore shall deliver to GSK [***] within [***] of the date of termination all Results, data, materials, drug, submission<font style="color: rgb(31, 33, 38);">s</font><font style="color: rgb(7, 7, 8);">, r</font><font style="color: rgb(31, 33, 38);">e</font><font style="color: rgb(7, 7, 8);">gulatory docu</font><font style="color: rgb(31, 33, 38);">me</font><font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(7, 7, 8);">tation, cl</font><font style="color: rgb(31, 33, 38);">in</font><font style="color: rgb(7, 7, 8);">ical materials, details of Third Party sub-contractors (</font><font style="color: rgb(31, 33, 38);">i</font><font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 33, 38);">c</font><font style="color: rgb(7, 7, 8);">luding </font><font style="color: rgb(31, 33, 38);">m</font><font style="color: rgb(7, 7, 8);">a</font><font style="color: rgb(52, 54, 66);">n</font><font style="color: rgb(31, 33, 38);">ufa</font><font style="color: rgb(7, 7, 8);">cturers), proce</font><font style="color: rgb(31, 33, 38);">s</font><font style="color: rgb(7, 7, 8);">s details and all other materials in its</font><font style="color: rgb(31, 33, 38);"> po</font><font style="color: rgb(7, 7, 8);">s</font><font style="color: rgb(52, 54, 66);">s</font><font style="color: rgb(31, 33, 38);">e</font><font style="color: rgb(7, 7, 8);">ssion </font><font style="color: rgb(52, 54, 66);">o</font><font style="color: rgb(31, 33, 38);">r </font><font style="color: rgb(7, 7, 8);">control solely related to the applicable Licensed Product arising</font><font style="color: rgb(52, 54, 66);"> i</font><font style="color: rgb(31, 33, 38);">n </font><font style="color: rgb(7, 7, 8);">the course of any terminated Collaboration Program, and in each case as</font><font style="color: rgb(52, 54, 66);"> re</font><font style="color: rgb(7, 7, 8);">asona</font><font style="color: rgb(31, 33, 38);">bl</font><font style="color: rgb(7, 7, 8);">y </font><font style="color: rgb(31, 33, 38);">n</font><font style="color: rgb(7, 7, 8);">eces</font><font style="color: rgb(31, 33, 38);">s</font><font style="color: rgb(7, 7, 8);">ary solely for th</font><font style="color: rgb(31, 33, 38);">e </font><font style="color: rgb(7, 7, 8);">purpose of p</font><font style="color: rgb(31, 33, 38);">e</font><font style="color: rgb(7, 7, 8);">rmitting






                  GSK (or </font><font style="color: rgb(31, 33, 38);">a</font><font style="color: rgb(7, 7, 8);">s relevant its Affi</font><font style="color: rgb(31, 33, 38);">li</font><font style="color: rgb(52, 54, 66);">a</font><font style="color: rgb(7, 7, 8);">t</font><font style="color: rgb(31, 33, 38);">es </font><font style="color: rgb(7, 7, 8);">or sub-</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">47</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;"><font style="color: #070708;">licensee) to continue with the research and development, sale, </font><font style="color: #343642;">s</font><font style="color: #1F2126;">upp</font><font style="color: #070708;">ly and manufacture of such Licensed Products; and</font></div>
      <div>&#160;</div>
      <table id="zc56fe72d7c954310997253a3a5be5a88" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.11.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">To the extent that any liquidator or admini</font><font style="color: #1F2126;">s</font><font style="color: #070708;">trator legally disclaims any continuing obligation or surviving obligation following
                  termination in a</font><font style="color: #1F2126;">c</font><font style="color: #070708;">cordan</font><font style="color: #1F2126;">c</font><font style="color: #070708;">e with Section 13.5, Immunocore shall offer GSK a right to </font>negotiate<font style="color: rgb(7, 7, 8);"> in good faith for (a) any continuing licences to manufacture,</font><font style="color: rgb(31, 33, 38);"> s</font><font style="color: rgb(7, 7, 8);">ell</font><font style="color: rgb(31, 33, 38);">,</font><font style="color: rgb(7, 7, 8);"> supply, u</font><font style="color: rgb(31, 33, 38);">se </font><font style="color: rgb(7, 7, 8);">and import the Lic</font><font style="color: rgb(31, 33, 38);">e</font><font style="color: rgb(7, 7, 8);">n</font><font style="color: rgb(31, 33, 38);">se</font><font style="color: rgb(7, 7, 8);">d Products</font><font style="color: rgb(31, 33, 38);"> s</font><font style="color: rgb(7, 7, 8);">ubje</font><font style="color: rgb(31, 33, 38);">c</font><font style="color: rgb(7, 7, 8);">t to </font><font style="color: rgb(31, 33, 38);">a</font><font style="color: rgb(7, 7, 8);">ny di</font><font style="color: rgb(31, 33, 38);">sc</font><font style="color: rgb(7, 7, 8);">l</font><font style="color: rgb(31, 33, 38);">a</font><font style="color: rgb(7, 7, 8);">im</font><font style="color: rgb(31, 33, 38);">ed</font><font style="color: rgb(7, 7, 8);"> licence or option right</font><font style="color: rgb(31, 33, 38);">; a</font><font style="color: rgb(7, 7, 8);">nd (b) supply of materials unde</font><font style="color: rgb(31, 33, 38);">r </font><font style="color: rgb(7, 7, 8);">Secti</font><font style="color: rgb(31, 33, 38);">o</font><font style="color: rgb(7, 7, 8);">n 13.11.4.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z019db9c3918f4620b2a00e62daff23bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1F2126;">T</font>ermination of this Agreement will not release any Party from any obligation or li<font style="color: rgb(31, 33, 38);">a</font>bility <font style="color: rgb(7, 7, 8);">which has fallen due or
                  arisen before the effective date of termination of this Agreement. Any payments due or arising prior to the date of termination shall immediately become due and payable on termination.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6c116295c42e4c35ae40f995c7dbec37" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.13</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Articles 1 (to the extent required), 6 (to the extent p<font style="color: rgb(28, 28, 33);">rov</font>ided in Article 13), 7 (to the extent provided in Article 13), 10, 11, 12 13 (and <font style="color: rgb(28, 28, 33);">a</font>ll S<font style="color: rgb(45, 45, 56);">ec</font>tions that ar<font style="color: rgb(45, 45, 56);">e </font>required to survive termination in accordance with Article 13) a<font style="color: rgb(28, 28, 33);">nd 16 </font>will survive <font style="color: rgb(28, 28, 33);">ter</font>mination or expiry of this Agreement for whatever reason.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z01a96262b452450ca607825796eb32f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Anti-bribery</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zbab83c25344749178ad60e393d6c57af" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party agrees to:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z94f0c408686e475397badc4c87256533" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.1.1</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>comply with all Applicable L<font style="color: rgb(28, 28, 33);">aw</font>s <font style="color: rgb(45, 45, 56);">r</font>elati<font style="color: rgb(28, 28, 33);">ng </font><font style="color: rgb(45, 45, 56);">to </font>ant <font style="color: rgb(91, 91, 103);">i</font><font style="color: rgb(63, 63, 77);">-</font>b<font style="color: rgb(45, 45, 56);">ribe</font>ry an<font style="color: rgb(28, 28, 33);">d </font><font style="color: rgb(45, 45, 56);">a</font>nti<font style="color: rgb(28, 28, 33);">-</font>corrupt ion including but not limited to t<font style="color: rgb(45, 45, 56);">h</font>e <font style="color: rgb(45, 45, 56);">Brib</font>ery <font style="color: rgb(28, 28, 33);">A</font>c<font style="color: rgb(45, 45, 56);">t 2</font>010 <font style="color: rgb(28, 28, 33);">(R</font>e<font style="color: rgb(45, 45, 56);">l</font>evant <font style="color: rgb(28, 28, 33);">R</font>equirements);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zeed0fba25a6f48a9be86a3e779e4224b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.1.2</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>maintain in place through<font style="color: rgb(28, 28, 33);">out </font>the t<font style="color: rgb(28, 28, 33);">erm </font>of this<font style="color: rgb(28, 28, 33);">&#160;</font><font style="color: rgb(45, 45, 56);">Agreement</font>&#160;<font style="color: rgb(45, 45, 56);">its</font> own policies and procedures, including <font style="color: rgb(28, 28, 33);">but </font>not l<font style="color: rgb(45, 45, 56);">imited </font>t<font style="color: rgb(28, 28, 33);">o </font>a<font style="color: rgb(45, 45, 56);">de</font>quate p<font style="color: rgb(45, 45, 56);">roc</font>edures under the Bribery Act 2010, to en<font style="color: rgb(45, 45, 56);">su</font>re <font style="color: rgb(28, 28, 33);">co</font>mpli<font style="color: rgb(28, 28, 33);">a</font>nce <font style="color: rgb(28, 28, 33);">with </font>the <font style="color: rgb(28, 28, 33);">Relev</font>a<font style="color: rgb(28, 28, 33);">n</font>t Requirements and will enforce them w<font style="color: rgb(45, 45, 56);">h</font>er<font style="color: rgb(28, 28, 33);">e </font>appropr<font style="color: rgb(45, 45, 56);">iat</font>e;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zc3ec0ba5d6484a5dbe79e912146bbe91" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.1.3</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>comply with a<font style="color: rgb(28, 28, 33);">n</font>y <font style="color: rgb(28, 28, 33);">ke</font>y a<font style="color: rgb(28, 28, 33);">n</font>t <font style="color: rgb(45, 45, 56);">i- br</font>ibery <font style="color: rgb(45, 45, 56);">po</font>li<font style="color: rgb(45, 45, 56);">ci</font>es o<font style="color: rgb(28, 28, 33);">f </font>the oth<font style="color: rgb(28, 28, 33);">e</font>r Party whi<font style="color: rgb(28, 28, 33);">c</font>h
                are communicated to <font style="color: rgb(45, 45, 56);">it </font>as of the Effective Date and in relation to which a Party can reasonably comply;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="ze5750ab6979741c0a38412928874b2b0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.1.4</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>promptly report to other Party any request or de mand for any undue financial or other advantage of any kind it receives in connection with the performance of this Agreement; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z46d38223ed724a2292c5a90234e40a10" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.1.5</td>
            <td style="vertical-align: top; text-align: justify;">
              <div>immediately notify other Party (in writing) if a foreign public official becomes an<font style="color: rgb(28, 28, 33);"> o</font>fficer <font style="color: rgb(45, 45, 56);">of </font><font style="color: rgb(28, 28, 33);">its </font>org<font style="color: rgb(63, 63, 77);">a</font><font style="color: rgb(28, 28, 33);">n</font>isation <font style="color: rgb(28, 28, 33);">or </font><font style="color: rgb(45, 45, 56);">acq</font>uires a <font style="color: rgb(45, 45, 56);">dire</font>ct






                interest in it (and it warrants<font style="color: rgb(45, 45, 56);"> tha</font>t it <font style="color: rgb(45, 45, 56);">h</font>a<font style="color: rgb(45, 45, 56);">s </font>no <font style="color: rgb(28, 28, 33);">foreig</font>n
                pub<font style="color: rgb(63, 63, 77);">li</font>c <font style="color: rgb(45, 45, 56);">o</font>fficials <font style="color: rgb(45, 45, 56);">a</font>s <font style="color: rgb(45, 45, 56);">offi</font>cers or direct owners as of the<font style="color: rgb(45, 45, 56);"> Effective D</font>ate).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z1637ad256ddb4dc9a268c2f023b9cba8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>F<font style="color: rgb(45, 45, 56);">o</font>r <font style="color: rgb(45, 45, 56);">th</font>e pu<font style="color: rgb(28, 28, 33);">rpose </font>of t<font style="color: rgb(45, 45, 56);">h</font>i<font style="color: rgb(45, 45, 56);">s </font>Article <font style="color: rgb(45, 45, 56);">14</font>, <font style="color: rgb(28, 28, 33);">t</font>he m<font style="color: rgb(45, 45, 56);">ean</font>in<font style="color: rgb(28, 28, 33);">g </font>of adequate
                procedures and foreign pu<font style="color: rgb(28, 28, 33);">bli</font><font style="color: rgb(63, 63, 77);">c </font>official and w<font style="color: rgb(28, 28, 33);">he</font>ther <font style="color: rgb(45, 45, 56);">a p</font>erson






                <font style="color: rgb(28, 28, 33);">i</font>s <font style="color: rgb(63, 63, 77);">a</font>ssociated with another person shall be determined in acc<font style="color: rgb(28, 28, 33);">o</font><font style="color: rgb(63, 63, 77);">r</font><font style="color: rgb(28, 28, 33);">d</font>ance with section 7(<font style="color: rgb(28, 28, 33);">2) of </font>the Bribery Act 2010 (and any guidance issued under s<font style="color: rgb(45, 45, 56);">ecti</font>o<font style="color: rgb(45, 45, 56);">n </font>9 of t<font style="color: rgb(45, 45, 56);">ha</font>t Act), sections 6(5) and 6(6) and section 8 of that Act respectively.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z9d95b41b487a4bf7a354ce657faed1c0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">Immunocore</font><font style="color: #1C1C21;">&#160;</font><font style="color: #3F3F4D;">a</font><font style="color: #070708;">cknow</font><font style="color: #2D2D38;">le</font><font style="color: #070708;">dg</font><font style="color: #2D2D38;">e</font><font style="color: #070708;">s re</font><font style="color: #1C1C21;">c</font><font style="color: #070708;">eipt of GSK&#8217;s &#8220;Pr</font><font style="color: #1C1C21;">e</font><font style="color: #070708;">vention






                  of </font><font style="color: #1C1C21;">C</font><font style="color: #070708;">orruption - </font><font style="color: #1C1C21;">T</font><font style="color: #070708;">hird Party Guidelin</font><font style="color: #2D2D38;">es&#8221; </font><font style="color: #070708;">attached as </font>Schedule<font style="color: rgb(7, 7, 8);"> 4 and agrees to comply with su</font><font style="color: rgb(28, 28, 33);">c</font><font style="color: rgb(7, 7, 8);">h as a key anti-briber</font><font style="color: rgb(28, 28, 33);">y polic</font><font style="color: rgb(7, 7, 8);">y of G</font><font style="color: rgb(45, 45, 56);">SK u</font><font style="color: rgb(7, 7, 8);">nder Section 14.1.3.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2b75e1434ac743f5b0568d3beedea8f7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Di</font><font style="font-weight: bold; color: #2D2D38;">spu</font><font style="font-weight: bold;">te Resol</font><font style="font-weight: bold; color: #2D2D38;">u</font><font style="font-weight: bold;">ti</font><font style="font-weight: bold; color: #2D2D38;">o</font><font style="font-weight: bold;">n</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">48</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z67217ac60d324a5ea9e28de8e58de8bd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2D2D38;">Either</font> Party <font style="color: rgb(28, 28, 33);">s</font>h<font style="color: rgb(28, 28, 33);">a</font>ll h<font style="color: rgb(28, 28, 33);">a</font>ve the right to refer any di<font style="color: rgb(28, 28, 33);">s</font>pute first to th<font style="color: rgb(28, 28, 33);">e </font>JSC for <font style="color: rgb(28, 28, 33);">resolution,</font><font style="color: rgb(45, 45, 56);"> provide</font>d the JSC is
                still in existence at time the dispute arises and has not c<font style="color: rgb(28, 28, 33);">e</font>a<font style="color: rgb(28, 28, 33);">s</font>ed to exi<font style="color: rgb(28, 28, 33);">s</font>t in accordance with Section
                4.10.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z40dbc72ae3bc457f8369ef361bd79d25" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Wh<font style="color: rgb(28, 28, 33);">e</font>r<font style="color: rgb(28, 28, 33);">e a</font>ny di<font style="color: rgb(28, 28, 33);">s</font>put<font style="color: rgb(28, 28, 33);">e </font>cann<font style="color: rgb(28, 28, 33);">o</font>t be r<font style="color: rgb(28, 28, 33);">es</font>olv<font style="color: rgb(28, 28, 33);">e</font>d by th<font style="color: rgb(28, 28, 33);">e </font>J<font style="color: rgb(28, 28, 33);">SC </font>within [***]<font style="color: rgb(45, 45, 56);">&#160;</font><font style="color: rgb(28, 28, 33);">o</font>f fir<font style="color: rgb(28, 28, 33);">s</font>t ref<font style="color: rgb(28, 28, 33);">e</font>r<font style="color: rgb(28, 28, 33);">r</font>al<font style="color: rgb(28, 28, 33);"> t</font>o the JSC or wher<font style="color: rgb(28, 28, 33);">e </font>JSC i<font style="color: rgb(28, 28, 33);">s </font>not in existence <font style="color: rgb(28, 28, 33);">a</font>t d<font style="color: rgb(28, 28, 33);">a</font>t<font style="color: rgb(28, 28, 33);">e </font>dispute <font style="color: rgb(28, 28, 33);">a</font>rises, eithe<font style="color: rgb(28, 28, 33);">r </font>Party sh<font style="color: rgb(28, 28, 33);">a</font>ll have a right to refer <font style="color: rgb(28, 28, 33);">s</font>uch di<font style="color: rgb(28, 28, 33);">s</font>pute to the respe<font style="color: rgb(28, 28, 33);">c</font>tive Executive Officer<font style="color: rgb(28, 28, 33);">s </font>(<font style="color: rgb(28, 28, 33);">o</font>r their designees), and such <font style="color: rgb(28, 28, 33);">Executive</font>&#160;<font style="color: rgb(28, 28, 33);">O</font>fficers shall
                attempt in good faith to resolve su<font style="color: rgb(28, 28, 33);">c</font>h dispute.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z8193260f23fe424598e7172e261c7102" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where the Executive Officers are unable to resolve the dispute within [***]<font style="font-weight: bold;">&#160;</font>of referral under Section 15.2, either Party thereafter may reque<font style="color: rgb(31, 31, 38);">s</font>t that the
                dispute be referred to Third Party mediation, by written notice to <font style="color: rgb(31, 31, 38);">th</font>e o<font style="color: rgb(31, 31, 38);">t</font>her; provided, that if the subject matter of a dispute is within a Party&#8217;s
                final de<font style="color: rgb(31, 31, 38);">ci</font>si<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">n-</font>making auth<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">ri</font><font style="color: rgb(31, 31, 38);">t</font>y pursuant to Article 4, then such dispute shall not be submitted <font style="color: rgb(31, 31, 38);">to m</font>ediation and <font style="color: rgb(31, 31, 38);">ma</font>y
                be finally decided by the Party having such authority. Where t<font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(54, 54, 66);">Parties</font> agree, <font style="color: rgb(31, 31, 38);">suc</font><font style="color: rgb(54, 54, 66);">h </font>dispute shall be submitted to mediation in accordance w<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">h </font>the Mediation <font style="color: rgb(54, 54, 66);">P</font>ro<font style="color: rgb(54, 54, 66);">c</font>edure of the International Institute for Conflict Prevention a<font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">d </font>R<font style="color: rgb(31, 31, 38);">e</font>solution (&#8220;<font style="font-weight: bold;">CP</font><font style="font-weight: bold; color: rgb(31, 31, 38);">R</font><font style="color: rgb(31, 31, 38);">&#8221;)</font><font style="color: rgb(54, 54, 66);">.</font><font style="font-weight: bold; color: rgb(54, 54, 66);">&#160;</font>Such mediation shall be attended on behalf of each Party for <font style="color: rgb(54, 54, 66);">at </font><font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(54, 54, 66);">ea</font><font style="color: rgb(31, 31, 38);">s</font>t <font style="color: rgb(31, 31, 38);">on</font>e session b<font style="color: rgb(31, 31, 38);">y a </font>seni<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">r e</font>xecutive with authority to resolve the dispute and s<font style="color: rgb(31, 31, 38);">h</font>a<font style="color: rgb(31, 31, 38);">ll </font>be <font style="color: rgb(31, 31, 38);">h</font>el<font style="color: rgb(54, 54, 66);">d </font>in L<font style="color: rgb(31, 31, 38);">ondo</font>n, En<font style="color: rgb(31, 31, 38);">g</font><font style="color: rgb(54, 54, 66);">lan</font><font style="color: rgb(31, 31, 38);">d</font>. Unless otherwise agreed by the Parties, the Parties <font style="color: rgb(54, 54, 66);">s</font>h<font style="color: rgb(31, 31, 38);">all </font>sel<font style="color: rgb(54, 54, 66);">ec</font>t <font style="color: rgb(31, 31, 38);">a </font>me<font style="color: rgb(31, 31, 38);">di</font><font style="color: rgb(54, 54, 66);">a</font>to<font style="color: rgb(31, 31, 38);">r f</font>ro<font style="color: rgb(31, 31, 38);">m t</font><font style="color: rgb(54, 54, 66);">h</font>e <font style="color: rgb(31, 31, 38);">C</font>PR Panels of Distinguished Neutrals. Notwithstan<font style="color: rgb(31, 31, 38);">di</font>ng <font style="color: rgb(31, 31, 38);">the</font>&#160;<font style="color: rgb(31, 31, 38);">fore</font><font style="color: rgb(54, 54, 66);">g</font><font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">i</font>ng, <font style="color: rgb(31, 31, 38);">ea</font><font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(31, 31, 38);">h </font>Party <font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(54, 54, 66);">a</font>s
                the right to pursue provisional relief from any co<font style="color: rgb(31, 31, 38);">urt, </font><font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(54, 54, 66);">c</font>h
                a<font style="color: rgb(31, 31, 38);">s </font>a<font style="color: rgb(54, 54, 66);">tt</font><font style="color: rgb(31, 31, 38);">ac</font>hm<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">n</font>t,
                preli<font style="color: rgb(54, 54, 66);">mi</font>nary injunction or replevin to avoid irreparable harm<font style="color: rgb(54, 54, 66);">, </font>ma<font style="color: rgb(31, 31, 38);">i</font><font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">t</font>ain <font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(31, 31, 38);">e status</font>&#160;<font style="color: rgb(31, 31, 38);">quo</font>,
                or <font style="color: rgb(31, 31, 38);">preserve</font> the subject matter of the dispute, prior to the c<font style="color: rgb(31, 31, 38);">om</font>menc<font style="color: rgb(31, 31, 38);">em</font><font style="color: rgb(54, 54, 66);">e</font>nt of, or <font style="color: rgb(31, 31, 38);">w</font>hile t<font style="color: rgb(54, 54, 66);">h</font>e <font style="color: rgb(54, 54, 66);">P</font><font style="color: rgb(31, 31, 38);">ar </font>ties are engaged
                in, the mediation process. An<font style="color: rgb(31, 31, 38);">y dispute</font> t<font style="color: rgb(31, 31, 38);">ha</font>t <font style="color: rgb(54, 54, 66);">cannot</font><font style="color: rgb(31, 31, 38);"> be </font>resolved






                <font style="color: rgb(31, 31, 38);">b</font>y mediation within [***] of notice by o<font style="color: rgb(31, 31, 38);">ne Party</font>&#160;<font style="color: rgb(31, 31, 38);">to </font>the other <font style="color: rgb(31, 31, 38);">Party</font>
                of <font style="color: rgb(31, 31, 38);">the</font><font style="color: rgb(54, 54, 66);">&#160;</font>c<font style="color: rgb(31, 31, 38);">o</font>mmencement of the mediation process shall be re<font style="color: rgb(54, 54, 66);">s</font>olv<font style="color: rgb(31, 31, 38);">ed </font>by arbitration<font style="color: rgb(31, 31, 38);"> i</font>n accor<font style="color: rgb(31, 31, 38);">d</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">nc</font>e <font style="color: rgb(31, 31, 38);">Section </font>15.4.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z0a314d21643f41b9a35a527a3f7332ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any dispute remaining un<font style="color: rgb(54, 54, 66);">r</font>es<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">l</font><font style="color: rgb(31, 31, 38);">v</font>ed <font style="color: rgb(31, 31, 38);">af</font>t<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">r T</font>hird <font style="color: rgb(31, 31, 38);">Party </font>mediation pur<font style="color: rgb(31, 31, 38);">su</font>ant






                <font style="color: rgb(31, 31, 38);">t</font>o Section 15.3 of the Agreement (if appli<font style="color: rgb(31, 31, 38);">cab</font>le) wi<font style="color: rgb(31, 31, 38);">ll </font>be submitted fo<font style="color: rgb(54, 54, 66);">r </font><font style="color: rgb(31, 31, 38);">resolution</font> t<font style="color: rgb(31, 31, 38);">o </font><font style="color: rgb(54, 54, 66);">arbitration</font> by the International Court o<font style="color: rgb(54, 54, 66);">f </font>Arbitration <font style="font-weight: bold; color: rgb(31, 31, 38);">(&#8220;</font><font style="font-weight: bold;">ICC&#8221;) </font>in accord<font style="color: rgb(31, 31, 38);">a</font>nce with the<font style="color: rgb(31, 31, 38);">&#160;</font>I<font style="color: rgb(31, 31, 38);">CC </font>rules in force at the time of referral. <font style="color: rgb(31, 31, 38);">T</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(31, 31, 38);">e
                </font>arbitr<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">t</font>i<font style="color: rgb(31, 31, 38);">on </font>sha<font style="color: rgb(31, 31, 38);">ll </font><font style="color: rgb(54, 54, 66);">b</font><font style="color: rgb(31, 31, 38);">e </font>in Lond<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">n, </font>England a<font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(54, 54, 66);">d </font>shall be b<font style="color: rgb(31, 31, 38);">y </font>a [***] arbitrator who sh<font style="color: rgb(31, 31, 38);">a</font>ll (i) be a l<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(54, 54, 66);">w</font><font style="color: rgb(31, 31, 38);">y</font>er of <font style="color: rgb(31, 31, 38);">n</font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">t </font>less th<font style="color: rgb(31, 31, 38);">an [***]</font> who is knowledgeable <font style="color: rgb(31, 31, 38);">in </font>t<font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(54, 54, 66);">e </font><font style="color: rgb(31, 31, 38);">l</font>aw c<font style="color: rgb(54, 54, 66);">o</font>n<font style="color: rgb(31, 31, 38);">ce</font>rnin<font style="color: rgb(31, 31, 38);">g </font>th<font style="color: rgb(31, 31, 38);">e </font>sub<font style="color: rgb(31, 31, 38);">jec</font>t matter <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">t is</font><font style="color: rgb(54, 54, 66);">su</font><font style="color: rgb(31, 31, 38);">e </font>in






                the dispute, (ii) not be or have be<font style="color: rgb(31, 31, 38);">e</font>n <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">n </font>empl<font style="color: rgb(31, 31, 38);">oye</font>e, co<font style="color: rgb(31, 31, 38);">ns</font><font style="color: rgb(54, 54, 66);">u</font><font style="color: rgb(31, 31, 38);">l</font>t<font style="color: rgb(31, 31, 38);">a</font>nt, o<font style="color: rgb(31, 31, 38);">ffic</font>e<font style="color: rgb(31, 31, 38);">r</font><font style="color: rgb(54, 54, 66);">, </font>directo<font style="color: rgb(31, 31, 38);">r </font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">r s</font>to<font style="color: rgb(31, 31, 38);">c</font>kholder of either Party or any Affi<font style="color: rgb(31, 31, 38);">l</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">at</font>e of eithe<font style="color: rgb(31, 31, 38);">r </font>Party<font style="color: rgb(31, 31, 38);">&#160;</font>a<font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">d </font>(iii) n<font style="color: rgb(31, 31, 38);">o</font>t
                have <font style="color: rgb(54, 54, 66);">a </font>conflict of interest under any applicable r<font style="color: rgb(31, 31, 38);">u</font><font style="color: rgb(54, 54, 66);">l</font><font style="color: rgb(31, 31, 38);">es o</font>f
                et<font style="color: rgb(31, 31, 38);">hic</font>s<font style="color: rgb(54, 54, 66);">. </font>Th<font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(54, 54, 66);">a</font>rb<font style="color: rgb(31, 31, 38);">i</font>trat<font style="color: rgb(31, 31, 38);">o</font><font style="color: rgb(54, 54, 66);">r s</font>h<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(54, 54, 66);">ll </font>be s<font style="color: rgb(31, 31, 38);">e</font>l<font style="color: rgb(31, 31, 38);">e</font><font style="color: rgb(54, 54, 66);">c</font><font style="color: rgb(31, 31, 38);">te</font><font style="color: rgb(54, 54, 66);">d </font>by mutual agreement of the P<font style="color: rgb(31, 31, 38);">a</font>rties, <font style="color: rgb(54, 54, 66);">provided</font> that<font style="color: rgb(54, 54, 66);">&#160;</font>if th<font style="color: rgb(31, 31, 38);">e </font>Parties <font style="color: rgb(31, 31, 38);">ca</font><font style="color: rgb(54, 54, 66);">n</font><font style="color: rgb(31, 31, 38);">not a</font>gre<font style="color: rgb(31, 31, 38);">e </font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(31, 31, 38);">n </font>the
                arbit<font style="color: rgb(31, 31, 38);">r</font>ator within [***] of <font style="color: rgb(31, 31, 38);">the r</font>el<font style="color: rgb(31, 31, 38);">e</font>v<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">nt a</font>rbitra<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">i</font>o<font style="color: rgb(31, 31, 38);">n </font>r<font style="color: rgb(31, 31, 38);">e</font>quest<font style="color: rgb(54, 54, 66);">, </font>th<font style="color: rgb(54, 54, 66);">e </font>arbitrator shall be sele<font style="color: rgb(31, 31, 38);">c</font>ted by th<font style="color: rgb(31, 31, 38);">e</font> [***]. Th<font style="color: rgb(54, 54, 66);">e </font>arbit<font style="color: rgb(54, 54, 66);">ra</font><font style="color: rgb(31, 31, 38);">t</font>o<font style="color: rgb(54, 54, 66);">r </font>m<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(54, 54, 66);">y </font><font style="color: rgb(31, 31, 38);">pro</font>ceed to a<font style="color: rgb(54, 54, 66);">n </font>award<font style="color: rgb(31, 31, 38);">, n</font><font style="color: rgb(54, 54, 66);">o</font>twithstanding






                the failure of either Party t<font style="color: rgb(31, 31, 38);">o </font>parti<font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(54, 54, 66);">i</font>p<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">t</font>e in the<font style="color: rgb(31, 31, 38);">&#160;</font>procee<font style="color: rgb(31, 31, 38);">din</font>gs<font style="color: rgb(54, 54, 66);">. </font>The arbitrator shall, within [***]<font style="color: rgb(54, 54, 66);">&#160;</font><font style="color: rgb(31, 31, 38);">a</font>fter <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">h</font><font style="color: rgb(54, 54, 66);">e </font>con<font style="color: rgb(54, 54, 66);">cl</font>u<font style="color: rgb(54, 54, 66);">si</font><font style="color: rgb(31, 31, 38);">o</font>n of <font style="color: rgb(31, 31, 38);">the </font>arbitr<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">ti</font><font style="color: rgb(54, 54, 66);">o</font>n <font style="color: rgb(31, 31, 38);">h</font>e<font style="color: rgb(31, 31, 38);">a</font>ring, i<font style="color: rgb(31, 31, 38);">ss</font>ue






                a written award an<font style="color: rgb(31, 31, 38);">d</font> sta<font style="color: rgb(31, 31, 38);">t</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">m</font>ent of <font style="color: rgb(31, 31, 38);">d</font>eci<font style="color: rgb(31, 31, 38);">s</font>ion <font style="color: rgb(31, 31, 38);">d</font>es<font style="color: rgb(31, 31, 38);">c</font>rib<font style="color: rgb(54, 54, 66);">in</font><font style="color: rgb(31, 31, 38);">g </font>the e<font style="color: rgb(31, 31, 38);">s</font><font style="color: rgb(54, 54, 66);">s</font><font style="color: rgb(31, 31, 38);">en</font><font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(31, 31, 38);">ia</font>l findings and <font style="color: rgb(31, 31, 38);">c</font>onclusions on which the award is based, in accordance with Appli<font style="color: rgb(31, 31, 38);">c</font><font style="color: rgb(54, 54, 66);">a</font>ble Laws, including the calculation of any damages aw<font style="color: rgb(31, 31, 38);">a</font>r<font style="color: rgb(31, 31, 38);">d</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">d</font><font style="color: rgb(54, 54, 66);">. T</font>he arb<font style="color: rgb(31, 31, 38);">it</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(31, 31, 38);">a</font>tor shall be
                authorized to award compensatory damages, but shall not <font style="color: rgb(54, 54, 66);">b</font><font style="color: rgb(31, 31, 38);">e </font>author<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(31, 31, 38);">z</font>e<font style="color: rgb(31, 31, 38);">d </font>to award non-e<font style="color: rgb(31, 31, 38);">c</font>onomic damages or punitive, special, consequen<font style="color: rgb(31, 31, 38);">ti</font><font style="color: rgb(54, 54, 66);">a</font>l<font style="color: rgb(31, 31, 38);">, </font>or any <font style="color: rgb(31, 31, 38);">o</font>t<font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(31, 31, 38);">e</font>r similar form of damages, or to reform, modify
                or materially change th<font style="color: rgb(31, 31, 38);">e </font>Agreement<font style="color: rgb(54, 54, 66);">. </font><font style="color: rgb(31, 31, 38);">Th</font>e arbitrat<font style="color: rgb(31, 31, 38);">o</font>r also
                shall be authorized to grant any temporary<font style="color: rgb(31, 31, 38);">,</font> p<font style="color: rgb(31, 31, 38);">r</font>elim<font style="color: rgb(31, 31, 38);">i</font>n<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">ry </font>or perm<font style="color: rgb(31, 31, 38);">a</font>nent equitable remedy or relief the a<font style="color: rgb(31, 31, 38);">r</font>bit<font style="color: rgb(31, 31, 38);">ra</font>tor deems
                just and equit<font style="color: rgb(31, 31, 38);">a</font><font style="color: rgb(54, 54, 66);">b</font><font style="color: rgb(31, 31, 38);">le a</font>nd wit<font style="color: rgb(31, 31, 38);">h</font>in <font style="color: rgb(31, 31, 38);">t</font>he scope of this Agreement, including an injunction or order for speci<font style="color: rgb(54, 54, 66);">fi</font><font style="color: rgb(31, 31, 38);">c </font>perform<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(31, 31, 38);">nc</font><font style="color: rgb(54, 54, 66);">e</font>. The award of the arbitrator shall be the sole and exclusive r<font style="color: rgb(31, 31, 38);">em</font><font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(31, 31, 38);">d</font>y of the <font style="color: rgb(31, 31, 38);">P</font><font style="color: rgb(54, 54, 66);">ar</font>tie<font style="color: rgb(31, 31, 38);">s </font>(<font style="color: rgb(31, 31, 38);">exc</font>ept






                for tho<font style="color: rgb(31, 31, 38);">se </font>r<font style="color: rgb(31, 31, 38);">e</font>m<font style="color: rgb(31, 31, 38);">e</font>di<font style="color: rgb(31, 31, 38);">es se</font>t forth in this<font style="color: rgb(31, 31, 38);">&#160;</font>Agreement), the<font style="color: rgb(31, 31, 38);"> P</font><font style="color: rgb(54, 54, 66);">ar</font><font style="color: rgb(31, 31, 38);">ties </font>hereby expressly agree to waive the right to appeal
                from the decisi<font style="color: rgb(31, 31, 38);">o</font>ns of the<font style="color: rgb(54, 54, 66);"> ar</font><font style="color: rgb(31, 31, 38);">bi</font>trator, and there shall be no appeal to any <font style="color: rgb(31, 31, 38);">c</font>ourt or other authority (government or<font style="color: rgb(54, 54, 66);"> p</font>ri<font style="color: rgb(31, 31, 38);">v</font>ate) from the decision of the arbitrator. Judgment on the award rendered by the
                arbitrator may be enforced in any court having competent jurisdiction thereof, and the d<font style="color: rgb(31, 31, 38);">e</font>cision of th<font style="color: rgb(31, 31, 38);">e </font>arbitrator shall be final and binding on both
                Parties in the<font style="color: rgb(31, 31, 38);">&#160;</font>abs<font style="color: rgb(31, 31, 38);">e</font>nce of m<font style="color: rgb(31, 31, 38);">a</font>nife<font style="color: rgb(31, 31, 38);">s</font>t <font style="color: rgb(31, 31, 38);">e</font>rror or frau<font style="color: rgb(31, 31, 38);">d</font>. Notwithstanding anything <font style="color: rgb(31, 31, 38);">c</font>ont<font style="color: rgb(31, 31, 38);">a</font>ined in this <font style="color: rgb(31, 31, 38);">Section</font> 15.4 t<font style="color: rgb(31, 31, 38);">o </font>th<font style="color: rgb(31, 31, 38);">e</font> contr<font style="color: rgb(31, 31, 38);">ar</font>y<font style="color: rgb(31, 31, 38);">, </font>each Party h<font style="color: rgb(31, 31, 38);">a</font>s the ri<font style="color: rgb(31, 31, 38);">g</font>ht before the arbitration is <font style="color: rgb(31, 31, 38);">commenced</font>, to seek and obtain from
                the appropriate court provisional</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">49</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">remedies such as attachment<font style="color: rgb(31, 31, 38);">, </font>preliminary <font style="color: rgb(8, 8, 8);">injunction or replevin to avoid irreparable harm, maintain the status quo,
          or preserve the subject matter of the arbitration.</font></div>
      <div>&#160;</div>
      <table id="zd1247a1e6edc467bb71040e66aa9310f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party shall bear its own attorneys&#8217; fees, costs, and disbursements arising out of the arbitration, and shall pay an equal share of the fe<font style="color: rgb(42, 42, 52);">es </font>and costs of the arbitrators; provided, that
                the arbitrator shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevai<font style="color: rgb(42, 42, 52);">li</font>n<font style="color: rgb(42, 42, 52);">g Party</font> reimbursement
                for its reasonable attorneys&#8217; fees, costs and disbursements.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2b96768e28444642a8d9c3cad880a5d6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All proceedings and decisions of the arbitrators shall be d<font style="color: rgb(42, 42, 52);">e</font>emed Confidential Information of each of the Parties, and shall b<font style="color: rgb(42, 42, 52);">e subj</font>ect to Article
                10.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2661bdf57a304917bb8fca25881ae1a1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>From the date of submission of the dispute <font style="color: rgb(42, 42, 52);">to </font>t<font style="color: rgb(42, 42, 52);">h</font>e Executive Officers, until<font style="color: rgb(61, 61, 73);">&#160;</font>su<font style="color: rgb(42, 42, 52);">c</font>h time as the dispute has become finally settle<font style="color: rgb(42, 42, 52);">d </font>by Thir<font style="color: rgb(42, 42, 52);">d Party</font>&#160;<font style="color: rgb(42, 42, 52);">mediation</font> or
                <font style="color: rgb(61, 61, 73);">arbitration</font>, the running of the time periods as to wh<font style="color: rgb(42, 42, 52);">ic</font>h <font style="color: rgb(42, 42, 52);">a b</font>rea<font style="color: rgb(42, 42, 52);">c</font>hi<font style="color: rgb(42, 42, 52);">ng </font>Party<font style="color: rgb(42, 42, 52);"> must</font> cure<font style="color: rgb(42, 42, 52);">&#160;</font>a breach of this Agreement becomes suspended as to <font style="color: rgb(42, 42, 52);">an</font>y
                br<font style="color: rgb(42, 42, 52);">ea</font>c<font style="color: rgb(42, 42, 52);">h </font>that is the subj<font style="color: rgb(42, 42, 52);">e</font>c<font style="color: rgb(42, 42, 52);">t </font>matter of the dispute.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zfcec49568c8a4a718059b69dc50cbca1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Unless otherwise agreed by th<font style="color: rgb(42, 42, 52);">e </font>Parties, disputes <font style="color: rgb(42, 42, 52);">r</font>elatin<font style="color: rgb(42, 42, 52);">g t</font>o patents and patent applications and
                non-disclosu<font style="color: rgb(42, 42, 52);">r</font>e, <font style="color: rgb(61, 61, 73);">n</font>on-use <font style="color: rgb(61, 61, 73);">an</font>d <font style="color: rgb(42, 42, 52);">mai</font>ntenanc<font style="color: rgb(42, 42, 52);">e </font>o<font style="color: rgb(42, 42, 52);">f Confidential</font> Information shall not be subject to arbitration, <font style="color: rgb(42, 42, 52);">an</font>d sha<font style="color: rgb(42, 42, 52);">ll </font>b<font style="color: rgb(42, 42, 52);">e </font>submitted <font style="color: rgb(42, 42, 52);">t</font>o a co<font style="color: rgb(42, 42, 52);">urt </font>of competent jurisdiction.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2e9406a73ec14f8b802c1c954548b382" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">General</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z4fbc9ddf2ef2458d93e10717e575bcbd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notices: </font>Any notice to be giv<font style="color: rgb(61, 61, 73);">en </font>under <font style="color: rgb(42, 42, 52);">th</font>is Agreement mu<font style="color: rgb(42, 42, 52);">st b</font>e
                <font style="color: rgb(42, 42, 52);">i</font>n writing and may be delivered to th<font style="color: rgb(42, 42, 52);">e </font>o<font style="color: rgb(42, 42, 52);">ther </font>Party <font style="color: rgb(42, 42, 52);">b</font>y
                hand or co<font style="color: rgb(42, 42, 52);">u</font>rier <font style="color: rgb(42, 42, 52);">(</font>in wh<font style="color: rgb(42, 42, 52);">ic</font>h <font style="color: rgb(42, 42, 52);">ca</font>se the notice shall be deemed
                received <font style="color: rgb(42, 42, 52);">o</font>n day <font style="color: rgb(42, 42, 52);">of </font>delive<font style="color: rgb(42, 42, 52);">ry). </font>Notice<font style="color: rgb(61, 61, 73);">s </font>fo<font style="color: rgb(61, 61, 73);">r </font>Immunocore shall be marked for the attention of <font style="color: rgb(42, 42, 52);">t</font>he CEO of Immunocore, sen<font style="color: rgb(42, 42, 52);">t </font>t<font style="color: rgb(61, 61, 73);">o </font>the add<font style="color: rgb(42, 42, 52);">r</font>ess provided in the preamble of this Agreem<font style="color: rgb(42, 42, 52);">e</font>nt. Notic<font style="color: rgb(42, 42, 52);">e</font>s <font style="color: rgb(42, 42, 52);">fo</font>r GS<font style="color: rgb(61, 61, 73);">K </font>shall be <font style="color: rgb(42, 42, 52);">se</font>nt <font style="color: rgb(42, 42, 52);">t</font>o the f<font style="color: rgb(42, 42, 52);">oll</font>o<font style="color: rgb(42, 42, 52);">w</font>ing:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">Attention: [***]</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #2A2A34;">GlaxoSmithKline</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt;"><font style="color: #2A2A34;">7</font><font style="color: #080808;">09 Swe</font><font style="color: #2A2A34;">de</font><font style="color: #080808;">l</font><font style="color: #3D3D49;">a</font><font style="color: #080808;">nd R</font><font style="color: #2A2A34;">oa</font><font style="color: #080808;">d</font></div>
      <div style="text-indent: -0.3pt; margin-left: 144pt;"><font style="color: #080808;">P.O. B</font><font style="color: #2A2A34;">ox </font><font style="color: #080808;">1539, MC </font><font style="color: #2A2A34;">U</font><font style="color: #080808;">W2318</font></div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">King of Prussia, PA 19406-0939</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt;"><font style="color: #080808;">Un</font><font style="color: #2A2A34;">ite</font><font style="color: #080808;">d States</font></div>
      <div style="text-indent: -0.3pt; margin-left: 144pt;"><font style="color: #080808;">T</font><font style="color: #2A2A34;">e</font><font style="color: #080808;">le</font><font style="color: #2A2A34;">p</font><font style="color: #080808;">hone: [***]</font></div>
      <div>&#160;</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt;"><font style="color: #2A2A34;">with</font><font style="color: #080808;"> a copy to:</font></div>
      <div>&#160;</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">Attention: [***]</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">GlaxoSmithKline</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">2301 Renaissance Boulevard</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">Mail Code RN0220</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">King of Prussia, PA 19406</div>
      <div style="text-indent: -0.3pt; margin-left: 144pt; color: #080808;">Telephone: [***]</div>
      <div>&#160;</div>
      <table id="z7301c78013954b00ac6368ca913a638e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; color: #080808;">Assignment: </font><font style="color: #080808;">Neither Party may assign or transfer this Agreement a</font><font style="color: #2A2A34;">s </font><font style="color: #080808;">a whole,
                  or any of its rights or obligations under it, without first obtaining the written consent of the other Party (which may be given or withheld at the absolute discretion of the Party from </font><font style="color: #070707;">which consent
                  is sought). Both parties may assign all of its rights and obligations under this Agreement to an Affiliate or to any successor to the whole or relevant part of its business (or as relevant its Intellectual Property Rights) and the other
                  Party hereby consents to such assignment. Any assignment of Foreground or in the case of</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">50</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="color: #070707;">Immunocore, the Immunocore Background, shall be m</font><font style="color: #212128;">ad</font><font style="color: #070707;">e s</font><font style="color: #212128;">u</font><font style="color: #070707;">bject to the terms of this Agreement, including as to any rights granted on term</font><font style="color: #212128;">i</font><font style="color: #070707;">nati</font><font style="color: #212128;">o</font><font style="color: #363642;">n </font><font style="color: #070707;">of this Agree</font><font style="color: #212128;">me</font><font style="color: #070707;">nt.</font></div>
      <div>&#160;</div>
      <table id="z16e632d734d6420d8c366643690c3731" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Illegal/unenforceable provisions: </font>If the whol<font style="color: rgb(33, 33, 40);">e o</font><font style="color: rgb(54, 54, 66);">r </font>a<font style="color: rgb(33, 33, 40);">n</font>y part
                of any <font style="color: rgb(33, 33, 40);">pr</font><font style="color: rgb(54, 54, 66);">o</font>vision of this Agreement is void or unenforceable in any jur<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">s</font><font style="color: rgb(54, 54, 66);">d</font><font style="color: rgb(33, 33, 40);">ic</font>tion, the other <font style="color: rgb(33, 33, 40);">prov</font>isions of this Agreement, and the rest of the void or unenforc<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">a</font>bl<font style="color: rgb(33, 33, 40);">e </font>provision, will<font style="color: rgb(54, 54, 66);">&#160;</font>continue in force in that jurisdiction,
                and the validity and enfo<font style="color: rgb(33, 33, 40);">r</font><font style="color: rgb(54, 54, 66);">ce</font><font style="color: rgb(33, 33, 40);">ab</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">l</font>ity <font style="color: rgb(33, 33, 40);">o</font>f that pro<font style="color: rgb(33, 33, 40);">v</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">s</font>ion in <font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">n</font>y other jurisdiction will not be affected.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="zea4d24640fc64c8e83525ea010c8d553" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Waiver of rights: </font>If a Party fails to en<font style="color: rgb(33, 33, 40);">fo</font>rc<font style="color: rgb(54, 54, 66);">e, </font>or <font style="color: rgb(33, 33, 40);">dela</font><font style="color: rgb(54, 54, 66);">y</font><font style="color: rgb(33, 33, 40);">s </font>in <font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">nfo</font><font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">c</font><font style="color: rgb(54, 54, 66);">i</font>ng, an <font style="color: rgb(54, 54, 66);">ob</font>ligation of the other Party, or fails to exercise, or d<font style="color: rgb(33, 33, 40);">ela</font>y<font style="color: rgb(54, 54, 66);">s </font><font style="color: rgb(33, 33, 40);">in </font>ex<font style="color: rgb(33, 33, 40);">erci</font><font style="color: rgb(54, 54, 66);">si</font>ng, <font style="color: rgb(33, 33, 40);">a r</font>i<font style="color: rgb(33, 33, 40);">gh</font>t un<font style="color: rgb(33, 33, 40);">d</font><font style="color: rgb(54, 54, 66);">e</font>r this Agreement, that failure or delay will not affect <font style="color: rgb(33, 33, 40);">i</font>t<font style="color: rgb(33, 33, 40);">s r</font><font style="color: rgb(54, 54, 66);">ig</font>ht t<font style="color: rgb(33, 33, 40);">o </font><font style="color: rgb(54, 54, 66);">e</font>n<font style="color: rgb(33, 33, 40);">fo</font>rce
                <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">ha</font><font style="color: rgb(54, 54, 66);">t </font>obli<font style="color: rgb(33, 33, 40);">ga</font>ti<font style="color: rgb(33, 33, 40);">on </font>or






                constitute a waiver of that right. Any waiver o<font style="color: rgb(33, 33, 40);">f a</font>ny p<font style="color: rgb(33, 33, 40);">rov</font><font style="color: rgb(54, 54, 66);">is</font>ion o<font style="color: rgb(33, 33, 40);">f </font>this






                Agre<font style="color: rgb(54, 54, 66);">e</font>m<font style="color: rgb(54, 54, 66);">e</font>n<font style="color: rgb(33, 33, 40);">t </font>will not, unless expressly stated to the contra<font style="color: rgb(33, 33, 40);">ry</font><font style="color: rgb(54, 54, 66);">, c</font><font style="color: rgb(33, 33, 40);">o</font>nstitu<font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">e </font><font style="color: rgb(54, 54, 66);">a </font>wa<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">v</font>e<font style="color: rgb(33, 33, 40);">r </font>of that p<font style="color: rgb(33, 33, 40);">rov</font>ision on a future occasion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z40f958c4ddb4418ba200e049168f288d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">No agency: </font>Nothing in t<font style="color: rgb(33, 33, 40);">h</font><font style="color: rgb(54, 54, 66);">i</font>s <font style="color: rgb(54, 54, 66);">A</font><font style="color: rgb(33, 33, 40);">g</font><font style="color: rgb(54, 54, 66);">r</font>eem<font style="color: rgb(54, 54, 66);">en</font>t cre<font style="color: rgb(33, 33, 40);">a</font>t<font style="color: rgb(54, 54, 66);">e</font>s, <font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">m</font>plies or <font style="color: rgb(33, 33, 40);">ev</font>idenc<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">s </font><font style="color: rgb(33, 33, 40);">a</font><font style="color: rgb(54, 54, 66);">n</font>y partnership or joint venture between <font style="color: rgb(54, 54, 66);">t</font>he <font style="color: rgb(54, 54, 66);">p</font>artie<font style="color: rgb(33, 33, 40);">s</font>, <font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 40);">r </font>the relationsh<font style="color: rgb(33, 33, 40);">ip b</font>et ween <font style="color: rgb(33, 33, 40);">th</font>em <font style="color: rgb(33, 33, 40);">of </font>principal and agent. Neither Party has a<font style="color: rgb(33, 33, 40);">ny </font>authority to make any <font style="color: rgb(33, 33, 40);">repres</font>entati<font style="color: rgb(33, 33, 40);">o</font>n <font style="color: rgb(33, 33, 40);">o</font><font style="color: rgb(54, 54, 66);">r </font>commitment<font style="color: rgb(33, 33, 40);">, </font>or to incur any liability, <font style="color: rgb(33, 33, 40);">o</font>n behalf of <font style="color: rgb(33, 33, 40);">t</font>h<font style="color: rgb(54, 54, 66);">e </font>other<font style="color: rgb(33, 33, 40);">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za01f857303c34ae1ae332473f4e73856" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Entire agreement: </font><font style="color: #212128;">T</font>his <font style="color: rgb(33, 33, 40);">Ag</font><font style="color: rgb(54, 54, 66);">re</font>eme<font style="color: rgb(33, 33, 40);">n</font>t
                <font style="color: rgb(33, 33, 40);">(</font>incorpo<font style="color: rgb(54, 54, 66);">r</font><font style="color: rgb(33, 33, 40);">at</font><font style="color: rgb(54, 54, 66);">in</font>g all <font style="color: rgb(54, 54, 66);">Sc</font>h<font style="color: rgb(33, 33, 40);">e</font>dules and Exhibits) constitutes the <font style="color: rgb(33, 33, 40);">e</font>n<font style="color: rgb(33, 33, 40);">t</font><font style="color: rgb(54, 54, 66);">ir</font><font style="color: rgb(33, 33, 40);">e </font>agre<font style="color: rgb(33, 33, 40);">e</font>m<font style="color: rgb(33, 33, 40);">e</font>nt b<font style="color: rgb(54, 54, 66);">e</font>tw<font style="color: rgb(33, 33, 40);">e</font>en the<font style="color: rgb(33, 33, 40);">&#160;</font>pa<font style="color: rgb(33, 33, 40);">rt</font>ies relating<font style="color: rgb(33, 33, 40);">&#160;</font>to its subject matter. Each Party ack<font style="color: rgb(33, 33, 40);">no</font><font style="color: rgb(54, 54, 66);">w</font>ledges <font style="color: rgb(33, 33, 40);">t</font><font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(33, 33, 40);">a</font>t it h<font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">s no</font>t ente<font style="color: rgb(33, 33, 40);">r</font><font style="color: rgb(54, 54, 66);">e</font>d <font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">n</font>to
                this <font style="color: rgb(33, 33, 40);">Ag</font>r<font style="color: rgb(54, 54, 66);">e</font>ement on the basis of any warranty, r<font style="color: rgb(33, 33, 40);">ep</font>resentati<font style="color: rgb(33, 33, 40);">o</font>n<font style="color: rgb(33, 33, 40);">, s</font>tate<font style="color: rgb(33, 33, 40);">ment, </font>agre<font style="color: rgb(54, 54, 66);">e</font><font style="color: rgb(33, 33, 40);">me</font>n<font style="color: rgb(33, 33, 40);">t </font>or






                u<font style="color: rgb(33, 33, 40);">nd</font>ertaking except those expressly set out in t<font style="color: rgb(33, 33, 40);">h</font><font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">s </font>A<font style="color: rgb(33, 33, 40);">g</font>ree<font style="color: rgb(33, 33, 40);">ment. </font>E<font style="color: rgb(33, 33, 40);">ach P</font>arty <font style="color: rgb(54, 54, 66);">wa</font><font style="color: rgb(33, 33, 40);">i</font>v<font style="color: rgb(33, 33, 40);">e</font><font style="color: rgb(54, 54, 66);">s </font>any cl<font style="color: rgb(54, 54, 66);">ai</font>m <font style="color: rgb(33, 33, 40);">fo</font>r breach of this Agreement, or any ri<font style="color: rgb(33, 33, 40);">g</font>ht <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">o </font>resc<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">nd </font>this






                A<font style="color: rgb(33, 33, 40);">gr</font>eement i<font style="color: rgb(33, 33, 40);">n re</font><font style="color: rgb(54, 54, 66);">s</font>pect of<font style="color: rgb(33, 33, 40);">, </font><font style="color: rgb(54, 54, 66);">an</font>y representation which is not an expres<font style="color: rgb(54, 54, 66);">s </font><font style="color: rgb(33, 33, 40);">p</font><font style="color: rgb(54, 54, 66);">rov</font><font style="color: rgb(33, 33, 40);">i</font>sion






                <font style="color: rgb(33, 33, 40);">of </font><font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">h</font>is Agreement. H<font style="color: rgb(33, 33, 40);">ow</font>ever, <font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">h</font>is <font style="color: rgb(33, 33, 40);">Section</font> 16.6 does not e<font style="color: rgb(33, 33, 40);">x</font>clude any liabil<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">t</font><font style="color: rgb(33, 33, 40);">y </font>w<font style="color: rgb(54, 54, 66);">h</font><font style="color: rgb(33, 33, 40);">i</font>ch e<font style="color: rgb(33, 33, 40);">ither </font>Party<font style="color: rgb(54, 54, 66);">&#160;</font>may have to<font style="font-weight: bold;">&#160;</font><font style="color: rgb(54, 54, 66);">t</font>he other <font style="color: rgb(33, 33, 40);">(</font><font style="color: rgb(54, 54, 66);">o</font>r
                any right which either Party may hav<font style="color: rgb(33, 33, 40);">e t</font><font style="color: rgb(54, 54, 66);">o </font>resci<font style="color: rgb(33, 33, 40);">nd </font>this A<font style="color: rgb(33, 33, 40);">gree</font>men<font style="color: rgb(33, 33, 40);">t) </font>in respect of any fraudulent misrepresentation or fr<font style="color: rgb(33, 33, 40);">au</font><font style="color: rgb(54, 54, 66);">du</font>lent <font style="color: rgb(33, 33, 40);">c</font><font style="color: rgb(54, 54, 66);">o</font>n<font style="color: rgb(33, 33, 40);">c</font><font style="color: rgb(54, 54, 66);">e</font>alm<font style="color: rgb(33, 33, 40);">en</font>t <font style="color: rgb(54, 54, 66);">p</font><font style="color: rgb(33, 33, 40);">r</font>ior t<font style="color: rgb(33, 33, 40);">o </font>the<font style="color: rgb(54, 54, 66);">&#160;</font><font style="color: rgb(33, 33, 40);">ex</font>ecut<font style="color: rgb(33, 33, 40);">i</font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 40);">n o</font>f <font style="color: rgb(33, 33, 40);">this</font> Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="za32db32ae6cb465d915a12c7b13022e7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Formalities: </font>Ea<font style="color: rgb(33, 33, 40);">c</font>h Party will take any ac<font style="color: rgb(33, 33, 40);">tio</font>n and execute any document reasonably required by th<font style="color: rgb(33, 33, 40);">e </font><font style="color: rgb(54, 54, 66);">o</font><font style="color: rgb(33, 33, 40);">ther </font>Party <font style="color: rgb(33, 33, 40);">t</font><font style="color: rgb(54, 54, 66);">o </font><font style="color: rgb(33, 33, 40);">g</font>ive effect<font style="font-style: italic;">&#160;</font>t<font style="color: rgb(33, 33, 40);">o </font>any o<font style="color: rgb(33, 33, 40);">f </font>its rights under this Agr<font style="color: rgb(33, 33, 40);">e</font>em<font style="color: rgb(33, 33, 40);">e</font>nt.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z51bf7b5cc077426090f9da8bd9722dda" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Amendme</font><font style="font-weight: bold; color: #212128;">nt</font><font style="font-weight: bold;">s: </font>No <font style="color: rgb(33, 33, 40);">v</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">r</font>i<font style="color: rgb(33, 33, 40);">at</font>ion or amendment of this Agreement (including the Schedules) w<font style="color: rgb(54, 54, 66);">i</font><font style="color: rgb(33, 33, 40);">ll </font>be






                e<font style="color: rgb(33, 33, 40);">f</font><font style="color: rgb(54, 54, 66);">f</font><font style="color: rgb(33, 33, 40);">e</font>ct<font style="color: rgb(33, 33, 40);">iv</font>e unless it is made in writing and signed by ea<font style="color: rgb(33, 33, 40);">c</font>h Party&#8217;s represe<font style="color: rgb(33, 33, 40);">nt</font><font style="color: rgb(54, 54, 66);">a</font><font style="color: rgb(33, 33, 40);">ti</font>ve.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z2bf1e181c8ad4011af87e55a0534f4d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold; color: #070707;">Thir</font><font style="font-weight: bold; color: #212128;">d p</font><font style="font-weight: bold; color: #070707;">arties: </font><font style="color: #212128;">No o</font><font style="color: #070707;">ne except a Party to this Agreement has any right to prevent the am</font><font style="color: #212128;">end</font><font style="color: #070707;">ment of </font><font style="color: #363642;">t</font><font style="color: #070707;">hi</font><font style="color: #363642;">s </font><font style="color: #070707;">Agreement or its termination, and no one except a Party to this A</font><font style="color: #363642;">g</font><font style="color: #212128;">ree</font><font style="color: #070707;">ment may enforce any benefit conferred by this Agreement,</font><font style="color: #212128;">&#160;</font><font style="color: #070707;">unless this</font><font style="color: #212128;"> Agre</font><font style="color: #070707;">ement expressly provides </font><font style="color: #212128;">otherwise</font><font style="color: #070707;">. The Immunocore Indemnified P</font><font style="color: #212128;">a</font><font style="color: #070707;">rties






                  and</font><font style="color: #363642;"> G</font><font style="color: #212128;">SK </font><font style="color: #070707;">Indemnified Parties may directly enforce the indemnities in Article 11.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z5b4ebb16e0cc40eba273e26107c311d2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Governing law: </font>This Agreement is governed by, and is to be construed in accordance with, Engli<font style="color: rgb(33, 33, 40);">s</font>h l<font style="color: rgb(33, 33, 40);">a</font>w.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table id="z6552e3c252334848a2af808bda80e1ab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Counterparts: </font>This Agreement may be <font style="color: rgb(33, 33, 40);">s</font>igned in <font style="color: rgb(33, 33, 40);">c</font>ounterparts, e<font style="color: rgb(33, 33, 40);">a</font>ch






                and every one of which shall be deemed an original, notwithstanding variations in format or file <font style="color: rgb(3, 3, 3);">designation which may result from the electronic transmission, storage and printing of copies of this
                  Agreement from separate computers or printers. Facsimile signatures and signatures transmitted via PDF shall be treated as original signatures.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">51</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36.6pt; color: #030303;"><font style="font-weight: bold; font-variant: small-caps;">In Witness Whereof</font><font style="font-weight: bold;">, </font>the Parties have executed this Agreement by their duly authorized
        representatives as of the Effective Date.</div>
      <div>&#160;</div>
      <table id="zd5396d5d2cc541c3b86b5cb534d8b2b0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="margin-right: 7.9pt; color: #030303;"><font style="font-weight: bold;">SIGNED </font>for and on behalf of </div>
              <div style="margin-right: 7.9pt; color: #030303;"><font style="font-weight: bold;">IMMUNOCORE LIMITED:</font></div>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div><font style="font-weight: bold; color: #030303;">SIGNED </font><font style="color: #030303;">for a</font><font style="color: #21232A;">nd </font><font style="color: #030303;">on beh</font><font style="color: #21232A;">alf </font><font style="color: #030303;">of </font><font style="font-weight: bold; color: #030303;"></font></div>
              <div><font style="font-weight: bold; color: #030303;">GlaxoSmithKli</font><font style="font-weight: bold; color: #21232A;">ne In</font><font style="font-weight: bold; color: #030303;">tellectual </font><font style="font-weight: bold; color: #21232A;">Pro</font><font style="font-weight: bold; color: #030303;">perty</font></div>
              <div><font style="font-weight: bold; color: #030303;"> Developme</font><font style="font-weight: bold; color: #21232A;">nt Ltd</font><font style="font-weight: bold; color: #030303;">:</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="margin-right: 7.9pt; color: rgb(3, 3, 3);">Name&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;"><font style="font-family: Times New Roman, Times, Serif;">James Noble</font></td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;"><font style="font-family: Times New Roman, Times, Serif;">Paul Williamson</font></td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="margin-right: 7.9pt; color: rgb(3, 3, 3);">Position&#160;&#160;&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;"><font style="font-family: Times New Roman, Times, Serif;">CEO</font></td>
            <td style="width: 5%; vertical-align: top;">
              <div>Position&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: Times New Roman, Times, Serif;"></font></div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;">
              <div><font style="font-family: Times New Roman, Times, Serif;">Authorized Signatory<br>
                </font></div>
              <div><font style="font-family: Times New Roman, Times, Serif;">For and on behalf of Edinburgh </font></div>
              <div><font style="font-family: Times New Roman, Times, Serif;">Pharmaceutical Industries Limited </font></div>
              <div><font style="font-family: Times New Roman, Times, Serif;">Corporate Director</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(3, 3, 3);">Signature&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;"><font style="font-family: Times New Roman, Times, Serif;">/s/ James Noble</font></td>
            <td style="width: 5%; vertical-align: top;">
              <div>Signature&#160;&#160;&#160;&#160;</div>
            </td>
            <td colspan="1" style="width: 45%; vertical-align: top;"><font style="font-family: Times New Roman, Times, Serif;">/s/ Paul Williamson</font></td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">52</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #050505; font-weight: bold;">SCHEDULE 1</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #050505; font-weight: bold;">RESEARCH PLAN FOR INTIAL TARGET PROGRAM</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #050505;">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #050505; font-weight: bold;">SCHEDULE 2</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #050505; font-weight: bold;">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #050505; font-weight: bold;">SCHEDULE 3 - IMMUNOCORE BACKGROUND PATENTS</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #070707; font-weight: bold;">Schedule 4</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #070707; font-weight: bold;">PREVENTION OF CORRUPTION - THIRD PARTY GUIDELINES</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: #070707;">The GSK Anti-Bribery and Corruption Policy (POL-GSK-007) requires compliance with</font><font style="font-weight: bold; color: #070707;">&#160;</font><font style="color: #070707;">the highest ethical standards and all anti-corruption laws applicable </font><font style="color: #2D2D38;">in </font><font style="color: #1D1D23;">th</font><font style="color: #070707;">e countries </font><font style="font-weight: bold; color: #070707;">in </font><font style="color: #070707;">which GSK (whether through a Third Party or otherwise) conducts bus</font><font style="color: #2D2D38;">iness. </font><font style="color: #070707;">POL- GSK-00 </font><font style="color: #1D1D23;">7 </font><font style="color: #2D2D38;">re</font><font style="color: #070707;">quires all GSK employees and any Third Party acting for or on beha</font><font style="color: #1D1D23;">lf </font><font style="color: #070707;">o</font><font style="color: #2D2D38;">f </font><font style="color: #1D1D23;">G</font><font style="color: #070707;">SK to ensure </font><font style="color: #1D1D23;">th</font><font style="color: #070707;">a</font><font style="color: #1D1D23;">t </font><font style="color: #070707;">all dealings with third parties, both in the private and government </font><font style="color: #2D2D38;">se</font><font style="color: #070707;">ct</font><font style="color: #1D1D23;">ors</font><font style="color: #070707;">, are carried </font><font style="color: #2D2D38;">o</font><font style="color: #070707;">u</font><font style="color: #3D3D49;">t </font><font style="color: #070707;">in compliance with all relevant laws and regulations and with the st</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">nda</font><font style="color: #2D2D38;">rd</font><font style="color: #070707;">s of integrity </font><font style="color: #1D1D23;">requi</font><font style="color: #070707;">red for
          all GSK business. GSK values integrity and transparency and h</font><font style="color: #2D2D38;">as </font><font style="color: #070707;">zero tolerance </font><font style="color: #2D2D38;">fo</font><font style="color: #070707;">r corru</font><font style="color: #3D3D49;">p</font><font style="color: #1D1D23;">t </font><font style="color: #070707;">activities of any kind, whether committed by GSK employees, </font><font style="color: #2D2D38;">o</font><font style="color: #070707;">fficers</font><font style="color: #2D2D38;">, </font><font style="color: #3D3D49;">o</font><font style="color: #1D1D23;">r </font><font style="color: #070707;">third-</font><font style="color: #1D1D23;">p</font><font style="color: #070707;">arties ac</font><font style="color: #1D1D23;">ti</font><font style="color: #070707;">n</font><font style="color: #2D2D38;">g fo</font><font style="color: #070707;">r or on behalf of the GSK.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;">Corrupt Payments </font><font style="color: #070707;">- GSK employees and any </font><font style="color: #1D1D23;">T</font><font style="color: #070707;">h</font><font style="color: #1D1D23;">ird </font><font style="color: #070707;">Party</font><font style="color: #1D1D23;">&#160;</font><font style="color: #2D2D38;">acti</font><font style="color: #070707;">ng </font><font style="color: #2D2D38;">fo</font><font style="color: #070707;">r </font><font style="color: #2D2D38;">or </font><font style="color: #070707;">on beh</font><font style="color: #2D2D38;">alf </font><font style="color: #070707;">of GSK, shall not, directly or indirectly, promise,
          authorise</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">r</font><font style="color: #1D1D23;">ati</font><font style="color: #070707;">f</font><font style="color: #2D2D38;">y </font><font style="color: #070707;">or </font><font style="color: #2D2D38;">of</font><font style="color: #070707;">f</font><font style="color: #1D1D23;">er </font><font style="color: #070707;">to m</font><font style="color: #3D3D49;">a</font><font style="color: #1D1D23;">ke </font><font style="color: #070707;">or m</font><font style="color: #2D2D38;">ak</font><font style="color: #070707;">e any &#8220;payments</font><font style="color: #1D1D23;">&#8221; </font><font style="color: #070707;">of &#8220;anything of value&#8221; (as defined in the g</font><font style="color: #1D1D23;">lo</font><font style="color: #070707;">ssa</font><font style="color: #2D2D38;">ry </font><font style="color: #070707;">sec</font><font style="color: #2D2D38;">tio</font><font style="color: #070707;">n</font><font style="color: #1D1D23;">) </font><font style="color: #070707;">to an</font><font style="color: #2D2D38;">y </font><font style="color: #070707;">i</font><font style="color: #2D2D38;">n</font><font style="color: #070707;">dividual </font><font style="color: #3D3D49;">(</font><font style="color: #1D1D23;">o</font><font style="color: #3D3D49;">r </font><font style="color: #070707;">at the request of any individual) including a &#8220;governme</font><font style="color: #1D1D23;">n</font><font style="color: #070707;">t </font><font style="color: #2D2D38;">off</font><font style="color: #070707;">icial&#8221; </font><font style="color: #1D1D23;">(as d</font><font style="color: #070707;">efin</font><font style="color: #1D1D23;">ed </font><font style="color: #070707;">i</font><font style="color: #2D2D38;">n </font><font style="color: #070707;">the g</font><font style="color: #3D3D49;">lo</font><font style="color: #070707;">s</font><font style="color: #2D2D38;">sary </font><font style="color: #070707;">section) for the improper purpose of influencing or indu</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">i</font><font style="color: #1D1D23;">ng o</font><font style="color: #070707;">r as </font><font style="color: #2D2D38;">a </font><font style="color: #070707;">r</font><font style="color: #1D1D23;">ew</font><font style="color: #070707;">ard </font><font style="color: #2D2D38;">fo</font><font style="color: #070707;">r </font><font style="color: #2D2D38;">a</font><font style="color: #070707;">ny act, o</font><font style="color: #1D1D23;">mis</font><font style="color: #070707;">sion or decision to secure an improper advantage or to </font><font style="color: #1D1D23;">i</font><font style="color: #070707;">m</font><font style="color: #1D1D23;">pro</font><font style="color: #070707;">per</font><font style="color: #1D1D23;">l</font><font style="color: #070707;">y ass</font><font style="color: #1D1D23;">i</font><font style="color: #070707;">st the </font><font style="color: #2D2D38;">co</font><font style="color: #070707;">mpa</font><font style="color: #1D1D23;">ny </font><font style="color: #3D3D49;">in </font><font style="color: #1D1D23;">o</font><font style="color: #070707;">btaining or retaining business.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;">Government Officials </font><font style="color: #070707;">- Althou</font><font style="color: #1D1D23;">g</font><font style="color: #070707;">h </font><font style="color: #1D1D23;">G</font><font style="color: #070707;">SK</font><font style="color: #1D1D23;">&#8217;s</font><font style="color: #070707;">&#160;</font><font style="color: #2D2D38;">polic</font><font style="color: #070707;">y p</font><font style="color: #1D1D23;">roh</font><font style="color: #070707;">ib</font><font style="color: #2D2D38;">its </font><font style="color: #070707;">pay</font><font style="color: #1D1D23;">m</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">nts </font><font style="color: #070707;">by GS</font><font style="color: #1D1D23;">K </font><font style="color: #2D2D38;">or </font><font style="color: #070707;">third parties acting for or on its behalf to any </font><font style="color: #3D3D49;">in</font><font style="color: #070707;">d</font><font style="color: #1D1D23;">i</font><font style="color: #3D3D49;">v</font><font style="color: #070707;">idua</font><font style="color: #2D2D38;">l, </font><font style="color: #070707;">p</font><font style="color: #1D1D23;">ri</font><font style="color: #070707;">vate or </font><font style="color: #1D1D23;">pub</font><font style="color: #070707;">lic</font><font style="color: #1D1D23;">, as </font><font style="color: #070707;">a </font><font style="color: #2D2D38;">&#8220;</font><font style="color: #070707;">quid </font><font style="color: #3D3D49;">pro </font><font style="color: #1D1D23;">qu</font><font style="color: #070707;">o&#8221; for business</font><font style="color: #2D2D38;">, </font><font style="color: #070707;">due to the existence of specific antico</font><font style="color: #1D1D23;">rrup</font><font style="color: #070707;">t</font><font style="color: #1D1D23;">i</font><font style="color: #070707;">on l</font><font style="color: #2D2D38;">aws </font><font style="color: #070707;">in the co</font><font style="color: #2D2D38;">unt</font><font style="color: #070707;">ries </font><font style="color: #3D3D49;">w</font><font style="color: #070707;">her</font><font style="color: #2D2D38;">e </font><font style="color: #070707;">we operate</font><font style="color: #1D1D23;">, </font><font style="color: #070707;">this policy is particularly applicab</font><font style="color: #2D2D38;">le </font><font style="color: #070707;">to &#8220;paym</font><font style="color: #2D2D38;">ent</font><font style="color: #070707;">s&#8221; </font><font style="color: #1D1D23;">of an</font><font style="color: #070707;">ything </font><font style="color: #3D3D49;">o</font><font style="color: #1D1D23;">f </font><font style="color: #070707;">value&#8221; (a</font><font style="color: #1D1D23;">s defi</font><font style="color: #070707;">ned in the glossary section), or at the request o</font><font style="color: #1D1D23;">f</font><font style="color: #070707;">, </font><font style="color: #2D2D38;">&#8220;g</font><font style="color: #070707;">ove</font><font style="color: #1D1D23;">rn</font><font style="color: #070707;">m</font><font style="color: #2D2D38;">e</font><font style="color: #070707;">nt off</font><font style="color: #2D2D38;">ic</font><font style="color: #070707;">ia</font><font style="color: #2D2D38;">ls</font><font style="color: #070707;">&#8221; (as d</font><font style="color: #2D2D38;">efi</font><font style="color: #070707;">n</font><font style="color: #2D2D38;">e</font><font style="color: #070707;">d in t</font><font style="color: #1D1D23;">he </font><font style="color: #070707;">glo</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">sary section).</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt;"><font style="font-weight: bold; color: #070707;">Facilitating Payment</font><font style="font-weight: bold; color: #2D2D38;">s </font><font style="color: #1D1D23;">- </font><font style="color: #2D2D38;">For </font><font style="color: #070707;">the </font><font style="color: #2D2D38;">a</font><font style="color: #070707;">v</font><font style="color: #3D3D49;">o</font><font style="color: #070707;">idan</font><font style="color: #1D1D23;">c</font><font style="color: #3D3D49;">e </font><font style="color: #070707;">o</font><font style="color: #2D2D38;">f </font><font style="color: #070707;">dou</font><font style="color: #1D1D23;">bt</font><font style="color: #3D3D49;">,
        </font><font style="color: #070707;">faci</font><font style="color: #1D1D23;">l</font><font style="color: #070707;">itatin</font><font style="color: #2D2D38;">g paym</font><font style="color: #070707;">ents (otherwise known as &#8220;greasing paymen</font><font style="color: #2D2D38;">t</font><font style="color: #070707;">s</font><font style="color: #3D3D49;">&#8221; </font><font style="color: #2D2D38;">a</font><font style="color: #070707;">nd d</font><font style="color: #1D1D23;">efine</font><font style="color: #070707;">d as </font><font style="color: #2D2D38;">pay</font><font style="color: #070707;">ments </font><font style="color: #1D1D23;">to an </font><font style="color: #070707;">indivi</font><font style="color: #1D1D23;">dua</font><font style="color: #070707;">l to secure or expedite the performance of a </font><font style="color: #1D1D23;">ro</font><font style="color: #070707;">utine gov</font><font style="color: #2D2D38;">ernm</font><font style="color: #070707;">ent </font><font style="color: #2D2D38;">ac</font><font style="color: #070707;">t </font><font style="color: #2D2D38;">ion </font><font style="color: #070707;">by </font><font style="color: #2D2D38;">g</font><font style="color: #070707;">o</font><font style="color: #3D3D49;">v</font><font style="color: #070707;">ernment </font><font style="color: #1D1D23;">o</font><font style="color: #070707;">fficials) are no exception to the general rule and </font><font style="color: #1D1D23;">t</font><font style="color: #070707;">h</font><font style="color: #2D2D38;">erefo</font><font style="color: #070707;">re p</font><font style="color: #2D2D38;">ro</font><font style="color: #070707;">hi</font><font style="color: #2D2D38;">b</font><font style="color: #070707;">ited</font><font style="color: #3D3D49;">.</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;"><font style="color: #070707;">GLOS</font><font style="color: #2D2D38;">S</font><font style="color: #070707;">ARY</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: #1D1D23;">T</font><font style="color: #070707;">he ter</font><font style="color: #1D1D23;">ms </font><font style="color: #3D3D49;">de </font><font style="color: #070707;">fined






        </font><font style="color: #2D2D38;">here </font><font style="color: #070707;">in sh</font><font style="color: #2D2D38;">ould </font><font style="color: #070707;">be con</font><font style="color: #2D2D38;">stru</font><font style="color: #070707;">ed






          b</font><font style="color: #1D1D23;">roadly t</font><font style="color: #070707;">o give effect to the letter and spirit of the ABAC </font><font style="color: #1D1D23;">Pol </font><font style="color: #070707;">icy. GS</font><font style="color: #1D1D23;">K </font><font style="color: #070707;">is com</font><font style="color: #1D1D23;">m</font><font style="color: #070707;">itted </font><font style="color: #2D2D38;">to </font><font style="color: #1D1D23;">the</font><font style="color: #070707;"> hig</font><font style="color: #1D1D23;">he</font><font style="color: #070707;">s</font><font style="color: #2D2D38;">t </font><font style="color: #1D1D23;">e</font><font style="color: #070707;">thical standards of
          business dealings and any acts that create the </font><font style="color: #3D3D49;">a</font><font style="color: #070707;">ppearance of promisin</font><font style="color: #2D2D38;">g, </font><font style="color: #070707;">offering, giving or
          authorizing payments prohibited by thi</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">poli</font><font style="color: #1D1D23;">cy w</font><font style="color: #070707;">i</font><font style="color: #2D2D38;">ll </font><font style="color: #1D1D23;">n</font><font style="color: #070707;">ot b</font><font style="color: #1D1D23;">e to</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">rated.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt;"><font style="font-weight: bold; color: #070707;">Anything of Valu</font><font style="font-weight: bold; color: #2D2D38;">e: </font><font style="color: #070707;">th</font><font style="color: #1D1D23;">is </font><font style="color: #070707;">ter</font><font style="color: #2D2D38;">m </font><font style="color: #3D3D49;">in</font><font style="color: #1D1D23;">cl</font><font style="color: #070707;">udes cash or cash equivalents, gifts,
          services, employment offers, loans, tra</font><font style="color: #2D2D38;">v</font><font style="color: #070707;">el expen</font><font style="color: #2D2D38;">se</font><font style="color: #070707;">s</font><font style="color: #1D1D23;">, e</font><font style="color: #070707;">ntertainment, political contributions, charitable donations</font><font style="color: #2D2D38;">, </font><font style="color: #070707;">subsidies, per </font><font style="color: #1D1D23;">diem </font><font style="color: #070707;">payments, sponsorships, honoraria or provision of any other asset, even if nominal in v</font><font style="color: #1D1D23;">alue</font><font style="color: #070707;">.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;">Payments</font><font style="font-weight: bold; color: #2D2D38;">: </font><font style="color: #070707;">this term </font><font style="color: #3D3D49;">r</font><font style="color: #070707;">e</font><font style="color: #2D2D38;">fe</font><font style="color: #070707;">rs to and includes any direct or indirect offers to pay, promises to pay, auth</font><font style="color: #2D2D38;">oriza</font><font style="color: #070707;">tions of o</font><font style="color: #2D2D38;">r </font><font style="color: #070707;">payments of anything of value.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;">Govern</font><font style="font-weight: bold; color: #1D1D23;">me</font><font style="font-weight: bold; color: #070707;">nt Official </font><font style="color: #070707;">shall mean:</font></div>
      <div>&#160;</div>
      <table id="zaedf3fc39a2c4ba4b656a40005bb5968" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Any officer or employee of a government or </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">ny department, agency or instrument of a government;</font></div>
            </td>
          </tr>

      </table>
      <table id="z5da7b66a5040445c90cf6f90c4e2796b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Any person </font><font style="color: #1D1D23;">ac</font><font style="color: #070707;">ting in an offi</font><font style="color: #1D1D23;">c</font><font style="color: #070707;">i</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">l ca</font><font style="color: #1D1D23;">pac</font><font style="color: #070707;">ity for or on behalf </font><font style="color: #1D1D23;">o</font><font style="color: #070707;">f a </font><font style="color: #1D1D23;">g</font><font style="color: #070707;">ov</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">rnment or </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">ny
                  department, agency, or in</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">trument of a government;</font></div>
            </td>
          </tr>

      </table>
      <table id="z6eab0bf21b7a46b6a0b4344a88009a8f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #050505;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">Any officer or employee of a company or business owned in whole or part by a government;</div>
            </td>
          </tr>

      </table>
      <table id="z80507e0534af40e6a97a8c5b1f17d382" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #050505;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">Any officer or employee of a public international organization such as the World</div>
            </td>
          </tr>

      </table>
      <table id="z082c0ec78aa94b85b5802e603d9f8afd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">Bank or United Nations;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z715ee7b49c3e47b792c53d10b87a2eec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #050505;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #050505;">Any officer or employee of a political party or a</font><font style="color: #212128;">ny pe</font><font style="color: #050505;">rson acting in an official capacity on behalf of a political party; and/or</font></div>
            </td>
          </tr>

      </table>
      <table id="zb378febf5ebf426aa72ab0dd83c84f48" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #050505;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">Any candidate for political office.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #070708; font-weight: bold;">Schedule 5</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #070708; font-weight: bold;">R&amp;D POLICY PRINCIPLES</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070708;"><u>A.</u></font><u>&#160;&#160; </u><font style="font-weight: bold; color: rgb(7, 7, 8);"><u>Ethical Conduct Requirements</u> Ethical Conduct</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #070708;">The Parties are committed to the highest standards of c</font><font style="color: #212128;">ondu</font><font style="color: #070708;">ct in all aspects </font><font style="color: #363842;">o</font><font style="color: #070708;">f t</font><font style="color: #212128;">h</font><font style="color: #070708;">eir respective businesses and to conduct their business with honesty </font><font style="color: #212128;">an</font><font style="color: #070708;">d integrity, and i</font><font style="color: #212128;">n co</font><font style="color: #070708;">mpliance with all applicable legal and regulatory requirements.</font></div>
      <div>&#160;</div>
      <table id="z9c6eacbda3ea449ab63e335fe3095528" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">Always act with integrity and </font><font style="color: #070707;">honesty and protect the Parties&#8217; public image and reputation in relationships with customers, competitors, suppliers, business partners and
                  staff</font></div>
            </td>
          </tr>

      </table>
      <table id="z65f156ab50bc45409e31e779aa209f9f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Promptly raise any concerns about possible unethical or illegal conduct</div>
            </td>
          </tr>

      </table>
      <table id="zd6f45c3be4444ec5b7334609a3505c70" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Be free from actual or potential conflicts of interest that might influence, or appear to influence their judgment or actions when performing duties on behalf of the Parties</div>
            </td>
          </tr>

      </table>
      <table id="z3397169a8ae74e47811c7614b25522eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The Parties&#8217; reputation and the respect of those who deal with the Parties must not be put at risk by acceptance of any entertainment, gifts or favors intended or perceived by others to influence their
                business judgment</div>
            </td>
          </tr>

      </table>
      <table id="z826006be605a41b290e3e2e3599025fb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Communications with external audiences, i.e., Investors and the Media, should be managed through appointed company spokespersons to minimize risk to the Parties&#8217; reputation</div>
            </td>
          </tr>

      </table>
      <table id="z492df11f6165407da4fc971ec8e80b03" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070708;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Provide accurate and reliable information in records submitted, safeguard the Company&#8217;s confidential information, and respect the confidential</font><font style="color: #212128;">&#160;</font><font style="color: #070708;">information of other parties with wh</font><font style="color: #363842;">o</font><font style="color: #070708;">m </font><font style="color: #212128;">the</font><font style="color: #363842;">&#160;</font><font style="color: #070708;">Com</font><font style="color: #363842;">p</font><font style="color: #212128;">an</font><font style="color: #070708;">y do</font><font style="color: #212128;">e</font><font style="color: #363842;">s </font><font style="color: #070708;">b</font><font style="color: #212128;">u</font><font style="color: #070708;">sines</font><font style="color: #212128;">s o</font><font style="color: #070708;">r com pet </font><font style="color: #363842;">es</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070708;">Management of H</font><font style="color: #363842;">u</font><font style="color: #070708;">m</font><font style="color: #212128;">a</font><font style="color: #070708;">n
          S</font><font style="color: #212128;">af</font><font style="color: #070708;">et</font><font style="color: #212128;">y </font><font style="color: #070708;">Info</font><font style="color: #212128;">r</font><font style="color: #070708;">mation</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.15pt;"><font style="color: #070708;">The safeguar</font><font style="color: #212128;">d</font><font style="color: #363842;">i</font><font style="color: #212128;">n</font><font style="color: #363842;">g
          of </font><font style="color: #070708;">hum</font><font style="color: #363842;">a</font><font style="color: #070708;">n </font><font style="color: #363842;">s</font><font style="color: #070708;">ub</font><font style="color: #212128;">j</font><font style="color: #070708;">e</font><font style="color: #363842;">c</font><font style="color: #212128;">t</font><font style="color: #363842;">s </font><font style="color: #212128;">participating </font><font style="color: #070708;">in clin</font><font style="color: #363842;">ic</font><font style="color: #212128;">a</font><font style="color: #070708;">l </font><font style="color: #212128;">tr</font><font style="color: #070708;">ials and patients who use d</font><font style="color: #212128;">e</font><font style="color: #070708;">v ic</font><font style="color: #212128;">es </font><font style="color: #070708;">or take inv</font><font style="color: #212128;">e</font><font style="color: #363842;">s</font><font style="color: #070708;">tig</font><font style="color: #212128;">a</font><font style="color: #363842;">t</font><font style="color: #070708;">ional </font><font style="color: #212128;">or li</font><font style="color: #070708;">cen</font><font style="color: #212128;">s</font><font style="color: #363842;">e</font><font style="color: #212128;">d m</font><font style="color: #070708;">edicinal pr</font><font style="color: #212128;">o</font><font style="color: #070708;">ducts, </font><font style="color: #212128;">c</font><font style="color: #070708;">e</font><font style="color: #212128;">rta</font><font style="color: #070708;">in consumer health</font><font style="color: #212128;">c</font><font style="color: #070708;">are products, vaccine</font><font style="color: #212128;">s, o</font><font style="color: #070708;">r b</font><font style="color: #212128;">i</font><font style="color: #363842;">o</font><font style="color: #070708;">logic</font><font style="color: #212128;">al pr</font><font style="color: #070708;">oduc</font><font style="color: #212128;">ts (</font><font style="color: #070708;">the fo</font><font style="color: #212128;">r</font><font style="color: #363842;">eg</font><font style="color: #212128;">o</font><font style="color: #070708;">in</font><font style="color: #212128;">g </font><font style="color: #070708;">collect</font><font style="color: #212128;">i</font><font style="color: #070708;">vely referred to as the &#8220;Products</font><font style="color: #212128;">&#8221;</font><font style="color: #070708;">) is of paramo</font><font style="color: #212128;">u</font><font style="color: #070708;">n</font><font style="color: #212128;">t im</font><font style="color: #070708;">port</font><font style="color: #212128;">a</font><font style="color: #363842;">n</font><font style="color: #212128;">ce.</font><font style="color: #363842;">&#160;</font><font style="color: #070708;">Products</font><font style="color: #363842;">&#160;</font><font style="color: #070708;">would </font><font style="color: #212128;">al</font><font style="color: #363842;">s</font><font style="color: #212128;">o </font><font style="color: #070708;">inclu</font><font style="color: #212128;">de </font><font style="color: #363842;">b</font><font style="color: #070708;">lin</font><font style="color: #212128;">d</font><font style="color: #070708;">ed, placebo</font><font style="color: #212128;">, </font><font style="color: #070708;">or control agents used in clinical stu</font><font style="color: #212128;">d</font><font style="color: #363842;">i</font><font style="color: #212128;">e</font><font style="color: #070708;">s. Therefore</font><font style="color: #212128;">, </font><font style="color: #070708;">th</font><font style="color: #212128;">e </font><font style="color: #070708;">Parties </font><font style="color: #212128;">re</font><font style="color: #070708;">quire </font><font style="color: #212128;">a f</font><font style="color: #070708;">r</font><font style="color: #212128;">am</font><font style="color: #070708;">ework for management of Human Safety Information. The framew</font><font style="color: #212128;">ork </font><font style="color: #070708;">includ</font><font style="color: #212128;">e</font><font style="color: #070708;">s, but is not li</font><font style="color: #212128;">m</font><font style="color: #363842;">i</font><font style="color: #212128;">t</font><font style="color: #070708;">ed to:</font></div>
      <div>&#160;</div>
      <table id="zb1d2eca2bd4045fb8240baafa4040df8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">Safety reviews </font><font style="color: #363842;">o</font><font style="color: #070708;">f </font><font style="color: #363842;">Products</font><font style="color: #212128;">&#160;</font><font style="color: #070708;">t</font><font style="color: #212128;">o </font><font style="color: #070707;">evaluate emergent safety data</font></div>
            </td>
          </tr>

      </table>
      <table id="zebb31903d902451fbfc74585cf14af7a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Creation of appropriate committees and safety departments to proactively address human safety throughout Product development</div>
            </td>
          </tr>

      </table>
      <table id="zbb27b4df423940309093b6c4eb05c441" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070708;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Reporting of Human Safety Information to safety departments in a timely fashion. This includes any information relating to human health and</font><font style="color: #212128;">/ </font><font style="color: #070708;">or wellbeing arising following expo</font><font style="color: #212128;">s</font><font style="color: #363842;">u</font><font style="color: #212128;">r</font><font style="color: #070708;">e of hum</font><font style="color: #363842;">a</font><font style="color: #212128;">ns </font><font style="color: #070708;">to product</font><font style="color: #212128;">s </font><font style="color: #070708;">including reports of drug abuse or overdo</font><font style="color: #212128;">s</font><font style="color: #070708;">e, reports of dr</font><font style="color: #212128;">ug in</font><font style="color: #070708;">t</font><font style="color: #212128;">e</font><font style="color: #070708;">ra</font><font style="color: #212128;">c</font><font style="color: #070708;">ti</font><font style="color: #212128;">o</font><font style="color: #070708;">n</font><font style="color: #363842;">, </font><font style="color: #212128;">o</font><font style="color: #363842;">r </font><font style="color: #070708;">inf</font><font style="color: #212128;">o</font><font style="color: #070708;">rmati</font><font style="color: #212128;">o</font><font style="color: #070708;">n re</font><font style="color: #212128;">ce</font><font style="color: #070708;">iv</font><font style="color: #212128;">e</font><font style="color: #070708;">d a</font><font style="color: #212128;">s </font><font style="color: #070708;">part </font><font style="color: #212128;">o</font><font style="color: #070708;">f produ</font><font style="color: #212128;">c</font><font style="color: #070708;">t complaint</font><font style="color: #212128;">s</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070708;">Care a</font><font style="color: #212128;">nd </font><font style="color: #070708;">Ethical Treatment of Animals in Research</font></div>
      <div>&#160;</div>
      <table id="z0c00bbe84e7847ad98274a4a6691636b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070708;">Animals should be used in research only when required by regulatory authorities or where there are n</font><font style="color: #212128;">o </font><font style="color: #070708;">alternative</font><font style="color: #212128;">s </font><font style="color: #070708;">through adherence to </font><font style="color: #070707;">the &#8220;3R&#8221; Principles--reducing the number of animals used, replacing animals with non-animal methods whenever
                  possible and refining the research techniques used. In addition, the Parties include two more R&#8217;s: Responsibility and Respect for animals involved in animal research.</font></div>
            </td>
          </tr>

      </table>
      <table id="z8d84fee79e2e4031890ef7f8e0ab1110" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The Parties believe in using the highest standards for the humane care and treatment of all animals used in research, development and testing, including adherence to the principles (listed below), and all
                applicable legal and regulatory requirements, with a default to which ever is more stringent.</div>
            </td>
          </tr>

      </table>
      <table id="zf4c6662ecbce4a10934f69efa817d0e9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Access to species appropriate food and water</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z14d739bc149b48cf92b97f7ead0ec7a8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Access to species specific housing, including speci</font><font style="color: #1D1D23;">e</font><font style="color: #31333D;">s </font><font style="color: #1D1D23;">ap</font><font style="color: #070707;">propriate






                  te</font><font style="color: #1D1D23;">mpe</font><font style="color: #070707;">rature and humidity levels</font></div>
            </td>
          </tr>

      </table>
      <table id="z31105dbfe3fe44e182667d86c2206519" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Access to humane care and a program of veterinary care</div>
            </td>
          </tr>

      </table>
      <table id="z9816aa65c3a1459b84fa5e0bd95fb1bb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Animal housing that minimizes the development of abnormal behaviors and allows for normal species specific behavior,</div>
            </td>
          </tr>

      </table>
      <table id="z2c21e92a934b4c6bad5ce0af6e273173" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Adherence to principles of replacement, reduction and refinement in the design of <font style="font-style: italic;">in vivo</font> studies</div>
            </td>
          </tr>

      </table>
      <table id="za61194b7eabe4fcfb9257ccffd265d4b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Study design reviewed by institutional ethical review panel</div>
            </td>
          </tr>

      </table>
      <table id="z43d347e433d34fcbad2b4d781c3ffb3a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Commitment to minimizing pain and distress during in vivo studies</div>
            </td>
          </tr>

      </table>
      <table id="z0e1582e9603744beafb192dffea7b884" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Work performed by appropriately trained staff</div>
            </td>
          </tr>

      </table>
      <table id="z74d477708bce4dc0ad72849a0810327b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">No Great Apes should be used for </font><font style="color: #1D1D23;">r</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">s</font><font style="color: #31333D;">e</font><font style="color: #070707;">arch</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;"><u>B.</u></font><u>&#160;&#160; </u><font style="font-weight: bold;"><font style="color: rgb(7, 7, 7);"><u>Requirements for Engaging E</u></font><font style="color: rgb(49, 51, 61);"><u>x</u></font><font style="color: rgb(7, 7, 7);"><u>te</u></font><font style="color: rgb(29, 29, 35);"><u>rn</u></font><font style="color: rgb(7, 7, 7);"><u>al Exp</u></font><font style="color: rgb(29, 29, 35);"><u>e</u></font><font style="color: rgb(49, 51, 61);"><u>rts </u></font><font style="color: rgb(29, 29, 35);"><u>and </u></font><font style="color: rgb(7, 7, 7);"><u>Health</u></font><font style="color: rgb(29, 29, 35);"><u>c</u></font><font style="color: rgb(49, 51, 61);"><u>a</u></font><font style="color: rgb(7, 7, 7);"><u>re </u></font><font style="color: rgb(29, 29, 35);"><u>P</u></font><font style="color: rgb(7, 7, 7);"><u>rofe</u></font><font style="color: rgb(29, 29, 35);"><u>ssi</u></font><font style="color: rgb(7, 7, 7);"><u>onals</u></font></font></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">Use of External Experts withi</font><font style="color: #1D1D23;">n </font><font style="color: #070707;">R&amp;</font><font style="color: #1D1D23;">D</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: #070707;">The Parties believe that the </font><font style="color: #1D1D23;">e</font><font style="color: #070707;">ngagemen</font><font style="color: #31333D;">t </font><font style="color: #070707;">of ext</font><font style="color: #1D1D23;">ern</font><font style="color: #070707;">al </font><font style="color: #1D1D23;">e</font><font style="color: #070707;">xperts in R</font><font style="color: #1D1D23;">&amp;</font><font style="color: #070707;">D sh</font><font style="color: #31333D;">o</font><font style="color: #070707;">u</font><font style="color: #31333D;">l</font><font style="color: #1D1D23;">d </font><font style="color: #070707;">b</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">done in accordance with the follow</font><font style="color: #31333D;">in</font><font style="color: #1D1D23;">g p</font><font style="color: #070707;">rincipl</font><font style="color: #31333D;">e</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">:</font></div>
      <div>&#160;</div>
      <table id="z79173b9a83b04d3691e086c81e8bf8b1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">There must be </font><font style="color: #31333D;">a </font><font style="color: #070707;">l</font><font style="color: #1D1D23;">egit</font><font style="color: #070707;">imate need for the services of the
                  expert that cannot be fulfilled in-house, and the minimum number of experts needed should be used</font></div>
            </td>
          </tr>

      </table>
      <table id="z6295fb12eb604e49b4f381c672ba928d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Selection of experts should be based solely on the expert&#8217;s qualifications and expertise in the subject matter for which such expert is retained</div>
            </td>
          </tr>

      </table>
      <table id="zad28798b299b47748695266a7a368975" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The expert&#8217;s services must be documented in a written signed agreement</div>
            </td>
          </tr>

      </table>
      <table id="ze8aa83923f42444b9929cecdf6428dec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Compensation must be based on fair market value for the services provided</div>
            </td>
          </tr>

      </table>
      <table id="z0359fdda2448407fbeba721293ac9cf1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Reimbursement or pre-payment for costs associated with travel, lodging, meals and hospitality (i.e. refreshments, background music at meetings) for an expert are acceptable if permitted by all law for the
                location in which the services are rendered and are modest in value</div>
            </td>
          </tr>

      </table>
      <table id="zcd1e95c6a40740308e63bc71bd9bfce5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Experts shall not receive any gifts of any value, especially where the expert is also a healthcare professional</div>
            </td>
          </tr>

      </table>
      <table id="z78d4905b9cb14d638481360cc61e2c34" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Gift includes anything of value, regardless of amount, given to show friendship, appreciation, or support, including meals, entertainment or recreational activities (excludes f</font><font style="color: #31333D;">a</font><font style="color: #070707;">ir </font><font style="color: #1D1D23;">m</font><font style="color: #070707;">arket </font><font style="color: #31333D;">v</font><font style="color: #1D1D23;">a</font><font style="color: #070707;">l</font><font style="color: #1D1D23;">u</font><font style="color: #31333D;">e </font><font style="color: #070707;">for services rendered).</font></div>
            </td>
          </tr>

      </table>
      <table id="zd974a26f8b7b4c128da4a9816eac9062" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Health</font><font style="color: #1D1D23;">c</font><font style="color: #31333D;">ar</font><font style="color: #1D1D23;">e </font><font style="color: #070707;">Professionals includes, but is not limited t</font><font style="color: #1D1D23;">o</font><font style="color: #070707;">, physicians, their allied health profes</font><font style="color: #31333D;">sio</font><font style="color: #1D1D23;">n</font><font style="color: #31333D;">a</font><font style="color: #070707;">ls, an</font><font style="color: #1D1D23;">d m</font><font style="color: #31333D;">e</font><font style="color: #070707;">dical office staff. Thi</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">term also applie</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">to pharmaci</font><font style="color: #1D1D23;">s</font><font style="color: #070707;">ts and empl</font><font style="color: #1D1D23;">o</font><font style="color: #31333D;">y</font><font style="color: #1D1D23;">e</font><font style="color: #070707;">e</font><font style="color: #1D1D23;">s </font><font style="color: #070707;">of ph</font><font style="color: #31333D;">ar</font><font style="color: #1D1D23;">m</font><font style="color: #31333D;">a</font><font style="color: #070707;">cy benefit managers.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="font-weight: bold;"><font style="font-weight: bold; color: #070707;"><u>C.</u></font><u>&#160;&#160; </u><font style="font-weight: bold;"><font style="color: rgb(7, 7, 7);"><u>Req</u></font><font style="color: rgb(29, 29, 35);"><u>uire</u></font><font style="color: rgb(7, 7, 7);"><u>ments for Funding for Charitable Donations and External Science/Medical</u></font></font><u> </u><font style="color: #070707;"><u>Pro</u></font><font style="color: #1D1D23;"><u>g</u></font><font style="color: #070707;"><u>ra</u></font><font style="color: #1D1D23;"><u>ms</u></font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #070707; font-weight: bold;">Charitable Donations</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.5pt;"><font style="color: #1D1D23;">C</font><font style="color: #070707;">haritable donations to an eligible Health-Related Organization are allowed.&#160; </font><font style="color: #1D1D23;">C</font><font style="color: #070707;">haritable don </font><font style="color: #1D1D23;">a</font><font style="color: #070707;">t ions of either funds or in</font><font style="color: #1D1D23;">-</font><font style="color: #070707;">kind suppo</font><font style="color: #1D1D23;">r</font><font style="color: #070707;">t are permitted if they are for the purpose of advancing the general mission of an eligible, health-related recipient organization and if they are not tied or directed to a specific
          event or program.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #070707;">To be considered eligible for a donation, the health-related organization must meet all of the following:</div>
      <div>&#160;</div>
      <table id="z6ac56ba5041d4d96b97baae02128a0fc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Non-profit organization</div>
            </td>
          </tr>

      </table>
      <table id="z64f864d3ef7747f2aac9f1af75a04503" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The organization&#8217;s principle mission involves advancing science, medicine, or public health (collectively, a &#8220;health-related&#8221; mission)</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="zcf17b5baac7e4d62867248253c884b81" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The organization does not prescribe, purchase or recommend the Parties products, unless the request for a charitable donation for such an organization is for a widely publicized fund-raising event or campaign
                in support of the health - related mission of the organization</div>
            </td>
          </tr>

      </table>
      <table id="z4fab5f0b3fe44c1dbaf96c0d026dedaf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The organization, as well as its management and leadership, are independent of the control of the Parties or undue influence of any of the Parties&#8217; employees or agents</div>
            </td>
          </tr>

      </table>
      <table id="z1ab92805f80e4d9ba07baf9c0c83ac64" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Even if the health-related organization is eligible to receive a charitable donation, the donation may not be provided if a donation is intended:</div>
            </td>
          </tr>

      </table>
      <table id="z5f6741ac63d2465c8e8500ff709ac25c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">As a means of rewarding the prescribing, recommending, or use of the Parties products or services, including the influencing of formulary inclusion or placement</div>
            </td>
          </tr>

      </table>
      <table id="z3f84b5ca239d4fc9a5964f3dcd3f0c2b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">As a means of promoting the use of the Parties products or services. Return on investment (ROI) analyses are not permitted</div>
            </td>
          </tr>

      </table>
      <table id="z72bdca9701854f99a5d6840f014930b8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">As a means of supporting political causes or candidates</div>
            </td>
          </tr>

      </table>
      <table id="z86bff269c2e2448dab8b77aba29f2a13" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">As a means of supporting</font><font style="color: #1C1C21;">&#160;</font><font style="color: #070707;">an</font><font style="color: #2F2F3B;">y </font><font style="color: #070707;">org</font><font style="color: #1C1C21;">an</font><font style="color: #2F2F3B;">izat</font><font style="color: #070707;">ion </font><font style="color: #1C1C21;">o</font><font style="color: #2F2F3B;">r activity</font><font style="color: #1C1C21;"> wi</font><font style="color: #070707;">thout a </font><font style="color: #1C1C21;">di</font><font style="color: #070707;">rect and bona fide scientific, medical, or publi</font><font style="color: #1C1C21;">c h</font><font style="color: #070707;">ealth






                </font><font style="color: #1C1C21;">p</font><font style="color: #2F2F3B;">u</font><font style="color: #1C1C21;">r</font><font style="color: #070707;">pos</font><font style="color: #1C1C21;">e</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">General Requirements for US In</font><font style="color: #1C1C21;">de</font><font style="color: #2F2F3B;">pe</font><font style="color: #070707;">nde</font><font style="color: #1C1C21;">nt </font><font style="color: #2F2F3B;">M</font><font style="color: #070707;">edical </font><font style="color: #2F2F3B;">E</font><font style="color: #1C1C21;">d</font><font style="color: #2F2F3B;">u</font><font style="color: #1C1C21;">c</font><font style="color: #070707;">atio</font><font style="color: #2F2F3B;">n</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.2pt;"><font style="color: #070707;">Funding for External S</font><font style="color: #1C1C21;">c</font><font style="color: #2F2F3B;">ie</font><font style="color: #070707;">nce/ M</font><font style="color: #2F2F3B;">edic </font><font style="color: #070707;">al Programs (FE</font><font style="color: #2F2F3B;">S</font><font style="color: #1C1C21;">M</font><font style="color: #2F2F3B;">P</font><font style="color: #070707;">) mean</font><font style="color: #2F2F3B;">s f</font><font style="color: #070707;">i</font><font style="color: #2F2F3B;">n</font><font style="color: #070707;">ancial support of specific activities intended </font><font style="color: #2F2F3B;">t</font><font style="color: #070707;">o further </font><font style="color: #1C1C21;">t</font><font style="color: #070707;">h</font><font style="color: #2F2F3B;">e </font><font style="color: #070707;">pro</font><font style="color: #1C1C21;">g</font><font style="color: #2F2F3B;">r</font><font style="color: #1C1C21;">es</font><font style="color: #2F2F3B;">s </font><font style="color: #070707;">of s</font><font style="color: #1C1C21;">c</font><font style="color: #2F2F3B;">i</font><font style="color: #070707;">e</font><font style="color: #2F2F3B;">n</font><font style="color: #070707;">ce, scie</font><font style="color: #2F2F3B;">nt</font><font style="color: #070707;">ific</font><font style="color: #1C1C21;">/</font><font style="color: #070707;">medical education</font><font style="color: #1C1C21;">, </font><font style="color: #070707;">and the public health, for w</font><font style="color: #2F2F3B;">h</font><font style="color: #070707;">i</font><font style="color: #1C1C21;">ch </font><font style="color: #070707;">the </font><font style="color: #2F2F3B;">P</font><font style="color: #1C1C21;">a</font><font style="color: #070707;">r</font><font style="color: #2F2F3B;">ti</font><font style="color: #070707;">es w</font><font style="color: #1C1C21;">i</font><font style="color: #2F2F3B;">ll </font><font style="color: #070707;">n</font><font style="color: #1C1C21;">o</font><font style="color: #070707;">t tak</font><font style="color: #2F2F3B;">e a</font><font style="color: #1C1C21;">ny i</font><font style="color: #070707;">ntell</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">c</font><font style="color: #2F2F3B;">tu</font><font style="color: #070707;">a</font><font style="color: #1C1C21;">l </font><font style="color: #070707;">property or other proprietary interest.</font></div>
      <div>&#160;</div>
      <table id="zec38d1d5cb414d6c9ef228a1d86f22ad" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">A re</font><font style="color: #2F2F3B;">ci</font><font style="color: #070707;">pie</font><font style="color: #1C1C21;">n</font><font style="color: #2F2F3B;">t </font><font style="color: #070707;">of F</font><font style="color: #2F2F3B;">ES</font><font style="color: #070707;">M</font><font style="color: #1C1C21;">P </font><font style="color: #070707;">must</font><font style="color: #1C1C21;"> be </font><font style="color: #070707;">reasonab</font><font style="color: #2F2F3B;">l</font><font style="color: #1C1C21;">y </font><font style="color: #070707;">qualified </font><font style="color: #2F2F3B;">t</font><font style="color: #1C1C21;">o </font><font style="color: #070707;">conduct
                  high quality educational progra</font><font style="color: #2F2F3B;">m</font><font style="color: #1C1C21;">s</font><font style="color: #070707;">, re</font><font style="color: #2F2F3B;">searc</font><font style="color: #070707;">h, or </font><font style="color: #1C1C21;">o</font><font style="color: #2F2F3B;">the</font><font style="color: #070707;">r act</font><font style="color: #2F2F3B;">ivity </font><font style="color: #1C1C21;">be</font><font style="color: #070707;">ing fun</font><font style="color: #1C1C21;">d</font><font style="color: #070707;">ed</font></div>
            </td>
          </tr>

      </table>
      <table id="z76d49977e1674619ac3e723ae060b54f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">F</font><font style="color: #2F2F3B;">E</font><font style="color: #1C1C21;">S</font><font style="color: #2F2F3B;">M</font><font style="color: #1C1C21;">P </font><font style="color: #070707;">is </font><font style="color: #2F2F3B;">n</font><font style="color: #1C1C21;">ot</font><font style="color: #070707;"> permitted if used as a means of rewarding the prescribing, recommending, or use of the Parties products or services, including the
                  influencing of formulary inclusion/ placement</font></div>
            </td>
          </tr>

      </table>
      <table id="za8fea7217e8c42039374112f1d79c507" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">A recipient of FESMP must agree to make meaningful disclosure of any financial sponsorship from the partner</div>
            </td>
          </tr>

      </table>
      <table id="z15ea7f1b8750469a8e1cea73c2289412" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">FESMP may not be &#8220;expensed&#8221; or paid with the personal funds of an employee or contractor, and then reimbursed</div>
            </td>
          </tr>

      </table>
      <table id="z31c2b13d39c34ff9b381185fbdcb239a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">FESMP is not permitted as a means of supporting political causes or candidates</div>
            </td>
          </tr>

      </table>
      <table id="zd1592d89bc43474abeb8f65ae0ffe103" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">FESMP is not permitted if used as a means of supporting any organization or activity without a direct and bona fide scientific, medical, or public health purpose</div>
            </td>
          </tr>

      </table>
      <table id="z40e66feffa9944599af042deee4674d5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">FESMP must comply with all </font><font style="color: #1C1C21;">s</font><font style="color: #070707;">ub</font><font style="color: #1C1C21;">s</font><font style="color: #070707;">tantive an</font><font style="color: #1C1C21;">d </font><font style="color: #070707;">pro</font><font style="color: #1C1C21;">ce</font><font style="color: #070707;">dural r</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">quir</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">ments </font><font style="color: #1C1C21;">es</font><font style="color: #070707;">tabli</font><font style="color: #1C1C21;">s</font><font style="color: #070707;">h</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">d by</font><font style="color: #1C1C21;"> the</font><font style="color: #2F2F3B;">&#160;</font><font style="color: #1C1C21;">la</font><font style="color: #070707;">w where the progr</font><font style="color: #1C1C21;">a</font><font style="color: #070707;">m or </font><font style="color: #1C1C21;">ac</font><font style="color: #070707;">tivity potenti</font><font style="color: #1C1C21;">a</font><font style="color: #070707;">lly
                  bein</font><font style="color: #1C1C21;">g </font><font style="color: #070707;">funded will t</font><font style="color: #1C1C21;">a</font><font style="color: #070707;">ke pl</font><font style="color: #1C1C21;">a</font><font style="color: #070707;">ce</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold;"><u>D. &#160; </u><font style="color: #2F2F3B;"><u>C</u></font><font style="color: #070707;"><u>li</u></font><font style="color: #1C1C21;"><u>n</u></font><font style="color: #2F2F3B;"><u>i</u></font><font style="color: #070707;"><u>c</u></font><font style="color: #1C1C21;"><u>a</u></font><font style="color: #070707;"><u>l Research Requirements</u></font></div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #070707; font-weight: bold;">Maintaining the Confidentiality of Protected Medical Information</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #2F2F3B;">T</font><font style="color: #070707;">he Parties r</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">spect the confidential nature of protected medical informati</font><font style="color: #1C1C21;">o</font><font style="color: #070707;">n (PMI) originating from both h</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">althy and patient volunteers involv</font><font style="color: #1C1C21;">e</font><font style="color: #070707;">d in clinical</font><font style="color: #1C1C21;">, </font><font style="color: #070707;">genetic, </font><font style="color: #1C1C21;">a</font><font style="color: #070707;">nd other research work</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #070707;">or from staff employed by the Parties. Therefore, a framework should be in place to safeguard PMI against inappropriate collection, retention</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">use and disclosure (in addition to compliance with law and regulations).</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #070707;">Safeguards include, but are not limited to:</div>
      <table id="zaf65123b6a7d483991cd162b0c053141" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Collecting PMI only for specific and lawful purposes</div>
            </td>
          </tr>

      </table>
      <table id="z9a717e6d8b5e4f89bf97ac53f33b2849" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Collecting, retaining, using, reusing, and disclosing P</font><font style="color: #1F1F26;">MI on</font><font style="color: #070707;">ly with valid </font><font style="color: #1F1F26;">c</font><font style="color: #363642;">o</font><font style="color: #070707;">nsent or as otherwise permitted by law or regulation</font></div>
            </td>
          </tr>

      </table>
      <table id="z4fcc64afffbc4dfeabcd4308d00d00ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">PMI obtained from external sources is treated as a re-use and all reuse must be consistent with the original informed consent</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z8028c5433cd44d1781f16094083586f7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Retention of PMI only for as long as business activities or scientific research requires and retention of only the minimum amount of identifying information necessary</div>
            </td>
          </tr>

      </table>
      <table id="z48ad17f39e6a406cab2f05981807afbe" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Ensuring the physical and technological security of PMI</div>
            </td>
          </tr>

      </table>
      <table id="z619db975465747c088ce5fea9f0010cf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Not using PMI in external publications</div>
            </td>
          </tr>

      </table>
      <table id="zef2a46c2c8db44159626c29bc3a9099b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Never transferring PMI from the pharmaceutical R&amp;D division to the marketing function unless permission is obtained from the in</font><font style="color: #363642;">d</font><font style="color: #1F1F26;">i</font><font style="color: #070707;">vidu</font><font style="color: #1F1F26;">a</font><font style="color: #363642;">l</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.8pt;"><font style="color: #070707;">If PMI is collected that indicates the ne</font><font style="color: #1F1F26;">ed f</font><font style="color: #363642;">o</font><font style="color: #1F1F26;">r </font><font style="color: #070707;">imm</font><font style="color: #363642;">e</font><font style="color: #1F1F26;">d</font><font style="color: #070707;">i</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">te cl</font><font style="color: #1F1F26;">i</font><font style="color: #363642;">n</font><font style="color: #070707;">ic</font><font style="color: #1F1F26;">al </font><font style="color: #070707;">interv</font><font style="color: #1F1F26;">en</font><font style="color: #070707;">t</font><font style="color: #1F1F26;">ion</font><font style="color: #070707;">, that information will be communicated to the study in</font><font style="color: #1F1F26;">ve</font><font style="color: #070707;">s</font><font style="color: #1F1F26;">t</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">g</font><font style="color: #070707;">ato</font><font style="color: #363642;">r </font><font style="color: #070707;">or p</font><font style="color: #1F1F26;">h</font><font style="color: #070707;">ysicia</font><font style="color: #1F1F26;">n </font><font style="color: #363642;">o</font><font style="color: #1F1F26;">f </font><font style="color: #070707;">rec</font><font style="color: #1F1F26;">o</font><font style="color: #363642;">r</font><font style="color: #1F1F26;">d w</font><font style="color: #070707;">h</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">re such PMI</font><font style="font-weight: bold; color: #070707;">&#160;</font><font style="color: #070707;">relates to information collected under a C</font><font style="color: #1F1F26;">lin</font><font style="color: #070707;">i</font><font style="color: #1F1F26;">c</font><font style="color: #363642;">a</font><font style="color: #070707;">l Trial. </font><font style="color: #1F1F26;">W</font><font style="color: #070707;">h</font><font style="color: #363642;">e</font><font style="color: #1F1F26;">re </font><font style="color: #070707;">such P</font><font style="color: #1F1F26;">MI rela</font><font style="color: #070707;">tes t</font><font style="color: #1F1F26;">o </font><font style="color: #070707;">Immunocore&#8217;s internal blood donors said dono</font><font style="color: #1F1F26;">r </font><font style="color: #070707;">s</font><font style="color: #1F1F26;">h</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">ll </font><font style="color: #070707;">be </font><font style="color: #1F1F26;">i</font><font style="color: #363642;">n</font><font style="color: #1F1F26;">fo</font><font style="color: #070707;">rm e</font><font style="color: #363642;">d </font><font style="color: #070707;">a</font><font style="color: #1F1F26;">n</font><font style="color: #363642;">d </font><font style="color: #1F1F26;">d</font><font style="color: #070707;">irected </font><font style="color: #1F1F26;">to </font><font style="color: #070707;">see </font><font style="color: #1F1F26;">t</font><font style="color: #363642;">h</font><font style="color: #1F1F26;">ei</font><font style="color: #363642;">r </font><font style="color: #070707;">physician in accordance with Immunocore</font><font style="color: #1F1F26;">&#8217;</font><font style="color: #070707;">s b</font><font style="color: #363642;">l</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">od </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">ollec</font><font style="color: #1F1F26;">t</font><font style="color: #070707;">i</font><font style="color: #363642;">on </font><font style="color: #070707;">polici</font><font style="color: #1F1F26;">es</font><font style="color: #070707;">.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; color: #070707;">Personally Identifiable I</font><font style="font-weight: bold; color: #1F1F26;">n</font><font style="font-weight: bold; color: #070707;">formatio</font><font style="font-weight: bold; color: #1F1F26;">n </font><font style="color: #070707;">(</font><font style="color: #1F1F26;">P</font><font style="color: #070707;">II) m</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">a</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">s informati</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">n wh</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">ch </font><font style="color: #070707;">i</font><font style="color: #1F1F26;">d</font><font style="color: #070707;">entifies a specific individual including but n</font><font style="color: #363642;">o</font><font style="color: #1F1F26;">t li</font><font style="color: #070707;">mited </font><font style="color: #1F1F26;">to</font><font style="color: #070707;">, nam</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">,</font><font style="color: #363642;"> a</font><font style="color: #1F1F26;">d</font><font style="color: #070707;">dress, </font><font style="color: #1F1F26;">an</font><font style="color: #363642;">d </font><font style="color: #070707;">national i</font><font style="color: #1F1F26;">d</font><font style="color: #363642;">e</font><font style="color: #070707;">ntification numbers (e.g. Social Security Nu</font><font style="color: #1F1F26;">m</font><font style="color: #070707;">ber)</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.25pt;"><font style="font-weight: bold; color: #070707;">Protected Medical </font><font style="font-weight: bold; color: #1F1F26;">Inf</font><font style="font-weight: bold; color: #363642;">o</font><font style="font-weight: bold; color: #070707;">rmati</font><font style="font-weight: bold; color: #1F1F26;">on </font><font style="color: #1F1F26;">(</font><font style="color: #070707;">PMI) </font><font style="color: #1F1F26;">i</font><font style="color: #363642;">s </font><font style="color: #070707;">PII that </font><font style="color: #1F1F26;">d</font><font style="color: #070707;">e</font><font style="color: #1F1F26;">sc</font><font style="color: #070707;">ribes c</font><font style="color: #1F1F26;">li</font><font style="color: #363642;">ni</font><font style="color: #1F1F26;">c</font><font style="color: #363642;">a</font><font style="color: #070707;">l and medical conditions, genetic status, tre</font><font style="color: #1F1F26;">a</font><font style="color: #363642;">t</font><font style="color: #070707;">ment of c</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">n</font><font style="color: #1F1F26;">d</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">t</font><font style="color: #070707;">ions</font><font style="color: #363642;">, </font><font style="color: #1F1F26;">h</font><font style="color: #070707;">e</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">l</font><font style="color: #070707;">th status, sexual </font><font style="color: #363642;">o</font><font style="color: #070707;">rientation, ethnic origin, etc., and includes both enc</font><font style="color: #1F1F26;">od</font><font style="color: #363642;">e</font><font style="color: #070707;">d </font><font style="color: #1F1F26;">cl</font><font style="color: #070707;">inic</font><font style="color: #1F1F26;">al </font><font style="color: #070707;">tr</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">l da</font><font style="color: #1F1F26;">t</font><font style="color: #363642;">a </font><font style="color: #1F1F26;">a</font><font style="color: #070707;">nd ov</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">r</font><font style="color: #1F1F26;">tly </font><font style="color: #070707;">i</font><font style="color: #363642;">d</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">ntifiab</font><font style="color: #1F1F26;">l</font><font style="color: #363642;">e </font><font style="color: #070707;">d</font><font style="color: #363642;">a</font><font style="color: #070707;">ta.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">Standards fo</font><font style="color: #363642;">r </font><font style="color: #1F1F26;">Colle</font><font style="color: #070707;">cti</font><font style="color: #1F1F26;">ng</font><font style="color: #070707;">, </font><font style="color: #1F1F26;">O</font><font style="color: #070707;">b</font><font style="color: #1F1F26;">t</font><font style="color: #070707;">a</font><font style="color: #1F1F26;">in</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">g and </font><font style="color: #1F1F26;">U</font><font style="color: #070707;">s</font><font style="color: #363642;">i</font><font style="color: #070707;">ng Hum</font><font style="color: #363642;">a</font><font style="color: #070707;">n </font><font style="color: #1F1F26;">B</font><font style="color: #070707;">iological Samples in Research</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt;"><font style="font-weight: bold; color: #070707;">ARTICLE </font><font style="font-weight: bold; color: #1F1F26;">1&#160; </font><font style="color: #070707;">Th</font><font style="color: #363642;">e
        </font><font style="color: #070707;">Parties</font><font style="color: #1F1F26;"> r</font><font style="color: #070707;">espe</font><font style="color: #1F1F26;">ct t</font><font style="color: #070707;">he int</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">re</font><font style="color: #1F1F26;">s</font><font style="color: #070707;">t </font><font style="color: #1F1F26;">o</font><font style="color: #070707;">f dono</font><font style="color: #363642;">r</font><font style="color: #1F1F26;">s </font><font style="color: #070707;">of human biological samples used in researc</font><font style="color: #1F1F26;">h a</font><font style="color: #363642;">nd </font><font style="color: #070707;">requ</font><font style="color: #1F1F26;">ire th</font><font style="color: #070707;">at c</font><font style="color: #363642;">e</font><font style="color: #070707;">rt</font><font style="color: #1F1F26;">ai</font><font style="color: #070707;">n stand</font><font style="color: #363642;">ar</font><font style="color: #1F1F26;">d</font><font style="color: #363642;">s </font><font style="color: #070707;">shou</font><font style="color: #1F1F26;">ld </font><font style="color: #363642;">a</font><font style="color: #070707;">pp</font><font style="color: #1F1F26;">l</font><font style="color: #070707;">y to the collection, obtaining and use of such hu</font><font style="color: #1F1F26;">ma</font><font style="color: #070707;">n biologi</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">al </font><font style="color: #1F1F26;">s</font><font style="color: #070707;">am</font><font style="color: #1F1F26;">pl</font><font style="color: #070707;">es, as </font><font style="color: #363642;">s</font><font style="color: #1F1F26;">e</font><font style="color: #363642;">t </font><font style="color: #070707;">forth b</font><font style="color: #363642;">e</font><font style="color: #070707;">lo</font><font style="color: #363642;">w.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt; color: #070707; font-weight: bold;">ARTICLE 2</div>
      <div>&#160;</div>
      <table id="zf36c0282880b40cda8e1bc2ec370dfee" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Ensure that </font><font style="color: #1F1F26;">s</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">mp</font><font style="color: #070707;">les ar</font><font style="color: #363642;">e
                </font><font style="color: #1F1F26;">co</font><font style="color: #070707;">llected with informed consent and ethics committee</font><font style="color: #1F1F26;">/</font><font style="color: #070707;">Institutiona</font><font style="color: #363642;">l </font><font style="color: #070707;">Review </font><font style="color: #1F1F26;">Board (</font><font style="color: #070707;">I RB) approval in accordan</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">e with the applicable research requireme</font><font style="color: #363642;">n</font><font style="color: #1F1F26;">t</font><font style="color: #070707;">s </font><font style="color: #1F1F26;">o</font><font style="color: #070707;">f Goo</font><font style="color: #363642;">d </font><font style="color: #070707;">C</font><font style="color: #1F1F26;">l</font><font style="color: #363642;">i</font><font style="color: #1F1F26;">n</font><font style="color: #070707;">i</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">al Pr</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">ctice (International C</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">nferenc</font><font style="color: #1F1F26;">e </font><font style="color: #070707;">on Harmonization). Addition</font><font style="color: #363642;">a</font><font style="color: #1F1F26;">l</font><font style="color: #363642;">l</font><font style="color: #1F1F26;">y</font><font style="color: #363642;">, </font><font style="color: #070707;">through informed consent, donors must be made aware that the re</font><font style="color: #1F1F26;">s</font><font style="color: #070707;">ear</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">h is bei</font><font style="color: #1F1F26;">n</font><font style="color: #363642;">g </font><font style="color: #1F1F26;">un</font><font style="color: #070707;">dertak</font><font style="color: #363642;">e</font><font style="color: #070707;">n </font><font style="color: #363642;">b</font><font style="color: #070707;">y a </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">ommercial entity and that</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">where </font><font style="color: #1F1F26;">a</font><font style="color: #070707;">pplicable</font><font style="color: #1F1F26;">, </font><font style="color: #070707;">the resear</font><font style="color: #1F1F26;">c</font><font style="color: #070707;">h invol</font><font style="color: #1F1F26;">v</font><font style="color: #363642;">e</font><font style="color: #1F1F26;">s t</font><font style="color: #070707;">he an</font><font style="color: #1F1F26;">aly</font><font style="color: #363642;">s</font><font style="color: #070707;">i</font><font style="color: #363642;">s </font><font style="color: #070707;">of DNA and </font><font style="color: #1F1F26;">/ </font><font style="color: #070707;">or medical information.</font></div>
            </td>
          </tr>

      </table>
      <table id="z96d7d8aa8c954bc8ae8c177037a10c01" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">W</font><font style="color: #1F1F26;">he</font><font style="color: #363642;">n </font><font style="color: #070707;">obtaining </font><font style="color: #1F1F26;">s</font><font style="color: #363642;">a</font><font style="color: #070707;">mpl</font><font style="color: #1F1F26;">es </font><font style="color: #070707;">from </font><font style="color: #1F1F26;">a</font><font style="color: #070707;">noth</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">r </font><font style="color: #1F1F26;">e</font><font style="color: #070707;">ntity that </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">oll</font><font style="color: #1F1F26;">ec</font><font style="color: #070707;">t</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">d th</font><font style="color: #1F1F26;">e samples </font><font style="color: #070707;">f</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">r reasons</font><font style="color: #1F1F26;"> u</font><font style="color: #363642;">nrelated</font><font style="color: #070707;"> to the Parties, </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">onfirmation th</font><font style="color: #1F1F26;">a</font><font style="color: #070707;">t the entity complied with relevant requirements for informed consent, ethics committee/IRS approval and data privacy is required</font></div>
            </td>
          </tr>

      </table>
      <table id="z5f5a9de351ff4b16b13749a065e5daab" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Human biological samples must be used only for purposes that are consistent with the consent obtained and in compliance with relevant laws and regulations</div>
            </td>
          </tr>

      </table>
      <table id="z3eccb8ffa13f4a84bd478796863d8b7c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Additional individual donor consent and ethics committee/ IRS approval should be obtained when the research use intended is inconsistent with </font><font style="color: #1F1F26;">/ </font><font style="color: #070707;">b</font><font style="color: #1F1F26;">e</font><font style="color: #070707;">yond the sc</font><font style="color: #1F1F26;">o</font><font style="color: #070707;">pe of the original consent. Additional </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">onsent </font><font style="color: #1F1F26;">s</font><font style="color: #070707;">hould also be obtained if the original </font><font style="color: #1F1F26;">c</font><font style="color: #070707;">onsent did </font><font style="color: #080808;">not include analysis of DNA (if relevant to the research proposal) or use of any associated medical information (if relevant to the research proposal).</font></div>
            </td>
          </tr>

      </table>
      <table id="z94a3df460a97444099593cf2d7b2e190" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #080808;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">In general, cell lines (e.g. Hela), derivatives (e.g. isolated proteins) and preparations of human biological materials (e.g. </font><font style="color: #070707;">sub-cellular fractions) that are well
                  established and made available for research use, do not require re- consen</font><font style="color: #080808;">t and</font><font style="color: #23232D;">/</font><font style="color: #080808;">or ethics committee/IRB approval for the
                  intended research use</font></div>
            </td>
          </tr>

      </table>
      <table id="zc605e0934cef4e87a3a09e706540f42e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #080808;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">Proposals to collect, obtain, or use human embryoni</font><font style="color: #23232D;">c </font><font style="color: #33333D;">or </font><font style="color: #23232D;">f</font><font style="color: #080808;">oetal






                  sampl</font><font style="color: #23232D;">es f</font><font style="color: #080808;">or research should be carefully reviewed and such research m</font><font style="color: #33333D;">u</font><font style="color: #080808;">st have the poten</font><font style="color: #23232D;">ti</font><font style="color: #080808;">al to benefit patients</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #080808;">Conduct and Public Disclosure of Human Subjec</font><font style="color: #33333D;">t Res</font><font style="color: #080808;">ear</font><font style="color: #33333D;">c</font><font style="color: #080808;">h</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: #080808;">The Parties carry out human subject research in ac</font><font style="color: #33333D;">c</font><font style="color: #080808;">ord</font><font style="color: #23232D;">anc</font><font style="color: #080808;">e with </font><font style="color: #33333D;">t</font><font style="color: #080808;">he </font><font style="color: #23232D;">e</font><font style="color: #080808;">thi</font><font style="color: #23232D;">ca</font><font style="color: #080808;">l pr</font><font style="color: #33333D;">in</font><font style="color: #080808;">ciples of respect for persons, beneficence, and justice. </font><font style="color: #23232D;">S</font><font style="color: #080808;">uc</font><font style="color: #33333D;">h </font><font style="color: #080808;">rese</font><font style="color: #33333D;">ar</font><font style="color: #080808;">c</font><font style="color: #33333D;">h c</font><font style="color: #080808;">on</font><font style="color: #23232D;">forms t</font><font style="color: #080808;">o high </font><font style="color: #33333D;">et</font><font style="color: #080808;">hical, medical and scientific standards. Specific principles </font><font style="color: #23232D;">fo</font><font style="color: #080808;">r </font><font style="color: #33333D;">di</font><font style="color: #080808;">f</font><font style="color: #33333D;">f</font><font style="color: #080808;">eren</font><font style="color: #33333D;">t
        </font><font style="color: #080808;">ty</font><font style="color: #33333D;">p</font><font style="color: #080808;">es of </font><font style="color: #23232D;">h</font><font style="color: #080808;">uman s</font><font style="color: #33333D;">ub</font><font style="color: #080808;">ject research are set forth below.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #080808; font-weight: bold;">All Human Subject Research</div>
      <div>&#160;</div>
      <table id="ze99700afe82b4f1e90d8888dc97ae113" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">All human subject </font><font style="color: #070707;">research</font><font style="color: #080808;"> must be </font><font style="color: #33333D;">c</font><font style="color: #080808;">on</font><font style="color: #23232D;">d</font><font style="color: #080808;">ucted in </font><font style="color: #33333D;">ac</font><font style="color: #080808;">co</font><font style="color: #23232D;">rda</font><font style="color: #080808;">nce with </font><font style="color: #23232D;">t</font><font style="color: #080808;">he </font><font style="color: #23232D;">fol</font><font style="color: #080808;">lowin</font><font style="color: #23232D;">g </font><font style="color: #080808;">principles:</font></div>
            </td>
          </tr>

      </table>
      <table id="z08a4872722924a5da85de67d39d653de" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">Human subject research is </font><font style="color: #33333D;">c</font><font style="color: #080808;">ondu</font><font style="color: #33333D;">c</font><font style="color: #080808;">t</font><font style="color: #33333D;">ed </font><font style="color: #080808;">in ac</font><font style="color: #23232D;">cor</font><font style="color: #080808;">d</font><font style="color: #33333D;">a</font><font style="color: #080808;">nce with the </font><font style="color: #33333D;">e</font><font style="color: #080808;">thical principles of respect for persons, benefic</font><font style="color: #23232D;">e</font><font style="color: #080808;">nce </font><font style="color: #070707;">and
                  justice</font></div>
            </td>
          </tr>

      </table>
      <table id="z9ef5a28a4a3243a9a34d96f6d27752eb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Human subject research always has a legitimate scientific purpose and is not designed with the objective of rewarding healthcare professionals for using, purchasing, recommending, or prescribing the Parties&#8217;
                products</div>
            </td>
          </tr>

      </table>
      <table id="z9d8b6233492045458fabeb5329d94257" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Sales/marketing/commercial staff generally does not participate in the initiation or conduct of human subject research</div>
            </td>
          </tr>

      </table>
      <table id="z7473df6d42764a72a97276168c8b0524" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Placebo controlled studies are conducted only when there are scientifically sound methodological reasons, where the risks are minimized and reasonable in relation to the knowledge gained, and when patients
                who receive placebo will not be subject to any additional risk of harm</div>
            </td>
          </tr>

      </table>
      <table id="z14f4875a454a494baafdc18c9b2d36fb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">The standard of care required by the study design is, as a minimum, consistent with local standards of care</div>
            </td>
          </tr>

      </table>
      <table id="z563f6cd9cdf841a69ea7e39efe969d40" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Human subject research should be publicly disclosed and ideally published in the searchable, peer reviewed, scientific literature</div>
            </td>
          </tr>

      </table>
      <table id="z82e43c08889d4d3a836f04a87232a43b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">In most circumstances, summary protocols and summary results of clinical studies are posted on publicly available registers and/ or in the scientific literature within appropriate timelines.</div>
            </td>
          </tr>

      </table>
      <table id="z7996de3853bf45f9ad794fad491ebeeb" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">External proposals for additional analyses of human subject research studies are assessed for scientific merit and undertaken as collaborations between in-house scientists and the proposer.</div>
            </td>
          </tr>

      </table>
      <table id="z72432cbd171648eb9f92d12ee53092b1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #080808;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">Clinical studies</font><font style="color: #080808;">&#160;</font><font style="color: #33333D;">are </font><font style="color: #080808;">never terminated for solely financial reasons.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #080808;">Interve</font><font style="color: #33333D;">nt</font><font style="color: #080808;">ional Human Subject Research</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #080808;">In a</font><font style="color: #33333D;">d</font><font style="color: #080808;">di</font><font style="color: #33333D;">t</font><font style="color: #080808;">io</font><font style="color: #23232D;">n </font><font style="color: #080808;">to the foregoing general principles applicable to all human subject research, the following principles apply to the conduct of Interventional Human Subject Research:</font></div>
      <div>&#160;</div>
      <table id="zfdaf1545ed48420f8dee2a6c5a994535" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #080808;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #080808;">Interventional human subject research is conducted in accordan</font><font style="color: #23232D;">c</font><font style="color: #080808;">e with the ethical principles of the Declaration of </font><font style="color: #070707;">Helsinki</font><font style="color: #080808;">, the principles of ICH GCP E6, ICH Ell (pediatrics)</font></div>
            </td>
          </tr>

      </table>
      <table id="z393b9c24169a4489b419da86d2d41f41" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">Interventional studies of medicinal and other products are conducted in countries where the products are expected to be sold in and suitable for the wider community of the country</div>
            </td>
          </tr>

      </table>
      <table id="z1b8e7be91add4e7dbd64b354dc470d6e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">All interventional human subject research is conducted only with the approval of Institutional Review Boards or Independent Ethics Committees</div>
            </td>
          </tr>

      </table>
      <table id="zb22f8698f7bc4ddea1c399c03d6e4890" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">When interventional human subject research is conducted in developing countries, the Parties seek agreement with key interested external parties in the country on the conduct of the research, including the
                  standard of care </font><font style="color: #1A1A1F;">p</font><font style="color: #070707;">rovided durin</font><font style="color: #2D2D36;">g th</font><font style="color: #070707;">e study, the scientific rationale for interventions,
                  including pl</font><font style="color: #2D2D36;">ace</font><font style="color: #070707;">bo, the provision </font><font style="color: #1A1A1F;">o</font><font style="color: #070707;">f healthcare for subjects after the study, and the fate
                  of any cap</font><font style="color: #2D2D36;">ac</font><font style="color: #070707;">ity </font><font style="color: #1A1A1F;">b</font><font style="color: #070707;">uilt for the c</font><font style="color: #2D2D36;">o</font><font style="color: #070707;">nd</font><font style="color: #1A1A1F;">u</font><font style="color: #070707;">ct of the study</font></div>
            </td>
          </tr>

      </table>
      <table id="z76a35ca9954a4b4faa4cdd10e4e2db89" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">All interventional human subject research req</font><font style="color: #2D2D36;">uires t</font><font style="color: #070707;">he </font><font style="color: #2D2D36;">in</font><font style="color: #070707;">formed






                </font><font style="color: #1A1A1F;">c</font><font style="color: #070707;">on</font><font style="color: #2D2D36;">se</font><font style="color: #070707;">nt of </font><font style="color: #1A1A1F;">subj</font><font style="color: #070707;">ects






                  (or their legal representative) who participate in the research</font></div>
            </td>
          </tr>

      </table>
      <table id="za98e88fde7194864900a165282526293" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">When nationally licensed medicinal products that are not the subject of the research study are required for the routine care of a patient during the conduct of the study, the Parties only fund these when they
                are not funded by the normal healthcare infrastructure and there is assurance that they or suitable alternatives will be available and funded after the study while the medical need exists</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table id="z57f4685864a243b3886fc214254c8877" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(7, 7, 7);">For diseases/conditions that continue beyond the end of an interventional study, the Parties must be assured the healthcare system is able to provide, and will take responsibility for, the continued care of
                study subjects</div>
            </td>
          </tr>

      </table>
      <table id="z243a2f6470de486a94a6e94f58f89399" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">When there is a compellin</font><font style="color: #1A1A1F;">g med</font><font style="color: #42424F;">ic</font><font style="color: #070707;">al r</font><font style="color: #2D2D36;">atio</font><font style="color: #070707;">nale </font><font style="color: #2D2D36;">for patient</font><font style="color: #070707;">s who </font><font style="color: #2D2D36;">h</font><font style="color: #070707;">ave de</font><font style="color: #2D2D36;">r</font><font style="color: #070707;">i</font><font style="color: #2D2D36;">ved </font><font style="color: #070707;">measurable medical benefit from an inv</font><font style="color: #42424F;">e</font><font style="color: #070707;">stiga</font><font style="color: #2D2D36;">t</font><font style="color: #070707;">i</font><font style="color: #2D2D36;">ona</font><font style="color: #070707;">l me</font><font style="color: #2D2D36;">dicinal </font><font style="color: #070707;">p</font><font style="color: #2D2D36;">ro</font><font style="color: #070707;">duct durin</font><font style="color: #1A1A1F;">g </font><font style="color: #070707;">an interventional study to continue to recei</font><font style="color: #2D2D36;">ve </font><font style="color: #070707;">that </font><font style="color: #2D2D36;">pr</font><font style="color: #070707;">odu</font><font style="color: #1A1A1F;">ct </font><font style="color: #070707;">after the
                  study, the Parties endeavor to provide that treatment either through additional clinical studies or through expanded access programs</font></div>
            </td>
          </tr>

      </table>
      <table id="z5cca085373314053adf19dc586de5ba6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">The Parties provi</font><font style="color: #1A1A1F;">d</font><font style="color: #070707;">e investig</font><font style="color: #1A1A1F;">ators </font><font style="color: #070707;">with the</font><font style="color: #2D2D36;">&#160;</font><font style="color: #070707;">summ</font><font style="color: #1A1A1F;">ary </font><font style="color: #2D2D36;">r</font><font style="color: #070707;">esults o</font><font style="color: #2D2D36;">f </font><font style="color: #1A1A1F;">i</font><font style="color: #070707;">n</font><font style="color: #2D2D36;">t</font><font style="color: #070707;">erventional studies in which they pa</font><font style="color: #1A1A1F;">rti</font><font style="color: #070707;">cip</font><font style="color: #2D2D36;">ate</font><font style="color: #070707;">, an</font><font style="color: #2D2D36;">d </font><font style="color: #070707;">e</font><font style="color: #1A1A1F;">n</font><font style="color: #070707;">cour</font><font style="color: #2D2D36;">ag</font><font style="color: #070707;">e</font><font style="color: #2D2D36;">s </font><font style="color: #070707;">inve</font><font style="color: #2D2D36;">st</font><font style="color: #070707;">igat</font><font style="color: #1A1A1F;">o</font><font style="color: #070707;">rs t</font><font style="color: #1A1A1F;">o </font><font style="color: #2D2D36;">inform </font><font style="color: #070707;">their
                  subjects of the results</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">Meta-analyses </font><font style="color: #2D2D36;">a</font><font style="color: #070707;">n</font><font style="color: #2D2D36;">d </font><font style="color: #070707;">P</font><font style="color: #2D2D36;">o</font><font style="color: #070707;">oled A</font><font style="color: #1A1A1F;">n</font><font style="color: #070707;">alyse</font><font style="color: #2D2D36;">s</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.15pt;"><font style="color: #070707;">The followin</font><font style="color: #1A1A1F;">g pr</font><font style="color: #42424F;">inc</font><font style="color: #1A1A1F;">i</font><font style="color: #070707;">ples </font><font style="color: #2D2D36;">app</font><font style="color: #070707;">ly t</font><font style="color: #2D2D36;">o res</font><font style="color: #070707;">earch t</font><font style="color: #1A1A1F;">ha</font><font style="color: #070707;">t use</font><font style="color: #1A1A1F;">s </font><font style="color: #42424F;">da</font><font style="color: #070707;">t</font><font style="color: #2D2D36;">a </font><font style="color: #070707;">from more than one
          previously conducted </font><font style="color: #2D2D36;">cli</font><font style="color: #070707;">nic</font><font style="color: #2D2D36;">al </font><font style="color: #070707;">stud</font><font style="color: #2D2D36;">y (Me</font><font style="color: #070707;">ta-</font><font style="color: #2D2D36;">ana</font><font style="color: #070707;">l</font><font style="color: #1A1A1F;">y</font><font style="color: #070707;">ses and Po</font><font style="color: #1A1A1F;">ol</font><font style="color: #070707;">ed Analys</font><font style="color: #1A1A1F;">es</font><font style="color: #070707;">) :</font></div>
      <div>&#160;</div>
      <table id="z4d3fc4f9298e4d27ad18b69ae2810395" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #1A1A1F;">Resear</font><font style="color: #070707;">ch utilizing data from the Parties&#8217; previous clinical studies in a manner inconsistent with, or beyond the scope of, the original informed consent requires re-
                  consent of the subjects, or if this is not practical, IRB/IEC approval. If this is not practical, the data are anonymized</font></div>
            </td>
          </tr>

      </table>
      <table id="zeffe2605042946638786d99016bc84e7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">The Parties re</font><font style="color: #2D2D36;">vie</font><font style="color: #070707;">w, bef</font><font style="color: #2D2D36;">or</font><font style="color: #070707;">e submission for publication, any
                  proposed manuscripts, presentatio</font><font style="color: #2D2D36;">ns </font><font style="color: #070707;">or abst</font><font style="color: #2D2D36;">racts </font><font style="color: #070707;">prepared by research collaborators
                  which originate from the Parties hu</font><font style="color: #2D2D36;">m</font><font style="color: #070707;">a</font><font style="color: #2D2D36;">n </font><font style="color: #070707;">subject</font><font style="color: #1A1A1F;"> r</font><font style="color: #070707;">e</font><font style="color: #2D2D36;">se</font><font style="color: #070707;">arch studies (including the Parties supported </font><font style="color: #1A1A1F;">s</font><font style="color: #070707;">tudies)</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #070707;">Non-Interv</font><font style="color: #1A1A1F;">entio</font><font style="color: #070707;">nal (o</font><font style="color: #1A1A1F;">b</font><font style="color: #070707;">ser</font><font style="color: #1A1A1F;">v</font><font style="color: #070707;">ational) Human Subject Research</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #070707;">Th</font><font style="color: #1A1A1F;">e </font><font style="color: #070707;">foll</font><font style="color: #1A1A1F;">ow</font><font style="color: #42424F;">in</font><font style="color: #1A1A1F;">g </font><font style="color: #070707;">prin</font><font style="color: #2D2D36;">c</font><font style="color: #070707;">ipl</font><font style="color: #1A1A1F;">e</font><font style="color: #42424F;">s </font><font style="color: #2D2D36;">ap</font><font style="color: #070707;">ply t</font><font style="color: #1A1A1F;">o </font><font style="color: #070707;">Non-interv</font><font style="color: #1A1A1F;">e</font><font style="color: #070707;">ntional (</font><font style="color: #1A1A1F;">o</font><font style="color: #070707;">b</font><font style="color: #1A1A1F;">se</font><font style="color: #070707;">rvati</font><font style="color: #1A1A1F;">o</font><font style="color: #070707;">nal) human </font><font style="color: #1A1A1F;">subject</font><font style="color: #070707;"> r</font><font style="color: #1A1A1F;">ese</font><font style="color: #070707;">ar</font><font style="color: #1A1A1F;">c</font><font style="color: #070707;">h:</font></div>
      <div>&#160;</div>
      <table id="z8ff57a2f8b454999bd8739356e2ee76a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right; color: #070707;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #2D2D36;">For </font><font style="color: #070707;">observation</font><font style="color: #1A1A1F;">a</font><font style="color: #070707;">l studies wh</font><font style="color: #1A1A1F;">e</font><font style="color: #070707;">re clinical data are coll</font><font style="color: #1A1A1F;">e</font><font style="color: #070707;">ct</font><font style="color: #1A1A1F;">e</font><font style="color: #070707;">d by or on b</font><font style="color: #1A1A1F;">e</font><font style="color: #070707;">h</font><font style="color: #1A1A1F;">a</font><font style="color: #070707;">lf of th</font><font style="color: #1A1A1F;">e </font><font style="color: #070707;">Parties</font><font style="color: #42424F;"> s</font><font style="color: #070707;">pe</font><font style="color: #1A1A1F;">c</font><font style="color: #070707;">ifically for the purpo</font><font style="color: #1A1A1F;">s</font><font style="color: #070707;">e of the research, the Parties abide by
                  the local legal requirements and regulations for informed consent for the use of these data and IRB/IECs approval is obtained</font></div>
            </td>
          </tr>

      </table>
      <table id="z25f25beb564240898f21687bdd519679" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #070707;">For observational studies using health</font><font style="color: #1A1A1F;">c</font><font style="color: #070707;">are databases, the Parties are assured that there is compliance with relevant leg</font><font style="color: #1A1A1F;">a</font><font style="color: #070707;">l requirements for dat</font><font style="color: #1A1A1F;">a </font><font style="color: #070707;">priva</font><font style="color: #1A1A1F;">c</font><font style="color: #070707;">y and that patients have provided informed consent for the use of their data in research, or IRB</font><font style="color: #2D2D36;">/</font><font style="color: #070707;">IEC </font><font style="color: #030303;">approval has
                  been obtained for that use; or other measures to protect privacy are in place (e.g. the data are anonymized)</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #050505; font-weight: bold;">Schedule 6</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #050505; font-weight: bold;">Invoice Instructions</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #050505;">Immunocore shall send each invoice in pdf format, specifying th</font><font style="color: #1F1F26;">e </font><font style="color: #050505;">total amount payable to:</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.2pt; color: #050505;">[***] and [***] with a copy to the Alliance Manager.</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: #050505;">Invoices must:</div>
      <table id="zdcd1d1c757a04772916286c8442787c7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">be on Immunocore company letterhead</div>
            </td>
          </tr>

      </table>
      <table id="z95c6a700fcab4d89afe710be0f96ba92" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #050505;">set out Immunocore&#8217;s bank details as noted b</font><font style="color: #1F1F26;">e</font><font style="color: #050505;">lo</font><font style="color: #1F1F26;">w</font></div>
            </td>
          </tr>

      </table>
      <table id="z3eceece9b76b4a68b618648c81eda398" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">have a contact name and contact number</div>
            </td>
          </tr>

      </table>
      <table id="z9bae7e9d6caf4fc5aa5cf9db3b8f7932" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #050505;">contain an invoice date and invoice num</font><font style="color: #1F1F26;">b</font><font style="color: #050505;">er</font></div>
            </td>
          </tr>

      </table>
      <table id="z89b5d28282e744809513aee2bf116446" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="color: #050505;">state the contractual payment terms a</font><font style="color: #34343F;">f</font><font style="color: #1F1F26;">t</font><font style="color: #050505;">e</font><font style="color: #1F1F26;">r r</font><font style="color: #34343F;">e</font><font style="color: #050505;">ceipt </font><font style="color: #1F1F26;">of </font><font style="color: #34343F;">i</font><font style="color: #1F1F26;">n</font><font style="color: #050505;">voi</font><font style="color: #1F1F26;">c</font><font style="color: #34343F;">e</font></div>
            </td>
          </tr>

      </table>
      <table id="z25aac46f61b74b83951505eb504efe8a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8722;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(5, 5, 5);">be addressed to:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #050505;">GlaxoSmithKline Intellectual Prope</font><font style="color: #1F1F26;">rty </font><font style="color: #34343F;">D</font><font style="color: #1F1F26;">e</font><font style="color: #050505;">velo</font><font style="color: #1F1F26;">p</font><font style="color: #050505;">m</font><font style="color: #34343F;">e</font><font style="color: #050505;">nt </font><font style="color: #1F1F26;">Ltd</font></div>
      <div style="text-align: justify; text-indent: 0.2pt; color: #050505;">Glaxo Wellcome House</div>
      <div style="text-align: justify; text-indent: 0.2pt; color: #050505;">Berkeley Avenue</div>
      <div style="text-align: justify; text-indent: 0.2pt; color: #050505;">Greenford,</div>
      <div style="text-align: justify; color: #050505;">Middlesex,</div>
      <div style="text-align: justify; color: #050505;">UB6 ONN,</div>
      <div style="text-align: justify; color: #050505;">UK</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(5, 5, 5);">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #030305; font-weight: bold;">Schedule 7</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #030305; font-weight: bold;">Technology Transfer</div>
      <div>&#160;</div>
      <div style="text-align: justify;">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #030303; font-weight: bold;">Schedule 8</div>
      <div>&#160;</div>
      <div style="text-align: center; color: #030303; font-weight: bold;">Nomination Notice</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #030303;">Under the Collaboration and License Agreement executed o</font><font style="color: #31333B;">n </font><font style="color: #030303;">June _, 2013 GSK hereby nominates the following as a
          Nominated Target.</font></div>
      <div>&#160;</div>
      <table id="zc1217f866e7e4ee88acc8d470e4c1a2a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Date Nominated :</div>
              <div style="text-align: justify; color: rgb(3, 3, 3);"> <br>
              </div>
            </td>
            <td style="width: 80%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Target name:</div>
              <div style="text-align: justify; color: rgb(3, 3, 3);"> <br>
              </div>
            </td>
            <td style="width: 80%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(3, 3, 3);">Protein identification number:</div>
              <div style="text-align: justify; color: #030303;"> <br>
              </div>
            </td>
            <td style="width: 80%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(3, 3, 3);">Target protein sequence:</div>
              <div style="text-align: justify; color: rgb(3, 3, 3);"> <br>
              </div>
            </td>
            <td style="width: 80%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-indent: 0.15pt;"><font style="color: rgb(3, 3, 3);">Date received </font><font style="color: rgb(28, 28, 35);">b</font><font style="color: rgb(3, 3, 3);">y </font><font style="color: rgb(3, 3, 3);">Immunocore:</font></div>
              <div style="text-align: justify; text-indent: 0.15pt;"><font style="color: #030303;"> <br>
                </font></div>
            </td>
            <td style="width: 80%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;"><font style="color: #030303;">Authorized fo</font><font style="color: #1C1C23;">r n</font><font style="color: #030303;">omin</font><font style="color: #1C1C23;">a</font><font style="color: #030303;">t</font><font style="color: #1C1C23;">io</font><font style="color: #030303;">n o</font><font style="color: #31333B;">n </font><font style="color: #030303;">b</font><font style="color: #31333B;">eh</font><font style="color: #030303;">alf






          of GS</font><font style="color: #31333B;">K</font></div>
      <div>&#160;</div>
      <table id="z408ead88cb2241be9105dd4c4fcd7d2b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Date:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>

      </table>
      <div style="text-align: justify; text-indent: 0.05pt; font-weight: bold;"><font style="color: #030303;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 0.05pt; font-weight: bold;"><font style="color: #030303;">Accepted/ </font><font style="color: #1C1C23;">R</font><font style="color: #030303;">e</font><font style="color: #1C1C23;">je</font><font style="color: #030303;">cted </font><font style="font-style: italic; color: #030303;">[o</font><font style="font-style: italic; color: #1C1C23;">pt</font><font style="font-style: italic; color: #030303;">ion to be inserted on signature] </font><font style="color: #030303;">on behalf of Immunocore Limited</font></div>
      <div>&#160;</div>
      <table id="zd612e877aa4d4e40aa44df4c17755840" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top;" rowspan="1" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; color: rgb(3, 3, 3);">Date:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: rgb(8, 8, 8); font-weight: bold;">Schedule 9</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(8, 8, 8); font-weight: bold;">Agreed Press Release</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;"><font style="color: rgb(8, 8, 8);">IMMUNOCORE SIGNS RESEARCH AND LICENSING </font><font style="color: rgb(35, 35, 42);">AGR</font><font style="color: rgb(8, 8, 8);">E</font><font style="color: rgb(35, 35, 42);">E</font><font style="color: rgb(8, 8, 8);">MENT WITH G</font><font style="color: rgb(35, 35, 42);">S</font><font style="color: rgb(8, 8, 8);">K TO</font></div>
      <div style="text-align: center; font-weight: bold;"><font style="color: rgb(8, 8, 8);">DISCOVER lmmTACs AGAINST NO</font><font style="color: rgb(35, 35, 42);">VE</font><font style="color: rgb(8, 8, 8);">L TARGETS</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.6pt;"><font style="font-weight: bold; color: #080808;">(Oxford, UK, [X] July 2013) </font><font style="color: #080808;">Immunocore </font><font style="color: #23232A;">Lim</font><font style="color: #080808;">ited, th</font><font style="color: #23232A;">e O</font><font style="color: #080808;">xfor</font><font style="color: #23232A;">d- ba</font><font style="color: #080808;">sed bi</font><font style="color: #23232A;">otech</font><font style="color: #080808;">nology company developing novel biological drugs</font><font style="color: #33333F;">, </font><font style="color: #080808;">ca</font><font style="color: #33333F;">ll</font><font style="color: #080808;">ed Im</font><font style="color: #23232A;">mT</font><font style="color: #080808;">A</font><font style="color: #23232A;">C</font><font style="color: #080808;">s </font><font style="color: #33333F;">(</font><font style="color: #080808;">I</font><font style="color: #23232A;">mm</font><font style="color: #080808;">une m</font><font style="color: #23232A;">obi</font><font style="color: #080808;">lising mTCR Against Cancer), to treat cancer and viral </font><font style="color: #23232A;">dis</font><font style="color: #080808;">e</font><font style="color: #33333F;">as</font><font style="color: #080808;">e to</font><font style="color: #23232A;">da</font><font style="color: #080808;">y ann</font><font style="color: #33333F;">o</font><font style="color: #080808;">u</font><font style="color: #23232A;">nc</font><font style="color: #080808;">ed it </font><font style="color: #33333F;">has </font><font style="color: #080808;">entered into a partnership with GlaxoSmithKline (GSK) </font><font style="color: #33333F;">fo</font><font style="color: #080808;">r multi</font><font style="color: #33333F;">ple </font><font style="color: #080808;">nove</font><font style="color: #23232A;">l tar</font><font style="color: #080808;">gets n</font><font style="color: #23232A;">o</font><font style="color: #080808;">t </font><font style="color: #23232A;">add</font><font style="color: #080808;">ressable using antibody-based technologies. This is Immunocore</font><font style="color: #42424F;">&#8217;s </font><font style="color: #080808;">secon</font><font style="color: #33333F;">d </font><font style="color: #080808;">major partnership this year.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt;"><font style="color: #080808;">Under the terms of the agreem</font><font style="color: #33333F;">en</font><font style="color: #080808;">t, </font><font style="color: #23232A;">Immunocore</font><font style="color: #080808;"> w</font><font style="color: #33333F;">i</font><font style="color: #080808;">ll re</font><font style="color: #33333F;">c</font><font style="color: #080808;">e</font><font style="color: #33333F;">i</font><font style="color: #080808;">ve up to </font><font style="color: #33333F;">a </font><font style="color: #080808;">total o</font><font style="color: #23232A;">f </font><font style="color: #33333F;">&#163;</font><font style="color: #080808;">142 million in preclinical
          milestone payments </font><font style="color: #33333F;">ac</font><font style="color: #080808;">ross </font><font style="color: #23232A;">th</font><font style="color: #080808;">e targets. In ad</font><font style="color: #23232A;">d</font><font style="color: #080808;">i</font><font style="color: #23232A;">ti</font><font style="color: #080808;">on, for </font><font style="color: #23232A;">e</font><font style="color: #080808;">a</font><font style="color: #33333F;">ch </font><font style="color: #080808;">product which reaches the market, up </font><font style="color: #33333F;">to </font><font style="color: #080808;">&#163;200 m</font><font style="color: #23232A;">i</font><font style="color: #080808;">lli</font><font style="color: #33333F;">o</font><font style="color: #080808;">n </font><font style="color: #33333F;">is due </font><font style="color: #080808;">to </font><font style="color: #23232A;">Immunocore</font><font style="color: #080808;"> i</font><font style="color: #33333F;">n </font><font style="color: #080808;">development and commercial milestone paym</font><font style="color: #23232A;">e</font><font style="color: #080808;">nts p</font><font style="color: #33333F;">lus </font><font style="color: #080808;">up t</font><font style="color: #33333F;">o </font><font style="color: #23232A;">d</font><font style="color: #080808;">ouble </font><font style="color: #23232A;">d</font><font style="color: #080808;">i</font><font style="color: #23232A;">git </font><font style="color: #080808;">royal</font><font style="color: #23232A;">tie</font><font style="color: #080808;">s. Immunocore will be responsible for all of </font><font style="color: #33333F;">t</font><font style="color: #080808;">he </font><font style="color: #23232A;">p</font><font style="color: #42424F;">r</font><font style="color: #080808;">eclini</font><font style="color: #23232A;">ca</font><font style="color: #080808;">l </font><font style="color: #23232A;">d</font><font style="color: #080808;">evel</font><font style="color: #23232A;">op</font><font style="color: #080808;">ment </font><font style="color: #23232A;">and </font><font style="color: #080808;">for the initial</font><font style="color: #33333F;"> cl</font><font style="color: #080808;">inical trials in patients and GSK will be </font><font style="color: #23232A;">res</font><font style="color: #080808;">pon</font><font style="color: #23232A;">s</font><font style="color: #080808;">ible </font><font style="color: #23232A;">f</font><font style="color: #42424F;">o</font><font style="color: #080808;">r the re</font><font style="color: #23232A;">ma</font><font style="color: #080808;">ining </font><font style="color: #23232A;">de</font><font style="color: #080808;">v</font><font style="color: #23232A;">elo</font><font style="color: #080808;">pment and commercialisation of the products.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.15pt;"><font style="color: #080808;">Immunocore h</font><font style="color: #33333F;">a</font><font style="color: #080808;">s cr</font><font style="color: #23232A;">eate</font><font style="color: #080808;">d a </font><font style="color: #23232A;">wo</font><font style="color: #080808;">rld- leading p</font><font style="color: #23232A;">l</font><font style="color: #080808;">at form of </font><font style="color: #23232A;">b</font><font style="color: #080808;">i-specific biological drugs, called ImmTA</font><font style="color: #33333F;">Cs, </font><font style="color: #080808;">which e</font><font style="color: #33333F;">xp</font><font style="color: #080808;">loit the</font><font style="color: #23232A;">&#160;</font><font style="color: #080808;">power </font><font style="color: #23232A;">o</font><font style="color: #080808;">f </font><font style="color: #33333F;">T </font><font style="color: #080808;">Cell R</font><font style="color: #33333F;">ec</font><font style="color: #080808;">ept</font><font style="color: #23232A;">o</font><font style="color: #080808;">rs (TCRs) to recognise intracellular changes </font><font style="color: #23232A;">that</font><font style="color: #080808;"> occur during c</font><font style="color: #23232A;">a</font><font style="color: #080808;">ncer o</font><font style="color: #23232A;">r vir</font><font style="color: #080808;">al infe</font><font style="color: #33333F;">ct</font><font style="color: #080808;">i</font><font style="color: #23232A;">on. </font><font style="color: #080808;">This unique recognition ability of TCRs sets them apart from </font><font style="color: #23232A;">tr</font><font style="color: #42424F;">ad</font><font style="color: #23232A;">i</font><font style="color: #080808;">tional </font><font style="color: #42424F;">a</font><font style="color: #080808;">ntibody-based therapies that can only recognise changes on the surface of c</font><font style="color: #23232A;">ells</font><font style="color: #080808;">, and p</font><font style="color: #23232A;">ro</font><font style="color: #080808;">v</font><font style="color: #33333F;">id</font><font style="color: #080808;">es, for the first time, the ability
          to develop extremely potent targeted </font><font style="color: #33333F;">ther</font><font style="color: #080808;">apies f</font><font style="color: #33333F;">o</font><font style="color: #080808;">r c</font><font style="color: #33333F;">a</font><font style="color: #080808;">ncers that are currently poorly served. The most advanced Imm</font><font style="color: #23232A;">T</font><font style="color: #080808;">AC drug,</font><font style="color: #42424F;"> I</font><font style="color: #080808;">MCgp100






          for the treatment of melanoma, is currently in Phase I/II clinical trials in th</font><font style="color: #23232A;">e </font><font style="color: #080808;">U</font><font style="color: #33333F;">K </font><font style="color: #080808;">and USA.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: #080808;">James N</font><font style="color: #33333F;">o</font><font style="color: #080808;">ble, Chief Exe</font><font style="color: #23232A;">c</font><font style="color: #080808;">utive Officer of Immunocore commented: &#8220;W</font><font style="color: #23232A;">e </font><font style="color: #080808;">are delight</font><font style="color: #23232A;">e</font><font style="color: #080808;">d to col</font><font style="color: #33333F;">la</font><font style="color: #080808;">b</font><font style="color: #42424F;">o</font><font style="color: #080808;">r</font><font style="color: #23232A;">ate </font><font style="color: #080808;">with GSK, our second major
          partnership signed this year. GSK is a leading pharmaceutical company with a proven track record in the development of biotherapeutics and this is an important partnership for Immunocore.</font><font style="color: #23232A;">&#8221;</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.3pt; color: #080808;">Laurent Jespers, VP and Head of Innovation BDU, Biopharm R&amp;D of GSK said: &#8220;We are very excited about the opportunity to, together with Immunocore, develop ImmTACs. We believe
        ImmTACs offer a tremendous opportunity in treating cancer and other areas where there is a large unmet need&#8221;.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; color: rgb(8, 8, 8);">END</div>
      <div>&#160;</div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">Notes for editors</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">About Immunocore</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; text-indent: 0.25pt;"><font style="color: rgb(0, 0, 0);">Founded in 2008, Immunocore Ltd i</font><font style="color: rgb(0, 0, 0);">s </font><font style="color: rgb(0, 0, 0);">a privat</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">ly owne</font><font style="color: rgb(0, 0, 0);">d, </font><font style="color: rgb(0, 0, 0);">clinical-</font><font style="color: rgb(0, 0, 0);">s</font><font style="color: rgb(0, 0, 0);">ta</font><font style="color: rgb(0, 0, 0);">g</font><font style="color: rgb(0, 0, 0);">e, biotechnology company, developing a highly innovat</font><font style="color: rgb(0, 0, 0);">iv</font><font style="color: rgb(0, 0, 0);">e platform tech</font><font style="color: rgb(0, 0, 0);">no</font><font style="color: rgb(0, 0, 0);">l</font><font style="color: rgb(0, 0, 0);">o</font><font style="color: rgb(0, 0, 0);">gy th</font><font style="color: rgb(0, 0, 0);">at </font><font style="color: rgb(0, 0, 0);">g</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">erates novel drugs called ImmTACs for the treatment </font><font style="color: rgb(0, 0, 0);">o</font><font style="color: rgb(0, 0, 0);">f cancer and </font><font style="color: rgb(0, 0, 0);">v</font><font style="color: rgb(0, 0, 0);">ir</font><font style="color: rgb(0, 0, 0);">al i</font><font style="color: rgb(0, 0, 0);">nf</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">ction.</font></div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; text-indent: 0.1pt;"><font style="color: rgb(0, 0, 0);">Immunocore traces its roots to Avid</font><font style="color: rgb(0, 0, 0);">ex L</font><font style="color: rgb(0, 0, 0);">td, </font><font style="color: rgb(0, 0, 0);">fou</font><font style="color: rgb(0, 0, 0);">nded in 1</font><font style="color: rgb(0, 0, 0);">99</font><font style="color: rgb(0, 0, 0);">9 as a sp</font><font style="color: rgb(0, 0, 0);">i</font><font style="color: rgb(0, 0, 0);">n-out






          from the University of Oxford to dev</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">lop nov</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">l </font><font style="color: rgb(0, 0, 0);">T </font><font style="color: rgb(0, 0, 0);">Cell </font><font style="color: rgb(0, 0, 0);">R</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">c</font><font style="color: rgb(0, 0, 0);">eptor te</font><font style="color: rgb(0, 0, 0);">ch</font><font style="color: rgb(0, 0, 0);">nology inve</font><font style="color: rgb(0, 0, 0);">nt</font><font style="color: rgb(0, 0, 0);">ed by the founder and chief scientist, Dr Bent Jak</font><font style="color: rgb(0, 0, 0);">obse</font><font style="color: rgb(0, 0, 0);">n. Immunocore h</font><font style="color: rgb(0, 0, 0);">a</font><font style="color: rgb(0, 0, 0);">s over </font><font style="color: rgb(0, 0, 0);">5</font><font style="color: rgb(0, 0, 0);">0 </font><font style="color: rgb(0, 0, 0);">s</font><font style="color: rgb(0, 0, 0);">taff and is located in Abingdon, Oxfordshi</font><font style="color: rgb(0, 0, 0);">re.</font></div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);">Immunocore ha</font><font style="color: rgb(0, 0, 0);">s </font><font style="color: rgb(0, 0, 0);">major </font><font style="color: rgb(0, 0, 0);">di</font><font style="color: rgb(0, 0, 0);">s</font><font style="color: rgb(0, 0, 0);">co</font><font style="color: rgb(0, 0, 0);">ver</font><font style="color: rgb(0, 0, 0);">y </font><font style="color: rgb(0, 0, 0);">co</font><font style="color: rgb(0, 0, 0);">ll</font><font style="color: rgb(0, 0, 0);">aborat</font><font style="color: rgb(0, 0, 0);">i</font><font style="color: rgb(0, 0, 0);">on</font><font style="color: rgb(0, 0, 0);">s </font><font style="color: rgb(0, 0, 0);">with l</font><font style="color: rgb(0, 0, 0);">ea</font><font style="color: rgb(0, 0, 0);">di</font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">g pharmaceutical companies Genentech a</font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">d </font><font style="color: rgb(0, 0, 0);">GS</font><font style="color: rgb(0, 0, 0);">K.</font></div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="color: rgb(0, 0, 0);">&#160;</div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; font-weight: bold;"><font style="color: rgb(0, 0, 0);">About </font><font style="color: rgb(0, 0, 0);">Imm</font><font style="color: rgb(0, 0, 0);">TACs</font></div>
      <font style="color: rgb(0, 0, 0);"> </font>
      <div style="text-align: justify; text-indent: 0.15pt;"><font style="color: rgb(0, 0, 0);">Immunocore&#8217;s ImmTAC </font><font style="color: rgb(0, 0, 0);">t</font><font style="color: rgb(0, 0, 0);">echnology ena</font><font style="color: rgb(0, 0, 0);">b</font><font style="color: rgb(0, 0, 0);">les the </font><font style="color: rgb(0, 0, 0);">i</font><font style="color: rgb(0, 0, 0);">m</font><font style="color: rgb(0, 0, 0);">m</font><font style="color: rgb(0, 0, 0);">une system to recognise and kill
          cancer or viral cells. T C</font><font style="color: rgb(0, 0, 0);">ell </font><font style="color: rgb(0, 0, 0);">R</font><font style="color: rgb(0, 0, 0);">e</font><font style="color: rgb(0, 0, 0);">ceptors </font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">aturally recognise diseased cells and Immunocore&#8217;s competitive adv</font><font style="color: rgb(0, 0, 0);">a</font><font style="color: rgb(0, 0, 0);">ntage is it</font><font style="color: rgb(0, 0, 0);">s </font><font style="color: rgb(0, 0, 0);">a</font><font style="color: rgb(0, 0, 0);">b</font><font style="color: rgb(0, 0, 0);">ili</font><font style="color: rgb(0, 0, 0);">ty to engineer high affinity T Cell Receptors and link them to an
          antibody </font><font style="color: rgb(0, 0, 0);">f</font><font style="color: rgb(0, 0, 0);">r</font><font style="color: rgb(0, 0, 0);">ag</font><font style="color: rgb(0, 0, 0);">ment, </font><font style="color: rgb(0, 0, 0);">a</font><font style="color: rgb(0, 0, 0);">nt</font><font style="color: rgb(0, 0, 0);">i- </font><font style="color: rgb(0, 0, 0);">CD3, which can activate the immune system to kill the targeted canc</font><font style="color: rgb(0, 0, 0);">er o</font><font style="color: rgb(0, 0, 0);">r viral </font><font style="color: rgb(0, 0, 0);">ce</font><font style="color: rgb(0, 0, 0);">lls. These bi-specific proteins, called ImmTACS, have the potential to be extr</font><font style="color: rgb(0, 0, 0);">em</font><font style="color: rgb(0, 0, 0);">ely poten</font><font style="color: rgb(0, 0, 0);">t a</font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">t</font><font style="color: rgb(0, 0, 0);">i-cancer or</font><font style="font-weight: bold; color: rgb(0, 0, 0);">&#160;</font><font style="color: rgb(0, 0, 0);">anti-viral agents.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 0.05pt;"><font style="color: #080808;">Immunocore</font><font style="color: #383846;">&#160;</font><font style="color: #080808;">has co</font><font style="color: #282831;">m</font><font style="color: #080808;">pleted






          development of the ImmTAC technology, including the gener</font><font style="color: #383846;">a</font><font style="color: #080808;">t</font><font style="color: #282831;">io</font><font style="color: #080808;">n of a Good Manufacturing Practice
          (GMP) compliant, fully scalable manufacture rou</font><font style="color: #383846;">te. </font><font style="color: #080808;">The Company has also established regulatory pathways approved by the Food and Drug Administration (FDA) and Medicines
          and Healthcare products Regulatory Agency (MHRA) that will form the basis of all future ImmTAC programmes.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: #030303;">The most advanced ImmTAC drug, IMCgp100, is currently in Phase I</font><font style="color: #232323;">/II</font><font style="color: #030303;"> clinical trials in melanoma patients in both
          the US and UK.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="color: rgb(3, 3, 3);">For additional information about Immunocore: </font><font style="color: rgb(0, 0, 0);">http:</font><font style="color: rgb(0, 0, 0);">//</font><font style="color: rgb(0, 0, 0);">www.i</font><font style="color: rgb(0, 0, 0);">mmu</font><font style="color: rgb(0, 0, 0);">n</font><font style="color: rgb(0, 0, 0);">ocore.com</font></div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: rgb(5, 5, 5); font-weight: bold;">Schedule 10 - Example of Gross to net deductions</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(5, 5, 5);">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: #030303; font-weight: bold;">Schedule 11 - Illustrative Example of Milestone Fees</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; color: rgb(3, 3, 3); font-weight: bold;">Exhibit A - Lead Candidate Criteria and Development Candidate Criteria</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(15, 14, 22);">[***]</div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; color: rgb(15, 14, 22); font-weight: bold;">Section C - Other Relevant Criteria</div>
      <div>&#160;</div>
      <div style="text-align: center; color: rgb(15, 14, 22);">[***]</div>
      <div>&#160;</div>
      <div> <br>
      </div>
      <div>
        <div style="width: 100%;" id="DSPFPageFooter">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="font-size: 8pt;">&#160;</div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center; font-size: 8pt; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>6
<FILENAME>nt10016217x4_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.7</div>
      <div>&#160;</div>
      <div style="text-align: right; font-weight: bold;">EXECUTION VERSION</div>
      <div>&#160;</div>
      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS
          THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">DEVELOPMENT AND LICENSE AGREEMENT<br>
        <br>
        BETWEEN<br>
        <br>
        IMMUNOCORE LIMITED<br>
        <br>
        AND<br>
        <br>
        ELI LILLY AND COMPANY</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="font-weight: bold;">TABLE OF CONTENTS</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd43797c520544957b11c2324877f171f" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div><u>Article</u></div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;"><u>Page</u></div>
            </td>
          </tr>
          <tr>
            <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a name="mpTableOfContents"></a>ARTICLE 1</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">DEFINITIONS</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">3</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 2</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">GOVERNANCE</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">17</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 3</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">SELECTION OF TARGET</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">27</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 4</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">RESEARCH PLAN</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">30</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 5</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">LILLY CO-DEVELOPMENT OPTION</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">35</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 6</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">IMMUNOCORE CO-DEVELOPMENT OPTION</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">37<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 7</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">CO-DEVELOPMENT PLAN AND CO-DEVELOPMENT GENERALLY</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">37</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 8</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">OPT-OUT RIGHTS</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">42</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 9</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">COMMERCIALIZATION</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">46</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 10</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">LICENSES</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">47<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 11</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">TECHNOLOGY TRANSFER</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">51</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 12</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">DEVELOPMENT OF ADDITIONAL PRODUCTS</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">51</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 13</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">FINANCIAL TERMS</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">53</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 14</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">ROYALTY REPORTS; AUDITS</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">61</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 15</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">INTELLECTUAL PROPERTY; OWNERSHIP</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">63</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 16</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">CONFIDENTIALITY</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">69<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 17</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">PUBLICITY; PUBLICATIONS; USE OF NAME</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">70</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 18</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">REPRESENTATIONS</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">72</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 19</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">INDEMNIFICATION</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">75</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 20</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">TERM AND TERMINATION</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">77<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 21</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">DISPUTE RESOLUTION</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">83</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 22</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">ANTI-BRIBERY</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">85</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">ARTICLE 23</div>
            </td>
            <td style="width: 80%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;">DATA PROTECTION</div>
            </td>
            <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="text-align: right;">86<br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;">
              <div style="margin-right: 36pt;">ARTICLE 24</div>
            </td>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-right: 36pt;">MISCELLANEOUS</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: right;">86<br>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc2cba17a184844a2a827951e83bf0e55" cellpadding="0" cellspacing="0">

          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit A</font> &#8212; Immunocore Licensed Patents as of Effective Date</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top;">
              <div><font style="font-weight: bold;">Exhibit B</font> &#8212; Nomination Notice</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit C</font> &#8212; Research Plan Template</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top;">
              <div><font style="font-weight: bold;">Exhibit D</font> &#8212; Lead Candidate Criteria</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit E</font> &#8212; Press Release</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top;">
              <div><font style="font-weight: bold;">Exhibit F</font> &#8212; Immunocore Sub-contractors</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit G</font> &#8212; Co-Commercialization Agreement terms</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top;">
              <div><font style="font-weight: bold;">Exhibit H</font> &#8212; Nomination Notices for Initial Targets</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit I</font> &#8212; Lilly Good Research Practices</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top;">
              <div><font style="font-weight: bold;">Exhibit J</font> &#8212; FTE Rate Principles</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 14.98%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><font style="font-weight: bold;">Exhibit K</font> &#8212; Exclusivity Examples</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">DEVELOPMENT AND LICENSE AGREEMENT</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold; font-variant: small-caps;">This Development and License Agreement</font> (&#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) is made and entered into on July 11, 2014 (&#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;) BETWEEN</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z128cb15e247e439ebd6b4660485a8079" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(A)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">IMMUNOCORE LIMITED</font> having its principal place of business at 91 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RX, United Kingdom (&#8220;<font style="font-weight: bold;">Immunocore</font>&#8221;); and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72db8c49c37249309b52fe6f264ef25d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(B)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">ELI LILLY AND COMPANY</font>, Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America (&#8220;<font style="font-weight: bold;">Lilly</font>&#8221;).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;">Lilly and Immunocore are sometimes referred to herein individually as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight: bold;">Parties.</font>&#8221;</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">BACKGROUND:</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z25f3424827614188bdba16aa722ef981" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(A)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore is a biotechnology company that is engaged in research and development of TCR technology for use in pharmaceutical products.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0e4a3fdefc214fd29952e7547bb4b4c9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(B)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly is a biopharmaceutical company that is engaged in the research, development, manufacture and sale of pharmaceutical products.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6f8a27d733f1458d9260db7b34414e88" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(C)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly and Immunocore desire to collaborate in the discovery and early development of Immune Mobilizing Monoclonal T-cell Receptor Products (&#8220;<font style="font-weight: bold;">ImmTACs</font>&#8221;) for use in pharmaceutical products on the
                terms and conditions set out in this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfd25c03e4de84f5083eef2af1a75b3e2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(D)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall be primarily responsible for the conduct of a research plan leading to the identification and initial non-clinical development of the ImmTACs, and Lilly shall be solely responsible for the further development,
                manufacture and commercialization of certain of the ImmTACs initially identified by Immunocore, subject to Immunocore having the right to opt-in to co-fund such further Lilly activities in consideration for Immunocore&#8217;s right to engage in a
                profit share with respect thereto and to potentially participate in co-promotion activities in certain countries.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;">THE PARTIES AGREE:</div>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478843" name="z_Toc58478843"></a><font style="font-weight: bold;">ARTICLE 1</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>DEFINITIONS</u></div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify;">Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings set forth below or elsewhere herein, unless otherwise specifically indicated herein.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9f650c481c104c6cb38fc521d3251b8d" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">AAC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.7;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Acceptance or Accepted</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Accounting Standard</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, either (a) International Financial Reporting Standards (&#8220;<font style="font-weight: bold;">IFRS</font>&#8221;) or (b) US generally accepted accounting principles (&#8220;<font style="font-weight: bold;">GAAP</font>&#8221;),







                in either case, which standards or principles (as</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z25380bb4ed9e406391ac12cd765c6701" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">applicable) are currently used at the applicable time, and as consistently applied, by the applicable Party;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Acquiring Third Party</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Third Party (including in each case its affiliates) which is (a) a company whose primary business includes the sale and supply of biotechnology products for treatment of humans; or (b) a
                multi-national pharmaceutical company, and in each case to the extent such Third Party is a competitor or potential competitor of Lilly as at the date of the Change of Control;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Additional HLA Compound</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, on a Selected Target-by-Selected Target basis, a Compound directed to an epitope derived from such Selected Target presented by a different HLA Type than the HLA Type used to develop the Selected
                Candidate directed to such Selected Target;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Affiliate</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any person that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of, (i) this Clause, &#8220;<font style="font-weight: bold;">control</font>&#8221; means the direct or indirect ownership of more than fifty percent (50%) of the voting stock or other voting interests or interest in the profits of the Party, and (ii) this Agreement, Adaptimmune
                Limited shall not be an Affiliate of Immunocore;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Agreement</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Preamble;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Alliance Manager</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the individual appointed by each Party as the principal point of contact for communication between the Parties under this Agreement;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Applicable Laws</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means all laws, rules and regulations and guidelines which are in force during the Term and in any jurisdiction in which any Clinical Trial or other activity under this Agreement is performed or in which any
                Product is manufactured, sold or supplied to the extent in each case applicable to any Party to this Agreement or any Sublicensee, including, as applicable to activities hereunder, data protection and privacy rules;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Available Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.4(b)(i);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Background IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means all Intellectual Property Rights Controlled by either Party as of the Effective Date or during the Term, but excluding the Licensed Patents and the Foreground IP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Back-up Compounds</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Research Plan Compound, other than the Selected Candidate, resulting from the same Research Plan, and including any additional Compounds to be generated that result from any</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z553e517193944774a4046d1503a84264" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">wildtype TCR identified during the performance of such Research Plan;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Biosimilar</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 13.6.2(b);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Change of Control</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to Immunocore, (a) the sale or disposition to an Acquiring Third Party of all or substantially all of the assets of Immunocore to which the subject matter of this Agreement relates meaning
                all of or substantially all of the Licensed Intellectual Property or its rights under this Agreement; or (b) (i) the acquisition by an Acquiring Third Party of more than fifty percent (50%) of the issued voting shares in Immunocore, or (ii)
                the acquisition, merger or consolidation of Immunocore with or into an Acquiring Third Party. A Change of Control will not include an acquisition or a merger or consolidation of Immunocore in which the holders of the voting shares in
                Immunocore, immediately prior to such acquisition, merger or consolidation will beneficially own, directly or indirectly, at least fifty percent (50%) of the shares of the voting shares in the Acquiring Third Party or the surviving entity
                in such acquisition, merger or consolidation, as the case may be, immediately after such acquisition, merger or consolidation;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Clause 15.3.2 Enforcement</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 15.3.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Clinical Trial</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or Phase IV Clinical Trial, as the case may be, and any clinical studies specifically including pediatric subjects, or any
                other equivalent, combined or other trial in which any Product is administered to a human subject;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">CMC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means chemistry, manufacturing and control;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Co-Commercialization </div>
              <div style="font-weight: bold;">Agreement</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 9.2.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Co-Development Plan</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a program of work for the development of a Joint Selected Candidate; provided, that, for clarity, a &#8220;<font style="font-weight: bold;">Co-Development Plan</font>&#8221; will only be deemed to have been
                terminated, abandoned, or otherwise no longer being pursued in the event that Lilly has ceased, or taken a decision to cease, all, without any intention to resume any, activities with respect to all Research Compounds directed at the same
                Selected Target as the Joint Selected Candidate referred to in such plan prior to receipt of first Regulatory Approval for a Product that was the subject of such plan, regardless of whether Lilly describes a given Co-Development Plan as
                being &#8220;abandoned&#8221; or &#8220;replaced&#8221; by a subsequent plan for</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3f6ba74625fe43d5bae3b441241761ce" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">one or more Research Compounds directed at the same Selected Target as the Joint Selected Candidate referred to in such plan;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Co-Development Term</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 7.6.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">CMO</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Third Party with which a Party has contracted to conduct manufacturing (including process development and scale-up) of one or more Research Plan Compounds on behalf of such Party;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Commercial Milestone Event</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 13.5.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Commercial Milestone Payment</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the payments to be made on the Commercial Milestone Events and as set out in Clause 13.5.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Commercially Reasonable </div>
              <div style="font-weight: bold;">Efforts</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, on a Party-by-Party basis, that level of efforts and resources required to carry out a particular task or obligation in an active and sustained manner, consistent with the general practice followed by
                the Party required to use such efforts in the exercise of its reasonable business discretion relating to other pharmaceutical products owned by it, or to which it has exclusive rights, which are of similar market potential at a similar
                stage in their development or product life, taking into account issues of patent coverage, safety and efficacy, product profile, the competitiveness of products in development and in the marketplace, supply chain management considerations,
                the proprietary position of the compound or product, the regulatory structure involved, the profitability of the applicable products (including pricing and reimbursement status achieved), and other relevant factors, including technical,
                legal, scientific and/or medical factors;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Completion</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means (a) in relation to any Research Plan, Development Plan or Co-Development Plan, or any phase of any such plan, completion of all activities under such plan or phase of such plan including as relevant
                delivery of any final report; and (b) in relation to any Clinical Trial, provision of a final report in relation to such Clinical Trial in accordance with the applicable Clinical Trial protocol;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Compound</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a soluble protein that combines a high affinity TCR directed to a Selected Target with an effector function (for example, anti-CD3 scFv or diagnostic label function), including modifications to the
                relevant soluble protein (for example, half-life extended, improved potency variants, variants to improve stability, manufacturability or immunogenicity thereof);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Confidential Information</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means proprietary information (of whatever kind and in whatever form or medium, including copies thereof), tangible materials or other deliverables (a) disclosed by or on behalf of a Party in connection with
                this Agreement, whether prior to or during the</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z992b74ec21494ff895a8ad060bca1e3d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">Term and whether disclosed orally, electronically, by observation or in writing, or (b) created by, or on behalf of, either Party and provided to the other Party, or created jointly by the Parties, in the
                course of this Agreement; provided, that, notwithstanding the foregoing, to the extent a Party is allocated ownership of Intellectual Property Rights embodied by or containing a given piece of information under this Agreement in accordance
                with Clause 15.1.2, such information shall be deemed to be solely the Confidential Information of such Party regardless of which Party initially disclosed or created such information;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Control or Controlled by</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the rightful possession by a Party, whether directly or indirectly and whether by ownership, license (other than pursuant to this Agreement) or otherwise, as of the Effective Date or during the Term, of
                the right (excluding where any required Third Party consent cannot be obtained) to grant a license, sublicense or other right to exploit as provided herein, without violating the terms of any agreement with any Third Party;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Covers or Covered or </div>
              <div style="font-weight: bold;">Covering</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to a particular Patent and in reference to a particular compound or product (whether alone or in combination with one or more other ingredients) that the use, manufacture, sale, supply,
                import, offer for sale of such compound or product would infringe a Valid Claim of such Patent in the absence of any license granted under this Agreement or in the case of a patent application would infringe the claim of such patent
                application if such patent application was a granted patent;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">CPA Firm</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 14.7.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Development Costs</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 13.8.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Development Milestone</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in clause 13.4.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Development Plan</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a program for the development of a Selected Candidate and its related Back-up Compounds (if any) for which Lilly has sole responsibility as a result of Immunocore not exercising the Immunocore
                Co-Development Option or exercising any of its Opt-out Rights; provided, that, for clarity, a &#8220;Development Plan&#8221; will only be deemed to have been terminated, abandoned, or otherwise no longer being pursued in the event that Lilly has
                ceased, or taken a decision to cease, all, without any intention to resume any, activities with respect to all Research Compounds directed at the same Selected Target as the Selected Candidate referred to in such plan, prior to receipt of
                Regulatory Approval for a Product that was the subject of such plan, regardless of whether Lilly describes a given Development Plan as being &#8220;abandoned&#8221; or &#8220;replaced&#8221; by</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1cb928eaeb07482394045284ff7a7dbd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">a subsequent plan for one or more Research Compounds directed at the same Selected Target as the Selected Candidate referred to in such plan;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Diagnostic Product</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 13.5.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Disclosing Party</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 17.6.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Dispute</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 21.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Effective Date</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Preamble;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Entity</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">EU</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the member states of the European Union, or any successor entity thereto performing similar functions;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Exclusive License</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 10.2.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">FDA</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the US Food and Drug Administration, or any successor entity thereto performing similar functions;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Field</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any and all uses, including human and animal therapeutic, palliative, prophylactic and diagnostic, but excluding any product that contains cells transfected with genes encoding TCRs or modified TCRs
                (whether transfected at the same time or by the same means as the genes encoding TCRs or modified TCRs or not);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">First Commercial Sale</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to a particular Product in a given country, the first sale of such Product to a Third Party following the obtaining of Regulatory Approval for such Product in such country, excluding,
                however, any shipment or invoicing or other distribution of such Product for use (a) in a Clinical Trial, (b) on a named patient basis, (c) for compassionate use, (d) under Treatment IND, or (e) in any nonregistrational studies (e.g., an
                investigator initiated trial) and in each case where supply is free of charge or at cost of goods;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Foreground IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any Intellectual Property Rights created in the performance of this Agreement including under any Research Plan, Development Plan or Co-Development Plan;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">FTE</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the equivalent of the work of one employee full time (equivalent to a twelve month period of work directly related to), including experimental laboratory work, recording and writing up results,
                reviewing literature and references, holding scientific discussions, managing and leading scientific staff, conducting development activities, carrying out related management duties,</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9afd9435753a4c8bb280cd35863b19c9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">writing up results for publications or presentation and attending or presenting appropriate education programs, seminars and symposia, and training (including health and safety training);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">FTE Rate</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means [***];</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">GMP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means all current good manufacturing practices applicable to biopharmaceuticals in the US and/or in the European Union, as are in effect from time to time during the Term and in each case as applicable to the
                activities being carried out under this Agreement;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">GLP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means all applicable current Good Laboratory Practice standards for laboratory activities for pharmaceuticals, as set forth in the FDA&#8217;s Good Laboratory Practice regulations as defined in 21 C.F.R. Part 58
                and/or the Good Laboratory Practice principles of the Organization for Economic Co-Operation and Development (&#8220;<font style="font-weight: bold;">OECD</font>&#8221;), and such standards of good laboratory practice as are required by the European
                Union and other organizations and governmental agencies in countries in which the relevant activity under this Agreement is being performed and in any event assuming that such data will be required to be submitted to the FDA;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">GxP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any of the following as applicable to this Agreement: GLP and GMP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Grantback License</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 10.3.1(a);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">HLA</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human leukocyte antigen;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">HLA Type</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human leukocyte antigen type;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">ImmTACs</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Background;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Immunocore</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Preamble;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Immunocore Background IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means Background IP Controlled by Immunocore or its Affiliates;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Immunocore Co-</div>
              <div style="font-weight: bold;">Development Option</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 6.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Immunocore Foreground IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means Foreground IP Controlled by Immunocore or its Affiliates, including Immunocore&#8217;s interest in Joint IP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">IND</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means an investigational new drug application filed with the FDA pursuant to 21 CFR Part 312 before the commencement of clinical trials of a product, or any comparable or equivalent filing with any</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z391530b57b5a4d1e8f7c551e71a713e2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">relevant regulatory authority in any other jurisdiction required before the commencement of any Clinical Trial;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Indemnitee</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 19.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Indemnitor</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 19.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Indication</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the intended use of a Product for either therapeutic treatment or for the prevention of a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function, system, tissue
                type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval is being sought and which
                will be referenced on any Product labeling in any country. For clarity, (i) label extensions (including front-line, metastatic, adjuvant, etc.) and (ii) diagnostically defined subsets of a given indication shall not be deemed to be separate
                Indications;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Infringement</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 15.3.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Initial Targets</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the two (2) Targets identified in the fully executed Nomination Notices attached hereto as Exhibit H.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Intellectual Property Rights</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means Patents, rights to inventions, copyrights and related rights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential
                information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar
                or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">JCC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.4.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">JDC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.3.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Joint IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in clause 15.1.2(b);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">JPT</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.5;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">JRC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.2.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">JSC</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.6;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Joint Selected Candidate</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Selected Candidate with respect to which Immunocore has exercised the Immunocore Co-Development Option relating to such Selected Candidate and has not exercised or been deemed</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5bbb0acb78c04da589956c93ade224cd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">to exercise any Opt-out Rights with respect to the Co-Development Plan covering such Selected Candidate (and any applicable Back-up Compounds);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lead Candidate Criteria</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Exhibit D;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Licensed Intellectual </div>
              <div style="font-weight: bold;">Property</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the Licensed Know-How and Licensed Patents;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Licensed Know-How</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, as Controlled by Immunocore or its Affiliates as of the Effective Date or during the Term, any Intellectual Property Rights specific to any Product or Research Plan Compound or provided by or on behalf
                of Immunocore for use in or used by either Party (or any of their Affiliates, subcontractors or sublicensees) in performing any Research Plan, Co-Development Plan or Development Plan, or performing any manufacturing or commercialization
                activities for such Product or Research Plan Compound, including all applicable Immunocore Controlled know-how contained in the Immunocore Background IP or the Immunocore Foreground IP, but in all cases excluding any Patents;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Licensed Patents</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any Patents Controlled by Immunocore or its Affiliates as of the Effective Date or during the Term and which Covers (a) a Product or Research Plan Compound or (b) any Licensed Know-How, including as
                applicable all Immunocore Controlled Patents contained in the Background IP or the Immunocore Foreground IP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lilly</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Preamble;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lilly Background IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means Background IP Controlled by Lilly and its Affiliates;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lilly Buy-Out Fee</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means [***].</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lilly Co-Development Option</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 5.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Lilly Foreground IP</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any Foreground IP Controlled by Lilly and its Affiliates, including Lilly&#8217;s interest in Joint IP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Loss or Losses</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 19.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">MAA or Marketing Approval </div>
              <div style="font-weight: bold;">Application</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a BLA, sBLA, NDA, sNDA and any equivalent thereof in the US or any other country or jurisdiction. As used herein: &#8220;<font style="font-weight: bold;">BLA</font>&#8221; means a Biologics License Application and
                amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. &#167; 600 et seq., for FDA approval of a Product and &#8220;<font style="font-weight: bold;">sBLA</font>&#8221; means a supplemental BLA; and &#8220;<font style="font-weight: bold;">NDA</font>&#8221; means a New Drug Application and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. &#167; 314 et seq., for</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9134d529c86348a2b5fef40499c833b9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">FDA approval of a Product and &#8220;<font style="font-weight: bold;">sNDA</font>&#8221; means a supplemental NDA;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Milestone Event</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means Development Milestone-related events and/or Commercial Milestone Events, as applicable;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Net Sales</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">of a Product, means, for any period, the amount which reflects the gross invoice price of such Product sold by Lilly and/or its Sublicensees less the following deductions in relation to each Product, to the
                extent in each case such deductions are actually made and accounted for within Lilly and/or its Sublicensees accounts:</div>
              <div style="text-align: justify;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(a)&#160;&#160;&#160;&#160;&#160; credits, reserves or allowances granted for damaged, outdated, returned, rejected, withdrawn or recalled Product;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(b)&#160;&#160;&#160;&#160;&#160; trade, quantity and cash discounts allowed;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(c)&#160; &#160;&#160;&#160; discounts, refunds, rebates, chargebacks, retroactive price adjustments, and any other similar allowances which effectively reduce the net selling price;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(d)&#160;&#160;&#160;&#160;&#160; that portion of the sales value associated with, and reasonably attributable to, drug delivery systems and to the extent invoiced with a Product;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(e)&#160;&#160;&#160;&#160;&#160; allowance for distribution expenses;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(f)&#160;&#160;&#160; &#160;&#160; fees paid to wholesalers in connection with inventory management;<br>
                <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(g)&#160;&#160;&#160;&#160;&#160; taxes imposed on any Product and paid by Lilly or an Affiliate or Sublicensee;</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(h)&#160;&#160;&#160;&#160;&#160; duties and any other governmental charges or levies imposed upon the import or export, or manufacture or sale of a Product, including the annual fee imposed on
                the pharmaceutical manufacturers by the US government (but, for clarity, excluding income or franchise taxes); and</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt;">(i)&#160;&#160;&#160; &#160; any other similar and customary deductions which are in accordance with the Accounting Standards and which are consistently used by Lilly in connection with its
                public financial reporting requirements.</div>
              <div style="text-align: justify; text-indent: -30.8pt; margin-left: 30.8pt;"> <br>
              </div>
              <div style="text-align: justify;">The supply of samples of Products to Third Parties will not constitute a Net Sale provided such supply of samples is [***] is made free of charge or at cost by Lilly or its Sublicensee. Notwithstanding the
                foregoing, the supply of Products for use (a) in a Clinical Trial, (b) on a named patient basis, (c) for compassionate use, (d) under Treatment IND, or (e) in any nonregistrational studies (e.g., an investigator initiated trial) shall not
                constitute a Net Sale provided such supply is in accordance</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze2dddf8b3dc64a9399a9b85ed42771d6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">with standard industry practices and such supply is free of charge or at cost of goods.</div>
              <div style="text-align: justify;"> <br>
              </div>
              <div style="text-align: justify;">In the event that a Product is sold or supplied in combination (in the same package, at the same time, as an associated supply, as part of the same supply (including where pricing or consideration paid is
                linked to, dependent on or associated with any other supply or series of supplies) and including as a co-formulation) with one or more other active ingredients that are not the subject of this Agreement (a &#8220;<font style="font-weight: bold;">Combination</font>&#8221;),







                the following shall apply:</div>
              <div style="text-align: justify;"> <br>
              </div>
              <div style="text-align: justify;">(i) where the Product is sold separately in the same country, the gross amount invoiced for such Product shall be calculated by multiplying the gross amount invoiced for such Combination by the fraction
                A/(A+B), where &#8220;A&#8221; is the gross amount invoiced for such Product sold separately and &#8220;B&#8221; is the gross amount invoiced for such other active ingredient(s) sold separately; and</div>
              <div style="text-align: justify;"> <br>
              </div>
              <div style="text-align: justify;">(ii) where the Product is not sold separately, then the Net Sales applicable to the supply of such Product shall be a reasonable amount agreed by the Parties;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Net Sales Report</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 14.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">New Product</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 12.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Next Generation Compound</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any Compound that is (i) not a Research Plan Compound, (ii) directed to a Selected Target and (iii) developed using Immunocore Background IP;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Nomination Notice</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Non-Disclosing Party</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 17.6.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Non-Validated Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.5(a);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Option Period</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a period starting on the Effective Date and expiring on the earlier of three (3) years from the Effective Date or two (2) years from the initiation of the second Research Plan hereunder;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Opt-Out Right</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 8.1.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Orphan Drug Designation</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means designation of a pharmaceutical product as an orphan drug in accordance with EU: Regulation (EC) No. 141/2000 on orphan medicinal products or equivalent foreign legislation;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Party or Parties</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in the Preamble;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Patent(s)</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any and all patents and patent applications and any patents issuing therefrom or claiming priority to, worldwide, together with</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc2e19737642546aab6a53c11b3fbaa0a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, reexaminations, substitutions, confirmation patents, registration patents, invention
                certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Phase I Clinical Trial</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human clinical trial, the principal purpose of which is preliminary determination of safety of a Product in healthy individuals or patients as described in 21 C.F.R. &#167;312.21(a), or similar clinical
                study in a country other than the US;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Phase II Clinical Trial</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human clinical trial, the principal purpose of which is a preliminary determination of efficacy of a Product in patients being studied as described in 21 C.F.R. &#167;312.21(b), or similar clinical study
                in a country other than the US; [***];</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Phase III Clinical Trial</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Product for one or more indications in order to obtain Marketing
                Approval of such Product for such indication(s), as further defined in 21 C.F.R. &#167;312.21(c) or a similar clinical study in a country other than the US; [***];</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Phase IV Clinical Trial</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a human clinical trial, or other test or study, of a Product for an Indication that is (a) commenced after receipt of the initial Regulatory Approval for such Indication in the country for which such
                trial is being conducted and that is conducted within the parameters of the Regulatory Approval for such Product for such Indication (and which may include investigator sponsored clinical trials), including a clinical trial conducted due to
                the request or requirement of a Regulatory Authority or as a condition of a previously granted Regulatory Approval, but shall not include any Phase III Clinical Trial (including any &#8220;<font style="font-weight: bold;">Phase III(b)</font>&#8221;
                trial), (b) an investigator sponsored clinical trial approved by the JCC that does not fall within the parameters of a Product&#8217;s Regulatory Approval, or (c) any REMS (Risk Evaluation and Mitigation Strategy)/RMP (Risk Management Plan)
                related study of a Product in a country in the Territory after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority in such country. Phase IV Clinical Trials may include trials or studies conducted
                in support of pricing/reimbursement, epidemiological studies, modeling and pharmacoeconomic studies, post-marketing surveillance studies and health economics studies;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Product</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any pharmaceutical preparation containing, alone or in combination with one or more active ingredients, auxiliaries and/or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z57226a3fd3d4439f9b18d954a6ad5143" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">&#160;</td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">additives, a (a) Selected Candidate (including a Replacement Back-up Compound in accordance with Clause 12.2), or (b) modified Selected Candidate provided that such modifications can be done without
                performance of any Reserved Activities. For clarity, &#8220;<font style="font-weight: bold;">Product</font>&#8221; does not include any &#8220;<font style="font-weight: bold;">New Product</font>&#8221;;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Project Co-Leader</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 2.2.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Proposed Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.2;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Prosecute or Prosecute and </div>
              <div style="font-weight: bold;">Maintain or Prosecution and </div>
              <div style="font-weight: bold;">Maintenance</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to a Patent, all activities associated with the preparation, filing, prosecution and maintenance of such Patent , as well as re-examinations, reissues, applications for patent term
                adjustments and extensions, supplementary protection certificates and the like with respect to that Patent, together with the conduct of interferences, derivation proceedings, pre- and post-grant proceedings, the defense of oppositions and
                other similar proceedings with respect to that Patent;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Quality Agreement</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, as relevant in the context of this Agreement, a written agreement that documents the responsibilities and quality expectations between (a) Lilly and any internal or external supplier, contract
                manufacturer or service provider (including, to the extent applicable, Immunocore) or (b) Immunocore and any internal or external supplier, contract manufacturer or service provider;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Regulatory Approval</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the technical, medical and scientific licenses, registrations, authorizations and approvals required for marketing or use of a Product (including approvals of, BLAs, investigational new drug
                applications, pre- and post-approvals, and labeling approvals and any supplements and amendments to any of such approvals) of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council
                or other governmental entity, necessary for the development, manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Products in a regulatory jurisdiction. In the US, Regulatory Approval means
                approval of any Marketing Approval Application or equivalent by the FDA. Regulatory Approval shall not include obtaining any pricing reimbursement or other pricing approval requirement;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Release</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 17.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Replacement Back-up </div>
              <div style="font-weight: bold;">Compound</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to a given Selected Target, a Back-up Compound that is being substituted for the Selected Candidate relevant to such Selected Target;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcaae6be78e9b49ff99e0997ebfaac67c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Research License</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 10.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Research Plan</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 4.1.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Research Plan Compound</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Compound or any wild-type TCR resulting from the performance of any Research Plan;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Research Term</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 4.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Reserved Activities</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 4.7;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Royalty</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the amounts specified in Clause 13.6.1, and as such amounts may be modified by the remainder of Clause 13.6;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Rules</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 21.2.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">SAE</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a serious adverse effect resulting from any Clinical Trial or administration of Product;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Selected Candidate</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Research Plan Compound selected by Lilly for further development in accordance with Clause 5.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Selected Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Sublicensee</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a Third Party or Affiliate who has been granted a sublicense under any license under this Agreement;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">SUSAR</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means a suspected unexpected serious adverse reaction resulting from any Clinical Trial or administration of a Compound, Product or any other ImmTAC to a human being;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the protein from which a peptide antigen is derived to form an HLA-peptide antigen epitope (including all HLA Types). A Target may be a pre-validated Immunocore protein from the Target Database or a
                non-validated protein suggested by Lilly;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Target Database</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">TCR</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means T-cell receptor;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Term</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 20.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Third Party</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any entity other than Immunocore or Lilly or an Affiliate of any of them;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Third Party Claims</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 19.1;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Third Party Infringement </div>
              <div style="font-weight: bold;">Claim</div>
            </td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 15.4.1;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6e9eaa83f9e74c33beb24843757e9230" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Third Party Partner</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means any Third Party to whom Immunocore licenses the Immunocore Background IP in relation to the development of Compounds whether before or after the Effective Date;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Third Party Sequence</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 4.8.2(b);</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Title 11</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 20.3;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Treatment IND</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means treatment of a patient in accordance with an &#8220;Emergency Investigational New Drug Application&#8221; approval granted under 21 USC 312 or equivalent local law provision;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Unavailable Target</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">is defined in Clause 3.1.4;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">US</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means the United States of America and its territories and possessions;</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">Valid Claim</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, with respect to a particular country, a claim in an unexpired Patent within the Immunocore Foreground IP in such country that has not lapsed or been disclaimed, revoked, held unenforceable,
                unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through
                re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding; and</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 72%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28%; vertical-align: top;">
              <div style="font-weight: bold;">VAT</div>
            </td>
            <td style="width: 72%; vertical-align: top;">
              <div style="text-align: justify;">means, in the EU, value added tax calculated in accordance with Council Directive 2006/112/EC and, in a jurisdiction outside the EU, any equivalent tax.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center;">
        <div><br>
        </div>
        <font style="font-weight: bold;">ARTICLE 2</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><font style="font-weight: bold;"><u>GOVERNANCE</u></font><br>
      </div>
      <div>
        <div style="text-align: center;"><font style="font-weight: bold;"><u> <br>
            </u></font></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f32b247483d4b4e8458ff809cdd1098" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Governance Generally</font>. Up to three (3) voting committees (the JRC, JDC and JCC) may be formed, and three (3) non-voting teams (each, a JPT) will be set up, to govern and act as reporting bodies
                during the Term. Subsequently, an additional oversight committee (the JSC), and/or reporting body (AAC), may be established to provide an overarching governance structure as a Product progresses from development stage to commercial stage
                (depending on whether such Product includes a Selected Candidate or a Joint Selected Candidate).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze14fe225c1ec4f0580fa7b0bcc56e246" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Joint Research Committee</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1302fbae03db48b8938ebe80781d740a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Formation and Composition</font>. As soon as reasonably possible and in any event within [***] after the Effective Date, Immunocore and Lilly shall establish a joint research committee (the &#8220;<font style="font-weight: bold;">JRC</font>&#8221;) to monitor and coordinate the communication and activities of both Parties under the Research Plans. The JRC shall be composed of at least [***] but no more than [***] representatives designated by
                each Party and in each case an equal number of representatives from each Party. Representatives must be</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">appropriate for the tasks then being undertaken and the stage of research or pre-clinical development relevant to any Research Plans, in terms of their seniority, decision-making authority,
        availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JRC contact (&#8220;<font style="font-weight: bold;">Project Co-Leader</font>&#8221;). Each Party may
        replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing
        notification in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers may attend meetings of the JRC
        but shall have no right to vote on any decisions of the JRC.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z21c1b4a3420542dda87f9733dd9eb5d1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JRC Responsibilities</font>. In addition to its overall responsibility for monitoring the activities of the Parties under any Research Plan, the JRC shall, in particular:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7568995ad9f04dc391f269e6f46b83d0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>work to resolve any disputes, controversy or claim between the Parties arising during the performance of any Research Plan and related to the matters under the authority of the JRC;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9251898898fb4624b09f2845ea500acf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve the allocation of resources and efforts necessary to perform the Research Plans to the extent not agreed by the applicable JPT;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaa9dc95e59e542658d92bebae9a3c002" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve any material amendments to any Research Plan proposed by the applicable JPT;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbe1c89415c2041e295cbdcd5092e8923" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>upon Acceptance of a Selected Target and prior to finalizing the Research Plan for such Selected Target, review and approve the initial Lead Candidate Criteria for such Selected Target to be included in such Research Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf9ce9003a7284701afc671a7032bb6a1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>prepare and approve, or review and approve to the extent initially prepared by the applicable JPT, modifications and/or additions to the Lead Candidate Criteria applicable to a given Selected Target and Research Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbc1c28646a3542b884cb01e12620bb59" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>oversee the implementation of the Research Plans;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ad4a4d7d7b549febba3df2521642fc0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>ensure that each Party is informed regarding all material activities performed by the other Party under any Research Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00f4c6e268564f958324cd7a1cc9107a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(h)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>maintain a list of all Research Plan Compounds identified under each Research Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7973cf5b8244a1492fc5494cd6b1181" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review each Research Plan Compound for compliance with Lead Candidate Criteria and assess viability of any Research Plan Compound which does not meet or otherwise is not in compliance with the Lead Candidate Criteria in accordance with
                Clause 5.1 and discuss selection of Research Plan Compounds as Selected Candidates by Lilly; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92a95027346f40d0b6c0de48b115388c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(j)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>perform such other functions as may be agreed to by the Parties (in each case subject to Clause 2.3) or as specified in this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6a05cacb377d40c9a85991f7eec89fb6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Decision making for JRC</font>. Each Party will discuss and attempt to resolve any potential or evolving disagreement related to a Research Plan through its respective Project Co-Leaders and/or the
                applicable JPT before it is brought before the JRC for resolution. With respect to the responsibilities of the JRC, each Party shall have one vote on all matters brought before the JRC. The JRC shall operate as to matters within its
                responsibility by unanimous vote. Each Party shall make decisions in good faith [***]. If the JRC is unable to achieve a unanimous vote within [***] days of any matter being brought before the JRC, then such matter may be referred to senior
                managers under Clause 21.1 at either Party&#8217;s discretion; provided, that, for clarity, the arbitration provisions in Clause 21 shall not apply and, unless otherwise provided explicitly in this Agreement, neither Party shall have final
                decision-making authority with respect to such matter. Unless otherwise provided explicitly in this Agreement, where (i) any JRC decision relates to a change to a Research Plan other than under the following Clause 2.2.3(ii) then in the
                absence of any decision being reached by the JRC, such Research Plan shall continue as un-amended; or (ii) any JRC decision that relates to a change in a given Research Plan as a result of a technical or safety issue that makes continuation
                of such plan impractical without change and such decision is not made within a period of [***] days of referral to the senior managers, the Research Plan shall be deemed Completed and the provisions of Clause 5.1 shall apply irrespective of
                whether a final report has been delivered; provided, that, in the event that Lilly does not exercise its right to further develop a Research Plan Compound arising out of such Research Plan, Immunocore shall have no right to develop, or
                grant any rights to any Affiliate or Third Party to develop, any Research Plan Compounds arising out of such Research Plan. Any JRC decisions are subject to the following: (i) neither the JRC nor either Party shall have the authority to
                amend or modify, or waive its own compliance with, this Agreement; and (ii) Immunocore shall not be entitled to withhold its consent to changes in any Research Plan where the change results in an increase in FTE effort of [***] or less of
                the total FTE effort that Immunocore is already committed to provide under the applicable Research Plan in any given [***] month period. FTE effort shall be calculated based on the FTE Rate and the amount of time that a given activity is
                reasonably projected to take.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b8414b56e7547f490a5654f6a3b1378" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Joint Development Committee</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf32a5f65e02e4ba8b60d64b56e25dea7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Formation and Composition</font>. As soon as reasonably possible after exercise by both (i) Lilly, of a Lilly Co-Development Option, and (ii) Immunocore, of an Immunocore Co-Development Option, and, in
                any event within [***] after exercise of such options, Immunocore and Lilly shall establish a Joint Development Committee (the &#8220;<font style="font-weight: bold;">JDC</font>&#8221;) to monitor and coordinate the communication and activities of both
                Parties relating to the development of all Joint Selected Candidates. The JDC shall be composed of at least [***] but no more than [***] representatives designated by each Party and in each case an equal number of representatives from each
                Party. Representatives must be appropriate for the tasks then being undertaken and the stage of research or clinical development, in terms of their seniority, decision-making authority, availability, function</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JDC contact. Each Party may replace its representatives from time to
        time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing notification in writing to the other Party&#8217;s
        representatives and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers may attend meetings of the JDC but shall have no right to vote on any
        decisions of the JDC.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fe93684c6da49569384e21f03834ed1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JDC Responsibilities for a Co-Development Plan</font>. The JDC shall have overall responsibility for monitoring the activities of the Parties under this Agreement during development (including Clinical
                Trials) of any Joint Selected Candidates or Products containing any Joint Selected Candidates (including any relevant Back-up Compounds directed to the same Selected Target as the Joint Selected Candidates). The JDC shall, in particular:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z555bb81bebbd4402b6fa4c8b02a18ea3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>work to resolve any disputes, controversy or claim related to the matters under the authority of the JDC;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z836bdca2183248e1be679c6e058bcca2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>approve each Co-Development Plan and any changes to a Co-Development Plan, including updating a Co-Development Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb46f8f34cddc4770b645a6fa19988669" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>monitor performance of any Co-Development Plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17a7bfb6634f4212b911f749dbd60b94" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review annual budget updates provided by Lilly in relation to each Co-Development Plan and review and approve any changes to an approved budget;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zff265fb5faef45c39c4abbe665f7e0d8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review any data arising from any Clinical Trials being conducted under a Co-Development Plan, including any SUSARs and SAEs;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcbfc8cac32164990886da79607d209c2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>discuss any material regulatory submissions or material correspondence related to Products containing a Joint Selected Candidate (and, prior to receipt of the first Regulatory Approval for such a Product, at a Party&#8217;s request, provide
                the JDC copies of such regulatory submissions and correspondence to the extent related to the US, the United Kingdom, Spain, Italy, France or Germany)</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bd25877b65141fcbc58f565e56470ba" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>discuss protocols for any Clinical Trial of a Product containing a Joint Selected Candidate, including patient numbers, location numbers, Clinical Trial site and any modifications or amendments to such protocols;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7bc5153fb1d44202814ca706ff50b3bb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(h)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>receive reports on any investigation or audit carried out by either Party or by any Regulatory Authority, to the extent such investigation or audit is initiated in connection with any Joint Selected Candidate or Back-up Compound with
                respect thereto or any facility used for the manufacture of such or any Clinical Trial involving such Research Plan Compounds; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f64c85d308849bdbdf4e241fe35bca4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>report on the progress of any corrections to any identified non-compliances with Applicable Laws to the extent relevant to any Co-Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48ae45d8df714d1c8282a16dccd35b2d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JDC Responsibilities for a Development Plan</font>. Where Immunocore has not exercised its Co-Development Option in relation to any Selected Candidate (in which case the following shall apply from expiry
                of the period for exercise of the Co-Development Option) or where it exercises any Opt-Out Right in relation to any Joint Selected Candidate (in which case the following shall apply from date of exercise of such Opt-Out Right), the JDC
                shall have no responsibilities related to such Selected Candidate, which Selected Candidate shall become subject to the jurisdiction of the AAC in accordance with Clause 2.7.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdf876a4a318c4fc5b2bca4ab67418c41" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JDC Decision Making</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81b4ea9deb9b4fe6bd1d3718094036b0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Provided Immunocore has exercised its Co-Development Option and up until the time that it exercises any Opt-Out Right, each Party will discuss and attempt to resolve any potential or evolving disagreement related to any Co-Development
                Plan through their primary contacts or Alliance Managers before it is brought before the JDC. With respect to the responsibilities of the JDC, each Party shall have one vote on all matters brought before the JDC and the JDC shall operate by
                unanimous vote. If the JDC is unable to achieve unanimity within [***] of any dispute being brought before the JDC, such matter may be referred to senior managers under Clause 21.1 at either Party&#8217;s discretion. Where any dispute remains
                unresolved for a further [***] after such referral, Lilly shall have the deciding vote, save that (a) Lilly shall not be able to make any amendments to the terms of this Agreement without Immunocore&#8217;s prior written agreement; and (b) to the
                extent that Immunocore is to perform any activities under a given Co-Development Plan, Lilly shall not be entitled to require Immunocore to increase any work effort under such Co-Development Plan by more than [***] of the total FTE
                obligation for Immunocore in any twelve (12) month period where Immunocore does not have sufficient internal resources to conduct such activities [***]; (c) any increase in budget will be subject to Clause 7.4; and (d) Lilly shall not be
                entitled to require that Immunocore perform any activity under the Co-Development Plan where Immunocore has not previously agreed to perform such activity under the Co-Development Plan (and save as provided under Clause 4.7). Each Party
                shall make decisions within the JDC in good faith.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6e6db46cda643189b3800783417397d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where Immunocore has not exercised the Co-Development Option in relation to any Selected Candidate (in which case the following shall apply from expiry of the period for exercise of the Co-Development Option) or where it exercises any
                Opt-Out Right in relation to any Joint Selected Candidate (in which case the following shall apply from date of exercise of such Opt-Out Right), Lilly shall take full responsibility for the Development Plan and all development, regulatory,
                manufacturing and commercialization matters relating to the relevant Selected Candidate (including any other Compounds developed as part of the Research Plan resulting in the Selected Candidate) and shall have</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">sole decision making authority in relation to the performance of such activities. Clause 2.3.4(a) shall continue to apply in relation to any remaining Co-Development Plans.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea66e6ec1a1046dc8347a3d6bc68f11d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Joint Commercialization Committee</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc39e3df109546c08bd70d22d923dcbd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Formation and Composition</font>. In the event that Lilly initiates a Phase III Clinical Trial for a Joint Selected Candidate, [***], Immunocore and Lilly shall establish a joint commercialization
                committee (the &#8220;<font style="font-weight: bold;">JCC</font>&#8221;). As of the Effective Date, the Parties anticipate that the JCC will monitor and coordinate the communication and activities of both Parties relating to the further supply,
                manufacture and commercialization of such Joint Selected Candidate, and any subsequent Joint Selected Candidates that enter Phase III Clinical Trials. Unless otherwise set forth in the Co-Commercialization Agreement, the JCC shall function
                in accordance with the remainder of this Clause 2.4 (for clarity, to the extent this Clause 2.4 is inconsistent with the Co-Commercialization Agreement, the Co-Commercialization Agreement shall control). The JCC shall be composed of at
                least [***] but no more than [***] representatives designated by each Party and in each case an equal number of representatives from each Party. Representatives must be appropriate for the tasks then being undertaken and the stage of
                development and commercialization, in terms of their seniority, decision-making authority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its
                primary JCC contact. Each Party may replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to
                attend such meeting by providing notification in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance
                Managers may attend meetings of the JCC but shall have no right to vote on any decisions of the JCC.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z917a33895a014f24a09a06ec64049ad0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JCC Responsibilities</font>. In addition to its overall responsibility for monitoring the activities of the Parties under this Agreement with respect to Joint Selected Candidates following completion of
                Phase III Clinical Trials thereof and during the supply, manufacture and commercialization of Joint Selected Candidates resulting from such Phase III Clinical Trials, the JCC shall, in particular, with respect to each Joint Selected
                Candidate (and Products containing such Joint Selected Candidates):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z634c6ad9f6774bd983880260af3246ee" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve a worldwide commercialization plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51f88d76824a473e9328e3bfa108cfec" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and approve changes to the worldwide commercialization plan;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z26135667e37d4eee8b26b1980d363a74" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provide consultation to the JDC regarding the Co-Development Plan, and amendments thereto, pertaining to Joint Selected Candidates (and Products containing such Joint Selected Candidate);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1fe8f78ce52949e992858f8186dce887" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>receive reports regarding material submissions to Regulatory Authorities pertaining to Joint Selected Candidates (and Products containing such Joint Selected Candidate), as needed;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z77d88256b8474f8eb15019ce41fb6286" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review manufacturing and commercial supply plans pertaining to Joint Selected Candidates (and Products containing such Joint Selected Candidate);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z82fbd7563be24b77a8a3cac766d953a3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>review and, to the extent permitted by Applicable Laws, approve any applicable policies with respect to pricing reimbursement required for sale and supply of any Product containing a Joint Selected Candidate;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z332b50b01afb4d68b62268939104a56d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>subject to the Co-Commercialization Agreement, discuss and agree to mechanisms for co-promotion in those specific countries where co-promotion will occur in accordance with the Co-Commercialization Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z30e649096aec44f4959b0956285511b2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(h)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>discuss pre-marketing and marketing activities pertaining to Joint Selected Candidates (and Products containing such Joint Selected Candidate);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39908dec9dd04b5da58c43fb38e1320b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>discuss launch of Joint Selected Candidates (and Products containing such Joint Selected Candidate);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z547761c2c23b4ea48df0d75dd5a893f0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(j)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>receive from Lilly reports on Net Sales of Joint Selected Candidates (and Products containing such Joint Selected Candidate); and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z15826a90396f49bf8d783346fb5c3fd5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(k)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>perform such other responsibilities as are assigned to the JCC in this Agreement or in the Co-Commercialization Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71fa8855ff354c3783c056e2ad5cb276" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Decision making for JCC</font>. Each Party will discuss and attempt to resolve any potential or evolving disagreement related to commercialization of any Joint Selected Candidates (and Products containing
                such Joint Selected Candidate) through its Alliance Managers before it is brought before the JCC for resolution. With respect to the responsibilities of the JCC, each Party shall have one vote on all matters brought before the JCC. Each JCC
                shall operate as to matters within its responsibility by unanimous vote. Each Party shall make decisions in good faith. If the JCC is unable to achieve unanimity within [***] of any dispute being brought before the JCC, such matter may be
                referred to senior managers under Clause 21.1 at either Party&#8217;s discretion. Where any dispute remains unresolved for a further [***] days after such referral, Lilly shall have the deciding vote (subject to Exhibit G and Article 9 below).
                The JCC shall meet at least [***] or such other frequency as may be reasonable and necessary during the commercialization of any Joint Selected Candidates (and Products containing such Joint Selected Candidate).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ba9c83eb8bd450e9486b20b20d5e96b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JPT</font>. The Parties shall also set-up up to three (3) joint project teams (each, &#8220;<font style="font-weight: bold;">JPT</font>&#8221;) [***] each Selected Target. Each JPT shall be specific to a Selected
                Target and to the corresponding Research Plan, save that the Parties may nominate the same representatives to be present on more than one JPT. The JPT for each Selected Target and Research Plan shall be responsible for governing the day to
                day performance of the relevant Research Plan including ensuring that activities thereunder are performed in accordance with the approved timelines and budgets and, as relevant, agreeing to any non-material changes to such Research Plan and
                for producing the final report and recommendations on completion of the relevant Research Plan. The Parties shall each nominate up to [***] representatives&#160; (and&#160; in&#160; each&#160; case&#160; an&#160; equal</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">number of representatives) to represent it on each JPT. Each Party may replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s
        representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing notification in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate
        will be entitled to perform the functions of such representative. The JPT shall report regularly to the JRC. The final report and recommendations following completion of any Research Plan shall be provided to the JRC within a maximum of [***]
        following completion of the relevant Research Plan and the Parties shall provide all support to the applicable JPT as may be reasonably necessary to meet such timelines. The first order of business for each JPT shall be to prepare a detailed
        Research Plan related to the applicable Selected Target in accordance with Clause 4.1.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7b236e1ce22495290e0410c6e19a323" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JSC. </font>In the event that [***] both the JDC and JCC will be in existence and the Parties shall also set up a joint steering committee (&#8220;<font style="font-weight: bold;">JSC</font>&#8221;) as soon as
                possible after formation of the JCC. The JSC shall serve as an overarching governance forum through which either Party, or any of the JRC, JDC or JCC may escalate a dispute, in each case for so long as such committee(s) are in existence.&#160;
                The Parties shall each nominate up to three (3) representatives (and in each case an equal number of representatives) to represent it on the JSC. Each Party may replace its representatives from time to time upon written notice to the other
                Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing notification in writing to the other Party&#8217;s representatives and following
                provision of such written notification the alternate will be entitled to perform the functions of such representative. In the event that the JSC is formed, each of the JRC, JDC and JCC, in each case for so long as such committee(s) are in
                existence, shall report regularly to the JSC, as relevant and depending on the stage of development of any Joint Selected Candidates (and Products containing such Joint Selected Candidates). The JSC shall be an advisory committee only with
                respect to Joint Selected Candidates (and Products containing such Joint Selected Candidates), with decision-making authority relating to Joint Selected Candidates (and Products containing such Joint Selected Candidates) sitting with the
                JDC or JCC, as applicable.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4860c0e04c044597a026865566dfd1cb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Alliance Advisory Committee</font>. In the event that Immunocore does not exercise its Co-Development Option with respect to any Selected Target, then the JDC and JCC shall, as it relates to Products
                directed to Selected Targets, never form in the first place, or, if Immunocore exercises an Opt-Out Right to any Selected Targets, shall be dissolved in accordance with Clause 2.9 and the Parties shall also set up an alliance advisory
                committee (&#8220;<font style="font-weight: bold;">AAC</font>&#8221;), with respect to Products directed to such Selected Target, as soon as possible after the later of the dissolution of the JDC or the JRC. The AAC shall serve as a forum for (i) the
                Parties to generally discuss matters hereunder, (ii) Lilly to provide executive updates with respect to its development and commercialization activities hereunder, (iii) Immunocore to provide executive updates regarding its progress in
                conducting any Clinical Trials relating to Compounds or ImmTACs other than those being developed by Lilly (subject to any Third Party confidentiality constraints, which in any event will not prohibit Immunocore from providing updates
                related to safety or efficacy), and (iv) the Parties to provide reports on any SUSARs, or other information which might be relevant to Immunocore&#8217;s or Lilly&#8217;s conduct of Clinical Trials relating to any Compounds or ImmTACs in each case as
                relevant to the Selected Candidate (including any Back-up Compounds) and material SAEs to the extent they are or could be generally applicable</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">to Compound or ImmTAC development; and (v) Lilly to provide an update of its planned activities and further development of the Selected Candidate (and any relevant Back-up Compounds) including an
        indication of when milestones, if any, will occur over the [***] after the date of the update. The Parties shall each nominate up to [***] representatives (and in each case an equal number of representatives) to represent it on the AAC. Each Party
        may replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by providing
        notification in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate will be entitled to perform the functions of such representative. The Parties shall each respond to any reasonable
        questions raised at the AAC and shall otherwise provide the reports and updates specified in this Clause 2.7. The AAC shall be a forum for discussion only, and Lilly shall, subject to the terms and conditions of this Agreement, solely control all
        decisions related to the Selected Candidates (including any Back-up Compounds) and Products.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b4c5ed0e1024e86a7125a3fa1274de7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Meetings</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96a1e3bfb8564920876bcc9d2d9694b0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JRC and JDC Meetings</font>. During the course of any Research Plans or Co-Development Plan, the JRC or JDC shall meet [***], or via teleconference or otherwise, in each case as agreed by the JRC or JDC.
                Where possible meetings will be held by telephone conference with only [***] meetings per year being face to face and at either Immunocore&#8217;s or Lilly&#8217;s facility, unless the Parties decide otherwise. Where necessary, for example to resolve
                any dispute or to agree changes to any Research Plan or Co-Development Plan, the JRC or JDC shall meet more frequently.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0c9e772d0554299a16352fbb2ccd116" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">JSC and JCC Meetings</font>. During the course of any Co-Development Plan that has entered Phase III Clinical Trials, and thereafter for so long as there remains at least on Joint Selected Candidate, the
                JSC or JCC shall meet [***], or via teleconference or otherwise, in each case as agreed by the JSC or JCC. Where possible meetings will be held by telephone conference with only [***] meetings per year being face to face and at either
                Immunocore&#8217;s or Lilly&#8217;s facility, unless the Parties decide otherwise. Where necessary, for example to resolve any dispute or to agree changes to any Research Plan, Co-Development Plan, or Co-Commercialization Plan, as applicable, the JSC
                or JCC shall meet more frequently.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9a22f4e945a0490a9a8c2ec25bdfb663" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">AAC Meetings</font>. Where there are any Selected Candidates (or Products containing such Research Plan Compounds) in existence and as a result the AAC has been formed, the AAC shall meet at least [***]
                per year via teleconference or otherwise and [***] shall be held face to face at either Immunocore&#8217;s or Lilly&#8217;s facility (such facility to alternate between the Parties), unless the Parties decide otherwise.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f4f619b263a4d40b35cb3cdcb72fcce" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Meeting Agendas and Minutes. </font>Not later than [***] after each of the JRC, JDC, JCC, JPT, JSC and/or AAC, as applicable, are formed the respective committees shall each hold an organizational
                meeting by videoconference or teleconference to establish their respective operating procedures, including establishment of agendas, and preparation and approvals of minutes. The Parties shall alternate responsibility for taking the meeting
                minutes; provided, that Lilly shall be responsible for taking the meeting minutes</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">25</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">at the first meeting of each committee or team.&#160; Meeting minutes shall be sent to both Parties promptly (and in any event within [***] after a meeting for review, comment and approval by each
        Party. Where minutes are not approved by both Parties, the dispute shall be resolved at the next committee or team meeting. A decision that is made at any meeting shall be recorded in meeting minutes.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1cf0d18b0d804aa6a4f241eb36b356ec" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.8.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">General</font>. Employees of each Party other than its nominated committee or team representatives may attend meetings of the JRC, JDC, JCC, JPT, JSC or AAC, as applicable, as non-voting participants. A
                Party&#8217;s consultants and advisors involved in a Research Plan or Co-Development Plan may attend meetings of the JRC, JDC, JCC, JPT or JSC as non-voting observers; provided that such consultants and advisors are under obligations of
                confidentiality and non-use applicable to the Confidential Information of the other Party as required by Clause 16.3(e). Each Party shall be responsible for all of its own expenses of participating in the JRC, JDC, JCC, JPT, JSC or AAC. In
                addition each Party may nominate the same individuals as representatives on multiple committees.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb2c02a65540e4c0e92dcc0749d8db375" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z49bc97cd07e54960a72e5684a3ec5ea6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution JRC</font>. When all of the Lilly Co-Development Options have been exercised or where such options have not been exercised but such Lilly Co-Development Options have expired or are otherwise
                not capable of exercise by Lilly, the JRC will have no further responsibilities or authority under this Agreement and the JRC will be deemed dissolved by the Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca010233527c4f7995649e4461d6ebb1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution JDC</font>. In the event that the JDC is initially formed, the JDC shall continue for so long as there is any Joint Selected Candidate (or Products containing such Research Plan Compounds)
                and, at such time as there are no Joint Selected Candidates (or Products containing such Research Plan Compounds), the JDC will have no further responsibilities or authority under this Agreement and the JDC will be deemed dissolved by the
                Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2eb9905a3b8a4854aa99e3297b2490c1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution JCC</font>. In the event that the JCC is initially formed, the JCC shall continue for so long as there is any Joint Selected Candidate (or Products containing such Research Plan Compounds)
                undergoing Phase III Clinical Trials and/or being commercialized hereunder and, at such time as there are no Joint Selected Candidates (or Products containing such Research Plan Compounds) undergoing Phase III Clinical Trials and/or being
                commercialized hereunder, the JCC will have no further responsibilities or authority under this Agreement and the JCC will be deemed dissolved by the Parties. The JCC will also be deemed dissolved by the Parties if all Co-Development Plans
                are terminated or if all Products resulting from any Co-Development Agreement fail to obtain Regulatory Approval in any country.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbc7632b4733143a192b936e3140838a8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution JPT</font>. Each JPT will be deemed dissolved by the Parties on completion or termination of the applicable Research Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc53543f51fcf4cf0b3bc26bae383dffe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution JSC</font>. In the event that the JSC is initially formed, the JSC shall continue for so long as the JDC and JCC continue to exist and, at such time as either the JDC</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">26</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">or JCC have dissolved in accordance with this Clause 2.9, the JSC will have no further responsibilities or authority under this Agreement and the JSC will be deemed dissolved by the Parties.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbc5f7d0eed7540d9a80a62e8b971703e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">2.9.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Dissolution AAC</font>. In the event that the AAC is initially formed, the AAC shall continue for so long as Lilly is developing or commercializing any Selected Candidate (or Products containing such
                Research Plan Compounds) and, at such time as Lilly is no longer developing or commercializing any Selected Candidate (or Products containing such Research Plan Compounds) the AAC will have no further responsibilities or authority under
                this Agreement and the AAC will be deemed dissolved by the Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za39604585235463d80c3b6f41b72c60b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">2.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Alliance Managers</font>. Within [***] of the Effective Date, each Party shall appoint an Alliance Manager to be the principal point of contact for communications under this Agreement. The Alliance
                Managers shall facilitate the flow of information and collaboration between the Parties and assist in the resolution of potential and pending issues and potential disputes in a timely manner to enable the JRC, JDC, JCC, JPTs, JSC and AAC,
                in each case for so long as such committee(s) are in existence, and the Parties to reach consensus and avert escalation of such issues or potential disputes. Either Party may replace its Alliance Manager at any time upon prior written
                notice (including by email) to the other Party&#8217;s Alliance Manager. Each Party shall ensure that its Alliance Manager is capable of performing the obligations required of an Alliance Manager under this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;"><a name="z_Toc58478845"></a><font style="font-weight: bold;">ARTICLE 3</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><font style="font-weight: bold;"><u>SELECTION OF TARGET</u></font> </div>
      <div> <br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf7ba25ce06f4a4a92d2c3aeffaa79eb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Selected Targets</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08cf9e12d5984bf49ea84d49a9beb769" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Target Database</font>. Until the earlier of (a) expiry of the Option Period or (b) Acceptance of three (3) Proposed Targets, Immunocore will provide Lilly access to an electronic data-room with
                information on all Targets evaluated by Immunocore and available for nomination as a Selected Target from time to time (&#8220;<font style="font-weight: bold;">Target Database</font>&#8221;). Lilly understands and accepts that the same Target Database
                will be made available to Lilly and all Third Party Partners (each an &#8220;<font style="font-weight: bold;">Entity</font>&#8221;). Immunocore and Lilly shall work together after the Effective Date to ensure that Lilly can access the Target Database
                and to agree the nomination and Acceptance of the third Selected Target and, subsequently to agree upon a written Research Plan for such Selected Target, with the first two (2) Selected Targets (i.e., the Initial Targets) being Accepted as
                of the Effective Date in accordance with Clauses 3.1.2 and 3.1.3. Immunocore may add or remove Targets from the Target Database during the period in which Lilly has access to the Target Database, however any removal from the Target Database
                may only be done where the Target would satisfy the requirements for an Unavailable Target as provided under Clause 3.1.4(a).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc3a75cc2db084bca957c76478216968d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Selected Target Identification</font>. The Parties shall consult on and discuss at the JRC any Target being considered for selection. The JRC shall agree which Target will be selected, save that where
                following referral to senior managers in accordance with Clause 2.2.3 no decision is made, Lilly shall have final decision making authority with respect to selection of Target. At any time during the Option Period, Lilly may notify
                Immunocore in writing in the form set out in Exhibit B that Lilly wishes to nominate a</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">27</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">particular Target (the &#8220;<font style="font-weight: bold;">Proposed Target</font>&#8221;) as a Selected Target (&#8220;<font style="font-weight: bold;">Nomination Notice</font>&#8221;). The Nomination Notice shall
        become effective on the date Immunocore receives the Nomination Notice. Lilly may nominate a maximum of three (3) Proposed Targets. Immunocore understands that Lilly has nominated the Initial Targets and Immunocore acknowledges receipt of the
        Nomination Notices set out in Exhibit H in relation to the two (2) Initial Targets as of the Effective Date.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcabed7c1a47c4104a45a429e4c889cab" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Proposed Target Available as a Selected Target</font>. Immunocore shall have a maximum period of [***] within which to accept or reject the Nomination Notice by returning a signed version of the relevant
                Nomination Notice to Lilly specifying whether accepted or rejected, and if rejected, the reasons therefor. Immunocore will accept the Nomination Notice (&#8220;<font style="font-weight: bold;">Acceptance</font>&#8221;) unless the Proposed Target meets
                any of the criteria set forth in Clause 3.1.4(a), in which case it will reject the Nomination Notice by written notice to Lilly, which notice shall specify whether rejection is under (a) Clauses 3.1.4(a)(i) or (ii) (without specifying the
                exact sub-clause concerned); or (b) alternatively is under Clause 3.1.4(a)(iii) (and, if under Clause 3.1.4(a)(iii), then Immunocore will also provide the specific reasons for such rejection). Acceptance shall be deemed to occur on the date
                of Immunocore&#8217;s signature on the Nomination Notice. On Acceptance the Proposed Target shall thereafter be designated as a &#8220;<font style="font-weight: bold;">Selected Target</font>&#8221; and such Selected Target shall be removed from the Target
                Database (to the extent such Target was present in the Target Database). Notwithstanding the foregoing, Lilly understands that Immunocore has Accepted the Initial Targets and Immunocore acknowledges providing, and Lilly acknowledges receipt
                of, Immunocore&#8217;s executed Acceptance of the Nomination Notices set out in Exhibit H in relation to the two (2) Initial Targets (i.e., Selected Targets) as of the Effective Date.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75dd8bc483d54de19b3558e1ef2a872b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Proposed Target Not Available as a Selected Target</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd55f4d8b71954cb686839b7587460a1f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Unavailable Target</font>. If Lilly nominates a Proposed Target as a Selected Target during the Option Period, then Immunocore shall have the right to reject such request if and only if:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze2ced53239c34556ac6adf2d5d37c7a1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b0de1dbfe064c6a8208a9b5d4521ac2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***]; or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfff0fe6d29104912b9fd9b9261e787f9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 108pt;">Where Immunocore rejects the Nomination Notice, the Proposed Target shall be designated as an &#8220;<font style="font-weight: bold;">Unavailable Target</font>&#8221;.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e46b3733fda4ffdafbd12cbcc8c80cd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Subsequently Available Target.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd38b277c0e334392b966bad6e0ed7f14" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Unavailable Targets under Clause 3.1.4(a) (i) or (ii).</font> If an Unavailable Target that was the subject of Clauses 3.1.4(a) (i) or (ii) above subsequently becomes available for license (each, an &#8220;<font style="font-weight: bold;">Available Target</font>&#8221;), Immunocore shall provide prompt written notice [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">28</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z26e78eec75744ea59930dd01e07cca1d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Unavailable Targets under Clause 3.1.4(a)(iii)</font>. With respect to an Unavailable Target that was rejected under Clause 3.1.4(a)(iii) above, Immunocore [***] Target (each, an &#8220;<font style="font-weight: bold;">Available Target</font>&#8221;). [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1dd54d3e91cf455fb29c3a901dc8206e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">3.1.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Target Validation</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3dcedb90a37941de828caa863906368f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly may request that Immunocore validate any Target which is not present in the Target Database (&#8220;<font style="font-weight: bold;">Non-Validated Target</font>&#8221;) prior to Lilly nominating such a Target. Any request for validation shall
                be made in writing to Immunocore and shall specify details related to the Non-Validated Target. Immunocore shall accept or reject such Non-Validated Target request within [***] of receipt of such request from Lilly; provided, that
                Immunocore may only reject a Non-Validated Target as a result of such Target being [***]. Where Immunocore rejects any request it shall provide its underlying reasons for such rejection and Clause 3.1.4 (to the extent relevant) shall
                control with respect to any such Unavailable Target/Non-Validated Target. Such request may only be made prior to Acceptance of three (3) Selected Targets. For clarity, (1) where the reason for rejection is provided under Clause
                3.1.5(a)(ii), Clause 3.1.4(b) will not apply to such a rejected Non-Validated Target; provided, that, if Lilly requests that Immunocore notify Lilly if such Non-Validated Target becomes available for validation, Immunocore shall so notify
                Lilly promptly following such Non-Validated Target becoming available for validation; and (2) where Lilly elects to continue with a Non-Validated Target given the communication of restrictions by Immunocore under (B) above, any license or
                rights granted in relation to such Non-Validated Target will be subject to the communicated, written, restrictions.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z26c5f8f0b9d247a7b79ce691cd658f00" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Provided Immunocore has not notified Lilly under Clause 3.1.5(a) that a Non-Validated Target is also an Unavailable Target or under Clause 3.1.5(a)(ii), Immunocore shall carry out validation of the Non-Validated Target. Such validation
                shall be carried out by Immunocore and shall incorporate the validation steps routinely carried out by Immunocore for validation of the Targets in the Target Database. Immunocore shall carry out such validation as soon as reasonably
                possible after expiry of the [***] period under Clause 3.1.5(a) above. Immunocore shall provide to Lilly a report on completion of the validation setting out the data obtained and including Immunocore&#8217;s view on whether such data suggests
                that the Target is viable or not.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z09b550ba69684da6b47bc9232ebb88dc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall be obliged to carry out a maximum of [***] validations of Non-Validated Targets. Any further validation shall be subject to prior written agreement by the Parties and will be subject to payment by Lilly for any
                Immunocore time, effort and cost reasonably incurred in performing any further validation work at the FTE Rate and subject to any other terms and conditions that the Parties may agree.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5fa80a03d57c4fc1b4611fcde70233a2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Without limiting the foregoing and notwithstanding anything to the contrary herein, Immunocore shall not pursue any internal development programs</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">29</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">related to any Non-Validated Targets preliminarily discussed with Lilly for a period of no less than [***] from notification of name of Non-Validated Target at JRC or JDC or in such other matter
        as it is documented that Lilly has identified such Non-Validated Target to Immunocore so as to afford Lilly the opportunity to make a final decision as to whether to request validation of the Target.</div>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478846" name="z_Toc58478846"></a><font style="font-weight: bold;">ARTICLE 4</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>RESEARCH PLAN</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7f31183dc89b483fa9a0da08f17cdd9f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Research Plan</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za80b4e154a004ac2a62a8ebe2543973b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Within [***] after Acceptance (or such longer time as mutually agreed) with respect to a given Target, and with respect to the Initial Targets, as soon as practicably possible following the Effective Date, the JPT shall draft and agree
                upon a research plan (&#8220;<font style="font-weight: bold;">Research Plan</font>&#8221;) for the generation of Compounds directed to the relevant Selected Target and which plan is intended to generate the data necessary to support an IND filing for
                at least one Selected Candidate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ac472aa770b4363a52dacc928cd6b1e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Under each Research Plan, Immunocore shall use Commercially Reasonable Efforts to develop:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87e95e6de91c4012ac1f3e171457417d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>at least [***] validated wild-type TCRs directed to the Selected Target;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb928a130cdd64df788097cad5f4ca686" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>further develop at least [***] of the Research Plan Compounds identified in the foregoing sub-clause (a) through TCR affinity maturation and through [***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a9112a39f9a4be19db11ccf7e62968c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>at least [***] additional Research Plan Compound identified in the foregoing sub-clause (a) through [***]; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfb54c4a66a694d25bf2567a309c60860" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>in addition to the Research Plan Compounds identified in the foregoing sub-clause (a), at the request of Lilly, at least [***] additional Research Plan Compounds&#160; as&#160; Replacement&#160; Back-up Candidates through [***]; provided, that the
                activities under this sub-clause (d) shall be reimbursed by Lilly at the FTE Rate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7156dcde8ba84f9281cc5716babc1b3a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>It is anticipated that at least [***] of such Research Plan Compounds under Clause 4.1.2 will satisfy the Lead Candidate Criteria, while any other Research Plan Compounds will become Back-up Compounds. The Research Plan shall, unless
                otherwise agreed by the Parties (including through the JRC) include the information outlined in the Research Plan Template set out in Exhibit C, as well as specific timelines, FTE allocations and delegations of research activities to be
                performed by the Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9dc4cf9c3f3d4a55aefcb2366fea52e7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.1.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The JRC may amend in writing the Research Plans from time to time. It is envisioned that after designation of a Selected Target, Immunocore will initially focus on conducting [***] (as such concepts are described in Exhibit C) in
                relation to Compounds directed to the Selected Target. Exhibit C sets out other responsibilities of each Party but may be amended for any particular Research Plan. There may be other activities</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">30</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">under a given Research Plan which are designated for Lilly to perform; provided, that Lilly shall not be entitled to conduct any of the Reserved Activities.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8790ef5738243f98b3f730df1a1c66d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Subcontractors</font>. Each Party may subcontract portions of its work under the Research Plan to (i) any Affiliate or (ii) Third Parties; provided, (a) there are no objections from the other Party
                regarding the use of said subcontractor, and (b) such subcontract is in writing and is consistent with the terms and conditions of this Agreement including the confidentiality provisions of Article 16 and any rights granted to such
                subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work on behalf of the relevant Party. The sub-contracting Party will remain responsible (at its cost) for all acts or
                omissions of any subcontractor it appoints (including any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement. Each
                Party shall notify the other Party of any sub-contractor appointments. In addition, [***]. Lilly understands that the sub-contractors listed in Exhibit F are required for performance of the Research Plan for the Initial Targets [***].
                Quality Agreements must be established with any subcontractor performing GMP activities prior to them supplying materials or services supporting any relevant GMP activities under any Research Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb0e2b18373f84b0f822f68cc167eb681" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Research Term</font>. The research term for a particular Selected Target shall commence on Acceptance, and shall continue, unless earlier terminated in accordance with Article 20, until the completion or
                waiver of all the tasks set out in the Research Plan and provision of final report by Immunocore (on a Selected Target-by-Selected Target basis, the &#8220;<font style="font-weight: bold;">Research Term</font>&#8221;). During the Research Term, each
                Party shall be responsible for its own costs associated with the activities it conducts under the Research Plan. The final report for each Research Plan shall (i) identify all relevant data necessary for assessment by the JRC of whether the
                Lead Candidate Criteria have been met by any Research Plan Compound and (ii) include such data and research records that have been compiled and which may be required to support an IND filing for any Research Plan Compound that becomes a
                Selected Candidate or Joint Selected Candidate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf47ec98339964f1eafa8fd0afa271508" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Multiple Selected Targets</font>. Immunocore shall initiate work on the Research Plans for Lilly&#8217;s first Initial Target within [***] of the Effective Date or such later date on which the Research Plan is
                agreed. For the second and third Selected Targets, Immunocore shall use Commercially Reasonable Efforts to start all Research Plans as quickly as possible following agreement of each respective Research Plan, save that Immunocore may in its
                sole discretion delay the start of any Research Plan other than the first Research Plan for a maximum of [***] from the start of any previous Research Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6fc146551a904180820f56b6f19f6198" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Reports; Records; and Inspections</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7b80749b28e64c43b224778917d9f9c8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Progress Reports</font>. Each Party shall keep the other Party informed of its activities under each Research Plan and shall provide to the other Party&#8217;s representatives on the JRC regular written summary
                updates at each JRC meeting and otherwise from time-to-time as the other Party may request. If reasonably necessary for a Party to perform its work under an applicable Research Plan, or otherwise exercise its rights hereunder, that Party
                may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party shall</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">31</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">promptly provide the requesting Party with information and data as is reasonably available and reasonably necessary to conduct such Research Plan, or otherwise exercise rights hereunder, and such
        other information as the Parties agree. Neither Party is required to generate additional data or prepare additional reports to comply with the foregoing obligation; provided, that, for clarity, upon such a request, the providing Party shall
        provide, at a minimum and without limiting other materials the requesting Party may request, primary data and assay reports that were used to generate data presented in the research reports and updates. Subject to Clause 16.2, all such reports,
        information and data provided by a Party shall be considered the providing Party&#8217;s Confidential Information.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z91ed1814b1f14eeca4bfa7f14abcbc01" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Research Records</font>. Each Party shall maintain records of its performance of each Research Plan (or cause such records to be maintained) in sufficient detail and in good scientific manner as will
                properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Plan. To the extent applicable, [***]. All other records shall be maintained by each Party during each Research Term and
                for [***] thereafter. All such records of a Party shall be considered such Party&#8217;s Confidential Information.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1fba4e210538400aa1189c816247807a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Research Efforts</font>. The Parties shall use Commercially Reasonable Efforts to conduct their respective tasks under each Research Plan. In addition, Immunocore shall assign such scientific and
                technical personnel and allocate such other resources as are reasonably necessary for performing the activities as are assigned to it in each Research Plan and shall perform such activities in accordance with all Applicable Laws (including
                GLPs) in each case to the extent applicable to performance of the relevant Research Plan activities by Immunocore, the terms and conditions of this Agreement (including Exhibit I), and within generally accepted professional standards.
                Immunocore shall be solely responsible for the safety and health of its employees, consultants and visitors, and for compliance with all Applicable Laws related to health, safety and the environment, including providing its employees,
                consultants and visitors with all required information and training concerning any potential hazards involved in performing such activities and any precautionary measures to protect its employees from any such hazards. Immunocore shall use
                Commercially Reasonable Efforts to train its personnel assigned to perform activities under this Agreement and ensure that any personnel so assigned shall be capable of professionally and competently performing the activities assigned to
                Immunocore in each Research Plan. [***],</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd83d829769824757abbc1819832c2686" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Reserved Activities</font>. The following activities shall be reserved to Immunocore under this Agreement (&#8220;<font style="font-weight: bold;">Reserved Activities</font>&#8221;):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z63dc2fd9d51841a4a3a87ee066add552" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1b2ad19c89a64e38b0766056c3eeedae" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37e99ea3d1334b808b762c71c3e8c290" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ca9d17d3f054f31be74c6f844f7f264" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z56fc4d2bf8574392b401df328edd8bf7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***]</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">32</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf049e7d44c904f01a5baf1e8110fe5d0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***]</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">Should Lilly wish Immunocore to carry out any Reserved Activity other than in the performance of any Research Plan, the following shall apply:</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaa58c482990d4375bd8aba7ca0ce6e55" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where such request is made as part of the performance of activities under a Co-Development Plan, Immunocore agrees to undertake the same as soon as reasonably possible and the costs and expenses of performing such Reserved Activities
                shall be a Development Cost; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z58560db5b48f4958a5b17a39ca2ed207" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where such request is made as part of the performance of activities under a Development Plan and such request relates to the performance of the [***] referred to in sub-clause (f) above for any Research Plan Compound (whether modified or
                not by Lilly as contemplated by Clause 12.1), Immunocore agrees to undertake the same as soon as reasonably possible and Immunocore&#8217;s costs shall be provided at the FTE Rate and Lilly will reimburse any documented Third Party expenses
                necessarily incurred in the performance of such Reserved Activities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2a54287c0ec94dffb10bb8374ea13222" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where such request is other than under sub-clauses (i) or (ii) above, then Immunocore shall have discretion as to whether it performs such Reserved Activities and Immunocore&#8217;s costs shall be provided at the FTE Rate and Lilly will
                reimburse any documented Third Party expenses necessarily incurred in the performance of such Reserved Activities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z059186a74dc14ebb9a396d240f950c2e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Identical Peptide identification</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">It is understood by both Parties that within any Target nominated by Lilly, there could be epitopes which have a sequence identical to an epitope comprised within a second Target. That second
        Target may have been nominated by Immunocore or a Third Party Partner before Lilly nominated its Target or may be nominated by Immunocore or a Third Party Partner after Lilly nominates its Target. The following shall apply in relation to such
        identical sequences:</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16610f17aea0427f816c78a77ed0938d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>For purposes of this Agreement an &#8220;identical&#8221; sequence means that an uninterrupted sequence of at [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4543e4ac9d8940f782393e475ae6ad3c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">4.8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The following shall also apply in relation to any identical sequences:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4255e69de7f94f448866d0e8f8056e24" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where Lilly is considering nominating a Target under Clause 3.1, Immunocore shall carry out a search to compare the sequence of epitopes identified for such potential Proposed Target as against the sequence of any epitopes of Targets
                which have been nominated by Third Party Partners or Immunocore (in Immunocore&#8217;s case in accordance with Clause 3.1.4(a)(ii)) and in each case in relation to the same HLA-Types to which the epitopes for the potential Proposed Targets have
                been identified. Where no identical sequences are identified then subject to clause 4.8.2(b) below, there shall be no restriction on</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">33</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">Lilly&#8217;s ability to develop a Compound to the identified epitopes within the applicable potential Proposed Target and Lilly shall be entitled to use such potential Proposed Target in accordance
        with the remaining terms of this Agreement.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9e135507af7430da28b175ec2a1554e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any identical sequences are identified as a result of such search, then:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca267850942f40a5853a84023bed255c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the case that an identical sequence is identified within a Target previously nominated by a Third Party Partner (&#8220;<font style="font-weight: bold;">Third Party Sequence</font>&#8221;) then [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2661a569a0e64c0bbaffaaf4d4a52ffe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the case that the identical sequence is within a Target nominated by Immunocore, then [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze29d7e9fe3c646bab8bb4b0ce592af88" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Both Parties accept that as of the date of nomination of any Target, it may not be possible to identify all possible identical sequences which may be present within any potential Proposed Target as compared to any other Targets (whether
                nominated prior to or after the nomination of the potential Proposed Target by Lilly) including in relation to any HLA Types relevant to such Targets. In the case where an identical sequence is identified after the Acceptance of any
                potential Proposed Target by Immunocore under clause 3.1.3, then the following will apply:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z671c802ce2d64e708e5872254c743dec" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where such identical sequence within a Proposed Target is identified in a Target nominated by a Third Party Partner [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbea07e87b3ef4916b779cfba07431a52" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where such identical sequence is identified in a Target nominated by Immunocore, then [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">Exhibit K sets out non-exhaustive examples of the application of this Clause 4.8.2 for illustration purposes.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z49c9b499424d41dda6bc97ca36baccb9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Inspections</font>. The Parties shall notify each other of any inspections carried out or requested by any regulatory authority and in each case to the extent such inspection or request relates to any
                activities under any Research Plan, or to the part(s) of the facility at which any activities relevant to activities under any Research Plan, or that relate to such areas, (including where such sites are managed by a CRO or other Third
                Party), are conducted. To the extent possible Lilly shall be entitled to attend any such inspection of Immunocore, but any access of Lilly shall not include any right to be present at any inspection of any Third Party activities or part of
                the facility in which any Third Party activities or Immunocore internal activities are being carried out to the extent access is not necessary for the purposes of such inspection. Where any inspection identifies any non-compliance with
                Applicable Laws and such non-compliance is relevant to any activities under any Research Plan or the part of a facility at which any activities relevant to activities under any Research Plan are conducted, or that relate to such areas, then
                the Party responsible for the facility shall correct any such non-compliance and shall keep the other Party informed of the steps being taken to correct any non-compliance. The Party accompanying any such inspection (as opposed to the Party
                being inspected) shall reasonably cooperate in minimizing its exposure to any Third Party confidential information.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">34</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2b63e3fa3c6148a5b73a2550e05d0347" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">4.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Audit by Lilly</font>. Lilly shall have the right to audit any part(s) of the facility(ies) where Immunocore is performing activities under any Research Plan, including reviewing such documents and
                records, as is reasonably necessary for assessing Immunocore&#8217;s compliance with this Agreement, each applicable Research Plan, all Applicable Laws (to the extent relevant to performance of activities under the Research Plan, or that relate
                to such areas), and any other applicable requirements of any relevant Regulatory Authority to the extent relevant to performance of activities under the Research Plan. Such audit and document review shall be conducted upon reasonable prior
                notice by Lilly and shall occur no more than [***] in any calendar year, except in the case of any subsequent &#8220;for cause&#8221; audits. It is understood that Lilly undertakes no obligation to inspect, audit or qualify the facility(ies) and any
                inspection conducted hereunder is for Lilly&#8217;s sole interest without undertaking any obligation or liability to Immunocore or any other person or entity. Any audit under this Clause 4.10 conducted by or on behalf of Lilly shall not relieve
                Immunocore from any of its obligations or liabilities under this Agreement. Any audit carried out by Lilly shall be subject to compliance with any Third Party confidentiality restrictions and any audit shall not include document, data or
                areas of the facility which are not relevant to the performance of activities under any Research Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478847" name="z_Toc58478847"></a><font style="font-weight: bold;">ARTICLE 5</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>LILLY CO-DEVELOPMENT OPTION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb44ef6f9266f476387c3ea1624addf11" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Selected Candidate Identification and Lilly Co-Development Option</font>. Following receipt of final report and recommendations from the JPT and/or Immunocore in relation to any Research Plan, the JRC
                shall consider whether any Research Plan Compound under such Research Plan (a) meets the Lead Candidate Criteria; or (b) does not meet the Lead Candidate Criteria but, in the view of the JRC, there is sufficient information to support
                further development of such Research Plan Compound. Based, in part, on the feedback provided by the JRC, Lilly may designate any Research Plan Compound as the Selected Candidate for a given Selected Target; provided, that, for clarity,
                Lilly shall not be obligated to designate a Research Plan Compound as a Selected Candidate with respect to any given Research Plan (even if the Lead Candidate Criteria are met by a Research Plan Compound). Lilly shall reach its decision as
                soon as reasonably possible after provision of final report and recommendations from the JRC, JPT and/or Immunocore following completion of performance of any Research Plan. Lilly shall formally record its desire, if any, to continue to
                develop such a Selected Candidate (&#8220;<font style="font-weight: bold;">Lilly Co-Development Option</font>&#8221;) by way of providing written notice specifying the Research Plan Compound to be designated as the Selected Candidate. Exercise of the
                Lilly Co-Development Option shall occur on receipt of written notice by Immunocore. Exercise of the Lilly Co-Development Option in relation to any Selected Candidate shall also include Back-up Compounds resulting from the same Research Plan
                as the Selected Candidate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zad59b088064d43e18c71f2bb191183ee" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Failure to Exercise Lilly Co-Development Option</font>. If Lilly does not exercise the Lilly Co-Development Option with respect to any Research Plan Compound directed to the relevant Selected Target
                within [***] of the Completion of the Research Plan pertaining to such Selected Target (or such earlier time as may be possible at Lilly&#8217;s sole discretion), then on a Selected Target-by-Selected Target basis the Lilly Co-Development Option
                shall expire with respect to such Selected Target and Lilly shall have no further rights to develop any Research Plan Compounds resulting from the Research Plan pertaining to such Selected Target; provided, that, by written notice from
                Lilly to Immunocore prior to the expiration of the aforementioned [***] period, Lilly may transition any given Research Plan Compound from such Research Plan</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">35</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">to another Research Plan for further development against the Selected Target that is relevant to such other Research Plan. On expiry of the Lilly Co-Development Option with respect to a given
        Selected Target without exercise, Immunocore shall be entitled to further develop the Research Plan Compounds (subject to the proviso in the foregoing sentence) resulting from the Research Plan pertaining to such Selected Target in its sole
        discretion and without the need for recourse to or financial compensation being payable to Lilly.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ebb9f2e64264f219938a3694225b607" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Plan Preparation</font>. If Lilly does exercise the Lilly Co-Development Option in accordance with Clause 5.1 then Lilly shall prepare an initial Co-Development Plan for the further
                development of the Selected Candidate, and any Back-up Compounds as relevant, directed to such Selected Target. Lilly shall take the lead in preparing such Co-Development Plan and the Co-Development Plan shall be discussed and refined (to
                the extent reasonably necessary) by the Parties. Immunocore shall consult with Lilly, [***], in relation to the Co-Development Plan. The Co-Development Plan shall:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9f4316398fc84c4a93644189c27bd5c9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>be prepared on a global basis;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ff58c05b4334dfaa980552b3e6564cf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>include the responsibilities of each of the Parties under the Co-Development Plan including as relates to any manufacture of Product for Clinical Trials;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze2cada9666df48f3b5f156fef9353706" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>include an estimated budget for Phase I Clinical Trials;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc3679e6f620048d4a28c033452e4049c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>include a high level plan setting out an anticipated route (including Phase III Clinical Trials and other required trials) to obtain Regulatory Approval for any Product including estimated timelines and estimated budget;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4369500767d94d0da56e4b549e744b2e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>include the basis for calculation of any budgeted costs, including relevant FTE and FTE Rate information to be applied to such budget (which FTE Rate(s) shall be used to calculate any Development Costs reimbursable in accordance with
                Clause 13.8); and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6bc3e7dbccdd4e0c87a6bbbb4cdae5da" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>in all cases, be prepared in accordance with Lilly&#8217;s internal requirements and processes for development plans and budgets relating to products at a similar stage of development to the relevant Selected Candidate or Back-up Compound.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For clarity, Lilly shall have the final decision in relation to the contents of each Co-Development Plan as prepared under this Clause 5.3.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10b387906ca1455e8bcf9eb39bf8c241" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">5.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Plan Performance</font>. Lilly shall have the right to initiate activities under any Co-Development Plan, including any updated or amended Co-Development Plan, upon finalization thereof and
                regardless of whether Immunocore has exercised the Immunocore Co-Development Option with respect to such Co-Development Plan in accordance with Clause 6.1 or determined whether it will exercise its applicable Opt-Out Right under Clause 8.1;
                provided, that, for clarity, should Immunocore exercise the Immunocore Co-Development Option, or not exercise its Opt-Out Right, with respect to any such Co-Development Plan, then Immunocore shall be responsible for its applicable portion
                of any Development Costs incurred by Lilly under such Co-Development Plan prior to the date of Immunocore&#8217;s exercise of the Immunocore Co-</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">36</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">Development Option or the date that Immunocore is deemed to not have exercised its Opt-Out Right under Clause 8.1.</div>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478848" name="z_Toc58478848"></a><font style="font-weight: bold;">ARTICLE 6</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>IMMUNOCORE CO-DEVELOPMENT OPTION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd19e1b533ca7422383a446575cb65357" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Immunocore Co-Development Option</font>. On a Selected Target-by-Selected Target basis, and within [***] of delivery by Lilly of the final version of a Co-Development Plan for a given Selected Target,
                Immunocore shall notify Lilly in writing whether it wishes to co-fund (in accordance with Clause 7.1) and, solely to the extent provided in the co-development agreement referred to in Clause 7.1, if any, participate in, the development of
                the Selected Candidate and any Back-up Compounds directed to such Selected Target (&#8220;<font style="font-weight: bold;">Immunocore Co-Development Option</font>&#8221;). Notification of exercise of an Immunocore Co-Development Option shall include
                notification as to whether Immunocore is exercising its option at the twenty five percent (25%) or fifty percent (50%) co-development level. Exercise of an Immunocore Co-Development Option shall take effect on receipt of written notice of
                exercise by Lilly and, for clarity, shall take effect with respect to all Research Plan Compounds directed to the relevant Selected Target. Where Immunocore exercises an Immunocore Co-Development Option, the Co-Development Plan shall
                continue as such and Lilly and Immunocore shall share responsibility for the further development expenses of the Selected Candidate and any Backup Compounds in accordance with the applicable Co-Development Plan and Article 7. For clarity,
                exercise of the Immunocore Co-Development Option shall be subject to the Opt-Out Rights of Immunocore set out in Article 8 below.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za4f4728d2e02455fa1c410e694455343" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Failure to Exercise Immunocore Co-Development Option</font>. Where Immunocore does not exercise an Immunocore Co-Development Option within the [***] described in Clause 6.1, (i) Lilly shall take over full
                responsibility for the research and development of the relevant Selected Candidate and any associated Back-up Compounds, (ii) the Co-Development Plan for such Selected Candidate shall become a Development Plan, and (iii) Immunocore shall
                have no right to develop or commercialize, either directly or through an Affiliate or Third Party, any Compounds directed to the relevant Selected Target.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478849" name="z_Toc58478849"></a><font style="font-weight: bold;">ARTICLE 7</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>CO-DEVELOPMENT PLAN AND CO-DEVELOPMENT GENERALLY</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za2ea1fc58f3a484997ab841b94f1eb5a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Generally</font>. As between the Parties, Lilly shall be responsible for performing each Co-Development Plan unless otherwise provided in such Co-Development Plan; provided, that the
                Development Costs incurred in the performance of the Co-Development Plan (whichever Party incurs such costs) shall be shared between the Parties with Immunocore paying either fifty percent (50%) of the Development Costs actually incurred or
                twenty five percent (25%) of the Development Costs actually incurred by either Party depending on the level at which the Immunocore Co-Development Option was exercised by Immunocore under Clause 6.1 and subject to Clause 13.8 below. The
                Parties acknowledge and agree that Immunocore will not conduct any development or manufacturing activities under the Co-Development Plan unless otherwise agreed by the Parties in writing, including, to the extent reasonably requested by
                either Party, pursuant to a separate written agreement, which sets forth appropriate quality, compliance, auditing and other terms and conditions applicable to such work.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">37</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z222f72149c08459bb60f5bc95d59d4f4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Regulatory Matters</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd5c3d401529b431cbb8867a3c6d15e05" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>As between the Parties, Lilly shall be responsible for holding and applying for any Regulatory Approvals or MAAs.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf17a3ac49a86479daa7f4ab2c0fd0e27" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly (or one of its Affiliates or Sublicensees) shall be responsible, and act as the sole point of contact, for communications with regulatory authorities in connection with the development, commercialization, and manufacturing of
                Products. During the Development Term and thereafter, Immunocore shall not initiate, with respect to any Research Plan Compounds or Product, any meetings or contact with regulatory authorities without Lilly&#8217;s prior written consent unless
                such contact or response is required for Immunocore to comply with its obligations to regulatory authorities; provided, that, in the event of any such required contact or response, Immunocore shall provide only such information as is
                necessary to comply with its legal obligations and shall promptly update Lilly regarding any such interactions. To the extent Immunocore receives any written or oral communication from any regulatory authority relating to any Research Plan
                Compounds or Product, Immunocore shall (a) refer such regulatory authority to Lilly, and (b) as soon as reasonably practicable (but in any event within [***]), notify Lilly and provide Lilly with a copy of any written communication received
                by Immunocore or, if applicable, complete and accurate minutes of such oral communication. At the request of Lilly, Immunocore shall make available to Lilly, [***], a qualified representative who shall, together with the representatives of
                Lilly, participate in and contribute to meetings with the regulatory authorities with respect to regulatory matters relating to the Research Plan Compounds, ImmTACs generally, Licensed Intellectual Property or Reserved Activities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z065f6a010f8a4f28a21033fb455ec040" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Prior to receipt of Regulatory Approval for a given Joint Selected Candidate (or a Product containing a Joint Selected Candidate):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f965722551d4110941b6c92924554fb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>to the extent that Lilly (or one of its Affiliates or Sublicensees) has any material communications with any regulatory [***] relating to any Joint Selected Candidate (or a Product containing a Joint Selected Candidate), Lilly shall
                provide a copy of such communication to Immunocore as soon as reasonably possible; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7c7745c03fb43d39c79d8f307cf7b00" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall be entitled to have a single representative attend[***], material and scheduled meetings, including material and scheduled oral discussions, with regulatory authorities [***] relating to any Joint Selected Candidate (or
                a Product containing a Joint Selected Candidate).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 72pt;">For clarity, the Parties&#8217; respective rights and obligations under this Clause 7.2.3 shall expire upon receipt of first Regulatory Approval for such Joint Selected Candidate (or a Product containing
        a Joint Selected Candidate).</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z61e658b54042439181a1035d837505ac" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Notwithstanding the foregoing, Immunocore shall provide such assistance as may reasonably be requested by Lilly relating regulatory matters (including preparation and filing for any INDs and MAAs and obtaining and maintaining Regulatory
                Approvals).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">38</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6cdfda4267f8440bb7f0f4db3d95b6c3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Nothing in this Clause 7.2 shall require Immunocore to breach its obligations to any regulatory authority under Applicable Law.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc96529c46a074bc285875be11e8f36a0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Plan</font>. The Parties accept that each Co-Development Plan will change and develop as the applicable Joint Selected Candidate progresses through development, Clinical Trials and to
                Regulatory Approval. The JDC shall be responsible for reviewing and amending each Co-Development Plan as necessary, however it is understood that Lilly will be responsible for preparation of any amendments (including such amendments as may
                result from proposals initially made by Immunocore either directly to Lilly or through the JDC). Lilly will update each Co-Development Plan (including the budget set out therein) in accordance with Lilly&#8217;s standard internal budgeting
                procedures, but in any event to cover the anticipated costs of the next phase of Clinical Trials. Such budget will be discussed at the JDC and approved at the JDC. Both Parties will use Commercially Reasonable Efforts to progress the
                Co-Development Plan and to develop at least one Joint Selected Candidate in each Co-Development Plan through Clinical Trials and through to commercialization. On a Co-Development Plan by Co-Development Plan basis, at any point during the
                Co-Development Term, Lilly may decide in its discretion to add a new Indication to the Co-Development Plan. Prior to such introduction, Lilly will discuss with Immunocore addition of such new Indication and associated changes to the
                Co-Development Plan and this Agreement, if any (it being understood by the Parties that neither Party has an obligation to amend this Agreement).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z73b6924b7956462784ffbf27696d8846" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Costs Generally and Changes to Co-Development Plans and Budgets</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01c729a995dd4c8d9c5be242d673f5fd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties shall share Development Costs in accordance with Clause 13.8 (subject to Immunocore&#8217;s Opt-Out Right with respect to any given Co-Development Plan under Article 8). For clarity, in the event that Immunocore does not exercise
                its Opt-Out Right under Clause 13.8 with respect to a given opt-out point under Clause 8.1, Immunocore will be responsible for its portion of Development Costs in accordance with Clause 13.8 up to the next opt-out point, if any, under
                Clause 8.1.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ba095084c354088a3847d1f38a87a7c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any changes to a Co-Development Plan (including to the budget set out in such Co-Development Plan) will be made in good faith and with a bona fide intention that such changes are required for the successful development and
                commercialization of any Joint Selected Candidate or Back-up Compound that is the subject of such Co-Development Plan. In updating a Co-Development Plan, Lilly shall make any updates in good faith and in-line with any internal budgets it
                has approval for. Immunocore may request additional information in relation to any changes to the extent reasonably necessary to justify or further explain any changes made to a Co-Development Plan. Lilly will respond to all queries as soon
                as reasonably possible.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z027214f7c9cc4708a355dcd87d079813" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Subcontractors</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8ec986efc454f50b39a7b2b51b71a7a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly may subcontract portions of its work under the Co-Development Plan to (i) any Affiliate or (ii) Third Parties as set out in the Co-Development Plan and otherwise in accordance with Lilly&#8217;s usual practices; provided, such
                subcontract is in writing and is consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article 16, and any applicable Quality Agreement, and any rights granted to such subcontractor are
                restricted to only those rights necessary for performance by</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">39</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">such subcontractor of the portions of work delegated on behalf of Lilly; provided, that Lilly will not engage any sub-contractor to provide CMC or manufacturing-related services whose primary
        business involves [***], without the prior written consent of Immunocore. Lilly will remain responsible for all acts or omissions of any subcontractor it appoints (including any acts or omissions which result in a breach of the terms of this
        Agreement and any applicable Quality Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement and any applicable Quality Agreement. Quality Agreements must be established with any subcontractor
        performing GMP activities prior to them supplying materials or services supporting Clinical Trials or other GMP activities. Without limiting the foregoing, if Lilly desires to use any subcontractor selected by Immunocore for use under any Research
        Plan to provide services in connection with a Co-Development Plan, then, unless otherwise agreed by Lilly, such work shall be done under a separate subcontract agreement directly between Lilly and such subcontractor (including an appropriate
        Quality Agreement between Lilly and such subcontractor has been executed).</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1c4188426b5e4f278e93b3a42bed14f0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If Immunocore is assigned any activities under the Co-Development Plan, Immunocore may subcontract portions of its work under the Co-Development Plan to (i) any Affiliate or (ii) Third Parties as set out in the Co-Development Plan;
                provided, such subcontract is in writing and is consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article 16, and any applicable Quality Agreement, and any rights granted to such
                subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work delegated on behalf of Immunocore. Immunocore will remain responsible for all acts or omissions of any subcontractor
                it appoints (including any acts or omissions which result in a breach of the terms of this Agreement and any applicable Quality Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement and
                any applicable Quality Agreement. Immunocore shall notify Lilly of any sub-contractor appointments [***].</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z23657de47ff74e8aadfa2e5eef2d0430" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Term</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf37708d0981343e9abcb3d3c915b273c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Co-Development Plan for a particular Selected Target (and the Joint Selected Candidate and any Back-up Compounds (as applicable) directed to such Selected Target) shall commence on the earlier of (i) JDC acceptance of the
                Co-Development Plan, or (ii) commencement by Lilly in accordance with Clause 5.4, and shall continue, unless earlier terminated in accordance with Article 20, until the earlier of (a) expiration of the Immunocore Co-Development Option with
                respect to such Co-Development Plan, without exercise thereof; (b) the obtaining of all Regulatory Approvals for the Joint Selected Candidate or Back-up Compound and completion of all development activities with respect thereto (including
                performance of Phase IV Clinical Trials and any other post market requirements, post market commitment studies, or other post regulatory approval development); or (c) exercise by Immunocore of any of its Opt-Out Rights in accordance with
                Article 8 (on a Selected Target-by-Selected Target basis, the &#8220;<font style="font-weight: bold;">Co-Development Term</font>&#8221;). Should Lilly at any time elect not to continue with any Co-Development Plan, Lilly shall notify Immunocore in
                writing. For clarity, consistent with the definition of &#8220;<font style="font-weight: bold;">Co-Development Plan,</font>&#8221; Lilly shall only provide such notice upon Lilly</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">40</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">ceasing, or taking a decision to cease, all, without any intention to resume any, development activities with respect to all Research Plan Compounds that were developed under the Research Plan
        relevant to the Selected Target that is the subject of such Co-Development Plan, prior to receipt of first Regulatory Approval for a Product that was the subject of such plan.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1ee0ae8786f4cd2bef50c15e3a83185" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Following receipt of Lilly&#8217;s notification, if any, under Clause 7.6.1 regarding permanent cessation of all development activities with respect to all Research Plan Compounds that were developed under the Research Plan relevant to the
                Selected Target that is the subject of a given Co-Development Plan, Immunocore shall be entitled to take over responsibility for the further development and commercialization of such Joint Selected Candidate and Back-up Compounds subject to
                the relevant Co-Development Plan in its sole discretion and including as relevant together with any Third Party and to terminate the relevant Exclusive License in accordance with Clause 20.5; provided, that, the Parties shall negotiate, in
                good faith, appropriate financial compensation to be paid by Immunocore to Lilly so that Lilly may share in the value received by Immunocore in connection with such Joint Selected Candidate or Back-up Compound, which compensation shall be
                in the form of a royalty, as soon as reasonably possible [***]; provided, that, if the Parties are unable to reasonably agree regarding such consideration, then either Party may refer the matter for resolution to an independent expert, by
                notice in writing to the other Party. The independent expert shall be appointed by the Parties by mutual agreement or in the absence of such agreement within [***] of written notice requesting expert resolution, by the International Chamber
                of Commerce; provided, that, in any event, such expert shall have at least [***] experience in the area of life sciences business development, such that the expert will have a reasonable appreciation for the various factors that determine
                the value attributable to a life sciences industry asset. The independent expert shall determine what documentation and evidence it requires from each Party in order to reach a decision on the level of compensation payable by Immunocore to
                Lilly and shall reach a decision as soon as reasonably possible. Such decision shall be binding on both Parties in the absence of fraud or manifest error.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7c8f6a3d91154b3facdc42609d35e542" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Reports; Records; and Inspections</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za1254e1004094da9903c5e26660bf784" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Progress Reports</font>. Each Party shall keep the other Party informed of its activities under each, if any, Co-Development Plan and shall provide to the other Party&#8217;s representatives on the JDC regular
                written summary updates at each JDC meeting. If reasonably necessary for a Party to perform its work under a Co-Development Plan, that Party may request that the other Party provide more detailed information and data regarding the updates
                it earlier provided, and the other Party shall promptly provide the requesting Party with information and data as is reasonably available and reasonably necessary to conduct a Co-Development Plan, and such other information as the Parties
                agree. All such reports, information and data provided by a Party shall be considered the providing Party&#8217;s Confidential Information.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf31d98eadccd49dcad94d85f39d61ebc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Development Records</font>. Each Party shall maintain records of its performance of each, if any, Co-Development Plan (or cause such records to be maintained) in sufficient</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">41</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Co-Development Plan. [***]. All other
        records shall be maintained by each Party during the applicable Co-Development Term and for a minimum of [***] thereafter. All such records of a Party shall be considered such Party&#8217;s Confidential Information. The Party responsible for any Clinical
        Trial shall also procure that any Third Parties involved in any Clinical Trial maintain all records relevant to the Clinical Trial for a minimum of [***] or such longer period required under Applicable Laws and that the other Party is given access
        to such records as may be reasonably necessary for such other Party to comply with Applicable Laws or perform its obligations hereunder.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0700ce331a754fe2b058e1abaeb26af2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Quality</font>. Each Co-Development Plan shall be performed at all times in accordance with all Applicable Laws including as applicable requirements of GxP. Lilly (or Immunocore, to the extent applicable)
                shall ensure that any manufacture and supply of Joint Selected Candidate for any Clinical Trials is carried out in accordance with cGMPs and applicable Quality Agreements.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ebd763abd9548e7b8cc3844115d2033" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">7.7.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Inspections</font>. The Parties shall notify each other of any inspections carried out or requested by any Regulatory Authority and in each case to the extent such inspection or request relates to any
                Joint Selected Candidate or Back-up Compounds under any Co-Development Plan or to the facility at which any Joint Selected Candidate or Back-up Compound is being manufactured or stored or any Clinical Trial site or other Third Party site or
                facility relevant to any Joint Selected Candidate or Back-up Compound (including where such sites are managed by a CRO or other Third Party). [***], both Parties shall be entitled to present at such inspections to the extent such
                inspections relate solely to such Product and to the extent reasonably possible; provided, that the Party who is not in control of the relevant facility (either directly or through a subcontract) shall only be permitted to attend such
                inspections as a silent observer. Where any inspection identifies any non-compliance with Applicable Laws then the Party responsible for the facility shall correct any such non-compliance and shall keep the other Party informed of the steps
                being taken to correct any non-compliance.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2068f5742f4a478aba471ddb538792a5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">7.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Efforts</font>. The Parties shall use Commercially Reasonable Efforts to conduct their respective tasks under each, if any, Co-Development Plan. Lilly shall notify Immunocore of any decisions to suspend
                or terminate any part of a Co-Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478850" name="z_Toc58478850"></a><font style="font-weight: bold;">ARTICLE 8</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>OPT-OUT RIGHTS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z71723b569364410d9fd0ea42bfe847ee" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Opt-Out Right Generally</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3429958e47654cb7b9c3f4b980013858" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In relation to each, if any, Co-Development Plan for each Joint Selected Candidate (and, as relevant, Back-up Compounds), Immunocore shall be given the right to opt-out of involvement in such Co-Development Plan. Such right to opt-out (&#8220;<font style="font-weight: bold;">Opt-Out Right</font>&#8221;) shall apply for a period of [***] from each of the following:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5e0d6655a686470f9fe6f5b1565ca7e0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the date that [***] Phase I Clinical Trials under such Co-Development Plan [***] for such Co-Development Plan as such Co-Development Plan (and the budget therein) was provided to Immunocore pursuant to Clause 6.1;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">42</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z80185478670645ea8a1e92b6de064b98" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the date that the JDC finally approves an updated global Co-Development Plan that was submitted by Lilly under Clause 7.3 covering anticipated Phase II Clinical Trials and including an updated budget covering Phase II Clinical Trials;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze01fb88ffb8f4142b05b752826ec9278" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the date that [***] Phase II Clinical Trials [***] under such Co-Development Plan [***] for such Co-Development Plan as such Co-Development Plan (and the budget therein) was provided to Immunocore pursuant to Clause 7.3 [***]. For
                clarity, this Clause 8.1.1(c) does not apply to Phase III Clinical Trials (including costs attributable to the Phase III Clinical Trial portion of any &#8220;<font style="font-weight: bold;">Phase II/Phase III</font>&#8221; clinical trial as specified
                in the applicable Co-Development Plan budget) or Phase IV Clinical Trials; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc91f598bec2e40ba8f08af8569293826" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the date that the JDC finally approves an updated global Co-Development Plan that was submitted by Lilly under Clause 7.3 covering anticipated Phase III Clinical Trials and including an updated budget covering Phase III Clinical Trials.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 72pt;">Without limiting the foregoing, the Parties will work together in good faith to expedite the decision-making process related to JDC approval of each Co-Development Plan, and Immunocore&#8217;s decision
        whether to exercise an applicable Opt-Out Right, to the extent reasonably practicable so as not to delay further development of the applicable Research Plan Compounds and Products.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3fc1898cbefd4555a9a204353cc22ae9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that Immunocore fails to pay its portion of any Development Costs in accordance with Clause 13.8, and such failure persists for a period of [***] after written notice of non-payment by Lilly, then Immunocore shall be deemed
                to have exercised the previous Opt-Out Right.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1aa4ddb1eda94bfd90ffa9cc37cf8ae9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Opt-Out Right Exercise</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ea009f54f694b51a53a2749755b6e2b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall exercise its Opt-Out Right, on a Co-Development Plan-by-Co-Development Plan (i.e., on a Selected Target-by-Selected Target) basis, by notice in writing to Lilly. Where no notification is received from Immunocore within
                the [***] period described in Clause 8.1, Immunocore will be deemed not to have exercised its Opt-Out Right with respect to such Co&#8212;Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd80fa69afb3a41609428f1320fb03742" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Opt-out from a Co-Development Plan shall occur on receipt of written opt-out notice by Lilly; provided, that Immunocore shall continue to be responsible for its share of Development Costs that are incurred through the date that Lilly
                receives the written opt-out notice (including, for clarity, costs incurred by Lilly but not yet invoiced to Immunocore to the extent such costs arose prior to date of receipt of written opt-out notice). For clarity, to the extent that a
                Co-Development Plan includes any activities to be performed by Immunocore, such activities shall be transferred to Lilly unless otherwise agreed. As of the date of exercise of an Opt-Out Right, Immunocore shall have no further obligation to
                pay any Development Costs incurred by Lilly after the date of exercise of the applicable Opt-Out Right.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">43</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d7f7fb0f86245dcae3d75c6e3b616a4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that Immunocore exercises its Opt-Out Right under Clauses 8.1.1(a) or (b), then Immunocore will be credited (for purposes of Article 13) for having funded development through the end of Phase I Clinical Trials.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z46252c27ee3d4f72aa2ab3e944511e1a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that Immunocore exercises its Opt-Out Right under Clauses 8.1.1(c) or (d), then Immunocore will be credited (for purposes of Article 13) for having funded development through the end of Phase II Clinical Trials.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z83c9b66838154a12b062350f9412addc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that Immunocore is deemed to have exercised its Opt-Out Right under Clause 8.1.2, then:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z234e81447006468582e7cf70904510b6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if such deemed opt-out occurs during Phase I Clinical Trials, Immunocore will not be credited (for purposes of Article 13) with having funded any Co-Development Plan and it will be, with respect to the relevant Research Plan Compounds,
                like Immunocore never exercised the applicable Immunocore Co-Development Option;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1c239c1c6be14ed3a5241e7577746fc9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if such deemed opt-out occurs during Phase II Clinical Trials, Immunocore will be credited (for purposes of Article 13) for having funded development through the end of Phase I Clinical Trials with respect to the relevant Research Plan
                Compounds; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf2cefa35768e464fbf1fa0e314559634" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if such deemed opt-out occurs during Phase III Clinical Trials, Immunocore will be credited (for purposes of Article 13) for having funded development through the end of Phase II Clinical Trials with respect to the relevant Research Plan
                Compounds; provided, that Lilly shall reimburse those Development Costs that Immunocore has paid for Phase III Clinical Trials, with respect to the relevant Research Plan Compounds, with such reimbursement being paid [***] until such time
                as the total reimbursable amount has been paid. For clarity, such reimbursement shall not include any amounts due under Clause 14.6 in connection with late payments.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc06f718beadc4f7fa93d78cd46e42d8f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Development Plan Conversion</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7dec2be0f0704c02a20860ee5c27716c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>On exercise of any Opt-Out Rights, the relevant Co-Development Plan shall become a Development Plan and Lilly shall take over full responsibility for such Development Plan and for the further development and commercialization of Research
                Plan Compounds directed at the Selected Target that is the subject of such Development Plan (including the relevant Selected Candidate (such Research Plan Compound having ceased to be a Joint Selected Candidate as a result of Immunocore&#8217;s
                exercise of its Opt-Out Rights with respect thereto) and Back-Up Compounds). Where Lilly takes over responsibility for any Development Plan (whether under this Clause 8.3 or under Clause 6.2), it shall use Commercially Reasonable Efforts to
                perform such Development Plan (as such Development Plan may be amended from time-to-time at Lilly&#8217;s sole discretion) and develop at least one Selected Candidate for each Development Plan through Clinical Trials and to commercialize such
                Selected Candidate. Lilly shall provide progress updates to the AAC in relation to the</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">44</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">performance of each such Development Plan and the anticipated next steps relating to such Development Plan.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4c2e99460b7a47abaa36497541ddab2b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Should Lilly request Immunocore to perform any part of a Development Plan, and subject to Clause 4.7, such participation shall be subject to agreement of Immunocore and will be subject to reimbursement of cost at the FTE Rate based on
                time and effort provided by Immunocore and all expenses necessarily incurred in performance of the activities under such Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze42f0f5066534a3a9fb360ae2881964c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Should Lilly at any time elect not to continue with the development of any Selected Candidate or Back-up Compound in any Development Plan, Lilly shall notify Immunocore in writing. For clarity, consistent with the definition of &#8220;<font style="font-weight: bold;">Development Plan,</font>&#8221; Lilly shall only provide such notice upon Lilly ceasing, or taking a decision to cease, all, without any intention to resume any, development activities with respect to all Research
                Plan Compounds that were developed under the Research Plan relevant to the Selected Target that is the subject of such Development Plan. Notwithstanding the foregoing, this Clause 8.3.3 shall have no further force or effect from and after
                receipt of first Regulatory Approval for a Product directed to the Selected Target that is the subject of such Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7b910f7663e74326bacfa0086cfaa287" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">8.3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Following receipt of Lilly&#8217;s notification, if any, under Clause 8.3.3 regarding permanent cessation of all development activities with respect to all Research Plan Compounds that were developed under the Research Plan relevant to the
                Selected Target that is the subject of a given Development Plan, Immunocore shall be entitled to take over responsibility for the further development and commercialization of such Selected Candidate and Back-up Compounds subject to the
                relevant Development Plan in its sole discretion and including as relevant together with any Third Party and to terminate the relevant Exclusive License in accordance with Clause 20.5; provided, that, the Parties shall negotiate, in good
                faith, appropriate financial compensation to be paid by Immunocore to Lilly so that Lilly may share in the value received by Immunocore in connection with such Selected Candidate or Back-up Compound, which compensation shall be in the form
                of a royalty, as soon as reasonably possible [***]; provided, that, if the Parties are unable to reasonably agree regarding such consideration, then either Party may refer the matter for resolution to an independent expert, by notice in
                writing to the other Party. The independent expert shall be appointed by the Parties by mutual agreement or in the absence of such agreement within [***] of written notice requesting expert resolution, by the International Chamber of
                Commerce; provided, that, in any event, such expert shall have at least [***] experience in the area of life sciences business development, such that the expert will have a reasonable appreciation for the various factors that determine the
                value attributable to a life sciences industry asset. The independent expert shall determine what documentation and evidence it requires from each Party in order to reach a decision on the level of compensation payable by Immunocore to
                Lilly and shall reach a decision as soon as reasonably possible. Such decision shall be binding on both Parties in the absence of fraud or manifest error.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">45</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="font-weight: bold; text-align: center;">ARTICLE 9&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>COMMERCIALIZATION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f8c3344847f4fc5a01b77c9b3f308f3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Commercialization Generally. </font>Lilly shall be responsible for the commercialization and manufacture of any Product which obtains Regulatory Approval and, where such Product arises from a Joint
                Selected Candidate, the Parties may co-promote such Product in certain countries in accordance with the Co-Commercialization Agreement and/or a subsequent detailing agreement (as described in Exhibit G).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1e035de0555e44a596fc39bd4f0d2fd5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Commercialization Agreement</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze98ec696a698472b9af3b01c17289544" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Not later than [***] after expiry of the last Opt-Out Right with respect to a given Joint Selected Candidate without exercise by Immunocore of the applicable Immunocore Co-Development Option, the Parties shall negotiate in good faith and
                agree to the terms of an agreement, or an appropriate amending and restating of this Agreement, covering the profit/loss sharing and governance that will apply to Products containing a Joint Selected Candidate, and including terms related
                to the possible detailing of such Product(s) by Immunocore (subject to sub-clauses (i) &#8211; (iii) below) (such agreement or amended and restated iteration of this Agreement, &#8220;<font style="font-weight: bold;">Co-Commercialization Agreement</font>&#8221;).







                Such Co-Commercialization Agreement, or amending and restating of this Agreement, shall include the principles set out in Exhibit G, and, until the Parties agree regarding the terms and conditions of such agreement or amending and restating
                of this Agreement, Exhibit G (in conjunction with this Agreement) shall control the rights and obligations of the Parties with respect to the commercialization of Products containing a Joint Selected Candidate. Without limiting the
                foregoing, the Parties acknowledge and agree that Immunocore&#8217;s right to detail, or otherwise co-promote, the relevant Joint Selected Candidate or Back-Up Compound shall be subject to: [***]. In the event that the foregoing sub-clauses (i),
                (ii) and (iii) are not all satisfied, then Immunocore shall have no right to detail, or otherwise co-promote, any Products containing a Joint Selected Candidate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z644be36d15dd48b380fb9780a131b156" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">9.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly acknowledges that on a Joint Selected Candidate-by-Joint Selected Candidate basis, Immunocore may in the future desire to nominate a Third Party to receive its relevant share of profits resulting from sale of any Product containing
                a Joint Selected Candidate in accordance with any Co-Commercialization Agreement. Such Third Party may be nominated at any point after the start of any Co-Development Plan. Immunocore may direct Lilly to pay Immunocore&#8217;s relevant share of
                the profits into an account other than one held by Immunocore. Such nomination right shall be subject to Lilly complying with its standard compliance policies in relation to the making of payments to Third Parties, the application of which
                will be carried out as soon as reasonably possible after notification of Third Party bank details by Immunocore and notifying Immunocore that such nominee is reasonably acceptable to Lilly.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8a9137899c504a97896a434823036628" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Lilly Independent Commercialization</font>. Where Lilly has exercised the Lilly Co-Development Option with respect to a given Selected Target and Research Plan Compounds directed to such Selected Target
                (including the Selected Candidate and Back-up Compounds directed to such Selected Target) and Immunocore has (i) not exercised the Immunocore Co-Development Option with respect to such Selected Target and Research Plan Compounds directed to
                such</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">46</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">Selected Target (including the Selected Candidate and Back-up Compounds directed to such Selected Target) or (ii) has exercised the Immunocore Co-Development Option with respect to such Selected
        Target and Research Plan Compounds directed to such Selected Target (including the Selected Candidate and Back-up Compounds directed to such Selected Target), but has also exercised (or been deemed to exercise) its Opt-Out Rights with respect to
        such Selected Target and Research Plan Compounds directed to such Selected Target (including the Selected Candidate and Back-up Compounds directed to such Selected Target), Lilly shall have responsibility for the commercialization of any Product
        arising from the applicable Development Plan. Lilly shall have the sole right and authority to control all decisions related to the commercialization and manufacture of such Products. Subject to Immunocore identifying and delivering [***] Research
        Plan Compounds that, [***], meet the Lead Candidate Criteria, on a Selected Target-by-Selected Target basis, and Lilly exercising the Lilly Co-Development Option with respect to such a Research Plan Compound, Lilly agrees to use Commercially
        Reasonable Efforts to research, develop and commercialize at least one Product that binds to an HLA-presented antigen derived from such Selected Target within the Field.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32bfd8010782442892997872a93e7b02" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">9.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Lilly Independent Updates</font>. In relation to any commercialization by Lilly under Clause 9.3, Lilly shall continue to keep Immunocore informed of the commercialization and further development of any
                relevant Product and shall provide regular updates to the AAC with respect thereto. Lilly shall also provide to Immunocore, on or about each anniversary of this Agreement, a written report summarizing Lilly&#8217;s progress in the development and
                commercialization of Products arising from any such Development Plan in the past year, including a forecast of the activities that may be conducted in the next [***] from date of report, which annual written report is intended to provide
                Immunocore during the Term with information reasonably necessary to determine Lilly&#8217;s progress in developing and commercializing the relevant Product, including any events for which Milestone Payments are required. Immunocore may address
                questions on the annual reports to the Alliance Managers or AAC following receipt of such written reports. Additionally, each Party shall provide to the other prompt notice of any material safety events pertaining to Products, Compounds or
                other ImmTACs including any SUSARs or other material events which might have general applicability to the use of Compounds or ImmTACs to treat patients.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478852" name="z_Toc58478852"></a><font style="font-weight: bold;">ARTICLE 10</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>LICENSES</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z518536910da941489d1eb5bae2cebe3c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Research License</font>. Commencing on the Effective Date and continuing in full force and effect conterminously with the relevant Exclusive License granted under Clause 10.2.2, Immunocore hereby grants
                to Lilly a royalty-free, non-transferable, sublicenseable, sole ((i.e., a &#8220;<font style="font-weight: bold;">co-exclusive</font>&#8221; license) with Immunocore with respect to each Research Plan and Co-Development Plan) and exclusive (with
                respect to each Development Plan) research license in the Field under the Licensed Intellectual Property for the purposes of Lilly performing each applicable Research Plan, Co-Development Plan or Development Plan (&#8220;<font style="font-weight: bold;">Research License</font>&#8221;). Each Research License shall be specific to the research and development of the Research Plan Compounds specific to the relevant Research Plan, Development Plan or Co-Development Plan and directed at the
                applicable Selected Target including any associated Diagnostic Products.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">47</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">For the avoidance of doubt, on a Selected Target-by-Selected Target basis, upon the termination of the applicable Exclusive License with respect to Research Plan Compounds directed to such Selected
        Target, the related Research License shall also terminate.</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For clarity, the Research License does not include the right to conduct any Reserved Activities.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbe43ccee80be4807bb4dd8f32e33ffdf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">License Grant from Immunocore</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb689ef9d0ada46ddbe4590ceffd31f4f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Option Grant</font>. During the Option Period, Immunocore hereby grants to Lilly an option to obtain up to three (3) Exclusive Licenses, on a Selected Target-by-Selected Target basis.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbc82b48481d24ba980f2c6bb0438e88c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Option Exercise and Exclusive License Grant</font>. The options under Clause 10.2.1 shall be exercised automatically on Acceptance of the relevant Selected Target and, on Acceptance, Immunocore hereby
                grants to Lilly an exclusive, worldwide, royalty-bearing (to the extent provided herein), right and license, with the right to grant sublicenses, under the Licensed Intellectual Property in each case to (i) make, have made, use, import and
                have imported Research Plan Compounds and/or Products, and (ii) sell, have sold and offer for sale Products, in each case of sub-Clauses (i) and (ii), in the Field and directed to the relevant Selected Target (each, an &#8220;<font style="font-weight: bold;">Exclusive License</font>&#8221;). The Exclusive License shall be subject to the following:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11989b468004445fa136b5b99b9bad13" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Exclusive License with respect to a given Selected Target shall terminate on expiry of the Lilly Co-Development Option with respect to such Selected Target without exercise of such option by Lilly;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z981ebeeb13b94015a05d74e89fc837b8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Exclusive License shall permit, to the extent applicable, co-development and co-commercialization of any Product by Immunocore as part of any Co-Development Plan or Co-Commercialization Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96cd7b8d6c5c400797650ab55067a6fe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Exclusive License shall not include the right to conduct any Reserved Activity; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z47e3a32cd68a4c6aa990c56933efccd2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Exclusive License with respect to a given Selected Target shall terminate on notification from Lilly (in accordance with Clause 7.6.1 or Clause 8.3.3, as and to the extent applicable) that it is ceasing, without any intention to
                resume, its involvement in the Research Plan, Co-Development Plan, or Development Plan applicable to such Selected Target prior to obtaining first Regulatory Approval for a Product directed at such Selected Target. For clarity, consistent
                with the definition of &#8220;<font style="font-weight: bold;">Development Plan</font>&#8221; and &#8220;<font style="font-weight: bold;">Co-Development Plan</font>&#8221; Lilly shall only provide such notice upon Lilly determining to cease all development
                activities with respect to all Research Plan Compounds that were developed under the Research Plan relevant to the Selected Target that is the subject of such Development Plan or Co-Development Plan, as applicable, and without any intention
                to resume any such activities and prior to receipt of first Regulatory Approval for a Product that was the subject of such plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">48</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za90c50fd7676451f8cfd740db69b66d5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Exclusivity</font>. In addition, on a Selected Target-by-Selected Target basis, from and after the designation of such Selected Target (including, for clarity, the Initial Targets) and during the duration
                of any Exclusive License, neither Immunocore nor any of its Affiliates shall work under an internal research program or conduct, or grant any license under the Licensed Intellectual Property to enable or otherwise permit, any research,
                development or commercialization activities relating to (i) such Selected Target or any epitope derived from such Selected Target (save as explicitly provided in Clause 4.8); or (ii) any compound (including any ImmTAC or TCR) directed to,
                such Selected Target or any epitope derived from such Selected Target (save as explicitly provided in Clause 4.8). Subject to Clause 4.8, there shall be no breach of this Clause 10.2.3 where any development or research carried out by
                Immunocore or any of its Affiliates or Third Party licensees (a) identifies any ImmTAC or other compound which is capable of binding to a Selected Target or any epitope derived from such Selected Target, provided such development or
                research was not directed to the identification of an ImmTAC or other compound directed to the Selected Target, or any epitope derived from such Selected Target, [***]; or (b) identifies any data relevant to a Selected Target or any epitope
                derived from such Selected Target, provided such development or research was of a general nature and not directed specifically to the Selected Target or any Research Plan Compound [***], provided, that such data shall also be promptly
                provided to Lilly (except to the extent prohibited by written obligations of confidentiality to a Third Party) and, for clarity, in no event shall this sub-clause (b) permit the use of Selected Targets including any epitope derived from
                such Selected Target, including any Lilly Sequence, or Research Plan Compounds, for any Third Party or Immunocore&#8217;s internal research.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4de0662e79344e31b515cffd40360013" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Sublicenses</font>. Lilly shall have the right to sublicense the rights granted under Clauses 10.1, 10.2.2 and 10.2.3 to its Affiliates or Third Parties (in each case through multiple tiers); provided
                that in each case such sublicense:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z064ede6c3b2d49a5801b7f945c6331e7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>is consistent with the terms and conditions of this Agreement; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z727d5176aef94b28b3c1f344ca7bc9e5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>is in writing.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">Lilly shall continue to remain responsible for all reporting obligations under this Agreement during the Term. Lilly shall be responsible for all actions and omissions of any Sublicensee including
        where such actions and omissions result in a breach of the terms of this Agreement. Prior to the grant of any sublicense to a Third Party [***], Lilly shall notify Immunocore of the identity of such Third Party Sublicensee and Immunocore shall have
        [***] to object to such sublicensee, such objection to be [***]. Where Immunocore reasonably objects to the granting of such sub-license, Lilly shall not be entitled to sub-license to such Third Party. For clarity, no grant of any sublicense to a
        Third Party or an Affiliate shall relieve Lilly of its obligations hereunder.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">49</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z62a97691247245e1b9308c2e451c6301" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Lilly License</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d3ccd20841a4bbbb64612f20e7cecb8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">10.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">License to Immunocore</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ba8f817080444279d93fe3c0e7fa374" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly hereby grants to Immunocore a non-exclusive, royalty-free, fully paid-up, worldwide license, with the right to sublicense to the Third Party Partners in accordance with Clause 10.3.1(b) and subject to Clause 10.2.3, under the Lilly
                Foreground IP for the purpose of making, having made, selling, supplying, using and importing ImmTACs (or products comprising ImmTACs) to any Target other than the Selected Targets (the &#8220;<font style="font-weight: bold;">Grantback License</font>&#8221;).







                For clarity, the Grantback License does not include any right under any Lilly Background IP.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z338ec25cccd44095b10a4ee3be11d725" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any grant of a sublicense by Immunocore under Clause 10.3.1(a) shall only be granted to a Third Party Partner to the extent that such Third Party Partner has granted to Immunocore substantially similar rights to its equivalent
                Intellectual Property Rights to those set out in Clause 10.3.1(a) including a right to sublicense such Third Party Intellectual Property Rights to Lilly and such Intellectual Property Rights are sublicensed to Lilly hereunder and Immunocore
                shall advise Lilly regarding the identity of any such sublicensee (provided Lilly hereby agrees to keep such notification confidential and that such notification will be held only by Lilly&#8217;s legal department and only accessed by such legal
                department and external legal advisers to Lilly). Where Lilly takes a sublicense under such Third Party Intellectual Property Rights then Immunocore shall be entitled to notify the relevant Third Party Partner (if such notification is
                required) that Lilly is a sub-licensee and the date it became a sub-licensee, provided such Third Party Partner has agreed in writing to keep such notification confidential and that such notification will be held only by the Third Party
                Partner&#8217;s legal department and only accessed by such legal department and external legal advisers to such Third Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2dbd8733a9b0489b8d44c3de7978fa50" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly hereby grants to Immunocore a non-exclusive, royalty-free, fully paid-up, worldwide license under the Lilly Background IP and the Lilly Foreground IP, in each case, as necessary for Immunocore to perform the Research Plan, any
                Co-Development Plan and any obligations under any Co-Commercialization Agreement. Immunocore shall not have the right to sub-license such rights without Lilly&#8217;s prior written consent.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbd8efacd2524404fb91fab98808e974b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where Immunocore takes over any development or commercialization of any Selected Candidate or Product in accordance with Clauses 7.6, 8.3 or 20.8.6, as applicable, Lilly will also grant to Immunocore a non-exclusive worldwide license
                under Lilly Foreground IP or Lilly Background IP, to the extent strictly necessary in each case for Immunocore to continue with such development or commercialization of any Selected Candidate or Product. Such license shall be subject to
                payment to Lilly of the amounts specified in, or otherwise agreed to pursuant to, Clauses 7.6, 8.3 or 20.8.6.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">50</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a437e98628f49cb9a3341a4030296cf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">10.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">No Additional Licenses</font>. Except as expressly provided in this Agreement, nothing in this Agreement shall grant either Party any right, title or interest in and to the know-how, Patents or other
                Intellectual Property Rights of the other Party (either expressly or by implication or estoppel).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478853" name="z_Toc58478853"></a><font style="font-weight: bold;">ARTICLE 11</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>TECHNOLOGY TRANSFER</u></div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">In addition to any technology transfer contemplated by any Research Plan, following completion of any Research Plan and as part of any Co-Development and/or Development Plan, Immunocore will, at
        Immunocore&#8217;s sole cost and expense:</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z343be001cc3f462b85720aefd5a1ab59" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>assist Lilly in establishing a CMC supply chain and will allow and enable Lilly to work with Immunocore&#8217;s CMOs (to the extent relevant). Such assistance will include technical training sufficient to enable Lilly or its designated CMO to
                use such manufacturing information and to make Back-Up Compounds, Selected Candidates, Joint Selected Candidate and Products; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1c9850daae6475e8a8aacf721d45c24" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provide ongoing technical assistance in relation to Lilly&#8217;s development and manufacturing of Back-Up Compounds, Selected Candidates, Joint Selected Candidates and Products as reasonably requested from time to time and during the Term.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">The details of what technical assistance and transfer of technology will be required from Immunocore will be agreed as part of a plan [***]. The level of assistance provided under this Article 11
        shall be limited to a total aggregate of [***] at any time prior to IND filing for the applicable Product coming out of the relevant Research Plan unless otherwise agreed between the Parties in writing; provided, that Immunocore shall provide such
        additional assistance as Lilly may reasonably request, with such assistance provided at the FTE Rate. For clarity, the technology transfer described in this Article 11 may be undertaken up to three (3) times (i.e., once with respect to each
        Research Plan).</div>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478854" name="z_Toc58478854"></a><font style="font-weight: bold;">ARTICLE 12</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>DEVELOPMENT OF ADDITIONAL PRODUCTS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34d8e85eee4c496d8375cce4e4797d53" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Minor Modifications</font>. Lilly may undertake modifications to any Selected Candidate that do not require the performance of Reserved Activities at any time in accordance with a Co-Development Plan or
                Development Plan, as applicable. Because such modified Selected Candidate is part of the &#8220;<font style="font-weight: bold;">Product</font>&#8221; definition, no Development Milestones will be paid in connection with any such modified Selected
                Candidate unless such modified Selected Candidate replaces the development of the Selected Candidate in which case the Development Milestones will become payable in the same way as for the Selected Candidate and, for clarity, such modified
                Selected Candidate shall deemed a Replacement Back-up Compound; provided, that, for clarity, Net Sales associated with any such modified Selected Candidate shall be added to Net Sales of any other Product(s) directed to the same Selected
                Target.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4508ae6cacbc4a5f8ab32e8c707970f6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Back-up Compounds</font>. Subject to Clause 4.7 with respect to Reserved Activities, Lilly may develop Back-up Compounds with respect to any Product at any time in accordance with a Co-Development Plan or
                Development Plan, as applicable. In the event that any such Back-up Compound becomes a Replacement Back-up Compound, then such Replacement Back-up</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">51</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">Compound would, with respect to Development Milestones, &#8220;step-in&#8221; to the place of the Product it is replacing in accordance with Clause 13.4.2(e). Without limiting the foregoing, Lilly has no right
        to commercialize any Back-up Compound that is not a Replacement Back-up Compound; provided, that should Lilly desire to commercialize a Back-up Compound (other than a Replacement Back-up Compound), such commercialization shall be subject to
        negotiation of applicable financial terms under Clause 12.3.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1394279f14d34adea2f7f6a1a89f162a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">12.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">New Products</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za986dc802dd34dceb67994a2a0f23fe5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">12.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that Lilly desires to pursue the development and commercialization of a Next Generation Compound, Additional HLA Compound or Back-up Compound (other than a Replacement Back-up Compound) (in each case, a &#8220;<font style="font-weight: bold;">New Product</font>&#8221;), it shall so notify Immunocore and the Parties shall discuss and agree in good faith regarding the financial consideration to be provided to Immunocore in connection therewith and any other
                applicable terms and conditions relevant thereto (and the Parties will either execute a separate agreement in connection therewith or amend this Agreement to include such New Product and related Compounds). The Parties agree that, as of the
                Effective Date they intend that, the starting point for any negotiations as to applicable terms for any New Product will be that the principles for development and/or co-development (including opt-in and opt-out rights) for a Research Plan
                Compound will apply to any such New Product.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z19e8d9f4827a4952a425379b640926af" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">12.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Without limiting the foregoing, the Parties acknowledge the existence of patient populations that may justify development of Additional HLA Compounds and the Parties will discuss in good faith the possibility of developing such
                Additional HLA Compounds with respect to a given Selected Candidate not later than the end of Phase II Clinical Trials of such Selected Candidate (or earlier to the extent adequate information is available). In addition, at any time during
                the Term, Immunocore may propose the development of an Additional HLA Compound with respect to a given Selected Candidate and Lilly shall consider such proposal in good faith; provided, that, for clarity, Lilly has no obligation to agree to
                such development [***]. If Lilly agrees to do so, the Parties will negotiate terms regarding such an Additional HLA Compound in accordance with the first sentence of this Clause 12.3 If, however, Lilly does not desire to develop an
                Additional HLA Compound, it will consider in good faith a proposal from Immunocore to permit Immunocore to undertake such development itself [***]. The Parties agree to discuss the possible development of an Additional HLA Compound not
                later than the end of the first Phase II Clinical Trial (or, if earlier, such time as the Parties agree that adequate information is available to support such a discussion. Notwithstanding the foregoing, in the event that the Parties cannot
                agree regarding the terms under which an Additional HLA Compound will be developed (whether by the Parties jointly or by Immunocore individually), then neither Party shall have the right to develop or commercialize either itself, or with or
                through an Affiliate or Third Party, such an Additional HLA Compound.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">52</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478855" name="z_Toc58478855"></a><font style="font-weight: bold;">ARTICLE 13</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>FINANCIAL TERMS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zec559605a3e14aecbc226af4ddc1a5a6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Upfront Fee</font>. Lilly shall pay a fee of US$ forty-five (45) million to Immunocore. Such payment is due as of the Effective Date and shall be made no later than [***] after the Effective Date.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za39595908bad4ad4803cc8f771559ca6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Opt-in Fee</font>. Lilly shall pay a fee of US$ ten (10) million to Immunocore within [***] of the date of exercise of each Lilly Co-Development Option.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5df2ff0c6d6e45a696c40db721096a77" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-commercialization Profit/Loss Sharing</font>. Provided Immunocore has exercised the Immunocore Co-Development Option with respect to a given Co-Development Plan and has not exercised any Opt-out
                Rights, Immunocore shall be entitled to a share in the costs and profits associated with the worldwide development and sale of any relevant Product. The level of cost share borne by, and profit share payable to, Immunocore shall be set
                based on the level at which Immunocore exercises the Immunocore Co-Development Option, namely either fifty percent (50%) or twenty five percent (25%). The mechanism for such payments and the calculation of cost and profit share shall be
                agreed as part of the Co-Commercialization Agreement in accordance with Exhibit G.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1183a8b34da44c9b205577aa6fde6df" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Development Milestones</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z108ed7d3ac474ea68abc806de2f2e739" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The milestones set forth below (&#8220;<font style="font-weight: bold;">Development Milestones</font>&#8221;) are payable on a Product by Product basis. Development Milestones will only be payable by Lilly where lmmunocore has not exercised the
                lmmunocore Co-Development Option or where lmmunocore (having exercised the lmmunocore Co-Development Option) then exercises any of its Opt-Out Rights, but in such case only with respect to Development Milestones occurring after the exercise
                of the Opt-Out Right. In such circumstances, Lilly will pay lmmunocore the following one-time payments upon each Product achieving the indicated Development Milestone, the level of payment being based on the point at which lmmunocore ceases
                to share the responsibility for the development of the relevant Product:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="margin-left: 36pt;">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze9fa958437b146058ede71e5118d802e" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="text-align: right; margin-right: 28.25pt; color: #000000;">Milestone Event</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="margin-left: 3.6pt; color: #000000;">Co-</div>
                <div style="margin-left: 3.6pt; color: #000000;">Development </div>
                <div style="margin-left: 3.6pt; color: #000000;">Option Not </div>
                <div style="margin-left: 3.6pt; color: #000000;">Exercised</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="color: #000000;">Exercised </div>
                <div style="color: #000000;">Phase I Opt-</div>
                <div style="color: #000000;">Out Right at </div>
                <div style="color: #000000;">25%</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="margin-left: 7.2pt; color: #000000;">Exercised </div>
                <div style="margin-left: 7.2pt; color: #000000;">Phase I </div>
                <div style="margin-left: 7.2pt; color: #000000;">Opt-Out </div>
                <div style="margin-left: 7.2pt; color: #000000;">Right at </div>
                <div style="margin-left: 7.2pt; color: #000000;">50%</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="margin-left: 3.6pt; color: #000000;">Exercised </div>
                <div style="margin-left: 3.6pt; color: #000000;">Phase II </div>
                <div style="margin-left: 3.6pt; color: #000000;">Opt-Out </div>
                <div style="margin-left: 3.6pt; color: #000000;">Right at </div>
                <div style="margin-left: 3.6pt; color: #000000;">25%</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="margin-left: 3.6pt; color: #000000;">Exercised </div>
                <div style="margin-left: 3.6pt; color: #000000;">Phase II </div>
                <div style="margin-left: 3.6pt; color: #000000;">Opt-Out </div>
                <div style="margin-left: 3.6pt; color: #000000;">Right at </div>
                <div style="margin-left: 3.6pt; color: #000000;">50%</div>
              </td>
            </tr>
            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div style="margin-right: 5.75pt;">[***]</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div style="margin-left: 3.6pt;">[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
              <td style="width: 13.85%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
              <td style="width: 13.85%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
              <td style="width: 13.73%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div>[***]</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); padding-bottom: 2px;">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
              <td style="width: 13.73%; vertical-align: top; background-color: rgb(0, 0, 0); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; background-color: #000000; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">53</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="margin-left: 36pt;">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z20230cbcc19048edb00a5ffe270aef23" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
              <td style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
                <div>[***]</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 27.33%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 17.51%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.85%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td rowspan="1" style="width: 13.73%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4acd99d89d5040fb916ed80ee51304b3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Certain Terms</font>. It is understood and agreed that the following terms shall apply to the Milestone Events achieved under Clause 13.4.1.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z010fcea410e04d0aa601bf30965e05b8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Payments under Clause 13.4.1 shall be due only once for each Product under each Development Plan in the first [***] Indications to achieve such Milestone Event for such Indication. Should the same Product receive Regulatory Approval for
                a [***] of the above milestones shall be payable where the relevant Product achieves the above Milestone Events in such [***]. Milestone payments shall not be due for the fourth Indication or any other Indications for the same Product.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z340a1f173dd04ef390ec6a1c35c5787f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Payments shall be due under Clause 13.4.1 by Lilly regardless of whether it is Lilly itself that meets the Milestone Event(as defined in the table in Clause 13.4.1) or where such Milestone Event is met through the actions of any
                Sublicensee of Lilly (including Affiliates of Lilly). Lilly shall procure that any Sublicensee agrees to notify Lilly, as applicable, promptly following any Milestone Event being met by such Sublicensee.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z61024330fd5e4b97868a14893ca69f1f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If, for any reason, a particular Milestone Event specified in Clause 13.4.1 is achieved with respect to a given Product and Indication without one or more preceding Milestone Events with respect to such Product and Indication having been
                achieved, then upon the achievement of such Milestone Event, both the Milestone Event Payment applicable to such achieved Milestone Event and the Milestone Event-related Payment(s) applicable to such preceding unachieved Milestone Event(s)
                shall be due and payable.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z598192fc295e457ea2178257e3e30853" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>In the event that [***] two or more Milestone Events are merged or combined with any other Milestone Event, for example [***]. For example, [***], the Milestone Event in Clause 13.4.1(c) would be deemed achieved and the relevant
                Milestone Event Payment become due.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8305529885b745c4a7900a4905d7b9ad" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where the Selected Candidate fails in any Clinical Trial or is replaced for any other reason and is replaced by a Replacement Back-up Compound, Development Milestones already paid in relation to the replaced Selected Candidate shall not
                be due and payable in relation to the Replacement Back-up Compound. Development Milestones shall be due for the Replacement Back-up Compound where it reaches any Milestone Event in relation to which a Development Milestone was not payable
                for the replaced Selected Candidate.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1c89c35e7d28449095c8ddbe5aef63fe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notice of Achievement; Timing of Payment</font>. With respect to each Milestone Event, Lilly shall inform Immunocore within [***] of the achievement of such Milestone Event (whether such Milestone Event
                is achieved by Lilly or its Sublicensees). Immunocore</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">54</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">shall issue an invoice for payment in relation to the Milestone Event and Lilly shall pay such invoice within [***] of receipt of the relevant invoice.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0aeb3d27747e49a7ab5b6fd4c8451b5c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.4.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Development Clarification</font>. For the avoidance of doubt, in the event that Immunocore has exercised the Immunocore Co-Development Option with respect to a given Selected Target (and related
                Research Plan Compounds) and Immunocore (i) has not exercised an Opt-Out Right with respect thereto, Immunocore shall receive no Development Milestone-related payments under this Clause 13.4 with respect to Products directed to such
                Selected Target, or (ii) then exercises any Opt-Out Right with respect thereto, Immunocore shall receive no Development Milestone-related payments under this Clause 13.4 with respect to Development Milestones with respect to Products
                directed to such Selected Target achieved prior to exercising such Opt-Out Right. For clarity, in the event of the preceding sub-Clause (ii), Immunocore may receive Development Milestone-related payments in connection with Development
                Milestones with respect to Products directed to such Selected Target achieved following the date of the exercise of the Opt-Out Right with respect thereto.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5ca1bb2957064fc594487fa551f6b5df" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Commercial Milestone Payments</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z431c4998964943daa48a30361a076b9f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Commercial Milestone Events</font>. Commercial Milestone Payments will only be payable by Lilly in connection with Products directed to a Selected Target with respect to which Immunocore has not exercised
                the Immunocore Co-Development Option or where Immunocore (having exercised the Immunocore Co-Development Option) then exercises any of its Opt-Out Rights. In such circumstances, Lilly will pay Immunocore the following one-time payments, on
                a Product-by-Product basis, upon such Product achieving the following Commercial Milestone Events, the level of payment being based on the point at which Immunocore ceases to share the responsibility for the development of such Product:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z38cf0157266e49e9b4f5891095941fdd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 7.2pt; color: #000000; font-weight: bold;">Commercial Milestone Events</div>
            </td>
            <td style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Co-Develop. </div>
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Option Not </div>
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;"> Exercised</div>
            </td>
            <td style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Exercised </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Phase I Opt- </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Out Right at </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">25%</div>
            </td>
            <td style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Exercised </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Phase I Opt- </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">Out Right at </div>
              <div style="text-align: justify; margin-left: 3.6pt; color: #000000; font-weight: bold;">50%</div>
            </td>
            <td style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="margin-right: 5.4pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Exercised </div>
              <div style="margin-right: 5.4pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Phase II </div>
              <div style="margin-right: 5.4pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Opt-Out </div>
              <div style="margin-right: 5.4pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Right at 25%</div>
            </td>
            <td style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Exercised </div>
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Phase II </div>
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Opt-Out </div>
              <div style="margin-left: 3.6pt; color: #000000; font-weight: bold;">Right at 50%</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 28.46%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.53%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.64%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.62%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 14.47%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.28%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37cfe9c524e2486f9355be1e0945c78e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Commercial Milestone for Diagnostic Products</font>. Where any Product is sold for diagnostic purposes only (whether by Lilly or any of its Sublicensees) (&#8220;<font style="font-weight: bold;">Diagnostic</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">55</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;"><font style="font-weight: bold;">Product</font>&#8221;), a single payment shall be made by Lilly of [***] upon First Commercial Sale of such Diagnostic Product. Lilly shall notify Immunocore within [***]
        of First Commercial Sale of any Diagnostic Product. For clarity, this is a one-time milestone payment for first commercial sale in the world, not payments for First Commercial Sale in each country. Payment of the [***] shall be due within [***] of
        receipt of invoice from Immunocore. No Milestone Event Payments, Commercialization Milestone Payments or Royalties shall be due and payable in relation to such Diagnostic Product.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc3953f3b09ab4b5faea0a8a4f588b708" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.5.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notice of Achievement; Payment</font>. With respect to each Commercial Milestone Event listed in Clause 13.5.1 above, Lilly shall promptly (and in any event within [***] of the end of the calendar quarter
                during which such Net Sales Event occurs) inform Immunocore following the achievement of such event by either Lilly or its Sublicensees. On or after Immunocore&#8217;s receipt of such notice of achievement, Immunocore shall submit a written
                invoice to Lilly for the corresponding Commercial Milestone Payment. Each such invoice shall specify the applicable Commercial Milestone Event, and shall be payable within [***] of receipt of an invoice from Immunocore with respect thereto.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z063e94e4a64a4614a5cb5bd1654cd4d8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.5.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Co-Commercialization Clarification</font>. For the avoidance of doubt, in the event that Immunocore has exercised the Immunocore Co-Development Option with respect to a given Selected Target (and related
                Research Plan Compounds) and Immunocore has not exercised an Opt-Out Right with respect thereto, Immunocore shall receive no Commercial Milestone Payments under this Clause 13.5 with respect to Products directed to such Selected Target.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za41547426e6a449b84785ef13174d43c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Royalty Payments for Products</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z762e18e8e25c46cd82f41caf8b750f96" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Valid Claim Products</font>. Lilly shall pay Immunocore, on a Product by Product basis, and subject to the terms of Clauses 13.6.2 and 13.6.3, the following royalties on annual worldwide Net Sales of such
                Product by Lilly or its Sublicensees.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zec06460def7a4391b31bd072b2a6d0d6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 31.77%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Annual Aggregate Net Sales </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Level of each Product</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Co-Develop. </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Option Not </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Exercised</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Exercised</div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Phase I Opt-</div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Out Right at<br>
                25%</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Exercised </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Phase I </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Opt-Out </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Right at </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">50%</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Exercised </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Phase II </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;"> Opt-Out</div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Right at </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">25%</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Exercised </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Phase II </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;"> Opt-Out </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">Right at </div>
              <div style="color: rgb(0, 0, 0); font-weight: bold; margin-left: 9pt;">50%</div>
            </td>
          </tr>
          <tr>
            <td style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
            <td style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div>[***]</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 31.77%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 15.8%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.2%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 12.87%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.25%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td rowspan="1" style="width: 13.1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9a62b4e993e045e0bd80c9dac8b5568e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Royalties shall be payable on Net Sales of each Product in each country, for the period set forth in Clause 13.6.3, where such Product either (i) is Covered by a Valid Claim and such Valid Claim Covers the composition of matter of the
                relevant Product itself, or approved use(s) for such Product, so long as there are no other approved uses of such Product that are not Covered by such Valid</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">56</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">Claim; or (ii) in the absence of any Valid Claim as provided in (a)(i) above, manufacture of such Product requires the use of any Confidential Information Controlled by Immunocore or where the
        manufacture of such Product is Covered by a Valid Claim other than a Valid Claim provided in (a)(i) above or such Product benefits from a period of market exclusivity granted in accordance with Applicable Laws, including Orphan Drug Designation,
        and in each case for the duration of any granted exclusivity period and in which case the amounts payable shall be reduced and paid at [***] of the level stated in the table above.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c553b290d86420f87c41fba6fc9ec33" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>For the purposes of Clauses 13.6.1 and 13.6.3(a), a Valid Claim will not include the claims of any patent application which has been pending for a period of more than [***] from its first priority date in front of the relevant patent
                office or administrative body. On expiry of such [***] period royalties under Clause 13.6.1(a)(i) shall be suspended and royalties shall instead be payable in accordance with Clause 13.6.1(a)(ii) until the claims of such patent application
                issue in which case the provisions of Clause 13.6.1(a)(i) shall again apply to such Valid Claim to the extent the Royalty term with respect to such Product has not expired in accordance with Clause 13.6.3.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z396b7246fb6f4c80b5eed20f55d44208" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>For the avoidance of doubt, Immunocore shall receive no Royalties under this Clause 13.6.1 with respect to Net Sales of Joint Selected Candidates (and Products containing any such Joint Selected Candidates), but rather shall receive, or
                pay, its share of profits and losses in accordance with the Co-Commercialization Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zac37d6e9cef9413ab3267191181a5fa8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Payment Offsets</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdaad839ee75c489cbd07b2daf03cd45e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Third Party Payments</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z892f93129b074c33b298c2d9781d56b6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">General Third Party License</font>. Subject to Clause 13.6.2(a)(ii), if, after the Effective Date, Lilly or its Sublicensee obtains a right or license under any intellectual property of a Third Party,
                where the making, using, selling, offering for sale, or importing of a Product by Lilly or the relevant Sublicensee is in the absence of such right or license [***] infringe the intellectual property of a Third Party [***], then Lilly may
                offset the payments due and payable to Immunocore with respect to such Product by the amount of payments paid by Lilly or its Sublicensee to such Third Party for such right or license; provided that in no event shall such reductions reduce
                the payments owed to Immunocore for such Product by more than [***] of what would otherwise be owed by Lilly, or their Sublicensee to Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f9342285e76472cb1a6a820b48be35d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 108pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Third Party Partner License</font>. If, after the Effective Date, Lilly or its Affiliate or Sublicensee obtains a right or license under a Patent controlled by a Third Party Partner, which Patent is
                registered in the name of Immunocore or any Immunocore Affiliate (a &#8220;<font style="font-weight: bold;">Selected Patent</font>&#8221;), where the making, using, selling, offering for sale, or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">57</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 144pt;">importing of a Product by Lilly or the relevant Sublicensee is in the absence of such right or license [***] infringe a Selected Patent [***], then Lilly may offset the payments due and payable to
        Immunocore with respect to such Product by the amount of payments paid by Lilly or its Sublicensee to such Third Party Partner for such right or license; provided that in no event shall such reductions reduce the payments owed to Immunocore for
        such Product by more than [***] of what would otherwise be owed by Lilly, or their Sublicensee to Immunocore.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z231206f3f3924236bd1aad0f5b897797" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Biosimilar</font>. Following the first commercial sale of a Biosimilar in a country and such Biosimilar is not being commercialized by Lilly, the royalties due and payable by Lilly or its Sublicensee
                hereunder shall be reduced by [***] in such country. The reduction in Royalties under this Clause 13.6.2(b) shall only apply during the period of time that the Biosimilar is being sold by a Third Party (excluding any Sublicensee) in such
                country and shall not apply where [***]. As used herein, &#8220;<font style="font-weight: bold;">Biosimilar</font>&#8221; means any drug or biological product that is subject to review under an abbreviated approval pathway as a biosimilar, follow-on
                biologic or generic biological product, as those terms are commonly understood under the FD&amp;C Act or the PHS Act and related rules and regulations, or the corresponding or similar laws, rules and regulations of any other jurisdiction
                and where such drug or biological product obtains Regulatory Approval based on, or in part on, reference to any data or Regulatory Approval applicable to a Product hereunder.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfe830783fd6644ec882af95c8c6699dd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The cumulative reduction made under Clause 13.6.2(a) and 13.6.2(b) in a country shall not exceed a total of more than [***] of what would otherwise be owed by Lilly to Immunocore in accordance with Clause 13.6.1 in such country;
                provided, that [***] in the event a royalty reduction under Clause 13.6.2(a)(ii) also applies.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z516f2daaa4744fa2bfcdbf2cfce88d2a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Royalty Term</font>. The Royalty obligations set forth in Clause 13.6.1 above will commence on a country-by-country and Product-by-Product basis upon the First Commercial Sale of such Product in such
                Country, and expire on a country-by-country and Product-by-Product basis upon the later of (a) expiration of the last to expire Patent containing a Valid Claim (as defined in Clause 13.6.1(a)) which Covers the composition of matter of such
                Product itself, or approved use(s) for such Product so long as there are no other approved uses of such Product that are not Covered by such Valid Claim in such country; or (b) ten years from First Commercial Sale of such Product.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd6d7021fc01e4047a48fb38bff1fa56a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.6.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Rights Following Expiration of Royalty Term</font>. Upon expiry of Lilly&#8217;s payment obligation hereunder with respect to a Product in a country, the license in Clauses 10.1 and 10.2 shall be fully paid-up,
                irrevocable, transferable and sublicenseable in respect of such Product in such country. With respect to the &#8220;surviving license&#8221; granted under Clause 10.1, the Parties acknowledge and agree that for purposes of such &#8220;surviving license&#8221; the
                license granted in Clause 10.1 shall be deemed to be amended to reflect the right to conduct research with respect to such Product instead of the right to conduct research with respect to any particular plan under this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">58</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb68bfe6043274d2fb4a9ec058eaaf934" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Costs of Research Plan</font>. Each Party shall be responsible for their own costs and expenses incurred in performance of any Research Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc6fcbe6961e8460b99b8729b6dd8278c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">13.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Reimbursement of Costs Under any Co-Development Plan</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a04f0022d3d4e15b696b98ee6fbcccf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where Immunocore has exercised a given Immunocore Co-Development Option and prior to exercise of any Opt-Out Rights with respect to the relevant Co-Development Plan, Immunocore shall share in the costs and expenses of such Co-Development
                Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a362c60a9c84a679c7697be114bb612" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The estimated costs of any Co-Development Plan shall be set out in the initial Co-Development Plan prepared in accordance with Clause 5.4, and such Co-Development Plan shall be updated in accordance with Clause 7.4.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d959265d6ef40ea911b709963135057" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>No later than the [***] after the end of each calendar quarter during the performance of any Co-Development Plan, each Party shall provide to the other Party a list of all costs and expenses reasonably incurred in the performance of the
                relevant Co-Development Plan (&#8220;<font style="font-weight: bold;">Development Costs</font>&#8221;). Such Development Costs shall include [***]. Subject to Clause 13.8.6(h), Development Costs shall not include [***]. Where Development Costs of
                personnel are included, timesheets will be made available to support such costs where reasonably requested by the other Party. Each Party shall provide reasonable evidence supporting any claimed costs on reasonable request from the other
                Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33843ad8f73945598a32991dc912acba" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Subject to Clause 7.4 and Article 8, Immunocore shall be obliged to pay either twenty five percent (25%) or fifty percent (50%) of such Development Costs depending on the level at which it exercised the Immunocore Co-Development Option.
                Payment shall also be subject to the provisions of Clause 7.4 in relation to changes to a given Co-Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7af043463d0e462b8e349593eadda651" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To the extent money is owed to Lilly, Lilly shall invoice Immunocore for such sums and Immunocore shall pay such invoice within [***] of receipt of invoice. Where Immunocore is owed reimbursement of Development Costs, Immunocore shall
                invoice Lilly for such sums and Lilly shall pay such invoice within [***] of receipt of invoice. Where any part of Development Costs is disputed, reimbursement of the non-disputed part of such Development Costs shall occur in accordance
                with this Clause 13.8.5 and the Parties shall resolve the dispute as expeditiously as possible in accordance with Clause 13.8.7.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7208d7b006d349c3b1a0711974b668ff" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">In calculating any Development Costs the following principles will apply:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z74632056789d48bbb9457b023647ca1d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5850eb3a9b364465a1428b5e91920bb2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any discounts or reductions are available in relation to any Development Costs incurred, such discounts or reductions will apply to any reimbursement under Clause 13.8.5;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fe2f8c45c494502869de195d45a8f89" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All Development Costs shall be calculated in US dollars, unless otherwise expressly provided in this Agreement. Development Costs incurred outside of</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">59</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">the US shall be first determined in the currency in which they are incurred and shall then be converted into an amount in US dollars in accordance with the incurring Party&#8217;s standard procedures
        for accounting in accordance with the Accounting Standards;</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z33f1c1ef3148477ab8477fb4a31eef41" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>[***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9905941fbc1f456ebbe7cbc5db6cbcde" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any Development Costs will be provided for at the rate actually incurred or otherwise accounted for in the accounts of either Party as relevant;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6166a6b0a9c4c3e8857491416bddf28" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any Development Costs incurred by a Party are recoverable from a Third Party (excluding Affiliates), such costs shall not be subject to reimbursement by the other Party under Clause 13.8.5;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01f413b259ce421bba764c205ee47855" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where any Development Costs relate to both the Co-Development Plan and any other work effort or research program applicable to either Party (including in relation to any capital expenditure or equipment acquired for the performance of
                any Co-Development Plan), the Development Costs shall be pro-rated on a reasonable basis and depending on the relative usage for each relevant program; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf885ab6fa2b44314b7fa5d8b05cededc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(h)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any Development Costs shall be incurred in accordance with standard practice of the Parties (including any expense or travel policy) and shall be treated or accounted for in the same way as other similar costs of a Party all in
                accordance with applicable Accounting Standards.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z114162e5e1724c5b82f644111a6d7862" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Audit Right. </font>Where either Party disputes that any costs are not necessarily incurred in the performance of any Co-Development Plan the dispute shall first be referred to senior managers in
                accordance with Clause 21.1. Where the dispute is not resolved within [***] of such referral, either Party may request the right to request that such report be verified by the audited Party&#8217;s then-current independent, certified and
                internationally recognized public accounting firm. Such right to request a verified report shall (i) be limited to the period covered by the disputed Development Costs being claimed; and (ii) not more frequently than once with respect to
                records covering any specific period of time.&#160; Each Party shall, upon timely request&#160; and on at least [***] advance notice from Immunocore or Lilly, as applicable, and at a mutually agreeable time during its regular business hours, make its
                records available for inspection by the relevant accounting firm at such place or places where such records are customarily kept, solely to verify the accuracy of the disputed Development Costs being requested under this Agreement. The
                accounting firm shall only state factual findings in its audit reports. The draft audit report shall be shared with both Parties at the same time. Following review and approval by all Parties of the draft audit, the final audit report shall
                be shared with Lilly and Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbd1bca23be01434cafdbbc2375287862" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Underpayment; Overpayment</font>. After reviewing the audit report delivered under Clause 13.8.7, any discrepancy in Development Costs and reimbursement of such costs shall be corrected by the relevant
                Party or Parties within [***] of delivery of audit report under Clause 13.8.7. Any audit shall be at the requesting Party&#8217;s expense unless</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">60</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">such audit shows more than the greater of (a) a [***] and (b) [***], discrepancy in the Development Costs being claimed.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d53a1c628014d75b57bf972a92ebab2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">13.8.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Payment and Related Matters</font>. All payments in connection with Development Costs will be handled in accordance with Clauses 14.3 &#8211; 14.6, inclusive.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478856" name="z_Toc58478856"></a><font style="font-weight: bold;">ARTICLE 14</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>ROYALTY REPORTS; AUDITS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc91a1a22687d43bbbd61939bb92bf878" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Timing of Royalty Payment</font>. All royalty payments shall be made within [***] days of the end of each calendar quarter in which the sale was made.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8770abe8564d48a391061d1630659342" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Royalty Report</font>. For each calendar quarter for which Lilly has an obligation to make Royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the
                following information (&#8220;<font style="font-weight: bold;">Net Sales Report</font>&#8221;):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9527a8e407174d64b522f34f3e5fe192" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>total Net Sales of all Products sold in all countries;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d7307cdca4d4b7499a94702ac83de50" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Net Sales on a country-by-country basis for all Products sold;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf8234ba264584efba09b8eb11d722e2e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the exchange rate used to convert Net Sales from the currency in which they are earned to US dollars; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbda744fbe7904065a1b0ad157ac68d6e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the total Royalties due to Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;">If Lilly is reporting Net Sales for more than one Product, the foregoing information shall be reported on a Product-by-Product basis.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2998adbe50554854b1b94f2af1a5b55c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Mode of Payment</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z85950bf682c3402f92aceafc2d5af7cd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All payments hereunder shall be made by telegraphic transfer in immediately available funds to the account listed below (or such other account as the receiving Party shall designate before such payment is due):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 72pt;">If to Immunocore:</div>
      <div>&#160;</div>
      <div style="margin-left: 72pt;">
        <table style="border-collapse: collapse; width: 50%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="z24047f6323194c1f9d4cf4dc5b7a61c5" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="text-align: justify;">Bank:</div>
              </td>
              <td style="width: 20%; vertical-align: top;">
                <div style="text-align: justify;">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="text-align: justify;">Bank Address:</div>
              </td>
              <td style="width: 20%; vertical-align: top;">
                <div style="text-align: justify;">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="text-align: justify;">Account #:</div>
              </td>
              <td style="width: 20%; vertical-align: top;">
                <div style="text-align: justify;">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="text-align: justify;">IBAN:</div>
              </td>
              <td style="width: 20%; vertical-align: top;">
                <div style="text-align: justify;">[***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 30%; vertical-align: top;">
                <div style="text-align: justify;">BIC/SWIFT:</div>
              </td>
              <td style="width: 20%; vertical-align: top;">
                <div style="text-align: justify;">[***]</div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 72pt;">If to Lilly, to such accounts as Lilly may designate in writing.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z179c88d54dfc473ca6411d391f5d4514" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Where either Party changes the details of the bank account into which payments due under this Agreement are to be paid, including nomination of an account other than one held by Immunocore under Clause 9.2.2, the Party so nominating
                shall reimburse the other Party in full for any additional tax liabilities or similar payments that are actually paid by such other Party as a direct result of the change in bank account details</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">61</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">(which, in the case of Lilly, will be deemed to mean a bank account outside of the US), excluding internal administrative costs incurred as a result of changing the bank details.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f25f390de104939bb118e54033397cb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Currency of Payments</font>. All payments under this Agreement shall be made in US dollars, unless otherwise expressly provided in this Agreement. Net Sales outside of the US shall be first determined in
                the currency in which they are earned and shall then be converted into an amount in US dollars in accordance with Lilly&#8217;s standard procedures for accounting in accordance with the Accounting Standards.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z935be073be5a4a74ad346c867e0c2e4c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Taxes</font>. Each Party shall comply with Applicable Laws regarding filing and reporting for tax purposes. Neither Party shall treat their relationship under this Agreement as a pass through entity for
                tax purposes. If any payments made by the Parties under this Agreement are subject to withholding taxes under Applicable Laws of any state, federal, provincial or foreign government, each Party shall be authorized to withhold such taxes as
                are required under applicable law, pay such taxes to the appropriate government authority, and remit the balance due to the other Party net of such taxes. The Party paying the taxes to the government authority shall secure and deliver to
                the other Party an official receipt for taxes paid. The Parties agree to fully cooperate with each other to enable each Party to more accurately determine its own tax liability and to minimize such liability to the extent legally
                permissible and administratively reasonable. Each Party shall provide and make available to the other Party any exemption certificates, resale certificates, information regarding out of state or out of country sales or use of equipment,
                materials or services, and any other information reasonably requested by the other Party to support the provisions of this Clause 14.5, including the appropriate organization of invoice formats and supporting documents to allow maximization
                of reclamation of VAT and other transaction taxes.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z837c3becbc8142a5b5757ddaaeb884bf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Late Payment</font>. In relation to any amount required to be paid by a Party hereunder which is not paid on the date due, the other Party may charge interest at a rate equal to the [***] effective for
                the date that payment was due, as reported by The Wall Street Journal (New York edition). Such interest shall be computed on the basis of a year of 360 days for the actual number of days payment is delinquent.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9aa31812bbde4226b0ce1b1ac4ae8492" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">14.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Records; Inspection</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z722d1f1e865f45439c4affaef883dcfd" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.7.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Records</font>.&#160; Lilly agrees to keep, for [***] from the year of creation, records of all sales of Products for each reporting period in which royalty payments are due, showing sales of Products for each
                of Lilly and its Sublicensees and applicable deductions in sufficient detail to enable the report provided under Clause 14.2 to be verified. Lilly shall procure that its Sublicensees keep records in accordance with this Clause.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za84de338eab24bcfb689c4b277e04258" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.7.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Audits</font>. Immunocore shall have the right to request that such report provided under Clause 14.7.1 be verified by [***] independent, certified and internationally recognized public accounting firm
                (the &#8220;<font style="font-weight: bold;">CPA Firm</font>&#8221;). Such right to request a verified report shall (i) be limited to a [***] period immediately preceding such request for a verified report; (ii) not be exercised more than once in any
                calendar year; and (iii) not occur more frequently than once with respect to records covering any specific period of time. Subject to Clause 14.7, Lilly shall, upon timely request and at least [***] advance notice from Immunocore and at a
                mutually agreeable time during its regular business hours,</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">62</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">make its records available for inspection by such CPA Firm at such place or places where such records are customarily kept, solely to verify the accuracy of the reports provided under Clause 14.2
        and related payments due under this Agreement. The CPA Firm shall only state factual findings in the audit reports. The draft audit report shall be shared with Lilly at the same time that it is shared with Immunocore. Following review and approval
        by all Parties of the draft audit, the final audit report shall be shared with Lilly and Immunocore. Lilly shall procure access to Sublicensee records relevant to verify the accuracy of reports under Clause 14.2 relating to such Sublicensee and in
        accordance with this Clause 14.7.2 and shall make such Sublicensee records reasonably available to the CPA Firm.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb69499549da4263a2ff4e8f511e4f12" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.7.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Confidentiality</font>. Prior to any audit under Clause 14.7.2, the CPA Firm shall enter into a written confidentiality agreement with Lilly that (i) limits the CPA Firm&#8217;s use of Lilly and its
                Sublicensees&#8217; records to the verification purpose described in Clause 14.7.2; (ii) limits the information that the CPA Firm may disclose to the Immunocore to the numerical summary of payments due and paid; and (iii) prohibits the disclosure
                of any information contained in such records to any Third Party for any purpose (except as required by Applicable Law). The Parties agree that all information subject to review under Clause 14.7.2 and/or provided by the CPA Firm to
                Immunocore is Lilly&#8217;s Confidential Information, and Immunocore shall not use any such information for any purpose that is not germane to Clause 14.7.2.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z756d1d83141841288625c116fb64012f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">14.7.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Underpayment; Overpayment</font>. After reviewing the CPA Firm&#8217;s audit report, Lilly shall promptly pay any uncontested, understated amounts due to Immunocore. Any overpayment made by Lilly or any
                Sublicensee shall be promptly refunded or fully creditable against amounts payable in subsequent payment periods, at Immunocore&#8217;s election. Any audit under Clause 14.7.2 shall be at Immunocore&#8217;s expense; provided, however, Lilly shall
                reimburse reasonable out-of-pocket audit fees for a given audit if the results of such audit reveal that Lilly and any Sublicensee underpaid Immunocore with respect to royalty payments by [***], or more, for the audited period.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478857" name="z_Toc58478857"></a><font style="font-weight: bold;">ARTICLE 15</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>INTELLECTUAL PROPERTY; OWNERSHIP</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1b66ff9cca6d4539a8d3e30f9f2bbd72" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Disclosure; Ownership; Inventorship; Assignment and Cooperation</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b70ad3754d74ba1a6a9461d9a1b4624" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Disclosure</font>. During the Term, each Party shall promptly disclose to the other any registerable Foreground IP conceived, or reduced to practice by or for the disclosing Party during the course of any
                Research Plan and/or any Co-Development Plan. Disclosure will be made via designated patent representatives for each Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z57829564852a438691bf080322665d13" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Ownership</font>. As between the Parties:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcf6722754f664d6cae04965cd40f4fc6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>subject to sub-Clause (c) below, Immunocore shall solely own any Foreground IP it solely creates or reduces to practice;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze96a8b142ea44ca1ab69afb65e6ac104" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>subject to sub-Clause (c) below, Immunocore and Lilly shall jointly own any Foreground IP created or reduced to practice jointly by the Parties (&#8220;<font style="font-weight: bold;">Joint IP</font>&#8221;); and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">63</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaf451fc69f3d4a838a658b0cc79fd378" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly shall solely own any Foreground IP (i) it solely creates or reduces to practice or (ii) that is created by either Party, solely or jointly, in the performance of any activities under a Co-Development Plan or Development Plan.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">In relation to any inventions, existence and ownership of inventions shall be determined in accordance with English law. Without limiting the foregoing, each Party retains an undivided one-half
        interest in and to the Joint IP (including Patents therein). Subject to the licenses granted in Article 10 and the allocation of Intellectual Property Rights herein (including, for clarity, Lilly&#8217;s exclusive right to exploit such Joint IP as Covers
        the composition of matter of a Research Plan Compound or Product, or approved use(s) for such Research Plan Compound or Product under Clause 10.2), (1) each Party may exploit fully the Joint IP, in any field, and may grant licenses under the Joint
        IP, without obtaining consent from the other Party, and (2) may transfer or encumber its ownership interest in any of the Joint IP, subject to obtaining the prior written consent of the other Party (which consent will not be unreasonably withheld,
        conditioned or delayed), in each case of sub-clauses (1) and (2), without accounting to the other Party.</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">Nothing in this clause shall effect or impact any ownership of either Party in relation to any Background IP.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z19122ea5163e4335bd1a1d1b0ebbbd39" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.1.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Assignment; Cooperation</font>. Each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation, to implement the provisions of
                this Article 15. Each Party shall to the extent legally possible under relevant national or local laws use Commercially Reasonable Efforts to cause all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on
                its behalf, to assign (or otherwise convey rights) to such Party any Patents and Know-How discovered, conceived or reduced to practice by such employee, Affiliate or Third Party, and to cooperate with such Party in connection with obtaining
                patent protection therefore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z44cd82dd3afa40fbaf65abaf0b387904" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Patent Prosecution</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc066d176a09f4f938bfe621a080f076a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Immunocore Controlled Prosecution and Maintenance</font>. Immunocore shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the
                Immunocore Background IP. Immunocore shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Foreground IP, to the extent any Patent does not include any
                claim Covering (i) a Selected Target, or (ii) the composition of matter of a, Research Plan Compound or Product, or (iii) any use of a Research Plan Compound or Product. Immunocore will provide Lilly with copies of any filed patent
                application, filings and other material correspondence with applicable governmental authorities relating to the Immunocore Foreground IP, and will keep Lilly reasonably informed of the status of such Prosecution and Maintenance, including
                providing Lilly copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Immunocore. Immunocore shall [***] regarding such activities and shall [***] with respect thereto.
                Without limiting the foregoing, in the event</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">64</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">that Immunocore elects not to Prosecute and Maintain any Patents under this Clause 15.2.1, Immunocore shall not grant any Third Party [***] the right to do so.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f903786009b4898ac327a5259046b86" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Lilly Controlled Prosecution and Maintenance</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z03e62712c9314d26b07f90d78bcb8b99" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Foreground IP to the extent such Patents include any claim Covering (i) a Selected Target,
                or (ii) the composition of matter of a Research Plan Compound or Product, or (iii) any use of a Research Plan Compound or Product (excluding Joint IP, which is addressed below in Clause 15.3.2(b)), and Lilly Foreground IP. Lilly will
                provide Immunocore with copies of any filed patent application, filings and other material correspondence with applicable governmental authorities relating to such Immunocore Foreground IP and Lilly Foreground IP and will keep Immunocore
                reasonably informed of the status of such Prosecution and Maintenance, including providing Immunocore copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Lilly.
                Immunocore will provide all reasonable cooperation and assistance to Lilly at Lilly&#8217;s reasonable request and at Lilly&#8217;s expense in Prosecution and Maintenance of such Patents, including generating data and reports, and making scientific
                personnel reasonably available to Prosecute and Maintain patent applications.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zedd86f9636de4bd490f2f746d026693c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Joint IP. Lilly will provide Immunocore with a draft copy of any proposed patent application, filings
                and other material correspondence with applicable governmental authorities covering the Joint IP for review and comment prior to filing or prior to submission of any response or communication with applicable governmental authorities and
                will keep Immunocore reasonably informed of the status of such Prosecution and Maintenance, including providing Immunocore with copies of all communications received from or filed in patent offices within a reasonable period of time after
                receipt by Lilly. Lilly will provide any filings or correspondence for comment by Immunocore where possible at least [***] prior to any due date or required response date. Lilly will [***] in good faith all comments provided by Immunocore
                to Lilly prior to any due date or required response date. Immunocore will provide all reasonable cooperation and assistance to Lilly at Lilly&#8217;s reasonable request and at Lilly&#8217;s expense in Prosecution and Maintenance of the Joint IP,
                including making data, reports, and scientific personnel reasonably available to prepare and prosecute patent applications.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9366ef8341864e46b087e3bd10eec947" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If Lilly elects not to Prosecute and Maintain any Patents within the Joint IP or Patents within the Immunocore Foreground IP under Clause 15.2.2, Lilly shall provide at least [***] written notice to Immunocore. Thereafter, Immunocore
                shall have the right, but not the obligation, to Prosecute and Maintain any such notified Patents, at its sole expense and in its sole discretion. Lilly will provide</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">65</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">reasonable cooperation and assistance to Immunocore in relation to transferring such Prosecution and Maintenance. Notwithstanding the foregoing, Immunocore shall have no right to step-in under
        this Clause 15.2.2(c) where Lilly has decided not to Prosecute and Maintain any Patents within the Foreground IP solely owned by Lilly; to the extent such Patents do not Cover [***] any Product.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9eacc106d343464883dbf6e9e3f20aa7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Enforcement Rights for Infringement by Third Parties</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zddbfe3b5a1074d9eb90120fda8a4a1ab" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.3.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notice</font>. Each Party shall promptly notify, in writing, the other Party upon learning of any actual or suspected infringement of the Patents within the Background IP or Foreground IP to the extent
                such actual or suspected infringement is relevant to any Selected Target, Research Plan Compound or a Product, or, of any claim of invalidity, unenforceability, or non-infringement of any Patents within the Background IP (to the extent
                relevant to any Selected Target or Product), Foreground IP or Joint IP (each an &#8220;<font style="font-weight: bold;">Infringement</font>&#8221;). At the request of the Party receiving such notice, the other Party shall provide all evidence in its
                possession pertaining to the actual or suspected Infringement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd86dc527d53347ccb73a71f026d4906a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.3.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Enforcement Actions</font>. The Parties shall consult as to potential strategies to terminate suspected or potential Infringement; provided, that:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z00e4cf2a250e4f0381f4ea8724a3828d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly shall have the first right, but not the obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Clauses
                15.2.2(a) and 15.2.2(b). If Lilly does not, within [***] of receipt of a notice under Clause 15.3.1, take steps to abate the Infringement, then Lilly shall provide written notice to Immunocore thereof, and Lilly and Immunocore shall discuss
                the strategy thereof.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc054c9a620404f5dbd128aba273ad3d0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall have the first right, but not the obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Clause
                15.2.1.&#160; If Immunocore does not, within [***] of receipt of a notice under Clause 15.3.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then Lilly shall have the right, but not the obligation,
                to take action to enforce against such Infringement; provided that if Immunocore is diligently pursuing ongoing settlement discussions at the end of such [***] period then Lilly shall not be permitted to exercise such right unless such
                settlement discussions cease without reaching settlement or Immunocore ceases to pursue such discussions diligently. To the extent this Clause relates to Immunocore Background IP, the obligations under this Clause will be subject to any
                Third Party Partner agreement entered into by Immunocore before the Effective Date.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z67e009a32f0a416fb16b5ec76b9cada9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the non-controlling Party shall reasonably cooperate with the Party controlling any such action to abate or enforce (as may be reasonably requested by the controlling Party and at the controlling Party&#8217;s expense), including, if</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">66</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 108pt;">necessary, by being joined as a party provided that the non-controlling Party shall be indemnified by the controlling Party as to any costs or expenses, and shall have the right to be represented
        by its own counsel at its own expense. The Party controlling any such action shall keep the other Party updated with respect to any such action, including providing copies of all documents received or filed in connection with any such action.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6e0c54ed08df482088614491d5ca61fb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.3.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Settlement</font>. The Party controlling any such enforcement action described in Clause 15.3.2 (a &#8220;<font style="font-weight: bold;">Clause 15.3.2 Enforcement</font>&#8221;), at its sole discretion, may take
                reasonable actions to terminate any alleged Infringement without litigation; provided, that if any such arrangement would adversely affect the non-controlling Party&#8217;s rights under this Agreement, then that arrangement is subject to the
                non-controlling Party&#8217;s prior written consent, which consent shall not to be unreasonably withheld, conditioned or delayed).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4501055e064d4c579474a5cb2c990fa2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.3.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Costs and expenses</font>. The Party controlling any Clause 15.3.2 Enforcement shall bear all costs and expenses, including litigation expenses, related to such enforcement actions, except to the extent
                agreed otherwise in the Co-Commercialization Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb6c6e9b1f75143d494c791efbca05dbc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.3.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Damages</font>. Unless otherwise mutually agreed by the Parties, and subject to the respective indemnity obligations of the Parties set forth in Article 13, all damages, amounts received in settlement,
                judgment or other monetary awards recovered in Clause 15.3.2 Enforcement with respect to activities of the Third Party that occurred prior to the effective date of such award shall be shared as follows:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f3c423e8d084300966886d9916fc413" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>first, [***]; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d8593f7adbb4dba99ea8c9e4bc03504" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>second, the controlling Party will retain the remainder.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">Any receipts by Lilly under Clause 15.3.5(b) shall constitute Net Sales and be subject to payment of royalties under Clause 13.6 (or appropriate treatment under the Co-Commercialization Agreement,
        as applicable).</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For the avoidance of doubt and in the absence of any relevant Co-Commercialization Agreement or Co-Development Plan, if any settlement results in the granting to the alleged infringer of a
        sublicense of any of the Licensed Intellectual Property with running royalties payable on post-settlement sales by the alleged infringer, such alleged infringer shall be deemed to be a Sublicensee and such royalties on post-settlement sales (i)
        shall be subject to all applicable royalty obligations hereunder [***] and (ii) shall not be subject to this Clause 15.3.5).</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ca85022abf246c88562e04e6e120737" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">15.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Third Party Infringement Claims</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z10e0f6b977d24f39a6f50216364e00fa" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notice</font>. In the event that a Third Party shall make any claim, give notice, or bring any suit or other inter parties proceeding against Lilly or Immunocore, or any of their respective Affiliates or
                licensees (exclusive of Third Party Partners) or customers, for infringement or misappropriation of any Intellectual Property Rights with respect to the research, development, making, using, selling, offering for sale, import or export of
                any</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">67</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">Research Plan Compound or Product or with respect to any Selected Target (&#8220;<font style="font-weight: bold;">Third Party Infringement Claim</font>&#8221;), in each case, the Party receiving notice of a
        Third Party Infringement Claim shall promptly notify the other Party and provide all evidence in its possession pertaining to the claim or suit.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8cc9e4a6c87244bb82edc520d733d8a0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Defense</font>. The Parties shall consult as to potential strategies to defend against any Third Party Infringement Claim, consistent with the overall goals of this Agreement, including by being joined as
                a party. The Parties shall cooperate with each other in all reasonable respects in the defense of any Third Party Infringement Claim or raising of any counterclaim related thereto. Subject to the respective indemnity obligations of the
                Parties set forth in Article 19, Lilly shall be solely responsible for defending such Third Party Infringement Claim including selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation. If Lilly
                does not, within [***] of receipt of a notice under Clause 15.4.1, take steps to defend the Third Party Infringement Claim, then to the extent that such Third Party Infringement Claim is brought against Immunocore, Immunocore shall have the
                right, but not the obligation, to take action to enforce or defend against such Third Party Infringement Claim provided that if Lilly is diligently pursuing ongoing settlement discussions at the end of such [***] period then Immunocore
                shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or Lilly ceases to pursue such discussions diligently. At the controlling Party&#8217;s request and expense, the non-controlling
                Party shall cooperate with the controlling Party in connection with any such defense and counterclaim, provided that the non-controlling Party shall be reimbursed by the controlling Party as to any reasonable and documented costs or
                expenses, and shall have the right to be represented by its own counsel at its own expense. Any counterclaim or other similar action by a Party, to the extent such action involves any enforcement of rights under the Licensed Intellectual
                Property, Foreground IP or Joint IP, will be treated as an enforcement action subject to Clause 15.3. Nothing in this Clause 15.4 shall prevent Immunocore from complying with the terms of any court order relating to or arising out of any
                Third Party Infringement Claim.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39bee1c9f7e4465fbf2c075187ecff22" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Settlement</font>. If any such defense under Clause 15.4.2 would adversely affect the other Party&#8217;s rights under this Agreement or impose a financial obligation upon the other Party or grant rights in
                respect, or affect the validity or enforceability, of the other Party&#8217;s Patents or any Joint IP, then any settlement, consent judgment or other voluntary final disposition of such Third Party Infringement Claim shall not be entered into
                without the consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z155320968cce413997ceda4e6d3f604c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">15.4.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Costs and Expenses</font>. The Party controlling the defense of any Third Party Infringement Claim shall bear all costs and expenses, including litigation expenses, to defend against any Third Party
                Infringement Claim; provided, that, [***]. For clarity such obligation shall not include any expenses incurred in the bringing of any counterclaim.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">68</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478858" name="z_Toc58478858"></a><font style="font-weight: bold;">ARTICLE 16</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>CONFIDENTIALITY</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd705d5ec52124c589439ec088d187e6a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Non-use and Non-disclosure of Confidential Information</font>. During the Term, and for a period of [***] thereafter, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed
                to in writing, keep confidential and not disclose to any Third Party any Confidential Information of the other Party; (ii) except in connection with activities contemplated by, the exercise of rights permitted by (including in accordance
                with Clause 16.3(e), or in order to further the purposes of, this Agreement or otherwise agreed to in writing, not use for any purpose any Confidential Information of the other Party; and (iii) take all reasonable precautions to protect the
                Confidential Information of the other Party (including all precautions a Party employs with respect to its own confidential information of a similar nature).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze4db85f0ba574febbebf317ddf91afb8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Exclusions Regarding Confidential Information</font>. Notwithstanding anything set forth in this Article 16 to the contrary, the obligations of Clause 16.1 above shall not apply to the extent that the
                Party seeking the benefit of the exclusion from the obligations set forth in Clause 16.1 can demonstrate that the Confidential Information to be excluded of the other Party:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z35597c96e0604537b2f24aba0dabb36d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>was already known to the receiving Party, other than under an obligation of confidentiality, at the time of receipt by the receiving Party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za283a18a883c44269b490a86f9f83282" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>was generally available to the public or otherwise part of the public domain at the time of its receipt by the receiving Party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z376c7a3736de40aa94a439f30a787d0b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>became generally available to the public or otherwise part of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02203f3b2c0f44c39760ede15164bd4c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>was received by the receiving Party without an obligation of confidentiality from a Third Party having the right (to the knowledge of the receiving Party) to disclose such information without restriction;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5be0dd660f1454b80a600cc0dbadd61" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>was independently developed by or for the receiving Party without use of or reference to the Confidential Information of the other Party; or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fcf06b7a3e446ee8187112aacea868a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>was released from the restrictions set forth in this Agreement by express prior written consent of the Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e9958280c4e499f99f15906c350d890" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Authorized Disclosures of Confidential Information</font>. Notwithstanding the foregoing, a Party may use and disclose the Confidential Information of the other Party as follows:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zec9b9edb2687485b93f1945539f7ead4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if required by law, rule or governmental regulation, including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the Party seeking to disclose the
                Confidential Information of the other Party (i) uses all reasonable efforts to inform the other Party prior to making any such disclosures and cooperates with the other Party in seeking a protective order or other appropriate remedy
                (including redaction) and (ii) whenever possible, requests confidential treatment of such information;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">69</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z731876aade6347db95f34a5b4f222862" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>to the extent such use and disclosure is reasonably required in the Prosecution and Maintenance of a Patent within the Licensed Intellectual Property, Joint IP or Foreground IP in accordance with this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z22da807bc72e479687ee5e6bb676183d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as reasonably necessary to obtain or maintain any Regulatory Approval, including to conduct preclinical studies and Clinical Trials and for pricing approvals, for any Products, provided, that, the disclosing Party shall take all
                reasonable steps to limit disclosure of the Confidential Information outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5a35b7703fe34d749e7350b50836bd38" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>to take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd460eba3c987499bab1d3370dbeb44a8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>to the extent necessary, to Sublicensees, collaborators (including collaborators, and potential collaborators, relating to use of Products in combination with other products), vendors, consultants, agents, attorneys, contractors and
                clinicians under written agreements of confidentiality at least as restrictive as those set forth in this Agreement, who have a need to know such information in connection with such Party performing its obligations or exercising its rights
                under this Agreement. Further the receiving Party may disclose Confidential Information to existing or potential acquirers, merger partners, permitted sub-contractors and professional advisors only to the extent strictly necessary for the
                relevant transaction with such Third Parties and provided in each case that such Third Parties agree to maintain the Confidential Information under written agreements of confidentiality at least as restrictive as those set forth in this
                Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1de066c1eaa54cc1bcc14b2b31ee492a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Terms of this Agreement</font>. The Parties agree that this Agreement and the terms hereof will be considered Confidential Information of both Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd5d1c9285ba8463e9b24cf9f65bf0dc1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination of Prior Agreements</font>. As of the Effective Date, as between the Parties, this Agreement supersedes the Confidentiality Agreement between the Parties dated 25th February 2014.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e56bbdda4374ad79d4ee79a7b29d6ea" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">16.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">No License</font>. As between the Parties, Confidential Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall
                not constitute any grant, option or license to the other Party, beyond those licenses expressly granted under Article 10, under any patent, trade secret or other rights now or hereinafter held by the disclosing Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478859" name="z_Toc58478859"></a><font style="font-weight: bold;">ARTICLE 17</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>PUBLICITY; PUBLICATIONS; USE OF NAME</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z875780ed59cb4ec4a58dd486776af6f4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Publicity</font>. The Parties shall agree and issue a joint press release, as set out in Appendix E, concerning the execution of this Agreement on or within fourteen (14) days of the Effective Date. The
                text of any other press releases, public announcements or PowerPoint presentations concerning this Agreement, the subject matter hereof, or the research, development or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">70</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">commercial results of Products hereunder (a &#8220;<font style="font-weight: bold;">Release</font>&#8221;) shall be addressed pursuant to Clauses 17.2 -17.5, inclusive, as applicable.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f160833134649e3865dbbdcd53dcbb8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Releases During the Research Plan</font>. Subject to Clauses 17.1 and 17.5, during the Research Term neither Party may issue a Release without the prior written consent of the other, which consent shall
                not be unreasonably withheld, conditioned or delayed and any consent or refusal shall be provided within [***] of request for such consent. In the absence of any reply to a request for consent within such [***] period, consent shall be
                deemed given.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1cd6425299b44030b5082c467ae4e8a1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Releases During any Co-Development Plan</font>. Subject to Clauses 17.1 and 17.5, during the Co-Development Term neither Party may issue a Release without the prior written consent of the other, which
                consent shall not be unreasonably withheld, conditioned or delayed and any consent or refusal shall be provided within [***] of request for such consent. In the absence of any reply to a request for consent within such [***] period, consent
                shall be deemed given. Releases related to any activities under the Co-Commercialization Agreement will be addressed in the Co-Commercialization Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze970a5696fe74bc68583957ba68b5c54" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Releases Related to Selected Candidates and Products</font>. Subject to Clauses 17.2, 17.5 and 17.6, after the completion of any relevant Research Plan:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6c65462cd87463ebba6f349c52b5d66" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">17.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore may not issue a Release without Lilly&#8217;s prior written consent; provided, that [***] Lilly shall not unreasonably withhold its consent to [***]; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z869b4a91b312407c8b3810daf1d43239" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">17.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly may not issue a Release without Immunocore&#8217;s prior written consent if it includes reference to Immunocore by name (unless such reference to Immunocore only identifies Immunocore as the licensor of relevant Intellectual Property
                Rights).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify;">In each case, consent shall not be unreasonably withheld, conditioned or delayed and shall be provided or refused within [***] of request for such consent. In the absence of any reply to a request for consent within
        such [***] period, consent shall be deemed given.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf96a3ecaa000457d8cb1e22fea52564c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Releases required by law or regulation</font>. Each Party may issue any Release it is required to issue by Applicable Law (including, in the case of Immunocore, any announcements required to satisfy the
                UK Takeover Panel or the UKLA listing rules; and, in the case of Lilly, requirements of any law or rule imposed by the US Securities and Exchange Commission or any securities exchange).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1f244e5a8e324758a28b0a63995b9814" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Publications</font>. Notwithstanding Clauses 17.1 to 17.5, both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations
                regarding results of and other information regarding the Research Plan Compounds, Products or New Products may be beneficial to both Parties, provided that such publications or presentations are subject to reasonable controls to protect
                Confidential Information, the patentability of inventions and other commercial considerations. Accordingly, the following shall apply with respect to papers and presentations proposed for disclosure by either Party:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z22ba1f182d2443c5971e6584dfed6468" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">17.6.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>With respect to any paper or presentation proposed for disclosure by Lilly which utilizes information generated by or on behalf of Lilly, so long as such paper or presentation does not contain any Confidential Information of Immunocore,
                Lilly shall be free to</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">71</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">make, publish and disclose such papers and presentations at its discretion. Lilly shall acknowledge Immunocore, as appropriate, in any publication that discloses Lilly&#8217;s use of the Products or the
        results of any Research Plan or Co-Development Plan. For clarity, Lilly shall not be permitted to publish or otherwise disclose any Confidential Information of Immunocore except as may be expressly permitted pursuant to Clause 16.2 or 16.3; and</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdc47c150c2f644cfab1c262ccf701169" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">17.6.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>With respect to any paper or presentation proposed for disclosure by (i) Lilly, which includes Confidential Information of Immunocore, or (ii) Immunocore, which utilizes information generated by or on behalf of Immunocore relating to any
                Selected Target, Research Plan Compounds, Products or New Products or any Confidential Information of Lilly, (in each case, the relevant Party is the &#8220;<font style="font-weight: bold;">Disclosing Party</font>&#8221;), the other Party shall have
                the right to review and approve any such proposed paper or presentation (the &#8220;<font style="font-weight: bold;">Non-Disclosing Party</font>&#8221;). The Disclosing Party shall submit to the Non-Disclosing Party the proposed publication or
                presentation (including posters, slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) at least [***] prior to the date of submission for publication or the date of presentation, whichever is
                earlier, of any of such submitted materials. The Non-Disclosing Party may review such submitted materials and respond to the Disclosing Party as soon as reasonably possible, but in any case within [***] for abstracts) of receipt thereof. At
                the option of the Non-Disclosing Party, the Disclosing Party shall (a) delete from such proposed publication or presentation any Confidential Information of the Non-Disclosing Party and/or (b) delay the date of such submission for
                publication or the date of such presentation for a period of time sufficiently long (but in no event longer than [***]) to permit the Non-Disclosing Party to seek appropriate patent protection.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zef6acc7869aa4fb2984658a95507a48b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">17.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">No Right to Use Names</font>. Except as expressly provided herein, no right, express or implied, is granted by the Agreement to use in any manner the name of &#8220;<font style="font-weight: bold;">Immunocore</font>&#8221;
                or &#8220;<font style="font-weight: bold;">Lilly</font>&#8221; or any of their Affiliates, or any other trade name, symbol, logo or trademark of the other Party or its Affiliates in connection with the performance of this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478860" name="z_Toc58478860"></a><font style="font-weight: bold;">ARTICLE 18</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>REPRESENTATIONS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z80831e28b71f43dc88cdee5132f9e6a2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">18.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Mutual Representations and Warranties</font>. Each Party represents and warrants to the other Party that as of the Effective Date:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za4332b88ee584234b04096c821c48882" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it is validly organized under the laws of its jurisdiction of incorporation;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb2b41231c9e84f91ab2382a4ec950b1d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it has obtained all necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to be obtained by it in connection with this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e3b6ffc4fae4c38ad95357ca74f0251" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action on its part;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb466dea4b3314ebabf17e61c226a9677" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it has the legal right and power to enter into this Agreement and to fully perform its obligations hereunder;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">72</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z61ccf95441ff40a19682c67ad673782b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>the performance of its obligations under this Agreement will not conflict with such Party&#8217;s charter documents or any Third Party agreement, contract or other arrangement to which such Party is a party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb72aa05b01314703a41d3170206687df" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it will comply with all Applicable Laws in the performance of this Agreement; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z899b114bb75f46bfbec6daf2b383b4ab" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.1.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it has the legal right and power to extend the rights and licenses granted to the other Party hereunder.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc2abd2f20f9c4ef7b615fb8d69518154" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">18.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Immunocore Additional Warranty</font>. Immunocore also represents and warrants to Lilly that:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2acec89344684746a01e75dde0fb2b50" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, it has not received any written letter, nor to Immunocore&#8217;s knowledge is any Third Party, threatening infringement or alleging infringement, of any Third Party rights in relation to the Immunocore Background IP;
                provided, however, that nothing in this Clause 18.2 shall be interpreted as requiring Immunocore to have undertaken any inquiries or to have obtained any freedom to operate opinion.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d485d4dbcdb4bfea4d6e0e8548f787b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date Immunocore is not aware of any opposition, third party observation, inter-partes proceedings, including IPRs, or re-examinations relating to any of the Licensed Patents listed in Exhibit A or (b) challenging
                Immunocore&#8217;s ownership or control of the Licensed Patents;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7fca3dae317847f787a0824ed1748a4a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, the Licensed Intellectual Property listed in Exhibit A, and all Licensed Intellectual Property which is owned or co-owned (as opposed to in-licensed) by Immunocore, is free and clear of any liens, charges and
                encumbrances (other than Third Party licenses, which are also subject to Clause 18.2.5 below) created by Immunocore and, except as set forth in Clause 4.8.2(b), Immunocore has not granted to any Third Party the right under any of the
                Licensed Intellectual Property to develop, manufacture or commercialize any Compounds against the Initial Targets in the Field;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11eaab89812c4048b2f1b1cd5f5b5e04" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, and except in relation to one epitope of nine amino acids identified from the Mage A1 Initial Target and presented on HLA-B60 the Initial Targets contain no Third Party Sequences and Immunocore is not internally
                pursuing development of any products directed against any epitopes contained in the Initial Targets;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd00c12e53a404a43b91eb87f8c7d85cf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date (a) it has not identified any epitopes in the Initial Targets presented on HLA-A2 [***]; (b) it has not identified any epitopes in the Initial Targets presented on HLA-A2 [***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb37f57a7df3f4f898862595ab8d10950" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>it has compared the sequences of each of the epitopes identified as of the Effective Date within the Initial Targets for HLA-A2 (&#8220;<font style="font-weight: bold;">Initial Epitopes</font>&#8221;) [***];</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc0c5ca8bddc144d4b977f59afef4c6a1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, Immunocore has not identified any Compound on behalf of any Third Party Partner, or for its own purposes, that are, to Immunocore&#8217;s knowledge, cross-reactive with or bind to the Initial Targets and save that
                Immunocore has not carried out any studies or assessment as to whether any Compound identified on</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">73</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">behalf of a Third Party Partner or for its own purposes is cross-reactive with or binds to any epitope from the Initial Targets;</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaae2bc4c37834360b1229dcca498a587" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore has not granted to any Third Party any licenses, sublicenses or other rights under the Licensed Intellectual Property that contravenes the rights granted to Lilly under this Agreement;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7d9923fe4731418cbfd0529c1be39cf6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, neither Immunocore nor any of its Affiliates is or has been a party to any agreement with any government or an agency thereof pursuant to which such government or such agency provided funding for the development
                of the Licensed Intellectual Property;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d2fabfc95064a7db8b068e89a6f5f3d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>as of the Effective Date, [***] to Immunocore&#8217;s knowledge (following reasonable investigation with respect thereto), the development and manufacture of Compounds directed to the Initial Targets in the Field (and Products containing such
                Compounds) will not infringe any published Patent Right of any Third Party (including any Third Party Partner) or misappropriate any know-how of any Third Party (including any Third Party Partner);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z98c69b0e93e94501b195f9e6502d4944" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>with respect to Adaptimmune Limited, (i) Immunocore has appropriate written agreements in place with Adaptimmune Limited that enable Immunocore to grant Lilly the rights and license granted to Lilly hereunder, and to permit Immunocore to
                perform its obligations hereunder, (ii) Adaptimmune Limited has no right to access or use any Foreground IP or any of Lilly&#8217;s Confidential Information, and (iii) Adaptimmune Limited does not have the right or power to control Immunocore
                other than as a result of the same individuals or entities holding shares in Adaptimmune Limited and Immunocore; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d94194b829a48c7ba61c5a70f88a315" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">18.2.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>further covenants that, it will not, and will not cause any Affiliate or Third Party to, file any Patents covering or claiming any epitope included in any Selected Target, on behalf of, or in connection with activities performed in
                conjunction with, any Third Party Partner except to the extent that any such Patent is licensed to Lilly hereunder. For clarity, the obligation under this covenant does not prevent any Third Party Partner from itself filing any Patents
                covering or claiming any Initial Target, or any epitope included in any Selected Target, where Immunocore does not have the right to control the Patent strategy of such Third Party Partner.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7cd02118d52f4001869f09a2b786d604" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">18.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Disclaimers</font>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, KNOW-HOW, MATERIALS OR CONFIDENTIAL
                INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. IN PARTICULAR BOTH PARTIES
                ACCEPT THAT GIVEN THE NATURE OF THE PRODUCTS AND COMPOUNDS BEING GENERATED UNDER THIS AGREEMENT THERE CAN BE NO GUARANTEE THAT ANY COMPOUND CAN BE SUCCESSFULLY GENERATED OR THAT IF GENERATED, THE COMPOUND WILL BE CAPABLE OF OBTAINING
                REGULATORY APPROVAL.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">74</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478861" name="z_Toc58478861"></a><font style="font-weight: bold;">ARTICLE 19</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>INDEMNIFICATION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z43ab852eb05a4709ae87c0ad862c2ee5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Indemnification</font>. Subject to Clause 19.3, Immunocore shall indemnify, defend and hold Lilly, its Affiliates, their Sublicensees and their respective directors, officers, and employees and the
                successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages, settlements, penalties, fines, costs or expenses (including reasonable attorneys&#8217; fees and other reasonable expenses of litigation)
                (collectively, &#8220;<font style="font-weight: bold;">Loss</font>&#8221; or &#8220;<font style="font-weight: bold;">Losses</font>&#8221;) arising, directly or indirectly out of or in connection with any Third Party claims, suits, actions, demands or judgments (&#8220;<font style="font-weight: bold;">Third Party Claims</font>&#8221;) relating to (a) the activities performed by or on behalf of Immunocore or its Affiliates under this Agreement, and (b) the negligence or willful misconduct of Immunocore or its
                Affiliates or any of its or their sub-contractors; (c) any breach of Applicable Laws by Immunocore or its Affiliates or any of its or their sub-contractors, (d) any breach of this Agreement by Immunocore, its Affiliates or their
                sub-contractors; and (e) direction by Immunocore under Clause 9.2.2 to pay its share of the profits into an account other than one held by Immunocore except, in each case, to the extent caused by the negligence or willful misconduct of
                Lilly or their Affiliates or Sublicensees or any breach of this Agreement by Lilly or its Affiliates or Sublicensees.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0b2617b27e8c451eaa33cc7f28c767d0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Indemnification</font>. Subject to Clause 19.3, Lilly shall indemnify, defend and hold Immunocore, and its Affiliates and their respective directors, officers, and employees and the successors and assigns
                of any of the foregoing harmless from and against any and all Losses arising, directly or indirectly out of or in connection with any Third Party Claims relating to (a) the activities performed by or on behalf of Lilly or any Sublicensee
                under this Agreement, (b) the negligence or willful misconduct of Lilly, its Sublicensees or any sub-contractor of Lilly (including its Affiliates); and (c) any breach of Applicable Laws by Lilly, its Affiliates, Sublicensees or
                sub-contractors except, in each case, to the extent caused by the negligence or willful misconduct of Immunocore or its Affiliates or breach of this Agreement by Immunocore or its Affiliates.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za7851677b04e40fd924c6eb1592fa3bf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Procedure</font>. If a Party intends to claim indemnification under this Agreement (the &#8220;<font style="font-weight: bold;">Indemnitee</font>&#8221;), it shall promptly notify the other Party (the &#8220;<font style="font-weight: bold;">Indemnitor</font>&#8221;) in writing of such alleged Loss and the Third Party Claim. The Indemnitor shall have the right to control the defense thereof with counsel of its choice as long as such counsel is reasonably
                acceptable to Indemnitee. Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason, provided, however, that if the Indemnitee shall have reasonably concluded, based upon a written opinion from outside
                legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action, in each of which cases the Indemnitor shall pay the fees and expenses of one law firm serving as counsel for the
                Indemnitee) in relation to such Third Party Claim. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party Claims covered by this
                Agreement. The obligations of this Article 19 shall not apply to any settlement of any Third Party Claims if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld or delayed. The failure
                to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any obligation to the Indemnitee
                under this Clause 19.3. It is understood that only Lilly and Immunocore may claim indemnity under this Agreement (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">75</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29a4114c637f4bfa8597082bd8bf1aac" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Insurance</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb59e6297d25e48f4a72a0204c8b269d6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">19.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Insurance Coverage</font>. Each Party shall obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z536bedb76e5c4688ae7cea5a5aec5e60" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">19.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Evidence of Insurance</font>. No earlier than [***] after signing this Agreement, each Party shall provide, upon request therefor, the other Party with its certificate of insurance evidencing the
                insurance coverage set forth Clause 19.4.1. Each Party shall provide to the other Party at least [***] prior written notice of any cancellation, non-renewal or material change in any of such insurance coverage.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0effde29dc2b4b3db51945b8d73736b4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">19.4.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Product / Clinical Trial Liability Insurance</font>. Commencing not later than [***] prior to the first use in humans of the first Product, Lilly shall have and maintain such type and amounts of products
                / clinical trial liability insurance covering the development of Products as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit per occurrence for
                clinical trials liability as follows: a minimum limit of [***] for any period during which Lilly or any of its Sublicensees is conducting a clinical trial(s) with any Product(s) or as otherwise required in order to comply with Applicable
                Laws. Such insurance policies shall be primary insurance. Immunocore shall also share in the cost of such insurance (to the extent such cost is separate from any general insurance policy or self insurance policy held by Lilly with respect
                to Joint Selected Candidates (and Products containing such Compounds)), such share equating to the level at which Immunocore exercised the Immunocore Co-Development Option with respect to applicable Joint Selected Candidates (and Products
                containing such Joint Selected Candidates)).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9e5105513a494519aea028f939f6fbc5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Limitation of Damages</font>. NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS
                AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF (1) A PARTY&#8217;S OBLIGATIONS UNDER ARTICLE 16, OR (2) INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 19 FOR CLAIMS OF THIRD PARTIES. WHERE IMMUNOCORE HAS
                NOT EXERCISED ANY IMMUNOCORE CO-DEVELOPMENT OPTION OR HAS EXERCISED ANY OF ITS OPT-OUT RIGHTS, EACH PARTY&#8217;S TOTAL AGGREGATE LIABILITY FOR ALL LOSSES ARISING UNDER THIS AGREEMENT WHETHER FOR BREACH, NEGLIGENCE, OR OTHERWISE (EXCEPT, FOR
                CLARITY, WITH RESPECT TO INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 19) SHALL BE LIMITED TO A SUM EQUIVALENT TO THE GREATER OF [***] OR FEES OR AMOUNTS PAID UNDER THIS AGREEMENT IN THE [***] PRECEDING ANY CLAIM. FOR THE AVOIDANCE OF
                DOUBT, NOTHING IN THIS CLAUSE SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY OR ANY LIABILITY ARISING AS A RESULT OF PERSONAL INJURY OR DEATH CAUSED BY NEGLIGENCE OF ANY PARTY. NOTHING IN THIS CLAUSE SHALL
                PREVENT LILLY CLAIMING DAMAGES, OR LIMITING THE AMOUNT OF SUCH DAMAGES FOR LOSSES AS A RESULT OF A BREACH OF THIS AGREEMENT BY IMMUNOCORE UNDER CLAUSES 3.1.4(b), 3.1.5(d), 4.8, or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">76</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">10.2.3. NOTHING IN THIS CLAUSE 19.5 SHALL LIMIT EITHER PARTY&#8217;S RIGHT TO PURSUE AND OBTAIN EQUITABLE RELIEF.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9d58aa1507634f25b09bed0bd281e1ce" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">19.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Product Recall</font>. Lilly shall be responsible for investigating any SUSAR or other complaint in relation to any Product. Lilly shall report its finding to the JDC or AAC, as relevant, once it has
                identified the reason for such complaint, SUSAR or has identified any requirement to recall any Product or any batch of Product. Lilly shall be responsible for carrying out any Product recall but shall keep the JDC or AAC, as relevant,
                informed of the status and process for such recall including any material correspondence with any Regulatory Authority. Where such recall or investigation occurs during performance of any Co-Development Plan or during the course of the
                Co-Commercialization Agreement, the costs associated with such recall will be shared between the Parties with Immunocore reimbursing Lilly at the level it has opted in to such Co-Development Plan unless (a) such recall is due to any failure
                of Lilly arising out of the manufacture or supply of Product; or (b) any such costs are covered by applicable insurance policies. Lilly shall pay the cost of any recall during performance of a Development Plan or where Lilly is solely
                responsible for development, manufacture and supply of any Product</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478862" name="z_Toc58478862"></a><font style="font-weight: bold;">ARTICLE 20</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>TERM AND TERMINATION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92b4971f572c4a02b95feba7d12e2cbf" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Term</font>. The term of this Agreement (the &#8220;<font style="font-weight: bold;">Term</font>&#8221;) shall commence on the Effective Date and, unless sooner terminated as provided in this Article 20, shall
                continue in full force and effect, on a country-by-country and Product-by-Product basis until there is no remaining royalty payment obligation in such country with respect to such Product, at which time this Agreement shall expire with
                respect to such Product in such country (except for such provisions of this Agreement as continue beyond its natural expiration). The Term shall expire on the date this Agreement has expired in its entirety with respect to all Products in
                all countries in the world. For clarity, in accordance with Clause 13.6.4, upon expiration of this Agreement with respect to a given Product and country Lilly&#8217;s licenses under Clauses 10.1 (subject to the license granted in Clause 10.1
                being converted to research with respect to such Product instead of any particular plan under this Agreement), 10.2.2 and 10.2.4 shall become fully paid-up, irrevocable, transferable and sublicenseable with respect to such Product in such
                country in accordance with Clause 13.6.4.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb95a09fbfdb04a988223182d56936a5c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination by Either Party for Material Breach</font>. Either Party may terminate this Agreement (i) in its entirety, (ii) with respect to any Exclusive License, (iii) with respect to a given Selected
                Target (and Compounds directed to such Selected Target), or (iv) on a country-by-country basis by written notice to the other Party for any material breach of this Agreement by the other Party if, in the case of remediable breach, such
                material breach is not cured within [***] for payment defaults) after the breaching Party receives written notice of such breach from the non-breaching Party; provided, that if such breach is not capable of being cured within such [***] (or
                [***]) period, the cure period shall be extended for such amount of time that the Parties may agree in writing is reasonably necessary to cure such breach, so long as (1) the breaching Party is making Commercially Reasonable Efforts to do
                so, and (2) the Parties agree on an extension within such [***] (or [***]) period. For clarity, this Agreement may be terminated in its entirety under this Clause 20.2 only if the material breach affects the fundamental purpose of this
                Agreement. Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i) whether a breach is material or has occurred or (ii) the alleged</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">77</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">failure to cure or remedy such material breach, and provides written notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute
        resolution provisions in Article 21, and the notifying Party may not so terminate this Agreement until it has been determined under Article 21 that the allegedly breaching Party is in material breach of this Agreement, and such breaching Party
        further fails to cure such breach within [***] (or such longer period as determined by the arbiter of such dispute resolution) after the conclusion of that dispute resolution procedure.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za64b43ceecaf4b77855b5bb7c526cfec" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination by Either Party for Insolvency or Bankruptcy</font>. Either Party may terminate this Agreement effective on written notice to the other Party upon the liquidation, dissolution, winding-up,
                insolvency, bankruptcy, or filing of any petition therefor, appointment of a receiver, custodian or trustee, or any other similar proceeding, by or of the other Party where such petition, appointment or similar proceeding is not dismissed
                or vacated within [***]. All rights and licenses granted pursuant to this Agreement are, for purposes of Clause 365(n) of Title 11 of the United States Code or any foreign equivalents thereof (as used in this Clause 20.3, &#8220;<font style="font-weight: bold;">Title 11</font>&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Title 11. Each Party in its capacity as a licensor hereunder agrees that, in the event of the commencement of bankruptcy proceedings
                by or against such bankrupt Party under Title 11, (a) the other Party, in its capacity as a licensee of rights under this Agreement, shall retain and may fully exercise all of such licensed rights under this Agreement (including as provided
                in this Clause 20.3) and all of its rights and elections under Title 11 and (b) the other Party shall be entitled to a complete duplicate of all embodiments of such intellectual property, and such embodiments, if not already in its
                possession, shall be promptly delivered to the other Party (i) upon any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not
                delivered under (i), immediately upon the rejection of this Agreement by or on behalf of the bankrupt Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z57fe0778eaf04a368d8b1c6c8a65bfc2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination by Lilly</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z72146f9a0657460593a15ac0ab9d24c0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.4.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly shall also have the right to terminate this Agreement in its entirety, or on an Exclusive License-by-Exclusive License basis, or a country-by-country basis, in its sole discretion, at any time by providing written notice to
                Immunocore; such termination to be effective [***] after such notice.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c557f8f3a734af0a6f421b226ce51f5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.4.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Lilly may terminate any Exclusive License as a result of data suggesting that any Selected Target, or any Product or Selected Candidate, covered by such Exclusive License is not viable or otherwise will not obtain Regulatory Approval on
                provision of [***] written notice to Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zec2fd3e8f6814ffdb5fb31c5093a8496" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination by Immunocore</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc272cf9514c74a1fa33f6aeee5a6149b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.5.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall be entitled to terminate any Exclusive License where Lilly has not conducted any development activities prior to receipt of first Regulatory Approval, or (where Product has received first Regulatory Approval) has ceased
                to commercialize, any Selected Target, or any Product or Selected Candidate, covered by such Exclusive License, in either the [***] and [***] of the [***] for a period of more than two (2) consecutive calendar years; provided, that,
                Immunocore shall not be permitted to terminate an Exclusive License under this Clause 20.5.1 where Lilly&#8217;s decision to not</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">78</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">conduct such further development or commercialization activities is reasonably reached in the best interests of the relevant Selected Target, Product or Selected Candidate (rather than for example
        because Lilly is advancing another product over and above the Product) and such decision and the full reasons therefor are communicated to Immunocore in writing and signed by a respective officer of Lilly. Where Immunocore disputes the reasons for
        Lilly deciding to cease development or commercialization, such dispute will be referred to the Alliance Managers and each Party&#8217;s respective officers in accordance with Clause 21 and thereafter to arbitration in accordance with Clause 21.2.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb78980ae20c64159a7ff2d9c723a74a3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.5.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Immunocore shall have the right to terminate any Exclusive License in accordance with Clause 7.6 or Clause 8.3 upon [***] written notice to Lilly.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd9767a3ce9f046429411981ebac0fde9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination for Patent Challenge</font>. If Lilly or their Sublicensees commences proceedings (whether before a regulatory or administrative body or a court) anywhere in the world, or voluntarily assists
                any Third Party in commencing or participating in proceedings (whether before a regulatory or administrative body or a court) alleging that any claim in any Patent within the Licensed Intellectual Property (including the Immunocore
                Background IP) is invalid, unenforceable or otherwise not patentable, then either (i) Lilly or their Sublicensee shall withdraw (or cause to be withdrawn) such challenge within [***] after being requested to do so by Immunocore in writing
                and Immunocore shall have no right to terminate the Exclusive License relating to such Patent pursuant to this Clause 20.6, or (ii) if such challenge is maintained or is not capable of being withdrawn and terminated, Immunocore shall have
                the right to terminate the Exclusive License relating to such Patent on written notice to Lilly; such termination to be effective immediately. Notwithstanding the foregoing, Immunocore shall have no right to terminate this Agreement
                pursuant to this Clause 20.6 if Lilly or their Sublicensees commences proceedings (whether before a regulatory or administrative body or a court) anywhere in the world, or voluntarily assists any Third Party in commencing or participating
                in proceedings (whether before a regulatory or administrative body or a court) alleging that any claim in any Patent within the Licensed Intellectual Property (including the Immunocore Background IP) is invalid, unenforceable or otherwise
                not patentable as a defense (including an affirmative defense) against a claim of infringement by Lilly or their Sublicensee.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5f18cf68cd4840d998f0f9d095d897b3" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Accrued Rights and Obligations</font>. Expiration or termination of this Agreement in its entirety, or with respect to a particular Exclusive License, a given Selected Target (and Product or Selected
                Candidate directed to such Selected Target), or a given country for any reason shall not release either Party hereto from any liability which, as of the effective date of such expiration or termination, had already accrued to the other
                Party or which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to
                the effective date of such expiration or termination.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z93389fdcb7254d45b4396d5766aafafe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Effects of Termination</font>. The effects of termination set forth in this Clause 20.8 shall apply either with respect to this Agreement in its entirety, if the Agreement is terminated in its entirety,
                or only with respect to a specific Product or Exclusive License or country, if this Agreement is only terminated with respect to a specific Product or Exclusive License or country, in all cases</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">79</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">as applicable. For clarity, this Clause 20.8 shall not apply to any given Product and country with respect to which the Term naturally expires.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9062961144d2404aa4bbd8a4ac47c306" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Termination of Licenses</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e3319b38be24eb9b7c71f399bf618ff" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon termination of a particular Exclusive License by Immunocore pursuant to Clause 20.2, Clause 20.5 or Clause 20.6, or by Lilly pursuant to Clause 20.4, such Exclusive License and the related Research License to any Product or Compound
                covered by such Exclusive License shall terminate as of the effective date of such termination;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za3234e7d625348708d3b8fa9fa71665c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon termination of the Agreement in its entirety by Immunocore pursuant to Clause 20.3, all licenses under this Agreement (other than the licenses set forth in Clause 10.3.1(d)) shall terminate as of the effective date of such
                termination; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5f382c0981a40b68c3ed3bf87f8fa83" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Upon termination of Agreement by Lilly in accordance with Clause 20.2 with respect to this Agreement in its entirety or 20.3, the licenses set forth in Clause 10.3 shall terminate as of the effective date of such termination.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z216601f355564d80b8510e6a4b314cb4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Continuation of Sublicenses</font>. Upon termination by Immunocore of this Agreement, or any specific Exclusive License, Immunocore agrees that on request from any Sublicensee it will grant to such
                Sublicensee a license on the same terms as set out in this Agreement (including all event payments and royalty payments) in relation to any Immunocore rights previously licensed to such Sublicensee. Unless otherwise explicitly agreed in
                writing, Immunocore shall not agree to vary or amend the terms of the licenses granted hereunder or take on any additional or further obligations or burdens. This Clause shall not apply where any Sublicensee is in material breach of the
                terms of the relevant sub-license prior to termination of this Agreement by Immunocore or any specific Exclusive Sublicense, whether or not such breach was the reason for termination or not.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z27370b74acc14e5b86261802b1fa3c09" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Clinical Trials</font>. The Parties shall ensure that where termination of any Exclusive License occurs during any Clinical Trial, that any such Clinical Trial shall be wound down in accordance with the
                protocol for such Clinical Trial and in such a way as to minimize any patient harm and at all times in accordance with all Applicable Laws or alternatively where termination is by Immunocore under any Clause or by Lilly under Clause 20.4,
                to the extent legally and ethically permissible to do so, Immunocore shall have the option of taking over the sponsorship of such Clinical Trial. Up until transfer of sponsorship to Immunocore under this Clause, Lilly will continue to
                conduct the relevant Clinical Trial, at Immunocore&#8217;s sole cost and expense (unless termination is as a result of Lilly material breach in which case such transfer shall be at Lilly&#8217;s cost), in accordance with all Applicable Laws and in
                accordance with the Clinical Trial protocol and in each case following the reasonable instructions of Immunocore.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbaa1c18cd74c499f9665749f0110b83c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Return of Confidential Information</font>. It is understood and agreed, that each Party shall have a continuing right to use Confidential Information of the other Party under any surviving licenses
                pursuant to Article 10 and/or this Clause 20.8 or Clause 20.9. Subject</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">80</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">to the foregoing, following expiry or any early termination of this Agreement, the Party that has Confidential Information of the other Party shall destroy (at such Party&#8217;s written request) all
        such Confidential Information in its possession as of the effective date of expiration (with the exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential
        Information), and any Confidential Information of the other Party contained in its laboratory notebooks or databases, provided that each Party may retain and continue to use such Confidential Information of the other Party to the extent necessary
        to exercise any surviving rights, licenses or obligations under this Agreement or any obligation under Applicable Laws.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z29644f8e18e64782b25aca4e96e152df" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Inventory at Termination</font>. Subject to Clause 20.8.6, upon termination of this Agreement and for a period of [***] following such termination, Lilly and its permitted Affiliates and Sublicensee/s
                shall have the right to sell or otherwise dispose of all inventory of Products in all countries then in its stock, subject to the applicable royalty payments due under this Agreement, and any other applicable provisions of this Agreement,
                and Immunocore covenants not to sue Lilly or its permitted Sublicensee/s for infringement under, or misappropriation of, any of the Licensed Intellectual Property that were licensed by Immunocore to Lilly immediately prior to such
                termination with respect to such activities conducted by Lilly or its permitted Sublicensee/s pursuant to this Clause 20.8.5. Following expiry of such [***] period, Lilly shall provide any remaining stock to Immunocore and Immunocore shall
                be entitled to sell such stock in, as between the Parties, its absolute discretion either directly or through any Third Party; provided, that Immunocore will reimburse Lilly for the cost of manufacture of any remaining stock plus [***]
                within [***] of a delivery of invoice therefor.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z06b4272e608643cc81553e78676e2286" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Immunocore Right to Manufacture, Sell and Supply</font>. On termination of any Exclusive License and where such termination is other than for a material breach by Immunocore or by Lilly under Clause 20.3
                (and including where termination is by Immunocore under Clause 20.5.2), Immunocore shall be entitled to take over the manufacture, supply and development of the Selected Candidate and any Back-up Compounds that are the subject of the
                terminated Exclusive License. Lilly shall provide to Immunocore reasonable assistance, documentation (including manufacturing process information) as may be required by Immunocore for the ongoing manufacture and supply of the relevant
                Selected Candidate or Back-up Compound at Immunocore&#8217;s cost and expenses (subject to value share as set out below). Such assistance shall include, to the extent relevant and depending on the stage of research and development of the relevant
                Product or Selected Candidate or Back-up Compounds:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4e57974b51ee4df3a3667fd768d38b33" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>transfer of any Regulatory Approvals held by Lilly to Immunocore (which Immunocore shall promptly accept);</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbfdfc35ec9f84a8eacc94396e34e6f29" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provision of all CMO and CRO details and other sub-contractor details where not already known to Immunocore and where reasonably possible transfer of all related sub-contractor agreements (to the extent such transfer is requested by
                Immunocore), subject where relevant to the consent of any relevant Third Party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">81</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z60f13fe41f844b6bb4271e233c7e9801" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provision of all master drug files and records or documentation required by Immunocore to continue with any Clinical Trials or Regulatory Approvals or as may otherwise be required in order to comply with Applicable Laws;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcbe9d57e101a4bea918ae20342a03686" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>transfer of sponsorship for any Clinical Trials and transfer of any Third Party agreements associated with such Clinical Trials, subject where relevant to the consent of any relevant Third Party;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbf18d9617f62430cb1c7185441d54ee8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provision of all reasonable assistance and technical training as may be reasonably required by Immunocore to enable transfer of manufacture, ongoing Clinical Trials and supply of the relevant Product, Selected Candidate or Back-up
                Compounds to Immunocore as soon as reasonably possible;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9ff09c2353334e988e4c54eb2296a3e2" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provision of any documentation relating to any associated diagnostics and diagnostic assays, to the extent not covered by any transfer of a Third Party agreement to Immunocore; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z88892de3899f44f0953d692dde6dbb71" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 72pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>at Immunocore&#8217;s request, supply to Immunocore of any inventory of Product, Selected Candidate or Back-up Compound at Lilly&#8217;s cost of manufacture [***], to the extent such inventory is not required for Lilly&#8217;s continuing responsibilities
                in relation to any ongoing Clinical Trial or other obligation under this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z34deb9726bf345c989f29114e795d64c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Compensation to Lilly</font>. On termination of any Exclusive License and where such termination is other than for a material breach by Immunocore or by Lilly under Clause 20.3 (and including where
                termination is by Immunocore under Clause 20.5.2), such termination occurs after completion of the Research Plan and where Immunocore has a continued or surviving right to manufacture, supply and develop any Selected Candidate or Back-up
                Compound that were the subject of such terminated license, the Parties shall negotiate, in good faith, appropriate financial compensation to be paid by Immunocore to Lilly so that Lilly may share in the value received by Immunocore in
                connection with relevant Products, which compensation shall be in the form of a royalty, as soon as reasonably possible [***]; provided, that, if the Parties are unable to reasonably agree regarding such consideration, then either Party may
                refer the matter for resolution to an independent expert, by notice in writing to the other Party. The independent expert shall be appointed by the Parties by mutual agreement or in the absence of such agreement within [***] of written
                notice requesting expert resolution, by the International Chamber of Commerce; provided, that, in any event, such expert shall have at least [***] experience in the area of life sciences business development, such that the expert will have
                a reasonable appreciation for the various factors (including the circumstances of termination) that determine the value attributable to a life sciences industry asset. The independent expert shall determine what documentation and evidence
                it requires from each Party in order to reach a decision on the level of compensation payable by Immunocore to Lilly and shall reach a decision as soon as reasonably possible. Such decision shall be binding on both Parties in the absence of
                fraud or manifest error.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">82</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z226e1958ff614c5a94dbd12f7cc7bc7a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">20.8.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">End of Obligations</font>. Immediately following receipt or dispatch, as applicable, of any notification of termination under this Article 20, the diligence obligations in this Agreement shall no longer
                apply and Lilly shall have the right, but not the obligation except as set forth in this Clause 20.8, to wind-down all then on-going development, manufacturing and/or commercialization activities.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb816a0dfa0e4fa487ad1bc4b17af6f7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">20.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Survival</font>. In addition to any provisions specified in this Agreement as surviving under the applicable circumstances, the following provisions shall survive: Clause 10.3.1(d) (as the Intellectual
                Property Rights that are the subject of such Clause exist as of the effective date of the relevant termination or expiration), Clauses 13 and 14 (to the extent any payment obligations survive termination), Clause 15.1.2, Clause 15.1.3,
                Article 16 (provided, that Clauses 16.1, 16.2, 16.3 and 16.4 shall only survive for the period set forth in Clause 16.1), Clause 17.1, Clause 19.1 &#8211; 19.3, Clause 19.5, Clause 20.3, Clause 20.7, Clause 20.8, Article 21, Article 23 (to the
                extent any Personal Data of the other Party remains in the control of a Party following termination), and Article 24 shall survive any termination or expiration of this Agreement. In addition to those provisions specifically referenced in
                this Clause 20.9, those provisions which by their nature are intended to survive, as well as any other provisions necessary to interpret or implement any other surviving provisions (including, to the extent applicable, the definitions in
                Article 1), shall survive.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478863" name="z_Toc58478863"></a><font style="font-weight: bold;">ARTICLE 21</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>DISPUTE RESOLUTION</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92bd291518d7487e8555e02afa826a0b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">21.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Disputes</font>. Immunocore and Lilly recognize that a dispute, controversy or claim of any nature whatsoever arising out of or relating to this Agreement, or the breach, termination or invalidity thereof
                (each, a &#8220;<font style="font-weight: bold;">Dispute</font>&#8221;), may from time to time arise during the Term. Unless otherwise specifically recited in this Agreement, such Disputes between Immunocore and Lilly will be resolved as recited in
                this Article 21. In the event of the occurrence of such a Dispute, the Parties shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral. If such
                Dispute is not resolved within such [***] period, either Immunocore or Lilly may, by written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for attempted
                resolution within [***] after such notice is received. Such designated officers are as follows:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For Lilly &#8211; [***].</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For Immunocore &#8211; [***]</div>
      <div>&#160;</div>
      <div style="text-align: justify;">In the event the designated officers, or their respective designees, are not able to resolve such Dispute, and such Dispute relates to a legal matter, within [***] of such other Party&#8217;s receipt of such written
        notice, either Party may initiate the dispute resolution procedures set forth in Clause 21.2.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9e504d2f64f74914bd158d7009a298e7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">21.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Arbitration</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0120c7a81c324f1e9fae2efc9888adc6" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Rules</font>. Except as otherwise expressly provided in this Agreement (including under Clause 21.3 with respect to Patent-related matters), the Parties agree that any Dispute not resolved internally by
                the Parties pursuant to Clause 21.1 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">83</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce (for purposes of this Article 21, the &#8220;<font style="font-weight: bold;">Rules</font>&#8221;), except as
        modified in this Agreement, applying the substantive law specified in Clause 24.1.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z96ef1778b6d4428b8c9432f4c861e067" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Arbitrators; Location</font>. Each Party shall select one (1) arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator. All three (3) arbitrators shall serve as neutrals and
                have at least [***] of (a) dispute resolution experience (including judicial experience) and/or (b) legal or business experience in the biotech or pharmaceutical industry. In any event, at least [***] shall satisfy the foregoing experience
                requirement under Clause (b). If a Party fails to nominate its arbitrator, or if the Parties&#8217; arbitrators cannot agree on the third, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such
                Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings shall be conducted in [***]. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any
                written evidence originally in another language shall be translated into English and accompanied by the original or a true copy thereof.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z342f54cee99440b89ad408fa71b361e1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Procedures; Awards</font>. Each Party agrees to use reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may determine any person as
                necessary. The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution
                and award shall be delivered to the Parties as expeditiously as possible, but in no event more than [***] after conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent
                court or application may be made to any competent court for judicial acceptance of such an award and order for enforcement. Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request,
                and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z141f7d502d7d4bf480e443b7212f3a7f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Costs</font>. The prevailing Party, as determined by the arbitrators, shall be entitled to (a) its share of fees and expenses of the arbitrators and (b) its reasonable attorneys&#8217; fees and associated costs
                and expenses. In determining which Party &#8220;prevailed<font style="font-weight: bold;">,</font>&#8221; the arbitrators shall consider [***]. If the arbitrators determine that, given the scope of the arbitration, neither Party &#8220;prevailed<font style="font-weight: bold;">,</font>&#8221; the arbitrators shall order that the Parties (1) share equally the fees and expenses of the arbitrators and (2) bear their own attorneys&#8217; fees and associated costs and expenses.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zabfb89a7ffdb40608391c927f05f6cfe" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Interim Equitable Relief</font>. Notwithstanding anything to the contrary in this Clause 21.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible
                pursuant to the procedure set forth in this Article 21, such Party may seek a temporary injunction or other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under
                this Clause 21.2. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of temporary injunction or other interim equitable relief.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">84</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze6eb50bf90fa4a99adfe4b80d0be5137" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">21.2.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Protective Orders; Arbitrability</font>. At the request of either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in
                the course of the arbitration proceedings. The arbitrators shall have the power to decide all questions of arbitrability.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z062f5219578840bcab6600db5e80d936" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">21.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Subject Matter Exclusions</font>. Notwithstanding the provisions of Clause 21.2, any Dispute not resolved internally by the Parties pursuant to Clause 21.1 that involves the validity or infringement of a
                Patent Covering a Product (a) that is issued in the US shall be subject to actions before the US Patent and Trademark Office and/or submitted exclusively to the Federal Court of the Southern District of New York, New York, US; and (b) that
                is issued in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za052aabcce2c4a988137f27ab1dc3b49" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">21.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Continued Performance</font>. Provided that this Agreement has not terminated, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution
                of any Dispute.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478864" name="z_Toc58478864"></a><font style="font-weight: bold;">ARTICLE 22</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>ANTI-BRIBERY</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0caa788a8b864884a5805a505b5907b7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">22.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Anti-Bribery</font>.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z28b2e5f238904a6d8e92200493003f2a" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">22.1.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>&#8220;Anti-Corruption Laws&#8221; or &#8220;ABAC&#8221; means all anti-corruption and anti-bribery laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the United Kingdom Bribery Act 2010, as amended, and any other
                applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z999400e8ea23406ea5156cddf12efdbc" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">22.1.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>&#8220;Government Official&#8221; means any person employed by or acting on behalf of a government, government-controlled entity or public international organization; any political party, party official or candidate; any person who holds or performs
                the duties of an appointment, office or position created by custom or convention; and any person who holds himself out to be the authorized intermediary of any of the foregoing.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7ef1f598e3d344dbb7cc1975c77b840d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">22.1.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties agree, on behalf of themselves and their respective officers, directors and employees, that in connection with this Agreement, it shall not directly or indirectly pay, offer or promise to pay, or authorize the payment of any
                money, or give, offer or promise to give, or authorize the giving of anything else of value, to (i) any Government Official in order to influence official action; (ii) any person (whether or not a Government Official) (a) to influence such
                person to act in breach of a duty of good faith, impartiality or trust, (b) to reward such person for acting improperly, or (c) where such person would be acting improperly by receiving the money or other thing of value; (iii) any other
                person while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit a Government Official in order to influence official action
                for or against any party in connection with the matters that are the subject of this agreement; or (iv) any person to reward that person for acting improperly or to induce that person to act improperly.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">85</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaebdca2adaee4e0eb638e44c1df5a1a5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">22.1.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties agree, on behalf of themselves and their respective officers, directors and employees that work in connection with this Agreement that they shall not, directly or indirectly, solicit, receive or agree to accept any payment of
                money or anything else of value in violation of the Anti-Corruption Laws to the extent applicable to that Party. In connection with the performance of the services hereunder, the Parties undertake to comply with the Anti-Corruption Laws and
                shall not take any action that will, or would reasonably be expected to, cause it to be in violation of any such laws to the extent applicable to either Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94ad4401a2ad4ea69f4e57d829e16c03" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">22.1.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Each Party shall promptly provide the other Party with written notice of (i) becoming aware of any breach or violation by the relevant Party or its sub-contractors or its or their respective officers, directors, employees, of any of the
                representation, warranty or undertaking set forth in this Clause 22.1 or (ii) upon receiving a formal notification that it is the target of a formal investigation by any governmental authority for an Anti-Corruption Law Violation in
                connection with the performance of this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478865" name="z_Toc58478865"></a><font style="font-weight: bold;">ARTICLE 23</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>DATA PROTECTION</u></div>
      </div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt;">For the purposes of this Article, Personal Data shall have the meaning given to it in the Data Protection Act 1998</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z61a628c09a8a4a199ba7eadca9f3cf80" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>To the extent applicable, the Parties will comply with all applicable national and international laws, regulations and guidelines relating to protection of the personal information of study subjects, including the European Commission
                Directive 95/46/IC as it relates to the protection of the personal information of EU/EEA persons, and the Standards for Privacy of Individually Identifiable Health Information (Privacy Rule) under the Health Insurance Portability and
                Accountability Act of 1996 (HIPAA).</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z84b45826ee5f4896b308a27b388b661c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties shall process the Personal Data only to the extent, and in such a manner, as is necessary for the purposes of performing their respective obligations under this Agreement and for other lawful purposes.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc8ce2fcf0cd94aaba501ae052365db5b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties shall not disclose the Personal Data to any person except as required or permitted by this Agreement or with the written consent of the other Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5dd983e87f146428a398352a846d5e4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Parties shall implement appropriate technical and organisational measures to protect the Personal Data against accidental or unlawful destruction or accidental loss, unauthorised disclosure, access, use, modification, alteration,
                copying and all other unlawful forms of Processing.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <div style="font-weight: bold; text-align: center;"><a id="z_Toc58478866" name="z_Toc58478866"></a><font style="font-weight: bold;">ARTICLE 24</font>&#160;&#160;&#160;&#160;<font style="font-weight: bold;"> </font><u>MISCELLANEOUS</u></div>
      </div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z405cea40b93d459192cb223e68b3d405" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.1</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Applicable Law</font>. This Agreement (including the arbitration provisions of Article 21.2) shall be governed by and interpreted in accordance with the laws of England and Wales, without reference to the
                principles of conflicts of laws. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions contemplated by this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">86</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za78bd50968eb497293a3b01fff06e24c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Notices</font>. Except as otherwise expressly provided in the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent
                via one of the following means and will be effective (a) on the date of delivery, if delivered in person; (b) on the date of receipt, if sent by a facsimile (with delivery confirmed); or (c) on the date of receipt, if sent by private
                express courier or by first class certified mail, return receipt requested. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Clause 24.2 by sending written
                notice to the other Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="margin-left: 72pt;">
        <table style="border-collapse: collapse; width: 60%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="z0a5b870d08ce4bd8b0925922d3134cf1" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div style="font-weight: bold;">If to Lilly:</div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Eli Lilly and Company</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Attn: [***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div><br>
                </div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Lilly Corporate Center</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Indianapolis, Indiana, US 46285</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 25%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div style="font-weight: bold;">With a copy to:</div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Eli Lilly and Company</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Attn: [***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div><br>
                </div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Lilly Corporate Center</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div><br>
                </div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Indianapolis, Indiana, US 46285</div>
              </td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 25%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div style="font-weight: bold;">If to Immunocore:</div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Immunocore Limited</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Attn: [***]</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;">
                <div><br>
                </div>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>91 Park Drive</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>Abingdon, Oxfordshire, UK</div>
              </td>
            </tr>
            <tr>
              <td style="width: 25%; vertical-align: top;"><br>
              </td>
              <td style="width: 35%; vertical-align: top;">
                <div>OX14 4RX</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8d5d6b7aa9ba4b8785b68258b54ec665" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Assignment</font>. Neither Party may assign or otherwise transfer, in whole or in part, this Agreement without the prior written consent of the non-assigning Party, such approval not to be unreasonably
                withheld or delayed. Notwithstanding the foregoing, either Party may assign this Agreement to (i) an Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party that relate to the performance of this Agreement,
                or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation or re-organization of such party with or into such corporation or entity, provided that the Party to which this Agreement
                is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement. Subject to providing Lilly advance written notice thereof (including the identity of the intended assignee),
                Immunocore may also transfer the Immunocore Background IP and/or Immunocore Foreground IP to any Affiliate that controls Immunocore and provided that any transfer is explicitly subject to this Agreement pursuant to a written agreement
                documenting such transfer, which agreement identifies Lilly as an intended third party beneficiary thereof for purposes of exercising the rights and licenses granted to Lilly herein. A copy of such written agreement by such assignee shall
                be provided to the non-assigning Party within [***] of execution of such written agreement, subject in each case to any confidentiality restrictions. Subject to the foregoing, this Agreement will benefit and bind the Parties&#8217; successors and
                assigns. Any assignment not in accordance with Clause 24.3 shall be null and void.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f96c97128e346d88d2eb15e7b4d1f46" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.4</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Non-solicit</font>. Neither Party shall (except with the prior written consent of the other Party) knowingly solicit or entice away (or attempt to solicit or entice away) from the employment of</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">87</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">the other Party any person employed in the provision of its obligations under any Research Plan, Co-Development Plan or Development Plan during the course of any Research Plan, Co-Development Plan
        or Development Plan and for a further period of [***] from expiry, termination or completion of such Research Plan, Co-Development Plan or Development Plan; provided that this Clause 24.4 shall not apply to advertisements of a general nature placed
        in newspapers, trade publications or online or if such employee initiates the contact. If either Party does breach this Clause 24.4 it agrees and accepts that the other Party will suffer damage and as a minimum it agrees to pay [***]. The [***] set
        out in this Clause does not prevent the other Party claiming damages in the ordinary course in relation to a breach of this Clause 24.4.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z04228d02ddef4cc8b7657e6df2a8fd2e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.5</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Independent Contractors</font>. The Parties hereto are independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment,
                franchise, agency or fiduciary relationship between the Parties.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zccc70bd7654a4480bf175ac6adddf3d1" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.6</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Integration</font>. Except to the extent expressly provided herein, this Agreement constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all
                previous oral and written communications between the Parties with respect to the subject matter of this Agreement (including the Mutual Confidentiality Agreement by and between Immunocore and Lilly dated 25th February 2014 and term sheets
                exchanged by and between Immunocore and Lilly). Nothing in this Clause 24.6 shall exclude any liability for fraud or fraudulent misrepresentation or exclude any remedy.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcab819a4f5ae4e059904a4fecffcf737" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.7</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Amendment; Waiver</font>. Except as otherwise expressly provided herein, no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorized
                representative of both Parties. No course of dealing or failing of either Party to strictly enforce any term, right or condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right
                or condition. The observance of any provision of this Agreement may be waived (either generally or any given instance and either retroactively or prospectively) only with the written consent of the Party granting such waiver.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39f24d3bf81b42a2a77814821cbd40f4" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.8</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Further assurance</font>. Each Party shall and shall use all Commercially Reasonable Efforts to procure that any necessary Third Party shall promptly execute and deliver such further documents and do such
                further acts as may be required for the purpose of giving full effect to this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f2de95a01fb485890ff5e1e4b473978" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.9</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Severability</font>. The Parties do not intend to violate any public policy or statutory or common law. However, if any sentence, paragraph, section, clause or combination or part thereof of this
                Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, section, clause or combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding, provided
                that such deletion does not alter the basic purpose and structure of this Agreement.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb9bd01f2ff2043e09d2fdc0ea95e292d" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.10</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">No Third Party Rights</font>. The Parties do not intend that any term of this Agreement should be enforceable by any person who is not a Party.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf7305b509bfe4634a553b5622904e21e" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.11</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Construction</font>. The Parties mutually acknowledge that they and their attorneys have participated in the negotiation and preparation of this Agreement. Ambiguities, if any, in this</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">88</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have drafted this Agreement or authorized the ambiguous provision.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z02615a31ea574eaa9a1c51faea5b3b61" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.12</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Interpretation</font>. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.
                Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words &#8220;include&#8221; or &#8220;including&#8221; shall be construed as incorporating &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;; (b) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221;
                and derivative or similar words refer to this Agreement, including the Exhibits; (c) the word &#8220;law&#8221; or &#8220;laws&#8221; means any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment,
                injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality of any (i) government or country or territory, (ii) any state, province,
                county, city or other political subdivision thereof, or (iii) any supranational body); (d) all references to the word &#8220;will&#8221; are interchangeable with the word &#8220;shall&#8221; and shall be understood to be imperative or mandatory in nature; (f) the
                singular shall include the plural and vice versa; and (g) the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;. All references to days, months, quarters or years are references to calendar days, calendar months,
                calendar quarters, or calendar years.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ad6de8303d94b63a0240a7881a4a61f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.13</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Other Activities</font>. The Parties acknowledge that each of them may now or in the future engage in research, manufacturing, development or commercialization activities that utilize technologies similar
                to or involve products competitive with those contemplated by this Agreement. Except as may be expressly provided in Clause 10.2.3 with respect to Immunocore, nothing in this Agreement, including any obligation to use Commercially
                Reasonable Efforts to promote Products or any restriction on the use of Confidential Information, shall create any obligation not to research, manufacture, develop or commercialize any product or any obligation to utilize a separate sales
                force for Products. Neither Party shall be prevented from using any publicly available research results or other information (including any publicly available information of the other Party) to the same extent as Third Parties generally are
                legally permitted to do so. Each Party agrees to inform its key personnel assigned to perform activities hereunder of the limitations on use of Confidential Information contained in this Agreement, instruct such personnel to comply with
                such restrictions, and where appropriate, impose firewalls or other appropriate measures to minimize the potential for misuse of information. However, each Party has limited resources, and as a result it is anticipated that personnel
                assigned to activities hereunder may also participate in other activities that may utilize technologies similar to or involve products competitive with those contemplated by this Agreement. In particular, it is anticipated that personnel in
                sales, marketing, clinical and regulatory functions, regardless of level, will participate in multiple programs and that management personnel will by nature of their leadership positions participate in multiple programs.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd1b85390c7f34f158960a9eaf51c3f53" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.14</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">HSR Filings</font>. Prior to any exercise of the Lilly Co-Development Options pursuant to this Agreement, each of Lilly and Immunocore shall make any necessary merger control filings under any applicable
                competition or antitrust laws, including pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended with any applicable governmental authority and shall obtain the necessary approvals or clearances or the applicable
                waiting period shall</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">89</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">have expired or been terminated (&#8220;<font style="font-weight: bold;">Antitrust Approvals</font>&#8221;); provided further that each of Lilly and Immunocore shall cooperate as may be reasonably requested to
        ensure any such Antitrust Approvals are obtained.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z482e17ab899b413b877861971b784a16" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.15</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Option to Terminate Co-Development</font>. At any time within [***] after the date of a Change of Control during any Co-Development Term, Lilly may deliver a written notice of its intent to exercise a
                right to terminate Immunocore&#8217;s right to co-develop and co-commercialize such Research Plan Compounds and Product(s) as are the subject of such Co-Development Term(s). Where Lilly delivers written notice of intent to terminate, the
                following shall apply:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2071521b0d464309b40015425648c7e4" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt;">&#160;</td>
              <td style="width: 36pt; vertical-align: top;">24.15.1</td>
              <td style="vertical-align: top; text-align: justify;">
                <div>if Immunocore still has any Opt-Out Rights with respect to such Research Plan Compounds and Product(s), then Immunocore will be deemed to have exercised such Opt-Out Right(s) as of the next opt-out date in accordance with Clause 8.2.3
                  or 8.2.4, as applicable, and shall also be entitled to receive the Lilly Buy-Out Fee, if any; provided, however, that, Immunocore shall remain responsible for its share of Development Costs through the end of the applicable phase of
                  Clinical Trials, subject to any further Opt-Out Rights it may have;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4a2f33ee56d342399a4611e3b11a46a8" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">24.15.2</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>if Immunocore no longer has an Opt-Out Right with respect to such Research Plan Compounds and Product(s), then Immunocore will be deemed to have opted-out as of the conclusion of Phase II Clinical Trials with respect to such Research
                Plan Compounds and Product(s) and shall receive (i) royalties and milestones from the date of deemed opt-out (for clarity, including any milestones associated with initiation of Phase III Clinical Trials and First Commercial Sales) to the
                extent the same would have been due and payable had Immunocore in fact exercised such Opt-Out Right plus (ii) the Lilly Buy-Out Fee, if any.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0d3811abe2ad4356ad17add7033814e5" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">24.15.3</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The amount of the Lilly Buy-Out Fee [***]. Lilly shall pay the Lilly Buy-Out Fee, if any, within [***] of an invoice from [***] regarding the Lilly Buy-Out Fee.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5b34313e14954b8b8eae8081940e7417" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt; vertical-align: top; align: right;">24.16</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div><font style="font-weight: bold;">Counterparts</font>. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. For
                purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the signature pages hereto, will be deemed to be an original. Notwithstanding the foregoing, the Parties shall deliver original execution
                copies of this Agreement to one another as soon as practicable following execution thereof.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div style="text-align: center;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">90</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 100.00%;">
                      <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify;">IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Agreement as of the Effective Date.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8af996b18e894b0981aa0b885b6ec733" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">IMMUNOCORE LIMITED</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Eva-Lotta Allan</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Eva-Lotta Allan</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Chief Business Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-weight: bold;">ELI LILLY AND COMPANY</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td rowspan="1" style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ John C. Lechleiter</div>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;"><br>
            </td>
            <td style="width: 45%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>John C. Lechleiter</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 45%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Chairman, President, and Chief Executive Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center;">Signature Page to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT A &#8211; Licensed Patents</div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center;">[***] <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit A to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT B &#8212; Nomination Notice</div>
      <div>&#160;</div>
      <div style="text-align: justify;">Under the agreement executed on July 11, 2014, Lilly hereby nominates the following as a Selected Target.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7cd1c1a7e6e84b32b0f2adbf1c02a08e" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 29.96%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: justify;">Date Nominated:</div>
            </td>
            <td style="width: 70.04%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.96%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: justify;">Target name:</div>
            </td>
            <td style="width: 70.04%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.96%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: justify;">Protein identification <br>
                number:</div>
            </td>
            <td style="width: 70.04%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.96%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: justify;">Target protein sequence:</div>
            </td>
            <td style="width: 70.04%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 29.96%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: justify;">Date received by </div>
              <div style="text-align: justify;">Immunocore:</div>
            </td>
            <td style="width: 70.04%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="font-weight: bold;">Authorized for nomination on behalf of Lilly.</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za8c3839bb2d247ae88dd4ecc4848996c" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Name:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Title:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>&#160;</div>
      <div style="font-weight: bold;">Accepted as a Selected Target on behalf of Immunocore Limited</div>
      <div>&#160;</div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7af236dc3e364cd9a2b4fefc3d5d84f0" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Name:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Title:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 35%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 60%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit B to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT C - Research Plan Template</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit C to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT D - LEAD CANDIDATE CRITERIA</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit D to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT E - Press Release</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zecc0a78ef2374795932fb24c1f50797b" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 65%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><img src="nt10016217x4_ex10-7img01.jpg"></div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: right;"><img src="nt10016217x4_ex10-7img02.jpg"></div>
            </td>
          </tr>
          <tr>
            <td style="width: 65%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Eli Lilly and Company</div>
              <div>Lilly Corporate Center</div>
              <div>Indianapolis, Indiana 46285</div>
              <div>U.S.A.</div>
              <div style="font-weight: bold;">www.Iilly.co.uk</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Immunocore Ltd.</div>
              <div>91 Milton Park</div>
              <div>Abingdon, Oxfordshire OX14 4RY</div>
              <div>U.K.</div>
              <div style="font-weight: bold;">www.immunocore.com</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="font-weight: bold;">Date:</font> July XX, 2014</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 12%; vertical-align: top;">
              <div style="font-weight: bold;">For Release:<br>
              </div>
            </td>
            <td style="width: 88%; vertical-align: top;">
              <div>Draft</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 12%; vertical-align: top; font-weight: bold;">Refer to:</td>
            <td rowspan="1" style="width: 88%; vertical-align: top;">
              <div>[***]</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">LILLY AND IMMUNOCORE ENTER IMMUNOTHERAPY AGREEMENT TO CO-DISCOVER AND<br>
        CO-DEVELOP NOVEL CANCER THERAPIES</div>
      <div>&#160;</div>
      <div><font style="font-weight: bold;">(Oxford, UK and Indianapolis, USA)</font> Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and
        potentially develop novel T cell-based cancer therapies.</div>
      <div>&#160;</div>
      <div>Using Immunocore&#8217;s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body&#8217;s own immune system to attack cancer cells. ImmTACs have shown potential to direct a
        patient&#8217;s T cells to specifically target the cancerous cells, avoiding damage to healthy cells.</div>
      <div>&#160;</div>
      <div>Under the terms of the agreement, Immunocore will receive an upfront fee of $15 million per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts
        a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10 million and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore
        does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.</div>
      <div>&#160;</div>
      <div>&#8220;We are very pleased to have entered into this strategic partnership with Lilly, and look forward to working together in an integrated fashion,&#8221; said Eva-Lotta Allan, Chief Business Officer, Immunocore. She added: &#8220;Lilly is a leading oncology
        player and we are delighted to advance novel T cell-based therapies into the clinic in collaboration with them.&#8221;</div>
      <div>&#160;</div>
      <div>&#8220;The major goal and challenge of cancer immunotherapy is to direct the immune system to recognize and destroy cancer. We believe Immunocore&#8217;s ImmTAC platform has the potential to do just that,&#8221; said Jan Lundberg, Ph.D., Executive Vice President,
        Science and Technology and President, Lilly Research Laboratories. &#8220;We are delighted to be working closely with Immunocore to develop potential novel therapies for cancer patients.&#8221;</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;"><u>Notes for Editors</u></div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About ImmTACs</div>
      <div>Immunocore&#8217;s ImmTAC (Immune mobilising mTCR Against Cancer) technology is designed to enable the immune system to recognise and kill cancer or viral cells.</div>
      <div>&#160;</div>
      <div>T Cell Receptors naturally recognise diseased cells and Immunocore&#8217;s competitive advantage is its ability to engineer high affinity T Cell Receptors and link them to an antibody fragment which can activate the immune system to kill the targeted
        cancer or viral cells. These bi-specific proteins, called ImmTACS, have the potential to be potent anti-cancer or anti-viral agents. The most advanced ImmTAC is in Phase II clinical trials for the treatment of late stage melanoma.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About Immunocore</div>
      <div>Founded in 2008, Immunocore Ltd is a privately owned, clinical-stage biotechnology company developing a highly innovative platform technology that generates novel drugs called ImmTACs for the treatment of cancer and viral infection. Immunocore
        traces its roots to Avidex Ltd, founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.</div>
      <div>&#160;</div>
      <div>Immunocore has major discovery collaborations ongoing with leading pharmaceutical companies. The company was listed in the top 15 private biotech firms globally for 2013 by Fierce Biotech and named Best Biotech Dealmaker of 2013 at the OBN
        Awards. Immunocore has over 120 staff and is located in Abingdon, Oxfordshire, UK. For more information, please visit <u>www.immunocore.com</u>. Images are available on request from Immunocore.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About Eli Lilly and Company</div>
      <div>Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today
        we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through
        philanthropy and volunteerism. To learn more about Lilly, please visit us at <u>www.Lilly.co.uk</u></div>
      <div>&#160;</div>
      <div style="text-align: justify; font-style: italic;">This press release contains forward-looking statements about the potential benefits of the research collaboration between Lilly and Immunocore and reflects Lilly&#8217;s current beliefs. However, there
        are substantial risks and uncertainties in the process of drug research, development, and commercialization. There is no guarantee that the research collaboration will yield successful results or that either company will achieve the anticipated
        benefits. For further discussion of these and other risks and uncertainties, see Lilly&#8217;s filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.</div>
      <div>&#160;</div>
      <div style="text-align: center;">#&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;#</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9cd20922186b4ea6a7faa329ef74dfbc" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 65%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><img src="nt10016217x4_ex10-7img03.jpg"></div>
            </td>
            <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: right;"><img src="nt10016217x4_ex10-7img04.jpg"></div>
            </td>
          </tr>
          <tr>
            <td style="width: 65%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Eli Lilly and Company</div>
              <div>Lilly Corporate Center</div>
              <div>Indianapolis, Indiana 46285</div>
              <div>U.S.A.</div>
              <div style="font-weight: bold;">www.Iilly.co.uk</div>
            </td>
            <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Immunocore Ltd.</div>
              <div>91 Milton Park</div>
              <div>Abingdon, Oxfordshire OX14 4RY</div>
              <div>U.K.</div>
              <div style="font-weight: bold;">www.immunocore.com</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="vertical-align: top; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
              <div><font style="font-weight: bold;">Date:</font> July XX, 2014</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 12%; vertical-align: top;">
              <div style="font-weight: bold;">For Release:<br>
              </div>
            </td>
            <td style="width: 88%; vertical-align: top;">
              <div>Draft</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 12%; vertical-align: top; font-weight: bold;">Refer to:</td>
            <td rowspan="1" style="width: 88%; vertical-align: top;">[***]</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">LILLY AND IMMUNOCORE ENTER IMMUNOTHERAPY AGREEMENT TO CO-DISCOVER AND CO-DEVELOP NOVEL CANCER THERAPIES</div>
      <div>&#160;</div>
      <div><font style="font-weight: bold;">(Oxford, UK and Indianapolis, IN)</font> Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially
        develop novel T cell-based cancer therapies.</div>
      <div>&#160;</div>
      <div>Using Immunocore&#8217;s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body&#8217;s own immune system to attack cancer cells. ImmTACs have shown potential to direct a
        patient&#8217;s T cells to specifically target the cancerous cells, avoiding damage to healthy cells.</div>
      <div>&#160;</div>
      <div>Under the terms of the agreement, Immunocore will receive an upfront fee of $15 million per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts
        a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10 million and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore
        does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.</div>
      <div>&#160;</div>
      <div>&#8220;We are very pleased to have entered into this strategic partnership with Lilly, and look forward to working together in an integrated fashion,&#8221; said Eva-Lotta Allan, Chief Business Officer, Immunocore. She added: &#8220;Lilly is a leading oncology
        player and we are delighted to advance novel T cell-based therapies into the clinic in collaboration with them.&#8221;</div>
      <div>&#160;</div>
      <div>&#8220;The major goal and challenge of cancer immunotherapy is to direct the immune system to recognize and destroy cancer. We believe Immunocore&#8217;s ImmTAC platform has the potential to do just that,&#8221; said Jan Lundberg, Ph.D., Executive Vice President,
        Science and Technology and President, Lilly Research Laboratories. &#8220;We are delighted to be working closely with Immunocore to develop potential novel therapies for cancer patients.&#8221;</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;"><u>Notes for Editors</u></div>
      <div style="font-weight: bold;">About ImmTACs</div>
      <div>Immunocore&#8217;s ImmTAC (Immune mobilising mTCR Against Cancer) technology is designed to enable the immune system to recognise and kill cancer or viral cells.</div>
      <div>&#160;</div>
      <div>T Cell Receptors naturally recognise diseased cells and Immunocore&#8217;s competitive advantage is its ability to engineer high affinity T Cell Receptors and link them to an antibody fragment which can activate the immune system to kill the targeted
        cancer or viral cells. These bi-specific proteins, called ImmTACS, have the potential to be potent anti-cancer or anti-viral agents. The most advanced ImmTAC is in Phase II clinical trials for the treatment of late stage melanoma.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About Immunocore</div>
      <div>Founded in 2008, Immunocore Ltd is a privately owned, clinical-stage biotechnology company developing a highly innovative platform technology that generates novel drugs called ImmTACs for the treatment of cancer and viral infection. Immunocore
        traces its roots to Avidex Ltd, founded in 1999 as a spin-out from the University of Oxford to develop novel T Cell Receptor technology invented by the founder and chief scientist, Dr Bent Jakobsen.</div>
      <div>&#160;</div>
      <div>Immunocore has major discovery collaborations ongoing with leading pharmaceutical companies. The company was listed in the top 15 private biotech firms globally for 2013 by Fierce Biotech and named Best Biotech Dealmaker of 2013 at the OBN
        Awards. Immunocore has over 120 staff and is located in Abingdon, Oxfordshire, UK. For more information, please visit <u>www.immunocore.com</u>. Images are available on request from Immunocore.</div>
      <div>&#160;</div>
      <div style="font-weight: bold;">About Eli Lilly and Company</div>
      <div>Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today
        we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through
        philanthropy and volunteerism. To learn more about Lilly, please visit us at <u>www.lilly.com</u> and <u>http://newsroom.lilly.com/social-channels</u></div>
      <div>&#160;</div>
      <div>C-LLY</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-style: italic;">This press release contains forward-looking statements about the potential benefits of the research collaboration between Lilly and Immunocore and reflects Lilly&#8217;s current beliefs. However, there
        are substantial risks and uncertainties in the process of drug research, development, and commercialization. There is no guarantee that the research collaboration will yield successful results or that either company will achieve the anticipated
        benefits. For further discussion of these and other risks and uncertainties, see Lilly&#8217;s filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center;">#&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;#&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;#</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit E to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT F - Immunocore Sub-contractors</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit F to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT G &#8212; CO-COMMERCIALIZATION AGREEMENT PRINCIPLES</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit G to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT H &#8212; NOMINATION NOTICES</div>
      <div style="text-align: center;">[***]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit H to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT I &#8212; Lilly Good Research Practices</div>
      <div>&#160;</div>
      <div style="text-indent: -18pt; margin-left: 18pt; text-align: center;">[***]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit H to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT J &#8212; FTE Rate Principles</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit J to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">Exhibit K &#8212; Exclusivity Examples</div>
      <div>&#160;</div>
      <div style="text-align: center;">[***]</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div style="text-align: center; font-weight: bold;">Exhibit A to Development and License Agreement</div>
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%%%-->
      <div>
        <div style="text-align: center;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)<font style="font-weight: bold;">&#160;</font>IS THE TYPE THAT THE REGISTRANT
          TREATS AS PRIVATE OR CONFIDENTIAL.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-weight: bold;">FIRST AMENDMENT TO THE DEVELOPMENT AND LICENSE AGREEMENT</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold; font-variant: small-caps;">This First Amendment To The Development And License Agreement</font> (&#8220;<font style="font-weight: bold;">First Amendment</font>&#8221;) is made and entered into,
          effective as of December 21, 2016 (&#8220;<font style="font-weight: bold;">Amendment&#160;Effective Date</font>&#8221;), by and between <font style="font-weight: bold; font-variant: small-caps;">Immunocore Limited</font>, having its principal place of business
          at 101 Park Drive, Milton Park, Abingdon, Oxon, United Kingdom OX l4 4RY (&#8220;<font style="font-weight: bold;">Immunocore</font>&#8221;), on the one hand and, <font style="font-weight: bold; font-variant: small-caps;">Eli Lilly and Company</font>, having
          its principal place of business at Lilly Corporate Centre, Indianapolis, Indiana 46285, United States of America, on the other hand.</div>
        <div>&#160;</div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Background</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, the Parties entered into a Development and License Agreement dated as of July 11 2014 pursuant to which Immunocore and Lilly agreed to collaborate in the discovery
          and development of TCR technology for use in pharmaceutical products (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;); and</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, execution of the Agreement triggered the nomination and acceptance of two targets, [***] and [***], as specified in exhibit H of the Agreement (respectively referred
          to in this First Amendment as &#8220;[***]&#8221; and &#8220;[***]&#8221;); and</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, Lilly has expressed a desire to replace the ongoing [***] programme with a new programme directed towards a new target, [***] (as defined below); and</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, pursuant to certain terms the Parties have agreed to amend the Agreement to introduce a process for the replacement of the [***] nomination with one for [***].</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">NOW THEREFORE</font>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Immunocore and Lilly agree as follows:</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d09770a616641ccb120bf200a7214c1" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>In this First Amendment:</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9779bc186fb848b29a9f412d721141de" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">1.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>expressions defined in the Agreement and used in this First Amendment have the meaning set out in the Agreement, unless the context otherwise requires; and</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c24f1589e924c06a1c80f412933379e" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">1.2</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>references to [***]; and</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd1cfc48c993d4bc5bae4ac1a5520ac70" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">1.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>reference to Druggable shall mean the [***].</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb1ded23c8934f479f56f431dca46fe1" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Upon execution of this First Amendment, Immunocore will present to Lilly a review of the [***] known to Immunocore and the anticipated [***] using a TCR based technology. For clarity, the recommendation will be made based on [***]
                  data. After such presentation has been made by Immunocore, Lilly shall have [***] to submit a Nomination Notice identifying [***] as a Selected Target in accordance with Clause 3.1.2 of the Agreement. Following receipt of such Nomination
                  Notice by Immunocore, [***] shall be deemed to have been accepted by Immunocore, the provisions of the first two sentences of Clause 3.1.3 of the Agreement shall not apply and [***] shall be designated as a Selected Target with effect
                  from the date of the Nomination Notice. If, however, Lilly does not submit a</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div> </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div id="DSPFPageFooter" style="width: 100%;">
            <div>
              <div>
                <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)<font style="font-weight: bold;">&#160;</font>IS THE TYPE THAT
                          THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
          <div style="page-break-after:always;" id="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify;">
          <div style="text-align: right; color: rgb(0, 0, 0); font-size: 11.5pt;">Execution Copy</div>
        </div>
        <div style="text-align: justify; margin-left: 18pt;"> <br>
        </div>
        <div style="text-align: justify; margin-left: 18pt;">Nomination Notice identifying [***] as a Selected Target, then the Parties shall continue to develop [***] and [***] targets as per the Agreement.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b602d4f41544c98a9af276b2db35bf6" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Upon receipt of the Nomination Notice for [***] from Lilly in accordance with Clause 2 of this First Amendment, the Parties agree that the Agreement will cease to apply to [***] and Lilly shall have no right to exercise the Lilly
                  Co-Development Option with respect to the [***] under Clauses 5.1 and 5.2 of the Agreement or to the grant of an any Exclusive Licence to [***] under Clause 10.2.2.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16e8f2fc2ee64a97b364846a8fdc19e9" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Parties agree that any Foreground Intellectual Property developed by the Parties relating to [***] shall be owned in accordance with Clause 15.1.2 of the Agreement and the prosecution and/or maintenance of any patents comprising
                  such Foreground Intellectual Property shall be in accordance with Clauses 15.2, 15.3 and 15 .4 of the Agreement.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z75b74d73279f4ddeb349e98ea7d675cc" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">5.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>For the avoidance of doubt, no payment shall be owed by Lilly to Immunocore for the replacement of [***] with [***] and the Parties agree that Lilly will be deemed to have exercised two (2) of its three (3) Proposed Target nominations
                  in nominating [***] and [***]. With effect from the Amendment Effective Date, Lilly shall have no rights to research, develop or otherwise exploit Research Plan Compounds pertaining to [***] and Immunocore shall own all rights in respect
                  to such [***] Research Plan Compounds.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4194ac2d81f4454da8b15a7f16644ac1" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">6.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>With effect from the Amendment Effective Date the Parties agree the following amendments to the Agreement:</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81d829751a2d49fb8bae6b31b2ffb5d9" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">6.1</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The following new definition shall be added to Article 1:</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">[***]</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z769e72f314a246a4a3f7566a18399844" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">6.2</td>
              <td style="width: auto; vertical-align: top; text-align: right;">
                <div style="text-align: left;">In recognition by the Parties that the successful delivery of the proposed [***] Research Plan requires target discrimination characteristics that have not previously been evaluated for the TCR technology, a
                  new Clause 2.2.4 shall be inserted as follows:</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;"><font style="font-style: italic;">&#8220;2.2.4 Following receipt of the Nomination Notice for </font>[***]<font style="font-style: italic;"> by Immunocore and solely with respect to the Research Plan
            for </font>[***]<font style="font-style: italic;">, Immunocore shall provide regular </font>[***]<font style="font-style: italic;"> updates and shall formally report to the JRC once it has isolated </font>[***]<font style="font-style: italic;">. The JRC shall discuss the likelihood of developing an ImmTAC for the treatment of </font>[***]<font style="font-style: italic;">&#160;</font>[***]<font style="font-style: italic;">&#160;</font>[***]<font style="font-style: italic;"> and
            whether further options should be explored and will jointly decide on the technical and clinical feasibility of the strategy. In case of disagreement, resolution will be per the original governance clauses but </font>[***]<font style="font-style: italic;"> shall have the final decision as to whether such a goal is technically feasible and if it deems, at its sole discretion, that such a goal is not technically feasible then </font>[***]<font style="font-style: italic;"> shall be entitled, at its discretion, to terminate further research efforts in respect of </font>[***]<font style="font-style: italic;">.&#8221;</font></div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z41c81526a4fa48248d02fd2d473d8266" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top; align: right;">6.3</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Parties agree that Exhibit H of the Agreement shall be amended to replace the [***] Nomination Notice with a copy of the Nomination Notice for [***].</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div id="DSPFPageFooter" style="width: 100%;">
            <div>
              <div>
                <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)<font style="font-weight: bold;">&#160;</font>IS THE TYPE THAT
                          THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
          <div style="page-break-after:always;" id="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div>
          <div style="text-align: right; color: rgb(0, 0, 0); font-size: 11.5pt;">Execution Copy</div>
        </div>
        <div> <br>
        </div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2fa711ad9ebe4459b12d34b0c960f60d" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">7.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Except for the changes expressly mentioned in this First Amendment, all other terms and conditions of the Agreement shall remain unchanged and continue to be in full force and effect.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2fb209265a3e4ebcb4756d65d68e9dc5" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">8.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>This First Amendment may be executed in any number of counterparts, each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9abbd564abc46ca9fe3c48e0ba02689" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">9.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The provisions of Clause 21.1 (Disputes), Clause 21.2 (Arbitration) and Clause 24.1 (Applicable Law) shall apply equally to this First Amendment.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: center;">[<font style="font-weight: bold; font-style: italic;">Signature page follows - the rest of this page intentionally left blank</font>]</div>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div id="DSPFPageFooter" style="width: 100%;">
            <div>
              <div>
                <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 100.00%;">
                        <div style="text-align: center;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)<font style="font-weight: bold;">&#160;</font>IS THE TYPE THAT
                          THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
          <div style="page-break-after:always;" id="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify;">
          <div style="text-align: right; color: rgb(0, 0, 0); font-size: 11.5pt;">Execution Copy</div>
        </div>
        <div style="text-align: justify;"><font style="font-weight: bold;"> <br>
          </font></div>
        <div style="text-align: justify;"><font style="font-weight: bold;">IN WITNESS, WHEREOF</font>, Immunocore and Lilly have executed this First Amendment by their respective officers hereunto duly authorized, on the Amendment Effective Date.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z13ba590ebffc43268d7f299e23e36798" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td colspan="2" style="vertical-align: top;">
                <div style="text-align: justify; font-weight: bold;">IMMUNOCORE LIMITED</div>
              </td>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">By:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">/s/ Bent Jakobsen</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">Name:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">Bent Jakobsen</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">Title:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">Chief Scientific Officer</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td colspan="2" style="vertical-align: top;">
                <div style="text-align: justify; font-weight: bold;">ELI LILLY AND COMPANY</div>
              </td>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">By:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">/s/ Greg Plowman</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">Name:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">Greg Plowman</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify;">Title:</div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">Vice President, Oncology Research</div>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter" style="width: 100%;">
          <div>
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)<font style="font-weight: bold;">&#160;</font>IS THE TYPE THAT THE
                        REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS
            THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">SECOND AMENDMENT TO THE DEVELOPMENT AND LICENSE<br>
          AGREEMENT</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold; font-variant: small-caps;">This Second Amendment to the Development And License Agreement</font> (&#8220;<font style="font-weight: bold;">Second Amendment</font>&#8221;) is made and entered
          into, effective as of September 20, 2017 (&#8220;<font style="font-weight: bold;">Amendment Effective Date</font>&#8221;), by and between IMMUNOCORE LIMITED, having its principal place of business at 10I Park Drive, Milton Park, Abingdon, Oxon, OX l4 4RY,
          United Kingdom (&#8220;<font style="font-weight: bold;">Immunocore</font>&#8221;), on the one hand and, ELI LILLY AND COMPANY, having its principal place of business at Lilly Corporate Centre, Indianapolis, Indiana 46285, United States of America (&#8220;<font style="font-weight: bold;">Lilly</font>&#8221;), on the other hand.</div>
        <div>&#160;</div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Backcround</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, the Parties entered into a Development and License Agreement dated as of July 11 2014 pursuant to which lmmunocore and Lilly agreed to collaborate in the discovery
          and development of TCR technology for use in pharmaceutical products (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;); and</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, Parties executed a First Amendment to the License Agreement on December 21 2016 in which Lilly returned its rights in the [***] Selected Target to Immunocore in
          exchange for obtaining rights to a new Selected Target, [***]; and</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">WHEREAS</font>, Lilly desires to commit [***] to the [***] programme through reallocating resources currently dedicated to the [***] programme to the [***] programme and returning
          Lilly&#8217;s rights in the [***] Selected Target to lmmunocore.</div>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">NOW THEREFORE</font>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Immunocore and Lilly agree as follows:</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z231e8374ca6d4acaaf66696c04569812" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>lmmunocore will transition equivalent levels of resources currently dedicated to the [***] Research Plan to increase resources dedicated to the [***] Research Plan.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd278b7f0c4d540ce829157854924463a" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>[***] under the Agreement and lmmunocore shall use Commercially Reasonable Efforts to develop [***] the deliverables as described in Clause 4.1.2 of the Agreement with respect to the [***] Selected Target.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdd86d2547cd946aaa512709d2ec851b3" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The JSC shall develop a plan to explore multiple [***] peptides and use emerging data to focus resources on the most promising peptides to accelerate delivery of Research Plan Compounds.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z353835588404489a8b4e61c5090dc42f" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>For the avoidance of doubt, no payment shall be owed by Lilly to lmmunocore for the replacement of [***] with an additional [***] programme slot and the Parties agree that Lilly will be deemed to have exercised three (3) Proposed
                  Target nominations in nominating [***] and [***] as the three Selected Targets. With effect from the Amendment Effective Date, Lilly shall have no rights to research, develop or otherwise exploit Research Plan Compounds pertaining to
                  [***] and Immunocore shall own all rights in respect to such [***] Research Plan Compounds.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6dbbc09276f74b618addf5c16f9b4933" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">5.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Parties agree that the Agreement will cease to apply to [***] and Lilly shall have no right to exercise the Lilly Co-Development Option with respect to the [***] under Clauses 5.1 and 5.2 of the Agreement or to the grant of an
                  Exclusive Licence to [***] under Clause 10.2.2.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd389e24fba2a4350b2f4bb1e3b0ecdc9" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">6.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Parties agree that any Foreground Intellectual Property developed by the Parties relating to [***] shall be owned in accordance with Clause 15.1.2 of the Agreement and the prosecution</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after:always;" id="DSPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%%%-->
        <div style="text-align: justify; margin-left: 18pt;">and/or maintenance of any patents comprising such Foreground Intellectual Property shall be in accordance with Clauses 15.2, 15.3 and 15.4 of the Agreement.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf4eb2c78435841ea8b098cff557dda7e" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">7.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Except for the changes expressly mentioned in this Second Amendment, all other terms and conditions of the Agreement and the First Amendment shall remain unchanged and continue to be in full force and effect.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z826c02d7a93949babcd1a49a2212c5d0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">8.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>This Second Amendment may be executed in any number of counterparts, each of which shall be an original as against the Party whose signature appears thereon, but all of which taken together shall constitute one and the same instrument.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z629a230da1f341caa16aeec07b956794" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 18pt; vertical-align: top; align: right;">9.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The provisions of Clause 21.1 (Disputes), Clause 21.2 (Arbitration) and Clause 24.1 (Applicable Law) shall apply equally to this Second Amendment.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify;"><font style="font-weight: bold;">IN WITNESS, WHEREOF</font>, Immunocore and Lilly have executed this Second Amendment by their respective officers hereunto duly authorized, on the Amendment Effective Date.</div>
        <div>&#160;</div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z457eded40a3e4249a960dd658ac94b66" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="font-weight: bold;">IMMUNOCORE LIMITED</div>
              </td>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>By: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Eva-Lotta Allan<br>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>Name: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Eva-Lotta Allan</td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>Title: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">CBO</td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td colspan="2" rowspan="1" style="vertical-align: top;">
                <div style="font-weight: bold;">ELI LILLY AND COMPANY</div>
              </td>
              <td style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>By: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Gregory Plowman</td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>Name: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Gregory Plowman, M.D., Ph.D.<br>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 55%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                <div>Title: <br>
                </div>
              </td>
              <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">VP, Oncology Research<br>
              </td>
              <td style="width: 55%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            </tr>

        </table>
        <div><br>
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageFooter" style="width: 100%;">
            <div>
              <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 100.00%;">
                      <div style="text-align: center;">&#160;<font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 100.00%;">
                      <div>
                        <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                      </div>
                    </td>
                  </tr>

              </table>
            </div>
          </div>
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <!--PROfilePageNumberReset%Num%1%%%-->
        <div>
          <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS







              THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">RD</sup> AMENDMENT TO THE DEVELOPMENT AND LICSENSE AGREEMENT</div>
          <div>&#160;</div>
          <div style="text-align: center;">(&#8220;<font style="font-weight: bold;">3</font><sup style="font-weight: bold; vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup><font style="font-weight: bold;"> Amendment&#8221;)</font></div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">between</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">IMMUNOCORE LIMITED</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">and</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">ELI LILLY AND COMPANY</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">Immunocore Limited, having its principal place of business at 101 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RX, United Kingdom (&#8220;Immunocore&#8221;), and Eli Lilly and Company, Lilly Corporate Center, Indianapolis,
            Indiana, 46285, United States of America (&#8220;Lilly&#8221;) entered into a Development and License Agreement On July 11, 2014 (&#8220;the Agreement&#8221;).</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The Parties desire to amend the Agreement to provide for transfer of Material and related confidential and proprietary information between the Parties. This is an Amendment to the Agreement, and this 3rd Amendment
            is entered into on the last date signed below by the Parties. The Parties are willing to provide each other with such Material and related confidential and proprietary information subject to the terms and conditions stated herein.</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article I.</u></font>&#160; <font style="font-weight: bold;"><u>Definitions</u></font></div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01debd75f282484a818b22a2cc8d8f3e" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Affiliates,&#8221; &#8220;Confidential Information,&#8221; &#8220;Disclosing Party,&#8221; &#8220;Intellectual Property,&#8221; and &#8220;Research Plan&#8221; have the meaning defined in the Agreement</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc86e6e8409ec4ad28c352eb5ff12aa8a" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Immunocore Material&#8221; means Material provided to Lilly for the Research Plan, including all derivatives or progeny thereof.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0323d661283443549c24b3de331c24a5" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Lilly Material&#8221; means Material provided by Lilly to Immunocore for the Research Plan, including all derivatives and progeny thereof.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f4ad3568cdb466c9bcb84523051ec3b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Material&#8221; means, collectively, Lilly Material and Immunocore Material.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z982255b8d50349d3a93453285f52b74f" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Material Providing Party&#8221; means the Party that provides Material to the other Party.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze430c7d8530443acac40bdc2743c7703" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Material Receiving Party&#8221; means the Party that receives Material from the Material Providing Party.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4f028ce040614fa7a9884ca67eb4d140" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>&#8220;Receiving Party&#8221; means the party receiving Confidential Information from the other party or such other party&#8217;s Affiliates pursuant to the Agreement or this 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>
                    Amendment.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article II.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Restrictions on Disclosure and Use</u></font>. The Parties will use the Material and Confidential
            Information solely for the Research Plan as described in the Agreement. All research under the Research Plan shall be conducted at the facilities of either Lilly or Immunocore, their respective affiliates, or their respective subcontractors.
            Neither party shall use the Material in humans. [***].</div>
          <div>&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
            <div style="page-break-after:always;" id="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%%%-->
          <div><font style="font-weight: bold;"><u>Article III.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Compliance with All Laws, Rules and Regulations</u></font>.</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z74fc4b6acf704ae78ed6958a4099dd07" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The Parties agree to carry out the Research Plan in accordance with the terms and conditions of the Agreement and this 3rd Amendment and in compliance with all federal, state and local laws, rules, guidelines and regulations
                    applicable to the Research Plan and the handling of the Material.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16fbca787e3846a19685932c8b9e3ddb" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Each party shall comply with applicable laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and all other export controlled commodities.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdaf6d55a23d841a9b44eb06d35a406f3" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Neither party shall, directly or indirectly, re-export any controlled commodities, which are subject to this 3rd Amendment, unless the required authorization and/or license is obtained from the proper government agency(ies) prior to
                    export. Each Party will not export, re-export or transfer any goods, technology, or software, or cause the export, re-export, or transfer of any goods, technology, or software, with the other Party listed as the principal party in
                    interest or exporter.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ce559308a984561b1bdee3e7402e878" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Each Party will not, and will ensure that its agents, subcontractors and others acting on its behalf, will not, export, re-export or transfer any such good, technology, or software if doing so would cause Lilly, Immunocore, or any
                    other person to violate the Export Administration Regulations (15 C.F.R. part 730 <font style="font-style: italic;">et seq</font>.), the U.S. Foreign Trade Regulations (15 C.F.R. Part 30), any trade or economic sanction regulations
                    (including those administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control (31 C.F.R. Ch. V), or any existing or future Applicable Laws related to export controls or sanctions.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article IV.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Provision of Material</u></font>. The Material Providing Party may provide the Material Receiving Party
            with Material in the quantities, and on the timing, required under the Research Plan. Any Material provided to a Material Receiving Party shall be accompanied by a Material Transfer Record substantially in the form of Exhibit L. Each such
            Material Transfer Record shall be signed by an authorized representative of the Material Providing Party, and then signed by an authorized representative of the Material Receiving Party, and then returned to the Material Providing Party.</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article V.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Delivery Terms and Risk of Loss</u></font>.</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8695d00a67444cdea952bc67be7d020d" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>When shipment by express consignment courier (e.g., FedEx, DHL Express, etc.) is preferred, each Party shall ship the Materials or other goods, if applicable, at its own expense, using an express consignment courier (Courier) agreed
                    to by the other Party. The shipping Party shall provide to the Courier for each article in the shipment documentation, as appropriate, that includes: (i) detailed description; (ii) statement of intended use;(iii) fair value; (iv)
                    country of origin, if applicable; (v) name and address of manufacturer if different than shipper; (vi) contact information for both the sender and receiver of the shipment; and (vii) other information or documentation as required by the
                    Courier to effect any necessary export and import clearances and enable transportation to the Material Receiving Party&#8217;s designated facility.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c0316f90a09411997fb895507701ef4" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Advance Shipping and Import Notification. Immunocore agrees to timely provide Lilly or Lilly&#8217;s agent with all information requested which is necessary for Lilly to submit advance import information required by customs authorities,
                    Immunocore&#8217;s failure to provide the required information in a timely manner could preclude importation or shipments to Lilly, and potentially result in increased costs or claims for compensation under the Agreement,</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div> </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div id="DSPFPageFooter" style="width: 100%;">
              <div>
                <div>
                  <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                      <tr>
                        <td style="width: 100%; text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></td>
                      </tr>
                      <tr>
                        <td style="width: 100.00%;">
                          <div>
                            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="page-break-after:always;" id="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div><font style="font-weight: bold;"><u>Article VI.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Restrictions on Access and Transfer of Material</u></font>.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The Parties agrees to retain control over and not transfer, sell or distribute the Material to anyone other than their respective employees, affiliates or subcontractors, <u>unless</u> prior written approval is
            obtained from the other party. The Parties shall exercise at a minimum the same degree of care it would exercise to protect its own similar material and Confidential Information (and in no event less than a reasonable standard of care) to keep
            confidential the Material and Confidential Information from Disclosing Party. The Parties shall not use the Material for any purpose other than the Research Plan.</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article VII.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Confidentiality</u></font>. Governed by the Agreement</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article VIII.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Warranties and Representations</u></font>.</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3a36c89f9e3f410e8b91eeb67e485e8b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top;">
                  <div><font style="font-weight: bold;">THE MATERIAL IS BEING SUPPLIED BY IMMUNOCORE OR LILLY WITH </font><font style="font-weight: bold;"><u>NO</u></font><font style="font-weight: bold;"> WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY
                      WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR PROPRIETARY RIGHTS OF ANY THIRD PARTY.</font></div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4801d122210e44c582a34bf3c0cd8dad" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The Parties each warrant and represent that: (i) the Research Plan is not funded by a third party, or subject to any rights of any third party; (ii) the Material or Confidential Information will not be used for any purpose other than
                    the Research Plan; (iii) the Material will not be used in humans; (iv) they have not entered into any agreement which would obligate them to license or assign information, data, know-how or Intellectual Property Rights derived from use
                    of the Material or Confidential Information to any entity other than the other Party; and (v) that their respective Scientists have an obligation to assign all Intellectual Property Inventions to them,</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc24cfa9efa564c0cbbbf1e6a6bff2ba2" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Each Party confirms that it and its subcontractors are not on any list of restricted entities, persons, or organizations published by any member state of the European Union, the United States of America government, the United
                    Nations, or other Governmental Authority, including the U.S. Treasury Department&#8217;s List of Specially Designated Nationals and Blocked Persons, Sectoral Sanctions Identification List, and Foreign Sanctions Evaders List, the U.S. Commerce
                    Department&#8217;s Entity List, Denied Persons List, and Unverified List, the U.S. State Department&#8217;s nonproliferation lists, and the EU&#8217;s Consolidated List of Designated Persons, (collectively, the &#8220;Sanctions Lists&#8221;),</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zda6d710db4b54775b827f03bd1b7a9c9" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Each Party confirm that it and its subcontractors are not owned or controlled in the aggregate at 50% greater interest, directly or indirectly by a person or entity which is included on such Sanctions Lists.&#8226;</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article IX.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Liability for Material&#8217;s Use</u></font>. Each Party assumes full responsibility for any claims or
            liabilities which may arise as a result of its use, handling or possession of Material; <u>except</u> as prohibited by law. Neither Party will be liable to the other Party for any loss, claim or demand made by or against it due to or arising
            from use of the other Party&#8217;s Material; <u>except</u> if such loss, claim or demand is caused by the gross negligence or willful misconduct of the other Party.</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article X.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Destruction of Material</u></font>. Unless otherwise agreed in writing, each Party shall properly dispose
            of any Material in its possession or control upon the earlier of [***] following completion of the Research Plan, the expiration or termination of the Agreement. Upon request by one Party, the</div>
          <div>&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div id="DSPFPageFooter" style="width: 100%;">
              <div>
                <div>
                  <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                      <tr>
                        <td style="width: 100%; text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></td>
                      </tr>
                      <tr>
                        <td style="width: 100.00%;">
                          <div>
                            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="page-break-after:always;" id="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div>other Party shall also provide to the requesting Party with written certification of the Material&#8217;s destruction.</div>
          <div>&#160;</div>
          <div><font style="font-weight: bold;"><u>Article XI.</u></font><font style="font-weight: bold;">&#160; </font><font style="font-weight: bold;"><u>Miscellaneous</u></font>.</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf8d30da3b3c3411e8c745e95f60de9f7" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>The rights and obligations of this 3rd Amendment may not be assigned or delegated by either party to a third party (does not include an Affiliate), in whole or part, whether voluntarily, by operation of law, change of control or
                    otherwise, without the prior written consent of the other party, and any assignment by a party in violation of the foregoing shall be void. Subject to the foregoing, the rights and obligations of the parties shall inure to the benefit
                    of and shall be binding upon and enforceable by the parties and their lawful successors and permitted assigns.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8a78d03ebfc42f294accd1ed91c60e1" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>This 3rd Amendment, when executed, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all prior written agreements, oral discussions, or understandings between them
                    with respect to the subject matter hereof.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z363c9be6497e46df86595819f24de874" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>If any of the provisions of this 3rd Amendment are found to be invalid or unenforceable, such invalidity or unenforceability shalt not invalidate or render unenforceable the remainder of this 3rd Amendment, but rather this 3rd
                    Amendment shall be construed as if it did not contain the particular invalid or unenforceable provisions, and the rights and obligations of the parties shall be construed and enforced accordingly.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze873e3e9379247b9903083cf7db950a2" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>No amendments of this 3rd Amendment or waiver of any of its terms shall be effective unless agreed in writing by both parties. No waiver of any provision of this 3rd Amendment shall constitute a waiver of any other provision(s) or of
                    the same provision on another occasion.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z87e09043cc8f4d03b2dae24ae8eaab0e" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>Capitalized terms used herein will have the same meaning as defined in the Agreement. All other terms, obligations, and conditions of the Agreement shall remain in full force and effect.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z80e1e08137ac467595deeb11e72e049c" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
                <td style="width: auto; vertical-align: top;">
                  <div>This 3rd Amendment, which shall be effective on the last date signed below, may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Amendment.
                    Scanned, electronic, PDF exchange, and facsimile signatures will be as binding as original signatures.</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The Parties have executed this 3rd Amendment by having their authorized representatives sign below.</div>
          <div>&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div id="DSPFPageFooter" style="width: 100%;">
              <div>
                <div>
                  <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                      <tr>
                        <td style="width: 100%; text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></td>
                      </tr>
                      <tr>
                        <td style="width: 100.00%;">
                          <div>
                            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="page-break-after:always;" id="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3eec76de38ea4555a42f5e8e2d09225a" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td colspan="2" style="vertical-align: top;">
                  <div style="font-variant: small-caps; font-weight: bold;">ELI LILLY AND COMPANY</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="font-weight: bold;">IMMUNOCORE</div>
                </td>
              </tr>
              <tr>
                <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Greg Plowman<br>
                </td>
                <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:&#160; <br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Stephen Megit<br>
                </td>
              </tr>
              <tr>
                <td style="vertical-align: top; width: 5%;">
                  <div><br>
                  </div>
                </td>
                <td style="vertical-align: top; width: 43%;">
                  <div>Authorized Representative</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top; width: 5%;">
                  <div><br>
                  </div>
                </td>
                <td style="vertical-align: top; width: 43%;">
                  <div>Authorized Representative</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Name:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>Greg Plowman</div>
                </td>
                <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Name:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>Stephen Megit</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Title:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>VP Oncology Research, Eli Lilly</div>
                </td>
                <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Title:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>VP, BD</div>
                </td>
              </tr>
              <tr>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Date:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>12/17/2020</div>
                </td>
                <td style="width: 4%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
                  <div>Date:<br>
                  </div>
                </td>
                <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>19/12/2018</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
            <div id="DSPFPageFooter" style="width: 100%;">
              <div>
                <div>
                  <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                      <tr>
                        <td style="width: 100%; text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></td>
                      </tr>
                      <tr>
                        <td style="width: 100.00%;">
                          <div>
                            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
            <div style="page-break-after:always;" id="DSPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: center; font-weight: bold;">Exhibit L to Development and License Agreement</div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">Material Transfer Record</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The Material described below is supplied by one Party to the other Party, subject to the terms and conditions of the Development and License Agreement between Eli Lilly and Company and Immunocore Limited, effective
            July 11, 2014, and as amended.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">For clarity, defined terms used herein and not defined herein have the meanings ascribed to such terms in the Agreement. This Material Transfer Record may he executed in one or more counterparts, including by email
            or PDF exchange, each of which shall be deemed to be an original as against any party whose signature appears thereon, but all of which together shall constitute but one and the same instrument.</div>
          <div>&#160;</div>
          <div>Direction of Transfer:</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd0f69b1b033e48f79edf0b816609776e" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>To Eli Lilly and Company, from Immunocore Limited</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2d8155a586c0407885674eeb6a2be625" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt; vertical-align: top; align: right;">&#9744;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>To Immunocore Limited, from Eli Lilly and Company</div>
                </td>
              </tr>

          </table>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3d1df4a90eef40bfbcab38b82ec5d1af" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 18%; vertical-align: top; padding-bottom: 2px;">
                  <div>Description of Material:</div>
                </td>
                <td style="width: 82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>

          </table>
          <div><br>
          </div>
          <div>In signing below, the Lilly representative and the Immunocore representative acknowledge that they understand and will abide by the terms and conditions under which the Material is provided.</div>
          <div>&#160;</div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8140bbc0b7bf4f919a0cc2874dc00129" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td rowspan="1" style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td rowspan="1" style="width: 4%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 48%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 48%; vertical-align: top;">
                  <div>Lilly Representative Signature</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td style="width: 48%; vertical-align: top;">
                  <div>Immunocore Representative Signature</div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Lilly Representative Name</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Immunocore Representative Name</div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Eli Lilly and Company</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Immunocore Limited</div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 4%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 48%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Date</div>
                </td>
                <td style="width: 4%; vertical-align: top;">&#160;</td>
                <td style="width: 48%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                  <div>Date</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div><br>
          </div>
          <div>
            <div id="DSPFPageFooter" style="width: 100%;">
              <div>
                <div>
                  <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

                      <tr>
                        <td style="width: 100%; text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></td>
                      </tr>
                      <tr>
                        <td style="width: 100.00%;">
                          <div>
                            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </div>
          <div>
            <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>7
<FILENAME>nt10016217x4_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p>
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; color: #14141E; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
        MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 4.5in; text-indent: 0.5in; text-align: right"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt; font-weight: bold;">Exhibit 10.8</font> </p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 4.5in; text-indent: 0.5in; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13121D"><b>LICENSE AGREEMENT</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #14131D"><b>RELATING TO MAGE-A4 [***] COMPOUNDS</b></font><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #13121F"><b>BETWEEN</b></font><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #141220"><b>IMMUNOCORE LIMITED,</b></font><br>
      <br>
      &#160; <font style="font-family: Times New Roman, Times, Serif; color: #14131F"><b>on the one hand,</b></font><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #141320"><b>AND</b></font><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #13131E"><b>GENENTECH, INC.,</b></font><br>
      <br>
      &#160; <font style="font-family: Times New Roman, Times, Serif; color: #15121F"><b>on the other hand,</b></font><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #13121D"><b>AS OF SEPTEMBER 27, 2016</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13121D"><b>&#160;</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"><font style="font-size: 8pt;">License Agreement relating to MAGE-A4 and [***] compounds</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(34, 34, 40); text-align: center;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">Confidential</font> </p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE OF CONTENTS</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0.5in 0pt 1in; text-transform: uppercase; text-align: center; text-indent: -1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%" cellpadding="0" cellspacing="0">

      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="width: 90%; text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 1&#160; &#160;&#160;&#160; DEFINITIONS</font></td>
        <td style="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 2 &#160; &#160; AMENDMENT TO EXISTING AGREEMENT</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 3&#160;&#160;&#160;&#160; DEVELOPMENT PROGRAM</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 4 &#160; &#160; LICENSES AND OPTIONS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 5&#160; &#160;&#160; DILIGENCE</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 6&#160; &#160;&#160; FINANCIAL TERMS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 7&#160; &#160;&#160; FINANCIAL TERMS; REPORTS; AUDITS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 8 &#160; &#160; INTELLECTUAL PROPERTY; OWNERSHIP</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 9 &#160; &#160; CONFIDENTIALITY</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 10&#160;&#160;&#160;PUBLICITY; PUBLICATIONS; USE OF NAME</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 11&#160;&#160;&#160;REPRESENTATIONS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 12&#160;&#160;&#160;INDEMNIFICATION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 13&#160;&#160;&#160;TERM; TERMINATION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 14&#160;&#160;&#160;DISPUTE RESOLUTION</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</font></td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 6pt; padding-left: 1in;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE 15&#160;&#160;&#160;MISCELLANEOUS</font></td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #1D1C22"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit A</b> - Patents relating to Existing MAGE-A4 Compounds and Existing [***] Compounds<b>&#160;</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit B</b> - Part A (Existing MAGE-A4 TCRs); Part B (Existing [***] TCRs)</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"><font style="font-size: 8pt;">License Agreement relating to MAGE-A4 and [***] compounds </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px"><br>
  </p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LICENSE AGREEMENT</font></p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>This License Agreement</b></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&#8220;<b>Agreement</b>&#8221;) is made and entered into, effective as of September 27, 2016 (&#8220;<b>Effective Date</b>&#8221;), by and between <font style="font-variant: small-caps"><b>Immunocore
          Limited</b></font>, having its principal place of business at 101 Park Drive, Milton Park, Abingdon, Oxon, United Kingdom OX14 4RY (&#8220;<b>Immunocore</b>&#8221;), on the one hand and, <font style="font-variant: small-caps"><b>Genentech, Inc</b></font>.,
      a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (&#8220;<b>GNE</b>&#8221;), on the other hand. GNE and Immunocore are sometimes referred to herein individually as a &#8220;<b>Party</b>&#8221; and
      collectively as the &#8220;<b>Parties.</b>&#8221;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #161620"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><b>Background</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #161620"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, Immunocore is a biotechnology company that is engaged in
      research and development of TCR technology for use in pharmaceutical products.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, GNE is a biopharmaceutical company engaged m the research,
      development, manufacture and sale of pharmaceutical products.</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1F1F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, Immunocore, GNE and F. Hoffmann-La Roche Ltd (&#8220;<b>Roche</b>&#8221;)
      entered into a Research Collaboration and License Agreement dated as of June 14, 2013, as amended pursuant to a First Amendment to the License Agreement ([***] and MAGE-A4) dated the same date as this Agreement pursuant to which Immunocore and GNE
      agreed to collaborate in the discovery and development of TCR technology for use in pharmaceutical products (the &#8220;<b>Existing Agreement</b>&#8221;).</font></p>
  <p style="color: #1F1F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Parties and Roche have agreed to amend the Existing
      Agreement to exclude certain compounds and targets.</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHEREAS</b>, the Parties have set out in this Agreement the rights and
      obligations of the Parties and the development to be undertaken by Immunocore concerning the Compounds, and Targets (each as defined below).</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOW THEREFORE</b>, for good and valuable consideration, the receipt and
      sufficiency of which is hereby acknowledged, GNE and Immunocore agree as follows:</font></p>
  <p style="color: #201F24; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 1</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>DEFINITIONS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalized terms used in this Agreement, whether used in the singular or
      plural, shall have the meanings set forth below, unless otherwise specifically indicated herein.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Accounting Standard</b>&#8221; means International Financial
      Reporting Standards (&#8220;<b>IFRS</b>&#8221;) which standards or principles (as applicable) are currently used at the applicable time by, and as consistently applied by Immunocore.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Affiliate</b>&#8221; of a Party, means any company, corporation or
      other business entity that is controlled by, controlling, or under common control with such Party. For purposes of this <font style="color: #202024">definition, &#8220;<b>control</b>&#8221; of a business entity (including &#8220;<b>controlled by,</b>&#8221; &#8220;<b>under
          common control with</b>&#8221; or the like) means direct or indirect beneficial ownership of more than fifty percent (50%) interest in the voting stock (or the equivalent) of such business entity or having the right to direct, appoint or remove a
        majority of members of its board of directors (or their</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> <br>
    </font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"><font style="font-size: 8pt;">License Agreement relating to MAGE-A4 and [***] compounds </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%2%%%-->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equivalents) or having the power to control the general management of such
      business entity, by law or contract. [***]</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Alliance Manager</b>&#8221; means that certain individual
      designated by each Party to act as the primary business contact for such Party for the purposes of the resolution of any dispute as required pursuant to Section 14.1, such individuals being as at the Effective Date in respect of [***], and in respect
      of [***], or such other persons as may be notified by a Party to the other Party in writing from time to time.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Applicable Laws</b>&#8221; means all laws, rules and regulations
      and guidelines which are in force during the Term of this Agreement and in any jurisdiction in which<font style="color: #939393">. </font>the Research Program or any Clinical Trial is performed or in which any product is manufactured, sold or
      supplied to the extent in each case applicable to any Party to this Agreement or any Sublicensee.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Biosimilar</b>&#8221; is defined in Section 6.4.3(b).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1F1E23">&#8220;<b>Clinical Trial</b>&#8221; shall mean a
        Phase I Clinical Trial, Phase II Clinical Trial (including for</font> avoidance of any doubt a Phase Ib or Phase IIb Clinical Trial) or Phase III Clinical Trial or any other equivalent, combined or other trial in which any Immunocore Product is
      administered to a human subject.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Combination</b>&#8221; is defined in Section l .54(c).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Combo Agreement</b>&#8221; is defined in Section 3.4.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Companion Diagnostic</b>&#8221; means any product or service that:
      <font style="color: #242328">[***].</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10&#160;&#160;&#160;&#160; &#8220;<b>Compound</b>&#8221; means a product that comprises (a) a TCR or a
      portion of a TCR that comprises a TCR alpha chain variable domain and a TCR beta chain variable domain wherein the TCR or portion of the TCR binds to an HLA presented antigen derived from a Target; and (b) an Effector.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11&#160;&#160;&#160;&#160; &#8220;<b>Compulsory Sublicense</b>&#8221; means a sublicense granted to a
      Third Party, through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Product in any country in the Territory [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12&#160;&#160;&#160;&#160; &#8220;<b>Compulsory Sublicensee</b>&#8221; means a Third Party that was
      granted a Compulsory Sublicense.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13&#160;&#160;&#160;&#160; &#8220;<b>Confidential Information</b>&#8221; means proprietary Know-How (of
      whatever kind and in whatever form or medium, including copies thereof), tangible materials or other deliverables</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed by or on behalf of a Party in connection with this
      Agreement, whether prior to or during the Term and whether disclosed orally, electronically, by observation or in writing, or</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;created by, or on behalf of, either Party and provided to the
      other Party, or created jointly by the Parties, in the course of this Agreement. For the avoidance of doubt, &#8220;<b>Confidential Information</b>&#8221; includes Know-How regarding such Party&#8217;s research, development plans, clinical trial designs, preclinical
      and clinical data, technology, products, </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt"> <br>
    </font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business information or objectives and other information of the type that is customarily
      considered to be confidential information by entities engaged in activities that are substantially similar to the activities being engaged in by the Parties pursuant to this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Control</b>&#8221; or &#8220;<b>Controlled by</b>&#8221; means the rightful
      possession by a Party, whether directly or indirectly and whether by ownership, license (other than pursuant to this Agreement) or otherwise as of the Effective Date or throughout the Term, of the unfettered right (excluding where any required Third
      Party consent cannot be obtained) to grant a license, sublicense or other right to exploit, as provided herein, without violating the terms of any agreement with any Third Party. For the avoidance of any doubt, GNE shall not be deemed to Control any
      Patents filed in the name of Immunocore by reason only that GNE undertakes the Prosecution and Maintenance of such Patents.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15&#160;&#160;&#160;&#160;&#160;&#160;&#160;I.15 &#8220;<b>Covers</b>&#8221; (including variations such as &#8220;<b>Covered</b>&#8221;,








      &#8220;<b>Covering</b>&#8221; and the like), means, with respect to a particular Patent and in reference to a particular compound or product (whether alone or in combination with one or more other ingredients) that the use, manufacture, sale, supply, import,
      offer for sale of such compound or product would infringe a Valid Claim of such Patent in the absence of any license granted under this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>CPA Firm</b>&#8221; is defined in Section 7.7.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Development Plan</b>&#8221; is defined in Section 3.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Development Program</b>&#8221; means, in respect of each Compound,
      the act1v1t1es to be conducted by Immunocore pursuant to Article 3 and the relevant Development Plan.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Diligent Efforts</b>&#8221; means carrying out obligations or
      tasks using commercially reasonable efforts and resources comparable with standard practices of pharmaceutical companies [***] to the Party concerned and exercising decisions in good faith and using prudent, scientific and business judgment.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Dispute(s)</b>&#8221; is defined in Section 14.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Effector</b>&#8221; means any protein or polypeptide having the
      ability to modulate immune cell function such as anti-CD3 scFv or a diagnostic label, including derivatives or variants thereof.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Existing Agreement</b>&#8221; is defined in the Background section
      of this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Existing [***] TCR</b>&#8221; means TCRs that bind to HLA
      presented antigens derived from [***] and which have the sequences set out in Part A of Exhibit B as updated from time to time by agreement between the Parties.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Existing [***] TCR</b>&#8221; means TCRs that bind to HLA
      presented antigens derived from [***] and which have the sequences set out in Part B of Exhibit B as updated from time to time by agreement between the Parties.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>EU</b>&#8221; means the member states of the European Union from
      time to time, or any successor entity thereto performing similar functions together with, should it cease to be a member state of the European Union, the United Kingdom.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Event</b>&#8221; means the events listed in Section 6.2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Event Payment</b>&#8221; means the payments on achieving an Event
      and as set out m Section 6.2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>FDA</b>&#8221; means the United States Food and Drug
      Administration, or any successor entity thereto performing similar functions.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Field</b>&#8221; means any and all uses, excluding any product
      that contains cells transfected with genes encoding TCRs or modified TCRs [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>First Commercial Sale</b>&#8221; means, with respect to a
      particular Immunocore Product in a given country, the first commercial sale of such Immunocore Product following Marketing Approval in such country by or under authority of Immunocore or any of its Sublicensees. As used herein, &#8220;<b>Marketing Approval</b>&#8221;
      means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale of Immunocore
      Products in a country or regulatory jurisdiction. For countries where governmental approval is required for pricing or <font style="color: #202024">reimbursement for the Immunocore Product, &#8220;<b>Marketing Approval</b>&#8221; shall not be deemed to occur
        until such pricing or reimbursement approval is obtained; provided, to the extent Immunocore or any of its Sublicensees sell a Immunocore Product prior to obtaining such pricing or reimbursement approval, such sales shall be accrued at the time of
        sale and any royalties thereon shall be paid in the quarter following the obtaining of such pricing or reimbursement approval. For the purpose of clarity and subject to Section l .54(a), sales of Immunocore Products between or among any of
        Immunocore, its Affiliates and their Sublicensees shall be excluded from &#8220;<b>First Commercial Sales</b>&#8221;.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>First Generation Immunocore Product</b>&#8221; is defined in
      Section 6.4.1(a)(i).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Foreground IP</b>&#8221; means the Immunocore Foreground IP.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Full Data Package</b>&#8221; means with respect to each Compound:
      (a) any relevant information within Immunocore&#8217;s Control relating to such Compound(s), including all information regarding safety, efficacy, toxicity, or potential side effects, as well as all data collected from performing any pharmacokinetic,
      absorption, distribution, metabolism or excretion study, and toxicology studies, and any information resulting from or related to clinical trials, (b) any relevant data and information in Immunocore&#8217;s Control relating to the manufacture, formulation,
      and cost of goods for such Compound(s), and (c) any relevant documentation, filings, correspondence or other non-privileged information in Immunocore&#8217;s Control related to existing or potential Patents related to such Compound(s).. The format and
      depth of data to be provided in such Full Data Package to be mutually agreed to by the Parties.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>GNE</b>&#8221; is defined in the introduction.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>GNE Background IP</b>&#8221; means (a) the Know-How Controlled By
      GNE in so far as it relates to MAGE-A4 and/or [***] developed pursuant to the Existing Agreement; and (b) any Patents claiming the Know-How in Section l.35(a), which Patents have an earliest priority date prior to the Effective Date. GNE Background
      IP will exclude: (i) any Patents or Know-How that Cover the manufacture (including without limitation, processes, expression technology,</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">formulations and assays developed for clinical or commercial manufacturing) of a Compound; and
      (ii) any Patents or Know-How to the extent such Patents or Know-How Cover CD3 Effector (including anti-CD3 antibodies, antigen-binding fragments thereof and other derivatives and variants); and (iii) any Patents which are filed in the name of
      Immunocore but which are Prosecuted and Maintained by GNE in accordance with the terms of the Existing Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>HLA</b>&#8221; means human leukocyte antigen type A2. For the
      avoidance of doubt, other genotypes of human leukocyte antigen are expressly excluded from these definitions.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore</b>&#8221; is defined in the introduction.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore Background IP</b>&#8221; means any (a) Know-How in so
      far as it relates to MAGE- A4 and/or [***] owned or Controlled by Immunocore as of the Effective Date, or created by Immunocore after the Effective Date; and (b) any Patents claiming the Know-How in Section l .38(a) which Patents have an earliest
      priority date prior to the Effective Date, including but not limited to the Patents listed in Exhibit A. For the avoidance of any doubt Immunocore Background <font style="color: #201F24">IP shall include any Patents which are filed in the name of
        Immunocore. but which are Prosecuted and Maintained by GNE in accordance with the terms of the Existing Agreement.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore Existing Effector</b>&#8221; means any anti-CD3 scFv in
      existence pnor to the Effective Date used to generate a Compound.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore Existing TCR</b>&#8221; means any Existing [***] TCR
      and/or any Existing [***] as described in Exhibit B.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore Foreground IP</b>&#8221; means (a) any Know-How in so
      far as it relates to [***] and/or [***] discovered, conceived or reduced to practice solely by or on behalf of Immunocore in the course of performing activities under the license granted under Section 4.1, the Development Programs or otherwise in
      connection with the Compounds containing an Immunocore Existing TCR; and (b) any Patents claiming the Know-How in Section 1.41(a).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Immunocore Product</b>&#8221; means any product containing a
      Compound containing an lmmunocore Existing TCR.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>IND</b>&#8221; means an investigational new drug application filed
      with the FDA pursuant to 21 CFR Part 312 before the commencement of clinical trials of a product, or any comparable or equivalent filing with any relevant regulatory authority in any other jurisdiction required before the commencement of any Clinical
      Trial.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Indemnitee</b>&#8221; is defined in Section 12.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Indemnitor</b>&#8221; is defined in Section 12.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Indication</b>&#8221; is defined in Section 6.2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Infringement</b>&#8221; is defined in Section 8.4.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Initial Data Package</b>&#8221; means the information to be
      provided by Immunocore to GNE pursuant to the right of first negotiation granted to GNE under Section 4.2 which shall include: [***], all where available.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Know-How</b>&#8221; means all information, inventions (whether or
      not patentable), improvements, practices, formula, trade secrets, techniques, methods, procedures, knowledge, results, test data (including pharmacological, toxicological, pharmacokinetic and pre-clinical and clinical information and test data,
      related reports, structure-activity relationship data and statistical analysis), analytical and quality control data, protocols, processes, models, designs, and other information regarding discovery, development, marketing, pricing, distribution,
      cost, sales and manufacturing. Know-How shall not include any Patents.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221; is defined in Section 12.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Major European Market</b>&#8221; means [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>MAA</b>&#8221; or &#8220;<b>Marketing Approval Application</b>&#8221; means
      BLA, sBLA, NDA, sNDA and any, equivalent thereof in the United States or any other country or jurisdiction in the Territory. As used herein: &#8220;<b>BLA</b>&#8221; means a Biologics License Application and amendments thereto filed pursuant to the requirements
      of the FDA, as defined in 21 C.F.R. &#167; 600 et seq., for FDA approval of a Immunocore Product and &#8220;<b>sBLA</b>&#8221; means a supplemental BLA; and &#8220;<b>NDA</b>&#8221; means a New Drug Application and amendments thereto filed pursuant to the requirements of the
      FDA, as defined in 21 C.F.R. &#167; 314 et seq., for FDA approval of a Immunocore Product and &#8220;<b>sNDA</b>&#8221; means a supplemental NDA.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>MAGE-A4</b>&#8221; means the protein known as Melanoma Associated
      Antigen 4 which has UNIPROT number P43358 and the gene that encodes for such protein.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Milestone Payment</b>&#8221; shall mean the payments to be made on
      the Net Sales Events and as set out in Section 6.3.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Net Sales</b>&#8221; with respect to an Immunocore Product shall
      mean an amount calculated by subtracting from the amount of Sales of such Immunocore Product by Immunocore or its Sublicensees to Third Parties (including distributors): (i) a lump sum deduction of [***] of Sales in lieu of those deductions which are
      not accounted for within Immunocore on a Immunocore Product-by-Immunocore Product basis [***]<font style="color: #212128">. The deductions under this Section will be those deductions as consistently applied by Immunocore or their Sublicensees in
        accordance with</font><font style="color: #939393">&#183; </font><font style="color: #212128">internal practices. As used herein this Section 1.52:</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #171720">Sales Among Affiliates and
        Sublicensees. Sales between or among a Party</font> and its Sublicensees shall be excluded from the computation of Net Sales provided (a) there is an arms&#8217; length sale or supply to a Third Party in relation to such Immunocore Product; and (b) any
      sale between a Party and its Sublicensee is made on an arms&#8217; length basis.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1B1A21">Supply as Samples/Test Materials.
        Notwithstanding anything to the</font> contrary in the definition of Net Sales, the supply or other disposition of lmmunocore Products (i) as samples provided free of charge to any Third Party and in accordance with standard industry practice (but
      not in circumstances where such Third Party is able to pass samples to any other Third Party other than free of charge); (ii) for use in non-clinical or clinical studies (provided such samples are provided to any Third Party in exchange for data from
      such study, </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at cost, or free of charge); (iii) for use in any tests or studies reasonably necessary to
      comply with any Applicable Law(s), regulation or request by a regulatory or governmental authority (provided such samples are provided to any Third Party in exchange for data from such test or study, at cost, or free of charge) or (iv) as is
      otherwise reasonable and customary in the industry (but not in circumstances where such Third Party is able to pass samples to any other Third Party other than free of charge), in each case of (i) through (iv) shall not be included in the computation
      of Net Sales.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #171621"><b>Immunocore Products Sold in
          Combinations</b>. In the event that a</font> Immunocore Product is sold or supplied in combination (in the same package, including as a co- formulation) with one or more other active ingredients or other products that are not the subject of this
      Agreement (for purposes of this Section 1 .54(c), a &#8220;<b>Combination</b>&#8221;), the following shall apply: <font style="color: #222127">[***].</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1820">Sales from Compulsory Sublicensees.
        The Parties shall discuss in good</font> faith and agree the reasonable treatment to be used on a consistent basis to fairly share Compulsory Sublicense payments between the Parties. For the purpose of clarity, any Party will not be penalized or be
      subject to Material Breach for delayed or deferred payments during the period of discussion.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.56&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Net Sales Event(s)</b>&#8221; is defined in Section 6.3.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Net Sales Report</b>&#8221; is defined in Section 7.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.58&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Patent(s)</b>&#8221; means any and all patents and patent
      applications and any patents issuing therefrom or claiming priority to, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, reexaminations,
      substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.59&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Phase I Clinical Trial</b>&#8221; means a human clinical trial,
      the principal purpose of which is preliminary determination of safety of an Immunocore Product in healthy individuals or patients as described in 21 C.F.R. &#167;312.21, or similar clinical study in a country other than the United States.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.60&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Phase Ib Clinical Trial</b>&#8221; means a human clinical trial of
      a Compound, consistent with 21 C.F.R. 312.21(a) or other applicable regulatory requirements outside the United States, which is designed to determine the Maximum Tolerated Dose (with the Maximum Tolerated Dose being the highest dose of treatment that
      will produce the desired effect without unacceptable toxicity, intended for use in a subsequent trial).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Phase II Clinical Trial</b>&#8221; means a human clinical trial,
      for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy of an Immunocore Product in patients being studied as described in 21 C.F.R. &#167;312.21, or similar clinical study in a country other
      than the United States. Phase II Clinical Trials shall include Phase Ila and Phase IIb Clinical Trials.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">1.62&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Phase III Clinical Trial</b>&#8221; means a human clinical trial, the principal
      purpose of which is to demonstrate clinically and statistically the efficacy and safety of an Immunocore Product </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for one or more indications in order to obtain Marketing Approval of such Immunocore Product
      for such indication(s), as further defined in 21 C.F.R. &#167;312.21 or a similar clinical study in a country other than the United States.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.63&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Pivotal Trial</b>&#8221; is defined in Section 6.2.2(d).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.64&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202025">[***] means [***].</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Prosecute and Maintain</b>&#8221; or &#8220;<b>Prosecution and
        Maintenance</b>&#8221; is defined in Section 8.1.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.66&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Regulatory Approval</b>&#8221; means the technical, medical and
      scientific licenses, registrations, authorizations and approvals required for marketing or use of a Immunocore Product (including, without limitation, approvals of, BLAs (as defined in Section 1.51), investigational new drug applications, pre- and
      post- approvals, and labeling approvals and any supplements and amendments to any of such approvals) of any national, supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity,
      necessary for the development, manufacture, distribution, marketing, promotion, offer for sale, use, import, export or sale of Immunocore Products in a regulatory jurisdiction. In the United States, its territories and possessions, Regulatory
      Approval means approval of any Marketing Approval Application or equivalent by the FDA.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.67&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Release</b>&#8221; is defined in Section 10.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.68&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Roche</b>&#8221; is defined in the recitals.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.69&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Rules</b>&#8221; is defined in Section 14.2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.70&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Section 8.4.2 Enforcement</b>&#8221; is defined in Section 8.4.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.71&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Sales</b>&#8221; of an Immunocore Product shall mean, for any
      period, the amount stated in Immunocore&#8217;s &#8220;<b>Sales</b>&#8221; line of its quarterly produced and reviewed financial statements with respect to such Immunocore Product for such period, which amount reflects the gross invoice price such Immunocore Product
      sold or otherwise disposed of (other than for use as clinical supplies or free samples) by Immunocore and its Sublicensees reduced by gross-to-net deductions (to the extent applied consistently by Immunocore and its Sublicensees with respect to sales
      of their respective other products) if not previously deducted from the amount invoiced, taken in accordance with the then currently used Accounting Standard. By way of example, the gross-to-net deductions taken in accordance with Accounting Standard
      as of the Effective Date are the following: <font style="color: #222127">[***].</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202025"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the purpose of clarity and subject to Section l .5.4(a), sales of
      Immunocore Products between or among any of Immunocore, its Affiliates or their Sublicensees shall be excluded from &#8220;<b>Sales</b>&#8221;.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202025"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.72&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Second Generation Immunocore Product</b>&#8221; is defined in
      Section 6.4. l (a)(ii).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Sublicensee</b>&#8221; shall mean a Third Party or Affiliate who
      has been granted a sublicense under the license granted by GNE to Immunocore under Article 4 and where such sub-license is in compliance with Section 4.1.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Target</b>&#8221; means MAGE-A4 and/or [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>TCR</b>&#8221; means T-cell receptor.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.76&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Tecentriq</b>&#8221;&#8482; means that certain GNE proprietary
      monoclonal antibody of IgG 1 isotype against the protein programmed cell death-ligand 1 (PD-Ll) having as its active ingredient atezolizumab.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Term</b>&#8221; is defined in Section 13.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.78&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Territory</b>&#8221; means all the countries of the world.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.79&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Third Party</b>&#8221; means any entity other than Immunocore, GNE
      or an Affiliate of any of the foregoing.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Third Party Agreement</b>&#8221; is defined in Section 4.2.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.81&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Third Party Claims</b>&#8221; is defined in Section 1 2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Third Party Infringement Claim</b>&#8221; is defined in Section
      8.5.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.83&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Title 11</b>&#8221; is defined in Section 13.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.84&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>US</b>&#8221; means the United States of America and its
      territories and possessions.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Valid Claim</b>&#8221; means, with respect to a particular
      country, (a) a claim in an issued and unexpired Patent within the GNE Background IP; or (b) a claim in an issued and unexpired Patent within the Immunocore Background IP or Immunocore Foreground IP, in each case which specifically claims the sequence
      of an Immunocore Existing TCR, in each case in such country that has <font style="color: #7B7B7B">&#8216;</font>not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of
      competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, disclaimer or otherwise, or lost in an interference proceeding.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.86&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>VAT</b>&#8221; means, in the EU, value added tax calculated in
      accordance with Council Directive 2006/112/EC, as implemented in each country member state and, in a jurisdiction outside the EU, any equivalent tax.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 2</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>AMENDMENT TO EXISTING AGREEMENT</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Parties acknowledge and agree that as of the Effective Date the Parties
      have amended the Existing Agreement to exclude the targets [***] and [***] and all Compounds to such targets. For the avoidance of doubt, the Parties agree that, as of the Effective Date and continuing in full force during the Term, the Existing
      Agreement shall cease to apply to the Targets. In the event that there is a conflict between the terms of this Agreement and the Existing Agreement, the terms of this Agreement shall prevail. The terms of the Existing Agreement shall continue in full
      force and effect in respect of any compounds that do not bind to either of the Targets.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0px"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 3</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>DEVELOPMENT PROGRAM</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>General</b>. Immunocore shall select one Compound containing
      an Existing [***] and one Compound containing an Existing [***] for further development and Immunocore shall notify GNE in writing of the identity of such Compounds it has selected as soon as practicable following such selection.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Development Plan</b>. Immunocore shall prepare a development
      plan for each of the Compounds identified in Section 3.1 above (each a &#8220;<b>Development Plan</b>&#8221;) setting out the Development Program that will apply to each of such Compounds. Each Development Plan will set out activities required for the
      development of the relevant Compound through to the completion of the first Phase Ib Clinical Trial of such and, subject to the Parties entering into a clinical combination agreement, the Development Plan in respect of the [***] Compound, will also
      provide for at least one arm of the first Phase 1b Clinical Trial to be the combination of the [***]. Subject to Section 3.4 below, should the Parties not enter into a clinical combination agreement despite the use of good faith reasonable best
      efforts to agree on such terms, then the [***] Phase I Clinical Trial or Phase Ib Clinical Trial and/or the [***] Phase I Clinical Trial or Phase Ib Clinical Trial could be as a monotherapy or combination with <font style="color: #202024">another
        therapeutic agent. Immunocore may amend the Development Plans from time to time at its discretion. At least [***] Immunocore shall provide GNE with a copy of each Development Plan and any amendments made by it to either Development Plan. Immunocore
        shall be responsible for IND filings and other regulatory filings.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Immunocore&#8217;s Obligations</b>. Subject to Section 4.3,
      Immunocore shall have sole responsibility for and will use its Diligent Efforts to carry out at its own expense the development of the Compounds as described in each of the Development Plans and shall have full authority to design the CMC (Chemistry,
      Manufacturing and Controls) and clinical plans including but not limited to the selection of any relevant combination agents that may be used in the development of the Compounds. Following completion of each Development Plan, if Immunocore decides to
      continue the development of the relevant Compound either alone or with a Third Party, all future development decisions may be made by Immunocore in its absolute discretion without reference to GNE.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Combination Trials</b>. GNE and Immunocore acknowledge and
      agree that they intend to enter into a separate written agreement, under which they will conduct a clinical combination trial with [***], the terms of which shall be negotiated in good faith using reasonable best efforts between GNE and Immunocore.
      Notwithstanding the terms of this Agreement, including without limitation Sections 3.2 and 3.3, any agreement under which the Parties shall conduct a clinical combination trial with ([***], shall be conducted under, and subject to, the terms of a
      separate written agreement between the Parties (the <font style="color: #201F24">&#8220;<b>Combo Agreement</b>&#8221;). For the avoidance of doubt, the supply of any materials between the Parties, and any intellectual property, data and or materials generated
        under such clinical combination trial shall be governed by the terms of the Combo Agreement. In the event that there is a conflict between the terms of this Agreement and the Combo Agreement, the terms of the Combo Agreement shall prevail with
        respect to the subject matter thereof.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #201F24"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 4</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>LICENSES AND OPTIONS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>License Granted by GNE</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Grant of License</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222125">GNE hereby grants to Immunocore an
        exclusive (even as to GNE and its</font> Affiliates) royalty-bearing, right and license with the right to grant sublicenses, under GNE&#8217;s rights in GNE Background IP to make, use, import, sell and offer for sale Immunocore Products in the Field in
      the Territory.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Sublicenses</b>. Subject to Section 4.2, Immunocore shall
      have the right to sublicense the rights granted under Section 4.1. l (a) to its Affiliates or Third Parties; provided that in each case:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;is consistent with the terms and conditions of this Agreement;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;is in writing;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;contains obligations on the Sublicensee equivalent to those
      applicable to <font style="color: #222127">Immunocore under Sections 6.2.2(b) and 7.7.1 and Article 9; and</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202024">is granted on an arms-length basis
        for monetary consideration and requires</font> the Sublicensee to sell or supply Immunocore Products to any Third Party on an arms-length basis.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunocore shall continue to remain responsible for all reporting obligations
      under this Agreement during the Term. Immunocore shall be responsible for all actions and omissions of any Sublicensee including where such actions and omissions result in a breach of the terms of this Agreement. Following the grant of any sublicense
      to a Third Party, Immunocore shall notify GNE of the identity of such Third Party Sublicensee. For clarity, no grant of any sublicense to a Third Party or an Affiliate shall relieve Immunocore of its obligations hereunder.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1E1D23"><b>Subcontracting</b>.
        Immunocore shall have the right to enter into subcontracts with</font> Third Parties and Affiliates to enable such Third Parties and Affiliates to provide services to or on behalf of Immunocore in relation to Immunocore Compounds and Immunocore
      Products. Any subcontract agreement must be in writing, consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article 9, and any rights granted to such subcontractor are restricted to only those
      rights necessary for performance by subcontractor of the portions of work on behalf of Immunocore. Immunocore will remain responsible (at its cost) for all acts or omissions of any subcontractor it appoints (including any acts or omissions which
      result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and conditions of this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>GNE Right of First Negotiation</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Option Grant to GNE</b>. Immunocore hereby grants to GNE,
      on a Target-by-Target basis, the option to negotiate the right to develop and/or commercialise Immunocore Products, if at any time during the development or commercialisation of such Immunocore</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif">Products, Immunocore decides to grant rights to a Third Party to develop and/or commercialise
      (including through co-development, co-promotion and/or co-marketing) such Immunocore Products. For the avoidance of doubt nothing in this Article 4 shall prevent:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #201F24">Immunocore from entering into an
        agreement regarding the conduct of a</font> clinical combination trial in circumstances where no rights to commercialise Immunocore Products are granted to a Third Party;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore from entering into negotiations with Third Parties
      regarding the same Immunocore Products at the same time as Immunocore is negotiating with GNE pursuant to this Article 4 regarding such Immunocore Products provided that no agreement is signed with a Third Party prior to the end of the period of
      negotiation granted to GNE pursuant to Section 4.2.3 and subject to the terms of Section 4.2.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notice to GNE</b>. Immunocore shall give notice in writing
      to GNE of its decision to seek and/or accept from a Third Party the right (including without limitation any option, license or other right to acquire the right) to <font style="color: #939393">.</font>develop (except as permitted under Section
      4.2.1) and/or commercialise Immunocore Products. In conjunction with such notice, Immunocore shall provide <font style="color: #201F24">to GNE the Initial Data Package for such Immunocore Products. Following receipt of such notice from &#183;Immunocore,
        GNE shall have [***] within which to notify Immunocore in writing whether it wishes to be granted the right to develop and commercialise such Immunocore Products. If GNE notifies Immunocore in writing prior to the end of such period that it wishes
        to be granted the right to develop and commercialise such Immunocore Products then Immunocore shall provide to GNE the Full Data Package for such Immunocore Products.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Exercise of an Option</b>. If GNE notifies Immunocore that
      it wishes to be granted such rights, the Parties shall negotiate in good faith for a period of [***] from (a) the delivery of the Full Data Package to GNE, or (b) such [***] period as the Parties may agree, the financial terms under which GNE shall
      be granted such rights. If at the end of such period the Parties have not agreed on the [***] terms of such rights, Immunocore may grant such rights to develop and commercialise the Immunocore Products to a Third Party under a written agreement (each
      a &#8220;<b>Third Party Agreement</b>&#8221;); provided that the [***] terms under such Third Party Agreement shall be no less favourable to Immunocore than the [***] terms which were last offered by GNE to Immunocore. If Immunocore has not signed a definitive
      agreement relating to a Third Party Agreement by the date [***] from the last day of the [***] negotiation period referred to above (or if such negotiation period is extended by the Parties, from the date that the Parties terminate negotiations) then
      the provisions of this Section 4.2 shall re-apply and before entering into any Third Party Agreement Immunocore must serve a further notice under Section 4.2.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>GNE [***]</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202025">On a [***] basis, GNE shall</font>
      have the right to request that [***]. Subject to Section 4.2.4(b), Immunocore shall, upon timely request and at least [***] advance notice from GNE and at a mutually agreeable time during its regular business hours, [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212024">Prior to [***] under Section
        4.2.4(a), [***]</font><font style="color: #202024">.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212025">[***]</font>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232127">[***]</font>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Expiration of Option to a Target</b>. The options granted
      to GNE under this Article 4 with respect to a Target, shall expire on a Target-by-Target basis, upon the First Commercial Sale of an Immunocore Product containing a Compound against such Target.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Financial Funding of Development and Commercialisation</b>.
      For the avoidance of any <font style="color: #1E1D21">doubt:</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">the obligations under Section 4.2
        shall not preclude Immunocore from</font> seeking funding from Third Parties in respect of the development or commercialisation of Immunocore Products; provided that Immunocore (i) does not grant such Third Party the option, right or license to
      develop (except as permitted pursuant to Section 4.2.1) and/or commercialise any one Immunocore Product, multiple Immunocore Products , or all the Immunocore Products; and (ii) Immunocore remains responsible for such development and
      commercialisation. For the avoidance of any doubt Immunocore shall not be permitted to seek funding from commercial entities that is specifically directed at the development of a Immunocore Product except with the prior written consent of GNE, such
      consent not to be unreasonably withheld, conditioned or delayed; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1E1D21">following the receipt by Immunocore
        of such funding by a Third Party</font> pursuant to Section 4.3(a), Immunocore shall continue to be liable to make the payments due to GNE pursuant to Article 6 provided that at no time shall Immunocore be <font style="color: #AFAFAF">. </font>obliged








      to pay to GNE [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>No Additional Licenses</b>. Except as expressly provided in
      this Agreement, nothing in this Agreement shall grant either Party any right, title or interest in and to the Know-How, Patents or other intellectual property rights of the other Party (either expressly or by implication or estoppel). For the
      avoidance of doubt GNE shall not, during the Term or subsequently, have any right or license under the Immunocore Background IP or the Immunocore Foreground IP to discover, research, develop or commercialise any Compounds.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 5</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif">DILIGENCE</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Development and Commercialisation of Immunocore Products</b>.
      Subject to Section 4.2, as between GNE and Immunocore, with effect from the Effective Date, (i) Immunocore shall have sole responsibility for and bear all costs for, researching, developing and commercialising Compounds and Immunocore Products; and
      (ii) subject to Section 3.3, Immunocore shall have the <font style="color: #202024">sole right and authority to control all decisions related to the research, development and commercialisation of Compounds and Immunocore Products. Immunocore agrees
        to use Diligent Efforts to research, develop and commercialise at least one Immunocore Product (i) containing each of the Existing [***] TCR and Existing [***] TCR selected by Immunocore in accordance with Section 3. 1 (ii) that binds to the HLA
        presented antigen against each of the [***] and [***] Targets within the Field in the Territory.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Termination of Diligence Obligations</b>. If at any time
      following the completion of [***], Immunocore wishes to cease the research, development and/or commercialisation activities with respect to a particular Target the following provisions of this Section 5.2 shall apply:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore shall notify GNE in writing of its decision
      including brief details of the reasons for its decision.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore and GNE shall discuss the termination of the
      research, development and/or commercialisation activities directed to that particular Target provided that Immunocore shall not be obliged to provide any Third Party Confidential Information to GNE.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;If following such discussions Immunocore, acting reasonably,
      decides that it wishes to terminate the research, development and/or commercialisation activities directed to that particular Target, Immunocore shall notify GNE of such decision in writing and the obligations of Immunocore set out in Section 5.1
      shall cease to apply with effect from the date of such notice with respect to the Immunocore Product(s) directed to that particular Target.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;If Immunocore subsequently decides to recommence the
      research, development and/or commercialisation activities directed to that particular Target, it will promptly notify GNE in writing of its decision and, subject to Section 5.2.6 below, the Parties shall discuss the proposal and any reasonable
      amendments to the [***] terms of this Agreement in so far as they relate to such Immunocore Product(s) directed to that particular Target and the consent of GNE, such consent not to be unreasonably withheld, delayed or conditioned, shall be required
      before Immunocore recommences the research, development or commercialisation activities directed to that particular Target. The Parties shall negotiate in good faith any reasonable amendments to the [***] terms of this Agreement for a period of [***]
      <i>f</i>rom the date of Immunocore&#8217;s notice that it has decided to recommence the research, development and/or commercialisation activities directed to that particular Target. If at the end of such period the Parties have not agreed on any amendments
      to the financial terms proposed by GNE, the provisions of Section 5.2.5 shall apply.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Parties are unable to agree on any amendments to the
      [***] terms proposed by GNE or if Immunocore does not agree that GNE may withhold its consent to Immunocore restarting the research, development or commercialisation activities directed to that particular Target in accordance with Section 5.2.4, such
      dispute will be submitted to arbitration for resolution as provided in Section 14.2 provided that such arbitration shall be modified as follows:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232228">within [***] following the final
        selection of the arbitrator,</font> the Parties, in consultation with the arbitrator, shall set a date for the arbitration, which date shall be no more than [***] after the date the arbitration is demanded under Section 1 4.2;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #201F23">the arbitration shall be &#8220;<b>baseball</b>&#8221;
        style arbitration; accordingly,</font> notwithstanding the Rules, and at least [***] prior to the arbitration, each Party shall provide the arbitrator with a brief outlining its position. Briefs may be no more than [***], and must clearly provide
      and identify the Party&#8217;s position with respect to the disputed matter;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212025">after receiving both Parties&#8217;
        opening briefs, the arbitrator will distribute each</font> Party&#8217;s brief to the other Party. [***] in advance of the arbitration, the Parties shall submit and exchange response briefs of no more than [***]. The Parties&#8217; briefs may include or attach
      relevant exhibits in the form of documentary evidence, any other material voluntarily disclosed to the other Party in advance, or publicly available information. The Parties&#8217; briefs may also include or attach demonstratives and/or expert opinion
      based on the permitted documentary evidence;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232228">the arbitration shall consist of a
        [***] hearing of no longer than [***]</font>, such time to be split equally between the Parties, in the form of presentations by counsel and/or employees and officers of the Parties. No live witnesses shall be permitted except expert witnesses
      whose opinions were provided with the Parties&#8217; briefs; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;no later than [***] following the arbitration, the arbitrator
      shall issue his/her written decision. The arbitrator shall select one Party&#8217;s proposed positions as his or her decision, and shall not have the authority to render any substantive decision other than to select the proposal submitted by either GNE or
      Immunocore. The arbitrator shall have no discretion or authority with respect to modifying the positions of the Parties. The arbitrator&#8217;s decision shall be final and binding on the Parties and may be enforced in any court of competent jurisdiction.
      Each Party shall bear its own costs and expenses in connection with such arbitration, and shall share equally the arbitrator&#8217; s fees and expenses.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of Sections 5.2.3, 5.2.4, 5.2.5 and 5.2.6
      shall not apply if at the time that Immunocore makes it decision, GNE is undertaking the research, development and/or commercialisation of a compound or product which is primarily directed to the same Target. In such circumstances GNE shall notify
      Immunocore that it is researching, developing or commercialising a compound or product which is primarily directed to the same Target and Immunocore shall be permitted to recommence research, development and/or commercialisation of compounds or
      product(s) directed to such Target in its sole discretion without further consultation with GNE and the consent of GNE shall not be required and the provisions of Section 5.3 shall not apply. For the avoidance of doubt, no Companion Diagnostic shall
      be deemed to be a compound or product which is directed to the same Target for purposes of this Section 5.2.6.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;Should Immunocore elect to cease the research, development
      and/or commercialisation activities with respect to a particular Target prior to the completion of [***]<font style="color: #222227">, the provisions of Sections 5.2.4 and 5.2.5 shall not apply.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202022">For clarity, if the research,
        development and/or commercialisation activities with </font>respect to a particular Target are terminated under Section 5.2 the obligations to develop at least one Immunocore Product to that Target under Section 5.1 shall no longer apply.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Progress Reports</b>. Subject to Section 4.2, on a
      Target-by-Target basis, Immunocore shall provide to GNE, on or before [***], an annual written report summarizing Immunocore&#8217;s progress in the development of the Immunocore Products in<font style="color: #A0A0A0">. </font>the past year, including a
      forecast of the activities that may be conducted in the current year; such annual written report to provide GNE during the Term with information reasonably necessary to determine Immunocore&#8217;s progress in developing and commercialising an Immunocore
      Product to each Target, including any events for which payments are required by Immunocore to GNE pursuant to Sections 6.2 and 6.3. GNE may address questions on the annual reports to Immunocore following receipt of such written reports. Additionally,
      Immunocore shall provide to GNE [***] notice of any material events in the development of the Immunocore Products.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 6</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>FINANCIAL TERMS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Consideration</b>. In consideration of the rights granted by
      GNE to Immunocore under Article 4 to the GNE Background IP, Immunocore shall pay to GNE the amounts set out in this Article 6.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Development and Commercial Event Payments</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>First Immunocore Product Events</b>. Subject to Section<font style="color: #BBBBBB">. </font>6.2.2, Immunocore will pay GNE the following one-time Event Payments on a Target-by-Target basis upon the first Immunocore Product (excluding Companion Diagnostics) to such Target achieving the following Events:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>Event</b></font></td>
        <td colspan="3" style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>Event Payment (US$)</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 41%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 19%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st </sup>Indication</b></font></td>
        <td style="width: 21%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd </sup>Indication</b></font></td>
        <td style="width: 19%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd </sup>Indication</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 16.65pt; text-align: justify; text-indent: -16.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>Total Potential Event Payments:</b></font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>[***]</b></font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>[***]</b></font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #151221"><b>[***]</b></font></td>
      </tr>

  </table>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In this Section 6.2, &#8220;<b>Indication</b>&#8221; means the intended use of an
      Immunocore Product for either therapeutic treatment or for the prevention of a distinct illness, sickness, interruption, cessation or disorder of a particular bodily function, system, tissue type or organ, or sign or symptom of any such items or
      conditions, regardless of the severity, frequency or route of any treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval is being sought and which will be referenced on any Immunocore Product labelling in any
      country. For clarity, label extensions (including without limitation front-line, metastatic, adjuvant, etc.) shall not be deemed to be separate Indications.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Certain Terms</b>. It is understood and agreed that the
      following terms shall apply to the Events achieved under Section 6.2.1.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1A20">On a Target-by-Target basis,
        payments under Section 6.2.1 shall be due only</font> once for the first Immunocore Product in the first three Indications to achieve such Event for such Indication.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #18181E">Payments shall be due under Section
        6.2.1 by Immunocore regardless of</font> whether it is Immunocore itself that meets the Event (as defined in the table in Section 6.2.1) or where such Event is met through the actions of any Sublicensee. Immunocore shall procure that any
      Sublicensee agrees to notify Immunocore, as applicable, immediately on any Event being met by such Sublicensee. For the avoidance of doubt, Immunocore&#8217;s (including where such obligation arises as a result of actions by any Sublicensee) cumulative
      obligation under Section 6.2.1 with respect to the: (i) first Immunocore Product binding to a particular HLA-presented antigen derived from a Target in the first Indication shall in no event exceed [***] per Target; (ii) first Immunocore Product
      binding to a particular HLA-presented antigen derived from that Target in the second Indication shall in no event exceed [***] per Target; and (iii) first Immunocore Product binding to a <font style="color: #202025">particular HLA-presented antigen
        derived from that Target in the third Indication shall in no event exceed [***] per Target. By way of example, <br>
        <br>
      </font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><font style="color: #202025"></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><font style="color: #202025">if two Immunocore Products are developed which bind to any HLA-presented antigen
        derived from the same Target, the maximum payable for the first Indication, whichever of the Immunocore Products reaches the Event first, shall be [***].</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #242328">If, for any reason, a particular
        Event specified in Section 6.2.1 is achieved</font> without one or more preceding Events having been achieved, then upon the achievement of such Event, both the Event Payment applicable to such achieved Event and the Event Payment(s) applicable to
      such preceding unachieved Event(s) shall be due and payable. For example [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222128">If any Event is merged or combined
        with any other Event, [***]</font>, the Event shall be achieved when the second Event starts or could reasonably be assumed to have been achieved. For example, [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the payment obligations set forth in Section
      6.2.1 above, <font style="color: #212027">Event Payments shall only be due under:</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0pt 0px 0pt 171pt; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222128">Section 6.2. l(a), if the Immunocore Product that achieves such Event</font> is Covered by a Valid Claim [***] at the time of achievement of such Event; provided, if no Valid Claim [***] Covers the Event
      in Section 6.2. l(a) at the time of achievement of such Event, such Event Payment shall be accrued at the time of such achievement, but shall not be due and payable unless and until such time as a Valid Claim [***] Covering such Event occurs. Any
      obligation to accrue payments under this Section shall cease once all Patent applications Covering the relevant Immunocore Product existing at the date of the Event in Section 6.2. l (a) and which if issued would constitute a Valid Claim have either
      lapsed, been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealed or appealed within the time allowed for appeal; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0pt 0px 0pt 171pt; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232229">Section 6.2. l (b), (c) (d), (e), (f) or (g), if the Immunocore Product that</font> achieves such event is Covered by a Valid Claim [***] at the time of achievement of such Event.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232229">For the purposes of Section 6.2.1,
        the first Immunocore Product shall mean</font> the first Immunocore Product to achieve the relevant Event set out in Section 6.2.1 and shall not mean the first Immunocore Product for which there is a First Commercial Sale.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #181720"><b>Notice of Achievement; Timing
          of Payment</b>. With respect to each Event referred</font> to in Section 6.2.1, Immunocore shall inform GNE within [***] of the achievement of such Event (whether such Event is achieved by Immunocore or its Sublicensees). Immunocore shall pay GNE
      the respective accrued and payable Event Payment within [***] of receipt of an invoice from GNE with respect thereto.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Net Sales Event Payments</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Net Sales Events</b>. Subject to the terms of Section
      6.3.2, Immunocore shall pay GNE the following one-time Milestone Payments per Immunocore Product upon each Immunocore Product achieving the following Net Sales Events (whether such achievement is by Immunocore or its Sublicensees):</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 73%; text-align: center; text-indent: 0in; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13131D"><b>Net Sales Event</b></font></td>
        <td style="width: 27%; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #141320"><b>Milestone Payment <br>
              (in US dollars)</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 25.65pt; text-indent: -25.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 25.65pt; text-indent: -25.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 25.65pt; text-indent: -25.65pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13121F"><b>Total Potential Net Sales Event Payments for each Immunocore Product:</b></font></td>
        <td style="text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131E"><b>[***]</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font: 10pt Times New Roman, Times, Serif">Milestone Payments under this Section 6.3.1 shall be due only once in respect of each Target,
      being for the first Immunocore Product containing an antigen derived from a Target. For the avoidance of doubt, Immunocore&#8217;s and its Sublicensees&#8217; cumulative obligation under this Section 6.3.1 shall in no event exceed [***] per Target.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #202024"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #181720"><b>Notice of Achievement;
          Payment</b>. With respect to each event listed in</font> Section 6.3.1 above, Immunocore shall promptly (and in any event within [***] of such Net Sales Event being met) inform GNE following the achievement of such event by either Immunocore or
      its Sublicensees. On or after GNE&#8217;s receipt of such notice of achievement, GNE shall submit a written invoice to Immunocore for the corresponding Milestone Payment. Each such invoice shall specify the applicable Net Sales Event, and shall be payable
      within [***] of receipt of an invoice from GNE with respect thereto. To the extent Immunocore elects to have GNE send an invoice to an address other than that specified in Section 15.2, Immunocore shall <font style="color: gray">. </font><font style="color: #242327">provide written notice to GNE thereof.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Royalty Payments for Immunocore Products</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Valid Claim Products</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore shall pay GNE, on an Immunocore Product-by-Immunocore
      Product and country-by-country basis, and subject to the terms of Sections 6.4.1(a)(i) through 6.4.1(a)(iii) and Sections 6.4.3 through 6.4.6, the following royalties on annual worldwide Net Sales of Immunocore Products by Immunocore or its
      Sublicensees, which at the time of sale or supply, are Covered by a Valid Claim in the country in which such Immunocore Product is sold:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 80%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131F"><b>Annual Worldwide Net Sales (in US Dollars)</b></font></td>
        <td style="width: 20%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131F"><b>Royalty Rate</b></font><font style="font-size: 10pt"><br>
            <font style="font-family: Times New Roman, Times, Serif; color: #14131F"><b>Percentage</b></font></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: center">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F27">Up to [***]:</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F27">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1D21">Portion equal to or greater than [***] and less than [***]:</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1D21">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #202025">Portion equal to or greater than [***] and less than [***]:</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #202025">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="text-align: justify; width: 80%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F24">Portion equal to or greater than [***] and less than [***]:</font></td>
        <td style="text-align: center; width: 20%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F24">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D22">Portion greater than [***]:</font></td>
        <td style="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1D22">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The royalties in the table in Section 6.4.1(a) above
      shall be payable on annual worldwide Net Sales of Immunocore Products containing the Immunocore Existing Effector (&#8220;<b>First Generation Immunocore Products</b>&#8221;) which at the time of sale or supply, are Covered by a Valid Claim in the country in
      which such First Generation Immunocore Product is sold.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;If there is no First Generation Immunocore Product
      on the market at the time of First Commercial Sale of Immunocore Products containing an Effector other than the Immunocore Existing Effector (&#8220;<b>Second Generation Immunocore Products</b>&#8221;) in any country, the royalties in the table in Section 6.4. l
      (a) above shall be payable on annual worldwide Net Sales of such Second Generation Immunocore Products which at the time of sale or supply, are Covered by a Valid Claim in the country in which such Second Generation Immunocore Product is sold. If
      there is no such Valid Claim(s), then the royalties as set forth in Section 6.4.2(a) below shall be payable on annual worldwide Net Sales of such Second Generation Immunocore Products.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;If there is a First Generation Immunocore Product
      on the market at the time of First Commercial Sale of Second Generation Immunocore Products in any country, and at the time of sale or supply, regardless of whether a Valid Claim covers [***] such Second Generation Immunocore Products, the royalties
      in Section 6.4.2(a) below shall be paid on annual worldwide Net Sales of such Second Generation Immunocore Products, subject to Section 6.4.5(b)(ii).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;If at the time of the First Commercial Sale of the
      Second Generation Immunocore Product there is no First Generation Immunocore Product on the market, and subsequent to the First Commercial Sale of such Second Generation Immunocore Product the First Commercial Sale of the First Generation Immunocore
      Product occurs, the Parties will discuss in good faith the royalty rate to be charged for each of the First Generation Immunocore Product and Second Generation Immunocore Product.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Know-How Products</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A181E">If in any calendar quarter, (i) the
        sale of an Immunocore Product is not</font> Covered by a Valid Claim in the country in which such Immunocore Product is sold; (ii) the Immunocore Product being sold is a Second Generation Immunocore Product, there is no First Generation Immunocore
      Product on the market at the time of First Commercial Sale of such Second Generation Immunocore Product and there is no Valid Claim Covering such Second Generation Immunocore Product; or (iii) both a First Generation Immunocore Product and a Second
      Generation Immunocore Product are on the market, only with respect to such Second Generation Immunocore Product, then Immunocore shall pay to GNE, on an Immunocore Product-by-Immunocore Product and country-by-country basis, and subject to the terms
      of Section 6.4.3 through 6.4.6, a royalty equivalent to [***] of the amounts specified in Section 6.4.1 on annual worldwide Net Sales of such Immunocore Product. In no circumstances shall Immunocore be required to pay to GNE a royalty pursuant to
      both Sections 6.4.1 and 6.4.2 in respect of the same Immunocore Product or Immunocore Products that are Companion Diagnostics.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Payment Offsets</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Third Party Payments</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #17161F"><b>Immunocore</b>.
        Immunocore shall continue to have the obligation to</font> make payments owed under written agreements entered into by Immunocore with Third Parties which relate to any Immunocore Product, as of the Effective Date or during the Term.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #17161F"><b>Third Party Licenses</b>.
        If, after the Effective Date, Immunocore or its</font> Sublicensees obtains a right or license under any intellectual property of a Third Party, where the making, using, selling, offering for sale, or importing of an Immunocore Product by
      Immunocore or the relevant Sublicensee would in the absence of such right or license infringe the intellectual property of a Third Party, then Immunocore may offset the payments due and payable to GNE with respect to such Immunocore Product by the
      amount of payments paid by Immunocore or its Sublicensee to such Third Party for such right or license; provided that in no event shall such reductions reduce the payments owed to GNE for such Immunocore Product by more than [***] of what would
      otherwise be owed by Immunocore or its Sublicensee to GNE.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Biosimilar</b>. Following the first commercial sale of a
      Biosimilar in a country <font style="color: #1B1723">and:</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1B1A1F">such Biosimilar is
        Covered by a Valid Claim [***]</font> <font style="color: #1A181F">Covering the Immunocore Product <br>
        <br>
      </font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><font style="color: #1A181F">in such country, and [***]</font>, no royalty reduction may be made under
      this Section 6.4.3(b);</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #201F23">such Biosimilar is
        Covered by a Valid Claim [***]</font> in such country, [***], the royalties due and payable by Immunocore hereunder shall be reduced by [***] in such country;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222027">such Biosimilar is
        Covered by a Valid Claim in such country, [***]</font>, and where [***], the royalties due and payable by Immunocore hereunder shall be reduced by [***] in such country; or</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">such Biosimilar is not
        Covered by a Valid Claim in such country, the</font> royalties due and payable by Immunocore or its Sublicensee hereunder shall be reduced by [***] in such country [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reduction in royalties under Section 6.4.3(b)(ii) and (iii) shall only
      apply during the period of time [***] in such country. For the purpose of this Section 6.4.3(b) [***]. As used herein, &#8220;<b>Biosimilar</b>&#8221; means any drug or biological product that is interchangeable directly with any Immunocore Product and which is
      subject to review under an abbreviated approval pathway as a biosimilar, follow-on biologic or generic biological product, as these terms are commonly understood under the FD&amp;C Act or the PHS Act and related rules and regulations, or the
      corresponding or similar laws, rules and regulations of any other jurisdiction and (1) where such Biosimilar obtains Regulatory Approval or is otherwise sold by a Third Party that is not Immunocore or a Sublicensee; and (2) where Immunocore or its
      Sublicensees have not directly authorised or permitted such Third Party to market, manufacture and sell such product in the market in question.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">The cumulative reduction made under
        Sections 6.4.3(a), (b)(ii) and (b)(iii) in</font> a country shall not exceed [***] of what would otherwise be owed by Immunocore to GNE in accordance with Sections 6.4. 1 and 6.4.2 in such country.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Single Royalty</b>. No more than one royalty payment shall
      be due under this Section 6.4 with respect to a sale of a particular Immunocore Product. For the avoidance of doubt: (a) multiple royalties shall not be payable because the sale of a particular Immunocore Product is Covered by more than one (1) Valid
      Claim in the country in which such Immunocore Product is sold; or (b) in no event shall Immunocore and/or its Sublicensees be obligated to simultaneously pay a royalty under Section 6.4.1 with respect to a sale of a particular Immunocore Product that
      is subject to Section 6.4.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Royalty Term</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222125">The royalty obligations set forth in
        Section 6.4.1 above will commence on a</font> country-by-country basis upon the First Commercial &#183;sale of any Immunocore Product, and expire on a country-by-country basis upon the expiration of the last to expire Patent containing a Valid Claim
      which Covers the sale of such Immunocore Product in such country. For clarity, if the last Valid Claim Covering the sale of an Immunocore Product in a particular country expires prior to the <font style="color: #202024">[***] of the date of First
        Commercial Sale of such Immunocore <br>
        <br>
      </font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><font style="color: #202024">Product in such country, royalties shall continue to be payable on the sales of
        such Immunocore Product in such country pursuant to Section 6.4.2 at the rates set forth therein, as applicable, until the [***] of the date of First Commercial Sale of such Immunocore Product in such country.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;The royalty obligations set forth in Section 6.4.2 above will:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1D1D22">for any First Generation
        Immunocore Product or any Second</font> Generation Immunocore Product in respect of which the royalty set out in Section 6.4.1(a)(ii) as may be modified by Section 6.4.2 is payable, commence on a country-by-country basis upon the First Commercial
      Sale of any such Immunocore Product, and expire on a country-by-country basis upon the earlier of (i) [***] of the date of First Commercial Sale of such Immunocore Product in such country; or (ii) such time as such Immunocore Product is Covered by a
      Valid Claim in such country, in which case such Immunocore Product shall be subject to the royalty term set forth in Section 6.4.1 above. For clarity, in the case of a First Generation Immunocore Product or any Second Generation Immunocore Product in
      respect of which the royalty set out in Section 6.4.l (a)(ii) is payable for which a Valid Claim first comes into existence in a particular country after the date of First Commercial Sale in such country, on the date of issuance of such Valid Claim
      royalties shall continue to be payable on the sales of such Immunocore Product pursuant to Section 6.4.1 at the rates set forth therein, and expire upon the expiration of such Valid Claim in such country. For the purposes of calculating the [***]
      period above for each Immunocore Product in any country within the EU, the [***] period shall start [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1E1D22">for any Second
        Generation Immunocore Product for which the First</font> Commercial Sale occurs whilst a First Generation Immunocore Product is on the market, commence on a country-by-country basis upon the First Commercial Sale of the Second Generation Immunocore
      Product, and expire on the last to occur of (a) the expiration of the last to expire Patent with a Valid Claim which Covers the sale of such First Generation Immunocore Product; or (b) [***] of the date of First Commercial Sale of such Second
      Generation Immunocore</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1821"><b>Rights Following Expiration
          of Royalty Term</b>. Upon expiry of Immunocore&#8217;s</font> payment obligation hereunder with respect to an Immunocore Product in a country, the license in Section 4.1 shall be fully paid-up in respect of that Immunocore Product in that country.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Companion Diagnostic Sublicensing Revenue</b>. Immunocore
      shall pay GNE, on a Companion Diagnostic-by-Companion Diagnostic and country-by-country basis, and <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">subject to the terms of Section 6.4.8, a royalty of [***] of the Sublicensing Revenue that Immunocore receives
      from a Companion Diagnostic Sublicensee from the sale of a Companion Diagnostic in such country. Notwithstanding the foregoing, in no event shall Immunocore be obligated to make <font style="color: #202024">any royalty payment on the Sublicensing
        Revenue of a Companion Diagnostic, where the sale of such Companion Product is not Covered by a Valid Claim in the country in which such Companion Product was sold.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Certain Terms relating to Companion Diagnostics</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #181721"><b>Sublicensing Revenue</b>. &#8220;<b>Sublicensing








          Revenue</b>&#8221; shall mean [***]</font>. Sublicensing Revenues shall exclude: [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #17171F">&#8220;<b>Companion Diagnostic Sublicensee</b>&#8221;
        means a Third Party or Affiliate who</font> has been granted a sub-license to research, develop and commercialise a Companion Diagnostic, and where such sublicense is in compliance with Section 4.1.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #171620"><b>Royalty Term for Companion
          Diagnostics</b>. The royalty obligations set</font> forth in Section 6.4.7 above will commence upon the effective date that Immunocore or its Sublicensee (as applicable) enters into a written agreement with a Companion Diagnostic Sublicensee, and
      expire, on a country-by-country basis, upon the later of (i) the expiration of the last to expire Patent containing a Valid Claim which Covers the sale of such Companion Diagnostic in such country, or (ii) the tenth (10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) anniversary of the date of First Commercial Sale of such Companion Diagnostic in such country. For the purposes of calculating the ten (10) year period above for each Immunocore Product in
      any country within the EU, the ten (10) year period shall start [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 7</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>FINANCIAL TERMS; REPORTS; AUDITS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Timing of Royalty Payment</b>. All royalty payments shall be
      made within [***] of <font style="color: #222125">the end of each calendar quarter in which the sale was made.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Royalty Report</b>. For each calendar quarter for which
      Immunocore has an obligation to make royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the following information (&#8220;<b>Net Sales Report</b>&#8221;):</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;total Net Sales of all Immunocore Products sold in
      the Territory;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net Sales on a country-by-country basis for all
      Immunocore Products <font style="color: #202024">sold;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;the exchange rate used to convert Net Sales from
      the currency in <font style="color: #1F1F23">which they are earned to United States dollars; and</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;the total royalties due to GNE.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If Immunocore is reporting Net Sales for more than one Immunocore Product,
      the foregoing information shall be reported on a Immunocore Product-by-lmmunocore Product basis.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Mode of Payment</b>. All payments hereunder shall be made in
      immediately available funds to the account listed below (or such other account as GNE shall designate before such payment is due):</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; color: #1E1E21"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; color: #1E1E21"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Currency of Payments</b>. All payments under this Agreement
      shall be made in United States dollars, unless otherwise expressly provided in this Agreement. Net Sales outside of the United States shall be first determined in<font style="color: #B8B8B8">_ </font>the currency in which they are earned and shall
      then be converted into an amount in United States dollars as follows: (i) with respect to sales by or on behalf of Immunocore, use Immunocore&#8217;s customary and usual conversion procedures, consistently applied in preparing its audited financial
      statements; and (ii) with respect to sales by or on behalf of a given Sublicensee, using the conversion procedures applicable to payments by such Sublicensee to Immunocore for such sales and where such procedures have been agreed prior to the
      Effective Date or as modified by Immunocore and its Affiliates after the Effective Date.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Blocked Currency</b>. If, at any time, legal restrictions
      prevent Immunocore or a Sublicensee from remitting part or all of royalty payments when due with respect to any country in the Territory <font style="color: #201F23">where Immunocore Products are sold, Immunocore shall continue to provide Net Sales
        Reports for such royalty payments, and such royalty payments shall continue to accrue in such country, but Immunocore shall not be obligated to make such royalty payments until such time as payment may be made through reasonable, lawful means or
        methods that may be available, as Immunocore shall determine.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Taxes</b>. Each Party shall comply with Applicable Laws and
      regulations regarding filing and reporting for income tax purposes. Neither Party shall treat their relationship under this Agreement as a pass through entity for tax purposes. All payments made under this Agreement shall be made free and clear of
      any and all taxes, duties, levies, fees or other, except for withholding taxes and VAT (if applicable). Immunocore and its Sublicensees shall be entitled to deduct from payments made to GNE under this Agreement the amount of any withholding taxes
      required to be withheld, to the extent paid to the appropriate governmental authority on behalf of GNE (and not refunded or reimbursed). Immunocore shall deliver to GNE, upon request, proof of payment of all such withholding taxes. Immunocore (on the
      one hand) and GNE (on the other hand) shall provide reasonable assistance to other Party in seeking any benefits available to either Party with respect to government tax withholdings by any relevant law, regulation or double tax treaty. All payments
      made under this Agreement shall be exclusive of VAT (if applicable) and such VAT shall be paid promptly on receipt of a valid VAT invoice.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Records; Inspection</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Records</b>. Immunocore agrees to keep, for [***] from the
      year of creation, records of all sales of Immunocore Products for each reporting period in which royalty payments are due, showing sales of Immunocore Products for each of Immunocore and its Sublicensees and applicable deductions in sufficient detail
      to enable the report provided under Section 7.2 to be verified. Immunocore shall procure that its Sublicensees keep records in accordance with this Section.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Audits</b>. GNE shall have the right to request that such
      report be verified by an independent, certified and internationally recognized public accounting firm selected by GNE and acceptable to Immunocore (the &#8220;<b>CPA Firm</b>&#8221;). Such right to request a verified report shall (i) be limited to a [***]
      immediately preceding such request for a verified report; (ii) not be exercised more than once in any calendar year: and (iii) not more frequently than once with respect to records covering any specific period of time. Subject to Section 7.7.3,
      Immunocore shall, upon timely request and at least [***] advance notice from GNE and at a mutually agreeable time during its regular business hours, make its records available for inspection by such CPA Firm at such place or places where such records
      are customarily kept, solely to verify the accuracy of the reports provided under Section 7.2 and related payments due under this Agreement. The CPA Firm shall only state factual findings in the audit reports. The draft audit report shall be shared
      with Immunocore at the same time that it is shared with GNE. Following review and approval by all Parties of the draft audit, the final audit report shall be shared with GNE and Immunocore. Immunocore shall procure access to Sublicensee records
      relevant to verify the accuracy of reports under Section 7.2. relating to such Sublicensee and in accordance with this Section 7.7.2 and shall make such Sublicensee records available to the CPA Firm at the same time and location as GNE&#8217;s own records
      are made available to the CPA Firm.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Confidentiality</b>. Prior to any audit under Section
      7.7.2, the CPA Firm shall enter into a written confidentiality agreement with Immunocore that (i) limits the CPA Firm&#8217;s use of Immunocore and its Sublicensee&#8217;s records to the verification purpose described in Section 7.7.2; (ii) limits the
      information that the CPA Firm may disclose to GNE to the numerical summary of payments due and paid; and (iii) prohibits the disclosure of any information contained in such records to any Third Party for any purpose. The Parties agree that all
      information subject to review under Section 7.7.2 and/or provided by the CPA Firm to GNE is Immunocore&#8217;s Confidential Information, and GNE shall not use any such information for any purpose that is not germane to Section 7.7.2.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Underpayment; Overpayment</b>. After reviewing the CPA
      Firm&#8217;s audit report, Immunocore shall promptly pay any uncontested, understated amounts due to GNE. Any overpayment made by GNE or any Sublicensee shall be promptly refunded or fully creditable against amounts payable in subsequent payment periods,
      at Immunocore&#8217;s election. Any audit under Section 7.7.2 shall be at GNE&#8217;s expense; provided, however, Immunocore shall reimburse reasonable audit fees for a given audit if the results of such audit reveal that Immunocore and any Sublicensee underpaid
      GNE [***] for the audited period [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 8</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif"><b>INTELLECTUAL PROPERTY; OWNERSHIP</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Definitions</b>. As used herein this Article 8:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<b>Prosecution and Maintenance</b>&#8221; or &#8220;<b>Prosecute and
        Maintain</b>&#8221;, with respect to a particular Patent, means all activities associated with the preparation, filing, prosecution and maintenance of such Patent (and patent application(s) derived from such Parent), as well as re- examinations,
      reissues, applications for patent term adjustments and extensions, supplementary protection certificates and the like with respect to that Patent, together with the conduct of interferences, derivation proceedings, pre- and post-grant proceedings,
      the defense of oppositions and other similar proceedings with respect to that Patent.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Ownership; Inventorship; Assignment and Cooperation</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Ownership</b>. As between the Parties:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore shall solely own the Immunocore Background IP and the
      <font style="color: #212028">Immunocore Foreground IP; and</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;GNE shall solely own the GNE Background IP.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1B1A20"><b>Assignment; Cooperation</b>.
        The assignments necessary to accomplish the</font> ownership provisions set forth in this Article 8 are hereby made, and each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and
      cooperation, to implement the provisions of this Article 8. Each Party shall to the extent legally possible under relevant national or local laws require all of its employees, Affiliates and any Third <font style="color: #202024">Parties working
        pursuant to this Agreement on its behalf, to assign (or otherwise convey rights) to such Party any Patents and Know-How discovered, conceived or reduced to practice by such employee, Affiliate or Third Party, and to cooperate with such Party in
        connection with obtaining patent protection therefore.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>CREATE Act</b>. It is the intention of the Parties that
      this Agreement is a &#8220;<b>joint research agreement</b>&#8221; as that phrase is defined in Public Law 108-53 (the &#8220;<b>Create Act</b>&#8221;). In the event that either Party to this Agreement intends to overcome a rejection of a claimed invention within the
      Immunocore Background IP, Immunocore Foreground IP and/or GNE Background IP pursuant to the provisions of the Create Act, such Party shall first obtain the prior written consent of the other Party and the Parties shall work together in good faith to
      agree how any rejection should be overcome. To the extent that the Parties agree that, in order to overcome a rejection of a claimed invention within Immunocore Background IP, the Immunocore Foreground IP and/or GNE Background IP pursuant to the
      provisions of the Create Act, the filing of a terminal <font style="color: gray">&#183;</font> disclaimer is required or advisable, the Parties shall first agree on terms and conditions under which the patent application subject to such terminal
      disclaimer and the patent or application over which such application is disclaimed shall be jointly enforced, to the extent that the Parties have not previously agreed to such terms and conditions. To the extent that this Section 8.2.3 applies to
      Immunocore Background IP or the Immunocore Foreground IP, any obligation under this Section will be subject to any Third Party agreements entered into with Immunocore prior to or after the Effective Date relating to the prosecution or maintenance of
      such Immunocore Background IP or the Immunocore Foreground IP and any co-operation or consultation by Immunocore under this Section 8.2.3 shall be subject to such Third Party agreements. In the event that Immunocore intends to enter into an agreement
      with a Third Party with respect to the further research, development or commercialisation of an Immunocore Product and such agreement is a &#8220;<b>joint research agreement</b>&#8221; as that phrase is defined in the Create Act, the Parties shall in good faith
      discuss whether GNE shall similarly enter into such agreement with such Third Party purely for the purposes of agreeing similar consultation rights in relation to any rejection under the Create Act as contained under this Section 8.2.3.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Patent Prosecution</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Immunocore Controlled Prosecution and Maintenance</b>.
      Immunocore shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Background IP and the Immunocore Foreground IP. <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Immunocore will provide GNE with a draft copy of any proposed patent application, filings and other material
      correspondence with applicable governmental authorities covering the Immunocore Background IP and the Immunocore Foreground IP for review and comment prior to filing or prior to submission of any response or communication with applicable governmental
      authorities and will keep GNE reasonably informed of the status of such Patents, including providing GNE with copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Immunocore.
      Immunocore will provide any filings or correspondence for comment by GNE where possible at least [***] prior to any due date or required response date. Immunocore will consider all comments provided by GNE to Immunocore prior to any due date or
      required response date [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>GNE Controlled Prosecution and Maintenance</b>. GNE shall,
      at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the GNE Background IP. GNE will provide Immunocore with copies of any filed patent application, filings and other material
      correspondence with applicable governmental authorities relating to such GNE Background IP and will keep Immunocore reasonably informed of the status of such Prosecution and Maintenance, including providing Immunocore copies of all communications
      received from or filed in patent offices within a reasonable period of time after receipt by GNE. Immunocore will provide all reasonable cooperation and assistance to GNE at GNE&#8217; s reasonable request and at GNE&#8217;s expense in Prosecution and
      Maintenance of such Patents, including making data, reports, and scientific personnel reasonably available to prepare and prosecute patent applications.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Transfer of Prosecution and Maintenance by GNE</b>. If GNE
      elects not to Prosecute and Maintain any Patents under Section 8.3 .2, GNE shall provide at least [***] written notice to Immunocore. Thereafter, Immunocore shall have the right, but not the obligation, to Prosecute and Maintain any notified Patents,
      at its sole expense and in its sole discretion. GNE will provide all reasonable cooperation and assistance to Immunocore in relation to such Prosecution and Maintenance. The Party assuming responsibility to Prosecute and Maintain said Patents may
      elect to require transfer of ownership or rights of said Patents at their sole discretion.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Interferences Between the Parties</b>. If an interference
      or derivation proceeding is declared by the US Patent and Trademark Office between one or more of the Patents within the Immunocore Background IP, Immunocore Foreground IP or GNE Background IP, to the extent directed to an Immunocore Product and such
      declared interference or derivation proceeding does not involve any Patents owned by a Third Party, then the Parties shall in good faith establish a mutually agreeable process to resolve such interference or derivation proceeding in a reasonable
      manner in conformance with all applicable legal standards, but which prejudices neither Party nor diminishes the value of such Patents at issue.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Enforcement Rights for Infringement by Third Parties</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notice</b>. Each Party shall promptly notify, in writing,
      the other Party upon learning of any actual or suspected infringement of the Patents within the GNE Background IP, Immunocore Background IP or Immunocore Foreground IP to the extent such actual or suspected infringement is relevant to any Compound or
      an Immunocore Product, or, except for the matters that are subject to Section 8.3.2, of any claim of invalidity, unenforceability, or non-infringement of any Patents within the GNE Background IP, Immunocore Background IP or Immunocore Foreground IP
      (each an &#8220;<b>Infringement</b>&#8221;). At the request of the Party receiving <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">such notice, the other Party shall use Diligent Efforts to provide all evidence in its possession pertaining to
      the actual or suspected Infringement that it can disclose without breach of a pre-existing obligation to a Third Party or waiver of privilege. In addition each Party shall also use reasonable efforts to notify the other Party upon learning of any
      actual or suspected infringement of the Patents within the GNE Background IP, Immunocore Background IP or Immunocore Foreground IP to the extent such actual or suspected infringement is relevant to any Compound.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Enforcement Actions</b>. The Parties shall consult as to
      potential strategies to terminate suspected or potential Infringement, consistent with the overall goals of this Agreement. If the Parties fail to agree on such strategies:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1821"><b>Relating to GNE Background IP</b>.
        GNE shall have the first right, but not</font> the obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Section 8.3.2. If GNE
      does not, within [***] of receipt of a notice under Section 8.4.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then Immunocore shall have the right, but not the obligation, to take action to enforce any
      Patent containing a Valid Claim against such Infringement; provided that if GNE is diligently pursuing ongoing settlement discussions at the end of such [***] period then Immunocore shall not be permitted to exercise such right unless such settlement
      discussions cease without reaching settlement or GNE ceases to pursue such discussions diligently.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #14131F"><b>Relating to Immunocore Background
          IP or Immunocore Foreground IP</b>.</font> Immunocore shall have the first right, but not the obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each
      case of any Patent under Section 8.3.1. If Immunocore does not, within [***] of receipt of a notice under Section 8.4.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then GNE shall have the right, but
      not the obligation, to take action to enforce any Patent containing a Valid Claim against such Infringement; provided that if Immunocore is diligently pursuing ongoing settlement discussions at the end of such [***] then GNE shall not be permitted to
      exercise such right unless such settlement discussions cease without reaching settlement or Immunocore ceases to pursue such discussions diligent}y.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212027">The non-controlling Party shall
        cooperate with the Party controlling any such</font> action to abate or enforce (as may be reasonably requested by the controlling Party and at the controlling Party&#8217;s expense), including, if necessary, by being joined as a party provided that the
      non-controlling Party shall be indemnified by the controlling Party as to any costs or expenses, and shall have the right to be represented by its own counsel at its own expense. The Party controlling any such action shall keep the other Party
      updated with respect to any such action, including providing copies of all documents received or filed in connection with any such action.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1D1C22"><b>Settlement</b>. The Party
        controlling any such enforcement action described in</font> Section 8.4.2 (a &#8220;<b>Section 8.4.2 Enforcement</b>&#8221;), at its sole discretion, may take reasonable actions to terminate any alleged Infringement without litigation; provided, that if any
      such arrangement would adversely affect the non-controlling Party&#8217;s rights under this Agreement, then that arrangement is subject to the non-controlling Party&#8217;s prior written consent. The Party controlling any Section 8.4.2 Enforcement may not settle
      or consent to an adverse judgment <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">without the express written consent of the non-controlling Party (such consent not to be unreasonably withheld
      or delayed).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1D1C21"><b>Costs and expenses</b>. The
        Party controlling any Section 8.4.2 Enforcement shall</font> bear all [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #201F24"><b>Damages</b>. Unless otherwise
        mutually agreed by the Parties, and subject to the</font> respective indemnity obligations of the Parties set forth in Article 12, all damages, amounts received in settlement, judgment or other monetary awards recovered in Section 8.4.2 Enforcement
      with respect to activities of the Third Party that occurred prior to the effective date of such award shall be shared as follows: [***].</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the avoidance of doubt, if any settlement results in the granting to the
      alleged infringer of a sublicense of any of the GNE Background IP with running royalties payable on post-settlement sales by the alleged infringer, such alleged infringer shall be deemed to be a Sublicensee and such royalties on post-settlement sales
      (i) shall be subject to all applicable royalty obligations hereunder, and (ii) shall not be subject to this Section 8.4.5; [***].</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Third Party Infringement Claims</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notice</b>. In the event that a Third Party shall make any
      claim, give notice, or bring any suit or other inter partes proceeding against GNE or Immunocore, or any of their respective Affiliates or licensees or customers, for infringement or misappropriation of any intellectual property rights with respect
      to the research, development, making, using, selling, offering for sale, import or export of any Immunocore Product (&#8220;<b>Third Party Infringement Claim</b>&#8221;), in each case, the Party receiving notice of a Third Party Infringement Claim shall promptly
      notify the other Party and use Diligent Efforts to provide all evidence in its possession pertaining to the claim or suit that it can disclose without breach of a pre-existing obligation to a Third Party or waiver of privilege.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202025"><b>Defense</b>. The Parties
        shall consult as to potential strategies to defend against any</font> Third Party Infringement Claim, consistent with the overall goals of this Agreement, including by being joined as a party. The Parties shall cooperate with each other in all
      reasonable respects in the defense of any Third Party Infringement Claim or raising of any counterclaim related thereto. If the Parties fail to agree on such strategies, and subject to the respective indemnity obligations of the Parties set forth in
      Article 12, Immunocore shall be solely responsible for defending such Third Party Infringement Claim including but not limited to selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation. If Immunocore
      does not, within [***] <font style="color: #202024">of receipt of a notice under Section 8.5.1, take steps to defend the Third Party Infringement Claim, then to the extent that such Third Party Infringement Claim is brought against Immunocore, GNE
        shall have the right, but not the obligation, to take action to enforce or defend against such Third Party Infringement Claim provided that if Immunocore is diligently pursuing ongoing settlement discussions at the end of such [***] period then GNE
        shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or Immunocore ceases to pursue such discussions diligently. At the controlling Party&#8217;s request and expense, the non-controlling Party
        shall cooperate with the controlling Party in connection with any such defense and counterclaim, provided that the non-controlling Party shall be indemnified by </font><font style="color: #A0A0A0">_</font><font style="color: #202024">the
        controlling Party as to any costs or expenses, and shall </font><font style="color: #ABABAB">.</font><font style="color: #202024">have the right to be represented by its own counsel at its own expense. Any counterclaim or other similar action by a
        Party, to the extent such <br>
        <br>
      </font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><font style="color: #202024">action involves any enforcement of rights under the GNE Background IP will be
        treated as an enforcement action subject to Section 8.4. Nothing in this Section shall prevent GNE from </font><font style="color: gray">&#183;</font><font style="color: #202024">complying with the terms of any court order relating to or arising out of
        any Third Party Infringement Claim.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Settlement</b>. If any such defense under Section 8.5.2
      would adversely affect the other Party&#8217;s rights under this Agreement or impose a financial obligation upon the other Party or grant rights in respect, or affect the validity or enforceability, of the other Party&#8217;s Patents or any Joint IP, then any
      settlement, consent judgment or other voluntary final disposition of such Third Party Infringement Claim shall not be entered into without the consent of the other Party (such consent not to be unreasonably withheld).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Costs and expenses</b>. The Party controlling the defense
      of any Third Party Infringement Claim shall bear all costs and expenses, including but not limited to litigation expenses, to defend against any Third Party Infringement Claim.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 9</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>CONFIDENTIALITY</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Non-use and Non-disclosure of Confidential Information</b>.
      During the Term, and for a period of [***] thereafter, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any Third Party any Confidential Information of the
      other Party; (ii) except in connection with activities contemplated by, the exercise of rights permitted by, in order to further the purposes of this Agreement or otherwise agreed to in writing, not use for any purpose any Confidential Information of
      the other Party; and (iii) take all reasonable precautions to protect the Confidential Information of the other Party (including all precautions a Party employs with respect to its own confidential information of a similar nature).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Exclusions Regarding Confidential Information</b>.
      Notwithstanding anything set forth in this Article 9 to the contrary, the obligations of Section 9.1 above shall not apply to the extent that the Party seeking the benefit of the exclusion can demonstrate that the Confidential Information of the
      other Party:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;was already known to the receiving Party, other than under an
      obligation of <font style="color: #232229">confidentiality, at the time of receipt by the receiving Party;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;was generally available to the public or otherwise part of the
      public domain at <font style="color: #232227">the time of its receipt by the receiving Party;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202023">became generally available to the
        public or otherwise part of the public</font> domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232228">was received by the receiving Party
        without an obligation of confidentiality</font> from a Third <font style="color: #A3A3A3">_</font>Party having the right to disclose such information without restriction;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;was independently developed by or for the receiving Party without
      use of or <font style="color: #222128">reference to the Confidential Information of the other Party; or</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;was released from the restrictions set forth in this Agreement by
      express prior <font style="color: #212127">written consent of the Party.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1720"><b>Authorized Disclosures of
          Confidential Information</b>. Notwithstanding the foregoing, a</font> Party may use and disclose the Confidential Information of the other Party as follows:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #202024">if required by law, rule or
        governmental regulation, including as may be</font> required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the Party seeking to disclose the Confidential Information of the other
      Party (i) uses all reasonable efforts to inform the other Party prior to making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible,
      requests confidential treatment of such information;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent such use and disclosure is reasonably required in
      the Prosecution and Maintenance of a Patent within the Immunocore Background IP or the Immunocore Foreground IP or the GNE Background IP in accordance with this Agreement upon reasonable notice and written consent of the other Party, such consent not
      to be unreasonably withheld, delayed or conditioned;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;as reasonably necessary to obtain or maintain any Regulatory
      Approval, including to conduct preclinical studies and clinical trials and for pricing approvals, for any Immunocore Products, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information
      outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;to take any lawful action that it<font style="color: #A0A0A0">. </font>deems








      necessary to protect its interest under, <font style="color: #202023">or to enforce compliance with the terms and conditions of, this Agreement; or</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222228">to the extent necessary, to
        Sublicensees, collaborators, vendors, consultants,</font> agents, attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such
      information in connection with such Party performing its obligations or exercising its rights under this Agreement. Further, the receiving Party may disclose Confidential Information to existing or potential acquirers, <font style="color: #212025">merger









        partners, permitted collaborators, Sublicensees and sources of financing or to professional advisors (e.g. attorneys, accountants and prospective investment &#183; bankers) involved in such activities, for the limited purpose of evaluating such
        transaction, collaboration or license and under appropriate conditions of confidentiality, only to the extent necessary and with the agreement by those permitted individuals to maintain such Confidential Information in strict confidence.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Return of Confidential Information</b>. Except as expressly
      permitted under this Agreement, following any termination of this Agreement each Party shall upon written request by the other Party promptly destroy all Confidential Information received from the disclosing Party, including any copies thereof,
      (except one copy of which may be retained for archival purposes solely to ensure compliance with the terms of this Agreement).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Terms of this Agreement</b>. The Parties agree that this
      Agreement and the <font style="color: #909090">&#183;</font>terms hereof will <font style="color: #201F24">be considered Confidential Information of both Parties.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Survival of Prior Agreements</b>. As of the Effective Date, it
      is understood and agreed that <font style="color: #202024">the Existing Agreement, as amended, shall survive in full force and effect.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>No License</b>. As between the Parties, Confidential
      Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses expressly granted
      under Article 4, under any patent, trade secret or other rights now or hereinafter held by the disclosing Party.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 10</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>PUBLICITY; PUBLICATIONS; USE OF NAME</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Publicity</b>. The text of any press releases, public
      announcements and powerpoint presentations concerning this Agreement, the subject matter hereof, or the research, development or commercial results of products hereunder (a &#8220;<b>Release</b>&#8221;) shall be addressed pursuant to Sections 10.2 to 10.4. Any
      such Release shall not include any financial terms of this transaction:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Releases</b>. Subject to Sections 9.2, 10.3 and 10.4:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Immunocore may not issue a Release without GNE&#8217;s prior
      written consent if it includes reference to GNE&#8217;s or GNE&#8217;s option under Section 4.2; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;GNE may not issue a Release without Immunocore&#8217;s prior
      written consent if it <font style="color: #222127">includes reference to Immunocore by name.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In each case, consent shall not be unreasonably withheld, conditioned or
      delayed and shall be provided within [***] of request for such consent.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Approved Releases</b>. If a Release requires consent pursuant
      to Sections 9.3 or 10.2, once consent has been given both Parties may make subsequent public disclosure of the contents of such statement without the further approval of the Party whose consent was required; provided, such <font style="color: #202024">content is not presented with any new data or information or conclusions and/or in a form or manner that materially alters the subject matter therein.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Releases required by law or regulation</b>. Each Party may
      issue any Release it is required to issue by Applicable Law or regulation (including, in the case of Immunocore, any announcements required to satisfy the UK Takeover Panel or the UKLA listing rules).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Publications</b>. Notwithstanding Sections 10.1 to 10.4, both
      Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the Compounds or Immunocore Products may be beneficial to both
      Parties, provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of inventions and other commercial considerations. Accordingly, the following shall apply with respect
      to papers and presentations proposed for disclosure by either Party:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1F1E23">With respect to any paper or
        presentation proposed for disclosure by GNE</font> which utilizes information generated by or on behalf of GNE, so long as such paper or presentation does not contain any Confidential Information of Immunocore, GNE shall be free to make, publish
      and disclose such papers and presentations at its discretion. For clarity, GNE <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">shall not be permitted to publish or otherwise disclose any Confidential Information of Immunocore except as may
      be expressly permitted pursuant to Section 9.2 or 9.3; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212027">With respect to any paper or
        presentation proposed for disclosure by</font> Immunocore which utilizes information generated by or on behalf of Immunocore, so long as such paper or presentation does not contain any Confidential Information of GNE, Immunocore shall be free to
      make, publish and disclose such papers and presentations at its discretion. For clarity, Immunocore shall not be permitted to publish or otherwise disclose any Confidential Information of GNE except as may be expressly permitted pursuant to Section
      9.2, 9.3 or 10.5(c);</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #232328">With respect to any paper or
        presentation proposed for disclosure by</font> Immunocore which includes Confidential Information of GNE, GNE shall have the right to review and approve any such proposed paper or presentation. Immunocore shall submit to GNE the proposed
      publication or presentation (including, without limitation, posters, slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) at least [***] prior to the date of submission for publication or the date of
      presentation, whichever is earlier, of any of such submitted materials. GNE shall review such submitted materials and respond to Immunocore as soon as reasonably possible, but in any case within t[***] for abstracts) of receipt thereof. At the option
      of GNE, Immunocore shall (a) delete from such proposed publication or presentation any Confidential Information of GNE and/or (b) delay the date of such submission for publication or the date of such presentation_ for a period of time sufficiently
      long (but in no event longer than [***]) to permit GNE to seek appropriate patent protection. Once a publication has been approved by GNE, Immunocore may make subsequent public disclosure of the contents of such publication without the further
      approval of the GNE; provided, such content is not presented with any new data or information or conclusions and/or in a form or manner that materially alters the subject matter therein.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>No Right to Use Names</b>. Except as expressly provided
      herein, no right, express or implied, is granted by the Agreement to use in any manner the name of &#8220;<b>Immunocore</b>&#8221;, &#8220;<b>Genentech</b>&#8221;, &#8220;<b>Roche</b>&#8221; or any other trade name, symbol, logo or trademark of the other Party in connection with the
      performance of this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 11</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>REPRESENTATIONS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Mutual Representations and Warranties</b>. Each Party
      represents and warrants to the other Party that as of the Effective Date:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;it is validly organized under the laws of its jurisdiction of
      incorporation;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">it has obtained all necessary
        consents, approvals and authorizations of all</font> governmental authorities and other persons or entities required to be obtained by it in connection with this Agreement;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;the execution, delivery and performance of this Agreement have
      been duly <font style="color: #222229">authorized by all necessary corporate action on its part;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;it has the legal right and power to enter into this Agreement and
      to fully <font style="color: #1E1D22">perform its obligations hereunder;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">the performance of its obligations
        under this Agreement will not conflict with</font> such Party&#8217;s charter documents or any Third Party agreement, contract or other arrangement to which such Party is a party; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222228">to the extent relevant to this
        Agreement it follows reasonable commercial</font> practices common in the industry to protect its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of
      confidentiality and non-disclosure, and to the extent permissible under national or local laws requiring its employees, consultants and agents to assign to it any and all inventions and discoveries discovered by such employees, consultants or agents
      made within the scope of, and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written confidentiality and non-disclosure agreements.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>GNE Additional Warranties</b>. GNE also represents and
      warrants to Immunocore that:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;it has the legal right and power to extend the rights and
      licenses granted to <font style="color: #201D23">Immunocore hereunder;</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212027">the GNE Background IP includes all
        intellectual property rights and Know-</font> How Controlled by GNE as at the Effective Date which is specific to the Compounds;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1E1E22">it will not grant during the Term,
        any right, license or interest in or to the</font> GNE Background IP, or any portion thereof, inconsistent with the rights granted to Immunocore herein;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">as of the Effective Date, it has no
        knowledge of any threatened or pending</font> actions, lawsuits, claims or arbitration proceedings in any way relating to the GNE Background IP (to the extent relevant to the Immunocore Product or Compound or to performance by Immunocore of a
      Development Plan); provided, however, that nothing in this Section 1 1 .2 shall be interpreted as requiring GNE to have undertaken any inquiries or to have obtained any freedom to operate opinion; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212027">prior to the Effective Date it has</font><font style="color: #B4B4B4">. </font><font style="color: #212027">not granted any licences, sub-licences or any </font>other rights or interest in or to the GNE Background IP or assigned the GNE Background IP to any Affiliate of GNE or to any Third
      Party.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Immunocore Additional Warranties</b>. Immunocore also
      represents and warrants to GNE that:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;it has the legal right and power to extend the rights granted to
      GNE <font style="color: #202023">hereunder; and</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;it will not grant during the Term, any right or interest in or to
      the Immunocore Background IP or Immunocore Foreground IP to the extent that they relate to [***] Immunocore Products, or any portion thereof, inconsistent with the rights granted to GNE provided that so long as Immunocore has followed the process set
      out in Section 4.2 any grant of any such right or interest to a Third Party shall not be a breach of this warranty herein; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #212025">in developing, testing,
        manufacturing, selling and supplying any Immunocore</font> Product it will, and it will procure that its Sublicensees will, comply with all Applicable Laws; and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1F1E22">as at the Effective Date, (i) the
        list of Existing [***] Compounds and</font> Existing [***] Compounds referred to in Exhibit B is true and correct and sets out all of the Immunocore Existing TCRs; and (ii) such Immunocore Existing TCRs constitute all of the material chemical
      structures that resulted from the research undertaken by Immunocore pursuant to the Existing Agreement. Immunocore undertakes that should it be discovered after the Effective Date that an Immunocore Existing TCR was not included in Exhibit B,
      Immunocore will amend Exhibit B to add such Immunocore Existing TCR and GNE agrees that such obligation shall be GNE&#8217;s only remedy in the event of a breach of this warranty. Notwithstanding the foregoing, Genentech shall have the right to seek
      recovery of any milestone and royalty payments, and any interest thereon determined in accordance with industry standard, that would have been owed had Exhibit B been amended as of the Effective Date.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Disclaimers</b>. EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS
      AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, KNOW-HOW, MATERIALS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR
      IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. NOTHING IN THIS SECTION SHALL PREVENT GNE CLAIMING DAMAGES FOR LOSS OF ROYALTIES ARISING AS A RESULT OF A BREACH OF THIS
      AGREEMENT BY IMMUNOCORE.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 12</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>INDEMNIFICATION</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Indemnification</b>. Subject to Section 12.3, Immunocore
      shall indemnify, defend and hold GNE, its Affiliates, their Sublicensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages,
      settlements, penalties, fines, costs or expenses (including, without limitation, reasonable attorneys&#8217; fees and other reasonable expenses of litigation) (collectively, &#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221;) arising, directly or indirectly out of or in
      connection with any Third Party claims, suits, actions, demands or judgments (&#8220;<b>Third Party Claims</b>&#8221;) relating to (a) the activities performed by or on behalf of such Party under this Agreement, (b) the activities performed by or on behalf of
      Immunocore to the extent Covered by any GNE Background IP, including, in the case of Immunocore and its Third Party Licensees and subcontractors hereunder, product liability and infringement claims to the extent relating to any products Covered by
      the GNE Background IP and/or (c) breach by Immunocore of the representations and warranties under Article 11, except, in each case, to the extent caused by <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">the negligence or willful misconduct of GNE or its Affiliates or Sublicensees or any breach of this Agreement by
      GNE or its Affiliates or Sublicensees.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Indemnification</b>. Subject to Section 12.3, GNE shall
      indemnify, defend and hold Immunocore, its Affiliates and its Third Party licensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all Losses arising,
      directly or indirectly out of or in connection with any Third Party Claims relating to (a) the activities performed by or on behalf of GNE or any Sublicensee under this Agreement and/or (b) breach by GNE, its Sublicensees or subcontractors of the
      representations and warranties under Article 11, except, in each case, to the extent caused by the negligence or wilful misconduct of Immunocore or its Affiliates or breach of this Agreement by Immunocore or its Affiliates.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Procedure</b>. If a Party intends to claim indemnification
      under this Agreement (the &#8220;<b>lndemnitee</b>&#8221;), it shall promptly notify the other Party (the &#8220;<b>Indemnitor</b>&#8221;) in writing of such alleged Loss and the Third Party Claim. The Indemnitor shall have the right to control the defense thereof with
      counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee. Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason, provided, however, that if the lndemnitee shall have reasonably
      concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the lndemnitee in the defense of such action, in which case the Indemnitor shall pay the fees and expenses of one law
      firm serving as counsel for the lndemnitee in relation to such Third Party Claim. The lndemnitee, its employees and agents, shall reasonably cooperate with the lndemnitor and its legal representatives in the investigation of any Third Party Claims
      covered by this Agreement. The obligations of this Article 12 shall not apply to any settlement of any Third Party Claims if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld or delayed. The
      failure to deliver written notice to the lndemnitor within a <font style="color: #232228">reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor of any
        obligation to the Indemnitee under this Section 12.3. It is understood that only GNE and Immunocore may claim indemnity under this </font><font style="color: #212127">Agreement (on its own behalf or on behalf of its Indemnitees), and other
        Indemnitees may not directly claim indemnity hereunder.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Insurance</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Insurance Coverage</b>. Subject to Section 12.4.4, each
      Party shall obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business, and in any case sufficient to cover its obligations.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Evidence of Insurance</b>. Within [***] of signing this
      Agreement, each Party shall provide the other Party with its certificate of insurance evidencing the insurance coverage set forth Section 12.4.1. Each Party shall provide to the other Party at least [***] prior written notice of any cancellation,
      non-renewal or material change in any of such insurance coverage.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Product I Clinical Trial Liability Insurance</b>.
      Commencing not later than [***] prior to the first use in humans of the First Immunocore Product by Immunocore or any of its Sublicensees, Immunocore shall have and maintain such type and amounts of products / clinical trial liability insurance
      covering the development, manufacture, use and sale of Immunocore Products as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit per occurrence for products /
      clinical trials liability as follows: (a) a minimum limit of [***] for any period during which Immunocore or any of its Sublicensees is conducting a clinical trial(s) with any Immunocore Product(s); and (b) a minimum limit of [***] for any period
      during which Immunocore or any of its Sublicensees is selling <font style="color: #A0A0A0">&#183;</font>any Immunocore Product(s). Each of the above insurance policies shall be primary insurance.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Election to Self-Insure</b>. In the event that either
      Party is an entity which, together with its Affiliates, has worldwide revenues from pharmaceutical sales in excess of [***] per year, the obligations set forth in Section 12.4.1, 12.4.2 and 12.4.3 above shall not <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">apply with respect to such Party, if such Party notifies the other Party in writing that it elects to provide
      coverage through a commercially reasonable program of self-insurance and such self-insurance in the case of Section 12.4.3 is permitted under Applicable Laws; provided, however, that the obligations set forth in Section 12.4.1, 12.4.2 and 12.4.3
      above shall resume with respect to such Party and its Affiliates, or successor-in-interest and its Affiliates, if such program of self-insurance is terminated or discontinued for any reason.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Limitation of Damages</b>. NEITHER PARTY HERETO WILL BE
      LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR- RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF A PARTY&#8217;S
      OBLIGATIONS UNDER ARTICLE 10 OR INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 12 FOR CLAIMS OF THIRD PARTIES. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY OR ANY
      LIABILITY ARISING AS A RESULT OF PERSONAL INJURY OR DEATH CAUSED BY NEGLIGENCE OF ANY PARTY.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 13</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>TERM; TERMINATION</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Term</b>. The term of this Agreement (the &#8220;<b>Term</b>&#8221;)
      shall commence on the Effective Date and, unless sooner terminated as provided in this Article 13, shall continue in full force and effect, on a country-by-country and Immunocore Product-by-lmmunocore Product basis <font style="color: #909090">&#183;</font>until








      there is no remaining royalty payment or other payment obligation in such country with respect to such Immunocore Product, at which time this Agreement shall expire with respect to such Immunocore Product in such country. The Term shall expire on the
      date this Agreement has expired in its entirety with respect to all Immunocore Products in all countries in the Territory.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Termination by Either Party for Material Breach</b>. Either
      Party may terminate this Agreement by written notice to the other Party for any material breach of this Agreement by the other Party if, in the case of remediable breach, such material breach is not cured within [***] for payment defaults) after the
      breaching Party receives written notice of such breach from the non-breaching Party; provided, that if such breach is not capable of being cured within such [***]) period, the cure period shall be extended for such amount of time that the Parties may
      agree in writing is reasonably necessary to<font style="color: #939393">- </font>cure such breach, so long as (1 ) the breaching Party is making Diligent Efforts to do so, and (2) the Parties agree on an extension within such [***] period.
      Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i) whether a breach is material or has occurred or (ii) the alleged failure to cure or remedy such material breach, and provides written
      notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in Article 14, and the notifying Party may not so terminate this Agreement until it has been determined
      under Article 14 that the allegedly breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within [***] (or such longer period as determined by the arbiter of such dispute resolution) after
      the conclusion of that dispute resolution procedure.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Termination by Either Party for Insolvency or Bankruptcy</b>.
      Either Party may terminate this Agreement effective on written notice to the other Party upon the liquidation, dissolution, winding-up, insolvency, bankruptcy, or filing of any petition therefor, appointment <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">of a receiver, custodian or trustee, or any other similar proceeding, by or of the other Party where such
      petition, appointment or similar proceeding is not dismissed or vacated within [***] an where such petition, appointment or similar proceeding is not a part of any bona fide reorganisation of a Party or its Affiliates. All rights and licenses granted
      pursuant to this Agreement are, for purposes of Section 365(n) of Title 11 of the United States Code or any foreign equivalents thereof (as used in this Section 13.3, &#8220;<b>Title 11</b>&#8221;), licenses of rights to &#8220;<b>intellectual property</b>&#8221; as defined
      in Title 11. Each Party in its capacity as a licensor hereunder agrees that, in the event of the commencement of bankruptcy proceedings by or against such bankrupt Party under Title 11, (a) the other Party, in its capacity as a licensee of rights
      under this Agreement, shall retain and may fully exercise all of such licensed rights under this Agreement (including as<font style="color: #A3A3A3">&#183; </font>provided in this Section<font style="color: #B4B4B4">&#183; </font>13.3) and all of its rights
      and elections under Title 11 and (b) the other Party shall be entitled to a</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complete duplicate of all embodiments of such intellectual property, and such embodiments, if
      not already in its possession, shall be promptly delivered to the other Party (i) upon any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue <font style="color: #222228">to perform all of its obligations
        under this Agreement, or (ii) if not delivered under (i), immediately upon the rejection of this Agreement by or on behalf of the bankrupt Party.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Effects of Termination in General</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1C1A22"><b>Accrued Rights and Obligations</b>.
        Expiration or termination of this</font> Agreement in its entirety for any reason shall not release either Party hereto from any liability which, as of the effective date of such expiration or termination, had already accrued to the other Party or
      which is attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to the effective date
      of such expiration or termination.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Termination of Licenses</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0pt 0px 0pt 171pt; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222128">Upon termination of the Agreement in its entirety by Immunocore</font> pursuant to Section 13.2 or 13.3, all licenses under this Agreement shall terminate as of the effective date of such termination;
      and</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin: 0pt 0px 0pt 171pt; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: justify;"><font style="font-family: Times New Roman, Times, Serif;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #222127">Upon termination of Agreement by GNE in accordance with Section </font>13.2 or 13.3, the licenses set forth in Section 4 shall terminate as of the effective date of such termination.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 171pt; text-align: justify; text-indent: 1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1A21"><b>Continuation of Sublicenses</b>.
        Upon termination by GNE of this Agreement</font> GNE agrees that on request from any Sublicensee it will grant to such Sublicensee a license on the same terms as set out in this Agreement (including all Event Payments and royalty payments) in
      relation to any GNE rights previously licensed to such Sublicensee. Unless otherwise explicitly agreed in writing, GNE shall not agree to vary or amend the terms of the licenses granted hereunder or take on any additional or further obligations or
      burdens.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1F1E25"><b>Clinical Trials</b>. Immunocore
        shall ensure that in the event any termination</font> of this Agreement by GNE occurs during any Clinical Trial, that, if Immunocore <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">decides, in its sole discretion, to wind down &#183;any Clinical Trial, such Clinical Trial shall be wound down in
      accordance with the protocol for such Clinical Trial and in such a way as to minimise any patient harm and at all times in accordance with all Applicable Laws.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #171620"><b>Return of Confidential
          Information</b>. It is understood and agreed, that each</font> Party shall have a continuing right to use Confidential Information of the other Party under any surviving licenses pursuant to Article 4 and/or this Section 13.4. Subject to the
      foregoing, following expiry or any early termination of this Agreement, the Party that has Confidential Information of the other Party shall destroy (at such Party&#8217;s written request) all such Confidential Information in its possession as of the
      effective date of expiration (with the exception of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information to confirm compliance with the non-use and
      non-disclosure provisions of this Agreement), and any Confidential Information of the other Party contained in its laboratory notebooks or databases, provided that each Party may retain and continue to use such Confidential Information of the other
      Party to the extent necessary to exercise any surviving rights, licenses or obligations under this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1A1820"><b>Inventory at Termination</b>.
        Upon termination of this Agreement</font> Immunocore and its permitted Sublicensee shall have the right to sell or otherwise dispose of all inventory of Immunocore Products in all countries then in its stock, subject to the applicable royalty
      payments due under this Agreement, and any other applicable provisions of this Agreement, and GNE covenants not to sue Immunocore or its permitted Sublicensee for infringement under any of the Patents that were licensed by GNE to Immunocore
      immediately prior to such termination with respect to such activities conducted by Immunocore or its permitted Sublicensee pursuant to this Section 13.5. l (e).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: #1D1C22"><b>Survival</b>. In addition to any
        prov1s1ons specified in this Agreement as</font> surv1vmg under the applicable circumstances, the provisions of Articles 1, 8, 9, 1 0, 1 1 , 12, (excluding Section 12.4 and provided with respect to Article 11 and 12, only with respect to those
      claims that arise from the acts or omissions of a Party prior to the effective date of termination or expiration) 14 and 15 and Sections 6.4.6, 7.7, and 1 3.4 shall survive any termination or expiration of this Agreement. In addition, Article 6 and 7
      shall survive with respect to any outstanding unpaid amounts that accrued prior to any termination or expiration of this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 14</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>DISPUTE RESOLUTION</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Disputes</b>. &#8220;<b>Party</b>&#8221; or &#8220;<b>Parties</b>&#8221; in this
      Article 14 shall mean GNE and Immunocore. Immunocore and GNE recognize that a dispute, controversy or claim of any nature whatsoever arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, (each, a &#8220;<b>Dispute</b>&#8221;)








      may from time to time arise during the Term. Unless otherwise specifically recited in this Agreement, such Disputes between Immunocore and GNE will be resolved as recited in this Article 14. In the event of the occurrence of such a Dispute, the
      Parties shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral. If such Dispute is not resolved within such [***] period, either Immunocore and GNE may,
      by written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">attempted resolution within [***] after such notice is received. Such designated officers are as follows:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #202024">For GNE - [***] </font><font style="font-size: 10pt"><br>
      <br>
      <font style="font-family: Times New Roman, Times, Serif; color: #222127">For Immunocore - [***]</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 1in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event the designated officers, or their respective designees, are not
      able to resolve such Dispute within [***] of such other Party&#8217; s receipt of such written notice, either Party may initiate the dispute resolution procedures set forth in Section 14.2.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Arbitration</b>.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Rules</b>. Except as otherwise expressly provided in this
      Agreement (including under Section 1 4.3), the Parties agree that any Dispute not resolved internally by the Parties pursuant to Section 14.1 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in
      accordance with the then prevailing Rules of Arbitration of the International <font style="color: #202024">Chamber of Commerce (for purposes of this Article 14, the &#8220;<b>Rules</b>&#8221;), except as modified in this Agreement, applying the substantive law
        specified in Sections 15.1.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Arbitrators; Location</b>. Each Party shall select one
      (1) arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator. All three (3) arbitrators shall serve as neutrals and have at least [***] of (a) dispute resolution experience (including judicial experience) and/or (b) legal
      or business experience in the biotech or pharmaceutical industry. In any event, at least one (1) arbitrator shall satisfy the foregoing experience requirement under Section (b). If a Party fails to nominate its arbitrator, or . if the Parties&#8217;
      arbitrators cannot agree on the third, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings shall
      be conducted in London, England. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in another language shall be translated into English and accompanied by the original
      or a true copy thereof.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Procedures; Awards</b>. Each Party agrees to use
      reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may determine any person as necessary. The arbitrators shall be instructed and required to render a written, binding,
      non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than
      [***] after conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for
      enforcement. Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Costs</b>. The prevailing Party, as determined by the
      arbitrators, shall [***]. In determining which Party &#8220;<b>prevailed,</b>&#8221; the arbitrators shall consider (i) the significance, including the financial impact, of the claims prevailed upon and (ii) the scope of claims <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">prevailed upon, in comparison to the total scope of the claims at issue. If the arbitrators determine that,
      given the scope of the arbitration, neither Party &#8220;<b>prevailed,</b>&#8221; the arbitrators shall order that the Parties ( 1) share equally the fees and expenses of the arbitrators and (2) bear their own attorneys&#8217; fees and associated costs and expenses.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Interim Equitable Relief</b>. Notwithstanding anything to
      the contrary in this Section 14.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this Article 14, such Party may seek a temporary injunction or other
      interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this Section 14.2. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of
      temporary injunction or other interim equitable relief.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Protective Orders; Arbitrability</b>. At the request of
      either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or <font style="color: #222128">exchanged in the course of the arbitration proceedings. The arbitrators shall have the
        power to decide all questions of arbitrability.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Subject Matter Exclusions</b>. Notwithstanding the provisions
      of Section 14.2, any Dispute not resolved internally by the Parties pursuant to Section 14.1 that involves the validity or infringement of a Patent Covering an Immunocore Product (a) that is issued in the United States shall be subject to actions
      before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the defendants resides; and (b) that is issued in any other country shall be brought
      before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Continued Performance</b>. Provided that this Agreement has
      not terminated, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>ARTICLE 15</b></font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>MISCELLANEOUS</b></font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Applicable Law</b>. This Agreement (including the arbitration
      provisions of Article 14.2) shall be governed by and interpreted in accordance with the laws of England and Wales, without <font style="color: #201F24">reference to the principles of conflicts of laws. The United Nations Convention on Contracts for
        the International Sale of Goods shall not apply to the transactions contemplated by this Agreement.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Notices</b>. Except as otherwise expressly provided in the
      Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in person;
      (b) on the date of receipt, if sent by a facsimile (with delivery confirmed); or (c) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested. Any notice sent via facsimile shall be
      followed by a copy of such notice by private express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Section 15.2 by sending written
      notice to the other Party.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: -1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131B"><b>If to GNE:</b> </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1B22">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Genentech, Inc.</font><br>
    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F25">Attn: [***]</font> <br>
    <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1B22">Fax: [***]&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; color: #1D1B22"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone: [***]</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; color: #1D1B22"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>with required copies (which shall not constitute notice) to:</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E22">Genentech, </font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1B22">Inc</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E22">.</font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #202023">Attn: [***]</font></font> <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212025"><br>
      <font style="color: #212025;">Fax: [***]</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: -1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #181620"><b>If to </b></font><b><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1D1B22">Immunocore</font></b><b><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #181620">:</font></b><font style="font: 10pt Times New Roman, Times, Serif; color: #181620">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Immunocore Limited</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: -1.5in"><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #202025">Attn: Chief Executive Officer </font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #202025">101 Park Drive</font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #1E1E21">Milton Park </font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #1C1C21">Abingdon </font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #212023">Oxon</font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #1F1E23">United Kingdom </font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #1F1E23">OXl4 4RY</font><br>
      <font style="font-family: Times New Roman, Times, Serif; color: #1F1F21">Fax: [***]</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 2in; text-indent: -1.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Assignment</b>. None of the Parties may assign or otherwise
      transfer, in whole or in part, this Agreement without the prior written consent of the non-assigning Parties, such approval not to be <font style="color: #202024">unreasonably withheld or delayed. Notwithstanding the foregoing, a Party may assign
        this Agreement to (i) an Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation or
        re-organisation of such Party with or into such corporation or entity, provided that the Party to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement.
        Immunocore may also transfer the Immunocore Background IP and Immunocore Foreground IP to any Affiliate that is controlled by or controls Immunocore and provided that any transfer is explicitly subject to this Agreement. A copy of such written
        agreement by such assignee shall be provided to the non-assigning Party within [***] of execution of such written agreement, subject in each case to any confidentiality restrictions. Subject to the foregoing, this Agreement will benefit and bind
        the Parties&#8217; successors and assigns.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Non-solicit</b>. Neither Immunocore on the one hand, nor GNE
      on the other hand shall (except with the prior written consent of the Other Party knowingly solicit or entice away (or attempt to solicit or entice away) from the employment of the Other Party any person employed or engaged by such Other Party in the
      provision of its obligations under any Development Program during the course of any Development Program and for a further period of [***] from expiry, termination or completion of such Development Program; provided that this Section 15.4 shall not
      apply to advertisements of a general nature placed in newspapers, trade publications or online. If a Party does breach this Section 15.4 it agrees and accepts that the Other Party will suffer damage and as a minimum it agrees to pay liquidated
      damages equivalent to two year&#8217;s basic salary or the annual fee that was paid by the Other Party to the relevant employee. The liquidated damages set out in this Section does not prevent the Other Party claiming damages in the ordinary course in
      relation to a breach of this Section 15.4. For the purposes of this Section 15.4, &#8220;<b>Other Party</b>&#8221; shall mean GNE if Immunocore is the Party <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">soliciting or enticing away a person from employment and Immunocore if GNE is the Party soliciting or enticing
      away a person from employment.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Independent Contractors</b>. The Parties hereto are
      independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Integration</b>. Except to the extent expressly provided
      herein, this Agreement constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the Parties with respect to the subject matter of this
      Agreement (including the term sheet exchanged by and between Immunocore and GNE). Nothing in this Section 1 5.6 shall exclude any liability for fraud or fraudulent misrepresentation. All Parties confirm that save as explicitly stated in this
      Agreement they have not relied upon or been induced to enter into this Agreement in reliance upon any warranty or representation made by any of the other Parties, save to the extent explicitly set out in this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Amendment; Waiver</b>. Except as otherwise expressly provided
      herein, no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorized representative of all Parties. No course of dealing or failing of a Party to strictly enforce any term, right or
      condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition. The observance of any provision of this Agreement may be waived (either generally or any given instance and either
      retroactively or prospectively) only with the written consent of the Party granting such waiver.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Further Assurance</b>. All Parties shall and shall use all
      reasonable endeavors to procure that any necessary Third Party shall promptly execute and deliver such further documents and do such further acts as may be required for the purpose of giving full effect to this Agreement.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Severability</b>. The Parties do not intend to violate any
      public policy or statutory or common law. However, if any sentence, paragraph, section, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, section,
      clause or combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic purpose <font style="color: #201F24">and structure of this Agreement.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>No Third Party Rights</b>. The Parties do not intend that
      any term of this Agreement should be enforceable by any person who is not a Party.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.11&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Construction</b>. The Parties mutually acknowledge that they
      and their attorneys have participated <font style="color: #AFAFAF">&#183;</font>in the negotiation and preparation of this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be
      deemed to have drafted this Agreement or authorized the ambiguous provision.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.12&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Interpretation</b>. The captions and headings to this
      Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any the provisions of this Agreement. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words &#8220;include&#8221; or
      &#8220;including&#8221; shall be construed as incorporating &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;; (b) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement, including the Exhibits; (c) the word &#8220;law&#8221; or &#8220;laws&#8221;
      means any <br>
      <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree,
      judgment, injunction, mandate or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality of any (i) government or country or territory, (ii) any state, province,
      county, city or other political subdivision thereof, or (iii) any supranational body); (d) all references to the word &#8220;will&#8221; are interchangeable with the word &#8220;shall&#8221; <font style="color: #202024">and shall be understood to be imperative or mandatory
        in nature; (f) the singular shall include the plural and vice versa; and (g) the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;. All references to days, months, quarters or years are references to calendar days, calendar
        months, calendar quarters, or calendar years.</font></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.13&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Counterparts</b>. This Agreement may be executed in two or
      more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. For purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the signature
      pages hereto, will be deemed to be an original. Notwithstanding the foregoing, the Parties shall deliver original execution copies of this Agreement to one another as soon as practicable following execution thereof.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Signature page follows - the rest of this page intentionally left blank.]</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN WITNESS WHEREOF</b>, Immunocore and GNE have executed this Agreement by
      their respective officers hereunto duly authorized, on the Effective Date.</font></p>
  <p style="color: #1E1D23; font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IMMUNOCORE LIMITED</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
        <td style="width: 37%; border-bottom: Black 1pt solid">
          <div>/s/ Bent Jakobsen</div>
        </td>
        <td style="width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E">
    <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; text-align: left">
          <td style="width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
          <td style="width: 36%; border-bottom: Black 1pt solid">
            <div>Bent Jakobsen</div>
            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td>
          <td style="width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>

  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232225">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">
    <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; text-align: left">
          <td style="width: 4%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
          <td style="width: 36%; border-bottom: Black 1pt solid">
            <div>Chief Scientific Officer</div>
            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></td>
          <td style="width: 60%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        </tr>

    </table>

  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENENTECH, INC.</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 3%"><font style="font: 10pt Times New Roman, Times, Serif">By:</font></td>
        <td style="width: 37%; border-bottom: Black 1pt solid">
          <div>/s/ Edward Harrington</div>
          <font style="font: 10pt Times New Roman, Times, Serif"></font></td>
        <td style="width: 60%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #17161E">
    <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; text-align: left">
          <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">Name:</font></td>
          <td style="width: 36%; border-bottom: Black 1pt solid">
            <div>Edward Harrington</div>
            <font style="font: 10pt Times New Roman, Times, Serif"></font></td>
          <td style="width: 60%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        </tr>

    </table>

  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif; color: #232225">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">
    <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

        <tr style="vertical-align: top; text-align: left">
          <td style="width: 4%"><font style="font: 10pt Times New Roman, Times, Serif">Title:</font></td>
          <td style="width: 36%; border-bottom: Black 1pt solid">
            <div>
              <div>Chief Financial Officer</div>
            </div>
          </td>
          <td style="width: 60%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></td>
        </tr>

    </table>

  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%; vertical-align: middle;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds </font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain confidential information contained in this document, marked by [***], has been
        omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%A-%%-->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #141320">EXHIBIT A</font><font style="font-size: 10pt"><br>
      <font style="font-family: Times New Roman, Times, Serif">PATENTS RELATING TO EXISTING MAGE-A4 COMPOUNDS AND EXISTING [***] COMPOUNDS</font></font></p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 22%; border-top: #343434 1pt solid; border-left: #2F2F34 1pt solid; border-bottom: #343438 1pt solid; border-right: #2C2C34 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13131E"><b>Case Ref.</b></font></td>
        <td style="width: 18%; border-top: #343434 1pt solid; border-right: #343838 1pt solid; border-bottom: #343438 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #13131F"><b>Official No.</b></font></td>
        <td style="width: 20%; border-top: #343434 1pt solid; border-right: #343434 1pt solid; border-bottom: #343438 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #17131E"><b>Title</b></font></td>
        <td style="width: 40%; border-top: #343434 1pt solid; border-right: #343434 1pt solid; border-bottom: #343438 1pt solid; text-align: center">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131F"><b>Case Status</b></font></div>
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131F"><b> <br>
              </b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: #2C2C34 1pt solid; border-left: #2F2F34 1pt solid; border-bottom: #343438 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #202024">[***]</font></td>
        <td style="border-right: #343838 1pt solid; border-bottom: #343438 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #202025">[***]</font></td>
        <td style="border-right: #343434 1pt solid; border-bottom: #343438 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1D24">[***]</font></td>
        <td style="border-right: #343434 1pt solid; border-bottom: #343438 1pt solid; text-align: center">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E21">[***]</font></div>
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E21"> <br>
            </font></div>
        </td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A-1</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <!--PROfilePageNumberReset%Num%1%B-%%-->
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT B</font></p>
  <p style="color: #15131E; font: bold 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part A - (Existing MAGE-A4 TCRs)</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #14131F"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #212127"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 20%; border: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151C"><b>[***]</b></font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1B1A1E"><b>[***]</b></font></td>
        <td style="width: 9%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151C"><b>[***]</b></font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151C"><b>[***]</b></font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151C"><b>[***]</b></font></td>
        <td style="width: 8%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #14131F"><b>[***]</b></font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #19171F"><b>[***]</b></font></td>
        <td style="width: 15%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #19171F"><b>[***]</b></font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="vertical-align: top; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D"><i>[***]</i></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B"><i>[***]</i></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E21">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E21">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31"><i>[***]</i></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; width: 70%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="12" style="border: #020000 1pt solid; text-align: right; padding-right: 60pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28232C">[***]</font></td>
        <td style="border-left: rgb(2,0,0) 1pt solid; border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28232C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center">&#160;</td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td colspan="12" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-left: rgb(2,0,0) 1pt solid; border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; text-align: center">&#160;</td>
        <td style="border-bottom: rgb(2,0,0) 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center">&#160;</td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="12" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="4" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 29%; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and [***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-1</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #24232B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #333138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: left; padding-right: 10pt; padding-left: 10pt; vertical-align: bottom"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-2</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383439">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-3</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F3031">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252927">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #38343A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252927">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="6" style="border: #020000 1pt solid; text-align: right; padding-right: 70pt; padding-left: 10pt">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></div>
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229"> <br>
            </font></div>
        </td>
      </tr>
      <tr>
        <td style="width: 13%; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 12%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28232C">[***]</font></td>
        <td style="width: 23%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 10%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28232C">[***]</font></td>
        <td style="width: 16%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 26%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: right; padding-right: 30pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="6" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding: 8pt 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262929">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262929">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-5</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B"><u>[***]</u></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #25282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343339">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343339">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-6</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343339">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232228">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E3033">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343339">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-7</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></div>
        </td>
      </tr>

  </table>
  <div><br>
  </div>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="9" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
            </font></div>
        </td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="9" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="9" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 22%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 28%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="11" style="border: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="11" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1D23">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="11" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F312F">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 14%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 9%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 26%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 9%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 27%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-8</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part B (Existing [***] TCRs)</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 21%; border: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E"><b>[***]</b></font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E"><b>[***]</b></font></td>
        <td style="width: 7%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16131E"><b>[***]</b></font></td>
        <td style="width: 14%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E"><b>[***]</b></font></td>
        <td style="width: 5%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161520"><b>[***]</b></font></td>
        <td style="width: 11%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161520"><b>[***]</b></font></td>
        <td style="width: 15%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E"><b>[***]</b></font></td>
        <td style="width: 17%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E"><b>[***]</b></font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161520">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="vertical-align: top; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[***]</i></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #181720">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D"><i>[***]</i></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-9</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="vertical-align: top; width: 21%; border: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 7%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 14%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 5%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">3</font></td>
        <td style="vertical-align: top; width: 11%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 15%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="vertical-align: top; width: 17%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1B1A20">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282D">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #16151E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #26252B">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #26252B"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[***]</i></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: #26252B"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="10" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td colspan="10" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td colspan="10" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt">
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229"> <br>
            </font></div>
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></div>
          <div><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229"> <br>
            </font></div>
        </td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #26252B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 20%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 29%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-10</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-11</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="10" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">[***]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
          </font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222129">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="10" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="10" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">[***]</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 20%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 11%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 28%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-12</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282729">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-13</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272828">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="vertical-align: top; border: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td colspan="7" style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232228">[***]</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232228">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232228">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="8" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232228">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="8" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262A">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343138">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343138">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343138">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 26%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 2%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 23%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-14</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232329">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #282328">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; text-align: justify; color: rgb(29, 28, 34);"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-15</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F3030">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>[***]</u></font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; text-align: justify; color: rgb(29, 28, 34);"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-16</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="vertical-align: top; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="vertical-align: top; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-17</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E3032">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E3032">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E3032">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262626">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #27282A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #BBBBBB">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="6" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1E22">[***]</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
      </tr>
      <tr>
        <td style="width: 13%; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 12%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 23%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 10%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 16%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="width: 26%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td colspan="6" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201E25">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font>&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td colspan="6" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222128">[***]</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
      </tr>
      <tr>
        <td style="width: 13%; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 12%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="width: 16%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="width: 26%; border-bottom: #020000 1pt solid; border-right: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-18</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222128">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: 1pt solid rgb(2, 0, 0); border-bottom: 1pt solid rgb(2, 0, 0); text-align: right; padding-right: 10pt; padding-left: 10pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt; color: rgb(42, 41, 43);">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222128">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F33">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #343838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-19</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F3030">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: 1pt solid rgb(2, 0, 0); border-bottom: 1pt solid rgb(2, 0, 0); text-align: right; padding-right: 10pt; padding-left: 10pt;"><font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2C2B31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #342F38">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; text-align: justify; color: rgb(29, 28, 34);"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-20</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292C">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28262B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="7" style="border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #222229">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E23">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1E1E23">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="7" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F32">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F3030">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="7" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 23%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 13%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
        <td style="width: 25%"><font style="font-family: Times New Roman, Times, Serif; font-size: 1pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-21</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242329">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383838">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F3031">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F38">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242329">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A2A2B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-22</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252526">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383438">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272A">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2C2E">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #383839">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262629">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2A292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: right; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2B2A30">[***]</font></td>
      </tr>

  </table>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 54%; border: #020000 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]&#160;&#160;</font></td>
        <td style="width: 29%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="width: 17%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font>&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 13%; border: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td style="width: 12%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td style="width: 23%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td style="width: 10%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td style="width: 16%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="width: 26%; border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="6" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #1F1E22">[***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #1D1C22"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-23</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div style="TEXT-ALIGN: center">&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Execution Version</b></font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="width: 70%; font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="border: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="3" style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-top: #020000 1pt solid; border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="11" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt">
          <p style="margin-top: 0; margin-bottom: 0"></p>
          <p style="margin-top: 0; margin-bottom: 0">&#160;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529"></font></p>
          <p style="margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif; color: #262529">[***]</font></p>
          <p style="margin-top: 0; margin-bottom: 0"><font style="font: 10pt Times New Roman, Times, Serif; color: #262529">&#160;</font></p>
        </td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252527">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #28272B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #272829">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #302F34">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2D2D2E">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #232229">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #262529">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #29292B">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; border-left: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="3" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td colspan="2" style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
        <td style="border-right: #020000 1pt solid; border-bottom: #020000 1pt solid; text-align: center; padding-right: 10pt; padding-left: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2E2E31">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 23%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 15%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 1%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
        <td style="width: 23%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40);"></p>
  <table style="border-collapse: collapse; font: 10pt Arial,Helvetica,'sans-serif'; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 45%;"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">License Agreement relating to MAGE-A4 and </font><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">[***] compounds</font></td>
        <td style="width: 10%; text-align: center;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-24</font></td>
        <td style="width: 45%;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin: 0pt 0px; color: rgb(34, 34, 40)"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential</font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; color: #222228"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 7.1pt 0pt 0; text-align: right; color: #14141E"></p>
  <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>8
<FILENAME>nt10016217x4_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin: 0">&#160;</p>
  <p style="margin: 0"></p>
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED
        BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</b></font> </p>
  <p style="font: bold 10pt Times New Roman,Times,serif; margin: 0pt 0px; text-align: right;">Exhibit 10.9</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="margin: 0"></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">LICENSE AND COLLABORATION AGREEMENT</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">BETWEEN</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">IMMUNOCORE LIMITED,</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><font style="text-transform: none">on the one hand,</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AND</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">GENENTECH, INC.</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AND</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">F. HOFFMANN-LA ROCHE LTD,</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><font style="text-transform: none">on the other hand,</font></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">AS OF NOVEMBER 15, 2018</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <table style="width: 100%; font-size: 10pt; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 60%; font: 10pt Calibri, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif;">License and Collaboration Agreement</font></td>
        <td style="width: 40%; font: 10pt Calibri, Helvetica, Sans-Serif; text-align: right"><font style="font-family: Arial, Helvetica, Sans-Serif;">Confidential</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <p style="margin-top: 0; margin-bottom: 0; text-align: right"><b>Execution Copy</b></p>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <p style="margin-top: 0; margin-bottom: 0; text-align: center"><b>TABLE OF CONTENTS</b></p>
  <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
  <table style="width: 100%" cellpadding="0" cellspacing="0">

      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="width: 90%; text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 1&#160;&#160;&#160;DEFINITIONS</td>
        <td style="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0">2</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 2&#160;&#160;&#160;OTHER AGREEMENTS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">14</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 3&#160;&#160;&#160;GOVERNANCE</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">14</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 4&#160;&#160;&#160;RESEARCH PROGRAM</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">22</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 5&#160;&#160;&#160;DEVELOPMENT PROGRAM</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">23</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 6&#160;&#160;&#160;CO-FUNDING OF DEVEOPMENT</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">26</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 7&#160;&#160;&#160;CO-COMMERCIALIZATION</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">28</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 8&#160;&#160;&#160;CO-FUNDING WITHDRAWAL NOTICE</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">28</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 9&#160;&#160;&#160;LICENSES AND OPTIONS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">30</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 10&#160;&#160;&#160;MATERIALS AND TECHNOLOGY TRANSFER</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">34</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 11&#160;&#160;&#160;REGULATORY</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">35</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 12&#160;&#160;&#160;DILIGENCE</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">37</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 13&#160;&#160;&#160;FINANCIAL TERMS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">37</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 14&#160;&#160;&#160;FINANCIAL TERMS; REPORTS; AUDITS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">44</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 15&#160;&#160;&#160;INTELLECTUAL PROPERTY; OWNERSHIP</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">46</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 16&#160;&#160;&#160;CONFIDENTIALITY</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">53</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 17&#160;&#160;&#160;PUBLICITY; PUBLICATIONS; USE OF NAME</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">55</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 18&#160;&#160;&#160;REPRESENTATIONS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">57</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 19&#160;&#160;&#160;INDEMNIFICATION</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">59</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 20&#160;&#160;&#160;TERM; TERMINATION</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">61</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 21&#160;&#160;&#160;DISPUTE RESOLUTION</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">67</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">&#160;</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">&#160;</td>
      </tr>
      <tr style="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">
        <td style="text-indent: -1in; padding-top: 0in; padding-bottom: 0; padding-left: 1in;">ARTICLE 22&#160;&#160;&#160;MISCELLANEOUS</td>
        <td style="text-align: right; padding-top: 0in; padding-bottom: 0">69</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit A &#8212; Certain Patents</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit B &#8212; MAGE-A4 Compounds [***]</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit C &#8212; Initial Pre-POC Development Plan and Budget</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit D &#8212; Agreed form of press release</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit E &#8212; Initial CMC plan</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit F &#8212; Material and Technology Transfer Deliverables</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit G &#8212; Modified Financial Terms for Other MAGE-A4 Compounds</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- i -</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the
      registrant treats as private or confidential.</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">LICENSE AND COLLABORATION AGREEMENT</p>
  <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-variant: small-caps"><b>This License And Collaboration Agreement</b></font> (&#8220;<b>Agreement</b>&#8221;) is made and entered into, effective as of November
    15, 2018 (&#8220;<b>Effective Date</b>&#8221;), by and between <font style="font-variant: small-caps"><b>Immunocore Limited</b></font>, having its principal place of business at 101 Park Drive, Milton Park, Abingdon, Oxon, United Kingdom OX14 4RY (&#8220;<b>Immunocore</b>&#8221;),









    on the one hand, and <font style="font-variant: small-caps"><b>Genentech, Inc</b></font>., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (&#8220;<b>GNE</b>&#8221;), and <b>F. <font style="font-variant: small-caps">Hoffmann-La Roche Ltd</font></b>, having its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (&#8220;<b>Roche</b>&#8221;), on the other hand. GNE and Immunocore are sometimes referred to herein
    individually as a &#8220;<b>Party</b>&#8221; and collectively as the &#8220;<b>Parties.</b>&#8221; The term &#8220;<b>Party</b>&#8221; or &#8220;<b>Parties</b>&#8221; shall not include Roche unless explicitly stated below.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, Immunocore is a biotechnology company that is engaged in research and development of TCR technology for use in pharmaceutical products.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, GNE and Roche are biopharmaceutical companies engaged in the research, development, manufacture and sale of pharmaceutical products.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, Immunocore, GNE and Roche entered into a Research Collaboration and License Agreement dated as of June 14, 2013 pursuant to which Immunocore and GNE
    agreed to collaborate in the discovery and development of TCR technology for use in pharmaceutical products (the &#8220;<b>Original Agreement</b>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, on September 27, 2016, (a) Immunocore, GNE and Roche amended the Original Agreement to, among other things, exclude the targets MAGE-A4 [***] and the
    related compounds from the collaboration under such agreement, and (b) Immunocore and GNE entered into a license agreement relating to such targets and compounds, pursuant to which the right to develop and commercialize such targets and compounds were
    granted to Immunocore (the &#8220;<b>Second Agreement</b>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, concurrently with this Agreement, Immunocore and GNE have agreed to amend the Second Agreement to exclude the target MAGE-A4, MAGE-A4 Compounds,
    Enhanced MAGE-A4 Compounds, Other MAGE-A4 Compounds and all Other HLA/MAGE-A4 Compounds.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>WHEREAS</b>, Immunocore, GNE and Roche now desire to enter into this Agreement to, among other things, develop and commercialize the MAGE-A4 Compounds, Enhanced
    MAGE-A4 Compounds and Other MAGE-A4 Compounds.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOW THEREFORE</b>, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Immunocore, GNE and Roche agree as follows:&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the
      registrant treats as private or confidential.</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 1</b><br>
    <b>DEFINITIONS</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capitalized terms -used -in this Agreement, whether used in the singular or plural, shall have the meanings set forth below, unless otherwise specifically indicated
    herein.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>&#8220;Accounting Standard</b>&#8221; means either (a)
    International Financial Reporting Standards or (b) United States generally accepted accounting principles, in either case which standards or principles (as applicable) are currently used at the applicable time by, and as consistently applied by, the
    Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Affiliate</b>&#8221; of a Party, means any company,
    corporation or other business entity that is controlled by, controlling, or under common control with such Party. For purposes of this definition, &#8220;control&#8221; of a business entity (including &#8220;controlled by,&#8221; &#8220;under common control with&#8221; or the like) means
    direct or indirect beneficial ownership of more than fifty percent (50%) interest in the voting stock (or the equivalent) of such business entity or having the right to direct, appoint or remove a majority of members of its board of directors (or their
    equivalents) or having the power to control the general management of such business entity, by law or contract. [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Agreement</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Alliance Manager</b>&#8221; is defined in Section
    3.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Applicable Laws</b>&#8221; means all laws, rules and
    regulations and guidelines which are in force during the Term of this Agreement and in any jurisdiction in which the Research Programs, Development Programs or any part of them, including any Clinical Trial, is performed or in which any Licensed
    Product is manufactured, sold or supplied to the extent, in each case, applicable to any Party to this Agreement or any Sublicensee.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Authorized CMO</b>&#8221; is defined in Section
    20.7.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Back-Up Compound</b>&#8221; shall mean the MAGE-A4
    Compound known by the reference number [***] as defined in Exhibit B.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Biosimilar</b>&#8221; is defined in Section
    13.5.4(c).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.9<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Business Day</b>&#8221; means a day other than a
    Saturday or a Sunday or a public holiday in California, New York or London.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.10<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Change of Control</b>&#8221; means any of the
    following with respect to Immunocore: (a) the sale or disposition of all or substantially all of its assets to a Competing Party; (b) the acquisition by a Competing Party, acting alone or in concert with other person(s), of more than fifty percent
    (50%) of the combined voting power of Immunocore&#8217;s outstanding voting securities or otherwise the power to control the appointment of the board of directors of Immunocore; or (c) a merger, consolidation, share exchange or other similar transaction of
    Immunocore and a Competing Party which results in the holders of the outstanding voting securities of Immunocore immediately prior to such merger, consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent (50%)
    of the combined voting power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or other similar transaction. Notwithstanding the foregoing, a Change of Control shall not be deemed to occur
    solely on account of an (x) initial public</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is
      the type that the registrant treats as private or confidential.</b>&#160;<b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">or secondary offering, or (y) the acquisition of securities of Immunocore by one or more institutional investors, or Affiliates thereof, which are
    not Competing Parties, that acquire Immunocore&#8217;s securities in a transaction or series of related transactions (i) primarily for purposes of equity investment, or (ii) as a sale of assets, merger or other transaction effected exclusively for the
    purpose of obtaining tax or other fiscal benefit or changing the corporate domicile of Immunocore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.11<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Clinical Trial</b>&#8221; means a Phase I Clinical
    Trial, Phase II Clinical Trial (including for avoidance of any doubt a Phase Ib or Phase IIb Clinical Trial) or Phase III Clinical Trial or any other equivalent, combined or other trial in which any Licensed Product is administered to a human subject.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.12<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Co-Funding</b>&#8221; is defined in 6.1,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.13<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Co-exclusive with Immunocore</b>&#8221; is defined in
    Section 9.1.1(c)(ii).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.14<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Co-Funding Withdrawal Notice</b>&#8221; is defined in
    Section 8.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.15<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Co-Promotion Agreement</b>&#8221; is defined in
    Section 7.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.16<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Combination</b>&#8221; is defined in Section
    1.100(c).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.17<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Commercialization Plan</b>&#8221; is defined in
    Section 3.8.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.18<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Companion Diagnostic</b>&#8221; means any product
    [***] and any other product or service that: [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.19<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Competing Party</b>&#8221; means a Third Party entity
    that [***], but, for the avoidance of doubt, excluding any Third Party entity [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.20<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Compound</b>&#8221; means an ImmTAC that comprises
    (a) a TCR (or a portion of a TCR that comprises a TCR alpha chain variable domain and a TCR beta chain variable domain), wherein the TCR (or portion of the TCR) binds to an HLA presented antigen derived from the Target, and (b) an Effector.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.21<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Compulsory Sublicense</b>&#8221; means a sublicense
    granted to a Third Party, through the order, decree or grant of a governmental authority having competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale, import or export a Product in any country in the Territory
    [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.22<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Compulsory Sublicensee</b>&#8221; means a Third Party
    that was granted a Compulsory Sublicense.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.23<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Confidential Information</b>&#8221; means proprietary
    Know-How (of whatever kind and in whatever form or medium, including copies thereof), tangible materials or other deliverables (a) disclosed by or on behalf of a Party in connection with this Agreement, whether prior to or during the Term and whether
    disclosed orally, electronically, by observation or in writing, or (b) created by, or on behalf of, either Party and provided to the other Party, or created jointly by the Parties, in the course of this Agreement. For the avoidance of doubt,
    &#8220;Confidential Information&#8221; includes Know-How regarding such Party&#8217;s research, development plans, clinical trial designs, preclinical and clinical data, technology, products, business information or objectives and other information of the type that is
    customarily considered to be confidential information by entities engaged in activities</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">that are substantially similar to the activities being engaged in by the Parties pursuant to this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.24<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Control</b>&#8221; or &#8220;<b>Controlled by</b>&#8221; means
    the rightful possession by a Party, whether directly or indirectly and whether by ownership, license (other than pursuant to this Agreement) or otherwise as of the Effective Date or throughout the Term, of the unfettered right (excluding where any
    required Third Party consent cannot be obtained) to grant a license, sublicense or other right to exploit, as provided herein, without violating the terms of any agreement with any Third Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.25<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Controlled Affiliate</b>&#8221; shall mean an entity
    that is controlled by GNE or Immunocore or their respective Sublicensees.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.26<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Costs</b>&#8221; means any out of pocket costs and
    internal expenses incurred by a Party in the performance of activities directly related to the research, development (including activities related to such Party&#8217;s efforts to obtain Regulatory Approval) and commercialization of a Licensed Product. Such
    internal expenses will be charged by each Party based on its actual FTE Rate basis unless otherwise mutually agreed by the Parties as set out herein; provided that [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.27<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Covers</b>&#8221; (including variations such as &#8220;<b>Covered</b>&#8221;,








    &#8220;<b>Covering</b>&#8221; and the like), means, with respect to a particular Patent and in reference to a particular compound or product (whether alone or in combination with one or more other ingredients), that the use, manufacture, sale, supply, import,
    offer for sale of such compound or product would infringe a Valid Claim or a Valid Platform Claim, as the case may be, of such Patent in the absence of any license granted under this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.28<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>CPA Firm</b>&#8221; is defined in Section 14.7.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.29<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Create Act</b>&#8221; is defined in Section 15.2.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.30<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Data Packages</b>&#8221; is defined in Section
    20.7.1(b)(iv).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.31<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Development Costs</b>&#8221; means, with respect to a
    Licensed Product to the extent incurred during the Term and in accordance with this Agreement and a Development Plan and Development Budget, as applicable, the following Costs incurred in accordance with Accounting Standard: [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.32<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Development Budgets</b>&#8221; means the Pre-POC
    Development Budget and the Global Development Budget.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.33<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Development Plans</b>&#8221; means the Pre-POC
    Development Plan and the Global Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.34<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Development Programs</b>&#8221; means the Pre-POC
    Development Program and the Global Development Program.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.35<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Diligent Efforts</b>&#8221; means carrying out
    obligations or tasks using commercially reasonable efforts and resources comparable with standard practices of pharmaceutical companies [***] to the Party concerned and exercising decisions in good faith and using prudent, scientific and business
    judgment.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.36<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Dispute(s)</b>&#8221; is defined in Section 21.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.37<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Effector</b>&#8221; means any protein or polypeptide
    having the ability to modulate immune cell function such as anti-CD3 scFv, including derivatives or variants thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.38<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Effective Date</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.39<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Enhanced ImmTAC Patent</b>&#8221; means a Patent
    owned and Controlled by Immunocore (a) having all of its priority date(s) between [***], and (b) claiming [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.40<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Enhanced MAGE-A4 Compound</b>&#8221; means a Compound
    [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.41<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>EU</b>&#8221; means the member states of the European
    Union from time to time, or any successor entity thereto performing similar functions, together with, should it cease to be a member state of the European Union, the United Kingdom.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.42<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Event</b>&#8221; means the events listed in Sections
    13.1.2, 13.3.1 and 13.3.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.43<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Event Payment</b>&#8221; means the payments on
    achieving an Event and as set out in Section 13.1.2, 13.3.1 and 13.3.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.44<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Excess Costs</b>&#8221; is defined in Section 6.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.45<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Executives</b>&#8221; is defined in Section 3.10.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.46<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>FDA</b>&#8221; means the United States Food and Drug
    Administration, or any successor entity thereto performing similar functions.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.47<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Field</b>&#8221; means any and all uses, including,
    without limitation, human therapeutic applications including, but not limited to, therapeutic, prophylactic and diagnostic uses, but excluding any product that contains cells transfected with genes encoding TCRs or modified TCRs [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.48<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Intentionally Omitted</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.49<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>First Commercial Sale</b>&#8221; means, with respect
    to a particular Licensed Product in a given country, the first commercial sale of such Licensed Product following Marketing Approval in such country by or under authority of a Party or any of GNE&#8217;s Sublicensees. As used herein, &#8220;<b>Marketing Approval</b>&#8221;
    means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport and sale of Licensed
    Products in a country or regulatory jurisdiction. For countries where governmental approval is required for pricing or reimbursement for the Licensed Product, &#8220;Marketing Approval&#8221; shall not be deemed to occur until such pricing or reimbursement
    approval is obtained; provided, to the extent the applicable Party or any of GNE&#8217;s Sublicensees sell a Licensed Product prior to obtaining such pricing or reimbursement approval, such sales shall be accrued at the time of sale and any royalties thereon
    shall be paid in the quarter following the obtaining of such pricing or reimbursement approval. For the purpose of clarity and subject to Section 1.100(a), sales of Licensed Products between or among any Party, GNE&#8217;s Affiliates and GNE&#8217;s Sublicensees
    shall be excluded from &#8220;First Commercial Sale.&#8221;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">5</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is
      the type that the registrant treats as private or confidential.</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.50<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Foreground IP</b>&#8221; means Immunocore Foreground
    IP, GNE Foreground IP, and Joint Foreground IP.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.51<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>FTE</b>&#8221; means, with respect to a person, the
    equivalent of the work of one (1) employee full time for one (1) year (consisting of in general a total of [***] per year (excluding vacations and holidays), or such other period as may be prescribed by Applicable Law, on a country-by-country basis).
    Overtime, and work on weekends, holidays and the like will not be counted with any multiplier (e.g., time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.52<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>FTE Rate</b>&#8221; means [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.53<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Full Data Package</b>&#8221; means, with respect to
    each Other HLA/MAGE-A4 Compound: (a) any relevant information within Immunocore&#8217;s Control relating to such Other HLA/MAGE-A4 Compound(s), including all information regarding safety, efficacy, toxicity, or potential side effects, as well as all data
    collected from performing any pharmacokinetic, absorption, distribution, metabolism or excretion study, and toxicology studies, and any information resulting from or related to clinical trials; (b) any relevant data and information in Immunocore&#8217;s
    Control relating to the manufacture, formulation, and cost of goods for such Other HLA/MAGE-A4 Compound(s); and (c) any relevant documentation, filings, correspondence or other non-privileged information in Immunocore&#8217;s Control related to existing or
    potential Patents related to such Compound(s). The format and depth of data to be provided in such Full Data Package shall be mutually agreed to by the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.54<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Global Development Budget</b>&#8221; is defined in
    5.7.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.55<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Global Development Plan</b>&#8221; is defined in
    5.7.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.56<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Global Development Program</b>&#8221; means the
    activities conducted by the Parties pursuant to Section 5.7.1 and the Global Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.57<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GMP</b>&#8221; means all current good manufacturing
    practices applicable to biopharmaceuticals in the United States and/or in the European Union, as are in effect from time to time during the Term.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.58<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.59<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Background IP</b>&#8221; means (a) the Know-How
    Controlled by GNE as of the Effective Date in so far as it relates to any MAGE-A4 Compound, Enhanced MAGE-A4 Compound, Other MAGE-A4 Compound or Licensed Product, or the manufacture, use, import, offer to sell, or sale of such Compound or Licensed
    Product, developed pursuant to the Original Agreement; (b) any Patents claiming the Know-How in Section 1.59(a), which Patents have an earliest priority date prior to the Effective Date; and (c) any other Know-How and/or Patents Controlled by GNE which
    the Parties agree to apply when carrying out the activities under this Agreement. For the avoidance of doubt, GNE Background IP will exclude any Patents or Know-How [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.60<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Background Patents</b>&#8221; is defined in
    Section 20.7.2(e).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.61<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Controlled Patents</b>&#8221; is defined in
    Section 15.3.3(b).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">6</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.62<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Foreground IP</b>&#8221; means (a) any Know-How
    discovered, conceived or reduced to practice solely by or on behalf of GNE after the Effective Date in the course of performing activities under this Agreement (&#8220;<b>GNE Foreground Know-How</b>&#8221;); and (b) any Patents claiming the Know-How in Section
    1.62(a), which Patents have an earliest priority date after the Effective Date (&#8220;<b>GNE Foreground Patents</b>&#8221;). GNE Foreground IP will exclude any Patents or Know-How [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.63<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Know-How</b>&#8221; is defined in Section
    20.7.2(c).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.64<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Patents</b>&#8221; is defined in Section
    20.7.2(b).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.65<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Regulatory Information</b>&#8221; is defined in
    Section 20.7.2(d),</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.66<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>GNE Reversion IP</b>&#8221; is defined in Section
    20.7.2(a).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.67<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>HLA</b>&#8221; means human leukocyte antigen type A2.
    [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.68<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>IMCC103C</b>&#8221; or &#8220;<b>IMC-C103C</b>&#8221; means the
    [***] MAGE-A4 Compound known by that reference number as defined in Exhibit B.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.69<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>ImmTAC</b>&#8221; means a bifunctional protein that
    combines a high affinity TCR with an anti-CD3 scFv domain or other Effector.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.70<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Immunocore</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.71<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Immunocore Controlled Patents</b>&#8221; is defined
    in Section 15.3.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.72<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Immunocore Foreground IP</b>&#8221; means (a) any
    Know-How discovered, conceived or reduced to practice solely by or on behalf of Immunocore after the Effective Date in the course of performing activities under this Agreement; and (b) any Patents claiming the Know-How in Section 1.72(a), which Patents
    have an earliest priority date after the Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.73<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Immunocore ImmTAC Improvement IP</b>&#8221; is
    defined in Section 15.3.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.74<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Immunocore Platform IP</b>&#8221; means any (a)
    Know-How in so far as it relates to MAGE-A4, any MAGE-A4 Compound, an Enhanced MAGE-A4 Compound or an Other MAGE-A4 Compound or Licensed Product, or Companion Diagnostic, Controlled by Immunocore as of the Effective Date, or created by Immunocore after
    the Effective Date outside the course of activities conducted under this Agreement; (b) any Patents claiming the Know-How in Section 1.74(a) or Covering any MAGE-A4 Compound, Enhanced MAGE-A4 Compound, Other MAGE-A4 Compound or Licensed Product, or
    Companion Diagnostic; and (c) any other Patents, Controlled by Immunocore that are necessary or useful for the purposes of researching, developing, making, importing, selling, offering for sale, or commercializing Licensed Products or Companion
    Diagnostic. Immunocore Platform IP includes but is not limited to the Patents in Exhibit A, Parts B and C, and Enhanced ImmTAC Patents; but excludes (i) Licensed Product IP; and (ii) Immunocore Foreground IP.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.75<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>IND</b>&#8221; means an investigational new drug
    application filed- with the FDA pursuant to 21 CFR Part 312 before the commencement of clinical trials of a product, or any comparable or equivalent filing with any relevant regulatory authority in any other jurisdiction required before the
    commencement of any clinical trial.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">7</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is
      the type that the registrant treats as private or confidential.</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.76<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Indemnitee</b>&#8221; is defined in Section 19.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.77<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Indemnitor</b>&#8221; is defined in Section 19.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.78<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Indication</b>&#8221; is defined in Section 13.3.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.79<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Infringement</b>&#8221; is defined in Section 15.5.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.80<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Initial Data Package</b>&#8221; means the information
    to be provided by Immunocore to GNE pursuant to the right of first negotiation granted to GNE under Section 9.2.1, which shall include: any relevant IMPD supporting reports approved for use according to Immunocore&#8217;s then current SOPs, IMPD &amp; IB
    documentation, Immunocore compiled headline clinical data reports/analyses generated during the course of any clinical trial and interim or final clinical study reports, all where available.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.81<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Initial Terminated Product Data Package</b>&#8221; is
    defined in Section 20.7.1(b)(i).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.82<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>JCC</b>&#8221; is defined in Section 3.8.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.83<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>JDC</b>&#8221; is defined in Section 3.4.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.84<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Joint Foreground IP</b>&#8221; means (a) any
    Know-How discovered, conceived or reduced to practice by one or more employees of, or on behalf of, GNE, and one or more employees of, or on behalf of, Immunocore in the course of performing activities under this Agreement; and (b) any Patents claiming
    the Know-How in Section 1.84(a), which Patents have an earliest priority date after the Effective Date. For the avoidance of doubt, Joint Foreground IP excludes any GNE Foreground IP and any Immunocore Foreground IP.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.85<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>JPT</b>&#8221; is defined in Section 3.6.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.86<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>JRC</b>&#8221; is defined in Section 3.7.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.87<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Key Business Terms</b>&#8221; is defined in Section
    20.7.1(b)(ii).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.88<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Know-How</b>&#8221; means all information, inventions
    (whether or not patentable), improvements, practices, formula, trade secrets, techniques, methods, procedures, knowledge, results, test data (including pharmacological, toxicological, pharmacokinetic and pre-clinical and clinical information and test
    data, related reports, structure-activity relationship data and statistical analysis), analytical and quality control data, protocols, processes, models, designs, and other information regarding discovery, development, marketing, pricing, distribution,
    cost, sales and manufacturing. Know-How shall not include any Patents.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.89<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Licensed Product</b>&#8221; means any and all
    pharmaceutical preparations (other than a Companion Diagnostic) containing a MAGE-A4 Compound, an Enhanced MAGE-A4 Compound or an Other MAGE-A4 Compound alone or in combination with one or more active ingredients, auxiliaries and/or additives or
    formulations.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.90<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Licensed Product IP</b>&#8221; means: (i) the Patent
    in Exhibit A, Part A; (ii) any other Patents or Know-How Controlled by Immunocore as of the Effective Date or during the Term of the Agreement</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">8</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">relating solely to: (a) any MAGE-A4 Compound, any Enhanced MAGE-A4 Compound, an Other MAGE-A4 Compound or any Licensed Product, or any combination
    of the foregoing; and (b) the manufacture, use, import, offer to sell, or sale of such Compound or Licensed Product,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.91<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221; is defined in
    Section 19.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.92<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>MAA</b>&#8221; or &#8220;<b>Marketing Approval Application</b>&#8221;
    means BLA, sBLA, NDA, sNDA and any equivalent thereof in the United States or any other country or jurisdiction in the Territory including a marketing approval application filed with the EMA. As used herein: &#8220;<b>BLA</b>&#8221; means a Biologics License
    Application and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. &#167; 600 et seq., for FDA approval of a Licensed Product and &#8220;<b>sBLA</b>&#8221; means a supplemental BLA; and &#8220;<b>NDA</b>&#8221; means a New Drug Application
    and amendments thereto filed pursuant to the requirements of the FDA, as defined in 21 C.F.R. &#167; 314 et seq., for FDA approval of a Licensed Product and &#8220;<b>sNDA</b>&#8221; means a supplemental NDA.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.93<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>MAGE-A4</b>&#8221; means the protein known as
    Melanoma Associated Antigen 4 which has UNIPROT number P43358 and the gene that encodes for such protein.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.94<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>MAGE-A4 Compound</b>&#8221; refers to IMCC103C or
    the Back-Up Compound [***], each as described in Exhibit B, and any variant of the foregoing that is considered by the FDA or the European Medicines Agency to be equivalent to either IMCC103C or the Back-Up Compound, and where &#8220;<b>equivalent</b>&#8221; means
    for these purposes that such variant [***] to IMCC103C or the Back-Up Compound.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.95<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Major European Market</b>&#8221; means [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.96<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Manufacturing Cost</b>&#8221; means the
    fully-burdened aggregate direct and indirect costs and expenses incurred by a Party in accordance with Accounting Standard to manufacture Licensed Product consisting solely of: [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.97<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Materials</b>&#8221; is defined in Section 10.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.98<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Milestone Payments</b>&#8221; means the milestone
    payments payable on the occurrence of the Net Sales Events in Section 13.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.99<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>MSA</b>&#8221; is defined in Section 10.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.100<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Net Sales</b>&#8221; means, with respect to a
    Licensed Product, an amount calculated by subtracting from the amount of Sales of such Licensed Product by a Party or its Sublicensees to Third Parties (including distributors): (i) a lump sum deduction of [***] of Sales in lieu of those deductions
    which are not accounted for by a Party on a Licensed Product-by-Licensed Product basis [***]. The deductions under this Section will be those deductions as consistently applied by a Party or their Sublicensees in accordance with internal practices. As
    used in this Section 1.100:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sales Among Affiliates and Sublicensees</b>.
    Sales between or among a Party and its Affiliates or Sublicensees shall be excluded from the computation of Net Sales, provided (a) there is an arms&#8217; length sale or supply to a Third Party in relation to such Licensed Product, and (b) any sale between
    a Party and its Affiliates or Sublicensee is made on an arms&#8217; length basis.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">9</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Supply as Samples/Test Materials</b>.
    Notwithstanding anything to the contrary in the definition of Net Sales, the following supply or other disposition of Licensed Products shall be excluded from the computation of Net Sales: (i) samples provided free of charge to any Third Party and in
    accordance with standard industry practice (but not in circumstances where such Third Party is able to pass samples to any other Third Party other than free of charge); (ii) for use in non-clinical or clinical studies (provided such samples are
    provided to any Third Party in exchange for data from such study, at cost, or free of charge); (iii) for use in any tests or studies reasonably necessary to comply with any Applicable Law(s), regulation or request by a regulatory or governmental
    authority (provided such samples are provided to any Third Party in exchange for data from such test or study, at cost, or free of charge) or (iv) as is otherwise reasonable and customary in the industry (but not in circumstances where such Third Party
    is able to pass samples to any other Third Party other than free of charge).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Li<b>censed Products Sold in Combinations</b>. In
    the event that a Licensed Product is sold or supplied in combination (in the same package, including as a co-formulation) with one or more other active ingredients or other products that are not the subject of this Agreement (for purposes of this
    Section 1.100(c), a &#8220;<b>Combination</b>&#8221;), the following shall apply: [***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sales from Compulsory Sublicensees</b>. The
    Parties shall discuss in good faith and agree the reasonable treatment to be used on a consistent basis to fairly share Compulsory Sublicense payments between the Parties. For the purpose of clarity, no Party will be penalized or be subject to material
    breach for delayed or deferred payments during the period of discussion.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.101<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Net Sales Event(s)</b>&#8221; means the events listed
    in Section 13.4.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.102<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Net Sales Report</b>&#8221; is defined in Section 14.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.103<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Original Agreement</b>&#8221; is defined in the
    recitals.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.104<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Other HLA/MAGE-A4 Compound</b>&#8221; means a Compound
    that binds to an antigen of MAGE-A4 other than HLA-A2. For clarity, no MAGE-A4 Compound, no Enhanced MAGE-A4 Compound, and no Other MAGE-A4 Compound shall be an Other HLA/MAGE-A4 Compound.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.105<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Other MAGE-A4 Compound</b>&#8221; means a Compound that
    binds to an HLA-A2 antigen of MAGE-A4 is (a) generated solely by Immunocore or jointly by the Parties during the Term as a result of activities under a Research Program or (b) generated solely by GNE during the Term as a result of activities under a
    Research Program; provided, that such Compound is not a MAGE-A4 Compound or an Enhanced MAGE-A4 Compound.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.106<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Party</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.107<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Party Vote</b>&#8221; is defined in Section 3.10.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.108<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Patent(s)</b>&#8221; means any and all patents and
    patent applications and any patents issuing therefrom or claiming priority thereto, worldwide, together with any extensions (including patent term extensions and supplementary protection certificates) and renewals thereof, reissues, reexaminations,
    substitutions, confirmation patents, registration patents, invention certificates, patents of addition, renewals, divisionals, continuations, and continuations-in-part of any of the foregoing.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">10</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.109<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Permissible Excess Costs</b>&#8221; is defined in
    Section 6.6.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.110<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Phase I Clinical Trial</b>&#8221; means a human
    clinical trial, the principal purpose of which is preliminary determination of safety of a Licensed Product in healthy individuals or patients as described in 21 C.F.R. &#167;312.21, or similar clinical study in a country other than the United States.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.111<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Phase Ib Clinical Trial</b>&#8221; means a human
    clinical trial of a Licensed Product, consistent with 21 C.F.R. 312.21(a) or other applicable regulatory requirements outside the United States, which is designed to determine the maximum tolerated dose (with the maximum tolerated dose being the
    highest dose of treatment that will produce the desired effect without unacceptable toxicity, intended for use in a subsequent trial).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.112<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Phase II Clinical Trial</b>&#8221; means a human
    clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy of a Licensed Product in patients being studied as described in 21 C.F.R. &#167;312.21, or similar clinical study in a
    country other than the United States. Phase II Clinical Trials shall include Phase Ila and Phase Jib Clinical Trials.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.113<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Phase II Supply</b>&#8221; is defined in Section 5.8.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.114<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Phase III Clinical Trial</b>&#8221; means a human
    clinical trial, the principal purpose of which is to demonstrate clinically and statistically the efficacy and safety of a Licensed Product for one or more indications in order to obtain marketing approval of such Licensed Product for such
    indication(s), as further defined in 21 C.F.R. &#167;312.21 or a similar clinical study in a country other than the United States.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.115<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Pivotal Trial</b>&#8221; is defined in Section
    13.3.2(e).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.116<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Pre-POC Development Budget</b>&#8221; is defined in
    Section 5,3.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.117<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Pre-POC Development Plan</b>&#8221; is defined in
    Section 5.3.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.118<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Pre-POC Development Program</b>&#8221; means the
    activities conducted by the Parties pursuant to Section 5.3 and the Pre-POC Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.119<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Pre-POC Term</b>&#8221; is defined in Section 5.3.4,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.120<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Project Co-Leader</b>&#8221; is defined in Section
    3.6.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.121<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Prosecute and Maintain</b>&#8221; or &#8220;<b>Prosecution
      and Maintenance</b>&#8221; is defined in Section 15.1.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.122<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>QAA</b>&#8221; is defined in Section 10.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.123<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Regulatory Approval</b>&#8221; means the technical,
    medical and scientific licenses, registrations, authorizations and approvals required for marketing or use of a Licensed Product (including, without limitation, approvals of, BLAs (as defined in Section 1.92), investigational new drug applications,
    pre- and post- approvals, and labeling approvals and any supplements and amendments to any of such approvals) of any national, supra-national, regional, state or local regulatory agency,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">11</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">department, bureau, commission, council or other governmental entity, necessary for the development, Manufacture, distribution, marketing,
    promotion, offer for sale, use, import, export or sale of Licensed Products in a regulatory jurisdiction. In the United States, its territories and possessions, Regulatory Approval means approval of any Marketing Approval Application or equivalent by
    the FDA.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.124<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Release</b>&#8221; is defined in Section 17.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.125<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Research Budget</b>&#8221; is defined in Section 4.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.126<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Research Plan</b>&#8221; is defined in Section 4.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.127<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Research Program</b>&#8221; means the activities
    conducted by the Parties either alone or jointly pursuant to a Research Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.128<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Research Term</b>&#8221; is defined in Section 4.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.129<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Roche</b>&#8221; is defined in the preamble.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.130<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Rules</b>&#8221; is defined in Section 21.2.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.131<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>RON</b>&#8221; is defined in Section 20.7.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.132<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Sales</b>&#8221; means, with respect to a Licensed
    Product, for any period, the amount stated in a Party&#8217;s &#8220;Sales&#8221; line of its quarterly produced and reviewed financial statements with respect to such Licensed Product for such period, which amount reflects the gross invoice price such Licensed Product
    sold or otherwise disposed. of (other -than for use as clinical supplies or free samples) by such Party and its Sublicensees reduced by gross-to-net deductions (to the extent applied consistently by a Party and its Sublicensees with respect to sales of
    their respective other products) if not previously deducted from the amount invoiced, taken in accordance with the then currently used Accounting Standard. By way of example, the gross-to-net deductions taken in accordance with the Accounting Standard
    as of the Effective Date are the following: [***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of clarity and subject to Section 1.100(a), sales of Licensed Products between or among any of Party, its Affiliates or their Sublicensees shall be
    excluded from &#8220;Sales&#8221;.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.133<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Second Agreement</b>&#8221; is defined in the recitals.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.134<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Secondary Data Package</b>&#8221; is defined in Section
    20.7.1(b)(iii).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.135<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Section 15.5.2 Enforcement</b>&#8221; is defined in
    Section 15.5.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.136<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Sublicensee</b>&#8221; shall mean a Third Party or
    Affiliate who has been granted a sublicense under the licenses granted under Article 9 and where such sub-license is in compliance with Section 9.1.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.137<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Target</b>&#8221; means Melanoma-Associated Antigen A4,
    also known as MAGE-A4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.138<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>TCR</b>&#8221; means T-cell receptor.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">12</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.139<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Tecentriq</b>&#8221;<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> means that certain GNE proprietary monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1) having as its active ingredient atezolizumab.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.140<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Tecentriq Combination Trial</b>&#8221; is defined in
    Section 5.3.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.141<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Term</b>&#8221; is defined in Section 20.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.142<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Terminated Product</b>&#8221; is defined in Section
    20.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.143<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Termination Effective Date</b>&#8221; is defined in
    Section 20.6.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.144<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Territory</b>&#8221; means all the countries of the
    world.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.145<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Third Party</b>&#8221; means any entity other than
    Immunocore, GNE or an Affiliate of any of the foregoing.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.146<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Third Party Agreement</b>&#8221; is defined in Section
    9.2.3,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.147<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Third Party Claims</b>&#8221; is defined in Section
    19.1,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.148<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Third Party Infringement Claim</b>&#8221; is defined in
    Section 15.7.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.149<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Title 11</b>&#8221; is defined in Section 20.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.150<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Transfer Agreement</b>&#8221; is defined in Section
    20.7.1(c).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.151<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>US</b>&#8221; means the United States of America and
    its territories and possessions.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.152<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Valid Claim</b>&#8221; means, with respect to a
    particular country, (a) a claim in an issued and unexpired (i) Patent within the Licensed Product IP or (ii) Enhanced ImmTAC Patent, or (b) a claim in an issued and unexpired Patent within the Joint Foreground IP or Immunocore Foreground IP, or (c) a
    claim in an issued and unexpired Patent within GNE Foreground IP claiming the Know-How conceived prior to, and reduced to practice either prior to or within [***] after, the issue of a Co-Funding Withdrawal Notice, in each case in such country that has
    not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been
    admitted to be invalid or unenforceable through re-examination, re-issue, inter partes review, disclaimer or otherwise, or lost in an interference proceeding.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.153<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Valid Platform Claim</b>&#8221; means, with respect to
    a particular country, a claim in an issued and unexpired Patent within the Immunocore Platform IP, excluding Enhanced ImmTAC Patents, in such country that has not lapsed or been disclaimed, revoked, held unenforceable, unpatentable or invalid by a
    decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through re-examination, re-issue, inter partes
    review, disclaimer or otherwise, or lost in an interference proceeding.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">13</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.154<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>VAT</b>&#8221; means, in the EU, value added tax
    calculated in accordance with Council Directive 2006/112/EC, as implemented in each country member state and, in a jurisdiction outside the EU, any equivalent tax.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">1.155<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Working Group</b>&#8221; is defined in Section 3.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 2</b><br>
    <font style="text-transform: uppercase"><b>OTHER AGREEMENTS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For the avoidance of doubt, the Parties agree that
    the Target, and any and all MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds, Other MAGE-A4 Compounds and all Other HLA/MAGE-A4 Compounds, are excluded from the Second Agreement and this Agreement shall govern all matters relating to the Target and such
    compounds.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 3</b><br>
    <font style="text-transform: uppercase"><b>GOVERNANCE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Collaboration Overview</b>. Subject to the terms
    and conditions of this Agreement, the Parties desire and intend to collaborate in the development of Licensed Products in the Field in the Territory and to share certain costs related to the development and, subject to Immunocore&#8217;s right to issue a
    Co-Funding Withdrawal Notice, commercialization of Licensed Products and any Companion Diagnostics. The Parties desire to establish the following committees to oversee the collaboration and to provide a forum for discussion of matters relating to it:
    Joint Project Team (JPT), Joint Research Committee (JRC), Joint Development Committee (JDC) and Joint Commercialization Committee (JCC).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Limits on Committee Authority</b>. Each Party
    shall retain the rights, powers and discretion granted to it under this Agreement and any ancillary agreements and no such rights, powers, or discretion shall be delegated to or vested in the JPT, JRC, JDC, JCC or any subcommittee of them unless such
    delegation or vesting of rights is expressly provided for in this Agreement or any ancillary agreements or the Parties expressly so agree in writing. Notwithstanding anything to the contrary in this Agreement, in no circumstances shall the JPT, JRC,
    JDC, JCC or any subcommittee of them have any power to amend, modify or waive compliance with this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Alliance Managers</b>. Promptly following the
    Effective Date and in any event within [***] after the Effective Date, each Party shall designate an individual to act as the primary point of contact for such Party for matters related to this Agreement (such Party&#8217;s &#8220;<b>Alliance Manager</b>&#8221;), unless
    another contact is expressly specified in this Agreement or designated by the JDC for a particular purpose. The Alliance Managers shall facilitate the flow of information and collaboration between the Parties and assist in the resolution of potential
    and pending issues and potential disputes in a timely manner to enable the JDC, JRC or JCC, as appropriate, to reach consensus and avert escalation of such issues or potential disputes. Either Party may replace its Alliance Manager at any time upon
    prior written notice (including by email) to the other Party&#8217;s Alliance Manager. Each Party shall ensure that its Alliance Manager is capable of performing the obligations required of an Alliance Manager under this Agreement. As of the Effective Date,
    the Alliance Managers are: [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint Development Committee</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Formation and Composition</b>. As soon as
    reasonably possible and in any event within [***] after the Effective Date, lmmunocore and GNE shall establish a joint development committee (the &#8220;<b>JDC</b>&#8221;) to act as the steering committee to oversee, review and manage the development of the
    Licensed Products in accordance with the Development Plans. The JDC shall be composed of at least [***] but no more than [***] representatives designated by each Party (and the Parties need not have the same number of representatives). Representatives
    must be appropriate for the tasks then being undertaken and the stage of development, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives
    as its primary JDC contact. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may
    designate an alternate to attend such meeting by informing the other Party&#8217;s representatives in writing (which may be by email) in advance and following provision of such written notification the alternate will be entitled to perform the functions of
    such representative, The Alliance Managers and Project Co-Leaders may attend meetings of the JDC but shall have no right to vote on any decisions of the JDC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JDC Responsibilities</b>. In addition to its
    overall responsibility for overseeing, reviewing and managing the Development Plans, the JDC shall, in particular:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>manage and govern the activities of the Parties
    with respect to the development, manufacture, and regulatory approval of MAGE-A4 Compounds, Licensed Product(s) and Companion Diagnostics;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>work with the Project Co-Leaders to coordinate the
    activities of the Parties hereunder, including review and approval of the allocation of resources and efforts under the Development Plan;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review and approve any proposed modification of
    the Development Plans, including the Development Budgets;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>analyse the opportunities for development of
    MAGE-A4 Compound both as a monotherapy and in combination, including by deciding whether to seek new indications, formulations or uses for the Licensed Products in the Territory where appropriate, such as for Licensed Product life cycle management;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review and approve the protocols for all Clinical
    Trials conducted under the Development Plans and any material amendments thereto (including any amendments which would change the primary endpoint of such Clinical Trial, dosage or similar matters), provided that such review and approval shall be
    conducted within a timeframe that does not extend beyond [***];</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review quarterly financial forecasts for
    development (including timing of expenditures) to ensure actual and anticipated expenditure is within the approved Development Budget for the relevant [***];</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss and oversee CMC related activities
    including CMC related regulatory activities and maintenance of regulatory submissions, including INDs, for Licensed</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">15</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Products to ensure regulatory compliance and timely management of responses to any regulatory authority queries pre- and post-approval as was during
    regulatory review processes;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review, discuss, coordinate and approve funding or
    supply of Licensed Product for any externally sponsored research in the Territory and establish a group to review and approve proposals for externally sponsored research involving the Licensed Product(s);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review, discuss, and approve publication
    strategy relating to the Licensed Products and the plan for scientific presentations and publications, in accordance with Article 17, save that publication strategy relating to Research Programs shall be reviewed and coordinated by the JRC;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss and approve plans for development of
    biomarkers, Companion Diagnostics and any other diagnostic products for use in connection with a Licensed Product;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review, discuss and approve in consultation with
    the JPT distribution of Licensed Product for &#8220;compassionate use&#8221; or as free goods;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>work to resolve any disputes, controversy or
    claim related to the matters and authority of the JDC, including any issues presented to it by, and disputes within, any Working Group or the JPT; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(m)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>perform such other functions as appropriate to
    further the purposes of this Agreement as determined by the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JDC shall consider at its first meeting whether any additional matters should fall within its remit.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Working Groups</b>. From time to time, the JDC,
    JRC and JCC may establish and delegate duties to directed teams on an &#8220;as-needed&#8221; basis to oversee particular projects or activities, and such teams shall be constituted and shall operate as the JDC, JRC and/or JCC determines (&#8220;<b>Working Group(s)</b>&#8221;).








    Each such Working Group and its activities shall be subject to the oversight, review and approval of, and shall report to, the JDC, JRC or JCC, as appropriate. In no event shall the authority of a Working Group exceed that specified in this Article 3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint Project Team</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Formation and Composition</b>. As soon as
    reasonably possible and in any event within [***] of the Effective Date, the Parties shall establish one or more joint project teams (each a &#8220;<b>JPT</b>&#8221;) to manage the day-to-day activities under, and facilitate communications between the Parties with
    respect to, the Development Plans and, if applicable, any Research Plan, The JPT shall be a non-voting team composed of representatives designated by each Party. Representatives must be appropriate for the tasks then being undertaken and the stage of
    development or commercialization, in terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JPT contact (each, a &#8220;<b>Project
      Co-Leader</b>&#8221;). Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may designate a
    knowledgeable alternate to attend such meeting and perform the functions of such representative. The JPT shall be subject to the oversight, review and approval of the JDC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">16</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JPT Responsibilities</b>. In addition to its
    overall responsibility for creating, updating and managing the Development Plans and, if applicable, any Research Plan, the JPT shall, in particular:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prepare any amendments to the Development Plans
    and, if applicable, any Research Plan, and submit amended plans to the JDC or, as applicable, JRC for approval;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>create and manage Development Budgets and, if
    applicable, any Research Budget; each Party shall provide to the JPT [***] forecasts of spend against the agreed budget for the next [***] on a rolling [***] basis. Within [***] of the start of each [***] each Party shall also provide to the JPT a
    forecast of its spend against budget for the following [***];</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>implement the Development Plans and, if
    applicable, any Research Plan, ensuring that activities thereunder are performed in accordance with the approved timelines and budgets;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prepare any proposed amendments to the
    Commercialization Plan and submit amended plans to the JCC for approval;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>report regularly to the JDC, JRC and JCC to ensure
    that each Party keeps the JDC, JRC or JCC, as appropriate, informed regarding all material activities performed by such Party under this Agreement that are within the purview of such committee;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>evaluate opportunities for new combinations,
    formulations, delivery systems, Companion Diagnostics, biomarker analyses and other improvements;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>develop an overall communication and publication
    plan for publications and public presentations related to Products and submit such plans to the JDC or, as applicable, JRC for approval, and implement such approved plan;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>discuss and attempt to resolve any disputed
    matters related to the collaboration before referring such matters to the JDC, JRC or JCC, as applicable; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>perform such other functions as agreed to by the
    JDC, JRC or JCC (subject to Section 3.10.2 and 3.10.3) or as specified in this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint Research Committee</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Formation and Composition</b>. Within [***] of
    a written request by a Party, the Parties shall establish a joint research committee (the &#8220;<b>JRC</b>&#8221;) to monitor and coordinate any activities under, and facilitate communications between the Parties with respect to any research program that the
    Parties agree to carry out with regard to MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds, Other MAGE-A4 Compounds and Licensed Products. The JRC shall be composed of at least [***] but no more than [***] representatives designated by each Party and the
    Parties need not have the same number of representatives. Representatives must be appropriate for the tasks- then being undertaken and the stage of research or pre -clinical development, in terms of their seniority, availability, function in their
    respective organizations, training and experience. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party&#8217;s representative is unable to attend a
    meeting, such Party</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">17</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">may designate an alternate to attend such meeting by informing the other Party&#8217;s representatives in writing (which may be by email) in advance and
    following provision of such notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and Project Co-Leaders may attend meetings of the JRC but shall have no right to vote on any decisions of the
    JRC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JRC Responsibilities</b>. In addition to its
    overall responsibility for monitoring and coordinating any agreed research program, the JRC shall, in particular:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review and approve Research Plans and Research
    Budgets, and any amendments thereto;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>work with the Project Co-Leaders to implement and
    coordinate the activities of the Parties with respect to any agreed Research Plans;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>review and approve the allocation of resources and
    responsibilities for the agreed Research Programs;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>keep the JPT informed of the activities of (x) the
    JRC; and (y) the Parties under any Research Program;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>develop and approve a publication strategy for
    research, including research not linked to the Licensed Products, which strategy shall indicate any such publications that require prior approval of the JRC and a process for approval of such publications;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>work to resolve any disputes, controversy or
    claim related to the matters and authority of the JRC, including any issues presented to it by, and disputes within, any Working Group or the JPT; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>perform such other functions as appropriate to
    further the purposes of this Agreement as determined by the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The JRC shall consider at its first meeting whether any additional matters should fall within its remit.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Joint Commercialization Committee</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Formation and Composition</b>. Provided that
    Immunocore has not issued a Co Funding Withdrawal Notice, within [***], the Parties shall establish a joint commercialization committee (the &#8220;<b>JCC</b>&#8221;) to develop and agree a commercialization plan throughout the Territory (&#8220;<b>Commercialization
      Plan</b>&#8221;) for the Licensed Products and to oversee, review and manage the activities under the Commercialization Plan. The JCC shall be composed of at least [***] but no more than [***] representatives designated by each Party and the Parties need
    not have the same number of representatives. Representatives must be appropriate for the tasks then being undertaken and the stage of development, in terms of their seniority, availability, function in their respective organizations, training and
    experience. Each Party shall designate one of its representatives as its primary JCC contact. Each Party may replace its representatives from time to time by informing the other Party in writing (which may be by email); provided, however, if a Party&#8217;s
    representative is unable to attend a meeting, such Party may designate an alternate to attend such meeting by informing the other Party&#8217;s representatives in writing (which may be by email) in advance and following</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">18</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">provision of such written notification the alternate will be entitled to perform the functions of such representative. The Alliance Managers and JPT
    Co-Leaders may attend meetings of the JCC but shall have no right to vote on any decisions of the JCC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JCC Responsibilities</b>. In addition to its
    overall responsibility for developing and agreeing the Commercialization Plan, the JCC shall, in particular:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prepare and agree the Commercialization Plan and
    associated budget and review and approve any annual updates (or any other updates) thereto submitted by the JPT to the JCC;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>establish a commercialisation strategy for the
    Companion Diagnostics;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>following the First Commercial Sale of Licensed
    Product, develop, approve and coordinate a publication strategy relating to the Licensed Products, and the plan for scientific presentations and publications, in accordance with Article 17, which strategy shall indicate any such publications that
    require prior approval of the JCC and a process for approval of such publications, save that publication strategy relating to Research Programs shall be reviewed and coordinated by the JRC; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>performing such other duties as are expressly
    agreed by the Parties or otherwise assigned to the JCC in this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.9<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Meetings</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JDC and JRC</b>. Unless otherwise agreed, each
    of the JDC and JRC shall meet in person [***] at Immunocore&#8217;s facilities, in the case of the JDC in [***], and in the case of the JRC in [***], or GNE&#8217;s facilities in [***], or via telecon or otherwise. Where possible meetings will be held by telephone
    conference with [***] meeting per year being face to face unless otherwise agreed by the respective committee.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JPT</b>. The JPT shall meet at least [***] by
    audio or video teleconference or as otherwise agreed by the JPT.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>JCC</b>. Once established, unless otherwise
    agreed, the JCC shall meet in person [***] at Immunocore&#8217;s facilities in [***] or GNE&#8217;s facilities in [***], or via telecon or otherwise. Where possible meetings will be held by telephone conference with [***] meeting per year being face to face unless
    otherwise agreed by the JCC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>-Meeting Agendas and Minutes</b>. Not later
    than [***] after the JDC, JRC, JPT and JCC are formed, the respective committees shall each hold an organizational meeting by video- or tele- conference to establish their respective operating procedures, including establishment of agendas, and
    preparation and approvals of minutes, GNE shall be responsible for taking the meeting minutes except for meetings of the JPT which shall be the responsibility of Immunocore. Meeting minutes shall be sent to both Parties promptly (and in any event
    within [***]) after a meeting for review, comment and approval by each Party, Where minutes are not approved by both Parties, the dispute shall be resolved at the next JDC, JRC, JPT or JCC meeting. A decision that is made at the JDC, JRC, JPT or JCC
    meeting shall be recorded in minutes, and decisions that are made by the JDC,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">19</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">JRC, JPT or JCC outside of a meeting shall be documented in writing and be shown to be clearly agreed by all representatives of the JDC, JRC, JPT or
    JCC as relevant.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>General</b>. Employees of each Party other
    than its JDC, JRC, JPT or JCC representatives may attend meetings of the JDC, JRC, JPT or JCC as non-voting participants, and, with the consent of the other Party, a Party&#8217;s consultants and advisors involved in the development and/or commercialization
    of Licensed Products may attend meetings of the JDC, JRC, JPT or the respective JCC as non-voting observers; provided, that such consultants and advisors are under suitable obligations of confidentiality and non-use applicable to the Confidential
    Information of the other Party consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article 16. Each Party shall be responsible for all of its own expenses of participating in the JDC, JRC, JPT and
    JCC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.10<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Decision-Making</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>JPT</b>. Each Party will discuss and attempt to
    resolve any potential or evolving disagreement related to a Development Plan, or Commercialization Plan through its Project Co-Leaders before it is brought before the JPT. With respect to the responsibilities of the JPT, each Party shall have [***] on
    all matters brought before such committee. The JPT shall operate as to matters within its responsibility by [***] Party Vote. If the JPT is unable to achieve [***] Party Vote within [***] after the dispute matter is brought to a vote before the JPT,
    matters relating to development and manufacture shall be referred to the JDC and matters relating to commercialization shall be referred to [***], for resolution.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>JDC</b>. Each Party will discuss and attempt to
    resolve any potential or evolving disagreement related to the Development Plans through their respective [***] members before it is brought before [***]. Each Party&#8217;s designees on the JDC shall, collectively, have [***] (the &#8220;<b>Party Vote</b>&#8221;) on all
    matters brought before the JDC. The JDC shall operate as to matters within its responsibility by [***] Party Vote. If the JDC is unable, after good faith efforts and with involvement of the Alliance Managers, to achieve [***] Party Vote on any issue,
    such issue shall be referred to the Executives.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>JRC</b>. Each Party will discuss and attempt to
    resolve any potential or evolving disagreement related to the Research Plans through their respective JRC members. Each Party&#8217;s designees on the JRC shall, collectively, have [***] Party Vote on all matters brought before the JRC. The JRC shall operate
    as to matters within its responsibility by [***] Party Vote. If the JRC is unable, after good faith efforts and with involvement of the Alliance Managers, to achieve [***]Party Vote on any issue, such issue shall be referred to the Executives.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>JCC</b>. Each Party will discuss and attempt to
    resolve any potential or evolving disagreement related to the Commercialization Plan through their respective JPT members before it is brought before the JCC. Each Party&#8217;s designees on the JCC shall, collectively, have [***] Party Vote on all matters
    brought before the JCC. The JCC shall operate as to matters within its responsibility by [***] Party Vote. If during the Term the JCC is unable, after good faith efforts and with involvement of the Alliance Managers, to achieve [***] Party Vote on any
    issue, such issue shall be referred to the Executives.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">20</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Escalation</b>. If the Alliance Managers are
    unable to assist the JDC, JRC or JCC in resolving a dispute within [***] after the dispute is first referred to the Alliance Managers, or such longer period as the Parties may agree, either Party may elect to submit such issue to the Parties&#8217; executive
    officers as follows: (i) for a research or development-related issue, the issue shall be referred for resolution to a [***] for Immunocore (or a person in an equivalent position at Immunocore), and a [***] for GNE, or (ii) for a
    commercialization-related issue, the issue shall be referred for resolution to a [***] for Immunocore (or a person in an equivalent position at Immunocore), and a [***] for GNE. These executives are referred to collectively as the &#8220;<b>Executives</b>&#8221;.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Final Resolution</b>. In the event that the
    Executives are unable to resolve a given issue referred to them in accordance with Section 3.10.5 within [***] after the dispute is first referred to the Executives, then [***] shall have final decision making authority; provided, that: (i) [***] shall
    not be entitled to materially vary the scope of work covered by a Development Plan, Research Plan or Commercialization Plan and any associated agreed budget; and (ii) [***] shall have final decision making authority with regard to operational decisions
    with respect to the activities it carries out under the Pre-POC Development Plan, and also with regard to any decisions which relate to its responsibilities under Applicable Law as sponsor of any Clinical Trial. Neither the JDC, JRC, JCC nor either
    Party shall have the authority to amend or modify, or waive its own compliance with, this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Decision-Making Exceptions</b>. Notwithstanding
    the foregoing provisions of this Article 3, (i) if a Party reasonably and in good faith believes that there is a material safety issue with respect to a Licensed Product being used in a given Clinical Trial that is being conducted hereunder, then such
    Party shall have the right to require the other Party to suspend, and such other Party shall suspend as so required, such Clinical Trial (subject to the other Party&#8217;s obligation to comply with legal and regulatory requirements) until such safety issue
    is reasonably resolved, or (ii) if a Party reasonably and in good faith believes that a change to any Research Plan or a Development Plan is required in order for either Party to ensure compliance with Applicable Laws (or to satisfy a specific
    governmental authority request), then such Party shall notify the other Party thereof in writing, including a reasonably detailed description of such changes and requirements to comply with Applicable Law, and such changes shall thereafter be deemed to
    an amendment to the then-current plan; provided that the determination as to whether such changes are required to comply with Applicable Law or satisfy a governmental authority request shall be subject to Article 21.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">3.11<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Cessation of JDC, JRC and JCC</b>. In the event
    that Immunocore issues a Co-Funding Withdrawal Notice, (i) the JDC will continue to operate until the Parties agree otherwise, but in any event shall have no decision making role, shall meet no more often than [***] (unless otherwise agreed) and shall
    solely become a forum for information sharing under the Agreement; (ii) where a Research Program is continuing in accordance with Section 8.2.1, the JRC will continue to operate as provided in this Article 3 until such time that there are no continuing
    Research Programs; and (iii) the JPT and JCC will have no further responsibilities or authority under this Agreement and will be deemed dissolved by the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">21</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 4</b><br>
    <font style="text-transform: uppercase"><b>RESEARCH PROGRAM</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>In the event that a Party wishes to conduct research
    activities in relation to any MAGE-A4 Compound, any Enhanced MAGE-A4 Compound, any Other MAGE-A4 Compound, any Licensed Product and/or any Companion Diagnostic, the representatives of that Party shall propose such research activities to the JRC,
    provided that GNE shall not conduct any of the reserved activities described in Section 9.1.4 without the prior written consent of Immunocore. The Parties shall discuss at the JRC the proposed scope, objectives, budget and resource to be allocated to
    such research and shall in good faith consider whether to agree to collaborate on the performance of such research activities with such research budget. The Parties shall have sole discretion in considering, and deciding whether to collaborate on the
    performance of, such research activities and the commitment of such research budget.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Research Plan</b>. In the event that research
    activities are to be undertaken within the scope of Section 4.1, the JPT shall prepare and the JRC shall agree a comprehensive research plan for the proposed research activities setting out the research program of activities the Parties shall conduct
    within the budget agreed in Section 4.1 (&#8220;<b>Research Plan</b>&#8221;). The Research Plan shall include, among other things, (i) a detailed description of the research activities to be undertaken, estimated timelines, decision points and relevant decision
    criteria; (ii) allocation of responsibilities between the Parties for the various activities to be undertaken under the Research Plan taking into consideration all relevant factors (including the strategic objectives and capabilities of each Party),
    including estimated timelines; (iii) identification of the lead party with responsibility for the Research Plan; (iv) a budget for the Costs and expenses relating to the activities in the Research Plan (&#8220;<b>Research Budget</b>&#8221;); and (v) the allocation
    of each Party&#8217;s funding obligations within the Research Budget for all such activities; all based on what can reasonably be foreseen and planned at the time of preparation of the Research Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any matters under a Research Plan which the
    Parties through the JRC agree to undertake and which are not explicitly covered by this Agreement shall be overseen by the JRC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall use Diligent Efforts to
    undertake activities allocated to it under a Research Plan. Each Party shall comply with Applicable Laws applicable to the conduct and documentation of its activities under a Research Plan. Each Party shall, in performing such activities assign
    responsibilities to those portions of its organization that have the appropriate resources, expertise and responsibility for such obligations.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Each Party shall maintain records of research
    activities undertaken in accordance with this Article 4 in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party thereunder. All laboratory notebooks shall be
    maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the course of such research activities and for [***] thereafter. All such records of a Party shall be considered such
    Party&#8217;s Confidential Information. Each Party shall keep the JRC fully informed regarding the progress and results of research activities conducted under this Article 4, and shall provide to the other Party&#8217;s representatives on the JRC regular written
    summary update reports at each JRC meeting. Each Party will promptly respond to the other Party&#8217;s reasonable questions regarding any such reports, and shall provide updates on research activities from time-to-time as such other Party may reasonably
    request. Neither Party is required to generate</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">22</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">additional data or prepare additional reports to comply with the foregoing obligations.. All such reports, information and data provided by a Party
    shall be considered the providing Party&#8217;s Confidential Information.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that a Party elects in writing not
    to participate in a particular research program jointly, and the other Party elects to conduct such research at its sole discretion and expense, the Party conducting such research shall provide to the JRC a copy of the Research Plan describing such
    research that such Party intends to conduct and such Party shall keep the other Party informed of its progress, including an examination of experimental results against such Research Plan through the JRC.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that a Party, or the Parties
    jointly, wish to carry out research in relation to a variant, derivative or otherwise modified anti-CD3 Effector, the Parties shall discuss in good faith a Research Plan for such proposed research.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">4.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Research Term</b>. Any Research Program shall
    commence on the date on which the Research Plan is agreed by the JRC and shall continue, unless earlier terminated in accordance with Article 20, until the completion of all the tasks set out in the Research Plan (the &#8220;<b>Research Term</b>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 5</b><br>
    <font style="text-transform: uppercase"><b>DEVELOPMENT PROGRAM</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Each Party shall use Diligent Efforts to develop
    MAGE-A4 Compounds, Enhanced MAGE A4 Compounds, Other MAGE-A4 Compounds and Licensed Product(s) in the Field in the Territory, as further described in this Article 5. The Parties have initially selected IMCC103C as the lead MAGE-A4 Compound for
    development.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>General</b>. All development by the Parties of any
    MAGE-A4 Compound and Licensed Product shall be conducted pursuant to a comprehensive, worldwide Pre-POC Development Plan or Global Development Plan approved by the JDC. Each plan shall contain a detailed budget for the Costs of the activities to be
    carried out. Each Party shall comply with Applicable Laws applicable to the conduct and documentation of its activities under a Development Plan. Each Party shall, in performing such activities assign responsibilities to those portions of its
    organization that have the appropriate resources, expertise and responsibility for such obligations.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Pre-POC Development Plan</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The JPT shall prepare and implement a development
    plan for the relevant MAGE A4 Compound setting out the Pre-POC Development Program of activities the Parties shall conduct in the development of the relevant Compound through to the completion of the first Phase I Clinical Trial (&#8220;<b>Pre-POC
      Development Plan</b>&#8221;). The initial Pre-POC Development Plan is set out in <b>Exhibit C</b>. Such initial plan shall be reviewed and updated by the JDC within [***] of the Effective Date. The Pre-POC Development Budget shall be further updated when
    the Costs of each Party&#8217;s resources and all Third Party service providers to be used in carrying out the Clinical Trials have been agreed.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Pre-POC Development Plan shall include, among
    other things, [***] a budget for the Costs and expenses relating to the activities in the Pre-POC Development Plan (&#8220;<b>Pre-POC Development Budget</b>&#8221;), and [***]. The initial plan [***] is in Exhibit E. The Parties shall through the JDC, within [***]
    of the Effective Date, review and update such initial plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">23</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Pre-POC Development Plan shall provide for:
    (a) at least one arm of the first Phase I Clinical Trial being a combination of the MAGE-A4 Compound with Tecentriq (such arm of the Clinical Trial being the &#8220;<b>Tecentriq Combination Trial</b>&#8221;); and (b) any additional combination studies agreed to by
    the JDC in accordance with Section 3,10.2. The Parties shall negotiate in good faith to agree the terms of a clinical supply agreement, quality agreement and pharmacovigilance agreement: (a) in respect of the Tecentriq Combination Trial, within [***]
    of the Effective Date; and (b) in respect of any additional combination studies, within [***] of the approval of a Development Plan including such additional studies. Such combination trial agreements shall take into account, and accommodate, the data
    usage rights in Section 16.3 of this Agreement. In respect of a Tecentriq Combination Trial, GNE shall provide supply of Tecentriq.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Pre-POC Term</b>. The Pre-POC Development
    Program shall commence on the Effective Date and shall continue, unless earlier terminated in accordance with Article 20, until the completion of all the tasks set out in the Pre-POC Development Plan (the &#8220;<b>Pre-POC Term</b>&#8221;). In the event of a
    Change of Control of Immunocore during the Pre-POC Term, Immunocore shall continue to be responsible for its operational and co-funding obligations as stated in the Pre-POC Development Plan until the end of the Pre-POC Term.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Lead party</b>. Subject to Section 8.9,
    Immunocore shall be the lead party in respect of the activities in the Pre-POC Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Scope of Development Plans: Back-Ups Combinations
      and New Indications</b>. Both Parties shall have the right to propose to the JDC (a) the inclusion of the Back-Up Compound in the Development Plan; (b) additional non-clinical studies or Clinical Trials not then part of a Development Plan with
    respect to a Licensed Product; and (c) the expansion of development under a Development Plan to include any new indication(s) for a Licensed Product covered thereunder or new combinations (including concomitant or sequential therapy) of a Licensed
    Product for use with another pharmaceutical product. The Parties will discuss any such proposal in good faith and shall discuss and agree the revised terms applicable to any such proposal, The JDC shall also agree how such studies shall be funded and
    which Party shall take the lead in carrying out such studies.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Reporting</b>. Each Party shall keep the other
    Party fully informed regarding the progress and results of development activities for Licensed Products at regularly scheduled JPT and JDC meetings. The sponsor Party for a given Clinical Trial pursuant to a Development Plan shall provide the other
    Party with an electronic draft of the final draft study report for such Clinical Trial as soon as reasonably practicable after completion of the Clinical Trial, for such other Party to provide comments to the sponsor Party, which comments shall be
    provided within [***] of receipt of the draft of such final study report. The sponsor Party shall consider in good faith such comments and, at either Party&#8217;s reasonable request, the Parties shall meet in person or via teleconference within [***] after
    the sponsor Party&#8217;s receipt of such comments to discuss such comments in good faith. The sponsor Party shall provide the other Party with a final version of the final study report for a given study promptly following database lock of the results of
    such study and approval by such Party of such final study report. The sponsor of each Clinical Trial shall ensure that all patient authorizations and consents required under HIPAA, the EU General Data Protection Regulation or any other similar
    Applicable Law in connection with safety information from any sources, permit sharing of safety information by the Parties under this Agreement. Where safety information is received outside the conduct of a Clinical Trial by either Party, the receiving
    Party shall ensure that all patient authorizations and consents required under HIPAA, the EU General Data Protection</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">24</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Regulation or any other similar Applicable Law in connection with safety information from any sources, permit such sharing of safety information
    with the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Recalls</b>. The Parties&#8217; rights and obligations
    with respect to non-conformance, Licensed Product complaints, recalls and returns of the Licensed Product will be governed by, as and to the extent applicable, the supply and quality agreements and the Pharmacovigilance Agreement entered into pursuant
    to this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Global Development Plan</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Within [***] or at such earlier time as the
    Parties may agree, the JPT shall prepare and submit to the JDC for approval a global development plan for the Licensed Products setting out the program of activities in the development of the relevant Licensed Product through the preparation and filing
    of MAAs up to commercialization (&#8220;<b>Global Development Plan</b>&#8221;). The Costs and expenses relating to the activities in the Global Development Plan shall be governed by a development budget approved by the JDC and set forth in the Global Development
    Plan (&#8220;<b>Global Development Budget</b>&#8221;). The Global Development Budget shall be broken down by Clinical Trial or other activities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Global Development Plan shall include, among
    other things, [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Lead party</b>. Except as otherwise agreed
    between the Parties in the Global Development Plan, GNE shall be the lead party in respect of the activities in the Global Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">5.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Supply</b>. During the Pre-POC Term, (a) Immunocore
    shall be responsible for providing all clinical supplies of IMCC103C, whether itself or via a designated Third Party, required for carrying out the Pre-POC Development Plan, and (b) GNE shall be responsible for providing supply of Compound as drug
    product to enable timely start of Clinical Trials under the Global Development Plan (the latter being the &#8220;<b>Phase II Supply</b>&#8221;). Promptly following the end of the Pre-POC Term, or at such other time as the Parties agree, Immunocore shall use its
    Diligent Efforts to conduct a technology transfer process to as further specified in Article 10 to enable GNE to manufacture IMCC103C itself or via a Third Party for the purposes of carrying out the Global Development Plan. Thereafter, GNE shall be
    responsible, either itself or via a Third Party, for manufacture of IMCC103C and all other Licensed Products for clinical supplies in support of the Global Development Plan and for commercial supply worldwide. GNE shall use Diligent Efforts to assume
    responsibility for the supply of all Licensed Product for use in the Global Development Plan and Commercialization of Licensed Products. Notwithstanding the foregoing, the Parties may agree that Immunocore may manufacture and supply Licensed Product
    either itself or via a Third Party for the purposes of clinical supply for (i) the first batch of Licensed Product required for the Global Development Plan; and/or (ii) other activities to be carried out in the Global Development Plan, in each case on
    terms to be agreed. In the event Immunocore issues a Co-Funding Withdrawal Notice, then upon GNE achieving the milestone that triggers Event Payment 13.3.1(a), Immunocore shall invoice GNE for Immunocore&#8217;s share of the Phase II Supply cost and any
    Costs incurred under the plan attached at Exhibit E that are not specifically related to the Phase I Clinical Trial carried out under the Pre-POC Development Plan, and GNE shall reimburse Immunocore for such costs within [***] of achieving such
    milestone.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">25</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 6</b><br>
    <font style="text-transform: uppercase"><b>CO-FUNDING OF DEVEOPMENT</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Co-Funding of Development</b>. Subject to the
    remainder of this Article 6 and Article 8, the Parties shall co-fund the development of the Licensed Products (i) in respect of the Pre-POC Development Plan in accordance with the Pre-POC Development Budget and, (ii) provided Immunocore has not served
    GNE with a Co-Funding Withdrawal Notice, in respect of the Global Development Plan in accordance with the Global Development Budget. Each Party shall fund fifty percent (50%) of such Development Costs (&#8220;<b>Co-Funding</b>&#8221;).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Forecasting of Development Costs</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the Pre-POC Term, Immunocore shall provide
    to GNE consolidated non-binding forecasts of Development Costs in accordance with its regular internal forecasting processes. This shall include forecasting of the Development Budget for a given calendar year, regular variance updates to the then
    current calendar year forecast, and multi-year outlooks. The forecasting process shall commence with the first forecast cycle at Immunocore following the Effective Date and shall continue as long as there are forecasted Development Costs. Immunocore
    shall provide notice to GNE [***] prior to each forecast to request GNE&#8217;s forecast of Development Costs that GNE expects to incur in connection with activities under the Development Plan assigned to GNE in accordance with the relevant forecast period.
    GNE will provide the appropriate data within [***] of receipt of any such notice.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>After the Pre-POC Term, if Immunocore has not
    delivered a Co-Funding Withdrawal Notice, then GNE shall be responsible for forecasting of Development Costs and the aforementioned roles in Section 6.2.1 shall apply mutatis mutandis. If Immunocore has delivered a Co-Funding Withdrawal Notice, then
    the forecasting provisions of this Section 6.2 shall no longer apply.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Reporting Development Costs</b>. Within [***] after
    the end of each calendar quarter, each Party will provide the other Party with detailed, itemized accounting of the Development Costs incurred by it in undertaking its activities according to the relevant Development Plan, which report shall be
    itemized on a Clinical Trial-by-Clinical Trial basis in such quarter or in such other form as the Parties may mutually agree from time-to-time. In the event any activity under the Development Plan is performed by a Third Party (including any
    subcontracted Third Party), such Development Costs shall be the pass-through costs, [***], charged to the applicable Party by such Third Party. Such report shall specify in reasonable detail all amounts included in such Development Costs during such
    calendar quarter (broken down by activity), and any FTE Costs and out-of-pocket costs shall be allocated to the extent possible to a specific activity in the applicable Development Plan. Each such report shall enable the receiving Party to compare the
    reported Development Costs against the applicable Development Budget previously approved by the JDC, on both a quarterly basis and a cumulative basis for each activity. The Parties shall seek to resolve any questions related to such accounting
    statements within [***] following receipt by each Party of the other Party&#8217;s report hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.4<font style="font-family: Times New Roman,Times,serif; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Reconciliation</b>. Following such resolution, the
    Party preparing a forecast in accordance with Section 6.2 shall prepare a reconciliation report for the Development Costs under the Development Plan for such calendar quarter. Within [***] after the end of each calendar quarter, the Party having</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">26</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">paid more than its share of the Development Costs (on a cumulative basis) shall deliver to the other Party an invoice for amounts to be reimbursed
    by the other Party, and the other Party shall make a balancing payment in order to effect the sharing of Development Costs as set forth in this Section within [***] after its receipt of such invoice.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Exchange Rate</b>. For the purposes of calculating
    the Development Costs, the Parties&#8217; Development Costs will be converted from local currency to US Dollars in accordance with Section 14.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Overruns</b>. Each Party shall use Diligent Efforts
    to conduct the Development Plan for each Licensed Product within the applicable Development Budget. Each Party will promptly notify the other Party upon becoming aware that the anticipated Development Costs to be incurred by such Party for a given
    calendar year are likely to be in excess of the applicable portion of the Development Budget for that calendar year as set out in the relevant Development Plan. If during any calendar year, actual expenses exceed the Development Budget for such
    calendar year by [***], the Parties shall share such overspend equally. Development Costs reported by a Party pursuant to Section 6,3 incurred with respect to a Development Plan in excess of [***] of the aggregate amounts budgeted to be incurred by, or
    on behalf of, such Party for its activities under such Development Plan in such calendar year in the then-current applicable Development Budget shall be deemed &#8220;<b>Excess Costs</b>&#8221; and shall be treated as described in this Section 6.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Party that is primarily responsible for
    causing the Excess Costs shall provide the JDC an explanation therefor. If and to the extent that any such Excess Costs were directly related to any of the following, (each a &#8220;<b>Permissible Excess Costs</b>&#8221;), then, provided the applicable Party has
    promptly notified the other Party, through the JDC, of such overspend and used reasonable efforts to mitigate the size of such overspend, the Parties shall share any Permissible Excess Costs related to the following: [***]. To the extent that any
    Excess Costs do not represent Permissible Excess Costs, such Excess Costs shall be solely borne by the Party responsible for performing or causing to be performed such activities.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Discrepancy</b>. In the event that either Party has
    any questions or concerns regarding the Development Costs reported by the other Party it shall promptly notify the other Party and the Parties shall work together in good faith, including through involving any applicable committee, to resolve such
    questions and concerns within [***] after the end of each calendar quarter, In the event that a Party disagrees with, or identifies a discrepancy in, the Development Costs submitted by the other Party and the disagreement or discrepancy cannot be
    resolved or rectified between the Parties within a period of [***] of the matter being first raised by a Party, the Parties shall appoint an independent, internationally recognised accountant to review the alleged discrepancy. The costs of carrying out
    such review shall be borne by the Party requesting it unless the accountant finds a discrepancy in favour of the Party requesting of [***] in which case the other Party will bear the costs.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>FTE Records and Calculations</b>. Each Party shall
    record and account for its FTE effort to the extent that such FTE efforts are included in Development Costs or costs incurred in respect of any Research Plan that are shared under this Agreement. Each Party shall calculate and maintain records of FTE
    effort incurred by it in the same manner as used for other products Developed by such Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">27</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">6.9<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Research</b>. In the event that the Parties
    agree to conduct a Research Program pursuant to a Research Plan, the provisions of this Article 6 will apply <i>mutatis mutandis</i> with respect to such program.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 7</b><br>
    <font style="text-transform: uppercase"><b>CO-COMMERCIALIZATION</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Co-Commercialization</b>. Subject to the
    remainder of this Article 7 and provided Immunocore has not served GNE with a Co-Funding Withdrawal Notice in accordance with Article 8, the Parties shall have co-exclusive rights in, and joint responsibility for, the commercialization of the Licensed
    Products, in the Field in the Territory; provided, that GNE shall have the sole right to book sales in the Territory.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the period of [***], the Parties will
    negotiate in good faith the terms of an agreement for the co-promotion of the Licensed Products (&#8220;<b>Co-Promotion Agreement</b>&#8221;) throughout the Territory. Such negotiations and the allocation of costs, obligations, roles and responsibilities for the
    commercialization of Licensed Products and any Companion Diagnostics shall consider, amongst other things, GNE&#8217;s and Immunocore&#8217;s respective [***]. The Co-Promotion Agreement shall:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>include a detailed
    commercialization plan based on the Commercialization Plan agreed by the JCC, and budget;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>include a mechanism for
    implementing and monitoring the implementation of the Commercialization Plan, ensuring that the Parties use the same marketing materials (which shall be provided by GNE) and that activities thereunder are performed in accordance with the approved
    timelines and budgets;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>include provisions for sharing
    the agreed commercialization Costs in respect of the commercialization of the Licensed Product, with each Party funding fifty percent (50%) of such Costs; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">7.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>provide for the sharing of
    profits from commercialization of the Licensed Products, with each Party receiving fifty percent (50%) of such profits.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 8</b><br>
    <font style="text-transform: uppercase"><b>CO-FUNDING WITHDRAWAL NOTICE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore may, in its sole discretion, at any time
    during the period of [***], withdraw from its co-funding obligation by providing written notice to GNE (&#8220;<b>Co-Funding Withdrawal Notice</b>&#8221;). If Immunocore provides a Co-Funding Withdrawal Notice, subject to the terms of this Agreement, GNE would
    have sole discretion over matters relating to research, development, and commercialization of Licensed Products and the provisions of this Article 8 shall apply.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Research Programs</b>: If the Parties are
    carrying out a Research Plan(s) in accordance with Article 4 for which the Research Term is ongoing, Immunocore shall have the right, on a Research Program-by-Research Program basis, exercisable by notice in writing to GNE within [***], to withdraw
    from any such Research Program.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">28</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that Immunocore chooses not to
    withdraw from a Research Program, that Research Program shall continue until its completion in accordance with Article 4. For the avoidance of doubt, the activities under such continued Research Program on which the Parties have agreed to collaborate
    shall continue to be funded by the Parties equally.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that Immunocore notifies GNE that it
    is withdrawing from a Research Program, GNE shall have the option to continue such Research Program at its sole cost. For the avoidance of doubt, the ongoing activities under such Research Program shall be carried out as originally allocated between
    the Parties but at GNE&#8217;s sole cost. Should GNE choose not to take over the conduct of any such Research Program, the Research Program shall be discontinued.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Global Development and Commercialization</b>. GNE
    shall have the exclusive right either itself or via its designated Third Party to conduct the Global Development Plan and any further development and commercialization of any MAGE-A4 Compounds and/or Licensed Products and any associated Companion
    Diagnostics, and shall be solely responsible for all activities, responsibilities, steps, costs, expenses and charges associated therewith.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Immunocore shall be responsible for completing all its
    obligations under the Pre-POC Development Plan, including close-out of the Phase I Clinical Trial for IMCC103C, documentation of the results of such trial in a clinical study report, and transfer of all data arising from such trial to GNE required by
    GNE to continue to develop and commercialize Licensed Products. Immunocore&#8217;s obligation to share the Development Costs in accordance with Article 6 shall be limited to the Development Costs incurred in relation to the Pre-POC Development Program and
    Pre-POC Development Budget. Immunocore shall not have any obligation to bear any of the costs of carrying out the Global Development Plan and accordingly the Parties shall not enter into a Co-Promotion Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>For the avoidance of doubt, the data usage rights in
    Section 16.3.6 shall continue to apply; provided, that GNE shall only be obligated to supply a summary of all such preclinical data and clinical data for MAGE-A4 Compounds (or an Enhanced MAGE-A4 Compound) or any Other MAGE-A4 Compound to Immunocore as
    may be required for the purposes of Section 16.3.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Exclusive License and Payments</b>. Immunocore
    shall grant to GNE the exclusive license in Section 9.1.8 and GNE shall pay to Immunocore the sums specified in Sections 13.3 to 13.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Assistance</b>. Immunocore shall provide GNE with
    ongoing technical assistance related to the research, development and manufacturing of Licensed Products as reasonably requested by GNE. GNE shall reimburse Immunocore its direct costs and expenses and pay Immunocore for its FTE time and effort
    incurred in providing such technical assistance at Immunocore&#8217;s FTE rate for each applicable role/activity type, being such rate applicable at the time of provision for Immunocore&#8217;s provision of such services to Third Parties. Immunocore shall use
    reasonable efforts to provide the assistance under this Section as reasonably requested by GNE and in any event as soon as such resource can reasonably be made available.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Progress Reports</b>. GNE shall provide to
    Immunocore annual written progress reports in accordance with Section 12.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">8.9<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Change of Control</b>. In the event of a Change of
    Control of Immunocore during the Pre-POC Term, Immunocore shall notify GNE of the Change of Control as soon as reasonably practicable.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">29</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">GNE shall have the option to treat the Change of Control as a deemed Co-Funding Withdrawal Notice, effective as of the end of the Pre-POC Term.
    Should GNE wish to exercise such option, it shall do so by serving written notice on Immunocore with [***] of receipt of Immunocore&#8217;s notice of the Change of Control event or such longer time as the Parties may agree in writing. In the event that GNE
    exercises such option, the Pre-POC Development Program will continue until the end of the Pre-POC Term, in accordance with Section 5.3.4, at which time the deemed Co-Funding Withdrawal Notice shall become effective.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 9</b><br>
    <font style="text-transform: uppercase"><b>LICENSES AND OPTIONS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>License Grants</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Grant of License</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE hereby grants to Immunocore a non-exclusive
    right and license with the right to grant sublicenses (in accordance with Section 9.1.6 below), under GNE&#8217;s rights in GNE Background IP and GNE Foreground IP solely for the purpose of researching, developing, making, using, importing, selling and
    offering for sale Licensed Products and/or any Companion Diagnostic in the Field in the Territory during the Term.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE hereby grants to Immunocore a non-exclusive,
    worldwide, royalty-free right and license under GNE&#8217;s rights in any GNE Foreground Patents claiming the GNE Foreground Know-How conceived and reduced to practice during the Pre-POC Term and in the [***] period thereafter, solely for the purpose of
    researching, developing, making, having made, selling, supplying, using and importing ImmTACs (or products comprising ImmTACs) and for no other purposes. Subject to Section 9.1.6, such license shall include the right to grant sublicenses to Third
    Parties where such Third Parties have agreed to grant to Immunocore equivalent rights which are licensable to GNE (and its Sublicensees) in accordance with the terms of this Agreement. For clarity, such license does not include any right to
    manufacture, sell, supply, use or import any products which contain GNE&#8217;s CD3 Effector (including anti-CD3 antibodies, antigen-binding fragments thereof and other derivatives and variants) and also such license does not obligate GNE to provide any
    material or technology transfer to Immunocore or any Third Party. The grant of such license is subject to any Third Party agreement that GNE has entered prior to or on or after the Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to Section 9.1.2 and 9.1.4 below,
    Immunocore hereby grants to GNE:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a non-exclusive right and license with the
    right to grant sublicenses, under Immunocore&#8217;s rights in Immunocore Platform IP and Immunocore Foreground IP solely for the purpose of researching, developing, making, using, importing, selling and offering for sale Licensed Products and/or
    any-Companion Diagnostic in the Field in the Territory; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a co-exclusive with Immunocore right and
    license with the right to grant sublicenses, under Immunocore rights in Licensed Product IP solely for the purpose of researching, developing, making, using, importing, selling and offering for sale Licensed Products and/or any Companion Diagnostic in
    the Field in the Territory. &#8220;<b>Co-exclusive with Immunocore</b>&#8221; means that Immunocore shall retain all rights under the Licensed Product IP other than those licensed to GNE under this Section 9.1.1(c)(ii), and Immunocore covenants not to grant a
    license under such</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">30</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">retained rights to the Licensed Product IP to research, develop, make, have made, sell, have sold, import and use the Licensed Products and/or any
    Companion Diagnostic in the Field in the Territory to any Third Party except as permitted by this Agreement. In the event Immunocore issues a Co-Funding Withdrawal Notice, in accordance with Section 9.1.8, the license granted in this Section
    9.1.1(c)(ii) shall become an exclusive license to GNE of the Licensed Product IP, even as to Immunocore and its Affiliates.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Research</b>. Notwithstanding Section 9.1.1,
    unless and until Immunocore issues a Co-Funding Withdrawal Notice, GNE shall not be entitled to carry out research in relation to any MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds, Other MAGE-A4 Compounds, Licensed Products and/or any Companion
    Diagnostic in the Field in the Territory, except in accordance with a Research Plan entered in accordance with Article 4. For the avoidance of doubt, in the event that Immunocore issues a Co-Funding Withdrawal Notice, the restriction in this Section
    9.1.2 shall be eliminated and GNE shall be permitted to carry out such research subject to the terms of this Agreement, in particular, Section 9.1.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Use of Joint Foreground IP</b>. Notwithstanding
    Section 9.1.1, and subject to Section 9.1.4, each Party may exploit fully the Joint Foreground IP, in any field, and may grant licenses and sublicenses of the Joint Foreground IP without accounting to the other Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Reserved Activities</b>. The licenses and rights
    granted to GNE in Sections 9.1.1(c) and 9.1.3 shall not include any right under any Immunocore Platform IP or Licensed Product IP or Joint Foreground IP to:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>develop Compounds to any target other than the
    Target;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>develop Compounds outside of the Field;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>modify the complementarity determining regions of
    any TCR within any Licensed Product; or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>create any new TCR or Compound capable of binding
    to the Target (other than the Licensed Product resulting from performance of a Research Program or from performance of any CMC-related activities under this Agreement).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, unless and until Immunocore issues a Co-Funding Withdrawal Notice, the licenses and rights granted to GNE in Sections 9.1.1(c) and 9.1.3 shall not include
    any right under any Immunocore Platform IP, Licensed Product IP or Joint Foreground IP to modify, change or vary the complementarity determining regions of the Effector within any Licensed Product or the fusion of any TCR developed as part of a
    Research Program to an Effector other than that generated by Immunocore (other than for diagnostic labelling purposes reasonably necessary to enable manufacture, sale or supply of or obtaining Marketing Approval for such Licensed Product) including
    addition of additional Effectors.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The activities in this Section 9.1.4 are exclusively reserved to Immunocore and its Affiliates and licensees. Should GNE wish to request that Immunocore carry out any
    reserved activities, GNE may propose such reserved activities to Immunocore as research activities in accordance with Article 4. Notwithstanding anything to the contrary, in the event that Immunocore issues a Co-Funding</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">31</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Withdrawal Notice, the restrictions in this Section 9.1.4 with respect to Joint Foreground IP shall terminate automatically.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Covenant not to sue</b>. During the Term, unless
    and until a delivery by Immunocore to GNE of a Co-Funding Withdrawal Notice, GNE covenants for the benefit of Immunocore, its Sublicensees and their Controlled Affiliates, that it shall not, and it shall procure that GNE&#8217;s Sublicensees and their
    Controlled Affiliates shall not, anywhere in the Territory, institute (or in any way assist any Third Party in instituting or prosecuting), at law or in equity, any claim, demand, action or cause of action for damages, costs, expenses or compensation,
    or for an enjoinment, injunction, or any other equitable remedy, against Immunocore, its Sublicensees and their Controlled Affiliates alleging the infringement of any Patents or Know-How Covering CD3 Effector (including anti-CD3 antibodies,
    antigen-binding fragments thereof and other derivatives and variants) against Immunocore, its Sublicensees and their Controlled Affiliates with respect to any acts or activities they undertake in researching, developing, making, using, importing,
    selling and offering for sale Licensed Products and/or Companion Diagnostic in the Field in the Territory. For the avoidance of doubt, the covenant not to sue in this Section shall only apply to activities undertaken in relation to the Licensed
    Products and any Companion Diagnostics.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Sublicenses</b>. Each Party shall have the right
    to grant sublicenses to its Affiliates without the consent of the other Party, but otherwise shall only grant sublicenses to Third Parties under the licenses in Section 9.1.1 with the prior written consent of the other Party. Any sublicenses shall:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>be consistent with the terms and conditions of
    this Agreement, including terms as to the scope of the license and restrictions on the use of the licensed Intellectual Property, in particular in Section 9.1.4;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>be in writing;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>contain obligations on the Sublicensee equivalent
    to those set out in this Agreement as applicable; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>each Party shall continue to be responsible for
    all actions and omissions of any Sublicensee that it appoints including where such actions and omissions result in a breach of the terms of this Agreement. For clarity, no grant of any sublicense to a Third Party or an Affiliate shall relieve a Party
    of its obligations hereunder. For the avoidance of doubt, with respect to any activities carried out by an Affiliate as a sublicensee, GNE shall ensure that such Sublicensee complies with the terms of this Section 9.1.6.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>-Subcontracting</b>. During the Pre-POC Term,
    neither Party shall have the right to enter into subcontracts with Third Parties without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed. Thereafter, if Immunocore has provided a Co-Funding
    Withdrawal Notice, GNE shall not require Immunocore&#8217;s consent to enter into such subcontracts. Any subcontract agreement must be in writing, consistent with the terms and conditions of this Agreement, including the confidentiality provisions of Article
    16, and any rights granted to such subcontractor are restricted to only those rights necessary for performance by such subcontractor of the portions of work on behalf of the applicable Party. The subcontracting Party will remain responsible (at its
    cost) for all acts or omissions of any subcontractor it appoints (including</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">32</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">any acts or omissions which result in a breach of the terms of this Agreement) and shall ensure that each subcontractor complies with the terms and
    conditions of this Agreement. For the avoidance of doubt, with respect to any activities carried out on GNE&#8217;s behalf by an Affiliate, GNE shall ensure that such subcontracting activities comply with the terms of this Section 9.1.7.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.1.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Co-Funding Withdrawal Notice</b>. In the event
    that Immunocore issues a Co-Funding Withdrawal Notice, (a) the license granted by Immunocore under Section 9.1.1(c)(ii) shall become an exclusive license to GNE of the Licensed Product IP, even as to Immunocore and its Affiliates, (b) the license
    granted by GNE under Section 9.1.1(a) shall terminate. The remaining licenses and rights in this Article 9 shall remain in full force and effect.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>GNE Right of First Negotiation in Respect of Other
      HLA/MAGE-A4 Compound</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Option Grant to GNE</b>. If at any time during
    the Term, Immunocore discovers an Other HLA/MAGE-A4 Compound and Immunocore decides to grant rights to a Third Party to commercialise (including through co-promotion and/or co-marketing) such Other HLA/MAGE-A4 Compound, Immunocore hereby grants to GNE,
    on an Other HLA/MAGE-A4 Compound-by-Other HLA/MAGE-A4 Compound basis, the option to negotiate the right to commercialize such Other HLA/MAGE-A4 Compound (including in each case any derivatives or variants thereof), in parallel with any Third Party. For
    the avoidance of doubt nothing in this Section 9.2 shall prevent:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore from entering into an agreement
    regarding the conduct of a clinical combination trial in circumstances where no rights to commercialise Other HLA/MAGE-A4 Compound are granted to a Third Party;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore from entering into negotiations with
    Third Parties regarding the same Other HLA/MAGE-A4 Compound at the same time as Immunocore is negotiating with GNE pursuant to this Section 9.2 regarding such Other HLA/MAGE-A4 Compound provided that no agreement is signed with a Third Party prior to
    the end of the period of negotiation granted to GNE pursuant to Section 9.2.3 and subject to the terms of Section 9.2.3.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Notice to GNE</b>. Immunocore shall give notice
    in writing to GNE of its decision to seek and/or accept from a Third Party the right (including without limitation any option, license or other right to acquire the right) to commercialise Other HLA/MAGE-A4 Compound. In conjunction with such notice,
    Immunocore shall provide to GNE the Initial Data Package for such Other HLA/MAGE-A4 Compound. Following receipt of such notice from Immunocore, GNE shall have [***] within which to notify Immunocore in writing whether it wishes to be granted the right
    to commercialise such Other HLA/MAGE-A4 Compound. If GNE notifies Immunocore in writing prior to the end of such period, that it wishes to be granted the right to commercialise such Licensed Products then Immunocore shall provide to GNE the Full Data
    Package for such Licensed Products.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Exercise of an Option</b>. If GNE notifies
    Immunocore that it wishes to be granted such rights, the Parties shall negotiate in good faith for a period of [***] from (a) the delivery of the Full Data Package to GNE, or (b) such longer period as the Parties may agree, the terms under which GNE
    shall be granted such rights. If at the end of such period the Parties have not agreed on the terms of such rights, Immunocore may at any time within [***] from the last day of the [***] negotiation period referred to above, and to any Third Party,
    grant such rights to commercialise the Other HLA/MAGE-A4 Compound under a written agreement (each a &#8220;<b>Third Party Agreement</b>&#8221;). If</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">33</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">Immunocore has not signed a definitive agreement relating to a Third Party Agreement by the date [***] from the last day of the [***] negotiation
    period referred to above (or if such negotiation period is extended by the Parties, from the date that the Parties terminate negotiations) then the provisions of this Section 9.2 shall re-apply and before entering into any Third Party Agreement
    Immunocore must serve a further notice under Section 9.2.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Expiration of Option</b>. The options granted
    to GNE under this Section 9.2 shall expire upon the First Commercial Sale of an Other HLA/MAGE-A4 Compound against such Target.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.2.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Funding of Development and
      Commercialisation of Other HLA/MAGE-A4 Compounds</b>. For the avoidance of any doubt the obligations under Section 9.2 shall not preclude Immunocore from seeking funding from Third Parties in respect of the development or commercialisation of Other
    HLA/MAGE-A4 Compounds; provided that Immunocore (i) does not grant such Third Party the option, right or license to develop (except as permitted pursuant to Section 9.2.1) and/or commercialise any one Other HLA/MAGE-A4 Compound, multiple Other
    HLA/MAGE-A4 Compounds, or all the Other HLA/MAGE-A4 Compounds; and (ii) Immunocore remains responsible for such development and commercialisation.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">9.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>No Additional Licenses</b>. Except as expressly
    provided in this Agreement, nothing in this Agreement shall grant either Party any right, title or interest in and to the Know-How, Patents or other intellectual property rights of the other Party (either expressly or by implication or estoppel),</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 10</b><br>
    <font style="text-transform: uppercase"><b>MATERIALS AND TECHNOLOGY TRANSFER</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Technology Transfer</b>. As part of the research,
    development and manufacturing of Licensed Products, Immunocore will assist GNE in establishing a CMC supply chain and will allow and enable GNE to work with Immunocore&#8217;s designated CMOs. Unless requested otherwise, Immunocore will (and save as provided
    below) transfer the assay development, manufacturing know-how and GMP manufacture to GNE (or its designated CMO) and will provide technical training sufficient to enable GNE (or its designated CMO) to use such manufacturing know-how to make Compounds,
    as further specified in <b>Exhibit F</b>. GNE shall be responsible for GMP manufacture via GNE&#8217;s internal facilities or Immunocore&#8217;s CMOs. As used herein, &#8220;CMO&#8221; means a Third Party with which a Party has contracted to conduct manufacturing (including
    without limitation, process development and scale-up) of Compounds on behalf of such Party. It is understood and agreed that any costs incurred by Immunocore in providing assistance, transfer and technical training in accordance with this Article 10
    shall be shared by the Parties in [***], provided that GNE shall reimburse Immunocore for its share of such costs if Immunocore issues a Co-Funding Withdrawal Notice. Immunocore shall use reasonable efforts to provide the assistance under this Section
    10.1 as reasonably requested by GNE and in any event as soon as such resource can reasonably be made available. Notwithstanding the foregoing, Immunocore shall not be required to provide more than [***] of Immunocore time and effort in relation to the
    carrying out of activities in accordance with this Section 10.1. Any additional time and effort that is required shall be provided as assistance in accordance with Section 8.7.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Manufacturing and Supply Agreement</b>. If a
    manufacturing and supply agreement (&#8220;<b>MSA</b>&#8221;) is required with regard to the supply of Licensed Product for the Development Program, the Parties shall negotiate and agree in good faith the terms of such agreement. The Parties shall also enter into
    a separate Quality Assurance Agreement (&#8220;<b>QAA</b>&#8221;) that shall define the manufacturing and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">34</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">supply quality responsibilities of the Parties. The QAA shall further include provisions obligating the manufacturing Party to report to the other
    any regulatory compliance issues with its suppliers as well as any critical quality non-conformances relating to the Compound. The MSA and the QAA shall be negotiated in good faith between the Parties and be executed within [***] following the
    Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">10.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Materials</b>. Each Party shall use Diligent
    Efforts to provide the other Party with the tangible materials and other deliverables for which it has responsibility under any Research Plan and the Development Plans (collectively, the &#8220;<b>Materials</b>&#8221;). The MC shall determine the specific format
    and timeline for the transfer of such Materials.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font> In the event that it becomes reasonably necessary
    for one Party to provide the other Party with tangible research or biological Materials (other than a Licensed Product for clinical or commercial use) in connection with the performance of activities hereunder, the Parties may enter into an appropriate
    material transfer agreement related thereto, which agreement will be subject to this Agreement and will be interpreted in a manner consistent with the terms hereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>With respect to the Materials provided by one Party
    to another Party pursuant to this Article 10, each Party shall have the right to use such Materials for the activities under any Research Plan and the Development Plans and to exercise the rights granted to such Party pursuant to Article 9. Subject to
    the foregoing, all such Materials (1) shall be used by a Party only in accordance with the terms and conditions of this Agreement, (ii) shall not be used or delivered by a Party to or for the benefit of any Third Party except as expressly provided for
    herein, and (iii) shall be used by a Party in compliance with all Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 11</b><br>
    <font style="text-transform: uppercase"><b>REGULATORY</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Immunocore shall be the sponsor of the Clinical Trials
    set out in the initial Pre-POC Development Plan. The Parties shall agree in the JDC which Party shall be the sponsor of any additional Clinical Trials that the Parties agree to conduct pursuant to any agreed amendment to the Pre-POC Development Plan.
    All other INDs, MAAs and Regulatory Approvals for Licensed Products will be prepared, filed and owned by GNE, unless otherwise agreed and stated in the Global Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>During the Pre-POC Term</b>. Immunocore shall be
    responsible for preparing and submitting regulatory documentation for IMCC103C during the Pre-POC Term. GNE shall support Immunocore, as may be reasonably necessary, in preparing and submitting, obtaining such regulatory documentation, and in the
    activities in support thereof, including providing information, documents or other materials required by Applicable Law for inclusion in or in support of regulatory documentation, in each case in accordance with the terms and conditions of this
    Agreement and the Pre-POC Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Regulatory Correspondence</b>. Immunocore shall
    promptly provide to GNE copies of any material documents or other correspondence received from a regulatory authority pertaining to the Pre-POC Development Plan or safety for IMCC103C, including, but not limited to, all IND amendments, regulatory
    authority meeting requests, and regulatory authority advice (including scientific advisory packages). Immunocore shall provide GNE access to a draft of all such regulatory</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">35</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">documents sufficiently in advance of the intended submission dates via the access methods (such as secure databases) established by the JPT, to enable
    GNE to review and provide comments to Immunocore concerning the content thereof. Immunocore shall consider in good faith any such GNE comments.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Regulatory Correspondence Related to
      Manufacturing</b>. Immunocore shall immediately and within [***] notify GNE in writing of, and shall provide GNE with copies of, any correspondence and other documentation received or prepared by Immunocore in connection with any of the following
    events: (a) receipt of a regulatory letter, warning letter, Form 483 (Inspectional Observations) or similar item, from the FDA or any other regulatory authority directed to the manufacture of IMCC103C or in connection with any general cGMP inspections
    applicable to the manufacturing facility; and (b) receipt of a regulatory letter, warning letter or similar item from the FDA or any other regulatory authority directed to or any regulatory comments related to IMCC103C where the comments relate or are
    attributable to any manufacturing, testing, packaging, storage or distribution activities by or on behalf of Immunocore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Meetings with Regulatory Authorities</b>.
    Immunocore shall provide GNE with prior written notice of any material scheduled meeting, conference, or discussion (including any advisory committee meeting) with a regulatory authority relating to IMCC103C, within [***] after Immunocore first
    receives notice of the scheduling of such meeting (or within such shorter period as may be necessary in order to give GNE a reasonable opportunity to attend such meeting). GNE shall have the right to attend as an observer all such meetings, to the
    extent permitted by Applicable Law. In addition, GNE may participate in any preparatory pre-meetings held prior to a regulatory authority meeting.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Adverse Event Reports</b>. Immunocore shall be
    responsible for investigating adverse events and other required safety information associated with the use of IMCC103C. Immunocore shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse events
    in accordance with Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">11.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>After the Pre-POC Term</b>. Upon completion of the
    Pre-POC Term, Immunocore shall transfer the IND for IMCC103C to GNE, and GNE shall thereafter be solely responsible for preparing and submitting regulatory documentation for IMCC103C and all other Licensed Products. Immunocore shall support GNE, as may
    be reasonably necessary or appropriate, in obtaining Regulatory Approval for all Licensed Products, including providing necessary documents or other materials required by Applicable Law to obtain Regulatory Approvals, in each case in accordance with
    the terms and conditions of this Agreement and the Global Development Plan.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Regulatory Correspondence</b>. In the event
    Immunocore has not issued a Co-Funding Withdrawal Notice, GNE shall promptly provide to Immunocore copies of any material documents or other correspondence received from a regulatory authority pertaining to the Global Development Plan or safety for
    Licensed Products, including, but not limited to, all IND amendments, regulatory authority meeting requests, regulatory authority advice (including scientific advisory packages), and core data sheets. GNE shall provide Immunocore access to a draft of
    all such regulatory documents sufficiently in advance of the intended submission dates, via the access methods (such as secure databases) established by the JPT, to enable Immunocore to review and provide comments to GNE concerning the content thereof.
    GNE shall consider in good faith any such Immunocore comments.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">36</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Meetings with Regulatory Authorities</b>. In the
    event Immunocore has not issued a Co-Funding Withdrawal Notice, GNE shall provide Immunocore with prior written notice of any material scheduled meeting, conference, or discussion (including any advisory committee meeting) with a regulatory authority
    relating to Licensed Products, within [***] after GNE first receives notice of the scheduling of such meeting (or within such. shorter period as may be necessary in order to give Immunocore a reasonable opportunity to attend such meeting). Immunocore
    shall have the right to attend as an observer all such meetings, to the extent permitted by Applicable Law. In addition, Immunocore may participate in any preparatory pre-meetings held prior to a regulatory authority meeting.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Adverse Event Reports</b>. GNE shall be
    responsible for investigating adverse events and other required safety information associated with the use of Licensed Products. GNE shall be responsible for the collection, review, assessment, tracking and filing of information related to adverse
    events in accordance with. Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 12</b><br>
    <font style="text-transform: uppercase"><b>DILIGENCE</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Development and Commercialisation of Licensed
      Products</b>. As between GNE and Immunocore, with effect from the Effective Date, the Parties agree to use Diligent Efforts to research and develop and commercialize at least one Licensed Product within the Field in the Territory. In the event of
    Immunocore issuing a Co-Funding Withdrawal Notice, Immunocore&#8217;s diligence obligations under this Article 12 shall be limited to the activities allocated to it in accordance with the Pre-POC Development Plan and the provisions of Article 8. GNE shall
    continue to use Diligent Efforts to research, develop and commercialize at least one Licensed Product within the Field in the Territory following such Co-Funding Withdrawal Notice.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">12.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Progress Reports</b>. Following Immunocore&#8217;s
    service of a Co-Funding Withdrawal Notice and continuing thereafter until First Commercial Sale anywhere in the Territory, GNE shall provide to Immunocore, on or before each [***] of such Co-Funding Withdrawal Notice or on such other date as the
    Parties may agree, an [***] written report summarizing GNE&#8217;s progress in the research, development and commercialization of the Licensed Products in the [***], [***]; such [***] written report to provide Immunocore during the Term with information
    reasonably necessary to determine GNE&#8217;s progress in developing and commercializing a Licensed Product, including [***]. Immunocore may address questions on the [***] reports to the Alliance Managers following receipt of such written reports or may
    raise such questions for discussion at meetings of the JDC. Additionally, GNE shall provide to Immunocore [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 13</b><br>
    <font style="text-transform: uppercase"><b>FINANCIAL TERMS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Upfront fee and Near-Term Milestone</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Upfront fee</b>. Within fifteen (15) Business
    Days of the Effective Date of this Agreement, GNE shall pay to Immunocore a one-time non-refundable irrevocable fee of Fifty Million US Dollars ($50,000,000).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>IND Filing</b>. Upon filing of the IND for the
    first Clinical Trial to be carried out under the Pre-POC Development Plan, GNE shall pay to Immunocore a one-time non-refundable</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">37</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">irrevocable Event Payment of Fifty Million US Dollars ($50,000,000). GNE shall pay Immunocore the Event Payment within [***] of receipt of an invoice
    from Immunocore with respect thereto.]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Consideration in the event of Co-Funding Withdrawal
      Notice</b>. In the event Immunocore issues a Co-Funding Withdrawal Notice, in consideration of the exclusive license granted to GNE in Section 9.1.8, the following milestones and royalties in Sections 13.3 to 13.5 shall be payable by GNE to
    Immunocore in respect of the development and commercialization of any Licensed Product containing IMCC103C and/or the Back-Up Compound and/or any Enhanced MAGE-A4 Compound. Payments of milestones and royalties in respect of Licensed Products containing
    any Other MAGE-A4 Compound shall be made in accordance with the provisions of Exhibit G. For clarity: (i) no payment shall be due in accordance with this Article 13 in respect of Licensed Products containing: (a) derivatives or variants of IMCC103C
    (except for the variant described in the definition of &#8220;MAGE-A4 Compound&#8221;), (b) derivatives or variants of Back-Up Compound (except for the variant described in the definition of &#8220;MAGE-A4 Compound&#8221;), (c) derivatives or variants of any Enhanced MAGE-A4
    Compound, or (d) derivatives or variants of any Other MAGE-A4 Compound. For further clarity any such derivatives and variants shall be Other MAGE-A4 Compounds and shall be subject to the terms of Exhibit G.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Development and Commercial Event Payments</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Development Milestones</b>. Subject to Section
    13.3.2, GNE shall pay Immunocore the following one-time Event Payments upon the first achievement of the following Events in any given Indication. In the event that multiple Licensed Products are in Development, the relevant Event Payment shall be
    payable in respect of the first Licensed Product to achieve that Event.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.6pt; text-align: justify"><b>Event</b></td>
        <td colspan="3" style="vertical-align: top; text-align: center"><b>Event Payment (US$)</b></td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.6pt; text-align: justify">&#160;</td>
        <td colspan="3" style="vertical-align: top; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td style="width: 8%">&#160;</td>
        <td style="vertical-align: top; width: 38%; text-align: center">&#160;</td>
        <td style="vertical-align: top; width: 18%; text-align: center"><b>1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Indication</b></td>
        <td style="vertical-align: top; width: 19%; text-align: center"><b>2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Indication</b></td>
        <td style="vertical-align: top; width: 17%; text-align: center"><b>3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> Indication</b></td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; text-align: center">&#160;</td>
        <td style="vertical-align: top; text-align: center">&#160;</td>
        <td style="vertical-align: top; text-align: center">&#160;</td>
        <td style="vertical-align: top; text-align: center">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
        <td style="vertical-align: top; text-align: right">[***]</td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td style="vertical-align: top; padding-left: 35.05pt; text-indent: -0.25in; text-align: left">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
        <td style="vertical-align: top; text-align: right">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="text-align: justify"><b>Total Potential Event Payments:</b></td>
        <td style="text-align: right"><b>[***]</b></td>
        <td style="text-align: right"><b>[***]</b></td>
        <td style="text-align: right"><b>[***]</b></td>
      </tr>
      <tr>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Section 13.3, &#8220;<b>Indication</b>&#8221; means the intended use of a Licensed Product for either therapeutic treatment or for the prevention of a distinct illness,
    sickness, interruption, cessation or disorder of a</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">38</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">particular bodily function, system, tissue type or organ, or sign or symptom of any such items or conditions, regardless of the severity, frequency or route of any
    treatment, treatment regimen, dosage strength or patient class, for which Regulatory Approval is being sought and which will be referenced on any Licensed Product labelling in any country. For clarity, label extensions (including without limitation
    front-line, metastatic, adjuvant, etc.) shall not be deemed to be separate Indications.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;">13.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Certain Terms</b>. It is
    understood and agreed that the following terms shall apply to the Events achieved under Section 13.3.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Payments under Section 13.3.1 shall be due only
    once for each Licensed Product in the first three Indications to achieve such Event for such Indication.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Payments shall be due under Section 13.3.1 by GNE
    regardless of whether it is GNE itself that meets the Event (as defined in the table in Section 13.3.1) or where such Event is met through the actions of any Affiliate of GNE or Sublicensee. GNE shall procure that any Sublicensee agrees to notify GNE
    immediately on any Event being met by such Sublicensee.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For the avoidance of doubt, GNE&#8217;s (including where
    such obligation arises as a result of actions by any Sublicensee) cumulative obligation under Section 13.3.1 with respect to the:(i) first Licensed Product in the first Indication shall in no event exceed [***]; (ii) first Licensed Product in the
    second Indication shall in no event exceed [***]; and (iii) first Licensed Product in the third Indication shall in no event exceed [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If, for any reason, a particular Event specified
    in Section 13.3.1 is achieved without one or more preceding Events having been achieved, then upon the achievement of such Event, both the Event Payment applicable to such achieved Event and the Event Payment(s) applicable to such preceding unachieved
    Event(s) shall be due and payable. [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If any Event is merged or combined with any other
    Event, for example [***], the Event shall be achieved when it starts or could reasonably be assumed to have been achieved such as, as part of a regulatory plan. For example, [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding the payment obligations set forth
    in Section 13.3.1 above, Event Payments shall only be due under Section 13.3.1(b) if the Licensed Product that achieves such Event is Covered by a Valid Claim [***] at the time of achievement of such Event; provided, if no Valid Claim [***] Covers the
    Licensed Product at the time of achievement of the Event in Section 13.3.1(b), such Event Payment shall be accrued at the time of such achievement, but shall not be due and payable unless and until such time as there is a Valid Claim [***] Covering
    such Licensed Product. Notwithstanding the payment obligations set forth in Section 13.3.1 above, Event Payments shall only be due under Section 13.3.1 (c), (d), (e) (f), (g), or (h), if the Licensed Product that achieves such Event is Covered by a
    Valid Claim in the territory in which such Event is achieved and at the time of achievement of such Event; provided, if no Valid Claim in such territory Covers the Licensed Product at the time of achievement of the Event in Section 13.3.1 (c), (d), (e)
    (f), (g), or (h), such Event Payment shall be accrued at the time of such achievement, but shall not be due and payable unless and until such time as there is a Valid Claim in the territory in which such Event is achieved Covering such Licensed
    Product. Any obligation to accrue payments under this Section shall cease once all patent applications Covering the relevant Licensed Product existing at the date of the Event in Section 13.3.1(b), (c), (d), (e) (f), (g), or (h) and which if issued
    would constitute a Valid Claim</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">39</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">have either lapsed, been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of
    competent jurisdiction, unappealed or appealed within the time allowed for appeal.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>For the purposes of Section 13.3.1, the first
    Licensed Product shall mean the first Licensed Product to achieve the relevant Event set out in Section 13.3.1 and shall not mean the first Licensed Product for which there is a First Commercial Sale.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Notice of Achievement; Timing of Payment</b>.
    With respect to each Event referred to in Section 13.3.1, GNE shall inform Immunocore within [***] of the achievement of such Event (whether such Event is achieved by GNE or its Sublicensees). GNE shall pay Immunocore the respective accrued and payable
    Event Payment within [***] of receipt of an invoice from Immunocore with respect thereto.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Companion Diagnostic Event Payment</b>. In
    addition to those Event Payments referred to in Section 13.3.1, GNE shall pay Immunocore, on a Companion Diagnostic-by-Companion Diagnostic basis, a one-time Event Payment of [***]. Payments shall be due under this Section by GNE regardless of whether
    it is GNE itself that meets the Event or where such Event is met through the actions of any Affiliate or Sublicensee. GNE shall procure that any Sublicensee agrees to notify GNE immediately on any Event being met by such Sublicensee. In the event that
    the Parties develop a Companion Diagnostic [***], the Parties shall agree in good faith commercial terms for such Companion Diagnostic. For purposes of determining whether the aforementioned payment is due, [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Net Sales Event Payments</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Net Sales Events</b>. GNE shall pay Immunocore
    the following one-time Milestone Payments per Licensed Product upon each Licensed Product achieving the following Net Sales Events (whether such achievement is by GNE or its Sublicensees):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 71%; text-align: center"><b>Net Sales Event</b></td>
        <td style="width: 29%; text-align: center"><b>Milestone payment </b><br>
          <b>(in US Dollars)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: center">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">[***]</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 35.05pt; text-indent: -35.05pt; text-align: justify">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify"><b>Total Potential Net Sales Event Payments:</b></td>
        <td style="text-align: center"><b>[***]</b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Milestone Payments under this Section 13.4.1 shall be due only once for the first Licensed Product containing MAGE-A4 Compound and/or any Enhanced MAGE-A4 Compound.
    For the avoidance</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">40</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">of doubt, GNE&#8217;s and its Affiliates and Sublicensees&#8217; cumulative obligation under this Section 13.4.1 shall in no event exceed [***]. Notwithstanding the payment
    obligations set forth in Section 13.4.1 above, Net Sales Event Payments shall only be due under Section 13.4.1 if the Licensed Product that achieves such Net Sales Event is Covered by a Valid Claim [***] at the time of achievement of such Net Sales
    Event.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.4.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Notice of Achievement; Payment</b>. With respect
    to each event listed in Section 13.4.1 above, GNE shall promptly (and in any event within [***] of such Net Sales Event being met) inform Immunocore following the achievement of such event by either GNE or its Sublicensees. On or after Immunocore&#8217;s
    receipt of such notice of achievement, Immunocore shall submit a written invoice to GNE for the corresponding Milestone Payment. Each such invoice shall specify the applicable Net Sales Event, and shall be payable within [***] of receipt of an invoice
    from Immunocore with respect thereto. To the extent GNE elects to have Immunocore send an invoice to an address other than that specified in Section 22.2, GNE shall provide written notice to Immunocore thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">13.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Royalty Payments for Licensed Products</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Valid Claim Products</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall pay Immunocore, on a Licensed
    Product-by-Licensed Product and country-by-country basis, and subject to the terms of Sections 13.5.2 through 13.5.7, the following royalties on annual worldwide aggregate Net Sales of a Licensed Products sold by GNE or its Sublicensees, which at the
    time of sale or supply, are Covered by a Valid Claim in the country in which such Licensed Product is sold:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 70%; border-bottom: Black 1pt solid; text-align: center"><b>Annual Aggregate Worldwide Net Sales (in US Dollars)</b></td>
        <td style="width: 30%; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 10pt"><b>Tiered Royalty Rate <br>
            Percentage</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">Up to [***]:</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">Portion greater than [***]:</td>
        <td style="text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: left">&#160;</td>
        <td style="text-align: center">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The royalties in the table in Section 13.5.1(a)
    above shall be payable on annual aggregate worldwide Net Sales of Licensed Products containing MAGE-A4 Compound and/or any Enhanced MAGE-A4 Compound which at the time of sale or supply, are Covered by a Valid Claim in the country in which such Licensed
    Product is sold.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Valid Platform Claim Products</b>. If in any
    calendar quarter, the sale of a Licensed Product that contains MAGE-A4 Compound or any Enhanced MAGE-A4 Compound is not Covered by a Valid Claim in the country in which such Licensed Product is sold, but is Covered by a Valid Platform Claim in the
    country in which such Licensed Product is sold, then GNE shall pay to Immunocore, on, a Licensed Product-by-Licensed Product and country-by-country basis, and subject</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">41</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">to the terms of Section 13.5.4 through 13.5.6, a royalty equivalent to [***] of the amounts specified in Section 13.5.1 [***] on annual aggregate
    worldwide Net Sales of such Licensed Product.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Know-Bow Products</b>. If in any calendar
    quarter, the sale of a Licensed Product that contains MAGE-A4 Compound and/or any Enhanced MAGE-A4 Compound is not Covered by a Valid Claim in the country in which such Licensed Product is sold, then GNE shall pay to Immunocore, on a Licensed
    Product-by-Licensed Product and country-by-country basis, and subject to the terms of Section 13.5.4 through 13.5.6, a royalty equivalent to [***] of the amounts specified in Section 13.5.1 on annual aggregate worldwide Net Sales of such Licensed
    Product.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Payment Offsets:</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Third Party Payments.</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Immunocore</b>. Immunocore shall continue
    to have the obligation to make payments owed under written agreements entered into by Immunocore with Third Parties which relate to any Licensed Product, as of the Effective Date or during the Term.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GNE</b>. Subject to 15.6, if, after the
    Effective Date, GNE or its Sublicensees obtains a right or license under any intellectual property of a Third Party, where the making, using, selling, offering for sale, or importing of a Licensed Product by GNE or its Sublicensee would in the absence
    of such right or license infringe the intellectual property of a Third Party, then GNE may offset the payments due and payable to Immunocore with respect to such Licensed Product by the amount of payments paid by GNE or its Sublicensee to such Third
    Party for such right or license; provided, that in no event shall such reductions reduce the payments owed to Immunocore for such Licensed Product by [***] of what would otherwise be owed by GNE or its Sublicensee to Immunocore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Biosimilar</b>. Following the first commercial
    sale of a Biosimilar in a country and:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such Biosimilar is Covered by a Valid Claim
    [***] Covering the Licensed Product in such country, and [***], no royalty reduction may be made under this Section 13.5.4(b);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such Biosimilar is Covered by a Valid Claim
    [***] in such country, and [***], and where [***], the royalties due and payable by GNE hereunder shall be reduced by [***] in such country;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such Biosimilar is Covered by a Valid Claim in
    such country, and [***], and where [***], the royalties due and payable by GNE hereunder shall be reduced by [***] in such country; or14</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>such Biosimilar is not Covered by a Valid Claim
    in such country, the royalties due and payable by GNE or its Sublicensee hereunder shall be reduced by [***] in such country [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>The reduction in royalties under Section
    13.5.4(b)(ii) and 13.5.4(b)(iii) shall only apply during the period of time that [***] in such country. For the purpose of this Section</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">42</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">13.5.4(c), [***]. As used herein, &#8220;<b>Biosimilar</b>&#8221; means any drug or biological product that is interchangeable directly with any Licensed Product
    and which is subject to review under an abbreviated approval pathway as a biosimilar, follow-on biologic or generic biological product, as those terms are commonly understood under the FD&amp;C Act or the PHS Act and related rules and regulations, or
    the corresponding or similar laws, rules and regulations of any other jurisdiction and (1) where such Biosimilar obtains Regulatory Approval or is otherwise sold by a Third Party that is not GNE or a Sublicensee; and (2) where GNE or its Sublicensees
    have not directly authorised or permitted such Third Party to market, manufacture and sell such product in the market in question.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The cumulative reduction made under Sections
    13.5.4 (a), 13.5.4(b)(ii) and 13.5.4(b)(iii) in a country shall not exceed a total of [***] of what would otherwise be owed by GNE to Immunocore in accordance with Sections 13.5.1 through 13.5.3 in such country.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Single Royalty</b>. No more than one royalty
    payment shall be due under this Section 13.5 with respect to a sale of a particular Licensed Product. For the avoidance of doubt: (a) multiple royalties shall not be payable because the sale of a particular Licensed Product is Covered by more than one
    (1) Valid Claim in the country in which such Licensed Product is sold; and (b) in no event shall GNE and/or its Affiliates or Sublicensees be obligated to simultaneously pay (i) a royalty under Section 13.5.1 with respect to a sale of a particular
    Licensed Product that is subject to Section 13.5.2 or Section 13.5.3, or (ii) a royalty under Section 13.5.2 with respect to a sale of a particular Licensed Product that is subject to Section 13.5.3,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Royalty Term</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The royalty obligations set forth in Sections
    13.5.1 and 13.5.2 above will commence on a country-by-country basis upon the First Commercial Sale of any Licensed Product, and expire on a country-by-country basis upon the expiration of the last to expire Patent containing a Valid Claim or Valid
    Platform Claim, as the case may be, which Covers the sale of such Licensed Product in such country. For clarity, if the last Valid Claim or Valid Platform Claim, as the case may be, Covering the sale of a Licensed Product in a particular country
    expires prior to the [***] anniversary of the date of First Commercial Sale of such Licensed Product in such country, royalties shall continue to be payable on the sales of such Licensed Product in such country pursuant to Section 13.5.3 at the rates
    set forth therein until the [***] anniversary of the date of First Commercial Sale of such Licensed Product in such country.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The royalty obligations set forth in Section
    13.5.3 will commence on a country-by-country basis upon the First Commercial Sale of any Licensed Product, and expire on a country-by-country basis upon the earlier of (i) the [***] anniversary of the date of First Commercial Sale of such Licensed
    Product in such country; or (ii) such time as such Licensed Product is Covered by a Valid Claim or Valid Platform Claim, as the case may be, in such country, in which case such Licensed Product shall be subject to the royalty term set forth in Section
    13.5.6(a) above. For clarity, in the case of a Licensed Product for which a Valid Claim or Valid Platform Claim, as the case may be, first comes into existence in a particular country after the date of First Commercial Sale in such country, on the date
    of issuance of such Valid Claim or Valid Platform Claim, as the case may be, royalties shall be payable on the sales of such Licensed Product pursuant to Section 13.5.1 or 13.5.2 at the rates set forth therein, as applicable, and expire upon the
    expiration of such Valid Claim or Valid Platform Claim, as the case may be, in such country. For the purposes of calculating the ten</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">43</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">[***] period above for each Licensed Product in any country within the EU, the [***] period shall [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.5.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Rights Following Expiration of Royalty Term</b>.
    Upon expiry of GNE&#8217;s payment obligation hereunder with respect to a Licensed Product in a country, the licenses in Section 9.1.1.(c) and 9.1.8 shall be fully paid-up in respect of that Licensed Product in that country.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 14</b><br>
    <font style="text-transform: uppercase"><b>FINANCIAL TERMS; REPORTS; AUDITS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.5in">14.1</td>
        <td style="text-align: justify"><b>Timing of Royalty Payment</b>. All royalty payments shall be made within [***] of the end of each calendar quarter in which the sale was made.</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.5in">14.2</td>
        <td style="text-align: justify"><b>Royalty Report</b>. For each calendar quarter for which GNE has an obligation to make royalty payments, such payments shall be accompanied by a report that specifies for such calendar quarter the following
          information (&#8220;<b>Net Sales Report</b>&#8221;):</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>total Net Sales of all Licensed Products sold in
    the Territory;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Net Sales on a country-by-country basis for all
    Licensed Products sold;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the exchange rate used to convert Net Sales from
    the currency in which they are earned to United States dollars; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the total royalties due to Immunocore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If GNE is reporting Net Sales for more than one Licensed Product, the foregoing information shall be reported on a Licensed Product-by-Licensed Product basis.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Mode of Payment</b>. All payments hereunder
    shall be made in immediately available funds to the account listed below (or such other account as Immunocore shall designate before such payment is due):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><b>[***]</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Currency of Payments</b>. All payments under
    this Agreement shall be made in United States dollars, unless otherwise expressly provided in this Agreement. Net Sales outside of the United States shall be first determined in the currency in which they are earned and shall then be converted into an
    amount in United States dollars as follows: (i) with respect to sales by or on behalf of GNE, use GNE&#8217;s customary and usual conversion procedures, consistently applied in preparing its audited financial statements; and (ii) with respect to sales by or
    on behalf of a given Sublicensee, using the conversion procedures applicable to payments by such Sublicensee to GNE for such sales and where such procedures have been agreed prior to the Effective Date or as modified by GNE and its Affiliates [***]
    after the Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Blocked Currency</b>. If, at any time, legal
    restrictions prevent GNE or a Sublicensee from remitting part or all of royalty payments when due with respect to any country in the Territory where Licensed Products are sold, GNE shall continue to provide Net Sales Reports for such royalty payments,
    and such royalty payments shall continue to accrue in such country, but GNE shall not be</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">44</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">obligated to make such royalty payments until such time as payment may be made through reasonable, lawful means or methods that may be available, as
    GNE shall determine.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Taxes</b>. Each Party shall comply with Applicable
    Laws and regulations regarding filing and reporting for income tax purposes. Neither Party shall treat their relationship under this Agreement as a pass through entity for tax purposes. All payments made under this Agreement shall be made free and
    clear of any and all taxes, duties, levies, fees or other, except for withholding taxes and VAT (if applicable). GNE and its Sublicensees shall be entitled to deduct from payments made to Immunocore under this Agreement the amount of any withholding
    taxes required to be withheld, to the extent paid to the appropriate governmental authority on behalf of Immunocore (and not refunded or reimbursed). GNE shall deliver to Immunocore, upon request, proof of payment of all such withholding taxes.
    Immunocore (on the one hand) and GNE (on the other hand) shall provide reasonable assistance to other Party in seeking any benefits available to either Party with respect to government tax withholdings by any relevant law, regulation or double tax
    treaty. All payments made under this Agreement shall be exclusive of VAT (if applicable) and such VAT shall be paid promptly on receipt of a valid VAT invoice.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">14.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Records; Inspection</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Records</b>. GNE agrees to keep, for [***] from
    the year of creation, records of all sales of Licensed Products for each reporting period in which royalty payments are due, showing sales of Licensed Products for each of GNE and its Affiliates and Sublicensees and applicable deductions in sufficient
    detail to enable the report provided under Section 14.2 to be verified. GNE shall procure that its Sublicensees keep records in accordance with this Section.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Audits</b>. Immunocore shall have the right to
    request that such report be verified by an independent, certified and internationally recognized public accounting firm selected by Immunocore and acceptable to GNE (the &#8220;<b>CPA Firm</b>&#8221;). Such right to request a verified report shall (i) be limited
    to a [***] period immediately preceding such request for a verified report; (ii) not be exercised more than once in any calendar year; and (iii) not more frequently than once with respect to records covering any specific period of time. Subject to
    Section 14.7.3, GNE shall, upon timely request and at least [***] advance notice from Immunocore and at a mutually agreeable time during its regular business hours, make its records available for inspection by such CPA Firm at such place or places
    where such records are customarily kept, solely to verify the accuracy of the reports provided under Section 14.2 and related payments due under this Agreement. The CPA Firm shall only state factual findings in the audit reports. The draft audit report
    shall be shared with GNE at the same time that it is shared with Immunocore. Following review and approval by all Parties of the draft audit, the final audit report shall be shared with GNE and Immunocore. GNE shall procure access to Sublicensee
    records relevant to verify the accuracy of reports under Section 14.2. relating to such Sublicensee and in accordance with this Section 14.7.2 and shall make such Sublicensee records available to the CPA Firm at the same time and location as GNE&#8217;s own
    records are made available to the CPA Firm.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.7.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Confidentiality</b>. Prior to any audit under
    Section 14.7.2, the CPA Firm shall enter into a written confidentiality agreement with GNE that (i) limits the CPA Firm&#8217;s use of GNE and its Affiliate&#8217;s and Sublicensee&#8217;s records to the verification purpose described in Section 14.7.2; (ii) limits the
    information that the CPA Firm may disclose to Immunocore to the numerical summary of payments due and paid; and (iii) prohibits the disclosure of any information contained in such records</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">to any Third Party for any purpose. The Parties agree that all information subject to review under Section 14.7.2 and/or provided by the CPA Firm to
    Immunocore is GNE&#8217;s Confidential Information, and Immunocore shall not use any such information for any purpose that is not germane to Section 14.7.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.7.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Underpayment; Overpayment</b>. After reviewing
    the CPA Firm&#8217;s audit report, GNE shall promptly pay any uncontested, understated amounts due to Immunocore. Any overpayment made by GNE or any Affiliate or Sublicensee shall be promptly refunded or fully creditable against amounts payable in subsequent
    payment periods, at GNE&#8217;s election. Any audit under Section 14.7.2 shall be at Immunocore&#8217;s expense; provided, however, GNE shall reimburse reasonable audit fees for a given audit if the results of such audit reveal that GNE and any Affiliate or
    Sublicensee underpaid Immunocore [***] for the audited period [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 15</b><br>
    <font style="text-transform: uppercase"><b>INTELLECTUAL PROPERTY; OWNERSHIP</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Definitions</b>. As used herein this Article 15:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.1.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>&#8220;<b>Prosecution and Maintenance</b>&#8221; or &#8220;<b>Prosecute








      and Maintain</b>&#8221;, with respect to a particular Patent, means all activities associated with the preparation, filing, prosecution and maintenance of such Patent (and patent application(s) derived from such Patent), as well as re-examinations,
    reissues, applications for patent term adjustments and extensions, supplementary protection certificates and the like with respect to that Patent, together with the conduct of interferences, derivation proceedings, pre- and post-grant proceedings,
    inter parte reviews, the defense of oppositions and other similar proceedings with respect to that Patent.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Disclosure; Ownership; Inventorship; Assignment and
      Cooperation</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Disclosure</b>. During the Term, each Party shall
    promptly disclose to the other any Foreground IP conceived, or reduced to practice by or for the disclosing Party. Disclosure will be made via designated patent practitioners representing each Party. Such disclosure obligation continues beyond the Term
    to the extent necessary to obtain patent protection for all inventions within the Foreground IP, and to establish inventorship thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Ownership</b>. As between the Parties:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore shall solely own the Immunocore
    Platform IP, Immunocore Foreground IP and Licensed Product IP;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall solely own the GNE Background IP and GNE
    Foreground IP; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Parties shall own jointly all Joint Foreground
    IP.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without limiting the foregoing, each Party retains an undivided one-half interest in and to the Joint Foreground IP (including Patents and Know-How therein). Subject
    to the licenses granted in Article 9, each Party may exploit fully the Joint Foreground IP, in any field, and may grant licenses and sublicenses of the Joint Foreground IP without the consent of and without accounting to the other Party, subject to
    Section 9.1.4. Further, each Party may transfer or encumber its ownership interest,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">46</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">without the consent of and without accounting to the other Party, subject to the license grants and covenants hereunder and only in accordance with any restrictions
    hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Assignment; Cooperation</b>. The assignments
    necessary to accomplish the ownership provisions set forth in this Article 15 are hereby made, and each Party shall execute such further documentation as may be necessary or appropriate, and provide reasonable assistance and cooperation, to implement
    the provisions of this Article 15. Each Party shall to the extent legally possible under relevant national or local laws require all of its employees, Affiliates and any Third Parties working pursuant to this Agreement on its behalf, to assign (or
    otherwise convey rights) to such Party any Patents and Know-How discovered, conceived or reduced to practice by such employee, Affiliate or Third Party, and to cooperate with such Party in connection with obtaining patent protection therefore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>CREATE Act</b>. It is the intention of the
    Parties that this Agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in Public Law 108-53 (the &#8220;<b>Create Act</b>&#8221;). In the event that either Party to this Agreement intends to overcome a rejection of a claimed invention within the
    Licensed Product IP, Immunocore Platform IF, Foreground IP and/or GNE Background IP pursuant to the provisions of the Create Act, such Party shall first obtain the prior written consent of the other Party and the Parties shall work together in good
    faith to agree how any rejection should be overcome. To the extent that the Parties agree that, in order to overcome a rejection of a claimed invention within Licensed Product IP, Immunocore Platform IP, Foreground IP and/or GNE Background IP pursuant
    to the provisions of the Create Act, the filing of a terminal disclaimer is required or advisable, the Parties shall first agree on terms and conditions under which the patent application subject to such terminal disclaimer and the patent or
    application over which such application is disclaimed shall be jointly enforced, to the extent that the Parties have not previously agreed to such terms and conditions. To the extent that this Section 15.2.4 applies to Immunocore Platform IP, any
    obligation under this Section will be subject to any Third Party agreements entered into with Immunocore prior to or after the Effective Date relating to the prosecution or maintenance of such Immunocore Platform IP and any co-operation or consultation
    by Immunocore under this Section 15.2.4 shall be subject to such Third Party agreements. In the event that GNE, or its Sublicensee intends to enter into an agreement with a Third Party with respect to the further research, development or
    commercialization of a Licensed Product and such agreement is a &#8220;joint research agreement&#8221; as that phrase is defined in the Create Act, the Parties shall in good faith discuss whether Immunocore shall similarly enter into such agreement with such Third
    Party purely for the purposes of agreeing similar consultation rights in relation to any rejection under the Create Act as contained under this Section 15.2.4.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Inventorship; Exclusive Dispute Resolution
      Process</b>. The determination of inventive contribution by or on behalf of a Party with respect to Foreground IP for purposes of determining ownership as set forth in Section 15.2.2. shall be made in accordance with the laws of inventorship under
    the US patent law. In the event of a Dispute between the Parties over inventorship of Foreground IP, the Parties shall, notwithstanding anything to the contrary in Article 15, refer such Dispute to a mutually acceptable independent outside patent
    counsel to determine inventorship and shall use all reasonable efforts to do so in an efficient and expedient manner. The Parties agree that the decision rendered by such independent outside patent counsel shall be the sole, exclusive and binding
    resolution and remedy between them regarding such Dispute, and the Parties shall share equally the fees and expenses of the independent outside patent counsel in resolving such Dispute.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">47</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Patent Prosecution</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Immunocore Controlled Prosecution and Maintenance
      of Immunocore Controlled Patents</b>. Immunocore shall Prosecute and Maintain Patents within (a) Immunocore Foreground IP that is not Licensed Product IP; (b) Joint Foreground IP solely relating to improvements to ImmTAC platform (&#8220;<b>Immunocore
      ImmTAC Improvement IP</b>&#8221;); (c) the Patent in Exhibit A, Part B and any other Patents relating to any Companion Diagnostic (including any derivatives and variants thereof); and (d) Enhanced ImmTAC Patent (together the &#8220;<b>Immunocore Controlled
      Patents</b>&#8221;) in consultation with GNE Immunocore will provide GNE with a draft copy of any proposed patent application, filings and other material correspondence with applicable governmental authorities concerning the Immunocore Controlled Patents
    for review and comment prior to filing or prior to submission of any response or communication with applicable governmental authorities and will keep GNE reasonably informed of the status of such Prosecution and Maintenance, including providing GNE
    with copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Immunocore. Immunocore will provide any filings or correspondence for comment by GNE where possible [***] prior to any due
    date or required response date. Immunocore will consider all comments provided by GNE to Immunocore prior to any due date or required response date [***]. GNE will provide all reasonable cooperation and assistance to Immunocore at Immunocore&#8217;s
    reasonable request in Prosecution and Maintenance of such Patents, including making data, reports, and scientific personnel reasonably available to prepare and prosecute patent applications.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Immunocore Controlled Prosecution and Maintenance
      of Immunocore Platform IP</b>. Subject to Section 15.3.1, Immunocore shall, at its sole discretion and expense, have the right (but not the obligation) to Prosecute and Maintain Patents within the Immunocore Platform IP (except for any Patents
    covered by Section 15.3.1). Immunocore will provide GNE with copies of any filed patent application, filings and other material correspondence with applicable governmental authorities relating to such Immunocore Platform IP, and will keep GNE
    reasonably informed of the status of such Prosecution and Maintenance, including providing GNE copies of all communications received from or filed in patent offices within a reasonable period of time after receipt by Immunocore. The obligations under
    this Section will be subject to any Third Party agreement entered into by Immunocore whether before or after the Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>GNE Controlled Prosecution and Maintenance</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall, at its sole discretion and expense,
    have the right (but not the obligation) to Prosecute and Maintain Patents within the GNE Background IP. GNE will provide Immunocore with copies of any filed patent application, filings and other material correspondence with applicable governmental
    authorities relating to GNE Background LP and will keep Immunocore reasonably informed of the status of such Prosecution and Maintenance, including providing Immunocore copies of all communications received from or filed in patent offices within a
    reasonable period of time after receipt by GNE.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall Prosecute and Maintain Patents within
    (1) any Joint Foreground IP that is not Immunocore ImmTAC Improvement IP; (2) Licensed Product TP; and (3) GNE Foreground IP (together, the &#8220;<b>GNE Controlled Patents</b>&#8221;). GNE will provide Immunocore with copies of any filed patent application,
    filings and other material correspondence with applicable governmental authorities relating to GNE Controlled Patents, and will keep Immunocore reasonably</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">48</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">informed of the status of such Prosecution and Maintenance, including providing Immunocore copies of all communications received from or filed in
    patent offices within a reasonable period of time after receipt by GNE. GNE will provide any filings or correspondence for comment by Immunocore where possible at least [***] prior to any due date or required response date. GNE will consider all
    comments provided by Immunocore to GNE prior to any due date or required response date [***]. Immunocore will provide all reasonable cooperation and assistance to GNE at GNE&#8217;s reasonable request in Prosecution and Maintenance of such Patents, including
    making data, reports, and scientific personnel reasonably available to prepare and prosecute patent applications. In the event that Immunocore issues a Co-Funding Withdrawal Notice, Patents falling within GNE Foreground IP shall be prosecuted in
    accordance with Section 15.3.3(a) instead of this Section 15.3.3(b).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Transfer of Prosecution and Maintenance</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If GNE elects not to Prosecute and Maintain any
    Patents under Section 15.3.3(b), GNE shall provide at least [***] written notice to Immunocore. Thereafter, Immunocore shall have the right, but not the obligation, to Prosecute and Maintain any notified Patents, at its sole expense and in its sole
    discretion. GNE will provide all cooperation and assistance to Immunocore in relation to such Prosecution and Maintenance.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Immunocore elects not to Prosecute and Maintain
    any Patents under Section 15.3.1, Immunocore shall provide at least [***] written notice to GNE. Thereafter, GNE shall have the right, but not the obligation, to Prosecute and Maintain any notified Patents, at its sole expense and in its sole
    discretion. Immunocore will provide all cooperation and assistance to GNE in relation to such Prosecution and Maintenance.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>The Parties agree to Prosecute and Maintain
    Immunocore Controlled Patents and GNE Controlled Patents on a coordinated basis with the goal of maximizing the enforceable patent coverage for the Licensed Products and the ImmTAC platform, including resolving any double patenting issues. The Parties
    acknowledge that coordinated filings of two or more separate Patent applications Covering Licensed Products or improvements to ImmTAC platform may be filed hereunder so long as (i) both Parties agree to the coordinated filings and (ii) the patent
    coverage for the Licensed Product(s) is not adversely affected.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>The Costs incurred by the Parties in carrying out
    the Prosecution and Maintenance activities set out in Section 15.3.1 and 15.3.3(b) shall be shared equally by the Parties. The Parties shall each bear their own costs in relation to the activities in Section 15.3.2 and 15.3.3(a). In the event that
    Immunocore issues a Co-Funding Withdrawal Notice, any costs shared in accordance with this Section 15.3.6 shall instead be borne solely by the prosecuting party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Interferences Between the Parties</b>. If an
    interference or derivation proceeding is declared by the US Patent and Trademark Office between one or more of the Patents within the Licensed Product IP, Immunocore Platform IP, Foreground IP or GNE Background IP, to the extent directed to a Licensed
    Product and such declared interference or derivation proceeding does not involve any Patents owned by a Third Party, then the Parties shall in good faith establish a mutually agreeable process to resolve such interference or derivation proceeding in a
    reasonable manner in conformance with all applicable legal standards, but which prejudices neither Party nor diminishes the value of such Patents at issue.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">49</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-weight: bold;">Trademarks </font><b>and



      Copyright</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.4.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>GNE shall select and shall Prosecute and Maintain,
    at its sole discretion and expense, trademarks and, to the extent necessary, copyright, used or intended to be used in relation to the Licensed Products. GNE will keep Immunocore reasonably informed of the status of applications and material
    correspondence with applicable governmental authorities relating to such trademarks and copyright.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Enforcement Rights for Infringement by Third
      Parties</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Notice</b>. Each Party shall promptly notify, in
    writing, the other Party upon learning of any actual or suspected infringement of the Patents within the Licensed Product IP, GNE Background IP, Immunocore Platform IP or Foreground IP to the extent such actual or suspected infringement is relevant to
    any MAGE-A4 Compound, Enhanced MAGE-A4 Compound, Other MAGE-A4 Compound or any Licensed Product, or any claim of invalidity, unenforceability, or non-infringement of any Patents within the Licensed Product IP, GNE Background IP, Immunocore Platform IP
    or Foreground IP (each an &#8220;<b>Infringement</b>&#8221;). At the request of the Party receiving such notice, the other Party shall use Diligent Efforts to provide all evidence in its possession pertaining to the actual or suspected Infringement that it can
    disclose without breach of a pre-existing obligation to a Third Party or waiver of privilege.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Enforcement Actions</b>. The Parties shall
    consult as to potential strategies to terminate suspected or potential Infringement, consistent with the overall goals of this Agreement. If the Parties fail to agree on such strategies:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall have the first right, but not the
    obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Section 15.3.1 and 15.3.3. If GNE does not, within [***] of receipt of a
    notice under Section 15.5.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then GNE shall provide written notice to Immunocore thereof, and GNE and Immunocore shall discuss the strategy thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore shall have the first right, but not the
    obligation, to seek to abate any actual or suspected Infringement by a Third Party, or to file suit against any Third Party for Infringement, in each case of any Patent under Section 15.3.2. If Immunocore does not, within [***] of receipt of a notice
    under Section 15.5.1, take steps to abate the Infringement, or to file suit to enforce against such Infringement, then GNE shall have the right, but not the obligation, to take action to enforce against such Infringement; provided that if Immunocore is
    diligently pursuing ongoing settlement discussions at the end of such [***] period then GNE shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or Immunocore ceases to pursue such
    discussions diligently. To the extent this Section relates to Immunocore Platform IP, the obligations under this Section will be subject to any Third Party agreement entered into by Immunocore whether before or after the Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The non-controlling Party shall cooperate with the
    Party controlling any such action to abate or enforce (as may be reasonably requested by the controlling Party and at the controlling Party&#8217;s expense), including, if necessary, by being joined as a party provided that the non-controlling Party shall be
    indemnified by the controlling Party as to any costs or expenses, and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">50</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">shall have the right to be represented by its own counsel at its own expense. The Party controlling any such action shall keep the other Party updated
    with respect to any such action, including providing copies of all documents received or filed in connection with any such action.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Settlement</b>. The Party controlling any such
    enforcement action described in Section 15.5.2 (a &#8220;<b>Section 15.5.2 Enforcement</b>&#8221;), at its sole discretion, may take reasonable actions to terminate any alleged Infringement without litigation; provided, that if any such arrangement would adversely
    affect the non-controlling Party&#8217;s rights under this Agreement, then that arrangement is subject to the non-controlling Party&#8217;s prior written consent. The Party controlling any Section 15.5.2 Enforcement may not settle or consent to an adverse judgment
    without the express written consent of the non-controlling Party (such consent not to be unreasonably withheld or delayed).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Costs and expenses</b>. The Party controlling any
    Section 15.5.2 Enforcement shall bear all costs and expenses, including but not limited to litigation expenses, related to such enforcement actions.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.5.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Damages</b>. Unless otherwise mutually agreed by
    the Parties, and subject to the respective indemnity obligations of the Parties set forth in Article 19, all damages, amounts received in settlement, judgment or other monetary awards recovered in Section 15.5.2 Enforcement with respect to activities
    of the Third Party that occurred prior to the effective date of such award shall be applied as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>[***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Third Party Intellectual Property Rights</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.6.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Third Party Licenses</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that Immunocore has not issued a
    Co-Funding Withdrawal Notice and the JDC agrees that it is necessary to obtain a right or license under any intellectual property of a Third Party, where the making, using, selling, offering for sale, or importing of a Licensed Product would in the
    absence of such right or license infringe the intellectual property of a Third Party, GNE shall take the lead in negotiating with such Third Party to obtain a license of the relevant Third Party intellectual property, with the right to sublicense such
    third party rights to Immunocore and, subject to the agreement of the JDC, GNE shall enter such Third Party License, The costs of such Third Party Licenses shall be borne by the Parties in [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event that .Immunocore has issued a
    Co-Funding Withdrawal Notice, and GNE or its Affiliate obtains a right or license under any intellectual property of a Third Party, where the making, using, selling, offering for sale, or importing of a Licensed Product by GNE or the relevant Affiliate
    would in the absence of such right or license infringe the intellectual property of a Third Party, then GNE shall (i) be solely responsible for any costs associated with such agreement; (ii) GNE shall procure that such agreement includes provision for
    sublicensing or assignment of GNE&#8217;s rights to Immunocore (in the event of termination of this Agreement); and (iii) GNE shall notify Immunocore if it enters into any such agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">51</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">15.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Third Party Infringement Claims</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Notice</b>. In the event that a Third Party shall
    make any claim, give notice, or bring any suit or other inter partes proceeding against GNE or Immunocore, or any of their respective Affiliates or licensees or customers, for infringement or misappropriation of any intellectual property rights with
    respect to the research, development, making, using, selling, offering for sale, import or export of any Licensed Product or Companion Diagnostic (&#8220;<b>Third Party Infringement Claim</b>&#8221;), in each case, the Party receiving notice of a Third Party
    Infringement Claim shall promptly notify the other Party and use Diligent Efforts to provide all evidence in its possession pertaining to the claim or suit that it can disclose without breach of a pre-existing obligation to a Third Party or waiver of
    privilege.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Defense</b>. The Parties shall consult as to
    potential strategies to defend against any Third Party Infringement Claim, consistent with the overall goals of this Agreement, including by being joined as a party. The Parties shall cooperate with each other in all reasonable respects in the defense
    of any Third Party Infringement Claim or raising of any counterclaim related thereto. If the Parties fail to agree on such strategies, and subject to the respective indemnity obligations of the Parties set forth in Article 19, GNE shall be solely
    responsible for defending such Third Party Infringement Claim including but not limited to selection of counsel, venue, and directing all aspects, stages, motions, and proceedings of litigation. If GNE does not, within [***] of receipt of a notice
    under Section 15.7.1, take steps to defend the Third Party Infringement Claim, then Immunocore shall have the right, but not the obligation, to take action to enforce or defend against such Third Party Infringement Claim provided that if GNE is
    diligently pursuing ongoing settlement discussions at the end of such [***] period then Immunocore shall not be permitted to exercise such right unless such settlement discussions cease without reaching settlement or GNE ceases to pursue such
    discussions diligently, At the controlling Party&#8217;s request and expense, the non-controlling Party shall cooperate with the controlling Party in connection with any such defense and counterclaim, provided that the non-controlling Party shall be
    indemnified by the controlling Party as to any costs or expenses, and shall have the right to be represented by its own counsel at its own expense.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Settlement</b>. If any such defense under Section
    15.7.2 would adversely affect the other Party&#8217;s rights under this Agreement or impose a financial obligation upon the other Party or grant rights in respect, or affect the validity or enforceability, of the other Party&#8217;s Patents or any Joint Foreground
    IP, then any settlement, consent judgment or other voluntary final disposition of such Third Party Infringement Claim shall not be entered into without the consent of the other Party (such consent not to be unreasonably withheld). For the avoidance of
    doubt, if any settlement results in the granting to the alleged infringer of a sublicense to any of the Licensed Product IP or Foreground IP, with running royalties payable on post-settlement sales by the alleged infringer, such alleged infringer shall
    be deemed to be a Sublicensee and such royalties on post-settlement sales shall be shared equally by the Parties in fifty percent (50%) shares; save that if a Co-Funding Withdrawal Notice has been issued, such royalties shall be subject to the royalty
    obligations under Article 13.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Costs and expenses</b>. The Party controlling the
    defense of any Third Party Infringement Claim shall bear [***], to defend against any Third Party Infringement Claim.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.7.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Attorney-Client Privilege; Common Interest</b>.
    Neither Party is waiving, nor shall be deemed to have waived or diminished, any of its attorney work product protections, attorney-client privileges or similar protections and privileges or the like as a result of disclosing information</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">52</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">(the party making the disclosure, &#8220;disclosing party&#8221;) pursuant to this Agreement or any of its Confidential Information (including Confidential
    Information related to pending or threatened litigation) to the other Party (&#8220;receiving party&#8221;), regardless of whether the disclosing party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (i) share a
    common legal and commercial interest in such disclosure that is subject to such privileges and protections; (ii) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (iii) intend
    that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding to which the disclosing party&#8217;s Confidential Information covered by such protections and privileges relates; and (iv) intend
    that after the Effective Date both the receiving party and the disclosing party shall have the right to assert such protections and privileges.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 16</b><br>
    <font style="text-transform: uppercase"><b>CONFIDENTIALITY</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Non-use and Non-disclosure of Confidential
      Information</b>. During the Term, and for a period of [***] thereafter, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any Third Party any Confidential
    Information of the other Party; (ii) except in connection with activities contemplated by, the exercise of rights permitted by, in order to further the purposes of this Agreement or otherwise agreed to in writing, not use for any purpose any
    Confidential Information of the other Party; and (iii) take all reasonable precautions to protect the Confidential Information of the other Party (including all precautions a Party employs with respect to its own confidential information of a similar
    nature). Any Know-How included in the Joint Foreground IP shall be the joint Confidential Information of both Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Exclusions Regarding Confidential Information</b>.
    Notwithstanding anything set forth in this Article 16 to the contrary, the obligations of Section 16.1 above shall not apply to the extent that the Party seeking the benefit of the exclusion can demonstrate that the Confidential Information of the
    other Party:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>was already known to the receiving Party, other than
    under an obligation of confidentiality, at the time of receipt by the receiving Party;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>was generally available to the public or otherwise
    part of the public domain at the time of its receipt by the receiving Party;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>became generally available to the public or
    otherwise part of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>was received by the receiving Party without an
    obligation of confidentiality from a Third Party having the right to disclose such information without restriction;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>was independently developed by or for the receiving
    Party without use of or reference to the Confidential Information of the other Party; or</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.2.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>was released from the restrictions set forth in this
    Agreement by express prior written consent of the Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">53</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Authorized Disclosures of Confidential Information</b>.
    Notwithstanding the foregoing, a Party may use and disclose the Confidential Information of the other Party as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>if required by law, rule or governmental regulation,
    including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the Party seeking to disclose the Confidential Information of the other Party (i) uses all reasonable efforts
    to inform the other Party prior to making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible, requests confidential treatment of such
    information;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>to the extent such use and disclosure is reasonably
    required in the Prosecution and Maintenance of a Patent within the Licensed Product IP, Immunocore Platform IP, the GNE Background IP or the Foreground IP in accordance with this Agreement upon reasonable notice and written consent of the other Party,
    such consent not to be unreasonably withheld, delayed or conditioned;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>as reasonably necessary to obtain or maintain any
    Regulatory Approval, including to conduct preclinical studies and clinical trials and for pricing approvals, for any Licensed Products, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential
    Information outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>to take any lawful action that it deems necessary to
    protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>to the extent necessary, to Sublicensees,
    collaborators, vendors, consultants, agents, attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such information in connection with
    such Party performing its obligations or exercising its rights under this Agreement. Further, the receiving Party may disclose Confidential Information to existing or potential: acquirers, merger partners, collaborators, Sublicensees and sources of
    financing or to professional advisors (e.g. attorneys, accountants and prospective investment bankers) involved in such activities, for the limited purpose of evaluating such transaction, collaboration or license and under appropriate conditions of
    confidentiality, only to the extent necessary and with the agreement by those permitted individuals to maintain such Confidential Information in strict confidence;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.3.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>Immunocore may also share certain preclinical data
    and clinical data for MAGE-A4 Compounds, an Enhanced MAGE-A4 Compound, or an Other MAGE-A4 Compound with Third Parties (a) in order to raise further investment for so long as Immunocore is not publicly traded on an major stock exchange; and (b) to
    support partnering discussions around assets emerging from Immunocore&#8217;s pipeline; provided, (1) such Third Parties are under suitable obligations of confidentiality and non-use applicable to the Confidential Information of the other Party consistent
    with the terms and conditions of this Agreement, including the confidentiality provisions of this Article 16, and (ii) such data is limited to the following;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>any and all preclinical data (other than toxicity
    data), elapsed time for which MAGE-A4 Compounds (or an Enhanced MAGE-A4 Compound) or an Other MAGE-A4 Compound have remained within specification from ongoing stability studies and Clinical Trial data and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">54</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">biomarker analyses that support the ImmTAC mechanism of action from any patients treated with MAGE-A4 Compounds (or an Enhanced MAGE-A4 Compound) or
    an Other MAGE-A4 Compound on a continuing monotherapy basis or as part of a monotherapy lead-in to a combination regimen; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>preclinical data or clinical data from a
    combination of a MAGE-A4 Compound (or an Enhanced MAGE-A4 Compound) or an Other MAGE-A4 Compound with any GNE proprietary compound (including Tecentriq) with purely financial Third Party investors.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any such disclosures under Section 16.3.6 shall be subject to prior written review and comment by GNE.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Return of Confidential Information</b>. Except as
    expressly permitted under this Agreement, following any termination of this Agreement each Party shall upon written request by the other Party promptly destroy all Confidential Information received from the disclosing Party, including any copies
    thereof, (except one copy of which may be retained for archival purposes solely to ensure compliance with the terms of this Agreement).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Terms of this Agreement</b>. The Parties agree that
    this Agreement and the terms hereof will be considered Confidential Information of both Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">16.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>No License</b>. As between the Parties,
    Confidential Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses
    expressly granted under Article 9, under any patent, trade secret or other rights now or hereinafter held by the disclosing Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 17</b><br>
    <font style="text-transform: uppercase"><b>PUBLICITY; PUBLICATIONS; USE OF NAME</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Publicity</b>. The text of any press releases,
    public announcements and powerpoint presentations concerning this Agreement, the subject matter hereof, or the research, development or commercial results of Licensed Products hereunder (a &#8220;<b>Release</b>&#8221;) shall be addressed pursuant to Sections 17.2
    to 17.4. Any such Release shall not include any financial terms of this transaction.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Releases</b>. The Parties hereby agree to the issue
    of press releases as set out in Exhibit D, concerning the execution of this Agreement. During the Pre-POC Term and, provided Immunocore has not issued a Co-Funding Withdrawal Notice, during the Term, the Parties shall agree the content of any Releases.
    In the event that Immunocore has issued a Co-Funding Withdrawal Notice, GNE shall have discretion as to the content of any Releases, subject to Article 16 and this Article 17. Subject to Sections 17.2, 17.3 and 17.4:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>GNE may not issue a Release without Immunocore&#8217;s
    prior written consent if it includes reference to Immunocore&#8217;s Co-Funding Withdrawal Notice or its right to issue such notice;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>GNE may not issue a Release without Immunocore&#8217;s
    prior written consent if it includes reference to Immunocore by name; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">55</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>Immunocore may not issue a Release without GNE&#8217;s
    prior written consent if it includes reference to GNE by name.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In each case, consent shall not be unreasonably withheld, conditioned or delayed and shall be provided within [***] of request for such consent.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Approved Releases</b>. If a Release requires
    consent pursuant to Sections 16.3 or 17.2, once consent has been given both Parties may make subsequent public disclosure of the contents of such statement without the further approval of the Party whose consent was required; provided, such content is
    not presented with any new data or information or conclusions and/or in a form or manner that materially alters the subject matter therein.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Releases required by law or regulation</b>. Each
    Party may issue any Release it is required to issue by Applicable Law or regulation (including, in the case of Immunocore, any announcements required to satisfy the UK Takeover Panel or the UKLA listing rules).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Publications</b>. Notwithstanding Sections 17.1 to
    17.4, both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds, or
    Other MAGE-A4 Compounds, Licensed Products or Companion Diagnostics may be beneficial to both Parties, provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the patentability of
    inventions and other commercial considerations. Accordingly, the following shall apply with respect to papers and presentations proposed for disclosure by either Party:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.5.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>During the Pre-POC Term and, provided Immunocore has
    not issued a Co-Funding Withdrawal Notice, during the Term, the Parties shall agree the content of any such publication or disclosure of papers, presentations, abstracts or any other written or oral presentations;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.5.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>In the event of Immunocore issuing a Co-Funding
    Withdrawal Notice, with respect to any paper or presentation proposed for disclosure by GNE which utilizes information generated by or on behalf of GNE in relation to Licensed Product, so long as such paper or presentation does not contain any
    Confidential Information of Immunocore (excluding Joint Foreground IP), GNE shall be free to make, publish and disclose such papers and presentations at its discretion. GNE shall acknowledge Immunocore, as appropriate, in any publication that discloses
    GNE&#8217;s use of the Licensed Products or the results of any Research Program. For clarity, GNE shall not be permitted to publish or otherwise disclose any Confidential Information of Immunocore (excluding Joint Foreground IP) except as may be expressly
    permitted pursuant to Section 16.2 or Section 16.3; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.5.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>With respect to any paper or presentation proposed
    for disclosure by a Party which includes Confidential Information of the other, that other Party shall have the right to review and approve any such proposed paper or presentation. The publishing Party shall submit to the other the proposed publication
    or presentation (including, without limitation, posters, slides, abstracts, manuscripts, marketing materials and written descriptions of oral presentations) at least [***] prior to the date of submission for publication or the date of presentation,
    whichever is earlier, of any of such submitted materials. The reviewing Party shall review such submitted materials and respond to Immunocore as soon as reasonably possible, but in any case within [***] ([***] for abstracts) of receipt thereof. At the
    option of the reviewing Party, the publishing Party shall (a) delete from such</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">56</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">proposed publication or presentation any Confidential Information of the reviewing Party and/or (b) delay the date of such submission for publication
    or the date of such presentation for a period of time sufficiently long (but in no event longer than [***]) to permit the reviewing Party to seek appropriate patent protection. Once a publication has been approved by the reviewing Party, the publishing
    Party may make subsequent public disclosure of the contents of such publication without the further approval of the reviewing Party; provided, such content is not presented with any new data or information or conclusions and/or in a form or manner that
    materially alters the subject matter therein.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">17.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>No Right to Use Names</b>. Except as expressly
    provided herein, no right, express or implied, is granted by the Agreement to use in any manner the name of &#8220;Immunocore&#8221;, &#8220;Genentech&#8221; or any other trade name, symbol, logo or trademark of the other Party in connection with the performance of this
    Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 18</b><br>
    <font style="text-transform: uppercase"><b>REPRESENTATIONS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Mutual Representations and Warranties</b>. Each
    Party represents and warrants to the other Party that as of the Effective Date:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it is validly organized under the laws of its
    jurisdiction of incorporation;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it has obtained all necessary consents, approvals
    and authorizations of all governmental authorities and other persons or entities required to be obtained by it in connection with this Agreement;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>the execution, delivery and performance of this
    Agreement have been duly authorized by all necessary corporate action on its part;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it has the legal right and power to enter into this
    Agreement and to fully perform its obligations hereunder;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>the performance of its obligations under this
    Agreement will not conflict with such Party&#8217;s charter documents or any Third Party agreement, contract or other arrangement to which such Party is a party; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.1.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>to the extent relevant to this Agreement, it follows
    reasonable commercial practices common in the industry to protect its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and
    to the extent permissible under national or local laws requiring its employees, consultants and agents to assign to it any and all inventions and discoveries discovered by such employees, consultants or agents made within the scope of, and during their
    employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written confidentiality and non-disclosure agreements.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>GNE Additional Warranties</b>. GNE also represents
    and warrants to Immunocore that:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it has the legal right and power to extend the
    rights and licenses granted to Immunocore hereunder;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">57</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it will not grant during the Term, any right,
    license or interest in or to the GNE Background IP or the GNE Foreground IP, or any portion thereof, inconsistent with the rights granted to Immunocore herein;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>prior to the Effective Date, if and to the extent a
    GNE Affiliate carried out any activities in relation to the Target under the Original Agreement, such activities were carried out in accordance with the subcontracting obligations specified therein; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>in developing, testing, manufacturing, selling and
    supplying any Licensed Product it will, and it will procure that its Sublicensees will, comply with all Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Immunocore Additional Warranties</b>. Immunocore
    also represents and warrants to GNE that:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it has the legal right and power to extend the
    rights granted to GNE hereunder; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>the Licensed Product IP includes all intellectual
    property rights and Know-How Controlled by Immunocore as at the Effective Date which are specific to the Licensed Products and/or MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds and Other MAGE-A4 Compounds;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>the Immunocore Platform IP includes all intellectual
    property rights and Know-How Controlled by Immunocore as at the Effective Date which are reasonably necessary or useful for the purposes of researching, developing, making or commercializing Licensed Products, Companion Diagnostics and/or MAGE-A4
    Compounds, Enhanced MAGE-A4 Compounds and Other MAGE-A4 Compounds;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>it will not grant during the Term, any right or
    interest in or to the Licensed Product IP, Immunocore Platform IP or Foreground IP to the extent that they relate to MAGE-A4 Compounds, Enhanced MAGE-A4 Compounds and Other MAGE-A4 Compounds or Licensed Products or Companion Diagnostics, or any portion
    thereof, inconsistent with the rights granted to GNE;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>as of the Effective Date, it has no knowledge of any
    threatened or pending actions, lawsuits, claims or arbitration proceedings in any way relating to the Licensed Product IP, Companion Diagnostics or to the Immunocore Platform IP (to the extent relevant to the Licensed Product or Companion Diagnostic or
    MAGE-A4 Compound, Enhanced MAGE-A4 Compounds and Other MAGE-A4 Compounds or to performance of a Development Plan); provided, however, that nothing in this Section 18.3 shall be interpreted as requiring Immunocore to have undertaken any inquiries or to
    have obtained any freedom to operate opinion; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.3.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>in developing, testing, manufacturing, selling and
    supplying any Licensed Product it will, and it will procure that its Sublicensees will, comply with all Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">18.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Disclaimers</b>. EXCEPT AS OTHERWISE EXPRESSLY
    STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO PATENTS, KNOW-HOW, MATERIALS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES,
    EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">58</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. NOTHING IN THIS SECTION SHALL PREVENT GNE CLAIMING DAMAGES
    FOR LOSS OF ROYALTIES ARISING AS A RESULT OF A BREACH OF THIS AGREEMENT BY IMMUNOCORE.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 19</b><br>
    <font style="text-transform: uppercase"><b>INDEMNIFICATION</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification</b>. Subject to Section 19.3,
    Immunocore shall indemnify, defend and hold GNE, its Sublicensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all liabilities, damages, settlements,
    penalties, fines, costs or expenses (including, without limitation, reasonable attorneys&#8217; fees and other reasonable expenses of litigation) (collectively, &#8220;<b>Loss</b>&#8221; or &#8220;<b>Losses</b>&#8221;) arising, directly or indirectly out of or in connection with
    any Third Party claims, suits, actions, demands or judgments (&#8220;<b>Third Party Claims</b>&#8221;) relating to (a) breach by Immunocore of this Agreement including the representations and warranties under Article 18, (b) the failure of any Licensed Product
    supplied by Immunocore to comply with its applicable specification, (c) Immunocore&#8217;s negligent conduct in the defense of any Third Party Infringement Claim under Section 15.7.2; except, in each case, to the extent caused by the negligence or willful
    misconduct of GNE or its Sublicensees or any breach of this Agreement by GNE or its Sublicensees.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Indemnification</b>. Subject to Section 19.3,
    GNE shall indemnify, defend and hold Immunocore and its Third Party licensees and their respective directors, officers, and employees and the successors and assigns of any of the foregoing harmless from and against any and all Losses arising, directly
    or indirectly out of or in connection with any Third Party Claims) relating to (a) breach by GNE its Sublicensees or subcontractors of this Agreement including the representations and warranties under Article 18; (b) failure of any Licensed Product
    supplied by GNE to comply with its applicable specification; and (c) if Immunocore serves a Co-Funding Withdrawal Notice, the research, development, manufacture and commercialization of Licensed Products, and (d) GNE&#8217;s negligent conduct in the defense
    of any Third Party Infringement Claim under Section 15.7.2; except, in each case, to the extent caused by the negligence or willful misconduct of Immunocore or breach of this Agreement by Immunocore.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Procedure</b>. If a Party intends to claim
    indemnification under this Agreement (the &#8220;<b>Indemnitee</b>&#8221;), it shall promptly notify the other Party (the &#8220;<b>Indemnitor</b>&#8221;) in writing of such alleged Loss and the Third Party Claim. The Indemnitor shall have &#8216;the right to control the defense
    thereof with counsel of its choice as long as such counsel is reasonably acceptable to Indemnitee. Any Indemnitee shall have the right to retain its own counsel at its own expense for any reason, provided, however, that if the Indemnitee shall have
    reasonably concluded, based upon a written opinion from outside legal counsel, that there is a conflict of interest between the Indemnitor and the Indemnitee in the defense of such action, in which case the Indemnitor shall pay the fees and expenses of
    one law firm serving as counsel for the Indemnitee in relation to such Third Party Claim. The Indemnitee, its employees and agents, shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any Third Party
    Claims covered by this Agreement. The obligations of this Article 19 shall not apply to any settlement of any Third Party Claims if such settlement is effected without the consent of both Parties, which shall not be unreasonably withheld or delayed.
    The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any such action, to the extent prejudicial to its ability to defend such action, shall relieve the Indemnitor</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">59</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">of any obligation to the Indemnitee under this Section 19.3. It is understood that only GNE and Immunocore may claim indemnity under this Agreement
    (on its own behalf or on behalf of its Indemnitees), and other Indemnitees may not directly claim indemnity hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Insurance</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Insurance Coverage</b>. Subject to Section
    19.4.4, each Party shall obtain and maintain comprehensive general liability insurance customary in the industry for companies of similar size conducting similar business, and in any case sufficient to cover its obligations,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Evidence of Insurance</b>. Within [***] of
    signing this Agreement, each Party shall provide the other Party with its certificate of insurance evidencing the insurance coverage set forth Section 19.4.1. Each Party shall provide to the other Party at least [***] prior written notice of any
    cancellation, non-renewal or material change in any of such insurance coverage.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Product / Clinical Trial Liability Insurance:
      Pre-POC Development Plan</b>. Commencing not later than [***] prior to the first use in humans of the first Licensed Product in accordance with the Pre-POC Development Plan, both Parties shall have and maintain such type and amounts of products /
    clinical trial liability insurance covering the development, manufacture, use and sale of Licensed Products as is normal and customary in the industry generally .for parties similarly situated, but, in any event, with a minimum combined single limit
    per occurrence for products / clinical trials liability as follows: (a) a minimum limit of [***] for any period during which the Parties or any of their Sublicensees are conducting a clinical trial(s) with any Licensed Product(s) within the scope of
    the Pre-POC Development Plan; and (b) a minimum limit of [***] for any period during which the Parties or any of their Sublicensees are selling any Licensed Product(s). Each of the above insurance policies shall be primary insurance.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Product / Clinical Trial Liability Insurance:
      Global Development Plan and</b>. Commercialization. Commencing not later than [***] prior to the first dosing of the first Licensed Product in accordance with the Global Development Plan, GNE shall have and maintain such type and amounts of products
    / clinical trial liability insurance covering the development, manufacture, use and sale of Licensed Products as is normal and customary in the industry generally for parties similarly situated, but, in any event, with a minimum combined single limit
    per occurrence for products / clinical trials liability as follows: (a) a minimum limit of [***] for any period during which the Parties or any of their Sublicensees are conducting a clinical trial(s) with any Licensed Product(s) within the scope of
    the Global Development Plan; and (b) a minimum limit of [***] for any period during which the Parties or any of their Sublicensees are selling any Licensed Product(s). Each of the above insurance policies shall be primary insurance.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Election to Self-Insure</b>. In the event that
    either Party is an entity which, together with its Affiliates, has worldwide revenues from pharmaceutical sales in excess of [***] per year, the obligations set forth in Section 19.4.1, 19.4.2 and 19.4.3 above shall not apply with respect to such
    Party, if such Party notifies the other Party in writing that it elects to provide coverage through a. commercially reasonable program of self-insurance and such self-insurance in the case of Section 19.4.3 is permitted under Applicable Laws; provided,
    however, that the obligations set forth in Section 19.4.1, 19.4.2 and 19.4.3 above shall resume with respect to such Party and its Affiliates, or successor-in-interest and its Affiliates, if such program of self-insurance is terminated or discontinued
    for any reason.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">60</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">19.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Limitation of Damages</b>. NEITHER PARTY HERETO
    WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT IN RESPECT OF ANY BREACH OF A PARTY&#8217;S
    OBLIGATIONS UNDER ARTICLE 16 OR INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 19 FOR CLAIMS OF THIRD PARTIES. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION SHALL LIMIT OR EXCLUDE ANY LIABILITY TO A THIRD PARTY FOR FRAUD BY ANY PARTY OR ANY
    LIABILITY ARISING AS A RESULT OF PERSONAL INJURY OR DEATH CAUSED BY NEGLIGENCE OF ANY PARTY.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 20</b><br>
    <font style="text-transform: uppercase"><b>TERM; TERMINATION</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Term</b>. The term of this Agreement (&#8220;<b>Term</b>&#8221;)









    shall commence on the Effective Date and, unless sooner terminated as provided in this Article 20, shall continue in full force and effect, on a country-by-country and Licensed Product-by-Licensed Product basis until there is no remaining royalty
    payment or other payment obligation in such country with respect to such Licensed Product, at which time this Agreement shall expire with respect to such Licensed Product in such country. The Term shall expire on the date this Agreement has expired in
    its entirety with respect to all Licensed Products in all countries in the Territory.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Termination by Either Party for Material Breach</b>.
    Either Party may terminate this Agreement by written notice to the other Party for any material breach of this Agreement by the other Party if, in the case of remediable breach, such material breach is not cured within [***] ([***] for payment
    defaults) after the breaching Party receives written notice of such breach from the non-breaching Party; provided, that if such breach is not capable of being cured within such [***] (or [***]) period, the cure period shall be extended for such amount
    of time that the Parties may agree in writing is reasonably necessary to cure such breach, so long as (1) the breaching Party is making Diligent Efforts to do so, and (2) the Parties agree on an extension within such [***] (or [***]) period.
    Notwithstanding anything to the contrary herein, if the allegedly breaching Party in good faith either disputes (i) whether a breach is material or has occurred or (ii) the alleged failure to cure or remedy such material breach, and provides written
    notice of that dispute to the other Party within the above time periods, then the matter will be addressed under the dispute resolution provisions in Article 21, and the notifying Party may not so terminate this Agreement until it has been determined
    under Article 21 that the allegedly breaching Party is in material breach of this Agreement, and such breaching Party further fails to cure such breach within [***] (or such longer period as determined by the arbiter of such dispute resolution) after
    the conclusion of that dispute resolution procedure.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Termination by Either Party for Insolvency or
      Bankruptcy</b>. Either Party may terminate this Agreement effective on written notice to the other Party upon the liquidation, dissolution, winding-up, insolvency, bankruptcy, or filing of any petition therefor, appointment of a receiver, custodian
    or trustee, or any other similar proceeding, by or of the other Party where such petition, appointment or similar proceeding is not dismissed or vacated within [***] and where such petition, appointment or similar proceeding is not a part of any bona
    fide reorganisation of a Party or its Affiliates. All rights and licenses granted pursuant to this Agreement are, for purposes of Section 365(n) of Title 11 of the United States Code or any foreign equivalents thereof (as used in this Section 20.3, &#8220;<b>Title








      11</b>&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined in Title 11. Each Party in its</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">61</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">capacity as a licensor hereunder agrees that, in the event of the commencement of bankruptcy proceedings by or against such bankrupt Party under
    Title 11, (a) the other Party, in its capacity as a licensee of rights under this Agreement, shall retain and may fully exercise all of such licensed rights under this Agreement (including as provided in this Section 20.3) and all of its rights and
    elections under Title 11 and (b) the other Party shall be entitled to a complete duplicate of all embodiments of such intellectual property, and such embodiments, if not already in its possession, shall be promptly delivered to the other Party (i) upon
    any such commencement of a bankruptcy proceeding, unless the bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i), immediately upon the rejection of this Agreement by or on behalf
    of the bankrupt Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Permissive termination by GNE</b>. GNE may
    terminate this Agreement in its sole discretion at any time by providing [***] written notice to Immunocore at any time. Any payments (whether royalties or otherwise) which have become due or relate to any Net Sales made prior to date of termination,
    shall remain due and owing following termination and become immediately payable on termination.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>[***]</b>. If GNE, its Sublicensees or their
    Controlled Affiliates voluntarily commence proceedings (whether before a regulatory or administrative body or a court) anywhere in the world, or voluntarily assists any Third Party in commencing or participating in proceedings (whether before a
    regulatory If GNE, its Sublicensees or their Controlled Affiliates [***], then either (i) GNE, its Sublicensee or their Controlled Affiliate shall [***], or (ii) [***], Immunocore shall have the right to terminate this Agreement on [***] written notice
    to GNE; [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Effects of Termination in General</b>. Upon the
    termination of this Agreement by a Party the following will apply with regard to the Licensed Product and any Companion Diagnostic that is being developed or commercialised by the Parties hereunder as it exists on the effective date of termination (the
    &#8220;<b>Terminated Product</b>&#8221;):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font>For purposes of this Section 20.6 &#8220;<b>Termination
      Effective Date</b>&#8221; means the effective date of such termination.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Accrued Rights and Obligations</b>. Expiration or
    termination of this Agreement in its entirety for any reason shall not release either Party hereto from any liability (including any payment obligations) which, as of the Termination Effective Date, had already accrued to the other Party or which is
    attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to the Termination Effective
    Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Termination of Licenses</b>. Upon termination of
    this Agreement, all licenses under this Agreement (except the license set forth in Section 9.1.1(b)) shall terminate as of the Termination Effective Date.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Continuation of Sublicenses</b>. Upon termination
    by Immunocore of this Agreement, Immunocore agrees that on request from any Sublicensee it will grant to such Sublicensee a license on the same terms as set out in this Agreement (including all event payments and royalty payments) in relation to any
    Immunocore rights previously licensed to such Sublicensee. Unless otherwise</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">62</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">explicitly agreed in writing, Immunocore shall not agree to vary or amend the terms of the licenses granted hereunder or take on any additional or
    further obligations or burdens.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Clinical Trials</b>. In the event GNE terminates
    this Agreement in accordance with Section 20.2 or 20.3, any ongoing Clinical Trial shall be wound down in accordance with the protocol for such Clinical Trial and in such a way as to minimise any patient harm and at all times in accordance with all
    Applicable Laws.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Return of Confidential Information</b>. It is
    understood and agreed, that each Party shall have a continuing right to use Confidential Information of the other Party under any surviving licenses pursuant to Article 9 and/or this Section 20.6. Subject to the foregoing, following expiry or any early
    termination of this Agreement, the Party that has Confidential Information of the other Party shall destroy (at such Party&#8217;s written request) all such Confidential Information in its possession as of the effective date of expiration (with the exception
    of one copy of such Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information to confirm compliance with the non-use and non-disclosure provisions of this Agreement), and any
    Confidential Information of the other Party contained in its laboratory notebooks or databases, provided that each Party may retain and continue to use such Confidential Information of the other Party to the extent necessary to exercise any surviving
    rights, licenses or obligations under this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Inventory at Termination</b>. Upon termination of
    this Agreement and for a period of [***] following such termination, GNE and its permitted Sublicensee shall have the right to sell or otherwise dispose of all inventory of Licensed Products in all countries then in its stock, subject to the applicable
    royalty payments due under this Agreement, and any other applicable provisions of this Agreement, and Immunocore covenants not to sue GNE or its permitted Sublicensee for infringement under any of the Patents that were licensed by Immunocore to GNE
    immediately prior to such termination with respect to such activities conducted by GNE or its permitted Sublicensee pursuant to this Section 20.6.7. Following expiry of such [***] period, GNE shall provide any remaining stock to Immunocore and
    Immunocore shall be entitled to sell, supply such stock in its absolute discretion either directly or through any Third Party. Save where termination results from a material breach by GNE (in which case any stock shall be provided free of charge to
    Immunocore), Immunocore will reimburse GNE for the cost of manufacture of any remaining stock (as evidenced by a Third Party invoice or other written evidence of cost incurred).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.6.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Survival</b>. In addition to any provisions
    specified in this Agreement as surviving under the applicable circumstances, the provisions of Articles 1, 16, 17, 18, 19 (provided with respect to Articles 18 and 19, only with respect to those claims that arise from the acts or omissions of a Party
    prior to the effective date of termination or expiration), 21 and 22 and Sections 4.2.3, 9.1.1(b), 9.1.6, 9.3, 10.3.2, 13.5.7, 14.7.1, 15.2.2, 20.1, 20.6, 20.7 shall survive any termination or expiration of this Agreement. In addition, Articles 13 and
    14 shall survive with respect to any outstanding unpaid amounts that accrued prior to any termination or expiration of this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">20.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Termination of this Agreement [***]</b>. In the
    event of termination of this Agreement [***], GNE shall grant to Immunocore a right to negotiate the commercially reasonable terms under which GNE may grant Immunocore the right for a transfer of all material activities including any ongoing Clinical
    Trials directly relating to the Terminated Product(s) and a license under the GNE Reversion IP for such Terminated Product(s) (collectively, the &#8220;<b>RON</b>&#8221;). Immunocore shall have [***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">63</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">following the effective date of such termination to notify GNE in writing as to whether Immunocore elects to exercise its RON.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.7.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>RON Notice and Data Packages</b>.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>If written notice is given that Immunocore does not
    want to exercise such RON, or written notice is not given by Immunocore to GNE within said [***] period, the RON granted to Immunocore under this Section 20.7.1 shall expire at the end of such [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>If GNE receives written notice from Immunocore within
    such [***] period that Immunocore elects to exercise such RON,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>GNE shall, within [***] following the date of
    such Immunocore notice, provide copies to Immunocore (at GNE&#8217;s expense), of [***] (the &#8220;<b>Initial Terminated Product Data Package</b>&#8221;);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore and GNE shall discuss (in person, by
    phone and/or by email), within [***] following delivery of the Initial Terminated Product Data Package, the key business and financial terms under which they would propose to form the basis of the Transfer Agreement (the &#8220;<b>Key Business Terms</b>&#8221;);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Following delivery of the Initial Terminated
    Product Data Package and during discussion of the Key Business Terms, Immunocore shall notify GNE of any additional information that is reasonably necessary for Immunocore to evaluate the RON. Following receipt of such notice, GNE shall provide to
    Immunocore such additional information (the &#8220;<b>Secondary Data Package</b>&#8221;). Any transfer of such additional information shall be at GNE&#8217;s expense. Any such notice and transfer shall be completed within [***] (or such longer period as mutually agreed)
    following delivery of the Initial Terminated Product Data Package and discussion of the Key Business Terms;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>It is understood and agreed that any such
    transfer of the Initial Terminated Product Data Package and Secondary Data Package (collectively, the &#8220;<b>Data Packages</b>&#8221;) to be limited to no more than [***] GNE personnel hours (with such personnel solely to be utilized solely to review, organize
    and transfer such Data Packages). In the event that any additional GNE assistance is required, Immunocore shall reimburse GNE its direct costs and expenses and pay GNE for its FTE time and effort incurred in providing such additional assistance at
    GNE&#8217;s FTE rate for each applicable role/activity type, being such rate applicable at the time of provision for GNE&#8217;s provision of such services to Third Parties. GNE shall use reasonable efforts to provide the assistance under this Section as
    reasonably requested by Immunocore and in any event as soon as such resource can reasonably be made available. For the avoidance of doubt, GNE shall not be obligated to generate any new data or reports that did not exist at the time the notice of
    termination was provided to Immunocore;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore shall have the right to use the Data
    Packages solely to evaluate whether to negotiate the RON, and for no other purpose;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>RON Negotiations. Immunocore shall have the right,
    following delivery of the last of the Data Packages from GNE to Immunocore, for [***] (or such longer period as mutually agreed) to negotiate in good faith with GNE the terms under which GNE may grant Immunocore the right for a transfer of all material
    activities directly relating to the Terminated Product, including</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">64</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">transfer of ongoing Clinical Trials and a license under the GNE Reversion IP for such Terminated Product (the &#8220;<b>Transfer Agreement</b>&#8221;); provided:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>if the Parties are unable to agree on the
    terms of the Transfer Agreement within such period, Immunocore may submit such dispute to arbitration for resolution as provided in Section 20.7,5 below;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the rights to discuss and/or negotiate granted
    to Immunocore under Section 20.7.2(c) with respect to GNE Background Patents that are useful, but not necessary, for the manufacture, use, sale, offer for sale, or import of a Terminated Product, including without limitation any dispute as to GNE&#8217;s
    election to grant or not grant Immunocore any rights under such GNE Background Patents, including the scope and/or terms thereof, shall expire at the end of such [***] period (or such longer term as mutually agreed) [***]. Without limiting the
    foregoing, GNE shall have no obligation to grant, and Immunocore shall have no rights to obtain, a license to GNE Background Patents that are useful, but not necessary, for the manufacture, use, sale, offer for sale, or import of a Terminated Product
    if a written agreement on commercially reasonable terms is not concluded within such [***] period (or such longer term as mutually agreed). For clarity, a GNE Background Patent shall be deemed to be &#8220;necessary&#8221; if the manufacture, use, sale, offer for
    sale or import of a Terminated Product would infringe such GNE Background Patent as at the Termination Effective Date; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Transfer Agreement shall be subject to laws
    of England and Wales and arbitration in accordance with Article 21 and Section 22.1 of this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.7.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Certain Terms</b>. In this Section 20.7.2:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#8220;<b>GNE Reversion IP</b>&#8221; means the GNE Patents, GNE
    Know-How, GNE Regulatory Information and GNE Background Patents, that are Controlled by GNE or Sublicensees as of (i) the effective date of termination of this Agreement);</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#8220;<b>GNE Patents</b>&#8221; means those claims within a
    Patent [***];</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#8220;<b>GNE Know-How</b>&#8221; means Know-How [***];</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#8220;<b>GNE Regulatory Information</b>&#8221; means any
    document [***]; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;<b>GNE Background Patents</b>&#8221; means those claims within Patents [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.7.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>GNE Reversion IP Limitations</b>. It is
    understood and agreed that the grant of the license under the GNE Reversion IP may be: [***].</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.7.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Manufacturing Limitations</b>. Under the Transfer
    Agreement, Immunocore shall be responsible (at its cost) for manufacturing the Terminated Product for clinical use and commercial sale; provided, to the extent GNE provides to Immunocore a cell-line proprietary to GNE for the manufacture of the
    Terminated Product, that manufacture of the Terminated Product [***] by a Third Party contract manufacturing organization [***] (the &#8220;<b>Authorized CMO</b>&#8221;). Alternatively, upon Immunocore&#8217;s written request, GNE shall [***]. GNE shall facilitate the
    transfer of any technology required to manufacture the Terminated Product to any such Authorized CMO in order to enable such Authorized CMO to manufacture Terminated Product on behalf of Immunocore. Immunocore</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">65</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">shall enter into a manufacturing supply agreement with the Authorized CMO and shall be responsible for all costs and other obligations related to the
    manufacture and supply of the Terminated Product by the Authorized CMO to Immunocore. If a Terminated Product is being manufactured (whether for clinical use or commercial scale) by GNE (and not by an Authorized CMO) at the time of such termination,
    the Parties shall also negotiate in good faith the terms and timelines under which GNE would continue to manufacture such Terminated Product until a manufacturing transfer to an Authorized CMO has been completed, and GNE will use commercially
    reasonable efforts to accommodate Immunocore&#8217;s supply demands. Immunocore will use commercially reasonable efforts to effect the manufacturing transfer to the Authorized CMO as quickly as possible.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.7.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Baseball-Style Arbitration</b>. If the Parties
    are unable to agree on the terms of the Transfer Agreement, Immunocore may submit such dispute to arbitration for resolution in accordance with the following provisions:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Immunocore shall notify GNE of its decision to
    initiate the arbitration proceeding pursuant to this Section 20.7.5 through written notice to GNE within the [***] negotiation period specified in Section 20.7.1(c) above.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Within [***] following GNE&#8217;s receipt of such
    notice, the Parties shall use commercially reasonable efforts to agree on an independent Third Party expert with at least [***] of experience in the licensing of pharmaceutical compounds or products. If the Parties cannot agree on such expert within
    such time period, each Party shall nominate one independent expert within such [***] period, and the two experts so selected shall nominate the final independent expert within [***] of their nomination. If the two experts so selected cannot agree on
    the final independent expert, such final independent expert shall be nominated by the President of the Chamber of Commerce of London. For the avoidance of doubt, it is understood and agreed that such final independent expert should have at least [***]
    of experience in the licensing of pharmaceutical compounds or products.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Within [***] of its appointment, the expert shall
    set a date for the arbitration, which date shall be no more than [***] after the date the arbitration is demanded under Section 20.7.5;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The arbitration shall be &#8220;baseball-style&#8221;
    arbitration; accordingly, at least [***] prior to the arbitration, each Party shall provide the expert with a written agreement on the terms the Transfer Agreement suggested by it. Such written agreement may be no more than [***], and must clearly
    provide and identify the Party&#8217;s position with respect to the disputed matter.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>after receiving both Parties&#8217; written agreements,
    the expert will distribute each Party&#8217;s written agreement to the other Party, [***] in advance of the arbitration, the Parties shall submit and exchange response briefs of no more than [***]. The Parties&#8217; briefs may include or attach relevant exhibits
    in the form of documentary evidence, any other material voluntarily disclosed to the other Party in advance, or publicly available information. The Parties&#8217; briefs may also include or attach demonstratives and/or expert opinion based on the permitted
    documentary evidence;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the arbitration shall consist of a [***] hearing
    of no longer than [***], such time to be split equally between the Parties, in the form of presentations by counsel and/or employees and officers of the Parties. No live witnesses shall be permitted except expert witnesses whose opinions were provided
    with the Parties&#8217; briefs;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">66</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>no later than [***] following the arbitration, the
    experts shall issue their written decision. The experts shall select one Party&#8217;s written agreement as their decision, and shall not have the authority to render any substantive decision other than to select the written agreement submitted by either GNE
    or Immunocore. The experts shall have no discretion or authority with respect to modifying the positions of the Parties. The experts&#8217; decision shall be final and binding on the Parties and the written agreement selected by the experts shall constitute
    a binding agreement between the Parties that may be enforced in accordance with its terms. Each Party shall bear its own costs and expenses in connection with such arbitration, and shall share equally the experts&#8217; fees and expenses;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the violation of the time limits prescribed in
    this Section 20.7.5 by the expert shall not affect the experts&#8217; competence to decide on the subject matter, and shall not affect the final and binding decision rendered by the experts, unless otherwise agreed by the Parties; and</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the above &#8220;baseball-style&#8221; arbitration shall be
    the exclusive remedy of either Party if the Parties cannot agree on the agree on the terms of the Transfer Agreement under this Section 20.7.5.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 21</b><br>
    <font style="text-transform: uppercase"><b>DISPUTE RESOLUTION</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Disputes</b>. &#8220;<b>Party</b>&#8221; or &#8220;<b>Parties</b>&#8221; in
    this Article 21 shall mean GNE and Immunocore. Immunocore and GNE recognize that a dispute, controversy or claim of any nature whatsoever arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, (each, a &#8220;<b>Dispute</b>&#8221;)








    may from time to time arise during the Term. Unless otherwise specifically recited in this Agreement, such Disputes between Immunocore and GNE will be resolved as recited in this Article 21. In the event of the occurrence of such a Dispute, the Parties
    shall first refer such Dispute to their respective Alliance Managers for attempted resolution by such Alliance Managers within [***] after such referral. If such Dispute is not resolved within such [***] period, either Immunocore and GNE may, by
    written notice to the other, have such Dispute referred to their respective officers designated below, or their respective designees, for attempted resolution within [***] after such notice is received. Such designated officers are as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For GNE &#8212; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">For Immunocore &#8212; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event the designated officers, or their respective designees, are not able to resolve such Dispute within [***] of such other Party&#8217;s receipt of such written
    notice, either Party may initiate the dispute resolution procedures set forth in Section 21.2.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Arbitration</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Rules</b>. Except as otherwise expressly provided
    in this Agreement (including under Section 21.3), the Parties agree that any Dispute not resolved internally by the Parties pursuant to Section 21.1 shall be resolved through binding arbitration conducted by the International Chamber of Commerce in
    accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce (for purposes of this Article 21, the &#8220;<b>Rules</b>&#8221;), except as modified in this Agreement, applying the substantive law specified in Section 22.1.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">67</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Arbitrators; Location</b>. Each Party shall
    select one (1) arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator. All three (3) arbitrators shall serve as neutrals and have at least [***] of (a) dispute resolution experience (including judicial experience) and/or
    (b) legal or business experience in the biotech or pharmaceutical industry. In any event, at least one (1) arbitrator shall satisfy the foregoing experience requirement under Section (b). If a Party fails to nominate its arbitrator, or if the Parties&#8217;
    arbitrators cannot agree on the third, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings shall be
    conducted in London, England. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any written evidence originally in another language shall be translated into English and accompanied by the original or a
    true copy thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Procedures; Awards</b>. Each Party agrees to use
    reasonable efforts to make all of its current employees available, if reasonably needed, and agrees that the arbitrators may determine any person as necessary. The arbitrators shall be instructed and required to render a written, binding,
    non-appealable resolution and award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than
    [***] after conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for
    enforcement. Each Party agrees that, notwithstanding any provision of Applicable Law or of this Agreement, it will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against any Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Costs</b>. The prevailing Party, as determined by
    the arbitrators, shall be entitled to [***]. In determining which Party &#8220;prevailed,&#8221; the arbitrators shall consider (i) the significance, including the financial impact, of the claims prevailed upon and (ii) the scope of claims prevailed upon, in
    comparison to the total scope of the claims at issue. If the arbitrators determine that, given the scope of the arbitration, neither Party &#8220;prevailed,&#8221; the arbitrators shall order that the Parties (1) share equally the fees and expenses of the
    arbitrators and (2) bear their own attorneys&#8217; fees and associated costs and expenses.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Interim Equitable Relief</b>. Notwithstanding
    anything to the contrary in this Section 21.2, in the event that a Party reasonably requires relief on a more expedited basis than would be possible pursuant to the procedure set forth in this Article 21, such Party may seek a temporary injunction or
    other interim equitable relief in a court of competent jurisdiction pending the ability of the arbitrators to review the decision under this Section 21.2. Such court shall have no jurisdiction or ability to resolve Disputes beyond the specific issue of
    temporary injunction or other interim equitable relief.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.2.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160; </font><b>Protective Orders; Arbitrability</b>. At the
    request of either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. The arbitrators shall have the power to decide all
    questions of arbitrability.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Subject Matter Exclusions</b>. Notwithstanding the
    provisions of Section 21.2, any Dispute not resolved internally by the Parties pursuant to Section 21.1 that involves the validity or infringement of a Patent Covering a Licensed Product (a) that is issued in the United States shall be</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">68</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the
    jurisdiction of the district where any of the defendants resides; and (b) that is issued in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the
    jurisdiction and venue of such courts and bodies.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">21.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Continued Performance</b>. Provided that this
    Agreement has not terminated, the Parties agree to continue performing under this Agreement in accordance with its provisions, pending the final resolution of any Dispute.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><b>ARTICLE 22</b><br>
    <font style="text-transform: uppercase"><b>MISCELLANEOUS</b></font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.1<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Applicable Law</b>. This Agreement (including the
    arbitration provisions of Section 21.2) shall be governed by and interpreted in accordance with the laws of England and Wales, without reference to the principles of conflicts of laws. The United Nations Convention on Contracts for the International
    Sale of Goods shall not apply to the transactions contemplated by this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.2<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Notices</b>. Except as otherwise expressly provided
    in the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in
    person; (b) on the date of receipt, if sent by a facsimile (with delivery confirmed); or (c) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested. Any notice sent via facsimile shall be
    followed by a copy of such notice by private express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Section 22.2 by sending written
    notice to the other Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <table style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in">&#160;</td>
        <td style="width: 2in"><font style="font-family: Times New Roman, Times, Serif">If to GNE:</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">Genentech, Inc.</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Attn: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Fax: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Phone: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td colspan="2"><font style="font-family: Times New Roman, Times, Serif">with required copies (which shall not constitute notice) to:</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td colspan="2">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Genentech, Inc.</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Attn: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Fax: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">If to Immunocore:</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">Immunocore Limited</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Attn: Chief Executive Officer</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">101 Park Drive</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Milton Park</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Abingdon</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Oxon</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">United Kingdom</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">OX14 4RY</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Fax: [***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">69</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <table style="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in">&#160;</td>
        <td style="width: 2in"><font style="font-family: Times New Roman, Times, Serif">If to Roche:</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">F. Hoffmann-La Roche Ltd.</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Attn: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Fax: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">and</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">F. Hoffmann-La Roche Ltd</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Attention: [***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td>&#160;</td>
        <td>&#160;</td>
        <td><font style="font-family: Times New Roman, Times, Serif">Fax: [***]</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.3<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Assignment</b>. None of the Parties may assign or
    otherwise transfer, in whole or in part, this Agreement without the prior written consent of the non-assigning Parties such approval not to be unreasonably withheld or delayed. Notwithstanding the foregoing, a Party may assign this Agreement to (i) an
    Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation or re-organisation of such Party with or into
    such corporation or entity, provided that the Party to which this Agreement is assigned expressly agrees in writing to assume and be bound by all obligations of the assigning Party under this Agreement. Immunocore may also transfer the Licensed Product
    IP and/or Immunocore Platform IP or its share in the Foreground IP to any Affiliate that is controlled by or controls Immunocore and provided that any transfer is explicitly subject to this Agreement, A copy of such written agreement by such assignee
    shall be provided to the non-assigning Party within [***] of execution of such written agreement, subject in each case to any confidentiality restrictions. Subject to the foregoing, this Agreement will benefit and bind the Parties&#8217; successors and
    assigns.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.4<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Non-solicit</b>. Neither Immunocore on the one
    hand, nor GNE on the other hand shall (except with the prior written consent of the other Party knowingly solicit or entice away (or attempt to solicit or entice away) from the employment of the Other Party any person employed or engaged by such Other
    Party in the provision of its obligations under any Research Program or Development Program during the course of any Research Program or Development Program, as the case may be, and for a further period of [***] from expiry, termination or completion
    of such program; provided that this Section 22.4 shall not apply to advertisements of a general nature placed in newspapers, trade publications or online. If a Party does breach this Section 22.4 it agrees and accepts that the Other Party will suffer
    damage and as a minimum it agrees to pay liquidated damages equivalent to two year&#8217;s basic salary or the annual fee that was paid by the Other Party to the relevant employee. The liquidated damages set out in this Section does not prevent the Other
    Party claiming damages in the ordinary course in relation to a breach of this Section 22.4. For the purposes of this Section 22.4, &#8220;Other Party&#8221; shall mean GNE if Immunocore is the Party soliciting or enticing away a person from employment and
    Immunocore if GNE is the Party soliciting or enticing away a person from employment.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.5<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Independent Contractors</b>. The Parties hereto are
    independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.6<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Integration</b>. Except to the extent expressly
    provided herein, this Agreement constitutes the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all previous oral and written communications between the Parties with respect to the subject matter</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">70</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">of this Agreement (including the term sheets exchanged by and between Immunocore and GNE). Nothing in this Section 22.6 shall exclude any liability
    for fraud or fraudulent misrepresentation. All Parties confirm that save as explicitly stated in this Agreement they have not relied upon or been induced to enter into this Agreement in reliance upon any warranty or representation made by any of the
    other Parties, save to the extent explicitly set out in this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.7<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Amendment; Waiver</b>. Except as otherwise
    expressly provided herein, no alteration of or modification to this Agreement shall be effective unless made in writing and executed by an authorized representative of all Parties. No course of dealing or failing of a Party to strictly enforce any
    term, right or condition of this Agreement in any instance shall be construed as a general waiver or relinquishment of such term, right or condition. The observance of any provision of this Agreement may be waived (either generally or any given
    instance and either retroactively or prospectively) only with the written consent of the Party granting such waiver.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.8<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Survival of Prior Agreements</b>. As of the
    Effective Date, it is understood and agreed that the Original Agreement and the Second Agreement, as each was amended, shall survive in full force and effect.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.9<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Further assurance</b>. All Parties shall and shall
    use all reasonable endeavors to procure that any necessary Third Party shall promptly execute and deliver such further documents and do such further acts as may be required for the purpose of giving full effect to this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.10<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Severability</b>. The Parties do not intend to
    violate any public policy or statutory or common law. However, if any sentence, paragraph, section, clause or combination or part thereof of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph,
    section, clause or combination or part of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic purpose and structure of this Agreement.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.11<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>No Third Party Rights</b>. The Parties do not
    intend that any term of this Agreement should be enforceable by any person who is not a Party.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.12<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Costs of Agreement</b>. The Parties shall each bear
    all of their respective costs and expenses incurred in connection with the negotiation and preparation of this Agreement and its Exhibits and any ancillary documents referenced herein, and in respect of the consummation of the transactions contemplated
    hereunder.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.13<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Construction</b>. The Parties mutually acknowledge
    that they and their attorneys have participated in the negotiation and preparation of this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of which Party may be deemed to have drafted this
    Agreement or authorized the ambiguous provision.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.14<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><b>Interpretation</b>. The captions and headings to
    this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless context otherwise clearly requires, whenever used in this Agreement: (a) the words &#8220;include&#8221; or
    &#8220;including&#8221; shall be construed as incorporating &#8220;but not limited to&#8221; or &#8220;without limitation&#8221;; (b) the words &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby&#8221; and derivative or similar words refer to this Agreement, including the Exhibits; (c) the word &#8220;law&#8221; or &#8220;laws&#8221; means
    any applicable, legally binding statute, ordinance, resolution, regulation, code, guideline, rule, order, decree, judgment, injunction, mandate</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">71</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">or other legally binding requirement of a governmental authority (including a court, tribunal, agency, legislative body or other instrumentality of
    any (i) government or country or territory, (ii) any state, province, county, city or other political subdivision thereof, or (iii) any supranational body); (d) all references to the word &#8220;will&#8221; are interchangeable with the word &#8220;shall&#8221; and shall be
    understood to be imperative or mandatory in. nature; (f) the singular shall include the plural and vice versa; and (g) the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and/or&#8221;. All references to days, months, quarters or years are
    references to calendar days, calendar months, calendar quarters, or calendar years.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">22.15<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Counterparts</b>. This Agreement may be executed
    in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. For purposes hereof, a facsimile copy, or email with attached pdf copy, of this Agreement, including the
    signature pages hereto, will be deemed to be an original. Notwithstanding the foregoing, the Parties shall deliver original execution copies of this Agreement to one another as soon as practicable following execution thereof.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>[Signature page follows &#8212; the rest of this page intentionally left blank.]</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#160;&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b><b>Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii)
        is the type that the registrant treats as private or confidential.</b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>IN WITNESS WHEREOF</b>, Immunocore, GNE and Roche have executed this Agreement by their respective officers hereunto duly authorized, on the Effective Date,</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;"><b>IMMUNOCORE LIMITED</b></font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif"><i><font style="font-style: normal;">/s/ Andrew Hotchkiss</font><br>
            </i></font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid">
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Andrew Thomas Hotchkiss</div>
        </td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">Title: &#160;</font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid">
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">CEO<br>
          </div>
        </td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 3%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 43%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 52%">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;"><b>GENENTECH, INC,</b></font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;">
            <div style="font-size: 10pt;"><font style="font-size: 12pt;">/s/ </font>Edward Harrington</div>
          </div>
          <font style="font-family: Times New Roman, Times, Serif;"></font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">Name: </font></td>
        <td style="font-family: Times New Roman,serif">
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif;">Edward Harrington</div>
        </td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;">&#160;</td>
        <td rowspan="1" style="font-family: Times New Roman,serif;">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">Title: &#160;</font></td>
        <td colspan="2" style="font-family: Times New Roman,serif">
          <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><font style="font-size: 10pt;">Chief Financial Officer</font><br>
          </div>
        </td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 3%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 2%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 43%">&#160;</td>
        <td style="font-family: Times New Roman,serif; width: 52%">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
  <table style="width: 100%; border-collapse: collapse; font-size: 10pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif"><b>F. HOFFMANN-LA ROCHE LTD</b></font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;&#160;&#160;&#160;&#160;</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td colspan="3" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; font-style: italic;"><font style="font-family: Times New Roman, Times, Serif">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid">
          <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-style: normal;">/s/ Stefan Arnold</div>
        </td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">By: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif;"><i><font style="font-style: normal;">/s/ Dr. Franziska B&#228;chler</font><br>
            </i></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="2" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif">Stefan Arnold&#160;&#160;&#160;&#160;&#160; <br>
          </font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td colspan="2" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">Name: </font></td>
        <td style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif">Dr. Franziska B&#228;chler&#160;&#160; <br>
          </font></td>
      </tr>
      <tr style="vertical-align: top">
        <td rowspan="1" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td rowspan="1" colspan="2" style="font-family: Times New Roman,serif;"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif;">Head Legal Pharma&#160;&#160; <br>
          </font></td>
        <td><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif"><font style="font-family: Times New Roman, Times, Serif">Title: </font></td>
        <td colspan="2" style="font-family: Times New Roman,serif; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif;">Authorized Signatory&#160;&#160;&#160; <br>
          </font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Times New Roman,serif; width: 3%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 43%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 3%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 2%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
        <td style="font-family: Times New Roman,serif; width: 42%"><font style="font-family: Times New Roman, Times, Serif">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  &#160;
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT A&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN PATENTS</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>[***]</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 20%; border: Black 1pt solid; text-align: center; padding-left: 5pt; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <table style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt; width: 20%; border-top: Black 1pt solid">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt; width: 26%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt; width: 20%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt; width: 14%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt; width: 20%; border-top: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 23%; border: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 17%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 41%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt"><b>[***]</b></td>
      </tr>
      <tr>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 25%; border: Black 1pt solid; text-align: left; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 13%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; text-align: left; padding-left: 5pt; width: 25%">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; width: 20%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 13%; border-top: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%; border-top: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr>
        <td style="vertical-align: bottom; border: Black 1pt solid; text-align: left; padding-left: 5pt; width: 25%">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%; border-top: Black 1pt solid">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; width: 20%; border-top: Black 1pt solid">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 13%; border-top: Black 1pt solid">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%; border-top: Black 1pt solid">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: bottom; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; width: 25%">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; width: 20%">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 13%">[***]</td>
        <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; width: 21%">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT B</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>[***]</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;<b>&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT C</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INITIAL PRE-POC DEVELOPMENT PLAN AND BUDGET</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <table style="width: 40%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 58%; border: Black 1pt solid; text-align: justify">&#160;</td>
        <td style="width: 42%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT D</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AGREED FORM OF PRESS RELEASE</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a broad international investor base. For more information, please visit www.immunocore.com.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit E&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Initial CMC Plan</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>[***]</u></b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 23%; border: Black 1pt solid; text-align: justify; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 61%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 8pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
  <table style="width: 96%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 4%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 41%; border: Black 1pt solid; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 39%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td colspan="11" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td colspan="2" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td colspan="2" rowspan="3" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td colspan="13" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td colspan="12" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td colspan="12" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="text-align: justify; padding-left: 5pt; width: 16%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
        <td style="text-align: justify; padding-left: 5pt; width: 7%">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; text-align: justify; padding-left: 5pt"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt"><b>[***]</b></font></td>
        <td colspan="12" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; border-top: Black 1pt solid"><font style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 10pt">[***]</font></td>
      </tr>
      <tr>
        <td style="width: 16%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
        <td style="width: 7%; padding-left: 5pt"><font style="font-size: 1pt">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 43%; border: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">
          <p style="margin-top: 0; margin-bottom: 0">[***]</p>
          <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
        </td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 43%; border: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 43%; border: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 43%; border: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 43%; border: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
        <td style="width: 38%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt"><b>[***]</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit F</b>&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Material and Technology Transfer Deliverables</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><u>[***]</u></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exhibit G&#160;</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Modified Financial Terms for Other MAGE-A4 Compounds</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Article 13 of the Agreement shall be amended as follows with regard to Licensed Products containing Other MAGE-A4 Compounds:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table of milestones in Section 13.3.1 shall be deleted and replaced with the following:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="border: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt"><b>Event</b></td>
        <td colspan="3" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt"><b>Event Payment (US$)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 46%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center; padding-left: 5pt; padding-bottom: 8pt">&#160;</td>
        <td style="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt"><b>1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> Indication</b></td>
        <td style="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt"><b>2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Indication</b></td>
        <td style="width: 18%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt"><b>3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> Indication</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***] </td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***] </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-left: 5pt; text-align: left; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt"><b>Total Potential Event Payments:</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt"><b>[***]</b></td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt"><b>[***]</b></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 13.3.2 (c) shall be deleted and replaced with the following new Section 13.3.2 (c):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">13,3.3 (c). &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the avoidance of doubt, GNE&#8217;s (including where such obligation arises as a result of actions by any Sublicensee) cumulative
    obligation under Section 13.3.1 with respect to the: (i) first Licensed Product in the first Indication shall in no event exceed [***]; (ii) first Licensed Product in the second Indication shall in no event exceed [***]; and (iii) first Licensed
    Product in the third Indication shall in no event exceed [***],</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 13.3.2(f) shall be deleted and replaced as follows:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top">
        <td style="width: 0"></td>
        <td style="width: 0.5in">13.3.2(f)</td>
        <td style="text-align: justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the payment obligations set forth in Section 13.3.1 above, Event Payments shall only be due under:</td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 13.3.1(c), if the Licensed Product that achieves such Event is Covered by a Valid Claim [***] at the time of achievement of such
    Event; provided, if no Valid Claim [***] Covers the Licensed Product at the time of achievement of such Event, such Event</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Payment shall be accrued at the time of such achievement, but shall not be due and payable unless and until such time as a Valid Claim [***] Covering such
    Licensed Product. Any obligation to accrue payments under this Section shall cease once all patent applications Covering the relevant Licensed Product existing at the date of the Event in Section 13.3.1(c) and which if issued would constitute a Valid
    Claim have either lapsed, been disclaimed, revoked, held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealed or appealed within the time allowed for appeal.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Section 133.1(d), (e) (f), (g), (h) or (i), if the Licensed Product that achieves such event is Covered by a Valid Claim in such country at
    the time of achievement of such Event.</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 13.4.1 shall be deleted and replaced with the following:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>Net Sales Event Payments</b>. Subject to the terms of Section 13.4.2, GNE shall pay Immunocore the following one-time Milestone Payments per Licensed
    Product upon each Licensed Product achieving the following Net Sales Events (whether such achievement is by GNE or its Sublicensees):</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>
  <table style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 14%; border: Black 1pt solid; text-align: justify; padding-left: 5pt">&#160;</td>
        <td style="width: 60%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5pt"><b>Net Sales Event</b></td>
        <td style="width: 26%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-left: 5pt"><b>Milestone <br>
            Payment (in US <br>
            dollars)</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">(a)</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">(b)</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">(c)</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">(d)</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; padding-left: 5pt; padding-bottom: 8pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Milestone Payments under this Section shall be due only once for the first Licensed Product. For the avoidance of doubt, GNE&#8217;s and its Sublicensees&#8217;
    cumulative obligation under this Section 13.4.1 shall in no event exceed [***]).</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sections 13.5.1 and 13.5.2 and 13.5.3 shall be deleted and replaced with the following:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">13.5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;Valid Claim Products. GNE or its Sublicensees shall pay Immunocore, on a Licensed Product-by-Licensed Product and country-by-country basis, and
    subject to the terms of Section 13.5.2. through 13.5.7, the following royalties on annual worldwide Net Sales of Licensed Products by GNE and its Sublicensees, which at the time of sale or supply, are Covered by a Valid Claim in the country in which
    such Licensed Product is sold:</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b>&#160; </p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Execution Copy</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p>
  <table style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; margin-left: 0.5in" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 70%; border: Black 1pt solid; text-align: center; padding-left: 5pt"><b>Annual Worldwide Net Sales (in US Dollars)</b></td>
        <td style="width: 30%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><b>Royalty </b><br>
          <b>Rate </b><br>
          <b>Percentage</b></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">Up to [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">Portion equal to or greater than [***] and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">Portion equal to or greater than [***]and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">Portion equal to or greater than [***]and less than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; padding-left: 5pt; padding-bottom: 8pt">Portion greater than [***]:</td>
        <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 8pt">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-indent: -0.5in; text-align: justify">13.5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Know-How Products</b>. If in any calendar quarter, the sale of a Licensed Product
    is not Covered by a Valid Claim in the country in which such Licensed Product is sold, then GNE or its Sublicensees shall pay to Immunocore, on a Licensed Product-by-Licensed Product and country-by-country basis, and subject to the terms of Section
    13,5.4 through 13.5.7, a royalty equivalent to [***]of the amounts specified in Section 13.5.1 on annual worldwide Net Sales of such Licensed Product.</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">13.5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>Not Used.</b></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively
      harmful if publicly disclosed.</b></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>9
<FILENAME>nt10016217x4_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 10.10</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
    <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE</div>
    <div style="text-align: center; font-weight: bold;">REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">IMMUNOCORE LIMITED<br>
    </div>
    <div style="font-variant: small-caps;">&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">CONVERTIBLE LOAN NOTE<br>
    </div>
    <div style="font-variant: normal;">&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">PURCHASE AGREEMENT<br>
    </div>
    <div style="font-variant: small-caps;">&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">DATE 13 SEPTEMBER 2017</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CONTENTS</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf597180d2b154cf5aa1308f58a9c200a" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>1.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Definitions</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">2</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Amount and Terms of the Loan</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>3.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Use of Proceeds</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>4.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Closing</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>5.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Warranties and Covenants of the Company</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">7</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>6.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Warranties and Covenants of the Purchaser</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">8</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>7.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Events of Default; Remedies</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">10</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>8.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Conditions To Closings</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">11</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Covenants of the Company</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">13</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Miscellaneous</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">14</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 88%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>SCHEDULE 1 WARRANTIES</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">19</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT A FORM OF FIRST TRANCHE CONVERTIBLE LOAN NOTE</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">25</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT B FORM OF SECOND TRANCHE CONVERTIBLE LOAN NOTE</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">26</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT C FORM OF LETTER AGREEMENT</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">29</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT D FORM OF DEED OF ADHERENCE</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">30<br>
            </div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT E BOARD OBSERVER LETTER</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">32</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 6%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>EXHIBIT F ORDINARY SHAREHOLDER RESOLUTION</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">33</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">NOTE PURCHASE AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">This NOTE PURCHASE AGREEMENT (this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) is made as of the 13 day of September, 2017 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;) by
      and among Immunocore Limited, a company registered in England under number 06456207 with its registered office at 101 Park Dr, Milton, Abingdon OX14 4RY (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), and the Bill &amp; Melinda Gates
      Foundation of PO Box 23350, Seattle, WA (the &#8220;<font style="font-weight: bold;">Purchaser</font>&#8221;). The Company and the Purchaser are each referred to as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; and collectively as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;.</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">BACKGROUND</div>
    <div>&#160;</div>
    <div>(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchaser desires to advance loans to the Company, in furtherance of the Purchaser&#8217;s exempt purposes described in Section 170(c)(2)(B) of the Code and the Letter Agreement, and the Company desires to borrow from the Purchaser, in
      two tranches, an amount not to exceed in the aggregate forty million United States dollars (US$40,000,000.00) (the &#8220;<font style="font-weight: bold;">Loan Amount</font>&#8221;) (each loan advance a &#8220;<font style="font-weight: bold;">Loan</font>&#8221; and
      collectively the &#8220;<font style="font-weight: bold;">Loans</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify;">(B)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Loans will be evidenced by subordinated convertible loan notes in the form attached hereto as <u>Exhibit A</u> and <u>Exhibit B</u> (each a &#8220;<font style="font-weight: bold;">Note</font>&#8221; and
      collectively the &#8220;<font style="font-weight: bold;">Notes</font>&#8221;). Each Note may be converted into shares of the Company as provided in the Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Parties agree as follows:</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><a name="z_Toc54145785"></a>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Definitions</u>. In this Agreement, unless the context requires otherwise, the following terms shall have the following meanings:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Accounts</font>&#8221; means the audited balance sheet and profit and loss account of the Company for the period ended on the Accounts
      Date;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Accounts Date</font>&#8221; means 31 December 2016;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Act</font>&#8221; means the United States Securities Act of 1933, as amended from time to time;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; means, as to any Person, any other Person that directly or indirectly Controls, or is under common Control with or
      is Controlled by such Person;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Authorizations</font>&#8221; means as defined in Section 2(a) of Schedule 1;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Board Observer Letter</font>&#8221; means the letter in the form set out in Exhibit E from the Company to the Purchaser setting out the
      terms on which the Purchaser shall be entitled to appoint an observer to the board of directors of the Company;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Closing</font>&#8221; and &#8220;<font style="font-weight: bold;">Closings</font>&#8221; means as defined in <u>Section 4.1</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Code</font>&#8221; means the US Internal Revenue Code of 1986, as amended from time to time, and the regulations thereunder;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Company Product</font>&#8221; means any product or service designed, developed, manufactured, marketed, distributed, provided, licensed, or
      sold at any time by the Company;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.10&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Company Subsidiaries</font>&#8221; means Immunocore LLC and Immunocore Nominees Limited;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.11&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Confidential Information</font>&#8221; means all information, inventions, trade secrets and know-how which is confidential and not generally
      known;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.12&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Connected Person</font>&#8221; has the meaning given to that expression in Section 1122 of the CTA 2010;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.13&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Constitutional Documents</font>&#8221; means the constitutional documents of the Company as applicable at the relevant time including the
      articles of association of the Company and any shareholders or investment agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.14&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Control</font>&#8221; means the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of an
      entity, or the right to receive more than fifty percent (50%) of the profits or earnings of an entity. Any other relationship which in fact results in one entity having a decisive influence over the management, business and affairs of another entity
      shall also be deemed to constitute Control and Controlled shall be construed accordingly;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.15&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Conversion Shares</font>&#8221; means shares of the Company to be issued upon conversion of the Notes as set out in the Notes;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.16&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">CTA 2010</font>&#8221; means the Corporation Tax Act 2010;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.17&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Data Protection Legislation</font>&#8221; means the Data Protection Act 1998, the EU Data Protection Directive 95/46/EC, the Privacy and
      Electronic Communications Directive 2002/58/EC (as amended), the Privacy and Electronic Communications (EC Directive) Regulations 2003 (as amended), the Regulation of Investigatory Powers Act 2000, the Telecommunications (Lawful Business Practice)
      (Interception of Communications) Regulations 2000 and all applicable laws and regulations relating to processing of personal data, including where applicable the guidance and codes issued by the Information Commissioner or other appropriate
      supervisory authority;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.18&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Data Room</font>&#8221; means the electronic data room prepared by the Company and made available to the Purchaser and delivered to the
      Purchaser on a CD-ROM on the First Closing Date;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.19&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Deed of Adherence</font>&#8221; means the deed of adherence to the Shareholders Agreement in the form set out in <u>Exhibit D</u> to be
      entered into by the Purchaser;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.20&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Disclosure Letter</font>&#8221; means the disclosure letter dated on the same date as this Agreement from the Company to the Purchaser and
      any updated disclosure letter provided by the Company to the Purchaser prior to the Second Closing in accordance with <u>Section 5.3</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.21&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221; means the date set out at the beginning of this Agreement;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.22&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Encumbrance</font>&#8221; means any mortgage, charge, security interest, lien, pledge, assignment by way of security, equity, claim, right of
      pre-emption, option or any other security agreement or arrangement (whether or not perfected other than liens arising by operation of law);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.23&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Event of Default</font>&#8221; means as defined in <u>Section 7.1</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.24&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">First Closing</font>&#8221; means as defined in <u>Section 4.1(a)</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.25&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">First Closing Date</font>&#8221; means as defined in <u>Section 4.1(a)</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.26&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">First Tranche Note</font>&#8221; means the convertible loan note in the form set out in <u>Exhibit A</u> to be issued by the Company on the
      First Closing;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.27&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Group</font>&#8221; means the Company and the Company Subsidiaries;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.28&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">HMRC</font>&#8221; means HM Revenue &amp; Customs;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.29&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Intellectual Property</font>&#8221; means all intellectual property rights of whatsoever nature including without limitation copyrights,
      registered designs, design rights, Patents, all rights of whatsoever nature in computer software and data, all rights of privacy and all intangible rights and privileges of a nature similar or allied to any of the foregoing, in every case in any part
      of the world and whether or not registered, and including all granted registrations and all applications for registration in aspect of any of the same;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.30&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Investment Documents</font>&#8221; means this Agreement, the Notes, the Letter Agreement, the Deed of Adherence and the Board Observer
      Letter, in each case as amended from time to time;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.31&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Letter Agreement</font>&#8221; means the Global Access Commitments Letter in the form set out in <u>Exhibit C</u> entered into between the
      Company and the Purchaser on or before the date of this Agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.32&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Loan Documents</font>&#8221; means this Agreement and the Notes;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.33&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Management Accounts</font>&#8221; means the management accounts of the Company for the period starting on the Accounts Date and ending on 31
      July 2017, in the Data Room;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.34&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;Material Adverse Change&#8221; means:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; any fact, matter, event, circumstance, condition or change in the business, operations, assets, liabilities, condition (whether financial, trading or otherwise),
      prospects or operating results of the Company which materially and adversely affects, or could reasonably be expected to materially and adversely affect, the Company&#8217;s ability to perform its obligations under any of the Investment Documents;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; a Charitability Default pursuant to the Letter Agreement which has not been remedied prior to the Second Closing Date and within the time period set forth in the
      Letter Agreement;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.35&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Material Adverse Effect</font>&#8221; means as defined in Section 2(a) of Schedule 1;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.36&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">New Investor Gross Proceeds</font>&#8221; means gross proceeds raised from one or more investors that had no affiliation with the Company
      prior to the Qualifying Financing and are investing on an arms-length basis with no Intellectual Property, licensing rights or other value provided by the Company to the investor beyond the equity securities;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.37&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Patent</font>&#8221; means (a) all national, regional and international patents and patent applications, (b) all patent applications filed
      either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisional, continuations, continuations-in-part, provisionals, converted provisionals, and continued
      prosecution applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications, including utility models, petty patents and design patents and certificates of invention, and (d) any and all extensions
      or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent
      applications;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.38&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Person</font>&#8221; means any individual, partnership, corporation, limited liability company, association, trust, joint venture,
      unincorporated organization or other entity;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.39&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Personal Data</font>&#8221; has the same meaning as the term &#8220;personal data&#8221; under the Data Protection Legislation;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.40&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Properties</font>&#8221; means the properties described in Section 14 of the Disclosure Letter;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.41&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Qualifying Financing</font>&#8221; [***];</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.42&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Safety Milestone</font>&#8221; [***];</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.43&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Second Closing</font>&#8221; means as defined in <u>Section 4.1(b)</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.44&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Second Closing Date</font>&#8221; means as defined in <u>Section 4.1(b)</u>;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.45&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Second Tranche Note</font>&#8221; means the convertible loan note in the form set out in <u>Exhibit B</u> to be issued by the Company on
      the Second Closing;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.46&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Senior Indebtedness</font>&#8221; means, unless expressly subordinated to or made on a parity with the amounts due under the Notes, all
      amounts due in connection with (i) indebtedness of the Company to banks or other lending institutions regularly engaged in the business of lending money (excluding venture capital, investment banking or similar institutions and their affiliates which
      sometimes engage in lending activities but which are primarily engaged in investments in equity securities), and (ii) any such indebtedness or any debentures, notes or other evidence of indebtedness issued in exchange for such Senior Indebtedness, or
      any indebtedness arising from the satisfaction of such Senior Indebtedness by a guarantor;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.47&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Shareholders Agreement</font>&#8221; means the amended and restated subscription and shareholders agreement relating to the Company dated 15
      July 2015 (as amended from time to time);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.48&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Special Damages</font>&#8221; means as defined in Section 5.6(d); and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">1.49&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Withdrawal Right</font>&#8221; means as defined in the Letter Agreement.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><a name="z_Toc54145786"></a>2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Amount and Terms of the Loan</u>. Subject to the terms of this Agreement:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser covenants and agrees to lend to the Company the Loans; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Company agrees to issue to the Purchaser a Note in the principal amount of each applicable Loan as set out in this Agreement. The Loan Amount shall be paid by the
      Purchaser to the Company in two tranches upon the closing dates as set forth in <u>Section 4</u> below.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><a name="z_Toc54145787"></a>3.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Use of Proceeds</u>. The Company shall use the proceeds from the sale of the Notes solely as provided in paragraph 2(c) of the Letter Agreement.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><a name="z_Toc54145788"></a>4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Closing</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing Date</u>. The closing of the purchase and sale of the Notes (the &#8220;<font style="font-weight: bold;">Closings</font>&#8221; and each a &#8220;<font style="font-weight: bold;">Closing</font>&#8221;) shall be subject to the conditions set forth in <u>Section 8</u> and held as follows:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>First Closing</u>. The first Closing (the &#8220;<font style="font-weight: bold;">First Closing</font>&#8221;) shall be held on the Effective Date or at such other time as the
      Company and the Purchaser shall agree (the &#8220;<font style="font-weight: bold;">First Closing Date</font>&#8221;), whereby the Purchaser shall lend to the Company and the Company shall issue to the Purchaser the First Tranche Note in the principal amount of
      twenty five million United States dollars (US$25,000,000.00) (the &#8220;<font style="font-weight: bold;">First Closing Amount</font>&#8221;); and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Second Closing</u>: The second Closing (the &#8220;<font style="font-weight: bold;">Second Closing</font>&#8221;) shall be held on a date specified by the Company (the &#8220;<font style="font-weight: bold;">Second Closing Date</font>&#8221;) after the successful completion of the Safety Milestone [***]. On the Second Closing Date the Purchaser shall lend to the Company and the Company shall issue to the Purchaser the Second
      Tranche Note in the principal amount of an additional fifteen million United States dollars (US$15,000,000.00) (the &#8220;<font style="font-weight: bold;">Second Closing Amount</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery on First Closing</u>. At the First Closing:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser will send to the bank account of the Company (notified in writing to the Purchaser) by wire transfer funds in the amount of the First Closing Amount;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company shall issue and deliver to the Purchaser the First Tranche Note in favor of the Purchaser in the principal amount of the First Closing Amount;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company shall execute and deliver to the Purchaser the Letter Agreement, and the Board Observer Letter signed by the Company; and</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser shall execute and deliver to the Company the Letter Agreement and the Board Observer Letter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Delivery on Second Closing</u>. At the Second Closing:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Purchaser will send to the bank account of the Company (notified in writing to the Purchaser) by wire transfer funds in the amount of the Second Closing Amount;
      and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Company shall issue and deliver to the Purchaser the Second Tranche Note in favor of the Purchaser in the principal amount of the Second Closing Amount.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145789"></a>5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Warranties and Covenants of the Company</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Warranties on First Closing Date</u>. The Company hereby warrants to the Purchaser as of the First Closing Date that, except as set forth in the Disclosure Letter,
      each of the statements set out in Schedule 1 is true and accurate as of the First Closing Date (the &#8220;<font style="font-weight: bold;">First Closing Warranties</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Warranties on Second Closing Date</u>. The Company shall warrant to the Purchaser as of the Second Closing Date that, except as set forth in the Disclosure Letter
      (as may be updated by the Company prior to the Second Closing in accordance with <u>Section 5.3</u>), each of the statements set out in Schedule 1 is true and accurate as of the Second Closing Date (the &#8220;<font style="font-weight: bold;">Second
        Closing Warranties</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Update of Disclosure Letter</u>. Prior to the Second Closing Date the Company shall provide to the Purchaser an updated Disclosure Letter which shall form the
      Disclosure Letter for the purposes of the Second Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Interpretation</u>. Each of the First Closing Warranties or the Second Closing Warranties (as the case may be) is to be construed separately and independently and
      (except where this Agreement provides otherwise) shall not be limited by reference to any other paragraph of Schedule 1 (Warranties).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.5&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Company&#8217;s Knowledge</u>. Any First Closing Warranty or Second Closing Warranty (as the case may be) qualified by the expression &#8220;so far as the Company is aware&#8221; or
      any similar expression shall, unless otherwise stated, be deemed to refer to the actual knowledge of [***], in each case having made due and reasonable enquiry.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">5.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitations on liability</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The total aggregate liability of the Company in respect of the First Closing Warranties (including all legal and other costs and expenses) shall not exceed an amount
      equal to the principal amount of the First Closing Amount.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The total aggregate liability of the Company in respect of the Second Closing Warranties (including all legal and other costs and expenses) shall not exceed an amount
      equal to the principal amount of the Second Closing Amount.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No claim may be made against the Company in respect of: (i) the First Closing Warranties unless written notice of such claim is served on the Company giving reasonable
      details of the claim by no later than the date which is [***] from the First Closing Date, and (ii) the Second Closing Warranties unless written notice of such claim is served on the Company giving reasonable details of the claim by no later than the
      date which is [***] from the Second Closing Date.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Purchaser shall not be entitled to claim in respect of a breach of the First Closing Warranties or the Second Closing Warranties for any indirect or consequential
      loss or for any loss of goodwill or loss of business, whether actual or prospective or for any punitive damages (collectively, &#8220;<font style="font-weight: bold;">Special Damages</font>&#8221;), provided that to the extent a third party has been awarded
      Special Damages against the Purchaser or any of its Affiliates in connection with any breach of the First Closing Warranties or the Second Closing Warranties, the Purchaser or its Affiliate(s), as applicable, shall be entitled to claim against the
      Company for such Special Damages (subject always to the other provisions of this <u>Section 5.6</u>).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(e)&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Purchaser shall not be entitled to claim that any fact, matter or circumstance causes any of the First Closing Warranties or Second Closing Warranties (as the case
      may be) to be breached if it has been fairly and specifically disclosed in the Disclosure Letter or the Data Room.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; No liability of the Company in respect of any breach of any First Closing Warranty or any Second Closing Warranty shall arise: (i) if such breach occurs by reason of
      any matter which would not have arisen but for the coming into force of any legislation not in force at the First Closing Date or Second Closing Date (as the case may be) or by reason of any change to HMRC&#8217;s practice announced after the First Closing
      Date or Second Closing Date (as the case may be); (ii) to the extent that specific allowance, provision or reserve has been made in the Accounts or in the Management Accounts in respect of the matter to which such liability relates; or (iii) to the
      extent that such breach or claim arises as a result of any change after the date hereof in the accounting bases or policies in accordance with which the Company values its assets or calculates its liabilities or any other change in accounting
      practice from the treatment or application of the same used in preparing the Accounts (save to the extent that such changes are required to correct errors or because relevant, generally accepted accounting principles have not been complied with).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The only First Closing Warranties or Second Closing Warranties (as the case may be) given in respect of Intellectual Property or rights in information (or agreements
      relating thereto) are those contained in paragraph 10 of Schedule 1 (Warranties), none of the other First Closing Warranties or Second Closing Warranties (as applicable) shall or shall be deemed to be, whether directly or indirectly a warranty in
      respect of Intellectual Property and the Purchaser acknowledges and agrees that the Company makes no other warranty as to Intellectual Property or rights in information (or agreements relating thereto).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145790"></a>6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Warranties and Covenants of the Purchaser</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Purchase for Own Account</u>. The Purchaser understands that the Notes and the Conversion Shares (collectively, the &#8220;<font style="font-weight: bold;">Securities</font>&#8221;),





      have not been registered under the Act on the basis that no distribution or public offering of the shares of the Company are to be effected. The Purchaser represents that it is acquiring the Securities solely for its own account and not for sale or</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">with a view to distribution of the Securities or any part thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise
      distributing the same, and does not presently have reason to anticipate a change in such intention.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Information and Sophistication</u>. Without lessening or obviating the warranties of the Company set forth in <u>Section 5</u>, the Purchaser hereby:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;acknowledges that it has received all the information it has requested from the Company and it considers necessary or appropriate for deciding whether to acquire the
      Securities;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; warrants that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and
      to obtain any additional information necessary to verify the accuracy of the information given to the Purchaser; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;further warrants that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risk of this investment.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Ability to Bear Economic Risk</u>. The Purchaser acknowledges that investment in the Securities involves a high degree of risk, and represents that it is able,
      without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Rule 144</u>. The Purchaser is aware that none of the Securities may be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met,
      including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the resale following the required holding period under Rule 144 and the number of shares being
      sold during any three month period not exceeding specified limitations. Purchaser is aware that the conditions for resale set forth in Rule 144 have not been satisfied and that the Company presently has no plans to satisfy these conditions in the
      foreseeable future.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Accredited Investor Status</u>. The Purchaser is an &#8220;Accredited Investor&#8221; as such term is defined in Rule 501 under the Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.6&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Further Limitations on Disposition</u>. Without in any way limiting the warranties set forth above and without prejudice to the provisions of Section 10.1 &#8211;10.3,
      the Purchaser further agrees not to make any disposition of all or any portion of the Securities unless and until:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There is then in effect a Registration Statement under the Act covering such proposed disposition and such disposition is made in accordance with such Registration
      Statement; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Purchaser shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
      surrounding the proposed disposition, and if reasonably requested by the Company, the Purchaser shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">Company, that such disposition will not require registration under the Act or any applicable state securities laws.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the provisions of paragraphs (a) and (b) above and without prejudice to the provisions of the Constitutional Documents which relate to the transfer of
      the Securities, no such registration statement or opinion of counsel shall be necessary for a transfer by the Purchaser to any person to whom the Purchaser may assign this Agreement pursuant to <u>Sections 10.1</u> or <u>10.2</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">6.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Market Standoff</u>. [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145791"></a>7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Events of Default; Remedies</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Events of Default</u>. Each of the following shall constitute an event of default (each, an &#8220;<font style="font-weight: bold;">Event of Default</font>&#8221;) under the
      Loan Documents:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall fail to pay (i) when due any principal or interest payment on the due date required under the terms of any of the Notes; or (ii) any other payment
      required under the terms of any of the Notes on the date due and such payment shall not have been made within [***] of the Company&#8217;s receipt of the Purchaser&#8217;s written notice to the Company of such failure to pay;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any warranty made by the Company pursuant to <u>Section 5</u> shall prove, when given, to be false or misleading in any material respect (save that the Purchaser
      shall not be entitled to claim that any fact, matter or circumstance causes any of the warranties to be false or misleading if it has been fairly and specifically disclosed in the Disclosure Letter or the Data Room);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Company shall fail to observe or perform any other material covenant, obligation, condition or agreement contained in this Agreement, the Letter Agreement, the
      Board Observer Letter and/or the Notes (including without limitation a Charitability Default pursuant to the Letter Agreement) or any material covenant, obligation, condition or agreement in the Shareholders Agreement which confers a benefit on the
      Purchaser, and, in each case, such default is not remedied within [***] (except that in the case of a Charitability Default such period shall be [***]) of the date on which the Purchaser notifies the Company of such default;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating
      to, debtors, now or hereafter in effect, or makes any general assignment for the benefit of creditors or takes any corporate action in furtherance of any of the foregoing except on terms approved in advance by the Purchaser, such approval not to be
      unreasonably withheld, delayed or conditioned;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(e)&#160;&#160;&#160;&#160;&#160; &#160; &#160; An involuntary petition is filed against the Company (unless such petition is dismissed or discharged within [***]) under any bankruptcy or insolvency statute now or
      hereafter in effect, or a custodian, administrator, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take possession, custody or control of any material assets of the Company;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; The Company or any of its subsidiaries (i) stops (or threatens to stop) payment of its debts generally or ceases (or threatens to cease) to carry on its business or a
      substantial part of its business or (ii) is deemed for the purpose of section 123 of the Insolvency Act 1986 to be unable to pay its debts or compounds or proposes or enters into any reorganisation or special arrangement with its creditors generally;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(g)&#160;&#160;&#160;&#160; &#160; &#160;&#160; The Company&#8217;s shareholders or board of directors affirmatively vote to liquidate, dissolve, or wind up the Company or the Company otherwise ceases to carry on its
      ongoing business operations, other than following the occurrence of a Change of Control as defined in the Notes.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company&#8217;s shareholders do not take the actions required under <u>Section 9.5</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)&#160;&#160;&#160;&#160;&#160; &#160; &#160; In respect of the First Tranche Note only, the Company fails to obtain the approval of the shareholders of the Company by 31 December 2017, by way of ordinary
      resolution pursuant to section 551 of the Companies Act 2006, to the grant of the conversion rights set out in the First Tranche Note on the terms substantially set out in Exhibit F.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Remedies</u>. Upon the occurrence of any Event of Default and while it is continuing, all unpaid principal on the Notes, accrued and unpaid interest thereon and all
      other amounts owing under the Loan Documents shall, at the option of the Purchaser, or, upon the occurrence of any Event of Default pursuant to <u>Section 7.1(d)</u>, <u>(e)</u>, <u>(f)</u> or <u>(g)</u> above, automatically, be immediately due,
      payable and collectible by the Purchaser pursuant to applicable law. In the event of any Event of Default, the Company shall immediately notify the Purchaser of such event pursuant to <u>Section 10.3</u> and shall pay all reasonable attorneys&#8217; fees
      and costs incurred by the Purchaser in enforcing its rights under the Notes and the other Investment Documents and collecting any amounts due and payable under the Notes. No right or remedy conferred upon or reserved to the Purchaser under this
      Agreement is intended to be exclusive of any other right or remedy, and every right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now and hereafter existing under applicable law.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">7.3&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Additional provisions</u>. Without limiting and in addition to the Purchaser&#8217;s other rights pursuant to this Agreement, the Letter Agreement and applicable law,
      the Company agrees that following the occurrence of an Event of Default pursuant to <u>Section 7.1(i)</u> above, even if the Purchaser exercises its rights pursuant to <u>Section 7.2</u> above, the Company will still be obligated to perform the
      Scope of Work and all other Global Access Commitments (as defined in the Letter Agreement) pursuant to the Letter Agreement as if the Purchaser had fully funded the First Tranche Note and the Company shall continue to comply with the terms and
      conditions of such Letter Agreement. For the avoidance of doubt, payment of the sums due under <u>Section 7.2</u> following the occurrence of any Event of Default and (where applicable) performance by the Company of its obligations under this <u>Section





        7.3</u> shall not limit or otherwise affect any other obligations of the Company or other rights or remedies of the Purchaser pursuant to this Agreement, the Letter Agreement or applicable law in respect of that or any other Event of Default.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145792"></a>8.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Conditions To Closings</u>.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">8.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conditions to the Purchaser&#8217;s Obligations at the First Closing</u>. The obligations of the Purchaser under the Loan Documents are subject to the fulfillment on or
      before the First Closing of each of the following conditions, which may be waived in writing by the Purchaser:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Warranties</u>. The warranties of the Company contained in <u>Section 5</u>, as modified by the Disclosure Letter and subject to the provisions of <u>Section 5</u>,
      shall be true on and as of the First Closing Date as though such warranties had been made on and as of such date.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Performance</u>. The Company shall have performed and complied with all agreements, obligations, and conditions contained in the Loan Documents that are required to
      be performed or complied by it on or before the First Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Qualifications</u>. All authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United Kingdom, United States or of
      any state that are required in connection with the lawful issuance and sale of the Notes shall be duly obtained and effective as of the First Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compliance Certificate</u>. A Director of the Company shall deliver to the Purchaser at the Closing a certificate certifying that the conditions specified in <u>Sections




        8.1(a)</u>, <u>(b)</u> and <u>(c)</u> have been fulfilled.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Proceedings and Documents</u>. All corporate and other proceedings in connection with the transactions contemplated at each Closing and all documents incidental
      thereto shall be reasonably satisfactory in form and substance to the Purchaser&#8217;s counsel, which shall have received all such counterpart original and certified copies of such documents as it may reasonably request.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing Documents</u>. The Company shall have duly executed and delivered to the Purchaser the following documents:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; margin-left: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; margin-left: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The First Tranche Note;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; margin-left: 36pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Letter Agreement; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; margin-left: 36pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Board Observer Letter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">8.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conditions to the Purchaser&#8217;s Obligations at the Second Closing</u>. The obligations of the Purchaser under the Loan Documents are subject to the fulfillment on or
      before the Second Closing of each of the following conditions, which may be waived in writing by the Purchaser:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warranties</u>. The warranties of the Company contained in Section 5, as modified by the Disclosure Letter and subject to the provisions of Section 5, shall be true
      on and as of the Second Closing Date as though such warranties had been made on and as of such date.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Performance</u>. The Company shall have performed and complied with all agreements, obligations, and conditions contained in the Loan Documents that are required to
      be performed or complied by it on or before the Second Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Qualifications</u>. (I) All authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United Kingdom, United States or
      of any state that are required in connection with the lawful issuance and sale of the Notes shall be duly obtained and effective as of the Second Closing, and (II) The Company shall have obtained the approval of the shareholders of the Company, by
      way of ordinary resolution pursuant to section 551 of the Companies Act 2006, to the grant of the conversion rights set out in the Second Tranche Note on the terms substantially set out in Exhibit F.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Material Adverse Change</u>. No Material Adverse Change shall have occurred since the First Closing Date.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compliance Certificate</u>. A Director of the Company shall deliver to the Purchaser at the Closing a certificate certifying that the conditions specified in <u>Sections




        8.2(a)</u>, <u>(b)</u>, <u>(c)</u> and <u>(d)</u> have been fulfilled.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Proceedings and Documents</u>. All corporate and other proceedings in connection with the transactions contemplated at each Closing and all documents incidental
      thereto shall be reasonably satisfactory in form and substance to the Purchaser&#8217;s counsel, which shall have received all such counterpart original and certified copies of such documents as it may reasonably request.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Closing Documents</u>. Each of the documents in <u>Section 8.1(f)</u> shall remain in full force and effect and the Company shall have duly executed and delivered
      to the Purchaser the following document(s):</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt; margin-left: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Second Tranche Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">8.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Conditions to Obligations of the Company</u>. The obligations of the Company under the documents listed in <u>Sections 8.1(f)(i)</u> to <u>(iv)</u> are subject to
      the fulfillment on or before each Closing of each of the following conditions, which may be waived in writing by the Company:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Warranties</u>. The warranties made by the Purchaser in Section 6, shall be true on and as of each Closing with the same effect as though such warranties had been
      made on and as of the date of such Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Qualifications</u>. All authorizations, approvals, or permits, if any, of any governmental authority or regulatory body of the United Kingdom, the United States or
      of any state that are required in connection with the lawful issuance and sale of the Notes and the Conversion Shares shall be duly obtained and effective as of each Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Purchase Price</u>. The Purchaser shall have delivered to the Company the purchase price in respect of the Note being purchased by the Purchaser in such Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145793"></a>9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Covenants of the Company</u>.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Prohibited Activity</u>. While the Notes are outstanding, the Company shall not make any distributions or pay any dividends to holders of equity securities of the
      Company or undertake any return of capital (whether by reduction of capital, purchase of shares or otherwise) without the Purchaser&#8217;s prior written consent, except for:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;dividends or other distributions payable on the ordinary shares of the Company solely in the form of additional ordinary shares of the Company; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; repurchases of shares from current and former employees, officers, directors, consultants or other persons who performed services for the Company or any Affiliate in
      connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Letter Agreement</u>. The terms and conditions of the Letter Agreement shall be in addition to the provisions of this Agreement and shall continue to apply in
      conjunction with any agreements related to the Conversion Shares and the Company shall continue to comply with such terms and conditions, unless the Letter Agreement shall expire pursuant to the terms thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Conduct of Business</u>. The Company shall use commercially reasonable efforts to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;maintain its corporate existence in good standing; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;carry on the business of the Company in a usual, regular and ordinary course in a manner consistent with developing the Platform Technology and in accordance with the
      provisions of this Agreement, the Letter Agreement and all applicable laws.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Events of Default</u>. The Company shall promptly and in any event no later than [***] from the date on which the Company becomes aware of an Event of Default, give
      written notice to the Purchaser that an Event of Default has occurred including reasonable details of such Event of Default.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Withdrawal Right</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Company undertakes a Qualifying Financing the Company shall use all reasonable endeavours to procure that the shareholders of the Company: (i) approve any
      amendments to the Constitutional Documents that are reasonably required in order for the Company to comply with the Withdrawal Right, and (ii) waive any and all pre-emption and other rights which could prevent the Company complying with the terms of
      the Withdrawal Right, and (iii) agree to provide, as and when required, any and all consents which are required in order for the Company to comply with the terms of the Withdrawal Right, including any and all consents which are required by applicable
      law and the Constitutional Documents to effect a share buyback.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160; &#160; &#160;&#160;&#160;&#160;&#160; If the Purchaser serves written notice on the Company pursuant to Section 3.3 (Voluntary Conversion after Twelve Months) or Section 3.5 (Voluntary Conversion on
      Non-Qualifying Financing) of the Note or in the event of a conversion pursuant to Section 3.2 (Automatic Conversion in the Event of an Exit or Change of Control) of the Note, the Company shall use all reasonable endeavours to procure that the
      shareholders of the Company: (i) waive any and all pre-emption and other rights which could prevent the Company complying with the terms</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">of the Withdrawal Right, and (ii) agree to provide, as and when required, any and all consents which are required in order for the Company to comply with the terms of the Withdrawal Right, including
      any and all consents which are required by applicable law and the Constitutional Documents to effect a share buyback, in each case prior to the conversion of the Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.6&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Books and Records</u>. The Company shall maintain the books and records of the Company in accordance with past practice, and use its commercially reasonable efforts
      to maintain in full force and effect all authorizations reasonably required to conduct the Company&#8217;s business.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">9.7&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Information Rights</u>. During the period from the First Closing Date until the conversion of the Notes, the Purchaser shall be deemed to benefit from the rights
      to receive information that it would otherwise benefit from if the Purchaser were a shareholder of the Company (and for this purpose the Purchaser shall be deemed to hold the number of shares that it would be entitled to receive on conversion of the
      Notes based on the Previous Qualifying Financing (as defined in the Note)) pursuant to the Constitutional Documents and subject to the confidentiality obligations contained therein.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><a name="z_Toc54145794"></a>10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Miscellaneous</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.1&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment</u>. Subject to <u>Section 10.3</u>, notwithstanding anything in this Agreement to the contrary, the Purchaser will have the right to assign this
      Agreement (in whole but not in part) to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any subsidiary of the Purchaser,</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any successor charitable organization of the Purchaser from time to time that is a tax-exempt organization as described in Section 50l(c)(3) of the Code, or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any tax-exempt organization as described in Section 50l(c)(3) of the Code controlled by one or more trustees of the Purchaser.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt;">The Purchaser will notify the Company of any such proposed assignment, including the identity of the assignee, prior to the date of such assignment.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.2&#160;&#160;&#160;&#160;&#160;&#160; <u>Exception to Assignment Provisions</u>. Except as provided in <u>Section 10.1</u>, neither Party shall have the right to assign or transfer (whether by sale or
      license of assets, or otherwise) this Agreement without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed except that any Party may make such an assignment without the other Party&#8217;s
      consent to (i) a third party who acquires all or substantially all of the business or assets of such Party to which this Agreement relates or (ii) a new corporate entity created as part of a corporate reorganization, in each case where such entity
      will continue to be bound by the terms of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.3&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Notices</u>. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;upon personal delivery to the Party to be notified;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient or, if not sent during normal business hours of the
      recipient, then on the next business day.</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt;">All communications being sent to the Company shall be sent to Immunocore Limited at 101 Park Dr, Milton, Abingdon OX14 4RY for the attention of the [***] and if being sent to the Purchaser shall be
      sent to Bill &amp; Melinda Gates Foundation, PO Box 23350, Seattle, WA: Attention [***], or at such other address or electronic mail address as any Party may designate by [***] to the other Parties hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.4&#160;&#160;&#160;&#160;&#160;&#160; <u>Entire Agreement</u>. This Agreement and the other Investment Documents, including all exhibits hereto and thereto, set forth all the covenants, promises,
      agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter of the Investment Documents, and supersede and terminate all prior agreements, negotiation and understandings between the
      Parties, whether oral or written, with respect to such subject matter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.5&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Modification</u>. No subsequent alteration, modification, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to
      writing and signed by the respective authorized officers of the Parties. In the event of a conflict between the terms of this Agreement and the terms of any other Investment Document, the terms of this Agreement shall prevail.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.6&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Binding Agreement</u>. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the
      Parties.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.7&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Third Party Rights</u>. The Parties do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act
      1999, by any person who is not a party to this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.8&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority</u>. Each of the Company and the Purchaser covenants and warrants with respect to itself that it has all authority necessary to execute this Agreement and
      that, on execution, this Agreement will be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other Person or third parties are required or necessary for this Agreement to be so binding.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.9&#160;&#160;&#160;&#160;&#160;&#160; <u>Waiver</u>. Failure or delay by either Party in exercising or enforcing any provision, right, or remedy under this Agreement, or waiver of any remedy hereunder, in
      whole or in part, shall not be deemed a waiver thereof, or prevent the subsequent exercise of that or any other rights or remedy. The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers and
      remedies provided by law.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.10&#160;&#160;&#160;&#160; <u>Further Assurances</u>. From time to time after the Effective Date, each Party shall execute, acknowledge and deliver to each other any further documents, assurances,
      and other matters, and will take any other action consistent with the terms and conditions of this Agreement, that may reasonably be requested by a Party and necessary or desirable to carry out the purpose of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.11&#160;&#160;&#160;&#160;&#160; <u>Interpretation</u>. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
      Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.12&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, including by signatures delivered by facsimile or pdfs, each of which shall be deemed
      an original, but all of which shall be deemed to be and constitute one and the same instrument.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.13&#160;&#160;&#160;&#160;&#160; <u>Severability</u>. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement
      and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.14&#160;&#160;&#160;&#160;&#160; <u>Survival of Obligations</u>. The warranties and all covenants, undertakings and other obligations set out in this Agreement (except for any obligation which is fully
      performed at Closing) shall continue in full force and effect after each Closing.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.15&#160;&#160;&#160;&#160;&#160; <u>Expenses</u>. The Company and the Purchaser shall pay their own costs and expenses incurred with respect to the negotiation, execution, delivery and performance of
      this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.16&#160;&#160;&#160;&#160;&#160; <u>Subordination</u>. The indebtedness evidenced by the Notes shall be pari passu in right of payment to any existing notes convertible into shares and shall be
      subordinated in right of payment to the prior payment in full of any Senior Indebtedness in existence on the date of this Agreement or incurred by the Company after the date of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">10.17&#160;&#160;&#160;&#160; <u>Governing Law</u>. This Agreement and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating to this Agreement or its
      formation (including non-contractual disputes or claims), shall be governed by and construed in accordance with English law and any dispute will be submitted to the exclusive jurisdiction and venue of the courts located in London, England.</div>
    <div>&#160;</div>
    <div style="text-align: center;">[SIGNATURE PAGE TO FOLLOW]</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">IN WITNESS WHEREOF, the Parties hereto have executed this Note Purchase Agreement as of the day and year first written above.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zea28549eab2547358217bc6a6880f284" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">COMPANY:</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">IMMUNOCORE LIMITED</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">&#160;</td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;"><a name="z_Hlk54141419"></a>By: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Eliot Forster</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Name: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Eliot Forster</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Title: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">CEO</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z04f45d1bee0842d99841449878f5d0c4" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">PURCHASER:</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">BILL &amp; MELINDA GATES FOUNDATION</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">By: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Jim Bromley</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Name: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Jim Bromley</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Title: <br>
            </div>
          </td>
          <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">CFO</td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">18</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>SCHEDULE 1</u></div>
    <div style="text-align: center; font-weight: bold;">&#160;<u>WARRANTIES</u></div>
    <div>&#160;</div>
    <div style="text-align: justify;">1.&#160;&#160; &#160; &#160;&#160;&#160;&#160; <u>Organization and Qualification</u>. The Company is a company duly incorporated and validly existing under the laws of England and Wales and has all requisite corporate power and authority to enter into
      and perform the Investment Documents and, when executed and delivered by the Company, the Investment Documents shall constitute valid and binding obligations of the Company enforceable in accordance with their terms. Immunocore Nominees Limited is a
      company duly incorporated and validly existing under the laws of England and Wales. Immunocore LLC is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">2.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Business Authorization</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Company and each of the Company Subsidiaries owns, holds and lawfully uses in the operation of its business all permits, authorities, licenses, variances, exemptions, orders and
      approvals of all governmental entities having competent jurisdiction which are necessary for it to conduct its business as currently conducted or for the ownership and use of the assets owned or used by the Company or the relevant Company Subsidiary
      in the conduct of its business free and clear of all liens, in each case where failure to do so would have a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, prospects or
      results of operations of the Group taken as a whole (a &#8220;<font style="font-weight: bold;">Material Adverse Effect</font>&#8221;) (&#8220;<font style="font-weight: bold;">Authorizations</font>&#8221;). Such Authorizations are valid and in full force and effect, and so
      far as the Company is aware, there are no circumstances which might lead to the suspension, alteration or cancellation of any such Authorizations, nor is there any agreement which materially restricts the fields within which the Company or any of the
      Company Subsidiaries may carry out its business other than agreements entered into in the ordinary course of business.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The statutory books, registers, minute books and books of account of the Company and each of the Company Subsidiaries are duly entered up and maintained in accordance with all legal
      requirements applicable thereto and contain true and accurate records in all material respects of all matters required to be dealt with therein and all such books and all records and documents (including documents of title) which are its property are
      in its possession or under its control and all accounts, documents and annual returns required to be delivered or made to the Registrar of Companies have been duly and correctly delivered or made.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance with Law</u>. Neither the Company nor any of the Company Subsidiaries is in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government
      or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of its properties, violation of which would have a Material Adverse Effect.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">4.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>Subsidiaries</u>. The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company,
      association, or other business entity, other than the Company Subsidiaries. Neither the Company nor any of the Company Subsidiaries is a participant in any joint venture, partnership or similar arrangement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">5.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;<u>Corporate Power</u>. The Company has at the First Closing Date and the Second Closing Date, respectively, all requisite corporate power to execute and deliver the Investment Documents required to be
      executed or delivered at the relevant Closing and to carry out and perform its obligations under the terms of such Investment Documents.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">19</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Authorization</u>. The Conversion Shares, when issued in compliance with the provisions of this Agreement, the Notes and the Constitutional Documents will be validly issued, fully paid and free of any
      Encumbrances. Subject to the terms of the Constitutional Documents, the issuance of the Notes (and the securities issuable upon conversion thereof) pursuant to the provisions of the Investment Documents will not violate any preemptive rights or
      rights of first refusal granted by the Company, and the Notes (and the securities issuable upon conversion thereof) will be free of any Encumbrances; provided, however, that the Notes and the Conversion Shares may be subject to restrictions on
      transfer under applicable securities laws or as otherwise required by such laws at the time the transfer is proposed or pursuant to the Company&#8217;s Constitutional Documents. Subject to the terms of the Constitutional Documents, the issuance and sale of
      the Notes do not and will not cause any dilution adjustment in any existing securities.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">7.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <u>Offering</u>. Assuming the accuracy of the warranties of the Purchaser contained in <u>Section 6</u> of this Agreement, so far as the Company is aware, the issue of the Notes is exempt from the
      registration and prospectus delivery requirements of the Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Compliance with Other Instruments</u>. Neither the authorization, execution and delivery of any Investment Document, nor the issuance and delivery of the Notes will constitute or result in a material
      default or violation of any law or regulation applicable to the Company, any material term or provision of the Company&#8217;s Constitutional Documents as in effect on the date on which this warranty is given, or the material terms of any contract,
      indebtedness or other agreement to which the Company is a party.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">9.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <u>Litigation</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no action, suit or proceeding, claim, arbitration, litigation or investigation (each, an &#8220;<font style="font-weight: bold;">Action</font>&#8221;), in each case related to the business
      of the Company or any of the Company Subsidiaries, pending or, to the Company&#8217;s knowledge, threatened against or affecting the Company that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by any of the
      Investment Documents. To the Company&#8217;s knowledge no event has occurred or circumstances exist that would reasonably be expected to give rise or serve as a basis for any such Action. There is no Action against any current or, to the Company&#8217;s
      knowledge, former director or employee of the Company with respect to which the Company has or is reasonably likely to have an indemnification obligation in each case that would be reasonably likely to have a Material Adverse Effect.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no unsatisfied judgment, penalty or award, in each case related to the business of the Company or any of the Company Subsidiaries, against or affecting the Company or any of the
      Company Subsidiaries or any of their respective assets, properties or rights and neither the Company nor any of the Company Subsidiaries is party to any undertaking or assurance given to a court, tribunal or any other person in connection with the
      determination or settlement of any Action, in each case that would be reasonably likely to have a Material Adverse Effect.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any of the Company Subsidiaries nor any person for whose acts or defaults the Company or any of the Company Subsidiaries is liable is involved (whether as
      claimant, defendant or any other party) in any civil, criminal, tribunal or arbitration proceedings, and as far as the Company is aware there are no facts likely to give rise to any such proceedings, in each case where such proceedings would be
      reasonably likely to have a Material Adverse Effect.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Intellectual Property</u>.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">20</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Details of all Patents owned by the Company or any of the Company Subsidiaries are set out in the Disclosure Letter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All renewal fees due and steps required as at the date of this Agreement for the maintenance of the Patents disclosed pursuant to paragraph (a) above have been paid or taken.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A list of all material licences, agreements and arrangements relating to the Intellectual Property granted to or by the Company and each of the Company Subsidiaries is set out in the
      Disclosure Letter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor any Company Subsidiary nor, as far as the Company is aware, any other party is in material breach of any of the licences disclosed pursuant to paragraph (c)
      above.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160; &#160;&#160; &#160; The Company has not received any notice that any third party is and, so far as the Company is aware, no third party is, infringing any material Intellectual Property or making
      unauthorized use of any material Confidential Information owned by the Company or any Company Subsidiary to a material extent.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; So far as the Company is aware, the activities of the Company or any of the Company Subsidiaries do not infringe the Intellectual Property of any third party to a material extent.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;So far as the Company is aware, and save in the ordinary course of business or to its employees, neither the Company nor any of the Company Subsidiaries has disclosed any Confidential
      Information to any third party other than under an obligation of confidentiality.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the Patents referred to in paragraph (a) above are the subject of any material litigation, opposition or administrative proceedings and such Patents are free from all
      Encumbrances. Neither the Company nor any Company Subsidiary has received any written notice, letter or complaint in respect of or threatening an Action related to the Patents referred to in paragraph (a) above against the Company or any Company
      Subsidiary and/or against the said Patents that challenges or seeks to invalidate or render unenforceable the said Patents.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; The Company is the sole legal and beneficial owner of the Patents referred to in paragraph (a) above.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; So far as the Company is aware, none of the material Intellectual Property of the Company or any of the Company Subsidiaries is owned by an employee of the Company or any of the Company
      Subsidiaries respectively and all material Intellectual Property created by employees, independent contractors or consultants of the Company or any of the Company Subsidiaries in the course of their employment, contracting or consultancy (insofar
      that such material Intellectual Property relates directly to the Company&#8217;s Platform Technology (as defined in the Letter Agreement)) has been assigned to the Company or the Company Subsidiaries.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Financial Statements</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Accounts have been prepared on a basis consistent with previous accounts of the Company and in accordance with the accounting principles standards and practices generally accepted in
      the United Kingdom and show a true and fair view of the state of affairs of the Company and the Company</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">21</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">Subsidiaries as at the Accounts Date and of the results of the financial period then ended in any material respect.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Management Accounts have been prepared in accordance with accounting principles generally accepted in the United Kingdom and on a basis consistent with those used in the preparation
      of the Accounts and the Company does not consider them misleading.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Provision has been made or disclosure has been made by way of note in the Accounts of all then known liabilities, whether present or contingent, including provisions and reserves for
      taxation and of all Encumbrances and onerous capital commitments then in existence in accordance with the accounting standards referred to in paragraph 11(a).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has no borrowings or other indebtedness other than as provided for in the Accounts or the Management Accounts, excluding bank overdraft positions and trade credit in the
      ordinary course of trading.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Accounts nor the Management Accounts include any unusual, exceptional, non-recurring or extraordinary item of income or expenditure (save as expressly disclosed therein).</div>
    <div>&#160;</div>
    <div style="text-align: justify;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Share capital</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The existing shareholders are the legal and beneficial owners of the number of Ordinary Shares and Series A Shares set opposite their respective names in part 12(a) of the Disclosure
      Letter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All of the shares set out in part 12(a) of the Disclosure Letter are fully paid and comprise the entire issued share capital of the Company. So far as the Company is aware, none of the
      share capital of the Company is subject to any Encumbrance. None of the share capital of any of the Company Subsidiaries is subject to any Encumbrance. No options, warrants or other rights to subscribe for new shares in the Company or any of the
      Company Subsidiaries have been granted or agreed to by the Company or any of the Company Subsidiaries and no dividends or other rights or benefits have been declared, made or paid or agreed to be declared, made or paid thereon.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company owns one hundred percent of the issued share capital and/or any other equity interests of each of the Company Subsidiaries.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Taxation</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; All returns which should have been made by the Company or any of the Company Subsidiaries for any taxation purpose in respect of any accounting period up to and including the Accounts
      Date have been made on a proper basis. There are no disputes, penalties, levies or requests for information extant with HMRC or any other authority.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Properties</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Properties (and the interest held by the Company or any of the Company Subsidiaries) are identified in part 14 of the Disclosure Letter and they are the only properties in which the
      Company or any of the Company Subsidiaries has an interest or occupies.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">22</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The details in part 14 of the Disclosure Letter are accurate in all material respects and incorporate all adverse rights (including, without limitation, charges, leases, contracts, title
      and planning restrictions and Encumbrances) affecting the Properties.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and each of the Company Subsidiaries has duly complied with the obligations affecting the Properties in all material respects and no termination notice has been given (by the
      landlord or the tenant) in relation to any lease relating to any of the Properties, and there are no current, or as far as the Company is aware, anticipated notices, claims, demands or investigations relating to the Properties, in each case that
      would be reasonably likely to have a Material Adverse Effect.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Contracts with Connected Persons</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no loans made by the Company or any of the Company Subsidiaries to any of their directors or shareholders and/or any of their Connected Persons and no debts or liabilities owing
      by the Company or any of the Company Subsidiaries to any of their directors or shareholders and/or any of their Connected Persons.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no existing contracts or arrangements to which the Company or any of the Company Subsidiaries is a party and in which any of its directors or shareholders and/or any of their
      Connected Person is interested.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Data Protection</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company and each of the Company Subsidiaries has made all necessary registrations and notifications of its particulars in respect of any Personal Data processed by the Company or any
      of the Company Subsidiaries, in accordance with the Data Protection Legislation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160; &#160; &#160; As far as the Company is aware, the Company and each of the Company Subsidiaries is in compliance with the Data Protection Legislation in all material respects and has not received any
      notice or allegation in writing alleging non-compliance with any such Data Protection Legislation.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Employees</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There are no outstanding or, so far as the Company is aware, threatened claims or disputes between the Company or any of the Company Subsidiaries and any trade union or other body
      representing all or any of the employees of the Company or any of the Company Subsidiaries.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160; &#160;&#160; So far as the Company is aware, no employee of the Company or any of the Company Subsidiaries will, as a result of the entering into this Agreement or a Closing, be entitled to receive
      any payment or benefit which he would not otherwise be entitled to receive (including an enhanced severance package on subsequent termination) or be entitled to treat either such event as amounting to a breach of his terms of employment or to treat
      himself as redundant or dismissed or released from any obligation.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assets, debts and stock</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All book debts shown in the Accounts have been realised or are expected to be realised for an aggregate sum not being less than shown in the Accounts and, save as provided in the
      Accounts, the</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">23</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">Management Accounts or in the books of the Company, no indication has been received that any debt now owing to the Company or any of the Company Subsidiaries is bad or doubtful.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither the Company nor any of the Company Subsidiaries has granted any security (other than liens arising in the normal course of trading or by operation of law) over any material part
      of its undertaking or assets.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160; &#160; &#160;&#160; All assets used by and all debts due to the Company and each of the Company Subsidiaries or which have otherwise been represented as being its property or due to it or used or held for
      the purposes of its business are at the date of the applicable Closing its absolute property or right to use or hold and none is the subject of any Encumbrance (save in respect of liens arising in the normal course of trading or by operation of law)
      or the subject of any factoring arrangement, hire-purchase, retention of title, conditional sale or credit sale agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Borrowings and facilities</u>. Full details of all borrowings of the Company and each of the Company Subsidiaries (excluding bank overdraft positions and trade credit in the ordinary course) are set out
      in the Disclosure Letter and, so far as the Company is aware, neither the Company nor any of the Company Subsidiaries is in breach of any of their terms and none of such facilities or terms of borrowing have been terminated as a result of the entry
      into of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Compliance and probity</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;So far as the Company is aware no director of the Company or any of the Company Subsidiaries:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; has been convicted of a criminal offence (other than a road traffic offence not punished by custodial sentence);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;has been, or is liable to be, convicted of a criminal offence pursuant to the Money Laundering Regulations 2007;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in the case of an individual, is or has been the subject of any bankruptcy order or any arrangement with his creditors (or other analogous arrangement in any jurisdiction);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; in the case of a body corporate, is in receivership, liquidation, administration, or is the subject of a scheme of arrangement with its creditors or a company voluntary arrangement (or
      other analogous arrangement in any jurisdiction);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;has been disqualified by a court from acting as a director of a company or from acting in the management or conduct of the affairs of any company; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; has been publicly censured or fined by the Financial Conduct Authority or the Panel on Takeovers and Mergers (or any analogous Authority or institution).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Neither the Company nor any of the Company Subsidiaries is nor has it at any time been engaged in any activity, practice or conduct which would constitute an offence under the Bribery Act
      2010 or the U.S. Foreign Corrupt Practices Act of 1977 (to the extent applicable to the Company or any of the Company Subsidiaries). Neither the Company nor any of the Company Subsidiaries is the subject of any</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">24</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">investigation, inquiry or enforcement proceedings by any governmental, administrative or regulatory body regarding any offence or alleged offence under any such laws, and, so far as the Company is aware, no such
      investigation, inquiry or proceedings are pending or have been threatened and there are no circumstances likely to give rise to any such investigation, inquiry or proceedings.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">21.&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Clinical Trials and Regulatory Matters</u>. All pharmaceutical research and development activities of the Company or any of the Company Subsidiaries including all preclinical and clinical investigations
      pertaining to Company Products are being conducted and have been conducted, in each case, in material compliance with applicable laws, including, as applicable, Good Laboratory Practices, Good Manufacturing Practices or Good Clinical Practices
      requirements and privacy laws.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">25</font> </td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT A</u></div>
    <div style="text-align: center; font-weight: bold;"><u>FORM OF FIRST TRANCHE CONVERTIBLE LOAN NOTE</u></div>
    <div>&#160;
      <div> </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-style: italic; font-weight: bold; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT B</u></div>
    <div style="text-align: center; font-weight: bold;"><u>FORM OF SECOND TRANCHE CONVERTIBLE LOAN NOTE</u></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; font-style: italic; font-weight: bold;">EXHIBIT B - AGREED FORM</div>
    <div>&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">IMMUNOCORE LIMITED</div>
    <div>&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">SECOND TRANCHE</div>
    <div>&#160;</div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">CONVERTIBLE LOAN NOTE</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; font-weight: bold; text-align: center;">
                <div>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div>BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div>TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div style="text-align: center; font-weight: bold;">CONTENTS</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6f561cfaec804034a0da3cefaed95064" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">1.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Definitions.</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">2.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Payment; Maturity; Default Interest</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">3.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Conversion</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">4.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Default; Remedies</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">5.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Prepayment.</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">6.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Register.</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">7.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Waiver; Payment Of Fees And Expenses.</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">8.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Cumulative Remedies.</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 88%; vertical-align: top;" rowspan="1"><br>
          </td>
          <td style="width: 6%; vertical-align: top;" rowspan="1"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">9.</div>
          </td>
          <td style="width: 88%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: justify;">Miscellaneous</div>
          </td>
          <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> </div>
    <div> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-weight: bold;">THIS CONVERTIBLE LOAN NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;) OR THE SECURITIES LAWS OF ANY STATE. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN
      COMPLIANCE WITH RULE 144 UNDER THE ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN APPLICABLE EXEMPTION THEREFROM.</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">SECOND TRANCHE CONVERTIBLE LOAN NOTE</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf99871e57fbe4738a04f65ce5f8d157b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">
            <div style="text-align: justify;">US$15,000,000</div>
          </td>
          <td style="width: 50.01%; vertical-align: top;">
            <div style="text-align: right;">[&#160; &#160; ] (the &#8220;<font style="font-weight: bold;">Note Purchase Date</font>&#8221;)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">For value received, Immunocore Limited, a company registered in England with registration number 06456207 (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;, which expression shall include its
      successors and permitted assignees) hereby promises to pay to the order of the Bill &amp; Melinda Gates Foundation of PO Box 23350, Seattle, WA (&#8220;the <font style="font-weight: bold;">Purchaser</font>&#8221;, which expression shall include its successors
      and permitted assigns), the principal sum of fifteen million United States dollars (US$ 15,000,000) with interest on the outstanding principal amount at the rate of [***] per annum, based on a 365-day year. Interest shall commence on the Note
      Purchase Date and shall continue on the outstanding principal only until the date 365 days after the Note Purchase Date. Thereafter [***] interest shall be payable until the repayment of the Note, except following an Event of Default in which case
      interest will accrue on the outstanding principal only at the rate of [***] from the date of the Event of Default (but only after the end of any applicable remedy period and, except for any Event of Default under Sections 7.1 (d), (e), (f) or (g) of
      the Purchase Agreement, only for so long as any such Event of Default is continuing) until all principal and interest on the note is repaid in full. Interest will not be compounded and added to the principal. Interest will accrue and be due and
      payable upon maturity of the Note (or, if sooner, upon accelerated repayment of the Note as a result of an Event of Default or as otherwise permitted pursuant to the terms of this Note).</div>
    <div>&#160;</div>
    <div style="text-align: justify;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Definitions</u>. In this Note, unless the context requires otherwise, the following terms shall have the following meanings. Capitalized terms used in this Note and not otherwise defined in this Note
      shall have the respective meanings given to them in the Purchase Agreement or other Investment Documents (as defined in the Purchase Agreement).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Change in Control</font>&#8221; means:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the acquisition, directly or indirectly, by any Person or group of Persons of the beneficial ownership of securities of the Company possessing more than 50% of the total combined voting
      power of all issued securities of the Company;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a merger, consolidation or other similar transaction involving the Company, except for a transaction in which the holders of the issued securities of the Company immediately prior to such
      merger, consolidation or other transaction hold, in the aggregate, securities possessing more than 50% of the total combined voting power of all issued securities of the surviving entity immediately after such merger, consolidation or other
      transaction; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the sale, transfer or other disposition (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company,</div>
    <div>&#160;</div>
    <div style="text-align: justify;">provided, however, that a Change in Control shall not include a transaction or series of transactions principally for bona fide equity financing purposes (save where the purpose or its effect is to enable</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">investors in the Company to realise value from their investment) in which cash is received by the Company or any successor or indebtedness of the Company is cancelled or converted or a combination thereof;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Charitability Default</font>&#8221; means as defined in the Letter Agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Conversion Price</font>&#8221; means as defined in Section 3.1(a);</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Maturity Date</font>&#8221; means as defined in Section 2.2;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">New Investor Gross Proceeds</font>&#8221; means gross proceeds raised from one or more investors that had no affiliation with the Company prior to the Previous
      Qualifying Financing (provided that such gross proceeds can include funds received from GT Healthcare if the remainder of this definition is true with respect to GT Healthcare) and are investing on an arms-length basis with no Intellectual Property,
      licensing rights or other value provided by the Company to the investor beyond the equity securities;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Note</font>&#8221; means this convertible Loan Note;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Previous Qualifying Financing</font>&#8221; means the issuance or sale (or series of related issuances or sales) by the Company of equity securities
      immediately preceding the Note Purchase Date [***] (excluding the conversion of this Note and any other notes in the same series) and that includes at least [***] of New Investor Gross Proceeds;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Previous Qualifying Financing Conversion Price Per Share</font>&#8221; means an amount equal to the price paid per share by investors in the Previous
      Qualifying Financing multiplied by an assumed [***] annual equity appreciation for the period between the final closing date of that equity financing and the Note Purchase Date. For example and for illustrative purposes only, if the Note Purchase
      Date was May 5, 2017 and the Previous Qualifying Financing closed on November 13, 2015 at a share price of [***], the conversion would occur at a share price equal to [***];</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Purchase Agreement</font>&#8221; means the agreement dated [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ] entered into between the Company and the Purchaser concerning the
      purchase of the Notes; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.10&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Second Tranche PQ Conversion Shares</font>&#8221; means as defined in Section 3.1(a);</div>
    <div>&#160;</div>
    <div style="text-align: justify;">2.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <u>Payment; Maturity; Default Interest</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">2.1&#160;&#160;&#160;&#160;&#160; &#160; &#160; This Note is one in a series of notes issued or to be issued pursuant to the terms of the Purchase Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If this Note has not been paid in full or converted in accordance with the terms of Section 3 below the entire outstanding principal balance of this Note and all unpaid accrued interest
      thereon shall be repaid by the Company on the date [***] after the Note Purchase Date (the &#8220;<font style="font-weight: bold;">Maturity Date</font>&#8221;). All payments of interest and principal shall be in lawful money of the United States of America. All
      payments shall be applied first to accrued interest, and thereafter to principal. If any payments on this Note become due on a Saturday, Sunday or a public holiday under the laws of England, such payment shall be made on the next succeeding business
      day and, if relevant, such extension of time shall be included in computing interest in connection with such payment. For the avoidance of doubt, the principal and unpaid accrued interest may not be prepaid by the Company without the prior written
      approval of the Purchaser.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">3.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <u>Conversion</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Automatic Conversion Following Note Purchase Date</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;One business (1) day following the Note Purchase Date, the outstanding principal balance of this Note and accrued but unpaid interest thereon shall automatically, without any further
      action by the Purchaser, convert into shares of the same class as shares issued at the first closing of the Previous Qualifying Financing (the &#8220;<font style="font-weight: bold;">Second Tranche PQ Conversion Shares</font>&#8221;) and [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160; &#160; &#160;&#160; Upon conversion, the Purchaser shall be required to: (a) execute and deliver the Deed of Adherence, and (b) execute, and shall have the full benefit of, any other definitive agreements
      executed by the other purchasers of the Second Tranche PQ Conversion Shares sold in the Previous Qualifying Financing (other than (i) any warranties given by the Company or (ii) any rights to appoint directors given in favour of any single purchaser
      of such Second Tranche PQ Conversion Shares, in each case pursuant to any subscription agreement); provided that in no event shall any such agreement result in a violation of any rule, law or other regulations relating to the Purchaser or the
      characterization of this Note as a &#8220;program related investment&#8221; (as defined in Section 4944(c) of the Code).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Automatic Conversion in the Event of an Exit or Change of Control</u>. In the event of (i) a Change in Control of the Company; or (ii) an admission to trading of the shares of the
      Company to a Recognised Investment Exchange (as defined in the Financial Services and Markets Act 2000) (together with the admission of such shares to the Official List of the UK Listing Authority) or to the New York Stock Exchange or the NASDAQ
      Global Market (or Global Select Market) prior to the repayment or conversion of this Note (as provided above), all outstanding principal and unpaid accrued interest due on this Note shall, on the date of closing of such event, automatically convert
      into shares of the same class as issued by the Company pursuant to the Previous Qualifying Financing. [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Previous Qualifying Financing</u>. The Parties agree that, unless the Company has issued or sold equity securities in the period between 31 July 2015 and the Note Purchase Date which
      sale or issuance (or series of related sales or issuances) constitutes a &#8220;<font style="font-weight: bold;">Previous Qualifying Financing</font>&#8221;, the issuance of Series A preferred equity securities by the Company to investors in July 2015 shall be
      deemed to be a &#8220;<font style="font-weight: bold;">Previous Qualifying Financing</font>&#8221; for the purposes of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Fractional Shares</u>. No fractional shares of the Company&#8217;s shares will be issued upon conversion of this Note. In lieu of any fractional share to which the Purchaser would otherwise
      be entitled, the Company will pay to the Purchaser in cash the amount of the unconverted principal and interest balance of this Note that would otherwise be converted into such fractional share.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Effect of Conversion</u>. Upon conversion of this Note pursuant to this Section 3, the Purchaser shall surrender this Note, duly endorsed, at the principal offices of the Company.
      Upon conversion of this Note pursuant to Section 3, this Note will be deemed converted on the date that is immediately prior to the close of business on the date of the surrender of this Note. At its expense, the Company will, as soon as practicable
      thereafter, issue and allot the shares arising on conversion of the Note, issue and deliver to the Purchaser, at such address requested by the Purchaser, a certificate or certificates for the number of shares to which the Purchaser is entitled upon
      such conversion (bearing such legends, if any, as are required by the Purchase Agreement, any other agreement entered into in connection with the Previous Qualifying Financing or any such conversion or applicable state and federal securities laws),
      together with a replacement Note (if any principal amount is not converted) and any other securities and</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify;">property to which the Purchaser is entitled upon such conversion under the terms of this Note, including a check payable to the Purchaser for any cash amounts payable as a result of any fractional shares as described
      herein. Each share arising on conversion shall be issued and allotted at such premium to reflect the difference between the nominal amount of the share and the amount of the Notes (and accrued interest) converted into one share. Such shares shall be
      credited as fully paid and rank pari passu with shares of the same class and shall carry the same right to receive all dividends and other distributions declared or paid in respect of such shares.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.6&#160;&#160;&#160;&#160;&#160; &#160; &#160; The warranties and rights and obligations of transfer and assignment of the Purchaser that are set forth in the Purchase Agreement are hereby made a part of this Note and incorporated
      herein by this reference.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">4.&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <u>Default; Remedies</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The occurrence of any Event of Default described in Section 7.1 of the Purchase Agreement shall be an Event of Default hereunder and the remedies described in Section 7.2 of the Purchase
      Agreement shall be the remedies available hereunder.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Upon the occurrence and during the continuance of any Event of Default, all unpaid principal on this Note, accrued and unpaid interest thereon and all other amounts owing hereunder shall,
      at the option of the Purchaser, and, upon the occurrence of any Event of Default pursuant to Sections 7.1 (d), (e), (f) or (g) of the Purchase Agreement, automatically, be immediately due, payable and collectible by the Purchaser pursuant to
      applicable law. The Purchaser shall have all rights and may exercise all remedies available to it under law, successively or concurrently.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Prepayment</u>. Prepayment of the outstanding principal (plus accrued, but unpaid interest thereon) prior to the Maturity Date may not be made without the consent of the Purchaser.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">6.&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <u>Register</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">6.1&#160;&#160;&#160;&#160;&#160; &#160; &#160; The Company shall keep and maintain a register of the Notes (the &#8220;<font style="font-weight: bold;">Register</font>&#8221;) at its registered office or at such other place as the Company may
      from time to time appoint for this purpose and notify to the Purchaser.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">6.2&#160;&#160;&#160;&#160;&#160; &#160; &#160; There shall be entered in the Register:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the names and addresses of the holder of the Notes for the time being;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the principal amount of the Notes held by each noteholder and the principal monies paid up on them;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the date of issue of each of the Notes and the date on which the name of each noteholder is entered in the Register in respect of the Notes registered in its name;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the serial number of each Certificate issued and the date of its issue; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the date(s) of all transfers and changes of ownership of any of the Notes.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall promptly amend the Register to record any change to the name or address of a noteholder that is notified in writing to the Company by that noteholder.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The noteholders or any of them, or any person authorised by a noteholder, shall be at liberty at all reasonable times during office hours to inspect the Register and to take copies of or
      extracts from it or any part of it.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">7.&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Waiver; Payment Of Fees And Expenses</u>. The Company waives presentment and demand for payment, notice of dishonor, protest and notice of protest of this Note, and shall pay all costs of collection
      when incurred, including, without limitation, reasonable attorneys&#8217; fees, costs and other expenses. The right to plead any and all statutes of limitations as a defense to any demands hereunder is hereby waived to the full extent permitted by law. No
      delay by the Purchaser shall constitute a waiver, election or acquiescence by it.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">8.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Cumulative Remedies</u>. The Purchaser&#8217;s rights and remedies under this Note and the other Investment Documents shall be cumulative. No exercise by the Purchaser of one right or remedy shall be deemed
      an election, and no waiver by Purchaser of any Event of Default shall be deemed a continuing waiver of such Event of Default or the waiver of any other Event of Default.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Miscellaneous</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Assignment</u>. Notwithstanding anything in this Note to the contrary, the Purchaser will have the right to assign this Note (in whole but not in part) or transfer this Note to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any subsidiary of the Purchaser,</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any successor charitable organization of the Purchaser from time to time that is a tax-exempt organization as described in Section 50l(c)(3) of the Code, or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any tax-exempt organization as described in Section 50l(c)(3) of the Code controlled by one or more trustees of the Purchaser.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Purchaser will notify the Company of any proposed assignment, including the identity of the assignee, prior to the date of such assignment.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.2&#160;&#160;&#160;&#160;&#160; &#160; <u>Exception to Assignment Provisions</u>. Except as provided in Section 9.1, neither Party shall have the right to assign or transfer (whether by sale or license of assets, or otherwise)
      this Note without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed except that any Party may make such an assignment without the other Party&#8217;s consent to (i) a third party who
      acquires all or substantially all of the business or assets of such Party to which this Note relates or (ii) a new corporate entity created as part of a corporate reorganization, in each case where such entity will continue to be bound by the terms
      of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.3&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Notices</u>. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;upon personal delivery to the Party to be notified;</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient or, if not sent during normal business hours of the recipient, then on the next
      business day.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">All communications being sent to the Company shall be sent to Immunocore Limited at 101 Park Dr, Milton, Abingdon OX14 4RY for the attention of the Chief Executive Officer, and if being sent to the Purchaser shall be
      sent to Bill &amp; Melinda Gates Foundation, PO Box 23350, Seattle, WA: Attention Director of Program Related Investments, or at such other address or electronic mail address as a Party may designate by [***] advance written notice to the other
      Parties hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Entire Agreement</u>. This Note and the other Investment Documents, including all exhibits hereto and thereto, set forth all the covenants, promises, agreements, warranties,
      representations, conditions and understandings between the Parties with respect to the subject matter of the Investment Documents, and supersede and terminate all prior agreements, negotiation and understandings between the Parties, whether oral or
      written, with respect to such subject matter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Modification</u>. No subsequent alteration, modification, amendment, change or addition to this Note shall be binding upon the Parties unless reduced to writing and signed by the
      respective authorized officers of the Parties. In the event of a conflict between the terms of this Note and the terms of any other Investment Document, the terms of this Note shall prevail.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Binding Agreement</u>. The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors and assigns of the Parties.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Third Party Rights</u>. The Parties do not intend that any term of this Note should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is
      not a party to this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Authority</u>. Each of the Company and the Purchaser covenants and warrants with respect to itself that it has all authority necessary to execute this Note and that, on execution,
      this Note will be fully binding and enforceable in accordance with its terms, and that no other consents or approvals of any other Person or third parties are required or necessary for this Note to be so binding.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.9&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Set-off</u>. Payments of principal and interest in respect of the Notes shall be paid by the Company to the Purchaser without any deduction or withholding (whether in respect of any
      set-off, counterclaim or otherwise whatsoever) unless the deduction or withholding is required by law.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.10&#160;&#160;&#160;&#160;&#160;&#160; <u>Waiver</u>. Failure or delay by either Party in exercising or enforcing any provision, right, or remedy under this Note, or waiver of any remedy hereunder, in whole or in part, shall
      not be deemed a waiver thereof, or prevent the subsequent exercise of that or any other rights or remedy. The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers and remedies provided by law.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">9.11&#160;&#160;&#160;&#160;&#160;&#160; <u>Further Assurances</u>. From time to time after the Effective Date, each Party shall execute, acknowledge and deliver to each other any further documents, assurances, and other
      matters, and will take any other action consistent with the terms and conditions of this Note, that may reasonably be requested by a Party and necessary or desirable to carry out the purpose of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.12&#160;&#160;&#160;&#160;&#160;&#160; <u>Interpretation</u>. The headings contained in this Note are for reference purposes only and shall not affect in any way the meaning or interpretation of this Note. Whenever the words
      &#8220;include&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Note, they shall be deemed to be followed by the words &#8220;without limitation&#8221;.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.13&#160;&#160;&#160;&#160;&#160;&#160; <u>Counterparts</u>. This Note may be executed in one or more counterparts, including by signatures delivered by facsimile or pdfs, each of which shall be deemed an original, but all of
      which shall be deemed to be and constitute one and the same instrument.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.14&#160;&#160;&#160;&#160;&#160;&#160; <u>Severability</u>. If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from this Note and the balance of the Note
      shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.15&#160;&#160;&#160;&#160;&#160;&#160; <u>Expenses</u>. The Company and the Purchaser shall pay their own costs and expenses incurred with respect to the negotiation, execution, delivery and performance of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.16&#160;&#160;&#160;&#160;&#160;&#160; <u>Subordination</u>. The indebtedness evidenced by the Notes shall be pari passu in right of payment to any existing notes convertible into shares and shall be subordinated in right of
      payment to the prior payment in full of any Senior Indebtedness in existence on the date of this Note or incurred by the Company after the date of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.17&#160;&#160;&#160;&#160;&#160;&#160; <u>Usury</u>. In the event any interest is paid on this Note which is deemed to be in excess of the then legal maximum rate, then that portion of the interest payment representing an
      amount in excess of the then legal maximum rate shall be deemed a payment of principal and applied against the principal of this Note.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">9.18&#160;&#160;&#160;&#160;&#160;&#160; <u>Governing Law</u>. This Note and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating to this Note or its formation (including
      non-contractual disputes or claims), shall be governed by and construed in accordance with English law and any dispute will be submitted to the exclusive jurisdiction and venue of the courts located in London, England.</div>
    <div>&#160;</div>
    <div style="text-align: center;">[SIGNATURE PAGE TO FOLLOW]</div>
    <div style="text-align: center;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z5fd6b75655e444dfb97841ec963528e8" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></td>
            </tr>
            <tr>
              <td style="width: 100%; text-align: left; font-size: 8pt;" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the parties hereto have executed this Convertible Loan Note as of the day and year first written above.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd61caf38c43d43b4b9b9a4a6df3501f1" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">IMMUNOCORE LIMITED</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;"><a name="z_Hlk54143925"></a>By:</div>
          </td>
          <td style="width: 37%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;"><br>
          </td>
          <td style="width: 37%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;"><br>
          </td>
          <td style="width: 35%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z72bfce25538e45da8b0a624a43208f81" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify;">AGREED TO AND ACCEPTED:</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;"><br>
          </td>
          <td style="width: 37%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">BILL &amp; MELINDA GATES FOUNDATION</div>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;"><br>
          </td>
          <td style="width: 37%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 37%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;"><br>
          </td>
          <td style="width: 37%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;"><br>
          </td>
          <td style="width: 35%; vertical-align: top;"><br>
          </td>
          <td style="width: 60%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 35%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;"><br>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div> </div>
    <div> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT C</u></div>
    <div style="text-align: center; font-weight: bold;"><u>FORM OF LETTER AGREEMENT</u></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT D</u></div>
    <div style="text-align: center; font-weight: bold;"><u>FORM OF DEED OF ADHERENCE</u></div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z044a3dfd3cb54eae878b9f989368ca3c" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 58%; vertical-align: top;">
            <div style="text-align: justify;"><font style="font-weight: bold;">THIS DEED</font> is made on</div>
          </td>
          <td style="width: 42%; vertical-align: top;">
            <div style="text-align: justify;">201[ ]</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 58%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 42%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 15%; vertical-align: top;">
            <div style="text-align: justify;">BY [</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div style="text-align: justify;">]</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">INTRODUCTION</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd8b9f141461b457896af7675e5a2d874" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(A)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Pursuant to the Convertible Loan Note dated [&#160; &#160; &#160; &#160; ] between Immunocore Limited (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) and the Bill and Melinda Gates Foundation (the &#8220;<font style="font-weight: bold;">Foundation</font>&#8221;)
              the Foundation has been issued shares in the Company (the &#8220;<font style="font-weight: bold;">Shares</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8fe6f67d18f84555a18d1dc9a096c684" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">(B)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This deed is entered into in compliance with the terms of clause [12] of the [Subscription and Shareholders&#8217; Agreement relating to the Company dated 15 July 2015] (which agreement is herein referred to as the &#8220;<font style="font-weight: bold;">Shareholders&#8217; Agreement</font>&#8221;).</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">AGREED TERMS</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc14aec2c6a54487996da4ee496800445" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Words and expressions used in this deed shall have the same meaning as is given to them in the Shareholders&#8217; Agreement unless the context otherwise expressly requires.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4359d187d2d54a8a8bf9870af19f2707" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Foundation hereby agrees to assume the benefit of the rights under the Shareholders&#8217; Agreement in respect of Shares and hereby agrees to assume and assumes the burden of the obligations under the Shareholders&#8217; Agreement to be performed
              after the date hereof in respect of the Shares.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze70340d43d134549a8f8f40f47e10bee" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The Foundation hereby agrees to be bound by the Shareholders&#8217; Agreement in all respects as if the Foundation were a party to the Shareholders&#8217; Agreement as one of the Investors and to perform all the obligations expressed to be imposed on
              such a party to the Shareholders&#8217; Agreement, to be performed or on or after the date hereof.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za0e8bba3aee5470b8d42f4ff284fb1bc" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This deed is made for the benefit of:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37c8ccc2897b43d3a76ce6bfc620a3f3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the parties to the Shareholders&#8217; Agreement; and</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf1d89be3bf5540e8a915ff32861460a5" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>any other person or persons who may after the date of the Shareholders&#8217; Agreement (and whether or not prior to or after the date hereof) assume any rights or obligations under the Shareholders&#8217; Agreement and be permitted to do so by the
              terms thereof, and this deed shall be irrevocable without the consent of the Company acting on their behalf in each case only for so long as they hold any [Preference Shares]/Ordinary Shares in the capital of the Company.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7629acc1df3547f38933472df582eac1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>None of the Investors:</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z08e27d2575594273954e5262123656ff" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>makes any representation or warranty or assumes any responsibility with respect to the legality, validity, effectiveness, adequacy or enforceability of any of the Shareholders&#8217; Agreement (or any agreement entered into pursuant thereto);</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z575e31a533a447bea09be5e692aacb3f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>makes any representation or warranty or assumes any responsibility with respect to the content of any information regarding the Company or any member of the group or otherwise relates to the subscription of shares in the Company; or</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      <div id="DSPFPageHeader" style="width: 100%;">
        <div style="font-weight: bold; font-style: italic; text-align: right;">EXECUTION VERSION</div>
      </div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf22b6eb3a29e4d14b2b31702a0d8739c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>assumes any responsibility for the financial condition of the Company or any Subsidiary or any other party to the Shareholders&#8217; Agreement or any other document or for the performance and observance by the Company or any other party to the
              Shareholders&#8217; Agreement or any other document (save as expressly provided therein),</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt;">and any and all conditions and warranties, whether express or implied by law or otherwise, are excluded save for the representations, warranties and undertakings contained in the Warranties.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za20c50ff227842008aab297cd36c2dc8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>This deed shall be governed by and construed in accordance with the laws of England and Wales.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify;">This deed of adherence has been executed and delivered as a deed on the date shown on the first page.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT E</u></div>
    <div style="text-align: center; font-weight: bold;"><u>BOARD OBSERVER LETTER</u></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
                <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
                <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>EXHIBIT F</u></div>
    <div style="text-align: center; font-weight: bold;"><u>ORDINARY SHAREHOLDER RESOLUTION</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">ORDINARY RESOLUTION</div>
    <div>&#160;</div>
    <div style="text-align: justify;">THAT, in accordance with section 551 of the Companies Act 2006, the directors of the Company (or a duly constituted committee of the directors) (the &#8220;<font style="font-weight: bold;">Directors</font>&#8221;) be generally and
      unconditionally authorised to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (&#8220;<font style="font-weight: bold;">Rights</font>&#8221;) to the Bill &amp; Melinda Gates Foundation (the &#8220;<font style="font-weight: bold;">Foundation</font>&#8221;), or any assignee or transferee of any Rights or agreement to grant Rights to the Foundation, up to a nominal amount of &#163;[&#8226;], provided that this authority shall, unless sooner renewed, varied or revoked
      by the Company, expire on the date that is five years from the date of passing of this Resolution, save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or Rights to be granted
      and the Directors may allot shares or grant Rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.</div>
    <div>&#160;</div>
    <div>&#160;</div>
  </div>
  <div style="width: 100%;" id="DSPFPageFooter">
    <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6dbf4b4fb0d146f3909e010cb77fcfff" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100.00%;">
            <div style="text-align: center; font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED</div>
            <div style="text-align: center; font-weight: bold;">BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE</div>
            <div style="text-align: center; font-weight: bold;">TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</div>
          </td>
        </tr>

    </table>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>10
<FILENAME>nt10016217x4_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right; font-weight: bold;">Exhibit 10.11</div>
    <div>&#160;</div>
    <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE
        TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Amended &amp; Restated Global Access Commitments Agreement</div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Amended &amp; Restated Global Access Commitments Agreement (including all appendices, exhibits and attachments hereto, the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;), is entered into as of 2 March 2020
      (&#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;), by and between the Bill &amp; Melinda Gates Foundation, a Washington charitable trust that is a tax-exempt private foundation (the &#8220;<font style="font-weight: bold;">Foundation</font>&#8221;), and
      Immunocore Limited, a company incorporated in England and Wales with registered number 06456207 (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;). This Agreement amends and restates in its entirety the Global Access Commitments Agreement
      entered into as of September 13, 2017 (the &#8220;<font style="font-weight: bold;">Prior Agreement&#8221;</font>), which was entered into by and between the Foundation and the Company in connection with the Foundation&#8217;s investment (the &#8220;<font style="font-weight: bold;">Notes Investment</font>&#8221;) in promissory notes issued by the Company (the &#8220;<font style="font-weight: bold;">Notes</font>&#8221;) of up to forty million dollars ($US40,000,000) and, upon conversion of the Notes (the &#8220;<font style="font-weight: bold;">Notes





        Conversion</font>&#8221;), equity securities of the Company. In addition to the Notes Investment, additional payments may be made from the Foundation to the Company in accordance with this Agreement and additional agreements as contemplated by this
      Agreement (such additional payments, if any, together with the Notes Investment and the Notes Conversion, are referred to as the &#8220;<font style="font-weight: bold;">Foundation Investment</font>&#8221;). The Foundation Investment is subject to the terms and
      conditions of the investment documents executed in connection with the Notes Investment and the Notes Conversion, including, without limitation, this Agreement, the Note Purchase Agreement, the Notes, the Deed of Adherence and the Amended &amp;
      Restated Board Observer Letter, and related documents, and any agreements entered into in connection with any additional payments made from the Foundation to the Company, in each case as amended from time to time (collectively, the &#8220;<font style="font-weight: bold;">Investment Documents</font>&#8221;). At the time of entering into the Prior Agreement, the Foundation completed an investment of twenty-five million dollars ($US25,000,000) in the First Tranche Convertible Loan Note. In
      connection with this Agreement the Foundation and the Company have agreed to convert the First Tranche Convertible Loan Note into Series B Shares pursuant to the terms of the Subscription Agreement relating to Series B Shares in Immunocore Limited,
      dated 3 February, 2020, the Deed of Variation dated 2 March, 2020 and the Deed of Adherence dated 2 March, 2020 (collectively, the &#8220;<font style="font-weight: bold;">Series B Investment Documents</font>&#8221;). The Series B Investment Documents are
      included within the term Investment Documents. Capitalized terms not defined herein shall have the same meaning as in the Investment Documents. The Foundation and the Company are each referred to as a &#8220;<font style="font-weight: bold;">Party</font>&#8221;
      and collectively as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;. In consideration of the Foundation making the Foundation Investment and converting the First Tranche Convertible Loan Note into Series B Shares on the terms and conditions in
      the Investment Documents, and for other good and valuable consideration, the undersigned hereby irrevocably agree as follows:</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0f331881739f4f2688a843130444a1c8" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">1.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Definitions</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The following terms shall have the following meanings:</div>
    <div>&#160;</div>
    <div> </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">1</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">Additional Global Health Program</font>&#8221; has the meaning given in <u>Section 3(c)(ii)</u></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Additional Product</font>&#8221; means, without prejudice to <u>Sections 3(b)</u> and <u>3(c)</u>, a sequence defined composition of matter created, developed
      and/or commercialized by the Company through the use of the Company&#8217;s Platform Technology without funding from the Foundation or a Foundation-Supported Entity that is applicable for the treatment, prevention or amelioration of any of the Target
      Diseases and Conditions. For the avoidance of doubt, Additional Product shall not include any product that a third party requests the Company to develop and such third party has the rights to develop and/or commercialize such product under an
      agreement between the Company and a third party. For the avoidance of doubt, as of the date of this Agreement, the [***] Candidates shall not be considered an Additional Product and shall be part of the HIV Program.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; means, as to any Person, any other Person that directly or indirectly controls, or is under common control with or is controlled by
      such Person.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Amended &amp; Restated</font>&#160;<font style="font-weight: bold;">Board Observer Letter</font>&#8221; has the meaning given in the Amended Note Purchase
      Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Amended Scope of Work</font>&#8221; means the Scope of Work to be developed in good faith by the Parties in accordance with Annex 3.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Change in Control</font>&#8221; means (i) the acquisition, directly or indirectly, by any Person or group of the beneficial ownership of securities of the
      Company possessing more than 50% of the total combined voting power of all issued securities of the Company; (ii) a merger, consolidation or other similar transaction involving the Company, except for a transaction in which the holders of the issued
      securities of the Company immediately prior to such merger, consolidation or other transaction hold, in the aggregate, securities possessing more than 50% of the total combined voting power of all issued securities of the surviving entity immediately
      after such merger, consolidation or other transaction; or (c) the sale, transfer or other disposition (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Charitability Default</font>&#8221; means the Company either (i) fails to comply with the restrictions in <u>Sections 2</u> and <u>12</u> of this Agreement
      on the use of funds from the Foundation Investment or fails to comply with the terms of <u>Sections 9(a)-(d)</u>, <u>10</u>, <u>13</u> or <u>14</u> or (ii) is in material breach of the Global Access Commitments.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Charitability Requirements</font>&#8221; has the meaning given in <u>Section 2(a)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Claim</font>&#8221; has the meaning given in <u>Section 5(a)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Code</font>&#8221; means the United States Internal Revenue Code of 1986, as amended, and the regulations thereunder.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">2</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">COGS</font>&#8221; shall mean, with respect to a product, the Group&#8217;s fully burdened manufacturing and sales costs, which shall include: [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Company Indemnitees</font>&#8221; has the meaning given in <u>Section 3(g)(iii)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Constitutional Documents</font>&#8221; has the meaning given in the Note Purchase Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Deed of Adherence</font>&#8221; has the meaning given in the Note Purchase Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Developing Countries</font>&#8221; means those countries listed in Annex 1, which list may be modified from time to time by mutual agreement of the Foundation
      and the Company; provided that [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Development Products</font>&#8221; means [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Diligent Efforts</font>&#8221; means (i) carrying out obligations or tasks pursuant to this Agreement using commercially reasonable efforts and resources
      comparable with standard practices of biotechnology companies of a comparable size and business activity to the Company and exercising decisions in good faith and (ii) in carrying out its obligations or tasks pursuant to this Agreement, the Company
      will use the same level of efforts, resources, time, and expediency as are consistent with the practices of the Company with respect to the research and development of any other Company products that are at a similar stage in development and
      applicable for the treatment, prevention or amelioration of infectious diseases.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Equity Securities</font>&#8221; means any equity securities of the Company issued in connection with the Foundation Investment, including the Series B Shares
      and any other equity securities issued in connection with or upon conversion of the Notes, and any securities issued in respect of or upon conversion or exercise of such securities.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Existing Agreements</font>&#8221; means collaboration or license agreements between the Company and third parties that were in effect as of September 13, 2017
      and in the form that such agreements existed on September 13, 2017.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Foundation Indemnitees</font>&#8221; has the meaning given in <u>Section 5(a)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Foundation Option Program</font>&#8221; has the meaning given in <u>Section 3(c)(i)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Foundation-Supported Entity</font>&#8221; means a third party that receives funding from the Foundation, collaborates with the Foundation, or both, for the
      purpose of accomplishing the Global Access Objectives.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Funded Developments</font>&#8221; means the Research Tools and Development Products. For the avoidance of doubt, Funded Developments does not include (i)
      anything that comprises Platform Technology or (ii) anything developed as part of or in relation to the Company&#8217;s research, development or commercialization of a product outside the Target Diseases and</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">3</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">Conditions that is not developed pursuant to a Global Health Program using any funds from the Foundation or a Foundation-Supported Entity; provided that the [***] Candidates are deemed to be Funded Developments.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Global Access Commitments</font>&#8221; has the meaning given in <u>Section 3</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Global Access Objectives</font>&#8221; means (a) the knowledge and information gained from the Foundation&#8217;s funding will be promptly and broadly disseminated,
      and (b) the Funded Developments will be made available and accessible at an affordable price to people most in need within Developing Countries.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Global Health Program</font>&#8221; means each of: (i) the HIV Program and the TB Program; and (ii) any other project funded as contemplated in this Agreement
      by the Foundation (including Additional Global Health Programs, as contemplated by <u>Section 3(c)</u>).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;[***]<font style="font-weight: bold;"> Candidates</font>&#8221; means the development candidates [***] upon the execution of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(bb)&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">HIV Program</font>&#8221; means the Company&#8217;s research, development and commercialization of a safe and effective product applicable to the treatment, prevention
      and/or amelioration of HIV carried out in accordance with the Original Scope of Work, the Amended Scope of Work and (if applicable) an agreed scope of work pursuant to <u>Section 3(a)(iii)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Intellectual Property</font>&#8221; means all intellectual property rights of whatsoever nature including without limitation copyrights, registered designs,
      design rights, patents and all intangible rights and privileges of a nature similar or allied to any of the foregoing, in every case in any part of the world and whether or not registered, and including all granted registrations and all applications
      for registration in aspect of any of the same;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Joint Steering Committee</font>&#8221; has the meaning defined in the Original Scope of Work.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Licence Trigger</font>&#8221; has the meaning given in <u>Section 3(g)(iv)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Note Purchase Agreement</font>&#8221; means the Convertible Loan Note Purchase Agreement dated September 13, 2017 entered into between the Company and the
      Foundation concerning the purchase of the Notes, as amended on [date], 2020 and as may be further amended from time to time.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Original Scope of Work</font>&#8221; means the Scope of Work set forth in Annex 2.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(hh)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Person</font>&#8221; means any individual, partnership, corporation, limited liability company, association, trust, joint venture, unincorporated organization
      or other entity.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">4</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Phase I Clinical Study</font>&#8221; means a clinical study, the principle purpose of which is preliminary determination of the compound&#8217;s safety in healthy
      individuals or patients as described in 21 C.F.R &#167;312.21, or similar clinical study in a country other than the United States.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160; &#160; &#160; &#8220;<font style="font-weight: bold;">Phase I Product</font>&#8221; means a sequence defined composition of matter created and developed pursuant to a Global Health Program (including under an
      agreed scope of work for an Additional Global Health Program): (i) which is the subject of its first Phase I Clinical Study; or (ii) for which all data that would be required for submission of an IND application is available. For clarity (A) the type
      and extent of data deemed required for IND submission shall be equivalent to that the Company customarily requires for its own wholly owned programs performed outside of this Agreement and (B) if the amino acid sequence of a Phase I Product is
      altered in any way (including by addition, substitution or omission of any amino acid) then it shall cease to be a Phase I Product.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Platform Technology</font>&#8221; means (i) the Company&#8217;s novel approach to discovering, researching, developing, manufacturing and commercializing bi-specific
      biologic reagents that combine an affinity-enhanced T cell receptor-based targeting system with an anti-CD3 effector function to activate a T cell response to eradicate disease causing cells; and (ii) any and all algorithms, code, data,
      documentation, designs, know how, methods, processes, programs, software, target antigens, test results or other technology that is owned or controlled by the Company or any of its Affiliates and that are necessary for the discovery, research,
      manufacture, development, commercialization or operation of Development Products. For clarity, the Platform Technology shall include any technologies, libraries, analytical techniques, techniques for the engineering of cell lines (but not necessarily
      the engineered cell lines themselves) materials and know-how that are generated by and on behalf of the Company before or after the Effective Date and which are owned, controlled or licensed in (to the extent sublicensable) by the Company or its
      Affiliates.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(kk)&#160; &#160; &#160;&#160; &#8220;<font style="font-weight: bold;">Post Phase I Product</font>&#8221; means a sequence defined composition of matter created and developed pursuant to a Global Health Program (including under an
      agreed scope of work for an Additional Global Health Program), which has successfully completed a Phase I Clinical Study. For clarity if the amino acid sequence of a Post Phase I Product is altered in any way (including by addition, substitution or
      omission of any amino acid) then it shall cease to be a Post Phase I Product.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;">Pre-Phase I Product</font>&#8221; has the meaning given in <u>Section 4</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(mm)&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Public Offering</font>&#8221; has the meaning given in <u>Section 8(f)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Public Sector</font>&#8221; means:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">&#8226;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; Governments including government ministries and agencies, together with government-funded institutions, such as hospitals and prison services in those countries;</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">5</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; NGOs including those recognized by the applicable local government authority as well as UN-related organizations working for or in those countries, including the International
      Organization for Migration and UNICEF;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Not-for-profit organizations including Medecins Sans Frontieres, Save-the-Children, OXFAM and the International Committee of the Red Cross;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; Public private partnerships that have agreed to public, not-for-profit, pricing, like the Initiative for Promoting Affordable and Quality TB Tests (IPAQT), or other collaborations or
      institutions bringing WHO-approved tests at affordable prices to patients in the private sector; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">&#8226;&#160;&#160;&#160; &#160; &#160;&#160; &#160;&#160; Not-for-profit funding mechanisms including GAVI, GDF, UNITAID, UNFPA, PEPFAR, USAID, Global Fund, etc. (including entities funded by such mechanisms on a not-for-profit basis) and
      agencies based outside of an applicable country but who are supporting implementation locally in an applicable country, including the USA-CDC and The Union.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(oo)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Research Tools</font>&#8221; means, to the extent that they were developed using funds from the Foundation or a Foundation-Supported Entity pursuant to a Global
      Health Program or they relate exclusively to an Additional Product and the Company has agreed in writing that they will be included as Research Tools, any (i) primers and/or probes for the detection and quantification of Target Diseases and
      Conditions (ii) cell lines engineered to express antigens relevant to Target Diseases and Conditions, or which are transfected or infected with vectors for antigens relevant to Target Diseases and Conditions (iii) HLA-antigen protein complexes
      relevant to Target Diseases and Conditions (iv) TCRs (other than those using the same scaffold as a Development Product) specific for antigens for particular Target Diseases and Conditions and (v) any other nucleic acid and/or amino acid sequences
      that are developed for use as research tools.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(pp)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Safety Decision</font>&#8221; has the meaning given in <u>Section 4</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(qq)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Safety Milestone</font>&#8221; means that each of the Foundation and the Company has made a decision [***], that the HIV Program has satisfied an acceptable
      safety milestone and that such Party desires to continue further development of the applicable candidate(s).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Securities Act</font>&#8221; means the United States Securities Act of 1933, as amended (and any successor thereto) and the rules and regulations promulgated
      thereunder.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ss)&#160;&#160;&#160;&#160;&#160; &#160; &#8220;<font style="font-weight: bold;">Shareholders&#8217; Agreement</font>&#8221; means the Shareholder&#8217;s Agreement relating to Immunocore Limited, dated 13 August 2019, as the same may be amended from
      time to time.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Target Diseases and Conditions</font>&#8221; means [***]. For the avoidance of doubt, Target Diseases and Conditions does not include any form of cancer,
      hepatitis or any autoimmune disease.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">From time to time, if the Foundation identifies more areas of global health as underinvested or disproportionately impacting poor and vulnerable populations, it may so notify the Company</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">6</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">and the definition of Target Diseases and Conditions will be so amended with the Company&#8217;s written consent.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">TB</font>&#8221; means tuberculosis.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(vv)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">TB Program</font>&#8221; means the Company&#8217;s research, development and commercialization of a safe and effective product applicable to the treatment, prevention
      and/or amelioration of TB carried out in accordance with the Original Scope of Work, Amended Scope of Work and (if applicable) an agreed scope of work pursuant to <u>Section 3(a)(iii)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(ww)&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Termination Dispute Period</font>&#8221; has the meaning given in <u>Section 3(n)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Tranche 1</font>&#8221; has the meaning given in <u>Section 3(a)(i)(A)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(yy)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Tranche 2</font>&#8221; has the meaning given in <u>Section 3(a)(i)(B)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Withdrawal Notice</font>&#8221; has the meaning given in <u>Section 8(b)</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(aaa)&#160;&#160;&#160;&#160;&#160;&#160; &#8220;<font style="font-weight: bold;">Withdrawal Right</font>&#8221; has the meaning given in <u>Section 8(b)</u>.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z433c007b5b914686b792b3d85cf434a7" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">2.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Charitable Purposes and Use of Funds</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Foundation is making the Foundation Investment as a &#8220;program-related investment&#8221; within the meaning of Section 4944(c) of the Code. The Foundation&#8217;s primary purpose in making the
      Foundation Investment is to further significantly the accomplishment of the Foundation&#8217;s charitable purposes, including the relief of the poor, distressed, and underprivileged, the advancement of science, and the promotion of health by seeking to (i)
      address global health challenges that disproportionately impact developing countries, and (ii) increase the access of poor and distressed individuals and families in developing countries to life-saving and other important vaccines, drugs and
      technologies that may assist in the prevention, treatment and detection of the Target Diseases and Conditions (collectively, the &#8220;<font style="font-weight: bold;">Charitability Requirements</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Foundation is making this investment to support the discovery and development of new, low-cost vaccines and drugs developed (in whole or in part) through the use of the Company&#8217;s
      Platform Technology and for the Target Diseases and Conditions in order to pursue the Global Access Objectives. The Foundation believes the Platform Technology has potential application in the Target Diseases and Conditions and, therefore,
      Development Products and Research Tools discovered using the Platform Technology (and any improvements and developments thereto), in conjunction with the Global Access Commitments described below, will further the Charitability Requirements.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Use of Funds</font>. Subject to the terms and conditions of this Agreement, the Company will use the proceeds from the Foundation Investment solely (i)
      to leverage the Company&#8217;s Platform Technology to create Development Products that comprise or result in drugs, therapeutics, diagnostics, prophylactics or other health products, services and interventions for</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">7</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">the treatment, prevention and/or amelioration of Target Diseases and Conditions which have the potential to treat people in Developing Countries affordably in accordance with the Global Access Objectives and (ii) to
      conduct the HIV Program and the TB Program with a goal to deliver and distribute an HIV and TB product reliably, sustainably and at an affordable price to people most in need within Developing Countries. At least [***] of the Foundation Investment
      will be used to conduct the HIV Program and the TB Program in accordance with the Original Scope of Work included in Annex 2 and the Amended Scope of Work which shall be executed by written agreement between the Foundation or a Foundation-Supported
      Entity and the Company no later than [***] days after the Effective Date. Specific deliverables and objectives with respect to development of the Platform Technology and the performance of the HIV Program and TB Program are set forth in the Original
      Scope of Work and will be included in the Amended Scope of Work. The Company is not required to segregate the proceeds of the Foundation Investment from other Company funds. Without prejudice to the foregoing, the Parties acknowledge and agree that
      (i) in carrying out its obligations under this Agreement (including its use of the proceeds from the Foundation Investment), the Company may cause improvements and developments to be made to the Platform Technology and (ii) the Company shall be able
      to freely use any Funded Developments outside the Developing Countries and outside the Target Diseases and Conditions.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z06df0697de714d44bdb2c85f6bdab1aa" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">3.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Global Access Commitments</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">As a condition to the Foundation making the Foundation Investment and in furtherance of the Foundation&#8217;s charitable purposes, including the Global Access Objectives, the Company agrees to the following commitments (the
      &#8220;<font style="font-weight: bold;">Global Access Commitments</font>&#8221;):</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold;">Development of Platform Technology; HIV Program and TB Program</font>. The Company will use Diligent Efforts to pursue the objectives and research plan
      set out in the Original Scope of Work and the Amended Scope of Work in furtherance of the Foundation&#8217;s charitable purpose.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; The Notes Investment will be divided into two tranches as follows:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(A)&#160;&#160;&#160;&#160;&#160; On or about the date of the Prior Agreement, the Foundation purchased Notes from the Company for twenty-five million dollars ($US25,000,000) (&#8220;<font style="font-weight: bold;">Tranche 1</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(B)&#160;&#160;&#160;&#160;&#160; Subject to the terms and conditions of this Agreement and contingent upon satisfaction of the Safety Milestone, the Foundation will purchase Notes from the Company for fifteen million
      dollars ($US15,000,000) (&#8220;<font style="font-weight: bold;">Tranche 2</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The activities that the Company will carry out using the Foundation Investment at each tranche are set forth in the Amended Scope of Work. The Foundation may consult with and provide
      guidance to the Company in an advisory capacity in relation to any clinical trial carried out as part of the Amended Scope of Work. For clarity, the Foundation will not be a sponsor or be obliged to make any decisions or perform any actions related
      to any clinical trial described in the Original Scope of Work or the Amended Scope of Work and all such</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">8</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">activities will be overseen and guided by the Company in compliance with its policies, regulatory requirements and input from the authorities at the respective clinical sites.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; After completion of the Tranche 2 requirements (or at such other time as the Foundation may elect), if requested by the Foundation the Company will, subject to this <u>Section 3(a)(iii)</u>,
      continue further development of the HIV Program and/or TB Program, including through commercialization of a final product. If the Foundation requests that the Company should continue with such further development, the Foundation and the Company will
      in good faith agree upon the reasonable funding arrangements necessary and a new scope of work for such further development and enter into a definitive agreement between the Foundation (or a Foundation-Supported Entity) and the Company and a project
      plan, which may include work to be undertaken, responsibilities, participation by other parties, timelines and milestones, project management, contributions in-kind and funding requirements, a product development and marketing plan, any additional
      Global Access commitments, and an affordable price cap for sales of the products in Developing Countries (if at a stage when price cap can be determined). Any additional work may be divided into milestones or phases, but the Foundation will have the
      right, at its sole discretion, to continue providing funding (directly or through a Foundation-Supported Entity) to advance each product through to commercialization of a final product in a manner furthering the Global Access Objectives. The Company
      will not be obliged to undertake any further development contemplated by this <u>Section 3(a)(iii)</u> unless and until the Parties have entered into a written agreement as described above; provided that the Company will cooperate with the
      Foundation in good faith to enter into such agreement as soon as possible after the Foundation requests the further development.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If (A) the HIV Program and/or TB Program fails as a result of scientific or technical failure or is suspended as a result of a Safety Decision; (B) the proceeds from the Foundation
      Investment have been exhausted; and (C) the Foundation does not agree to provide further funding after being given a reasonable opportunity to do so, the Company will have the right to continue funding the HIV Program and/or TB Program either on its
      own account or through a third party. If the Company continues further development pursuant to this <u>Section 3(a)(iv)</u>, the Company shall notify the Foundation in the event that the scientific or technical issue is resolved or Safety Decision
      is reversed (as applicable) and the HIV Program and/or TB Program results in a Development Product that includes any Funded Developments and that can be used for any Target Diseases and Conditions in the Developing Countries. If, following such
      notification, the Foundation notifies the Company of its desire that such Development Product be made available and accessible at an affordable price to people most in need within Developing Countries, then the Company will make such Development
      Product so available in the Developing Countries, subject to the Company and the Foundation or Foundation-Supported Entity as soon as is reasonably practicable negotiating in good faith and agreeing upon applicable agreements relating to such
      Development Product which will set forth, among other things, an agreement on equitable funding (and taking into account the amounts previously funded by the Foundation or a Foundation-Supported Entity with respect to such Development Product), which
      shall include provisions for the [***]</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">9</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; If the Foundation does not agree to provide funding for the further development of the HIV Program and/or TB Program (other than in the case of scientific or technical failure to which <u>Section





        3(a)(iv)</u> applies), the Company will have the right to continue funding the HIV Program and/or TB Program either on its own account or through a third party. If the Company continues further development pursuant to this <u>Section 3(a)(v)</u>,
      and the HIV Program and/or TB Program results in a Development Product that includes any Funded Developments and that can be used for any Target Diseases and Conditions in the Developing Countries, and the Foundation notifies the Company of its
      desire that such Development Product be made available and accessible at an affordable price to people most in need within Developing Countries, then the Company will make such Development Product available in the Developing Countries in accordance
      with <u>Section 3(l)</u> below, subject to the Company and the Foundation or Foundation-Supported Entity negotiating in good faith and executing applicable agreements relating to such Development Product which will set forth, among other things, an
      agreement on equitable funding (and taking into account the amounts previously funded by the Foundation or a Foundation-Supported Entity with respect to such Development Product), which shall include [***].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Notification of Company Research</font>. Without prejudice to <u>Section 3(c)</u>, if the Company is considering carrying out research and development
      with a view to developing a sequence defined composition of matter through the use of the Company&#8217;s Platform Technology that is intended to be applicable for the treatment, prevention or amelioration of any Target Diseases and Conditions (except if
      such research is being considered at the request of a third party pursuant to an agreement between such third party and the Company) then the Company shall notify the Foundation in writing of its intentions.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Additional Global Health Programs</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In addition to the HIV Program and the TB Program described above, which may include development through to commercialization, the Company agrees that as part of the Global Access
      Commitments, if requested by the Foundation it will, subject to this <u>Section 3(c)(i)</u>, accept and perform an additional product development program for each of malaria and human papillomavirus (each a &#8220;<font style="font-weight: bold;">Foundation





        Option Program</font>&#8221;). If the Foundation requests that the Company conduct a Foundation Option Program, the Foundation and the Company will in good faith agree upon the reasonable funding arrangements necessary and a scope of work for such
      program and enter into a definitive agreement between the Foundation (or a Foundation-Supported Entity) and the Company and a project plan, which may include work to be undertaken, responsibilities, participation by other parties, timelines and
      milestones, project management, contributions in-kind and funding requirements, a product development and marketing plan, any additional Global Access commitments, and an affordable price cap for sales of the products in Developing Countries (if at a
      stage when price cap can be determined). Any additional work may be divided into milestones or phases, but the Foundation will have the right, at its sole discretion, to continue providing funding (directly or through a Foundation-Supported Entity)
      to advance each product through to commercialization of a final product in a manner furthering the Global Access Objectives. The Company will not be obliged to undertake any development program contemplated by this <u>Section 3(c)(i)</u> (A) to the
      extent such program relates</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">10</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">to the research, development or commercialization of a product in the field of oncology or autoimmune diseases and (B) unless and until the Parties have entered into a written agreement as described above; provided
      that the Company will cooperate with the Foundation in good faith to enter into such agreement as soon as possible after the Foundation requests the Company conduct the Foundation Option Program.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; In addition to the Foundation Option Programs, if requested by the Foundation, additional programs relating to the Target Diseases and Conditions may be added if mutually agreed in writing
      by the Company and the Foundation and/or Foundation-Supported Entity, as applicable provided that the Company will not be obliged to undertake any further development contemplated by this <u>Section 3(c)(ii)</u> (A) unless the Parties have entered
      into a written agreement (as set out below) providing for adequate funding arrangements and including an agreed scope of work or (B) if the Foundation is making its request more than [***] after the Company has issued a notification under <u>Section
        3(b)</u> and in that time the Company has entered into an agreement with a third party in respect of research and development in the same Target Disease and Condition. Upon entering into a written agreement and agreeing upon a scope of work, the
      Company will employ its Platform Technology to discover, research, develop, manufacture and/or commercialize products in any mutually agreed Target Diseases and Conditions subject to terms and conditions set forth in the agreements entered into
      between the Company and the Foundation or Foundation-Supported Entities (as applicable), and the program will be funded by a grant, contract or program-related investment from the Foundation or Foundation-Supported Entities (as applicable) on terms
      acceptable to the Company and the Foundation and/or Foundation-Supported Entity (as applicable), as applicable. Any additional program mutually agreed to by the Company and the Foundation and/or a Foundation Supported Entity pursuant to this <u>Section





        3(c)(ii)</u> and each of the Foundation Option Programs is referred to in this Agreement as an &#8220;<font style="font-weight: bold;">Additional Global Health Program</font>&#8221; and they are referred to collectively as the &#8220;<font style="font-weight: bold;">Additional






        Global Health Programs</font>&#8221;.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160; Without prejudice to <u>Section 3(k)</u>, the Company maintains the right to develop products in all Target Diseases and Conditions for its own account or together with any third party
      provided that the application of the Global Access Objectives to the distribution of Development Products in the Developing Countries and the other Global Access Commitments are not restricted.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Coordination with Foundation-Supported Entities</font>. The Company acknowledges that the Foundation is currently funding and may continue to fund
      research and development projects at various Foundation-Supported Entities that are relevant to the HIV Program and the TB Program as well as other Target Diseases and Conditions. In order to complete the work required to be performed on the HIV
      Program and TB Program pursuant to this Agreement or any Additional Global Health Programs in the future, the Foundation may request that the Company coordinate its development efforts with various entities, including with respect to the specific
      requirements set forth in the Scope of Work, and acquire rights from or work in coordination with these Foundation-Supported Entities to fulfill the Global Access Commitments. The Company will consider any such request by the Foundation in good faith
      but will not be required to undertake any coordination of development efforts or enter into any</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">11</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">agreement with any entity; provided that the Company will not knowingly use the Foundation Investment to duplicate work (either internally or with a third party) that was funded by the Foundation and could be
      reasonably obtained from a Foundation-Supported Entity. If the Company agrees to coordinate its development efforts or enter into an agreement, the coordination, acquisition of rights and completion of licence agreements referred to in this paragraph
      would be the responsibility of the Company to effect, and the Foundation will assist in these efforts, in particular those that relate to work funded by the Foundation. Nothing in this Agreement constitutes a commitment by the Foundation to make any
      grants to the Company or a Foundation-Supported Entity and the decision to proceed with a grant will be made solely at the Foundation&#8217;s discretion. For clarity, no provision of this Agreement will limit or restrict the Foundation&#8217;s rights pursuant to
      any grant agreement or other contract with any third party.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Compliance with Intellectual Property Rights</font>. The Company will, to the best of the Company&#8217;s knowledge, take Diligent Efforts to obtain the
      appropriate rights appropriate to the stage of development of the product at the date of the Licence Trigger to exploit any Development Products in the form in which they exist at the date of the Licence Trigger arising from a Global Health Program.
      Such appropriate rights shall include rights in any patents, copyrights, trademarks, trade secrets, data, confidential information, know-how or other intellectual property or proprietary right required to use the licences in (g) below at the date of
      the Licence Trigger. The Company shall comply with all applicable laws and regulations in countries where it is operating at the date of the Licence Trigger. The Foundation acknowledges that the fees may need to be paid for rights to use third party
      licences necessary to exploit a Development Product in a Developing Country. The Company agrees to give reasonable assistance to the Foundation in any necessary negotiation with third party licensees to seek to minimize any such fees to help make the
      Development Product available and accessible at an affordable price to people most in need within Developing Countries.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Building the Field and Publication</font>. While undertaking the Global Health Programs, the Company may generate information and develop Research Tools
      comprised in the Funded Developments that have the potential to further the advancement of science and the promotion of health within the Target Diseases and Conditions and the following provisions shall apply in respect of such information and
      Research Tools subject to contractual and confidentiality obligations to third parties and in each case the Company may have due regard to reasonable delays or limitations on content of publications or provision of information that is necessary or
      desirable to protect intellectual property and confidential information.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company will make Diligent Efforts to make available at the Foundation&#8217;s request know how, data, assays and other Research Tools comprised in the Funded Developments with the goal to
      further the efforts of Foundation-Supported Entities and other Persons which are active in the applicable Target Disease and Condition. The Research Tools will be made available under the terms of license or material transfer agreements, as the case
      may be, that are consistent with industry standards; however, the Company will not require royalties or other fees related to the sharing of these Research Tools except for the reimbursement of reasonable out of pocket expenses and third party
      licence fees associated with their transfer or publication to the extent the Research Tools are being used for the purpose of benefitting people</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">12</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">in Developing Countries and in relation to the Target Diseases and Conditions. For clarity, use of the Research Tools other than for the purpose of benefitting people in Developing Countries or other than in relation
      to the Target Diseases and Conditions is not contemplated by this Agreement and may in the Company&#8217;s sole discretion be negotiated between the Company and Foundation-Supported Entities and other Persons on such terms as are agreed upon by the Company
      and such third parties.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; The Company will make Diligent Efforts, which are reasonably consistent with industry standards at the time, to satisfy the publication requirement (necessary for scientific research to be
      regarded as carried on in the public interest) set forth in Treasury Regulation 1.501(c)(3)-1(d)(5)(iii) to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(A)&#160;&#160;&#160;&#160;&#160;&#160; Publish scientific results and information developed in connection with each Global Health Program within a reasonable period of time after the information or results are obtained.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(B)&#160;&#160;&#160;&#160;&#160; Promptly provide upon the Foundation&#8217;s reasonable request and with the agreement of the relevant Foundation-Supported Entity (as appropriate), reasonable access to data and information
      regarding each Global Health Program.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(C)&#160;&#160;&#160;&#160;&#160; Promptly provide to the Foundation, upon the Foundation&#8217;s reasonable request, rights to share data and information regarding each Global Health Program.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(D)&#160;&#160;&#160;&#160; &#160; If the Company seeks publication of Funded Developments in a peer-reviewed journal, such publication must be under &#8220;open access&#8221; terms and conditions consistent with the Foundation&#8217;s Open
      Access Policy available at: http://www.gatesfoundation.org/How-We-Work/General-Information/Open-Access-Policy, which may be modified from time to time.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Non-Exclusive Licence</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; Subject to (iv) below, on a Global Health Program by Global Health Program basis the Company hereby grants the Foundation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(A)&#160;&#160;&#160;&#160;&#160; a worldwide, non-exclusive, perpetual, fully-paid up, royalty-free licence (with the right to sublicense subject to <u>Section 3(g)(iii)</u>) under the Intellectual Property owned by the
      Company relating to the Platform Technology and any Funded Developments in the form that the Platform Technology and Funded Developments exist at the time of the Licence Trigger solely to the extent necessary to use, make, have made, manufacture,
      sell, offer for sale, and otherwise exploit any Development Products that are in existence at the time that the Licence Trigger (as defined below) occurs. Such licence shall not include any right to modify the sequence of the relevant Development
      Product in the form that it exists at that time. For the avoidance of doubt this licence does not include any right to use the Platform Technology to generate additional TCR&#8217;s or other molecules; and</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">13</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;">(B)&#160; &#160; &#160;&#160; a worldwide, non-exclusive, perpetual, fully-paid up, royalty-free licence (with the right to sublicense subject to <u>Section 3(g)(iii)</u>) under the Intellectual Property owned by the
      Company relating to the Research Tools solely to the extent necessary to use, make and have made any Research Tools that are in existence at the time that the License Trigger (as defined below) occurs in the form such Research Tools exist at that
      time. Such licence shall not prevent the Foundation or a Foundation-Supported Entity from modifying or further developing the relevant Research Tools provided that the Foundation and any Foundation-Supported Entity does not use the Platform
      Technology in undertaking any such modification and/or any further development:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">provided that (i) the licences granted in this <u>Section 3(g)</u> will be limited solely for the purpose of benefitting people in Developing Countries (which, for the avoidance of doubt, excludes
      intentionally placing any Development Products on the market for use outside the Developing Countries) in relation to the Target Diseases and Conditions in furtherance of the Foundation&#8217;s charitable purpose and (ii) the Foundation shall not use
      and/or exploit the rights licensed to it under the licences granted in this <u>Section 3(g)</u> except as expressly authorized under this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160; The Foundation and the Company agree and acknowledge that in order to achieve the Global Access Objectives and make the Funded Developments available and accessible in Developing Countries
      and in relation to the Target Diseases and Conditions, certain activities may be required to occur in one or more developed countries, such as manufacture, distribution, or sale (such as to an entity procuring a product for use in Developing
      Countries and in relation to the Target Diseases and Conditions). Accordingly, the licenses granted in <u>Section 3(g)</u> to the Foundation are intended to permit such developed country activities which are incidental and necessary to making the
      Funded Developments available and accessible in Developing Countries in relation to the Target Diseases and Conditions provided that such activities do not include intentionally placing any Development Products on the market for use outside the
      Developing Countries and provided that the Foundation has made all reasonable efforts to prevent any Development Products being made available and accessible for use outside the Developing Countries. The definitive agreements with respect to any
      Additional Global Health Program will include license provisions with respect to the Global Health Program consistent with the license provisions set forth in this Agreement. Subject to the licences granted in <u>Sections 3(g)(i)(A)</u> and <u>(B)</u>
      above, the Company reserves exclusively, whether itself or with third parties (including licensees) all rights to develop and commercialize all Platform Technology, Research Tools, Development Products and other Funded Developments anywhere in the
      world. The Company acknowledges that such reservation of rights does not limit the Company&#8217;s obligations pursuant to this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Prior to granting any sub-license, access or any other right in respect of any Development Products or Research Tools to any third party, the Foundation shall procure an agreement from
      such third party that it shall indemnify the Company and its directors, officers, employees, agents and representatives (collectively, the &#8220;<font style="font-weight: bold;">Company Indemnitees</font>&#8221;) on commercially reasonable terms, reasonably
      acceptable to the Company and comparable with standard practices of biotechnology companies of a comparable size and business activity to the</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">14</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">Company where such terms are expressed to be for the benefit of and enforceable by the Company Indemnitees.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding the forgoing license grants, the Foundation shall have no right to exercise its rights under the license (including its sublicensing rights) unless and until at least one
      of the following occurs (each a &#8220;<font style="font-weight: bold;">Licence Trigger</font>&#8221;) for the applicable Global Health Program:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(A)&#160;&#160;&#160;&#160;&#160;&#160;&#160; a Charitability Default that the Company has not remedied within [***] of the date of the Company being notified by the Foundation;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(B)&#160;&#160;&#160;&#160;&#160;&#160; the Company (or any successor or acquirer of the Company&#8217;s assets, Platform Technology or Funded Developments) is unwilling or unable at any time to proceed or continue with development of
      the HIV Program, TB Program or any other Global Health Program for which a Development Product has been identified and for which the Foundation or a Foundation-Supported Entity is willing to provide reasonable funding (except where such unwillingness
      or inability results from a scientific or technical failure in which case <u>Section 3(a)(iv)</u> applies); or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(C)&#160;&#160;&#160;&#160; the Company institutes any bankruptcy, insolvency, reorganization for the benefit of creditors, dissolution, liquidation or similar proceeding relating to it under the laws of any
      jurisdiction or any such proceeding is instituted against the Company and in any such case, such proceeding is not dismissed or stayed within [***] after the filing thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">If either the Foundation or the Company becomes aware of a License Trigger it will promptly notify the other Party in writing of the occurrence of a License Trigger. If the Company disputes the
      Foundation&#8217;s belief that a License Trigger has occurred, the Company and the Foundation will negotiate in good faith for a period of [***] in the event of the License Trigger in <u>Section 3(g)(iv)(B)</u> or for a period of [***] in the event of the
      License Trigger in <u>Section 3(g)(iv)(A)</u> or <u>3(g)(iv)(C)</u> in each case in an effort to resolve the dispute, after which time the Foundation may exercise the license, but both Parties will retain their respective rights to exercise legal
      or equitable remedies that may be available.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Ownership of Intellectual Property</font>. Notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that all
      Intellectual Property (including any improvements and developments thereto) created by or on behalf of the Company pursuant to this Agreement and the Platform Technology and Development Products shall be owned by the Company. Except as expressly
      provided in this Agreement, nothing shall operate to grant any rights to the Foundation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Modification</font>. The principal purpose of the license granted to the Foundation is to enable the Global Access Objectives to be achieved efficiently
      in the event of the occurrence of a License Trigger. The Parties acknowledge that commercialization and/or distribution of Company products and processes for the benefit of end users in Developing Countries may require worldwide commercialization and
      /or distribution rights to be maintained by a single</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">15</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">party. During the implementation of the Global Health Programs, the Company may demonstrate, on a case-by-case basis, to the satisfaction of the Foundation that the Global Access Objectives can best be achieved in a
      particular case without such a license. In such a case, the Foundation and the Company shall in good faith agree to modifications to, or to modify or terminate in whole or in part, the foregoing license as mutually agreed in writing between the
      Parties.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Cooperation; Technology Transfer</font>. After the occurrence of a License Trigger, the Company agrees to use Diligent Efforts to enable the Foundation
      or its sublicensees to exercise their rights hereunder, which steps may include, as may be reasonably required or requested by the Foundation, (i) the Company licensing relevant Intellectual Property owned or controlled by the Company to the
      Foundation or in respect of a Foundation-Supported Entity, good faith negotiations with such entity for a license of relevant Intellectual Property (with the Foundation having the ability to consult the Company regarding such negotiations) or
      agreements to not assert such Intellectual Property, (ii) executing documents reflecting or recording the licenses in <u>Section 3(g)</u>, (iii) providing reasonable information sharing to enable the Foundation or Foundation-Supported Entities to
      implement the license rights and technology, and (iv) reasonable technical assistance related to the implementation of the license rights and technology to enable the Foundation or its sublicensees to exercise the licences in <u>Section 3(g)</u>,
      subject to contractual obligations to third parties. For the avoidance of doubt, the obligations under this paragraph shall not require the Company to secure rights to any third party Intellectual Property at the Company&#8217;s expense.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Additional Products</font>. If the Company creates and develops an Additional Product, the Foundation can request to have the Global Access Objectives
      apply to such Additional Product by delivering written notice to the Company. If the Foundation provides such notice to the Company, then the Foundation or a Foundation-Supported Entity (as applicable) and the Company will as soon as possible
      negotiate in good faith the terms and conditions of applicable agreements relating to such Additional Product which will set forth, among other things, an agreement on equitable funding, [***]. Such Additional Product will not become a Development
      Product for the purposes of this Agreement and the Company will not be required to make such Additional Product available in the Developing Countries unless and until the Parties have negotiated in good faith and reached such mutual agreement and
      executed applicable agreements. For the avoidance of doubt if the Company incorporates any Funded Developments into an Additional Product or product developed with a third party that is applicable for the treatment, prevention or amelioration of any
      of the Target Diseases and Conditions, the Global Access Objectives will apply to such product.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Global Access for Development Products</font>. Without limiting the requirements set forth above, the Company will use Diligent Efforts to make all
      Development Products (to the extent that such Development Products are at a stage of development that makes them capable of being commercialized in accordance with applicable laws) available and accessible at an affordable price to people most in
      need within those Developing Countries affected by the disease or condition which is treated, prevented or ameliorated by the Development Product, provided that such price enables the Company to recover an amount that does not exceed [***]. The</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">16</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">Foundation agrees that to the extent it provides funding for the purchase of Development Products for use in the Developing Countries it will use all reasonable efforts to require the purchasers of such Development
      Products to agree to use all reasonable efforts to prevent any such Development Products from being made available and accessible for use outside the Developing Countries, which may be satisfied, among other ways, by including such a requirement in
      the applicable funding agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Duration</font>. The Global Access Commitments will commence upon the Effective Date and be ongoing and will continue for as long as the Foundation
      continues to pursue a charitable mission. For clarity, the Global Access Commitments will continue as to any Funded Developments that are assigned, sold, transferred or exclusively licensed to a third party.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Termination of Licenses for breach</font>. On a Global Health Program by Global Health Program basis the Company will have the right to terminate the
      licenses granted under <u>Section 3(g)</u> and any sublicences with respect to a Global Health Program on [***]<font style="background-color: #FFFF00;">&#160;</font>notice if the Foundation, its Affiliates, a Foundation-Supported Entity or sub-licensees
      have, in respect of such Global Health Program, committed a material breach of the licenses granted under <u>Section 3(g)</u> (which, for the avoidance of doubt, shall include use outside the scope of such licenses or in contravention of the
      limitations set out in <u>Section 3(g)</u>), which has not been remedied within [***] of the Company giving notice to remedy. If the Company terminates a license granted pursuant to <u>Section 3(g)</u> and the Foundation disputes such termination,
      the Foundation can bring an action in court for breach of contract, declaratory judgment or other action to reinstate such license. During the period in which such action is pending, including any appeals (the &#8220;<font style="font-weight: bold;">Termination





        Dispute Period</font>&#8221;), the Company waives the right to seek, and will not seek, an injunction or other equitable relief to prevent the infringement of the Intellectual Property that is the subject of the sub-licensable licenses granted to the
      Foundation under <u>Section 3(g)</u>. If the court of competent jurisdiction finally determines that the Company was entitled to terminate the license then the Company will be entitled to exercise legal or equitable remedies that may be available,
      including seeking damages resulting from the use of the Intellectual Property that is covered by the license(s) at issue during the Termination Dispute Period.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">No Violation of U.S. Tax Law</font>. Notwithstanding anything in this Agreement to the contrary, under no circumstances will the Foundation be required
      to provide any funding to the Company if such funding is reasonably likely to cause the Foundation to violate applicable U.S. tax law (including by conferring improper private benefit on the Company) or is reasonably likely to subject the Foundation
      to penalties under applicable U.S. tax laws, provided always that if such rules do prevent a fair and equitable portion of the development costs being shared as contemplated by <u>Section 3(a)(iv)</u>, <u>Section 3(a)(v)</u> or <u>Section 3(k)</u>,
      the applicable funding agreement shall make provision for the Company to be compensated by some other legally permissible means.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z40cd562d82d549bca2500f5ca829d000" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">4.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Suspension of Development for Safety Reasons</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Foundation recognises that the therapeutic compounds developed by the Company are exceptionally potent and have the potential to cause significant harm to patients without</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">17</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">appropriate safety testing and that as the leader in the field the Company is the only entity capable of reviewing pre-clinical safety data for its compounds and determining whether they are safe enough for
      administration to human subjects. The Foundation therefore agrees that prior to the completion of a Phase I Clinical Study in respect of a Phase I Product (a &#8220;<font style="font-weight: bold;">Pre-Phase I Product</font>&#8221;) the Company may decide, at
      its reasonable discretion, acting in good faith and following good faith consultations with the Foundation, that upon review of the available pre-clinical and clinical data that to administer said Pre-Phase I Product to a human subject would place
      such subject at unacceptable risk of harm (a &#8220;<font style="font-weight: bold;">Safety Decision</font>&#8221;). Within [***] of making such Safety Decision the Company shall provide the Foundation with a report detailing the reasoning as to why it made a
      Safety Decision and an indication as to the data that would be required for the Company to reverse said Safety Decision. In the event that the Company makes a Safety Decision in respect of a Pre-Phase I Product any license rights granted to the
      Foundation or any Foundation-Supported Entities or sub-licensees of either of them with respect to such Pre-Phase I Product shall be limited to non-human uses of such product. Following notification to the Foundation of a Safety Decision, the Company
      agrees acting reasonably and in good faith to review any data generated by the Foundation, Foundation-Supported Entities or sub-licensees through the use of the respective research use license that addresses the reported safety concern [***]&#160;with a
      view to lifting such Safety Decision.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za660f51c31ad497a87f6af4c5f50d7a2" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">5.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Indemnification</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Subject to Section 5(b), save to the extent that any Claim is caused by the Foundation&#8217;s negligence, fraud, or willful misconduct, the Company will indemnify, hold harmless, and defend
      the Foundation and its co-chairs, trustees, directors, officers, employees, agents, and representatives (collectively, the &#8220;<font style="font-weight: bold;">Foundation Indemnitees</font>&#8221;) from and against any and all third party causes of action,
      claims, suits, legal proceedings, judgments, settlements, damages, penalties, losses, liabilities and costs (including reasonable attorneys&#8217; fees and costs) (each a &#8220;<font style="font-weight: bold;">Claim</font>&#8221;) finally awarded to such third party
      by a court of competent jurisdiction against any of the Foundation Indemnitees or agreed to as part of a monetary settlement of the Claim and arising out of or relating to: bodily injury or death directly caused by the activities or omissions of the
      Company, relating to the Company&#8217;s development of the Funded Developments (including any failure to comply with applicable laws, regulations or rules in connection therewith) or any knowing infringement upon a patent, proprietary, or other
      intellectual property right of a third party arising prior to the date of any Licence Trigger. For the avoidance of doubt, the Company will not be liable for any Claims that result from (i) the Foundation&#8217;s or any Foundation-Supported Entity&#8217;s use,
      manufacture, sale, or other exploitation of any Development Product or Research Tool pursuant to the exercise by the Foundation of the rights in <u>Section 3(g)</u> or (ii) changes to any Funded Developments that are made by the Foundation, a
      Foundation-Supported Entity or a licensee (such expression including further sublicensees) of either of them under a license granted herein. The Foundation will give the Company prompt written notice of any Claim subject to indemnification; provided
      that the Foundation&#8217;s failure to promptly notify the Company will not affect the Company&#8217;s indemnification obligations except to the extent that the Foundation&#8217;s delay prejudices the Company&#8217;s ability to defend the Claim. The Company will have sole
      control over the defense and settlement of each and every Claim, with counsel of its own choosing which is reasonably acceptable to the Foundation; provided that the Company</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">18</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">conducts the defense actively and diligently at the sole cost and expense of the Company and provided further that the Company will not enter into any settlement that adversely affects any Foundation Indemnitee without
      the applicable Foundation Indemnitee&#8217;s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed. The Foundation will provide the Company, upon request, with reasonable cooperation in connection with the defense and
      settlement of the Claim. Subject to the Company&#8217;s rights above to control the defense and settlement of Claims, the Foundation and any Foundation Indemnitee may, at its own expense, employ separate counsel to monitor and participate in the defense of
      any Claim under this <u>Section 5</u>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Parties will not be liable to each other for any indirect, incidental, consequential, or special damages (including lost revenues, lost savings, or lost profits suffered by such other
      Party) suffered by such other Party arising under or in connection with this Agreement, regardless of the form of action, whether in contract or tort, including negligence of any kind whether active or passive, and regardless of whether the party
      knew of the possibility that such damages could result; provided that to the extent a Foundation Indemnitee is entitled to be indemnified hereunder for Claims of third parties and such third party has been awarded indirect, incidental, consequential,
      reliance, or special damages (including lost revenues, lost savings, or lost profits), the Company&#8217;s indemnification obligations to the Foundation Indemnitee shall extend to and include such third party&#8217;s indirect, incidental, consequential,
      reliance, or special damages (including lost revenues, lost savings, or lost profits).</div>
    <div>&#160;</div>
    <div>
      <div>
        <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z5e678acdfda941afb20d65bd6f945c9f" class="DSPFListTable" cellpadding="0" cellspacing="0">

            <tr style="vertical-align: top;">
              <td style="vertical-align: top; width: 36pt;">
                <div style="font-weight: bold;">6.</div>
              </td>
              <td style="align: left; vertical-align: top; width: auto;">
                <div style="font-weight: bold;"><u>Obligations in the Event of a Sale of the Platform Technology or the Company; Preservation of Global Access Commitments</u></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">In the event that all or substantially all of the Company&#8217;s assets (including the Platform Technology or the Funded Developments) are transferred to, exclusively licensed to, sold to or acquired by a third party,
      including through a Change in Control, the Company shall enter into and procure that the purchaser, transferee, licensee or acquirer (as relevant) enters into a novation agreement in respect of this Agreement pursuant to which from the date that such
      novation agreement is entered into, the purchaser, transferee, licensee or acquirer (as relevant) shall perform this Agreement and be bound by it (including the Global Access Commitments) and which gives the Foundation a direct right of enforcement
      against such purchaser, transferee, licensee or acquirer. Subject to the Existing Agreements, the Company will not grant to a third party any rights or enter into any arrangements or agreements that would limit or restrict the exercise or performance
      of the Global Access Commitments, in whole or part, including the ability of the Foundation to fund further development as contemplated by the Global Access Commitments. For clarity, notwithstanding anything to the contrary in this Agreement, the
      Foundation&#8217;s rights hereunder which exist on the date of the transfer, sale or acquisition of the Company&#8217;s assets (including the Platform Technology or the Funded Developments) to or by a third party shall not be terminated by such transfer, sale or
      acquisition. The rights of the Foundation set out in this <u>Section 6</u> and the Global Access Objectives shall not apply to any services, products or Intellectual Property rights that are licensed to or owned by any company that merges with or
      acquires the Company prior to such merger or acquisition and that are not included in Funded Developments.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">19</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="ze5eb56e0101445fd8bd6f5d93e11461a" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">7.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Right to Enforce Global Access Commitments</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Foundation has certain rights to transfer its Notes and or Equity Securities issued by the Company in the event of a Charitability Default as set forth in the Note Purchase Agreement and this Agreement. The Company
      agrees and acknowledges that the Foundation will be entitled to such rights for as long as it holds Notes and/or Equity Securities issued by the Company, as set out in the Note Purchase Agreement and this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">If the Foundation ceases to hold any Notes and/or Equity Securities issued by the Company following a Charitability Default, the Foundation will continue to be entitled to enforce its rights under this Agreement,
      including the Global Access Commitments.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zda616ba2788743f0aefceb499e6ccce8" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">8.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Withdrawal Right</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Foundation&#8217;s rights described and defined in this <u>Section 8</u> will be triggered only as a result of a Charitability Default and will only be exercisable following the conversion
      of a Note. For the avoidance of doubt, the Withdrawal Right will not be triggered by a Safety Decision or the inability, for technical or scientific reasons, to carry out the Original Scope of Work, Amended Scope of Work or successfully develop a
      product, so long as the Company has not breached its Global Access Commitments or any other obligations under this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party will notify the other promptly upon becoming aware of any Charitability Default, and the Company shall thereafter provide to the Foundation a proposed strategy to remedy the
      Charitability Default. If the Company fails to cure the Charitability Default within [***] of the date of notification by either Party to the other of the Charitability Default and if and to the extent that the Foundation holds any Equity Securities,
      the Foundation shall be entitled to elect to sell all of such Equity Securities by notice in writing to the Company (the &#8220;<font style="font-weight: bold;">Withdrawal Notice</font>&#8221; and any such entitlement to elect being the &#8220;<font style="font-weight: bold;">Withdrawal Right</font>&#8221;). On receipt of notice from the Foundation, the Company shall either buy back all of the Equity Securities held by the Foundation, provided that such buyback shall be made only to the extent
      permitted by applicable law and the Constitutional Documents, or locate a third party that will purchase the Equity Securities. For the avoidance of doubt if the Company fails to effect the Withdrawal Right as a result of a failure to obtain
      necessary shareholder approvals, such failure will constitute a breach of this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Company is unable to buy back all of the Equity Securities, and no third party purchases the Equity Securities within [***] of the Withdrawal Notice, then the Company shall use
      best efforts to effect the Withdrawal Right, consistent with the Code and applicable law, as soon as practicable thereafter.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the period when the Company is unable to exercise its obligation to buy back or find a purchaser of the Equity Securities, the Company shall not pay dividends, make any
      distributions or undertake any return of capital without the Foundation&#8217;s prior written consent except for: (i) repurchases of shares from current and former employees, officers, directors, consultants or other persons who performed services for the
      Company or any Affiliate in</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">20</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the buy back or purchase by a third party pursuant to <u>Section 8(b)</u>, Equity Securities shall be valued at the greater of:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; the original purchase price attributable to such shares plus a [***] compounding interest rate per annum until the date of the completion of the share buyback or third-party sale, as
      applicable; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the then current fair market value as determined by a mutually agreed upon (such agreement not to be unreasonably withheld) independent third-party appraiser.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to <u>Section 8(g)</u>, if the Equity Securities are sold or bought back due to a Charitability Default, the Foundation will have a look back right by which, in the event that,
      during the period of one (1) year from the date on which the Equity Securities are sold or bought back, the Company consummates a Change in Control or an admission to trading of the shares of the Company to a Recognised Investment Exchange (as
      defined in the Financial Services and Markets Act 2000) or to the New York Stock Exchange or NASDAQ (&#8220;<font style="font-weight: bold;">Public Offering</font>&#8221;), representing a per share valuation for the Company in excess of one hundred and fifty
      percent (150%) of the valuation used for the sale or buy back of the Equity Securities, then the Foundation will receive from the Company a payment equal to the excess of what it would have received in such transaction if it still held the Equity
      Securities at the time of such Change in Control or Public Offering over what the Foundation actually received in the sale or buy back of the Equity Securities.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The provisions of <u>Section 8(f)</u> shall not apply in the event that a Change in Control occurs as a result of the acceptance by the shareholders of the Company (by way of takeover
      offer, scheme of arrangement or otherwise) of an offer for the entire issued share capital of the Company in circumstances in which such offer was not, at the time it was made to shareholders, recommended by the board of directors of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In the event that the Foundation exercises its Withdrawal Right, the Foundation&#8217;s rights under the Global Access Commitments pursuant to this Agreement and in relation to all Global
      Health Programs (as such terms are defined in this Agreement) will survive.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If prior to the exercise of the Withdrawal Right the Foundation transfers the Equity Securities to a third party other than as permitted by <u>Section 11(a)</u>, the Withdrawal Right
      will no longer apply to such transferred Equity Securities unless otherwise agreed in writing by the Company and the Foundation.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zea4c7ac808b44f9eba5db934ffc6ba1e" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">9.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Required Reporting</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">In addition to any and all reports required to be delivered to the Foundation under the Investment Documents, the Company shall furnish, or cause to be furnished, to the Foundation the following reports and
      certifications.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">21</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Within [***] after the end of each Company fiscal year during which the Foundation owns any Notes and/or Equity Securities, a certificate from the Company signed by an officer or director
      of the Company and substantially in the form attached to this Agreement as Annex 4, certifying that the requirements of the Foundation Investment were met during the immediately preceding fiscal year, describing the use of proceeds of the Foundation
      Investment and evaluating the Company&#8217;s progress on the Global Health Programs including, specifically, information regarding progress against the Global Access Commitments;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Within [***] after the end of the Company&#8217;s fiscal year during which the Foundation ceased to own any Notes and/or Equity Securities, a certificate from the Company signed by an officer or
      director of the Company and substantially in the form attached to this Agreement as Annex 5, certifying that the requirements of the Foundation Investment were met during the term of the Foundation Investment, describing the use of proceeds of the
      Foundation Investment and evaluating the Company&#8217;s progress on the Global Health Programs including, specifically, information regarding progress against the Global Access Commitments;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Any other information respecting the operations, activities and financial condition of the Company as the Foundation may from time to time reasonably request, not more than [***] per
      calendar year, to discharge any expenditure responsibility, within the meaning of Sections 4945(d)(4) and 4945(h) of the Code, of the Foundation with respect to the Foundation Investment, and to otherwise monitor the charitable benefits intended to
      be served by the Foundation Investment, provided that the [***] associated with preparing such information at its request; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At least [***] for each period during which the Foundation continues to own any Notes or Equity Securities issued by the Company, full and complete financial reports of the type
      ordinarily required by commercial investors under similar circumstances. For the avoidance of doubt this provision will be deemed to be satisfied so long as the Company is in compliance with its obligations pursuant to Section 9.7 of the Note
      Purchase Agreement and/or the Constitutional Documents (as applicable).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Within [***] of the end of each calendar quarter during which any Global Health Program is ongoing, if reasonably requested by the Foundation, the Company will confer with the Foundation
      (by teleconference or in scheduled site visits as appropriate) regarding progress with respect to the Original Scope of Work and Amended Scope of Work including information regarding progress against the Global Access Commitments and, if requested by
      the Foundation, the Company will provide written discussion materials prior to such teleconference or meeting; (ii) coordinate with the Foundation to determine reasonable times for the Foundation&#8217;s representatives to make site visits to the Company&#8217;s
      headquarters [***] for the purpose of the Foundation conducting any inspections with respect to a Global Health Program; and (iii) at least [***], if requested by the Foundation, an in person meeting with the Joint Steering Committee.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the Disclosure Letter provided to the Foundation pursuant to the Subscription Agreement relating to Series B Shares in Immunocore Limited, dated [&#160;&#160; ], 2020, [***].</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0a64025ff46a4c51966381281dc93779" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">10.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Access to Records</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">22</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">The Company shall maintain books and records adequate to provide information ordinarily required by commercial investors under similar circumstances and showing the expenditure of the Foundation Investment, as well as
      copies of the reports submitted by the Company to the Foundation pursuant to Sections 9(a) and 9(b). The Company shall provide the Foundation or, subject to the Company&#8217;s written consent, its designee(s) [***] with access at reasonable times on
      reasonable terms of confidentiality to such books and records pertaining to the period during which the Foundation owned any Notes or Equity Securities issued by the Company and continuing for a period of [***] after the date on which the Foundation
      no longer owns any Notes or Equity Securities issued by the Company or any successor thereof. For the avoidance of doubt, access to records under this Section 10 shall not be dependent upon the Foundation&#8217;s percentage ownership in the Company.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z702fed363f37450ea6befce50e26743e" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">11.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Assignment</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, the Foundation will have the right to assign this Letter Agreement (in whole but not in part) to: (i) any subsidiary of the
      Foundation, (ii) any successor charitable organization of the Foundation from time to time that is a tax-exempt organization as described in Section 501(c)(3) of the Code, or (iii) any tax-exempt organization as described in Section 501(c)(3) of the
      Code controlled by one or more trustees of the Foundation. The Foundation will notify the Company of any such proposed assignment, including the identity of the assignee, prior to the date of such assignment. For the avoidance of doubt, if the
      Foundation transfers the Equity Securities to any permitted transferee in accordance with the Constitutional Documents, the Foundation may assign to any such permitted transferee all of its rights attached to such Equity Securities, including the
      Withdrawal Right.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Except as provided in <u>Section 11(a)</u> and <u>Section 6</u>, neither Party shall have the right to assign (whether by sale or license of assets, or otherwise) this Agreement without
      the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed except that any Party may make such an assignment without the other Party&#8217;s consent to (i) a third party who acquires all or
      substantially all of the business or assets of such Party to which this Agreement relates or (ii) to a new corporate entity created as part of a corporate reorganization where such entity will continue to be bound by the terms of this Agreement.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zc4737037a6604f3ab061681fd8b04605" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">12.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>No Use of Foundation Funds for Political Activities; No Personal Benefit</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company shall not expend any proceeds of the Foundation Investment to carry on propaganda or otherwise to attempt to influence legislation, to influence the outcome of any specific public election or to carry on,
      directly or indirectly, any voter registration drive, or to participate or intervene in any political campaign on behalf of or in opposition to any candidate for public office within the meaning of Section 4945(d) of the Code. The proceeds of the
      Foundation Investment shall not (a) be earmarked to be used for any activity, appearance or communication associated with the activities described in the foregoing sentence, nor (b) be intended for benefit, and will not benefit, any Person having a
      personal or private interest in the</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">23</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">Foundation, including descendants of the founders of the Foundation, or Persons related to or controlled by, directly or indirectly, such private interests.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z2569c16cd6c448dca657f27c9d0060c4" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">13.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Disqualified Person</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company confirms that, as at the Effective Date neither the Company nor (to the best knowledge of the Company) any shareholder of the Company is a &#8220;disqualified person&#8221; with respect to the Foundation (as the term
      &#8220;disqualified person&#8221; is defined in Section 4946(a) of the Code). The Company agrees that it will promptly notify the Foundation if the Company becomes aware that the Company or any shareholder of the Company is a &#8220;disqualified person&#8221; with respect
      to the Foundation. The Foundation confirms that as at the Effective Date, the Foundation does not, and one or more disqualified persons with respect to the Foundation do not, directly or indirectly, control the Company.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zda5f261da0694404aeec63c545eefa95" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">14.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Compliance with Anti-Corruption, Anti-Bribery and Anti-Terrorism Laws</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company will not offer or provide money, gifts or any other thing of value, directly or indirectly, to anyone in order to improperly influence any act or decision relating to the Foundation or the sale of the
      Company&#8217;s products and services or the other matters contemplated by this Agreement, including by assisting any party to secure an unlawful advantage. Training and information on compliance with these requirements are available at
      www.learnfoundationlaw.org.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company will not use any portion of the Foundation Investment, directly or indirectly, in support of activities (a) prohibited by US laws related to combatting terrorism; (b) with any Person on the List of
      Specially Designated Nationals (www.treasury.gov/sdn) or entities owned or controlled by such Persons; or (c) in or with countries or territories against which the US maintains comprehensive sanctions (currently, Cuba, Iran, Syria, North Korea and
      the Crimea Region of Ukraine), including paying or reimbursing the expenses of persons from such countries or territories, unless such activities are fully authorized by the US government under applicable law and specifically approved by the
      Foundation in its sole discretion.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z90185ff9a9ea416cb2f09586c301096c" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">15.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Publicity; Use of Name</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">Each Party may include pre-agreed information about the Foundation Investment (including the other Party&#8217;s name) in its periodic public reports and may make such information available on its own website, in
      presentations, speeches, tax returns or other public disclosures and press releases and any other disclosure that is required by Applicable Law or (to the extent relevant) the rules of a stock exchange on which the securities of the Company are
      listed (or to which an application for listing has been submitted). Without prejudice to the foregoing, the Company may also confirm the existence of the Foundation Investment and disclose that the Foundation is a shareholder in any confidential
      discussions with any existing or potential investor. Except as otherwise provided herein, any announcement of the Foundation Investment by any other Person, including the Company, its representatives, directors, stockholders and agents, or any
      investor, will require the Foundation&#8217;s prior written approval, such approval not to be unreasonably withheld, delayed or conditioned. Such Persons shall also obtain the Foundation&#8217;s</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">24</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">prior written approval for any other use of the Foundation&#8217;s name or logo in any respect; provided, however, that the Company may use the Foundation&#8217;s name for any uses that have been pre-approved in writing by the
      Foundation. Except as provided above or with the Foundation&#8217;s consent, the Foundation&#8217;s name and logo will not be used by any Person in any manner to market, sell or otherwise promote the Company, its products, services and/or business.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zcb2a04daa5834273adf343a275cf1322" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">16.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Confidentiality</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party shall treat as confidential all information obtained as a result of entering into this Agreement which relates to:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; the provisions of this Agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the negotiations relating to this Agreement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the subject matter of this Agreement; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the other Party.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to <u>Sections 16(c)</u> and <u>16(d)</u> below, each Party shall:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160; &#160; not disclose any such confidential information to any person other than (A) any of its trustees, directors, officers or employees who need to know such information in order to discharge
      his duties and (ii) (in respect of the Company only) any potential investor and their advisers or representatives;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not use any such confidential information other than for the purpose of complying with its obligations under this Agreement; and</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; procure that any person to whom any such confidential information is disclosed by it complies with the restrictions contained in this Section 16 or similar terms of confidentiality.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; The Company shall be permitted to disclose the subject matter and provisions of this Agreement to any existing or potential investor and their respective advisers or representatives,
      provided the Company procures that such investor complies with the restrictions in this <u>Section 16</u> as if it were a party to this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the other provisions of this <u>Section 16</u>, either Party may disclose any such confidential information:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; to the extent required by law;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent required by existing contractual obligations;</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">25</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to its professional advisers, auditors and bankers provided they have a duty to keep such information confidential;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent the information has come into the public domain through no fault of that party;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent permitted pursuant to <u>Section 15</u>; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(vi)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to the extent the other Party has given prior written consent to the disclosure.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any information to be disclosed pursuant to <u>Section 16(d)(i)</u> (other than information required to be disclosed in tax returns or other tax filings) and <u>Section 16(d)(ii)</u>
      above shall be disclosed only after, to the extent permitted by law, written notice to the other Party. The restrictions contained in this <u>Section 16</u> shall continue to apply after the termination of this Agreement without limit in time.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the avoidance of doubt, as between the Foundation and the Company, nothing in Section 9 or 10 of the Shareholders&#8217; Agreement will limit or restrict the Foundation&#8217;s rights pursuant
      to this Agreement and in the event of any conflict between the terms of Section 9 or 10 of the Shareholders&#8217; Agreement and this Agreement, the terms of this Agreement will prevail and control.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z21dc6d08f6ed41ea9e4e74a87b3fa975" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">17.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Entire Agreement; Modification</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Agreement and the other Investment Documents, including all exhibits hereto and thereto, set forth all the covenants, promises, agreements, warranties, representations, conditions and understandings between the
      Parties with respect to the subject matter of the Investment Documents, and supersede and terminate all prior agreements, negotiation and understandings between the Parties, whether oral or written, with respect to such subject matter. No subsequent
      alteration, modification, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties. In the event of a conflict between the terms of
      this Agreement and the terms of any other Investment Document, the terms of this Agreement shall prevail.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7ee850e210f34351af6930bcf36c958e" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">18.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Specific Performance</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">Each of the Parties acknowledges and agrees that the other Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise
      are breached or violated. Accordingly, each of the Parties agrees that, without posting bond or other undertaking, each Party will be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and
      to enforce specifically this Agreement and the terms and provisions hereof in any action instituted in any court having jurisdiction over the Parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity,
      except as otherwise provided in Section 3(n). Each Party</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">26</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">further agrees that, in the event of any action for specific performance in respect of such breach or violation, it will not assert the defense that a remedy at law would be adequate.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z28735ca30a134d7283a97459acd41916" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">19.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Binding Agreement</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the Parties.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z23beed991fc64002a89483431402da12" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">20.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Third Party Rights</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Parties do not intend that any term of this Agreement should be enforceable, by virtue of the Contracts (Rights of Third Parties) Act 1999, by any person who is not a party to this Agreement.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="ze20143d2f3d740448e08701fd667c72f" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">21.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Authority</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">Each of the Company and the Foundation covenants and warrants with respect to itself that it has all authority necessary to execute this Agreement and that, on execution, this Agreement will be fully binding and
      enforceable in accordance with its terms, and that no other consents or approvals of any other Person or third parties are required or necessary for this Agreement to be so binding.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd64fd1bd696047c8bca725cd3446a138" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">22.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Waiver</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">Failure or delay by either Party in exercising or enforcing any provision, right, or remedy under this Agreement, or waiver of any remedy hereunder, in whole or in part, shall not be deemed a waiver thereof, or prevent
      the subsequent exercise of that or any other rights or remedy. The rights, powers and remedies provided in this Agreement are cumulative and not exclusive of any rights, powers and remedies provided by law.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9610a1377a454e84aa24b58bbeb2e2ac" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">23.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Further Assurances</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">From time to time after the Effective Date, each Party shall execute, acknowledge and deliver to each other any further documents, assurances, and other matters, and will take any other action consistent with the terms
      and conditions of this Agreement, that may reasonably be requested by a Party and necessary or desirable to carry out the purpose of this Agreement.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z53a7f5fadf054ad989bdb02445986894" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">24.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Interpretation</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used
      in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation.&#8221;</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">27</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z95f1b8efa8ca49429ad732256bcceff4" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">25.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Counterparts</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Agreement may be executed in one or more counterparts, including by signatures delivered by facsimile or pdfs, each of which shall be deemed an original, but all of which shall be deemed to be and constitute one
      and the same instrument.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7273400d8ae54146864d4655347f325f" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">26.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Severability</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such
      provision were so excluded and shall be enforceable in accordance with its terms.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z5cdd8f960c99453cb0ba366f458ae49b" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">27.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Expenses</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company and the Foundation shall pay their own costs and expenses incurred with respect to the negotiation, execution, delivery and performance of this Agreement.</div>
    <div>&#160;</div>
    <div>
      <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4e9954a5de734ebfbdddd7e67c55aff1" class="DSPFListTable" cellpadding="0" cellspacing="0">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-weight: bold;">28.</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-weight: bold;"><u>Governing Law</u></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">This Agreement and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating to this Agreement or its formation (including non-contractual disputes or claims), shall be
      governed by and construed in accordance with English law and any dispute will be submitted to the exclusive jurisdiction and venue of the courts located in London, England.</div>
    <div>&#160;</div>
    <div style="text-align: center;">[Signature Page Follows]</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">28</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; font-weight: bold;">Exhibit 10.10</div>
    <div>&#160;</div>
    <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE
        TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Global Access Commitments Agreement - Signature Page</div>
    <div>&#160;</div>
    <div style="text-align: justify;">IN WITNESS WHEREOF, the Parties have caused this Global Access Commitments Agreement to be executed by their duly authorized representatives as of the date first written above.</div>
    <div>&#160;</div>
    <table id="z02168d9cbd8a4e328038139feaaa8fe5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Immunocore Limited</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;"><a name="z_Hlk54126630"></a>By:</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify;">/s/ Bahija Jallal</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div style="text-align: justify;">Bahija Jallal</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="text-align: justify;">Chief Executive Officer</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table id="z12d21a1c3e5447b08805cae8b5b4f476" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Bill &amp; Melinda Gates Foundation</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify;">/s/ Carolyn Ainslie</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div style="text-align: justify;">Carolyn Ainslie</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="text-align: justify;">Chief Financial Officer</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">29</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%Annex % of 1%-->
    <div style="text-align: right; font-style: italic; font-weight: bold;">Execution Version</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Annex 1</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Developing Countries</div>
    <div>&#160;</div>
    <table id="zb7a81ff88b2542ec91b71059e1f7d99f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: justify;">&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div style="text-align: justify;">Afghanistan</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: justify;">&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div style="text-align: justify;">Haiti</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div style="text-align: justify;">&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div style="text-align: justify;">Philippines</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Angola</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>India</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Rwanda</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Azerbaijan</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Indonesia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Russian Federation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Bangladesh</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Kazakhstan</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>S&#227;o Tom&#233; e Pr&#237;ncipe</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Belarus</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Kenya</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Senegal</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Benin</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Korea, DPR</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Sierra Leone</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Botswana</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Kyrgyz Republic</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Solomon Islands</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Brazil</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Lao PDR</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Somalia</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Burkina Faso</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Lesotho</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>South Africa</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Burundi</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Liberia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>South Sudan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Cambodia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Madagascar</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Sudan, Republic of</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Cameroon</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Malawi</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Swaziland</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Central African Republic</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Mali</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Tajikistan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Chad</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Mauritania</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Tanzania, United Republic of</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>China</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Moldova</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Thailand</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Comoros</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Mozambique</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Togo</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Congo, Dem Republic of</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Myanmar</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Uganda</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>C&#244;te d&#8217;Ivoire</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Namibia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Ukraine</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Djibouti</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Nepal</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Uzbekistan</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Eritrea</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Nicaragua</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Vietnam</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Ethiopia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Niger</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Yemen</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Gambia</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Nigeria</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Zambia</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Ghana</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Pakistan</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Zimbabwe</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Guinea</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Papua New Guinea</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div><br>
            </div>
          </td>
          <td style="width: 31%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 31%; vertical-align: top;">
            <div>Guinea Bissau</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div>&#8226;</div>
          </td>
          <td style="width: 32%; vertical-align: top;">
            <div>Peru</div>
          </td>
          <td style="width: 2%; vertical-align: top;">
            <div><br>
            </div>
          </td>
          <td style="width: 31%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 1 of 1</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%Annex %-1%-->
    <div style="text-align: right; font-style: italic; font-weight: bold;">Execution Version</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Annex 2</div>
    <div style="text-align: center; font-weight: bold;">Original Scope of Work</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">Project Governance Plan</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">Formation and Composition of a Joint Steering Committee</div>
    <div style="text-align: justify;">As soon as reasonably possible and in any event within [***] after the Effective Date, the Company and the Foundation shall establish a Joint Steering Committee (the &#8220;JSC&#8221;) to monitor and coordinate the communication
      and activities under the Original Scope of Work and the Amended Scope of Work. The JSC shall be composed of at least [***] but no more than [***] representatives designated by each Party and, in each case, a simple majority of representatives will be
      from the Company. Representatives must be appropriate for the tasks then being undertaken and the stage of research or pre-clinical or clinical development relevant to any research plans, in terms of their seniority, availability, function in their
      respective organizations, training and experience. Each Party may replace its representatives from time to time upon written notice to the other Party; provided, however, if a Party&#8217;s representative is unable to attend a meeting, such Party may
      designate an alternate to attend such meeting by providing notification in writing to the other Party&#8217;s representatives and following provision of such written notification the alternate will be entitled to perform the functions of such
      representative. Each Party, with prior written approval may invite subject matter experts to attend and contribute to JSC meetings. The committee will meet in-person, annually to discuss progress against key deliverables and investment milestones.
      Additional meetings may be scheduled either in person or via tele/video conferencing to address specific challenges as they arise. For the avoidance of doubt, the JSC shall be advisory in nature and shall not have a decision-making role provided,
      however, that the Company will consider any recommendations made by the JSC in good faith.</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-weight: bold;">JSC Responsibilities</div>
    <div style="text-align: justify;">In addition to its overall responsibility for monitoring the activities performed under the Original Scope of Work and the Amended Scope of Work, the JSC shall, in particular:</div>
    <div>&#160;</div>
    <table id="zec54c6e0d5b442b38c4ff310ef4883e3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>monitor and communicate (as far as legally permissible) developments and target products made by parties external to the collaboration that may influence the Original Scope of Work and the Amended Scope of Work and take into account such
              developments and products when undertaking the remaining JSC responsibilities;</div>
          </td>
        </tr>

    </table>
    <table id="z0e4f3ba7795c441b97c3959dbc8bfc3b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>review treatment and payer trends in the Developing Countries that may influence the Original Scope of Work and the Amended Scope of Work;</div>
          </td>
        </tr>

    </table>
    <table id="z95ca9b70dae94246ae5b723eb5fef11b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>generate and maintain a list of all Research Tools created under the Original Scope of Work and the Amended Scope of Work;</div>
          </td>
        </tr>

    </table>
    <table id="z44ece1d9236247e38d68fb4dbae1be34" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>generate and maintain a plan of future publications;</div>
          </td>
        </tr>

    </table>
    <table id="z9fc91167475d48cd8836e89c3cb584d1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(e)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>generate and maintain target product profiles for each Global Health Program;</div>
          </td>
        </tr>

    </table>
    <table id="z9edd4835b8d243e79e5a4ea0ce1c8d94" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(f)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>monitor the budget for each Global Health Program, and as data emerge, ensure the appropriate allocation of resources to the most promising Program(s) review CMC and regulatory strategy for appropriateness relative to TPP</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 2-1</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%Annex %-2%-->
    <table id="zacb9c38e503b4daba65293f6dd7a0ca2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(g)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>review plans for the development and Phase I testing of any Development Products; and</div>
          </td>
        </tr>

    </table>
    <table id="zfee9a0f4ea4e4f288e84a2b8f670f1d4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(h)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>review the scientific appropriateness, planning and execution of NHP models for the Development Programs.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; font-weight: bold;">[***]</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 2-2</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%3%Annex %-1%-->
    <div style="text-align: right; font-style: italic; font-weight: bold;">Execution Version</div>
    <div style="text-align: right; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">Annex 3<br>
      </div>
      <br>
      <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-style: normal; font-weight: bold;">Amended Scope of Work Framework and Goals</div>
      &#160;&#160; </div>
    <div style="text-align: justify;">[***]</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 3-1</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; font-style: italic; font-weight: bold;">Execution Version</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Annex 4</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">OFFICER&#8217;S/DIRECTOR&#8217;S] CERTIFICATE TO BE PROVIDED</div>
    <div style="text-align: center; font-weight: bold;">IN ACCORDANCE WITH SECTION 9(a)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Immunocore Limited</div>
    <div>&#160;</div>
    <div style="text-align: center;">[DATE]</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">This certificate is being delivered by Immunocore Limited, a United Kingdom corporation, (the &#8220;<u>Company</u>&#8221;), pursuant to <u>Section 9(a)</u> of the Global Access Commitments Agreement between
      the Company and the Bill &amp; Melinda Gates Foundation (the &#8220;Foundation&#8221;) dated as of [&#160; &#160; &#160; &#160; &#160; &#160; ] ______, 2020 (the &#8220;<u>Agreement</u>&#8221;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the
      Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company certifies as follows:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; During the fiscal year ended [DATE], the Company met the requirements of the Foundation Investment as set forth in the Agreement that were required to be complied with or performed by
      the Company during such time period.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached as <u>Exhibit A</u> to this certificate is a description of the Company&#8217;s use of proceeds of the Foundation Investment during the fiscal year ended [DATE]. Such exhibit shall
      describe the purposes for which the proceeds were used with sufficient detail to enable the Foundation, in its reasonable discretion, to confirm that the Company expended such proceeds consistent with the uses permitted under <u>Section 2(c)</u> of
      the Agreement. In addition, with respect to any year in which a loan from the Foundation to the Company is outstanding, such exhibit shall also include the specific dollar amount of loan proceeds from the Foundation that were expended by the Company
      during the relevant reporting period.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached as <u>Exhibit B</u> to this certificate is the Company&#8217;s evaluation of the Company&#8217;s progress with respect to the Global Health Programs, including information regarding
      progress against the Global Access Commitments (as set forth in the Investment Documents) during the fiscal year ended [DATE].</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the undersigned has executed this certificate and has caused this certificate to be delivered on the date first above written.</div>
    <div>&#160;</div>
    <table id="za46e8abc79af401f97cac64910adfc71" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 60%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="3">
            <div style="text-align: justify;">Immunocore Limited</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 24.52%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Name:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 60%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Title:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" id="DSPFPageFooter">
        <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z6753ae516fa34a84ae23bed6ee0f14b6" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 4-1</font></td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; font-style: italic; font-weight: bold;">Execution Version</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Annex 5</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">OFFICER&#8217;S/DIRECTOR&#8217;S] CERTIFICATE TO BE PROVIDED</div>
    <div style="text-align: center; font-weight: bold;">IN ACCORDANCE WITH SECTION 9(b)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Immunocore Limited</div>
    <div>&#160;</div>
    <div style="text-align: center;">[DATE]</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">This certificate is being delivered by Immunocore Limited, a United Kingdom corporation (the &#8220;<u>Company</u>&#8221;), pursuant to <u>Section 9(b)</u> of the Global Access Commitments Agreement between the
      Company and the Bill &amp; Melinda Gates Foundation dated as of [&#160; &#160; &#160; ] ___, 2020 (the &#8220;<u>Agreement</u>&#8221;). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Letter Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify;">The Company certifies as follows:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; During the term of the Foundation Investment, the Company met the requirements of the Foundation Investment as set forth in the Agreement that were required to be complied with or
      performed by the Company during such time period.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached as <u>Exhibit A</u> to this certificate is a description of the Company&#8217;s use of proceeds of the Foundation Investment during the term of the Foundation Investment. Such exhibit
      shall describe the purposes for which the proceeds were used with sufficient detail to enable the Foundation, in its reasonable discretion, to confirm that the Company expended such proceeds consistent with the uses permitted under <u>Section 2(c)</u>
      of the Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; Attached as <u>Exhibit B</u> to this certificate is the Company&#8217;s evaluation of the Company&#8217;s progress on the Global Health Programs, including information regarding progress against
      the Global Access Commitments (as set forth in the Investment Documents) during the term of the Foundation Investment.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the undersigned has executed this certificate and has caused this certificate to be delivered on the date first above written.</div>
    <div>&#160;</div>
    <table id="za81d46f2d638407b9d1bde030b19ddc1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="3">
            <div style="text-align: justify;">Immunocore Limited</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="3">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 22%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Name:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify;">Title:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
  <div style="width: 100%;" id="DSPFPageFooter">
    <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 100%; text-align: center; font-size: 8pt;" rowspan="1"><font id="DSPFPageNumber">Annex 5-1</font></td>
        </tr>
        <tr>
          <td style="width: 100.00%;">
            <div style="text-align: center;"><font style="font-weight: bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)</font>&#160;<font style="font-weight: bold;">IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>11
<FILENAME>nt10016217x4_ex10-13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">
  <p style="margin-top: 0; margin-bottom: 0"></p>
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #242436; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit 10.13</b></font></p>
  <p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #242436"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 16pt; color: #242436"></font></p>
  <table style="border-collapse: collapse; font: 16pt Times New Roman, Times, Serif; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left">
        <td style="width: 50%"><img src="nt10016217x4_ex10-13img01.jpg" alt="">&#160;</td>
        <td style="width: 50%; text-align: right; vertical-align: top"><img src="nt10016217x4_ex10-13img02.jpg" alt="">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 16pt; color: #242436">&#160;&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 16pt;">DATED 28 March 2017</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 20pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 18pt Times New Roman, Times, Serif; color: #242436; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 20pt;">(1)</font></td>
        <td style="width: 96%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 20pt;">MEPC MILTON PARK NO. 1 LIMITED AND MEPC MILTON PARK NO. 2 LIMITED</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 18pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.75pt; color: rgb(36, 36, 54);"><font style="font-size: 20pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 18pt Times New Roman, Times, Serif; color: #242436; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 20pt;">(2)</font></td>
        <td style="width: 96%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 20pt;">IMMUNOCORE LIMITED</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 18pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 18pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-style: normal; font-weight: normal; font-size: 16pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">LEASE</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 18pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt; font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 14pt;">relating to</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 14pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 14pt;">91 Park Drive&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 14pt;">Milton Park</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt; color: Black;">+44 (0) 1235 836600</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt; color: Black;">BSDR.COM</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt; color: Black;">DX 144160 ABINGDON 4</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt;">BrookStreet des Roches LLP</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt;">25A Western Avenue, Milton Park,</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-size: 10pt;">Abingdon, Oxfordshire, OX14 4SH</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107); text-align: right;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><img src="nt10016217x4_ex10-13img03.jpg" alt="">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-size: 12pt;"><b>PRESCRIBED CLAUSES</b></font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 50%; border-top: 2px solid Black; border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR1. &#160;Date of lease</font></td>
        <td style="width: 50%; border-top: 2px solid Black; border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt;">28 March 2017</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR2. &#160;Title number(s)</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>LR2.1 Landlord&#8217;s title number(s)</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;">&#160;</td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"> BK102078</div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>LR2.2 Other title number(s)</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="border-bottom: Black 2px solid; padding-top: 5pt">
          <div style="margin-left: 9pt"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">ON122118, ON122717, ON130606, ON145942, ON146219, ON225380</font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(51, 51, 51);">, </font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">ON38283</font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">ON72772</font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">ON96949</font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">ON216090</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR3. &#160;Parties to this lease</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>Landlord</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>MEPC MILTON PARK NO. 1 LIMITED </b>(Company number 5491670) and <b>MEPC MILTON PARK NO. 2 LIMITED</b> (Company number 5491806), on behalf of MEPC Milton LP
              (LP No. LP14504), both of whose registered offices are at Lloyds Chambers 1 Portsoken Street London E1 8HZ</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>Tenant</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>IMMUNOCORE LIMITED</b> (Company &#160;number 6456207) whose registered office is at 101 Park Drive Milton Park Abingdon Oxfordshire OX14 4RY</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;">&#160;</td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><b>Other parties</b></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;">&#160;</td>
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt">None</div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR 4. &#160;Property</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>In the case of a conflict &#160;between &#160;this clause and the remainder &#160;of this lease then, for the purposes of registration, this clause shall prevail.</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="border-bottom: Black 2px solid; padding-top: 5pt">
          <div style="margin-left: 9pt"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(15, 15, 15);">91 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY shown edged red on the Plan with a net internal floor area
              of 2,808.65 square metres (30,233 square feet) measured in accordance with the RICS Code &#160;of Measuring Practice (sixth edition</font><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt; color: rgb(51, 51, 51);">)</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR5. &#160;Prescribed Statements etc.</font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR6. &#160;Term for which the Property is leased</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">From and including 17 March 2017</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">To and including 28 September 2040</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR7. &#160;Premium</font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR8. &#160;Prohibitions &#160;or restrictions on disposing of this lease</font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">This lease contains a provision that prohibits or restricts dispositions</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt; color: rgb(15, 15, 15);">LR9. &#160;Rights of acquisition &#160;etc.</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9.1 Tenant&#8217;s contractual rights to renew this lease, to acquire the reversion &#160;or another &#160;lease of the Property, &#160;or to acquire an interest in other land</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9.2 Tenant&#8217;s covenant to (or offer &#160;to) surrender this lease</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9. 3 Landlord&#8217;s contractual rights to acquire this lease</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif'; font-weight: bold;"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 5pt; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">1</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="margin: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 50%; border-bottom: 2px solid Black; border-top: 2px solid Black; padding-left: 0.375in; text-indent: -0.375in; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>LR10. Restrictive covenants given in
              this lease by the Landlord in respect of land other than the Property</b></font></td>
        <td style="width: 50%; border-bottom: 2px solid Black; border-top: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>LR11. Easements</b></font></td>
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt;"><b>LR11.1 Easements granted by this lease for the benefit of the Property</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt;">The easements specified in Part I of the First Schedule of this lease</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt;"><b>LR11.2 Easements granted or reserved by this lease over the Property for the benefit of other property</b></font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></td>
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt;">The easements specified in Part II of the First Schedule of this lease</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>LR12. Estate rentcharge burdening the Property</b></font></td>
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>LR13. Application for standard form of restriction</b></font></td>
        <td style="border-bottom: 2px solid Black; font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-left: 0.375in; text-indent: -0.375in; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>LR14. Declaration of trust where there is more than one person comprising the Tenant</b></font></td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt"><font style="font-size: 10pt; color: rgb(15, 15, 15);">None</font></div>
        </td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">2</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><img src="nt10016217x4_ex10-13img04.jpg" alt=""></font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><img src="nt10016217x4_ex10-13img05.jpg" alt=""></font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><img src="nt10016217x4_ex10-13img06.jpg" alt=""><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><b>This lease</b> made on the date and between the parties specified in the Prescribed Clauses <b>Witnesses</b> as follows:</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0%"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Definitions and Interpretation</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">In this lease unless the context otherwise requires:</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0%"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.1</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Definitions</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Adjoining Property</b> means any adjoining or neighbouring premises in which the Landlord
      or a Group Company of the Landlord holds or shall at any time during the Term hold a freehold or leasehold interest;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Agreement for Lease</b> means the agreement dated 14 September 2016 made between (1) MEPC Milton Park No. 1
      Limited and MEPC Milton Park No. 2 Limited, on behalf of MEPC Milton LP, and (2) Immunocore Limited, as varied by a Deed of Variation dated 14 March 2017 made between (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited, on behalf of
      MEPC Milton LP, and (2) Immunocore Limited providing, inter alia, for the grant of this lease and the grant of the 95 Lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Base Rate</b> means the base rate from time to time of Barclays Bank PLC or (if not available) such comparable
      rate of interest as the Landlord shall reasonably require;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Break Date 1</b> means 28 September 2020;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><b>Break Date 2 </b>means 28 September 2025; </font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><b>&#160;</b></font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><b>Break Date 3 </b>means 28 September 2030;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;"><b>Break Date 4</b> means 28 September 2035;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Building Specification</b> means the specification marked &#8220;Building Specification&#8221; annexed to this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Centre </b>means the external part of the Property (being all of the Property excluding the building marked
      &#8220;91&#8221; on the Plan) and includes any part of the Centre and any alteration or addition to it or replacement of it and any additional buildings or structures constructed on it;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Centre Common Areas</b> means the roads, accesses, the parking and other areas of the Centre;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Centre Services</b> means the services provided or procured by the Landlord in relation to the Centre as set
      out in Part III of the Fourth Schedule;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Common Control</b> means that each of the companies concerned has 50% or more of its outstanding voting stock
      in the ownership of the same persons or companies;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Conduit </b>means any existing or future media for the passage of substances or energy and any ancillary
      apparatus attached to them and any enclosures for them;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Contractual Term</b> means the term specified in the Prescribed Clauses;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Encumbrances </b>means the obligations and encumbrances (if any) specified in Part III of the First Schedule;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Estate </b>means Milton Park, Abingdon, Oxfordshire (of which the Property forms part) and the buildings from
      time to time standing on it shown on the Plan together with any other adjoining land which is incorporated into Milton Park;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Estate Common Areas</b> means the roads, accesses, landscaped areas, car parks, estate management offices and
      other areas or amenities on the Estate or outside the Estate but serving or otherwise benefiting the Estate as a whole which are from time to time provided or designated for the common amenity or benefit of the owners or occupiers of the Estate;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Estate Services</b> means the services provided or procured by the Landlord in relation to the Estate as set
      out in Part II of the Fourth Schedule;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Group Company</b> means a company which is a member of the same group of companies within the meaning of
      Section 42 of the 1954 Act or is within Common Control;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Guarantor </b>means any party to this lease so named in the Prescribed Clauses (which in the case of an
      individual includes his personal representatives) and any guarantor of the obligations of the Tenant for the time being;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">3</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Insurance Commencement Date</b> means 17 March 2017;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Insured Risks</b> means fire, lightning, earthquake, explosion, terrorism, aircraft (other than hostile
      aircraft) and other aerial devices or articles dropped therefrom, riot, civil commotion, malicious damage, storm or tempest, bursting or overflowing of water tanks apparatus or pipes, flood and impact by road vehicles (to the extent that insurance
      against such risks may ordinarily be arranged with an insurer of good repute) and such other risks or insurance as may from time to time be reasonably required by the Landlord (subject in all cases to such usual exclusions and limitations as may be
      imposed by the insurers), and <b>Insured Risk</b> means any one of them;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Landlord </b>means the party to this lease so named in the Prescribed Clauses and includes any other person
      entitled to the immediate reversion to this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Landlord&#8217;s Surveyor</b> means a suitably qualified person or firm appointed by the
      Landlord (including an employee of the Landlord or a Group Company) to perform the function of a surveyor for the purposes of this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Lease Particulars</b> means the descriptions and terms in the section headed <b>Lease
        Particulars </b>which form part of this lease insofar as they are not inconsistent with the other provisions of this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Permitted Use</b> means use within Class B1 of the 1987 Order</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Plan </b>means the plan or plans annexed to this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Prescribed Clauses</b> means the descriptions and terms in the section headed <b>Prescribed





        Clauses </b>which form part of this lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Principal Rent</b> means SIX HUNDRED AND SEVEN THOUSAND EIGHT HUNDRED AND SEVENTY SIX
      POUNDS AND TWENTY SIX PENCE (&#163;607,876.26) per annum subject to increase in accordance with the Second Schedule;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Property </b>means the property described in the Prescribed Clauses and includes any part of it, any
      alteration or addition to the Property and any fixtures and fittings in or on the Property;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Quarter Days </b>means 25 March, 24 June, 29 September and 25 December in every year and
      <b>Quarter Day </b>means any of them;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Rent Commencement Date</b> means 17 March 2017;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in"><font style="font-family: Arial,Helvetica,'sans-serif'; font-size: 10pt;"><b>Review Dates</b> means 29 September 2020 (<b>Review





        Date 1</b>), 29 September 2025 (<b>Review Date </b></font><font style="font-family: Arial,Helvetica,'sans-serif';"><b>2</b>), 29 September 2030 (<b>Review Date 3</b>) and 29 September 2035 (<b>Review Date 4</b>);</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Service Charge</b> means the Service Charge set out in the Fourth Schedule;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Service Charge Commencement Date</b> means 17 March 2017;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Services </b>means the Estate Services and the Centre Services;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Subletting Unit</b> means part of the Property consisting of a whole floor or a part of a floor comprising a
      Wing;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Tenant </b>means the party to this lease so named in the Prescribed Clauses and includes its successors in
      title;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Term </b>means the Contractual Term together with any continuation of the term or the
      tenancy (whether by statute, common law holding over or otherwise);</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>This lease</b> means this lease and any document supplemental to it or entered into
      pursuant to it;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Uninsured Risk</b> means an Insured Risk against which insurance is from time to time unobtainable on normal
      commercial terms in the London insurance market at reasonable commercial rates for a property equivalent in size, layout, type and location.</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>VAT </b>means Value Added Tax and any similar tax substituted for it or levied in
      addition to it;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>Wing </b>means any of the ground floor east wing, ground floor west wing, first floor east wing or first
      floor west wing as shown on the Plan;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>95 Lease</b> means the lease of 95 Park Drive Milton Park as contemplated by the
      Agreement for Lease;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>1954 Act</b> means the Landlord and Tenant Act 1954;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">4</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>1987 Order</b> means the Town and Country Planning (Use Classes) Order 1987 (as originally made);</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>1995 Act</b> means the Landlord and Tenant (Covenants) Act 1995;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;"><b>2003 Order</b> means The Regulatory Reform (Business Tenancies) (England and Wales) Order 2003.</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Interpretation</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">If the Landlord, the Tenant or the Guarantor is more than one person then their covenants are joint and several;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt; margin-left: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Any reference to a statute includes any modification extension or re-enactment of it and any orders, regulations, directions, schemes and rules made
            under it;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt; margin-left: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.3</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Any covenant by the Tenant not to do any act or thing includes an obligation not knowingly to permit or suffer such act or thing to be done;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.4</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">If the Landlord reserves rights of access or other rights over or in relation to the Property then those rights extend to persons authorised by it;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.5</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">References to the <b>act or default of the Tenant</b> include acts or default or negligence of any undertenant or of anyone at the Property with the
            Tenant&#8217;s or any undertenant&#8217;s permission or sufferance;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.6</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">The index and Clause headings in this lease are for ease of reference only;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.7</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">References to the <b>last year of the Term</b> shall mean the twelve months ending on the expiration or earlier termination of the Term;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.8</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">References to <b>Costs</b> include all liabilities, claims, demands, proceedings, damages, losses and proper and reasonable costs and expenses;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>1.2.9</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">References to Principal Rent, Current Rent, Indexed Rent and Revised Rent are references to yearly sums.</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Demise</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">The Landlord with Full Title Guarantee DEMISES the Property to the Tenant for the
      Contractual Term TOGETHER WITH the rights set out in Part I of the First Schedule, EXCEPT AND RESERVING as mentioned in Part II of the First Schedule and SUBJECT TO the Encumbrances;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Rent</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">The Tenant will pay by way of rent during the Term or until released pursuant to the 1995 Act without any
      deduction counterclaim or set off except where required by law:</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.1</b></font></td>
        <td style="padding-right: 5.1pt; width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">The Principal Rent and any VAT by equal quarterly payments in advance on the Quarter Days to be paid by Direct Debit, Banker&#8217;s
            Standing Order or other means as the Landlord requires, the first payment for the period from and including the Rent Commencement Date to (but excluding) the next Quarter Day to be made on the Rent Commencement Date;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.2</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">The Service Charge and any VAT at the times and in the manner set out in the Fourth Schedule;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.3</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">The following amounts and any VAT:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.3.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the sums specified in Clauses 4.1 [interest] and 4.2 [outgoings and utilities];</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.3.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the sums specified in Clause 6.2.1 [insurance];</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>3.3.3</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">all Costs incurred by the Landlord as a result of any breach of the Tenant&#8217;s covenants in this lease.</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Tenant&#8217;s covenants</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-size: 10pt;">The Tenant covenants with the Landlord throughout the Term, or until released pursuant to
      the 1995 Act, as follows:</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.1</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Interest</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">If the Landlord does not receive any sum due to it within 14 days of the due date to pay on demand interest on
      such sum at 2 per cent above Base Rate from the due date until payment</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">5</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in;"><br>
  </p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td rowspan="1" style="width: 0in">&#160;</td>
        <td rowspan="1" style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td rowspan="1" style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(both before and after any judgment), provided this Clause shall not prejudice any other right or remedy for the recovery of such sum;</font>
          <br>
        </td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td rowspan="1" style="width: 0in">&#160;</td>
        <td rowspan="1" style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td rowspan="1" style="width: 97%; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.2</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Outgoings and Utilities</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.2.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To pay all existing and future rates, taxes, charges, assessments and outgoings in respect of the Property (whether assessed or
            imposed on the owner or the occupier), except any tax (other than VAT) arising as a result of the receipt by the Landlord of the rents reserved by this lease and any tax arising on any dealing by the Landlord with its reversion to this lease;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.2.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To pay for all gas, electricity, water, telephone and other utilities used on the Property, and all charges in connection with such
            utilities and for meters and all standing charges, and a fair and reasonable proportion of any joint charges as determined by the Landlord&#8217;s Surveyor;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.3</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.3.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Any payment or other consideration to be provided to the Landlord is exclusive of VAT, and the Tenant shall in addition pay any VAT
            chargeable on the date the payment or other consideration is due;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.3.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Any obligation to reimburse or pay the Landlord&#8217;s expenditure extends to irrecoverable VAT on that expenditure, and the Tenant shall
            also reimburse or pay such VAT;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.4</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Repair</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.4.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To keep the Property (excluding the Centre) in good and substantial repair and condition (damage by any Uninsured Risk or by the
            Insured Risks excepted save to the extent that insurance moneys are irrecoverable as a result of the act or default of the Tenant);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.4.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To make good any disrepair for which the Tenant is liable within 2 months after the date of written notice from the Landlord (or
            sooner if the Landlord reasonably requires);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.4.3</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">If the Tenant fails to comply with any such notice the Landlord may enter and carry out the work and the cost shall be reimbursed by
            the Tenant on demand as a debt;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.4.4</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To enter into maintenance contracts with reputable contractors for the regular servicing of all plant and equipment serving only the
            Property;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.5</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Decoration</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.5.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To clean, prepare and paint or treat and generally redecorate :</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 8.7pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">all external parts of the Property (excluding the Centre) in every third year and in the last year of the Term;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">all internal parts of the Property in every fifth year and in the last year of the Term;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.5.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">All the work described in Clause 4.5.1 is to be carried out:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">in a good and workmanlike manner to the Landlord&#8217;s reasonable satisfaction; and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 10.2pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">in colours which (if different from the existing colour) are first approved in writing by the Landlord (approval not to be
            unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.6</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Cleaning</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.6.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To keep the Property (excluding the Centre) clean, tidy and free from rubbish;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.6.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To clean the inside and outside of windows and any washable surfaces at the Property as often as reasonably necessary;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.7</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Overloading</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">Not to overload the floors, ceilings or structure of the Property or any plant machinery or electrical
      installation serving the Property;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">6</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.8</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Conduits</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">To keep the Conduits in or serving the Property clear and free from any noxious, harmful or deleterious
      substance, and to remove any obstruction and repair any damage to the Conduits as soon as reasonably practicable to the Landlord&#8217;s reasonable satisfaction;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.9</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>User</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.9.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to use the Property otherwise than for the Permitted Use;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.9.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to use the Property for any purpose which is:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">noisy, offensive, dangerous, illegal, immoral or an actionable nuisance; or</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 2.9pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">which in the reasonable opinion of the Landlord causes damage or disturbance to the Landlord, or to owners or occupiers of any
            neighbouring property; or</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 8.8pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">which involves any substance which may be harmful, polluting or contaminating other than in quantities which are normal for and
            used in connection with the Permitted Use;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.10&#160; <br>
            </b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Signs</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,'sans-serif';"></font></p>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td rowspan="1" style="width: 0in">&#160;</td>
        <td rowspan="1" style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td rowspan="1" style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to erect any sign, notice or advertisement which is visible outside the Property without the Landlord&#8217;s prior written consent;</font>
          <br>
        </td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td rowspan="1" style="width: 0in">&#160;</td>
        <td rowspan="1" style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td rowspan="1" style="width: 97%; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.11<br>
            </b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Alterations</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.11.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to make any alterations or additions which:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 7.35pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">affect the structural integrity of the Property (including without limitation the roofs and foundations and the principal or
            load-bearing walls, floors, beams and columns);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">affect the external appearance of the Property;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.11.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to make any other alterations or additions to the Property without the Landlord&#8217;s written consent (which is not to be
            unreasonably withheld or delayed) save that the Tenant may install or demount internal, non-structural partitioning without the consent of the Landlord provided plans showing the extent of such works are deposited with the Landlord promptly on
            completion of the works;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.12&#160; <br>
            </b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Preservation of Easements</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.12.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to prejudice the acquisition of any right of light for the benefit of the Property and to preserve all rights of light and other
            easements enjoyed by the Property;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.12.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Promptly to give the Landlord notice if any easement enjoyed by the Property is obstructed, or any new easement affecting the
            Property is made or attempted;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13&#160; <br>
            </b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Alienation</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.1</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 8.7pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">assign, charge, underlet or part with possession of the whole or part only of the Property nor to agree to do so except by an
            assignment or underletting or charging of the whole of the Property or an underletting of a Subletting Unit permitted by this Clause 4.13;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">share the possession or occupation of the whole or any part of the Property; </font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">(iii) </td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">assign, part with or share any of the benefits or burdens of this lease, or any interest derived from it by a virtual assignment or other similar arrangement;</td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.2</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Charging</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;"><font style="font-size: 10pt;">Not to charge the whole of the Property without the Landlord&#8217;s written consent (not to be unreasonably withheld or
      delayed).</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.3</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Assignment</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 8%;"><font style="font-size: 10pt;">Not to assign or agree to assign the whole of the Property without the Landlord&#8217;s written consent (not to be
      unreasonably withheld or delayed), provided that:</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">7</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 20.05pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the Landlord may withhold consent in circumstances where in the reasonable opinion of the Landlord</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 5.25pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the proposed assignee is not of sufficient financial standing to enable it to comply with the Tenant&#8217;s covenants in this lease;
            or</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 7.95pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">such persons as the Landlord reasonably requires do not act as guarantors for the assignee and do not enter into direct
            covenants with the Landlord including the provisions set out in the Third Schedule (but referring in paragraph 1.2 to the assignee);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 35.6pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the Landlord&#8217;s consent shall in every case be subject to conditions (unless expressly excluded) requiring that:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 2.45pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the assignee covenants with the Landlord to pay the rents and observe and perform the Tenant&#8217;s covenants in this lease during
            the residue of the Term, or until released pursuant to the 1995 Act;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 12.9pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the Tenant enters into an authorised guarantee agreement guaranteeing the performance of the Tenant&#8217;s covenants in this lease
            by the assignee including the provisions set out in paragraphs 1-5 (inclusive) of the Third Schedule (but omitting paragraph 1.2);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 47.95pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">all rent and other payments due under this lease are paid before completion of the assignment;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.4</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Underletting</b></font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">Not to underlet or agree to underlet the whole of the Property or a Subletting Unit nor vary the terms of any underlease without the Landlord&#8217;s written consent
            (not to be unreasonably withheld or delayed). Any permitted underletting must comply with the following:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(i)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the rent payable under the underlease must be:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">not less than the rent reasonably obtainable in the open market for the Property or the Subletting Unit without fine or premium;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">payable no more than one quarter in advance;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 7.35pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">subject to upward only reviews at intervals no less frequent than the rent reviews under this lease;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 59.95pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the undertenant covenants with the Landlord and in the underlease:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';">(a)</td>
        <td style="width: 83%; font-family: Arial,Helvetica,'sans-serif';">either:</td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 17%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(I)</font></td>
        <td style="padding-right: 37.25pt; width: 79%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">to observe and perform the Tenant&#8217;s covenants in this lease (except for payment of the rents) during the term of the
            underlease or until released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 17%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(II)</font></td>
        <td style="width: 79%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">to observe and perform the Tenant&#8217;s covenants in the underlease during the term of the underlease or until released pursuant to the 1995 Act</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.95pt;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">not to underlet, share or part with possession or occupation of the whole or any part of the underlet premises, nor to assign or charge part only of
            the underlet premises;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -28.45pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 16.8pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">not to assign the whole of the underlet premises without the Landlord&#8217;s prior written consent (which shall not be unreasonably
            withheld or delayed);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 3.65pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">all rents and other payments due under this lease (not the subject of a bona fide dispute) are paid before completion of the
            underletting;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(iv)</font></td>
        <td style="padding-right: 12.2pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">in relation to any Subletting Unit Sections 24 to 28 of the 1954 Act must be excluded and before completion of the underletting
            a certified copy of each of the following documents must be supplied to the Landlord:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">8</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the notice served on the proposed undertenant pursuant to section 38A(3)(a) of the 1954 Act; and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 5.35pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the declaration actually made by the proposed undertenant in compliance with the requirements of Schedule 2 of the 2003 Order;
            and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 5.65pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the proposed form of underlease containing an agreement to exclude the provisions of sections 24 to 28 of the 1954 Act and a
            reference to both the notice pursuant to section 38A(3)(a) of the 1954 Act and the declaration pursuant to the requirements of Schedule 2 of the 2003 Order as referred to in this clause 4.13.3;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td colspan="2" style="font-family: Arial,Helvetica,'sans-serif';">
          <div style="margin-left: 9pt">
            <div style="margin-left: 9pt">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">and before completion of the underletting the Tenant must warrant to the Landlord that both the notice pursuant to section 38A(3)(a) of the 1954 Act has been
                      served on the relevant persons as required by the 1954 Act and the appropriate declaration pursuant to the requirements of Schedule 2 of the 2003 Order as referred to in this clause 4.13.3 has been made prior to the date on which the
                      Tenant and the proposed undertenant became contractually bound to enter into the tenancy to which the said notice applies;</font></div>
                </div>
              </div>
            </div>
          </div>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="padding-right: 6.25pt; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(v)</font></td>
        <td style="padding-right: 6.25pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">in relation to any Subletting Unit the underlease grants such rights as are appropriate for the separate occupation and use of
            the Subletting Unit, reserves such rights as are appropriate for the separate occupation and use of the remainder of the property let by this lease and to enable the Tenant to comply with its obligations under this lease, and reserves as rent:-</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 4.6pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">a fair proportion of the cost of insuring the Property and the whole cost of insuring the loss of the principal rent and service
            charge payable under the underlease; and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 3.5pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">a service charge which provides for the undertenant to pay a fair and reasonable proportion of expenditure incurred by the
            Tenant in relation to the maintenance, repair, renewal, decoration and cleaning of the Property (including without limitation the Conduits, plant and equipment therein) and the provision of services to the Property</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(vi)</font></td>
        <td style="padding-right: 3.05pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">there shall be no more than four (4) units of occupation at any time and no more than two (2) units of occupation on a single
            floor (and for this purpose a unit of occupation shall comprise (a) each Subletting Unit which is separately underlet and (b) the residue of the net lettable area of the Property (if any) retained by the Tenant);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(vii)</font></td>
        <td style="padding-right: 26.55pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(in the case of an underletting of the whole of the Property) the underlease reserves as rent the Service Charge payable under
            this lease;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(viii)</font></td>
        <td style="width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(in the case of an underletting of a Subletting Unit) the underlease reserves as rent a fair and reasonable proportion of the Service Charge payable
            under this lease;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -33.95pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(ix)</font></td>
        <td style="padding-right: 26.5pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">if the Subletting Unit comprises less than a whole floor of the Property then unless the underletting either:</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 7.95pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">contains a covenant on the part of the undertenant to observe and perform the Tenant&#8217;s covenants in this lease (except for
            payment of the rents) during the term of the underlease or until released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 13%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 7.1pt; width: 83%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">is on terms obliging the undertenant to take a lease of the whole of the Property for the unexpired residue of the term of this
            lease (less one day) on the same terms as those contained in this lease (including as to rents and rent review) in the event of the immediate reversion to such underlease becoming vested in the Landlord</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="padding-right: 7.1pt; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';" colspan="2"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">the underlease shall contain a break exercisable by the landlord on three (3) months&#8217; notice in the event of the immediate reversion
            thereto becoming vested in the Landlord;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"><br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">9</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">&#160;</p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 5%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(x)</font></td>
        <td style="padding-right: 16.65pt; width: 87%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the underlease is in a form approved by the Landlord (such approval not to be unreasonably withheld or delayed)</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.5</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To take all necessary steps and proceedings to remedy any breach of the covenants of the undertenant under the underlease and not to permit any
            reduction of the rent payable by any undertenant;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.13.6</b></font></td>
        <td style="width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>Group Sharing</b></font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">Notwithstanding Clause 4.13.1 the Tenant may share occupation of the whole or any part of the Property with a Group Company;</font></td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
      </tr>
      <tr style="vertical-align: top; text-align: justify">
        <td style="font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="text-align: left; font-family: Arial,Helvetica,'sans-serif';">&#160;</td>
        <td style="font-family: Arial,Helvetica,'sans-serif';"><font style="font-style: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-size-adjust: none; font-stretch: normal; font-feature-settings: normal; font-language-override: normal; font-kerning: auto; font-synthesis: weight style; font-variant: normal;">PROVIDED THAT</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(a)</font></td>
        <td style="width: 88%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the relationship of landlord and tenant is not created; and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 4%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(b)</font></td>
        <td style="width: 88%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">occupation by any Group Company shall cease upon it ceasing to be a Group Company; and</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 8%"><br>
        </td>
        <td style="width: 4%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 24.45pt; width: 88%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">the Tenant informs the Landlord in writing before each occupier commences occupation and after it ceases occupation;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.14</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Registration</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-size: 10pt;">Within 21 days to give to the Landlord&#8217;s solicitors (or as the Landlord may direct) written notice of any
      assignment, charge, underlease or other devolution of the Property or a Subletting Unit together with a certified copy of the relevant document and a reasonable registration fee of not less than &#163;50;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.15</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Statutory Requirements and Notices</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.15.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To supply the Landlord with a copy of any notice, order or certificate or proposal for any notice order or certificate affecting or
            capable of affecting the Property as soon as it is received by or comes to the notice of the Tenant;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.15.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To comply promptly with all notices served by any public, local or statutory authority, and with the requirements of any present or
            future statute or European Union law, regulation or directive (whether imposed on the owner or occupier), which affects the Property or its use;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.15.3</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">At the request of the Landlord, but at the joint cost of the Landlord and the Tenant<b>,</b> to make or join the Landlord in making
            such objections or representations against or in respect of any such notice, order or certificate as the Landlord may reasonably require;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.15.4</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To observe and perform the obligations of any agreement entered into prior to the date of this lease under any statute or European
            Union law, regulation or directive so far as the same relates to the use and/or occupation of the Property;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.16</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Planning</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.16.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">Not to apply for or implement any planning permission affecting the Property without first obtaining the Landlord&#8217;s written consent
            (not to be unreasonably withheld or delayed in cases where the subject matter of the planning permission has been approved by the Landlord pursuant to the other provisions of this lease);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.16.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">If a planning permission is implemented the Tenant shall complete all the works permitted and comply with all the conditions imposed
            by the permission before the determination of the Term (including any works stipulated to be carried out by a date after the determination of the Term unless the Landlord requires otherwise);</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"><br>
        </td>
        <td style="width: 3%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.17</b></font></td>
        <td style="width: 97%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>&#160;Contaminants and Defects</b></font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.17.1</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">To give the Landlord prompt written notice upon becoming aware of the existence of any defect in the Property, or of the existence
            of any contaminant, pollutant or harmful substance on the Property but not used in the ordinary course of the Tenant&#8217;s use of the Property;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 3%"><br>
        </td>
        <td style="width: 5%; text-align: left; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;"><b>4.17.2</b></font></td>
        <td style="text-align: left; width: 92%; font-family: Arial,Helvetica,'sans-serif';"><font style="font-size: 10pt;">If so requested by the Landlord, to remove from the Property or remedy to the Landlord&#8217;s reasonable satisfaction any such
            contaminant, pollutant or harmful substance introduced on the Property by or at the request of the Tenant;</font></td>
      </tr>

  </table>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="font: 10pt Arial,Helvetica,'sans-serif'; margin-top: 0pt; margin-bottom: 0pt; text-indent: -34.1pt;"><font style="font-size: 10pt;">&#160;</font></p>
  <font style="font-family: Arial,Helvetica,'sans-serif';"> </font><!-- Field: Rule-Page -->
  <div style="font-family: Arial,Helvetica,'sans-serif';" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page --><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';"> <br>
  </p>
  <p style="margin-top: 0px; text-align: center; margin-bottom: 0px; font-family: Arial,Helvetica,'sans-serif';">10</p>
  <p style="margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
  <p style="margin-top: 0; margin-bottom: 0"></p>
  <title></title>
  <!-- Licensed to: ditech
         Document created using EDGARfilings PROfile 7.0.1.0
         Copyright 1995 - 2020 Broadridge -->
  <p style="margin-top: 0; margin-bottom: 0; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin-top: 0; margin-bottom: 0; margin-left: 0"></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Entry by Landlord</b></font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To permit the Landlord at all reasonable times and on reasonable notice
      (which shall not be less than 72 hours&#8217; notice except in emergency) to enter the Property in order to:</font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">inspect and record the condition of the Property or the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">remedy any breach of the Tenant&#8217;s obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">repair, maintain, clean, alter, replace, install, add to or connect up to any Conduits which serve the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">repair, maintain, alter or rebuild the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.18.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">comply with any of its obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Provided that the Landlord shall only exercise such rights where necessary
      and shall cause as little inconvenience as reasonably practicable in the exercise of such rights and shall promptly make good all physical damage to the Property caused by such entry;</font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.19</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Landlord&#8217;s Costs</b></font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To pay to the Landlord on demand amounts equal to such Costs as it may
      properly and reasonably incur:</font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.19.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">in connection with any application for consent made necessary by this lease (including where consent is lawfully refused or the application is withdrawn);</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.19.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">incidental to or in reasonable contemplation of the preparation and service of a schedule of dilapidations (whether before or within three (3) months after the end of the
            Term) or a notice or proceedings under Section 146 or Section 147 of the Law of Property Act 1925 (even if forfeiture is avoided other than by relief granted by the Court);</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.19.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">in connection with the enforcement or remedying of any breach of the covenants in this lease on the part of the Tenant and any Guarantor;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.19.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">incidental to or in reasonable contemplation of the preparation and service of any notice under Section 17 of the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.20</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Yielding up</b></font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Immediately before the end of the Term:</font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to give up the Property repaired and decorated and otherwise in accordance with the Tenant&#8217;s covenants in this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">if the Landlord so requires, to remove all alterations made during the Term or any preceding period of occupation by the Tenant and reinstate the Property in accordance
            with the Building Specification, as the Landlord shall reasonably direct and to its reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to remove all signs, tenant&#8217;s fixtures and fittings and other goods from the Property, and make good any damage caused thereby to the Landlord&#8217;s reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iv)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to replace any damaged or missing Landlord&#8217;s fixtures with ones of no less quality and value;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(v)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to replace all carpets with ones of no less quality and value than those in the Property at the start of the Contractual Term;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(vi)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to give to the Landlord all operating and maintenance manuals together with any health and safety files relating to the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(vii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to provide evidence of satisfactory condition and maintenance of plant and machinery including (without limitation) electrical installation condition reports in respect of
            all of the electrical circuits and supply equipment in the Property, and any other condition reports as required under any relevant statute or European Union law, regulation or directive and copies of all service records;</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><br>
    </font></p>
  <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">11</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(viii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to return any security cards or passes provided by the Landlord for use by the Tenant and its visitors.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.21</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Encumbrances</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To perform and observe the Encumbrances so far as they relate to the
      Property.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.22</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Roads Etc</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 9.5pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Not to obstruct the roads, pavements, footpaths and forecourt areas from
      time to time on the Estate in any way whatsoever and not to use any part of the forecourts and car parking spaces or other open parts of the Property for the purpose of storage or deposit of any materials, goods, container ships&#8217; pallets, refuse,
      waste scrap or any other material or matter.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.23</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Parking Restrictions</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Except as to any right specifically granted in this
      lease not to permit any vehicles belonging to or calling upon the Tenant to stand on the roads, car parking spaces, forecourts, pavements or footpaths on the Estate.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.24</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Regulations etc</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.24.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">At all times during the Term to observe and perform such regulations (if any) in respect of the Centre or the Estate as the Landlord may reasonably think expedient to the
            proper management of the Centre or the Estate and which are notified to the Tenant.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.24.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Not to cause any obstruction to any part of the Centre or the Estate.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.25</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Land Registration Provisions</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.25.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Promptly following the grant of this lease the Tenant shall apply to register this lease at the Land Registry and shall ensure that any requisitions raised by the Land
            Registry in connection with that application are dealt with promptly and properly and within one month after completion of the registration, the Tenant shall send the Landlord official copies of its title;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.25.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Immediately after the end of the Term (and notwithstanding that the Term has ended), the Tenant shall make an application to close the registered title of this lease and
            shall ensure that any requisitions raised by the Land Registry in connection with that application are dealt with promptly and properly and the Tenant shall keep the Landlord informed of the progress and completion of its application.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Landlord&#8217;s Covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Quiet Enjoyment</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord covenants with the Tenant that, the Tenant may peaceably enjoy
      the Property during the Term without any interruption by the Landlord or any person lawfully claiming under or in trust for it.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Provision of Services</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord will use its reasonable endeavours to provide or procure the
      provision of the Services PROVIDED THAT the Landlord shall be entitled to withhold or vary the provision or procurement of such of the Services as the Landlord considers necessary or appropriate in the interests of good estate management and PROVIDED
      FURTHER THAT the Landlord will not be in breach of this Clause as a result of any failure or interruption of any of the Services:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5.2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">resulting from circumstances beyond the Landlord&#8217;s reasonable control, so long as the Landlord uses its reasonable endeavours to remedy the same as soon as reasonably
            practicable after becoming aware of such circumstances; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5.2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">to the extent that the Services (or any of them) cannot reasonably be provided as a result of works of inspection, maintenance and repair or other works being carried out
            at the Property or the Centre or the Estate.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Landlord&#8217;s insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord covenants with the Tenant as follows:</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">12</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To insure the Property (other than tenant&#8217;s and trade fixtures and fittings) unless the insurance is invalidated in whole or in part by any act or default of the Tenant:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">with an insurance office or underwriters of repute;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">against loss or damage by the Insured Risks;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">subject to such excesses as may be imposed by the insurers;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iv)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">in the full cost of reinstatement of the Property (in modern form if appropriate) including shoring up, demolition and site clearance, professional fees, VAT and allowance
            for building cost increases;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To insure against loss of the Principal Rent thereon payable or reasonably estimated by the Landlord to be payable under this lease arising from damage to the Property by
            the Insured Risks for three years or such longer period as the Landlord may reasonably require having regard to the likely period for reinstating the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord will use its reasonable endeavours to procure that the insurer waives its rights of subrogation against the Tenant (so long as such provision is available in
            the London insurance market) and to ensure that the Tenant&#8217;s interest is noted on such policy (which may be by way of the policy providing for a general noting of the interests of tenants);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">At the request and cost of the Tenant (but not more frequently than once in any twelve month period) to produce summary details of the terms of the insurance under this
            Clause 6.1;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To notify the Tenant as soon as becoming aware of any material change in the terms and conditions of the insurer in relation to the policy under which the Property is for
            the time being insured;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1.6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Property is destroyed or damaged by an Insured Risk, then, unless payment of the insurance moneys is refused in whole or part because of the act or default of the
            Tenant, and subject to obtaining all necessary planning and other consents to use the insurance proceeds (except those relating to loss of rent and fees) and any uninsured excess paid by the Tenant under Clause 6.2.4(ii) in reinstating the same
            (other than tenant&#8217;s and trade fixtures and fittings) as quickly as reasonably practicable substantially as it was before the destruction or damage in modern form if appropriate but not necessarily identical in layout</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Tenant&#8217;s insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Tenant covenants with the Landlord from and including the Insurance
      Commencement Date and then throughout the Term or until released pursuant to the 1995 Act as follows:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To pay to the Landlord on demand sums equal to:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the amount which the Landlord spends on insurance pursuant to Clause 6.1;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the cost of property owners&#8217; liability and third party liability insurance in connection with the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the cost of any professional valuation of the Property properly required by the Landlord (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To give the Landlord immediate written notice on becoming aware of any event or circumstance which might affect or lead to an insurance claim;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Not to do anything at the Property which would or might prejudice or invalidate the insurance of the Property or the Adjoining Property or cause any premium for their
            insurance to be increased;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To pay to the Landlord on demand:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">any increased premium and any Costs incurred by the Landlord as a result of a breach of Clause 6.2.3;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">any uninsured excess to which the insurance policy may be subject;</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">13</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the whole of the irrecoverable proportion of the insurance moneys if the Property or any part are destroyed or damaged by an Insured Risk but the insurance moneys are
            irrecoverable in whole or part due to the act or default of the Tenant;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To comply with the requirements and reasonable recommendations of the insurers;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">To notify the Landlord of the full reinstatement cost of any fixtures and fittings installed at the Property at the cost of the Tenant which become Landlord&#8217;s fixtures and
            fittings;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2.7</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Not to effect any insurance of the Property against an Insured Risk but if the Tenant effects or has the benefit of any such insurance the Tenant shall hold any insurance
            moneys upon trust for the Landlord and pay the same to the Landlord as soon as practicable;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Suspension of Rent</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Property is unfit for occupation and use because of damage by an
      Insured Risk then (save to the extent that payment of the loss of rent insurance moneys is refused due to the act or default of the Tenant) the Principal Rent (or a fair proportion according to the nature and extent of the damage) shall be suspended
      until the date on which the Property is again fit for occupation and use.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Determination Right</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.4.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Property is destroyed or damaged by an Insured Risk such that the Property is unfit for occupation and use and shall not be rendered fit for occupation and use
            within two years and nine months of the date of such damage then either the Landlord or the Tenant may whilst the Property has not been rendered fit for occupation and use terminate the Contractual Term by giving to the other not less than
            three (3) months&#8217; previous notice in writing. PROVIDED THAT if the Property has been rendered fit for occupation and use within three years of the date of such damage then such notice shall be deemed not to have been given.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.4.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Termination of this lease pursuant to the provisions of Clause 6.4.1 shall be without prejudice to the liability of either party for any antecedent breach of the covenants
            and conditions herein contained (save for Clause 6.1.6 which shall be deemed not to have applied).</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Uninsured Risks</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">For the purposes of this Clause 6.5:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">These provisions shall apply from the date on which any Insured Risk becomes an Uninsured Risk but only in relation to the Uninsured Risk;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">References to an Insured Risk becoming an Uninsured Risk shall, without limitation, include the application by insurers of an exclusion, condition or limitation to an
            Insured Risk to the extent to which such risk thereby is or becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord shall notify the Tenant in writing as soon as reasonably practicable after an Insured Risk becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If during the Term the Property (or part thereof) shall be damaged or destroyed by an Uninsured Risk so as to make the Property (or part therefore) unfit for occupation or
            use:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Principal Rent and the Service Charge or a fair proportion according to the nature and extent of the damage sustained will not be payable until the earlier of the date
            on which:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(a)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Property shall again be fit for occupation and use excluding fitting out and replacement of contents; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(b)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">This lease shall be terminated in accordance with Clause 6.5.2(ii) or 6.5.5</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord may within one year of the date of such damage or destruction serve notice on the Tenant confirming that it will reinstate the Property (a &#8216;Reinstatement
            Notice&#8217;) so that the Property shall be fit for occupation and use</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">14</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1.5in; text-align: justify"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">and if the Landlord fails to serve a Reinstatement
      Notice by the expiry of such prescribed period the lease will automatically end on the date one year after the date of such damage or destruction.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Clause 6.5.2(i) shall not apply if an Insured Risk shall have become an Uninsured Risk owing to the act or default of the Tenant or any person deriving title under the
            Tenant or their respective agents, employees, licensee, invitees or contractors.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Landlord shall have served a Reinstatement Notice the provisions of Clause 6.1.6 shall apply as if the damage had been caused by an Insured Risk</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Landlord shall have served a Reinstatement Notice and such reinstatement has not been completed by the date two years and nine months of the date of such damage at
            any time after that date the Landlord or the Tenant may terminate this lease by serving not less than three months&#8217; notice on the other stating that it terminates this lease, and if by the end of such notice the Property has been reinstated so
            that the Property is fit for occupation and use the notice shall be void and this lease shall continue in full force and effect.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.5.6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Service of a Reinstatement Notice shall not oblige the Landlord to replace any Tenant&#8217;s fitting out works or property belonging to the Tenant or any third party.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Provisos</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Forfeiture</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If any of the following events occur:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant fails to pay any of the rents payable under this lease within 21 days of the due date (whether or not formally demanded); or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant or Guarantor breaches any of its obligations in this lease; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant or Guarantor being a company incorporated within the United Kingdom</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">has an Administration Order made in respect of it; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">passes a resolution, or the Court makes an Order, for the winding up of the Tenant or the Guarantor, otherwise than a member&#8217;s voluntary winding up of a solvent company
            for the purpose of amalgamation or reconstruction previously consented to by the Landlord (consent not to be unreasonably withheld); or</font></td>
      </tr>

  </table>
  <p style="font: 9.5pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">has a receiver or administrative receiver or receiver and manager appointed over the whole or any part of its assets or undertaking; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(iv)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">is struck off the Register of Companies; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(v)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">is deemed unable to pay its debts within the meaning of Section 123 of the Insolvency Act 1986; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">proceedings or events analogous to those described in Clause 7.1.3 shall be instituted or shall occur where the Tenant or Guarantor is a company incorporated outside the
            United Kingdom; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.1.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant or Guarantor being an individual:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">has a bankruptcy order made against him; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">appears to be unable to pay his debts within the meaning of Section 268 of the Insolvency Act 1986;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">then the Landlord may re-enter the Property or any part of the Property in
      the name of the whole and forfeit this lease and the Term created by this lease shall immediately end, but without prejudice to the rights of either party against the other in respect of any breach of the obligations contained in this lease;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Notices</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">All notices under or in connection with this lease shall be given in writing</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any such notice shall be duly and validly served if it is served (in the case of a company) to its registered office or (in the case of an individual) to his last known
            address;</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">15</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.2.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any such notice shall be deemed to be given when it is:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">personally delivered to the locations listed in Clause 7.2.2; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">sent by registered post, in which case service shall be deemed to occur on the third Working Day after posting.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>No Implied Easements</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The grant of this lease does not confer any rights over the Centre or the
      Estate or the Adjoining Property or any other property except those mentioned in Part I of the First Schedule, and Section 62 of the Law of Property Act 1925 is excluded from this lease;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Break Clause</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the 95 Lease shall not have been granted or required to have been granted pursuant to the Agreement for Lease prior to the last date for such notice to be given by the
            Tenant under this sub-clause 8.1 the Tenant may terminate the Contractual Term on Break Date 1 by giving to the Landlord not less than six (6) months&#8217; previous notice in writing PROVIDED THAT if the 95 Lease shall have been granted or required
            to have been granted pursuant to the Agreement for Lease prior to the last date for such notice to be given by the Tenant then any such notice given by the Tenant shall be of no effect and the Contractual Term shall not end on Break Date 1;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Tenant may terminate the Contractual Term on Break Date 2 or Break Date 3 or Break Date 4 by giving to the Landlord not less than six (6) months&#8217; previous notice in
            writing;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any notice given by the Tenant shall operate to terminate the Contractual Term only if:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.3.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Principal Rent reserved by this lease has been paid by the time of such termination; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.3.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant yields up the Property free from any subleases and other third party occupational interests on termination;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Upon termination the Contractual Term shall cease but without prejudice to any claim in respect of any prior breach of the obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.5.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the 95 Lease shall not have been granted or required to have been granted pursuant to the Agreement for Lease prior to the last date for notice to be given by the Tenant
            under sub-clause 8.1; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.5.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant shall not give such notice under sub-clause 8.1 to terminate the Contractual Term on Break Date 1;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">then the Principal Rent shall be suspended from and including the date
      falling immediately after Break Date 1 for a period of one hundred and ninety (190) days, after which period the Tenant&#8217;s obligation to pay the Principal Rent shall resume;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Tenant does not terminate the Contractual Term on Break Date 2 the Principal Rent shall be suspended from and including the date falling immediately after Break
            Date 2 for a period of one hundred and ninety (190) days, after which period the Tenant&#8217;s obligation to pay the Principal Rent shall resume;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.7</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Tenant terminates this lease in accordance with this clause 8 the Landlord shall promptly reimburse the Tenant in respect of any sums received under this lease
            which relate to a period following termination of this lease.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.8</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Time shall be of the essence for the purposes of this Clause.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Contracts (Rights of Third Parties) Act 1999</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A person who is not a party to this lease has no right under the Contracts
      (Rights of Third Parties) Act 1999 to enforce any terms of this lease.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Environmental Conditions</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 9.5pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">For the purposes of this clause the expression &#8216;Environment&#8217; includes air,
      man-made structures and surface or substrata any surface water or ground water, any life form (including human) or eco system and notwithstanding any other provisions of this Lease to the extent that the Property, Centre or Estate are affected by
      contamination or pollution, the Environment or the&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">16</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">presence of any substance harmful to the Environment present or occurring
      prior to this Lease otherwise than through the act or default of the Tenant or any party under their control (an &#8216;Environmental Condition&#8217;) the Tenant shall not:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">be responsible for (or contribute to whether by Service Charge or otherwise) any management compliance with statutory requirements, clean up, remediation or containment of
            any such Environmental Condition; nor</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">be responsible to repair any damage disrepair or injury caused by or arising from any Environmental Condition; nor</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">be responsible to contribute to any cost, fine or liability of any kind arising out of or in any way connected with any Environmental Condition.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Executed </b>by the parties as a <b>Deed </b>on the date specified in the
      Prescribed Clauses.</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font: 10pt Arial, Helvetica, Sans-Serif"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif"> <br>
    </font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">17</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>The First Schedule</b></font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>Part I - Easements and Other Rights granted</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">There are granted to the Tenant (in common with others authorised by the
      Landlord)</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to use the relevant Estate Common Areas and the Centre Common Areas for access to and from the Property and for all purposes for which they are designed;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Free and uninterrupted use of all existing and future Conduits which serve the Property, subject to the Landlord&#8217;s rights to re-route the same subject to there being no
            unreasonable interruption of services;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to enter the Estate and/or the Adjoining Property excluding any buildings which are occupied as necessary to perform Clause 4.4 [repair] on reasonable prior
            written notice to the Landlord, subject to causing as little inconvenience as practicable and complying with conditions reasonably imposed by the Landlord and making good all physical damage caused.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Part II - Exceptions and Reservations</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">There are excepted and reserved to the Landlord (and others authorised by
      the Landlord):</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to carry out any building, rebuilding, alteration or other works to the Centre, the Estate and the Adjoining Property (including the erection of scaffolding)
            notwithstanding any temporary interference with light and air enjoyed by the Property but provided that the Tenant&#8217;s use and enjoyment of the Property is not materially compromised;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Free and uninterrupted use of all existing and future Conduits which are in the Property and serve the Centre, the Estate or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Rights of entry on the Property as referred to in Clause 4.18;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Rights of entry on the Centre in order to provide or procure the provision of the Services;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to use the Centre for access on foot to and from parts of the Estate not comprised in the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to regulate and control in a reasonable manner the use of the Estate Common Areas;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right to alter the layout of the roads forecourts footpaths pavements and car parking areas from time to time on the Estate in such manner as the Landlord may
            reasonably require PROVIDED THAT such alterations do not materially diminish the Tenant&#8217;s rights under this lease and that such works do not materially compromise the Tenant&#8217;s access to the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The right in the last six months of the Term to view the Property with prospective tenants upon giving reasonable notice (not to be less than 72 hours) and the right
            throughout the Term to view the Property with prospective purchasers upon giving reasonable notice (not to be less than 72 hours).</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Part III - Encumbrances</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The covenants declarations and other matters affecting the Property
      contained or referred to in the Landlord&#8217;s freehold reversionary title number BK102078 as at the date of this lease</font></p>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">18</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>The Second Schedule</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.1pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Rent Review</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In this Schedule:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Review Date </b>means each of the Review Dates and <b>Relevant Review Date </b>shall be interpreted accordingly;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Current Rent </b>means the Principal Rent payable under this lease immediately before the Relevant Review Date</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Index </b>means the Consumer Prices Index (<b>CPI</b>) published by the Office for National Statistics or (if not available) such index of comparative prices as the
            Landlord shall reasonably require;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Indexed Rent </b>means:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Current Rent </b>multiplied by (A/B) per annum where:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">A</font></td>
        <td style="width: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">= </font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The figure shown in the Index for the month immediately before the Relevant Review Date; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">B</font></td>
        <td style="width: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">= </font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(In the case of Review Date 1) the figure shown in the Index for February 2015, (in the case of Review Date 2) the figure shown in the Index for August 2020, (in the case
            of Review Date 3) the figure shown in the Index for August 2025 and (in the case of Review Date 4) the figure shown in the Index for August 2030.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">PROVIDED THAT:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">At Review Date 1 the maximum value of (A/B) shall be 1.2409860 and the
      minimum value of (A/B) shall be 1.0562651;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">At each of Review Date 2, Review Date 3 and Review Date 4 the maximum value
      of (A/B) shall be 1.2166529 and the minimum value of (A/B) shall be 1.0510101;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Revised Rent </b>means the new Principal Rent following each Review Date pursuant to paragraph 2 of the Second Schedule.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Principal Rent shall be reviewed on each Review Date to the higher of:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Current Rent (disregarding any suspension or abatement of the Principal Rent); and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Indexed Rent ascertained in accordance with this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If a Revised Rent has not been ascertained by the Relevant Review Date:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Current Rent shall continue to be payable until the Revised Rent is ascertained;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">when the Revised Rent is ascertained:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3.2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant shall pay within 14 days of ascertainment of the Revised Rent:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(i)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">any difference between the Principal Rent payable immediately before the Relevant Review Date and the Principal Rent which would have been payable had the Revised Rent
            been ascertained on the Relevant Review Date (the <b>Balancing Payment</b>); and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 1in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(ii)</font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">interest on the Balancing Payment at Base Rate from the date or dates when the Balancing Payment or the relevant part or parts would have been payable had the Revised Rent
            been ascertained on the Relevant Review Date;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3.2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Landlord and Tenant shall sign and exchange a memorandum recording the amount of the Revised Rent.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Time shall not be of the essence for the purposes of this Schedule.</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"> <br>
    </font></p>
  <p style="font: 8.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">19</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>The Third Schedule</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Trebuchet MS, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Guarantee</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Guarantor covenants with the Landlord as principal debtor:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">that throughout the Term or until the Tenant is released from its covenants pursuant to the 1995 Act:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.1.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Tenant will pay the rents reserved by and perform its obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0.5in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.1.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Guarantor will indemnify the Landlord on demand against all Costs arising from any default of the Tenant in paying the rents and performing its obligations under this
            lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant [(here meaning the Tenant so named in the Prescribed Clauses)] will perform its obligations under any authorised guarantee agreement that it gives with respect
            to the performance of any of the covenants and conditions in this lease.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The liability of the Guarantor shall not be affected by:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any time given to the Tenant or any failure by the Landlord to enforce compliance with the Tenant&#8217;s covenants and obligations;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord&#8217;s refusal to accept rent at a time when it would or might have been entitled to re-enter the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any variation of the terms of this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any change in the constitution, structure or powers of the Guarantor the Tenant or the Landlord or the administration, liquidation or bankruptcy of the Tenant or
            Guarantor;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any act which is beyond the powers of the Tenant;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2.6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The surrender of part of the Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Where two or more persons have guaranteed obligations of the Tenant the release of one or more of them shall not release the others.</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Guarantor shall not be entitled to participate in any security held by the Landlord in respect of the Tenant&#8217;s obligations or stand in the Landlord&#8217;s place in respect
            of such security.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If this lease is disclaimed, and if the Landlord within 6 months of the disclaimer requires in writing the Guarantor will enter into a new lease of the Property at the
            cost of the Guarantor on the terms of this lease (but as if this lease had continued and so that any outstanding matters relating to rent review or otherwise shall be determined as between the Landlord and the Guarantor) for the residue of the
            Contractual Term from and with effect from the date of the disclaimer.</font></td>
      </tr>

  </table>
  <p style="font: 10.5pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>&#160;</b></font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If this lease is forfeited and if the Landlord within 6 months of the forfeiture requires in writing the Guarantor will (at the option of the Landlord):</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">enter into a new lease as in paragraph 5 above with effect from the date of the forfeiture; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">pay to the Landlord on demand an amount equal to the moneys which would otherwise have been payable under this lease until the earlier of 6 months after the forfeiture and
            the date on which the Property is fully relet.</font></td>
      </tr>

  </table>
  <p style="font: 9pt Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: Red"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif"> <br>
    </font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">20</font></p>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
    <div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; COLOR: #000000; FONT-STYLE: normal"></font>&#160;</div>
    <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
      <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade"> </div>
  </div>
  <p style="FONT: 10pt Arial, Helvetica, Sans-Serif; MARGIN: 0pt 0px">&#160;</p>
  <title></title>
  <p style="margin-top: 0; font: 10pt Arial, Helvetica, Sans-Serif; margin-bottom: 0; margin-left: 0"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="margin-top: 0; font: 10pt Arial, Helvetica, Sans-Serif; margin-bottom: 0; margin-left: 0"></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>The Fourth Schedule </b></font><br>
    <font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Service Charge</b>&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Part I&#160;-&#160;Calculation and payment of the Service Charge</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 106.7pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In this Schedule unless the context otherwise requires:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Accounting Date </b>means 31 December in each year or such other date as the Landlord notifies in writing to the Tenant from time to time;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Accounting Year </b>means the period from but excluding one Accounting Date to and&#160;including the next Accounting Date;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Centre Service Cost </b>means all reasonable and proper costs and expenses paid or incurred by the Landlord in relation to the provision of
            the Centre Services (including irrecoverable VAT);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.4</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Estate Service Cost </b>means all&#160;reasonable and proper costs and expenses paid or incurred by the Landlord in relation to the provision of
            the Estate Services (including irrecoverable VAT);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.5</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Estimated Service Charge </b>means the Landlord&#8217;s Surveyor&#8217;s reasonable and proper estimate of the Service Charge for the Accounting Year
            notified in writing to the Tenant from time to time;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.6</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Service Cost </b>means&#160;the sum of the Centre Service Cost and the Estate Service Cost ;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.7</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Tenant&#8217;s Share of the Estate Service Cost </b>means a fair and reasonable proportion of&#160;the Estate Service Cost;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.8</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Tenant&#8217;s Share&#160;of the Service Cost </b>means&#160;the sum of:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.8.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Centre Service Cost; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1.8.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">the Tenant&#8217;s Share of the Estate Service Cost.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td style="text-align: left; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Service Charge shall be the Tenant&#8217;s Share of the Service Cost in respect of each Accounting Year,
            and if only part of an Accounting Year falls within the Term the Service Charge shall be the Tenant&#8217;s Share of the Service Cost in respect of the relevant Accounting Year divided by 365 and multiplied by the number of days of the Accounting
            Year within the Term.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Landlord shall have the right to adjust the Tenant&#8217;s Share&#160;of&#160;the&#160;Estate&#160;Service Cost&#160;from time to
            time to make reasonable allowances for differences in the services provided to or enjoyable by the other occupiers of the Estate.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Tenant shall pay the Estimated Service Charge for each Accounting Year to the Landlord in advance by equal instalments on the Quarter Days,
            (the first payment for the period from and including the Service Charge Commencement Date to (but excluding) the next Quarter Day after the Service Charge Commencement Date to be made on the Service Charge Commencement Date); and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">If the Landlord&#8217;s Surveyor does not notify an estimate of the Service Charge for any Accounting Year the Estimated Service Charge for the
            preceding Accounting Year shall apply; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any adjustment to the Estimated Service Charge after the start of an Accounting Year shall adjust the payments on the following Quarter Days
            equally.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td style="text-align: left; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">As soon as practicable after the end of each Accounting Year the Landlord shall serve on the Tenant a
            summary of the Service Cost and a statement of the Service Charge certified by the Landlord&#8217;s Surveyor which shall be conclusive (save in the case of manifest error).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The difference between the Service Charge and the Estimated Service Charge for any Accounting Year (or
            part) shall be paid by the Tenant to the Landlord within fourteen days of the date of the statement for the Accounting Year, or allowed against the next Estimated Service Charge payment, or after the expiry of the Term refunded to the Tenant.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The Tenant shall be entitled by appointment within a reasonable time following service of the Service
            Charge statement to inspect&#160;the accounts maintained by the Landlord and the Landlord&#8217;s Surveyor relating to the Service Cost and supporting vouchers and receipts at such location as the Landlord reasonably directs.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8</b></font></td>
        <td style="text-align: left; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">For the avoidance of doubt any cost charged as a Service Cost in respect of any element of the Estate
            Services or of the&#160;Centre&#160;Services shall not be charged as a Service Cost in respect of any other head of charge under which charges are made for services by the Landlord.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">21</font></p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Part II&#160;-&#160;Estate Services</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 196.8pt"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In relation to the Estate the provision of the following
      services or the Costs incurred in relation to:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>The Common Areas</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Repairing, maintaining and (where appropriate)
      cleaning, lighting and (as necessary) altering renewing, rebuilding and reinstating the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Conduits</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The repair, maintenance and cleaning and (as necessary)
      replacement and renewal of all Conduits within the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Plant and machinery</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Hiring, operating, inspecting, servicing, overhauling,
      repairing, maintaining, cleaning, lighting and (as necessary) renewing or replacing any plant, machinery, apparatus and equipment from time to time within the Estate Common Areas or used for the provision of services to the Estate and the supply of
      all fuel and electricity for the same and any necessary maintenance contracts and insurance in respect thereof.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Signs</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Maintaining and (where appropriate) cleaning and
      lighting and (as necessary) renewing and replacing the signboards, all directional signs, fire regulation notices, advertisements, bollards, roundabouts and similar apparatus or works.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Maintaining, tending and cultivating and (as necessary)
      re-stocking any garden or grassed areas including replacing plants, shrubs and trees as necessary.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Common facilities</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Repairing maintaining and (as necessary) rebuilding as
      the case may be any party walls or fences, party structures, Conduits or other amenities and easements which may belong to or be capable of being used or enjoyed by the Estate in common with any land or buildings adjoining or neighbouring the Estate.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Security</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Installation, operation, maintenance, repair,
      replacement and renewal of closed circuit television systems and other security systems.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Outgoings</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any existing and future rates, taxes, charges,
      assessments and outgoings in respect of the Estate Common Areas or any part of them except tax (other than VAT) payable in respect of any dealing with or any receipt of income in respect of the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Transport</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The provision of a bus service to and from Didcot or
      such other transport and/or location (if any) deemed necessary by the Landlord.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Statutory requirements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The cost of carrying out any further works (after the
      initial construction in accordance with statutory requirements) to the Estate Common Areas required to comply with any statute.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT) of any person properly employed or
            retained by the Landlord for or in connection with surveying or accounting functions or the performance of the Estate Services and any other duties in and about the Estate relating to the general management, administration, security,
            maintenance, protection and cleanliness of the Estate:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Management costs fees and disbursements in respect of the Estate of 10% of the&#160;Estate&#160;Service Cost (excluding costs under this clause 11.2).</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">22</p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Providing staff in connection with the Estate Services and the general management, operation and security of the&#160;Estate and all other incidental
            expenditure including but not limited to:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.3.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">salaries, National Health Insurance, pension and other payments contributions and benefits;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.3.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">uniforms, special clothing, tools and other materials for the proper performance of the duties of any such staff;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>11.3.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">providing premises and accommodation and other facilities for staff.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>12</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Enforcement of Regulations</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The reasonable and proper costs and expenses incurred
      by the Landlord in enforcing the rules and regulations from time to time made pursuant to Clause 4.24 provided that the Landlord shall use all reasonable endeavours to recover such costs and expenses from the defaulting party and provided further
      that there shall be credited against the&#160;Estate&#160;Service Cost any such costs recovered.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>13</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Insurances</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>13.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Effecting such insurances (if any) as the Landlord may properly think fit in respect of the Estate Common Areas the plant, machinery, apparatus
            and equipment used in connection with the provision of the Estate Services (including without prejudice those referred to in paragraph 3 above) and any other liability of the Landlord to any person in respect of those items or in respect of the
            provision of the Estate Services.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>13.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Professional valuations for insurance purposes (but not more than once in any two&#160;year period);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><b>13.3</b></td>
        <td style="text-align: left">Any uninsured excesses to which the Landlord&#8217;s insurance may be subject.</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>14</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Generally</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any reasonable and proper costs (not referred to above)
      which the Landlord may incur in providing such other services and in carrying out such other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Estate.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>15</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Anticipated Expenditure</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Establishing and maintaining reserves to meet the
      future costs (as from time to time estimated by the Landlord&#8217;s Surveyor) of providing the Estate Services;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>16</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Borrowing</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The costs of borrowing any sums required for the
      provision of the&#160;Estate&#160;Services at normal commercial rates available in the open market or if any such sums are loaned by the Landlord or a Group Company of the Landlord interest at Base Rate.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>17</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font: 10pt Arial, Helvetica, Sans-Serif">23&#160;</font></p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Part III&#160;-&#160;Centre Services</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 194.05pt; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 33.85pt; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">In relation to the&#160;Centre, the provision of the
      following services or the Costs incurred in relation to:</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 33.85pt; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>1</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Repairs to the Centre plant and&#160;equipment (including Conduits)</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Repair, renewal, decoration, cleaning and maintenance
      of the Conduits, plant and equipment (which are not the responsibility of the Tenant).</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>2</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Centre Common Areas</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(a)</font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Repair, renewal, decoration, cleaning, maintenance and lighting&#160;of the Centre Common Areas and other parts of the Centre;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0.5in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">(b)</font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Providing signs, nameboards and other notices within the Centre.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>3</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Services</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Procuring water, electricity and sewerage services for
      the Centre Common Areas.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>4</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Maintaining, tending and cultivating and (as necessary)
      re-stocking any garden or grassed areas including replacing plants, shrubs and trees as necessary.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>5</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Fire Fighting and Security</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Provision, operation, repair, renewal, cleaning and
      maintenance of fire alarms, sprinkler systems, fire&#160;prevention and fire-fighting equipment and ancillary apparatus and security alarms, apparatus, closed circuit television and systems as the Landlord considers appropriate.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Effecting such insurances (if any) as the Landlord may properly think fit&#160;in respect of the&#160;Centre Common&#160;Areas&#160;and all Landlord&#8217;s plant,
            machinery, apparatus and equipment and any other liability of the Landlord to any person in respect of those items or in respect of the provision of the&#160;Centre&#160;Services;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Professional valuations for insurance purposes (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>6.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any uninsured excesses to which the Landlord&#8217;s insurance may be subject.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>7</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Statutory Requirements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">All existing and future rates, taxes, charges,
      assessments and outgoings payable to any competent authority for&#160;or in connection with&#160;utilities.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.1</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT) of any person properly employed or
            retained by the Landlord for or in connection with surveying or accounting functions or the performance of the&#160;Centre&#160;Services and any other duties in and about the&#160;Centre&#160;relating to the general management, administration, security,
            maintenance, protection and cleanliness of the&#160;Centre:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Management fees and disbursements incurred in respect of the&#160;Centre&#160;of 10% of the&#160;Centre Service Cost (excluding costs under this&#160;paragraph&#160;8.2).</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>8.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Providing staff in connection with the&#160;Centre&#160;Services and the general management, operation and security of the&#160;Centre&#160;and all other incidental
            expenditure including but not limited to: </font></td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: left; width: 0in"></td>
        <td style="text-align: left; width: 0.5in">&#160;</td>
        <td style="text-align: left; width: 0.5in">(i)</td>
        <td style="text-align: left">salaries, National Health Insurance, pension and other payments contributions and benefits;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: left; width: 0in"></td>
        <td style="text-align: left; width: 0.5in">&#160;</td>
        <td style="text-align: left; width: 0.5in">(ii)</td>
        <td style="text-align: left">uniforms, special clothing, tools and other materials for the proper performance of the duties of any such staff;</td>
      </tr>

  </table>
  <p style="margin: 0">&#160;</p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="text-align: left; width: 0in"></td>
        <td style="text-align: left; width: 0.5in">&#160;</td>
        <td style="text-align: left; width: 0.5in">(iii)</td>
        <td style="text-align: left"> providing premises and accommodation and other facilities for staff.</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>General</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9.1</b></font></td>
        <td><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Establishing and maintaining reserves to meet the future costs (as from time to time estimated by the Landlord&#8217;s Surveyor) of providing the&#160;Centre&#160;Services;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">24</p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9.2</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Any reasonable and proper costs (not referred to above) which the Landlord may incur in providing such other services and in carrying out such
            other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Centre;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font: 10pt Arial, Helvetica, Sans-Serif"><b>&#160;</b></font></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-bottom: 0; width: 100%" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify">
        <td style="width: 0in; text-align: left"></td>
        <td style="width: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>9.3</b></font></td>
        <td style="text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">The costs of borrowing any sums required for the provision of the&#160;Centre&#160;Services at normal commercial rates available in the open market or if
            any such sums are loaned by the Landlord or a Group Company of the Landlord interest at Base Rate.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial, Helvetica, Sans-Serif">
        <td style="width: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"></td>
        <td style="width: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>10</b></font></td>
        <td style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">&#160;</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: left"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">25</p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><b>Annexure: Building Specification</b></font></p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">26</p>
  <div style="font-family: 'Times New Roman', Times, serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after:always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <title></title>
  <br>
  &#160;
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></p>
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 30%; padding-right: 5.4pt; text-align: left; vertical-align: middle">EXECUTED AS A DEED by <b>MEPC MILTON PARK NO. 1 LIMITED </b>acting by a director and the company secretary or by two directors</td>
        <td style="width: 70%; text-align: left; vertical-align: middle"><font style="font-size: 48pt">}</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director/Company Secretary</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">EXECUTED AS A DEED by <b>MEPC MILTON PARK NO. 2 &#160;LIMITED </b>acting by a director and the company secretary or by two directors</td>
        <td style="text-align: left; vertical-align: middle"><font style="font-size: 48pt">}</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director/Company Secretary</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">27</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <br>
  </p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"> </p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>12
<FILENAME>nt10016217x4_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font: 10pt Times New Roman,Times,serif;">
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54); text-align: right;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Exhibit 10.14</b></font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <table style="border-collapse: collapse; font: 16pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: left;">
        <td style="width: 50%;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-13img01.jpg" alt="">&#160;</font></td>
        <td style="width: 50%; text-align: right; vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-13img02.jpg" alt="">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt; color: rgb(36, 36, 54);">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt; color: rgb(36, 36, 54);">DATED </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt; color: Black;">28 December</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt; color: rgb(36, 36, 54);">2017</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">&#160;</font></p>
  <table style="font: 18pt Times New Roman,Times,serif; color: rgb(36, 36, 54); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">(1)</font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">MEPC MILTON PARK NO. 1 LIMITED AND MEPC MILTON PARK NO. 2 LIMITED</font></td>
      </tr>

  </table>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.75pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">&#160;</font></p>
  <table style="font: 18pt Times New Roman,Times,serif; color: rgb(36, 36, 54); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">(2)</font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">IMMUNOCORE LIMITED</font></td>
      </tr>

  </table>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid rgb(74, 85, 123); width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font: 16pt Arial,Helvetica,sans-serif;">LEASE</font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid rgb(74, 85, 123); width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font: 14pt Arial,Helvetica,sans-serif;">relating to</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">92 Park Drive&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">Milton Park</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">+44 (0) 1235 836600</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">BSDR.COM</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">DX 144160 ABINGDON 4</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">BrookStreet des Roches LLP</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">25A Western Avenue, Milton Park,&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Abingdon, Oxfordshine, OX14 4SH&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 12pt;"><b>PRESCRIBED CLAUSES</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"></p>
  <table style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 50%; border-top: 2px solid Black; border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR1. &#160;Date of lease</b></font></td>
        <td style="width: 50%; border-top: 2px solid Black; border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"></font><font style="font-family: Arial,Helvetica,sans-serif;">28 December 2017</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR2. &#160;Title number(s)</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR2.1 Landlord's title number(s) </b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">BK102078</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR2.2 Other title number(s)</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">ON122118, ON122717, ON130606, ON145942, ON146219, ON225380</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(51, 51, 51);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">ON38283</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">ON72772</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">ON96949</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(68, 68, 70);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">ON216090</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR3. &#160;Parties to this lease</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>Landlord</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>MEPC MILTON PARK NO. 1 LIMITED</b> (Company number 5491670) and <b>MEPC MILTON PARK NO. 2 LIMITED</b>
            (Company number 5491806), on behalf of MEPC Milton LP (LP No. LP14504), both of whose registered offices are at Lloyds Chambers 1 Portsoken Street London E1 8HZ</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>Tenant</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>IMMUNOCORE LIMITED</b> (Company &#160;number 6456207) whose registered office is at 101 Park Drive
            Milton Park Abingdon Oxfordshire OX14 4RY</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Other parties</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR 4. &#160;Property</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>In the case of a conflict &#160;between &#160;this clause and the remainder &#160;of this lease then, for the
              purposes of registration, this clause shall prevail.</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">92 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY shown
            edged red on the Plan with a net internal floor area of 2,840.7 square metres (30,578 square feet) measured in accordance with the RICS Code of Measuring Practice (sixth edition) </font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR5. &#160;Prescribed Statements etc.</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR6. &#160;Term for which the Property is leased</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">From and including 25 December 2017</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">To and including 24 December 2037</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR7. &#160;Premium</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR8. &#160;Prohibitions or restrictions on disposing of this lease</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">This lease contains a provision that prohibits or restricts
            dispositions</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9. &#160;Rights of acquisition &#160;etc.</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9.1 Tenant's contractual rights to renew this lease, to acquire the reversion &#160;or another &#160;lease
              of the Property, &#160;or to acquire an interest in other land</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9.2 Tenant's covenant to (or offer &#160;to) surrender this lease</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>LR9.3 Landlord's contractual rights to acquire this lease</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>&#160;</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;">&#160;</td>
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;">&#160;</td>
      </tr>

  </table>
  <p style="margin: 0px; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin: 0px; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';">1</font><font style="font-family: Arial,Helvetica,sans-serif;"><br>
    </font></p>
  <p style="margin: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="margin: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 50%; border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px; border-top: 2px solid Black; padding-left: 30pt; text-indent: -30pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR10.
              Restrictive covenants given in this lease by the Landlord in respect of land other than the Property</b></font></td>
        <td style="width: 50%; border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px; border-top: 2px solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 2px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11. Easements</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 2px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11.1 Easements granted by this lease for the benefit of the Property</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The easements specified in Part I of the First Schedule of this lease</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11.2 Easements granted or reserved by this lease over the Property for the benefit of other property</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The easements specified in Part II of the First Schedule of this lease</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR12. Estate rentcharge burdening the Property</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>None</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR13. Application for standard form of restriction</b></font></td>
        <td style="border-bottom: 2px solid Black; padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>None</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px; padding-left: 30pt; text-indent: -30pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR14. Declaration of trust where there is more than one person comprising the
              Tenant</b></font></td>
        <td style="padding-top: 6pt; padding-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(15, 15, 15);"><b>None</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 6pt; padding-bottom: 0px; padding-left: 30pt; text-indent: -30pt; border-bottom: 2px solid Black;">&#160;</td>
        <td style="padding-top: 6pt; padding-bottom: 0px; border-bottom: 2px solid Black;">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"><font style="font-family: Arial,Helvetica,'sans-serif';">2</font><font style="font-family: Arial,Helvetica,sans-serif;"><br>
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-14img03.jpg" alt=""></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(15, 15, 15);"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-14img04.jpg" alt=""></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-14img05.jpg" alt=""></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;"><img src="nt10016217x4_ex10-14img06.jpg" alt=""><font style="font-size: 10pt;">&#160;</font></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="margin: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin: 0px;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.05pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: Red;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">This lease made on the date and between the parties specified in the
      Prescribed Clauses Witnesses as </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(17, 17, 17);">follows:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Definitions and Interpretation</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">In this lease unless the
      context otherwise requires:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Definitions</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Adjoining Property</b> <font style="color: rgb(35, 35, 35);">means any adjoining or neighbouring premises in
        which the Landlord or a Group Company of the Landlord holds or shall at any time during the Term hold a freehold or leasehold interest;</font></font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Agreement for Lease</b>
      means the agreement dated 14 September 2016 made between (1) MEPC Milton Park No.1 Limited and MEPC Milton Park No.2 Limited, on behalf of MEPC Milton LP, and (2) lmmunocore Limited providing, inter alia, for the grant of this lease, as varied by a
      deed of <font style="color: rgb(35, 35, 35);">variation dated 28 December 2017 for the landlord and authorized by the tenant made between (1) MEPC Milton Park No.</font> 1 Limited and MEPC Milton Park No. 2 Limited and (2) lmmunocore Limited;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Bank Guarantee</b> means
      a guarantee issued by the Nominated Bank in the form set out in Schedule 2 to the Agreement for Lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Base Rate</b> means the base rate from time to
      time of Barclays Bank PLC or (if not available) such comparable rate of interest as the Landlord shall reasonably require;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Break Date</b> 1 means 24
      December 2024;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Break Date</b> 2 means 24
      December 2029;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Break Date</b> 3 means 24
      December 2034;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Building Specification</b> means the
      specification marked "Building Specification" annexed to this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Centre </b>means the
      external part of the Property (being all of the Property excluding the building marked "92" on the Plan) and includes any part of the Centre and any alteration or addition to it or replacement of it and any additional buildings or structures
      constructed on</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);">it;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Centre Common Areas</b>
      means the roads,accesses, the parking and other areas of the Centre;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Centre Services</b> means
      the services provided or procured by the Landlord in relation to the <font style="color: rgb(35, 35, 35);">Centre as set out in Part III of the Fourth Schedule;</font></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Clearing Bank</b> means a
      bank which is a direct participant in the CHAPS system operated by the Bank of England shareholder in CHAPS Clring Company Limited;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Common Control</b> means
      that each of the companies concerned has 50% or more of its outstanding voting stock in the ownership of the same persons or companies;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Conduit </b>means any existing or future
      media for the passage of substances or energy and any ancillary apparatus attached to them and any enclosures for them;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Contractual Term</b>
      means the term specified in the Prescribed Clauses;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current








        Lease</b> 1 means a lease of Property 1 dated 28 October 2004 made between (1) MEPC Milton Park Limited and (2) Concateno UK Limited (then called Cozart Bioscience Limited) as varied by a deed of variation dated 10 April 2013 made between (1) MEPC
      Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited (2) Concateno UK Limited and (3) Alere Toxicology PLC and includes any statutory or other continuation of the tenancy thereby created;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Lease 1 End Date</b> means the date
      when Current Lease 1 actually ends and the immediate reversioner secures vacant possession of the premises currently demised by Current Lease 1;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Lease 1 Rent</b>
      means the greater of:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(17, 17, 17);">(a)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the annual rent first reserved by Current Lease 1 for the time being payable; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(17, 17, 17);">(b)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the annual rent first reserved by Current Lease </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1
            <font style="color: rgb(35, 35, 35);">for the time being payable as set out in Current Lease 1 as at the date of the Agreement for Lease;</font></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Current Lease 2</b> means
      a lease of Property 2 dated 16 May</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);">2005 </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">made







      between (1) MEPC Milton Park Limited and (2) Concateno UK Limited </font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);">(then called </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">Cozart Bioscience Limited) as</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);">varied by</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"> </p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"> <br>
  </p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"> <font style="font-family: Arial,Helvetica,'sans-serif';">3</font><br>
  </p>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">a deed of variation dated 10 April 2013 made
      between (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited (2) Concateno UK Limited and (3) Alere Toxicology PLC and includes any statutory or other continuation of the tenancy thereby created;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Lease 2 End Date</b> means the date
      when Current Lease 2 actually ends and the immediate reversioner secures vacant possession of the premises currently demised by Current Lease 2;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Lease 2 Rent</b> means the greater of:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">(a)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the annual rent first reserved by Current Lease 2</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">for </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the time being payab</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">l</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">e; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(b)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the annual rent first reserved by Current lease 2 for the time being payable as set out</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">in Current Lease 2 as at the date of the Agreement for Lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Leases</b> means Current Lease 1 and
      Current Lease 2 (and includes any interests created under or pursuant thereto);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Tenant 1</b> means the tenant for the
      time being under the Current Lease 1;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Tenant 2</b> means the tenant for the
      time being under the Current Lease 2;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Discounted Initial
        Principal Rent</b> means the annual sum which shall for the time being be calculated as follows:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(a)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">if Current Lease 1 and Current Lease <i>2</i> shall both be in existence: the aggregate of Current Lease 1 Rent and Current
            lease 2 Rent;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(b)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">if Current Lease 1 shall be in existence and Current Lease 2 shall have ended: the aggregate of Current Lease 1 Rent and 50% of
            the Initial Principal Rent;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.3in; margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(c)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">if Current Lease 2 shall be in existence and Current Lease 1 shall have ended: the aggregate of Current Lease 2 Rent and 50% of
            the Initial Principal Rent;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.3in; margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 4%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(d)</font></td>
        <td style="width: 93%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">if Current Lease 1 and Current Lease 2 shall both have ended: the Initial Principal Rent; </font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.45pt; margin-left: 0.5in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Encumbrances </b>means the obligations and
      encumbrances (if any) spe<font style="color: rgb(61, 61, 61);">c</font><font style="color: rgb(35, 35, 35);">ified in Part Ill of the First Schedule;</font></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estate </b>means Milton Park, Abingdon,
      Oxfordshire (of which the Property forms part) and the buildings from time to time standing on it shown on the Plan together with any other adjoining land which is incorporated into Milton Park;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estate Common Areas</b>
      means the roads, accesses, landscaped areas, car parks, estate management offices and other areas or amenities on the Estate or outside the Estate but serving or otherwise benefiting the Estate as a whole which are from time to time provided or
      designated for the common amenity or benefit of the owners or occupiers of the Estate;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estate Services</b> means the services
      provided or procured by the Landlord in relation to the Estate as set out in Part II of the Fourth Schedule;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Group Company</b> means a company which is a
      member of the same group of companies within the meaning of Section 42 of the 1954 Act or is within Common Control;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Guarantor </b>means any party to this lease
      so named in the Prescribed Clauses (which in the case of an individual includes his personal representatives) and any guarantor of the obligations o</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">f
    </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">the Tenant for the time being;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Index </b>means the Consumer Prices Index
      (CPI) published by the Office for National Statistics or (if not available) such index of comparative prices as the Landlord shall reasonably require;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Initial Principal Rent</b> means SEVEN HUNDRED
      AND SEVENTY EIGHT THOUSAND SEVEN HUNDRED POUNDS (&#163;778</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">,</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">700) per annum;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Insurance Commencement Date</b> means 25
      December 2017;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>Insured Risks</b> means
      fire</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">,</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">lightning, earthquake, explosion</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">,</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">terrorism, aircraft (other than hostile aircraft) and
      other aerial devices or articles dropped there</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">f</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">rom, riot</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">,</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">civil commotion, malicious
      damage</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">,</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">storm or tempest, bursting or
      overflowing of water tanks apparatus or pipes</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">flood and impact by road vehicles (to the extent that insurance against such risks may ord</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">i</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">narily be arranged with an insurer of good repute) and such other ri</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">s</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">ks or insurance as may from time</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;"> <br>
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">4</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">to time be reasonably
      required by the Landlord (subject in all cases to such usual exclusions and limitations as may be imposed by the insurers), and <b>Insured Risk</b> means any one of them;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Landlord </b>means the
      party to this lease so named</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">the
      Prescribed Clauses and includes any other person entitled to the immediate reversion to this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.35pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Landlord's
Surveyor








      means a suitably qualified person or firm appointed by the Landlord (including an employee of the Landlord or a Group Company) to perform the function of a surveyor for the purposes of this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.35pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Lease
        Particulars</b> means the descriptions and terms in the section headed Lease Particulars which form part of this lease insofar as they are not inconsistent with the other provisions of this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Nominated Bank</b> means
      the bank which shall provide the Bank Guarantee, which shall be a Clearing Bank;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Permitted Use</b> means
      use within Class B1 of the 1987 Order</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Plan </b>means the plan
      or plans annexed to this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Prescribed Clauses</b>
      means the descriptions and terms in the section headed Prescribed Clauses which form part of this lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Principal Rent</b> means:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">From and including 25
      December 2017 to and including 28 September 2019: the Discounted Initial Principal Rent per annum;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">From and including 29
      September 2019 to but excluding 25 December 2022: the</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">Initial </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">Principal Rent per annum subject to increase in accordance with the Second Schedule;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Property </b>means the
      property described in the Prescribed Clauses and includes any part of it, any alteration or addition to the Property and any fixtures and fittings in or on the Property;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Property 1</b> means 92
      Ground Floor Park Drive, Milton Park as currently demised by Current Lease 1;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Property 2</b> means 92
      First Floor Park Drive, Milton Park as currently demised by Current Lease 2;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Quarter Days</b> means 25
      March, 24 June, 29 September and 25 December in every year and <b>Quarter Day</b> means any of them;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Release Tests</b> means
      the following tests,</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">Test </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(17, 17, 17);">1 </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">and Test 2 being:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Test 1</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Up to and including Break
      Date 1 the Principal Rent shall have been paid in full and no more than three instalments (and no two consecutive instalments) of the Principal Rent shall have been received by the Landlord more than 7 days after the due date for payment (as to which
      time shall be of the essence);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(63, 63, 63); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Test 2</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(63, 63, 63); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">The 95 Guarantee shall have been released without
      having been replaced by the 95 Deposit or the 95 Deposit shall have been released without having been</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">replaced</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">by the 95 Guarantee;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Rent Commencement Date</b>
      means 25 December 2017;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Rent Security Deposit Deed</b> means a</font>
    <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">rent </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">security deposit deed in the form of the
      settled deed set out in Schedule 3 to the Agreement for Lease providing for the quantum of the initial deposit as referred to in clause 2 of the Rent Security Deposit Deed to be calculated in accordance with clause 1.33 of the Agreement for Lease;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Review Dates</b> means 25
      December 2022 (<b>Review Date 1</b>), 25 December 2027</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">(<b>Review </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">Date 2</font></b><font style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(40, 40, 40);">), 25 December 2032 (<b>Review Date 3</b>);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(40, 40, 40); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Service Charge</b> means the Service Charge</font>
    <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">set </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">out </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);">the Fourth Schedule;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(40, 40, 40);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(40, 40, 40);"><b>Service Charge Commencement Date</b> means 25
      December</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(63, 63, 63);">2017;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">5</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);"><b>Services </b>means the Estate Services and</font>
    <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">t</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">he Centre Services</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Subletting Unit</b> means
      part of the Property consisting of a whole floor or a part of a floor comprising a Wing;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.35pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.35pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);"><b>Tenant </b>means the
      party to this lease so named i</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(12, 12, 12);">n </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">the
      Prescribed Clauses and includes its successors in title;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.35pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Term </b>means the Contractual Term together
      with any continuation of the term or the tenancy (whether by statute,common law holding over or otherwise);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.7pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>This lease</b> means this
      lease and any document supplemental to it or entered into pursuant to it;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.7pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.7pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Uninsured Risk</b> means
      an Insured Risk against which insurance is from time to time unobtainable on normal commercial terms in the London insurance market at reasonable commercial rates for a property equivalent in size, layout, type and location.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);"><b>VAT </b>means Value Added Tax and any similar
      tax substituted for it or levied in addition to it;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(38, 38, 38);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);"><b>Wing </b>means any of the ground floor east
      wing,ground floor west wing, first floor e</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">as</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">t
      wing or first floor west wing as shown on the Plan;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1954 Act</b> means the Landlord and Tenant Act
      1954;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1987 Order</b> means the
      Town and Country Planning (Use Classes) Order 1987 (as originally made);</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1995 Act</b> means the Landlord and Tenant
      (Covenants) Act 1995;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2003 Order</b> means The Regulatory Reform
      (Business Tenancies) (England and Wales) Order 2003;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>95 Deposit</b> means the rent security deposit
      required to be given to the Landlord pursuant to an agreement for lease dated 14 September 2016 made between (1) MEPC Milton Park No.1 Limited and MEPC Milton Park No. 2 Limited, on behalf of MEPC Milton LP, and (2) lmmunocore Limited providing,
      inter alia, for the grant of a lease of 95 Park Drive Milton Park;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);"><b>95 Guarantee</b> means the
      bank guarantee required to be given to the Landlord pursuant to an agreement for lease dated 14 September 2016 made between (1) MEPC Milton Park No</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">.
    </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">1 Limited and MEPC Milton Park No. 2 Limited, on behalf of MEPC Milton LP, and (2) lmmunocore Limited providing</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">inter alia, for the grant of a lease of 95 Park Drive Milton Park.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Interpretation</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: rgb(38, 38, 38);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 7%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.1</font></td>
        <td style="padding-right: 45.1pt; width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord, the Tenant or the Guarantor is more than one person then their covenants are joint and several;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 7%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.2</font></td>
        <td style="padding-right: 20.7pt; width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any reference to a statute includes any modification extension or re-enactment of it and any orders, regulations, directions,
            schemes and rules made under it;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 7%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.3</font></td>
        <td style="padding-right: 41.75pt; width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any covenant by the Tenant not to do any act or thing includes an obligation not knowingly to permit or suffer such act or thing
            to be done;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.4</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord reserves rights of access or other rights over or in relation to the Property then those rights extend to persons authorised by it;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(38, 38, 38);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">1</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">.</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">2.5</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">References to the act or default of the Tenant include acts or default or negligence of any undertenant or of anyone at the
            Property with the Tenant</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">'</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">s or any
            undertenant</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">'</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">s permission or sufferance</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.05pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">1</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">.</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">2</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">.</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">6</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">The index and Clause headings in this lease are for ease of reference only</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.7</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">References to the last year of the Term shall mean the twelve months ending on the expiration or earlier termination of the Term;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.05pt; color: rgb(38, 38, 38);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">1</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(84, 84, 84);">.</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">2.8</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">References to Costs include all liabilities</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">claims, demands, proceedings</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(38, 38, 38);">damages, losses and proper and reasonable costs and expenses;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -33.75pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 7%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1.2.9</font></td>
        <td style="width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">References to Principal Rent, Current Rent, Indexed Rent and Revised Rent are references to yearly sums.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; color: rgb(38, 38, 38);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; color: rgb(38, 38, 38);"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; color: rgb(38, 38, 38); text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;"> <br>
    </font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; color: rgb(38, 38, 38); text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">6</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Demise</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord with Full Title
      Guarantee DEMISES the Property to the Tenant for the Contractual Term TOGETHER WITH the rights set out in Part I of the First Schedule, EXCEPT AND RESERVING as mentioned in Part II of the First Schedule and SUBJECT TO the Encumbrances;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Rent</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant will pay by way of
      rent during the Term or until released pursuant to the 1995 Act without any deduction counterclaim or set off except where required by law:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.1</b></font></td>
        <td style="padding-right: 7.35pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Principal Rent and any VAT by equal quarterly payments in advance on the Quarter Days to be paid by Direct Debit, Banker's
            Standing Order or other means as the Landlord requires, the first payment for the period from and including the Rent Commencement Date to (but excluding) the next Quarter Day to be made on the Rent Commencement Date PROVIDED THAT the provisions
            set out in the Agreement for Lease entitled "Principal Rent Suspension" shall apply as set out in Clauses 13, 14 and 15 of the Agreement for Lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Service Charge and any VAT at the times and in the manner set out in the Fourth Schedule;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The following amounts and any VAT:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.3.1</b></font></td>
        <td style="width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the sums specified in Clauses 4.1 [interest] and 4.2 [outgoings and utilities];</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.3.2</b></font></td>
        <td style="width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the sums specified in Clause 6.2.1 [insurance];</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 3%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.3.3</b></font></td>
        <td style="padding-right: 4.8pt; width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">all Costs incurred by the Landlord as a result of any breach of the Tenant's covenants in this Lease.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant's covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant covenants with the Landlord throughout
      the Term, or until released pursuant to the 1995 Act, as follows:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Interest</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35); margin-left: 0.25in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord does not
      receive any sum due to it within 14 days of the due date to pay on demand interest on such sum at 2 per cent above Base Rate from the due date until payment (both before and after any judgment), provided this Clause shall not prejudice any other
      right or remedy for the recovery of such sum;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.7pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Outgoings and Utilities</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 3%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.2.1</b></font></td>
        <td style="padding-right: 7.3pt; width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To pay all existing and future rates, taxes, charges, assessments and outgoings in respect of the Property (whether assessed or
            imposed on the owner or the occupier), except any tax (other than VAT) arising as a result of the receipt by the Landlord of the rents reserved by this lease and any tax arising on any dealing by the Landlord with its reversion to this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 3%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>4.2.2</b></font></td>
        <td style="padding-right: 2.75pt; width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">To pay for all gas, electricity, water, telephone and other utilities used on the Property, and all
            charges in connection with such utilities and for meters and all standing charges</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(82, 82, 82);">, </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">and a fair and reasonable proportion of any joint charges as determined by the Landlord's Surveyor;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 3%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.3</b></font></td>
        <td style="width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 3%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.3.1</b></font></td>
        <td style="padding-right: 13.7pt; width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any payment or other consideration to be provided to the Landlord is exclusive of VAT, and the Tenant shall in addition pay any
            VAT chargeable on the date the payment or other consideration is due;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.3.2</b></font></td>
        <td style="width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any obligation to reimburse or pay the Landlord's expenditure extends to irrecoverable VAT on that expenditure, and the Tenant shall also reimburse or
            pay such VAT;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Times New Roman,Times,serif; color: rgb(35, 35, 35); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 0%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Repair</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 3%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>4.4.1</b></font></td>
        <td style="text-align: justify; padding-right: 6.45pt; width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">To keep the Property (excluding the Centre) in good and substantial repair and
            condition (damage by any Uninsured Risk or by the Insured Risks excepted save to the extent that insurance moneys are irre</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">c</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">overable as a result of the act or default of the Tenant);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 3%;"></td>
        <td style="width: 5%; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);"><b>4</b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(82, 82, 82);">.</font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">4.2</font></b></td>
        <td style="width: 92%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">To make good any disrepair for which the T</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">e</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">nant is liable within 2 months after the date o</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">f </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">written notice from the Landlord (or sooner</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">i </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">f th</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">e </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">L</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">a</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">ndlord reasonably requires)</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 0px; margin-bottom: 0px;" align="LEFT">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">7</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;"><font style="font-family: Arial,Helvetica,sans-serif;">
        <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"></font></div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;"></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -34.55pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -34.55pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -34.55pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font> </p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif;"></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.4.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Tenant fails to comply with any such notice the Landlord may enter and carry out the work and the cost shall be
            reimbursed by the Tenant on demand as a debt;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.4.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To enter into maintenance contracts with reputable contractors for the regular servicing of all plant and equipment serving
            only the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Decoration</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.5.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To clean, prepare and paint or treat and generally redecorate:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 33.7pt;">(<font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">all external parts of the Property (excluding the Centre)</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">every third year and in the last year of the Term;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">all internal parts of the Property in every fifth year and in the last year of the Term;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.5.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">All the work described in Clause 4.5.1 is to be carried out:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">in a good and workmanlike manner to the Landlord's reasonable satisfaction; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">in colours which (if different from the existing colour) are first approved in writing by the
            Landlord (approval not to be unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Cleaning</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.6.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To keep the Property (excluding the Centre) clean, tidy and free from rubbish;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.95pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.6.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To clean the inside and outside of windows and any washable surfaces at the Property as often as reasonably necessary;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.7</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Overloading</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.7pt; text-indent: 0.05pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to overload the floors, ceilings or structure of the
      Property or any plant machinery or electrical installation serving the Property;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.7pt; text-indent: 0.05pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.8</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Conduits</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.5pt; text-indent: 0.05pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To keep the Conduits in or serving the Property clear and
      free from any noxious, harmful or deleterious substance, and to remove any obstruction and repair any damage to the Conduits as soon as reasonably practicable to the Landlord's reasonable satisfaction;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.5pt; text-indent: 0.05pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.9</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>User</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.9.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to use the Property otherwise than for the Permitted Use;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.55pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.9.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to use the Property for any purpose which is:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">noisy, offensive, dangerous, illegal, immoral or an actionable nuisance; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">which in the reasonable opinion of the Landlord causes damage or disturbance to the Landlord, or to
            owners or occupiers of any neighbouring property; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">which involves any substance which may be harmful, polluting or contaminating other than in
            quantities which are normal for and used in connection with the Permitted Use;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.10</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Signs</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.35pt; text-indent: 0.2pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to erect any sign, notice or advertisement which is
      visible outside the Property without the Landlord's prior written consent;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.35pt; text-indent: 0.2pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.11</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Alterations</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>4.11.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Not to make any alterations or additions</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">which:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.2pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">affect the structural integrity of the Property (including without limitation the roofs and
            foundations and the principal or load-bearing walls, floors, beams and columns);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.9pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">affect the external appearance of the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.11.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to make any other alterations or additions to the Property without the Landlord's written consent (which is not to be
            unreasonably withheld or delayed) save that the Tenant may install or demount internal, non-structural partitioning without the consent</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> <br>
    </font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> </font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div><br>
  </div>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">8 <br>
    </font></p>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 126.65pt; text-indent: 0.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">of the Landlord provided plans showing the extent of such
      works are deposited with the Landlord promptly on completion of the works;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 126.65pt; text-indent: 0.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.12</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Preservation of Easements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.12.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to prejudice the acquisition of any right of light for the benefit of the Property and to preserve all rights of light
            and other easements enjoyed by the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.12.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Promptly to give the Landlord notice if any easement enjoyed by the Property is obstructed, or any new easement affecting the
            Property is made or attempted;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 5%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.13</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Alienation</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.95pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.13.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">assign, charge, underlet or part with possession of the whole or part only of the Property nor to
            agree to do so except by an assignment or underletting or charging of the whole of the Property or an underletting of a Subletting Unit permitted by this Clause 4.13;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">share the possession or occupation of the whole or any part of the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">assign, part with or share any of the benefits or burdens of this lease, or any interest derived from
            it by a virtual assignment or other similar arrangement;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.13.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Charging</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125.8pt; text-indent: -0.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to charge the whole of the Property without the
      Landlord's written consent (not to be unreasonably withheld or delayed).</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125.8pt; text-indent: -0.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.13.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Assignment</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 128.55pt; text-indent: -0.05pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to assign or agree to assign the whole of the
      Property without the Landlord's written consent (not to be unreasonably withheld or delayed), provided that:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 128.55pt; text-indent: -0.05pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(1)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the Landlord may withhold consent in circumstances where in the reasonable opinion of the Landlord</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 160.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the proposed assignee is not of sufficient financial standing to enable it to comply with the
            Tenant's covenants in this lease; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 160.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">such persons as the Landlord reasonably requires do not act as guarantors for the assignee and do not
            enter into direct covenants with the Landlord including the provisions set out in the Third Schedule (but referring in paragraph 1.2 to the assignee);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 125.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the Landlord's consent shall in every case be subject to conditions (unless expressly excluded)
            requiring that:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 165.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the assignee covenants with the Landlord to pay the rents and observe and perform the Tenant's
            covenants in this lease during the residue of the Term, or until released pursuant to the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 165.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(b)</font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the Tenant enters into an authorised guarantee agreement guaranteeing the
            performance of the Tenant's covenants in this lease by the assignee including the provisions set out in paragraphs 1-5 (inclusive) of the Third Schedule (but omitting paragraph 1.2);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 163.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(c)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">all rent and other payments due under this lease are paid before completion of the assignment;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 91.75pt;"></td>
        <td style="width: 34pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);"><b>4.13.4</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>Underletting</b></font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.2pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 123.85pt; text-indent: 0.35pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to underlet or agree to underlet the whole of the
      Property or a Subletting Unit nor vary the terms of any underlease without the Landlord's written consent (not to be unreasonably withheld or delayed). Any permitted underletting must comply with the following:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 123.85pt; text-indent: 0.35pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the rent payable under the underlease must be:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 163.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.45pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">not less than the rent reasonably obtainable</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the open market for the Property or the Subletting Unit without fine
            or premium;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div><br>
  </div>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px; text-align: center;">9<font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><br>
    </font></p>
  <div style="font-family: 'Times New Roman',Times,serif;"> <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 169.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">payable no more than one quarter in advance;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 169.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(c)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">subject to upward only reviews at intervals no less frequent than the rent reviews under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 130.35pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the undertenant covenants with the Landlord and in the underlease:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 168.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">either:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 193.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 32.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(I)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to observe and perform the Tenant's covenants in this lease (except for payment of the rents) during
            the term of the underlease or until released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 194.2pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 32.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(II)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to observe and perform the Tenant's covenants in the underlease during the term of the underlease or
            until released pursuant to the 1995 Act</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 168.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(b)</font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">not to underlet, share or part with possession or occupation of the whole or any
            part of the underlet premises, nor to assign or charge part only of the underlet premises;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 168.35pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(c)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">not to assign the whole of the underlet premises without the Landlord's prior written consent (which
            shall not be unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 129.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.5pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">all rents and other payments due under this lease (not the subject of a bona fide dispute) are paid
            before completion of the underletting;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iv)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">in relation to any Subletting Unit Sections 24 to 28 of the 1954 Act must be excluded and before
            completion of the underletting a certified copy of each of the following documents must be supplied to the Landlord:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 167.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the notice served on the proposed undertenant pursuant to section 38A(3)(a) of the 1954 Act; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 168.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(b)</font></td>
        <td style="text-align: left; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the declaration actually made by the proposed undertenant in compliance with the
            requirements of Schedule 2 of the 2003 Order; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 168.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(c)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">the proposed form of underlease containing an agreement to exclude the provisions of sections 24 to
            28 of the 1954 Act and a reference to both the notice pursuant to section 38A(3)(a) of the 1954 Act and the declaration pursuant to the requirements of Schedule 2 of the 2003 Order as referred to in this clause 4.13.3;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 2.25in; text-indent: 0.35pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">and before completion of the underletting the Tenant must
      warrant to the Landlord that both the notice pursuant to section 38A(3)(a) of the 1954 Act has been served on the relevant persons as required by the 1954 Act and the appropriate declaration pursuant to the requirements of Schedule 2 of the 2003
      Order as referred to in this clause 4.13.3 has been made prior to the date on which the Tenant and the proposed undertenant became contractually bound to enter into the tenancy to which the said notice applies;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 2.25in; text-indent: 0.35pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(v)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">in relation to any Subletting Unit the underlease grants such rights as are appropriate for the
            separate occupation and use of the Subletting Unit, reserves such rights as are appropriate for the separate occupation and use of the remainder of the property let by this lease and to enable the Tenant to comply with its obligations under
            this lease, and reserves as rent:-</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 166.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">a fair proportion of the cost of insuring the Property and the whole cost of insuring the loss of the principal rent and
            service charge payable under the underlease; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 166.2pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.9pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">a service charge which provides for the undertenant to pay a fair and reasonable proportion of expenditure incurred by the
            Tenant in relation to the maintenance, repair, renewal, decoration and cleaning of the Property (including without limitation the Conduits, plant and equipment therein) and the provision of services to the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> <br>
    </font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> 10</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(vi)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">there shall be no more than four (4) units of occupation at any time and no more than two (2) units
            of occupation on a single floor (and for this purpose a unit of occupation shall comprise (a) each Subletting Unit which is separately underlet and (b) the residue of the net lettable area of the Property (if any) retained by the Tenant);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.45pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(vii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">(in the case of an underletting of the whole of the Property) the underlease reserves as rent the
            Service Charge payable under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 32.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(viii)</font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">(in the case of an underletting of a Subletting Unit) the underlease reserves as
            rent a fair and reasonable proportion of the Service Charge payable under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(ix)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">if the Subletting Unit comprises less than a whole floor of the Property then unless the underletting
            either:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 165.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.55pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">contains a covenant on the part of the undertenant to observe and perform the Tenant's covenants in
            this lease (except for payment of the rents) during the term of the underlease or untfl released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 164.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">is on terms obliging the undertenant to take a lease of the whole of the Property for the unexpired
            residue of the term of this lease (less one day) on the same terms as those contained in this lease (including as to rents and rent review) in the event of the immediate reversion to such underlease becoming vested in the Landlord</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 159.7pt; text-indent: 0.45pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the underlease shall contain a break exercisable by the
      landlord on three (3) months' notice in the event of the immediate reversion thereto becoming vested in the Landlord;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 159.7pt; text-indent: 0.45pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(x)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the underlease is in a form approved by the Landlord (such approval not to be unreasonably withheld
            or delayed)</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 88.95pt;"></td>
        <td style="width: 34.65pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.13.5</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To take all necessary steps and proceedings to remedy any breach of the covenants of the undertenant under the underlease and not to permit any reduction of the rent
            payable by any undertenant;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125.1pt; text-indent: -34.15pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 88.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.1</b></font><b>3.6</b></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Group Sharing</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125.1pt; text-indent: -0.1pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Notwithstanding Clause 4.13.1 the Tenant may share
      occupation of the whole or any part of the Property with a Group Company;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125.1pt; text-indent: -0.1pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">PROVIDED THAT</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 125pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 125.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the relationship of landlord and tenant is not created; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 125.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.35pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">occupation by any Group Company shall cease upon it ceasing to be a Group Company; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(c)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Tenant informs the Landlord in writing before each occupier commences occupation and after it
            ceases occupation;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.14</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Registration</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.25pt; text-indent: 0.25pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Within 21 days to give to the Landlord's solicitors (or as
      the Landlord may direct) written notice of any assignment, charge, underlease or other devolution of the Property or a Subletting Unit together with a certified copy of the relevant document and a reasonable registration fee of not less than &#163;50;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.25pt; text-indent: 0.25pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.15</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Statutory Requirements and Notices</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 88.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.15.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To supply the Landlord with a copy of any notice, order or certificate or proposal for any notice order or certificate
            affecting or capable of affecting the Property as soon as it is received by or comes to the notice of the Tenant;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 89.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.15.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To comply promptly with all notices served by any public, local or statutory authority, and with the requirements of any
            present or future statute or European Union law, regulation or directive (whether imposed on the owner or occupier), which affects the Property or its use;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> </font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> <br>
    </font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> 11</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 92.65pt;"></td>
        <td style="width: 34.05pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.15.3</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">At the request of the Landlord, but at the joint cost of the Landlord and the Tenant, to make or join the Landlord in making such objections or representations against or
            in respect of any such notice, order or certificate as the Landlord may reasonably require;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 127.45pt; text-indent: -34.15pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.15.4 </b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> To observe and perform the obligations of any agreement entered into prior to the date <i>of </i>this lease under any
            statute or European Union law, regulation or directive so far as the same relates to the use and/or occupation of the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.16</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Planning</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.16.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to apply for or implement any planning permission affecting the Property without first obtaining the Landlord's written
            consent (not to be unreasonably withheld or delayed in cases where the subject matter <i>of </i>the planning permission has been approved by the Landlord pursuant to the other provisions of this lease);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.16.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If a planning permission is implemented the Tenant shall complete all the works permitted and comply with all the conditions
            imposed by the permission before the determination of the Term (including any works stipulated to be carried out by a date after the determination <i>of </i>the Term unless the Landlord requires otherwise);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.17</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Contaminants and Defects</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.17.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To give the Landlord prompt written notice upon becoming aware of the existence of any defect in the Property, or of the
            existence of any contaminant, pollutant or harmful substance on the Property but not used in the ordinary course of the Tenant's use of the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.17</b></font><b>.2</b></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> If so requested by the Landlord, to remove from the Property or remedy to the Landlord's reasonable satisfaction any such
            contaminant, pollutant or harmful substance introduced on the Property by or at the request of the Tenant;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Entry by Landlord</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.15pt; text-indent: -0.1pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To permit the Landlord at all reasonable times and on
      reasonable notice (which shall not be less than 72 hours' notice except in emergency) to enter the Property in order to:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.15pt; text-indent: -0.1pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.95pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">inspect and record the condition of the Property or the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">remedy any breach of the Tenant's obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 90.95pt;"></td>
        <td style="width: 34.15pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18.3</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">repair, maintain, clean, alter, replace, install, add to or connect up to any Conduits which serve the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 124.95pt; text-indent: -34.1pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">repair, maintain, alter or rebuild the Centre or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.18.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">comply with any of its obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.95pt; text-indent: -0.15pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Provided that the Landlord shall only exercise such
      rights where necessary and shall cause as little inconvenience as reasonably practicable in the exercise of such rights and shall promptly make good all physical damage to the Property caused by such entry;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.95pt; text-indent: -0.15pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.19</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landlord's Costs</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.7pt; text-indent: -0.1pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To pay to the Landlord on demand amounts equal to such
      Costs as it may properly and reasonably incur:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.7pt; text-indent: -0.1pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 91.15pt;"></td>
        <td style="width: 33.95pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.19.1</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">in connection with any application for consent made necessary by this lease (including where consent is lawfully refused or the application is withdrawn);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 123.75pt; text-indent: -34.35pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 91.15pt;"></td>
        <td style="width: 33.95pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.19.2</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">incidental to or in reasonable contemplation of the preparation and service of a schedule of dilapidations (whether before or within three (3) months after the end <i>of </i>the







            Term) or a notice or proceedings under Section 146 or Section 147 of the Law of Property Act 1925 (even if forfeiture is avoided other than by relief granted by the Court);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 123pt; text-indent: -33.6pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.95pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.19</b></font><b>.3</b></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"> in connection with the enforcement or remedying <i>of </i>any breach of the covenants in this lease on the part of the
            Tenant and any Guarantor;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 91.15pt;"></td>
        <td style="width: 33.95pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.19.4</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">incidental to or in reasonable contemplation of the preparation and service of any notice under Section 17 of the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 1.7in; text-indent: -33.75pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div><br>
    </div>
    <font style="font-family: Arial,Helvetica,'sans-serif';">12</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.20</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Yielding up</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.7pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Immediately before the end of the Term:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.7pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.35pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to give up the Property repaired and decorated and otherwise in accordance with the Tenant's
            covenants in this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.95pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">if the Landlord so requires, to remove all alterations made during the Term or any preceding period
            of occupation by the Tenant and reinstate the Property in accordance with the Building Specification, as the Landlord shall reasonably direct and to its reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to remove all signs, tenant's fixtures and fittings and other goods from the Property, and make good
            any damage caused thereby to the Landlord's reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iv)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to replace any damaged or missing Landlord's fixtures with ones of no less quality and value;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(v)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to replace all carpets with ones of no less quality and value than those in the Property at the start
            of the Contractual Term;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.3pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(vi)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to give to the Landlord all operating and maintenance manuals together with any health and safety
            files relating to the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(vii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to provide evidence of satisfactory condition and maintenance of plant and machinery including
            (without limitation) electrical installation condition reports in respect of all of the electrical circuits and supply equipment in the Property, and any other condition reports as required under any relevant statute or European Union law,
            regulation or directive and copies of all service records;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(viii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">to return any security cards or passes provided by the Landlord for use by the Tenant and its
            visitors.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.21</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Encumbrances</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.75pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To perform and observe the Encumbrances so far as they relate to the Property.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.75pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.22</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Roads Etc</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.3pt; text-indent: 1.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Not to obstruct the roads, pavements, footpaths and
      forecourt areas from time to time on the Estate in any way whatsoever and not to use any part of the forecourts and car parking spaces or other open parts of the Property for the purpose of storage or deposit of any materials, goods, container ships'
      pallets, refuse, waste scrap or any other material or matter.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.3pt; text-indent: 1.15pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.23</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Parking Restrictions</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.95pt; text-align: justify; text-indent: 0.9pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Except as to any right specifically
      granted in this lease not to permit any vehicles belonging to or calling upon the Tenant to stand on the roads, car parking soaces. forecourts, pavements or footpaths on the Estate.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.95pt; text-align: justify; text-indent: 0.9pt; color: rgb(28, 28, 28);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.24</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Regulations etc</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.2pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.24.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">At all times during the Term to observe and perform such regulations (if any) in respect of the Centre or the Estate as the
            Landlord may reasonably think expedient to the proper management of the Centre or the Estate and which are notified to the Tenant.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 89.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 35.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>4.24.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Not to cause any obstruction to any part of the Centre or the Estate.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.25</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Land Registration Provisions</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(28, 28, 28);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.25.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Promptly following the grant of this lease the Tenant shall apply to register this lease at the Land Registry and shall
            ensure that any requisitions raised by the Land Registry in connection with that application are dealt with promptly and properly and within one month after completion of the registration, the Tenant shall send the Landlord official copies of
            its title;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.55pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>4.25.2</b></font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Immediately after the end of the Term (and notwithstanding that the Term has
            ended), the Tenant shall make an application to close the registered title of this lease and shall ensure that any requisitions raised by the Land Registry in connection with that</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div><br>
    </div>
    <font style="font-family: Arial,Helvetica,'sans-serif';">13</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 128.15pt; text-indent: 0.3pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">application are dealt with promptly and properly and the
      Tenant shall keep the Landlord informed of the progress and completion of its application.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 128.15pt; text-indent: 0.3pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.26</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Bank Guarantee</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.75pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If, pursuant to the Agreement for Lease, the Bank Guarantee shall have been
      completed the Tenant shall procure that:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.75pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.26.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Bank Guarantee shall be maintained in force on its current terms until such time as the earlier of whichever of the
            following events set out in this sub-clause 4.26.1 shall first occur:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the liability of the giver of the Bank Guarantee shall end</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">accordance with the terms of clause 3 of the Bank Guarantee; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 128.45pt;"></td>
        <td style="width: 33.65pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">at least one of the Release Tests shall have been satisfied;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 128.25pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 32.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>4.26.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">if, at any time prior to the Bank Guarantee no longer requiring to be maintained </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">force pursuant to sub-clause 4.26.1, any payment
            shall be made to the Landlord under the Bank Guarantee (or under any guarantee substituted for or additional to it) an additional guarantee will be procured from a Clearing Bank on the same terms, mutatis mutandls, as the Bank Guarantee and
            providing (when aggregated with the Bank Guarantee) a guarantee to the Landlord for a maximum sum calculated in accordance with clause 1.1 of the Agreement for Lease) and any additional guarantee required pursuant to this sub-clause 4.26.2
            shall be maintained in force until such time as the earlier of whichever of the following events set out in this sub-clause 4.26.2 shall first occur:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the liability of the giver of the additional guarantee shall end in accordance with the terms
            required to be incorporated in the additional guarantee; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">at least one of the Release Tests shall have been satisfied.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.26.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant may at any time substitute the Bank Guarantee with the Rent Security Deposit Deed provided that the Bank Guarantee
            shall not be terminated until the Rent Security Deposit shall have been completed; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.2pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.26.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Forthwith upon completion of the Rent Security Deposit Deed in the circumstances set out in sub-clause 4.26.3 the Bank
            Guarantee shall be terminated and the original Bank Guarantee shall be returned to the Nominated Bank with notice in writing to the Nominated Bank that the Bank Guarantee may be cancelled.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.27</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Rent Security Deposit Deed</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.4pt; text-indent: 0.15pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If, pursuant to the Agreement for Lease, the Rent Security
      Deposit Deed shall have been completed the Tenant shall procure that:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.4pt; text-indent: 0.15pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.35pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.27.1</b></font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Rent Security Deposit Deed shall be maintained in force on its current terms until such time as the
            Rent Security Deposit Deed shall end in accordance with the terms of clause 8 of the Rent Security Deposit Deed;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.27.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant may at any time substitute the Rent Security Deposit Deed with the Bank Guarantee provided that the Rent Security
            Deposit Deed shall not be terminated until the Bank Guarantee shall have been completed; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.27.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Forthwith upon completion of the Bank Guarantee in the circumstances set out in sub-clause 4.27.2 the Rent Security Deposit
            Deed shall be terminated and the Deposit or such part thereof as shall be remaining shall be repaid to the Tenant.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 56.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landlord's Covenants</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 56.55pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Quiet Enjoyment</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.05pt; text-indent: 0.55pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord covenants with the Tenant that the Tenant may
      peaceably enjoy the Property during the Term without any interruption by the Landlord or any person lawfully claiming under or in trust for it.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.05pt; text-indent: 0.55pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(54, 54, 54);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 55.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Provision of Services</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.65pt; text-indent: 0.2pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord will use its reasonable endeavours to provide
      or procure the provision of the Services PROVIDED THAT the Landlord shall be entitled to withhold or vary the provision or</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.65pt; text-indent: 0.2pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><br>
    <font style="font-family: Arial,Helvetica,'sans-serif';">14</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.85pt; text-align: justify; text-indent: 0.2pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">procurement of such of the Services as
      the Landlord considers necessary or appropriate in the interests of good estate management and PROVIDED FURTHER THAT the Landlord will not be in breach of this Clause as a result of any failure or interruption of any of the Services:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.85pt; text-align: justify; text-indent: 0.2pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.9pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5.2.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">resulting from circumstances beyond the Landlord's reasonable control, so long as the Landlord uses its reasonable endeavours
            to remedy the same as soon as reasonably practicable after becoming aware of such circumstances; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.7pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(45, 45, 45);"><b>5.2.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">to the extent that the Services (or any of them) cannot reasonably be provided as a result of works
            of inspection, maintenance and repair or other works being carried out at the Property or the Centre or the Estate.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landlord's insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.6pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord covenants with the Tenant as follows:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.6pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To insure the Property (other than tenant's and trade fixtures and fittings) unless the insurance is invalidated in whole or
            in part by any act or default of the Tenant:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">with an insurance office or underwriters of repute;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">against loss or damage by the Insured Risks;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">subject to such excesses as may be imposed by the insurers;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 126.3pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(iv)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">in the full cost of reinstatement of the Property (in modern form if appropriate) including shoring
            up, demolition and site clearance, professional fees, VAT and allowance for building cost increases;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.55pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To insure against loss of the Principal Rent thereon payable or reasonably estimated by the Landlord to be payable under this
            lease arising from damage to the Property by the Insured Risks for three years or such longer period as the Landlord may reasonably require having regard to the likely period for reinstating the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 33.55pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord will use its reasonable endeavours to procure that the insurer waives its rights of subrogation against the
            Tenant (so long as such provision is available in the London insurance market) and to ensure that the Tenant's interest is noted on such policy (which may be by way of the policy providing for a general noting of the interests of tenants);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">At the request and cost of the Tenant (but not more frequently than once in any twelve month period) to produce summary
            details of the terms of the insurance under this Clause 6.1;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b> </b>To notify the Tenant as soon as becoming aware of any material change in the terms and conditions of the insurer in
            relation to the policy under which the Property is for the time being insured;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.15pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1.6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Property is destroyed or damaged by an Insured Risk, then, unless payment of the insurance moneys is refused in whole
            or part because of the act or default of the Tenant, and subject to obtaining all necessary planning and other consents to use the insurance proceeds (except those relating to loss of rent and fees) and any uninsured excess paid by the Tenant
            under Clause 6.2.4(ii) in reinstating the same (other than tenant's and trade fixtures and fittings) as quickly as reasonably practicable substantially as it was before the destruction or damage in modern form if appropriate but not necessarily
            identical in layout</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(45, 45, 45);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant's insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.3pt; text-indent: -0.4pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant covenants with the Landlord from and including
      the Insurance Commencement Date and then throughout the Term or until released pursuant to the 1995 Act as follows:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 89.3pt; text-indent: -0.4pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 89.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To pay to the Landlord on demand sums equal to:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 123.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.35pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">the amount which the Landlord spends on insurance pursuant to Clause 6.1;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">the cost of property owners' liability and third party liability insurance </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">connection with the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div><br>
    </div>
    <font style="font-family: Arial,Helvetica,'sans-serif';">15</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 130.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.35pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the cost of any professional valuation of the Property properly required by the landlord (but not more than once in any two
            year period);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To give the Landlord immediate written notice on becoming aware of any event or circumstance which might affect or lead to an
            insurance claim;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 96.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);"><b>6.2.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Not to do anything at the Property which would or might prejudice or invalidate the insurance of the
            Property or the Adjoining Property or cause any premium for their insurance to be increased;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 96.1pt;"></td>
        <td style="width: 33.4pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2.4</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To pay to the Landlord on demand:</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 95.3pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 130.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">any increased premium and any Costs incurred by the Landlord as a result of a breach of Clause 6.2.3;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 129.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.9pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">any uninsured excess to which the insurance policy may be subject;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 130.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.35pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">the whole of the irrecoverable proportion of the insurance moneys if the Property or any part are
            destroyed or damaged by an Insured Risk but the insurance moneys are irrecoverable in whole or part due to the act or default of the Tenant;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To comply with the requirements and reasonable recommendations of the insurers;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2.6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To notify the Landlord of the full reinstatement cost of any fixtures and fittings installed at the Property at the cost of
            the Tenant which become Landlord's fixtures and fittings;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.3pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.5pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>6.2.7</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Not to effect any insurance of the Property against an Insured Risk but if the Tenant effects or has
            the benefit of any such insurance the Tenant shall hold any insurance moneys upon trust for </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);">t</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">he Landlord and pay the same to the Landlord as soon as practicable;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Suspension of Rent</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.85pt; text-indent: 0.15pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Property is unfit for occupation and use because of
      damage by an Insured Risk then (save to the extent that payment of the loss of rent insurance moneys is refused due to the act or default of the Tenant) the Principal Rent (or a fair proportion according to the nature and extent of the damage) shall
      be suspended until the date on which the Property is again fit for occupation and use.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.85pt; text-indent: 0.15pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Determination Right</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.4.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Property is destroyed or damaged by an Insured Risk such that the Property is unfit for occupation and use and shall
            not be rendered fit for occupation and use within two years and nine months of the date of such damage then either the Landlord or the Tenant may whilst the Property has not been rendered fit for occupation and use terminate the Contractual
            Term by giving to the other not less than three (3) months' previous notice in writing. PROVIDED THAT if the Property has been rendered fit for occupation and use within three years of the date of such damage then such notice shall be deemed
            not to have been given.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.35pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.4.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Termination of this lease pursuant to the provisions of Clause 6.4.1 shall be without prejudice to the liability of either
            party for any antecedent breach of the covenants and conditions herein contained (save for Clause 6.1.6 which shall be deemed not to have applied).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(56, 56, 56);"><b>6.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>Uninsured Risks</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.2pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.5.1</b></font></td>
        <td style="text-align: left; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">For the purposes of this Clause 6.5:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">These provisions shall apply from the date on which any Insured Risk becomes an Uninsured Risk but
            only in relation to the Uninsured Risk;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">References to an Insured Risk becoming an Uninsured Risk shall, without limitation, include the
            application by insurers of an exclusion, condition or limitation to an Insured Risk to the extent to which such risk thereby is or becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.2pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The Landlord shall notify the Tenant in writing as soon as reasonably practicable after an Insured
            Risk becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> <br>
    </font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> 16</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.2pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>6.5.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">If during the Term the Property (or part thereof) shall be damaged or destroyed by an Uninsured Risk
            so as to make the Property (or part therefore) unfit for occupation or use:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.65pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.2pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The Principal Rent and the Service Charge or a fair proportion according to the
            nature and extent of the damage sustained will not be payable until the earlier of the date on which:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 165.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 27.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(a)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The Property shall again be fit for occupation and use excluding fitting out and replacement of
            contents; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 165pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 28.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(b)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">This lease shall be terminated in accordance with Clause 6.5.2(ii) or 6.5.5</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 127.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The Landlord may within one year of the date of such damage or destruction serve notice on the Tenant
            confirming that it will reinstate the Property (a 'Reinstatement Notice') so that the Property shall be fit for occupation and use and if the Landlord fails to serve a Reinstatement Notice by the expiry of such prescribed period the lease will
            automatically end on the date one year after the date of such damage or destruction.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.3pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>6.5.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Clause 6.5.2(i) shall not apply if an Insured Risk shall have become an Uninsured Risk owing to the
            act or default of the Tenant or any person deriving title under the Tenant or their respective agents, employees, licensee, invitees or contractors.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.5.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord shall have served a Reinstatement Notice the provisions of Clause 6.1.6 shall apply as if the damage had been
            caused by an Insured Risk</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 92.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.5.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord shall have served a Reinstatement Notice and such reinstatement has not been completed by the date two years
            and nine months of the date of such damage at any time after that date the Landlord or the Tenant may terminate this lease by serving not less than three months' notice on the other stating that it terminates this lease, and if by the end of
            such notice the Property has been reinstated so that the Property is fit for occupation and use the notice shall be void and this lease shall continue in full force and effect.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.5.6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Service of a Reinstatement Notice shall not oblige the Landlord to replace any Tenant's fitting out works or property
            belonging to the Tenant or any third party.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>7</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>Provisos</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>7.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>Forfeiture</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.4pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If any of the following events occur:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 90.4pt; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 91.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.1.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant fails to pay any of the rents payable under this lease within 21 days of the due date (whether or not formally
            demanded); or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.3pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.5pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.1.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant or Guarantor breaches any of its obligations in this lease; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 90.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.1pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.1.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant or Guarantor being a company incorporated within the United Kingdom</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.4pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">has an Administration Order made in respect of it; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.4pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">passes a resolution, or the Court makes an Order, for the winding up of the Tenant or the Guarantor,
            otherwise than a member's voluntary winding up of a solvent company for the purpose of amalgamation or reconstruction previously consented to by the Landlord (consent not to be unreasonably withheld); or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 124.1pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">has a receiver or administrative receiver or receiver and manager appointed over the whole or any
            part of its assets or undertaking; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 123.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(iv)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">is struck off the Register of Companies; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 123.75pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.75pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">(v)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">is deemed unable to pay its debts within the meaning of Section 123 of the Insolvency Act 1986; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 89.5pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.65pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.1.4</b></font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">proceedings or events analogous to those described in Clause 7.1.3 shall be instituted or shall occur
            where the Tenant or Guarantor is a company incorporated outside the United Kingdom; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 88.85pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.05pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.1.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant or Guarantor being an individual:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> </font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> <br>
    </font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> 17</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 129.9pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.6pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">has a bankruptcy order made against him; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 130.25pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.3pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">appears to be unable to pay his debts within the meaning of Section 268 of the Insolvency Act 1986;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 94.6pt; text-indent: 0.15pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">then the Landlord may re-enter the Property or any part of
      the Property in the name of the whole and forfeit this lease and the Term created by this lease shall immediately end, but without prejudice to the rights of either party against the other in respect of any breach of the obligations contained in this
      lease;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 94.6pt; text-indent: 0.15pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);"><b>7.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Notices</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.8pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.2.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">All notices under or in connection with this lease shall be given in writing;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 95.05pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 33.8pt;"><b>7<font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">.2.2</font></b></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any such notice shall be duly and validly served if it is served (in the case of a company) to its registered office or (in
            the case of an individual) to his last known address;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 94.6pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7.2.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any such notice shall be deemed to be given when it is:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.95pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 33.85pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(i)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">personally delivered to the locations listed in Clause 7.2.2; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 128.7pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.2pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">(ii)</font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">sent by registered post, in which case service shall be deemed to occur on the third Working Day
            after posting.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>7.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>No Implied Easements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.5pt; text-indent: 0.2pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The grant of this lease does not confer any rights over the
      Centre or the Estate or the Adjoining Property or any other property except those mentioned in Part I of the First Schedule, and Section 62 of the Law of Property Act 1925 is excluded from this lease;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 93.5pt; text-indent: 0.2pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(47, 47, 47);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Break Clause</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" border="0" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant may terminate the Contractual Term on Break Date 1 or Break Date 2 or Break Date 3 by giving to the
            Landlord not less than twelve (12) months' previous notice in writing;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Any notice given by the Tenant shall operate to terminate the Contractual Term only if:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.8pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.15pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.2.1</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Principal Rent reserved by this lease has been paid by the time of such termination; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 93.45pt; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 34.25pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.2.2</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Tenant yields up the Property free from any subleases and other third party occupational
            interests on termination;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.3</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Upon termination the Contractual Term shall cease but without prejudice to any claim in
            respect of any prior breach of the obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.4</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Tenant does not terminate the Contractual Term on Break Date 1 the Principal Rent shall be suspended from
            the date falling immediately after Break Date 1 for a period of seventy six (76) days, after which period the Tenant's obligation to pay the Principal Rent shall resume;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.5</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">If the Tenant does not terminate the Contractual Term on Break Date 2 the Principal Rent
            shall be suspended from the date falling immediately after Break Date 2 for a period of seventy six (76) days, after which period the Tenant's obligation to pay the Principal Rent shall resume;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.6</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">If the Tenant does not terminate the Contractual Term on Break Date 3 the Principal Rent
            shall be suspended from the date falling immediately after Break Date 3 for a period of seventy six (76) days, after which period the Tenant's obligation to pay the Principal Rent shall resume;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.7</b></font></td>
        <td style="text-align: justify; font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">If the Tenant terminates this lease in accordance with this clause 8
            the Landlord shall promptly reimburse the Tenant in respect of any sums received under this lease which relate to a period following termination of this lease.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>8.8</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Time shall be of the essence for the purposes of this Clause.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Contracts (Rights of Third Parties) Act 1999</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.75pt; text-indent: 0.05pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">A person who is not a party to this lease has no right
      under the Contracts (Rights of Third Parties) Act 1999 to enforce any terms of this lease.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 91.75pt; text-indent: 0.05pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0%; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 3%; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>10</b></font></td>
        <td style="font: 10pt Arial,Helvetica,sans-serif; width: 97%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Environmental Conditions</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Arial,Helvetica,sans-serif; margin-right: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 92.9pt; text-indent: -0.25pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">For the purposes of this clause the expression
      'Environment' includes air, man-made structures and surface or substrata any surface water or ground water, any life form (including human) or</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px 0pt 92.9pt; text-indent: -0.25pt; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif;"></p>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;">
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"><font style="font-family: Arial,Helvetica,'sans-serif';"></font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';"> <br>
    </font></div>
  <div style="font-family: 'Times New Roman',Times,serif; text-align: center;"><font style="font-family: Arial,Helvetica,'sans-serif';">18</font><br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
  </div>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif;"></p>
  <title></title>
  <p style="margin: 0px; text-indent: 0px;"></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(52, 52, 52);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The First Schedule</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(52, 52, 52);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>Part </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">I </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(89, 89, 89);">- </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);">Easements and Other Rights granted</font></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; text-align: left; margin-bottom: 0px; color: rgb(29, 29, 29);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">There are granted to the Tenant (in common with
      others authorised by the Landlord)</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(29, 29, 29); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The right to use the relevant Estate Common Areas and the Centre Common Areas for
            access to and from the Property and for all purposes for which they are designed;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0in;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Free and uninterrupted use of all existing and future Conduits
            which serve the Property, subject to the Landlord&#8217;s rights to re-route the same subject to there being no unreasonable interruption of services;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The right to enter the Estate and/or the Adjoining Property excluding any
            buildings which are occupied as necessary to perform Clause 4.4 [repair] on reasonable prior written notice to the Landlord, subject to causing as little inconvenience as practicable and complying with conditions reasonably imposed by the
            Landlord and making good all physical damage caused.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(29, 29, 29); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Part II - Exceptions and Reservations</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(29, 29, 29); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(29, 29, 29); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">There are excepted and reserved to the Landlord (and others authorised by the
      Landlord):</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(29, 29, 29); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The right to carry out any building, rebuilding, alteration or other works to the
            Centre, the Estate and the Adjoining Property (including the erection of scaffolding) notwithstanding any temporary interference with light and air enjoyed by the Property but provided that the Tenant&#8217;s use and enjoyment of the Property is not
            materially compromised;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Free and uninterrupted use of all existing and future Conduits which are in the
            Property and serve the Centre, the Estate or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Rights of entry on the Property as referred to in Clause 4.18;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Rights of entry on the Centre in order to provide or procure the provision of the
            Services;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The right to use the Centre for access on foot to and from parts of the Estate
            not comprised in the Property;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The right to regulate and control in a reasonable manner the use of the Estate Common Areas;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The right to alter the layout of the roads forecourts footpaths pavements and car parking areas from time
            to time on the Estate in such manner as the Landlord may reasonably require PROVIDED THAT such alterations do not materially diminish the Tenant&#8217;s rights under this lease and that such works do not materially compromise the Tenant&#8217;s access to
            the Property;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>8</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The right in the last six months of the Term to view the Property with
            prospective tenants upon giving reasonable notice (not to be less than 72 hours) and the right throughout the Term to view the Property with prospective purchasers upon giving reasonable notice (not to be less than 72 hours).</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);"><b>Part Ill </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(89, 89, 89);">- </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">Encumbrances</font></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">The covenants declarations and other matters affecting the Property contained
      or referred to </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(1, 1, 1);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(29, 29, 29);">the Landlord&#8217;s freehold
      reversionary title number BK102078 as at the date of this lease</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">20</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(49, 49, 49); text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(49, 49, 49); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>The Second Schedule</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(49, 49, 49); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Rent Review</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">In this Schedule:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Review Date</b> means each of the Review Dates and <b>Relevant Review Date</b> shall be interpreted
            accordingly;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49); letter-spacing: -0.05pt;"><b>1.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Current Rent</b> means the Principal Rent payable under this lease immediately
            before the Relevant Review Date</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Index </b>means the Consumer Prices Index <b>(CPI) </b>published by the Office for National
            Statistics or (if not available) such index of comparative prices as the Landlord shall reasonably require;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Indexed Rent</b> means:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>Current </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Rent </font></b><font style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(31, 31, 31);">multiplied by (A/B) per annum where:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8);">A&#160;&#160;&#160;&#160;&#160;=</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(87, 87, 87);"></font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">The figure shown in the Index for the month immediately before the Relevant Review Date; and</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif; width: 40pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">B&#160;&#160;&#160;&#160;&#160;=</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(70, 70, 70);"></font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">(In the case of Review Date 1) the figure shown in the Index for November 2017 and (in the case of the subsequent Review Dates) the figure shown in the Index for the month immediately before the Preceding Review Date</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">PROVIDED THAT:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">At each of the Review Dates the maximum value of (A/B) shall be
      1.2166529 and the minimum </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8);">value of (A/B) shall be 1.0510101;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Preceding Review Date </b>means the Review Date next before the Relevant Review Date;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Revised Rent </b>means the new Principal Rent following each Review Date pursuant to paragraph 2 of
            the Second Schedule.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">The Principal Rent shall be reviewed on each Review Date to the higher of:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49); letter-spacing: -0.05pt;"><b>2.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Current Rent (disregarding any suspension or abatement of the Principal
            Rent); and</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49); letter-spacing: -0.05pt;"><b>2.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Indexed Rent ascertained in accordance with this lease;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8);">If a </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Revised Rent has not been ascertained by the Relevant Review Date:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>3.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Current Rent shall continue to be payable until the Revised Rent is ascertained;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49); letter-spacing: -0.05pt;"><b>3.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8);">when </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Revised Rent is ascertained:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt;">&#160;</td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>3.2.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Tenant shall pay within 14 days of ascertainment of the Revised Rent:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 80pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8); letter-spacing: -0.05pt;">(i)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">any difference between the Principal Rent payable </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);">immediately </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">before the Relevant Review Date and
            the Principal Rent which would have been payable had the Revised Rent been ascertained on the Relevant Review Date (the <b>Balancing Payment); </b>and</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 80pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(8, 8, 8); letter-spacing: -0.05pt;">(ii)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">interest on the Balancing Payment at Base Rate from the date or dates when the
            Balancing Payment or the relevant part or parts would have been payable had the Revised Rent been ascertained on the Relevant Review Date;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>3.2.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Landlord and Tenant shall sign and exchange a memorandum recording the amount
            of the Revised Rent.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(49, 49, 49);"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Time shall not be of the essence for the purposes of this Schedule.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;"> <br>
    </font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">21</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>The Third Schedule</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Guarantee</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Guarantor covenants with the Landlord as principal debtor:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">that throughout the Term or until the Tenant is released from its covenants pursuant to the 1995 Act:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant will pay the rents reserved by and perform its obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Guarantor will indemnify the Landlord on demand against all Costs arising from any default of the
            Tenant in paying the rents and performing its obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant (here meaning the Tenant so named in the Prescribed Clauses) will perform its obligations
            under any authorised guarantee agreement that it gives with respect to the performance of any of the covenants and conditions in this lease.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">The liability of the Guarantor shall not be affected by:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Any time given to the Tenant or any failure by the Landlord to enforce compliance
            with the Tenant&#8217;s covenants and obligations;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">The Landlord&#8217;s refusal to accept rent at a time when it would or might have been
            entitled to re-enter the Property;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Any variation of the terms of this lease;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Any change in the constitution, structure or powers of the Guarantor the Tenant
            or the Landlord or the administration, liquidation or bankruptcy of the Tenant or Guarantor;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Any act which is beyond the powers of the Tenant;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>2.6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">The surrender of part of the Property;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">Where two or more persons have guaranteed obligations of the Tenant the release
            of one or more of them shall not release the others</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);">.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">The Guarantor shall not be entitled to participate in any security held by the
            Landlord in respect of the Tenant&#8217;s obligations or stand in the Landlord&#8217;s place in respect of such security.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">If this lease is disclaimed, and if the Landlord within 6 months of the
            disclaimer requires in writing the Guarantor will enter into a new lease of the Property at the cost of the Guarantor on the terms of this lease (but as if this lease had continued and so that any outstanding matters relating to rent review or
            otherwise shall be determined as between the Landlord and the Guarantor) for the residue of the Contractual Term from and with effect from the date of the disclaimer.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54);"><b>6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">If this lease Is forfeited and if the Landlord within 6 months of the forfeiture
            requires in writing the Guarantor will (at the option of the Landlord):</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>6.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">enter into a new lease as in paragraph 5 above with effect from the date of the forfeiture; or</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(54, 54, 54); letter-spacing: -0.05pt;"><b>6.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(28, 28, 28);">pay to the Landlord on demand an amount equal to the moneys which would otherwise
            have been payable under this lease until the earlier of 6 months after the forfeiture and the date on which the Property is fully relet.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;"> <br>
    </font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">22</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(33, 33, 33); text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(33, 33, 33); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>The fourth Schedule</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(33, 33, 33); text-indent: 0px;"></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(33, 33, 33); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Service Charge</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(33, 33, 33); text-indent: 0px;"></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);"><b>Part </b>I </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(91, 91, 91);">- </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);"><b>Calculation and payment of the Service Charge</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);"><b>1</b></font></td>
        <td style="text-align: left; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(3, 3, 3);">In </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);">this Schedule unless the context otherwise requires:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Accounting Date </b>means 31 December in each year or such other date as the Landlord notifies in
            writing to the Tenant from time to time;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Accounting Year </b>means the period from but excluding one Accounting Date to and including the next
            Accounting Date;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Centre Service Cost</b> means all reasonable and proper costs and expenses paid or incurred by the
            Landlord in relation to the provision of the Centre Services (including irrecoverable VAT);</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estate Service Cost </b>means all reasonable and proper costs and expenses paid or incurred by the
            Landlord in relation to the provision of the Estate Services (including irrecoverable VAT);</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52); letter-spacing: -0.05pt;"><b>1.5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);"><b>Estimated Service Charge </b>means the Landlord&#8217;s Surveyor&#8217;s reasonable and
            proper estimate of the Service Charge for the Accounting Year notified in writing to the Tenant from time to time;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Service Cost </b>means the sum of the Centre Service Cost and the Estate Service Cost;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.7</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant&#8217;s Share of the Estate Service Cost</b> means a fair and reasonable proportion of the Estate
            Service Cost;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>1.8</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant&#8217;s Share of the Service Cost </b>means the sum of:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(33, 33, 33); margin-top: 0in; margin-bottom: 0in; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 40pt;"></td>
        <td style="width: 40pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.8.1</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Centre Service Cost; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(33, 33, 33); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; color: rgb(33, 33, 33); margin-top: 0in; margin-bottom: 0in; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; text-align: justify;">
        <td style="width: 40pt;"></td>
        <td style="width: 40pt; text-align: left;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.8.2</b></font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant&#8217;s Share of the Estate Service Cost.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(33, 33, 33); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>2</b></font></td>
        <td style="text-align: justify; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);">The Service Charge shall be the Tenant&#8217;s Share of the
            Service Cost in respect of each Accounting Year, and if only part of an Accounting Year falls within the Term the Service Charge shall be the Tenant&#8217;s Share of the Service Cost in respect of the relevant Accounting Year divided by 365 and
            multiplied by the number of days of the Accounting Year within the Term.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord shall have the right to adjust the Tenant&#8217;s Share of the Estate Service Cost from time to
            time to make reasonable allowances for differences in the services provided to or enjoyable by the other occupiers of the Estate.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant shall pay the Estimated Service Charge for each Accounting Year to the Landlord in advance by
            equal instalments on the Quarter Days, (the first payment for the period from and including the Service Charge Commencement Date to (but excluding) the next Quarter Day after the Service Charge Commencement Date to be made on the Service Charge
            Commencement Date); and</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>4.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord&#8217;s Surveyor does not notify an estimate of the Service Charge for any Accounting Year the
            Estimated Service Charge for the preceding Accounting Year shall apply; and</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52); letter-spacing: -0.05pt;"><b>4.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);">Any adjustment to the Estimated Service Charge after the start of an Accounting
            Year shall adjust the payments on the following Quarter Days equally.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);">As soon as practicable after the end of each Accounting Year the Landlord shall
            serve on the Tenant a summary of the Service Cost and a statement of the Service Charge certified by the Landlord&#8217;s Surveyor which shall be conclusive (save in the case of manifest error).</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(52, 52, 52);"><b>6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(33, 33, 33);">The difference between the Service Charge and the Estimated Service Charge for
            any Accounting Year (or part) shall be paid by the Tenant to the Landlord within fourteen days of the date of the statement for the Accounting Year, or allowed against the next Estimated Service Charge payment, or after the expiry of the Term
            refunded to the Tenant.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant shall be entitled by appointment within a reasonable time following service of the Service
            Charge statement to inspect the accounts maintained by the Landlord and the Landlord&#8217;s Surveyor relating to the Service Cost and supporting vouchers and receipts at such location as the Landlord reasonably directs.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(29, 29, 29);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">For the avoidance of doubt any cost charged as a Service Cost in respect of any element of the Estate
            Services or of the Centre Services shall not be charged as a Service Cost in respect of any other head of charge under which charges are made for services by the Landlord.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;"> <br>
    </font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">23</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; text-align: center; margin-bottom: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; text-align: center; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Part </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">II </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(93, 93, 93);">- </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);">Estate Services</font></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">In relation to the Estate the provision of the following services or the
      Costs incurred in relation to:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>The Common Areas</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Repairing, maintaining and (where appropriate) cleaning,
      lighting and (as necessary) altering renewing, rebuilding and reinstating the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Conduits</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The repair, maintenance and cleaning and (as necessary)
      replacement and renewal of all Conduits within the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Plant and machinery</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Hiring, operating, inspecting, servicing, overhauling,
      repairing, maintaining, cleaning, lighting and (as necessary) renewing or replacing any plant, machinery, apparatus and equipment from time to time within the Estate Common Areas or used for the provision of services to the Estate and the supply of
      all fuel and electricity for the same and any necessary maintenance contracts and insurance in respect thereof.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Signs</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Maintaining and (where appropriate) cleaning and lighting and
      (as necessary) renewing and replacing the signboards, all directional signs, fire regulation notices, advertisements, bollards, roundabouts and similar apparatus or works.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Maintaining, tending and cultivating and (as necessary)
      re-stocking any garden or grassed areas including replacing plants, shrubs and trees as necessary.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Common facilities</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Repairing maintaining and (as necessary) rebuilding as the case
      may be any party walls or fences, party structures, Conduits or other amenities and easements which may belong to or be capable of being used or enjoyed by the Estate in common with any land or buildings adjoining or neighbouring the Estate.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(66, 66, 66);"><b>7</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Security</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Installation, operation, maintenance, repair, replacement and
      renewal of closed circuit television systems and other security systems.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Outgoings</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any existing and future rates, taxes, charges, assessments and
      outgoings in respect of the Estate Common Areas or any part of them except tax (other than VAT) payable in respect of any dealing with or any receipt of income in respect of the Estate Common Areas.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Transport</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">The provision of a bus service to and from Didcot or such other
      transport and/or location </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">(if </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">any) deemed
      necessary by the Landlord.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>10</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Statutory requirements</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The cost of carrying out any further works (after the initial
      construction in accordance with statutory requirements) to the Estate Common Areas required to comply with any statute.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>11.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT)
            of any person properly employed or retained by the Landlord for or in connection with surveying or accounting functions or the performance of the Estate Services and any other duties in and about the Estate relating to the general management,
            administration, security, maintenance, protection and cleanliness of the Estate:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31); letter-spacing: -0.05pt;"><b>11.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Management costs fees and disbursements in respect of the Estate of 10% of the
            Estate Service Cost (excluding costs under this clause</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5); letter-spacing: -0.25pt;">11</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31); letter-spacing: -0.25pt;">.2).</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">24</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>11.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing staff in connection with the Estate Services and the general management, operation and security
            of the Estate and all other incidental expenditure including but not limited to:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif; width: 40pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">salaries, National Health Insurance, pension and other payments contributions and benefits;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">uniforms, special clothing, tools and other materials for the proper performance of the duties of any
            such staff;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">providing premises and accommodation and other facilities for staff.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>12</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Enforcement of Regulations</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The reasonable and proper costs and expenses incurred by the
      Landlord in enforcing the rules and regulations from time to time made pursuant to Clause 4.24 provided that the Landlord shall use all reasonable endeavours to recover such costs and expenses from the defaulting party and provided further that there
      shall be credited against the Estate Service Cost any such costs recovered.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>13</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Insurances</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>13.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Effecting such insurances (if any) as the Landlord may properly think fit in respect of the Estate Common
            Areas the plant, machinery, apparatus and equipment used in connection with the provision of the Estate Services (including without prejudice those referred to in paragraph 3 above) and any other liability of the Landlord to any person in
            respect of those items or in respect of the provision of the Estate Services.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>13.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Professional valuations for insurance purposes (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31); letter-spacing: -0.05pt;"><b>13.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Any uninsured excesses to </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">which </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">the Landlord&#8217;s insurance may be subject.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>14</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Generally</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any reasonable and proper costs (not referred to above) which
      the Landlord may incur in providing such other services and in carrying out such other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Estate.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>15</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Anticipated Expenditure</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Establishing and maintaining reserves to meet the future costs
      (as from time to time estimated by the Landlord&#8217;s Surveyor) of providing the Estate Services;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>16</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Borrowing</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The costs of borrowing any sums required for the provision of
      the Estate Services at normal commercial rates available in the open market or if any such sums are loaned by the Landlord or a Group Company of the Landlord interest at Base Rate.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>17</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">25</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>Part </b></font><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Ill </font></b><b><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">- Centre Services</font></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">In relation to the Centre, the provision of the following
      services or the Costs </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">incurred </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5);">in </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">relation to:</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Repairs to the Centre plant and equipment (including Conduits)</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Repair, renewal, decoration, cleaning and maintenance of the
      Conduits, plant and equipment (which are not the responsibility of the Tenant).</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Centre Common Areas</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;">(a)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Repair, renewal, decoration, cleaning, maintenance and lighting of the Centre Common Areas and other
            parts of the Centre;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5); letter-spacing: -0.05pt;">(b)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Providing signs, nameboards and other notices within the Centre.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Services</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Procuring water, electricity and sewerage services for the
      Centre Common Areas.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(31, 31, 31); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Maintaining, tending and cultivating and (as necessary)
      re-stocking any garden or grassed areas including replacing plants, shrubs and trees as necessary.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>5</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Fire Fighting and Security</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Provision, operation, repair, renewal, cleaning and maintenance
      of fire alarms, sprinkler systems, fire prevention and fire-fighting equipment and ancillary apparatus and security alarms, apparatus, closed circuit television and systems as the Landlord considers appropriate.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);"><b>6</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>6.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Effecting such insurances (if any) as the Landlord may properly think fit in respect of the Centre Common
            Areas and all Landlord&#8217;s plant, machinery, apparatus and equipment and any other liability of the Landlord to any person in respect of those items or in respect of the provision of the Centre Services;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>6.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Professional valuations for insurance purposes (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>6.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any uninsured excesses to which the Landlord&#8217;s insurance may be subject.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="text-align: left; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Statutory Requirements</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">All existing and future rates, taxes, charges, assessments and
      outgoings payable to any competent authority for or in connection with utilities.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px; color: rgb(31, 31, 31);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="text-align: left; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; letter-spacing: -0.05pt;"><b>8.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT)
            of any person properly employed or retained by the Landlord for or in connection with surveying or accounting functions or the performance of the Centre Services and any other duties in and about the Centre relating to the general management,
            administration, security, maintenance, protection and cleanliness of the Centre:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47); letter-spacing: -0.05pt;"><b>8.2</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Management fees and disbursements incurred in respect of the Centre of 10% of the
            Centre Service Cost (excluding costs under this paragraph 8.2).</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47); letter-spacing: -0.05pt;"><b>8.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Providing staff in connection with the Centre Services and the general
            management, operation and security of the Centre and all other incidental expenditure including but not limited to:</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5); letter-spacing: -0.05pt;">(i)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">salaries, National Health Insurance, pension and other payments contributions and
            benefits;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5); letter-spacing: -0.05pt;">(ii)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">uniforms, special clothing, tools and other materials for the proper performance
            of the duties of any such staff;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(5, 5, 5); letter-spacing: -0.05pt;">(iii)</font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">providing premises and accommodation and other facilities for staff.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9</b></font></td>
        <td style="text-align: left; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>General</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31); letter-spacing: -0.05pt;"><b>9.1</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Establishing </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">and </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">maintaining reserves</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">to meet the future costs (as from time to time estimated</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">by the Landlord&#8217;s </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">Surveyor) </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">of providing </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">the </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(31, 31, 31);">Centre </font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(47, 47, 47);">Services;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">26</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61); letter-spacing: -0.05pt;"><b>9.2</b></font></td>
        <td style="text-align: left; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(36, 36, 36);">Any reasonable and proper costs (not referred to above) which
            the Landlord may incur in providing such other services and in carrying out such other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Centre;</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(36, 36, 36); letter-spacing: -0.05pt;"><b>9.3</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(36, 36, 36);">The costs of borrowing any sums required for the provision of the Centre Services
            at normal commercial rates available in the open market or if any such sums are loaned by the Landlord or a Group Company of the Landlord interest a</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(61, 61, 61);">t Base</font> <font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(36, 36, 36);">Rate.</font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(31, 31, 31);" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top; font: 10pt Arial,Helvetica,sans-serif;">
        <td style="width: 0pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"></td>
        <td style="width: 40pt; padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>10</b></font></td>
        <td style="padding-right: 0px; font: 10pt Arial,Helvetica,sans-serif;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin: 0px; font: 10pt Arial,Helvetica,sans-serif; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 40pt; color: rgb(36, 36, 36); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(36, 36, 36); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(36, 36, 36); text-indent: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(36, 36, 36); text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; color: rgb(36, 36, 36); text-indent: 0px; text-align: center;"><font style="font: 10pt Arial,Helvetica,sans-serif;">27</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Annexure: Building Specification</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;" align="CENTER">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"> <br>
  </p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;">28 <br>
  </p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-align: center; color: rgb(54, 54, 54); text-indent: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <br>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: justify;"></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: justify;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: justify;"></p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="vertical-align: bottom; width: 40%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top; width: 10%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top; width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom; width: 45%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td rowspan="3" style="text-align: left; vertical-align: middle;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 36pt; color: rgb(35, 35, 35);">}</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">EXECUTED as a DEED by <b>MEPC MILTON <br>
              PARK NO. 1 LIMITED acting by</b></font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom; text-align: center;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">A director in the presence of:</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom; border-bottom: 1pt solid Black;">[***]<br>
        </td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">Director</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom; border-bottom: 1pt solid Black;"><font style="font-size: 10pt;">/s/ Philip Campbell</font><br>
        </td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Witness Name: PHILIP CAMPBELL</font></p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Address: 99 PARK DRIVE, MILTON PARK, OX14 4RY</font></p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Occupation: COMMERCIAL DIRECTOR</font></p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr>
        <td style="vertical-align: bottom; width: 40%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top; width: 10%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top; width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom; width: 45%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td rowspan="3"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 36pt; color: rgb(35, 35, 35);">}</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">EXECUTED as a DEED by <b>MEPC MILTON <br>
              PARK NO. 2 LIMITED </b>acting by</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">A director in the presence of:</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom; border-bottom: 1pt solid Black;">[***]</td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt; color: rgb(35, 35, 35);">Director</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr>
        <td style="vertical-align: bottom; border-bottom: 1pt solid Black;"><font style="font-size: 10pt;">/s/ Philip Campbell</font><br>
        </td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: top;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td style="vertical-align: bottom;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>

  </table>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Witness Name: PHILIP CAMPBELL</font></p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Address: 99 PARK DRIVE, MILTON PARK, OX14 4RY</font></p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0pt 0px; color: rgb(35, 35, 35);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Occupation: COMMERCIAL DIRECTOR</font></p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: justify;">&#160;</p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: justify;"> </p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: center;"><font style="font-size: 10pt;"> <br>
    </font></p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: center;"><font style="font-size: 10pt;"> 29</font><br>
  </p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: center;"><font style="font-size: 10pt;"> <br>
    </font></p>
  <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in; text-align: center;"> </p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>13
<FILENAME>nt10016217x4_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="line-height: normal; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <hr style="height: 4px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); margin-left: auto; margin-right: auto; border: medium none;" noshade="noshade">
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54); text-align: right;"><font style="font: 10pt Times New Roman,Times,serif;"><b>Exhibit 10.15</b></font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 16pt Times New Roman,Times,serif; color: rgb(36, 36, 54);"></font></p>
  <table style="border-collapse: collapse; font: 16pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 50%;"><img src="nt10016217x4_ex10-15img01.jpg" alt="">&#160;</td>
        <td style="width: 50%; vertical-align: top;"><img src="nt10016217x4_ex10-15img02.jpg" alt="">&#160;</td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 16pt Times New Roman,Times,serif; color: rgb(36, 36, 54);">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 16pt Times New Roman,Times,serif; color: rgb(36, 36, 54);"></font></p>
  <table style="border-collapse: collapse; font: 16pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td rowspan="1" style="width: 27%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt;">DATED 28 MARCH</font><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt;"> 2017</font></td>
      </tr>

  </table>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="font: 18pt Times New Roman,Times,serif; color: rgb(36, 36, 54); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 6%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">(1)</font></td>
        <td style="width: 94%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">MEPC MILTON PARK NO. 1 LIMITED AND MEPC MILTON PARK NO. 2 LIMITED</font></td>
      </tr>

  </table>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">&#160;</font></p>
  <table style="font: 18pt Times New Roman,Times,serif; color: rgb(36, 36, 54); margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 6%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">(2)</font></td>
        <td style="width: 94%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 20pt;">IMMUNOCORE LIMITED</font></td>
      </tr>

  </table>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 16pt;">LEASE</font></p>
  <p style="font: 18pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 2px solid Black; width: 100%;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">relating to</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">93 Innovation Drive</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; color: rgb(36, 36, 54); margin-top: 0px; margin-bottom: 0px; margin-left: 0in; text-indent: 0in;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 14pt;">Mitton Park</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(36, 36, 54);"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;"><b>+44 (0) 1235 836600</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;"><b>BSDR.COM</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;"><b>DX 144150 ABINGDON 4</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;">BrookStreet des Roches LLP</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;">25A Western Avenue, Milton Park,</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font-family: Arial,Helvetica,sans-serif;">Abingdon, Oxfordshire, OX14 4SH&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"><font style="font: 10pt Times New Roman,Times,serif;"><img src="nt10016217x4_ex10-13img03.jpg" alt="">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; color: rgb(91, 91, 107);">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 12pt;"><b>PRESCRIBED CLAUSES&#160;</b></font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Times New Roman,Times,serif;">&#160;</font></p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%; padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR1.</b></font></td>
        <td style="width: 37%; padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Date of lease</b></font></td>
        <td style="width: 58%; padding-right: 0.5in; padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">28 MARCH 2017</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR2.</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Title number(s)</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR2.1 Landlord&#8217;s title number(s)</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">BK102078</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR2.2 Other title number(s)</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">ON122118, ON122717, ON130606, ON145942, ON146219, ON225380, ON38283, ON72772, ON96949, ON216090</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR3.</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Parties to this lease</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landlord</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>MEPC MILTON PARK NO. 1 LIMITED </b>(Company number 5491670) and <b>MEPC MILTON PARK NO. 2 LIMITED</b> (Company number 5491806), on behalf of
            MEPC Milton LP (LP No. LP14504), both of whose registered offices are at Lloyds Chambers 1 Portsoken Street London E1 8HZ</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>IMMUNOCORE LIMITED </b>(Company number 6456207) whose registered office is at 101 Park Drive Milton Park Abingdon Oxfordshire OX14 4RY</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Other parties</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR4.</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Property</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>In the case of a conflict between this clause and the remainder of this lease then, for the purposes of registration, this clause shall
              prevail.</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">That part of the Building known as 93 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ shown edged red
            on the Plan with a net internal floor area of 2,197.0 square metres (23,649 square feet) and a gross internal floor area of 42,506 square feet (including plant rooms) measured in accordance with the RICS Code of Measuring Practice (sixth
            edition)</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR5.</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Prescribed Statements etc.</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR6.</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Term for which the Property is leased</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">From and including 17 March 2017</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid rgb(0, 0, 0);">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">To and including 23 June 2039</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR7.</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Premium</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR8.</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Prohibitions or restrictions on disposing of this lease</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">This lease contains a provision that prohibits or restricts dispositions</font></td>
      </tr>

  </table>
  <p style="margin: 0px;">&#160;</p>
  <p style="margin: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">1</font></td>
      </tr>

  </table>
  <p style="margin: 0px;">&#160;</p>
  <p style="margin: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; width: 5%; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR9.</b></font></td>
        <td style="padding-top: 5pt; width: 37%; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Rights of acquisition etc.</b></font></td>
        <td style="padding-top: 5pt; width: 58%; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR9.1 Tenant&#8217;s contractual rights to renew this lease, to acquire the reversion or another lease of
              the Property, or to acquire an interest in other land</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR9.2 Tenant&#8217;s covenant to (or offer to) surrender this lease</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR9.3 Landlord&#8217;s contractual rights to acquire this lease</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR10.</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Restrictive covenants given in this lease by the Landlord in respect of land other than the Property</b></font></td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11.</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Easements </b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11.1 Easements granted by this lease for the benefit of the Property</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The easements specified in Part I of the First Schedule of this lease</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;">&#160;</td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR11.2 Easements granted or reserved by this lease over the Property for the benefit of other property</b></font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;">&#160;</td>
        <td style="padding-top: 5pt; border-bottom: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The easements specified in Part II of the First Schedule of this lease</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR12.</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estate rentcharge burdening the Property</b></font></td>
        <td style="padding-top: 5pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR13.</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Application for standard form of restriction</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>LR14.</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Declaration of trust where there is more than one person comprising the Tenant</b></font></td>
        <td style="padding-top: 5pt; border-top: 1pt solid Black;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">None</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial,Helvetica,sans-serif; margin: 0pt 0px;">&#160;</p>
  <p style="font: 12pt Arial,Helvetica,sans-serif; margin: 0pt 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">2</font></td>
      </tr>

  </table>
  <p style="font: 12pt Arial,Helvetica,sans-serif; margin: 0pt 0px;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0pt 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0pt 0px;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;">&#160;<img src="nt10016217x4_ex10-15img04.jpg" alt=""></p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;"><img src="nt10016217x4_ex10-15img05.jpg" alt="">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;"><img src="nt10016217x4_ex10-15img06.jpg" alt="">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;"><img src="nt10016217x4_ex10-15img07.jpg" alt="">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;"><img src="nt10016217x4_ex10-15img08.jpg" alt="">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin: 0pt 0px; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-size: 11pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center;"><img src="nt10016217x4_ex10-15img09.jpg" alt="">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Times New Roman,Times,serif;"></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>This lease</b> made on the date and between the parties specified in the Prescribed Clauses <b>Witnesses</b> as follows:</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><b>1</b></td>
        <td><b>Definitions and Interpretation</b></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">In this lease unless the context otherwise requires:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><b>1.1</b></td>
        <td><b>Definitions</b></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Adjoining Property</b> means any adjoining or neighbouring premises in which the Landlord or a Group Company of the Landlord holds or shall at any time
    during the Term hold a freehold or leasehold interest;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Agreement for Lease</b> means the agreement dated 14 September 2016 made between (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited, on
    behalf of MEPC Milton LP, and (2) Immunocore Limited, as varied by a Deed of Variation dated 14 March 2017 made between (1) MEPC Milton Park No. 1 Limited and MEPC Milton Park No. 2 Limited, on behalf of MEPC Milton LP, and (2) Immunocore Limited
    providing, inter alia, for the grant of this lease and the grant of the 95 Lease;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Base Rate</b> means the base rate from time to time of Barclays Bank PLC or (if not available) such comparable rate of interest as the Landlord shall
    reasonably require;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Break Date 1</b> means 23 June 2019;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Break Date 2</b> means 23 June 2024</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Break Date 3</b> means 23 June 2029;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Break Date 4</b> means 23 June 2034;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Building</b> means the building known as 93 &#8211; 96 Innovation Drive, Milton Park (of which the Property forms part) and shown for the purposes of
    identification edged blue on the Plan and includes any part of it and any alteration or addition to it or replacement of it;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Building Services</b> means the services provided or procured by the Landlord in relation to the Building as set out in Part III of the Fourth Schedule;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Building Specification</b> means the specification marked &#8220;Building Specification&#8221; annexed to this lease;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Common Control</b> means that each of the companies concerned has 50% or more of its outstanding voting stock in the ownership of the same persons or
    companies;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Common Parts</b> means the accesses, lifts, roads, parking and other areas of the Building from time to time designated by the Landlord for common use by
    the tenants and occupiers of the Building;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Conduit</b> means any existing or future media for the passage of substances or energy and any ancillary apparatus attached to them and any enclosures for
    them;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Contractual Term</b> means the term specified in the Prescribed Clauses;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Emergency Access</b> means the emergency access route on the first floor of the Property shown shaded brown on the Plan;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Encumbrances</b> means the obligations and encumbrances (if any) specified in Part III of the First Schedule;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Estate</b> means Milton Park, Abingdon, Oxfordshire (of which the Building forms part) and the buildings from time to time standing on it shown on the Plan
    together with any other adjoining land which is incorporated into Milton Park;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Estate Common Areas</b> means the roads, accesses, landscaped areas, car parks, estate management offices and other areas or amenities on the Estate or
    outside the Estate but serving or otherwise benefiting the Estate as a whole which are from time to time provided or designated for the common amenity or benefit of the owners or occupiers of the Estate;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Estate Services</b> means the services provided or procured by the Landlord in relation to the Estate as set out in Part II of the Fourth Schedule;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">3</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Group Company</b> means a company which is a member of the same group of companies within the meaning of Section 42 of the 1954 Act or is within Common
    Control;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Guarantor</b> means any party to this lease so named in the Prescribed Clauses (which in the case of an individual includes his personal representatives)
    and any guarantor of the obligations of the Tenant for the time being;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Insurance Commencement Date</b> means 17 March 2017;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Insured Risks</b> means fire, lightning, earthquake, explosion, terrorism, aircraft (other than hostile aircraft) and other aerial devices or articles
    dropped therefrom, riot, civil commotion, malicious damage, storm or tempest, bursting or overflowing of water tanks apparatus or pipes, flood and impact by road vehicles (to the extent that insurance against such risks may ordinarily be arranged with
    an insurer of good repute) and such other risks or insurance as may from time to time be reasonably required by the Landlord (subject in all cases to such usual exclusions and limitations as may be imposed by the insurers), and <b>Insured Risk</b>
    means any one of them;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Landlord</b> means the party to this lease so named in the Prescribed Clauses and includes any other person entitled to the immediate reversion to this
    lease;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Landlord&#8217;s Surveyor</b> means a suitably qualified person or firm appointed by the Landlord (including an employee of the Landlord or a Group Company) to
    perform the function of a surveyor for the purposes of this lease;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Lease Particulars</b> means the descriptions and terms in the section headed <b>Lease Particulars </b>which form part of this lease insofar as they are
    not inconsistent with the other provisions of this lease;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Lettable Units</b> means any part of the Building which is let or separately occupied or constructed or adapted for letting or separate occupation from time
    to time;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Permitted Use</b> means use within Class B1 of the 1987 Order;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Plan</b> means the plan or plans annexed to this lease;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Prescribed Clauses</b> means the descriptions and terms in the section headed <b>Prescribed Clauses </b>which form part of this lease;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Principal Rent</b> means FOUR HUNDRED AND FORTY THOUSAND POUNDS (&#163;440,000.00) per annum subject to increase in accordance with the Second Schedule;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Property</b> means the property described in the Prescribed Clauses and includes any part of it any alteration or addition to the Property and any fixtures
    and fittings in or on the Property and includes:-</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(i)</td>
        <td style="padding-right: 23.65pt;">the floorboards, screed, plaster and other finishes on the floors, walls, columns and ceilings, and all carpets;</td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(ii)</td>
        <td style="padding-right: 16.65pt;">the raised floors and false ceilings (including light fittings) and the voids between the ceilings and false ceilings and the floor slab and the raised floors;</td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(iii)</td>
        <td style="padding-right: 2.9pt;">non-load bearing walls and columns in the Property and one half of the thickness of such walls dividing the Property from other parts of the Building;</td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(iv)</td>
        <td>all doors and internal windows and their frames, glass and fitments; </td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(v)</td>
        <td>all Conduits, plant and machinery within and solely serving the same;</td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(vi)</td>
        <td>all Landlord&#8217;s fixtures and fittings;</td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(vii)</td>
        <td>all alterations and additions;</td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">but excludes:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(i)</td>
        <td>all structural and external parts of the Building;</td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;">(ii)</td>
        <td>all Conduits, plant and machinery serving other parts of the Building;</td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Quarter Days </b>means 25 March, 24 June, 29 September and 25 December in every year and <b>Quarter Day </b>means any of them;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Rent Commencement Date</b> means 17 March 2017;&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">4</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Review Dates</b> means 24 June 2019 (<b>Review Date 1</b>), 24 June 2024 (<b>Review Date 2</b>), 24 June 2029 (<b>Review Date 3</b>), 24 June 2034 (<b>Review






      Date 4</b>);</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Service Charge</b> means the Service Charge set out in the Fourth Schedule;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Service Charge Commencement Date</b> means 17 March 2017; <b></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b> <br>
    </b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Services</b> means the Estate Services and the Building Services; <b></b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b> <br>
    </b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Signage Zones</b> means the signage areas at the Building;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Subletting Unit</b> means part of the Property consisting of a self contained unit suitable for underletting and approved as such by the Landlord (such
    approval not to be unreasonably withheld or delayed);</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Tenant</b> means the party to this lease so named in the Prescribed Clauses and includes its successors in title;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Term</b> means the Contractual Term together with any continuation of the term or the tenancy (whether by statute, common law holding over or otherwise);</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>This lease</b> means this lease and any document supplemental to it or entered into pursuant to it;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Uninsured Risk</b> means an Insured Risk against which insurance is from time to time unobtainable on normal commercial terms in the London insurance market
    at reasonable commercial rates for a property equivalent in size, layout, type and location.</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>VAT</b> means Value Added Tax and any similar tax substituted for it or levied in addition to it;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>Wing</b> means either the first floor north wing or first floor west wing as shown on the Plan;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>95 Lease</b> means the lease of 95 Park Drive Milton Park as contemplated by the Agreement for Lease;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>1954 Act</b> means the Landlord and Tenant Act 1954;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>1987 Order</b> means the Town and Country Planning (Use Classes) Order 1987 (as originally made);</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>1995 Act</b> means the Landlord and Tenant (Covenants) Act 1995;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;"><b>2003 Order</b> means The Regulatory Reform (Business Tenancies) (England and Wales) Order 2003.</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><b>1.2</b></td>
        <td><b>Interpretation</b></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.1</b></font></td>
        <td><font style="font-size: 10pt;">If the Landlord, Tenant or the Guarantor is more than one person then their covenants are joint and several;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.2</b></font></td>
        <td><font style="font-size: 10pt;">Any reference to a statute includes any modification extension or re-enactment of it and any orders, regulations, directions, schemes and rules made under it;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.3</b></font></td>
        <td><font style="font-size: 10pt;">Any covenant by the Tenant not to do any act or thing includes an obligation not knowingly to permit or suffer such act or thing to be done;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.4</b></font></td>
        <td><font style="font-size: 10pt;">If the Landlord reserves rights of access or other rights over or in relation to the Property then those rights extend to persons authorised by it;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.5</b></font></td>
        <td><font style="font-size: 10pt;">References to the <b>act or default of the Tenant</b> include acts or default or negligence of any undertenant or of anyone at the Property with the Tenant&#8217;s or any undertenant&#8217;s permission or sufferance;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.6</b></font></td>
        <td><font style="font-size: 10pt;">The index and Clause headings in this lease are for ease of reference only;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.7</b></font></td>
        <td><font style="font-size: 10pt;">References to the <b>last year of the Term</b> shall mean the twelve months ending on the expiration or earlier termination of the Term;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.8</b></font></td>
        <td><font style="font-size: 10pt;">References to <b>Costs</b> include all liabilities, claims, demands, proceedings, damages, losses and proper and reasonable costs and expenses;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1.2.9</b></font></td>
        <td><font style="font-size: 10pt;">References to Principal Rent, Current Rent, Indexed Rent and Revised Rent are references to yearly sums.</font></td>
      </tr>

  </table>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">5</font></td>
      </tr>

  </table>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Demise</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Landlord with Full Title Guarantee DEMISES the Property to the Tenant for the Contractual Term TOGETHER WITH the rights set out in Part I of the First
    Schedule, EXCEPT AND RESERVING as mentioned in Part II of the First Schedule and SUBJECT TO the Encumbrances;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3</b></font></td>
        <td><font style="font-size: 10pt;"><b>Rent</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Tenant will pay by way of rent during the Term or until released pursuant to the 1995 Act without any deduction counterclaim or set off except where
    required by law:</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.1</b></font></td>
        <td style="padding-right: 9pt;"><font style="font-size: 10pt;">The Principal Rent and any VAT by equal quarterly payments in advance on the Quarter Days to be paid by Direct Debit, Banker&#8217;s Standing Order or other means as the Landlord requires,
            the first payment for the period from and including the Rent Commencement Date to (but excluding) the next Quarter Day to be made on the Rent Commencement Date;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.2</b></font></td>
        <td><font style="font-size: 10pt;">The Service Charge and any VAT at the times and in the manner set out in the Fourth Schedule;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.3</b></font></td>
        <td><font style="font-size: 10pt;">The following amounts and any VAT:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.3.1</b></font></td>
        <td><font style="font-size: 10pt;">the sums specified in Clauses 4.1 [interest] and 4.2 [outgoings and utilities];</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.3.2</b></font></td>
        <td><font style="font-size: 10pt;">the sums specified in Clause 6.2.1 [insurance];</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3.3.3</b></font></td>
        <td><font style="font-size: 10pt;">all Costs incurred by the Landlord as a result of any breach of the Tenant&#8217;s covenants in this lease.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4</b></font></td>
        <td><font style="font-size: 10pt;"><b>Tenant&#8217;s covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Tenant covenants with the Landlord throughout the Term, or until released pursuant to the 1995 Act, as follows:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.1</b></font></td>
        <td><font style="font-size: 10pt;"><b>Interest</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">If the Landlord does not receive any sum due to it within 14 days of the due date to pay on demand interest on such sum at 2 per cent above Base Rate from the
    due date until payment (both before and after any judgment), provided this Clause shall not prejudice any other right or remedy for the recovery of such sum;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Outgoings and Utilities</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.2.1</b></font></td>
        <td><font style="font-size: 10pt;">To pay all existing and future rates, taxes, charges, assessments and outgoings in respect of the Property (whether assessed or imposed on the owner or the occupier), except any tax (other than VAT) arising as a
            result of the receipt by the Landlord of the rents reserved by this lease and any tax arising on any dealing by the Landlord with its reversion to this lease;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.2.2</b></font></td>
        <td><font style="font-size: 10pt;">To pay for all gas, electricity, water, telephone and other utilities used on the Property, and all charges in connection with such utilities and for meters and all standing charges, and a fair and reasonable
            proportion of any joint charges as determined by the Landlord&#8217;s Surveyor;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.3</b></font></td>
        <td><font style="font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.3.1</b></font></td>
        <td><font style="font-size: 10pt;">Any payment or other consideration to be provided to the Landlord is exclusive of VAT, and the Tenant shall in addition pay any VAT chargeable on the date the payment or other consideration is due;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.3.2</b></font></td>
        <td><font style="font-size: 10pt;">Any obligation to reimburse or pay the Landlord&#8217;s expenditure extends to irrecoverable VAT on that expenditure, and the Tenant shall also reimburse or pay such VAT;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.4</b></font></td>
        <td><font style="font-size: 10pt;"><b>Repair</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.4.1</b></font></td>
        <td><font style="font-size: 10pt;">To keep the Property and any Conduits plant and equipment serving only the Property in good and substantial repair and condition (damage by any Uninsured Risk or by the Insured Risks excepted save to the extent
            that insurance moneys are irrecoverable as a result of the act or default of the Tenant);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.4.2</b></font></td>
        <td><font style="font-size: 10pt;">To make good any disrepair for which the Tenant is liable within 2 months after the date of written notice from the Landlord (or sooner if the Landlord reasonably requires);</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">6</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.4.3</b></font></td>
        <td><font style="font-size: 10pt;">If the Tenant fails to comply with any such notice the Landlord may enter and carry out the work and the cost shall be reimbursed by the Tenant on demand as a debt;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.4.4</b></font></td>
        <td><font style="font-size: 10pt;">To enter into maintenance contracts with reputable contractors for the regular servicing of all plant and equipment serving only the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.5</b></font></td>
        <td><font style="font-size: 10pt;"><b>Decoration</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.5.1</b></font></td>
        <td><font style="font-size: 10pt;">To clean, prepare and paint or treat and generally redecorate all internal parts of the Property in every fifth year and in the last year of the Term;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.5.2</b></font></td>
        <td><font style="font-size: 10pt;">All the work described in Clause 4.5.1 is to be carried out:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">in a good and workmanlike manner to the Landlord&#8217;s reasonable satisfaction; and</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 11.15pt;"><font style="font-size: 10pt;">in colours which (if different from the existing colour) are first approved in writing by the Landlord (approval not to be unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.6</b></font></td>
        <td><font style="font-size: 10pt;"><b>Cleaning</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.6.1</b></font></td>
        <td><font style="font-size: 10pt;">To keep the Property clean, tidy and free from rubbish;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.6.2</b></font></td>
        <td><font style="font-size: 10pt;">To clean the inside of windows and any washable surfaces at the Property as often as reasonably necessary;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.7</b></font></td>
        <td><font style="font-size: 10pt;"><b>Overloading</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Not to overload the floors, ceilings or structure of the Property or the structure of the Building or any plant machinery or electrical installation serving
    the Property or the Building;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.8</b></font></td>
        <td><font style="font-size: 10pt;"><b>Conduits</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">To keep the Conduits in or serving the Property clear and free from any noxious, harmful or deleterious substance, and to remove any obstruction and repair any
    damage to the Conduits as soon as reasonably practicable to the Landlord&#8217;s reasonable satisfaction;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.9</b></font></td>
        <td><font style="font-size: 10pt;"><b>User</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.9.1</b></font></td>
        <td><font style="font-size: 10pt;">Not to use the Property otherwise than for the Permitted Use;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.9.2</b></font></td>
        <td><font style="font-size: 10pt;">Not to use the Property for any purpose which is:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">noisy, offensive, dangerous, illegal, immoral or an actionable nuisance; or</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 2.55pt;"><font style="font-size: 10pt;">which in the reasonable opinion of the Landlord causes damage or disturbance to the Landlord, or to owners or occupiers of any neighbouring property; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 8.7pt;"><font style="font-size: 10pt;">which involves any substance which may be harmful, polluting or contaminating other than in quantities which are normal for and used in connection with the Permitted Use;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.10</b></font></td>
        <td><font style="font-size: 10pt;"><b>Signs</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Subject to the Tenant&#8217;s rights in paragraph 7 of Part 1 of Schedule 1 not to erect any sign, notice or advertisement which is visible outside the Property
    without the Landlord&#8217;s prior written consent;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.11</b></font></td>
        <td><font style="font-size: 10pt;"><b>Alterations</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.11.1</b></font></td>
        <td><font style="font-size: 10pt;">Not to make any alterations or additions which:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 4.95pt;"><font style="font-size: 10pt;">affect the structure of the Building (including without limitation the roofs and foundations and the principal or load-bearing walls, floors, beams and columns);</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">affect the external appearance of the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td><font style="font-size: 10pt;">affect the heating air-conditioning and ventilation systems at the Building;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.11.2</b></font></td>
        <td><font style="font-size: 10pt;">Not to make any other alterations or additions to the Property without the Landlord&#8217;s written consent (which is not to be unreasonably withheld or delayed) save that the Tenant may install or demount internal non
            structural partitioning without the consent of the Landlord provided plans showing the extent of such works are deposited with the Landlord promptly on completion of the works;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">7</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.12</b></font></td>
        <td><font style="font-size: 10pt;"><b>Preservation of Easements</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.12.1</b></font></td>
        <td><font style="font-size: 10pt;">Not to prejudice the acquisition of any right of light for the benefit of the Property and to preserve all rights of light and other easements enjoyed by the Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.12.2</b></font></td>
        <td><font style="font-size: 10pt;">Promptly to give the Landlord notice if any easement enjoyed by the Property is obstructed, or any new easement affecting the Property is made or attempted;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13</b></font></td>
        <td><font style="font-size: 10pt;"><b>Alienation</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13.1</b></font></td>
        <td><font style="font-size: 10pt;">Not to:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 8.55pt;"><font style="font-size: 10pt;">assign, charge, underlet or part with possession of the whole or part only of the Property nor to agree to do so except by an assignment or underletting of the whole of the Property
            or an underletting of a Subletting Unit permitted by this Clause 4.13;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">share the possession or occupation of the whole or any part of the Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td><font style="font-size: 10pt;">assign, part with or share any of the benefits or burdens of this lease, or any interest derived from it by a virtual assignment or other similar arrangement;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13.2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Assignment</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">Not to assign or agree to assign the whole of the Property without the Landlord&#8217;s written consent (not to be unreasonably withheld or delayed), provided that:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 20pt;"><font style="font-size: 10pt;">the Landlord may withhold consent in circumstances where in the reasonable opinion of the Landlord</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 5.15pt;"><font style="font-size: 10pt;">the proposed assignee is not of sufficient financial standing to enable it to comply with the Tenant&#8217;s covenants in this lease; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 7.45pt;"><font style="font-size: 10pt;">such persons as the Landlord reasonably requires do not act as guarantors for the assignee and do not enter into direct covenants with the Landlord including the provisions set out
            in the Third Schedule (but referring in paragraph 1.2 to the assignee);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 35.1pt;"><font style="font-size: 10pt;">the Landlord&#8217;s consent shall in every case be subject to conditions (unless expressly excluded) requiring that:</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 2.35pt;"><font style="font-size: 10pt;">the assignee covenants with the Landlord to pay the rents and observe and perform the Tenant&#8217;s covenants in this lease during the residue of the Term, or until released pursuant to
            the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 12.8pt;"><font style="font-size: 10pt;">the Tenant enters into an authorised guarantee agreement guaranteeing the performance of the Tenant&#8217;s covenants in this lease by the assignee including the provisions set out in
            paragraphs 1-5 (inclusive) of the Third Schedule (but omitting paragraph 1.2);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 47.9pt;"><font style="font-size: 10pt;">all rent and other payments due under this lease are paid before completion of the assignment;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13.3</b></font></td>
        <td><font style="font-size: 10pt;"><b>Underletting</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">Not to underlet or agree to underlet the whole of the Property or a Subletting Unit nor vary the terms of any underlease without the Landlord&#8217;s written consent
    (not to be unreasonably withheld or delayed). Any permitted underletting must comply with the following:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">the rent payable under the underlease must be:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td><font style="font-size: 10pt;">not less than the rent reasonably obtainable in the open market for the Property or the Subletting Unit without fine or premium;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td><font style="font-size: 10pt;">payable no more than one quarter in advance;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 0.1in;"><font style="font-size: 10pt;">subject to upward only reviews at intervals no less frequent than the rent reviews under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 59.85pt;"><font style="font-size: 10pt;">the undertenant covenants with the Landlord and in the underlease: </font></td>
      </tr>

  </table>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td><font style="font-size: 10pt;">either:</font></td>
      </tr>

  </table>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">8</font></td>
      </tr>

  </table>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 134pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(I)</font></td>
        <td><font style="font-size: 10pt;">to observe and perform the Tenant&#8217;s covenants in this lease (except for payment of the rents) during the term of the underlease or until released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 134pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(II)</font></td>
        <td><font style="font-size: 10pt;">to observe and perform the Tenant&#8217;s covenants in the underlease during the term of the underlease or until released pursuant to the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td><font style="font-size: 10pt;">not to underlet, share or part with possession or occupation of the whole or any part of the underlet premises, nor to assign or charge part only of the underlet premises;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 15.75pt;"><font style="font-size: 10pt;">not to assign the whole of the underlet premises without the Landlord&#8217;s prior written consent (which shall not be unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 2.5pt;"><font style="font-size: 10pt;">all rents and other payments due under this lease (not the subject of a bona fide dispute) are paid before completion of the underletting;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iv)</font></td>
        <td style="padding-right: 2.35pt;"><font style="font-size: 10pt;">Sections 24 to 28 of the 1954 Act must be excluded and before completion of the underletting a certified copy of each of the following documents must be supplied to the Landlord:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td><font style="font-size: 10pt;">the notice served on the proposed undertenant pursuant to section 38A(3)(a) of the 1954 Act; and</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 4.25pt;"><font style="font-size: 10pt;">the declaration actually made by the proposed undertenant in compliance with the requirements of Schedule 2 of the 2003 Order; and</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 4.4pt;"><font style="font-size: 10pt;">the proposed form of underlease containing an agreement to exclude the provisions of sections 24 to 28 of the 1954 Act and a reference to both the notice pursuant to section 38A(3)(a)
            of the 1954 Act and the declaration pursuant to the requirements of Schedule 2 of the 2003 Order as referred to in this clause 4.13.3;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1.5in; text-indent: 0px;">and before completion of the underletting the Tenant must warrant to the Landlord that both the notice pursuant to section 38A(3)(a) of the 1954 Act has been
    served on the relevant persons as required by the 1954 Act and the appropriate declaration pursuant to the requirements of Schedule 2 of the 2003 Order as referred to in this clause 4.13.3 has been made prior to the date on which the Tenant and the
    proposed undertenant became contractually bound to enter into the tenancy to which the said notice applies;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(v)</font></td>
        <td style="padding-right: 5.15pt;"><font style="font-size: 10pt;">in relation to any Subletting Unit the underlease grants such rights as are appropriate for the separate occupation and use of the Subletting Unit, reserves such rights as are
            appropriate for the separate occupation and use of the remainder of the property let by this lease and to enable the Tenant to comply with its obligations under this lease, and reserves as rent:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 3.45pt;"><font style="font-size: 10pt;">a fair proportion of the cost of insuring the Property and the whole cost of insuring the loss of the principal rent and service charge payable under the underlease; and</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 2.4pt;"><font style="font-size: 10pt;">a service charge which provides for the undertenant to pay a fair and reasonable proportion of expenditure incurred by the Tenant in relation to the maintenance, repair, renewal,
            decoration and cleaning of the Property (including without limitation the Conduits, plant and equipment therein) and the provision of services to the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(vi)</font></td>
        <td><font style="font-size: 10pt;">there shall be no more than 2 units of occupation at any time and no more than 2 units of occupation on a single floor (and for this purpose a unit of occupation shall comprise (a) each Subletting Unit which is
            separately underlet and (b) the residue of the net lettable area of the Property (if any) retained by the Tenant);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(vii)</font></td>
        <td style="padding-right: 25.45pt;"><font style="font-size: 10pt;">(in the case of an underletting of the whole of the Property) the underlease reserves as rent the Service Charge payable under this lease;</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">9</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(viii)</font></td>
        <td><font style="font-size: 10pt;">(in the case of an underletting of a Subletting Unit) the underlease reserves as rent a fair and reasonable proportion of the Service Charge payable under this lease;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ix)</font></td>
        <td style="padding-right: 35.65pt;"><font style="font-size: 10pt;">if the Subletting Unit comprises other than a Wing unless the underletting either:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 7.65pt;"><font style="font-size: 10pt;">contains a covenant on the part of the undertenant to observe and perform the Tenant&#8217;s covenants in this lease (except for payment of the rents) during the term of the underlease or
            until released pursuant to the 1995 Act; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td style="padding-right: 7pt;"><font style="font-size: 10pt;">is on terms obliging the undertenant to take a lease of the whole of the Property for the unexpired residue of the term of this lease (less one day) on the same terms as those contained
            in this lease (including as to rents and rent review) in the event of the immediate reversion to such underlease becoming vested in the Landlord</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1.5in; text-indent: 0px;">the underlease shall contain a break exercisable by the landlord on three (3) months&#8217; notice in the event of the immediate reversion thereto becoming vested in
    the Landlord;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(x)</font></td>
        <td style="padding-right: 2.85pt;"><font style="font-size: 10pt;">the underlease &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;is in a form approved by the Landlord (such approval not to be unreasonably withheld or delayed);</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13.4</b></font></td>
        <td><font style="font-size: 10pt;">To take all necessary steps and proceedings to remedy any breach of the covenants of the undertenant under the underlease and not to permit any reduction of the rent payable by any undertenant;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.13.5</b></font></td>
        <td><font style="font-size: 10pt;"><b>Group Sharing</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">Notwithstanding Clause 4.13.1 the Tenant may share occupation of the whole or any part of the Property with a Group Company;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">PROVIDED THAT</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td><font style="font-size: 10pt;">the relationship of landlord and tenant is not created; and</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td><font style="font-size: 10pt;">occupation by any Group Company shall cease upon it ceasing to be a Group Company; and</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(c)</font></td>
        <td style="padding-right: 24.35pt;"><font style="font-size: 10pt;">the Tenant informs the Landlord in writing before each occupier commences occupation and after it ceases occupation;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.14</b></font></td>
        <td><font style="font-size: 10pt;"><b>Registration</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Within 21 days to give to the Landlord&#8217;s solicitors (or as the Landlord may direct) written notice of any assignment, charge, underlease or other devolution of
    the Property or a Subletting Unit together with a certified copy of the relevant document and a reasonable registration fee of not less than &#163;50;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.15</b></font></td>
        <td><font style="font-size: 10pt;"><b>Statutory Requirements and Notices</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.15.1</b></font></td>
        <td><font style="font-size: 10pt;">To supply the Landlord with a copy of any notice, order or certificate or proposal for any notice order or certificate affecting or capable of affecting the Property as soon as it is received by or comes to the
            notice of the Tenant;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.15.2</b></font></td>
        <td><font style="font-size: 10pt;">To comply promptly with all notices served by any public, local or statutory authority, and with the requirements of any present or future statute or European Union law, regulation or directive (whether imposed on
            the owner or occupier), which affects the Property or its use;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.15.3</b></font></td>
        <td><font style="font-size: 10pt;">At the request of the Landlord, but at the joint cost of the Landlord and the Tenant<b>,</b> to make or join the Landlord in making such objections or representations against or in respect of any such notice,
            order or certificate as the Landlord may reasonably require;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.15.4</b></font></td>
        <td><font style="font-size: 10pt;">To observe and perform the obligations of any agreement entered into prior to the date of this lease under any statute or European Union law, regulation or directive so far as the same relates to the use and/or
            occupation of the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">10</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.16</b></font></td>
        <td><font style="font-size: 10pt;"><b>Planning</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.16.1</b></font></td>
        <td><font style="font-size: 10pt;">Not to apply for or implement any planning permission affecting the Property without first obtaining the Landlord&#8217;s written consent (not to be unreasonably withheld or delayed in cases where the subject matter of
            the planning permission has been approved by the Landlord pursuant to the other provisions of this lease);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.16.2</b></font></td>
        <td><font style="font-size: 10pt;">If a planning permission is implemented the Tenant shall complete all the works permitted and comply with all the conditions imposed by the permission before the determination of the Term (including any works
            stipulated to be carried out by a date after the determination of the Term unless the Landlord requires otherwise);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.17</b></font></td>
        <td><font style="font-size: 10pt;"><b>Contaminants and Defects</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.17.1</b></font></td>
        <td><font style="font-size: 10pt;">To give the Landlord prompt written notice upon becoming aware of the existence of any defect in the Property, or of the existence of any contaminant, pollutant or harmful substance on the Property but not used in
            the ordinary course of the Tenant&#8217;s use of the Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.17.2</b></font></td>
        <td><font style="font-size: 10pt;">If so requested by the Landlord, to remove from the Property or remedy to the Landlord&#8217;s reasonable satisfaction any such contaminant, pollutant or harmful substance introduced on the Property by or at the request
            of the Tenant;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18</b></font></td>
        <td><font style="font-size: 10pt;"><b>Entry by Landlord</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">To permit the Landlord at all reasonable times and on reasonable notice (which shall not be less than 72 hours&#8217; notice except in emergency) to enter the
    Property in order to:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.1</b></font></td>
        <td><font style="font-size: 10pt;">inspect and record the condition of the Property or other parts of the Building or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.2</b></font></td>
        <td><font style="font-size: 10pt;">remedy any breach of the Tenant&#8217;s obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.3</b></font></td>
        <td><font style="font-size: 10pt;">repair, maintain, clean, alter, replace, install, add to or connect up to any Conduits which serve the Building or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.4</b></font></td>
        <td><font style="font-size: 10pt;">repair, maintain, alter or rebuild the Building or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.5</b></font></td>
        <td><font style="font-size: 10pt;">comply with any of its obligations under this Lease;</font></td>
      </tr>

  </table>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.18.6</b></font></td>
        <td>
          <div><font style="font-size: 10pt;">repair and / or maintain the Emergency Access should the Tenant fail to do so; </font></div>
        </td>
      </tr>
      <tr style="vertical-align: top;">
        <td rowspan="1" style="width: 0.5in;">&#160;</td>
        <td rowspan="1" style="width: 0.5in;">&#160;</td>
        <td rowspan="1">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td rowspan="1" style="width: 0.5in;">&#160;</td>
        <td colspan="2" rowspan="1" style="width: 0.5in;"><font style="font-size: 10pt;">Provided that the Landlord shall only exercise such rights where necessary and shall cause as little inconvenience as reasonably practicable in the exercise of such
            rights and shall promptly make good all physical damage to the Property caused by such entry;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.19</b></font></td>
        <td><font style="font-size: 10pt;"><b>Landlord&#8217;s Costs</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="margin: 0px 0px 0px 0.5in; line-height: normal; font-family: Arial, Helvetica, 'sans-serif'; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px;">To pay to the Landlord on demand amounts equal to
    such Costs as it may properly and reasonably incur:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.19.1</b></font></td>
        <td><font style="font-size: 10pt;">in connection with any application for consent made necessary by this lease (including where consent is lawfully refused or the application is withdrawn);</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.19.2</b></font></td>
        <td><font style="font-size: 10pt;">incidental to or in reasonable contemplation of the preparation and service of a schedule of dilapidations (whether before or within three (3) months after the end of the Term) or a notice or proceedings under
            Section 146 or Section 147 of the Law of Property Act 1925 (even if forfeiture is avoided other than by relief granted by the Court);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.19.3</b></font></td>
        <td><font style="font-size: 10pt;">in connection with the enforcement or remedying of any breach of the covenants in this lease on the part of the Tenant and any Guarantor;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.19.4</b></font></td>
        <td><font style="font-size: 10pt;">incidental to or in reasonable contemplation of the preparation and service of any notice under Section 17 of the 1995 Act;</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">11</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.20</b></font></td>
        <td><font style="font-size: 10pt;"><b>Yielding up</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Immediately before the end of the Term:</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 19.75pt;"><font style="font-size: 10pt;">to give up the Property repaired and decorated and otherwise in accordance with the Tenant&#8217;s covenants in this lease;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 7.4pt;"><font style="font-size: 10pt;">if the Landlord so requires, to remove all alterations made during the Term or any preceding period of occupation by the Tenant and reinstate the Property in accordance with the
            Building Specification, as the Landlord shall reasonably direct and to its reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 27.85pt;"><font style="font-size: 10pt;">to remove all signs, tenant&#8217;s fixtures and fittings and other goods from the Property, and make good any damage caused thereby to the Landlord&#8217;s reasonable satisfaction;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iv)</font></td>
        <td style="padding-right: 30.25pt;"><font style="font-size: 10pt;">to replace any damaged or missing Landlord&#8217;s fixtures with ones of no less quality and value;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(v)</font></td>
        <td><font style="font-size: 10pt;">to replace all carpets with ones of no less quality and value than those in the Property at the start of the Contractual Term;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(vi)</font></td>
        <td style="padding-right: 16.8pt;"><font style="font-size: 10pt;">to give to the Landlord all operating and maintenance manuals together with any health and safety files relating to the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(vii)</font></td>
        <td style="padding-right: 4.95pt;"><font style="font-size: 10pt;">to provide evidence of satisfactory maintenance of plant and machinery including (without limitation) electrical installation condition reports in respect of all of the electrical
            circuits and supply equipment in the Property, and any other condition reports as required under any relevant statute or European Union law, regulation or directive and copies of all service records;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(viii)</font></td>
        <td><font style="font-size: 10pt;">to return any security cards or passes provided by the Landlord for use by the Tenant and its visitors.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.21</b></font></td>
        <td><font style="font-size: 10pt;"><b>Encumbrances</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">To perform and observe the Encumbrances so far as they relate to the Property.</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.22</b></font></td>
        <td><font style="font-size: 10pt;"><b>Roads Etc</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Not to obstruct the roads, pavements, footpaths and forecourt areas from time to time on the Estate in any way whatsoever and not to use any part of the
    forecourts and car parking spaces or other open parts of the Property for the purpose of storage or deposit of any materials, goods, container ships&#8217; pallets, refuse, waste scrap or any other material or matter.</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.23</b></font></td>
        <td><font style="font-size: 10pt;"><b>Parking Restrictions</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">Except as to any right specifically granted in this lease not to permit any vehicles belonging to or calling upon the Tenant to stand on the roads, car parking
    spaces, forecourts, pavements or footpaths on the Estate.</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.24</b></font></td>
        <td><font style="font-size: 10pt;"><b>Regulations and Common Parts</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.24.1</b></font></td>
        <td><font style="font-size: 10pt;">At all times during the Term to observe and perform such regulations (if any) in respect of the Building or the Estate as the Landlord may reasonably think expedient to the proper management of the Building or the
            Estate and which are notified to the Tenant.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.24.2</b></font></td>
        <td><font style="font-size: 10pt;">Not to cause any obstruction to</font></td>
      </tr>

  </table>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">the Common Parts and / or</font></td>
      </tr>

  </table>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">any part of the Building and / or</font></td>
      </tr>

  </table>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td><font style="font-size: 10pt;">the Emergency Access.</font></td>
      </tr>

  </table>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.25</b></font></td>
        <td><font style="font-size: 10pt;"><b>Land Registration Provisions</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.25.1</b></font></td>
        <td><font style="font-size: 10pt;">Promptly following the grant of this lease the Tenant shall apply to register this lease at the Land Registry and shall ensure that any requisitions raised by the Land Registry in connection with that application
            are dealt with promptly and properly and within one month after completion of the registration, the Tenant shall send the Landlord official copies of its title;</font></td>
      </tr>

  </table>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">12</font></td>
      </tr>

  </table>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4.25.2</b></font></td>
        <td><font style="font-size: 10pt;">Immediately after the end of the Term (and notwithstanding that the Term has ended), the Tenant shall make an application to close the registered title of this lease and shall ensure that any requisitions raised
            by the Land Registry in connection with that application are dealt with promptly and properly and the Tenant shall keep the Landlord informed of the progress and completion of its application.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5</b></font></td>
        <td><font style="font-size: 10pt;"><b>Landlord&#8217;s Covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5.1</b></font></td>
        <td><font style="font-size: 10pt;"><b>Quiet Enjoyment</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Landlord covenants with the Tenant that the Tenant may peaceably enjoy the Property during the Term without any interruption by the Landlord or any person
    lawfully claiming under or in trust for it.</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5.2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Provision of Services</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Landlord will use its reasonable endeavours to provide or procure the provision of the Services PROVIDED THAT the Landlord shall be entitled to withhold or
    vary the provision or procurement of such of the Services as the Landlord considers necessary or appropriate in the interests of good estate management and PROVIDED FURTHER THAT the Landlord will not be in breach of this Clause as a result of any
    failure or interruption of any of the Services:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5.2.1</b></font></td>
        <td><font style="font-size: 10pt;">resulting from circumstances beyond the Landlord&#8217;s reasonable control, so long as the Landlord uses its reasonable endeavours to remedy the same as soon as reasonably practicable after becoming aware of such
            circumstances; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5.2.2</b></font></td>
        <td><font style="font-size: 10pt;">to the extent that the Services (or any of them) cannot reasonably be provided as a result of works of inspection, maintenance and repair or other works being carried out at the Building or the Estate.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6</b></font></td>
        <td><font style="font-size: 10pt;"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1</b></font></td>
        <td><font style="font-size: 10pt;"><b>Landlord&#8217;s insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Landlord covenants with the Tenant as follows:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.1</b></font></td>
        <td><font style="font-size: 10pt;">To insure the Building (other than tenant&#8217;s and trade fixtures and fittings) unless the insurance is invalidated in whole or in part by any act or default of the Tenant:</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">with an insurance office or underwriters of repute;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">against loss or damage by the Insured Risks;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td><font style="font-size: 10pt;">subject to such excesses as may be imposed by the insurers;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iv)</font></td>
        <td style="padding-right: 8.4pt;"><font style="font-size: 10pt;">in the full cost of reinstatement of the Building (in modern form if appropriate) including shoring up, demolition and site clearance, professional fees, VAT and allowance for
            building cost increases;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.2</b></font></td>
        <td><font style="font-size: 10pt;">To insure against loss of the Principal Rent thereon payable or reasonably estimated by the Landlord to be payable under this lease arising from damage to the Property by the Insured Risks for three years or such
            longer period as the Landlord may reasonably require having regard to the likely period for reinstating the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.3</b></font></td>
        <td><font style="font-size: 10pt;">The Landlord will use its reasonable endeavours to procure that the insurer waives its rights of subrogation against the Tenant (so long as such provision is available in the London insurance market) and to ensure
            that the Tenant&#8217;s interest is noted on such policy (which may be by way of the policy providing for a general noting of the interests of tenants);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.4</b></font></td>
        <td><font style="font-size: 10pt;">At the request and cost of the Tenant (but not more frequently than once in any twelve month period) to produce summary details of the terms of the insurance under this Clause 6.1;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.5</b></font></td>
        <td><font style="font-size: 10pt;">To notify the Tenant as soon as becoming aware of any material change in the terms and conditions of the insurer in relation to the policy under which the Building is for the time being insured;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.1.6</b></font></td>
        <td><font style="font-size: 10pt;">If the Building is destroyed or damaged by an Insured Risk, then, unless payment of the insurance moneys is refused in whole or part because of the act or default of the Tenant, and subject to obtaining all
            necessary planning and other consents to use the</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">13</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">insurance proceeds (except those relating to loss of rent and fees) and any uninsured excess paid by the Tenant under Clause 6.2.4(ii) in reinstating the same
    (other than tenant&#8217;s and trade fixtures and fittings) as quickly as reasonably practicable in modern form if appropriate but not necessarily identical in layout and (in relation to the Property) substantially as it was before the destruction or damage;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Tenant&#8217;s insurance covenants</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The Tenant covenants with the Landlord from and including the Insurance Commencement Date and then throughout the Term or until released pursuant to the 1995
    Act as follows:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.1</b></font></td>
        <td><font style="font-size: 10pt;">To pay to the Landlord on demand sums equal to:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 23.65pt;"><font style="font-size: 10pt;">a fair proportion (reasonably determined by the Landlord&#8217;s Surveyors) of the amount which the Landlord spends on insurance pursuant to Clause 6.1.1;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">the whole of the amount which the Landlord spends on insurance pursuant to Clause 6.1.2;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 37.85pt;"><font style="font-size: 10pt;">the cost of property owners&#8217; liability and third party liability insurance in connection with the Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iv)</font></td>
        <td><font style="font-size: 10pt;">the cost of any professional valuation of the Property properly required by the Landlord (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.2</b></font></td>
        <td><font style="font-size: 10pt;">To give the Landlord immediate written notice on becoming aware of any event or circumstance which might affect or lead to an insurance claim;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.3</b></font></td>
        <td><font style="font-size: 10pt;">Not to do anything at the Property which would or might prejudice or invalidate the insurance of the Building or the Adjoining Property or cause any premium for their insurance to be increased;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.4</b></font></td>
        <td><font style="font-size: 10pt;">To pay to the Landlord on demand:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 15.3pt;"><font style="font-size: 10pt;">any increased premium and any Costs incurred by the Landlord as a result of a breach of Clause 6.2.3;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 22.95pt;"><font style="font-size: 10pt;">a fair proportion (reasonably determined by the Landlord&#8217;s Surveyors) of any uninsured excess to which the insurance policy may be subject;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 6.6pt;"><font style="font-size: 10pt;">the whole of the irrecoverable proportion of the insurance moneys if the Building or any part are destroyed or damaged by an Insured Risk but the insurance moneys are irrecoverable in
            whole or part due to the act or default of the Tenant;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.5</b></font></td>
        <td><font style="font-size: 10pt;">To comply with the requirements and reasonable recommendations of the insurers;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.6</b></font></td>
        <td><font style="font-size: 10pt;">To notify the Landlord of the full reinstatement cost of any fixtures and fittings installed at the Property at the cost of the Tenant which become Landlord&#8217;s fixtures and fittings;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.2.7</b></font></td>
        <td><font style="font-size: 10pt;">Not to effect any insurance of the Property against an Insured Risk but if the Tenant effects or has the benefit of any such insurance the Tenant shall hold any insurance moneys upon trust for the Landlord and pay
            the same to the Landlord as soon as practicable;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.3</b></font></td>
        <td><font style="font-size: 10pt;"><b>Suspension of Rent</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">If the Property (or the means of access thereto) are unfit for occupation and use because of damage by an Insured Risk then (save to the extent that payment of
    the loss of rent insurance moneys is refused due to the act or default of the Tenant) the Principal Rent (or a fair proportion according to the nature and extent of the damage) shall be suspended until the date on which the Property is again fit for
    occupation and use and/or accessible.</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.4</b></font></td>
        <td><font style="font-size: 10pt;"><b>Determination Right</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.4.1</b></font></td>
        <td><font style="font-size: 10pt;">If the Property (or means of access thereto) is destroyed or damaged by an Insured Risk such that the Property is unfit for occupation and use and shall not be rendered fit for occupation and use within two years
            and nine months of the date of such damage then either the Landlord or the Tenant may whilst the Property has not been rendered fit for occupation and use terminate the Contractual Term by giving to the other not less than three (3) months&#8217;
            previous notice in writing PROVIDED THAT if the Property has been</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">14</font></td>
      </tr>

  </table>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">rendered fit for occupation and use within three years of the date of such damage then such notice shall be deemed not to have been given.</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.4.2</b></font></td>
        <td><font style="font-size: 10pt;">Termination of this lease pursuant to the provisions of Clause 6.4.1 shall be without prejudice to the liability of either party for any antecedent breach of the covenants and conditions herein contained (save for
            Clause 6.1.5 which shall be deemed not to have applied).</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5</b></font></td>
        <td><font style="font-size: 10pt;"><b>Uninsured Risks</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.1</b></font></td>
        <td><font style="font-size: 10pt;">For the purposes of this Clause 6.5:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">These provisions shall apply from the date on which any Insured Risk becomes an Uninsured Risk but only in relation to the Uninsured Risk;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 31.15pt;"><font style="font-size: 10pt;">References to an Insured Risk becoming an Uninsured Risk shall, without limitation, include the application by insurers of an exclusion, condition or limitation to an Insured Risk
            to the extent to which such risk thereby is or becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 6.85pt;"><font style="font-size: 10pt;">The Landlord shall notify the Tenant in writing as soon as reasonably practicable after an Insured Risk becomes an Uninsured Risk.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.2</b></font></td>
        <td><font style="font-size: 10pt;">If during the Term the Property (or part thereof or the means of access thereto) shall be damaged or destroyed by an Uninsured Risk so as to make the Property (or part therefore) unfit for occupation or use or
            inaccessible:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 10.35pt;"><font style="font-size: 10pt;">The Principal Rent and the Service Charge or a fair proportion according to the nature and extent of the damage sustained will not be payable until the earlier of the date on which:</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 3.85pt;"><font style="font-size: 10pt;">The Property shall again be fit for occupation and use excluding fitting out and replacement of contents and made accessible; or</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 107pt;"></td>
        <td style="width: 28pt;"><font style="font-size: 10pt;">(b)</font></td>
        <td><font style="font-size: 10pt;">This Lease shall be terminated in accordance with Clause 6.5.2(ii) or 6.5.5</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">The Landlord may within one year of the date of such damage or destruction serve notice on the Tenant confirming that it will reinstate the Property (a &#8216;Reinstatement Notice&#8217; so that the Property shall be fit for
            occupation and use and made accessible and if the Landlord fails to serve a Reinstatement Notice by the expiry of such prescribed period the Lease will automatically end on the date one year after the date of such damage or destruction.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.3</b></font></td>
        <td><font style="font-size: 10pt;">Clause 6.5.2(i) shall not apply if an Insured Risk shall have become an Uninsured Risk owing to the act or default of the Tenant or any person deriving title under the Tenant or their respective agents, employees,
            licensee, invitees or contractors.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.4</b></font></td>
        <td><font style="font-size: 10pt;">If the Landlord shall have served a Reinstatement Notice the provisions of Clause 6.1.6 shall apply as if the damage has been caused by an Insured Risk</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.5</b></font></td>
        <td><font style="font-size: 10pt;">If the Landlord shall have served a Reinstatement Notice and such reinstatement has not been completed by the date two years and nine months of the date of such damage at any time after that date the Landlord or
            the Tenant may terminate this Lease by serving not less than three months notice on the other stating that it terminates this Lease, and if by the end of such notice the Property and/or access to it have been reinstated so that the Property is
            fit for occupation and use and is accessible the notice shall be void and this Lease shall continue in full force and effect.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6.5.6</b></font></td>
        <td><font style="font-size: 10pt;">Service of a Reinstatement Notice shall not oblige the Landlord to replace any Tenant&#8217;s fitting out works or property belonging to the Tenant or any third party.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7</b></font></td>
        <td><font style="font-size: 10pt;"><b>Provisos</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1</b></font></td>
        <td><font style="font-size: 10pt;"><b>Forfeiture</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">If any of the following events occur:</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1.1</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant fails to pay any of the rents payable under this lease within 21 days of the due date (whether or not formally demanded); or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1.2</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant or Guarantor breaches any of its obligations in this lease; or</font></td>
      </tr>

  </table>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">15</font></td>
      </tr>

  </table>
  <p style="font: 8.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 11pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1.3</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant or Guarantor being a company incorporated within the United Kingdom</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">has an Administration Order made in respect of it; or</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 12.75pt;"><font style="font-size: 10pt;">passes a resolution, or the Court makes an Order, for the winding up of the Tenant or the Guarantor, otherwise than a member&#8217;s voluntary winding up of a solvent company for the
            purpose of amalgamation or reconstruction previously consented to by the Landlord (consent not to be unreasonably withheld); or</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iii)</font></td>
        <td style="padding-right: 23.3pt;"><font style="font-size: 10pt;">has a receiver or administrative receiver or receiver and manager appointed over the whole or any part of its assets or undertaking; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(iv)</font></td>
        <td><font style="font-size: 10pt;">is struck off the Register of Companies; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(v)</font></td>
        <td><font style="font-size: 10pt;">is deemed unable to pay its debts within the meaning of Section 123 of the Insolvency Act 1986; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1.4</b></font></td>
        <td><font style="font-size: 10pt;">proceedings or events analogous to those described in Clause 7.1.3 shall be instituted or shall occur where the Tenant or Guarantor is a company incorporated outside the United Kingdom; or</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.1.5</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant or Guarantor being an individual:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">has a bankruptcy order made against him; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td><font style="font-size: 10pt;">appears to be unable to pay his debts within the meaning of Section 268 of the Insolvency Act 1986;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">then the Landlord may re-enter the Property or any part of the Property in the name of the whole and forfeit this lease and the Term created by this lease
    shall immediately end, but without prejudice to the rights of either party against the other in respect of any breach of the obligations contained in this lease;</p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.2</b></font></td>
        <td><font style="font-size: 10pt;"><b>Notices</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.2.1</b></font></td>
        <td><font style="font-size: 10pt;">All notices under or in connection with this lease shall be given in writing</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.2.2</b></font></td>
        <td><font style="font-size: 10pt;">Any such notice shall be duly and validly served if it is served (in the case of a company) to its registered office or (in the case of an individual) to his last known address;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.2.3</b></font></td>
        <td><font style="font-size: 10pt;">Any such notice shall be deemed to be given when it is:</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="width: 100%; font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(i)</font></td>
        <td><font style="font-size: 10pt;">personally delivered to the locations listed in Clause 7.2.2; or</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0" width="100%">

      <tr style="vertical-align: top;">
        <td style="width: 73.05pt;"></td>
        <td style="width: 33.95pt;"><font style="font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 14.05pt;"><font style="font-size: 10pt;">sent by registered post, in which case service shall be deemed to occur on the third Working Day after posting.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7.3</b></font></td>
        <td><font style="font-size: 10pt;"><b>No Implied Easements</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">The grant of this lease does not confer any rights over the Building or the Adjoining Property or any other property except those mentioned in Part I of the
    First Schedule, and Section 62 of the Law of Property Act 1925 is excluded from this lease;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8</b></font></td>
        <td><font style="font-size: 10pt;"><b>Break Clause</b></font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.1</b></font></td>
        <td style="padding-right: 5.6pt;"><font style="font-size: 10pt;">If the 95 Lease shall not have been granted or required to have been granted pursuant to the Agreement for Lease prior to the last date for such notice to be given by the Tenant under
            this sub-clause 8.1 the Tenant may terminate the Contractual Term on Break Date 1 by giving to the Landlord not less than six (6) months&#8217; previous notice in writing PROVIDED THAT if the 95 Lease shall have been granted or required to have been
            granted pursuant to the Agreement for Lease prior to the last date for such notice to be given by the Tenant then any such notice given by the Tenant shall be of no effect and the Contractual Term shall not end on Break Date 1;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.2</b></font></td>
        <td><font style="font-size: 10pt;">The Tenant may terminate the Contractual Term on Break Date 2 or Break Date 3 or Break Date 4 by giving to the Landlord not less than six (6) months&#8217; previous notice in writing;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.3</b></font></td>
        <td><font style="font-size: 10pt;">Any notice given by the Tenant shall operate to terminate the Contractual Term only if:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.3.1</b></font></td>
        <td><font style="font-size: 10pt;">The Principal Rent reserved by this lease has been paid by the time of such termination; and</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.3.2</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant yields up the Property free from any subleases and other third party occupational interests on termination;</font></td>
      </tr>

  </table>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">16</font></td>
      </tr>

  </table>
  <p style="font: 7.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0px; margin-bottom: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.4</b></font></td>
        <td style="padding-right: 33.1pt;"><font style="font-size: 10pt;">Upon termination the Contractual Term shall cease but without prejudice to any claim in respect of any prior breach of the obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.5</b></font></td>
        <td><font style="font-size: 10pt;">If:</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.5.1</b></font></td>
        <td><font style="font-size: 10pt;">the 95 Lease shall not have been granted or required to have been granted pursuant to the Agreement for Lease prior to the last date for notice to be given by the Tenant under sub-clause 8.1; and</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 11pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0.5in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.5.2</b></font></td>
        <td><font style="font-size: 10pt;">the Tenant shall not give such notice under sub-clause 8.1 to terminate the Contractual Term on Break Date 1;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 1in; text-indent: 0px;">then the Principal Rent shall be suspended from and including the date falling immediately after Break Date 1 for a period of three hundred and four (304) days,
    after which period the Tenant&#8217;s obligation to pay the Principal Rent shall resume;</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.6</b></font></td>
        <td style="padding-right: 7.55pt;"><font style="font-size: 10pt;">If the Tenant does not terminate the Contractual Term on Break Date 2 the Principal Rent shall be suspended from the date falling immediately after Break Date 2 for a period of three
            hundred and four (304) days, after which period the Tenant&#8217;s obligation to pay the Principal Rent shall resume;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.7</b></font></td>
        <td><font style="font-size: 10pt;">If the Tenant terminates this lease in accordance with this clause 8 the Landlord shall promptly reimburse the Tenant in respect of any sums received under this lease which relate to a period following termination
            of this lease.</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8.8</b></font></td>
        <td><font style="font-size: 10pt;">Time shall be of the essence for the purposes of this Clause.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>9</b></font></td>
        <td><font style="font-size: 10pt;"><b>Contracts (Rights of Third Parties) Act 1999</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">A person who is not a party to this lease has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any terms of this lease.</p>
  <p style="font: 8pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>10</b></font></td>
        <td><font style="font-size: 10pt;"><b>Environmental Conditions</b></font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">For the purposes of this clause the expression &#8216;Environment&#8217; includes air, man made structures and surface or substrata any surface water or ground water, any
    life form (including human) or eco system and notwithstanding any other provisions of this Lease to the extent that the Property, the Common Parts, Building or Estate are affected by contamination or pollution, the Environment or the presence of any
    substance harmful to the Environment present or occurring prior to this Lease otherwise than through the act or default of the Tenant or any party under their control (an &#8216;Environmental Condition&#8217;) the Tenant shall not:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>10.1</b></font></td>
        <td style="padding-right: 8.75pt;"><font style="font-size: 10pt;">be responsible for (or contribute to whether by Service Charge or otherwise) any management compliance with statutory requirements, clean up, remediation or containment of any such
            Environmental Condition; nor</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>10.2</b></font></td>
        <td><font style="font-size: 10pt;">be responsible to repair any damage disrepair or injury caused by or arising from any Environmental Condition; nor</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>10.3</b></font></td>
        <td><font style="font-size: 10pt;">be responsible to contribute to any cost, fine or liability of any kind arising out of or in any way connected with any Environmental Condition.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Executed</b> by the parties as a <b>Deed</b> on the date specified in the Prescribed Clauses.</p>
  <p style="font: 7pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 7pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">17</font></td>
      </tr>

  </table>
  <p style="font: 7pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>The First Schedule</b></p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Part I - Easements and Other Rights granted</b></p>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">There are granted to the Tenant (in common with others authorised by the Landlord)</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 21.95pt;"><font style="font-size: 10pt;">The right to use the relevant Estate Common Areas and the Common Parts for access to and from the Property and (in the case of the Common Parts) for all purposes for which they are
            designed;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>2</b></font></td>
        <td style="padding-right: 5.05pt;"><font style="font-size: 10pt;">Free and uninterrupted use of all existing and future Conduits which are in the Building and the Estate and which serve the Property, subject to the Landlord&#8217;s rights to re-route the
            same subject to there being no unreasonable interruption of services;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 2.45pt;"><font style="font-size: 10pt;">The right to enter the Building (excluding the Lettable Units) to perform Clause 4.4 [repair] on reasonable prior written notice to the Landlord, subject to causing as little
            inconvenience as practicable and complying with conditions reasonably imposed by the Landlord and making good all physical damage caused;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4</b></font></td>
        <td><font style="font-size: 10pt;">The right of support and protection from the remainder of the Building;</font></td>
      </tr>

  </table>
  <p style="font: 6.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5</b></font></td>
        <td style="padding-right: 23.45pt;"><font style="font-size: 10pt;">The right to use such areas of the Building as the Landlord from time to time designates for plant and equipment serving only the Property (subject to approval under Clause 4.11.2;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6</b></font></td>
        <td style="padding-right: 4pt;"><font style="font-size: 10pt;">The right to use 70 parking spaces at the Building in such locations as the Landlord from time to time allocates the initial allocation being shown for identification only coloured
            yellow on the Plan.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7</b></font></td>
        <td style="padding-right: 8.65pt;"><font style="font-size: 10pt;">The right to display signs giving details of the Tenant&#8217;s name and business in any of the Signage Zones subject to the Landlord giving its prior approval to the form, design and
            location of such signs (such approval not to be unreasonably withheld or delayed) and subject to the Landlord retaining control of the installation and removal of any such signs.</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8</b></font></td>
        <td style="padding-right: 9.2pt;"><font style="font-size: 10pt;">The right to use in common with all others with like rights such cycle racks as may be provided by the Landlord from time to time on the Common Parts.</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <p style="font: 13pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Part II - Exceptions and Reservations</b></p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">There are excepted and reserved to the Landlord:</p>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>1</b></font></td>
        <td style="padding-right: 17.9pt;"><font style="font-size: 10pt;">The right to carry out any building, rebuilding, alteration or other works to the Building the Estate and the Adjoining Property (including the erection of scaffolding)
            notwithstanding any temporary interference with light and air enjoyed by the Property but provided that the Tenant&#8217;s use and enjoyment of the Property is not materially compromised;</font></td>
      </tr>

  </table>
  <p style="font: 6.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>2</b></font></td>
        <td style="padding-right: 20.85pt;"><font style="font-size: 10pt;">Free and uninterrupted use of all existing and future Conduits which are in the Property and serve the Building the Estate or the Adjoining Property;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>3</b></font></td>
        <td><font style="font-size: 10pt;">Rights of entry on the Property as referred to in Clause 4.18;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>4</b></font></td>
        <td><font style="font-size: 10pt;">The right to regulate and control in a reasonable manner the use of the Common Parts and Estate Common Areas;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>5</b></font></td>
        <td style="padding-right: 6.9pt;"><font style="font-size: 10pt;">The right to alter the layout of the roads forecourts footpaths pavements and car parking areas from time to time on the Estate in such manner as the Landlord may reasonably require
            PROVIDED THAT such alterations do not materially diminish the Tenant&#8217;s rights under this lease and that such works do not materially compromise the Tenant&#8217;s access to the Property;</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>6</b></font></td>
        <td><font style="font-size: 10pt;">The right of support and protection for other parts of the Building;</font></td>
      </tr>

  </table>
  <p style="font: 5.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>7</b></font></td>
        <td style="padding-right: 6.75pt;"><font style="font-size: 10pt;">The right in the last six months of the Term to view the Property with prospective tenants upon giving reasonable notice (not to be less than 72 hours) and the right throughout the
            Term to view the Property with prospective purchasers upon giving reasonable notice (not to be less than 72 hours);</font></td>
      </tr>

  </table>
  <p style="font: 6pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <table style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0px; margin-bottom: 0px; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0in;"></td>
        <td style="width: 0.5in;"><font style="font-size: 10pt;"><b>8</b></font></td>
        <td style="padding-right: 8.25pt;"><font style="font-size: 10pt;">The right for the Landlord, its employees, agents, tenants, invitees and any persons authorised by the Landlord at any time in the case of emergency (where for the avoidance of doubt
            no</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">18</font></td>
      </tr>

  </table>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0px 0px 0px 0.5in; text-indent: 0px;">notice shall be required) to pass over the Emergency Access on foot only and without interference or obstruction of any kind.</p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;&#160;</p>
  <p style="font: 9pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"><b>Part Ill - Encumbrances</b></p>
  <p style="font: 7pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 9.5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">The covenants declarations and other matters affecting the Property contained or referred to in the Landlord&#8217;s freehold reversionary title number BK102078 as at the date of
    this lease</p>
  <p style="font: 5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <table style="border-collapse: collapse; font: 10pt Times New Roman,Times,serif; width: 100%;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 100%; border-top: 1pt solid Black; padding-top: 8pt;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">19</font></td>
      </tr>

  </table>
  <p style="font: 5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="font: 5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;"></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="font: 5pt Arial,Helvetica,sans-serif; margin: 0px; text-indent: 0px;">&#160;</p>
  <p style="margin: 0px; text-indent: 0px;"></p>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;<b>The Second Schedule</b></font></p>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>Rent Review</b>&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif; color: Red;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">In this Schedule:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1</b></font></td>
        <td style="padding-right: 15.85pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Review Date </b>means each of the Review Dates and <b>Relevant Review Date </b>shall be interpreted accordingly;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.2</b></font></td>
        <td style="padding-right: 42.45pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Rent</b> means the Principal Rent payable under this lease immediately before the Relevant Review Date</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.3</b></font></td>
        <td style="padding-right: 15.3pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Index </b>means the Consumer Prices Index (<b>CPI</b>) published by the Office for National Statistics or (if not available)
            such index of comparative prices as the Landlord shall reasonably require;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Indexed Rent</b> means:</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Current Rent</b> multiplied by (A/B) per annum where:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 4%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">A</font></td>
        <td style="width: 3%;">=</td>
        <td style="padding-right: 39.4pt; width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The figure shown in the Index for the month immediately before the Relevant Review Date; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 4%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">B</font></td>
        <td style="width: 3%;">=</td>
        <td style="padding-right: 6.55pt; width: 88%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(In the case of Review Date 1) the figure shown in the Index for May 2014 and (in the case of the subsequent Review Dates) the
            figure shown in the Index for the month immediately before the Preceding Review Date</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td>&#160;</td>
        <td>&#160;</td>
        <td>&#160;</td>
        <td style="padding-right: 6.55pt;">&#160;</td>
      </tr>
      <tr style="vertical-align: top;">
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td colspan="3"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">PROVIDED THAT:</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td colspan="3"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
      </tr>
      <tr style="vertical-align: top;">
        <td><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">&#160;</font></td>
        <td colspan="3"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">At each of the Review Dates the maximum value of (A/B) shall be 1.2166529 and the minimum value of (A/B) shall be 1.0510101;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.5</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Preceding Review Date </b>means the Review Date next before the Relevant Review Date;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.6</b></font></td>
        <td style="padding-right: 13.5pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Revised Rent</b> means the new Principal Rent following each Review Date pursuant to paragraph 2 of the Second Schedule.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Principal Rent shall be reviewed on each Review Date to the higher of:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Current Rent (disregarding any suspension or abatement of the Principal Rent); and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Indexed Rent ascertained in accordance with this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If a Revised Rent has not been ascertained by the Relevant Review Date:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Current Rent shall continue to be payable until the Revised Rent is ascertained;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">when the Revised Rent is ascertained:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.2.1</b></font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant shall pay within 14 days of ascertainment of the Revised Rent:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 10%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 6.45pt; width: 85%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">any difference between the Principal Rent payable immediately before the Relevant Review Date and the Principal Rent which would
            have been payable had the Revised Rent been ascertained on the Relevant Review Date (the <b>Balancing Payment</b>); and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 10%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 8.75pt; width: 85%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">interest on the Balancing Payment at Base Rate from the date or dates when the Balancing Payment or the relevant part or parts
            would have been payable had the Revised Rent been ascertained on the Relevant Review Date;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3.2.2</b></font></td>
        <td style="padding-right: 15.1pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Landlord and Tenant shall sign and exchange a memorandum recording the amount of the Revised Rent.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Time shall not be of the essence for the purposes of this Schedule.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;">20&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>The Third Schedule</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>Guarantee</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Guarantor covenants with the Landlord as principal debtor:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1</b></font></td>
        <td style="padding-right: 29.55pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">that throughout the Term or until the Tenant is released from its covenants pursuant to the 1995 Act:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1.1</b></font></td>
        <td style="padding-right: 16.9pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant will pay the rents reserved by and perform its obligations contained in this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1.2</b></font></td>
        <td style="padding-right: 7.8pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Guarantor will indemnify the Landlord on demand against all Costs arising from any default of the Tenant in paying the rents
            and performing its obligations under this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.2</b></font></td>
        <td style="padding-right: 36.35pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">the Tenant (here meaning the Tenant so named in the Prescribed Clauses) will perform its obligations under any authorised
            guarantee agreement that it gives with respect to the performance of any of the covenants and conditions in this lease.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The liability of the Guarantor shall not be affected by:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.1</b></font></td>
        <td style="padding-right: 28.6pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any time given to the Tenant or any failure by the Landlord to enforce compliance with the Tenant&#8217;s covenants and obligations;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.2</b></font></td>
        <td style="padding-right: 21.45pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord&#8217;s refusal to accept rent at a time when it would or might have been entitled to re-enter the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any variation of the terms of this lease;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.4</b></font></td>
        <td style="padding-right: 6.55pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any change in the constitution, structure or powers of the Guarantor the Tenant or the Landlord or the administration,
            liquidation or bankruptcy of the Tenant or Guarantor;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.5</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any act which is beyond the powers of the Tenant;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2.6</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The surrender of part of the Property;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 26.45pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Where two or more persons have guaranteed obligations of the Tenant the release of one or more of them shall not release the
            others.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="padding-right: 15.9pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Guarantor shall not be entitled to participate in any security held by the Landlord in respect of the Tenant&#8217;s obligations or
            stand in the Landlord&#8217;s place in respect of such security.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="padding-right: 14.7pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If this lease is disclaimed, and if the Landlord within 6 months of the disclaimer requires in writing the Guarantor will enter
            into a new lease of the Property at the cost of the Guarantor on the terms of this lease (but as if this lease had continued and so that any outstanding matters relating to rent review or otherwise shall be determined as between the Landlord
            and the Guarantor) for the residue of the Contractual Term from and with effect from the date of the disclaimer.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="padding-right: 9.25pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If this lease is forfeited and if the Landlord within 6 months of the forfeiture requires in writing the Guarantor will (at the
            option of the Landlord):</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">enter into a new lease as in paragraph 5 above with effect from the date of the forfeiture; or</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2</b></font></td>
        <td style="padding-right: 10.6pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">pay to the Landlord on demand an amount equal to the moneys which would otherwise have been payable under this lease until the
            earlier of 6 months after the forfeiture and the date on which the Property is fully relet.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">21&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>The Fourth Schedule </b></font><br>
    <font style="font-family: Arial,Helvetica,sans-serif;"><b>Service Charge<br>
        Part I - Calculation and payment of the Service Charge</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">In this Schedule unless the context otherwise requires:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.1</b></font></td>
        <td style="padding-right: 5.7pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Accounting Date </b>means 31 December in each year or such other date as the Landlord notifies in writing to the Tenant from
            time to time;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.2</b></font></td>
        <td style="padding-right: 7.1pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Accounting Year </b>means the period from but excluding one Accounting Date to and including the next Accounting Date;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.3</b></font></td>
        <td style="padding-right: 12.9pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Estimated Service Charge </b>means the Landlord&#8217;s Surveyor&#8217;s reasonable and proper estimate of the Service Charge for the
            Accounting Year notified in writing to the Tenant from time to time;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.4</b></font></td>
        <td style="padding-right: 33.95pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Service Cost </b>means the reasonable and proper costs and expenses paid or incurred by the Landlord in relation to the
            provision of the Services (including irrecoverable VAT);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1.5</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Tenant&#8217;s Share </b>means a fair and reasonable proportion of the <b>Service Cost.</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="padding-right: 6.95pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Service Charge shall be the Tenant&#8217;s Share of the Service Cost in respect of each Accounting Year, and if only part of an
            Accounting Year falls within the Term the Service Charge shall be the Tenant&#8217;s Share of the Service Cost in respect of the relevant Accounting Period divided by 365 and multiplied by the number of days of the Accounting Year within the Term.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="padding-right: 29.25pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Landlord shall have the right to adjust the Tenant&#8217;s Share from time to time to make reasonable allowances for differences
            in the services provided to or enjoyable by the other occupiers of the Building or the Estate.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="padding-right: 5.65pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant shall pay the Estimated Service Charge for each Accounting Year to the Landlord in advance by equal instalments on the
            Quarter Days, (the first payment for the period from and including the Service Charge Commencement Date to (but excluding) the next Quarter Day after the Service Charge Commencement Date to be made on the Service Charge Commencement Date); and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.1</b></font></td>
        <td style="padding-right: 12.2pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">If the Landlord&#8217;s Surveyor does not notify an estimate of the Service Charge for any Accounting Year the Estimated Service Charge
            for the preceding Accounting Year shall apply; and</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4.2</b></font></td>
        <td style="padding-right: 31.25pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any adjustment to the Estimated Service Charge after the start of an Accounting Year shall adjust the payments on the following
            Quarter Days equally.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="padding-right: 21.65pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">As soon as practicable after the end of each Accounting Year the Landlord shall serve on the Tenant a summary of the Service
            Cost and a statement of the Service Charge certified by the Landlord&#8217;s Surveyor which shall be conclusive (save in the case of manifest error).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="padding-right: 22.4pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The difference between the Service Charge and the Estimated Service Charge for any Accounting Year (or part) shall be paid by the
            Tenant to the Landlord within fourteen days of the date of the statement for the Accounting Year, or allowed against the next Estimated Service Charge payment, or after the expiry of the Term refunded to the Tenant.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="padding-right: 16.65pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The Tenant shall be entitled by appointment within a reasonable time following service of the Service Charge statement to
            inspect the accounts maintained by the Landlord and the Landlord&#8217;s Surveyor relating to the Service Cost and supporting vouchers and receipts at such location as the Landlord reasonably directs.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="padding-right: 12.9pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">For the avoidance of doubt any cost charged as a Service Cost in respect of any element of the Estate Services or of the Building
            Services shall not be charged as a Service Cost in respect of any other head of charge under which charges are made for services by the Landlord.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;">&#160;</p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;">22&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>Part II - Estate Services</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0px; text-indent: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;">In relation to the Estate the provision of the following services or the
      Costs incurred in relation to:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>The Common Areas</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Repairing, maintaining and (where appropriate) cleaning, lighting and (as necessary)
      altering renewing, rebuilding and reinstating the Estate Common Areas.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Conduits</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">The repair, maintenance and cleaning and (as necessary) replacement and renewal of all
      Conduits within the Estate Common Areas.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Plant and machinery</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Hiring, operating, inspecting, servicing, overhauling, repairing, maintaining, cleaning,
      lighting and (as necessary) renewing or replacing any plant, machinery, apparatus and equipment from time to time within the Estate Common Areas or used for the provision of services to the Estate and the supply of all fuel and electricity for the
      same and any necessary maintenance contracts and insurance in respect thereof.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Signs</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Maintaining and (where appropriate) cleaning and lighting and (as necessary) renewing and
      replacing the signboards, all directional signs, fire regulation notices, advertisements, bollards, roundabouts and similar apparatus or works.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Maintaining, tending and cultivating and (as necessary) re-stocking any garden or grassed
      areas including replacing plants, shrubs and trees as necessary.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Common facilities</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Repairing maintaining and (as necessary) rebuilding as the case may be any party walls or
      fences, party structures, Conduits or other amenities and easements which may belong to or be capable of being used or enjoyed by the Estate in common with any land or buildings adjoining or neighbouring the Estate.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Security</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Installation, operation, maintenance, repair, replacement and renewal of closed circuit
      television systems and other security systems.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Outgoings</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Any existing and future rates, taxes, charges, assessments and outgoings in respect of the
      Estate Common Areas or any part of them except tax (other than VAT) payable in respect of any dealing with or any receipt of income in respect of the Estate Common Areas.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Transport</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">The provision of a bus service to and from Didcot or such other transport and/or location
      (if any) deemed necessary by the Landlord.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>10</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Statutory requirements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">The cost of carrying out any further works (after the initial construction in accordance
      with statutory requirements) to the Estate Common Areas required to comply with any statute.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.1</b></font></td>
        <td style="padding-right: 23.6pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT) of any person properly
            employed or retained by the Landlord for or in connection with surveying or accounting functions or the performance of the Estate Services and any other duties in and about the Estate relating to the general management, administration,
            security, maintenance, protection and cleanliness of the Estate:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.2</b></font></td>
        <td style="padding-right: 21.75pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Management costs fees and disbursements in respect of the Estate of 10% of the Service Cost (excluding costs under this clause
            11.2).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b></b></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">23<b>&#160;</b></font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3</b></font></td>
        <td style="padding-right: 15.9pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing staff in connection with the Estate Services and the general management, operation and security of the Estate and all
            other incidental expenditure including but not limited to:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.1</b></font></td>
        <td style="padding-right: 34.1pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">salaries, National Health Insurance, pension and other payments contributions and benefits;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.2</b></font></td>
        <td style="padding-right: 13.15pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">uniforms, special clothing, tools and other materials for the proper performance of the duties of any such staff;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>11.3.3</b></font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">providing premises and accommodation and other facilities for staff.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>12</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Enforcement of Regulations</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">The reasonable and proper costs and expenses incurred by the Landlord in enforcing the
      rules and regulations from time to time made pursuant to Clause 4.24 provided that the Landlord shall use all reasonable endeavours to recover such costs and expenses from the defaulting party and provided further that there shall be credited against
      the Service Cost any such costs recovered.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>13</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Insurances</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>13.1</b></font></td>
        <td style="padding-right: 8.5pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Effecting such insurances (if any) as the Landlord may properly think fit in respect of the Estate Common Areas the plant,
            machinery, apparatus and equipment used in connection with the provision of the Estate Services (including without prejudice those referred to in paragraph 3 above) and any other liability of the Landlord to any person in respect of those items
            or in respect of the provision of the Estate Services.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>13.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Professional valuations for insurance purposes (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>13.3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any uninsured excesses to which the Landlord&#8217;s insurance may be subject.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>14</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Generally</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Any reasonable and proper costs (not referred to above) which the Landlord may incur in
      providing such other services and in carrying out such other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Estate.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>15</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Anticipated Expenditure</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Establishing and maintaining reserves to meet the future costs (as from time to time
      estimated by the Landlord&#8217;s Surveyor) of providing the Estate Services;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>16</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Borrowing</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">The costs of borrowing any sums required for the provision of the Estate Services at
      normal commercial rates available in the open market or if any such sums are loaned by the Landlord or a Group Company of the Landlord interest at Base Rate.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>17</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">24&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b>Part III - Building Services</b></font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">In relation to the Building, the provision of the following services or the Costs incurred
      in relation to:</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>1</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Repairs to the Building (including lifts and Conduits)</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Repair, renewal, decoration, cleaning and maintenance of the foundations, roof, exterior
      and structure, the lifts and all lift machinery, the Conduits, plant and equipment (which are not the responsibility of any tenants of the Building).</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Common Parts</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 19.3pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Repair, renewal, decoration, cleaning, maintenance and lighting of the Common Parts and other parts of the Building not comprised
            in the Lettable Units;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(b)</font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Furnishing, carpeting and equipping the Common Parts;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(c)</font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Cleaning the outside of all external windows;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(d)</font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing and maintaining any plants, or floral displays in the Common Parts;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(e)</font></td>
        <td style="padding-right: 8.4pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing signs, name boards and other notices within the Building including a sign giving the name of the Tenant or other
            permitted occupier and its location within the Building in the entrance lobby of the Building.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Heating etc. services</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(a)</font></td>
        <td style="padding-right: 20.9pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing heating, air conditioning and ventilation other than to the Lettable Units to such standards and between such hours as
            the Landlord reasonably decides;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(b)</font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Procuring water and sewerage services.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>4</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Landscaping</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Maintaining, tending and cultivating and (as necessary) re-stocking any garden or grassed
      areas including replacing plants, shrubs and trees as necessary</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>5</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Fire Fighting and Security</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Provision, operation, repair, renewal, cleaning and maintenance of fire alarms, sprinkler
      systems, fire prevention and fire fighting equipment and ancillary apparatus and security alarms, apparatus, closed circuit television and systems as the Landlord considers appropriate.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Insurance</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.1</b></font></td>
        <td style="padding-right: 9.8pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Effecting such insurances (if any) as the Landlord may properly think fit in respect of the Common Parts and all Landlord&#8217;s plant,
            machinery, apparatus and equipment and any other liability of the Landlord to any person in respect of those items or in respect of the provision of the Building Services;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.2</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Professional valuations for insurance purposes (but not more than once in any two year period);</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>6.3</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any uninsured excesses to which the Landlord&#8217;s insurance may be subject.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>7</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Statutory Requirements</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">All existing and future rates, taxes, charges, assessments and outgoings payable to any
      competent authority or for or in connection with utilities except in respect of the Lettable Units.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>Management and Staff</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.1</b></font></td>
        <td style="padding-right: 15.35pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The proper and reasonable fees, costs, charges, expenses and disbursements (including irrecoverable VAT) of any person properly
            employed or retained by the Landlord for or in connection with surveying or accounting functions or the performance of the Building Services and any other duties in and about the Building relating to the general management, administration,
            security, maintenance, protection and cleanliness of the Building:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.2</b></font></td>
        <td style="padding-right: 20.7pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Management fees and disbursements incurred in respect of the Building of 10% of the Service Cost (excluding costs under this
            Clause 8.2).</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font: 10pt Arial,Helvetica,sans-serif;">25&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>8.3</b></font></td>
        <td style="padding-right: 7.95pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Providing staff in connection with the Building Services and the general management, operation and security of the Building and
            all other incidental expenditure including but not limited to:</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(i)</font></td>
        <td style="padding-right: 34.45pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">salaries, National Health Insurance, pension and other payments contributions and benefits;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(ii)</font></td>
        <td style="padding-right: 13.15pt; width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">uniforms, special clothing, tools and other materials for the proper performance of the duties of any such staff;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 5%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">(iii)</font></td>
        <td style="width: 90%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">providing premises and accommodation and other facilities for staff.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>General</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9.1</b></font></td>
        <td style="padding-right: 11.2pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Establishing and maintaining reserves to meet the future costs (as from time to time estimated by the Landlord&#8217;s Surveyor) of
            providing the Building Services;</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9.2</b></font></td>
        <td style="padding-right: 13.3pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">Any reasonable and proper costs (not referred to above) which the Landlord may incur in providing such other services and in
            carrying out such other works as the Landlord may reasonably consider to be reasonably desirable or necessary for the benefit of occupiers of the Building.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>9.3</b></font></td>
        <td style="padding-right: 16.95pt; width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;">The costs of borrowing any sums required for the provision of the Building Services at normal commercial rates available in the
            open market or if any such sums are loaned by the Landlord or a Group Company of the Landlord interest at Base Rate.</font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <table style="width: 100%; font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top;">
        <td style="width: 0%;"></td>
        <td style="width: 5%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>10</b></font></td>
        <td style="width: 95%;"><font style="font-family: Arial,Helvetica,sans-serif; font-size: 10pt;"><b>VAT</b></font></td>
      </tr>

  </table>
  <p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,Times,serif;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.45in;"><font style="font-family: Arial,Helvetica,sans-serif;">Irrecoverable VAT on any of the foregoing.</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;">&#160;</font></p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;"></font></p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;">26&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>&#160;</b></font></p>
  <p style="margin-top: 0pt; font: 10pt Times New Roman,Times,serif; margin-bottom: 0pt; color: Red;"><font style="font: 10pt Arial,Helvetica,sans-serif;"><b></b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Arial,Helvetica,sans-serif;"><b>Annexure: Building Specification</b></font></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px;"><b>&#160;</b></p>
  <p style="font: 10pt Arial,Helvetica,sans-serif; margin: 0pt 0px;">&#160;</p>
  <!-- Field: Rule-Page -->
  <div style="margin-top: 3pt; margin-bottom: 3pt;">
    <div style="font-size: 1pt; border-top: 1pt solid Black; width: 100%;">&#160;</div>
  </div>
  <!-- Field: /Rule-Page -->
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <p style="font: 10pt Times New Roman,Times,serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font: 10pt Arial,Helvetica,sans-serif;">27&#160;</font></p>
  <div id="DSPFPageBreakArea" style="margin-bottom: 10pt; clear: both; margin-top: 10pt;">
    <div id="DSPFPageNumberArea"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"></font>&#160;</div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; height: 2px; width: 100%; color: rgb(0, 0, 0); clear: both; margin: 4px 0px; background-color: rgb(0, 0, 0);" noshade="noshade"> </div>
  </div>
  <br>
  &#160;
  <table style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" cellpadding="0" cellspacing="0">

      <tr style="vertical-align: top">
        <td style="width: 30%; padding-right: 5.4pt; text-align: left; vertical-align: middle">EXECUTED AS A DEED by <b>MEPC MILTON PARK NO. 1 LIMITED </b>acting by a director and the company secretary or by two directors</td>
        <td style="width: 70%; text-align: left; vertical-align: middle"><font style="font-size: 48pt">}</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]<br>
        </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director/Company Secretary</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***] </td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">EXECUTED AS A DEED by <b>MEPC MILTON PARK NO. 2 &#160;LIMITED </b>acting by a director and the company secretary or by two directors</td>
        <td style="text-align: left; vertical-align: middle"><font style="font-size: 48pt">}</font></td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle">&#160;</td>
        <td style="text-align: left; vertical-align: middle">&#160;</td>
      </tr>
      <tr style="vertical-align: top">
        <td style="padding-right: 5.4pt; text-align: left; vertical-align: middle; padding-bottom: 2px;">Director/Company Secretary</td>
        <td style="text-align: left; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">[***]</td>
      </tr>

  </table>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
  <div style="margin-top: 3pt; margin-bottom: 3pt" align="LEFT">
    <div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&#160;</div>
  </div>
  <p style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt;"><br>
  </p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <br>
  <p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-family: Arial,Helvetica,sans-serif;">28</font></p>
  <hr style="height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); margin-left: auto; margin-right: auto; border: medium none;" noshade="noshade">
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
  <p style="margin-top: 0px; margin-bottom: 0px;"></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>14
<FILENAME>nt10016217x4_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<html>
  <head>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body link="BLUE" bgcolor="#FFFFFF" vlink="PURPLE">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Exhibit&#160;10.16</font></b></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">CONFIDENTIAL</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="text-align: right;"><font size="2"><font face="Times New Roman"><b><font style="font-size: 8pt;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS
              THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><br>
          </b></font></font><br>
    </div>
    <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">(1)&#160;IMMUNOCORE LIMITED</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">and</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">(2)&#160; ADAPTIMMUNE LIMITED</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;text-align:center;" align="center">
      <hr align="center" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">ASSIGNMENT AND EXCLUSIVE LICENCE</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
    <div style="margin:0in 0in .0001pt;text-align:center;" align="center">
      <hr align="center" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font><br>
    </p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">THIS DEED</font></b><font style="font-size:10.0pt;" size="2"> is dated 28 January&#160;2015 and is made <b>BETWEEN:</b></font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(1)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">IMMUNOCORE LIMITED</font></b><font style="font-size:10.0pt;" size="2"> (company number 6456207) whose registered office address is AT 57c Milton Park, Abingdon, Oxfordshire, OX14 4RX</font><font style="font-size:10.0pt;" size="2"> (the &#8220;<b>Immunocore</b>&#8221;); and</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(2)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">ADAPTIMMUNE LIMITED</font></b><font style="font-size:10.0pt;" size="2"> (company number 6456741) whose registered office address is 9400 Garsington Road, Oxford Business Park, Oxford, OX4 2HN</font><font style="font-size:10.0pt;" size="2"> (the &#8220;<b>Adaptimmune</b>&#8221;).</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">BACKGROUND</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">A.</font></b><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore </font><font style="font-size:10.0pt;" size="2">is a company engaged in identifying modifying, developing and commercialising products containing soluble T-Cell Receptors for use in certain
        applications.</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">B.</font></b><b><font style="font-size:3.0pt;font-weight:bold;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><font style="font-size:10.0pt;" size="2">Adaptimmune is a company engaged in identifying, modifying, developing and commercialising products containing cells that are transfected within genes encoding T-Cell Receptors for use in certain applications.</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">C.</font></b><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties previously entered into an Amended and Restated Licence Agreement (&#8220;<b>2011 Agreement</b>&#8221;), which amended and restated the terms of an original licence agreement dated 1 July&#160;2008 between Medigene
        Limited and Adaptimmune (&#8220;<b>2008 Agreement</b>&#8221;). This 2008 Agreement was novated to Immunocore on 1 October&#160;2008.</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">D.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties entered into a further agreement in May&#160;2013 (&#8220;<b>2013 Agreement&#8221;</b>) which amended the previous agreements and provided for exclusive licensing to each of the Parties in their respective field.</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">E.</font></b><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties now wish to rationalise the 2013 Agreement further.</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">OPERATIVE PROVISIONS</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Definitions and Interpretation</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">In





        this Deed the following words and phrases have the meaning set out below:</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Adaptimmune Licensed Product&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means (i)&#160;any product that contains cells that are transfected with genes encoding TCRs including any product containing cells that may also be
                transfected with one or more additional other molecules as well (whether transfected at the same time or by the same means as the TCRs or not); and (ii)&#160;any process, service or method including such a product and where:</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(a)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">such





                product is covered by any claim of the Licensed Patents or which is generated or derived using any of the Know-How or Results; or</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(b)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">such





                service, process or method is covered by a claim of any of the Licensed Patents or which requires the use of any Know-How or Results.</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .4in;text-indent:-.4in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">For the avoidance of doubt Adaptimmune Licensed </font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">2</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="font-family:Times New Roman;">
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Product shall not include any product, service, process or method comprising or containing Soluble TCRs;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Affiliate&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means, in relation to any entity, any company or legal entity in any country which Controls, is Controlled by or shares common Control with that
                entity. The Parties shall not be Affiliates for the purposes of this Deed;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Authorised Parties&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means Affiliates, contractors, employees, licensees (and prospective licensees), sub-licensees (and prospective sub-licensees) and potential
                acquirers;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Confidential Information&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means (a)&#160;in relation to each Party, all technical, financial and commercial information disclosed by that party to the other party in the course
                of or in anticipation of this Deed, together with the terms of this Deed; (b)&#160;all Know-How; (c)&#160;all Results;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Control&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means:</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(a)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">ownership





                of more than 50% of the voting share capital of the relevant entity; or</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(b)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">the





                ability to direct the casting of more than 50% of the votes, exercisable at a general meeting of the relevant entity on all, or substantially all, matters;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Core Patent&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means a patent or patent application designated as &#8220;Core&#8221; in Schedule 1;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Divisional&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means any divisional patent application or continuation-in-part application claiming any of the same priority as a Full Application, Later
                Application, Granted Patent or Core Patent;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Effective Date&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means the date set out above;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Full Application&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">shall have the meaning given in Schedule 3;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Granted Patent&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means a patent or patent application designated as &#8220;Granted&#8221; in Schedule 1;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Immunocore Licensed Product&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means (i)&#160;any product that contains Soluble TCRs; and (ii)&#160;any process, service or method including such a product and where:</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(a)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">such
                product is covered by any claim of the Licensed Patents or which is generated or derived using any of the Know-How or Results; or</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(b)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">such





                service, process or method is covered by a claim of any of the Licensed Patents or which requires the use of any Know-How or Results.</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">For the avoidance of doubt Immunocore Licensed </font></p>
          </td>
        </tr>

    </table>
    <br>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">3</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font>
  <div style="font-family:Times New Roman;">
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Product shall not include any product, service process or method containing or comprising cells that are transfected with genes encoding TCRs;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Intellectual Property Rights&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means patents, rights to inventions, copyright and related rights, trade marks, trade names and domain names, rights in designs, rights in
                computer software, database rights, rights in confidential information (including know-how as summarised in schedule 2) and any other intellectual property rights, in each case whether registered or unregistered and including all
                applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Know-How&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means all confidential information (excluding the Licensed Patents) created by either Party and relating to t-cell receptors, modifications to
                t-cell receptors, processes for the production of products comprising t-cell receptors, products comprising t-cell receptors, whether patentable or not as at 20 May&#160;2013. Know-How shall include all know-how summarised in Schedule 2 existing
                as at 20 May&#160;2013;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Later Application&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">shall have the meaning given in Schedule 3;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Licensed Patents&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(a)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">the





                patents or patent applications listed in Schedule 1;</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(b)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">any





                patents granted from the patent applications listed in Schedule 1;</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(c)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">any





                patents or patent applications filed in accordance with clause 4.3 and any patents granting from such patent applications;</font><font style="font-size:10.0pt;" size="2"> </font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(d)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">any





                corresponding patents and patent applications which are based on or derive priority from or common priority with the patent applications in (a)&#160;or (b)&#160;or (c); and</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt .35in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">(d)</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">any





                continuation, continuation-in-part, division, reissue, renewal or extension of any of the patents and patent applications in (a)&#160;&#8212; (d);</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Licensed Product&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means an Adaptimmune Licensed Product and/or an Immunocore Licensed Product;</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">4</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="font-family:Times New Roman;">
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Market&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means, in relation to a Licensed Product, offering to sell, lease, license or otherwise commercially exploit the Licensed Product or the sale,
                lease, licence, export or import, distribution, marketing or other commercial exploitation of the Licensed Product;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Materials</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means the materials provided by one Party to the other Party for the performance of the Project including all constructs, libraries, derivatives,
                portions, improvements or components of them or obtained from them or as a result of their use but excluding Results;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;NCI Patent&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means (i)&#160;patent application PCT/US2007/79487; and (ii)&#160;any corresponding patents and patent applications which are based on or derive priority
                from or common priority with PCT/US2007/79487; and (iii)&#160;any continuation, continuation-in-part, division, reissue, renewal or extension of any of the patents and patent applications in (i)&#160;and (ii);</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Prior Agreement&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means the 2013 Agreement;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Project&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means a project agreed between the Parties in relation to the development, modification, creation, adaptation, mutation or other work in relation
                to any TCR and as listed in Schedule 4;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Required Countries&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means European Union, United States of America and Canada;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Results&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Means all Intellectual Property Rights (excluding Licensed Patents and any Divisional filed in accordance with Clauses 4.4 and 4.5) generated or
                created by either Party in the performance of any Project;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Soluble TCRs&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">TCRs in any form (whether alone or combined with other compounds or molecules) and which when administered or supplied are not comprised within
                or attached to (including via transfection) any cell;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;SUSAR&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means a suspected, unexpected, serious adverse reaction, in relation to which notification to a competent authority is required;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;TCR&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means T-cell receptor;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:28.08%;" valign="top" width="28%">
            <p style="margin:0in 0in .0001pt .5in;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#8220;Territory&#8221;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.1%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:69.82%;" valign="top" width="69%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">means worldwide;</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">In
        this Deed:</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.2.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">references





        to clauses are to the clauses of this Deed;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.2.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">references





        to the parties are to the parties to this Deed;</font></p>
  </div>
  <div style="font-family:Times New Roman;">
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.2.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">headings
        are used for convenience only and do not affect its interpretation; and</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.2.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">references





        to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Assignment</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Nothing





        in this Deed will assign or transfer any Intellectual Property Rights between the Parties unless explicitly otherwise provided.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Adaptimmune





        hereby assigns and agrees to assign all its right, title and interest in the Know-How, Results and Licensed Patents to Immunocore.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">In





        consideration of the assignment under clause 2.2 above,&#160;Immunocore hereby assigns and agrees to assign a one half undivided interest in all its right, title and interest in the Know-How, Results and Licensed Patents to Adaptimmune.&#160; Following such
        assignment the parties shall own such Know-How, Results and Licensed Patents jointly in equal undivided shares.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Each





        Party agrees to execute or procure the execution of any further document or confirmatory assignment which may be reasonably required to effect ownership in accordance with clauses 2.2 and 2.3 above.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Save





        for the Results, any improvements or new Intellectual Property Rights created after the Effective Date shall, unless otherwise agreed in writing at any time by both parties, be owned by the Party or Parties creating such rights.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Either





        Party may on provision of reasonable notice, have access to and make copies of any documentation, files, programs or other materials which embody or set out any of the Know-How or Results to support any regulatory filing, provided such Party
        reimburses any reasonable costs incurred.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        either Party identifies a SUSAR as part of any clinical trial on any TCR which is the subject of the Licensed Patents, it shall provide details of the SUSAR to the other Party including where necessary any documentation or underlying materials
        relevant to the SUSAR in sufficient detail for the other Party to determine any regulatory notification requirements and safety implications in relation to its own products. Such obligation shall not apply where the SUSAR is specific to a
        particular Licensed Product and which does not have utility or is not relevant to Licensed Products more generally.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Grant of Licence</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore





        grants to Adaptimmune and Adaptimmune accepts an exclusive, royalty free, irrevocable licence under Immunocore&#8217;s rights in the Licensed Patents, the Know-How and the Results to develop, make, have made, use and have used and Market Adaptimmune
        Licensed Products in the Territory.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Adaptimmune





        grants to Immunocore and Immunocore accepts an exclusive, royalty free, irrevocable licence under Adaptimmune&#8217;s rights in the Licensed Patents, the Know-How and the Results to develop, make, have made, use and have used and Market Immunocore
        Licensed Products in the Territory.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .55in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The





        licences set out in clauses 3.1 and 3.2 shall include the right to use the Licensed Patents, Results and Know-How for the purposes of clinical research </font></p>
    <font style="font-size:10.0pt;" face="Times New Roman" size="2"> <br>
    </font></div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt .55in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">and development including the performance of clinical trials in relation to Licensed Products.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .55in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">All





        implied licences and rights are excluded to the full extent permitted by law.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .55in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Adaptimmune





        and Immunocore may sub-license the rights granted to them in clauses 3.1, 3.2 and 3.3, subject to clause 3.6 provided that each will ensure that any sub-licensee agrees to treat the Confidential Information in accordance with confidentiality terms
        at least as strict as those set out in this Deed. There is no requirement to seek consent from the other Party in relation to the grant of any sub-licence, consent is deemed given. Each Party is responsible for the performance of any sub-licence by
        its sub-licensees.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .55in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">For





        the avoidance of doubt and save as explicitly provided in this Deed, both Parties are free to further develop their rights in the Licensed Patents, Know-How and Results independently of the other Party. Where any further development or research by
        Adaptimmune (including any development resulting in a new TCR) uses any part of the Licensed Patents, Know-How and Results, Adaptimmune understands and agrees that it has no right to commercialise or exploit or otherwise supply any Immunocore
        Licensed Product and it is given no licence by Immunocore under Immunocore&#8217;s rights in the Licensed Patents, Know-How and Results in relation to any Immunocore Licensed Product. Where any further development or research by Immunocore (including any
        development resulting in a new TCR) uses any part of the Licensed Patents, Know-How and Results,&#160;Immunocore understands and agrees that it has no right to commercialise or exploit or otherwise supply any Adaptimmune Licensed Product and it is given
        no licence by Adaptimmune under Adaptimmune&#8217;s rights in the Licensed Patents, Know-How and Results in relation to any Adaptimmune Licensed Product.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The





        licences set out in clauses 3.1-3.3 are subject to the following:</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.7.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">the
        rights of the National Cancer Institute as a joint owner of the NCI Patents to use the NCI Patents and to grant non-exclusive licences under the NCI Patents;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.7.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">the
        exclusive rights of Sanofi Pasteur Limited to certain soluble TCR reagents under a collaborative research and exclusive licence agreement dated 1 December&#160;2006 (as amended and novated).</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Obligations and Prosecution of Intellectual Property Rights</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Any





        Licensed Patents including those which have been filed prior to the Effective Date shall be prosecuted, maintained and enforced in accordance with Schedule 3 to this Deed. Where Licensed Patents have been filed prior to the Effective Date, such
        Licensed Patents shall be designated as either Provisional Applications, Full Applications, Later Applications, Granted Patents, Lapsed Patents or Core Patents in accordance with Schedule 1; and Schedule 3 shall apply to such Licensed Patents in
        accordance with their designation. Prosecution of Licensed Patents in accordance with this Deed shall be overseen on a day to day basis by a joint patents committee, which shall have at least one participant from each of the Parties attending. The
        joint patent committee shall meet on a monthly basis or as often as reasonably required in order to manage the prosecution of Licensed Patents in accordance with Schedule 3. Decisions of the joint patent committee (to the extent any decisions are
        required) shall be made unanimously.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Should





        either Party wish to file any patent or patent application (other than any Divisional filed in accordance with clauses 4.4 and 4.5 below) which is based on the Know-How or Results or covering or including any of the same subject matter as in a
        previously filed Licensed Patent, it shall notify the other Party (&#8220;Notification&#8221;). Such patent or patent application shall be filed, prosecuted, maintained and enforced in accordance with Schedule 3.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Should





        either Party (&#8220;Filing Party&#8221;) wish to file any Divisional which is specific to in the case of Adaptimmune, the Adaptimmune Licensed Products, and in the case of Immunocore, the Immunocore Licensed Products it may notify the other Party (&#8220;Recipient
        Party&#8221;) in writing. Such notification shall include sufficient detail to enable the Recipient Party to determine whether the Divisional does or does not relate solely to the Filing Party&#8217;s Licensed Products. Where it agrees that the Divisional does
        relate solely to the Filing Party&#8217;s Licensed Products, it shall notify the Filing Party in writing within a period of 30 days from receipt of notice from the Filing Party. Following receipt of such notification, Filing Party shall be entitled to
        file the Divisional and to control the filing, prosecution and maintenance of such Divisional in its sole discretion. Unless otherwise agreed in writing by both parties, the Divisional shall be filed in the joint names of Immunocore and
        Adaptimmune.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        the Recipient Party under clause 4.3 either (a)&#160;does not respond to the notification from the Filing Party within a period of 30 days from receipt of notice; or (b)&#160;notifies Filing Party that Divisional does not solely relate to Filing Party&#8217;s
        Licensed Products or that it has not received sufficient information to enable a determination of whether the Divisional does relate solely to Filing Party&#8217;s Licensed Products then on expiry of a period of 30 days from receipt of notice by
        Recipient Party either Party may refer any outstanding issues to an independent expert (&#8220;Expert&#8221; for the purposes of this clause) by the service of written notice on the other Party (&#8220;Dispute Notice&#8221; for the purposes of this clause).&#160; During the
        referral to an Expert, Filing Party shall not be entitled to file the Divisional until the Expert has provided his decision. The Parties shall use reasonable endeavours to agree the Expert within 14 days of date of Dispute Notice, failing which the
        Expert shall be appointed by the President of the Law Society of England and Wales as soon as reasonably possible. Following appointment of Expert, both parties shall simultaneously serve written arguments in relation to the dispute on both the
        Expert and the other Party within 14 days of appointment of Expert. Within a further period of 14 days from date of service of written arguments, each Party may serve a further written reply on both the Expert and other Party. The Expert will make
        his decision based on the exchanged written statements and shall issue his decision in writing to both parties within a period of 14 days of service of last reply from a Party. The decision of the Expert shall be final and binding on the Parties,
        save for any manifest errors contained on the face of his decision. Unless otherwise provided by the Expert, the Expert&#8217;s charges shall be borne equally by the Parties. Where Expert finds in favour of the Filing Party then following issue of
        decision, Filing Party shall be entitled to file the Divisional and to control the filing, prosecution and maintenance of such Divisional in its sole discretion. Where Expert finds in favour of the Recipient Party, then Filing Party shall not file
        the Divisional.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">For





        the avoidance of doubt where a Divisional is agreed to relate solely to the Filing Party&#8217;s Licensed Products under clause 4.3 or is found by an Expert to relate solely to the Filing Party&#8217;s Licensed Products under clause 4.4, the Recipient Party
        shall have no licence under such Divisional or right to sub-licence such Divisional to the extent such Divisional continues to relate solely to the Filing Party&#8217;s Licensed Products.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Financial Provisions</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Payments





        under this Deed shall be made in pounds sterling by bank telegraphic transfer to the credit of a bank account nominated by Immunocore or Adaptimmune as relevant.&#160; All payments shall be due within 45 days of receipt of invoice. Where any amount in
        an invoice is disputed, paying party shall pay any un-disputed amount whilst the dispute as to remaining amounts is resolved.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">All





        payments under this Deed shall be made without deduction of income tax or other taxes, charges or duties that may be imposed, except and so far as Adaptimmune or Immunocore is required to make those deductions to comply with applicable laws.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">If





        full payment of any amount due is not made by the due date, the invoicing Party may charge interest on the outstanding amount on a daily basis at a rate equivalent to 2% above the base rate for the time being of HSBC Bank Plc from the date when
        payment was due until the date of actual payment.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">NOT APPLICABLE</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Confidentiality</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Subject





        to the remaining provisions of this Clause 7, each party will keep confidential the Confidential Information and will not disclose or supply that Confidential Information to any third party or use it for any purpose except in accordance with the
        terms of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Both





        Parties may disclose Confidential Information to Authorised Parties to the extent reasonably necessary for the development, manufacture, Marketing or use of Licensed Products or to facilitate acquisition or merger of either party, provided that
        both Parties will ensure that such Authorised Parties accept a continuing obligation of confidentiality in terms at least as strict as those set out in this Deed before making any such disclosure.&#160; Each Party shall be responsible to the other Party
        under this Deed in relation to any breach of confidentiality by any Authorised Party as if such breach had occurred under this Deed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The





        duty of non-disclosure in Clause 7.1 will not apply to any Confidential Information which:</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.3.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">is or
        becomes publicly known without the fault of any Party; or</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.3.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">is
        obtained from a third party in circumstances where the Party receiving from such third party has no reason to believe that there has been a breach of an obligation of confidentiality; or</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.3.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">is
        approved for release in writing by an authorised representative of the other Party.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-31.0pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The
        restrictions of confidentiality in clause 7.1 will not apply to the extent that any Confidential Information is required to be disclosed by law, pursuant to an order or rule&#160;of any court of competent jurisdiction, in order to fulfil a court order
        or rule, or pursuant to the requirements of any recognized stock exchange or any regulatory body, provided that the relevant Party gives the other Party prior written notice of such disclosure and that it discloses the Confidential Information only
        to the extent required to comply with such law or fulfil such order, rule&#160;or requirement and that it takes all reasonable steps to ensure, as far </font></p>
    <font style="font-size:10.0pt;" face="Times New Roman" size="2"> <br>
    </font></div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt 1.05in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">as it is possible to do so, the continued confidentiality of all Confidential Information disclosed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Duration and Termination</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .55in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">This





        Deed will come into force on the Effective Date and will continue in force until the later of (a)&#160;the expiry of the last to expire of any patent within the Licensed Patents; or (b)&#160;the Know-How or Results ceasing to be confidential.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Both





        Parties agree and accept that where there is any breach of this Deed, there shall be no right to terminate this Deed and damages or other available relief shall be the only relief applicable.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        any Party (&#8220;Defaulting Party&#8221;) becomes insolvent, admits insolvency, has a receiver appointed, voluntarily or involuntarily over substantially all of its assets, or is dissolved or liquidated (whether voluntarily or involuntarily), the other Party
        (&#8220;Non-Defaulting Party&#8221;) shall be entitled by notice in writing to the Defaulting Party to (a)&#160;take over and prosecute, file and maintain any or all of the Licensed Patents in its sole discretion; (b)&#160;request assignment of the Defaulting Party&#8217;s
        interest and title in the Licensed Patents, Know-How and Results to the Non-Defaulting Party on such terms as reflect reasonable arms length commercial terms including reasonable consideration for such assignment. The Defaulting Party and
        Non-Defaulting Party shall use best endeavours to negotiate the terms of such assignment as quickly as reasonably possible following date of notice by Non-Defaulting Party of its request for assignment. The Defaulting Party shall provide all
        reasonable assistance in relation to the ongoing prosecution, filing and maintenance of the Licensed Patents by the Non-Defaulting Party including in relation to the transition of the filing, prosecution and maintenance of the Licensed Patents to
        the Non-Defaulting Party.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">9.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Prior Agreement</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">9.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">As





        of the Effective Date both Parties hereby agree that the Prior Agreement will be superseded in its entirety and replaced by the terms of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">Warranties and Liability</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Each
        Party warrants to the other that it has the full right and power to enter into this Deed.&#160; Save as explicitly notified to the other Party at the Effective Date, each Party warrants that as at the Effective Date it has not knowingly misappropriated
        any third party confidential information or knowingly infringed any third party Intellectual Property Right.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Each
        Party warrants that save as explicitly otherwise provided in this Deed (a)&#160;it has the rights to grant the licences in clause 3 of this Deed; and (b)&#160;it has not granted to any third party any option, licence or right of first refusal in relation to
        the Licensed Patents, Results or Know-How; and (c)&#160;it has not assigned, transferred or granted any option to assign or transfer any of its rights in the Licensed Patents, Results or Know-How.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Both
        Parties acknowledge that in entering into this Deed they do not do so in reliance on any representation, warranty or other provision except as expressly provided in this Deed and any conditions, warranties or other terms implied by statute or
        common law are excluded from this Deed to the full extent permitted by law.</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Without





        limiting the scope of clauses 10.1 to 10.3, neither Party gives any warranty, representation or undertaking:</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .85in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.4.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">&#160;&#160;&#160;&#160;&#160;as to the
        efficacy, usefulness or quality of the Licensed Patents, Results or Know-How;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .85in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.4.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">&#160;&#160;&#160;&#160;&#160;that any
        of the Licensed Patents are or will be valid or subsisting or (in the case of applications) will proceed to grant; or</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .85in;text-indent:-.35in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.4.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">&#160;&#160;&#160;&#160;&#160;that the
        exploitation of any the Licensed Patents, Results or Know-How or the manufacture, Marketing, or use of Licensed Products or products or the exercise of any other rights granted under this Deed will not infringe any Intellectual Property Rights or
        other rights of any third party.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Both
        Parties accept that there is no restriction imposed on the other Party in relation to the independent development of any Adaptimmune Licensed Products in the case of Adaptimmune, or Immunocore Licensed Products, in the case of Immunocore using TCRs
        which do not form part of any Project or which are not comprised within the Licensed Patents, Know-How or Results (&#8220;<b>New TCRs</b>&#8221;). In particular, subject to clause 3, (a)&#160;each Party is free to enter into agreements with third parties in
        relation to development of products comprising New TCRs; (b)&#160;each Party is free to enter into any licence in relation to New TCRs; and (c)&#160;each Party is free to independently isolate New TCRs for Adaptimmune Licensed Products in the case of
        Adaptimmune, or Immunocore Licensed Products, in the case of Immunocore respectively.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The
        liability of either Party under this Deed (whether arising for breach or arising in any other way out of the subject matter of this Deed, including whether under contract or tort) will not include any indirect, incidental or consequential damages
        or loss (including as relevant any indirect loss of profits).</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Nothing





        in this Deed will operate to limit or exclude the liability of either party for death or personal injury arising from its negligence or for liability for fraud.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b><font style="font-size:10.0pt;font-weight:bold;" size="2">General</font></b></p>
    <p style="margin:0in 0in .0001pt .5in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Each
        Party must take out and maintain (for the term of this Deed) adequate product liability and other insurance in respect of its activities under this Deed. Each Party must at the other Party&#8217;s request from time to time provide the other Party with
        reasonable evidence to demonstrate that it has fulfilled its obligations under this clause. Each Party understands that such evidence may be provided to any sub-licensees or potential sub-licensees of the Party making the request for evidence.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Registration of Licence.&#160; </font></i><font style="font-size:10.0pt;" size="2">Either Party may register its interest in the Licensed Patents with any relevant authorities in the Territory as
        soon as legally possible.&#160; Neither Party shall, register a copy of this or any part of this Deed with the relevant authority in any Territory without the prior written consent of the other Party.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Use of Names.&#160; </font></i><font style="font-size:10.0pt;" size="2">Neither Party may use the name of the other Party in any advertising, promotional or sales literature, without the other
        Party&#8217;s prior written consent, such consent not to be unreasonably withheld.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Force Majeure.&#160; </font></i><font style="font-size:10.0pt;" size="2">If performance by either Party of any of its obligations under this Deed is prevented by circumstances beyond its reasonable
        control, that Party will </font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt .55in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">be excused from performance of that obligation for the duration of the relevant event, provided that if either Party is unable to fulfil its
        obligations under this Deed for a continuous period of six months or more due to any such circumstances, the other Party may terminate this Deed with immediate effect by serving written notice on the affected party.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Amendments.&#160; </font></i><font style="font-size:10.0pt;" size="2">This Deed may only be amended in writing signed by duly authorised representatives of the Parties.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Assignment.&#160; </font></i><font style="font-size:10.0pt;" size="2">Save as explicitly provided in this clause neither party may assign, mortgage, charge or otherwise transfer its rights or
        obligations under this Deed in whole or part to any third party without the prior written consent of the other Party which may be given or withheld at the absolute discretion of the other Party.&#160; Either Party may assign some or all of its rights
        and obligations under this Deed (including as relevant its interest in a Licensed Patent) to (a)&#160;a successor in title to substantially all the assets or business of the relevant Party; or (b)&#160;an Affiliate. Any such assignment shall be subject to
        the terms of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">No Waiver.&#160; </font></i><font style="font-size:10.0pt;" size="2">No failure or delay on the part of either Party to exercise any right or remedy under this Deed will be construed or operate as
        a waiver thereof, nor will any single or partial exercise of any right or remedy preclude the further exercise of such right or remedy.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.8.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">No Agency.&#160; </font></i><font style="font-size:10.0pt;" size="2">Neither Party may act or describe itself as the agent of the other, nor may it make or represent that it has authority to make
        any commitments on the other&#8217;s behalf.&#160; Nothing in this Deed creates, implies or evidences any partnership or joint venture between Immunocore and Adaptimmune or the relationship between them of principal and agent.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.9.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Notices.&#160; </font></i><font style="font-size:10.0pt;" size="2">Any notice to be given under this Deed must be given in writing and must be delivered personally or sent by first class mail or
        reputable courier to the address of the relevant Party, set out at the head of this Deed, or such other address as that Party may from time to time notify to the other Party in accordance with this clause, marked for the attention of the Managing
        Director (or equivalent) in each case.&#160; Notices sent as above will be deemed to have been received at the time of delivery (if delivered personally or by courier on any day which is a working day in the country in which the notice is delivered and
        otherwise on the next working day) and three working days after the date of posting (if sent by first class mail).</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.10.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Further Assurance.&#160; </font></i><font style="font-size:10.0pt;" size="2">Each Party agrees to execute, acknowledge and deliver such further instruments, and do all further similar acts, as may be necessary or appropriate to carry out the
        purposes and intent of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.11.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Announcements.&#160; </font></i><font style="font-size:10.0pt;" size="2">Except to the extent required by applicable laws or regulations, neither Party may make any press or other public announcement concerning any aspect of this Deed, or
        make any use of the name of the other Party in connection with or in consequence of this Deed, without the prior written consent of the other Party.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.12.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Entire Agreement.&#160; </font></i><font style="font-size:10.0pt;" size="2">This Deed (including its schedules) sets out the entire agreement between the Parties relating to its subject matter and supersedes all prior oral or written
        agreements, arrangements or understandings between them relating to such subject matter.&#160; Except in the case of fraud, the Parties acknowledge they are not relying on any representation, agreement, term or condition which is not set out in this
        Deed.</font></p>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">12</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div style="font-family:Times New Roman;">
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.13.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Severability.&#160; </font></i><font style="font-size:10.0pt;" size="2">If any clause or part of any clause in this Deed is declared invalid or unenforceable by the judgement or decree by consent or otherwise of any court or authority of
        competent jurisdiction from whose decision no appeal is or can be taken, all other clauses or parts of clauses contained in this Deed will remain in full force and effect and will not be affected thereby for the term of this Deed, but the Parties
        will negotiate appropriate amendments to this Deed with a view to restoring the balance of commercial interests as it stood prior to such invalidity or unenforceability being declared.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.14.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Rights of Third Parties</font></i><font style="font-size:10.0pt;" size="2">.&#160; No person who is not a Party to this Deed has any right to prevent the variation or cancellation of any provision of this Deed or its termination, and no
        person who is not a Party to this Deed may enforce any benefit conferred upon.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.15.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i><font style="font-size:10.0pt;font-style:italic;" size="2">Law and Jurisdiction.&#160; </font></i><font style="font-size:10.0pt;" size="2">This Deed is made and will be construed in accordance with the laws of England and Wales, and the Parties submit to the exclusive jurisdiction of the English
        courts, except that a Party may seek an interim or emergency injunction in any court of competent jurisdiction.</font></p>
    <p style="margin:0in 0in .0001pt 39.9pt;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">[SIGNATURES ON NEXT PAGE]</font></b></p>
    <p style="margin:0in 0in .0001pt;"><br>
    </p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">EXECUTED AS A DEED</font></b><font style="font-size:10.0pt;" size="2"> by the authorised representatives of the Parties on the date
        set out above.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Executed as a deed by Adaptimmune Limited acting by James Noble a director and Margaret Henry, its secretary</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">/s James Noble</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">James Noble</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Director</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">/s/ M Henry</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Margaret Henry</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Secretary</font></p>
          </td>
        </tr>

    </table>
    <br>
  </div>
  <div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Executed as a deed by Immunocore Limited acting by Eva-Lotta Allan, a director and Bent Jakobsen, a director</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">/s/ Eva-Lotta Allan</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Eva-Lotta Allan</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Director</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">/s/ Bent Jakobsen</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Bent Jakobsen</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Director</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:50.0%;" valign="top" width="50%">
            <p style="margin:0in 0in .0001pt;text-align:right;" align="right"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>

    </table>
    <br>
  </div>
  <div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">SCHEDULE 1 &#8212; LICENSED PATENTS</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Status column is included for information only and is as at Effective Date.</font></p>
    <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:25.14%;" valign="bottom" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Imm/ADT<br>
                  Case&#160;Ref.</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:19.0%;" valign="bottom" width="19%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Official&#160;No.</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:33.5%;" valign="bottom" width="33%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Case&#160;Status</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.24%;" valign="bottom" width="16%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Designation<br>
                  for&#160;purposes<br>
                  of&#160;Schedule&#160;3</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 14 mTCRs</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 -PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB02/03986</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2003/020763</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2002321581</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - CA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2457652</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2819279.6</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - EA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">6601</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - EP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1421115</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (AT, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR,&#160;IE,&#160;IT, NL, PT, SE, TR)</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - HK</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1066018</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - IL</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">160359</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - IN</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">212621</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - JP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4317940</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - KR</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10-0945977</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - MX</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">246738</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - NO</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">331877</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - NZ</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">531208</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - PL</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">208712</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - SG</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">102850</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7329731</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - US1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7763718</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 14 - ZA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2004/1197</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 18 scTCRs</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB03/04310</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2004/033685</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2003271904</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - CA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2501870</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">100338217C</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1549748</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (CH, DE, ES, FR, GB,&#160;IE,&#160;IT, NL)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - IL</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">167652</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - IN</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">227369</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - JP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4436319</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Lapsed (application for restoration filed)</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - NO</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">335365</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - NZ</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">539225</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - RU</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2355703</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - US</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7569664</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 18 - ZA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2005/02927</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 19 display</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB03/04636</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2004/044004</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2003276403</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - AU1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2010202953</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - CA</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2505558</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - CA1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2813515</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">200380102928</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1558643</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, GR,&#160;IE,&#160;IT, NL, PT, SE, TR)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - EP1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2048159</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, GR,&#160;IE,&#160;IT, NL, PT, SE, TR)</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - IL</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">167745</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - IN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">232673</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - JP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4975324</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - NO</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">333840</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - NZ</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">539226</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - NZ1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">570811</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - RU</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2346004</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - US1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8741814</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - US2</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">14/248919</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - US3</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">14/249904</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 19 - ZA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2005/03336</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 30 CD1</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB03/02986</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2004/074322</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2003254443</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - CA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2516702</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">03826014.X</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1594896</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (GB/FR/DE)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - JP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4478034</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - NZ</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">541596</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - US</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7666604</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 30 - ZA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2005/06516</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 53 CDR2</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2005/001781</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2005/114215</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2005246073</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - CA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2567349</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">200580015878.1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1756278</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (CH, DE, FR, GB,&#160;IE)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - HK</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1105995</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - JP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4972549</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - NZ</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">550815</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7608410</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 53 - ZA</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2006/09462</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 58 MTCR adoptive</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 58 - PCT</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2005/002570</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2006/000830</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 58 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1791865</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (AT, BE, CH, DE, DK, ES, FR, GB,&#160;IE,&#160;IT, LU, NL, SE)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 58 - JP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5563194</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 58 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8361794</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 58 - US1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">13/716817</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">18</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 74 HIV TCRs</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2006/001147</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Converted, published as WO 2006/103429</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - AU</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2006228308</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - AU1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2012211503</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - AU2</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2013202288</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - CA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2,602,463</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">200680011470.1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - CN1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">201210563915.4</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - EP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">6726555.3</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - EP1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10008612.3</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - EP2</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10014971.5</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - JP1</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5612623</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - JP2</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2014-094723</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - NZ</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">561338</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - NZ1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">584523</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8378074</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - US1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">13/733545</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 74 - ZA</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2007/08037</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 82 VYG Tel TCRs</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 82 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2006/001857</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2006/125962</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 82 - CN</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">200680018255.4</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 82 - EP</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1885754</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered (DE, ES, FR, GB,&#160;IT)</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 82 - JP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5149789</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 82 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8017730</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Granted/registered</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 91 Kinetic window</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 91 - PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2007/003676</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO 2008/038002</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 91 - EP</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7823938.1</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 91 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">12/443078</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 120 ala scan</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 120 -PCT</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2013/053320</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Published as WO2014/096803</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">UNPUBLISHED applications</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 118 PPI TCRs</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 118 - PCT</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">PCT/GB2014/053625</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 121 Blind date</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 121 - GB</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1404536.3</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 121 - US</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">61/953114</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Core</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 123 TRAIP peptide</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 123 - GB</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1409010.4</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 129 ETV4 peptide</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 129 - GB</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1410686.6</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 130 CDC6 peptide</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 130 - GB</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1412731</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:25.14%;" bgcolor="#CCEEFF" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Case 134 all peptides</font></b></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:19.0%;" bgcolor="#CCEEFF" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:33.5%;" bgcolor="#CCEEFF" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.04%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:16.24%;" bgcolor="#CCEEFF" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:25.14%;" valign="top" width="25%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Case 134 - GB</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:19.0%;" valign="top" width="19%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1420645.2</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:33.5%;" valign="top" width="33%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Pending</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.04%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:16.24%;" valign="top" width="16%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Full application</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">19</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">SCHEDULE 2</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">know-how</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">know-how shall include the following:</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to the selection of target peptide-MHCs;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">T-cell





        lines and clones;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Genes





        encoding T-cell receptors and vectors encoding such genes;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to T-cell receptor design, engineering and production by any method;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to production of soluble T-cell receptors;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to production of soluble T-cell receptors linked to other reagents;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to the determination of the affinity and kinetic characteristics of T-cell receptors/pMHC interactions;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to the transfection of cells with genes encoding T-cell receptors including transfected cell lines;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">9.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to phage display-based generation and selection of high affinity T-cell receptors;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-27.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 27.3pt;text-indent:-26.3pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">confidential





        information relating to the design, conduct and interpretation of T cell assays with soluble T-cell receptors or adoptively transferred T-cell receptors in cells;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">20</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">SCHEDULE 3</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">PATENT PROCESS</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Where any Notification is received under clause 4.3 of this Deed, any resulting patent or patent application will be filed, prosecuted and maintained in
        accordance with the following process. Performance of and decisions taken in relation to any notified invention, Provisional Application, Full Application or Later Application may be recorded and approved in accordance with the template set out in
        Schedule 5.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">In relation to Licensed Patents filed as at the Effective Date, Schedule 3 shall apply to such patents and patent applications in accordance with the
        designation set out in Schedule 1.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">1.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Any Notification shall specify a summary of the invention in relation to which the patent application is proposed to be filed.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">2.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties may agree not to file a patent application in relation to any Notification. If no patent application is filed then the relevant invention shall be maintained as confidential in accordance with clause 7 of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">3.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where the Parties do not agree to maintain the notified invention as confidential, then Immunocore shall be responsible for the filing of the patent application (&#8220;<b>Provisional Application</b>&#8221;).&#160; The Provisional Application shall be
        filed in the joint names of both Parties.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">4.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties will use all reasonable endeavours to agree the contents of the Provisional Application within 3 months of original notification under paragraph 1 above (or where any Provisional Application is being filed or re-filed in
        accordance with paragraph 5 below, within a period of 12 months from filing date of original Provisional Application). Any disagreement as to scope and content of Provisional Application shall be resolved in favour of Adaptimmune. The Provisional
        Application shall be filed as a minimum with the UK Intellectual Property Office.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">5.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Within a period of 12 months from filing date of Provisional Application the parties shall agree whether to (a)&#160;file a full patent application or applications corresponding to the Provisional Application; or (b)&#160;add additional matter to
        any Provisional Application; or (c)&#160;withdraw any Provisional Application and maintain the contents and invention as confidential; or (d)&#160;withdraw any Provisional Application and re-file the same application or a variation of such application. Where
        the Provisional Application or a variation of such application is re-filed the provisions of this Schedule 3 shall apply as if such re-filed application was the first Provisional Application. The content of any additional matter added to any
        Provisional Application shall be agreed by both Parties. Any disagreement as to whether or not the Provisional Application is withdrawn, a full patent application filed or the Provisional Application re-filed or the content of any Provisional
        Application shall be resolved in favour of Adaptimmune.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">6.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where the parties agree to file a full patent application or applications corresponding to any Provisional Application,&#160;Immunocore shall file a full patent application or applications corresponding to the Provisional Application (&#8220;<b>Full
          Application</b>&#8221;). Both Parties will use reasonable endeavours to agree on the contents of the Full Application. Any disagreement as to scope and content of Full Application will be resolved in favour of Adaptimmune if the Full </font></p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">21</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Application contains Adaptimmune-only mutations. If the content of the Full Application contains both Immunocore and Adaptimmune mutations, any
        disagreement as to scope and content of the Full Application shall be resolved in favour of Immunocore save that Immunocore shall be obliged to include all mutations or combinations of mutations in the Full Application as are requested to be
        included by Adaptimmune. For the avoidance of doubt, the Full Application may be identical in content to the Provisional Application.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">7.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Full Application shall be filed as an application in accordance with the Patent Co-operation Treaty. The Full Application shall be filed in the joint names of both Parties. The Parties shall agree which filing strategy is appropriate
        in each case. In the event of any failure to agree, an application in accordance with the Patent Co-operation Treaty at the UK Intellectual Property Office shall be filed as far as possible specifying all Patent Co-operation Treaty countries.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">8.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore shall be responsible for the filing, prosecution and maintenance of the Full Application in accordance with the following:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">use best
        endeavours to file, obtain and maintain valid patents pursuant to the Full Application so as to secure the broadest monopoly reasonably available in the countries chosen by Immunocore after consultation with Adaptimmune. Such countries shall
        include as a minimum the Required Countries unless otherwise agreed with Adaptimmune in writing;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">ensure that
        Adaptimmune is kept fully informed, and consult with Adaptimmune in relation to all matters relating to the filing, prosecution and maintenance of the Full Application; and</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">supply
        Adaptimmune with copies of all correspondence to and from Patent Offices in respect of the Full Application, including copies of all documents generated in or with such correspondence.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">9.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where any later filed patent application relates to the same TCR or subject matter as any previously filed Provisional Application or Full Application (&#8220;<b>Later Application</b>&#8221;), the following will apply:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The Parties
        shall use reasonable endeavours to agree on the contents of the Later Application within 30 days of notification of Later Application under paragraph 1. Any disagreement as to scope and content of Later Application shall be resolved in favour of
        Immunocore save that Immunocore shall be obliged to include all mutations or combinations of mutations in the Later Application as are requested to be included by Adaptimmune;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Prior to
        publication of the subject matter of the earlier of the Provisional Application or Full Application, the Parties shall discuss and agree whether the Provisional Application, Full Application and any Later Application should be withdrawn and
        re-filed to incorporate subject matter and/or claims from all of the Provisional Application, Full Application and Later Application. The parties agree that where any Full Application or Later Application which has been filed relates to any
        Adaptimmune Product in relation to which clinical trials have been started or in relation to which a clinical trial is pending, the Full Application or Later Application shall not be withdrawn and re-filed.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where the
        Parties do not agree in relation to the withdrawal and re-filing of the Provisional Application, Full Application and any Later Application or the contents of any re-filed Later Application,&#160;Immunocore shall have the right to file the Later
        Application but shall be obliged to include all mutations or combinations of mutations requested to be included by </font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">22</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt 1.0in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Adaptimmune. Adaptimmune shall provide all its requested mutations and combinations of mutations within 14 days of written request from Immunocore.
        Pending receipt of such request,&#160;Immunocore will not file the Later Application or do anything which may jeopardise the filing, prosecution or maintenance of the Later Application.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">d.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where the
        Parties agree that the Later Application should be withdrawn,&#160;Immunocore will withdraw the Later Application prior to its publication and the contents shall be maintained as confidential in accordance with clause 7 of this Deed. The Provisional
        Application and/or Full Application shall continue to be filed, maintained and prosecuted in accordance with paragraph 7 above.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">10.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        the Parties agree to withdraw any Full Application and/or Provisional Application and/or Later Application and re-file or file the Later Application, the parties shall use reasonable endeavours to agree the subject matter of such Later Application
        within a period of 30 business days from agreement to withdraw and re-file. Any dispute shall be resolved in favour of Immunocore save that Immunocore shall be obliged to include all mutations or combinations of mutations in the Later Application
        as are requested to be included by Adaptimmune within such 30 day period. Once the contents of the Later Application are agreed or deemed agreed,&#160;Immunocore shall be responsible for the filing, prosecution and maintenance of the Later Application.
        The Later Application shall be filed in the joint names of the Parties and Immunocore shall file, prosecute and maintain such application in accordance with the following:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">use best
        endeavours to file, obtain and maintain valid patents pursuant to the Later Application so as to secure the broadest monopoly reasonably available in the countries chosen by Immunocore after consultation with Adaptimmune. Such countries shall
        include as a minimum the Required Countries unless otherwise agreed with Adaptimmune in writing;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">ensure that
        Adaptimmune is kept fully informed, and consult with Adaptimmune in relation to all matters relating to the filing, prosecution and maintenance of the Later Application; and</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">supply
        Adaptimmune with copies of all correspondence to and from Patent Offices in respect of the Later Application, including copies of all documents generated in or with such correspondence.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 54.6pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Immunocore shall not be entitled to remove any mutations or combinations of mutations from the claims of any Later Application or re-filed Later
        Application (or any patent, patent application, divisional or continuation of such Later Application or re-filed Later Application) without the prior written consent of Adaptimmune unless any relevant patent office has provided a final
        non-appealable opinion that such mutation or combination of mutations is not patentable or capable of patent protection.</font></p>
    <p style="margin:0in 0in .0001pt 54.6pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">11.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore





        shall maintain Granted Patents in accordance with the following:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Use best
        endeavours to maintain valid patents pursuant to the Granted Patents to the extent valid patents have not already been granted as at the Effective Date;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Pay all renewal
        and grant fees associated with such Granted Patents in the country in which such Granted Patent has been granted as at the Effective Date or in relation to which the Granted Patent is granted subsequent to the Effective Date;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div style="font-family:Times New Roman;">
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">23</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Ensure that
        Adaptimmune is kept fully informed of any substantive communications in relation to such Granted Patents including communications and payment of renewal and grant fees.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">The provisions of paragraphs 1-10 of this Schedule 3 shall not apply to any Granted Patents.</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">12.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">There





        shall be no obligation on either Party to maintain, prosecute, seek to re-instate, reissue or otherwise re-file any Lapsed Patent (as designated in accordance with Schedule 1) and the obligations set out under Schedule 3 shall not apply to any
        Lapsed Patents.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">13.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore





        shall file, prosecute and maintain Core Patents in accordance with the following:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Use best
        endeavours to file, obtain and maintain valid patents pursuant to the Core Patents so as to secure the broadest monopoly reasonably available in countries chosen by Immunocore, but at a minimum including the Required Countries unless otherwise
        agreed in writing with Adaptimmune;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">To the extent
        such Core Patents are granted in any countries as at the Effective Date, to pay all renewal and grant fees associated with such granted Core Patents in the country in which such Core Patent has been granted as at the Effective Date;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Ensure that
        Adaptimmune is kept fully informed and to the extent reasonably possible consult with Adaptimmune in relation to any substantive communications to or from any Patent Office in relation to such Core Patents.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Adaptimmune understands and accepts that subject to the obligations imposed under this paragraph 13,&#160;Immunocore has the final decision in relation
        to the content of the Core Patents and the content of any communications relating to such Core Patents with any Patent Office.</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">The provisions of paragraphs 1-10 of this Schedule 3 shall not apply to any Core Patents.</font></p>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">14.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Adaptimmune





        will reimburse Immunocore, within 30 days of the date of an invoice from Immunocore, for 50% of the reasonable costs (including patent agent costs), fees and charges incurred by Immunocore in the course of filing, prosecuting and maintaining the
        patents and patent applications in accordance with this Schedule 3 (including as relevant Granted Patents and Core Patents).&#160; Such invoice will set out an itemised list of the costs incurred by Immunocore to a level of detail reasonably
        satisfactory to Adaptimmune. Adaptimmune may also request copies of invoices received from third parties including patent agent costs.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">15.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">If,





        at any time during the term of this Deed, either party (&#8220;Notifying Party&#8221;) no longer wishes to prosecute, file or maintain any of the Licensed Patents, it shall provide at least 30 days notice to the other party (&#8220;Recipient Party&#8221;). The Recipient
        Party shall be entitled in its sole discretion to take over and prosecute, file and maintain any notified patent or patent application. The Recipient Party shall make such decision within 30 days of receiving notice from the Notifying Party. The
        Notifying Party shall assign its rights in such notified patent or patent application to the Recipient Party and the Notifying Party agrees to use all reasonable endeavours to consent to and procure the </font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
  </div>
  <div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">24</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt .75in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">signing of all documentation required to transfer full title in the notified patent or patent application to the Recipient Party. Following
        assignment, the Recipient Party shall be solely responsible for controlling and paying all the costs of prosecution, filing and maintenance of the assigned patent or patent application. Following assignment the Notifying Party shall have no further
        interest in the invention and patent or patent application shall be removed from the definition of Licensed Patents.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">16.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        Recipient Party states in writing that it does not want to take over and prosecute, file and maintain any patent or patent application notified under paragraph 15 above, Notifying Party shall be entitled to allow such patent or patent application
        to lapse either through non-response to any office action or through non-payment of any fees due and payable in relation to such patent or patent application or by withdrawal of such patent or patent application. Where such patent or patent
        application has not been published as of the date the Recipient Party states it does not want to take over the prosecution, filing and maintenance, the Notifying Party shall use reasonable efforts to procure lapse or withdrawal of the Licensed
        Patent prior to its publication.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">17.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Prior





        to any decision being made by Recipient Party under paragraph 15 above,&#160;Immunocore or as relevant Adaptimmune (where Adaptimmune has taken over filing, prosecution and maintenance under paragraph 20 below) shall continue to prosecute, file and
        maintain the relevant patent or patent application in accordance with paragraphs 8, 10, 11 and 13 above (as relevant) and shall not do anything to jeopardise the filing, prosecution and maintenance of such patent or patent application.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">18.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Each





        party will inform the other party promptly if it becomes aware of any opposition, revocation, re-examination, interference or other action attacking or challenging the validity of any of the Licensed Patents. Where such challenge relates solely to
        claims covering Adaptimmune Licensed Products, Adaptimmune shall be entitled (but not obliged) to defend any such challenge. Where such challenge relates solely to claims covering Immunocore Licensed Products, Immunocore shall be entitled (but not
        obliged) to defend any such challenge. Where any challenge does not relate solely to either the Immunocore Licensed Products or the Adaptimmune Licensed Products or there is any dispute as to such, then (a)&#160;Adaptimmune shall be entitled (but not
        obliged) to defend any such challenge in relation to Provisional or Full Applications and Immunocore agrees to assist Adaptimmune in any such defence; and (b)&#160;Immunocore shall be entitled (but not obliged) to defend any such challenge in relation
        to any re-filed Later Application, Later Application, Granted Patent or Core Patent and Adaptimmune agrees to assist Immunocore in such defence. Where reasonably possible each Party will act in the best interests of the other Party in defending any
        such challenge.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin: 0in 0in .0001pt .75in; text-indent: -.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">19.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">E</font><font style="font-size:10.0pt;" size="2">ach party will inform the other party promptly if it becomes aware of any infringement or potential infringement of any of the Licensed Patents in the Field, and the parties will consult
        with each other to decide the best way to respond to such infringement.&#160; If the parties fail to agree on a joint programme of action (and as relevant the sharing of costs in relation to such joint programme) within 14 days of notification of
        infringement or potential infringement then the following shall apply:</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">a.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">(i)&#160;Adaptimmune
        shall be entitled (but not obliged) to take action against the third party at its sole expense for any infringement or potential infringement where such infringement or potential infringement relates to any product that contains cells that are
        transfected with genes encoding TCRs including any product containing cells that may also be transfected </font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">25</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <p style="margin:0in 0in .0001pt 1.0in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">with one or more additional other molecules as well (whether transfected at the same time or by the same means as the TCRs or not); and (ii)&#160;any
        process, service or method relating solely to any product that contains cells that are transfected with genes encoding TCRs, in each case excluding any infringement or potential infringement of any Core Patent;</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">b.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Immunocore shall
        be entitled (but not obliged) to take action against the third party at its sole expense for any infringement or potential infringement where such infringement or potential infringement relates to (i)&#160;any product that contains Soluble TCRs and any
        process, service or method relating to such a product; and (ii)&#160;any Core Patent.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">The other Party
        agrees to be joined in any suit to the extent necessary to enforce such rights subject to being reimbursed and secured in a reasonable manner as to any costs, damages, expenses, or other liability and shall have the right to be separately
        represented by its own counsel at its own expense.</font></p>
    <p style="margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">20.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Should





        Immunocore fail to file, maintain or prosecute any patent or patent application in accordance with this Schedule 3, Adaptimmune may provide Immunocore with 30 days notice of such failure. Where such failure is not corrected within the 30 day notice
        period, Adaptimmune may serve a further written notice to take over the filing, prosecution and maintenance of such Licensed Patents. Immunocore shall provide all reasonable assistance required by Adaptimmune in relation to the transition of the
        filing, prosecution and maintenance of such patents and/or patent applications to Adaptimmune.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">21.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">Where





        Adaptimmune takes over the filing, prosecution and maintenance of any of the patents or patent applications under paragraph 20 above, paragraph 14 shall cease to apply. Adaptimmune will file, prosecute and maintain any patents or patent
        applications in accordance with the obligations previously imposed on Immunocore. Immunocore will reimburse Adaptimmune, within 30 days of the date of an invoice from Adaptimmune, for 50% of the reasonable costs (including patent agent costs), fees
        and charges incurred by Adaptimmune in the course of filing, prosecuting and maintaining patent and patent applications under this Schedule 3.&#160; Such invoice will set out an itemised list of the costs incurred by the Adaptimmune to a level of detail
        satisfactory to the Immunocore. Immunocore may also request copies of invoices received from third parties including patent agent costs.</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt .75in;text-indent:-.5in;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">22.</font><font style="font-size:3.0pt;" size="1">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size:10.0pt;" size="2">This





        Schedule 3 shall apply to the filing of patents and patent applications in relation to Results, Know-How or the Licensed Patents both during the term of this Deed and following any termination or expiry of this Deed.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">26</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Schedule 4</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Projects as at Effective Date</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.8%;" valign="bottom" width="11%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Unique&#160;ID</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.64%;" valign="bottom" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">TCR&#160;Source</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:9.0%;" valign="bottom" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Target</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.0%;" valign="bottom" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">MHC&#160;allele</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.0%;" valign="bottom" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Sequence&#160;of&#160;wt<br>
                  epitope</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:11.4%;" valign="bottom" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">In-<br>
                  licensed?</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.0%;" valign="bottom" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">TRAV</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.0%;" valign="bottom" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">TRBV</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c001</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c002</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c003</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c004</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c005</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c006</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c007</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c008</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c009</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c010</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c011</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c012</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c013</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c014a</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c014b</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c015</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;">
      <hr align="left" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]Portions of this page&#160;have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">27</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c021</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c022</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c023</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c024</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c025</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c026</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c028</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c029</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c30</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c31</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c32</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c027</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c018</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c019</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c020</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c017</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c033</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c034</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c035</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c036</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c037</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c038</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;">
      <hr align="left" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">***Portions of this page&#160;have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">28</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c039</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c040</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c041</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c042</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c043</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c044</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c045</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c046</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c047</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c048</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c049</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c050</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c051</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c052</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c053</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c054</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c055</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c056</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c057</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c058</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c059</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c060</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;">
      <hr align="left" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">***Portions of this page&#160;have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">29</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c061</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c062</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c063</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c064</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c065</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c066</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c067</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c068</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c069</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c070</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c071</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c072</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c073</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c074</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c075</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c076</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c077</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c078</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c079</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c080</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c081</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c082</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;">
      <hr align="left" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">***Portions of this page&#160;have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.</font></p>
  </div>
  <div>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">30</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c083</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c084</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c085</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:8.0%;" bgcolor="#CCEEFF" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c086</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c087</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">c088</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:8.0%;" valign="top" width="8%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.8%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.64%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:9.0%;" bgcolor="#CCEEFF" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.0%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.0%;" bgcolor="#CCEEFF" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:11.4%;" bgcolor="#CCEEFF" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.02%;" bgcolor="#CCEEFF" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.02%;" bgcolor="#CCEEFF" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:11.8%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.64%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:9.0%;" valign="top" width="9%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.0%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:15.0%;" valign="top" width="15%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:11.4%;" valign="top" width="11%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.02%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:18.02%;" valign="top" width="18%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">[***]</font></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div style="margin:0in 0in .0001pt;">
      <hr align="left" color="black" size="1" noshade="noshade" width="25%"></div>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">***Portions of this page&#160;have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;">31</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%32%%%-->
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">SCHEDULE 5</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">PATENT PROCESS TEMPLATE</font></b></p>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">This template may be completed for each new patent family/ notification to record steps taken in accordance with this Deed and, in particular, Schedule 3
        of this Deed. Should there be any conflict t between any template and Schedule 3, the provisions of Schedule 3 shall supersede and override any template unless Schedule 3 is explicitly stated to be amended and such amendment is agreed to in writing
        by both Parties.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">Immunocore agrees to use reasonable endeavours to complete this template and provide a copy to Adaptimmune following any changes or updates to this
        template.</font></p>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:29.16%;" valign="bottom" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Step&#160;in&#160;patent<br>
                  process&#160;procedure.</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:30.0%;" valign="bottom" width="30%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Action/&#160;decision</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="1">&#160;</font></b></p>
          </td>
          <td style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:35.0%;" valign="bottom" width="35%">
            <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><b><font style="font-size:8.0pt;font-weight:bold;" face="Times New Roman" size="1">Authorisation&#160;by&#160;Parties</font></b></p>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:62.08%;" valign="top" width="62%">
            <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Assigned family number:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="border:none;padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:62.08%;" valign="top" width="62%">
            <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Granted patent details when available:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><font style="font-size:1.0pt;" face="Times New Roman" size="2">&#160;</font></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification of invention</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification made by:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification date:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification relates to same TCR or subject matter as previously filed application: see template for <i>[insert application
                    details/ family number</i>] for further information.</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Decision to maintain invention as confidential:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Decision to file patent application:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font><br style="page-break-before:always;" clear="all">
    </p>
  </div>
  <div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: normal; font-style: normal;">32</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Where no agreement is reached between the Parties: patent application will be filed.</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application filed</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application details:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Immunocore:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date filed:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Adaptimmune</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Any dispute as to content to be resolved in favour of Adaptimmune.</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application withdrawn</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application details:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date withdrawn:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Any dispute to be resolved in favour of Adaptimmune.</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application withdrawn and re-filed</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application details:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date withdrawn:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date new provisional filed:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">New Provisional Application details:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Any dispute to be resolved in favour of Adaptimmune.</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Full Application filed</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Full Application details:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date filed:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;">33</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Any dispute as to content to be resolved in favour of Adaptimmune.</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Later Application notified</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification made by:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification date:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Provisional Application to be withdrawn:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date withdrawn:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Full Application to be withdrawn:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date withdrawn:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Later Application to be re-filed:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Later Application re-filed:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Application details:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date filed:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;">34</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Content agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td colspan="3" style="padding:0in 0in 0in 0in;width:67.92%;" valign="top" width="67%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">N.B. Where no agreement on withdrawal of Provisional Application or Full Application,&#160;Immunocore can file Later Application
                  but must include all Adaptimmune requested mutations:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date Later Application filed:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Application details:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Responses to Official Actions/ Search Reports/ Examination reports</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Details of office action/ notification etc:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Response agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Response agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Changes to claim scope</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Details of changes made/ response to office action/ opposition:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Changes agreed by Immunocore:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Changes agreed by Adaptimmune</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification that either party wishes to cease being involved in prosecuting/ filing or maintaining any Licensed Patent</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification made by:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Notification date:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Licensed Patent(s)&#160;affected:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Agreement by other party to take over prosecution, filing and maintenance of Licensed Patent:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Signature:</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date:</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">Date title to patent </font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;">35</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <table style="border-collapse:collapse;width:100.0%;" border="0" cellpadding="0" cellspacing="0" width="100%">

        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">transferred to party taking over prosecution, filing and maintenance of Licensed Patent:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>
        <tr>
          <td style="padding:0in 0in 0in 0in;width:29.16%;" valign="top" width="29%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:30.0%;" valign="top" width="30%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:10.0pt;font-weight:bold;" face="Times New Roman" size="2">If party is not taking over prosecution, filing and maintenance of Licensed Patent, date of lapse or withdrawal:</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:2.92%;" valign="bottom" width="2%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
          <td style="padding:0in 0in 0in 0in;width:35.0%;" valign="top" width="35%">
            <p style="margin:0in 0in .0001pt;"><b><font style="font-size:1.0pt;font-weight:bold;" face="Times New Roman" size="2">&#160;</font></b></p>
          </td>
        </tr>

    </table>
    <p style="margin:0in 0in .0001pt;text-align:center;" align="center"><font style="font-size:10.0pt;" face="Times New Roman" size="2">&#160;</font></p>
    <br>
  </div>
  <!-- TOCEXISTFLAG -->
  <div style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: normal; font-style: normal;">36</font>
    <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>15
<FILENAME>nt10016217x4_ex10-17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div style="text-align: right;"><font style="font-weight: bold;"> Exhibit 10.17</font><br>
  </div>
  <div> <br>
  </div>
  <div>
    <div style="text-align: center; font-weight: bold;">LOAN AND SECURITY AGREEMENT</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">THIS LOAN AND SECURITY AGREEMENT</font> (as the same may from time to time be amended, modified, supplemented or restated, this &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;)



      dated as of November 6, 2020 (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;) among OXFORD FINANCE LUXEMBOURG S.&#192; R.L., a Luxembourg private limited liability company (soci&#233;t&#233; &#224; responsabilit&#233; limit&#233;e) with registered office at 2 route
      d&#8217;Arlon, 8008 Strassen, Grand Duchy of Luxembourg and registered with the Luxembourg commercial register under number B243395, acting in respect of its Compartment 1 (&#8220;<font style="font-weight: bold;">Oxford</font>&#8221;), as collateral agent (in such
      capacity, &#8220;<font style="font-weight: bold;">Collateral Agent</font>&#8221;), the Lenders listed on <u>Schedule 1.1</u> hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a &#8220;<font style="font-weight: bold;">Lender</font>&#8221; and collectively, the &#8220;<font style="font-weight: bold;">Lenders</font>&#8221;), and IMMUNOCORE LIMITED, a private limited company incorporated under the laws of England and Wales and limited by shares under registration number
      645207 with offices located at 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK (&#8220;<font style="font-weight: bold;">Parent</font>&#8221; and &#8220;<font style="font-weight: bold;">Borrower&#8221;</font>), IMMUNOCORE LLC, a Delaware limited liability company
      and wholly owned subsidiary of Parent with offices located at Six Tower Bridge, Suite 540, 181 Washington Street, Conshohocken, PA 19422 (&#8220;<font style="font-weight: bold;">Core Sub</font>&#8221;) and IMMUNOCORE COMMERCIAL LLC, a Delaware limited liability
      company and wholly owned subsidiary of Core Sub with offices located at Six Tower Bridge, Suite 540, 181 Washington Street, Conshohocken, PA 19422 (&#8220;<font style="font-weight: bold;">Commercial Sub</font>&#8221;) (Core Sub and Commercial Sub, collectively,
      the &#8220;<font style="font-weight: bold;">Guarantors</font>&#8221;, and Parent, Core Sub and Commercial Sub, each, a &#8220;<font style="font-weight: bold;">Loan Part</font>y&#8221; and collectively, the &#8220;<font style="font-weight: bold;">Loan Parties</font>&#8221; ), provides
      the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders.&#160; The parties agree as follows:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z294bd4aaed4546049fa516a6fe014e03" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>ACCOUNTING AND OTHER TERMS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounting terms not defined in this Agreement shall be construed in accordance with IFRS.&#160; Calculations and determinations must be made in
      accordance with IFRS.&#160; Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13.&#160; All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to
      the extent such terms are defined therein.&#160; All references to &#8220;Dollars&#8221; or &#8220;$&#8221; are United States Dollars, unless otherwise noted.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6d848e0b2cca436da64cf5c06f2b8b31" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>LOANS AND TERMS OF PAYMENT</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Promise to Pay</font>.&#160; Borrower hereby unconditionally promises to pay each Lender, the outstanding principal
      amount of all Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Term Loans.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Availability</u>.&#160; (1) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans
      to Borrower on the Effective Date in an aggregate amount of Fifty Million Dollars ($50,000,000.00) according to each Lender&#8217;s Term A Loan Commitment as set forth on <u>Schedule 1.1</u> hereto (such term loans are hereinafter referred to singly as a
      &#8220;<font style="font-weight: bold;">Term A Loan</font>&#8221;, and collectively as the &#8220;<font style="font-weight: bold;">Term A Loans</font>&#8221;).&#160; After repayment, no Term A Loan may be re&#8209;borrowed.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term
      loans to Borrower, upon Borrower&#8217;s request, in an aggregate amount up to Twenty Five Million Dollars ($25,000,000.00) according to each Lender&#8217;s Term B Loan Commitment as set forth on <u>Schedule 1.1</u> hereto (such term loans are hereinafter
      referred to singly as a &#8220;<font style="font-weight: bold;">Term B Loan</font>&#8221;, and collectively as the &#8220;<font style="font-weight: bold;">Term B Loans</font>&#8221;).&#160; After repayment, no Term B Loan may be re&#8209;borrowed.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period, to make term
      loans to Borrower, upon Borrower&#8217;s request, in an aggregate amount up to Twenty Five Million Dollars ($25,000,000.00) at each Lender&#8217;s sole discretion (such term loans are hereinafter referred to singly as a &#8220;<font style="font-weight: bold;">Term C
        Loan</font>&#8221;, and collectively as the &#8220;<font style="font-weight: bold;">Term C Loans</font>;&#8221; each Term A Loan, Term B Loan or Term C Loan is hereinafter referred to singly as a &#8220;<font style="font-weight: bold;">Term Loan</font>&#8221; and the<font style="font-weight: bold;">&#160;</font>Term A Loans, the Term B Loans and the Term C Loans are<font style="font-weight: bold;">&#160;</font>hereinafter referred to collectively as the &#8220;<font style="font-weight: bold;">Term Loans</font>&#8221;).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Repayment</u>.&#160; Borrower shall make monthly payments of interest only in arrears commencing on the first (1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding
      the Amortization Date.&#160; Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof.&#160;
      Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter until the Maturity Date (or such Term Loan is otherwise paid in full), Borrower shall make consecutive equal monthly payments of principal, together with
      applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender&#8217;s Term Loan advanced to Borrower, (2) the effective rate
      of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to (A) twenty-three (23) months, if the I/O Extension Event does not occur or (B) eleven (11) months, if the I/O Extension Event occurs.&#160; All unpaid principal and
      accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date.&#160; Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Mandatory Prepayments</u>.&#160; If the Term Loans are accelerated following the occurrence and continuance of an Event of Default, Borrower shall
      immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date,
      (ii) the applicable Final Payment, (iii) the applicable Prepayment Fee, if any, plus (iv) all other Obligations that are then due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts (if any).
      Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to Collateral Agent, for
      payment to each Lender in accordance with its respective Pro Rata Share, the applicable portion of the Final Payment still due in respect of the Term Loan(s).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Permitted Prepayment of Term Loans</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided
      Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with
      its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the Prepayment Fee, plus (D) all other
      Obligations that are due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Notwithstanding anything herein to the contrary, Borrower shall also have the option to prepay part of Term Loans advanced by the Lenders under
      this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, (ii) prepays such part of the Term Loans in a minimum principal amount of at
      least Ten Million Dollars ($10,000,000.00) or such greater amount that exceeds Ten Million Dollars ($10,000,000.00) by whole number increment(s) of Two Million Five Hundred Thousand Dollars ($2,500,000.00), and (iii) pays to the Lenders on the date
      of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) the portion of outstanding principal of such Term Loans being prepaid plus all accrued and unpaid interest on the principal
      amount being prepaid through the prepayment date, (B) the applicable Final Payment, and (C) all other Obligations that are then due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts, and
      (D) the applicable Prepayment Fee with respect to the portion of such Term Loans being prepaid. For the purposes of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied
      pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Payment of Interest on the Credit Extensions.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Interest Rate.</u>&#160; Subject to Section 2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per
      annum rate equal to the Basic Rate, determined by Collateral Agent on the Funding Date of the applicable Term Loan and monthly thereafter (on the last day of the month prior to the month in which interest will accrue), which interest shall be payable
      monthly in arrears in accordance with Sections 2.2(b) and 2.3(e). Interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding under such Term Loan
      through and including the day on which such Term Loan is paid in full.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Default Rate</u>. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a
      floating per annum rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the &#8220;<font style="font-weight: bold;">Default Rate</font>&#8221;).&#160; Payment or acceptance of the increased interest rate provided in this
      Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral Agent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>360&#8209;Day Year</u>.&#160; Interest shall be computed on the basis of a three hundred sixty (360) day year, and the actual number of days elapsed.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Debit of Accounts</u>.&#160; Collateral Agent and each Lender may debit (or ACH) any deposit accounts, maintained by Borrower or any of its
      Subsidiaries, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes the Lenders under the Loan Documents when due.&#160; Any such debits (or ACH activity) shall not constitute a set&#8209;off; provided,
      however, Collateral Agent and each Lender shall first debit (or ACH) the Designated Deposit Account and to the extent that the amount therein is not sufficient, debit (or ACH) another account of Borrower or any of its Subsidiaries.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Payments</u>.&#160; Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective
      Lender to which such payments are owed, at such Lender&#8217;s office in immediately available funds on the date specified herein. Unless otherwise provided, interest is payable monthly on the Payment Date of each month.&#160; Payments of principal and/or
      interest received after 12:00 noon Eastern time are considered received at the opening of business on the next Business Day.&#160; When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or
      interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses, indemnities and reimbursements, shall
      be made without set&#8209;off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Secured Promissory Notes.</font>&#160; The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the
      form attached as <u>Exhibit D</u> hereto (each a &#8220;<font style="font-weight: bold;">Secured Promissory Note</font>&#8221;), and shall be repayable as set forth in this Agreement.&#160; Borrower irrevocably authorizes each Lender to make or cause to be made, on
      or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender&#8217;s Secured Promissory Note, an appropriate notation on such Lender&#8217;s Secured Promissory Note Record reflecting the making of such Term Loan
      or (as the case may be) the receipt of such payment.&#160; The outstanding amount of each Term Loan set forth on such Lender&#8217;s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender,
      but the failure to record, or any error in so recording, any such amount on such Lender&#8217;s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to
      make payments of principal of or interest on any Secured Promissory Note when due.&#160; Upon receipt of&#160;an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note<font style="font-weight: bold;">, </font>Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Fees.</font>&#160; Borrower shall pay to Collateral Agent:</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Good Faith Deposit</u>. An amount of One Hundred Thousand Dollars ($100,000.00) has been received by Collateral Agent as a good faith deposit
      from Borrower on or about August 18, 2020, which amount shall be applied towards the Lenders&#8217; Expenses due under Section 2.5(e) that have been incurred through the Effective Date, with the balance, if any, towards the facility fee due under Section
      2.5(b).&#160; For the purposes of clarity, Borrower shall be responsible for the entire documented amount of the Lenders&#8217; Expenses payable under Section 2.5(e) and for the entire amount of facility fee due under Section 2.5(b).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Facility Fee</u>.&#160; A fully earned, non&#8209;refundable facility fee of One Hundred Fifty Thousand Dollars ($150,000.00) to be shared between the
      Lenders pursuant to their respective Commitment Percentages payable on the Funding Date of the Term A Loan;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Final Payment</u>.&#160; The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata
      Shares;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Prepayment Fee</u>.&#160; The Prepayment Fee, if and when due hereunder, to be shared between the Lenders in accordance with their respective Pro
      Rata Shares; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Lenders&#8217; Expenses</u>.&#160; All Lenders&#8217; Expenses (including reasonable attorneys&#8217; fees and expenses for documentation and negotiation of this
      Agreement) incurred through and after the Effective Date, when due.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Taxes</font>.</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as required by applicable law, payments received by Lender from the Loan Parties under this Agreement will be made free and clear of and
      without deduction for any and all Taxes.&#160; However, if at any time any Governmental Authority, applicable law, regulation or international agreement requires any Loan Party to make any withholding or deduction from any such payment or other sum
      payable hereunder to Lender, then,&#160; (i) the applicable Loan Party shall withhold or make such deductions as is required by law, (ii) the applicable Loan Party shall timely pay the full amount withheld or deducted to the relevant Governmental
      Authority, and (iii) subject to the provisions of Section 2.6(b) to the extent that the withholding or deduction is made on account of Non-Excluded Taxes, the sum payable by the applicable Loan Party shall be increased to the extent necessary to
      ensure that, after the making of such required withholding or deduction, Lender receives a net sum equal to the sum that Lender would have received had no withholding or deduction been required.&#160;&#160; The Borrower shall, upon written request, furnish
      Lender with proof reasonably satisfactory to Lender indicating that the applicable Loan Party has made such withholding payment.&#160; The agreements and obligations of the Loan Parties and Lender contained in this Section 2.6 shall survive the
      termination of this Agreement, and shall apply to any successor, assignee or participant (or other transferee) of Lender or any Loan Party under Section 12.1 (Successors and Assigns) as of the date such Person becomes party to, or otherwise obligated
      under, this Agreement, provided, however, that no participant shall be entitled to receive any greater payment under this Section 2.6(a) with respect to any participation than the participating Lender would have been entitled to receive, except to
      the extent such entitlement to receive a greater payment results from a change in law that occurs after the participant acquired the applicable participation.&#160; For purposes of this Section 2.6, the term &#8220;applicable law&#8221; includes FATCA.</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the provisions of Section 2.6(a), a payment by a Loan Party shall not be increased under Section 2.6(a) by reason of a UK Tax
      Deduction if, on the date on which the payment falls due:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the payment could have been made to the relevant Lender without a UK Tax Deduction if the Lender had been a UK Qualifying Lender, but on that
      date that Lender is not or has ceased to be a UK Qualifying Lender other than as a result of any change after the date it became a Lender under this Agreement in (or in the interpretation, administration, or application of) any law or UK Treaty or
      any published practice or published concession of any relevant taxing authority; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the relevant Lender is a UK Qualifying Lender solely by virtue of paragraph (b) of the definition of UK Qualifying Lender and:</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an officer of HM Revenue &amp; Customs has given (and not revoked) a direction (a &#8220;<font style="font-weight: bold;">Direction</font>&#8221;) under
      section 931 of the UK ITA which relates to the payment and that Lender has received from the UK Obligor making the payment a certified copy of that Direction; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the payment could have been made to the Lender without any UK Tax Deduction if that Direction had not been made; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the relevant Lender is a UK Qualifying Lender solely by virtue of paragraph (b) of the definition of UK Qualifying Lender and:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the relevant Lender has not given a UK Tax Confirmation to the relevant UK Obligor; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the payment could have been made to the Lender without any UK Tax Deduction if the Lender had given a UK Tax Confirmation to the relevant UK
      Obligor, on the basis that the UK Tax Confirmation would have enabled such UK Obligor to have formed a reasonable belief that the payment was an &#8220;excepted payment&#8221; for the purpose of section 930 of the UK ITA; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the relevant Lender is a UK Treaty Lender and the UK Obligor making the payment is able to demonstrate that the payment could have been made to
      the Lender without the UK Tax Deduction had that Lender complied with its obligations under Sections 2.6(c) or 2.6(e)(i), (ii) and (iii) (as applicable) below.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Original Lender hereby confirms that it is a QPP Lender and that it will provide the Borrower with its QPP Certificate on the date of this
      Agreement to the extent that it has not already done so.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the Borrower receives a notification from HM Revenue &amp; Customs that a QPP Certificate given by a Lender has no effect, the Borrower shall
      promptly deliver a copy of that notification to that Lender.&#160; Any Lender which was a UK Qualifying Lender when it became party to this Agreement but subsequently ceases to be a UK Qualifying Lender shall promptly notify the Borrower of that event.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-weight: bold;">(e)</div>
    <div style="text-align: justify; text-indent: 108pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to sub-section (ii) below, a UK Treaty Lender and any UK Obligor which makes a payment to that UK Treaty Lender shall co-operate in
      completing any procedural formalities necessary for the UK Obligor to obtain authorization to make that payment without a UK Tax Deduction.</div>
    <div style="text-align: justify; text-indent: 108pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
    <div style="text-align: justify; text-indent: 144pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Original Lender shall provide its scheme reference number under the DTTP scheme and its jurisdiction of tax residence to each UK Obligor in writing promptly following the obtaining
      of such reference number; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a UK Treaty Lender which is not a Lender on the date of this Agreement, holds a passport under the DTTP scheme, and wishes that scheme to apply to this Agreement, shall confirm its
      scheme reference number and its jurisdiction of tax residence to each UK Obligor in the relevant documentation which it executes on becoming a Lender under this Agreement,</div>
    <div style="text-align: justify; margin-left: 108pt;"><br>
    </div>
    <div style="text-align: justify; margin-left: 108pt;">and, having done so, that Lender shall be under no obligation pursuant to sub-section (i) above.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a UK Treaty Lender has confirmed its scheme reference number and its jurisdiction of tax residence in accordance with sub-section (ii) above
      and: (a) the UK Obligor making a payment to that Lender has not made a Borrower DTTP Filing in respect of that Lender; or (b) the UK Obligor making a payment to that Lender has made a DTTP Filing but (1) that DTTP Filing has been rejected by HM
      Revenue &amp; Customs; or (2) HM Revenue &amp; Customs have not given the UK Obligor authority to make payments to that Lender without a UK Tax Deduction within 60 days of the date of the DTTP Filing, and in each case, the UK Obligor has notified
      that Lender in writing, that Lender and the UK Obligor shall co-operate in completing any procedural formalities necessary for the UK Obligor to obtain authorization to make payments without a UK Tax Deduction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a UK Treaty Lender has not confirmed its scheme reference number and jurisdiction of tax residence in accordance with sub-section (ii) above,
      a UK Obligor shall not make a DTTP Filing or file any other form relating to the DTTP Scheme in respect of that Lender&#8217;s Term Loan(s) unless that Lender otherwise agrees.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A UK Obligor shall, promptly on making a DTTP Filing, deliver a copy of that DTTP Filing to the relevant UK Treaty Lender.</div>
    <div style="text-align: justify; text-indent: 108pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Lender which is not an Original Lender shall, in respect of each UK Obligor, indicate in the relevant documentation which it executes on
      becoming a Lender under this Agreement which of the following categories it falls in: (A) not a UK Qualifying Lender; (B) a UK Qualifying Lender (other than a UK Treaty Lender or a QPP Lender); (C) a UK Treaty Lender; or (D) a QPP Lender.&#160; If a
      Lender fails to indicate its status in accordance with this sub-section (vi) then such Lender shall be treated for the purposes of this Agreement (including by each UK Obligor) as if it is not a UK Qualifying Lender until such time as it notifies the
      UK Obligor(s) which category applies.&#160; For the avoidance of doubt, any such documentation shall not be invalidated by any such failure of a Lender to comply with this sub-section (vi).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The UK Obligors shall promptly on becoming aware that a UK Obligor must make a UK Tax Deduction (or that there is any change in the rate or
      basis of a UK Tax Deduction) notify the Lender accordingly.&#160; Similarly, a Lender shall notify the UK Obligors on becoming so aware in respect of a payment payable to that Lender.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without duplication of the Loan Parties&#8217; obligations under Section 2.6(a), each Loan Party shall, jointly and severally, indemnify Lender, within
      ten days after written demand therefor, for the full amount of any Non-Excluded Taxes paid or payable by or required to be withheld or deducted from a payment to Lender and any reasonable expenses arising therefrom or with respect thereto, whether or
      not such Non-Excluded Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.&#160; A certificate as to the amount of such payment or liability delivered to the applicable Loan Party by Lender shall be conclusive absent
      manifest error.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority pursuant to this Section 2.6, such Loan Party
      shall deliver to Lender the original or certified copy of a receipt issued by such Governmental Authority evidencing such payment (if any) or other evidence of such payment reasonably satisfactory to Lender.</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If Lender receives a refund of any Non-Excluded Taxes or amounts with respect to which a Loan Party has paid additional amounts to that Lender
      pursuant to this Section 2.6, it shall pay to Borrower an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by a Loan Party under this Section 2.6 with respect to the Non-Excluded Taxes giving
      rise to such refund), net of all reasonable out-of-pocket expenses of Lender, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that each Loan Party, upon the request of
      Lender, agrees to repay the amount paid over to Loan Parties pursuant to this <u>subsection (h)</u> to Lender in the event Lender is required to repay such refund to such Governmental Authority.&#160; This subsection shall not be construed to require
      Lender to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to Loan Parties or any other Person.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Stamp taxes</font></div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Borrower shall pay and, within three Business Days of demand, indemnify each Lender against any cost, loss or liability that Lender incurs in relation to all stamp duty, registration and other similar Taxes payable
      in respect of any Loan Document, provided that (save in respect of any such stamp duty, registration and other similar Taxes payable by a Lender in respect of a HoldCo Transaction) this Section 2.7(a) shall not apply in respect of any stamp duty,
      registration and other similar Taxes payable in respect of any assignment, transfer or other alienation by a Lender of its rights and/or obligations under a Loan Document.</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">VAT</font></div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All amounts expressed to be payable under a Loan Document by any party to a Lender or Collateral Agent which (in whole or in part) constitute the
      consideration for any supply for VAT purposes are deemed to be exclusive of any VAT which is chargeable on that supply, and accordingly, subject to paragraph (b) below, if VAT is or becomes chargeable on any supply made by any Lender or Collateral
      Agent to any Loan Party under a Loan Document and such Lender or Collateral Agent is required to account to the relevant tax authority for the VAT, that Loan Party must pay to such Lender or Collateral Agent (in addition to and at the same time as
      paying any other consideration for such supply) an amount equal to the amount of the VAT (and such Lender or Collateral Agent must promptly provide an appropriate VAT invoice to that Loan Party).</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If VAT is or becomes chargeable on any supply made by any Lender or Collateral Agent (the &#8220;<font style="font-weight: bold;">Supplier</font>&#8221;) to
      any other Lender or Collateral Agent (the &#8220;<font style="font-weight: bold;">Recipient</font>&#8221;) under a Loan Document, and a Loan Party&#160; is required by the terms of any Loan Document to pay an amount equal to the consideration for that supply to the
      Supplier (rather than being required to reimburse or indemnify the Recipient in respect of that consideration):</div>
    <div style="text-align: justify; text-indent: 108pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(where the Supplier is the person required to account to the relevant tax authority for the VAT) the Loan Party must also pay to the Supplier (at
      the same time as paying that amount) an additional amount equal to the amount of the VAT.&#160; The Recipient must (where this paragraph (i) applies) promptly pay to the Loan Party an amount equal to any credit or repayment the Recipient receives from the
      relevant tax authority which the Recipient reasonably determines relates to the VAT chargeable on that supply; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(where the Recipient is the person required to account to the relevant tax authority for the VAT) the Loan Party must promptly, following demand
      from the Recipient, pay to the Recipient an amount equal to the VAT chargeable on that supply but only to the extent that the Recipient reasonably determines that it is not entitled to credit or repayment from the relevant tax authority in respect of
      that VAT.</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Where a Loan Document requires a Loan Party to reimburse or indemnify a Lender or any Collateral Agent for any cost or expense, such requirement
      shall include a requirement for that Loan Party or, (at the election of Borrower) where such Loan Party is a member of the Borrower&#8217;s group, the Borrower, to reimburse or indemnify (as the case may be) such Lender or Collateral Agent for the full
      amount of such cost or expense, including such part of such cost or expense as represents VAT, to the extent that such Lender or Collateral Agent reasonably determines that it is not entitled to credit or repayment in respect of such VAT from the
      relevant tax authority.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any reference in this section 2.8 to any Loan Party shall, at any time when such Loan Party is treated as a member of a group for VAT purposes,
      include (where appropriate and unless the context otherwise requires) a reference to the representative member of such group at such time (the term &#8220;representative member&#8221; to have the same meaning as in the Value Added Tax Act 1994).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In relation to any supply made by a Lender or Collateral Agent to any Loan Party under a Loan Document, if reasonably requested by such Lender or
      Collateral Agent, that Loan Party must promptly provide such Lender or Collateral Agent with details of that Loan Party&#8217;s VAT registration and such other information as is reasonably requested in connection with such Lender&#8217;s or Collateral Agent&#8217;s
      VAT reporting requirements in relation to such supply.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">FATCA</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to paragraph (c) below, each party to this Agreement shall, within ten Business Days of a reasonable request by another party to this
      Agreement:</div>
    <div style="text-indent: 144pt;"><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;confirm to that other party whether it is:</div>
    <div><br>
    </div>
    <div style="text-indent: 180pt;"><font style="font-weight: bold;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a FATCA Exempt Party; or</div>
    <div><br>
    </div>
    <div style="text-indent: 180pt;"><font style="font-weight: normal;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;not a FATCA Exempt Party;</div>
    <div style="text-indent: 144pt;"><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;supply to that other party such forms, documentation and other information relating to its status under FATCA as that other party reasonably requests for the
      purposes of that other party&#8217;s compliance with FATCA; and</div>
    <div style="text-indent: 144pt;"><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;supply to that other party such forms, documentation and other information relating to its status as that other Party reasonably requests for the purposes of that
      other party&#8217;s compliance with any other law, regulation, or exchange of information regime.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a party to this Agreement confirms to another party pursuant to paragraph (a)(i) above that it is a FATCA Exempt Party and it subsequently
      becomes aware that it is not or has ceased to be a FATCA Exempt Party, that party shall notify that other party reasonably promptly.</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Paragraph (a) above shall not oblige any Lender to do anything, and paragraph (a)(iii) above shall not oblige any other party to this Agreement to
      do anything, which would or might in its reasonable opinion constitute a breach of:</div>
    <div><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any law or regulation;</div>
    <div><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fiduciary duty; or</div>
    <div><br>
    </div>
    <div style="text-indent: 144pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any duty of confidentiality.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a party to this Agreement fails to confirm whether or not it is a FATCA Exempt Party or to supply forms, documentation or other information
      requested in accordance with paragraph (a)(i) or (a)(ii) above (including, for the avoidance of doubt, where paragraph (c) above applies), then such party shall be treated for the purposes of the Loan Documents (and payments under them) as if it is
      not a FATCA Exempt Party until such time as the party in question provides the requested confirmation, forms, documentation or other information.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each party to this Agreement may make any FATCA Deduction it is required to make by FATCA, and any payment required in connection with that FATCA
      Deduction, and no party shall be required to increase any payment in respect of which it makes such a FATCA Deduction or otherwise compensate the recipient of the payment for that FATCA Deduction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each party to this Agreement shall promptly, upon becoming aware that it must make a FATCA Deduction (or that there is any change in the rate or
      the basis of such FATCA Deduction), notify the party to whom it is making the payment and the other Lenders.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ac1a4f7d1ae4e458ffd3c81d0b567a4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>CONDITIONS OF LOANS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Conditions Precedent to Initial Credit Extension.</font>&#160; Each Lender&#8217;s obligation to make a Term A Loan is
      subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as
      Collateral Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation:</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Loan Documents, each duly executed by the Loan Parties, as applicable;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the UK Security Agreement, together with:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;signed copies of all notices required under the UK Security Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;duly executed Control Agreements with respect to any Collateral Accounts maintained by Borrower or any of its Subsidiaries required to be subject
      to Control Agreements in accordance with Section 6;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;original duly executed Secured Promissory Notes in favor of each Lender according to its Term A Loan Commitment Percentage;</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a separate Guaranty (in such form and substance as acceptable to Collateral Agent) entered into by each Guarantor;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Operating Documents and, where applicable, good standing certificates of the Loan Parties (other than any UK Obligors) and its U.S.
      Subsidiaries certified by the Secretary of State (or equivalent agency) of Borrower&#8217;s and such Subsidiaries&#8217; jurisdiction of organization or formation and each jurisdiction in which such Loan Party and each Subsidiary is qualified to conduct
      business, each as of a date no earlier than thirty (30) days prior to the Effective Date;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a completed Perfection Certificate for each Loan Party;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Annual Projections, for the current calendar year;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;duly executed officer&#8217;s certificate for each Loan Party, in a form acceptable to Collateral Agent and the Lenders;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;certified copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, or in the case
      of any UK Obligor, a search of Companies House, as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens
      or have been or, in connection with the initial Credit Extension, will be terminated or released;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a landlord&#8217;s consent executed in favor of Collateral Agent in respect of all leased locations of Loan Parties (other than UK Obligors) where such
      Loan Parties (other than UK Obligors) maintains its books and records or Collateral having a book value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee where the Loan Parties maintains Collateral having a
      book value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a duly executed legal opinion of counsel to the Guarantors dated as of the Effective Date;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evidence satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section 6.5 hereof are in full force and effect,
      together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Lenders; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a copy of any applicable Registration Rights Agreement or Investors&#8217; Rights Agreement and any amendments thereto;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(p)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;duly executed original Success Fee Letter;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(q)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a copy of a resolution of the board of directors of the Parent:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;approving the terms of, and the transactions contemplated by, the Loan Documents to which it is a party and resolving that it execute, deliver
      and perform the Loan Documents to which it is a party;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;authorizing a specified person or persons to execute the Loan Documents to which it is a party on its behalf;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;authorizing a specified person or persons, on its behalf, to sign and/or dispatch all documents and notices (including any Disbursement Letter)
      to be signed and/or dispatched by it under or in connection with the Loan Documents to which it is a party;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(r)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a specimen of the signature of each person authorized by the resolution referred to in paragraph (q) above in relation to the Loan Documents and
      related documents who will be signing Loan Documents;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(s)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a director&#8217;s certificate of the Parent (signed by a director) confirming that borrowing or guaranteeing or securing, as appropriate, the Term Loan
      Commitments would not cause any borrowing, guarantee, security or similar limit binding on Borrower to be exceeded;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(t)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a certified copy of the group structure chart; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(u)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section 2.5 hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Conditions Precedent to all Credit Extensions.</font>&#160; The obligation of each Lender to make each Credit
      Extension, including the initial Credit Extension, is subject to the following conditions precedent:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;receipt by Collateral Agent of an executed Disbursement Letter in the form of <u>Exhibit B</u> attached hereto;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the representations and warranties in Section 5 hereof shall be true, accurate and complete in all material respects on the date of the
      Disbursement and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;
      and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or
      result from the Credit Extension.&#160; Each Credit Extension is Borrower&#8217;s representation and warranty on that date that the representations and warranties in Section 5 hereof are true, accurate and complete in all material respects; provided, however,
      that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly
      referring to a specific date shall be true, accurate and complete in all material respects as of such date;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in such Lender&#8217;s sole discretion, there has not been any Material Adverse Change;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes, in number, form and content acceptable to each
      Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section 2.5 hereof.</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Covenant to Deliver.</font>&#160; Borrower agrees to deliver to Collateral Agent and the Lenders each item required to
      be delivered to Collateral Agent under this Agreement as a condition precedent to any Credit Extension.&#160; Borrower expressly agrees that a Credit Extension made prior to the receipt by Collateral Agent or any Lender of any such item shall not
      constitute a waiver by Collateral Agent or any Lender of Borrower&#8217;s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in each Lender&#8217;s sole discretion.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Procedures for Borrowing.</font>&#160; Subject to the prior satisfaction of all other applicable conditions to the
      making of a Term Loan set forth in this Agreement, to obtain a Term Loan, Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 noon Eastern time five (5) Business Days prior to the
      date the Term Loan is to be made.&#160; Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to the Lenders by electronic mail or facsimile a completed Disbursement Letter executed by a Responsible Officer or his
      or her designee.&#160; The Lenders may rely on any telephone notice given by a person whom a Lender reasonably believes is a Responsible Officer or designee.&#160; On the Funding Date, each Lender shall credit and/or transfer (as applicable) to the Designated
      Deposit Account, an amount equal to its Term Loan Commitment of such Term Loan.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3fef70cb172a40eba99a8d033d843b6d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>CREATION OF SECURITY INTEREST</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Grant of Security Interest.</font>&#160; Each Loan Party hereby grants Collateral Agent, for the ratable benefit of
      the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or
      hereafter acquired or arising, and all proceeds and products thereof.&#160; Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the
      Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement or applicable law to have priority to Collateral Agent&#8217;s Lien (provided that for the avoidance of doubt no filing or registration of this Agreement shall be
      made with Companies House in the United Kingdom).&#160; If any Loan Party shall acquire a commercial tort claim (as defined in the Code) with a value that could exceed $50,000, such Loan Party, shall promptly notify Collateral Agent in a writing signed by
      such Loan Party, as the case may be, of the general details thereof (and further details as may be required by Collateral Agent) and as to such Loan Party&#8217;s grant to Collateral Agent, for the ratable benefit of the Lenders, in such writing a security
      interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">If this Agreement is terminated, Collateral Agent&#8217;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations) are repaid in full in cash.&#160; Upon payment
      in full in cash of the Obligations (other than inchoate indemnity obligations) and at such time as the Lenders&#8217; obligation to make Credit Extensions has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, promptly release
      its Liens in the Collateral and all rights therein shall revert to the Loan Parties.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Notwithstanding anything in this Agreement to the contrary, the Loan Parties shall not be required to deliver certificates of title, or other similar evidence of ownership, with respect to vehicles
      owned by the Loan Parties to Lender or Collateral Agent during the term of this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Authorization to File Financing Statements.</font>&#160; The Loan Parties hereby authorizes Collateral Agent to file
      financing statements or take any other action required to perfect Collateral Agent&#8217;s security interests in the Collateral, without notice to the Loan Parties, with all appropriate jurisdictions to perfect or protect Collateral Agent&#8217;s interest or
      rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by the Loan Parties, or any other Person, shall be deemed to violate the rights of Collateral
      Agent under the Code. Notwithstanding the foregoing, or anything to the contrary herein, no filing or registration of this Agreement shall be made with Companies House in the United Kingdom.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Pledge of Collateral.</font>&#160; The Loan Parties hereby pledge, assign and grant to Collateral Agent, for the
      ratable benefit of the Lenders, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted in
      connection therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations.&#160; On the Effective Date, or, to the extent not certificated as of the Effective Date or not delivered pursuant to a UK
      Security Agreement, within fifteen (15) days of the certification of any Shares, the certificate or certificates for the Shares will be delivered to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by the applicable
      Loan Party.&#160; For the avoidance of doubt, nothing in this Agreement shall require the Loan Parties to certificate shares.&#160; To the extent required by the terms and conditions governing the Shares, the Loan Parties shall cause the books of each entity
      whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares.&#160; Upon the occurrence and during the continuance of an Event of Default hereunder, Collateral Agent may effect the transfer of any securities included
      in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and cause new (as applicable) certificates representing such securities to be issued in the name of Collateral Agent or its transferee.&#160; The Loan Parties
      will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Shares.&#160; Unless an Event of Default
      shall have occurred and be continuing, The Loan Parties shall be entitled to exercise any voting rights with respect to the Shares and to give consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent,
      waiver or ratification given or action taken which would be inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of such terms, provided that if such Event of Default is waived, then the Loan
      Parties&#8217; foregoing rights shall revive.&#160; All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default provided that if such Event of Default is waived, then the Loan
      Parties&#8217; rights to vote and give consents, waivers and ratifications shall revive.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4800d81d5e1c4ef197d94685a86f7899" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>REPRESENTATIONS AND WARRANTIES</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Each of the Loan Parties hereby, jointly and severally, represents and warrants to Collateral Agent and the Lenders as follows:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Due Organization, Authorization: Power and Authority.</font>&#160; The Loan Parties and each of their Subsidiaries are
      duly existing and, where applicable, in good standing as a Registered Organization in its jurisdictions of organization or formation and the Loan Parties and each of their Subsidiaries is qualified and licensed to do business and, where applicable,
      and other than in respect of a UK Obligor, is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property requires that it&#160; be qualified except where the failure to do so could not reasonably be expected
      to have a Material Adverse Change.&#160; In connection with this Agreement, the Loan Parties and each of its Subsidiaries have delivered to Collateral Agent a completed perfection certificate signed by an officer of such Loan Party or such Subsidiary
      (each a &#8220;<font style="font-weight: bold;">Perfection Certificate</font>&#8221; and collectively, the &#8220;<font style="font-weight: bold;">Perfection Certificates</font>&#8221;).&#160; Each Loan Party represents and warrants that (a) Borrower and each of its
      Subsidiaries&#8217; exact legal name is that which is indicated on its respective Perfection Certificate and on the signature page of each Loan Document to which it is a party; (b) each Loan Party and each of their Subsidiaries is an organization of the
      type and is organized in the jurisdiction set forth on its respective Perfection Certificate; (c) each Perfection Certificate accurately sets forth each of the Loan Party&#8217;s and their Subsidiaries&#8217; organizational identification number or accurately
      states that such Loan Party or such Subsidiary has none; (d) each Perfection Certificate accurately sets forth each Loan Party&#8217;s and each of its Subsidiaries&#8217; place of business, or, if more than one, its chief executive office as well as each Loan
      Party&#8217;s and each of its Subsidiaries&#8217; mailing address (if different than its chief executive office); (e) each Loan Party and each of their Subsidiaries (and each of its respective predecessors) have not, in the past five (5) years, changed its
      jurisdiction of organization, organizational structure or type, or any organizational number assigned by its jurisdiction; and (f) all other information set forth on the Perfection Certificates pertaining to each Loan Party and each of their
      Subsidiaries, is accurate and complete in all material respects (it being understood and agreed that each Loan Party and each of their Subsidiaries may from time to time update certain information in the Perfection Certificates (including the
      information set forth in clause (d) above) after the Effective Date to the extent permitted by one or more specific provisions in this Agreement); such updated Perfection Certificates subject to the review and approval of Collateral Agent.&#160; If any
      Loan Party or any of their Subsidiaries is not now a Registered Organization but later becomes one, such Loan Party shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person&#8217;s organizational identification number
      within ten (10) Business Days of receiving such organizational identification number.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">The execution, delivery and performance by the Loan Parties and each of their Subsidiaries of the Loan Documents to which it is a party have been duly authorized, and do not (i) conflict with any of
      the Loan Party&#8217;s or such Subsidiaries&#8217; organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene,
      conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which a Loan Party or such Subsidiary, or any of their property or assets may be bound or affected, (iv) require any
      action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect) or are being obtained pursuant to
      Section 6.1(b), or (v) constitute an event of default under any material agreement by which a Loan Party or any of their Subsidiaries, or their respective properties, is bound.&#160; N Loan Party, nor any of their Subsidiaries is in default under any
      agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Collateral.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Loan Party and each their Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which
      it purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and no Loan Party, nor any of their&#160; Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment
      accounts other than the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent in connection herewith (as updated from time to time by notices in accordance with Section
      6.6(b)) with respect of which such Loan Party or such Subsidiary has given Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected security interest therein to the extent required in Section 6.6 of this
      Agreement. The Accounts are bona fide, existing obligations of the Account Debtors. For the avoidance of doubt no filing or registration of this Agreement shall be made with Companies House in the United Kingdom.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the Effective Date, and except as disclosed on the Perfection Certificate, and/or as and to the extent required to be updated to Lender or
      Collateral Agent in accordance with Sections 6.11 and 7.2, (i) the Collateral is not in the possession of any third party bailee (such as a warehouse), and (ii) no such third party bailee possesses components of the Collateral in excess of Five
      Hundred Thousand Dollars ($500,000.00).&#160; None of the components of the Collateral shall be maintained at locations other than as disclosed in the Perfection Certificates on the Effective Date or as permitted and updated pursuant to Section 6.11.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All Inventory held for sale or lease or to be furnished under a contract for services is in all material respects of good and marketable quality,
      free from material defects.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as disclosed on the Perfection Certificate, the Loan Parties and each of their Subsidiaries is the sole owner of the Intellectual Property
      each respectively purports to own, free and clear of all Liens other than Permitted Liens.&#160; (i) Each of Borrower&#8217;s and its Subsidiaries&#8217; Patents is valid and enforceable and no part of Borrower&#8217;s or its Subsidiaries&#8217; Intellectual Property that is
      material to Borrower&#8217;s or any Subsidiary&#8217;s business has been judged invalid or unenforceable, in whole or in part, and (ii) to the Borrower&#8217;s knowledge, no claim has been made in writing that any part of the Intellectual Property or any practice by
      Borrower or its Subsidiaries violates the rights of any third party except to the extent such claim could not reasonably be expected to have a Material Adverse Change.&#160; Except as noted on the Perfection Certificates, or as updated from time to time
      in accordance with the provisions hereof, no Loan Party, nor any of their Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which such Loan Party or such Subsidiary is the licensee that (i)
      prohibits or otherwise restricts such Loan Party or its Subsidiaries from granting a security interest in such Loan Party&#8217;s or such Subsidiaries&#8217; interest in such material license or material agreement or any other property, or (ii) for which a
      default under or termination of could interfere with Collateral Agent&#8217;s or any Lender&#8217;s right to sell any Collateral.&#160; The Loan Parties shall provide written notice to Collateral Agent and each Lender within thirty (30) days after (or if earlier,
      with the submission of the next Compliance Certificate of Borrower) the Loan Parties or any of their Subsidiaries entering into or becoming bound by any such material license or material agreement with respect to which a Loan Party or any Subsidiary
      is the licensee (other than over&#8209;the&#8209;counter software that is commercially available to the public).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Litigation.</font>&#160; Except as disclosed (i) on the Perfection Certificates, or (ii) in accordance with Section
      6.9 hereof, there are no actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against a Loan Party or any of their Subsidiaries involving more than Two Hundred Fifty
      Thousand Dollars ($250,000.00).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">No Material Deterioration in Financial Condition; Financial Statements.</font>&#160; All consolidated financial
      statements for the Loan Parties and their Subsidiaries, delivered to the Collateral Agent fairly present, in conformity with IFRS, in all material respects, the consolidated financial condition of the Loan Parties and its Subsidiaries, and the
      consolidated results of operations of the Loan Parties and its Subsidiaries.&#160; Lender acknowledges and agrees that such financial statements delivered hereunder (that are not annual audited financial statements) may not be audited nor include all
      adjusting entries, such as, for the sake of example only, changes in the fair market value of warrants, and further understands that such financial statements do not include footnotes required under IFRS. Lender understands and agrees that such
      financial statements are therefore considered to be in draft form and subject to adjustments. There has not been any material deterioration in the consolidated financial condition of the Loan Parties and its Subsidiaries since the date of the most
      recent financial statements submitted to the Lender.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Solvency.</font>&#160; The Loan Parties are Solvent and the Loan Parties and their Subsidiaries taken as a whole are
      Solvent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Regulatory Compliance.</font>&#160; No Loan Party nor any of their Subsidiaries is an &#8220;investment company&#8221; or a
      company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.&#160; No Loan Party nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X,
      T and U of the Federal Reserve Board of Governors).&#160; The Loan Parties and each of their Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.&#160; No Loan Party nor any of their Subsidiaries is a &#8220;holding company&#8221;
      or an &#8220;affiliate&#8221; of a &#8220;holding company&#8221; or a &#8220;subsidiary company&#8221; of a &#8220;holding company&#8221; as each term is defined and used in the Public Utility Holding Company Act of 2005.&#160; No Loan Party nor any of their Subsidiaries has violated any laws,
      ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change.&#160; No Loan Party nor any of their Subsidiaries properties or assets has been used by&#160; Loan Party or any of their Subsidiaries or, to each Loan
      Party&#8217;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.&#160; The Loan Parties and each of their Subsidiaries has obtained all
      consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">No Loan Party, nor any of their Subsidiaries, or any of the Loan Party&#8217;s or their Subsidiaries&#8217; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions
      contemplated by this Agreement is (i) in violation of any Anti&#8209;Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions
      set forth in any Anti&#8209;Terrorism Law, or (iii) is a Blocked Person.&#160; No Loan Party, nor any of their Subsidiaries, or to the knowledge of any Loan Party and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the
      transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any
      transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti&#8209;Terrorism Law.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Investments.</font>&#160; No Loan Party nor any of their Subsidiaries owns any stock, shares, partnership interests or
      other equity securities except for Permitted Investments.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Tax Returns and Payments; Pension Contributions.</font> Each Loan Party and each of its Subsidiaries has timely
      filed (or filed timely extensions for) all required tax returns and reports, and each Loan Party and each of its Subsidiaries, has timely paid (or filed timely extensions for) all foreign, federal, state, and local taxes, assessments, deposits and
      contributions owed by such Loan Party and such Subsidiaries, in all jurisdictions in which such Loan Party or any such Subsidiary is subject to taxes, including the United States and the United Kingdom, unless such taxes are being contested in
      accordance with the following sentence.&#160; Each Loan Party and each of its Subsidiaries, may defer payment of any contested taxes, provided that such Loan Party or such Subsidiary, (a) in good faith contests its obligation to pay the taxes by
      appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Collateral Agent in writing of the commencement of, and any material development in, the proceedings as to such tax matters with a value that would reasonably be
      expected to exceed Fifty Thousand Dollars ($50,000.00), and (c) posts bonds or takes any other steps required to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a &#8220;<font style="font-weight: bold;">Permitted Lien</font>.&#8221;&#160; Neither any Loan Party nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of such Loan Party&#8217;s or such Subsidiaries&#8217;, prior tax years which could result in
      additional taxes becoming due and payable by such Loan Party or its Subsidiaries.&#160; Each Loan Party and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance
      with their terms, and neither any Loan Party nor any of such Loan Party&#8217;s Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to,
      any such plan which could reasonably be expected to result in any liability of any Loan Party or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.&#160; &#160; Neither
      any Loan Party nor any of its Subsidiaries is or has at any time been an employer (for the purposes of sections 38 to 51 of the Pensions Act 2004) of an occupational pension scheme which is not a money purchase scheme (both terms as defined in the
      Pensions Schemes Act 1993); and neither Parent nor any of its Subsidiaries is or has at any time been &#8220;connected&#8221; with or an &#8220;associate&#8221; of (as those terms are used in sections 38 and 43 of the Pensions Act 2004) such an employer.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Use of Proceeds.</font>&#160; Borrower shall use the proceeds of the Credit Extensions solely as working capital and
      to fund its general business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Shares.</font>&#160; Each Loan Party has full power and authority to create a first Lien on the Shares that it is
      granting a Lien pursuant hereto and no disability or contractual obligation exists that would prohibit the Loan Parties from pledging the Shares pursuant to this Agreement.&#160; To each Loan Party&#8217;s knowledge, there are no subscriptions, warrants, rights
      of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares.&#160; The Shares have been and will be duly authorized and validly issued, and are fully paid and non&#8209;assessable.&#160; To each Loan Party&#8217;s
      knowledge, the Shares are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and the Loan Parties know of no reasonable grounds for the institution of any such proceedings.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Full Disclosure.</font>&#160; No written representation, warranty or other statement of the Loan Parties or any of
      their Subsidiaries in any certificate or written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements
      given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized that the
      projections and forecasts provided by the Loan Parties in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the
      projected or forecasted results).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Definition of </font>&#8220;<font style="font-weight: bold;">Knowledge.</font>&#8221;&#160; For purposes of the Loan Documents,
      whenever a representation or warranty is made to the Loan Party&#8217;s knowledge or awareness, to the &#8220;best of&#8221; the Loan Party&#8217;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation,
      of the Responsible Officers.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z259b11fde0e14b07b8f4c441c92919f4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>AFFIRMATIVE COVENANTS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">The Loan Parties shall, and shall cause each of their Subsidiaries to, do all of the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Government Compliance.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Maintain its and all its Subsidiaries&#8217; legal existence and, where applicable, good standing in their respective jurisdictions of organization and
      maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change.&#160; Comply with all laws, ordinances and regulations to which the Loan Parties or any of their Subsidiaries is
      subject, the noncompliance with which could reasonably be expected to have a Material Adverse Change.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Obtain and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by the Loan Parties and their
      Subsidiaries of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Lenders, in all of the Collateral.&#160; The Loan Parties shall promptly notify
      Collateral Agent of any material Governmental Approvals obtained by the Loan Parties or any of their Subsidiaries, and if requested by Collateral Agent in writing, promptly provide copies thereof to Collateral Agent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Financial Statements, Reports, Certificates.</font></div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deliver to each Lender:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;as soon as available, but no later than thirty (30) days after the last day of each month (other than January month-end reporting of each year,
      for which month only the following summary financial reporting shall be due each year: (A) the month-end unrestricted cash balance (inclusive of investments), (B) the cash burn for the month (net of cash received from collaboration revenue or
      financing activities), (C) any cash from collaboration and/or product revenue, and (D) any cash proceeds from financing activities), a company prepared consolidated balance sheet, income statement and cash flow statement covering the consolidated
      operations of Parent and its Subsidiaries for such month certified by a Responsible Officer, prepared in accordance with IFRS, and in a form reasonably acceptable to Collateral Agent, provided, however, that in the event that Parent, SPAC or HoldCo
      becomes subject to the reporting requirements under a U.S. national stock exchange and Parent, SPAC or HoldCo becomes subject to the reporting requirements under the Securities Exchange Act of 1934, then Parent, SPAC or HoldCo, as applicable,&#160; shall
      no later than the due date of its filing of its quarterly report on Form 10-Q (or equivalent) under the Securities Exchange Act of 1934 (but in any event if not provided in accordance with the foregoing clause, no later than 90 days after the end of
      the applicable fiscal quarter, deliver a company prepared consolidated balance sheet, income statement and cash flow statement covering the consolidated operations of Parent and its Subsidiaries for the applicable fiscal quarter certified by a
      Responsible Officer, prepared in accordance with IFRS, with a Compliance Certificate, and in a form reasonably acceptable to Collateral Agent);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;as soon as available, but no later than one hundred twenty (120) days after the last day of Parent&#8217;s fiscal year or within five (5) Business
      Days of filing with the SEC, audited consolidated financial statements prepared under IFRS, consistently applied, together with an unqualified opinion (provided that such opinion may include going concern explanatory language and exceptions as it
      relates to a Loan Party&#8217;s cash level);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;on the financial statements from an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;after approval thereof by Parent&#8217;s Board of Directors, and no later than sixty (60) days after the last day of each of Parent&#8217;s fiscal years,
      Parent&#8217;s annual financial projections for the entire current fiscal year as approved by Parent&#8217;s Board of Directors, which such annual financial projections shall be set forth in a month&#8209;by&#8209;month format (such annual financial projections as
      originally delivered to Collateral Agent and the Lenders are referred to herein as the &#8220;<font style="font-weight: bold;">Annual Projections</font>&#8221;; provided that, any revisions of the Annual Projections approved by Parent&#8217;s Board of Directors shall
      be delivered to Collateral Agent and the Lenders no later than ten (10) Business Days after such approval);</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;within five (5) Business Days of delivery, copies of all statements, reports and notices made generally available to Parent&#8217;s security holders or
      holders of Subordinated Debt;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in the event that Parent, SPAC or HoldCo becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended,
      within five (5) Business Days of filing, direct Collateral agent to the links to all reports on Form 10&#8209;K, 10&#8209;Q and 8&#8209;K filed with the Securities and Exchange Commission,</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with the next due Compliance Certificate notice of any amendments of or other changes to the Operating Documents of the Loan Parties or any of
      their Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with the next due Compliance Certificate notice of any material amendments of or other material changes to the capitalization table of Parent
      (unless Parent, SPAC or HoldCo is a reporting company), provided that for the avoidance of doubt, no reporting is required for changes solely due to stock option plan issuance and changes.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;with the next due Compliance Certificate, notice of (A) any material change in the composition of the Intellectual Property, (B) the
      registration of any copyright, including any subsequent ownership right of the Loan Parties or any of their Subsidiaries in or to any copyright, patent or trademark, including a copy of any such registration, and (C) any event that could reasonably
      be expected to materially and adversely affect the value of the Intellectual Property;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;as soon as available, but no later than thirty (30) days after the last day of each month, copies of the month&#8209;end account statements for each
      Collateral Account maintained by the Loan Parties or their Subsidiaries, which statements may be provided to Collateral Agent and each Lender by Borrower or directly from the applicable institution(s), and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;other information as reasonably requested by Collateral Agent or any Lender.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Notwithstanding the foregoing, or anything herein to the contrary herein, any statements, notices, or other documents required to be delivered to Collateral Agent pursuant to the terms of this Agreement (to the extent
      any such documents are included in materials otherwise filed with the SEC, including any filings in respect of the departure of a Key Persons) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on
      which Borrower posts such documents, or provides a link thereto, on Borrower&#8217;s website on the internet at Borrower&#8217;s website address.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Concurrently with the delivery of the financial statements specified in Section 6.2(a)(i) above but no later than thirty (30) days after the last
      day of each month, deliver to each Lender, a duly completed Compliance Certificate signed by a Responsible Officer.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Keep proper books of record and account in accordance with IFRS in all material respects, in which full, true and correct entries shall be made of
      all dealings and transactions in relation to its business and activities.&#160; The Loan Parties shall, and shall cause each of their Subsidiaries to, allow, at the sole cost of Borrower, Collateral Agent or any Lender, during regular business hours upon
      reasonable prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any of its books and records, and to
      conduct a collateral audit and analysis of its operations and the Collateral. Such audits shall be conducted no more often than once every twelve (12) months unless (and more frequently if) an Event of Default has occurred and is continuing.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Inventory; Returns.</font>&#160; Keep all Inventory in good and marketable condition, free from material defects.&#160;
      Returns and allowances between the Loan Parties, or any of their Subsidiaries, and their respective Account Debtors shall follow such Loan Party&#8217;s, or such Subsidiary&#8217;s, customary practices as they exist at the Effective Date.&#160; The Loan Parties must
      promptly notify Collateral Agent and the Lenders of all returns, recoveries, disputes and claims that involve more than Five Hundred Thousand Dollars ($500,000.00) in the aggregate for all Loan Parties in any calendar year.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Taxes; Pensions.</font>&#160; Timely file (or file timely extensions) and require each of its Subsidiaries to timely
      file (or file timely extensions), for all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely file, all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by each Loan
      Party or its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to
      fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Insurance.</font>&#160; Keep the Loan Party&#8217;s and their Subsidiaries&#8217; business and the Collateral insured for risks
      and in amounts standard for companies in the Loan Party&#8217;s and their Subsidiaries&#8217; industry and location and as Collateral Agent may reasonably request.&#160; Insurance policies shall be in a form, with companies, and in amounts that are reasonably
      satisfactory to Collateral Agent and Lenders.&#160; All property policies shall have a lender&#8217;s loss payable endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show,
      or have endorsements showing, Collateral Agent, as additional insured.&#160; The Collateral Agent shall be named as lender loss payee and/or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each
      provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral Agent, that it will give the Collateral Agent thirty (30) days prior written notice before
      any such policy or policies shall be materially altered or canceled (other than cancellation for non-payment of premium, which shall only require ten (10) days prior notice).&#160; At Collateral Agent&#8217;s request, the Loan Parties shall deliver certified
      copies of policies and evidence of all premium payments.&#160; Proceeds payable under any policy shall, at Collateral Agent&#8217;s option, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.&#160; Notwithstanding
      the foregoing, (a) so long as no Event of Default has occurred and is continuing, the Loan Parties shall have the option of applying the proceeds of any casualty policy up to Five Hundred Thousand Dollars ($500,000.00) with respect to any loss, but
      not exceeding Five Hundred Thousand Dollars ($500,000.00), in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired
      property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and during the
      continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.&#160; If the Loan Parties
      or any of their Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and/or any Lender may make, at the Loan Parties&#8217; expense, all
      or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral Agent or such Lender deems prudent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Operating Accounts.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Maintain all of the Loan Parties&#8217; Collateral Accounts (other than Excluded Accounts) (i) located in the United States (and all other jurisdictions
      where it is either customary to obtain Control Agreements or necessary to obtain Control Agreements in order to perfect security interest in bank accounts) in accounts which are subject to a Control Agreement in favor of Collateral Agent and (ii)
      located outside the United States (in jurisdictions where it is neither customary to obtain Control Agreements nor necessary to obtain Control Agreements in order to perfect security interest in bank accounts) subject to such instruments or to a lien
      filed by a Notice of Charge, if any, as may be necessary for Collateral Agent to perfect its security interest in such Collateral Accounts.&#160; No filing or registration of this Agreement shall be made with Companies House in the United Kingdom.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Loan Parties shall provide Collateral Agent five (5) days&#8217; prior written notice before any Loan Party establishes any Collateral Account.&#160; In
      addition, for each Collateral Account that any of the Loan Parties at any time maintains, such Loan Party shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control
      Agreement or other appropriate instrument in accordance with Section 6.6(a), if any, with respect to such Collateral Account to perfect Collateral Agent&#8217;s Lien in such Collateral Account in accordance with the terms hereunder prior to the
      establishment of such Collateral Account, which Control Agreement or instrument, as applicable, may not be terminated without prior written consent of Collateral Agent.&#160; The provisions of the previous sentence shall not apply to the Excluded
      Accounts.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Loan Party shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Sections 6.6(a) and (b).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Protection of Intellectual Property Rights.</font>&#160; The Loan Parties and each of their Subsidiaries shall: (a)
      use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to the Loan Party&#8217;s business; (b) promptly advise Collateral Agent in writing of material infringement
      by a third party of its Intellectual Property that is material to the Loan Party&#8217;s business; and (c) not allow any Intellectual Property material to the Loan Party&#8217;s business to be abandoned, forfeited or dedicated to the public without Collateral
      Agent&#8217;s prior written consent.&#160; If a Loan Party or any of their Subsidiaries (i) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as
      owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then such Loan Party or such Subsidiary shall provide written notice thereof to Collateral Agent and each Lender with the next due
      Compliance Certificate, and shall execute such intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first
      priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property.&#160; If any Loan Party or any of their Subsidiaries decides to register any copyrights or mask works in the United States
      Copyright Office, Borrower or such Subsidiary shall: (x) provide Collateral Agent and each Lender with at least ten (10) days prior written notice of such Subsidiary&#8217;s or such Subsidiary&#8217;s intent to register such copyrights or mask works together
      with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto); (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent
      may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be
      registered with the United States Copyright Office; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States
      Copyright Office.&#160; Upon Collateral Agent&#8217;s additional request, such Loan Party or such Subsidiary shall promptly provide to Collateral Agent and each Lender with evidence of the recording of the intellectual property security agreement necessary for
      Collateral Agent to perfect and maintain a first priority perfected security interest in such property.&#160; For the avoidance of doubt, no filing or registration of this Agreement shall be made with Companies House in the United Kingdom.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Litigation Cooperation.</font>&#160; Commencing on the Effective Date and continuing through the termination of this
      Agreement, make available to Collateral Agent and the Lenders, without expense to Collateral Agent or the Lenders, the Loan Parties and each of such Loan Party&#8217;s officers, employees and agents and Borrower&#8217;s Books, to the extent that Collateral Agent
      or any Lender may reasonably deem them necessary to prosecute or defend any third&#8209;party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or relating to the Loan Parties.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Notices of Litigation and Default.</font>&#160; The Loan Parties will give prompt written notice to Collateral Agent
      and the Lenders of any litigation or governmental proceedings pending or threatened (in writing) against a Loan Party or any of their Subsidiaries, which could reasonably be expected to result in damages or costs to the Loan Parties or any of their
      Subsidiaries of Two Hundred Fifty Thousand Dollars ($250,000.00) or more or which could reasonably be expected to have a Material Adverse Change.&#160; Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in
      any event within five (5) Business Days) upon a Responsible Officer of a Loan Party becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, a
      Loan Party shall give written notice to Collateral Agent and the Lenders of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or
      both, would constitute an Event of Default.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Non-Borrower Entities.&#160; </font>The aggregate value of assets held by Immunocore Ireland and Immunocore Nominees
      shall not at any given time exceed One Million Dollars ($1,000,000.00).&#160; Immunocore LLC may not hold assets with an aggregate value in excess of Ten Million Dollars ($10,000,000.00) and Immunocore Commercial LLC may not hold assets with an aggregate
      value in excess of Three Million Two Hundred Thousand Dollars ($3,200,000.00).&#160; Furthermore, none of Immunocore Ireland, Immunocore Nominees, Immunocore LLC, or Immunocore Commercial LLC shall maintain any Intellectual Property.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Landlord Waivers; Bailee Waivers.</font>&#160; In the event that any Loan Party or any of their Subsidiaries, after
      the Effective Date, intends to add any new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, with a Collateral value in excess of Five
      Hundred Thousand Dollars ($500,000), in each case pursuant to Section 7.2, then the Loan Party or such Subsidiary will notify Collateral Agent and, in the event that the new location is the chief executive office of the Loan Parties or such
      Subsidiary or the Collateral at any such new location is valued in excess of Five Hundred Thousand Dollars ($500,000), in the aggregate, such bailee or landlord, as applicable, must execute and deliver a bailee waiver or landlord waiver, as
      applicable, in form and substance reasonably satisfactory to Collateral Agent prior to the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as the case may be, unless waived by Collateral
      Agent.&#160; Notwithstanding the foregoing, or anything to the contrary herein, no landlord agreements shall be required for any locations of the Loan Parties or their Subsidiaries in the United Kingdom.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Creation/Acquisition of Subsidiaries.</font>&#160; In the event the Loan Parties, or any of their Subsidiaries
      creates or acquires any Subsidiary, such Loan Party shall provide prior written notice to Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably required by Collateral
      Agent or any Lender to cause each such Subsidiary to become (i) if such new Subsidiary is a Foreign Subsidiary, become a co-borrower hereunder and, among other things, enter into a joinder agreement hereto, and (ii) if such new Subsidiary is a
      Domestic Subsidiary, provide a guaranty of Borrower&#8217;s obligations hereunder (and for the avoidance of doubt, any such Domestic Subsidiary shall not be required to be a co-borrower under this Agreement or the Loan Documents), and, in each case where a
      Subsidiary becomes a co-borrower or guarantor hereunder, grant a continuing pledge and security interest in and to the assets of such Subsidiary that constitute Collateral (substantially as described on <u>Exhibit A</u> hereto); and the applicable
      Loan Party (or its Subsidiary, as applicable) shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security interest in the Shares.&#160; For the avoidance of doubt, Collateral Agent and Lender have waived any
      requirement that Immunocore Ireland and Immunocore Nominees become co-borrowers or guarantors.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Further Assurances</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral
      Agent&#8217;s Lien in the Collateral or to effect the purposes of this Agreement, including, without limitation, entering into a pledge agreement under Irish law with respect to the pledge of the Shares of Immunocore Ireland, promptly when requested by
      Collateral Agent in its discretion.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Deliver to Collateral Agent and Lenders, within five (5) Business days after the same are sent by a Loan Party or received by a Loan Party, copies
      of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to a Loan Party&#8217;s business or
      otherwise could reasonably be expected to have a Material Adverse Change.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbec9d153bb674b9096c00b3bf9c8636b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>NEGATIVE COVENANTS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">The Loan Parties shall not, and shall not permit any of their Subsidiaries to, do any of the following without the prior written consent of the Required Lenders:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Dispositions.</font>&#160; Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, &#8220;<font style="font-weight: bold;">Transfer</font>&#8221;), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business; (b) of worn out, or obsolete
      Equipment; (c) in connection with Permitted Liens, Permitted Investments and Permitted Licenses and (d) of property that is not material to any Loan Party&#8217;s business with an aggregate value for all Loan Parties together that does not exceed Two
      Hundred Fifty Thousand Dollars ($250,000) during any fiscal year;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Changes in Business, Management, Ownership, or Business Locations.</font>&#160; (a) Engage in or permit any of its
      Subsidiaries to engage in any business other than the businesses engaged in by such Loan Party as of the Effective Date or reasonably related thereto; (b) liquidate or dissolve; or (c) (i) any Key Person shall cease to be actively engaged in the
      management of Parent unless written notice thereof is provided to Collateral Agent within five (5) Business Days of such change, or (ii) enter into any transaction or series of related transactions in which the stockholders of any Loan Party who were
      not stockholders immediately prior to the first such transaction own more than forty nine percent (49%) of the voting stock of such Loan Party immediately after giving effect to such transaction or related series of such transactions (other than by
      the sale of Parent&#8217;s equity securities in a public offering, a private placement of public equity or to venture capital and or strategic investors so long as Parent identifies to Collateral Agent the venture capital investors prior to the closing of
      the transaction, or in accordance with the provisions of Section 7.3(b) with respect to any SPAC Transaction, or Section 7.3(c) in accordance with any HoldCo Transaction.&#160; The Loan Parties shall not, without at least ten (10) days&#8217; prior written
      notice to Collateral Agent: (A) add any new offices or business locations, including warehouses (unless such new offices or business locations (i) contain less than Five Hundred Thousand Dollars ($500,000.00) in assets or property of the Loan Parties
      or any of their Subsidiaries and (ii) are not a Loan Party&#8217;s or their Subsidiaries&#8217; chief executive office); (B) change its jurisdiction of organization, (C) change its organizational structure or type, (D) change its legal name, or (E) change any
      organizational number (if any) assigned by its jurisdiction of organization.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Mergers or Acquisitions.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its
      Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person other than pursuant to the consummation of a Permitted Acquisition. A Subsidiary may merge or consolidate into another Subsidiary (provided
      such surviving Subsidiary is a &#8220;co&#8209;borrower&#8221; hereunder or has provided a secured guaranty of Borrower&#8217;s Obligations hereunder) or with (or into) a Loan Party provided such Loan Party is the surviving legal entity, and as long as no Event of Default
      is occurring prior thereto or arises as a result therefrom.&#160; Without limiting the foregoing, no Loan Party shall, without Collateral Agent&#8217;s prior written consent, enter into any binding contractual arrangement with any Person to attempt to
      facilitate a merger or acquisition of a Loan Party, unless (i) no Event of Default exists when such agreement is entered into by such Loan Party, (ii) such agreement does not give such Person the right to claim any fees, payments or damages from the
      Loan Parties in excess of Five Hundred Thousand Dollars ($500,000.00), and (iii) a Loan Party notifies Collateral Agent promptly upon entering into such an agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing Section 7.3(a), or anything herein to the contrary, Parent may merge, reverse merge or consolidate with a SPAC, or
      become a wholly owned subsidiary of a SPAC pursuant to Parent&#8217;s acquisition by a SPAC by a transaction or a series of related transactions (&#8220;<font style="font-weight: bold;">SPAC Transaction</font>&#8221;) (and for the avoidance of doubt no further
      consents and/or approvals from Collateral Agent and/or Lenders shall be required), if:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SPAC Transaction is consummated on or before April 30, 2021;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Either (i) such SPAC must have cash assets in the US or UK of at least Eighty Million Dollars ($80,000,000.00) upon closing of the <font style="font-weight: bold;">SPAC Transaction</font> (not including any amounts raised by private or public investments in such SPAC in connection with the SPAC Transaction) or (ii) no later than 14 days after the closing of the SPAC Transaction, the
      surviving entity/entities must have cash assets in the US or UK (including any amounts raised by private or public investments in such SPAC in connection with the SPAC Transaction) of not less than One Hundred Fifty Million Dollars ($150,000,000.00);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such SPAC must be incorporated or organized under the laws of a state in the United States or Cayman Islands and its principal place of
      business must be in the United States or the United Kingdom and, for tax purposes, be considered a resident of the United States, United Kingdom or such other jurisdiction as is reasonably acceptable to Collateral Agent;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the equity securities of such SPAC must be traded on a major national stock exchange in the United States immediately prior to the SPAC
      Transaction and after the SPAC Transaction, further provided that for the avoidance of doubt, Lenders hereby agree that the NYSE and NASDAQ are deemed acceptable major national stock exchanges;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such SPAC must not have any outstanding Indebtedness or liabilities (other than liabilities incurred for reasonable fees and expenses incurred in
      connection with the SPAC Transaction);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;at least one (1) reputable institutional life sciences investor(s) (acceptable to Collateral Agent in its discretion) must be a major investor
      in such SPAC at the time of the consummation of the SPAC Transaction;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such SPAC must (i) if such SPAC entity is formed outside of the United States, become a co-borrower hereunder and, among other things, enter
      into a joinder agreement hereto, and agree to comply with and be bound by all of the terms, conditions and covenants of the Loan Agreement and Loan Documents, as if it were originally named a &#8220;Borrower&#8221; therein (but effective on the date of such
      joinder), and (ii) if such SPAC entity is formed in the United States, provide a guaranty of Borrower&#8217;s obligations hereunder (and for the avoidance of doubt, any such SPAC entity formed in the United States shall not be required to be a co-borrower
      under this Agreement or the Loan Documents), in each case in form and substance acceptable to Collateral Agent, and in each case grant a security interest in all of its assets constituting &#8220;Collateral&#8221; in accordance with the provisions of the Loan
      Documents, make all of the representations and warranties (subject to applicable qualifications set forth in this Section 7.3(b)) in the Loan Documents with the same force and effect as if it were originally named a &#8220;Loan Party&#8221; herein and a Borrower
      or a Guarantor, as applicable, in the applicable Loan Documents (but effective and as-of the date of such joinder or guaranty, as applicable);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the consideration in such SPAC Transaction must consist entirely of equity securities of such SPAC (other than cash paid in lieu of issuing
      fractional shares, the aggregate amount of which cash may not exceed $100,000.00); and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;there must be no actions, suits, investigations, or proceedings pending or threatened in writing by or against such SPAC immediately prior to
      entering into and publicly announcing the SPAC Transaction; furthermore, no lawsuit filed or threatened against such SPAC after the announcement of the SPAC Transaction, could be expected to jeopardize the consummation of the SPAC Transaction or have
      a Material Adverse Change, in each case, as determined by Collateral Agent (for the purposes of clarification, nothing herein is a waiver of or intended to be construed as a waiver of any Event of Default that may occur from such a lawsuit).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Further, notwithstanding the foregoing Section 7.3(a), or anything herein to the contrary, Parent may become a wholly owned subsidiary of a HoldCo
      pursuant to a transaction or a series of related transactions, whereby each of the shareholders of Immunocore exchanges their shares for shares in HoldCo (&#8220;<font style="font-weight: bold;">HoldCo Transaction</font>&#8221;), if:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo Transaction is consummated in furtherance of an initial public offering of the equity securities of the HoldCo on a national stock
      exchange in the United States or the United Kingdom (which, for the avoidance of doubt, may include the offering of shares or American Depositary Shares);</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No later than ninety (90) days after the consummation of the HoldCo Transaction, HoldCo must receive unrestricted net cash proceeds of not less
      than Seventy Five Million Dollars ($75,000,000.00) from the sale and issuance of its equity securities (whether in a public market or otherwise) and/or in the form of upfront payments from the entrance into a collaboration agreement or similar
      business development agreement with an unaffiliated third party (which agreement must otherwise be permitted under the terms of the HoldCo Loan Agreement (as defined herein)), and/or Subordinated Debt (or any combination of the foregoing), and
      failure to do as much shall constitute an immediate Event of Default under the HoldCo Loan Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the HoldCo Transaction, Parent shall become a wholly owned Subsidiary of the HoldCo and all shareholders of Parent
      immediately prior to the consummation of the HoldCo Transaction shall become shareholders of HoldCo and own a majority of the issued and outstanding voting capital stock of the HoldCo; </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo must (i) be incorporated or organized under the laws of United Kingdom or Cayman Islands, (ii) be a resident for Tax purposes in United
      Kingdom and (iii) and have its principal place of business in the United Kingdom or such other jurisdiction (other than the United States) as is acceptable to Collateral Agent;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo must not have any outstanding Indebtedness or liabilities (other than liabilities incurred for reasonable fees and expenses incurred in
      connection with the formation and maintenance of legal existence of HoldCo, the HoldCo Transaction, the Loan Documents or the equity financing contemplated to be consummated following the HoldCo Transaction);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Concurrently with the Holdco Transaction the parties agree that following shall occur:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At Parent&#8217;s written request, Lenders shall concurrently with the HoldCo Transaction effectiveness, assign all of their right, title and interest
      in the then-outstanding Credit Extensions made by Lenders to Parent hereunder, any Secured Promissory Notes evidencing the same, together with all of its right, title and interest under this Agreement, the Guaranties, the Success Fee Letter and all
      other Loan Documents (collectively, the &#8220;<font style="font-weight: bold;">Assigned Debt Documents</font>&#8221;) to HoldCo;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Concurrently with the effectiveness of the HoldCo Transaction and in consideration for the assignment of the Assigned Debt Documents, HoldCo
      shall (i) enter into a new Loan and Security Agreement (the &#8220;<font style="font-weight: bold;">HoldCo Loan Agreement</font>&#8221;) as the borrower thereunder, which shall be in the same form as this Agreement with such changes as are acceptable to
      Collateral Agent in its discretion or are reasonably required by Collateral Agent (in each case, only to the extent that such changes provide that the Lender and the Collateral Agent shall have the benefit of the same terms under the HoldCo Loan
      Agreement as they had under this Agreement immediately prior to the relevant HoldCo Transaction), with appropriate adjustments to reflect the HoldCo as the &#8220;borrower&#8221; thereunder and Parent and the other Guarantors as secured guarantors, and a loan
      shall be deemed to have been made pursuant to the HoldCo Loan Agreement, which shall be deemed outstanding and owing by HoldCo to Lender in principal amount of the then-outstanding Credit Extensions under this Agreement (the &#8220;<font style="font-weight: bold;">Restructuring Loan</font>&#8221;), (ii) issue one or more Secured Promissory Notes evidencing the Restructuring Loan and comply with all conditions and provisions of the HoldCo Loan Agreement, and (iii) execute and deliver, and
      cause Parent and the other Guarantors (as guarantors with respect to the Restructuring Loan and the other obligations pursuant to the HoldCo Loan Agreement) to execute and deliver, guarantees, collateral security documents and other Loan Documents,
      including without limitation a success fee letter, on the same terms as the Loan Documents in effect as of such date (HoldCo Loan Agreement together with all the foregoing loan documents to be entered into in connection therewith, the &#8220;<font style="font-weight: bold;">HoldCo Loan Documents</font>&#8221;);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 144pt;"><font style="font-weight: bold;">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In consideration of the debt assignment (described above) HoldCo shall (i) procure that the stock transfer forms in respect of the HoldCo
      Transaction are submitted to the stamp office of HMRC no later than ten (10) Business Days following the consummation of such HoldCo Transaction, (ii) procure that the transfers of the shares to HoldCo are registered in the company books of Parent as
      soon as reasonably practicable, and in any event within five (5) Business Days of the stock transfer forms being stamped (or otherwise able to be registered without penalty) and (iii) as soon as reasonably practicable upon such registration and in
      any event within ten (10) Business Days thereof, pledge all shares of Parent to Collateral Agent pursuant to a pledge agreement in form and substance acceptable to Collateral Agent;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the terms of the HoldCo Transaction must not adversely affect the enforceability of the HoldCo Loan Agreement and HoldCo Loan Documents or
      Collateral Agent&#8217;s rights and remedies with respect to the Collateral of any of the HoldCo, Parent and all Guarantors, except that each of the parties to this Agreement acknowledge and agree that entering into the relevant Holdco Loan Documents will
      re-start any applicable hardening periods under any English law governed security documents;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(viii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no assets of Parent shall be transferred to any other Person except for transfers to Holdco or any other Transfers permitted pursuant to
      Section 7.1;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ix)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;following the assignment of this Agreement and the other Loan Documents, the Assigned Debt and the related Loan Documents shall immediately be
      amended and restated as an unsecured intercompany note in form and substance satisfactory to Collateral Agent (which shall be pledged to Collateral Agent pursuant to the HoldCo Loan Agreement) and collateral security documents, filings and
      registrations shall be released or terminated, as applicable;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Parent shall have given Collateral Agent notice not less than thirty (30) days prior to the effectiveness of the HoldCo Transaction and shall
      deliver such documents or take such other actions as Collateral Agent or any Lender request to establish a basis for relief from applicable withholding taxes with respect to payments made by HoldCo as Borrower or a Loan Party; provided, however, no
      Lender shall be required to take any action to seek such relief other than provide information reasonably requested by Parent from such Lender or other actions required by Section 2.6;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo (as new Borrower) shall agree to promptly and fully compensate and make whole each Lenders for any Tax liability to such Lender of the
      HoldCo Transactions; provided Lenders shall provide information upon Parent&#8217;s reasonable request if necessary to allow Parent to determine any such Tax liability;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo must be a newly incorporated entity and have no prior existence or operations and HoldCo must be otherwise acceptable to Collateral
      Agent as a Borrower based on Collateral Agent&#8217;s diligence of HoldCo;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xiii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the officers and directors of the HoldCo immediately after the consummation of the HoldCo Transaction must be reasonably acceptable to
      Collateral Agent (it being agreed and understood that if such officers and directors are the same as the officers and directors of Borrower immediately prior to the consummation of the HoldCo Transaction, they will be acceptable to Collateral Agent
      for the purposes hereof);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xiv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HoldCo and the terms of the HoldCo Transaction must otherwise be acceptable to Collateral Agent in its sole discretion; provided, however, if
      Collateral Agent determines the HoldCo Transaction to not be acceptable or unduly conditions or delays confirming that the HoldCo Transaction is acceptable, but the conditions for the HoldCo Transaction set forth in this Section 7.3 (other than this
      subsection (xiv) are otherwise satisfied, then the HoldCo Transaction may still be consummated if HoldCo covenants in the HoldCo Loan Agreement to prepay all Obligations no later than ninety (90) days after the consummation of the HoldCo Transaction;
      provided, however, no Prepayment Fee will become due in connection with such prepayment; provided further, failure to make such prepayment shall constitute an immediate Event of Default under the HoldCo Loan Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no Event of Default shall have occurred and be continuing immediately prior to the consummation of the HoldCo Transaction or shall result from
      the consummation of the HoldCo Transaction.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">24</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(xvi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Further, notwithstanding the foregoing Section 7.3(a), or anything herein to the contrary, Parent may become a wholly owned subsidiary of a
      HoldCo pursuant to a transaction or a series of related transactions, whereby each of the shareholders of Immunocore becomes a shareholder of Holdco wherein Parent does <u>not</u> request Lenders to assign its interest in the Loan Documents as
      described in subsection (c)(vi)(1) above, subject to compliance with subsections (c)(i), (ii), (iii), (iv), (v), (vii), (viii), (xii), (xiii), (xiv) and (xv) above and provided that in such case Holdco shall become a Guarantor with respect to the
      Obligations and shall concurrently with Holdco becoming the owner of the outstanding shares of Parent, enter into such Loan Documents to grant Collateral Agent a Lien on its assets on substantially the terms of the security interest granted in the
      Collateral pursuant to this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Indebtedness.</font>&#160; Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do
      so, other than Permitted Indebtedness.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Encumbrance.</font>&#160; Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any
      right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, in each case as to the foregoing, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest
      granted herein (except for Permitted Liens that are permitted by the terms of this Agreement to have priority over Collateral Agent&#8217;s Lien), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral
      Agent, for the ratable benefit of the Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting the Loan Parties, or any of their Subsidiaries, from assigning, mortgaging, pledging, granting a security interest
      in or upon, or encumbering any Loan Party&#8217;s or such Subsidiary&#8217;s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of &#8220;<font style="font-weight: bold;">Permitted Liens</font>&#8221; herein.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Maintenance of Collateral Accounts.</font>&#160; Maintain any Collateral Account except pursuant to the terms of
      Section 6.6 hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Distributions; Investments.</font> (a) Pay any dividends (other than dividends payable solely in capital stock)
      or make any distribution or payment in respect of or redeem, retire or purchase any capital stock (other than (i) repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans,
      director or consultant stock option plans, or similar plans, provided such repurchases do not exceed Two Hundred Thousand Dollars ($200,000.00) in the aggregate per fiscal year, (ii) conversions of any of its convertible securities into other
      securities pursuant to the terms of such convertible securities or otherwise in exchange thereof provided no cash payments are made or will become due in connection with such conversion, and (iii) cash payments in lieu of the issuance of fractional
      shares upon conversion of convertible securities, provided, such cash payments do not exceed Fifty Thousand Dollars ($50,000.00) in any given year); and (iv) dividends, distributions and/or payments by and among Borrowers, any Loan Parties, any
      co-borrower(s) and/or any Guarantor(s) under this Agreement; or (b) directly or&#160; indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Transactions with Affiliates.</font>&#160; Directly or indirectly enter into or permit to exist any material
      transaction with any Affiliate of a Loan Party or any of their Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower&#8217;s or such Subsidiary&#8217;s business, upon fair and reasonable terms that are no less favorable to
      Borrower or such Subsidiary than would be obtained in an arm&#8217;s length transaction with a non&#8209;affiliated Person, (b) Subordinated Debt or equity investments by Borrower&#8217;s investors in Borrower or its Subsidiaries; (c) transaction explicitly permitted
      hereunder between Affiliates, (d) compensation related arrangements for the Loan Parties&#8217; employees, directors and consultants that are consistent with the Loan Parties&#8217; past practices, prevalent standards in the Loan Parties&#8217; industry and approved
      by such Loan Parties&#8217; Board of Directors (or equivalent) and (e) transactions that are explicitly allowed among the Loan Parties&#8217; Affiliates under this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Subordinated Debt.</font>&#160; (a) Make or permit any payment on any Subordinated Debt, except under the terms of the
      subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof or adversely affect the
      subordination thereof to Obligations owed to the Lenders, except in accordance with the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject,</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">25</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Compliance.</font>&#160; Become an &#8220;investment company&#8221; or a company controlled by an &#8220;investment company&#8221;, under the
      Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds
      of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate
      any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete
      termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of the Loan Parties or any of their
      Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Compliance with Anti&#8209;Terrorism Laws.</font>&#160; Collateral Agent hereby notifies the Loan Parties and each of their
      Subsidiaries that pursuant to the requirements of Anti&#8209;Terrorism Laws, and Collateral Agent&#8217;s policies and practices, Collateral Agent is required to obtain, verify and record certain information and documentation that identifies the Loan Parties and
      each of their Subsidiaries and their principals, which information includes the name and address of the Loan Parties and each of their Subsidiaries and their principals and such other information that will allow Collateral Agent to identify such
      party in accordance with Anti&#8209;Terrorism Laws.&#160; No Loan Party nor any of their Subsidiaries shall, nor shall any Loan Party nor any of their Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments,
      agreements or contracts with any Person listed on the OFAC Lists or similar lists produced by an Authority.&#160; The Loan Parties and each of their Subsidiaries shall immediately notify Collateral Agent if a Loan Party or such Subsidiary has knowledge
      that any Loan Party, or any Subsidiary or Affiliate of the Loan Parties, is listed on the OFAC Lists or similar lists produced by an Authority or (a) is convicted on, (b) pleads <font style="font-style: italic;">nolo contendere</font> to, (c) is
      indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.&#160; No Loan Party nor any of their Subsidiaries shall, nor shall any Loan Party or any of their Subsidiaries, permit any
      Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the
      benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti&#8209;Terrorism Law, or (iii)
      engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti&#8209;Terrorism Law.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5076b5b37fde418095b37cf41d68b741" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>EVENTS OF DEFAULT</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Any one of the following shall constitute an event of default (an &#8220;<font style="font-weight: bold;">Event of Default</font>&#8221;) under this Agreement:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Payment Default.</font>&#160; A Loan Party fails to (a) make any payment of principal or interest on any Term Loan on
      its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration
      pursuant to Section 9.1 (a) hereof).&#160; During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Covenant Default.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A Loan Party or any of their Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports,
      Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.10 (Other Entities), 6.12 (Creation/Acquisition of Subsidiaries) or the Loan Party
      violates any covenant in Section 7; or</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">26</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A Loan Party, or any of their Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or
      agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default
      within fifteen (15) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the fifteen (15)) day period or cannot after diligent attempts by a Loan Party be cured within such fifteen (15)&#160; day
      period, and such default is likely to be cured within a reasonable time, then such Loan Party shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time
      period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period).&#160; Grace periods provided under this Section shall not apply, among other things, to financial covenants
      (if any) or any other covenants set forth in subsection (a) above;</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Material Adverse Change.</font>&#160; A Material Adverse Change occurs;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Attachment; Levy; Restraint on Business.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) The service of process seeking to attach, by trustee or similar process, any funds of a Loan Party or any of their Subsidiaries on deposit
      with any Lender or any Lender&#8217;s Affiliate or any bank or other institution at which a Loan Party or any of their Subsidiaries maintains a Collateral Account, or (ii) a notice of lien, levy, or assessment is filed against a Loan Party or any of their
      Subsidiaries or their respective assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise);
      provided, however, no Credit Extensions shall be made during any ten (10) day cure period; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) any material portion of a Loan Party&#8217;s or any of their Subsidiary&#8217;s assets is attached, seized, levied on, expropriated or comes into
      possession of a trustee or receiver (or any analogous process occurs in any relevant jurisdiction), or (ii) any court order enjoins, restrains, or prevents a Loan Party or any of its Subsidiaries from conducting any part of its business;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Insolvency.</font>&#160; (a) (i) Parent is or becomes Insolvent or (ii) a Loan Party and its Subsidiaries on a
      consolidated basis become Insolvent; (b) a Loan Party or any of its Subsidiaries (which is a co-borrower or secured guarantor) begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries
      (which is a co-borrower or secured guarantor) and not dismissed or stayed within forty&#8209;five (45) days (but no Credit Extensions shall be made while such Loan Party or such Subsidiary is Insolvent and/or until any Insolvency Proceeding is dismissed);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Other Agreements.</font>&#160; There is a default in any agreement to which a Loan Party or any of their Subsidiaries
      is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) or that
      could reasonably be expected to have a Material Adverse Change; provided, however, that the Event of Default under this Section 8.6 caused by the occurrence of a breach or default under such other agreement shall be cured or waived for purposes of
      this Agreement upon Collateral Agent receiving written notice from the party asserting such breach or default of such cure or waiver of the breach or default under such other agreement, if at the time of such cure or waiver under such other agreement
      (x) Collateral Agent or any Lender has not declared an Event of Default under this Agreement and/or exercised any rights with respect thereto; (y) any such cure or waiver does not result in an Event of Default under any other provision of this
      Agreement or any Loan Document; and (z) in connection with any such cure or waiver under such other agreement, the terms of any agreement with such third party are not modified or amended in any manner which could in the good faith business judgment
      of Collateral Agent be materially less advantageous to the Loan Parties, taken as a whole;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Judgments.</font>&#160; One or more judgments, orders, or decrees for the payment of money in an amount, individually
      or in the aggregate, of at least Two Hundred Fifty Thousand Dollars ($250,000.00) (not covered by independent third&#8209;party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against a Loan Party or any of
      their Subsidiaries and shall remain unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof (provided that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or
      decree);</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">27</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Misrepresentations.</font>&#160; The Loan Parties or any of their Subsidiaries or any Person acting for the Loan
      Parties or any of their Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and/or Lenders or to induce Collateral Agent and/or the
      Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Subordinated Debt.</font>&#160; A default or breach occurs under any agreement between a Loan Party or any of its
      Subsidiaries and any creditor of a Loan Party or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any creditor that has signed such an agreement with Collateral
      Agent or the Lenders breaches any terms of such agreement;</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Governmental Approvals.</font>&#160; Any Governmental Approval shall have been revoked, rescinded, suspended,
      modified in an adverse manner, or not renewed in the ordinary course for a full term <font style="font-style: italic;">and</font> such revocation, rescission, suspension, modification or non&#8209;renewal has resulted in or could reasonably be expected to
      result in a Material Adverse Change;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Lien Priority</font>.&#160; Any Lien created hereunder or by any other Loan Document shall at any time fail to
      constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, to the extent such perfection is required in this Agreement or the Loan Documents (including, without limitation, pursuant to Section 4.1 of this
      Agreement), subject to no prior or equal Lien, other than Permitted Liens which are permitted to have priority in accordance with the terms of this Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Delisting</font>. After the initial public offering of any class of equity securities of Parent (or HoldCo or
      SPAC as applicable), the shares of such class of equity securities of Parent (or HoldCo or SPAC as applicable), are delisted for thirty (30) days from the primary stock exchange on which they are traded because of failure to comply with continued
      listing standards thereof or due to a voluntary delisting which results in such shares not being listed no later than thirty (30) days after such delisting on any other nationally recognized stock exchange in the United States having listing
      standards at least as restrictive as the aforementioned primary stock exchange;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Guaranty.</font>&#160; (a) Any Guaranty terminates or ceases for any reason to be in full force and effect, unless
      terminated by written agreement with Collateral Agent and Lenders; or (b) any Guarantor does not perform any obligation or covenant under any Guaranty (subject to the same cure periods that would be available under this Agreement in case of a breach
      of the same or equivalent covenant).</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z22cb10e65fda4c779634b3566b1e193f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>RIGHTS AND REMEDIES</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Rights and Remedies.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon the occurrence and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required Lenders
      shall,<font style="font-weight: bold;">&#160;</font>without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to a Loan Party, (ii) by notice to the Loan Parties declare all Obligations immediately due and
      payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to the Loan Parties suspend or terminate the
      obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s (or the Loan Parties&#8217;) benefit under this Agreement or under any other agreement between the Loan Parties and Collateral Agent and/or the Lenders (but if an Event of
      Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between the Loan Parties and Collateral Agent and/or the
      Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">28</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance
      of an Event of Default, Collateral Agent shall have the right at the written direction of the Required Lenders,<font style="font-weight: bold;">&#160;</font>without notice or demand, to do any or all of the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;foreclose upon and/or sell or otherwise liquidate, the Collateral;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;apply to the Obligations any (a) balances and deposits of the Loan Parties that Collateral Agent or any Lender holds or controls, or (b) any
      amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of the Loan Parties; and/or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;commence and prosecute an Insolvency Proceeding or consent to the Loan Parties commencing any Insolvency Proceeding.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the
      continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers
      advisable, notify any Person owing the Loan Parties money of Collateral Agent&#8217;s security interest in such funds, and verify the amount of such account;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the
      Collateral.&#160; The Loan Parties shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates.&#160; Collateral Agent may enter premises where the Collateral is located, take and
      maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. The Loan Parties grants Collateral Agent a license to
      enter and occupy any of its premises, without charge, to exercise any of Collateral Agent&#8217;s rights or remedies;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral.&#160; Collateral Agent is
      hereby granted a non&#8209;exclusive, royalty&#8209;free license or other right to use, without charge, the Loan Parties&#8217; and each of their Subsidiaries&#8217; labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks,
      service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent&#8217;s exercise of its rights under
      this Section 9.1, the Loan Parties&#8217; and each of their Subsidiaries&#8217; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;place a &#8220;hold&#8221;, or Notice of Charge, on any account maintained with Collateral Agent or the Lenders and/or deliver a notice of exclusive
      control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;demand and receive possession of Borrower&#8217;s Books;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vi)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent
      court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of the Loan Parties or any of its Subsidiaries; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents or
      at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">29</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section 9.1
      without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.&#160; As used in the immediately preceding sentence, &#8220;<font style="font-weight: bold;">Exigent Circumstance</font>&#8221; means any event or circumstance that,
      in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof,
      destruction or material waste thereof, or failure of the Loan Parties or any of their Subsidiaries after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably
      be expected to result in a material diminution in value of the Collateral.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Power of Attorney.</font>&#160; The Loan Parties hereby irrevocably appoints Collateral Agent as its lawful
      attorney&#8209;in&#8209;fact, exercisable upon the occurrence and during the continuance of an Event of Default, to: (a) endorse the Loan Parties&#8217; or any of their Subsidiaries&#8217; name on any checks or other forms of payment or security; (b) sign the Loan Parties&#8217;
      or any of their Subsidiaries&#8217; name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Collateral
      Agent determines reasonable; (d) make, settle, and adjust all claims under the Loan Parties&#8217; insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment
      based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits.&#160; The Loan Parties hereby appoints Collateral
      Agent as its lawful attorney&#8209;in&#8209;fact to sign the Loan Parties&#8217; or any of their Subsidiaries&#8217; name on any documents necessary to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Collateral regardless of whether an
      Event of Default has occurred until all Obligations (other than inchoate indemnity obligations) have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to make Credit Extensions hereunder.&#160; Collateral Agent&#8217;s
      foregoing appointment as the Loan Parties&#8217; or any of their Subsidiaries&#8217; attorney in fact, and all of Collateral Agent&#8217;s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations)
      have been fully repaid and performed and Collateral Agent&#8217;s and the Lenders&#8217; obligation to provide Credit Extensions terminates.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Protective Payments.</font>&#160; If the Loan Parties or any of the Subsidiaries fail to obtain the insurance called
      for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which a Loan Party or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain such insurance or
      make such payment, and all amounts so paid by Collateral Agent are Lenders&#8217; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral.&#160; Collateral Agent will make reasonable efforts to provide the
      Loan Parties with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter.&#160; No such payments by Collateral Agent are deemed an agreement to make similar
      payments in the future or Collateral Agent&#8217;s waiver of any Event of Default.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Application of Payments and Proceeds.</font>&#160; Notwithstanding anything to the contrary contained in this
      Agreement, upon the occurrence and during the continuance of an Event of Default, (a) the Loan Parties irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or
      on behalf of the Loan Parties or any of its Subsidiaries of all or any part of the Obligations, and, as between the Loan Parties on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and exclusive
      right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the proceeds of any sale of, or other
      realization upon all or any part of the Collateral shall be applied: first, to the Lenders&#8217; Expenses; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy
      Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of the Loan Parties owing to Collateral Agent or any Lender under the Loan Documents.&#160; Any
      balance remaining shall be delivered to the Loan Parties or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct.&#160; In carrying out the foregoing, (x) amounts received shall be applied in the
      numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">30</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category.&#160; Any reference in this
      Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation &#8220;ratably,&#8221; &#8220;proportionally&#8221; or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise.&#160; Collateral Agent, or if applicable,
      each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&#8217;s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by the Loan
      Parties.&#160; Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a
      Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as
      instructed by Collateral Agent.&#160; If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in
      excess of such Lender&#8217;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders&#8217; claims.&#160; To the extent any payment for the
      account of the Loan Parties is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis.&#160; If any Lender shall obtain
      possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent&#8217;s security interest therein.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Liability for Collateral.</font>&#160; So long as Collateral Agent and the Lenders comply with reasonable banking
      practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any
      loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person.&#160; The Loan Parties bears all risk of loss, damage or destruction of the Collateral.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">No Waiver; Remedies Cumulative.</font>&#160; Failure by Collateral Agent or any Lender, at any time or times, to
      require strict performance by the Loan Parties of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter to demand strict performance and compliance
      herewith or therewith.&#160; No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given.&#160; The rights and remedies of Collateral
      Agent and the Lenders under this Agreement and the other Loan Documents are cumulative.&#160; Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity.&#160; The exercise by Collateral
      Agent or any Lender of one right or remedy is not an election, and Collateral Agent&#8217;s or any Lender&#8217;s waiver of any Event of Default is not a continuing waiver.&#160; Collateral Agent&#8217;s or any Lender&#8217;s delay in exercising any remedy is not a waiver,
      election, or acquiescence.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Demand Waiver.</font>&#160; Each Loan Party waives, to the fullest extent permitted by law, demand, notice of default
      or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Collateral Agent or any
      Lender on which the Loan Parties or any Subsidiary is liable.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze99902b536574426890c1ea3d48dc61b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>NOTICES</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All notices, consents, requests, approvals, demands, or other communication (collectively, &#8220;<font style="font-weight: bold;">Communication</font>&#8221;) by any party to this Agreement or any other Loan
      Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return
      receipt requested, with proper postage prepaid; (b) upon transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with
      all charges prepaid; or (d) when delivered, if hand&#8209;delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.&#160; Any of Collateral Agent, Lender or
      the Loan Parties may change their mailing address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">31</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z63fe2a311eb34076815b29c2740690c0" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>If to Borrower and/or</div>
            <div>Guarantors:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>IMMUNOCORE LIMITED</div>
            <div>IMMUNOCORE LLC</div>
            <div>IMMUNOCORE COMMERCIAL LLC</div>
            <div>92 Park Drive, Milton Park</div>
            <div>Abingdon</div>
            <div>Oxon</div>
            <div>OX14 4RY</div>
            <div>United Kingdom</div>
            <div>Attn: Brian Di Donato, Chief Financial Officer</div>
            <div>and Lily Hepworth, Chief Legal Counsel</div>
            <div>Fax: +1 (610) 828-5918</div>
            <div>Email: brian.didonato@immunocore and</div>
            <div>lily.hepworth@immunocore.com <br>
            </div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>With a copy to:</div>
            <div>&#160;</div>
            <div>&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>IMMUNOCORE LIMITED</div>
            <div>IMMUNOCORE LLC</div>
            <div>IMMUNOCORE COMMERCIAL LLC</div>
            <div>Six Tower Bridge, Suite 540</div>
            <div>181 Washington Street</div>
            <div>Conshohocken, PA 19422</div>
            <div>Attn: Brian Di Donato, Chief Financial Officer</div>
            <div>and Lily Hepworth, Chief Legal Counsel</div>
            <div>Fax: +1 (610) 828-5918</div>
            <div>Email: brian.didonato@immunocore and</div>
            <div>lily.hepworth@immunocore.com</div>
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>with a copy (which shall not constitute notice) to:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>Cooley LLP</div>
            <div>55 Hudson Yards</div>
            <div>New York, NY&#160; 10001-2157</div>
            <div>Attn: Divakar Gupta</div>
            <div>Fax:&#160; (212) 479-6275</div>
            <div>Email: dgupta@cooley.com</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4f74a642ee5b4f67a1eded03696e7195" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>If to Collateral Agent:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
            <div>2, route d&#8217;Arlon,</div>
            <div>L-8008 Strassen,</div>
            <div>Grand Duchy of Luxembourg</div>
            <div>Fax: +352 26 11 94 78 90</div>
            <div>Email: oxfordfinance@cscgfm.lu</div>
            <div>and,</div>
            <div>&#160;</div>
            <div>133 North Fairfax Street</div>
            <div>Alexandria, Virginia 22314</div>
            <div>Attention: Legal Department</div>
            <div>Fax: (703) 519&#8209;5225</div>
            <div>Email: LegalDepartment@oxfordfinance.com</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 20%; vertical-align: top;">&#160;</td>
          <td style="width: 30%; vertical-align: top;">
            <div>with a copy (which shall not constitute notice) to:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div>Greenberg Traurig, LLP</div>
            <div>One International Place</div>
            <div>Boston, MA 02110</div>
            <div>Attn: Abdullah Malik</div>
            <div>Fax: (617) 897-0983</div>
            <div>Email: <u>malikab@gtlaw.com</u></div>
            <div>&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">32</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7eec019224144aa3a9b6e730b4d909ba" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">New York law governs the Loan Documents without regard to principles of conflicts of law.&#160; The Loan Parties, Lenders and Collateral Agent and each Lender each submit to the exclusive jurisdiction of the State and
      Federal courts in the City of New York, Borough of Manhattan.&#160; NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND THE LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER
      JURISDICTION WHICH COLLATERAL AGENT AND THE LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT&#8217;S AND THE LENDERS&#8217; RIGHTS AGAINST BORROWER OR
      ITS PROPERTY.&#160; Each Loan Party expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and each Loan Party hereby waives any objection that it may have based upon lack of personal
      jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court.&#160; Each Loan Party hereby waives personal service of the summons, complaints, and other
      process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to each Loan Party at the address set forth in, or subsequently provided by a Loan
      Party in accordance with, Section 10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of such Loan Party&#8217;s actual receipt thereof or three (3) days after deposit in the U.S. mails, first class, registered
      or certified mail return receipt requested, proper postage prepaid.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, COLLATERAL AGENT, AND THE LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS
      AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR EACH PARTY TO ENTER INTO THIS AGREEMENT.&#160; EACH PARTY HAS REVIEWED THIS WAIVER WITH
      ITS COUNSEL.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z155304d4a1964c92a1b99efb8f8ae106" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>GENERAL PROVISIONS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Successors and Assigns.</font> This Agreement binds and is for the benefit of the successors and permitted
      assigns of each party.&#160; The Loan Parties may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&#8217;s and each Lender&#8217;s prior written consent (which may be granted or withheld in Collateral
      Agent&#8217;s and each Lender&#8217;s discretion, subject to Section 12.6).&#160; The Lenders have the right, without the consent of or notice to the Loan Parties, to sell, transfer, assign, pledge, negotiate, or grant participation in&#160;<font style="font-weight: bold;">(any </font>such sale, transfer, assignment, negotiation<font style="font-weight: bold;">,</font> or grant of a participation, a <font style="font-weight: bold;">&#8220;Lender Transfer&#8221;)</font> all or any part of, or any interest in, the
      Lenders&#8217; obligations, rights, and benefits under this Agreement and the other Loan Documents;<font style="font-style: italic;"> provided</font>, <font style="font-style: italic;">however</font>, that any such Lender Transfer (other than a transfer,
      pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an &#8220;<font style="font-weight: bold;">Approved Lender</font>&#8221;)<font style="font-weight: bold;">.</font> The Loan Parties and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so
      assigned until Collateral Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other
      information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require.&#160; Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender
      Transfer (other than a Lender Transfer in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to
      a Lender&#8217;s own financing or securitization transactions) shall be permitted, without the Loan Parties&#8217; consent, to any Person which is an Affiliate or Subsidiary of the Loan Parties, a direct competitor of the Loan Parties or a vulture hedge fund,
      each as determined by Collateral Agent in its good faith business discretion.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">33</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Indemnification.</font>&#160; The Loan Parties agree to indemnify, defend and hold Collateral Agent and the Lenders
      and their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &#8220;<font style="font-weight: bold;">Indemnified Person</font>&#8221;) harmless against:&#160; (a)
      all obligations, demands, claims, and liabilities (collectively, &#8220;<font style="font-weight: bold;">Claims</font>&#8221;) asserted by any other party in connection with; related to; following; or arising from, out of or under, the transactions contemplated
      by the Loan Documents; and (b) all losses or Lenders&#8217; Expenses incurred, or paid by Indemnified Person in connection with; related to; following; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral
      Agent, and/or the Lenders and the Loan Parties (including reasonable attorneys&#8217; fees and expenses), except for Claims and/or losses directly caused by such Indemnified Person&#8217;s&#160; gross negligence or willful misconduct.&#160; The Loan Parties hereby further
      indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever
      (including the fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a
      party thereto and including any such proceeding initiated by or on behalf of the Loan Parties, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or
      compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified
      Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims,
      costs, expenses and disbursements directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct. This Section 12.2 shall not apply with respect to Taxes including any Taxes that represent losses, claims, damages, etc. arising
      from any non-Tax Claim.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Time of Essence.</font>&#160; Time is of the essence for the performance of all Obligations in this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Severability of Provisions.</font>&#160; Each provision of this Agreement is severable from every other provision in
      determining the enforceability of any provision.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Correction of Loan Documents.</font>&#160; Collateral Agent and the Lenders may correct patent errors and fill in any
      blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties<font style="font-weight: bold;">.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Amendments in Writing; Integration.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent
      thereunder, or any consent to any departure by the Loan Parties or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by the Loan Parties, Collateral Agent and the Required Lenders
      provided that:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&#8217;s Term Loan Commitment or
      Commitment Percentage shall be effective as to such Lender without such Lender&#8217;s written consent;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral
      Agent&#8217;s written consent or signature;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">34</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of,
      rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of
      principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment); (C) change the definition of the term &#8220;<font style="font-weight: bold;">Required Lenders</font>&#8221; or the percentage of Lenders which shall be required for the Lenders to take any action hereunder; (D) release all or substantially all of any material portion of the Collateral, authorize the
      Loan Parties to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case
      with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder); (E) amend, waive or otherwise modify this Section 12.6 or
      the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance of this Section 12.6; (F) consent to the assignment, delegation or other transfer by the Loan Parties of any of its rights and obligations under
      any Loan Document or release the Loan Parties of their payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the
      provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral
      hereunder; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations; or (I) amend any of the provisions of Section 12.10.&#160; It is hereby understood and agreed that all Lenders shall be deemed directly affected by an
      amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the provisions of the foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the
      Lenders and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other than as expressly provided for in Section 12.6(a)(i)&#8209;(iii), Collateral Agent may, if requested by the Required Lenders, from time to time
      designate covenants in this Agreement less restrictive by notification to a representative of the Loan Parties.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.&#160;
      All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Counterparts.</font>&#160; This Agreement may be executed in any number of counterparts and by different parties on
      separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Survival.</font>&#160; All covenants, representations and warranties made in this Agreement continue in full force
      and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been
      satisfied.&#160; The obligation of the Loan Parties in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.9 below, shall survive until the statute of limitations with respect to such claim
      or cause of action shall have run.&#160; Notwithstanding anything herein to the contrary, the Loan Parties&#8217; obligations under the Success Fee Letter shall survive the termination of this Agreement in accordance with the terms of the Success Fee Letter.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">35</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Confidentiality.</font>&#160; In handling any confidential information of the Loan Parties, the Lenders and
      Collateral Agent shall exercise the same degree of care that it exercises for their own proprietary information, but disclosure of information may be made: (a) subject to the terms and conditions of this Agreement, to the Lenders&#8217; and Collateral
      Agent&#8217;s Subsidiaries or Affiliates, or in connection with a Lender&#8217;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization
      transaction; (b) to prospective transferees (other than those identified in (a) above, but including parties described in Section 12.11 of this Agreement) or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and
      Collateral Agent shall, except upon the occurrence and during the continuance of an Event of Default, obtain such prospective transferee&#8217;s or purchaser&#8217;s agreement to the terms of this provision or to similar confidentiality terms); (c) as required
      by law, regulation, subpoena, or other order; (d) to Lenders&#8217; or Collateral Agent&#8217;s regulators or as otherwise required in connection with an examination or audit; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under
      the Loan Documents; and (f) to third party service providers of the Lenders and/or Collateral Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less restrictive than
      those contained herein. Confidential information does not include information that either: (i) is in the public domain or in the Lenders&#8217; and/or Collateral Agent&#8217;s possession when disclosed to the Lenders and/or Collateral Agent, or becomes part of
      the public domain after disclosure to the Lenders and/or Collateral Agent; or (ii) is disclosed to the Lenders and/or Collateral Agent by a third party, if the Lenders and/or Collateral Agent does not know that the third party is prohibited from
      disclosing the information.&#160; Except as limited herein, Collateral Agent and the Lenders may use confidential information for any purpose, including, without limitation, for the development of client databases, reporting purposes, and market analysis
      so long as Collateral Agent or a Lender does not disclose the Loan Party&#8217;s identity or the identity of any person associated with the Loan Parties unless otherwise expressly permitted by the Loan Parties in writing. The provisions of the immediately
      preceding sentence shall survive the termination of this Agreement.&#160; Notwithstanding the foregoing, The Loan Parties hereby agrees that Collateral Agent and each Lender may, after providing advance notice to the Loan Parties and after the Loan
      Parties&#8217; review and written approval of the following items) make a public announcement of the transactions contemplated by this Agreement after the Effective Date, and may publicize the same in marketing materials, newspapers and other publications,
      and otherwise, and in connection therewith may use such Loan Party&#8217;s name, tradenames and logos.&#160; The agreements provided under this Section 12.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the
      parties about the subject matter of this Section 12.9.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Right of Set Off.</font>&#160; Each Loan Parties hereby grants to Collateral Agent and to each Lender, a lien,
      security interest and right of set off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the
      possession, custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them.&#160; At any time after the occurrence
      and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of the Loan Parties even though unmatured and
      regardless of the adequacy of any other collateral securing the Obligations.&#160; ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING
      ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">36</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Cooperation of Borrower.</font>&#160; If necessary, the Loan Parties agree to (i) execute any documents (including
      new Secured Promissory Notes from Borrower) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Term Loan to an assignee in accordance with Section 12.1, (ii) make the Loan Parties&#8217; management available to
      meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions (which meetings shall be conducted no more often than twice every twelve months unless an Event of Default has occurred and is
      continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of the Loan Parties as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may
      request; provided that, unless an Event of Default has occurred or is continuing, such prospective assignee is not a direct competitor of the Loan Parties as reasonably determined by Collateral Agent (other than a prospective assignee for a Lender
      Transfer in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to a Lender&#8217;s own financing or
      securitization transactions). Subject to the provisions of Section 12.9, the Loan Parties authorize each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender&#8217;s possession
      concerning the Loan Parties and their financial affairs which has been delivered to such Lender by or on behalf of the Loan Parties pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of the Loan Parties in
      connection with such Lender&#8217;s credit evaluation of the Loan Parties prior to entering into this Agreement; provided that, unless an Event of Default has occurred or is continuing, such prospective assignee is not a direct competitor of the Loan
      Parties as reasonably determined by Collateral Agent (other than a prospective assignee for a Lender Transfer in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency; or (y) upon the
      occurrence of a default, event of default or similar occurrence with respect to a Lender&#8217;s own financing or securitization transactions).</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z76b7f004d0fe4bd299e3e32d45b12ed8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-variant: small-caps; font-weight: bold;"><u>DEFINITIONS</u></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">13.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Definitions.</font>&#160; As used in this Agreement, the following terms have the following meanings:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Account</font>&#8221; is any &#8220;account&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts
      receivable and other sums owing to the Loan Parties.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Account Debtor</font>&#8221; is any &#8220;account debtor&#8221; as defined in the Code with such additions to such term as may hereafter be made.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common
      control with the Person, and each of that Person&#8217;s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person&#8217;s managers and members.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Agreement</font>&#8221; is defined in the preamble hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Amortization Date</font>&#8221; is, (i) January 1, 2024, if the I/O Extension Event does not occur and (ii) January 1, 2025, if the I/O Extension Event occurs.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Annual Projections</font>&#8221; is defined in Section 6.2(a).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Anti&#8209;Terrorism Laws</font>&#8221; are any laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA
      PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Approved Fund</font>&#8221; is any (i) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or
      otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the
      preceding clause (i) and that, with respect to each of the preceding clauses (i) and (ii), is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) a Person (other than a natural person) or an Affiliate of a Person (other than
      a natural person) that administers or manages a Lender.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Approved Lender</font>&#8221; is defined in Section 12.1.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-weight: bold;">&#8220;Assigned Debt</font>&#8221; is defined in Section 7.3(c).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Authority</font>&#8221; is any relevant government, agency or legislature in the United States, the United Kingdom, the European Union or any of its member state, or other relevant
      jurisdiction, including but not limited to: OFAC, the US State Department, the United Nations Security Council, the Commission of the European Union and Her Majesty&#8217;s Treasury.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">37</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Basic Rate</font>&#8221; is with respect to any Term Loan, the per annum rate of interest (based on a year of three hundred sixty (360) days) equal to the sum of (i) the
      lesser of (A) the greater of (1) thirty (30) day U.S. Dollar LIBOR rate reported in <u>The Wall Street Journal</u> on the last Business Day of the month that immediately precedes the month in which the interest will accrue and (2) Sixteen hundredths
      percent (0.16%) and (B) Three and Sixteen hundredths percent (3.16%), plus (ii) Eight and Eighty-Five hundredths percent (8.85%).&#160; For the avoidance of doubt, in no event (including upon any occurrence of a LIBOR Transition Event and/or any
      replacement with a LIBOR Replacement Rate) shall the Basic Rate under this Agreement exceed twelve and one hundredths percent (12.01%) at any time.&#160; Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of
      a LIBOR Transition Event, Collateral Agent may amend this Agreement to replace the Basic Rate with a LIBOR Replacement Rate. Any such amendment with respect to a LIBOR Transition Event will become effective at 5:00 p.m. (Eastern Standard Time) on the
      third Business Day after Collateral Agent has notified the Loan Parties of such amendment.&#160; Any determination, decision or election that may be made by Collateral Agent pursuant hereto will be conclusive and binding absent manifest error and may be
      made in Collateral Agent&#8217;s sole discretion and without consent from any other party. Notwithstanding the foregoing, the Basic Rate for the Term Loan for the period from the Effective Date through and including November 30, 2020 shall be 9.01%.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">BLA Approval Event</font>&#8221; is the approval by the U.S. Food and Drug Administration, on or before June 30, 2022, of a Loan Party&#8217;s Biologics License Application for
      the use of the Loan Parties&#8217; product candidate Tebentafusp for the treatment of metastatic uveal melanoma such that any Loan Party may be allowed to immediately commence the sale of Tebentafusp in the United States.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Blocked Person</font>&#8221;<font style="font-weight: bold;">&#160;</font>is any Person:&#160; (a) listed in the annex to, or is otherwise subject to the provisions of, Executive
      Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited
      from dealing or otherwise engaging in any transaction by any Anti&#8209;Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#8220;terrorism&#8221; as defined in Executive Order No. 13224, or (e) a Person that is named a &#8220;specially
      designated national&#8221; or &#8220;blocked person&#8221; on the most current list published by OFAC or other similar list.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Borrower</font>&#8221; is defined in the preamble hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Borrower&#8217;s Books</font>&#8221; are each Loan Party&#8217;s or any of their Subsidiaries&#8217; books and records including ledgers, federal, and state tax returns, records regarding
      such Loan Party&#8217;s or its Subsidiaries&#8217; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Business Day</font>&#8221; is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Cancelled Certificate</font>&#8221; means any QPP Certificate in respect of which HM Revenue &amp; Customs has given a notification under regulation 7(4)(b) of the QPP
      Regulations so that such QPP Certificate is a cancelled certificate for the purposes of the QPP Regulations.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Cash Equivalents</font>&#8221; are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having
      maturities of not more than one (1) year from the date of acquisition; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &amp; Poor&#8217;s Ratings Group or Moody&#8217;s Investors
      Service, Inc., and (c) certificates of deposit maturing no more than one (1) year after issue, provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement (if required pursuant to Section 6.6(a))
      in favor of Collateral Agent.&#160; For the avoidance of doubt, the direct purchase by the Loan Parties or any of its Subsidiaries of any Auction Rate Securities, or purchasing participations in, or entering into any type of swap or other derivative
      transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by the Loan Parties or any of its Subsidiaries shall be conclusively determined by the Lenders as an ineligible Cash Equivalent, and any such
      transaction shall expressly violate each other provision of this Agreement governing Permitted Investments.&#160; Notwithstanding the foregoing, Cash Equivalents does not include and the Loan Parties, and each of their Subsidiaries, are prohibited from
      purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without limitation, any
      corporate or municipal bonds with a long&#8209;term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an<font style="font-weight: bold;">&#160;</font>auction rate security (each, an &#8220;<font style="font-weight: bold;">Auction Rate Security</font>&#8221;).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">38</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Claims</font>&#8221; are defined in Section 12.2.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Code</font>&#8221; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that, to the extent
      that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; provided
      further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code in
      effect in a jurisdiction other than the State of New York, the term &#8220;Code&#8221; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment,
      perfection, priority, or remedies and for purposes of definitions relating to such provisions.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Collateral</font>&#8221; is any and all properties, rights and assets of each Loan Party described on <u>Exhibit A</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Collateral Account</font>&#8221; is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by a Loan Party or any Subsidiary
      at any time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Collateral Agent</font>&#8221; is, Oxford, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Commitment Percentage</font>&#8221; is set forth in <u>Schedule 1.1</u>, as amended from time to time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Commodity Account</font>&#8221; is any &#8220;commodity account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Communication</font>&#8221; is defined in Section 10.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Compliance Certificate</font>&#8221; is that certain certificate in the form attached hereto as <u>Exhibit C</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Contingent Obligation</font>&#8221; is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend,
      letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co&#8209;made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any
      obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to
      protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but &#8220;Contingent Obligation&#8221; does not include endorsements in the ordinary course of business.&#160; The amount of a Contingent Obligation is the stated or
      determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of
      the obligations under any guarantee or other support arrangement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Control Agreement</font>&#8221; is any control agreement entered into among the depository institution at which any Loan Party or any of their Subsidiaries maintains a
      Deposit Account or the securities intermediary or commodity intermediary at which the Loan Parties or any of their Subsidiaries maintains a Securities Account or a Commodity Account, the Loan Party and such Subsidiary, and Collateral Agent pursuant
      to which Collateral Agent obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Copyrights</font>&#8221; are any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative
      work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">39</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Credit Extension</font>&#8221; is any Term Loan or any other extension of credit by Collateral Agent or Lenders for Borrower&#8217;s benefit.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Default Rate</font>&#8221; is defined in Section 2.3(b).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Deposit Account</font>&#8221; is any &#8220;deposit account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Designated Agreement</font>&#8221; means that certain Gates Foundation Collaboration Agreement, dated as of September 13, 2017, as amended, restated and/or supplemented from time to time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Designated Deposit Account</font>&#8221; is Parent&#8217;s current account, account number ending in 544, maintained with Bank of Scotland-USD account.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Direction</font>&#8221; is defined in Section 2.6(b)(ii)(1) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Disbursement Letter</font>&#8221; is that certain form attached hereto as <u>Exhibit B</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Dollars</font><font style="font-style: italic;">,</font>&#8221;<font style="font-style: italic;">&#160;</font>&#8220;<font style="font-weight: bold;">dollars</font>&#8221; and &#8220;$&#8221; each
      mean lawful money of the United States.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Domestic Subsidiary</font>&#8221; means a Subsidiary organized under the laws of the United States or any state or territory thereof or the District of Columbia.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">DTTP Filing</font>&#8221; means an HMRC Form DTTP2 duly completed and filed by the relevant UK Obligor, which:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">(i) contains the scheme reference number and jurisdiction of tax residence stated opposite Lender&#8217;s name in <u>Schedule 2</u> to this Agreement, and</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(A)&#160; &#160; &#160; &#160; &#160; where the UK Obligor is a UK Obligor at the date of this Agreement, is filed with HMRC within 30&#160; days of the later of the date of this Agreement and the date on which the Borrower is
      notified of the Lender&#8217;s scheme reference number and jurisdiction of tax residence pursuant to Section 2.6(f)(ii)(1); or</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(B)&#160; &#160; &#160; &#160; &#160; where the UK Obligor becomes a UK Obligor after the date of this Agreement, is filed with HMRC within 30 days of the date on which that UK Obligor becomes a UK Obligor under this
      agreement; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">(ii)&#160; &#160; &#160; &#160; &#160;&#160; where it relates to a new or additional lender to which Lender assigns or transfers its interest under Section 12.1 (<font style="font-style: italic;">Successors and assigns</font>) of
      this Agreement, contains the scheme reference number and jurisdiction of tax residence stated in respect of that lender in the documentation which it executes on becoming a party to this Agreement as a lender, and</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(A)&#160; &#160; &#160; &#160; &#160; where the UK Obligor is a UK Obligor as at the date on which that new or additional lender becomes a party to this Agreement as a lender, is filed with HMRC within 30 days of that date;
      or</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 72pt;">(B)&#160; &#160; &#160; &#160; &#160; where the UK Obligor&#160; is not a UK Obligor as at the date on which that new or additional lender becomes a party to this Agreement as a lender, is filed with HMRC within 30 days of the
      date on which that UK Obligor becomes a UK Obligor under this Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">DTTP Scheme</font>&#8221; means the UK double tax treaty passport scheme operated by HMRC.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Effective Date</font>&#8221; is defined in the preamble of this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">40</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Eligible Assignee</font>&#8221; is (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any commercial bank, savings and loan association or
      savings bank or any other entity which is an &#8220;accredited investor&#8221; (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual funds,
      lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard &amp; Poor&#8217;s Rating Group and a rating of Baa2 or higher from Moody&#8217;s Investors Service, Inc. at the date that it
      becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each case of clauses (i) through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition of
      any withholding or similar taxes; provided that notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include, unless an Event of Default has occurred and is continuing, (i) the Loan Party or any of such Loan Party&#8217;s Affiliates or Subsidiaries
      or (ii) a direct competitor of any Loan Party or a vulture hedge fund, each as determined by Collateral Agent in its good faith business discretion.&#160; Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced
      divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender&#8217;s own financing or securitization transactions, the
      restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a
      default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations
      hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed,
      delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Equipment</font>&#8221; is all &#8220;equipment&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery,
      fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">ERISA</font>&#8221; is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Event of Default</font>&#8221; is defined in Section 8.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Excluded Accounts</font>&#8221; are deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of any
      Loan Party or any of their Subsidiaries&#8217;, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;&#8220;<font style="font-weight: bold;">Excluded Taxes</font>&#8221; means, any of the following Taxes imposed on or with respect to Lender or its successor, transferee or assignee under Section 12.1 (<font style="font-style: italic;">Successors and assigns</font>) or required to be withheld or deducted from a payment to Lender or its successor, transferee or assignee under Section 12.1 (<font style="font-style: italic;">Successors and assigns</font>),




      (a) Taxes imposed on or measured by net income or profits (however denominated), franchise or capital Taxes, and branch profits Taxes, in each case, (i) imposed as a result of Lender or its successor, transferee or assignee under Section 12.1 (<font style="font-style: italic;">Successors and assigns</font>) being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or
      (ii) that are Other Connection Taxes, (b) United States federal withholding Taxes&#160; imposed on amounts payable to or for the account of Lender or its successor, transferee or assignee under Section 12.1 (<font style="font-style: italic;">Successors
        and assigns</font>) with respect to an applicable interest in a Credit Extension pursuant to a law in effect on the date on which (A) Lender or its successor, transferee or assignee under Section 12.1 (<font style="font-style: italic;">Successors
        and assigns</font>) acquires such interest in a Credit Extension or (B) Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.6, amounts with respect to such Taxes were payable either to the Lender&#8217;s
      assignor immediately before Lender became a party hereto or to Lender immediately before it changed its lending office, and (c) any withholding Taxes imposed under FATCA.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">41</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">FATCA</font>&#8221; means Sections 1471 through 1474 of the IRC as in effect on the date hereof or any amended or successor version thereof that is substantively comparable and not materially
      more onerous to comply with (and, in each case, any current or future regulations or official interpretations thereof), and any applicable agreement entered into pursuant to Section 1471(b)(1) of the IRC, and any fiscal or regulatory legislation,
      rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities with respect to the implementation of the foregoing Sections of the IRC.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">FATCA Deduction</font>&#8221; means a deduction or withholding from a payment under a Finance Document required by FATCA.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">FATCA Exempt Party</font>&#8221; means a Party that is entitled to receive payments free from any FATCA Deduction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; font-style: italic;">&#8220;</font><font style="font-weight: bold;">Federal Reserve Bank of New York&#8217;s Website</font><font style="font-weight: bold; font-style: italic;">&#8221; </font>means



      the website of the Federal Reserve Bank of New York at http://www.newyorkfed.org, or any successor source.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Final Payment</font>&#8221; is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to
      occur of (a) the Maturity Date, or (b) the acceleration of any Term Loan, or (c) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d), equal to the original principal amount of such Term Loan multiplied by the Final Payment Percentage,
      payable to Lenders in accordance with their respective Pro Rata Shares.&#160; For the avoidance of doubt, the calculation of any Final Payment shall not include the principal amount prepaid in accordance with Section 2.2(d)(ii) if a Final Payment based on
      such principal amount was made at the time of such prepayment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Final Payment Percentage</font>&#8221; is (i) Three and One-Half percent (3.50%), if the I/O Extension Event does not occur and (ii) Three and Ninety-Five hundredths
      percent (3.95%), if the I/O Extension Event occurs.</div>
    <div style="text-align: justify; text-indent: 36pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Foreign Subsidiary</font>&#8221; means any Subsidiary which is not a Domestic Subsidiary<u style="border-bottom: 1px solid;">.</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Funding Date</font>&#8221; is any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Gates Note</font>&#8221; means that certain note, to be issued pursuant to that certain Immunocore</div>
    <div><br>
    </div>
    <div>Limited Convertible Loan Note Purchase Agreement, dated as of September 13, 2017, and related agreements, as amended and/or supplemented.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">General Intangibles</font>&#8221; are all &#8220;general intangibles&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be
      made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks
      and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise
      agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or
      hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Governmental Approval</font>&#8221; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice,
      of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Governmental Authority</font>&#8221; is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory
      body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self&#8209;regulatory organization.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">42</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Guarantors</font>&#8221;, is defined in the preamble hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Guaranty</font>&#8221; is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">HMRC</font>&#8221; means Her Majesty&#8217;s Revenue and Customs.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">HoldCo</font>&#8221; means a corporation or company incorporated under the laws of England &amp; Wales, Cayman Islands, the Channel Islands but which is resident for tax purposes in the UK (or
      such other jurisdiction and place of tax residence as acceptable to Collateral Agent in its discretion) that has been incorporated specifically for the purpose of the HoldCo Transaction and has not conducted any business other than to establish legal
      existence or any other filings, registrations or similar actions necessary in connection with the HoldCo Transaction or in connection with a contemplated equity financing to be consummated following the effectiveness of the HoldCo Transaction.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-weight: bold;">&#8220;HoldCo Loan Agreement</font>&#8221; is defined in Section 7.3(c).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">HoldcoTax Deduction</font>&#8221; means a deduction or withholding for or on account of Tax imposed by the jurisdiction in which the Holdco is resident in respect of&#160; payment made by the
      Holdco under a Loan Document, other than a deduction or withholding required by FATCA or a UK Tax Deduction (and for the purposes of this definition &#8220;Holdco&#8221; shall mean the Holdco and/or SPAC).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-weight: bold;">&#8220;HoldCo Transaction&#8221; </font>is defined in Section 7.3(c).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">I/O Extension Event</font>&#8221; is the occurrence of the BLA Approval Event and the receipt by Collateral Agent of written notice from a Loan Party requesting the extension of the
      Amortization Date from January 1, 2024 to January 1, 2025 (which I/O Extension Event, if so elected by a Loan Party, shall result in the corresponding increase of the Final Payment).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-weight: bold;">&#8220;IFRS&#8221; </font>International Financial Reporting Standards, a collection of guidelines and rules set by the International Accounting Standards Board (www.iasb.org) which is applicable to
      the circumstances as at the date of determination.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Immunocore Ireland</font>&#8221; means Immunocore Ireland Limited, which is formed under the laws of Ireland, and which is a wholly owned subsidiary of Parent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Immunocore Nominees</font>&#8221; means Immunocore Nominees Limited, which is formed under the laws of England and Wales, and which is a wholly owned subsidiary of Parent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Indebtedness</font>&#8221; is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety
      bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Indemnified Person</font>&#8221; is defined in Section 12.2.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Insolvency Proceeding</font>&#8221; is any proceeding by or against any Person under the United States Bankruptcy Code, the Insolvency Act 1986 or any other bankruptcy or
      insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, moratorium, receivership, administration or proceedings seeking reorganization, arrangement, or other relief.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Insolvent</font>&#8221; means not Solvent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Intellectual Property</font>&#8221; means all of each Loan Party&#8217;s or any Subsidiary&#8217;s right, title and interest in and to the following:</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">43</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;its Copyrights, Trademarks and Patents;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know&#8209;how, operating
      manuals;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any and all source code;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any and all design rights which may be available to a Loan Party;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to
      sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Inventory</font>&#8221; is all &#8220;inventory&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes
      without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of any Person&#8217;s custody or possession or in
      transit and including any returned goods and any documents of title representing any of the above.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Investment</font>&#8221; is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance, payment or
      capital contribution to any Person.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">IP Agreement</font>&#8221; is that certain Intellectual Property Security Agreement entered into by and between&#160; the Loan Parties and Collateral Agent dated as of the
      Effective Date, as such may be amended from time to time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">IRC</font>&#8221; means the US Internal Revenue Code of 1986.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Key Person</font>&#8221; is each of the following officers (i) Parent&#8217;s Chief Executive Officer who is Bahija Jallal as of the Effective Date, and (ii) Parent&#8217;s Chief
      Financial Officer who is Brian Di Donato as of the Effective Date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Lender</font>&#8221; is any one of the Lenders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Lenders</font>&#8221; are the Persons identified on <u>Schedule 1.1</u> hereto and each assignee that becomes a party to this Agreement pursuant to Section 12.1.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Lenders&#8217; Expenses</font>&#8221; are all audit fees and expenses, costs, and expenses (including reasonable attorneys&#8217; fees and expenses, as well as appraisal fees, fees
      incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or
      Insolvency Proceedings) or otherwise incurred by Collateral Agent and/or the Lenders in connection with the Loan Documents.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">&#8220;LIBOR Replacement Rate&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means the sum of: (a) the alternate benchmark rate (which may include
      SOFR) that has been selected by Collateral Agent after giving due consideration to (i) any selection or recommendation of a replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or
      then-prevailing market convention for determining a rate of interest as a replacement to the LIBOR rate for U.S. dollar-denominated syndicated credit facilities and (b) the LIBOR Replacement Spread<font style="font-weight: bold;">; </font>provided
      that, if the LIBOR Replacement Rate as so determined would be less than zero, the LIBOR Replacement Rate will be deemed to be zero for the purposes of this Agreement.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">44</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">&#8220;LIBOR Replacement Spread&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means, with respect to any replacement of the Basic Rate, the spread
      adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by Collateral Agent giving due consideration to (i) any selection or recommendation of a spread
      adjustment, or method for calculating or determining such spread adjustment, for the replacement of the LIBOR rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or
      method for calculating or determining such spread adjustment, for the replacement of the LIBOR rate for U.S. dollar-denominated syndicated credit facilities at such time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">&#8220;LIBOR Transition Event&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means the occurrence of one or more of the following events with respect
      to the LIBOR rate:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(1)&#160; &#160; a public statement or publication of information by or on behalf of the administrator of the LIBOR rate announcing that such administrator has ceased or will cease to provide the LIBOR rate,
      permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the LIBOR rate;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(2)&#160;&#160; a public statement or publication of information by the regulatory supervisor for the administrator of the LIBOR rate, the U.S. Federal Reserve System, an insolvency official with jurisdiction
      over the administrator for the LIBOR rate, a resolution authority with jurisdiction over the administrator for the LIBOR rate or a court or an entity with similar insolvency or resolution authority over the administrator for the LIBOR rate, which
      states that the administrator of the LIBOR rate has ceased or will cease to provide the LIBOR rate permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to
      provide the LIBOR rate; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">(3)&#160;&#160; a public statement or publication of information by the regulatory supervisor for the administrator of the LIBOR rate announcing that the LIBOR rate is no longer representative.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Lien</font>&#8221; is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising
      by operation of law or otherwise against any property.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Loan Documents</font>&#8221; are, collectively, this Agreement, the Guaranties, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, the
      Prepayment Fee Letter, each Guaranty, the Post Closing Letter, the Success Fee Letter, the IP Agreement, the UK Security Agreement, any subordination agreements, any note, or notes or guaranties or other agreements, documents or certificates executed
      or delivered by Borrower or any other Loan Party for the benefit of the Lenders and Collateral Agent in connection with this Agreement; all as amended, restated, or otherwise modified.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Loan Parties</font>&#8221;, is defined in the preamble hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Material Adverse Change</font>&#8221; is (a) a material impairment in the perfection or priority of Collateral Agent&#8217;s Lien in the Collateral or in the value of such
      Collateral; (b) a material adverse change in the business, operations or condition (financial or otherwise) of any of the Loan Parties or the Loan Parties and their Subsidiaries taken as a whole; or (c) a material impairment of the prospect of
      repayment of any portion of the Obligations.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Maturity Date</font>&#8221; is, for each Term Loan, November 1, 2025.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Non-Excluded Taxes</font>&#8221; means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of the Loan
      Parties under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes (and for the avoidance of doubt &#8220;Non-Excluded Taxes&#8221; shall include, without limitation a Holdco Tax Deduction and a UK Tax Deduction).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Obligations</font>&#8221; are all of the Loan Parties&#8217; obligations to pay when due any debts, principal, interest, Lenders&#8217; Expenses, the Prepayment Fee (if applicable),
      the Final Payment, and other amounts the Loan Parties owe the Lenders now or later, in connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents (other than the Success Fee Letter and any
      stock or equity issued to Lenders and their Affiliates), and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of the Loan Parties assigned to the Lenders and/or Collateral
      Agent, and the performance of the Loan Parties&#8217; duties under the Loan Documents (other than the Success Fee Letter and any stock or equity issued to Lenders and their Affiliates).</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">45</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">OFAC</font>&#8221; is the U.S. Department of Treasury Office of Foreign Assets Control.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">OFAC Lists</font>&#8221; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed.
      Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Operating Documents</font>&#8221; are, for any Person, such Person&#8217;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#8217;s
      jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited
      liability company agreement (or similar agreement which, in the case of a limited liability company incorporated in England and Wales, shall be its memorandum and articles of association), and (c) if such Person is a partnership, its partnership
      agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Other Connection Taxes</font>&#8221; means Taxes imposed as a result of a present or former connection between Lender and the jurisdiction imposing such Tax (other than
      connections arising from Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any
      Loan Document, or sold or assigned an interest in any Credit Extension made by Lender pursuant to this Agreement or any Loan Document)save for the avoidance of doubt &#8220;Other Connection Taxes&#8221; shall not include a UK Tax Deduction or a Holdco Tax
      Deduction.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Other Taxes</font>&#8221; means any and all present or future stamp, court or documentary, intangible, recording, or filing Taxes or any other similar Taxes arising from
      any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are (i) Other
      Connection Taxes imposed with respect to an assignment&#160; or (ii) imposed with respect to any assignment or transfer by Lender under Section 12.1 (Successors and assigns) of this Agreement (other than any such assignment or transfer by Lender effected
      under a HoldCo Transaction).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Patents</font>&#8221; means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues,
      extensions and continuations-in-part of the same.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Payment Date</font>&#8221; is the first (1<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup>) calendar day of each calendar month,
      commencing on January 1, 2021.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Perfection Certificate</font>&#8221; and &#8220;<font style="font-weight: bold;">Perfection Certificates</font>&#8221; is defined in Section 5.1.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Permitted Acquisition</font>&#8221; means an acquisition pursuant to which a Loan Party acquires either (i) substantially all of the property of another Person, for stock and cash, provided,
      however, cash consideration may only be paid by the Loan Parties for one such transaction in any given calendar year and the aggregate amount of such cash consideration shall not to exceed $2,500,000 in any given calendar year, or (ii) a Person or an
      ownership interest in a Person through the issuance of a Loan Party&#8217;s capital stock, so long as the number of shares or the voting power of such Loan Party&#8217;s capital stock issued with respect to any one Person is less than twenty percent (20%) of the
      total shares or voting power of such Loan Party&#8217;s capital stock outstanding before the issuance, to the extent that each of the following conditions shall have been satisfied:</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;immediately prior to, and immediately after giving effect thereto, no Event of Default shall have occurred and be continuing or would result therefrom;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">46</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all transactions in connection therewith shall be consummated, in all material respects, in accordance with applicable law;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such acquired Person or assets shall be in the same or substantially similar line of business as is conducted by the Loan Parties as of the Effective Date (or a line
      of business reasonably related thereto);</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such acquisition shall not cause the focus or principal locations of the Loan Parties&#8217; and its Subsidiaries&#8217; operations (when taken as a whole) to be located outside
      of the United States or United Kingdom;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in the case of the purchase or other acquisition of Shares, all of the Shares acquired or otherwise issued by such Person or any newly formed Subsidiary in connection
      with such acquisition shall be wholly owned by Borrower or a Subsidiary;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in connection with such acquisition, neither the Loan Parties nor any of its Subsidiaries (including for this purpose, the target of the acquisition) shall acquire or
      be subject to any Indebtedness or Liens that are not otherwise permitted hereunder;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all of the consideration paid in connection with such acquisition shall be in the form of stock of a Loan Party (provided, however, a Loan Party may also pay cash
      consideration for one such transaction in any given calendar year and the aggregate amount of such cash consideration shall not to exceed $2,500,000 in any given calendar year) plus the Loan Parties shall be permitted to pay reasonable closing costs
      in cash;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Loan Parties shall have delivered to the Collateral Agent and Lenders at least five (5) Business Days (or such shorter period as may be acceptable to Collateral
      Agent and Lenders) prior to such proposed acquisition (i) a copy of the purchase agreement related to the proposed acquisition (and any related documents reasonably requested by the Collateral Agent and Lenders), (ii) a general description of the
      acquired assets or acquired business line or unit or division and the competitive position of such business line or unit or division within the industry, (iii) the sources and uses of funds to finance the proposed acquisition, and (iv) to the extent
      available, quarterly and annual audited financial statements of the Person whose Shares or assets are being acquired for the twelve (12) month period immediately prior to such proposed acquisition;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such Permitted Acquisition shall only involve assets principally located in the United States or the United Kingdom; provided, however, any such Permitted Acquisitions
      may also involve assets located outside the United States or the United Kingdom, so long as the value of such assets outside of the United States or the United Kingdom does not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate
      at closing;</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Collateral Agent and the Lenders have received a certificate from a Responsible Officer together with Board approved projections certifying and setting forth in
      reasonable detail that the Loan Parties have enough cash on hand to pay its projected expenses and all debt service when due for a period of twelve (12) months after the consummation of such transaction (after giving effect to such transaction); and</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;such Permitted Acquisition shall be consensual and shall have been approved by the target&#8217;s board of directors.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">Notwithstanding anything to the contrary contained herein, in order for any acquisition of Shares or assets of another Person to constitute a Permitted Acquisition, the Loan Parties must comply with all of the following:
      (a) within fifteen (15) Business Days of the closing of such Permitted Acquisition, the applicable Loan Parties (or Subsidiary) making such Permitted Acquisition and the target shall have executed such documents and taken such actions as may be
      required under Section 6.12; (b) the applicable Loan Parties shall have delivered to Collateral Agent and Lenders, in form and substance satisfactory to the Collateral Agent and Lenders and sufficiently in advance (and in any case no later than five
      (5) Business Days prior to such Permitted Acquisition), such other financial information, financial analysis, documentation or other information relating to such Permitted Acquisition and the pro forma certifications required by clause (c) below, in
      each case, as Collateral Agent and Lenders shall reasonably request; (c) on or prior to the date of such Permitted Acquisition, the Collateral Agent and Lenders shall have received, in form and substance reasonably satisfactory to the Collateral
      Agent and Lenders, a certificate of the chief financial officer of a Loan Party certifying compliance with the requirements contained in this definition of &#8220;Permitted Acquisition&#8221; and with the other terms of the Loan Documents (before and after
      giving effect to such Permitted Acquisition); and (d) the Loan Parties shall provide to the Collateral Agent and Lenders as soon as available but in any event not later than five (5) Business Days after the execution thereof, a copy of the executed
      purchase agreement or similar agreement with respect to any such acquisition.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">47</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Permitted Indebtedness</font>&#8221; is:</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Loan Parties&#8217; Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indebtedness existing on the Effective Date and disclosed on the Perfection Certificate(s);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subordinated Debt;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;unsecured Indebtedness to trade creditors incurred in the ordinary course of business;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by the Loan Parties or any of
      their Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the aggregate outstanding principal amount of all such Indebtedness does not exceed Five Hundred Thousand
      Dollars ($500,000.00) at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness
      (each measured at the time of such acquisition, repair, improvement or construction is made);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of the Loan Parties&#8217; business;</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;business credit card Indebtedness in an aggregate principal amount not in excess of Two Hundred Fifty Thousand Dollars ($250,000.00) at any time
      outstanding;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;reimbursement obligations under letters of credit related to existing leases, together with such obligations in respect of such other letters of
      credit as may be established in favor of the Loan Parties or their Subsidiaries, not to exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate at any time outstanding</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indebtedness consisting of the financing of insurance premiums in the ordinary course of business; provided, however, the aggregate amount of such
      Indebtedness outstanding at any given time may not exceed One Hundred Thousand Dollars ($100,000.00) at any given time;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intercompany Indebtedness that are Permitted Investments;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;other unsecured Indebtedness not otherwise enumerated in this defined term in an aggregate principal amount outstanding not to exceed Two Hundred
      Fifty Thousand Dollars ($250,000) at any one time;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;unsecured convertible Indebtedness with respect to the Gates Note, any portion of which that remains outstanding for longer than five days must do
      so strictly in the form of unsecured convertible Subordinated Debt; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (k) above, provided that
      the principal amount thereof is not increased in excess of the amounts above or the terms thereof are not modified to impose materially more burdensome terms upon the Loan Parties, or their Subsidiaries, as the case may be.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">48</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Permitted Investments</font>&#8221; are:</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments disclosed on the Perfection Certificate(s) and existing on the Effective Date;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Investments consisting of cash and Cash Equivalents, and (ii) any other Investments permitted by the Loan Parties&#8217; investment policies, as
      amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
      the Loan Parties&#8217; business;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments consisting of deposit accounts in which Collateral Agent has a perfected security interest, to the extent required pursuant to Section
      6.6 of this Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments in connection with Transfers permitted by Section 7.1;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of
      business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of the Loan Parties or their Subsidiaries pursuant to employee stock purchase plans or agreements approved by the applicable Board of
      Directors; not to exceed One Hundred Thousand Dollars ($100,000.00) in the aggregate for (i) and (ii) in any fiscal year;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
      of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not
      Affiliates, in the ordinary course of business; provided that this paragraph (h) shall not apply to Investments of any Loan Party in any Subsidiary;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cash and non-cash Investments in joint ventures or strategic alliances in the ordinary course of Borrower&#8217;s business consisting of the
      non&#8209;exclusive licensing of technology, the development of technology or the providing of technical support; provided that the Cash portions shall not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in any fiscal year;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Investments consisting of Permitted Acquisitions; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Investments by any Borrower in any other in co-borrowers or other Loan Parties that are direct Foreign Subsidiaries of Borrower, (ii)
      Investments by Subsidiaries in Borrower, (iii) Investments by Borrower or the Loan Parties in Immunocore Ireland and Immunocore Nominees in an aggregate annual amount not to exceed $1,000,000, (iv) Investments by Borrower or the Loan Parties in
      Immunocore LLC and Immunocore Commercial LLC in any given year in an amount sufficient to fund their respective operations in accordance with the then applicable Board approved Annual Projections, and (v) Investments by any Guarantor that is a parent
      entity of Borrower or any other Loan Party (a &#8220;<font style="font-weight: bold;">Parent Guarantor</font>&#8221;), in Borrower.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">49</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Permitted Licenses</font>&#8221; are (A) licenses of over-the-counter software that is commercially available to the public, and (B) non&#8209;exclusive and exclusive licenses
      for the use of the Intellectual Property of the Loan Parties or any of their Subsidiaries entered into in the ordinary course of business, <u>provided</u>, that, with respect to each such license described in clause (B), (i) no Event of Default has
      occurred or is continuing at the time of such license; (ii) the license constitutes an arms&#8209;length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of
      the Loan Parties or any of their Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property; (iii) in the case of any exclusive license, (x) a Loan Party delivers ten
      (10) days&#8217; prior written notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral Agent and the Lenders copies of the final executed licensing documents in connection with the
      exclusive license promptly upon consummation thereof, and (y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as
      to discrete geographical areas outside of the United States; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to the Loan Party or any of their Subsidiaries are paid
      to a Deposit Account that is governed by a Control Agreement or which is subject to a lien filed by a Notice of Charge delivered to the relevant bank (or equivalent under applicable law) and is otherwise maintained in accordance with Section 6.6 and
      is not an Excluded Account.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Permitted Liens</font>&#8221; are:</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens existing on the Effective Date and disclosed on the Perfection Certificates or arising under this Agreement and the other Loan Documents;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and
      for which a Loan Party maintains adequate reserves on its Books;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;liens securing Indebtedness permitted under clause (e) of the definition of &#8220;<font style="font-weight: bold;">Permitted Indebtedness</font>,&#8221;
      provided that (i) such liens exist prior to the acquisition of, or attach substantially simultaneous with, or within 30 days after the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness
      and (ii) such liens do not extend to any property of a Loan Party other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens of carriers, warehousemen, mechanics, materialmen and suppliers, or other Persons that are possessory in nature arising in the ordinary
      course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed One Hundred Thousand Dollars ($100,000.00), and which are not delinquent or remain payable without penalty or which are
      being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens to secure payment of workers&#8217; compensation, employment insurance, old&#8209;age pensions, social security and other like obligations incurred in
      the ordinary course of business (other than Liens imposed by ERISA);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;leases or subleases of real property granted in the ordinary course of a Loan Party&#8217;s business (or, if referring to another Person, in the
      ordinary course of such Person&#8217;s business), and leases, subleases, non&#8209;exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of a Loan Party&#8217;s business (or, if referring to another
      Person, in the ordinary course of such Person&#8217;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent or any Lender a security interest therein;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;banker&#8217;s liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection
      with the Loan Parties&#8217; deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section 6.6(b) hereof;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">50</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7;</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens on a segregated bank account of a Loan Party and identified to Collateral Agent in writing securing Indebtedness described in clause (h) the
      definition of Permitted Indebtedness provided that such Liens may not secure obligations in excess of Two Hundred Fifty Thousand Dollars ($250,000.00);</div>
    <div style="text-align: justify; text-indent: 72pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens on a segregated bank account of a Loan Party and identified to Collateral Agent in writing securing Indebtedness described in clause (g) the
      definition of Permitted Indebtedness provided that such Liens may not secure obligations in excess of Two Hundred Fifty Thousand Dollars ($250,000.00);</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom duties that are promptly paid on or
      before the date they become due; provided, however, the aggregate amount of payments secured by such Liens may not exceed One Hundred Fifty Thousand Dollars ($150,000.00) at any given time;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens consisting of Permitted Licenses; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (l), <u>but</u> any
      extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Person</font>&#8221; is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
      association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Post Closing Letter</font>&#8221; is that certain Post Closing Letter dated as of the Effective Date by and between Collateral Agent and Borrower.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Prepayment Fee</font>&#8221; is, with respect to any Term Loan funded by Lender subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary
      prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term
      Loan, Two and One-Half percent (2.50%) of the principal amount of such Term Loan prepaid;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the second
      anniversary of the Funding Date of such Term Loan, One and One-Half percent (1.50%) of the principal amount of the Term Loans prepaid;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan through and including the
      third anniversary of the Funding Date of such Term Loan, One-Half percent (0.50%) of the principal amount of the Term Loans prepaid; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;for a prepayment made after the third anniversary of the Funding Date of such Term Loan and prior to the Maturity Date, no Prepayment Fee shall
      be applicable.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;&#8220;<font style="font-weight: bold;">Pro Rata Share</font>&#8221; is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place)
      determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal amount of all Term Loans.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">QPP Certificate</font>&#8221; means a creditor certificate for the purposes of the QPP Regulations, given in the form set out in Exhibit E.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">QPP Lender</font>&#8221; means a Lender which has delivered a QPP Certificate to the UK Obligors, provided that such QPP Certificate is not a Withdrawn Certificate or a
      Cancelled Certificate.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">51</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">QPP Regulations</font>&#8221; means the Qualifying Private Placement Regulations 2015 (2015 No. 2002).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Registered Organization</font>&#8221; is any &#8220;registered organization&#8221; as defined in the Code with such additions to such term as may hereafter be made.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">&#8220;Relevant Governmental Body&#8221;</font><font style="font-weight: bold; font-style: italic;">&#160;</font>means the Federal Reserve Board and/or the Federal Reserve Bank of New
      York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York or any successor thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Required Lenders</font>&#8221; means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an &#8220;<font style="font-weight: bold;">Original
        Lender</font>&#8221;) have not assigned or transferred any of their interests in their Term Loan, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loan, or (ii) at any time from and after any Original
      Lender has assigned or transferred any interest in its Term Loan, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance of the Term Loan and, in respect of this clause (ii), (A) each Original Lender that has
      not assigned or transferred any portion of its Term Loan, (B) each assignee or transferee of an Original Lender&#8217;s interest in the Term Loan, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original
      Lender, and (C) any Person providing financing to any Person described in clauses (A) and (B) above; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to
      such financing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Requirement of Law</font>&#8221; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or
      regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Responsible Officer</font>&#8221; is any of the President, Chief Executive Officer, Chief Financial Officer, or Controller of a Loan Party acting alone.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Restructuring Loan</font>&#8221;&#160; is defined in Section 7.3(c).</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Second Draw Period</font>&#8221; is the period commencing on the date of the occurrence of the BLA Approval Event and ending on the earliest of (i) June 30, 2022, (ii) the date that is 60 days
      immediately after the occurrence of the BLA Approval Event and (iii) the occurrence of an Event of Default; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of the BLA Approval Event an Event of
      Default has occurred and is continuing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Secured Promissory Note</font>&#8221; is defined in Section 2.4.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Secured Promissory Note Record</font>&#8221; is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender and credits made
      thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Securities Account</font>&#8221; is any &#8220;securities account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;&#8220;<font style="font-weight: bold;">Shares</font>&#8221; is one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by a Loan
      Party or a Loan Party&#8217;s Subsidiary, in any Subsidiary.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">SOFR</font>&#8221;<font style="font-weight: bold; font-style: italic;">&#160;</font>with respect to any day means the secured overnight financing rate published for such day by
      the Federal Reserve Bank of New York, as the administrator of the benchmark, (or a successor administrator) on the Federal Reserve Bank of New York&#8217;s Website.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">52</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;&#8220;<font style="font-weight: bold;">Solvent</font>&#8221; is, with respect to any Person: the fair salable value of such Person&#8217;s consolidated assets (including goodwill minus disposition costs) exceeds the
      fair value of such Person&#8217;s liabilities; such Person is not left with unreasonably small capital after the transactions in this Agreement; and such Person is able to pay its debts (including trade debts) as they mature.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">SPAC</font>&#8221; is a company with no commercial operations that is formed strictly to raise capital through an initial public offering of its shares for the purpose of
      acquiring an existing operating company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Subordinated Debt</font>&#8221; is indebtedness incurred by a Loan Party or any of their Subsidiaries subordinated to all Indebtedness of the Loan Parties and/or their
      Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between Collateral Agent, the Loan Parties, and/or any of its
      Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent and the Lenders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221; is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the case of
      Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Success Fee Letter</font>&#8221; is that certain letter agreement entered into by and between Parent and Oxford on the Effective Date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Supplier</font>&#8221; is defined in Section 2.8(b) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Tax</font>&#8221; and &#8220;<font style="font-weight: bold;">Taxes</font>&#8221; means any present or future tax, levy, impost, duty, assessment, charge, fee, deduction or
      withholding (including backup withholding), imposed by any Governmental Authority, including any interest, additions to tax and penalties applicable thereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#160;&#8220;<font style="font-weight: bold;">Term Loan</font>&#8221; is defined in Section 2.2(a)(iii) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Term A Loan</font>&#8221; is defined in Section 2.2(a)(i) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Term B Loan</font>&#8221; is defined in Section 2.2(a)(ii) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Term B Loan</font>&#8221; is defined in Section 2.2(a)(iii) hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Term Loan Commitment</font>&#8221; is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on <u>Schedule 1.1</u><font style="font-weight: bold;">.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Term Loan Commitments</font>&#8221; means the aggregate amount of such commitments of all Lenders.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Third Draw Period</font>&#8221; is the period commencing on the Effective Date and ending one day immediately prior to the Amortization Date.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Trademarks</font>&#8221; means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like
      protections, and the entire goodwill of the business of the Loan Parties connected with and symbolized by such trademarks.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Transfer</font>&#8221; is defined in Section 7.1.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK CTA</font>&#8221; means the UK Corporation Tax Act 2009.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK ITA</font>&#8221; means the UK Income Tax Act 2007.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Obligor</font>&#8221; means any Loan Party incorporated under the laws of England and Wales or resident for tax purposes in the United Kingdom.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">53</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Qualifying Lender</font>&#8221; means a Lender which is beneficially entitled to interest payable to that Lender in respect of an advance under a Loan Document and is
      (a) a Lender: (i) which is a bank (as defined for the purpose of section 879 of the UK ITA) making an advance under a Loan Document and is within the charge to UK corporation tax as respects any payments of interest made in respect of that advance or
      would be within such charge as respects such payments apart from section 18A of the UK CTA; or (ii) in respect of an advance made under a Loan Document by a person that was a bank (as defined for the purpose of section 879 of the UK ITA) at the time
      that that advance was made and within the charge to UK corporation tax as respects any payments of interest made in respect of that advance; or (b) a Lender which is: (i) a company resident in the United Kingdom for UK tax purposes; or (ii) a
      partnership each member of which is: (1) a company so resident in the United Kingdom; or (2) a company not so resident in the United Kingdom which carries on a trade in the United Kingdom through a permanent establishment and which brings into
      account in computing its chargeable profits (within the meaning of section 19 of the UK CTA) the whole of any share of interest payable in respect of that advance that falls to it by reason of Part 17 of the UK CTA; or (iii) a company not so resident
      in the United Kingdom which carries on a trade in the United Kingdom through a permanent establishment and which brings into account interest payable in respect of that advance in computing the chargeable profits (within the meaning of section 19 of
      the CTA) of that company; or (c) a UK Treaty Lender; or (d) a QPP Lender.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Security Agreement</font>&#8221; is that certain Debenture, dated of the Effective Date, entered into by Collateral Agent and Parent, granting a security interest in
      the assets of Parent to secure the performance of the Obligations, as such agreement may be amended or amended and restated from time to time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Tax Confirmation</font>&#8221; means a confirmation by a Lender that the person beneficially entitled to interest payable to that Lender in respect of an advance under
      a Loan Document is either: (a) a company resident in the United Kingdom for United Kingdom tax purposes; or (b) a partnership each member of which is: (i) a company so resident in the United Kingdom; or (ii) a company not so resident in the United
      Kingdom which carries on a trade in the United Kingdom through a permanent establishment and which brings into account in computing its chargeable profits (within the meaning of section 19 of the UK CTA) the whole of any share of interest payable in
      respect of that advance that falls to it by reason of Part 17 of the UK CTA; or (c) a company not so resident in the United Kingdom which carries on a trade in the United Kingdom through a permanent establishment and which brings into account
      interest payable in respect of that advance in computing the chargeable profits (within the meaning of section 19 of the UK CTA) of that company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Tax Deduction</font>&#8221; means a deduction or withholding for or on account of Tax imposed by the United Kingdom from a payment under a Loan Document, other than a
      deduction or withholding required by FATCA.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Treaty Lender</font>&#8221; means a Lender which: (1) is treated as a resident of a UK Treaty State for the purposes of a UK Treaty; (2) does not carry on a business in
      the United Kingdom through a permanent establishment with which that Lender&#8217;s participation in the Term Loan is effectively connected; and (3) meets all other conditions in the UK Treaty for a recipient of interest to be able to benefit from full
      exemption from United Kingdom tax on interest, if and to the extent that those conditions relate to the recipient of interest (not including, for the avoidance of doubt, any condition which relates (expressly or by implication) to there not being a
      special relationship between the Borrower and a Lender or between both of them and another person or to the amounts or terms of any Term Loan or the Loan Documents), provided that for this purpose it shall be assumed that any necessary procedural
      requirements are satisfied.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">UK Treaty State</font>&#8221; means a jurisdiction having a double tax treaty with the United Kingdom (&#8220;<font style="font-weight: bold;">UK Treaty</font>&#8221;) which makes
      provision for full exemption from tax imposed by the United Kingdom on interest.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">VAT</font>&#8221; means any tax imposed in compliance with the Council Directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112) and
      any other tax of a similar nature, whether imposed in a member state of the European Union in substitution for, or levied in addition to, such tax referred to in paragraph (a) above, or imposed elsewhere.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Withdrawn Certificate</font>&#8221; means a withdrawn certificate for the purposes of the QPP Regulations.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-weight: normal; font-style: normal;">54</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[<font style="font-style: italic;">Balance of Page Intentionally Left Blank</font>]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">IN WITNESS WHEREOF</font>, the parties hereto have caused this Agreement to be executed as of the Effective Date.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zea7aba2cde39425999c8966657636bde" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">
            <div>&#160;</div>
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">BORROWER:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">IMMUNOCORE LIMITED</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Brian Di Donato </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Brian Di Donato <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Chief Financial Officer <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 10%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 40%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">GUARANTORS:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">IMMUNOCORE LLC <br>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">By <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Bahija Jallal </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Name: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Bahija Jallal&#160; <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Title: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Chief Executive Officer&#160; <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">IMMUNOCORE COMMERCIAL LLC <br>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">By <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Bahija Jallal </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Name: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Bahija Jallal </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Title: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Chief Executive Officer&#160; </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">COLLATERAL AGENT AND LENDER:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="width: 10%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">By <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">/s/ M&#233;lanie Florsch </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Name: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">M&#233;lanie Florsch <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">Title: <br>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Manager <br>
          </td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-weight: bold; text-align: center;">[Signature Page to Loan and Security Agreement]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 1.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Lenders and Commitments</u></div>
    <div style="text-align: center; font-weight: bold;"><u> <br>
      </u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze6c60ad1632b46409ac47472be601d39" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Term A Loans</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Lender</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Term Loan Commitment</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Commitment Percentage</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">$50,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">100.00%</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">TOTAL</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">$50,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">100.00%</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8cd902fb4a3143979845ff7c828062c3" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Term B Loans</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Lender</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Term Loan Commitment</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Commitment Percentage</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">$25,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">100.00%</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">TOTAL</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">$25,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">100.00%</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z70373e03c448486ebd3de534a6f018be" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Aggregate (all Term Loans)</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Lender</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Term Loan Commitment</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Commitment Percentage</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">$75,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">100.00%</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">TOTAL</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">$75,000,000.00</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">100.00%</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SCHEDULE 2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Lenders</u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5bae7c21e996413ea09426ba3a8450e4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Lender</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Scheme Reference Number</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-weight: bold;">Jurisdiction of Tax Residence</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-style: italic;">[Confirm.]</div>
          </td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
            <div style="text-align: center; font-style: italic;">[Confirm.]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 33.33%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT A</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Description of Collateral</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Collateral consists of all of each Loan Parties&#8217; right, title and interest in and to the following personal property:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All goods, Accounts (including health&#8209;care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles
      (including all Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit,
      fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
      located; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and
      improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, or anything to the contrary herein, the Collateral shall not include any of the following property, whether now existing or hereafter acquired or created:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">&#160;(i) any interest of a Loan Party as a lessee or sublessee under a real property lease or an Equipment lease if such Loan Party is prohibited by the terms of such lease from granting a security interest in such lease
      or under which such an assignment or Lien would cause a default to occur under such lease (but only to the extent that such prohibition is enforceable under all applicable laws including, without limitation, the Code); provided, however, that upon
      termination of such prohibition, such interest shall immediately become Collateral without any action by the Loan Parties or Lender,</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(ii) any license if the granting of a Lien in such license or the enforcement of such Lien is prohibited by or would constitute a default under the agreement governing such license (but (A) only to the extent such
      prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the
      termination, lapsing or expiration of any such prohibition, such license, shall automatically be subject to the security interest granted in favor of Lender hereunder and become part of the &#8220;Collateral&#8221;; and</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(iii) the Designated Agreement and the Loan Parties rights and agreements thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the terms of a certain negative pledge arrangement with Collateral Agent and the Lenders, the Loan Parties have agreed not to encumber any of its Intellectual Property except in
      accordance with the terms of such agreement</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT B</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Form of Disbursement Letter</u></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[see attached]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">DISBURSEMENT LETTER</div>
    <div><br>
    </div>
    <div style="text-align: center;">[DATE]</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The undersigned, being the duly elected and acting ________________________ of IMMUNOCORE LIMITED, a private limited company incorporated under the laws of England and Wales and limited by shares under registration
      number [____] with offices located at 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK, on behalf of itself, does hereby certify to OXFORD FINANCE LUXEMBOURG S.&#192; R.L. (&#8220;<font style="font-weight: bold;">Oxford</font>&#8221; and &#8220;<font style="font-weight: bold;">Lender</font>&#8221;), as collateral agent (the &#8220;<font style="font-weight: bold;">Collateral Agent</font>&#8221;) in connection with that certain Loan and Security Agreement dated as of November [_], 2020, by and among the Loan
      Parties, Collateral Agent and the Lenders from time to time party thereto (the &#8220;<font style="font-weight: bold;">Loan Agreement</font>&#8221;; with other capitalized terms used below having the meanings ascribed thereto in the Loan Agreement) that:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties made by the Loan Parties in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects as of the date
      hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No event or condition has occurred that would constitute an Event of Default under the Loan Agreement or any other Loan Document.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Loan Parties are in compliance with the covenants and requirements contained in Sections 4, 6 and 7 of the Loan Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All conditions referred to in Section 3 of the Loan Agreement to the making of the Credit Extensions to be made on or about the date hereof have been satisfied or waived by Collateral
      Agent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Material Adverse Change has occurred.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned is a Responsible Officer.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">[Balance of Page Intentionally Left Blank]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The proceeds of the Term [A][B][C] Loan shall be disbursed as follows:</div>
    <div><br>
    </div>
    <div style="margin-left: 72pt;">
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z92988047fc2143e590e7cdb2ba3e4b38" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div>&#160;</div>
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Disbursement from Oxford:</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 12.6pt; font-family: 'Times New Roman', Times, serif;">Loan Amount</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">$_______________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="text-indent: 24.6pt; font-family: 'Times New Roman', Times, serif;">Plus:</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 24.6pt; font-family: 'Times New Roman', Times, serif;">&#8209;&#8209;Deposit Received</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">$__________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 24.6pt; font-family: 'Times New Roman', Times, serif;">Less:</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 24.6pt; font-family: 'Times New Roman', Times, serif;">&#8209;&#8209;Facility Fee</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">($_________)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 24.6pt; font-family: 'Times New Roman', Times, serif;">[&#8209;&#8209;Interim Interest</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">($_________)]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="margin-left: 24.6pt; font-family: 'Times New Roman', Times, serif;">&#8209;&#8209;Lender&#8217;s Legal Fees</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">($_________)*</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">Net Proceeds due from Oxford:</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$_______________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">&#160;</td>
            <td style="width: 20%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 80%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">TOTAL TERM [A][B][C] LOAN NET PROCEEDS FROM LENDERS</div>
            </td>
            <td style="width: 20%; vertical-align: middle;">
              <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-weight: bold;">$_______________</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The [Term A Loan] [Term B Loan] [Term C Loan] shall amortize in accordance with the Amortization Table attached hereto.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The aggregate net proceeds of the Term Loans shall be transferred to the Designated Deposit Account as follows:</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="margin-left: 72pt;">
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z805e5eb2fcee4b84b8ec08517eed0d57" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 30.3%; vertical-align: top;">
              <div>&#160;</div>
              <div>&#160;</div>
              <div>Account Name:</div>
            </td>
            <td style="width: 69.7%; vertical-align: top;">
              <div>[_______]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30.3%; vertical-align: top;">
              <div>Bank Name:</div>
            </td>
            <td style="width: 69.7%; vertical-align: top;">
              <div>[_______]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30.3%; vertical-align: top;">
              <div>Bank Address:</div>
            </td>
            <td style="width: 69.7%; vertical-align: top;">
              <div>[_______]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30.3%; vertical-align: top;">
              <div>Account Number:</div>
            </td>
            <td style="width: 69.7%; vertical-align: top;">
              <div>____________________________________</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30.3%; vertical-align: top;">
              <div>ABA Number:</div>
            </td>
            <td style="width: 69.7%; vertical-align: top;">
              <div>[_______]</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">[Balance of Page Intentionally Left Blank]</div>
    <br>
    <hr style="background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;" align="left" noshade="noshade">
    <div>* Legal fees and costs are through the Effective Date.&#160; Post&#8209;closing legal fees and costs, payable after the Effective Date, to be invoiced and paid post&#8209;closing.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">Dated as of the date first set forth above.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z5971afdb364a482ab2218928158f3c65" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">BORROWER:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">IMMUNOCORE LIMITED</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">COLLATERAL AGENT AND LENDER:</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.</div>
          </td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">[Signature Page to Disbursement Letter]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">AMORTIZATION TABLE</div>
    <div style="text-align: center;">(Term [A][B][C] Loan)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[see attached]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT C</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Compliance Certificate</u></div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zecbd0b2da5484e5b99d011a4ec086602" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 13.66%; vertical-align: top;">
            <div>&#160;</div>
            <div>TO:</div>
          </td>
          <td style="width: 86.34%; vertical-align: top;">
            <div>&#160;</div>
            <div>OXFORD FINANCE LUXEMBOURG S.&#192; R.L., as Collateral Agent and Lender</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.66%; vertical-align: top;">
            <div>&#160;</div>
            <div>FROM:</div>
          </td>
          <td style="width: 86.34%; vertical-align: top;">
            <div>&#160;</div>
            <div>IMMUNOCORE LIMITED, on behalf of itself and all other Loan Parties</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">The undersigned authorized officer (&#8220;<font style="font-weight: bold;">Officer</font>&#8221;) of IMMUNOCORE LIMITED, hereby certifies on behalf of Loan Parties that in accordance with the terms and conditions of the Loan and
      Security Agreement, dated as of [****], 2020 by and among Borrower, the other Loan Parties, Collateral Agent, and the Lenders from time to time party thereto (the &#8220;<font style="font-weight: bold;">Loan Agreement</font>;&#8221; capitalized terms used but
      not otherwise defined herein shall have the meanings given them in the Loan Agreement),</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Loan Parties are in complete compliance for the period ending _______________ with all required covenants except as noted below;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no Events of Default, except as noted below;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as noted below, all representations and warranties of the Loan Parties stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a),
      above; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and
      warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Loan Parties, and each of the Loan Parties&#8217; Subsidiaries, have timely filed all required tax returns and reports, the Loan Parties, and each of the Loan Parties&#8217; Subsidiaries, have timely paid all
      foreign, federal, state, and local taxes, assessments, deposits and contributions owed by such Loan Party or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Liens have been levied or claims made against any Loan Party or any of their Subsidiaries relating to unpaid employee payroll or benefits of which a Loan Party has not previously provided written
      notification to Collateral Agent and the Lenders; and</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached are the required documents, if any, supporting our certification(s).&#160; The Officer, on behalf of the Loan Parties, further certifies that the attached financial statements are prepared in
      accordance with IFRS and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year&#8209;end
      audit adjustments as to the interim financial statements.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N/A under &#8220;Complies&#8221; column.</div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z1243b9d02ac74f3eb4374952136c1905" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.26%; vertical-align: bottom; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Reporting Covenant</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Requirement</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Actual</div>
          </td>
          <td colspan="3" style="width: 22.81%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Complies</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">1)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Unaudited (consolidated) financial statements</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Monthly within 30 days (except otherwise permitted under the Loan Agreement) *</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">2)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Annual (CPA Audited) statements</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Within 120 days after FYE</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">3)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Annual Financial Projections/Budget (prepared on a monthly basis)</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Annually (within 60 days of FYE), and within 10 Business Days of revisions approved by Board</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">4)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">A/R &amp; A/P agings</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">If applicable</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">5)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">8&#8209;K, 10&#8209;K and 10&#8209;Q Filings</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">If applicable, within 5 days of filing</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">6)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Compliance Certificate</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Monthly within 30 days</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">7)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">IP Report</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Monthly within 30 days (if new IP)</div>
          </td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">8)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Total amount of Loan Parties&#8217; cash and cash equivalents at the last day of the measurement period **</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">
            <div style="font-family: 'Times New Roman', Times, serif;">$________</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 28.95%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 12.28%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.6%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">9)</div>
          </td>
          <td style="width: 28.95%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman', Times, serif;">Total amount of Loan Parties&#8217; Subsidiaries&#8217; cash and cash equivalents at the last day of the measurement period **</div>
          </td>
          <td style="width: 30.7%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 12.28%; vertical-align: middle;" nowrap="nowrap">
            <div style="font-family: 'Times New Roman', Times, serif;">$________</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Yes</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">No</div>
          </td>
          <td style="width: 7.6%; vertical-align: middle;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">N/A</div>
          </td>
        </tr>

    </table>
    <div><font style="font-weight: bold;"> <br>
      </font></div>
    <div><font style="font-weight: bold;">* </font>January month-end reporting of each year shall only require the following summary financial reporting to be due: (A) the month-end unrestricted cash balance (inclusive of investments), (B) the cash burn
      for the month (net of cash received from collaboration revenue or financing activities), (C) any cash from collaboration and/or product revenue, and (D) any cash proceeds from financing activities).</div>
    <div><br>
    </div>
    <div><font style="font-weight: bold;">**</font> Cash account reporting: UK Obligors shall be &#163;GBP; US Obligors shall be in $USD</div>
    <div><br>
    </div>
    <div style="font-weight: bold;"><u>Deposit and Securities Accounts</u></div>
    <div><br>
    </div>
    <div style="font-style: italic; font-weight: bold;">(Please list all accounts; attach separate sheet if additional space needed)</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0ec5eb8d4d28426994a11ec7519df202" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5.26%; vertical-align: bottom; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td style="width: 22.81%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="font-weight: bold;">Institution Name</div>
          </td>
          <td style="width: 26.62%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="font-weight: bold;">Account Number</div>
          </td>
          <td colspan="2" style="width: 14.61%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="font-weight: bold;">New Account?</div>
          </td>
          <td colspan="2" style="width: 30.7%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="font-weight: bold;">Account Control Agreement (or subject to a Lien filed by a Notice of Charge in place)?</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="text-align: center; font-weight: bold;">1)</div>
          </td>
          <td style="width: 22.81%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 26.62%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 7.3%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 7.31%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
          <td style="width: 17.66%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 13.04%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 22.81%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 26.62%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 7.3%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.31%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 17.66%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 13.04%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="text-align: center; font-weight: bold;">2)</div>
          </td>
          <td style="width: 22.81%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 26.62%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.3%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 7.31%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
          <td style="width: 17.66%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 13.04%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 22.81%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">&#160;</td>
          <td rowspan="1" style="width: 26.62%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.3%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.31%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 17.66%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 13.04%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="text-align: center; font-weight: bold;">3)</div>
          </td>
          <td style="width: 22.81%; vertical-align: middle;">&#160;</td>
          <td style="width: 26.62%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.3%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 7.31%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
          <td style="width: 17.66%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 13.04%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 5.26%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 22.81%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 26.62%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.3%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 7.31%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 17.66%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
          <td rowspan="1" style="width: 13.04%; vertical-align: middle; background-color: rgb(204, 238, 255);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5.26%; vertical-align: middle;">
            <div style="text-align: center; font-weight: bold;">4)</div>
          </td>
          <td style="width: 22.81%; vertical-align: middle;">&#160;</td>
          <td style="width: 26.62%; vertical-align: middle;">&#160;</td>
          <td style="width: 7.3%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 7.31%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
          <td style="width: 17.66%; vertical-align: middle;">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 13.04%; vertical-align: middle;">
            <div style="text-align: center;">No</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;"><u>Other Matters</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4c6b009e495247d38a85b99744d14722" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7.06%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">1)</div>
          </td>
          <td style="width: 72.77%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div>Have there been any changes in Key Persons since the last Compliance Certificate?</div>
          </td>
          <td style="width: 9.65%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 10.53%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 72.77%; vertical-align: middle;">&#160;</td>
          <td style="width: 9.65%; vertical-align: middle;">&#160;</td>
          <td style="width: 10.53%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">2)</div>
          </td>
          <td style="width: 72.77%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div>Have there been any transfers/sales/disposals/retirement of Collateral or IP prohibited by the Loan Agreement?</div>
          </td>
          <td style="width: 9.65%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 10.53%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 72.77%; vertical-align: middle;">&#160;</td>
          <td style="width: 9.65%; vertical-align: middle;">&#160;</td>
          <td style="width: 10.53%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">3)</div>
          </td>
          <td style="width: 72.77%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div>Have there been any new or pending claims or causes of action against a Loan Party that would reasonably be expected to involve more than Two Hundred Fifty Thousand Dollars ($250,000.00)?</div>
          </td>
          <td style="width: 9.65%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 10.53%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">No</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle;" nowrap="nowrap">&#160;</td>
          <td style="width: 72.77%; vertical-align: middle;">&#160;</td>
          <td style="width: 9.65%; vertical-align: middle;">&#160;</td>
          <td style="width: 10.53%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7.06%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">4)</div>
          </td>
          <td style="width: 72.77%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div>Have there been any amendments of or other changes to Operating Documents of the Loan Parties?&#160; If yes, provide copies of any such amendments or changes with this Compliance Certificate.</div>
          </td>
          <td style="width: 9.65%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 10.53%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">No</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zecfe44d10af94a5bbe04d2b3dc232d96" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7.06%; vertical-align: middle; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div style="text-align: center; font-weight: bold;">5)</div>
          </td>
          <td style="width: 72.77%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div>Have there been any material amendments of or other changes to the capitalization table of Parent (unless Parent or it successor is a reporting company)?&#160; If yes, provide copies of any such amendments or changes with this Compliance
              Certificate. For the avoidance of doubt, no reporting is required for changes solely due to stock option plan issuance and changes.</div>
          </td>
          <td style="width: 9.65%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Yes</div>
          </td>
          <td style="width: 10.53%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">No</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;"><u>Exceptions</u></div>
    <div><br>
    </div>
    <div>Please explain any exceptions with respect to the certification above: (If no exceptions exist, state &#8220;No exceptions.&#8221;&#160; Attach separate sheet if additional space needed.)</div>
    <div><br>
    </div>
    <div>IMMUNOCORE LIMITED, on behalf of itself and all other Loan Parties</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z9c48bc4cded24d52a20292786889c534" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 7%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 53%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 53%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 53%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 53%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Date:</div>
          </td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
          <td style="width: 53%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="ze061129c16984684bf255f64283eb3e0" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 44.39%; vertical-align: top;"><br>
          </td>
          <td colspan="4" rowspan="1" style="width: 55.51%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">LENDER USE ONLY</div>
            &#160;&#160;&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.39%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Received by:</div>
          </td>
          <td style="width: 16.68%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; padding-bottom: 2px;">
            <div style="margin-left: 27pt;">Date:</div>
          </td>
          <td style="width: 16.68%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.39%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Verified by:</div>
          </td>
          <td style="width: 16.68%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 11.12%; vertical-align: top; padding-bottom: 2px;">
            <div style="margin-left: 27pt;">Date:</div>
          </td>
          <td style="width: 16.68%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 44.39%; vertical-align: top;">&#160;</td>
          <td style="width: 11.12%; vertical-align: top;">&#160;</td>
          <td style="width: 16.68%; vertical-align: top;">&#160;</td>
          <td style="width: 11.12%; vertical-align: top;">&#160;</td>
          <td style="width: 16.68%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="margin-left: 365.4pt;">Compliance Status:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font>&#160; Yes&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font><font class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;</font>&#160;&#160; No</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT D</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Form of Secured Promissory Note</u></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[see attached]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">SECURED PROMISSORY NOTE</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">(Term [A][B][C] Loan)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zb970728ac5024b168ce486a2c4426b1d" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">$</div>
          </td>
          <td style="width: 25%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 70%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: right;">Dated:&#160; [DATE]</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">FOR VALUE RECEIVED, the undersigned, IMMUNOCORE LIMITED, a private limited company incorporated under the laws of England and Wales and limited by shares under registration number [____] with offices
      located at 92 Park Drive, Milton Park, Abingdon, Oxon, OX14 4RY, UK (&#8220;<font style="font-weight: bold;">Parent</font>&#8221; and &#8220;<font style="font-weight: bold;">Borrower</font>&#8221;) HEREBY PROMISES TO PAY to the order of OXFORD FINANCE LUXEMBOURG S.&#192; R.L. (&#8220;<font style="font-weight: bold;">Lender</font>&#8221;) the principal amount of [___________] MILLION DOLLARS ($______________) or such lesser amount as shall equal the outstanding principal balance of the Term [A][B][C] Loan made to Borrower by Lender, plus
      interest on the aggregate unpaid principal amount of such Term [A][B][C] Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated [DATE] by and among Borrower, the other Loan Parties, OXFORD FINANCE LUXEMBOURG S.&#192;
      R.L., as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;<font style="font-weight: bold;">Loan Agreement</font>&#8221;).&#160; If not sooner paid, the
      entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement.&#160; Any capitalized term not otherwise defined herein shall have the meaning attributed to such term
      in the Loan Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Principal, interest and all other amounts due with respect to the Term [A][B][C] Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured
      Promissory Note (this &#8220;<font style="font-weight: bold;">Note</font>&#8221;).&#160; The principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer
      hereof, endorsed on the grid attached hereto which is part of this Note.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Loan Agreement, among other things, (a) provides for the making of a secured Term [A][B][C] Loan by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of
      certain stated events.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Note may not be prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Note and the obligation of Borrower to repay the unpaid principal amount of the Term [A][B][C] Loan, interest on the Term [A][B][C] Loan and all other amounts due Lender under the Loan Agreement is secured under
      the Loan Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Note are hereby waived.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Borrower shall pay all reasonable fees and expenses, including, without limitation, reasonable attorneys&#8217; fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower&#8217;s obligations
      hereunder not performed when due.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The ownership of an interest in this Note shall be registered on a record of ownership maintained by Lender or its agent.&#160; Notwithstanding anything else in this Note to the contrary, the right to the principal of, and
      stated interest on, this Note may be transferred only if the transfer is registered on such record of ownership and the transferee is identified as the owner of an interest in the obligation.&#160; Borrower shall be entitled to treat the registered holder
      of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Note on the part of any other person or entity.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">[Balance of Page Intentionally Left Blank]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z1135b3504c1442ad863bed88ed200a7b" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">BORROWER:</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">IMMUNOCORE LIMITED</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 10%; vertical-align: top;">&#160;</td>
          <td style="width: 40%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">By</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za51f2fee49994679b275e404e5933b76" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20.21%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div>
              <div>&#160;</div>
              <div style="text-align: center; font-weight: bold;">Date</div>
            </div>
          </td>
          <td style="width: 18.93%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div>
              <div style="text-align: center; font-weight: bold;">Principal</div>
              <div style="text-align: center; font-weight: bold;">Amount</div>
            </div>
          </td>
          <td style="width: 20.21%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div>
              <div style="text-align: center; font-weight: bold;">Interest Rate</div>
            </div>
          </td>
          <td style="width: 21.71%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div>
              <div style="text-align: center; font-weight: bold;">Scheduled</div>
              <div style="text-align: center; font-weight: bold;">Payment&#160;Amount</div>
            </div>
          </td>
          <td style="width: 18.82%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
            <div>
              <div style="text-align: center; font-weight: bold;">Notation By</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.21%; vertical-align: bottom;">&#160;</td>
          <td style="width: 18.93%; vertical-align: bottom;">&#160;</td>
          <td style="width: 20.21%; vertical-align: bottom;">&#160;</td>
          <td style="width: 21.71%; vertical-align: bottom;">&#160;</td>
          <td style="width: 18.82%; vertical-align: bottom;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">CORPORATE BORROWING CERTIFICATE</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z6dd22d3de7684217988d7450a98d8739" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 13.69%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="font-variant: small-caps;">Borrower</font>:</div>
          </td>
          <td style="width: 43.53%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">[BORROWER]</div>
          </td>
          <td colspan="2" style="width: 42.67%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;"><font style="font-weight: bold; font-variant: small-caps;">Date</font>: [DATE]</div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.69%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-variant: small-caps; font-weight: bold;">Lenders:</div>
          </td>
          <td colspan="2" style="width: 56.79%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.,</div>
            <div style="font-family: 'Times New Roman', Times, serif;">as Collateral Agent and Lender</div>
          </td>
          <td style="width: 29.52%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">I hereby certify on behalf of Borrower as follows, as of the date set forth above:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I am the Secretary, Assistant Secretary or other officer of Borrower.&#160; My title is as set forth below.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Borrower&#8217;s exact legal name is set forth above.&#160; Borrower is a [BORROWER ORGANIZATION] existing under the laws of the State of [BORROWER STATE].</div>
    <div><br>
    </div>
    <div style="text-align: justify;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attached hereto as <u>Exhibit A</u> and <u>Exhibit B</u>, respectively, are true, correct and complete copies of (i) Borrower&#8217;s Articles/Certificate of Incorporation (including amendments), as filed with
      the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above; and (ii) Borrower&#8217;s Bylaws.&#160; Neither such Articles/Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked
      or supplemented, and such Articles/Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate
      action).&#160; Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation
      from Borrower.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[<font style="font-style: italic;">Balance of Page Intentionally Left Blank</font>]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Resolved</font>, that <font style="font-weight: bold;">any one </font>of the following officers or employees of Borrower, whose names,
      titles and signatures are below, may act on behalf of Borrower:</div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zd74367e817cf4955bfb75619d6359064" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 20%; vertical-align: bottom;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><u>Name</u></div>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: bottom;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><u>Title</u></div>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: bottom;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><u>Signature</u></div>
          </td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: bottom;">
            <div>&#160;</div>
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Authorized to</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">Add or Remove</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;"><u> Signatories</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 20%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">&#9744;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Resolved Further, </font>that <font style="font-weight: bold;">any one</font> of the persons designated above with a checked box beside
      his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Resolved Further</font><font style="font-weight: bold;">, </font>that such individuals may, on behalf of Borrower:</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold;">Borrow Money</font>.&#160; Borrow money from the Lenders pursuant to the that Loan and Security Agreement, dated of even date herewith, as amended (the &#8220;Loan Agreement&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold;">Execute Loan Documents</font>.&#160; Execute any Loan Documents (as defined in the Loan Agreement).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold;">Grant Security</font>.&#160; Grant Collateral Agent a security interest in the Collateral (as defined in the Loan Agreement).</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold;">Negotiate Items</font>.&#160; Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive
      cash or otherwise use the proceeds.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold;">Further Acts</font>.&#160; Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement
      that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-weight: bold; font-variant: small-caps;">Resolved Further</font><font style="font-weight: bold;">,</font> that all acts authorized by the above resolutions and any prior acts
      relating thereto are ratified.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[<font style="font-style: italic;">Balance of Page Intentionally Left Blank</font>]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="za1d5d07a4fe24d9c9cf66825a1fc2792" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">By:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic;">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this
      Certificate must also be signed by a second authorized officer or director of Borrower.</div>
    <div><br>
    </div>
    <div>I, the __________________________ of Borrower, hereby certify as to paragraphs 1 through 5 above, as</div>
    <div style="text-indent: 36pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[print title]</div>
    <div style="text-align: justify;">of the date set forth above.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z1dec8002ab2442908efabeadc2311f5f" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">By:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Name:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 10%; vertical-align: top; padding-bottom: 2px;">
            <div>&#160;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Title:</div>
          </td>
          <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[<font style="font-style: italic;">Signature Page to Corporate Borrowing Certificate</font>]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT A</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Articles/Certificate of Incorporation (including amendments)</u></div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[see attached]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT B</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Bylaws</u></div>
    <div><br>
    </div>
    <div style="text-align: center;">[see attached]</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zb07a829d8cf044c1a52bda4d8935db15" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 33.33%; vertical-align: top;">&#160;</td>
          <td style="width: 51.44%; vertical-align: top;">&#160;</td>
          <td style="width: 15.23%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">DEBTOR:</div>
          </td>
          <td style="width: 51.44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">[BORROWER/GUARANTOR]</div>
          </td>
          <td style="width: 15.23%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">SECURED PARTY:</div>
          </td>
          <td style="width: 51.44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">OXFORD FINANCE LUXEMBOURG S.&#192; R.L.,</div>
          </td>
          <td style="width: 15.23%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 33.33%; vertical-align: top;">&#160;</td>
          <td style="width: 51.44%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">as Collateral Agent</div>
          </td>
          <td style="width: 15.23%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT A TO UCC FINANCING STATEMENT</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><u>Description of Collateral</u></div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Collateral consists of all of Debtor&#8217;s right, title and interest in and to the following personal property:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All goods, Accounts (including health&#8209;care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles
      (including all Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit,
      fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever
      located; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">All Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and
      improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, or anything to the contrary herein, the Collateral shall not include any of the following property, whether now existing or hereafter acquired or created:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">&#160;(i) any interest of a Loan Party as a lessee or sublessee under a real property lease or an Equipment lease if such Loan Party is prohibited by the terms of such lease from granting a security interest in such lease
      or under which such an assignment or Lien would cause a default to occur under such lease (but only to the extent that such prohibition is enforceable under all applicable laws including, without limitation, the Code); provided, however, that upon
      termination of such prohibition, such interest shall immediately become Collateral without any action by a Loan Party or Lender; and</div>
    <div><br>
    </div>
    <div style="text-align: justify;">(ii) any license if the granting of a Lien in such license or the enforcement of such Lien is prohibited by or would constitute a default under the agreement governing such license (but (A) only to the extent such
      prohibition is enforceable under applicable law and (B) other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-408 or 9-409 (or any other Section) of Division 9 of the Code); provided that upon the
      termination, lapsing or expiration of any such prohibition, such license, shall automatically be subject to the security interest granted in favor of Lender hereunder and become part of the &#8220;Collateral.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the terms of a certain negative pledge arrangement with Collateral Agent and the Lenders, the Loan Parties have agreed not to encumber any of its Intellectual Property except in
      accordance with the terms of such agreement</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Exhibit E</div>
    <div style="text-align: center; font-weight: bold;">Form of QPP Certificate</div>
    <div><br>
    </div>
    <div style="text-align: justify;">To:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[&#160; &#160; &#160; &#160; &#160; &#160;&#160; ] as the Borrower</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e2453cfd07b4f3aabc3b16c44a20401" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">From:</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>[<font style="font-style: italic;">Name of Lender</font>]</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">Dated:</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">[Borrower] &#8211; [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; ] Facility Agreement</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">dated [&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; ] (the &#8220;Agreement&#8221;)</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za2f3d2e5e6774cb494d946b9ba2eef60" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>We refer to the Agreement.&#160; This is a QPP Certificate.&#160; Terms defined in the Agreement have the same meaning in this QPP Certificate unless given a different meaning in this QPP Certificate.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z308ac7e6012842e0bee3dfd480f00878" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>We confirm that:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z01db995900414096b13718f954b1826d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>we are beneficially entitled to all interest payable to us as a Lender under the Credit Extensions;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb1a47f92c33447ada4d924c02c7df1e9" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>we are a resident of a qualifying territory; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2bf484bbbd2d4cc5872b5c0b4f0acecb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>we are beneficially entitled to the interest which is payable to us on the Credit Extensions for genuine commercial reasons, and not as part of a tax advantage scheme.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; margin-left: 36pt;">These confirmations together form a creditor certificate.</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z42cd99780d314195823f09869b78bd01" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>In this QPP Certificate the terms &#8220;resident&#8221;, &#8220;qualifying territory&#8221;, &#8220;scheme&#8221;, &#8220;tax advantage scheme&#8221; and &#8220;creditor certificate&#8221; have the meaning given to them in the Qualifying Private Placement Regulations 2015 (2015 No. 2002).</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">[<font style="font-style: italic;">Name of Lender</font>]</div>
    <div><br>
    </div>
    <div style="text-align: justify;">By:</div>
    <div><br>
    </div>
  </div>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>16
<FILENAME>nt10016217x4_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <font style="font-family: 'Times New Roman',Times,serif;"> <font style="font-weight: bold;"> </font> </font>
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right; font-weight: bold; font-family: 'Times New Roman',Times,serif;">Exhibit 21.1</div>
    <div> </div>
    <div>
      <div><font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font> </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Immunocore Holdings plc*</div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif;">List of Subsidiaries</div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze481c08843cf4a65aebb863e0c11c093" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" nowrap="nowrap">&#160;</td>
          <td style="width: 35%; vertical-align: bottom;" nowrap="nowrap">
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Subsidiary</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Jurisdiction</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="2" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="vertical-align: middle; width: 10%; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman',Times,serif;">Immunocore Limited</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">England and Wales</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="2" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="vertical-align: middle; width: 10%; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman',Times,serif;">Immunocore Nominees Limited</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;" nowrap="nowrap">
            <div style="font-family: 'Times New Roman',Times,serif;">England&#160;and&#160;Wales</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" nowrap="nowrap">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="2" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="vertical-align: middle; width: 10%; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman',Times,serif;">Immunocore Ireland Limited</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">Republic of Ireland</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="2" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="vertical-align: middle; width: 10%; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" nowrap="nowrap">&#160;</td>
          <td style="width: 35%; vertical-align: top;" nowrap="nowrap">
            <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman',Times,serif;">Immunocore, LLC</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">Delaware</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="2" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td colspan="1" style="vertical-align: middle; width: 10%; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="text-indent: -12pt; margin-left: 12pt; font-family: 'Times New Roman',Times,serif;">Immunocore Commercial LLC</div>
          </td>
          <td style="width: 10%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">&#160;</div>
          </td>
          <td style="width: 35%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman',Times,serif;">Delaware</div>
          </td>
          <td colspan="1" style="width: 10%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>

    </table>
    <div>
      <div><font style="font-family: 'Times New Roman',Times,serif;"><br>
        </font> </div>
      <div style="font-family: 'Times New Roman', Times, serif;">*Following the completion of the corporate reorganization described in the prospectus that forms a part of the registration statement to which this list of subsidiaries is an exhibit.</div>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif;"><br>
      </font> </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>17
<FILENAME>nt10016217x4_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
      <div style="text-align: right;">Exhibit 23.1<br>
      </div>
      <div><br>
      </div>
      Consent of Independent Registered Public Accounting Firm</div>
    <div><br>
    </div>
    <div>The Board of Directors</div>
    <div>Immunocore Holdings Limited:</div>
    <div><br>
    </div>
    <div>We consent to the use of our report dated January 15, 2021, with respect to the statement of financial position of Immunocore Holdings Limited as of January
      7, 2021, and the related note, included herein and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
    <div><br>
    </div>
    <div>/s/ KPMG</div>
    <div><br>
    </div>
    <div>London, United Kingdom</div>
    <div>15 January 2021</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>18
<FILENAME>nt10016217x4_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Finanicial Soultions, Inc.
         Document created using EDGARfilings PROfile 7.3.2.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: center; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
      <div style="text-align: right;">Exhibit 23.2<br>
      </div>
      <div><br>
      </div>
      Consent of Independent Registered Public Accounting Firm</div>
    <div><br>
    </div>
    <div>The Board of Directors</div>
    <div>Immunocore Limited:</div>
    <div><br>
    </div>
    <div>We consent to the use of our report dated November 17, 2020, with respect to the consolidated statement of financial position of Immunocore Limited as of December 31, 2019 and 2018, the related consolidated statements of loss and other
      comprehensive income, changes in equity, and cash flows for each of the years in the two-year period ended December 31, 2019, and the related notes, included herein and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
    <div><br>
    </div>
    <div>Our report dated November 17, 2020, contains an explanatory paragraph that states that the Company has suffered recurring losses from operations which raise significant doubt about its ability to continue as a going concern. The consolidated
      financial statements do not include any adjustments that might result from the outcome of that uncertainty.</div>
    <div><br>
    </div>
    <div>Our report refers to a change in the method of accounting for leases as of January 1, 2019, due to the adoption of IFRS 16, Leases.</div>
    <div><br>
    </div>
    <div>/s/ KPMG</div>
    <div><br>
    </div>
    <div>London, United Kingdom</div>
    <div>15 January 2020</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>logo_immunocore.jpg
<TEXT>
begin 644 logo_immunocore.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M%T']H7]FGQU=1RW%E(Y2X33-3N!I1BFCFAUBS\%?%?PA#>1)XET_0;.XU;]
M7!&1\2>'7#F#PF&R_!<58G)IYIEE>G0H8?$YG4P*I1Q=#$XB,(2Q$*L<51@W
M6J.5*I.GB-:=*LGX3SG&Y=Q!F%6K4Q%;+*>,6&Q-.4YU*>'C7YG2J4X-M4Y0
M=*37+%*45*GI*<6O]*:BO+O@I\9?AW^T+\)O 'QL^$_B"V\4?#OXE^&K#Q1X
M7UFV9-TME>H5FL=0MU>1].UO1KZ.ZT;Q!H]R5OM$UW3]1TC4(H;ZRN(4]1K^
M9*M*K0JU*%:G.E6HU)TJM*I%PJ4ZM.3A4ISA)*49PDG&49).,DTTFC]'C*,X
MQG"2E"<5*$HM.,HR2<91:T:::::T:=PK^(__ (*_?\%X_CYH?[46H_!S]@_X
MQ_\ ""_#CX+IJ?A#QOXWT3PSX,\2K\3/B8E\D?B4Z=>>,_#OB*'_ (13P1-9
M+X:T6\T>WL8=;U=?%&L1WVO>'[OPO>0_KO\ \%[/^"FQ_8J^ 2_ _P"$^NFT
M_:6_:%T+5-/T:_TS45MM6^%/PPF>72?$GQ(_T9CJ%AKNLN+WPI\.;J-M/>+6
M8]?\4Z=J9O/ C:;J'\,_Q+_9&^*/PA_9G^ 7[3?C^S/A_P -?M*>)?B/IOPN
M\/WUM-!K>I^%/AQ:^$3<^/;B.0K]FT'Q+J?BF6Q\+I+&EUJ=GH=UK\:'0]5T
M"^U+]^\(>",NK*CQ'Q+0PM6CF%6KEW#N78^E3KTL?6C1KU<5BWAJT)PJJG1P
M^(AAE.+2]EB:[BG3P]1_"\5YUB(.>7Y=4JPGAXPQ&/Q%"<H3H0<Z<*5)5(-2
MCS3JTW4:=_>IPN^:I%?Z+W_!';X[?%C]I?\ X)R?LZ_&WXX>+[CQY\4?&O\
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M-:IZH_#7_@WH_P""A/[8O[9OQE_:'\,?M,?&K4_BEH7@OX9>%]>\,V%]X5\
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M7B'ESDW_ *B<**[;LL#0LKN]E_LW33[D;K(,0DE_;F:.R2NZ\[OS_B'^;O\
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M ,Y>F:E^T;_P;^_\%*KZ&>T?QIH.DP7%K/:2O/H'A_\ :'_9T\6W[-I]_;W
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M<]2;>F>9?1RS!9#@Z"O&GF5-SFU:56K))U*LM]9O97?+%1@G:*/](BOX/O\
M@ZD_Y/8^ ?\ V:UHW_JV?BM7]X-?P??\'4G_ ">Q\ _^S6M&_P#5L_%:OC?!
M3_DO,%_V 9E_ZC,]?C'_ )$=;_K_ (?_ -.(_KZ_X)U_\H^_V%?^S./V8_\
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MY.#_ &K_ /LC?@O_ -3:6O[@*^]\9O\ DX&:_P#8-E?_ *KL.>%P?_R(L/\
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M?_*/OX/?]GC_  ^_]4G^T+71?\&O_P#RCH\9?]G2_$K_ -0#X154O^3&4_\
MLJ7_ .EU"8_\EK/_ +%J_P#2(G!_\'1_QNU#P3^QS\'_ ()Z1J]WIL_QR^,J
MZAXBLK=!Y'B#P/\ "C1)-;OM)OY6R%MX/'7B#X<:['$JK+)>:-:R+*L4$T4_
M2_\ !L/\ ;'X>?L->,?CE=Z3;0^*/VAOBWKLMMKD;,US?_#KX61CP7X<TR=2
M-L2Z9XZ_X6E<H$YE75$:0GRXPGR!_P '9FD7\VC_ +"&O1P.VF:;J?[2>D7E
MR(Y3'#?ZW:_ F\TV!Y1&84>XM_#^JR1QR2I+(MK*T,<B13M%^NO_  ;_ .MV
MFL?\$G/V78K<VPGT2;XT:)J$-JBQI!=P?'OXG7D0E168BYN=-OK"^N7?:TTU
MV\Y4"4$Z8]O ^!>2K"^ZLXXDK+,G'3F]EB<U=-3Y;<W_ "*\"TYWMR072%E0
M7MN-L8ZNOU3+H/#WZ<U/"J5K_P#837^&V\O._P"RE%%%?B!]F%?-?[8O[/FA
M_M5_LN?';]GO7K&POH?BC\-_$?A_1SJ0/V72_&26;:EX"\294@I<>%?&UAX?
M\26<A#)'>:5 \D<L8>-_I2JM[>VVG65WJ%[*(+.PM;B]NYV#,L-M:Q///*RH
MK.PCBC=R$5F(7"J3@'?"XBOA,5AL5AIRIXG#5Z.(P\XWYH5Z-2-2E.-M>:-2
M,6K:W6AG5IPJTJE*HE*G4ISIU(O9PG%QDG?HXMIG^?7_ ,&T_P :=<^&G_!1
M<?"1KJ]AT+X_?"SQ]X0U70I)F@LV\3?#_39OB=H6LW5C)<6_FZKHNE^$_%^C
MV3^1=W%I:>)=9C%O'%<7-U;?UD_\%LOCEK?P!_X)E_M0>*_"]];:?XH\5^%]
M&^$FBSSS""81?%OQ/HW@+Q3+ICI=6MTNLV/@77/%6J:1/8M+=6-_8P:D83;6
M=Q)%_%A_P0B^W^)/^"O7[,&I6YFLI)]8^.&O7KVJS2);6Q^ OQ:O+FWDD1D9
M+6\,@TII)6$;_;$CD67S?)D_K%_X./M&U/4_^"7?Q#O;"SEN;3P[\4?@]K.M
MSQ[-FG:9/XNA\/Q7D^YE8Q/K.NZ1IX\L._G7T)*B,.Z?T/XA8#"5/&#@Z%:%
M-+,(\.U<;3:7+5J1S?%890FWI)5*6&HT+;N$4EO$^!R&O5CPEFTH.5Z#Q\*4
ME>\8O"TJCE'JN652<[]'=]&?C1_P:N_LYZ!XK^,?[1G[3OB'2I;K4_A#X6\)
M?#;X<W5W9V\VFVNM_%%_$5]XUUC3KF:W>>V\1Z-X:\):9H*SV=S"T>@>/]9M
M+J*:+4HC'_;M7\D/_!I_XEMKKX7?MF>#UC1;O0_'WP@\2S2_:%:22V\4^'?'
M&EV\9M0@>)(9?!UTRW!D=;AIVC5(S:LTO];U?GGB_B,17\0,[A7E)K"K+\/A
MX-W5+#K+L+6C&&KM&I.M4KM?SUINRO8]_A2G3IY%@G!).JZ]2H^LJGUBK!M^
M:C",%_=@O4****_-#Z,**** /\UGXXM=_P#!1S_@MWXC\)^*+R74?"WQ7_;+
MT_X/&XTJX33IK?X(> /&%I\.8+G2G+20VNJ1?"CPB=5+Q;A=Z_)<W>)+B\=W
M_P!)/1=&TCPYH^D^'O#^F6&BZ#H.F6&C:)HVEVL-CIFDZ1I=K%8Z;IFG65LD
M=O9V%A9P0VMG:V\<<-O;Q1PQ(L:*H_S</^"?(T?]G#_@N#\*?"OBVVF-MX+_
M &P/B1\$O(N&@N+B#Q'K^K>.?@UX;>XEDBMXI);/Q5K>E33SI! X:%YK>**4
M1HO^E%7[?XTR>'K<'Y7AKK*L%PU0E@E'W:3E.?U>3C!-Q4HX?"X6]KVC)).S
M/C.#DJD,VQ52WUJMF,U6N[R24?:*[:NTZE6KZM/0****_$#[,*_B'_X.H?V<
M]$\*?&7]G;]IWP_IBVE[\7?"OBCX;?$*XL[%8;:\U_X82:'?>$-9U6[BA N=
M=U;PQXJO- 26[G:=]$\":7:P)]GTYMG]O%?R<?\ !UUXSL+'X(?LB?#R2QLI
M-3\4?%7XC>,[/4Y+>)M2M+#P'X1T70]2L;2[,ZS066HW'Q'TJXU"WCM9HKJ?
M2],EFGMGM(([K]*\(L3B,/Q_D<<.Y6Q7U[#8B"=E4P\L!B:TU/O&G.C3Q"7\
M]&/8^=XKITZF18UU$KTO85*<GO&HL12@FNSDIRI^DVNI^LO_  0_^-FI_'3_
M ()B?LP:[KUY%>>(O WAK6?@YJS1+M\JU^$OB75O!/A".<EW>6\D^'VE>$+J
M^N)"KW%[<7$Y!$@9OYX?^#K;_DX/]E#_ +(WXT_]3:*OU\_X-I/!VH>&/^"9
M^GZW>B86WQ$^.WQ7\8Z29;;R$.GV*^&OA_*;:7SI?ML/]J^!=3#7.RVV7 GL
M_);[)]HG_(7_ (.ME8?M _LGN58(WP<\;*K8.TLOC6 LH;H64.A8 Y =2<!A
MG[+@_#T,)XWYEA\-RJA3S'B54XQ5HT^:CBYRI17149RE22[0/(S:I.KP9AZE
M2_/+#Y=S-N[E:I12DWWFDI/S9_2G_P $=?\ E&+^QA_V1S3?_3OK%?I77^>/
M^S'_ ,%]_P!O?]F;X!_"WX"_#3X(?L\^(O ?PO\ #$'ACPOK?BGX:_&;5_$.
MI:9!<W-RESJNI:!\9- T:\NFDN95:;3]'T^W*J@%N&#,WN5Q_P '-_\ P4MB
M@GDE_9]_98M8HX9'DN6^$WQZ1;>-$9GG9YOCTT*+$H,A:56B4+F0% 17!G?A
M!QCCLZS?&T(96Z.,S3'XJCSYE2C-TL1BZM6GS0<;QER5(\T=T[KM??!\6910
MP>$HSEB>>CAJ%.=L/)KFITH1E9WLU?9]5KU5_P"\:OX\/^#I?]K/X=ZKX<^"
M?[%WAS5;;7?B%X?\=6WQU^)$.FZI!<0^!;6W\(^)/"O@?0-?LK<3>3XC\46'
MC36O$<-A>36>HZ3X=M='U22RGT[QGI-X?S7M_P#@M;_P60_;4\8V/P'^!OB^
MPTGQK\2/[=TW2/!WP(^'/A'0O%6H6ITR\U/4H="\4^*/[>\3^'?[ T6QU#4Q
MXATCQ/H^L:-I]E=ZM<ZXBV3WD/W?_P $^O\ @W'^,OBWXG:9\>/^"D>IV%EH
MD?B"Z\5ZQ\#X_%J>//B%\2]?DO;N\FE^*GCS0M4U'0=,T75M1:WU?5DT+Q-X
ML\1^*+:XOM.U2Z\*7DLER_HY#P9@?#?,Z'$G&^>Y72Q&7TJF*RW(LNKSQ68X
MVO.G5HTING*%"?LXSYU3<(SP[K*+Q&*HTZ=2,^?'9Q7XAP\\NR;!8F=.O*-+
M$XW$05/#T8*49RBI*4X\SC9M2:J<EU3I3E*+C^U?_! ?X#ZQ\"?^"9?P7'B3
M1[O0O$GQAU3Q9\<M3L+R9997TSQUJ$=MX$U-40LEM#KGPST'P5K<-L':2./4
M5-RL-V]Q;PW_ /@O]_RB/_:S_P"Z#_\ K3'P9K]AK2SM-/M+6PL+6WL;&RMX
M+.RLK2"*VM+2TMHEAMK6UMH52&WM[>%$B@@B1(HHD6.-550!^//_  7^_P"4
M1_[6?_=!_P#UICX,U^=9-FE7._$C)LWKQ4*N9<9Y7C)4TW*-)5\YP]2-&+>K
MA2A*-.#>O+!7/H,7AHX/A[%X2#O'#Y/B:*E:SDZ>#J1<VEHG-IR?FV?A[_P;
M _'?X'_!GPO^V7#\8/C+\*?A1-XAU_X%RZ!%\2OB)X0\"RZY%IFG?%9-2DT>
M/Q1K&EOJ<>GO?62WSV0G6T:\M5G,9N(@_P#57_PW+^Q/_P!'A?LM?^)!?";_
M .:ZO\[7_@G+_P $G_CA_P %+M-^+6I_!_X@_"GP1#\'[[P98:_'\2KWQ?:2
MZE+XW@\37&FOHX\+^$O$R21VJ>%KU;XWK6;*UQ:^0LX:4Q?I=_Q"M_ML?]%\
M_9:_\'/Q9_\ G55^N\=\+\!9AQ7FV,SGC?\ LG,JTL&\3E_U-U?J[AE^$ITE
MSV][VE"%*MY>TMT/E,DS//*&5X6EA,E^M8>"J^SK^UY?:)UZLI/EOIRS<H>?
M+<_M5M/VEOV<M0M+6_L/C_\ !.]L;VWAN[*]M/BKX$N;2[M+F-9K>ZM;B'7G
MAN+>XA=)89HG>.6-UDC9E8$[>C?''X*^(M4LM$\/_&#X7:[K6I3"VT[2-&^(
M'A/4]4O[A@S+!9:?9:M/=W4Q568100R.0K$+@&OXC_\ B%;_ &V/^B^?LM?^
M#GXL_P#SJJ^M/V$O^#=K]J_]EC]KWX!?M"^-?C+^SSK_ (4^$_CRS\5ZYH_A
M;5/B3-XAU"QM[*^MGM]*BU;X=:5IKW3/=(RK>:C:0[5;,H. ?@\;P=X>T,)B
MZ^%\1J6)Q%'#5ZN'PW]ESB\16ITI3HT.?VUHNK.,:?-:RYKVTL_<HYOG\ZM*
M%7A^5*G.I3C4J_64U3A*45.IR\NO)%RE:^MK7[_V&T445^2GU)_F[_\ !O-_
MRE=_9[_[%WXW?^J3\?5_I$5_F[_\&\W_ "E=_9[_ .Q=^-W_ *I/Q]7^D17[
M7X\_\EG@O^R>P7_J?FA\;P/_ ,BBO_V,*W_J/A3_ #^_^#H'_E(MX,_[-9^&
MO_JP?B]7]\?A'_D5/#'_ &+VB_\ IMMJ_@<_X.@?^4BW@S_LUGX:_P#JP?B]
M7]\?A'_D5/#'_8O:+_Z;;:N?Q _Y(+PK_P"Q9FG_ *3E1ID7_(]XF_[",-^>
M)*?C[P'X0^*/@?Q?\-O'^@V/BCP/X\\-ZUX1\7>'-25VL=;\.^(=/N-+U?3+
MGRGBF2.[L;J:$RP2PW$)836\T4R1R+^%'_!+;_@A_P"%/V!?VD?CG\>?%OB+
M3_B/>6^NZQX2_98FNH8KK5O!GPLURTBN-3\4^)IWL;.WB^)^I65\_P /KNZT
M2TL+2UT72_$]Y:22:?X_.DZ'_0)17YM@.(<WRS+<VRG!8RI1P&=4Z5+,*$=J
MD:4^9<CWI2J1YJ-9P:]M0G*E4YH62^BKX#"8G$87%5J49U\'*<J$W]ES5G=;
M246E."E?DFE.-GJ%?R"_\'9'_(I?L.?]C%^T#_Z;/@_7]?5?R"_\'9'_ "*7
M[#G_ &,7[0/_ *;/@_7UGA+_ ,G"X<_Z^9C_ .JC,#RN*_\ D09AZ8;_ -3,
M.?K9_P $ ?\ E$?^R9_W7C_UICXS5^MOB[_D5/$__8O:U_Z;;FOR2_X( _\
M*(_]DS_NO'_K3'QFK];?%W_(J>)_^Q>UK_TVW->#Q?\ \EIQ1_V5&=_^K;%'
M?E/_ ")\L_[%N"_]1:1_ Y_P:_?\I%O&?_9K/Q*_]6#\(:_T!*_S^_\ @U^_
MY2+>,_\ LUGXE?\ JP?A#7^@)7V_C?\ \ES4_P"Q5EWY5CQ>"_\ D2Q_["L1
M_P"V'Y*?\%?_ /@F?HW_  4>_9ZM]$\-OHV@_M"_"V[N=?\ @KXQUB::TTQF
MU)[&/Q9X#\37-O;7DR^&O&&GV-K(EQ%;-<:/XFTCP]JJ2-IL.LZ;JOUG^PY^
MQW\-OV$_V;/ /[.WPT1+NU\-6LFI^,/%LEC#8ZI\0OB%J\<$GBOQQK,<3SR+
M<:K=0Q6FEV5Q>7[Z#X8T[0?#,%]<V.B6CU]<45^<U>(,WK9'AN'*F,J2RC"8
MRMCJ.$;]V->M%1=Y;NE!NK4I4M(0JXC$5+.=2Z^@C@,+#&U,PC1BL75HPH3J
M]7"#;VVYI+EC*7Q.-.G&Z4;,K_-W\4?\K#=K_P!I;/"'_K5>B5_I$5_F[^*/
M^5ANU_[2V>$/_6J]$K]3\&/XO&?_ &2^)_\ 2F?-<7[9/_V,Z?Y(_P!(BOX[
MO^#KSX1ZS-9?L?\ QXT_1YIO#^GW/Q0^$OBW7UD/V?3]7U:/PQXP^'VDRPO=
MD&75K/1_B7>036UBFU=&GCOKN3?IL,?]B-?'?[?'[(WAG]N/]E#XM_LX>(I[
M?3+SQEH:7O@CQ)<0B7_A$OB+X=N(]:\$>(BRPS7*6-MKEG;67B"*Q$5YJ7A:
M_P!=T>*>(:B[CX'@3/J?#/%F39Q7O]5H8B5'&6YGRX3&4:F$Q%7ECK-T*==X
MB$%\4Z459GN9W@99CE>,PD/XM2FITME>K1G&M"-WHE4E!4V^BDV?$G_! G]H
M+2_CQ_P31^"VFQWTESXH^!-QKWP*\8VTTEQ(]C<>$+T:GX/2%[J1YI+*7X;>
M(/!;0O'BR@NEO=+LPD>F&&+]GZ_S-_V2?VH_VMO^")/[7WBC2/'/PZ\0Z2S/
M#X7^.?P'\5W=UHNC?$7PSIVH7RZ-XC\/ZQ!%J&CW5]IDS:IJ'PU^)FC0:_HT
M]EJ.K0Z?/JGAOQ%J]M??V+?!;_@X/_X)@_%[3[!]8^,OB#X*>(;WSMWA3XQ^
M /$^D7=H+=7=Y+KQ3X1L_&GPZBCE5";97\:+<S[HXQ;+<,8%^R\0O#S.L/G6
M-SG(L#B,ZR+.:U3-,+B<JI2QRH_7)/$5:52GAO:S5*$ZDI4,0E*A4P\J;515
M%4A#R,AS_!U,%1PF-K4\%C<)".&J4L5)4.?V25.$XNIR1YI))3IMJ<:BDN7E
M<6_VRK\3?^#@WXU:'\(_^"8GQFT*]U*2R\2_&W6O 7PB\%VT 5I-0U#4/%FF
M>+O$\$_S!X;%?A[X0\8&>X"21_:7LK)_+:^C<-^,_P#P<(_\$P?A'9W_ /9'
MQD\1?&G7[$)CPS\'OA]XHU::Z,MN+B(VOBCQ=9^#/A]<)\R13&#QA-+;3,T4
MT*R12HG\F_[2G[1'[6G_  7W_;3^'WP\^%O@!= T72;34-&^%_PX_MN_N_"7
MPP\'2W\5YXR^*WQ0\3M;?8X;ZXA&F?\ "4Z]I^BVIN;32O"O@WPSH>M>(3IE
MOK\< < YU+.L#GN?8+$9'D.1UJ6;XO&YK2E@8SC@9+$TJ=.GBE3J3IU*E.+J
MUN1484%4;J<[IPF\]SW!_4ZV!P-:GC<=C82PE*CAI*LTZZ]E-RE2YHJ48R:A
M"_/*IRKELI-?L_\ \&HOPGUS2OAA^U]\;[ZVC7P]XX\<?"[X8^&[DNXN'U/X
M9Z'XM\3^+AY)PC6C0?%/P>D-QAP]S;7L",K03JW];M?)_P"Q!^R3X(_8=_9C
M^&'[-G@2^N-;L? FEW4NO>*KVUBLK_QEXSU^_N=<\7^*;JUBDG^QQ:IKE]=_
MV1I<EYJ$FAZ!#I.@_P!HW\>EI=R_6%?&<;Y[3XEXJSK.:%_JV+Q4885RBX2E
MA,)1I8/"U)0>L)5:&'IU9P>L9SDGK<]C)L%++LKP>#G_ !*5)NK9II5:LY5J
ML4UHU&I4E%-:-)-:'^=Q\"O^5C[6_P#M)7^T3_ZM;XG5_HCU_G<? K_E8^UO
M_M)7^T3_ .K6^)U?Z(]?>>,G^]\'_P#9(X#_ -.5CP^$/X&:_P#8UK_^D4RM
M>V5GJ-G=Z?J%I;7]A?VT]E?6-[!%=6=[9W43P7-I=VTZ20W%M<0N\,\$R/%-
M$[QR(R,0?\_/_@KG_P $\OB/_P $HOVH/!?[7/[)>JZ_X2^"OB?Q\GB;X6^(
M=%4O>? CXIPM<ZS<?"_4+B6*XLM2\*:A:0:E>>!H];@GBU[P='KO@;Q-9Z[_
M ,(YJ6M>*/\ 05KR;XZ_!#X9_M)?"+Q[\#?C#X:M?%OPX^)&@SZ!XET6Z 5F
MA:6&[L-3TVZ"M+IFO:#JUK8:]X=UFUV7VB:]ING:M82Q7EE!(GQW W&.(X0S
M;V\H?6\HQT5A,ZRZ2C.GB\'*\925.I>G*O04YSH\R2G&53#SE&E7J,]?.LII
MYMA>12]EBJ#=7!XA74J596=G*+4E"?*E*UW%J-1)RA$_C:_X*I?\%%_ W_!1
MW_@C=\#?B/8+I'A[XO\ @S]LCX7>&?CM\-]/GEQX4\8R_ G]HB2VUO1K2]N+
MG4AX$\;Q6EYJ_@Z[NKB_\D6^L>%[C5M4UKPKK5Q7ZE_\&O\ _P HZ/&7_9TO
MQ*_]0#X15_'C_P %%?V#_BG_ ,$\/VA_$OP.\;R76L>#-4<^*_A-X^A1HM'^
M)'@)KJ]M=%UJ2",^18^*=#\V[T3Q9H4H^T:'K2WCV$E[X<U;0];UG^P[_@U_
M_P"4='C+_LZ7XE?^H!\(J_9^/,JR?*O"SER#$K$Y-C^(,-FF7R3YE2H8[VM1
M8=2;<I1H34J<544:U.*5*LG5ISE+X_(\3B\3Q-?'4W3QE# U,-B$]'*I048^
MT:6B=16D^5N$FW*'N2BE]%?\%]OV6;K]IK_@G3\2K_P_I[ZAXY_9ZU*P_:!\
M,06ZP+<76E^#;'5-/^(MBTT@\][9/AMKGBG7DTZV)EU/6O#VB6Z12SK;A?Q"
M_P"#8?\ ;HT7P+XR^(O["_Q#UFTTK3_BGJLGQ2^"%U?RB"&X^(MGI%CI/CKP
M.D[[PU[XI\+:+HGB#P[:NUG9I<^#_$=LDESK'B+3K6;^V1T21&CD571U9'1U
M#(Z,"K*RL"&5@2&4@@@D$8-?P8?\%D?^"._Q,_8V^+$_[87[%_A_Q7+\"I]>
M?XC:C:?#V.\C\2_LO^.=+U5?$"ZCID>@10ZCI/PTM+U(=8\&>*-, 7P%-8SZ
M)KDVEV]AX;U;7?C?#W,\JS[A[-?#?/<3'!_VC6>,R#'U6O9T,P_=RCAKR<5&
M3KTHUJ4.:/UE5L7AN>-2K1C/U\_PV*P./PO$."INM]7@J..H13;G0U3J62;:
MY)RC.5FJ7)2JV:C-K^]&BOXVOV#O^#GF'2] TGX>?M]^!M;UK4]/@ALK7X_?
M"?2M+FN]81%M(8[CXB?#0W&C6EO? )>WFI>)? 5V8+QY+2RL_AS9&*YU*X_;
MW0?^"Y__  2H\1:+?Z[:_M<^&;"WTNWM9[ZRU[P'\6_#VM#[7/';+!8:)K/@
M"RU37;B":0"ZC\/6NK"V@62^E9;"-KH?%YQX=<99+BIX:OD.88J,9\M/%Y9A
M:^88.LG)1A*%;#4Y\GM&URTZ\:-:[M*E&5TO8PG$&48RE&I#'4*3:O*EB:L,
M/5@[7:<:DH\W+UE!SAU4FM3]:*_$/_@O-^W3X;_9)_8F\=_#K1]>MX_CC^TQ
MH.L_"CX?Z#:SQG5M-\)>(+9M+^)GCZYBCO+2^T[3-%\)7>HZ)HVL6IDN8?'&
MO^&6M[>:VMM4N+#YU_:P_P"#F']BSX7>%M1M/V7K3Q3^TQ\1[JPE70KF3PSX
MG^&WPNT?47+P++XIU?QQI7A_QI?K8L4O5TSPSX1NK;6HD:Q'BC0FG748/YM/
M@9\ _P!MW_@O%^V;>?$KXD:AKC^%KW5;.T^*/QF_L&]L_A9\%_A[HTBWEM\.
M?AY:RF724UBVL-2>+P5\/[6_NM:UK6-6N_&?C*_E6]\:>-Z^PX)\.L9AL33X
MHXSHRR#A[)IQQU2&91>'Q6-K8>4:E&A]4J)5X495%'VBJ4U4Q/NX;#4ZDZKG
M2\G.>(*-6G++<GG]>Q^,3H1EAG[2E1A47+.?M8WA*:BWRN$G&GK4J2BH)2_5
M7_@UG_9'U2X\4?&[]MGQ-I\L&A:9HLGP%^%CW5K;O#JVM:K=Z)XJ^)6OV+3$
M7EM)X=T_3?"7ARRU&UC:SU >*O%>EBY^T:3?6Z_U'_MR_LV6W[7_ .R/\?/V
M;YKNVTZ]^*/@#4=*\-ZE?-,FGZ7XVTFXM/$O@'5-3-O'+<-I>F>-M$T"_P!3
MBMXWGFL+>XBA7S'6O4/@)\#?AQ^S5\&_AW\"/A)HB>'_ (>_#'PU9>&?#M@!
M ;N>*WWS7^LZQ<6UO:QZAXB\1:K/?>(/$NKFWBFUC7]3U+5+A!/=R5Z[7QG%
M7%^*S_BZOQ-A^;#2HXO#5,JA*SGAJ&7R@\$Y+5>T<J:Q-6-Y15:K446X*)[&
M5Y32P.50RZHE44Z52.*?2I.NG[9+^ZE+V<'9-PC%M7N?YRO_  1:_; U/_@F
M_P#M_P"L?#/X\^?X!\ ?$G4]0_9]^/%AK\T-G%\./'?AWQ%=6/A?Q3K[-/'9
MVH\#^-8=1\->(]0N;S^SM%\*>*/%NLM]IDT^U4_Z-5?R=_\ !>[_ ((T:C\7
MGU_]M_\ 9.\(ZGK'Q71+.3X[?!_PMIEYJNH_$JRMXHK"/XE^"-(LO/NY/'6D
MVD-G:^+O#.EV4B>,=(MU\26$-OXMTW65\;_G1_P30_X.'?BA^R?X7T+X"_M9
M^%?%'QV^$7AJ5-+\,^.=-U2,_&SX<:%!&T2^&IH?$ES;:7\1_#VD20Q6WA_2
M]<UOPOKWANRFNM/3Q/JFA:=X=\-:/^H<4Y##Q1R["<:<)1I5<YIX:EA.(LD]
MI"EB5B*$$H5:/M)J,YPA>%)SFEB\'"A[)K$T:M"7S.68Y\,XBKD^:N4<)*I*
MK@,9RRE3Y)RUC)13:BW[T[)^RJN?.O9SC-?WMT5^1'P]_P""[G_!+#XBP VO
M[4ND>$K]+"&_N]*^(7@;XE>"I[,2^4K6AU36?"$/AK4+^"67RYK71==U1OW<
ML\1EM$^T'P_]H+_@XT_X)P?!_2M53X=^,O&/[1GC&R-Y:6GASX9^#/$&C:*^
MJ0"1;<:AXY^(&G>%= _L2:=$676_"H\8LEO)]HLM.U$KY+?DE'@CC"OB5A*?
M#&>JNVDXU<LQ="$;NRE4K5J5.C3@[K]Y4J1IV=^:Q]5/.<IA3]K+,L%R6;O'
M$TIR=MU&$)2G*2_EC%ROI:Y^[-_J>FZ5';RZGJ%CIL5W?6.F6LM_=V]G'<ZE
MJ=S'9:;I]N]Q)&LU]J%Y-#:6-I&6N+NYEC@@CDE=4-ZO\X/XP_M=?\%&O^"W
MO[4/A#P'\*])\2:98^'?$D'B[X8?"'X:ZSJND^!/@Q#I5[##9?%3QWXV0:=Y
MGB#PY]I@6;XH^(O[/GL]3OWTOP%I.@S:_:>&;O\ T%_V>/"GQ9\#? SX4>$/
MCO\ $"Q^*GQD\.^!M TOXD_$+3-.72]/\5>+K:QC35]2L[9;6P:6W^T;K>+4
M9M.TNYUA8!J]WI.E75]-I]MZ?%W U;@["94\QS7 5<WQ\:E3%Y-AY.IB,OI6
M3HU)U8N5.I"7O4ZDW[*/MERX5XJE"I6ASY5G4,WK8I8?"UXX2BXQI8RHE&G7
MG]N"B[2C)74HI<SY-:GLY.,'_G\_\%T_V9/&/[&/_!2+Q1\7/!EYKNC:!\>?
M$K?M-_"[QG:&6VNM&^(5]XC_ +9^(%C8:Q;P6T"Z]X5^)0F\36<5KNN]*T#Q
M-X/DO)9[NX-W<?W0?L#?MB> OVYOV7?AC\>O!FLZ'>:SK/A[2=-^*?AK1[DO
M+\/OBQ8Z58MXY\%ZA97#G4; :=JTTEUH3ZC%#)K7A:]T+Q%:";3M7L[B7D/^
M"CW[ OPT_P""A_[-_B/X.>,HK31_&^F1W?B+X,_$CR<ZC\._B)!:.FG7KRQP
MSSW?A/72L>B^.M $<B:OH$[W%B++Q-I7AO7-'_A$^$7QF_;U_P""#G[6OB+P
MQX@\+2:)=7\%C'X^^%_B::]OOA)\=? <=U=IH7B_POK5@T5M??9W.I-X-^(&
MA$:SX4U<Z[X6\0V _P"*X\#77Z/AX8;Q8X-R[*Z6)H4.->%*$J6&H8BI"FLU
MP$84J3E&3]YJI2I4%4J:JAC:3=94Z&+C57SU253A?-\1B94YU,GS2:E4G3BY
M?5:[E*6JV]V4ZCC'1SHRM#FG2<'_ *6M%?@3^S;_ ,''?_!/+XV6VFZ?\3-;
M\:_LS^,I[2W%[IWQ-\.W.M^#7U4VZS7EIHGC_P #1Z_:2:9;N)8[;5_&6C^
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M+3C.$L+4E&46M'&2:::T:=S\D_\ @TW_ .12_;C_ .QB_9^_]-GQ@K^OJOX
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M_P""=/\ T.7[4O\ X<KP!_\ .BHHKZ+_ (B+QS_T4^;?^%'_ -J>?_J_DO\
MT+<+_P""_P#@A_Q"_P#_  3I_P"AR_:E_P##E> /_G14?\0O_P#P3I_Z'+]J
M7_PY7@#_ .=%111_Q$7CG_HI\V_\*/\ [4/]7\E_Z%N%_P#!?_!#_B%__P""
M=/\ T.7[4O\ X<KP!_\ .BHHHH_XB+QS_P!%/FW_ (4?_:A_J_DO_0MPO_@O
$_@G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>nt10016217x4_ex10-7img01.jpg
<TEXT>
begin 644 nt10016217x4_ex10-7img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  ^ &\# 2(  A$! Q$!_\0
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%N@\@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>nt10016217x4_ex10-7img02.jpg
<TEXT>
begin 644 nt10016217x4_ex10-7img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  _ ,@# 2(  A$! Q$!_\0
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M18X(=-MHXT48"J%C %>GQZ181ZS+JR6L:ZC+$('G'WF0'(%>;>$_^3@_&?\
MUX0?R2CVO.I65M/QN@]BZ;C=WU_"SL<W:>&X_%GB_P"+6DOM$DKV[0N?X)%#
ME3^?'T)K'\.76N_%#6=&\,:^LB6>@EI=3D  ,\B,53/OCC_OHUW7PQ_Y*]\2
MO^NUO_)Z]+L-(L-/O;Z[L[:.*XOG$EQ(HP9& P"?\]S1.MR-JW16\M!4Z'M$
MG?J[^>K/,OAJJI\7/B,B *JO   ,  *:F_9N_P"1"N_^PG/_ .RU'\->?C#\
M1Q_TT@_]!-<[X5\20_"KQKK_ (?\3K-;Z1?7)O+*[$99 &]>^, #C."IIR3D
MI16]E^01DH.,I;7DOQ.K_:0('PNN\G&9XA^M5?C-][X>_P#8:MOZ5@^/_$]K
M\4-9T?PEX29KVR:X6YO[H(RHJ+V^8#L2?K@"NB^.("7?@-1P!KL 'YBB"<>2
M+WU"I)3YY1VT7XF5XH>;X7_$A-?MP%\,:[*$U"-1Q%+_ '_KR6XZ_,*T-(=9
M?VD-4>-@R-HD;*P.002F#7H?B[0+3Q/X>O=)OUS%<(0&[HW\+#Z&O"?@;:ZI
MIWQ=U#3-=W&\T_3&M 3WC5TV8]1@C'MBE!J<'+JD.:=.I&/1N_H=_P#L^1Q+
MX0U*10/M$FJW)GXP0P8  _AC\Z].8 J0>01@UX'%J\_P;\=ZE;ZG;SR^$]8F
M-Q%-&I;R7/7'J>Q'7 !'OT'C+XRZ$VCRV?A.>;5-:O$,-LD$3+Y;MP&)8#IG
MH,_AUJ:E*4Y\T=4RJ5>%.GRR=FNAYU;M+!\&_B-%8;ELEU94BQTP70./IC%?
M1'@J."'P?HJ6F/(%G%L([C8.:Y+P=\.UL/A//X9U$@76H1.]TXYVRN./KMPO
MY5R'PX^(B>"H6\(?$#S+"XT\E+>Z9&9)(\G .,GZ$<$?2JJ?O4^36S(I?N7'
MGTNO^">[5Y)\,G,GQ?\ B(;C?]I$T:@$8'ECA/TJ6'XL?\)!XUTW1?!%B=3M
M3)F_NY%9%CB[E?IUR>O0=<U0\?3W?P\^(R>,;6VEN=$U.%8-4CC&2C+@*X[9
MQC\B.]1"G)7@]VC2I5C*TT]$]3V6O*=!$</QB\?QVA(B?3X))E'3S=O7ZX/Z
MFI=8^.'@^TT=KK3[N2_NV3,=HD3JQ;' 8D8'OU_&CX1:1J,7AW7O$.OQ>7JV
MNR-<NI!&V,*=@P>1U/'IBE&$H1;DK7T'*I&I.,8.]M3SSX1_$:Y\,>!8+&/P
MOJ6HQ1R22?:8&&PY.2.G:NB\.S:Q\6_%FCZ]=V26'A;2)FF@0R!WFE&.#^(&
M>. />N@_9LY^%5GW_P!(F_\ 0JP_#\[_  T^+%UHEVPC\.^(9#/9M_#%,3P/
M;^[_ -\UO)IRGRKWOZN<\5)0ASOW?ZL1_%!]<C^.&@MX5CMI-5&E-Y:7/W"-
MTN[/([9[UJQ7OQC,J"33_#X3<-V/3O\ QU0^(WB#3O#'QV\/ZIK$QALXM)=6
M94+'+-*!P.>IKH/^%X^!1_S$Y_\ P%D_PJ&I<L>6-].Q:<.>7-.VO<],'3GK
M145I<1W=K#<0'=%,BR(<8RI&117&=XR2QM);V*\EM8'NX@5CG:,%T!Z@-U H
M2QM$OGO4M8%O)%"/.(P)&4= 6ZD>U9.K>*=/TOQ'IVCW<B1S7D4DHD:156,)
MM^]DY^;=Q]#6A)J^FQ77V:34+-+G(7RFG4/D]!C.><C\ZJTB>:)>JO'8VD5[
M+>16L"7<H"R3K& [@= 6ZD4V?4;*WG$,]Y;13,0HC>558D]!@GO4$FNZ1%=/
M:RZI8)<I]Z)KA R_49S22?0&UU+%O86EM<SW%O:V\5Q<$&:5(PK28Z;B!D_C
M5FJ=_JNGZ<T:ZA?6MJTGW!-*J%OIDUFZMXJTW2M=T[3+R:.-[U'=97E550*,
M\Y/?M3492!RC'<UH+&TM[J>YM[6"*XGP9I4C"O)CIN(Y/XU!K&C:;K5OY&KV
M-M>0CHL\8?'TSTJO#JS)J6JQW_V2VLK4Q"*<W*DOO7)WK_!SP,]>U6[#5+#4
M6D&GWUK=&(X<0RJ^P^^#Q1JM0O%Z$6BZ'I>APM#H^GVUE&WWA#&%S]<=:LW=
MC:7C0F\M8+@PN)(C+&'V,.C+GH?<56M]<TFYN3;V^IV,LX(7RTN$9LGH, TW
MQ#>:E8V2RZ-I0U2X+A3";E8,+@Y;<P(]./>CWF]1>ZEIL:=5UL;1;YKU;6 7
MC+L:X$8\PKZ%NN/:N7\#>*M5\2O+)=>'CIUE&TD7GF]24F5'VE-H /4'GIQ7
M2ZCJ=AIB*^HWMM:(WW3/*J _3)]Z'%Q?*$9QDN9;#]0L;34;9K?4+:&Y@;K'
M,@=3^!K,T;PGH&BR^;I.CV-I)G.^*$ C\:OW>JZ?9V\=Q=WUK!!(,I)),JJ_
MT)/-9>N>(18W.@K:+%<PZI=BW\U7R%4JS;@1P?NTUS;()."U9T%9FM^'](UV
M-4UC3;2]5?N^?$&(^A/(JKX1UR37;?4Y)(%A^R:A<60"MG<(VVAOJ?2M2;4+
M.&X6":[MXYV*A8VD 8D]!C.><''TI6<6.\9*_0AT?1M-T6W\C2;&VLX>ZPQA
M<_7'6KD\,5Q"\,\:2Q.-K(ZAE8>A!ZU5&K:<;W[&+^T-WG'D><N_/IMSGM1=
MZMIUG<I;W=_:07#C*QRS*K,/8$YI:MA>*5C,L_!?AFSOOMEKH6G1W6<^8(%R
M#Z_6M]@&4A@"",$'O5.\U?3;*X2"\U"TMYY/N1RS*C-] 327VKZ;IYQ?ZA:6
MQP&Q-,J'!. >3ZTWS2W!<L=B:PL;33[<6]A:P6L )(C@C"*">O XIM[IUE?M
M"U]9VUR86WQ&:)7V-ZKD<'@=*S/$'BC3=%TVUOIYXI+>YN([>-DE7#%FQD$G
M! Y)]@:O7.M:7:V\-Q<ZE9103?ZJ1YU59/\ =).#U'2BTMQ7CL)J.B:5J<RR
MZEIEC=RJNU7GMTD8#T!(/%5?^$3\.?\ 0 TC_P  H_\ XFM"34K&.WCGDO+9
M8)>8Y&E4*_&>#G!X!/X5%<:UI=L81<:E91&90\>^=5WJ>A&3R/>A.70&H;LN
MQHL<:I&JHB@*JJ,  =A13J*DL\\\:-IEO\3/"<^J_9(X'MKQ&DN-H5F_=[02
M?QQ7 _$>_%]:>+9FNO#EHMK>?9UMUM=U[.RA=K[PP(.,<X(PIKW/5=(T[5TB
M35+&VO%B?S(Q/$'"-ZC/0U6N_#.AWE\]Y=:/I\UVZ%&FDMU9V4C&"2,]*Z(5
M5&S?3_,Y:E"4[I=?\CB-.T6SU/XL:K?7D*3W5KIUL8#(-P1R#\X'][WKSV^O
MO#UK\-;S0M2L-OB]+EFGC>$B4R>;N\XOC[I7'.?05]$Q6=M%=27,4$27$BJC
MR*H#,J] 3Z#)KC[_ ,!2:C#]DU'Q)J]UIK3B9[:7RB7 ;<$,FS=MR!QFJA65
M_>\OP)J4)6]WK?\ $X;Q\LC_ !$UZ*_E\/PP3Z7&D+ZR' \GG?Y1'\0;)/?I
M6FJ6.G:A\/%UV[L+B'[!+&;J4 12XB&PY<#MC&>:]-U;1-+U@PG5=.L[TPMO
MC-Q"LFP^HR.*=J6D:=J<4,>HV%K=1PL'B6:(,$8=",]*GVRLD5[!W;_K>YXY
MX_ACN+CXB0RJ&BEO-%1QZ@E :W]9T=+7QYJUGX>MXK.>X\*RK&L"A 9!)M0X
M'&1T!KT6;2M/G:<S65O(9V1I2T8/F%/N$^N,#'I4DUE!+,\_EJETT1@$ZC$B
MH><!NO7GZTO;:6_K9?Y#^KZM_P!;O_,\'TG4/#%S-\.[+1K$P:O97L:7@,11
MH#L8,LAQRQ;D=>AZ5] UQMAX':/4],N]5U[4]5&FL7MXKD1@;R" [%5!9@"<
M$FNRI5IJ35BJ$)03YCCOA7_R+U[_ -A2]_\ 1[UBZ\VE0_%Z%_$YMEM&TC;8
MM=X$(D$A\P?-\N[;M_"O1;6U@M(S':PQPHS,Y5%"@L3DGZD\U6UC1M-UF%(=
M7L+6]B1MRK<1*X4^HS24US-]QNF^1170\>\0R6J^-/#<FAMH,6BMI#KIW]JJ
MXM@V_P"?9CHVW;U[5+X:MA::+X*CCU"TOX#K\K126>[R44K)\B;@#@'->MZC
MHFEZE8I9:AIUI=6D8 2&:)71<=, CBI%TNP2&TB6SMUBM&#6Z", 0D @%1VX
M)Z>M7[962,_J[YF[_P!:?Y'+?"S_ (\?$7_8>OO_ $96?#I-G?\ QLU.\NH4
MEFL=+MF@W#(1F>0;L>HQP?>N_M;2WM%D6UACA$DC2N$4#<[')8^Y/>A;6!+N
M2Z6&,7,BA'E"C<RC. 3Z#)_.L_::MKJ:^R]V*?0^<O#]O<7FBZ=:S:EX8LK^
M+606>02?VA]I\TY!Z]>F<8QZ5VEK<>%K?7/&\?C<V?VMK]6Q=C<SVY5?*V=R
M.<?+7IC:!I#:N-5.EV1U(=+KR5\P?\"QFG7^A:5J%]!>7^FV=S=V_P#JII85
M9T^A(R*UE74F8QPSBNAXGXBADE\6>.K>^G\,01W"1 /JXD$BV_E (8B.P.>!
MSN'TK4TT:+9?$32O^$IN;*X>/PU;K!=3\0NV]\D%NY7IGGK7JVIZ!I&JW,%Q
MJ>EV5W/!S%)/ KLGT)%9^H>#M)U+7I]2U.WBO%FM([0VT\2O$%1V8, 1URWZ
M4*LFK,3P\D[KN>7VGV ?#R:Y"Q?V(GB97LFD4%$@,Z@D9Z+DM^!K<>?PV/B=
M/+KDFG'3I-)B_LEYBGV;9N;S=A/RY)V_AFO2Y]*L)],.G365M)IY39]F:,&/
M;Z;>F*K7GAS1;W3X+&\TJQGLH!B*"2!61![ CBE[5.]RO825K6Z'BMGI=AK&
MC>%; Q,^@W'B>Y-HCDX:V"2LH'?:<'\ZV/B0-/T7Q!J&J65QH%U)!9PPWFBZ
MC&OS1*?E$7H?FZ#CIQ7KO]GV>VU7[+!MM3N@ C&(C@CY?3@D<57U'0=)U.ZA
MN=1TRRNKB$[HY)H5=D/L2*/;^]=[!]7?+9;EVTE$]K#*$9!(BN%8<KD9P:*E
&HKG.H__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>nt10016217x4_ex10-7img03.jpg
<TEXT>
begin 644 nt10016217x4_ex10-7img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !" '(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHHH **
MXGQO\3?#OA"1K>^N6N+]1G[+;C<X]-QZ+^)KB=+^)GCCQ'>PR^'_  >1I7F
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M%<0VUY<KY9DE) "'[P!'0D<?C6#\&O 9\$Z!*M\(FU:Z?=.\9R HX50?3O\
M4US5HRJ25-?#U_R/;RRM0P5&>+DTZJTBNW][Y=#I/!GA?3O".AQ:9I4>$7YI
M)&^_*_=F/K_*MVBBNA)15D>/4J3JS=2;NWN%%%%,@**** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nt10016217x4_ex10-7img04.jpg
<TEXT>
begin 644 nt10016217x4_ex10-7img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !! ,D# 2(  A$! Q$!_\0
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M2[2WL[922(H(PB@GV%6ZQFU*5T;4XN,4F%%%%26%%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>nt10016217x4_ex10-13img01.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 8@!D P$1  (1 0,1 ?_$ (T   (# 0$! 0
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MO+$1JCU;>4LXQO+X.,<D6^,TW=U!JU7VW;OIU.'TA+B55IN4:>%/*FG+$QF
M2\I\GMX5"A,1(2[OD-V<+-KM;9HI:AW6JE5;033H.IU*URH3G9)]Q=FM1R*?
M;+/.AM)#TRRQO=$IIE(JO:JI"E =Z;J>6KBJ"^)RE;+EQ?*SRV,J>9BQ'GW(
M*SM6EY@>MA2@.X5XC4Y=<*R[[S;:[)A5AOTF&J3=\B;:5;K'%<"W%J= K1RE
M-J=U*T[]-(IJ9,"U29TB"P]/BB',<0%/10L.^VH_+O  5361VTIH)H$A]R[$
MV1)P-B _]+.=NY1%E$5]IU24A"Z>.T]==*<4D/R;/EF'\QX=/S.Y-Y8NYK7
MMT@CV5Q%J(!<2WV--_\ GYZN8F)P.2].<E,\C<G2L(E,QU1$L/7!M38<D.(#
M(VB,2%46D;CU_P"NK&,1D,'[<K?96>,V95HD*DRKDX[(N;KOQ)FTV+1M\ GI
M3S[ZY]2=1F_;-<+>SC]YQMT)8R"WW24Y<(:_2Z4K6 ES;Y"FW\-:ZA#Y_=!(
M9E6/'L=B+"K_ #[JPY!B)_Y2E.Y!7_I&Y0%=.F2KDF7%L7,_'UYOH"+4B*_$
M,YS_ (FY2N@4I7[55_STKM(<<ZX0+?!>N,QY#$",VIYZ0L^A+:1N)K^S7,?G
M/C>-*' _(UQ6"+=<7)SUO)Z!2$HHI03X5/376WV@<W S4./FT'^=DN.WZ5;V
M',+E2%AR/]*$FJ(]/0' .WEU'?5OMH/T\@5H::XD/IHJ: &Y0XS&<HM!3=7K
M3(L\A4J-)CH2M?N%( /J(IMI4'6JVP,C'^%K>SDL;)+]D$[*[K;0$PC/6@ML
M+KN"@E'S#N*ZLV008_@L>SYAD>2ID&0[D2F2ZRI*0&DLIV[ :^H*[FNI-M,#
MXX/QM"PVX7ERU2W#:KQ(^J3:E!(:BKZ[O9(]5%#IU\M2TY&5EW"-EOE_5DUJ
MN$S'<C6DAR?;E!(<)%"I:#W41T)!ZZL7QH)AG"UJL5]3DEWN4O),D2@(:N-P
M57VNFW\I [&AI4UII-@49K@V/YG8UV>^1BY&)WM.(]+K3@Z!;:J=#X:D3@+L
M_;NN2E%KN687F=C#.SV[,MQ.S:V:I0I0^6G;IK?.&#=L*MLK!9>'VY*;;!D0
MUP8X0C<EE*AM!"2?53OU/77/FUR!N]<,Q+GQ[9\9^L4Q=\>;:_1[ZVC:XT^U
M\^T&NU7BFNM1;7)@;8]'OT>U16+V^U*N32 B5+826VW5#IO""24U\1YZS*M3
M030*K[E;I>+;QFZ[;)#T3WI;#$Q]BH4([A(6"H=0#T'^6MTC4D/\9\<6N+=[
M5DG&^9+D64A(R.#(7[ZI%!0)+?I]I7?XA5/AJVM\PCG^XOCZS1<<O&<HE3T7
MD&.VVTW(4F.*K#8JT/\ 2?/3ISP!GQ)QA8\9B0[_  Y$]V?=+>Q]6W+D*=;!
M<2EU6Q"AZ3NUFULA/VJP6.XX/F5_NN23K==[?<IZ;?MGK:1^4HJ:;2R5>K>H
MT[?LUTSK 9&.9'?[U]M\F\75Y:[FJUS!]50MN*2UN0VNHIUVI^(=^^L3'] (
MXIX_L618M9+[<LUN46Z..$O6],]("EM/$(1L6=XW)2.FM6G$[ FY\/OYM@=L
ME761:+7/=DMW"1'D&-M;&RBE+J$BGFK4IM(->,\1QFR/SI5BR.5?T/I0R_\
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3!-!#H*T$T$T$T%C05XZ#UH/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>nt10016217x4_ex10-13img02.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 8@"6 P$1  (1 0,1 ?_$ +4   $$ P$
M       !!08' @,$" $!  ,! 0$               $#! (%!A   0(% @(#
M" L+"@<!     0(# !$$!082!R$Q05$387&Q(C(C%@B!T5)RLI.S%'05-I&A
MP4)B,X/#1547X8*2HG,D9"8G-]*C-%1U5B@X$0 " 0(#!@,'! ,!
M 0(1 P04!2$Q47$24D$R,V&!H<$30Q61T2(CL4)B<O_:  P# 0 "$0,1 #\
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MRR)]"9<NH1YV+N*Q94([WL_=GIX.V\1><Y;EM_9'H1L2)$?/,^D1F8@D( (
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= $ $ $ $ $ $ $ $ $ $ $ $ $ $ (8 3H@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>nt10016217x4_ex10-13img03.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ ) #( P$1  (1 0,1 ?_$ *D   $% 0$!
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M]>M]O!#I2\5@=2CB-L/UXJ4LR3]*6M;:_P!5*^K5;[Y6OS-2B/>/B)Q(DA'
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LD'5BE[>"<<#JAICT\$OP</W(5BL>G@DGA][+/KB)*H9IY*1.Z*'!795?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>nt10016217x4_ex10-13img04.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@"(P,6 P$1  (1 0,1 ?_$ .0   ,  P$! 0
M       %!@(#! <!" $!  ,! 0$               ,$!0(!!A   0,# @($
M!0<2#PH,! 0' @$#!  1!1(&(1,Q(A0'05$R%19A([1UE396<8'10E*3L],T
M5'24U#55M687D:%BLM(S4Z,DU9:F)S<(<H*2PD-S@X0E9;'!HN)CI$6E)G:V
M5_!$Y"C#Q.5&9_'C9(48Q1$!  (  @0'# D% 0$!      $"$0,A41($,9&Q
M4A,4!?!!87&AT3)RDK(S<X'!X?$BTE.S%4)BHD,T@B-C_]H # ,!  (1 Q$
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M; _ZW]"2@QSWW_VU]ER/83] ;)][X)X!E31%/$(S'D%/B(B6H'M 4$/A?OQ
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MCAIX+0:]N0.S[/AMP GO8]MN#%B6SD4B2,C)()-.M-BVHJ@)POUE\FR)06.
MW](E8:*<&$Q, #[,JCE&)+B-@R#K;SI@)(O-9-'.GH5"7@5T#L9WQEU<-).#
M1EI":%I])L<P<U@I&H>2JZ%TIT76]Z#$M\YU'D#S"!-*2"D@9["MJBF@ZDN*
M+ITF*IP\*)0;_33(*ZB)B$!@F%>%TYL:XEV?G\IU&R<1"%>J2@1CX44DH)7'
M]]>7F[EE8$-L!VF*,A25,DPJKV=J$ZJ>0@)?SB-^OPTKX;H@4$GO#EQ1F&_C
M&&V(C//)\LC'$+"0*YK4]&A&VB)PBZ.%NE:#$^\#,ZGA'",W:15%3R+ ZUNB
M  IH4M1<>&GP4&+W>//&2_%9Q##\IA1,HX9*-S%CFCFE[2O0)<NR>K?Q7H,#
M[RLJV:-.81@9!-NO!'\Y1^:3;6E%+19"TZW $E^5OQH%.V^^#=&5EQX^0V8Y
M@T>;<<<>GS.6 <IJ(YIN3 ]95EF.E;*BM%=-2$(!2.;UR_/?:8PS;ZBB)&()
MS%G7-3>H.*<%%MQ36U^A$Z52@<8G<+$O'-RIJL07'%5.1VAMVW&PW,;#=>FR
M4#4#!P!<;)# T0@,5NBHO%%14H);>7OBV)[>/?B/)T!W3_U6;-]H\;[#;H*J
M@X)NW\!.?Y\[&Q93]D'FO,-N'9.A-1"JT$-N/NR[M8^3PG)VCA0$WY'-!,=%
M030(3QBAHC?61"%%X^&@V[+[I>[%-G8)'MJ8B4\F.B(Y*D8^(X\Z7("[CIJW
M<C)>)+X5H*+'=W/=[C)K4_&[8Q,&<PNIB5&@QFG0545+@8 )#P6W!:"AH"@Y
MLDUDG83H8V0U%FJGK+[[)2&A6_RS0N,$2>HAI\6@7[>S$Z6Y,QV4::9R^-(!
MD(PJJRZVZ.II]I"ZXB=B327$2$DN2)J4->]OO OV7 ]FLT!L_P"H9_MID/9;
ME!Q=[']5F\O:/)>PW*"JH"@* H"@* H"@* H"@* H/.-L(H[FV4VO2SMS--*
MOC5J;B@5?CZ:#T>@29;WS8'_ %OZ$E!CGOO_ +:^RY'L)^@-D_>!/LN?[->H
M'M 4'GT7(P<=.A2YSX1HHY7-"3SBZ00B>/2BJOCM04GIWLW\,Q/GH_)H#T[V
M;^&8GST?DT!Z=[-_#,3YZ/R:"->GPY^]\-,A/#(BN;HLV^VMP+3M>8A67PV7
MA0>GT!0)]VS9T/!.O0748E$[&9;>44-!Y\AMI2TKP6PFM!MVSD)>0P,.7,T=
MK<"TA6D405P%4"(15244)1NB76WC6@3+F\NYO\<>$@1Q+0$RY&1M-1OJRC^L
MG5NO5$A1!%$Z5O?P!64!0(MS?5VW?;1/8DB@5;1W1@X.V,9#ER"9E1X[;;S1
M-.H0F*65%ZO@H&_IKMGZ\_>W?V% >FNV?KS][=_84$_O?/XK*XF#"QSIR919
MK!N(T#3JKH9S$1UPO)X(#8$1+X$2@?;/^H9_MID/9;E ]H)L=SY>9E<M Q.*
M"0.&DA#DOR)*,(3IQ&):<L1;>540)0HJK;C0=>V864C!D'<BTTP[-F');CLN
M*\( 3;86UJ#?%2 B7J^&@6]YI".VXA$J(*9S;ZJJ\$1$SD.@I%GP45$62TBD
MMA13'BMK\./B2@VMNM.(JMF)HG!5%47_ (*#*@* H"@*"%@?>W;GM_-_73J"
MZH)SO*ANS>[K=4)I11V3AY[+:E=!0G(K@I>R+PNM!$9/:6+QC>,RD#8^"PKX
MS8FG(048%\ ?<1LT'EQ6EZP.*BIJ2@]#V?[TL)]@1?H(T#>@* H"@* H"@1,
M>_F;[5Q/9$F@^['33M/&M]/):Y*+XT:)0O\ 'TT"+O&5$EPE7@@PYBJOB1'X
M:JM!7Y: WD,5-@.(BMS&'6#1>A4=!06_Z-!Q[1R)Y/:N'R#@$V[+A1WG6S1$
M(3-H2(21%5+B2V7C0-J H)&*XK?>9N9Q"$5# 84D(^ I:5EUN5O!XZ")G>CJ
M[DR67<>Q2RI$?D/._P"T7$,D U:$K(3/+-]\E+2*W$K=:@30F2@XK$A/FX-,
MH$9@I.0Y&1 W2OR#<!P&V5;U&T2(MD3HZJ):@ZFF]I;7@PXN5?PS6 AN,,,F
M+61=*S<A8P\M#1ZQB6H?VQ5%5U$2ITAAAL/M["-3,?&7$QW59<8<;0<H\)O1
MXR1HX&C@K=L$:; A15U(E^)%0=K#>,G*T+4W!H(HR(FXW.2SZ."TVG--6^+I
M(+8<4)2TVU*J)08Q\OC,<BLS,GB5QH2V8V4:::R1&AS'P;9!M;.74T:TZO)6
MR7L- P69$F20[%.Q"9A.7')P6I@IV9QML&1%00+$B$7J#PZ%NJ!Y[/@8&=N1
M,GMK)8.+#4Y OQWF,E<D"7";D*K3K!@2E'QI,*@H-U7I)2U(%<W(VMGQT3Y.
M,DL2^TP,B -Y/43#!.-S&&#46C_:Q<34BVU];BI(J!=8W#]V.<0(\&*W(%M'
M#;!!? 1L:$XHZM*(6IY+VXVLG0ED!@?=OLDY'/7&#S.4RQ9''4!&XYNFU8$/
M0B@4ERQ6OUNF@^.=VNR',B.2/&#VX!<%M]'7D4><;;AJ-CLA*3 +J3BEN'2M
M!V.[,VP\TK+L #9)]91-$1J"O$BB1J.JUS1>M\UX:#XWLK:X*TJ0!+D:N2AD
MX:"A:+HB&1);UD?_ (5:#ZYLO:[HDCL '-8H!D9&1$B+J342EJ54+K(JK>_'
MIH&T:,S%C-1F!T,, +;075;"":12ZW5>">&@F=Y>^+8GMX]^(\G0(^ZO9N#=
M[L=I/.=L)Q[#0'359\VVIR,!J@ISK"**O5$>J*<$1$1$H*GT)P'BE_;\WZ=0
M?4V5MSY:.ZZOC=DR753XBFX5J#!S8>TW2 G,>)DVJJVJN.JHJ0J*VZWA%52@
M&]A;0;:!E,6T;+0H+;3FIP104LEA-21+)0*=L[,VPOG5$@ "#D9 BC:FVEDT
MV2P**>&@:/["V\\WR]6092]]4?*9*.26\"&S( K>I>@Q;V-!CL*W"R>7CGQ5
MMTLE,ED!+\M_#7)(E_<FBCZE!BLO>6(7^%1@W!!0D3M$/1'F@*DB7..X2,NZ
M455(FW!7AU6U7A0:\=D(,[=T+(PE7E93$.$2F!-N$,62'+0@-!,5!93B*BIP
MO0=F]OO OV7 ]FLT$=CG-H1VLU)R.+GN$SDLFY(D-1IIMV&4XI$A-IH5+)X*
M!@[&V%-B&T[@<B_%DMJ+C90IY ;;@V5%11LJ$*T&Q8VPR6[FVYCI?-NXV6X7
M^$8$M!]3';*)+CM!\A7H58&F_P 8M))\=*#[YLV;\#W_ +2'Y- >;-F_ ]_[
M2'Y- >;-F_ ]_P"TA^30?%QFS;<-G/JO@3L0?\94&EEON^D08LJ)MGM+DN1*
MB##;CLH\#L!UQB2AZS /6W&2&Z$M_!=*#;YJVU\!)'SF%]T4!YJVU\!)'SF%
M]T4!YJVU\!)'SF%]T4'([M+N_><)U[NP9>=-;FZ[CL49DOC(B=4E7XM!CZ&]
MW/\ [5QO<O$_3* ]#>[G_P!JXWN7B?IE!UQHLQ[,X;+[:Q#,:!A(62PSN(?,
M82LD^]!<;Y8L!(:T"D,DLENE*"@P^?R,O,R\3.@-Q7XC#,DS9D=H&SYN" E=
MMK27K)+\2@^Y;WS8'_6_H24&.>^_^VOLN1["?H,(^SFHZ. SE<BVR;KKHL@\
M @"O.$Z:#I!%MJ->E5H-NRYSLW;41Q]]9,IA78DMY512*1$=..]JMPOS&BO0
M*XD.7-W3GX<W)RXYM.L2,<PP^H"L)V.V"%H4>'\);>%;>IX5H,H*YC&Y*9@\
M'&8D,11"8_*GRG4=-V<Z\9^0RYX6U7I\- PY^^?K+%_;<C[FH#G[Y^LL7]MR
M/N:@.?OGZRQ?VW(^YJ!7G<+O#,=A-UB%&D8V0LN%)CS'A<;=5AV,2]>(X"HK
M4@QL0KT^.@XVMO=Y2-BAY6Y(EE7MH+>WA^]J4&C(PM^8V.$N7DS*-SX[+O*E
MMJ:"^^#*D*%CQ15'F7XK0.<U@HT3&/3<OGLB[CH.F6^V:QM)=F-'A2P,"2]8
M$X(MUZ*!GLZ)-B[7QC,]M&9_9P.8PBZD;><36X"%8;H)DJ7M0(Y>*:=WO(CN
MRI&/?EMA/QDJ.0(KA@WV64UZX#@KH 6BM:_6X="T'S,XK+,Y3'XW&Y.63LQN
M0Z;LF2>D1C\M+(@#TES:#YZ+[V_"_P#UA_\ 8T WM3=B3(LIZ<U**&XKS#;[
M\@@1S03>I11$OU7%H'?_ (V_W;^_T!_XV_W;^_T!_P"-O]V_O]!IFR=ZQ8;\
ME1QI(PV;JBG/2^@5*WZ5!R)B\7&PSN=DY.5B8;C1Y*<@25&.RK@\Y\[D/ ;J
MJT#/9R9+T:@GDC>.6\)/DDG2KX \9.-M.:41-3;9""_$H-6 1$S^YK):\R.J
M^JO86$O^E0/J#5*B1)D<XTMEN1'<MS&710P*RW2XDBHO%*"2W)M/:HS=OH.&
M@BAY)!)$C,I=.RR%LO5]2@VP(<[;^5RXXS;ZNX^<^T^PL,XC#::8[;1(H&XT
MJ+J;7P4'5*W7DX0-O3=OS&8QOL,&]SH9H':'@90U$7U)1%7$4K(JVZ$5>%!1
MT'G63WCN],_F8.-9*6D/)#CX4*)&CN/*"8R).<===ESH+7ERU&R<>CATK0=0
MSN](A1>QJ-TOI*/#NGJ+;(JE_B+0?4E]YJ\'(SB#XVF8(E?XIS7$_2H-+PR(
M&UR8RNW9\N-CU?R#D@9,1EU#4G'C,%9D 0KZX2<%Z.% Q<P\#'Y[;C\ Y3:2
MGWA=!R7)=$@6&\:(0..&*V)$7HZ:"JF1@E1'XKBJC;[9-&J=-C%16U_BT$_N
MB.S&Q.(B+<X[,V&*WLI$+"ZTOPMQ5M+T"+'8C#R<;$F1]ALK%DLMNL T<34@
M&*$%Q,FQ3JKX%H.CS%C/@#_RH'TZ@/,6,^ /_*@?3J#IP> VADSFLO;89@28
M#PLO,O P:JIM Z)"31.#;2XGAH.)[$YZ-MS+[;A85Q69;LP8<EM^.+(LR72)
MOJDXC@H(G940?B4&_<&(VEB7XD:-L]<Q,F(Z3<:"$("$&=.LR*8_$"UW!3@2
MKZE!P(VP*6#NUS38^ &Y.' 4^((Y5$2@U3),2'$?F2>[K.-QXS9//'VK%+I
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M(BH&C;^&S<2?.GYB='FR98,LB46.<84".3JBI ;TCK*CO&Q6X="=% \H"@*
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MFYI[F.&:.]J[&HN FFUGE0=8:A\-]'KE!VN;YSG);5D<69FCSA*4I!0605M
M.VI=5]1\-7@&ZC?@# <IW@.*#C.-A'&-$-#%[4I(2(J:;D*<?"ORO2FOHH,'
M\GWE)(B"QAH:M'-%N61/\ A+'?)74)"1>8+XLBHH"\%6U_* -Z3N\+M0AYM@
M]FUHA.J\0D@:NM84U\;>3X_#IO80V[/G;XE0XQ[HQT:!).*T<D(YZM$I0%76
MT1#>32A*5EUK\?I4**@E=Y>^+8GMX]^(\G0'=/\ U6;-]H\;[#;H*J@* H"@
M1;8X3-P#\J.4+2G@35&8);?%(E6@>T!0%!YKLYQ)&4[OIK2*45_:N1-IVRHB
MH^]B76T6_0I BJB+QX+XJ"MWM]X%^RX'LUF@ELT!KLJ6Z($81=T1I;^A%)18
MB[A9?>/2-U70TV1+;Q4'H462Q*C-28YHXP^ N,N)T$!IJ%4^*BT&R@* H"@*
M H$6.WOMW(YAS$1'9!RVS?:YA0Y;<8G(AJT^#<LVAC.$V:*)"#BJBHOB6@>T
M!0% 4!0% @D[ZVW$R#\*6\[&6,YR7Y;T=\(8.:0/24M0[.*Z7!X$:7\'0M _
M145$5%NB\45* H$6>^_^VOLN1["?H'M!SY#'PLC#>A361D17Q4'6C2Z*B_\
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M$UMQD?1N*9GD#CHO,:%'$T*JHI6\"4'JHX+"H*(L",JHG%>2WQ_Y-!W4!0%
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M"1DL:,-IM513!N9CPFJA6XV4H()XKV\-J#T:@* H/+\5@)[O>9WCQ"-H&LC
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MIH<06F2U(XCFBYG9%3CX*!SA=GPEA1SW%B\3*S$;GLMRXT0!'L_-5&=*."I
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M0% 4!00V935$WJVODNR(S9_W+D6,!?I+0/L3[YL]_JGT):#@[R_>[#]O-O\
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M:J@+E\2XJC:]V,BP^/3?@I-)?U*#5W=/./8&:ZZ6IQ<UG 4OU+68E- G#Q
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M30/P\;',4-',KCS02XC=B2$A%7XBM73U;4&>)]\V>_U3Z$M!CO#ZA@>VF/\
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M$^.>5?[1].OR\OW(6U2J H$FZ/\ LCVRC_XU ;*][,/_ $GT4Z!W0% 4!0%
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MOQ%H.P\SNN)/Q;61A0 C3Y/9G#CR7G#!59<=140V&D7BU;IH*%XU;9-Q$U*
MJ2#X[)>U!Y[N&;N;/=WQ2WAQT>'EHS#@ VXZZ:#(T$&DU%L27K>*H-XC\$M/
ML:V&]4G5,\DNW$>_)O\ S^8_71*G9BXH$F)7_P 39[_5/H2T#N@* H"@*"5[
MM/>[,]O-P?CR;0=N.]^6;^Q,?^NDT#V@* H$6R?O GV7/]FO4!@?O_N7[+C^
MPF*![0(M]^\W,_8COZU:#S@+0(F$2(');@ $%QTAL@!MO,M,$VJ=4NM%>D:%
M1+615Z+7#V2@\\Q2,XO-8R,T"JB;@S$-U12Z-^<6G\O<UNFD2+3;IXJ*?$#J
MW+MQK$"QF(TJ6X#.9BR^P\T!CM]MEBS*<01$"5-,EQQ4(E]3Q4%S0%!*XW^M
M/</M'A/9F6H*J@* H"@* H"@* H"@* H"@* H"@E=Y>^+8GMX]^(\G0'=/\
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M7&<9N!]HM+S&T\TZT:=(FV+1@7QB1%H/1: H)_?.E<-&;*]G<IB@X>V4=?\
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MK2RQ+!ML"8)LP013J*G!*#GV=L'!2X,\G967%6LID6!Y.;R["*+4QP14D:E
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M>- [\^83\(1OGS?R: \^83\(1OGS?R: \^83\(1OGS?R: \^83\(1OGS?R:
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ME%!ITN830%T^2+P.CY"JHVN$Y@-Y8L,7D!R.\8S,!Z=.?5O"QS<E.B<IUPG
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MR9(K+PX\41:!)W(,S'=N[<F%@WL7$;VWCHZ3'EAZ99\H"YK:1WGG-*CUO71
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M$<-UY1<F0LE(=QJJ0FJ(*,PG!7AQX?$4+S9FZMJ1H,R$>8B,K'F/JVP_*!'
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M^CW;;>%4))F<NG%+Y_-JGZ"S%1?CT'9Z'P?K_*>Z$OZ90<+ Q\)NZ-$+(O\
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MK5;6XT#^)C,K,BLS(>ZY$F));%Z/(9:@&VXV:(0&!BRHD)"MT5.F@V^8<_\
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M2CS,=9 CVA$)4%=/1T4%)W<??/-?&]GSZ!_EO?-@?];^A)0&)]\V>_U3Z$M
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M5OI5 J^Z?^JS9OM'C?8;=!4FVVXFDQ0D14)$)+I<5NB\?$M  VVV" V* "=
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MT*]^:^*JOS"WU4%#AL#B\.P;4%G03I<R2^9$X\\Y:W,>=-2-PK>$E]3HH&%
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M74&F;"ASX;T*:R$B)(!6WV'$0@,"2RB2+0>=KW12H^>>RL3)M2.8VK+23&I
MR0;NA")2X<F*3UNC4^!G:W7Z;@VQ/=V[$-YPYX0ED%JDCAXXPS?1$TCVB4Z4
MJ6X2"B=871H'V*VIMW%2"E0H+8SC% <GN:GI1B-]*'(=4WC1-2^42]- VH.?
M(9&!CH;DR?(;BQ&4U.OND@ *>JJT$'NC?Y-Q!???<V_B'ELPX8)YVFHJH/\
M!8KB>L I$B<UY+I\R/ J!1M*.YD7XL'.8J1@-OY1"<QF.<<-7<@ZVFM5RCSE
MI3CQLIKY3MM5C0]:"BJ'K###+#(,,-BTRT* VT"((B*)9$$4X(B4')FL-C\S
MC7<=/!3CNZ21151,'&R0VW6S3B#C9BA@2<1)$5*!9M[-RTG.[=S1?[:B CK,
MBVD)L6^E)+=NKJ%>J\">05E\DP50H: H"@* H"@* H"@*"5QO]:>X?:/">S,
MM055!X?_ &C=N]Y6[%PF+VMM<\A%Q,]K*.Y$YD)AMPV@41: '7A<^7741"GJ
M7H/7<!D,IDL8+V6Q#N'EDB(]"?=8D<5%%+2;!N"0W6W&WQ*#R+ =W^_.Z[?N
M2D;.Q:9[N_SSG/D85E^/'DP7[+UF4DN,M$*>2B:DN-D7R;J'=_:.PO>!NW:"
M[4VMMEW(),-B1)R)RH3#;2-&I\I =?!PCN(W6VFR\%5:"[VCEMREM(',QMJ3
MC<M!8%M<6DB$^3YMM)^T.MO<JQ%U4YI!ZMDXT'C_ '>8[OIVUWC[OW+.V"[)
MQ^ZI O<MG(XT7F :-Q6DTE(T&NARQ=9./10>L.[C[P)T=6\9M,\9+)4%)&9E
MQ.2VBVNYH@.S#<M\S<+^-*#HV-L=K;+,Z3(EED]P9EY)6;R[@H!/O(* (@"*
MO+::%-+8772GA5:"%[P.YO<'IVQWD=WDYG'[I;00R./E:AASFT322.*"*J$0
M61;I9;"O5)-5!30=^[Z[.@9/N[RK<].J8PY>+?CJ7C%UR5'+2OJA0),WW<;F
M[P]P8C*[P-,%A<!(&7B\#"=&1)=D"0DCTN0HJT*6#2C;8KP5>O04/?!&W'D-
MB93"8#$/969F8[L%59=BM(P#P*).'VEYA"X+P055;^*@D.[N?WJ;0V-B]MN=
MWDN:]BV>0,@<EBFA<341745DN*/2B>&@;[2+OEW%NQG*;MQ[6T=O8K6<;"1I
M34MZ:^XV3:%)?9(AY3:&I(-AZUKHMJ#TV@E=Y>^+8GMX]^(\G0'=/_59LWVC
MQOL-N@JJ H"@* H"@*#S/(15FSM[9"3*ED_B<K$B8YL9<D([+7F_'R;#'!P6
M%579#A*2AJ6]KV1*!!O:"_.+=,8,>&08+=C)21.%&R)-"&UXQM&#,IMYM-4@
M6VB+3J0#*RITH%1W/8*'BX>16+B QHOK&4GO-\?'N/$+-W$48[3*&VVZ1Z+H
MMKKQH/0Z#AR>"Q.45HI\<7R8U<DE4A(==M5E%47CI2]!PKL?:9?MF-:>MT(]
MJ=1/B:U*U!\]!-F_@:)\Z'Y% TQV,QV,B#$Q\9N)%%2(6610!0C)2);)X2)5
M5:#IH$SVR]IORBE2,3&D/DXKZD\VCJ(Z2ZE<03U")*7&Z)TT#D1$1011$%$L
MB)P1$2@*#DRF'Q.6C=ERD-F=&0Q<1F0V+HH8+J T0D6Q"O%%Z4H%OH)LW\#1
M/G0_(H.G';6VWC97:X&,C1I2"K:/MMB)H!*BD*%:Z(NE+T'?*BQI<9V+*:!^
M,^!-OL."A@8&EB$A7@J*G2E G]!-F_@:)\Z'Y%!NA[0VM"E-RXN*BLRF5567
MA:%#!511516UQ722I=/ M WH(*/C.Y]HG,WC,#A_.#2F^Q*;Q[++KAW%.8V]
MR=2B1/#=T;C9;WM0;9^Z)^>V^U.PG;,<@.LG*!&@=D%'D,<QL@1D9MDNX*^0
MI<%14%+T''@<#WC.9K&Y*?.<8AM$;TJ(_*)U521K<)A6FFVVC1KGJV!%91Y8
MKQNJ4'HE BR/ORPGV)D/UT:@>T&F=,CP84B;)+1'BMF\\:] @V*D2\?$B4"?
M94"3&P82YPZ<KE3+(9)%MJ%Z18D9510;HPWH9%>G2"7XT#Z@*"<R&>RLS*.8
M;;C;1/Q20<IE)**4>(I ABV+8*)/OJA"NC4(B*W(KV$@X,CBMO8PXSNX)T_-
M9)\T2-&<<=<YQ@J%ZWCXNB.J ME4N5U4\HJ#JESMK[BD-X?)-R(60!>=";?Y
MT&1?2HJY%>!04E%%5"Y9W3Y;@M 1,GE<#DX^)S;JS<=-)6\7FR01-'>&B+,0
M;#S"2_+=%$$[:21#TZPJ* H.3+,8V3C),;)HVN/D-DU)%Y40%;--)(2KPXHM
M!"%N,9FQ<?)&4&2=Q^?QN+=F-F#@OJ&88A\[6WU%(P-'"1.@KC07^0 3@20)
M+B31H2>-%%:".V.U_MIN81J3LO;.$!R__0.3"1?BDLA;T#W:_P#VO[92/\6@
M=T!0% 4 JHB77@B=*T$IF.\" Q&D.XH6YS49"65E'GAC8N/INA*]-.X+I4;$
M+2&2?+(E CQCV\<QD?.<%.T/BVXQ'RTY@X>-C@X2Z^R0;I,EEJ:"YNFV!#UF
MSZ4H*G%;1C1IP93(RY&8S :N5,EDFAG5J14C1VT!EGJN*&H1UD/ R*@:Y3)1
M<9CI.0EJ21HC9/.Z14RT@EU013B2KX$3IH/.<[MW>>6VYEAEQ8>.BSLC%S)-
ME(<=DM-078TCE&(-<KF$D.RZ7%%%+I*W$*;9J(LV:2^5V3'#?]2D=51/B7)5
MH*F@* H"@*"=S&\&F'GX&(9')9*/?M5W$:B1$0=2E,DJA"U9..A$)RW'3;C0
M>?YC)Y^4]C)^/ <M,G3&HL+<<\.3B89NB2ZH$4E(EU(&@))Z[F8H*F*Z4"OV
MKW:XK"R2S67DGF]Q'8W\M,XZ"%%_:0551L1UE9;JJ(NE%0;"@89J=(WC&3'[
M<;188N@[Z3.71AAQI=;;L%$XRG!,4Z%1JU[D7$%"V2]DNMU\*T!0*MQ8/SK$
M!6'NR9.(7.QL\1U$R\B6NH\-39)U7 OUANGJT&.W<Z638=9EL]CR\(D:R4'5
MJY9KY)@7#6TXB:FSMQ3IL2*B WH"@* H"@* H"@*"5QO]:>X?:/">S,M055!
M%YQ[OF'+R$P,3;CN'N/9#G29S4E4TIJY@M,.-IUKVLO1:@XNT?V@/K#:?V[D
MON6@%D?V@;<(&T[_ &9DON6@PY_]H;ZRVC]MY+[FH#G_ -H;ZRVC]MY+[FH,
MDD?V@K<8&TU7QI,R2?\ Y6@^]H_M ?6&T_MW)?<M!NC/=^I$O:8FUVAMU5;D
MY!Q57U4)ANU!OU]\_P"Y;<^>3OV% :^^?]RVY\\G?L* U]\W[EMSYY._84!K
M[YOW+;GSR=^PH.5Y_O[1PD9A;5-OY4CEY$"7XHI&.WZ-!T8E_OJ+)QDR\/;;
M>,4T[6<25/-]&_#RQ<C@"E_=$E!;4$KO+WQ;$]O'OQ'DZ [I_P"JS9OM'C?8
M;=!54!0% 4!0% 4'G1>1WC^WD3\48J@7Y9F&\]O096 QVXFTW-&5(65%TV +
MT?@>NBC,/)%K3R4];1+*O63H4'W==$AQXN46+"@8@') J6$Q8NA'C*C0I>ST
M>"6IU.LJ\D4^+TT#3<6[D@/NP<>#3TUAM'Y\B2YR(<%A454>E/*BVO9=+8]8
MOU(]9 E'LAELCC<PZYGLJ,F/BW9;!,1&L;",@ QYD<'1<FVUHBIK=5%2VE5X
MW"NB[:(XK)EE\DI$ JJ]H\*HB_,T&WT7_P![Y+[8_P";09[-E296U,3)E.D_
M(=BM$Z\=M1DHI<EM;BM XH"@TR9L.*@E)?;80N JX8@BJGBU*E!H\^83\(1O
MGS?R:#)K+XEUP6VIL=QPUL("Z!$J^)$1:#KH"@* H"@@\+M_<S6X7'I2.F,2
M<X\Q/><N#L4]8(UUGI#BJC;M[(VT"$*63PT'5%[J]L@KXR1)^,[U6XC2##9%
MNS@\L@AHPC@J#J@2.7111.%!5PX$&$V;<..U&;<,G7 9 00G#XD9(*)<B\*T
M$9EYD8]V38<M[*..:&NQQ,<\^"((MH3I*+1@/2X/%:#K[N)Q2(^6:;DR).+9
ME,EACF../2!B/P(SVEUUY2=,D?-WRR5;6XT#+(^_+"?8F0_71J![03O> ?\
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M6,1"V7.(71< KH6NZKP74&K9O]G+$81<F.:R(;G8R3N)?Y.1A-$#1XMIQI1
M%(VT;,7B!H$%.4W8.M:]!FSW!R&M\YC=H[D-).4QT& #8Q;&R[ 6$0R$<YW6
M4BQ]].E+:NE;<0Y-Y_V<G-S9#,3G-TOMN9C"0\*3;\?M ,+#E19*NL(KS>EM
MQ8?%KYLR/4M]- ISW]FF;EMH,;6F[S9;;C.P7&##'DB(,&(<,;MG-/KN"8J1
M(2)=. \:#T'!]W.<Q>4R4STA;FPLED94M<6_ ;2*W#FNHZ[' 6G&B-TKE=YP
MB156_+\K6&F%W7OQ )&=QNQVC@1( Q(D>/'BM.P7&GFWXX!ZZ)<\7S43=/\
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M-DE$HCXZ4U)IX>!+4#^'LS&C*9GY5QS-91@N8Q+G:31D[*FJ.P*"RRMB4=0
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M&US(,SW@F*V(<RV0KZJ8+&K0,]B168FR-O16!TL1\9#::&ZK8 C@(I=>/0E
M\H(;<B(LW<J^$8V),5\1!)>(5^,J7H+F@\ZVP1M[FV>P)%RAP&:;4;\"[/.Q
MC;:DB<%5!)>/JKXZ!EC\IG69>7Q^*P[K\E<B\2S)=XL(!- 5"YA"3CW!>')
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M9URMUKA$0[ZX="@*"5WE[XMB>WCWXCR= =T_]5FS?:/&^PVZ"JH"@* H"@*
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M_P ;?[M_?Z#0N8S\'+XJ'E!A*QE7G(S1,*ZAHZW'=DHB(? K@P7#X_@H&4[
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M8]CCA2,9E!8%$UO,-/JH3!'4-^4@VZ+J75H+:!/AY"$Q.A.B_$E-B]'>#R3
MTU"2?%1:#S\VLCC3\PQ9(PH,'+LLM.\MI]WS=D62)@!YP$(:)I\L>"^MCXUX
M PPN%S4Q[*-O9UZ\*:48%&) 3J<IMT?\ATV<XT#0=K9020ASSZ$BW14BP$5%
M3_04&[S#G_A++^UX7TB@D9<?>!;@<B#O')LLKDV8" S'Q-A;/']J4DYD%TM6
MM/"JI;P4%#Z&[B^'><^<X/\ BR@X<QA=S8>*UD WGEY?*E1!.+(9P_*<!V4V
MT8'RL>TY91-?)-%]6@N*#3-^HW_\V?ZU:!=L_P!Z6$^P(OT$:!O0%!IF_4;_
M /FS_6K00G<[]2;@^S<?_P"G<50>@T$IN#N_;R^=/,M9F=C9+D5F&ZU':QS[
M1!'<><;+3.B3%$KR315!4NEK]%!'3=K99C=#>*#<\Y8YNQ&U-8."UHDAJ6X=
ME3&HET6*-N'A7U+!:8788X[(QYTC,SLF<53*,U):QS+8$X"MD5H,2(1*HE\L
MJT'3O]MMS9&<:<%#;<A/@X!)<2$@5"$D7I146RI01+.0P^'[V4?FO,P6#8S;
M8N&HMBI?[")!O\1%H+CT[V;^&8GST?DT!Z=[-_#,3YZ/R:#XN_-EHBJ6:AHB
M<557A1$3U5O03.%[T>[-O-[@<<W=A0;>E,$R99&(@F*0V15157.*(0JG#PT#
M+<F[,%E=K*6&=@9_&Y22.)DRPD ]!8[0BBIR#9(ETHI".D>.HAXBBJ2 KQS,
M.#D$@02+>>]8K21,AEI9 C4$' 0E%XA10CB>D5Y+0JX?!2NG70-VP\(]@]Z9
M;%.R>UE%P.%$7$!&P$%G9<@:;"Y*+;0JC;:*1+I1+DJ\:#T"@*#QW^T>UCO-
MN!D3I-F@E.M+ %5UN"ZUQ?%$,?VA13Y5>)IT7L6EV=CC;#5W<:KO6&$8OS[.
MG.S'[-B++96%&1(A;X+U4]<,_)2R74O!=>-UK7K7"%"UL7Z![BY$K%=V&;F1
MHPRI$6;(?"*KO+1Q0BL%I1W20]9$X$B*/JUD;]$6S:Q,X1A'+*[D3-<N9B,9
M4\KO1.-W?%NEW%*D\'G([N'Y_$'67#1P2>5M/):;)S@'J)XZBKND3F[&.C7@
M6WJ8RMO9TZL?K:<SWH93%GF&G,1#>=PL4);XM99@R+]K1T.2+:R T*[9"-I$
M6W@N-_<O=(MLZ9_%.'HS]WE<YF]S7:C",:QCZ4?3X?(HX6]]NR\KEH 38XIA
MP$Y;Q.B@IP)7;ZK)I:04UE>R7XVM5>V1>(B</268SJS,QCZ+&#WA['FXIK*L
MYR&$!XR:;>D.C']<#R@47^62$B66RIT*B]"I7MMUS(ML[,X\?(XKO65:NU%H
MPXN5S9;?D=-H/;FVPW'W#&C(AOM!)1A1;TH9\5!S2X D)$V:"5O5LB]4W:>D
MV+XU^CNXWE]YQR]O+PO].'=XB@.]8H&?Q6)W1 BX9O+PEFL3$R#;P,KI4D;D
MH;<?EWTJ*$BD*EP%2XZ9>I;5)M29MLSAZ/)PH>N[-XKF1%=J,?2Y>!2COO9*
MQ&I?G_'#&>(@:=*4R(D0()&/6).L*."I#TI=+]-5^K9F.&S;'Q+/6<O#':KA
MXX+<3WCXB7D<RW*>A1,3C>RE%S/;6CCR0E<U$5"5 $"$V"!1U+UK^+C)?=;1
M%<,9M..C#3&'WHZ;U69MCA%8PTXZ)Q^Y51Y$>3':D1W0>CO +C+S9(8&!I<2
M$DNBHJ+=%2JTQ,3A*S$Q,8PV5X]%!*[R]\6Q/;Q[\1Y.@.Z?^JS9OM'C?8;=
M!54!0% 4!0% 4$-/3E[*W6(JOK,J<XVOA0E/G7^,9<*!YMGZNW%[:+[$CT#V
M@0Y?:B29I9'&S"QN0='1+L O1I8(*B(RHYV0]-^! 0'X-6GA0*<-LO*X62Y(
MQ,?;V/>?1>TO0\6Y&)PB5%(B1N1\LHW6ZJO1QH.]S;.7RLUH]R36)6-C:7&<
M7$9<89<>157F25-UY7A'AH;X"B\2U+IT@X\QX3\'QOG+?R* \QX3\'QOG+?R
M* \QX3\'QOG+?R*#!W;N >:-IW&Q3:<%0,%9;5%$DLJ+P\- I@8'=.(8[!C,
MI'>QK2JD,<@P\_(:;\#2O"^WS!#H%235;@JKTJ'=@,3DX3^2E9&0S(DY!\'K
M1VC: !;8;90;&;JJOK=[WH'% 4!0% 4!0% 4"+=&!R&4D827 E-1I6%GE.#G
MM$\VYKA28:@J ;2IPEZKW\%!S/;8S>6U-;DRK<C&J76Q<".41EX+)U)1F[(=
M=&][B) ))U2$DZ0I0   0 4$!1!$12R(B<$1$2@URXD69%=B2V@?BO@3;[#@
MH0&!)8A(5X*BI0(&L!N?&HVQALRV>/;542-E([DMT M80;D@]'.PKX74<)>B
M]!M<C;^)LA;R&*;<5%0'"A2#05\:@DH-5O%J3XM!T87;H8^3(R$J2YD,M+00
MD37D$;-@JJ#++8V%IL=2\$XKTDI+QH-6]I[L/:^06.*.3I+:P\>T5['*E>LL
M"NE"5!5PTU+9;#=?!0-X<88L1B,*ZA8;%L57I5 %!_XJ!1LI/_#D<O"Z[)=7
MU%=DN&J?&U4#R@* H/.=QB18K+Z45=.[L$2VXV$<ABR)?B(B76@]&H)TSST[
M/9&+%R(PHT(6$ $8!U25T%(E4B6@7YS".X_#39,B<[/E39N-5UUT6@LC<MD1
M$1: $M\6@LJ!=FL!C,PTT,QM4>CDKD26T1-2&#5+:V705#!53@MELJ<%NE H
MD;?WD$5(\3<+$P;:2/,X]N22\%1"_@;F/"]^*]3CT<+W0(_.Y3"1=PM8S+3O
M/3T9Y'769H@U C.M<AWDQ8,9OF2Y?KS3C8'K(=:$A)P10]59<%UH'!110A1=
M))I)+I>Q"O0OJ4$[F=YLLN28>(!N;,B?5\EUQ&H,(434I2Y"W1%0>/+&Y]%T
M$>M03N+Q.8ST],FS(<4U%6UW+*:T*@\;IAX#FL&!+4OK[J*1);]L&RH%QA\'
MC,/')F SHYI<R0\2JX\\XJ(BN/.FI&X:HGE$JT"[>\9LL0W/1-,S&26)4-]$
M34!"Z(F*+\RXV1-GXQ):#[L]L(X9> VEF(>3D"R-[H@OH,I13Q(A2%1$\"4$
M7ODS]+<JWJ7EH6Q30+\-1;FD(I6\:H I?U$H+;;/U=N+VT7V)'H'M 4$+)]]
MI^W\;\3K075 MW%BW\IB7(<=X6'U<9=:=<!7 0F'@>34*$"JBJW;IH.%X-\M
M,N.=LQBZ!4K=ED<;)?ZYH)W<&Y-VRL7"=Q4F% "1BV9T[GQ7))DL@P#0P22&
M!;TH:\3 _B4%SC(#6/QL2 T1$U$9;8;([:E%H4!%6R(E[)0=- 4&F;]1O_YL
M_P!:M!"=SOU)N#[-Q_\ Z=Q5!Z#0%!"Y7^L!C[(QWL;(T%U0(M]^\W,_8COZ
MU:"*'&M9#O:%EUY]D19SAH49YR.:JGF)+*32B2IQZ*"U]#X/U_E/="7],H#T
M/@_7^4]T)?TR@/0^#]?Y3W0E_3* ]#X/U_E/="7],H$FS<- *9O[$R1.9"=S
M(-/!*,GR<!S"8W4)FXI$7E6XKT4'5EL(UMM8V=P$466(#?)R\!AM5*3 34:J
M CQ)Y@R5T%XJ2*8])W0/F$DQY7>5G)49P7H[^ P3C+H*A"8'*RRB0JG2BHM!
M7T!0>8]^>Q]S;JQN+;P<9J241UTGP-Y6G$UH*"H(1 R2=5=6KK)PT])5>W'/
MIES.TK;QEVM$8/(&.Y+O" C)_%.F#;B O(>90S#KHI-H9(ENJGE67BG5\6C.
M_9?>E6C=[]^'JW=I@]TX#NSSL:=AWW,L_)D'&QZN-\QU'F&FQ7F&>E!U7U+>
M]D6R*O!:&\7I?-KA/X=:>D6KESHQG4X)&W-W2,5FW#PDA&LA%!Z+B%)A3'(2
M6Q8DF1:A'2B1B6][J+GDWNB21F9<6K^+@GAT\$:8Y?(AFEYK;&O#'!HX>">3
MRN_<,3/Y&7NEYC;,^V:QD6/'U]F12<:4M8.)SETV1SU;V7]3?C+FM8I^*/PV
MG7YG69%IFWX)_%6-7G\)-O.-O;/9#<>'QV G)$R)P,D;KPM,@3;$>.)14)T7
M&'7$<74J(XEE!;*7DU/D3ETBMIM&,8QY9TZXXN^KY_27FU8K.$X3WM4:-.,3
MQ\;',;=SV>W%,W,6W<BN*EY#%/KB)3,+F/-P@)M\G&7'-2*@HH"A%UD<\7DJ
M9M:5BFU&,1;3&UW^#N\#V^5:]IOLSA,UT3L][Z?H^E0EB\Q)V9O7'>CTZ/)R
MLR1*BQT-AHGEEVTW-E]4ZBM^NW*RCPZUU2H(O6,RD[4:(\.C#Z.)/-)G+O&Q
M,8^*,<?%/']:?[PNZW&N[-A93&8"8YG'G(C>5<5R5-G,1T'0X3;!R-+I@HB"
M#Q33T61-0V-TWRT9DUM:-G3AP1&/CP5=\W*LTBU:SM:,>&9B./2U0\/DLDQ)
MPDW:65=Q<G.MYF9)G"T!DQ*8 "4M!-^O$*F3B-<6RZO!>"+7BN%HO7&*[.C'
MO3R>/A=5IMXUFEL)MCIP[\<NO#@,I^RLAB<M.C8+ /R=OQ.QG'Q#W(>A3&P<
M<[2V1/NFXIBLE7&M:6117AY%1USXM$3:V%YQTZ<8U<$>#"?O26R)K,UK7&D8
M:-&$Z=/#/AQC[GK\1\I$5E\F7(Y.@)E'>04<;4DNH'I4AU#T+953U:R[1A.#
M2B<8Q;:\>B@E=Y>^+8GMX]^(\G0'=/\ U6;-]H\;[#;H*J@* H"@* H"@@LL
M&=\U;APT?!S)+V2D/]FDME%%C0^@HCA$Z^V2"/%2ZM^'!%6U TV<1+N'?(JJ
MJ(9QE 3P(BX7&DJ)XNL2K05- KRVY,9C'VHCBN2,@^*FQCXH$](,45$4] ^2
M"*ME,["GCH.%C<NX7@ UVGD&$)%50>?QR&-ELB$C<IT>/3P)?T:#8SNMQN>Q
M#RN*EXKM9"U$E/*PZPX\6I4:UL..JV?5X<Q!0KH@JI<*!]03K6]L>]FHN.9C
M/G&ER'84?*>MC%.4PTX\XRW<T=-1%ARY"&FXJE^"V"BH"@3Y;/OPLG'QT7&O
MY"3(9=D+R38;$ :, 74KSC?%5=2UJ#+#YUV?,F0I$!['RH8M.&V\3)Z@?UZ%
M$F3<3_)%>] VH"@* H"@*"7V;OV)N6+"=*#(Q;V1AM9+'LRE;7M$1UL'.:T3
M1FBZ.<(F)6(5\%E15"CF2XL.(],ENBQ%CMDZ^\:V$&P12(B5>A$1+T$JUOK(
MOY!N,S@'V6GV%E1G)K[$5QQL30-7))2,?*1;'8DOUA1:#M;WDVR^VSF8$C$@
M^8M1IKJM.Q'#-=(BC[!N("D75'FH%UX)=:"BH!51$556R)Q55H)L-ZC,.^$Q
M4S+PT15+),\AF)P1%ZCLEUE7D*_ FA(."]:@W>?\_:Z;:EKXK2(/T^@Z,'N:
M%EG'HO)?@9.*(%+QDP$;D-(XEQ+JD;;@+Q3F-&8:D5-5T5*#DRHK,WCA(:BI
M,P6I62<+CI1T4&*RBIX;C)=5/[GXE!0T$SCL/O'&Q!A1I^.*.T1\I7(KZGI(
MU)-2C(1+IJ\5 PVUE9F0A/I/!MO(PI+T28VS?1J;.[9BA*JHCK)-N(BKPU4#
M:@F,5F-U9B,61@,PF<:\ZXD#M"N*ZXPV:@#RJVI#I>0>8'ZE4OQO0:I&W,X6
M#R@*L=[)SL@QD!; C;9]9..NC62&27&/TV\-!W^<=Y?@2)[H%]S4!MR)GAG9
M6?F(T:(Y,<:2.Q%D'*]:9#2A.&;,;297XBB$B?-+0:=UH&1FXG !UG'I3&1E
M654T1\<\$A"54^:D T%O"BKX$6@HZ#CRN6AXR([(D*I*VVXZ$=M-3SO*%3(6
MF_*,K)P%*#R?*]YA;B0X\68U';BMLY/LV(GB],D0U)2-&U: 5*3'$6WE::5U
MLD7EG="2X.)6")DLAD-USVF(Y2(4S"9O'W;GNRQ:..XHQ^6XHO.QD!E1;UZT
M4K(/ 4#2]/1CLVWF&)&+9F<PXFWH9J>9G)TG(FRM2I#;+I(R<YA</7!+J4%+
MA-DBK$0\XU'0(J"4/ Q$_P!FQ#1=2$B*(+(=0N/-<%./$0!;W"MH"@TSH,*?
M#>A3H[4N'(!6Y$9\!<:< N"B8$BB2+XE2@G=B8C$XCS]!Q4)C'P6LH7+BQ6@
M9:&\6.JZ0;012Z^I03NZ&FW-Z;@0QU($':3H7\!M9R>X!?WI"BT%;MGZNW%[
M:+[$CT#V@*"%D^^T_;^-^)UH+J@*#3-^HW_\V?ZU:#SAW[Q0/_+L'Z,U0>FT
M!0%!IF_4;_\ FS_6K00G<[]2;@^S<?\ ^G<50>@T!00N5_K 8^R,=[&R-!=4
M'+E,;%R>-E8Z6A+&EM&R\@$H%I--*Z2&RHO'@J4"?$;&Q6,SI9P)$N3/)M]K
M5)>Y@H,I8ZNJ@V3B78FOT*"BH"@* H)79OOBWW[>,_B/&4%50>3>@<1-_;K:
MCOSU1C#8R1B843(38 -*])RA*Q_ GXJNM\T%(!<+J:E$5$:!;,VGO(,CBH[$
M?)I&F./M2Y!Y?<!\I0B2'F25&\LJ )NL-HJD5D5Q NI)J4.N/LW=*R48DQ,H
M#-U4IC6>S9C:]Q%&BRK974>"KJLB\>/10=$?8NXNVL-/#DG(Z<E9;J9W.L\#
M04<1I?.CRJHJ5^L/!$7RJ!9*VSNU,CC8<:%ET1]F8].D/9G<'+;5@HHL )-9
M1P$)SG/60BN6E%ZJ(5!V[-VQEIV16-N*'FHC3[F55EYG-[B;%EO'36XT<7#<
MG.(XLMIY76RZEQ!5$2%>J%I^;3;OUYG/Y09S[MH#\VFW?KS.?R@SGW;0'YM-
MN_7F<_E!G/NV@/S:;=^O,Y_*#.?=M ?FTV[]>9S^4&<^[: _-IMWZ\SG\H,Y
M]VT!^;3;OUYG/Y09S[MH#\VFW?KS.?R@SGW;0'YM-N_7F<_E!G/NV@/S:;=^
MO,Y_*#.?=M ?FTV[]>9S^4&<^[:":W9W>X%G/;+;"5F5&3F7FG%/.9@R04P^
M0<NV1RR)LM3:=8%0M-QOI(D4.ONNV7M.1W9[1D/XF*X^]A<<XZX38J1&41M2
M)5\:JM!3^@FS?P-$^=#\B@GMB['VTY@GG)F+C/.GD\L39F"$J,+DY*L!=?F&
M= HG@M:@H?039OX&B?.A^10)]G[0VX[@T,X::NU31ZIN"EAF.B*(@DB<$1$H
M'7H5MGZS_?'?V= >A6V?K/\ ?'?V= >A6V?K/]\=_9T$GE-OXJ(]N)Z,T;3L
M0H)1B1UWJ*6F^GK>&@>[-]\6^_;QG\1XR@<;DS*8;"R,AH1YX-#42.I('.DO
MF+,=G4O!%<><$$^+02&%VW+R,V9&>F.#%:=1-P9&,2LR,G.TZC91T?7&HD9#
MT"+9HM^I=$$T,#>_=ML%G;&6GQ=O8V-E&HYO,9-J''26V\":A=!]6R/6*I="
MO>@=9#9#T\&6I.XLH4=M]F0XPO82%U8[HO )*44B%-;8K<%$O$M!3T'FF!CY
M6=L+NQS<=MI]Z $3*36C<%C7VK#26#T$2*-^;,0K+X+T%0NX-PDOK>*B(GAY
MN0 5^-H:=_X:#YY_W+^#('NG_P#3T'-C\DY(W$.4R3N/AM,0W(S0,SAD$9/.
MMF2K<&M*"C2>/IH,)&4DP]R3I\ L=,BS(\9M%<GBP8FP3REU4;=145'4LMZ#
M;Z6Y?ZTQ?NL/W/0'I;E_K3%^ZP_<] >EN7^M,7[K#]ST!Z6Y?ZTQ?NL/W/0'
MI;E_K3%^ZP_<] >EN7^M,7[K#]ST'!@<._A<1W<8F2;;LK&QFX3SS"J39$SB
MS U;)4%5 B;NG#CPH*[+XN/E<;(Q\@C%F2.@R;5$).-[I="3P>%*"*WQM_L<
M&!D7Y[V3<;RN*B(U/:AOM\F?DXT5\;+'0DU-.KY*IQLM!V;DVSB,+#<R>,A,
MQX"D@9_%M@@1)4)Y=#Y&P*<OFMB7,0T&Y6456RT#79<EWL,S$OO+(D8*6>.-
MXU4G";%L'XRN$2JI'V9]K42^4O'PT&G>B#,=Q6#=6T'(ON'DQX^N1(K).FSP
M\#CF@33PAJ3PT'!@=I8K<.+C9K<\5O*/Y%IJ2QCY8H]#AM$G,899C%J80VQ)
M$)W3J(N-[:40.;<FQ^ZS 8P<B.Q\.^ZLJ'$8;:Q\-L^=.EM1&E0U;33I<?%5
M7P)0:\-@MVM9J&;T#D0\;.<7'R7)0O.CC9$9$>B.$NHW$21UPXIP$$^5NH4^
M7PV3<RL?+XB4U'FMM%&D,R6E=9?94D-$50(# P).J2*J<5N*\+!H/.9W&3(K
M>;B1U@3'@C-Y"&X2HT^ZJ T+S3J"J"X:Z!("+K*B*G&]!14$YE<-F(F87.[?
M5MQ^0@-Y7%/FK;,H0L(O X@GRWVPX(NE4,40"M82$-62+=N;C%C&H*X.+)%6
MYN1>?:.0#1<#2,VPKB<PANB&9CH\JQ=%!1Q(D:'$9B16T:C1VQ:8:'R1 $01
M%/41$H-M 4&#[[$=AR0^X+3#(DXZZ:H(B I<B)5X(B(E!.[.:.8$K=,H";D9
MM .,TZ*@;./:1>RM$)()"1(9/&))<2-1\%!HSO>3MG&2X4-<C%!V;)C,MNON
M(VP02"<NK;JJ@&2=G,;"O K(O303V\-IR7<CECAXCS\NY66UQ^1(PUXR8P@H
MV22'%4V8XJB/M\I%47$*R*II0;UFXO P9F-Q*1YZ8]]9TW(9!1:Q&*,UU/DC
M^GRA/6XC $I"I64FP45H-,:)+=%[.R)Y08S0F4O>67%ME](Y=8AQ\9U$9AL=
M"<QT;JB=836QT"WNU]'CWUF'MORVLAC7,C,Y60:D=L1Y4Q6&5PED:G.8O-([
M];@5Z#UZ@* H)J5WG]VL22]%E;LPT>5',FGV'<A%!QMP%TD!B3B*)"J65%H,
M-BY?%9;S]/Q4UC(07<H7*E170>:+3%CHNDVU(5LOJT"'<PD.\=PF2*@%CMKH
M)*G!=&8GJ=E_4H:7\5TH*G;/U=N+VT7V)'H'M 4$-/1!WF")P0LK#-4_5+C9
M W_0%$H+F@*#3-^HW_\ -G^M6@\VDJHX3$HG0]MV.J^IRGXMOT>:M!Z?0% 4
M&F;]1O\ ^;/]:M!&]U;#;,+(*"660N.?=\-S\SPFK_X#(T%Q0%!"Y7^L!C[(
MQWL;(T%U0)]XRY4/:N6DQ'58DM1729>%$4@)!6Q)J0ANGJI026W966B]YCF)
M/)RY>/<8RIK'DN(XB%$7$<E172BII[:[\750>BT!0% 4$KLWWQ;[]O&?Q'C*
M"JH)7&_UI[A]H\)[,RU!54!0% 4!0% 4!0% 4!0% 4!0% 4$KO+WQ;$]O'OQ
M'DZ"+_L]]W;V"V5M[,/Y9R<4['M2FV>6K8MMS&@>%FZN.:D:UJET04+@MDM0
M>O4"+9/W@3[+G^S7J![0(MD_>!/LN?[->H'M 4!00^X303W(*JB<Y_$L(JK;
MK/NMM#^F?1X:#NV;[XM]^WC/XCQE!W[I1%'$BJ7%<G&NB]'5523]!41:##8S
M+;>VF% 4'G/2I#ED1+N/RG'7"X>$C-56@^[[]YN9^Q'?UJT#V@*#R;&1,8[&
M[N]DY#D.Y+;,A&LEC90CJ<:A8>9#"0#1:M;;AF!@7D^KJ2U!Z%Z'[2_ D#[5
M9_8T!Z'[2_ D#[59_8T'5YCPGX/C?.6_D4!YCPGX/C?.6_D4!YCPGX/C?.6_
MD4!YCPGX/C?.6_D4!YCPGX/C?.6_D4!YCPGX/C?.6_D4!YCPGX/C?.6_D4!Y
MCPGX/C?.6_D4'G/=9E86:VOW>1\4X,P,+B(SF4DLJALL.CCTC=F(TZO.UN+<
M$XCI75;A</4Z"5[R_>[#]O-O_CR%0=N^_>;F?L1W]:M!Q;-]\6^_;QG\1XR@
MSW4Z89?'Z$ZP0\D\"KQN0--B@_'UW^-0-=L@TWMO$MM%K:"''%L[HMQ1H41;
MIPZ*!/WE^]V'[>;?_'D*@JJ H$6^D'T3R+A"A=G 9*(OS4=P7A5/$J*'!? M
M ]H"@* H"@DMQ[Z2(,UC#-M2I&/&\^;(4P@QB7@+1N@)*Z^2\$9:12XIJTW&
MX*<EG6LE&AS-WMG@\(\H.QMO.(;T^68Z3O+9CHX2--KQ)H=2>%U42X4"7?&^
M5R;F6VZK0(TPK$K'36U*3%>95II]OSDRU<AA25<)GF>2JB5].E"(-V(VK$Q,
M/&;@S\YEB*#A36H[D!(TT94UOE/PA9:)QMQMT+ C+;6K4**A$O&@ZY,A\T#"
M0L>6+AGJ<C[4QBML3'6W25>=.>:ZD&.1:E5 767S2K=N@HL%LEMI(K^:Y$AZ
M%][L=&;5K'0A3R$8855UN"/#G'UNG2@(NF@[=[?>!?LN![-9H)##2HL;O1W
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MF(-0UYB+"QXMZ6V&A32*W\/'I#T6@E<;_6GN'VCPGLS+4%50% 4!0% 4!0%
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M%$5:#G?GXK%Y.8SMJ,,C)A&CQ)UW5:QT!B&CA-+(/B#9"#R]0$4R33=$%-2
MJQ.,RV;G#D8<@GC,"!W=LEM!(1)4NUAH1H3;31)?U\[ZD0?V[RD"XPV"QF'C
M$Q!:T*X7,D/FJF\\Y9$5QYTKFX:HGE$OZ5!WT"+>WW@7[+@>S6:!9M:'#E;A
MWR,EAM\1SK*BC@":(OF/&=&I%H.G=6)Q;$;'NLPV&G!RF/TF#8"2?PMOH5$H
M*>@*#4D2(CBN(RVCBEJ4]*74O'>W30;: H,'([#JHKC8&J<$4A1?^&@^MM-M
MCI;! 'IL*(B?I4&)QHSA:C: R7I(A15_3H,>Q0_W!O\ P!^109-QH[9:FV@
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M_P#:V'^30':=V_-Y_P"UL/\ )H/A/;K(5$CS]B2R_P 'PZ<%^(5!-8_83,6
MQ$3&YEQ(S8LB](B85UXT;30AN.$JJ9%:ZDO%?#0<+^P)@.:6<;NN2'[JVQLL
M!^)9YMH_^30:_03)?@7=J^'BUL7P?&H*D/.9PL7);WCN=P\LPLF-&;B8(W1
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M*"*S\=Z%,CP=LI+SN?>>$MT9!MUM)PX]&3+EMRG-+$8G'N5H9;T=74H(*]=
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ME00.2Z#2$1+I$1UJEU5>"(G30*BWHW(4QP^)R.5,"0%-N/V5GK6ZPOS5C-N
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M9B?/1^30'IWLW\,Q/GH_)H,DWKMA4NDU"1>A4;=5%^(J#0'IKMGZ\_>W?V%
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MM?"*:T54(;!8=VGO=F>WFX/QY-H/N\OJN#]C9'V-0/,']Y,?]C,_0TH.V@*
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MU#E."2&AA=+D(P8R"2_-*GCH*C:F)##[6P^( 5$,=!C1!$N*HC#(MHB]/S-
MTH"@*#GR$EZ+ DR6(YRWF6C<:BMV0W2$546QU*B7)>"76@X=KX8\3AVX[Y\V
M<\1RLB^BDJ.2I!*Z\0ZE)4#62H WZHH@IP2@;4!0+<QEY,#EC%Q<O*/.]#<7
MDB@I=$U&Y(<8;1$O?RKVZ$6@7\W?\PC0&,;AVKIRG'3>R#JC9+J30)# "\5G
M3\?J4''F,'/;BF[D<EF<SSE1L<?C":@V516^AR/V5T$6WE'(X<.-!R0MLS4E
M+,Q^VL7BI1@@ID\B2SI_!55!<1M+D@WO]5T&$N/O-^>L<WLI-0 (73C=CQ6.
M4^''62OY#XBMJH]-^-J#"!W>Y%7HTJ2&-A266E#GJ#V9R *6F_+R61+5;J\=
M3'6X+PM0/!V+C7N666FS\RX :"[9),63O:ZG%C=GB$JV_<N'@M0-\7AL1B8P
MQ<7!CP(H(@@Q%:!D$1.A$$$%* RF0<@QD>;AR)[BEI"/%$%<5;*O2X;8"G#I
M(D2@4%+W[.$TBP(.& A3E/SG3FO":WOKBQ^2W9.'1*X^IX0#VE/FB:9C/SY+
M;HH)Q89CCF4M>Z@<5 E#>_AD+ZGAH._';6VYC7RDPL=':EG;7+T(3Y6Z-;Q7
M<+XY4#2@* H"@* H"@* H"@* H"@* H"@* H"@* H"@C1A,SN\7=,)^ZLR=O
M89EU$M?2<K+BO2BIT+X4H&K>S,*#S;Z(\KK;+4<2)TENVSHLA7\I5Y(*JKQX
M4'/B]@83&[D#<,=R0L](K\,T,Q5LQDFPXXX2:47F7B!946UK\.BP4M 4$GN[
M=^1PF9BPXL9J4V_B\A.5LU4#)Z))@,- A\1$22<>JXKT)T<;@HR'>R".8\<9
M#%\9\EJ(2ND[J9=*/.>>;<;8:D.<QES&JT0H/ E6]M-!TS.\+*,X_-95J"PY
MC=L,@[F]3KP.DO8VI[J1P)I%];C/B2<Q!4BZO5Z:!>SWON///A'@-R"8?R[3
ML=MQU'6F<2Y(;22XIM"WRW2C *Z2515Q$LMEH&#7>E#_ (*<ED&(S<"5-SCJ
MN*J1#B*X!MIU4U]>,\BJMO)3AQH.,>]+)R-GM9Z% A/2&LBQBLG"2:IBR_+F
M,1F=#K33B&FB4#JW05LM!U0]\[BD[FR&V0B0_.S$IP624W48"+&Q^-DOD9:5
M)P^?E4 +"'5Z>A;@EF]^@0AS/:,0H^9\7)E.NH\JLKDHC^0CE"4^6BH+A8IS
ME.Z>/1I0E1%#U-ASFL-N6MK%"MXKI>@SH"@*"5WE[XMB>WCWXCR=!K[KI#$?
MNFV>](<%ED,%C5-QPD$43LC72JV1*"J;DQG1:)MT#%\=;)"2*AC9%U#;I2RI
MQ2@V4&I9D1)0Q%?;260<P8ZD/,4+VU(%]5K^&@VT&#DAAK5S'!#0*N'J)$L"
M=)+?H1/'08A,B.2'(S;[9R641761(5,$7BFH46Z7]6@VT&J+,B2V^;%?;D-(
MJCK:(3&Z=*7%52]!\=G0FI 1G9#;<AQMQ]MDC%#)IE0%UQ!5;J(*Z"$70FI+
M]*4&$C)XV,J))ELL*JDB<QP X@.HDZRIY(\5]2@R:GP7C0&9+3AE?2(&)*NE
M!4K(B^!#%5^*GCH-#6=PCV4+$M9",YE0:60>/!YLI",BYRB<5I%UH".=12M;
M5PZ:#='R./DQ6)<>4T]%D@V[&?;<$VW&W;<LP)%5"$]2:53IOPH.B@*# I#
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MG-ULYV?FHT]<;CY$2/'BXF5C44<BY%?5U7),N7S$1(8V043RN*^"@]!H"@*
MH/.LMC-PY+O*S\7%38$2.Y@<.$YO(0GIJ."4O*H*!R9<'1;K7OJOPZ+<0GMQ
MPMS866#(N[<DO0V6W13S'*#2*$6@&T7*%<NDK<$4!);]2U!,,-S,-NO;,5&,
M)&D3VG9./EEBI0BV[D)N/?44%_--@Y_"9B'9%4V^79L%UVH*_,;/W1LJ%N#?
MF.EX%<I!Q\V8\(8K(-B\@,-&X&E<N;8<Q,>RBDC?RM_"5P8Y&/WA[/P\:)A9
M.W6X0D0L0(>!DQF0UEJ5&P;R:CJ,S4K:4OUB5:#DV]N[O1RF?9P,O(8>!D7X
M+F0 "PTPT ([C+3P.7RC:B>N2.E$1;I?5I6R*&<O=G>;%<S(N9?!_P"R<HUB
MP%,1+UR%<Q\>?J!%RB"A(,E10%+K:>"W)!H%,3O+[RW=T.8-_(8)@1&#R)A8
MYT0?*=*>B(K".Y9H3%#8U#8M3@^0*EI$@VQ.\3O)?60A9##ZHLW)0G0:P\MP
MK8V847F(GG05]<0>9I\"7XK:]!]A]XG>1)S>W<.F2PC<G<#\AI$/%O(3 1X3
MDM35I<OSG+JV@=4-(JO6-%T"84.8R7>KC'C;+)8J0 @)HXQ@Y1W4D,M.A,OK
MO9DNA%\"=*I0<^VMR=XF>R>0QC.8Q4:9C6F'I(/X*4-DD.R&1'AEU76)0SU)
M:UE&RKQL"7'=X?>;*PV*R3DW$->=(,2<()AY2@*RXX/JT+AY5M'"#F(-A34O
MS*<+ATQ]\=Y,C<<7"L97!DLG(+ [1YK>6P=EGR!>1H<N3FDEQA".H1$D*XD2
MB0H"G\[^]PDY5B3D\4T6-D)' /,TA7'4*$U+$]"Y<=.HWN4/2B\"OQL@;YW>
MQO"'@9F;/+XQV+!$W)#+."DD]RV]5S05S CI70J(I$G'AXKAU9+O![Q,;F<C
MC9>2Q2]AF'$%]G!S'0)&X4*8KAVRB<OCD4!!XWT\.*Z:!-GM[[PE;FP$8\MC
MNTXO*,F#GF60VUS)N-RS =.5<)U$6*Z!)U+*HEJ5$45#U'NG_JLV;[1XWV&W
M055 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4
M!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0% 4!0<\['8_(1UC3XS
M4N.JH2LO@+@*J="Z314X4&MK#8=J0[):@QVY+_[<^+0(9\%'K$B7+@JIQH!O
M"X=MP7&X$<' +4!BT"*)*M[HJ)P6Z7H,SQF-<D]J<B,G*T&WSR;%7-#O+Y@Z
ME2^D^0WJ3PZ1\24&D]O8 R$CQL4B'F(*DPVJISDTNVN/RZ<"\?AH.QAAB.PV
MQ';%EAH4!IIM$$!$4L(B*<$1$Z$H,Z H"@* H"@U,0XD?]H8;:X(/4$1ZH\$
M3@G0E!MH"@* H/.<A/RD/OE=2*XV,*3CL,Q/;5M3=,>9FW 1M;V'K-W7@JKP
MM0*8_>;F<DWDB>D2-O@Q(<<$IT!V(K+205?9CD4YEL#,B%2<TW_4KI(2H&$C
M>>7;GS1<RB]F'&29Y-16HZO,2(KC(K&%LQ,Q6SB@JO7UDO5TVXA/]Y.[]PQM
MM9C:^522X]Z-Y-,C/''2DCR998UQ[UJ0#/9A:9O951SB7!=.GK T]--VLJ;T
MN4Y"C.Q)3[;TI(G+/E26VT<C<MKJ\L"53%\EX*BVZ:#M?W3D3DOXUK<:KC.>
MX+&X6!A(\1#&;=&&VX\"P5=(C54(@M9--KW*@BN[_O FYC-YIF%G%@9.3G =
MGLSVX+:E%CX^#'5Q1 W@)R43) RK+NA>+B<$TJ%,/>-N4,&VZVXL]Q]N%)DY
M)B(;C<0GQUR(J@R#EC$M(@+MB1"5255%$(.#"[OS.*8R80I#:I%R>6<CX<@%
M7992<_E!<.Z^N(C0LHO53P%J]0'3.6FY#-;3&3/;R@1=QD#&0;  1P7-LS7R
M1>7U%TFZJ</!9%XHJJ&Z3N3?3NZMRL8]MTL9A9C;".F$/L8LKC(LMQ"57$F*
M^AR"4;-J%E%/FK!=X/(M9#%19(/MOF;39/$V0DB&0(2HNGHZ>B@\UQ6X<OAN
MZKNO;QBZ7,I%Q\-]4%DCY8X1^4FCM#C#2+S(P>4:<+VXVH#=FZLJ[M'9>Y8[
M02\NU(G2FH[:=1R4QM[+*C8VU70G MP54\7"@R].LX$[)1QS .QL8\H8R481
MT\[%R8#B,BH@@<');C/K5BU6XW%44&F<W%NR*YD(PY""PX&6!AEUTPB"$1<>
MLKE@;P21-W4B74AZ-2I:U!Q[7W?V'#[SW1YKR>4UY+'R/-D*-S<B?:<'B4LD
M>[?7#F:G$X:41?%0=^\L_P"L;$W#YMG?5SV0\T<G_:/O=R;W9NSZOJCY3EZO
M+X7H(GN]]//0';79?3+LWFJ#R.R>AW9]'9@T\GM7\(Y=O(YO7MY7&]!0?TB_
MES_,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB
M_ES_ #'H#^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0'
M](OY<_S'H#^D7\N?YCT!_2+^7/\ ,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YC
MT!_2+^7/\QZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0'](OY<_P QZ _I%_+G
M^8] ?TB_ES_,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YCT!_2+^7/\QZ _I%_+
MG^8] ?TB_ES_ #'H#^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB_ES_,>@/Z1
M?RY_F/0'](OY<_S'H#^D7\N?YCT!_2+^7/\ ,>@/Z1?RY_F/0'](OY<_S'H#
M^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0'](OY<_P Q
MZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YCT!_2+^7/\
MQZ _I%_+G^8] ?TB_ES_ #'H#^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB_E
MS_,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YCT!_2+^7/\ ,>@/Z1?RY_F/0'](
MOY<_S'H#^D7\N?YCT!_2+^7/\QZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0']
M(OY<_P QZ _I%_+G^8] ?TB_ES_,>@/Z1?RY_F/0'](OY<_S'H#^D7\N?YCT
M!_2+^7/\QZ _I%_+G^8] ?TB_ES_ #'H#^D7\N?YCT$Y&]//S@9;3Z8=I\V8
MKF^\[M.CM&1T:M7\'T7U\O1U[Z]?#ET#3)?G%Y)>^[]M;^J?0?1TIT_J_F?C
M4'T?SB]MF>^_H;Z/0?F]'^6_Q:!5WB^GGH+N+M7IAV;S5/Y_;/0[D:.S'JYO
M9?X1R[>7RNOI\GC:@;R/SB\EOWX?+?MGH/IZ%\G_ (Z#3,_.+YE/WV='^6]!
M^R^5X?\ XZ:!#@?3SS_N;E>D_,\YL=HT^AW-U^:X-N9S>IKT:=/)ZFC3?US7
M04[?YQ>2[[\_+7R?0?1T_+?JO'03VS/3SLR]G]*^7YRS>KD>AVO7YUD\S3VC
MKZM=^=;J:[\OUO30&2]/.W;1YOI7S/.[_9]'H=;7YLGW[/RNIS=&K5SNIIUV
M]<T4%,GYQ?7O?MT_D/\ ,IY?_P =%!IQ_P"<7E%[\O*_^7]!]/1X?5H)7;_I
MY^;/:W9?23LWFZ!R.=Z'=AT=E'3V?M7\(M;R.;U]/E<;T';FO3SMFS>;Z6\S
MSB?9_>=IU^:9U^R\KJ:M&K]NZG+U6]<T4#!C\XO9X'OI_;R_:_0?1\M^T?\
M2>/X]!T9/\XO97O?=Y8?57H/R_!Y?J_,T"[;/IYYZW9RO3+F>=6NT<GT.UZ_
M-4&W/YO4YFC3;D]31IOZYKH#<WIYYZVGS?3+F>=7>S\[T.UZ_-4Z_(Y74YFC
,5?G=31JMZYHH/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>nt10016217x4_ex10-13img05.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@"(P,6 P$1  (1 0,1 ?_$ -H   ,  P$! 0
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M/R&_\(H#_P"UC\AO_"* _P#M8_(;_P (H#_[6/R&_P#"* _^UC\AO_"* _\
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MTIT76]Z#R6^<ZCR!YA FE)!20,]A6U130=27%%TZ3%4X>%$H,_IID%=1$Q"
MP3"O"Z<V-<2[/S^4ZC9.(A"O5)0(Q\**24$KC^^O+S=RRL"&V [3%&0I*F28
M55[.U"=5/(0$OYQ&_7X:5\-T0*"3WARXHS#?QC#;$1GGD^61CB%A(%<UJ>C0
MC;1$X1='"W2M!Y/O S.IX1PC-VD514\BP.M;H@ *:%+47'AI\%!Y>[QYXR7X
MK.(8?E,*)E'#)1N8L<T<TO:5Z!+EV3U;^*]!X/O*RK9HTYA&!D$VZ\$?SE'Y
MI-M:44M%D+3K< 27YV_&@4[;[X-T967'CY#9CF#1YMQQQZ?,Y8!RFHCFFY,#
MUE668Z5LJ*T5TU(0@%(YO7+\]]IC#-OJ*(D8@G,6=<U-Z@XIP46W%-;7Z$3I
M5*!QB=PL2\<W*FJQ!<<54Y':&W;<;#<QL-UZ;)0-0,' %QLD,#1" Q6Z*B\4
M5%2@EMY?"+8GNX]^(\G0'=/_ &6;-]P\;[3;H*J@T)NW\!.?Y\[&Q93]D'FO
M,-N'9.A-1"JT$-N/NR[M8^3PG)VCA0$WY'-!,=%030(3QBAHC?61"%%X^&@R
M[+[I>[%-G8)'MJ8B4\F.B(Y*D8^(X\Z7("[CIJW<C)>)+X5H*+'=W/=[C)K4
M_&[8Q,&<PNIB5&@QFG0545+@8 )#P6W!:"AH"@ULDUDG83H8V0U%FJGK+[[)
M2&A6_P \T+C!$GJ(:?)H%^WLQ.EN3,=E&FF<OC2 9",*JLNMNCJ:?:0NN(G8
MDTEQ$A)+DB:E#'O;[P+]EP/;K- ;/^H9_NID/;;E!I=[']EF\O</)>TW*"JH
M"@* H"@* H"@* H"@* H.<;811W-LIM>EG;F::5?&K4W% J_+TT'1Z!)EOA-
M@?\ 6_I24'G/??\ VU]ER/:3] ;)^\"?9<_VZ]0/: H.?1<C!QTZ%+G/A&BC
ME<T)/.+I!")X]**J^.U!2>G>S?PS$^BC\V@/3O9OX9B?11^;0'IWLW\,Q/HH
M_-H(UZ?#G[WPTR$\,B*YNBS;[:W M.UYB%9?#9>%!T^@*!/NV;.AX)UZ"ZC$
MHG8S+;RBAH//D-M*6E>"V$UH,NV<A+R&!ARYFCM;@6D*TBB"N J@1"*J2BA*
M-T2ZV\:T"9<WEW-_CCPD".): F7(R-IJ-]64?UDZMUZHD*((HG2M[^ *R@*!
M%N;ZNV[[J)[4D4"K:.Z,'!VQC(<N03,J/';;>:)IU"$Q2RHO5\% W]-=L_7G
M\&[^TH#TUVS]>?P;O[2@G][Y_%97$P86.=.3*+-8-Q&@:=5=#.8B.N%Y/! ;
M B)? B4#[9_U#/\ =3(>VW*![038[GR\S*Y:!B<4$@<-)"')?D2480G3B,2T
MY8BV\JH@2A156W&@V]LPLI&#(.Y%IIAV;,.2W'9<5X0 FVPMK4&^*D!$O5\-
M M[S2$=MQ")404SFWU55X(B)G(=!2+/@HJ(LEI%);"BF/%;7X<?$E!E;=:<1
M5;,31."J*HO_  4'J@* H"@*"%@?>W;GN_-_93J"ZH)SO*ANS>[K=4)I11V3
MAY[+:E=!0G(K@I>R+PNM!$9/:6+QC>,RD#8^"PKXS8FG(048%\ ?<1LT'EQ6
MEZP.*BIJ2@Z'L_X)83[ B_21H&] 4!0% 4!0% B8^',WW+B>V)-!]V.FG:>-
M;Z>2UR47QHT2A?Y>F@1=XRHDN$J\$&',55\2(_#55H*_+0&\ABIL!Q$5N8PZ
MP:+T*CH*"W_1H-/:.1/)[5P^0< FW9<*.\ZV:(A"9M"1"2(JI<26R\:!M0%!
M(Q7%;[S-S.(0BH8#"DA'P%+2LNMRMX/'01,[T=7<F2R[CV*65(C\AYW_ &BX
MAD@&K0E9"9Y9OODI:16XE;K4":$R4'%8D)\W!IE C,%)R'(R(&Z5^0;@. VR
MK>HVB1%LB='51+4&TTWM+:\&'%RK^&:P$-QAADQ:R+I6;D+&'EH:/6,2U#^Z
M*HJNHB5.D/&&P^WL(U,Q\9<3'=5EQAQM!RCPF]'C)&C@:."MVP1IL"%%74B7
MXD5!NL-XR<K0M3<&@BC(B;C<Y+/HX+3:<TU;XND@MAQ0E+3;4JHE!YCY?&8Y
M%9F9/$KC0ELQLHTTUDB-#F/@VR#:V<NIHUIU>2MDO8:!@LR),DAV*=B$S"<N
M.3@M3!3LSC;8,B*@@6)$(O4'AT+=4#GL^!@9VY$R>VLE@XL-3D"_'>8R5R0)
M<)N0JM.L&!*4?&DPJ"@W5>DE+4@5S<C:V?'1/DXR2Q+[3 R( WD]1,,$XW,8
M8-1:/]S%Q-2+;7UN*DBH%UC</W8YQ CP8K<@6T<-L$%\!&QH3BCJTHA:GDO;
MC:R="60&!]V^R3D<]<8/,Y3+%D<=0$;CFZ;5@0]"*!27+%:_6Z:#XYW:[(<R
M(Y(\8/;@%P6WT=>11YQMN&HV.R$I, NI.*6X=*T&X[LS;#S2LNP -DGUE$T1
M&H*\2*)&HZK7-%ZWZKPT'QO96UP5I4@"7(U<E#)PT%"T71$,B2WK(_\ X5:#
MZYLO:[HDCL '-8H!D9&1$B+J342EJ54+K(JK>_'IH&T:,S%C-1F!T,, +;07
M5;"":12ZW5>">&@F=Y?"+8GNX]^(\G0(^ZO9N#=[L=I/.=L)Q[#0'359\VVI
MR,!J@ISK"**O5$>J*<$1$1$H*GT)P'BE_;\WV:@^ILK;GST=UU?&[)DNJGR%
M-PK4'AS8>TW2 G,>)DVJJVJN.JHJ0J*VZWA%52@&]A;0;:!E,6T;+0H+;3FI
MP104LEA-21+)0*=L[,VPOG5$@ "#D9 BC:FVEDTV2P**>&@:/["V\\WR]609
M2]]4?*9*.26\"&S( K>I>@\M[&@QV%;A9/+QSXJVZ62F2R E^>_CKDD2_P $
MT4?4H/*R]Y8A?XU&#<$%"1.T0]$>: J2)<X[A(R[I154B;<%>'5;5>%!CQV0
M@SMW0LC"5>5E,0X1*8$VX0Q9(<M" T$Q4%E.(J*G"]!N;V^\"_9<#VZS01V.
M<VA':S4G(XN>X3.2R;DB0U&FFW893BD2$VFA4LG@H&#L;84V(;3N!R+\62VH
MN-E"GD!MN#945%&RH0K09%C;#);N;;F.E^K=QLMPO\8P):#ZF.V427':#Y"O
M0JP--_E%I)/EI0??-FS?B>_]I#\V@/-FS?B>_P#:0_-H#S9LWXGO_:0_-H/B
MXS9MN&SGU7P)V(/_ (E0866^[Z1!BRHFV>TN2Y$J(,-N.RCP.P'7&)*'K, ]
M;<9(;H2W\%TH,OFK;7Q$D?087W10'FK;7Q$D?087W10'FK;7Q$D?087W10:C
MNTN[]YPG7N[!EYTUN;KN.Q1F2^,B)U25?DT'GT-[N?\ VKC>]>)]DH#T-[N?
M_:N-[UXGV2@VXT68]F<-E]M8AF- PD+)89W$/F,)62?>@N-\L6 D-:!2&262
MW2E!08?/Y&7F9>)G0&XK\1AF29LR.T#9\W! 2NVUI+UDE^10?<M\)L#_ *W]
M*2@\Y[[_ .VOLN1[2?H/$?9S4=' 9RN1;9-UUT60> 0!7G"=-!T@BVU&O2JT
M&79<YV;MJ(X^^LF4PKL26\JHI%(B.G'>U6X7YC17H%<2'+F[IS\.;DY<<VG6
M)&.88?4!6$[';!"T*/#^,MO"MO4\*T'J"N8QN2F8/!QF)#$40F/RI\IU'3=G
M.O&?D,N>%M5Z?#0,.?OGZRQ?VW(^YJ Y^^?K+%_;<C[FH#G[Y^LL7]MR/N:@
M5YW"[PS'83=8A1I&-D++A28\QX7&W58=C$O7B. J*U(,;$*]/CH--K;W>4C8
MH>5N2)95[:"WMX?O:E!@R,+?F-CA+EY,RC<^.R[RI;:F@OO@RI"A8\451YE^
M*T#G-8*-$QCTW+Y[(NXZ#IEOMFL;279C1X4L# DO6!."+=>B@9[.B38NU\8S
M/;1F?V<#F,(NI&WG$UN A6&Z"9*E[4".7BFG=[R([LJ1CWY;83\9*CD"*X8-
M]EE->N X*Z %HK6OUN'0M!\S.*RS.4Q^-QN3ED[,;D.F[)DGI$8_+2R( ])<
MV@^>B^]OPO\ ]H?_ &M -[4W8DR+*>G-2BAN*\PV^_(($<T$WJ441+]5Q:!W
M_P"=O]V_P] ?^=O]V_P] ?\ G;_=O\/089LG>L6&_)4<:2,-FZHISTOH%2M^
ME0:B8O%QL,[G9.3E8F&XT>2G($E1CLJX/.?.Y#P&ZJM SV<F2]&H)Y(WCEO"
M3Y))TJ^ /&3C;3FE$34VV0@OR*#%@$1,_N:R6O,CJOJKV%A+_I4#Z@Q2HD29
M'.-+9;D1W+<QET4,"LMTN)(J+Q2@DMR;3VJ,W;Z#AH(H>2021(S*73LLA;+U
M?4H,L"'.V_E<N.,V^KN/G/M/L+#.(PVFF.VT2*!N-*BZFU\%!M2MUY.$#;TW
M;\QF,;[#!O<Z&:!VAX&4-1%]2415Q%*R*MNA%7A04=!SK)[QW>F?S,'&LE+2
M'DAQ\*%$C1W'E!,9$G..NNRYT%KRY:C9./1PZ5H-H9W>D0HO8U&Z7TE'AW3U
M%MD52_R%H/J2^\U>#D9Q!\;3,$2O\DYKB?I4&%X9$#:Y,97;L^7&QZOY!R0,
MF(RZAJ3CQF"LR (5]<)."]'"@8N8>!C\]MQ^ <IM)3[PN@Y+DNB0+#>-$(''
M#%;$B+T=-!53(P2HC\5Q51M]LFC5.FQBHK:_R:"?W1'9C8G$1%N<=F;#%;V4
MB%A=:7X6XJVEZ!%CL1AY.-B3(^PV5BR66W6 :.)J0#%""XF38IU5\"T&QYBQ
MGQ!_Y4#V:@/,6,^(/_*@>S4&S@\!M#)G-9>VPS DP'A9>9>!@U53:!T2$FB<
M&VEQ/#0:3V)ST;;F7VW"PKBLRW9@PY+;\<619DND3?5)Q'!01.RH@_(H,^X,
M1M+$OQ(T;9ZYB9,1TFXT$(0$(,Z=9D4Q^(%KN"G E7U*#01M@4L'=KFFQ\ -
MR<. I\@1RJ(E!BF28D.(_,D]W6<;CQFR>>/M6*72 "I$MARJJMD3P4##-X/
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MUF]+FFPT*:R >+CB)Q6@K,4P['Q<-AU-+K3#8.#>]B$$14NGJT&U0% 4!0%
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MS*N(TJ@Y&=:N*DBIY3B4'WSMN;\ _P#:VOF4!YVW-^ ?^UM?,H#SMN;\ _\
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MND5LO A\I098R=B9 Y#" >'&9*1L";AQIW+=DH^5^8B-AK%1TJFDKW'5>R\
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M:LFZZ %U5QVWYZ-(BHBB@R'R=!_P]=NR?(M0;*9G.$J"W,R9DO0/F8P_Y3B
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M@*!%LG[P)]ES_;KU 8'[_P"Y?LN/[28H'M @WRVV>W[&*$@S<<8H27L03V"
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M4K7LE[)9+(@7- 4!0% 4!0% 4!0% 4!0% 4!0%!*[R^$6Q/=Q[\1Y.@.Z?\
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M$>(53@HJBITWH,VZ[!YGD+_D,G&Z/^NU1_\ \Z@G\BTVYWI05,=2LG'=;O\
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M"TQ66Q^6@-3\>\C\5V^D[**HHJHD!B2(0&)(HD)(BBO!4O0+<=\,LW]B8_\
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M% 4!01.WMZ[.QTC(8?(9['0\N.2G$N.D2V&I*(<@W07DF:'8FU0DX<4XT##
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M (EA>S3P.)S'>(IA<B=N)?J@2@^=UN*W"7=GM$V<X3;)X7'$#11F34!6(VJ
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M@%SL2D916RN#"QD43LB=9L"D9,Q157H<X_\ "H?&-H[\CO$\PJODZ5M#\^'
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M5,D5%%*!YLW$RL5M]F/, &IKSLF=-::-7 "1.DN2WP$R1%)!<?)$*R7\2=%
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MFVV-NMI<4=7RJ"3P7?)N+/X>+F,-W?9>7CIPJ<1_M&/;0Q152]CD"0I<?"E
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M4?>\VQ)+,F:2&WRD<"*"\TD13TJHCPO0:\K?&[MQR7,3@\6]C'@+3)4W&"D
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M']PO?U:!+DH[,C=63:64_"EEO%.PR6 :<TN)LUM3Y@NHJ*),(XG#CJTT'UJ
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MW)98766I)3CQJK=M5D+R;ITVL'5N[K?6)WQM#'[CQBV:E!9]A?*9?#@ZR7^
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M_B<*RXW 8T'()')<DU5Q]]Q!0>8^\=S</2B)<EZ."<*!C0:.9S4##PNUS2)
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M142%;$) 265%\:*E!S3+1LI!Q:[.R>0 \:XT[&QN/QZ++S.0@I8  ^T)RV1
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M#J'CV$<)!'YYP45>E:"Y@8C=>X(,=S=IAC&2:!9&"QSI$AN6N:2):(V9!?\
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M0),C\,L)]B9#]E&H'M BWA]0P/=3'^VVZ![08IDN/#B/S))\N/&;)YX[*ND
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MW"UC,M.\]/1GD==9FB#4",ZUR'>3%@QF^9+E^O-.-@>LAUH2$G!%#JK+@NM
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M?A%OOW<9_$>,H*J@E<;_ &I[A]P\)[<RU!54!0% 4!0% 4!0% 4!0% 4!0%
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M46"V2VTD5_-<B0]"^]V.C-JUCH0IY",,*JZW!'ASCZW3I0$730;N]OO OV7
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M_,H/3<:.V6IMH +QB*(OZ5![(1(5$D0A7@J+Q1: $1$4$4013@B)P1*#[0%
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M^9$R 8Z64.4D^;=IY&#5MQ/7OG2LM!:LN(ZT#B)9#%"1/DI>@]4!0% 4!0%
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M3170%^"1JX+[:*UJNHVL0\.-!.R=^[M<EQ2%Y8;8/8K'3(_*;(2EKF,?%R!
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M@*#1RN=PF'91[*Y"/ :)4$#DN@TA$2Z1$=:I=57@B)TT"HMZ-R%,</B<CE3
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M*6B__ --S+8[(CHD;GGYY'M3!QMML.!&1P;H?\8A(Z\RMQ5+G+2R\.F@W\3
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M+\?:T<'052&?N*84Z8TJ^$!%9O3XDD#PH'P8#<4E \Y;@< 1OJCXMAN(T2>
M5)WM3Z6\8.#0*'8/=;BY@-S28R.684GF@F.NY:>)+=%-L'2DR!\I4ZB<.A.'
M"@;CN3)R1$<1M^6XVHW;D3=$!E/$) ZJRA^@4'U(>]YEEDY"'BFR'K-0F2DO
M"7C&1(4&UMZL:@G$@;;D;C3;^<=RF6F*I14=R,AP8TA5C#)(ACQ^1$-=%]7K
M2**IPX+0/<5W;;*Q6,3&P<8#49+(EC<5Q!3E]1'-6M ]9"XHMEMQ2@I&VVVV
MQ;;% ;!$$ %+(B(ED1$H/5!&]J.)WA[KE@T4@X^W<.Z+ >4XH2<N2 /3Q*UJ
M##B>\.9/B-NA"9?MD8L"3)8=/D"$H62UAS ;,B%7]%D2UT5;IY-!DW!OG*8_
M=<G"PX RTBPH4U007R>>6:_*9Y8*TVX :.R7N?!=7@M>@4S>^.*AYIK'C'E/
M8^;"AQ!!Q73,9&2#%R#-EG6[J9>)204'KBHVZ:#73OG?!]ED\:+PRBGL0Y;9
M.MLN/0GH$?4[S6Q.,T+T]QMXG1N*M+9"U"BA49G<FX(NX\;@8,:(_*E8V7DI
M#C[CC3=X;L5HFP5!.VM9=T(NBU CPW>K(RV0QPQH8I%RCT=N(RXW*!XFWXC4
MLS1U6NSJ33;JD3>J]AH/6U^\S*93;V(=E0V1SN38QLE&&E-&5CSH23'7T15,
MP$.5( 4)?*!$OQH'.P-X3-S05EOQSCIR6'4 X60AI=X5*P'-98!Y$MY36I/'
MTI<*N@* H"@* H"@*"5WE\(MB>[CWXCR= =T_P#99LWW#QOM-N@JJ H"@* H
M"@*"'S/4;W>)<%.1!<'U4)I@$_Y0+0/-J%K:RCB<!/)RT2_3ZVYRU_Y0+0:&
M[?OO$]R\M^QCT#[!_>3'_8S/TM*!-ND'L3/C[JB-$X,84C9MEL=1N0%)5YJ)
MP52B&2NV3CH5Q$125*"D9>:>:!YDQ<:<%#;<%442$DNBHJ=**E!ZH-+.0',C
MA<ACVS1IR9&>C@X2*0B3K:@A*B*ET2] BC[KR49J+C)&!FEFU1&^0R"G#5 L
M)O).5!8%NW61#47%\ 7X4&\N:W&'E;>=._1R9,8K?)YAM?I7H-W;^98S>!QN
M98;<99R45F6VR\B(Z OMHX@.(BJB&.JQ)?IH-^@* H"@T<YE@Q.-<G$R<C03
M;8L-:4,S><%H$13413K&G2M GD;KW"RYH39>7DI:_,COXA0^1Z]/9*__ !:#
M7CY.=G\YAI43$S8<. X^<Z1D&^R*BDP;7)!HEYCB\TAN2#RU1+B9<+A74!0:
M&;S4+#8\ILK42:A;98;34Z\\XNEMIH?GC,ELGZ*\+K0:&U\//8[1E\SH+/9/
M2LE&^+<=D%568C1+TBTA+J+Y\U(K)=!0'U!*9C>K1M26L"ZPXD9"[?FWU_V;
M"$+H:N.HHB\X-OW("O?RE#IH%VV]N><Q!]\'QPO.&8X4T=$S*RTMIE2P5!5M
MD+)RF5%.@>J(B(T%Y0%!X>?88:)U]P6FAXDX:H(I\E5X4" ^\/9VATXN1')J
MR2@ZWBVW<DX)BME%0A ^6I%X6M0#V[)UT6+M^>;%E4IDE8T-D+=&M'W1?X^H
MTOJVH$+O>#D)"R&(T_"QY;*JBM1#E9YX%M=.9'B!%-"LM]"%\N@\O;HW*D-9
M#4Z0G50A-S:^4<Z?"4<'0?7_  >!4&;;,WO*S;3TH\ICXL)I\F6T?V_D84AT
M! 2YB-3)XFVFHE'K-K>UTZ:!X6V\S)-%G[BF$UI43BPP8B-$JVXZQ Y(V\&E
MY/ET&UB-J;?Q#JR(4,4FDV+3D]XCD2W "^D7)+RN/N6NOE&O30-J H"@* H"
M@* H"@* H"@* H"@* H"@*#RZZTTV3CIBVV*7(R5!%$]55H$+F_-L*NB%*+*
MNZ^7R\8TY.L?ZDRCBX#?JJ9"B>%:#7D;CW.3': P[.(B(1([)S<QIE0!+V,6
MHO:A*]DZIN@MNFR\*!$SGGLFC:)N*7F.8A.".V(/+A. J]5%FN=J!%L2<1D@
MI=*<."!Y3%C$1G(/;>@XYML")<KNC(=KFL$MEMTS!7]=:4*)X/4#VF;E3^6
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M\C="2D%8J[?PR/H:7%6^U9?5J3Q6Z:#?;QVSL/CF>JVQ$G3([[;KKAF3TM=
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M#7,YIM4'HLQE9+ ]-^D6DOZM!AW=PRT15X(N,RHHOJJ+"V^385H'V#^\F/\
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MG"[ACA%FR;ICI[*_Q280B1FVVA*IM/" *:M'?JW42/26D*&@* H"@* H"@*
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MI;J*]'415;JG!52U!O;=[1Z/XSM+1,2.R,<Y@^! ?+'4"^J*\*!A0% 4!0%
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M _K%_+G^@] ?UB_ES_0>@/ZQ?RY_H/0']8OY<_T'H#^L7\N?Z#T!_6+^7/\
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(-5O7-%!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>nt10016217x4_ex10-13img06.jpg
<TEXT>
begin 644 nt10016217x4_ex10-13img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!Z *\ P$1  (1 0,1 ?_$ ,$  0 !!0$!
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MJAU&5&F8W9^V(^V-OQL+'>7(:C:M+K@ 4=2BKC;AVUHOWG<E5E-NWQKZMO\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * H?>2RRMU7)
M)H"/C65(8ZJ_XKYZBSV\>0^04!+H#@WFQNV; WL^TQ9Q*&$-E"E$)2I*M:56
M';ZZQWITD>1F7W&YIV-G\G,DYG)^3S;D9J.LH;BD-)T@Z#J*CZ235EA\JLT8
M4^;<J>AU*M!O+,Q03%=)Y!)H!"3IBM#]44!>H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!!A#KR7I9]V_39_
M93S/RF@)U 8?=2].+4+^\H"B!@]WS!C_ "VF.E02"P4$\OXAT_GJNZZ191DR
MI;9\UXMA,C(0XQXAUUMLCUD"O.CN?.VU621]A06BS#8:/#IMI1;]D 5ZB/J$
MJ(O5))"RG%$<=[[?#T7H";0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M[^B@'4RO]TW^]_10#J97^Z;_ 'OZ* =3*_W3?[W]% .IE?[IO][^B@'4RO\
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MX 5 +$7,8N5;H26UWX 7L3ZKU":.5),F5)T* AR^,V(GO*S;U 4!,H!0"@%
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M.&Z-MG,M7/I9/U#O%4&D\*T#FH#Y:FA%4>%YH<UI'RBG%D<EW/ \R38+23W
MBG%A27<KJ#H4 H!<4!YJ3WBE!4]H!0"@% 0,SDSCHH>"-94H(L3:U^V@->_U
M;D.Y'LJ: K:W?+2J[K:%I[@=-* C3<LK)S(I+?3"%!-KWO=5"#8-UR1%VQDW
M=6@HC.A"AP(44$ CY:XF]&<7G2#^!PG:6]E9#+0,?)QZ9"GW&1U5K)4A8LE3
MB2.7A[*QPN5=*'DV,GE))H^C$@  #D. K<>T* A2!?*1/U4N$_*!0$V@% *
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MFNEY&G\J.7X:N\V>)V%TR%-9!Q*QVZ0/ST_4:[Q(7AJ:J;)2-L90"QS4@6Y
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M H"$BZ\LX>QMI(!]))O0&,W2^IQ4> WQ4ZH%0^:I!EX\2,VAE 2DK93H2>T
MCC4 U+<>31\)-A1<9(=?6 V'4 %!(4.T]E9[MQT:HRR,3:XDA+>-:>D692A
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M36FW.I'A'HMJ!N">9/MX5Y.3/E+X'Z/X+%]K'3ZRU.N^4C"-J;/B_%1' YD
M)<EY(U%'4.E"=(\1Y5JL+C$^=\O/[B^Z/Z=$:LSL;+[E\TDYQY]B9B.MUU+:
M<22@-<F5M^\FJO:<KE>AZ#SX6,/VTG&=*?\ S4Z"XZA2Y9>);D*-D"W8.!3[
M*WGR!;C-+"522/LVNT\M78* E-N+AXI3B24O3%6![0A//VT!#W%(EXW9$AN$
MH-Y3+GX:*XHV2DK!\2CV)TWXU,=RJ^WQHMV<^\G-FR<!'R^3F!/QKRO@HJVU
M:DJ;O=P@CA[U6W9U,7C\9PJWN=UP\-,3&MMJ'$C6Y?O/&J#TS59\G$?%R)N1
MD-P<:VH(ZI(2DJY"Q/#TU*1S*2BJO1%]6,TQ3,QLUN5"M<*2H*21Z_=-"4Z[
M&-ULK%UME'<I/*_IO0 L$B[:@X/1P/LH#V-'+LE+2@4B]U^A(YF@)+L\1T9#
M,%LNB$THQV$BY<<M9"4CO)J4BVS;YS2-<\K,UN?<..RTW=)*XL19:8;4@-O)
M<N2I*N Y BN[D4MCT_*V+-II6]V:MYO9U<;#,XIEU23,7J6@'^S3V$>FNK,:
MNI9X/'Y7'-[1,#Y/X%V1DW\NMM18AIT-JMX=:O3Z*[O2Z&[SN1Q@H+>1V!J9
M*:4%-O+21RLHUF/E28SFIO7;6[H?4E0TZT@D=G \Z$ILW514I@FUE%/+TD5
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M(3:Y',GA1DF,RO'(R">)UGC0@B6'=0"P[J 6'=0&=>41M-%CS= ^2@-@PO\
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M9B;B3$>R$A<A;;[96$ZS<I%B*HE8JZGL8_EN$5%QT2-:E?AESJ/^4SL.4>P
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MW(,1)@Y*&W)D.M*:9EM'IJ2I22-:@;W(JIV%4VQ\K+BTUJ;%^'3.;?AXZ?\
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M@]ZC8US>N\+3:ZZ&RWBRDX0I3EK4E;*CS$;<1D,A_P"IYUQ61ECZH7P0W;L
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M DWX)-BFNU<[JIFGBO\ DDU_ U+-+SN(DQ&]Z;=;R6,2XIQ<N'9Q)6K@5Z
M4"QN1724&]'_ "T*9SNQ24X\E7H8>)C<BYET/;'RR68DP..,8B82I#3;9L5K
M"N*4USQ<4U+7CK7_ %U'+E).TZ*6E/7_ (*,/YVQXDY<7+L&/(866E2HIZC:
ME Z5&W#PU*M5540O(J,G&:U78Z)BMV[<S@9<0F%D6XZ@MM("0M"P;@CEQKAI
MHVPG">JHR1E'Y\E,Z3C^FG)*;48:7E:4]0BR3?T5".[E>+X[G/QN[=.TMN*,
M^=*9S#9)7%R*.LU))-U?"D>XFK>*DSSO>E:AJWR]>OP(^.\RL9NG&G'N17D9
M"0ZA#\9NZ];1/VF@]IMV5U&WQ=7LCU?$7O?;DE3@OV5Z%6Z-QZ\W$F"&^UB]
MO1T+APWD%O6XHZ6U=,7TFXYFJXQ;DV]V?3X]BEK@FN4WJ_XF3PGGU%^,3]XE
M^.URTN>/BKZU[<$5T[+*;OAI4^6C+:?Q%)$MQF9AT3(@60B0E00K1];18U/L
M:$OP-8U4J/L;EL[>6R]ZRG(4&)(CRFD=1RZ=+8'[5^=5S@X[GEY?CIV%65*'
M08:66D?"M>ZP FY]-<N-%4\Y23;78^4OQ#$_]TYW$C_+1>T_W=?1>-_LKXL\
MW*^LYO6\SB@% * DXO\ ]4A_\9'^]7%SZ7\#J.Z/M'.$_P"GX@["AN_[HKY%
M[GLD0YR,[BSCWHZUM*;Z;A!Y@\^RN7&NAU&5'4P>*\L=B9%3H$%UOIV)NL\=
M7R5E^RM]C5]]<[FLY_:^$V]YD;9C8M!;#CZ5.I4K4?0:QW;,878<>YLM7I3M
M3<CI.=2Y$S3,]2.HSPX>D=E>N>0<4\V\A\3NHJ:NRD-I.A!*?>[[6YUXGDI?
M.D>UXZ/R5]3IODW!2_Y<H:=)"7W7K]]M7]%;?'K^DC%Y#^ZR<]%PS+Y95)<.
MDV4H)N+UN,)D(N"PTD#HRRH]HO8^RA)?<VM!90IY3JBEL:B/5QH#5\UG&L+M
MW+Y]]12EM'09<O925N'2DCTB]76+;G-)'$Y<54UC'>;;$7;YR47.IF*C-!R3
M E^)XJ]U* OA;4H5MEAMRHXTKU*5>5*U,YL;S\V[N>='QCT-Z'E)/!#5NHW?
MM\?#YJKR/'SMJM:HFWD*3IU.GON-LLK>4  A)4?DKSS0<[R,I?P[KQ4>I)60
M%#G8<Q\M>AX^W6=>QY'E[W&VHK^8R&S<BZVQ-C$DH2@N(/.QMQJ[R-M44C/X
M:ZZN'0S&T6@([[W:M=K^JO*9[YL!( N>50#D_G_GC'PL/$-*LN<OJ+L>;:.!
M'M-9LF6E#SO(W*14>YP@<.1M?G;A>L1XI>A0US9K$- )5(<2V+<3XC:_R42J
MZ'48\FD?7F$QK>,Q,2 V $QFDM\.TI%B?EKU8JBH?3PCQ21-J3H4!"C_ &V0
M?>^BT TGU\R: FT H!0"@% * 4 H!0"@% * LS7.G#>7]5!(]E 4Q@&8*.Y*
M-7M%Z T^-BI$]J1(9\2T+/A/TN/94D$0H?C.@+"F7!S[Z$F3A.39SLAP/E$=
MI-R%@*%AR%C4.*>C1*DUJB!(S?W3A\ON*8X2U CK5Q-KJM9-O4:B3HCNS;<Y
MJ/<TO\,Z<QD(N8S^3FJ>3-D'X=A2K@$$ZU:3Q'95-FKU/3\JHQ:A%;(ZUN!.
MW'XQA9=AJ2ROBJ.XD*!])%7M5/*C-Q=4Z&M;T\O-N;UVJ<5!#$1UE*41)0:2
MI;.CDE/*W=7$X55#3C9<K<^6Y)V3Y?X_:FQV<'(<#GP^MZ1* L2H^(J/J%3"
M/%4.,F^[UQR[F+Q.1V]FL=+R&(FJDM0WC'<;6@H(7\O81Q%3&2>QQ=L2MTY=
M3;,%%:C8AR1(2%!P%:@H=@[*Z*CFF2G"?O:'C6HW68BMN3))U%"&RKPLZB ;
M$*Y5W%T39?"%(<N[&P=LY/<FZ\[N'-/-O?!J&/QI2-: E/B4M*N%SQM>L&-&
MM9/=F_,N*$(VX_%E65D>>NU)[\J/'9W-@U+NB&C_ )A".ZYY "K6YKU.+<<:
MXDF^$OP&)\Y_+[*N_!YZ.]MS)@Z7!(24-ZSPL%_2]E2KRZG%SQMQ*L?F7H;B
M,*B4R)&+EM36%#4DH4";'U5:F8)1:W+<'&R!,'Q#2D-,^-TJ'  5)R7(TM0>
ME910!4DZ60>04KE[* NHW%UFU,Y&,W):7P7P'+U5#1U&;3JC7<KY6>7^<=^)
MQBUX7)#BVN.HMI"N>HMC@35$\:+VT/8Q_.7H*DOGCZF-=QWG)M5!2TXWNO$H
MXEIT7D*3W7[*KI<A_P!D:N>#D[KVI_@4P_,S:4Q3C&2B2<%E6D*6IEU"BT5)
M%]"5=I-=QR5L]&9[W@KBU@U.+[$"'B_@MJS,Q)6',WN1P-Q7?><;2ZK0V$ ]
MR3<FJ\I<8\5]4F;(W.5V,%_;M+^&_P")D?,C:ZIV&Q.T(>19A/P64/!EU00F
M0H^%S4?U?>J;MO113V./&Y?"Y*_*+DI/]W^MBGRTVZ<%M I4 J?EGU$N#GTF
MU%*0/02*LQH4B9/.9,;M_14HCI3F4B8B*W"L5/);OP'"Y[ZO/&(.W<=%F!]^
M2 XK5P0>SMO4@L*DQCDI$]TAN#CFU.:NQ*6QP_+4-T1U;@Y245NSYKRN^<],
MR>7D-R5HCY1;G58O=(0LV\/=RKR)76V_4_2+/C[<8036L*&R^1.W_CMUKRKP
M)AX9LO:B3P>/N5;BPK*O8P?Y!D^W8XK>?\#NV&7XIV7>^B#I]9KTSX,Q$N3C
MHL!64R[[C2'WNDTM"2KQ'B;@=E<SFH[E]C'E==(DQ>,R#C#$AA?QL0@+84DW
M&D\1P/?4IU*I1<71D67C-LY60HSH!@9!Q)9^/B_9.@*X$:@.5=<G2G0IE9BW
M7KW.;[J_#+/2IR3MS(ID!1U)BRO"JW;]H+ZC5T+_ $9Y=_Q;;;B_WG)<OMK=
M>UYNF=%?@OH)T.)O8^D%-7J2D>9.S<M/54,WM_S<W/BPEJ2H9&,GFE[^)_B<
MZXE93--GR5R&CU.BX7S:VCERVWD$B,\D<$2DA;5U\"E*C>J96I(].WY"U/?3
MXFKYG=F+P&^3/V["9:CL-EM:&/ E3C@\2VSQTFKK=7%I]3[3QOBH/&I]/-\C
MJ.RG-P*Q;F>R#0<D9U76.M 79H<$-_)65Q2T1YGD;B4U"'TPT)\_%[/R"5?>
M&WXSCY%B\ $JOZQ4J374SV\V]#:3->D^3_EQ.0I4=V3CI"[DZEZVTG]4=U=J
M](WV_-WEO1FR^57EYCMI/SW&,H,DN7I"%% ;* D<1:_;7-RYR*<_R/W"6G&A
MMN&FMK^/?<4$MI?4G4>5A5N1&G%>AX&)/DY/_L<P\Q?)N%O#=;^>3N!$,/--
M-=#IA5NDG3>]^VM6-Y#VH<:5.[N-SE6IK8_#5![=U)O_ ,%/Z:O_ %?_ *E?
MV?J/_MJ@?_VI/^"G]-/U?_J/L_4?_;5 _P#[4G_!3^FGZO\ ]1]GZE,G\-L)
MB#)FJW/K8B-J>>*6 2$H&H\+]PJ8^5;=%$AX=.IH\/;WEXS)8DC<\A0;6EP)
M^$YV-^^M<KMUIKA^)4K<$Z\CIFR-X3=P;FW0!.D2<*RB-]UL/7"&P/"HH2>5
M[5YF994+<-/FUJ:K,^4I=CI2<1-9AF6Y+2S'2C6I1/)([Z\QNAJ2;+T#+8[$
MQI$W(3Q\*G2%.J]U-^^W?7$KL4JO8LC:DW1;G,MY[LV[-\R<%E(DUMZ!%4@O
MOIOI2!>]Z\J_?@[L6GHCU+%F:M236K.G2MS8'.8=]S%RD2T-J"5*1<A)/KKU
M;=V,_I=3RKEJ4/J5#@7F.\'-SOJ'T&D)_=%>'GO^JSW,!4M([GL<)QGES!7V
MJ8Z@'I<KV,54MH\C*=;C($B<UCL?'<4RW)DSGBE"'2$V2D'C<]YX5W=N<3BU
M;Y5+$K*X*,N,B<'\3)DJ2A&L:V2XKZ*5@\;'A7+R$J<M#O[9NO'4RN05F8+)
MCOO:V71X3>_#T5>9SE/XA,S\'A</MMM5G7[S)5OI(Y)!^6O7\5:JW(Q9<]$C
MA=A7MF ['^&C;?QNYY>;=1=K'-:&5'D7'."OE KRO*W:14>YLQ(5=3Z"W1*Z
M./Z0-EO'2/4.=>">@:S%P$C+20A*NG%C (=7SNOF=->I:O*S;7YI'AW\>63>
M>M(1T-K:PT.#C7F(J+%2#J6>*E&W::P7;TKCJSU<?&A:5(HB;1<!B/-]J%W/
MRU6R\F[AFN0\1(=:25O%.AM"?>*EG3P]5[UQ)T1Q-T1\V^9F67-W&88>4^SB
MFTQ$J6;DK0/M%7])K!>E5T['@YDZSIV-3JHRG0/)/ ');P1,6/L,:@NW(NDK
M/A"?RWJ_'C653=@6^4Z]CZ/K>>Z* MR7@RPXZ>2$D^R@+.,9+4-&KBM?C4?2
MKC0$J@% * 4 H!0"@% * 4 H!0$/*JM%"?[Q:4?O&U 59%71QKY'T6R![+4!
MCMKCI8E3JN&I2ED^BU2#"QH,K+OR70Z XD\-7;<\J$%M\9+',N0W$A"'^9^M
M;N- 0-_;'>W+L48./E$8YUQ:7G5$!07^HKCP%5W(\E0UXF0K4^353);)Q>VM
MIX&#CFU-*F1F4MR)+2>+B_I*OZ:F,:(KR+[N3<NY>B2\:[F)#\XA;2R>DI?%
M('9<5V4DK"=-6<?7"!$33Q[J U[SI\QH&U-N.-N)4Y-DJ2AEE)*"I%[K(4/U
M:JN3HC;@XKNS]!A5LR\3CWD,F*G*!N0MIS@I*;!*0I7;X:[AM4HOZ2X]C9]T
MSV(6)#06 WINM0/)"!<FI*:5T."3-V,P=N3MR8C,VW3DY70:@(2%IZ5]"4J2
M?;>J,J=$HQ=:[_Z[GM8V-6?&<?DBMS?\>QNS:6R(Z=JL)S$X!+LB(5^)2G#K
M=YVL>-JZ47&-$9'<A>NMS=$5X7\0F!#WP.[8+^W)Z39SXA"BP#Z'+<?9175U
MT.Y^-EO!J:]#<,A@=@;WA)6^S$RC2T_9O(TJ6D'M2H>)-=M*1DC<N6GI6)SZ
M?Y!9?!N*F>7^X9.+<!U" \XI3*SW+5SM\E5NU3Z6;H^14]+L5+U-CV]/W^WM
MM^/O/H_>2W>DP6!I"VD\U<.^K(5ZF+*]OE_3V)F0LPQ'B#FE/4=_:5V'U5V9
MB#0"@)D3+Y"+P:=)3]17%/LH#!^:&39R&WXL9O&_$9B8^&FNBD%Y+2!K<6@]
MGA!%4W$NQ[7AJ\W)RXPBNNU>AB=J1X$_>C4AN2^]@=LPS)4B1?P/%-BDI-K*
M0*RP^:ZY;J)OR7*&/1I*Y=E30YK,G9+?WF($]11,R1TFPDD:(P-B1;EX>-4M
MNY,]V%N&'B_!5_:?1>,C,+RC;3=A"QK80CLLEH6!]HKU4J*A^>3FY2<GU,7/
MDF3,>?/TU&WJ'"I.#,[;B/&)+?;]Y:2AL>D4),/(CP)F&GX7(]5A,X%MUYO@
M;=Q]%<SCR5"[&ONU-36Z.:[@\@EM8]4K;62^\W&QQB+2E"U6[$<>=89XC2T/
MJ\7_ "2,Y4N+CZFX[ VS(VML5$>8T6<ME'"Y)0?>"!P2A7I%:,:WQCKN>+YK
M,5^]\KK&.QMV3!B8B+CT<'7R%N?+V5H/(.7^:OF!-V_GH>(Q?37\''M-;6 M
M"END'A?MT\*PY%YJ5$?5>%\7&[9<I]7H<_9WMO+(Y@1L9/D0VYSB&FH;*SI0
M-0 T^D=]9E<DWH>X\"Q;MUG%2X]6?1DIA]4C'8QQ?6E,-MID/'B5K !4J]>M
M%41^>79*4FUHC9Y\A,2 X[?W$62?3R%#@UB#MQG,0''9A"BZH\% *!'IO4D-
M5- W)Y);8R4A]N"4QYS5PXF/P"21<70;)_+7<;[1EO>+A)5I2IRO<OE+GL&E
MR3K1*A,\7%@Z5@?K)J^-Y,Q6/#2E>C%:Q;53%8'%N97,PX#2%.==Q(4$\PB_
M$U9)T1^K7IJS:;_*CZIA[A?A--1?ATICLH#:$ :;!(M6$^"E)MU9&QZVR'RH
MM*<<4+(=[K\;4.38).&PJXG5<T,(";EX* 2/E/"A*5=BS#P\2"AR<S(ZX2VK
M21;3Q'.X-=056D<77QBV:_$<6O;2UJ/B7*NH]_.MF>J37P/-\2ZVV_4B5A/4
M% * 4!E]LMH=EO,N)"VG6BAQM7%*DGF"*5!!R&THT=A;CF,B(92;#2VD&U^%
MJL]V7=D<5V+$3#MQX;TF-$2RTHI"G&T@7L?17,IM[LE)(V"1G<+,QB\?+;<4
MRZWTGD@#B"+'C>JY135&=1DTZHQ4J)LZ5&7%?3*7'<MK:*O";"PN*X=F+5&6
MJ_).J,<G97E>1_R3@]!-5?96^Q9][<[DUJ)M7#XM^-A6E-!Q74<"N7A%ZNMV
MHP6A3<NRN/4X)E9*LGF7W1=7Q+VEL>A1T@"OG+TN<V^[/HK4>$$NR.^,G)1L
M- PDEOIF.VVV.%B0D6%?26X\8I=CYNY+E)LY_P"=\^.<KC,9'7=>/8^WT'@%
MJ((Y=M>3Y*=9)(]?QL*1;?4Q7EM$R>X]UX^+*D./P\=>04.'6$@'A8']:J<1
M2N32;T1;EN-N#:6K.VY:T_/LQ0? T/&>RWO&O?/!/E?S7W$,]OO)RFS_ )9A
M?PT='8E+7A-O617U&':X6TCR;\^4F:B3:M12?47E-C)NU_+S'N-,Z9.34J5)
M*A<@G@D>P5\UGW>=U]D>KCPXP-BR.6=G.-N.HTAA%U([R.9K+;ARDEW.KUSA
M!R[(S&!GXN"VUC7I"49%Q(D.M&][.'@2>7Y:ZRKJE<:[&?"2A!)_4]7^TSZ5
MMNHU(4%H5]))!'Y*I-IK*\3F<<^X] 4%MJ-] YGUBI!<:W,1]ED8Y21PU@=O
MJ-10@U#-^4&T<^Z[+QDU<28\2MTWU@J/ZJK6JB>.F8KN!"3JM&<^S_DUO+%:
MG&&4Y!@<0I@^(#O4#:LTK$D>?<P+D=M3I_DCMI_$[:<DRF5,S)SI4XVL64D(
M\(]M:<>%$>A@6G"&N[.BU>;A0$+)?:%B*.;RP3^RCB: F@ "PY"@% * 4 H"
M'B)GQ<%#I-UCPK]8H"90"@% * 4 H!0$*=XI,1KZRRK]P7H")N>8VUCRS?[5
MTV2GT=M 81>_ME;>C,8W,9-J+++(=6RI*U$(4;!1TI4 *OMXUR:K%:%<KL4Z
M-F-=SFSPM3V/SS2$GC;QV%^-K@4]B?8GFNY;.:VXZM/Q.?94H^[P638<[7%1
M[$^PYHO,Y/8A(*LZATD:K)2KB!S/ 4]B?8<T3\?F/+:2^(T?*1W7S]%3FD_[
M5A1V)I5HQSCW)>18VTR\E@DI4IM3O42;I"!VFO/O9D+;:ET5?V&RUB3G'DN]
M".(^0Q["9T![J1' %A5N8/(E-:+=Q3BI+9E$X.$G%[HPFZL9MW>#,9G<D,R$
MQ%AQEQI900H'M Y@U,H)[EMC)G:;<>IG7Y6 DQV6 ER/\.@-,D 6"$BP%=%#
M=6<Z\Y,Y'PNR9 9EAR5-/PT9OC?2??\ ]FJKTJ1-WC;'N75V6IQWR9VM)S>\
M&7&F0^QC 'W4&U[\D$ \#8UFM1JSWO(WE"W3K([5DO-+:^+W%)Q6:CRL0MA8
M2WDPA1BKN ;W(X<>ZM/O).C/"CX^4X*4&GZ=39-6$W/CTZDPMR8]2? ;)<6
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MKC83_-J=.VEA&\;Y8XR*.HU.R[QG:D#4H+;X@>JPJBY*LCR\N]SR)/I'0SF
M^-1MM2Y;_P 4_D):W#)TI25(38)!">'"N9'G9S7-)*B2V-@G,F-"6I49*"$I
M:1(0J^H'G<5R8C5=R9>1%S>V,-"A%Y60NEY]:24-APW*KVM?PUW&-4V>IAV4
M[4YMTH=)RPDC%NMQVB\\I.A*!8<^%^-=6*<U5T1XN4Y<'Q56S386-W=#2E#2
M%,LA04JZTA(X\;\:]6Y>L2U>K/G[./EPTBJ(V.=O7:V,8U9'+16EH'VMG$JL
M0./!-S7E*Q*3T3/HU-):LY=NWSM\O_CNM!=<GIL LL)L%>K5:M4/&W7OH52R
MH(Q&3_%"XAI+6%PHTI&D*DK(( %N2:U0\3^:15+,[(TW+_B \QYQ4&YK4)E7
MT&FT@C^OSK5#QMI=*E4LJ;-2D9_>>:U%V=/R"7#Q2E3CB3Z $WK2K=N'1(J<
MY/N9+%>4_F%DPA<3"O=)9%W';( ![2%D&N)YMJ.\CI6)OH;'A_P][TR:G$B5
M$C*:]X.E9[;?1!K,_*VUT99]I(V6-^%O*DI^)S+2>'CZ:%'CZ+BJ7Y9=(EBP
M_4IRGX7,LW%U8S+M/20>+;Z2E)3Z"GMI#RRK\R(EA]F<XW#Y8;ZVZX5S<8[T
MD'P26+N)/I&BY%;[>7;GLRB5F<>AC7-W;H5$&-E9%]Z,VH+$9]15I4.7!7*J
M\CQ]B\J2CIZ%EC,N6G6+-U\K/-;$;4GR9.5@./K?2&T/,6*D)OXK@VKR8_X_
M&W)NV]^YNN^6E<24D=D@;QV-N=]4C#YEEF6;%R.^>D0H^E5A>J+F)<ANB(W8
MRV9FG?OAE@MR6A,A+YI6 ZA8]?&LS2>C+4VMB^E2&MKN-Q8B8;"562RV+) )
MN;#UU$8J.B)E)R=6:QOC9QWCM*-AL?DD0Y++A><0X/"X;<$K/=ZJV8F0K4JM
M5*+UOFJ'"=R>3N_L#K<>QYEQ4<Y47QI/J3[WY*]VUG6I]:&">/.)MWX=-JRG
M]QS\PZPIIS',E$;JI*3UG!8BQ[A67REY<%%=2W$AK4[)(GYIEMQF45:7;I5J
M'ML:\(] P^6R*<1MS+98^%;+/PL95_[9SA<5=DR]NREU>IY,KE9SN?E7%?$^
M?KJ42I7O*-U'TGB:\(\H4 H 0#0'9?(%O,2I,Z4_+><Q\9*6FHZU$MZU<=20
M>X"M>-5GK>.Y.K;T.U5K/5% * H?=#+"W3R0DJ]@H"QC&2W$05>^Y=Q1_:XT
M!*H!0"@% * T>>HL3FIS/!+MG4D=A[14D&UK98R<1I2E'I*LO2.%SZZBA-2R
M,$T1I==6M 24I'*P/>1SH"?&82PPAE))"!8$\ZENI"1<J"10$'*9B+ ;\9U.
MGW&QS- :A/RLR<LEU=D=C8]T5)!:AP9,QT-,(U'M/8/70&TX[;4.. M_[9WT
M^Z/DJ"3)OO,0XRG560TV+V'#Y!0&GY/,,RPAV?*^$C..AF*T$J45K/H3>NXP
M;V.6Z&::V[AI,-MR.O6E8NF0A6H*]/=7+JB3&SL;+PX#S,NR";)3<@D^KE0D
M]C;JG-I'Q#8=2?I\OFX4H"QE,!Y>[I;4C*8YGJKYK*0VY^^FQJVWD3ALSB5N
M,MT<^W%^&+%R M_;F2,=1]R._P"-H?UD^*O1M>5DOJ53-/$70Y9N/R;\P,$I
M2G\:J5'1Q$B,>H#;N2+JKT;6=:GUH9IX\T1-KYK>_P![1\!%RTN 9ZTL+;<6
MM.@*-KA)]VIO6[?'DTG0BW*=:5-S\U/(^)M7 )SOWH]D;.I3.3("0M07S*%#
MB3?OKSK=V&3_ $Y12['H0NW,=J<9/0Z1M?*[<SF!BPL;)BY2(TRAI6.?"2I)
M"0"G0OF?2*\V]C2MZ21=#(Y/DGJS!Y;RAVJY+5+Q#DO:V6)U%Z*M6@D=Z3R'
MJK([*Z:'HV_)32I-*:]2,N;YR[8:'Q\6-O'#HYOL>%]"!ZK+4JU16<?4LX8U
M[9\)&1V[YL[,R,E,82W]OY4FWP4])1<_M#@!ZZZC>3*;WCKD=5\R]#;I:W$!
M3:V64K?*7''F4I!='T2HI]ZK4C"V]F,RO/RH*E;9D,"2TWI1&DFP]=O=)%57
M%+H;<2Y8JE=3XFFJW_D,8XF/O7;S^.<Y'(0QK:X?27]$?)5*R)1^I'IR\-:N
MJN/<4O1[FU8W,XG.Q+8^=%S,1?$Q7M*E6[M"^/LJ]3A-'E7<:_CRU3B^YK^3
M\MMKO2%28!D[;RA))?BJ4$$^E)Y#U55+&6ZT-UCSEU+C<2N1]33_ #)RN\,5
M@$;;S.9:R:)2PY'4TFRC'2+?:*YDZN^LUYRBN+9[GBH6+MSW;<>--_B6?)G%
M/RIKDU]:U1(Q#,=LDZ4N+YJ2.7*N\2-75]"C_)+ZC%06\M6=B+[L-];<245(
M2=(2KD>_@>%;SY P>?VEL_/7.4Q26) Y3(G@5J/TE >%54SL1D>CB^6OV=I5
M79FA9+R5S<-TS-IY42=/NM%19DW[@19-998LEK%GT5C_ "&S<7&]&GXHZ5Y1
M/[Q:V]/>W4\\78KBFF8SZ1<)0 =6OFO5>U7X_*GS'B^:]CFO92HU6J,OCY"H
MT.9D>2W3TV?63Q-:3Q2N-&Q,:'\;F'/$ZE3J4\=6A/O&PXFN922+;=J4]BW*
M9C,,1<OBUJ3'>(+85<&QY&QX\?34IU.9P<71[HF[@F*E)AQ4<WK+6GUU)R8>
M9D,)'DN,SHZHL)I)OE$J!;3I('C'/Q7X54[E'KL;8X3E'Y7678E0FPX=6$RS
M,NPN&6W$E5CWI!KM23,URQ.'U)HS&#S,F0\[&F =5D$E8'=SO7168"9+,G).
MRCQ2@W3ZD\$T(,M@,UD)$T,/'J(4"2;6TVH2<'\T,B]O/S/:Q$-75CL+1":*
M#<6)NXK^J;UYEY\YT/NO%VUC8CN2W>O_  ==FH98Z$"/;X>"TF.WIY'0+$_*
M:]**HJ'Q%VXYR<GU/GKS%!&]<M?^\3_NBMUKZ4?9^,:6-"NFAU/.,Q,MLC;J
M8NZ8V(D08RM:2[Q/4&E04$'4.%5PMRK]+9\_#/M6;T^24DV26=^;+PN*PV*;
MEKE1X#:6RZVR[I62;J4%J%B+GG7:PKLGL>1E9L)SE/N3=V;\9Q$(N.;=R#<5
MQ2"W(4MOIJ4Y[@%U$\:6L3G+BI+EV*97J1Y4T+[V[O,16-AOQ<) C)<=#$=N
M2XI;R3:^LZ+I KKV+2=')O2N@A=G)52H8+S WAYB83:+>3?S<:+EG'@E>.CI
M:4 RKDNZO'5MBU:E=45%N--_7L<\I\')NE-O4XE,WEO;-/*4[E)LE1]YMI:]
M/']5/"O85BW!;(P.Y.74JQ7E]O+,7=A8MUPK)NITALD_U[5$\JU#1R)C9F^A
MO&(_#=O>:E"Y<F) !L5MK45K'H\%Q62?E+:V39='$EU-VQ/X7<$TI*\GE'Y)
MMXF6TI2B_KYUEGY6;V5"Z.''JS=,1Y(^6^+4%LXI+R^U3ZE.7/J)M62>==EN
MRV-B"Z&WP<+AX"0F%"8C)'(--H1_N@5FE-O=EJ26Q=GN=*$^Y>Q2A1'KM7))
MAMHHM%??5P*E6)]7&I8,%+R4UV4XYUEINH@!)(  /HH0>,Y;),FZ)"[_ *QU
M?/0&4C;L= T2V0X@\%%/,_)RH20,OL_RUW2@HGX]E+RN:T)Z+E_VD6O5]O)N
M0V97*U&6Z.>[@_#!%<2M[;N5*%*XH8DC4V!W!2>->A:\L_YD9IX:Z,Y;N/RC
MW[@2M<O&+?CMGA)C?: ^D)3=5>C:S;<]F9IV)QZ$3">8N^MM/E$/*/LJ3;7&
MD7<2 .SIKY5U<Q;=Q:HB-V<>IW?;WF=YA+PK62SVU_BL0ZUU52XI 5H'TE(5
M8<>?"O&OXMJ,N*E1^IMLWI35::?\&3C;GV1DW&PSD/NN6^ M$2<DM#Q"_!2K
M _(:S3QIKI6G8N5R+53.MC/0D!V.YUX_-+C9#J"/1:]9V=DG%9]AN06EPTM/
M2%C6MI(25*/"ZJ-L%_<T+(R'6ULM=5EI).D'CJJ8)-I,YN2:BVMSDWG%/5"Q
M>*P \#[EY<U'?JX(]E4^2O<IT6QX=U.%J,'N]6<JKS3&* 4 /*@/I;R:Q1@;
M(C:V5-.R%*=45BQ(4>'R5Z%B-(GT&%#C;1O-7&L4 H"%DB5AF,GF\L7_ &4\
M30$T   #@!RH!0"@% * 4!HK/^8QSS!XN1SU6_V3[U209G:4[4TN(L\4>)OU
M'G1DFPU % * QV:RR<?'\-B^O@VG\] :4\\Z\XIUU14M7$DU)!?QN/>G20RW
MP3S6OL H#;<#&:9A7;%@M1X]IL;?FJ"3)4!KFZI*G'&(#?%2R%*3WWX"I!QC
MS7WKE8>^,9M[;^EUR(UT5M\BIZ1P6F_8H#MKV,+&B[3E(Q7[K4TD=VVPTAC"
M18R(ZHG00$*CKM=!M<BXX'B:\FXZR;W-D=C%[E(5E(R'C9CA^4\:Y1)L)BPC
M'T%M'1">X6M4 U''XN/.R,E@**6$:BVM/KL*D@7>A9!V##R"52V-.N.3:VL7
M2/%X;D=E=<'2HJ9!K<TV,KISXYX<-0%B?S5R2:!Y_8[#.[*:W%#80UD8KZ'&
M);:0AP*O](BQ/RUZ/C9OW./1F;)BN->IRS")\P_-AQ[#R,REP8UH2&VGQI2O
MCIMX>9]=>E<]K&^91W,L>=W2IK.=V;O/:<O5/AOPG&^*9;))2!WAQ' >VM%N
M_;N+1U*Y6Y0-EVSYY[LQ;:(^2#>9@"PTR.#B4]NEP>(GUUFO>-MSV^5ED,J2
MWU.I[7\T=A9Y:1$R"L+D5?\ Y:4;)OZ'!P]M>5>P+D.E4:X9$)&<W!M##YB.
M/OW$1\DPNQ3,: "R!Q!ZB.)^6L$H)[FZUDW+?TLR4)]A4AQ:;-EMKIPV2!8:
M0 D<>'"I>Q7%IRU-9W)O,X3))9S&"DF M"2<I% 4E*C[VNWAL*SRON+U6A[%
MCQ<+\*PG'EV9D\-N/"YN-;$Y./D6%\#"D6U>KIN<_DJR-R,S%?P<C'?S)KU1
MB,QY<[3F22_\._@,H?\ \Y")1R_5/+Y*XEC1>JT->/YR]!<94G'LR.W$\TL(
M$IC2(VZL3< H>.AYM%^*E*/C)%<4NP]4:7<P<A:IVI_Q.1;_ ,R<ONF6^VV4
M);(9;8!N I'!03ZS6.]/E*I]/XO&5FPE^T[KM#:,G;^T\2$-%U2V^O(X>(*<
M\0"K=P->C8AQBD?#^5R?>R)2Z;?N)BPA:U$'2HGW%<[FKCSA]LWZA\J?T4!<
MCI:>>2EP]+F2ZGF+=M 5.SYG25'^(+K)X<;\0/70$MX(?^ QS"M218N*3]97
M.@(7F%DY#.:VW@\79.0FOZ%OA(66HP'VO ]BJSW9:I+<]?QUE.W<G/Z8K][Z
M$^;!1%7&PT=Q;H2K6M;AN;JX_)ZJNBJ(\V[<<W5D7)2I*&,GD8;"I3L-A2(;
M*!=2ED:4@>VHFZ1T.\6VIW(J3HJG,8?DUO\ R>UER',DIJ7*65R,9(4HZDI]
MQ.KE\AX5A6/-QW/K)^9QH7J*.BVDC/\ D_Y>Y;:+N2S&?:3$EJ;Z,5@+2O4D
M\2KPGG>K<:RXNK,'G/*6[\8PMNJW9O$-Q4?%RIJC]M)5TFU=]^*JV'S1C%#I
ML"_ *\14>%@* N0-Z;-P##TO*96.TL^$-I4%KL./NIN:NACW)[)G+N16[.;9
M?S7\J,?N).>P&%=DY=&LHEI^S:)<%B5()Y_)6FWX63?)T3+I^<N.U[57*!I>
M7\Z=VS2Y\*&H 62;MC4;$_K5Z5OQEN.^IY4LN3VT-0>DYK.SW9)#LZ:\072T
MDJ43RY)K8K<(*FB.'?NR5*NAFL?Y4>8&12%QL&]97$%P=,_[5JKEFVH[R.58
MF^AV3;VU/-P8%C#RL9C68S,=,9 D*UJ";DJ5='::\N_>LN;DFZMUT-EB$X12
MHM"G(; \Q<BXQA-Q[E9>AK6E:6X[(&CCX;%0^C:N%EVH24H1^9$JS*C3>C,[
MN#RTB-!J?GL_D)ZFR$,QVBB.GE8^%NW'O-,>ZYND(I?B4Y-R-F%9.I3BO+[R
MSD)?FIQ3K\N,U;JRW5ND)[ +J(J<FY>MK66_8XQ,BW>>B>G<RVW]FX<L%R,U
M'B &UDH2%FWIKSY79/=L]%12V)6/QC,N3)0Z\4,1TE75X<D]IOZ*X)*X\;$R
M1_Y;G8[W=H>2KVZ37<H26Z(4D]B:,1N%D79E=0=GB/YZX.AU=VL>^G6!Z$GY
MJ ]_U#FFC9V'?O-E?FH"UD-R*D0W(ZF"VM?"_90$['?Y7;2G.2E(4H>L\* U
M.]^)YGC0@4 H!0$B-D9T8W9>4GT$W'L- 9B+NUY("930<3VJ3P/LY4H21<OM
MKRZW4TIK)X]A3CGOKTAIS]]-C5UO(N0^EG$K<9;HUS)^3>78(?VKN63$2@ -
M0)*B]%"4BP3I[K5ICFIZ3BGZ]2EX]/I=#"[DB;Q7 BP-W[?;FPXQLYE(*$NE
M2$FZ4E%BM(_9JVV[;GRA*C[,Y^>,>+5>S[?Z1C<"SC%)F2=L[IDX&:'$AG$R
M"5(0%'3;IN]BE<JZN*:2Y14_4F+BY-)\3+93S0W?LA^.-X8N)DHS_!C(0RE+
MRU)YW2>%56\6W>;4&U)=&=2N2A'D]4;;MOSP\O\ .%#29XA2E"Y8DC1;^O[O
MY:INX-V'2IU"_"74T?S+V%NW-YV1G<=TLGCW !'+"PHH; Y<^/R5Y%^S/E4\
M[+QKDY<EJCETR#.A.=.;'<C+O;2ZDH]EZR--;GFRBX[HL4.10&4VOB',QN+'
MXU%[R'DA1'8 =1O[*ZA&K2+;,.<TCZX890RRVTA(2AM(2E([ !:O4/IDBN@%
M * @LGK9-USZ#"0V/VCQ)H"=0"@% * 4 H#1;*QV5*%\4I5I5Z4FI("%JQF6
M"DFZ$JN#]9"J WAMQ+B$K0;I4+@^@U!)50'BU!"2I7!*023Z!0&A92:N;-<>
M)\-[-C]45)!$ )( %R> 'IH#=,=!3CL4M1'VI05N*]-KVJ"2;CT:(;0[TW_>
MXT!?4H)25*-@!<F@-5QJAD,Z[)6H (N6P3QOR3:I(.=X#R>SK/FZ[G\RZB;"
M0HS424W!ZZC9M-E<]/;7J7,V+L<(Z/8RQL/W.3.SY"?&Q\-V9)5I89&IQ0!)
MMRX <37EQBVZ(U-T,;(^Z=P,*1&D)4^P?%I(*VR>.E:>:;^FI<6MPG4@?<6=
MT_#_ !'V'?J-OTU!)<RC3>W-MS9Z9(9<C-J>6\H722D>%)]!/"N[4>4DNYS)
MT53C?E!G]P;NW#.R.9*3CL<Z<B%I%K22DH0T3S4G2;B]>KG6X6H)1W>G[#)C
MSE-U>QUR-*ES,;.=E$.,H'@U 7"B>PUXYM.=>=KW2\KF&RO3UY@ 3]:PO:O1
M\8OZO[#-E/Y#2?P^O.,9C-N-DI68:$I6.R[G&MGEOHC\2C#W9VR?"?1%8,AP
M2&Y N&'!K3\H5<5X:=-C>S6_^V&TAE59=S# 3(Z2\F/Q#3J[<%*1R\/<*MO>
M0O1MM)U)Q\2W.XJZ%W=7ESM+<T0,RF QT0TMB;!2VVLN.&RF> T'Y>5>=@^7
MO6IRUYQ27[^QNR?'0N)47%U?[EU-6D;4\Q]FO-/[&R,C)X\J+<S'S%)6IM;8
MOH-^!![-->QC>2Q\J+]Q<9)T_:>9>P[MEKC\RI4D8?SUV[*=5!WCBUX?(-$H
M>?92K2E8X64V?$#5]WQCW@^2*8Y2VEHSHN.$?)1.O@<BSDX:AXF-25\.Y2#P
M_)7FSMN.DD:H3ZQ9K.>\O]JY!Y3LN YB<C]&?!^S4#WV]WV5FGCQ?H>MC>9O
MVE1OE'LS'MX[S1P#8^Z9[&Z,6CE"E>%U*?2I7B4?557&Y#;5&[W\')^M>W/N
MBQD/,&,=OY1UW%R\-EXS)3T'04MK4OPD(4>/;>I>1\KJJ,YM^%2O0XR4X-]#
MENP<.<MNN&VZDNL,K$B2;]B#<$^M58[,.4DCZ?RF3[./*2WV1]+AO)36%39$
MM,**GW2M6A 2/9PKUFTC\XC%R=%JRP] GI:#I;3*CJ%VW6^((/:--2F0TTZ,
MAHTZ]*%EM0X:%\KT(*G"MH*94T@.J_M0>-OFH"3$A-S,@S$1_#0G[1Q/;;B3
M0&?A;=9A2E/M+*CI(0%=A/JJ"4<ZV9B]]J\QIN8SL<2XL5MR$QDB0V-*3<=-
MKA?5>UZRVXRYU9]#FW<=8JA;=&_F<?\ Y-J;=65SLB\"E8NAL'ZROT5K/G3,
M;:AJ:QBW?==?N0?1V&A)KN7RD/')*LON"-$(XELN@K_=2;U9"U.6R9S*:6[-
M"S/G/L6'=,9Z3F%I-B&ATTW'_$K;;\9<>^AGEE06VIIVX_/W<&02B/BX;6.B
M- AKFIRY^D;^&];;?BX+ZG4IEEOH:1/W=N[..H;DSY$EWDAMJZ2?ZJ+7K;#'
MMPV21G=V<NI/POE9O_.J+D3#O<3XG9/V-_3=?.N9YEJ&[.HV)RZ'0\%^&#./
ME+F:R;49L^\RP"IP?UO=K#<\M'^5%\<-]62]\>7_ )<>6N#BSI,)>;R+KZ4,
MIE+*00.*R0BW(<JYL9-V_)I/BCJY:A;5:5.B;7RF.R?EX_N#;F%;Q;ZX[BX2
M"VA2RM .DW0+J\0K#=@XW>,W4OA).-4J&I^6/F9YBY!&08S,%,E[&Z"XRM)C
MR7.JH@!.JR*U9>);BE*+TD4V+\I2<9=CHT7S%VLY/3BY4QN%E;#J0WE *2H_
M1U<B:\_V)-52K$U.25$]V>Y@)_U##6..K3[+FJCHO97%NY/.,M26B<>RV5!8
M/ K/96VS>5NVVG\S9YF3CN]>2DOD2_$FX[;N/@!]+()1(%EI5QX51>R)7*5Z
M&G&PX66^/4@.;3:N51Y*D GD>ST<*I-15)P;\7 9%B&.O-E,.-HN0 2I) %S
MZZZMM*2;.9+0^96_)K=^%AJDYF>QMP*=#3 4[</+(U<%-FPMZ:^B>=;DZ17,
M\Y8\ENZ&R9;=^ZMA;)P$3'Y=$J;*=>>?D!8D)=:"BD *5J-AZ*SPLPO7)-JB
M+)3=N*HRW@_Q(;X7-BPG8<.1\0ZAK6O6%>,@7\-3<\9;2;JR(Y<JTH?2T=3B
MX[:G0 XI(*QV7(XUX3/0,#NXMI880A("EJ-[#C:B!<S9^'P#;(-BH) ^<T!J
ME"!0"@/4I4I02D7)-@* FG%JZBF Z#*2+EK2H#OL%^[5'W4.?#^8O>--0Y="
M#Z#SJ\H% 2(V1G1C=EY2?1>X]AH#,1=W/IL)+06/K(X&E"25.VOM/<</JR\>
MRZE\<70G0YS^NFRN?IJR%Z<-F<N">YH>^_(B/G(K:HV8>83";(B1W[.-( _6
M]\_*:V6,_@VVM7N4SQZQXIZ'$LKY.;XAMNO,POO&(S[ST?Q$V[D>]7JVO(6I
M=:,QSQIKU,-C]R;SVQ*2(TR7C7T#PL.Z@ /^&KA5\K5NXM4F5J<HF^8W\0&1
M=9$;=&(BYAFUE/Z0EZWH^B*\^]XB$OI="Y9-?J53+1G/)/<]DQ);NW9ZQ?H.
M_P /5Z5FZ?RUY%_P\X[+]QP\>S/;Y66LEY/[A;9,K#R(^:A6U!Z,X.7MXGU5
MY=S%G$SSP)K6.IL7D;M*>SN&;D<C%<CJAH#2&WDE-U+XZA?G:U=8\'6K+O'V
M6I-M4H=RK8>N* 4!0\X&FEN'DA)5[!0$?%M%$1*E<5NDN*/;XN(H"70"@% *
M 4 H#6-W0[+;EI'!7@6?FJ4#&/\ ^9QK;_-R.>D[^R?=H09_:T\O1#'6?&S[
MOI2?T4),W4 QVX)!8Q;Q2;*4-*?EH#3HC06I2E>XVDJ5^;\M203-NQ/B<D@J
M%TM#6K\WY: VO*KTPU#ZY2C]XVJ"24VG2A*?J@#V4!AMQ95EF&N.VX"^YX2!
MQL.V] :_ BPGVK?%&/+!\.K@FWKJ2#(?'YS%A)?L_&)LE=[BWH(H2:KYX;CS
M[.V<>WMZ,\]+ENA[J,H+A0VUQ5J [.-;L"W"4GRV,^1)I:'!,%YG[YV[EI<M
MB6?B)CO5R#+Z!9USE=7"X^2O:N8ENY%*FVQAC>G%G9/(WS'WSNS-3V<H6GL:
MP@N+>";*0M1\#:;<+6[Z\O/Q;=J*IN:\>[*;=3(_B-RF3:VBWBL<RX\N>Y_F
M0V"HAE'%7+TVJOQL8^Y5]#K*;XT1'\L=O*VYY<1D.IT3\PKXB0".);_L_8*X
MS[W.X^R.L>'&)L+,F68ZHB' &%\5(-@#\M8BXYIY^2WCM7#P5MV0B8IQ#G?X
M"+?EKU?$_7+X&3,^E&-\B&UB)E7=(T*4EO7VW'&U=^6>L2,/9G>LMT6XL K0
ME2UI"6M8)0E5KW4$\:^>OW91HH[OOL>OBV%<;KLC'YS+;G5@ES,)"$O)0U%!
MBW"&G!;C?5XBFW*U=>,OQOQ^?3H__@XS+/M/Y=36]K>9N-S^1;P&6QLG!YU9
M"F8:VO 5HYN(L!8?M5NR?&*,*P:X^A18SI*6M:^IN\F#DHJ^G$8Z[;J@XZZ%
M)0OJ?24J_?Z*\&[CS@N-N-:NK=>IZ4+L)JLG1K3]AR_S*\F]P9'=#6Z<4W'G
MA"6U2<:O[-3JT<2HJ/ ZJ^I\=FJW;X2W[GAYF/[DFX[$+'IV]F,D?O<R-D[N
M!0E"F 8["U"X&@'P*'??G5DX2C'Y'[D-=SE7$W22X]B0UYK;IP6;?V]EX@W8
MU#;UORX;92\EOZZOHD6[JX6+"Y#FOD^/<LE<<)*/U5U_8;;M_=?E]NFRL-DA
M$F\OA7CTEA7: %6)^2LEW%N6]UH=PNQEL<Z\^<M*:E1-NN/I>Z-I#Q'O D>"
MYY\1WUY&9/6A]I_C6,U&5Q_!&1\D-J.';>3W 47<?5T8QMS;3[_^U76'#2IG
M_P ER:RC:735F\;EVLWO?;;&)9DF')C.)6XY=7%N]E"R2+W'?5]ZUS5#R?&Y
MWVT^35=#(L0MT;4VZIJ*I6?5%2.BAU2&BEE'T;\+D)%0E**[DRG:R+M7_3K^
MW4Q&T=VJWIB\G*F8_P"[G(KA^$.D@+;3P)U^ZHZN'"EFZYG7D\"..XI2Y56I
MG\)@HT^+UWEK!O8)!X5>>41I&0A;7RBES'4,0U#@XZH)\)[;FIC%RT2J&TMS
M,_ZXV?\ !B8<S$$8\G"\@#YZ[5F=:4=2.<=ZFG9S\0GE[C%+:CON3WV_H,((
M2?4L\*U6_'79=*%4LF".6[J_$5E\FO1B\:W#CBY'6.I=^_P\*W6_%17U,SRS
M'T1H^5\SM]Y-CX:5F'OACX4LM?9@#N!18UMMX=J.R,\K\WU(\39F\\N>NG&2
MGDVN)+Z5:>/ZZZZED6X=4%:G+H;[MK\.&ZLHPW)GRV<<RH\6^+BR/1IX5BN>
M5@OI52^.(^ITC"?AKV-".O(+?R:C[R'5:4?($V/Y:Q7/*7'MH7QQ8+?4\\S<
MQMCRRV^PC 8N*UEI*@B&E385I2GWEDFZK=G.HQ;<[\OF;H+LE;6BU-JPF_&<
MOLZ!F8:3KE)"3K24@+0++L#V:N59+]IVYN++H3Y*IL^+D/2(#3SR=+BQ=0'K
MJD[.0[RS4;.922RB6A+CSB8&-0UTY"E@JLHK:();LNX*NZO2C!PBM/5__9G3
MY2;>R.M8/%L8K$1,>RA*&X[:4:4BR;@>*WRUY\Y<G4O2/9F&QTO4764ZU^\X
MD:5'NNH<>'94J;1#BF<W>\B<&-\,;HDY%U]+;OQ#L=_2;N)]RQ^J.VMD<]JU
MP2H52LUER;-FW$^A[)-?"K"U)2 G1QX]PM6$O)^.W0W8,SDEMQ/#7;@?6* S
M3LEOX-R0VH%"4*6%#B. O1+4'S#A]Y[-D2)LG*9:=C\D\^_H=C*<4"%. H40
M24"R1V"O>N6+B222:,$;D*ZNC,,YYS[^@922C'YMR3C&W5"*EY";J:!\))M>
MKE@VW%5C1E3R))Z/0O93SLRN>AMP-SX:#F(+:M80[U$J"K6U I(XU$,!0=82
M:9+R7+22J:[O7=<'/G%M8_&HQ4+%L*CL16S=(UJUJ(]9J_'LN%:NK97=FI4H
MJ4*/+W&');WPT07_ .90Z0.T-D*_-4Y4^-N3]!9C621]N  #A7R9ZYJ^>>3)
MS4:,DW"%)2OUDU()^X\=*EQF1&&HM$E2;VN+6J :H]%DL$AYI2+=I'"I(+5
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M.O<P?F?*$#R?R2.1F(Z:>SWU _FKG!C6\C???R,^4AR%?3GDB@% * [7^%V
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MQ[&7]&GW1<3Y?/FVJ6D=]DWJ/U)=CI>$?YOP*_\ MZK3_P Z+_L</GJ/U/\
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M$/<V/? #I+"^T*Y>VH),FW)CN"[;B5#T$4!6%)/(@T![0"@% * 4 H!0"@%
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MJ^.?=74K>/!]#>NDU"Q/1:/V<=G0WZDILFL;=74O,7M!%V'WCS4NWYZ,&P5
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M 4 H!0%#K[+22IQ80!WFU 8J5NC',W#1+ROU>7MH#$2=USW.#*4LC]XU-""
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MSFT8*O<<6C\OSU-01G-GJ'\.1?\ :'Z*5!%<VIDD^ZI"_5?\]*@C.8#+(/\
M )'>"*$%HIRT<_VR+=U_S4!=1G,NS_;*_KB_ST!*:W;/3[Z4.?D^:E"28UO!
M/]K'(_9-_GI0$IK=6,7[VIO]H?HJ* F-9K%N^Y(2?7<?/0$I$AA?NN)5ZB*
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MW$.(2M!U(4+@BH!50"@% :'F7 YE)"D\M9 -209;9P.J2>SPT9)LU0!0"@%
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MN)ZGU+\:[."Y0"@/%*2D740!WF@/: 4!2XZTTG4XH('>3:@"'6W!="@KU&]
M54 H!0"@% * 4 H!0'BFT*]Y(/K%Z CNXV [_$80?DM\U 1'=M8E?)K1^R?T
MT!$=VA$/\-Y8_:XU-01'-H2D\6GTJ[A:QI4%@X//,&Z+D?JKO^2A!Y\5N6.;
M'JZ1WIN/;0%:=TY1HA+J$J[]0(- 2F]XV_BQR?V3;YZ4))C>Z\:KW]2/DO\
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M^XR4/A;VI;Z0DJTVM;NIT"W)4&"J-J*W.H2  ;6X"IJ10EU!(H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * QK^W<4[_9:/V#:@(#V
MT&3_  7U)]"A>IJ#'O[6R3=RC2XGT'C2I!CW\?.8_C,+0.^WZ* C\N!X'NH!
M0'J5*0H*2;*2;@^D4!N>%S34UE+;B@F2D64D]OI%0296@*'V6GVE-.C4A0L0
M: TV1$?QDM;T90=9;-E$<; _14*D@I6 RI.2@_P2;.MGCI)YI([C0$B%BX>0
MF)6TX$,J&MQB_B![4CT4!FLSAFI,$(92$N,#[*W<.RH)(NV,D5MF"\;.M>Y?
MF1W?)4@S]0!0"@% * 4 H!0"@-4E[OEKGR6,>RVMN$?M2XO25D<P@6KQ+WE)
M\I>W%.,-ZO?X'L6_'14$YMUEM3I\3/XC*,Y. W+:%@L>))Y@CF*]/%R8WK:G
M'J>=DV':FXLM.9<-.J2XWX4FU@;K/<;?TUH6I0RZ<HP+@I7J2+K3;BD=YH"V
M,RT5\&G.G:X7;GQMP%30BI?>G(:+6L:4N]I[.%021SFF0V%%)U*)">XV]-&$
M2XDCXB.EW3IU7X<^1J6J$)U+U02* 4 H!0"@% 8G.YA^"E+45H.R5I*P%'2D
M)3S-ZQ9N3*U'Y55FS$QE<UDZ1*<'FGI>AF6E")"T%Q ;5J!2#8W[C>N<7+E*
M7"=%/?1UT.LK%4-8UX[:DF7DU,/*;" K2 >)L3?N%JWHQ4/6\NT6]2VUH58G
M3;L':*DY1X,U&5[K;JA:^H)X?/4$E2LO%2G4H+2. 5<<K]] >_>C%P%)6FX*
MDDC@H#NJ:"I+2K4D*'(B]0#V@% * 4!A<OGI,9\QX3"7W$:>J5JT)&KE6#*R
MIP:4$I.M-70WXV)&2Y3=$2\5E$SD.)4 F0R0E]"3J2">5CVU;BY*NI_F6Y1D
M6/;:[/8\7ET(6XE:""A5A^L!S(K4C.]"XO*QTJ"=*U$@*\*;\"+T 7E8Z$:U
M)6!IU'AQ [SQH$>L9)AXI 2M*E&R0H6/*]_54T(J2Z@D4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0 @'G0$21B<?(OU&4
MW/T@+'VT!BI.T8ZKF.ZION2KB/;4U!AY> R4:Y+?40/I(XT(,>"I"P02E:>1
MY$4!DF=QY9I.D.A8':L:C0%N3G<G(&E;Q2D\PCPT!8A2W([UP-:%^%UOGJ!H
M"4\%XR9X4$QG@"6EC@I![#0%M]E4=29L%9Z"CX5#F@_550&S87.-3D!ISP24
MCB.Q7I%020L_C'&'1DX8TK0;NA/^]4@RN)R34^*'$\'!P<1W&H!-H!0"@% *
M 4 H!0&J2MISV\A(D8U]MMN8;O!Q 44WYZ#7B7O&7.4O;DE&>^G\#V+?D(."
M5Q-N.W_R9[$8MG&0&XC1U! \2C](GF:]/%QHV;:@NAYV3?=V;DRB9B6WFU!*
ME:BK4D%1T@WYBM"T:*&73BXQO<KU*%EJU&ZAW&@/3C8]D@%2=*2D:56X&@+B
M8C*0V #]E[MS?G0BA'5AH2B2=8NK40%&UZ$DMAAMAH-M^Z.5^/.I;J0D5U!(
MH!0"@% * 4!AMP8)W(AMZ,Z&I30*4J4-22E7-)%8,[#=U5BZ2V_8;L/+5NJD
MJQ9Y@L))BN?$S5H7*".DCIITI2@=GIJ,3#E"3G<:<]M%30965&:XP3XUKKW,
MMT&^HM=O$L657H&$L.8N*LI)U H! (5;@: -8N*VC0G587YFYXT!2YB(CBE*
M5JNJP597.U 4NXM!Z0020A0-U*)L!V"I3U(II0GU!(H!0"@% :UN#;F1D353
M<8ZVEUT)2\V\+I.GE7D9N%=E+G::JZ5KMH>KAYMN,>%Q.BVH9/"8MV$RI4A:
M7)3NGJJ0G2FR19( ]%:L/%=I-R=9RW,F5?5QTBJ11)=QL5T66DGQ%=[]IK:9
M64MXR,VLK!7J( N57L!PX4!0O"PEWU!1)%E'4;GUT!6W""):70+(0V$(%^/K
MJ4]_4BFQ+J"10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0$.7B,?+OU6AJ/TD\#[: Q3NSV"J[3ZDCZI /Y:FH+
M9V=X56DG5;PC2+7]-*@QD1U[#S_\PR%$<"".-N])H0;0\U S$+PJ"@?=6.:3
M4$FKK;EXF2IMY&ME?!23[JT_IJ2"W)C='3,AK)CDW2H>\A7U54!L.%SS<Q C
M2;!^UKGDL4)(,Z-(PDX3(P)BK/C1V"_90&QPYC,MA+[)NE79V@]QJ 7J 4 H
M!0"@% ";"_=0&DNYO.9#)STPWTQHV.!*4D J6H=A![Z^=NY=^Y*XX/C&WLNY
M[T<6S;MPY+E*?X&Q[<RJ\IBFI3B=#A\*QV7'.U>K@93OVE-JC9YF;CJU<<5L
M4+GSDK<6!K;0Z4$$ )"1P][G6U=/4R,N?>;VI22E"=-P5ZN%P.%J J3*D+9C
M@K2VIT74Y8$>KC4]1_R0WLGD0O2VI&E-P5$>];MJ ]"^,RL,MK4E #G 7-N(
MYDCL%2]P9")(Z["7;6O?\AM1HA%VH)% * 4 H!0"@-:W=N&3C78D.-=+LLV+
MH&HI -N"3ZZ\GR.;*W.%N.\^N]#U?'8<;JE*6T>A3MO<#\C+2<2^Z9*HZ=29
M!2$&XX*20*I\;Y&5R[*U)\N/\VQ.=AQC;C=2XUZ&:G2)#;S:&B;$$JLD*/#U
MU[AY70C??3B$W=0FZ1<@$ZB/0*DY+J,FIUAY2=(4A.I)'$?+?MJ'L2MR"]F9
M;*V@5:@JQ4-(U$$=EJE;D$YG+:WTME*>)TD W5QXCA1(-EN5DY+;3I2DW0YI
M#EAIM4+6A/4\&9= &M"!VCB;D>CTU*U(,JDZD@]XO4$GM * US,Y6>N<Y!@R
M$QELZ"M2DZR0L7[>5J\S*O3<N%N7%IJNE=ST\;'@H*<URJ9#"Y%R3UF'25/1
M].MTI"->L7!"1RJW#R7.L7]4?Q,^584*26TBIV>\AA:K@N)<4D)[=(K=V,KZ
MEE.7DH#CCR6] *;)"N(U"I(*T9=Y:B TGP"Z_%V7MPJ 7),QX+64+#:6T!6D
M@$JOZZ#L659IP%*4-I7KL$G5VGG>A!2YF7T/-)4&TI=!L"KD0>WNH2]BL9E]
M2"XEE)1JT)\5B34T!D(SW69"S:YYZ3<7HR"[4$B@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$7(8V-.9+;R>(]Q8
MY@T!JRV\E@I>I)NTH\_HJ'I]-209YM_'YR&6SP6.:3[R3WBH)->?8E8>44.)
MZD9S@0?=6G]-206941*4"7")5')_K-GN- 9C$YMF6R8.0L2H:4K/)7K]-"2/
M>3@)_:N&Z>'=;](H0;1'D-2&4NM*U(4+@U!)<H!0"@% * 4!KN3V7C)D\S M
M<=US^,$&VN_.O)R/$6KDW/6+>].IZ=CR=R$.-*I;>AG(<./#C-QHZ AIL62*
M]*U:C;BHQ5$C!=N2G)RENRYTF]*DZ1I5Q4+<#>K"LH$6,+?9)X<N [: ],=A
M2 V6TE Y)MPH!\.Q8#IIL. X#E0'AB13>[2#?@> H"XE*4I"4@!(Y 4![0"@
M% * 4 H!0&,SF AY=E"7B6W6C=EY'O)/HK'F84;Z5=&MFMT:\3+E9>FJ>Z+6
M!VS"P_46VI3TEW^*^OWE57@^-MXR=-9/=G67G3O43TBNAERA).H@$CA?T5Z!
MB*#&CD@EM)(Y&PX4!ZF.PE*DI;2$J]X #CZZ I$.*""&4 CB#I% >IC1TKUI
M;2%#DH 7H#U3+*DE*D)*2;D$<+T!X8T<VNVDZ?=X#A0%R@% * PF<VM'RCR7
MTR'(CX "W6N:@.0(KS<SQRO/DI.$NZ-^+GRM*E%)>I.Q6*9QT?I(6IU9XN/.
M&ZU'TFM.-C1LQHM?5[LSY&0[LJO3T))CL%>LMI*_K6%ZTE!X8D4JU%I%^^P[
M* ]3%C)OI:2+\[ 4 <C1W+%QM*["PN >% >")%"@H-("AR-A0'AAQ"22R@D\
MSI% 5&-'*=);3IO>UA:] 5H0A"=*$A*1V#A0'M * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * MR([,AI33J0M"
MN8- :ID<-,Q;PE0U$M)-PH<T^@^BI(,A"R\+*L?"3@$NJX GD3W@]AH28J7#
MF8:3J3]I'7PN?=4.Y0H06'X;3S1E0KE XNL<U(/?ZJ F0,LS)8^[\EXFU<&W
MCS2>R] >QI4O!3.BZ>I$7Q!'(@_230&UL/M/M)=:4%(4+@BH)*Z 4 H!0 \J
M YY+E2)N0RIEO*:<BJ"8HZI;2@#ML#XJ^4R)NX[CF^,H?3K3\.I]-;MQA"WQ
M55+?2M3;-J39<S",/2N+MK:S](#DJO<\9>G<L1E/<\;R%J,+K4=CU;BTN+4>
MHJ6%G2@7TZ>S]6U;UL8_B4B5D%NE*'#TTHU:]%KJ[11D(I5/R0(U)4E*3I6I
M*;DWXBU&06G)F5,(.G45J)^S";$6/HJ>J)+S<S(N*.DJ2E*=7% N3;W:A@"?
M-Z"5J*]:A]HD(]SCV=]2PBJ2\^N.RM94E1!N/$ ?7IXWJ'N%L4-R9B%+NM:4
MDW%TZN2>%2!\;DDA*EZB5>Z @<^XT1#,R@DI!/ D"XJ&2CV@% * U7><Z4W,
MQT)*RS$DJ/7="M'+DG5V7KQ_)77[ENVW2W)ZNM/V5/7\;:BXSG2LH[%.VYCS
M>X)6-9<+T!+*74J*RYI6>:=1K/XV])9$[2?*VE7>M/2IUFVT[$;C5)UIV-@E
MF2)*.C]15]5[?DKW^YX_;XF+=G9!+80DKOJ 4-)OWW!J?^"%N7)4G()C*NZL
M.<"V$HY\?14]1$J7-R*"$%2BOA911X2"+W-NZH(Z%3D^6E&I*EK(3[O3XE7?
MZJ$ER%)FOR0%*4EH<3J0 3PY5*(?0RE02* 4 H#3-T9!:Y[T5;BV^@&U,I2L
MMA6OWKD<37A>0NJ4^#=*./6FC/<P+-(*25:UKI4RVU<HN8F6T$GX>(X&F72H
MJU\.)U'G6CQ>4[JEI\L71/N9,^PH<7UDJOT+CRW$J=4VISXH+.A/B*;>KE7J
M(\^74OQ'YI?2PZO6=(<*BD"X(Y</377?T.>WJ1WG%I0L@NF9<^%-]-NST5R]
MM#KXE*,C/Z0]\$IXJ*.2AV5TSE'J9V2#*'3=6M5E)"+:0.T4 :F9%8<6IQ2&
MT$!%V^*AW^NA/4S+*M325<>([>!HR$55!(H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@! (((N#S!H#7<OM
MG45/P?"OFIKE^[4@Q\7-/-(5#R*"\Q[JDJ]]/MH06GV%0UB9CW>I&/TAS3^J
ML=U >+88GI4[% ;D@7<C]BO2B@/(\Y*V#!G7+0_AN'WFS^B@+V/R,C$R>DL]
M2*KCPY6/TDT!N##[3[276E!2%"X(J"2N@% * 4!A<MCML/RT.9$,B3PTZU!)
M/K[Z\_*L8TIIW./+U-V/>R(Q:A7B9AI+:&TI: #8%DA/*WHK?%)+38Q2;;UW
M >9*M 6DJY:;B_LJ2"KE0'FI.G5<:>=^R@"5H4-25!2>\&XH"@R(XYNH%^7B
M% 5!UH@*"TE*N"3<6/JH"J@% * 4 H!0"@(>6B8R5$4WD4H,?Z160 /E[*SY
M5JU.#5RG'U+\>Y<A*L*\BUA(&%B1BG%);Z)/%2#JN?2>-<8=BS;A2U3CZ'>5
M=NSE_4K4GK=:1[ZTIORN0/GK692H$$7!N#R(H 2 +G@!VT!X%I(N""!SL: ]
M!!%P;COH!0"@% * 4!BLYB\!-2V<JENR3X%+5H/MN*P9N+CW4O>I^W0V8F1>
MA7VZ_P 29CHL&-%0U"2E,<>YHX@_+VUIL6X0BE"G'T*+UR<I5G]1?+K07H*T
MZ_JW%_95Q4>!IL.*< \:A8GT4!70 D 7)L/30"@% >+<0@76H)'>3;YZ )6A
M7NJ"O4;T![0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4!!R.&ASD_:)TN]CB>= :Q,Q>2QBRI/C9/-:>
M((_6%208WJ$.=1OP*!N".PT!/#D?(C2\0S-Y)=Y)7Z%=QH"*\)#%XSZ;:>(!
M[/2#W4!+PV9=@.Z5>*,H^-'=Z10&YQY#,AI+K*@I"N1%027* 4 -[<.?90'-
MYCS,7)Y5&6!$F0H"(XI&NZ>YO@0*^2R;D(.Y&[]<G\NE:]J'U%J+G"V[?TK?
M6G[S<-I-SD8*.F9?J6\(5[VGLO7N^+C-6(J>]#Q?(N#O/CL4O0IO46IMJYZI
M6#=(%CZ1XJ]!&%E*(&0*7BH*U6/1!7WU)#),:+-:B.MK&MQ20$F_"W=\E0]4
M2MQ#CS&(3K"6@DWLU<BY!YDVJ9:A;E#.->;4VA;:%H0K4%#N*>//TU#!::QD
MQ*FT%(Z+3G40+CF3QJ4]40]F9NH)% * 4 H!0"@-1WTM]J3CGG 3C$*)E"UT
MW["H5XGE9N%RW*7]I?5U/:\4DXS2_N="WM1WXC/RGX!4<264IU:="5.CF0GE
M6;Q,G+(G*W_9I^)UY"/&S%3_ +E?P-CR,9YUU"FT%0"2#;3V_M5]&>)T(*8>
M62E*>GR(U$+M=/=:NB"I43)F*MHH4HN< 2L<!?MH B!,0%CI$I4 $("[65:U
MS4= MRDP<F5-ITJ2D*'4TKL"FI(Z&6AM.--%"[\"=-S?A3H.I?J"10"@% :3
MN>:Q'R[B<FG_ "B@V8[BDE2;@>(#LKP/(9,+=VEU?)5-:5^)[V#:<K2]OZM:
MF<VU(,E+[S))@*T",=.CD/'8=UZV>-FYJ37]MOY>GQ,&=#C1/Z^O^Q?7&D@N
M(2RE;BE%29!(X _EX5Z9A9:3 F*<!(4E"4^[KYKMSYT(92864&GFM".&G78J
MU<3Q]!J04C'9+X=-[EXKNNZK@)'*H"W/40,BMX%Q)2@)5P"SQ7V'G4D=BI43
M(Z$@(*G 07%%=@H=PX\*@DO.192HC*5(*G$DWL02F_+WN!H]PB.S F()*FCI
M-]24KM<]GLJ>@ZCX#))3>Q6M15J\9%OJFA",T@*"$A7O6XU#"/:$B@% * Q>
MZ<L]A]O9#)L(2X[$94ZAM=])*1R-N-=056D1)T53@^%_$5YEYIWI8W;4)]6D
MK4H*>"$I3S4I1-@!6^6+;CNS)'(F]D7)7X@O,^*SU7]LPDIN0$A;Q40/I!(-
M]/IJ%C6WU)=Z:Z&*5^*O>(!/W+C_ -][]-=_8Q[LX^ZEV/I'#37)V)AS7$A#
MDEEMU:4\@5I!(%_77FR5&;4ZHF5!(H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M?KUZM5Z\OWY<N5=3TO9CQX]#/526B@% * 4 H!0"@% * 4 H!0"@% * 4 H
M2.TT!BLK@(LT%QNS3_8H<CZQ0&JNL3L;)\0+3B?=4.1'YZD@OZ8V1XITL3>U
M/)#A]'<: M0ILO&2R0"D@V=:/(B@-TQ^0CSF ZT?VDGF#4$DF@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M\)2DH#R"I:BE(OQ*AS%6*['N<\6!.AE"UAY.EO@LWX"I]R/<<6%3H:0DJ>2
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1IRY5IJ_;V^6G[2K^;?4__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>nt10016217x4_ex10-14img03.jpg
<TEXT>
begin 644 nt10016217x4_ex10-14img03.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@",0,@ P$1  (1 0,1 ?_$ ,(  0 # 0$! 0$
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MQA[B\PH*;&';=A>SQ>6@OL(.XO-0-A#W%YJ!]/!\M>:@?3P=Q>:@?3P=P<U
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MO0&8PQF8!9BHV@72 UM-O)>@S0,<*XBHLQT6[WEH-43 "+DW-R305=Y@UE"
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M-MI#WEYQ0!+#P.O.*"X(.HT"@JZLPZK82.&P/KH+*;CR\-!G-K7D;U4!)8L
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MZ#$Q*=J HN>B@L'E  V7XA02DA)(9<)'E!H)D:R$@B_!097G)-KD D7ZNFU
M_P SQ'\- MF"02"0#>UU%!(17D.TBPL1>][WMHX*"\*A0P&@8C84%["X/"*#
M!],A4IM-.C4+6 H(V8U[ 7Y103LQ\@<XH(** 28= UZ106>! MT7K@@C3Y:
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M8LI!!/*LN9BC19G70"P6Q:QN1<B@UF^&>4>N@\3Q687R;0YP11Y(X2)I<P8
MTMR-E<"XZNF]Z#Y-8(%6-X8H2B(-N@WFX59+'\NU_P Q;:=-!#0B3(31M!#'
MF =JL*[T?KJW4+LRVPKHMJH-LV,CF'G5E@,:-&7D3>)N +!;D$!1BX#>@AXL
MH)$V2Y<SILX4EAW@X)4"Q[1ZY4@#@-!>;*21;3(_3P!E<H=IGR),*C$!>P:Y
MXO30<\(6(!MA'@,>&69=ZDD9;66#"P[7G\M$/4R.\Y=T9=X<F<I--*!*L4V>
MQ%E*@(P+C0&X3YZ)>BOBK-M(=FF2D@5&,L@S2K@D &%&!'"]UOZ*"DGBG>R
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M X4)KC0!G\Y/5!H 2<Z2)/.Z_903LYN*3WQ0,$W=?WQ01@G[K_XE!.";NO\
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M4&4W@O=<Q0R+(QCOLR)Y5PWUVPE==!ZF0W>,A 8<LJK&6+F[,Q+-K.F@Z?\
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M4%)3;![0H+T"XH% H% H% H% H% H*)]_P!HT'@[@CD.]M_ 2%/\S#H !_\
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M&FPA[@YJ!%A (&@!B *"]QQT"XH% H%!A%EX3&I*@FVN@EXEC!DC!# 7L#K
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MT<H"T'10*!0*!0*!0#J-!6+X:\@H*YC'@7!;%B6U]6N@?YG]STT%77,.I4X
M#K.F@VH%!#BZD<8(H* 3V NHYS03AE[X'(*"LJR+&QVAN!HU#[*!&N':Z2QO
MK/(*"\7PD]D>J@S<_F-R)_-0;4&:?&DY%^V@TH% H% H% H% H% H%!D#:.4
MGC;U4%X_AKR#U4%!\.8>5O2+T'E^';',[Y8<.?8>=88A41OELYJ,5T_@^N7L
MU+&4&,0LR#@P'UB@VH% H 922 02-8XJ!0*"LOPVY*"(K6:W>/KH+T"@\'Q
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M'_4O<J6(H,81UE]D^N@VH% H% H%!2;X3<E C^][1H+T"@\/?GQ]T#CWDO\
M[N2J6WQ_70U\K]_X)^F'LH/S'\WJJ[(O0*#'7-R-_NT&U H% H% H(;LGDH*
M1:_X5H-*!08D"YMWC?W:#2+X:<@]5!6;'9<%KXAKU4&&9GECP(RAMI< )=CH
M%]5!O!F%F#65D*FQ5QA/'JH/D]^>%M]S[QWE+N_-R6WAE D4LT\@7+S)*&*1
MJIZB2QG3A&L>6@Y=V?I3NGZ: [^D.],\DNWFG;J[23JV+GM-A*74WT$FVN@^
MXCC6.-8UOA0!5N238"VDG2: P_-3D/V4"34OM#UT%J#Y_P :9;Q#/NZ'^AR,
M,PDRF2%2$QH>-[@J%.G1KH/=@,IAC,P"RE1M%4W :VD Z.&@-\5.0_90)?N>
MT*"] H*IVGY?LH*.;3)S'D/[10:.H92IX1:@Q@?KZ?OC3[2Z&H+O C/B)8&U
MB 2 ;<E &7@!O@!/&=/KH)< ;, 6&+5YC07H% H! .N@\_>F\$A5H$E6&0H7
MEG<@+#%J,C$Z/9\M!7*YO=63W81DF$F7RPP*(SBQN3H ;[S,QYZ#RX]RY;,O
M.V?M+GIF63>&9#$+"JZ8\NAN.JH.K^(ZZ#T9<SEHLM'N_=11'=2D&S V<2+H
M:31HLOKH*9'>>ZLO$N3W=M,^T>AVA!ENYUM)*;)B)U]:@]:-F9%9UP,1I0D$
MCSC106H% H% H%!#]AN0T!.PO(*"LOW/:%!>@4"@4"@4"@K+HB;DH*+?#-RG
MU"@TC["\@H,G^)_$OVT&U .HT%8?A)R"@M0*!04'QFY!]M!>@I-\)O**"P50
M    -5!D-MM9,)7#<:[WU"@.F88#2F@@ZCP>>@IF-N(KMA(!&@7H.A>R.2@I
M +1@G6UV/*:#YCQWO3>&[MUY9\C,T4LV99&6/")'ZCL K.LB"S*"UQI&@4'L
M;LFWA+NS+2[Q1$SK9=3F!&<28^$J;+KU^2@Y_#>G.;];@.\&'-#$*B&[F_<T
M_@_ZE[=2PE!C!]WV3ZZ#:@4"@4"@4%9?AMR4"/[WM&@M0*#Q-]W^JW-Y=X?_
M '4M4MOAKY7=?X/KA["?$DY1ZJNR+T"@RT;;^(_RT&M H% H% H(;LGDH,X?
M]U?50:T"@PN;_P 37YJ#6/X:\@]5!#]I!Y?L-!SYR6.+,Y9Y#A0%^MY<-!?*
MR))),Z'$I(L>04'10*!048C:H.,'[*!+J7VE]=!>@4"@HWQ4Y#]E E^Y[0H+
MT"@JG;?E'JH,LT"+.!<BX\XZP](H-D8,H8:F (\]!SRJRR=07)_,3BQ 6*D\
M&(4&T4JR+<:#]Y3K!XC03)+'$A>1@JC630<XDS$LT;8-G &T!NVV@Z;?='IH
M.J@4"@4',-W9/'F7:,2?5V^H5^L&"KA L=%K<%!Y"S/O7/&/**T.5R384E*V
M4/:Q=%.@D#0G -?%0>@=QY-KQR%I<H4P')O8Q,2;L[BUW9N'$:#CROA:(/(^
M?S,F>,C7,1 BA"*>I'LTM=4&@ DB@]J.*.*-8XD"1J+*B@  >0"@M0*!0*!0
M*!00_9/(: G87D%!67[GM"@O0*!0*!0*!05F^$W)04'9FY3_ "B@O'\->0>J
M@S>VT_B7[:#:@'4:"L7PUY!06H% H,FD"3-U6/5'9!/'0:(X=;B_%8Z#HH*S
M?";DH,MC$,N6PC%AO?AH(BG9I),"7!L02;7%@-%!KCF^6/>_909SF9HB"EAK
M)O?50;_=\U!$?PUY!0?"?JJU]S92.&2!<^D[YB!9I$0X8T?:%4<JK]5K4'UF
M[W:7=64=[!Y,K$S :KE03:@Y?#!O+OO_ /:4HYHXZI7I[V[G=VG^W'TV>W5V
M$H,8-:\6 ^N@VH%!G]3!WO70/J(>]Z#075E874W%!-!67X9H(B^][1H+T"@\
M/?1OG-RCA^O)YH9:YV]Z/ZZ&SE?=U/@^N'LIVY.4>H5T8UZ!09?VW\1_EH-:
M!0+CCH%QQT"@4$-V3R4&< _E7U4&M H,.'^)_4:#:/L+R"@J_P 2/E/JH(D=
M$D0N;"Q )\U!='1Q="&'&--!- H%!1OC1\C?90)M2^TOKH+T"@4%3\5>0_90
M1+]SVA07H%!5.V_*/501,N)"!KUKRC2*#/)O>,KW3H]DZ1T4&LL22QM'(+HP
ML10<HRTT;!M,C 8=LI"R81J# ]5N6@M@NZNT3R2+V2^$!>33:@N1.98V<@+B
M["Z> ZR:#>@4"@4"@4'@OO'>K^.(]VPN@W5!N]LQG%*W8SR3!(0&X.JCDBNO
M!'!Q=.3,/>KD% H% H% H% H(?L-R&@)V%Y!05EUI[0H+T"@4"@4"@4%)OA/
MR&@J.S-RGU"@TC^&O(*#*0$.6X 5;S#70; @BXU&@AS9&/D-!$7PTY!ZJ"U
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M06,UM<WX#00)KZIQ;V*#1(8B"Q"N6-RUJ"3EX#_9KS4&1,<3L%D"#A7#>QH
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MC3YG9/@>BGSZ?XH='^J5_P"E;R__ $S=-/F=D^"?13YZ?B@_U2HU[JWE?_\
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M#7>@I+!"]CMA<:L6%N@^F@JHD30'! X5D^Q\7KH+[2;O'GCH(M,VG';E?_A
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M!&NMSZ*"(<K(26):-6[;L;S/RG[@\@H.F.-40)"HC0<0H-%55U><\-!- H%
MH% H% H,W^-'_%ZJ#2@^._6/_P#Y;XG_ /R$WJH/GOTF\=^"=V?I5N!=X;^R
M&5DRF149F*7,Q+)&4OB#1EL8(XK40K^E6X\YG?&WBS]09,O)DMV[_:*#<T,R
MF.67+0@7S+QFS()2 4!TVTT2_0O$W_\ K>]O_P GF/\ W34'YO\ ]KH _23)
M6T?YK,_ST(<GC D_]S'@D<"[JS9Y]K0?LM!^(_\ <9DCN/,^&/U!W:-CO;=6
M\(LK-,F@R02W.![:UZK#D:B)3XHS(\5?]PWAKP]F>ONG<.3.]OIFTJ^:92T;
ML-1PW2U$OVV@X-[;TW#E$^FWMG,KETS2L@AS4L<8D4BS##(1B%CIH.+P5N_P
M[NOP[EMU>'LRF:W7D,4,#1RK/@!8OLRZD]G'8#BH/QS]'_%WA;</C;]21OO>
MV5W;)F=\8H%S4J1%U1I0Q7&1>Q.FB'ZEN7]2?"7B+Q6WA_<F:AWJ^6RAS^8S
M>7=9(HB)%C1,0N"YQDZ#H'+1+ZV@K-\)^0T%AJH*2=N/VCZC07H% H% H% H
M*3_";_;AH,LP/B']U1Z:#\I\3S9M=[;S5_"TF;G)S^SWC_2XI5,F&+Z!Q.RZ
M57KXF/GHB'ZM&L@12=+E5)XL0%CJHE='5Y0RFXP_;05 )RIL"3IT#7K-!;;_
M -V_NT%6GDO<+@70!B4DDGB H FDX?Y'H GD)"@@$ZKJP]=!;9,VEVLU[@IH
MX+<-!52RY@1AV<82SWMHXM0H+YF^Q-C8W&GSB@;.;YQ]T4&$>6D./\T]LWO?
M["*#5,L%4 R.2-9Q'IH(;+/B)65@.(DG[:"!EI?G-SGIH++EK#K2.3QXB/MH
M(?+.6!25U%M())^V@R"YA)L& S#JL9<0%K$Z+$WH.C:2_*/.*!CF^5^(4$;6
M46Q1V%P+X@==!K0" 18Z0=8H/,ZV5EU%F@'5X2\!.GSQ_P"VN@ZCF6EG$4%F
M5=,TO O#A'&Q]%!O%%'$N&-0JZ[#C-!:@4%6FB4V9P#KL306H% L+WX>.@P7
M,E<QL)1A9M,3\#@:QRCBH-Z"D)NA]IO709R]I^1?YJ#277'[7V&@O0*!0839
M_)0S1PRSHDTS8(HV8!F8B]@*#>@4%9/AMR'U4%8M;?P^J@TH%!S+:Y]L>N@Z
M:#'-Y<S1C"0)$.*,G5?58^0C0:"N3=ERPVO5*#2&U@#5?IH+-FX0;+=V.I4!
M8^B@KCS4FA L0XV.)N8:/304;+R,W6_,_>D.CW%T4&JY9;6D.,=RV%?=%!L
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MW\O=.^LF,BV8.A$:QBTG4,+&,GR&B'[U1+X7];<AN[,_IAXBES>6BF>#)2/
M\J*Q1Q:S(6'5-^*@G]#LOEX/TH\-"")(A)DUD<(H7$[$EF-M9/":$/A/T-W-
MN?>/BS]29<_D<OG&3?16-IXDE*@F0D+C!MIHB'ZED_ _A_=OBEO$N0R\61G;
M(MD,Q%!&D4;IM5E#MA ZRX;7XC1+Z($$ @W!T@B@K+\-N2@M04?MQ\I]1H+T
M"@4"@4"@4%)L.R;$<(MI/%08%L44G7+G0#=</#0?G'C7>'B'-9[/[DES_P!/
MNS.2KE%C W:'PS 653+FDENPO;$E_)0?I^ 8 @T "P/%:@K% $8NS8Y&T%R
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M.LRRQJ&)!5Q>UQK'-05P!I@TD(#,,..X)L--J"T:+',ZJ+*P!MY=5!>2-9%
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MIZX.#18B^).F@G;F3&D?5D"W!-CZC09Y9LNL[K'$59S>28K8,_"+\)]%!T6
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M#D;U4&HU"@4'+CC( Q F]BO#VZ#IP)W1S4# G='-0,"=T<U P)W1S4%  )]
MMU/MH+.@=;'E!XB.&@QVZ+,HD(5PI!'(10:?4P=\4#ZB ??%!P;[R62WMNV?
M(32A8Y@ 25#C0;Z58$&K4O-9B81:,QA^;9?]"O#T&\3F1F4E#!]IC7K.9,/
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MJ#(3L1<1.0=1T=-!.U;Y;^CIH(,TA8JL1T"_6(&OGH 9S*N)<.@VTWXJ"9R
M@)U!EN?/08QYB/'@TEXRRNH!)!O?3;R4&ZSHS8;,"=(NI&KEH)>54(!N2=0
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MXUNK(QU,-!X*#HH% UT"@4"@Y\P#%(,RO9'5F'[O>_A]5!T:Z!0*!0*#)\S
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MICU0K!V.LA+@<^B@SRV 3,%14LHN P8ZSKM0=5 H% H% H% H% H% H% H%
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MT*"U!E(ZK*A;B;@OQ<5!/U$7&?=/10/J(N,\QZ*"=O%QGF/105^IAXS[K=%
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M\VZ$WQFYYX\HL6UE3"&5FQ+@Q8>Q8V&GAH/SQ/\ N=\5HJQQ^$45% "J&S
M4#18;*@]W]/_ -28_P!0/%C;OWMX6@R$C99Y7W@&E#G9%;(6*1FQOWM5!^U
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MV7NM[IH&V7NO[IH(VR]U_=- VR]U_=- VZ]U_=/10-NO=;W3T4#;KW6]T]%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>nt10016217x4_ex10-14img04.jpg
<TEXT>
begin 644 nt10016217x4_ex10-14img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@",0,@ P$1  (1 0,1 ?_$ +<  0 # 0$! 0$
M       ! @,$!08'" $! 0$! 0$!              $" P0%!A   @$# 00%
M" @#!P$&! (+ 0(# !$$$B$Q$P5!47$B!F&1L=$R4I(4@:'!0G(C,U/A8@>"
MHK)#8R05%O#2<Y,T"/'"XJ-41"47@[-DTY0U138G$0$  @$"! ,%!P4!
M     0(1,0,A01($46$R<8&1P1/PH='A(D(4L5)R,P4C_]H # ,!  (1 Q$
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M'^- "S^^#_9_C03IF]]?A_C00!.;C6HL=^G^-!"+,0;R;;D#NCHH*N,A;?F
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MWM_U4%HPP!+"Q)O;?01'8L[@@JUK$>2@K/T_A^T4&M!G(RK+&6( VBYV4&E
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M<C:*"4]I^W[!07H*I[;]H]%!1[7EONL*#6@4$/[#=AH*1>U_96@TH% H,HP
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M!2;],_1Z:"] H%!5]Z?B^PT"*^DWZSZ:"CB[D>1?\5!(8"=E)VL!8=E[T&E
MH% H% H(=U12S&RC>: CJXNIN*":!0*!0* 2 "3N&^@I'/#(2$<,1O'3YJ"]
M H*K[;]H]%!:@JT2%Q):S@6#>0]%!3C2)LDC/XD[P\V^@T1U=0R[C030*!0*
M!05DECC74[:1>US02CHZZD8,IW$;1030"0!<FP&\F@JDL;DA&#6WVH+4"@4"
M@4 D $DV WF@Q^;AO9=3 >TP4V'::#:@$@;300K*PNI!'DVT$T$,B.+,+CRT
M%/EX?<%!62/'C6Y2]S8 "Y-!2V./_P NVS^2]!T*P90R[B+B@F@4%)_T7[*
M?UE_"?LH+D@"Y-AUF@YI9()4!(<JIN&4,-W9T4'2+6V;J!0*#"4Q<0@EPVR^
MG5;ZJ#5%30-([MMG906"J-P H%!#^PW8:"A'<B\A'HH+1>Q])]-!2?80>I6]
M%!8L0RK[P.WRB@HS&-Y&L7[FK2HVG3T#RT'PS_U$BBY9-##@?\;S!T+X>,0=
MA=@JED,:=^[,=(!!TM8T'T?A+F?.^88#R<VQN!,C!5;AO#JNBEQPY"S=QRRZ
MMS6O0>L[!..[*655N54:B0 =@ WT'Q'-LS,;+;Y;(YHJN-<<"X2,L8L"$34
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MT?-.796/CQR%!!','+(H-W#;@NH7T[Z#GQ_%_.@,>7*YAROY=WX3O$)K&1"
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MXL/4?A/JH*M)&2H VEA:ZD?903(FJ5!J*[&VJ;=5 >)])*.VKH%QZJ">)/\
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M\%C8W*R[2Q_(E1(9EE7/D<F1^[8#V5N.C<?)0=,6(CP/I&*9I"%P8&YA(ZR
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M_P"&:"\6]^T>@4%G]ANPT&4Z:\-T]Y-/G%J"L>-,K1EYM8CW#2!T6Z*#HH%
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M(ZE7 93T&@S&,JBR.ZKN"AK@>>] &-%<,P+L-Q<ZO306A]CZ3Z307H%!^?\
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MI$:0[>'-^[_=%<VC1-^[_=% *3]$H^'^-!4C(X@7B"Q!/L]GEH+:)_W!\/\
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ML,.!"@BX0;A/D3IDY'!C-]G=!?=NO0?IJ&S#K*V!_M&@U< 1-V'T4%7]F/\
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M5;"5[=%R#Z10# QWRO;Z/50:@ "PW"@S,)U$B1EOT"UOK% X+_NO_=]5!:-
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MD_S>9/703?(_F^%?704)R6V=^W38(#Z:"Q7^27Z&_P#JH*E!^W-\?_U4$@Y
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ML;*%<7'W[4'TG@KE63C1/EGG.3S3&F7AQ190*M"8V((L3L;H:_2-FR@^GH%
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MV0:?Q;=GTT%Q/< B-B#N( ]= XW^F_F_C0.-_(_FH'&_D?S4#C_Z;^:@<?\
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MK.2Q2/4=()-KVO:@]I(%5RY[TA%BYW_1U4&@ &Z@4'.1=P.N1O\ ":#012
M"0V&P;!0( 0A!-SJ;;]-!I04DC9F5E;25OT7O>@A(2'#NY=QL6]@!?J H-*#
M%L9.(TB$HS^W;:#;K!V4$B W!+#80?9 W4%Y8^(FF]MH(._<;T%. WO#X101
MP#[R_"*#2- B!0;V^B@J8Y-;,KV#6V6!W"U X<W[O]T4%!C6Z5^!: <7RK\
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M:@P;)+R&+' >1=DC_<3M/2?)0;QII&_4Q]ICTF@L2!04T*UP18$W*CI[:"X
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M]!2(;&_$?307H% H,V_4?\'KH(A]H]6E;?706F)""WO*/K% B)(;\3>F@N2
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M% H% H% H!V"@H=8!8[>I!;TF@Y'D0*0BQH3OL=3;_Y10=U H% H% H% H%
MH% H% H% H%!5?;?Z/101!^F.T^DT%Z!0*!0*!0*"LOZ;]A]%!2'>>Q?106E
M%]'XA054,<<A?:(-NW;0569T55>)E L+@@CJZZ#>@RXS&^B-FL2M]@%QVF@J
M?]OB]U=3@;%'2['[2:!'AQ!N)*!),VUF;: >I;[A0;T'G<S\1<EY9/%!GY2P
M33*SQ1D,695L"0%!O:]!VHN/(BNBJR. RL ""#M!H)X,/N+YA0.##[B^84$\
M*+W%\PH)5$6^E0M]]A:@F@K)%'(+.+@;J#&2!-' <EHWV*2;E6&T;=_903%.
M50"8$2#8Q -B1TC9TT&X((!&X[J"LDJ1@:NG8  23YJ#.#499'T%$>Q&JP)(
M%CL\U!M0*#GA&ET'D9/A.R@Z*#.+VI>O5]@M0:4"@S>WS$?7I;S;*#2@QR2J
MA'?V0=+'J#;*",68,IB8_FQ=V1>GR'L(H-Z 2 +G=08K(CS$HP8*I!(W7O09
MK!%>'8=H).T[[=M!K\M#[OUGUT$_+0]1\Y]= ^6AZC\3>N@CY:'J/Q-ZZ <:
M$[U^L^N@GY:'W?K/KH'R\74?.?70/EXNH_$?70.!%U'XCZZ!\O%U'XCZZ!\O
M%U'XCZZ" BI*NF^T&^TGJZZ" (^#>0@*&)N3;I-!6(!I0\898U!VDGO$]0/0
M*#2<]U5Z68 >>]!I04 T2'W7V]A_C01D1&2.RG3(IU1MU$?]MM!GPI9E''[B
MD;8E._M:@W5%10J@*HV #8!0+CHVT$[:!0*!0*!0*!0*!09-E0+<!M;#[J#4
M?JH*/+,4+-;'C'WW(+>;<*"F.SMW8-1CO=YY;W;\(/\ \*#J90R%3M!%C]-!
MDPTXI"K8@6T[MU!R9O/<#!D,>9-' X3BE68^Q?3JV+UT&F/S;%R)WQX)(Y)X
MU5WC5[D*XNI.SI%!TZY_VQ\7\*"0\W3&/B_A01KF_;_O?PH&N?\ :_O"@<2?
M]K^\*!Q)_P!K^\*".)/^U_>%!(DFZ8O[PH'$F_:_O"@<2;]D_$*!Q)OVCYQ0
M.)+;](^=?70.)+^T?.OKH'$D_:/G7UT 22_M'SKZZ!$S%I-2Z3<;#8]'DH$+
M((P+C>>GRF@OJ7K% U+UB@:EZQ0-2]8H)N.N@7% N.N@K(?RG_"?105AWGL7
MT4$R[T_$/0:"B+JQ=(-BRD C>+T%<?'@$:/H!:P.H[3?Z:#HH,GQH7#=T!C]
MX;[]=!EQ))X&"=W)A8:D/O+M\S#<:#:#(CGC#H=^]3L8'I!'DH-*#SN9>'N2
M\SF2;.Q4GFB4I'(UP55MIL010>@B(B*B *B@*JC< -@%!- H% H% H.=Y-<H
M"B\4?>9QN+;@HH+)#(1J:1E<[2 ;@7Z+&@U1=*A>H6H*R1ZRI#%2NXCR]M!$
M1;6ZEBP6PN;;_HH-*!08+^J/Q/Z*#>@QG8P@RI&9#LX@7VK#I Z;4%X<B&9=
M43AAY-X[1T4"2:./8S=X^RHWGL%!GC)*6:>8:9'V!+WTJ-P[>DT&]!#HDB,C
M@,C"S*=Q!H.%L-XF1KNXC_2D4_F*ON-[ZT&@RWVW>/M(93YK4%=$DS7-Y.HL
M"L0[%WM]-!NN-<?F.S^0=U?,*"Z00H044 @6'907H% H% H% H% H% H*O&C
MVU"]MU!08N.""(Q==J]-C0)\F*&P-V<^S&HNQ^B@B-)&<2RBQMW(_=OON1O-
M!M0"+BU!F9E#:-K.-X47H%YVZ!&/B/JH+!!O))/EH+4"@4"@4"@4&;9,(-M6
MINI>\?JH(XLS>Q$0.MR!]0N:"C2./;F1#[JBY^OU4%2JL=D;RGWG-E^OU4$L
M6C7\R5(%]U0/2?509H<8L&2.3(?H=@3];6 ^B@M/EO"H:9XL9#L#2M<D@$[!
MLZ!UT'RN7XUQ\SE_,Y.49#SOR]H!+D*A9%BE<++,L*V=^" UU\E!Y>%X@\9<
MRS,.' 22;DT608<SF CC03PAP>*C=! (V ;;,-^X/J?$7-N1XF=#C9.'/S#F
M,L32+BXD332B!&&J1@" %#$#RG=>@\O%\3^#N7<SE./C9<?$.*N5G&*4PHV6
M!\NLK.;H>^!M7NWVT'8?ZC>'5$DD@R8L94DEQ\IX66+)2%@LA@;[^F]^BXVB
MXH.O.\:^'L#G,')\O(,.9DY$>)"&5M!FEB::-->X:E0V\NR@XY/ZD>&TEL1D
MG'0(V1F+CR&" 22-$O&<#N7>,]F\T'H\P\4X.%S>/E/ RLG->)<@IC0M*$B=
MS&'=AL4:E-!2;QCR6/E.)S-&EGBY@W#P888W>>9]ITI&!JV!"3T 4')+_43P
MW'!',K9$]TDER(H<>623'CA<QRMD(JZH]#@@WV[-EZ#3_KSP]\ZN/KF,3S18
MJ9PB<XIGR$5XHQ,!INXD6W1MH.F3Q7R]>=R<F2#+GRH3$N0\./))#$9AJ3B2
M@:5[NV@RD\<^&E@S)5RC*<'+'+IHHD=Y#EM;3%&@%W9BUAIV>:@R?Q[R))\*
M 1YCR<PN,94Q)S=D)$B-W.ZT>DZ@=U!Z&1XDY/C\[QN233Z>992&2&'2Q!7O
M?> TB^AK;>B@KE>*>18N4,3(RA'D-EQ8"QD-<Y,\?%C38/O)MONH.;'\;^'\
MG,&+C233OW=4D6/.T2:B0"\H30@[IVDT&$G]1O"4>#+GOE2C$BTLTHQ\@@QR
M7T3+:.[1-I-G'=\M![V!G09V'%EP:Q#,NI.(CQ/;RHX5E^D4&B?J2=H]%!2*
M&$H"44DWN;#KH+\"']M?,*!P(/VU\PH' A_;7S"@<"#]M?,*"/EX/VU\PH'R
M\'[:^:@?+P?MKYJ"K(J\4* HT='TT$P;V\@7_#06D]J,?S?8:!!^DO905QR!
MKBZ8S]1VB@UH%!SY.,[.L\!"Y""VWV77W&]?105#09$3R<.TB75K[PR]&H=5
M!U#<*!081X\3("0;G:>\WKH);%BTD*"#;8=3;_/00J/*UY4*!1:VK>>ONF@M
M\M#U'XF]=!5-"Y1C4F^@,022-Y'30;T&&2L9*"0%DV]T7VGHV#?0:1*=(NH0
M#V4'1YJ"] H(=PB%CN O04@1UC&LW=N\Q\IH-*"LLB11M(^Q5%S088Q+. VQ
MD%W'4S[;?0*#IH%!F^/ [:F0%O>MM\]!*0Q(;H@!ZP-M!>@4'$HECNTC.DA)
M)<=]#<[!;H%!TX\C21!F WFQ%[$ []M!I04EGBB ,C6N;*.DGJ H,U.7+<D"
M!;[!L9R/+T"@D(R2H-;-JO?41T=@H-J!0*!0*!0*!0*!081I(ZZC*P))V"VS
M;V4%^"W[K_5ZJ 8218ROYP/LH)BABBOH6Q;:QWD]I-!>@4"@4"@4"@4"@H\\
M*FS.+]6\^84%>,Y]B)CY6[H^O;09R2N-DDR1'W5[S?7ZJ"FA6VB*28]<AL/,
M?50&E=0%,L<(Z$0:C_V^B@CAACM26<CID.E?-L]%!LD<PMI2.)>FUR?_ ):"
M3CEOU96;R Z1_=H+)# FU$ /7;;YZ#Y#Q?!XJ;G,#<K>::&6(1QXRAD@2340
M[RR*;>RP8:A]VPWT'C\N\ <^YASJ9_$<K-CQ0V7*CE+/+D2-K,D0<OP= "J-
M 7V?*:#[+D/A#D'(U;Y#&M+)^ID2,9)6W;W8D] H/6G_ $FOY/30?/\ B+PD
MW,^8IGXN:,/*?&?!R4DB$\4V.S<32R%D(96%PRMUT'CXO])N3X[PY*Y<LW,<
M-\1L?/F"R2+\HFAD>^QUE4M<'=?9M H-6_IPN1@+R[)YO)/RW$AFQ^4Q+&BM
MC\0:5=Y+MQ6C3NK<#RW-!K)_3W'SLQ\GG>><_)G9FG58UA4KP.!&$4%BA3VP
MU[ZJ#DQOZ9Y,'+6Y6>>R2X>5CPXO,F>!#/.L+R.Q$@8!#()2&.D^2@][)\(<
MIR_$R<_RD6>:#%CQ<>)U!$1CE:7B*U[W);ZJ#R\/P-S3&P^71Q<X0S\GD:3E
M<_RPL$D5TD2=>):0,K[UTD$7H*P> .8X4N1E<NYQP<_F22)S?(DQUD$K22-)
MQ8DUJ(V3654=X6WWH*8_]*>3XF9BYV',8\[!RXLC%F=>)^3% F.8)%)TO=$N
M'MJ5C<;J#IS? T[^*<KQ!BS8HGR>"5;(QWDDA:",QJ8W65%\O>4T'GI_2I,7
M&>'"YB94G@ACS<?F$?S<,\D$C2!RK,K)J,C^P01<6.R@]CD_@Z7 3DO%SVR&
MY2^3( P8@C)5E$:%V=E2(-9=3,;#?0</.O .?G>,L;Q)C<T&++C-%I/#9I>
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M^[$@NWF%!(?);:(U0?S&Y^J@,^2O^6''\K6/F-!:/(CD8IM5QO1A8T&E H%
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MXM:PUG:UM_30:R<CY;+!)!+R_'>&:!<26,@%6@2^B,@CV5U&PH(R>3X4\>3
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M_A&SS[J!JR&W*J?B-SYAZZ!P7;VY6/D7NCZMM!988EW*+]9VGZZ"] H% H%
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M%\CW4^(^J@7R/=7XCZJ!JG]U?B/JH&J?W%^+^%!.J?W%^+^%!!:?W%/]K^%
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I4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>nt10016217x4_ex10-14img05.jpg
<TEXT>
begin 644 nt10016217x4_ex10-14img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@"+0,@ P$1  (1 0,1 ?_$ +L   ,! 0$! 0$
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M[:]= ;^'VUZZ W\/MKUT!OX?;7KH#?P^VO70&_A]M>N@-_#[:]= ;^'VUZZ
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M"2 J)$N2%&%_**"B=Q>@4$Y/BC^'TT#2X!3S,/503FCD,N9 "K+E;&U!2-9
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M:=;QG1S"#4Z_5/G>/)DT0R* ,S#.I^U?9R4''-QCC#9I!Q'B$03(%@7AQ8$
M7+9CBV;R4'L\(\1A-'&-1\[KIY [F4Z4Q$A2%MD'=VWM06C\9:%U5AH]<,V;
M+?3N+Y#;#GO]GG% #QGPX_\ TVL S903 P!PO>^RWE-![,<ZSP03("$ELRAA
M8V(OB*"1.77.)+E) H0XV# 8@VYQ0=&XBYCUGUT&;B+F^DT&[B+V?I-!GR\/
MLT#+%&INJ@'9>@:@*!9)8XP"[!;[+\M!'-(ZNZH>U9(P<#;VC?9MH.@"P YJ
M"2FSXBW:('GV4&DLDC'(6S6Q%N3ST!O3^6WT>N@-\WY3_1ZZ WS?E/\ 1ZZ
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M;E9I%XG*J20B(1IK&"A +YD&;LFVUAMH(?V/PNX:4<8E)6SF5=;;*H %P0;
M8#&@--P;PS"9;<<FE60+O$DUH9<JG"V.&/-0=IX/P1YH-6O$)<L'= U)*-D7
M'-<]H!=HH)MPG@;K,J\6E"N1*]M2&R+ER#*3?*N.'EH%T? ^"0*--'Q;43''
M>B75[V1R5(NQ)O< X6H$CX#P9Y,Z\;U,A1ED/]6&L4PMY%OM%!ZG#7X1HHWA
MCUZRF1VD)EF5VN3B!<X <U!W1:W1S-DBGCD;;E5@38>0&@H^U/>^J@BXE,KY
M55T-@ZL;'9R8&@S=3<BL!S;P^J@T)-;NM_Q/V4 (Y?9;_B'U4!NY?98_^\-
M;M_8/_$-!N[?\L_\0T!NV_+_ )S0*('5\T<2*Y[TC$L;>3_[:"Z*5':8LQVD
MT#4$M2LAC.1<YV%+Y</(>>@C'J) 2I86&P2!E8=/(:!_F3[4=^D^J@!J&/VD
MZSZJ#?F&MM3Z?50(=4W(T?\ -ZJ#?F7]I/YO50:=0_M)?^*@SYB38&3^;U4!
M\Q)[2=34&?,O[2?=>@/F7]I/NO0:-1(?M)]UZ ^8D]I/NO0'S#[<R_=>@&U$
M@[I#'D4(UZ#8X)GE$VH()7X4:]U;\IYVH.B@YM2LT;C40+G(%I8MA9><7^T*
M#8]69%S*GF) (\A!V4#[Z3V!]X4&;^3\L?>%!HF?V!]X4&&=QM0??%!GS$GL
M+]\4&B>0_87[XH#?O[*_?% ?,/[*_?'JH,^8?V5^^/508VK*BY"= >YZ@*!8
MUGGE625=W$F,<=[EC[3<UN04'2RAE*G818T'##FA8J2(9!9;-\-P-C+S&U!?
M?O\ F1=?[: WS_F1=?[: WTGMQ=9H#YAOS(NLT =0P_S(NLT -22._$?XK4&
M[]^>.WO_ +*!6F9GC2Z$E@;*Q)L,>:@Z:"4T37,L5A.!E!:]B+WL;4'/=1(3
M=]-*W>6UT)Y_9H*+,PVZB-O+:W^]0;OC^='_ +>>@W>G\Z/_ &\] ;UN2:/J
M_;0897M\:,>6W[: WK_GQ=7_ +5!@F?EGBZO_:H&WIY)H^K]M C:A\V6-U=C
M@ J$]9O84%X8V1+,07.+D8 DT$]4)QEEAQ9<'7:2IVV\HH%2<NMQ,!S@H01Y
MB:#=\<1OU^X?709O]GXX^X:#3*0/C?R&@!-?_._D-!AE-_C'HW9H 3#\W^0T
M!OO];^0T"O(3_GM;E")VC]!H'1997O(F2%3=$;%F(^T>:@Z*".J1S&S(#FM]
MFV:PQ&6^%[T',9VE"K,BOE-SB4\F*G&@978?"A5;<H5C]2T#'YYMA(Z J^G-
M04C34A MU4#EQ8_[M ITT.HTTD&J19XV8YT=05-FN,/(10?G>OXGI]1JFE@U
M6@SS9H9S)P^9GD5&S,&(M;*>?#EH(:63@FK,:+/PM]:JEM)*=%,%C( +$9]G
M+S4'?K9=!#HLY?1QZ94RA)=!*5R74R#(,1=[$;:!F&CB36:;42\.&KD.]E+Z
M*4H=+'9B&3[3!B"+&@G..!C2&6=N'I*F4::5M+(R@D'.Q3O*K @7!]- X5]5
M*K-)PZ1M:ITTW]#(6F8]J,!C@(\H4VMR4'/I(X89))9IN'--HXQ('AT.H61-
MW902"3@H:V')0)K-7H9%75S3\,;72(P&J.BE(;-81YK8X1DJ=@H*II.':>80
MP0<-BU$, D>-M+,0(UQ8BXL.R1A02GBX)(BQZ9N$_-3(DD:3:63)OG<KF! [
MK6:@[I)8--J%T_\ ^GJA"S:*&6";-$\B92S7VAK'FPH(<+FX++!JN&2-PPSZ
MMEB*:;3S;N1\Y9D=2!<91R&@DD?#84.HB;AL+Q(T6M*:>?*753W!R (1_P#;
M04BAT,S9">$G42Z<;D)IILQB= S!P1E"D;</IH0X]9+P"6:,3+PF;Y;*LP.F
MU"_B 9>S@;#FMYZ#U^%1\0U.NE;1/PMN-::)3O4AF551R <I/.F'3MH/MX5G
M$$ U!#3BV\9< 6MC:@="-[(+B^&'+LH*4!0% 4$S/$&*WNPP( )]% '41#:;
M=(/JH&22-^ZP;GL:!J H"@* H"@* H"@* H"@* H"@* H"@* H"@*!6CC8W9
M03SD"@-S%["]0H#=1#["]0H#=1^P.H4!NHO87J% ;F+V%ZA0 BC&Q!U"@-W'
M[(ZA0&[C]D=0H#=Q^R.H4'YIK_%OBG3>(V^3==1HM#KM?\_P\1J9)=#IX-*<
ML) OO(FG:11]KN\U!X\/ZC^)EX5J.+OK1-P:?0:,0:I81G@U6K>3<SL+?"E&
M5#<=DVYS0>P/$'%]0\>H3CK1\8UG$Y>%OP!5B(@A,CQ9A'E,HDBC GWA-B.3
M*:"<GCCQ!/PW4S0R.-9HH(^#/IXH@[/QR:3+*RJ1VOEXTWF799J"L?%N-\4X
M5P"4\3UG#^(CB0X-QF&-(HBSQK(6E:-XWR/(J(XL; -0"^(=?JN.OPKB/&WX
M3PT:KB*)KEW44DC:1XEBTXE=2BV5VD.%VZ+T'CR^/O%FDT7$.*S:H3\(TG"R
MK:A(5$F]DFU$>EXFJ@=Q]TF\798YAA0?0>*.,30\1TT.K\0R<$BCX,^M5XVA
M02:H.B@E9%;>6]A=MZ#Q=-XB\:S<1T^MU1U&CADXAH--J93,@TFF$NF@DDBE
MTAC,EI&=D5\^#L,1:@]#AGBGQ"T6CT+ZMI-?X@6)N$S/&I,6ZF9-=A:QW<*J
MXOST'J^!.,\1XIJ%U&LULDV\29A%OM+NL)2H"Z>-!,N51M8T'W( &P4!0% 4
M!E7F%!F5>84!E7F%!MAS4&95YA0;E7F% 95YA0%AS4!0% 4!0% 4!0% 4!0%
M 4!0% 4!0% K21KWF"])M0)\S#>P)8_N@GT4&P]I&-B+LV!P.V@^"UF@XS$V
MIG.IXL[HQ!T\<FG-UMF&0,!F#>4T#.O$(9=0LB\6U431W4@P@!C9[H<&N+<N
M'FH$9N+RZ/3A&XW%()=Y([G3B9U& 5E-U5%V@C;06XM_=(9W"/Q>9(U*Q[AM
M.R2 8%E)&;,>6@FFGXHG%-1(TG%8U9%U$2?TXC&8!MPM]F78<U!+)Q4Z82LW
M'5(U R1#<";*QQR$=DQCK(H.DZ7BT;ZE5?C$K1PL8X][#^(,V4;M]I=1VN2]
M!-QQ.T1W'%SF5D>-!$J+RYW%L;;+ F@[I%XN-6JHG$U,:G4S.IA9)"%6T))V
MD6[(&&V@Y%AXE+JT<R\7@#1QW#PPL@*DJQ( P)L"W3A0=&LDXBNL@673\1S*
MOXS1"-XBT@L"S6/<VV'+0<48XOJGW"MQN$JP1=28H82W:[Q.(R6Y;4%TFXBN
MDU<9CXPK1!1%*8HB[6D%V2,YE\I/-018<8.IC99N-PK(MRC)"R  VRL2&Q)Y
M>6@KJH.*Q22(TG%W5W, CB$)RAR"'60J; >B@Z>&<+XKJY'A/$>*Z,PV)>>.
M-5D^R;,NT]F_10?5:33RZ;30PRS-J'0D-,_>:]SC0-D3YDO89PP ;EL5H+T!
M0% 4$(8Y1"H5P,/9_;0/DF_,'W?VT$W@8W+ .W(R]ANN@:!WR M<K;:PLX]X
M"@M0%!.6;)F"V+@7-S8 <['DH(JVH8!BY<-L$0 4?Q-0;DF_U/O+0;EF')(?
MXEH"TWLO]]:#,DW-)]\4!EF]E_OB@,DQ^R_WQ0&2;F?_ (E 9)O9?_B4!NY?
M9?\ XAH#)-[#?\0T&A)KXH?^(?50;DE]@_\ $/JH%200V60LI<V4.<POS9O7
M0=(-^GFH"@"P N:"3/(R@I9+]X,+L.; 4"!Y?:?IW= AU$@DR6E/[PC[/70*
M^IE5B,LQ\HBN*"D4KME9G9 6RY)$RD]%!TT!0%!C,%4L=@H.=7U<IOV8%VA6
M[4A'E&P?30!>8,1F<VY<@M03$05]XJD27)+B);]JU\?+84"B!!&8Q&<C  KN
M5L0-@M;DH,&EA&J.L$5M4PRMJ!"F\*\Q>V:U XC -\K7S9[B)>\1;-LVVY:#
M<HO<JV:^<G=+?,!:^S;:@E/I=/J(C#/!OHF;.T<D*,I;VB"+7H*&-2I7(UF7
M(PW2V*C[)PV>2@6330RLCRQ&1X\8V>%&*^Z2,*"HC:0,,Q%\6$D:V/T"@P,L
M4D8U$2+8Y89D'9!;DYUO0-!POAL$YU$&DABG:^:5(T5S?$W8"^-!TT!0<TFH
MD9V6)@D<9M),V./,HY:!F74 X,S] 0>F@/Q^9_Y* ._YW\V2@S^H_P!3^2@"
MTPN3O+#$GL4 6D+%5+M:UR,G+CRT!^/_ *G_ ,.@/QO]3^2@ 9N:3^2@/Q?]
M7^2@S\7_ %?Y*#?Q>:7^2@ 9>:4].2@W\3FDZTH% D_U>M: M)S2]:4!:3FF
MZUH"TG--UK0;=QA:7^6@ 6L?C><+0%W.'XH\O9H*0-F3OY[$@DBQN.<4%*!9
M),@PQ8]T;/IH.=OG3LQV[+*/I#&@58)Y%#F0 $7'>;TD#Z*"0BC.(DF?_P I
M HZ\OUT'1I83&[$*ZHP%]XY8DCI)M0<VOXG%PW3-J-2V6 R%+JC.1>YN0O(
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M H.J&%(EL+D_:=L68\Y- ] 4!0%!S:HS!E5=C7R->Q$@Q /D-!>)]Y&KVMF
M-N:@:@E-*%4Y5S." H\K8"@=(HT+%5 9C=CRDT#4!0% 4!0% 4!0% 4$&@=)
M<\6*2'\:-C<>\M]AH+!A<J-JVOYZ#:">H9UA;=_$/93I.%Z!=.H*6MV%-DOR
MV^UYS06H"@* H$G^"_NGT4!%WGZ1Z!0/0(9H@2"XN,"+T&?,Z?\ ,7KH ZB
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M='5U#(0RG81B#0;01GVW_<;ZJ!X]K^]]0H'H(0P0F,$H"3>^'EH-DT\(C:R
M&QM067NCHH"@*!)>Z/>7TT#T$]/\%.B@I0% LGPVZ#Z*#5[HZ*!-/\%?/Z:"
ME!.0=M#S7]% T7PDZ!Z*"6H6^8<Z6^F@GI%54@-@&*E&MRD<_50== 4'S7CP
MI#PV#72:W5:6+2S*S1:218S-F-@CEN3EPH/H-(XDTZ2# .,P!VV;'&@K0% 4
M!0% 4!0% 4!0% 4!0% 4!0*W?3I/HH,C[TGO?4*!Z",D<CR'+*4  [(%!GR\
MWY[=7[:#/EIOSVH$:.1) &U#!2+@VY;T#+IY2+B<D'$''UT&_+S?FD^<^N@P
MZ68L"9BJC;8DG'IO:@=%"I&,>\=N)Y>>@M02C%G7W3Z:!Y68*,N!) !..TT"
MY=1^8OW?VT&9=3^8OW3ZZ!7@=VS,4)V7RG9UT&?+-M[&'[IY//04(U'(R]1]
M=!C).PL2A!VBQ]= OR[G;E_F]=!C:9R+#+;^+UT&?+2?N=;^N@/EI+[$\F+^
MN@T:>7]WK?UT ().4*?.WKH*?U'[GTT"LSE'5P+BVSR]-!8[*"2_^F7H%!,;
M_*=W>USEOEYZ#I%["^WEH(;PQM(6C=L;YA8BWDQH$?5+ V61XD)NRAY I()V
MV(H$_N<&'X^GQV?BB@T<1B)L)].2<+;T;:"]]5[*=9]5 ?U7,G6?501?6JC%
M7FTZL-JL]B#YZ ^>C.R>"_OB@8:@R=E)86+# !KGZ*#%U*L=T89&"X9\O9.7
ME&-!>'/NESWS>7;Y*"4IU6=\@;*!V N3'#]Z@II[F(,;YFQ-[7OYL*";@[Q\
MHDY+E2+7MY:"FG5E0YK@DD]JQ.//:@9@Y=;&R ',.<\E!(NY?. $L,I$F&W'
M"U ;]OS(K\G:H%^8D]N'[QH'229A==V1SAB?JH&OJ.9.L^J@G)-+';,8P3LN
M3ZJ!1JI#]J+K;U4&_,R8W,?\WJH&220$.0'W@[.3F&-S>U ::,(TF5#&C',%
M-MIVVMST#S&0 9+[<<H!/TT$7+$/F+7"FRLH&WHH+Q;7]X_50/03T_P5\_IH
M&D^&W0?10,-@H"@*!)>Z/>'IH'H$T_P4Z*!Z H%D[C=!H&&P4"0?"7S^F@>@
M1_B)Y_10$)O$O10+,,?X6'HH$>&-=W*J@,&!)][ ^F@Z* H.#C6@U>NT>XTN
MJ^3ESJQGW:R$*#V@H;NL1L;DH.C01O'I(HWD,KH,K2M@SD8%C;E-!>@* H"@
M* H.36<4T>D(1V+SGNZ>(&24]"+<T%M+.T\"2M"\!;'=26SC'EREA]-!6@*
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M"*\@>0+&6&;;<<PH&WDOY1ZQ0$><NS,N6]@!>^SHH*4!0(V<2!@N86MM Y:
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M1G&4( 68_:-AL\E!-Q+VF?+:P "WYZ"L8L#[Q]-!LE\C6VV-J 3!%Z!0;0%
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MBZ\0AUO$>,2ZK<!\FDBC2#3YG&6[*N9GRC9F:IO>F,5KCSRND6C?.7MUQ4*
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M_A@'4P\.6.8L$2>-9S)D2)KQQ_NJI6P6@[^%<&TG"8FTVAT^ZBE9I&&\)-R
M!:_(  !0>;I_#OA*+61QP11?.:67>Q1#4$O'J#B\@7-?>..^VUA>^TT'MZMD
M.FU(U/X.G*D2R[S)E4K8G,+9>F@\/1<)\(<,U6FU6F,&GD@7=:.VI&6.*3_*
MC4FPC9L<NR^/)0?2*SF49ER]DVQORB@:+NGWF]-!R<;XQI>#\.DU^J#-#&5!
M""[7=@H]-!G!N-:7BT$LNF#!896A<-;: &N"I(((8&@[Z!5[[^;T4#4!0% O
M^;_#]=!\]XS?)X/XJ?EQJ@=)('TS*TBNC&SJ42S-=2<!0?%^ Y_#L?B&/0\
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MY;7*%E8%2""#R$$7H/$_Z?\  !J?FDTXCU) 5YHW=6< DD/SYB;F@^BC602
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MC%M2.'2,JK[1129 /X*#U?#/COPAXGTJZG@?%=/K59C&8U;+*KJ+E&B?+(K
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MIPQH/Z!H/Q/]8S?]9/TP48GYQR1Y-XE!^N>(VR^'N*-S:2<]434'YS_VQ_\
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M4^%N*\'CW;/\WK5@$5UM9+QRR-F-\,*#ZB@3#?>7+]= 0F\?G/I- ] 4!0%
M4!0%!,_$D]P?70>-XGFT4'A_62ZV"/5:5=.N^T\S[J-P6 LSV:W50?*?IU)P
MS4^)-9J.$1Z/AVD32".?ANEU;:AI9&D!2=H\J(@105##$WQH/T:23(,%+,<
MHH.:.:267*)0-H(C6X!')G.%Z"L22,@8RMCT>J@;=/\ FM]'JH-BS68,<UF(
M!/-0/0% 4!0% 4!0% 4!0?$^*X/$TGB)8=.=5)PO5:0I#\MF AU%RK%RK1KL
M97#2,;6("T%M=X$;B^KT^NU\JZ:26*+^Z1:?.'EEC3*?Q X3+TQWP&-!Z_!O
M"/ ^$S?-00F77MF,FNG8R3N9&+,68\I+'8!0>K,;9>T4&-R-N \] D;?BC+(
MS*00RL-A&-]@H*3?";HH'H"@G!W"WM,3]-!2@1FD+$)E-N]>^V@4*-X))2H=
M191? 7VD7YZ#'RRR".]T':8@\H. -J"I52N4@%3@1R4$(E332;D66%A>)>12
M-H'IH,CB,<LAA=,DAS&/F;E(MST%8W<R,CVN "+7V&@S4H[H,E\&!90<MQRB
M] B)'$<P@RDX%[@G'RWO05BMV_>- D^U^?=F@=ML?3]1H'H"@A(S;W*"W( %
ML.<\M T:EE#9W&T6N.0VYJ#FDU6J!W2+D()&]DQ)Q^PBXMTFU 0Z)V<2R7S\
MDDEF<>Z.ZGFH.N.&..Y4=H[6.)/G- ] 4$4<-.3'VD(LS#9<;,>6@R>^9K;<
MH_Q4%Z H"@*",^KCB81@&29N[$F+=)YAY30<<RZB52[J)RN(TZ'\,>\3;.1S
M4&P;^()/*K3BV+JI5EOR;L]T#R4%E8M,9=*RND@_$4FUF&QK;?(10533#.))
M3O)!L)V+[HY*"DK%(V8;0+B@6VH]I/NGUT!;4>TGW3ZZ!9$F*,&*,I!!4J;$
M<VV@G%IW"Y4<JB !1<GD'+>@;Y:;\YOI]=!BK(DR@N6!YR;<O)0=- 4!0% 4
M!08_<;H-!D7PD]T>B@CQ*'5S</U,.CE$&JDB=8)CB$<J0K>8XT'S>IX'XS4:
M@:?BYE5HM+' 7M&P:+XTA(5A>3;;S<M!T_VGQ2FK$PXEO87U<LSPFRA(#$4B
MC6PQ >SF] FFX+XM3AHBEXOFX@NEEB&IL"AG:0-%(4*_96ZF@Z6T?BE?$*S1
MZJ,\&^1,+1/\3YH&XFL%\QQH.1.%^,3#&@UPA?Y)XWD9Q*1JB<)+;M<PY1S#
M"W+0/'PWQ?)F&HURHS:;3J7A:RC4))FF* IW73#&@V+A_C"/4L7UT<D#ZV24
M"UBFD-MW'W<2+?304T_#O$HTT#/K"NI2"5)59PZM,TBE7OD7 (&L.2_+0170
M^-1J$==9$(1KW>:)[-GT;6 52%&5EVJ.LT%7TGBKY@%)P(_GFD>[J0=+;LJ%
MR7  P*WO?&]!SP:+QTGRRSZR*5HWU(FE6R*T;1_T[,N7O*^T##EH+QZ7Q;+H
MWBU$ZQ3210LLT3+>.42L94Q3$&.PO:@GJ--X[,DC0ZG3*GSXDAC(_P#H2N1H
M6.7O@C.&\U!UP:3Q##Q32EM3ON'@ZHZH.5S=M[Z<"R@G*N%![= G^?\ P_70
M$/PQTGTF@>@* H"@* H"@F?B2>Z/KH%B^(O_ ):T'..#Z%>,OQHAVUS:<:4.
MSL52$-G*HG=&9@"QY;"@NCK,2AOB Q%K=EM@- Y55>)5 "BX '10103E 4!"
M?9&<?^&@-WJ?WOOC_P - "+4?O"YN?Q!_P"&@W=ZC][[X_\ #0&[U'[WWQ_X
M: W,K"S@LO*K/A_AH-W/^@G7^R@PPW_^G3[W[*#=U/:UV^__ .S09NM1;O-]
M_P#]F@W=3^TWW_\ V:#-UJ><_?\ _9H-R:CF_G/_ (: ":BW_MGU4&Y-1_LY
M]5 9-1_LY]5!)DDSA;L6N18M<8B]\1R4%8DF$F9Q?;=L.:PP%!2?X3=% ] 4
M'+:,@Y(Y"#L() ]-!T1!A&H;O "_309$,7/.Q]5!A1&F.90>R-HORF@=45>Z
M .@6H-H,95;O 'I%Z";1HKQE5 -]H%N0T#?YY]T7ZZ!Z!)NZ/>7TT!%MD]\^
M@4"RWS'_ ,MOJH--R8NG_=-!2@626.,7=@HY+\O100C<R3A\C(#?+F%B0!MM
MY^6@98M1BI=40$V*#M$$WY=E!2.&..Y4=H[6.)/230/0%!)YP#EC!D?E5=@Z
M3R4&"%WQG;-S1K@OGYZ"P  L, -@H.2>4F?=JA.8JF<6L#<L?HH.N@* 9@HN
M38#EH.66:5[!"8D/VK7D;W%Y.DT&PZ0!2",BMBRWNS'G=MIH*:@E(<L?99K(
MEN0G#Z*",<.^#.'= IR1,IL;+@3S&YYZ!)H9A(KR1"6VR>(Y)!TCEZ_-05#:
M@(K+(KJQ !=2#CSV(H";YD@H62Q4DFQY+>6@Z: H,?N-T&@6'[72/0*!Z",A
M_J4_VYZ"U 4!0% 4&,RJI9B HQ). %!R/J)]0K#3#)%;'4.-ON*=O2<*#P..
M:G2R\;T6@BXU)PWB;PJ(X5#,'#L+'*?PRW888B@\?2<0TZZ&/12>*0^KWIF,
M\V]C9XV#(C;5P5U) [IMC0<?]RTMXI'\:/I]-,LK)&!+9C&MF:-Y+M@X5K<]
MP,*"VNU++JY86\9M#+!(4W#1LIWL$7XB!AW@55F-OM;*#UO!&H.JXCJIX>/#
MBFF2)5?2KO6W+L;KC)L[.R^)H/LZ H"@* H"@*#X;7:D1<5FU,'B-(8%:=FT
ML[R!5,+Q[RU_LIBK6P&:@^IULI;@D\HU(A)A9AJ<;+<7OA9L.N@^(XC-+E@W
M7C,:=LGX@8LV9\B;.4#[7/\ 30=6]GOH\_BI8U,>K)4%KO:=0K7;$[H]C'GH
M.$2:YFRIXPCN;E+M(>S<G$X=T B_EYPM!]]PI9%T>E$D_P R^X2^H]NXOFQY
MZ#JA^&.D^DT#T!0% 4!0% 4$',HE<(F:ZC$FPY:!M-"\4=I&SR'O,!8>0 <P
MH'E)$3VP-CC09& "YY;VOT 4 Y_%C\_HH)Q+=8QF(&4G VY:"FZ_?;KH$F,,
M,3S33&.*,%G=FLH VDDT":;4:+59OEM4LV6V?=R!K9A<7MLN*"VY_??KH#=?
MOMUT&& '[;_>- ;@>V_WC0&Y'MO]Z@-P/;?[QH-$('VG^\: W(]IOO&@PP@C
MO/YF- ;@>V_WC0&X'MO]XT"O" C$.]P#;M&@EJ#VUNSK<@ H+GNGR&@IIP]@
M2SD78=O X'#"@?4?!;_;EH*4!0+#\-:!J"</V_?-!H^,?='I- ] 4!0))WH_
M>^HT OQWZ%^N@>@2;N#WE](H"+;)[WU"@67O_P #?509>VYO_MV:!GWS7"60
M>V<3YA03BA0L7%RX-B[8MAS<WFH+)$B7RC$XDG$D^>@R:98DSL#EY;"]J!Z!
M))D0Y<6<[$7$_LH$W<LGQ3D7\M3Z6]5!5$5%RJ  .04&D@"Y-@-I-!$ZE<X5
M>7$7VM;V10+I8I1FDE 5F)*QC'*#SGE8\M!T4 2 +G 4$<S2G\,=D?YC##^$
M<M \<2I<C%CM8XDT#T'/J7(:XVHI8>\>RM!:*,1Q*@V* *!J"&24INVC5E\K
M;<>B@3*$)!B5"RFS WV>:@ZJ H,D^&W0:!(-C^]_NB@I01D_]2G1ZZ"U 4!0
M%!";5*C;N-3+-^6O)Y6.P4"KI6D8/JF$A&*Q#X:^;[1\IH.B3N-T&@^2\2:/
MB<NM2?0\&TVOF2!/EYIP 2X+&QES*8\IRVP.T\U!POH^.Q)#)!P+A[:E2S:0
M%5M&K$+9G+G=X$D6N#LPH(1<-XVVAG63P[PT:R JVECD1!$KYQG*DNUQ:[?9
ML:-5U)\42+&7\,Z346<R:AF6,&)VQO&I<F4YPK$W%Q<49$/I_#N@T^GT23MH
MH-%K9%/S*0HL>UB1F )M<6-KFVR@]<,#L-^B@P.AV,#RX&@V@* H"@*#S-5X
M8\/ZNWS.@AERW(S+[3%F'0Q8YAR\M!V-H=(VC.B:.^F*[LQDD]GFO>]!Y^I\
M(^&M2J+J.'Q2"-<B!@39; <_,M X\,< #(WR2%HQ(J$YB0)FS2;3]HB@G%X/
M\-13":/0(LJL6#W8FYVDW.-^7S<PH0].*)(BL<:Y8T0*BC8 , *!H?ACI/I-
M ] 4!0% 4!0%!!YTBD<O?+8$D D#;MM061U=0RFZL+@CF-!DV,3#R4&1[7][
MZA0#_%C\_HH(1S*'A52#=2"+B^WFH.J@AK]%!KM%-HYP3#.ACDL;&S"V!H(<
M(X)P[A.G,&BCR(V7,22S'*H5;L<< *#NH"@* H"@* H"@* H"@EJGR0DX8X7
M; 8T"*Z-,,I!L<2,?LT'103U'P6_VY:"E 4"0_#7HH'H.=9V61T$,C',3F
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M?V4^F@1X647RQXD#[7*;4 NG)%\D>TC8>3"@WY9O8C^F@>.".Q#HMP>39]-
MWR\/L"@%0+, H 4)8 =-!2@* H(ZC8?=/U4%J .R@Y3#*D9)(.4;2SXV\] )
M',P;NBQMM?98'GH+PQM&A!;-<D\N'DQH)ZA5=K->P6]O+<4%(@ EAL!-NN@>
M@*!91>)QY#Z*!EV"@XY4E;59]*0K@!)RP.4C:+<[+05,&2)CF+L0<[-M.%!9
M.XO0*#: H/QOQKQCBG"/$O$I>(>*-7I]$\T2:7AVD:.-85E4%6>1U8VLK-@*
M^IH:<6I&*Q,\Y>>]IB9VOC?$?BKQO#P5N/<!\5:Z?AN<+)%,JJZ*38.KY>TM
M_:"GR5Z=+1TYMT6I'4YZE[1$6K.Q^[:[Q9PS@7!.':[C,KI#JA!$VI",ZB68
M +G*@Y<S';LKX]=&U[3%8>FUXKC+LU_B7A6AXQH.#3,YXCQ,2-I(41FNL0N[
M,PP4 <]972M-9M&Z";Q$XXN?1^,^":O4<.T\1F63BOS'R0EADBS'2D[T'.%*
MVM<7VC96VT;1GT>\C4K./2];1ZS3ZS3)J=.V\AD%T<;" ;?57.U9B<2J)RM6
M->9QCQ%P[A$VBAU8DWG$)?E]((XV?-*5+!.SL)52<:NFG-LXX(M>*XSQ-PCC
M_"^+-JH]'(3/HI-SK--(K1RQ2$9@'1@"+J;@["*7TYKC/%M;Q.YZ#&P)M>V-
MAMJ%.+@W&=#QC0+KM"S- SR1]M2C!XG,;@JUB+,I%7>DUG$IK:+1F'=4*% 4
M"#XQ]T>DT!#\,?[<M ] 4!0% 4!0%!,X"4_[;*#(<7)_=3ZZ"M!.6,LIR6#'
M:&%U/2*"212JP;=KF%]CM;'R$4%,LL@*N,BD;48W]%!ORT'L"@SY73C[ QH#
MY73^P*#1IH!L04"VU*.ULLD9[H)(8<]SC>@9!*7+. HM8 &_U"@I0% 4!0%
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M;.PPN1;+;D"\E!:@CJ(F8+(GQ8C=?*.5?/0+IY4N%4_AR#/%T<H\U!T4!0%
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MSK.IL&LLPY".1O,:#HH"@X-1$ZRY$PN=]IV_U!WT/O#ZZ#MC<.BNNQA<4#4
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MF!%P6;*/NK0=M 4!0% 4!0% 4!0% 4!0% 4!0% 4"K\1^@4&0_"7HH'H"@*
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M/(7+D;MB+&1B&D(\G(OFH++IH5-\N9O:;M'Z:"M 4!0% 4!0% 4!0% 4!0%
M%@!<FPYS0<[:IWNNE42'89";1CS\OFH*0PY"7<YY6 SML&',.04%* (N+&@F
MQFS9446'VV/U"@-R2;NY;]T8#Z*"@ &P6H"@* H"@* H)MJ8%-L]SS+VC]%
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MB>T.N@,R\XZZ S+SB@,R\XH#.O..N@C##"R9BH))8W./*:!_EX/8% ?+:?\
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MT'K^(?#OB[B7#_"^FDBBU>OTVCU!XB=696TYU/RZ*@F,#Q$LSWLW2:#R?#W
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MO(,2>B@DVI9!FDB94VEL&MT@4%E964,I#*PN"-A!H-H)S3Q1 9CVCW4 NQZ
M*# ^H;$1A!^^<>H7H&_J/W/IH("1Y&DN!D0A XY6OVAYJ"\0L&\K-Z:#)>^G
M\7HH'3N+T"@V@* H$>"%S=D&;VA@>L4"_+D=R5UZ3F'\UZ W<Y%FD!'+V>3K
MH*T!0% 4!0%!+Y:&Y-CCM&9K=5Z";G11G+E#/^6HS-U4"O-);(MH+[% #O\
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ML<<<:#L@J .C&@>*^4W%KDGZ:!90<RV_>]% \?<7H%!M 4!0% 4!0% 4!0%
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M(],;(24.,987'+:@Y]?X*XQQM-.O'.(:=_DEBATZZ:"6,/&L\4LSR$MF#2+
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M[1VN0F87/+0=?$.!<6U6J>9.(&%'C53"N8+F (O@>0XB@E-X7XBT^IEAXK)
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M$>67"[!V8N1<B^-A:@^@H"@* H"@* H"@* H"@* H"@* H"@* H"@* H"@*
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M'+0?&\'XMX-\0:_3Z(\*,6LFLL4\<D4Z*$A$ZL)H69<^6, CO#H-!^@RP1M
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B_.KIO[GV_P"V[TC>WR_B;JXOLVVH/1CS9GS8&XV=%!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>nt10016217x4_ex10-14img06.jpg
<TEXT>
begin 644 nt10016217x4_ex10-14img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@$!P+9 P$1  (1 0,1 ?_$ ,8  0  !P$
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M(" @(" @(" @(" @E<P.T*"#X6R1&-XJUVA'L01;&QH:UHH&Z- 03(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @MLE
ME,=C+1UYD;F.TM&$!\\S@Q@+C05<=-2K4I-IQ$9E%K1$9EAO^8W O_S@L/\
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M 9*"IT" )6?O!3@1$C2=NX5[NU1@1W-[T"H[T"OM01" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" 4$"@@@BWH@L<B:N:T=5D
MKV8Y[KR%NV)H]@JJ2R0G4 @(" @(" @(" @X_E/U!2V66OL?%QJYNQ8SR6[I
MXI"6N,;BVM/+-*]RZM/69K$^41EHVYF)F/%@,_ZPX_.X2?#7_![HV4U2&L<6
M%DA)<)&$1"C@XUJLVO@S2WE%XRQWY,6C$U8O@'J19</Q;+:WX9/-?ZBXR3=S
M9917PUW1N+=*>%IHLO)XL[;9F_3Z*:=\4C]O5V/TKY!><@XL[+76YK[F\NG,
MB?0NB9YIVQU ;\@TZ+D\S5%+^,?2&]Q[S:N9^K;WN#6EQ%0!6@U*U)G#8B,K
M"VC<)=WT9A:\DN>7@G7O'=[%K:Z]?VX_Q9]ENG[L_P""^8T-%!T6S#73*00$
M! 06]ZT&W<"*U_H04<@/_#3[F_T(+N/Y&?PA!.@YUZ_9">Q]-[N2"5T$LD]O
M&V6-[HWBKZG:6Z_A6_ZZL3MC+6Y<XHX9?\9Y?9<9;FY.1%UPVWCOKK#B[F^K
M@M)W!L4SV[J4<2-/:NQ7;2;^/C^F<=,N?-+17.?\&P_IYRF4NO4!\=S>W%Q%
M]#,?+EFDD;4/9K1Q(6#V=(C5TCY9>':9OW^'I=>?=00$!!#\=$$4! H@(%!W
M((>6SN00\J/]T( 8UO040"TG\1'N00V.['% VO\ WD$-LO[X^Q!&DG[P0*O[
MP?8@;I/W4#=)^Z@;W#JT_!!#S1V@@H)A(VB"9 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 0$! 0$$A^9 /RE!,.B(8V4EUWXC759O]*D]V2'RA889(10
M$! 0$! 0$! 0$%CB,+C\3%<1V3"QMS<2W4VYQ<3+,[<\U/M[%>^R;=_CHK6D
M5[.1<;SGK)FN:6V2C('&Y+R2"[M1Y0CMXH9',?'(UWY@E ;6O;7N74VZ^/37
M,?Z\?YM*E]MKY_TY=K7(;[%<<BPD5M=-P[]\)O+AUSJXTN3(3./%W/JLNV;3
M,>7TC_)2D1\?5E'"K2*D5%*CJ%AEDABH6M;,V/RKIC&D%DSW$MK7MUK0K2I&
M)QB^/JV[3F,YK_!EEO-,0$! 0$%M?G\CXA!)?_\ ES_X11!6M36VB/\ 9;J@
MK(.8_J)M;BY].S%!#)-(;VW\$37/=3Q5-&@E=#UDQ&WK]):G,C-/\7*[7U/Y
M1#9-M9>%V5T3:Q6,\\UE<.DF@A #&RG\7R@KI3Q*3.?.8ZY[PU(WVQCQC_)E
MO0\9"[]4KS)R8@XJ":RE/T\4,D5O&:Q@-9O&E:5ZK%[#$:8C.>J_%S.S.,='
MHQ<)TQ 0"@@$$4! 0$"H[T! 0$! 0$! 0*#N0$! J$!!"@*"'E^U!% ""* @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @'H@E0 @B?E*E#'PBMSJ.U9?]
M*D]V0[%AADA% 0$! 0$! 0$! 0$'!^,^GOJAE!=Y^TY-)B'Y*>7?$]L@E>V*
M1T;'2-HT5HW0TK1=K;R=-<5FOEASM>G9/W1;&5WFN*^I&$ACFROJ2VSCE<61
M.F#VAS@*TJJZ]VF_[=64VU[*][MR]%HKF+A(9<W#;N<7MWYEVQWF-F=YSJR-
M?^(.ZU6ISYC\G3ITAGXO[/\ &6Z7=U# P>;NVNTJUKG?L"YVS9%8ZMW7KFT]
M%FR^ADD:PSR.#G"C3&6U'2A=3O6O&Z)G&9_R9IU3$9Q'^;)K<:H@(" @()9&
M,>*/;N'<@E?"Q\?ED4:@F;&UK0UNC6H)D&B^L_*LUQCA;LIAYVV]Z+F&(2/C
M;*-KR=PVNT[.JW.#IKLV>-NV&OR=DTIF'%;GUE]9K42&XG$388XII7.LXJ,C
MN!6%[B!H)*^'O76C@\>>W_MHSR=L?_X;OZ2^H?J)F.=S8+DTH#(+1\TEM]/'
M$]KZL+"2P5U:]:G,XVJNORI]6?C[KVOBSMJY#?$! 00;T*"62>",L;)(UAD-
M&!Q +CW"O5$3,(^8RE0:CV:J#,(@@BH.BD[H?>I1F5%D['S.BVZMU*)\I5@A
MF4RA(@(" @(" @%!)3[%**M6Y1ZC\=XY<MM;USWSFGY4+=Y%>E:=%&6OLY$1
M.)7/'N;X#/\ F,L9_P#,QBK[>3PR ?PJ4Z>16\X;#&:L:>E0DMB8PF4 @A1!
M AQZ&B"'C;U\54$0\=NB"8$'H@(" @(" @(" @(" @(" @(" @(" @(" @(!
MZ()4$"#4((2NVL<[N"4CJ+2S+GS[R.PU6:_9"^"UX2BK @(" @(" @(" @$@
M"IT 0<,SOJ7ZNY"TOLUQ[%LL^,VKI?+O'QLDD=% XATA$CM1X3\K5V=?$T5F
M*WG-Y<Z^_;,3-8^U:Y/._J*L\6,C/%#<V+HQ-OMX+:X(C<*[BQH)Z==%:FOB
M3;$=_P#%%K[XC/PZ'Z+X>[QO!H775S#=29">6_#[=P?$&SD':TB@TIJ!T.BT
M>?>+;.D8QT;7%K,4Z_+>)'AK'&M" M&>S9A;"Y9&W891+,2T;1U)/]D= L/G
MX])G,LGAY=<8A=K,Q"D$! 0$! 0$!!RW]2(KZ;.%:5O;<?\ 271]7_-_PEJ<
MW^7_ (N8/YYZ7WN*GM<G8Y<W&0LK"SR+K>2$,/\ +P-ACW'2I&JZ/]/NBV8F
MO29F/\6I^77,8F)ZQ'_AM'HUF<=R#U<Y%F+.%\=O+81_3,FH9&-88HM:$C78
MM;G4FFBM9^K-QK1;9,Q]'>5QG0$! 02CH@T7U*;:3SXYDK-\EF_ZD>(B@)VZ
M!I&OAT5+3'RT^5%9QGX<MRF<R%KE+AV.O+VWC+R\,?(X4+M3X7=%'G#3V;K*
MUGZD<TMSIDW2 ?AD:'?>K1>%*<C9'\&[^GGJ#R3.9U^/O_(?;B R[XVEKJ T
MU4UG+<X_*\YQ\MKS&=&$L);]L#KJ4O;&V-NE2X^$55IZ-BVR88-WK#86[V1Y
M+%W=D9/EW;':=XH=57RABGF5CNR-GZL<)G;5UZ8 -'><QS:?'51Y0FO-USVE
MF+'F7%[Z1L5IDH9I'T#&-.IK[U:)RRQOI]68#@=!U1F0=(UIUT]J#$Q<QXO+
M/)!'D[<S0FDD9> 6GIK6BC*GY*_5D(LC8S-W07$<H_L/:[]A4Y3YQ]582-(K
MV%,K9/-;NVG0E +Q7;VH84[J5T5M+(P;GQL<YK.\@5 295GI#C/IQQ_$\GR>
M<OLQNNKALVUL+W&H#M:CV-.B1.7.XU8O>;3\2I\NPEEQ+F6&EP+W032O:YT5
M:@U>&N:[^)JF>BO)U_CV1,?+MT?R"O7KK[5$RZE<X35")$! 0"@AM!ZH(&/7
M0D>Q \8TZ^U \QJ":H0*H" @(" @(" @(" @(" @(" @(" @((.Z()1H@F""
MC=D"!X/:*!6I'5$RI6 .TN[.BMLDA> +%$)%((" @(" @(" @(*-Y=65O"77
MDT<,+O"72N:QIKV5<0IK$SV1,Q'=Q:QYCRW"S8C@UMQ\7E@V4VEW?ALDT%Q:
MS2G;) ]G@#?*?XMQZKKVT4OG9-L3WQ])_5H1MM7%,=%M9^JV2]-Q=<0S6,FO
MOY;*]F*N_,$8?:$DPU+@:@-(%1[E:W#CD8V5G&>_\41R)U?9,9QV;UZ(VV4B
MX,R;(1&W-[=W-W;6Y!;Y<,[][6AIZ"M2/8M+V$UG9T^(B&QQ(GPZMYE$CG4;
M3;3J>]:,Y;484X8I][9';6#HZ/:":?Q+%6MLYEDF:Q&(7*S,0@(" @((.<&B
MI-!WE W5Z:CO01!.NE$!!I'K#GL9@^'F^R6)AS5L+F%GT5P0&;G5H^I:[5ON
M6YP=<WV8B?'HP<F\5KF8RY?!FG3Q,E@]'!+%(T/8]D3B'-<*@@B'H0NA.O'?
M=_\ 7^;4BW__ #;5Z0\HQ.1Y7D\7!Q"#C60M+7=<NCH)3^8T>4]NQA'6JU^;
MIM6D6\_.)EEXVR)M,>/C+KJY;=$! *""#2^9<5O\O?/>VVCN('LCC\4A8[:W
M<:4TZ/=6M5CM7JUM^J;2YKD?3;F,$LM+(S1@^!\;M]6]G4DJO@Y^SAV^&!GX
MYGK7=Y^/N&=_Y;C^Q)C$,%>/>)Q+=/1BRF&4RMQ(QT9B@;&!("T@N-3U634W
M.%IFM^K8_46X<W'6<,>PR7EX^5@E?Y;:Q-\-3W*VSLW-]XPY'EIW7%W65^]S
M!X")!(UI[FD#HL,.+LM.5B&,!H TO/74U4J=9[,_P2!\_+L4SL$P<1KIM%5:
MO=GT5F+=7HY@<":FOM61WI[+?(S^3:7,Q&D,3Y 1J:AI/15E6\1CJ\]7>3D&
M"D:V!S//.YTDT#F[S(XN\+_ETJJN-MQGNPD<TD((B<8R>QCRVGV&B,'E=>VW
M*.3VK0RTR=Q& ==CS3[ZHM&Z\,Q:^I_-;4M;]?YX!%1,QCZC^*@*MEDGFVB'
M6N!\AR68XXW)Y!K/.=(]K-HIX1T5JQETN+LM:F67_FKMQWQU8?"*=:E3:K/2
M<N(\WMY^*\QN'82ZEM&SL;,YK#U\SQ.:?BL?9R>1$ZYQ'SU97TRQ3N2<@GS&
M8F?=S8_RW0B0U\;CI\&J:3E'&K;=;,_#J=ER2SN<Q/B8VR&6V&Y\IH6]>BS[
MN':*1>?ETZ;HFTU^C,@U"PXQ#/,)D! 0$! 0$"@00VH!.T5ZH(!]>Q!&J"*
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MT3H(5-4$4! 0$! 0$! (J@402ES@: 50/,;VZ%!-4(" @(" @(" @(" @("
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M-^^-MN7&NP.J:&E/%TU6O2UKQ$YCQ;%JUK,QB?)?+9:X@(" @(%=:(%0@("
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MAI2&SIFN,1+/HS,%S3 W>=P$^,M9FP23%M7O!+2&N!(T[U%HRK>OE&'%>2\
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MJR5TQ=+*/,;_ +.*@93V]25@UQ,SF9Z_HS7F(C$1T_5>K.P"D$! 0$! H$!
M0$! 0$! 0$! 0$! 0$! 0$!!*SH4$R#4/4C_ ,EB_P"_:NGZG^=_@T/8_LAG
ML6-F+M!3I$P ?!:&[]]OXL^K^557AGDD,@<T!E/"1]]5CEGGL\N9L#^<7G_?
M2?\ 3*PR\WN_F2Q\GF;? />H8)[HT<-FX4J%,,CK'H62;G, ]/+A-/<XK+5T
M?5?ZG2?WO>LT.G7LC$28S752E4BZ*HD>356KW$A)^]19+,CY![EBQU35ALQD
M9,;C+N\C89)(Z> :TKVT6QJI%KQ$L7)MXQES:_S^8R#RZXN7>76K6L):T#V
M+T>GBZZ1UCJ\WR.1MM/3LV_@O)GW##C;N3=+&*6TCSJ\?N_!<CV'$\)\H[2Z
MWKN7YQXSW;M31<MU&#YAESC>.W=Q$3]0YOEV[1J2]YVZ#V5JJV[,6ZWC29>=
MLQBXK1QD;.7S.E>V>-[:.$@ +BL+@[(ZY8H_*U&.T)G-&FBA13=U5H2;F#J-
M4'1/1VSAM9,MRB\H+;&VQ:TG\+G'>?\ 1 ^];%*]<.IP->8RX7E<D_)96^R5
MP2V2ZGDF<.VCW&G]2]=QJ>%8ADV3F7J/T'XW_)^!VDTK2R[R1-Y,.T!PVM:?
M<%YSV.[.S#9X]>CI%:K3;*SR]R+3&75T3000R25_A:2K:ZYM"*]GA:ZG-S=W
M%P3N,\KY*G^TXE>RI7%8AS-O[E$C52Q#G.:/":(E",DCVJ1 ,<.KJ#M*D1!-
M:4T_>21,"5"$3\J5G[B65X[9'(YO'6 KYMU<PQ,<.Y[P"%CVV\:6E.ON]Q01
MLCA9&P;6,:&M:.P 4 7CI[NK3LB\D4IHH6 @BHD27!(B-%:JMEG8 &0D]5:R
M*L@J+B @(" @(" @(" @(*5VYS;69S31S6.(/<0"ICNB>SA?&?U#6EAQZULL
MO87N1O8&NCN;W<QPE.XZDN([.]=G;ZR;7F:S$0YVOFQ%<3$RR4/ZE.,Q1-BA
MP5W'%& &,880UH'0  T 6.?57G_5"\<ZOT3._4UQ\-/_ (+>BG>Z(#XZI_U-
MO]T']?7Z2W/T@NY;ST]Q=U*XNDF\]Y+J5\4[R : #1:G.KC;,?\ UV;'&G-(
MEM\[6NB<UPW!VFTFE?BM*\9ALTG$J5M%)%5A9&R+38(Z@_%4UUFO3$8_1:]H
MMUS.?U7"R,8I! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$ ]$$L?0^]!,@U'U"
MV'&Q!W_6G[=JZGJ?WS_!S_8=H;!CF@8VV!U_);^Q<S9^Z?XMW1'V0A9-#62-
M: "!0@&OWJ;'S+S]<8R$V>4G=#;T$L_YE3YN[S-!4E89</QQ,S+57[*[XW T
MIX6U[E#6O:,JDVK8W?O"OWJ$UG-G4?0G_>,O_P!W%_TBLM71]9^Z720L\.FB
M/8I$P=MU[E IN\3]U?@D"9JBR68TV?!8L#'-:YWF "H<:.! +2.Y9*S@GKW8
M7(<-P-U5SHGVLSM=T9J*^XK9U\W92<=X:>W@:[SY=I8%_"<K8W3;G&3,F\CQ
M1>8:2[NVG8MZ/84M&+PT;<#96?L;3:\KM@V-F2CDL+JGY@E8=M?XAHN9/'F>
MM75U[9^6"]1;7)9>U@&,ADO+9C7/<;5X#MQ[M=- M6U+1/7LP\B/*.CC&9CO
M&W9%W!/&6 ",7>DK*_,-!XJ]ZI,?1S+UM'=CZ: ]G>J=?EK^42E+=W;T]J'C
M$HEH#*=?:K037$)!$"*_$HBD-_YI*.+^BUMCJ^5?Y]^^:G7:?&__ %  NKZZ
MOEMB7>XVOPTRXMQO"39O.V6-B/YEW/'$/=N!=]@7H=D^$6M/T:E+9Q#VS8VL
M5K;0VL(I% P1QC^RUM&_<O'WG-\RZFN,0N0.BK?O#)+4?5G)OQO <M<L-)'0
M^3$>Y\C@T%;/$IG;#%L[/'=U97%O2-[FN@-3'*TBKR3J=/:O71+GW6[ X-(=
MJ5+%5+V:HM*8(A,>B"1_RZ=Z(3#HB$KZZ(F.[H'HKC?KO47$,.H@>Z[/;I$W
M^M:GLKXU2OI_>]? @@$=%Y1U4A^=!$((H+>_?M@]^BM56R7',I$3WJ;HHNU1
M<0$! 0$! 0$! 0$! (!%#J#U"#3KWTJXQ).^YQAGPES)N,CK!X9&\N[7PO#X
MC_HK;KS+XQ;[OXL$\>O>.G\%O_)N>8BH@CQG(K8[0X31-L+HM'>Z,/A=3L\(
M4_DU6[^59_SC_P#='C>OTM_X6C_4O@T%V[&\GL!A+V05DANXX9HG4-!^9"96
M^[=17_I-DQFD^4?HK^>F<6C#9N#8S$XSB]G9XB\%_C6^8^VNFEK@YLDCGTJS
M0[=U%K<B]K7F;1B6;56(K$1.89F[<1;2%H:3M.CS1OQHM;9/VRSZX^Z%I9OQ
MX<UPE:Z9Q VAY< XCHT%8-4Z_KU_BS;(O].G\&06TUA 0$! 08[,W]Q:,B^G
M8'RR/VT*"2YO,K! )3;L>13=1W0%!D8Y"Z-KB*$@&GO03H" @(" @(" @("
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M)0A_DN/5CP?@@J9 %UH]HZNI1!7C:YL;&D:@ 'X()T! 0$! 0$! 0$! 0$!
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MVIV\EY YP'\RN14TJ)#VJL;IRMKXE._B[%Z/WU]?<?O9KRXDN'MNG,:Z0[B
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M3EM4[,\L2P@(" @(" @L\EDA9,8[RG2[W;0&H*3LL(_+#[>4;S30;D&10$!
M0$! 0$! 0$! 0$! 0$! 02LZ%!,@TOU)N6MLK2W.KI)MP_NKI>KK.;2YWL;1
M]L-L\1MO#JXQC;I76G<N;/[G0C]L+(!W\LNR:_))I_=*65K\O*]PX_52Z_C=
M^U8)>9O^Z5-S]H]ZACKW;'QR<"_M1%X+CZ=YBE<W=%$=VDDHW,\#>W53\-S3
MGSC^#HOI*&?\29_:U[?!'42=:[C4C^R3JWV*^ONZ/#Z7EOSOF?[ULRWHZS+3
M/5.!T_%;2(/#0;T5<_7L*U>9'1U?2S]\RY%E<2['/C:^2OFC<UM-O_M/_:N=
MLAZ;5?R6+>JI"\UE4;\P]ZB.ZT_O=K]&?_R.NCVFZ=7_ $&KI\;L\G[C^:VP
MDU6[5RF3L!6W'_Z]JI?NFDSE;9$^;/% -*G7X)$S".LV6UOR#C5\]\$-Y;R3
M0.#98]X:YKA["L4;:RSWXEZ]ZKR3&V[SOC=H_4CJ#[E?,2PXB)_5+Y>0B/@H
M6#J#THIB(2QL^'XY/D(,E=XN$WT#M\-R&-#PX=#7KHLGY+Q&,SA6:1/65\#]
M9<5 (8P^$$4]JI$S"<.#>N>;M<KZA6N(DN RRP\%)/W?J):/<TFC@/#M%:+N
M^NUS75-L=;-+D6S;'T4/27#_ ,_]4VW;W&>SPD9N-S@ WS!^7%M#2YO4[M.M
M%;F[/#1CYLC37RO_  >BLE+Y=O2OB<O/U;TL;[.Q9D)F@5IV=RKA"H'.#30D
M)@RJ17,[0#4N[ZIB#*]M[ELQ+2*."QVC"]5P*454H!)&(R1;+=B-Y\#/$[W#
M4K-3LQVEXMY7ESEN3Y;(]/J[N22/VQD^'[@O6<6OCIPT-UHEC'4#FDBM"#HK
M:^T?Q8*O2WZ9L6UG%LCDG-J;N[,0+NM(!M(^TU7#]Y>+;(K#<XE>[LS0 -%Q
MV\B@D;JY]>PJ0[40G4"TOR0T '0]BO3NBRK:?X(5;]RJL%"P@(" @(" @("
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M;%9S&645$B @(" @(""RR4?F"$=T@0+ZH=;T_P"L07J @(" @(" @(" @("
M@(" @(!Z()8^A03(.<>HU7YVRB["QM/?O7<]7'V6EQ/96GSB'00'>10:'90>
M^BX<_N=FO[86;@\XZZ:[5WEO&G\)2RL?+RO=0CZBX_[P_M*P2\S?]TK=S-I'
MQ12O=L_$(8ILC#'.8_I76[VW$4S6N9*TN%&&I%*'Q?!/AT./CR=!]*W@<LS\
M8<7M9#&T.H *--- "=!T"OK;7&G[Y;ZXDNKWK8ET*-7]1K>>7CE@8(Y)',O&
M.D,3#(YC:&IVA8.5$S'1T_46BMYS.'+,I8Y[(/:]F,NA%$S:W=!LI\&[ES]M
M)^(>BT[:5CK:O^;'?R'.MU=8W% *G\I_]2QUI;Z,L\FDSCRC_--'ALP7M L;
M@D]/RGZU^"K$3EDG;3RSF'8O22UN;;B%S'<PO@D-RX[)&EAIM;V&BZG'B</*
M^VO%MN8G+9&]"MNKELK8 -M=WO5+]UH8?+7HM+7(7Y( @A=Y=?WS_6HF8CNR
M\2GE?#@>4Q)M&F[DF>V:9H=Y9!:YQ)K[URK:<?+V<QYQU9##>H'*\1'&RWO7
M2P-Z02M\Q@'<2:.6.+VB6I?UNJ_3'5NV(];"70QY2P$8<:231.J .UVQ;=.1
M]7-W^IFO9T+%9S"YJT?<V<S9[=AVRD@AS3UH05MUMER-NF=<XMW7,U]CK#'7
M-\7!MK:QNFE=THUC2X]?<LD5F9B/JQ3..KR$,P[(9#+9XWAAREU</N6PF01F
M2-SMVP5;JX _O"E.U>K_ !^,17'VQ#F>69F?EW/].?'C8\0N,S*TB?,3E['.
MZ^1#5C-?:[<5Q?:[<[/'_:W.+7%<_5T/(RATH;W+G1#,MEE!O50JF+BU ;-7
M3O09/'Q[83IU=58K]UZKH*JR&FJ2-%YUDV6''\YDS7\FTE$5/WW?EM^VM5M\
M6N;Q'ZL.SM+Q[&)'-!E(+R"[3O)7K)C$X<BUIE,T@.U[ 33M.T5%/B$PF9Z/
M8OI#AW8GT]Q%N_\ QY81<S'^U/X_Z5Y'G[/+=,NIQ*XJW5O:M>6<=T*A*2/Y
M I0C^-!.H&.R!K*VBR4[HE>6XI$%2_<JJA0L(" @(" @(" @(" >B"E/#%-&
M8YHVR1GJQP#@?@4@A:.PN'?3=80&AJ 8F=?L2;S"/%=>1 ^(P.A!AI0QN:"T
MCW=$_4PA'9V<0:V*"-C6$N8&L  <="10=5.9/&%.?$XJX:&W%G!, XO DB8X
M!SOF=J#J>U/*?B3$+F***&-L43&QQL%&,: UH [ !T4)3(" @(" @(""WO 2
M(Z=CM4$EX"3#3_K @NT! 0$! 0$! 0$! 0$! 0$! 0#T02Q]"@F0<[]06N_X
MAQQIH=E#[GKN>M_E7<?V'\VCH$E?)=M-#MT)[Z+B2Z\+"V.W'2DC:[8XOZGQ
M$'XE+,<=<O,F3QM]"9)Y3&8I)26!KV.=0CKM!)"PO-[:8S/ZL8YSQ393MK5%
M:LQB,U/B)H;UL;)7^46!CJT^<&NGN1GU7\;Y=&]&KZ2_Y#F[N1K6ND@CT;6F
MCJ=JMK;_  )\KS+HK+>>7<8ZD#K[%GETYZKJ*#(M9L&C>P[@HS B(LI6NYWQ
M(4+88[+6M]F<;<8HW+[*2:@^HCH7!H-2*>WHIZ,VC;^.\6QEQGCIOK+GMKC&
MW4DOE7@B!+W4<&GMJ5RZ?S'I]OX[<6;8P[]?$?3/-=%U*O(9Z,4/D![%=#(1
MR;<=N&I-?VJL1U7JU3F>#RV9P,%MCFMG'G"6\A,GDN>UO1NY8.13R;OK]^NE
M^KDG(,5GH;J.VFL+J$1@F.)Y=*W:.I:\ K1M27H=&[7\2PKFN:[:X%KA^$Z'
M["L6)K.6]6(F<Q*75HK3KT]NJK6\39%XGR\OH] <1Q#<'Q&UMR-UQ<M\ZX?3
M4N?J*_PC1=K16(C+QGL-T[-LRQWJAD;?&>G>1A>X&7)0OAA:30_+4T]P6WQ?
MNVUQ]6E>/LG^#RQ:VLUW<0VD W3W+V0Q#^T\AHZ>TKU%IB(S+EQ&7MG"XR'"
M<?LL;  ([&".$4Z>!H!/Q.J\=MOYVFT_+KUKB,+"1XFEW*\*(G0T/52(MU*)
M1)'3M02QLW$U[Q13;LAG812-H]BUF2J=$J,[RR-[O9HICN.*_J!S3+7@GTC7
MEDN3O&L.W]R!M3\%U/5Z_P#EF6MOV=)><0[M;V+TCF+_  V/=D,M96;!66ZN
M(H6 =:O> ?N*KLOXUF?T(C,O<MA;QVMK%;1?X4,;(V#L C&VGW+Q.R<NW7I"
MY;V^U5CLL@\BBE"#0:!!$:]$$3T422QEP0^Y(;J= MBO9CCNR3-&@'J!JM>W
M=D3*00$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%ED'O8^ @>$O -$#(R!AA
MIU\P507J @(" @(" @(" @(" @(" @(!02LZ%!,@Y]ZBEK<UBW%P J![='C^
MM=KUEO\ BNX_L(_Y*RWQ[F^2:]-NM>G1<:8=>.V5E"R,V4^W2(M.H[J>VJ2K
M7IF7 >87V"VOLK$6KKB)[1+):L>""!0AQVAJQVKAPN3\Q$?+3PTFGOIT/:JM
M6*S]%>XK]+;FA%6DT.AU*(OF.KI?H.X?S;*Q_B=;,^%'GJK4=/U72)RZK')?
M0%[&L.VO<LV8EU(GHG%[?]W^H4Q"<JGUUW_U9^P_U*%\I+."0S.GDT=J WMU
M22'*K#@_*H?42/*OQ[_H&7GGF8.;\E3V5JM*NFT6R[V_V.NW&_''[G7;QCC;
M/8.ZJWJR\_%8B,0QUO!-*T;!5@T)KVJT]##)P1L;;B)]-PK45]JI,]5JK=^-
M\6^&2CA^&NBF+1\L<:NN4K3?04#]TK1T! /WJ/MEEM7':6$S_&./9R$17MOY
M,H.YMS &L>">\@:JEM,3#-HY5M<YAIKO165N0MYK7(,N+-CPY[9:B4-!K2O0
MK7GB1$]'3U^W_P".:V[ND7$;WW,,$>L;-K WLH MVE8BLN%,S,]7#/U&\L>.
M18[#6I;(S'0NFG@<*L+YP6AKJ:_(NQZSCQ%/.6KR-GCT8CT7X^W,>HF-NO)9
M';XZT9D)FQ M9YE-L>A)ZO-?@MCG;9KIGKUMT8N/7-_X/3.1EVV[F_B=T7G8
MC+HS9ABUP V]>U96+*=GB%3U3*4S-'54@X&M5,PB+*]@S=< $5%*E5O;HM$,
MNWHL"\0BB5EE7EMJ[;U4T[Y^A,='FO\ 4=DW29;$XEITM(/.<.PNG<=3_=:O
M0^HIG-OAS=\3ER!@\-.W^I=C'1K37#H'HEACDO4?%-<W<RS+KMX_[MOA/^D0
MM#V.SQTS^O1DT1Y7P]>,!.[WKRGPZ\]D[00-5$(A+(?$T=I4I1) %>Q 8*-U
M[4$3T48)8M@+KLD?O56>)Q#''=E "L$LB*D$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$!!!S&NIN%::A!*Z(.IN .UU0@G0$! 0$! 0$! 0$! 0$! 0$! /1
M!*P:%!,@T+U&8PY/$DM!J^E?[[5UO6?R[N3[+]U6\M%1[*+ERZD?MA;OEMK9
MCF]2==J)8YXPHJ]]C"2XZGRV??HHF%9U5CJD)PAIMQ\![?\ #9W>Y1XJ_9]'
M&?61\0Y1!'#$R*+Z:/:Q@:T"NNM%CO#D>SFG1BN%9W,8S*/ML3/'%<7D895[
M0X':X'JL,WPZ7H=-+=VY1\Q]3'S&!MU9F8;B8P*N  <6[M--P85'E>>SU$\3
M1GL'GOJ4T2 NM=\#FLFC\H[@YQ 'L/6O51Y;">'Q\X33<^]2H(KF>4V0M[,D
M7$FT$ CH  ==U0GEL6_Z[CJIYYZDAD,C;>T<V9K7,HVE=[2\:UT\(JDWV1U4
MG@\>/E3D]0_4*$O,D=D\"40[:.'C<:!NH[U'YMA7AZ)5(_4GG<T <VTL9!,Y
MT4;:G5[#M+??51^>\)KZS3/RD;ZF<OL()A)86)-J\-N2'2':]U/#H*?>LL[[
MXRK/K-&8C/=)%ZZ9>@\W%6Y[]KW@U^Q5CE?5?_I<QFMNC)VWKKC]&W>+EC<1
MJ6.!%?94)_5PU[^FO'RRMMZT<2FHV2.Z@)TJ^,;17M)!Z++7=##?U6VK,X;/
M\=RCW^1?PS.>:,C#@''W K+&Z&ILXVRG>.C*G' NJQYCKTKU5XV1+7M6$&VS
M+/S;J63<UC2YU>P-%25,SF8B/E6M(CJ\9\QS;L]RG*Y=QUNIW%@[HVDAK?[H
M"]9Q=7CK\9<[;;SL]$_IYP#+7B/\Y<T>=DVQLCD[3! TM;[JN+BN'[3;F\5C
MM5N<:O3+?<C/NF+1J M&K+9;$Z*\]$1?*>.*>@_+.UPJUU0-/<=5CG?6&3PF
M3H:&H<.H5ZSY,=H\4>JB)G.$S$8RO\4RL;Y"*$Z!4NM5?-%!146108K,.)?%
M$#\YHLFN/ME6;/(OK!EVY+U"S+XW%[()1;,;^Z(0&_>:KU/KJ>&J/U<W?;JT
MZ/>XDAOR>*G>!K1;U9S.&#.7=OTOXJ23,9G+2 .\B&*TC?\ VG'>XCX4"X/M
M]G3Q_5L\2OWY_1Z* HN$Z0@IOUE;_9_I4B+NE% F T02R/#8W./8%,$L?:#?
M<DCH:E9+=F.O=DUB9! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$$L9Z^PT03(-(]0-INL:YW9*&Z==7M75];/V7<KV
M7[JPW4-H/@N7EU([1"Q9&QUY('"M!4$JRENLM=YOSFSXH;5D]@Z\-SNV["UH
M&WVE8YOA@W[_ ,<=>K5'>N>) J<%)I7I)'W>Y1^1K?\ 8UQG#7.4>1S3E7'G
MMB^CBR=JUTS*ASO):YU6Z :^%5O>/&9-T1MM3ITEG[.RQ%KC63P6-LS&U$;-
MK*W(;OVE_F$@UJ.BY']5F<8>NXW KIGQI]&GYN.PQN5O+"3)WH+9"V0EHJ6T
M.P5!_"V0K8F9B.DNCHF;T\II'_E<\;AN<YEH\=99.9CY][F2R1-) CI0O>!N
MZ:=5DU9M\IWVUZZ><UC+;Y?1O+26SK;^=M\DEG@V.I2/1H.NNFBV/P?_ '2Y
M7_:Q_LA-'Z3<I@8X0<AC;JTLK&\AH:PL &O[I3\'ZRK/LXG_ $0IR>FO)P]T
MG\^M-[I!*2;<5\P:@U(/0ZI^']97I[#7\TC_ #6X]..4M<TMSEK^5+]0P-C+
M:3?O^$#O*I;1/U99]GI_VK&X],N6.9)#%?VL\<[MTU10N?NW5)<-W5)U3]4?
M]EHSG"PN/2'ET %76TCNT->:_>L<\6TMBGM-+'7'IYRZW=7Z!\E/W'L(/VE/
MZ2S9ISM$L9=8?-6=1/931#M)C)'V@+!.FT,W]32>UEF)#!(QS:M?V4T/VZ+'
M-K0V(CRCM$LQA^<<HQ3J663E,8U,5Q29ON&[HL]=GC&6GNX%+_&&4Y3ZWWMS
MQ+(V,UD(KVYB\F.YB=M W:.<:^Q=;U4_EVQ^C@<_B5T4\HEPVSLY+F^CL[;Q
M37$C&-:#6I>0*"G>O9[)B)F9>3\ICK'R]O\ ',3!@^.V>+BH(K&%L0IH*@:_
M>O&[;^=YGZNS2OC7"T>_=,9#K4]%;QPI:4T5'/%=":D =XZ!4O/E296UWK%X
MB&BW.0D$K[FZ<_\ F\<SA;QM)<:$Z"@T7FYM>TS/T>JKQHBL?[<.@2O?LB$@
M_-=&TO\ 8?:O1<:,4\GE^1,3?QCLIMJ7:++G,95\<3AF+1FR!K>U8;2O$*P5
M8254C7\S>L@FEN9" RQBDFE[J-;4++3/E%?JQS#Q+D[R:\R%Q>3.W2W$DCY'
M=Y>ZH/P7LJ5Q6*_1R]GW3*C$'!X!=4.(#O=756I/_(Q5Z0]5_IRP[;+@+;S;
MM?DKB6?7]T':W]B\S[:^=TPZG&ITRZJN8V1!3ZRGV!$(NZCVHE.@H71_(</W
MA2JFG56TK?&-'B/:%>Y6/E?K&L(" @(" @(" @(" @(" @(" @(" @(" @("
M @H7-[;VVWSG[-YVM/M02NR%FW:'3-:7FC*]I07* @(" @(" @(" @(" @("
M @(!02Q]OM*":HU]B#0LG*W-\VM[*,%T%B=\Q'2H(/[0NOKC\7'F?]SE;)_)
MOB/HWNM15<BLY=2>ZRB<?K9OX5D^%8_<Y+Z_ ?4X?LHR4Z$CM"U[]W-]G&:N
M3;*C<*[F]#4Z5!57%FD>#9LID;W%CC&0MGGS[6RC>T'6OC=4'O5;8GI+<VS^
M/\=XGLW'CF9Q&8M,CD8H+F.?&0?4/LGNI!(X&O@^/8L%^+6.KU_#]W/*V_CQ
MCIW:?R/R[OR<B^%\,MX\ND=-4;BX5&M2 L5HZ0]+Q9M6OAW\6S^B; WE,H&@
M-K*7 &HJ'M']*S<9H>WS&N/XNY;0M]YWHIS@MA>YM*@::)$(G#'65JR:(OEK
M7=V44S"B>*WLI7%@<:C0@BBG&%JQE0$4UG<DM ?&?8IZ+>,IYWRWA;'&PM'X
MG$*LY8[5ZIFX8MU$M/@"HS/U6C$,;;YOCMW>?009*.2\=5H@%2:CKU5?RTLV
M=G&VUZ]E'+\/P-TYHO+"&X>XT\RFUP]Q%%%M$6A&OD[-?W>79K69]$,3-NEQ
M-R^U=U$$GBC)]_4+#LXU9C#HZ?<7_P!75P;U1Q=]@\O'@[YT<D\;/-D=%4LH
M[H->U>A])Q(UQ:[G>ZYL;:TB/K++>@G'H\MZA6LTC=T6*C==N%--PTC_ -;5
M;WM-N-6?JXG%KF^)^'J:_>&6P;NJ7&IKUU7F*]W5M+&;0-%LRP60VOW-<#JW
MHHB,1A;PB>L)@6-D\X11^;K^9L&[7VK'&BL?XLMMFV8Z6Z*VI;4FKCJ2>I5_
MC##6)B<RFM&%\[/?K[E3QFL+1UMEF0L<LC4_4GG\/"<+!DY+4WIGN66[;=KQ
M&2' N<X$@] U;/#XT[K37..C%MV^$96/I]ZN8?FMU<VEI8W-I<6D(GF\[88Z
M$[:![3UK[%DY7!MIB)F8G*-6^+L-ZN9B7'<#SUV*"2=K;6/O<Z=U#3V!BG@T
M\]M43;N\ID1D4[A0?!>MQU<J;=93QP.>6MKJXAHI[314GI'D?#V_P?$_RGBF
M)QU-IMK:-KV_VMH+O]8E>,Y%_+9,NMQ_V,\L3,(A38:U=V]$$7?,U$IT%I?O
M<V,4[3JK:E+H8YH#">TJUUH[+Q8TB @(" @(" @(" @(" @(" @(" @(" @(
M" @(,=E+5LTUL7M#FL?6A[T$<C:QRR6HV TD[D&00$! 0$! 0$! 0$! 0$!
M0$! 02-[?>JVGH+>_N!!:7$KSX8V%Q^Q9==/*T0KNMXURU7T^LB^.\RTHW37
M;RT./4AI71]C>(F*1VAS^#7-IM/=N8&BY4='2GNL(?\ ?I_X5D4IW<F]??\
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MHLE&.ZXL0/IV$=3U*K:5JKA56$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M;DVDS98QX7.8ZNIZ56/9JMKG[UM.V-D9A9YCAG$LO*Z7)XBVNYG !TSXQYA
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MSQ)!.15[:[2]NGA![*+?]56_E:9G-7-]M;7BM:_NANZ[CB" @(" @(" @("
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M5Q:NY(R1TUM&Z%E[9D-<&N[XG#848-7#KH_9'5TKT<N^%8BQR(L\W#=9"^+
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M*DUY%L=FWH\9KAD,AP3!7<K9HXW6<PU+X';*K'JY=XCKU8K\2DSTZ,V7-MX
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M1-;% 6Q17S0X&=_XAM.GA[PJO)^WXVO1;[9;D(L>?)MG31LOI!O9"YP#]O\
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MU \D-CQ2/"P[_J<P_8?+K7Z>*CI:T[] N9ZS5F_E\5;?)MB,?5R;THXPW/\
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M" @(" @(" @(" @(""UE\T7;"UE6TU*"2<3&[MBUA+17>>Y!>H" @(" @("
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M=W:*1.>B@4B'$Z  ]?\ T*4*@4)10$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M!%!(Z&-QJ14_%3E&$X%!0*$H.8UXHX5""#8V-^443(F02&&,UJ.O7JIRC"<
M!0D0$! 0$! 0$! 0$!!(9H_-\K=XR-U/8@>;%YFS?X_W4$Z @(" @(" @("
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MZ?RS9OG \9=66.D?=@,GNGF4Q@$4!]Z[7K--Z:_N>?\ 9[ZWV8KVALZZ3FB
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M![EYR.[NV[88?,.\Y\5MU#C1WL4]I17,1U<QO/7%V-Y!D;"6R%UB;4.B@,5
M_P#*T>37K7HM.=_W8>HU?V[^37%LXEOEID;3+86SR=M:OM3>L#V0R -+1[:+
M=B<P\WOU?CO-?HOA97D+ ]DC=U*T::%2Q)V9"Y8 +N/S&]Q&OQ4)GI'55@.)
MG)!8(W=:'13/1,1E2FQDK9?,@K)&[L'8H\H5QE,)LA;C4'RQ\P<*Z*29PXOZ
M^9F[;B;+C5J"+W-2[IVBE?*8[Y?%X!4T^;1;/%K,Q-OAJ<J?NB([M0O,''F<
MQ@N"8HLB9,YDF5M8@7-B#*%SGNE\SQZ:^4[:LL6B*VF?\&&L9F*_+T9<VAM(
MK>T@=MMZ!D4(Z-:T;:#[%I4GOEOYBG26B>N/T,?&\=8>)]X)]\+(_P (I5Q>
M M7=>,='J/[;B:[O*8^UP^VF=&[=$71R?]8WPG[05H5M,2]AOB)OF8Z-RX[Z
ML<PPI$9NCD+4$?DW7CH!W/ZK+3?9RM_I=.WO'C+M7">40\OP4F4EL/HWM>Z,
MG<'!Q;U+2MZEIEX_V'#_ *>_AG+-XBRA>73&KF@D-:>BR3+GLO2A[AV*EI3$
M*<S87-/F 4]JM"8LQ,EGC9'GRWF-W9UVU5_*8Z$VK:,3'1*VSR$+3)#+O8WY
M0PAVZO6M>GP3,*6K.,1*JW+R1^&XB-1T(T_:J3,937OU<2_4_86]U98;+P#\
MV)[[65P_"US?,9]NJ[/I[3$VB?GLIR(B8<Z]&,]_)O4C$SN)\FY=]'(WV2#:
M'? KH<W5^37..N'+TWBMWI7U9Y)%QW@>5O2[9-+$;:W=T.^7PAW]VM5Y[B4\
M[QCX[NS:>F7E#@G&[KD?*<?B&5W7$K1>/.M(VG<]WN-%Z;E;HUZ\_&'%B+6V
M/8[H(S-!91MVVT8$<;!V-8*#]B\G6T]<NK$?1G6M#6AHZ 4"I+)"*)4'D>>W
M^R*GXJ4)WGPE0)R/"B6$RLI=<[3\H  ]ZR5ACM*^Q#6"V+F&H<?O"BZ:0OE1
M<0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$%$VD7FOF:W;*\ .?[
M @?20BY%R&UE#=E?8@K(" @(" @(" @(" @(" @(" @()(_Q>]!.@E(UJJW[
M(QU:%<6KI?4R,"E&-$SO<&T7:KLQQ<.3>GGR/X-\>\-:X]*"JY#KSVRT'F.?
MDQ''<GF"X L8Z*V)-"9)/"*?>J;+8AM>IXUM^^(G]O=P'BN#N,[GK'&,>7_4
MRM;</[=E=SR?@M"M<V?0>;NCCZ<O3/T@?,+2W.QEO&(VM.@#8O"*4[UU'S/9
M;RM,_50#3N-7ESFZ5)T%.Y%%S;WTK7,9(1-#7;(]VE"D536<]/HDD;;R77Y%
M&VNI=,XZ"A]O14O)2)M.(7,<.3A\4;B81J TAP(]ZR?:FUICX7-EDG3%S+@;
M7-J==!0:FJK*N,]7D/U3YI<9WG^4R=K)2&U?]+9=K/+@TW4U^;4KI<:F*X<C
MD[\WRZE^FO W&0N<CRZ_\4D8%C9.I0.:!ND=3[%@Y<^,15L\*)M,VEV&AN,G
M(7#;Y9#X@30%S10+4IV=&MJS;JXIR'"\BM,ID[WD<%P#=/>Z":,&6(1UJ&MV
MUV^VJTMFN<O;\#E:II$5M$.=%QFDDG:P-8YQ.UIT;[*K6FLN]'AC[H\EUB\9
M+D<C:V41;ON98XNHJ/,/7X*:UZL.[;%-,W^8>GK3$66!Q=KB<>S;'""VG>7?
M,X^VJZ=*XA\TY')MNV3-N[8+6$0PM8!J!XO>I8U1]10]W55F,K0Q,F^^N#&'
M%L+14GMZK)VACM^[#%9?+\1Q;FQW^19;.<[8"7 ZT[0.BIYQ#<IPMMJYB)PR
M$5O=1QMFLYFR0/ <PC\33J" LD3#3V4\>Z)R6ZL5Y;AP[>]5O6%H:=ZP\3BS
M/I_DI[0?F6S!=0M]L6KO]1;G W>.RL?&5;QF)>3;.[=;W-O<LJQ\;FRL/:"T
M[A\=%Z?9&(F(^7(O7QLZYZ]\WBY!:X#$V[P^+Z-F0NFL.IEE;4,]XHN9ZW1%
M-EO)N;=L_CC#.?IKXP\19/EEQ0Z&RL7#H0*&1P/OH%@]KNSC7##Q*SF9EW'#
MPO<Z2=^HK1E>M0%Q[1AT:LJ.BHLB@MZ;KAY'8 /C6JD3N&NWM*A*H=&J)&NW
M,@?<2//0. ^Q9Z=F#Y9G&Q[+1@[ZG[5CMW9H72JD0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$$D?XO>@G02
M.>.G;_0D1E&<1EI/%YVY'F66OV^)L0$4?LI[5U>77PT5CZN=Q?NV39L>;N#%
M:UJ1N/B Z@=JYE>LX="]HF,.)^MV>+3C^/PN!\H?47<9U&]^K ?<-5I\N_\
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M;+&*,:.X!8I9H3*$B @(" @$T02!Y-"VA:?M""= 0$! 0$! 0$! 0$! 0$!
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M#X'Q7;@&PQBA\S<:-+:==P[UU)MBKCWIUCZR]@\2XS;8/CF+P%FUH;:P-,I
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M"M7NK?LQ=DQOU<0II59;=F&O=L0ZE:\-E%2@0$! 0$$'5(H$$FP @@#N*D5
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MQXEGA&,???37;Z%EI<GRW_W3VK9C?$],O.;O5[-.>F89ZXDOH_\ *3.+FOT
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MES&O:TUT[BL>O5+M\_V.K1R,;(REDQ^9XQ:LQF6Q$]I;.G$MQ>, E9*P:D5
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M:+E;K>4]7:XU?#5# ^MF:98XJRX_$\B28_4W>TFH:#2(4_M.T6IR+8KA[/\
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MYOZH-8UU;83[(R.C+6#YB/>!1<^(\[]7M^G!X?\ ]UH=VLF1S70(:61Q ,B
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M6<L6,2R.,N"'NA/1VH*K:JT6998V00$&B^J-]<16]E9MD=#;W3RV:5HK2A%
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M2S,B:7O- .Q2JP][/+/)J:Q#H!H5,(E>8V#RY"[]YH\/:%:R*LCVK$R"D$!
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MR#(8ZU,6YYZN[U%DU7RI#(*00$! 04VS;WN:T:---W8@ECF8][V4UB/[4%9
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M(" @()7R,8TN<: (AA+V\\YVV,?E5U'>5>%+(6]OO<XGPPQ4J#VU1!=3MDD
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MI<;J/N'_ "E@?JUC1KHN?[*:S/1EU9=@N7NN)GO;J&=?8 5RHKCJVL,AB?\
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M0MD%MZ<L9''+%.^ZF%P^=GENDDKHYH_= T7&Y]XG9,PW.-6,.A6-P^"C*AH
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M*]NB+VFT]9RFL8FW$S6=6,% K3*L)WVU_:7+I88Z@B@[559 LNKZY8)F[0P
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M;NZB:0X,?,ZNVHTT '18N1LBULQV6UUQ#<U@7$! 0$! 0$! 0$! 0$! 0$!
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M6-L<D<HU;HW:'"O4.6+7OM6>O6%K4B4?2KE=WR7B$%Y?-#;^VD?9WA:*-=)
M:;@!TJ*)R-<5MB.Q2V8;@L"X@(" @(" @(" @(" @(" @(" @(" @(" @("
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MR83.12AUM:REPWR6Q;(QS:@&C]0*]JFLUU[(Q.8)S:K"Q^NM]'@A93<?O_\
MBIK?IS!Y+O*,U-H>33=J==M%D_I(SG,>*OY>G;JV_P!(>,9#CW#(+?)-,>0N
MY9;RZA-*QOF-=AIV@ 56#D[(M?IV7UUQ#=5@7$! 0$! 0$! 0$! 0$! 0$!
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MCCCN9Y)0!$TM86,>6M(!+CV*V^D4MB$4G,9;8L*X@(" @(" @(" @(" @("
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M1_5[/J?BJWS&XVPQEC#86$#;:SMVAD,#!1K6CL6O:TS.97B,+E0D0$! 0$!
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M;UKW+(Q(-(##]GVJ4PV.QA\JUC92FE2L=EUP%6$BD$! 0$! 0$! 0$! 0$!
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MQ++8&,B*1Y&I- ?8L<RR1#*J%A 0$! 0$! 0$! 0$! 0$! 0$!!!_P J"FX
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MYVJO6%+2P<;?.(:[7=H%>RL-JB9L9&WM:T#[EA9512" @(" @(" @(" @("
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M" @(" @(""5TC&M<XF@:*N0&2->QKVFK7:@H)D! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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(" @(" @__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>nt10016217x4_ex10-15img01.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ < !P P$1  (1 0,1 ?_$ :(    & @,!
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MLOA<;D:J*EUM)]LD]93S3) '=F"*0EV)M<FX.M9YE74KE78FM"16G2\HCKD
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M(_H3S]23<^XKB:W*I')4SZ<GSKT?L4$(90,#HFW\QV$)_+[^<3_EOB7\@ .
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MWC'C8LR^WLWBMF4V+S"_PK(92E:DK9<?.B$2ZKQL"![MS7<6^[[N;NS=C!H
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MI#8^8_S=:/W).?3\6Y;/J_T_61OYXO1$EB>DNX%*FXM5[)%[_4'_ '\-F7_
M_0\CW4^[6R$@ -^W_8Z]_P !'S[_ -'+9_\ >SUX_P \CHD64])]P?T %3L@
MVM]" ,_^+>U#>Y^PK'XDQ8(/.H_S=>_X"3GWRW/9O][_ ,_7%OYX_0K:?+TO
MW""OZ5:IV3]+:?SN &UKC_C?M/\ ZZ_*O\;]:/W)/<#_ *.>S?\ .3_8Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>nt10016217x4_ex10-15img02.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 7P"7 P$1  (1 0,1 ?_$ :(    & @,!
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M_95_T)U[_AE3X4?ZCNG_ -&A5_\ UM][_P""F]U?]_6'_9./\_6_^ <]A/\
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M *W^_?\ !2>['^_=J_[)$_S]>_X!WV#H3]/N/_94?^@.O?\ #*7PG_U'</\
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M9 '"0GS\@?7A7JWKN_OKIOXX;#R':'>_:&Q^I.O\0ZQY#=6^LWC\'B4J)/\
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M!A<Q$ :OBH*_Y3\_3@,?3<_E&D?\-B_!CG_N6KK3_P!TD'N(-^(._34_B/\
M@ZR$Y9QRW;5_A_Y^/00?S*O^9W_RR/\ Q<O:/_NTVG[GWV+_ .5:YZ_\56Y_
MZM2]8R_>8_Y7CVS_ /%UM?\ J]:],G\HS_BV?-K_ ,7)[)_Z&B]D7O+\7+__
M $I(O\'3?W6_]PN;_P#I=M_S]U@_X4 :G_E _,^-(WD)VCL#4L2-)(1_I>Z_
M9F"*"6"*A)_H 3^/<2<M2QIND&HY!'62O."2OR\X3AH'^#K7T_X3,?'CJWY5
M?#;^9A\?>[-MMN'K7L_=W4&!SE&RO1UT!&TMX3XW<& KGB>3'YW;>5@I\A05
M:*'@J(4<J5!5A7SCN/@[S#+ :2 ?X:?MX?Y>/0&Y!V>._P!ANK*YR)0 O^F!
M:A'H17_".!Z+%\/_ /A.7W5G?YE6]>C_ )(XC(/\3?CSE,-O?<O9\5'7XW _
M(G9&>J:BNZXV5L^NA>G6#+[MI\>Z[HBIY3)AH::IB+AY:4RWO^; ^V:!7QBM
M!\O6OV?S/V]%^S>W]Y%N[)>+6TA;53C^ROF?*O 9.1T&G_"I_;V+P/\ ,*VK
M@,!B8,/@,#\0>L</A,1AJ 4V(Q6+QF8WS08_%8VDI8DI:&EH:&!8X:=;)'%&
MH4<@>U7*5S&-FN)9<\3GYYZK[@0R1;[9QVL8 [!CT  I^0%.K#/^%48EF^,?
M\KU%AD8M0]@1MHC=S&7ZQZ>8-)9/0ER0;V-@3] ;%_)EQ%'O$E>!K_A/1M[A
M6L\^T;=JPPCS]NE:_P"7IR[X+?\ 0(MTO"\4T;"'J50K1.)OW/E76.@,(!EC
M+( 1J &E@?I[36\J1\WF8? '_P W6KZ.=_;=(574^H?]7&_P=:^WP<_G#?-C
M^7AU?N'J'XV9#KG';.W1O*K[!R\>]NL7W;EI=RY#$XG!U'AR4V3H9(:*/'X.
MG"PZ2$()!]1]C+>=OV+>+Y'NW\,Z:5K3_5\N@7M/-',&QVOTEI$"#.V"H/ #
MU!I^76PE_)L_GG?/WYO?S!>K/CKW[E.JJSJ_=VS^ULSFZ;:O4XVQFGKMF['R
M>?PHI\Z<K5F",9.FB,L85C(H"\ GV#>8]CV[:X-=FY=2/4G_ &.'0^Y2YLWW
M=]T,=W" H'DJ@\&/I7B!U6G_ ,*<A,?YM=6?MJJ5'Z4Z "M!!+-<C(9HE1XT
M*_T%[V!(O]1[.>6;F)>6'C^W_#CH.\^VTTG-EO,/Z/\ QWUZ^CYC9=6$QLJ7
M)_AE*PLK"Y%+'R 1<CCC^OX]QDQ!N#3X0QZG*!6>U5?Q:%_;0=:(G\Y?^1'W
M[U;WGN/YN_R\MN;GW3LW<&Z?])VZ.K.IY*^D[;Z4[&DKOXSEMY]6X_#U%/E,
M[M&MS).12'%:LCB*F:18X7I+-'(>Q[]M]W;_ +LW632  %/KY9\@:?M_EU$'
M,7*&YVUZ=UVA*D$E@/+S^TCT],5]>B$8O_A0A_.?V/@J+I_)[YIJO>5'0P8*
MCR6]_C=1U/<DC)!)21SU-//B:&7+9Q]8_P HDQDDTDL8;3(=6HW;E?E4,+EI
M:QUK2I%>BB#G+F\GZ,H=0J*T4G[:Z:@_(Y^8Z&+^7M_)D^:7\SCY"TWRB^?4
M7:FT.D\_N#'[Q[*WWW%]]B.X/D&:):>3';,V/MS+4M-D,3M7)TBQ4,^1>FH\
M?CL6CPX^)Y!&(2O==]L;&#Z/::  4%. _P!7\_Y]*MAY5WK>-S.X;\2;<L3F
MN<GA7-:^>:<:^1-W_P *Z,'C,!FOY>V V]BHL7M[;_7W?.W\)B,11>'%8G&8
MFJZDQ^/QE+! @CI:;'4-(L<,8LJ1QV' ]L\D7 2]F9JEF!S]O'I;[H6K)#:Q
MQXB0 #[ <#_ .MH/^4!&6_E??!-F$D7_ #C=UR=,D312H_\ "]0UI( Z,M_T
ML RG^G/L&[S*W[RF=/A,AZDCET,NQ6R28/A#_">J,?YWG_"?&A[Y&]/ES\%-
MMX[ ]Y31Y#<7:G0N+BIL9MWNFI6)JG(;HZ_IPL%#@.UZL*6J*5?'19]_6/'6
M,SU FY<YG:P/@79)MR*"OD?3[/0_MZ!_-W(Z;DGUMB +D/4@8!'F0/\ "/7A
MZ=7T_P IW&93#?RU_A-A\YC,CA<UB/CSL#&9C#YC'U>*RV(R>/Q:T=?B\IC,
MA#3UN/R./JXGBGAEC5XY492./86WB19]XEFC^%B3^6.AGR] ;;8X+>7XE6GY
MZCT"G\RK_F=_\LC_ ,7+VC_[M-I^\@O8O_E6N>O_ !5;G_JU+UB]]YC_ )7C
MVS_\76U_ZO6O3)_*,_XMGS:_\7)[)_Z&B]D7O+\7+_\ TI(O\'3?W6_]PN;_
M /I=M_S]T>?Y>]QQ?'[H#L7N2HVK2[WIMC46'K9]IUE7'0TV;3)9[$X3P2U4
M]#E((C"V1$@+T\BG0!P>1&G(W+K<S\S66QP-INKJJ*1Y&AH?+TZG?W:YR3D+
MV_ON9ID$D-O;QM0@$?VJ \:\1CJE&A_GMXK$:CBOB7CL0LV@&&@[ H,>E3+I
M*HTWVNQHU?Q(YT@\K<V^I]Y02?="WOP72^W=;><R?B0N2/0&IT]801??WV=;
MA8[#9%EI@,K>&D9'%FI2M1BG1Z/B;_-CZ,^3.Z\9UGG,-FNG^PLYHI=MX;<E
M?CJO;.YL@(V<XK;>Y:5:73E7\)\-+5P4\E25/BU, IBSW$^[[SK[?6(W"%HK
M_;%[GD4,65/,LOH/45 XFG4\>U'WM?;SW6W#^K5Z6VS?G.@%G[)&/DC5P33[
M3Z]67;BI-G4V,K]R;BQFWI:'#XVMR&4R^;QF.J!C\7BZ>HKJRHJ*NLIY)5AI
MXX69@38"_P"?<'6O[POVAM;76L[S!"J_B)-*4X9..LFMRDL(K&?>]P$/@0V[
M2AF53I$8KQ/K3RZ";X\=V=7?++J+:G:VTL50Y#;>6ER]%#C<W08VNK<)78:O
MJL94T55!)%/'23.M,L@"V)A>,_0^S?F;9MTY/W3]UWJ/'<$CU!H<_L_S=!CD
M7G/9/<OEP;[9B*1%K@@-I/F,@T_V>DI\SN]<3\5/CUN'M=>NL3OG&;;R>U<<
MNS'EHL-C9VW+N"FQ"3ZVQ62IXOLI*KS "G8LP_%[^S?D/E6;G3F^'8DN9(I9
MD?@NH552U3Y^5./0:]YO<3_6H]M+CG"*RAN+6!HUT&BJ-;A:A>&"1Y=4OR?S
MQ-J'4P^&6VP0J65]Z8-;O<W.O^X0-A_: !(L!^?>3I^Z1O)E%LF\Q?6-$'"L
MK#!)'"I].L/=P^_1L-O.A7E^.>W=0"0RC2] 3W?G^P=6"?#;^9-\;OD[NR'9
M-!LZ+J#M>JIZIL)MW.4.WPFYHZ>F\U9'M7=&(AABKJB.(R%J67[>I:-&81L
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M UK'(1_MQIK]E,=<_P#9*OYC7_>SG._^BCPO/_K6]N?ZYGLI_P!,'_V?R?\
M0'5/]9+[QU?^GEW'_9"G_077O]DJ_F,_G^9SGK?0VZCPMQ_ZUO?O]<SV4_Z8
M/_L_D_Z Z]_K)?>.K_T\NX_[(4_Z"Z\?A1_,7_[V=;@_UO\ 1'AC_O69'O1]
MS/9;RY#_ .S]_P#H#KW^LE]XZG_3S+C_ +(4_P"@NN_]DH_F+_\ >SK</_HH
M<-_]=_?O]<KV5_Z89!_U'R?] =5/LO\ >,&#[ES_ /9$G_077O\ 9*/YB_\
MWLZW#_Z*+#?_ %V]^_URO93_ *89/^R^3_H#K7^LO]XS_P *7/\ ]D2?]!==
M'X3_ ,Q>W_;SO<0_\I#AO_KN/?O]<KV5\N1E/V7\G_0'7O\ 67^\7_X4N?\
M[(4_Z"ZX_P"R3_S&+_\ ;SS<7XX_T0X>WU'T_P!S//O7^N5[+4_Y43_L_?\
MZ ZW_K+_ 'C/_"F3_P#9"G_076?_ &2?^8IQ_P!C.]Q_^B@PG/\ ZVN/=?\
M7.]F?^F$B_[+Y?\ H#IS_62^\5_X4RY_[(8_^@^NO]DG_F*\?]C.]Q_^B@PG
M/_K:X]^_USO9G_IA(O\ LOE_Z Z]_K)?>*K_ -/,N?\ LAC_ .@^O?[)/_,5
MY_[&>;C_ ,/^,083C_UM<^]_ZYWLS_TPD7_9?+_T!U[_ %DOO%8_YB9<_P#9
M#'_T'UTWPF_F*&__ &,\W(/];J'""W^Q_C7O7^N=[-$4'(D7Y7TE?^K?7O\
M62^\3Q/N9<T_YX4'_/\ UC_V23^8G_WL_P!S_P#HI,)_]>O=?]<SV<_Z85?^
MRV3_ *U]>_UDOO"_^%,NO^R)?^MG7O\ 9)/YB?\ WL_W/_Z*3"?_ %Z]^_US
M/9S_ *85?^RV3_K7U[_62^\+_P"%,NO^R)?^MG7$_"?^8DIM_P .?;FN?[1Z
MCPQ_V&G^-%?K_A[;/N9[0,_AKR*@6G'ZV3_H =>_UD?O$ ^*/<RY('E]$O\
MUL/^#J!-T_\ S?.J7-7L3Y/=0?(+'TAB>/;O9FS$VQE,F7;_ "E)<E1XU5C@
MB470+D8I">+\^V7Y@]C=Y?P;W9[O:HR/[2"X\4@\ "C<1FM?EU8<H?>BY<!N
M=FYEL][N$^*&[M?"1D\RCBGZE: ?(D]1\)_-%WOU)FZ#9GSP^.N^/CQD*NH2
MEI>RL!33;MZNKY"%4/)/2K4U4*.]]1I*FNTBP*KR"]<^R=ES' ;SVRW>VW5*
M%OIR1%<+YT8-@_905X=4LOO-;CRM=KM'O'R]N>TW&H*;F%3) ?+6*#"^9-2
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M:(O4?MZ]XXA_NQ?]B5/^]GZ>]%(DQ(01_2-3^T]>$8K5&(ZQ^"$L"LP#7_#
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7:]MO"6W=XQ<*DOBT.F'43Y@<<9Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>nt10016217x4_ex10-15img04.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img04.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!Y@*\ P$1  (1 0,1 ?_$ :(    & @,!
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M'LRDSZG^%X/[G[Z;.5N.<&;^'Z?!]O3K9=-]5S?\>_=>Z6?\&S/_ #UF4_\
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M "N-_P"?##?_ &)^_=>Z]]IOW_E<;_SX8;_[$_?NO=>^TW[_ ,KC?^?##?\
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M7Y$[4H=K;3;=65K\7N*3!9';>&Q\F( K\]24<8R'B!024KKH+,;#W7NG#/\
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MZ$'@GZ^_=>Z46?W7MZ=\ 8LG'((-PT51+H@JW\<*4]8K2/HIVT(I< DV O\
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MDC*@+,0!SR??NO= UO"NH\OO;;U#B*RBRE?)U[VFL5%15U'-4.\XV=# "HG
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MW/\ ^A!L+_[*??NO=>_OAO+_ )]/N?\ ]"#87_V4^_=>Z]_?#>7_ #Z?<_\
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MU)%5T?#8Y'1P&5T;&Y(,K*>"K V(_I[]U[I/=3 +@-N*HLJ]9]9@ ?0 8>M
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MNZLG%+&LL,FW<.)(Y%#Q/;(YJP=&!1K7-K_U]^Z]T[?PG%?\ZS'_ /G%3?\
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M?_LG]^Z]UT>L]KD$&;=Q!^H/8G8)!_UQ_>?W[KW7'_1?M3_5[L_]&%O_ /\
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M;LV_1U,V)3<^!V31;E@H]D-ELO0=!]U4=+D=I1SY)-OP4<5'FWH<568_%Y&
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M1<@7(]^Z]T_[OVAA]ZX=\1EXG5HYHJ[%92D?P9; 9FD;R8[.X2N4>6@RN.G
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M\CW5M=E/NO=!+M#Y>8;?]+AY8OCN,HV<H<HL+XW/]>9RC.0QV8D%8L4;;?\
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M[]U[KWOW7NO$ @@BX/!!Y!!^H(]^Z]T%N^*"@I\SU=+!14<,H[%B DBIH(Y
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M!57<"UM3?4^Z]T*/<'_,O\O_ -K#:_\ [UF#]^Z]UFZS_P"+5N7_ ,2-V/\
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M]U[I$=F?\RXW_P#^&5NG_P!T==[]U[K!NK_F5VX__#!S'_O.U'OW7NG[:?\
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M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HL?\
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M[HAE1E/(9)$(/^(]^Z]T8#W[KW7O?NO=>]^Z]U[W[KW7O?NO=(CLS_F7&_\
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M1%]Q),].KK!Y*FJFJG6(2DR>-#-I!;D@7/OW7NGGW[KW7O?NO=)N;_C[L?\
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M60&_2#?\W]^Z]U(W&M)C^MNN+/'#C\=N#J&T\DBF"GHZ7/[?59YIS^VD,42
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MI?0")ZIV)^IN!] /?NO=*WW[KW7O?NO=>]^Z]U[W[KW2;F_X^['_ /ANY?\
M]V6&]^Z]TE=S?\S-ZN_Z@=__ /NNPOOW7NA.]^Z]U[W[KW2([,_YEQO_ /\
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M1*JOIMQ8?+50G6:<R.HCW%2T\AABT*?(Q ^OOW7NAG]^Z]T'/;W_ #+#??\
MX;.4_P#<=O?NO="*/H/]8?[U[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%C_[EZ_\CG_S
M5O?NO=#Q#_Q]V0_\-W$?^[+,^_=>Z4GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[I ;W ,F,) )7'[LTD@7%]NU8-C^+CW[KW3!D/^/YZ<_[4.\O_ '2X#W[K
MW3WVC_QZ:_\ AU]??^]_MGW[KW2AVK_Q9(/^HS+_ /NXK_?NO=*+W[KW11.A
MJI)?D7\X:94G#TG:74&MWA=:=_/\<NKG04\Y18YF0+ZU4DH2+_4>_=>Z-749
M%*?(8['-2Y"5\BE:Z55/0U$^/I10QQ2.N1KHT,%"]0)0(1(0965@MR#[]U[K
MV4R*8JAEKI*7(5J1/3H:;%T-1D:YS45,-,K14=,CS2)$TP>0@62-68\*??NO
M=.'OW7NJ_/Y<?7V'P/1%+V+3Y?=N6SG962W5'E$W-FYLG1X;%[2[4[/I\%@=
MLXZ2GIX\#A: YJJ=:=0S!Y3J9K#W[KW5@?OW7N@ISO>/4FV]VR;$S._,#2[N
MIGVXF1P25$E76X4[ORE)A=K?WA^RBJ(=NKN')U\,5&:YJ<5!D4IJ4W]^Z]T2
M/LS^8[MO9,G9>SVZ[W;@^S<2^[\1UA@-P4<QEWME=O5T^WZ>OFHZ>FM2T63W
M$(HL=!!/529$U-+$&AFJ41?=>Z1.Z]@_*/Y?]6];;HW!MRFZS[%V3OW(XVJP
MF7J=U[!Z]W'MG/;;PHRF\ZKKC=.%W7NBNJMJ9QJK&4D-5+135]''4U%)4PQ5
MT93W7NC!_%WX18+XV;XW-V)'V#G=X;CW'LG;_77VYQE-@,'3[2VI.K;;@K:1
M:S+Y+/YC#4D*PP5U96231I-4@>F?3'[KW1Y??NO= ENS=>7EW5/'A:G-G"[
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MC=A[;BK-I8';^_<UL*>HJL)F:7+YVLJ\YASCJ:NAHJFLQM)2554V.I@E2%I
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M[KW0A=F?\RXW_P#^&5NG_P!T==[]U[K!NK_F5VX__#!S'_O.U'OW7NG[:?\
MQZNV?_#?PW_NNIO?NO=*#W[KW1=X,9D:[:G:ZX>2?^,X'M'/;EV^(9?MY)LI
MAWPVY8,?)*D%1JILG4^2EE!C?5!.5L?K[]U[IIZSW!CX>Q*NDQ)I5P6ZJ&JR
M6,CQ>,F2 P9R-.Q-NUU=63B.2G:OASV<B2*,/3^6B>WC?4A]U[H1NWL?!_=^
MCW5)04V0&RZ\Y;)4T]%!6/5[1KJ2HPF^:!/N)Z:.))]K9&IE)+%2T"W4\>_=
M>ZD=4902;?GVM/7TU=DMBU8VY+/ :9?O<(M/%5[0S2Q4K-"L&:VM44LJLA9&
MD$@!)5@/=>Z%#W[KW05=WY7%X?J??=;E\E0XJC_N_64PJLC50T=.:FL44U)3
M++.Z(U15U,JQQ("6DD8*H)('OW7NA4'T'^L/?NO==^_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H
ML?\ W+U_Y'/_ )JWOW7NAXA_X^[(?^&[B/\ W99GW[KW2D]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=!3V343PY+9<44K1QUE3O*FJD6UIX%Z^W/5K$]P3I%
M32QOQ8W0?CW[KW4?(?\ '\].?]J'>7_NEP'OW7NGOM'_ (]-?_#KZ^_][_;/
MOW7NE#M7_BR0?]1F7_\ =Q7^_=>Z47OW7NBC]$4M/%\B?F]4QP1)457:/4/W
M,ZH!+.(/CIU>D(ED_4ZPJ2%'T6YM]3[]U[HULM!0SU=)7ST5)-78]:E*"MEI
MH9*NB6L6-*M:2H=#-3+5)$HD"%0X4!KV'OW7NO5U!0Y.FDHLE14F0HY6B>6D
MKJ:&KII&@FCJ(&D@G22)VAJ(E="1=74,.0#[]U[J7[]U[HG_ ,"XTB^*O6T<
M:A$7)]G:5' 4'MO?9LH_"B_ ^@'T]^Z]T<#W[KW0(8S>^?CW!O;;VWMBU^Y/
M[O[CE&1R*Y[ XFG%3EZ>'*PTU/!D:E:J00TE0FMRH0N2%O8^_=>ZD_P#;?9.
M:QN7W1M9#41[5"I25M4TTV,G.;K(*RD^YQE6*.H!FI?UJ6#!05-K^_=>Z<9^
MD.J:D1"IV5BJ@03Q5,(G>MF$-3"VJ&HB$E4WCGA;E7%F4_0^_=>Z!CN?K_:&
MUY^K*W;V#@Q-6_:>UUEK*::M,TD$4DTS4#F6JDC-+5N@,B%3J\8M]+^_=>Z,
M3OS'4^8P<&+JS**2MW#M5:E8GT/+%3[CQE9X2UC^U,],JR#^U&67\^_=>Z<-
MS?\  7&_^''MS_W<T?OW7NJI>A.N=A9?Y/\ R]SF8J33;]VO6]N8RGV/B=[5
MPQ6,V;O?<D^9DS>0V=C:N:@IWWO,8,E-]S/+JKU^X6"GFNJ^Z]U86[:NT]I$
MAK_Q#?9)86U$[.V2Q8'^T"3]?Z^_=>Z'+W[KW7O?NO=!CLS_ (N4'_AOU?\
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M_%L5_P [/'_^=M-_U\]^Z]U[^+8K_G9X_P#\[:;_ *^>_=>Z]_%L5_SL\?\
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M 4,<020LVN/2P8@W/NO=.>]-X41V=NL8*MR0S9VUG!AS08S+_??Q0XRJ&/\
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M)3 /)'2P#QP01K%34T?IAC121[]U[I8>_=>Z][]U[KWOW7N@XS?_ #-'K_\
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MW*;?Z3_CNV-&(ZK$?GRWE44>TE#C^&2Z-4>@>4*W/T.D\\>_=>Z47]W^CO\
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MGJ!2TR*SZ07(N>2??NO=1]I?\S#[9_ZCMF_^\I2^_=>Z4Z_\?G+_ .&Q3_\
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M7J[_ )YS8/\ YY]N_P#U/[]U[KW]U>KO^><V#_YY]N__ %/[]U[KW]U>KO\
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M%05>.QF3J<='/A<C/4T4$L,C&IH*>GFE_P H>;W[KW0S_P"AKK+_ )Y*A_\
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M\MD<+4FCR4<^&IZ>J6"&I>%:_.XS'U#I#41RPM)]K5.%+*P5K&W'OW7NGC^
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ML;#3;IW]DDDE:;*9+!+-&VGQ1B@VYCX8O%8:KN)"6O\ GZ>_=>ZG+_Q^<O\
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MIX_]SV;%1DIEDND;J5*^Z]TJ]JXW*9:BDQW4V.J]D[3RC-49[MK==+55^_\
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MWJRIQ$4=%C8J' U.2WK-)04JP1+2T;1Q!?1<^Z]T8KW[KW18_P#N7K_R.?\
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MHK/\A;_MSI_+S_\ %<]K?^YF4]^Z]U._GJ[TP>QOY0WS^K<[(X&Y_CQN[K#
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MQT^0#;8QT246 ;M"GP&S>Y=C[XS&/Q\$:5&0I7H:VM8%Y_),6F?W7NI'9?\
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M[CJH7FH-I;<HY<WNBOC2.23R18JDN]+2%8FO4U34](MCJE7W[KW0$UF^]_\
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M!B:13)65LD:Z+^)97&@^Z]T6G'Y3+]YYBE%-E]L[NI*>LR)6ICEJ*WIK;\V
MKH\?D*C;.(4T^1[AW3AZNI6*2KR)I<)35!!@C+J5/NO=/_6>T-F[5KMY[Y[>
MW#)N+L_:>6FI-P[HWU54/V>"Q<LLM5MBJV9C52''87"YK%-&\'@B$[50F@!U
MQL@]U[H4SD]]=E Q;=CKNN]D3:U?=&4H8AO;<=*S:+[:V_D8)8=LT%3$&9:W
M)1O5LK*8Z1.)![KW2PQLFQ.ML-A=H1YK$;?Q^'QE/28F@S6X8A6#'P:H8G,V
M8KGKJI=2$:V9KD$7XL/=>ZYOV5UU&[1OO[9:R+8LC;IP8==0NNI37:EU#Z7^
MOOW7ND/OG-];;MQ]*]#V;LS![IP-6,KM+<L.X\!-487+(AC;R1-7@5N(R=.S
M4U?2,0E32R,MU<(Z>Z]U)H>Z=J4V/H!O&MHML9V>DCJ)\?)64]51U4+/)%#F
M,'7P2R19/;F6\+2T52+>6$C4JN'1?=>ZE?Z<^K/^>OQ?_4Y?^*^_=>Z5&VM_
M[3W=4RTFW\M%D9XJ-<@1%%-XGHVJI:(S0U)C^VF$=7 T;JKED8>H"XO[KW2R
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW0<]O?\RPWW_X;.4_]QV]^Z]T(H^@_UA_O
M7OW7NB _.C';7W.O5FSLS\M/DS\5,S7?Z2-T8C(?&F; 4^6WGC-C[5ASNZ*3
M=E1N'K'LNBAQ6!Q:">F_;HM=3*(Q([NB'W7NJ\</UOL/(#:LN,_G$?S1*^'>
MLG5D.UI'KNJYUS [FIZVJV//3PO\515".:+'RFL:1%.."WJ!&O/OW7NE)7](
M8A<C1X.+^;;_ #2<AF*[9^W=_P".QV!K>GZ^KK]J[JWQ3==8?)4[4?Q=DAD$
MVZ:Z")XBXEBCF69E$=V'NM]/M/\ ''%)N/JW:?\ P\1_,E&=[JS_ &%M7KND
MK=V='QIFMR=4QU)WYA#5U'QCCH\9DL%44DU,T=0\35%5$T4/D=2/?NM=)"MZ
MGV9#!CZVO_G$_P SG'4V0V?NS?=+/+E>HJ2)]H;,W##MS-9V4'XL%HZ,U<_G
MIV8 U-"CU$8:)&8>Z]TH1TEBJ/.9_:U+_-D_F>Y[(;5S.'Q.?JZ"KZFR]!CC
MN#K_ "G9^,RDN9H_C(N-EVY-L["550,A&[TBR1&'R>6R>_=>Z3FU>J]C]C[;
MQ^^-G?SC?YF>6P.;HNO<ECVQF;ZABEDI>SY*:'9YCQ51\7!DD-<)_)*I0FGC
MCD>32J,1[KU>E;/T5CL31T$V:_FH?S1\/]WNS&[*A3.5O6%!729/)[NS.QJ/
M(5%,WQI1XL%-N/ 5435Y5:58X_*6$;*Q]U[IK@Z'VK6XK"[CQW\X_P#F793"
M9O<N]]K+5XS='3E9%B<UUOCJS+;YH=Q10_%QJO;Z;;IZ(QU$E4L:B:2)%9FD
M2_NO=1\OUCU[B-NR[@R?\W#^9UBZ=MH;.WM'339KKP9P;=W[FJ;;FWLC#A6^
M+TE9*1FZR*GJD,9-"[@U(C4ZO?NO=*.L^,$&/H-[9/\ X=S_ )GV93KO&9S-
M;GQ>#W5TGELO'C=MOC8LW/18[&_&2:LR!H'S%/J2 -(1)Z0;&WNO=1YOCSM8
M9^@VB/YQG\R2'=.0WW4]71X;^_G2DE?2=E4>UL-O.38&2C/QC:GQVZ9]O9^F
MFAIIF0S.S11EI8Y$7W7NC5_!J+:>T-V[XV)#\P_EG\F=Y9_8&Q.S_P"[?RGI
M<!#D-A[+R>3W+B,1E-M-MSJ/K.EA?<]5"QK()I:V=(X*9BD(?]SW7NK)O?NO
M=%C_ .Y>O_(Y_P#-6]^Z]T/$/_'W9#_PW<1_[LLS[]U[I2>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NDQEO^/AVG_P M\S_[JI??NO=%HW#L3<?9W4&Y]@;1
MWA4=?[EW5B.V\7AMYTC[@CJ=NUC]K2RKD(7VKN39^XD=4B*WH\G13#5Q(!<'
MW7N@7^&'0/:W07;/;V(['B3LFDK=F;&GHODAG,SV17;FS-6<AN*:HZIQZ=I]
ML=LYN;:>U:9DR33TLV*I$K\C)&T-3(OEC]U[H<-Q;BW!VS7KB,%1QY# 92*6
MHVYMNJKZ_$8?*[>CFEH).Q>RJ[%RQ9:79^2JU=<+@H&BDS"1^:<^$M]M[KW2
MDP/WFU8MQXS(+!FZ?9&^MKZDV=LJBQ;4]%6;,Q-;*E+MO;R3U!I(LCDG,>MI
MYHXGL794O[]U[H0U[.IG56&QNR@&4, VRJ]6L1<:E9PRGGD$ CW[KW2(W#O*
M:OWCU[EZ;8'94E'@:O<LN1G&SJ@"F3([?J*&F8AZA)6\M0X7T*QYYL.??NO=
M+K_2;!_SQ'97_H&UW_7SW[KW7O\ 2;!_SQ'97_H&UW_7SW[KW7%>QJJKJ:*C
MQFPM[O+5U)BFJ<SB5V]BL=3I35%0]979+(2Z%C+PK$B1K)(\LJ@+;4R^Z]TX
M56\ZBAD$5;18&CE90XCJMY8JGD*$D!PDL",5)4B]K<>_=>Z9*[M)<=-2^3 ?
MQ>EJ/.DT^V-S;6R\U!)&BO :RBJ\IB)_MZH:U$D7ET.H# !@??NO=8O],6,_
MYY7=W_).U?\ [*O?NO=>_P!,6,_YY7=W_).U?_LJ]^Z]U[_3%C/^>5W=_P D
M[5_^RKW[KW7O],6,_P">5W=_R3M7_P"RKW[KW13=\]+='=B=RYON?<FU>SI\
MENS9>V=C[TVI!5;$CVMN[&[.RV2R^W:C*>3*R[AHJFDGR6F88_(44=8*2D-0
MLAI82ONO=&.H^S^O<'DLOD*#8M7B,OFYXJC/5U%1;#H,EEZF)"(9\O4P;FBJ
M:^>.-R%:9G90>/K[]U[IV7O7;3,%7";B9F("@3[/))/  '][>23[]U[I$U&]
M-VF#=RT%'D<=2+DL:V'P>3V\)*BNASFXJR/=RY.KAFJ(:.7%4LDDA E41( [
M:@;>_=>Z,9@0BX/#+$08QB<<(RMM)04<(0KILMM/TMQ[]U[INV=_Q[U'_P M
M\G_[M:[W[KW2G/\ A]??NO= E@<YN#8^V<=B9.J]QQ8["0)3SU-%F]FU,.DU
M!^YKHH6W(M;)%)+*TQ!3R:2;B_'OW7NA)WCFDVYM/<N?<.1AL%E<DJQ$++))
M1T,\T44)*L!-+*@5+@C41[]U[H)O]$_7&U]C?QBIV)C:O);>VL,M60UM14SU
M60R.(Q[Y2496NDDE;(U4U?&YDFG64L[%B#>WOW7NLV0HNW]^;2&.FEZ^P-!N
MK&4*5];CZC<=?D:/$91:>3*14<%30T=-/628R66*,R,J!V#," 5/NO=#I%%'
M#''##&D4,2)%%%$BQQQQQJ%2.-% 5$10     /?NO=(#>VV<UDZ_:VY=J/AH
MMT;6K:](&SSY5<;68'.47VF<Q<W\*E659)Y:>DJ8G>.95FI$]/)(]U[I.R87
M,Y?<&$'8VS^K,U3U7WE!25E/25F6RU$T=)49%4A.<P_B6C=J4ZU613J((!L?
M?NO=*3:-)C\7N3L#&XZ8+$V7P^8EQBRJT6-GR6WZ"GD^UI5110TM:<9Y= ]+
M3&1Q8L??NO=.6X-E8?<=;29.JGS>/R-%2U%#%78#/YC 54E%4S0U$E)52XFL
MI#5P">G5T635H:Y6VIK^Z]TBFQU/MO)/CQF,Y64?]X-AS0G<>X,CFWBK*^OR
M=*8Z6IRU1430BK:*)1&K6:2UA<^_=>Z4O9^.ERNQ\S1PRQPR&7#U(>4.8]-!
MG,;7NA" M>1*8J#^"1?CW[KW3-'6TM7M?LB.FU:J#<.Z**K#1&.U4%@JFTD\
M2JT-4AU#@DV_'OW7NA6'T'^L/]Z]^Z]UW[]U[HIN[,GDL_NWMC%)5YRG&U-D
M;HS&)Q^W,YN'#5#YZFPVWUQ62J),'64LU36R@LD$+>10$)5"6-_=>Z467W?2
M]A[3@V3M.BW+OK(S4.";)[IVUDCMK;^*RV*EQ&52>HW]64T\,=<M;#'(\5!!
M7U:KJO$K#CW7NIVV.B,?!23Q[QJX<E3Y"9:O);6P9KZ+;61J51HUEW7D*ZKJ
M]U]C5BJ1>;-5DT#,H9*6+Z#W7NAZI*.DH*:&BH*6GHJ.FC$5/24D$5-34\2_
MICA@A5(HHU_ 4 #W[KW4CW[KW03Y'M!,A6U>"ZVP\F_\[2,]/65M)5)1;*P-
M6%A819_=K1U%+YXQ.K/24,=;6@ @Q+:_OW7NG':^R\Q2YQMY;QW#_'MUR8NJ
MPU/#C*08C;&!Q%;64F0GQF)QWDGK:UVJ:*+75UL\\TGC&A85)C]^Z]T'BLLG
M<,K)(DCCLN"!HX;R-!'0=$U,DTM04U"$&3-1I9M/)4<EO?NO=&*]^Z]U[W[K
MW35F\[A]M8NLS>?R='B,3CX6GK*^OG2GIH(U']IW(U.YX1%N[L0J@D@>_=>Z
M+GNKM+<.Y*NCP>V8<[MFCR\,DF.I:''0S=L;MHQ4_:_>8/ 9.-L?UYM:478Y
MS/")PA!BIT8I)[]U[J.W2>#?96X#VA$*;:8IJW<&1V'M;+9<T\T]+&^0FRV\
M]VF:BW)V3NWR4Z2">JDBI$FC58X&TK(?=>Z2.*P5?Y:7,'9&[*G>NW=N8BBW
M=V7LNLQ6W^P*:2OIZ_<>+V96X*6BI,/V'3[4PF5I(ZI9WJ'DK&5A TFIE]U[
MI1XS/4N4ST6Z,IMO ]O97:=-/3C)X7%?W?[7VO!#/)6M#G.L=PR4_P!U5T+S
M1I#44<B3^5Y/!3KY&!]U[H9I>X=@4]0M'69/)T->:6GK'QU9M;=4%=!!4HKQ
MM/3-A?)$?5I8']+@J>01[]U[I)[-R>R.P^Q-_97'PX[<-+3[<V!2K4U^#G5H
MG%5O<O%$<QCH)6CU<GQW35?G5<>_=>Z&.# 8*E4I387$4Z,VIE@QM'$K-8#4
M5CA4%K "_P#0>_=>ZS_PG%?\ZS'_ /G%3?\ 7OW[KW0.=;T%#-NG>'EHJ.3Q
M[<ZY2/72P-HC%#G],:7C]$:_A18#\#W[KW0R?PK%_P#.MH/_ #CI_P#KW[]U
M[H(MNQ10]T;HCABBAC79U'ICAC2*,$YI[D)&JKJ:W)M<GZ^_=>Z&SW[KW7O?
MNO=>]^Z]U[W[KW7O?NO= 9WUO?;^ V+N; 5,U57[CS>V\E_"]MX2DDRN=J:;
M2(:C)O00$&CPV/#&2IK)VBIXHXW.HL A]U[I@[;^0.5ZDAW765'2W:&]L;MR
MDHZJDKMAXN'.C*Q3TM/454K4Y>FGHH*-YC$605#-(C>E0+^_=>Z#C?OR0PM-
M6,S_ !_WWONN.S*=:**CP"U62RV'W]M_$YR?;N'^ZH&IYZ;=,\4>,B22>&*L
MRM!+#.(4A65O=>Z#O!]R;)VGCLAV=C?@KVKM22E.%IIJO']8;<BW]-_<>FJM
MK8]7V_BI9-R24^U=IY^HEH90KQ?PF6H$+!M43>Z]TFNNN]NJ:?'[8V_B?A7O
M[85'#F-E[63;E7U]14-;L^DW1G<5N_"U%=C::BDAI\5!N/()7QQP2RF.JIII
M66+PZC[KW1^LET[U3F,ILW-Y7KG9F2S'7>X,[NO8>3KMNXNJKMG;FW/45%7N
M+/[;J9J9Y</E\W55<LE540%)9GD9F))/OW7NFC$_'[HS R4LN&ZAZXQLM%AM
MT[<I)*39V"B:GV_OC</][-XX.(BANN(W/N3_ "VNIO\ ,U-02SJ2??NO=/%!
MT]U3BLCG,OC.N=E8_*;FFQ4^X*^BVWBJ6JS,F"VO/LK"_P 1FAI4>JCQ&T:J
M7&TR-=(*.5XD 5V!]U[IA_V77H4-4L.F^M0U;2[&HJLC9N!7[FDZRS$V?Z\I
MI[4(\L.RLU425.,5KBCE<F/3?W[KW3[G>G>J=T-CVW'UULW.MBL_B-U8TY;;
M^-K_ ++<F SN3W/A<W3_ '-/)X\EB]Q9JKK8)1ZXZFIDD!U,3[]U[K#7]*=/
MY.7"3Y#J_857+MS<.7W;@VFVIA&_ANY\_AZG;^=W!3#[,*,QFL'62TE74$&6
MH@<I(6'OW7NBN]_TG4/5-+U[LBJ^(M+V=L'.8S#;#-9MW9V'R."V)M[%[IVL
M,'@\O2G%54U'MJCR9I:Z.*,^%30EREXP1[KW0I[2VET'N?;N:[#VQT_@#41R
M;USE?3+LR/$YK*Y_>F#QM5OREGI*J@HJBMR6XOM(*.M,L;+4S4ZCU!5/OW7N
M@-;N_ 2YK YRN^$W8*Y+,Y+#[IIMQC8N!JY*3*O48BGI-U5]1%1MD*7)X]\D
MK)4RQK7QPQ,P"A7">Z]TXT';>U]L[_FW?MOX>[VH=TY#JG8E)ENR:#:&(Q<B
M;0DFW55XG84N<^VCRD^.VSD,3Y#2HGBC-?%+XP??NO=+S;7RNR^XM[[5V>_Q
MY[IPM/N?,5&*?<>6V\]-B,%'#(B)79F1XA]K#,K.X!;A:6IN;QQB;W7NE/\
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MJJ& 4T530TE1%3+HM3QS4\<B0#Q?MVB5@OI]/'''OW7NF;9W_'O4?_+?)_\
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M<T%12S1I)3STTD<M/+"R@QO#)$6C>-E^A4D$?3W[KW2#[1_X]-?_  Z^OO\
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M34I(91U'V,2"/J"!4FQ'LP_UH_<>E?W5<4_TT?\ T'TF_KSRF/\ B;'^Q_\
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MW7O])]/_ ,\-V=_Z!&2_XK[]U[KW^D^G_P">&[._] C)?\5]^Z]U[_2?3_\
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M+WW6N^JZTG6^_6T*H!+2/+MV&- 20!=KD_0>_=>ZX_Z3,5_SS78W_HN=Y?\
MUG]^Z]U[_29BO^>:[&_]%SO+_P"L_OW7NNO])N)_YYOL7_T7.\?_ *T>_=>Z
M1$=?_%-^;#R2T.8Q\%;N[?$M-#G,36X6M>%-@TL#3"AR$4-4L#3Q.%9E :Q(
M]^Z]T/WOW7NBH9KX^YO&?(3;W=?6N<I\&F<>;']LXW*UF4JJ;(X5*2KE\V"Q
MB.U++E,K7BECD65X8*;PK4J)'01/[KW1K_?NO=%WZ3_X^#??_+.E_P#>^[6]
M^Z]T8CW[KW3'4;CQ%-5U%#)/.U52>(5,=/C\C5B$SQK-$LDE+231*[Q,&MJO
M8C^OOW7NN!W-B%_4]>/]?"YH?T_KC_\ 'W[KW4[&9;'YB"2IQM0*B*&IGHYC
MXYH7AJJ9M$\$L-1'%-%)&2+AE'!!'!!]^Z]TC=T]K;"V7D(\7N3.M05L@4E(
ML3F\C%!KIJBM45M7B\;6TE QHJ22:T[QD0H9#Z!?W[KW0A^_=>Z][]U[KWOW
M7NDCM6EIH#NE(8(HDGW9EIYD1 JRS5$%$]1+(OT9YW8EC_:)-_?NO=(;9[-U
MYNF7K.K8)MC+I7YSJ^H8!8Z.DA/W6X-A&32J>3;[RFKQR7+'%NT8N*-V]^Z]
MTP]B]F[/W!M3?FV,/D)JZK;:FXVI<C%158V_DZK%4?GRV-P^>>)<9E\EC*61
M9IXJ:231&2;DI($]U[HP@^@_UA_O7OW7NN_?NO=(+LSM+KCIG9^2[![8WOMG
MKO8^'DHH<KNS=V6I,'@<?+D:R''T"5>2KI(J:!JNMJ$BCU,-3N /K[6[?MM_
MNUTMCMD,D]X]:(BEF-!4T R: $GI/=7=M90FXNY%C@6E68T J:"I/SZ*QGOY
M@7P)S.WZ[&9'Y:=(4V*W+C*W%+7+V%@J>.JILI1U%+(^,K9IC35$AA9V1D+B
MZDV(!]B.#DCG2*<21[9>&6-@:>$QH00<CB.BJ3F#8'C*-=P!&!%=8\QY'JG/
MJO\ X3^_RT.[-H0;TZA^2?>G9FR?XED\52[@VIVEL/<.!3)XZ?QY7'PU5+L6
M:E2JI)V"SHMFU6U<^Y6W+WO]PMHNC:;IM]E;W>D,5>&16H1VFADK0CA_+H$6
MGMSRQ?0^/:75Q+#4BJNA%1Q'P?MZ.%U!_(G^*'3&R_D9L?;O8'?63QOR9ZFA
MZ=WS5Y_>&WJW)8S;4&<AS\=9MJICVC3BBRXK($423K41"(:1&/K["VZ>\W,^
M[7=A>7$%DLFW7/CQA8V +Z=-'&O*T]*&OGT<V7M_M%C!<P12W!6ZA\-B66H6
MNJJ]O&H\ZX\N@1IO^$V?PTHHWAH^Z/E?202J5FIJ7LO;M+23 @JPFI:;9,,,
MNH$@Z@;WY]F[>_\ S8YU-:;86]3"Q/[3)TA'MALB\)[NG^G7_H#H:<?_ "(/
MB9C?C#NGXI4V_>]AU_N[N[;/?.1R[;KVS_>J#=>U=K5>TL=C:*N&SA00X"3'
M5CO+$U,\K2V(D &GV4R>]',\G,4?,S0V7UT5F]L%T/HT.X<DC77548-:4\NE
MJ>WVSIM3[0)+CZ=[A9B=2ZM2J5 ';330\*?GT!9_X31_"%[>7M/Y-3V4(IJ-
M\;/F*1K^B.)GV$6BC0'TJI"K^ /9R/O!\XCA;;</LC?_ *V=(?\ 6NV+SFNC
M_ME_Z Z'_LS^1?\ %?M+IKXU](YOL3OK';7^+NVM^[5V)D,)N[;=)G<QCNP]
MT+NS--NRJEVA44V1G@R"Z(/##3JL/I96//LCV_WDYDV[=MPWB&"R:YW&2-Y
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M\%73/ZHY4TR(>5(]^Z]TBWZ?Z]=W<X6L#.[.P3<FZ(TU.Q9M,<>:6.-;G@*
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MO=%VZ-_X&YS_ ,-K;W_O;=K>_=>Z,3[]U[HI>^\I38?L?*P9&#+PODL]35]
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MT[']F@HT@HX;>F/5=C[KW0@>_=>Z][]U[KH_0_ZQ_P!Z]^Z]TG=H?\>O@?\
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M/,$3QNT<MYFU)'XV]U[HX/OW7NDQMK_.;D_\.?(?^XU#[]U[K/NS_CU=S?\
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MV<>9_P!Y'WEC[]U[KE_=FE_YV6X__0CS/_U9[]U[KW]V:7_G9[C_ /0CS/\
M]6>_=>ZZ;;%(PL<GN0?3E=RYI3P;_45@/X]^Z]U[^[%)_P [+<7_ *$>8_\
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MT[(TNIETQ*L1N1<_X>_=>ZF[/_X]^D_ZB,I_[MJ[W[KW2F]^Z]TV9/#8W,+
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MZ][]U[KWOW7NO>_=>Z+5VU_P/[-_\19LK_WM=S^_=>Z5FPO^9M=\?]K/KO\
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M)(5=@NR-152]R!S;W[KW62CRG:5+24M,VP=KNU/300%U["J@K&&)8RRAMD7
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M7KC^H_VX]^Z]UZX_J/\ ;CW[KW7KC^H_VX]^Z]UZX/T(]^Z]T6[J[_C\<?\
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ML35$2R-&K9+,EE75] 2+^_=>Z=/[H;7_ .=#C/\ SEC_ .*>_=>Z]_=#:_\
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M+W6'_/=[9_\ /I3_ /1WOW7NO?Z7NL/^>[VS_P"?2G_Z.]^Z]U[_ $O=8?\
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M0X>2>9>='W.I1RVD<^_=>Z2V5[@J:"3$1R;<QFWCE'9&3?F^MK[?R%(XD1!
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M@A18X8846***- %2..- J(BJ+    >_=>ZR>_=>Z][]U[KWOW7NO>_=>Z#3
M1&7LO?M=41Y.HFCQ^V<1054U'2IB,?CJ6B;)38ZAKDG:KEKJS(9=YZE'C5="
MPV)M[]U[JAK_ (518#<E9_)Z[9WWL^:JH=S]*=P?'KMW"9K'MXLEMVOP':>"
MP<&?QU0JM)2UN+;<OD21;,O/-K^_=>ZLZ_E@?,?$?/GX%?&?Y4X^:G;*]E=<
M8Q=]T=/*LJXCL_:TD^TNR\2=,4&E*3>V$K?$"BZH&C8"S GW7NC.5M6*/N[
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M^"PN0^)>X)*/,[@H$S59A]J8"HIL/3Y:MK<7C\W4RML I/-1T5*\^1+2::>
M@7/E0GW7NCI4W6.W*)&CHHXJ*-XL3 R4>"VE2JT& *-@8"L&W(QX,(T2FD3]
M-.5!0 CW[KW2A_@%9_SU&XO^2L/_ /6?W[KW2*W!UGLC/Y2DJMTU,66S,:TJ
M44V83;\M<JI!G<;1K3K+BU<A:?<F2@CLIXK9E'ZC;W7NI)DVEMI\+MENR(<%
M+*L&(V]@9LWM2AJ)EI'3&T^-Q-!/0I45+4\D:P+'&K,& 2U^/?NO=2)<IMN"
M#-54W::PTNW*I:+<-3+G]IQP8&M9E1:3-3/0B/%U3.P CG,;DD"WOW7NO4V+
MP>:FBR-)ORMRPKL%*T)ILIMRNHZW 3U"^6K2.'&R0U-!),F@S"\9Y6_OW7ND
MW/UWU1C\*T%1+M7'[>HJ2//NC8W85!BZ6B+3&+.R2K@X(HX6>60BK9K,7?UF
M[7]U[J-G]K]1]K[1R6W=R[IP'8.Q:?[7(Y?$5F4VEE]O4PVQ5T69HJZN%+2>
M&E& KZ2GJDD9U%/)'&]P0#[]U[KC5=4]0;R:BW#6_P!W=TEVIMT4&:GAVCET
MG.,BFHZ?-QU@Q<T-;2TL-4\;.QD@</\ N!C:WNO=-4GQ6Z%K8*56Z^VF]'!@
MLEMVAIJ3;>V*3&P;:SV2_CF6PU'0X_#T^/AQ64RY%9)''&%:H E%F (]U[I;
M#IK9(SN'W0N.IDW+MZ">EP&>CP^VHLGAJ6II(*":FQM3'@U-- U!3)"JJ+1Q
M+I32&:_NO=++^ 5G_/4;B_Y*P_\ ]9_?NO=>_@%9_P ]1N+_ )*P_P#]9_?N
MO=%^\$G^RW_;?=U/D_BOB^]O#]WK_P!*>G[B_A\'GOZO\WIU?V;<>_=>Z'DT
ME)5;NK_N:6FJ"NW<3I,]/#,RWR69N%:1&90?Z#CW[KW3Z,5BU(9<;0*RD%6%
M'3@@@W!!$=P0??NO=3_?NO=,XP.)&?;= HU7.OATP,E>LLP:3$Q5KY"&CDA$
MGV\BP5DKNC%"Z>1P" Q!]U[J3D<709>".ER5+'64T=90UZPS M']WC:R&OH9
M62X#FGK*=)%!N-2BX]^Z]U@SN$H-QXFNP>56HDQN2A^VKH::LJJ"2II693/2
MM4T4U/5)!51@QRA'77&S*38GW[KW4RCH:+'4E-08^DIJ*AHH(J6DHZ2".GI:
M6F@01PT]/!$J10PQ1J%55   L/?NO=99X(ZF":FE#&*>&2"0*S(WCE0QN%="
M&1M+<$$$?CW[KW3+@]L87;BA,/2O2H,9AL.B&IJITCQV II*3%4\:5$TJQBG
M@E8%E :0F[ECS[]U[J7DL-CLN^-DR%,*AL37-DJ EY$$-8^/KL6TI",HD#4.
M2F0JUU]=[7 (]U[KGB,50X+%8W"XR(P8[$T-+C:" R22F"BHH$IZ6'RRL\KB
M*"-5!8DD#D^_=>Z<??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW0?Y#J_9>:R$^2W%BY=T332.ZTVYLAD,[B*9'J5JU@I,#D*F;!T\,$Z
M*4TT^I=(%[#W[KW4C-]<;.W))3#/8A<KCZ.(14VWJNHJFVLO,A=YMLI,F#KI
M)/*03402\?2WOW7NEE3TU/1P14M)!#2TT""."GIXD@@AC7A8XHHE6.-%_
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MP/R(Z-W71RY':=9C=ST%/N3$;2JJS"082JIZ3/9W(4N*Q5'/(:V,!*O)5L,
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0O3QH^R\&C^SXO5[]U[K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>nt10016217x4_ex10-15img05.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img05.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!Y@*\ P$1  (1 0,1 ?_$ :(    & @,!
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M -'N_P#]PA[]U[KW^R>?SD/^\SL/_P"CW?\ ^X0]^Z]U[_9//YR'_>9V'_\
M1[O_ /<(>_=>Z]_LGG\Y#_O,[#_^CW?_ .X0]^Z]U[_9//YR'_>9V'_]'N__
M -PA[]U[H*.@'^2_=NYO@K!FOG7\QME4GR2V1\S\GV?M[;V[_CKN:EQ.Z?C-
MOO9.Q,$=C[HSGQ.P^53 96JR>0J95JZ+SRQRPH=!B.OW7NK2O]D;[$_[V-_S
M ?\ T)_BY_\ <I>_=>Z*_M'H#O#._,3O;H2M_F+?.E=D=:] ?&WL_;TT&9^+
M\>>DW)VUOCY)[=W7'DLD?BVT=7BX\=U+B31PB)#!*U0Q=Q*!'[KW18]O[C['
MVGM;L3-]K_./^9SO_-_[/IWA\0.GMC] X'XR;JWIN6'KK&;LW=A/N\*?C730
MS5='LC8>6K,CD9*B"$FG%D#,JGW7NA-Z)ZU^5_>?R(SF#;Y'?S:^FOCO@NEX
M,LVX>]]M?$[8.YLSW14[X6CCPVWZBGZ#SL^1P4&QU:>9#2QI'4:3Y6)T#W7N
MIGR[V5V?\6-^_%VLW%_,5_F%TG2'8^_NQ-J]T[LH-N],=BUVUJ'%]1;NW1L*
M2G78'PZW!D]O?QG?N)HZ1ZF:CD@E20PW1I%;W[KW04;T[%PF\-O8IOB__-7^
M=V\MX8CY#?"_KSLC;^[,)T]M;)8'K;Y.?([;O3M3G8<+O[X8[,R#R9;$IG(<
M7D(%J(*?(T19PQB,;>Z]U9U_LC?8G_>QO^8#_P"A/\7/_N4O?NO=>_V1OL3_
M +V-_P P'_T)_BY_]RE[]U[K!5?"7?5#35%;6_S(_GU1T='!-55=75;L^+%/
M34M-3QM+/45$\OQ42*""")"SNQ"JH)) 'OW7NB8;RW[\1]AX&IW%G_Y\?>=1
M14U=AL6E!M7Y _"K?NY\CE=PYO'[<PF)P6S-B_&?<>\-Q9;*9O*T]/#2T%#4
MSN\@]%@2/=>Z0_\ IQ^+G_>W#^9G_P"B>H?_ +WG[]U[KW^G'XN?][</YF?_
M *)ZA_\ O>?OW7NE%UGV9\9NW^W-K]#;$_G$_/RM[@WK#4U&UM@YW"=8[)SF
M:@I<-N;<$DU(F^/@SMRF\4N'V7EYX6:114#&50BUM!(J^Z]TE5^0'Q$GRNZ<
M-B_YRG\PC<E9LK=NXMA[IDV=LO9F],;A=Y;2R4V(W-MNJS6T_@1F<,<MA,E
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M?Z CS&.S%9L;9^.GJGG2,U<\K5"(D<R*/=>Z'3[_ .+W_>^GM+_TK#^7[_\
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M?NO=>_V1OL3_ +V-_P P'_T)_BY_]RE[]U[KW^R-]B?][&_Y@/\ Z$_Q<_\
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MOD\9V+C,YCJKS;.R/47;'7>T*J++34E324-1D8I9##(L,GOW7NJ9\M\^LO\
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M>_=>ZO>]^Z]U[W[KW0(_)G_LF_Y _P#B$>UO_>#SWOW7NJP_Y0W_ !<N^_\
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MOV1PZV*CATJ*RD^-*1-15]-T8L$*28MZ2LAV"(HHZ)I'EQS03*$1*1Z9BT)
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MU*:;&)!&Z:U9C[KW1>OY=O:.S:7?WS;^,69K:S;/?777S$^2/;V?ZRW3CJG
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M&$;$9>FJ:^N K1*[CW[KW5C'P(^46ZODGU+E\;W#M6IZ\^3_ $7NB?J'Y/\
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MGM=*K[^OWGN%<=E<VTM;2H&!HP9352I&I=5-QO.14$?LZWFA%01]E*]'DC^
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M6/39O:^Q<GM_?6W5HMPXZ*JC6GKDC637Z2)) WNO=!K_ ,-U]<_]Y&_S /\
MTOKY5?\ VSO?NO=>_P"&Z^N?^\C?Y@'_ *7U\JO_ +9WOW7NO?\ #=?7/_>1
MO\P#_P!+Z^57_P!L[W[KW7O^&Z^N?^\C?Y@'_I?7RJ_^V=[]U[KW_#=?7/\
MWD;_ # /_2^OE5_]L[W[KW3?3?RM_B-7Y^IW1V?A^V?D/G9,11X''5WR4^0'
M=?>J[;Q-'6UV0-)M2A[#WSFL=MPUU97L]5+2PQSU&B-7<K&JCW7NG[_AL#X
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M3M3#8SM6IQ^]MB44F3S>+KJAL3+)%CJB!?OHY?=>Z%C_ &0?Y$?\^(_DJ_\
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MSX*+/XVH@W)NS%561:H#Y*2;[ID5)F*6M[KW3ZN\7^TP%'+\R_ER\&UUW.N
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MZ[,YB/J[Y&1Y#=.6JD:."-JNH,-/#&0D>IV;W[KW3K_<GLC_ )]E_P *!/\
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MY8?_ &D??NO=>_X=,^%'_/?=H?\ I+'RP_\ M(^_=>Z]_P .F?"C_GONT/\
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M;BHM\5'RGWG@L)F:%L@)X5DP\U-+.1$$4,H]^Z]T5/\ G([$^/\ \]]S]5?
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M?_I3'2__ -FGOW7NO?\ #C'\OG_O.GX=_P#I3'2__P!FGOW7NO?\.,?R^?\
MO.GX=_\ I3'2_P#]FGOW7NO?\.,?R^?^\Z?AW_Z4QTO_ /9I[]U[KW_#C'\O
MG_O.GX=_^E,=+_\ V:>_=>Z+Y\MOYE_PZV]\4_DUG^IOG9\5X^U,'\?.Y\QU
MG)MCY#=,YK<J=@8SKC<E;LU]O8=-T9%\MG%W'!3&DIA3SF>HT((WU:3[KW1?
M\_N/YD_ O9.RODB?D-N/Y>?$S,Y+JRK[\ZS[LVU@\W\@NE,)V#+U9MC<&_>J
M^U-CKLBAW=M[:=7/E,K7;>SF),T:5K?:5)$2P'W7NKCNU>TM@](=:[[[@[4W
M'3;0ZWZSVKFM[;YW164U?64N VOMVAFR68RLU'BJ2OR=6E'14[OXJ>":>2VE
M$9B ?=>ZJIWCWWN[YL=A_":IZE^)WRSV[UUL#Y@4';F;[A[<ZZVGU?L23KS9
M?67?&Q*C<4&'W)V'#VK31YW.[CHOX;3UFVJ6LG@J$E>*)#<>Z]T/'S6I^R=L
M=]_!SO39?2':G>>V>F][=Z'L# ]/4VRLCO'$4/872.>V=MW*IB=[[VV)15N.
M;/U4<4YAJWEB#AO&5N1[KW2 ^+/;61[C_F*_*G<65Z;[CZ0JL=\._AOAQM3N
M[#;-P>Z,A"G<7S2K$SF+IMD[ZW_C9\#,U285EEJH)_N(95\.A5=_=>Z'#YJ_
M*3L#I#(?'_IKH/:FR]\_);Y1=DUNSNML/V/D-RXCKG9VQMD85]W=R]S]A9';
M&+K:]MJ==;;%+31T44]%4Y3-YO&T<,JF9V7W7NBK=,_,G?/Q>^0>^?C=_,J^
M5O2,M5F.E>KNXNEN[<[@NN?C9UAO&O%;FMJ=\[(VU4Y?L?(MDJK9^[I</-04
MM9IR/\,K#([S:&<>Z]T<O_AQC^7S_P!YT_#O_P!*8Z7_ /LT]^Z]U[_AQC^7
MS_WG3\.__2F.E_\ [-/?NO=>_P"'&/Y?/_>=/P[_ /2F.E__ +-/?NO=>_X<
M8_E\_P#>=/P[_P#2F.E__LT]^Z]UG7^8=\ F 9?G#\0F5A<,OR3Z;((/T((W
MG8@^_=>Z[_X<,^ G_><'Q#_]*2Z<_P#LR]^Z]U77/N[LKYO?*WY4Y'X<_P R
M.?8F!Z V+\9VZFEZSR'4?>/QFR^]M[XGNZKWYA>T]K14E7/N]ZVHPN(^[2BW
M%CZ_'PQ1F$Q.]W]U[JQKX.]^]@?(SH#';S[=V=MG8O;VT]^]L=+=LX#9&XI=
MU;%;LOHSLG<_4^]<UL7.55)0U]3LS<>?VE-7XQ*N):RGHZF.&?5+&['W7ND7
MOGYY8G;/<G:/2.R?C)\K.]=R]-3;,H^P\WTYLKK7);2P>4WYL_&;ZP&(&4WO
MVWL2MK:^3;67IYY?#2O%$9-)<L"![KW5!7QQVGO797?6S<'V'LS/]=[NJ/YA
MGQ!W7D=D[J.'_O-MRB[!Q/\ ,=[ V[0Y]-OY?/X6'+/MC<]%+/%35M5'$\A3
MR,5/OW7NMN7W[KW5?_Q8_P"RO?YG?_B?/C[_ / 5_'OW[KW2K_F2_P#;O'YU
M?^*@?(__ -]!N_W[KW1L=F_\>AM7_P -O!_^ZRE]^Z]TI/?NO=>]^Z]U7C\?
MO^WA_P#,4_\ #'^$7_O%]R>_=>Z=>J/^WDGS4_\ %7/@?_[V_P V_?NO='Y]
M^Z]U[W[KW5=_\PW_ (#_  E_\:(?%S_W9;G]^Z]TX_S$_P#F77QR_P#%_P#X
M$?\ P4W6GOW7NC_^_=>Z*1\_O^R$/FO_ .*D?)#_ -\YO+W[KW19OY?6?;']
MY?-OK;*X'<.)S-75_#?OW 92OHZ-=N;KZQ[(^%O373V"S6W<E39&IJ9ZFC[%
M^-F[<=74U33TLM.]%%(HDCG1_?NO=++Y^U3T>^/@C5( S4WR6[?J51B0KM!_
M+V^;4BJUOP2+?ZQ]^Z]U3%\!.A?DW\/^N/Y(V6S/8/3':7QQTOUEU?0C9^[]
MI=X8#!?-?H*H[IRD&Z:^BSN1V!G)>N-T;'JZ6EJ(J:"3(8ZL0S*D\):3W7NM
MKOW[KW7O?NO=44_+[;VY:7^9M\'<Z]!VE4[6R/R=V.XS5=08?&]18[*1?%;Y
M54$6%PU6DM1G=R[IJ8H'FG+?;TM$#81O(YD]^IG5UK3G57_5]G5ZWOW6^O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZKO_FM?]D&]T_]KCI/_P!_]U;[]U[JQ#W[KW5?'1?_ &\7_F!?
M^(B^"W_N!\D_?NO=6#^_=>ZKR_EWDG%?,H$DA?YAORV"@FX4'>="Q _H"S$_
MZY]^Z]U8;[]U[HO?RLZOZS[G^//:G6?<>]LAUMUINC;J1;KW_BMS8+9N1V?1
MXS)X_-4VX:/<^YZ')[=PT^,R6-AE$M;3STOITR(RD@^Z]T4W^7EVEE][[Y^:
MNQ8OE'E_ESUWT[W9UOMKK+M3.Y?I[<F2CQ6Z?CEU)V!N;;LVYND=F;%V=F$Q
M>\]SUQ351&KIUE$4CL%6WNO=6.Y7;FW\Z86SF"PV9-.'%.<KBZ+(F 26+B$U
M<$QB#E1?3:]O?NO=%7^:FW-O8+X2_,ML)@<+AFJ/BK\@EJ&Q6+H<>TZIU+N\
MHLQI((3*J$FP:]K^_=>Z+)\-?^RL]X?^,R?Y;?\ [UOS$]^Z]T)7SY_X^[X$
M?^+C;C_^ :^:7OW7NA'_ )<W_;OGX+?^*>?&C_WS&R_?NO=?/*_X5%_&+Y%=
MD?S%.].Y>K^I=[[DZEV9+LG;.[M];:QA_NQ@]V/T5UIN=<)E*V!H8H\_E<;&
M\M+ P:HR$Y\4 EG=8V '+UN'YQYAED0%#+9@$@'A;"O^3K+WWEWM[?[MWLWM
M]E=/'=)MW,3-&KLI ;?)2K$ C!HVDYI0C'6P_P#"W^:QTOU-F?D /]E%^>_8
MV]>RZ;XTT74?7^"^$/;E+D=[;HZY^)?3_4>7VY'G-P[>H-N;6?*]E[1K:85>
M2J::BCA(JWD\3%O8Z^GM_P#?:?[R/\W6*?[XW<\;NZ(^<TA_95C2O$^IR:GH
M*]Q?S6.B-[_S5?BO\S1\7_G3@.F=D_!GN/J;L/#57PB[GK<UM[MCL'?FQ=T8
M?;K8K&;6J:7.C'46)K89\E1M-2)+" DC)(&&OI[?CX:5_P!*/\W7OWSO%-(N
M[K0?+QI*?LU4_EZ>@I/_ )@_\UGX/_*WJ/XM]2?)?X:_-?J+);X^1O4&Y-\=
M#]D?$_L./-;AZMK:7+9_(8C!9_9M%48[=FXMP]>5M%F:;'8:MFR=,D_CEBCJ
M:>9(B/?.6-MW]+=;HS1&VG65&A?PGU*"*%U&H*02#I*DCSZE'VN]\N=_:6ZW
M2YV!=OOEW?:I=OGBW*W6_M_!E9'UBVG+0-+&\:/&9HY8U85,;=40_P \;=W\
MIS:GQBZXKOY=7Q+[Q^/O=Z=][?AW-NSN?X\=][.P%9UVNQ.Q)<GA<7EN_7RN
MVDW&^YXL34114<*Y$P4\S*ZQ)*&H>4]I/X[[_LMO/^M_1BOWB?<1:CZ?E,@B
MAKRORU_(C:A3[>/I3JR#_A//\%MT]6?+7XK_ "-S'RAZ'^2O4_R#Z/\ D7FM
MI2=)X'(T5=M/L'JZ@ZCQ^[-A]@S[DV3@Z*KI\+#VS/!4048:9,K0QNDPB1ED
M2IR3M,>[VV\I+>F>U#A4>XDFB;Q%TL668R$&G H5.!6O1W-]Z'W!N?;K>_;6
M;;^6$VO?FMC/=6VT6>W7T?TDPGB6&?;([-2A<'4EQ'.NEF"A200?/^:UF_D'
MO#Y+?S#_ (>?%CJ#IG=.\>Q/CW\">\M][V^0>[^O]B=#;'Z8ZY[([/HMPXC=
M3[OW!MLY"KWMN>DHZ.1(V:D?'O41SLK,EQ5X$'^^T_WD?YNH"_>^\>5Y=CTI
M-**?91L5\Z4KY]9OEI_-RAZ/VS\2/ECWE\:.E:3!?$W=N3SG<>S_ (X_,_XD
M=Q5V?R?:/2V\NA*+&]4[#V]O--WYK;N)WQV%2UMZNGIVHL1322RJ6B)'O @_
M@3_>1_FZ\=XW<FIN[K/']:3/VC5G\Z^O31\(OG/\J.O^I_E"?D'TY\(-[[;^
M0G8_:??74&2ZL^=GQ,VEN_:6,[T@R&Y:G8_8>V=]]D30#*X):RF:F>CJ#*DC
MSP2PD1QR-[P(/]]I_O(_S=>_>^[_ /*7=5\OUI*C[#JJ*>5*4\NBQ?R_?YBO
M?>Z>U_CE\@NM>M/AQN/XH]5?"7J?X1;WVGV-\P?CKU7WEF][]:;<VWN/<?96
MS#O'>])CJW#ONJI@IDAR-'2/+"M5$TB3PJQ]X$'\"?[R/\W6OWON_G=W1'SF
MD(KZD%LGYG/SZ]C/GI\H=P?(3K_I?X;?%KH#M3O/X3=S?/+YC]T;-W%\J^G]
MWT.^NI?D1G]Y=D878?5N1ZGFS\&YMQXSK?Y%T:FHI?OY*?-X6JIHJ*2*![>^
MGM_*./\ WE?\W6_WQO!XWEX?MGE-?MJYK3R!X'(SU1__ #;?F?\ /O\ G=;I
M^+/5./\ Y8?9GQWW]U=5=H56SMJXB#>]7N/M9>R<GU'MS(#&8S=^P.N9JZGV
M=D,50-5/2+6K1T^2>HJC3TT;R^_?3P'_ $-/]Y'^;K7[XW534W=R!P_MI*9^
M6JE3@<*^76Y'_)@VQF]D[E^,FS]SXBIP&ZMJ_P I3JG;>[,)6Q)#D,3NG;_R
MJ[LPNX<;DTC++_$\?E:"6"H.ICY8S=C]?8=Y.I_5Z+333XL_#A_N1+]G4Q_>
M1\3_ %X-P,NKQ#9;43J-22=HL#4FIJ?G4_;U9AD/^WKVT?\ QGGV)_\ !(]7
M^Q/U!G587P5^./0/R(^9_P#,%I^^.FNMNXH=G[\WV^TXNR-I8?>$.VFSO\P+
M^8R<XV"@SE+608MLR<72_=-"J-/]M%K)"+;W7NM@/JOI_JGHW:,&P>F>N-D=
M5[(IJ_(Y6#:?7^V<1M/;T>4R]0U7E<D,3A*2BHCD,G5,9*B8IY)I#J<D\^_=
M>ZJJ_F!?RX/@Q3_'7^8]\EJGXR=89SOCLCX\]X]F;G[/W7B:C=^Z$WWLWH7/
MXK;&Y-L56Z*S+P[$K\12X*C:/^!ICD:HITG<-,HD]^Z]U@Z,Z:["^2&_/DV9
M_E/W?U!MKI_M3JWJ[8NQ>H]F_%2';>.V]4_#SXP]IY*LK*SLKXV=E[NRV<R^
M]NS,M53SU&4=0LJ1QHB1@>_=>Z,?_L@N[O\ O/7Y@_\ H+_!?_[BSW[KW1+O
MFIM#N[X,X3H?N/8_R>[)[EQ>4^0>#V!V5L[Y,===*9GI3_1[N#K'M;)5.5WG
M5_&7X8IW%MF.BW9@<0M'D<:LD4=?)##4+X)Y&7W7N@:_X<SW+_SKOY:7_GJ^
M=/\ ]Q%[]U[IWZ4[F[H^='RIVGU#C.V=@](=7[>Z$[B[%W5N#X0[ RV0K,IO
MK%]@=#;<V+B.R-T_,[X708/$TK8'=&X)L70X&.2KK7BJI:HK'30ZO=>ZL?\
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M/?W7NI7='QI^//R-IL!1]^](]5]STVU)LC4;8A[-V+MS>B[>FS"44>6DPO\
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MU[I2>_=>Z][]U[JO'X_?]O#_ .8I_P"&/\(O_>+[D]^Z]TZ]4?\ ;R3YJ?\
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M.'S>Z)*C:K8VBR>9I)LY+7T1K(*B*ER21U"('4'W[KW5??SW_E7_ !!^*_\
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ[_YK7_9!O=/_ &N.D_\
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MH;J*REW:^2V%Q*K/'!K!)ED1.]E0*253N/ =('*_";^8_P#,;8G54/R!QO\
M,_[BZ'ZDP2K\*HL5\9?A161X7IC?G5> VI!7[HH<UO7#P5.YZW:\,*44S_?O
M1)#3UD$T%>OD1&M_OU2'VN@!Q_C<'\\?ZOY]"B;E'VC$<;6W/>MBE6KR]N8
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MCM5LA#5U%97QU^0J:KS5)JI"9 VU_O\ JHFV#33B;N'_  4_U?EE9!RA[/\
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M^Z]U[W[KW7O?NO=5[_S2O^R*M]_^)2^*_P#\%CTA[]U[I0?RR/\ MWQ\._\
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MW<O0>7R&4.<>3(Y:ER]#E'EE^]+GW7NKA_?NO=5__.+_ )F-_+B_\: ;=_\
M@5?EC[]U[JP#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5W_P UK_L@WNG_ +7'2?\ [_[JWW[K
MW5B'OW7NJJ.F>IMN9#^<+\X.^YJK+#>&V?B'\/.E:"ACFI1@7VKNK=7>6_\
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MKW6O3C=OT^SOYY*[>P^1SC[?S^Z,WW!-@\GE9\EB\7O[L3X@YG;.]LKM^GJ
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M!4QB01U$,<\8EBD@E"2HLBB6"9$FAD"MZD=0RG@@'W[K?5>_Q^_[>'_S%/\
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M&=D-1S2)Z7>AR"4\C4M2@:GJEC8Q.X4D>Z]T6C^5C_V6K_,H_P##ZW/_ /#
MOYD_OW7NKX/?NO=$^_F&?]D!_./_ ,4^^3'_ +Y?>OOW7N@>_E]?\?;\ZO\
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MG\I]R[0W#%2U"O",QM;<>.I\ACY[&2DK:>*>,K)&K#W7NG?YO_\ ,Q?Y<_\
MC\^\ !_KGXJ?+$ '^H)^O^'OW7NJ6-BS;6Z\V%T_OC>N\,]+F]J_S'_AM'VM
MD-P*TVW>KMM5$79.!V'M3&?P'KK:.&Q'7N%S6X4H,5*9LU%3??I$<G+&ZN_L
M4QPZ]BF,@]'$_E8_]EJ_S*/_  ^MS_\ PP+^9/[]U[J^#W[KW1/OYAG_ &0'
M\X__ !3[Y,?^^7WK[]U[H'OY?7_'V_.K_P 6<ZI_^%]?"/W[KW5D7OW7NO>_
M=>Z][]U[KWOW7NO>_=>ZK[_FB?\ 9&.]/_$M?$__ ."WZ-]^Z]T\?R]_^92=
MS_\ B]G\P_\ ^#;[W]^Z]T>SW[KW1 /YG/\ V2+E?_%@?A-_\&S\>??NO=-W
M\P[_ ("_"?\ \:(?%G_W<;C]^Z]U8A[]U[KWOW7NJ!LO_P!OX<!_X;6&_P#@
M8.VO?NO=7\^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?O\ EP_]E9;-_P#$
M#_S,/_AO._??NO=; GOW7ND+VA_S+/L3_P ,7=W_ +H,A[]U[K5=^,W_ !]W
MPM_\.#^1I_\ "_/DE[]U[K;<]^Z]U57\4ZDT?QJ_F!5802&E^7G\QNI$9.D.
M8.S]^2Z"P!*AM-KV-O?NO=56?RO?Y,?=^V=L?RI/D7V1_,6W=VWT[\5.MZ3N
M3HCXR5OQLZTV?B-CR?(7I2LIMQ[=3M+;VY_[YYV#'_WY+)4Y2*M>3[4!8X?(
M=/NO=;4_OW7NO>_=>Z][]U[JO'X_?]O#_P"8I_X8_P (O_>+[D]^Z]TZ]4?]
MO)/FI_XJY\#_ /WM_FW[]U[H_/OW7NO>_=>ZKO\ YAO_  '^$O\ XT0^+G_N
MRW/[]U[IQ_F)_P#,NOCE_P"+_P#P(_\ @INM/?NO='_]^Z]U[W[KW55?PCZ@
MVM\@/Y//0'2&]:3'UNUNU_AU@MA9F+)XFDSM'#2[FV7)BUKWQ%?:DKY<7-4)
M4Q(Y4>6)2&4@,/=>ZUW?A/O?=?QE_F:]+;SWYU=MW";PWWO;-?"KY"[\ZLZ\
MDWG#N#<NSL9UE\6]WUV_=P[:W'-#UU6S?(G8W4NZJ26M?+R5U)VYD)JB."6*
M2=O=>ZW#_D3T+UW\HNC.U?CSVSC&RO7O;^R<YLC<L,$= V1H:?+TK1T>?P,V
M3H<G18_=.U\FL&2Q-8]/*:')4D%0JEXE]^Z]UK&YW??S._EG]S[MW=VOOW,T
M6_=Q=C]=OO?L3>U#3;?_ )=_\R39^)V4W7F'[&W7OJ/!9N'^7K\_7Z_VOC,?
MN:6JK:+KW<^9V]CJDH]/D&DI?=>ZLHWO\]OE5VQLK;4W3FR_C=\4=E[B[*QV
MR=[?,3OCY3_&GN[JOJ[%4^)K-Q;@QNUMB]2=MANPNY<ICJ:&##X>MRN-H8/N
M_OJR1J> Q2^Z]T17K+(_!G'?)3X-X'X[=G=G_,CY(;C^7FT\O\DOG;NW%[[[
M!QN_'VC\>_E]MVGVM/WAF:9NM=JXBIW5_$),#LC9U0N%I*>!FCA(3SR>Z]UM
M-^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[JN_\ FM?]D&]T_P#:XZ3_ /?_ '5OOW7NK$/?NO=5
M\=%_]O%_Y@7_ (B+X+?^X'R3]^Z]U8/[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZUY/YMG_,\-T?^**8'_X8O\0O?NO=61]?_P#;S7Y2_P#BEOPJ_P#?Q_-_
MW[KW2=_F!5E'1;K^ DE=6T=#%+\S<Y2Q2UU73T<4M75?![YHPTM)%+4R1))5
MU<[".&($R2R,%0%B ?=>Z$;^6W64>0_EY?!2JH*RDKZ63X??&U(ZJAJ8*NFD
M>#I[9\$ZI44[R0NT,\3(X!)5U*FQ!'OW7NCJ>_=>ZU2ZW^8M\;?Y>W\T'Y*U
M_9ORB^1@^*.X8.S9NT<%NSJ#LO,=4]6?+_<G8>V:NIV_LF+9/5L25FTZ386!
MK:N?<4SY&CADE>*7(7946+MLEM8/<N>QVBYD>Q>QFEN(A(7C6[\>,,64U$<F
M@CM%,$FG6>O/&W;_ +I]QW;.;?<79;2WYKMN:]MV_:+^2SCMKV?EU=INY+=(
MID >[M#<+(3-)J[EC ;A76"^6'RT[ V!\A/G1AOY7'9^]^M]AX3Y#[TW]L/Y
MM=?_ "<[DGZDWOM+MO'T_:N<^-&RX<9_%NF?[Y]B=RS;BRV)J*FJIY\I6X\X
MJF9JLP+/*/6!72.Q_P Z_P";A0=XTWQRR_\ ,4[ODW?@Z?<N-W7NK,5W\Q?&
MPXZKZKR4.]MUYO<FSZ/IZEWS0G<N*KZO:-2*+"?9XN';U17.*.::GKZOW7NA
M2Z+^7?878/S0Z9^47S_^5&_*?I+(_&7Y%8CX_=>_PGYY]BUU!F_D'U'V5T%N
M[;_3?8G;_5^2EBR[;TV/C\AN7)56?7#1TLBI25<JTDT-,1<T/:1\MW[7S.EE
M])+K9/C5=!J5X9 X9'V]2O[#VF^7OO;RC;\LP6USS">8[#Z:&X.F"6;ZB/0D
MK:7TQL?B;0VD=VDTIU95_P )OOF_\G^YOYD=)T7V)\L.T.V>M<!\4^YLA4=2
MYKN*O[)V'M/*;-WUU%@=FRXO'U..Q:8>7"87)U-'31&!7@B+)<@^P?[:;GO]
M_9R1;M',NVPPVXMFDMC;,RZ*-VZY ] %.H,0:XIUD=]]WD;V?Y2YBL=P]O+S
M;IN=-QW+=WWN"RWH;U#!,+H-%^I]+9O;EB\JF&2!'4H0U3GK?F]R;U@UUJO_
M ,J6;Y6=6_R>-J_'*'X#=\=E3]C;.^3F;VAV#M/LOXF4.P]R;;^1O9/;&_MA
MY9:?>_R&VIO3&4C[=[ HOO(JO$15$,BR 1N M_=>ZK0_ET?R].V]G?(W=U7\
MG/Y>WR;^2^^NLNL]I=<?*C#YWY4=);NQ53W'N'ICX[[@V)N7;>+W3\GMK;:K
M:&@QV)SWV4]+*?X9A\I2T"QH8FA@]U[J\G_95^@/^]$'>W_HU_B'_P#=L^_=
M>Z1.,^.N2ZI^5'Q;^17QP_DU=T]7574&0[@INR<M2]J?#<;OS^T.P>J,_M#$
M;>P#UGRWS,-321[OKJ.MK(9)Z1!'3"13(ZJA]U[HU?=W:'RV[,[<^(&_\+_+
M5^3U-B?C[W;O3LK=]/DNV/A'3Y#(X3<?QO[QZ>HJ7;T-/\I:V"MR<6YNS*">
M5)Y:6,44,["0R!$;W7N@F^7'R9^0/:7>/P,Z3Q/PH^1O37:N2[V[/[JV#N7?
M>4^.6\=EPT73WQ>[MV_EZK<%3U3WCV1+M^*+=/;FWJ6"7*TU-C9ZBN2-YUO8
M^''K8XYX=!WN_P"/F].C/Y=_R:R/9.R<KLOL#?W:OQ<FS"UN*Z>Q$&4P.V/D
M;UEA-FRF#IS-YC!_QZ/;,L/\715I,?#72/%00_;+K?V*8ZUBF,=)7X3_ "B^
M//QC^9O\P"K^0?;^R^H*;?&_^P(MFU&^<B^%IMSOMW^8%_,7_O F%K)X#1UT
MF#.7HQ51I)Y(?NXBRV<'W[KW6P)TYWAU!\A=DP=C]'=D;0[4V)4Y/*X6+=>R
M<U1YW#',8.J:AS.*>LHY)$BR.+K%,=1"^F2)Q9@#[]U[JMKYS?,[KC?W07SK
M^-'5W6WRC[@[0I.H>]?C_4IU'\4/D%V-LR+M[='3%8N+V4>Q-K=?9#8QR2G>
MN,^Y?[_P4GW0\SII;3[KW20V'N?Y'_&KL7Y"#8^'^$N]-N]P]A]<]E0Q=K?,
MS-]+=B[.R>"^+_Q^Z3W'LS=FQZ#X]]GT--7XS<G4-7.DT>4)D@JD#QQNK+[]
MU[H6/]G"^7G_ #[#^7+_ .G)MR__ '&WOW7NDR=[_.WY(=G=?[5Q_?'Q9^(>
MP\;B][5N[JOXV=Y["^6?;W8V?F@P(V5A<7MSNKXN;>VUM?;N#BI\K59&J@6I
MK*@O"BJB*[>_=>Z';_95OEW_ -[/?D%_Z(#X2_\ W.GOW7N@:RF:^>WQ?[-S
MV-KN_/CO\M.M=V['V77;8B^57;77GQ#[,Z_WKC,YORGWL<52])?%S/8'?6R-
MSX2IP/VTU8D%715U!5H-4<H/OW7NG7_9POEY_P ^P_ER_P#IR;<O_P!QM[]U
M[H%?D#V)\I?D_P!;ITMN##?R].NL!N+L;I//Y[>6)^?6XM]9;"X3K?NGK_LW
M+-B=H2_%K:$.?RM=C]G24U-!)DZ*,SS*7E50??NO=2_BK_,$^%'Q_P!H]\;"
M[P^3?4?4N]<-\W/GIE,UMGL#=--M?*8>@W)\Q^Z<[M^KKX\JM-#%2YK"Y.EJ
MZ68.T-13U,3QNP<>_=>ZMUW/V=UYLKKC,]O[OWGMS;/5VWMI5._,]O[.92EQ
MFU</LRCQAS55N;)9BKDBI*/#4^)!J'GD946(:B;>_=>ZIY^<O\P#X6]X]"47
M5?3_ ,D^K>R>Q]V_(?X9T^V=D[/SXSFX\Y-COF+T/FJ^/'8RBAEJ*C[+$8VH
MJ9B!IB@A>1R$5B/=>Z,__,DR^)P.$^&68SN5QN$Q%!_,+^+<]=E<Q7TF,QM%
M"N8W'>6KKZZ:"EIX[D %W +$ <D#W[KW1[=L]D=>;TJJBAV=OW9>[*VE@^ZJ
MJ/;.Z<'GJJFI?(D7W-13XNNJI88/+(JZV 74P%[D>_=>ZG;FWKLW94%-5;RW
M;MG:5-6R/#1U&YL]BL#!5S1*KR14TN5JZ6.>2-6!95)(!%_?NO=4!;JR6^<Y
M_-GWSW_\?>L,E\J-N=*X;J.GW_@>G.P^F*7.XRE[+Z&[FVG@,C35G9/8^P]J
MY".#,T3)54\>2^\AC=)!$R&_OW7NK*O]FX^27_>LCY;_ /HS?@S_ /=;^_=>
MZ179'RU^;DNP-YQ=-?RR^^8NV9=M9B+K>;M3M#X=1]:4^]9:&:/;E3OYMH_+
M"HW2=HTV4:)\@N.0UKTJNL-I"I'NO=+,;0_FB?GY!?!"_P";?$COT_[S_LYX
MO[]U[I#]D)_-MV)LO,[PV5NGX3=[;BV^<=D*7J' =!=K]8[@W_11Y:@7-X#;
M^_MY_,+);2VOGI\&]2]%4Y*"2B%4B+* C$CW7NEU_LW'R2_[UD?+?_T9OP9_
M^ZW]^Z]U[_9N/DE_WK(^6_\ Z,WX,_\ W6_OW7NJ]?AE393H+Y;]58GY%4N'
MZ(WAN#XG_.+?<NS-^;ZV#)D,+0]L_P R[*=M;6Q%9G=O[ES&T<GFHMF[QH9:
MM,=7UD4$SM'K)4^_=>ZOPP^:P^X<?!EL!EL9G,55>3[;)X>OI<GCZCPR/#+X
M*VBEFIIO%-&R-I8Z64@\CW[KW28[0_YEGV)_X8N[O_=!D/?NO=:KOQF_X^[X
M6_\ AP?R-/\ X7Y\DO?NO=;;GOW7NJQ_Y<=1L_MCHSY1UV-KJ+=?7G9?S>^=
M)QV9Q52\N'W3M//]W[QQLM?ALI3E%K<;70F5(ZFG<H]B4<V!]^Z]T6?X6[0B
MZ]_F';_Z)^+/R0[OW]\/OB[\8ML]8=O];=C[UWQWIL#:GR(EW08MA]=[&[.W
MYD<E'L?='5_4^,C.8P6)J:G_ "?(TD=<D$T"@^Z]U>A[]U[KWOW7NO>_=>ZK
MQ^/W_;P_^8I_X8_PB_\ >+[D]^Z]TZ]4?]O)/FI_XJY\#_\ WM_FW[]U[H_/
MOW7NO>_=>ZKO_F&_\!_A+_XT0^+G_NRW/[]U[IQ_F)_\RZ^.7_B__P "/_@I
MNM/?NO='_P#?NO=>]^Z]T0+^5;_V[B^%?_BO'7'_ +HX/?NO=:\_\\OXS[!P
M??79F;W6-S;9QO=FT]B_+;J7?&UZ;H_%Y##]H_' X3JOYM[8VOE=WS87+R;J
ME^(]7MCLK"TE::AJG<NP&R%%4+/CC3M[KW6QO_+V^16\ODA\:MOYOMG')A^_
M.K\_N#HOY%8VEI:NGQ#]U=6S087=6Y=LRS[?VS2UVS^QJ.2CW1AI:.E%&,7F
MH(XV;QL??NO='+S.%P^XL57X+<&)QF=PF5II:+*8?,T%+E,5DJ.9=,U)7X^M
MBGI*RFE7AHY$9&'U'OW7NB@G^7-\#F[-7N(_$7H#_2*M2*\9_P#T:;9$7\3&
MU7V,,P<$*$;=;.+LZ1L8*XTAJQ0DP^31Q[]U[H*OF^FS>NL__+>B3^ZVPME[
M;^>>V884+8C:FUL#0)\6/EA%#!$&./Q&+IO+($C1="EW"J"S 'W7NC9[B^3_
M ,;-HXB?/[H^0/2NW\)2SX^FJ<KENT-DT-!3SY7(TF)QL4U549M(8WK<G70P
M1W(U2RJHY(]^Z]T]_P"GKHS_ )_/U/\ ^C%V?_\ 7CW[KW7O]/71G_/Y^I__
M $8NS_\ Z\>_=>Z]_IZZ,_Y_/U/_ .C%V?\ _7CW[KW7O]/71G_/Y^I__1B[
M/_\ KQ[]U[KW^GKHS_G\_4__ *,79_\ ]>/?NO=>_P!/71G_ #^?J?\ ]&+L
M_P#^O'OW7NO?Z>NC/^?S]3_^C%V?_P#7CW[KW7).]^CY"0G<O5+E59V"=A[1
M8JB L[FV8-E11<GZ >_=>ZX_Z>NC/^?S]3_^C%V?_P#7CW[KW7O]/71G_/Y^
MI_\ T8NS_P#Z\>_=>ZY'O?H\(LA[EZI".S*CGL/:(1F0*756_C%F9 XN!]+C
M^OOW7NO)WOT?(ZQQ]R]4R2.0J(G8>T7=F/ 557,$L3_0>_=>ZX_Z>NC/^?S]
M3_\ HQ=G_P#UX]^Z]T0+^:#W!U)N+X0=NX3;_:77.<S.0SO2D./Q.(WQMC)9
M.NG'??5\G@HJ&CRDU553E$)"1JS&W ]^Z]U:K[]U[JOCHO\ [>+_ ,P+_P 1
M%\%O_<#Y)^_=>ZL']^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:[?\YJ/.[3[
M<Z_W+)BJ2NVIW'\=L[TC!DXLNL&3V[NW97RC^-O?*5%5A)*)CDL-F=O;/JJ0
M315"/359CU(R/<>Z]U99U_\ ]O-?E+_XI;\*O_?Q_-_W[KW0M_+_ .+NU?E_
MT=G.GMQ;@S&Q<PF=VAV!UEVIM:BPE9O7I[N#K7<N-WIUEVELS^/X_(XY,YM/
M=.'@D>)XQ'7T#U-#,?MZJ8'W7NJ<OB+V1W7_ "CMG;UZ[^>O0NU-B_'W?WR%
MW1O;$_*KXL923+_$SJ*J[*K=J;<\>_.HLY)0;T^+/7N]][4-7N69J*/+;1P6
M2W+-3M-10+K]^Z]UL14E72U]+35U#4T];15M/#5T=9231U-+5TM3&LU/4TU1
M"SPST\\+AT="592""0??NO=$3^(^.V[O';'R_P!H[KPV%W#MO*?,7Y,;>S^W
M=PT6/S.$SV&RV7HAD<7F,-D8JFAK\9D*2N>&:GGC>*:-F#*5)'L(<HLNG<EQ
M4;O=?S93_EZR0^\7;R"7DB8!B)/;G8CP/X894X^?P_Y.@8^ ?573-/COF5L*
M3K;J^GV1L'^9!VMN#8.RSLW:<.U=E9C;^S^I,CM_.;0VW_#4Q&W,IALC/)44
ME51PPS4\\CR1LKLS$6ET&"PK]HZQV6UNF%5BD(_TK?RQGI?[KCP>:_F@['Q6
M83$Y;!97^7?WKBLKC<DM'7XG(T>0^0O0M-6X[(455Y:2KI:ZC=XY8959)8RR
ML"MQ[UXD?\2_M'6_H[O_ 'U+_O#4_;2GY=!'_,]H\#,OQ%V_#2X27 1[R^3^
M/?!B''OADQD'\N[Y<T]-0OC"IH100QJL:1%/$OI4#Z#V2<S/&W+>X*2I!LY<
M$C^ ^O4G^R45_;>\_*4\:3I(O,=@0RJX*GZA,AE%5/H:CK2H_P"$D?9&\\]_
M-?WAU?D\A25&R=@_'GY2;CVSC(MO[?I*W'9;=?:W2\6=J:O<5%B:?<N7AJ_M
M8@D%=65%/3$?L)&6:[^P?\D&R_YY(?\ JVO17[N"GNQS1Z_UAW'_ +3)NOIG
M^S?J/.J)O@Q_+C^'N^.J^S:G<'6NZI!M;Y<_-#KG;='C>]OD+@L3@=C=<_*3
MM?9FQ=K87"X3M;'XC$X3:VT\-28^CIZ>"*.*FID6UP2?=>Z,/_+_ .H=@=%?
M)7^91UIUAB*_!;-Q'='Q]KZ#&Y+<^Z]XUD57FOBCU17Y&63/[VSFXMQ5*S5+
MDJDM6\<2^F-57CW[KW5J7OW7NO>_=>Z][]U[HJ7R-^(VS_DAN;J[>^2[*[NZ
MEWUU!3;\Q^SMY]&]@_W!SZ8CLJ':\.\,-E99<1FZ/*8S)G9N.<))!JBDIPR,
M+F_NO=5G_/\ ^%]3UO\ %S=>]_\ 9N?FOV'_ '>[$^.]7_<OLONW&;DV)N$R
M?(WJ:D%#N;!0['QDF3QUZC68A417=%.H6]^Z]U.^./SSZ9Z!^.F[=U38'N/M
M'=/?_P D_P"8EWK\<.I^I>DNU]Z]C=W]>1?+?>,N'W+M_$XO9\M-M/:^Y)>P
M<$*/,;DFPV*EBRL$XG,1+#W7NCS_ ,NGH_L7HSXPX"B[KBKH.^>TMW[_ .]>
M]*>OW52[SDH>T.V]TU^Z<UAHL]CL?B\550;=Q]128X"C@2D4TA\1=+.WNO=%
MDW!F>R?Y>GRW[5[#R.PNS.U?A'\R]WXK?.Z,]U?MG>W;>]OB[\D*':5-MW/Y
MC/=7;(V]N'>65Z8[EP6V,:#7X>EK7P><H@M1 L%:LJ>Z]UD^!_Q)^,';/2>[
MNU.U?B'U-G=S]F?*+YG]@4>?[P^,>W\3V;N#9^\?EGW-N'8>>W%C^T]A8_L&
MECS.S<A0U%$N4@BJ!020V58] 'NO='._V0GX,?\ >%_Q._\ 2=.G_P#[#O?N
MO=$@^9OQW^-'QMW%\*>^.L?BKL?92]8_,S:^<[ WA\=OBX,[OO;G7U?T5\@-
MN9"NK,9T=UWF>P*C;$^X<YC*:J\%-+ ))XO*+6(]U[HRW_#F'Q4_K\EO_2%/
MG+_]SG[]U[HLO5FT?CA\XOG;\CNWMU?'>#M;K?"_%_XH=?[1W5\EOB7O':\%
M/O#$=E_+7/;SP.R:?Y'=5[:R\[T>)W-AI\BV,A:G_P IIA*Q<(![KW1X_P#9
M"?@Q_P!X7_$[_P!)TZ?_ /L.]^Z]T6?YI? /XCU/PY^65-U[\*?CC4[^J/C/
MWO!L>GV=\<>L)-W3[PEZMW5'MF':T>'V<<O)N.7-- M"M+_E)JB@B]>GW[KW
M18^ZN\=V_-GI'JWX)_%SJ+M[(9OM#:VQ*3OWO#NSH[O+H[J?XZ];=?UFR\GN
MW(U5;VML;8>1[*[4W+7T2XW;FW\)]TLT[35E;44]'2R-)[KW1Y?YJ\L<'\MK
MYO5$[K%3TOQK[3JZF9S:."FI=LUM14U$K?2.&G@C9W8\*BDG@>_=>Z)ATA@\
MA\M/DS\U-G;K^:?RZV1N?8':&V-]]6;0Z:[QV)M[K+,?%+MK86W,UTGV#UM1
MX7;^Y9\YM?/5E!F$GR,LAU5JE=1!3W[KW1A.R_Y;'7&X]DYZF[F^9GS-W)UO
MCJ*7/[GI.U.[M@9[8E#C\ C96;-Y^DWCU=6;=IJ3"1TK5+550H2F$9DU+IN/
M=>ZK?_DX[)QVY/DIBNS]H[*VGM'KC:?Q5[DW5UAO3,=?;"VQ\@>]ND/EY\S=
MWR?'C<79F<ZMQ6#VED=O[(ZG^(=*V+6IAERDR[CURM'XV#^Z]U8O_-"^+&Z^
MXL3T/\BNK^F=@_)/M#XA;RW9NT?&KM*GV[6;.^0W3_8.VXL!W#U3C5W?A\WM
M;#=IUE/AL3F-GY6NA6FIL[AH::>2*EK:B1?=>Z(7L>I^$WSS^5WQ]Z(^-73-
M/U1U#UIUGVEWO\P.I<'@M[?#3L3;._,W@-F;+ZLZT[DZBV#C^M-X3[\VS7;O
M?(1RU]3+B13+,]#+6*1*/=>ZL\_X:M^#G_/KM[?^E%_)C_[</OW7NDMOK^5I
M\-*;9.\:G;O5F_FW!3[5W#/@UI/D3\FWJVS$6)JY,8M*B=PZWJ#6JF@#DM:W
MOW7N@V^)'\POI/9GQ3^,FS^V(_E=3]I[4^/?2^VNRZ?</PI^<><S\'8&"ZXV
MWB]Y0YS-KT#DUS&8BW%2U*U-4*FH%1,&D\LFK4?=>Z1/R\^1G4_S)Q_QV^/_
M %?B?E)G(MX_+7H=^S\;3?'3YI]$XZ;I[&9ZMK=^MN7LO+=9=9T."VS%11QM
M5A\Q3"90$L]])]U[HU'_  U;\'/^?7;V_P#2B_DQ_P#;A]^Z]U[_ (:M^#G_
M #Z[>W_I1?R8_P#MP^_=>ZJ%PV^?C/UONCYQ_$79?P[J?G-\F^JOF'_=?XX=
M$]D]4[_[MVCU?M?N'H/H3.;:R6^_DGW#M?L#9W3G31W%1YK-Y;S;@^[$<%0*
M6BDG>*,^Z]U=W_+Y^)N(^#_PZZ+^,F,I=I4];UOM$)N^IV)09'%[2S/8>XLA
M6[H[#W#@L=EJFKKZ+'Y_>69K:N..1AH64 )&+(ONO=&0[294ZR[&=W2-%V)N
MYG>1UCC11M_(%F=W*HB*.220 /K[]U[K4SZ?WQM/K6D^+_9>^<W2;=V+U]1?
MR5M][QW'5K/-1X3:>T_Y<?R>W!N#,SQT<-35SPX_$4$LQ2&.260+IC1G(4^Z
M]U=5L7Y-?S"OE5+0;Y^./QFZZ^-WQ^K\%#F-J[U^<L^[?],':<.;PFR<YM[*
MXGH3J;-4]=U9MOQ9K*0R-N/.-F99:*,/C*02&WNO=$.^"'Q7^2_?7QA["^+7
M8O\ ,1S.W]@= _(7MSXO=M]9?&;KC9G6VY9-G]8]HU-4VT*+MY\GF.Y>NXNS
M]DST_P!Q6)/!FFQ&49Z6H7RQU)]U[J_/I#HCI_XV]=8GJ;HS8& ZUZ]PM5E<
MA1;<V_#,L,F4SN1J,OG,UDZZLGJ\IF\[FLI5R5%975L]15U4SEI9&//OW7NA
M;]^Z]U[W[KW7O?NO=5X_'[_MX?\ S%/_  Q_A%_[Q?<GOW7NG7JC_MY)\U/_
M !5SX'_^]O\ -OW[KW1^??NO=>]^Z]U7?_,-_P" _P )?_&B'Q<_]V6Y_?NO
M=./\Q/\ YEU\<O\ Q?\ ^!'_ ,%-UI[]U[H__OW7NO>_=>Z(%_*M_P"W<7PK
M_P#%>.N/_='![]U[H&/YI,VV<YF_Y?\ U=)4T^<[![(^;NT\7A.J*S ;&W;A
MNQ^EZGJWM+9WS$J=]8#>V6QT=+UWL7XH;[W9DZG+T<5948_.+B(A!(:M5;W7
MNB._R+ZVEV#O3LOK;;=77;LZO[EZ<P'=?5/8+[\?=D&?V]T?W3VO\28:_(4?
MV\>.DRN=V'L':C09G'D4V;QU#!,Z>4%W]U[K9&]^Z]U[W[KW55/\U"NZ/QU)
M\$:GY'U'5=-TM'\\=J-ON3NO^ZAZQ&./QI^445"=U+O=7VN:49N6E$)JQH6K
M,14B30??NO=5Z?S$-W?R2I_B3V!%U7E_Y7TF^#N[HQL6FQ1\6I-SFAC[]ZPD
MW&:),#$V4:D7;*UAK= *?8B;R?M:_?NO='8_OG_('_YW?\I#_DKXA?\ 1GOW
M7NO?WS_D#_\ .[_E(?\ )7Q"_P"C/?NO=>_OG_('_P"=W_*0_P"2OB%_T9[]
MU[KW]\_Y _\ SN_Y2'_)7Q"_Z,]^Z]U[^^?\@?\ YW?\I#_DKXA?]&>_=>Z]
M_?/^0/\ \[O^4A_R5\0O^C/?NO=>_OG_ "!_^=W_ "D/^2OB%_T9[]U[HEWS
M?W;_ "1Y]F]"+UYEOY7DM<GS1^'T^YAM ?%EZM-@0=\;-FWS+F?X/$TR;3CV
MXDYRK36I!1"3SGQ:O?NO='1_OG_('_YW?\I#_DKXA?\ 1GOW7NO?WS_D#_\
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M]*W^/W_7_P!^Z]U[_9EOG?\ ]ZT<Y_Z5O\?O^O\ []U[KW^S+?.__O6CG/\
MTK?X_?\ 7_W[KW7O]F6^=_\ WK1SG_I6_P ?O^O_ +]U[KW^S+?._P#[UHYS
M_P!*W^/W_7_W[KW7O]F6^=__ 'K1SG_I6_Q^_P"O_OW7NJP_YF@^6W=NR]@=
MD]H?$P_'_KOHG(5M;G=R93OGK/LBLS&0[-WCUAL3;V'Q.W=D+-7B3^)U EGJ
M)GCBBA0_J8@#W7NK4NO_ /MYK\I?_%+?A5_[^/YO^_=>Z'7Y0_*'IKX>=-;F
M[T[TW,VWMF;>>BQU#0XZBGS>[]\;OS<_V.U.NNNMJ4(?+;T["WIEG2CQ6*HT
M>>JG>YT1))(GNO=5O?&#^:YUQ\RM]4?Q^[>^,67ZLV[W-)V5U9MK([V[&Z'[
MLZI[)WULC8>S]Y]H]$YNKZZW9NK ONNEV!V)3/-C9164M?X,C2AV>CF4^Z]T
M-_\ ++V;4=(X'Y6_$[%9N;,]4?%'Y7[GZVZ I*U,O)D]D=*[^ZLZF^0^TNIZ
MC)YS<6Y<CF\1U#4=T5>VL'4R3QE=O8R@@\,?AL?=>Z+'\8_@'\5/DOG?F#VO
MW1U]N#=>_:_YX?*S;U9FZ'M[NC9D4V'VCV/5X';E(<+L7L+;6!3^%X>DB@61
M:42NJ NS-S["MQR1RK=74E[-9H;J9R[L&D74YXL0K@5/K3J?]E^]+[_<O;%9
M<L[5S+=)L6VVRV]K$T-K*((%^&*-I8'<1J22%U4%3ZGH=:_^2%_*^RM;4Y+)
M_&/[_(UDIGK*ZK[H^0D]95SE50SU51)VP9:B=D0*7<EB !>P]H']MN1Y&+R;
M?$SGB2TI)_XWT)[;[['WIK*%;>TYQOXH$^%5ALU4?8!; #IJ;^1-_*I=S*?B
MNGD(*ZU[J^1*N$)N8U9>VP5B+<E19;\VO[N/;GD<"@VVW_XT?^?ND\GWT/O3
M2R&1^=MXU'T,*C/D (@ /D !T&_<G\DK^6-LWI[MS=FV?C5+B=P[>ZL[#RV&
MRD/=?R&EGH:^AVAEZFFFC2J[8G@=1)$ R.C1R)='5D)4V_UNN2.'[MMZ4I^+
M@>/XO/IL_?+^]&2K?UVWK4K!E.J*H92"I'Z6"I ((R",= W\*OY*O\M?97Q@
MZ7^2.P>@MQ=<=[[]^*>P=U;P[4ZU^0_R:Z]WAGLUO/K/;>[]U35>2V=W'A0E
M)G=RJM9/21HE(TJ):(*B@#"&*.")8(5"PHH50.  % !\@,=8X[AN%[NU_/NN
MY2O/N-S,\LLCFK222,7=V/FS,2Q/F2>K8OY?NX,]NOX(?"W=&ZLYE]S;FW%\
M4OCWF]P[CW!D:O,9[/YO*=3[3K<IF<WEZ^6>ORN6R=;,\U34SR/-/,[.[,S$
MESI'T@?Y=7_,HN[/_%[?Y@O_ ,&5W3[]U[J!\6_^RT?YG7_B7/C3_P# B]2^
M_=>ZL(]^Z]U[W[KW7O?NO=>]^Z]U7W_-'_[(E[+_ /#Z^.7_ ,$ST][]U[JM
MGX==P=4]-[F_E>;A[@[2Z\ZIP&4_E?\ R5PV.S?9>^-M;%Q&2RB]Z?#FJCQ-
M!DMTY3%4==D$HZ9Y13QN\HBC9].E21[KW5L.Z/YB?P&V;MO<&[MQ?-/XLT>!
MVOA<GN#-55/WQUEE:BGQ>'HILA7RTV+Q&Y:[+9.H2EIV,=/2P35,[V2*-W95
M/NO=!S_PZO\ !7_G[>Z__2?_ )'_ /VH_?NO=&ZZ6[MZM^1'7>([8Z:W=2;W
MV!G:[<6+QV?I*'+8L/E-H[CRNT-SXNKQ>>Q^*S.,R6!W-@ZNAJJ>IIH9H:BG
M=646]^Z]T*OOW7NO>_=>Z+9G/F9\/]LYC+;>W)\K?C9M[/X#)5V&SN#SG>?5
M^)S&%R^+G>ER>*RV,K]T4];C<ECJF)HYX)D26&12KJ""/?NO=#UMW<>WMWX+
M$;IVGGL-NC;.X,?2Y; [CV[E*'-X+-XJMB6>CR>(R^-GJ<?DL?5PN'BFAD>.
M12"I(/OW7NGGW[KW29WKO+:_76S=V]@[WS5'MO9>Q-LY[>6[]Q9%G3'X#:^V
M,559O/YJN:-))%H\7B:&6>4JK,$C-@3Q[]U[HB-)_-D_E[U%5@(*[Y&XC:M)
MN;*8K"X;<78.Q>U>M=E5&3SLJ0X6FGWYV!L7;6R\=_%II%2G>IKX8YG=51B6
M /NO='3VYNSJ[O#8L^5V9NO9':W7&ZZ/+X.7-[.W'A=X[2SM(WW&(S>.CS6W
MZZOQ=8J-Y:>H1)24<,K68$>_=>ZUI-__ !@[(^(T>3V5N_:OSAHX?C5UWNJD
M^$?\P7X"0Y_M#?6V/C@9]ZYW$?&GY/=";MW/NC$=H4W0U7FU&+I:[$9J#<&&
MHJ$44M!70RJ_NO=*#L"#OCY$8JOQGRKV/_-.^6>T<A5==C#_ !2V?\4NI?A?
M\>.R)MOYVIR+XOOK*9;L;>FZ\[MG<63KZ.?-P5NYL;A118L0S4$R-+%)[KW5
ML?P*^-7;W764[I^2?R;IMF87Y&?)2NV125O676F7SF8ZS^.71G4^#J=O]+?'
M/8U;7URX7,0[.ARN5S&9RV-Q>(I<IN3/Y"2*G%,M-;W7NK&??NO= OM?OKX[
M[O["S?76RNY^E]T=K8N7)TFX]B[7[%V/F^PL=/MN<T.9I<WMC$YBIW)22X&I
MC,-2D\"FE==#A2+>_=>Z&CW[KW7O?NO=!#V5\@NA>F:S&X_N#N[J'JBOS-)/
M7XBA[*[*V9L6LRM#32K3U-9C:;=&:Q<U=24\[!'DB5D1R 2#[]U[IPZU[MZ9
M[G@R]3T]VYUCVO3;>GI:7/U'6N_MJ[Z@P=37)4245/EY=KY;*1XV>L2EE,23
M%&D$;E0=)M[KW0G>_=>Z][]U[K&D,,;RR1Q1QR3LKS.B*KS,JA%:5E :1E0
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MN?(3%U6TOA_\1MR[CKMB[&^-M?3;7H*N7?6]9HMV[IR%53-3:T*V]U[JVO\
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M8L21;\CW'4Y&?L'^_/G_ (VZ5&WY8\;_  DQ?:H8_N WD8CW[KW7NP-O[\W
MFS1L/L%.OGPW8&U]P;O=]J8O=?\ ?/8>+GG?<O7R+E)X!MU]TPR1H,M3ZZJB
M\=XU8L??NO=)OY%_]D^=[?\ B&^S_P#WB<Y[]U[H%?B;_P!N\OC1_P"*8]-?
M^^/VY[]U[K'_ "WO^W>GP5_\4_\ C=_[Y[9_OW7NDQ_+J_YE%W9_XO;_ #!?
M_@RNZ??NO=0/BW_V6C_,Z_\ $N?&G_X$7J7W[KW5A'OW7NO>_=>Z][]U[KWO
MW7NJ^_YH_P#V1+V7_P"'U\<O_@F>GO?NO=,W\NK8.Q-\_P OKX@)O;96TMX)
MCNGL&V/7=.W,/N!:%JCRBH:C7+4=6*5IQ$FLIIU:1>]A[]U[HXD/0G1=/-%4
M4_2_4T$\$B2PS0]<[/BFAEC8/'+%(F'5XY$8 A@001Q[]U[H6??NO=5)=#;M
M^8'QLP?9_6M1\ NX>TZ:K^3GRR[*P?8.S>\?B90[>W7M3N/Y*=I=K[/RM)CM
M]=Y;4W=C:B;:^\:05-/7T$$\-2LBD$ 'W[KW0X?[-3\M?^]8?R)_]'U\(/\
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MRN^5&^-T=7]-3;JZEAJ:&AZLW/U[O3Y"PC;%!W13]#]*9K:N[^D]A=$=/9[
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MW?@]FX?#[KHGDVM@ZC#2UM)N*@J8:B2%W5IXW]1()]^Z]T3Z;>-3WQ\J-O\
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M /V$>_=>Z]_L[W\G+_GX/Q8_]%MC_P#["/?NO=>_V=[^3E_S\'XL?^BVQ_\
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M8U-')I<31VY]0^OOW7NMBSW[KW5.E7\3/C)\JOYA/S<QWR0Z&ZJ[MI=F==_
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MH(Z:EBIZ."GIXO=>Z,K[]U[I@W1NO:^R,#D=U;TW)@-H;8Q$<4V6W'NC,8[
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MQ,Q"*%-AXFO7B:]1-N[U^>.(^3'R'[MG_ER]J0X#N3I7X]]88*@QWR=^)_\
M>+;V6Z@SGR'RF;S,Z3=GQXZ"FKHNXZ(T/AGFD\U)4&54!CU:ZUT"G9VVOYAV
M[_AY\B/CH/A_\DNR-\=T=8[FV)B-]=N_*SXHOB\!59K"38Z"62EQ/:F6JZ;'
MO7U,L]2T<514/&XA4"..-1[Y]:IFO0Y=R;S_ )@W:.?Q^4VU\/OE+U#14N K
M<344VQ?E#\2(YIZRH:8P5R4E9W3)MIBOF'DDJ,?45H\:B"HIQ>^Q3\^K BGS
MZ*7\J=V?,[;/Q![IVMV]\9/D!)M3>.[?C]3UW9_9G?WQQW73]?8W&]S=;TM1
ME:O;^S^V]S9K)RY>IT-5PX7&TT4DI!CI4&H^]>?6O,GRZV3??NO=5\=%_P#;
MQ?\ F!?^(B^"W_N!\D_?NO=&O[JZ3Z\^06P:SK3M#$U&:VG6Y;;N=DI*3)5^
M(JH\OM3.4.X\#74^0QL]/5P34&8QL,RZ6LQ2S J2#H@'CUH@$4/3UUCUIM/J
M'9>*V#LFEJZ/;N'>OFI(J_(UF5K&GRF0J<I735%?72S5,\D];62.=36%[
M#W8FO5B2>/1??YA7_9 GSB_\4_\ DO\ ^^7WK[UUKHP'4W_,J^M/_$?[-_\
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MS]/VGN?Y2"DV]O";-R8:MR^2SF:S"5\V5D>I>2264CW[KW6'^+_S*?\ E?\
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M_?NO=6#^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ\\I_P!O7MB_^,\^U_\
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M9'P7_P##V^3O_P +U^!?OW7NMLCW[KW6I%\N-\=C?R3?YD."^9F[-H=F;S^
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M2=ST.S.Z<1TQ4[JJH-I[FW)L[(;MQ6%$=!]_(J&5O=>Z%KJ_YF?%SXR?)_\
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M-_+?_EG9V/"G"X;<E%F:?!_)/YY5M319;!;AW%M7$9/'*H\S)-6+IDB5@CL
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M$]1+&2WNO='"^>?_ !]_P#_\75KO_@*OF7[]U[HE6"_[(&_D0_\ B3OY>/\
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M^)F*Z6B;^]/Q@.8_OI2=PYG?-0IQ/^S(_<+C/X'6Q6J+:&ENGU'OW7NC9_\
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M((DWB=X_(ITL18^_=>Z6O^CSYS?]X<?RM_\ T=/;_P#]Q1[]U[KW^CSYS?\
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M"2HGU^Z]U8E\^?\ C[O@1_XN-N/_ . :^:7OW7NA'_ES?]N^?@M_XIY\:/\
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M%'05$":)8D>,>Z]U=S\+O^R.OB;_ .*T=$?^^MVK[]U[I*_S#/\ L@/YQ_\
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M #C/AU@J&NR>:H_D5B\=C*&HR>1K*WXQ=V0PT6.I('JJJMG)V>66G@IHV=B
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MWOW7NB-_R7?^R1=Q?^+ =M_^Y6&]^Z]U;=[]U[JM?YV?$7XGY#XK_,7?M?\
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M B;XN]6+>E=2,,?(#RK7JRBBQ7<OR3Z>Z"VGU-\=>ULQUC\8\2W6V!R'0O\
M,7^)57B]Q34.Q*+9.2P7:]1C=F;@HLMDVV3DGIZW$RK20K%DF:6E#F!HPSMW
M/M]MU]?[DMG83W6X2:W,T;N8SXGBCP2)%*$/I8-E@5&:5!5;MR=:[O!9VS7E
M_!;6:Z0L,B(LHTA")@8VU@K52N%(9@1G$;._$/Y"Y?#YG;&.^$WR0VEM'-=
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MH*_:E/'AZ^@3;>3W!%DI$^TD-/\ =_<6 ?6![KW1R_\ AU_^7?\ ]Y2["_\
M.#=__P!C?OW7NO?\.O\ \N__ +REV%_YP;O_ /L;]^Z]U[_AU_\ EW_]Y2["
M_P#.#=__ -C?OW7NO?\ #K_\N_\ [REV%_YP;O\ _L;]^Z]U[_AU_P#EW_\
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MZV:+"_>3R2^ IUX CSZ(I4X?Y0]Q=UY#<\VY.[>L=R9')?%_;W8/SB^06#?
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M/QIZ4ZZSM31Y79_36?Q=134N\=H9&E219M$ZTXFB+PR1R-[KW5LW_#A/3/\
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MP2;/;?W%N;HZ3M.JVK55]?MW%=\=I=S_ "%VAB<ED\178&KRM+L+O+L3L+9
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M/3J__P"RGW[KW7O]G-^'W_>5WQK_ /1Z=7__ &4^_=>Z]_LYOP^_[RN^-?\
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M&-GW%AL%\ NQMQX3$9V:CADRV,P^X:[Y)[;K<[BZ"O:2*GK)L=02U42+(]-
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M5_!ZO=>Z/-T3\:?CY\8-IT^Q_CQTMUITSM>#%X##RXWKO9^$VR^5H]KX\XO
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MM[?U#6T.Z,KDLXM72X3:\5(N5V_4TD==)' 7?W7NC0?[(_V1_P!['OG_ /\
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MS$E :[#U[4U.:_%5-/4&*/R:![KW0&?S,^FNQNW.B-CYGJ_JW:_?&X^@^_\
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MEA\=O'MW+_[-K\@T:3$XRCVENG&]6]89W:70VV)X,K55M6JUN]-TQD4M.D]
MRR2I[]U[I%;"_DL?$N@K-X97O;*=I?*RNW]VIOONK=>V^Y-W#'])UW9G9F Q
MN WUNRG^-G6-%L+H&GS>YEHIZRMK'V[+6U60R%74S322RZE]U[JT_9FQ-D=<
MX.#;'7VSMK;%VW2E6IL!L_;^*VUA8&2GIZ17BQ>&I**B1Q2TD4=PE_'&J_10
M![KW2K]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1$_EA\^NK_C/E,9U9MS;V[/D1\J
MM[8K/5G5OQ5Z4H&W5VENB7#8ZBK7R^[A1K48SJ/KBFDS%"*[<^XWHL72Q52,
MC3R%87]U[JB'O?MSL3O7LCLK!?*C.87Y-UO2U+CNW>Y?B_U#\CUZ*_E5_ [J
M<[JZYRVU:GYT?*2BVI1]C?([NO'XG9]?NH[73%9FD-(M<J;>IL?-1UL_NO=)
M7H3MS,;U^1'\L?&;%^/'375_QPS7S%WI7];9SXY_"CNSKSJ+$[8VU\<OD;!M
M"2B^9';LO6=)V^W9M?7Y*LI8L/U]2TV22!JC[M8]$E3[KW6WI[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NJ[_YK7_9!O=/_ &N.D_\ W_W5OOW7NK$/?NO=5\=%_P#;Q?\ F!?^
M(B^"W_N!\D_?NO=6#^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH8_D
M]?\ %XV9_P",L/@)_P"_U^?/OW7NG7^<;_GI?_&7_P#-Z_\ > ^-'OW7NC)?
MS Z;O2H/P7R?3WQPW]\@L%UU\IMF=Q=K'KC=/6&&W-LS:&Q.O-[4%'-C\!VA
MO38.-W95;CS6ZX:9(H,G"]*L;RN&6RGW7NC$?&'YF=:?*3*]G;,P6U.U^J^W
M.DZ_&4/;O2_=>Q9]F;^V,FX<[OC [2RTE7CJ[<>P=W;;WG)UWE*C%Y/;V<S%
M#44L(9I4=O&/=>ZQ?*?YG]:?%+*]([/W'@-V]C=I_(O>^XMC=.]0=<9'K*E[
M WC5;,V+G^Q=[[@HX.U.QNL-N1[4V7MO 7R=8V2'V]37T4.AGJHP?=>Z*CT9
MM_+;O^5?R3_F#?)WK3LOHG9O6G4VTMD_'J3O_L'K)\-U?U33[3K-V_)#>F-P
M?5O:78_7VV*'<^=Q-#-DLU6UYK:BAQL:_M4\-F]U[H&NB/CYGOYJ6U-P_*WY
MB9WOK"?&;O/<.W=S?%OX54_;(VAUM/\ %[&;=II=@[S[\VYU:,5/O#>G?&0R
MU9N;(8;(YK*4F-PL^*QLNJ2GJHV]U[J[W"X;%[=P^)V_@Z&GQ>%P6,H,-A\9
M2((J3'8O&4L5%CZ&EC'$=/24D"1HOX50/?NO= /W)OWXW[C7</QK[HS6U<M#
MVMMIMC[FZVW!'6STNZ-L=EQU>TGP64%/!X(Z/<J5CT9#S1L?.@NID0GW'KPS
MT7E?Y4/P%50J=$S(J@*JKVSW<JJH%@JJO9("J!] .![]U[KO_AJ/X#_\^*J/
M_1M=W_\ VRO?NO=>_P"&H_@/_P ^*J/_ $;7=_\ ]LKW[KW2JV%_+7^$O6>_
M-G=F[/Z-H:/?'7V:;<>RLYE=Z]E[I;;6?;%Y+"_QK%X_=>\\WBH,I'BLQ50)
M/X#+''4.%(U'W[KW1YO?NO=%0^0GQ"V3\B-Y=>=B9+L;O7JG?G66W-^[/V[N
MWHGM3,=8YFHVIV5D=B9C=NWL[+C8:J#,XRMRO6V'J(TFC+0RTET(U-?W7NJ+
M/D1UY\JNJ.VH^OJG=M3W/\M/B-L/LKYI_P L[Y-;DZVS^]>S_DGT[M*#*8OY
M"_R]>^HMGX;#1;TW/D,3N#'4M+68BN@R&1:NP662A.0H)A+[KW5R^VOYB?QU
MS6Z>M]C9JB^077NZ>U-RXC8VSU[5^(GRMZGVUE=]9FBJZR@VLF].Q^FML[0I
M,G6KCZ@0+45T0F:(A238'W7NCU^_=>ZI%[\^26-^<>X_CSMSX?=4?+7?V4Z3
M^67QZ[JH_DOMW85?TS\>=L8; =LYSJ7O7&9/>O=5=UY6=PX?(="Y/?6.JZ':
M>*W%3R"OIF69)6B(]U[J[KW[KW4:LHZ/(T=5C\A2TU=05U-/1UU#60155'64
M=5$T%32U5-.KPU%-40NR.CJ5=2000??NO=:ZO\KS$;_Z9^3VQ>I\K5=?9;:=
M#T'\M_B/%+MO 9W 9"E_X;D^9T]-LO=6/IZG.9#%4F.[ VS\OYH<ACA#:AJ\
M%"U++X)FB3W7NMAO<*L^ SB*I=GP^3554%F9FHIP%51<L6)L!^??NO=$=_E7
M;GP&[_Y;7P8S&VL]C-R8R+XN=,X"7)8BOAR-+#F]H[(Q&T]SX.:>%W6'*;8W
M+A*O&5U.UI:2MI)8)%62-E'NO='Z]^Z]U7/_ #<*O:\/\MGYAXW=6$?<T>\.
MG<SUQM3;5/L^NW[D-Q]I=G5F/Z]Z=P&&VOC<5FJZOW#FNU]S8:FQTD=.6I*^
M6&HUQ>+RI[KW5A>.22/'T$<H998Z*E256Y99$@17#&YNP8&_OW7NJE?YP&$Q
M.(ZLZ+[VW)NK<.S-B=-=XTN#[EW+AML/NC'[:^/?R)V7NOXZ]Z;QW'%2XO+9
M+ XO9.P.R*G*+EX(BN,FI4FG!IA-[]U[I5_RH_DSB.T?CY@/CQO3<2I\G/BC
MM?:W6G<FR\IC\+@LS5;;HZ)Z+J3N#;%%@*VOV[NOJ7M[K^@HLG@MQX6:HP^2
M#2HCQS1301^Z]U:9[]U[HG_=OSX^(OQ[W=0=;]D]U[=';66J,)2X?I/8=#N#
MMGO/,2;CK,C0X9\7TMU7B-Y=GUU+65&(JQYX\4T"+2RL[JL;$>Z]UKH[CR/Q
MTVMT/_+SZZ^9>^<+U138K^6C\U\IMG8'9?;.YNE,S1_(#&;K^,M?L:AJML8O
M=^SLY)V=BMOY7(_;8RNB>NI8I*L+"DBRZ?=>ZM=^)G\LKX7;U^*_QHWEO;IS
M,9C>>[?C]TUN;=V7R_;7>?\ %<IN?/=<[<RN>R.3\O8Z2?Q"NRM7++-J ;R,
M;@'W[KW1@?\ AJ/X#_\ /BJC_P!&UW?_ /;*]^Z]U[_AJ/X#_P#/BJC_ -&U
MW?\ _;*]^Z]U[_AJ/X#_ //BJC_T;7=__P!LKW[KW7O^&H_@/_SXJH_]&UW?
M_P#;*]^Z]U[_ (:C^ __ #XJH_\ 1M=W_P#VRO?NO=>_X:C^ _\ SXJH_P#1
MM=W_ /VRO?NO=>_X:C^ _P#SXJH_]&UW?_\ ;*]^Z]U[_AJ/X#_\^*J/_1M=
MW_\ VRO?NO=>_P"&H_@/_P ^*J/_ $;7=_\ ]LKW[KW1%,YD/A[_ "[?F3\A
M^O*KL7:7QQZY[1^ 77.>V]MWLON#<L>WMV]CP]I_(W!Y>MVS'V5NW+T]1N2+
M!1XV"J2@*SM :<2*P\?OW7NBC=9[U_ES=N?'?X78'J_X]R?/7YWYSXE_$'K?
M<?7O1F]^Q]JP;0QNU.NMN;7J<G\G.X]DUR]==*;8ZS9LF)6W )<T94:DHJ&H
MEDTCW7NKJOY9WQ'W9\-?C3-LKLO-T^0[0[%[-[%[P[*P^"[ [)["ZSZYSW8>
M76?&=3]/9;MC+9;=U'U=U9LO&8K!T"S/"M;-0SY$P02ULD:^Z]TCOY:VXLCW
M/-\P_EQ]Q0R;)^3?RGW-6]/C'[<W-M^')]/]%;4VM\<]A[V+[K,5?F/](^-Z
MN.;2JAIZ:C:*M1859%\C^Z]UW_,GZ6[$.U]G_-KXV4.;K?E;\*Z?/[YVAM/;
MBTGW'?\ TO7U."R/?OQGS=.^UMV5^7/9>Q=N3-MI*:F:JHMWTN.G@*WE#^Z]
MT,VX,1\8?YI7PJ>/'93"=H?'[Y)]=R5VU=W8VF2>LPE;4)408G=>!7*4L.0V
MMV3UCNVD+QB:*FR6%SF.:*9(IX9(U]U[HI_6O\L/=F[(NN]Q?S*/E5N+YQR]
M-5.!S&Q^K<CLW;W4OQ6P^4V"^]*?:?8&\NF<3/E:3M/?]#A-QT\\V1W37Y*E
MI<ECXJFEIH&C1A[KW0Z=G_S-?A7TUE\CU5M7?-9WCVUM3!;GDI_CK\1]C;A^
M0_:U''L&CPT=9MRIV;U%C,]C^OYDFSF/H*0[BJ<'CA454<;3QJDC1^Z]TA,M
MVQ_-'[Z?,XSI'XX=1?"[:+MNG%8SM'Y=[O@[B[6G7^[N.3;FXL3\>NA<^=EX
M=HMRY"H91D]_URRP8\&6D43JH]U[KJG_ )6/7O:.XZS>WSI[B[5^=VY)1)38
M;:_:M;2[&Z!VCBYJ;8XJ<?MOXZ=8G;O6M1)7Y+8T574U68@R]74/55$;R&*0
MH?=>ZLBV7L79'6^WJ/:/7>S=J["VGCGJ9,?MC9>WL1M;;U!)6U$E96/1X7!T
M=#C:5ZNKF>64I$IDD<LUV)/OW7NE5[]U[KWOW7NO>_=>Z][]U[KWOW7NB^=W
M_++XR?&K!G<??G?75'4N*-958VGDWOO? X6LR.5HL57YNHPV'Q-16C+9K.+B
M<743K14D$]6\<+%8VM[]U[HHN0_F7-O7%YFH^*GPP^9GR9J*?85#O#![DJNI
MO]E?ZCR>0SZ94[8P%7V/\M<GTS6O#6QXV.JKJ_!X7<$&+QU7!/*K-(D+>Z]U
M7=WO\WNZ]];NS75O:GR_ZYZ*J,57[HRV0^)?\JO:G8/SA^>>Y<#LFDV;N5=F
M;@[;Q.SJG;W3F1W-!)-3O6?W/P?CBRU+$N3B8R3)[KW2F^._\O3N_>F,FVOM
M?K.3^61\8]PUZ/V35[?['J>R_P":#\K,?B:7-[.2;O;Y.4V4W#2=18O>>$VW
MMG)UE#B<MN7.!1+3KDJ!P57W7NCR=I5O\MSX2?%7<OQ=._OB=\9.OMV]5]B;
M3V]LO>>Z-B[>Q^Z),;LNEVSG<WN/%Y*HGS6_\G0PUN.&:KZJ+(5]0TD7W#22
M2(&]U[HC6+SF_>[O@1_([BVUN+,_';L?)]W=(;?P^XSM_";XS>"I]E_$'Y0;
M4H-Z8[:_8NW\=1Y3"]B8+;BY&@.3QD,T6.RT4IB6>,6]U[I5X_L+YSU7R%^1
M/1-5\N/D-34GQYRG6./R&_Z7XQ_%?(XW>-/VIUIN_L/!9C;^&CZVAGCQ%/4[
M4.%EF:ID'\2J-/'C(;PKUX5/V=#Y\<\!\N_DIUQ-V+MG^8EW9M*#'[Y['ZVS
M6W]Z_$OXJ8_-X[=O5.^,[UWN^%%HMKUU-6X@[CVY4FAJU=?NZ0QRE(RY1?=>
MZ'?_ &6'YO\ _>S7?_\ Z2U\7_\ ["_?NO=>_P!EA^;_ /WLUW__ .DM?%__
M .POW[KW7O\ 98?F_P#][-=__P#I+7Q?_P#L+]^Z]U[_ &6'YO\ _>S7?_\
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M>_=>Z]_PXKMS_O$/^8;_ .D:=J__ %)[]U[KW_#BNW/^\0_YAO\ Z1IVK_\
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M9QHXHY*B:0)&"SDD^_=>Z2W\XW_/2_\ C+_^;U_[P'QH]^Z]U>%B?^+5C/\
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M2I<W3[<^"'P^IZO<,*9:7JKI#+?,?Y#2==[+I=XT_6NTJWY&_+RKRFTZJO\
MXUN*+-9:MI.OJ*5ZE98X6#S/4>_=>ZY]N]:_RMNFFQV6^?WS\WS\F]Y[>VQV
M#OJ':_>_RCSFXZ?)QY+(25VX-P[*^-?3F1P.W$KZ5:$8G"T.(P,C1HGVE'"]
M1(VOW7NARZR[YVCUKBJW9W\NW^4KWC6P;9V?L';&$W'D^F=B?!+JVHHZN>?&
MXC;63W1WTVP^W<UA=GX?$+6Y&LQ.T-QQP)) JB:HFT#W7NAEKMM?S8.X)LM3
MY+LGXE_"_:4^[ML#'0]7;5WC\J^Y:?9&+@V]6[KDINQ.T(>JNI*#<&Z\E'DZ
M&FCJ.OLI#C*!X9B]147">Z]U$7^5WL3?]32Y+Y6_(WY6?+FJAWED=\5&V.RN
MX,KLGIR?*U&)RF#Q%+%T?TS#UWUQ3XG;..R\K45/]FZ_=VJ9?)*J,ONO=&[Z
M5^*'QG^.5!08[HKH?JKJQ,;#EZ>FK]G[)P6+SS1Y_+56=SOWNY8Z-MPY*3,Y
MFMEJJIZFJE>HGD+N6;GW[KW1@O?NO=4B_,_M_P"9_P F?DA6_"SX.9*39'4G
M5%3UIB?GYW_L_/4.V>\-JXGY TF8P]!L'XV9O?FP-Q]94^_NJ=BY"EW_ +FJ
MON?XU'C)J"DQ3T^1EM)[KW5?>/Z6^*W\O/\ G>]*_%*IV=U/DOCO\]?B;!3[
M,V3VKLFO[/W%A>__ (_5-3BL;GW["WW6[PK\INKM;:\U9_$J_(M"L\F.B1G>
MIF1I/=>ZLF[7_E6[@V/W+3?(O^6_W#@/@]OS$;![8@RO5VVNOJ/-]"]\]C]@
M;NV[O*DG[LV-55TV%H-H05N+R*F3;>/QF<HZS,RUT%63&U-/[KW1Y/A)\GA\
MMOCUM7M;*;6DZ\[$H\EN7KSNKJVI?)M7]5]V=;YVNV=V?L"L.9Q>%RLBX'=6
M)J%IIIJ6$U-&\,R@I(K'W7N@S^<7_,QOY<7_ (T V[_\"K\L??NO=0=[5?PB
MW/@?ESVAO+K+%9M>I-]-UGWG75^WI1FLYOG;&U.O-Z8?&;69J^$U.4R-/OK!
MTU%4TLE')45\JQ.XT:O?NO=)#)_(?^7U29_9AJ=K[:7=75_QTV5VMU/04FT:
M"')4'1NZMY[:KX8^NX*>>&E--M;>VPL'/E:.$HU%4TU(]F"DKOYCK8'F.F/9
M-;\#,UM7OG.5/Q13KV&IZWB[_P"Q]N[LZIP6,G[.Z[J]][H[@H-]8D8O)9/;
MFX!4]GQY#,Z/N8:JGS$_GF2-I0YU0<.M4'P] ]LGY7?R[:;L3?>*V'\=,O\
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M-EW>>E0I)6)42Q"ZHRJ2#[KW1B?^&L?A-_S[_LW_ -*D^5O_ -NWW[KW7O\
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MYL%B<;N?;'8&U:&6MQN2Q,]=13Q1M^Z&!7W[KW5F7OW7NNB0H+,0JJ"68D
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M=N5FUZS>7=OV/SD^3U5N/;=2<C2;HQM;N3!_%J#,;.Z#J:? XO+9#'X>+";
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MV;>65^9F=DPR5DM+53P4U7.'4!(UCC1HE]ZSQ/6L\3U<Y_H5_F-_]YY]$?\
MI!]9_P#=:>_=>ZJ?WEU;W=G>W=J]<=M?(38.$W3#V9N*79!_V1G%[FV]G=T?
MZ9MK;URF=RD^V/EM.F%I_P"^>\J:>*/(M$&H9ZBFLUV5O5QGK1-!W>HQ_@ZM
M@_T*_P QO_O//HC_ -(/K/\ [K3W[K?7O]"O\QO_ +SSZ(_](/K/_NM/?NO=
M59[(ZS^4@Q/\Q:+LCY==/S['C^<4^([!HF^$M7F3NO<M+\</B[FH<_CZ>D^5
M.VY=NXY<=#0TYH14U<DLM&[^>0U8IT]GRZ]GRZ ;)?'G9??&/V+LW.]Y;'W#
MA?D_DL/MZDGSOP*[.VNV\GQ>X,7A,?CM_P ^4^<N!W%)2[)S%9 M-15RR2T
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M#'IO,]O8&NKMR8[_ &:/OO(U7Q7^"^U:?:NZ*/:^<W+6=]]F8JDKNUZ"E/\
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M[^_=>Z]_PY3\9_\ G2?+#_T@?YR__<[^_=>Z]_PY3\9_^=)\L/\ T@?YR_\
MW._OW7NB1_S%OG9T-VC\0^QNO]K8GY&4^X-T[HZ2QF*FWA\.OEMUYMF.J;OG
MK*8-F-Z[_P"E-M;-V[2:(3>HR%?30!K+KU,H/NO=7K>_=>ZK9ZUQ60SOSO\
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MR>?^%$/77??3N\_E!VCV'\@N@MEYBLJ.TNG,+_,P[JVOE^UL+44&5CIJ"MW
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M2U*1/3.KG0.:=>!S3HS7\Q#:?QW[+^)O?&3Q_P 9,ULC=GQL[7ZGAV9N_?\
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M">_=>Z]_HMZ&_P"\DOYV/_GB_F1__:$]^Z]U[_1;T-_WDE_.Q_\ /%_,C_\
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..ZQ:B/=;ZOM]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>nt10016217x4_ex10-15img06.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img06.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!Y0*\ P$1  (1 0,1 ?_$ :(    & @,!
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M"];;9W'N;;N)V/U[O'&;XK<'N[Y3X/(8\9=][2P(L4;TS)2!T<EF ]U[H]6
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M^_=>Z+SD/^WKNTO_ !GIV'_\$CUA[]U[JPOW[KW5?FW_ /MZEVY_XS\^.O\
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M?=0(U?-'MTK<:@/C+_+:4D7Y 8_")K$C\V/OW7NJ=INK\KOK=WQT[:[&V_\
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MCD-12F6-G0(ZL?=>^?0V>_=>ZU[/Y3NP]C[VRNP_[Y[,VIN[^'?RK_@(N/\
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MS<S&#RC8;<'QIZSI-W9*#-8RNRU!WQT#4;2VG183.04@B[*R^4W/A-WT.)W
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MN*OCQB5U7A8<Y44V*DJIUI%R,4],M0PTB4.@:]Q[]4]>J?7I*?-JG@IOA/\
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M="\BHP34PT^_=>Z/-_L^>\/^]>/\PG_T6W1?_P!T7[]U[KW^SY[P_P"]>/\
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M7O[I_P Q;_O'O^6-_P"C&[S_ /N</?NO=0\?U#_,JW+N^GR,FZO@!\8MOXC
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M9:+M;M+JK'28R>680K]E4UE2LG+PI'Z_?NO=#O\ [.OVG_WK=^>W_G'\/_\
M[K_W[KW7O]G7[3_[UN_/;_SC^'__ -U_[]U[KW^SK]I_]ZW?GM_YQ_#_ /\
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M_P#9G[]U[KW\$^"G_>AKLK_TW[\5O_LS]^Z]U[^"?!3_ +T-=E?^F_?BM_\
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M]&GP*;(WUU%M??FU<U7;OPDVWI\EM;>.R>N/CSN*3%X"DK%PNV\?M[&X@U>
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MR\/_ +B+W[KW7O\ AO3=?_><7R*_]$M_+P_^XB]^Z]U[_AO3=?\ WG%\BO\
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M]_-._P#18_R/O_ME>_=>Z]_$OYE?_*]_-._]%C_(^_\ ME>_=>Z]_$OYE?\
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MZ]T2_P"9/1N+^2GS;R/264W]5=8#>?\ +SSE3CM]T%%A\G7;:S>SOF)T9OC
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MD60,@WI:A/D/\O6]#4+4P*5_/J)GZ3XD[7EZQASG\VSYKT/^F7<DFT>LI_\
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M@,SUE7UV)DI]RI7P:LBT<-=11/X6/(]U[I;_ .@S^8O_ -[ .G__ $A:C_\
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MJ,Y!CGIX\A/AX=U9K%29.&ADJXEF:$.L1E0,06%_=>Z"X?/'X.-<+\S/BBQ
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MPG^/V]L;M&3;$3X&@W=N'O;Y+8/.;DI,>TI@@S.5PVU\=2SU"@2204<2$E4
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MOW7NO?\ #I/\N+_O-_XQ_P#HX-F?_77W[KW7O^'2?Y<7_>;_ ,8__1P;,_\
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MO>_=>Z][]U[KWOW7NO>_=>Z(S_,T_P"W?7S$_P#%?^QO_=#4^_=>Z3W\K?\
M[(KV'_XE'Y3_ /P5_=WOW7NK!_?NO=5__P Q/_F7GQO_ /&@'P*_^"BZW]^Z
M]UF_F3_]DW;:_P#%N/@'_P#!R_'GW[KW1^O?NO=>]^Z]U0_\D/\ M]U\1_\
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MNCI[:N1P%)%\B>K)8LODJON7LGK/#U-#4R.T2)15-75"1;O"L9\@]U[H=_\
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MVUNO"T<6!R>/SM%BI_CI4T==33U>/D5<G%-$\AB>(^Z]T2KX>?\ ;X_YG_\
M:F[U_P"MOP4]^Z]U?G[]U[I =K_\RM[*_P## WE_[SN1]^Z]U3C_ ";?\_O?
M_P 4@_E+_P#P)E=[]U[J\WW[KW7O?NO=>]^Z]U[W[KW7O?NO=$9_F:?]N^OF
M)_XK_P!C?^Z&I]^Z]TGOY6__ &17L/\ \2C\I_\ X*_N[W[KW5@_OW7NJ_\
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M58_=N%P&V\AN.D.(S%+W/6X]J?,P402.I1IXT$FL"0"QM^Z=Z\MVF_[)[?\
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M\L/_ (+?O+W[KW5@GOW7NM0WYW=J_"#XR_S$OE'\U/FGV_\ (RF[(ZMK-T=
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M>_=>Z][]U[KWOW7NJ./YQ_\ P+ZN_P#%3/YJ?_P&&;]^Z]T.F]_^9N?R9O\
MPX>RO_@".W_?NO=#-_,)_P"92]+_ /B]O\O#_P"#:Z)]^Z]TT?RN_P#LC'9?
M_B6OEA_\%OWE[]U[JP3W[KW6C)_.@P&"WY\AOYHNU]^]54FY]L;3^/OR;[)V
M3N[/4>WMP86C[,P'\O?X29+&UF,Q4LU3FMM;FV!+AJ.LILK+3PQ&;(PI2RM-
M',(P9O04\X[(6%6"7E,5H?"7S\L5%?/AY]9,^V+3K]VOW0$,@2)KGEL.I8+X
MB_7RD* ?C(<*^D< I;@#T(__  F4^"7P(^0/\K_IG<WR!^$/1?>'96[^S_D8
MM1VIO[X_;,W]4TF,V3N_#T5!A=U;]S.!KJG'/)2Y1$P])436F2GJ?"H\4GL9
M]8S=;-G7OP6^!GP_SK]U=!?";I'K+L"AI(MKQ[DZ$Z$VCBNQ3A]W9?$X;(T5
M)-M'!T>9DPI>:*HR(5_%%1T[S2#1$??NO=-O\S?(+B/AKV-EWI,A7IB-S]09
M9Z#$4<N2R]>F,[AV+7-08G'0!JC(Y6M6 Q4U/'^Y/,RHO+#V"?<+_E59O^:U
MO_U?CZR:^Z!_T_C;?^E?NO\ W:KSHCW_  G/R2YG^6^V72CR..3*_+?YMY),
M?F**;&Y:A6N^3W9-4M'E,=4 3T&1IA+HG@<!XI593R#[',G]HW^F/^'K%VT_
MW$B_YIK_ (!U>W[ITHZ!/<WR)Z@VGO.#K[+[NIANU\OM_"UV*HZ6MK!@ZO=%
M_P""/N"N@@;'X:GK/3ZYY5T"6,L KJ3[KW1#NR_YE3;<7M_9V)ZGW51=F;:?
M=>%ZWQLD3[G_ +Q;DV_)D,;34V;H-IT>=J<,U=FZ6"%(W!4FKCC>2.74J^/#
MKQP.D[N[I#Y0_-+IKJ3<._XL+U3W!L#=>Z*"O7.8.MVKM>>DRN/H<97;YQ76
MVZ]N=I5\F6VWDJ>H3"B2KQ<V2I )Q74<54T/O7'\NM<?M'[#T8OXI? 78OQ4
MW_O7LW ]@]@[IW+OG:^%V5D<5D\A%0[$HMM[7>EAVQ]AM2$53ON+'8O'PT\N
M4J:RHJJF\S$HLOC3?G7K?F3Z]'T]^Z]UKE_,[Y$=[=G_ "6S79G0>Y^T6Z;^
M!7R9^'OQLH>N.L.P:OKNC^6/RF[O^1_3\/>VP=RYD]D[>V-GMG]3=39+'[76
MAW3C!C$W!N/+$U(-(I7W7NA>_F!?)'Y.U_Q@W#E.POY?/=/6_6^P>TOC9W!V
M7V"G;/QT['_N5UGTE\E.I.WNP]U2;'ZV[-W'OG<,&#V;LBMJ)8<;0U,ZQHSE
M=",1[KW2%ZP*M_,SQ$B,&2;^8A\W9XV4W#Q3_P MWXGS1,/\&C<'W[KW6PA[
M]U[I =K_ /,K>RO_  P-Y?\ O.Y'W[KW5./\FW_/[W_\4@_E+_\ P)E=[]U[
MJ\WW[KW7O?NO=(KL?-[KVUL+=VX-C;67>^[\+@,CD]O;0:O7%G<F2HJ=YX,-
M%7O%,E-45Y0QQ$K8R%02 ;CW7N@J^,V\>]=\["K<_P!_; H>N=SUN<:MP.WZ
M,+%+2;3R6(Q.1H<=F(#F<Q4#/X')557054K?;+4FG69((@Y1?=>Z,5[]U[H@
M_P#--_[=Q?-K_P 5M[4_]Y>N]^Z]TU_ +_B^?/S_ ,:&=U?^^[Z8]^Z]U89[
M]U[JL[^;3L?961^ 'RXW%D-H;7KMP+U%6JN=K-OXFJS*K3Y'%"G5<G/2/6A8
M HT#7Z;"UO?NO=+?^:1AL1D?Y;WS=I,ABL;7TM#\6>[:NBIJRAI:JGHZN@ZY
MW U#54L,\3QT]11L 8G0!HR/21[]U[HY>R=J[8VK@Z.GVQMS [<IZNCH)ZJ#
M X?'X>&IG6CBC6:HBQ]/3I-*J>D,P) X]^Z]TK_?NO=4/_)#_M]U\1__  Q^
ME?\ WV7\VGW[KW5\'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JA7X>_]EQ[6
M_P#$J?SV?_@R_AO[]U[J^KW[KW7O?NO=:E/Q]_X\'XC?^&+_ ,)Z_P#X,GYK
M>_=>ZVUO?NO=4:].?!#XM_,#M;^87V9\ANMIM_\ ::?-VMV#MSM:7>6^L'V=
MUSL_I38'36?ZNP/4>_-N[DQ6Y>I*+:6>RU96PC;E1C#-55D\DYE:5[^Z]T;O
MX!T&3VMGOG+UE-OGM#?6V>JOF96;3V'4=M]H[^[@W3@-L93XQ_&3?E1M^+>O
M9FX=T[MJ<1%NO>63JX8)JV2.!ZMQ&%4V]^Z]T:W?_?O5'6.\=F=?[SW7#B]Z
M=@19>KVGMU*'(UE?E<;MVBJ<IN/+*:2DFIZ?&[?Q-%/5U<DCIXJ:"22Q"&WN
MO5Z)!V7_ #0>L,7/B_\ 0;M+=OR!Q:;LV[MS<NX=BX',9# TYW-CT:CH=N5E
M'15%1N/<M)E,OC%J**G@<QPR5()$U,\8U6O#AUJM>'#JS3&U\&4QU!DZ4NU-
MD:*EKJ<R12P2&"K@2>(O!.D<\+Z)!='574\$ @CWOK?1$^KO^WE7S(_\5.^"
MG_OQ/F_[]U[K!MO_ +>G=S?^,_\ XS?_  1?RT]^Z]U8![]U[H..M>WNL^XL
M=F<QU=O3!;YQ&W]Q97:F5RNW:M<AC:?<&#J7HLOC4KHA]M52X^LB>&1HF=!*
MC+>ZGW[KW11OYB?_ #+SXW_^- /@5_\ !1=;^_=>ZS?S)_\ LF[;7_BW'P#_
M /@Y?CS[]U[H_7OW7NO>_=>ZTXJC8VY:GXP]-C;>Z)QE.XOY9':6^=G;-V]@
M,75]AUW;_P#+1^8F,^2'6M+LN;.568Q6[J+>U!WKG:;-;>_@<U;/18M)*2K@
M<N5]U[J\G^3/V)3;S^"^R]I4D>[Q2=&[SW]TS@:K>F?GW1DJ_KK"9L[LZ2J*
M+/9#-9[.UV'BZ)WIMB"G7)S+DZ7PM3U*++";^Z]U77W9O"N^,O\ ,ZR6:S&_
M=G8_;6W_ )B_'3Y!/1;FV3GJ>K7J_P">?2N1^#W:E54[EIMXQ8XXGKCL;I;:
M,M!FUHEIZ2OW+_#Z^G<34U0/=>ZLP_F(;LINEM_? WY0;CVYD,KUCT7\H<GC
MNVMQ8:GIZS(]>;-[XZ0[3Z$H-]UM$3_$ZS:.W]\[_P /-FA1)/404*M4^)T@
M8K[KW6*#^9Y@=[;9QF?Z#^('SE[S;=64QN,V!4XOX[;EZZV3O&GR6XHL"-RI
MV7VK)L_9NV]G4T)EKWR64J*2$T,7D4,70-[KW1;?DGW%\L>R.]/Y?V)[*^'<
MGQXZ?QOS:ZMR.0WIOOO/K'>^^,[OJ7KOO.FPNV-G;(ZAK=\XJ3!Q8]6J<EDL
MOE\2\-TBIJ:J8NT?NO=7G^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HKOSA_P"R*_E]_P"*N]__
M /OI]V^_=>Z1_P#W3M_\LM_^8;[]U[I#9#_MZ[M+_P 9Z=A__!(]8>_=>ZL+
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4<?SC_^!?5W_BIG\U/_ . PS?OW
M7NATWO\ \S<_DS?^'#V5_P# $=O^_=>Z&;^83_S*7I?_ ,7M_EX?_!M=$^_=
M>Z:/Y7?_ &1CLO\ \2U\L/\ X+?O+W[KW5@GOW7NM)O^;_E<:G>_\TC$MGJ.
MDRC?&SYIS_P3ST+5V2IZC^6M\&6IU:FE+5D,%L?/.DD876:5QJ*JX]@S>F Y
MQV0%J$I>4&.[])33/IQQG'I7K)GVQC=_NU>Z#I"9%2YY;+-W?I W\JAS0T[B
M1'W5%7QW4Z.I_P )+-Y[2Q7\HSHO8^3W)A*#>6\>VOD_F-J;7J\E2P9W<>*V
M?OC$)NK(X;&22K5Y&BVZVY,>*V2)&6G-;#K(\BW&?6,W5QO=/QUJ<=\G=E?,
MS=GSR^1O3G577T.T]O9GXW4V_MG;<^+.\<ID:[);1PLV]<1E]MR9BIR^ZMQ;
MTH8%$>3A^XKH*-$7596]U[J5_,VRF.P?PV[%SF8K(,=A\'NCI_-9C)5<JPTF
M-Q.([BV)D<GD:N9B%AI*&AII)97/"QH2?I[!/N%_RJLW_-:#_J_'UDU]T#_I
M_&V_]*_=?^[5>=$>_P"$Z&6QF>_EP/G,+74V3P^:^7'S;RV)R5'*LU)D,9D?
MD]V564%=2S*2LM-5TLR2(PX96!]CF3^T;_3'_#UB[:?[B1?\TU_P#J]KW3I1
MU0;DE[*^77RC[\[A^.OQ2_OOTMLW/8OX\[IWGWC\@LI\<-I?(7L3HC=^?I]Z
M5_5NV\-\?NW=^U6Q>M-\4'\!K,_+4X:CW'E,<\=-%54V.6H;W6CGS/2=Z<VC
M\O\ :_R)[$ZD[T_F&[4Z0[*I_CET#WKV!DNMNC?AQC,3F^S.Y>P?D)A-[[<P
M^ZM\=%87<F^-G;03J['K0Y#(4T>4J)JN:6K):2-5]UOI=]X;F^0O66]OBWMK
M;G\W3+9_']X_(1NI=XUE3U=\&IIML;87I#NGLP9[&O0=2)!35YW%UOCZ'R5:
MRTWBKG71Y6B8>Z]T$7RL^1/R]^*';WQ+?K3^87BODQM3>_8.0;N+K_?74?QL
MJ:',[ QN[NH]C5&'P^8Z3VEL3=6TLY45';/WD&2:LGACFH8HWII8Y)$;W7NK
MIOE_WXWQ=^,O=/?=/MNMWEE>M]D9#+;;VECQ0_<;GWA6R4^$V7@&?)YG;M!!
M29?=F4HH*B66NI4AIY'D,BZ;^_=>ZK0S_P >-R_&;X(_$OK_ +"W%4[Q[CW!
M_,!^$':_?.[ZFIKZC^\W>O;OS@ZN[![4R-$M?G]SO2XB#=N>J*2@@CK9X8J&
MFA5#;W[KW1I?Y@_:G6^\O@E_,0V=M3?&V=P[JV9\2/D1%NO;^(R])6Y7 2'J
M[>-)IR='!(TU+_E=/)$2PL)$9?U CW[Y>?7O.GGT0+J7_MY+M?\ \7]^9?\
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MSJJE>HI(*LT\[Q>5%C<NONO=&!WO_P S<_DS?^'#V5_\ 1V_[]U[H9OYA/\
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MBW%V6NR>O_D3U]N/?.1VW@-FX1]RYB7&;4HZN>:"D5Y7IDD&DBX]^Z]TM_\
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ML[<ZQ_X3\YS<.X<]D:/#X/!X;&?,'YLU>1RN7RN0FIZ''8ZAIHVDEFFD2.-
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M[KW3UVQ_V\E^%7_BKOSP_P#>V^$WOW7NC]>_=>Z][]U[JO\ _F)_\R\^-_\
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M=(']U[K7/_F]=>29#Y;_ ,S_ + V[@)*C(X7XM?*C(]J9CQM6TU3U!M;X+?
M+$5.VG%1N[!KMC)9:I[(JJ;'9>BQ^9GBKJN,5-&].//3!7F/9-TW.YL[_9[F
M&VO;0RD&2(R@^*F@T4.F0"3FM>I_]EO=+D+D;8^8^4O<C8]PWSE?F&.Q$D=G
M?)82(;&Y^I2LKVUR2KN IT*K >?0A?\ ">SXU]E?(7^6/\=-]]6Y7I':6RNI
M?D'W3NWJ? ]K;,[3WSN_9N^J?>-"^2W$VYMD]O\ 6F$S\%77XV.2"CK\3/!
MB!6\NIO:*';^?XTTR;EM\C^IM''\A/3'0CW'FW[H5[=_46G)?.5G;BE(DYAM
MI%J"<EI-H+FHIBN. /F=BW=72G\PG>V#J=N;H^0'Q3RN&JJC%UDU$_QY[*I%
M:MPF5H<[B:GS8[O6BJP:+,8V"<() CF,*X9"RM<6//H.=PV\_P#4*_\ UOZ9
M/-'W2"/^51YS'#_EO6GE_P!2GSX'Y<.B;_S%>I/FYE?AMW/C>_.^^@]]].9&
MEV;BNQ=F;(Z+W5LC=>YMIYKL':F#S>&PF\*GM7.P[;KJS'Y)]%9]E4M$P&E
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MW7NJV_YHNZL;L;H_I/>F9I<_6XG:WSH^"V<R5'M7;&XM[;FJ:.A^3_6\DT.
MV=M#%YO=>Z,JZ_YJBQM'55DYXCB8\>_=>Z _Y9_*O9/R/ZYV%U)U1U;\MLIO
M7-_*7X89NFAW#\*/EML7 4>#V+\MNE]^[OS><WAO?IG;^TMNX?;^TMLUU;4U
M-?6T\*10'U7L#[KW5RGOW7ND9V%V+L#J39>XNR.T][;4ZXZ^VC0'*;JWQOC/
MXO:VT]MXT314YK\YN#-U5%BL71B>=$\D\J)K=1>Y'OW7NM?GXE_/WKOXZ_%B
M?J3H+:_;'RD[9[ [;^4V\/@1\<,)@MY_WNWA\8:OY%9C;/4G:V^MW;KP%%2]
M(_%.#([D0P;\WE)C\7+@J>:3&OD7IQ"WNO=5Y]Y?(+M_=^X]S?(W>?>^=WMO
MG86_<_\ 'FM^571VV(JKXT_'+=/86T=O;0WO\3_Y2'1^>W+G>S?F3\^NS]P8
MV?:J[XGI9,#MZIGJJBIGI(J2>@C]U[J\+^5S\).Q>D<+@.\.]<5!UEOC_0CM
MOH/I#XK[7S=)G=D_$CXV83)4.XL5USG=TX^""+MSY ;RSE!3YGL+>$FJ'(9X
M-!0@4<"RU'NO=7!^_=>ZJQ^27\TWK+K+>6]NF?CUMW#?)GNOK'"UNXN[IX>U
M=A=3_''XH[<Q6X\;@<QG_EY\E-XUL^T^G9:&GGKJV';])19W=]=3XFI:/$K"
M!/[]U[K7EW%OS=/>W=OPP^8?S SN'[M^-&-^7&V^ONSOE9V\^%ZI^"N,JJ7
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M\CNOJO?,^5&-H$F;;$&U(*MLIY+TWV0D$W[9(/NO=')_TZ?R'/\ GKOY8_\
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M7NO??47_ "N4O_G1%_T?[]U[KWWU%_RN4O\ YT1?]'^_=>Z)I_,7W5M;;?\
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MW4IL?Y?'\PGC^G5G33#_ &Z]_D'W[KW7:_//=3<C^7Q_,(_Y"ZNZ97_>&^0
M/OW7N@:[K_FN;$Z>V\B=O?%SY9]0G>%)F\3M.?L^B^-FP(=P92GQQDJ*/"3[
MG^2V+7)5-%'41O,L&MH4=6:P(/OW7N@,^"_S<_EO?"WX:_%GI#,]Q]!=<[WQ
M'Q^ZDW%W?A.F*'';[VYLG?\ 6X786PM];V[XWET%A]X=?[!R&1[$R$%#D=Q;
MHR5%!65=W:KE2-I%]U[HO?8W="?)_P"4M3\C^E\=D\M\1]Q]_P#\G3J?:/<.
MY=E[RV=3=P=H=<_*OMS>V7RG2LNYJ+$'>74^ VOW#34]9GA1K15^5D1,;/4P
M0SR>_=>ZN!_F9?\ ;OCYE_\ BNG:?_O*Y#W[KW2:_E;?]D6[*_\ $M?+'_X+
MCO/W[KW5A'OW7NO>_=>Z][]U[KWOW7NO>_=>Z(+VQ_V\E^%7_BKOSP_][;X3
M>_=>Z/U[]U[KWOW7NJ__ .8G_P R\^-__C0#X%?_  476_OW7NK /?NO=$O^
M77SFZ@^(E%@\#GJ3=79_?'8F)S]7T?\ &CJ? 9/>7<G<F1P+4%-4PX'!XFCJ
MX-M[8HLCEZ2+);CS4E!@<2DVNIJEL$;W7NJON\-G2[5QF!^9_P#.$J<3VKOI
M\]UCMSX=?RV^@\ANS=G6]#WJU1C]Q[2VEMW8\U=CU^5'R:S>_*4:<QF:.7;F
MW:"@-52P4M+%45H]U[JHKKW9WR^^;?;^_.B>H>I=K=HXGM#/5O=7\TWY(YS=
M6Z=L?'[LWOANQY]O[+^!T7>6W_XAN#O#XT_$'8$+XG+[5Z]KTH,QF,?54%15
M4E'55C5ONO=;(/Q _E==5_'S(=9]K=LYZL[^^1_76 JZ#:.[<M04&TNG.BY]
MP8^:BW5@_BI\>=ITV'ZKZ*VI5T]9+2)+18Z7/5%$S+59"8RS!_=>Z-U\G/EA
MT%\/.M:_M/Y ]BX38V B6HI]O8B>IBJ]Z]B;BCA\M%L;J[95.[;C[$W[FY2D
M-%B,53U-942R+9 MV'NO=:^ORC^;_P NOE-O;>7QTVEL[NGJ(U$5'68[X9?'
M[#--\ZMY;*R5)2;EV/G/E7\AZ//'IW^7KUUVI%M;*QB"#+UO8'\%JHI*:%9I
M0%]U[I)XGX^]1] [PZXZ#[=ZQVY\W?E7M;<5)OKHS^53\=Z#(S?"SXO4G;M-
MD*>J[P^0>[.Q]N;DH<QO%GHMQ92I[![1R-?F\G65\CX3%&>:.4>Z]T8#OWJ'
MMOJ+>WP8^:W\Q+Y/;=?L&/YC=*;=EV/A=RR=5?#WXM[:S.QN^JK+8?$4^6S^
M.PO8FYZJLRE#BY]Y[K0UDAID3'PT"3F-_=>Z,'_,X^<?P:W9\&.^-O;0^8'Q
M0W+N#(T6PEH<'MOY =09G,U_VW:NQ:RH6DQF+W;4UM5X*:F>5PB-I2,L;!21
M[KW1]&_F"_R]RS%_F]\-2Y8EBWR4Z1U%K^K5?>E]5_K?W[KW7'_AP7^7I_WF
M[\,__2E.D?\ [-/?NO=>_P"'!?Y>G_>;OPS_ /2E.D?_ +-/?NO=>_X<%_EZ
M?]YN_#/_ -*4Z1_^S3W[KW7O^'!?Y>G_ 'F[\,__ $I3I'_[-/?NO=>_X<%_
MEZ?]YN_#/_TI3I'_ .S3W[KW7O\ AP7^7I_WF[\,_P#TI3I'_P"S3W[KW1'O
MGM\YO@QN+KOH>EVU\P_B=G:C'?.3X,[AR=-@_D%T_DYJ' ;=^3_6N6S^<KH:
M#=T[TN'P6'I9ZFLJ9 L-+31O)(RHK$>Z]T>'_AP7^7K_ -YN_#/_ -*4Z1_^
MS3W[KW7O^'!?Y>G_ 'F[\,__ $I3I'_[-/?NO=$AZW^<_P %Z7^89\M-S5GS
M#^)U/MG-?%[X58?"[@J?D'T_%@LME<!OWYC5&<Q>+RTN[EQ]?D,)2YO'O5P1
M2/)31U=.9%42QEO=>Z-!VO\ /SX 5G5G9E'0?-;X>55;5]?;TI:6EH_D?TK/
M55,]1MK)PQ4]/!#O)I9IIV<*J*"S$V -_?NO= K\%OG=\#]O_"+X;X#<GS*^
M(^$W#@OBI\>,-G,+G/D/TWC<SA\OB^HMH4.1Q66QU?N^&NQ^1QU7 \,\$R)+
M#(A1E# CW[KW3M\ROGE\"LU\/_E=AL%\S?B'ELUE_C5WMB\3BL3\B>F:_*9/
M(Y#JW=5)1X['4-'O"6KK:VNJ)EBBAB5I)78*H)('OW7NC(>*7_AO+P>.3S?[
M)CXO#H;R^7_0?H\?CMK\FOBUKWX]^Z]T6#O;X]]%?(O^:%UWMOOKJ'KKN+ ;
M?^ O968P6'[(VCA-WX[#9:J^1/5M)4Y+%TN;HZR*AKYZ6,1/+$%=H_23I)'O
MW7ND-\B?CG_*YZ#RT6SY_@#\;LWOC*;%W/OC;U)6=+[)V_M/)0[9Q^4KY,,^
M\ZK;53BXMQ5ZXF44V/4/5U)TK$CNZ*VZ=; _9T7GL/XJ=)[QKNH%^-?\LKXL
M9/;W8?1^)WCNK>,GQ_Z[W'A.O]Y[_P '1;SVQ25\>6&TZNN.*VGC)XXD5522
MOS5&9K!&C]Z->M&OET<'XZ?RGOBWMW8M1C_D%\4OB?O[>3YJMJZ7.TO1'5^-
MEBQ<R0QC&RTN$VO0XT4L-9!+/1D!YHZ2ICAF9Y86D?QX_+KQX_+H?/\ AKS^
M7)_W@[\7/_1+;$_^LOOW7NO?\->?RY/^\'?BY_Z);8G_ -9??NO=>_X:\_ER
M?]X._%S_ -$ML3_ZR^_=>ZEX_P#EE?R[L5D<9E\?\(_B]2Y+#9/&YK%5B=*;
M!,U!E\-74^4Q.2I2^$815N,R5)%402 :HIHD=2&4$>Z]T9SM7L+#]-=:;J[$
MR>-J:S"[+Q!R=5C,5]G3U$E+'/!3F.E^[EI:*$1^8,2[H@4'GW[KWV<>JROE
MI\G-A]P[:ZIV7M%)JFHQ/SF^$;UU>N0Q%73PS[)_F#]%;1R$)BH*VJF$=96#
MRTTILDD8/T(M[]_AZ\/Y]%YI?^W.V"_\79VQ_P##C<;[]U[JP'I7_MXY\]/_
M ! _P._]S/EK[]U[JFS^X%?EO^%+G?W2V_?BWT_V-U7\CO@=N/L?L?L+>%9M
M?,Y+</QZS^TOCIT?'M/<NS,I@<@^Z,/C.Z^B*O%QX>JG\9H=T5=<$6-&6H]U
M[JZ'Y"]F4_\ +O\ CID=W=.?&+;^3^,/QOZ,[8["W=L?J?+;)ZSJMA[=ZRIM
MO9[$[;ZXV+7Q83:M71Y/;]3N&NF1*BC2F.)2)$EEK(U'NO=4K_&/_A4-U1\T
M]Z]2]:_'3XB]KR[R[E[UVUT3M=>R^R^G=KT6/S-9C7WMNO/YS%XG=6?W;'MK
M;W6>(RE=#64^/GBJLI3PT *23AU]U[JZ#^:)_P!D)=\_]0O7W_OU]B>_=>Z)
MO_PGN_[=^9S_ ,7.^=O_ ,%5VA[]U[HW/\K#_LB/KG_Q(OR;_P#@INZ??NO=
M0OA/M['U'R%_F:=EULN7R6\\U\P-M=7U.5RN?SN4AI.ONK?C#T-F]B;1P>)R
M&1J<-MS"8+-=H;@K!#CZ>F$]7EIYIO)(VH>Z]T_]>?\ ;S3Y5_\ BF7PF_\
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M=.#Q1ICUYV/VWNC8=0E-2U[FE,N-=J.4+)3F*10WOW7NCJ?S,O\ MWQ\R_\
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MDQ2Q&6.:G<%HU86901[KW1,<9V3#U%NSM#L&:OI,5_ NM?YY<5/E:_:%#O\
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MZ][]U[KWOW7NO>_=>Z)A_,<_[=^_-S_Q5#Y ?^^MW1[]U[H/OY6'_9&>V_\
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MW=_-7^%^)KMY[=ZQWUO#Y5[[V-MB3<N:V#\->J>R/E/FH)&S69VUC-LY3/\
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M-D)FR-37RD2CW7NK!/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7E\^_\ CX_Y??\
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M)%MG=N0QOQK_ )9L]>$ER6UZC?%7D):7*Q9*HBH<K$(Q@*9U2. UZ57NO=;
M];A\A5;BP6;@W-FL?C<10YVDK]JTD.#?![DGRYQ)H,EF)ZS#U6?AK-MC'3"C
M6BK:2!Q6S?<QU&F#P^Z]UUNC#9#/X6?%XK=&:V=6S56*J(]P;>@P51E::+'Y
M:AR-710Q;DPV?Q!I\U24CT527I7E6FJ)&A>*<1S1^Z]T2/\ FB?]D)=\_P#4
M+U]_[]?8GOW7NB;_ /">[_MWYG/_ !<[YV__  57:'OW7NKQ/?NO=4D?"#K_
M .<&:Z9WCD^I/DY\?=@=>U7RP^=;;;VAO3XE;P[(W/A:9/FKW[%5PY7>V,^5
M77E#GI:C*1SSH\>%H1%#*D15RAE?W7NIWP7Z![&Z6_FB?S+]W]N]K[7[=[&^
M1'1?P![0W%F=E=6UW4.U<&NTJ;Y+]+X? 8G:N3[*[6R$ML/US#53U<N5O+/4
M.%AC51?W7NKJ??NO=>]^Z]U[W[KW7O?NO=$P_F.?]N_?FY_XJA\@/_?6[H]^
MZ]T'W\K#_LC/;?\ XG+YD_\ P97?GOW7NK$/?NO=>]^Z]U[W[KW6M=_."Z]W
M!N7Y:;#R6)I\?V=F\-\1LUW5UM\<^PMJ;<W+USW=GOB%\HND.^.P^H\7C:I]
MIR9[=78'7%-45?VN3S5534]1@*&H@I JU8G]U[J\#:I^.?S4^,VS,TNT-C=L
M?'7O/KC![CQ.UMT;;P6>VIF=G;LPT573X[([?J8:[$))#25A@G@ ;P2JZ7NI
M]^Z]T7O!?RNOBML7^-0=6U_R.Z0VQF-QY7=\VP>C_E[\GNGNL,1G<S]O)F*[
M;77.P.U\!LO:D60FI5EEAQ]%34YEU/H#,Q/NO=$9V;V'\ /BUV'N;K[^6Q\5
M:KYK?,HQ9Z@WANGK"L_TAYK'9?/YC([SK*KY+?.#M7+YK&[<IJS=F<2HK!D=
MP9#+A*A?MZ*;QQPCW7NC@OUU_-C[8P6[O[T_([XF_$=]Q5.-H=M8/I?I'>?R
M8WKL7;W\*P,F9RU/VWVQO?J79=?OVHS*Y*.F2IZ\R&'H:=H'=*Y@X/NO=%4W
M5\C?EQU)US\^_CUB.^\9W+WOUC\G/B]T'\=NZ.P-M[!V3O;8NW_G.>FL3L3=
M':N(V)L;*;"W94].9[L_(FAKZ?9]!3;@CPZP5%)Y%GE/NO=&S_T._P U+KW9
M\5'LGYG?&;OS.;=RL,N)I_D!\5=Q=<Y[?^W&W<M948;?W:72O<<NV]N[D@V5
M424469PO7/VLE;3PSOB@LDJ^_=>Z2V5_F,]J?'JBR=5\[_A9W#TCMG;U%N3*
M9[OKI*HI_E!\<J3!X+>46"AW+E=R[%HL?V7U_M^IVS7TV:FGW3M?"FFI4J@X
M_P F<GW7NK0-M;EV]O+;V#W=M'.8G<VUMS8G'Y[;NXL#D*7*X3.X3*TL5=C,
MMB<G0RS4>0QV0HYDEAFB=HY(V#*2#[]U[I[]^Z]U7A\C?^R__P"6[_U!?,O_
M -]'M+W[KW03_P RO9F<['[-^&W7NV8H)]R;\?YN[,V_#55$=)339S='P*[_
M ,'B8JBJE(BIH)*^NC#R,=**23P/?NO=!)V/V%2]I?\ "?\ W+O2DPN6VX:S
MX"OAJ_ YQ\9+E,1FMH;$CV?N#'U,^%R&4Q54M+G,#4+'-3U$L4T05P1JL/=>
MZO"]^Z]U[W[KW2"R'5?6&6K:W)97KC863R.2D,V1R&0V?MZMK<A,65S+6U53
MCI)ZJ0NH.J1F-P#[]U[J+'T[U%"8FBZLZXB:"9:B%H]C[90PU"Z=,\17%@QS
M+H%F%F%ASQ[]U[H1_?NO=>]^Z]U0K\/?^RX]K?\ B5/Y[/\ \&7\-_?NO=7U
M>_=>Z][]U[K6'^#_ ,A]D[[K_P"2AT)MO"]AU6YNE)-ZP=@;MGV!N.CZLQVX
M,W_+[[;W;0;+H.R*JCBVSF-Z-M7?6-R,F.I9I9HJ29G>VA@/=>ZV7-SX2+<V
MV]P[;FG>EAW!@\MA):F-!))3Q9:@J*"2>-&*J[PK4%@"0"1[]U[K2X_E&R]^
M_'?YY]^5'5W2E?\ *2HR'QWVUU+V[A]IY+KWHC<^(WY\;NQ]R]!S[PH?]*$V
M"PFZ<0V(ZPV_!6X7);PR>;VW/FA-1*^-JU0>Z]ULO_[--\Q_^]8G=G_I1GPX
M_P#MW^_=>Z]_LTWS'_[UB=V?^E&?#C_[=_OW7NO?[--\Q_\ O6)W9_Z49\./
M_MW^_=>Z);\^/G+VU@_BUW_USV_\/\GT,>W>B^UNN\%N/M/Y:?"_#T%-7;]V
MCDMA8W*?P>F[NK-SYS'T>>W-2).F,HJRI_<"I$[LJGW7NJ_-\?\ "@#M:/JG
M;OQ?^*/P6^09^76X-O;8ZIZ:S.^:7K+-;(S61Q>Y]L=0;J[3V7MG ]A5&Y=]
MX':%?E1EL>F1@P6*R-$BU536TU$)7]^Z]T/'Q)_D;[C[1[)S/RX_FL;US'>O
M<F^ZK(U]9TME<W25F/IJ-=W[:R^W,1WGO3KVNP&R>TL)B\)U]@8H-@8##87K
M+$LE2CT&;J)GR4GNO=;"'879'3WQUZWRF^.R]W[$Z=ZMV9C:FIK\[N3)X?9^
MU,)04-)4U\L$+U,E%1))]M2RO'30@RRE2(T9N/?NO=:]?RI_FH=]]VO2=7_&
MK$;Y^.>RNY<5MW&=0Y5^M\OGOYBGR;P._:;'4<F]OBG\=MUS[1VAT)UKC*C,
MI".UNT,G3XRC"U-52XB9J6.5O=>Z '-?&OJ[H&BH<5\[,)EGJ.YM_;7[<ZK_
M )1OQ[["RGR?[]^8O;"STVW<OV3\[_D;OG$4O9?RAW!4[\W1025&/K,Y@^GM
MMP8*B69LC!3_ +7NO=6?;<^$/R#^8M+M_'_.REVU\>OB!LI.NTZQ_EE_'?=.
M&R>QLS1]=S9*?$1?+;M+#[3Q,_8&#BG&,>GZ_P!I5='LFG7%4RUTV:&M1[KW
M5P.SMF[2Z\VIMS8FPMLX+9FRMGX7';<VIM/:^*HL'MW;F Q%+'18O#83#XV&
MGH,9C,?20K'###&D<:*  ![]U[I2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNJ\OGW_Q\?\ +[_\:&]0?^^J[T]^Z]U8;[]U[K71_P"%55A_)@[X)L+=H_&L
MW-N/^,[[$Y!(.GC\\<>_=>\NK%OD+7_'ZD_E@[L'R?GVB.DLA\2:6@WE!O T
M,V,R=-7=7TT-#CZ"FK!)_$-PUV1>%,9#3J]5+7F(0*92GOW =:K0= 5_(!ZE
M[HZ0_E#_  OZY[\Q&9V[V'BMA[@R;[9W$TW\=VWM3<^_MV;GV)ALI#42RRT-
M13;-R]"RTC:&HHG6G9(VB9%]6O6ZUZ)#_,39A_PHE_DA ,1_QB_Y:#@D7#;>
M4,./PP'/]??NO#H5?^%2:(W\E[Y'%E5FCWY\;Y(R5#&-_P#9@^MTUJ3^AM#D
M7'X-OS[]U[J]CJDD]7=;$\D[!V<2?ZD[>QWOW7CUK1_S:^NC_*^^7GQ>_FW?
M%;$IL:A[/[SV'\:_GSUIMB48/97>>P^SLBN*VQOO<&VZ6$X:?L7;>35E3*>*
M.JE80-([LC:MCUZV/,]"/V;N7,?S%OY\M+\.]V3RY'X<_P M'I/9OR0W_P!;
MR_:R[6[B^4G9*X>LZHJ-^8R;RKN;;77FWMPI7XZAGC-/!E\=.\JOY4 U^VO6
MOVUZV4E5454155%4*JJ JJJBRJJBP"@#@>_=>ZK1^47\M_K7OKY@?#/YP[9J
ML?U_WW\5NQZJOS>YJ&F>"3M3J#/[9SNW]P]<;H>@,4E?-25F3@K,7/,6%.\<
MD3ZHY %]6HIUZI(IU5A_PI/E@ASW\G.2IDAAIX_YHG5#S25+11TZ(NW\T2\L
MDQ$2*O\ 5N/?AQZ\./5^??O;GQ]VYU[78'N/=.W:C:'9V9P72=1@(ZR'*UFY
M,KVYF*3KW';9BQF.EFKYCE*W/K%,RKIIX"\LA6.-F'NO'TZ&?9NT=O[ VAM3
M8>T\?'B=K;)VW@]H[:Q4)9HL9M_;>+I<-AL?$6)8QT>.HHXU)-[+[]U[H ?G
M#_V17\OO_%7>_P#_ -]/NWW[KW2/_P"Z=O\ Y9;_ /,-]^Z]TALA_P!O7=I?
M^,].P_\ X)'K#W[KW5A?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JO'^8'_Q
M<?@;_P"-#NA/_>5[4]^Z]U29V14[5HL5W?5[WQ.;S>U*?K?^=G-FJ';F7AP.
M;6E3^<'T2RY"@R]3BLW344F'G"5C-)23QE(&5ETDD>Z]T*O9N/VCVU\:?YA^
MW>INR>V>[MP4WQ/W_N")MK9C%UVZ9*_:G=/8N[GVGAJ+K+:F(K<K!V5D\+-4
M3XSQU,F1Q=<U"D<D4@U>Q3KPI3\^F78W?^PMP?!3O/XO4>_]O;DW7U)\ROB_
MW!UBL&U-U; S79WQ&^3OS_Z)[\Z/[WQ>W=XSU%1GMLYO_21782IR>,DDHX,G
MB)*>IBHJLM3#W7NKA.E?^WCGST_\0/\  [_W,^6OOW7NOG]_S_?E)\H?C5_P
MH([0[3^/4^1RVXOC]_H<[$ZXQM=M)]_[4V1OWL'XL=3;3SF\%VM/2UF(_CF5
MPVW**,2U,;JYQ\-U816]^Z]T"-!_-V_F;_+G>?6N0[T^3?9V%W?O;?V%V!N7
MJCJ:@V)\*,H=A]*T^2[QZMWO2?)'?VT:GI#;T^2[6R-7#5XVMH9:S(P8.*";
M7'-2JGNO=7=?\/0_S-P/^/AEL!R3\U_Y/)X Y)/^@3_"Y]^Z]T-.6[,_G=_-
M7JG T5=\:._>]>@]U9?K;L&K3J'YZ_RCL/BNPMO;<W-A-_X#$5F\^NNHAF(-
MH[MEPL*5<*R1&LHR\9])=3[KW5AW\LGHG^:G\1?@]N!.S*CXF_&X47:GRA[V
MW/U;VGUQO'O3>FS,!OCM#>?:50U5V7U#\I-F]>[@B;'9.26G6&CI&AA").1)
MK(]U[JY7X,]P=L?(/XB= =Y=W;2P&Q^R.V^O,5V%EMM;8C$&$I,-NJ6IS&RJ
MVEHAN_?QQ4N<V/58VOGHFS62>AJ*F2G:=VC/OW7NJ]OA!V!\X,+TSO'&=2?&
M/X^[_P"O:7Y8?.M=M[OWI\M=X=;[GS5,_P U>_9:N;*[)QGQ5[#H<#+3Y22>
M!$CS5<)88DE+(7,2>Z]T6_>.\/YT&3_F(=Z5OQDZ-_ES;+W6/B-\4J?LC;_?
MG??R$[%PTF&C[4^6DFQ\KLG<O7'2O6=3#D*JLGS464HJ_'2)"E/2205,AEEC
MC]U[JP;JS'?SG<ULVCR'<N]OY9W7N_I*[(QU^U^O^H/D_P!H[8IL=%.%Q572
M[QS??G5V1K*NMI[O/ V&A6G:RK)*#J'NO=!3VW5?\*!L'NW['H^A_E%]D;(_
MA6/F_O)V/2_+SJ7<?\:E\W\3Q_\ =/ ;G[;H/X?1E4\-5_%M<X8ZH(M-C[KW
M08G<?_"F;_GV?\D[_P!&'\UO_L7'OW7NCL0[>_FO-AXJB?M_^7O'G6P\<\V,
MC^-OR-EQL>=./$LF-CR[?*^*>7&)E+PBL-&LC0?N_;AOV??NO=5&?-7<?_"A
MQ?AY\IW[FZ]_E 4/44?QZ[@E[1J^NM\_,"O[!INO8]A9U]YS;%H<_MN'!5F\
M(MNBI;&Q5CK2R5@C60Z20?=>Z-[\!OF'L_IGXRX'8F_NA_G+A=PIVC\D=W)0
MK\"OE[E+[;[)^2/;/9&RL@:S$]-UE"QR^S-V4%6460O"9O'(%D5E'NO='*_X
M<7Z<_P"?.?.?_P!-]?,__P"TC[]U[ICW+_,_^.NRMO9G=^]>O_F5L[:&VZ";
M+[FW;NCX'?,3";:VUA:72:W-[@S5?TM#0XC#X^,^2HJ9G2*",%W8*"??NO=6
M* A@&!!! ((Y!!Y!!_H1[]U[HBG\P#XQ[Q^1'4> W'TMGZ79GRD^..]*+OWX
MN[PK,1B\SCHNU]HXS)TR;$W1197(86&IZ_[=V_D:S;.>1:^@=*#)-.LZ/ A]
M^Z]U6!_*4^8O5&R\QG>B:_.8GKOI;O[&;W^6/Q.Q>Y,OCJ?&]89J"HS.2^=W
MPTRV8Q6$CV!MO>?Q,[GQ68SO\$;<F7R5-LK/TT[E:>@GD7W7NAKQ^6[/_G![
MER-?M/>'9G1O\JS;\>X]O8S=FP\[F^M>W?YA^;K:#([9RV8V]N7'F@W5U_\
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M<NO_ /A(.WO?NO=;:/OW7NM47^8YA>UOY8/\Q/J?^89US@IM_=&]T]AY6A[
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MO^8I_P!Q$W\D+_Q%_P L_P#WGE]^Z\.A9_X5(W_X9=^2-@3_ +_GXW_3\?\
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MMVOORB[YR/7.[-X[*JM@=D]A8+9?6^T*9\KM_(Y2DQ4$C0ZUDJ9 ?=>Z%_\
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M[^)QTE2S;1VLU73Q-_&9HG*'W7NC"?#[X)[6^+V3W5VOO#LOL/Y'_*_MC;>
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M7^RL_&&?[/*X?)P56/R%+YH4?QS1NFI ;7 ]^Z]T*7QQRF^NUMC]9_)/H?\
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M]O\ _:N_G>?_  U_J;W[KW1\/YA/_,I>E_\ Q>W^7A_\&UT3[]U[IH_E=_\
M9&.R_P#Q+7RP_P#@M^\O?NO=5Z?*'_MXGGO_ !97^35_[T7S9]^Z]T'VV.JO
MYG/QG^2WRC[(Z ^-\F;H.W.SNU8FR6Z\#T3V'MC<6RZKY*]^=V=<;PV?5_[/
MM\>]V8"HR6$[TFH\GCLQA#-#/1*48 F_NO=#G_I]_GB_]XK;"_\ 1/\ 3?\
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MX:N2FV(*6."3+0TQ%2QE611I/NO=$IHNE.\/B3MO^7;\%.JOE)N#9=?V?O\
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M^U]ET-1G\565U&)<G@,74F,UE120U#11S1%(Y&EC5O5Q7K5<5Z*AT_\ +?Y
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M'=G?)7<_:'QX[.W=N/M&#^6W\5MO[<P/<$5%W?+L+-=I[ ^2_P PLO@8NO\
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MLM156(W3BEJ,)DZ6MA,<XE+Q)[KW0>?'C'T%=\^?YE KJ&CK LOPY(%530U
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MZQ&D8C:-?$0*N/"H"VICI9M(OM]P/U-?7O?NO=%=^</_ &17\OO_ !5WO_\
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MQSQX1Q44ACIY)[J6]U[JP?\ V='^;Y_WA;A__1+YC_[KSW[KW7O]G1_F^?\
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M2NS&>SF3JMO25F4S&5K97FJ:F9WFGE8N[,Q)]^Z]TQ?\-C_RZ/\ O!?XG?\
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MNO=>]^Z]U[W[KW7O?NO=>]^Z]T5WYP_]D5_+[_Q5WO\ _P#?3[M]^Z]TC_\
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M?_?NO=>_V9OXV_\ >0G1_P#Z-C87_P!?_?NO=>_V9OXV_P#>0G1__HV-A?\
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M^]N3V]C,H:9<>E730U7NO=6$_$+^5#M[9]=MSL[Y9X?K'<VZ]B[SW#N7X_\
MQ7Z>7-4_P@^(F&KZ?*8?&P]8=:YO%[?H>T.Y,MC<K59#<?8^YL,N=K\QD)_L
M8<=2QQQO[KW5S2(D:+'&JHB*J(B*%1$4!5554 *J@6 ' 'OW7NN7OW7NO>_=
M>ZU[.L*VCK_YF&.GH:NFK88_YE?S:HI)J2>*IB2LQW\L[XQX_(4CR0NZ+4T-
M?32031DZXIHV1@&4@>Z]U81_->_[=U_+#_Q&3_\ N_PGOW7NK"_?NO=>]^Z]
MU[W[KW2<W/O':.R:&+*;RW3MS:6,J*I*&#([GSF,P-#-6RQRS1T<57E:JDIY
M*J2&!V6,,7*HQ L#[]U[I#?[,!T/_P _LZC_ /1D;-_^O/OW7NO?Z?\ H?\
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MCW?312UN1KYJ>CI8Y*F=(U:1U!=U4<D#W[KW1LO]F;^-O_>0?1__ *-C8?\
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MYU-31[*K.P5AEZHZ7PF]]YX>GK-JT?W,5;D:6CQVF:'74()4)]U[H'X?D/\
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M_*8[!X/#4-5E,QF<O6TV-Q6*QE! ]379')9&MEAHZ&AHZ:)I)9I72.-%+,0
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M[KW7O^'>?B'_ ,J7R+_])<[V_P#L']^Z]U[_ (=Y^(?_ "I?(O\ ])<[V_\
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M]%C:RIWRO7II=Y=H0/B^E.LHZ//QU35-1N7<F)@@I*"IF+E8K-[KW3)08O\
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M4GOW7NO>_=>Z][]U[KWOW7NNF8*"S$*J@LS,0 H N22>  /?NO=%+[W^=WQ
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M7JUZ/Y[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*[\X?^R*_E]_XJ[W_ /\
MOI]V^_=>Z1__ '3M_P#++?\ YAOOW7N@EWGM':>\?YJ>RZ+=VV-O;IHZ7^7S
MV+/34FX\+C<Y2T\[_(_JY'F@I\G3544,KJ@!90"0![]U[H[/^@SI/_GSO5G_
M *+[:7_UH]^Z]U[_ $&=)_\ /G>K/_1?;2_^M'OW7NO?Z#.D_P#GSO5G_HOM
MI?\ UH]^Z]U[_09TG_SYWJS_ -%]M+_ZT>_=>Z]_H,Z3_P"?.]6?^B^VE_\
M6CW[KW7O]!G2?_/G>K/_ $7VTO\ ZT>_=>Z(=\XNM.N-I;@^!N4VKU_LG;.3
M_P"'">B(/XCM_:F"PU?X9MI=K1RP_=XV@IJCQ2QL59=5F!(/'OW7NBS?!S_L
MM/;_ /VKOYWG_P -?ZF]^Z]T;3^87_Q]?P?_ /%A>[__ (7;\WO?NO=/OQIZ
MJP?>W\J+X_\ 2&YJ[*8S;?<?\O7JCJS/Y/!RTL&;QV%[ ^.& VGE*_#S5U'D
M*&+*4=%EGDIVFIYX5F52\;K=3[KW6?\ EM=[;V[8Z!JNN.[9*2+Y/?%+>66^
M,GR2HJ:-Z6+*;^ZYIJ&/ ]GXFCDVQLP#:7>'7E=A]WXN2GQ=+0K#F&IH-7VS
MD>Z]U8+[]U[I']@]?;&[8V/NSK/LS:> WWU]OO 9/:V\MF[IQE+F=N[EV]F:
M62BR>(R^,K8Y::LHJRFE961E/UN+$ ^_=>ZJ3^%>+[L^.WRV[$_EVX/L6H^1
M/PXZ4Z+QO8&(W!VYMK=<?;GQSI>S-SU.,Z7^,3]O5==GMO?)#:U%L[;>;EHY
MLI38O/X+!P45-5UF5LFGW7NN'Q;^0R?%#:?;/2N[_BA\SOO,-\L_F+N7!S=8
M?$GM'>'7U?LGL+Y-]I;_ -B97:.XMJX.;;V1P>4VCN6CFA-*VB,.4(!4CW[K
MW0N]G_/O [DZT[$V[B/B?_,(DRV=V)N_#XJ)_A/WA$LV2R>WLC1T$!E_N]IB
M\U5,BAC95)N2 "1[KW0P?#CXV]?[4^(?Q5VMO[H_86+WUMGXW=&[>WGB\_U]
MMC^.8S=>$ZPVOC-PX[,_<8IZ@92ARU+-%4!R7$J-<W]^Z]TU_(CX3R;[W9T)
MVW\:]Y;%^-'=?Q[WUGMS;=W >D]M;^V'O7:N]]JUFS.P.O.P]F8W-==;AKL1
MN#"U,<E/68O<&)K\?64T4JR2+JB;W7NE7\7OA1U3\>OCST_TCG]L]<]H9OK+
M8^(VMF.PLAU;MK#U6\<K1K)+D]P28FKDW)4XS^*5\\DP@DR%:\8:S32-=S[K
MW0.?S!>E-KXOX\XW=/5WQ_I]S;IZ^^17Q![.EPW3_56.SG9$VU^M?E5T]O;?
M%5M7"[:Q2Y[+5^-V9@Z^H:GI;S2PQ.H!N0?=>Z4I_F*[0!(_V5+^82;'ZCX2
M=XV/^(OMX&Q]^Z]U71\]/F!N+<6:Z%[XZR^)7?U15_%EN^.R'_V:;X^=F]-]
M/Q[LWCTSG.H>K%W'NW<>VIB(I>Q-_4+O#CHILFU-#,8 C6D7W7NK%OBA\$YN
MG]_9#Y.?([MW<7RL^;&\=@X'8>Z>[]WX?;VWMK]=[4H42NRO5WQLZVVYB<;A
M.G^JLCN%GK:N)36YW.5(2?+Y&MDCB$7NO=6%>_=>Z][]U[JI3#;CF^:?\R:C
MRFU:NJJ/CA_+0AWIA\GGX<?HPW8_SG[,P><Z[W!M#'5V:V%+%EL;\:.HJ[)Q
MY>7#YZ+Q;FW534\\3/CW"^Z]U;7[]U[HL'RU^6G5OPZZJE[*[(?,YG)Y?+46
MS>KNK=E8YMP]H]U]H9XM!M/JWJW:5.ZUNY-X;DK@$1%T04L(DJ:J6&FAEE3W
M7NJ2_P"5)U[NSN[Y/Y?OK?>3J=[571-#VWN[NCL#&;V[*JNMMP?S'OE9E,-1
M]Q;$ZLQ$VX=W=9[MVE\)_CML3#]3QY.@S^8H(I)WBI(*69*IO?NO=;*?OW7N
MO>_=>Z][]U[KWOW7NO>_=>ZJG[U_EHY;>_;?;_=74/?T>V\I\@\KL>7O/IGY
M&])=<?++XW]D[9V9L'-]>':,FU=XIM/N+8N'RN&RJ2&EVUOO$XF"I2:08]_N
MZD2>Z]TOOY7GQ,[B^&WQLRW5_=NYNJ\CNO</</9/9N/V)T&G9\/0'2>W=Z5U
M#+0=4])4?<&Z-U[XQ>P:.LH:G-+0RRTU%C\EFZNEHJ>.DAA9_=>Z&?Y'?.7X
MK?%&BD;NGN#;.$W*\\%#B>L\%+-O/M[<^6K,=/EL?A=J]4[2BS&_-P9;)8ZG
M>:GAIZ!S)&-0.GGW[KW1+*ZL_F&_/RIH<7B,9O[^6)\2:MLZNY-W5>2VC/\
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M3O#_ .Q[W[KW7O\ AQ;:'_>*7\PK_P!(D[P_^Q[W[KW7O^'%MH?]XI?S"O\
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ME7_+;_[>7OW7NO?\-;?"W_GB.V/_ $J_Y;?_ &\O?NO=>_X:V^%O_/$=L?\
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M7W\O/^6/VXVQ8<UV'BMG9CL':6R?A%\<Z&CP<NX:B7=N+P>:AE[-I,1O#><
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ML5'[*HJ225&^_G/+)-Z %=YG8LS?5B;DGW[KW1J/YA?_ !]?P?\ _%A>[_\
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M-O02Y7>6+G:L;4T,N/GC6R$JWJ8J:=>IC4:=68_Z%?YCG_>>?0W_ *0=6_\
MW6WOW7NO?Z%?YCG_ 'GGT-_Z0=6__=;>_=>ZK(W%U[\T,-\H/G]/N/Y,].[[
M.)^/7P?GWOBXOA3)DJ/?&&K=R_*&';V)H=MUOR>B@PL^!JZ:LGJ9Y*NL6O\
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M/Y]'8'\J_P#EY".2$?$[JH12JB2Q#'Y,1RI&=2)(G\4TNJ-R 00#[WUOJ/\
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MD#D/^WKNTO\ QGIV'_\ !(]8>_=>ZL+]^Z]U[W[KW2,_T>[)'89[6_NYC?\
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M<\TW[_A^Z(,S6'J^9X]>KQ)R>GB3XM=FY/=/:&7R_?FXH\+O]-X4F%PF.BR
M796/S!$6,AH&;*TT58E<6^^R*!:=DK8U2FE2!BBU()\^J$$GCTPO\+NR(:IV
MPGS#[LV[C*K<E#F*S"XN.@EH(,'%4"IR.RL"V6K<E58/;U9*H,)62:JI-3JL
MK1LJ)O-*5QUO---<?E_JST]5'Q!WO)3;0T?)[M&?-;5VY5[>_O5E:>*OW#71
MRYG*9"EJ/)!EL?C(VCH:Z"FG\]+5/5&@IY&=;2))[[>/5OMR>B&?(#^49WKW
M[DOCONC<?SS[%J]T?%+NW$]]=3Q9S;%-D<)E][8S%9'&Q5&Z&H<IB\QC#14^
M6FIJ5Z*>0QTZW*L\TEMUZ]7_ %8Z-=!_+]W6W4]#UED_ECW/E*E=RX#<V1WE
M65M?)N=Y<'C,Q#_"<3D(-Q4;XW$UN9R<=5-&_G$L4'@92LA9=9IGK6:4)X]&
M(P'QWSVTJW9V4VUV[N>#)83.[BK=TRYN#(;EHMV[?W+M^GQ]5MVGQ64W*U!M
MLX_/XVCR%%5Q)/)3+#)3*ACJ)&]^Z\<]4TM_PGGVQC.TOG+W'@OF;WQD-Z_,
M[KW8.T)Z_>M%B-P9?9>6ZTWGUUOO;66K=U)5TN2W=0'+=;4E,]++#3>.AE*!
MW*+?PP*=>% *#JQ[KGX6=T;>J.L=T;M^8G:^1WCMJDS<_8-!B2U1LS>^:W+3
M9&'*-%0Y^NK:V@QM*];$]*&+RI)21R7#%[[J?R_+K=3^7Y?YNFD_ ON@5F,D
MA_F$_)^&@I*[&5>0H1_=22;*Q4;,:ZB>OEHGFI:;+":42:%+)K&@C0@&N-:]
M:.:UZ5DGPW[HI=^X/>^%^;?<BTF'WEMW<LFR-RX' ;EV;D,9@*JMI3MV:@2L
MPU<L-?M2M-#)/]PQ>K1:Z2.28:?>L^9ZUGS/2*[*_E\=A[S[HW[W/LWYF]P=
M/Y??NPNM.O:VDV%M_;R5$.&ZJW5VCN;;+3Y3)U58,C,Z=HU-'4&2G4O!3II*
M%FM:O'JU>/SZ%+&_$/L7'[CCRO\ LWG>4^%39&Y-G/MN23%-#53Y_!1XFGW-
M5Y&7SU3YW;U9$M90RQB-DE%F9P6)U4DU)ZU5B:DY_+I';Q^#G:F\7P[5/S9[
MVQ\6!Q>.Q%%0T$&-I<?D(,1DJ'*4%9N2&EKJ:?-Y@3TC+-4^6%IXI-+"R\^S
M2G7LTIY=")M;XD[IQ6TMT;;W?\F.YNR*[.;HH=RXC<&Y<A%0UFUDH(,\B87'
M0;<GPZ56)JZC/O)4QS,PF6*)+!8TT[)/EULL?+H!,9_+6W#B]FUNSD^7?=M;
M%DZFG>NS63J\G5YU*-*V:JJJ;%Y ;MBFQ<U1'4>-9E+F$4U*P4F!O+[4:4\N
MMZFII\J_+J1EOY;FY<ILW%[8'S1^2-+68W)8'(?QB/-0E67"XW#XMZ2&B%3'
M-##54V'!!>IF9)*B=V,AD:^LUK7JN=5:XZM IH33T]/3F66<P0Q0F>=@\\QB
M14\LS@*'EDTW8V%R??NO=9O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0\A!+54%=2P3&GGJ:.I@AG!93!
M+-"\<<P9"'!C=@UQSQQ[]U[K0;V?_*__ )@]3LGM[H=?YIG;6\^X?]*^'KXN
M\,QV3\X\)N[IC9^Q<EN#"[NPM-M^7MC$;:JNK-_Y5T%3FJA#*!1*]('C8NO@
M0>O @]/&^_A%\K^QNF?C]O;JO^8KN?:='TM_H[V)V_N7J_MW^8?N_>ORGWAO
MCL23KS#9/?VV,MVTM/M;)Y3<O66;IJV/"D04U'E9*A"4--I]7]O6@:_;U:)N
M[XT]F[+SE?M[/[2ZDILW1;<V]NML71?*;^<7EII\9NK'[LRN(AIZC%]LS8]:
MM:;9612I,\E-2TU1$L+S"66.-O=;ZKV^<?Q%^3?8U?@.LNK/EENWX(;VV5N/
M.1;BSG2O:_\ ,S[)@[.J*ROQNU\/L>HSG8/;67V=3Y1<LS5./HX*R'(U$<CO
M+%&BB_JXKY=>KBN:5ZP87_A.G_.1W#M^FS. _G9;XDQ>YL%B*S&9"L[>^9%3
M7TL4\$=6F4QS5'9%(]!4Y".0&2*6.41@Z18B_OW7O\/1]_BE_):_F']#;"SV
MU.]/DYL3YL;GRN[:C<&,[*[B^6G\R'8^X-N8.7#XG'0[*H,5UMVOC\-58BDK
MJ">N2HF4U)FKI$8E%C"^Z]T9F;^6-\J'@GC@V[\;J.:6":*&KA^<W\V(S4LL
ML3I'4QK)W,R,\#L' (L2+<?7W[KW5.D7_":W^=0L=<M1_/"[-JI:F)8Z*8]U
M?+N'^&.LJN94B3?SK6 Q QA'( !O]1[]U[H2^KO^$\O\W_9';NS.Q-\_S:,O
MV_L?;F?QF6W)T=G>\OFSM?8W8&*H45*K;.9R^ [.DW-BZ#*E=<TU+-YE<DK8
M&WOW7NK1/^&R/E']?[J_&F_UO_L\_P#-E_\ MT>_=>Z%;^63U?N';?R [RW<
M>W]B9K:]-UW@^LZSJ7KCMOYF=L[>Q^_-J=B[P;<&_*O)?+//9V*DRRK_ +A&
M_@$C12+1GS,;1@>Z]U=U[]U[KWOW7NO>_=>ZJ]_F@GL48OX.GJ1-E2=D#^8%
MTQ_=-.QI<[#LAJ[_ $<]T_=#<4NV8I\\E)_"_/XS3(S_ ''COZ-7OW7NB&_*
MCXV?(S"S2]W]\;'^#6<S-3D:W%T,>([.^7N,K\B^Y*Z;+Y'"X_$8$X*FK*!J
MLRU,S5)=H8-:/,M+>+WH 5KYGK045KYGJGWOW+[2^.*[0^1V^-G=,Q8S<W>F
M\^U\KN7;^[OES5C9N>Z?^-/9.W\JDFWL]M:+%YO"-L/8T]!2X>*=:U:ZO2HI
M:I*=9T]VJ2=75JECJ_XKHZ=9\).[.ENL?EC_ #1NM<3T!2?[,!\=.^OD5O!=
MG=W?)G9.?;;/=W3&"S^[<MU?3C: EZP[(J]K;7HY<17_ '=3+A<JS2*[J%5=
M=:Z/_N+Y!?S"OAWUWTOUUGZ;XH;PQM%UI@,1MW-93*_*[M7L7,XG:6(PF!I<
MAO3.QX"ISV\=XY16CER.1>,M/4-+55!C5F8>Z]_AZ>^N?FI_,0[6Z7[I[MV;
MMWX-5&!Z*;?5+N[#92K^06,S55EMA;,I-\Y#&8Z(TU2].U5BLA!$KUD=.5F9
MF5)8!'-+[KW16>\_YPWS7Z%Z'W?WAN#87PTW$^S>BMM=YY+K_;>3[WFSPI-U
M]3T/<&*V?49.HHDI*+*_W;KT26M\$M)"UG<*AL/<33->O#)H :]!9\>_Y^GR
M$^1T6R)MIXGX=X.'<(W30;QJ-Q4_R)AIM@;MVQT1MWY MM*&2''F;?53DMK9
MV2BBJ:**GC&1HI%"/')$YT2!D\.M$@"IX=&1[C_FN_*KI7J'NSN+<-5\*:_$
M]&]<[A[&SV!AP'RAPV8W'38&D$L>W]K3Y_%T&-K\SE*V6*GC/D\49=I"66-Q
M[WUO'1BL[\L?YCFU=N=:Y_<>V/A?')VAUQ%V9AL3MS#_ ">WA54.)\.T/N,9
M72XC%A7RT=?O>AIH4C1A4,6?T*/>JTZT33H/.BOYA/S:^1VZ=_;'ZNIOAL^[
MNM-AQ=C;JP>]MG_*[8%71[?JLOFL'1((=Q8B"L7(U>0P,]HGA0K R2$^K3[W
MY5ZV,BO2$ZA_FD?,'MG:VW]P/'\)MB5V5VIU1NC,8C=6,^3J4.WF[@V3M;?.
MW<9'NM,1!AMT?8X_=]+3UE3CA)'#4!@ZHH!]Z) X\.M$@<>'35M;^:]\O=W;
MJ^8^$QM!\-/[O_![:O2.YNX]XK@_E#71U;]Z;3W?OK XK:6U\?AZG<.6?![6
MVM'/65!18VEKEC11X97][ZV>FS*?SBN^,1L[!;[J-V?"FHVYN*AP61QM3CME
M_*[)3?:[CV_2[BQ+545%C9HX&G@J6I6&MM%?3S0'F/4WNO<#0UZ89_YS'RBF
M[BRG1^WL7\2LWO/:>;Z_I-_2UFT_E#M?$;9VSV-M#M?>&%WABI\SC17;SIX*
M/J&OADI*.GC>22IA,4K@.![AQZ\<<>H/R _F*?*'LWXQ]W[9JLY\-,-!V3T_
MVSL'#T.5V?\ +#:^?S>5W!TKN3.Q8C#C/;=^PH<U58R9H(/X@:> 9%?MY&#
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MCAY]#M24E+04E-0T-/#245%3PTE)24T:0T]+2T\:PP4\$,85(H88D"JJ@!5
M ]^Z]U(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW24VYL39>SWJI-J;4V]MQZV6LFJ
MWPF)H<:U3-D<C4Y>OEG-)#$9'K<K62U,I-R\\C.;LQ/OW7NE7[]U[KWOW7NO
M>_=>ZKC_ )B$64GK_@;#@ZJAH<U)\_\ JI,56Y.CGR..I,@>I.]_M:FNQ]-6
MXVHKJ6&:S/"E1 TBC2)$)U#W7OLZ(9G/FU\\ZSH[XW[HAZ7WCE-T;K^(6&WQ
MOS)47159E<#NCNW<^U,#D-P5M!I3*G85%UM2/7U:XBJ@\]=4,(V#P4SI-XXR
M>O'&3T*-+W?\@MP;ZZOPK;RSN=ZYRU;WMC-P1_Z!MM_W@S?5^T-H=DU_4??N
MVURNS*C UNX.RLMAJ*GG<4T6+H8U-,V+=ZU98_#CUX<<>G#_ %?ZO3HO_P Q
M.ZOE_A/A[VQU1VMMS>F8P.ZOY:?S4W_OWL2+J2CI=OOO6MZ*W+N_8.RJ_*[7
MHJ+;VRL=UE@9X,5D"\%+-E,VS)$G@*>_?/K?SI_/J+\?OEA\RLMU%\<,K\AM
MW[TZ.J^TNG/B/O3/;GRG66RMVY'&T_:.S:FJW_G]C5."ZQDVWM';J9=*2AKL
M#G(JW/8>>J@\LGC=F/O+YG]G6O+'Q$_EUR^0_P KOD/MWXZ]C#=^-[$DSVX>
MN<SM[;FT]B]6;%VI%WALS<W76^\=4=\;UQN[<=39&:7.R45%12[>P&0QN6P"
MQK52Q/3-I7WR\Z?ZO]1Z]Z#SI_J_U'J-\;?D]W)E/B'U#O?9F?CJ]CR]']1;
M?ZOV_N3XVY3<^_MP3[4Z-Q=!0XW=4$&WMOG'T/=.]*.:BP\,ODJ(\5CXW>HC
MFK JZ/RSUHFG#.?Y=)K?/?O=]3\C?CKE\QM_;$.[MC93YE4U!N#9'6.<K=H[
M2VUG8.HML9.*MV3D=J[3S6<WOU1L*5I<JJR9.DD6$U(G:DO![V:<0#ULTR0#
M3Y]#-VO\C?D!V'U5WAM#=&U:#/;&W3\>OE_C,MY>I\AM04/4.V/C;NS/]7_)
M%,U74WCT=S[P9<4,23'#1B6RQ*X)/O0C@>O$<".!'1@\[V'\RL5L#XH[&^+/
M7O\ >?\ B'Q!ZZW+6;NS/]PZ?8>S]QTV+VI1T_\ ?X[IKZ'=N>P63Q22@4.U
M_+E$F19631I/O8^?6QZGA_JQT=;I?M3!]P]#YO=B2T%1O>':6;QO8!I]N5FW
MJN@SR464>3&5E/7X^AG$D*KJ* NJDWOR"=?+K7G3JIBC^07;O0O\OK^6[5=5
MX>BR,=;\%^LMTY6B?:FV=PU6X,GM#I;KFOQ^W:6//RP5F1K\S3&:&#'XDOEZ
M^<QQP#40?>C6F.M-6E0.EYW'V3OK8/RZ^3^ZNOOXELFHW/\ $OX3Y'<F6Q'7
MO]Y:^BRM#!\\<[L;:F3VS/@\_)3)OS>^.QVW)C+2M51Q5/ABEAFT.NZ#K=!3
MI%UWRQ[UP.SA4[USM?L#>>XZ':XJ^I]O?&Z@6?K'M?.?WC@P73F$W%G]H9#"
M8G;V3EI&R>9S6?BR+4&,Q%64>&6JA,?JDFGGUJI)I7/2O[63NK*]_P#Q5K^Q
M]Y)NK8F*^=7QTV;AXO[C;8V_C\QO\?&;Y';B[#R>VLM0;8P&X<AUWB9<W!0X
MBGR#UQ(,KF4.&4[\OGU:N/GT-W=O8U'\@_C9_,JP6^_A=V1THOQWV/WA%U_O
MWNK9.R(,%W'F\!UEVE2X3NGI6MQ>1S-;/08V.C^XI,C41T== F2A*!9&D":Z
MUT:7_NG;_P"66_\ S#??NO= Q\[_ /AKS^_?6_\ L]_^B?\ TC_W0W/_ *-O
M[X_WF_O;_<;^-8+^]7\._NC_ +D_[M?W@_A_G\W^3_=^*WKM[]U[HCW_ &SR
M?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'
M_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-
M'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[
M]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=
M>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_
M &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_
M 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY
M'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_
M]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8
MT>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U
M[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]
ML\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/
M)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?
M]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1
M_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C
M1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7
MNO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[K
MW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_
MVSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR
M?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-'OW7NO?]L\G_ 'Y'
M_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[]U[KW_;/)_WY'_V-
M'OW7NO?]L\G_ 'Y'_P!C1[]U[KW_ &SR?]^1_P#8T>_=>Z]_VSR?]^1_]C1[
M]U[IOR'_ $#EZ\9_&/\ 9=_)_%J;^!?QG_2MY/[P^&J^Q_@/\1]?]XOMO/X/
MM?\ *_%Y='IU^_=>Z<A_T#S:^/\ 0CY+FUO],^KZ'5IMS^F][?CW[KV>NV_Z
M!Y])U?Z$='C-[_Z9M/@U1W_P\'DTW_LZK7YM[WGK>?.O39E?^@<O^&9'^\'^
MR[_P+[&J_C/]X?\ 2M_ ?X5X6^__ (Q_%O\ <7_"?MM7W'W'['BOY/3?WKK7
M4[_MG>M%_P R'TZ5^W_YG!X]%E\?VW]CQVTZ='IM:WX]^Z]UDJ_^@>3[>L_B
M/^@S[/[7(_Q'^)?Z8_L_L/M'_C/\0^]_R?[#[#5]YY?VOM[^7T7]^Z]UE@_Z
M!Z_LZ'[/_0C_  S[*C_A7V7^F;^%_P ,^W@_AO\ "?M?\A_AOV?B^V^W_9\.
MCQ^G3[]U[INK?^@=/^)XK^)_[+Y_&_%E_P" ?Q'_ $L_QO[?[2F_O%_ ?N_]
MR7@_AWA_B/VOI^W\?W'[>CW[KW63(?\ 0.U]C7_QC_0)_"_L:G^+_P 7_P!+
MW\+_ (5X)/O?XM]__D7\)^UU^?S_ .3^+5K].KW[KW7&E_Z!V/MJ7[#_ $"_
M8_:T_P!A]A_I@^R_A_A3[/\ A_VO^3?P[[;1X?%^SX].CTV]^Z]UR'_0.UHF
MT_Z!?'I?[GQ_Z7_'HT'R_=:/1H\=]6OC3>_%_?NO=,L/_0-G]C@?M?\ 97_X
M3X:/^Z?VO^D;^$?:^*/^&_W3\'^X_P"S^WT?;?8?M^/3X_3I]^Z]TXQ?] Y?
M\6R'A_V7;^\'V6-_C/B_TJ_W@_AGGK_X'_&='^Y7^%_=?=_8?<?L>7S^#U>7
MW[KW3C-_T#QZ'^Y_T%^.X\GW/^F+1JT1V\GFXU>/3]>=-OQ[]U[ILKO^@<G7
MBOXK_LNGE_BE/_ /XK_I4\O\?^VJ_M/X!]]Z_P"\/V/W'A^U_P K\'ET>CR>
M_=>ZYY3_ *!T/X9DOXW_ * /X)_#J[^-?QC_ $O?P?\ A'VLO\3_ (O]_P#Y
M#_"_L?)]SY_V?#J\GHO[]U[J^S_C'?\ HP_YA[_1-_<+_FQ_=7_1W_=[_P Y
0O[O?W:_Y ^V_P]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>nt10016217x4_ex10-15img07.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img07.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!YP*\ P$1  (1 0,1 ?_$ :(    & @,!
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M[7[<WCC*C^X.0H7HY!33TM=1U$=0BVB9_=>ZM)_T%_S&?^]@?4'_ *0I0_\
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M8S&](]-UV0R-?63)3TE#0T5+\PI:FKK*J>14CBC5G=V 4$D#W[KW1G_]!?\
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M10P) !!/NO=;'OOW7NB!]Q_]O'O@O_XKK\]?_=_\-/?NO=5Q?S3?^RD]T_\
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M>E)Z_);KJ]B]=K)E-P[CZIR&1^VBQPCI:>JB3R.P:WNO=1/YI_\ V[A^;?\
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MYHG^TJ)"C!PI]^Z]U>WL7-5>Y-D;.W%7I#'79_:NWLU6I3JRP)5Y7$4==4)
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M=V[V3L#JO:;?R^NXL4NY^R-Y;<V-MY\K6]1_#"2CQB9K=&2Q>-?(U<=-*T<
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M #5]CT.[=L[>W114O\OGLJKI:3<6%QN;IZ6J/R.ZKA:HIH<G354<$S1,5+(
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M%_F'?^E@=@_]>_?NO=!!LGX1_+GXV=Q=T[]^,7R3V!O3;?>-!U>VXA\UMO\
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M#JK_ .WI[]U[KW^S][C_ .]??\PW_P!%!U5_]O3W[KW7O]G[W'_WK[_F&_\
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MJ?+4&T\K'D:"=:.Q>/W7NC<XW=W\G7#8Z@P^'^9GRRQ>)Q5%2XW%XR@^9/\
M,DI:#'8ZA@CI:*@HJ:+?ZQ4])1TT2QQQJ J(H X'OW7NIO\ I _E#?\ >;?R
M]_\ 2T/YE'_VP??NO=>_T@?RAO\ O-OY>_\ I:'\RC_[8/OW7NO?Z0/Y0W_>
M;?R]_P#2T/YE'_VP??NO=>_T@?RAO^\V_E[_ .EH?S*/_M@^_=>Z]_I _E#?
M]YM_+W_TM#^91_\ ;!]^Z]U@_O3_ "31MR@P,?R [3I\AC>W<[WK3=A4W=_S
MBINX#V?N;K/$]-YW<-3W%#G4[+K(,EUA@J/"O0RY1Z 4=.@$(8:O?NO=9_\
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M4?:9/%5D.0QM;''45\L/W%#74T<T3%3HD16'(!]^Z]T:S_33_+T_Y^S\,_\
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MC-U)MNIPG2'6F['P&!QM/1=FU;[AS.=W+1QUF3IL;69:+'1S'[!B?=>Z5_\
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M6H\OR_P=;K50<<:XK^P]!5W'\\/D'\<MCTV^=U;N[1[C&[,A2[>Q%!U[\?\
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M]U[KW_#=6U?^\L_YA?\ Z6IW+_\ 7CW[KW7O^&ZMJ_\ >6?\PO\ ]+4[E_\
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MOW[KW7O^&HLW_P!Y0XC_ -(+_EW_ /W-?OW7NO?\-19O_O*'$?\ I!?\N_\
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M6AR>PL)1EJ'=LE+BLQ3R?[C%H:\UB5<D<,D1\,\.O#)H/3JMOK?#?'G;6_\
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M.Y[]U[K5W[MG[I^57\T?>W76Q^Q\3U!O^NK-^_$SKWL'"XMMR]H?&SXK]9;
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M>_=>Z>?[G?S0_P#O(;X)?^DA]]__ ':?OW7N@:^1>[_YGGQ[^/W>'?53W/\
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M1_=>Z,+_ +*M\N?^]GOR%_\ 1!?"/_[G#W[KW7O]E6^7/_>SWY"_^B"^$?\
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MAK:AJY\%D:&>=5>8J-=5Z(?_ -R\?^; 7_T4?W[KW1],C_V]AV=_XSQ[)_\
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MJ_+G,4:-))M]^L:@DDV\P  XDDI0 4-2<"G5DWW8Y'6..^LFD9@ !/$2230
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MNO=5ZY?_ +>N=?\ _C/7N#_X)#HWW[KW5A7OW7NJ\OY5/_9"73?_ &O>\/\
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M8"_^BC^_=>Z/ID?^WL.SO_&>/9/_ ,$EU3[]U[JP[W[KW5771O6'6F_OG/\
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MRN2IGI\56PK6U],5J8()(-,GOQWG>#_Q+NL?\-D_Z"ZT-HVD<+6V_P"<2?\
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ME=74]=C!$*^O:E>H>E'D(+&[;L!3ZNZX_P"_I/\ H+^7#H6G:]K)K]+;</\
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MIMU0[>Q.QNZ-YY'(Y?=V^/CAFJ44-&Z4IQE;4UKS-/#+1S>_>^[$D_5W6?\
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M7_BGGR6_]\SO/W[KW7?R;_[=Z?(3_P 4S[8_]\CG_?NO="]\9O\ LF_X_?\
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MU?A[]U[KWOW7NM2_YR_]E;_S9O\ Q3/Y-_\ P,O\K/W[KW6VA[]U[JO7+_\
M;USK_P#\9Z]P?_!(=&^_=>ZL*]^Z]U[W[KW7O?NO=>]^Z]T0/N+_ +>/?!?_
M ,5S^>W_ +T/PQ]^Z]TV?(G_ +>"_P N'_M2?-'_ -]AL#W[KW5A_OW7NO>_
M=>Z)E_,;_P"W>_SJ_P#%//DM_P"^9WG[]U[KOY-_]N]/D)_XIGVQ_P"^1S_O
MW7NA>^,W_9-_Q^_\0CU3_P"\'@??NO=#=[]U[K3H^5U><%\J_F^V3P^6?%=G
M]J9WK?:V?AH8ZK C?>R.TOY87;F7V[E*L3>7&9*38=!-6T9:(QS^)D#JX /N
MO=;B_OW7NM>G^4/<]N[78W/_ &+[VX6)YY?Y\?-0@D_U:Q/^/OW7NCK?&AML
M=??S)/YA_5E!493 U?9.U?C)\D,7L^MJ=SR8;<%?DMM;LZX[.[*VM!E7GV]#
M)5Y/;> QN7&-:/\ RBEIC-$'8.WNO=6@>_=>Z(-_-/\ ^W</S;_\5L[5_P#>
M6KO?NO='W3]"_P#!5_WH>_=>ZY>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7]_[EX_\V O_HH_
MOW7NCZY$'_AV#9YL;#^7EV0"?P"WR2ZKT@G\%M)M_6Q]^Z]U8;[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>ZI<_FY_P#%V^.__B,OYC'_ , %W9[]U[I8Y/\
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MZBV3V#D>H<MO#;&![+W]A]HC-_W+K(-XPTAAGFES*TN<DVM+11U$%+.%G?\
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MLK3XFGI,53Y+*BB\\Z4L,-.DLC"-$0*H&WN'-]3S9<7%%7Q(;5J*20-5I :
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MGV"+2HME0 +[]U[JZ+W[KW7O?NO=>]^Z]U[W[KW7O?NO= 9\H/\ LFGY#_\
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MUWD]L5.V(-F)'5+7XU*F:I+.':,K;W7NMO'W[KW5>V6!_P"'6^OS8V'\O7N
M$_@$_)#HZP)_J;'_ &WOW7NK"??NO=>]^Z]U[W[KW7O?NO=$#[B_[>/?!?\
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MU[KWOW7NO>_=>Z][]U[K7]_[EX_\V O_ **/[]U[H^F1_P"WL.SO_&>/9/\
M\$EU3[]U[JP[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2Y_-S_XNWQW_P#$
M9?S&/_@ N[/?NO=+')_\!/Y'?_B0,9_\+9^2OOW7NC!_S(O^R7HO_%F_@?\
M_!U_'#W[KW7?\N3_ +)QW!_XMI\_O_@[/D;[]U[H]WOW7NJI]^?%&3Y.]_\
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M .:5U_VDMT$=D_Y6?>O^:EK_ -HR]:N^_M\?!GL?_A69AJ_>F1R4?8'QP^+
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M  %!T:^.*.%0D4:1("2$C144$FY(50!<GW[K?1!NXO\ MX]\%_\ Q7/Y[?\
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M7NBL]/\ _91OR^_\.#I7_P!]%A_\3_O0]C'?/^56V/C_ &5U_P!I+=!'9/\
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M(-%("C$>_=>ZV /?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5!^Y/^WE&4_\
M&I7QW_\ A,_?'OW7NK\/?NO=>]^Z]UJ3]_\ _'B_+O\ \,'_ (41?_!:?#3W
M[KW6VQ[]U[JOOI+_ +>.?/C_ ,0;\#_^MWRN]^Z]U2#M_P#E<_(/Y?=7_P R
M/K+:OR%Z8Z\Z,^3O\W+NKOS=5/G^E=\[N[;VSN7H#Y$;2Q$."P.YZ#N/:VS9
M<+N23H>CE9JC"2S4Z9"9=;E4(]U[K;"]^Z]U[W[KW7O?NO=$#[B_[>/?!?\
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M:[ 8BNRE/7RX)*+/S53U>.*T\]/6R2^>)9"??NO='D_X:Y_EQ?\ >#GQ<_\
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M_=>Z%[XS?]DW_'[_ ,0CU3_[P>!]^Z]T-WOW7NJ_O@W_ ,S#_F-?^- =T?\
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MB@Q!3J]^Z]T<W_9O?D3_ -ZR?F%_Z,#X-_\ W7?OW7NO?[-[\B?^]9/S"_\
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M<9#6Y:)?'05-07"P(C$$CW;=;O>K]]ROO#^ID"@A$6- $145510%5555  X
M='>T[7:;+8)MMCXGTT98C6[2.2[L[%G8EF)9B22:YZV^O@)V#V;V-\?\A7]O
M;[G[-WOM#O[Y5]2U&_JS;6V-GY'=."Z:^2_:W5NT<IEMO;+QV(VMC\O)M3:5
M$M5]C2P02SJT@0%C[+NC'I,;5_[>C=[?^*$?%+_X(3YE>_=>Z;:3_MZ_G_\
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M &>>_=>Z]_LB'\H;_GW7QS_]&A+_ /9Y[]U[KW^R(?RAO^?=?'/_ -&A+_\
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M="]-;EV+'4C=^'K::N42QU7W<#^5;V)]U[HV7_#F_P 2/^=A\B/_ $A_YO\
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M0&/NO=.R_P S7XENP1*[Y%.S&RJOP>^<#,3_ $ 'QU))]^Z]U2K_ #L_DO\
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MC_[AS>_=>ZHU_P"$_N#PM-\6^T=QTV'Q5/N'.=A=%X[-9Z#'TD.9S&/V_P#
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M=7T/\*SV0;#YD9'#P^7S1PZ$T3#5J-[>_=>Z&L_R]BH);YR_S#P +DGY*0@
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M9LW:%+!AZ;OIZ3<IQN]<O2530U#HE,L?G6\D:CW[KW4O:6QL=3=V;TW)N_\
MDW=B5W2E3--)LKKVA^'?\N(UU.),?CZ:DBKLK_IPCR=)2T4ZU,SH)I'J*@HQ
M98_1[]U[H#\%T;FMK;,^1E)M?^3/OO$[Y[$^5&_NT>KLQD?CA\ MR4.W^HMQ
M8/;U!MS;M;!EN[JF'%'$YC&R5<N)A0P-$C1+(OW#,ONO=+_K3KS=.#[2HLCV
MC_*!W/OOJ^.CW(M9C,/\+_Y=.V:R9ZD0Q[9ICBZ?O2:3[G'RPM42U:58U)+X
M&1M&LZS7Y=:[B1PI3IF\>TO^&V_'_LMV9_N/_P /4Z?]E+_N7UE_>#^[_P#P
MYK_S)W_1_P#WE_T/?Q'[?]C^'_Q?^"WX^YT^KWOK?5N.1_[>P[._\9X]D_\
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M(119&FKHI'E>H2>.1?=>ZV6??NO=>]^Z]U[W[KW7O?NO=5W_ ,J+_L@'X_\
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M?'YZ6BI*N7'TE,Q@=O=>Z!;&_'/XS_&/#[4V%\P-I;.[D[HK</BLATA_)/\
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MU7C_ #$?^+3\-?\ QH=\2/\ WM*WW[KW5+7:%/M.KQ/R9I=^9?*[?V74;/\
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MU[HK?PB^27;%)V3V/\#_ )B[JVAG?E9T3A<'N7:?9&&B&V8OEAT'F4DIMO\
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MIXL=0K'3QSR^Z]T5;*+.?YDE4Y64TR_S6.ME#6?P+._\CG?]P&_S8F:-1?\
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MKX1[5H=XT^*Z^[BQ&W<W#NWYD5>>VW29NIHL[3XO(1+-32U=)%(C*6C,BA@
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MLU+MZDTTS59FE-28_(68M?W[KW01_P NK_CU?EG_ .-"_FI_[^7,>_=>Z/\
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M_+>VQ\L,%U#N3I&K[@^0-3G<3WK%M2?K>7.T?QE[!?:\V0BWJR[>;+0Y)_\
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M3@GR65S,F)VSMK'08K#T,N7SE;DLUE)J>BID5ZBKJ)ZF9KO)([DL?=>Z)O\
MRZO^/5^6?_C0OYJ?^_ES'OW7NC]Y;_BU9/\ [5];_P"XTGOW7NB3?RPO^W<W
MP9_\52Z)_P#?<;?]^Z]T8KY!W/0?=X )/^B#LJP ))/]S,UP .23[]U[JLSX
M@?S#_@C1_&+XB_'O*_+;HO%=IY/XL=![0_@=5OS#_94&YZ_H+%9:#;64W*D[
M;4Q>Z)<3AJNHCQ=3715\L=.VB$FP/NO=,VU:[^99\%/A+@\37=6?!3L#:7P_
M^,%'35V2QWR!^0&%SV]]O=#=7+]W746+JOC5D<=BLSN7'[6:1('K9:>&>8+Y
M2@U>_=>ZM-3NG96'Z8P/=W8>:Q'7^T<AL;;^]\Q7YS((F/P5+F\)1YF2&:L:
M.,U HTJBI98[L$+:0+V]U[H+/E=\B,[TI\?:?MSJ7 ;/[-W#NC?_ $#UYL"@
MW'NS(;:V-E*[OWNCKOJ'"Y[,;JV]M[>&3IMOXG^_RY&1J3'U<L\=/H1;OJ'N
MO=5P?+'M#OO:^^/AY7_-_=7P;^/77&S_ )-X+N''5.R>U_D'V5V-ONJZTV3O
M2GK]K;-V=5_';:]+5S)#O"*HJZJ6K6*DIT)*L67W[KW1GOY>.^MD=M=@?S"^
MW^MJHYW8?8GS"VW7;6WI_=K.[>AW;08+X<?%/;-=44$FY,+A,KE:##[AQ-=0
M>7QO3I4T\Z1L=+^_=>ZLR]^Z]UKV_P SO_LJ#=?_ (K+\(/_ (;%TI[]U[JW
MKYI_]D<?+/\ \5G[W_\ ?6[J]^Z]U5U\0>BMI_)WJ/\ F'?'G?>4W/A-G=S;
M.^)77>X\ULK)4N&WAA\5N?\ EI?%?&U.4VOEZW'Y:DQF?QZS>:DJ)*6=89T5
MBC6M[]U[JQGXQ_ _XT?$R3*9_K+9-5F^UMTP4J]A?(+M//9;M/Y"=G5U/2BF
MER6^^W]Z5.5W?E&JF+RFCAGIL73O*XIJ6",Z![KW1'.R.R]D?RV?Y@6[^R^S
MM[[?V#\3/G]LRLWAO//[MW%!C\5US\L^@]K8G#29JCAS.ZGJ:FF[LZ;@H,=)
M18C%2329?;E"%5FJ)"?=>Z6-+\KOFQ\T/MZ?X,]()\>ND,H**5OF9\S=H9[$
M5N:PM6NP,M_%>A?B<M5@.Q=[2UVW=QY1:+)[OJMJ845V-%EK(VT-[KW19_D#
M\+9_B.FR?YA.U>_OE%\H/F%\8NQ^N:[Y&[SW#GMZ]K;@[#^*>^L_CL'\C>J,
M%\6^J]R;-ZRV1M# ;(W54=@X#%X;;=16TF1VQ2,@K69W?W7NC'Y++_S!_GI5
MI@ML8#?7\M/XHU-=FZ7/]C9VOVQ)\\.V=NJ-V;>AI.OMA56 WGM#XS8G+214
M617+YN:LW;#!)']O0T4NJ5?=>Z.K\;/A3\:OB;#N"HZ8ZVHL9O#>E=4Y?L3M
M?=&2R^_NZ.S<U69;.YVIS'8_;F]:[.;_ -Y5K9;<^0EB%;7RPTHJY(Z>.*(B
M,>Z]T-G:?:G7'2'7>\.V^WM[[:ZXZSV!A*O<>\][[ORM+A=N[=PM$!YJW)9&
ML>.&)6D=8XD%Y9YG2*-7D=5/NO=:]'RI_F^=L]M]@;/^/WP?V;V;M3^_V>V*
M,'ON7K:HA^3O=FU:WL'-X#=.3^*_2O:^T_[C;4ZTI<=M.I:O[6[1DP^U*"BE
MDDQ]%E*D0>_=>Z4OP_\ Y(\N7H8^S_Y@^YZWL?<W8&6V?V#V/\;9MRS=I8+=
M>[=FX7<FU-DGY:?(;>2Y7LCY9;AVGLG(8J.3%4K[5ZPH\Y05$^.VVT%1K?W7
MNKR.TNV^A_B?U%7;\[6WIL#H_IOKG;YA_B6=K<5M/:^"PNW<)55=+@<!CU^W
MCGGIL)AY%H<7CX9*F5(/'3PN0%]^Z]UK\?+#^9M\@OD3GMK?'KX\;,[W^.&%
M[MQ6!HMJXK"[/PT7\Q?O7:^^-P8FF;=?376^Y=PT& ^$_4U)LC'Y^:M[5[3%
M+/CFC5\5B7K8(W]^Z]T.GQ2_DZ'*[*PE7\V&VW'LS.[USO=N=^!W6U14[HZ8
MG[1WGF=W9;(9[Y:][[YJ-R=T_/'M*CQV>QD5=DMQ9.BVI_$L.C4F'>ECIF'N
MO=7V8K%8S!8S'83"8Z@P^&P]!1XK$8C%TE/C\9B\9CZ>.DH,=CJ"DCAI:*@H
M:6%(H88D6..-0J@  >_=>ZG^_=>ZUP?YSV\,EGNX*#KW&;TZ[VZ=@_#GM!L?
M3Y[#TNX<X=W?-7MGK'X1?<STS[IPLU*N"V#V1E\MB:)(TFR^3I!&)?#%,A]U
M[K83V)M.DV'LC9VQ\?(DU#L[:VW]K4<R4L%"DU-@,528J&845-_D])YHZ0-X
MX_0E[#@>_=>Z5?OW7NO>_=>ZH?\ Y3#O)\KOYD<DC,\C[\K7=W8L[LWSV_F=
M%F9F)9F)^I//OW7NKX/?NO=>]^Z]U0Q_*"_[*/\ YB?_ (>Z_P#P;_\ ,L]^
MZ]U?/[]U[JB?XR_]Q /\T/\ \4U^!W_6[M'W[KW5['OW7NO>_=>Z)!\J/G/L
M3XW;IV1TYMS9&^OD!\H.U*O;T76/QNZGH8)]YYO#Y_*YG'3[_P!V;DS4E!LC
MK'JO;4.V<I4Y3<.=KZ2B@CQ\D<7FJ6B@D]U[HKV#^"O=?S,S>*[-_FGYG:6X
M-G8W(8G<?7W\O/J[+)N;XN;'K)-EKC*RM[WW)F-I8'<GR:["H,QF<AH2L%/L
MZ@*1M2X^H8_<>_=>ZMNP^%P^W<70X/;^)QF"PN,ITI<;B,/04N,Q>/I8[Z*:
MAQ]%%!24E.E^$C15']/?NO=5J_SB^W.K.K/Y<WROINRNQ-G;$JM^=)[[V5L>
MBW/GJ'%Y#>.[]Q8^';V#VWM?&SR_Q#/9?(YO.4=.L5+%*8VJ$>71'J<>Z]T,
M/<O3OR@W9V-E=P]:=H=:[<V/6[:H\93;>SVR<)6[FARU"!5QUJ;JK]E;H:&"
M>N=HF22"K2*F6\:"5BZ^Z]\^@RS/0WSMK37RT?>G3YR&3-2U?ELCL? SM5L*
M>&FI5GH#U;-+-1)&K+3PR5CR4*W#3588>/6:GA3[.M9!/"E/3SK]OI]O3CG_
M (_?,2;&5.+Q'='761@CQ]5#BAG=K;/HXJ!VGICC:.FI:7I?*TU''BXX?^!.
MF=9H%%,:16M5+:O5J_9Y?/\ R]/4'3GS Q_76$QN([(ZGQ?<5%6QKO#LS"[6
MP6V,=V!C13862!9<-3]<9V7"QT$U-5TPI0);I)'.*FX\"Z/RZT2?+IUV/UG\
MY*+=N1JM^]^;$RNT:C;6[,534>$P5%'D8MQU. Q]-M3=E-!-U_1)0+3[B-54
MS8Z2KKHJ> 11B6K+/I\>-1PZ\<M48'6?J[K;YP8;M?"Y[M#OW8.Y^J<?492+
M-[*Q.UJ2+*[FAJ]JR4E#E8LJFT<+/MEL=NQ4J4QJ35J_;LP>MD($9]Z=>/ET
M>'W[KW7O?NO=>]^Z]U[W[KW1;N_]M_)7/OM0?'SL':.QXXZFJ_OC)NK P9QI
MJ1/":(8B&6DF GF\LPE+N@4QQ6!N_O8ZV*>?1,>RJ'^;=L;;E/N+K:NZ'[UW
M+D<_BMOUW7597T765+M[;V>R%51Y3L*@W;D=O5<65J]B44=-6?P>2-3DEDGA
M24.L9;U1Y#RZW4>0\N@>^-'5O\ZZES'R9H?DAW_UED\(.\<M%\>MP8_%==8Z
MLK>EH5V_)AJZEPNV.N<BF(GJY8JSS19V:?((I>&PUQ5,6CQKU0Y-1PZ,W#M;
M^8_F<YN7;V2WOU[MW;FVZK#KMCL/%UF ILIV)3;GEJ,SNV2HVA+L'=D.W?\
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MD<?+/_Q6?O?_ -];NKW[KW54'Q5^1'5'PS[F[-QWR+[QZ:ZPZV[\^+7\O+Y
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M]U[_ (<\^(/_ #N>_?\ TBKYK?\ W/?OW7NO?\.>?$'_ )W/?O\ Z15\UO\
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M*P>WLM-)/_$LO5=8RY:OG1(8Y:K(-9+@LWNO='X]^Z]UKV_+7_F8'\S_ /\
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M $5/=G_VM_?NO=>_X=<^ O\ S_B3_P!%3W9_]K?W[KW7O^'7/@+_ ,_XD_\
M14]V?_:W]^Z]TS_RP]QX_>_6'R.[ P/\7FVAV%\Y/E7O38^5R^ W!MMMP;0S
M?8#38?/8_&;GQF(RXQ.11&:"5Z=$E4%DNI!/NO='4[LZ5ZX^0_66Y.G^VL)6
M;AV%NQL'+F,9CMQ;EVCDC5;9W%B-V[?R&,W-L[+X'<^#R6&W+@:.LIZFBK*>
M>.:G4AK7!]U[JG+J&7XE?RSOGG\UL?G*[LG8&#[^ZA^&V_(=V[XD^2'?N4[+
MWKM6?Y*;-W3D*GLS<<7:&8K\AMK;-'MV@>CFR0^SI13!8D1P6]U[H[<W\T[X
M)4ZAZCNRN@0L%#S=0]XQ*6()"AGZU4%B >/\/?NO=1O^'6_@/_S_ &E_]%1W
M9_\ :W]^Z]U[_AUOX#_\_P!I?_14=V?_ &M_?NO=>_X=;^ W_/\ :7_T5'=G
M_P!K?W[KW77_  ZY\!?^?\2?^BI[L_\ M;^_=>Z]_P .N? 7_G_$G_HJ>[/_
M +6_OW7NO?\ #KGP%_Y_Q)_Z*GNS_P"UO[]U[I*;\_FF?!#+;&WGBJ#O*:>N
MR6U-Q8^C@3J?NYWFJZS$5E/3Q(J=;,[-)-(   22>![]U[HDG\F#Y =#]+_&
MWL+8?<?=?4G4F^L=VGL*3);)[.['V?L#>&-5OAY\4Z<?Q+:^[,SB<YCV\]-(
MFF:!&#QLI%U('NO=; >$S>&W+A\7N';F7Q>?P&<H*3*X7.82OI,KA\OBZ^!*
MFAR6+R=#+/19"@K::19(IHG>.1&#*2"#[]U[H@_\NK_CU?EG_P"-"_FI_P"_
MES'OW7NC]Y;_ (M63_[5];_[C2>_=>Z)-_+"_P"W<WP9_P#%4NB?_?<;?]^Z
M]T<[<NX,7M+;F?W5FYGIL+MG"97<&7J(XGG>#%X6AGR60F2"(-+,\5)3.P10
M68BPY]^Z]U4;V[_,EW5VA\7NR<Y\4?BY\^9.RNP^BMUY;XX[ZC^*>27!2[SW
M9L.NK>I=U)4;KKC@X\3+F*^@JQ)D8'IDA.J>)T#1GW7NA6[*^/6VOC#_ "M/
ME9U7MW+[HW/+%\:?F#O7<^\-]2[=JM[[MWQVGM_MGM/?.<W-7;5V]M7!U-95
M[RWK7M$M/04\,%.8XD6R7/NO=';^/_\ S(?I/_Q$?6__ +QN&]^Z]T6'^9+_
M -D[;/\ _%POY?\ _P#!R?'OW[KW0;?S+,]V!@\K\'\ELWH'NWNW!;,^8.U>
MV.Q:_I3:E+O;);#VEL'86_:,UF4VW_%,?F,B=P93=<%-2BC24HR2/)8*H?W7
MNCJ?'GO[9?R6ZSINTMB8S>F"Q+[JW_L?)[=[$VID=D[VVWN_K#?&X.NM[;>W
M'MC*?Y9B\CAMV;8K*=E)99%0.C,K GW7NAO]^Z]UKW_+,@=A?S/B1J4=P_R8
M]2_ZI?\ 3WUM=?Z\CCW[KW1D]_\ PEQW4?6ORM[$WGV;GLGU[1==?+K=^$P&
MW<7--N?![8[-V1OR;)897RFX:/:%?2;1VUG9Z/&XY,=2BLGHJ.IKJZ:6-F]^
M&/LZT,>E*=%Z_E/]-Q;)[CVKD=\[#VYB^V)OY4?P&RF\,K#65>[:],WFNROE
MK1-)'NO.YC=.4:2OVQA,;%+%'D9X(EIE@A8P1(![CQZV<\>M@+W[KW7O?NO=
M:L/S ^:?7G3?SJ_V:[^7O6]09:OGVSD_CI_,)[9["R&]-J_$S=^XFWE#LWH#
M#1[EV%%F<QW[\T^J-[;6S5'C-O;+VWN;<%9M&3)XZLK*"-<>T7NO=-_QS^ G
MRR^=786/^1_R$WWVMUKC*_&U>)R'R8[-VEMO9GS1WI@:OKS(X>DVY\.^F\UL
MC,[*_EW=!RYKL3-SKE=&2[8SJ4U.]75T32LZ>Z]UL;?'OXR]'_%C955L'HS8
ME%LW"97<FXMY[EKYLCFMS;OWMO3=V5J,UN?>>_\ ?N[,CG-Z[\W;G,E4L]1D
M<O7UE6R*D0<111HGNO=#Q[]U[JNG^:+2[&K_ (S;0QW9T>V)^M\E\Q?@#C]^
M4N]VQJ[,K=IUGS<Z"@S5%NQ<TRX:;;U71NT=5'5WII8F*R J2#[KW1-O@=\T
MOAE\8>DMS=:=D[K;J[MQ_DA\MMS=JX:?IOMF'/9?=>?^3O;-71;EW-D\7UY5
M1;CRF6V>,68:]JBI,V/2F"2&%(P/=>Z.A_PZW\!_^?[2_P#HJ.[/_M;^_=>Z
M]_PZW\!_^?[2_P#HJ.[/_M;^_=>Z]_PZW\!_^?[2_P#HJ.[/_M;^_=>Z]_PZ
MW\!_^?[2_P#HJ.[/_M;^_=>Z]_PZW\!O^?[2_P#HJ.[/_M;^_=>ZZ_X=<^ O
M_/\ B3_T5/=G_P!K?W[KW55^Z^V=B=]?-V?MSJG)Y7<O6^:^:_\ *WVYB-VU
M6T=Y;6Q>4SNU]A?,+^\6,QK;QV_M^?)3X5<O2&I-.DL<7W,89@S6'NO=;,'O
MW7NB)]E?&WL&#Y.[#^0W4.Z9Z*?)9+'8#M+!9:>";$G:(QM71Y;(4R5$\=34
MFH@I,>J4D0+BHI8F#)'J,?J]>K^8Z/9[]U[J@#^6=)NC9'S=^0^-GI]OU^S/
MDKC_ )C[SQ=;#792+=.U]P_$K^9W\D=BY?%Y+&/CSAJW"[QH_E!35-+4Q50J
M*>3$RQR1%94<>Z]U?_[]U[HFW;O\P/X?]$]B9;J;M'N?&[>[&P&,PF9SNTZ+
M:V_=U9+"XW<D$]5@*G+_ -T-JY^FQO\ %Z6FDDITFD222-"P6W/OW7N@Y_X=
M;^ __/\ :7_T5'=G_P!K?W[KW1EN@OD[T1\H<)N?</1'8>-[ Q>R]RKL_=K4
MF.SV&K]N;F?!8?<\6'S&'W+B<+F*"KJ-O;@H:V+R0!9::JC="58'W[KW03?(
M7^8K\(_BEO.DZ[^0GR0Z[ZQWS682GW(NULS59*MS-)@:S^)M1Y;+4F#QN5?"
M4-;#A:V6%ZSP":"BJ)4U1P2LGNO='.BECGBBGA=989HTEBD0ZDDCD4.CJ1P5
M=2"#_3W[KW63W[KW7O?NO=5Y_!&..;=G\Q&&:-)8I?Y@W9D<L4BJ\<D;]$_'
M57CD1@5='4D$$$$'W[KW1</BGE9/Y>'R>J?Y<N^LU)#\:NYCNCM'^6YO'>78
M<F>R&W,=C*?:_P#I0^#L\FX,;0Y;[WK?.9*LW%L"*6ORU15;-JIL>LU\'X_?
MNO=![_,L_F._#_>'2OS3^%>S^UZ3=W=D_P 5.Y:O7M;%97<77%/NG&;!SFY:
MOJBL[3P])6[$I.Y(MF8NKSK;8DK5RL>&II*IXD0+J]U[J]M/T+_P5?\ >A[]
MU[KE[]U[I.;MW?M78>W\CNO>NX</M3;.(CCERF?S^0IL7B,=%+-'3QRUM?62
M14U-&\\JJ&=@-3 >WK>WN+N9;>U1I)V- J@LQ^P#)ZI))'"ADE8+&!DDT ^T
MGH+%^2OQQRM#*U)WUT_4TU1!)']S2]C;0J(D$L1Y+1Y=D#*C7()!_K[,/W'O
M<3C79W084-#$X_PKTF%]8R(=$T16G$.I_P !ZUL]C_\ "=;K'?>,R.<ZS_F,
M9G=N"FS-9#49C9G6^P]P4D%='+'4U&(.=PW8%48FIXY(A) LJ'3H++R/<_WO
MOM?VTJP[EL*1SA 0LDLJX/!M#1CCFAI]AZC"#VXCD5GM-T9E)^)8U.1Y:@]<
M>E<>?1MOC[_(3V]T+B/DSAZ3Y2;KW'3_ "/^-^[?CS*LO6>,QL.R(MV93;V3
MFWGC(GWIE9,ID*4[>1/M))(87#\.@55]AK>_>JYWJ7;Y7VZ-&L+]+K^V8^)H
M5@(S2-=([CD D?.O1KMWM]'MZW2+=L4N;5H:>'31J*G6.\U/;PP/LI3HM]3_
M ,)C]N9%Z,Y?YL;TS$=$3HBK^D]LL)U\8B5:N>GWU3U=24C 4,TA8*  ;<>S
MY/O"W$080;3%&6]+A\?8#&0*^>.BQ_:U)2#/?,]#YPKD>A(<$_;7HQ&V?Y!V
M&VW\6>Y/C-%\LMZ3Q=M=P=4]L1;Z7K/#P9':!ZKQ]?CZ';.+Q+;QJ$JZ#(15
MUA-)5))3J@ 5[D^R*X]ZII^8[7F [9#6VM9H3'XK$2>,02['0*$4X4H?ET9Q
M>W_A[7-MHO9*RSQR!PE"GA@@*!K.,^9QT!-/_P )I<=!5U-<?G)OV2HJJ?P2
MLG36 H07#2.E45QF_P"AUU:O,[:VU:F8E@2?9PWO](T8C79X0BFH_78^@IW1
MF@P.%*>72%/;-D<O^\'U%:'](#/KVR"I^WCY]#QO[^0?A-]_&3XY?'&?Y7;O
MHO\ 9?-]]U[YBWU+U9M[*5V])^YLKC,G5X[+X*KW4*&D@P9QHC5O+4"K5SK5
M;6)18^]<UCS!?[ZFV1$7T-O'X8F=1&(%9058)4ZM5> TTQTNN/;_ ,?:[;;C
M>N'MI)6U^&"7\4@D%2U,4IQ-?/HMTO\ PF%VM/!6QS_-;?,\]6E/''62=.X4
M2T,5*"*6"B@B[#BHHZ:EU'PQ&)D@N?&%O[/E^\/=(R%-HA"J3CQVS7C4F(DU
M\S6I\^BG_6IA[C]:VL\#X0Q]E) *>@I0>76R/T%U3#T3T=U#TK3YVHW/3]3=
M;;+ZZAW'5T,6,JL]%L[;V/P"9>HQT$]5#0S9%:#RM$DLBQEM(8@7]P'O>YMO
M.\76[L@C:ZN))2H-0OB,6TU(%:5I6@KU*&W6GT%A#8AM8AB5-5*5TJ!6F:5I
M6E>A<]E?2SKWOW7NO>_=>ZU_?^Y>/_-@+_Z*/[]U[H^F1_[>P[._\9X]D_\
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MQ>;ZZ[J/8/6N[<#G:6F>CK:3)8JH1Z>=BA20*X]U[I0_[*M\M_\ O9[\B/\
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MWS2^?>'V_MS;N+H<'M_ X>@^9W>%/08G"87%T]+C,3BZ&! D-/3Q1PQ( JJ
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M]E_[(W_IQONS_1__ ,/G_P!_K_Z.>Q/[[_W<_P"'/ONO^94?W6_TJ_Q[Q?\
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M'.3Y8D8>J<4\NO5."*8^711]A?RD^I-D;.I=KIW1W^^0H>Q^]=]0[LPN_JW
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MVGO';E3\$?FM73X3<.'P=-29/&RUF)Z"R&,J7I:E&4O!/+$UKJQ'OW7NC?\
M_#E/QG_YTORO_P#2!_G/_P#<[>_=>ZCU7\S7XLT$+5.0I/E!CJ92 U5DO@I\
MW,?2JS&RJU36_'R" .Q^@U7/X]^Z]U7C_,>_F:_%7'[+^,>X:R3Y T%)L[YI
M?&3L2L@SGQ"^5FTJC+X'";MJG2#;3[SZ<V[0Y_,9ZLGAH\72T\[25]9.D<5[
MDK[KW2+_ )5-33YKNSXX]>;5V-O*'<'Q.^+'R@@^:6ZZ]4R>VMD_+3Y@=Q_'
MWMI^H=T[\FS^8CW;\B4PVP,CE]ZXW'39"';4D]+3UL\%3.E,ONO=6J?S(O\
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MT7P9VQGJO=/]Z-O[Y^4+1[GRF+[N^8^&Q>!K=OYZIW]W1C*/(;_CRV+GR(W
MV/POVBY"&DJ<31)1BOUKL=;'01=^= _$[X]9+KWM_P"8O8>_^VNRMX=0;)V7
MU5LCJ"F[2W#\B^W^Z>OML;PKJI>G^H-GP93?.Z:C(=6N^!G.4+8]J!47.NK2
M?<+H8'6A@?;T1;?F^_E'\_<TWQ3V/L?%O@-@[?ZYQ6*^"?3W9E'N[XY?&;'T
MN-J]AU-1_-2^7>U<UM[.[UWEM7=$N6=>B]@3UD]2-F"'+5$T52]2/=>ZO?\
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M $J'(?\ V+>_=>Z1F]OY576/9F/I<1V9\E?F=V5B:&K&0H<5V)W3AM]8RAR
MADIQ7T6/W7L#+TE'7?;S/'YHT630Y6]B1[]U[H,_^&/OB-_SUO=__GXZK_\
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MEX%\+>Z]T6O_ (;B^9?_ #^7_A2K_P"G5OY>W_U]]^Z]U[_AN+YE_P#/Y?\
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M_P"G!/F'_P#;C]^Z]U[_ (;JZH_Y_K\\_P#TX)\P_P#[<?OW7NO?\-U=4?\
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MW#D4VYD\&'R.\<+\D<3O3!5F)K:^.<)3X>IIZB&!AY$D=4]U[H0/],G\Q_\
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M-MFOW+D-Q5/97Q<[+Q&1V1N7R4%"\=-3XJIECU5@9O=>ZN9[,ZSZ_P"Y>O\
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M4ZT^5/4G;'QD[E7YC;?ZJ^0?>O7/R V7O7J7<<._<K\8^INL<IN+:?<G4/\
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M';$[FZMS^]J9X</EL"]2N+VZ,10U8@D2-/?NO=7.^_=>Z][]U[JICMRLW/\
M#S^8=L;OI4H,I\?/GVW6?Q@[8BJ]Q;6P61ZX^1>R,=O+(=%[_HZ7)X>@KMP;
M8WCLZ/*;=R%/'E9:F&O6ADBIG4D#W7NK9_?NO=$T^>OQ9PORY^-F\.NWJ*[
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MY4CW[KW1(/YB/_,B.OO_ !=#^7I_\'7\>/?NO=0OY9W_ &27CO\ Q8/YL_\
MP;'R%]^Z]T?GW[KW7O?NO=:YF:W/MG9F\9-S;QW'@-I;;Q7_  H1S4^4W#NC
M,XW;^"QL)^).9C62OR^7J:/'T:22NJ(9)%UR,JB[, ?=>ZNL_P!F[^)__>3_
M ,>/_1U=;?\ V2^_=>Z]_LW?Q/\ ^\G_ (\?^CJZV_\ LE]^Z]U[_9N_B?\
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M[=^X"K4?P+"8W$>=5)91-_#Z:G\H5F)&J]B??NO=$7R__;USK_\ \9Z]P?\
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MPT@>_=>Z&S_9;OGU_P![*9/_ $COI/\ ^O'OW7NO?[+=\^O^]E,G_I'?2?\
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MW+2["Z_Q#5<^0AGCK,!DJ2EI9!1U\T?NO=$!_P"%:W3F3[1_DY]A;NQVXZ3
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MT[Z[;W7C^]OD5OK?'QDPVU-N8["TW9_=G<N-^67\P_*;8VQ+VAC:G<-1W5O
M9;XT_!U=XXS<M)F:Z@ZOPN0R=))5U%,F;H1!%''[KW1A/C]W7\8>J\IG.I_Y
M/OQ'J_EMOO([CAI.YODW'N6NP'2<>86KZWH]R9KO'YV=C4&]=R]R;Q@VSF(J
M\8O;*;URTSXB2%J>F*!E]U[HL7SR[YZDZ5QPW%_.J^=^(JA7U!R.Q/Y7WP8K
M]VX7;V]*FBS5/F]J8#?U5AYZ+Y ?(.3*UFWL?3339V;:.QUK:MDGQ\5/-K/N
MO= =TWNC^;I\]]H4^UOY?WP^ZV_DY_R^#@L)C=A[RWL:?J_Y!]K;5Q@PXV7D
M\9@]C;/RFX]J;.K>N\O1U,4>%IL14M)2U-+1[Q.HE/=>ZLN^%W\A'XA?&6MQ
M_8/<'\0^6O>*5M)GJS>W;E''4;-H=TPT77D4F?V_UO45F8H*O._?]98NJ&;W
M%5[AW')-#KER#L??NO=7C4]/3TE/!24D$-+2TL,5/34U/$D-/3T\*+'#!!#&
MJQQ0Q1J%55 55  %O?NO=5\_S._Y>_67\R?XF=B_'K?,7\+W368R7/=2;_H:
MUL+FMA=I8%6RFR,U%GJ7&Y7(4V!7<=-3#)T\<$PJ*,-:,RK$R^Z]U0K\'/EU
MO;Y"?#'^5[OKN/>\=+\ROA__ #)^K/A?D-QAL#OFK[J?>VSEV'VOBZFNS[[J
MW>-T5/Q2[2FRN[A(<-EL/N/"U,]1#!%2*GOW7NMO;W[KW7O?NO=>]^Z]U[W[
MKW57/QB[(W]\K/FE\DN\\+OG<U'\4_CLU5\2>IMH8?/5,&R>V.Y-O9&+,_(#
MMG-XK'[FK,9GSL7.RTNTL/-4X^!H)J/(Z&+!C[]U[JT;W[KW7O?NO=>]^Z]T
M5_N#YL?$3H&>CH^Y/DCTUU]DJ_,UNW:/#9_?NWXL]49S&TT]9DL8F IZRHS/
MW>-I::1ZA3 / J^O3Q[]U[HM6,_F;;<[(HMC5GQN^)7S=^0M-V%++5[>W!C/
MCYG^DNN7VG'@<MGX]\5';?R<JNENM$VYD8L;'!0A,G)5UU160"&!E9G7W7NB
MA;S_ )F??\.X=IXC?/;/\LCX.G*8/<NY\CLOLON[=OS0[V...;BP^R:6NZ\Z
M/J.F-@[9%4E!D&R%92[QW'"U8L=+2+*4FE'NO=$P[)^6N[JW:E#V+VY\C_YC
MO<F(Q>Q-R]QT4> QO3W\F#XU5=/O_*FDZIP]/N;N#,]6?)[<^V33Y2CH<<D.
M;WI+Z&KJN.>H9:7W[KW1<MB8.AW95U%)\-_A[T%D\[LE]@]3['[4Z.^,_?O\
MR'?%)V!N[#*_9N\*SYK?+V?XR?%#!;BVUL#=N-3(U^?IMS"6KJ<C]U/*Y%(W
MNO='PE^"G\QSOK:F^]O[YF[$VAMGL+<./V/18[OOYZ;EV)0;*Z(H'Q&U<_CZ
MOX?_ ,MGK;J7X^Y9]V;(IJ^>+&TW8,$\E=6K]YD$C#1#W7NC)=2?R7,=M7,U
MNX=V]\TVP6RO8=!OG);1^%O1_6_Q;P\M/MS!MBMGX&/MBMA[8^5L%/A:Z:7(
M/+!V) 9:AE1$AB30_NO="-O+XN_R>_B::+>7R$'1LN\-L;V3=,V_OE;VG-VY
MVGD.P]];CJL[C<SF,AVYN?=&Y\_N7)9C.EL;KAE>"'Q+3*D4487W7NECL_\
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M[0V[W'L?%;^VO3Y:CQ.5EKX$HL[34U)EJ2?&UT]!40UL%%6Y&D1_)!J7QSR
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M_AS35_H@_P!"WW']UOO_ +?]C^!^3[3^S>W'OW7NK@LC_P!O8=G?^,\>R?\
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M;>/^2FXLQO67/8#8\>?K\502=?[VW%MI:B3-2-C8Z6:KI95H[TCB/WY#KWY
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MK_%[_P"PSW[KW7O]E@^<7_>SC?W_ *2O\7O_ +#/?NO=>_V6#YQ?][.-_?\
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MSW[KW7O]E@^<7_>SC?W_ *2O\7O_ +#/?NO=>_V6#YQ?][.-_?\ I*_Q>_\
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MK_%[_P"PSW[KW7O]E@^<7_>SC?W_ *2O\7O_ +#/?NO=>_V6#YQ?][.-_?\
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3<_NQ]K]_Y_\ )/']Y[]U[K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>nt10016217x4_ex10-15img08.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img08.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!YP*\ P$1  (1 0,1 ?_$ :(    & @,!
M      <(!@4$"0,* @$ "P$   8# 0$!            !@4$ P<"" $)  H+
M$  " 0,$ 0,# @,# P(&"74! @,$$042!B$'$R( "#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL? F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M  (! P($! ,%! 0$!@8%;0$" Q$$(1(%,08 (A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M  P# 0 "$0,1 #\ VO\ =>Z_F+W#\Q?D)TKTM\A.LNB>O^B>L_CKN&"#</QT
M;N3/[ISW<A[=J,S55>9J.W]@4^+H<7!U_2QT]/'22$F61FD-U4>Z]TL?]!G\
MQG_O8#T[_P"D)TO_ -TS[]U[HN=))_,EJ?EOG_C&?FYTBE!A?CGM#O>/> ^$
M2G(5-7N?LS>_7TVVGQA^2HI(Z.BAVBE4LX<R.]0R$!5!/NO=&,_T&?S&?^]@
M/3O_ *0G2_\ W3/OW7ND-V?U[_,>Z[ZU[#[ A^>73&5EV-L;=N\8L9/\&8*>
M'(R;9P&0S24$U1%\F&D@BK&HA&SJ"RAKCD>_=>Z*I\->S_YEORKJ=_T^1^8O
M16RALK8WQAWA%)C?A9)EAD9?D-\?]H]V5V/E^\^2-.(8]JU6YVQ\+K=JB&)9
M7"NQ4>Z]T>3_ $&?S&?^]@/3O_I"=+_]TS[]U[HN7RYE_F2_&'XV]O=^4'S=
MZ1WA6=7[5?<=/MG(?")<719F1:^AHA25.0I/DK-4TD9^\U%T1B-/T]^Z]U*^
M3:?S(OCUUEC.PJ7YP=)[HFR'<7QXZL.+K/@^E!#%3=Y=^=;=+UV:%13?)AY6
MJ=MT._9,C!%;143TJ0N521G7W7NHWRPD_F2_&GHS<O<5#\W>D=W5. W+U;@%
MP-?\(EQE+4Q]B]K[(ZUGJGK*3Y*RSI)B:?=[5D:A;2R0*C$*Q(]U[H#<3OS^
M<UO;8]1OGIOMWH?N1ML_*KY+?'_?^S:#X[;7ZVS^.V7T3V)VKUA@NQMM9K?7
MR-.W<KF=Q[DV/BGR&+G:%::FR50T$CM3H)/=>Z0N_.__ .=7UMF^J=O;KVGC
M*;*=T]C-U5L&.DV-\7*N&LWDNP-^=F&ER4Y^4<(QE"=I];9603D.#41Q0A=4
MJD>Z]T(_]Z/Y[_\ SQ&WO_04^+G_ -TY[]U[I#9;=O\ PHP7-RK@.NNDY=L_
M=;)$$V=P_1D&XC02Y;+KV:T]-C?D/48E:ZBV^N/?;:K*8JFO>J2O,$*0N_NO
M=+G^]'\]_P#YXC;W_H*?%S_[ISW[KW7O[T?SW_\ GB-O?^@I\7/_ +ISW[KW
M4#*[J_GZ+C,BV"V)LN7.+05APT6;VS\:8,-)E13R''1Y>;'?):HR$.,>KT"H
M:"-YEBU%%+6'OW7NNL1NK^?LV*QC;@V)LF'/-CZ(YN+ [:^-51@XLN::(Y*/
M#3Y/Y+4^2FQ25NL4[U$<<[0A3(JL2![KW3A_>C^>_P#\\1M[_P!!3XN?_=.>
M_=>Z]_>C^>__ ,\1M[_T%/BY_P#=.>_=>Z]_>C^>_P#\\1M[_P!!3XN?_=.>
M_=>Z]_>C^>__ ,\1M[_T%/BY_P#=.>_=>Z]_>C^>_P#\\1M[_P!!3XN?_=.>
M_=>Z0"?)K^9R,%V)'N?NW8'4W9/4WRL^)7QGWOL#>7Q:V#OFD--\J=W]*8O&
M;ZP&[>M_D_/C:O\ @.T^XEK%HIDB=ZZA\,A$4GD'NO=68?Z#/YC/_>P'IW_T
MA.E_^Z9]^Z]T7?)'^9)0?++9GQG7YO=(RT.Z_COV;WI+NYOA$JU]#5]?]E=2
M[ I]MQ8P?)4TD]'E(>S):J2=G62)Z-$4,)&*^Z]T%_;O<'SQZ+[)^1.W^QOG
M%U13=<?'/XB[(^5^Y=W;>^!DVX-UY+&[EWKWAM;,[8QNTZ7Y+**ZIQM'T_'/
M1B%S-5U&0:(A0B%O=>Z16&[Q_FM[Y[#ZFV'L3<?:V(H]Y]@TV#["WQW/_+ H
MNMME=;]?+MK<V5R>]'S7^S@Y(Y#*09O&8Z@IZ'PMYS7LW'C]^Z]T,7RWW=\_
M_B=M'J_?.Y_G_P#'.GVKOCY ]0=,[GW'O3X=8W:&W-D8+L[<)P==O6OSE;\G
M8,;3C * Z)5214\KL%9Q<>_=>Z#WNOY'_)S970/?G;W2?\UCX5?(3=O2'4F[
M.UY>NMC?'/8NYJS(X[:]/$S-EDV;\LLUE\3A9*ZJ@@EK!"4B>9!RS*#[KW1[
M?]!G\QG_ +V ]._^D)TO_P!TS[]U[KW^@S^8S_WL!Z=_](3I?_NF??NO=>_T
M&?S&?^]@/3O_ *0G2_\ W3/OW7NB\[N['[JZ_P!QY39^_?YS_P %]D[MP<ZT
MV:VMN[X^]6;;W'B*EXHYTI\IA,S\OJ+)X^=X)4<)+$C%&!M8CW[KW2;_ -/.
M^_\ O>3_ "\__1,],_\ W9'OW7NO?Z>=]_\ >\G^7G_Z)GIG_P"[(]^Z]TZX
M/MSM?<^8QFWMM_SL?@1N'/YNOH\5AL'@^B.I,MF,OE,C4Q46/QN,QE!\PZBM
MKZ^NK)TBAAB1Y)9755!8@>_=>Z=MZ;^[SZWW'DMG=B?SE_@[L+=V%>FCS&UM
MZ?'?K#:VX\3)64<.0HX\E@\Y\O:')T+U=!4QSQB6)#)#(KK=6!/NO=)3_3SO
MO_O>3_+S_P#1,],__=D>_=>Z]_IYWW_WO)_EY_\ HF>F?_NR/?NO==CO??K$
M*O\ /(_EZ,S$!5'3'3)))-@ !\R+DD^_=>Z-'3=*_P Q&MIZ>LH_YA/2U725
M<$532U5-\&*&>GJ:>>-98*BGGB^3;13031,&1U)5E((-O?NO=9O]!G\QG_O8
M#T[_ .D)TO\ ]TS[]U[KW^@S^8S_ -[ >G?_ $A.E_\ NF??NO=$GZZ[Q^7.
M1VKN_<O>'\S[X@?'\83Y$?)/HK;,/8'QBVCM*GWA3_'KMO<'64^X<74;S^5F
M%-;6Y*EQ5-65U/3"2.BEK%CN5*,WNO=9.J^Y_F3W?\IMX?'SJ#^9?\2>U-K[
M.Z V=W)D^QNM/BWM;?BT>>W7V+O39/\ <G*P[8^5.4Q6,:GQ^U8Z^)I)5J)?
MN&&C0H)]U[KW:7='S(Z2^4VU?CWV_P#S,/B3U7MC=O0&Z>Y<7V+V7\6]K;$%
M=GMM]B[5V0=E8J#='RIQ>+R1EQ^XGKI7CE:HB\*C1H8D>Z]T93KG"?,;N'"U
M.Y.I/YIGQ=[2V[19&7$5F?ZY^(NTM[X6DRT%/35<V+J<IMGY5Y.A@R,-+60R
MM T@E6.5&*V92?=>Z#;?+?S)-G?);X^?'^/YO=(U]'WAL+O_ 'G5;GE^$2PU
MNW9NDY.HUI,?28Y/DJ::NAW"O9TIFDD=6@-&@0-Y&*^Z]T8G_09_,9_[V ].
M_P#I"=+_ /=,^_=>Z]_H,_F,_P#>P'IW_P!(3I?_ +IGW[KW7O\ 09_,9_[V
M ]._^D)TO_W3/OW7NO?Z#/YC/_>P'IW_ -(3I?\ [IGW[KW7O]!G\QG_ +V
M]._^D)TO_P!TS[]U[KW^@S^8S_WL!Z=_](3I?_NF??NO=5T=3=]?S+^S-R?%
MC S_ "YZ%Q"?(_L/YN['K*JG^&,U3)M2#XB;^WKLO&9*BBE^2*KD9]]0[26H
MJHY2JT3SLD1=5!/NO=6+_P"@S^8S_P![ >G?_2$Z7_[IGW[KW7O]!G\QG_O8
M#T[_ .D)TO\ ]TS[]U[HN/7<W\R7?7R/^2/0LOS<Z1QM)T'@>BLS2;FA^$:S
MUNYG[CPF]<O4T]9CY/DJM-CTP!VDB1-&[&83L6 TB_NO=&._T&?S&?\ O8#T
M[_Z0G2__ '3/OW7NO?Z#/YC/_>P'IW_TA.E_^Z9]^Z]U[_09_,9_[V ]._\
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M;I_V<7[7_1+_ *;?L?[R?WV_W&?Q#^-^/^&\_;>7U>_=>Z.1T9_V\9_F _\
MB'?@G_[B_)GW[KW5A'OW7NJUOC/MW!R_S$?YF&\Y<723;LAD^(^RX-Q3(TV5
MI]H0=$TVXX=L4M3*[FDP<>X,M5UWV\02-JNIDE8%V)]^Z]T-/RQ^8FV/B3C<
M!E-S]<]F[]I]P4^7G@7KO;YSTU.V(%(TM/-$LBN)Y8ZK6HX&A&-[V!]^RO7O
M+RKT(GR#KX\K\7N[\I#%-#%DN@^RJ^*&I0Q5$4=9UYFJA(IXCS'-&L@#+^&!
M'OW7NM<[ ?&^A^<75^0ZJZ]^$/Q;W!OW8WPH^'W6FY_E3V#WQO3J3NRCS_9O
MQ"V;G]H;IV/!LSXZ=J4XR?5F-S$'\+JLA7L5JZ5!X?"-)]U[K85QV^MU_'#X
MD;;WY\H,SD.P-]=0=(;2R7?^Z.I=B[DWC/NC>.V=IXJ+LS=FR]A;/VY_>7)X
MRMSL%9D(J6BQ4<L=&213QA"B^Z]U5E\G?G-LWY__  EW1L'X=]%?+GNF?Y2;
M=VKMGJ3>]/\ &;M78O4-?C=V[KPD)WWG.W>Q=O[7V%@-C[<H(YZW(5,]:)DB
MIGB2%Y[1^_=>Z.%_-$WML_;G174FU<]N7#XG='9OS6^".UNN=MUE6JYW?6Y,
M5\P.E=Z97";5Q2"2MS%?B=F[8R66JUB1EIL=CZBHE*1Q,P]U[IY_FG?]D1]C
M?^)$^,O_ ,%+TO[]U[IS_EW_ /,K.^/_ !??^81_\&1W-[]U[IH^=F<P>W.S
M/Y;V6W%F\/M[$T_SRC2?*9[*4&&QL4D_PX^8,5/%)7Y*HIJ5)JF9A'$A?7+(
MP1 6(!]U[JP[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=:]/;V?P6X^T/G77[>S>(SU#%_-1_DYX^6MPN2HLK215]!F_
MA#3UU#+44$\\,=;1SH4EB8B2-A9@#[]U[K86]^Z]U7YN'_MZEU!_XS\^1W_P
M1GQ7]^Z]T0S^95_Q]/\ -(_\8Z]4_P#OY/F?[]U[J_;W[KW3+N#;6W=VXN?!
M[JP&%W-A:EHWJ</N#%4.9Q=0T+B2%I\?D8*FDE:*10RED)5A<<^_=>ZH$_FR
M=<]>;#KMWOL;86R=F29#^55_,U3(3;3VI@=N3U\<.\?A"88JZ?#X^CFK(8&8
ME$D9E1F)4 DD^Z]UL*^_=>Z][]U[KWOW7NM9CI'JC<W?'SZ^:74&![/BZ=V]
M1=I]Z]NYG*[<Z)^,?96Z=U[KF[!V5L.E7,;@[\Z:[6JZ7$XK;^.C2GIJ(4R^
M1F9BW ]^Z]U8G_PVCNK_ +S*W]_Z23_+=_\ N-O?NO=>_P"&T=U?]YE;^_\
M22?Y;O\ ]QM[]U[JI_OCX[Y?NKHK;V"W?C>SNPLY\4OYS5%32]\?&?XL=0Y#
MY&;7ZWZ'V)N#>FPMW'KWJ+IM=IY^+#=HY'$4F1,6VIJ>HI)P)Z=N2/=>Z078
M.Q,IL#>OR6^3.P-I_)7<>]LI\?LSD=X_*#YJ_"79_7>8C[C[2^0WP\ZQPU!M
M;;&]NBM@]>9^7;_4>PZJ6CIEP=53TK12R3E_*5]^Z]U<[_PVCNK_ +S*W]_Z
M23_+=_\ N-O?NO=>_P"&T=U?]YE;^_\ 22?Y;O\ ]QM[]U[H@WSA^/\ N;XZ
M45%LO-]O4O>FQ^\/CA\]L;NC:_8?QE^&VV!CJOK?XF;\W]M7.;>W#T[\?.M=
MS8_*46>H8RP>KE@DB)!0$ ^_=>ZOB^.#I%\<^AI)'6../I3JYWD=@J(B;%P;
M,[NQ 5547)/ 'OW7NL$GR2Z43L3:O5D>_,55[PWK69/&;<I<>M3D,;7YC%8+
M^\]3A/X[1PS8:',R;<5ZV&F>=99Z:-W0,%-O=>IT.7OW7NM?CXM;+V;OCYH;
M0QN]MH;6WECZ;=_\]VJI:'=>W</N.DI*K_AQGXSI]U24^9HZV*DJC&2AEC"N
M48J3I)!]U[J]7:G7/7VPS6-L?8FS=F-D1$N0;:FV,)MTUP@+F 5AQ%#1FJ$)
MD;1KU:=1M]3[]U[KK=?7/7N_&HWWQL39F\WQZRK0-NO:^$W$U"LY4S+1MEZ&
ML-,LQ0:@FG587^GOW7NB.?"O;6V]H_(K^9I@]I[>P6UL)3?*SJ>2GP^V\/CL
M%BH))_@W\4I)Y8L=BZ:DHXY:B0EI'"!G8W8D\^_=>Z<>[O\ MXY\!?\ Q!WS
MP_ZV_%/W[KW5@OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K7M^*O_,P_Y8'_
M (GS^=#_ ._S[C]^Z]UL)>_=>Z][]U[JAOY&]F=D=0]L?S6-[=2;OEV!V!'C
MOY6^U<'O.GP6W=S5>VX>Q>PLSUWG,I08/=V,S.V:_(T^WMU5?VZUM)44Z3E'
M:-M-O?NO='J_V4_Y2?\ >SOY1?\ HF_@O_\ <J>_=>Z]_LI_RD_[V=_*+_T3
M?P7_ /N5/?NO=>_V4_Y2?][._E%_Z)OX+_\ W*GOW7NDGNCX)=T;X6C7>W\P
M/O'>2XXS-CQNSXY?R^MR"@-2(Q4&B_C7Q%K?M#4"%-?CTZ](O>P]^Z]TD?\
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M"NDER\^>AH?YC'S<-=08K'59J!44,3=C'$5U73X:)TJHDKF,=:0B>0C2U6#
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M\@>F^ELKN;,_%3+[<QO:G8^TMA5N?Q-)\>\10563PM/N?*XR3*4%/7QM!)+
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MPV1^PRM##.B5$$L?EB4E38>_=>ZL.]^Z]U[W[KW5)G\W[_BZ=&_^(&_F9?\
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MU=K=M]/4&$Q.(Q_6<,UY$K)IIJI_4JJ![]U[I[_V3GY=?\]U_+0_]-N;M_\
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ML[K[(8H;6WAF]O["WG2[:VS!D7R-/B5&0K(H(JFK26/W7NG_ *HZ#Z-^/_\
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MO='!_P!)G\IG_O9G\K/_ $X1\VO_ +8/OW7NO?Z3/Y3/_>S/Y6?^G"/FU_\
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M-LJ?'97<NW:U=GT%/-C,R,ECGI8?&( #?W[KW2 _X;PHO^\U?YB'_I5>?_\
MK%[]U[KW_#>%%_WFK_,0_P#2J\__ /6+W[KW7O\ AO"B_P"\U?YB'_I5>?\
M_K%[]U[KW_#>%%_WFK_,0_\ 2J\__P#6+W[KW7O^&\*+_O-7^8A_Z57G_P#Z
MQ>_=>Z]_PWA1?]YJ_P Q#_TJO/\ _P!8O?NO=>_X;PHO^\U?YB'_ *57G_\
MZQ>_=>Z]_P -X47_ 'FK_,0_]*KS_P#]8O?NO=>_X;PHO^\U?YB'_I5>?_\
MK%[]U[KW_#>%%_WFK_,0_P#2J\__ /6+W[KW7O\ AO"B_P"\U?YB'_I5>?\
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M /ZQ>_=>Z]_PWA1?]YJ_S$/_ $JO/_\ UB]^Z]U[_AO"B_[S5_F(?^E5Y_\
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MSW[KW7O^&I/@1_SXVL_]&_WG_P#;,]^Z]U[_ (:D^!'_ #XVL_\ 1O\ >?\
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M;&3UV26MQVQ<%EIC-@*ZEII)ZI/&/=>Z!?\ X=>^0?\ SU7PN_\ 1-_S-/\
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M=?,7_P!-.==?_=F^_=>Z]_LQ?\R/_G=?,7_TTYUU_P#=F^_=>Z]_LQ?\R/\
MYW7S%_\ 33G77_W9OOW7NDAU9_-\[GZNW=OG$=ZQ8#Y";&V%5Y'+]J87"]7;
MA^+WSP^-VS<=E\=M?+;T[ ^&6\LONJ+N_J3"UNVMUYJ7<_6V=S9BV_CTJ)*5
M@&8^Z]UL/[$WWLSL_9FU^Q>N]T8/>NQ-[8/&[FVENW;61ILM@=Q8#+TT=9C<
MMB<E1R2TU715E-*K(ZL?K8V((]^Z]TJ_?NO=5Y_)+^8]U'T9OW,]$=?;1[ ^
M3WR?PN(Q.;S'0W2.+ILA6[!P^X<3F\W@=Q]X=DYVIQ/5W16U,CB]OU%2E7N/
M*TE1)2Z)H*:>.1"WNO=5O0_S@^ZMP9K=-/BMP?R_\$V$SU312[.VUO7Y4?*[
M*[3Q]0D>0VW2[X[0^*_1F]^GEW=F=MU5+DIL;09&=Z&&LB21B]_?NO=.'_#K
MWR#_ .>J^%W_ *)O^9I_]R_[]U[KW_#KWR#_ .>J^%W_ *)O^9I_]R_[]U[I
MWZ__ )NW=M7V91[1J>NN@?DM$F(H<KNKJWXN;F[=V%\K]OX7+9^"BH-^[(^/
M?RRV%U%GN_=ET.$PNY*S*)M.>HK\>N$;4CF14]^Z]U<!\9OE5T+\O^L\7VO\
M?^Q,)OK;5;%#'EZ"FG6DW=L7.'RQU^S>R-G531[BV!O?"5E--35V)RE/35E-
M/"ZLEA<^Z]T8;W[KW7O?NO=5*=\?S4,#A\_V;U]\1^N<7\EMT]/8C=R=R=J[
ME[,V]T5\2NAMYX>JHMOX#9?:GR-WY2KL^LW7E-V9..GJ<-@#E,G0PPS&=(I1
M'')[KW11:?\ FV=UU[5_\#[2_E[[RHL;F<YM^?<76^UOY@W9VR*S+[9S-=M[
M/P;?W]L+X[9_9VZ:3&YW&5%*U5CJRHIGDA8*YM[]U[H@FRL[UKLS<'R9W-)M
M_P"'>]<G\N-X=[[N[F3L#K[^:+N''9%/DIC>M,7W#M/!XR'XOXRBP^T=S0]1
MX)XX2D]91RTEX*I VD>Z]PSTO<3VUUQA*'K[&T'5WP!-%U5OO,]F=?PY#J;^
M:KF#MO>NX^LEZ:W!EJ>7+_'BNFJZ?.=9(N(K**I::@J8$5Y(6F59![KW3I3]
M\[?BV)OWK.MV]\-MQ;*[-VC1[ WGBMY[8_F][WJ,CL?'2F?'[2H,UN[HS-9W
M;NWZ&HM+%38ZII8UE19+:T5A[KW2IKOE5!E)LK4Y3;'P4R=5E]R=8;OFK,CU
M1_-0KJW'[DZ7QVWL7U=E-MUM5\<Y:K:4NS:7:U$U*F+>DC-0DD\BO/45$DNJ
M=:H.@H[>[+VQWAV/TGV=OZB^']9F.A]_]T=G;3P='US_ #/8-H9S>'?VQY^O
M^RJ[>N!JOBS7#.4^2P<^NGAAEI$I:I1(G!9&W\^M\#7H2]D_)ZEZ^KVR^W,#
M\*)LW*[?=;@W7L'^;-O[<>1ICM?)[+CQ>7W#OKH#<>9S&!I=K9NLHJ?'U4\U
M#3Q5<QBB5I9&;U<4ZW4TIY=,^\?D#B=\]9=9]/9G$_$/&]>=.5<U9UGA-C8;
M^<3UE5[1>IQ>5P=32X_<?7'2NU=SRXJIQ&;JJ:6BGK):.2&72T9"II\<]>)K
MT]U7RRH<GB)>MZ'_ (:OP>;>GPW9&PMB]F[V^;WQ.BWCNGHK'X:AVA1[)[)[
MEZHZ]P>,W!1)4T6/G:DJY))J6NE-=#4TTU4)/=:H.K!.A^R_B/7=JTGQ%^07
MQ7R?PP^0B]&XWXL]2]<[[W1DMQ;-[H^-!V8V1Q^V^AN]-JY$;'WW+@L515]!
M5T:5E-O/%/13!D$,BR/[KW5GG1GQVZM^..W\EM;JBCWK0X3*UU/D*FFWIVUV
MWVW/#-2446/IXL9DNW-\;YR>$Q\5) JBDHYH*6XU>/42Q]U[H;_?NO=%;^7'
MRXZP^'/5Z]@]@QYS<FX-Q9JBV3U)U'L>A&<[3[O[2SFJ+;'6766V$D2?-;DS
M=2/6Y*4E!2K)55<L--%)(ONO=4_5_P#--^:]+NU.K<?UI\7-_P#?=%F*?;O8
M'Q\^/^,^57R)W;TKNU]DGL',[+[1[)V=UWA>E<5G]F8*2"GR@_CL4@R%3!!%
M [3H/?NO=*O_ &?W^:?_ -X+?^P5[]_^O7OW7NO?[/[_ #3_ /O!;_V"O?O_
M ->O?NO=>_V?W^:?_P!X+?\ L%>_?_KU[]U[I,;(^3?\PC-[SZNV3W%W'V5\
M>]S=R;JSVU=OY/<?\L>@HNF,?NZ@V1OSM-=FXW>>9^5&3W9/%#LG8&2%+5Y&
M@@DK9J3UK"\JQCW7NF#9?R]^?'8NS]J=@[%WO\N=T;(WUMK![QV=N;'?RFMA
MICMQ;6W-C*7-;?SM M;\Q:2L%%E\36PU$7EBCD\<@U*IN![KW2E_V8O^9'_S
MNOF+_P"FG.NO_NS??NO=>_V8O^9'_P [KYB_^FG.NO\ [LWW[KW7O]F+_F1_
M\[KYB_\ IISKK_[LWW[KW7O]F+_F1_\ .Z^8O_IISKK_ .[-]^Z]U[_9B_YD
M?_.Z^8O_ *:<ZZ_^[-]^Z]U[_9B_YD?_ #NOF+_Z:<ZZ_P#NS??NO=>_V8O^
M9'_SNOF+_P"FG.NO_NS??NO=>_V8O^9'_P [KYB_^FG.NO\ [LWW[KW7O]F+
M_F1_\[KYB_\ IISKK_[LWW[KW7O]F+_F1_\ .Z^8O_IISKK_ .[-]^Z]U[_9
MB_YD?_.Z^8O_ *:<ZZ_^[-]^Z]U[_9B_YD?_ #NOF+_Z:<ZZ_P#NS??NO=(/
MLCYK?.[J3:\F]=_]R=M=/[:I,K@\=/V-\DOY7%-M'X_[;KLUEZ/%8J7N+?76
MWREWCNKKW8-?D:J*DKL]'030XE)Q436C1O?NO=6Q_"KYEY?Y%5'8G4G<G7#=
M+_*;HX8"H[3Z\Q]?6;HZ]W)LW>;Y9NMN[NC>R&Q]#C^QNF.T*/"53XVL58JZ
MBJZ2JH:Z"&HIVU^Z]T>/,9C$[>Q.4S^?RF.P>"P>.K<QFLUF*VFQF)P^)QE-
M+6Y'*93(ULL-'C\=CZ.%Y9YY72**)&9F"@GW[KW6LKN7^<[\KOF/W+O+J+^5
M7T&^_MA;6WULO:L/>NZ=@[OK#NK;2OMO.=@=I[>J]W?W"Z8VCUQ7;8WGB6VA
M49K.U.4W32R5.1IL>E(E.\ONO=-'3=?_ #E/F?VWWW!2?(.@Z:PGQRSN,Z+W
M7U]F<ULKIW<M+W!BZS/[EW+G#B>N>K_D$=P;1W%L3<&VZS"Y:HR-%35]%,LE
M+ ?WG]^Z]T1C*?'?9'9^SJ'JWM7Y_P#RF^8'8^Y^\,G1=B[,^-7QR^7'=66W
M#F=D=S9S?.Y=O8_?G;79F)^,68P.U'V5)A*[)Y3:0P<3TQCCQA;Q1>_=>ZNQ
M_E6?&/;W5'<7R?S^$^/';G7/6M9LGHK#]9;G^3?0GQKZM[<R.X*G(]MUW<^"
MPN0Z.V/M*MR6PECQVS9_#D59!7*6BN58CW7NB&=<_(WO##?RY_C'TO6]+[SZ
MPVAD,KM?<&R.\.O_ )A=.=5;EWK@.L>](M[Y'%QTV>H36;,P?8./Q,F&KH*]
MKI15DT9$S*87]4@X!/6JD' )Z!COC^:+MWXG/UMB>S]K_,/+R]BOVM4[3EVK
M_, Z W^12]6[7RN>W319]Z79E-'AZ+[7!UHPYF0O6Y']L.%\)7U3Y=;J:XZ,
MKD_FUO7$#I7;$G3WR5&8^2$D55U=GL9\^NA)\V(=B;,RV?GJ\PR;)T8&BR^'
MQ$L-1/544_W%>(UD:)G\A\23Q]/]7Y]>))%3P ^7^JO5;G6W7W>70-#VYUMV
M!\HOF]G]U_._/-\=>A,GV!_,+ZA@SFP^V]R2;WV_AMO]91T>1W)]YO*?([D0
M4<9DV_$)L7"T<L>J,KH'[>M ^>>K/>QOB#_,%WQ\6C\=,-LSYT[&W2-A;6V7
M'WSA_P"8GTG4;Z2NP%?M?(97=C4<6.Q50V8W1+MR1*BV366*/(3JLS#ZVKU:
MO1CXNMOFPJX<S_%KY954^$Q_V-+4-_,>Z.@>9AF<MFDK:Q*;9L4=9602YB2G
MC:82!:.*&$@K$I]Z\Z]5\PU>'0@=8P_.3K+<L&Z?]DV^0O85;3T<U#'0=E_S
M!NCMQ80P3030AI\32;5Q-)55$'G=HY)5>17-[FRV]_@ZWG\NC&Q_(GYWPW\/
M\LTQ:F+GQ_+SHQ+LP(9CIQ8NS FY_/OW7NN1^1?SQ(13_+/<K'_FU/R^Z-(3
M_@@_A=E^GX]^Z]UQ3Y$_.^*(P1_RS3'"3<PI\O.C$B)X-S&N+"$W']/?NO=<
M8_D+\[(01%_+*$0:VH1_+KHI ;#2+Z<4+V46_P!;W[KW65OD9\\F)+?RT)&)
M%B6^7W1I)%K6).+N1;CW[KW7 ?(CYWJ2R_RS2&-KL/EYT8"=/Z;D8J_I_']/
M?NO=<C\B_GB6+'^6>Y8WNQ^7W1NHWN#<_P +OR#S[]U[KE'\COGI"NB+^6C+
M$@).B/Y?]'(MS]3I7& 7/OW7NJF/])GR"_V<G_2%_LL,G^G#_ATWP_[+Q_IL
MV!Y/L_\ AD[^'?Q+_2Q]I_<RW\!_W)?;^/R_\H]_)S[]U[HX/9?QWWG\B?G/
M\M*+KKLG!=5[\ZCR7\L[O3:&YMU=?U?9NUZG-]>4_P KO'@\_M+'[WZ[R%;C
M<G3YEP[T^6II86"L-7T/NO=&_P#]&W\S'_O+GX>_^D.]J?\ W</OW7NO?Z-O
MYF/_ 'ES\/?_ $AWM3_[N'W[KW3+2?&3YU;ISN9SO9O\R/<6UZ>6DP]#MS:'
MQ@^,?1?6^TL8*+^(OE\KFY._\=\K-XY_-9N2J@4&'+8^BI8J4!*9FD=_?NO=
M+SJ/X>[@V%WKC/D%V5\I^]OD3O/;O56^.H=IT/9V$Z$VYM[;6V^Q=V=<;PW7
M64E%TUTQU?5Y#,5N2ZLQ2)+6SU,<,*RJD8:34/=>Z.Q[]U[KWOW7NJ'?YJ/P
M4IL?M7O[YA=#82NJ*S>_6O\  OGE\:\"V6H=L_-+H_:U,CG<M''MNGJ<ILKY
M>=(86G?([#WUC:=\B?LEQ.06IH6@^T]U[HP'\L#Y1;Z[&P>Y_CKW+NS<O:N_
MNK-L[1[*ZD^164VQ08?%_*;XA=H&N_T#=X2Y'!9'(85^Q*JEPU9A]VT;1X^K
MASF-EF>DC$X]^Z]T-G\T#<NZMM? SY&1;)R./PVY-\[7P'3-#GLG1Y#(4^VZ
M?OK?6U>DLKN>&BQ>6P5=4Y/;6([ GKZ)$K*<&LIXM3:=0/NO=5P_!+I+X2=:
M[_[:[6[\R7Q[I.V>H.[-^_&SXV;-W6F+V]B/B]\=/BW69WH#KS =1;#W9N?.
M8C8M=VHF*S>^<_EL/2XV3,Y#>4ZR!X8(3[$5ORCS5=P)=6VW7LEM(H966%V5
ME(J&!"D$$<#T22<R\NPR/#+?6BRHQ5E,J JRDA@02""""#U<>?EK\7E!)^0?
M3H"BY_XR%MC@<?\ 5RO^?;PY(YQ)H-KOZ_\ -"3_ *!ZI_6GEK_HX6?_ #FC
M_P"@NF[_ &<OXG?]Y&=-_P#HP-N?TO\ \K_]/;W]0>=_^C3N'_."3_H'IK^M
M_*O_ $<;+_G-'_T%TE-T_P P/X1;)6A;=7RHZ/PBY)Y8Z%JO?^"TU+PV\J(T
M55*-2:OH;>WH?;GGV<$P[/N+ $#^PDXFM/P_(]);CGWDJT(%SNM@A8$BLR9I
M@^?SZ1[?S0_Y>",R-\R.@0R$*P_T@X?TL;6!M+P>?=V]M?<!6TMLVX@_\T)/
M\W3 ]QN0R-0W?;Z?\UD\_P ^N/\ PZ+_ "[O^\R>@?K;_C_\1]3^/\[]?>O]
M;?G_ /Z,^X_\X)/\W6_]<7D3_H[V'&G]LG']O6"7^:=_+G@*B;YG?'Z/5?3J
M[!Q'-C8\^6WU]U/MQSZHJ=GW&G_-"3_H'JR^X7(S?#NUAQI_;)_GZP_\.K?R
MX./^<T_CWS>W_&0L/^/K_NWWK_6[Y\_Z,^X_\X)/^@>M_P"N!R/_ -':P_YS
M)_GZX2?S6?Y;L,;2R?-3X]I&B>1F;L+$65!]6/[GT'NK>WO/2@LVT;C0?\(D
M_P"@>MKS_P D.0J[MMY)X?KQ_P#073=_P[A_+,_[S@^.W_HPL5^+_P"U_P"'
MMC^HW.?_ $:MP_YP2_\ 0/2C^NO*'#]YV'_.>/\ Z"ZG2_S7OY;4,7GE^:_Q
MZ2*RG6>PL1:SVT?20GU:A;V\WM]SRB>(VT;B$]? D_Z!Z93GWDIWT)NM@7_Y
MKQ_]!=2<%_-2_EQ[FS>'VY@?FA\?LIG-P97'83#8VF[ Q)J,AE<M5PT..HH0
MTBIY:JKJ$1=1"W;D@<^TS\E<X1H9'VN_"*"2? DX#B?AZ4)SERE(XC3<K$N2
M !XT?$X'XO/K%\P>B/BQ\P]DT&,W'VGL[K_MK8V3H]W=&_(C8F[MG4/;O1O8
MF%6N.!W9LS/RUC25%!$]?409/"59DQ.;QU54T=9"\4S6+?W%O?\ RAW7_.*3
M_H'HR&];.<B[MJ?\U4_Z"ZJ?_E$]L9/I#N;<72>]&INOM@=L[)[7W)F]EXS=
MW6\?0'5WS$^-_=M5UM\G:OI3 4>YLMFNMNJOD3@]^[/WI@,)3U53@4R$N;-$
ME+H>'W7]R;U6GT5W7_FC+_T#_/S\NK?OC9_^4NU_YS1_]!?M]//JQW^9Y_,$
MV3\0_A]O_L?8O:/7=%VENS([<Z<ZCW#7YB#-[6V-V/VKDDVO@NS=^C!8/?!Q
M^P^K*>IJ-R926JQTU)-3XHTK^JH0'9V/>QQL[O\ YPR?] ]:&\[.33ZNUK_S
M5C\^'XNJPOY;/P+Z'^6>SMW]@=C9WLS?'Q$W!O5MQ]-=*=D[LFPNZ/FGE]&U
M\[V%_,-^>&.PFZY-W]Y[Y^0'9%)4ML[;F\J?'X7:NP:'&PPX&G%8$A3W&W;A
M:()+NWGBC)H"\;H*^G<!TH@O[&Z8I:SPRN!4A'5Z#U[2>MEC9FQ=D]<X"DVK
MU]L_;&QMLT"11T6WMH8'%[;PE(D%+3T,(I\7AZ6CHHO%1T<40L@(CB1?HH 1
M]*NE5[]U[KWOW7NBS?)CXA]#_+7;NWL)W'M2JJ<OLC=6W]^=;=D;/SV9V#VY
MU7OK:M5-6;?WAUGVCM&MQ.\]EYW'R54\9>CJTBJ::IGIZB.6GGEB?W7NM>[K
M'<G??\N[^8-58SMO=>Z^SL1D<GTSU7\@.S:/;N5HZ7Y#] =Q9:NZZ^)WRTW_
M +=P^S:S;T7R&Z/[K8=;]B9?%5E#3[AHMPX_+54:O'*%]U[K:J]^Z]T13^9!
MOWM;9/Q1W;A^C*[$8/N'NG>?4WQHZYW=GJLTF(V!NGY*]H;3Z1Q_8M<%P&YS
M6IL([X;+)2_8SBKEI%B(4.6'NO=5J?R\/@/T[WOMW =L]N;&@W)\:/CYNK<G
M2?P#^,F\,5M6?KG9NTNC]\)M?<'RC[-VAM^LKMM=A_)SNCMO8E?F*S,Y>G$N
M,BCC:GIH)ZF=S[KW6P)B,/B-OXVEP^!Q6-PF(H4:*AQ6(H:7&XVCC:1Y6CI:
M&CBAI:=&ED9B$4 LQ/U/OW7NG+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW2![)ZJZR[CVME=C]L]>[+[+V=G,9E<+E]L;ZVSA]TX/(8K.4$V*S%!4X
MW-4=92O39/&U#P3+I_<B<J>#[]U[K7\^7'PMZZ^*<?6'56X=X[_S'\LCY!]\
M5>T\[UKG,KA9,Q_+Y^0'95=29CH3OKXE]SS28WM'J+;6)[DIIX!BI*O-8O"U
M6X2:.*FHW>E;W7NK6/Y<_9/;W8GQCQ6.[^R^.W3W3TSV-W#\<.R]]8FJ6IH.
MR=T_'OLW<_4U;V5"J[?VNM%+OQ-K)DYZ84,*TU14O&NI5#'W7NCT^_=>ZUC_
M )6Y;OCY/_S%9-G]5[L[&ZXRNV.TXOA=\?NPX*S8,V!Z(C/1B]V?/SY([+VE
M4Y.GK\CW,_4>]]I;2V5D\N*PXV>MR,]+060RO[KW5_7QL^-G3OQ*Z>VKT;T7
MM.':>P]JQU4RI)4U&4S^Y=P96H>OW)O;>VY*]YLQO#?>[\O-+79;+5TLU97U
MDKR2.;@#W7NAV]^Z]U[W[KW7O?NO=5X_/;_C[O@+_P"+G9G_ . @^:'OW7NE
M[_+?_P"W>?P3_P#%//C5_P"^;V;[]U[H7>^/DST'\8<%M[<O?W:FU.K,+NW<
M!VIMBLW1624YW!N1<1D\^^&P]+305-9D*^+!X6KJW2*-BE/322-95)]^Z]T6
M?_AU_P#EV?\ >5O6_P#R3N3_ .L/OW7NFK;_ /-!Z0WMC?[Q=<],?-GLS9=1
MD<WC\'O[8?PL^0^>V5NJ/ YK(8"LR^U<ZNQH(<W@:C(XR;[6LB7PU40$L1:-
ME8^Z]T]_\.*['_[Q?_F#?^D+_(C_ .PSW[KW7O\ AQ78_P#WB_\ S!O_ $A?
MY$?_ &&>_=>Z]_PXKL?_ +Q?_F#?^D+_ "(_^PSW[KW7O^'%=C_]XO\ \P;_
M -(7^1'_ -AGOW7NO?\ #BNQ_P#O%_\ F#?^D+_(C_[#/?NO=,]7_,%W1N#-
M8/;/37P*^=W9N>RBY2JR+;HZ7@^..U=N8[%T\4OW.4WU\E-P=6;5J:S(S3B*
MDHJ*HJJR9E=C&J+J/NO=/W^S5?+K_O6#\A/_ $?WPC_^Z.]^Z]U[_9JOEU_W
MK!^0G_H_OA'_ /='>_=>Z]_LU7RZ_P"]8/R$_P#1_?"/_P"Z.]^Z]TS[A^1/
MR<W;@<UM;=/\JCO#<>VMQXJOP>X-OYSN_P"#.5PV;PV5I9:+)XG+8RM^1,U'
MD,=D*.9XIH94:.2-BK @D>_=>ZJ2^"FT=Q]6]D? C>]#A7V96[$^4'S_ /Y7
M&2V'V+C]H[B[1PGQLQU'V+WYTYL7+]C]69^+9.4R?1&X_CPM!0/''F**?'[B
MK?'+'-JE?W7NK=_YJM#_ !SX+]L;0GR.<QN&[&W?\>^I]X';N;R.W<KE.O.V
M_DEU#UGV3MF/-8B>ER=!1[OV#NO)8JJ:"1)&I*R10PU7]^Z]T3_XL_(WHOX6
M=;[]ZUP/2_<>]>P.R?E3_,J[,Q77GQJZ-WKVQNC<>V^F/F-O7I6ES.XY-JX^
MHQF$.*P-#M3:V.FRE520"DHZ2!&2"G)C]U[H!]]8C^=9NGM?NG??P@Z0V5\6
MXOF%F=B;CWEN/YI1=.[H;HE=G] 8GKFFW%MJNZ2^0W:.>R6[JJ?9>+%)A\IU
M_DZ"ER%=,]:[4\#1O[KW0X_!GX8_S8OC%L'L'K/+_*[XJT6QZ[MK>_9'7%%N
M[K+MGY0;WQ%)V;E9]X;RP>9WM2;S^'FU,3B*??61KZO&8W#[2AHZ:&N=;@@
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M6ZNQZ]3$'CBIJ>.) MPQ]^Z]T*?^RP?.#_O9QV#_ .DL_%S_ .PCW[KW7O\
M98/G!_WLX[!_])9^+G_V$>_=>ZP_#GMCLBBWM\P^G/D-\@L'VYFN@^_]J;'V
M?O;/;9Z\ZKW%6[3W5\:^A^W)*/,;;V:,;A*AL=N;L7(QP5:4\3S4PC5[LA/O
MW7NH?SCS&(S6Z/@/4X?*8[+4R?-+-1/48RNIJ^!91\'_ )H$QM+2RRQK( 0;
M$WL??NO="=_+?_[=Y_!/_P 4\^-7_OF]F^_=>Z2/RH/_ #ES_+#_ ,?D%W\#
M_B/]DE^1AL?\+CW[KW1__?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0
MJ_(X_%4SUN4KZ+&T<9425=?504=-&7(5 \]0\<2EV-A<\GW[KW2>_P!(&P_^
M>VVC_P"A)AO_ *M]^Z]US;?FQD?QMO/::N" 4;<6'#@FUAI-8#<W]^Z]TJ(Y
M(YHXY8I$EBE19(I8V5XY(W4,DD;J2KHZD$$&Q'OW7NN?OW7NM?;K#_F:'1'_
M (WE^>O_ +X#YH>_=>ZL:_F=[5K=T_ +Y4SXG<=7M/<'7G5>3[WVGGZ/&XO,
MM0[U^.5=C^_=DK5XC-4]3C,GB*S=G6M%!74\J_O4<LJ*R,5=?=>ZJ@Z'S&)Q
M.\_Y;'R,WC09+&Y'<?\ ,"_FA=.YW?V(Q>Y9<93M\C^UODM7[<V#GS@HZC'T
M6U]]=V8K#M2?Q&,T<67I*2TL3JI/NO=;)WOW7NO>_=>Z('_-$VA7[Q^"/R!A
MQ.SAOK*[5P&W^RZ+;T4&#GR<R]6[TVWV%E*O '<5508N'<5!@]MU4M"[U%._
MW"J$D1B#[]U[K7ZV50Y3>?Q__EJ_("BP/<_9&PMS] [(S?4>T-F_$>3Y#4W2
MV]MW=N=I2Y;N'.96/L#;F.V?6;IZZ[9H<-G(4BR#PXO%S3*7C0L-B@R1UL:1
MDC\_3I8=:_#_ "'QZ[XW/V7@9.S<GLW,8W&[@P73--\%7RNV.M33;CK<QL6C
MV[7'LIQ_&]J5E?D)*94>=DI<JT1=BNB/U#Z]H/#KU#YFB@\!Y_ZOV_+H3>_U
M[(W3L;:>[,?LKY)8;?>V.SMK]O\ 8]1B/Y?>.W/F^^,/C-[55+N?#K@Z3M)<
MEC3NW#9.>@JJ:JJZ>0T$+3& 1,!)HD$\*5_U?9UHD$\*5\O3_)]O05]A_!''
M;?ZTV;M;IW9N3ZYV'C.YMC]L?P;KWX"/65E-E>J.W<1V7N/#2T5/VU2YK'8[
M=.3@G> 3J/NH'] EL8VVU !\O]6.K-0 ?(_G^70I[V^.&Y=Y=R=,;[Q."S$-
M#T'UIW/N.BT_!%XMK[Y@[HP>P:*MR-(N7[5Q><QF4IL)'>'#5%)!DX*B&K#0
MQ3QA'\2>!^&G6B3P/PT_U?ZN/0E[\ZYH\C7;EVY/U5VI/M/>?7,NV<S1Q?!O
M ;EVC'A?!"E7AL]EE[(=\]BLYL&JCP45%.)\C0M'J5X&2XJP% #P_;U5P*!3
M\-,>?0+=A=0;TWKC>G^J-FX'=_2M'D:/K+=V6R5%_+URLVT9]G=;=A[=P57U
M9O\ R=;VG5P;>KMW;*W)+2/CJAG<8&*MF9AH"-OC3_4>K98C_4?]C_-T(NU_
MBK/ANM.KMB=3[%H]@[.IL;"NQMJXGX,8;<F(VO30Y#)MEY:BBG[:S&;P]1D6
MJ))*9:N=HJ>-Y9% U(5WPP:_M_U8ZW6F#7]O^K'1=J+9%+6=D=I=YUOQO^4(
M7O+LGXY8;L+9]3_+@W75[HK.^OCEN7L[;^,^1>23)=O57VNWJ_;6?IHH\CCV
M$,6.I:6I=)!*5&J#-:TIU6@S6M*=._QMVM\IOC1LW(;,^0N=^;7S)QF\]Y;J
MWQUOEJCX Y&NJ.B\'EI=G]4;?V=4IE>U9:NFH,-7YFBS'V<<,L+8.CK)U2/[
M>73K&G(ZU@K0CTZ-%)U;1X]L;E]O].=O[5GQF @PD4N"^!3//!O;*4$5=M[=
M>':3?#Y6CPFU,B\<]922ZH!41<-Y%N+FGV"G3AIY8%/7_5_+SZ+ALR/Y4X_X
M2;IZ]ZHWO\T^J?D!NS:U)UX_>F"_EU9';V^IMT['W!*-U]M[@PE5V(U;DJ_L
M,82>:EKGKDJY(\O#)&/$P5*G'K_L^O53CUK_ )?7JR+^8#\Z\M_+'_E7;R^1
M':78;]D]RKL' [-ZA;<>W<?LC<N^^Z-\8&EQ6T\16[2@SN/KWJ\3DS4Y?,K2
M3S9"EQE#5SZ)?MVO[R'6AP'V=?*A?K3>>[,_)N+?>0W7EZS?E'G-P=Q[JCI<
MA5157979N6SN9V[4;NK/L$QM)D\SE*"MJ*)Y@DSU^/F"BT?.Z=6IU].;_A-E
M\_LM\T?Y?V%ZU[-R-37?(;X8UV+^/O:U16#(25>X]MXO'RCI_?L];5XVF2KG
MW%LK&FAJ))*FKKZRMP\]?5,K5J ZZKTI?^ZHG_F4+_Z!;[]U[H\W1G_;QG^8
M#_XAWX)_^XOR9]^Z]U81[]U[KWOW7NO>_=>Z][]U[KWOW7NF[,8?$[AQ.4P&
M?Q>.SF"SF.K</FL+F**FR>)S&)R=-+19+%Y3&UL4]'D,=D*.=XIX)4>*6)V5
ME*DCW[KW53':?Q7^,70WS0_EI;BZ.^.G1?36X,QWKWYA,MG.JNIMA]>9?*84
M_"GY&5YP^1R.T<#B*NNQ9KJ.&?[>5WB\T*/IU(I'NO=%1_E]8/"X7='\JQ\-
MB,9B7SG4?\US<6;?&T%+0OF-P93Y!=&/D\[E7IHHVR.9R+QJ9ZJ8O/,5&MC8
M>_=>ZL;_ )I__9$78_\ XD/XS?\ P4G2_O1X=;''J3\!:=89/FC*&U&K^>GR
M+F8>FR%,A@:?2+ ?B $WN;GW)WN6Y9>7U( T\MV(_DY_R]1W[>HJC>F7\7,%
MZ3]H=1_DZL"]QEU(?7O?NO=5^?*DG_9P?Y8 N;'OOY"DB_!(^%7R" )'TN 3
M_M_?NO='-[)[&V1T_P!>[W[6[*W#1;2Z]ZXVKG=[[WW1D5J7H-O;5VSC:G,9
MW,UD='!55<E/CL;222LL4<DC!;*K,0#[KW1)A_-4^#[ ,O9'8K*0"&7XQ_*<
M@@\@@CI4@@CW[KW2YZN_F'_$3N/LG:O46Q.S<U/V)OG^.#9VW-T=1=U=>/N6
M7;6!R&Z,[38;)=B==[5PU=6XS;N*J:R2!*@S?;P.X4A3[]U[HZWOW7NO>_=>
MZ][]U[KWOW7N@Q[D[EZS^/O6VY>WNX=U4VRNNMH)BVW#N2KHLKDHZ%LYF\;M
MK#01X[!T&4S&0K,KG\S2TE/!34\TTL\Z(JDGW[KW1/\ _AU/X0?\_'[&_P#2
M8OE1_P#:5]^Z]T:/H7Y'=$_*+8=-V9\>^UME]M[(J)_LY<UL[,P9$XK)K!%4
MRX/<>,/BS&UMQ4L%0C3XW)4])70!U\D2W'OW7NBO?/C_ (^K^7K_ .-#.J__
M 'S/R!]^Z]U4A\A^N,+W%_PHKV?U;N_(;S@V#NOX.[#J-X8G8_9'8W5>2SR[
M;K_E!F=O4];N?JW=.SMTMC\=G(DJ?M_O5IY)476CV ]R)LT7B>V.]R44^'NE
M@<C(JDXQZ?/Y8ZC_ '>8Q^Y.S1U(63;;X<:5H\!R/,#CYT.>KH]@?R\?BEUK
MV-L?M?;NT.QLAOKK7)Y7-[$RF_?D;\D^U:#;&:S>UL_LG)9C&;:[0[<WAM:/
M+3[4W3D:$5+433105DHC92U_<=]2!T=CW[KW7O?NO= '\@OC%TI\I-N[9VOW
M;M7)[FQ>S=TOO3:LN#WSV#USG,#N:;:^Y=DU.2QFZ>L]U;/W/3?>[1WCE,=4
M0BL^WJ*2NECE1U/'NO=2>AOC'\=_B[M5-D_'7I+K#I7;/V>'HJO'=<;,P6UG
MS*8#&PX?$U6Y<AC*.#)[IRU+CJ=8S6Y*:JK)>6DE9F9C[KW0Y^_=>Z][]U[H
MB/<O\LSX.=];SW?V'V+T-BQO3L;;M7M+L[<.P-Y=D].5O:VW*X3)5XGMD=/;
MRV)3]ITT\%0\)_O F2?[=S"#XB4]^Z]T>:DI*:@I*6AHX4IZ2BIX:2E@CN$@
MIJ>-88(4!).B.) H_P ![]U[J1[]U[H(^]NE^O/D)U3NOJ/M/;;;MV5N9<-6
M5V#CSFXMLU$V6VGN'$[SVG7T6X=I9? ;DPN1PF[MO4-=35-'64\\4],C!Q8W
M]U[K42ZT^:V=VQ\<^KMG;<^8G\QK%_+CK<]:=6=@[6[U[3^%>-ZAV]VSUAOC
M;W7WR VQORH[%GINRZC9VW,CMW<%&U?75DV1K(($J5J:AY%FD]U[K9^^?6]^
MR-I?!KY,;_Z%R^XH.RL/TGNW</7.?Z\PT>\MT4^47$FIH,UL["0X?<T>X<K3
MTSFHHXDH:X3NJZ89;A&]U[JENAE^.OR ^<7Q/Z,J/G#\XOD+U]OGK[Y/5^Y>
MON[]\]O_ !MQM9NK;&,ZGJMDR[7K]A]8?%+,[WW!'1UN89L<*[,B*C6:;[6-
M5>7W[KW6QUUOUWLOJ'KW8W5/7&"I]K]?=:[1V[L39&VJ2>MJJ; ;3VGB:3!;
M>P\%5DJFMR-3%C<50Q0K)/-+,X34[LQ+'W7NEK[]U[K%/!%4P34U1&LL%1%)
M!-$_*R12H8Y(V'Y5T8@_X'W[KW1$^GOY9/P9Z)WIL[L/KWH3%-O+K; 0[8ZO
MSF_]Y=D]Q3=3X&FDI)(,?U)3=O[RWU0]5QPK00QJ^WXL;(((EAU>(:/?NO='
MQ]^Z]U[W[KW24WQL/8W9VU<QL7LG9FU.P=D[AIA1Y_9V]]NXC=>ULY2++'.M
M+E]OYZCK\3DJ=9HE<)-"ZAU!M<#W[KW2;ZIZ2Z9Z)P-=M;I#J3K+IS;.3RTN
M>R6W>K-A[6Z_P>1SL])1X^;-5^)VGBL305F6FH,=3P-4R1M,T,$:%M**![KW
M0G^_=>Z][]U[HM/8?PO^'O;N[<EO[M?XI?&[LW?6:2ACS&].P.CNLMX[LRR8
MRAIL7C4R>XMP[8R.7KUQ^,HX:: 2S/XH(DC6R*H'NO=4A9#K#K7ISYQ;PV!U
M'U]LGJW8F._F*_'VOQVRNN]K8/9>TJ"NRW\HGY15.4K:+;FW*'&X>DJLE4CR
M5$D<*O-)ZG)//OW7NK@OY;__ &[S^"?_ (IY\:O_ 'S>S??NO= 1_,$[%EZG
M[\_EL[[@Z\[+[4DQ7R,[IIEV1U%MZBW5OW)C*?#3Y#4!JL9A,CF<!25%'C!-
MYJIVJD,4*D@,>/?NO=+G_AP/*?\ >!/\P_\ ]$/L_P#^VS[]U[HTGQW[XVA\
ME^H]N=R[&Q6[\#M_<62WI@S@=_8!MK[RP6>Z]WUN7K?=V$W%@355HQV1Q&[=
MI5U,RK-*CB(.K%6!]^Z]T-?OW7NO>_=>ZJ]^;NQL5V_\L?@%TSO+-=ATW6V]
M)_E+E]V[;V%VOVAU)_>2OV;U?MS([7DS69ZHWALK/Y"GPM=62RPP25;4XD<L
M4)M;W7NBY_-?X)_'_JW;?QXK=@5GR+VW5[T^9WQ6ZPW/-2?-+YESMEMA]@]K
M8;;^\MN3BN[[JDCI,[A:F2GD>,).BM>-T:Q]^Z]T<[_AL3XA_P#.I^0'_I;'
MS8_^Z%]^Z]U"J/Y57P5RU=@:O>/46YNTJ3;>:@W%B]K]V]]?(KO/K_\ C=)2
MUE%1Y+)=:]P]L[XZ^SM3109";PFNQE2(7?6@5P&'NO="#_PW+_+X_P"\%?AW
M_P"DS],?_87[]U[JO?\ EO?R^O@[V5_+ZZ6KMU_$+XPYC<NZ=I;]H<AO#+=
M]59?=#33;\WMBZ?(/FLEM6HR4];CZ9(Q"[REHQ$@4@*+>Z]T=#^5AD-R5'P)
M^/VWMU9FEW'E.J\?OWH*FW#2X=<!_'MN_'+M7?70NS\U6X>.OR<-%E\KM+KB
MAGKECG>)JV25DTH55?=>ZL$]^Z]UKYXC;_\ <7YVR]=8[-9S)[2PO\Y&B[%V
MYC<Y4TE8=M9CY!?RIOD)W%V5CL/4TU#15 P61W_N&KK:>"H:HDIO,8UD\851
M[KW5I7\PUBOP"^<C*;,OP]^3#*?Z$=+;U(//'!]^Z]UK5=@=][DZBW1\L/CW
M\=.AMS;\PGPZ^>OPS^>7;^Y-R]A_P#I_J+;?;'6/Q2[#EV?MU=PY'.[IS^[.
MX>Q<YO?<PPV"I8,;CJPSS2&,U*0R^Z]UN+^_=>Z][]U[HLOR6WYU3'MJ7H#L
M#>4^T\Y\E=L;TZMVDU%BZC)U[R;FPDNVJ_(4<7B-%)-BOX_%(L4CAI6( 5@&
M(T33K1-/LZKY_E=_$[IC=O\ +O\ @7-OK;DFZL]U%\?QU5M_-SY3,XW[C;N*
MRF;VY7+6XK&Y.+%S-F8Z 32:TE>%F*Q2!;ZMG.#PZV<X/#HYM#_+X^*6,1EQ
M_7-12Z\C@\LSINS=DDC9+;5-#28*J+3YF4_[C(:=?#'_ )E&NP0,S$^%!Y=>
M%!Y#KM?Y?/Q2CR=9F(.N:N#)UU1DJJHJTWGO1Y#/EY*^3(,@GSTR115!R<X,
M*@0@2&R"RV\0&X@4ZTP5N(%!UQ/\O?XH&@RV+_T<50Q^<W'AMV9.E3>&\8UJ
M<Y@,:<3BZDRIG%J$@@H+(8%<0.55F0L ?>@ *T\^O  5IY\>E15?"CXV5FU=
MO[+J.O(7V_M>DRM!A:89C-)44U#F:^'*5]))7I7K755-)D(%E5)9'5&X MQ[
MWUOCZ=)*3^7A\2Y=LC9S];5/]V_X_GMR2XI=X;QCI*G*;GHZ;'YUZN!,XL55
M#D*.DCC*2*P0+=-+<^_8K4#KV*U  KU&R'\N3XA9'"Y?!3]83K19I\I/6,-Y
M;UFJ?N\O@!MJLK5GJ\_4EZO^$*D:/*)"GC6W L?>=?/KWG7%>@9Z7_D]_#/X
M_P#4W474_5N,[1VR.E,OMC.;.[&Q_:6Y,;VE-7;7W[#OV)-P;HP[XRES.-S4
MJ2XG(T3T:T=7@JJ>B:()(6'O.OGUZF:^?5I'OW7NO>_=>Z][]U[KWOW7NB)_
MS"OY='QG_F<=&4?Q_P#E%AMT5^T,-O;!]B[8S.R=R2[5W=M3>.!I\CCJ?,X/
M*_:Y*A$M7@LU7X^=*JDJ8VI:V70J3".6/W7NJ6I?^$A_\JR>K@KY]W_,R:OI
M0135LO?^,DJZ8'R7$%2W79FA'[K_ *2/U'^I]^Z]U:Y_+<_E._%W^5CB.W\/
M\:,EVYE8>[LUM'/;XJ^VM]4^^<A)7[*Q^:QF%.,J:? 8'[2,4F=F$VM96DTI
MR @'OW7NBC?]U1/_ #*%_P#0+??NO='FZ,_[>,_S ?\ Q#OP3_\ <7Y,^_=>
MZL(]^Z]U6%OK^;G\1]A=C=C]7UB=R9[<G5.],KU[O2?:O3^Z\QA*'=N$BI)<
MKBJ3+&&FI\E]DM=&&F@UP,6LKM8V]U[I-?\ #R_Q&_YT'R&_]$?NC_H_W[KW
M7:_SE?B0Q"KM[Y#LS$*JKT=N@EB38  /<DGW[KW7;?SE/B0C,C[>^1".C%65
MNC=TJRLILRLI<%64BQ!^GOW7NN/_  \O\1O^=!\AO_1'[H_Z/]^Z]T3/Y%?S
M9?B5G?D=\!=WRCN?!8KK;NCNO<&3CR_2N^)<MN"3,?$#Y ;4PFV-D[?PE#F=
MP;NWGG<_FZ6GH\;14DLLVMF)14)]^Z]TY?R_JL5^7_E$9 4N0H1D/C[_ #0:
M]:'+44V,R]"M;WMT35+19;&5 %1C,K2"7QU--(!)3SJT;>I3[]U[JQ'^:?\
M]D1=C_\ B0_C-_\ !2=+^]'AUL<>E)\&J3[>D^5\WC"???-_Y)5&H/J,FC=%
M)2ZR-;Z#:GM;C@7M[D7W$DUR;*M:Z.7K ?\ 5,G_ "_ZN'0#Y#CT0;J]*:]]
MOC_U6I_D^71E-V]Y])[ R[[?WWW%U9LK/1P0U+X3=O8.TMMY=*>H773U#XW,
M9>CK%@G3E'*:6'()]QWT.^DQ_LU/Q@_[R/Z%_P#1P=>__9%[]U[JOWYI=_;-
M/:?PK[HZ8W+T]WT.A>XNSMQ[YV-MKY+_ !UV-N3^[N^_CGVSU=09;$UW:796
MS]L5XH=R[OHON*?[Y)_ [.BOH*^_=>Z+S\N?G3OGY&_%SY"=![;^-&,V]N#N
M7I[L#K7"9[<7SC_E[I@,+E=Y;:R."H,KFFQ'R8R^5_A>/J:U99Q34L\YB0A$
M9B![]U[JX*F^4_QDCIX(Y?DET*\J0Q)*Y[AZ^8M(J*'8L=Q78LP)N>3[]U[H
M@GS1^0&T!VE\+>YNF-S=0=]1]#]P=G;CWUL3;/R9^.VQ=Q' ;Y^.O:W5^,S&
M+K.TNRMG[7R'\/W'N^D$\'WR5 @D=XU?2RGW7NN_^'4<_P#]XH3?^EP?RYO_
M +JGW[KW7O\ AU'/_P#>*$W_ *7!_+F_^ZI]^Z]UAPO\Y7I"DJ,]ANU>FN].
MM]SX++14*4&!H^N>^-M9W&56$P^9I,_M[L7H+L'L78N0HVDRDE%/3FNCK:6M
MHIXY85 1G]U[I^_X>7^(W_.@^0W_ *(_='_1_OW7NBN?,?\ F1]"?)/HR3IG
MK' ]RQ[TW7V_\9JW'5>[>N*S9&V,90;.^2_4>^-QYG/[MW)D<=@\!B<)MG;=
M95SU-1,B)' ;7:P/NO=7%_[-3\8/^\C^A?\ T<'7O_V1>_=>Z(K@-L]7;0_F
MB=8=L_'[/[67;7S"^)G>U/W=1]=Q['K=B=B[L^+78W2,75_8M1F-N8^2MK-_
MX;%]]9_#5U7]](M5CHJ*"5+T<17W7NE[\K,)3;Q^=O\ +0VKGJO,3[8PV<^4
MG;E/MVDS>3QN$K.P^N>K]KXO8VX\UCJ"IIZ?.3;6H]]9<4<54)8(I*UI-!<*
M1[KW57W??9_772O_  H=P/:7:VZ*39NR=N?!WKF@R.X*ZER572TM9N'*_*#&
MXR"6/%4.1JQ]Y5-H4^,+J^K?@RCRZH;VHYDJ1V[AMI'S/ZPQ^1ZC3F!M/NAR
MZ *ZK+<!]@ B-?ED4ZOWZ-^2O1/R6Q.Y,WT5V;MSLG';.ST6U]UR8&2K6HVY
MN"?$8[<%/B<S09"EHLACJRIP>7I:N)98E\E/4)(MU8'W%W4E]%B^3/R%^3G^
MG_9WQ%^(.Q>JG[-W#U8>[-^=V=\YK-GK+J7K:'L3&;''\,ZXV6:?>G;._LZZ
M9(46-7([?QE.\$4E5D45_&?=>Z6_PQ[4[QW]-\GMC]^Y[KG=V\/C[\D)NG<?
MO/K#8.X.L]O[HV]/T7T;VW25U7M#<?8/9U7C\S15_:M31RM'EI898J:)PB,6
M!]U[HZQ(4%F(55!+,2   +DDG@ #W[KW0$-\I_C$C,C_ "-Z'1T8JZ-V]U\K
M*RFS*RG<(*LI%B#]/?NO=<?]FI^,'_>1_0O_ *.#KW_[(O?NO=>_V:GXP?\
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M2=WQTKT7\>^M^U>XNFNA>C>O.QMA=5=C[BVUNG:G4NQ-O9:BK\7L[,UT,?\
M$,)@\?7FBJ)*<)/")56:(LC7!/OW7NJW?B/L5.O-V_R7L#_'*[<E5DO@U\P]
M^Y?.9&DQU!4Y'</:C?$7L_<DPH,3!38ZAI%S^[ZE*>&) L5.J)<D%C[KW1T/
MYI__ &1%V/\ ^)#^,W_P4G2_O1X=;''I=_"N&2+$_)5W "S_ #.^2TL1YNR#
M?4D1)NJ_VXB/]A['W/Q4S[4 :D;#85^7Z(-.@3R/7Z7<:_\ 1[O_ /M(;HMG
M4'0W1O;7SL_F4Y3M7I;J;LS*8S?7Q>H<7E.P>M]G;RR5!CY/B]L69Z&AK]QX
M7(U=-0FIU/XD<1B0LUM3,2 NAKT<S_9+OAU_WB;\:/\ T1'5O_V*^_=>Z]_L
MEWPZ_P"\3?C1_P"B(ZM_^Q7W[KW7O]DN^'7_ 'B;\:/_ $1'5O\ ]BOOW7NO
M?[)=\.O^\3?C1_Z(CJW_ .Q7W[KW7O\ 9+OAU_WB;\:/_1$=6_\ V*^_=>Z]
M_LEWPZ_[Q-^-'_HB.K?_ +%??NO=>_V2[X=?]XF_&C_T1'5O_P!BOOW7NO?[
M)=\.O^\3?C1_Z(CJW_[%??NO=>_V2[X=?]XF_&C_ -$1U;_]BOOW7NO?[)=\
M.O\ O$WXT?\ HB.K?_L5]^Z]U[_9+OAU_P!XF_&C_P!$1U;_ /8K[]U[JG_X
M2[<V]M#YL["VOM+ X7:VV<%V_P#SQ<=@]N[<Q5!@\#AL?!\E?AGX:'%8?%T]
M+C\=21W)$<,:("2;7)]^Z]U81\A?^WA?\N;_ ,-3YL?^^_ZK]^Z]U5;WQU1U
M_P!W_P#"A/&]:=H8.;<FR\W\'.LJW(X:'-[BV\:JLPF:^3^1QDCY+:^5PN50
M4M2FL(*E4<\,C#Z2IRV0/:7F92>-_MN*?.;SZC3F$$^Y_+I%*"RW#UKPB_*G
MV]7T]#_&/HKXR8O=6(Z-Z]QVPZ3?&X(-U;PDILEGLUDMR[AI<)C-MTF5S6:W
M-ELUF*^HH\!AJ2CA\DY6*GIT1 %%O<5]27T%??OPKZ^[P[*Q?=D_9?R%ZF[(
MP/7=1UH=P]#]R;BZMFS6R1GY]VPX7/TV)2HHLJE)GII)X9)(O)&7(N5-O?NO
M=4)= ?&O=?S1EV)EL7L7XOYSLFJ^"OP([Y[W[J^0%%\D\]V5W9VKWCU]OW:E
M9N7/#I7O?IW:JUN,VYT3CH)*J6AFJZMG]3HD4:^_=>Z,Y+_)^[5GBD@GV=_+
MMG@FC>*:"?9?SPF@FBD4I)%-#)\U&CEBD0D,K JP-B+>_=>ZG=P_$OOGXP_&
MSM+LW%?'7^31G-N?'GH_>V^L;L;&?!OL.CJLOA.IMAY//T>U,?E)^W\S/2U&
M0H< M'%4/!5O&SAV24@JWNO= IBOF1\0\AB\;7S?%#^132S5N/HZN6EJ?GOT
M'25--)4T\<SP5%))\,))*6>%G*O&S,R,""21?W[KW26WM\M.D<U+UWL;I?XA
M_P D/*=D]K=U=*=/;=?;/R'ZR^3&1PK=J]H[5V)D-SR=+; ^.'5.ZMY8[;6,
MSLU;4I3;@QPIH86GDD,<;HWNO=6"?[(A\E/^?0_R8/\ T@S?O_VZ??NO=!OW
M'\5?D;U!U#VIVS5=&?R9,Y3=7=;[X[$J,)#\%]]X^;,0;)VQE-RS8N*O;N"M
M6BDR$>,,*S&&41E]6AK:3[KW4KX-] UORSZEWIVUN?Y(?+GK2&J[T[HVMMGJ
M_I7OC*]9]2=>;#VSO.MQFSMA;'V)MS#TN'PNV]K;?6&A@C"LTB0ZG)9C;W7N
MK</CG\?NN?BSTML;H3J6DRU%U]U[296DV_!G<O4YW+G^-Y_+;GRM1D,M5VFJ
MZBLS>;J9B;*J>32BJBJH]U[JK'^8M\)_C-T]\;NZ/D'U5US5=<]OTG8VQ>QZ
M3>.RM_\ 9FV9:3?.^/D-LO*;OW)38;#[RH]NPUVY,GN.OJ*T+2"*IFJY6D1O
M(U_=>Z-__-0K:_'_ ,NGYCU6,R.3Q-:O16](HLCALGD,+E:5:FC6EG>ARV*J
M:/)X^H:"9E$L$L<J7NK*;'W[KW6/:_\ *]^$>QNQNK^V-D]056U]^]/[S;?>
MR,W0]B]FURT>=DVKN?9DWWV,SN\,OB<G0S8+=]:C0S0,!(R.I#(I]^Z]T.OR
M=^+W6GRTV!A>O.SZC>&.QVV.P=F]I[7SFP]T5NS]U;<WWL&ODR6U=P8C-T22
MO#4XRLE9U5T="UB1< CW7NJ;?F+LZ7X?[MW+5MO+L;Y:[5Q7P+^6_?M)T_\
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MO^/1^*'_ (T+^$G_ +^_ >_=>ZL+]^Z]U[W[KW7O?NO=5W_RG_\ MWS\</\
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MNO=7-?R;>SZ?L?X>5E+3X.KPT>RN^>\Z2EJ*JJHZ@;CP/:F]ZOY*;*W)%!2
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MW7NGSX&?]D-?#'_Q5#X[?^^@V?[]U[HU_OW7NJ%OYPW_ !>-Z_\ C*SY]_\
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M-15E13TD>9DI<:(H)Y-:T[2&0(S*![]U[I7_ ,QK_F275'X_YS@_E[<GD?\
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M;1[CPN(WKL7"U&2QE54TD<-33I<$:E#>Z]U9C_PXKMC_ +Q(_F&?^D7=O?\
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MZ?\ >2^V/_07[$_^P[W[KW7O^'8OY>G_ 'DOMC_T%^Q/_L.]^Z]T''3ORO\
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MYWJ;OF&IZ\WMO*+>\>QNF.X^O^R^W1MF'<'8-!A\IE9.HMKYQ(\?/*!DM1I
M':94;W7NCG4?\U3^6_64E+6+\V?C; M53P5*P5?:^TJ:JA6>)91%4T\N2$E/
M41AK.C ,C @\CW[KW1(>U]W?%W^8W\_?B-M7IOY6[HW'0=/_ !Y^8W863S7Q
M&^1&X=G93:>Z<INGXJ[*VY5;SRG7>4%'64N8VSG\_2T5+D0X8M420@-&Q]^Z
M]T<__ANK;G_>7G\PW_TLOM7_ .J_?NO=>_X;JVY_WEY_,-_]++[5_P#JOW[K
MW56O3WSD^ =/\'.K=V?("7J+Y@?.:BZ]Q6Q9^J\IL/9G=WR_[=[E&9GV1L;K
MW(;:GP<F\\GN[+9AJ"CJ9JO[6FHH2]34RT]/')*ONO=7#?R[^C-Y_&_X7]"]
M0]C4>W,5V!@]LY;<.^-O[/QU/BMJ;1W=V/NW</9>XMC[:HJ3)YFD7!;&R^[Y
ML/2215,L4\%$LJ$*X4>Z]U21T3T7!W=VYLGIK:V;ZHZ=.Z:S^:5WIO#>'^RP
M?&CMSL/?^[]G_P T'?/7N#BR&<[IZ[WG5B@P^WMR5!;[=1,S"/7($C5??NO=
M6WU7Q"^7%;B:C 5G\RGM.JP57CI</5X:;XQ?#IL94XFHIFHI\9+1?Z&Q U!-
M1N8FBMH,9TVM[]U[JEWJ7XV;"^*_SAZUZKVUE,-D\YTS\]/CAUUM#>6W\10]
M99FHZY[7^"_R*W]NKK;-;0V#E,;L?+[?QV8P=#/3P-BT>GBCBN+1Q,/=>ZO<
M_F1]==B=K?!SY&[)ZHQ-5N/?U9L>#-X/:5#FL[MW(;XCV;N+";SS&P,=F=LT
M]7G:+);^P6WZK#4YIXV9YJY4/I9B/=>ZI5H]O_$C-]/]/[_^*7R=^6FT.Q(?
MD?\ '/X+[EZY[ ^27<6/[L^+6T^U_E#\?:7OKH3";([=DHNQ.L,_48O;>)I'
MJFHA5U&&@@GI)FI)4F;W7NK?/^&ZMN?]Y>?S#?\ TLOM7_ZK]^Z]TS9_^7')
M48JH79?SG_F&['W7#+1UF!W4WRAW+OJ#$9&@KJ:N@EK=F]@4&XMF;GQU0:?P
MU-%D:*HIJBGD=&4$AA[KW0-_%[^93T;L7:/976/S/^;/3([UZC^1_P D>ILC
M6]AY/KWJ3>>9V=UUW/O':W76=SVR,+%@,)0U>7V3CJ&83T=)#35B,)T7]P^_
M=>Z'_._S3?Y=J8/,MCOG!\:1D%Q61:A,7;6T9916"DF-,8XTR$CR2"8+90K$
MG@ ^_=>Z+7\-OAO6]U?$;XO=P]A?+_\ F$R[][4^/?3?8N]9H?EOV;@X)]V;
MTZ]V]N+<,]/A*0T5+AZ>?+9&5XZ2.&-*=&$8 "^_=>Z,E_PW5MS_ +R\_F&_
M^EE]J_\ U7[]U[H@W9?5GQ7ZK^4?9O2_S9[]W;V-\5]L_&'I'Y$XRF^:'R%R
MVZL7L7N:O[I[FZBHMW[(W-N?+XG.[?S66P.0BPXBHJG_ "EZM80A>:S^Z]T.
M/\HG8&,EB^3OR6ZTZWW+TG\8OD3O;84'Q4ZNW90;ZPN>S/3_ %CMK*4%/\@\
MIMW?V\=R9K;+]^Y_==75XZBEHL+4OMW%XNKGI1)57'NO=7*^_=>ZU(OG9_V1
MM\E__&K?\PWZ<_\ <D7RZ]^Z]U=AV3_,-Q.$W[DOC;\5^D^QOF9\E=D1[6Q/
M8>T.N9*/:73W2=?F\=0Y*EI^_P#Y&[HIVZ\ZYR(P$S5PPM$,[NB2()IQ1$T;
M'W7NB28;MC^85D_YD/R V)L_IOX8]4=W;U^*GPWSE5%V)\D^Q.V\-@.F=G=V
M_*7&;K[ VYL+;'2W3VZ.T<E3UF\/X?444>5P%)AJR?&/45DRY%8X_=>Z/K\<
M?@CDME=QU7RQ^57<%5\K?EQ4;7DV3M??F3V?A]D=:=";'KYA5YW9/QQZOQ\N
M3AV!0[GJDC.9S%779/<F:2GBCJJYH$6 >Z]U8G[]U[KWOW7NO>_=>ZKP_F _
M\7GX"?\ C0_I#_W@NX_?NO=9/YBW_'H_%#_QH7\)/_?WX#W[KW5A?OW7NO>_
M=>Z][]U[JN_^4_\ ]N^?CA_VH]Y_^_.WO[]U[J5_*Z_[(UVK_P")H^8'_P &
M)WU[]U[JP;W[KW1 -M_]O3>Y_P#Q0#XR_P#P17RV]^Z]T9CY&].[.^0O0'=7
M178,JTNRNWNK=]==[ER)IL-5RX;%;MVWD<+49^BAW#2UV#&3V^*L5M))50R0
MQ5,$;L"%]^Z]UJP?%P;UP/?_ ,/_ )5T^X]HY_=N]I?Y:_9?84;;#P^SX\Q7
M_P R?H;?/Q9[^I-N5/6\^W*%\/ELG\7=E[ZCILK3Y.G_ +Q4<\B:?*C+[KW6
MX-[]U[KWOW7NO>_=>ZH5_EQ_RW_A7VI\*.@^Q>P^A<-GM[[PVYG,WN;-5.YN
MP**?*96KWIN4SUTM)0;LHZ&!ZC2&*PQ1QB_I4#CW[KW63^7G_+@^&':'Q2V=
MO3L7H^FW1NVO[!^1&,KLSG-\]HU>2EH-K_(_MK:NWJ*6>HWLTS08?;F$I*.!
M6)T04Z+^/?NO='7_ .&H/Y?/_>-^ _\ 0P[+_P#LU]^Z]U[_ (:@_E\_]XWX
M#_T,.R__ +-??NO=>_X:@_E\_P#>-^ _]##LO_[-??NO=>_X:@_E\_\ >-^
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M1[KW1K?YI\$%3\(NQX*F"&I@E[$^,J34]3#'44\T;?*7I<-'-!,KQ31N."K
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MJL#[]U[I7RR1PQR32NL<42/))(Y"HD:*6=V8\!54$D_T]^Z]UJK]I_.7Y_\
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M[JC_ ,1KL7_WE\7[]U[HF_\ *>_[=]?'7_M5[]_]^MOOW[KW7?QZ_P"WAO\
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M[]U[KW_#?G\IW_GVW2?_ *-K/?\ VPO?NO=>_P"&_/Y3O_/MND__ $;6>_\
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M6?:^$V!M/#;9J^O:RAS&S/[GT@C:KEKTDHUIXH(HO&JCW[KW5L/^R ?R_/\
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M[<5)MG;GPSQN I\ID5E-1%B:"L^)>3JJ6B4IZ$>HE8?EC[]U[HTW^R9]U_\
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ME_U#JS;#.L?\U7M)W941/Y>W13N[D*J*OR-^1I9F8D!54"Y)X ]QUT/^L?\
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MK?-=W=VAN/%X";)=#UV[*'?VWXVDVQE9LKA-_P"_:7;6W):3:V,W5OG,)1[
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MS/D:_:6SJW(P;BW'14"8^H:>6CIIHXA!(6(T-;W7NMDGW[KW6D'O'=2?#?\
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MFI:'=&XZ*CQ4./P=%2104U#'+53>)))CKWUO_#U:S[]U[JA'_NJ)_P"90O\
MZ!;[]U[H\W1G_;QG^8#_ .(=^"?_ +B_)GW[KW5A'OW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[JL#^81U;L?OGM_^7OT3VSB*G=_3W9GR&[9@['ZZFSNX<3M;
ML#'[4^(O?^\L%A-[XW 9;%1[LVU2[GP=)6/B\A]QCJF6G3SP2!0/?NO=4L=
M;"CW?TAOK8&&VKM7,T-1_+8V-CJ79>7H,/2[8J\%AOYE'RGGEV_14M9LG?N$
MP<BX:@:#%3?P*NBQE4L$L<*^%2OJ5P>O4!P>'1_?Y,'2E)U?DNYJ]NH.D^JL
M]48+:6*W*VQ=P;/W)O\ W1EFS6Y<A3Y[<?\ !>DNE\QMW S;:_AE)'3M32T-
M=64,M3&%DUWT,8\^M#&*U/5]/O?6^JW:3H?XV=W?*_Y72=W](=(=N9/;B]'1
M87(]J];=?[^K,+05O7;?=4&*JMVX;+5>.II*RGURQ1LB&1@2+FY'._A_ZE[
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MZ '*_.FVVNY7^]\QLL6X;@\("06]TZ1)%#0(\K0CQ*'55U 6I I7JX*3;?\
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M^097%/38J9\?V9B\-0=(_%#";HAVAB\K+A>H=NQ9F%\C74\V[:DL9&]U[K8
M^.OQ5^/'Q,V6NP?COU-M+J_;TCT]1E7P=%)4;AW3DJ?&X[$#/;WWCE9LAN[?
M.Y9\=B*6*;)9>NK:^=8$\DK:1;W7NC!>_=>Z)+\I/GUT7\6,WANN,Q'O?MGY
M![QP=5G>N_C/T;M')]D]V[WH(7J*6#)4^V<0GVFU]LU&2IS3'-9RIQF(BE#!
MJCT,![KW1:^F^@_EK\@_F5U9\\/E+A\+\6\)T7U?W)UATE\8.M=]_P!]=];P
MQ?<^Y**/<>=^7&_<130[&SU!0;=V%MS)[?V?@CD:/#;@>6LFRDLL"0M[KW10
M/G_V;L:H^<6]]ETN>2MW3+B/Y0O4<>%H,?EJ^J?LRO\ YE=1WQ3[)5J.@GIV
MSXZ8VW7[HFA#DTN#I):R?QP+K]^Z]UL6^_=>Z][]U[KQ-N3P!R2?Q[]U[JB/
MY8?SHMH[9P'8(^("=9=@[>Z_I\MB=]?+CMK=>1VW\4MB[XIZ[<NW:78&PSMS
M'Y/L?Y;=PC<FWG@CVAUS19&2HF>*"7(4LDZ$>Z]T3WH3^7I\M_E/N'>GR$[H
M[3[,^/$NZHX=K9GYC=O;>P.%_F5[JV#L/"[<VW62_&C:U#0X[J?^5KTEOA:_
M>\M+38NGS^_*JCR\==EIDJ)5>/W7NJR_CSUCTQTO3[2['ZVB^;K]K[1C^5/9
M76GS9^*WQQVOVA_=CX\05>X>G.NOF/\ *[IKLBO[5QO=W:G=60ZPSM--N79>
M(P.ZLU@HZT5<T=)5H\GNO='_ -_;@V;\P,[L/OCY@]:;Q^8_473U'O;!Y3Y*
M_P J??6],SUMW+UQM/>&;WE_H)^=WPJBRM1W+M_%[=S^SZ7)RX&.3.4,V?HY
M8S/X':DD]U[J][H;YE?RWJ;J?:E%T1\@OBQL'JO T\^U-M[*Q>\=@=2TVSEV
ME656UJK:D_6^:J-J9C9=;M^LPDM')CZO'4D\!I])C  ]^Z]T5WOQ/AY\VOGM
M\+.N\U6_'OY4;.V]T#\V]U9C9?\ &MA]OX'"97^\'Q!H=N;CRF HZ[.4-#6^
M&HKH**JGB!"RSK$WJ?W[KW1J?^&O/Y<7_>#'Q5_]$=U[_P#6+W[KW7O^&O/Y
M<7_>#'Q5_P#1'=>__6+W[KW5+O0OQ ^*/:GRKZSZ1[0^-G1G9'3VQ^\?YTE/
MLSK'?G5VS=W[%VI#M?O;X@4>VXMO[8W!B,AB,7'@*+,UD-$L42K2PU4J1!%<
MCW[KW5OO_#0W\JG_ +UN?!C_ -)7Z3_^POW[KW57> ^.'QZ^-/\ .SZ8V5\=
MNC.HNBMHU.(Z_P _4[:ZCZ[VGU[A*C.9'XQ_S%:3(9>;&[5Q6+I&R-=28VFB
MFET:I4IH@U]"V]U[K97]^Z]U[W[KW7O?NO=>]^Z]U[W[KW09]P=R]6= =>;B
M[9[HWWMSK;KG:D%//G]W;IKTQ^*H/O*N"@H*<.0\U77Y+(5,5/2TT"25%342
M)'$CNRJ?=>ZJ9^!7R\ZB^/O\O#XI579#[JH-OUW0>[^SJ;=./VQDLGA7P.&W
M/NS)S43?;I_$H<[4T(22*EDIT:TJZRAU:?4)X=; 8\/\/0U]O_(WX*_(S8'1
M^Y.U=C5?<^RJ7>&WN^^KL;7[8&:Q&'WWLO/Y+8^U-QYO%U&5HL2^6P.?SL_B
MIZ]:BFHI]%3*L;QP2+H<"?3JHK0GS'56W5OP8_X3W=>UO8/8'6OQ"W,DF:VS
MO'9/856U;\BMR8S(;1W)CI,INK$9?"YSL?*8P8?<5-B*JG/^3J)GI)Z9.;H^
MQGK8SCH0]U]6_P CW?&[=T;ZJ^F-^XS=>WNXNW^TZ[=VS=U=\];Y*@[3[)ZX
MV9M3M3,;9EVOV3MBLIL7N/86TL=B*BGQL2X6D%))3K'!))*)/"IR/3KRU;('
M ?GU8/G?Y3'\MSO7J+=>U-R?'M-P=;=][TZG[]W?C*CL/M_$5FY-]]>==4NQ
M^MMW5%?C]^4.<P^3P^QW2FDBI9Z>*IE9IJE):EFE/NO=.^$_D^_RZ]M[XW)V
M1@OCO2XO>^[N]<C\E\]N"E[%[92JK.\,KM_?.V*[?T<1WVU)15\N&[)S2"G@
MCCHDDK3,L(FCBDC]U[K+MS^43\!-I-B)]O=.;AQN2P/54O2&*ST?=O>TVY*;
MJ>H[HH_D%4[&.XJGLJ;,SX6I[7H8\A(LDSR/!JHBQH7:F.ZDFIX];U$FI.>@
M@J?Y!/\ *8K=R=H;HK?B;05E3W5N+-[M[5PE7VQWE4;)WSN;./NF=L[G-@2]
MF-LF;)X.MWIDJK#2I0(V"K:@5&/^VGBBDCUUKH>9_P"51\%:KJW<'251T[E)
MNH]S[+P/7F7Z\;MKN4;7DV=MKK'$]/XC#4>.3L!4QB1;"P5)3RS4QBJ*FKA%
M=,[UQ:H/NO=)78_\G/\ EW]==+;\^.^U^B\K%TMV5D.HLGNO8&8[G[UW-B):
MKHC=G]^.J_X++N3LK*Y':U-M?<P6H\.+FHX:Q46*J6:)0@]U[H"^R?Y5/\K/
MXXKV=WA7?&_>L</8^6[IW;VM2[6[@^0&1P.>R?:?6_8&/[>W+F-@_P"E9=K2
M56=Z_P QFZ7R0T2O3+,JTHBD6$I[/ <.O5/ <.D'\0?Y=?\ )LZ<[3HNO/BM
MTOF^NNRNQNM,1WWX=N=R_(6I\FR.HNUMHC%U<V6K>U,I1X?Q[^SE TV-4PC+
M4CR)4QSTIEC/L]>SU@[?ZT_E =<[HW#N;?/QRW32;JFQE!\<=U;ZVQA.U4R^
MYMK;4W#M#?.-V5N'=&WMU4N0W-@*/.["P\FFKDF?3&()?VIYHWU3).>M4R2*
MG]O^K]G2^9OY8N5[C^/GR./6?9.:[?ZSW[VF_2>;@F[?RHV9NS-]=4$78.5.
MVHMW2;4FI*[K[(0P125E+4PT\"A85A* C=2<'B.MU)-#Q'1LZ'^95\:LCC*W
M+4DV_9Z/'UDF.JGAV;5R%*Z Z*JG5!4AY&I*B\,C %!,K*I;23[UW<"#UKNK
M0J1U7_\ Q:B_X<K_ (_JF_AO_#E?\<U?;3_<?P__ (8?_B.K[/Q_<^?[7GQ:
M?)J]-K\>]];Z/QT9_P!O&?Y@/_B'?@G_ .XOR9]^Z]U81[]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZKX^6U728_Y5_RS,C7U-/0X_'_(#Y UM?75DT=-1T-'
M3_!SY*O45=953,D%-2P(+O([*BCDD>_=>ZK,_D?9RN[8WANGLW:NT]V1]4]4
M="/\6ZKLW-XH8?:>^>X]L?+CY+=G;TQ76<]54??;TVUL[";_ ,;356<IX?X3
M/D9)(*6><PR,/=>ZL_\ YH>;W7AO@GWS3;*W3D=D9W>M'L#J9MW8:"AGSFWL
M#W3VKL7J+=V4P'\1BGHZ;<%+M/>U<U!4.C?:UGCF U(/?NO=%M_D[]%=5;<Z
MO[3^2>R=L5$$O=_:&[=D]3;BSNQ8]EY3%?#/X[9JJZ-^)&P]F8^KQ6+SN/ZO
M?JG85)N:G6I19,GF-Q5^2DU&J33[Y^?7OEY=%W[>H]P;E^=7<'6.)[*[6ZPP
M7;W\Q#XH;&W[E^FNP<[UCO+,;2I/Y7'<&_(]OKN_;4M/FJ+%S;MV1BJN>."2
M,S_9JC-I)!U0 U R>MU)%#P'3=E*'X.]C4N>V_D=[_SHOD!UUCM[;@VCN.EQ
M4?\ ,O[,Z?WSENK-_P!=MO=>WI,YM/;,N!WKMFDWIM"JH*P4E9+1U@IY8]<D
M3'5X@,*$5'7@2IJ#0]3\#TQ\6]Z4E7G-B_R/_ECF=I?QK/XK!YW=<_4?364W
M#18+-5V%3<,77/=WRLZ[[4V]A\XU :K'C-83&U<]%+%,8$60#W3PHOX5_8.K
M>+)_$W[3T]?[+;T1_P!Z+_D;_P"C7^)W_P!W![]X47\*_L'7O%D_B;]IZ]_L
MMO1'_>B_Y&_^C7^)W_W<'OWA1?PK^P=>\67^)OVGKA)\:.@YD,<W\BOY%2QD
M@E).U/B:Z$@W!*M\WR"0?>Q&BFJ@ _9UHN["C$D?;U&_V5SX\?\ >B#Y _\
MHS?B1_\ =N>[]5ZS0_&/X_TY8P?R)_D/"6%F,/:/Q+C+ &X#%/F\MP#[JRJW
MQ '[>K*S+\)(^SK-_LMO1'_>B_Y&_P#HU_B?_P#=P>Z^%%_"O[!U;Q9?XF_:
M>O?[+;T1_P!Z+_D;_P"C7^)W_P!W![]X47\*_L'6O%E_B;]IZ]_LMO1'_>B_
MY&_^C7^)_P#]W![]X47\*_L'6_%E_B;]IZ]_LMO1'_>B_P"1O_HU_B?_ /=P
M>]^%'_"O[!U[Q9?XF_:>N:?'#HN-M2?R,?D>C#Z,G;'Q05A_L1\X ?>PB U
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M;L^R,1GZB3(9:2?-XW;,E+#5.U54LTZ,3+(3K/NO= %_+=_[)]WS_P"+D_S
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MN5IMI]9=?8YIMT;XW5E:?"U(IJ2AIY&=HF+%$5W7W7NM>/\ EW[1[P_F"_S
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M?E/B7N*@WWUYA\;G>W/AW78GK:3L.'K_ *TR.XZ_81DDIZB*?$TB4E2[HD8
MN?=>ZV1??NO=>]^Z]UK]?$C_ ++\VW_XG?\ G@_^_P#OA=[]U[K8%]^Z]U0A
MV=_V_;Z2_P##2ZS_ /@:_P"9%[]U[J^_W[KW7O?NO=>]^Z]U[W[KW577=?\
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MHOK3974W6^V*2GH\)LW86WL;MO!4:4U'2T"U#TF-@@%9DIJ:BB$]7.9:JI9
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M?SE<MV;E:3=>Q>E<)U]6_'G9F[,3/3R8*,8#NS=6\=\OGM@5>0DRF1K\[6[
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MNMG=55%5$5515"JJ@*JJHLJJHL H X'OW7NN_?NO=:W7S%^4FP_B]\^&[O\
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M$??OR2['R_9N]\-M>NR]9G]QXOK_ !-2*'8W4^,W7F*P29&EVQBL5!4Q4]/
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M,TV#Q&^\O'3TTDPA1ZYW*E@/?NO= %\N_AAU;T#TGN[MC ;K[T["[%W9V_\
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M_?SNF0D$!E'=OPO0LI/Z@'4BX_((]^Z]UL$>_=>Z][]U[K7Z^)'_ &7YMO\
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M]L=#X?-))(LL(DNO<OVXG#V4,6_PV W*"_C8&V+B>(T9/#U*$0KE7$K/K-:
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MKM2/Y _,3XAP]O08Y:?>LG4G8F8RW7U;DX'>+^)[=FW3@,#G:6FR4*+.U+/
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ML3M?K6:"MR2U!EIUI(ZQ#'&Q=XVTJ?=>Z,9_L]&__P#O7-_,$_\ 0/\ C/\
M_=2>_=>Z0NQOYFDW98W>=C_ ;Y_9\;!WUN+K/=QAV'\>J/\ @N^=IM2IN';\
MO\2^2]%]U-C6K(@TU/Y:9]?[<C6-O=>Z=-Z_S&LUUWL[=O8&\_Y??\P#!;/V
M+MG/;QW9FYMD?'.JAP^VML8JJS>=RLM-C_DY5U]3'C\70RS-'!%+,X2R(S$
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M1_\ M&^_=>Z!CH_Y"?S/^]\!O;<.W>I_@1A:?8W<_=/261I\QW-\AYIZO/\
M2'9>Y.L,]F*5J/HTQIBLUE-LRU5(C$RI32H)+.& ]U[H5OY21R3?R^N@FS4>
M/AS32]MMFH<1-55&(BS#=X]EG*Q8BHKH::OJ,3'7F1:9YXXYW@"F1%<LH]U[
MK71[P[RRWQ+R7S'V/V!@Z3=E%L38G\P7X5;YCZZH-T93>.S<=\[.PLA\J/B'
MWAN7;^8QV'I<3U;V)O?L^MZ_R&<DJ#@\?G<,SFM".R)[KW5H."_G$KTCTQM
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M_66PL5DZ"KW&]/54.0Q^U<525M'4T\U)'-!44U3"R.CJK*RD$ CW[KW0F_\
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M=>ZM&P7<7\QC"8/#8;_9 NHZG^$XK'8S[@_.C'(:C["DAI?,57XU(JF7Q:K
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M_A0?_P"B!^*W_P!SU[]U[KW][NQO^>]_X4'_ /H@?BM_]SU[]U[KW][NQO\
MGO?^%!__ *('XK?_ '/7OW7NO?WN[&_Y[W_A0?\ ^B!^*W_W/7OW7NO?WN[&
M_P">]_X4'_\ H@?BM_\ <]>_=>Z]_>[L;_GO?^%!_P#Z('XK?_<]>_=>Z]_>
M[L;_ )[W_A0?_P"B!^*W_P!SU[]U[H=/C;LS)_)INSZ#;OSG_FM];;IZ=W9A
M]F[_ -C]U;>^+?7N\,-E-P[.P6_,%4+BZCXK9"&LQ>6VQN.EJ(9XIG4EF0V9
M2/?NO="YO_XG=>=1+M3Y)?*+YY_*+=76'Q6W._?[IWMO;X_X7JG 9G:^UMS[
M?@W/NV?8_0'7V=JJ7$XK==9X:=<E&DU3)&/'*^A#[KW51&[^C?E5_-9^<._.
MU^OMQ9RJ^!VV<?L6K^-_;ORFZA3 [=Z0WI3;CR.PN]<Q\2/C5NW:DN(^0.^-
MTX3K^/*;:[+[*I?LMJ'/U*8K'U*R0S>_=>ZOG^/GQ ^.'PGQ'8?8>)KLYE-[
M;JQU!G>]/D]\@^Q*_?O;6^:#9&%FI:++=B=J;TJUBP^U]JX19C3XV@3$[<Q,
M3S-3T=.))2WNO="?L[Y8_%CL3<>-V=U_\EOC_OG=V:>:+#[5V=W)UUN;<>6D
MIJ::LJ(\;@\+N.MR=>\%'3R2N(HG*QQLQLJDCW7NG#Y&?'3J7Y6=/[MZ.[KV
MW_>78F[Z>F,Z4U94XG/8#-XNJBR6W-X[/W#0/#E-K;TVEFJ:&OQ63I)(ZFBK
M($D0\$'W7NM9CKG*_+'X!_*/8N'DVYFX/DUVQO.OZS[@V3OW<^/P7Q8_FU8G
M:&-PDFTOD=T5W/6TF.V?TK_,CQ_7E=$<]M[.TF)@["7!9""22>I@HJX>Z]UL
M&?$SYW?'WY?[<IGV+NFFVIVUC3F,9V7\;>P*[$[<^073N[]JU4&-WIM'L/K.
M:O?/XVKVQE:A(FK8HIL9612PU%+434\\4C^Z]T<OW[KW7O?NO=$%[9_F6_%'
MK+?F,Z@VYNW.?(?O+*UU91)T=\6MNU7?79^)CQ@S8S&1W?A]D2U>,V#B\-+M
MZKBJ9\]6XU4GB\2ZI"%]^Z]U3KW=_,6^0_?FY<OU;D=Z[J^*,2TV(IZCXA?"
MO"8_Y6?S-]V3;JIZ:FQVTNQ^P]O46X/CE\+,S)E\!N6@K8JZKK\[B/L1/)4T
M9 ?W[KW0X?&S^5=OCL7J^LZY[QV_C?A=\/<SE;57P/\ C]D,!/V;WSM_$R]?
MIC]R?/WY=XILAO;N'=F_J3:-?#N+"8"JH(:C%9<4%;E\@L++[]U[J^/8'7FP
M>J-GX/KWJ_9.T^N=A[9IGHMN;+V-M[$[4VK@:26HFK):?$;?P=)0XK'0S5=3
M)*ZQ1('ED9S=F)/NO=:Z_P _OYK?8_;]'D?CC_+RPVZ\Z>Q.S\A\><%\DMC9
M? 1[E[AW]@:'*/VSUY\+,76O43;B/7,L-/C]W]NU<2;'V")ZF6*>OR--!#[]
MU[I;]3?RC(^N^KNP>R?ES6[*W[B=K8W?'=^"^'NP\SVAF?CSD.Z,;N:3M&F[
MC^4^_=_[JJ>TOG?W/(=F[=H#DM^%<!C*;'S08_#Q13AD]U[KEF/E%\U^NNE/
MB;V%O+Y7X7)[D^4/1L'=.$Z[Z2_ENMOY=H;=PW7VQ-]=@5N8R=7\L=O8["[1
MV1!O^BB:OK98%9&#$"S:?=>Z 7_AU+N7_O,^3_TW]T[_ /?"O?NO=>_X=2[D
M_P"\SY/_ $W]T[_]\*]^Z]U[_AU+N3_O,^3_ --_=.__ 'PKW[KW0$[7^3'4
MF[_F'U7VM\C?G/EL=1[\[X^,^1R,&;^*73W46P\AN[X_4G;$O5&*RO86.^6?
M9M9L#"Y";L?*?Q.OJ:*IAE,=/$)*87\GNO=;-7^SS?";_O,/XL_^E!=2_P#V
M7>_=>ZH=^)GS3^9G6/1>W]D?'+XY4OR)Z/PN[>W&ZX[KPG3_ ,D6Q'8>W\IW
M!OS,KF\;/B-NY+#U]$M9D98(ZJCGEI*M81- QBD3W[KW1D/^'#_YF_\ W@55
M?^B?^4/_ -B'OW7NO?\ #A_\S?\ [P*JO_1/_*'_ .Q#W[KW04=L?*[^:QW;
MA7V;C-B=U_#;$SX^KDKNR_C_ /!KL#Y ]N39>++[=J\-0X#'][9S8?7.U\.]
M!1Y&'(U-11YNIG2ICC@AIW!J4]U[HKG]W?YKO_>QW^<-_P"FA/BI_P#9)[]U
M[KW]W?YKO_>QW^<-_P"FA/BI_P#9)[]U[H2_BGGOD!TAV'\D8^S?YD/<77_:
M^\>M*CY4]F;O^>?\L7![!K]R]0]#;5H-C[FW1LC)]>]T;4V-78/JK;U%1?QB
MAAB;)TZUT$[QNM0&/NO=&C^"_?([S_F=[JEG^6&R_E3D]H_!*MI:ZNVE\<=V
M_&RIV#39[OO:=;C<=F]L[RW-N;)Y\;F2AEJ*2L1H(D2ED4*Y8L/=>ZV!/?NO
M=>]^Z]U7GT$S'^8A_,/4L2%Z^^#X4$DA;[5[P)TCZ"YY]^Z]T^]Q?RZ?CYV_
MNOLSL>/.?(3J+M3M:JPV7W-V/T/\G.^.JLD-T[;VKMS9.WMXTVS<!OT=2U6X
M\3M7:&,H1)7[<K8*FGHHTJ89U!!]U[J!_LD'9/\ WL>^?W_G^^*'_P!R5[]U
M[KW^R0=D_P#>Q[Y_?^?[XH?_ ')7OW7NJ?L]LS9_>NZMV=#?R^MQ_*[YF=Q4
M6=W#5=T?/+NSYK_*/;'QAZ2W#E^W<IM_/XF3'=,]F],]>=U[WV?%CLVF/V9U
M[AZ#$8^EQ--#6UM,)1K]U[I]^2_\LS>OP^^-'6??NVOD1\Y_EQN3XO;LW=VM
M\LME9[YO?*7K^?Y.?'[*;>W.=_[?V7MK:O9V1& WCTLM319_8N*I*^!JY<-+
MC*VLKI:V.1?=>ZL_V-\"/AGV7LG9_8VQ-T?)C<VR-_[6V_O;9NY,=\]?G8V/
MW!M7=6)I,[M[-T#3?(>&9J+*XBOAGB+HK%)!< \>_=>Z5/\ PVE\7?\ E=^4
MG_I>?SG_ /NB_?NO=>_X;2^+O_*[\I/_ $O/YS__ '1?OW7NO?\ #:7Q=_Y7
M?E)_Z7G\Y_\ [HOW[KW7O^&TOB[_ ,KORD_]+S^<_P#]T7[]U[KW_#:7Q=_Y
M7?E)_P"EY_.?_P"Z+]^Z]U[_ (;2^+O_ "N_*3_TO/YS_P#W1?OW7NO?\-I?
M%W_E=^4G_I>?SG_^Z+]^Z]U[_AM+XN_\KORD_P#2\_G/_P#=%^_=>Z2&;^5G
M\NS^6[L+$_'NC[0V]MJ78>/WM6[>Z#V/F-Z]^=Z554LM=V-NJ-]EX>I[$[<R
MN?SN4W.]6:C+>JKJ\C&#->5/?NO=,U9\ROF-VUESMWXN?R^NRL)1QR;/7)]L
M?-;<6+^.6Q<.N<R&8.?%#L7$#?\ V]O"3;F$Q<4CFDQE/$U5D(8O(-$I7W7N
MJP_BSTS\SJ'X$?&???1'<WROW;-G=A93.[BZWV)VU\=-D[(V573;_P C13[7
MZRAWQ\6]Y;MRN$I!/534HR>1FJA30+Y9"[:1[KWIZ=&#_P!''SQDF6AINW?Y
MC %/#))E-Q5^\OBY3XJGD>JHS11XW"P?$J;/9Q'I)IHIQ$JR0S0^2QB<>]&O
MD.M&OD/Y]#K\=?C7\M.RL;V5+W?\M/GITME=H]ER;3V;3T&^_BYGJ#L'8_\
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M_@<KN;(T*;LVQN&DS7??;6(PM)0_[]G:AFI*&HS5%_%LE0@RQ#W7NAG^*O\
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MA'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM>;^45_S.+:?_C/[&?\
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MP>[9'2,M-WQUCC>]_BSW'UST-U!\:LEVJO7,_P#=?O;H[>VW.MJS$8C>&_\
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MD9XZW<J=C]3=F335N-6G,5.:22CC$<C"1)&TL/=>Z,;_ +(SV#_WL;_F!_\
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M'I=BX7-;<QV&@V1OC:/R4Z\Q>-H]SU[[.S]+LO<,^W=T;<2*=VQ&#Q^Q]H9
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M++5E=7T\-+C*2>2Y955O=>ZL0W!O#^:]58'-TVUOC]\!<+N:HQ&2@V[F,_\
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M]&5=%@MM[=V;O'86 VSE]O34#XF;.4=-O2NJ7KZE!625P4A51/'[V :?;UL
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M:&HCF@FC9HY8G5U)4@^_=>Z&#^<;_P #NJO_ !4_^:E_\!AF_?NO=6Y=%?\
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M_9>U>N>NMKX/9.P]CX#%[6V?M#;6.IL1M[;6W,)1Q4&(PF%Q=''%2T&-QU%
MD4,4:JB(H 'OW7NE7[]U[KWOW7NO>_=>Z][]U[HJGR3^;_Q2^(E'!-\@^[-F
M[ RV0Q&:S>"V9-5SYOL3=-%@,?/DLA_=/KS;M/EMY[DJ/! 4BCHZ*5IIV2)+
MR.JGW7NJL?D-_-R[8P1P$&T^L-H?$3:^<W%D\92[V^:0K-V?('>D.+W*E+B\
M'TC_ "Y^BMT5?R>WGO/L':&-R.9Q5-NF;9"T^-6EJ)E<5"QCW7NBS;.^%'S0
M^:NXMO[]^074\V]OXCA*JLR/;'\TNCQ&Y-D[9Q>Z<9D,;E=I?&O^59\=^Q\+
MUYUI//7[$VO6U>6['W.-SQTM=6T\ZU[M(OOW7NK7.C_Y7'2^R]R;7[:^1NYM
MS_-+Y";8I*88/LGO>AV\VQ^N*TXJ&@R<70'QZVSC<5TCT1A*JH-1+&F%Q'\4
M J76HR%2Q,A]U[HY'>?R3Z"^,NVZ+=WR [>V#U'M_*9&FP^'K=[[BH,+)G<M
M5U='0T^+P%!/+_$L]D9*O(0)X*.&>4>525 -_?NO=5"=U_S?<]EH=LU?1>&Z
MZ^.736[<S14>$^7GS[BW3L#;_8-!&-K[EKA\9OB3A:C"_)+Y!U65V$VXIJ#(
MU<>S]MFJPCE,C4IZ#[KW1.MH?&;Y=_S!MPXGM+)X_=79.-$\F>V+\L?YCW6E
M1LOI;82Y&"7.;6W9\+?Y2.W\W04$V8P4DV!J\=NKN+*-D))L8\C&O5C$?=>Z
M--UCO7^7]\/>V.P*7J7$=S?S-/Y@U3)G\UVAV+U?UUC.^^Z,2^7J=@#%=>9;
ML/:V&VQT%\7.ML)B<MM^DP6U::MVQ@L3B*%)/MM4<T\GNO=-_P L/D)WSLGK
M3</;W\RGYS]??RFNB<MMG<>-VY\?/C'N':/8WRMW&V8VW09"GBS7?FZ=I[EF
MD[#I(]J[CCQF+ZPVQ'+'-41/%G:J>F3W[KW5:/Q_^4_<_=.1R?7G\B'X.5'5
M>S=[YK&YGLOYR]W8\[I[@WYC<UO+!9BMW;OKMOM]=UX7 5FX-JU64JJ>+/57
M8.[TIY:>2':L2^-E]U[JQ+XL_P#"?/KNAW!!W=_,4[?W5\V_D!FZ+!5&[Z+/
MYS=#]6U.7H-M=8T%1!N*MW%DZWL7N*EH\_UV:JFCSM=2[<C6MD6DV[CD/B'N
MO=;#&VML;;V7@<7M;9^W\+M7;.$I4H<-M[;N+HL+A,51QW*4N.Q>.@IZ*CIU
M+$A(T5;DG\^_=>ZJB_G/?RQM@_S*OAMV7L>CVE@4^2NR<#6;[^-'9L='34>\
M=L=H;7C7+8? X[<PR^VY*+%[Z2A;#5'WE;_#Z0UD=<\3R4D5O=>ZK/\ BC\I
MMT_,GH;^6O\ ,S=60J:/Y5_&[YY8OX,=E;_H=M[&P\79FP^WL'B,?OW#[KVS
MA<KO.AVKD<_L;<>VJK/X>FK*63 =@8FJBBCCCI8D/NO=;5/OW7NO>_=>Z][]
MU[KWOW7NJ[NGN[>T>\OGY\G-L;;WYC:7XS_%#9^P>H<KL[$4F&R<^^ODAOJA
M'86[,WF\]5[-&7PJ=8[.J<;BDQE!FVC:KK)9:N"_A"^Z]U8C[]U[KWOW7NO>
M_=>Z2>[]_;%Z]H(,KO[>FT]CXNJJA0TN2W?N/#[:H*FM:.29:."LS5914\U4
MT,3.(U8N54FU@??NO=$5W+_-7^$>,W3!L#8?:&5^0O8T^[,[LO\ T>_%[8&^
M?D1NVGS6U<?G,CNK[RAZKP.Y*6BQVV8]NU45=52SI#3U2K3LWF=4/NO=!?N?
M^8%\F*G"[,S6U/@EE.FL!O?<F1HZ'?WSN^2/1/Q@VGB=I8NCS\[[@SNT<'N/
MM[O*@S>3J,;1)385]I)5Q19!9JMJ9(G!]U[JORM_F']R]H8^DW(OSLH<_C,1
MANP>R\_L'^4W\(MV?(E:;9T5954W7.$W#\N/D=CMZ=.P4U9C:R@<5]3L_:HR
MM>9G22EQ\?D;W7NB3=S=J[!KY\Y1]S-1]Q[]VOB&[HVMC/YCO\P#<?R8R66W
MMVA7]EX"FGV?_+I_EK8KLWHW,8S9.($V+V_B#/LZMK*B4P402:CER'OW7NC*
M[1ZC^;VY,+OS8WQ?ZL^0'5NW:9MJ]9]<Y7J'XG_$3^57TWUUMG=^/QN-[$SN
M)R7R-QOR8^=$%?@\=F\GDI\_MB">5\E&*>@@\I:<>Z]T-Y_DK=L]X9_<^X_D
M?O/H7 Q;JW'M_'UPR]-W/_,([MI>I=JX.>"FV1A_D'\V]X2;(P46YMP9K(S9
M"G@ZK:F2D:*,--+JE7W7NCGT?\JKXD]?;&K'[[[<[P[&V?'NRDWIOF/M/O[,
M=6]([CK*3=HSFS\-NWI7J2JZC^/";+VGD):2AQ.&_N_%CD@@AB>.5V<R>Z]T
MF-K_ ">_D_\ QIRV,ZF^..UNI=Y[^H>Q<KBL9UE\.^BJKO+L*#?ZX[*[PW)E
M6@ZCVEN:OBK<51X>:HR.1FJA]K(L<<DBRO$A]U[H4(/E%_,([PI<G5?&[X&8
MSJ/;$^#WG_=CL7Y[]M_Z(*W*YW'9^NVWM.LAZ&ZBVOW'VQ1X?)1T9S,M-N3^
MZ=;)CGBC7Q33:H_=>ZGY+XD_.CMZ+/4O>_\ ,;W/L+;^<VS@, NS/A'TGL?H
M2.CFCJ<Q4[OR\G9O:U=\B>W8LYG(:ZDHZ2MP67VVV.@H?+%']Q.TB>Z]TJMN
M_P J[X/8W=L_8>].H:COOL>;<>V=TQ]B?)[?>_ODGO2ARNRUQG]T!BLYW1N7
M>E1BJ#;51AZ>HHZ:G$4$-6GG"^7U^_=>Z/EM_;6W-I8U,-M7;^$VSB(Y9)H\
M5M_%4&&QL<TQ#32I0XZ"FI4EE(!9@MV/U]^Z]T]^_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I,;VV3L_LG:&Y^ONP=L8
M'>NQMZ8+)[8W=M#=&+H\WMS<NW<U22T&6PF;Q&1AJ*')8S(T4[Q30RHR.C$$
M>_=>ZJ7Q7P0^7/QCZXK>BOB5WUUSW)\26PM)L+ ?$KYDXK=]-D.O.I<ID-VT
M6ZNL>JOEIU---V+@=H8S8VXZ3$[;IMR[7WE68>EPU/!'7+$QT>Z]UK2_#+_A
M'I\A^IOD_MGY"=E_,CK/I6DZH[>V;VMU)A_CGM[<7;FZL:=N;NFW+#BO[S]U
M[9V=AMO9;;$%%0QXO*5.(W*LU1JGJ*0&)5F]U[K=4^*'Q.Z;^&G46.Z?Z9PU
M938TY/*;JWIO'<58,WV)VQV1N6H.0WIVKVGNV2&&MWAV'O7+N]5D*^8*"["*
M%(:>.*&/W7NC*^_=>ZU3>C]A=W;C^'_PNPVZ>TOCKE-J;MVOVC/U-L;._%/L
M_=.7HMO;>W3D,[EL%OK=N'^8O6^$WC64M- E; !B:*.62CD>.!77U>Z]\_LZ
M3V?ZYP(Z_I]\9GM7X[3[ Z^VW4[LVO0+\+?D0L<VVLG)6KN+<6$VM/\ /FDK
M&R$JXR5:V.H2.LGTQ1A298@WL"H%*5\AULT%0*4KY#^?1X<#_+G[8[RZ_P!D
M[W3M7X?9_:>\NL<I%MT;O^%?R!H,R=A]O;2H*+)8_-8?)_.[[J@R<FUVIZ1$
MG!J,9X$2)E:,'W[[.M<.'1V=J=(_S%]D;6VULO;'RF^'&.VUM# 8;:^WL>?A
M1V_5&AP> QU-B<31FIJ?G')45!I:"DC3R2,SOINQ))/OW7ND!VA\2OGSV_4X
M:HWI\J/A]6C"8K<F%@ID^#_9K4]1C=UR8%\S352U/S6J'*5"[>@3T,GH9P;W
M%O=>SY=*/K;XY?S"NI]I4VR-E_*7X;XW;=#E=S9:@QR_"#M18J&3=>YLONO(
M4E,L7S<B5**GR6;F6!2"R0A5)-K^_=>Z7?\ HY_F9_\ >67PW_\ 2(>V?_NX
M/?NO= [VQ\3/YA?<.6Z7S.Y/F'\4Z"JZ+[BQ?=FTX\-\)NRHX,ENG$[)WYL*
MGQV>6N^:5:\V#?$=AULK+3F"H^XBA(E"AU?W7N@7R_\ + ^2^?SVX-S9KOWX
MAY3-;GWA)OG*U==\.^Y:I#G9=Q3[K;[.DF^<#TF/H/X_,)S!$BJQB0-<"Q\?
MY]>(!&,'UZP_#/\ EI?-SX,?%^D^)O3?S6^.U9U[09GM#.4&>W/\,-^G>E%6
M]K[PW#O;._:9#;_S$PF,@&)RVY9DQS+2AX(8X@Q=EU'W7ND9B?Y1OREPT^3R
M%'\LOC.N;RFV]K[;GW#_ +)CV$F;8[/SM-N3![AJ:V+YCI_%-S4^8@>8U54)
MCJJJD@ U$A;=3UNI_P!7']O3T?Y4WRDAQ67P&,^4GQFQ6W\_N7*;FS6"C^(W
M;V1Q>3ESU)C:?<.%JX,Q\V*\R;;SE5B*:LJ**_B-7"CJ!H4#7G7K7G4=*G<7
M\MGYA;MV_M? [D^5/Q4S$NU-S4&[:+/U7PL[*&?J\U0G=<?GKZR+YGQI(DU#
MO7(4RA47[>*13!XW0-[\:DUKUXU)K7HX'^CG^9G_ -Y9?#?_ -(A[9_^[@]^
MZ]U[_1S_ #,_^\LOAO\ ^D0]L_\ W<'OW7NJB?[M?*/_ &=3^ ?Z8.D_]F+_
M .'3O)_I1_T#[O\ ]$G\._X9)^X^S_T-?Z=/[T???W:_R3S_ -\M/WO^4Z/'
M_D_OW7NCLU'Q)^/OR=_F2?-JN[OV%-O.KV;TC\)J#;DT.\M^[4_A]'F%^2-7
MD(6CV7NG;L-=YJBD1@U0LKI8A2 2/?NO=&"F_E-_R^ZM!#D?CW2Y>D\L$TN-
MSG9/<.=Q%6U-/'4PI7X?,=A5V+R-.L\2L8IX9(FMZE(]^Z]U8K[]U[HHVQ_C
M'7]>_,CNWY-[:WEBJ79WR"ZHZSVKV+U@FR<12Y&I[.ZCR6=IMH=EP;YH9*;(
MUB5.R=U5N+KJ&LAJ&<P4DD<Z)"8C[KW3Y\K/CI3?)O977>R:_(82DQ.SOD+\
M?NZLS0[BV]%N?$[EQ/2O:FV^QJ[:=1BZBH@I=>XHL!]M%/*)HZ:5UE,4FG2?
M=>Z4_P F.N>U.W.D=\]:=,=SY#X];_WI!AL%1]RX3;U!N?<VQMO5>XL1_?K(
M;.QV4FAQM-O>LV*N2I,+D)Q+'B<K44]:8IOM_$_NO=%-V]_*-^!> P&#P4G4
MVZMQ287$8W$ON#=/>7>^:W/G7QU'#1MF-Q9B;LE)<MG<FT/GJZEE5IZAW<@%
MK>_=>Z,%MSXA]+]4?';LSXZ_'O8NUNF]J=B8/M".J&$QU15_<[R[2Q^6AS^^
M=TUM96RY[=^X*[(Y3SU5775LU9.D:Q>8(D87W7ND!\-?B#E?BQ5]B5.3WUC]
MYC?&ROC%M.%*' 5.$..E^/OQ]V=TG75LK5&5R8J8]T5FUVR$,8"&DBF$+-*R
MF0^Z]US^87PU3Y6[AZ1RLN_)MIXCKR?M[:?8NW?X-%DX.R^EN_NK<QU5VILF
MDRD=70979FY:K$5\$^,S5)(TE%+"X,4@D]/NO=#E\:.LMX]+?'WIOJ/L#L*K
M[8WGUKUUM;9.X>RLA2-0U^]LAMO%4^*;<-;2R5%5)%5Y".F5Y-4CLSW)-S[]
MU[H</?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW59M5\,
M/E-VYNG([C^1?\P'N3&;<7);_;:O4?Q%Q>'^-NT<#A]PYO&G:46<WS"N[NV-
M\93:^UL48&DJ\K!325M?4SI"@$*I[KW0';:_DZ[:Z\[3JLYTIWQO7X[]7R8#
MKW"9"/J#"8F;Y1]CKM' 9/&YA.T_F9V?)V+W3D,+G\K+0UC8W$3XFF+T;F7R
M/42O[]U[H\WQK^!WQ1^)U+3S=-]0;>H=ZD+-G>X=VBHW_P!Y;RRTFW</M;(Y
M[>7<>\Y<UV#G\MF<-@::*J,M>(7"66-$.GW[KW1O??NO=%S^4'6/=_;_ %M'
ML3HGY!5GQFS^8SL4&[.T<'L7;V_-YT>PJC"9ZAS..Z_IMUM)M[;F]JC)UE#/
M19BJI:]*#[9R*:1V4K[KW1!MU?REL5C]V8#LSI3OS>VVN_*K-9MM_?*_OG"8
M7Y8?)&'9U7L6AVWB-H]*[A[B7(;&Z1CHMP[=P^3FJ<1@D>5J%E"AYGD]^Z]T
M:7XU?R]_CA\9MR5W9V'PF?[5^0N>@\6[?DYWMN"L[6[[W'JFW#/+3Q;ZW)YY
M=GX,MNO(1IB=OPXG%1T]28A3Z ![]U[H.>U?@KVM\D^P]RS?(OYB=M9/XXR[
MSFS.U?B]TE1X[HC;5?M>EEVC78/;/;?:6T)CV_V)2PY3 UDE93P9?$T-9#7F
M%X2B$/[KW0K[M^)]5L;XY8KX[?!+<VRO@[BJ+);9QZ;BZYZDVCGIL!LBAIJ3
M$;E3:VWLLD.WSV'E=O8^"GI<[E8LE)3S1)//%4LH4^Z]U6'\5O\ A/%\8.N>
MSA\EOFQV!V'_ #(/E?)EGS$7:/R8KGSFS]L3QYW$[FQ<6S.KI:FLVYCTP^?Q
MTU33FJ-5'&<A4HD21N%'NO=7_P".QV/Q&/H<3B:&CQ>+Q='38[&XW'4T-%C\
M=CZ*%*:CH:&CIDBIZ2CI*>)8XHHU5(T4*H  'OW7NIGOW7NO>_=>Z][]U[JD
M#I'^3IC^J/E"_?62[(P6X=IY'Y6=C_,'<O6M/MW=./Q^XNZ=WY+Y&U.W>P*]
M)=[5>#DWMMBA[@V_ :XT!6H.U8I#&KM"T'NO=7?^_=>Z][]U[KWOW7NFO.09
M>IPF8I\!74N,SU1B\A!A,E749R%%CLO+231XVNK*!9J=JZEI*QDDDA$B&5%*
MZEO<>Z]T63X5_%ZD^(G06W^IYMU3=A[XK<UNCL3N#M&KQPQ%=VEW%V'FJK<W
M8.^JG%+5UZ8J'*9FM,5'1K-*M%CJ>GIP["+4?=>Z-?[]U[KWOW7NJ[M^?$CY
M1]O;_P ]D-]_S NW]B]/2=C9/<NV.H_CGLCKWJ+-4>R8\'5XS;.S=P=T38K=
M'9.4:ERM:<CD9Z6>A6NE@AA"11*XD]U[KAL+^5/\&]G9;';JW-T\.^>P*&OW
M=F)NQODWNC<WR#W9D\WOG)9')[ESE<.T,IN';L66K3DY*=)J7'TQIJ()3PA(
M5">_=>Z"[;G\OKY%9S"8_:/9/S?W1U9U/0;QW[GZ3H/X*]4]??$_8>*V]N"?
M>%/M?9N/WUA:#</;/\,P]#N2&NR,B9.FDRN<ION'T1GQ'W7N@;[*_DA]49S=
M^'J>F]ZX+IG:6'Z<K.N(LMN3J;;GRC[K&YL]7JFY=\X7LKY3Y+M?$[.RU;A,
M/BM%1C<+%D6R5*]3-4R(W@]^Z]T9/&?RD?A]6SK4]Q4/;/R?:EI=GXS"X[Y)
M=Q[Y[(VCMO!;$K*C([;VU@.MTR>%ZRH-MTF1J#/)1'#/!.Z1B162*-%]U[H]
M77'2W3G3L66AZBZFZSZLAS[T4N=BZXV'M;8\6:DQJU2XZ3+1[9Q6+3)/0+6S
M"$S!S$)GTVUM?W7NA,]^Z]T1;OOXX?*7NO?FX4VW\X]\?'OHW)X79&-I-A=,
M=7];P]E"KQN3KZ_?V1?N?>F-W3F\+4;LI#1T=&V,HZ63&0QSNK22RHT7NO=(
M/#?RG_AM+GJC>';^V-^_*;>M1N[![T;='RI[3WOW:Z93:U!@J#:U+'M7<F6'
M7HQ&W#MZ"II*8X<HE:TE0VJ9R_OW7NC\;(V#L3K/;U-M+KC96TNO]J44M3/1
M[8V1MS#[4V]23UDS5%9-387 T=!C8):J=R\C)$"[DLUR;^_=>Z5OOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z [9_R,ZCW[O238&U-Q5N5W+#)NZGJ(!MK<M)04M;L
M;,K@=QXZJR]=B:;%TV2I,@W[=.\HEJ85,L2O$"_O=#UNA_9T+N<S>*VUA,QN
M/.UL6.PF Q>0S>8R$X<PT&*Q5)-79"MF$:O(8J6D@=VTJ6LO )]ZZUTQ[#W[
MM3LS;-%O#9>2?*X"OFKZ6"IFQV3Q%2E7BJ^IQ>2HZS%YFCQ^5Q]919"DDBDB
MGACD5T-Q[]U[I/\ 9G<W6_3T.&G[#W$<"NXI,U!@HH\1G,S596IV_@J[<N5I
M:*DP6,R=5-5PX;&S2I$$\DY3QQ!Y&5#[KW''2VVYN'$[LP&'W/@:B2KPV>QU
M)E<9434E9032T5;"D\#3T&0@I<A0U 1P)(9XHYHG!5U5@0-D4-#UL@@T/'H(
M\Y\E>F=M]AIU3FMTUM%OV3,;;PB8,[1WG,/N=W15$F!K&RE/M^;#I@JMZ5X7
MR35 Q]/4@0S3)*50ZZUT.<CB-'D;45C1G8(CR.0H+'3'&K.[6' 4$D\ >_=>
MZ ?K'Y.](=Q[@JMK==[S?.YZAH),A78^;;6[<&]$L-744530U<NX,%BZ>GS=
M)/2N9L>[BNAC D>)496/NO4\^A0WMOG:77.W*[=V^,]0;;VYCGI(JO*Y&1D@
MCFKZN&@H:=%C22:>IK*VI2**.-6=W8  ^_=>Z:^N>T=B=LX6IW%U]GX]PX>D
MR=;B)JR.BR6/M6T$IBF\<&5HZ&IFI)"-4-0B-3U$9#Q.Z$-[]\^O>5>@PSWR
MV^/.VNU*_I/,]C4E+V?BH]O3Y+:Z8/=%7+04VZ:NDH,+5U63H\)486&CFK<A
M3132FI\=+)4Q+.8S(FK=.MTZ,=[UUKKWOW7NO>_=>Z][]U[JN#^51B,76?R^
M?BE6UV+H*NNH-B;@2@JZNBIYZJCAR&\]Q_=I25$T334\5='#'Y A E55U7 '
MOW7NCW[AZ]V!NZBJ\9NS8^S]SX[(457C:_'[AVSA<U15N.KU5*Z@JZ7)453!
M4T5:B*)8G5HY  &!M[]U[I[P>"PFV,+B=M[:P^*V]MW XZBP^"P.#Q])B<+A
M<1CJ>.DQ^+Q.+H(:>AQV.H*6)(H8(8TBBC4*J@ #W[KW3K[]U[JAW^<+M7Y5
M9WY#_P LG,?&S%=^5.(VUV-\J*CM3.]+8W>>1Q.V*/)?&S.T.Q,EV -M0U&&
MAIWWD8AB?XLAADR*A(;RM8^Z]UFQ^"_F(=H]OX+K/>N0[+VC2; R>)VEN_L.
MGJ-\[(ZH[6I<)U1N6KA[*V]F]BK2R4+[QK\ABY*ZA,JP8_<44])I80H7]\CU
MK-*'I\W=5?*.BSN],;MVL^6=?\@8>U>UJ"6,[5W6WQ]I?CK_  7>$>Q:O;6X
MH,1_<#*UL>*AQQQ34=?4[MDW"=5=3HTDVGW6QC]O07[8J/YB74E=5U6Y:'O?
M>>0ZWW_UOO\ .U<#'V#V)L+LKJF/KO3O:GQ6[<Y1U>XJO>5?45>0^YVDZ0R4
MF>HZ3[?SI4"3W[A]G7N&:X/RZY8[>W\RW;>>V9*O77<^^<7TMO*7LWO_ %U6
M9Q57V+2=S[WAQM1USU#B\UMN.C[3VSUEL&7+55+3T%=#48&HI*)7\CRQ1R:H
M?,]5 ;S.<] 3_,KZ.^;6/Q'Q7RGQ?K/F-V'O7"?S@.H,D]+)N/?^YL1M_P"/
M>+ZYWS6UFY-S4T5/0X_&]44^>KH8ZNLS#_P<5(AAJGX ][IY5QUNF--<="WO
M:H^=N<[(Z2H_AUN?Y78;J>I[#Z.R78F?^16PNPJ;-S=D;7P'R R_9FR-VXO?
M^UL/DL9TQORDP&!Q>XLQ20_P6GS&0I*C&U)E,6O8(^=.K CYT_R=7%_#;<W9
MF]/CGL'=O<.UM\[&[#W)5;WS.=V5V33"DWMM*&O[!W5/A-N9R%&DBUX?;[4L
M$#QO)%)3)&Z.Z,&.NJBOGT9[W[K?7O?NO=>]^Z]U0GI;_AT7]+?]O0-7T/Z?
M^&+?U?\ !?\ 'W[KW1T^I*C(4G\P/^8M5XF@7*Y6EZ,^$-1C,6U2E&N2R$.+
M^3TE'0-5R!HZ5:RI58S(P*IJU'@>_=>ZSP_(WYFG)[<Q2?$"KKZ;)5M5'E=T
M/N"GP>,HH(#*#&^'K*^KRU 4D9%CJ)&ECJ4C9U5?(@&OLZUD\/\ 4/\ /TVX
MCY9_,'*[9WKFY_@'V#@\EM[-YS"[7V]E-\;0?);X3&T]34XW-TGV=?+!A<)G
M2\$,<E4_DAE24NFDQD[ZWTK,M\D/E1C-U'%T_P .MVYC"Y?;>SZ[!Y"AW%@5
MBP>YMP8S%U6<P&\*^;)"%:;:=?65$%564<4D;_;WB#W][Q\Z_P"'K9T\,U'\
M^I'7'RB^06?[4H-@]F?#_?/6&V\Y6T]'M_?S[EPVZ,76*N&ES&2KLI28-9I-
MO4M$\!H@*J16>KEA"ZE<LFJBG6JBE<]9,3\COD%GHMP+0_';.TDE$^XTP]16
M4F06+(46#WCAMOP9VFAGFI&KH<MAZVLKJ:AU053_ &!!(66-C[_!U[_!TGI_
MDW\OJ"+"0'X1[GS];DEIFKJO$[TV]B\7BX+3I-6529BJ^]22K:-)8Z0!YJ>-
M]$K%Q[U7' U_R_YNM5H.!K3^?R^72GW?W]\GMN14N6QOQ=S6Y*=-F8#,5NTL
M-70U6>FW%6UTT&<QE%N UT6"B.+CC7QT\D1F=&\I?253W8?RZL,_9]O^K\^B
MJ]Z_.GYM;.PO6F[NO/A'O7(8'"]H8+%=^X^LI*K,YN#9&Z>OM]5>)39^,QKP
M91JO&[X;;<64K(H:]*+[AH3$R/)/3Z'&C8ZT#FC @=& F^0GS2&VMIU@^*,,
M&Y\GN?!8W<F'7+S5]'BML5>S?X[N+<U-7Q5U.B3X'-S)114,MY:Z:*2*-@Q2
M3WL4KGK8I7/IT*,G>'>VV*C9#;Q^/^XL_2;ZJ,U@X:?J^DFSM=LW/)+3UFV\
MAV)/E\AC*+;>S*[#M)%5U\1JWIL@@3QM&0YUUH^=./5/6SOF3_/1P^Y_FGG.
MYO@YMC'[ ZY[@^-L7QUPNRZ6@W!6YSI'.]LU"?(O,C<%)O>6I["R^T.H*,/"
M\%!CI8JRH,T5-4F,4S^\OGU[R^?5C>U?EI\N,WN_9L%1\)-V3]:[NV?F-P'?
M%#N*AQM7ALF,9ELIM7&9?;FX7H,K1#-_PI*:;R1++2S9"F++I$H3U?MKUZH]
M#7_-Z_Y.L"?+?YIKO"FVI-_+QWW]G4YLXT[S@[-V,^U:7&?>STZYZID>I7(K
M3>!Z=S"L+36\I^B*&WBM.MXK3ITK?E[\HMO[DR<&ZO@5W"-EXC,8"#^\NP<Q
MM'L3,Y_$9.6?&Y"?";1I<YA*Z*JQN2\51(9Y0D>-+2$-*!&=>5?GUKRJ/7_5
M^720SWRG^<NV^]^X-O8WX5;T[$Z@QM!U:G5F=QU7MG:DE=E*VJWO0]I-59?*
M;GK&R5'BTQV'K*771TA,=8T:&1@Q7W6NA;Q/R,^5-9OB3:60^&FYJ#$KM3=F
M0;?']]MN';<.[,)C*6JV]A%4S_Q&MH-VULLD,51'$&I?'^ZO/O9I2HX]6(%*
MCCZ=)[,?*#Y<'/3XG;WPFW>,9B=K19/-;CSFY<&*.LW-%E:6@KMM[3H,?D'K
M<Y$U'4-5T]6YIT>*-E*AP =#/V]:&?D>EALGO;Y7;VZSW]NS)?%*HZKWGM;,
MUE#MG8F]MXXW.UN^<=34.5J8\IBZC:DDM/21U%0E%"BSR(69Y?H%0G1KUHU]
M.@7J/DY\_P"+:M%DH_AK22;IK/%%'MY<E6R4PK)JEDB@KLDN65</1M1K%+)5
MR"5*=JIHV1C32&2QIBG5SIQ3J?N/Y,_/O'87#9+!_"&+-2UV<QU#70KOK&05
MU-B9MOU%56Y23"2UR55$R[A44JH\T@CA02.3YE":X]5X_(=658F>NJL5C*K*
M42XW)U./HI\CCDG6I2@KIJ:.2KHEJ5"K4+2U#,@< !PM_P ^_=>Z</?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]UJ\?+S^8EWA\7OYJ]=T3UE\$<#1["DV>,G4_-_>^%^6V?ZOH:[
M?6Q9NS-R4VX-O]']6;_PN0RF4WAC(,#%54L53705=7&':*'S(/=>Z)5)_P *
M*/YBF]NA>R=T[I_E804>:I\[@>OT^/&;V5\SWW[V;M'>^(RD6Z=W8'(4'Q]?
M;=/M?:21BCR,=14Q5<CU ,*D:=?NO<>CN?'K^:1WMC>ENNGHMH?%7HM\SMC&
M[JR_3^].K_YFN>WIUQN#=L0W%N#:6\<X/C=E(\ONK"YK)3T^0J8JFH@FJD=H
MI'C*,?=>Z0?S$_FI=_0]%[DW.G1_QP^7F<VA4T%?MOHCJKK?^9-MCL7=E=N)
MWV#EY]J9W*_'?!8K'5N$VCO')5LTE15P!:2"8Q,LXB(]U[HA>T?^%+W\SC;&
MW=L;<Q7\E#?.WL%BX8]OT6.FP?RMR^1PF+Q5'3I2U=>LO2]57Y""H1@BS-4S
MU$\H=I"6#-[]U[I^^+W\VSY%_)#OC>FZ^Z/Y9FW/AKN%:C!]LGM_OVB_F'[@
MV]O;?6T)<5MG;FV,3A.N^H\S#3RT6%K)*Q:">FAP[QT;.\$D]F7WRZ]Y4ZMS
MD_FL]_RQR1/NOX8%)4>-PO3G\S9&TNI5M+I\8E=#8\$$$?@^_=>ZI9RW\ZKY
M;_%;Y#[YP/0?\GV'MBA@EHL''\D=ATOSH'7785'58VBRE1G:.C[*Z?J-RQ5%
M+65DF.JJVJHOO99:5E\LE.(V/O.OGU[SKYGIG[._X4>?S$^U]H4^U.Q?Y$6[
MNP-O5U?2Y:JVUE=H?)UH,9E,!DHJW!9):B;IJ!6KH:F%*FFFIV62!EY(;W[S
MZ]FO5LG27\Q3LOK/8>*QNQL=\.NMJ'-04NX\EL_(]7_S1\UDL#E\O2055;AJ
MZNROQOR,OFP\KFF,43K31&(K$B)8>_=>Z>]@?)NN[F^7O0=3NOJ+X]=O[@[.
M[+Q6Q=S[AZMVQ_,-VWNGK[:M+A<WO8;S=NX.H=F]44NT<7N;9>,_B%'4U-+%
M65$L#E9IHXU/NO9ZV7O?NO=>]^Z]U[W[KW7O?NO=:5_4<GQAJ/BY\?X=C]E]
MG;8[3AH]X?Z98<[OK^:'0[%AS2;QW))+2;=QG26278U'!)-I6%MNQ_PV(K)Z
M=#!AHU\NM$GR'15_F?C=[9>3K?*_'#YD9;JC:>R,/WIG.Z=SUG>G\US:F&KZ
M3(]<;@_T;RY]=[IFUH<1UYNR2D;[^.>FA@FIFK:P/2:HA:G5J="UWX-T?Z,^
MD,Y\9NW\SD.UL-MK>4W9V"WYW!_-OIMG;QW)7[1S&.V+D*^9,B<7G=KQ9N:C
MKVCQ]90RI51K(7> R1^]>?6JU.<"G1Q_C3W!\&MU;H[JA^2<N]=K]:;(R6#V
M]U?V+TQ\NOYOO8F3WMFL6,S0]HIV/M4U&-HNI\EM?,45+&,=)65,\<E1+"]C
M 6;W7NCB4VZOY+L\DD%'V7\O)I1%YI8*7M?^;S+*(%F,'FDAAW0S^%:A"FHC
M2'%KW]^Z]TW4O8'\D6OER=)0]O?*FMGPF5. S-+2=R_S;JF;#9T8ZAS38++0
M0[M>3&YD8C*4M8:28)4"EJ8IM'CD1F]U[CPZ;JKMO^1=0TVZ)JWO?Y*T5'L1
M*>HWO-5]\?S8J6EV3'5X^ES%)/NZ6?>D<.UXZK$U\%7$U<8!)33QRJ3&ZL?=
M>Z5XS/\ )M !7??S* OK!'9?\X$<@_J'^_C^M_S[]U[IJQV]OY*.8J,I28CM
M7Y9Y:JV]DSA<Y2XSM[^;GD*C 9HX_'Y<X?,04FZII,1EOX3E:2J--.(Y_MJJ
M&73HEC9O=>Z=URW\G#D)OGYF>I60A>ROYP7J3]3(;;CY7BY'T]^Z]TST>^OY
M*&5RF8PN/[9^663S>WA01[BP]%W#_-SK<O@!E:85N*CSN-@W7+6XC^)T:^:F
M%0D?GB&N/4O/OW7NN.=WK_).VUC*K.[G[5^6&W<+1/31UN;W#V]_-QPN)I'K
M*J"@HDJ\IE-UTM%3M5UM3%!$'D!DFD1%NS*#[KW3M_%?Y-?I_P!_O\R/4-2_
M\9)_G >H7M<?[^+D7]^Z]U[^*?R;.?\ ?[_,G@$G_C)'\X"X %R?^/B^@ O[
M]U[IKPV\/Y*&XJ$Y3;W:/RQS^,%9D\<<E@^W/YN67QXR.$R57A<UCS6X_=53
M3"OPV9H)Z.KAU>2FJX)(9%62-U'NO=$<^\^$_P#I9^Z_C_<_^RC_ /#KNG^,
M_P!YOF?_ *6OXU_PS5H\7]X?XC_LU_V_]\O1H^X^S^T]'_ #CW[KW5^_1G_;
MQG^8#_XAWX)_^XOR9]^Z]U81[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB)=V?#S<W:O;M?V=B>VZ
M7;6.K]N[?P]7LK+;.S.Z<-EY<!G,%F(Z7.*O86!I)-M5QP@%11T5-0U,\KAI
M*IU01GV*4Z]BE*?;_J_U5Z0D/P8[8Q^XL[N3%?*G-Q?WVVQN;![OVO7;&J:C
M9N,K,WL3'];8>IZNQ5%O[&5VQ,/M/:V.0T=!4566 KF>I\H+:![[<];!SG.?
ME_FZ7*_#7-TO4W4NPL3VQ48'<W4#[W;![LP%%O[!TM;_ 'VQ>3Q55)54F)[8
MH]TT]93)DVE$\.<63R:EC,4<CH?=5I^SI ]T_P OO,=L[AJZR@[MK=E;?I]M
MUN'VI28?!;NBW3MO+9#/R;A?.U6Z\3VG@DW1%CJU:=Z+'U]%+0T\E*"4=99T
MD]BE.K8TT\A^S_!_EZ-M\=NFJ_HOK]MDY'>E7OJ=LU4949:IH:G&I"DN-Q.-
M^VIZ*JS.=EB:JDQ;5M4_W!6?(5E1*$C#A![' =:P!0<.AW]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW1<LST=NS+]ZXKM]>[^QL=MS$/B1%U)C<OF:+8E7!083-XVN
MBRF)I<[!B<I)E<AE8JQI)Z-V22DC47X9?=>Z,;[]U[KWOW7NO>_=>Z][]U[J
MA7X)_.'I'J+^5CA]Q[[R78>V,?T/MG^Y>Y:^AVO)3[ARN=W+GMP5M!)UC3Y=
M)(MST^,Q]6*AZ]8FH:>"FFG<F&"1A[AU[AQZ17=^VOAY'UG\B-E;XA^:-?UW
M7=/=C]>[PS.%W)M^FP62ZFRFZ,[LWL'MC$5<CTN*H*W9N\<-64:RYE%KJZ<0
M(*6JAFC4Z('F*#K1"TR !7]O0R?#S/?'?^7+L_Y-]4X0?*_<^VZ?L@_)G,;I
M[ES>T^R\UF]Q?(N3#X+9O7W5\&TIJ/(T./S-!LHU^-PE72155!3?<3U4BAN-
M_9^SK?V<?3H&.C?F#TSA,)\MNA^PZ+L"*.I_F.?)O"YC+[*K]GY'<.%K]X]W
M9+>^V*JCV-5Y>JW9G=K42U<'\5KX<35XN@19I*EUBC=UW0>=.MT'G0CJ%T9C
M_B?ANQ^@.WNN=O\ R]PO8=)BJ+O'J/J#?^>ZRW<W<&P>^.OJV.E[2J=S;VJM
MQ/L7:>$P=-)%D\@,[@9:&<)2U3.LOC;62?EUK)/R'GTR;0[?Z7[HSWRGJ-_U
M7>V#VSN[^81O7<>W\9U;3]?[UFR^0V/\%OC-1[D_O!0TZ[U.0V_L"EQ%151Y
M7$.U&LDD 6>03"-MC_#UL?X>B>?+?X^?##;G77RLWOUUVS\Q\'W5OCHK=NY\
METYV9N_'XG9LF9QG0^Y?C?BZC<6#R>$AKZS)U^R\W4Y.DH*7(2QI/#!+%#'!
M%'3BHH!0=5% *#JRO)[A^)$&Y=^UX[8^9>[=T5&7WKV;7OMW(PY1]R[)V>U1
ML/=78&V<1C<7%02];==;@Z_KJ59!#'5-DO*BK.)T'O9]#ULGR/'_ %?ZCU+^
M*>U>HOC?TI_-8H-\[UW_ +PZNK/YB_86_MQ[OSN<PK;MKZOO;J+XJ=BUL0S+
MP8# X["4NZM_FDI/*L$-'BTCCD8Z&<Z/#K1&,],0^%GPB_F*X+L':&Q.TOEC
MUS+M_-[8.\*W9':U1C(A-LGM,UM#C]MY*MCWEM+)X.?=O5=4#7XD/'6T54YC
MJ&5H3#NG#UIUN@QC('2PWEL'KG<_RE_F8=A=J;J[-VWM;HG_ &7/L%_]&V>.
M,JJF-_C1-2Y(Y'%31S8W<L4&.@D\-'6*U(TDI:16(4K[KU*]%I^5?7O1V_OA
MSO[Y2['[@^0F2J/B_E-N=.UFU]^[CP9V[CY)^Q>K7W#3;AQ>V<3]AN1\-@-Z
MI74=325DD:5+("6:$QK[SZ]Y]"+G-M_&?(=H=\Y2OW%\\-K5/>79 [F[FV52
M;EP"[5Z\Q<.S.N=E8_L'$U;+D,CBNN-T;?W9C#_!L;5558M77UFJFA-*R1ZH
M#CU'6J BGJ/\/'[*^O37M7K_ .)\4F&V##NSYWR[CZG^0>R]Z;PILAV7MS(Y
MOJVKV#VGU]VGC*SLJ/&S24']SMQ9LXJEKL4(ZC.PXV6J@5(&65O?ACUIUH"G
MK3]O^K_)TJ/BM\/^F-^;*7OK?W>_8O7&YMU?+SYW04^+I>UWVGMG.9*3YF_(
MG"XJ@V_A\A704B9B"FDEEC\"22SR3DR)(0MM]6_P]%8_V73M/_3%_LJG^S0=
MD_Z7O]G8_P!%G^S>>.J_TK_WC_X8V\G^E#Q?W@^Y_O7]I^U_Q<OU>KR6]/OW
ME3K5,4ZMOW7U3\E\9\Q?D)V=\5N\_B4N3["ZS^.N#[0ZL[DV3O\ WOOC8,FP
M3VZNS,^Z]<]O[,GQ&#W]1[IKOM1D* &=\7,8)9%60)[K?2Q_@G\UG_GYO\O?
M_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GY
MO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\U
MG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_
M@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?N
MO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#N
MB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/
M_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T
M1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]
M_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?
MF_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9
M_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX
M)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[K
MW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[H
MCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_
M /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$
M9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?
M_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GY
MO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\U
MG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_
M@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?N
MO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#N
MB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/
M_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T
M1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]
M_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?
MF_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9
M_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX
M)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[K
MW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[H
MCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$9\C_
M /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?_P!$
M9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GYO\O?
M_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\UG_GY
MO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_@G\U
MG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?NO=>_
M@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#NB/?N
MO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW7OX)_-9_P"?F_R]_P#T1GR/_P#N
MB/?NO=>_@G\UG_GYO\O?_P!$9\C_ /[HCW[KW5-S?#RKQGQ,I>GNTOES_*>W
MKT]7[?3!Q]I;OD[<VQ/+)'M?<L%-GML[LP_RTQN'V]FHME5=;=Z"81S44$LD
MBO'Y;^%:XX];6M>WC3H=*SXF]Z9$[EJJ3Y1?R^,8F?V9F*EQA*[Y$0T&W^I:
M;=^;;>V,P5#-\HJO&4?6>0["K:]\M)-%-"F8!1IDDA6-?&GGUHT\^'2A[$Z$
M[;R/6N_-L]G]Y?RIEZZW3O?#9;<=;NC&_(/$P87>B]7;4V]MJEQNZ9/EICJW
M;]?'UIAL=4T=(E5&7I9C5*C)4,S[4_P];4D?#^?^ST _6?Q%W?@9>Y=N;?\
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MVDQF1K8/DG0=?;.AR5/MO$44E+:F,@K?+8SU"LWNO=*3(_$GOL9C+/FOE'\
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11U_PK_*/L_L?\H]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>nt10016217x4_ex10-15img09.jpg
<TEXT>
begin 644 nt10016217x4_ex10-15img09.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@![ *\ P$1  (1 0,1 ?_$ :(    & @,!
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M:F^7<;$V0<(9/'BT!R"0I?7IU$ D+6M 32@Z3Y^9OP^ )/RN^-8 Y)/>G5X
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M[(!I]#M0D 412[9/HH/V\.D=]?VVW6_U-V2L.I5J 3EV"K@9XD=#B#< CZ$
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M=1!48G+2SX]):F0:!XT]GW*-Q9V]GNML]M%))%M\I=P\E)5$D8TFC !3@AE
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M1QH)]E^\7AL-ON+M6T/'$Q4G^*G;CYL1^WH/<U;I^X^6;[=ED6.6"UD9&(!
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M02?6O3-VGVCANK,'#E,E3SY&MKIS2XK%4K+'-63JNN5GF<,M/301\NY#<D
MD^]JNK[.O$Z14\.@.A^1'9%;&&H.E\U.98Q+ ZC(O$T; %)?30*S1D,/IR?=
M]"^N.O&OIY]"EU7V)OG>F0RU+NS8%7L^FHJ."HI*JHCKD6LFDF,;P*:J*-2R
M(-7!O;W5E4"JFO6@2>(Z&WW3JW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UC$T+/
MXUEC+\^@.I?CZ^D&_'OW7OEY]9/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2
M3WUNVDV)M#<&[ZZGEJZ; X^2M:DA=8Y:J0,D5/3)(X*1&HJ)$3400M[V-O9K
ML>TR[[N]OM$+!))Y NHY"CB6(\Z $T\Z=$/-&_V_*W+UWS!=(TD-I"7**:%C
M@*H)P-3$"IX5KT$,O<':$( ;X[[QED,,<H-+N;;=53DR1APJU$3:6 )M] 1^
M0#Q[%Z\G\L.:CF*S"ZB.Z&93@T^$C_+^?4?O[@\\1BC<H;@SZ0>VYMF7(KA@
M<_LKZ@<.HQ[6[REB,M/\;<J@0*SK4]B;561@X](BB$2R.P_M  D?GVZ.5>1E
M?1+S)$:D_#:3TQZFM.DIY\]TF37%R7, !4ZMQM:_D*5)]>@ZS'R ^1-%*8:7
MXR9]GN]G6IJLI#I_L S8VG\=Q<7YYYM[$-GR![>3H'DYFMQPQ0(:_8YK^?EY
M] _<O=OW@M)/#AY'O"U3D.TJ_+NB6G^?-.D</E%\AL/5++NGX^5-+C2JEXH8
MLU052WU ,D]:LT-G;_5)^./9S_K7^W=Y'IVOF%7N*X),;+CC4+0X^1ST&_\
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MPI7P BBOF%;'K3I64W0OR.S%'$=U_)')TDSPWJ*+!XXB*"3@E4KX6Q#3H/\
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M]0DD9^J.LT;JZ&_T/'M^*ZN8"#!)(A!J-+$4^RA'26>QLKI2EU#%(K"A#(K
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M/.]T'I3,4A_PSD?G2O7O]EY^27_>2E=_YR9'_P"J?>O]</VX_P"F:C_WI/\
MH'J_^M'[T?\ 3;2_\XW_ .@^L,WQ[^3*A3!\CJJ4DG4)(LG#I'X(*M-J-_\
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MSEREOCCF/QX]SF9W\757Q:LP,BR D-4@GCJH<@$]&RZ!_G2_,3JE*;$=EYG
M_*;9?\6IZZIHN[?XAE-\4U$*JLJ<MC]N]K8BKI-VXTY9ZVQ^^.5IZ;PQ^*!0
M&#%UWRQMEV-4(\*2AH4H!CU7ACRI2OF>AMRU[[\^<NL(+Z4;A9:E)2YU,X6N
M0DM1("W](O3!4#-;I?CG_.B^(N^*7&3;FWEO7XD=C&GJ&RV-W3#E]W=8RU-#
MCJ*H>7$]B[2Q\V4BILS7RSPTU-D</YE\(,C@.#["=[RKN-N3X-)H@ 1D*<F@
MJ":5\^/60_+'W@N3-YC5=X\3;[\G((,D>%KAD!< FHRA%0*G/5[.P_D_O-]O
MXS=#+MOMWK_(P_<8OL+K_+XS.X7+4*5E30M64.X=N2UV#JE^\HY8;2+ ZR1L
MK@,I'L,RP/$_AR!DD!R&%"/RZF^RO[3<;9;S;Y8KBT855XV5U.2#0J2,$$'Y
MCR/1G=B=[=>[^FIL?CLFV.S52-,>'RR"FJ990+O%2RAGIJME(L CZF_ ]LLI
M7[.EH((Z&)F5%9W941%+,S$*JJHNS,QL%50+DGZ>Z]>ZK6S'?/9&1[)JJG:V
M=J?X9-GAB\%@?'!+CJFA^\2F@26E>,B2HJPMS)_G 6])''M[2I45P0,_ZO\
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M3^+<1W#5Y/*]AX>HFJG^S^TCIDIZ3 0Q0+''_:N=7Y]EP]R8P:_1M_O8\O\
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M28B$-74?([=T4M6."TIAI-HB&( D@ !20 2 3[6GVY]L@!2]W$FG^^!@_/\
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M/>7R<[7Q5#MO,;DQ6.EQ>T=J;4QTE/+%@-K4=3!2U)AEDHX!K,%,L,,0B2,
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MLZG_ (Q,<I0OFZ&@D2:O;&4[32,L,"-JD(K(4+I^HA38&Q'MY"NJI/#HO=7
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MO]EDW]_SM=G?^?O\_P#G/]/\/?J'T;]AZ]CU'^K_ "?+RZ]_LLF_O^=KL_\
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M3D&H!5JE:GT/Y=9X<@_WJWWDN7^4+KD7G66RY@VJYLGM8[J6,07]LKH4UI/
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MPUM;E-Q_RQOC_4R5];55U944&QL_#Y:JLJ):FKD ILG6TL1DJ)BP1%"*#90
M  7'EW9":BWCJ:GAT.4]Y_=2)%C7?-P$:@ =^: 4]./^'UZ+;FOY0/\ *@RN
M<S&:S?Q0[/VH<ODZS)OBMM]\=CX;;^+>MG>H;'X'!&KH:7$8BD:313TL;%((
M@$' 'M(W*&S,Q?0P!/DS4'RXX'IT*K?[R7NO;P)!]; ^A0-3V\+.P IJ9BM6
M8\6)XG/0S_$#X6?%;X%X'Y'4GQSW'WCF*CY$S;$CR6$[5K-GY+#[/Q.Q<]N+
M,8K&;=R6W\=09>LCBI=RRTKSY!JB>98HW+:S(65;3L-OL\DCP,["2F#3%*T
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MW/W4#?ZO]7^3UZ]_OO\ &_\ 6W^J_P /Q[UUOS_U?ZJ_+RZ]_MOI;_"W]/\
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M/1-&QEHZ;(YNJ<61A>"  $CW'OG3\ 'I\_\ (.LT*&M3@'S_ ,A_/J;M3?\
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MST==#(T4:T]9*9(V]4(U6]E]QLM_;KX^CQ(JX>,ZACSQD"OJ.AELGN?R;O\
M-^[9IC:;DPHUM=KX+D-Y=_8Y/HK''$#AT3WM'^25\/>XNR]X]@[5[>WS\<L#
MO:CCRF#ZUVQL[%;RZ_VEO2I?*MFZC%9ZHK!7-UWD*@T<U'CJ:(34!:IA67Q"
M *<VO-M[;Q)%*@D9":L30D8^1[N.?/'G7J.-^^[GRYNVYW&X[==M:6LR@QQ*
MFM$<ZJT.H5C)TE5&1D5H%ZLE^-WQ6Q7PW^)_27Q>VIO':W9&>JMW;ZWUOO>>
MSH,ECL=O7?&YLW3T&$R4N&R.5R\^*FH-JQT6.:,2(K&A\@169B2+<]P;<KQK
MIAI72%"GB !FA]-1)\^/4J^WO)L?(_+<6PQNLLXFD=Y%!4.[-1202:%8U1#2
M@.FM,]%CWU\O/BS\G?\ 2=\>\IU7\@9=M_'3=F]>IML?+#X\Y(9'L# [OKZ/
M P=L9[']9XNK@W+-L]I4CH:NJ>DRT-50#4L,9O(AA!9W-BL<I>$M*H<Q2?"0
MOP@MPU9JHJN?V="7VY^\7/R;S%>MM&WO?<OV]Y'%<(\(GBN7A+T+P "=4A=F
M*RQDG51J:*]#U5_*#X_;EZ"R.[?CWN39^7Z$^,G5>27;^)P=?1T57B-O;4QJ
MQTAW/@IUH<ACMQ9>JIXHYD>F262:344U,;E\EG?R7GAW2/\ 4RR#B.)8^1\Q
MQ/V="OES=O\ 7HYRA7;+R.^W7>=P =E;4RM*X\0LA.M1&">TY4*%-.JP>WZ_
M&=1?&3I?I/L;*92#>OR_WE_LR_RIWKC,EF<6=C;=SF<P>Z,DTU3'34V7R5#D
M-D5M%@9C) ^!H:V>19:@)*Z*(+>MY>R75KW16T?AQ*0"6(!  K@'55OXB!CK
M/WEF*;?N<]QYBV%$;:>6+,;9M4#(CF>2.-X8PH)**XF5[A0&^H=%!520";K>
MO?DI\.^RWHME;:ZRJEKJ;;U'6[:Q_4.[=M;G6+9U)3X3'8FHR-0V9V_AL-6S
MSY*.DIZ-#5/+/#*JNS)8AB2TGC4R/4"M"65@:YKY'AY\.L2>8O:KF*P\3==T
MF$9:X82O<QS0DSL7=]("2,] I=W(6@921G#?MGO'X"[XR>6H>L/FSU_MG<.#
MW?4[%FP&^\XNQ<NNZJ6LBQ\N/H:+=O\ =+,9537S"!*FEBFII)@460LK /2;
M5N<2ZY+=RA4,"HU"AR"2M1^W/1?N7LK[J;3!%=7.Q;@UK+:B=7AC\=/"(U:V
M: R*G;W:6*L!0E:'HW>)V]\A\29&V5V/AM]4-+-%%,M-N*AS0B\EB@J(\IY6
MI[Q@MI$]R!Q[+F 'Q@C\J=1K/:75JP%Q')&6X:@5J!Y@&GY]'DIO)]O#YI%E
MF$2+-(@"H\RJ%E954D*#(#Q?CZ>VB",'IL$,*@@CKYX/\P_^;I\POD?#\@_B
M3V74]5R=0TG<VY<!#'@-@U.)W2,?U;VI5S[4!S\NY*^/SA]N4WW4@IAYAK%E
M#\9_<@>U/*7+IL.:MM%U^]C9HW?*&2LT #]N@?QG2*XQZ=8Z<Q\W[SN7U&T7
M7A?1B<CM0AJ1OV]U3Z"IIU2U_P 5/^\_C_ #\?U_'N8N@3_L_P"K\O+U\NO?
MC_86_-_]>WUU?X?7W[K5,4^7^H_;\N/7O^*C_>/P/\#^3^/?NMGC_J_U4/F>
M \^O?\;_ -Y^H_P _']??NO?ZO\ 5]GEZ^76YS_PEIXZ&^8MOJ.X=E6/Y_YE
MO'S_ %!_U_>'GWG?^2UM/_/'+_U=/4U>U/\ N!>#_AR?\<ZO1^,FZ=L;=IM]
M_P!X,_AL-4U>>@:$97(4M%/4Q1QU&ID^YDC:5(Y'-[7 )_K[QE*LP! )QU*H
M95PQ :OGQ_/_ "=4*_)'^4W\CN_OD]WIV9UQO[XZY+"=F=E[IWKMK&3]GU_]
MXQA,G4)/"V1Q5!M+("FJ88_\ZJ22JE_U'WBIS5[+\Y;OS+?[O:M9BTN;IY$U
M2.&TL:C4!&0#\@3UE1RK[S\G;1RW8;1="\-W;6J1OIC0KJ49H3("1\Z#H@?R
M9_E^=\_"JJZBSW<E7U]54._^P<=@L$-E;BRF<J$KL168W*59KX\AM[""GIS3
M. C(TA+\$#@^XVYF]OM^Y*:TGWEK<QW%P%7PG9C52&-=2+04]*]23RU[@;#S
MHMW!LPN!);VY9O$15%&#**4=JFOV=;>?R>K:K([OZZV77Y&;$;3RTD=3DZP:
MOMON)<B*-I)U%EF:BI[,@;A#)J/O/2,A26].L#F%<>7\O^+].J._GSWG3?"[
MY;[!SFUMK;'[L@QG7V57!X_>=37?;[5RU3N&CK/XM1UF) EAS],:01L\;:'C
MX:S @0)[M<VR\I\S;=N,5K!<R&TD"K+6B'Q%(=2N0V* ^E>L@/:7E6/FGE;<
M+![F>U3ZR,L\0%9 (V&A@V"N>C:_RU^L*?LKX%578./VE3IV%NCL[LO<5&U+
M+44D4L=9NF*HJ(<?%)*M+-$D*R11$K=M%KW]BSV?N#<<E17;HJ>/<3R$**"K
MR$X^0X#[.@I[QQK#SK);JS/X-I!&#7-%3S^?G^?0\_Z%.U=6C^Y.5\@%S&&I
M?(%/Y\?W&L(;\\>Y3U+Z]110_P"K_5P]>N7^A'MG_GA<S_3],%N/Z_O?0?CW
M[4OKU[_5Y_ZJ>G3QA>JMT[<J*O<>_MF3Q;4P>*RE?D4RTPIZ>JJ#134N)I5-
M/4)/)42Y>H@LJD< WX%CHL. (KUZE?(G_5_A_P G0"]C]\];_&S:_6DF\.F\
MMW9OKN7([\RFUMK8S<E/M>3&[!ZJQ>+K-XYM*NI>05^:J:G,PPXG'^%1DYM2
M"HA,?J&'*O*,W,Z7,YN%M;.V\-2[(7K),6$:T!%%[27>IT"ATM7HHW7=UVQX
MH5C,T\NI@ P';&!J.:U.0%6@KZBG0O;0^5/\NK=^?;K?>DM5\;NT*S)9K;]+
ML?Y TV4ZHW%/F<1NE=F55'MG<67S&1ZYW9E%STL2+3XG,9&91*ODC4AU5R[]
MON:H+4[A81+N&VZ%8RVC>.H5D\0%T $L8T@YDC08-"<=-1<Q;3))]/<LUK=:
MB LP\,E@VDZ6)*,:T^%F.<]'!H?BYU-DZ2&NQN8SF0HJA6-/6T.=I:NEG"NT
M;O#44\#PRC6A5M)(U CZ^P4_B1N4E4JXX@BA_,'/1ZNAE#(:BG$</G^WSZ!O
MO+JW8?6>#PV,VY25M=N?=&7CCI*O*5TE5-04-& DL5+'&(88OOJJJB0LZN;
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ML:8:H/1O/D'OB*J[+W!EF/DQW6N#EIZ-" 4ES1"+3Q,"65DES==$FH L O\
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M<W,SRL: 5:1BQ-  !4G@,=98VD$5G;1V<6(XD"#B<* *5.> XGH#^IL)+O\
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M-'31[SJ:W<>+S,R8]/XA7U<WVDM;733::>.ZWC#?.2+Z:82[?(C1(BHJ.2"
MN/B)(.,DXJ:XZQLYT]D][O;I;SEZXBEM(X(HHX92RNJ1C0!XA+AL#6S'26<F
MBCJ@KM[H'NSH+-3X'N7JW>O7E;!6G'QU.X<'5P83(50I4R 3#[CACGV_F0U!
M(LY^VJ92D9]81@RB/KS;[ZP<QWD3QM6F0:'%<'@<9P>H!W?8-ZV&8P;S:S6[
MAJ5=2%)X]KTT-C/:30<:=7I_\)[NDDS&_.[?D371)+3;4PN-ZIVO*M312J,K
MN!Z7<VZIY*&6CDJX98,91XV.FJX9HU*5%5$P8$V'?M[8ZYY]Q;@BB->'$]S8
MX\--#\R.IS^[[LGC7U[S$]"D2"!,@]S4=S2E110@# CBPZVI?<J=93=>]^Z]
MTB-T,<CF-K;=0@I49!L]DE^ML=M\QU$*./IIJ<O-3+SPRJPY][%0*^77NEO[
MUU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I'[;W5
M#G<MO##$(E;M3.1XV:);W:EJL;1U]'4&YY,HG<&W *>_=>Z6'OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7ND9@R*K=F]*WDBF.!P2'U6!HZ"3*3!;^FY
M;-KJM_J0#]/>SP Z]7RZ+1NZNIMQ?*+:%$M1#)1[0QIJ:^9I (*&:DI:[*5
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M&ISP8TK]H%3Z4ZZ;^]V^_P!7?;BYM+*1;>]W&2';K<U*B,W3+$66GE%"6<C
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MJ00?#I?M#X5_,"GHI/B_\B-N2[KR..DR9ZJWA5?PO>V.C2J>C>"KV]D_M,_
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M(!H34:-EUU!V)V;2[T-!64'7756UZ-J-*YEJ#2TFW,<%QU)/.7,,]=+5!IB
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M\!A0E=4Q_P!P\Q+G*F&KK7I(8Y) E;X)I;+<$LK7_21[)5-3P'^7K&ZAR?\
M+C_8KU5I\@>WMMYCY<_$SX4+4KF=P;SV7LK.T<6,VS1[BEZOWAO7L6IWSE\]
MOJ*')4N17&UFTMD862CAE1J>.*1ZDE#I;V?V-A(=MDW0=J(SUJQ&I=( "XXA
MB<_EUE;[5\G;A8^T&Z>Y@7P[.WN9]>N1HOJH8X!"B0'25U)+-,'((9B F<CJ
M\;Y839*HZ=SVVL-MW/;BRNZFI,72P83&U%<M*$K*>KFJJZ2)2E-"L<%EU&[L
M; 'GV)?:F.VCYO@W.]N+>WM;0-(QE<+J[64*H/Q$DY\@./7.WW\>^N/;F[V3
M;+.[O+^_*1*L$;/HHZN7<C"J M!7).!T7CX_[R^3V*S^P]B9OKZOI^OL?&N(
MKJG([;.,>AQ:1R,E?+EC,J^>CL J:?WOI8L?<A^X&S^V-W87^^V.X1MS!(WB
M($FUAW)%4$=.#>OX>/#J'_:3F+WRL-WVGE7=MGE3E"%/!=I+?PC'$ :2&75\
M28HM._AQ/1M>U>\N@NL\3EH.X.VNLMCX_P#A]2,I2[QWGM["3?8212)4,]%D
M*^&K:/QZN5C-O]?W VW[)O.ZL%VRUN)RQH-$;,*_: 1UE_<7UE: _52QQX_$
MP7'YGK7]QG\W3^73TAV;69O(=PY'L#&[?.;DVY#UQL_-;I_BDP9Z7&O'D_%1
MXB-OM78J9:A ;@W]R7M_LG[D[FN=O^G4D9GD2.F>.FI;'R!Z"USSURO:D5N?
M$:A_LU9QCYT _;T$G:W_  J8Z[I$GIND/BKO?<,C))]KFNS=XX3:M/$PXB:H
MV_MZGW%4SHQY(6OC('Y]R)MGW9-S<UWG=+>,5^&&-Y"?]LV@#_>3T&KOW5LU
M'^(VLKFE:NRK_(:J_M'58W:__"CO^8AOX30[-?I[I:@E22*6/:>S)MR5X20W
MCDARV\LADI:2:)?[2)R?Z#CW)&U_=XY!LC6]-Y>-Y:Y @_9&HK7Y]!>[]S.8
M9L0+! !Z*6)KP^(GAU7/NWYD?S OE+41XK.=]?)7MYWK#!%A-IY?=D]"M35.
M$%)+B.OJ:AH3&WE"K'.A5 0>/K[D*VY.]O\ ED&6.PVVU[:EI%2M!YUE)/YC
MCT')=[YEW8B,W%U-5J (6I7T[*<?0_GT_P"U/Y7OS]W_ )/'0)\8NP<'7;DJ
M4DQ57V8,?L9,W-5SI":BGK=V5U*:G54S 22M]&/)]ENX^[?MQLX$<VZP-04T
MP!I=-/(B-33Y#I1;<F<T7U94M)!FOZA"$U]-1R?4]'>V[_PG,_F59>""7*;3
MZ<VA))3^22FR_:.&R$M-*\FDTLC[;I\O \JKZRR.T9' :_'L+7/WAO;R%BL+
MWLP!XK"0#\^\J:?:*_+HWB]M.9'4:Q;H:'!>M*_Z4'\Z="'7_P#":'^8-283
M(9.FWA\<<KD*2!GI=MTF]-VP9/+21J&6GI*W(;+I,'3R2DZ0:BIA0$<D#V@C
M^\?R&\JQM!N*H3EC'&0M?,@2%L?('I0WMAS %)$MJ308U/FG^TIG[>JR.TOA
M[\^/@MN09_>G4W=O2V0H9=--V)L&HS+X&4HOF=:/?O7U9/CY:= EY"TRQ?AO
M<D;;S=R%SQ;_ $UK=65XA&8I0H<>53'* 1\J"OIT&KK9>9.7Y3-+#/"0:ZXR
M2OV:D)'S-<>O0IU_\WWYV;OZ/W'\?NQNX!VQUONJ/%P9"HWCBZ&KWB*3%Y.C
MR<-#!O/'+1Y">@G>B2*6.<2EXK@MR;QI[A_=I]N.?]GN-H=;K:C<+1GM'"TH
M0?[.0,E"0-0P"*CH;<D>\?-7).\P;S&MO?O 31;A3^(4KJ0JU0":'R-#T<[^
M4%_,"^*'QO\ D%G>Q_DRVZMG553LR?:NQ\_BMOU.Z]O82NS&0IOXY79AL29,
MW1BIQT"PJT='/&J,Q=EL#[Q'V7[C7,WMUO\ <;YL6XVV\V9AT0JR?3W"5-6)
M#,8V-!IJK+JK\/60W-?WI-FY^Y?@V:[LI]MNO'US=PEA?2"%"L ' J=7<N*<
M3UM/;1WYU_WGN++]J_#?Y ]:=F4V?FJ<E+BMD[TQ1W-3NZK49.&KP=5*M2].
M*@,Y2:)'#$J5N/:7=^7-^V"0V^^V=S;.#_HB,HSP 8C2:_(]!.RW+;]Q7Q=N
MGBF4_P + X]:5J*?9T#'='2W2_:U%_=WY(_&;;$U:N1JLE'N_:>''5&_X<CD
M:NDK,C6KN7;5/2Q9*?+-2VJ/.)6F21^59RWN-M_]ON4.982FX6<(?46#QCPG
M!)!;O2A.HC-:X)^WH?;!S_S=RY*'VZ]F90 I20F2,JH(7L>H&FO;2F0,XZ,M
MO"EVGLKXT]&]8]9X_,8'KNDH*/!8"EW#729#(4N VG M%C8<EDGEJ)JQM3+-
MYF9FD2.Y%S;V(-GVRTV7;X=IL PL[:,1I4DD*N "3DFGF>@_NVZ7.];C-NMZ
M0UW<RL[T 4%FR<#@/D.J ?YUW\O?YQ?)CM?:';?06QL;W?\ '_JCI[ [*VA@
M.O-Z8;,[WQE>^2IYMUY9=A5M-A<Q/EMXY.N@>2GQ\F42.FQ7GEEB+&)<NO8[
MG[D/EK86V;=KGZ3>[BY+R/(C"-@%H@\4%E 0 Y<(2SZ0#QZA+G[E[F+==Q6^
MM(O&L8X@JA6!85/<=)H26J*!=0 6I].M5G>>R-Z=;[@JMI=B[/W1L+=%)45]
M%4;>WE@<GMO+B?$UL^.R20T>6IJ5ZR.AR%-)#)-#Y(/(A 8^\J;.\L]P@%UM
M\T4]L0"'C8.O< 14J32H((!H:>74136\ULYAN4>.3AI8%3BM0*\2#Q/#TZW1
MOY*/4F]_C#_+YP/;^'VHB;K^56_LWOW<F5K]JU4M9!UOMJG_ +L=88:N5ZVI
MI\IA<S1FOS6/K$A@'VV5:-@U@WO!_P"\!S"-YYX_=,3ZK/;81$ &!'BMWS$8
M[6!*QLM3F,'J>_;C;?HM@^L=?U[IRY-"#H7M3SR*58'&&/1^][;WEW%6QYR/
M;F%VWD,1BC"E%@J):.*OSTU2T%%4FD8!GFFK:F"\5B0B/;W'')>S#?>9K.PD
MS:&7Q)*\!%$-;U/I04KY$CISW+YD;E?D;<=V@--P$!B@IQ-Q.1%$%'F0S:J>
M84^G6O\ ?S<NQ!E?D/M?HS&U7EP7QJZ\PNR*V**7*I#+V'N..+=F^JJHI*UT
MQ\]7#/D*>**MIHQYJ8JC._CX@3WAYH/-?/5Y?J?T!(0HR*"O:-)P"$"BHZQ$
MYU@79FV_DR$CPMFL(X7H30W$@$MPQK@G6V' RM 2:=56?[[_ 'OW%W0('7O]
M]_O'^O[WU[_5_+K&\4<E]:(UP5]2@G2?JM_KI(/(_/O76B >/5P_\JSY%_,7
M<7RIZ?Z-V9WCO>JZ_P UE\MF=Z;7W1EJ+=F+I]F8/"12[@JL7#O-JVHIZJFH
ML;2T]/#2S*($=GAA+@GV,>5=QWF3=8;&&>0V[$EE8AAI S357R  H<>0ZF#V
MLYBYPN.:K/8[.^G.WNS-(CL'41JO<5$E2" J@!3CB!7K=-J*:GJX9*:K@AJJ
M>5=,L%1$DT,BGZK)%(K(Z_X$'W-76:/7..-(HTBB18XXT6..-%"HB( J(BBP
M5546 ' 'OW7NN?OW7NFG/9-<+A<IE64O]A0U%0D:C4\LJ1MX(47C4\TVE5'Y
M)][ J:'AU[/EQZB;3Q4F%V[BL=.P>KCIA-D)!>TN2K'>LR,@N2=+UL\A']!8
M>_'B?3K0K3/'I0^]=;Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZK6^1D,4^^LGN/&+]M5XS,T^ RWBLOBR%)CJ#*8:OO;AZRDG(+'
MZM#I_'M]!1<]-,!7'$G_ %?8?GT;S Y.;N7J?$M2UT%+)F8J;';GD=/-)%]G
M(L6:IHH2IC:>J,5@'LFB2_\ 3VT:JWH>G 01Z]1X^L=RRU<$DN:QF,E@Q$^*
MESF)@G.3R<,M+2T0%;1SHD$=0(*07GCF!"MH5%MJ.JU^+K5*U\J]"?LW!U.V
M]L8;!5E1!55&,I!2O/31O%"X61RGC1R7 6-@.>21[UQSU;I3>_=>Z][]U[H!
M.V>^=O=<+)BZ%(\]NME(7%Q3!:;'%ENDN6G3481R"(E_<<?ZD<^[JA(J<#K1
M8>7&O5>>\NP=W;]K'K=SYBHK4U,\&/1C!BJ07)"4M"A\2A/I=M3GZDW]N!0O
M3=:_/_5_JQY]+?K'H_=G9;QU\:?P3;6L";.5L3-]P%($D>+IB$:ND4<:KK$I
MX+?CWXL%PU:TZ\ 3_J_U?D/+H^.R.C>O=C)#+1X>/*Y6,>K,YI8ZZM+D69H4
M=!34H/X$: _U)//MHNQZ<  Z3'</<TFRZN@V5M"EARF^\V])2T4+@-28DY"9
M:6ADJ(A?RU,TCCQQ&RA?4WIX/@ !J;" <>M$FM%XGHI/1$GQ_P#D/D\IDE^1
M6U>TMQY',[IPU)B]MYZ;&9K)9#9=1#1;OJ:#&[CH\=G<Y0;;R,X@EJ*"EDQT
M,@*>4L&13[=>7M^V7_DI6DL*!48DBJJ) 3&&9254L,A6(8C-.B^TW#;[[_<6
M97!) S0L4/<0#0D \2 1\^ADS'QPWALQZG,]9=B5>/CIUEJGI<G6R8ITB0$R
M"2OIKX^5!'<N\T4:Z0;^R16!-".C CS'K7I"[;^5>^<'(:/<M'B-V00%HC5T
M[?PZL?QL4\L=32Q/1U$7IX)A!?ZZO>S'FHZUK/$_ZO\ 5_Q70>=M?'S^7'\T
MZ:6#O?HO8D&Z*N)X4W)48J/:&[X)*AE+34&_-J28ZO>5W/)EG-P/4MK#V+-@
MYZYQY68'9;Z>.($50MKC-/(QO5:?D.BC<-AV;=E/U]O$[_Q4HPKYAA0_SZJ)
M^07_  F#ZYW#3UVX/B5\C,QMB2H\DV,VAVQ14V\=L,'NRP0;TVU%19NFI8_T
MIKHJM[?JD/U,X<O?>6W&$K#S/81SH.,D!\-_MT,2A)_TRCY= +<O:VSD#-M5
MP\3TH%D&I?LU"C ?DW5#'R&_E#?S#?BM5SY_<G1NY]SX/#2-44O8_2=5/OBB
MHXD8JE9_OVPN[,'+(@+$-3*8UOJ8>YSV#W:]O^:$%O#>QQ3.*&&Y CJ?3O\
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MREH'98V9QI=7^!9$98SK8.12A/0S?&_Y,?%GXV?'3J[IKM/Y'];[Q[ZR&_\
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MK(#PK2-G#5U/5VK]K$_LX=6+[0ZYZ^Z^I5H=A[%V?LNC5!&*;:FVL-M^$H
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M?V'25>;CEFK*6*IB2F3(VD<(&9H(W]!M8C;E^]MN7N3MZYCDD5;MX!:0BH#
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M_P!:9'"Y3;/7XK8]WIV'MZ@:MP&XZ*AK\%62Y.1X3B*[$YH9#%5]&67ZSQD
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M&*XDUNB!@0R'X=!KI!TY92?ETHY!WJ3=X9T-G;V_@A5UQKI#-0@AAQJ*5I7
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MANVE:'I6IU3TWU3UGOJ@KHZ?;_7/V>5W;O&OS>5D%!A\=B<;]WDLS-DJM_\
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M@?31I&NE52LCE&)21@:L H P2IK:UVNWEN-DN+C;[^!W=HI%8B1:U"B$D@H
MP[D'D:U/5B'6_P#,T^4.V-F8&L_F,_!:JWGL:IQV,DR7R"^,:4F_!M>:KI:&
M:LQ_8/7>/JY=QX#=&W8,G3'+08^4KCI9T22&,V!C_=O;#D_<[N1.1MYC2\#,
M%MKX>$7 KW0S$!'C;2VAF U4PQZ$%ES5O-M&IWZQ;P2HK+!^H ?1T%65A45
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M"*MF2,A//54<GCIZXA1<S4SD/]=-[DT*@Y7JP)&&Z2'\R?NFBZ^_EO?+'MG
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MK'D*Z2)!59.L>G"KYJEY9=  U6 'O&G>MWWG>;][K?;B:XOP2I:1BQ%#E17
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M;(TC22.RF4\V4#VQNNZ;CO5]-NNZRO/N$S:GD:@9C0 $T \@!@>73UG:V]C
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MB.CC>PCT<](+<G5^P-VASG=JXBKF<L35I2I2UNMKWD-72B&=W%^-1;W;4P%
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M1J.%10/Q[Y92SRW5PUS<,7GD<LS')9F)))]22:GK+B-$@C6*(!8T4 #R  H
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M;E^CNQ<GCY,;7[MIZZED@H(V^WFK/N-6/?4CJ]?**=9*@6$A\?/^'O0D [@
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MUCK[AW(N.9Y4TT\&.-#\\:Z_\;H/F*GJD[_??B]_^C_ZGZ>YF_U?ZOET!_\
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MA?GC^?7NZII3_-_Q?\NE11?*[<,2A\OUG421+;RU.-K*Q(5XYT>;'U$3<_\
M-W_8^_-'0T\Z^?7M>*T\J](VLW?)WYW!UZ^)P.1I,7@'IGRD%28Z@0)!62U]
M56S2PH8HH0JQHH:S,PXY/OQ 5#YGKU230_"#_/JPGVUU?KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z+EVO\ $#XL]YXW+XKMSX^=0[]I<]E*;-YJ3/;$V_-D,KEZ
M2H2J@R5?EX:&#*U-8L\89G:8L]K-<<>Q#M7-O,^R2)+M-_=P.BE5TRM15(H0
M%)*@4\J=%MWLVU7ZE+RWAD#&IJ@J3QJ32M?SZJR[;_X3K?RX^QX\K-M3;'9'
M2V9RVXFSSY3KC?\ DI:2@IYIJB:IV[B-L;SCW7M3$X&0SA8XH*)'ITC58G1;
M@R;M7W@?<+;RBW4MO>0I'ITRQ"I.*.SQZ'9O4EC6IJ#T%;SVYY;N:F)98'+Z
MJHY_8%;4H'R QY=5J]O_ /"67(HFY,AT#\M()I6K*0[0VEW#L%H*:GQTDE(F
M0BW'OW9F0JJFKK((O/)!)3;?B25O'&Z(-4GN1MI^\W&3''ONU$"A\22WES7-
M-$4@  X @RFF2"<#H,7GM4P#-M]YG\*R)Y&E=3J?MI1/EU57W#_(2_F9=2IN
M"OH>G,%V[@<-F8,3CLEU+O;"YS,;GI9ZA*>#.XK9N4?#[BI<62^N454<4T$8
M+.EA[D_:??/VXW4QH]X]I.Z%B)XV54-*Z6D&I"WI0D$\#T%+SD#F>T#%85FC
M! !C8$MGB%-#3[<_+JMWM'XR_([I&LW!1=O]#=N]<OM,44NYJS=&P=QTF"P<
M>2@HYZ"3(;IAH*C:\457'D8-#BM9"\JI?6=/N1-LYDY>WI(WVF^M+CQ:Z DJ
M%FH36B5#XH:]OD3PST&;O;-RL687EO-%H(+:D( ! I5J:?,>?5NW_"</JVKW
M_P#S&\=O^FKZNDQO1_4'8VZZUZ?$S9#'9:LWA1TW7%!M^LRT<D5+@ZF2'=$^
M0A+ZWJ5QTD:1D:Y(XH^\-N:V'MZU@R@R7MW"@JU"HC)E+!>+"J!3Y#6"3P!&
M'MM:-<<R"X!HMO"['%02_8!7RPQ/Y4^?7T!/>!_60G7RT?G_ -G#N/YP_+'L
M>#>1[ P^?[X["AVKNU:G[NFRFR<%G:G;^RHL=.8:=FQ&+VQBZ6DHP4!%/ @-
MR+^^FO(FV_NCDO:MO,/@2I8Q%TI0K(RAY*C^)G9F;YD]8J\P77UF^W=R'\1&
MN'TMZJ&HGY!0 OJ!GHHG^W^O].;_ -;?ZK_#V+.BBOV\?]7Y^HZ]_OO\/]:_
M^I_J?Q[]UK_5_J^7J?+H_G\J[KC_ $K?S&/AWM'^--@#!W1@=[C(K1"O9FZN
MI<AV8F-%/]Q2:?XT=I?9";7> 3^72^C0P$]S]P_=?M]N]WH\2MFT=*T_MR(:
MUH?A\352F:4Q6O0@Y4MOJ^9+.'5I_75JTK_9U<#RXZ: _.N>OIV^^;/6477O
M?NO=(?>CFL. VU'RVX,Q!]XOUMA\05RF2+#\QS&"*!A^1,1[V/7K1.1TN/>N
MM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7E\H=KIM[?^*W?'3ZL=N2"/[] K
M>-J[&B*"J5K&[/58]D-K@$K[>B)H1U1J:@3_ ,5\^@7HEBV?NFIQ&3=IML[@
MH(Z*ME%V2JV[FDCJ<9E8?H&GH)3'.K"Q$D+ >[$>5<CK0]#P(_U#\^G/;F"#
M9W,]5;@FAIY<G5&+ Y*0E:>CW5!$?X-5J_T_AV>IW6"2W&F5&Y*^_$XJ/]7[
M>!Z\=5-)P/\ +Z?ET.OQT[)KMIYRIZFWB9:)?OZFFPXK;J^,S"R,*G$R,Q.F
MGK9+M#_9$AL.''MMQ4 CJRUJ0?\ 5\^CV^V^K=>]^Z]U!GQF-J;_ './H:B_
MU\])3RW^GU\D;7^GOP)'#KW2:RG76P\U#)!D]H[?J4D#!B<7212C4+%DGACC
MFC?^C*P(_K[W4\*GKW5>W?/44/6>:HZS#&63;&>,WV"3NTLV.K8 'GQTDK>J
M6$1-KA8W;2""3:Y>5M7V]-L*<!C_ %?X./43XZ[CGV_VI@H5E9:3<'GPE='<
MZ9141/)12,H(#/'71H 3] S6^OO3CMK_ *OLZVI-<''^'Y_Y/3JT?VSU?KWO
MW7ND[5;1VO72U$]9@,54S51E:IEFHH9))FG""9I&9"6,@C%S^;>]U-*>77NL
M7]R]I:@W]W<1=?(1:BA O*H60E0NDE@/Z?7GZ^_$EN/7CGCU*J-L;?JZ5:*H
MP]#+2)4SUB4[0*(EJ:IG>IE"K;FH:1O(/H]S<'WZIZ]QZB+LG:*2M,FW,.DK
MI+$SI0P(?'.K),@TJ %D5S>WUO?Z^_:F]>O#!J./3_1T=+CZ6"BHH(Z:EID$
M<$$0TQQH/HJC^ES[UQZT  *#AU)]^ZWU[W[KW7O?NO=>]^Z]U[W[KW21W1OS
M:&S*<U&Y<_CL6--T@FG#UDOUL(:*'R54MR+7"6O]3[V 3PZU4=%>W;\N<?#Y
M:;9.WIJ]QJ5,GG&:CIKVMKBH(2U5*4;\,\8(_/NXC)&<=:+>G'HLNZ^Y^R-X
M&5<KN>LI:&0F^.Q#'%4"QF]@R4S++.JDV!D=S_C[N% X<>JDU_TO^3U_R=)3
M;^S]U[MJ#'M[ 9;,S.UI)Z>FEDA#$7_RBOFTTZ:QS=Y![V6 X\.M 'C2G^KA
M^?GT.>$^*O9&257R=1@]OQL VFJJ9*^<#\J\-$NE&%N!K/\ K^Z^(.K:3_J_
MU<!Y="?C?AY0*%;+[VKI6L-<6/Q<$":ORRS3SR/_ ,F^Z^)GACK>G/\ JX^O
M2NA^)/6RH!49+=LTGY>/*4D"_3FR#'26N?\ 'W[Q&Z]I'^K_ %>?7.3XE=9L
MA$60W=&_%F;+4DJ@7'!3^&)?CZ<^_>(W7M(_U?ZO+I.5GP^V])<T&\LU2'Z@
M5%!1U@)_Q(DIR/?O$->&.O:?4Y_R^OV])"O^'V=0G^%[TQ<RB]A7XVJA<CGB
M]-+*H+?GCW82#SX]:*XQQ_U?X?/I%Y#XK=H4I(H_[OY1!?U19-J5B!:P$=3
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MPC5$=?$E'E%K:6J;:F!JV%(L;(T$IVMD,=7S3/K+,5"*Y.DJ0![\K@&@R/\
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M9/'!%- E)2Q,TC2(P"Z#(6V?>7Y=F;3NVWW=N @.J-DE!?%0%/AD+Q(.IC@
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M   %HS40DV_ *VX][+(10_\ %=;HWY _ZAUQ&Z/DSM$:ZS^^PAC  &3Q*Y>
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M6"?Y?;T(&+[TVE7K(98ZF PM!YFBEI*B&..I5#3S@RSTE3+3U!D4))'$ZL6
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M04E12. M7@JHB:)722.>E*C1S<;()%/,>O7J4S^$_P"K_4>H>/Z:WSF=QU6
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MW[KW#CT%.Y.\^K]L>1*W=5#6545P:+#DY6I+#ZH?M-<$;W_#R+[MH;TZU4=
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M53*D%/34\*&26:>:0K'%%&BDLQ(  ]M3SP6L#W-RZQV\:EF9B%55 J69C0
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MOMS[D2;5S'RGN>^W$N[[G<6]]9VD,IN8-P:W-NIE=&4R0B)[:3ZEAX<+GPR
M!UT!V<\M<Z\E0[GLG,-CM<$6UV,$UI<W,D8AFLQ*)6\-7!5'+K/'X*GQ)47Q
M 23U83U%U_N#'=%X;9>ZO]P^8JJ*NJ6QD<BU<6V(LCE:C+XW;:,"$J*3!4\T
M=*5!TLD94&WO.7V<V'>>6/;K;-IW]!#N:1N[0!@PMEED>5+8,*@BW1UB!&.R
M@P!UA_[J;UM/,'/-]N6R/XM@S(@F*Z3<-'&L;W#*<@SNID(.>[/3SN78V\=T
MI!/6UVW*2HAJ(@V/H4JA0STT--4QQSU-;44$M345$=14:XX7A:.( Z'#,6]R
M;4#AU'HK^?29VYTSN+";BI,X^X:.[93&9&O^U^X$P%#2T4%=!3O4TLU1*N?D
MIG:JO-"/W/H_T][#>O#KV:U\_P#5C[/Y]&-]UZWU[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U3GVSMBEVGW)ON?M3KJLW'5[E[(3<NS]XQ;"S78-)E]AU>*
MG@CVM51T[UU'128NJ$=-#!%3-)$Q,IBELK#F?[@[!8\L^YV]W'N;L$FYS;AO
M8NK"^7;+C<TFV]H67Z.309$A,+Z(D18M2YE\.3##H!R/O,V_<@;7%R1NR6EM
M9;/]/=VIOHK%XKU958W*EM#N)$U2,[2!6 ":X\@V'_'W:.2VQU/%A):7)[?H
M:S);GK]J8+*G_<GM+:^9R575[?PM1&)'^WEQU)."(;WA#!#8J0,V_9;E^?EC
MD&WVR2">TLOJ+F6VMIJ>):VLT[R06[ $A?#C842OZ8(C.5(ZQ+]V]ZM-_P"<
MI+VWDBN+I;:"*XN(_@N;F*)4FG4_B#N/B_'34,&O67^ZV[((L/!1[;I*%<+1
M''9FNP^?3$Y[=T?B@2.:CRE(()<?$U;3BJJ!4MYI#Z%87<M+-5U5)\_V?Y^H
MR H*'TZDC:W94:BL.X*N;*QLSZ/XS,F*J$H=OXE\?3-0%!3PBMS]//%4R*FM
MHY"YN"![]5">';_Q?GUJA\CTRML_MV7+T8GW+5_PVHR6(JLO+2YFIIA'B9:F
MBJ,YB:#16>2&>"4U AE6!7-/IC$OX]Z#*/+_ %>7^K\^O4- //SZR5FU.UEB
M0T&7D1_OE\A&4<U4R0T=/38^LK*M:NADJ8:00MYHW:4SE@2C$>] BM2.MYX=
M3J?:_8U'C<9%59++Y=OLL3-GJ>#=M10UU9F_M\M%D9<=EI+/C\=%4O2RF!-,
M3J" O!!T35L8'6J'CYTZ>=L8+L>CGW:V>RT&02MI)HL-%554T]$:J26J>G9?
M%(LM-3PT4D4$NB*F,DB-)H).HV)4@>M>O"M#Z_ZO/I$)UWO*&6@JL12SX@XR
M>*''1S9ZA6NIXQB,Q1O4555AZ6DILO1P/50I#]TDE:-3EG93;WZJG+9)_E]G
M7J$=.N1VKV;54Z2X_*9;&0TPGEH\3/NFIKJ[QR56(6>BK\I'54K9">>*&KDI
MY7J *=9%35_2U4\_]7^KSZ]GR'0O;3I<S1;>Q=+N"I^[R\,#"KG+F5B3-*T$
M<DI>4RRPTS(CN7<NZDZFO<MM2N.'6QPSCI1>]=;Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZAU6/H*T6K:&C
MJQ]+55-#4#_;2HX_'OW#AU[I#Y/J7K3,,TE?LK;\DK<&:*@BI)OZ?YVD$+_[
MS[MJ;UZT0":^?0=Y/XO=3UX;[?'Y?$,U_5C<Q4D"Y)X2O%<@%S] +"W'NPD8
M>AZJ4%*=!YE/A[AI2S8C>63I1>ZPY''4U:I(^FJ:*:F86_P3WX2'SX=;*U-1
MT@*SXH=B8O6^"W-AJH!F:.."IR>'F-Q]79;Q!B?Z$_X^[:U/6M)'^KUZ@'9/
MR?VF!]A5;GGBB^D>+W#%E("HO8FGGJ 9 /Z:3_K>_%D:E>O:6 K_ ,7]M/7^
M77)>Y/D7MABN9QU?4QQV!&9VC((18@F]914],7']3Y"1[\%0C'7B6_U?ZN'K
MT^8[Y?[FI]"YG:6&J[6$KT=96XUO]J*QU"URBY^@)Y_K[T8QY'/7@_K_ *O^
M+\NA"QGR\V?4V3*[:SV/!%GD@>BR,5S>ZA8Y(I3Q;C3^?>C&?+AULL/*O^SZ
M?;TK\9W/T3N>KI8WEH:6OJ:RFCI1E<#)25,E8TZ)2!9TII"7-0P"DO:Y]ZTN
M.'6Z@BGK_/HQ7NG6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[J*M=1/-)3)64KU$
M+!)8%J(FFB<J&"21!RZ,58&Q -C[]U[J5[]U[KWOW7NO>_=>ZZ)"@LQ"JH))
M)   %R23P ![]U[JG_LO-0;A[!WCF::02TE;GZ\TL@)(>E@D\$# FQLRQ?ZQ
M'M0M=(KQITT2#\O]7^K[>CE?$3$0P;/W#F]*FIR><^T9[+K6'&P*J1@_J5#)
M.S6^ES[;DXTZNM*5KGS^71LYH8JB&6GGC2:">-X9H9%#QRQ2*4DCD1@59'0D
M$'@@^V^K=5H]P]<9/IW>5)N/;0>+;U;6/582HT>2+&U1#&HP58K762G>)F50
M_$T#%3<@^WT)(^?3; :N%!T'M>9,14XKLC8[OC:4Y!)'@IW#/M7<B_NSXB=0
M=7\,K5U/2EAIE@8QFY4^]\.T_P#%CK5*"H_V:_ZO+JQ_J3M#&]G;;CR$1CIL
MW0B.GSN+#>JEJM(M/"I)9Z&JL6C;FW*GD'VRP"FE>G :]"/D\E18?'5V5R,Z
M4U#CJ6>LJYW("Q04\;2R-R1<Z5X'U)X'NO6^J=MW[CFW7N?<&YJ@%7S&2JJY
M(R;F*!I"M)!<\D0TB(@_P'M2!3'ETT37/G3^?^KR_EU9]T=A:?!=6;0IH(T1
MZO&1Y.K=+'SUF0)J)IG(^KL& _P  _'MEZZJ'RZ<6E,="S[IUOKWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND)V9V'M_JG8VX=_;HDF3#;=HC53I3H
M'J:J9Y$@HZ&E1BJM4UM7*D27(&IA<^PCSWSKLGMWRE?<Y<PNR[38PEWTBK,:
M@(B#S=W(1032I'0GY-Y3W7GCF6TY6V4*=PNY-*EC15 !9G8_PHH+&F:#HHO7
M?S2KL]NK9N,[!ZRJ]A[7[/J7I>OMSC.8_,0SU>B&6GH,_!32:\7554-5$5#A
M&'E0Z-+ ^\<>2OO276\\P[3M_.?+MQLFP\PN4VV[:XAG5Y**RQ3K&:PNZ,I
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M\NM5]>/3W@=T4.XJK*0X\-)38X8UDK-5DJER-*:FPA94FIY*9E,<B. RNI!
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MM^=?Z71N.OND=\[IZ[R=!G8L538FJIGR^QH<BY;*8S-5(20Y"CJ*37]EBLK
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M!B8?0%]3"N&J:]3S[A^[7O;O_*T>V<VP26.PW875(MFUM]73(\20@"3@"0M
M?,4QT<RI:E6%OO&@6G:RO]R8Q";FX5O+Z#<CZ'WE)UCMU#IL5BX*NJR=-24Z
MU>06G-15(-;3)3TZTU.$)++'&E. H":01];^_<?LZ]U-%/3A/"L,(C"E?$(T
M"!7;4PT!=(5V%SQ8D>_=>ZPQR4&F98GH]/ETU"QM#I\TATZ9@IMY9#Q9N3[]
MU[KF%HZM=06FJ4#_ *@(IE$D5U^OJ&N/Z?U'OW7NLZ(D8LB*@XX10HX  X
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M5+14\-'3K%3T])3Q0P0*0J04T*"*)%!/ICC1 H_UO?NO=9U97 9&5E-[,I#
MV-C8BX-B/?NO=<O?NO=>]^Z]U[W[KW1->[?B_P#';?F\J+=V^<S4[*W/F)*>
M&9\-NZGVJ=S30#PQR3TTH/W%?X;1&:+3(4X))Y]XQ>Z_W>?9+GCFB'F;FZ:3
M;.8)V56:"\%H;LKVCQ%/QOI[-::7TX)/607MO[T>['*_+\NP\M6Z;CLT 8@2
MVK7/TX;)"L/A2O=H:JUR !T:39^TMM[%VQA]I[3QU/BMN82B2DQM%3DO%'3W
M:1I'E=G>>6HDD:221B6D=BQ))]Y \M<N;'RCL-KRWRW;QVNR6D02*-."KDUJ
M:EBQ)9F)+,Q+$DDGJ%=_WS=^9=XN-\WV9Y]VN)"TCMQ)X4I@*% "JH "@
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M&;]W[V.@,8<-ZAP#R#[ZD>P%OS9:^SVPP<[>+_6);%-8E),H7)B$M<ZQ'I#
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M]1=_2_4*#IU!=0_3+40.]%)P#ZF5VWN[ ;JVS1[LP56:G"5=)+51RM3STU1
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MIZ^V56(D=3MK%2I'0IC0#3V+X^,3A:.9E96GIKU,A*.6#,Y)N3?WLLQ\^M
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M=C;WWEA=S[GR60IT%/!D*FDS^7='OH$P@%R+D^U_-U[%?>T%K<IW68YBE6,
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M0U''K1 (H>'1(.U_C!/2?=9[K9'J:?USU&UI9"]1#_:=L-.Y+3J.;0.2_P!
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MEK*6)X$629)*B)&A1R CRJS@QHY/!-@?9@T\"$JSH&6E02,5X5]*^73 CD8
MJK$'Y'K$N5Q;?IR5 W*#TUE.>9#IC'$GU<\#^I^GNHNK9OADC/\ MA_GZV89
M1Q5OV'IGS>ZJ/#9#'XC[2OR65R5-75U/C\="DLYQ^,:E2OJSY9(8RL#5D8"!
MC([, H//M'>[K!9W45D5>2[E5W5%%3HCTZVR1PU* .))H!T]#:O-$TU56)"
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MCIHJ:6LIXZB6HE4O%!'"\@D>:5%)5 "S 7 ]MO=VD<@ADEC68L%"E@"6(J
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z##=^W<M+O38F]<9
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%=>Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>nt10016217x4_graphic01x8.jpg
<TEXT>
begin 644 nt10016217x4_graphic01x8.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** /Q7_;C_ .2]:C_V+/AO_P!)IJ^/Z^P/VX_^2]:C_P!BSX;_ /2::OC^
MOZBX7_Y)S)/^Q;A/_343_/'Q#_Y+KBS_ +'V9?\ J3,****]X^-"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /2_A__P @/XM_]DT'_JP_
MA]7FE>E_#_\ Y ?Q;_[)H/\ U8?P^KS2N/#?[QF'_812_P#4/#'IX[_<LF_[
M L1_ZL\>%%%%=AY@4444 %%%% !1110!V6E_\B/XO_[#7@__ -%>)ZXVNRTO
M_D1_%_\ V&O!_P#Z*\3UQM<]'^)B_P#L(C_ZB84[<5_ RW_L"J?^K''A1117
M0<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7>?"S_ )*?\./^
MQ\\(?^I#IU<'7>?"S_DI_P ./^Q\\(?^I#IU<V-_W/%_]@U?_P!-3/0RG_D:
MY9_V,,%_ZDTC\4Z***_<3^#PHHHH **_HO\ A+\*OV>=-UW]GS7/'7PC^&-Y
MX3C_ .":,GQ5\=K=_#OPUJ2ZGK>E7GP@O-7\:ZC:+I$LVJ^+4TV\UH+KCI-K
MT@O[V.*[+WDPD^6_B=^R5X:^!'[/_P"W;<MH.@>+-!2;]G'Q?^S[\4;S2])U
MG5$\ >-OB6895\.^*S;S7%G>_P!GO_PCWB672KBQ&MP6\.H2VHTG5]/63\WP
MGB7E>*Q<<%+!8K#UZN*RW#8559T_9XJ6/SVGD=54JB]UU,%*M1QE6AK4GAIR
ME!6ISDOZ$S3Z._$>7974SFGG.68[!87+>(<QS)X>E7]OEM/)."J_&F&>)H-N
MI'#YQ2PF+RG"XRRP]',:,*=:5\11C+\=**_H+^.FL? 3PY^V9X;_ &2M9_9(
M_9\U#X<?$7_A7^B1^(/"W@FR^'WQ%T'5?'%Q'9G4K;Q7X56RE>RL)W286-E;
MZ5>RH77^UPN(V_$KXZ_#N#X2_&;XI?#.TO'U"Q\#>._$_AK3;Z6:VGN+O2M+
MU:ZM]+N+Q[,FW34)M/6V?4+= AM+TW%K)'%+"\:>UPWQ9#B#V$9Y=B<MJ8O*
ML-G6"5:MAL1#%9=B9^R52,Z$W.G5HU;0K4:U*FU[2G*G.JI3Y/D/$/PNK<!_
M7*E'B#+^(,/E?$V8<'YQ+"8/,,#6RW/\OHK$RP]2EC:,:6(PN*PSG5PF+PF)
MKJ3H5Z>(I8>4:?M?*:***^N/RH*]0O/^2+>'O^RH>,O_ %%/ M>7UZA>?\D6
M\/?]E0\9?^HIX%KCQ?QX+_L,C_ZCX@];+/X&<_\ 8IE_ZL,O/+Z***[#R0HH
MHH **** "BBB@ HHHH [WX5?\E0^&_\ V/O@_P#]2'3J/BK_ ,E0^)'_ &/O
MC#_U(=1H^%7_ "5#X;_]C[X/_P#4ATZCXJ_\E0^)'_8^^,/_ %(=1KS/^9RO
M^Q8__4J)]%_S27_=Q?\ O,."HHHKTSYT**** "BBB@ HHHH **** />M(_Y-
M?^(7_9>O@Y_ZKWXZUX+7O6D?\FO_ !"_[+U\'/\ U7OQUKP6O,R_^/F__8S_
M />=EQ]%GO\ N?"W_9.K_P!7N>!1117IGSH4444 %%%% !1110 4444 ?M[\
M:_\ DLOQ;_[*;X]_]2K5:\RKTWXU_P#)9?BW_P!E-\>_^I5JM>95^%Y=_P B
M_ _]@>%_],0/[TSS_D=9Q_V-,P_]2ZP4445V'EA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Z7\5/\ D.>'?^R:?"O_ -5YX;KS
M2O2_BI_R'/#O_9-/A7_ZKSPW7'4_W["?]@^,_P#2\&>G0_Y%&8_]AN5_^FLS
M/-****[#S HHHH **** "BBB@ HHHH **** /Z:****_C\_U "BBB@ HHHH
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M4_?4FG>K3E[U&JYTI-N#9V6E_P#(C^+_ /L->#__ $5XGKC:[+2_^1'\7_\
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MH>)^)S/B2CA.',FPV687!X?Z[PIEF(R[#4:,<RJX/)L?FM7&5J4J:^??!G[
MWQ4\?>!X/%/ACQY\&-1\47OPUA^+>F?"*'QQ<S?%'4O UP;V.#4+;1K?0IM'
M%W+<V?V-K*77D;3[V>"PUN72;^>VM+BEX _86^)7CGX:^#/B;>?$+X+?#K3O
MB.^N#X?:%\3?&U]X4\0>,(_#\L\%[-I2-X=O='C6:2W=K%-0UFREN;;9?-'#
M8W%I<W'W+\&?^"BG[.?PG\.^!=*TOPW\5O#&BVGPFL_!?C/X9>"/ 'PJ@\)S
M_$,6:C6OBE_PE%SXGT[QKXMU+5)XH=-MK'7M3M(H[%[O5;D#5#Y%WY]^RM^W
M;\(?@Y\)? GP^\9ZO\=)=-\-_P#"8+XX^&MOX9^&'Q"^'/Q!M->ENI],LM+O
M_%UYIGB/P796]S-)>ZCHNGXTR]O+V_:>>Y^U&>VBOG7B0J.:5*.5.]',<,\#
M">"_?U<#4H9M]8HI0A6AST\1ALNC"7L\13:Q+C4S&G2JK%X;?!<'?1Z>+X:H
MXOBB$EBN'\RCG=6EG%L%ALZHXSA18#&R=:OA:OLJ^ S'B&I5I?6,!B(RRU3H
MY#7Q6&EE./\ EWX8_L%_&/XG_#_P_P"/;3Q#\*_!\GCNYU^T^%G@GQ_XXB\,
M>.OBQ<^'4'VZ/P)I,^GSV-\LURLME:2:GJVDJ\JPWMQ]FT.]L-7N?E/2?"5Q
M<>.],\">)+^S\#74_BVS\):_J?BE9[*P\'W$FL1Z/JM_XC58GN;2S\/R-/<:
MNJPO/;PVEP!$TB;3^M_P]_X**_"(^"OAE8>/-*^)O@?6?A+K'CL:1X<^%G@_
MX5^(O#NJ^$M<O;JZ^'^A:;XA\>2KXA\'W7PWC_L73[*\TF('4+'1#-JCZO=:
MC#'H_P"1/C7Q/>>-O&7BWQGJ#7#W_B[Q-KWB>^>\EM)[M[S7M5N]5N6NI[#3
M])L9KAIKMS/+9:5IEI)*6>VT^RA*6T7U7#F-XMQN-SJEGN#I9?AH3JK+ITZ7
MOTF\9C*5"-.K+FHXR/U*GA<3.I%U(JK5M*4?:2PF%_,O$#*/"S)\GX.Q/!6;
M8C/<QK4\/+/Z5?$/V6*C'*LGQ6+G7P\'3Q>455G&(S3+:6'E'#U)87#*<(5%
M0IYGF7WE^V+\"_V>OA?\"/V7/&?P'OM2\61_$'_A9EMXC^)FJ_\ "1:;<^/K
MCPGJ.A:8-1B\*:Q<+9^&-.MM4FUF#2+"STNSO?[*^Q#5[S6+V-]1G_.>OK+X
MN?'?PCX^_9H_9>^#6CZ=XDMO%'P3_P"%H_\ "57^IV>F0Z#J'_";>);;6=*_
MX1^ZM=8O-0N_L]K"T>H?VCI>D^5.56V^UQDRCY-KTN%</F.%RF5#-:^-Q.*I
MYIGL8XC,*D:F+KX/^V\P>7U:DH1A34:F >&E2A2ITJ-.DX4Z5&E3C&G'YOQ,
MQV09EQ1''<-8/)\NRS$<-<$SG@,AH2P^68/-?]3<BCGV%H4ZDZM=U*&=K,*>
M*JXFOB<57Q4:U?%8K%8BI4Q%3O?A5_R5#X;_ /8^^#__ %(=.H^*O_)4/B1_
MV/OC#_U(=1H^%7_)4/AO_P!C[X/_ /4ATZCXJ_\ )4/B1_V/OC#_ -2'4:]#
M_F<K_L6/_P!2HGA?\TE_W<7_ +S#@J_8WX3_  $^#$'[)W[-/Q/N/V.O%O[2
MOCKXH^*?'>B>-9_!_C;XLZ3J.E:7H7C_ ,5:18ZN^G>$]3D\/VJPZ1IMI8QO
M=V^@Z<[VAN;_ %%9)+JZK\<J^]-5_;(U'2?V1O@-\"/A5XJ^+7P]\=_#K7/B
M!>>.=;\-ZY/X3T#Q!I'BGQ3XFU[2K"TU+PYXHBUG5EMH=:M_M=KK&CV-K#=K
M<_9FN$5)I?"XQP6<9A1R3#914Q-*4L\@\?4P^.S#+HQP"RG-DWBL1E>(PN,^
MK+&2P;=.E52G75#F7*FU]OX2YQPGD6,XQS#BO#Y?BH4^#*L<DH8[)<ASZK4S
MM\4\*RC'+<!Q)@,RRC^T)91#-XJMB,+)TL%+&^SDIR49?6WB7]@OX.1>(OV[
M_ ?@VYT0ZE\*[;]GG5OAKXK^('CR_P##^C?":V\?W&L:Q\0$\6:T+K3M$OM*
MTG0+&6X6XUS3O$&HVNAV]C%:_;?$TER]Y\2ZQ^PY\3-#^)-CX U#QO\ "&WT
M?5?A/+\;])^*DWC&[B^&6I?#*&%9Y?$-EJC:$=>NI(U89TRT\.7&H2P@ZE:P
M7.B[=3;#^&'[06C>%O@1^UQ\._%__"7Z[XY_:%7X4S:+XA7[+J=I_:'@SQ?K
MOB+Q+>^,-6U/6K?6/M&J0ZJGV6YM+'6Y[V]-Q]O-JA$\GV)X<_;E_9Y-U\##
MXE\$^-_[0^$_[*&G?!C3?&DO@CP!XLU3P)\6=,L_#=I9>/\ P5X=\2^)KOP]
MK&G61TS4);>[UVUL]5R+.%=+BM[S4HZ^5BN/,CJ8VG2K8S/*/-2PL*U;#*M.
M53"\*9%%YGAW/$2=.CB<XI8V,\+"G47UB6,KRIXS$U4I?ILY>"'&=#)L1B<+
ME7!>*<<5F5;"83,'A:-.AF/B?QG5CPYCXT<#2CB,5@.$\3E$J695<3AVL#3R
MG!PQ&59?AIRA\U:O_P $_OC?8_%SX8_";1M4^'GC'_A</A^^\6> _B)X4\27
MFI_#;4O#.EVCZAJNL3:]_8T5]';:;I[65U.UII-\EX-5TN'1I-5GOH(VR[W]
MASXGS_$/X;_#GP+XT^$/Q:U/XFWWB*STS5OAKXUGUO1?#:^$GM?^$EN_&[WV
MBZ3J?ANUTBWNC<R&33+F6^^S7%CI$6HZJ(-/G^L_B)_P4"^$GC7XK?LJ>.S_
M ,- 31_ [2O'>D>-/$T:^!?#'CO7[CQ!8:'IVG>)-*32-:O_  [?RZLNF7D_
MBKPI>V^A:*MO?R:+:7M_9,TX[V^_X*;_  PT?QW\#?%-II'CSXHZOX6G\9Z9
M\6_B=XL\"_#?P/X_\0^ _$EC/:Z9X0T'3/!VICP_<P:;J+Z5XAO(KV31XKB_
M\+Z?!9WMI#KNKM:Y?VUXF1I8&<<FI5J\\IS%UZ#P_LH+,Z$\[CA*E6I)1@Z=
M6GALIJ*E[? 3J5,3R4L/.&(E+ ]7^I_T<JF)SFG/B[$83!4N*>'HX/&K'_6:
MO^KN.H<%U<TP^&H4Y5:ZK87$9CQ1AY8GZEGE*A0RYU<1CJ%; TJ6<_FM\=OV
M6O'/P'TKPYXIOO$WPY^)/@+Q3>7^C:7\1/A'XK7QEX-7Q-I+2C5?"M[J+6.F
M7-EKME'$UR()[%;:[MA*UE=7$]CJEO8>L?L@>&_V9_%6H>$?"?Q!^&7Q#^.'
MQ@\>_%+3?"&F^ =&\1:EX+\(>'_ -[8PM?\ CJYUG0(QK.J:IH<ZZC?ZAILV
MHZ3I,.C6AO;R]L;:SO+J72_:P_:@\!?%7X9>!?A9\.-:^*>NZ=H7B_6?&7B3
M5/'_ (5^%/@;3[_49(M1L/#;Z?X;^&^G,CZIIV@ZQ/HVIZLVH:3:7OV".Y;0
M[J6[@FTGL_V-?VF_V8OV>?AEXULO%.F?'+2_C9X\EN]+O/BG\+/#WPUNM9\*
M># ]B;3P_P"#=5\>>([JWT^6^DM;F]UO4!X3ANIKB[LUBF>X\/:'J=I[&-Q/
M$V)X-G/%X+,:F=U<74P^'I914Q668B5+ZS4I8;&8R=%4<;AL-"DEB<3#"QP^
M(Q$84Z=.&'>(=.'RF49?X<Y?XNT:65YQP_1X-PV5X7'8[$<58?+N(L!3Q3P&
M%Q&993E%+&3Q>3YECZN*G/+\NJYG4QV P4ZU>O7K8V.!C7J_(/[3?@'P1\+/
MC[\5/AU\.=8O==\'^#O%=YH6E7^HRQ7%\DUE% FKZ9=7$,%K%<S:'K7]HZ(U
MTD$8N?[.\\@F0L?"J[KXEO\ #B3QQK[_  D;QT_P\>>V?PX_Q+;0F\</$UA:
M'4&U]O#).AM.VKG4#;-8$J; VAG/VGSZX6ONLMC5AEV7PKU<17K0P6%C6K8N
MFJ6*K58T*:J5<32BY1IXBI-.=:FI-0J.44VE<_$N(JF&K<09[6P>&P.#PE7.
M,SJ87!Y76EB<LPN&GC:\J&&R[$3C">(P-"DXTL)6G&,JN'C3G**<FE[UI'_)
MK_Q"_P"R]?!S_P!5[\=:\%KWK2/^37_B%_V7KX.?^J]^.M>"UCE_\?-_^QG_
M .\[+CJSW_<^%O\ LG5_ZO<\/KG]A/X8>!OC+^U7\+/AM\2=#_X23P5XD_X3
MC^VM%_M/6-'^V_V/\./%^O:=_P 3'0=0TO5K?[/JVEV%W_HE_!YWD>1/YMM+
M-#)]E_%W]FSX-ZO^SG^T)\1[3]F?QM^RKXD^"?BC1K7P7KWB#Q?\0M;\/?%W
M3=2\2GP]);6MC\08Y[IU,:B2&?0H(8(]3U/1'.NW=C%JUFOPK^QU\9_"_P"S
MW^T=\.OB_P"-+#7]3\->$?\ A+O[2L?#%KIU[KD_]O\ @3Q/X7L_L-MJNJZ+
M82^5?ZU:S7/VC4[;99QW$D7G3)';R\9\7?CG\2_BWK>NGQ/\2/B1XJ\*7'B?
M5-;\/>'_ !GXPU_7++2+:>]U!]*2#2M0U?4M-L+FPT^^DM(UL=T=K'+/;VTI
M@=B_R>;93Q!F'%]&O@\PQF7Y3A,OR*LZD<9F$,+5Q%#.,SK9EA:>7T,33R_$
MU\9@%AL+B*F88>NJ5"K1J4HNI3CR_J/"_%/ >1>%.,P6;9%E6>\4YIGO&V#A
M0J91D-7,<+@<;PGPW@^'LRKY[C<MQ.>Y=@LISN>99EE^'R/'8*6*QN&Q='%3
MC0KU'/\ 0G]K+_@GA)HWQ.^,-U\"+SX8Z#X6\!^";'X@Z9\&9_B+JVL?%2Z\
M$Z)X;T#_ (3+QA9:/JSZ_?Q:0GB2\U"&S'B3Q#IUQJ,]O=6VBVLJ'28+_P"7
M_@E^Q!X_^.GAKPOKV@?$GX)^&=2\>-XMC\ >"O&?C>]TWQIXQE\$3PP^(H]*
MTC3- UB**6U64SQ6M_>6NH3V:?VH+)=%$NJ1?2S_ +>/PC?]KG]H?X^?\([\
M2#X.^+/[/][\*/#6F'2/#/\ PDMAX@N=)^'UBEWK5G_PF!TNUT43^%-3D>XL
M-9U*]"7%FPTYGEN$MM3]EK]NKX#? /X=_"'2SX?^(_A?Q/X1N_$H^+.E?#WP
M-\,KW3?C,=6OKI/#VL>(/'/B/6[7QM"WA+2YS=P:)92Z?8W^JF+3&>#1X+>X
MM?FZ6-\1LNX<HX>&%Q&.S2E@\D='$8C#*K7=6KDF+JXW"XV<JN(JUJM',L/A
M*%;%SA*=:OB9JO6P5&K];P?Z)BLG^C]G_B#B\=5S/ 9+PUB<VXQ6+P.!S*6&
MP<<-A^,,IPV39CE%"EALOP^#P^+R#,,UQV%RNE6IT\+@LNHSP>$S?%X5Y7FW
MSAX=_P""??Q>U7P?HGBOQ3XU^#?PINO%&K^*]$\+>$OBIXWN_"OB?Q#J'@O4
M+W2M>@L%30-0T)'CO["YBM4O-<M6N846^Q'I]Q9W5SF_#']@OXQ_$_X?^'_'
MMIXA^%?@^3QW<Z_:?"SP3X_\<1>&/'7Q8N?#J#[='X$TF?3Y[&^6:Y66RM)-
M3U;25>58;VX^S:'>V&KW/W'\,/\ @HM\#O"T6I6NL:G^T&OA.]^(7QD\4>(?
MA?>^$OA1XY\&>.]!\?>*-<U[P[IR3>(]876? ;6BZDMUKGA[1;^\T2XU2[U-
M3J6I1W*WL7/_  ]_X**_"(^"OAE8>/-*^)O@?6?A+K'CL:1X<^%G@_X5^(O#
MNJ^$M<O;JZ^'^A:;XA\>2KXA\'W7PWC_ +%T^RO-)B!U"QT0S:H^KW6HPQZ.
MZV=^)JCC?9Y/3O''1=&I]3G*-/"NGFTZ="&'Y?:595*M#+*5>K"MC*=.&(YY
M8K"2KU/[/,+P9]'"53)O;\6U^2>33CC*#S6E"IB,RCB.%J6)QM;'*HL/A8T,
M+C>(\3@L+6PN45Z]? >QIY;F=/!X?^WOR5T/2-#TCQ]INA?%2+Q1H>@:5XHA
MTOQ_:Z#8V3^,=,L-/U(6OB.RTRQUF>TL8]?MTANK6!-2D$%K>J'N8+A8FMI?
MT'_:H^#/[/FF?LU>!_CK\./A9XN^!FI^,_B7<Z%\._#OB'QO>>-I/BC\*4T!
M]4M_B1J5E>W.I/X-U"XN)+)(]'AU66*T3S$*ZM;ZIIVIV?PG_P )SH^N_&&;
MXD?$'P]/XST+7?B'=>,O&GAF]U:;3[SQ'INL>(9=8U_2Y=;\-Q>&VL]0O[>Z
MNHDU/2+32((;UUN;?3K:V46(^V?B[^TO^S7IW[.'Q"^ /[./AGXMK8?%;XF:
M=X]U7_A:YT1M,^'NDZ;<:9?V?AGP*FE^(]=N-UI/HEAIB7U\LFHW&B7%W#JF
MO:Q*MJMO]7GBSF6;<+U,)1S;GCBL,\SC@L1*&3K"U)<F/ABFL5&$JE!25>G]
M<P.*C7HT7A\#4PN+K2KT_P NX,GPE3X7\2L/FF+X6]C4RS,(<.U,XP$*W%LL
MSHP=;(ZN6QEEU6K3H8R5*6"KK*<YRV>"Q>+6.SFAF65X6G@<1^;-%%%?;GXR
M?M[\:_\ DLOQ;_[*;X]_]2K5:\RKTWXU_P#)9?BW_P!E-\>_^I5JM>95^%Y=
M_P B_ _]@>%_],0/[TSS_D=9Q_V-,P_]2ZP5](:3X!\)W7[+/BCXCSZ3O\9Z
M=\5[?PU9ZS]NU)?)T1]&\.W;67]G)>+I4F;B^NI/M,MB]V/-V"<(D:I\WU]+
M_"OXG_#FS^%OC+X/_%.Q\7#P_P"(/$-AXKT?6O!:Z;-J>F:S;6]I;W'VFWU>
M]M[-[:6'3+*)0MO<O)'->(X@E%G>6G)G/UN-##5<)'$3=#,<#6Q%/"M^VJ82
M%>*Q,%!2@ZL?9MRG2N^>$6N63LGZ7"O]FSQN88?,YX&E'&9'F^%P-?,8Q>%H
M9G4PDW@:LJLJ=18:HJT5&EB;1]E4E%\\$W)=GJOP!TSQ5X9_9@TKP#9Z9HOC
M/XK:%X^O->U;6=5UUM-U"Y\,V&EZM#)<H!K*Z?Y=FNHQ0II.EPQS3W$2W*[%
M6:'SW7OV9/B/H^BZ3K6G7/A+QBFH>([+P=J-CX,\26FN7GAGQ9J-S;V5IH'B
M*1%ATZSO7O;NVLIG@O[JUM;J6-+JXABGM9[CZ4^%OQ3\*^./V@?V=?!O@'3=
M:L/ WPQ\/^-](T:?Q-]D_P"$AU.^U+P/K9U;4+_[!<7-FB7']F6+PQ0-&JS&
MZD2WM(98;*VX^V_:-^&OPQT:\T;X6:%XPN[K7OBMIGCSQ4GBV+1;>ULM,TO6
M++4I?#>@3V%[?N[%M+@L[;4;RT69()Y[J1VF,-M;?)T<PXFHUZ>#H4*E>M[.
M./GA\73]I*-',,YSSDABL6ZZEA?8Y?1PRHTE[11G25!.,4XR_2<3DOA_B\)7
MS3&8NA@L-[>63T\;EM?V$)XK)>%N$/;5<NRV.#E#,'B<ZQ68/%XB7L7.CB7C
M9*<Y*I#Q+Q]^SEXU^'^@:AX@N];\#^(X-"OM/TOQ5I_A+Q(NKZOX2U+4SLM+
M'7[![2TDM[AYBEL5MVNAY[':7@1YQN7_ .R?\3+'2;RX&H^";[Q5IFA1^)=3
M^&6G^)4N?B/8:,\<4LEU/X?^R)$[6T<RM+!;W\\TSM%;6*WEY<6]M++\5_'_
M ,"M:N?$OBOX?^'/',GQ!\6>+;/Q2=6\736=EIGA%S=3:GJT6BV>B:S<)J=Q
MJ>HL!(NLVUW#:VLFZRN(IH2)?7+W]ICX10^+/%7QJT#0OB'9_&#Q+X*/AR#2
M+X^'KOP/I&LG2[#3H]56\CNH-6OK:UCTVQ1%DM(3="*Y,FGV[W<4MEVSQ_%"
MPV$G2PU6=6?MG557+Z=)RQ$5@'1PU:$<;4='!SE5QZGCDH32P\$J:7)6Q/ET
M\G\/'C\RIXC,,/1PU/ZK&A]6SNOB8QP,Y9NL5F&%K5,JHQQ6:TX4,HG3RARJ
MT)/&U6\1S^TPN \KT_\ 9%^(NJ6NCO9>(_AU+JOB3P98^-O#7AIO$UQ;^(M=
ML+VTDO6LK33[K2K<0W=G"L$=Y=WTUKH27-[;0PZS,$OY+'+?]GS7O"OBCX4S
MZG=^!_B%X/\ '/CS0?"Z7_A+Q9=W7AR\U";6K2TO_#.IZ]I^G)J&E37$1N89
M;[3+2^EMH4N;BT\VZMC /4_#G[3?@/1_B9\)_&=SI'BY]+\"?!;3_ASJ\$%A
MHS7]SK=I#/')=:;%)K\5O-I3-*I2>ZNK.[(!W6*D 'S?PC\:_"N@?#_X/^%+
MS3_$$NH_#[XX:5\2]9FMK73GLKG0K&Z>>:TTR27589YM69& C@NK:RLRV0U^
M@YI0Q'%<G+VM+FI2A"+IQPRI37UBGFD9N%:G74X2PLL-@)J2]Z4L9*[2]FJ;
MJ8'PXA&G]6Q#C7IU*DU6J8]XBDW@ZW#U2E[3"UL)*E4AF$,?G5*5.=XPIY7"
MRE+VTJUV_P#V:M9UN_\ B-XCL-:^''P]\%>$OB=XC\#747B7Q?K/V/0IM,6"
M\BBM]6U#0C<ZQ8F.^LM+TZ>;9K6HWTB^=ID,9EN$Q;;]EKXCMXK\;^&-6O\
MP?X9MOA]:Z?>>(_%WB/7FT[PC#;:S&\NBSV^I&QENY8M4CBF>)GTZ'[(T+V^
MI"RO#%;27_B+\;?"_BWX?_$/PII=CXAM[_Q=^T!K/Q5L9;VVT^&RC\-ZAHZ6
M$%C?R6^K7,R:PERBRRVL-M<V"HJNFHO( @^I-.^)&C_M$:E\>+#2/!_CW6_
MOB7PKX#^VZ=I-SX1L?'6DZGX=FU*XAU+3-!U/Q!_9^K6ES<V]JMTUGJ=S>QR
M6>G6ATV7^T5>+GKYCQ+@,,J]=4Z>&452JU*]*GS8.G#$Y/1C7=6MB(_6<16I
M8K,7"%>HE4JX>FKRGS*MV8/(^ LYQ\L)A)5J^.<Y8BA0PF)K*&:5JF!XHQ4\
M(L/A<%-X'!X;$9?D<:M7!T)2H4,;7:C"ER2PWPE\5/@[XD^$<GAE/$.I^&M5
M3Q7HYUS2;CPSJ5QJMF^G^8J12M>26%G;2K<HZ3VTMC)>6TUNZ2+/\P%?2NF?
M [X?Z[^R/:^.]-T(GXKOHOBKQ0NHKJVM%[W1?!_C^73-=D_LI]1;10EEX<EM
MXOW.GQS/,()%+7$DKOS_ .V*VFZ==_!KPA96EYID_A3X4Z+9W.C:E=V=]JNB
MPRE8;#3=9N;#;:OK,-M8A]1\B-+=Y)$GM3);S1.;'PN_:6\)>!=$^"&B:AI7
MB2[M/ UA\5]'\>V]M8:3/!K.E>/-3DU;2K;1UN=9MQ>""]@TR35(]133400R
MI;F[&TMKB,3G>8Y%DN/P;K3QD<QJ8VO#"R^KQQ6%P=+,ZE'#U8TZDH2P^-G2
MPE&5/GJ4JDJT)7:M-<^#P'".1\8\69-FL<)2RNID=#*L'4S"*QL\NS',\5P]
M0Q6-P]2O0C5IXS*:>(S/%QK*E0KTJ>%K0<8/FIOTSXG_ +/'PU\&:!\"]/TS
MPM:7?C+5/B=\.O GC]KCQ+XGMK+7K[5-&M[O6].N+A+O4H]%M=4N+B"234-"
MTPW6G03EK&)FB^SOY5XI^">CS^ O&+>&/!L<7C^+]J+4OA;H-GI>OZWJT%KH
M:Z#%<VWAZUN=6FL;:]M;>_=I/[>U;3;34# K37US;VZR)'9UO]ICPQKR^#Y[
MW3O%#7NA?M)?\+?OB;72Y(_^$1AU6>XLM(L9#K"O-K-IIAM;..WGBMK#=!M_
MM(( Y=%^U!X?TA=6O-"TOQ"=4N?VF[_XS6D=Y;:7!:S>#M1T<:/>:+=W$>IW
MLEMKMW:RW=NZPVEW96Z3">+4))4"5PX2AQ50I8=5/KN(Q-.K4J3E6Q-?V56?
MUN4XTJB]NXK"RBU%+E;C0M!2Y58]?,<7X<XS$XUTGE6!P%?#T*%*.$R_!_6<
M-1>6TZ4\11?U15'F%.:E.4N=1J8SFJRASRYEY-\0?V<O&_P_TR35SJW@[QE:
M6&MQ>&O$*^!=<DUVZ\*^(+ETBL](\0V4MC87=C=WD[_9856&9$O%%I<M!//9
MI=:WB?\ 9B\4>#TV:]X]^%%CJ5K=>&[?7=%F\6W,6K>&XO$^H66GVNHZO;3:
M-$C:78-?1W6JWFF3:BMM8P7=W EU!!O;T#XP?M#>"?%OA+Q)H'A.X^(%Q+XP
M\7VFO:G::SHW@7PUIEAH=M>0:M%H1N= @U+5=7N['5;8R:?J5Q-!>1PW6;W4
M-1:WFBO^F^('[3_P_P#%7PV\7^%G_P"$]\8W>MZ/I>G^%M(\?Z)X0D@\&ZE#
M#';ZAKB>+M*NQK^KWRL)-0L+J]@>X>\2.WN52SN9U@[J6/XM=/+G4PBO5Q=2
MGBN3#.-54'+ *%249Q]G2<'5QVDUAZ<J5"%3ZQ*<?9XCQ\1E'AK'$9ZJ&8RY
M:&6T:^6JICE4P[QD:>;SJT:<Z-3V]>-58?*5>G+&UZ>(Q=:B\%3I2=?!<K\3
M_P!E"?2OB?IGP_\ AQKFDZC;GPI-K^MWGB'7(X;OPU::8(&U+7O&!@TZ&VT;
M2KR6_MX=%6SAO))8(7\Y&DAN+J3RCQ#^SQXTT#6? 5A#JWA#Q)H?Q)UZP\->
M%_'/A76Y-;\&3:U?ZG'I9L;O4[>Q%W:S6<\GF7*_V=)YD4-X+#[=/87T-O\
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M:^\/]=>#?^BMX8_\/V5?_-?FOO/I:BOFD?M@_LXDX_X67:<^OA[Q@!^)/AX
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MZM++\74IU(2Q$W&<*D*,HSC)--2BVFFK/4\>HKV'_A07Q;_Z%%__  =>'?\
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M=>'?_EO1_:>6_P#0QP/_ (5X?_Y8'^KO$'_0BSG_ ,-F-_\ E'FOO,GX?_\
M(#^+?_9-!_ZL/X?5YI7TWX.^#'Q*TS2OB-;WWAHV\VM^!1I.EH=7T)S=ZC_P
MFG@W5/LRF/5'6-OL&F7UQOF,<6VW*>9YKQH_"_\ "@OBW_T*+_\ @Z\._P#R
MWKDP^99<J^.;Q^"2E7IN+>*H)22PF'BW%NI9I23BVKI--;IGHXS(,]EA,IC'
M)<VE*G@Z\9QCEN,<H2EF.-FHS2HMQ;A.$TG9N,HR6DDWX]17L/\ PH+XM_\
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MKP[_ /+>C^T\M_Z&.!_\*\/_ /+ _P!7>(/^A%G/_ALQO_RCS7WGCU%>P_\
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M6K9K5;V8:),SZ?K-U86S21+)JUAIEY=WVC%I$$>K6UE(6 3->D_\,(_M7?\
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MJ[_HD\__ (6'P_\ _FLH_P!9>'/^A_DG_AUP/_R_S7WA_P 0X\0_^B"XT_\
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M<>(?_1!<:?\ B+9Y_P#,/FOO/D:BOKG_ (81_:N_Z)//_P"%A\/_ /YK*/\
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M]$GG_P#"P^'_ /\ -91_PPC^U=_T2>?_ ,+#X?\ _P UE'^LO#G_ $/\D_\
M#K@?_E_FOO#_ (AQXA_]$%QI_P"(MGG_ ,P^:^\^1J*^N?\ AA']J[_HD\__
M (6'P_\ _FLH_P"&$?VKO^B3S_\ A8?#_P#^:RC_ %EX<_Z'^2?^'7 __+_-
M?>'_ !#CQ#_Z(+C3_P 1;//_ )A\U]Y\C45]<_\ #"/[5W_1)Y__  L/A_\
M_-91_P ,(_M7?]$GG_\ "P^'_P#\UE'^LO#G_0_R3_PZX'_Y?YK[P_XAQXA_
M]$%QI_XBV>?_ ##YK[SY&HKZY_X81_:N_P"B3S_^%A\/_P#YK*/^&$?VKO\
MHD\__A8?#_\ ^:RC_67AS_H?Y)_X=<#_ /+_ #7WA_Q#CQ#_ .B"XT_\1;//
M_F'S7WGZ"?&O_DLOQ;_[*;X]_P#4JU6O,J^G?BG\&?B5K_Q.^(VNZ1X::\TG
M6O'GB_5M,O%U;0HENM.U+Q!J-Y97*Q3ZI%/&L]M-%*(YHHY4#[9(T<,HX/\
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M_M/+?^AC@?\ PKP__P L#_5WB#_H19S_ .&S&_\ RCS7WGCU%>P_\*"^+?\
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M/_\ +#SO]7>(/^A%G/\ X;,;_P#*/-?>>/45[#_PH+XM_P#0HO\ ^#KP[_\
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MW_I;"BBBNP\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *<GWU_WE_F*;3D^^O^\O\Q0..Z]5^8VBBB@04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 .'W&_WE_D]-IP^XW^\O\GIM);R]?T0WM'T_5A11
M13$%%%% !1110 4444 %%%% #G^^W^\W\S3:<_WV_P!YOYFFTH[+T7Y#EN_5
M_F%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'XUP_ZJ+_KFG_H(J2HX?\
M51?]<T_]!%25^X'\;1V7HOR"BBB@84444 1S?ZJ7_KF__H)K^E_3?^0=8?\
M7E:_^B(Z_F@F_P!5+_US?_T$U_2_IO\ R#K#_KRM?_1$=?D7BO\ P\A_QYG_
M .DY>?TW]&_^/QC_ ->L@_\ 2\Y/G7XIND?BBYDD=8XX["T>21V"(B)$S,[L
MQ"JJJ"68D  $D@"OQ/\  _[3O[<G[4[>.OB+^RWX)^!OAOX+>$/$>L:)X,F^
M+<OBN;Q-\5I]%CD$B6YTJZLH-,2^@FL+Q8KFV\/6&E:K=PZ%)XMU<:?KMW9_
MM'\9=-M-:U?6-'OT,ECJVAC3;V,':9+2_LYK6Y0$@@%H974$@X)S@]*_ O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8VBBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU'_"GHO^@_)_X+5_^3J]HHH_MG,O^@E_^"J/_P K#_5K)/\ H!C_ .#\5_\
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M?^"U?_DZO:**/[9S+_H)?_@JC_\ *P_U:R3_ * 8_P#@_%?_ "_R_/NSQ?\
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ME_S_ %U_WQ%_\31_P@EE_P _UU_WQ%_\37Q;_P -Y_\ 5*O_ "^?_P #Z/\
MAO/_ *I5_P"7S_\ @?1_JQQ[_P! <_\ PMRG_P":@_XB+X/_ /0UI?\ AJXC
M_P#G?Y?GW9]I?\()9?\ /]=?]\1?_$T?\()9?\_UU_WQ%_\ $U\6_P##>?\
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M[L^TO^$$LO\ G^NO^^(O_B:/^$$LO^?ZZ_[XB_\ B:^+?^&\_P#JE7_E\_\
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M]6./?^@.?_A;E/\ \U"_XB+X/_\ 0UI?^&KB/_YW^7Y]V?:7_""67_/]=?\
M?$7_ ,31_P ()9?\_P!=?]\1?_$U\6_\-Y_]4J_\OG_\#Z/^&\_^J5?^7S_^
M!]'^K''O_0'/_P +<I_^:@_XB+X/_P#0UI?^&KB/_P"=_E^?=GVE_P ()9?\
M_P!=?]\1?_$T?\()9?\ /]=?]\1?_$U\6_\ #>?_ %2K_P OG_\  ^C_ (;S
M_P"J5?\ E\__ ('T?ZL<>_\ 0'/_ ,+<I_\ FH/^(B^#_P#T-:7_ (:N(_\
MYW^7Y]V?:7_""67_ #_77_?$7_Q-'_""67_/]=?]\1?_ !-?%O\ PWG_ -4J
M_P#+Y_\ P/H_X;S_ .J5?^7S_P#@?1_JQQ[_ - <_P#PMRG_ .:@_P"(B^#_
M /T-:7_AJXC_ /G?Y?GW9]I?\()9?\_UU_WQ%_\ $T?\()9?\_UU_P!\1?\
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MKS9XO_PIZ+_H/R?^"U?_ ).H_P"%/1?]!^3_ ,%J_P#R=7M%%']LYE_T$O\
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M"U?_ ).H_P"%/1?]!^3_ ,%J_P#R=7M%%']LYE_T$O\ \%4?_E8?ZM9)_P!
M,?\ P?BO_E_E^?=GB_\ PIZ+_H/R?^"U?_DZC_A3T7_0?D_\%J__ "=7M%%'
M]LYE_P!!+_\ !5'_ .5A_JUDG_0#'_P?BO\ Y?Y?GW9XO_PIZ+_H/R?^"U?_
M ).H_P"%/1?]!^3_ ,%J_P#R=7M%%']LYE_T$O\ \%4?_E8?ZM9)_P! ,?\
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M^?=GB_\ PIZ+_H/R?^"U?_DZC_A3T7_0?D_\%J__ "=7M%%']LYE_P!!+_\
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M^"\>C_$_]GK]HBV^'7AW3_@9\3O%W[%O[1'[1/['/C31?CI^S_\ '?Q1=/\
M"OP#J'C!=.^-'PQ\"ZQXIO?V?OC#I_A>\T#X@6'PW\=6'B[0;ZPM/&6@7GBA
M?$_@C6/#T_UO\5?^"SOA+]GNY^)G@W]I']G+QQ\!_C78:%\&/%W[/GPD\>?%
MCX&P2_'SPG\>_%=Y\./!NH:C\0[/QM<?#CX-WW@;XAZ+XEL?CS;^,?$=]H_P
MQ\%Z,OC[2O$'CNPOX=-C /VLHK\//AY_P6?M?BT_A+X??"_]G.V^(_[1NI_M
M++^S9XM^%?P^_:1^$?CGP#H=QK/P$^)W[0W@SXL^$_CYX575O WCSX6ZOX)^
M&FK#Q%,MGX;\<>$+_1_'>D7'@C5/$WA'3_#GBS8^'7_!1_\ :0^,'[2W[)/@
MGP]^R_%X+^&GQ$^'O[:T?[16@^(/B=X:UWX@?#WXQ_L>_'CP1\!OBOX>\,GP
MMH>MZ?XYT'X:>)-2$F@W7A^[M+CXSVOQ'T:]L4\%R_#_ %?1O$H!^U=%?SE?
M%/\ X+:?$'7/AS^USX8^$'P3^'.A_&SX=_L5_'[]I_X5R:-^UE\!_C/XA\ 6
M'PBN/#FG^(X_VD/AOX&M?$H^#GQ6\ >&?'&D_$V#X3ZM>^-= \>ZGX9\1_#+
M2_'+7ECJ.M6GU)^S9^W!\3_ W[)/CO6_CYX)\;^*/BS^S]^UY^S_ /LD>/)_
M&OQ5^&OB[Q/XQUK]IOQ9^RI<Z3XZG\6?"KX'_!_P!!IO@C2/VP=#M=/\,Z+\
M,K":[T;X>P:9J6OW.MZM>^(T /V1HK\IOV<?^"GUE^T5\>?B[\(-$^#=GI^B
M_"_5_C=H5UK.G_&WP!XA^)WAC4/@CXLU/PE<7'QV_9_^SZ/\1/@EH7Q)N=(O
M-0^%NOR?\)MI_B&PFTPZJV@7.J6MN8/V0_\ @ISK?[17BS]F?PU\5OV6?&?[
M-%E^V1\ -=^/7[-'B3Q)\3?A]\0=-^)5EX-TGP'X@\8^$_L/A"2/7?#&M0>%
MO'EAX]\*R>)-*T^/Q1X @EU2>'0?$MMK/@_10#]8**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBO@+]J#]M;Q;\&OC+X'_9U^!G[.7B7]J;XX>)?A+X
MZ^/WB3P-X<^(W@;X9)X'^#/@+Q+X5\(3^);_ %KQY+'9:OKWC'Q/XG;PW\/?
M">EH\^NZYH^I_P!LZCX9T"SO?$-D ??M%?AE'_P63\:ZO\/Q\4? _P"PS\0O
MB'X(\,?L*? ;]OCXPZMX8^,OPWLIOAG\,OC+8?%;5=2\,VVG>,+3PK>^./%_
MA71_A1KVMZ39:!#'_P )EIFF^(XU3P]K>G>'-%\9>U^/?VE/VDM2_;O_ & -
M&\$:[\*+']A[]HZW^*6I:%J/AO4-5\3?$[XW1V/[+/B3XLZ!K_B:'6_!6D:3
M\-/!.AZL=/E\-Z3X5\1>)=?\73VL6M^(=3T+3C'X6D /UBHK^=G2?VSOVOO!
MX^!G[;'B7XSS^/?@+^T1^VC^TY^S+>?L:2?";X>:%:_#?X7_  \U3]IC2_A9
MXP\$?$;1K ?%34OC'H[?LU1ZAX_TKQ;KOB3PKXH'Q$U_0[#P_P"#)/".BZPG
MJ?[%_P ??VRK3XL_L$7/Q[_:!T_X^^#/^"C_ .R'X]_:$U'P._PN^'?P\L_V
M:/B%X+\-_!WXF6&C?"7Q!X$T^UUWQE\--3\+?&<> ]4L?B==>*_$::OX,T/Q
MI9>-K:3Q)J_ANX /W3HHHH **** "BBB@ HHKXT\+_$[QU?_ /!0KXY?!F[U
M^:;X9^$_V,_V5/B=X?\ "QL]-6#3?'7Q!^-W[9/A7QCKZ:A'9)K$\VM:!\,O
M VG2V=UJ$^FVJ:!#/865K=7FI3W@!]ET5^%O[.W_  5&N/ =GXTTG]K66Y/A
MR.7_ (*B_%/P9\;+C4_#MK_;7AW]AW]K3XD>$O$?P,T[P-IFAZ*T_B7P1\"%
M\%>*?#.J)J=]?>+]'TCQ0NI01:EX?N-5UE/C[_P6Z\+_ +/>L:?X4\6_ C3E
M\=_#WX!_"GX^_M:_#_6_VFO@;\./&OP4MOBAHA\4?\*D^%'ACXGZGX.UW]IK
MXW^$_"VF^(/$6N^"?"^G>#-/>R'@O3K#Q'<>)O'^BZ!$ ?NG17XO?$__ (+)
M> ? 7QK^%'@?1OAUX/\ $OPL^*_CG]G?P1X;\:ZM^TK\(O _QK\7VG[2#^#4
M\)?%'X2_LHZ[)+\4OB5\&]&E^(O@^VU[Q@UYX6UDM%XTU;2O".H^$/"*^*-9
M]7^&O[8GC/X>_P#!./\ :(_; ^*$-W\6==^!'C?_ (*+ZZ^C"YTKPG=>(O"/
M[.?[6/[2'@[P)X.AU+3="GL-+_L_P#\/_#?A2VUB31-0NWCL(]3U5-5U*6\N
M+H _4JBOQ7^)O_!6_P"(7P2?XX/\7/V!_C%X5T[]FGP9\-/C-\<M5L/B]\#O
M$%MX2^ GQ?UG7_#W@7QAI4%KXHMK_P 3?$"?6/!OCV'7?AA96=O'I-MX"\1W
M%MXUU:2[\)6WBG+^,G_!<3X$?!W]H;QW\,-0\*^']5^#_P &OC+X3_9]^-7Q
M??\ :!^"F@_$#PQ\2_$TFA6&K:CX(_9BUGQ%!\7?BC\+/AAK_B_PMX=^*GCW
M1(=/O]"U"'Q_/X9\(>,]-^'&NWTH!^WE%?A2G_!3OX@? W]FOPWXV\<^'? O
MQ/\ &/B;]H'_ (*#Z"?&7QP_:*^"W['WPLTSP7\ /VS?C?\ "OX>> ;3XC_$
M"T32?$/Q-O/"NC^#/#'@KP?I'AFX.H:)X<\0>*O'_C+P]<V]A<>+-O6/^"QF
MO7G@75OBU\+?V,OB#\3?A3X&_8@_9\_;[^+/B5/BU\./!^L^ /@S\9U^*&J>
M(=#A\.>(%5/%7Q%\$^$/A/XL\5Z-H.DZU'I'CFVT+7]+D\1>$=6M_#=KXM /
MV[HK\>_'G_!7/0?"7B?XE^*M(_9T\?\ BK]CS]G[X_>$_P!FK]HW]KB'QU\.
MM'TOX;_$KQ:G@33)KCP]\(+_ %9OB+X_\&_#KQI\4? 7A/XL^(H(?#\_ATZA
MKVK>$-(^(%MX4U>!*.G?\%3OBWK?B#P9I'AW]@OXB^)=,^+_ .T!^TI^S%\#
M_$VD_&[X1V^E^.?BM^S7XT^+^C>(Y_$%IXBN- UKP/X OO!OP1^(/C2Y\52Z
M9KVIZ9<^%?$'A>Q\+>(+I?"VI>+@#]DJ*_ #XG?\%YO!W@?X*^$?COIW[/UG
M8^$[GP7XS\6>.M"^-?[3_P !_@/X^;5OAQ\5_'_PC^('PY_9]\(>(-5U^\_:
M8^(7A'6_A5XXU"_TWPE/X<T+5+.;P-I7A?Q%X@\5^++[P]X9_?+3+^#5=-T_
M5+82+;:E96E_;B50DH@O(([B(2JK.JR".10ZJ[@-D!F R0"[1110 5%/_J)O
M^N4G_H#5+44_^HF_ZY2?^@-0!^ '[0G_ "6KXC?]C%/_ .B+>O&Z]D_:$_Y+
M5\1O^QBG_P#1%O7C=?U=DW_(GRK_ +%N!_\ 46D?YN<4?\E-Q%_V/<W_ /5A
MB HHHKTCP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /I#X
M ?'_ %7X1ZJ-,U,W&I^!-3N VIZ8I\R?2IY-J-K&CJ[!5G50OVRSW)%J$2!6
M,=S'!/'^NNC:SI7B+2K#7-#O[?4])U.W2[L;ZT?S(+B"3.&4\,K*P:.6*14E
M@E1X9DCEC=%_GZKZ7_9V^.NO?#'7K7P_-!J&O^$-?U""WN-!LXY+O4+34+N2
M.WBU#P_;)N>2^D=HXY].B 75%"1@+=K;S)^;<:\%PS2%7-<LA&GF5.+GB**M
M"&.A%:RNVHPQ,(KW9NRK)<DVI*,E^[>%'BI5X?JT.'<^JU*V1UJD:>"Q3YJE
M7**M25E"RYIU,OJ3E[].*<L-)NI23@YTW^YD'^HA_P"N4?\ Z M2UXQ\8OBC
MJ_PJ\):!X@T3P-J/CZYU;Q'I/AZ32;"\N--GL+6_TW4[Q]8G>+1M:F,%I)I\
M5O- UG%S>*S3HT8BEQ? WQIU_P 7_%_QQ\,;_P"&NI^'=)\(VVLSV7C:XU2Y
MN;'Q =+UG2M+@CM[%_#]C!;'4(-1DOXS'K%\8H[-XPLP<S1?R-F'BGP-E7%E
M'@?'9KC*7$U?,<CRJE@(</\ $F(H2QW$F!SC,<GI/-<-E%;*(4\3@\AS6I6Q
M,\?'"X">'IT,PK87$8S!4L3_ '7A.%,]Q>3SSW#X2A/*Z6%QN+J5WF664ZBP
M^75\'AL7-8.KC(8V3IUL?A8PIQP[JUU4E4P\*M.C7G3^@:*_*?\ X*5?$;]I
M_P ":]^S[;?"\?M0>'/V<-;E^(Y_:.^)_P"Q5\*/AQ\<?VD/!^MV0\#0?"'3
MM/\ AWX]\)_$G4T^&6MG4_']_P"/O%/@#X4^._%&DW7AWPS;SS^&='O;Q?$D
M7[*?[<%[XC\%_LKZ#K7Q*\*_M03_ +0?[4'Q]_9TT/XQ^'-+U3X7>,/#NB_"
M'X2_'/XSZ%<?M ?"36_ '@JY\(_M P:!\'8?!WQ7\ :9X1^'N@V'B;7D\7>&
MM)T_PW-I^@S_ *$?/'ZNT5^(/B#_ (*'_M#^(_VF_ FA_ 3]GGQ?\8K*?P%_
MP5$\"77P$T;XA?"[PAIWB'XB_L7_ +8'P7^!'A;XL>*/B?\ $"WT&3PAH6M:
M99>-M*TO2-%@\2RV7B#XK^'M+UC2-7T[3;OQMX>K7?\ P6OT+7_ OB;XV?!K
M]ECXE?%SX"?#G]E?X.?M=?%KQQ:_$#X=^$/%OPY^'GQ'\3_'#PKXQ\+ZAX!\
M17J0ZW\2?A=?_ GQ@NJ>'- \77^G:[-HOBBSL]>LKK2- C\8 '[CT5^*OQ-_
MX*4?$J[\,?%[P7;?LX?%+X1_M)_ [XZ?\$^-$_X5)>_%?X.0Q_$#0?VS/CKH
M?A/X5^']4^)MGX<^+GA;PQI_BM]*\1^"?C/I</AR;6O"ED=67P-XV:>XT'QW
M!!IO[9/[4'C7_@AAX^_;9\5Z?HOPD_:(N/V)O''QK\)>(/"%_HOBC2WU=/A7
M<>+?"/Q$TS1=1T)]*T!=1NY(M3M_ >MVWB4^'XXHM+U75_$$BS7<X!^V-%?S
M_P#[/?[5'QNT;]L?P/\ !D_';]IWXA_"+XO?LK_%_P")DMO^W'^SCX;_ &?/
M%FD?%SX:0^"KC2M*_9K\20_!GX!:W\8&U#1=<\1>)/B)X4O/!GB[2O!7AC0-
M+\1V7B:)]8O[)?T'_8J_:(O]9_X)H?LX?M5?M%>.([B]G_9!\!?'+XU_$;5;
M.PTZ$K;?"ZR\:^/?%^H6.AV%CIMG%%!!J>K75OI6FVMK#&CI:6D:*D0 /OFB
MOY_?^"2W_!0+XS?''XOZ]\*_VF_BCX/\9^)OVE_@-I'[?G[//ACPU_PB<W_"
MD_AEXX^)_C?PQK'[+>L:YX8CL%U?Q)\)O ;? OQ:+7Q)8?\ "?"3Q[XS7Q!<
M7<7AXO:?T!4 %%%% !1110 4444 %%%% !1110 4444 %%%(651EB%'3)( R
M>@R: %HIN]"-P9=HX+;A@'IC.<=>*-RX)W+@9!.1@$=03G QWH =13=Z8)W+
MA?O'<,#ZG.!^-&]""0RX'4[A@?4YP* '44PRQAQ&9$$C L(RZARJXW$+G<0,
MC) P,C/6@R1JZQM(@D8$JA=0[!?O%5)W$#(R0"!GF@!]%,\V/?Y?F)YFW=LW
MKOVYQNVYW;<@C.,9XS2++$Q(62-B.2%=20/4@'C\: )**C66)SM26-VZ[5=6
M.!U. 2>*DH **** /YDX?]5%_P!<T_\ 014E1P_ZJ+_KFG_H(J2O[ /\OH[+
MT7Y!17KWP8^#^K?&7Q/=Z'8ZKI_A[3-'TJ?7O$?B+50YL='T>VF@AGG*!H8Y
MKDF?S(;>:[LH7BAN9I;NWAMY9%T_AS\*?#7CWXJZS\.I?B)I&A:;#<:Y9>'?
M%=RMM+:>([RRU2/3M#@TZWDO[.*ZFUY94N;2VAOA++%N%J;B7RXI?/KYI@</
M+%PJ5GSX##QQ6+C"E6JNA1GS.$I>RISO*2C*2I0YJK@N?DY6F_<PG#N<8VGE
ME:AA8^RSG'5,NRRI6Q.%P\<7BZ7(JL(/$5J?+3A*<*<L14Y,.JLO9^UYU**\
M.HKL/'_@?7/AOXPUWP1XC6W76- NDM[IK.5I[2>.XMH+ZRO+65XX9&MKVQNK
M:[@\Z&&=8IT6>&&8/&O'UV4JM.O2IUZ,XU*-:G"K2J0?-"I3J14X3BUHXSBU
M*+6Z:9Y6)P]?!XBOA,52G0Q.%K5</B*%6+C4HUZ$Y4JU*I%ZQG3J1E"<7JI)
MI[$<W^JE_P"N;_\ H)K^E_3?^0=8?]>5K_Z(CK^:";_52_\ 7-__ $$U_2_I
MO_(.L/\ KRM?_1$=?DWBO_#R'_'F?_I.7G]*_1O_ (_&/_7K(/\ TO.2[7RW
MX4_9#^$_A;XR_M:?&F5O$'BG5OVS](^%6@?&+P=XNFT#5? ']B?"7X>ZK\,M
M'TKP]HD/AVQU&&P\0^&=9OD\76OB+6O$L6IW3@V*Z59&2RD^I**_'#^I3\IM
M._X)0>#!\)]=^ /BK]K7]LKQO\"'_9G\>?LF_#SX3:MX\^%NA>$_A9\)O'NA
MZ)X8DDTVW\$_!SPO-\3/&?@OPQH-EX:^'/B?X\R?%=_"6C&=H;&[UJXN-:FO
MZA_P2D^%/B^U\4:W\6OCG^T'\8?C;J</P$L_ ?[2GC2X^"5K\9O@E9_LP_$#
M5?B?\%%^$\WA+X)^&OA_I=]H'C?7-9\0>)M5\2^ O%-_\0[S6-4MO&LNL:-/
M!I-I^I5% 'PGX _84TKPYXU^'GQ0^(W[1O[2WQ^^)OPY^.OB'X_:3XH^*WBS
MP-_91\1^(?V=?&W[,K>$-+^'G@7X=>"_AOX&^'6F>!?'WB#7[70_AOX5\':Q
MJOCZ2#Q+XM\1^)8UGTV?E;[_ ()K?"B7Q5X0\3:7\4/C3H4&@^)OVZ-6\4^'
M]/U7X?MIGQ)\+?\ !0KXHZ;\8/CW\./$M]<?#J7Q'H?AFU\8Z'H2^ -:^'^N
M>#?B#X9T7319W/C35]2N9M8K]%J* /QO\+_\$6O@MX?\*6W@2^_:+_:=USP5
MI'[)/QQ_8E\+^$E;]G#PIX<\-? OX_>%-*\+>.9+72O W[.?AF#4?BA=R^'_
M  YXLOOBGK?]I>*/%'B_P_IEWXTE\1Z%%)X>D]2\<_\ !+CP+XX^(WB7Q4W[
M2/[3?A;X<^-/CY\!?VG_ !A\ _"NL?!VU^&GB;XV_L[:5\(-#\%>(=5U35?@
MSK/Q-E\/:MIWP/\  $OBWP5%X_B\/ZAK>E0Z]I,&A:A8Z.^F?I]10!^7]G_P
M3#\$Z7^T!X8_:6U;X[_M$?%KQ7\(XOV@[GX%>"_BIKOPN\3:;\.Y/VB-.\8V
M7B_PTOQ.D^%EC^T!XX\&:/;^--7TWX=>&OBA\9?&.F> ]/FCMM/,L-K9_9>3
M_P"";O\ P3HU']FOX6_LD^+/CK\2OBQ\3?C;\#?V5- ^$'A3P-\2-4^$^M^#
MOV9K[Q_X?^'VK_';P;\+-2^&_@'PWJ&OV]YXN\&Z7X3T[Q3XS\7_ !%U/3OA
M_P"%=#\+>&]?BT>75[G7OULHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "OR*_X*,_LW_'[Q_\6_@Q\;OV<_"7Q1UOQ3X9^#OQ\^"'BV[^!_QX^#?P
M!\<ZAX8^+>J?"O5+/PKXQU_XV?"KXJ:+JGPMO;SP9?:GJ&M>!+?P_P#%OX9:
M_8:;XH^'[>(-4U!K;2?UUHH _GN^"_\ P2"^)$>HQ?#;XN?&GXG^!?@_9?\
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MX7N?@UKOBA_#7[6OQ]\4?M&_$C3="N/B)\&_&NG?#S7M#\<>,?$.B^ ?B/\
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M>/9O%]II6A^(=>%CIL.H7D6H6W@3_P#!'SP[=_LWVO[(.K_MX?M[:S^S1:^
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M]$1U_-!-_JI?^N;_ /H)K^E_3?\ D'6'_7E:_P#HB.OR[Q7_ (>0_P"/,_\
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ML'_/1O\ 8KQ^U_9_\"&ZMA_;WQMYN(1Q^TO^T<#S(O0CXJ@@^X(([477[/\
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M^8>SI_\ /N'_ (#'_(]@_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
MXBO'_P#A0'@3_H/?&S_Q);]HW_YZM'_"@/ G_0>^-G_B2W[1O_SU:.>?\TO_
M  )_YA[.G_S[A_X#'_(]O&G:?_9DG^@V?_'_  _\NL'_ #[S_P"Q5#^SM/\
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M_FYS]I,?P#T^+-2_\,]> O\ H/\ QQ_\2=_:4_\ GLT&ZV7HCW&BO#O^&>O
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MZN(;<WE[*DDD5G:B5T-Q=21PS21V\6^9TBD94*HQ%J@ HHHH **** "BBB@
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MC\1^(/'5GX;O]%GTFR\9Z[X@\8>+==UCQ5:VD.O:EK'BGQ'J=[?S7NN:I/=
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M8UEN=+FG<!F8[I97;GEL8KS+_AI[XZ_]% O/_!/X;_\ E-63^T)_R6KXC?\
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M\%Y:FTNS:BUNOM$/V>Y-\\<=D+>??Y4QO))HDM1&S?:'EC6'>74&R2 "20
M223@ #DDD\  <DGI0 M%103PW,,-S;317%O<11SP3P2)+#/#*@DBFAEC+))%
M(C*\<B,R.C!E)!!HCN()I)XHIX99;618;F..1'DMI7ABN$BG16+0R/;S0SJD
M@5FAEBE *2(Q ):*** "BFEE#!"RAV5F5"1N94*AV"YR54N@8@84NH)!89K&
M_L5MKB\:]M%L[1KE;JZ-S"+:V:RDDBO%N)R_E0M:2Q2QW(D93!)'(DNQD8
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M*\B*6#.H/3U^6/\ P3DTRZ\->"OAIX9\2:)I^D>*]'^!?@C2-0TY/V,OB?\
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M2?P]IMYXDU^YL].AFUC47N?QP_J4_D8^%6K?%K4+'_@KE\0/B)X@\9>#;/\
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MJWQ1^(?[*O[.GCSXCZ])ID^M^.?&GP6^'/BGQ5J]UHUMI=EI-_J6MZ[X<O\
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M'+'X*Z3JGAW2_A+JVN:U\:X6OO'WBVRM/#*>,_%7B>WTU[32-"L-6\:3>"]
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M7B#2X+^34/#7B*UMXM:\+Z];Z?XAT"^T_6=-L;V#X>_8O_:%_;1UA_V+K_\
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M_9^_:#^#W[4_PE\,_'3X!^,[?XA?"CQC=^*['PSXPM-)\0:):ZQ/X)\8^(/
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MZD8YMA\DA5=!810<\?7IU9<T/:RY,-3BO:J4YSFE149_JWAME6%Q^$XBQ-;
M4<95PD\FI4:D^&L;Q95P\<7+,G5]ED^$K8>*C5^K4U4QU>HUAW"G1ITI/%2G
M3_);XB3> I_%NI2_#*UURS\&M'8_V7;^(VB;5TD%A;#4#<M#<7495]0%T\&)
MW(@:,$*?E'$5['\?-0\;:I\4O$%]\1/#6F^$?%DL&BC4=!TDH;&SCCT73X[%
MXC'J&J(3=6*6]U+B]EQ),X(C(,:^.5]/ETG/ 8*;ESN6%P\G+ZS'&\S=*+YO
MKD8QCBK[_6(QC&M_$22E8_/L\@J6<YK3C!4XT\QQL%36 GE2@HXBHE!994E.
MIEZC:WU*<Y2PMO8RDW!LCF_U4O\ US?_ -!-?TOZ;_R#K#_KRM?_ $1'7\T$
MW^JE_P"N;_\ H)K^E_3?^0=8?]>5K_Z(CK\N\5_X>0_X\S_])R\_H?Z-_P#'
MXQ_Z]9!_Z7G)=HKS'Q5\6_"O@[5GT75])^)UY>1P07#3>%?@G\9O'6DF.X4M
M&J:_X(\!>(="DG4 B>UCU)KFV;"W,,3$ \Y_PT+X"_Z 'QQ_\1B_:4_^=-7X
MX?U*>XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
MG34 >XT5X=_PT+X"_P"@!\<?_$8OVE/_ )TU'_#0O@+_ * 'QQ_\1B_:4_\
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M,OC'^W1/^RY\'_$/[;W[2>C>'+/X+_\ !5*#Q?XL^"OQWO)O'7BX?![]L/\
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MO#>L^!?A0->\>>/O"'A[0K6R%A#Y]#^T_P#&[]G&Q^*/[5_@;]HOXQ_M:_\
M!/']A[]LGP=X2TWX@:K\3E^*6K?'?]G7]HSX-^&/#O[0EJ?%GA?1_P"S?V@-
M._9._:@\<>"M<^%7C>[.KZ]X>TW1_BO\+QXJDTCPQ)%)_1L?VA/ )!!\/_'
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MHQ5@02*>G[07P_C1(X_#OQOCCC54CC3]F#]I)$1$ 5415^$P5550 J@
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MRONE_P!"GS/R_P#^&8?CK_T3^\_\''AO_P"7-'_#,/QU_P"B?WG_ (./#?\
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MHW_YU5'_  O_ ,"?] 'XV?\ B-/[1O\ \ZJ@1[917B?_  O_ ,"?] 'XV?\
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M!^-G_B-/[1O_ ,ZJ@#VRBO$_^%_^!/\ H _&S_Q&G]HW_P"=51_PO_P)_P!
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M(JKO-J?B?QEXDT#PSHMG$CSW^LZO86,"/-<(I .OHHHH *BG_P!1-_URD_\
M0&J6HI_]1-_URD_] :@#QBX\3>&[.>2VN_$.AVMS"VR:WN-6L()XG !*212W
M"R1L 0=K*#@CBH?^$O\ "?\ T-'AW_P=Z;_\DU^-O[0G_):OB-_V,4__ *(M
MZ\;K]=P/AEA\7@L'BGF]:#Q.%P^(<%@X24'6I0J.*D\0FU%R:3:5]'8_F'-O
M'[%Y;FF99='AG#58X#,,9@E5>:58.JL+B*E!5'!8&2BYJGS.*E)1;M=VN_WV
M_P"$O\)_]#1X=_\ !WIO_P DT?\ "7^$_P#H:/#O_@[TW_Y)K\":*ZO^(58;
M_H<U_P#PBI__ #1Z_P!+7S_^)B\9_P!$KA?_  [5?_F#U_I:_OM_PE_A/_H:
M/#O_ (.]-_\ DFC_ (2_PG_T-'AW_P '>F__ "37X$T4?\0JPW_0YK_^$5/_
M .:/7^EJ?\3%XS_HE<+_ .':K_\ ,'K_ $M?WV_X2_PG_P!#1X=_\'>F_P#R
M31_PE_A/_H:/#O\ X.]-_P#DFOP)HH_XA5AO^AS7_P#"*G_\T>O]+4_XF+QG
M_1*X7_P[5?\ Y@]?Z6O[[?\ "7^$_P#H:/#O_@[TW_Y)H_X2_P )_P#0T>'?
M_!WIO_R37X$T4?\ $*L-_P!#FO\ ^$5/_P":/7^EJ?\ $Q>,_P"B5PO_ (=J
MO_S!Z_TM?WV_X2_PG_T-'AW_ ,'>F_\ R35X^,/"/]FQK_PE/AS=]NF./[;T
MS.#;P ''VK."00#TR#7\_=%+_B%6'_Z'5;_PBI__ #2/_B8O&Z_\8KA=?^IM
M5[I_] 'E_5M?WV_X2_PG_P!#1X=_\'>F_P#R31_PE_A/_H:/#O\ X.]-_P#D
MFOP)HI_\0JPW_0YK_P#A%3_^:/7^EJO^)B\9_P!$KA?_  [5?_F#U_I:_OM_
MPE_A/_H:/#O_ (.]-_\ DFC_ (2_PG_T-'AW_P '>F__ "37X$T4?\0JPW_0
MYK_^$5/_ .:/7^EJ?\3%XS_HE<+_ .':K_\ ,'K_ $M?WV_X2_PG_P!#1X=_
M\'>F_P#R31_PE_A/_H:/#O\ X.]-_P#DFOP)HH_XA5AO^AS7_P#"*G_\T>O]
M+4_XF+QG_1*X7_P[5?\ Y@]?Z6O[[?\ "7^$_P#H:/#O_@[TW_Y)H_X2_P )
M_P#0T>'?_!WIO_R37X$T4?\ $*L-_P!#FO\ ^$5/_P":/7^EJ?\ $Q>,_P"B
M5PO_ (=JO_S!Z_TM?Z%(9H;B&*XMY8YX)XTF@GA=989H95#QRQ2(622.1&5T
M=&*NI#*2"#4E?E9^S=^TC/X GM?!7C6ZEN?!%S*(].U&0O-/X4GF?)( W22Z
M'+(Q:YME#/8NS7=HI4W%O/\ J=;W$%U!#=6LT5S;7,4=Q;W%O(DT$\$R+)#-
M#-&S1RQ2QLKQR(S(Z,K*Q4@U^;\0\.XWAW&O#8E>TH5.:6$Q<8M4L133]7R5
M872JT6VX-IIRIRA.7[GP3QME7&^51QV!DJ.+HJ$,RRVI-2KX&O)7LW:/M<-5
M:D\-B8Q4:L5*,HTZU.K2IW;3_C[M?^OB'_T8M%W_ ,?=U_U\3?\ HQJ+3_C[
MM?\ KXA_]&+1=_\ 'W=?]?$W_HQJ\ ^TZ+U?Y1*]%%% @HHHH **** "BBB@
M HHHH OK_P @N3_K_A_])YZH5?7_ )!<G_7_  _^D\]4* "BBB@ HHHH ***
M* "BBB@ HHHH ]+@_P!1#_URC_\ 0%J6HH/]1#_URC_] 6I:#>.R]%^04444
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTVTOQI(\2Z'!JMKIS6@!_1]\%?B'X]^)GA&X\0_$7X"_$/\ 9UUZ'6[S2XO
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M@]\-$\*6VD^/1\6O!/AS5/"]Y\3/ 7@66+XGOX8:7P1#86VO^,?#]O<_H_\
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M%OP#X-T*73?$/R_H'[.E_K'P<\9?#/QK^R+^T)\4_AOX+TS]@SXU>-?B;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"25XSQ$XMQQ>+CI).6'P\O8>TJ8FQ:?\?=K_ -?$/_HQ:+O_ (^[K_KXF_\
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MX=CXI?\ SEZ/[5_;%_Z$3]FC_P .Q\4O_G+U]+T4 ?-']J_MB_\ 0B?LT?\
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ML7_H1/V:/_#L?%+_ .<O7TO10!\T?VK^V+_T(G[-'_AV/BE_\Y>C^U?VQ?\
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M[7G_ $(W[-__ (=7XG?_ #FZ/[4_:\_Z$;]F_P#\.K\3O_G-UYU_PW)\-_\
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M  'T'_Y>4?\ #<GPW_Z%7QO_ . ^@_\ R\H_U-XG_P"A/BOOI?\ RP/^(H\
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MT(W[-_\ X=7XG?\ SFZ/[4_:\_Z$;]F__P .K\3O_G-U](44"/F_^U/VO/\
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MC?LW_P#AU?B=_P#.;KZ0HH ^;_[4_:\_Z$;]F_\ \.K\3O\ YS=']J?M>?\
M0C?LW_\ AU?B=_\ .;KZ0HH ^;_[4_:\_P"A&_9O_P##J_$[_P"<W1_:G[7G
M_0C?LW_^'5^)W_SFZ^D** /F_P#M3]KS_H1OV;__  ZOQ._^<W1_:G[7G_0C
M?LW_ /AU?B=_\YNOI"B@#S.#5?VQ?)AQX$_9HQY4>,_%CXI9QL'7_BR]2_VK
M^V+_ -")^S1_X=CXI?\ SEZ^DH/]1#_URC_] 6I:#=;+T1\T?VK^V+_T(G[-
M'_AV/BE_\Y>C^U?VQ?\ H1/V:/\ P['Q2_\ G+U]+T4#/FC^U?VQ?^A$_9H_
M\.Q\4O\ YR]']J_MB_\ 0B?LT?\ AV/BE_\ .7KZ7HH ^:/[5_;%_P"A$_9H
M_P##L?%+_P"<O1_:O[8O_0B?LT?^'8^*7_SEZ^EZ* /FC^U?VQ?^A$_9H_\
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MX=CXI?\ SEZ^EZ* /FC^U?VQ?^A$_9H_\.Q\4O\ YR]']J_MB_\ 0B?LT?\
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M'<^(_&6EWVGW;^#=.H^+/^"M'Q9B^.'QS_8K^'_@;X8:U^W5XA_:#\-?!O\
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M;4[^W696:)I[.RGN(A*JLC-&9(U#JKHQ7(#*3D &Q17\\/[.W_!7CXV_%?\
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M_@)XG\,_&?5;'P7^T19^-?@E=_"FRUSX(ZU\"?&^B?&_Q3-\?)+V'X#-X(\
M:G:VUQJEO\6I].U"'1KO5KW0K7P>-,UNX^+$WP\L_#?B2YTCVW]E_P#:L\&_
MM3Z1\2;GP_X&^+'PL\6?!WXDWGPH^*'PQ^-G@^V\&?$#P;XO@\,>&/&UC%?6
M.F:UXET'4=*U[P=XR\,>)_#^MZ!XBU?3-4T?6;2XBN59FC4 ^GZ*** "HI_]
M1-_URD_] :I:BG_U$W_7*3_T!J /P _:$_Y+5\1O^QBG_P#1%O7C=>R?M"?\
MEJ^(W_8Q3_\ HBWKQNOZNR;_ )$^5?\ 8MP/_J+2/\W.*/\ DIN(O^Q[F_\
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M_!MUX0\(^$;+Q9;_ !$\1?$^^LH9]0CU6Z\,VWP^\*Z1=6FH76LZ_K4Z^&X
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MC=?U=DW_ ")\J_[%N!_]1:1_FYQ1_P E-Q%_V/<W_P#5AB HHHKTCP@HHHH
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M-(?"FV^&/_"5?\(9]G^+W[./Q5_MO^P_^$BW_P##/W[1/PK^/O\ 8/\ 9O\
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MDYAU33K25W(@_G;TGQ;"H#R3J#\OS;H^<_Q$'&#P<G@DD9R,"OW%_P""9_\
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M_P"^U_\ B*/^$U\5?]!R^_[[7_XBC_5W%?\ /_#_ /E3_P"0]?Z>A_KG@/\
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M4?\ Y;Z_T]/K"BOD_P#X37Q5_P!!R^_[[7_XBC_A-?%7_0<OO^^U_P#B*/\
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MZ!<9]U'_ .6^O]/3ZPHKY/\ ^$U\5?\ 0<OO^^U_^(H_X37Q5_T'+[_OM?\
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M 'T/_B:/^$AUO_H)7/\ WT/_ (FJ^H9Y_P!#>O\ ^%>,_P _7^GI']H\)_\
M1-X/_P -F6_Y>2^XZ#_A2GPA_P"B9^"/_";TK_Y&H_X4I\(?^B9^"/\ PF]*
M_P#D:N?_ .$AUO\ Z"5S_P!]#_XFC_A(=;_Z"5S_ -]#_P")H^H9Y_T-Z_\
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M_7^GHO[1X3_Z)O!_^&S+?\O)?<=!_P *4^$/_1,_!'_A-Z5_\C4?\*4^$/\
MT3/P1_X3>E?_ "-7/_\ "0ZW_P!!*Y_[Z'_Q-'_"0ZW_ -!*Y_[Z'_Q-'U#/
M/^AO7_\ "O&?Y^O]/0_M'A/_ *)O!_\ ALRW_+R7W'0?\*4^$/\ T3/P1_X3
M>E?_ "-1_P *4^$/_1,_!'_A-Z5_\C5S_P#PD.M_]!*Y_P"^A_\ $T?\)#K?
M_02N?^^A_P#$T?4,\_Z&]?\ \*\9_GZ_T]#^T>$_^B;P?_ALRW_+R7W'0?\
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MG3A"A"$(02C&$(QJJ,8QBDHQ2222222/=[3_ (^[7_KXA_\ 1BT7?_'W=?\
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M31_PD.M_]!*Y_P"^A_\ $T_]7<5_S_P__E3_ .0]?Z>B_P!<,#_T#8O[J/\
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M^0]?Z>A_KG@/^@7&?=1_^6^O]/3ZPHKY/_X37Q5_T'+[_OM?_B*/^$U\5?\
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M*/\ A-?%7_0<OO\ OM?_ (BC_5W%?\_\/_Y4_P#D/7^GH?ZYX#_H%QGW4?\
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M_P#T$U_8WH__ ""=+_[!UE_Z315\CQ9\& _Q8K\L,?UW]%+^/QW_ ->N&O\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3D^^O\
MO+_,4VG)]]?]Y?YB@<=UZK\QM%%% @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH </N-_
MO+_)Z;3A]QO]Y?Y/3:2WEZ_HAO:/I^K"BBBF(**** "BBB@ HHHH **** '/
M]]O]YOYFFTY_OM_O-_,TVE'9>B_(<MWZO\PHHHIB"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC)1Q-?&<TX3G&G.>)Q-;$UZM65%4Y5I5,3B9*JYQ6(KI*K,HHHKSCWPHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "G)]]?]Y?YBFTY/OK_O+_,4#CNO5?F-HHHH$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK8G_ *!Z_P#X*J?_ "/FOO,FBM;^P-=_Z NK?^"Z\_\ C-']@:[_ - 75O\
MP77G_P 9H]M2_P"?M/\ \#C_ )A]6Q/_ $#U_P#P54_^1\U]YDT5K?V!KO\
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M9-.3[Z_[R_S%:G]@:[_T!=6_\%UY_P#&:5=!UP,"=&U4 $$DZ=>   Y)),.
M .23TH]M2_Y^T_\ P./^8UAL1=?[/6W7_+JIW7]WS7WF116C_8^K?] O4?\
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M "5#>5C< 02N<@$'&"*/;T/^?U+_ ,&0_P P^JXG_H'K_P#@FI_\B9E%:/\
M8^K?] O4?_ *Y_\ C5']CZM_T"]1_P# *Y_^-4>WH?\ /ZE_X,A_F'U7$_\
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M&UA25;2M25E)#*;&Z!!!P008L@@\$'D&CV]#_G]2_P#!D/\ ,/JN)_Z!Z_\
MX)J?_(F;16C_ &/JW_0+U'_P"N?_ (U1_8^K?] O4?\ P"N?_C5'MZ'_ #^I
M?^#(?YA]5Q/_ $#U_P#P34_^1,ZBM'^Q]6_Z!>H_^ 5S_P#&J/['U;_H%ZC_
M . 5S_\ &J/;T/\ G]2_\&0_S#ZKB?\ H'K_ /@FI_\ (F=16C_8^K?] O4?
M_ *Y_P#C5']CZM_T"]1_\ KG_P"-4>WH?\_J7_@R'^8?5<3_ - ]?_P34_\
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M^!Q_S#ZMB?\ H'K_ /@JI_\ (^:^\R:*UO[ UW_H"ZM_X+KS_P",T?V!KO\
MT!=6_P#!=>?_ !FCVU+_ )^T_P#P./\ F'U;$_\ 0/7_ /!53_Y'S7WF316M
M_8&N_P#0%U;_ ,%UY_\ &:/[ UW_ * NK?\ @NO/_C-'MJ7_ #]I_P#@<?\
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MMO$^JV>BVFHIIMC/IMK)_8VCV.CVUS]BN+BY:&>ZM;*&XN1&Z6[7$DCVT%M
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M .!MM_\ '*/[6TK_ *">G_\ @;;?_'*_DWHH_P!5%_T'O_PF7_R\/^)J:O\
MT0U/_P 227_SB]?Z6O\ 61_:VE?]!/3_ /P-MO\ XY1_:VE?]!/3_P#P-MO_
M (Y7\F]%'^JB_P"@]_\ A,O_ )>'_$U-7_HAJ?\ XDDO_G%Z_P!+7^M9'21%
MDC971U5T=&#(Z, RLK*2&5@058$@@@@X-.K\2?V-?VRI?AW+IWPM^*6HR3^
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MHHH **** "BBB@"^O_(+D_Z_X?\ TGGJA5]?^07)_P!?\/\ Z3SU0H ****
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M^'_@.;QMX1CO]5TFWN]5\,#4QI+ZMI2:W#IDFI623_SP_"?]@_\ :;\"P?\
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MUIFI6-IZS7QK^P%\ _$G[.7[*?PQ\#_$2Y;4_C/XDBU_XP?M":]*]G/<:_\
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M_$#G4/!?BO\ :;_9>UGQ_P#LVW=WXAL;7Q#J'Q"\*^#%U2YNM25;=_-OV?\
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MKE\ ?V@_AS^TQ\/[+XG_  J;Q?<^"M5M_#%_HFK^+O 'C7X??\)#I'C+X?\
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MKG_TEM:^=Z^B/VL_^3C_ (O_ /8W7/\ Z2VM?.]?J^"_W/"?]@U#_P!-0/\
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MS3T74[G7O@W\1M'USPU,(O$OA+5/#EQIWBK2='O9K>"7\]_B+^SA^U3\2/\
M@IE^T3XU^#G[07Q2_9.\%7W['O[)_AA_B/X=^!7PT^)'AWXDZ_I'Q-_:KO=2
M\-Z1XA^,7@WQ-X9MO$/P^LM;TO4]2T_P\9KZUM_&NCW'B*R:UNM&\SX=^*__
M  2W\-_##2?V\-'^%G@']HWQ'KO[.'_!,SX,ZI^QE\2]#\2_%JQ\=^,?VN=#
MUS_@H/\ %;7/'?AK5?AG<>&--^)7[1-S\4_$?A7Q#K5MHFE7VJ:?/\7M1\.6
M6@:9X;^*EWH>M@']/]>)^+_VC/@MX$^,WPC_ &>O$_C_ $:P^-/QSB\7W?PR
M^'49N+WQ'K^E> _#6J>*_%6NS6EC!<#1= TS2M(NT&M:V^GZ=?:GY6CZ?<7>
MIR"U&K\-_B1)XQU3QAX1OO"GQ$T37?ANG@C3M?U_Q=X#UOPKX2\7ZGXK\#:)
MXQEO/ASXBU"SM=(\;Z?HW]K_ -A>*+OPZTUKX;\7V.K>%[\6^IZ9<V\?PE^T
M%^SQHD7_  44_8"^/?@'X(V \0W?CS]H23X]?&;PI\.HGU=](MOV3/&7@?X=
MCXK?$'2M(:[BTB&[DL/"W@R'Q5JR6"7]S%I6B(+R[,,H!]9?M"_M8_!C]F(>
M#+/XF:AXTU'Q5\1[K6K7X>?#CX5_"WXE_&OXI^-O^$9ATZY\47_AWX;_  D\
M*>,O&-WH?A>#6-&/B7Q))I$'AW0I];T&QU35;74-?T6TU"*+]L']G2X_9O\
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M*^-/[%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  [Y!_\ /7S_ #[,_*.BOU<_X==:K_T6?3__  A+G_YJZ/\ AUUJO_19]/\
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MRG*4(P<L+A9NBZ];%V+3_C[M?^OB'_T8M%W_ ,?=U_U\3?\ HQJ+3_C[M?\
MKXA_]&+1=_\ 'W=?]?$W_HQJ^?/W[HO5_E$KT444""BBB@ HHHH **** "BB
MB@"^O_(+D_Z_X?\ TGGJA5]?^07)_P!?\/\ Z3SU0H **** "BBB@ HHHH *
M*** "BBB@#TN#_40_P#7*/\ ] 6I:B@_U$/_ %RC_P#0%J6@WCLO1?D%%%%
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M$?LT?^)9?%+_ .@MKZ7HH ^:/^$J_;%_Z(1^S1_XEE\4O_H+:/\ A*OVQ?\
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MJ_;%_P"B$?LT?^)9?%+_ .@MKZ7HH ^:/^$J_;%_Z(1^S1_XEE\4O_H+:/\
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M^KOMIZI_PE'[7G_1#OV;_P#Q*GXG?_0;T?\ "4?M>?\ 1#OV;_\ Q*GXG?\
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M?M>?]$._9O\ _$J?B=_]!O1_PE'[7G_1#OV;_P#Q*GXG?_0;U](44!\E^/\
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M!?\ (N^'/^$H_P"*=X?]F#_@F[_PS?>_"B\_X7-_PF?_  K#X0?MW?"GR_\
MA7?_  CO]N?\-L?M9>"_VHO[>W_\)UKO]F?\*S_X1#_A!O[+VZA_PF?]H_\
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M:YXA^'5O\2O#-A?^+_!EY%X2U3QQ\,O%/B;0?$FAZ_IAM/">M6/BD^H^'O\
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MH_@^ZBU2YU+58?!$_BNR\*>)[W4-*TB"W\7Z?K>D:<=2CTN:\/N\_P#J)O\
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M:"K[?\@N/_K_ )O_ $G@JA5]O^07'_U_S?\ I/!6)["VEZ?JBA1110(****
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MTCX:ZA\7-!^&OB"S\>ZWX/F^$NE>$=5CTR[\(Z)J\.NW%IJET ?L-17XC?\
M"TO^"E__  \$_P"&)O\ AJ']DO\ LW_AD[_AJ[_A8/\ PP]\1OM7V+_A=G_"
MI?\ A7/_  C7_#<'E_:/(_XG?_":?V]L\S_0/^$2V_Z96MXA_P""E?Q$T/\
MX*-+\'&\.^ X_P!B#3/C+\-_V$]?^*]TU^WC&7]N[XI_"/Q?\>=#T;0=8L=5
MN]!NO!FC:+IO@#X,^(O#M_HEAKVG_%CXDZ2S:PUM;OIA /VCHKYH^.OQM/PG
M^)'[+GA:35%LK+XT_%7XA>"]1L!X/;Q'<Z[9^#?V:/CG\:GT^SUS_A,?#4?@
M6XMY/A?'JHU^;0_'::I'IS^#O[ TIO$R^,O#'AG[*G_!2CX)?M<>)_ /A;P9
M\/OVA?AW<?%SX&']H?X/ZO\ &GX1ZAX"\-?%?X;Z;JGAO1/&5UX%UX:EK&GZ
MGJ?@#5O&G@R#Q'8W4MA'J.F>+_#7BSP3=>+O!6L6?B20 _0JBOR?_:=_:K_;
M!_9X^)VB^)]4\,_ FQ^!/C#]JS]GO]E[X+?!Z\TGQ-XD_:1_:1_X6[J7@G3_
M !M\0?"'CK1?BCIOP\^&<G@*VU+XD^)](\$>,/ &N3:WX1^%&O:SXJ\2^![?
M5],GM_,O'O\ P5)A\%?L6_MS?%F\\;?!RP_:+_9V\>_\% /"'PT\ ZC'?K8Z
MG_PS=\;/C'\/_@[!XB\.CQ!'JNIWVO>'/ _AFY\1'3]8TE=9U"\O;G3(M&@N
MH+6V /VMHKYY^,?BG]H"+X)6&L?LY>#_  /XN^-'B6X^'.GZ1#\0M0GTSX<^
M%K'Q3K^@6GC/Q]XL@LM9TCQ!K6A> O"M[KOBA?"?AG4H_$WBF[TRR\.Z9<6L
MVHOJ-I^5^A_\%"?VKO'&NG]F?X=S?LV>*/VAK[]N;QY^R%H/[1LWP^^)VE?L
MV:MX?^#/[,Q_:"^.OCJT^$4/Q8UGX@S^,?AAXEM-0^ ]_P"#Q\7T\,:A\06M
M=6L_&SZ?8^(-#TD _=:BOQ5\'_MI?MO_ !,^"NI^,SI7[*G[/I_9JU_]K;P5
M^V]\?OB1IGC[XC_ [1O&'[)OC2V\*N_P6^'6C_$_X8_%(^#OBKHMEXE^(I\0
M^-M;D;X9>'-,'A^X@\>>()K&XU"YXF_X*+_M-'X4?\$TOB)H?[*5QX4TK]L;
MQ?\ L=V?QP\=>-_$OAD^$?A-:_M%>(])TK5/A[X*\+6?B^'XF^)?B!>6MQ<:
MKI&J:UX6TOPKX4\+W^DWWB2YO/&$MUX+T\ _9ZOG#]J/P;XE\<_#[PGI'A72
M9M9U'3_CM^SKXKO+6"2WB>#0/!GQO\!^*?$NI,US-!&T6E:!I.HZC-&CM<2Q
MVS1VT,]PT<3_ $?16V'K2P]>E7@HN=&I"I%23<7*$E)*233:NM=495Z,<11J
MT)N2A6ISI2<;*2C.+BW%M-72>ETU?=,_$B\_8"^(5Q\#/%%JM]KJ:9JWC'QO
M\5KC]FWR].?2-9^.5U\:=;O_  [\3IM7?5S:)8MX+GTWQ4_@]HAI<GC_ $[1
M?'[/;^)[.X^TV_B?^P3\0_'/P\_;0>QU#Q!H^F_&CQ;^TEXH\1?!"T_L]M,^
M.GB..WUF7X!>)&U,ZG''H)GO+C28_$ULS6__  F&G^%O NC^(#;:5H=]:ZE^
MUE%>S'B3,HRYTZ7-[=UXMTU[MYTZB@NCY)TH3A5ES8B$X4YQJJ=*G*'EO(L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNKI$P9&5U/FR'#*05."Q!P0#@@@]Q0^C:>[L[Q,SNS.Q\V099B2QP& &22<
M #L *!\CLEIN^_6WEY'!T5W7]B:=_P \6_[_ $O_ ,71_8FG?\\6_P"_TO\
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M]^RW_P $JM _:5^#?C#3_@+X(^!/[7VE^//A7\??V#_VG/VX/"OPY_:'UO\
M:.U/5O _B7XT?LM?!3QM\'/'MGXI\1_"S6]>L/A;\5O$]GXIT31IK[6X]/\
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MQ/XS\57'[06I>&;'X4^/OV:_B!^SQ;:!\//A_P#LU:'X]MHVUV:TT[1O!_\
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M.?D;RW23#8.QU?[K F*WN[6[1)+6YM[F.2&"YC>WFCF1[>Y4O;3HT;,K0W"
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M-:R_"CQUJ=K#H/Q(@\.P'^Q_&LWAFYNT\)^) =!U<P:@/*KY[\ ?L8P?#_\
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M'=;U>W\3_%CXCR/J&H>.=3\!>"]+GO\ 2OA7X,\=^-KF^W:%9:-K/V?7R/\
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M_A/X?\-Z?XBT2W_9S^$WAF]U;1_&6E>+O#MU;7WB?QA<:E9?1$7_  3<\/\
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M]X.^*#"7PA?>$K6#P1IMA>?#[1VT+X3TCX!?M0K\)/A3-^UE\(?BKK\NB?\
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MBCK/@G4+)_B?HGARQ\%Z+8WWAC^V?AGXK_L.?&WX$?LB?\$XO&?[*OP8\?\
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M,/!/B"ZAT;L/V//V>_#OA_\ ;?\ ^"/?B3X<_L>_M"_#+XM_"3X'?M(>'O\
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M4\)?$W69M+NOAOIJZK>KJEE;>()K/6.(^//P!_:G\#7/[*?[/^I3Z]>>//\
M@K/^QM^S3^Q)^W+XPL]2TO7?$.A?&#]FO1_">N_'_P"+.M^*M4N;B3Q)KOC_
M /9 \0_M7>!;K6[19KC4M8\"^ ;V2[:6.Q< ']&_QT_:!^$W[-_POO\ XR?%
M_P 51>&?A[I^K>"M ;6X+#4]<:[UOXC>+] \!^"=-L+'0K34;VZ?7O%?B?0]
M-2[2#^S=-M[R36M:O=-T&PU+5+.M\ OC_P"!?VC_  5JOCSX?Q:W;:+I'Q,^
M,7PJGB\16EC8:A/XB^!_Q0\4?"3QC>6EO8:GJL,VAS^*/">HSZ)?&Y2>\TBX
MTZZO+/3[FY>RA_/;_@M#\"_#_P 0_P#@F_XM\'Z-\"A\6U^&GQ+_ &4O%?@[
MX>^%/A-/\4]>\/>'O!G[1?PFTWQSJ'@3P)H7A_Q!K:G2?@9>?$?0];7PSI+7
M/_"MM2\8:+=*WAW4M8M9_P M?A=^Q==^#_!O[%'[3?PG_9@^)W@_X^WW_!;#
MXC:WX@\8+\'OB%X5^*7@G]BGXD?M ?M*V%[I^N^']5\.Z;XE^''[..L_"[6?
M#VMWFB:YI&B>!-/?Q?<^)VM['5?%%W?W@!_5_P"9&9#$)$,JHLC1;E\P1LS*
MLA3.X(S(ZJQ&TLC $E2!\4?M,_MR>#_V:/BC\*O@O+\&OCY\;OB;\8O!/Q7^
M(/A'PC\"?#7@7Q%JK>&/@Q#X8N/&]Q<P>-?B/\/VN=0BA\6Z4VCZ)H0UK6=;
ME%Q::?8RW@M[>Y_G8^ ?[/?[0UE^UM\+I_&N@_$'1_VM;3_@I!XX\8_&#XQ:
M-^P'^TC-\3/$O[.NC?$3Q]KYN/%7_!17Q-^TEX4_9P\4?LC^._@KHGA/X8:%
M\-]'^'B7>@'5O"OASPS\&_$'C#PF^IZO^E7_  4B\%ZO<?\ !0K]@#XGZMI_
M[7NB_"7P3\%_VP]"\:_%3]D;X/\ QV^*?B;P?X@\7-\%%\'Z#K;_  (^%OQ7
MU_1K7Q8^D:LL27N@Q6]]#I=VWVF..TF=0#]$OAW^V]\)_BU\&X_C-\./"_Q>
M\46EE\8=!^!'C;X;1_#?5=%^,OPI^)>J>.?#?@;7-!^*GPV\2S:)K?@I_ #>
M*M*\8>.CJ.9=+^'[GQ=I\.KZ=<:>;W/^$/[>?P5^-?Q,\(_"GPAIGC^W\2^-
M/^&L_P"R)]<T/1[/28_^&-/CCX>_9_\ BQ]NNK3Q'J%S#_:'CCQ-I]UX*\JR
MN/[7\/)=7^J_V#>QQZ9-^+O@#X+_ !DE_9*^/GAGPG\)_P!H+7?A_K/_  60
M_9?^,_P?\0_&/X0^/O"?[4?Q3^'L_P"U-^S#\0/C#\8OC%X&U_P;X:\=?V!X
M:UW3?&RZ#X[\:>%O#VMK\)?!MC?>)M+T;1/#UG>3^S_L+?!;XQ^$?VN_@;XE
M\6?";XF>&/#FD?\ #[K^U?$'B'P)XIT71-,_X6Q_P47^%OC?X6_VAJNI:5;6
M%E_PLKP7I]_XO\ ?:9XO^$R\+V-YK_AW^T=)MIKM #]+_CQ_P4&^ /[.GQET
M#X*?$&+XAS:S>:;\+=;\;^,/#/@B]USX<_!K0_CE\3+_ .#/P7U?XL^*H[B!
M= M/B9\5-,O?!6@1Z/9>(;W3[R(:SXJM/#OA62/7V^X:_DH_X*.>%/VC]9_;
M&^-?QQTWX5_M%_$;]IW]G[XF?L\Z7^P'\$_"W[,7C/XB_L=?M&? 1=/\&>,?
M$-M\5_BIX9\#Z;H-WXW^&GQDUGQM\6WO/C'\2=(T+X'^.O 7@C4OA[I>OSZC
M=7=U_3)^S'XO\4>/OV=?@?XS\<R>*)O'/B+X6^"-2\<S>-/AIK/P;\43>-9?
M#]BOBV;5_A9K]M:ZKX$GE\1)J4D?AR<7,-A;M#'8ZEJ]@;;5+P ]SHHHH **
M** "BBB@ HHHH \O^-_Q;\+_  !^"WQ>^._C>#6+KP7\%/A?X_\ BWXNMO#U
MI;7^OW'A?X<>%-6\8Z_!H=C>WNFV=YK$VE:-=QZ9:7>HZ?;7%ZT$,][:Q.\\
M?R1XP_X*:_LO>"?^"?VG_P#!2?5=4\5W7[.VI^"?"7C*TM=+T?2[SXAR3^+_
M !'IG@VV\%?\(X=>ATL^-]&\7ZD_AKQ)I2>(GL-(U+2M:>75I+#39KVO0?\
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M2VBNK:2XA9TF@CGB>:)XH[:65)(E8NC1Q7MG(ZLH*1W=L[ +/$7\C^.WQ_\
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MZ-\*O%/A+QQ=?&&<Q^(/B]H7PQ\&V?@O6;"7QQ=7,G@]?"FF>"]$33I;FYT
MZ%;Z/;RV,EB&\A_;1_8I\0?LZ^%M)\/_ +"WPRO/@;I>C?\ !+[]OFWU+QGX
M9T;4-#TB/XN>./$?[%LMYH>N_$6\EL=*\,_&OXR^%/ ?BK0/"&O:YKEGKH\0
M6,GB6Q@O#X9NTB /Z"?CQ^T-\/OV=_"&C>-/'+:M?Z;KOQ-^$GPHLK/PQ!IV
MIZLOB3XR_%?PI\&O"]W/9WFJ:8B:)I_C'QCI0\1WJ3R7&FZ?'>RV]G?7L,5A
M/H?';X_?"C]FOX9:K\7_ (Q^*4\+> ](USPAX8N=6CT[4]:FE\1^/?&FA_#S
MPCHUMIVB6>H7\USJWC'Q'H^CO,+=;'2$N)]6UV[TO1--U34[+^._XX? ;X&?
M$;]N2;X-?L<_L@_'OX*?#OQ!^S!^Q!KOCKX<1_!7XR_ W7;L?\/0OV9A\3_B
M!H_PQ\0^%?#OCC0+OPE\/?")'Q&^-]A$NG:_<>"]0\2G7+J+P=>>,=9^E/VL
M_P!B"'P5X$_X*^_";X?_ +'.O7'[-WAW]H7_ ()5_'?]F_X6^"_V>M>\7>!/
M[<37?ACI/[6GC;]GGP9I'A+6+74]2A^'%IXI\/\ Q>'PPL+E[+PM=>)]!U^W
MM]-UC6K.\ /ZUX[VSEF%M%=VTMP;:*]$$<\3S&SG=XX;L1*Y<VTSQR)%/M\J
M1T=4<E6 X/QM\1[;P1XB^%_AVX\)^./$+_%'QG>^"[;6/"NA1ZMH7@J6Q\%^
M*_&K>(OB'J#WUH?#?A2>#PG+X>M=7C@U!I?%6M^'=)-JB:DUW;?R\>,/A.OA
MW_@HLGQK^%_[+7C[XDZAXO\ VIOV4O$/@+P-\5/V*?VD/!'C3P7\/;KP#\$=
M$L_BW\!?V]OAE9Z;X<^#_P "/ACX9DN8?B-^R;\?K:U\,^&Y_"'Q%^'?BWP#
M;+XDM])B_:/]OKP)XX\9?%G_ ()XZEX0\&^*_%6G>"?VI?B5XA\9W_AOP]J^
MN67A+0+_ /8H_:J\*6.N>)[K3+.Z@T'1[SQ1XB\/^&[34]5DM+*XU_7='T>&
M=]1U.RMIP#](;>[M;M$DM;FWN8Y(8+F-[>:.9'M[E2]M.C1LRM#<("\$JDI*
MH+1LP!-?(WQW_;H_9Z_9ZOOC?H'C7Q!K&I>-/V?/V9M3_:W^(O@;POH5S?\
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M#%AIVI267C[XLMKR^%M0\1I?:OI3:=X55O#>IKJ6J6@U*]@9$%KI5Z?-$/\
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M^DT:VBT35?B!XPNXKJQTZVO[MM:DCU"[NX;6PBM?1:* "BBB@ HHHH ****
M"O")?V9?@=<?M$V?[5]UX%AO/CYIOPZO/A5I/CJ]UWQ1>Q:+X*U+4K;5-4M=
M"\(76MS>!M#UW5IK*RLM7\::3X9L_&NK:%9VGAK4?$-SX=MH-+C]WHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>nt10016217x4_graphic02x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic02x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MPM/_  '_ /ME+_B N$_Z*2O_ .$<?+^__5WYV/\ B=#-_P#HWV6=/^:EQ/\
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M_P .EX)_^7%'_#6O[+/_ $<C\$O_  Z7@G_Y<5_G9")"H;R;/J1C[/R..O\
MK.]-V*#@V]H!W/V?( ]?]9GUX SZX%)> V#<8R7$E=QDDT_J2T6EG+WO=O;[
M5KW?<(?3/SF?-;P]RV\5)R4N),3!V@TI:3RF+>L7M>][JZW_ -$__AK7]EG_
M *.1^"7_ (=+P3_\N*/^&M?V6?\ HY'X)?\ ATO!/_RXK_.R,2@9%O:$>OV?
M ]1DF3TP?\\KY28_U%H/;[/_ /;*:\!<'SRA_K)7YHI2DG@XK3W=;N:3OIHF
MW9M["_XG0S?3_C7V6/9_\E+B7_+O_P ).E_/N_,_T3/^&M?V6?\ HY'X)?\
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M7%'_  UK^RS_ -'(_!+_ ,.EX)_^7%?YV?E)_P \+3_P'_\ ME'E)_SPM/\
MP'_^V4?\0$PG_125^G_,''R_O_?ZOSL?\3H9O_T;[+.G_-2XG^[_ -2GR_%]
MF?Z)G_#6O[+/_1R/P2_\.EX)_P#EQ1_PUK^RS_T<C\$O_#I>"?\ Y<5_G9^4
MG_/"T_\  ?\ ^V4>4G_/"T_\!_\ [91_Q 3"?]%)7Z?\P<?+^_\ ?ZOSL?\
M$Z&;_P#1OLLZ?\U+B?[O_4I\OQ?9G^B9_P -:_LL_P#1R/P2_P##I>"?_EQ1
M_P -:_LL_P#1R/P2_P##I>"?_EQ7^=GY2?\ /"T_\!__ +91Y2?\\+3_ ,!_
M_ME'_$!,)_T4E?I_S!Q\O[_W^K\['_$Z&;_]&^RSI_S4N)_N_P#4I\OQ?9G^
MB9_PUK^RS_T<C\$O_#I>"?\ Y<4?\-:_LL_]'(_!+_PZ7@G_ .7%?YV?E)_S
MPM/_  '_ /ME'E)_SPM/_ ?_ .V4?\0$PG_125^G_,''R_O_ '^K\['_ !.A
MF_\ T;[+.G_-2XG^[_U*?+\7V9_HF?\ #6O[+/\ T<C\$O\ PZ7@G_Y<4?\
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MO[+/_1R/P2_\.EX)_P#EQ1_PUK^RS_T<C\$O_#I>"?\ Y<5_G9^4G_/"T_\
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M.G_-2XG^[_U*?+\7V9_HF?\ #6O[+/\ T<C\$O\ PZ7@G_Y<4?\ #6O[+/\
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M2KU'U'\Z<=UZK\QQW7JOS/[G?^"/G_*/KX#_ /7/QM_ZL'Q111_P1\_Y1]?
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MTWY6.2/G]_\ 7]-^5BBBBCDCY_?_ %_3?E8Y(^?W_P!?TWY6****.2/G]_\
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M^7_VRC:_]Y/R_P#ME?TH_P#$.?K7_1U^D_\ AD/_ ,9E'_$.?K7_ $=?I/\
MX9#_ /&91_Q%O@G_ *'6(Z?\R^KY?]0_E_5D'_$MOCA_T1E;I_S/^"O[O_4X
M^_\ [>/YKMK_ -Y/R_\ ME&U_P"\GY?_ &ROZ4?^(<_6O^CK])_\,A_^,RC_
M (AS]:_Z.OTG_P ,A_\ C,H_XBWP3_T.L1T_YE]7R_ZA_+^K(/\ B6WQP_Z(
MRMT_YG_!7]W_ *G'W_\ ;Q_-=M?^\GY?_;*-K_WD_+_[97]*/_$.?K7_ $=?
MI/\ X9#_ /&91_Q#GZU_T=?I/_AD/_QF4?\ $6^"?^AUB.G_ #+ZOE_U#^7]
M60?\2V^.'_1&5NG_ #/^"O[O_4X^_P#[>/YKMK_WD_+_ .V4;7_O)^7_ -LK
M^E'_ (AS]:_Z.OTG_P ,A_\ C,H_XAS]:_Z.OTG_ ,,A_P#C,H_XBWP3_P!#
MK$=/^9?5\O\ J'\OZL@_XEM\</\ HC*W3_F?\%?W?^IQ]_\ V\?S7;7_ +R?
ME_\ ;*-K_P!Y/R_^V5_2C_Q#GZU_T=?I/_AD/_QF4?\ $.?K7_1U^D_^&0__
M !F4?\1;X)_Z'6(Z?\R^KY?]0_E_5D'_ !+;XX?]$96Z?\S_ (*_N_\ 4X^_
M_MX_FNVO_>3\O_ME&U_[R?E_]LK^E'_B'/UK_HZ_2?\ PR'_ .,RC_B'/UK_
M *.OTG_PR'_XS*/^(M\$_P#0ZQ'3_F7U?+_J'\OZL@_XEM\</^B,K=/^9_P5
M_=_ZG'W_ /;Q_-=M?^\GY?\ VRC:_P#>3\O_ +97]*/_ !#GZU_T=?I/_AD/
M_P 9E'_$.?K7_1U^D_\ AD/_ ,9E'_$6^"?^AUB.G_,OJ^7_ %#^7]60?\2V
M^.'_ $1E;I_S/^"O[O\ U./O_P"WC^:[:_\ >3\O_ME&U_[R?E_]LK^E'_B'
M/UK_ *.OTG_PR'_XS*/^(<_6O^CK])_\,A_^,RC_ (BWP3_T.L1T_P"9?5\O
M^H?R_JR#_B6WQP_Z(RMT_P"9_P %?W?^IQ]__;Q_-=M?^\GY?_;*-K_WD_+_
M .V5_2C_ ,0Y^M?]'7Z3_P"&0_\ QF4?\0Y^M?\ 1U^D_P#AD/\ \9E'_$6^
M"?\ H=8CI_S+ZOE_U#^7]60?\2V^.'_1&5NG_,_X*_N_]3C[_P#MX_FNVO\
MWD_+_P"V4;7_ +R?E_\ ;*_I1_XAS]:_Z.OTG_PR'_XS*/\ B'/UK_HZ_2?_
M  R'_P",RC_B+?!/_0ZQ'3_F7U?+_J'\OZL@_P");?'#_HC*W3_F?\%?W?\
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M8]>F^C$G]Y/R_P#MGN?SK^E'_B'/UK_HZ_2?_#(?_C,H_P"(<_6O^CK])_\
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MR_JR#_B6WQP_Z(RMT_YG_!7]W_J<??\ ]O'\UVU_[R?E_P#;*-K_ -Y/R_\
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M_E_5D'_$MOCA_P!$96Z?\S_@K^[_ -3C[_\ MX_FNVO_ 'D_+_[90 P()9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM;'5#H,-V9=7GDU6U2<06@L[AIIY89I@DAC?*NRW[;>;[?U\SF?=].K7Y/\
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ML5PDT3LD\9L+2V>*96*.DHV?(JD_7I3+(V[[CJV,=0J%-N>V<Y)Q^'-?BO\
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MO4;:]EC_ -?;1,R7D .>9K"=(;Z(<<^9;I@9/:MMOE/0D<9.QP>?1656[<Y
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M^.+;QN^C:<MH;JY@\&6USX@=EEO;JUM;51)9Q1K=7#^5#<30$LLIB#_V _\
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M"C ]!^0I^WEV7]?+^KORM/U:GV73HO+R\OZLC\^?["^*'_1)/%__ (%>&/\
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M8^K4^RZ=%Y>7E_5D?GS_ &%\4/\ HDGB_P#\"O#'_P MJ/["^*'_ $23Q?\
M^!7AC_Y;5^@V!Z#\A1@>@_(4>WEV7]?+^KORL?5J?9=.B\O+R_JR/SY_L+XH
M?]$D\7_^!7AC_P"6U/30/BG)D1_"7Q-N!QBZU/PU9*3Z"1]2F5LG^)5/&2%.
M,5^@>!Z#\A2T>WEV7]?(/JU/LNG1+MV]/R6R/@6#X??'+4&5;;P7X9T,/GYO
M$'BN*ZEB(&<R6^D68+#J#ME!!YZ9 ZW2OV?/B+J)7_A*OB7IVC12[2^G^"]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8$GJ2K%2<<8)(R1@8/%3U^'?*WEV\C_1%6LK.ZLK/NNC"BBB@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -?[I_#]2*IW0+QL@ (8LI!.,D[?E)VMM# X)"L0"<
M*:NLH8%3G!QTZ\'-,$:@L<D[CN.<<'CIQ[=\TT[7?72WJFG^@K)N-TG'5237
M1I)^NUFOSNSP3X#_ +/GA#]GGPOXJ\*^!KG6KO3_ !;\3/B!\4]0EUZ__M"[
M7Q#\1O$^H^*M<CAF6&$1:?%J.I3K96P1C! J1M)(V7;QW7OV#OA%XAM/VO+/
M4;WQ=]G_ &S_ .RQ\5?LFK645S9KH_A:Q\)60\)3#2@-'==.L8W:2Z74Y/M+
M&9)$&U4^W6B##&YQAMV00#USCH?E'IZ=Z5HPP())!QGD<@#'/'?O6RQ%55'5
M4W[23C)RMJG!IQ:\]%KT\C@EEN!GAZ.$GA*,L/AXU(4:3BO9QC6HSH58*-M(
M3HU*E-KK&<EU9^<?A'_@GZ/!FJ^%[ZQ_;!_;2OK#PMJ.@WUOX3UCXU17?AC4
M;?0)["X@T35=)7PPL-SHEZM@MEJ-EO3[387$\)8>97TU^S[^SUX+_9U\'Z[X
M0\$OK5W'XF\?^-?B3XDUCQ#>17NMZYXN\>:Q)K>O:M?W4%M"LQ:YDCM+")U/
MV'3K6TL(V,%I#7OIM8<Y"XQZ?_7!/ZU(8EV[0649!X(SD8]0>.*<L14DIKVD
M[5I*=5-KWI*SOIV=VEMY;6SPF3Y?@ITJM#!THU,/"5/#2YZLWAZ<U&,H4O:3
ME&*<8Q3:2NE;JSYS\._LT>"?"_[17CK]I;1KC6+#QO\ $CP-X;\"^,],M[RW
M7PQK]IX1U.\O_#>MWVE"Q667Q+H\%_?:3::PU[YB:-<M8-$R1Q/']'."PP#C
M/4\' [\$,#GH0<<$\@T! ,X)Y*GJ/X3GT[]#[>E.K&4W-IO=)+;HMM=W_7<[
MJ&'I8:$J=&G&G"52I6DHZ)U:TW.K/9:SFW*3ZR;;U;/C+]M;]C;X2?MJ?"/4
MOA5\4])B$L<,VJ^#O&EC"@\2> O$L*^59ZUX=O'W/",R>7J>GL\=CJ>G&>RO
M5DBD&S^9;_@FE^R#\6OV+_\ @KMX9^$_Q4TV-77X=?%:]\'^*[".1/#OCKPN
MFD"*VU_0Y)LB-Q%+;+K&BF:YN]!O9'M9)KNS2#4KK^R>\4,8\YX)8$<'(]^N
M#GGUP*_,KX[QAO\ @I]^P5$<D+\$_P!KR4L0K.S"W^%<2_,X;:%220 QA&82
M.KLRD*/>RG-L5A\+F67J7M,-C,#6ISIRD[0:]Y2@G[J::?3K>[LD? \6<(Y-
MCLXR#B9T(8?-\KSO)I/$TH14\;".*=.%'$R24IQIJL_9-MN&J3Y79?J)1117
MSY^B!5626-58G@HK.1T&U2<\G@8/<X ^F*M53EM8P6F+R9"," R[<,P8D@KD
MXQTS@C((-*]FK*[?G:UK:AU3>R:O_AZ^EEJM'_G\4?M<?M9VWP*MM&\'>$='
ML?%GQ<\602W>B:'J-Y-::/X>T."=K.[\9^)[BP$NH1Z79W3>1I=A:QPWGB#5
M8I+&UOM,@MM1U?3/S=/[0W[5FKWQU!/C++8*;AY(['1_ O@BQT=06/R1VFIZ
M%XAU0VTF6D*2Z[+>!G='U*=D$[TOBUJ9\:_M)_'/Q%=%KF:T\90> [61R^(-
M'\!:796-MIL2,6V6MMK>H^);V-48&2[U/4IY-TDV5[;1_#$%Q%&=KIA< 1;%
MV# *@;XV)Z@\[B2QSGH/W'(^'\KRO+<%B<5@*&8XG%8:CBJGMN5JU>$:B@E+
MGC%03Y6U%-M-WU5OX]XPXSXMX@XGS? Y=G.*RC*LLS&O@,)0R^I4PM>:PE5T
MIUZF(I.,Y.M.+GRMN,$X04;Q<I>0_&+]J']MB]\()X3T/QAHUQI=S)+;>)_$
M'@C1D\)?%M](>(P2V/AG49;N_P##R:A.P:675;.W\/>(+!=T.ES-?F.]C^?O
MA!X \)^(],O-3\,/#<75K?R6WB9;N!H?$=GKC.9[S_A+[:]4:U%K=W+(\L]W
MJZ7%_>?Z\:E>0,BQ?<FH^"872=?+ED!\PJ)&1P"2V0(]@B._/SDQDGD@@D$?
M._BSX?ZUH6O+XY\%W@T#QK91HG]H20_:=,\06%L3.^C>++*-K:;5-&:&)_+$
M-[:WNDL//TF1W,VF:E[%.AEBH5)9;EV'P.-FI65-)1=VM')))Z=E[JZ26I^;
M\0T^(,PQ]'$\29KF>=Y=34*<,%B<1*=+"*$5'ZQAZ<E&,JLK7J*;O5;5JM)K
M7HU^%L4%LL:6X5"#(OE_,I+<L=Q49R23G&5Z$YKS/Q9X#2"-FCB0R%3$6D0D
M*A&<!0I5N22"2"."""*^S/A?XL\._%CPQ<WUO87.A>)=&NSI?C#PE>,DE]X9
MUI8DEE@\Q$2/4M%OXW2\T+Q%8[M-U&TG0*5N;>[@AXGQUH,=M'=J%!"9*GY3
M@':,'"C!3!!/&&#>U>5A\RQ5'&1IXCW*D)>]&[<MU&Z[KHFKIWOL[G7F_!N6
MU,L6*P<*3HUJ%Z5>"UBG3YDU&T90:LTT^249)Q:4DT?(?[$W[-_P;^(W[36H
M_#GXKV6KZMX>\1^$]5^(/AKP0VHC3O"FJ>)?#VM"S\2V^I1VC+JNI66I:7=:
M1J\>CQW]I:17%MXI2]AU""]:6[_J(T32M+\.Z=8:!HUC::3I>F6MO9:7IVG6
MT5I8Z?:01)#;VEO;Q!8H+>WCC2***&-(E"L4C12(T_FU_9E@D@_;W_9<^QLZ
MO<>)_BQ8WGE$AFTX_ 7XJ:C=PS9!_P!%.H#2KB%1MQ<11,S.0 /Z;%7/(=OH
M" , D#MGIUY_*OA^/YUY9OA_:UJDZ57 TL3"C[1RA"4JU>CS<OPQ;5!<RM=M
M7;=S]T^C/3P4>!,9'"Y=@L)B<OXAQV55L92HP^L8VE3P>6XZ,L154(U)<DL?
M4A"$W)4X1BH63LB(,J -URWMU8GMZ]?QJ2@#'J?KUHKX3U/Z+_K31?)= HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E=]4^C?
MS%?F7\=?^4H7[!G_ &0[]KS_ -%?"FOTTN^J?1OYBOS+^.O_ "E"_8,_[(=^
MUY_Z*^%-=N!_B5?^P:O_ .D'@Y]_ PG_ &.,G_\ 4ZB?J#1117$>\%12LC1N
M"RE65@?F&"O(<9&>@R..<\=:EKYX_::^,VG?L_?!#QY\3[F"._O/#VCRQ>']
M,D=(EUGQ3K%Q%I?A?1E9CDG5/$.H:;I^$^<":1E.4(K2C1GB*U.C2BYU:LE"
M$4KW<FE^=OO9RXW&8?+\)B<=BZD:.%PF'K8G$5I?#3IT8.I*4NR4(R;=G:VQ
M^./B>W73_P!H'X^:8)891;_%K6K^39(D@4^(]/TGQ3%%(%)VNBZTRE6P0#G'
M)S] ^&K83(I"A0&V] !@(ASCCJ"/RZU^7/PEN?$?ACXB:KJ7C'5Y=>O_ (Q6
M;>,=:\3W49C>^^(6BWEW+XNGN'+&*"WU'2M;L+W2[&W"Q6-CX?U01+]E2W1/
MT[\$WPG2%=Q W,I!X(9 $8'D8.X$'K@CD9K^@L=1E0P&7PIR]HJ&7X.A*27*
MG4HT80J63V]^,EWT\S^&>',XPN=YOFV/ITIT88[-\PQ5*E5^.-+$XF=:A?2*
M:="5.7-%6;EOI<]2;0XY(\D*VY 1P"1N7@CCIWX&>,9KSKQ-X366*8&-6'7!
MC^]M^9%Y')# ,.X8!NU>V62))&G(/[M>I[!1TX^O'!].I)J:IIZ21.I 8,#M
MYP1@$#K^0YX&?:O I8NI2^&7+*Z]Z]^5Z=+I2:[)KSULG^F8S*\/BJ+YZ:E&
M4+.*2M*ZMJ^E_+3;3O\ F[XG;7OA9XLM/BAX8AO+C4-&@ELO$N@VX80^,_ Z
MOY^M:3)$=L,FK:1&%UGPQ*Y6<:K:1Z;%-#IVIZLEQ[5XQ\5:-X@T"U\1:#>I
MJ6A:Y86]]I6I(Q"7MM=1Q/')EUC99V,@$\#)'+#.6@EBBE0Q+U'CK0U:&<;%
M/S!D,@5X3("<%TQN**N3(H($J_NR0.3\&-XCN/ &H^(OAI>I)%H%Q'J'C7P)
M=-*_V:&Q2^ME\:^'K>,Y>-=,U_4+'68B!B&RUV*&(,+24U[E3"T\QEA\PI0_
MVK#J"JQCM6HW7M).^J<+<ZLI>[&5VE:WY%F>/K<-X?'Y=B*LY8/%.J\*W%OV
M.+E%QA3;5U&E77N-R:2J^RC&-ZDI2^F/V!/"8\8_ML:=XD,,L]E\*_ASXYUZ
M6?Y]EIXA\7#2O!.AY.=K"X\.#Q2P9LDRS2%3DO7]#@ '0 ?2ORM_X)8?"[4]
M"^%WBSXU^(49=4^./B!+_P ,VLL0CETGX7>%[8Z=X2AW$$SCQ#JT_B7QTDP.
M6L/%^EVC#&GJ3^J5?D'%F+I8O/,4\/6=?#T%##T*CTYJ<+R:2NTDJDZB5GJD
MI;MG]6^#/#TN'N <JIUJ#P^,S257.<=3:M+ZQC8TX0<NKD\+0PR;=GI:R221
M1117S9^J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)&# !S(L9_UIC"&1HS\I"DL#M KQSXR>$#\)/%5U\4]"CN/^%=>+[Y;KQY%
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M4XI)*$/9PM%):)+4****DT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JUV0(3GNR+^;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT/AO_P!%0\#_ /A6:%_\G4?\+0^&_P#T5#P/_P"%9H7_ ,G4>RK_ /0+BO\
MP73\O^GWG^'K8^LX?_H(P_\ X,EY?]._/\/6WJU%>4_\+0^&_P#T5#P/_P"%
M9H7_ ,G4?\+0^&__ $5#P/\ ^%9H7_R=1[*O_P! N*_\%T_+_I]Y_AZV/K.'
M_P"@C#_^#)>7_3OS_#UMZM17E/\ PM#X;_\ 14/ _P#X5FA?_)U'_"T/AO\
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M_P#)U'_"T/AO_P!%0\#_ /A6:%_\G4>RK_\ 0+BO_!=/R_Z?>?X>MCZSA_\
MH(P__@R7E_T[\_P];>K45Y3_ ,+0^&__ $5#P/\ ^%9H7_R=1_PM#X;_ /14
M/ __ (5FA?\ R=1[*O\ ] N*_P#!=/R_Z?>?X>MCZSA_^@C#_P#@R7E_T[\_
MP];>K45Y3_PM#X;_ /14/ __ (5FA?\ R=6SH'CKP5KUVNF^'O&7A;6[U8Y9
M#9:1XAT_5;DI%_K9#%;7,\P6/<H=B-J$KD@FCV=>S_V;%*T93;=)<BC%+FYI
M0G/EW5N9)/771I..(H2:2Q&';;2257WG)VLDI1BY-Z[7:MMKIWM%11=.N1@
M')/KD$'H1P3W^;J>M2UFM4F]+I/1WW\]#;]--58**A8HKL[,PVKN;GY0!C)Q
MG' ]L]>:2&2*7:T;[\J<?-NXW=\$\@^O..F.E.ZM=7MLW:UI:>Z_/5ZK305]
M;.R>Z5]7'3WO177F3T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]\6/'V@^!M+O[D66G7&N3O%<:E=J4,T6FZ?;I<W^H>5&ZRR&V@*11*\TSJ@
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M*A#%0PM'!Y94JU</4A&I"HH^S<E%0Y5S*-GJ[]N2_P"&&_V.>_[-'P=!Z_\
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MY,E^ /\ V*VL_P#J9^(J^T/$G_( U[_L$:C_ .D-Q7Q?_P $S/\ DR7X _\
M8K:S_P"IGXBKW<'_ ,DCG/\ V5'#_P#ZK>+3YG&?\EMD'_9*\6_^K7@@^]:*
M**\$^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ#2K%;>UM%,WE$OP,BN;12UK&X>/]XBFXC. A41^8LGF-!L=T>TG>:S<']Y
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MS:OI\0N5?XM1Z-97_P )=2<D%4@EA\2>(K&6<H&5M-MPV^,!5]N.18663X[
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MW<'_ ,DCG/\ V5'#_P#ZK>+3YG&?\EMD'_9*\6_^K7@@^]:***\$^H"BBB@
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M56/FM ULYP,.:^5O^&IM5_Z-1_;$_P##+-_\OZ/^&IM5_P"C4?VQ/_#+-_\
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M'_CC_P!(X?VF?_"H^#?_ ,W-/_5_-?\ GSANG_,RRSK;_J,_O+\0_P!2\_\
M^?>5?^)'PY_\]O/\^S/UCHK\G/\ AX_\<?\ I'#^TS_X5'P;_P#FYH_X>/\
MQQ_Z1P_M,_\ A4?!O_YN:/\ 5_-?^?.&Z?\ ,RRSK;_J,_O+\0_U+S__ )]Y
M5_XD?#G_ ,]O/\^S/UCHK\G/^'CWQR_Z1P?M,_\ A4?!O_YN:7_AX[\<_P#I
M'!^TU_X4_P &_P#YN:/]7\U_Y\X;I_S,LLZV_P"HS^\OQ%_J7Q!_SZRM^G$7
M#GE_U-O/^F?K%17Y.?\ #Q[XY?\ 2.#]IG_PJ/@W_P#-S1_P\?\ CC_TCA_:
M9_\ "H^#?_S<T?ZOYK_SYPW3_F999UM_U&?WE^(?ZE\0?\^\K_\ $CX<\O\
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MK5-IIIIM-/R.3\8+O\)^)VP-QT/5N^#E;&Y5>,XZ#H>O&.37\8/_  3_ /\
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M:7::=J,-S%-!?:/:/#8:H6-W/LEO(7DBW%E^9VS<^)7[,'PT^*GQ0^#WQ?\
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M^._B+?7,\]]=Q^'_  ;X.T&%-5\<?$/Q;J5P;;2O"?@KP_;N]]KFKWLX7?'
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M3E+B-4UC\KK0G3<L5AO9X.=*G4NZ3H5:4:%9J<J?M(7]K/Y?_9"U_P#91?\
M:#\#+^UMK7C+3O@;%J5K?>('\(:*-72]U&RO(WL=%\4O:W]OJUKX-O)(KR36
M+GPU:ZWJ4EI;QPK:1M,6C_LO_; _:#^#GQV^%/P1C^ ?Q&\&^//AG?\ B"\U
M&XA\':A87>DB'PKH=K'HNEZEHL'[VRBTRYOXYET;6K2U6"XMK=9+*1H%6/\
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M_P#0Y*^X*^RQ7_(PS/\ [&.*_P#2S](SS_DH>(O^QQ6_]1L(%*.H^HI*4#)
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M(WD^L0Q,LLVI2RRK<W44-R\8DC&/T7+'D[FY()RYP2.02. <'IG/IC%.>5G
MW22/P-H=BP7;R#&&)$;>Z!2>YXJWFN-E4=3VL)RG"M"4G0PUJJKQ2K^UC[*U
M5S^U*HG)-<R<979MB.,.(,17C6G4@W-8M8Z,<)@J<,=3Q_LEBXXRG3P\88I5
MXT:2G&O&:7(G%1=V_P MKC_@GEXF\5?LU_'WX.?%+]H/Q7X^^(7[0FMV'B_Q
M!XXO;>];PKX8U_2M<M_$NG67@[P3=73KI?AQ+ZWC:_M]/GMS-:,UM;I$$B"X
M^M_\$\?B9XR^&'P%B\5?'S2-._:)_9BUB"?X0?%KP;X$CT[P[I?ABQT[0M(T
MOPCXA\+WVHS3ZS;B+1+>\U#5,+//)/J%HR^1?SI-^KY(88;."<D;@ 6+;RY
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M4)XX=;C-]JJP7D=LJFYLH@J,A8X_68Y)R?O  ;R/W@7?'( )/O@!XHR,-QC
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MI_P4%;X+)K<V@3K_ ,$Y?CU:Z/K-N@>ZT'6/C3XTT7X>KK-LC*T;O!8^&[Q
MXS/#&+E%\O[1;F3^/'XG?#GQ?\'_ (@>,OAAX\TJXT7QEX#U^^\-:_IL]N]M
M)'<VZBYMKNUC)99=.U/39K/6='O[=Y;&\TF_L-1MIY+.[MYY?[7_ (L6<?@7
M_@J)^R]X\F4>7\:/V>OCC\%0S%HUEUCP'K7A#XI:%8M)B17:73[GQ=>0@*C.
MEM=D%O)(/PI_P6Z_8?N?'G@V#]KCX?:?'+XN^'-A#IGQ:TFSL=][XA^&L1N)
M;?Q/ T"/)<ZOX O;FSCN$D(,OA*ZU)!<(FB6EK+^5^._!U;B3AO+,WR[GGC<
MCRZ.*AAX.*]MAHU*BQFC:;J4)4I5%&-I23FK2?*E_<WT7/&'"^'W%O#O"V=U
MJ*X5XVR++J2Q-=2A' Y_A,;F^'PL9SY;PHXC%RK86K4J+V,*DJ-1SA"<Y2_$
MC]C#XQ06,U]\&/%TUK+HFJB]U7PC)<K']FM[]H1-K/A=Q-@&RU.)3>:7&,.+
MNUOH S37]M'-D_M2?!/]GKXDY\5?\)CXF\&W&C:1K0U+4?!OA.X\6V5S+#$M
M[ID.H:!/?>'KJXTV6\@&E3W6AZQ;:C;)=I>I%?V4;JOQ 8V2<&&[N+*XB>!H
M+JTD$5[:78(DMKBSDC=D,L=Q$VV5953R'@G1G%QLB^W_ (>#6?B%X&7Q/86T
M>JS6$\FC>+;'3=K2Z3JD5OO,-S89C>2TNM*D6]MI(X_*DE\ZS65I+9Y#_&/"
M^>X_@/C+)N/\JQ.+IYCEN)I2Q%"DU.-?)ZLU+'X&,;*5*>.CSJ4I27)-WGRI
MI']^\6\&9?CJ&.YL94P.'SZA#GIQMRQQ->/[QOGIU(.3FXR@YQ]G*6O[SG/Q
MV\.1>+? ?B&#Q3X'\8ZQX<U[0]0DDT3Q/X7U'6O#FNVS1$I#>V-[IEU9:I92
M721I,RF^=H7;;*CNA4_MM^SO^V-\??BSHFDW7[0'C>^^*]YX8BMO!?A_Q-JE
MAIEIXIA\/O?_ &M1JFH:5!:)KNH17I>)[V^MY]5FB02W%U<$M(?R^^+V@6'P
M@^(6E:AJOAB\\3_#S4KV+49] LM<E\.7-XIDQJ^@0Z^^C:['IMY%-YDUI<S^
M']7C$021K"ZC1D?]9OV;+W]DWQ+IFG:Y\(_#7BWP'H.H2:/>:?X6^*.O6&MZ
MQ9^)[.QL[3Q,BZQHJVFDZII_]LHZZ;>OI^F74JRF273+ D0'^[/I3\;<,<7?
M1MR?B3(*.*K0XKS#A>GE^)5U"A6IXROCL9@L5"HHUZ-7"K+,;.>'JTJ<JOU5
M>RC*52@JG\\\/</</93Q[+!5<@Q6+S;+LLQE99NJ,I.%)*G&$(.351N5.JTZ
ME&'+&$*D9M*\9>(?MPZ@+GXT6%N9 RZ=X#\/PP*"-JI=:AK-V1M',;X8&17P
M2QW 8*D_4/\ P14T0ZI^WO\ #JY,9<:#X'^(>N$@@+&ZZ%)H6]N<D'^U"@"G
M.6'!!S7Q=^U_?1ZA^T-XZ1)"4TVS\&:=&I*$*#X.T749=@3(6-KC49BH$DF[
M[^X;MB_IM_P0+\/'5OVOO'>KOMQX6^!6ONS;0QB?7O&/@^VLWSN78733M6C
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M ,$S/^3)?@#_ -BMK/\ ZF?B*OH,'_R2.<_]E1P__P"JWBT^7QG_ "6V0?\
M9*\6_P#JUX(/O6BBBO!/J HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JW&-T1R=^6"C
MUSM#?^._Y'6K5&!Z4?T_-=5Z-73\F)I--/\ X9]'\G9_(_-[_@I%\.O'&O\
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M_P"K7@@^]:***\$^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG+B_(ZZIRY(<-\4TG45W%.>8<%S47T4I.$FKZM1E963:^W:***\0^B"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBFNXC1G()"@L0HRQQV [GT% ;CJ*^3/VH/VT_@=^R#IWA'5/C-?^);&U\;ZI
MJ>CZ /#GAJ\\2W,][I-I;7ETDEII[FY1##=PB&1(I1)*3%\KE0WS_P##O_@K
ME^Q/\1O&OA[P%:>-O%GA36_%FI6NC>'9_'_@+Q%X0T?5-7OI5@M-.CU74[=;
M6VN)YY;>!/M[6D7FW4"&4%FV>#B^*.'L#CO[-QF;X+#8[]Q_L]:KR32Q2<L.
MVY)0BJR3<&Y)/OJCZ; \&<5YGEKSC+^'\TQN6*GB:OUS#86I6HNG@ZBI8J<7
M!.4XX>HU"LX1E[.6DK69^F=%51>V[+N#@C..,9R.HVYSD=P1D\8!R,UI-7LX
MW$9,K$R-&3''Y@5U(&'V%BFXGY=P&<'.,&O<4HMV35[-OR4;7;[6YHWOM='S
M23;26K>RNKOT[_\ #]F:=%9C:K;K(8REP2%W9$8VD?(<!BX&[Y^%.&)5PH)4
MBF2:S:1YW)<X6-9'(A)"!F"A9"6&Q@6 8-C;G!(/%4K/ELT^9RC&S3O**O)+
M75Q6K6ZUOLQ;7OI:R?ES2<8W[7DFKO30UJ*HC4;<EAE@R,4=3M#(P .'4OE0
M<C#$!1SD@ FL[4?$VCZ1:W=_J=U'8:?I]I<W^HZC=S6]M8:?9V<;S75U?7D\
M\=O:V]M#'++//+(L,,<3O*Z* 2G**YKR2Y$W.[2Y5&*E)N^UHRC)]DT]F-)R
M<(Q7-*I.-.$5JY3E)PC%)7;;DG%:;IHWZ*\X^'OQ9\ _%;PII_CGX=:_:^+?
M"6JW6I6FG:_I&9M,O9-(U"?2[Z6UNFV17-K'>VMQ'%>0-):W*1--;RRPXD/1
MZMXN\.Z#:+?:YJUCHUH^\BXU2\M;&((C;6D:2XGC18E/+2%@BJ0S, <UG1K4
M<11IXBA5IUJ%:G"M2K4YQE3J4JD5*%2$DVI0E%J2DM&G?8JK3J4*M2A7ISHU
MJ,YTZM*K&5.=*I3:4X5(S2<)1;2<96:>EKIG0OMP Q #$C!Q@\$]#U]<>U?B
MS_P7(^$$_C[]BO4O&EC&TNI?!/Q=X-\>I&BL)'TB\U5O!'BE1(O*0PZ5XL36
MKI0-LO\ 84'G'$:%/T@UK]IWX563O:Z/?ZWXQO4&YK?P;X=UCQ!&H*2,#_:-
MG:MI1'R$%H[Z15)7<0"2/FSX]_$'7_C1\&/BE\,;#X7WRV/Q \ >*_#37/BG
M6K#3S&^HZ->P6LXL["*\NC*EXUNL4)D1UGD3YT*;6\SB++XYKPWGV#<55AB,
MHQ<.6RDY.K0DZ+A%_%)SY'!+5NUFMSZ?@#B:7"7'O!G$5)J57)N)LHS6$)*]
M.M# X[#RJTG)IPE&=.52,T[KEYW9V:/X/)5GW2BQ<VMY&TALYT#12PW8D\VW
MFB*!721+M(YU9"KK,JR##JK#]Z?!'B"S^)/PP\/Z\KQ^1XP\*:7<72*!'&E]
M>:4L-[8QQ [?):399PP*,/,+FW52XD2OP:F@GM9IK>8JEW:7$MM<1*6S'=V[
MM%/& P#Y@N(WAD##*R#:>037Z@_L@^*KS5O@^=%CU6]AF\&>(-<T,PV\Z1I%
M9WSVVJ:)(ORF4Q0_VBRVIRH989=H^3G_ ##XLPLJ.75H-RE]6Q4:-36SC)R=
M&4*E];N7)%)Z*4G9)RN?[D\?X>EC\ORO.\+5A7A.&$J.M!JI%X?&QB\-7YU]
MBO)1<7JIMQ\CZ[\&RP:[X(T5-2B:Z273[O1M4MW4OYUU87=_H_B&.99-V^(Z
MK9W_ )4<F5:$0$+C9C\&O$WAFZ\%^*O$'A&8,Q\-^(M5\.,S,T@N(=.O9;>R
MNHWY647%FUC.DREA()XF4D2(3^S7A^T6UUGQCHBW5\L/]L6NNVGEW]PHM+?Q
M5:PWEXN PP@U\:H!A2I^T(>&=E'YG_M0>'D\/?&36I(4DCM?$6EZ+XEL]TCR
ML9IH9-.O?WC@9DAOM%C6X&3L\^$EB6(7R.%:O)4JY;%WIRP[K1LVTZT)0BH)
M+1M*4I)+5<N^C;\?@.L\)G->FINV+P5>,(6:2J249TK)NRFFU9VNY1NG'1']
M!/\ P;V_%B%O 7Q[^$.JZS!#!X:\<:/\0M!@O;Q8-MCXO\.6F@ZS!&L\B*T=
MOJOA*.X81@J'O?-?#2AF_HT_X2GPQDK_ ,)'H.X8R/[7T_(SG&1]HR,X.,^A
MK^%#_@ECXPT;0OVMO#O@_P 2:?9ZCI'Q8\,^)/!/EW\*RVT.L:=92>,-"E#O
M)'\TK>'YM-@,BRN;G4UA5<OYB?U)#X>>!UB1O^$5T1$8!E5;"UR%8 J2# 3A
MAAE^8Y5@0.I/^D/@MF3SW@3!3JU$JF55JN65&W>;5*-"O"=1N[;:Q7(G=WY%
MJME_EM],'AR'!_CGQ+&%-T\+GV"P'$V&ERVIU*-:@L'C:U*UDZ<,;@L2JC2T
MJJ=[O5_I)%K^A3_ZC6M)F_ZY:C9R=.OW)C6A%<V\Z[H)X9E_O12I(OYHQ'ZU
M^9;?#OP*0,^%-&)(SN%I%$W)]4C Z<=!_6HA\.?!BD&+0X+<@Y#6]SJ4!0^J
MF&_1@1URK*0>F!G/ZH\-:3BY6:E9W?;=[?=W_ _F#ZVM+I>?X:_$_/Y6/T^W
M+_>'YBJ6H6-CJ5I=6.H6EO?V5[;RVEY:7444]O<6EPCQ7$$T,RM'+%-&[1RQ
M.&21&*L"I(/YP0>%K2TYL-8\6Z<P^Y]@\7^(;=$'3Y(WOKA .A *CGCIG.G
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M:/\ AWY^PK_T9O\ LN_^&&^&'_S,U]?44?7\=_T&XO\ \*:W_P F'^L&??\
M0[S?_P .6-_^7'R#_P ._/V%?^C-_P!EW_PPWPP_^9FC_AWY^PK_ -&;_LN_
M^&&^&'_S,U]?44?7\=_T&XO_ ,*:W_R8?ZP9]_T.\W_\.6-_^7'R#_P[\_85
M_P"C-_V7?_##?##_ .9FC_AWY^PK_P!&;_LN_P#AAOAA_P#,S7U]11]?QW_0
M;B__  IK?_)A_K!GW_0[S?\ \.6-_P#EQ\@_\._/V%?^C-_V7?\ PPWPP_\
MF9H_X=^?L*_]&;_LN_\ AAOAA_\ ,S7U]11]?QW_ $&XO_PIK?\ R8?ZP9]_
MT.\W_P##EC?_ )<?(/\ P[\_85_Z,W_9=_\ ##?##_YF:/\ AWY^PK_T9O\
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M^&/ Z06VIM/J&MWT;2:;X:TI5N=:OU7C?%;LT*00!]JR7-U+!!'N&7+,B/\
M-/B+7_&WQ!WIXEO'\/\ AZ60LGA+P]=R*MU;C_5KK>NPI;W%^&R8[BRM$@M
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MK+_WR?\ "J,DGBK1PS>)/"&HK''DRZGX7>/7].*G&9;J.)+>]LESC:LL#'.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY-1?-:S=GM'9.VEW;2YZ]13$8% <]B3DYP03N![\$$?ABGUD;A1110 4444
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MS^%-J<C(Q3=@]3^G^%(9%43(>3QW/^>*F88)'^>E(>01ZT$2BW:WG^A58$C
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M35W7]?+\[Z?J-)VLDUK?YWC;]?Z19\OTQCM_D"FLAVGD?KZ_2KGEXX).1WX
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M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'A#P=XC^(/C9X&!33[^_T^2#PR;E4+ 2Q77]DK!%,JM/9:^UW%NBC+'],3&
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M)]KZ:VM9:V;^_P#I>G44T,&"D$,&&0RD%2,9!!'!!'0CK3JP-0HHHH ****
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M@].^#@_F "/J#67>>'KB2:.[M0D=VAPY)41SQ<;HY4(*MG@!L;P.]=M00#U
M/UIJ<H[/[]?S!PB^G]?U^)R*:1<E06C16YRH9<*02,+P?E&,#G@8%._L>X_N
M+_WT/_B:ZRBG[27?^M/\OZLK+V<>WX^G^2.3_L>X_N+_ -]#_P")J*30IY04
MD16C9&1HR1M;=T9L 99?X",%:['&?_UD?RI,#W_,_P"-)SD^OX+R_P D-0C'
M9:VMN_+S\D86C6]_8HUG=%'MXMBVC^:&D,? V.#UV#@$9+8R>3D[U)M7C@<=
M#CD?CUI:3=W<H****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>nt10016217x4_graphic03x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic03x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MW_\ +&C_ (:?_9S_ .BX_"K_ ,+OPW_\L:_SEOL]O_SPA_[])_\ $T?9K?\
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M ,-]#R_ZB?7\/,/^)T,Z_P"B$RO_ ,/>+_\ F _T:?\ AI_]G/\ Z+C\*O\
MPN_#?_RQH_X:?_9S_P"BX_"K_P +OPW_ /+&O\Y;[/;_ //"'_OTG_Q-'V>W
M_P">$/\ WZ3_ .)H_P"(#Y?_ -%'C/\ PWT/+_J)]?P\P_XG0SK_ *(3*_\
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MJ'_$Z.=?]$)E>]O^1WB]][?[AO;6Q_HU_P##3_[.?_1<?A5_X7?AO_Y8T?\
M#3_[.?\ T7'X5?\ A=^&_P#Y8U_G)^79EVC$=N70 L@2,LH.W!(QD [EY/'(
MI_V>W_YX0_\ ?I/_ (FC_B V 3L^(L8FMU_9]&ZV_P"HGU_ /^)T,Z_Z(/*_
M_#WB_P#Y@/\ 1I_X:?\ V<_^BX_"K_PN_#?_ ,L:/^&G_P!G/_HN/PJ_\+OP
MW_\ +&O\Y;[/;_\ /"'_ +])_P#$T?9[?_GA#_WZ3_XFC_B ^7_]%'C/_#?0
M\O\ J)]?P\P_XG0SK_HA,K_\/>+_ /F _P!&G_AI_P#9S_Z+C\*O_"[\-_\
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M]GM_^>$/_?I/_B:/^(#Y?_T4>,_\-]#R_P"HGU_#S#_B=#.O^B$RO_P]XO\
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M%_\ S ?Z-/\ PT_^SG_T7'X5?^%WX;_^6-'_  T_^SG_ -%Q^%7_ (7?AO\
M^6-?YRWV>W_YX0_]^D_^)H^SV_\ SPA_[])_\31_Q ?+_P#HH\9_X;Z'E_U$
M^OX>8?\ $Z&=?]$)E?\ X>\7_P#,!_HT_P##3_[.?_1<?A5_X7?AO_Y8T?\
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M (@-@/\ HHL9_P"&^CY7_P"8GU_ 7_$Z.=?]$)E??_D=XO;O_N!_HT_\-/\
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M'_$Y^>6B_P#4+++2ORO^VL7:5G9\K^H6=GH[;,_T:?\ AI_]G/\ Z+C\*O\
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M^SV__/"'_OTG_P 33_X@/E__ $4>,_\ #?0\O^HGU_#S%_Q.AG7_ $0F5_\
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M $0F5_\ A[Q?_P P'^C3_P -/_LY_P#1<?A5_P"%WX;_ /EC1_PT_P#LY_\
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M3=1PC)QBY))M)NR****XSU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "OK;]@G_D]7]E__LL7A+_TL-?)-?6W[!/_ ">K^R__ -EB\)?^EAKR<_\
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M.@LM(_X3=XK.+3EM;*QACMX+O6M/UFR\S$8$LEB[L=P.?LZ#Q[^SO_P42_8
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MC\ /8  ?D,"BOI?_ (8Q_:Z_Z-E^./\ X;GQ#_\ (M'_  QC^UU_T;+\<?\
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MM%AB;RURAVC&#7TO_P ,8_M=?]&R_''_ ,-SXA_^1:/^&,?VNO\ HV7XX_\
MAN?$/_R+3AFF34XJ%/,,LIP6T88K"PBKVVC&HDKW73J*KPQQ?7FZE;AWB6M4
MDHIU*N49I4G)1C&,4YSP[DU&/+&-WI%)*R6GS117TO\ \,8_M=?]&R_''_PW
M/B'_ .1:/^&,?VNO^C9?CC_X;GQ#_P#(M5_;&4_]#/+_ /PLP_E_T\\T9_ZI
M<5?]$SQ#_P"&7,O+_J&\T?-%%?2__#&/[77_ $;+\<?_  W/B'_Y%H_X8Q_:
MZ_Z-E^./_AN?$/\ \BT?VQE/_0SR_P#\+,/Y?]//-!_JEQ5_T3/$/_AES+R_
MZAO-'S117TO_ ,,8_M=?]&R_''_PW/B'_P"1:/\ AC']KK_HV7XX_P#AN?$/
M_P BT?VQE/\ T,\O_P#"S#^7_3SS0?ZI<5?]$SQ#_P"&7,O+_J&\T?-%%?2_
M_#&/[77_ $;+\<?_  W/B'_Y%H_X8Q_:Z_Z-E^./_AN?$/\ \BT?VQE/_0SR
M_P#\+,/Y?]//-!_JEQ5_T3/$/_AES+R_ZAO-'S117TO_ ,,8_M=?]&R_''_P
MW/B'_P"1:/\ AC']KK_HV7XX_P#AN?$/_P BT?VQE/\ T,\O_P#"S#^7_3SS
M0?ZI<5?]$SQ#_P"&7,O+_J&\T?-%%?2__#&/[77_ $;+\<?_  W/B'_Y%H_X
M8Q_:Z_Z-E^./_AN?$/\ \BT?VQE/_0SR_P#\+,/Y?]//-!_JEQ5_T3/$/_AE
MS+R_ZAO-'S13)/\ 5R?[C?\ H)KZ:_X8Q_:Z_P"C9?CC_P"&Y\0__(M,D_8P
M_:Z\MQ_PS+\<22C@ ?#KQ!UVDXYMAUZ4XYQE*:;S3+__  LP_;M[2_5?U<F7
M"7%;32X8XAUM_P R7,NZ_P"H;S1_;'_P3:_Y,7_9A_[)1X?_ /0)*^X:^-_^
M"?OASQ#X/_8T_9T\,>*]$U/PYXBT7X9:'8:QH>M6<VGZKIE]"L@FM;VRN$6:
MWFC;Y620*W<J,XK[(K^%,]E&>>9S.$E*$\TQ\H2BTXRB\34:E%K1Q:U36C5F
MM&?[*\&0G3X/X5IU(2IU(<.9)"=.<7"<)QRW#*4)PDE*$XM.,HR2E&2:DDTT
M%%%%>4?2A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %-V)DG:N6ZG:,GMR<<\ #FG44 -V)_=7_ +Y'
M^%&Q/[J_]\C_  IU%*R[+^O^&7W -V)_=7_OD?X4;$_NK_WR/\*=119=E_7_
M  R^X!NQ/[J_]\C_  HV)_=7_OD?X4ZBBR[+^O\ AE]P#=B?W5_[Y'^%&Q/[
MJ_\ ?(_PIU%%EV7]?\,ON ;L3^ZO_?(_PHV)_=7_ +Y'^%.HHLNR_K_AE]P#
M=B?W5_[Y'^%&Q/[J_P#?(_PIU%%EV7]?\,ON ;L3^ZO_ 'R/\*-B?W5_[Y'^
M%.HHLNR_K_AE]P#=B?W5_P"^1_A1L3^ZO_?(_P *=119=E_7_#+[@&[$_NK_
M -\C_"C8G]U?^^1_A3J*++LOZ_X9?< W8G]U?^^1_A1L3^ZO_?(_PIU%%EV7
M]?\ #+[@&[$_NK_WR/\ "C8G]U?^^1_A3J*++LOZ_P"&7W -V)_=7_OD?X4;
M$_NK_P!\C_"G44679?U_PR^X!NQ/[J_]\C_"C8G]U?\ OD?X4ZBBR[+^O^&7
MW -V)_=7_OD?X4;$_NK_ -\C_"G44679?U_PR^X!NQ/[J_\ ?(_PHV)_=7_O
MD?X4ZBBR[+^O^&7W -V)_=7_ +Y'^%&Q/[J_]\C_  IU%%EV7]?\,ON ;L3^
MZO\ WR/\*-B?W5_[Y'^%.HHLNR_K_AE]P#=B?W5_[Y'^%&Q.NQ<YSG:.O3/3
MKCBG44679?U_PR^X HHHI@%-VK_=7\A_A3J* &[$_NK_ -\C_"C8G]U?^^1_
MA3J*5EV7]?\ #+[@&[$_NK_WR/\ "C8G]U?^^1_A3J*++LOZ_P"&7W -V)_=
M7_OD?X4;$_NK_P!\C_"G44679?U_PR^X!NQ/[J_]\C_"C8G]U?\ OD?X4ZBB
MR[+^O^&7W -V)_=7_OD?X4;$_NK_ -\C_"G44679?U_PR^X!NQ/[J_\ ?(_P
MHV)_=7_OD?X4ZBBR[+^O^&7W -V)_=7_ +Y'^%&Q/[J_]\C_  IU%%EV7]?\
M,ON ;L3^ZO\ WR/\*-B?W5_[Y'^%.HHLNR_K_AE]P#=B?W5_[Y'^%&Q/[J_]
M\C_"G44679?U_P ,ON ;L3^ZO_?(_P *-B?W5_[Y'^%.HHLNR_K_ (9?< W8
MG]U?^^1_A1L3^ZO_ 'R/\*=119=E_7_#+[@&[$_NK_WR/\*-B?W5_P"^1_A3
MJ*++LOZ_X9?< W8G]U?^^1_A1L3^ZO\ WR/\*=119=E_7_#+[@&[$_NK_P!\
MC_"C8G]U?^^1_A3J*++LOZ_X9?< W8G]U?\ OD?X4;$_NK_WR/\ "G44679?
MU_PR^X!NQ/[J_P#?(_PHV)_=7_OD?X4ZBBR[+^O^&7W -V)_=7_OD?X4;$_N
MK_WR/\*=119=E_7_  R^X!NQ/[J_]\C_  I0JCH .W  X]*6BF 4444 (54]
M5!^H!I-B?W%_[Y'^%.HH ;L3^ZO_ 'R/\*-B?W5_[Y'^%.HI679?U_PR^X!N
MQ/[J_P#?(_PHV)_=7_OD?X4ZBBR[+^O^&7W -V)_=7_OD?X4;$_NK_WR/\*=
M119=E_7_  R^X!NQ/[J_]\C_  HV)_=7_OD?X4ZBBR[+^O\ AE]P#=B?W5_[
MY'^%&Q/[J_\ ?(_PIU%%EV7]?\,ON ;L3^ZO_?(_PHV)_=7_ +Y'^%.HHLNR
M_K_AE]P#=B?W5_[Y'^%&Q/[J_P#?(_PIU%%EV7]?\,ON ;L3^ZO_ 'R/\*-B
M?W5_[Y'^%.HHLNR_K_AE]P#=B?W5_P"^1_A1L3^ZO_?(_P *=119=E_7_#+[
M@&[$_NK_ -\C_"C8G]U?^^1_A3J*++LOZ_X9?< W8G]U?^^1_A1L3^ZO_?(_
MPIU%%EV7]?\ #+[@&[$_NK_WR/\ "C8G]U?^^1_A3J*++LOZ_P"&7W -V)_=
M7_OD?X4;$_NK_P!\C_"G44679?U_PR^X!NQ/[J_]\C_"C8G]U?\ OD?X4ZBB
MR[+^O^&7W -V)_=7_OD?X4;$_NK_ -\C_"G44679?U_PR^X!NQ/[J_\ ?(_P
MHV)_=7_OD?X4ZBBR[+^O^&7W -V)_=7_ +Y'^%&Q/[J_]\C_  IU%%EV7]?\
M,ON ;L3^ZO\ WR/\*-B?W5_[Y'^%.HHLNR_K_AE]P#=B?W5_[Y'^%&Q/[J_]
M\C_"G44679?U_P ,ON ;L3^ZO_?(_P *-B?W5_[Y'^%.HHLNR_K_ (9?< W8
MG]U?^^1_A1L3^ZO_ 'R/\*=119=E_7_#+[@$  Z #Z#%+113 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *#Q_G_/^>:*XOXC>,].^'7@+QCX\U=BNF>#_#6L^([[&W)M
M]'T^XOY$ 8J"SK 54;@2Q !!J9SA3A.I4DHPIQE.<GM&$$Y2D_))-OR14(2J
M3A3@G*=2<:<(K>4YR48Q7FY-+YGDWQI_:T_9Z_9[N].TSXM?$WP_X5UC5H_M
M%CH<LEQ?ZW+9YVF_?2-,@O-0AL 00U[-;);@@CS#BO4OAS\3O /Q<\,67C/X
M;>+-#\9^&-04&VUG0+^'4+)GQEX)'B.Z"YA/RS6MPD5S"W$L2$C/\[7PETS4
M?&%OJOQS\?0IK'Q-^-=W+XYUS5;^*&[N-)T;66:[\,^$M(-TDG]FZ+HFB365
MG%86FV)G1W<R.2]=W\-?B++^QA\9(?BMI=G=6_P)^(UW;Z+\>O#NDQ.]CX<U
M)Y3#X=^*^E:3%MAM1837,EEXO-JD2W6G2)>M&TEJ ?R3 >)TJ^;1IXO!T,/D
MM>I&E1Q2E5^L4(SERTL5B7)*DZ4U*$JT(Q@Z$'S*=7EDG^D8K@7#PP,Z>$Q>
M(K9Q0IJ<J4E2^JXJI&/-7PN'C&*J4YPM)8>I*I56)FE!TZ4JD7'^B6BLC0==
MT?Q-HVE>(- U.RUG1=9L+74M+U73IX[JQU"QNX5FM[NUN(6>*6&:-U='5B""
M.<UKU^N1E&45*+4HR2:E%J46FDTTUHTTTTUHTTT?FS3BW&2<9)M2C)6E%IV:
M:>J:>C71Z!1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445GZKJVEZ'I]WJVLZA9:5I=C"]Q>Z
MAJ%S%:6=I!$I>2:XN9W2*&)%!9GD=54 DG%&^P&A17YN_$[_ (*0_#C2+R\\
M/?!;PYK'QF\16\DT$FK:<T>E?#^PGC48%YXHN"6NDW'D:79W9(P5D.],_&?B
M_P#:*_:R^*33)J?Q'L?ACHMP2!X>^%VE6ZW*P-PT-QXJUZWN=6DG*DHTEG'9
M1CEE3TTC2E)7T2]5?RTOWZ;BOY?UI_GMY'[J:QXC\/\ A^$W&NZYI&C0*"QE
MU74K2PC"CJ=]U+&,#U&:\)U[]K_]F/PT\D6L?&_X=P31,4>"#Q#:7TP8$@CR
M[)KAC@@@GH""/3/X=-\']/UN[^W^*+CQ!XTOFR9+SQAX@UGQ!(Y;!++#?71L
M8R6YVI:QQ+U1!A:Z_3_A3X?T]0MEH&D6JD#BWTVUC]N<0CG@9QSBJ]G&VLGT
M[>2_71>0^OEU_J_^?R/U7F_X*#?LC0N$_P"%O:3-_MVVG:S/&.O61-/V@#N>
ME:VF_MW_ +)6J/Y<7QM\(VK9 SJ4UUIBC./O/?6T"J!GDL0 .<XK\LHO L"C
M MH(SC^&W@'U&55>/;I^-5[CX>V$RM'+I]G.N#@2V<$BY(_VHW[GG!]?I3]G
M"RU=WOIHMN[7GY:BU[_?;?3TW_72Q^W?A?XX?!SQJ$_X1/XH>!-?,F-D>F^)
M])N)6W=,0K=>:<]ODKU!)$E57C=9$8!E=&#HRG."KJ2K#CJ":_F]U3X*>$+H
MM)<>&-($[-N%S:6QL+E6!R'%Q9-:S@@D'Y9.OXBM#0(OBS\-I#<_#'XQ?$'P
M:8]ACTZ75F\4Z Q0_*AT7Q,FHPB(]#%'-&-HPI!QF7371_D^B[/O_5TT/IYG
M]&M%?C1X'_X* ?'+P.\%K\7_  !H_P 3="C/EW'B;X=C^Q/%44:#!N;OPMJ$
MO]F7;-_K)%L+^W(VD1PDD*/T4^"W[4/P5^/4#K\/_&%I/KELJ-J7A'5O^)1X
MLTMW4DQWFAWC)=84I(HFMA/;.8W,<S;6(AQE'=>=UJM;?=NMP/H.BBBI ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BD)P"3T'/ )_09)_"L[5=8TK0M.N]7UK4K+2=*L('N;[4M1N8;.QL
M[>,$R3W-U</'#!$@!+R2.JJ 22!4RE&$7*<HQC%.4I2:C&,8J\I-MI)12;;>
MB6KT*C&4Y1A",ISG)1A"*<I2E)VC&,4FY2DVDDDVV[)7-*@G )]!FORE^+?_
M  57^%.BW]_X6_9]\*Z_^T3XLLYI;2;4O#4L6E_#/3+M&V8U7QU>-Y$RHQ_>
M)H]GJ#$?=;N/ASQE^T?^W'\9Y)4USXM:3\%/#=R[AO"GP7T>RFU5;=OF%O>>
M._%%GJ&I_:$3,;7&E6VG1.Y9E"+@C\US?Q7X7R^I/#Y?+%<0XN#E"5/)J=.M
MA:<XNSC6S*M4HX!6E>,U1KUZL&O>I6:/U#)_"'BO,*=/$YHL%POA*D8U%4SV
MK6I8R=.24E.GE.%HXK-$I1:=.>(PF&HSNK5M3^AS7/%GAGPQ;F[\1^(-$T&T
M7)>YUG5;+3($ _B:6]FA0+P<G=@8X)S7S7XF_;O_ &//!\DL&O\ [1?PIM;F
M%RDEK;^+--U"Z#*V& @TZ6ZD..O3/J!@X_ G_AG/PUXANSJGC>?Q9\2=6D8R
MW&I?$/Q7K?B>>::0ER_V6^OO[.B!;+-';VR19V_* JUZ)HOP2\(:/&L6E^$/
M#.G1@#BUT/38B<C(W;("6.?4M@Y.><U\77\5N+,2Y/+^',IP%/[$L?CL5F51
MKHW3PM++J<'T<57JV;?+*229]KAO"7@[#)?VCQ-G68U/=YHY?@,#E5)/3F4:
MN,KYI4FOY9/#4W9IN%]#]8[C_@J3^PQ [)_PO31KC:Q4M9Z/XBNT.,#<LD&D
MO&RGU#'C!Z&M;2O^"F/[#NK2)$G[0?@VP>0@+_;/]IZ0FXMM :6_T^&-/^!,
M/RYK\LX_AW:1KM2RM(QC;MCM+=%VCH-JQ@=\<#IQ52Z^%^DW*E;C2-*N%;AU
MN=-LY58$8P5:!@>/45QQ\2/$%.\L/PQ*-T^599FD7;JE/^VY)?XG3EMI'OVR
M\-O#:2Y8U>+(2VY_[:RBIKIKR/AR&U[\O/KJKK1G[J>#OVF/V?/B"0O@KXT?
M#/Q)*Q %OI?C+0Y[D[L[3]F^V+<#..,Q >]>UPW$%Q&LL$T4T3@,DD4BR1N#
MT*NA96![%2:_EWUW]F_X:ZNQ:\\">&VF4AEN[73(-,NE;.?DO=.6WNU([,LJ
MD'I@$YC\/>"_BA\*)Q>_!CXY?%WX:21'=%IL/B0^+_"[;2&2*?PYXQ&KV30%
M@ ZP-:G8 JL 37IX3Q=SN@TLXX5HUJ::YZN3YC-5DNO)A,PPU*C-VN[2S*F^
MCLES'E8OP?X?Q*;R;BW$X6;7N4L[RN$Z"=E95,=E>*JUXK5WE#*9)6U2OI_4
ME17X(^ O^"B_[5GPO,-K\9?ASX9^/'AF' N/%'PTSX1^(<4*@LTUQX1U*7_A
M'=5F5 1(FEWVF[G&Y(L!R?T]_9Z_;5_9\_:55['X?>-K>#Q?:Q[]4^'?BB(^
M'?'FE8V[_M7AV_9+J:*,NJ_:['[59N65DG970G]!R#Q$X6XAJ4\+A\=/ YC4
M^#+,VI/ 8VH]$UAU5;P^,LW9O!8C$I--MVU/SWB'PUXMX<H5,=B,##,<JI:S
MSC)JJS'+Z46THRQ;I)8K+N9M*,<SPN#G)M*,6V?6-%(&5NA!Q@\<CG..>AZ'
MI2U]P?!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\Z_M-
M?M)^#/V8?AXOCCQ59:KKVHZKK-GX6\&>#O#\,5QX@\8>+-2CFDL-$TN*66*&
M,M%!-<W5W<RQ6UE:PRSSR*  WYOR_MS_ +;&IS/?:9\&_@+X:L7=FA\/^(_&
M'B_5]=CBR=L5YJ&B6:Z9]I*8\Q;;=&C957<88_.9OQ7DF25X87'XFHL1."J>
MQH8>MB)QA*_+*I[*$HP4N5\JDTY)72MJ>]EG#>:YM0>*PE*DL,INFJ^(Q%'#
MPJ5(VYHTO:SC*IR\R4G!.,7HVG=+]JJ*_('0_P#@HM\=M =5^)W[*\^LVN$\
MS4O@_P".-+UR0#&7:/0_$<FEW\I #$"*9B<H,9)(].A_X*A?"7R56Y^#?[2E
MIJ!4DZ?+\*IY'4@D%6N[?4Y+ $'@L;A5).<@9(PP_&O#&(@YK-J%"UDXXN%;
M"S3DKI6KTX*3?:+D^VAK5X3X@IRY5E\JZ_GPM;#XJGTU<J%6?+'5:R44KZV>
MA^F%?G__ ,%,O'-CX7_9)^(7AE;D_P#"3_%3^ROAGX.TF!U-]K>L>)]6L[.X
MM+2$.LDBP:6;VZO&0'R;:)V;J,^.>(O^"B?Q,\31M9?!C]EWQG'>7&8[7Q#\
M9-5T?P7H%GN)"W5QI>GW^I:_>(!\_P!FMXHY9,"/>N2R_.-G\/OB5\2?']I\
M7_V@?%T?CWX@:;!<VGA31]+LWTWX??#BRO0PNX?!^BS%YY=2NED*7NOZH\FH
MW4:QQ@PPH$/A<0\9Y?7P&*P&3.>88G&4IX5U:=.I3PN'A7BZ=2I.M4C#VDXP
ME+V=.@JO-4<%.5.'-./K9+PSBL+C<+F&;.CA:&$K4\2L-[:E5Q6(J49QJ4Z7
MLJ,JCH4YRBE4JU^3E@W*$*DK0>MX7\,C2M(T?2D5?+TO2=,TU O*!-/LK>S5
M4X V!8E"G@;1P*Z"[\.PWUK<6MU:P7-K<P2VUS;SQQ303V\Z[)H)HI R21S1
M[D>-P5="RD'((]5L/#;1HBF/@   !@0%XYSNR>#SNZY("@8&ZF@(0,QN..^?
M\X_7^GYMALG?)"/+HHQBM6M$DFI::IK1IJTMK-.S^JJ9BG.4W)N3;;=[6DVF
MY123UOJG>Z>JU5SY#^'W_"_?V7[N9_V<_%>FZG\/I;J6]N_@1\2C>WGA&TDD
MF::Z?P'X@M-^K>$#>.\A_L]WGT99F61+5$!(^L]%_P""E^H:5%'!\5?V7OC)
MX>OD4+=W_@6#0_B%H#2J!YDEI/I^JVFI&W))V-<6$;@ AE)!HF\-HQ/[MN<_
M_6Z^O_UCFL>;PH.2%[]&R#P>A^7'.?PZ$'I7LY?CN(\GBJ& Q\UA8V]GA<32
MABJ--77NTG53J4X]H4ZD::3=HZ7.7%PR?-*CJX_ 4:N(:]_%495,)B9NT4Y5
M949JE6J/>56K1E4D]93;;/06_P""H_P)5!_Q;S]H8S][8?!_7#*I]-PF,)YX
MSY@ZBH7_ ."I7P43:P^%G[1[QXS)(/A)?J(AZLCZ@LC <9$:L0/H:\SF\+8R
M0&Q@GY <]<\_+TX/TQZ8%9<_AI@.8V'&=QW9X'7&/8@]/7TKMGQ?Q?&W[S+=
M'JGEU2W3JL7?7K;[T<L<AX9EMAL>W?KF4%VVM@_Z^1]*^!_^"E?[*/C+6;7P
MYJ/C+6/AKKU_*D%AI_Q6\+:WX&2\GD8(D4&IZK;+I#2,S1J$>_C8EQCC!/WK
M!/#<PQ7%M+'<6\\:RPSPR)+#+$X#))'(A971U(9'4E6'(/(S^'OBCP+I/B/2
MKK1_$&DV.MZ3>1/!>:;J=E!>VES%(H5UDAN(I5P1C[@C?L9,#%<!\*OB]\1?
MV&-4A$4NO^/OV4YKEO\ A)/!EQ+<ZYXK^"4=Q)EM?\$/*7O-2\$6H)FU3PY*
MUS<:9$\DFGE4A>.;T\H\0<53KPP_$.'P\*-22A',,%"I2A0;:5\5AZM6O+V3
MYHN5:E47LDG*5*4&YPX\?P?A<13<\DJUHXF*;CE^+J4ZKQ.B]W#8F,*"C7NK
M4\/5IOVTI<L*RFH4Y_T#45R_@SQIX6^(/AC1?&7@S7-.\1^&/$5A!J>BZUI5
MS'=6.H6-R T4]O-$Q!4A@&1L21/F.54D!4=17ZK&49QC.$HSA.*E"46I1E&2
M3C*,E=2C)----IIIIV/SZ490E*$XRA.$G"<91<91E%VE&46DXRB])1:33T:0
M44451(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%!. 3Z<U^8?[6W[:6HZ+J^J_!'X W=K>>/[<"T\<^.W03Z-\.(;@!6L[1R?)
MU/QA*C!;:QC$L6G/(EQ>X*"%FDWH@/=_VDOVRO 7P#<>%-.MIOB!\6M0MS)I
M/P^T&6+[3:K( +?4?$U\["VT'2=SJ6FNG$\R*YMX7P2/R4\=:]\6/VB=475_
MC7XE_M73$N6N=*^&GAZ2XT_X?Z("PDB62W5EG\27,2@1R7^KR30M)YACC4.B
MK7\#?#N"PDN[N22_U;6M;O7U+7_$>KSO>ZYK^J3L[3ZCJE_(&EFGD+$I&#Y%
ML&:."-%+%_ICPSX'WJG[EN",YW=AUR%(_P#U]0,BMXQ4;)*[OJ]-5NE:SL_F
M_3<EM+1O?I^G_#GDOA_P'';P06UM:PV]M"BI#! B1PPHN-J11JH6-5&%"HJ@
M  #I7J^D^ Y"%)A7!(S]W'7IDCD<>Y..U>_Z%X&1!&3'@X YSD  <\K_ /JZ
M=Z]1T_PA%&BY0Y'KD],<#C_/;I5).U[M+_@QU[^ENUGW%>3V5K];7[:]--?/
MT/F>U\ E<'RAZ_>/YXVD?ICGCFM6/P5M'S1 D=,8Z?\ ?(_0?C7U+%X9A51^
M[8\=@QY!'<+ST]_2FS^'8@O"$ ]B&&<>GR@GZ#THLM-?QZZ=+/\ 6]K]+!RM
M_:?_  UO/T_,^6'\*%#C8H' YP/IVQV_SBH6\+]A&A)Z]#^H_P _I7T9=:"L
M61M&T8Z ^^.-N<]L5C2Z2F,A3C)ZY/.?7&1@_GG&><T*-U\_Z6K2]+7\VC-J
MVJU7?I>R>UO71_HSYYN?"@8']R,=\8R23CH0>OI@^^!7,7WA13D")>_! '3U
MX].WX<"OIN;1UY^7/IMSZ]P0.O?MU]ZP[S1%<'Y"1SP<CN1Z<_3UZ\8P6:VZ
M]KKM;>U[].]M-A\S[]]_/^KZ^GK\AZIX2S_RQP5S@@D8R23P, Y/)R!]:\7\
M4_#*QU*]@U9$N],U_3',VD^(]#NIM-\0Z5.C!X9;/5+1H[Q1"ZHPB>5XG"!'
M1T9E;[UU#PZCH<(RG#=.>><8XZ_ER<9ZUYUK'AH<@Q["20"S ,689 (Y SM.
M,XW#H>*2O?9NRWLVEVOI9)[)MKI:[+4T]'9-NR5]7\MW\KV6KLE<Q_@W^W1\
M2?@_/9^&OV@8[KXB?#\/#:VWQ1TFR_XJ[PU;@E5?QIH]O'%%K.GP1C=+K.F1
MB\C2-WN;:0AI*_87PGXL\-^.?#VE^*_".M:?XA\.ZU:QWFF:OIEPES9WEO(,
MJ\4B$@$'*O&V'C<%' 8$5^&NO>&%(DQ&W(<$=%;(P0VY&&UL8(93P<%?7A/A
MK\0_B+^RSXKF\4_#1;K7/!.I70N/'OPFFF?^SM7AR%N-;\)QG,>B^)XH]S[(
M?+L=1/[JZC&(V6)0OJK)^>E^_P ]?5E>GW7]/)[:[.WYG]$]%>6_![XP^!?C
MEX'TKQ]X U5-2TC48]ES X,.HZ-J4)*7NCZQ9/B>PU*QG#PSV\Z*V5\Q-T;(
MY]2K%JVC&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 44UFVY)!P!G(Q[\<D>@Z]21COC\EOVU/V\=7\*:_??L\?LS2Z9K/
MQC\J.+QUXYN(A?>%?@SIMS&"7NRG^CZIXXF@DC;2/#\?FI:K*MWJ*I'$8W\+
MB+B/*^&,NGF6:UG3I*7LZ%"FE/%8S$R3=/"X2C>+K5ZEFTKJ,(*=6K.G1IU*
MD?H.&N&<VXKS.&6931C*?)*OBL57E['!9?@Z;BJV-QV(:<:.'I<R3>M2I4E3
MH4*=6O5ITY?0_P"UA^W7\,?V96@\'Q6MY\2?C/KEIYWAOX3>%6CFUJ6*4$1:
MKXBNV;[+X;T!7!\S4-09'D /V2&=@17XN?$'4/CC^U/J<6L_M(>+I;W0&N3<
MZ1\$_!<]]IOPRT2-6S;IJBJT6I>,KZ'&+B[U>YFL7D5A!9B,4_X9?"&UT*34
M=5N;K4_$?BOQ)<'4O%WC7Q#=2ZEXH\5ZI<$23W>K:A<AI"%ERMO9PE+2WC/E
MP11;%)^N_"G@3S/*S">@Z;L\CK]W/7IV(SZ '^=\US?B/CNO+^T*DL%DTI+V
M&0X2K)X5T^:#C+,ZT?9O,Z[2?M(5$\!!M>PHRY?;5/Z/RG*^&_#Z@EE4(XW.
MH1MBN),71A]<=1QM..3T9>T6485-OEG3D\RK1UQ&*A!_5:?C/A7X;VME9VNG
MV.G6MC8VBI%;65C#':VL$2#'EQ00JL:)SNV!2 03]/:-(^'Y.S]R.@P,[N.>
M,E#@8Z#H!C&,5]!^'OA^F(R8CD;3U( X&,G;G)Q['VXY]=T[P7$BJ3&0  !C
M(QC/^R#CCD'/.?I7T65<(0IP@I4U&+4%%<B22BDE:TMHI1BHI))62T5CYG->
M,)2J3Y:DI.4I2DY.[E*;3DVVU=R;<I:MMMMZNY\LV7P^?'$"C..NT]<D<XR,
MYQSZ8S6NO@-HQEHEP.N-@'M@;<]>>W3GI7UJGA6!5 $9ST.,D<>G ]^U13^&
M(@I(0DXZ8/0GGJ,^OKWQCO\ 2+AF$(VY$[J^S757V=E]UK_(^:GQ/5F_CT;6
MB_[=OUT3UTMI9H^3#X0 ./(7\D'YY&>OU_I5=_"8VD^2I_W0N<?B.?R/Y9KZ
M9O?#\:#E",9Z]>_Z>F#^%8$^CKNP5)QZ[CVZ\9[$?R[5S2R2E"]X+3OIU7EY
M]]G=&]+/*DDGS/UOKKR]MOOM:_H?.-QX20JV80,@DCY<=NVW&>G -<K?>$!M
M;;"!ZYP?_9?K7U3-I"8(V]!C !XZGN >AY[CG.>_/W>@1."=GXG=G)X]#^7!
M%<-?)*;5^1:O\VFMEMYZ'H4,[FFGSNWY.R[N^_X_(^-=5\'+N9_* < X.0,
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MF!I2S?*NP'+<#GBOSJ_X)7_L]?#;X;?LU?#GXP>'[35+OXC?&CX=>%-6\?\
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MP=HYS@?RYS[C\:TLDDWJ]U>_2VG^6U^]C/9MRU>BMH][;+T_3<H6&C)&%(X
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M1D=#R**9&040C."BD9ZX(!&>O/KS3Z_I@_EW^NP4444 %%%% !1110 4444
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M@ 7)V@9I8_!WA.+0)?"L7AC0(?#,\,EM/X>ATC3X]$FMY0!)!+IB6R6<D4@
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M'MV_PXI[^"O"$FHZ1K#^%_#[:KX?M7LM"U$Z18?;M&LY %>TTNZ^S^?86SJ
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MOJ1?0;?6O[+BGM==LK9%")>.)#+'/N8[P2.]>L?\$T_'GC;XC_LQZ9XE\?\
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MRYTW*K[.K6Q%&KCZ$ZLY5*U&M2KT<315*K'DQ'+4GAZZA3I3K\'\%(O^$/\
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M2ZQ&QKX_'<2<,Y7C<?E^:SP&74L%'+L35Q&+>"AAJN(S'ZY]7A[/GE6CB.7
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MU8RE]FWGP\\":A>:KJ%]X,\+7M]KEJUEK-[=:#I4UUJUF_#VFHSO:>;>6[@
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M\?),T22_K?:[_ R]4OFNIY7W%AG )/4#^N0!G@D<$9S6)2LQ8Y/3T_\ K_\
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M0Z7971;A@21\I 8'^D6PLH-.L;/3[5%BMK*V@M((U "I#;Q+%&J@  !54
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MUTW9\M?&36X]&\*>+M79]JZ7X<UR]8]_]'T^Z=5 )4?,RA1@@Y("@\9_9?\
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MUX';ICVXSU[5XWHEXN!DXX!'(_,=#@\^@->D6%VF%''3/?V&>.W&>3CTKZO
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M?2M"\NPJD^@Z>OX9Z?SYY]?/M:U(*C'..N<'N>W/IR>1QC\*F4K;?KH]&O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$8//X>G-:1BH^NU_NV_JYE*7,67D"?7_ #_GJ*R[J\50^6QCI[^V#SP3T_\
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MUM=(3%(C1C.T'>&X(QT^P/#OB+A!Y@#%1R<C))/!S@_0XP><$CFO1+RR\/\
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M<^QX]8B?^(#KT(ST],@]>G7/2I6U9%ZL#GU([?\  O>O!K/Q0' _>*V>2X;
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M*=\1'$JHJ;HJG%R<IN;7+R-JHI*4&XM,[>'9Y9Q)EF7YUDF-PV8Y3FF$IX_
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MK\T(4E*:CS4[]91117["?FH4444 %%%% !1110 4444 %%%% !1110 4444
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MJM>O6J/FG4J3DVY2D_DE:,4HI)%%%%=)R!1110 4444 %%%% !1110 4444
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MORV_X*NZ18K^SUI>J0V%FE^GQ#\-*]\EK MV(I6G1U^TJBS%6'5&D*L0"5.
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M"@8QTQ@<8R<4ZBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGC,70P\ZL(2493IQJSBYQC*2C*44TFTF[M'Z6T5^;O\ P];_ &0?^@I\7O\
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M_P"D5%?F[_P];_9!_P"@I\7O_$?OC3_\Q%'_  ];_9!_Z"GQ>_\ $?OC3_\
M,11_9>9?] &,_P#">K_\CY_GV8?ZX<*_]%'DG_ASP?\ \N_JS\K_ *145^;O
M_#UO]D'_ *"GQ>_\1^^-/_S$4?\ #UO]D'_H*?%[_P 1^^-/_P Q%']EYE_T
M 8S_ ,)ZO_R/G^?9A_KAPK_T4>2?^'/!_P#R[^K/RO\ I%17YN_\/6_V0?\
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M-/=/LS^X4U)*46FFDTUJFFKII]4UJ@HHHH&%%%% !1110 445YA\9?C#X!^
M7PT\5?%OXGZO)H7@;P7I_P#:?B#58=/O]5EM;4RQP*T>GZ9;W5]=2/++'&D5
MM;R2,S !:J$)U)QA3C*<YR480BG*4I2=HQC%7;DVTDDFV]$95Z]'#4:N)Q%6
MG0P]"G.M7KUIQITJ-*E%SJ5:M2;484Z<(N4YR:C&*;;21Z?17YN+_P %7?V/
MF56&K_%PJRJZ,/@!\:&5T=0Z2(R^"65D=&#(P)#*01P:7_AZW^R#_P!!3XO?
M^(_?&G_YB*[?[+S):/ 8Q/L\/57;^YY_U9G@_P"N'"O_ $4>2_/,\&OP=:Z_
M/1^1^D5%?F[_ ,/6_P!D'_H*?%[_ ,1^^-/_ ,Q%'_#UO]D'_H*?%[_Q'[XT
M_P#S$4?V7F7_ $ 8S_PGJ_\ R/G^?9B_UPX5_P"BCR3_ ,.>#_\ EW]6?E?]
M(J*_-W_AZW^R#_T%/B]_XC]\:?\ YB*/^'K?[(/_ $%/B]_XC]\:?_F(H_LO
M,O\ H QG_A/5_P#D?/\ /LP_UPX5_P"BCR3_ ,.>#_\ EW]6?E?](J*_-W_A
MZW^R#_T%/B]_XC]\:?\ YB*/^'K?[(/_ $%/B]_XC]\:?_F(H_LO,O\ H QG
M_A/5_P#D?/\ /LP_UPX5_P"BCR3_ ,.>#_\ EW]6?E?](J*_-W_AZW^R#_T%
M/B]_XC]\:?\ YB*/^'K?[(/_ $%/B]_XC]\:?_F(H_LO,O\ H QG_A/5_P#D
M?/\ /LP_UPX5_P"BCR3_ ,.>#_\ EW]6?E?](J*_-W_AZW^R#_T%/B]_XC]\
M:?\ YB*/^'K?[(/_ $%/B]_XC]\:?_F(H_LO,O\ H QG_A/5_P#D?/\ /LP_
MUPX5_P"BCR3_ ,.>#_\ EW]6?E?](J*_-W_AZW^R#_T%/B]_XC]\:?\ YB*/
M^'K?[(/_ $%/B]_XC]\:?_F(H_LO,O\ H QG_A/5_P#D?/\ /LP_UPX5_P"B
MCR3_ ,.>#_\ EW]6?E?](J*_-W_AZW^R#_T%/B]_XC]\:?\ YB*#_P %6OV0
MNVJ?%X]_^3?OC1T'7KX)4<=SG@<GC)!_9>9?] &+ULO]WJ];?W//^K,/]<.%
M/^BCR1>N9X))>K]MTZ^C\K_I%17E7P4^-/P]_:#^&GAKXN?"O69/$'@7Q=!<
M7.A:K-IVH:1-=0VE[<:?<&73M5M[34+5XKNUN(FBN;>*3,>0I4JS>JUQ3A.G
M.=.I&4*E.4H3A-.,H3BVI1E%V:E%IIIJZ:LSWZ%>CB:-+$8>K3KX>O3A6HUJ
M,XU*5:E5BITZM*I!RA4ISA)2A.$I1E%IQ;3/S8\:_P#*5'X$_P#9I7Q=_P#4
M[\*5^D]?FQXU_P"4J/P)_P"S2OB[_P"IWX4K])ZZL7\&!_[ :/\ Z<JGC9)_
M'X@_['U?_P!5^6C695QN(&<XS[=:_F=_X*A_M2:C\?/BQ+^R[\/[]V^%WPRU
MB/\ X6A=6$I">,_'L#Q36_AEW#&.31?"C1NVI1E7BO-9DC@8'[!,M?M#^W=^
MT,/V9_V:O'WQ$LG0^*KBR7PMX$M6P6N_&/B5O[,T;8AY86<LS:A-G"+#:2%V
M'RY_F,_9]\!W$P34]6,FHZKJ%S-J^L:K<NTUUJ6KZG/)>ZI?7,KG=-+?7]Q<
M7DKRAG,LO'W17U/"F7PBJN<UTG'#3]E@XR5U+$.*<ZMK._L(RCRO1*I.,MTC
M\%^D!Q?B^7+?#G)J\Z.*S^D\;Q!7HR:JX?(H5?94\%=)N/\ :U>%:G6=US8/
M#XBEM6N>U_"SX50VMO;8MHV9DRP$2G#.S.P4J,$DG+-R7?<S$,23?_:-\*#1
M_"OP[N!"L<8^*WA2*;"A5VM#>E%;&,?OA'L)YW<#KD_97@GPQ#;VMN?*5,1X
MS@<D@'U]\=R..0>#YO\ M9^&Y+SX'^)=0LXM]WX.U#0_&\(5=T@C\-7\5W>"
M)0=VX6(N'.T'Y$?/!%>[@\PY\VP52I-6^MT.>4G*RYJL$Y/HE'\+,_)L;PC2
MPW!F=4,-14:O]BX[V<817-.<,).:BENW-Q45K]KL].7^&FG)/;P @']S#P!T
MS$&.<?K@?7W^H--\.)- @**>GRD9[#/]>,GKUKY<^#NI075O;2QL-DT44D>"
M#N22,.AR.Q!R>!C.#TK[I\-+%-;Q':#\H/09YP,'CT_.O9SJI4IXF23LW.23
MOTZ)[WW;\G^/-P'A<+B\NH-1B[P7YIV]4K?)6Z'B/BKP2DT4H:('(/\ "2,A
M6ZCV)X/)!Y!! -?*!U?QK^S]\2_#OQI^&P/_  DOA,R1:EHOFM#9^,?"=PT;
MZSX1U(?)&;:Y@#WVE2;R;#6K6UGC11+,)/TWU/28KB"3]V"Q!X( XP>1GN.F
M/R%?*GQ,\)Q2QS,8L%%9MP4$\+D$#!)]<<],;>36.78R%93PF+4:V'Q$73J4
MY+W9TY64E=[/M:S3U5K'5Q3P_7P53#9UE%6>#S3+J]/&8'%T;*K0Q%":G"<>
M9---^[.$_<J0<H33C-H_<;X1?$_PO\9OAQX1^)O@V]-]X<\8:/;:OI\C@)<0
M>>")["\BP#!>Z?<+)9W<#@/%<0R*PZ$^CU^'7_!,?XL7'@;XC^.?V;-7NF&A
M^*1>_$SX<0SES'::O&(+7QQH5DKG_1[>1([#7H;9 (_M%WJ4D:DR,!^X@Y /
MJ!7YAG>5SRC,L1@G=TXRY\/-Z^TP]3WJ4[M*[Y7RR=OCC);IG]=^'O%M+C;A
M/*L^BH4\56I2P^9X>#;6%S3"3=#'44FW)4_;0E5H<WO2PU6C4VFFUHHHKR3[
M4**** "BBB@ HHHH ***^6?VB?VR/@5^RWJG@O1/BYKVNZ?K'Q!CUB7PKI7A
MSP9XL\::EJ4/A]+:36)UL?"FCZM<0PV,=Y;/-).D:A9,@M@XTI4:M>:I4*52
MM4DFU"G"4YM13E)J,4W:,4Y2=K))MZ(YL9C<)E^'GBL=B:&#PT)4XSKXFK"C
M1C*K4C2I1E4J.,4ZE6<*<$W>4Y1BKMI'U-17YNC_ (*M_L@D#_B:?%[_ ,1^
M^-/_ ,Q%'_#UO]D'_H*?%[_Q'[XT_P#S$5U_V7F7_0!C/_">K_\ (^?Y]F>)
M_KAPI_T4>2?^'/!__+OZL_*_Z145^;O_  ];_9!_Z"GQ>_\ $?OC3_\ ,11_
MP];_ &0?^@I\7O\ Q'[XT_\ S$4?V7F7_0!C/_">K_\ (^?Y]F'^N'"O_11Y
M)_X<\'_\N_JS\K_I%17YN_\ #UO]D'_H*?%[_P 1^^-/_P Q%'_#UO\ 9!_Z
M"GQ>_P#$?OC3_P#,11_9>9?] &,_\)ZO_P CY_GV8?ZX<*_]%'DG_ASP?_R[
M^K/RO^D5%?F[_P /6_V0?^@I\7O_ !'[XT__ #$4?\/6_P!D'_H*?%[_ ,1^
M^-/_ ,Q%']EYE_T 8S_PGJ__ "/G^?9A_KAPK_T4>2?^'/!__+OZL_*_Z145
M^;O_  ];_9!_Z"GQ>_\ $?OC3_\ ,11_P];_ &0?^@I\7O\ Q'[XT_\ S$4?
MV7F7_0!C/_">K_\ (^?Y]F'^N'"O_11Y)_X<\'_\N_JS\K_I%17YN_\ #UO]
MD'_H*?%[_P 1^^-/_P Q%'_#UO\ 9!_Z"GQ>_P#$?OC3_P#,11_9>9?] &,_
M\)ZO_P CY_GV8?ZX<*_]%'DG_ASP?_R[^K/RO^D5%?F[_P /6_V0?^@I\7O_
M !'[XT__ #$4?\/6_P!D'_H*?%[_ ,1^^-/_ ,Q%']EYE_T 8S_PGJ__ "/G
M^?9A_KAPK_T4>2?^'/!__+OZL_*_Z145^;O_  ];_9!_Z"GQ>_\ $?OC3_\
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M5.[6BBBO!/TL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** / _VJ?^3:/C]P#_ ,6>^(PYZ<^$]5'/KUZ5\O\ [',S_P##)/[,
MO. ?@?\ #H<<#=_PCUHQ. #R0I&>YQFOJ']JC_DVCX_?]D>^(O\ ZBFJ5\C_
M +*>KZ7X>_8Q_9Y\0:WJ-MI.B:%\ ? NK:SJEZ2MGINFV'ABWN+R^NG'*V]M
M;+)+,^1L168_=S7M81-Y;.*N[X^"LKW?^SSLM-=7IIKK;J?"YY+EXCH-RY4L
MAK.3<E%**S+#N3;;45:-VVVDDKMV1]3^8WJWYC_XFCS&]6_,?_$U\,#_ (*6
M?L"E%D_X:U^#NQ@2'&NS!2.3G)M.!CH" 0!DDYS7V3X=\0Z)XLT/1?$WAO4[
M76O#_B+3;36="U>P?S;+5=*U&);BPOK24X,EO<P.LD+!270A\X(HJX?$T$G6
MHU:2>WM:=2GS646TN>,;NUF[=_,XL+F678V4X8+,,'C94[.I'"8O#XF5--I)
MU%0J3<$VFDY6N^9*YO>8WJWYC_XFCS&]6_,?_$U$2!R2 #T)..Q/\@3] 32^
MW?KCV]?U'YUS\TOR[^7YV_%]SNMMJ_OWM;_+7U?<D\QO5OS'_P 31YC>K?F/
M_B:BW+Q\R\DJ.1RRYRH]2,'(ZC!STH#*2 &!).  023UP/4X(XZ\T^:7GT[^
M37WI7\[ON%EW;VZ[[?GI]_F2^8WJWYC_ .)H\QO5OS'_ ,34?_Z_PP3G\@3]
M 3VI"R@@$@%ON@D M]!U/X4N:2M?RM>^NWYV_%]PMYOIU]/SM^+[DOF-ZM^8
M_P#B:/,;U;\Q_P#$U%N7.,C. <9&<'H<>AR,'OFDW* "67!Z'(P>0.#G!Y('
MU('>CFE]VO7;17?SLOGYA:VEW?M?T?Y*_P WW)O,;U;\Q_\ $T>8WJWYC_XF
MHLC&<C''.>.0".?<$$>H((ZBN2\<^/?!?PT\-7OC+Q_XGTKPAX5TRXL;74=>
MUJX2UTVTN-4OK;3-.@FG?.)[W4;NUL[:%1NDFG0$J"#5152348IMNUEKKLM-
M=;Z>MWW)G*-.$ISFHP@G*4IR48QC%)N4I2:BDDKMMI)7.R\QO5OS'_Q-'F-Z
MM^8_^)KY\^+7[3GP<^"NKZ%X=\:Z]K5UXI\2Z7=Z]H_A'P5X4\1>/?%-QX?L
MES<Z_+H/A32]4O['1(S\JZG>B&UEE!AADDD!2O:=#UNP\1:)I'B'3&G.FZWI
MMGJU@UW:W-A<FSOX$N;<W-E>Q07=G/Y3KYUM=0PSP2!XI8T=&45*%:$(5)PE
M&$_@FT^6>B>CV>VJWU;2L[F-+%86M6JX>EB:52O0LZ]&%6$ZM&_+R^UA%N5-
MR5FE-)M2O;4W$E8/'\QY<9R?9O13GKT^E?*7_!,_G3OVP20,_P##;'QU.<=V
MU:TW'V)[^O>OJA 2\9 R-XY'3OWKY7_X)G?\@W]L'_L]?XZ?^G:TJY-O+L;?
M^?!_->U>HL/_ ,E+D7E2S??>WU2A^>Y^F]?GY_P5+_Y,0^/O_8$\/_\ J8>'
MZ_0.OS\_X*E_\F(?'W_L">'_ /U,/#]<&!_WW!_]A6'_ /3T#Z7BC_DFN(?^
MQ)FO_J#7/NCPS_R+GA__ + FE?\ I!;U\8?\%)/BQ<?!W]C?XS^(]-N#:Z[K
M/AY?!/AZ9',<JZQXSN8M @:%ARLT%O>75Q&1T:,$8ZC[/\,_\BYX?_[ FE?^
MD%O7X\?\%P-6N+3]FSX:Z,CRK::]\<?",=Z(P2DL>G6&LZA'%+@8(,L2R*I(
MRT?0UV91AX8K.<#AZBO"IC*:FFKWA&?/)6ZW46DGHV[/0\#Q(S>OD/ASQAG&
M&FZ>)P/#.9U<-46]/$/!SIT*B;V]G5G"=];6O9GX_P#[.OA:ULK#3H(HPB6L
M%O @X/RB).02!@EPQ)'7KUK]0_!T4-O:1;<# 3.0,97@DGKV_P X(K\X_@C>
MQV]G; E<A8F+ @_,, C\.>"1SUQUK[MT7Q#!!;JI((V@DA@!GJ,GMUSC/.<\
MC-?=YLIU,1/=M2=[[._35]UJFUWVU/Y \.'AL'E.$2Y()4J:2LU9+D:O;TMI
MUOINCV'5]3C@MY&#H,!01P!C_('7@D<\ BOS0^(E[%X3_:!.K12*NE?%#3HY
M7;@1Q>,/"T'DWD0Y!$^I:(;:?D$R-9!5W$<?4/C/X@06]I.3*H(XSYB@#'7=
MR.< >N>@.,FOS9^+VL^*/BEXI\,?#[X?6,VM?$3Q!XLTZW\!:?8*YO)?$4=Q
MYUO*TF +;3HX5G_MBZ9EAM=(%U-,62)4;;A^G4PV*]O)J-)4ZBQ#E)1A'#M)
MRG4G)6BJ;2J;[Q5VMC/Q*S:AC<!0R^C&I6QT\?@GEM&C&56O4QSK*C0HTJ<?
M>E+$.K+#I13?[ZZ3V/UN^&?B-9XH%$HQL7^('().",L2<]1D \\KVKZBTR^$
MMN@+ @XXSSC&.F>?Z@9ZU^7?PO\ %FM^'M3U/PEXRT]_#WC7P?JLOAKQCX>G
MW>?I&OV!V742RL EW97#@SZ=?)^[OK*6WNHB5D!'V]X:\7)<6\1,BE2JD@LI
MZ@D8YZ8!''L.*ZLWP+C4]M2?M*=5*4)PLZ<X2M*,XRC=2C)6::;6G:Q[/!?$
M2J8;ZKBHU,/C,/*>'Q.&K1=.M0Q%"7LJM&K3>L)TJD9TYPE9QG"2:NG;TGQ-
M"DT,VXG!C?&/3).?TZU\#?&OPU:ZKINI65PFZ&]MKBSE]TN5>)SG&<HI)7W[
MCFOM/4]=ADC8;U8>61D,O3;T/H>PR!R>YYKY3^)]Q'+!*$ (^;"YR2?G)'.>
M^,GH.W45KDG-#$)Z:2BVM;[I-?I:_?<Y_$!8;&Y;75XR;IRO:U]H]KW\E<_6
MK_@GM\1;OXE?LG_"_4=4G-QKGAJRU+P%K3N<RF]\%:O?:! \Q)8^;/IEGI\\
MA8DEY">003]K5^4/_!):_F?X4_&/1B6-GHOQHUA[)2Q*J-9T/1M3N0@_A'VJ
M24L!P6).!W_5ZOS'B##0P>=YIAJ=O9TL;65-+2T)2YXQMTY5+ELM-#^M_#7-
M*V=< <'9GB9RJ8G%</96\35E9RJXBEA:="O5;6C=6K2G-NROS7LM@HHHKQS[
M<**** "BBB@ K\\/^"JYQ^P?\=CC.-+\/="!C_BJ]%SU!'L>#D&OT/K\\/\
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MSAOV:O\ U</AH_RYK3 WEC,*GLZT/T77RU^?F<>??\B3-=7_ +AB>NJ_<O\
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MM/;>&C7 ) YQWZ \5XEX[\5PR6TK/<*D:H[O*TJK'&D89I&D=BH01Q[G).
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M#%=HUM!#:V,4/GR2GP_Q)^V5\<OA9\.?BY\+?$&OIXQ^+W@#]J_PE^S+X?\
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M%&(D:[OH[;2K=X9(3$J.S80C 7FKS]B7X):MX&^+'P]UZW\1ZQHWQ<^+=_\
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MF8<14L/+"T,RS[,*E"A-\U2%&C2P>&INK))+VDU1YYJ*Y8RE*"NH*4OY:/\
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MTWP_X?T2SEO]5UC5KN&QTW3[.W!>6XNKN9XXH8XU1CEG!+ *H+$*?Q3^/_\
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M=>M4G!Q3G.<YZR<ES<L5&"32C36I_&L^+/$3B2.(Q%;BC,\-#&PG"6%RV5/
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M05>*'4VT:]"N-J26B-'M<N6^YAXE\*?$3PA;>,?"=Y]OTB^2:(AU\G4--OH
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M"7P7SU^T?$'I_P!E$\4U^CE8YE_R,,=_V%XC_P!.S/8X0_Y)3AK_ +$.4_\
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MN0<<=?TR<5IW6A)+$P* X&-WRD@=/3."./I^G-^%]6AF@B);/W<8ZY(.>/?
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M/>_]'L_ML_\ AVM'_P#F/H_X=SWO_1[/[;/_ (=K1_\ YCZ_2FBM_P"U<?\
M\_X]/^7&&Z6_Z<_W5^)P?ZG\.?\ 0N_\O,P\O^HKR_JRM^:W_#N>]_Z/9_;9
M_P##M:/_ /,?1_P[GO?^CV?VV?\ P[6C_P#S'U^E-%']JX__ )_QZ?\ +C#=
M+?\ 3G^ZOQ#_ %/X<_Z%W_EYF'E_U%>7]65OS6_X=SWO_1[/[;/_ (=K1_\
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M#_\ V!-*_P#2"WK;K$\,_P#(N>'_ /L":5_Z06];=<\_CE_BE^;/:I_PZ?\
M@C_Z2@K\=_\ @K#K[3C]G7X?"4K!K/CO7/%M] &.)HO"6@2-I[2(,Y"7^H'!
M(P IYR1C]B*_$#_@JLDD/Q?_ &:[LHPMY-'^(MHLA!VBY2WL+@H#@KN,.YL
MYVY. N[/T?"%.-7B++5*WNU*LXII-.<*-24.JO:232[[)GY3XY8FKAO"WBF5
M)\OMJ66X.J_^H?&YQE^$Q$7H_=G0K5(23T<9-/1G@D7PN3Q_X2L/[)O(M&\;
M>'I&U3P;KDH!MX+MT5;O2-1&QGDT;6K16L=1B3+(7MKM SVB@[/PV^(MT+J]
MT36[.?0O$_A^Z_LSQ-H%[N-WI&H L[<EV^TZ3>A5NM*U*,O:W=O*K1RLPD1.
MI^%>KQQ6UH-V!P P;!"8&.F.,]?[P^5NE=[\3_A=HGQ0@L?$.EZBOA3XDZ%:
MBWT/Q5!;F:&\M0!)_8/B>T78=6T&=D^0"2*\TR>1[BRD)W02_J-/,XX>O4P.
M/3E@ZDI2A447*>$J2UE)15VZ$MZE*/O1;]K3O)2I5?YER_)_K66X3,LGG"GF
MF&H4X5,.YJE2S"C3BK0E-^[#%05U0K2M&I%+#UW&"IU:'K>@>*8)UCS*N=HS
MRO7T')STQD9'<$]:ZR35(YH6 D!)'!!Z8SU]L@=,GBOSRT'XD:QX3UY/!OC_
M $YO"?BB$M';6L\JW.C>((HC@W_A;71LM=2M'#*PM)G@U6W1@MQ8AHV%>^6/
MC^&2- 9%4N <%E&_/((SD'&?X<8!SGIC;$Y/*#5:DXU*-11=.I2DI4ZD7:TD
MXOE<6GJ[W3TWV][+N,*,X/#XF]#%4I.G6H5E*G6I3C9.%2G-*49)[7U:LUHT
MST'Q3)'*D@+ _>S[]LCZG.,?7':OG'PYK\G@7X\_!/QC:L$DL/B/H?AV\885
M9=%\<W7_  B^I6TCY!VM+?6-T1@*&LHB#DX/>:SXLBE21EE3HV2&0A<*21P3
M@XR<<G\Z\>T+3KKX@_&3X-^"-+A-U?:M\3/"FL3Q0N6:WT'P9K-IXIUW49?+
MW>3;V]M8Q6QN'!B%Q>6L6Y7F3/=A<*J6 S!8F/+A_J&,5:4OA]F\-/GWMKR)
M[;.VUFUXF.S&6)S[()9>V\=_;^3_ %-1O=XJ.8X5T4M_^7EKW322;;M>W]&P
M.1D=#T^GK]#U'M2T@ 4!1T  'T Q2U_.I_> 4444 %%%% !1110 5XM^T-\#
M/"?[2?P>\:_!7QO>:WIWAGQSIT>G:E?^'+V/3];LTBNH;N&YTV]EM[J.WNH9
M[>.2.1[>505P4()KVFBJA.=.<:E.3A.$E.$HNSC*+NFGW35S'$X:AC,/7PF*
MI0KX;$T:F'Q%&HN:G5HUH.G5ISCUA.$I1DNJ;1^:,'_!.&YMH(;>+]M;]M9(
M;>*."%$^*^C(J0PH(X8\#PA@^7&JQ@@+\JKD9!)E_P"'<][_ -'L_ML_^':T
M?_YCZ_2FBN[^U<>O^7\?_"?#>7_3GR7XG@?ZG\.?]"Z^M_\ ?,?W3_Z"O+Y?
M)6_-;_AW/>_]'L_ML_\ AVM'_P#F/H_X=SWO_1[/[;/_ (=K1_\ YCZ_2FBG
M_:N/_P"?\>G_ "XPW2W_ $Y_NK\0_P!3^'/^A=_Y>9AY?]17E_5E;\UO^'<]
M[_T>S^VS_P"':T?_ .8^C_AW/>_]'L_ML_\ AVM'_P#F/K]*:*/[5Q__ #_C
MT_Y<8;I;_IS_ '5^(?ZG\.?]"[_R\S#R_P"HKR_JRM^:W_#N>]_Z/9_;9_\
M#M:/_P#,?1_P[GO?^CV?VV?_  [6C_\ S'U^E-%']JX__G_'I_RXPW2W_3G^
MZOQ#_4_AS_H7?^7F8>7_ %%>7]65OS6_X=SWO_1[/[;/_AVM'_\ F/H_X=SW
MO_1[/[;/_AVM'_\ F/K]*:*/[5Q__/\ CT_Y<8;I;_IS_=7XA_J?PY_T+O\
MR\S#R_ZBO+^K*WYK?\.Y[W_H]G]MG_P[6C__ #'T?\.Y[W_H]G]MG_P[6C__
M #'U^E-%']JX_P#Y_P >G_+C#=+?].?[J_$/]3^'/^A=_P"7F8>7_45Y?U96
M_-;_ (=SWO\ T>S^VS_X=K1__F/H_P"'<][_ -'L_ML_^':T?_YCZ_2FBC^U
M<?\ \_X]/^7&&Z6_Z<_W5^(?ZG\.?]"[_P O,P\O^HKR_JRM^:W_  [GO?\
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M5FK<E\/?B'8:G9V5W:7T%W97D"7%O/;N)(;B!P"LT3EB6C+'8-^UPZE75'!
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M'2W_ %%^7]65OS6_X=SWO_1[/[;/_AVM'_\ F/H_X=SWO_1[/[;/_AVM'_\
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M_AS_ *%W_EYF'E_U%>7]65OS6_X=SWO_ $>S^VS_ .':T?\ ^8^C_AW/>_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBBBO $%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7UWIJ:7?VL+8>YCMKIEW>6,97A/Q]#';P?OL!2O\3'&#GV_'GVQ7WQ_P5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+=PMG[\<D2%)$'WE)!^7-?QT6/P_M/$MDBWVGV=^H'[I+VVW^6H+ -&VPR0
MY)9H"K$=3C*G^P?_ (+1>)O!?A[_ ()\?&,>+M3%A/JMYX*L/"=NBB6[U7Q4
M/&&BW5A8VL 96<F"WNYKF1=RVUK%+<."J%:_E]^$5G:ZA;6.!%(9(X@3&0R
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M/_S^_JS\K_J%D>H_,49'J/S%?E[Y_P"W_P#]'"? ;_PQ&N?_ #<T>?\ M_\
M_1PGP&_\,1KG_P W-'^I\O\ HH>'O_ \Z\O^I)YO[O,/]=/^J8XF_P# ,A_^
M?W]6?E?]0LCU'YBC(]1^8K\O?/\ V_\ _HX3X#?^&(US_P";FCS_ -O_ /Z.
M$^ W_AB-<_\ FYH_U/E_T4/#W_@>=>7_ %)/-_=YA_KI_P!4QQ-_X!D/_P _
MOZL_*_ZA9'J/S%&1ZC\Q7Y>^?^W_ /\ 1PGP&_\ #$:Y_P#-S1Y_[?\ _P!'
M"? ;_P ,1KG_ ,W-'^I\O^BAX>_\#SKR_P"I)YO[O,/]=/\ JF.)O_ ,A_\
MG]_5GY7_ %"R/4?F*,CU'YBOR]\_]O\ _P"CA/@-_P"&(US_ .;FCS_V_P#_
M *.$^ W_ (8C7/\ YN:/]3Y?]%#P]_X'G7E_U)/-_=YA_KI_U3'$W_@&0_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?&^B31G!.H>&=3M=6@A(!&8;P6C6US&3LDMYI8Y@8G93_;9\*O'6F_$_X:>
M?B-H[!M,\<^$/#WBNS(*MB#7=*M=11&9>"\8N/+?'1U(.""*_C9_:"@@NH+]
M66,B17#=.!(PB8$'I^[;H1D9R1VK^D/_ ())>*;CQ5^P'\!Y+IY))] TS7_"
M1>1B[&#PSXGU?2K, DDA([."WB0$\+'Q@8 \SQLP$<7PMPQGCUQ&"QM;*JD^
ML\/C,/+%TE)ZW]G5PM7E5U;VD]^G=]'S,9X+C+C'AV,G]5QV7X;.:4-$H8G
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M2P])=HN/1-G[#> A;W%O 2R9PAX"DD;,8_Q[ _IZ])I5M-;.#&'_ '>5QM'
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M)J6E>$+GP-81^(]2TV%F$^H:?I$FKK=75K%LD$D\<311%6+,I6OT^Y[,PZ'
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MU*U+,Y+#>TBYRK04,16A&3JT_P"D[ RPVX*D Y&.2,_RZ^F1ZT8'H/R%>2?
M+7M3\4? [X/>(];O)-0UG6_AIX/U/5;Z;'FW=]=:+://<R[0JF2>3=)(V!N<
ML0 .*]<KX'$T'AL1B,-/E<\/6JT).-^5RI3=-N-TG9N-U=)I63U1^FX3$0Q>
M%P^*IQ<88FA1Q$(RMS1C6I0JQC*VEXJ23:;3M=,3 ]!^0KY+_:P5=W[+_ Y_
M:\^$&>!S^\UC_ ?D/2OK6ODO]K'[W[+_ /V=Y\(/_1FLG^5>IP\E_;&#T7_,
M1_ZBUSQ^*$O[#QNBWPG3_J-PQ^ME%%%?DI^P!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M_G_/I^- !7\?7_!=#P]?^&/V\?AWXTN(1'I'C?X%Z+8V-U@E)K_PAXF\2B_A
MW%=HFAM]6MY"@;<(G5SPPQ^NO[?/_!8'X6_L@^)[CX1>!/"UU\:/CA:V]O=:
MKX=T[4H=+\*^#$NT:2UA\8^("\DT.IW$1CN(]#TZTN+T6\D<]RUO$\9D_FZ_
M;J_X*#?&;]NGPGX3TSQK\$/AOX6USP#XA;Q!X2\5^%M8\0S:M:6UW$;36="N
MX]3<6=]8ZK9B/+/&IMKR&*XA4L #_0'@UPCQ9@\]RSBEY/4CD.)H8K#5,37K
MX2A.>%Q5)QCBJ&&KUH5Z].%6-.?NT_WD$W#GNC^8_'SC?@G'\-YQP<L]IRXE
MPF)P6,P^%PV&Q>*IT\;@<31JRP>*Q-##U,-AZM6C.K2M4JKV51IU?9J,FN^^
M'/CJVBM8T>>-HY(&#I((WC>*:)HY8I8V&'26-V208(*LPQ7A'B"1?@[XP-YH
MDH_X0#Q#>M<Z?ME,@\+ZE=,)9]&FQDQ:;<$?:-,EF+$ O;J05 /R?X>^-ATI
M8K"_>?2K\X@^PWT9AN1,P 2!4E($LC-A81""92RA07*K7U=\*/@!^UC^UK?Q
M^&/A%\$_%^NZ=?F.SO\ Q5XITN]\+> +"%W"R3:IXAU2"&%T@CS)Y&G)>:@#
MM$$'(9?Z2JT,)D-3$9CC<PP."R^=.7UF6,Q%&CAZE+FC*_OROSPDGR*G%SYG
M**3YG%_R=1Q>8<3X;"Y5EN49EF&:TJL)X5Y?A:]:O1K64&G[.E4_=5%I4YY0
MI."C.<E&"DOM?X=_&!+BU@5KQBKI$P^Z<=#R58X) [''3FO7[WXCPSV39G(8
MHY4N0O0#. <Y.,9R." ?0&CX]_X(R_M<? /X;^&/$_PZ\7Z'\=]6M-+6X\=^
M!=(2;0=:T>]V!WM_ MUJ!>'Q3I=JK-$(M6?3]7G>(30F9I%MS^=?BCQWXU^'
MDUQH_P 1_"OBSP'JEB[6MW8^,M"U+P]/:W!W*(F&HPQJ6+1N%=92DVPM&H"-
MGYO+/]5>*IRQ/#N=8''<M249X=5%0Q5*2GR^_A*ZIXA4WHZ=14G1J1:<)MWY
M?K\W?&W!4%@^*,AS# ?N82AB_9RQ.7SC*DI>[CL,ZV%<X:QJTG55:G)/G@ER
MREZ=\:?&,,MM?NTL6WRY9V8E<*(EW$N3@!1MW,<$ !NN:_J*_P""2'@^^\'?
ML"_ F+489(+KQ'INO>,_*E#*ZVGBKQ)JNKZ>Q5PK*)=/N+:51@ K(".#7\5V
ML^,M2\>WUI:Z3I+Z[I O;2769YGNK73;C38[J-KW2TU&W597GO[>.:W66V.^
MU$@8.C*N/W2^&/\ P6^^+OPYA\.^&_$_[,_@(?#3PYIVFZ%9:1\/?$NM6NNZ
M1H6EVD%G;0Z=_;UNVE7DEI:Q)''#<26PF"9:6)B#7D>+'!W$>?<-Y5DG#>7T
M<?\ 5\=+,<?-8W!8><94</*AA\/0IXBO2G7G-XFM4DX1<8J$4I7DTO7\$N/N
M$N'.*\\XBXKS:KEOUO+J.4Y9!X#,,53<:^*AB<7B:];"X:O2P]*#PV'I1=2<
M92<IN44H)G]4=%?/7[,W[3GPI_:P^&&E?%3X2ZT^I:-=R2V.K:5?1I:>(/"V
MNVNT7N@>(]-$DK:?J=JQW;"SPW5N\-Y:2S6TJ2-]"U_&&+PN)P.)KX/&4*N&
MQ>%JSH8C#UH.G5HU:;<9TZD)).,HM:IKS5TTS^_L'C,)F&$PV.P.)HXO!XNC
M3Q&%Q6'J1JT,10JQ4Z=6E4@W&<)Q::DFUJ%%%%<YTA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52U*!KK3[
MVU7[UQ:SP#_MK$T?_LU4_$/B'1?">AZOXE\2:G9:+H&@Z=>:OK.KZC<):V.F
MZ;I\#W-[>W=Q*5BAM[>WCDEDD=E557D]Q_-G\??^#@H0>+=2\/?LI?!JR^(/
MAO2[V[LT^(_Q"U2\T;1O$?V1A$][X8T+2)'U*?299 S6=_?W-J;J$+,EHD;J
M3]-PSPAQ%Q;B:F'R#+JF,EAU&>(K.=.AA<.I7Y/;8FO*G1A*5GR0<^>=GRQ:
M3/D^+.-^%^"<+1Q7$N:T<OABIRIX:CR5<1B\3**7/]7PF'A5KU5!-<\U3]G!
MRBISBY*_X.:19WWPW^,'Q4\$:RCV>K^$/BMX[\/W\$I".MQI_BK4XB=IP0DD
M16:)SC?"5<<,#7UEJT_ASX@>";SPEK[YAO(ENK"\A.+S2-6MSFQU:T=<,)+*
M9Q))&6$<\0>*4%6"CX;_ &E_CKXP^,WQV\5_M!:K\,M!\ 7GCJ+3KGQCI'@>
M[U/4M,N/$6GVGV:;Q&MKJS-<P/K%M%''?QVTBJ+I6NBKR2.3AZ!\8[S5FBL-
M#BU/6]3*;5TS2-.N]0U%F8[%"V5G#+.Q+80YCV%RJ;LD5_=KRO%XO 9;BL9&
M&!S*AA<)]<I?6*36%QE&G#VCI5Z<Y4YTE57-3JPFXV:4N5IH_P W_P"V<%@<
MUSG!8!U,URC%X[&_49/#5HO&8+$5JDJ5.IAJM.%6%5T9<LZ4J49W3E%.+C(^
MEOAG\2-8\$Z]=>$?$,J0ZMI):/SH^(-3LV*?9]3T\EMDL-TA5Y$C#"VF9X'(
M*@M^@7A3XLQSVL:-=@AHPH+,JG<<$'&<D<^XSD@DDU\Y?LW?\$OOVQ/VQ->T
M+7-?\+:C\ ?AK9W,%W)\1/B'8W&G>*+BS;898/"?@N6-;^]DO86*,^K+8:1M
MC\\F>4*I]0_:"_8&_;#_ &3-2O9G\):G\9/AE;O*VF_$/X:Z?>:Q>QVI65XV
M\6>$H =3T:ZCAAV7%U:1:AI0D*-%+&)1&GSV.SS@K-<R635N(LHAGBIQE5A'
M$0AA:M7F4/9QQ;2POUKX7/#JJY7;LUK&/TN5\.^(.19///J7"V?/AQUIQHN6
M&G4QV'HV515JF BWC7@$KQI8OV#5DG448WJ2]!\5>/H+FW8"YV@(5RRX7)5C
MPQSSZ#TY[9KXXTG3;CXF?M"_ WP-IJ2W5YXD^+W@*U2*(%V:"TUZWU.^?Y 6
MQ%8V5[-)V2.!G)P5KQ+7_C8=/26PU26YTO4EY.G:E;3V6HH S1N?[.N$CO"0
MP9-IA&3D=0<=1^S!^T!XY^!WQMT[X_Z/\+]!\;:GX:TW4[+P9:>/+[5].M-,
MU;5$^Q77B=+/2?WCSQZ4USIMA#=$")+ZZO"BNRD_0+(\7@,HS2>74J6)Q];+
ML72P%%5Z5*-;$5\/*E1YJ\Y0I0I0G*-2<Y5$E&+2O.48OYF7$V S?B')*6;5
MZN!RW#YM@,1F^(GA,75GA\)AL52KUX1PU*A5Q%2O6A2]A3A"D^2512G*$8MG
M^@#"@CC2,# 1$11Z*BA5'U '/UJ6OYW/V?\ _@NS9:GXKTKPK^U#\*+7X<:3
MJ]S%9Q?$;P-J=SKGAK19I9%CAE\2Z7J?EZS8Z<SLD<^I6B7L5JS!KB-(MTJ_
MT+:=J6GZQ866J:5>VVHZ;J-K!?6%]9S1W%I>6=U$D]O=6T\3-'-!-#)')'(C
M,CHZL"017\)<2\(\0\(8JEA.(,OJ8*I7BYX>K[2E7P^)C&W-*AB</.I1J.#:
MYXJ?/"ZYHQ35_P#2#A+CGA;CG!UL=PQFM',:6&J1I8FGR5L/BL+.45*$,1A,
M53HXFCSQ_ARG34)I/DE*SM=HHHKYH^M"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1B I).  23G&
M .3D]AZFOP&_;+_X+F>!/@OX\USX2_L[> 5^-OC+PO?SZ1XI\7:AK!T?X:Z+
MJUK(T=]I-G?V+7.I>(]2TV5/)U :=;164$A,27LLJR1+[O#_  UG?%.->7Y%
ME];'XF--U:B@Z=.E0IJ2C[2O7K3IT:,&W92J37,[J*;T/G.)^+>'N#LO>9\1
MYG1RW".:I4W4C4JUJ]5IR5+#X>A"K7KU>5-\E*G)I6<N5.Y^*G_!0SP_=_#/
M_@I)^T;9ZBA@A\4>(?#_ (\TEG!5KG3/$>@6<)N8V<'S(TOK"Z@9U)7S(73(
M/ V/#WB?1-8\.WN@ZXMO?Z1J5A)I^HV<[*(KFTN8EBFC9P=\9 &^*=")() )
M(RK**^;/VX_VPOBI^V5XW\%?%GQ9\'/!/@WQCX/T6[\,ZEJO@/4==N;OQ-X7
M:\-_ING7=IK,CQ23Z->S7]Q97$"K,\5_.C!0NROG'P]\:@%BTZ*2XEU*0A$T
MQ(;A]0DD7):..Q >>650"7CB1@H5F(5%8C^Y<FR/,*G#&0X3-:-/!YKEF7X?
M!8NE'$4*D$\'35"&(IUJ-2I3E&I2I0J<RFI0D[24;'^=&=\2970XTXEQV1UJ
MF89-G&:XG,<)5>'Q-&3>8UGB*N&K8:O2IU(3IU:TZ4(R@X5(13A*?O6^E]&U
MN^^$/BW_ (1B]U&2YT*Y=W\)ZW-(&^VZ="S%=,NI"-HU;38L6[1[B]TJ+*K'
M>-OWGX(^+D=Q;H&O-V%0!,H6&%'! (P1CD9QTS@C!^1O@I^Q'^V3^VG?6>D^
M"?A-K?A;P/>SV\MU\4/B?8ZGX2\(Z3 K+*-1TGSH$U?6[Z-5,EK#HMM*K3K$
MEY<P12$G[=^//_!*7]KC]F"SM=:^',\W[27@>'2K=]7O?"]C_9WQ!TK48HHE
MOA)X/4/#JNEF0NUC)HT\VH>4@6XL1,?/7CS/B+@VKC<-DF9\1933SMTY*[Q,
M'2E*#7+3QF,C_L>%Q$U;DI5JU.=1I[2E%2]#).%_$##Y?B>(LHX5SNKP[&LI
M.'U:I#%0A*SE4P6 J6QV-P<)<SE5P]"K"GS6;<:=1POZ[\08;BQE_P!( 9HP
M/FP&(^;U)&#SZ]^O-? ?QW\2+?6.H6]N?M$UP@M+>%,/+/<7+K;Q10HHRTLC
MRJL2#)=RH')KE/$GQ7U;PLTVF^+],UKPGJ$3O;/8>)],U'0+]9H#MEB:UU2*
M"831L=LB1F0IP2PS7!^"/B'K<GQ-\%>/8O ]EXU\.^"/$VE^*IM%\23:EIFB
M^(K_ $2Y2]TNQE-DG]HO917T=M<W)5O+N3 %82)\I^ERS)EEM.>/PT*.+E3I
M3K8.E3K4>7%5XQ;I4XUI3C2C"I.*@YNI&,;\SDK:?(YWQ''-\11RS&2Q& C4
MQ%*CC:E;#8E2P5"52$:]:=%49592I4W*HJ<*<ISY;*+ND?WS?LT^%+SP-^SS
M\$O!^HH([_PW\+? ^D7D8)(2ZLO#NGQ3KR ?ED5A@C<N,'D&O;J_F7^&?_!>
M+Q]H^N6-M\=_V?M'B\&/+##>ZQ\+-9U"YUG1K4R*ANH]!\0+"FJP6\1\R6UM
M[Z&ZVIY<"R-A&_HF^%?Q3\!_&KP!X9^)_P ,_$5AXJ\%>+M-BU30]9TZ3S(9
M[>3*R12H<26]Y:3+);7MI,B3VMU%+!,BR(17\,<8<%\5<+8E8CB++)86&8UJ
M]6CBJ5:AB\)5JRFZE2G'$8:I5IJJN;F]G-QFXWDDTFU_HSP+Q_P9QEA'AN%<
MWAC9Y70H4:^$K4<3@\=0HTX1I4ZM3"XRE1K.E+E455A&=/F:BY*3L>A4445\
M6??G\UO_  <)[UM?V8YHV>*2+5_'#1SQO)%+%*EGI,D4D,T31RP3Q2!9(98Y
M$D21 58=:G_X);?\%6_[1;0?V<OVF_$6=37[/HOPU^*6K3*B:L%Q;67ACQA>
MOLB745<+!I6N7!#ZI)/%:73&Y6-YE_X.%@/[%_9G'&]]>\<!1D9=AINF;54?
MQ,79 J@$LS*J@D@5@_\ !+3_ ()2O=/X>_:3_:8T )$K6NL_#+X7ZI&[,&C(
MN-/\6^,+.:)")06CGT?19S(MO)%%>W2+.(TB_JW!1X-GX!9/+BYJ+@\Z61RP
MZ@\U_M5YKC'367N6C@[_ .V1J?[.J'-*K::IW_B['RX^I_27SV/ _,Z4J7#[
MXCABW5_L5Y1+*L'S/,G!VA47))8"=*,L4\3[M)2I>WY?Z9D8.H88PP!!!R""
M,@YP,Y![9'H33J:BJBJB@*J@*JJ J@#@!0. ,= . .*=7\I?U_5C^T1DGW#]
M5_\ 0A7Y5?#/_D[3]N?_ +'3X0_^JVLZ_563[A^J_P#H0K\JOAG_ ,G:?MS_
M /8Z?"#_ -5M95]MP?\ [MQ3_P!B7!_^M)D1\#QM_O7"/_908W_UE.(3Z>V+
MZ?J?\:-B^GZG_&G5Y)\4_CK\*_@M%I!^(GB==*O?$,EU#H.AV.G:EKGB36FM
M!')=S:9H6C07VI7-I9++&MU=I;+!"SHLCACMKT,/A\1BZL:&%H5L37G?DHT*
M<ZM6=DY/EA!.3M%-MVLDFVTDV<V)Q6&P=&>)QF(H83#T^7VE?$U84*-/GG&$
M>>I4<8QYIRC"-W>4Y1C%.4DGZSL7T_4_XUY;JGP5^&NL_%CPU\<=3\.+=_%'
MPAH5YX:\/>)WU#48S8Z)?F5KNS_LR*Y72IO.::7,LEF9D5R(Y5!8-F0_M$?!
M*;X<1?%W_A8OAZ#X<2:E!HDGBJZN'MM/TS6I[P:<-(UE)Q!<:7J4-\1:7-I?
MI!+;RY,ZQH=U4/AM^TK\%?BWXIOO!7@/QI#JWBBPTZ36%T>ZT[5=(N]4T2*=
M+:37="CU6VMAK>C)<2Q0_P!I:=YMN7EBVLRR*Q[:6$SG#0QE>CA<RH0HT\1A
M<?6IT,13C1IR4:6*P^*J*,53@XU8PKTZC2Y:D8S5IJ_F5\?P_C)X##8C'91B
M:F)J83&Y;AZN*PE:=>LINK@<7@J4IR=6HITYU,)B*47)2IR]C/F31S_CC]CW
M]FWXE>/9/B;XX^%>BZ]XUNK:"TU357O=9L8-=@MHVA@77])T[4;72=:,43LJ
M'4[.Z;B++8AC"KI'[(?[/FA6'PTTO2_ *VVG_![Q3J7C3X;VQ\0^))H_#'B3
M6"7U"\M1+JC--;32,WEZ;<O+I\"D>5;*0,9NJ?MJ_LPZ)K>L:)J_Q7T:P?0K
MVXTS4]:N+35E\)PZO9MMN]!@\5K;-X>O-<MSD3:7;W;7@?\ =;1)BNTO?BSX
M;\/^-O'9\1?$OPK;^%/!OPTT#QUJOAA],N(=>\+Z5J-U=[?&&KZR)66YT+5+
M>)8;>S6(3VDL$TDK[&"CTI5N+:5&C0JXKB'#X=8=_5*%6MFE.E.BH1P?L\)2
M3<+*EF/U>*@HQ]GBO8II5XPEY,:7 U;$8C$4,+PQB,2\2GC\1AZ645*L*W/+
M'.MCJNE1R5;+'B9<SG/VN"5=1D\/*=/PG]M+X*_$3XQVO@5/"_PP^$WQ@\/Z
M!J-Q?:[X0^(&L:YX+\2QW)D0V^I^!O'WAZ>&^T6=XU\J\@:!H)@I)#%F-><_
ML?\ [(GB?X;_ !)^,GQ7^(W@;X>?#RP^)/A71_ FA_!WP=K5UXST?1_#EB[M
MJ$_B+7-5M8;K5]1U@;5OWN1*]U)NDEE+/D?47A/]J_\ 9]\;>-]+^'WAKXB:
M;J?B7Q"D\GAM39:M!HWBDVUN]S=6_AC7KJVBT;Q!-;VR22S6^G7$LJ*K;0Q4
MX?X\_:P^ 'PT\4WG@WQA\0++3]<TI;1O$,5IINL:II_A(7I#6A\6ZII5A<Z;
MX<:8%2J:S<P.D;)(ZQHZ,?2HYCQ51RJ?#&'RK&TXUL-*52$<)F;QD\(\;3Q$
MJBPZQ'U2,'BZ-.#QL,"L1:+H>UY7*+\JME?!>*S:GQ?B,WP%:IAL;&%.M/%Y
M/]2IXZ& J8:%.6+6$6.<HX*O6J++ZF8RPBE/ZQ]7YTJBQ_ /[%O[+_PP\:P?
M$'P1\(M#T?Q38SW5QH]])?ZYJMIX>EOG=[R7PWHVKZE>Z/H,T_F/NDTRS@*@
MA8PBJN.IN?V9?@A=_%J[^.DG@>"/XJ:C87&F:GXHM-6URR;4K6ZTZ;29FU#2
M[;4DT6\G.FW$ULL\^G-,HD+B7S KC5^(_P ?_A%\*-,\-:KXU\86=I%XQ"R^
M$++2[:_\0ZMXJ@,23M=:!I&A0WE_JEE'!+'/->6L3VT<<D;,Y#BJMO\ M'_!
M"X^&C_&$?$?P_#\-H-3@T6]\3W4L]O:Z5K5Q=QV"Z/K4$D2WNDZFE[-%;36-
M]!!/;RNN]0I5CY$L1Q3B;8V5?B"NL9!Y4L6ZN85/K5*I42>71K\[E7IU*E/E
M>$4G"4Z?)R.4;+VX8;@S"N>7PH<-89X&:SB>$5/+*2P=2C3C-9I.CR)8>I1H
MU(26,E&,J5&<9*I&$DWRP_9 _9Y3X<>'_A+'\/T3P#X5\;K\1M!T$:_XC"V'
MC(7\VIG5_MPU3[?.#>SRS?8Y;@V0#F,6XC^4^@:Y\%_AOK_Q.\)?&;5O#XN?
MB9X$T74M \(^)S>ZF/[&TO5?,6[M_P"RDO5TF\$GG!B;FS>5]A59%W-GBC^U
M9\!XO K?$>X\=?8?"C^(1X4L9[_1-9L]6UOQ&P#PZ3H&@7=G_:^M3W,+K-;?
MV9:.D]N5N%<QG=77>!/CO\)_B/X5\0>,_"OC33;GP_X1:Z3QA/JD=SH=UX0:
MQMFN[H>)].U1+/4-%6.S5KP/?0P)+ !+"\D?S%5I<3Q57%8EYYRQK8G#XBO6
M>.LJ^8N%/&T*M25U[7'.5.GBJ<Y7Q%X0JJ3E&+K#0X.G*CA<(N'7.6'P.)HX
M>@LO4YX;*U*IEF*ITJ:3G1R[EG/!5;<F&M.=!Q2FU^3/Q/\ V)OCSXUOOBII
M;?LY?LVS^)?B/>:E:6GQRTCQUXL\/Z=HUCJ-R(E\37/PF=[WP^?&D%EM;^TK
M9('-QYNV11*P/Z_?"#P!%\*?A9\/?AI#>?VBG@7PCH_AMM1V[!?3Z?;A+FZ4
M9/R2W!E:,<;4*KC"BOE#7OVVO 'BCQY\"/"/P8\7:7K[^/\ XLV/A;Q+;:OH
M>J6-UJ'@JYT'6;UM;\)3:G:VJZE8_P!H65I&FKZ>]Y:JDT<;RJSBOK3XE:7\
M2=7T!;3X4>+?#G@SQ,-1@FDUCQ1X;E\5:8VEIYYNK)=*BO=/;[5.Q@2*Y^TK
MY*(^W.X5Z^?YAQ!C<-D^6YU"CE>'FZF+H0Q$<QAR.FUEOM\3"O/&UL/3A&@X
MT</@:%/#QIN<Z>'3DXKP>&,JX9R[&YYFW#]2OF^+IQHX+%5,-+)I*I"LEFGU
M;"5,#3P-#%U9U,9"K7Q68XBIC)U%&&(Q3C!2?DOC7]C?]F?XB^.[KXD^,OA-
MH>K^,-1C1-7U!;[7--M-;,41AAFUS1]+U*STK6;F&/"I<:C:SR@A&))1<:W_
M  RK\ #\(M/^!%Q\-=*U+X6:-<3WND^&M4N=2U Z7?7-P]W+?:?JT]VVM6EX
M)Y9F2>#4%D59612J!4'S1\*/%O[9?Q)\?_&OP7)\7_@]I\?P1^(&C^#+ZZ7X
M2WD[>*8;_0-*\17%W"%UF(Z2WDZA)8H2;GRI0LNTA4:N_B^(WQN^/?Q&^)7A
M+X)>+?#7PJ^''P?\0Q>!O$/Q'U7PS!XT\3>-?B!#I\=[K.F>&]%OYUT;2_#N
MAI=PQW6I78DO;J]#6T,21Q^89KX;B"A*&$J\3P>%RO#X/,/:QS/.'A,JA4HT
M999.$7A(U(5ZM#&16$IX"C7Q$85*L7&G"%7DTP^*X6KPGC*/"'+BLYQ./RF-
M"649)3QF=585JZS>E.<,7*BZ%.ME]2IF%;-,1A,-.5*C4]I5JU*/-[1\*?V:
M_@A\%M/\1:=\-? >G^'U\5V\]EXDU*:[U36]?UNSGMVMVMM0U_7+[4-7EMUC
M>18H!=K%&&^5<JI&%_PR+^S[_P *:M_V?_\ A (O^%26WB!/%$'A,:YX@V1Z
MW'JD>LB\&J'4CJS?\3&,3^2]V8&_U;Q-'\H\QNOB?^TC\-/AA^T=+\4-%\/Z
MQXD^$?@>_P#&/PX^+6BZ6-.\&_$:S&EFXM;?5/#37SRZ7XATF_26/6+&!O[/
MN+<P2VD[%GCCQM,N/VW;KX2:5\68/C)\!)S>> ;/QV?#FM_##4]%TR99-%75
M[C2[GQ"FL3/8(4,D0O(X)/+=%<JJMBLUAL\]I/%SXFP].;S/!1HXRIFV85'B
M\?##PKX'$T:]'#UYTZF&HXA1I3Q;PM;!NI.C*%&:J0CK]8X=5&E@Z/!]>I3I
M93CE6R^GDN4T%E^5U\8L/F&%K87$8G#4ZE#%XK".=:A@(XS#XZ.'AB8>WISH
MU*GT]JGP,^%VN?$#P'\4]7\+Q7GCSX9:)?>&_!&MM?ZDJZ-H>I6\ME>V#:>E
MTFG7T=Q9RF!WO[6ZD"EBCJS;AXA>?\$^_P!CZ_E\327/P3T,KXMFFN=5ABUC
MQ/!:0W-Q<+=W%YHEC!K4=CX?O;BX&^:\TBWMKE@2@E"?*/:OV?\ XJ'XW?!;
MX;?%DZ2="D\=>%[/6[G2'=I4LKMT:.[BM+ALM<637$,LEC<-@S6SQ2$ M6#9
M?%74_$'QK\<>#='DL(? ?P:\*VE[\2]:G@+W5QXOU^VDU'2M!TZ56\NUM_#^
MA6DVK:X\D;37,MW8P*%4RUPTL3Q+@*V,PM',LSP57**4Z6+C2S/%THX>G@L<
MU'#J5*M:48YEB;4*<;PEB<3*:LJDYGI5\'PEF-#+L97RC*L?2SRO1KX*>(RG
M"5I8FMF&7PY\54C7H-PG_9.$C]:K5+58X/"1HMODA3-RT^ GPJLOB#HOQ4A\
M,;O'WAWP&GPRTCQ!-JNL32VW@J.![9='>WDOFM;K$+;?MMY#<7Q;<YN#*?,K
MG]-_9:^!FD_"7Q;\"]/\$K:_"OQS?ZUJ7BCPNFM:\XU.[\07S:AJDIU*34O[
M4M_M%R0YBM[R.",#;%$BY!P-'_;+_9HU[Q#H7AO2/BII%[=^);NVTS1=4CM=
M4'AJ\UB](%MH0\3S6L>AQ:Y*Y"1Z5+<I?B4BWV&8A3XAK?[4OQ*\-_MQ#X*Z
MG;>'C\$'C\#^&I=0^P,GB33/'/CW0-1U/P\;C45N=DFF7NHZ7<::(FMPPEF@
M4L26"=&'P'%=>=:C*KF>%G@,!_:L:685\7AIRHY/72H/"QK7]I7PF(QE3ZI"
M+3IUJM54W"<VGQXO,^",-##UU3R?&T\?F*R2=;+L/@\;&&)SS#Q>)CC)T$W2
MP^*PN I?VA5D^2I0H4G64X4H\OWCX8\,:)X-\.Z%X2\.68T_P_X9TBQT+1+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML<I0M&A'Z1HB(JA5"@ 8 X PNT  = !P!T  P!BO@OX\?\GN_L6?]@#X_?\
MJ.^'*^]EZ#Z#^5?49_4J2RK@VG*<Y4Z>08J5.FY2<*<JG$F?*I*$&^6#FH0Y
MW%+FY4Y7:/E.'J5*.;\;58TX1JUN(L)&K4C"*G4C2X7X>]DJDTN::I\TN12;
M4>:7+:[%HHHKY<^K&2?</U7_ -"%?E5\,_\ D[3]N?\ ['3X0?\ JMK*OU5D
M^X?JO_H0K\JOAIQ^UG^W.?\ J=/A!_ZK:T/]#7VW!_\ NW%/_8EP?_K29$?
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M_'UK!IWB"T\*7>I65U;""[T>#R))K-=/GG4PQH*OBCPS;ZY^SM\<O&&FZO\
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M^>O"OQ%B\0\93=*E*6%PT:6$H7J2E^+7B:]USXN?"+3/VDM7\/:OI6K?&O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)NSYE9^=U=Z]C]QJTZ&%P4G>,;0=V].B^[;MW>Q\1?'>_BMK6]+$;0H<<XP
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MA'_X?F3_ .8ZC[1^WE_T;%\(_P#P_,G_ ,QU?I]17L_ZX?\ 5-\.?=G_ /\
M/_U_I:^-_J9+_HJ.)?\ S7O+_JGO+\7W/S!^T?MY?]&Q?"/_ ,/S)_\ ,=1]
MH_;R_P"C8OA'_P"'YD_^8ZOT^HH_UP_ZIOAS[L__ /G_ .O]+4_U,E_T5'$O
M_FO>7_5/>7XON?F#]H_;R_Z-B^$?_A^9/_F.H^T?MY?]&Q?"/_P_,G_S'5^G
MU%'^N'_5-\.?=G__ ,__ %_I:G^IDO\ HJ.)?_->\O\ JGO+\7W/S!^T?MY?
M]&Q?"/\ \/S)_P#,=1]H_;R_Z-B^$?\ X?F3_P"8ZOT^HH_UP_ZIOAS[L_\
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MB^Y^8/VC]O+_ *-B^$?_ (?F3_YCJX'Q?\+/VS_C!XE^"ECXO^"7PS\"^%_
M7QQ\$_$W7-=TSXN2>([\:;X7-Z9;2UTG_A%[,W$EPUSG N(\*"NX9W+^OE%:
M4N-J^'FJN&R'A_#UXQJ1IUZ<,ZG.DZE.5-SA&OG=:BY*,I<OM*4XIM/E=M<J
MW E#$T_8XKB+B+$X>4Z<JE"I/)(0JJE4A44)RP^1T:RC*4%S.G5ISM?EDFQJ
MDE03P><Y^I^GX>U.HHKXD^Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\8O^"RW['>I
M_';X(:9\:/AII#7GQC^ <MSKMA96$9_M'Q9X G1W\6>%8_+9))YX46+7]+C&
M]Q>Z<T443O<;:_"/]F;XV6][8:?+%?120-$'1URNY&164LCG>C*"%=' DC?<
MCJ&4@_VZ31)-&T4BJ\;JR.C*&5T92K*RM@%6!(([@XZ$U_(S_P %/OV#_$/[
M(GQ+U?\ :7^">AW5Q^S[XZU:35?'6@Z/;%U^$/B_4KMI+[4(+*U5C!X%\0W,
MPG5X8XK/P_J4ERDJQVMQ$4_?O"?BO"XO"3X'SJO"DJDY5.'\56:C"->HW*ME
MLZC348UY)5,+S)15:52DIQ]I&+_F?QHX,QV!Q]/Q%X>H3K2I4:>'XGP="$I5
M)X6C**P^;PIP:YGA8-TL=RIU)8>%&K:U"HW]I^!_B+!>6UNK7<).8ERLBX)#
M#()W8YR <^O:OQKU'6SXE_:;^-NNW3J\EQ\3M7LX9<DC[%I=O96%M".HQ&MN
M'4YXWL/KWWPF_: CN+6SD_M,L&6$JQF#*YPDAD4D[7#(RL)%)5@2 Q&<_-MI
MKHT[XV_$@RRAFO?%T^O(Q?(DMM:M[::.<8)#!Y(Y<$9).\D ,#7[3PGP_5RS
M-<Z4Z/LYU<JJ4Z=[J2MB\+SI7VT2;26R\KGX#QOQ13SC).'7&K%TZ.=T:U5+
M5+_8<73BY>\[6<Y6VM)VUT1^R/PHU*."RL6#JNV"'<"1P2  <;N..>1STY%?
M2'_"51P6A99E! P067'T'.?H,>HK\WO GQ CM;2.,S("L,)W;V! 50>#SC !
M(], =0*[77?B_%;V;[+Q!B,D8G=<[0 V0,'C<.IYR3ZBOF<PX?KXG&R;I\TG
M._+9O>U[76FCOZJ_8^TROBG"X/+H-UE&U-72MT2?1VWZ;;*W0]C^*7Q,AM+6
M[S=1*ZP2X4MD$XP2 FYN!GH.W8 FOSLT3P5XS_:\^//@OX ^!GF>?Q?JZR^+
M-:@0R1>$O EA-;MXH\1W4F8RC6EC(]MI\4KH;G4[RUB@$A9S'S_Q#^*'B+QE
MKNF^#O!UAJ/BCQ;XIO8M%\-^&]$,UWJVMZK>SI!:V-G!$'*F2:11-<N!;V49
M:XN9$AB=A_3+_P $V/V#[?\ 9%^'5WXE\<FSUOX]_$RWL=0^(6MJL-Q#X?M8
MU,^G>!- N0&9=*T4RG^T)X76/6-45KYU*K!LKB+.<)X:\/3Q+E3_ -8LQHSI
M9+@K\U2G)\L)YA7IWBXX?"QE*4')VJ8A4Z:A)*;CR\+9%C_%SBF&$<9QX3RF
MO3K\08U<\(5X1E[2GE%"I&=IXG'6]GB(Q=J.#E5J3?.Z4:GWY\-/A]X<^%/@
M/PE\./"&GP:9X8\%Z#IWA[1+.! BQ66GVT<*LP7@RS2*\\[\M+/))(Q+.2>Z
MHHK^/ZE2=6I4JU9RJ5:LYU*DYMRE.I.3E.<F]7*4FVV]VS^Z:=.%&G"E2A&G
M2I0C3ITX1480IP2C"$(I)1C"*48I*R2204445!84444 %%%% !1110 4444
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M^'^;4,%"M[65JGUFO*;=E[SJR<I-::RE>3VU?F?H#=>,+>U@<M.JG 5<L ,
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M/+[%PRS+LM]FG=\Z:P"J\S4;.HXV]V[****\X],**** "BBB@ HHHH ****
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MQ'^%_BK2O%OA+7[6.ZL=2TR=)!&64"2SO;<'S;#4+217M[RQN4CN+:>.2*5
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M****U-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I" 00>A_S_GOZ<TM,D94C=WQL12S$G "KR6)[!0,D]@*/E?\
MK^M.H'\V?_!Q3\<_!>C_  F^&'P BTK1M1^)'C+Q"GCBUUZ:WMI==\!>'?#4
ML<9O]&O'A>73KKQ)J$Z:8X$T*76GVU\KB14.W\*OA+^SG^VKJ_P&TG]H3PW\
M'/%/Q ^%&JWVK:?:ZKX.1M9\03VVC7+:?>ZE>>#+=#KDNEM/'/;1ZEID%[#+
MY%RQ18U5VU_V\OB'X@_;>_X*.>+M$\,7$M_;ZU\4-&^!'P^CCD>>*UTW2=6C
M\+-<VL;9"0R:D^J:Q-(@"[!YV< &O[M/@9\*?#WP0^#_ ,.OA)X8LHK+0_ 7
MA#1O#=K#$B1B1K"SCBN[F14 4S7ET)KNXDQF2:=W8EB37]78_/9>#O 7!F68
M7!X;&YYG4YYQFE#'.I.E"C6HPJ8BFE3G"5*475PF%I25[2P^(G9MN)_%F6<-
M_P#$=O$SC_.<;CL7@.&N'E2X?R7$9=[&G6GB\-/V=.KSSIU%6I.%/%XJK&=N
M;ZUAZ<'%4U-?YWWACQCJ_@GQ%=:!=>'O%E@DMX\EC87?A;Q+;ZE97-S*7FTZ
M[TN33EOX LC,EK(T 78,2 'K]+:9\5/$5TPTK2M$\4ZEJCLUO'I6G>&O$-_J
M4D^ $CCL;2QN;Z0JWRE4MMQX.VO[X9O"7AFXNS?S^'= GOAG;>3:/I\EXN>?
MENGMFF7GGAQR:DM_"WAVUN7O;?0-#M[R0?/=V^E6,-TYXY>XCMUE<^[,>W'%
M>7/Z1,*L(JMP90J3A"T)/.*J2E;:7^P\TH7;2O+G4;>_?4]BE]%?ZO5D\-QY
MBZ%*I4E*<8Y)2<E&4D_<MF*C&?=V<&TY..K1_#-\2_V6_P!N.W^#.I_'#4O@
MUXH\&_#RQGM4U/4-?"V_B^QTV?:)=?7P1_R'+;1[=CF>_P!2BLGM(R)Y[,0*
M\J?HK_P1Q_X*#?"SX0Z'8_LN_%?3= \$0ZIK,M_X0^*\=O!9Q>)M7U-TWZ;\
M1;](E\S5GD"PZ/XBO;@6=S;?9]-4P"WMO-_I ^-WQ=^$'P?\"ZKXE^-'BKPY
MX8\(-$]A<IX@>*<:T]W&\']C6&BE9KK7KV]5VBBTJRM+NXN2=JP,>G\]TO[(
MWPMUW4?'OQT^$O[$EOX1^%>W4O%3^.OVKM:\36WA71M)C47%S?>!?V=_!]A<
M^,9M,!5[VTM=;N=-:.-V6VLXH1'$GSF9>.G"'$7#^<\.>(&48R.(E)8_)8<)
M49XG%85TU^YGB*5?$*G0^K7G+ZWC:E/"XFG4G3DH3C&3RK>%.;^&?%^09]X>
M<3T<?B:>$J4.(\IXCIU,57Q.!J<LZV*;RK+JL\%A,1[*,55Q'U6E@Z]&%6&+
MG3=:DOZ;8+B&YBCGAEBEAFC66*6*1)(I8W&4DCD1F5T=<,C*2"I!!.:GR/7I
MUK^8GP#_ ,%!=+\8^,_!?PFTK_@H;<>#H-8OM.\*^'KKP#^R59>&/AKHC/&E
MKI%A+J_CKQ9J&K064DZQ6%K<W-K"HDEC6Y$>2R_K++\'?^"@WA*%KWP?^UO\
M,?B4J+'+#H?Q1^!R:4E[C#>5_P )!X,\4PSV7G1[E^T#3;H)D,(GSMK^9,+Q
M+2QSJRP.6YCBJ%&IR2JTJF3U9Q3UBZE&CFM2HG*.MH1FKJ2CS-6/Z%R7CO!Y
M_1JU\GR[$YM2PM2-#&U,IS+AS,8X6NX1FZ<X8?/)UOA?/"/)[6<=J?/>*_1'
M(]?;\?2BOS@7]M'XE_!.[@L?VR/@)JOPR\.R3I;?\+M^&5_=?$WX0"5G\M;W
MQ')8Z;:^)_ UK.VQC/KFD36-L91Y^H!$,M??WA7Q9X:\<:#IGBGP?KND^)O#
M>M6D%_I.N:)?V^I:9J%G<()(I[6\M9)898W1@05<XS@@$$5ZV$S'"XR4Z=*<
MHUZ:O5PU>G4P^)I+3WIT*\*=7D;=HU5%TYN_).5G;ZC 9O@,QG4I8>K*.)HJ
M,J^"Q-&KA,=0C+X9U<'B84L1"G)W4*KI^RJ-/V<Y)7.AHHHKN/3"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH _)W_@LS\=_ _P8_8C^(FE^*-"\.^+-<^*@M_A_X*\->([&WU&SEUO4
M9%FFU];:XC=5F\*V$%QK5G<+Y<EOJ%K9R0S)*%)_D%_93_9[_:\^,W@?QUXW
M^"?P]U?XI^$/A;-I6FZ\^GZE:1^)9;BYMS=_8]&TV^E@/B;4+*R1+F]L]/G%
M['%/;LD,DDRHWZ#_ /!P/^T%<?$3]JKPY\%-,O7G\.?!3PC:F]M8I"T1\<^+
MI'O=1,T*Y1I[31(-)A@/,@^UW$>,=?Z1/^"7G[-UO^S5^QA\(?"$EFEEXI\3
M:-!\1/'3M$BW4_BGQA;0:C=0W+H%9SIMF]EI<)<EDM[*./ "@#^H\LS)^%'A
M1DV90PU#%9]Q=F4<PIX?&.M+#QP3A&5ITJ=6F^7ZA"DN:/+*&)Q?.Y-04)_Q
MUF^51\:O&S/<GJXC$X3AG@7*)9=5Q>!]G2Q<\S=7E?LL1.E52;QU6LN2;<98
M?+G%4U[;G7\/6O:UXS\ >-[^7Q9X+\<>$]2OKG_B?:+KO@_Q+I6JV&L0%+>6
MZ:PN[&"6X6Z)5+@1;R'A659'25:^@=)^+6J6\%O -,\0?:+B*$V]M_8.N?;I
MTD1?*,5F]HLSF4,IC"!V8,,#G-?W[ZAX8\.ZK*D^I:!HFHSH0RS7^EV5Y*K
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M+ JP.5(9A@C!(YJ6OH3ZK^N_Y:?<%%%% !1110 4444 %%%% !1110 4444
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MK7NM^(M7U#7]9NV4$;)]1U"XN[DA,E0#,J*.BJ.*_0_]B3X+?\$X_BVVDO\
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M<<8?EFLVS#,Z,,=F:KXFEB\=A\=BJ&.KUZ>)QV%Q=>AB:JE43A4=2E3^#/\
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M^8P.[^NDR"5/W>6W#(^4X((S]YL*1@C."1VYK^;_ /;@_P"",/QO_:8_:O\
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MC@\1.G][Z#HUAX=T32= TJ!+73-%TZSTK3[:,;8[>RL+>.UMH4&!A8X8D0
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M5<8QBIU9R<81C3ARTX0A$HHHKK.X**** "BBB@ HHHH **** "BBB@ HHHH
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MZ&8_'-W=7D>G7$EPT&KZCX;UC1;^2"UU6YC2:U76'BU:/R)I&A0F0./[8?\
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M#29^<G)HMOMKY>:=_731^8N?;W>EM6GIV>GG?3K^/\^O_!)_X0Z?\=OVU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+'Z@KG:,^GZ=OTI::AR/IQ3J^W/TU;+T04444#"BBB@ HHHH **** "BBB@
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MX;BXM)7;O9VM9.VE^K2OJEOU[?0]%%%,@**** "BBB@ HHHH **** "BBB@
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M,H3C-QOM=1;M?I<LT445J:!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 454OK^QTNSNM
M0U*\MK"PLH)+J\O+R>.VM;6VA4O+/<3S,D<,,:*S/)(RHJ@EB #7G9^-OP;4
M GXK_#D!B ,^-?#@R2,CKJ/<<_2LYU:5-I3J4X-IM*<XQ;2M=I-IM*ZOZH[<
M+EV88Y2E@L!C<9&#49RPN%KXA0DU=1DZ5.:BVM4G9M:GY3^(=49?VPOVNK?<
M +34_A&>P),WPZL67&#DX'!SC!Z#O7F/[3FM-%\&O$$A;IK'@L=><GQIX?Z9
M/Y^WKTIE_P"*]%\1?MG?MFW_ (?UG3==TEM6^#"6^I:/?6NI6$KK\-;))XX[
MNSEF@D>.9&20+(6C=2A"D,*\T_:YU5+/X#^*;EY%@B@U?P/++-*ZI%%$OC?P
M^99)'D^5$2/<SLWRJH+<8)'\YYOC4\PSA1Y9169YJU)-<KC3S'$3333:DG%)
MIIKFNEL[G^BO#&1M<5>%U"K0G3K3R7P;C.G.#C4A.MP?P?*5.<)<LHSYYM2@
MXJ2;M:ZU_HRT@YTO3SZV5H?SMXJT:\>TCXV?!U=-TV-OBK\/%?[%:(4?QEX=
M5O,^SQG9C^T =VW!VXSCG&*]&T'Q-X<\4V(U/PSKVC^(=-,TEN+_ $74K/4[
M(SPD"6$7-E--"98RP#H'+*2,@9K^BJ=:C.T85:4Y<M^6-2,I6NE>R;=KZ7VO
MIN?YWX[*\SP;J5L7EV/PM%UI057$X3$4*;DY2Y8J=6G&+DU%V5[NSMLS;HHH
MK8\T**** "BBB@ HHHH **** "BBB@ HHHH \T^+7P?^''QR\$:O\.OBGX3T
MGQCX/UN$Q7VDZK"S!7',-Y8W4+PWFG:C:2!9K/4+"XM[RUG1)8)XW4&O@NQ_
M9Z_;7_9IC:Q_9M^,GA3XY?"JR.-%^#O[3-QJ\/B3POIT?R0:)X5^,N@Z?JNN
M7UE;P$6UG%XQTO5)K>"*.,ZC*-U?I_2$ C! (]",CU_G7EXW*,)C:L<5>MA<
M=3A[.GC\%6GAL4J:;DJ52</<Q-!2;DL/BZ=>@I-SC34[27V_#?'^?<-X&ODL
M8Y;GG#6+Q'UO%\+\2Y?0SG(JF+Y(TY8["X?$)8G)\SG2C&C/-\BQ>5YM*A&-
M!XUT5[,_.(?M.?MK:7FRUK_@GUXAO]21%7[9X3^.'P\U30)9-NUWBO=5&C7R
MV[$$JT^GK)MP'C!XJA=>(/\ @IA\8BVEZ!X ^!G[)^@W/[N?Q;XK\6W?QH^(
MEA;N"KSZ1X2T+1]*\'#4!E7B.K:]<VL;Y66WG (/Z5A%'0?S_P FA4122J@$
MC!/<CKC/I7,LFQ4DX5^(<ZK49*SI1>5X636FCQ."RS#8R+TMSTL12G9OWKZG
MMP\1<BPC5?*_"3PVP&81M*EC:\.-<_I4*JLU5IY/Q/QEG60XA*2YO8YEE>88
M>3;4Z4HWB_C3]G?]BSP)\#?$>I_$_P 0>(?$GQH^/7B6U%KXI^-GQ*NUU/Q3
M<VQ8NVD>&M/B6+0O!?AU7(\O1O#=A8PNJ0BY>X:)'K[-HHKT\'@L+@**P^#H
M0H4N:5248W<JE6;YJE:M4DY5*U>K+WJM:K.=6K*\JDY2;9\3Q%Q+GO%F9U,X
MXBS/$YIF%2E2P\:U=PC3P^$P\%3PN!P.%HPI83+\NP=)*C@LNP-##X'!T8QH
MX7#TJ48P111174>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<GXY\#^%OB3X3U[P-XVT:R\0^%?$VFW.DZW
MH^H1F6UOK&[C,4T3A61T;:=T<L;I-#(%DBD1U#5UE%3.$:D90G&,X3C*$X22
ME&49)J491=TXR3:::::;3(J4X583IU(1J4ZD90J4YQ4H3A).,H3C)-2C)-J4
M6FFFTU8_F?\ BU^Q_P##S]BWQN=)\?\ PT\.>-_V:/&NN2Q>!/BWJ.E?;-;^
M%.K:K<Q)%X)^)UVS+Y_AJ>>[:U\.^++EY62-8[+4660(\GTIX5\-^%?!.DQZ
M/X*T/1_#VA22-J$%CHD*V^G2O>!)GO(50[)#<XC=YXR4E9=R$J0Q_:3QIX-\
M,_$'PMKG@OQEH6F^)?#'B33;K2-;T35K>.ZL=1TZ]A>"YMYXI 1AXI&"NA22
M-R)(W1U##\%/BM\,O%7[ WB2#2O$=]JGB?\ 9!\2:D+/P3X_O&EU'5_@/?7D
MNZW\'^/;UML]SX'FDG:#P]XCEF>32TMX;._D48FE_,\TR&GD-66+PF'I?V95
MD^:<*-.-;+I5&OW=6I&'M9X&I-^[6;G+#RE&%:]']['\9SGAC#<(U)8S X.A
M3R"I)\U:E0HPJY%*<H_NZ]2,8SGD\VDH8B<G++VJ=+$-X)1JX;T+QCX=\'>,
M=#FL/'NB:%KWARP8:K<V_B*))=.M&M$<_P!HO+(\4=LULK$^>\L:HC.2Q^Z?
M O@5^Q?\./VT?&EGK>A?"[P_X"_94\':N7O?&-AH\FD^)?COKNEW&UM)\*SA
MA/IWP\MI_/BU?6XI$O-;G46]H_D^9*/2_@I\&/%'[?&O+JFJ#5?#/[&GA_40
M;JZ/G:3KG[2.JV%T5EL-/EC"W5I\*[6:.:WOKI98IO$$L*QVS-;,\P_>KP_X
M?T3PMHNE>'?#VDV&B:)HEE;Z;I.E:;:PVECI]C:1K#;VMK;P*D4,,42(BHB@
M8'.3S593P_2SRI#'8W#4UEL)QG256C3=?,)TVG%JHXN=/ *:^S)2Q3CHU0;]
MIIDW"^'XKJ4\QS'!X=Y)!P=*57#498C/E3DY17M)0<Z>2PFTX24E4S*:ER*G
M@%SX^/PSX9T+P=H6E^&/#.EV6B>']$LX-.TC2=.@6VLM/L;:,1PVUO"AVI'&
MHXP 2268LQ+'=HHK]+C&,8QC&*C&*48QBDHQBE91BE9)))))*R6B/V.,8PC&
M$(QA"$5&$(I1C&,4E&,8I)1C%))))))))6"BBBF4%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZWG7_03E?_A!BO+_ *F_]?-A_:?$W_05D7_AHQ__ ,_OZL_*[?\ AY-^P_\
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M=O\ P\F_8?\ ^CC_ (??]_=4_P#E?1_P\F_8?_Z./^'W_?W5/_E?3O[#T/\
MZ >B?^"31_\ Y H_L/0_^@'HG_@DT?\ ^0*/K>=?]!.5_P#A!BO+_J;_ -?-
MA_:?$W_05D7_ (:,?_\ /[^K/RNW_AY-^P__ -''_#[_ +^ZI_\ *^C_ (>3
M?L/_ /1Q_P /O^_NJ?\ ROIW]AZ'_P! /1/_  2:/_\ (%']AZ'_ - /1/\
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MC_A]_P!_=4_^5]'_  \F_8?_ .CC_A]_W]U3_P"5]._L/0_^@'HG_@DT?_Y
MH_L/0_\ H!Z)_P""31__ ) H^MYU_P!!.5_^$&*\O^IO_7S8?VGQ-_T%9%_X
M:,?_ //[^K/RNW_AY-^P_P#]''_#[_O[JG_ROH_X>3?L/_\ 1Q_P^_[^ZI_\
MKZ=_8>A_] /1/_!)H_\ \@4?V'H?_0#T3_P2:/\ _(%'UO.O^@G*_P#P@Q7E
M_P!3?^OFP_M/B;_H*R+_ ,-&/_\ G]_5GY7;_P /)OV'_P#HX_X??]_=4_\
ME?1_P\F_8?\ ^CC_ (??]_=4_P#E?3O[#T/_ * >B?\ @DT?_P"0*/[#T/\
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M_P""+2?_ )"H_P!:.(/Y\EZ?\R_,/+_J:_UK?=V/]5/!O_H0^)W_ (GG"O\
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M<_\ !%I/_P A4?ZT<0?SY+T_YE^8>7_4U_K6^[L?ZJ>#?_0A\3O_ !/.%?\
MZ6W]7?E:_P#\/0?V"O\ HYOX<_\ ?[5?_E?1_P /0?V"O^CF_AS_ -_M5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>Y['SMV.6(!"A6)()VY  R1GJ1D 9)P 37\76H?M1?M91_\ !.C_ ()"^(?
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MCT/4?$L6BW4\/@_Q;KVG64HMXGU*VDLHM4>W6!9GM;ZZ5%:02'\:?V+?C/\
MM'>%?VZ-!^#O_!1[XS_M@?#_ ..OQ?U_X@:7\-_#UCJWA"Z_9,^*/AW5]/O=
M.T*V\'1Z+:/?Z'?:$9CJ>B:MIUU<6K:G#9Q70@:.0R3&A=R7-=QM=QU5F]]M
M%'[7;KV.>&"G.6(BJM)_5_B<)<_.M?>II:SA:+NUMS1?K_5,$<L$".6/1=C;
MCWX&,GC)^@)Z T!&;.%)V]< D9QG /0MC^$9;VK^*KQ9^UQ^V9\-?!7QI_X)
M?WOQM^*.I?M>WO[=?@OP%\+_ (G7&NWL_CJZ^!OBFW34FO=.\02'[<+#R;.T
MN-R$H+749T,W+N/I3]J'XF?M6?LN?MH13_M>_&_]KWP!^QSHOB#X;^!/@!\6
MOV>-;\):O\/)SI<^FV]W;_'?3M1BFU36M?\ %+6=\/%"3R0:JCWD]S:VDUJ+
M6-:^K:7Y[W5XJ.K:].[7XZ6ZF_\ 9=1-+VU)N4)U()1GS5(15-Q<(I2<N?VC
MVU7(]'=,_J*'Q+^'3^/C\*8_&_A9_B>-#?Q._P /X]9M)?%T7AV-@KZW/H:R
MM?6VF!B +J>&.%B5V,P()[<(Q0R!6* %BX!*A1WR.,=P>XY&17\F>@_ #_A(
M_P#@X8^*^FP_M&?&;P[&WPH\/?'33M?T3Q1I>F^(?$VG7UMIOB"W^#BW%U:@
M7?PY-FQTVST*"V:Z73F6+S Z>8/F#4?VW_\ @H5^U'XD_:0^,?P9O/VU[KXI
M_#;XV:IX<^#?P]^!VC^#9OV9O _A;PSKLT+^$_B]H.I1OXAUG6]4TN*=)[NZ
M3<)@KI+M=O+;PUVO>2T2=]-7LO/2ZO9*]EI9E_V6Y.*A6@DJ5*I4=1."C*KR
MJ,;^<G;572U=S^VL(Y( 1R6("X1OF+ D*..6(!(4<^W(H".0S!'(7ASL;"'G
MASC"'@\-BOY5/&GC;]M?]J#_ (*1>)OV>=-_:<^*O[)NG^*/V$OAQ\7_ !YX
M2\)+!-<>$?'MIX$A\2>(M!T73=2CFB\-7EWXK+0:_>6,AU Z5'+9Q7+$9KX-
ML?VH/^"A8_8&T']O*\_;@^)MUK/[/W[3^E?L_P"G?#$:?I,'A[QKX>M-3 O=
M?^(%X;2.[\5ZW?M_H3C4@\8TP;&9;@O(96&OM-/X5IWEMK]_339NZ(CEDY1I
MR]O2_>*G:/OJ2=;G]FK6:=W!WU6EGUT_N;__ %_G_G\^.HHKGO"&LS>)/"'A
M+Q'<Q1P7/B#POX?UVYABQY45SK&DVFHSQQ8)'EI+<LB %L* -S8R>AKF:LVN
MW]7/-:LVGNFU]P4444A!1110 4444 %%%% !1113CNO5?F!XM^P#_P ED_;]
M_P"S@_#/_JM-!K].:_,;]@'_ )+)^W[_ -G!^&?_ %6F@U^G-=/#/_(GH_\
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M"OA]^TO\'_&WP+^*EMK%[\//B'I]II?BJPT+6;O0-1OM/L]1M=4BM8]4LO\
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MM$M/)V1^>GQ]_P""67[$_P"TEXVLOB7\1?AEK%A\0[31-)\.77C7P!X[\5^
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MWFD?#OX>Z7+H_AG3-3U2ZUN\M[&:_GU&5+G4;_S)[IFN+F9OWH,>R1HA$J8
M]@ )( SDD 8 +$D$C /!/&<'CUXKS#P_\;/@WXJ\::I\-_#/Q5^'OB+X@Z&D
M\FK^"]$\7Z%JOB;3EM25NOM>D6-[+>(;4JPNE$)-L01/L(I.KB*L9J56I.*<
M)SBVVDZ<.2$GI9<D$XQU5ES)%+#X.C.+5.C3G:<8M)1E:I)3G%/324K2:ZNW
MD?#&O_\ !'O_ ()[^)OBM=_%W5O@1 VM:CXC3Q?JWA>S\4^)+'X;ZSXJCN9+
MI->U3X?VU]'X>NK\SR--(#;K:,[;5M512'^F/%G['_P)\:?M&_";]JG6_#>H
M'XO_  2\+7?@OX=ZC8:Q=:?H.C>';Q+Z*2Q?PW;A=.NA'#J-U%;&0*MNC($4
M^6@'NWC'QMX-^'GA[4/%WC[Q5X=\%>%=)6-M3\1>*=8L="T6Q$SB.$7.HZC/
M;V\;S2,L<,7F&65R%1&)K)\&_%/X9?$61HO /Q#\&>-)%TBQ\0-'X6\2Z1KK
M)HFIW%Q:Z=JCKIMU<M'8WMS:W-O;3R[%EE@EC!WHP%2Q&+G!2E5KRA&$H1DY
M2<5!KEG&_P +4D^6=[MIV;Z&:P67QE*,</AXRE*-224(IN<9*=.;TW4DI0Z<
MRNE='D7P+_9$^"'[.7CWXZ_$KX6:%JVD^*_VC?%X\<_%*[U'7[_6;;5?$0N]
M1O?M.G6EX3'I,'GZK>L;:V)C(D0<+&BBIJ7[&WP&U?\ :5U7]K.^\/:O+\:=
M9^&5[\(;_6U\1:E'I4G@?4;&YTV[L5T-'%E'=R6=W-&+V,+,C%9%(D425TG[
M5GQMN?V;?V<OC%\>+3P_!XJNOA=X,OO%-MX<N;UM.M]9GM9K>"*RFO4CE>VC
MD-QN>5(W=0G"GFO)/@!\6_VQ_&K^'/%_QV^"/P-^%_P=UWP''XVE\4^%?BYK
M'B?Q%I<%_HUGK>DQWVDZAH=A8);"TN)7U>Y>\06<<;,N=G[S2/UJ<*F*]O;F
MO2G.=6U2I%*'N6>LXQC&&FJ5HK>QG-8"G4IX1X>.C]K&,:5X4Y2;]]M?#*3E
M)WW=Y=W?B1_P2R_8Z'[,=S^R&/!?B8?!*[^)*?%B;13XUUEM8_X31+O[:M\F
MO@K>BV6;A;1@T6P[?O#>?7[O]B;]GZ^^/WA']IFX\.ZR?BUX)^$UQ\%-!U=?
M$FIC3;;P#<:8^CM82Z1O^RW5^-/D>$:I+_I =C.09<%?6=&^/OP*\0>)=%\%
MZ'\9?ACK/C#Q'I=OK6@>%],\;^&[OQ!K6E7EN+RTU#3=(AU&2]N[>[M&2XMV
M@AD\VW*S1[D8-6GXX^,7PC^&NIZ#HOQ#^*'@'P)K'BB7R?#FE^+?%>BZ#J&N
M2;UBVZ99ZC=0W%X!*PBW0Q%/,81[BY"U'ML:W9U:[<G5D[N5VZB_?-Z=5&U3
M3:+3V-%A\O:NJ-"T?91^%:>S?-16J^PY7@OLWNK7/C&/_@EA^QU%^S)JO[(:
M>#?% ^".M_$@_%?4-%/C75_[7?QH;H7AOH]< ^UBU\[</L#;K?RR%P3DGVH_
ML7_ ,_M$?#G]J0^&]6/Q@^%/PU3X2^"]7_X2+4AI5GX+CLVTV.RO-#+-97MT
ME@\D!O) )'+;I [*I7U76_CM\$?#7@^W^(/B+XO?#K0_ UYJ5[HUGXOU7Q?H
MECX=O=6TV[N;&_TRQU6>X6VN[ZTO+*[MKFUM_.FAEMY4DC4QL1U6D_$#P#KW
M@V/XB:+XU\*:MX!DT^;54\:Z?X@TN[\*-IMMN^TWQUZ&Y_LU+:W*.L\KW"+"
MR%9-K BAUL8]?:UFZCJ1O>5YNI[-54VUKS\L%/ORI=$)8;+^9)4</S1C3:M&
M/NQI\SI._10YI\G\MY6M=GYF^*?^")?_  3A\7Z_\2_$>J_ ZZAU#XIO>W&N
MQ:=XT\26>F:1J.HW:WU]J_A+25O&TWP_JMQ<*1]JAMIC!#)/#;)%'<2*?J30
M_P!A[]GKP[\>OAK^TMIGAS6H_BS\)OA/8?!7P7JTOB749M,L? .F::VDV>GW
M>D.3;:A>Q6,CP_VE<$SMD.P+@,/8O!?QX^"/Q(N=.LOA]\7_ (<^-[S6/[3_
M +)M/"GB[1==NM071EADU8V\.GW,SS#3DN;=[PQJWD)/$TF%=2;-C\;?@WJ?
MCZZ^%6G_ !6^'E]\3K$3&\^']IXOT2;Q;;_9T\VX2;08[E]1$T$699H?+$D4
M69)%1!D5/$8Z:Y:E>NXQBX\DG+EC%QC3E&UM$XQC&2ZJ*WLB88/+86E3P^&7
M/)23C3@G*7,ZG,VDFVY3<[MZN5]6T?.'@G_@G3^R/X$\"?'KX8V/PR_X2#P#
M^TMXQN/'?Q=\,>,-:U#Q#I^O>)+AS*M]9FZ<7.D&UGVW-E]AN(IK2X5)8I\H
MH&1^S1_P35_90_9'\=2_$7X*>&?&VE^)O[#OO#=B?$?Q,\;>+-)T?0M2:,W>
MF:1HVMZQ=:=8VY\J/RF2W:6, HK@$L?JNZ^,WP@LOB!:?">Z^*/@*V^)]]$)
M[/X>S>*]$C\8W<30/<J;?P^]Y_:#LUO')<*@@WM"C2JNQ2U?.W[7'[37Q!^
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\JOVA?^4BG[/?\
MV;=\9_\ U(/#5?0M?/7[0O\ RD4_9[_[-N^,_P#ZD'AJOH6OC,/_ +WG'_8U
MG_Z@X _.:'_(TXF_['S_ /5+DP5^8/\ P65-S_P[>_:0%DT(OCIO@;[$MSY@
MM'N_^%E^#A;"Z: &X%OYYC,_V<-.8/-,*F0*5_3ZO(OCQ\#OAS^TE\)O&/P4
M^+6DWFN?#WQU96MAXCTO3]7U'0KVZ@LM0M-4M3;:MI5Q:W]G-#?6-M,DD,Z\
MIA@17;%I23>W6_;Y:_+J>C2FH5:<W>T)PD[*[LI)NR1\P_ N^_X*517%M/\
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MPS\0_ N@CQ1KK7FE>*_"7BRY\;Z'?S:RUX-2U""U\27EQ=R6EW<26]Q&P@>
M1*BITNK34FXVUM]BRTO=6=TF[IN7EK>QU.O13]U74IQ<W[%1?LX\W,K.=1MO
MF6MXMVLDK'Y8^)?'G[6OQ\^$G_!03]J;P;^V+XR_9^F_9E^(7[0WP]^%/P=\
M,>&_A[=_#[3=)^ >DR-+>_%2+Q-X=U3Q!K/BGQ]+#)J=E?66N:;;Z-+>Z7+8
MVMS&IM6Y#QO^TU\>?B9X=^ ?AGP=\>_VK-7^(%M^PY\&_C%X^\"?LA?#/X=W
M/C&T^(/CSP+8:VWQ%^.OQ4^*5M_P@^C^&]:8R7FC>"]%MM-O;E3<ZK<2&W\J
M"3K/VP?^":OQQ^.GQ._:)'ACX1_ "X\/_M!2+;K\4K;XT_&CX965E:WGAZWT
M-O$?QG_9]\/2ZCX-^+WQ"\(,UU<^%]<M+S1M/U.2STF;Q#83/'<"3[SO?^"8
MG[+GB'1_AS;>+-&\9WVM^!_@Q\//@9KVM>&/B/XX^'\?Q3\"_#?1;/1M#T7X
MGZ5X-UO2+#Q?8+%9@BWU!-\<,SV8G^RJD5.4XJ*DFD[JRLFTN6SW6J;MT:72
MQNJN&A&FY--\T7&,81E*G'D2:EW]Y.ZDU*\OY5S'YY_LY?M0?M2?MR+^PU\%
M]0^.OB'X :A\2?V//'?[3'Q@^)WPNT7PG;?$7XB:]X,^*Z?"#2?"/ABX\0:-
MXD\/:!:QK*GBGQC/I>D32W3JUK8+;6<L,L/D>M?ME?MK_"/P/\?/@K#\8O$O
MQZ^*M[_P4WT#]C?P-\6K'0/AKI?BCPQ\.M1^#/@SQO=1>&-/U670/AI9_$;4
M+A[[3;*X\4RW.B#Q7?:E=/;JIMH(ONK]H_\ X)U#2?A[^SE\._V7_@[\/_%/
M@'X!R^.+;0?#_B+XR?%3X.?&'P7:^,=1FU?=\+OC[X3OM2U33="-U>ZE8Z_X
M-\1Z5J6EWVEOI8TZ2TN-/##8_9#_ ."7G@;P!^S;\9?@[^T=X,\"Z[#^T#\<
M]4^._B'P%X.U[QAK'AOX;:P=*T#0_"EIX1\?:]<VOCJ^\5^'K3P[#JMUXZ>Z
ML]5N_$&HZE=03K;RF-ZYZ:3DDK7O%/5QUNG9[Z76]]>X*KAX4^:T90;7+1Y*
M;FI<_,Y-MMI<MDTWROE2BV[\ORQIOQ=_X*4?#_0OVG?AS8ZAXUL=2A^"'AKQ
MQ\&=9_:]^(W[+\GQM\.?$&_^(6G^%M2TJSG^'.M6WA34_#OBK0[C5(_A]J?C
M/0+.VM_'MDFES7=W!,L#?2W_  3U^.'Q"OOC;\3/@9\8_BG^U%)XR@^&^A?$
M;1_@M^V-\,_!&@_%71;>+66\/>)/&/A#XG?#%+;P1XU^'EYJ+VVFC2;:QEU#
M2=5$K1ZA+;*R)]3^%?\ @G3^R5X9\#_%7P'>?#J_\=6/QOTO3-#^*7B+XH^,
M_%WQ&\<^+-%T.6"[\/Z/=>-/%&KWWB*ST[PYJ$$>HZ#;Z7J-G'INIHNH6\<=
MT!,>O_9^_8I^ ?[-7B37O&WP[TGQ=J?CKQ#H%CX2O/''Q(^(/C#XF^+K7P=I
MEU%>Z?X-TC7/&>JZO=:1X6MKV);T:1IS6L,MRJ2W!F=(S'GSP<6KJ[M;[-MF
M_7]6K;7,*E:C.%6/)K+D<)1@H/F2BG=.4M+III:[N[OI\;ZH=/?_ (+>:&/B
M*ENR1?L'0S_L[/JYS!#XP'Q.UZ'XNKX3:8?9U\1/H$?A\7[P?\3-]&#1QLUN
MTJGLOV[]:_9:M)?C[H^I6N@3?MAZM^P-^T?_ &!>VMCJLWB:'X,Z;X2U^XU.
MTUN^M-VEZ;I,FKL9M)@\1>1/<W2SKI+MF2-_KS]HK]E'X%?M5:'H6B?&KP8N
MOR>$]4EUSP7XFTG5]9\)^-_!&KS*(9[_ ,)^,?#-[IOB#19[JW"V]VMKJ M[
MN"-$NK>4HA7SGX7_ /!/S]ECX1>%_BUX8\)^ M2NKCXZ>%=1\$_%?QQXM\9^
M*_&?Q)\8^%-4TZ^TNXT&_P#'GB;5-3\20Z;%:ZC=FTM+&^M(+::2.YB1;F&*
M6(4XWBW*R5M$[;-._KN_5;F<:M-.G.7M%*$(04(J/*^24=9-/[44W)<J3GKS
M6;1\=_$^3P9)_P $'84^)+Z:OAL_\$\_!8LAK:"2)?$Y^#VC1^#WTI9S(QU]
M?$S:4=#:R!OH]1-N;1DEVD]+\(](\>ZQ^SYX/3]G;6?V>]"_X*+7?[(_[-6D
M?'/7/C+IWB37]>TWPS/\.+EO")\3V'A;4;+5;3_B:-J4VBW>H0SZ062[DU?3
M]0,=O&O8^ ?^"/?["W@#5_"FK0^!/'WC.#P/=Z1J/A7PM\3OC%\2OB%X$T>^
MT!UDT.XA\$^(/$=QX;E.BND+:9%<Z=-;VCV\1CB*C ^@/CU^PQ^SG^T;XIT_
MQY\0?#/B73/'=AX=N/!LWC3X;^/?%WPO\4:UX,NF#S>$/$NJ^!=6T.?Q#X95
MC(T.EZL]W';>=,ML8%E<%NK"Z2DVKN=VGVU3=[W?1-VLW:QHZU+FY5.I*#J.
MJY2A>SZ4^3G=X--\UI>\U'91:?B7_!(35/"VI?L&_"31_#&EZOI#>"/$/Q2^
M'?C&'6=6L-<>\^(_@SXF^)M&^(^LZ5JVFVEAIU[X;UCQ;'JNI>&WL["U@BT6
MYLK<1R-"]Q-^9GA[]I#]L?P1^QW^U7_P4!\0_M,>/OB%=_"OXG?M!_"CX3?L
M_P!UX?\  5M\+[.VM?B]<?#KPOXO\?W2^'++Q)KNI>#9[]K_ $_[-XDTC1H=
M/TG2;355N(VNW/\ 0_\ "?X5?#KX'_#WPO\ "KX5>$]+\$> /!M@=,\.^&M&
MC=+'3[5IY;F=]\SRW-S=WUW-/?ZA>7<UQ=WE]<SW-S-+-(SGSKP5^RS\"_ ?
MPD\:_ K1_ UI?_"GXCZUX_U_QOX/\3WE[XFT[Q!?_%#5KW7/&JWIU6::>2SU
M34M0N9(K0311V49C6T\DPQD*-2FI?W.:+M:[M%IM;)JZ32>ZO=7=R(8B"JU9
MNFW&I5A*TDI/DNY35Y+1R_\ M;]5^,?P_P#CO_P4!_9_\?\ A#Q3\0],^/GC
MKX<>*_A7\4O%'CGPY^T[XV_9;D.IZ_X-^'>H>/\ 0M>_9ZTSX*ZU!XM:TEU'
M3O[/UGPS+9^([2+P[JD%\U]:75J95]Y_9M7]IO7_ (2?LO?MF^._^"A:QGXU
M:IX(\1>._A'X_P!'^'.G?L[:CX=^(GVEH?A1\+(K#2M+\7Z3\1+ O:Z1X<U.
M7QAJMYJ&N6>J17FEM%/L@^T_@A_P3]_9@_9_\:1?$#P+X/\ $FI^*M.\.7W@
MSPMJ/Q&^(/C/XFIX#\':DR#4/"W@.U\:ZSK-MX4T*^BCBMKNTTN.*2>QC6RE
MF>V+POA^"/\ @FI^Q[\//B%H'Q$\,_#G5HY_"'B2[\9^"/ NJ^/?&NN?"3P%
MXQO7>6X\4^"?A=J>M7'@[P[K:32S7-C=6.E1)IUS<32V$=J[*Z#J0E=72TBE
MIT6_SU3?1<O=LTEB*+YDDXZ1BI*DKU(J]X-24E"_,O?Z**25E8_%'PE^U]_P
M4B^,7PKU+]L_P+:_&K18)?B/K;>%?">I^*/V6/#/[&&E>"_#OQ$G\(-X&^(5
MIXN\267QC@UV]L[2XM=6\2W.NZ=K<7BB>T.F:8--\C?]A>"/^&M?VDOBM_P4
M,U33_P!N7XB_!#P_^S=\7KS0?A1\./".D?##4-)\-7$7PK\)>-F?XDWNM^$]
M4O\ 6_ 375Q/8V^EVUYIYG6#7=0BUDNL*5]SZK_P3-_8YUOXBWOQ$OOAGJ;?
MVKXVA^)6N?#N#Q[XUMO@UKWQ!@E6Y3QEK/PB@UJ/P+J.MF]47\TLVCK;SWW^
ME7%M+-^\KYI\*_\ !*?P!XU^.?[:'Q5_:)TS5;Z+X\_'-?%'A(?#OXN>/O":
M^)_A+_PA/A339?!_Q0TCPU?:#9:O8/XETW5;D:+J"ZBH@GF*7B0WGE+7-"\F
MO=7*[)QW=T[7MI97Z.[O?HE;Q.'FVTHT^6"M^Z3E%.=)^S46_?M%3]ZU[2TL
MK(^ ?@C\7_B)\=_VSOV9OVS_ !-XT^(&C>*K_P#X)3^/OC9X@^&WA"30K?PA
MK=_\/OBCJ>@ZIX.TVSO= O=:C\ ^/]4T@>,S8_VH=8.IW5C)8ZS9VZB!O8&^
M,_[87@+]BWX*_P#!3;4OVN]?\=ZO\1/$/P8\2>+_ -F.;PWX$3X"7_@GXR_$
M70/!=Q\-/AW#9:$OC>P\8>$]/\1>;8^(KCQ5?7VHZMI-['>6,<;M(O[">(?V
M,OV>/$/C[X*?$D>"KOPQXH_9^\.MX,^&<O@;Q#K?@W2]-\$;K>5/ ^KZ1H-]
M9V'B+P7%+;121>&M9MKS3UE,S%&69P_E/AG_ ()C_L:>$?B#HWQ"T7X::J#X
M8\97'Q$\)?#Z]\>>-=1^#WA#QW<3/<MXO\+?">]UN7P5HNMQ73O=VDUKI:6]
ME>2FXL[>W=(V1>TIZ:I644^J;O=M6[O>VW?2XOK-!M/DDDK>ZZ<9>YS5+T[R
M::TE!\ZNTXM))H^*/A'KG[8?Q=^(?_!03XK6W[77B3P[H/[+_P >_CS\.O@=
M\%-6TWP!HGPEU74='^'\.H^'(/C/XGU;PY<>()?!NAZ_K.BRVL6GZWI<MA;6
M=_-J.HW"7/R9W["?Q[^/VF_M%?#'X8_M._%G]J+0_&OQ<^%>OZI)\+/VD/AI
M\,]1^'?Q$^(/AW3K'7M;\0?LQ_&'X3R0Z):>$](L9-2U6+PYKQU>[U'PDVDS
MPW4%^KF7];O"G[-7P6\':;\<-$TOP9#=Z)^T?XP\5^./C)HNNWM[KVE^+M=\
M;:1::'XE\^TU.>X2UTO4]*LX[*;2K81V8C:0K '??7CWP/\ ^"?'[,'[/?CC
M1OB+\/O"WBF[\4>%-%U+PU\/IO''Q&\=>/M.^%WAS5HFMM2T+X:Z-XLU[5-/
M\':=>V!32YH](C@E;3X8K,2I;+Y="J1M+6.MN5;;--/R:5ONL[7N0\11<:D7
M!I2BHPY:<;K]VD[R=GK4O)MQ;2>Z:N>,_M2>/?C+\1/VR?@1^Q7\-/C#K_[.
M_ACQ?\&?B%\>_'GQ.\%:=H%W\2?%$/@[Q-H_AC1_AY\/[[Q;I6OZ-HTZRWL^
MN^*=171K[4AI#6B0+:QAV;\]?B?^TU^V/X5L_&'[+>B?M(ZG=_$'X7?\%*_V
M//V9=#_:=/A'PM<>)/$7PQ_:0\-ZWJ5]H?CW0[;38O".M^+/!UP]M9^(6TW3
M],_M&ZM]+>XM[;SK@2_MU^T'^RE\%?VG+;PD/BIH&K2ZY\/]2N]6\!^-O"'B
MC7_ ?C[P7?ZBEK%J<WA?QGX2O-*US34U."SMH=3M1</:7Z0P+/$1"I/">&OV
M!_V6_"'@'P/\.- ^'MS9^'_ /QP\)?M(Z;=MXE\0WGB?6_C9X*OY-2T+Q]XS
M\47VI7&M^+M6CNY6:Y&N7UW;7D(AMIX#;V\4:D)TXI.4KVL]$K\UM[;:7\]K
M]14JU&,::E#6$8JW)&24[MNHY7YI73Y>5Z):]$SYO_94\3?'3X8?MT_'C]D7
MXC_M ^//VC? VB? 7X9_&_PCXK^*NE^#[7QSX>UGQ1XHUOPWK^@)J'@K0?#6
MG7WAZ=K&*\L+>XTQI].*K;K<,#*9.K_X+&33#_@FQ^T_")9%B.@^#&$:22(O
MS?$_P2KAE#[&WDMN^5<JQ5@P&:^TK#X'?#;3/CAXB_:*L]%NH_BQXK\ :#\,
MM=U]M5OY+2Z\'>&M6NM;TK3TT=ICIMO/%?7D[R7L%LMS,K*DC[5;?-\;/@O\
M/OVAOAAXK^#OQ6TJZUWX?^-+6QL_$&E66IWVC75U#I^J:?K5F8M3TZ6&\MF@
MU'2[.0F&0>:J/'(KQ2.C+VD>>,D]$X7L^5Z)7T5K>GS70SC5@L12K6?N^R]H
MTN7F<>7G:2=MUI:U[(] T">:?P]H)FEEE)T+2!^\<MC.G6I(&>PYPIR,G+;N
M0?QLT74OVF_VP?BC^VWK7AW]L;QC^REX<_98^+NJ?!CX;> O!6A?#Z;P['<>
M%/!NA^*KSXD?'B7QCH6L:KK>C>)+S59I+?3-.U#P_96_ABU:6">.1P8_V?M+
M:*RMK:S@!6WM+>WM8%)+%8;:&.")2S$LS!(URS$L3DDD\GXH^,__  3M_93^
M/'CO7OB-X[\$>(;?Q)XSL-.TGXCIX)^(7CCX?Z+\5-*TH;-/L/B=H/A#7](T
MGQK!;VZQ6(?6+6>ZDT^-;.6=H$2,1"HN:;;O=>ZY+M*+Z][6U>UWNA4JD(2J
M2FVG)>[/D55Q;DF_<D[/FC>-WM<_*WQQ^T[^V=^T-^T7XU^#?PC\0_&3Q'X2
M^!?P9^"VMZEXY_8?U;]GK1;#XF^/?B;X3/B2\^)%]J7QWUC4VO?A?*[RV7AK
MPYX5B-HMQ:SQZMK2!X8'Y73_ (D?&3XK_&;]A+QC^T!;^&D^*[_L;_\ !131
M_%%[X2UGPOK>BZZ^A:'!I-AX@6X\&:IK?AJTU34M.MK5M>TS2M2N+2PUV'4(
M;=+>W$$$?["_%O\ X)\?LL?&+5O#6O:WX&UGP;KGA7P1:?#'3M9^$7CCQ?\
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M22^#/#WP[^%VI:=IQTOP]:6>EVM['=:YJ%SJJ)&^-8NM182+$\<$/FW[3O\
MP3YOHO!W[-O@K]FCX._#SQ9X'_9\T3Q9X:\/:5KWQF^*?P5^-_A.RUYXI[>7
MP!\>O!]W?7G]BWQ:]M?%WA7Q3IFH6VI0M9S:?=6TL3@>Z_\ !-;]C?6OV,?@
M_P#$3P]XI3PEIWBOXQ?&SQA\;_$/A3P%JGB/6_!_@:X\2Z5X;T+3/".A^(O%
M;?\ "1^)#IFE^%[*XUCQ#K ^V:OK=WJ=V&,4T9#<HRI[K[+U23NGKKVO?2_7
M5#JSH.A-PY5SVY(6CS1E[3FE)O\ B)<CY;22CI=-ZI?F/^W3^U;^T'H?BK]L
M#QS\"/CC^U'KB_LQS0VEEHGP-^%GPQTK]F;X8ZSX:M-*U/Q'X9^/7CGXEK<:
MU\1?$%S+<Y\16?@FZ@.F6=U8VVG6]Q>,JI_01\)O%%_XX^%/PP\;:M'!#JOC
M'X=^"?%6J0VJLEM%J/B+PUIFLWT=LK,Q6V6ZOIA C.[I'A7D<_,?COXK_P#!
M,#]CKXT>*/B-XH\=^!_%=RGQ<OI=:^)7A'1?BA\1/#/P]\9>*9-._LP>,M;\
M!Z'XAM?#=WXJBMRDD6L-9K-]NM;>^D1KE?-K[@\'>%-&\!^#_"?@7PY%<P>'
MO!7AG0?".@07EY<:C=P:)X:TFST728;K4+MGN;ZYBL+*".>\N':>ZE5IYB9)
M&K.<HN%DU?39W[:7ZV5M=6[&%6I2G3IJ$6I1;O=1V<8+1KIS1D];/WK;:'1T
M445A'=>J_,YSQ;]@'_DLG[?O_9P?AG_U6F@U^G-?F-^P#_R63]OW_LX/PS_Z
MK30:_3FNGAG_ )$]'_L*S3_U:XT[^#/^1!1_[&.?_P#K09H%%%%>\?4A1110
M 4444 %%%% !1110 4444 %%%% !1110!^/_ ,4?^4HVJ?\ 9E^B_P#JUM1K
MZ0KYO^*/_*4;5/\ LR_1?_5K:C7TA7X[C/\ D:9U_P!C;$_^FZ!_6?$G_(I\
M./\ LV'!_P#Z8Q04445B?*!1110 4444 >*?M*1?$2Y_9W^.5O\ "073?$^;
MX6>-H?A^MBXBOW\3RZ%=)IRV$N1LOVED/V!@0PNEB *D@C^?#]E+P-I7Q5T3
M]AWP[H7[1G['OPZ\??!GQMX-\50^#?#7PE\<>%/VIV\3:-I]S'\2_A[XVO-:
MOTO[[4?% N-8M?&-WJME)I>IW.V^MKAH5C4?T]'/;!(Y&<X!Y]"I[GHP/)YK
M'3PYX<BU9]?A\.Z!'KTS;I];71=.CUB4@%<R:G';B[=BI8;FDD?!(+<D'KH8
MCV5.4.6+;FIQDU&27N2IRBXR:BTXR;U3U2;V1YN+P+Q->G5YY<L8M.'-RJ_-
M3DI)I.2E>"5TU+E;2>K/Q/\ VG/C_P# #XP_M&_L1_&/Q;KMGXM_8F\$?$3X
M_>!?'.O^(/#VNI\.O"_[2&@:);:?X(G^(NG:MIB(=+LYC=VN@:UJ=C)HB:O-
M'*MVA5RN'^R]\6OV8O ?[>'_  4M^-?@*^T'P]\!O"OP-^ _BSQ-XJ\*>'=0
MC\+SW=E+KR^*?$7AO3=-T\2:EIMW<M$&NM#TQK74;V*\GLVF!EFD_7'XT_#?
MXC^-/#%AHWP>^(?A3X47T&MOJ6N1>(?A?HOQ&\)^+]/F247.E:WX=O;[2/*,
MES*M^M_9W:W3W,.9RRN:\T_9M_90B^".M_%?XA>.O'4OQA^+WQMET"W\>^++
MKPSI'A+PM:>%O"%A-IWA+P'X+\#:7]IL-!\)Z+%=7DZ6LUS>W%S<7<DMS,S@
M5TQKX?V$HM1C^YE2C3NY2E>M"MS3]U0YFE*FVG&6UHJ*BSBE@L4\73J+EERU
MH8B524+<DE0=/E@VG>*;O&,7=.4F[W<5Y'_P4;\5Z%X\_P""8W[2GC3PM>_V
MEX9\9? !_$WA[4EM[JV>^T+7X]+U'3;T6MU;Q7EJT^GW,4WDSQPW,#MMEB5H
MV ^6?V<=7_8ULOA)J-G\)_VRO''Q;^+&K_LC^)M-?X4>*?COJOC[2+.6/X2_
M:]:BTWP5>6D-E;7.A/$]O;B!VCTVV2:WCC58PR_MK-8V=Q9R:;<6-E<:;- M
MK+I\]O#+8-;*H1;=K62)X&M]@"^2T+1@* %  QS^G^ ? 6D7*WND^"/!^EWJ
MQ3P+>:=X8T2QNA!=(([J!;FUL(Y5AN8P([B-=JS1_*ZD8%8T\3&%%4N622K3
MJQE&4;KF5-).ZYKQ]FM4T]-&NO76P%2KB)5G.%IT849JSO[JFI22O9W531-6
M]WST_FRO?@[\,_!/_!'#]B;XL>%/ FAZ%\4]&^*G[+OC>Q^(6FZ4D'CBU\2:
M_P#%NQM-:OO^$A\LZP8KS3;B32YK.:X?3DT\0P&W6&&%$^H]'\2_LZ>"OVS?
M^"A\/[<MMX2B\;>-_P#A!V^"5Q\3?#TVM6OBG]GQ? <MI!H/PB>73[V.348O
M$S746NZ/X?,>L3ZY-9RK;O+$TL?[@MH>B-IT&D-HND-I-H]O)::2VG6CZ7:O
M9RK-9M:V!B2V@:UG1)[9TC#P2HLD95U!'RA\=?@9^T/\3/%-S??#W]HSPO\
M#;PC?:/;Z5'HVL? [PWX]\4>#KDVMQ::IX@^'WC#4]6M9M'UO4H[@S12WEC<
MP:?>1PSP1D1[3M'&1J\\:B4>>563JR;<[3G"2CI&7-K!-IN$6];Q;E(Y*F63
MI<DZ=JKC"C#V?)'EO3C*/.VVVI*_NR46XZ7YDDC\/_V8?CSI7PO_ &*?V!?A
MC%X3^"WA?0?BG\0?VG;K3?CI^TMX2U#Q#\-?@[;^&OB=XP>PTE=)6$S-\0/%
M%C-'9Z-#K5[I=N8[.:.>XFD?">5>'I)KG]F_X^6&H7R^-OV8_!G_  5:^'/B
M+X[0_#[P5K?A+P?>?L^:KX>.L^)]7TOX<Q/>ZEI?PSO?%KZ+K6J:5"+BSN[!
M&O5BE@G3'],GP/\ V=OAK\!_@CX#^ ?AK2UU_P $>!+&2.V;QA;V.MZAJVLW
MFI7FN:OXDU8S6IM9-7U;7=1U'4KB2&&..&2\,< 5(U!Z?XF>"_$_B'P3X@T/
MX6>+=,^$WC'6&LI;;QE'X,T;Q9;P/9E(G@U;PYJ#Z?9:W9WNGK_9DZ3S1RPV
M9,<# A:MX^DJLY1I1:J5I3<Y3DFOW[E"IISN,XTVHKE2]Y*>KB[PLJQ+HTU4
MJ\SIT:<5248V?+2C&=*S:YH3FG*TI/W6XVU5OP]\3>*/@/XY_P""G'PBUC]B
M=O =]XH/[#O[2=C9>(OAOID.F^#+SQB+/3SX$LTO[.UM="N=:TL/90W(MD>Y
ML[)H+74G4PF*/Y=_9A\"+\4/A!^RW\-+S]HS]D+X0?%_X??%GP1XMOM!O/A5
M\0-"_:]TOXPZ#XDN;[QCHOB/6]3U%KO5];\633:EI.M:H;:7P_J]C>+Y3QQ+
M&]?N7\#_ -C[7?!/QI;]H?XR_%&Q^*GQ.TKP#?\ PP\ Z9X3^'^B_"WX:?#C
MPAK6K+K?B4^'O">DW&H3W7B'Q-J,,$VJ:WJ.HNXB7[)#"(E#C[/?P]X<EU;^
MWY?#NA2:\1_R')-'TUM9Z, /[3-JUX,!B/\ 6-]YL,,D4GC8THQI4KR2I0BJ
MB<5*,XNJI*\X-NFU52:Y8RGRMNU[)T\LJU9^UJQ]FG4<W1B[1E%^S:<X\LHN
MHG%Z]$TE)J/,?A+IOBSP3^SE^W2NF?!OQC\'_P!I_2OVE_VJM<N/B%\,]2\*
M2WW[3?[/'C_4-"FM?$WB_0_&L>EE3\,O"XTB"&YT[Q ]DFFVD]Q!I-[=O+)*
MWT%_P4OT+Q5XG^/7_!,[0O!7C:Y^'?BC4/VGO',6C^.;+1--\2S:!,OPD\1.
M;M-%UB1=/OEN(EELV2]9(@ER9HY&E1*_5NVT'0;/4;G6;30]$M=9O$:.[U>U
MTJQMM3NXB2?+N+^"WCNI1DDGS789)/<YLW%A874MG/=6=K=SZ=*UQ83W=M#<
M3V,[Q/ \UG)(A:WE:%WA:6(I(T3O&Q9&8'G^MKVM*JH+FA3<';W4VXN"?*KQ
MND]U%7BE'6UWUK+6J5:C[7]W5JQJ))+W%%P;2:M)N33=V]'=I:I'XV?M=_LG
M:9\$_P!BC_@H+\6=?^(?CGXW_'7XO_!:/3O'7Q-\;1:7;7[^'?"=U$="\)^%
MO#WAZSM],\.>$]*FN[Z]BTJT2:66Y>2>YN'5$VZOCW]N'X"M^Q!HGPE^$GBV
MP^/'QU^(G[.'A[X4>"/@_P#"Z"\\8^([[QEXC^&UCX5$7B!=,M9M.\-Z3H5Y
M=27GB'4-;OK*'3[*SN2WF3*L+?L'/;V]U#+;7<$-W;3(8YK>ZBCN()XF^]%-
M#*C12QD<-&Z,A'!!')R-&\+^%_#KRR^'O#'ASP_)-DSR:-H>F:9+/D[B))+"
MV@=QN+, S$ LW8\D<6I*+K0=1PJJKI)14E&%.$*>B4E!*FEHWRK9;W'ECA.7
MU>I&G"I1=*2<$VFY2E.I_>G)M7;W=V]S\;OVR/A1K/P+_P""-?A/X+Z[<_;?
M$7PT\(?LM>#->EMG>X@.MZ)\0OA]!J\5LR(/,M+:]^T06[%"IA2(J< 5^T>G
MD'3M-(! .FZ<1D@G!LH#U'!YS@@D$8(/-+>V-CJ5N]IJ5C9ZC:2-&TEI?VT-
MY;.T,B30L]O.#$S0RQI+$6'[N1$D7#*M6L 8   Q@ <  < 8[    <X'>L*E
M=U:<8R7OJM4JR:V?/"$>5*RLDXM_)7UU.NCA50JN<9/D]A3HJ+_Z=MM._H[6
MU[W?0HHHK ZPHHHH *?'_K$^K?\ H#4RGQ_ZQ/JW_H#4UM/_  2_(BI\$O0\
M]_X)-_\ )I7_ '6OX]?^K3\25^E]?FA_P2;_ .32O^ZU_'K_ -6GXDK]+Z_2
M>%O^2;R'_L4X#_U&IGR/CM_R>;Q1_P"RYXD_]6>("BBBO>/R@**** "BBB@
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M>D/_ ($P?_%UQ_\ PZC_ &,/^A.\??\ AYOBM_\ -;1_PZC_ &,/^A.\??\
MAYOBM_\ -;1_JWQ+_P! N2_^';%?_.+^K/RN?ZQ>#G_19^(7_BL\A_\ IH_U
M9^5^P^3_ )Z0_P#@3!_\71\G_/2'_P "8/\ XNN/_P"'4?[&'_0G>/O_  \W
MQ6_^:VC_ (=1_L8?]"=X^_\ #S?%;_YK:/\ 5OB7_H%R7_P[8K_YQ?U9^5S_
M %B\'/\ HL_$+_Q6>0__ $T?ZL_*_8?)_P ](?\ P)@_^+H^3_GI#_X$P?\
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MV.$QV-K8C#K%4:-?%4:6(5.<?:TZ6)KPA.ZC6J)*3****]0^'"BBB@ HHHH
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MTJ4Y4Y9-DR4U&<HR<&U)*25FXR2=TT?8=%?'G_#<7P;_ .A5_:!_\1U^,/\
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M7P;_ .A5_:!_\1U^,/\ \R5'_#<7P;_Z%7]H'_Q'7XP__,E1_:V6?]###?\
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M?_"RAY?]//ZMZ7^Q,DX/<8P>_#%A^3$L/0\]:,G&,\9!_$# _($X].U?'?\
MPW%\&_\ H5?V@?\ Q'7XP_\ S)4?\-Q?!O\ Z%7]H'_Q'7XP_P#S)4+-LLZ9
MAANGVW_=_N^:#_63(/\ H<9;_P"%E#_Y9_5GY7^P^^>_KW_/K2$9## .001Q
MAN.%;(/RGH>.F<<U\>_\-Q?!O_H5?V@?_$=?C#_\R5'_  W%\&_^A5_:!_\
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MPZ*^//\ AN+X-_\ 0J_M _\ B.OQA_\ F2H_X;B^#?\ T*O[0/\ XCK\8?\
MYDJ7]K97_P!##"]/MOK;^[_>7XA_K)D'_0XRW_PLH?\ RS^K/RO]AT5\>?\
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M<ZK4YIWC.E6SS,:M*I%[.-2G.,XR6DHR36C"BBBO>/J@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV7]?\,ON"BBB@++LOZ_X9?<%-*J>JJ<]<@'/YBBB@=EV_K^DA0 !@  #H ,
M?@*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>nt10016217x4_graphic04x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic04x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M+?WNME]^MC^LO_B(0_9V_P"B)?'W_P %_P -_P#YY-'_ !$(?L[?]$2^/O\
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M?L[?]$2^/O\ X+_AO_\ /)K^33;%@G+\9_N]N/3OVH"Q$$Y?@$GE<_E[]O\
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M_+^LS_B(0_9V_P"B)?'W_P %_P -_P#YY-'_ !$(?L[?]$2^/O\ X+_AO_\
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MZO\ ^._X4+P:X(T_V3%]/^7V(_N_]/O)7]&'_$U/B[_T-\LZ?\TYA^EO[_\
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M_P &7WC2\U/Q?:^%+;3'M;#5-&T>6QB_L?Q=K=Z]R]SK<<J?Z&L7EHSM(H(
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MA#]G;_HB7Q]_\%_PW_\ GDT?\1"'[.W_ $1+X^_^"_X;_P#SR:_DUV1^K_\
MCO\ A1LC]7_\=_PI+P:X(T_V3%]/^7V(_N_]/O)7]&3_ ,34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\
M\\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N
M"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]97_$0
MA^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\ P7_#?_YY-?R:[(_5_P#Q
MW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\E?T8?\34^+O_ $-\LZ?\
MTYA^EO[_ /=7XG]97_$0A^SM_P!$2^/O_@O^&_\ \\FC_B(0_9V_Z(E\??\
MP7_#?_YY-?R:[(_5_P#QW_"C9'ZO_P"._P"%"\&N"-/]DQ?3_E]B/[O_ $^\
ME?T8?\34^+O_ $-\LZ?\TYA^EO[_ /=7XG]9)_X.#_V=6!#?!#X^,#P0VG_#
M?!^O_%R#TZ_A1_Q$'?LY.,#X'_'PA2K$/I_PV885EW>6H^(RLS;"<#(W?,."
M01_)J8XR",N,_P"[_A21",-M4N7Y(+;0/F4D=,Y]^.W7J:7_ !!K@:/O/#8M
M3:Y:<%6Q"<Y1479/VV]FM-KCE]*GQ<5*H_[7RQOW4D^',.^R>G.KW2\GZ['^
M@]^Q9^UUX+_;2^%.H?%KP+X:\5^%M&M/%NJ>%'TWQA!I%OJCWFDVUA<3721Z
M-K&M6QMIA?H(V:Z61BC9C"@,2O@7_@@B<_L5ZWZ?\+F\8D=<\Z5X;Z]NW:BO
MY>XGP.%RS/\ -LOP490PN$QE2C0A)MRC"-M)-MMN][ZO7JS_ $8\/\YQW$/!
M/"^>9E6IXC'YIDV#QF+K4J/U>G4K5J:E.4*"<E3C?11N[6W/S:_X.$67_A?O
MP.4')7X.ZL",=CXNU$9_GVQ7X C[S?\  ?Y5^_/_  <&HO\ PT7\$1CAO@[J
M0(R>0?%^J ]_85^!&!F3VD51]/+1L>_+$Y//;H *_K7PN37 O#2[4<5+Y2Q"
M:6RU5^Q_F)](-I^,?'$E>RQV&;OY91D%!V_[?UU^SYZ!1117Z,?C04444 %%
M%% !1110 4444 &6'*@LPY50,EF'0 =R3P!W/%?I/^PA_P $]9OVR_#7Q;\6
MZCXXG\!:5X/_ +,T#P9=K:VLEOXP^(&KV-_J5OH@>ZW#[+!!#9K,+4&[?^T$
MDB^5"&_-E59F54W;V8*FQ9&?<3A=JQ)+*S9QM6..20G 1'8A3_0[JWQ'_9?_
M &)/@7^R'\ OBIK7QKN/B)X2U?P[^UEXS/P"A^'^HZ:/B1K,VI2_\(UXPFU_
M7M/O+BU\,M/J7AVRT.V@-M>:?IRW! ET^TMH/SOQ$SK-LOR["X#(:-:MFN85
MN>FJ,(3E'#X5PJ5Y/G]Q1UA"\D]9JWO6/U[P@X>X;S'-LUSWC6KAJ/".0X"E
M3Q_URM]7PV+S#-<33P>682556E&=.HZF804)1;>#:?-#F3_!O0?A;\2/$7B7
MQ!X%\,^!?%'B3QEX/;5SXE\/:)HUYJ6JZ$FA7T&EZW?:K96D<EQ:Z?IEY<1P
MW\J)--922QP-!+*KJ.POOV;/CWHVL^ O#WB/X1^.O#5_\4-?L=!\$GQ!X?U'
M3[?6]0U(M<0P6,B0W+7-U%IT4NIR6)2WNI+2&:01Q%'5/Z,/!>E_#KP5_P %
M!?'_ .TS\,/$&BVW@#]I3]B7QS\8_#LPU+3;=M(\<:O-X FU2RGA>X&G66LZ
M@QTKQ#=6W]H37)U?4-6,2E)7+_GIX8^+.OZW_P $U/"/B#Q/\2->U;QUX?\
M^"@?A#4-.\4:SXLU6X\::%H][H^EWM]?:7J5WJ1\3:;8O=:CJ%DAL)+*TMK;
M4;J."5;7?&GC1XYS[,?90P-/"4*:CD6'D\8L33KQQ>;2QF%FI1I4*T%#"8S
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MLY/$>CKK5_%/-IENUI/!IL3K!Y6F#4+B"2&9K_R5> R^N_\ !735]'U'XO\
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MIRWD=[(B#SK>"YANF$P4"9I(+>5-H#EXT^?)^M_C/^V'XI^+GP=\&_ ;P_\
M#WX>_"+X3>$/$;^,T\'?#/3KS3;;7_%-SIL=M_;NMG4IHKC*O<:F5M'6YG>X
ME2:7=)$I3]:/VD?V8?V8/VJOV]/CU\$='\4?%;0/VD=:\-IXL\/:[=2>'X_@
MW::]X?\ !]C.G@IM&A2;695;2I='U2\\07<T-V\TE[%IYLQ;I+>?#>B_LJ?L
MP?!_X>?LV:U^U?XE^,D7CC]J:W;6O#NG_"F\\,0:+\+_  @=8TC1+7Q'XFBU
MR.YU+Q&+R[UFREG:Q%YNMXKXJL#6^V7&GQ7D&:X?+\9C,FQ$\VP=/"YG3RRA
MAZ<<3B)8C+<7C/:X5>T5+ZOAW@I1G5Q-IQC5_=6G)\WKXKPPX^RG,,^RW)N(
M,GQ^1YSC<TRK,.(JF8?5L#BL+@<RP>72X>S'$XBC6KX'&?VEC</+&87#\T,5
M5Q3<:LJ>'FX?F#&DH8"W;<(E647$;-A541D.LJ%2FT2QX<,H!=1D$X-V>'5(
M["T>^^W+IVH)+/9RW,^H+9WL< V326C3?Z/=I")T5S&[K&)@KX##/ZP-_P $
MY?A_\'+_ /:[\8?M#^+_ !IK'PC_ &9+CPSHNAQ_#H6&E^+O'>J>.K*TU3P^
M&U#4H[G1_#=M:Z9JFEV^HQ1Q-"U_;R7F!!:?O_IWX@?!G]G/XU^ ?^"47PE'
MBCQ_H7P>^*^D?'[3?#/B"Z?P[I_C;2=5U/4]#U70;/Q/=Z>FH>'+[^Q=:7_A
M%+RYTJ<Q:J+BSGC4QSW4D/?F7'&6U*^#K_4ZF-P57&3I5\S>$I5:%+#QR"EG
ME7 I/FKU,51JRA&K2C3C#E5Z<I334?)RKP3XLGE^83S+-L%EF<PJT'2RZK5K
M?6<QJ8SBC \*+,:[C.G3PV&ECZV-?UN#K*M3C1FJ,8UH2E_/RKNHEV2311RX
M26-)9XH;C:5"BZAC=8IPN5V><C\$;1P"-'3-(U[4P;W0])UW43"WE+>Z39ZM
M=RQNR"58&O+)))(RR$-Y;2*2GS!< D?='C']CG1OA'^S'\8_BO\ &+6O$FD?
M%+PU^T==? /X9>#=.N[.ST7Q%JOAZZ'_  EWB:^BN[(:AJ.D6&FVNLZEIDMG
M+;I;Q0V,HA,DJHA_P3Q_:(^-/PN^.GPK^%W@/QS=>'_ 7Q)^,'@NV\;Z%%X:
M\&:Z==M;[6+#3Y8GOO$OAS6M8MVDT8'3WETS4M.D1B;F%DF&ZO4Q'$L<=DF:
MYKDV&P6.E@)8GV_UK#NC1J0H4_:5:E*<*<I56TGRNW*Y<T>:Z;/D\%PCB<LX
MEX<X;XSQF9Y2\X6#J4L/E]6.+K913S'%O+,LI3HXFOA51JRQ].K/$\U5RC@)
MT<133E4L_A;5]'US38X+_6-&UNP$TT30WFJZ;JEL9+@1L82EY>1*SSB.-O)"
MR^9Y:-M 2-@,V>2:\PUU)/<RSB.V\RYEGFF.<I'$KW#NX RVV,;<=E]?W'_:
M<\>>-?VF/VW?C%^R[\:_%_Q=\6? [X9?$#5=>\ _#;X(_"CPIKGC?4-;T70;
M"ST?1X-0L/"\M[I-B8_$FLPS>(/$-Y-I5K=36UFTL1NX)&PO&_\ P38^&%IX
MV_8EL8+/XX?"[0OVG_B%XI\#^/\ X:_$K5? FH_$3P0N@0:DT.H6NL^%;==-
M UT6-C<"UE-S?VECJ=J);:QU$7&G1>'1X[P&#IY<\_PF#PU;&94\RP,<OI*O
M#DEAI5U3Q$JU&G.,G2A=QA&T:G+!S>DG]9CO!S/L5BL\I\-YE5SC+<@SZ>6X
MNKFF+IX#&XG-:>;83*\95@\)B<TRJ-*CF.*PU2C*IF7UZI*FO:8"DXU%3_%=
M;B5U!:YN;@);;5:6YN96-H6#A-S2']QN" 1CY,J@QD "H3M<$J 2&R#Q@*VQ
M@?[JJ0 2"-IY/)S7[/:5^P[^QQXT^.'Q#^&G@;XD?&N;PI^R_P"$OB=XN_:5
M\9Z[:>$H[G6D^'FH>7#IOPS2/3;A;=MEMKMCJ.J:K:1!X=.4VEG'-,MVW!P_
ML5_L]?&#]GWX?_&C]FWQ/\6X==^)_P"T_P""_P!FS3O!OQ8G\,3P^#;KQ/+I
MNDSW.KWOAVT/]NW%M%?:-XGBOS=VC2V&I_8)K:XN(C&_7'Q*X;C3IJI3Q=*M
M6HT)34,'"GR^W<[4ZC7*XTZL:<JMZEDH<LI.,I*+XJW@WQTUC98C$93F.*P&
M&S%RHPXAP>(J8AX!8*.;T\O514XJGEN=X[^R\RFYMU,PHUE04J<5-_E Z)^]
MD8&X1X62X::9YMD,2/-Y:M(S;(HD::3RQA$!=@H#&G&4Y +S@#($WVJ59R0%
M#)YHD\PJJE(V4/A5VH0%(K]L/CE_P3)^''A3P3^T%;^"=+_:+T3Q7^SWX2U#
MQC<^.?B9-X0A^%OQLTKPQ8IJ_BS3?A\NE_\ $UT'5;>P6XE\/O/&]I=R1HNJ
MO 68)Z[\>OV6O@!^T9\0/^"?OP,^$4?CCP!JOCOX':;XH?5KJ#PE'IMM\*K?
M[5J&NZUK.GVDDMWJ7Q>O[Z&.U6ZBM[K1F^T3R3R3K;YDPAX@\,S>%J+"5I83
M$U,SHUG4I**HX?"92\R]FHIM2IXB=.'-O[G,FHU(6/1GX#\;8>>90Q689>\U
MH8;)<1A,##,)U,7C\7F6*CE*IK$4:RP]'$99CY5</5G--2H\CIMJJI+^?:&Z
MNK.0BRGFLW>-!BUN;JWD9,*$\\V[IOC8C(#9!X&. *GT^VU"^W6NF6=U>2RH
M'DL=,6ZN6EBA95,YM+9'\R.!G4!WC*Q>8,N-U?L)\8?^"</@IOAU+XR^#&F_
M&SX<^(M#^-GA/X.ZIX/_ &A9O"\W_"8:9X\\3:+X.T'XD>$;SP_(EY9Z7'J>
MHF]FTZ\ EAA22!=.WHL;?7?['GP)_9+^!G[;7C/X,> O$/Q:U[XS?#3X&?$>
MW\3ZUXJ?P?+\.O&&HZCH/AVZ\4Z9H.G6Z_\ "5:)J.@)<:?>6I6*XTF\MIM2
M2>ZB>WC2ZRK^(?#W]F_6\NPE3&XMT,PG.A2H.G]5J8/%4\/!8J=2\?9JE5I3
MJ2IRFG)ODDE&2BLM\!^,WG.&R_/L5E&6Y>Z^4T*>:SS:4Z>-CF[Q5.5#**-7
MV=;%8U87!257 U%0K4:5-^TYO<YOYM8[PM$IBN)Q;S""[VQWDT<$V"DJ7+6Z
MR+#+SY3K(Z$GY#D84U]0^ _C;\8/ ?[,?Q;^!NF> I+CX5_&;5O"/B#Q-XXN
M=)UYI],U;PC=Z)?Z9%I>LQE+$VLTFEAIKF:256:>-4).0<;]B;X<^&_B[^TW
M^SY\/_'"Q:CX5\5^./#5OKUG<R^3%JM@H_M*[T^[E#()H=2DLXK(PAE$D$LD
M6QRXC;](/C1_P4,_:(^%7[9/QA^&WA;0]#\3?!3P%\1O&7PMT#]FX^#[2/PM
MK'A+P[=W?A[3V$>EZ-<:VU[>QVXUL2:=++(MG-$GV.2PMY&BZ,[S&6+QN#R/
M Y?EV.KT,-@LVQTLQGA\!3J3H8RBZ5.AB)QC3<U5A[2+K.,/W5I2;G&)X_!F
M3X:CD>)S[-N-,UR3#8W,L?P!EL\IP=;-N7%8[(J6%QU;%X2515?[.GAL7'#Q
MAA(RQE=XI1P_LYQ<E^,.GI?:C?0(D5W=:I<EXXY;-97O+B2&!T"QO9P6\UU(
M8(26E".[QGYI'4,0^$:G93G2[47EO=-*NES6$+W]M<FY1_LWV&:UB*R27"3*
MT)MI(C()%*[-RX'[&_\ !+_X=Q)XY_:+_;1?X87WB.Q_9^\*^)-3^'/PL\*Z
M5J>O2:C\5_'<>KMI_AO3-)L8+[6KB3PKI4MSIIMKZV\VWN=?L9[GRKW27BA[
M_P#:T^#4?A;_ (*%_LD?'K1/#=_X6\+?M/>)O@3\0;[0]0TBXTN71?B'<Z[X
M,?Q[HFHZ5JUO;7EKJ<L,]M?:S97D,4T6H:I?+-!#/OA&&*XZR^AG^89/6R[#
M4J%+"O%4ZE"OA\12GF$<-"L\)&>'ARN/L9TI<_OJ+YXWC*%GZF&\(\=B.$,M
MX[IYQB*V SKBJ&6RC4PF9T:M+(,9G2X9P_$3PLTZM*>)S.K%XC!8JKAW]3I8
M2O[;WW _$AO#7C#3$>\;0/$]A#;EO.NQI>M6B LVX^;<BWB PP65B\F-P5V)
M-8"I-?3111PW%W<W,Z)#';QS7%Q<S2RK%&B!2\L\TDS(B*H=VD8 !F.:_L?\
M1W_[0/A_]I7XP>/O%7[6'P>U[]D#X4:AJ^K?$W]G[0_ OASQC\0/"'@N?PB)
M+'P[XIL]#\#S^+])U*;5VCUJ*0:RTDEI'&&%[9//:S?R7>(?'\6B_'+7_BY\
M%B?!MI8?%+6_'/PL<6&F7I\.V\FK7-UH-R=*UBSU/3F-K"ZVATR:V^PR1#SX
MXSO262N">,<1Q)]>=#**5+%97A%C\/+#2]K"I5Q%Z<<-BI8BA3JTFHTXU%[)
M5$X5%-.\FCG\2?#3">']#ASVV=9U'#5.(LRP$L#F6%P.#QU98:5&EC>(,DHY
M?G>;X>IA,944\-2J8ZME^+G7PM2G7P].,83ER)\(^-7MV@/A7Q@MHDOF-#_8
M?B 6XEC?*S-#';K$)5E'^M*;Q( 0VX"N<DW+(RSI<">&5EDBFEF4>=&3&S7,
M4LF?M"'*EID,JE=I(V\?T#>,/VT_VH],_P""8/P5^/6G_% 0?%/Q=\>/&_@_
MQ#XK'@KX?33ZIX>TN]\2PZ9IHTN\\)WNA:?'936%BS3Z?IMO?W45H UY%YS!
M/P!U+4-0UC4]1U75KDWNJZM>7>IZG=&-8VN]1OIWNKVY,,>%C$]S++*(H\(@
M;8@"J /9X:S#,\UEB8X_+L#@_JF:5<NKNDO:UE4IR7MI5(3HQ@K)I1DIR<G=
M.$.77Y[Q!X;R3AN'#%#),WSS,*>=Y/0SJKA\QI4<+'#9;F4/AB\)BJMZU>FI
MT<3!Q5.,6G&K/F(2WG2))*9=\"QI;2-<2%[=8FS$L#"3?$D9+%!&1L+%E"Y.
M8@9I%G>>:1WN;CSIPT\\AGE"*HGE\UR9)0%"B5@7 4+G& %HKZSZO3E=U(4J
MDO=Y9^PI0E#EWY7&*MS65WOIN?!+%XJ*KQCBL2H5UAHN+KU)1C&A3]G4BE*3
MYEB8QH^U4KZ4*:C97 YY&>?7K_\ 6QV_#CCFD ( !Z\_SI:*Z)+FFIJT4H<B
MBEING?UTL<[=[>ENNNUK^:M^+"BBB@ HHHH **** "BBB@ K]L_^""__ ">?
MXN_[(5XJ_P#4T\ U^)E?MG_P07_Y//\ %W_9"O%7_J:> :^$\2_^2*SW_L$7
M_IZD?K?@3_R=S@7_ +&\_P#U$K']C\/W?\^IJ:H8?N_Y]34U?Q%TC_AC_P"D
MH_UVEN_5_F%%%% @HHHH **** /@/_@J4P7_ ()^?M4DD*#\+=17)..6U'3%
M4?5F(4#N2!WK^"#!"S ]?,?KUYD!'Z$'Z5_>Q_P52_Y1\?M3_P#9-)__ $]:
M/7\%+];C_?\ ZQU_2W@?_P B'B/_ +&&%_\ 35,_SI^F-_R7G##_ .J5P?X\
M19A_D+1117] 0^"/^&/Y(_D.'P1_PQ_)!1115%!1110 4444 %%%% !1110
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M&.<=13P,@E29,'!$<<K'KZ!,U]LQ>&?#,!!BT'1D(Z$6%L2/Q*$]JUH;.Q@
M%O:VL*C&%BMH448[ *H'!]N>O-"SF*UA!U6[7B[1LG;5./JE9Z:MVNBJ>03D
M[/$022O?5W>FZY4UYVEWV9\-Q:=J$XS#I]_,>0!%97#DD>B[ Q[X !Z8K2M/
M"'BJXD+6_AS69<^7R;*6(;6DCB)/F $;=VXYQ7VT JX*?)CIL41C\0A /X@]
MSW-.4MYBY;(.0222&(!<=<],#C."1R.34SS:I.>%<<,]*TU\3O?V<'V>ZZ?Y
M&KX?2I5>?$P;3I.+Y7;6:C9KFONV_1>=C^C7_@A%HNJ:'^QOKMKJUG+8W$OQ
MA\67*0S##^5+I'AP*V/0[3^O6BO5/^"/^T_LLZB0%!/Q*\2 [5501'8:-$F0
M@ )"1JI;DMMW,2Q))7\4<75'6XFSNI*/*YYA7;CV?-L?ZW^%^'CA?#S@[#1E
MS1HY#@::EW4:>C/@;_@M&3_PO/X2C)P/A=J1 [9_X26X&<=,X)'XGUK\:XB?
ML\'/17Q[?.U?LK_P6D4_\+R^$K\$?\*PU%< \@GQ-/SCT&>37XUQ _9X#ZJ_
M_H;5_1_A]_R1F0KK]6KZ?]Q:B_,_@OQNU\7>+N75*BKVVT?"Z=_G;YV%I<GU
M/YTE%?7GY>+DX(R<'((R<$'J".^>]&3C&3CKC/&?7%)10#;>[;]0//7GZ\_S
MHHHI63W2^X! JJ20J@G.2  3GDYQZGDT[)Z9..F,GIZ4E%,7+%JS2:[65M=R
M)X().)(8I!Z/&C?^A UGS>'M"NABXT?29<]Y["$CT'S1-')C\L=JU:>& '.[
M\#Q_,4W*>EI26JOJ]4NG]>AE4H4JD>5PA:Z?PK_(X.Z^'/@J]9S-H%FC OAK
M-[VW4MDD%1)(1MR3@(2,<+T%<]<_!OPE<Y\E]4LW_A\BZ/E+C!/RW$8)&!A?
MF!SZG@^O%EP<;OQ)(_'FF9/M^0_PJX5\32NJ57EYK.7-[UWMN[=_^&2LN.>6
M82;3G2;:V<&XV7NMWY7&[NKW=[]4>#S? ^R&?L>OZA&2>EU;03QC'3&&5N><
M\-[8'!R)_@IK$>3;ZSIEV<94RP7%J0,G"E8XW1L8!SO&<X('&?HXY/\ $%_X
M".?R%)M/_/0?]\G_  K3^T,?'3GC):.]NNFMUJG\]%Y)G++),%*7,HU8[;:V
MM:]FV[)VUMOOHU<^6+GX1^,HR?)@L;O&0/(U!8%R#C_EX5 PQCC./<\US]YX
M \;60(DT"]<<?\>4:7XY..!9B9VSQD*/E&2WR D?8WS^JGWYY]Z<I(8%@A'.
M0<^AQ^1P:W6:5;*]-W6[2:NWRW=[O?7R\M[<SR"A)-1]HG+12DHVC=6N]GI=
MMMW>BO=GPK<:;JUI\ESHVJ6[J<,9]/N8@>W62%1GC)[_ (8J@"3D,I1@2-K#
M:>.^,#OQTZC%??;DL-H<@$\JRIMP>N-J;O898C'I6?<Z9I]UQ/96=PI #">T
MMY@1DDY9T$@&#PJMM!R0068UI3S1*5ZM&4HVLTE=]+-:+;Y_A8YI\-U(+FI5
MJ<Y:64DUK=)W?O=-M%?K9'PID>H_,4N%]6_7_P"*K[1F\%^$[H$7'AW22#SN
MBMA$V>Q.TC\>:Y^Y^%/@JY!"Z5)89 '^@WUSP,CC$YD!X&.>O4\\UK_:6%J;
MT*D+6M[MKW:[-O2WRO\ =S5,BQD>5VA.Z;?))W5N6VG*M]U=]&][GR=A?5N>
M#GG^;4AV \D GD9 !^O6OI.Y^"NA2!OLNK:O;9Z!F@F XQ@[HQD>X(/& <9S
MS\_P.N5RUIXBA<Y^5;BS=#@9P"T+8/;)()SST"@;PQU'E7))02=TI:-/2^ZZ
MV^79*Z.6>49C"5HT)M66L4WO9V=GY6LD[7?;7PTD#G/'J<#^O]:*]:F^#7BI
M&/EW^DSKQ@K+=6TA&.YV.H/T'XGDG$N?AAXVM@2-&>Z _P"?2>WFW?0>8I))
MX (!)[4?6*#G!RK0;<DVG);W3=EZO]-T9_4,9%VEAJ]HO5NG*VEN9ZK9=]C@
M**W[KPIXHL@3<^'M7C"G!(LY'QU_YY[_ $[9K E66%MDUM=Q-SD26ERA&.OW
MHAG'?&<=^:]*-;#R=HSIM]E8P=*I'>$E\O3_ #7I<3 ]!^5+@>E/ABFN"%@M
M[J9CT$=I<L>N,<18Z\9S@$8)K9MO#'B6](%IH&KSEB -EE*HY.!DR! HR1DL
M0 #DD#)IRKX>DES5*<$_ANTK[7M]ZO\ \ 2A4;:BI-K1VOHWHE\[;>GD81ZC
MZG\L'].E*.02.0.I'0?7TKO8?AAXVN%_Y <D7(^6ZFBBQ[D(TC''; QGO6[!
M\&_%C!#-=:7:@C(1Y9I6C/<$11KGG'WB<\8QDXX*U?#3G>->E;E6TH_?N;PP
M.+J1<X8:O*-VKQI3:NK=D^ZVO]VIY("#T(/TP<?E^-.VMC.TX]<''YU[G!\#
M[AL->>(U4G[RVE@O0'@"29MY)P#R."1S@5NVWP3\/QX%WJFL70&"=AM83G'(
M#!&*\\97!'4$FI^O8**Y7'FE%6;2TDU973LT[ZM6?W6.N.3XZ2B_9.*DD[22
M35[:23=TU]I22MKK=L^;N^._IW_*FLP3&[C.?;ICUQZBOK6V^%/@>W"K)I<]
MX <[[N_N)') ^7(78O!YZ''.., ;]IX*\)VI/E>']+4#;L,D#7+)C=RIF=@I
MY!) P3@D<<\_]K4/L8><9Z6ERI);7U=MU==+W2]>J/#^,YE[]&*\Y.ZT751M
MOI]^]W?XK5PYPH9CZ*,G\@36C;Z5K%V!]DTC4;H'[I@L+B;.>G^KA;.<COWZ
MU]P06&G6H$=O8VD<8)8&.VBA()](XT"8R,Y/S'OTQ5T>6!@JK ?=#%@% ' 4
M(%QZ <@#CGMG4S6327LW+5=/))WLW_5]MSII<.U9-^VQ%))+2S;=[K9^ZFFN
M_9[;GQ?9_#_QI?L/+T#48>HW73V^G(, GE;HHW(! [[B #726_PA\9S<RP:;
M:J<8\S4H'8'H=ZP^:6&1D #'/6OJK([+@_7/Z'BDR?;\A_A62S3%?\N^6"TN
MI+6ZM=ZJ]MDNFFNS.F'#^%IJU2=2I*][T_@4=$HVDFT]&W9VV^7S7%\%M:R!
M=ZSI\0(R3:VUU<%1T ),(^;(^8 $8(.>36Q;_!*W^7[9XAO)%XS]DL886///
M-PRD#'J,YX*@5[YD^WY#_"C)]OR'^%82QN,E)R=2&K3M96Z=_P"M?[HWD6"_
MZ?67G;_TEQ7?I^1Y+;?!WPE"<3'5KK_;DO  /4%1$F>^.1USG(Q706GPW\%V
MAW+H-K.X &^YDNI'ZYR09TC)R/X<GD 9&:[K)]OR'^%&<]<#\,?R%2\7C))Q
MG63C))22T;6G5:]O^&31TPRO!4YJI&C+GBVX\R<DF[=)2EINON\S$M= T.T8
M&UT?3X&4G&RQB0 X&/F8.Q]-V[' YR#6NL4<;%DBAB8\DPQI'U'&-BKV]./3
MBI,#U'Z_X4'K^ 'Y#%8\TFU>4GH]V_+Y?A^IVTZ4(O\ AQ6G\B7;R$/)R>3Z
MGDTF!G.!GIG'./3-+12NWN[F_+%;12^2# ZXY]:#SUY^O-%%*RWLK][#%W-_
M>/YF@DD8))'H2<?E244PN^_]?TE]P4N3ZG\Z2BBR[+^O^&7W"LNR_K_AE]PX
M$Y')ZCN?6OUB_P""/G'[3?B/''_%I_$W3_L8?!5?DXO4?4?SK]8_^"/G_)S?
MB/\ [)/XF_\ 4B\%5\AQWIPKG%M/]F7_ *=I+\M#]0\&TO\ B)7!SLKK-I6=
ME=?[)6V/Z=+?[I_#^56*KV_W#^'\JL5_)W2/^&/_ *2C_3*6[]7^84444""B
MBB@ HHHH ^*O^"BIQ^Q3^T& <,W@N-% ."Q?7-(0*!U)<L$"CEBP4 D@'^/)
M_P#CRC/K)G/KQD'/XY%?V$_\%&#C]BWX]L>@\*Z?G\?%/A__  K^/=U*VT$!
MQOPK?[.-GKU[>E?T#X0O_A$SK_L98=M]K4*:_4_A/Z5,7/C#(XQUG_J9BHJ*
MW<J^=PIT8^M6<9Q@OM.+2'M]X_Y[4VE)#$D?YQQ_2DK]@EN_5_F?S9)J4I--
M-2;:>Z:;O?S30F!Z#\A2CCIQ]./Y444K+LOZ_P"&7W$I);)+TT#)]??\?6@@
M-]X;OKS_ #HHHLELK#N^XN3C&3CTSQ^5)DD8)R/3M112LNR^X [8[>G;\NG<
M_G0>>O..F>U%%, IP9@" S 'J 2 ?J*;10+EC_*ON0QXT<8=$<>CJ&'Y$&JD
MFF:;-D2V%C)NR"9;.&4<\9(*98>H!!/0$5>I<#U'Z_X4^:2VE+Y-F52G!V]R
M+W^RGV\CFI?"'AN[)27P_H[@G)D%I]G/RX(P$E7'3KUY/)SBLR;X9>"I<AM!
MMHV;(+P7%Y 1SU4QRRJ<]?GQST!R17;D<'##/T/K[@"FX;^]_P".BE[>K#W8
MNI).S?Q/LK=.BOY-W5M;X_4\)-\U7"\TMDXQ@ERW3M9V>]]5W\F>93_!_P &
M2 J(]5M@2?FBU#>1G!^ZT)X';)!Z>G./<?!#P_M+6VLZO ,$KE[>9L=L@H&!
MQC)<*>H8#FO9P2!R0?J!^5+D^WY#_"MHXO&**Y:JBDE9-:K;1];[7_R1S2RG
M 2;?L:BNV[-RLD[732E;OLNRU/GN;X)%3F'Q%,% ^7SM-$C#/JUNTF3V.%SW
MQM.:SI?@IKAR;?6M-<+G'GP7,!?CC($+8P2?0>_!%?2>T_\ /0?]\G_"E&1_
M$&S_ +/3\Q6L,SS!23<X_-66RUV^^_?R9S+(L$K:5DKW_F=NWO.6G;_(^6YO
M@_XM0'8VDW)' 6.[E@8X_P!N6-$R?7/I[5E3?##QQ ,-HT4PQ_RQO["7/']X
M3F0CGC<H;L5!!KZZR?;\A_A2Y7NOZD?IVK5YKBO^7EIKIRK5/3?7:U_GO;5B
MGP_A:MO9U*E.2=VZEFFK+16BW>_IZK8^)Y_!?B^V.7\-ZT0.<6]F;E".^[[.
MDK''&",=\\9K*FTW6+<XN-'U. YQB;3[B(YYX^>%>>#^1]*^["00<*0?59&0
M_@R\CZBH]K'.>1Z&1V)]B64Y'KQ^'6A9I4>].6WSOIW_ .'T^[FJ<-*ZY<1%
MZ;\KMZ='Y_@?!+%TSYL4D1'!#H4]N00O?(^HQ48E0C(((]001_.OO9K2SF!$
MUK"3T&8H9<C'7+H,=_EQCOU-4)O#GAZY!^T:3IMP2<D3Z=;,3P.K(J-S@ \C
MCCI71#-II).+5DM-_P"73==NQF^'<3'2%>DXK9N3CIITL];]+]]=;'PZ.1D<
MCU'(_2C(SC//7'?''/ZC\Q7V7<> O!MPP,OA_3F /*Q1-;!@>H+1/N'U!!]"
M*R;GX6>"+@$)I$EL2V?W5_=;%&"/E#,2#S[@#@"KCFN%<HIX>I%-V;<=MO-V
M_P"!Y:\[R+&*+:]G)K:*>K6G>*7WM=7LV?)5&W///X$X_0XKZ;E^"WA*3<8K
MC6;5CT(NHKA1WX$L9=>0, ,1WQGFLB?X(6>W%GXAOXV'_/S;6TR8SG 5%7IW
M)Y/T&#NLQP2:M!K:[LUIIV7E\K+L<]3*,?&*E&C*3NO=C&,GM?\ F6FEFW9K
MMJ?/84GD!CCD\L1QZ\TN#UP<>N*]OG^"%_D-;^(K1F'(\^P?.1S@%'XYZ'MQ
MZ"LV3X->)5),5_I4C?WV:X7(//W71U'(&3C((R">AEXO#UM8S5/ETM)I7V::
MO9Z:+U7D8/+<?&REAJ[NU\-&3LK*]W%27WVU]6>0D$=01]:*].E^$7C),M':
MZ=<8SDV]XBLV/5)A&2><#&<9Y/2LB?X<>-K?[WA^[DQ_SR:WDXXP>)AP<]>E
M==+%X6-.*>(I)K36:773KI>ZT\S.6#Q47RRP]9/31TY*U[;Z66Z.(HK;N/#/
MB.UXN="U6 \CY[*;&>.C*K*<YX(8@]02""<N2UO(6V365[$PSD26EPO3W,>.
MI P#G/:NOGA_,M?/T_S1S\KUTV_JWKY;D%%&1G;\V[IM\F?=GTQY76K$5G?3
MN$@L+^8GH8[.Y9??YA'@8[@\CTHYX?S1^\?+*Z7*U?:Z:O\ >5Z*W(/#'B6Y
M.+?0-7F/^S93 #GNSA%'KR0 #SBMJ#X<^-KC&WP_>1Y_Y[-;Q\ $YYFZ8'49
M_GC.>(H4[>TJTX7VYI)7VVOZKYNQ4*-6?-R4Y3Y;*7*G*S>R=KVO_GV9Q-&#
MUQQZUZ=#\(_&3@&2VT^WS@C[1?X89[A;82'([A\#NN<&M%/@UXE<@RW^E1MC
M&X/=28 !P,;5!Y)[=3D\5P5<1AY5)-8BFT[;3711VZ;WZ[K;0W6 QC2DL+B&
MGI=4IO6]M;)M+SM_F>/D8Y.0#[D#^=*%R>,D^F2?TS7N$/P/OR2UQXEAC)Y(
MM[)C\W?)D8Y![\'(ZUJ6_P #K#G[9XBOY"?^?:VMX$QG."K;SG(&&'?D@T?V
MC@TK-2=M';6]N576EFGY=EIH=,<KS"5KT)I2MJXQ25[7NFTUN]&NFMCY[((Z
M@CZT9&<9YZX[XYY_0_D:^F8?@KX1BVM)/K5PX&&W7<4*'W/DQAB/]DMC/(QQ
M6Y;?"SP1;C#Z1)<$'/[V_N@A& .0C*Q;CKD#'&*SGF6#C'FC2E)W7NJ-W]G7
MIM^GD:PR3&R=G!05KWDTD]NRD_P;T=[7/DEB%^\0O^\<?SQ3/-3U_E_C7VA;
M^!?!UL3Y7AO35&.!+&USCV#2N7/'!+'/''7C6B\.>'K<?Z-I&EVY!R!%IMOM
M!QZME^,G&&!&>,5DLVIW_=4IT]N:\;7^%JVJVLT][76_7HCP_BVK^TI1>FG-
M:_\ Y)Y=>^MKL^'%+L0(XI)">@5"Q[<X /<@=.X]:O0Z;K%P<6^CZG.?2'3[
MB4\]/N0MUR*^Y%MK:(!8K:( ?PB.&-!D=5"1[N.@4DC!).2!4F&!&  /02.I
M'T*J,#\/7@<5A4S2;=^1O1*]NR6^_P!ZOLM-+%_ZMU):U,1"^SLG+3IJK>>Z
MO]]U\60>#/%]R=R>&]: .#B>S:U08X&//CB89YR2#ZCC!.[!\,?'$X^71HX@
M?^>VH:?#C(Z;GG$B\=2JDC! &<5]= J ,JQ]VD9S^+-R?;/0<#@4N5[+^I/Z
M=ZA9I5TM"2>EFT[+:S\NO?3T;73'AJE:+EB$[)-I)\UE9\NJ:OHUHUJ]SY8A
M^#_BYE4NNE0%N&6:^>8KWR&A5P.F.I'/7H:T(_@KX@8;I]8TJ 9'RPQW%P??
M(,6<CH-N1^1)^ELGV_(?X4AR?X@N/]GK^0I3S3'M:3ATV6^J?2UOGY]F;?V%
M@;;5K^?*[NR75/I?M^)\^0_!-F(-QXBE;/WOL^FB/. >C3L@'0 $CDG.,<UK
M6_P/T,$?:-9UB8YR3F"$#GG!4$  <?*K'C(!/!]LVG_GH/\ OD_X4[/T_('^
ME8/,,?/1U(QMM=+R]/QO;7:Q=/)<#!MN%25[;N2LM-DI)+OMONF>7V_P>\'1
M(J2IJ=TP.2[Z@$SWQM2$<=N#G^FQ%\,O!46%70;>1EP \]Q>3EN1RQDEB48Y
M/R9R3@@845VY)((R!^ ]?8?S_GBFX;^]_P".BL9XO$N5YRE.6C4HIVMI9:/I
M9_>=5++L!3CR_5ISUO=M.VUTO:.3WV;N[==&<[%X/\+6GR)X>TI2.1)]C-R3
MDD_QRL#U()P3^?&I'I6EP!?*TVP PH&RR@3:O8;1&2H7 ^7<=O=CUK0 X&6&
M?H?7V!%+@>H_7_"I52<E=RGKJT^;=VZ=+/Y;]M-5AZ46E"BH16D5R*\8Z63T
ML[)+[M'U(DAAB_U<4<?^XBIVQ_"!VX^E3%F(P68@= 22!^%-HIW?=_U_PR^X
MZ>6*VC%?)?Y 0#P1D>AINQ/[J_\ ?(_PIU%(?+'LON08&,8XXX[<=./;M1U
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M04444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRL[V[^E+@^A_*G-&\8/FJT((ZR*8STZKY@0L<="OMST-0#[.%4M?*J/G 9@
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M"9,_A^PUL^(-%N]$:YO(UEOM%M=1N5FT]C>0V\_^@I'Y]Q&6F+E(]OM7P?\
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MBH05-0G*K3I\[2JSES\G1117V1^:!1110 4444 %%%% !1110 4444 %%%%
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M!N.U7N_"NHZ8 3G!W:I!9%0#W8@#'WAS7IEA_P $Y_VQM86 I\&=5LBQ!/\
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M(T<(N!##=7"S0:G$Y@O2"BW\#-'J*JL$=C*O]IH?[0"SV]M%',@N=C#=A%R
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M9%Q/\.]3^,'[-%M\6_"7BZ+XAP)\1I=$\3_&R#X5Z;KWBRZAAEG\+V/B70O
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M\4^![OP?K'C&&6QUO1K3PQXCUBTT32['Q;XI\-V2M;IH7B#Q1:VD6K:KILL
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M.F6[8_*BI:*25MA_\-KJ]--7N_5ZOJ%%%% !1110 4444 %(54]5!^H!I:*
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M,@5(T<;?>1&_WE4_S%/HK!MMW;;?=N[^\[4E'X4H^BM^0Q8HT^Y&B_[J*O\
M("@QQGJB'ZJI_I3Z*FR[+[AW?<:J(IRJ*I/!*J <>G %+M7^Z/R%+13 3:O]
MT?D*"JG&5!QTR <?3/3\*6B@!"JGJJGZ@4FU?[J_D/\ "G44 )@>@_(4;5_N
MC\A2T4!9=OZ_I+[@I, ]0/R%+119=@&F-#U1#]5'^%+@8Q@8' &.,#H,>U+1
M19=OZ_I(!NU0<A5R,X.!GGKSC//>G444 %%%% !1110 4444 %%%% !1110
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M":/9R?;YW7SVTUTUMJ'/'S_RVW^_^M#ZN-Y;@X\P'Z D?F!2?;+?^_\ H?\
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M;76E:K'+IS:>L-C!IN+:]M-3D:9KB6VD(\G>_ >'/@]\2_#]KK7@.+5_ O\
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MCEF@,>-PQ6M*?*FK7UONEO9?Y?\ #[\V)T@GUO\ JCHYIA+$\<CL%=61CN/
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MRQC+;+35$9$9MB:E#"B0IA5IQ23BK.Z6^]]OZ\O5G13KZVF]+;V2U]WMZ_\
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M$,5^H.T]?KUJFUZ"",]?]_\ PH_K^OZ83<HVY;/>]F[*RBUN_P NR?D:<DI
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MV?\ Y-TMY^7]796.B:(1@V=R1Z&[U(C_ -&T@T+0QTLK@?2[U(?RE%6M\O\
M<;\O_L:-\O\ <;\O_L:.5_R_A_P YI]G_P"3>7GY(J'0M#/6RN#];O4B?S,I
MH_L+0O\ GQG_ / K4?\ X[5O?+_<;\O_ +&C?+_<;\O_ +&CE_N_A_P YI]G
M_P"3>7GY(I?\(_H'_0/E_P# C4/_ (Y1_P (_H'_ $#Y?_ C4/\ XY5W?+_<
M;\O_ +&C?+_<;\O_ +&CD_N_^2_\ .:?9_\ DWEY^2*?]@:".EA,/^WG4?\
MXY0?#NA-UT_(ZC=/?EOQ)<G]:N;Y?[C?E_\ 8T&211EE*C_:PO\ ,"AI1W7+
MZJP<T^STM_-TMY^2$M]*T2T;=;Z78Q-_>%G 6!'0AF0L"/4$&M0S(<9R<# R
M,X'H,]!QT'%9F^0IOVMY?=@,@#N3@9 '?.!UK'.O:;)=KIUA.=7U1\A-.T2&
M77+U<$*7FL],$\L40=EB:2=[:*.62)9)D9E5U>*ZK[T)1JRVC4E;LI/MV3\O
MP.J\U!PH YYX( /T'3M5*XU!4N;6PMX;J^U;4)5@TO2-.A:ZU#4I222(;8#>
ML4/+W^H.5L+&R"RR S;B>L\/_"3XC^*$C>[BA\!:9, 9;O4!;:OXG,&X$QV6
MF":?2M-EF&2MS?S7\\(;;Y ( 'TKX-^''ASP/"XT>SFDU"<*M[K6H7)OM7O]
MN/FN+R8,T<>  +6U6WMD151(U4 #.56,=FI/7;5?/_@:_IU8?"R<G.=TG:T7
M?RZ/]-'\[G"?#;X52:/>1>*/&26MWXB.3I>F6^)M*\-03?*?L[$;;[5Y2?\
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M7$A8"5UC+1Y(8S)*W+G:H:2<-(1M1MXR","G':6($[1P6A6>1[BY,<5JPEE
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M<2HYC15*ND<6X-M5#AE084 ;@ !7\5_Q#\6^&-<^(O[8OA_P=??M&ZG_ ,%
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M44[ZZKI]W756_#KH?U6[XW8B-PY7AP#$2K?-D$0LP&-K?>PWRMD "BOY??\
M@AYXJ,WQU\9^"_#'@J#Q1H$?P(TT>,/CW\.S^U-X+\&1^*?#GB&WA/A;XO\
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M]S_R7_@!S3[/_P F\O/R1#_9&D_\^]Y_X':I_P#'J7^R=*'2"]'_ &_:I_\
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M9@USQF^GZI<.1^]BTN(7)T6S+.KML>WNWO<%BX%VZML(7'\5^*6<8KQ9\?\
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M\_(GV4.S_KY>7Y]V>&?\,]^ /^>GBG_PKM=_^2J/^&>_ '_/3Q3_ .%=KO\
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M8VX(C^R.RQB1;6'.\-_)!^P#X?\ CW_P3%_:V^"7PU^*/[-L_P !?A;^UU\
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M^&X_!>C:IXOU[PSX>^*'CCP'H/B#5-1LK'XAS>%TU.X^'EU>7^EZD)=+BU&
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M6;X;?^G>PKZ]3H?K_04I_$_E^2)'T445(!1110 5$\>XYR,'A@5R2N "H.0
MIP<[E<\G&.,2T4 <)K?PT\#^)',^N^%]#U"Z*;/M;:?'#<X[?Z5"5O<[>,_:
MB 0"%&!7&R_L^?#-V9H-+U*Q#')33_$6O6L0]=L27Y0 _3/H:]MHIIVZ)^JN
M3*$96NKV]'^:9X9_PSWX _YZ>*0.RCQ=KV!ZXS=GKW^E'_#/?@#_ )Z>*?\
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MCVM7^[TZ?X?\OS\@]E#L_P"OEY?GW9X9_P ,]^ /^>GBG_PKM=_^2J/^&>_
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M4 %%%% !1110 4449Q^/% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6HJUE=)]6MY/=MW9\E^(O#*&*7]VF2H&?FXP#M_A[ C!Y)R>ISGS3P%XXE^
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M8GX9?&%06+)YG@78[(WS*61-7F"$ [64R$[E)P 0!<&E>[MMO]WZCZ):[O\
M&QW%%</_ ,)M=?\ 1-/B]_X0[_\ RRH_X3:Z_P"B:?%[_P (=_\ Y95?/'^9
M??Z?YH7R?W/R\O-'<45P_P#PFUU_T33XO?\ A#O_ /+*C_A-KK_HFGQ>_P#"
M'?\ ^65'/'^9??Z?YH/D_N?EY>:.XHKA_P#A-KK_ *)I\7O_  AW_P#EE1_P
MFUU_T33XO?\ A#O_ /+*CGC_ #+[_3_-!\G]S\O+S1VY"LK!@",?=Y!<$@.@
MD#8BWH65G:&Y5D+Q& ^8)8LA_#/A>77X_%4_AS0)_%$%I)IMMXH?0=);Q3;Z
M=)'Y1@@\136T^K6RB,A!#;7,,7EH(@0K;DY__A-KK_HFGQ>_\(=__EE1_P )
MM=?]$T^+W_A#O_\ +*CF@^J\OPM^:^\-^C^Y];?YKT^\Z!?#GAL>(E\7_P#"
M/:!'XN:TBTZ3Q5!HFFQ^)ETQ%?=IB^(4@37'TYW*AK+^TH86A'D'Y5#-0'@?
MP0UM/9S^"_!\UG=Z_!XJOK0^%]#%K>^*;5X+B'Q/-:264UO)XC6YM+4)KMS'
M=ZS#'$C#49/*CBK._P"$VNO^B:?%[_PAW_\ EE1_PFUU_P!$T^+W_A#O_P#+
M*ES0?6/_  ]O\T'R?3H_*WYK]>IX3^T?^Q_\,/VE=-^'MCXD>\\(77@#]H/X
M4_M'-K'@G3O#^G:KXQ\:_"76'U+1K;QA=SZ3/-J]CJ-I(^DZC<7<EQJC6!%O
M#?109B/T;)X/\'-I)T$>#?"+:$NI-J\?A_\ X1O0XO#HUA;B.\@UQ-#?3KO3
MH=5CNH+>9[KR);MI88YX;VWD4[\C_A-KK_HFGQ>_\(=__EE1_P )M=?]$T^+
MW_A#O_\ +*A.'1QU_P"!_F@M>VC\M'UM_FMS>N/#'ABYU^W\52^'=!?Q396L
MVGV/BZ70]+F\5V5A-A7MK'Q"UN-:L8&B58WM+?4EM9%+))&R@ Y\?@7P(EC:
M:2O@/P3%HUEK(\1V>C1^%?#[:18>(!/-<'7;32SI:6D>O2RWEW))KD*6VI,6
M99II_M<SQT?^$VNO^B:?%[_PAW_^65'_  FUU_T33XO?^$.__P LJ.:'>.OI
MUM_FOZ0:]G]S\O+S1P/[/'P \*_LZ>#?$OACP[JFM^)-5\=?$GQY\7?'_C3Q
M.]G/XE\8_$#XB:]/KOB#6=4FT^VL+&.)C/;Z98V=K9106.F:)I4*+-*\TT?N
MU</_ ,)M=?\ 1-/B]_X0[_\ RRH_X3:Z_P"B:?%[_P (=_\ Y94U*"T37W][
M?YK[P[Z/5WV?EY>:^\[BBN'_ .$VNO\ HFGQ>_\ "'?_ .65'_";77_1-/B]
M_P"$._\ \LJ.>/\ ,OO]/\T'R?W/R\O-'<45P_\ PFUU_P!$T^+W_A#O_P#+
M*C_A-KK_ *)I\7O_  AW_P#EE1SQ_F7W^G^:#Y/[GY>7FCN**X?_ (3:Z_Z)
MI\7O_"'?_P"65'_";71Z?#3XO?\ A#O_ /+*CGC_ #+[_3_-!\G]S\O+S0>.
M?]?\-O\ LLWPV_\ 3O85]>IT/U_H*^(M3U3Q#XKUCP!IVG_#?XD6)L?B=X$U
MZ]OM;\+_ -F:;::9I&JF35)[BZ:_F,0BBMK=XCY;AC*R')92GVW$Q.X<$ C#
M Y#9 ;(]@I4$]VSTQBLY.[;7E^2 EHHHJ0"BBB@ HHHH **** "BBB@"L_WQ
M]6KXY\;_ /)]W[.'_9O'[3W_ *E?[-E?8S_?'U:OCGQO_P GW?LX?]F\?M/?
M^I7^S975A]Z__8+5_P#2(GEYE_!P_P#V-,N_]3:!]GUY5\:?B;H'P<^&7COX
MG>*)6BT3P5X9O]=N@OEEYGM(G:"T@$LL,;75]=-;6ELKRQJTTBJ[H""?5:_(
MW_@LGXNNO#W[,?A[P[ Y6U^(OQ:\(^%=60;\RZ3I]AK?C6_CRK!?WJ^%+> I
M()(WCDE4H69&!@J"Q.,PU%[5*T(OO9O6WG8X>+<ZCPYPSGN>2VRO+,7BUT]^
ME2DX7;O9<_*C\AOAJOBGXW_$GQ/\8OB44N?&7CK7)==U>(!IK/3%G,RZ?H>E
MM,$:WT[PIIS0:/IF$1]3AA:XO8[:5BM?H]H/AVTTS3T$8C1#$B;2N,$@ 'IG
M"Y!SR?:OBWX'7EM8Z1933RQQRE$+JI !DV+DC/NW<]SDX)KWKQ+\3;+3M.FW
MWL<3)$<9=0O+!1GYER03P 06. #DXK[_ #*CB'.&&HI1^K.G&C&,4K4W;F4E
M:T]E9M77R/X^X1QF#P665\YS2K[?'9E5KYE6Q<I6Q$IXEN=+FJMMM<LFG&]G
MWO>_BV@QQCXZ?%E P43>*M$NT+GEX;KP1X8V$8!R4>*6-NPD1@">M?H/X?TR
M"32HBRAE\@95>O( &>@Z').2>V:_(?PC\3M/U7X_:W&DV[^T]$TRY 1RP>_T
MR>:*:SD*CRX+R33YFFMXIG9Y8+(D#$3U^M?@'7+>:Q@CD="5MX5(!^7<;>-I
M,9/(68R(O/"A<\DL?7S&G7EAL+4;M*%*"NM(\T5&+TT^U=ZV[7W/.X!Q6%JX
M[.J;45[;,<55A)NZ:KU75C:^]XSWU=M>J/#/C5X+M[O0=15X8V6X$BK'ABDT
M%TR>9#.2N02I<#9YFW (/''Z+?\ !/3XH2?$+]GKPWHM_<O<>(_A;?ZA\,?$
M9D8>8_\ PCL%M=>&KJ4>8[M)J7@W5/#>IR%U0B:[D4!@F]OD3XG7%I=:7=QJ
M =L:@]!R&!!&?0 ]>^<#'-;_ /P3'NCI_P 0_P!H'PZA407]I\/?%K*I)#WU
MU#XHT&ZFQG8K_P!GZ'HD#%5#&.")&)1(U7Q<YIQQF15:TKN>75*<:3OHE5<7
M6YK_ !-MMI]&HI:7/TG@3$SR7Q1P>%PTE]6X@RK%87&0MHYX+GQ6&G&S2C.$
MXR@W;6%2:;O8_8VBBBOSD_JL**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:W0?[R?^AK3J:W0
M?[R?^AK0!\O>+?\ DN]W_P!D<TK_ -3BXKXR_P""D?[3_BG]D']D?XA_&/P%
MIFEZK\0Y/$'@#X<_#R/7%DET&P\9?%/QQI'@?2]<\06\9C,^C^'(]4N=:GMV
MN+6"_NH+&Q>ZC\V1&^S?%O\ R7>[_P"R.:5_ZG%Q7DW[3'[._P ./VKO@GX]
M^ ?Q6L=0N_!?CRULX[VZTB\&G:[H6JZ'JUMKWAGQ)X=O3D6FN^&/$-C8ZWIE
MPP*F>(Q," :TC?DERZ/6WW(KJK[>[?TLC\RM6^-?[6_[#_[3'[*GP_\ VC/V
M@K?]JCX8_M60?$_PKK _X51X+^&_BOX9?$GX<_#F;Q[:7O@<^%-1FAU[P?K?
MV9]"O--\3&'4--NY4O9[ZUBX/;_#/_@JSX>^-D_@C3?#WP"^-'PMTWX^?L_?
M&SXM_L[?$SXB/\/+K0O&.L?!GPWJ6J>*])N- \-^*M=UO15T9M.>\L[_ %*Q
MN+?742ZAM;!;6./49NX^'_\ P3>U&V^)O@[XO_M&_M1_%?\ :B\2?"#P/XU^
M'OP13X@>'_!7@_2/AG!XZ\/7/A?Q%XPELO#-DUMXR^)>H^';J72;OQ;X@N(9
M2YAEFD:9%D39\%?\$T_ASX&TC]DO1;'XD>,KN+]D;X0?'[X0>$I+N#2PWB[1
M/CMX4U;PUXBUKQ(H@+V>I:)8ZG=W>@6UI$EE<7,%A'>2-;-(]3:ITND];-IO
MI=-MW5]6K;.RTZ*\=GNM-$TO5:6\K?CHV?/7[-O_  5@\)VG[,_A#Q=^U-9^
M+(/B+HG[">B?MG>+/&.EZ-X8M?#?Q8\/'Q!K/A?5]"^&UK;:QIA?QO!XFLM*
M\,RZ!J.EZ'IB7^O:?<+K"Q,X'Z"?$+]KCX9?!_X+?#_XV?%S2O'_ (*TKX@Z
M5X6O+/PIIW@+Q!\1/'>E:GXJT.;7AH6H>%OAY;^(YDNM!L[*X.N7K7O]E696
M94O;B5/+'Y4?&3_@EWK7C/QM_P $WOV:=#\!:KJO[,W[(>EZ=-\4/V@]>\:>
M"[+4_B=\/K#7[7Q/)^S[J7PPTY!K>H_V_P"+/!_@O4]<N 3X-ATJ>ZFL)&OH
MI4?]^E9FE:6-@IWCHA\J+S0VQ<R@F%64LJ1R;2H)C;Y@150YVFFVK))-KJTK
MOI>STW=WJ#Y>BZ[7TT>BTO9O1VW5]%T7Y@?%[]OBZ^(G[*GQC^,?_!/6'PO\
M?/$_P\L=9MO$.O\ BA]>\"^"_A/%I_@KQ!XNUOQ9K]OXIT'3-3\7:GX1T_1[
M>6/P#H5G+J5UK.I6FFZS=V=FLTA^*M>_;B_;'^)?P[_8-\!_![XH>"OAQ\6_
MB_\ L$?$W]L[XP_%#Q%\-M*\8VFLW'PS\+:;/H_@S3/!WVRPL='L?%_B.35H
M?$E[I]Q>ZCIUG!9SZ/:/''/%-^[WQ%\":;\2_AK\1/AI>7CZ/IGQ&\">,_ N
MIW^FP11WUE8^.?#VI>'[_5;"$1%)KVUMK^>YMF:*0//"JN&Y6OSC\>?\$JOA
MYXQ^%/[,WPZ\/_&OXO?"[QA^S+\&M=_9\T+XM> 9?#L7C'Q?\'_&?AZT\.^/
M_!7BW2]=LI]'>SUO3;&W2&\TZVDN]!OY)3HDB1;I%4E-O1NUM;/E5^9/36Z;
M5]6_*^HXM=;:-?WGMU?7I;1;W:>Y\8:!_P %+?VH]=N?V?OVB_$OA/5_!'[,
M'B7X'_ GXO>/]*TCX9/XD\#ZQX-U[P/\5-5_:5\6?\+:E!D\,^*?AMXQT/X>
M:#\.O!%S=Z;>>*AXFTV*VM=?DUE'L?U(_8?_ &@M3^./@#4F^(WCOP)J/QWM
M=7U+Q5\2/@MX7U71KS7OV>M'\9ZY=W?@?X/^+;?2U@G7Q3X$T"WM_"/B?6KY
M+R"Z\=VVO6=Y>6\L$,0V_$?[''P[U+X+_L]?LY>'-0U/PS\$?@/XG^%.IKX'
MB"7B_$+P[\'+1+[P?X&\4:G=1B5-$D\1:?H_B3Q)=M!$-4U72+72(8Y+:]O#
M%P_[,W[!/A3]F?XX?%WXX:1X^\4>,+SXE:1XA\/Z!X8UK3M+TVV^'_ACQA\7
M?&/QT\1Z(+BQ@1_'-U+\0O&6IS:7X@\0;=0TC2EAT^!OLJQBB*FI+5R75MZ)
MM)O2ZOIHK+SMKH-Q<;62?1[7M;U:[O6WR=CS[XO_ /!4#X?_  E\>_%G3%^"
M'QB\<_!O]G#QSX6^'?[2_P"T7X8;P-#X%^#_ (M\76^FM:67_"'ZMXGMOB%X
MWT[0&UO2F\;:AX=T,P^&'GCC,NI.^UN5_8;_ &I/VA?VD?VPOVY= ^(&C^*_
M!7P9^ GB_2?A=\/? VH>'OAA+IUOJ@TSP[J3:EK7C;PUXNUWQ9J7C/6;.2]\
M0VT%MI4O@-O#&MV)DUG3]<M8]*EZ[XL_\$QOAU\5?'_Q<UL?&?XK>#_A1^T9
MXU\*_$']HCX >&I?#%QX+^+GBSPFE@T>HOK.H:-JWC+P?8ZXV@Z0WC*R\):B
MB^*?L\,+1VD2,!]0_ O]FKPK\!/B#^T?X_\ #VO:MJ=U^TA\3])^)&OZ9J M
M[?2?#MWI/A+2?!EAX?\ #2Z<L-S=:6^E^';9BVL,)BT>R.&6<(LK2FY:MV3Z
M;/32UM;;;]4WI?17BEIVO?5WNUI^=K;JR5]3XGO?^"NGPVL?%WBV*\_9Y^/=
MG\&_AE^U9K/[&_Q;_:%G3X;OX!\#?%VU\:0^"]%N4\/VGCNX\;:YX/UW6)K>
M&ZUJQTBWG\+IJ&GV]_97]S.J5%IG_!7OX7ZE\./BA\89OV>?C_I?PR^'?Q5O
M?V>M!\0W,?P\N+_XO?M&P?$]_AI9?!SX7>'[#QC=ZAK&I:CJ!@U;_A*=7;0O
M#6G:%]L%[=_VC8W$*^"_ '_@EK\0?%OC/]J"^_:3\<?$?PE\(/%W_!2'XE?M
M5^'/@#HNI_#[6/ OQET/3/&6D^,?A7XZ\07&G:?KNO\ AN._NO,N?$/A$ZO8
M7U]_9VGS:]IMAJ,0E;[!L/\ @F'\&XOV6/&'[*^J^,?'U_H7B/\ :)\4?M-^
M&_']O=Z5HOCOX=?%?7_B"WQ*T+6O!LUM!>:9'+X<UE3'8QS6S1W6GW%W#>[%
ME/E)>TOUM;K;?3Y^GG=OH'N*R]$[-Z7Y7_P.R3275'R%^TS_ ,%@?B#\._#,
M'A?P=^RW\1/ O[1WA7]IS]G?X,_&#X0_$J]^'VM7'ACPM\;[BWUSPEK/A#Q+
MX6\<S>&?%-Q\3=&M[KPSX3U*:[L-*\/Z_P#;I/%BV&EC2]<OO:9?^"SW[-ME
M^TE%\ ;_ ,&>.++3+7XV>&/V;?$7Q,O/$GPG%GX=^/7BJ#3_ +'X2D^&D'C^
M7XH:SX/TG6]3M/"&O_$[1-!OO"MGXLCELK4W5@?MU:/BS_@DQX"\>^%?'][\
M0_V@/C/XP^.WQ%^+WP.^,VK_ +16K6O@,>)8O$/[.23#X0Z)IW@33]+A^'(\
M'>&Q.Z7?A6;3KN/5KB*&\U28RPI&.U\*_P#!,KP;X&^/FK?&/PI\=_C%X:T+
MQ?\ &2U_:"^(/PFT@^#=/\.^./C)'INFV>K>([SQ':Z._CC2/"WBF_TJUUGQ
M;\,='UB#PW/J96[TW3X(A!$%^^[]?[NWX+O=J_2Q7N6\_G:[MY7LNG31W[GE
MWP[_ ."F,5IX4^'6B0^!?CK^TU\5OC5\=?VLOA9\,M&TGPK\(?AMK-QJ_P"S
M[KFHR77AK6$'Q!N/"ND^'H-)$5OHOC&34+NYN;2S34=?TZSN&DMGYCQ9_P %
MO/@AX9\!_ 'Q98_!7XK:QKGQSTOXGZK_ ,(?K?BWX-_#D^#F^#?BZZ\!_$#P
M]+XU\?>/]#\%>-/&UOXCL[M/#G@[PUJBZEXFMTLIH); :E:12?2GPC_X)O?#
MOX2>,_@1XST/Q]XTU;4O@7\7_P!J?XR^'+"^TSP[:V'B#5_VH(KT^(]'U*2U
M(GCLO#0G,.BR648NY0BC40)7$*^.Z_\ \$B/ >L_!;PO\#=/_:#^*VE^"M%U
M/XRW'B#2-6\-_#CQ_P"#_%=M\:O&^M>-=5U"Y^'GCKPMXD\-Z7XY\+R:U?:?
MX6^(VCV>G^--(@-J(KETMK18G^]M96O9?RMIVCW=M7S+MIZ"3@]>E_/5:[Z+
MJE:R6CZGZI^"/%=IX[\&^%/&MAIVJZ19>+?#NC>)+72M=@@M=:TVWUK3[?48
MK'5;:UN;VU@U"U2X$-W%;7EW;I.CK!=7$069]?X-?\E9^.7_ %Z?"[_TT>(J
M\\^"/PB\*? 'X/\ PW^"G@0:L?!_PM\%Z-X$\.OKNHR:OK%QI6B6RVT%WJ6H
M2*C7-Y=;6N9RL<443RF&"&&&..)/0_@U_P E9^.7_7I\+O\ TT>(J<[\JOOI
M?UL[D_TO3H?3-%%%9@%%%!..30 5\$?\%!M=,/PJ\,>"89"MQ\0/'WAZQNHU
M=D<Z!X8EE\9ZVQV89H)5T&STZYCSME@U%XG#([*WWMD8SG@X_4X'Z\5^7'[?
M5[]L^(OP6T7(>&TT'QKK+(.2TM]J'AK1HU '=H9;EQGC;$]?SG]+7B*7#'T=
M?%/,:;JJMB.')Y/AW1J.E55?/<7ALHI2A*/O-QGC5)Q2?.DXV=S[OPSRQ9MQ
MOD&%?+RQQ4L7)R5XVP5&KBT]FKWHII]'KHU<\=\ :7MCC15'RJQQT^=&<#/3
M^('C'KD8KZO\-Z< D9V\D1D=\MC)SVX[C_$"O!?A_:X6 A?E*N.N<$R,RC'
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M/ P.2:=10 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM% "8'O\ F?\
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M39]5\3_'KQXT,PTY+GP=X M)Y"-DVLZ1!KGB778XP -R6VG>)_"R@DG!D8@
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M>%_#TW[3&HZ5H>H:5I?AE/"-U'X(\3Z9=>(6/B;4WN=;3Q#/I]@9[#3[.W,
M^W[G_@DG^R7<?#_X:_#R/4/V@M,L_A3X:\5_#[POXIT+]H7XD:%\0)_A%XTO
M$N]>^".O>--*U.UUO6?@[)Y,$&G> [F<:7HT4<BZ3]B6>96Z_P ?_P#!,/\
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MWUVND>7X\R3XCR6.G.N'<'*7>TZE9QOZZNV_>UBY1117]]GX8%%%% !1110
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M)%NW:Y5A.QD-A-&TF.\;48],L(]0:!;5KV.T@2[:V3.VW:X1!*T"YP(BY0#
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M [NS$#(X(X+#C([ _,!TKRK[73UMLFW=Z6M\T?1)IW2:NE?5V5M.OH[EJBJ
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M/M/I]B?EY>?]71LT5C;F_P"?E/\ R'_A1N;_ )^4_P#(?^%'M)?\^:OWT?\
MY;_5GY7+/M/I]B?EY>?]71LT5C;F_P"?E/\ R'_A5H7<,:HKW$0.%'+Q@D@
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M]_9#LO%-AKWQB\%Z#!J<DNG^5\5/!\=JUPOB+1H(I+67Q%:6\;H]S>6D!/\
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MJ]:2IS/;M/M8+*RM+2VA6"WMK>&"")-VV**)%1(QN9V"HJA0"['CDD\UY?\
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MM<T75/#NDW>FZII5Y#?6%_:RVD3QW%K=6[O%)$RNN&5R2VY< HV.TG/S8]%
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M_!4#3[:-QX;^$6K3-L,D=QXC\2V.DP;#R/,_L[3M<:-USM9=LHR#ACR!YO\
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M3C3]_P!C4KZRDK)<E)VOI>VJ>A^J)>,DG8YYZHS[3CCC:<8^E)NC_P"><O\
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M .&<OA__ -!3XH_^'O\ C'_\WM'_  SE\/\ _H*?%'_P]_QC_P#F]I?V,_\
MH(?_ (!_]V\U]YK_ *PYC_T+,JZ?\SK&?W?^J;]?O1^DFZ/_ )YR_P#?4O\
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MM?\ #.GP^_Z"?Q2_\/;\9/\ YO*/^&=/A]_T$_BE_P"'M^,G_P WE+^RX_\
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MGC7_ .:.IGF^6NUIXQZW:CAXTE=VNW_MM7FOUV=EN[V50R?-H7Y8X:+:2?\
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MV2R@3>EHF>GCT>SC2W0:19(D-F^G)';Z?:Q);Z8861=-MA]F/EV@80K);?\
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M\'?B(/#5JD&L:UIL5EKD>O:[IG@W5;BX37(+:"*.[A\/:M)IEQ?0SVCMXK\
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MB*-*O34U3KTJ=:"JTY4JG)4@IPYZ<TITY.,DW":4HO22332]CHHHJ#4****
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M]A__ ))7XF_[+=\>O_5J^):^SJ^8S3_D8XS_ *_S_,^TR+_D3Y;_ -@>'_\
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M4[2Y9)Z2:/RK^$G["'Q#^'__  Q[)JWBGPAJLO[.$'[0EOXC^SPZGO\ $/\
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ME!).S<5)K2Z2/T"_X3GPY_T-WA?_ ,'6D_\ R;1_PG/AS_H;O"__ (.M)_\
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M>[?LK?LOID/^SE\#4*DJV[X2^#%VL!DJ<Z",$#D@\XYZ4G_#*_[+X*@_LY?
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M@_+_ ':V?^$Y\.?]#=X7_P#!UI/_ ,FU^>W_  RG^R\H+?\ #-_P,4 !B?\
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MQC_[O_4'_7O'Z$?\)SX<_P"AN\+_ /@ZTG_Y-H_X3GPY_P!#=X7_ /!UI/\
M\FU^>X_96_9?)('[.7P-)'4#X2^#"1B/SCD#0<C]R1+S_P LSO\ N\T?\,K?
MLOYQ_P ,X_ W//'_  J7P9GC&>/[![;ESZ;AGJ*/[*P7_0>^G_,-2_N_]/?Z
MU\[G]N\0?]"O)^F^<8_^[O\ [']__;Q^A'_"<^'/^AN\+_\ @ZTG_P"3:/\
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MJ6EZ9?B_F71],32-8TR;6=(%Q:R--',]Y(MNY,,E?K-1_7]7 **** "BBB@
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M2OS7\)L!^TO^V%)D OX\^$!.0QSGX+>"BQP![ 8SP!GG-?I3."R@#)()( .
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M2I*,DYE1E."IP,*L<B B/RHE)!(AA$)]QOB1)-K$;G3?M9N2.U8?_#&WAO\
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MXM!O#X>LC8V,*7NBZ;:6#0W.DQ+!+=6VIR169_F[_P""K?C;X)?%O]I7QO\
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M^)WCJ[^#.N_$7X8_#GP=\/\ X\?"KXN^-?"-_I?Q!U274O#VM? ZWL)O%O\
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M7,-R-7T_RU75]+M+F:"TN,W]H3_@GSXP^,GQ?_:/^(W@WX_3?#30/VGOV;-
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MHWKHKG0\)@8QC)U$DU>]]=+:-)-K7HXW\]K;5G_P5>A\86W[1B67A]O@S:?
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MKR;W>F2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&FE1W5K;:Y>O"\EU=>*[:PU".'3=6U&:YNTT2YECM/LEC="VKUV0!0%5455
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MBTS2K:.WOM6T&]O=$U*[B5;B\TB[N--FD:RD, ]CHH$>6R_!#X.3Z9<:-/\
M"WX?3:1>>#;/X=7>F2>#O#SZ?=> +"[N+ZT\$W%FVG&VF\*075W=31:!)$VE
MQ27,[QVJ/-(S<G=_LJ?LS7_A'0? %_\ L_\ P:OO _A?4;K5_#OA"[^&G@R?
MPUH>JWP9;W4](T-]%.F:9?WBNR7=W86MO/<QGRIY'C 6O?J* ,ZPTG3M*LK+
M3=+LK73M-TVVMK/3M.L;>"ULK"TLT6*VMK.WAC1+:WAB2**."$)%'%$B1HBA
M@VC110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7BWQU^#_A[XX?#WQ'X!U^>]T[^TX["\T7Q!I4L,.M>$_%&BWD.
MK^%_%V@W$T-PEKK/AK7K/3M7LWDM[B":2S2"Z@N+62:"3VFF-'&_+(K'(.2H
M)R,X.>O&3CTR<5=.<J<U.+M*+37JFFOQ5_D:4JM6A5I5Z,Y4JU&I&I2JP=IT
MYQ=U.#Z26R]6?E'XOUG0OCEX#\9_L0_MI6>@^$_BEKGA]]$\,>*!;II_@?XV
M)I[QR:'\3?A'?ZG-):Q>)=-O[33]7\3?#JYOI/$W@[4YFM(FU/P_<V&NZG_&
M_JFA^(OV??CG?^'?$T20^*/A3\1-2\.:W;W$-OY4TGAS6;G0]5=[>>.,3:5J
MMA9Z@;.X2*:"XM;VTEA=2PFK_0\^(?PP^'7Q3\,WWA3XC>"?#GC3PY.'EETC
MQ#I-EJ5L)T#F.ZM1=QG['?0DL]M?VTD%U;2D2PSQ.-X_EP_;\\0_#?\ 9)^/
M[?"^Y\*_$#7O ]_X1T3Q+X2M_&5]\)OCMHUI#J<M]826EBO[0?PP^(?CG1;&
MSNM(NH;'2]-^)UIH=I9VT%CI^DV@:"!?QWQFX0X<XBRJCF^8YW3X<QF!4L/4
MKXG"U\1EV+P]=P<Z6(6#IUL3!P]FW1M2G&//-2ERRBH_V;]%'Q*SG),[S_A3
M),DQ6>TN(<KKXK_5VAF&"P=-9AA*/LJF.R^>/J17ML3"K'ZQA=Y>RIRI5%"F
MXQI1P6G_  EWALZ7;VTG_"2:5)I\?V")'$PTV+^V-*=V7RK6.&2RDOX8IFGA
M$;FW1$N'8(?DFZ_8_FT?XX^+O$?CNTM_[#MO$2>-=$\!7&K6NFW%]H]_!;Z[
MJWBWXI:V9L_![X-^'=9>:V\0ZQK\NG^,O&*1IX3^''ASQ%X@U2U9/LOP7\=M
M$^(7POTWXA:-XB^*UIH\/FQW'@OP;;? [X$V6GV6CZE'HMUIMQX@^%7P[TKX
MLP6T%I>I(?["^(.D9LI_(AD@B:1#\(?MZ:MJ%M%X1TOPG!8^#/AKK$&M?VAX
M,\+M-9:+K'B#3+])X_$?B>]NKN^UWQOXBG2^D9]>\4:IK.JSRB5S?'!2/^5.
M&\'X6\!9Q#&SXKAQUGU.-6>!X9R:&/PF3SQOM_:X/$Y]BLVP]'%>SPT*=/"S
MP&"<:,Z5.2JQ=2I4Y?Z<R?$>)W$^8RX;R_*H\"X+-*#RS-<QQN+PV*S)\U6;
MQT:$\'6]E2JSPDWAXJS2@G*.*ISLU_6U^P;X8\"V_P  /"_Q(\(>))/'VJ?'
M-_\ A;'CCXEW5E<:?=^._%>N6T.E7-T-/OOW^CZ'X9TG1[+P;X1\,M%%'X=\
M*>']&TV6*34(;V^NNQ_;K8C]B[]JIE1Y&7]G_P"+#)'%%Y\LK+X(UIECAMQ\
MUQ-(0$AMU^>>1EB3YW6OS?\ ^"#WQ>E\9_LBZ]\-=3O))M1^#GQ&UO2=.CE>
M5Y8/#/C.WM/%NDJ!(SF-(M<U7Q/9A(RL:"U&U<LQ/[:-91WT*6FH1)?64]F(
M;NUNT2XMK@'S-RSP2[XY5<%0P=75@ ","O[XX9SQ9WEF49]*%.$\33H5ZM&B
ME&E3K4N7V]"@DY*%*G5IRI4HWER4XQ5W8_S4\0LBK\"^)G$>0XF4\1_J]Q#7
MC3G.RJ5\)1QD*V"E*2A"*E5PDZ3O"$:2?-[./)RHR_!Q/_"->'D^\D?AS1PL
MO #$VZJT84?=\M4C.#VD !.#6]<=9?\ =/\ Z$E7$BBB54CC2-%7:JHJJJJ,
M84   *,# ' P/2JMT-I9^,&(+CC!8RKSCU/ )]./2O1E[TI2VYJCDEO\3T73
MON? 7<JG,EO4YK=DYWM?RO8_*']F;_D6?B'_ -E\^/W_ *MSQ/7T)7S%^SEX
M@T73]!^(=O>ZKIEM,/CY\?-T-Q?6\,R^9\5O$LB!HI+E&!=#YBY091E;!!%?
M1_\ PD.C_P#/[HO_ (-=/_\ DROKIR<:D[1<DWNG%;;_ !2C?1WTOMTNK_H&
M)YJ-1.I3GRSA#E<4I)\L8J75;73\^AH)U/TX^N1BOF7]JSQYXD\#^!?"2^'_
M !5-\/K'Q=\6? G@CQG\2+2'3I+OP!X'UQ=<?6/$=M<:U:W>B:9='4[/0/#M
MEJ>L03Z=:77B-+RY@DALY4;Z*_X2'1_^?W1?_!MI_P#\F53O]1\,:I:7-AJ8
M\-:C8WD307=E?WNDW=I=0M]Z*XMKBYDAFC;^))$93W!J(SM44Y4I22:=N>DG
MI;JY26CVNFM-MC+#8FE1Q$:M6E5J4URW@H13Z7UES1?=*46G9W36_P"6'A?X
MK?%[QA\?/ ?P(\._M%^*]5^'<OCSXPV/_"W-)TOX<7GB_P ?:1\.OAC\/_&#
M^&SXA_X1"Y\(:K<:!XI\37VDZKK?AS0H+74-"COM,M6BU:&2_C]\_:X^)_CO
MX;Z]I(\%:S8Z+./V=?VH?%UK<SZ)H=[<KXC\'6?PWG\-ZC;ZCJ.FW%[#:Z?+
M=W)N+&VGMK/7UD\K5;2_\N-XOL+3H/ 6D+IB:5I?@K3$T2&>WT9+ Z#9II4%
MTD4=S#IRV\L:V45PD,*3I;"-9EBC60,$4"]?WGA/5&#ZG'X7OV%G>:<)+V[T
M:Y9;#4#:F_L@US<2 6MX;*S-U;G]S<&UM_-5O*3;URQ<'6HU%@XJ%.FH2A)T
M'[2=I)U)6:5Y<R<E:R<7RV5D>O4SK!RQF%K0RYQPU&BJ=6BZ5/FK5%S*5>32
M47*?-&4HVLI0?)9-(_(;X[7?Q8M_#WCGX9ZW\8/%WC*UU_1?V-/B-I/B+Q7H
M_@3^T_"/BSQ#^TKX4T'4Y=!M/#^@:-9)X>C>RL];T[3[ZSU.:U%KYD^K:A 9
MHU[+Q!\0?BKX3^(FM?!C6?B+J_Q"T71/CYI7A2#7?&FF^#'\8W'A;QY^R5\3
M_B;<:%=WVC^'])L(8[/Q1I$*6=_H-IIFL)ITTUC<W=S9SW5O<?J!-)X+N69[
MB+PG.SI9QLTUUX:D9H].O!J%A&S/,Q,=E?JMY:(3LM[I1/$$D 8,D_X0B:XD
MNY;?PC)=370O9;E[CPRUQ)>#39=&%V\QF,C7(TF>;3!,6,@L)9+0,('9#K',
M'RJ,L)3:U=E]6C[[CAHJ<;2]UI4I+W4DU.5]E;NI\4X91<:F6\Z2;A;#TH<M
M5K!P55.,4X2C3H5(VARINJY63CK^,O@GXL>,O _[/FA1^"OCW>_%JUO/V)?B
MUXV\2>'[_3/ >K:9\)O$GP^\!VDGA/4M'T>S\/6]QIMK-?WLOA?^POB%+J\&
ML7P^U1V[2Q'.YX=\9>-?!_Q/^-VA7'QWUWP3IGQ&_:U\(:'X[\4-_P *[2Y^
M'OAO4/V7? /B/0;W2'U/P]/:^%CXY\1QZ9\+=,\2:[97VA);^';"&Q6VUYM0
MU:]_7&STSX;:='J46GZ/X#L8M9B$&KQV:>$K9-5@6W-H(=12%D6]B%J3;B.Y
M$J"$F,+L.*?=6'PZO3J1O-&\"W9UFUM['5WN4\.3MJEE:(([2UU%IG9;VWM8
MP$MX;KS(85 6-54 4/'P;K-X32K4G/66'<ESN$HK^7]TU>-DDVE>.C1<N*L+
M*5=_V;)*O5K5)2="ASVJU*52G?W%"]!P?*E%4Y2C%RA\2E^<GPJ^(_QD^)?Q
M-\!?#:'XZ^++SP)I7C'X]PV_Q)\/:1X"@\0_&3PM\)I_A'=^&)]3OE\*7/AR
MZTU=5\9^(_"VL^(/!FGV-GXH71)9;.;3Y"<?6OQ'N[N\_:9^ 'AS4"L7AZT\
M&_&SQ]##+Y)M[WQEX?N_AWH6ES.DY-OG1=#\<^*;Z&''FQK&;B'+6@9?<;,^
M"=-%@--M_"5B-*M9[+3%L;CPY:C3K*Y>"2YM+%;2:/[);3O;6TDT, CBE>WA
M:16:-",/Q)HOA+Q9KO@77K[4K2UU;P'XCEUS0=1L]=TF*2.74;"YTG5M,O//
MNS;W&DZUIMU/!>6EPKQ37L6F7#*6ME(QJ8B%2<'##QHQC2J0:YZ5W.;G[[<9
M)7<9QB]';E?+96BO+Q.=8>OBX5X8)T*4<-4I.$:,(RE4FZS=67(H1NXU(1EH
MU'D:@DE&*_&3XF_$KXUS?LMZ+XK\=?%_Q5XWMOV@?V2_VIM2\7>%/$>E^#;/
MPKH.I?#WP"NOZ1J/A"#PYH>E:W9W;6UZUCKT&J7>NVM_;GSTCM)MR5A_%];X
M?"35?V78K$P:#^S9K,/Q2U))8[4VUCX1UKQ/X)E_9WT*"SLA)8+]HE^(GB][
M&&Q,3Z?9_"58HE(O+9V_<@VW@"XTVUTRYT_P7<:?;6-WI\%E/)X:GM(;'4H&
M@U"SAM[B1HH;:^@D>&_MX$6UN0TBM&T;;:N2GP3<F[,]MX0N#J$-E;7_ )MU
MX:S?6^G.SZ?;W<AE+2PV3NS6BREUM&9G@"$DUUPS3V;26$C:-24XJ,Z$$I.5
MH2]V2NZ=&<J<=$KQC)KW;'J4N+,/2]BHY=)1I8NOB4H4H0_BSDJ=N1*/-1P]
M65%/ELW"$W?D2/$/"5]<Z9^US\=/#&GC?X:UWX8?"KXA7R*R&VTOQK/XG^)'
MA*=(BJ+F[\0>&-$T:6X7"XB\,Q7"JD=UL;Z7=B21QU)_4^]>9>&M!\'^&O$/
MC/Q;::G97GB#Q_J&E:AK^J7NMZ2+BYM]"TF+1]%TRSLUNRMEHVE6_FW<5K$5
MBMM3UG4)(4#W]VS]TOB#2!G-]HYS_>U;33_*\KS>:R24+M*%VIPU:A&+>L]^
MBVT6NMSYK%XJA7Q%.K2IUHQCA,/0DI4TY2G2A3C*>DMN:+Y>MDF[-V-"O,/C
MU_R1#XL?]DL\?_\ J+ZS7H/_  D.C_\ /[HO_@UT_P#^3*\D^._B?0I/@O\
M%FW35M%,K_#+Q]$(UU&S>02'PSK \M0MT=S%B$ 4')(P#G%*,I2J4WR-)23;
M<H/K'I&3>]UVTO<,'S5<=@Y4Z=1JG53GS)123Y;/5N^MU9:Z7/N7]G[_ )(=
M\'O^R8^!O_4.TFO5)O\ VC!_Z-->5?L^?-\#_@W\PX^&7@3)'0AO"&D=<'!X
M()Z]1V(KV*:-"" !R"N<#(VAB!D]E."!Z].:^7KM>VJVU_>Q;\E[2+^>D;Z=
MUUT/A\8FL;B6U\.)J2MU?([NWKT>NI\H?LG?\?\ ^U-_V=A\0/\ U"?AI7UU
M7R'^R5%-%<?M/^>L@:3]JOX@2JTBD&2-O!GPW"2*2!O1@ORN"5;'!XP/KRO1
MSJ<9YEB)1::<<,DUJGRX6C%_BF?-<-TY4LGPL)JTE4QLFFFK*IC\346CUVDO
M4****\H]P**** "BBB@ HHHH _.GXHW$)_;<T-]_RC]E+703M<<K\9?#K, "
MN20LB,< X#<]#CU)9HW^ZP_$%?\ T("O2?B5^S5\&?C!K.E^)/B%X'T[Q!KV
MC:5<Z'INJRWFJV5[;Z1>7MOJ5UIZW&F7UE(]M)?VEM<;)"V'B!& 6!\YN/V&
M?V7EB7?\,;,'>,LWB/QFX/RMCY1KK8/OCUYYQ7T>&S/+UA</3FL3[>G3=*T5
M#DY7)2;U]]RO>UDEY=3XBKD&9T\9F%6A+!RHXS&5L:U6JU*4U4KT\/3G#GC2
MJQITTJ$>5N%62;E?FT44WI_>7_OH?XTNY/[Z?G5'_AAO]EO_ *)G8?\ @]\:
M?_+FC_AAO]EO_HF=A_X/?&G_ ,N:V68X).ZABOG!>7E_5GY7B.49NG=T<KEM
MI+-:UOLZZ94GU?6V]T7MR?\ /1/S_P#K4;D_YZ)^?_UJH_\ ##?[+?\ T3.P
M_P#![XT_^7-'_##?[+?_ $3.P_\ ![XT_P#ES5?VG@_Y,5_X OZ_X9^5Z659
MOI_L^4=/^9KB?[O_ %+/7[GYWN[T_OJ?^!#^N*-Z?WE_[Z'^-4O^&&_V6_\
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ML?./^?>6=/\ F:U?[O\ U*/-_=Y,N[T_O+_WT/\ &C>G]Y?^^A_C5+_AAO\
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M[7UA::9\0_ R6EO'$)/ UY+,Z>=YDS0>*+<;IGGN+AI6)R0V4P3RI&,?$4@
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MJ\\14IRQ-%2I4XU(4HSJIU%[.,YU(*+FU&TN:4H14G']@C=0 @%_F) V[7+
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M;#8]-SG;]]"G*HHV::3DVM'=0=KO8VO^"'WQZMOA=\</B?X#U&WU?4+'XD>
M;'5=.TW2XX9Y8]4\&:S+')(L4UQ:0!O[-O[VY8M-YGDPRL<A*_J/C_:(T0W
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M@TWPMK7_  BJ)#!H,_B2QOYK*W2*U-Y]D41'WT0A6+ +N(52P&"53A%Z9"J
M J_=484  8IXB8LI&,@@@\\8(.?PQFMGD642@TLMP=W*G4O["GK4I)*E)^[J
MZ:24&[\JV.2'$6?4^54LSQT(1C.FJ<<344?95)*52FK3O&-1I.<8VYFDW>R/
MDCPE^RIX$T3Q?\1?''BNRM?%OB/Q;\?O%/QM\.W7G^+;/2M#EOVTZ3PNM_X;
MN+ZU\'>(=?\ #5Y;7EY9:K=:'K$-JTMI):W+N)GE](O?@/\ "#5K3QG9:AX#
MLY[/Q_XZ;XG>*(!KGB^+[1\1?/N+E/&VCW,/B)+WPCXA2YOM2G>[\(76@K=2
MZE=F^BNE-NL'L5R+2QA:2YN;6PM58F6YN)8+>"-VQ@&6X(BWR8PH;+OM(7!!
MS9TRQUS6D4Z%X<U.]MV)":C,/[(T^89_UJWVJ23I/$PPP>PT_!4Y1F&#6-+A
MW)Z<:<)9=@O9TJ:ITDZ--\D$I6BI<O,U:I533;5IR33NSJK\5<2YG6>+EFN8
MTY)QC.<,76IMSA.C.#M"48IJ5"E)62LZ<.QXII?P$^#NAKX3.F> =/MIO WC
M76?B1X:O9-5\3WFHVOCKQ!H^I:%K7BG5-3O]<N]0\4:QJ&EZI=6\UYXLN-=E
M3*20F.12S=OXH\,6OBKPIKWAN[C#V7B#1=0T"[$L;/')9ZO9S:;=,2XC0D6]
MP[@G(++@J5.T^N6GPN\7:@-VJ:_8^'[4C+6NBZ>^KZD03@K_ &IJT:VF<?QP
M:')$WWDFVX)WXOA-X/MU1M2.M^(98PH:76M9NI(]TA9 6L;!K&PA5&&[8+)L
M;1@*VUU[:6 P5"EB,-A<-1H4\90J4<0J4%%5:4J?(X226JY6HZVY4K722MQU
ML=F^,Q%&OB\QQ>*KT90CA*N)KU*\L-7EC*6+A4I2J2;@X5Z<JJBO<]I*4K7D
MV_\ /\BCOOA+\6);*Y5H-0^&GQ,O-"NE8,I2^\&^+YM U..105?[+C3]0B&U
ME,D")(KA&R_Z_2WEJFN:3/$)%BU729+2%T1V5Y;58-5@,92%P0MH=6EPQ8^8
M=XPFY6^:O^"N/P@TKX1_MO?$:'0=.CTOPY\3-*\.?$?3+6!66VAE\1:4UGK\
MENI"A6G\3>']3FEX+/)JES*V3*6/M_PP\3?\)5\$OAKXUQC4-&AT]KQ,DF2Z
MT.ZN?"'B=7YR1+HQU?49!T9U#G.0:_R\\4<CEEF=X["12@\#FN(4'%6Y8.LY
M046VGK%-I6NUJE9J_P#M]_;D.+^"> >-J,'&'$.28&M*/_3QT84[3^):5:51
M.SLM==3\O?C/X?F\%?%_QIIT$8MQ#K(U_2 T;A7L/$MJVO1F,#RVQ:M?74$3
M(BF.ZM80X<QRI+_9#\"/B,OQ(^"GPH\?)I?BJZ7Q5X \-:Q+=VOA'Q/=6CW]
MQI5I!JB174&ESQRF/5+6]BE!?<'0@L2I!_EM_;J\.):^,/ _BZ  PZKHEQX=
MO'"AC)>Z1J5W>60D*@E_-AUF"U)).((D3H*_H@_X(C_%2X\>?L:R>"[U&2]^
M"OQ(\2>"(7W']]H.MQ67CS1)5'&Q(#XHO],C1<*L.GQK@#BOZ$^C5Q!2GG&.
MP,7[F:9?"5*.ZC6R]*-97T2<K2E):].K/YP^FEP_+B/PI\/^,E%.MPWBL9DE
M:M)^_#"8[%4Z;IJ_Q0GC\O\ ;<MDU*<I*22:?V%+KVEP!?M,>M66203?>'/$
M=HH(&<;[C1XD![D%^ ">U.CU_P /3-MCUW2]Q&?*DNUMYNN.8KA(GQ[E0"0P
MSE2!]<3,2HW.V ?4\Y!X/7(]CQ65<Z?IMXI2[LK.Z0C!6XL[>92#ZB2%@?QK
M^T#_ "\^K-[/^KKRZ)_>FNESYTB-I-&'BN8)5QDO%<12@#V5?O#W5R/J>*D%
MNP^^"GNQ"[_9%P2QZ]^!ZU['>> /!5R49_#VG6S@9%U81II4R<_=62T$/4^W
MKGK7,W?PMM0W_$EUS7=(;CRH3*-<L%;'!6*_%_*>."$O82.N_/! ^JWMKZ^6
MJ?37IOZ/9G"B'8<@N#TSDC_T';GZ'([XR 0AB!]!DY.!G)]26)/MQ@8[5NW'
MA3QGI^Y5_LGQ#&F<26\S:+?D>T5V6T]Y,<>5D%B2P.U#7/RZK!92"WUF'4]!
MNF8!%UFU-C!+D[1Y.IN/[(N 2" (#O8CCBJ4Y15E)I&<H.DU'6UD]&O+RN[:
M7^?2Y4NM'TZ]=);FUBDN(QB*Z4/%=0_]<+F%XYH/7]R\>3R<DDUU?A[QIX^\
M(R0BPUE/$VD%0HT7Q23/<P@-DC2/$-I'#J2PD?*5UBTU$#/$F #4"*Q4'(Y&
M0?4'E6! P0PP0P^5@05^4BGB,DG[N6^4G')!XP3C)&.,$XK-QC)N32;;NWU=
M]_O*C.I%KWI65NJELT]M.E_/4]Z\,_&CPSKDUOIVJK)X5UJX!6WL]:DBBL=3
M<8#'0]7W+8:JBNRAA'+%*I;8T8<$5ZZCLZA@%(/0@DJ1V(8[=P/JH*G^%FKX
MDNM.ANH9(;J*"XC<ABETH:$N@(1WW@\JK,$(PREOE(YK4\.^*/%O@R95T6\?
M6M#50'\/:W=2!4VD;CI>LNS_ &"102(;6Y!M)E*ABC(M8SI)*\7MT>M]=_E?
M:S.RGBHSDHNZWUM_PQ]DY?T'^?QIXZ#/7O7G7A3XBZ)XM+6MO)+8:S JO>:#
M?@6FJ1(55C+%!*3]OLRK!EO[$&%U*E&S@5Z(.@^@ZDD_F>2?KR>_-8--;IKU
M.I24MG?^E\^HM%%%(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:6P
MP4@X(R&R.3SD;<[N!@YQCGK0 %U7)8X ZDYPHP3ECC"K@'YF('O7"^+/'&C^
M&(TMY2;_ %B[C9K+1+1H_M]S&,K]JF#*QM;)6PLEY/&MNC,%+,Q"-E^+_&LE
MH\NCZ J3:HQ$5Q?R+YMAI#R B,RC'EWET3_RXAQM&#(R!AGR"+3=EQ/>2R/=
M7UT^ZZO[DK+>W"C&$DG.&501Q'$8[?N( 0"-(TY-)V>NW:WGZWT?J^EGA5K*
M%K:MW^5K>G?_ #,O69M9\6S&[\37*R1;VDL_#]F5&A:;&K?NEGMI!YFLWRJ2
M)+B>2.UW$O:6]N%V,P6S'N3P  Q&5"J%50>?E  VKT0?(,A<UT9M\=%)/OR
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MBD[;X#'* !A^F.$OO 36N9/#.JR639.=/U1)-2TH@Y^5-\B:C;J/X4BO-J@
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MU\_3XQ)?VTP'(F+W,:#)((&*]Q:([C@$#CC;[>W%,,+9;&X>8=TK\G<>VZ'
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MU[/5WCO;JXGCF)6*%452,FN=^7X_JW<7LKO7E_KY/]3DO _Q\TVZ^%FK>/\
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M>*]/Z:_K3J6J***DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[-;_ //)/RH^S6__ #R3\JGHH @^S6__ #R3\J/LUO\ \\D_*IZ* (/LUO\
M\\D_*C[-;_\ /)/RJ>B@"NUM"!\L,9.>XQQ3/LZ?\^\56Z* *GV=/^?>*FFQ
MMCG_ $9 3GD,>">_7^GX5=HIIV_I_HT3**E:_3_@?Y%!M-LFE:9H%\QU"LWL
MO0>OO_/!IW]GVB]+=#GKDD?UJ[11=_TW^GHON1/LUY_AY?Y?EV*@L;0CFW0>
MV2<?K3[>VAM@ZP0QPH[L[!."SLQ9F;W8DD\GDU8HI7+2LDNR2^Y6"BBB@844
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>nt10016217x4_graphic05.jpg
<TEXT>
begin 644 nt10016217x4_graphic05.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M%[IIV?W=3^R(U(SC"<&I4YI.$XM.,DTFFK=&GH]MN^DM%%%26%%%% !1110
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M=Z<X7.<_E_G-?PH_L+_\%+OC#^R#XITO3=:UK5?'/P*OKRWM_$W@6^N+F=M
MA\Y(IM>\%WUQ+)+I\]A:9DN=$,4=AJ;1_*RR-&X_MH^%?Q.\'_%_P7X9^(?@
M76(=?\+^*],@U71]2MW1UEM+B'S$=P!NAF&3%=VSL7M+E?(=0VXC\'XRX)S3
M@_$TXUHQQ&!Q#MA\?2A-8>JO=NH\Z4HSL[V>Z:<6TFE_8_A7XM\/>*N53Q.7
M>UP68X.WUW*L7.D\503;4:L?92E&I1GRM1GHTXN,XQ?*Y>FT445\8?JX4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBOAS]E"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M24WR+%)8;!W^K.2?[JJU1_G#C<&1E8 [AM9FZ,B_+ASU*H,D9ST(Z&OZ5_\
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M^Y_UU7W@?3]%?,'_  VC^RU_T6KPA_WWJ/\ \KZ/^&T?V6O^BU>$/^^]1_\
ME?1RR_EE]S_KJOO ^GZ*^8/^&T?V6O\ HM7A#_OO4?\ Y7T?\-H_LM?]%J\(
M?]]ZC_\ *^CEE_++[G_75?>!]/T5\P?\-H_LM?\ 1:O"'_?>H_\ ROH_X;1_
M9:_Z+5X0_P"^]1_^5]'++^67W/\ KJOO ^GZ*^8/^&T?V6O^BU>$/^^]1_\
ME?1_PVC^RU_T6KPA_P!]ZC_\KZ.67\LON?\ 75?>!]/T5\P?\-H_LM?]%J\(
M?]]ZC_\ *^C_ (;1_9:_Z+5X0_[[U'_Y7T<LOY9?<_ZZK[P/I^BOF#_AM']E
MK_HM7A#_ +[U'_Y7T?\ #:/[+7_1:O"'_?>H_P#ROHY9?RR^Y_UU7W@?3]%?
M,'_#:/[+7_1:O"'_ 'WJ/_ROH_X;1_9:_P"BU>$/^^]1_P#E?1RR_EE]S_KJ
MOO ^F9=P!95+$J5P!D\Y.>W']?SJ!XS*%5T;D+NXZ?,C8!^;'*CKG 'TKYM_
MX;1_9:_Z+5X0_P"^]1_^5]'_  VC^RU_T6KPA_WWJ/\ \KZ$I*UHRNG=.S\K
M=/ZN*VK;U35G%[?A;^MM3^/'_@K=\'M0^$7[<_Q9N9[1H=$^*&H:=\2_"\[1
M.EO<+XBTRR3Q%")"JK)-:>)K'4[J4*3Y8NX=Y4L!7YJ [CPI4L>%/!!)Z8^N
M:_KZ_P""E'PS^!/[?7@2SM?@S\1?"FL?'WP'#>ZOX#MHI3;MXIT]8HI=;\'M
M>ZC%8V>Z_M[=9K2WDNDF2_BM)@@@9WK^1'5]#UK0-<U70/$&FWVB^(M!O9]/
MU[0]1M)K/4]'O;:9H9;?4K*94GL6\U&CC:YBB2X(W6[R*5)_L/PQXAPO$?#V
M'P+JT</F>5X/#X.%&<N6-586C3H0JRYI<SYXP7,XV2G=65K'^4_TB/#?'\#^
M(&=8^K&I2R;B:OB^(<NQN)BU26*S2O4QV(P3E&G",8TJE=RH1UE+#3I24I:L
M_L"_X) _L-^'_@I\&]*^.'C/1HKWXO?%/3%U2"\O88[N3PAX7NG9-)TG2O.M
MW:V:^MVBU#59U8,T4JQOB*,5P7[0'_!%;Q?^T?\ $/7_ (H_%3]LCQ-KFM7T
MUV=.M4^%VB)I'AW1"XDM_#^@Z7-XCN(+6QLR@-O<N9KV5P)KV:YRRM_,?8_M
M$?'_ $FVM--TSXV?%NPLK"VBAM;"S^(/B.TL[>T@18HM/M+?^V8D@1(E5$0(
MD42J%RH  LG]I?\ :+ .[XZ_&8J<JQ'Q%\42*N>I<1:S(0@_BPIPN?E(X/S5
M/P\X]PN<8G.L'Q'@*&,K.<?:RC2KU(47+2E35:51)<GN\J6NMS[>AXX^%M7A
M#)N$,?X68K$93E%.$Z>$I<3X6C2Q&(<$IXRO##*A+%5:E1RJ1==2:E)<O*[%
M3]H/X4P? 7XZ?%7X*VVL77B.R^'/C#5?#-MX@O-/L](N]0CTX6,L,D]EICR6
MRB2&ZDER BE03M4&O,='T74O$VJ:5X;T6QFU35?$^IZ;X>TG3K:)KB?4M3U^
M[BTK3;"VAC!:6>^N[J*WAC49DDE"@C.1#J>HZQKVM:CXB\1ZO?ZQJ>L3QWFK
M:OK=Y-<WFHZBT)DNK^;4)[M[JY:8QP6LC7$**=JL3Y98U^YO_!*C]E7P?X&\
M2^%?VP/VH]0TWX=^#K&:YA^!FA^+XYK/4/%.N/97JS^,+S2&66^&GZ="TAT1
M[VPMP+M(+^!L"W>3[[B'-*O!G"T\3G.*HXC&5<'4C@8QMS5<Q5"U&-6E&2E&
MG.ORNKR6Y*;?*^9(_&.!^"Y^)_B \KX;RZOA^'<5G%+%XZI-3>$R7*/KD'6P
MM2O-37]HK#IT<+2FW[;%*/-%P;/ZBOV=/AX/A#\#OA5\,2R22^"O ?A[PS>W
M$2;8;B_TC3X;*]N$&U2#<W<<\YW L3)SSFO<(?N\]1P!_L@#!_\ K]*^6(OV
MS/V6$58_^%T>$%5"0#YFH_-EBY;:+ [>2>#SW[@U8C_;2_9:W%1\:?" 4*,'
MS-1.2#U_X\,CC! _QK^*:]2>(KXBM+WIUZTZLG9ZRG+F?*NVNG6Q_K]A,/0P
M&$P."I15.GAL-1PM&&B2ITJ<(026FT8+9=-M#ZEHKY@_X;1_9:_Z+5X0_P"^
M]1_^5]'_  VC^RU_T6KPA_WWJ/\ \KZQY9?RR^Y_UU7WG6?3]%?,'_#:/[+7
M_1:O"'_?>H__ "OH_P"&T?V6O^BU>$/^^]1_^5]'++^67W/^NJ^\#Z?HKY@_
MX;1_9:_Z+5X0_P"^]1_^5]'_  VC^RU_T6KPA_WWJ/\ \KZ.67\LON?]=5]X
M'T_17S!_PVC^RU_T6KPA_P!]ZC_\KZ/^&T?V6O\ HM7A#_OO4?\ Y7T<LOY9
M?<_ZZK[P/I^BOF#_ (;1_9:_Z+5X0_[[U'_Y7T?\-H_LM?\ 1:O"'_?>H_\
MROHY9?RR^Y_UU7W@?3]%?,'_  VC^RU_T6KPA_WWJ/\ \KZ/^&T?V6O^BU>$
M/^^]1_\ E?1RR_EE]S_KJOO ^GZ*^8/^&T?V6O\ HM7A#_OO4?\ Y7T?\-H_
MLM?]%J\(?]]ZC_\ *^CEE_++[G_75?>!]/T5\P?\-H_LM?\ 1:O"'_?>H_\
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M:_8>(?#]^";75-/=WMY-KF-U82)'+$Z,IWQS1QNBC>RA"&,@=91110 4444
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M_P *K\;,?F51L6?0MPY!8\E3\I &TDYP*9G%)M)_UH6/#W[*G[/_ ,0KZ_\
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M."T6UC18(;6VU26SB1<J\*1F3+;J_+GY?NHNU% "=/F! 8D'JPW,1D].@P
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MQYJWB)]"TKPM9>#+S5H[@O<6]KIUQ#K$-D]NXU">X,9BF?;!)&X:XQE8N_\
MCG^SA^SQ\%YO%?AO4/VA]=NOB7X>TO[?;>#+KP1*(]4NKC3[;4],L9+FTCD@
MC.HV]S$R7+2$J Y,#8 /S%\' (_C+\+UD(51X\\+D.T2Q_;(I-<LS;R,-CR.
MK!1=1ER,^;_<50/I#]O2:WM/VN?&4MV\BVBZ;\/[J_CC5PDJ)I^FQD21CAGB
ML( AY&5)+"@/Z_+[^OYB>'_V5/"'ASP)X8\=_M%_&"V^#5KXS2&?P[X4TW0K
M[7_$=[9S$>7>RQ6#336L6QEDVK92*B';(\3#97-_$W]E@^!/$GPN?1/'%CX\
M^%?Q@U_1=,\.>.M&AG6>T&IZA;VK--I\@NEC>..5I(6DN_+D= LBH"V/:_\
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M68([>9RH8@#@8P3W&#VQWH GHHZ].G:B@ HHHH **** "BBB@ HHHH ****
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M0"#\Q;V'<?\ ?*_X4%W((&,D8'RKU/X4#YI=W_7]?GW9V/CKXA>,/B1XQO\
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MVL>E)9SV-G8M!;,5CW6LZ+S\FTE3\^TH."&P"5.1D C.".A!!X)[4!S2[O\
MK_ACZF_9'\)Z+J'Q+T'QWJWQ4\,_#FS^&NNZ#KTYUR86VI:_;1R7TES8Z0L2
MQK(SP6;V.I[L+]BU7R@JF8.E7]KKXR6?QK^-OB#Q/HMX]]X:TV*WT+PW.VX(
MUG8NSW$T"-PB7-RS,6"J7CV@^I^7VCB<AFBC+#=M;8NY-V-VQL97=@!MI&0
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M'8_%Y/C=>:_;Z_XWM].U'2+)M<L_/T;3M+U)=D]C8:59RV,5O;QIA( )&9
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MME>W]+MJ;2C'EEHM%?1:WNOROKY'EU%%%,P"BBB@ HHHH 5CN3RS]W.>.O\
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MYM(71&-+MK_P#=16FB;UMHK7]U:=[:];*U]M_F;PA^S-J=O\:?A5X)\9>)/
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MQH\R/_GHG_?2_P"- #Z/Z=/:F>9'_P ]$_[Z7_&CS(_^>B?]]+_C0 [ ]!T
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MZ*1_=]NE*."2."<9(ZG:,+D]\#@9Z#I110 8'I[_ (XVY_+CZ<=*, = !_\
M7&T_FOR_3CI110 =L=L8QVQC&,=,8XQTQQ1VQVP!CM@9P,>@R<>F3CJ:** #
MMCL!@#L!@KCZ;21CT)'0TN3ZGKGKW]?K[TE% "Y//)YZ^_ '/X*H^@'H*2BB
M@ HHHH **** "BBB@ HHHH *559W6- 6=V"(@^\SGHH'4M[#FDK[<_8.^ T?
MQB^,$?B#6[7[7X'^&TT.M:G'-$_V?4/$+X70-&FDV-$2&\VXU>S9O-2!8#*B
M+*C4 M=M?37\C]:?V(/@*OP2^#^E/J]E]F\:>-5M?$/BCS@#-:O/;AM.T?<
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M?CYC34E>,FUW5O\ (_.3_AVM\*_^AW\;_GIO_P 9H_X=K?"O_H=_&_YZ;_\
M&:_1NBGRQ[+^O^&_/NQV?=_A_D?G)_P[6^%?_0[^-_STW_XS1_P[6^%?_0[^
M-_STW_XS7Z-T4<L>R_K_ (;\^["S[O\ #_(_.3_AVM\*_P#H=_&_YZ;_ /&:
M/^':WPK_ .AW\;_GIO\ \9K]&Z*.6/9?U_PWY]V%GW?X?Y'YR?\ #M;X5_\
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M!SC^'KV.>/EP<?,"=I']\,GWABBT5O9>O]>7Y]V%GW?X?Y'YR_\ #M;X5_\
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MZK][]SFH+6]L[Z$W%E=6U[ 'N(A-9W$-W&T]K,()K=7MWE4W"3$1F+.\.=I
M;("]S^[]Z\O^!_38=GS/6UMNNW0_.W_AVM\*_P#H=_&_YZ;_ /&:/^':WPK_
M .AW\;_GIO\ \9K[Y\1>+O"WA"WTZ[\5>(M'\.6NL:UH_AS2KG6K^WT^'4=?
MU^X%IHVCVCW#H)M1U*Y(AL[5?WD\F5C5B#@\.^+O"_B]=9;PKX@TCQ%_PCNO
MZIX4U]='O[>_;1O%&BE!J_AS4U@=S9ZUIID1;S3I]EQ S!70$XH]S:\;]KK_
M #\OS[L=GW?X?Y'P-_P[6^%?_0[^-_STW_XS1_P[6^%?_0[^-_STW_XS7Z,[
MTR%# L2 % ).,(=W3&T+('/.0BNQ&U&(<2 2&(7'EDDD8"RL0CG!.(^-Q?[H
M0AR=O-%H>7W^G^7Y]V%O[S_#_(_.3_AVM\*_^AW\;_GIO_QFC_AVM\*_^AW\
M;_GIO_QFOT:# D@G:P!)4_> 5]A) S[-CKY;+)C:P-*OS,ZCGRQEFR-@.[:%
MW9QN)(*@_>0[QE<FG:']W[_Z[?GW8MOM/\.Z7;S1^<G_  [6^%?_ $._C?\
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M_7]-#]I"Z5]7:VCUOMT\_P"K#Z*:'4G *GC/RL&_,C('7UIU!84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Z3JG_(,F_ZX)_Z":\VKTG5
M/^09-_UP3_T$UYM7+2Z?XE^@J_Q0]8_^EH****ZAB$@#)Z=SZ$D!1ZY9B%7
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ML@CU-'V,_ER(X5A]/Z%_P5+^+EHBKK_@7P)KDP4*TMHE[HY/J0F-009P>.0
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MAT?A%X79XBIBLY?'/CO4/$<6B:29/M#:1X:FU619(8%5OU*JX_:[*6GI9/\
M"]OT3)[>G>_]?/UZA1115 %%%% !1110 4444 %>DZ)_R#;7_<;_ -"%>;5Z
M3HG_ "#;7_<;_P!"%<D]EZ_HR,-O4]7^9KT445D=84444 1Q]_P_K7G&O?\
M(3O/K;?^A5Z/'W_#^M><:]_R$[SZVW_H5:4OC7R_-&=7X5_BC^9E4445V&84
M444 %%%% !1110 4444 %%%% !1136) !4!F&2%)(#[59F4D<_<#,N",L%&>
M: 'C!P,.2S*B>6NYV=CA453P6<\+G ]QUK\ZOVN_VOSX FN?A3\+;C^TOB)>
M2?V;JNIZ6!>GP_+=A8K?2M,""1;KQ3.'D$EH,M9J@;Y=_/HW[8G[1B?!?P3_
M &-X=NHY/'GBZ%[722L@\S1-)G7R[S6+B-072^C!,>G *,W!! R<CSO]@_\
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MJ8[!U\-3C+FO-U:;IM*R=TN9-WU=]/+^<-U(9@.@;K^!XZ^H].A]>:2OV?\
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M9)'X\XQ7Z^?\$N-.OH_A[^V%XC:(1:=%\*'TPYWG9?R:-K.HI '/$C" I)*
M28R\:G 8"L?PU_P2.^.M[J$"^)/%?P_T/1S-F_U&'4[C4I;6V4MYC168AM1*
MY4;07F6-"0[_ "J17Z?>!?A7X ^%'POC_9C^!MVOB#4/$=[GXJ>.T"WMCIVG
M3QQ+K\^K:A )+&+4M7LX8]!TW28)!+!;WTEVGE26K2U\/QWQED^:Y)6RO+IS
MQ-7%*E)5E&*H4TIRYHU).7M%-**:BH.+YH/FW2_8O!#PCXLR3B_ \3YYA:6
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M2TMWKH?T/ @@$$$$ Y'0^X]O2NC\,_\ ']-_U[G^9KGF"AF"J%7)VJN< 9X
MR!T'M70^&?\ C^F_Z]S_ #-7/6%_./\ Z4A+9$OB7_C[M/\ KDW_ *#7,5T_
MB7_C[M/^N3?^@US%%/X(^@EO+U_1!1115C"BBB@ HHHH **** &E02K'DKO
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M/-244%6$Q\V[)WAMX<'#*0I0!2/NKY1,6Q<(8OD92*:$ 9V'&\DD * ,\L
MH!5GS*5?<!(2R@< /HH YO3_  =X6TGQ)XD\8Z9H&F6/BSQ?;:%9^)O$5O;*
MNKZS9^&(KR'P_9WMXVZ1[32(M0ODLK9=L,/VJ=E3?(S5TE%% !1110 4444
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M6YUVT"B*>7$DL9/3]^+6"&")88H4CBB CB1<%%B"(%2)0 (X4 $:1J H6,8
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MZ>E9)V:?8;5TUL?DA_P4?_9_DEL]-_:&\$6[V7B7PS)90>+VL(<27VGPR/\
MV3K<B1*I-YIER1%<7SEICIZ10%Q' BCW[]E7XS)\:OA+H^MW,L0\3:)*GAOQ
M7;>9YK+?6]F(X+Y&)8B.^BCCOH>>$F&#D5]G^*- T_Q/HNJ:!JL$=UIFMZ;>
MZ5?6\@1A+!>0O"YVR JWDQO)* 1]\*PZ5^$W[,VHZC^S=^UKXE^"OB!V@T'Q
M-JMUX2V&0E3J%H/[6\ WJ\[1)J5M+=Z=)*!N8:A9QNY6&/;M3G>25NEMVWNO
M3?O?Y&4X:7OK=;)*S\NG3LK^1^S@Q@ 9X &3U)4 $GW)!-%*<[FRP;YF^8#
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M&HU)R5[NHVTK._L2G(!]0#^8I2"00 &)& I#,"3P 0C*Y!Z81E8]%8'!#?D
MVJ,(HP <DX!QSGG(XZ]<Y]37):\VI:E?^'/!V@W[Z=JOBB[N+6YU>(H)/#^A
M::/-U[4U:1647%G9K;V$3L&5+B83D-M)J:S]C#F>NEVMFM$_UU+H495JZPZ;
MYE92E:]G>SNKK5>NIS7C&7P&;JUFU?Q)_P (OXITJ.2/3M9\/ZA-9>)=-M9+
MA[EX9!!#>R3Z6]T6N+C3M59M/G<MY\;!B*PK*U\1>-6^S6OQR75;:/*W3:5X
M1T2'7Q:J-T8::/4K:*RN-RH'OSHTLLB[EB,,SQW$?H-K\2/!_P -9O[%^'O@
M6QO+6RGGAU'Q+JFV35-2O4D'VUKR[9&NB]]("\5S)*UE'N)V!3BNMU"V\%?&
MOP[<ZO8V,7A/QSI\I-AX@TY8;;4-%U,KLLKFXN8D2*^TXW310WL5YYR&QEN"
MBB0*:\>>*C.I&;H<L8RC)VGK9--;*-]K;-J^I]5#+<11H1HT<3>W1TW>7:*]
M[W;Z+R>MCE?"_@_P_P"#K>>UT*SDDN+]UGU+5[^=[O5=7N596,FI7%P6GD<K
MO14WM&J,R@!< \6FJW6D_!_P_J.F/+%JGQ7U_P 8>*?%.LR2O]NFMXM;NH=*
MTJ2[#":6&RTEK*QL8'=DMK*RC@B58D11V'@O7;C7=#%SJ:6MEK&E7TVB:VKS
M">PAU;295%S=QW:8)@F(34F3H%D2$84D5S</]AZ):ZC\./&]Y)H7AG4-<O\
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M9;.6**\L]8A>._M;^)+VUD2X0,/00 .@ Y)X&.6^\?JW<]^]&!DG R< G')
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M/:Q8:]HVFZWIT\<UEJUE:7]K*DB/')!=01RQ-&R$HZD-C=&2CL"RDY-:<DB
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M^A]<<X)IU>9%65NS^_K^I]5%6E./6$HP?:\*5.+MW6GWW"BBBF4%%%% #7(
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M>J;@<Y)Y%>C_  ^2[T"VUO5[A#:0SVJQVRRCRR%M66Z-W,'"F.",Q>8TK8C
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M"%<D]EZ_HR,-O4]7^9KT445D=84444 1Q]_P_K7G&O?\A.\^MM_Z%7H\??\
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MZ=H'A;0X8S)>:QXGUZY^Q:!HUM"H)DO+YV^VQQ+DPV$;W-RT"[5;^P#]BO\
M9_MOV9/V=_AU\+25GU?3=).I^+=0!+O?^,-:8ZIXEO9)2J-,'U.\N(4E=5_T
M>WA^50,#\3\;<\PN$R*CD49QGC,9B*<Z\4TU"-*49>[%:Q3GR+WKO5V:L[_T
M)]'CAG%8_B%<35Z"C@LFHX^.75FGSU:N9P<*OM92NIN%)U>3V2I<EUSQG>Z^
MM"0!DG J&:58XC(SB*, O)(X*K'&@+N[D@",*H)+.5 ZGIBGE\KE03G[A(^4
MG'RMD9PISP2/TQ7RK^T;\4M2\.:5=>$/# :/6=2TQ+O5=2D1I/['TR]F>QC\
MJ$D;[R:?:5C8>4+3SY2Y941_Y62N[']JGNWA'QWX9\=QZQ/X?O7O[72-5ETF
M[G>WN8K=KFW5)-UL]Q%$EQ;.'!BN[<RVUPPQ#-+M('9Q2))N*D\;05*LI7*A
M@&#*I!P02",KT.",#\U-&N-8\.7C:AX8UFYT.\EM(M/NXX;:*ZTVXLK92]O'
M<Z==%+66:V:(6]G<JJ,3<L9#DKCZ]_9XOO&.L_#BS\1>-[FYFUCQ!?WNI1Q7
M*0PO;6(9+.V18(%6*"*46KW$,:Y!AECDSER!I.GR:WTZ>?\ 7I_F'I_7]=_R
M/<Z^+/\ @H''%)^RM\2Q)%YGE-X1N$X!Q(GC#1=IYZ$8'>OM.OA3_@HQJXTO
M]EOQA &02ZSKG@W2(%<X\R4^)-.OWB'7)^RV=S+P"=L;9&!D1'XD!YQ_P3^9
MV_9UT,O(7_XJ/Q$B#=D1(U_ V!G.,$GZ'.*^T578JH#D( H/7.T8S^.,U\>_
ML(6']F_LX^%)75T.H:AKVHNK@@JD^H QX R-P6(A@#A6& 2#D?8**41$)R55
M5)'0E0 3VZXS7;'9>B_)?<<4?XM3T7X)#J***9J%%%% !1110 4444 %%%%
M!1110!Z3JG_(,F_ZX)_Z":\W&<C'7/'UKTC5/^09-_UP3_T$UYN.H^M<M+I_
MB7Z$XC>/R_\ 2D>4>.(%DU:&0 <6@7)ZYWC(Y'XYQCT/-<K96Z_;+7I_Q\0G
MC'.)%)[#' )_#CG%>B^)8!+>Q-@DBT49./\ GHN<Y!]L?XYK!M[7%Q <#(E0
MC&."#QT&?:NH2>BUZ:+K;2VNEGK;INGT+7CR(27]FS8W>3,P_P!R1HBAZ$?-
MM/'48Y XKA?LX]OT_P#B:]3\4PB2ZM<C+BV4=L;0 .ISSGM^73GEOLA]!^8_
MPH!/1:^5K=FE_5]=?(Y7[./;]/\ XFC[./;]/_B:ZK[(?0?F/\*/LA]!^8_P
MH'?^]VZ?X?SO^/D<K]G'M^G_ ,31]G'M^G_Q-=5]D/H/S'^%'V0^@_,?X4!?
M^]VZ?X?SO^/D;'AF()X>UI"!L=I.?4_9!V'/'3H >#TKSS[)&3S]/ISUXP3G
MJ>1^>:]8T6()I.HJ0-K,Y.<YY@$> .A&\>W%<E]D/H/S'^%)J[3YI)K9JU^G
M5I]EL+XKIN\'\4;>[+X;<W7KHD]GKM8W? UJGV"]#8=UGV1&5=B%&X.PI)-(
M&QDCS !D<BN\"-&@0(N H"B-R[,PP#YLDP0A"!P$W8.!C&37->%X##;3J,<S
M*PYYQNR?7MG'Y BNKIMSE;GJU)VVYY)V^Y(FC1HT)5)4:5.G.I!TW.%^:"E9
MN4-;*?FTU;6UW<B3S"%+KM8[MPRI YPO3U7!X]L\C-2T44%PBH0A!7?)'EYG
MK.;NWS3:LG+6UTDK)*V@4444%!1110 4444 (<]>OMC&?Q)K!U[PSH/B;3;K
M2/$.B:5K^E765GL=4L+:Y@E5AM8/:W:WMG.".-Y2TF R4*N0R[]%5&<X6Y).
M%G?W;+5==GU5_4SE2HU+^WI4\3?3]\G*R[+D<-#Y2U+]C3X*-=3WWA33O$GP
MVU&Y_>27GPX\;^)O",+..B3:9I\_]F/$.OER6=Y <?/#("5.;_PRGJ$)\NT_
M:&_:$BA/RB)_%^A7J0KTQ%<:AX;GG&U<A6:%FST*$AT^OZ*[(YGCXV_VJK*U
MK*34EI;NO+Y=+'EU,@RBH[QP-&CM=45R)V:?O;MW:UN[.[ON?(B_L;^ [W9_
MPF'CSXS_ !#&[=);>+/B?XF_LF<CI'<Z3H=[H^GO"06! M6 4D>4V>/;? 'P
M<^&/PPMFMO /@;P[X6B;<93I>FVUG>R2NRES]O"W=Y=HY7>TM[=K,7"DQ]2/
M3J*SK8[&UU:IBZSCHN5./+IZQ;^YFE#)<KP[YJ>"HJ6_,X^]_P"!*SZ]1H!5
M0HRP!)!=BTAW'D.YX8#^'TY]J4$\Y&.@'(Z8]@,?C2T5R6N^9^]+^9[_ (6_
M+J>C[.*E!P7LXP5E3AI!Z6O).[;MUYEJ%%%%,L**** "BBB@ HHHH **** "
MBBB@ HHHH *Z+PS_ ,?TW_7N?YFN=KHO#/\ Q_3?]>Y_F:BI\#]8_P#I2 E\
M2_\ 'W:?]<F_]!KF*Z?Q+_Q]VG_7)O\ T&N8HI_!'T$MY>OZ(****L84444
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MP4L3"E32PTXJ52I@X0A%\_+C*F+JRJU9_*7@O]@_X%>'O%M_\7E\'06'Q?\
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M>?IL88.:J4:<F_WZARXB*DI0A5B[3C![\L976K=[/7N4445!V!1110 4444
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MZQ_]+04445U#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]:\XU[_D)WGUMO\ T*M*7QKY?FC.K\*_Q1_,RJ***[#,**** "BBB@ HHHH
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MFK*R639@\OJ?#))5ZD:^'53#RVJTG/W[[.UG^*7_  3%^$OB8ZWI7Q1_8?\
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MO5NR:NS[CFUBQM[V*R.H6[7;Q*QM)1&DY.\H2EDEP+ITX_UHD"$\A<9!UE#
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M=ZPDFI/>06TMG>6Z)96SL8I8T_ #PC^P'\,_AE\=?VE/A;^W%^U5!^S7X-^
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MSOB_MZ!O+?/WH]RJVPY7<H.,@&OT\;[A^I_]"K\P_P#@KI_R89\5/^P[X/\
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M;HDG[&NFO(JR./B;X8P[J&88>Y889@2,,S,.>&9CU)S^RR=$_P!P?R6OQO\
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M*S_9]Q6 RMYC-$A(3Y1DC:!^7^)-#"8G,.'^(LORNKEV$X@RW$XR>'5/+:6
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M4Y2:ED\X1:2U:E).,6E9R3BM58_C(7[S_P"\_P#(U_1C_P &^_\ Q\?M5?\
M77X/_P#O2J_G.;]T["3"DEB.0<@C(.1D<@@]>AS7]%__  ;\NBS_ +51+#&?
MA%+N!RNU/^%D;QN&5#KO7=%GS &!*8-?U/XL:\'YFUJOK*U6J_WJEUVZ/[F?
MYT_1K:EXP9!4B^:G7I8N-&HM85I++J[<:4E[M222;:@VTDW:Q_2,G1/]P?R6
MOQK_ ."V@/\ PQGIW'3XF^&0?8YGX/I7[*)]U#VV#^2]NO:OQR_X+:12?\,;
MVR["3%\3O##RD<I$CR7D*/*XRD:/+&R(SLJLVT*3O3=_,7!<E_K=P_--<D<7
M1<IW]V+4J>DI;+YM;'^A7C!9>%W'JDU&W"O$=.5].6<X7A!WM:4HIRC%V<DF
MTFDS^1=_N1?\!_D*_J'_ ."!_P#R1[X\_P#92](_]1JTK^7621%\J-W5),QA
M8W(21]Q"@Q(^&E7/5X@Z*/F9@O-?U(_\$%;6XM_@O\;[J>&2*WO?B;8):2NI
M"7!M/#=@MP8C_$D331HSCY"Y9%8NCA?Z1\74Z?!<E43@ZN/IRIJ:<74C[2+Y
MH*5N=6UO&ZMJ?P#]%FG-^+N4)0FW#*.)<1-*+;C0EAX*->22]VBW4II5':#<
MX)2O)7_>JB@$'D45_)A_J*M4VM4MVM4NFMMM0HHHH **** $W*,Y(&, \C@D
M$@'TR 2/4 GL:\&^)O[1/P]^$?Q4^!/PD\6_\)%'XM_:)U[Q)X=^';:=I-C?
MZ5%J/A+17\0:TVOZE)>PWVG6<NE!?L'E6%TOVJ38&"@R5^2/[;VE?#CXB?\
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ML]#C\2K'X_\  OCJ^N4;7O''A>22.VN]%UW6K\(+W5/!.I!6GM('WMIMY9W
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M?ANZL()[./RIH_*VJ.^HI**3;MN[OUT_R^\.WDK=/QT/*=:^!GP5\2:1X_\
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M+4M)'\W_ .W3^VO\6/V6?#'[(OPAO/!GA<>*OA[X9^%_QD\4ZGK@ T6\\5^
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M=0TRPO+FSG90J26MQ/;O);M$ 0AA*$<'.1FM(1<,7(>4MYCR, [NP[L6''
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M_P ?TW_7N?YFHJ? _6/_ *4@)?$O_'W:?]<F_P#0:YBNG\2_\?=I_P!<F_\
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MKWPX\,^"_$^N2P7/AZ_E_L::_MQX.CU!#;W[>'Y[*[DDU/0[=AI<FH@:BO\
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ME@:=.\:-"5E%QY8>[%2DI5)2E)JC P" H)X   9FWN % QF1F;TPW.3DTX8
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MG/45T/\ PC.H_P!^#_OH_P"-'_",ZC_?@_[Z/^-'M8=W_7S\_P ^S#EEV?\
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M=1_OP?\ ?1_QH]K#N_Z^?G^?9ARR[/\ K_A_S[,YZBNA_P"$9U'^_!_WT?\
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MR;_T&N8KNM8TF\OYK>2+R5\M"KY9N"1T&<9YXSCIS[5C?\(SJ/\ ?@_[Z/\
MC1"I%12=[I6_K7S_ *LQ<DDWI>[Z>B1SU%=#_P (SJ/]^#_OH_XT?\(SJ/\
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MUE:_3SMIM]]]M+]E+G4HPC"*>L8W6FFFWGKMY[,YZBNA_P"$9U'^_!_WT?\
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MB,8'F'."%W<$G@'@D'BOM/\ 8C_8B^(O[;GQ%UKP?X/U!/"WASPKISZCXO\
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M2JYR3C/N/\* ,Z]GM[4232R+&JYD<LQC0>7&"SR2#.T! .<8]>Y'X+?MV_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'X%?\%^/B5JOAO]G;P-\/=,O7L8_B-\0;"/5O*+
M*;G1?#=J=7O(96!^:.>[&G0LA&"N>!R3_(VQ.\J5"J1P!QGD@ ?AWZYZ9%?U
M6_\ !PEX5O+_ .%/P1\6113O9^'OB%J-A>R(A,*)KGAZ6.V#G!R7NK..-2 0
MKL@;&Y37\J3L!(H7## RV>I+<CWX!Y]^QXK^NO!R.&AP=0E2A!XC^TZU2K.R
MYG*\4H/5-QY5'3?7LS_+OZ5E;$U_%RM1KPE[/#9!@%@IRYK0IR]I-RIJ_+K6
MG45[7NK.]CO?A;\,/&GQM\?^%/A3\.-&;7?&?C;5(='TG3F222TAEFD:*ZU&
M\E1<Q:9I%LDFH7\C$1K&C*I>1@M?V3?LOVWP3_8:\1_!?]ACP(\/B;XM>*M'
MUKQO\2=:A-LU^'L=,BED\0ZXP_TE%U1$@T?1+=Y%VV6GM,(RYE:7\R_^"#_A
MKX0Z1#\6_BUXTU'0--\>Z;K.E>%?#MQKNJ6-C<6_A^6QDGNUTP7=Y 4:[O;I
M!/=I&R;5C5Y0$-?J7\+?V+/V?=!_:UU7]JO2/C_XR^(?QD\2-XCN)-*UCQIX
M4U'26L=6@:T?3;/2M)T*"Y71?#>F1P:=X>@@PEC;PLT[22.9&_/O%+B6KF.<
MYAE&)^M4,HRU-T*&'I5'2JXJ5.+@ZLVI05*"DVN3E;;=GII^W?1V\/L7D'#6
M5\98&ED^/SOBO,Z2J?7<QH\W#_"D)2C4>50IP]I/-<75A"I7IUIRI\DH0:@Z
M<E/^=/\ X+/7"S?\%!_B=*,D-X,^'*@X(7']@1A/FP5RWFH -V3N!P!7Y7HQ
MC$KMD,BO(H'\6Q6?;UZ,,+U'!P??^E/_ (+:_LO_  ;LT\8?M0VGC/69/C7?
M-\-O"UYX).OZ)_8@T-+RWTU[]= ;23JYN8M,6*Y:[2X1&P662&(;A_-6\9F2
M2/E2Z2("#@C<K(>>/KD\<]Q7ZSX;8JGBN$<IKT*3BL$J6%JN<))R5-4_:[OW
MHN+TDM'TU1_,WCWD.*R3Q+XOECWAJBS7,)9I"M2J*I.&!Q%:35*;BK4Y<M.<
M:E.2E.,;._O:_P!(G_!OI\3]4@\2_''X13W4LVDMI^B>.["T9R;6RO5E.BZD
MUM'N"HUW!+8NY4<BW!/3C^HV$*TOF#&?)"8&!D;MV[UYSU]NE?R=_P#!OMX6
MN[SXR_'#Q:D4O]GZ3X(T3P^]PHQ!)<ZGJ,-]"NXGYF:"TF>,J""B,2W05_6)
M& LX5?N^0"?][?C^7;I7\W^*%+#TN,\SAAWS*4:56K>UXU94X2G'W4ELXO7S
MZJY_>_T;JF-J>$'#'U[FYHRQD,+S7N\''&UUAWKKRJ"Y8='%)I6=RW1117YZ
M?O 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% $;??'L 3] 35*[DD4M@D(FT[QT7
M.W_T+)'?UZ8JZQPS#'2(G]>E5+@%T95/+HJID8!?[P'Y*3DX':J@TIQ3ZM+7
M;=7^=K_CV(G%RC*SLU%R5D[W7Z:^I_!)_P %-_B5??%#]O+]HK6;V5KBQ\+>
M,1\-= C>9WCT_2/ &G0:!<06\3#;"MSKD>KWC(@ :2X=VR3S\(8RQ )*J>2>
MN0<'=]1UXKZ[_P""@7AN\\(?MK_M2:1J4;QS3_&'Q/XCC$B@,^G>,;D>+=+F
M4 L,3:;K5NZ+DN 61U61)%7Y')VYVMN&,\8P?IU!SQR,U_=_"LJ3X5R&A1FY
M489)E5.3M&+O' X>,G[J2=VG=V[]S_&'Q$K2K>(W'M3$.HL16XMXDI34W[D.
M7.<6E&',FU""M&*N[0MH]6?UC_\ !$+X<^(-&_8Q^*/C'PTMM#XM^(GBKQ7+
MX9N+P[;-M0T729M#T1KFY0%WT]+Z-)I,-B/;(JJ'%>*?$3]AS_@KYX+\(:AX
MJT#]N/XA?$37+&Q\S4/#6G?$'QA9W=XT<;?;%TR#Q )=#N)$2.01VX@C>9P$
MC#$AF\)^ GAO_@ICX&_X)_:KX[^"'Q5^&ME\%[+P?JGB?2/#GAC3GO?C!#HW
M]N^9XCLM OU\,2PVVNI"-3N(Y9_$$,MIC *85Z]8_P"")W[0/[2_Q'^./C_P
M=XY\;>-/'_PPM_!^H:IJM]XONM0UB;PYXL.HVYLK6TU+4@WV;[=#+=QS::S+
M/;A$=H4!##\&QM+,\IQG%7%&7YOPKC*$<:X5<#7PU+%5Y1A9JC&E5H1]E4<)
MV:I2FG.]IMIG]HY/B^%\VRCP6\-LZX:\0,#BLTR6M4RW,,NQ>)RG!8:M3PT'
M4Q6/GEN+I^VA*4/:TY5XI4XSC.5.,JMC^=KQ3=^*;[Q7XCO_ !S>ZIJ/C.;6
M]9/BV_UE=NL7&LWVII?:@VJRE4$MVNH37L,G[I6,D1!()&_$:6:#]Y9S/:W$
M++<VEW$2LEK>6SK/9W2LI&&MKJ.*8G!X0Y!Y%?>O_!4W3?#>D?M[_M$V'A..
MVMM+?Q7H=U<VMC"PC?6+KP+H-_XEB+*!$B_\)(UU=SS(PC%PDEKGSYDB;X#D
MF1(SO.R,PS)(>T:-$RLY;'"Q@EB<]!G(QS^^91CJ69Y%E5>%-82&,P7UK%X6
M$;4H4HTE4J)1E=OW+[R:ZL_AOBO+<3D/%N>93'$2Q^*R?.LTPCQGM'*6-K9>
MY/#YC[2#4GC'4IPJQ:LG52]QK1_Z(O[)'Q$NOBK^S1\$OB'>RM-J?BWX9^&=
M4U29O]9-K+Z=%%JCM@G#/J$5R^ 0,L0. *^DH"V%# @^6I;.<AN,@Y[^O?UZ
MU\:?\$^O"E]X+_8W_9Q\.:G'+%>V'PC\)RW$<Y'G1W%]IT=_(D@R2"#='J>/
MNMA@17V@O4?[@_G7\-YJJ<<SS*%)+V2Q^)5)K^15)*"\THV_,_V8X:J5Z_#^
M05\4I+%5<ER^>)C)--5IX6C*IS)ZJ7.Y-KHVT/HHHKSSW HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#VFVWG:[XKCO[K=I]_JC:;>V[QVEI%8E-$D*1WOFDS;F#HGK?[8.NZG\<O\
M@CQHOQ/^-NFP6OQ$U3P3X$\5S7,FGKI5Q!XLAURSLAJEE8;2+%_$D0FOVM%,
M8CL]3$84F/ _GWAJO6R6/!N-S+ \/8S X_$^PING&M/,,--3498N<G44?:<S
ME)J*DDWR\J;L?VEQ_E_#G$F/\9\#D^;<;Y)Q+E/#^'S//Y8ZKBX<.9QET<-4
M]EE&&HSO0_L^,(.,WA50K3E.53VM:*FG_)!A3^\8[7P.!C(YR-HSG=N. <]>
M*_7G_@B#\3M5\$?MTZ#X2AN9H]%^+/@;Q5X3U*S>1TM9[WPYH6J>-- N&0-Y
M;ZA97&E:Y9DL&"KK)(()+5^12 ,0I]<Y_+CM]1SGTK]._P#@C;X0U#Q1_P %
M#/@R]G%.UGX-T?XD^+=7N$4B.*RC\#Z]HR2.S%0RG5]?TBS(0NPDNU5EP)63
M]ZXXEAEPEQ!2Q5.G-/(\S^KRJ*[A46"J2HN.R4HUHPE#2_-%=3^,O"/%XFAX
MJ>'_ /9_MEC9\6\.T.:BI-T\GKYKA*&94FU9.A+ U*].JVVE3E-ZI-/^Y9&&
M ,@LV2<<\C 8>Q!X.>^:DIBK@Y*@<-Z=V)[>H_PI]?PZ?[(!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 'Z_P"?>HO.4D*
MQ)8J!@#YAYF1DD X\INA/8]#FI&&Y67^\I';N,=P1^8(]0>E?AG^UG^UU^T%
M\,?V@/'G@CP5X[&D>&= DT.'3-.?0/#]Z8Y=1T+2]3N':YN=.:<KF:Z51N8A
MI1G*@!3MYNPTKG[E[C_<;\T_^*HW'^XWYI_\57\UG_#?/[5O_12HO_"9\-__
M "LH_P"&^?VK?^BE1?\ A,^&_P#Y657LZO;\/_M@LNZ_'_(_I3W'^XWYI_\
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M;\T_^*HW'^XWYI_\57\UG_#?/[5O_12HO_"9\-__ "LH_P"&^?VK?^BE1?\
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MNZ_'_(_I3W'^XWYI_P#%4;C_ '&_-/\ XJOYK/\ AOG]JW_HI47_ (3/AO\
M^5E'_#?/[5O_ $4J+_PF?#?_ ,K*/9U>WX?_ &P67=?C_D?TI[C_ '&_-/\
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M)=0L;:QN88=>\,75YYC:BEI%<*;74=,OI'RUA,]KY3AF61B[ _>?Q._X+?\
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M^BE1?^$SX;_^5E'_  WS^U;_ -%*B_\ "9\-_P#RLH]G5[?A_P#;!9=U^/\
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MN/\ <;\T_P#BJ-Q_N-^:?_%5_-9_PWS^U;_T4J+_ ,)GPW_\K*/^&^?VK?\
MHI47_A,^&_\ Y64>SJ]OP_\ M@LNZ_'_ "/Z4]Q_N-^:?_%4;C_<;\T_^*K^
M:S_AOG]JW_HI47_A,^&__E91_P -\_M6_P#12HO_  F?#?\ \K*/9U>WX?\
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M91DMU*+33U33.BG0HT:7L:%&GAZ?*X..&A'#-Q:LXRG05.<HM:-2DTUN4<<
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MA9%N+90L=PK=%E! ?<, ,!C &*_H6_94^)FA?M1?LXW_ (+\9F"_\1:+I+^
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M*57Y <@FJH<L,HNX>G<_3K]>A_K1[6I_-^$?\@YY=_P7^0>7[_I_]>CR_?\
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MD;6)7(W$]AD9[>G3W[4C[<CRSN'<G^G Y_"CVM3^;\(_Y!SR[_@O\B'R_?\
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M4:7"AN[-4N=-NK[3]0,"64,D8@ELKJRED:9;?[-KEP9%9K>(QW?VY/%&DO\
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M*Z@BI<Z@56ZBDC5]B!D*HP;)\$?&_P %M\ ?VJ] UWQU>W_C#Q]XF6Y\,_\
M"52.OB?Q+8V\UL+2\O\ RX[J!9WB5V:.(I&,%-JJ,5R/PH^)W@C0OV-OC_\
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M\:PW6AI::!>W=H;P2QZ'<O(LD]D[VLR07;'>Q@??$I-? T;EP6("DL?D!)V
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M/A]I%@D6J7(N%.K^(]=&FG6OLD$%U!;W>+Y%6:U:4L\TTTCB73R\NFW;\/\
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M&W)N"$8=!,TE*RVLG]Z_K_A[L****" HHHH C7[[?C_,5_3E^Q9_R;+\(O\
ML7U_]&WE?S&K]]OQ_F*_IR_8L_Y-E^$7_8OK_P"C;RJQ'V?\/_RLWCLO1?D?
M55%%%<HPHHHH *_F@_;R_P"3J_BK_P!?_A7_ -0W2J_I?K^:#]O+_DZOXJ_]
M?_A7_P!0W2JZ<-O4_P #_,:VEZ?JCY&HHHI',%(5!ZC/!7\&X(_$=:6B@!NQ
M,,-B ,Q9L*H+,=I)) !)^1>I["G8!4*0-H9VV]MTDC2NV.FYI'=R>I+'UHHH
M /X2O&TXXP,<=,>A]Q@TA )4D#Y'$B<#"N!@,!TW =^M+10%VMG8]7\!?&SQ
ME\-/#'C[PEX7&D'3/B3ID6C^*UU.W:XNA8017$,,NGSKQ'+&EU<,D9SY9F?H
M<UY.JA%"K]T,&! "DLHP&('0XZCI0  ,  #<6P!@;B<EL#^(GDGJ3U-+0.[[
MO[V(% )*C:6W;BOREMP(;<5P6R&(.<]32GDD\9(4'  !"*BKD# )58XP"03\
MB\\444!=]W]XW:H.X* VX/N PVX=#NZY'U_G2E5961@"K;MV>IW9W#=]X AF
M! (X)'0TM% 7?=_>Q'57:1V52TV[S6V@,^^,1/N( /S1@(WJ ,YQ00I<N57>
M26+[5W$L222<9ZDD>F3C&:6B@+ON_O/>/A%^T;\1?@GINLZ7X#B\+6\NL337
MTFL:SHBZCJ]C/-9+ISG2;WB:V;[.IVQ(X422/)C+$GQ?6-3U#7=5U'6]7N+B
M]U;6+JYO]2O;H[I[R[O96FN9Y,DG][(Q8!B6 P.PJ@&9>02".002.?7BDP.3
MCDDDGU)ZD^I/<GF@+ON_O8@4 Y &=ACS_L,JH5^A157Z 48&% & JLB@< *\
MD,K#C&=TEO YSDEHD/\ "*6B@0'G&<';G P-HR<GY?NG)Y.1UI%55.Y0%(((
MP ,$'(( X&#Z"EHH 0  E@ "0 2 !N"H\8#8'S )(Z\Y^5B.E(%4 *!\H8.!
MS@,"I!QTX*J?^ CT%.HH 4L6<R$Y=A@MQD\8_EQQVIN %VA5 '/W5SUSUQD\
M\GGFEHH ;L7+$* 7*EMOR[BCK(N<8SAT1N?XE!-=GX ^('BWX6>*M.\:^!M4
M.B>(--+QVUZ;?[1:.DV?-M;RVC97DMYP2)!@J03G)KCJ!P=PX;&,C@X],CG'
MM0.[[O[V?6?C']M'XW>,O#VM>&YY/!OAZW\4QSP^*+_PGX8MM+U+5TD_>W9F
MOX=EU,;H./.$K.QP,L0!CY*4Y"D;0%4)&RDY\E7\R/+$*V[=AV!Z/D=!BE"J
M&#@ .N=K@#<N>N&ZC/?!Y[TM 7?=_P##?\,!YQGLZR?\#0DHQ'<J68@G."3Z
MTI.X$$  KM(4!5(W;\%5 'WOFSC.:2B@3;>[;]1<D9Q@%AM) &2/0G&?UII5
M2""H8' PP#<#H/F!P/84M% 7:V;0$ XR!D8P0 ",=.1@\=N:3:/W9QS$K+&>
M<QJS[V"-U7+_ #'!'-+10.[[O[V(%4=!C[O3C[AW+G'4J>03DBNJ\%>,O$?P
M]\3:7XO\(:G/HOB'1I?.T^_M8$N'1BK(\;6K-''<I,C%'CD8!E)R37+4A 88
M(!'H0"/R- 7?=_>SZ[\1?MO?'7Q-HVMZ3+=>%-#D\0P_9M;U+PWX1M='\4:G
M;M&8Y_[0O(&5H?.0@ ++(LF9/E7'S?(@*<K'('1"54882(.&*READON);(R,
M$#/:EP/3IP/IZ4>GMP/8>@H%=O=A1110 4444 %-?;L;<Q1<<L 6('T')STQ
MWS3J0XP<EE !)*#+@#D[1W.!Q0..Z]5^9]5_L2ZOXXTK]I?X<Q^ H#/>ZKJ$
MNG^*[)B[6,W@2=6G\07FH3(=EN=)MK9YM/648^WQ6T:?,XK]"O\ @J)I?@G_
M (0GP/JMZT,/CR+6)+/0EC<?:+O1'C:36!< <O#;3^08CT21VQ@,*N_\$Y?@
M;!X#\ :Y\;/%-G#I^J^,;2Y32)+X*C:3X.MA]JN+J4OA=FHRP/J;DG_CU5HF
M.Q2!^;/[6WQPE^.GQ?UK6[6Z>7PMX?N;KP_X0M 6>&'2K5]EQJ)R2JS:M>H]
MRDB /);&)78@"IWEZ)I^=[:>GZ_CO+52O>_*[_EKM;MUU]3YDP#U&:4G/7G@
M+R!G 8, #U W*I^H&>E-$;2R10J>9943:#M9]S!0JN?E0EB#N;@ $'K@_5 _
M8[^,$=Q:6DVJ?"VWU:^CLV71;SXEZ#::\9=1MDN[2V31KGRY7N[BTDMVM((<
MF1S(6!!S5'.?+)))<DG,F[><G+;P%<,>I#* &!/(ZTS8NXOM 9O+W,."WE+M
MCW$8W;%X4G.!70>)_#.O>#-?U/PKXITJ\T7Q#HET]IJ6GW\4<=S&P.89"899
M(98IH_GAEC"*\9!P>M8- [ON_O8SRX\8"(!DM@* ,E0A) &"2H .1TI_<'^Z
M,*.H QC@=!P, XR!110%V]VW\Q,  #'170'N%?&X!NHS@=\C'&*4?*5*X7:=
MRA0  P;?G:,+G=\Q)')Y-%% KM;.PBJ%S@#YB&.>>0XD!&<XQ( W&.14;HHC
M( "\$!LL-NX\G<OS<'D#D%@*LPV\MW-%:P1---<R1V\,*.L;RRS,(XXED<JL
M;2.P579E520S$ $CT7XF_"/QM\']2TW2?&X\/VNM:A$TTFEZ9XAT_5]9TIXX
M8YI8/$.GV5P6T>ZDBGAEMD,962,EL<AJ/T'=]W]YWMM^U%\6;'X6?\*?T>?P
MQHOA,:6-'N[S3-"AM-:UC3MSM]DU+5(MD\D?[YU97W&5248@&OG1 "L($1VQ
MQNKR,PYD;*[5C[*8WD!8]CM/7F3 W%L#<3DMCYB?4GJ3^--D5MDKQA1(L4DG
MF28$*F%#-&;EA^\,#2QQQL(R'9G0 [2P(*[>[' !<8 &U2@XZ(4*%?H4)4CT
MI"B-C<B'$C2\JIS(\DDKN<CEFDED<YS\SL>]>]^!?V</B/\ $+PU%XOTFY\#
MZ3X>O=4O]'TRZ\7>,M-\*7-[-I#)#J+6-IJ162:);J1A'*3(S*!P *\;UW1K
M[P[K.IZ%J,MA<7FDWDUC//I5[:ZIITKPM@M;:I92/;WH&?F9 NS@');@'=KJ
MU_P?\]#)4!<;0!@,H  P%8DL O0 EB2 ,9)I"B$8**1Y;1#<H8K&^=R(2"4!
MR<["I]Z1G1!(Y8[XD$@7G:5+%1D=#R/3/Y"O2])^$GC'7;'P=J-O+H.GV7Q!
MO==TWP[?:QX@LM#@>]\.6PO=1AFN+Y3!;D)A80P+3Y*I@YP!>7=_>SS=0$VE
M?E*>7M(ZCRBACYZG88TQDG[HS30JC> H D38Z@85D+^85*CY<;_FZ=>:<4$;
M/'E2R.Z2LCF2)IU=EG:&4DB6W,PD-O,A\J:$QRPXB=!6_HWAO5=<T[Q5JEG<
MZ-#:^#M(M]?U*#5M6M--N+FSFNA8>7I-I(!<ZC=EB"L4;%&D(P,M@@7?=_>S
MGR WW@&.,9(R<8(QD\XP3QTJ2UDDLKF"\LY);:[M9H;BVN8"1<03P.DD$L+;
M@?,B>-'C^8?,J\TTA02%#JH)"K*"LBJ#P)%/*N!@.#R&R*5<AE(&2&&!C=DY
MX&T<MGI@=>E 7?=_>?8L'[>7[04%I;1R7G@N_P!9T[37L+'Q+>^"K2Z\46EL
M\ B-P=7EW3M=; A*QRA9&49!XS\B:IK&JZ[K%_KNLWMSJ.KZS<W.HZOJ.H+Y
M=W>ZE=2;YI5A!<(I7(&\XV*57H!70Z#X%\0>(_"_BOQ9I$<#Z)X"LO#\_B"2
M2ZA@F6V\27T\.E3+!(/,DE>XADC(4^8ZH$!V\5R1Y8L>6;[S'[S8Z9/4X]Z
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M@]S'("RQQ1_-&REOXAA_CKQMK?Q)\6^(/''B7[$VN^*-3DU;5FT^V-G:/>N
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M9]!TK]Z4>":XM&GUB_BDV.U]?Q6N&_LZ,J#L^S_X<R/V^_C-;_![X/Z7\&?
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MF^-'Q!?XM7/QEMM6MM,\<7&HW=X;NWM'N-):&Y18;G0Y+(Y+Z,\""W3=Q)&
MPSN#4:?C^&GFK_A_D'V!X^M_A1XL\)037NJ?LTW/CW2_%'@UO!\?P%TF_P!!
M74]"U'6K"VUG0_$>E:CIT=EK.G2:?_IUO/=2A[F4X(#[@.PO]2^&_BS]H;XD
M_LZI\$?A1I7@F#1O&B0:YI_A:"'QW!XOT+PIJWB:/7-+\0(JO:1S?V.%?145
M+1"#*CD9B;XP\5_M$>+O$NFPZ/9>$OAGX(TQM>TWQ+J\7@7P=:Z*_B/6]-N?
M[4LI=3DDN;^Z-M%<'9?+#<:;%?2[V2UM5*PQY-C\<O&FG?%O6?C+%:^'9/%G
MB%-?^V VE^N@Q1ZYHFI^')533]QODN5L]5E=7)\L%2Q.P9H?WZ+\OTV#3_/^
MO^&[>9S/PIU^?PS\2? ^LVVE:'K=Y#XBTJR^P>(=&BUK3)WU#4K6 336]Q@R
MZF&<&"0C;YN-S '(_0KXO:]X:LO%?[2_QGU7X9?#?Q3KGPR\=:+\.O"6BZAX
M;CC\-W$>KB\O;OQ=XQTR,NGBW6+4J]I;7=W&AB\T10G#%C^8MC=RV6H66IP;
M?M.GZI9W\ D9E1I+2XCGCW%#YBIOC4LRX95R5Y%>YZ3^TA\0;#QOXW\<W%CX
M3U#_ (69>QWWCKP7KFCG7/!6J2S/%)' --DGMIS_ &7' BP7D=Q&WG2.Q;@J
M4!]-^$]"^'7Q1U;]E_XK7'PU\*>$+[QI\7/$/PZ\?>%M!TB/3_!GBI?#%NTM
MAKVD^'(V^QZ:)K&1XFO8#F1E*%V=37R5\;O&EKXP\7:E9Z9X$\"^#-*\)ZGJ
MOAS2-+\&Z##X:>]LM-UR62WNM7N+5B-2O@%>1-3DVR(0\ !6X<UN:C^TK\1M
M3\:_#WQB8/">D6GPQNIKWP5X+T;0GTKP1I*FZ8""TT>QENKH:A+&Y-SJ6J7!
M$D.8X> N[PK5+NXUK4+[4[KROM>JZC=ZK<I;N;:T2>\U"75+N!$D/F(GFA8(
M"W!CD<=P"_ZZ?U_F!]8+\2OA3;>!/@UX"^*WP)\5Z];:/IEQ%IFJMXUO_#4U
M]:ZSKX>;Q+X<T*Q<66NZC%<21Q6\\S-*[0;%R^X5XM\=OAS!\(/BOXY^'-CJ
M!OM+\,7UI_96H&..":2UUJRLO%,$.IR(?FU>&'6S#J5TN?M$MCC[T#A>R\)?
MM+>./"'A[1?#[^'?AQXRM_"-Q+<>#]2\;^#_ /A(-=\'1W$IN&L?#]PU[9QM
M'#<,LT,DOG1QNI(C!RU>&:[KFN^)];U/Q!XFU2?7->UB_N;W5M2NP7EO[ZY#
M"?:$'V2VL5LI5M; H[I;>48L@G%#U_#LM%^?_ ^X/NWQ9KG@;X-:U\/O@K8?
M ?P+\1M"\1^"?!VH^*-7O--.J?$OQ=KOBRSCGT^7PKX@D'GZ(=.G0?9XH<I?
M3VMU&2FUVKM_@YX2TO4A^R5X3\2^'UN],/Q%_:#L;WPQXMLX9VABLM$O+ZRL
M];M2&0:A8S"'*0JR@*)%.XG'RYH/[57Q+\/:%H&FPZ=X)UO6/"&G/I?@_P ;
M>+/"-EJWC;PK9>7-;V$&@ZS#?0H;FPAN;I5GU6TFMH(9U-HYN/,08'A?]HKX
MB>$[KX>WEG%H6HS_  VU[QAXDT6ZU@ZE>RZKJ?CFPFT_6Y?$+86Z< SO+;):
M',8)W,T87 GWVTOTTTWMOM]^HT[7\_\ -/Y['T GC/PC\+/@5^SSK$7P>^$_
MC3Q7XZU+XD6VN:SXW\&V6N20^'['XA:A83Z39I*59/+B>"+3KYF)M+:"U1 <
M<Z'B+X:^"="\:_MHZ/I?A?1(++1?A]X(U_PJDVGI=_\ "*SZ_J?AR[N8M'O9
M=]Q8V]LUVZ6T$9(2.W8*Q\IA7QIX@^(GB'Q)X6^'_@Z]@TC[!\-I-<.@7%O;
MW4!:7Q3K_P#;^J?VFLO_ !]V5OJ44HM%MB'336LDF_>AR>TUCX_>-M>U/XJ:
MI=VNAM/\7_#.D^#O%YMK>\L8K/3?#EK:S:)>:(LY\XRO-&\=RIRZ.-K$..1M
M?E^5G^(OQ_ ^D?'.K>"/ WCJ3]G+3_V>O"?C;0H/#UAI[:OH.FNWQHU[Q/<^
M&#JZ>,-(\5E4F@BM=4>-K/306MIXHS-(S*CH>@^"VC:/X3\%?#I?%OA?]FWP
MI;>,B+N[E^,.E:AX[^(7Q&L=2UR:"2X\-:)!%+9^"],NXG=-+LH&;R)GCP@V
MG/SU:_M7_%.UTB.VBM/!+^++?0)?"FF?$E_#$"_$C2]!EM)-/6UL_%QNUCA@
MAAF&R:339=5A6/$$A4;C3\*?M1_$'POX=\,:$-!^'>OW_@FV6T\(^+O%'@]=
M>\8>';7[3)=KINFZG=WEE:?8[9[@B"ZGCENHS$&C1W7!1T7C;IYN_IK^-W96
M:>VS/:O$OAS1?!.G_P#!0+PKX>M+;3]"T+5?A'IVEV"H<6UO)XPUN6%>F!:A
M;T?V9!]^WA&UP#BO)?V6F^'D'C'Q9<^.[3PX9K;P/>)X*U7Q]H-QXC^'GAWQ
M5>7 MH-2\8:5!'*#IS/.B6[7(2,W30%&#!6'&^)?COXQ\67'Q=N[ZR\,6L_Q
MKF\-#QA-96-^BK-X4N5U"SNM'MIL-:+=.&34GOLM/.V; @!0.=^&7Q3\4_"S
M6;[4= 33KJQUVUAT?Q/H6O:7IWB'0?$&D"13<07VFWEQ:,8O+#21@7,<L4Z1
MS0AYTCC=]5K\[;:]$OOT,(_%%>:_-'Z"^'M.OO#W[2'[/GB]/ ?P5@L/%NL:
MEX9_X3'X0VZ7O@3Q%+"#/#J>D^')RO\ PAVOV%G$D.^(F5(KFY4[O,7/GW@:
M]76[WXM?%O5/ ?[-7A*SD^(]YX:M/&WQ2TN\G\!:8^CJZRZ5X+^']A')'=ZC
MJ21KJ>MZO)MFFO0^[$<XKYKU[]HWQ_J^O^ -<LK'PCX/M_AGJCZYX3\)>!?#
M[:9X5T[5))MCZB+&\N'^UW-Y;K'%?)<73;(6E$ +%<;MG^U+XR@?Q"DG@#X.
MWWA[Q+K=KXHD\&ZAX)EOO"_AWQGI^FVNDWOBGPM976J0WMI<ZP8/MUS%?B:"
MYO':2)#;%VI'2FM-ME=76J33_&Z;;??38^J?$/PD^%6J_'KPQK</A+PGJ/A6
M+]FK5OCSJ/A7PCI*Z%X/\=>+-&;6-+CMK#2MHEMM(U@3&XNK,Q@7T5I$)@1!
M7%^'M:\*_M%_!CQ)+?\ PI^&?PZ\4Q?%+X3^#(/%/@'PQ:Z#<Z?X>\3ZI!93
M:=:7<2DV^J6-C(U@US%)M>-R[!>%'GO@[]H'7?B1\;?A]XI^)OC;2/AG?^$O
M#^J^%](\:>%/#Z)I$L$FGWSZ=IGB[0)M-O\ 2SX;U"6Z>TU>+3Y([>$)"4?S
M7)7T'XU?%&#2/@GJ_P /)/%?P)UCQ!XF\;>&M>L='_9ZTN]L?"VA6GA^Y_M"
M?6M>UV>.WO+K5];NE@C6ULT)TJ0-,2(8\EK3]5Y:,B;]WXKZ+2][:KS:MMM^
M![%XU\'_  'TO6/&?PKUJ\_9AT+P)X<@O_#^A0Z1IGB#3_CMH>M:3IT<=GK.
MH^+X+-I+O75OX'-Q K"'RKM'\]C)(*_-_P"#MC:7GQC^&.F:E;6NI65U\1O
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MZY1=P^2:BPR':K,ZO*A)?/RQ6T$L0<YZ2SRS>8V>2NXY/.):!!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 1K]]OQ_F*_IR_8L_Y-E^$7_8
MOK_Z-O*_F-7[[?C_ #%?TY?L6?\ )LOPB_[%]?\ T;>56(^S_A_^5F\=EZ+\
MCZJHHHKE&%%%% !7\T'[>7_)U?Q5_P"O_P *_P#J&Z57]+]?SR?MJ?"/XH>*
M/VEOB;K?AWP%XGUK2+J\\-26VH:?ILEQ;3K#X8T^QE,3J?G,<\$@8 $A &[@
M5T8>48N=VE>-E=[N^PUU]/U1\!45ZS_PH?XT_P#1+O&O_@CNO_B:/^%#_&G_
M *)=XU_\$=U_\33L^S_K_AU]YS6?9_U_PZ^\\FHKUG_A0_QI_P"B7>-?_!'=
M?_$T?\*'^-/_ $2[QK_X([K_ .)HL^S_ *_X=?>%GV?]?\.OO/)J*]9_X4/\
M:?\ HEWC7_P1W7_Q-'_"A_C3_P!$N\:_^".Z_P#B:+/L_P"O^'7WA9]G_7_#
MK[SR:BO6?^%#_&G_ *)=XU_\$=U_\31_PH?XT_\ 1+O&O_@CNO\ XFBS[/\
MK_AU]X6?9_U_PZ^\\FHKUG_A0_QI_P"B7>-?_!'=?_$T?\*'^-/_ $2[QK_X
M([K_ .)HL^S_ *_X=?>%GV?]?\.OO/)J*]9_X4/\:?\ HEWC7_P1W7_Q-'_"
MA_C3_P!$N\:_^".Z_P#B:+/L_P"O^'7WA9]G_7_#K[SR:BO6?^%#_&G_ *)=
MXU_\$=U_\31_PH?XT_\ 1+O&O_@CNO\ XFBS[/\ K_AU]X6?9_U_PZ^\\FHK
MUG_A0_QI_P"B7>-?_!'=?_$T?\*'^-/_ $2[QK_X([K_ .)HL^S_ *_X=?>%
MGV?]?\.OO/)J*]9_X4/\:?\ HEWC7_P1W7_Q-'_"A_C3_P!$N\:_^".Z_P#B
M:+/L_P"O^'7WA9]G_7_#K[SR:BO6?^%#_&G_ *)=XU_\$=U_\31_PH?XT_\
M1+O&O_@CNO\ XFBS[/\ K_AU]X6?9_U_PZ^\\FHKUG_A0_QI_P"B7>-?_!'=
M?_$T?\*'^-/_ $2[QK_X([K_ .)HL^S_ *_X=?>%GV?]?\.OO/)J*]9_X4/\
M:?\ HEWC7_P1W7_Q-'_"A_C3_P!$N\:_^".Z_P#B:+/L_P"O^'7WA9]G_7_#
MK[SR:BO6?^%#_&G_ *)=XU_\$=U_\31_PH?XT_\ 1+O&O_@CNO\ XFBS[/\
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M:+/L_P"O^'7WA9]G_7_#K[SR:BO6?^%#_&G_ *)=XU_\$=U_\31_PH?XT_\
M1+O&O_@CNO\ XFBS[/\ K_AU]X6?9_U_PZ^\\FHKUG_A0_QI_P"B7>-?_!'=
M?_$T?\*'^-/_ $2[QK_X([K_ .)HL^S_ *_X=?>%GV?]?\.OO/)J*]9_X4/\
M:?\ HEWC7_P1W7_Q-'_"A_C3_P!$N\:_^".Z_P#B:+/L_P"O^'7WA9]G_7_#
MK[SR:BO6?^%#_&G_ *)=XU_\$=U_\31_PH?XT_\ 1+O&O_@CNO\ XFBS[/\
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MG_@K_P#MM'_#.'QY_P"B3>-/_!7_ /;:+/L_Z_X=?>'R?W/R\O-'BM%>U?\
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MISXUWOQX^,'B3QQ+),V@_:6\-^"]/DDWQZ7X>T&>15EC2,LBWFH7<DU]<7!
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M_7_#K[P^3^Y^7EYH\5HKVK_AG#X\_P#1)O&G_@K_ /MM'_#.'QY_Z)-XT_\
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M=?>'R?W/R\O-'BM%>U?\,X?'G_HDWC3_ ,%?_P!MH_X9P^//_1)O&G_@K_\
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M-7^G[9;I,+^\7+E@BA[@LQ7YFR!>?+B$&<%L!HQA2TGR4[][_P ]!_WU=?\
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MAK[Z5O.VR3T]%;[O(.3;25FK]?*WI>VWW6LC[;_>_P#/0?\ ?5U_\ET?O?\
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M\ET?O?\ GH/^^KK_ .2Z?11=]W_7_#+[@Y5Y_?Z?Y?U969^]_P">@_[ZNO\
MY+H_>_\ /0?]]77_ ,ET^BB[[O\ K_AE]P<J\_O]/\OZLK,_>_\ /0?]]77_
M ,ET?O?^>@_[ZNO_ )+I]%%WW?\ 7_#+[@Y5Y_?Z?Y?U96]$U!6739V)P6B!
M8@[C(S1JGS@@  ,I(VGH<C!KS?##N.P_C/7C/WQZYP<_4UZ9J@_XE<P_Z8H?
MT)KS<C/Y@_D<UST6E%IO5R_1)#KJ\H7[Q_\ 2DAFUO[P_)O_ (Y1M;^\/R;_
M ..4^BMQ<J\_O?\ GY+[AFUO[P_)O_CE&UO[P_)O_CE/HH#E7G][_P _)?<,
MVM_>'Y-_\<HVM_>'Y-_\<I]% <J\_O?^?DON&;6_O#\F_P#CE&UO[P_)O_CE
M/HH#E7G][_S\E]PS:W]X?DW_ ,<HVM_>'Y-_\<I]% <J\_O?^?DON&;6_O#\
MF_\ CE&UO[P_)O\ XY3Z* Y5Y_>_\_)?<,VM_>'Y-_\ '*-K?WA^3?\ QRGT
M4!RKS^]_Y^2^X9M;^\/R;_XY1M;^\/R;_P".4^B@.5>?WO\ S\E]PS:W]X?D
MW_QRC:W]X?DW_P <I]% <J\_O?\ GY+[AFUO[P_)O_CE&UO[P_)O_CE/HH#E
M7G][_P _)?<,VM_>'Y-_\<HVM_>'Y-_\<I]% <J\_O?^?DON&;6_O#\F_P#C
ME&UO[P_)O_CE/HH#E7G][_S\E]PS:W]X?DW_ ,<HVM_>'Y-_\<I]% <J\_O?
M^?DON&;6_O#\F_\ CE&UO[P_)O\ XY3Z* Y5Y_>_\_)?<,VM_>'Y-_\ '*-K
M?WA^3?\ QRGT4!RKS^]_Y^2^X9M;^\/R;_XY1M;^\/R;_P".4^B@.5>?WO\
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M_O#\F_\ CE&UO[P_)O\ XY3Z* Y5Y_>_\_)?<,VM_>'Y-_\ '*-K?WA^3?\
MQRGT4!RKS^]_Y^2^X9M;^\/R;_XY1M;^\/R;_P".4^B@.5>?WO\ S\E]PS:W
M]X?DW_QRC:W]X?DW_P <I]% <J\_O?\ GY+[AFUO[P_)O_CE&UO[P_)O_CE/
MHH#E7G][_P _)?<,VM_>'Y-_\<HVM_>'Y-_\<I]% <J\_O?^?DON&;6_O#\F
M_P#CE&UO[P_)O_CE/HH#E7G][_S\E]PS:W]X?DW_ ,<HVM_>'Y-_\<I]% <J
M\_O?^?DON&;6_O#\F_\ CE&UO[P_)O\ XY3Z* Y5Y_>_\_)?<,VM_>'Y-_\
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M[3=6,AGBCV(=E?L@N]<(%,)<P0*P=64PEY2RR23PRR.Q^4+(+?S2\:!KIBI
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M=>%;_P"(G[</QZ^)>@-?^1%=>*?"?B;4=(?PYXF#6K[)X;O3[=K>V$WELL:
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M HHHH *Z+PS_ ,?TW_7N?YFN=KHO#/\ Q_3?]>Y_F:BI\#]8_P#I2 E\2_\
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MZ;K6F6>J0!\^1+;*Z@E M?F'\)O&7[1WA+]FC]A/]KV__:D^-OB_Q_\ %O\
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M-VW6G4_%CX4_%+]I[X"_$AF^).O?$SX;?!3Q3^S+\</B5X]\3?M1_M)_ /\
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M2.*.YOI4@MYI)V"11O)(54-*S!8T)#,V H)."ESRJ*G"#G)IO3LG;:SO\O\
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M0!FG-]J5O/+;VC0*&+B1U"H"[''-5[1=O37?\#/VD_\ GV_O7EY?UIW.HHK
MT#Q9X6\5V=Q?^%O$7A_Q+8V4TD-W?Z'K]AK6F6,T,0FE^V7EI-)';R) PD:.
M0J%CP^=I:C0O%GA?Q:EV/"OB;0/$2:9</;ZG+H>JV&I):7 9MT%P;*>8P2*5
M<!90C';D#&:/:+33?;7_ ( XSDV[P<4MW>_:RM;K=&_17RUX\_:J\!^#_C5^
MSM\%-(2S\;:G\?\ QK\0?!4>L>&_%7AYD\ :IX!\ :S\0[C^W--26:YN);Y-
M%:TCB?RGWE@5?!C;ZESGG.<\YPHS[X3Y!GT3Y1_#QBG&:FW;IOKUT?Y/H::]
M5:ZNM_R:7R[[A1115@%%%% !1110 4444 %%%% !7I.B?\@VU_W&_P#0A7FU
M>DZ)_P @VU_W&_\ 0A7)/9>OZ,C#;U/5_F:]%%%9'6%%%% $<??\/ZUYQKW_
M "$[SZVW_H5>CQ]_P_K7G&O?\A.\^MM_Z%6E+XU\OS1G5^%?XH_F95%%%=AF
M%%%% !1110 4444 %%%% #),B.0CDA'P ,DG:<<#KSV[U^5O_!79YA^R7882
M0;OBY\)]YVGY=OB6U*YSP.^,]0#]1^JC=#]#_*OR[_X*]?\ )H\'_97?A+_Z
MD\->KD-.-7/,KI25XU\2J4O).SNN^^WH?$>)$ZE/@/C&5&I*E4_U>Q\Z=6/Q
MTYT:-2K&4?.\4O)-GZ4:1(1::4JX/EV-GN4AG'%J"JL%^9?,Z*3@#).<9->&
M?!GPOX?U_P#:&_:8_MOP_I&KM!<?#PPG5M-TS4A K^'Y6*0RSQSMM!)X(#+D
MCOS[CH?^KM_^O+3/_2*O+_@!_P G!_M-_P#7S\/?_4?DKPJDW[[22YJM3_R6
M<H?BH7?FV?:0=Y4W9+GI07I]7M@T]+.\UAU5EK\<FEHD?28^&O@(?\R+X/\
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M97R6G+'Y=0EGT91BXPJQS/%9+2HP?)5E2AC7']VIL_K@%]#)(ML=P?RTE.T
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MW>*>1/(#,/IF_O\ :2"W.#CD\<$<9YZ\]R!]":XR^ON3\Y![E3R".N#TZ<9
M&3U.1FNM5*M2ZK5*]>G*+C*$JTTK.RM?7O>[NN]U=+Y_%4\+3E1J87#83"UJ
M%:%:%:&%HMWIRB^5IQBE%VLVK2M)I2BR])^VY\,TGC^V> _VA--MLYEO]1^
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M(J\O^ '_ "<'^TW_ -?/P]_]1^2O4-#_ -7;_P#7EIG_ *15Y?\  #_DX/\
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M/H*MUP*]O>M?7;;=VW;Z6^9[;5F^W3T>J^=M_,****8@HHHH **** "BBB@
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M!Z3JG_(,F_ZX)_Z":\VKTG5/^09-_P!<$_\ 037FU<M+I_B7Z"K_ !0]8_\
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M;6EKNS6KV2\[:_@S]X RD Y&"SH,_P!Y$>0CVRD;LO9@K8S@TI(!&2!DGDG
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M/;!YW XR2.>3GV]>PIM[>D!CD[OPY.#UZ')&/H.V37,7E[A3\QS]1QGTYX_
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M9_X_IO\ KW/\S7.UT7AG_C^F_P"O<_S-14^!^L?_ $I 2^)?^/NT_P"N3?\
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MB;P;XE\=R^*_$WQ;\$WWCO3CXI^$6O\ B_3M=N]?3PM\,=6\,>(_#WC:?5+
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M=?9Y9 VI6;/^I2%LLK'<%(5&"HH 4 2 *BC :3+CYFX;GFOPCT'1OV@OB?\
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M'0V6E]>O_'GFO+_@!_R<'^TW_P!?/P]_]1^2O4-#_P!7;_\ 7EIG_I%7E_P
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M6L4>R2?ZT_[B_P A24LG^M/^XO\ (4E,4=ON_P#28GCWQA_U'P\_[*GX._\
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M4X(PO"%6.YU>,820N_SEW5G5CE6%+13 #AFWE5+&19"<#DJ82"?]O]R )?\
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M_9J^$^/_  ;I_C7ZQ+]U/]Q/_0!7Y._!W_E+Q^U?_P!FU?"?_P!.Z5X?$O\
MO/"O_93X/_U#QY^N^$VF2^,;6C7A+F-GU7_&4\);,_3#QA)JD?@_Q-)I&J:/
MH.J#1M0DTW6_$,)O_#UC?/IK,VH:QIWFPR7]IIT:-)-*EQ;X7*O)D@C\>/#_
M ,3=5^,_BGP7\*O&7[2W[-OCWP[J?Q"\&7]OX;D_9R\=>%++Q7J/A#Q1I/B6
MT@\"^-KKQPNAZOJPN=.@O-#NK<7<?V](?M-KJMFLUE-^I/[0.A:7XI^!7Q;\
M/ZOXD?PCI^L^!/$>EWOB<0WEPVC6^I6"N=533["*6XNK>S,7DRVD$;RQPR.Z
M1MG:?R4O/C/\-OC3\(_V8OV?[/QY\!O"7CG2/BW\%7\8ZIX?LOB)=P:3!\//
M%GAZ\TK4/@JEQ\-[9;C7/&"Z79Z*$UZ?1K32+;4;T3W4<3R36O#FU2FJV4T:
MM94X5<OPS=&52I&&)3H8:'LY1C5A3NG4C[U53BHSF^50A4:]3PEP*J9%FV.I
MX12JTLRG2Q&;0PN75*W#^%E0S+$_VM.MBLDS+%_5HXK"X:A.&$QN6/V\\+&=
M>I6K86#_ %E^"7PPTKX36WC^SL(-+MF\>?%OQW\2;J/0H-4MK)-2\675LUQY
MUO>W5Q%#<SVUE;M<-9K;V,TBF6. -(Q;W>N.\,>+O#OBM=2F\/7\-\FBZ_J7
MA'4MEO=VIM=:T!H[>_TYAJ")/--8H8RUY"#!?"3"MB$$]C7V&&C2A0IQI*T+
M7LFFDW9OEMHEK?32[V1^-YSBL?C<TQF)S.5=XZK*D\2L5*I+$*HJ---U'5M*
MTTHSIJT8JG*'*DK!1116YYH4444 %%%% !1110!Z3JG_ "#)O^N"?^@FO-J]
M)U3_ )!DW_7!/_037FU<M+I_B7Z"K_%#UC_Z6@KRCXYMM^$7CX_]0";]9X/2
MO5Z\H^.85OA%X^#%L'090 F=[$SV_P JD<J2,X8?=Z]*Z9<UGR*\K>ZN[Z"F
MFXNTXTWI[\K.,;->]*]U9;NZ/3;(YL[3/_/K; #D8_T6WYY ]OPZ>HED.4FR
M,8@N<>_[EQGZ#K[]*\NU;XM^"/#!@TZ^U2>6]BM;?=:65NMVUNWV> ;)[C<1
MO[",X;H0/E-&A?%_P1XFNH],LM1NK74;H/#;QWUH(XIF<#,:$87>P!4;CGY@
M%[ULL'BE2>(G3DJ4>7FEJDFVHJZZ)R:7J[=3S)9K@'5C1CC\-/$TWR_5X**=
M1I)/X4DW%7E=W^'4B^!>/^%7^'P!C_3/$WK_ -#1K'K_ )YJA\8[R'39_AGJ
M%VZQV=G\0K"ZGD8A!&EKI>J3R,KGY<^6AW;P55?FP.2+?P)9F^%?AC*%'+ZZ
M&W=6<>(-5+R8["5OG/'))/>N(_:;=HO"GA]P?F_X2"=3C@D/X;UY&'^[@G/3
MKS44:<:M2A2DY14ZE.-XNSO?17\[6L=57$.."Q6*II?NJ-2K;>UN6S6RLN9-
M_GK<Y+_AJ>'6Q]N\(:;I&J:1(6>&\;5XKA'C4E6S):?NP5<%2N0Z$%9#N#"N
M?\:?'[1?'GPY^*G@JY_LVQ\2#X=^(=9BL;34[>ZDGLK.*&*9T@!>>)!/<6Q)
MG ;<H .QBI_B:;Q1XLT74=:AT?Q/K^E0G5M400V.K7UK"%%_< J(X9U0*<]
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MS8?M#?"KXO?LVZ]\ /AUHWQ=\0>'/'Q\"^*+WQ+\/=>U!=%TK5O"%Y\-M?\
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M@B::0X\ZYD5I"N=S$<5^<7_!7K_DT>#_ +*[\)?_ %)X:_41NA^A_E7Y<_\
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M41)X)\&W<:>9=7?C;Q.LMOIL<6FQ6MY)<6Z7L?ERP+%-<0-(#7PK\:/V5O\
M@K1\3O _@ZS^-VNWOQ/^&MDJWGC+X-_##XBZ%\._$GB%!!&D^E^)]=TCPDMK
MXCEN[(R6<ZQQV]A-*S!+6'>S'Z,_9V_:S_9P_8Y\(R>!/$O[%GQQ_92TS?%)
MK%R_P_U_Q9IE]?(YA?4=3\8:2VJ7&I^=,08Y;FZ 0S*L5M"C!!S3X:XBS:FZ
MV5+"T\G]G^^K4Z]+%9LZ3Y5*G')).$L U"Z>+KSG&G)-+#S?+./U&1<>>"?
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MANT\%C4X[23Q7X]U&634&M;GQ%J7V=+5)II=/%G*5A;]6/B)^T!\,?A=X_\
M@;\.?%6NI:^*?V@/$7BCPO\ #>*"[A:RN;SPCX,OO'NH7=[/<W\46FV5S9Z-
M%H]K>6@9;K4M0L;6/=/=1HWL4NI:=#?KI,FHV$>JR0?:TTQM2M%UE[7.T7(T
MPRB]^SEN#.(/*W<%ZRY(/3FOLM';73[WHM=?OU*YZBVU6^NE]5=?/Y6MY*_X
MX_$[_@G7\7_VM=,_:2\=_M+>*?AOX:^+7QA\"_!KX;?#KPSX L];\0?#WX;^
M%?@QXBU#XG:-9>)=5UE-,U3QO=^-?''B.ZU+5KJ>TL#;Z/(-)T^#;"''+Z!_
MP3>^*>I^%_C^-9^'O[(GP1U_QG^RU\4?@!X!TWX/Z!K5VM[XT^(VDC1F^(GB
M?QMXF2+Q%X?\/6=G!863>#?#:7&E1VU[)+=R:CJ%K;SC]MI-2T^VO;+3;K4-
M/@U#4E=]/T^^U.UMM1U".,.)6L;*25;N\"!)%;[/%+C8RM@@X\'^$_[1GA+X
MI^._VC?!%GI]YX;?]FCQ_9?#SQ7K&O7-E8:;>76L^$O#_C-=3L+GS5BM]%2S
MOK>U(O7C"W*(V=^U0[036NM[;W=[W[V5E?Y>B%>7+JEHEHMELM.W:ROI>U[G
M@5[^RCX[NOB/_P $ZO&4.O>'SIW[(7P_\6^$OB):3"]35O$5_KGPG\+>"H)/
M"]G<6Z?:A_:FASW4EKJ(L_\ B7RVK1@^8X/PO!_P3P_; TCX(?"#X&'Q!\)O
M&?P_^!WQT^+OB)/ ,7CCXL> =$^/'PX^*'B[Q;XQT75OB!K/A!+#5_#OC#P-
MK/C)YK30=-NIO#UW'IT<=ZKQ*RR?N[)JVBI>6NFR:OI<&HWR>;9:9+JED-0O
MH@C/Y]G9&87-S"$1G,L,3H%!8D <6Y;FWBC+W%Q!;P1E TT]Q#;1!I'\N-3+
M,R)F1]R(N06<%5R1@/D3OJ^B=G:]E%:K7M>PHU7!J25WJ[M7;;:VL[VL[*S?
MX7/P3^'?_!+7XU>%OA9^T%X);7O@IH__  MS]M']E[]IOPY9>%AXLA\+>'?#
M/P@\1^!]8\5>$+B77)-5U)]1^R^%I)?#VHWVJW-UK5_<";4XK-KXQ#U/X[_L
M3_M<ZK/_ ,%!? _P.\1?!8?#C]O+0=7^V:[\0H_&D?C?X=>(M7\"3>!]:TJR
MTS2[";2O$NE:C;7)>SU8O'_8$CM=7%O=P1>6?V"D\1^&TM[B[_X2/0EM+*__
M +*O;XZ]I8M+#5"D<BZ9>7/VH0VVH21R(Z6<[I<,I5A&5/-^[U/3=+M9+S4]
M2T[3[)#")+[4]4L['3\SX$):\N9XK<-,640@R9D++LSN&5R1ZO\ %?UY?U8K
MZS.?N\OQ--WB]7[KO=K5W2?ROU9^*O[1'_!/#XQ?$S3? .BV?AG]FWXFZ;H/
M[/?PX^$^@:WX[;Q9X+^(_P $O''@'PH?#,WC;X;_ !$^&EQ:^)_&>AW-P4U?
M_A%=9NDM+?4-/%PHLX;NZA;QWX5^!/VO/A-_P4!^,'PZ^"_C3X9?%?QOX%_X
M)X_L<?#[XDZY\<IO%5O)XMOHO%OQ>LM(^(^GZ[HUG<WES/IIM=;EO=$NI;I_
M$YN[.W>X2:W74#_04^KZ.D%M>3ZOID-K=VS7EI>S:M8QVES9I$)WNK2Z><0W
M%HD)$QN(G>$1,)"X0@FK%>:!(JZW9W?A^:WU**"&WUZWN=-GBU*2>9;6SAM=
M7BG=+V2279:6T<4CN\H6WB#. I7+&]U))[NUM4K+O^/=KYI2FTKQTT2Z]EV[
M-Z/7?U/G_P#8]_9\/[+_ , O!WPCN/$$?BK6M.E\1^(?$GB-+233=-UCQ=XS
MUS4?%_B;5+:SF=YM.TF"^OQ!9VTK^8MK;PF;,I;'Y8-_P39_:9\/?#?]FKP)
M;^(_AE\3O#/P@7XP1>-?@UXH\<_$_P  ?#_7M=^('QE\3>/_  U\0&U+X>WE
MCK&OWWA;P]K%EH]SH>I2'1VO;67RYX8Y2%_8']H'X[^ /V;/@]\4/C;\1-52
MW\+_  J\%:IXX\165C/8OX@N[#2X6N%L['3YYD:]U/7;G3X]'T5)E#23-)Y>
M3$VVG\$_C'/\2OA-X5^)OCKPE;_!:;Q;']JT_P +^)/''AC5GAL;C$FG2'6M
M+U&31Y)]3MWBEN=+2<7-E,[6LT:RQE:;Y;VN[)=&NKBKO6V_==V@3DM;;M.3
M?=KHK=MFGZ^?Y"_"?_@F1^T?\#OA?X37P7XM^"&I?%?X0_M]_$_]K?X>:!/!
MXMTKX:>(_"/Q$\&6'A35O .K_)?Z_P"'+K0Y[K4FT_48)M1ETR*ST1+^622[
MW5UVH_\ !/?]I[QWIGQ\U7XC>-?A)_PF7QI_;7_9&_:?AMO#3:_;^'O#WA'X
M$^*_ .I^)_"T(O[+^U9]<N-+\+75GHFI+:S+JMTL N!9^<6C_;"ZO['3+>2[
MU*_TS2M/A6-WOM1OK6QLT\U0\):YN98H!YP.Z+,@$BX921@UY'XM_:"^&7@C
MXQ_"7X%Z[KR)X[^-NA^/?$7@*V-U'<6-UIGP\M="OM<:YO[B]WV<FH7.LZ<-
M$MHD>#5)M/NH+83&"557+%=5;1+7;;[V^FEOP#F>B25KW[WVNGT7WO;9]/A+
M]K?_ ()Y^)_VI/C#\?\ Q9)XXT7PAX6^+/[+WA7X0>&+V%;C4M>\,?$KP9\5
M++XK>&]=U+22@L[S0X]7T?3%NK*.Y%_=6C2V\4<4S(R\E\;?V8/^"@O[4OPO
M^(7@GXK_ !*^"_P_TJZ^#-O\.O#G@;X=3>)]1\(^.?'3>(/#&H7'Q-\9WGB7
M3H=3T.RMM.\.W*Z!X7TU;[[->ZE<3ZAJMQ!"2?UT74M-^RVUW'J6E-97=T+6
MRO(]1LS;7E\]R]E]BM;GSO)GNS=QRV@MXG>8W$<D&PRQL@D34M)DN5L(M5TR
M?4Y!<F/38M5L9+]A92".]=;-)C.RV4A"73"/%NWRS%&XI\L;[_*^C3=UI?TL
M_0.:717M;97:LHZ^6VMVE;Y'QIJG[-OC&_\ VN/V4/CU'JWAU/"WP*_9M^-G
MP9\3:?+/<)K&I>)?B9/\)9=.N=%0(]J='MX/!6L&XF%Q'<K+=Z?'Y3Q[C']L
M#( 4]E38 00J>6JA2W4L"I).><Y/O0TW5=.U1I_[)U'3=:%M/]CNI--U&TU*
M.TNBGFFUN#9RS""Y$8W^3*4E" OMV\UX+\4?VDO!OPT^)OP%^%DUK)XEUOX_
M>/\ Q!\-]+NO#U]IM[#X1UC0O!NI>,IG\21+<,]HMW9:9)!!%(J2,['Y<8S4
M>6*T:UMK??9;]?QL+WG*S3Z[6TT3LUT?Y]$?15%-#!FD*L&C9]\#*3M^S. U
MNH7HICA*1,%_CC93\RFG50PHHHH *])T3_D&VO\ N-_Z$*\VKTG1/^0;:_[C
M?^A"N2>R]?T9&&WJ>K_,UZ***R.L**** (X^_P"']:\XU[_D)WGUMO\ T*O1
MX^_X?UKSC7O^0G>?6V_]"K2E\:^7YHSJ_"O\4?S,JBBBNPS"BBB@ HHHH **
M** "BBB@!K<*Q 9B%.%0@.W!X0L"H8]%+ @'!(Q7XD?\%3_C5\+_ !K\$?%G
MPNTCQ1;6_P 1OAU\:?A+:^+O#%X8M*UE+9=?LKJVUR""^D\R\T#4+20NE_;0
M_9I5BD=)<QD#]M9=_E2>6 S^6^Q6;:K/M.T,W\(+8!;L.:_F4_X+E?L]R6OB
M/X=?M&:1IJ+_ &UID'PU\:R101R37=[8&YU/PCJFH*DRB62."XN=+A01/>23
M&)0H(05]7P/@\KQG$^"AFF*JX.BH3DJT5'V:E3:G&-24[1CSV<5+F3BW%I.[
M/R3QQS+.\J\->(<3DV61S7VE".#Q^#4:L\17P6.DJ%1X:G1C.=:IAYNG7G2C
M"5Z2FVEHU^^_P8^._P +OBW>>)/#'PW\0V_BJX^'"Z+IWB[4-%B,WA[2=9O[
M1YET#^VXWFM+_6(XE-U<6-O.9;:$^;,B8*FS\ /^3@_VF_\ KY^'O_J/R5\V
M_P#!-7]GV7]G3]E+X:>%[S36M/$_BF*[^(GCURF;A_$WBJ""=+.5$>:>2;1M
M%MM*L6+/)'G[0\;;BX7Z0_9_=3^T%^TV>01=_#]"K*RR!DT"0-F-@)  ?XBH
M4]B:^=SS#X3#YICZ. JU,1A:6+JTZ5::UJ1IMPC.-M.2I&*J0LW932O>Y]UP
MMB<UQN2Y-CL[P]/#9EC<KP6-QE*DYRITJV-H4<74H<\]9SPDJ[P=:6G[[#U$
MU%IQ7VC13=P]&_[X?_XFC</1O^^'_P#B:\>S[/\ K_AU]Y]1==U]Z/ ?VC+#
MX[ZG\./$UA^SAK/@30/BY<Z7;+X0U;XFVVJ7O@FSNUU*%[Q]3M='L[J^DEDL
M5ECM@B.OF%7,8\K<?S%D^$O_  6PU.1TN?VJ_P!D/PTS,P\S3O /B^YF@!+$
M&UBU/PQ/ 5!)\L2.6VXR<=?U*^*/QATCX;^+_A1X3U'1]4U*\^+/B6Z\*:+<
M6;VL-K87]G8R:D\VH_:YH6:W\L!0MN)9F+?+&P#$>I?99!OF:T>2<MPI=2H&
M1_J]V0%()P"0003W&?(Q^24L=6I5:F)S6CS124<#FU7!TW9RUG3H5823;=O>
M<6XJ-M+-_?\ "7B+B>$,#B\+A.&. \[=;$*I/%<6\(X#B'%T/<IKDP<L?&HE
M1T4N6G3E'G<[RWBOQ F_8Q_X*K^+=1(\;_\ !2J+P]:RLGVS_A5_PJATV1D\
MM4 M+E[K2(U C4!C]BC;S2Y;><R/U9_X)#2>.H(Y_CW^VQ^UW\7;EHPEU82^
M/]-\,Z#.[*3)MTNVT74KB"*1R?W8OW9%^4NS?/7[-6<4J11^;:M&XW;@SK)M
MR[8)*@@_+@C!)[=JL20!_P"%_P %90.OI@'\OJ:XZO"V5U)0=6GF>(=-JTL1
MG./QD9-6LY4L1C*E%K5-)QY4M+:I'UDO'_Q'C",,IQ/"_#U&,%"$.&N >#.'
M91A[KC;$X+(*>.<H^[RSGB955:+<N:[?YX_"S_@EK^Q%\)I;34=#^!7AG7M>
MMT7?XA\>QIXWUNXF*8EN'N]?6YB229]TLABAA0NYQ&@P@^ZM'T'2M"MK?3]#
MTO3-'L8F0QVFEV,%E:JNX/E;:UAMH@>200G'<8&*ZGY]@01D8 &XJ6/&.>1W
MQ7B'PE^*^F?%Y/&-WI&GZII,?@GQWK/@F\74O)#W6I:%.L%]<0K%*Q6 R$I'
M'(%D(^;:5(->O@\MP.7P:P. PF&CHY*C1ITVW9+FERP7,W=W;YGUO9IGYKG_
M !=Q3Q96C7XGXCSSB"M3NJ<\VSC$8WV2DT^6C'$UIJG33U5.BH1C:*Y8I(]Y
M;.#CK@XX+?\ CH()^F1]:P]6TNQU.TDMM0TZTOK8X_<ZC!:75J=S DO'<QRE
M.IV@#&\*" ,UM[AZ-_WP_P#\33)#E" K,3C@HV#R/4 <=>M=B;BU)73BTTU>
M^C335M;[6MK>UCYYI--2BI1::<9*\6FM5)=8M.S75/S/F;Q?^RC^SAX]$B^+
M_@C\(_$&]LO+>^!/#MQ,2V<DS26BN6_VE4#.2,$U\[:U_P $J/V"-?DDD?\
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ME"22NW:R6K=FGT';F]WOI]Y_$#_P4 5A^VK^TR#W^+&JS#'7RY+#3VB<^B.
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M^_3X?**TM;5<ONV2M<?.K[2TML[WU36N[6KNM=D?S7:H_P"S*/%O_!0'6/\
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M:VUWJ_AM/'FEZAX[DT_7/#=[-9"QU#6=+&H6UFFO6;276B>3)8K!<A7D&_\
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M +C?^A"O-J])T3_D&VO^XW_H0KDGLO7]&1AMZGJ_S->BBBLCK"BBB@"./O\
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MK:AGW[!_PK?1<N4BDF=5_>]1%%(_. 0I ). ?HP\ GT!)Y X'7&2,GT49)/
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M6UZ7]/\ ,X&W)U7)WE]:Q3C+^:E.JZT)+R<ZM2U]='L%%%%4(**** "BBB@
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MBA5CC4  <!]%%4(*Z+PS_P ?TW_7N?YFN=KHO#/_ !_3?]>Y_F:BI\#]8_\
MI2 E\2_\?=I_UR;_ -!KF*Z?Q+_Q]VG_ %R;_P!!KF**?P1]!+>7K^B"BBBK
M&%?G7_P4DMKJ#X:_!SQ4B?\ $M\&?M!^"-1URY.=EC8>(=%\5>!;.[EP"!"-
M?\5Z-!,YP(89Y)B2(RK?HI7F'QE^&.A?&7X8^,OACXB80Z;XQT.]TB2]&!+I
MDSQ_:+#5;5W5HX[W2]6M].U&TD/SQRVH>,%E-=^68I8/'X;$MV5.H^9_W9QE
M"7X29X7$V6U,XR'-,NI?Q<3AI*G=I+GI2C6C=O1+FIJ_E<_#FXOF4W!.]=[/
MP1@%@SAM@S]T,&1C@89&ZD$UP>HZ@0'^?CG'KDD]S[>V,@^O.=J__"7> /$&
MI_#'XGV\FE_$?PS"(;OS#Y5GXITQ9)%T[Q)X=N)!%%J=EJ%J8YYQ!_I,-VT\
M=Q;Q. #Q^IW\BB0>8'8'[HD167(R1M=@0P)(V'YAUV]*_=L)AZ6(C0KX:<:U
M*=-.=2&J4WRZ-6YFK]4GU3/XHQ^8U,.UEN(HU*6(P=2K3JQJP<9PE&5G"2DE
M[S=]FUYM:BZGJ#R!RI 7.![\ <Y]!]WKV/6N&U'42$.6.1P>.3C/ .>#[=NW
M.*CU#4@JL-S*<<[E93R#Q@X/0D@]""""17!ZEJ8(;YF."<YQC@<<CC'')^F>
M*]W"82*F_=:]W=PEO>+L]+VT7IL?'8['RBFY.W,U%:Z<SN[*RO>V[':G?2>N
M!G(R3WSR<]R.2?H!COQ&I:F<'YSP,#GTX//'7GG')[8I+_5%8$!FRI./E)''
M!SC..?4]/:N U._9MPW' R3D8&3^? XX(YR,@X->SA\-;F]G&4GHY64M.UK]
M[O6]][>7Q&9X^<=;MWYN1=W:+N[:VWL_*]K7&ZEJG)^; Y ]\^N>W/7\STSP
M>IZEG(5MQ(QR#CCWYYP>@YSR?0MU'4 -Q,T08!CCS%)X! P,@8Z8],\<Y(X+
M4=24.Q\X$C(X<<],=_8Y/. 0>M>Y@L)*I&;E3GI)?9>J:5U:UK)[ZJ_XGP.8
M9C.G%\^CFVXIJ[ML]%>SOTMHMW>Y)J%^X=B7   ST[G'&#VZCICKD<FN'O\
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M^TTC493;V>J7.DJ5U33;":=7C74;^"PLC)&]K'=R7J3VUO\ S:_M7?%WQ_\
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M&TM;>QM;:RM(8K:TLK:WL[2VMXUB@MK6UA2"WMX(D $<,,4:I'&,A$4*N%
MY_QKXQ\/?#SP=XO^('C#4HM&\(>!/"^O>,/%.L3JS0Z5H/AW3+G5M3OI5!4O
M';6=K-*Z(3)L1B!TSM%*,4K)62OVOU_$6K=]V^W^7?\ KJ3>)O%GAWP7H>L>
M)O%VKV7AWP[H5K'>:IK.I2.EE86LCR*;Z^EACF6STY#%*);N9E-L899;R&VL
MS;7ES\9_MM?&'Q9X'\&?!ZP\'?$W3/@AX/\ C9\0U\">*?VGY--MO%VB_!^P
MU/PKK6N>!]:CMU,NA07'C_Q'I>E>"M&\4>(3_P (CI+:M<2WEV6EM-1?YO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7I.B?\ (-M?]QO_ $(5YM7I.B?\@VU_W&_]"%<D]EZ_HR,-O4]7^9KT445D
M=84444 1Q]_P_K7G&O?\A.\^MM_Z%7H\??\ #^M><:]_R$[SZVW_ *%6E+XU
M\OS1G5^%?XH_F95%%%=AF%%%% !1110 4444 %%%% !1110 A .,]B#^(.:
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MQP@4')!)***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN2>R]?T9&&WJ>K_,UZ***R.L**** (X^_P"']:\XU[_D)WGUMO\ T*O2\ =
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MY'E=%>J?V=I__/C9_P#@-!_\11_9VG_\^-G_ . T'_Q%'MU_*_O0<C[K\?\
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M?RO[T'(^Z_'_ "/*Z*]4_L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
MXBCVZ_E?WH.1]U^/^14U3_D&3?\ 7!/_ $$UYM7KK1QNI1T1T(P49592!T!4
M@@@>F*K?V?8?\^-G_P" T/\ \16,)\MM+ZW_ ""I3<W%II<MGZV=_P!#RNBO
M5/[.T_\ Y\;/_P !H/\ XBC^SM/_ .?&S_\  :#_ .(K;VZ_E?WH.1]U^/\
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MLHQ2LW9>0>S>NJUUZ]DOT/*Z*]4_L[3_ /GQL_\ P&@_^(H_L[3_ /GQL_\
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MBC^SM/\ ^?&S_P# :#_XBCVZ_E?WH.1]U^/^1Y717JG]G:?_ ,^-G_X#0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>nt10016217x4_graphic06.jpg
<TEXT>
begin 644 nt10016217x4_graphic06.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M\SV_7_ZU'F>WZ_\ UJ38/4_]\FC8/4_]\F@#\-?^"\_P!^-'[27[*7PP\)?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)PCS;ZI6V[>O9_?Y'0MXRC3&[2K_ )SC@=L?[/O4,GC>-4)72K_(QU QR?\
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MC\J.2/;\7_F)8J7_ #[O?9W].T?ZNCT/_A:L7_0M:E_W\_\ M553\6X@2/\
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M?Y]F=517*_\ "1VO]UOR;_XFC_A([7^ZWY-_\31R>;^[T\_/\'V#VT?+[_\
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M49:&](S_ '2?YT<LNS_K_A_S[,+KO_6G^:.UHKA3XUTG!_<7W_?'_P!>HO\
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MP]Y_9M_Z WQ!_P#!-'_\?H/_  5Y_9O_ (=$^(+M_"@T:/+'LO\ K^YXI?\
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M2]&?:,8RV_4A@YQG:"!VZ9KCXO\ @O?^RX8T)^'WQ<&5!Q_9.A#]#JN1_G
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M-%46D!/*,< #/T'M17G:=W]R_P SU^6?9?>_+R\_ZLR]5*XLUG))D=>#@<8
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M1E&!P#]?6M%**MJ[^:\EYO\ I/N')"^R^[;X?\OP\SPO_A2]M_T-GBC\M/\
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MSZC\C_C1SZC\C_C5^SJ=H_\ DO\ 7_#/RN7EV7W^G_!_K>CY2_WS_P!]M_\
M%TX* ,!^![Y_FU+Y?O\ I_\ 7H\OW_3_ .O2]C/LOO7]?\,_*\^_W7X?Y?U9
M^5VE W5S^#$?R84!%4Y#G_OIC^A8BG>7[_I_]>D*8!.<_A[TG2FM6E]Z\O\
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MA'S_ '>&\K_\N_7[OODVG^^?U_QHVG^^?U_QJ/)]3^9HR?4_F:+T?^?*Z?\
M+W$?W;_\O?\ %_5A>TE_S[AT_P"76&\K_P#+OU^[[Y-I_OG]?\:-I_OG]?\
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M=(UL!8+/Q&EN,>6[+M@;5'0%KBUCVO'(LBF-=I5?HA9%(DD>4GG?(K_+Y (
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M4_SJ_5!NI^I_G09U.GS_ $$HHHJX;OT_5&84C=#]#_*EI&Z'Z'^5:@04444
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MH1B%4'CD  ]152@ J!NI^I_G4])@>@_*@""BGN #P,<?U-,H **** *]0O\
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M\%?A)XE^'OP6?]DM?AUK6GW'AMM)G\7?%.'Q+;7@OK;0;:X6&6>QTLR)]KC
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M:=Y+=G92@+_F_P#M%_M%>./%'[6/BW]K+PQ\)?C?XP^%_P"R9XY\'>%O"GQ
M\*6QO/AIJ7P^\*RVVK?'&]NI(UCB\ZZ;4-4\+QW!ENXH9-)DN'W!U@BCG:UU
M>JZ]&UO=/I\UK=LV=*-G9+X5;3KIYJV^OZ']-,#O)E9"R[5!23RQLG:/$<J\
M'Y/-+B9#QA8RH'/-BL'P]KFC>)M*TGQ!HU\-0L-?TFRUO3;VSD273[JQFCC$
M4T;*/W;2+<+^Z#ONPS!L*:WJU3O_ %Y7T[G))-/:VGW]_GY=/0KT444R0HHH
MH :_W&_W6_D:HU>?[C?[K?R-4: "BBB@".3M^/\ 2HZDD[?C_2HZ "BBB@ J
M)^H^G]34M1/U'T_J:"H?$OG^3&4444&P50;J?J?YU?JMY)82RYQ OW9<??;N
MH7/&/7)SZ5<%=O1-)=;=S.?3Y_H1^7O3=&74Q9,I>/\ =,#RH1^^!]['(/T)
MIDLMI'&SR7*Q1>7)++=L!Y5DL."WF[RB@.&)$DC") GSNI8 \_XJ\8>'/!VD
MOKGB35H[+3-/C:2.!I%2XU"<L3':6T!&Z6>>4B&% 29)"H^4-FO@OQ_\2/%7
MQ!NE/B6ZN="\*W4TB:-X#TI)8M8U4LR>2VI3P2+<27L8V 6D8AMX$G87!NC)
M'Y55&H1;2ULMGKO9[+3^NXZ<4Y*ZNM]5Y)]=&M_ZL?1WB/\ :.\':=>W&@^$
M;74?'NLVSLL]QI4 M]+M"G,J7&HWCVVFW3*.VDW-\4((DV,"!XKK_P ;OB#>
MNXD\0^&O %L^Y4C$$>J:B5?Y0 ;F(+'+@X5[>1I$DP8@6 KL_AS^S9XU\8V4
M,OBBX_X0+PLP66QTO3$@_P"$GN+? ,8U*X:%8K)I.3(OV2:66,@F96.ZOKGP
MC^SU\*/!T*_8O"]MJ=[\IEU'77DU6XD8$%F*7#&W0DC(\N%<-@CCBN7VD[?&
MUZ/7IUW_ !WOL=*IP7V5]U_\]?D^I^:,WC7Q5JCFV_X3CXG:PS\"ZT;2?%HL
M2",9\_3K*4#D$\8]LYR7_P!O>+-#9"_B_P"+-N7 VSG3/'%Y;Q$C.9WO-.CC
M4+GYBS#N> ,U^P=MH^GV"B/3]/TRRA486&WL((D'.<_NU7)]_P ,58FL+62/
M9-;6DD;#+QFVB=9,_>#+('&&)YXSCITI<\_YI?>_\Q\L=N56[67^1^3FD_&'
MXAZ8Z1Z?\0-)\5(3YAT_Q#8_9KY2V T37,L+:@@  VQ[!$K%BK%F<#US2/VD
MK2T,,'COPW>Z)'<,L/\ ;UC_ *=HMK+U::X$+O?I#MSAC9D9('7K]@>)?A/\
M-O%$,MOJ_@_1Y(Y%(,MI!]@NQ(<_,+JT,+XZ$ @X(SR.#\K^+_V6-6TJ*]OO
MA?KOFP^6YD\*^)(1J5G+;@%A%9WCR1O:W#,-@EN$O$*D((E<B0-5)K:4OO?_
M  XN2'\D?N7E_E^9[AH^J:;KVG1ZIHVJV>K:;,BO#?V+I,DA;Y@@@0FXC<*#
MN^T0P@8QG=@5I%SL\U8"T:<."^)'(XX0G<N3Z#\?7\Y-"U3Q/X%UF4:,UUX)
M\36<S&]\.:O'(UEK1CW!U@C>1(EM2"S^?;QH4 #>6P!4_8WPR^*WA_XDPATC
MN-/\8:,5B\0>'9Y K.>"+_3_ )$-WI]VI62UN%1-ZL-Z(0:ZZ-1RB^9MNZ5V
MWY7UZ;?*^SNS"K!)^ZE:W:WWZOYM6TO=KKZ=U]O;THIPV2J[PMO*$90KL(7/
M)'+=/3'..HII*'E&WKQAL8YQ\PQD_=;*]><9XZ5U73_KT_S, IK_ '3^'\Q3
MJ:_W3^'\Q4S^%_+\T3/X7\OS1 W0_0_RJ"IVZ'Z'^505B8C6VK<J#]P1,2,G
MJ1@<\X^?VY^E?A!_P4U\8Q:C\:O!WA2VE#S:'X:N'NHR-T<4U\T,ZDJ3@.9;
M"(@]E#+G#L1^\)A-P(Q&W[R8BW=2,F%5F9S.QSEAL(^08 QG<37\R/[97BFU
M\6_M(?$G4[93NLM3CT6VD,PE6)=-DD5PFU$&)3+]W(VD?>)K]5\&L''$<98K
M%SBI4<%E[A2BU>%/%3Y4JD8]*EG>Z5]-S\4\?LT>$X+6!HU'2K9MG.#Y>63C
M*=*A&-2I'1WY;TK.+:5Y:W5SY?RJ(D3 _:':>ZNF_A,TL\@(4?P*$5,*/E&:
M;2N0TLC$?.2/FS_#M7"X_P![<2>^125_54>;EBI-RDHQ4I-MMR22DVWJVVFW
M?J?QO7=)UJSHQC"'M)I1BN5<R=INR2UE).4G;5MMZL****9D%%%% !1110 4
M444 %%%% #DQO0L<*KH[YX&Q&#/D]AM!YKX8\8WSZGXOUW4)&4^?=/:1,H"K
MY,+,54#NV<9;J1@\<U]L:G>QZ=I>J7D@RL&FW[@;@I+BUEV ,0<'=CG!(ZCU
MKX&>1IP9F.)%N9KE\X)D$K% F< KMSG.&W=,# -?4<-TX.I*<HJZGRIM)O:#
MM>VR;OIK^OR?%&(<:,:$9--Q<W9VM?W4];:Z-*U[7;=KC>I]S4XZ#/7 S3
M.N#\PP<XX]?P/7_ZU/'^/Y9X_2OK*VE1K:R\K=/O]5YGY_2IRC34Y-N[23OO
M>*DOG9]]+V%HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^@#_@
M@#_R5O\ : _[$OP1_P"G#Q57]32?ZJ3_ *Z5_++_ ,$ ?^2M_M ?]B7X(_\
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M]I# @$:II'A;5M1T_!/ (NK:'!/ .":=M&^VB\W_ ,-_6A/(I2ZW=NWHO/\
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MLZXSCAU89&."03[=>_ITJ!YB Z(RJS*-K.K-'U^\=H()7JG4A@#QCCQWX?\
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MW;?UOZK7Z), ?#>8^TH5"C80$;;N4';D@A0,DDXSSDYJ2*)85*KDY.23C)P
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M6FC22R>'M+BT[5K34]*O]/U6TGNK6^M9[>>2-K$'_!+_ .#5I\-+CP1:>/\
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MAXWP9[<]N429'8'D\E5(';)[ 5Y1XY@:QUGP=J1(*2WM_I4P0_.7NDBG@8Y
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MV^D6UI(2RY9Q]F$(4DG.5 R?FY8G/S?XD_X)R_L[7LMQJFG6_BKPS<#<8?\
MA'-?N[)+0L=PG6-S,B0QGD_+P. P&:^^1'.9"ZLJKT (.3CCT(QQVZ@\^WCG
M[27C2V^'?P ^,OC2^EFMX=!^'/BNXAFMB!<_VC-I5Q::7'#N:-=T^H7%O%&2
MX/G.F<+EEZ\)FV:4\11H1Q>+M.<(*+DJL%>44E'GE+1O96U[(X,ZX1X0Q^"Q
M>+S3A_*L9]6PU6O[:OA*="=%4J;E*4)T(^T?(HM\W-'I9)G\WGB_3O$&J_%;
MQ?X6^''QC^+NH_"+PQ?+H<<>H>,K^+^V=<LY)8]5C2XTO^SQ/H\&Z*#R&\Q9
M)?.$[R[46/Z1^'WPQTS2[.V6ULTL8F>.2>*"&(K<R;PS27#21O)-(_):1W+,
MQSNSS7R'^SWXUT35O#6G:E9S,CR+,;JPF9/M2M<W4NHO</$C2$W$UW?7BW<F
M2NV&']XW('WIHOC#2+>RA+SJA" _-+&K# )&$W[V/HJHS$CY03P?V?&4,PY*
M-.%/#QC]7I)RE2C"O.7*N:<N2\;NU[WNVM59H_@CA^KE..S''8^I7Y:-7&8B
MMA<%4Q>(KX2C@W6?U=4E7JU)0I\EH\BDE=-2@G<[C_A#],MHQ.MLA/\ =:-=
MN/0A5'&>W;&,=QYWXOT=+*QN9VC%K;HRB18C;^9(]P%:)(4FBD.3O7*CIT!K
M:U3XD:?;6A=KOR(57)FE.U /]TXD'([)N[X[5\_7&O\ C7XJ^*X_!?PC\(ZK
M\0O$37MK+_:,$+6_A[1W<1S?:=0UR[,&C1P:?$PEFMEO&O@(VMTM'NL0-Y%+
M"5\-/ZQB*U>G2I^_4<I0C2C&+3N[RO\ *U^EGL?8XW$87,'1RO*\)'&XS'3=
M#"X;"<OM*M7D<W&*4)2E[L6WM&T7S2BG<^6M=MO$'B[XLV\'A7Q-J_AR#P$4
MG?Q'X6N9-.\06VJ:D6272%N7-Q"+><0I]J @$JA4\B2$EMWU?HOP_P#B'=A=
M8G\9_$>:^56>]3_A9GCA3+.ZCR]CSZ_+';R8"2O"BK&7D98HXUPHX*7X*^)?
MV>/C+XE\'?$+6+76O$_BZST/Q]::C90ZBFEW9N9Y8M8@LFOK2VN&M- EEL+>
MY+VR,)K^W6)) X->\:KX^OM3EU'P)\-#;_VF5MF\0^*KR*5[+1=1NX(]VF:=
M&(G:[U,6!M+]RR16UO!>6\9N!>K=6UO]'[;#YQ3P]+!83"5J-5>S683C>,'3
M7-4<Y<BDKRC);7;DN7WCXC(LCQ>2XC.*.?U\SRK&TL34;R>AF4N>4I2Y<+"%
M.%.=)S]C&C-I2<$FW.;IKF7%:3\>?V@OV?->T^WT+XK:CXQNY;F>>?X8>/%;
MQ.FJ0+:SN;*"XM3:>*M/ECXN(+N366B::"*.:.6*1XV^Y/#_ /P4/^(VM>'-
M+GG_ &=3HGB&=F2YL/$/BRU@2X50JFYL+9[6&ZAB<@LB3RSLJX#.S#)\&^'G
MP4T+0Q-<"&6ZU6X"2WVN7TCW>L7UTS!I?/O)@91;,=_EP!RJ?+C&!7L5YH<5
MC!N/SO$F+<*GDE,#^.X7,N">"H1L@=\UX&,RGAOVJIXO#SQ%6+]YX1^SYG9)
M^ZXI6UM9W;:3T:5OUGA7/?$+)L'45'.(0R^?^[X;,*<\PE0I\RTCB)U(3E-\
MK?N0A#WFE3>LI>S?#?\ ;OT?5]1T_P /_$_PA-X!NM6O;?2M.UFTO3KOA^[U
M'4"$T]%N;>,"")YI(XY#+.<.2 RDBOOBWN/-BBN4A%T$0;43<'F60!PRA#DP
MA2KQ\EOG.YB.G\U7[:FO>*/ _P &O%WB_P #Z=877BRV33KZ87"S"RMM/-Y;
MRW6K6-C"8H_W:_/;+YBSHI!DB7!"^X?L6_\ !:/X)^+/@F;[]I+Q-;_#CQ]\
M,(M,L=1N8M#U.ZLO%>FSVTD-O+H-MHEKJEU)/;_82+Y;R&U"M+"T;REI/+_*
M^,<1D.5<499PU@:&-H8_.X1GE>'J2C)XWF=E'#M1UG*TDHSY>:UH>\W$_L_P
MGX"\4>)O!/BOQNQM?A_-N"^#L[629S7P<JE/B+)<)R4_^%//,#KAZ>!G*I2B
ML3AY3Y92;J0C%>U/WE5H"K36Q99<".X+J6:12V6AD$N]<+DQ[HUC8J "Q()H
M\J8$J)"JLO!$<)((;/&Z(@#(]CD XP :_.3X;?\ !67]@WXDWDVFZ/\ '.RT
MVZ-U(B+XL\-^+?#,#F1C)O74-8T&TTT1EFP'>\3ICCDUZ7XE_P""A7[''A;;
M'J'[0'@JZ=F#!-"36_$Q*D$Y8^'-)U5448PS-A%. S D9TK\.9S0Q+H5<IS.
M-2G.GI+#U)/FI)N-W&+C_P O)66FQ\_3XEX?J8>GBZ6>Y/4P]6BJRK0Q5*%&
M<FTE&+J2C*]2$H/5*[CV9]J$NJ1DJ9)2'1MBQI).S#!W.$^]MP%;' ]N*HF1
MA&6GN6NHLB"TN$VQFTE&5\O:B@3.V?F#;E+*,#@5\6Z!_P %%OV+O&%Q;Z=9
M_'+0()+B86P?4=/\2Z)'NE8+DW.JZ+9PVZ@-S-/+%$@R7= "1Y?^WI_P4#TW
M]F?X<>"-3^&T&D^//&_Q0GN=/\#165S:W^@6$-O;23SZ[=ZI:RS6:PVRK&A4
M2F>26XCVQE=S+TX;A+.\9BL'D]+*\33Q&/M0HK%4ZU",DZ;I.TI12<(THR<F
MI<J5T]4CFQ?&7#F59?F&<8C.<'5RW+Z:=:IA:M.M?F]G2]I:$G)2=2I&44XW
MDVK-'Z0&)BT;7@>/&]?,N&19)8W1%DC6,*D:I,$!)5/,&3A^15@N9;@RI'/+
M_JPH@<S%E"%&2XM4_=B%N#YDJ,V!N5P*_D>3]MO]OCQ9J*ZY+\9+[3IEE-S'
MH^D:+#9Z(-[&46\\5M>JM\D8/E><\8\Y5#E07P?I[X<?\%6/VG_AO.)_C=X#
MTCXL>&;=XEO+_P )64&@>)])M=RJ]S#8SFUL-4=$R2K7X=@23A\"ON,R\%>,
M\OHT,=3JY-C(5+P^H83$5'C'.48<\_WD*=->SC3497G[W,K-GYME?TAN!L9B
MJM&5/.LMP[<6\;C<&E@E*IS*$&Z,JM754W._LK)2U:=[?TAO(A955XO/C8-(
MD0!8 $F(2@#8HR6 VHI 4YR0*:6)SN"Y:1I,C((+ Y  PI^I!/O7S/\ L[?M
M:?!K]I[0O[8^''B".XUBWM(+O7/#&J1P:;XLT1)S*%34-,,K":*-X90LUE->
M#._=M^7=]'-.JK%,%=EF7>BJC2.86.V*9BNX(LA*@!RKKN^=$ 8C\SS'!XS
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M-I:B6YS;H06DEF CB1%ZD.Q7*@<Y_2OY2M?_ ."O_P"W!\2DNM)^&GP[\/\
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M+:WMM::]I,.HPPW$+X9)X8KE(W.$W.A8*%( ^&(U5(T6-F>, ['<AG;)YW$
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M*G.=.KDV#R*O6Q$ZM:G&7LYY=[:KRT*]FW&E*/+)'C"M(\,4LC(S2(D@*&+
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ME:U]4F_5KH5J*.M.V-Z?J/\ &@0VBCI10 4UAE3C_/-.HH @P?0_D:2K%5Z
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MOB*!AQRIDAF11VQD%L?RXKU;;N)Z#$<W)]XG]CQZUYE\5HL>'+-O[OB#2_\
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M.7EG>HJ<%>.LI04FDHM<#\)M&M]1BM7S&UO-$CPO(J%F15"DN$1%W@@[\)&
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MMRDA>!Y8),O(%V;F##\'?A5\7OB!\)O%">(? 'B6?2+^YM&TR0V+0#3]6TZ
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MZD+[3[FYUG1?$$\MG!/=1/>R6J>3$TYN+B9FVQ$,@!#N^,;?%3]HG_@JA?\
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M_?#J[O$B\/?LO_'S4YW!N8X!IVG33_9_+,H,=M#.UX548;8L3$*,!#BOV_\
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M8?(L\S/+<5.AB98B%>%7 1JTJ=?GJ*[C6E/X$W=22DK.)[X_P5^)7[0'BO\
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M8_V2-OX4H=PD<>XE8I#(H/.6((.\]9%P?NON7OBF8 S@!02S84!5!8EC@#
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MHR6KVWT=U9M/[U9M:;/1]44TLPDK2^:Y+*5*=(R,DYVYZ\]<Y. ?6O+?B?\
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M_P %S/@)XCO+C[!8?$?X0Z9X>$]Q''BZO;O7O$5M';PSA%?,GEH)5#D*-FX
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M9N;EKBS6Z,")$%&\N(U)8!2I) !QFOJ"UN-YB6-9II)$:3R8T:2:%5 W/+$
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M].LFA_#SQ)KFILVU;[Q-<>39*N<JI=A+)^[9F8J+0@;N&))4>[^'O@%XGUE
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M:-;-7>M]=[52#AN#T/;VJ#!]#^1J\W0_0_RJ"OIHU+W=MVEOV7H>(M$EV*+
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M10 4F!Z#\A2T4 1. #P,<?U-,J8J"<G-,90!D9Z_XT ,HHHH **** "BBB@
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MINAZ;%86 N&;=(\D-I$D,3/&) )7"C>P&[)KJF0*< D CIP1^H-1-$K$'+
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MN_"UY(NGWD>IV5SI2)->R$1C3G,1!"K7S[^TQ\._B7XS_:G\ _'KPEIOQ#\
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M?@C_ -.'BJOZFD_U4G_72OY9?^" /_)6_P!H#_L2_!'_ *</%5?U-)_JI/\
MKI7\"^/O_)SLV_[ \A_]5."/]/\ Z-?_ "9SAS_L+XB_]7N8#HONG_>;^=%$
M7W3_ +S?SHK\>I_!'T/W.?Q/Y?DBY11161L%%%% !1110 4444 %%%% !111
M0 5$_4?3^IJ6HW4D\#M[>] $=%.V-Z?J/\:"K#G'\J &T444 %%%% !1110
M4444 %-8$C ]?\:=10!"4(&>/\_A3:G8$@@?YYJ+8WI^H_QH ;1110 4444
M%%%% !4,D;.P((Z <Y]3Z ^M344 4G0IC)!SGIGMCU ]:95J9&;;M&<9SR!U
MQZD>E0&-U!)& /<?3L: &4444 1LA))X_P CZ4P@@X-3U&ZDG@=O;WH CHI2
MI'4?RI* "LV_T];RWN;;9!LNH;J*4RH9"3>6XM9G7<"$9(43RPN 7!+5I44
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MHH **** "BBB@ I&Z'Z'^5+10!7HJQ5>@ HHHH **** "BBB@ HHHH ****
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M-J?G3B_O29^1?\_/*LT_514=]G?E>S\M0HHHK(04444 %%%% !1110 4444
M%%%% !1110 4444 ?T ?\$ ?^2M_M ?]B7X(_P#3AXJK^II/]5)_UTK^67_@
M@#_R5O\ : _[$OP1_P"G#Q57]32?ZJ3_ *Z5_ OC[_R<[-O^P/(?_53@C_3_
M .C7_P F<X<_["^(O_5[F Z+[I_WF_G11%]T_P"\W\Z*_'J?P1]#]SG\3^7Y
M(N445\C_ !S_ &L;;X(_$_X6_#2;X/?%SQZWQ-OY+$>+/ GAL:SX8\)>6]O'
MY_BB]%Q')81L9]X*Q28CCD8_=P<C;<^N**^*?VJ_VT])_96N_"5GJ/P6^-OQ
M8E\70SSVI^$O@RX\3Q::L+RJ$U></##8RR"(E(IG5SD';M()[3X0?M.VOQ=^
M MS\>+;X6_%#P?:V]IK5T/A_XP\./IGQ D_L6$3/%'HPDD1Y+W(2Q"S$SOD
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M@6\_9Z^/GQ7;6O#]OKB^(_A3X.7Q'X>T]I[[4+0Z?J%VUW;O%>1)8K,\:1,
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M7_9L\=Z/X"N_@;^T#\3[K5=,&J'7?ACX%?Q!X>MHRSJ()+W[1"WVG"%O+$?
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MM1E_?\O_ *U?-/[1'[3%O^SQ\--+^)=[\(_BU\28-7GTV"+PE\-/#L6O^+K
MZB8P'U2P-U#!;1VY<B5DN)/NG%97[,_[5=M^TOX>\6^(+'X._%_X4KX/O8;2
MZT_XM^&5\,WVM"6TDNR?#\:W%PM\RA5B(+(OFG:6!QFO:PO:T;]ON\O7TZ[:
MKZM*UVW96N[.W3_-_AYGU7E_?\O_ *U&7]_R_P#K5^8^F?\ !3;2=1^*%K\+
MW_9/_:OM+J\\?)X$B\4W'P[MT\)1F;7/[%A\17&K?VEY<.@H2M[<738:.T#R
MA"!7NO[4W[8VF_LNZEX*TZ[^"/QO^+O_  F]GKES:W/PB\*1>)8-&FT'^SO.
ML]<=[NW%E/??VE&=./S1SK:WA+KY0W'MH=HZ;O3R_P"#_2U/JTDTG>[Z6=WM
M>WX_A?J?83%]K9SC![>WTJK7SY\$/VBX/C?\&+KXQP?##XE_#V&T36O.\ _$
M#0X])\?7#:29PHL-(@N+F&Y%[Y(-L?M*[]ZC&<BOE_X(_P#!1[1_C=\2?#'P
MYL_V9/VGO K^)[FYMX?%/CWX>?V)X7TW['97=W-+JFHM>.+:-VMDB@8J?,,J
M]*SG7IIQ3LK[63UV7;[OZ8?5IN]NFCT>CZ_C^!^D=.!'=<^^2*^$/VE/VZM*
M_9M\;VG@B\_9]_:&^*4UWH\>LC7OA7X''B/P_%"T]Q UK)J!NH%%ZIMS)Y(&
M/+DC;=\U>N77[1MM;_LX?\-(1_##XF7>G#PU8^)#\,K;0HF^*2QWTMJ$L6\/
M/<I']MACN2T\/VC<AC88(4T0Q%-R<=&TKM/HM-=NE[= ^K3TN]&[;:_U_P
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M(^#)%>(I#Q88#FOH/]I_]J&S_9G\,>$?%>H?!_XO_%"#Q==V]C'I7PL\*_\
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M(UY;BR>X?4(OL@&[S4@NF./*Y[#X2?M$VWQ9^"&M?&^'X7_%7P5:Z(GB4O\
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M66O;_D5R[1?_ #ZOM;[[+5*WI)1L'"$''7.<?AWJ)!('!Y 4C^#KALYSC/\
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MH=I5G+E><MA"0.QZ5E6\5/#V+A;CW@V/-HO^%W)%_+NXXC3_ +>LD]MK./\
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M+V\VN6RW:6M+P6\7.?D_XASQ:Y))ZY'FJ@U[M_?]BH=[I2OY::>F8;_GL/\
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M/U/\Z2E;J?J?YTE !1110 4444 %%%% #7^Z?P_F*AJ9_NG\/YBH: "BBB@
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M4FA)'51GJQY_/M_G\^N*C2;L]NWT&/Y_T-1S2 D\^O?IZ<Y'MSTQ^M*24E2
M>.?J3_0#T_/TK.4TK:JSW>]ODK_=^ALHRA)<R:YD];IKH[7BW%-+[+:EUMNV
M339P%QA9(^3SD^8N#_A[<FOF/]K-V/PDLQ_U-_AC]9+_ /S^ ]\_1V_#$$GE
MHC[?ZQ3^?\Z^:_VLI ?A+98[^,/# _\ (FH?YYQQ^&>;$3I_5ZUG_P N:E][
MWY5Y?\#>QM!^]#SE&WWGEK_Z^X^G_M&.O;/V+?\ DOOQ5_[)UX7_ /2R*O$W
M_P!?<?3_ -HQU[9^Q;_R7WXJ_P#9.O"__I9%7G\/?[]3_P 4OS-\1_R+Y^D?
MSI'ZB#I^+?S-+2#I^+?S-+7Z++=^K_,^=CLO1?D,?H/K_0U%4K]!]?Z&HJ0P
MHHHH **** &O]T_A_,5#4S_=/X?S%0T %%%% $3]1]/ZFF4]^H^G]33*XZO\
M27R_])0!11168!52;[Y^@JW52;[Y^@JX;OT_5 14445J 5GUH5GUG4Z?/] "
MBBBLP&/T'U_H:C') ]2*D?H/K_0U&,Y&!DY''XUK#X7ZO\D!)L'J?T_PKY6_
M:/\ &@\RU^&NGW9BNM<BDUCQ%/;MLFL]!TXQ1R65U,#\@U&6[62 8'RV4^0<
MDCZFN9TM4N)7YCM$NIKER0JQ6]HCN\[$Y&PJAQZ9ZD<G\R3'JWQ&\3ZA?('7
MQ%\0_%5AH4;R;IOLOAJP>_$4D2J0WDJ);@7'E[1(9K<Y'DX-T;2YE+5JUOOU
MU\[+\^Y$_LOM_P #^NQ]%?LV_#'3O&.LP_$'6=&A@\,>$YUTOP39/$?L]]=V
MBBT3Q T!^68J4Q#(3PL:$J<;C^A($I6;R650K!4+C;PG$C XPB $!!CH&Z=:
MQ_#/ANR\+:!I7AW1XX8+/1--L],L5VMY>VTMXX7F=01OFD=6D=LY+,2>2<^
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M?G&;4\LQZIX+]ZK8)\D(3DW/]I)(Y+>,I:QK*REE,4;H&0DGYG526C4OG#.
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M\#V#7OB*Q<=+5_./7@$%>WY=NM<<V_:?+0R/)^[C49)#=<@#J>0/Z5[I\/\
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M_DB:BBBF(**** "BBB@ HHII8 XYH &8KC'>HRY(QQ_G\:5F#8QGC/7\*90
M4444 %%%-+ '!S0 ,2!D>O\ C3"Y((XY^O\ C0S C SU_P :90 4444 %-9B
MN,8YSU_"G5')V_'^E ";SZ#]?\:-Y]!^O^-,HI.26[ ?O/H/U_QJ(H"23GDD
M_G^%.HK'FEW?]?\ #?GW8%24;6 ']T']34533_?'^Z/YFH:1O'9>B_(**0G
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MWTE3VD%Y?RF"SL;JX?=MW1(SHIS@;V"X&#U.<=:^JI?!_A.+[V@6I_W9V/\
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MZ[:W_P :KO5OC/X(DU?X=6QBT.\MQ>3-;+H=OKUH=2M?LLLVIS64)6UN;N.
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M&F>"+^P?3")?%B:8X\4R:-< M;P:B=6B@!GC9$$Y$D[84D>)_'&P_:9\/?\
M!*3Q+;?M*ZOK6H_&:S^)]O>?;H]5AU'6K'2H)9)+&65])GE20VNQOW>6PDBL
MZDL,_P Y=EK&NZ3?)KVAZMJ>GZS%,UQ:ZE;ZA,ES!<7>6O5^U1/'-<#S"OD^
M8HW$#(7C.OJ/CKQKK\%W9:WXK\5:O8W<XGU+3[K5[V6VO9 L(9KJ.0LJ$[9.
M0LO!!'4[4LVIUU)\G([3C92M%>T:=W%JS<+))W71:6#^RYT'#W^:_(]8^]^[
MM&U^;12OM;5WT=[K^H_X=?$;P+XX^"?@G_@H_JNH:9>^.?A-^S3XD\$>(KYX
MLZM=?$%--:S>,,Z^=%//J)>RDCDVS1QS21X#5_+-XC\0ZCXI\1:]XGU:4W&K
M>(M7OM:U*>3)GENM0G:<-.> 95@:"/@8V(@Z@U]V?'G]M#1?$_P \%_LQ_ ;
MP)+\+OA380VNI>-YYY(WU+QAXAFC2YU>=XX9G2*TO-3\RYW-,[R_*Q@BR8A^
M>SRH=J^>+AHXHQ)(BG"<LB*2,EBJ*H9L ].,8)RQ=>%>$8+WK<KEO:51I*4K
M>=DKM:M-EX;#RI2E.5U>\8)VT@G[L79[J[=KNR:70DWGT'Z_XTH<D@<<D>O^
M--*D-MZG("\,%;(!!5RH0C![L".XIQC=&4,N&/(&Y&)[]58@=^I'2O-=.%G[
MJV9V[[$E%,D<1CGYC_=4KG]64?K3ZXP/WN_X()?\EA^.'_8D^%O_ $YZ[7]2
M:]%_WV_F*_EL_P"""7_)8?CA_P!B3X6_].>NU_4FO1?]]OYBOT7(?^172]:G
MYGR>;_[U_P!PX?\ I*%?[Q_#^0HH?[Q_#^0HKVH[+T7Y'F/?Y1_)$U%%%,04
M444 %%%% "9'J/S%1-]X_P">U(W4_4_SI* "BBB@ HHHH *B?J/I_4U+43]1
M]/ZF@!E%%% !1110 5'(0,9('7K^%257G_@_X%_[+0 F1ZC\Q1D>H_,5!2KU
M'U'\ZAP3=[@3TW<HZLOYC_&G51?[[?[S?S-9%15W;RO^*'S$%A@@_*!QSW-1
M9 ZG%%,?H/K_ $-!LE9)=E85B"" 0?Q';FH:4=?P;^1I*N,4U>_7_+_@DRER
MVTW_ . %%%%7&*CK?^M"@) ZD#ZU&Y!'!!Y]?K1)V_'^E1U0!1110 SS$'\0
MJ-V4GAAT]?K5=NI^I_G25A*JXJ]D];=0)'(.,$'K_2HR0!DD >IX%%1R_P"K
M;\/_ $(5@WSSN]+M;?) .WI_>7\Q_C6?O3^\O_?0_P :=6?5.\-M;]UV^?F
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M5,-EV68B4Z4W"M5KQ^KX?#RCR\U*O5K<BIUH)WE3^*S32:/T/+J,DL !U)X
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MCD\/^.O#5U)XO\.^"='\$)87RA]>#^"=!LKNP$T5P)M62"Z6>UNFCD=[(1M
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M$[3I!!%*TOV>-Y)?+G1D<*$!8EE?;GH,[B0!FOZ7_P!B/5OC/IW_  3 N?\
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MZCZ?U- #**** "BBB@"K*S!V 9@.. 2!T%1$D]23]3G^=/E_UC?A_P"@BHZ
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M6?&$&,,5>/QM\%4D4'&_:X^)(*[L#=SS@9JN/VX/BL':0?L5?&,.S!\CQO\
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M(K5HO*\6L97JJACL-6HSJ5J>&H5,,J5:C.G*/,Z-+^M.%<YAQ3P7@88/%O\
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M0?-[2]64%;F@[-R5[6/USTZY^UV$%WAC#>PVMQ'DEG26>$S7"DG)"(WR*IP
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M?J]>?"SX=WL#I)X+\.7,\DGVA3#810W83L D94 ''W0,9Y(IB?#'X9KMEE\
M:.74#RWEL)LQ$#Y1+NF,3NN.2(PN1G:!P/@O]B[XR_&CXYV'[2?P^U[XHZ7X
M\TSX8^.W\'?"W]IKP9HVFVVF>,]&N/#.@:I-=6MEIVS2M9U/0=1U*[@FFT.;
M4]%E0112ZH\R3+'\Z_!2+]L3Q-^W=\<_V<_$?[;_ (ZU/P9^S_X6^&/C%8IO
MAMX35?&EKXITWPWJ%WH\HCU,W.C078UEHX[PES;)M9%0@5C[2K:+45[VB:<;
MW5K)W72UTUHTM&V]<E25Y)NW*KOXMM-=+=;)];VT[?LG9Z!H&FR>9I>C:+9,
M!A)-/TVUM751T1I(XQ(6!ZDMZ=Q6JV78!,-<MGR ^&#8&9<JV0Q6(,1P>1VK
MYL^/W[4/A#X#ZKX2\(7OA_QC\0/BAXMMK^7PQ\*/ 6G6FK^+=>T_219+J&K2
M7;W,6BZ/96C7L#C4/$&J:;:W33RPQ32O:LJ^;^/OVV_#?@>+PAI4'PF^,'BK
MXE^(/!*_$+6?A;X9T#3M4\9^!O!XW_:=2\6-;W[:)IKW,<<EE#90:G+JT\LT
M,^G65Q;W%K-*KS3=YQLGJM7O;;W=7Y;WOIJ5&*LO=D]/P5M5K>R[O3I>^A]I
MJLLF/(BU#:S;3''$C*L48\R2<@QD;-R*@.,?-CJ>5\S \N**:&9XIKP2W"!%
M\N<L4&55<*!]T9 ';'2OQC^*/[9OB?Q+\;O%E_\ "/XA:A;_  YO_P!@KQC\
M6?#.CO93V]Y:>+M*\3^&K**]U!KB*.6TNK!YKRTFTNY:.2</(Z02QHSC]//V
M</%NO^.OV=?@3XP\3WSZGK_C/X-_#37=>O)0!]IU+7O">DZIJ4T48^6!9;R[
MG=(X\)$K!$ "BLW)RGRO=)2O>Z:3LK:+KUZZWOH:J*45);-V:V=[)O\ .WJK
MGL'UHHZ45D(CD[?C_2HZDD[?C_2HZVA\*^?YL!"_E@N!DH"X'7.T9Q@Y!SC'
M(-?-7[6WBV^\'?L\?%35K-9&G.CR:0/++!ECU.6VB>4%2&4HH(##! 8@'!-?
M2V0.6Z#D_3O^E>-?'[PPOC7X0?$#PN\)GDU7PSJ-Y$J_*2VGHDX'&#N^5".,
M\,.,FE4OR2M_*^E]>FG?^O-5"W-&^W,OS/Y9X(O(AAAW%O)BCBW$DEO+0)N)
M/))QDD\DGFOISX0>'?V8-3\-W?\ PN3QUXWT3Q?JEQ<6NC6OAS3+2?2="TV!
MXDFU;59YK:9YEGN)K3Y0\9BC20*P#&OF=8Y(@(I05EC CD4]1(@VN#[A@0?>
ME;#^3O59!!(9(ED4.JEE*N-K9&Q\AG3[K.B,1N12/F8KDFVTI+71WMO\NA[_
M +.3BDI6T6J_X8^P]&UWX0?LV_%G1]3^&NI:!^T-=/ITL2:MKEA*NA:1J]TN
MZ..ULH[DVEW?Q:=+8"99D=(9AYD*1R,S-^AWBB.UO?\ @I1K=W<1Q3ZII7P@
MN];\,*\*2BVU^W\+2Q6@M[697CG,45Q/,B;#S$KJ/D!'X:Z;=RZ+/!>VTH@B
MM+M+V3+NCF993)'Y;H"5RV(V&0#$D<9^5 *]U\6?M*?%3Q3\8-$^/,^HMI_Q
M T:UL;*UU32[=+2.WL;&S.GQ+<06X2*2&YM7:TNUD!%U%,\<H=785ZF'Q5&G
M2C&<)Z5%-1A&\5:3OK*5V[.*3=U>YSSPU>4[QE#6$H-MN[YN3HH^3VMKT/T
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M<@GCT_QH ;1110 444S>/?\ S^-)M+=I>H%:7_6-^'_H(J.I9 6<D#@X].P
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M.J>-]3\+& Z*\X::V*:VT4*7#J=NT*J]G@WK[6FE:_\ $A=*\EU<;[+1:ZZ
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MU'=\2/ FK>+5\+Q:-?/JL&H_:Q;I?V<L=Q;VVFWMGI"/@2P:E>; P$A7Y/\
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MM]/=>_7;_@]1)9 N0N!G)P/7U^O7/IT'-9LLHR0.<]?\,_3_ "!U620<C/\
M]?V]A_GI67<7 B4X(+=\GIG\>M<52<N=V=W97O?31:Z=DMK]K(M+HO\ A_\
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MUT]/Z^?H%,+@$CGCZ?XT^H&ZGZG^=4:@S;CP.G')QSU[ ^M0R-M R.I['/\
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M/-U()PN3CV'/KU.![_3BLVXGPBLI\QF_Y9KC>N.[ X!_,].O%*_F2.T:*68
MG:.I !))[_3^N:X/Q3XIT_P?HFI:W?7L,3Q2"WMH)&^::ZD'[JWB5=Q>5S@*
MJ@\GG&<URSK5KQY6K:MZ)NVC7SW5EY]AN/)917Q:V:OJK6OHW?796ZIWW,SX
MA>+9=$TRWT728FN?%WB>X?3/"ND/M+3W-R2FH:K<A&<Q0Z/&;B[@D(W$VZ;!
MD@5UW@+P38^$/#+:%%=B_OKY_P"T=?\ $#L?M&JZVRJ;QI9) LIM[>/[/:Q;
MSO/DL @7!/(?#WP/JMW=WWQ!\:QR)XHN8(YK1+D!(O"NCW!4PV%O&S'R]6>!
MDMKW[Q\QYL 9->CZMJ6F:+I-]KFI,VGZ+99N+DS-LW"$1[(8SSF:]EEP%VDM
MQC@<=M&&):C.FDI2M#6*=J4M)Z624GI?K'1)[D5*R4;2?NZ7>UY:65TME?SU
MU:L8OB6]U^]ETGP;X ']I?$'QOJ4&F^%;-0Z+:W8 :77+K<%>#3=(MTDU&6?
M87*V[+$DCE5/[(?!?X9Z+\'?AUX>^'^BPQ1+I=G'+J%PJ+OO]9N0)=6NY)!\
MTLEQ<,J^:Y)9($!(X%?*'['GP:U,O?\ Q]^(^BM8^*_%-B=.\#:>(O)D\,^"
M-07-C<QVL@8IJMU92))+<$J3;S2+LZ&OOE=RK%'MW$2!8Y""62VB##]\0<">
M9Y0P&!D1L<#%?H6197# 05>,)1JU^52YI.5HMJ]E)WBY/5[/X;IV9\UCL0YR
MY(.\8M-[N[TNN^E[*[ZLLT445].<//+R^[^OZ;\K%%%%!HM4O1#'Z#Z_T-15
M*_0?7^AJ*@84444 %</\2?&MO\.? _BGQS=V.I:G:^%M!U36IM.TJ)+B^O%L
M+9IQ;VULSH9YY"N(EX0.097C4AJ[BJMW!#=1/;7-M;W5M<1RPW$5RH>-H9%"
MR(R,&2177*O&RG>. 5Y-)VMKM_7]7Z"DVE==&ONNK_@?SC_!7_@JSXCN?&NO
M'6]=DOK2[U"1Y/"?C0Q6P@M+F<O::9IVHV\M]ID.I180>1<7EL"5\L-@XK]I
M_@G^U+\*OC(+>#1=1B\.>)(H4;5?"FNNEC-&74%9;2Z=CIE_%)R8S9WL[=F5
M3P?E/]J;_@EO\ _V@;:X\0^%=*B^%OC_ ,QM0AUCP[ MCH^H:A&D@2/5/#RD
MJ@E:1LWD%U"8GQ-L.T*?PZ\?_"W]L#]B[Q%;:=XY\.77B;PI)>K#H/B+1VO;
MNV>W\T+;_8M<M L@N,%6>UN$F",P7=@FH]V&O-=-ZW;=]5UULUZ$.<I>J2V2
M\M+=NEUKML?3W_!7>)H_''Q/F?<F)/A@Z(T4H,HF71K;]W(4\G,;3!GW2* J
MM@D\5^P7_!-S>/V*/@;%)&8Y+3PQ<R2*S(V5?7-6*[&1F5LKANH'(&<@X_$+
MXH#4OBAJ@7XUZ;XEU#3;L>'K+Q187TPLM<LKO2+FR MIE^SY6X!MLA=IR1@<
M8K^C3]GC0? 'ACX+?#_1?A:DT7@.U\/6\6B17$YN;B"W:262>*XF.&>1;V2Z
MSN (X&,5M6I0<GOMW\X_Y>G8QI7=E+57271]%KY=>_33<]?7]Y&CC@-N;!Z@
M%VP#C(S@9X)ZTNP^H_7_  IZX&44@JF ".F#\W7H>O;\_1U<,I.+LME;SZ*^
MO;>WDSJ6B2[$6QQRCA&!RK@;BI'0X. <>A(!I!$R%OL\ILTD_P"/A8D60W/.
M?G9ROEY[[=U345',VT^WW"<4[7Z?\#_+\SA/'G@S1OB#X9UCP?K\,=SI_B"R
M;3[II54+9>2)7M+TL-VR^1IRJ.H.8HH]S@_*/YY[_0?B5\ _BM!() ?$?AOQ
M%:P7M[')<&744&[;JEOYL4<TFG:O$IGWNL<BB9/.1"6 _I!DMV^T7)9&D@G>
M(R!<Y?$:C*8Z;<8;WXK\S_VQ/!UXWC+3/&.KVVF;/(;1=,%DK-J&H6;Q-+)+
M>PC@RV*Q>3:2#E4(SG.1^*_2'\5<S\&_"KB#Q#RW)GG]?('AIRRQ5(T(UJ>+
MJ?5%5J5U3JRHT\-6K4L3.4:<_=IN$E&$ISC]=P-P[A^)N),%E&(Q?U.CB'.4
MZEG-RC#E;IQ5T[S75--6;O9'VE\._C)X:\9>#O#&LW&I06VI:W;XDTYF66^;
M5H$A6_B-M:F=T\M)+60NZJI$HP<A@/7][!(MT;J)P64MMX4#<"P#$C<!P#\P
MR,@5^./[/=SXA?XEZ9)X6CT2VUPQLT$6LR7$FG+IKNL<Q:WWQHFIR&V^8QO\
MRK'N'RX/[#0/,RQBX4M< 9N0!Q#<LN92,<+;LY981R0"HW&OS;Z(OC[G_P!(
M3@#&<1<1Y'3R/-<ES?#9%BY89^UH8[$X3*\MQF)Q<8JG1CAYYA]:6-=!4WA<
M-AL50AA<5BIQJ1A[/B5P9A>"L^_L_"8JIBL-5H>VIMP]ZFYSDH*<G*5X1LHJ
M5[RM)M+1NS6?6A6?7];5.GS_ $/SD8) =X RZR11I&"OF3;XII9'BC+;W6 0
MXE(7@NFW<"2)Q&Y>-2C*DH=E=E*YB2-',JQ-MGD3<S18CB9P\;%E"%&:I>7,
MEI:W=]'L9=/TV^NPJ0;[QI((A(Z+*7"1Q2!?)#E'9?,S@CI^1'A3_@HI\<-3
MO/ _B/Q#\$OAJ/A7\0/BS<_"[3I/!_QIL=8^*VF%/&FJ^!H]9/@F;09+J2:2
MXT:>XN;/SK:".#R")5,WF'*4HQM>^O9-]8I[7MJ^JO:VCUM48N5[6TMNTM_5
MKL_N/U[5)#);7"JP\EV*O'+ P2:2&2-4<B4A9 CM*N3M!3#,K "OR"_:#_X)
MM^(OB-^UIIOQU\%^)O#G@[PUKL-M)XXM[F743KS:S 6MVO-'M]-T^[L9()K*
M.U,INKZSD^T+(/*90';Z97]OS]G#PEI5H_Q1^*/@SPWJ>K>,O&^@:)8>'+V[
MUN"YM/!FL#1;F[OW%J)(I[.>6*VU-A"D<5Y*D4;,&!'2>-/^"@G[(/@;Q;8_
M#_Q9\9?#FC^++ZU\/WD>G".Z=K.R\4H\GA^]U:7R)(K&WU*.)Y('ED0[1N=4
M4J3I"O[/6$H:VWL]7:VC[K]7M8:C-/2,MGT;OY[=/+0^AOAIX);X<^ _"?@>
M74Y]8?PWIUMIL.H31L)+J"T5!;LF2SC_ %:$^8JX [UV;2*#<[SAX3(0@^?S
MBAARL<D>^+?^^!VLZL-K C( /S%XQ_;*_9G^'_Q2L_@OXB^+FCZ=\2=0O=$T
MV.RO+C*6.H>(GM4T2SN)HH)+6"?4'O;2.WBEN$9GFC#;23C*_P"&X/V:M3\=
M>,_A1HGQ0\.ZG\3O ^@Z_K6JZ.CR6_AY;C1+07.H6QU;R7C>\M8%AGN(8I9-
MJN& 8 @0IQYY3YHJ4K1EKHN6UE:^FCV7IIT7+)_9>U]G:W?LEY['U?( KR+D
M^8GWHRCH<Y PKR*D;''S85R<8QDG%,4H\1E21"#,T2*S>6T@7&9%$FS$9SA2
MQ4MSM!P<?D#H?_!5#1O%'Q[\,?!O0-.^'DV@7GA3X,^(=?\ %^M^*M0@DU75
M/B^/#=QX?L?"$0TY8KMYXO$VFVULDLP,UR64[5.:^TO^&W?V5+?XI^(/A+<?
M%WPY#\1?"^F7RZEH]ZTJZ:DV@6TMWJ\#WGD);"]TVW#O)"ERSM&';:=AJ5.$
MKOF6_72[[*]O70'":^R]KZ:Z=W:]OG8^K%(;S/F4,A7Y21N8-W0?Q =RN1QU
MHKY[^!?[5GP$_:7&N0?!OQ]9>,=3\(,O_"36]M:7$"V45S,8+6XLY)H85N+.
M>0%8Y5,I8<Y ()^A#QUX^M---73NGU0FFG9II]F%4I/OM]:NU2D^^WUKCAN_
M3]4(93'Z#Z_T-/IC]!]?Z&E/XG\OR1O'9>B_(BHHHJ1A1110!')V_'^E1U))
MV_'^E1UM#X5\_P V U_N-_NM_(U1J\_W&_W6_D:HU1K#9^OZ($ZP[^@!:<+_
M !R1W#R6Y7H"%B$2L3M.X-M!&"?YZ_V__#G]A?M(^(9T1$@\1Z=:^(H/+# 8
MF+^>LA*J/.CRADVEDYX<]*_H4K\=/^"HWA;[)??#;QS;VSN;E=6\-WUPJY16
MFACN;6.1AT;R;2ZD0'JD;D< UY&(2=.[5U&2;MO;;]=?+T+P522J;[WZ=N5_
MHW\WKJ?D^K[F9<$;=I4GHZLH8.O<KDE<G'S*PQC!+Z@A(8+M.4AC2WB<=)D1
M5<S*23N&^1HR>,M&?K4]>>]']WY:KY'OQ;:3>X4444AA1110 4444 %%%% !
M1110!%<1I+;7<4@RLMI=1@=1ODMY$0D'L'*D]^.E?"VI@V^I:A9NI#6MQ)G@
M8;<QQL'!X R<A>N>M?=;GA1V9T5CZ*S@,3[ $Y]J^.?B58+IGC:\BVF..[0R
MPD\"7G+%3WR,YY_F*PK4:<TYR3;5E>[VO=:??W[>ND'NOG^1QJ.'!(!&.N:?
M4$'1OJ/Y5/7DU(J,VELK?BDS0*8REL8QQGK^%/HJ4W%IK= 1;#ZC]?\ "C8?
M4?K_ (5+16GMI^7W (. !Z 4M%%9;@%%%% !1110 4444 %%%% !1110!^]W
M_!!+_DL/QP_[$GPM_P"G/7:_J37HO^^W\Q7\MG_!!+_DL/QP_P"Q)\+?^G/7
M:_J37HO^^W\Q7Z+D/_(KI>M3\SY/-_\ >O\ N'#_ -)0K_>/X?R%%#_>/X?R
M%%>U'9>B_(\Q[_*/Y(FJ%_O'\/Y"IJA?[Q_#^0IB&T444 %%%% !1110!')V
M_'^E1U))V_'^E1T %%%% !1156?[P_W?ZG_ 4 23_<'^\/Y&JM/3J?I_44Z3
M[C?2H<[-JVWG_P  :5VEW=B*J]%%1*7-;3;_ (!I&-G>_2WY!4<G;\?Z4U_O
M'\/Y4VB'Q+Y_DQS^%_+\T%%%(>A^AK84-GZ_HA:@;J?J?YTE0S$A>#C_ /6*
M'I^'XNQ9%-]\_05%29)+9.>?Z"HIR0%P2.>WTKDF[RE&V\K7^=]O^" ^3[C?
M2J5-D)V-R>GJ:I9/J?S-*_)I:]]=_P#@>0 W4_4_SI**A?[Q_#^0J(KF=KVT
MN Z3M^/]*@?H/K_0TU^H^G]35:?[@_WA_(TYRY(M6O97O^.W_!&E=I=W8D?[
MC?[K?R-4:0\ GT!J/>?0?K_C7.JZ:M9*SZR[V\O)_P# N7[/S_#_ ((UNI^I
M_G4+]1]/ZFD).3R>I[GUJI.3O')^Z.Y]36:C9MWNG?\ &S-8QO97V7_ '3]%
M^I_E5<$@Y'6D+X!R2<_C^6?\_C51I1G)[].>W^?Y\X/%9SJJ,G'EO:UW>VZ3
M[>9?PJV[?_ 7S^[4EEF"Y]?7\?SXQ^6?8U5IQD4]ESZY!_I57S_;]/\ Z]8U
M)\[6EK>=][?=M\R-_+;?Y+_@^FQ%)]]OK5=^H^G]31(=SL?4_P!!33)L4C')
MSCVX'/X?Y]LS>*=DNME^0UGV G\/\_E5!Y,GDXY'T'OU&,<C/;TQ4KR$Y&<C
MN3T_ =/Z>V*S)YUSM&.O7U^O'3_]9(XJ')-.SU6NG2S7]=5WT+]F][I:K9=K
M/?[]+:^07%P,8&<'OZ_G_7N,GM5>6X9E4>P_#_/^>.IY@/7:?\_6H)901Q@G
MC QC _S_ %''%8JLOY>]G>[3TUO97ZW^[8N[[=NZ_-;?>_+>S3-A0.O7&2>G
MX^__ .JJ,DP&3U/?^G^?T--EF"@\Y)[GMQZ>OIT'?H*R9+@?-S_AU^F/Z^W:
MN.=?WG[O7HUY6Z6U7EZ6UL[6OYN[OK_6FGW;BS7!))S@<\=S[G^G]365-/\
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MJV 25>/OQG;CMW_QQTX^F P"R _QQ2QC/8RHT8/X%NW.?2O)?B]I9N/!UK,
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M*A=VW'GT[#T'M2;SZ#]?\:KR38<C;GISG'8=L'^=4ZL';E;7?W6NW6R^[_@
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M_6J4CE4P#TX&>OU/\OSQ6-2<7%6=VFGU2=K.UFO.^Y;][331Z_@^V^ZMMW[
M\BJ"!QR>,G.<8SSW'' Z=..36;)+^O7'?Z>W^>E175RL2%L[F_N@')'KD @#
MM[X[#KG/=JT2."(V9MI63()!4D+%M#9?/02>6A&?G!P#R33<6DKOI?;=%#KF
M<1JV#\^"<]<?S_S[U@SW+')W=#Z#WZ9_SU)YJQ>>>JM)Y+K"HS('> W#KW^S
MP033&5SQM1VBW=R,9/+:OJ=CI4'VO5+ZUTRTQD27T\4+X/3,0=W!QUR,Y_"N
M64)]M^K:5]O-+T73KL/\?Z7_  Q:DN(R#$?.BE7+,UPFPX_V$P P.<YQR.>M
M8\]W:P6TUY=W(@T^%'=[II+>T91%D2R+/>[+,1QL&5EDS*VTB/DC/EEY\5)]
M>UB33_AKX=U3Q1K00(_B'40-+\'V:@E0R7\@FO+F1",^6NG(K ?+(<YJ&R^&
M%YXKF74?BSKZ^*+N*9IHO#5FDEAX<@DC<^2EQ:;F?43&$3;,7MA)@.8^><TI
MS?N1OTO)\D>B^*5MO*ZMU1VMQII<\N71;*[V6EE?SU=O*[*G_";^(/'-U>:9
M\+;&<&#=;W/CK6X;BT\*6]O)D3K9&411:CJN$S;;//A&&PF&&>U\!_#G3? @
MDU"03^)/$NK2D2>(]<9[[5FGN#MN$TZ!B\6C60)*Q)'#;1R1A3)N#$GO;>WA
MM8K6UA6*UCLT\NQLX9!'!#'@#9%!%$^UUVH(S(=BX8-*I*@\[JWB&'1;EM(T
MNSOM9\5^(W%M;>%=&Q<ZUX@>0B,1,\8DBTV) 5$ES?FSC5#O@:XQ@NCA7.O=
MQYYWBKQ:<4Y*-N5QNFWI:TF]-[IHYJE6*7,O=I.VNMY)6B[[/[+M==^FVUJ6
MH6'A^&_O]<U.RTVPM(WDO+BX:#[-&57=A[C)M!>\?Z-'"PE:<*$5G(KJ/A/^
MSWXL_:<*:[K%SK?@WX&RWUI<6Z;YM-\0_$Y[%L.MP!Y5_9:"=ODB2T%HEZ#*
MSO,5^7V7X)?L=:MKIT_Q=^T/8VD]S9S6]UX<^%NG7;R^'="B$J30R^*+IXHY
M-3U6%57:MO:F$3Y#3%22/TJL[2WL+>&ULH8K2"WA2UAAMHUA@M[2+(BM[:)?
MEA"*<%AN+'+$ U]KE>20DO:XR')RN+IP=VY*R;YDMEMH]6K\UMCQL3CH.T:$
MN9J_-)II*]K**:5WH[O9=+O4JZ'H.B^&=,T_1="T;2]'TO3+:.ST_3M-L[:V
ML+&UCC$:V]G##&(H8 OR[(E5"N 0>VH0H/RCC^?U^@PHST  Z "E9MQ) "CL
MHZ*/04VOK.9*/LXI**M9K3962MI_2/*UNVV];[]].N^NK^>MGN4445<-GZ_H
MC*?Q/Y?D@HHHJR0HHHH-X[+T7Y#'Z#Z_T-15*_0?7^AJ*@84444 %,:58WB#
M@['D4,XR2#GY8\>DS?(6ZKU!!YI]5;N[AL86NY\"*W5YI7=D2**&)2\TLC,P
M("("PV*YX/ [IZ>0&';>*/#]YXBO_!\>O:;)XGL-/&K7>@6UW:S:S::5=SP0
MZ=J$]@':>*UF-Q'LFEB$;N\8+%6P==?,E<VZ.R;&\FXN7B,GDLJAR1+&ILUN
M6##,,N45-K;!DFOY>]!_:!^->B_M0Z;^WW_PH[XGVGP:^('QM_X5MXO^+4ES
MH\_@6\_9@\07-SX.^%2V.EQ:H^LK?IXWOOAU)=W,FG1)%;P2RMRK@^V>'?BC
M^T[_ &_IOQLU?]HWXB:_HGBO]NVT_9I;X26T D^'(^%GB+2;2=-6MH/MBRI?
M:899S_;OD,&>XCB%NIM1)<8*MULWJWY.+M9Z_A;;[S5TGWZ+H]9=8K1[;.]G
MJ?O)K'Q&\":1=6<>L>-O!NC7-R;RWTJPOO$6E0-*-/O##=Q;;N['VE[*-)4U
M)(PSVSQRA!&\:[=Y8K&:9-26QL;QF@7[+J<JPG4)K5B)FBL;T8O+2V(:.2!K
MB58W5MT)(=L_RC^%O$'CGP/\#D^']C\7?$FNZ;KQ_;"EU:[\3F35M4\*7VAZ
MMXQ72[NVA4-J.F+HK6L5Y>F94$X@FC0QEU*_1OB7]I#X^? /2?B5X7\!_M.:
ME\;/ T_P4^"7B^?X@WMO-K>I_!+Q+XGO-0T+6A836LLME#H$MI9V?V70Y-2@
MOM.NX);NXC*W0 2JK[222L[Z7T2M?5-^3VL]=@]D^CUTZ/K;\KZ_EW_HW$XD
MD5E$L_G-+<1VSPSF5XR6NKJ*-HE >XM[<R&%%)>>2-&Q(KX;B(/B1\/I[^VT
M>/QSX9FU"_\ $5[X+M8H/$&BR7;>,M*MC?:GX8AMUN#GQ#8V<D5Q>Z#+&VJ+
M$5FBMUB29J_#3Q[\8_C!\-_&$G[.FA?MB>+?'OPN\3?$3X<V_BG]J9C;ZIXE
M^%%GXIL-#US5/#MGXFM=2FTZW7Q NHRVND7,5S,/#,%];VUU'<RZ?,C>/^#/
MB9X^^"7@#QC?_#WXC2?&6ZU#_@H)^T,+WQDE@U[-XUDT[X-Q:MHLL[EYO,OI
M-1TZ.]U"ZM)=MQ^Y2+>I=E'56EXI:I-Z-JS2Z;_<E96N@5.]M=]M'UVOVUZ;
MZ'],">:&$91Y-D;.[QQLD[QH[()HH7&UI%*G[3 $W(%)1%&"6N\XC:1V:(K,
M\1$4#3$%I8S"63;))%&8EE5YIL1J#N8@A37\V/P/_:0_;)U#PKX_\4/\9V4^
M*/V=O$OQ!DU/XG>/8/%MOX"^("^&[W5+;4_"'AGPM8:KJW@SP_I.I+%I&H>'
M=3@DNHVTZZU!9I)+L6$/V_\ \$POC'\2/'%[\7?AU\8/%7Q%\6>.?"-EX4\0
M)_PFNNZ'XYT"QTWQ#%?QW%SX#^)6AZK.^N:=<R-;;]&U;PWX>O-.A>, 74D<
MJQXSJIRBN5JZ?:U^GEK;S$Z;2;NM+::IZNVS[?,_0']H/X%>%OVC?AQK'PH\
M;7VNV'A'Q)J&GWVL-H;+%=:C9Z85W:)?26ZB::PO'5BXD8K-%(JDM&B >+_&
M;]@[X*?%2ZM=6TG0;'X6:Q#X1\>^ -1U'X::!HWA:?5_"GQ!\*:WX?NK'4H]
M(LK.VO9HY]5M[Z/[0DC65];02PF)HDV_;8M8RBHXX&PL8\QNS1@+&2W/"J "
M-H+$9."<57FA1)"\'[B8R+,9$R59@"23&3C+28D)R.1@#O2Y(R^RF[*Z?E;K
MV;;T5M?E:%)K9_T[?Y(_.;X7_L!Z9X9\6?#77/B7\?OBQ^T':?!R.UOOA9X$
M\=RZ!HW@KPAJ4%K#I6GW=QI^@Q:?:^(-0T^TTY(;"Y\11W]Q8JURUJ\;WMTT
MM+Q5_P $U?"WB"_\5Z;8_'7XW^$_@OXY\1W_ (P\>? OPYK<D'@W4->U?4Y=
M8\0V^D:M;R#Q'HVD:O?7%VUUHGA^_M-(G6=H9[5K=F2OTJ$C;65P),RM*A(4
M&,LJ#"D#LRLX]"Y  ZF+&2&>2=Y%.Y)7FS)&^<DQD( JMR'4@Y4D;AG--T8[
M<JMHM+WT2ZM[:6LV].CL/GE>]^ENGY6M?SW,O3+'3M'TC3=)TQ+BST?3=.LM
M+T>T1IA=6D&GV\=M$;I&)DN'>&) TESYC@AW+!I&)EK07_6/+)\\KC!< (>F
M!_>Y]2",BL^G)-6TMI9;;)+31+;^MB0HHHJ0&N2!QZ_XU'N8]_T'^%/?H/K_
M $-15I!*VRW_ ,@"BBBM (7^\?P_D*;3G^\?P_D*;6$MWZO\P"BBBD 52D^^
MWUJ[5*3[[?6N*&[]/U0#*8_0?7^AI],?H/K_ $-*?Q/Y?DC>.R]%^1%1114C
M"BBB@".3M^/]*CJ23M^/]*CK:'PKY_FP&O\ <;_=;^1JC5Y_N-_NM_(U1JC6
M&S]?T0]NB?3^@JO>6HN;"YADPT=Q')!L/!99898Y5XP2'0D$9..HP1FIB<@#
MTZ4C9\RS;>?+C>6:9-H(V*AC.3GH1)G/JN.]9I-;KNOOY==/1]MMS*G"4'>2
MLKK=IWM?32_]=3^5/XK:*_AOXI?$70IHFAEL_%^M/&AR MI=737-JH![>5,K
M!NK Y)/!K@Z^R/V\O"7_  C7[1OB>_CB,=KXJT_2]=M,)L3RS;KIS[3D[]TU
MA+*6PN&D*8.W<?C>OG\0U"M.+>S73R7;0^BHU(2IP:>Z[/?JM@HHHK)-/8U3
M3V"BBBF,**** "BBB@ HHHH 4!2R[NS*5Y(^<$%.F,_-CCH>A!&0>2\<0/?^
M#=9ML!YMXE/&/E168$ 8 QCGGJ,G)Z]4P)QAMI#*V?\ =8-CMUQCVZX-4[Z)
M9[74(V (N[>>/!&=A,;H#Z,<D'H.F,TI? ^^O37HE^OYV8X[KU/@^$%5.[(Z
M9R,?7K4V0>G3M4FI6S65WJ%H<YLY'C1L;3(0/O%"3M.>P+=^:I12-Y:9ZXYS
MU_'&/Y5XLHRG.5O5WTMTZ]O^ ;EFBHMY]!^O^-&\^@_7_&E[&?9?>OZ_X9^5
MPEHJ+>?0?K_C1O/H/U_QH]C/LOO7]?\ #/RN$M%1;SZ#]?\ &C>?0?K_ (T>
MQGV7WK^O^&?E<):*BWGT'Z_XT;SZ#]?\:/8S[+[U_7_#/RN$M%1;SZ#]?\:-
MY]!^O^-'L9]E]Z_K_AGY7"6BHMY]!^O^-&\^@_7_ !H]C/LOO7]?\,_*X2T5
M%O/H/U_QHWGT'Z_XT>QGV7WK^O\ AGY7"6BHMY]!^O\ C1O/H/U_QH]C/LOO
M7]?\,_*X?OG_ ,$$O^2P_'#_ +$GPM_Z<]=K^I->B_[[?S%?RU_\$$3GXO\
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MOS'_ .%<_#__ *$_PS_X!1__ !NC_A7/P_\ ^A/\,_\ @%'_ /&ZY5Q%!?\
M+N/3=O\ N_W?3[GU1NL%!;.6MNWE;\U]_J?I?)\4OAQR%\>^#R02,_V[8?\
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MU35K/37S_+U5\D7;X^FBE"VC3_KU7S]ED^(W@-@0OC3PP/3.LV7Y_P"M//\
M+]:YN^^+GPSM&>.;Q[X5WQDJZ+K5DSJPZJ567(/J,9/I7 _\*X\ _P#0H:'_
M ."VR_\ BZNP>#?!VG8>V\-Z5:%1P]MIUL7'OABB9]@Y'3!K+FJ/=)?)^2LM
MO^!N"4-$E/IV[+U;_P K%F^^.GP\MHFN+7Q1:ZI$A*M9Z19G5IY7 R0IMBS
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MP_/XI@O(/$T^D>"/#EA+J\5^)#/:ZK+:Z<D^HV<SRR-J%C)(;"^+R^9;,LC
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M27_1$?%?_@OT_P#^3J/^&4/VDO\ HB/BO_P7Z?\ _)U'LJG_ #[J?^ 2\O\
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MF?\ RTH_X8B_:[_Z-^^)'_@#IG_RTH]E4_Y]SZ?8GY>7G^+MT'[6E_S\I_\
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MK<6<'J2/[)Z\_GZ]*_;  #H /H,?RHP,YP,^N.?SH618/36?3M_<\O/3L/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>nt10016217x4_graphic07x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic07x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>QQ.85<4\7)49R2C4]C!/G:<FG4@Y-<Y]"4445_-A_H,%%%% !1110 4444
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MXD) !)/0%CZ[00"<=2!D$GL.33F&W[Q"C)!). /G* D] &<$+G[V..*.>/\
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MZ<=3@4T."< ,1M#;PC^7RQ3;YFW9O!!RF[<!AL8(-'/'_GU#[O3_ "0>U?\
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MELAT'P^SZLK6A^U3_P %#/VG\8'BG1#@[@3X7T\9(Z' EZC/4G.<^]?$@&T
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M7_+'I^G^3^]GVW_P\0_:C_Z&G1?_  E[#_X]1_P\0_:C_P"AIT7_ ,)>P_\
MCU?$O.W<05ZG:P(;: 6W;>NT@8#'@D@#)-(""3@Y& 0P^XP(SE&Z.!T;:3M/
M!P>*.>/_ #ZA]WI_D@]J_P"6/3]/\G][/MO_ (>(?M1_]#3HO_A+V'_QZC_A
MXA^U'_T-.B_^$O8?_'J^):*.>/\ SZA]WI_D@]J_Y8]/T_R?WL^VO^'B'[4?
M_0TZ+_X2]A_\>H_X>(?M1_\ 0TZ+_P"$O8?_ !ZOB6BCGC_SZA]WI_D@]J_Y
M8]/T_P G][/MK_AXA^U'_P!#3HO_ (2]A_\ 'J/^'B'[4?\ T-.B_P#A+V'_
M ,>KXEHHYX_\^H?=Z?Y(/:O^6/3]/\G][/MK_AXA^U'_ -#3HO\ X2]A_P#'
MJ/\ AXA^U'_T-.B_^$O8?_'J^):*.>/_ #ZA]WI_D@]J_P"6/3]/\G][/MK_
M (>(?M1_]#3HO_A+V'_QZC_AXA^U'_T-.B_^$O8?_'J^):*.>/\ SZA]WI_D
M@]J_Y8]/T_R?WL^UY/\ @H=^U(T;JOBS1$8JVQV\*V#!7 )0D!I3PX7D1MCK
MQC(_2C]@[]JW7/CI;^*?"'Q%U#3I/'^@!=6L/L=NME'JWAF:2WA:XAB$,,<D
MVFWMS#!>)$TC0F[AWA003^ %>D_"'XG:S\'OB-X6^(.AO.+G0M2CEO+>)F":
MAI#JRZQIL\8XF6^T[[1;VT;!@-0>SE"EXUK*<5.2:2BE&UHK1^?KLO0/:/LN
MGZ?G^?SO_6<"#T(/ /!!X.<'Z'!P>^#Z4M<GX)\5Z3XW\,:+XLT*Z2[T?7],
MLM4L)XV5E>"[A$N,KT:%F-I(A"LDMM("BDXKJPP;D=CCH1SU[@>M8M6=BT[I
M/N+1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVF_BEX8^+_Q"TWQ/X1EOI]*@\ ^!_#L[ZE;#3KN+4])T9[;5T6VNFC,EOB'
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MNK+POI%E:WWV_0X+Z:!(5U!);*2Q,AG2>!D\Q3^OZZ_UYL/Z_K^O^#ZCXO\
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M4 %%%% !^GN.H^E*3E2I (P!R >@(S@@J2V26)!+'D\TE% #=B[2BJ%0E24
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MF-#^'$DNGZC8I9VNB2WVB2/<V$1T[R(]4L_M$HAFE'EI(C%^&P/L2?PK\*M
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MUW4OZ8C\T0 $V?>7:4VN Z[&^\H5@556[A0 ?2@*BC"QQJ, ,%15#JIRJR
M"1%(X1PR=BI!(H#!@&&S!&?W;,R?\!9_F(]VY]:6@!GEI\HV@! =H'&&.0S_
M .^RDH3W0E<4X#&0,A2<[1]T'ID#M2T4 %%%% !1110 4444 %%%% !1110
M4444 (55L;B@P5*E^@<,,%NVQ%WRR9X98_+.0Y!_?'_@F;X-\8Z!\%=3UW7+
MBZM_#?B_Q&^L^#]"N$*-!IL5O'#?:RBM\T7]OZE&UR8,A/W;S  W+U^-_P !
MO@_J'QQ^*OA7P#:+.+"_N_M'B2YA0D6/AFVDA?5KB1QS'YT6W3H''W+J^@DP
M=F*_J>\/:-IGA_1-+T'1[2*RTG1K&UTS3+6(*$ALK"*.WMT55 52JQ D ?>R
MQ^8FBJH*$&HKGE>\K:V3LKOSM9>2?;7>+?(EWOTZ7?7M>YKQYV)N^]M!;/\
M>/+#\#D8[=*?0 !T&/I17.,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _/3_@II_R;5)_
MV/?@_P#]+9*_GNB^Z?\ >;^=?T(?\%-2!^S5)D@9\=^$,9( XO92>20.@)YK
M^>V-UV_>&"202<!@>0RD\,I!^\N1D$9R"!U0E'V/+S+FYV^6ZO;36V]B9-./
M*FG*[]U:O[/1:]']Q-13=Z?WE_[Z'^-&]/[R_P#?0_QJ3)IK=->J:_,=13=Z
M?WE_,?XTGF)_>%-1D]HM^B;_ ""S>R;^0^BF>8G]X4>8G]X4^2?\LO\ P%_Y
M!9]G]S'T4SS$_O"CS$_O"CDG_++_ ,!?^06?9_<Q]%,\Q/[PH\Q/[PHY)_RR
M_P# 7_D%GV?W,?13/,3^\*/,3^\*.2?\LO\ P%_Y!9]G]S'T4SS$_O"EWI_>
M7\Q_C1R3_EE_X"_\@L^S^YCJ1L$$-MVG&[<B28&01M24B-FW  ;SM ))(QFD
MWI_>7_OH?XT9C;AG0 ]<G/\ +FCDG_)+_P !?^0GIOIZZ'Z/^(_VHO"O@KX=
M_LOIX<\)_#;XF>)? _PTTZ9Y]<2\NM;^'/C:T2S2-+>YB=;B)D0%C8.HMXY+
M?,#;E./G>']I_P >#PQK^AZA9Z5>ZCXB^,.G?%^Z\312RPZA%KVAW5M<Z;9P
M64_VJW&F.+<6KRNT<\<7*H%(=_FC]RGW'0YZX..G3K2>8@_B'YY_E1R3ZPE_
MX"_+R_KYA?L^VWE;_@/\3ZW\8_M?^-?&VM?&/6M5\,Z"K?&'P?X5\$7-NMU?
M%/#>C^$VNKN-=,9(%>>6^O+^>[F%TD<2W<DT4+/"BL?,O@Q\:M2^$#^,-.E\
M,:!XW\*?$+0T\.^+O"_BG[0UCJ]B;N1"LM]IZ2WMI&8&+-#$KP1H1L.P*U>*
M^8G]X4N]?7]#_A1R3_DE_P" O_(#ZRNOVM/$%UXR^"WC"#X>>"M"D^!Z:U;>
M&=!\.M>Z3X>ETK5XA%!ITFFP1O#90V6U2);'S;RZ&];Z*)'<5P4'QYUY/ WQ
MC\"#1=-%I\:_%MMXMUB]D8B30YK.\GO5MM.6&W194=[GRR]TRW**'>%6D7:?
M"MZ^OZ'_  HWKZ_H?\*'"=KN,DEK\+26VNWI=@?7A_;!\5CQEIGCH>#M#DN]
M(^"DWP=@M&O[X?:--GLFC?59;H1?VBE[OC"_95BVL9/G;YLGSO0?COK7A;X?
M?#_X>6>B:1=:;\-?BQ!\5-,NY);OS]4U*PDN+:/2YX(T9+.SD2?S%OK1GN)$
M4.4&2:\'W*>_]/YTN1ZC\Q4_IM_7ET[ ?5=K^U3KRZC\=)M:\#>#_$6@?';4
M[/5/$?AG5Y-2GL++4+&WO19WME-:R+<,UH7A.YH(I9IHXG.)"M>I^(?BSH/P
MY_9#A^!^D_$?0/'GBKQ;KKZ@O_"-QZE-_P (5X&U2\L=9U?PU?ZO>"6<3S:Q
M9W3/I]O*TZ17**(C'Y;M\!#!YW+^+J/T)!I?*B4%E="YY(+IU/4 D^OOCTH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )*%WW_K3_)'Y"'_ ()/:&#@_'/7O_"'T_\ ^:2D_P"'3^A_]%RU[_PA]/\
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M_B)ISA=9^'=H$'$C#_A,M*8 ]"/MGA>>-3NP!ON%#$[026 -\T>Z_'R\O/\
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M&\JBC%SE\2C*;VL[:NU10555/50 <G)R!@Y.3GZY.>N35=NA^A_E5I@ Q &
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M^1/M?^OR\_\ 2N>ODV?^/_KG+_Z*-?67PF_Y$^U_Z_+S_P!*YZFM_ _[B?\
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M3E"#C^[3:4G=LI3_ ,?_ %SE_P#11KZR^$W_ ")]K_U^7G_I7/7R;/\ Q_\
M7.7_ -%&OK+X3?\ (GVO_7Y>?^E<]:5OX'_<3_VU&F!_B3_P?^W(].'WF_X#
M_*G4T?>;_@/\J=7$]_E'\D>DMOG+\V%%%%(84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MA>(5+6*XQ\L\;'/HN2<>_I7!2(!@L,D ] #QN8]Q[UZ%K@W61&<?O%/Z&N->
M$;<9R<]<=./K[5T47O?S7WM?JS"K"*]]7YKKKWW[]D8,T(<;ACD C/!YXP<
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M;F!CY\'0D;HCG#8^Z:=-IS;[V_+_ #=O,EQ:<5_*FG]VA'<=#]3_ #%8=Z,
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MJG[R)Q:ZCK&GQ>)YK:TBT2]E\Q[G3[S4)[R2W>YAM3',F?V,:SC1BT>U227
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M].'WF_X#_*G4T?>;_@/\J=7$]_E'\D>DMOG+\V%%%%(84444 %%%% !1110
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MX^?8RK)1BI:^7=Z_EK>W2W<ZCX!G-QXTSZ>'A^5EJ8'Z"OHX<J!Z@?RKYP^
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MDVY-N]M_._0R-7U;3]#TZZU35+J.SL;2)Y)YY2 H 4E57+ M([86-!DNY"@
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MG/\ =/X?S%-C[_A_6JA\2^?Y,S)*C:)7W!BQ#$G&<;<QB,[2N#T&>2?FYZ8
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M/]I+Q%I_Q<^-FBB/4%AMO,D^&_A#5T*?95\.65TD%SK5Q8+"JVGB'7;$79N
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MRDD_*2/IGL*Y[Q- +GPYXD@V[A<^'M:A4;<CYM(U%. >#N/'N?I7F>@_M)_
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MM&U2,(L0F:#7_*4!1'+XBL8[[4844<)%%K2ZD%10%4DG 8FOT.^$W_(GVO\
MU^7G_I7/7YF_#:867BO6]+C!6WDC\1K;#LMO::G#J5E'[%;37S&.P%JWMG],
MOA-_R)]H>S7EZ1[@7<_^/X]JBK_NZ\JEG;;X8OTV[&%!6Q%2ZM^[7_I2/3A]
MYO\ @/\ *G4T?>;_ (#_ "IU<;W^4?R1VK;YR_-A1112&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMOG+\V%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2A+9*,8MRTLXQ2;ZZ-_#U?8AE^^OU'_LM+49WDJ'.6SG( _+C@XQZ>^:0/\
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MO$_C#Q)J6HWFN:9X)T32O&.B:C>>)_$5C8PW.E:%I-G;P2237>HP)!!&P8D
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M^U_Z_+S_ -*YZ^39_P"/_KG+_P"BC7UE\)O^1/M?^OR\_P#2N>BM_ _[B?\
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M(ED8@J"%2'S&8*S .X!1#]XC#;7[B2=HRHR,DE"2#]T!U7YR 7"YY3YLX(-
M$+#((%0E2.H_E4Q.&4$,%;.#Y<KDXP68+%'("@!^_N"D\<9&213@;06W!GC^
M23]XHC9UVD(5#. =J,5?/8DXH JN"<8'KGGZ8_.O*_C)%M\"ZB[[E/VO1PK(
MXWJK:C"DOE@JZ(Y#J#)U<$ \+7K+*RDAE9<$@;E92>X/(QR"#@$D9PP!QGRC
MXVS+'X'GC;C[3J>CV\9R/OG4;>0\<9VI$21GH?:MJ";J1492@[I<T':2O):I
MZZK?:VB9E5A"I1K*<(U8M6Y)I2@U))--:73]>IQ'P*TNS^W^,)DTNQ\VWE\.
M0I.(+))48PW2.Y:*S@EWR 8=O/EWX+'!.![YJ'AK2]:TZ[TO5])TW4--OK=[
M>XT^]MHKFTFMI%VO;W,,_GQW"R$]70;$X R,'QSX"JQG\<.%)#:EH,1/99(K
M&:[D4GU59HD/H6!Z<5]%+]U?H/Y4ZM2JJDU[:JW&;2DYOF:B[1N]KV2V2^73
M+#T**H4HJC2Y'2A^[]E2Y$G&+LER7:225VW)K64I-MOY*N?V+_V>)M3BU*Y^
M'4%RT,@N4TFX\2^+KGPFLZ'?'Y?@^XU]_"D2Q'E!'H" ':<94$%]\'_V;O!G
MBGP;X)D^%_A*TUKXB/XDLM ^R^'(I(B=#TX:WJJ75\S22VB""Y,D6TJLLCM$
MJ# Q]6R_?_!O_017S)\6O^3B?V5?^PM\7_\ U K&KEC\;9+ZU6MHK>TELVM-
MSCI\/Y!3G.=/)<KIU)IN=2G@J$9S=MYR4+R;LKWW6]SV[PYX=LO#5A;Z-H>E
M6&D:)80"UL-/T^WL[2UMK="X6&*"V@B6.-2Q?;ER68L6+$FN@@CDB0QN  AV
MQX(.4'0G@$'.1@DX '/I:B^Z?]YOYTC]1]/ZFL'-R3325VFVKW;5[-N^KU>Y
MZD8QCLE974%TIQ:@N2"^S%*$4EK97&5 W4_4_P ZGJ!NI^I_G4%'E'QO^,?@
M']G_ .%_BKXM?$[7K'PYX-\*Z>;J\U'4&VQW-S,WDV&EVD>0]SJ.IW;1V=C:
M1@R3W$J(H.:_&OX$?\%?]<O(G\2_M%_"N7PG\,_&GB?6;OX<>+/!6DWTUYH?
MA$W>S2K?XAZ1>W5U)<ZI'IPAU"ZUS18[.W:&ZB@;1H)(WDD_9KXR_"#P%\>O
MAKXJ^%'Q1\.Z?XJ\&>+K%[35M*OXMP,B,EQ8:A:3C$MGJ>EWR?;-.O;=DFMI
MUC>-U* U_,E^T_\ "3QI\"=?\(?L[>-=(UV^T#7_ !3'=^!OB#X'MK;7-;U;
MP1X=UFP%YK,MH9;467C;P[IU]]FU*TNU:.\OKT7]J]Q!&EJOZ;X?93P[G:QF
M79I&L\QJ5.?"N%2-.V'A2O/V:Y)2E54TY.*O>"7NO6WY'XH9YQ;PZL!FF23H
M?V52CR8ZE5HRJQGB:E>,:7MI*<'3HN#48R4HVFVY2^%/^DWP9\>_@C\0[[3-
M*\#?$[P/XEUO4]#M/$UKHND^(]*O-8NM$U* 7-EJ?]D174E[#%/!*C!6MXY@
M?D>)2"!Z\^Z2,%E$>1\I#;@5YPZX494CE<X!4CCFOY ?ASX%^'?PP.LV.EW'
MBOX:?$/0/'VL^*?@[\4O%VCV&@>)]3>+4YI]%U[4=<C\K3HM<UBRN?L]QH^L
MW5IHURDJPPVZL8HA_47^S9\9+#X[?!7P!\2XY=,6_P#$7AJRNO$5KIMW'>PZ
M/X@@!L]:TRXD1W\AK'4X+FU,-Q(LT(54=3P3Y_&?!+X=C2K4JE3&8&M-I.K"
M-Z4TN=J*@HI7M):W<9QDG9V/8X%X\I<4*OA*U.CA,=AZ<)SH4)OV<U/E5YRD
M_:R:;4DW*SA.,HW3=O<8EV6P7>7PTGS$;3RS<8))XZ<FHZM,A2+:0 >2<$,/
MF!(((X(((((X(Y!(.35KX%<MER)J%O=3W4>B?FE8^\Y7'W7:Z23M>UUVNV[=
MKMOOJ6*CE&4P/4?UJ2H9R1'D==P'YY^E=25VEW=A2:2;E=I+5+=KLO-]"LP*
M]?TY[X[5DZ@NQUN7G6WMX(V:[=D4A;9$FD>0NV#''&ZQM*ZG*)EL<8.JQ*KN
M8$G:3R3M 4;B"0&Y(SL7&6;@<D5XC\3?&<<\=]X0T2:"XOYK QZU<07#"30K
M*]#)G9'R;VX ""%F&R,F1QM%:X7!U,;4=&TU"3Y7*E.=.<4[)RC.$HRBU>\6
MGH]'>]CBQN,I9=AY8FI+E7+[L92DG/F:2@U'E<HMZ2B])1OSKEN?D/\ '7]G
MO]IC]K#X\>++;XD?%S6/!G[+>A:TTGA73_  BO?$/C;0_*A"VL$<\MOIGAY2
MRO#<7\L%W>S.S2S?;K0I8Q>^? S_ ()L_L2Z9<W^KM\'-*\1:G SZ=;6OQ"O
MO$'CC6;>U$K6[7]XOB36-5TJ2YU%U\Z26RTVSM$=V\B&&+;&/?\ 3?$6I[;#
M2(KS1)-25;VWOAB0/ID%C-%;^?-#E@_VD2;HE38#M.,@\=1X"\'S>(O$>ORS
M:WX@@L8+*WT_4[C2KV;2AJLMQ,;B'3A)%B2.&V#>6YA=9HLX=\@U5+PPX1RR
M>*S+$8:KF>:3AS2S#/*\LSQ'+*=U0IJNHTJ=*',XTE3IQE:S=23U.N?COXC9
MXLER#!9M+A_(LNPW]GT,LX.C/A?"UXPI*3Q6:+)J^'EFF+J_%7K9A+$+G][E
MA422\6^%.H>%?V;/B'K'PG\,^%_#L*:L;:WT2>QT_2])T[3GEWQ>'=7UR^L[
M)/L%G/;366@:\'U*66?7=.2Z6%4O!M_4K27OTL[>'4Q"NH-$KSBU!-MO0+YB
MHS@L4C>1%!R&+=MN<_+7C/X(^%]>\,G2=!LK'1-2M);FYTR[\G?;7,MY,TUY
M8Z]N;SM4L-2?/VN2>07%O*QN;22.1%8<E\,/CEJWPZNS\/OB_:WMO'H^R*TU
M^X9[ZYTK31F&TNM9N3&9-0\.PKY=G:^*(V>2&.1(M4A5(WNDYY4<!AL-1P^6
MX6GA:%%2C*G3BH0YG)2O&,4HQ6MFDKNVK;04J^:8W$SS+.<PK8W%8MNTJU6=
M2:C%I+VE2JYUJE3:\YU&W;11NT?<C.BL<ABY3!VJ2.IZX]QUZ9^M(A^20X/W
MLX(P?7H<?Y]JSXM6L+ZUM;[3IX;^TOD22UO+">.>VN8Y$\Q&@N8F:&:-PVY9
M(Y&CP&W.K#:98YPXD7@'RWDRKJY_=CY@#&6#$%L8##G/H<\UY2@W"*G*"7-'
MGCS:I->[JU=:J_W/8ZGRPFHR;CS-62A+E=^5:3>CMU[7U)6^Y] W^-9[=3]3
M_.K@&(R,ECNDSDY()P<'/((S@@DU3;J?J?YTHMN*;BXMI-Q;NTWT;75%-6;7
M;MJ1OT'U_H:H2]_]X_UJ^_0?7^AJA+W_ -X_UK6&[]/U1+V^<?S1D7?5OJO\
MA6'==1]?Z"MR[ZM]5_D*P[KJ/K_05K3_ (C^7_I+)ZP]'^2,>XZ'ZG^8K$OO
MN'_/85MW'0_4_P Q6'>DD,J@,P/**R^<5P.4MV*SRC_:BC>+MYF>*Z CNO3]
M('.3C.1D#.\9.<#/<X!.![ GT%<-XCUS3- L'U'5KD6MMOC@C(^>XFNI)4AM
M[>UA0F6:ZGG>..W1%*B5T:9HH@[KD^,OBKX:\.F]LK2ZM]:U:R1VU""SN&73
M=#RFX1Z_KD:-8:9>,.8-,6YDU2[.V*T@>=T0^6:1X1\6>/K^+Q%XOGDTG3I%
MEAM(XH5L;N2QN(Y";30=/<2/8:-?6K-!?:K<DZE>)++$C0K-Q-]6ENW?T5DK
MO_+<*DHPCS2TZK1ZZIVMYZ&1;V>M?$SQ")YHY[#1=/FEMY9DD4IHT+*5N;6V
M!W)>>)]8LVGT^>_C$EOHUA=ZA"_^D7$#+]!6EI!I]I%86<,5O9VL21VT,2[5
MBC1=HC!QE@D2Q1EFRTDJ22D_.#4]KI^G:186VE:9:PV5C9HD=G:0QKY=K$%.
M](I"/-Q*^UY-S,97422$LJT]NA^A_E32M_GUU_K\$>76J>VW>FBLM-[7WOKK
M_6I1E^Z>,#)XX[;0>GN#7T%\#/\ CQ\0?]?-O_Z+DKY]E^Y^+?\ H0KZ"^!G
M_'CX@_Z^;?\ ]%R56)5J4?\ !'\6F&'5J]%+I3Z^D3W:7[B_0?\ LM5JLR_Z
ML8!)QP!C)Z<#) R>@R0/4@<UGK<0MC$B'(1P=Z >6[%%E)=D_=.RN89 "EPB
M&2$NC*6\X]<E8$CCUJ(@CJ*E#;U#1%) WW&!?RI.6'R2A&5OE4L-N03A0<D$
MC*6 8!MH!8@QR[PO _U8C+EBV0$ )(!8>E $-1LI)) _4>E2[) 0#&X'))".
MWRA58$!4+9(; 5E4[E9<Y!PTEE."CACPH,<F/FXCW/L\M=[85OF/ED@-SD
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MV'BO1--\/:OI=NEO)'K6@>#[7^P++3KVW21FN-*\.V]W;6**F$M6NHHIAO9
M0+KM?\.J_1/ON?,.G_M"^/M;\,_''XTPW>AZ?X"^!VH_$'1X/A19Z4FI>,/$
M4O@#PZFI7FH>(O$9O6?P]+X@U$O?Z'IUEI,D47@Z;1];N;F[_M9XK'R[5OVF
M?VA-!^&?C3Q>_A:XO]GA7X:>(?#7B77_  +;^#/#5GXJ\7?$KPQX5NO"26\'
MB_5W\1:(=/UAM2MM3MKR22WMXI+>]OVN[N%$^\U^"_PM3Q2/&L?@G0XO$QL[
M2PGU.&V,3WMK8VD]A9QZA;QNMIJ!M[*YGM8WO8)Y! _E%BBH%RM/_9]^#.E:
M-JOAW3_A]H%MH.MC25U+1E@E?3)X="U:VUW2+9;*65[:"UL=7L[:^@MH(XX5
MGB5BA&00=UVU]-.FF_2V^[OJ=]X;L]=M-!L+?Q/JUEK.OPP$ZGJ.GZ8^CV5S
M=/+(7CL],>6X>WM[< 11/)/+)*@5G<D5XU\=]2'E>%O#S%//O;O4-99<G;'9
MZ7;"W5Y<$[!)>WULJ;@-PAGQRA(^@YG6!/,)1(XHR2\K$11(N.3D$*&8H)&P
M,1AF)&P$?#OB;4[KXA>++N]L#*__  D%W#X4\.1,/GMM)M;N:W2_48!19YY]
M;U>X=B2T45C#(Q@B@1-J*?,I*VB;OVZ>EW_6]GC5NH22^TTFN_R^1]"? ZRF
MM_!MSJ[XB?Q-XBUK68&>-\_8%OQINCJZCYW6>RTV.=@I4+'<EAA6 KV43YR
M H$>X$LC_,&V.@4.I98M\+O+E4V/CA@VWXH_;G\3^*O@]^Q1\5/$?PNU&[T?
MQ3X+\,^$8_"EQ8ZDFDWK2KXL\,:3'9KJ=U!=PVCZK9326+W-Q;R^6]PTDK%0
M7'PKXZ_:F^->D?M?> -&^*#ZG^S]X-/QH_9XT34_"FJ?%#PEJWA6?PQXM^#O
M[66HZG<ZIKEK:1:?;VWB/Q1X7\*VNI:-<%;I[W3-'NX)K=BH;.;O.3>K<FW\
MV]_4JG&U."6RC&*MY)+]5_5K_MZTBM(%+!00I#MC:^\NK1HJ/(6DC";I2Q0*
M'0@-DX\@\:_#[6O%'Q3^"OCJRN["VTWX<77C:\URUNA*;FZ7Q3X:M]%MX[%D
M94#VES;RM<"4'Y"F,'=7YA?&']L#QCIW[:?@[6/!>N^-M4_9F^$.J?#/X3_$
MJ]\*::NK_"/Q?XL_:"L-1U+6-8\4>,[6ZN=-@O?A+IFI_ >]\-S12YO+CQKX
MHM3''%;E&](_:(_X*!>/?A7K$UKHWPU\'>$%T3X&?$;XZZGHO[0'C&;P1XI\
M3Z;\,/$]EI%WX"\$6.B6>NVDGBOX@V5TT?A/4[Z>\CL=9FTY+SP[K"7$EF8?
MGW7YJWX_U8TY7HUU3[;/3\K?>?JLHVA0,D,"X8#Y<%B ,G!S@ XQWJ*:0*QR
M.%3>QR@&"2!N+.I3D97Y7\P!E0;E.?QP\2_\%/\ XAZ;IW[0?BG3O@AHMCX3
M^"NB>,;J2W\;>+X_#7B+1-6\%Z]X'TY8_'NG0KJ=[IVE>+X/%MU'I]YINF-:
M>&?[&BUC5-1U73->C&A5_%G[</QZO?&/@GPM87G[/]GX<TSXW_%7X1_$WQ;X
M;\0^)-=\-?$6#1OV:-5^-/@ZW^$GC59=(70?%MG?F\\+Z_926^M7]KXPT(6E
M@TUNT\4Y=;7UT[]7;0%%O9?U9/\ 5?>?LH7&XHK*2#MW A\-\H):-3N"*7BE
M8E@5BF0$!E?$1.23C&><9#8SVR.#CU'!ZCBOPI\2?MO_ !"\;V7PB\*^%I_!
MW@+1O#?Q4_8U\/Z];^(_BKK&K?'7QU+\3O!?@GXI7]_X>TJ/3-$A\9^ Y-.\
M56'@_4=;N;^.[U[Q%X?\;>;9Q0:?;(WV[^Q3^U_XU_:PTJ_\3ZS\,--\$>&-
M0\)>%_&/AF6P\9Z1KNMZ>WB;[2UWX$\9:;:^;=V?C?PK;I -=:WTFQTE/$+7
M?A](HI+*1V?EZO[MQ6>]NB?R>Q]\$9!'J".1D<@]1Z>M?&G[5'[)-A^T'/X4
M\7:/XE/@SXF^!(]0M_#/B.33?[:TF73M2$#WFB:_I/F6[W.F3W5K;W:SVES:
M7UM<Q)+%<8^0_93DA&*C+!20/4XXZ\5&A=D_>  GU*^^""!@G &. >.,UVX#
M'XG*\5#'8.JZ6)I74)QLY6>DERR3C*+BVFI)IIOK8X,QR[ YOA:F6YC0>(PM
M9*4X6?+>,HN,KQ<91E"45*,HR332?0_G&_:;^!WQ2T#4O 'PF^/7B_X)^!_A
M_P#%%M?T>?XK/=:@^G:):>#]!.M7+:CHNN6>FPQ:G?6L7VCPXD^N75G%J%HL
MM[,LD%N)OUJ_9H_9)_9Y^ D=CXG^"VF69U>Z\+V7AC6/%^E^([O43XTMK5S/
M<Z[XBAL[O^P=1\2ZCJ+S7FHZNM@MY+/(T3W#Q1QA=_\ ;8_9OTS]JG]GGQY\
M)+Y[:UU+5+#^U?"]]=2QVMG:^+M'D2]\/3ZK>+I^IWEOHCZE';1:^=-LVU"Z
MT=[RSBEB2>02?*?_  2?^$G[3/P6^ VJ^"?V@M,BTBQL?$UW<?#VVU'49)_$
MEMHMS=2Q36FNZ<MO&FE037$#WT/[Z6YN+V]NI6:&W,%O']]F6=_V_P &K'5<
MU6#S')<7]4K9#%J$<ZIYA.K5>8P;YIREAHN%"I1YN2$81J)1G-\_YCE&0KAS
MCF> HY'4QF69W@?K=/B:I[]3**F7PHT5E=6*Y80A7=Z]&KRJ4VYTY\ZIJ4?U
M3(Q" >PQ]>#R>G)ZGMD\<56J=<F$D@@EG.#C.,MC=C@-C&1V.:@K\U:Y6XWO
MRNU^]M+GZI?F]Y+EOK;M?6VNNA8I&4,,'IU_*EHK<"M,I"$J26 +!!D;RG(&
M!D?RYQZ5\9ZC\+O%_A?QWK-GX7M+S5_#_B>.ZUJUU*^N8]FCZG>R-]JAU&^D
MW7$\:N2]M:A',4>U8W0=/L^8D!2.#GKWJC)@D$A2<\\*"1UP<=CCI@C^O;@\
M=7P$G5I1]HGHZ?\ ,WI&3_P7YDKI=SR\URRAG%.-"NW"4)1<*B?*XI.,I15F
ME::BHNZ=MT]-?FW1O@#IUO%'>ZYKFH-K9"_Z;I(6RB1',SW5HD4R3/-%.\Y9
MYYV>0LB-"8E 2O9]"T+3O#>FV^E:7$T5M;$NC2.9+B29^9I[B9\O--,V7D=^
M=Q)7%=%(%S@ 8'\/8?3ZU5;J?J:JOC\7CIMXFK.46K^S=DHM6MLE_6O46!RC
M+LIC!8+#4Z55)J5:/-*<EU3<V]6W=M+:RO96&,=JN<@C#$AU#IC!.&5@05]5
M8$$<8YKAO%_@KP]XVLHK/Q!:+,8%E_LR_A8QZEI4\JF,W-C>+B:-F5S'-$S/
M#+"SQ/$R.5/;RQF6*6)65&DC>,.RLRH74J&949695)R55E8@$!@2"/EO]JK]
MI+P%^RS\)-7^)'C34HENPLNC^!_#_F";5/%GBRZMMVC:9IUO"K/<L)0)]6*0
M!+&UBD+2K( #Y688W!Y;A,1CLPJJA@,!AJV*Q-1VLJ=*G)J+OW<5;JV[+4][
M*,IS'.L=ALKRC"SQN8XRM2H8'"4XRE*M7KUH4YN*C[S=&FW7TT7+S--(_ #]
MN#XV>(?!G[3E[X(\ ?$CQ+IWPZ_9>M'\0^(;S0-9N]#BO_B/XBB^W76CS6UI
M,FG76H:'I5W;:;=+%;V\/VFXO/M,9=5"_J?^QY^UW\8HOV5--UC]H:76]6^)
M>OZ+KGBO0]=BT>P-]I6CWK277AK1?$.@K-INJ27-G9KYCW]C:WB75E<VLI8W
M!8R_@-X$^&WB7XM?%'P'\-_%UG?7OB#XK^*]<^,_QSGN$N&G/A*PO)?$NMVU
MY(Q6Y5]0AN=.T:(J$0^2UU$/*NK>*/\ JR^*!\!:Q\-]7T9+/P[JTMQH(T'0
M=/5M*ED@O-1<:5I5EI\:6WVA+6U6>P1(HI?+_=&/&%*U^&>#:S[BS/.+>.,9
MB,3'*\9C*>'RS"2E+ZNL%AI3ITY1BO=YO9TX/FDG.TE:2U/Z;^DW/A?@#@3@
MWPTRO"X!\383(<+Q)C,YA3HK&58XJ&89?*'M/XWL\9FE/%8O$1O",94\J5))
M5'$^@_ WQ<\$>*M%TJ:W\6:#/J-Y9V<US:F_CLKT7-S:PR3A[#5ETN:$+*S*
M%4S$@#!?K7IH>"0;XI/.5N5:%K:56![C9<EL'J"4%?%K?L\^"KS2]/C677]!
MNK>PLE)TZ_M+NR65+2%7_P!"\11ZG BA@04L(K9L@A6!KF)?@1XETYY&\/\
MQ!506^1;O3]6TPA3]T//HFMZ>'8 ?,R1QJ3R%4';7[[6I1=6;IWY'*\>;62C
MI\2]U7[KU7I_+-&JH4:,*C7M(T::J6O;GY(<S3>NLF]6[W\[GWH^2O1B>H(1
M\=^IQ@>^6 '4L!5&3'0L=Q.<*J-[G@39/![ D>AQ7PT/ 7QKLR%3X@(W/RD>
M-O&T6WL"([FTN"V.R*^3@ -W#)/ 7QKNB4E^("D/][S?%_C2:/ Y.Z&&&T=Q
MQP!<1@-AF+ %6SC2DG?7M>RLEHNGRZE_6*??33OY=+?K^3M]GWS>6"\A54+
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MCKMS=RMQ"UC)%<V<<#)B1@TC,!E0/R^^%/[8/Q"E_:Z\?>*M4T[XN^,?@?\
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MU-'WF_X#_*G5Q/?Y1_)'I+;YR_-A1112&%%%% !1110 4444 %%%% !1110
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M+7"R*1(MQ^^5A( U?1WQ0T./4/#TNI17,EGJ/A^UN+NVN/)^T0S[M_\ HUQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% #=O^TWYT;?]IOSIU% #=OT/^\,G\\CBC;_ +O_ 'S_ /7IU% #=O\ N_\
M?/\ ]>C;_N_]\_\ UZ=10 W;_N_]\_\ UZ-O^[_WS_\ 7IU% #=O^[_WS_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV4XXR.73ERU+\T,-4Q%:>#@E+6,8X65*,4[M179HDHHHKX<_8 HHHH ****
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M?D_[^2?_ !5'*NR^[T\_+\?6YSR\ON_K^F_*W[(_\/9=,_Z(UJ/_ (5FG?\
MR)1_P]ETS_HC6H_^%9IW_P B5^-WS?WY/^_DG_Q5'S?WY/\ OY)_\51RKLON
M]//R_'UN<\O+[OZ_IORM^R/_  ]ETS_HC6H_^%9IW_R)1_P]ETS_ *(UJ/\
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MGY?CZW.>7E]W]?TWY6_9'_A[+IG_ $1K4?\ PK-._P#D2C_A[+IG_1&M1_\
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MD?\ A[+IG_1&M1_\*S3O_D2C_A[+IG_1&M1_\*S3O_D2OQN^;^_)_P!_)/\
MXJCYO[\G_?R3_P"*HY5V7W>GGY?CZW.>7E]W]?TWY6_9'_A[+IG_ $1K4?\
MPK-._P#D2C_A[+IG_1&M1_\ "LT[_P"1*_&[YO[\G_?R3_XJCYO[\G_?R3_X
MJCE79?=Z>?E^/K<YY>7W?U_3?E;]D?\ A[+IG_1&M1_\*S3O_D2C_A[+IG_1
M&M1_\*S3O_D2OQN^;^_)_P!_)/\ XJCYO[\G_?R3_P"*HY5V7W>GGY?CZW.>
M7E]W]?TWY6_9'_A[+IG_ $1K4?\ PK-._P#D2C_A[+IG_1&M1_\ "LT[_P"1
M*_&[YO[\G_?R3_XJCYO[\G_?R3_XJCE79?=Z>?E^/K<YY>7W?U_3?E;]D?\
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M;^_)_P!_)/\ XJCYO[\G_?R3_P"*I<J[+[O3S\OQ];X\\O+[OZ_IORM^R/\
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MNM^GSF=JD)TYJ,H5(N$XR2:E&22::?1I=+=3XP_:8_8YU7PL=4^+WP(TZ_\
M&WP&O;B>ZO;32K>;4O%_PANII9I3H?CS0X'O;^+1H$ ATCQ5;FXLM50>8\=J
M$8U\ W#Q+&ZFZ@10?+DEG6")(&8;5$WVH>7G)^X\<B,.&0CY3^\OACQ1XE\%
MZS'K_A/6]2\.ZS"&C34=)N!:3R6[G=+:7BQ*(=2L+@[6NK#4XKNTNR ;J";
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MUN<\O+[OZ_IORM^R/_#V73/^B-:C_P"%9IW_ ,B4?\/9=,_Z(UJ/_A6:=_\
M(E?C=\W]^3_OY)_\51\W]^3_ +^2?_%4<J[+[O3S\OQ];G/+R^[^OZ;\K?LC
M_P /9=,_Z(UJ/_A6:=_\B4?\/9=,_P"B-:C_ .%9IW_R)7XW?-_?D_[^2?\
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M1M!!*(Q/)&Q=Y)YKO+,C*H&W;5]4M^]K/?\ X*MWLC2"4IW=F[?$U=ZM=_\
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M^.2JCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQDOS</J]OIEEKDVG26-S]FN==M]+06PN/M"746G'Y9I-)6Q,A8(IK\R:!/\
MR_(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (_\
MEI_G^[7]''_!.S_DUCP3_P!ASQO_ .I3J=?SC_\ +3_/]VOZ./\ @G9_R:QX
M)_[#GC?_ -2G4Z>(^"G_ ((_^E0-X[+T7Y'W)1117,,_/C_@I;_R;9<?]COX
M7_E?U_/*_P#KE^J?S%?T-?\ !2W_ )-LN/\ L=_"_P#*_K^>5_\ 7+]4_F*Z
M\+O/_!/\D8/?Y1_)%FBBBH$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %='X<\8^,/!T]Q=^#O%_BCPC=W2Q1W5QX
M8\0ZOH4M]#"SLEM>G3KF*.XMP9'*I-&WS,P9MNU:YRB@#V'X1?&'5OAG\7]
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .#P1D'J,@9'<9) &?4D
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MI!$DB32#3'L/.N(()V55B>.3Y#I0<=@0>H(S[@@]596 =64JP91SC()>WST
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MGQ^U .3X:\*$#KGQKI 'YX%+_P ._/VG/^A9\)?^%QI%?OPX&T\#MV'J*K.
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M-/AE^S)XI_:]_:S^)O@J?QT/A!X:\4>'?!>@>"/A[9WBV4OC?XH_$7Q7G2_
M^BOKZP:7X=N$M+Z;7M5^UVS^5:RP;N95$]>FEW?TZ6NWKMOY'3[)]^K6B[6N
M_+?<^.-9\.ZEH%]9Z9J,<9O;V":Z@2UD:Y1H%8!%9HX]HF']W<.,DCO3%\.:
MQ()RENLOV6,RR>5<0@A=I8"2%LR;N,;%PV>!S7V9X=U;X;?'3X::O\3/B)X(
M\2_L.>-?@AXHNOA]\7?!/QHUK0;#3M&\2:M;1W]G-I'C*.<^%?''A37+1_\
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M%Q,DJ78N].P+ZW,4K3+$T4K+A>.O@[\,_"FD:6/$O[3OP_\ A[\-_&4+:O\
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M6\RRH#_O*3CCG#8(HYY+>/Y^7_!_#MJK1[K_ ,"]/+U_K;^=[_AW/^U#_P!
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M_G\::J)?$E;OKUM9;]]/GTL9NSV3OVO?MKMVNW^!_/W_ ,.[/VGO^@'X)_\
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M^\D>A#*\7/+<1FJIWPF&DHSFI+5OETMK;XO/1K31GXW_ /#OW]I/_H#^#/\
MPM],_P#C5-/[ '[2(.#HWA//^QXSTEE_ E5)]\@<Y'O7[S, 3T&.W YY//\
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M.)=AB>5TQB$#<6.P8-?MVMPD>BIK%J7\R3SX-ILO,(THC$9D9F#&3' +_,2
M0!@FH](MD@TS]PMWHMH0\DJA%\V\EN,K&\[#+?OF8*LLF=HX!^7%+G7G^=MN
MJ]==K?,%!OM^/^7Y77F?BW)\!OB] P^T^#-2ME8(4$J#>R2,$CE"@!OG9E[!
M0&SC S4G_"A_BN%E9?!^HR"W95=A!(^\L#@!4Z?[W"]N2<5^VNIVZ:G<++).
MT:/-9I+YEY+]JB%LT>Q8(L+E?,53(H*AH]Y(-;=I=16JLH^WQB<W5O*DFQHK
MR!$:;[1 Z$O'*CPQ1@9&!(PZXJN:+>E]O)ZZ=5T5_P -;!R.V]W;[[V^7>^O
M;N?AC_PH/XM!_+E\%:M#^Z,_F,J;=@[ %>.O.[)Z8/6H6^!7Q854D'@O4C'*
M $)4MGDC=E,#!X/0# Z"OVQDO+1]/LQ>7]S;F:Y#J&,DK;'<K';R29:=F.21
M$A(X.Y>E:'DWEH)K6*[$$5@XNGBO+=Y9KBP50\GV7#;EW#Y8EV^9N#'!!S24
MD[V\MVO5_<K]%ZZ,.1]_P?E_G_P=[?B"?@-\6% W^#M34]2SA4CY.1@E<GC@
M\\<_@/\  ?XKHD,K^#]2C6YW"$84@E<@8)7+!CS@'('7UK]N[FVU>]?,MI E
MC<PFXAN&N9)'C>(>9$OV+*2KOC"[D+G<<@]<5AZEJ$P-U=2+YA@2&"9X7\N/
M3+IE"9CM02$5X"'W!/E<Y8EAP<T?/>V_IY=>^VJ^8H-]5^/EOY_Y>MOQ>_X4
M9\5#\S>#M02/B(MY;\2@\GG/WC\O.!R,8IS? ;XL%TB7PAJ:RR'"*(2Q*X)W
MX(Z=!Z#(K]H=.O+Z^6[U"TD2TL1<RW+I>J\L;QW/V=#(MV7*6I40R/#&82J2
M2 ;5#EJLR[II9)8A>2?9W2YM$TS5?,GN#:!;F1+@RQQK%<>7&2MNCFVDMC,K
MJ7\K*YE:[[7Z;>5]=]+VU>V@<C[K\7V_1GXG#X%?%A06D\(ZDH+O&-\)7+18
M#D< ]6&0>G'K3O\ A1OQ5VECX.U(J,YD4!0"!G;\PQG'/T/XU^TBWD#0W6JZ
MG'=VBS7,EOI-I!>RW4<LBA9M0U*=6.8VN(+Y$:! 8HGLP8P#BJNH2WEC:QVQ
MBEG@$4I%_$LC03Q2#S+:!YMSE)XK5HI99 AYD(WLRL%?,O/_ (>UM/2[[V6W
M<Y//7LUZ=F^Y^,B_!#XGE%8^%KR/.?FF4A3@D'!7"G_/K3_^%%_%?ROM(\&Z
M@UL)Q:^<L<A!F,>\%?8C&!@]N3UK]CHF&HVLFD->66HV+V46HQW%I--]JTL1
MOF2SN)U1!,TK!I"Y(*I( <A:N6UTTEH1IUU/)'$1.NFW,BX>^B7RH]/C96/^
MLMP+E9SSC )SP5SQM?7^FOD_O#D??7\/O^_^F?C'+\"_BO;%([KP?JL;S+&T
M+- P#^:ZHHQC'!;.?4 'C-(/@=\4UDD#>$=1(MI7BGS$P'[L@.WM]X< CGMV
MK]D]0U"YU"QM&:]@T]XIF-PD]Y+.T<<(,DBJP<LI55)"KC!"D#.*??W=TEG>
M-;ZA82PW&DQW<D:7#QWE]!<SVR02HSAGBDVLRRE<.Q*DMP#1SQUW\G=>72U^
MK_X=!R/NOZM_P?P/QJG^!GQ3AB65O"NH"&1B4F\D\$D;(CQ_%R,XW<=:@'P1
M^*8C:X;PI?BVAD*W$K*$V2[4)M\,,_*C1R9[^:>3@8_9K6)9EL&M;*6.XO87
MABCTFVNY[O81&CQFXN"-D<K;F,8#;FVR#G'&6FH17:66G:KM%S>7%K;7\"2-
M']CC;YUEE Q%)( <M,^6:+RE+;43!SQTT>J[K>W^=]-WII<.1]U_5O\ @_@?
MC?=?!_XB6-K)?7V@SVMC$J22W<[I%#!YDA2..:5@(EW$!L]@0"1SC.'P[\3;
ME3R].E,DDD2^3JUB?FC)5LDM@<KSD\ D]A7W5\>/B2(+?7_!NG-;ZJ7DNH+J
M._9+738=*LV:*.5(HE<:C.)49@83%+@@9RH+?#WA W6JK/;QZ-I-M?7=Y::-
MI.KFXO-/=[J^O);622WM)3-')&/M8<3 &54C#,<H")=172L]?Z\_QL4J3:W7
MGY;?YOUMMN5K#X>>)=5G\C24TS59Y"ZP6=CK.G7ETS6Q"WJE+:0G,#$#&.XZ
M\UOK\$?BI*PCB\'WQ9CUWJ=J]VQWQ[\5]B_!?X,S> -5D\4^)8XM*32;.]L(
M;;P]J0NAJ.HZPP_TO;,AZ.5=A(A7*_-UP/I/P]IYT2<Z5JFN:AJ\UY)*;S5)
M'>S.GQ$&2$7MP66WBFC#!(X;10MQD[S\H!?.NWX^GHM=?07L_/\  _):^^$W
MC[2K*YU#4]"N;.QA>.V-W.0MO'=2SQ11B5HDDE4.695V1/R<$ CEM_\ "[QK
MI<HAU+3+.P>02S6PO-5LK,W=J"2US E[+;S/;PQC/FF)<N'5@2A!_1/XZ_$7
M3/A+\.;SQA=:3<7\ZZOIMEIHE9KR R75V84OI82%B@QM1]\HQN*88$KG\Y_C
M%KWB7XE:IH'Q>LO%!E\+66+75;'4+@V4VG^;);I<%[3#O>:>YD(619,2 2H%
M"IEAU(KHUU^7?IM_P79/05._7?;UNOZZ%FR^$OCS4H!>:9I":I9E@@ELKNVN
M8V!X65)K=WBD#=3L8A22K ,K 7+KX*_$JS^:Z\,W5K$2)4DN)X8U>", .0#@
M@.1N.>F<#%<#\;?B)XO\+_$/1M6^'GB0QZ#9>'_#%QIUMX,U:2V\.V\-C)>3
M:HMWHR-#%-=W=U/)YWVCS&8[$&(1$B_9/Q>L?C5XU\,>#O$6@2W$.EWT?AZ.
MYN(/M!O(#<[&U:6ZT=9]]QYL[N3LD6, _NXP@"A>TC;9O;9JW3R[-Z^FG0?L
M]O>W[K\>UCY/3P3K4M[#I*7.@RZI=S2I:6%GKNG76H2O P#0K:QS/)(\A("H
MBER>!S742? _XJ*K7#>$-02V:5H(F*%06C0,[AF&"<'IGV SC/WWX'^$/ACP
MM%I.OOH.G7GB:SL(9KC6+U=.;5(;Z]46%[/I\2RF=K:-T%PDAVW0;YX_F.ZO
M<K6_OY;2WCLGN=6M[^#R4L+FWN0RF G[5=*\LC;6VDXD4@R#"[C@52FGNG\G
M_P #\$A>S\_P/R17X(_%*3RQ#X2OY#(6$(4!S.RC+CY -HC0A^,9'4XIY^"'
MQ.10\WA6_BC4G+F)OG+Y1!D]-K@@8ZXYZD5^R-Y"EO\ 9[K3;*[B:R@A4A9)
M8!;R2@H78>9AP_W9#Z#+$CI@)=2^3:(LUU#JLTMR\\MV)K_1XQ9EIA+A)&"R
MR"Y55A"%2(U<#/S4.2VL^FSO?;;;K?\ (2A?K_P-M_Q_ _(__A1?Q1P0WAJX
MMV("QM<31(9W7AO*A($F20>,8)R5^7%?OQ^PGX4\0>"_V:O!FB^);!M/U5-1
M\4W;6Y8.RP:CXAO[BVE95'RM)%(KE.J\Y%?/^K6>DVIT^]UB::;5;*$"*YE7
MRK>5H^#]EA9CYLDP&Y&ER59L A0!7W5\$[J"]^&GAZ\A\\)<2:S*PN6S<1A]
M8U-C%(P)PT/^K(4D*4 7Y0H$RE=-6:]?O_K_ (.FJT26FB7X*V^YZY11168'
M&>-QNT9@.3]IB'Z8KPV:$ @CH>,<G/7U_P ^QKW;Q@A.DL!C)NHS^'%>/30C
M(XXSP>1Q_G\_?%=E%W@EV;V]$N_9(\_%4UIJ][[KLEV.4N;<,&Q_^OD'O^?]
M1R3AS6^%=652&!4AN5/?E>A)]#@'KZUV<T(!/''/_P!?'L/0]/QK'N;8,#@=
M#_C_ /6/X\<\UJU;5.Z_X"=G]_=G-:,8O66EGT[I=OO5O^#YAJ'AJSE+7-N7
MTZ\3)BO],7R;B(\D-);DFTOD+$!XIX]Y!(5@,"N:-S?Z5>V\^JRRV-[;3*=+
M\2Z.9+9VG8 IYB[VCTVX<D+<K?)=Z;.-RQPH6#+ZQ/ 02",Y[>OZ#GN".N,]
M36#>V*S13QNJ2PW*B.:&49$B[< AL$HR\@%1GOD$\Q**DK;:WTZ^O^>C71F;
M4O=M)K5233WM;35-]7===+:Z'NOPU^*S:R\'A[Q5Y%MXC,&RVOH?W6F:_# J
M@3PH686E_,O[QK96V;F*6[R!17NY(P1ZKGH<8/3G& ?8G/MP:_-@VQTB6STF
M:>4Z7+=H^BZBS%;_ ,/:C;2;M-L7O<Y*QW.+_29&W?NRMK(I09K[*^%7CZ;Q
M;IT^GZPT?_"3Z2EK'JC1HL$&HQS1%X=6M[09\GSVCE@N(AQ;7$,T89U0,>>I
M3Y;-/5IMW[JU[:+S=ON/1P^(YGR3TM9)[-^K;M=>7R/5Z*0D!@IZGD?Y_P *
M6L%?JK?._P SM=M+:Z?C^!')V_'^E1U))V_'^E1TQ$#=3]3_ #I*5NI^I_G2
M4 5ZC/WG_P!T_P A4E1G[S_[I_D*"9_"_E^:*[?Q_P# :DJ-OX_^ U)6E/K\
MOU,0K/?^+_@7]:T*SW( <D@ ;B2S*J@#.2S,0J@=2S$*!R2!S6\-WZ?JC.IT
M^?Z%5_NG\/YBJS]!]?Z&K3 DE!DL1E%9'C,N/F/V<2JGVG"@MFW\U6 .PL2
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M'Q67O$EEEMH;1DM()2)W/E@Y#A4.(_F"GY3C@C/LGAC3/AC!IFHZMXNTB_\
M$UH\$<<FZY'V:TO2@\Y(T5GBG DWA9&)>3[S<DBOEKPQK4GBV^U&SL?#UGIJ
M0W+LUPT37D%I$7+,6:9EQYF2ZJ!C+8Z]/I'PO;VXBCTK4K24:3;-;7UNB0?8
M[#4+CRU>2Y,<;S+(\\A,OER.F-V#@C@_KN%^S=M]K=MK7_R5M#YC^(GBK0O
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M, L9?O %FQ4UW8V-U#+;-;K'/J5U;7[3VDWEW!1XVCMH) ^" 3"\Q5@<*I#
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MXUX1UJ70)K9M/)L8='0%;6WDN(1+JJVRQZI>:C!"[-.UQ*JRPE1,5,894R2
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MX&3DV)))QU))]2:[YONR_P">YJHW0_0_RJ7*3W;^\I*VB//KOX;?#JZ7RY_
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M?_&!_%.KQW^M-K]O;Q:FSZQ;R27XNKBPMC?O:MIS7$?]FRS6^$$TTDT?GDA
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M580QNVE#QG;@+$?Q+?4[=;;5$B6:*7$$$6K,Z))97<V3!)#$RGS&!)7@8.X
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MO! \KW@WV_D6\<D)9$NRS,J !-NUKZ;6O;^O\_,:M=/L_P -/\NQY?8Z_?\
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MUN+N!8+?4A///:QI;^7*08OL2R0K)$;8+S_:'E"!0!%Y08Y%1T2OK^#M=?\
M#:7ZF;\O+_@[_P!=K'6!(TLH9KRWEG6*XN8YKAX+..8R,WE^;9SI,!/$6(RR
MK&=FY@&Q@X,FG/*-5CM-3L+>%;>,RK;3")X)E*A/M4LR(9X2CMYRPJ%# #SA
M@9R[Z2T32[J/3EMKRZTF)(UCMI9;^=HVE87BB)C'#)Y,1BD0HL13YW9GPHKY
MM^*_C]X9;#P1'?QVD$T4#ZSJ>F[KK5$MKT%K>Q666X*VB.JO]J8_:2DD<82
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M%9'Q!(FIOI#7:J\]LM[Y?FQ!VUXBXQAQ1E^/P^)X3XAS# Y=AJ[RRGE>=8?
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M,[I$:7'(RV1NX'0GK@8SC)& .G'J'A)]^EHP!4&XDPI.<#8W\\9_*IGM\_\
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M, L>53U88/OVJ&TFVK<Z;8W#))&B65TC7*$P7'VI4N&BM6C+.C)D*S.P(RP
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M%4:4]6EI'?\ PH[\/_ I_P"']1LG;\?Z5'3I&'!YQSS@X[>U,!!Z=/7I_/\
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M$=65AR"5+*0,!@2O>OH?P3\5UU&2+1_%<D<=Y*RQ6&KPQB..X<#"1WZ$X$S
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MN?'$&FV]BFG>%=;TY=4NU\*_:._8T_;&^(7ACX^>#+#P;X$:P\?_ +,_P?\
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M9IW1 RKJ"DYS@8)&?$_$US!X1O[*\(TZXLKZ.ZU/S+BYF>?S2CN%U$[_ ++
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M\._#Z._\,&Z\$>$-/+ZY,GBA-7LVU:PMK5CJ"Z%*9=0U5HOL<4<KNBMZF2\
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M (7TZLM>[UT2LKI]K?A;3KLEH;'QEU"]6ZD\.7NNI';:S:G3S=:;=;'!A47
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M<:= ^HPVUW+JE\[/J>D0Q745S?K?0V$<3$O,2/OA0'&7^(K3Q7XC7_A(=?\
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M6]L[677UUBPB\*7NDO<1#7--U7Q!IC.M_P"'==TZ&73[W3I;>)[NRN)+>_M
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MMDG^N^S6B.X1$1FV3>6 2,[R<C'S+I/A74HO&DTEM-(VA1M=6\TJWLH:&1B
M8X]K$H#C&!@'.#UY_2OX6?%L?"SP7;^%+CP?.=4M6>X)>[$*7XU(?;8+F5VP
MS-]G94WJ1.(QMC8=*J-KZZ)>KOL_ZWV%*_K?77L[=.CLKWW=]3ZD\0Z]X%^
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MCI=Y/JWBW6;[[1/-INE:9I<DUZ(S<BYO9VNX558\+&K6R8.W:&(#MDJ"/O\
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MD  3:#Y9*@'Y0>^3YU)'-+<K_K(U.\><2V&AP"(V.[)7AB5.<[B<5Z?X./\
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M1HT\QX;RO&4:=>MB/]KRS#5JDL3B7#ZS7YZE-R4JS47-VO.45*3;NSY T?\
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M^/GAV]UW2O#=S8:3>ZK>:/XH@D2.UT^YU 1V-U%^_EEAMHY6$,>U5>0J$20
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MX?B.*NTNYTOA31'U[7K"P(/V>.9;N\.UB!!!\ZAB!@!G  +8Y(Q7TY<A0@"
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M:Z66VR7NNUV_/Y/?N3?"K]E/XD?"/XM?&CP78_&[QEX;^!$?[&W[/O[/EO\
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MKU31[/PW:37]Y<ZCXAN+ZR@VZ+-<:9']DU"[@;]U?0VRR SQ01(/,C=/F?\
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M;S2[O%S)=)97KP(D=T%D666P+_:"KJ60C!KY3^%W[&W[<_[$GP'L_A[^P_\
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MD:1HOB?7[6[B\0Z+HEU-<Z;INJV%]/:7=K9S7 $TD,"QHTC2 .KDC&TH3]*
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M=ZF%[J[V:5ON>_\ 7Y"2C?3M?KY6_/\ S\N?6VAM($M[9!';Q )#$H $:#:
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MH#Y!"+O5Y-Q(SF78JC&<8/TK\=/C1X9T#Q;XT\;W5Y<70>\\2:CHFF6-[=M
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M@;?&%W,A"_&FF?8/!>K11)IL]V[03O;_ "2)IMYY,C&,;)8PINFR/+1G?)#
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MLOA^*WAM]-O#:^4\D2+9HFB0.,VT++'&&"@D:O\ UZ/\T@C)W7W;:]/\DO\
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MAO2?"VM:!=7=];ZE;#2=5TY]-UK3KNX^P/%?2.=1:U$D8O)-0MHV7@Q>0N"
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M$6W2;15\,R>(/",YO_ FF:;>ZLMC<6VM:)?QP2G44EDEDU.RU256*BY#Q/)
M"^W<5.5&XJW0/&]_IOC'PU)K>F6EKK GDM-$\52VR:6VI):R+8SWET;F1+-K
M*VN)BOE^3$Y9%?>T08GU?Q/X9N/ ?BFX\=Z!JFC17?B"+[9KEAJMPCZ3/>6=
MK<NVL:5<H'L[>YNDED6*.+?)(\IAB23S6*B\M%=;+=:>7Y:+U0]]]6[+71_9
MMT>VUVM>[.F\(ZOX2ETJ/Q+J4$4FN1)=C5)+$RI<:;=VQLU%E;:=&'CU2>QB
MND3>2$M@/E9A/D\'XQ\9^%=1&H:58WPU::WUVTGMIK*Z%MK,:W1M!++<6H8)
M&T"!Y+F.XE1!'$P1=W!M^*-.TK4DM_B#X(5+C^T=3M]4O=+O1=03:J+=4A%R
M8 B(IU+R[IE@B6-L6Z&8,)8MO/WMK\/[7XB6?BWP_IUQHFI^(]"%KXC75]/_
M '%F_FNT5T\%P!;()6-U:0>2[SLFYI !Y8(]5;3IKO?;OW];]KL2LGUV3OVV
M?;Y*^FJ.]\87VF^);73K'3_$D":7=7*V!@AMK9+_ $[4K:U>*#7;D0LXETRY
M9E5/M$GDLY)D"D8'SWXBUO6M,=O!AO=(L1I4-I)?>*!';C4=2U+>ZW\=];(1
M:06C6PB>V^P2-]H*E9-K&O>=3T#0/%VCZQINF27^A:K ]M'J:Z=IY@F&BPI)
M<(LM_ #:V-M/(8H[:.60"8R#>5)P/D?7/AMXAC\0:@^@:#K%QI.M6T>F9UF-
M[YYY(6WB*WG+$*ZR\M.I!5>/N $%KO7K]VC6GWWTOW[Z'3>UK7TLUMJDGY[Z
M7MWL>U:-XX\;+!:VX^Q^,=4T:ZFDM=6MP]I8Z%:P6Y6TM;BWFM)/,-R'CP@;
MRV8Y+9P*3Q+X#M/".E:7XWM]9U"S\3>*KI[WQ5HUK<K?W5O+?RAPOV17)T[2
MI&C279:Q</'%D*=JGH].U/2/A[8W<']DPVEP8M+N=1OYXI1#?WP2U6XL#&V2
M&MECD4R!6C8J2#G;7C'CWXB7'BZ]FU;1(3I=W=7MO8W]_P"7]DB6QA;SHXHY
MW&/+*VX5/E&^4QTGYZOSLE;2^NVENC;7G:X^B6UM7:]WJM;;[:W:MM;>Q?U+
MQ?XA\)WUWJLUS)<>#[BVTB6&,Q,GF7UK>S"[>2Z(%Q$R P&)+C8)-S>6#LDQ
M[!HWCXZIH6J>(=$:28^*+>^2/3VLA-!#<6[,B7.H3PB1@ZEL*R;VVHA88QGQ
M7Q6FJC1D\.ZU>0+X7NK32M7\GRX[N6[827=S:K?75N7N8[T,MPHM@@1TD#$F
MO7/@AXC\*MX?C6XBO--N)Y+JVMVAL5CO1HI6Y\^\CL7E1R8KLQ0P2&/,V^0L
MP,0HC?3JEIVV2MIKW>M[/ST%9K3NEH_EI?37;3MUT.>^'6@16]G>76HVMAKD
M^G7J:C'=7\<T]X-5OIR$T_3YS)%';A<O/Y#I+,T$>Y8V8A#[?9:MJ5S_ &C&
M=1M;DV\L:VUO'IS'2[R9W'^AKJ)19[6Z"X\M50>8=HFV$L!Y=_:EEHWGW-IJ
M5Y"_FV[7EI<:=+=LMX) JZI):IN\J>WB9X(YY@"L>UAP$SUPUBQGO=.T]=0N
MI=":SN;]H+:62W2_U4$M #9M&MS,YAQYD@(&XLZG'(<=$KOR6UGUNM%_7F.^
MVEM=DEHGRV\[^>CN]'T.FB^)/BR'Q+I&B^'&U"T31;E8KQ;:'[1;""_;<)-2
M5%4BW6YRBLK$CR6] #^B]G]AFLM.N)K(HS1$M>P,PM[EIH[9YHV97=8U:X62
M14=5.P] <BOS.622*T>Z,)%K)+&T-QJ5^!86-K%_J-+-M:'[1*D$SR3"2Y<O
MN?!4;23^B'P1D\6:QX+LGO+$6)E>.#3880T.D:G9HIW7EJ]VN7,F%#2 [T)*
MC*DXI:]'_EMY?TWOT):MOI\DOP6WKJG][/6KVUDG@M[M9;=)88H9H[:(E(5A
MMR%*^8B[BL@FQ<*QWG;&45MK8??Z'I-A$MNRQQSW$$TUG8?VC)]A@O)HHY)+
ME;LAL3*A0R6SL%6+RB%WNP'0QPBYN$L)+?4[5K4PSB'S+?=%-;AQ(VU0?-MW
M\P;5? ?9G VD5+<: \5G"AMS<0ZI>M';B4PW(CB4^9?23;V46LDBR*AF<[-B
M)&C9C8"K?.UNE]K)Z/5VOZ:>>D^O7_-6U7]>;LV<A=>%XOL>E7-M,MC=JD<$
MEPJBZCNVN499;N4;2EM%E7AAD4!Y'"S,!O+5QUIH45JDUVME/<0Z9;7K#4-2
MB5$C1<$M),'VR#+A-R!BS#*Y!!'J5G;W*QQ:;=.+V*#4I9+5(G$BR:;:O*\-
MBUCA2ZQ[RA8R$.R;DRC(:OZ?/,;6\^PV;6EW<R26UQ=RVJ+=V>EM L1M[C3W
M,L=C9LT:M;S31E7!41N>&);6WHOGIMWW[I=4[.P_3J>(3:,FN6$%G)8V M[R
MUO98<!7:5;E?L%Y#()D+B2.1!+&63;Y+!D)8$5S'ACX/^%_#9U#18[3_ (2"
MZO)(YTFU3-X4DM4CC;3UN4@2XM+*R+G9)%N3:1UQQ[:VG0K?06UW-&FK7TQD
M@^P*K3/#;0+;PQ0V\66MV(#2,2H\QV)).VMR\TBWGEM=.TX1SZG<6Y\PRS-+
M-:6MMAV@-N_E!WD.-\CR!G!P0V!A6TO]_P"GW_UN!C:1X1%IL2R-OIUUIS._
MV&RM+5H(8T1#&D7EN'NMS%P)9,S''S@#KU&HV1T^'3[V6WM/(>9[2XMOL=J)
M,NBS+=2>9(K0RL\Q62,@?NTC89)K.O+FZ7R[@:9!9Q-;2(LYEC@M;:>QV?Z1
M%(KED )!O26( ,(Y!)K=ECMM5T^":]U.VT\W\]M+,\<T06>]D1(%D^;>"9(;
M8,C;@614) R2*TL[7T2WT6K71W7;?3=[)!_7]?B4#IAGEN(]/LQ=Q)IXN+F[
MWB&XM9'?RYX6=&>(P&VBA^SK$"X4$,H)K4FN'U^%(H&6#RH3<265BKR?9=0/
MS+.BSQQA8V)+2JRHV[)"CH'6PNFBO+&&\CETX77V:.5$=&F@51)%=&_@#+/+
M)*2HA&8T $18LIJ[%>RVHFB66SEGU"*TTJ4K_H=S8ZAYAMGCE4J&E=2C>=(!
M@R[L$C!JEK=7T[K5O2UKI:[7[M6;T30ME]RVMOIM^GXHQYX=8@^RVACBBM++
M3$GNKR2UCFBG* ^7+)NF6)Y(\!RN_:>FXY%4--BCO'$M]?6PEO8 LTJE[:;4
M]/B;>)8(65R/**J!;!T,H##&,$]/J<EY/!8:,TT< @M(+JV\ETCCC-N%+),E
MP1)<(.AB(PX(!YQ6;_:$#7%O-_9[QR/?0RRK=F.Z\NZB^4W,4*#S+2TD !,<
M8,2#+L.2:32[O2WI9)=N;1)]5UW>HD]4M]W=>6FO1_+;MU+*:/%??V<9[YX;
M6%+V[B^PE[2,*T<PD9[23+I<22R (=S(47'!P*5AK$,HN[:YN);HW9M8K'4K
M:5[>^@N+>(!\%"?-MXR)#,N8E&%#E@0,Q]3U34K:_A#6IMKO[9$LTC+$ZL&.
MYXI8P94@5<&/*@$Y&*M0ZU,NRZBEN;EM+2'3I))+P31&)X%$SJ9 K*@1P!,@
M9@=PR".#3S5^JNM$EZOS]&];Z#UZ[^5K].]OG]^FRW0\UG<VD:02V<D"&RN2
M+N0V\QO'D'V^9T23,229$2S,&5-JA !@?5?PTCD@\%:+'(S2O&LZ&0E2TVV_
ME7SMR@(1)C?D8ZGY1TKX^ECCN[/3]/@N,1_;FGM=/U".[F:X@CDENMUGJ$0!
M&+AW*"3>F %.!\H^O?A8+W_A!= -\TCW;02M,9=OFAS>REQ*%&T2*=P<* -P
M./6E+;SOIM:W*M-/ETMV[ NE^WGY=;^FFOJST:BBBH&13?</U%5*LMR2#R,G
M@\CKZ56H " >#4;J  1ZU)1@'J,T 5BH/4?SJ)@ 2!_GBK+@ \#'']34>!Z#
M\J *VU3V_4_XU\]?M+> _"7C/X>N?%.CQ:R-,U_PO>62SRW,?D7-UXBT33[B
M=/LTT!\R6UE=&R2I8AMN17T0>I^I_G7DOQK93\.]10Y+OJO@U%/'#2>*-" /
M/)(<J_'< ]>FU"4H5(SA)QDMI1;35VMFM5<Y\70HXC"UZ5>E3K4Y12E"I%3C
M)-ZIQ::=S\[?V?O^"9G[#-OXR\1>-K?X >&U\3:)KEO>:7J,NH>(+@6=QJVC
M2#4)([:YU66U8SB>;(>%U0ONC5&56'V1XA_8H_9PU>U1;;X=:;H>I6WVB33-
M<T22>PU?2+FXC5)+NQOUD9K>5A'&&+*\<@4(4.XUU7P#!_XK64G(?5='C&?5
M-(7GZGOP/\?H9I%1@#U[=.,Y]>A_4=:ZIYACHU;PQ6(4H\K5JL[Z):Z/M9?K
MJ>+#AKAV>"5&MDV6.A5C:<'@J$DW>]VG3>U_=>\=T[GYA^)_V =5\72V6DZM
M\8]8F\*V-[87@AB\/:3;^*F_LZ\BOK$QZT+^/3S+#<0HS7;Z1<33!?FPV6/H
MNB_L,>%-+O9=3N?B+\19KN2W-B91>Z;8QO$B;(VU"W2TA&J7,:X6*XN%9D&=
MLC@5]X2*!P &#\'(SG!&-QX!P>F<XP,8J,F4'@*/3@GCC&1R.F,?I71#/<VI
MI.GBZ\&OMJI-R>VKDY-O9+7HDK66OF1\/>#(UI8B61X6OB)N'-*=-U(VA%*"
MBIN2C&";45%)1YGM=V^4=!_8F_9ATK1_[-U?X-^ /&MY/JM[K^I>(?&O@_PY
MKWB#5?$&I&$W^LWNHW>GS3?;;@P1@F*41HH*QJ S9\-^+?\ P3%_9O\ &6B(
MWP\\.P?"'QM8:I::UHWC?PTEUK-S9RQ6[V5UI<^EZOJ$D#6-]92/;SQ0F(@/
MYD;JR"OT?.>_7 SUZXYZ\]::^&5@XW##$Y ).1SUZY'K[^IK#"9OF> J2J8+
M'XO"RG4A5FL/7J4HSG"<JD)3C"2C)QG*4DY)V<I?S._T>9Y/E.=QC'.,OPN8
MJ.&IX.,\;1IXBK3PE*E"C2H4ZM52J0IT:-.G"E",HQIQIP4$N56_-'P1_P $
MW_ 2W,=_\=?&.O\ QTCMHYDT_P .:_;V6B^"+6:<96X?P[8O<76J7<<D4$EK
M'J]W+8V=Q''>6L*75O U?GI_P4*_X)E^%? W@G6OV@?A?\1_B_IR>!-#TZSG
M\$KJ7B3QS>W%F-9\NRM/#'G7[WFG6>C:+J=Q96>FVJPV"0>1]KN[:"VWQ_T4
MDR&;>&1(T (W?*N%5MHDP,;> "[']V"9.-M?+OQ)\7)KWBK2--TV*YU31+&5
M[-X+>-C;2:U<S0VL;J3-&E['"@,!DRPC9D49)RON87/>+LV^NX; \05\NGB\
M+4H3Q5?#X7,L)04HM*K4RW,%/+\1:3;4*]/D<DI?%%-?+XOA_@C):>78W&<,
MK'K!9AAJN'C0Q.,R['XZ%*K3G+"RS7+IT\TITJE.FX572K-NE>+BX2DG_/%\
M$OV+OVH?C)X'T?6/&_BS0OV?/#YLDTOPGI.MZ>WCCXS^.9I[V[F?6=:TM;R+
M2_#]E)?7%Y# FJW%GJEO;6D :Q%J(;NY^IO&?_!'SX?>#/!^E>*?'?Q5^*'Q
M2O+6XA3Q3 =3M?"^DV-GJ4*Q0:S;Z7HVZX&F:9J<ENNH;+OS3:W+,#M@<U^G
M'B'5$\0V=R-+TB6SGM5E6:\N;>&P6QNK69X+N2)C+-)<S6C0R3Q11E3OWL.6
M)KU/0/"GC;QKX3TNR\:>(H[;P]?Z;]GO[#1;-X]3\0:?+$]NQU34+O,VF1W$
M&UY(;!/,DWLLCJI"G\LCX)< X#V./QV!IYMF>,K5*^:YCG52=3&8VM*JIRE0
MR^E3CEE'#.3>E&$)13A!-Q39^VP^D_XHX_&8W \-8RIPGD%"GAXY)E7"M.&"
MP&60HT704*F93?\ :U7$RC)RG.KB)*I*[DG.,8K'_9%TCX)_#;X<>&?A7\#/
M#-SHOAVSAU+4M:LK6:]U2UT#Q),]NNM6VKZUJEU/.^JWEZSRQ0+/)/+;*LQ6
M-&&?LX#  ] !_G/-?G%8V&O?LJ^+<:+827_PQUJZA$ULD.^WNK=0$2VFU L)
M+/QW9LR26,T^--\0Z/'/%<2KJ45L#]X>$?&6@^-M*BUOPYJ,=_82E0ZKM$]E
M.0N_3]0MCFZLKV$G+1RJH8=0!T^JGA\%A8T\/EU"GA\'1@J="E2C&%.$())0
MA"*48QBK144K));NY\8\3FF.E5Q^;UZN)Q^-K5,1B<17G*K5K5ZCYJE2I5G*
M4ZDYR?-.<I.3DW?:QUC_ '3^'\Q5=AD'VY_*K#_=/X?S%0-T/T/\JS J,QVR
M>@[8'8G\?U[U2)(W$,XR#QO?'Y;L?ITXJVWW9?\ /<U4;H?H?Y4 59'8GDDY
MYSDYSR*S)?E&\#YB<$G)R"#[UHOU'T_J:SI_N#_>'\C6L-OG^B)N[R\G&WSW
M,N?[X_W1_,UAWGWF_P ]C6Y/]\?[H_F:P[S[S?Y[&KC\7_;R_*),?B_[=7Y1
M,>;[O^?45SM]]T_[H_FU=%-]W_/J*P;M,A3C>2"$CW>6I9>6+OT"!2#C'K70
MU?[T_N=RUM\Y?FSF)NC?4_R->;>,/$NG>';&6XN_](N)BT&GZ3$R_;-5NB#E
M(@Q"1640.;JZF*+& P4DX%1^-?B?HOA]+BSTYH-8UB)POE13M'I5C/+A(UU2
M^B!EN2C$21Z5IH;5;ACL=!;.K#A/#GP^U;Q5?CQ/XWEN?(N<1K830BWU#5P7
M\Q86MU)BTCPVF=T6CQ9O;G"3WNV8R*)OM%-7MOT5OOU_KM>*DU23<E\7PWZM
M*.W^>A3\"^&+[QEJC>,O$,:SZ<L\;Q3,K"W\0W=FVVV_LV"91)!X4T7:+.UN
M+I8YM=U&&>6%7MX(Y&]WF8Y;.&9W9V<\LS-SDGV!"+QPBJO05>DCBA"QPQK$
MD:1Q1I&H1$CA0)&B(N%6.-1M10 J')4 DDTIP-H..=P&?P/^ K>C&/6*;;UZ
MZZ=]UY/\6>7*M.KKS-14K.-W;>/]/H9CI\S (&'[O[WW06=5VD]0&4MS@D8S
MUK\IOC[9VCZCXIO;+4?(?3?$-[+-806KZK+>ZG>W\TCV5DA5526S#Q74\FX8
MAN8E+$(,?JVX9G<)U*I^7F1Y_(5^6GQE\.R:[J/B4Z9XCDTI--\2:I)J,2S1
MPPW(S$TEM=SJ1/:1%0NVX *R%FCR2AQ.+25**T2L]+=7R]-.NK[ZG3@-*\HI
MVC)JZ3W?NO576C^?EJSY;UKQ%XIM;N.QUZWM=8TZ?3;=F%LC36YE&#"\EJV"
M#;IM@N\JJI<13*K% &.]>P:3?^%[F]6WT46]W8VEO.UI8"RU2TN+>[E\]HDN
M04>$NK!'C?$B8* @YJEH7B.S_P"$AN[NR@L[F2P\.ZA9QG7#<V]O?JL3V[65
MG<3*1)Y91IK>7!WD^:&^;-=9\//A[H=WX<M[C6WN[M]7L#Y=I<7-S=6D$EPP
MN8P"P DD@#L$<$!B,C :O)5WYZ:7Z-*/7?SZ;)KN>I-*,Y*VBDXV\DU9;6:7
MHM%OJ8'P?\3:E?>$]2\.Q-)J>G0ZN9M+N@9&FT^'(VLT+*1'&F!Q&_ )^M>N
M27.IFW@TDV@U6XMYY7OH[*:T:;R+I2L/F1$K(B $!LKV!+=2=3PYI.C>!I[?
M1WAMVL%MVN(Q;6)6(0R\QQ7WEY:208P2#G'('!->Q>#/&/P]\%>&]4E?3+27
MQ-J>I/J6I(R_:KB^T9F<6]K9S2)F"*+Y0MN#U( & :I*RMV7WD+5Z)7OY]TE
MZ>K[]SY./AR".SU#3;C0+ZYUZ*"9[.WO+8QVEKON(6>XBF9MC216AG*!,X)!
MP3MKSWP'X0U;2?$>MRZ%>"VTV\DO(X2EQ)%%#%)(0Z2HPVR-)$$\S) =CNQD
MUV">)O&'B'XF^)=1N0VB^#9KF9[=[^X9&@B9XH[>&W0_+YNUG21%(^60*01@
MUT%XLU[=7.DP+*-"B:22[FLY1:SB5+B4*R0@9DB,"P@2<YP4))6E9/I\]->S
MNM?RW8]/RO>^FMK6ZJRVWTW=C7T>2=))-$TJU#/!"':\N[EPK3"0B1K2,!E@
MCWL1M4D2$>83N=A5R_\ ">DW/B*"]U:PMQ?0+:>3<2RR3(+QXE-Q*I;*(SS;
MGV\XR0.!67JNLW.E:9:-X5L%O-4CMI;![>2S(DMG$LEQ;SANMT\ML\5PWHTN
MTDD$57\ ^*/%NM7J:3XNTY8);F_L+J2]G@\F."VNKMBF=/M]TQ=HF5#YA!Y&
M\<$4]-%]VFFG]?@+:_DMT^NEVKV_2ZV;W/4&\8^);VS:W4VMXVEZG!9&Y!V2
M"(*(8[IFQEC:H0T+''E, R\\5]9V_P 8/BA\*8]+LO$&OZ7KNEW-O:W6FOJ=
MXM\1%-$JQ)#-M+QW*N!F(G]ZY&[I5'P[\._A5X(M=4U#Q1XFT?6K?5]/N7\G
M+VNL6.L&%O(TN+2X@8'5Y"%%Y(0H(R01S7S%J%Q>WUQ)X>TN"+6&$%N^DK);
MWEQ>6<MRK%HA,H:!(K:(B8!3E7(9>2!5:JSNK^33_(3L[VV_1]-=[>7GN>J?
M$GXCZ?\ $35H/%5S9OH^H2I+:ZSI]U/$L<5Y&@%O)'=!B/)N0 \31DF%CD\\
M"II.G6,]GHVK^(+"]N_#K->/!*MS;30:M<V\(6&W!207-D6N9/+6^"CS!"VW
M)//V1X,_9G^%&J_#SPW')H-]-=1V<+7<]W<3_P!HW$]UAM02_9U+2%9=YASD
MI%M7Z>O^'?@W\,_#_A_4/#UMX?:XLM45;>XENIY9)8U0E(!%*Z$0I Y8H$VX
M=B>YJN23UTUU^_7L*Z5DMUIO_6U_DK==7^7]_$]O;ZMJ$,-E/K4*+9V<$5Q*
M]FKR2$J;RX?#1M:VK1Q1)&'6<1B5B&<XP]3@U.WOM-,<4]Q&88'2^CO(;8(H
MC7;;1IE2D1'#.01(%#, ",?H_P".OV=/"4OA,V?@S38]&U?1UFGTVX>0W)O+
MN)'\V*_9@'GM9$SM20_)*0 0 *_.*\OIX=771M0LW\ZT7^S;N*^6>VGM4LO]
M'*P6NW$R)Y>U9%X8+GD$FI::W XZVU6VU"\:.XTZZU!H1?QO//,\MZI9&%H[
M6Y(#(C$-'-'O9"H(7.2,KQ#X9OK326TR[MUC,5V8Y9U:20RH0+@RI"K%A^[)
MC5!G#\@YQ6_=^(['P9H<7BUO!^KZL;%2]KHVG/'<:K$#?*MO%:7D@\FYL1PF
MR^VW;(=J+D@5I>#/%,7C.WNO$5S8R1W+26UF=.F>0O:7L=L]S<7=V;E5"6_D
M83;:J8S,OS-M) EVV[I_=U_,J[Z=/Z[^5_-WO=&=X8O[O2],L8-/WZGY:E]2
ML-4M+F"W\.1PC+/!=7R^5>13P\^3&9 LAR<!!CC/B%KGPO\ #WC?P5IE]IFJ
M?$KQ3>)!KFBZKIJ3PII32SE9M/ME\O[%/<,@VZK#.$CFT^,,6)517._&GX"_
M%KXEZ5;>(/ /B^.UL-.S8W&@B^NK ZC+)<M+(+6:)Q;G]UQBZ_=@ @$Y KDM
M:\"?$G3?AHOAS3#<VNIZ1:R+KM]#/+>WX5CL$$ETN RI]Y1:/M(X8Y-']?BO
MZ^6@*V^^JNM=;VOMKH_+YO8^F_B+\6/#WA:^\*6-CI%WK.O>-=2TCP\ATJWF
MU.VL+G4)!)=:EK%Y'M2"WLT_T9CM"K(N!G;7R%^VY^W!J7[(]_JNGZ5X'G\5
M0V^G:!?ZIJ\4-Q-:Z)'JL"RH+ET21YTG4[K9Y0A"$<'I7$?"GQ+\0]'\<^'O
M"2W]Y<:(J2:GXI\4:OI5T++2+*V+12K<7K%@(;1RMVHR"DC,<YKH/$WPQ>\T
MCXVR_%/4K+XB:G\4M5TV2*>0&321X6@9M/\ #L6FLIED$-BOEM9 A610IQV!
M?^NFR?Z];/RZ@E9K31VZ>E_\M-_F=_\  /3M'^*_P*E_:&T;POHJ^(/%.D:G
M;>'=#MP^H06M]-))>K;:?<; (/[4OTBMH9Y&$4(D&6$89JH:!<:=\8-*\#^.
MM ^(.I^!H+.YUK0?$7P^URT$MCXEO=,N#::M#J4%R?LZQPWC136L,Q*$QQ##
M=#YOX]^.?CG]DC2O@AX3T_P?INI? &WL+7PGX\_X1ES:>*_#T%U.EM9Z](UJ
MOV.X3;*;B2&R#75SL,<)$KHU?E1_P48_;3_:*_8^^+'AB/X0IX*OO@E\13-X
MYTJ]UCP^+]?% U>ZMM9N_+N;O;-8R1V]Q!8SR1 ,'CR_(.2Z6NR]/3Y_TUN"
M6F_GWTNM;+[]=&K6[K]0/C!\ OC/XCUK4_%G@)K'4;BRNDEAM+&Y-GKDMB2B
MM::5IMN%TZ2.(I')"L>UXT3Y,CKW/B7Q_P#&'PQH'@WPGIUS#H]ZND:7JE_X
MCFO[FWN3J"0O%>VEK8LBQ7VK6RY@FCE?9O/(8X-?+/[*/[4>K_MA^$+GX@?#
M'5;KP[KO@^*U'B3PI'KK6VIZ'<0QI/=W<%N9%,^E2RJ/LUP!^[1U@YW9/V<W
MBSPQ\4O G_"+>*))F\2H9)M&\76JQ26EEJ33!':\CC):9#(=L\N5 R<G)S2Y
MD[;J^W3MZJ_:_6Z8)=_*Z7RL[=;W:=MKW['@?A/XQ:A\5O$OB3X6_$FU\BPT
MBT;6M-\1Q31070-N?.F6Y-POV);F\PPFBR<,VW(.37YQ?\%-/C/K6M?LQ>+/
MA1\&)-2T'0/[;T^&_MEO(AKVLPVH:.]3=9;FN+&9QN\E"L8!Z8YK]'?C;\-K
M[P)X7T.#1;BVOY]3,MKKFMZ5;@I)+,1Y2R!?FV2D@Q*6 '/K3/V;_P!DJ/6=
M;L?%?Q>\-H?!MA(2UIK-E%=3ZW-=89 ]@J/+:V3 ADO)%R0<D'&06>NMGMH_
M):][_IH[Z M/\^NMKVOU7Y.ZMN?PJ:%+KGPXUR3^V+%6\TE+FTO;6.2"X$V4
MD53<1%M\@8J)H2K*WS*#C-?I#_P3>_8P\4_M8?'<_%A])L=&^%/PDU[1O&OC
M:W$IMGO+J&Y%Y;>'M DC!MH[NYN8;>2-+F6.-D5XE)+!3_3[\:_^":?[-OQF
MM/%FDW_PRVP-:7FG>'/$=C-%8:EH$\=QLFN[:"TMMMQY".7$#E?/5/*+KN+#
MZ._9._94^&O[*?PX?X0^%--+V#WEIJNK:CK"[;[5[N)TF@$D5J@GN7C56BB+
M[_*5RQ 4$U*A9IWV_K^O^#HK62[+9/7I'?RM;_)'O/@6UOO&_BG0-/T^TMM(
MU&[\11Z(+&]O[>X7PKI^HZ=83:3_ &K)8F2$>=;FXGN(;1I+W>(CPD4I'Z\>
M#O@Y$GPCM?AMXZN-.UB,37]RL^BQ7EO;1I=:Q=W]NMK)=;+J25;AII)'E4?N
MI8HP-H&?)/V;O@%I=A90?$_Q=I,5KK6JWCW.F:%';K;P01HD5M8:I+O02/?-
M;(L*2N"PAD=00!Q]UDPDD7")'*$"[2\C;7B "L @.WAE/)R<<8YKHA'J^JMK
MU6C[=?Z1+>UG9Z=NC5_GKZ_,^1+K]D;X=7%I!;F;5U>*1N3.B,\9WAH&W,"T
M061PHZ@$<C!(^CO"GA71O!WAO2_#6AVR6^F:7;I% @50SE5QOF92?,?)/S$D
M\GG!Q7174 $:W.Z)U S\X9CO);<VYR#DC Z8)'&,U229S&Q2)VBQRZ'"H,?P
M\<#.?7'J:JUMEKI?TNK[^7]7(O)IV:WT];Q:WMY]/OT+J;)^$*0@ JP "YQC
MOR>1T(Z_48J"1_)D;S 6+*4C>/@$+WVCC.!UX]1FF1/" DJQ.BM')N$W0MM.
M",\]1GGM[8II>2,J[[9@Q_=HGWL,ISM]@#DX'"Y'3I7]?U_7X!:ST_/WGW6G
M;32]K=^C@0T )>21HSQYV3\IR"H/;)P1CT.<#K VP[&+QQ;BP",2",8Z]3GG
MN.!]35J23S(45&529%/EC&]6"L,YQT&<?4]*K&0*RH0/,0G>3@EL_=SZ'J!_
MCQ0-=+?+9::=KZ-K=?+1W3K@2;(WC9)4#[3'&,D8QDYR>,<8XQ@GU->D^$PO
M]G';T^TR$?B@S_,BO-)KH*)%7(>:-8XR."K!CDCT//49KTCPCQI@&?\ EZD'
MU^0U,_A_X/G]S'%62_RMT6_?^KZH\_\ '_A;6?$_B#1X+:%+?1H[*3^U]5EF
MC5(H!-N:W2V9A<-)+'N"R-^Y0D,20#7BGQ>_:.UKX=?$3X7^%/#FGZ3=^$9;
MC2X_BAKVK0:@)O#NA>*?$EE\-O!&HZ8+0^3%;7_CG4[1[R^U4164?AVPU._A
M9Y!&6^I?%]PME8VYD!%I/?P0W9!8XMPDCJF%*L5FG5(G7.'#E2>01\(^/_V<
M/ ?QI\8?%B+QK/'K>I?&#2+7PEH&J6EMJ-I>_#+P5X8\*7&DZ)!HZM>M!>:Y
M9>-3K?C1[^2-K<7,FEV[0(4$II)RIIV5DFMM$TKWVWZ;?G<S7+S=7=I^=]/^
M"FW<]U\>?M-_#?PUK'B+PMKU]XH2;P$NE7'Q.N- \%^)=<TOP?8ZO8/>VFH:
M_K.E:;=VVG>'C$6GO-0R);2VM_M$S11DB2S>?M%?";3-;3PQ#JU_);6VKZ;X
M8O\ Q5I'A/Q'??#O2/%&L0PMI/AW4O&=II+Z)'KE_)=6S&"*><6L5Q8MJLUC
M)>6HG^7M/^$/QW\1:[\>M#U#QMX?T;P]\2/#/P[\*>-_&.I^ KV^O/$EU;?#
MI/#GC3Q'\.&M/$]E9QW6HW37>E"S\06D]OIM^\364,[ J>XE_9QO[*UUKP'I
M/CO3;'X*^)O'VE?$#4_#ESX<N;KQY#J%C<:+>WGAZT\7?VW+H\FBZOJGAZ*[
M>\N]'35-/WRV*3SQLCQY03<DDGIIMUUW\^KOM^6LE'E>N_+KOORWV^>WX=?0
M8OVF?A/K&MRZ'8:AXC,*^/\ 7_A-J/B#_A!/%3^%-*^(WA_6+SPY>^#[OQ"^
MCKIR:[<:O83II V76DZD\EO9C4TGNK2-N#\+?M'>%?$WA^[\50^%_B/X(OI/
MB9XX^&/A[PC=>"M6\4:_XNU?P5XBUS1[R[T3PWIMENNK:SL=#O=6\2PW!M9?
M#DMK<Z1=W$EU!YEQYWX$^$GQ)U+1]<T/QEXBTK1/AX?VKOBG\4SX6N_ ]]!X
MXU"RT/X[:UXN\*QV'B,>+X-%MO".J:EINB>+XM5N-%&J7>D_:H(U,$T93;M?
M@WXET348=<T3XAZ!;:GX:^)WQC^('@<ZQX%UG4-.M]"^.UUJVJ>._!'CXP>-
MK6YUB8:WK"KX>\5>%CHUQ:V>FVYOK>=]1NKB7H2ET5MK62V=OO5N][>NJYFZ
M<;.23UND[:.RL];=MNGF>IZY^U7X<OM2^"?AK0_"7B_Q78?&35_%N@MK/AGP
M]JD=OX(UKP-I=WJE_I7B31=5LK'4[36)I--OK&ZT(%)]$BL]2U"_O&LX;.6Z
MR;/XV>&M3\,> -0;6;SQEK_CK0WUK3=.^''@;Q-JE]JEIH.J2:5K/B!?#$TT
MUQX8\.P7IMX'U7Q#KEO:OY]O;VZ-?3>77(:)\*;W3=;^$NLZ3XVM9_'W@_XL
M^,?'WB#6]2\+W::!XRG^+VDZWX<\9Z3;Z)I^JI<^&5LH;JV?PU<W%YJMQNTI
M%OI;HO<R2VM-_9M\<?#"#X<ZOX;\3:/J>O>&/ $GPV\5OK/A/6-=T+Q1X=G\
M8W7C>"XM]/\ #NN:'K?A[6M*U6_N[;3[B#5=0TJ[MKF1K[3]RPQP2ERV5DKN
MZU5[W5[7?6RT^[J:\\*U.4=XQDFETYE>S^6B3LNZ74^F?AL[Q>*_%%BTD<ZV
MUM;A)X6;RI ES,I+1R /%,=W[R,M,$*[1*P KW%>C_3^AKQOX8:#=6%YKVK2
MV=SIUEJ#6]OI5G>I(+S[+:IF6ZE$TLEQ!'/<R2K##<F2<1QKNE;;7LB]'^G]
M#6=;XWULDOP_R%0OR7=[N4F[[N^S^ZQ4H(!QGMT_/-%%9&Q\X^+?V2OV9O'E
M_KFK^)_@7\,+[7O$EP;K6_$<7@[1=/\ $VJ7/G).;F\\1:;:VFLSW!DC61YG
MO3+(V=[-GGXS\=?\$O\ X<#QU%XX^"7B>[^"S76BV&AZ[H^G:/;^)]%U1M*O
M-3N;#4XUU.]_M"UUE?[4NHYY7N'^T1"WB946##_JBQ"[CR.3P,Y&3CM]?7CZ
M8J-CN1RN,LI!.,!O0,!U//4CUY%>[EO$>=Y6FL#FF-A"<'2G!XFI.ER22O&5
M.;E3<5IO'2*LNM_GLTX6X>SB<99AE.7UL12<:M.M+"48U^>'O1<:T8QJQ=[K
M2:6ZDF?GIIO_  3@^"3Z0W_"7:IXW\4^/C>1:CI_Q1G\1-HOC7PIJ-N&6"?P
M?/H$ME:>%+?]XT,MMI<;M>P2/'J#S=*_"3]L;]@GQI^RQ\9/!,WP;USXR?%[
M_A;GB'6M2\.>$('OL6#V]\\LFB^+?%]Q>S6\=E96.JV\DVHZHKW-TK2F&T,=
MM=7-M_67K.J6NB:9<:EJ,L<-O:)O:0@.P.<JD2')DDD^ZL:99L\#(%?']UXE
MBU7Q!XCUG6+74KM(C<W]E)+;K<-%I4DXB@C2V:96A#;)2UN && S\G%;8ZOQ
M/Q7DN;9-4XIKY=AL:L-&KBE0PN82A3AB\-4G3H8;,%/"_P"T4Z3PK;2=)5G5
MIQ=6,4^;+X<%\%\29)GSX0RW-\=A)UJD,NQ.(QF4X3&36&K*C+,,7E,Z&,J4
ML+7G#'1I<_+B:V%A0JM4YS:_&[P1_P $QOCC\3-6TEOBA^TCH7@+7]6CCU37
M? /PJ\/S:O'X.TF<D06$_C&[O397FKSS)=6\D.G+/IT;QK/%<W"2>?+ZS>_\
M$O?V9_@Y\2?#VH?%.Z\?_%7P/JHM;Z[U3QKXMN=-M+=H9;6SO8]5ATVYLX)6
MT:]B_MQ C*&TDZC"X?["CR?I-=S:Y-XD\/7WAK2[?1Y!J<8LIYV:"2_-SYVR
MTDBAEEDMK61&DDNV(PRPJH7(+'TWQ9\$+SXGZ+]F\?\ B.*^N;8R7&@VNCVR
MP:#I>I1"6**_FBO%:?5))HG-K/;WL@LGMR\D4?F2EJ_/,'X0\ 9#C*>+IY+@
M56<)2J8O,E*KF^(QD)4W]:6'C3^HT:+;ES2H>SY92A"$.64N7]=Q'TFO&7B_
M#XW#5^(,5A*-'_8,'@<@PV'R+)\+EM2'-'"+ZJJ..Q=2$8PI^VQ4ZTZD8.<Y
MR<HM?0'@?Q'I/B+3F.@07HT73_*T_3;^:":*'4K6TA0QW&G/<8GOK*2 (EO?
M*'2Y0"5'=7#GO:^!_A1\4=3^#^I'X7_$^V&F:7IRK!I=_$LDMGH";V2)(),&
MXO/ MP=LFEZB")M!MV33]66&VACFK[LM+J"]@@N[*YCO;.Y43PSQ212QRPR'
M*36\\!:.6+!! R<@@9S@5])5A"$VJ:2IV2BTK)I+3[E;^F?#8=UY4HRQ/-[:
M=YS<MW*5N9WNV]>K=WN]R4?Z[\&_F:@?[Q_#^0J<?Z[\&_F:@?[Q_#^0K,V*
MLY.5&3C!.,G&?7'3/O\ G59F;!.YCTQ\QX' P/8#M5B?JOT/\ZK/]T_A_,4
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MCGV8AV@AAM))..O7OQQUSQ7%B\?B,=5YZ\DU&_6R3=M4KVUM_P &]ST<LRG
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M@"1-I8.H!&5.*YCQ*PTO39=1OK4&*^:,Z>\YFAO+N_N9!#<RS6ZJ)HHX%;=
M/+5'52X&T9'?>+O GB_P?9^'[KQ'H26TFMJ+Q;YYK>2._M(T66RCMY8YY(E-
MC;MFY2>2(RMCRP^,#DH-2LM9U'R9KJ'[!"I73[H6JR1S,L9,T$3'>-RO\NX
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M:61%D:P>55DDC#S?(&1F9"J/GJ.@Y<4Y/\_*W;:_KU]-AM76B].ZLMW=_P#
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M;1D\E1[]&R,]:K'S0D+AHYC^_20%2 B,HQN8C;SW&<CC@'H:.]GUUMW5OZ_
M2TL_*VNE[*^FBTTW?Z:\_P"&]=@\4:1;ZU EU;;MT,MO) ZO9$DQ,JH5R4W
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MQE0$$FOI)>C_ $_H:^1OV?O#%OX;U?5]-T^_NM6@/B;XP>.KV]N=/6Q-O/\
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MIXK\0>)'MOA_>>,[^SCO-3TKQ)'=);R:?>W4UO';QQ1^4,[S)E8HPQ:1PT:
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M+BYEDMH+J2YBM@B"2Q!\:OAE?SZ#:VWBJUGD\3V]A/H[1QSM#.VKB8Z5#=7
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MY5E24WF^WNTN"MQ$EO\ 96\M=LC2!UP /7]"N]3OM T&]UN(6^LWVB:5>ZG
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M_AZ]E.5O:24DG>RO]^O7?^KF/H&@:3X:TNTTC1+*+3["S3$,$2GAV):665Y
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MPW>-::=IRVNN:>;(%96DN+AK*1MQO(YIK:)YKC(VNB*%7-?4CV%Z&\T02/(
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MH^WK*/M;N4834$DKI)JZ3:NU?6RT2/Y@O@O%\7-&N/V(_P!D1M9^)6B^ /\
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ME&Y-Q*MD%CC)'MN]]M;;7?EN_P!>J#]?Z7X?TCT*BBBI&)@'J!^5+110 48
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.. !1@>E%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>nt10016217x4_graphic08x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic08x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W=_P"%U_&7_HK?Q-_\
M+WQ5_P#+6C_A=?QE_P"BM_$W_P +WQ5_\M:\RHK^M/[.R_\ Z <'_P"$U#_Y
M _S3_MS.O^AQFG_APQ?_ ,N/3?\ A=?QE_Z*W\3?_"]\5?\ RUH_X77\9?\
MHK?Q-_\ "]\5?_+6O,J*/[.R_P#Z <'_ .$U#_Y /[<SK_H<9I_X<,7_ /+C
MTW_A=?QE_P"BM_$W_P +WQ5_\M:/^%U_&7_HK?Q-_P#"]\5?_+6O,J*/[.R_
M_H!P?_A-0_\ D _MS.O^AQFG_APQ?_RX]-_X77\9?^BM_$W_ ,+WQ5_\M:/^
M%U_&7_HK?Q-_\+WQ5_\ +6O,J*/[.R__ * <'_X34/\ Y /[<SK_ *'&:?\
MAPQ?_P N/3?^%U_&7_HK?Q-_\+WQ5_\ +6C_ (77\9?^BM_$W_PO?%7_ ,M:
M\RHH_L[+_P#H!P?_ (34/_D _MS.O^AQFG_APQ?_ ,N/3?\ A=?QE_Z*W\3?
M_"]\5?\ RUH_X77\9?\ HK?Q-_\ "]\5?_+6O,J*/[.R_P#Z <'_ .$U#_Y
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MAQFG_APQ?_RX]-_X77\9?^BM_$W_ ,+WQ5_\M:/^%U_&7_HK?Q-_\+WQ5_\
M+6O,J*/[.R__ * <'_X34/\ Y /[<SK_ *'&:?\ APQ?_P N/3?^%U_&7_HK
M?Q-_\+WQ5_\ +6C_ (77\9?^BM_$W_PO?%7_ ,M:\RHH_L[+_P#H!P?_ (34
M/_D _MS.O^AQFG_APQ?_ ,N/3?\ A=?QE_Z*W\3?_"]\5?\ RUH_X77\9?\
MHK?Q-_\ "]\5?_+6O,J*/[.R_P#Z <'_ .$U#_Y /[<SK_H<9I_X<,7_ /+C
MTW_A=?QE_P"BM_$W_P +WQ5_\M:/^%U_&7_HK?Q-_P#"]\5?_+6O,J*/[.R_
M_H!P?_A-0_\ D _MS.O^AQFG_APQ?_RX]-_X77\9?^BM_$W_ ,+WQ5_\M:/^
M%U_&7_HK?Q-_\+WQ5_\ +6O,J*/[.R__ * <'_X34/\ Y /[<SK_ *'&:?\
MAPQ?_P N/3?^%U_&7_HK?Q-_\+WQ5_\ +6C_ (77\9?^BM_$W_PO?%7_ ,M:
M\RHH_L[+_P#H!P?_ (34/_D _MS.O^AQFG_APQ?_ ,N/3?\ A=?QE_Z*W\3?
M_"]\5?\ RUH_X77\9?\ HK?Q-_\ "]\5?_+6O,J*/[.R_P#Z <'_ .$U#_Y
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MAQFG_APQ?_RX]-_X77\9?^BM_$W_ ,+WQ5_\M:/^%U_&7_HK?Q-_\+WQ5_\
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M;B6+?;+'(WZ+?M#_  )^&)^#WB6'X::#H]IXM^#,^A-XCGTVPMX-;O\ 3HM
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MYEZ***_L _R_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_D2C_A"?!G_0H^&/_!!I7_R)7XE_\-;?M#_]%)O?_!'X5_\ E%1_PUM^T/\
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MPUM^T/\ ]%)O?_!'X5_^45'_ !#;B7_H:9?_ .%6/_\ F,/^(\\!?]$[G?\
MX;LF_P#GH?MI_P (3X,_Z%'PQ_X(-*_^1*/^$)\&?]"CX8_\$&E?_(E?B7_P
MUM^T/_T4F]_\$?A7_P"45'_#6W[0_P#T4F]_\$?A7_Y14?\ $-N)?^AIE_\
MX58__P"8P_XCSP%_T3N=_P#ANR;_ .>A^VG_  A/@S_H4?#'_@@TK_Y$H_X0
MGP9_T*/AC_P0:5_\B5^)?_#6W[0__12;W_P1^%?_ )14?\-;?M#_ /12;W_P
M1^%?_E%1_P 0VXE_Z&F7_P#A5C__ )C#_B// 7_1.YW_ .&[)O\ YZ'[:?\
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M /12;W_P1^%?_E%1_P 0VXE_Z&F7_P#A5C__ )C#_B// 7_1.YW_ .&[)O\
MYZ'[:?\ "$^#/^A1\,?^"#2O_D2C_A"?!G_0H^&/_!!I7_R)7XE_\-;?M#_]
M%)O?_!'X5_\ E%1_PUM^T/\ ]%)O?_!'X5_^45'_ !#;B7_H:9?_ .%6/_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ/JVKZAI>EV%[J6I::LUV)O$CZBTL$VE7,D\5IH6I'R'A,*3S,T4?YW^"O\
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M(CIWEC>+HKS79_\ "*^$O^&>/^$L_P"$&\6?\)?_ ,)9]A_X3S>W_"(?V?\
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MBP\JM&OE.)I8>=6.(P<GAJE/$NJ_]G7[_!5:-6AB)3DX2;:***^D/@@HHHH
M**** "OU _X)U_\ (/\ BS_U^>"__1'B>OR_K]0/^"=?_(/^+/\ U^>"_P#T
M1XGKXWC_ /Y)3,_\6!_]6&%/U3P5_P"3D9!_U[S?_P!4N8'Z44445_.)_=@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUOK#P-64ZLG4P;Q'[]X:;='VW[WDY_>/<KS]HWXN7_@73/AW=^(K:?PWH_\
M8*6$;Z'HAOH;?PQ/IUUH-J;[[!YTD>G7.E6<JROF\N@CPW]U=V\TL+1?\-%_
M&3_A-O\ A8O_  F/_%9?\(__ ,(O_;'_  CWA7_D!?;/M_V'^S_[#_LK_C[_
M 'OVK[#]L_Y9_:/*^2O$J*R63Y3%3BLLR]1J.NZB^IX=J;Q/)]8YDZ;YE7]G
M3]JGI45."DFH1MTSXHXEG*C*7$&=N6'CA(T)?VIC5*DL![5X+V;5=.+PCQ%=
MX:2M*BZU5TW%U)\WT-J7[5/QTU;PE/X,O_&T\^F7=G+IU[>G3M,37+S3IH5@
MDLKG6DM%OG62,,LUVLBZE<B65;J]F21EKD_AG\<?B;\(A=P^!_$;Z?IVHW,5
MWJ&D7=G8ZII=W<0IY0F^RW]O.;.>6()%<76G265U<Q0V\4\\B6T"Q^2T41R?
M*8T*V%CEF CAL1-5*]!82@J-:HG>,ZE-4^2<XM)PDTW!I.+5D$^*.):F,PF8
M3S_.9X_ TG0P>,EF6,EB<+0:<94:%=UG4ITYQ;52$9*-1-JHI)N_I'Q(^+GQ
M!^+5_9:AX\\03:R^F130:7:I;6=AIVG1W+K)<?9-/T^"VM5FN#'"MS>21R7M
MS';VL5Q<2Q6MND7:Z#^T[\:_#7@P>!-(\9W$&APV/]EZ?*UE82ZQI&F^5)"+
M/2M9>W.HVD<4,@BLY!.]SI<<5NFE3V*01!? J*J>5994P]'"3R[!3PN&FJF'
MP\L+1=&C--M3I4G#DA*[DVXI.7-+FOS.\4N(^(*.-Q>94<[S:GF&.IRHXW'0
MS#%1Q>+I2C&+IXC$*K[6M!1A!1C4E)1Y(<J7)&WTEX;UB?\ :*^(UO>_&[XO
MV?A";1_#L2:?XHO='T+3DN(-,UE;J'0;>33Y/#FGV%])_;&J7]IJ<\5Y*KP-
M&T4X6WB7M?VQ_C9H?Q5\7:#H_@_4QJOA/P?872QZC'%<0PZCKVJ2QC4IXOM$
M<#W%K:VMCI]M:W#1;&E-_+:O);7"22?'%%<:R+"K,L'F"DXT\MP]:AEV I4<
M-1PF#>)C&&(JTHTJ,*CE4A%1493<*=YN$5S:>G+C#,9Y#FF2RA&I7SW&X;%Y
M[G.(Q6.Q69YK' U)5<%A\1/$8JI1C"A5G*;G3I1JUK4U4F^1N5JRO+G3KVTU
M"SD\F\L;J"\M9MD<GE7-K*D\$GERJ\3[)45MDB/&V-KJRD@_1[?MB?M'.K*?
MB,P#*5)7PGX&1@",':Z>&5=6P>&5@RGE2" :^9J*[L7EN78]PECL!@L9*DI*
MF\7A:&(=-2:<E!UJ<W!2<8N2C:[2OLCQ\MSW/,GC6AE&<YKE4<0X2KQRW,<7
M@8UY4U)4W66%K4E4<%.:@YJ3BI24;<SOV>J_$3QMKOBVS\=:UXDU'5O%>GWU
MEJ-CJ^I/'>O9W&G7G]H6"6UK<QR6,%E:7>9H--CM5TZ/<Z+:B-W1F^./'WBW
MXD:^_BCQGJQUG79+:VM'OQ8Z;II-O9J4MHQ;:39V%HIB5B ZVXD;J[L0#7'4
M5K#"86G.E4AAL/"I0I.A0G"C3C.C0DXN5&E)14J=)N$6Z<&H-QBW'16YZF99
MC6I8BC6Q^-JT<7B8XS%4JF*KSI8G%PC.,,5B*<JCA6Q,(U*D8UZBE5C&<TI)
M2E?Z2F_:X^/\VDZ5I \>3PII,UE-'?PZ7HZZK>G3I;::SCU2^:P>34(5>V07
MD4X9=8BDN(-;_M*&XEC;K_@9\5=+UOXM>(O&_P 7/B9XG\&>*];TJS2R\=^'
MET?3K:XFT^VM=*;1-<T9/"^K>';FPN]-MK">$WVBK90WNAP7$D@U":&8_'U%
M>;6X?RJ>&Q6&P^#PV >*I5*-3$8+"X6E7Y*DZ=2I%R=&49TZDZ5/VE*I&=*I
M&*C*#25O?PO&W$=+'Y?CL=FF/SF&6XBCBJ&"S7,<PQ.#]K0HUL/1J*$<53G2
MKT:5>LJ&)H5*6(H3J2J4ZBE*7-^HGC/XP^&_!GPS^+&F^(/CU9_'+QU\0O#D
MOA?1K31-)M=+TG2-.N;35-($L4>@_:]!LYH[?7+K5=1=Y[6>]EM;:P2.=X!<
MR?EW113R;)*&34\2J525:IBZL*M>HZ6&P\+TZ,*%*G1PV#HT,/0I4Z=-*,(4
M[MN3E*5U:>*>+,9Q56P,L10IX7#Y;AJN&PE".)Q^.JVKXFKB\16Q6.S/%8S'
M8O$5J]:3E4JU^6,(PA3IP2DY>T?#?]H+XL_"FT.E^#_%4UOHC3-.="U&TL]7
MTI)':1Y#:P:A!/+IOGR2/+<_V7-9&YE(DN#*X!'-?$3XK?$#XK7]GJ/CWQ'<
MZ[/IT,T&G1-;V-A96$5PZ/.+33],M;.RBDG,4(N+D0&ZN5M[=;F>401;//**
M[(99EU/%RQ\,!@X8V=^;%QPU&.)DY)QDW64%4;E%N,WS7E'W9-I)'EU,^SRM
MEM/)ZV<9I5RFER^SRRIC\5/ 04)*=-1PDJKH*-.<5.G'DY:<[R@HR;;^A?!O
M[4WQO\">'[;POH7B\/HVGV@L]*M]5TC2-6FTF!7W1QV=Y?64MXT4"?Z/:VMY
M/=V5I:A+>UMH88HECXC3?C+\3-)\>7WQ-L_%5U_PG.HI<QWFOWEEI6I2RPW4
M,=O) MGJ5A=Z;!;QVT,-K:6\%G%!86L,-M91V\$4<:^8T5$<IRJ$L3.&6X",
M\9&<,7)82@GB85'S5(5W[/\ >PJ27-4C/FC.7O23EJ:U.)N(ZM/ 4:F?9S.E
ME=2G5RV$LRQCC@*M&/)1JX->V_V>I1@^2C.ERRI0]RFXPT/3?"?QB^(_@CQ5
MKWC7POXC_LOQ/XG^WC7-3_LC0KW[:-4U*/5K[_0]1TN[T^V\_4(8[C_0[2W\
MK;Y4/EP%HS]2_%W7_A7X'_9K\/?!SP3X]TWXAZSJ'B@>(+S4=)5HHX+4W5]J
M$EQ?6XFO8[":)7T[2HM/FN(;NX*3:B]M;[98!\&T5S8O),+B\5@<2G]7^IXF
MCBIT\/2H4_KE3"0E# K$U52]M*G@E4J^PI1J1@E5FG'X7'NRSBW,<MR[-\O:
M^O?VI@<5E]&OCL3C*_\ 9=#,JU.KF\L!AGB%A(5\U=##?6\1.C.LWAZ4HS5Z
MBJ>_Z7^U!\;M%\%V_@32_&EQ::+9V::98W,=CIW]MV&EQQ/#'I]GK;6IU""&
M&-U2UN$F^WV,<,$-C>6T$*1#/A^*^J?$+XI^#?%OQF\3:U=VVER:?I-SXA\.
MQ6'AS7-!TJ"\OKNSU32W\.Z5 %O-!U/4I=:BDBL;B_G,/V9#)^XC3Q"BMUD^
M60=>=# X7#5\1'$1GBL-AZ%'%)XF/+6G"O&GSQG.R<G=J4HIR4FCE?%/$%6.
M$I8O-\QQ^$P53!3I9?C\=B\3E\HY?4]IA:53"3K^RG2I/FC"-DX0E*,)0N?L
M%:_%;P/H/BG3_&^O?M8_\)?X$T:WNI]#\#-H>C?\)%<:A=:3<:3*VOS>$])T
MJ_U..W>XN+K3H;_P[;;)9K9YI5:P>^OO@;2?VF?B7X1\4_$37/ VJ)HVE_$#
MQ9K_ (JNM#U"QL-8M;2\UF^O+F.>$7MO((KRW@N8[>:6 QPWJVUL+V&YCMK=
M(_G:BO(R[A++,$L0J\89A'$4:&&E2Q.$P%/#QH8>I.M37U?"X:A1G6=6;J5<
M14C.K.HHRYHM._TN=^)>?YJ\$\'.IDD\%BL7CHU\#F><8C&U,7CL/1PM>3QV
M8YAC,32PL</1C0P^!P\Z6&HT93@X5$XN/K_C;X]?%GXC:''X<\:>+I-=T>'5
MUUV"VN-'\/V\UOJB"\6.YM[^RTFVU"!88[^[AAMXKI+6&WE^S10I D<::WC3
M]I+XP^/K#P]8>(_%0E/AC6+;Q#I6H:=I>EZ-JL6N62745EJ?]H:5:6EQ%<6L
M-Y-'&EJUM;N?+FG@EN8HYU\*HKV(Y1E4?8<F6X"'U:=6IAU#"4(*C.O%1K3I
M*--*$JL8Q51Q2Y^6/-?EC;Y:?$W$=3ZVZF?9S4>.I8>AC74S/&U)8JCA)2GA
M:5>4ZTG5AAI3FZ$9MJC[2I[/E52:E](^(OVM/CMXG\.77AC5/%\2V.HVD]AJ
MES8:)HNFZEJ-G<#9+;S7ME8PO;(\9>)SIJV+R0R2Q2M(DC _-U%%;8/ 8'+X
M3IX'!X;!PJ3YYPPU"G0C.=K<TE3C%-I:*^RT5EH<^9YUF^=5*57-\TS#-*M"
MG[&C4Q^+KXN=*E>[A3E7J3<(M^]+E:YY7E*\FV%%%%=9Y@4444 %%%% !7Z@
M?\$Z_P#D'_%G_K\\%_\ HCQ/7Y?U^H'_  3K_P"0?\6?^OSP7_Z(\3U\;Q__
M ,DIF?\ BP/_ *L,*?JG@K_R<C(/^O>;_P#JES _2BBBBOYQ/[L"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#^9>BOZ#O^%"_!/_ *)1\/\ _P )31O_ )$H
M_P"%"_!/_HE'P_\ _"4T;_Y$K]N_XBGEO_0KQW_@S#__ "1_)'_$NF??]%#E
M'_@C&_\ R!_/C17]!W_"A?@G_P!$H^'_ /X2FC?_ ")1_P *%^"?_1*/A_\
M^$IHW_R)1_Q%/+?^A7CO_!F'_P#D@_XETS[_ **'*/\ P1C?_D#^?&BOZ#O^
M%"_!/_HE'P__ /"4T;_Y$H_X4+\$_P#HE'P__P#"4T;_ .1*/^(IY;_T*\=_
MX,P__P D'_$NF??]%#E'_@C&_P#R!_/C17]!W_"A?@G_ -$H^'__ (2FC?\
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M17]!W_"A?@G_ -$H^'__ (2FC?\ R)1_PH7X)_\ 1*/A_P#^$IHW_P B4?\
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M7X)_]$H^'_\ X2FC?_(E'_"A?@G_ -$H^'__ (2FC?\ R)1_Q%/+?^A7CO\
MP9A__D@_XETS[_HH<H_\$8W_ .0/Y\:*_H._X4+\$_\ HE'P_P#_  E-&_\
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M#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-\?&S_H%_#__ ,$6L_\ S25\2T4?ZI<-?]"7 _\ @K_@A_Q$SC[_ **K-_\
MPH7_ ,B?;7_#?'QL_P"@7\/_ /P1:S_\TE'_  WQ\;/^@7\/_P#P1:S_ /-)
M7Q+11_JEPU_T)<#_ ."O^"'_ !$SC[_HJLW_ /"A?_(GVU_PWQ\;/^@7\/\
M_P $6L__ #24?\-\?&S_ *!?P_\ _!%K/_S25\2T4?ZI<-?]"7 _^"O^"'_$
M3./O^BJS?_PH7_R)]M?\-\?&S_H%_#__ ,$6L_\ S24?\-\?&S_H%_#_ /\
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M%'^J7#7_ $)<#_X*_P""'_$3./O^BJS?_P *%_\ (GVU_P -\?&S_H%_#_\
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MM;'XC#RQ-*ERNTJ<.>Z<_A4W&E4E&#?,X4Y2M9*_OT>&,YQ'#N+XII87FR7
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MFCQ4JF%J+%5X^TG*--\RQ4DIPYY0N]6_:R?CW 9$J5'#9QBZG/X@Y;G>8XK
MY5#):6.X>CE].CF-"6782?L*-.=>/(\N@W2K*E"KRKW5'[5\'V]M\)/AI^U3
M\2/A]H>FMXT\-?%[QEX3TBXDTY;K^Q/#.E:_HEM';VMO@1Q6FEV&L7^L3I"L
M=G<&SLUU"&XM]-CC3,U;QQXJ^(W[#_Q+\6^,;2R36M0\3:%!)K%GH\.CMXGA
MTWQ5X TV/7+U+6.&TO;T-:2:-+>VD,-NL>CPV*11&Q9%YG]E[QEXE\2:K\7-
M>T7XB^"?"WC;Q?KNH^(+CX>^,]&>Z\&^)K[7);N^LYM)F7Q)IWB+3FM-3N+_
M $O4&LI=;,.F7VFR7UCJMQ%:!>[^/WC:^T#]G3Q/X'^(WBKP'J7Q$\6^(-#C
MTKPI\/KB$Z7X3T+3-1\/ZE;Z?'82,NH6^FV4'AV[#W5S&Z?VGJD=G!<7$*)+
M7@5</.GGF'P=6C0Q68KB'(<7+&-XEX^E@Z5/!NMA8QGAE">"H.C*N\13Q,L/
M:W-%5^6,/M<-C*-?A#&YIA\7BLNR)\$<99=3RN$<!')L1FF*KYFL-F%2I2Q[
MJ4<TQ:Q-/!QP5;+X8WG4O9R^J<\ZJ?#K5_B5X!^&?PG3Q'\0?AI\#/#&II97
M?AO2='\&7WC3QG\0;:[%A/NUW26NKTK=:JM]:WE]=Z!+!?6KZU!%>1:5<QPV
M4?IS>!/!VH_MJ7%U>:'I;SZ?\'[?QG;P?8H1#<>*#XH&BG7[J,((+K4;>QN=
ML4]RDDRW M;Z-UN;&&5/A;1?VM_&.D^#O"?AB[\&_#[Q%J?@.WM[3P;XL\1:
M%)J>L>'X;2%;>SN+)'NDMX=4L8(+*"UU"W6W!2PM7O;>]N%>=^I\"_'#Q#\7
M/C[X1\6^*?%?ACX4^(-.\.7'AW2?$>GZ/+-X<O!#<7FHII'BBP\0>)3!)9ZM
M#?ZM8K-;ZEITZWT^FBSDAO8[6XBZ,7P]G,)9KC:E/#X&-3 YW3K8C".FU55>
MK&O0G[/"X>>95X3ITW&M+$U<76@YS]C1I0CRU.'+.-^%JM/AS*:-;&9O4HYO
MPC6PN#S)5HRP\L%AY83%T?;9CC:6182K2KU8SPL,OPV6X2K&E2^M8NO5G[2A
M]-?LL?&GXF_%CXE^.K/Q[IFFM!X<TG4#:7,/AZ*QO?"5S?:WI=O+X2CU..-9
MUL[X:9+=36>IR7.H7EUH23M<NFG^7%R_PX6Q^%G[*GA#Q;X7\:^&?AIXC\;:
M[NU_Q_J?AB[\3R76V^\1"VT006VE:I*CVEOID5G$+NTDTRT>/5I+?R]0U%+B
M7W2R\<^*?AYJ/B[QG\7/&_P>M?!EMH^J7'AS2O 7F:9J_CC4&>QN;/7KNQU?
M4-0N)]:N-*TU-+LM/L-7U-#-=31>=-;6EM?7'YD_#']HWQ+\//"UUX"U+PWX
M3^(/@2ZO#?KX9\:::=1MK&Z9S/(=/8N88X9[K9>26]W:7L45VC75DMG<7%W+
M<<>"RROG#S*MEF!PN'P4<5P]6E@,)4@\'BZ>%P^8K$X>G4QF$CA*M6G6Q%'$
MU:-?#RH>TM&LW73D>GFN?X3A:.0X?/\ .,QQN;5,NXVPM/.<RHUHYGEM?,<9
MD,L!C*]'*\SGF6'PU7#8+$X&AB<'C88MT4YX50P<HP/M&;7O ?BO]HK]FOQ'
MH%YI^H>-[[3?$2>/M4TWPUK_ (:M->DC\%EM'UNWAUS3-/:[M;IVU=;*Z$E[
M<#3A8V<MU)!9VI'D_P >?V@_$*?%[4_AKJFEZ?=?"WPW\2?"^I:KX8T_2X'O
M]?L]$O[76=;LKIR\,&HKK^IS7.J3VEW'Y<M]%9"6;:MX]YXAK?[4?Q%UWXE^
M$OB9<6GAN.[\#6]W:>%_#,5EJ">%M.AO[&?3[QC9QZI'?R3W4,R-/,NI1%FM
M+*-52UM8K8>7:Y\2_$^M?$>X^*B26>C^+)O$%MXF@ETFW86-CJMG+!-;26MI
MJ4VI;X(Y;>-FM[Z6\BF7?%.LL+M&?I,NX6K4\3A*V.PU.M#"Y%/"X>-?%JO/
M#8]YEBL52C3K4L/15-8>A6C2HUZ-"^&C>E1YXQ4I_!Y[XBX:M@,RPN4X_$8>
MMF/&%+,<;4PF6RPE',,GCD&79;B95L)B,=BG6EC,9@ZF(Q.#Q6-:QU1K$8IT
MI5'"E^O=YXHU/Q_J^HCX3?&CPI+>7NB-;CX*?$SP=9P6IAETF(EGL/LWA[Q]
M9V<MM*;^::ZMM?L)HKS/E3Z6;."/\8O%.E:EH7B;Q#HNL6-OI>K:3K>JZ=J>
MFV;(UI87]E?3V]W9VCQRW$;VMM/&\-L\<\\;PHC)-*I#M];/^VQXK:Z/B%/A
MC\*H_'S6OV%O'(T"Z;5Q:BV:V")*U_\ ;@RQMA4?4Y+/8#"UFT)\L?&^H:A>
MZM?WVJZE=37NHZE>7.H7]Y<.9+B[O;R9[FZNIY#R\UQ/))+*YY9W9CR:ZN$<
MES#*)XN.)P]##X:=#"TZ4;X2IBIU:3J*;J5\%1P\*]*,9+DJXFD\7-R?/**C
M9^?XF<5Y+Q/2RR>!QV+QV/I8O,*V(FUF='+Z6'Q*P[I1HX3-L5CJN#Q$YTW[
M7#9?B5EM*-./LH2E+FC3K]0/^"=?_(/^+/\ U^>"_P#T1XGK\OZ_4#_@G7_R
M#_BS_P!?G@O_ -$>)ZTX_P#^24S/_%@?_5AA3'P5_P"3D9!_U[S?_P!4N8'Z
M44445_.)_=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S+T445_8!_E^%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5^H'_!.O_D'_ !9_Z_/!?_HCQ/7Y?U^H'_!.O_D'_%G_ *_/!?\ Z(\3U\;Q
M_P#\DIF?^+ _^K#"GZIX*_\ )R,@_P"O>;_^J7,#]*****_G$_NP**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P *?6__ ).H_P"%B_$'_H>_&7_A3ZW_ /)U'L.)/^BIS/\ \*<9_P#-0?\
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M]V3_ /SD/Z3_ /AB_P#9X_Z$R]_\*OQ5_P#+BC_AB_\ 9X_Z$R]_\*OQ5_\
M+BOYL/\ A8OQ!_Z'OQE_X4^M_P#R=1_PL7X@_P#0]^,O_"GUO_Y.H]AQ)_T5
M.9_^%.,_^:@_XCAX<_\ 1G<F^[)__G(?TG_\,7_L\?\ 0F7O_A5^*O\ Y<4?
M\,7_ +/'_0F7O_A5^*O_ )<5_-A_PL7X@_\ 0]^,O_"GUO\ ^3J/^%B_$'_H
M>_&7_A3ZW_\ )U'L.)/^BIS/_P *<9_\U!_Q'#PY_P"C.Y-]V3__ #D/Z3_^
M&+_V>/\ H3+W_P *OQ5_\N*/^&+_ -GC_H3+W_PJ_%7_ ,N*_FP_X6+\0?\
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M'$G_ $5.9_\ A3C/_FH/^(X>'/\ T9W)ONR?_P"<A_2?_P ,7_L\?]"9>_\
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MX4^M_P#R=1_PL7X@_P#0]^,O_"GUO_Y.H]AQ)_T5.9_^%.,_^:@_XCAX<_\
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M\0?^A[\9?^%/K?\ \G4?\+%^(/\ T/?C+_PI];_^3J/]5*G_ $&P_P#!$O\
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M^)J\O_Z(O&?^'NA_\[3^O:BOY"?^%B_$'_H>_&7_ (4^M_\ R=1_PL7X@_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#^&:***^D/YO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .-4?ZUK_H ?_A2O_E ?\2I5?^BZI_\ B-R_^?I_'117]B_]CZ3_ - O3O\
MP"MO_C5']CZ3_P! O3O_  "MO_C5'^M:_P"@!_\ A2O_ )0'_$J57_HNJ?\
MXC<O_GZ?QT45_8O_ &/I/_0+T[_P"MO_ (U1_8^D_P#0+T[_ , K;_XU1_K6
MO^@!_P#A2O\ Y0'_ !*E5_Z+JG_XC<O_ )^G\=%%?V+_ -CZ3_T"]._\ K;_
M .-4?V/I/_0+T[_P"MO_ (U1_K6O^@!_^%*_^4!_Q*E5_P"BZI_^(W+_ .?I
M_'117]B_]CZ3_P! O3O_  "MO_C5']CZ3_T"]._\ K;_ .-4?ZUK_H ?_A2O
M_E ?\2I5?^BZI_\ B-R_^?I_'117]B_]CZ3_ - O3O\ P"MO_C5']CZ3_P!
MO3O_  "MO_C5'^M:_P"@!_\ A2O_ )0'_$J57_HNJ?\ XC<O_GZ?QT45_8O_
M &/I/_0+T[_P"MO_ (U1_8^D_P#0+T[_ , K;_XU1_K6O^@!_P#A2O\ Y0'_
M !*E5_Z+JG_XC<O_ )^G\=%%?V+_ -CZ3_T"]._\ K;_ .-4?V/I/_0+T[_P
M"MO_ (U1_K6O^@!_^%*_^4!_Q*E5_P"BZI_^(W+_ .?I_'117]B_]CZ3_P!
MO3O_  "MO_C5']CZ3_T"]._\ K;_ .-4?ZUK_H ?_A2O_E ?\2I5?^BZI_\
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M\<27>H:'I-[=2!$C$ES=6%O/.XCC540/+(S!$544':J@ "O\WK_@\:_Y2;?
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M5$2;3C;J_P#(_P!'FBBBK+"BBB@ HHHH **** "BBB@ HHHH **** /XH/\
M@GM_P6/_ ."@GQ[_ ."]GC?]ASXH?&/1M>_9KT;XY_MH^"M.\#V_PM^%VC7T
M/ASX/:?\7I_ %DWB_1O"-CXNE?1Y?"FAM-=RZT]WJGV1UU2:[6YN1+_:_7^:
M_P#\$D_^5J/XE_\ 9SW_  4?_P#33^T#7^E!40;:=W?7_(B#;3N[Z_Y!1115
MEA1110!^)O\ Q$8?\$7_ /H^#PO_ .&H_:!_^=-1_P 1&'_!%_\ Z/@\+_\
MAJ/V@?\ YTU?CG_Q!B?LR_\ 1Z/QV_\ " ^'_P#\?H_X@Q/V9?\ H]'X[?\
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MOG_5GY7_ &,_XB,/^"+_ /T?!X7_ /#4?M __.FH_P"(C#_@B_\ ]'P>%_\
MPU'[0/\ \Z:OQS_X@Q/V9?\ H]'X[?\ A ?#_P#^/T?\08G[,O\ T>C\=O\
MP@/A_P#_ !^B\^R_KYA[_:/]?/\ JS\K_L9_Q$8?\$7_ /H^#PO_ .&H_:!_
M^=-1_P 1&'_!%_\ Z/@\+_\ AJ/V@?\ YTU?CG_Q!B?LR_\ 1Z/QV_\ " ^'
M_P#\?H_X@Q/V9?\ H]'X[?\ A ?#_P#^/T7GV7]?,/?[1_KY_P!6?E?]C/\
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M1^T#_P#.FH_XB,/^"+__ $?!X7_\-1^T#_\ .FK\<_\ B#$_9E_Z/1^.W_A
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M]C/^(C#_ ((O_P#1\'A?_P -1^T#_P#.FH_XB,/^"+__ $?!X7_\-1^T#_\
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M1^.W_A ?#_\ ^/T?\08G[,O_ $>C\=O_  @/A_\ _'Z=Y]E_7S'[_:/]?/\
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M ((O_P#1\'A?_P -1^T#_P#.FH_XB,/^"+__ $?!X7_\-1^T#_\ .FK\<_\
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ME?\ 8S_B(P_X(O\ _1\'A?\ \-1^T#_\Z:C_ (B,/^"+_P#T?!X7_P##4?M
M_P#SIJ_'/_B#$_9E_P"CT?CM_P"$!\/_ /X_1_Q!B?LR_P#1Z/QV_P#" ^'_
M /\ 'Z+S[+^OF'O]H_U\_P"K/RO^QG_$1A_P1?\ ^CX/"_\ X:C]H'_YTU'_
M !$8?\$7_P#H^#PO_P"&H_:!_P#G35^.?_$&)^S+_P!'H_';_P (#X?_ /Q^
MC_B#$_9E_P"CT?CM_P"$!\/_ /X_1>?9?U\P]_M'^OG_ %9^5_V,_P"(C#_@
MB_\ ]'P>%_\ PU'[0/\ \Z:C_B(P_P""+_\ T?!X7_\ #4?M _\ SIJ_'/\
MX@Q/V9?^CT?CM_X0'P__ /C]'_$&)^S+_P!'H_';_P (#X?_ /Q^B\^R_KYA
M[_:/]?/^K/RO^QG_ !$8?\$7_P#H^#PO_P"&H_:!_P#G34?\1&'_  1?_P"C
MX/"__AJ/V@?_ )TU?CG_ ,08G[,O_1Z/QV_\(#X?_P#Q^C_B#$_9E_Z/1^.W
M_A ?#_\ ^/T7GV7]?,/?[1_KY_U9^5_V,_XB,/\ @B__ -'P>%__  U'[0/_
M ,Z:C_B(P_X(O_\ 1\'A?_PU'[0/_P Z:OQS_P"(,3]F7_H]'X[?^$!\/_\
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M]_M'^OG_ %9^5_V,_P"(C#_@B_\ ]'P>%_\ PU'[0/\ \Z:C_B(P_P""+_\
MT?!X7_\ #4?M _\ SIJ_'/\ X@Q/V9?^CT?CM_X0'P__ /C]'_$&)^S+_P!'
MH_';_P (#X?_ /Q^B\^R_KYA[_:/]?/^K/RO^QG_ !$8?\$7_P#H^#PO_P"&
MH_:!_P#G34?\1&'_  1?_P"CX/"__AJ/V@?_ )TU?CG_ ,08G[,O_1Z/QV_\
M(#X?_P#Q^C_B#$_9E_Z/1^.W_A ?#_\ ^/T7GV7]?,/?[1_KY_U9^5_Y^?\
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M -'P>%__  U'[0/_ ,Z:OQS_ .(,3]F7_H]'X[?^$!\/_P#X_1_Q!B?LR_\
M1Z/QV_\ " ^'_P#\?HO/LOZ^8>_VC_7S_JS\K_L9_P 1&'_!%_\ Z/@\+_\
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M(,3]F7_H]'X[?^$!\/\ _P"/U5Y]E_7S*]_M'^OG_5GY7_8S_B(P_P""+_\
MT?!X7_\ #4?M _\ SIJ/^(C#_@B__P!'P>%__#4?M __ #IJ_'/_ (@Q/V9?
M^CT?CM_X0'P__P#C]'_$&)^S+_T>C\=O_" ^'_\ \?HO/LOZ^8>_VC_7S_JS
M\K_L9_Q$8?\ !%__ */@\+_^&H_:!_\ G34?\1&'_!%__H^#PO\ ^&H_:!_^
M=-7XY_\ $&)^S+_T>C\=O_" ^'__ ,?H_P"(,3]F7_H]'X[?^$!\/_\ X_1>
M?9?U\P]_M'^OG_5GY7_8S_B(P_X(O_\ 1\'A?_PU'[0/_P Z:C_B(P_X(O\
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M -:V^ U?NU7XA_\ !QUX6\3^-?\ @C)^V1X9\'>'->\6^)-2_P"&>?[.\/\
MAG2-0U[6]0^Q_M5? [4+S[%I6E6]U?W7V6PM;J]N?(MY/(M+:XN9=D,,CJI;
M/T?Y">S]&?GI_P &<O\ RC)^.G_9]OQ-_P#6?_V8:_K'K^63_@T7\!>.OAU_
MP3<^-FB?$'P7XL\"ZS=?MO?$C5;;2/&/AS6/#&IW.F3_  '_ &:[2'48+#6[
M.QNIK":ZL;VVBO(XFMY+BSNH4D,EO*J?U-T1V7HOR".R]%^04444QA1110 4
M444 %%%% '^:_P#M=?\ *W9X3_[/L_8D_P#4(^ =?Z4%?YU/[5WP8^,.H?\
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MU_5'^BO1115EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%% !1110 4444 ?YK__  23_P"5J/XE_P#9SW_!1_\ ]-/[0-?Z4%?YU/\
MP2I^#'QA\/\ _!SS\1_'6O?"CXE:)X(F_:4_X*&WT/C'5_ OBC3?"LMEK.E_
M'A=(O(_$-YI<.D26NJM=VBZ;<+>&*^:ZMQ:O*9H]W^BM40V?K^B(AL_7]$%%
M%%66%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;_A9E[HVKZ98Z=/HU[XQM=2\.O8B*TBT?TKX!_ WX>_\$K?^"@?_  1&\0_
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M?%%]XPL=,M]#M=1T[P/I^A:58ZC;^"K"Y\-:B ?Z7]%<3\-/%\?Q!^''P_\
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MRNJW.F13V]Q#)?PVCVB2P31M*'B<+T5?Q;?L8_ ']I[X!?\ !QWX @_;(_:
MTO\ :-_:*^*_[$7BSXM_$/QAX<T%O#O@[PW>ZK_PD'@ZQ^'O@BS^SZ3%<>$_
M"VF^![5=*U"#PKX*2[^W3M)X6LKE;B[O_P"TF@ HHHH **** "BBB@ HHHH
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M(=/NWL+^;PUXW\/ZAX9UV*QOHU>2RO)-+U.Z2VNT5GMIBDRJ60 _RK_MB?\
M!JS\!O$OA/X1:/\ L4ZM?>$-2T?XP^&]3^+$'QW^-7Q"O_#]_P#!:.SUE?%F
MD>!+/0? OBY;3QW>7]SIDFE7%W::38B!=0\_5[=I DW]<=% 'G'P=^%?A+X%
M_"/X6?!+P##?6_@7X._#CP/\*_!=OJEZ^I:G!X2^'OAG2_"7AR'4=1D5)+^^
MBT?2+-+N]D1'NKA9)W56D('H]%% !1110 4444 %%%% !1110 4444 %%%%
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M9)X8G73/&-CK.E^)O!6ER^)0#^C3_@JG_P %&]'_ ."7W[.'AS]HG7?A5?\
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M,O\ @GAJ>H_\%,OBOIO[87BG1_BLGPL_93G^$][XBU+XD?$;3M7\,ZA?>!?
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MF#3=)N2F(Y#NQA&^Z?XAM1_X(R_\%*)_^"+7Q)_9+B_9OW_M!:__ ,%4[_\
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M_#NC_JL7_F/?_P .*/[*\._^BFS+_P (<3_\ZP_UB\<?^B R'_P[X'_Z(3[
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M_P#P[H_ZK%_YCW_\.*/^'='_ %6+_P Q[_\ AQ7U/]E>'?\ T4V9?^$.)_\
MG6?G?^L7CC_T0&0_^'? _P#T0GV!_P -,_ 7_HJ'AG_O]<__ "-1_P -,_ 7
M_HJ'AG_O]<__ "-7Q_\ \.Z/^JQ?^8]__#BC_AW1_P!5B_\ ,>__ (<4?V5X
M=_\ 139E_P"$.)_^=8?ZQ>./_1 9#_X=\#_]$)]@?\-,_ 7_ **AX9_[_7/_
M ,C4?\-,_ 7_ **AX9_[_7/_ ,C5\?\ _#NC_JL7_F/?_P .*/\ AW1_U6+_
M ,Q[_P#AQ1_97AW_ -%-F7_A#B?_ )UA_K%XX_\ 1 9#_P"'? __ $0GV!_P
MTS\!?^BH>&?^_P!<_P#R-1_PTS\!?^BH>&?^_P!<_P#R-7Q__P .Z/\ JL7_
M )CW_P##BC_AW1_U6+_S'O\ ^'%']E>'?_139E_X0XG_ .=8?ZQ>./\ T0&0
M_P#AWP/_ -$)]@?\-,_ 7_HJ'AG_ +_7/_R-1_PTS\!?^BH>&?\ O]<__(U?
M'_\ P[H_ZK%_YCW_ /#BC_AW1_U6+_S'O_X<4?V5X=_]%-F7_A#B?_G6'^L7
MCC_T0&0_^'? _P#T0GVCI'[0?P7U[5-/T31_B)X>U#5=6O+?3].L;>:X,]W>
MW<JP6UO$&MU4R32NJ("P!9ADBO8Z_/CP%^PA_P (1XV\)^,?^%J?VG_PB_B'
M2=>_L[_A!_L7V[^R[V&\^R_:_P#A,+O[-Y_E>7Y_V6X\K=O\F3&T_H/7S.>X
M;(L-6H1R+,,1F-&5*4J]3$4:E&5.KSM1A%5,-AFTX6DVHR5W:ZV/O^#\?QAC
M\)BY\8Y)@LDQ<,1&&$HX+%4<5"MAG2BY59RHX['*,E5<H*,IP=E?D:U91117
MAGUX4444 ?-'[0'PW\7ZAJO@'XZ?""PMM2^-OP5'B"RT7P]?:E9Z5IGQ0^%'
MCV^\*3_&'X,:CJ&HPR66DW?BZW\%>$O%O@+Q ;K0ET3XN_#OX<R^(]?C^&MQ
M\0O#_B3?^"_[2?PE^.SZYH_@[Q =-^(W@N.P7XG?!?Q?'%X:^,_PFU#4/.6V
MT[XC?#N\N&UK0H[V6VNCX?\ $D"7_@GQQIT">)/A]XH\6>$[[3->OO>*\<^+
MG[/7P-^/5GI]G\9?A-X"^(YT9;S_ (1[4O%/AK3-1\0>%9K^$V]W?>#_ !,\
M"^(O!^J2PL4_M;PQJFDZG&,&*[1@"#T_R ]CHKXCU7_@GI^S3K%_/J-TW[1=
MM/<>5O@T;]MG]M3P[ID0AACMXUM-&T#]H+3-'L4$<2%H[*QMTDE+SR*\\LLC
MY_\ P[A_9A_Y^?VGO_$\_P!NS_Z)"EKY??\ \#U_IZ&O]/\ X'K_ $]/NRBO
MA/\ X=P_LP_\_/[3W_B>?[=G_P!$A1_P[A_9A_Y^?VGO_$\_V[/_ *)"C7R^
M_P#X'K_3T6OE]_\ P/7^GI]V45\)_P##N']F'_GY_:>_\3S_ &[/_HD*/^'<
M/[,/_/S^T]_XGG^W9_\ 1(4:^7W_ / ]?Z>AKY??_P #U_IZ?=E%?"?_  [A
M_9A_Y^?VGO\ Q//]NS_Z)"C_ (=P_LP_\_/[3W_B>?[=G_T2%&OE]_\ P/7^
MGH:^7W_\#U_IZ?=E%?"?_#N']F'_ )^?VGO_ !//]NS_ .B0H_X=P_LP_P#/
MS^T]_P")Y_MV?_1(4:^7W_\  ]?Z>AKY??\ \#U_IZ?=E%?"?_#N']F'_GY_
M:>_\3S_;L_\ HD*/^'</[,/_ #\_M/?^)Y_MV?\ T2%&OE]__ ]?Z>AKY??_
M ,#U_IZ?=E%?"?\ P[A_9A_Y^?VGO_$\_P!NS_Z)"C_AW#^S#_S\_M/?^)Y_
MMV?_ $2%&OE]_P#P/7^GH:^7W_\  ]?Z>GW917PG_P .X?V8?^?G]I[_ ,3S
M_;L_^B0H_P"'</[,/_/S^T]_XGG^W9_]$A1KY??_ ,#U_IZ&OE]__ ]?Z>GW
M917PG_P[A_9A_P"?G]I[_P 3S_;L_P#HD*/^'</[,/\ S\_M/?\ B>?[=G_T
M2%&OE]__  /7^GH:^7W_ / ]?Z>GW917PG_P[A_9A_Y^?VGO_$\_V[/_ *)"
MC_AW#^S#_P _/[3W_B>?[=G_ -$A1KY??_P/7^GH:^7W_P# ]?Z>GW917PG_
M ,.X?V8?^?G]I[_Q//\ ;L_^B0H_X=P_LP_\_/[3W_B>?[=G_P!$A1KY??\
M\#U_IZ&OE]__  /7^GI]V45\)_\ #N']F'_GY_:>_P#$\_V[/_HD*/\ AW#^
MS#_S\_M/?^)Y_MV?_1(4:^7W_P# ]?Z>AKY??_P/7^GI]V45\)_\.X?V8?\
MGY_:>_\ $\_V[/\ Z)"C_AW#^S#_ ,_/[3W_ (GG^W9_]$A1KY??_P #U_IZ
M&OE]_P#P/7^GI]V45\)_\.X?V8?^?G]I[_Q//]NS_P"B0H_X=P_LP_\ /S^T
M]_XGG^W9_P#1(4:^7W_\#U_IZ&OE]_\ P/7^GI]V45\)_P##N']F'_GY_:>_
M\3S_ &[/_HD*/^'</[,/_/S^T]_XGG^W9_\ 1(4:^7W_ / ]?Z>AKY??_P #
MU_IZ?=E%?"?_  [A_9A_Y^?VGO\ Q//]NS_Z)"N@M?V)/ _A73;F/X2_&?\
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M]F'_ )^?VGO_ !//]NS_ .B0H_X=P_LP_P#/S^T]_P")Y_MV?_1(4:^7W_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<W7C#5K2P\1%M8M]%US3+G6([;7+[5K2#^B:B@ HHHH **** "BBB@ HHHH
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MI:9>:!/IK^$O&/B'5]:\2VNJ>+TMK#P^MMY?_P %6_VA?C_^WA%_P;]?M2^
M/'WA/X:_\-!^*=&LO GA9?"1U#2?A5^USX>^,GP\\*?$'XAN-:M]0O\ Q+X"
MM/%A\*67ASPUK5WK$8TCP=>RNMR_B&]N;_,_X(\?\$U_VP?VS?V'OVMO"OPR
M_;[\9?LF_!#XK_M0_$SX0?'#X&77P*T;XBZ9X\T/3? WPHURX\6>']>UCQ9X
M3\1^#M3\3:7XMG\&^+;?PU<Z;;^,/#^@Z3I>O:E>Z=:?V<G]#_[7O_!$KP]\
M:?V;/V"/@E^SK\<[G]GCQE_P3M\3>%?$?P2^)_B#X=Z=\5[G4;C0+'1)-1O/
M$?A^7Q!X1TMM>U_QCX8\-^/M2OO*O=#GU;3KW2G\+_V9JJ-I@!^>7A;]L+XT
M?LP?\%6/^"C</QFTOX$?%3QQ^R1_P1NT_P"-GC7XB>&/@+\)_AU\1/C+\9/A
MS\)OV2=:\31:O\8_"_@"S^+3_#_QUXUO-6?3?!6K^(+_ ,)^%[&Y\-I::#:P
M>#M!CTS\DO\ @H)\8/\ @KQ^U+_P2#M?VROVJ?C#^SEXF_9._:.^,&@ZMX5^
M"'ACP9#X8^(WP@33/'?B'3O MWX9U;1O"UI_:VAWM[X?U^PN](\;>/\ X@>)
M+'PM<>&]3O=6O/$5WKT'AW^I;X>_\$;IH_VN/VB/VJOVB/VEI_C_ '/[5?[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
>%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>nt10016217x4_graphic09x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic09x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MM?H'7Y^>"_\ E)S\=_\ LSC]G_\ ]6U\=:!K:7I^J/T#HHHH$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4X
M9H90APY1MI&,@XXZ\=:_&C_@F!\6_AA\(/A?\6OV>?C#XS\*?#W]I'X7_M _
M'O6OC)HGCS7-(\)^(_&+>.?BCXJ\:>&/BQ:0ZU?6\^N^%O%?@G6/#R:7KUHU
MQ8I'I;:<)(H[&-:_9RO"_BI^S#^SE\<K[3=4^,GP)^$7Q2U31T$6F:IX_P#A
MYX5\6:E8VP?S3:6M_K6EWEU%9/)\\MD)?LDK?ZV!\FE;K_6MK_D-/H]G;U5O
M^ V?"7B/]HKPSX0_X**R:CXH^-&E>'_V?[C_ ()[6?Q-M)]9\=VME\,+N_3X
MWZS#<>-=,>XU >'+S4?^$=:RMY-<TT3W<FE2:?!).UM+9*WY462>%OVB_@;_
M ,$NOBQ\8/BY\48="U_]MS]JS1[KQM>?&7XA_#R6W\&#Q%^U#J/AFYOM5A\1
MZ%<:'K.F:?H&A>'=*U*XFLM6T/1TG\+0R0:=<3V4G])?B7]FO]GOQDW@-_%G
MP0^$WB,_"Z*"W^&XUGX?>%M1C\"6MJ(!;67A**ZTR6/0+&#[+:-#8Z8EM:12
M6EI*D*R6MN\5[Q'^S]\"_%_A/3_ 7BCX.?"_7_ VE>(6\6:;X-U;P'X9OO"]
MAXG?4;K6)?$%GH,^FOI5OK,^K7]]J5SJ45HMU<WM[>7-Q)+-<SO(6_KT:?Z>
MNNZ6A2DE;3;?[FOO=]?1'\\7[6G[2.BZ!\>9_$'PB\8_%BWUGP#^V+^S9\%=
M9^('CS]J9/#?A/1PNN_#;2O&WPQ^%7[.MEK#W_Q%\*>(?"FLSZCXQ\6>-_#_
M ).K:AJ_B#Q!IOB/4+73[* ^H?&WP5XS^*WQ;_X*\>)?$/Q[^/.D>%?V;O W
M@WQ!\(?ASX$^)WBKP-X8\/>./^&88/&\/BYY?#&KV.HW2V.N645Y9^&5GC\,
MOJMS?ZMK&DZI?S6\]I^WVL_LT?L[>(O$FK>,?$'P(^#NN>*]>L[#3];\2ZO\
M-/!NHZ_J]EI4MC/IEKJ6L7>CRZA>0:?-IFG2V44]PZ6TFGV+0A#:0;.^_P"%
M>> BWBZ0^"?"32?$"&*V\>.?#FD%O&UO!I?]B06_BUFM"WB."'1?^)1%#K!O
M(X],S8HJVI,5&O?KV\MOOU_ %)+H[^OG'=^B:Z+4_G*^)_BC]H+]HGXM? 3X
M9:M\4-"\*^&+O_@GY\&_C/H47C+]H/XH_LY6OC[XH>,TO(/B!\0K7Q'\+-(E
MOO&6O_#]['PZZ^'M:OHM,\/IKR:S/I=Z=9W6GKFC0>//&_Q?_9P_9C_;,_:A
MU,>"- _8GLOB;IOC[X0?%SQ'\*_#?[2GQ?MO&-YX>\1>*!\3]$U+PSKGBH>!
M/ <'AKQ)%HT>I6T-[?\ B5_%^H:?<1);BV_:'XA?LY? 'XLZ)X<\-_$SX+?"
MSQ[X?\'QI#X2T;Q;X#\-:]IOA>".WM[1+?P]9ZCIT\&C6HL[6WLVM=.CM[>2
MT@AM7C:")(Q+XZ_9X^!'Q.\*Z#X&^(?P;^&'C7P;X5-I_P (OX6\3^!O#FL^
M'_#0L+5;&S3P]I-]I\UGHL=M8JMA#'IL5M''8C[$$^RDPT6??^M+Z>?X7#F7
M:V^UKK;6]M]^Q^&_P&_:+^)E[-_P3LNO&OQ>\2ZQ\-V_;+_;-^%&E_%?Q'XE
M.FV/QV^!_P .OA!\=[;X/^,/'NK++8:'XL^W?V)IMQ8ZSJ*/;^(M5T*R\4PO
M/?W@N+G3@^)GC;]K+2?^"GD?P!_:?TSP_H&C?M7? ?0/AGXP\0?$;Q1X/\ W
MV@:+\)/@U<^-OA=X<\?Z-=IJW@CP_P#$S7(/$>AQ^*_A^WG7=_K5UJ^CM>G4
M?M4W[=^-O@#\$/B3X+TCX<>/_A'\-O&7@#0)=.FT'P5XD\%>'M7\+Z')I%N]
MGICZ+H=Y82Z=I36%G))8VOV"W@$-A+/8H!:SRQ,S4/V??@3JGA/7O NH?!CX
M57G@SQ2=(;Q-X4G^'WA1_#OB"3P_I^GZ5H$NLZ,=*^P:E-H6F:3I6G:-/>03
M3:78Z9I]K8R6\-E;+$6\_7ITM;]>_GM9)KM;TMW3\M?P\K;?'G_!-KXD>&O%
M_P ,OBCX.TOPEX_\#>*OA'\8]9\!_$?PCXT^->K_ +0ND:)XN'AGPGK31_#?
MXK:SK6MW&N_#^[T;5M)U+3+(R:9/I6H7NJ07^AZ;?R7"2_I&.@SU[UY[\-_A
M5\-/@YX8A\'?"SP%X/\ AUX3MKFYOXO#W@KP]IGAO1EOKPHUY?-8:3;6UO)>
MW;1QFZNY4DN;@QH9I9"BD=9'KVC3&W$.I64QNY98+7RKB)_M,T'FB>&WVN3-
M+"89A+''N>,Q2[P/+;#$]6_^'-:BF"6,@$,.1G\Z*!#Z*** "BBB@ IDD:2K
MM<;E.#@],@@@X/!P1WXZT^B@#S4_!SX5GQPOQ-'P[\$#XD+ UJ/'X\*:$/&?
MV9X)+9[<^)OL']LM"T$LL)C:\*^7(R !6(JSXD^%/PX\9:SX:\1^+? WA'Q/
MX@\&WC:AX2US7_#>CZOJ_AF^9@YN] U&_M)[O2+CS )/-L)8&\Q4;/[N,+Z#
M10!&D83.#G.>P'4Y/3CDY)P.2<U\ >"_^4G/QW_[,X_9_P#_ %;7QUK] Z_/
MSP7_ ,I.?CO_ -F<?L__ /JVOCK0-;2]/U1^@=%%% @HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]J;3ZYH]M=ZA#8:3/>BUO[9_U_P%\_\ @V*M'R]=>\=_.S=TCW+XJ_MU^,?
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M9Q^S_P#^K:^.M UM+T_5'Z!T444""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;L7KM&>N>_XGJ?QIU% &
M7JVB:-KUI]@UO2=.UBQ,]M<FSU.RMK^U-Q97$=W9SFWNHY8C-:W4,-S;2%-\
M$\4<T961%8:6Q.?E'/M_G'X4ZB@!I1#U53]5'^%((T48"*!G. !C-/HH 3 ]
M!^0I-B9)VC)QG@<XZ?E3J* &E5.,J..G''UQTR.Q[=J4JIX('Y"EHH 0 #H
M.,<>E-,4;=44\YY&>:?10 W8G7:/R'^1_7O1L7.=HSZTZB@ HHHH **** "B
MBB@ HHHH **** "OS\\%_P#*3GX[_P#9G'[/_P#ZMKXZU^@=?GYX+_Y2<_'?
M_LSC]G__ -6U\=:!K:7I^J/T#HHHH$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^?G@O_ )2<_'?_
M +,X_9__ /5M?'6OT#K\_/!?_*3GX[_]F<?L_P#_ *MKXZT#6TO3]4?H'111
M0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHII+#NH'OF@!U%-!8]U(]LTZ@
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MF;E-)).4IN4G9)**<K)*R22/<Z"0.I ^OTS_ "!/T%?&/P]_;W_9N^*OCQO
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MU4I<'>'^ =XX:GEF14\_S*G%M/FQ..XFEF>!Q-96<5.CD^"H\C2>'=1>T?\
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MQ%DT:"E4K9?7Q6,SF@E[7"8C-:=2=# _U4T445^Y'^4@4444 %%%% !1110
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MSOQ))\@^ /\ @G!^T1X*_9A_:=_8WM]-TB?P;^U!\!=.\46/Q8U3Q%9S>+/
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M** "BBB@ HHHH **** "BBB@ HHHH *0D $D@  DDG  ')))X  ZFEK\4/\
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MN4FK-/JU?TUU^3LSX0_8O_:9\>?"S]@?_@G!\'?A!X2T/QY\>_VC?"OB_3?
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MFUK4=-ETR[TN06D5Z_\ V-_&-S^T#\,/V@E_:)\<)XE\-_!.U^!OQ9M$\%>
MT7XS^&M.\0:AXJL[RZNX-+CA\!W\VOZK>W>HS>$-.MIKFW6TM+.XTI899+A[
M]UJM?G_5^_0+K6UMG:]V[Z=?OM^)X?\ ##]OOXA:W^UEX%_9G^(D7[.]U?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7/B!\1O%7A_P1X(\,VHO_$7BSQ5JUGH?A_0[!IHK87FJ:KJ$L-G96_VB>"
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MV=CJBE]T*77CHZ:UK%("!=Z3=JJF196'ZZH"%4'KCM3[_*WW)_K8A].ETO\
M+\;7^8ZB@\ GTK*U77-)T.PN=4UG4+72].LXWENKV^FCMK:"-!N9Y)I65%&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBULD&Y4-Q&2S?>.E:-IFBV%MIFE6%KIFG6<:Q6ME8PQVUM!&@ "1PPJJ(N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "DY^.__ &9Q^S__ .K:^.M UM+T_5'Z!T444""BBB@ HHHH **** "BBB@
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MJHH&%50 HX %6:?.[6BW%/6R;UTMK_7J%_DO*_Z^B^XCCC2, *H7@<   ?3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=OJLOQY^S3XA_9&^$_\ P3-^"OAK^QM+\6>,?BA\?-)\%_%[PG=_M!:S\+?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/>W[YN;AB<L5=_*5B1'&B84>BJ"  >WX_K2UFI<U_=4;6T5_UU[=>OF2_N]
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M\T6#5]4MKW5;30KIO.LA<23@217:74_[64+5+T1$E9M:?+;\ HHHIB"BBB@
MK\_/!?\ RDY^._\ V9Q^S_\ ^K:^.M?H'7Y^>"_^4G/QW_[,X_9__P#5M?'6
M@:VEZ?JC] Z***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !11TI 0>A% "T444 %%%&1ZB@ HHHH **,C_/^>** "BBB@ HHHH ****
M "BBB@ HHHH **** "BF2,51F W$*2%) R<<#)X&3Q7.:)XO\.>(-0\0:3I&
MO:)JFJ^%;RVT_P 2Z7I>J66H:CX>O[RS2_M;'7;&TGFNM)O+FQEAOK:VOXK>
M>>SFBN(HWA=9& .FHI,CU'X\?SIKOM1B"N0.,\C).!G!SC)% #Z*X#2OB5X/
MUOQGXJ^'>D^(]&O_ !QX&T_PSJ_C#PO;7:RZQX<TSQDNJOX6O-5LU)>UAUR/
M0]9;3G=O](73;E@HV@'OAR ?4"@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M/IFI6'BJX\:Z?:D:-:0TG>ZMV?;RW\M=;:E12=[^5OQT6J5]-+Z']26H>/\
MP9HFKZ1X<UCQ3X=TOQ!KH_XDNB:CK>EV.L:N06##3=+N;N._O2I5@PMH)3N1
MU +*15?6_B9X!\-)</XA\8>&="6TOK/3+EM8U_2-+6WU'48EGL+&<WUY!Y-Y
M>P.D]I:R[;BXB=)(8G1@U?S$?&_X(^#/'_[47[7OA?\ :E^/5]\&_B#\0OC?
MX5U7X"ZH_P"S9!\2?'FN_">ST3P)<?#*Z_9W^+C:/J6O^';OPYXALM3TWQ/H
M'@J:TN]$U>*\UK646UU8W4GT)\4OV2O WQ#^(O\ P6=^)7Q!^%UW\1/%>D_"
M#0=,^#5WXQ\-W6NZ2NJP?L:Z8)_$WP_T/4+6YT>;QV_B72["Q7Q1H5E-XCL;
MK3K;2K&^MAYEK<%_)KUMM9N^C?;\1\NVNZ3T7>W?UZ7V/W[\1?$+P1X16Q?Q
M5XL\-^&DU.YCL],?7]>TK1DU&[E&8[6P?4KNU6\G?C;%;M([;EP/F%?,VL_'
M;Q=I_P"W5\,/V<[.VT%_ /C;]FGXJ?&74;Z2VO9/$</B3P5\0_AOX3TJUL[Y
M=133TT:?3?%VHS7EM-I=Q</=QVDD%[!%$T4OX??M@>,+B3X;_!?X8:Y\$/!%
M_P#$34_^"<.@VWA_XF_&+X(_%OX\^,?$OB7Q+X:DTK4OA'\&?!OA.&#1M ^*
M6F:KI^GZ_P")?%/BK5;;4M+AU'2'DTZ[L;&Z:/ZQ_9]L_B/XC^,O[ 'B;PVF
MI6OB4_\ !'WQ)X>3Q?XQ\/:_?Z/H_P 3)M1_9XC@@\8)<MIE[=:A%K6G7MYJ
M>CW.I:?K&J6]E?-%/&Q-U&-O3>[L_E=7_!ARI*^^C:Z=FNOKO]VA^X.O>(]#
M\+Z=<ZQXBU;3-"T>R3S+W5M8U"TTS3+-,A0UU?WTL%K;J6(&Z:5$R>6KG9OB
ME\.;;PS%XTN?'/A&W\'S.J1>*IO$FC1^'9"\@A39K3WJZ<Q>;,2(+DR/*/+5
M"V!7XR?M9:%\1]!\=_L0>(/^"@=QX+^+/[.?A/Q?\:[GX]:I\/?AMXLM/@KI
M?CC4_#FBP?L^:_\ $[P!?:OX[O+SPGHUVGB>RGU37GN_#UAXHN](U6]CL;=0
M@^>/VK]%_9Z\5^._V2/&7P\UKP#\+?\ @GUINC_M :<FO6/[-.G>.O@'H7[0
M6MZ[X<DL-9\8?#?Q#X:L?#&GV/B/0G\90^%/'UUH\VC1:M]NCTJ_MQK NW?]
M+5:[=[6M>S$DG;7>]_T2\_\ @?/]@OB5^T+XET#]JG]E+X->%QX:U+P'\>O"
M/Q\\1Z_K;QSW^J12?#+PUX9UKPU+X<U"UU%=-6TOI-<N!?23V.HQW5NEJ;.6
MW;>[=)^PE\<_%_[2?[*OPM^-7CRST*P\5^-#XX&JVGAJUO;+1(?^$;^(WB_P
MC9?8K74-0U6[B$FG:!:2SB6^FW74D[Q^7&R1)^7O[.?P=TGX:?%__@F=IWPV
M\;^-?C#\+]'\+_MYZMIWQ$UOP'K'@JPTO3?&K:)JFBZ'!X=NM.M$\)^%K.YN
M[W1_ =G/';V=QH=I8KHTES9"VK[N_P""4VBZQX>_8'^!&C>(-)U30M7LF^*?
MVS2M9T^[TO4K3[3\:/B+=V_VFPOX;>[M_/M+B"ZA\Z%#+;S13)NCD1BNOE9?
MC&+_ %?]6!JR_7KO)?+1:^A^AM%%%,D**** "BBB@ HHHH **** "BBB@#SK
MXL?$KPS\(?AK\0?BCXRNEL/"?PY\&>(_&_B6^D=(TMM%\,:1>ZSJ,F7= 6%I
M8S;%W NY51R:_EW_ ."67[27PL\+_M??#K7[/XM:;XK^(?\ P4?\"?$GQE^T
M5X6MXO$D$?@;]HW1/&>N_%7X;Z;)/K-E:Z7"D7P?\3:U\+HK?3)[J.>_\ V
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MMTU=.\(^'[2P8QJESJ4BK<ZMJ!VJ'>^U&4-//O9 _D@I;(<".!0BX]-"*IR
M 2,9P/?\NO;BJ4K+1)/O_P /_P -Y#O;;3SZ_P##:?\ !.9\+>#?#?@O2X-%
M\,:/IVBZ9;JH2UL+5(58J%7S)7RTD\K*H#S3.\CD<L1Q748'I_D=***D0444
M4 %%%% !1110 4444 %%%% !1110 44C?=;_ '3_ "^H_F/K7X ^//VZOV\/
MVL?VL/CI^RM_P36T#X*>&/"'[+FK67A?XX_M*?'ZWU[7=&_X6!<FX:3P1X&\
M+^'9/,OI-.FL]0TV[GO[:Z6XNM+U"=I])M([5KX_71?U^KT[C2O^KZ*Y^_\
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M75)D>H].O?KC\N:_(GXI_P#!:W]@;PY\$?CA\6?A5^T%\-OBWKGP:\*7.O\
M_"!:=XAN_#FI>+-3,C6>B:+HMUK6DP_;8M>U/986FKZ7:ZI8^:05D=67=@6/
M[=\/[0WB3_@GK\4?@7^U3\!?A_\ "SXL:K\0$^,WP@\1W:^(/&OQ-UC2?AQH
MNN7/PV^'NJQ:)*P\1_#'5]6:Y\3-'=>'PHELIC+J,,4FCWBNNZ^_SM_7^>@6
M?:W]?K=6/V6HKY67]MW]DM?@WX?_ &@'_: ^&@^#/BCQ-;^"O#_Q''B*V?PS
MK'B^YU>YT&'PW87RY-QK+ZQ97FGBQ2/SQ<6LZE (V(Y;Q[_P44_8A^%_QBT[
MX ^/_P!I;X7^%OB[J=WI^G)X-U/6VCN[#4]7\G^R=*UW4(X)-'\.:KJ9N;<:
M?IFO:CIU_>&>(6]O(9$#,+/L_N/M'('4@?C1D'H1^8KYH_; ^+WB#X%?LJ?M
M#_&_P9!IE]XF^%?P:^(7Q!\.6VLP3W&D7.L>%/#&I:QIT6IV]O<V5S-827=G
M$MU%#=6TLD)=4FC8AA_/UX&_X*L?\%(/AOX&_86_:0_:2\*?LC>,OV;/VU?B
M+\/_ (;6>C_",?$G1?C=X*O?B.NIMI&J3:5KNHWWA^^BT]-,N9]2%C)JT#!+
M73UELY[^"^8_KY::ORU&H-J^G9>;[=KVUU[']3M%?%/C[_@HA^Q3\)?B]IGP
M#^)7[2OPQ\)?%S4KNPTY?!VK:[LNK#4=6VG2M/UV_CADTCPY?:B)8#8VFOZA
MIEQ=B> P1OYT>ZO\7O\ @I'^PO\  3XHP?!?XO\ [3/PS\"?$V1=-:Y\*ZOJ
MERUSHXUF..;21XDO+*SNM,\,/J<$T%Q8Q^(;W3)+JWN+:>!'BN(7<%9]G]Q]
MO45\1?&'_@I)^PI\ ?$?B#P?\8?VGOA9X$\7>%9?#T/B'PKJ^MR-XDTG_A*K
M*'4]!FNM#LK:ZU-;2^TV>'4?MJVS6EM82+=W4\$!WUW_ ,4?VTOV4_@O\)/#
MWQW^)OQZ^''A;X1^+X+"X\'>.+G7[>]TGQBFJ6OVW3T\(KI@O;SQ/<75GFZC
MMM#M;ZX^SJ\K1*B.RFVX6?9Z[>9]/45\EV'[=_['6I_ P?M+6/[1?PMG^!*Z
MSI_ARY^)8\26J>'=.\1:IJ-MI%CX?U>639<Z-KDVIWEM9'2=5MK/4(IIXUFM
MXPP)M_"S]N']D3XW^._&GPR^$G[1/PJ^(/COX>Z?=:MXP\.>%_%FFZI>Z-I-
MC<1VFH:K(\$K6UUIFFW4T-KJ6H6,]S::?<RI!>30RL$H"S[,^J:*^(O@[_P4
MB_89_: ^)US\&_@W^TM\-O'_ ,2K<ZMY/A?0]1NWN=630HKF?69O#MY<65OI
MGB>VTRWL[JYO;KP]>ZG;V]M#)<R2K"I<7? ?_!1/]B+XG_&BZ_9Z\ ?M+_"W
MQ3\8K:ZU#3T\%Z5KHFN=2U+24N)-5TK0=3:%-$\1:KI<=K<OJ.F:#J>HWUDD
M$S7,$8C<JKKNOO"S[/35Z/1=S[0I,@=2!^-?EI_P6#_;,^*_["/[&FK?'SX,
MZ7X.U?QS;_$?X;>#;"T\<V&HZCX?^Q^,M>72[^:>VTJ_TV\\^*(K]GD6ZV1%
MFD>"XV",_+/P;_;S_;E^%G[>?P:_8M_;FT3]F'Q!9?M!_"WQK\1? 7Q(_9RO
M/'%@WAB3P5I.J:[>VOCG2?'-Y(8--GL-!U""*ZM[2".&XF@?^U;Z&*]BM2_3
MT^][+U8U!N/.K-:[/73=G[Y45\'_  [_ ."E_P"PC\6_'VI?"SX<_M0_"[Q7
MXZTW3/$.L2:/I>LS&&^TKPE;W-WXHOM#UB>VM]$\0P:#96=Y>:H^@ZE?_8[2
MVFN9=D43NOC'[$/_  5G_9J_;"T;]HC4XO&G@7P%_P ,^_$/XEZ5JB:GXZTV
M]M]3^#?@:[TNUTKX\3ZA+:Z79:5X*\5&_E>TFGDECMUMR9+N42!R77=?>*S6
MZ:MKKIOM]Y^J]%?*/[.O[<G[)7[6=_XETG]G7X[>!OBIK'@^.*X\0Z-X?O;F
M/6+"PN)1!;:N-+U.UL+^[T*[F(BM->LK>YT:[D^2WOI&! ^KNM,04444 %%%
M% #)!E&&<9&,^F>]?R^?MM_'7QEJ/_!43P7%X1^''[*.B6'[+OQ1_9 ^'_BK
MQM\3_ >@^+/VD?&VB_M+>++*U?4?A=JFLVDG_",^$_!J7T]FVN6<L.HZ5K$T
MMS:7R/J0M:_H7_:0^-_A_P#9N^!'Q@^._BJQO-2\/_"'X<^+/B'JFFV$D$-]
MJMMX6TBZU5M+L9;EEMTN]0:W2SMWF81K-.I8G&T_R ?M0?M3_"3X_:O\&/B9
M_P %??\ @F)?>!_#'QH^&U_XM_9&^*/P$^)'B#Q'\9/&%G;-H?B'P_\ ##6=
M+\(ZAH5]=7VLVOB;3-0TV/Q%);6>BW.K"6#3;2:>YN()D]O6_P!W=V=M;?D:
MTEJW:^ZM>S>S=M==+Z?GLOZ!/^"6?Q4T[X@77[<_AO2?"_POTFQ^%_[<WQ@\
M-V_BOX1>'8/#WA7XC+J6G^'=9/BG4%@U'5(]5\9JUT=/\8:S'=*FH:I:BYCB
M59FS^M(.0#7Y6_\ !)/P]K'AG]F./2E_8\@_8<\!-XTUJ\^%/P7N]<N_$?CB
MY\"7FG:7<6WC3XGZGJLUQKA\<^(]3_M"2_MM;9-4M+&VTVSNE=+:WFE_5)1@
M 'M5?UU_77[[>B(E\3_KI\_S%HHHH)"BBB@ K\_/!?\ RDY^._\ V9Q^S_\
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M;.F3ZS)87F(4EC:&OZ#OB3_P4&_8Q^$'Q<T[X#?$K]H;X9^$?B]JUWI%E;>
M]3UY#K4-[X@DA70+35(K:*>#1;S69+BU&E6^K3V<]Z+BUD@C:*ZMY)OL:W*R
M!G &#@X!'OZ8R<8&<X].<FCYKI?3LU)== YFNGFFV[;)?/[]+G\@_P %_P!B
M'X_)_P %)D_8HU_X:>)[+]@O]GO]KKQY_P %"_"/C.\T74[?P-X@N?$_A3PY
M)\-OAEI6MSVQT&^_X0_QOK-Y+-HUK.;J4IXCN+NTBBMH%B^5M1_9_P!1\,ZE
M^VY^S%^V5;?\% 3XN^-G[5'B_P")ND^'?V=_V=_"OQ(\'_M%>';[Q#9:UX%\
M7Z%\3;_P+K6KZ5?:++;+-=6UWXQTFPT&SF:QT^W2=M6LT_NFWCT.1P3GG\>,
M'@^E(54#?@>I!YZ'KGL>!T _'I1;S?SU5NWIV[!SOJK[?>NO;7T[=CX*_;A\
M(:]J7_!.G]IWP'X4TOQ)XJUV\_93^(_AO0=*2QNM4\6:[J;_  XU'3[&S.GV
MT,EW?^(-0EV>?;V\,DT^H2210Q$E0/YC/V8/^">NK?L?_$'_ ()0?M=^(_@%
M\6?B]\/?&GA#P_X.^.7PV\4Z1\0O''B#]F7X\ZRTEWX;^-FD>!KAY[WPKI&G
MR1VJ:M8W>C2:;X8DT^[NXXK.^O-%^S?V82?$SP(GCI/AB_B[PROQ$F\.2^,(
M/ S:]IJ^+9O"L%Z-,G\1)X=^TC5GT6/4&6Q;4EM#9"Z/D&;S05'<G 520><?
MQ'@G&,9R>#TZ ?C0U>U^FWX/]/N$IM*W2[;^:MONO\[/H?PMZY\ -5\-ZS^W
M3^S)^V6G[?\ %XC^.7[4_B_XG:+X>_9T_9[\,_$GPI^T5X;U37M/UKX?>*=!
M^)5[X%UK6=)U'0I[6"2YL+CQ?I5MH-OY*VL-M?G7K&#Z%_:8TCQ?\ OVO_B5
MXE_8W\'_ +2'BSXO?$[QO\'O#7Q3_99^/?[(VH_$GX(?M.Z=X>TK0?#U[\0O
M"GQ@N=*O-)\"6VGZ2U[=:MJU_J&EVUIJRWUU9M9Z:8X+?^QY0I( 7'4C!_'D
M="/J#SSUYIY0<XR,X[G''3CI]>">M%OSNGU_/7=[Z:[,?/KMZKHWIY=+:=?,
M_CU^*WQT^$WP5_X*P_\ !5-_BI^SYX^^.'B#XA_LX?!GX?\ @7P[X$^$>H_%
M69_$>N?"K2UG\&7M_I>G7P\,6GBV22UMX]4N3;V=P-'NTENH[BUM;>?SKP#^
MRE\??V+/"'_!'GX]?M-?!7XA_%KX-?L]^'OCK#\7_A?X:\*77Q,US]G_ ,0?
M%W6_$'B?X=^*[_P-8Q7U[J!\+V.KZ/'JYM]/O9O#>K:$UE:NEVFEPR?T]_"K
M]BKPM\*_VQ?VEOVQ;#QCKFJ>*?VEO#?PV\-:_P"$[NQT^'0_#EO\-M+CTJPN
M=+O(!]NNY=1BA26X2]W+!*TH@VH^!]J%%/&/3H2.F>.O(YY'?CT&"WYMKRO)
M2Z[[?=]XW)6BDMDKWZOE2=NW7_AM#^&WXS?LV?&_XM_L=?\ !57XR?#?]G'X
MK>"/@K^UE^UI^S#XF_9_^ TO@'7M/\:ZMH'@OQW:I\0/B;%\,K&WFU;PSIWB
MQK^#4VCM[2&-H+"XFF(TVVAN:_3GQ-^RSH7PR_X*E:%_PA_[.GBS3/V9]+_X
M)!^.OA_XDL_A'X#O['2M6U.3Q?XQ34?A]IFJZ1;6EG=_$G7=!>---L[G4CX@
MN;J>RNFG#SM,O]+>T$ 8X'3D@_F#GGOSSWI"BMR1GC'X>A]1STI**_+\'?Y7
M?0GF>OG?KY)+YJVY_&]^P]H/[0NF^-_$/[*'[+-C\7?B)^STW[-'[0&G>#_&
MO[27[+5S\"_C%^Q5\2-=\)Z[:>#? UC\7K[1].C\:7&OZ[?0:3>1:'?W9CM+
MMM5A2V@T^^E?SK]@KX(^&[V^_8)^!/QHTS_@HMH?Q[_9<^.FG^))/A-:?LY^
M%]*^#WPO\46GB6]N];\<:U\7[;P-8:GJ/PS\5Q!9]3O+OQ=K&L7<=R(=EQ#:
MZ;J4_P#9I\0OB!X*^$_@GQ-\1_B)XDTGP=X&\&Z1=Z]XI\4Z]=K8Z+H&BV*>
M9>ZGJ5Y)F.VL[9/GFE;A%_*KW@[Q9X:\?>%O#WC?P=K%AXA\*>*](T_Q!X;U
M[2[A+O3-9T75;6.\TW5-/N8R4GL[ZTFBN;:525DBD21<@@T[;>7W;KY]._\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D) Y-+36&5./\
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MW-;6L&JVY@N+*"Z>.Z^T1+WM-;ZJ^WG=:6TV\^PKQUM;9I;^5GL]=_R/ /\
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M#!%E@N;FWG>MNO3M=[7TU2>_5Z]; ^7F6UK*]OU[^?7YGY9>$O\ @O'\1/\
MA%M=UCQ7\./@SXQLO@C^U?\ !3X&_M"_$_X+^.?$OBGX2R?"OXZ_VQ'X4^,'
MPPU>YBBFG73-4\.ZCHFN:7K[36\>I2:9#]KMAJ4B6?VAJ/\ P4>_:#\>^,_V
M]]&_9L^ GA#XJ>&?V1_$O@;X3^#?$FM?$"'P1I?C/XL:S%:7GQ&G\1^(M<N+
M+PUHW@CX4V$ES>>()K?43JERD=E##-8_;UN5ZB^_X)Y_'?XV?LH_M1_L_?M>
M_'[X?_$G6?V@]$T_3_#&I?#+X&:)\,?#'P?U'089+S0-4TBPL=6GUGQ9/:^)
MH=*U^236=1M[@2V,UK;SPQ7LH7PW5?\ @B]J/_#L"]_8)\-?'S4=,^(6O_$A
M_B_X]^-]UX>O;BU^)WC^;Q/<Z]?)XX\,_P!NF^U/PYJ%BNBZ-=6CZW)<,= L
M+VX:[*RVTJ7-ZZ7U23OVT;2]=>NVB!<C>ME=VZO31WUMYKYGR3\6/^"BWQ+_
M &J/V1_^"P'[-?Q>L_@'J_C+]G7]F@Z_;_$K]F;QIJ?C;X4>*],\=^'9[F[T
MF#4=8DGNH]=\)7X32=7\FX:$WG]H6,MO#-IZ7&I?9_[%?[:7B7PGXV_X)L_L
M,6W@S1KCPQ\2O^"</A#XVWWCR34+U-:TK4O"7AK1]*M=#M=*CB:PFLKR.%Y;
MB>9Q<1R,IC( "/Y'X _X(F_%G04_;2?Q/^T3\*XS^V?^S#I7P+\1Z%\,OV=[
M#X;>"_ ?B30X[/3]%UOPIX9T'Q.MG%X;TO0+=K5]+46E_K&I7UUJE_>)-&JR
M>M?$+_@DS\:7\9_L=_$SX"?M91_!?XD?LV?LNP?LG^)_%4OPHL/&,WB?P0^F
MV^GWOB'PC9:GKL%EX8\3E_M=U93:E'KEK;3M8R@9M)%N37>VOKTYK^FWYL;4
M+I*2:UUULFU'71:_\.WT+GP\_P""FG[3/QN_99^)OQ@^$7P&^%]]X]\$_M??
M$']FY_\ A,OBC!X)^%'@GP)X(G=KKXS_ !)\2ZY=V-^VEV-L+>+4-$T&=[Z]
MO=2LSIH,*2H?SN_:._X*I?M7?'K_ ()N?\%"-0\!3?"GP?\ %3]E#XL^%/AQ
MXW^./[//Q?\ &-IX4U'P+JVNZ9-8?$#X'>(M/ANM;NM:OM0M[71[S3K[6-,T
MJ30M4O;Q-3:X5]+;Z4O_ /@A3X^T_P#8UT[]F?PW^T]:ZUXBT#]M+4/VN;;Q
M'\1_AY<>)_"/CTW=E]@3P+\6O"/_  D>WQ=;3N%U75KR286&J:CYXDT2**<&
M#7\/_P#!$7XGV'[/O_!0_P""NM?M(^!KV7]NC_A7'B.VU'PQ\#8/ 7A_X=>.
MO"%Z-3UC['X2T'Q,]E_PA]_);66E:)I&DMI[:5IJ--<"^N%*2CYNW36S6]G^
MMGIIVL.T-U)74E;1[7C?>WF]?\S9^//_  5>^.G[.4G[-7[.'CJS_9-\"?M8
M?%7X9ZO\5/'?BWXI?&3Q?I7[-OP[\!:7J&H:9X/FNO%U[H6D^+?$GB[X@QZ;
MY46E6MC:OI^K1:E<RB\L%@:N"^'?_!<KXF?M#_#K]G/P'^SE\#_!?BK]L[X^
M?%7XJ?"R;PKK_CC4H?@3X/B^#-II>J^,/B;/XHT^WN?%&L> ]1T/6=.U3P]#
M9V27MQNU:U2:^DTRR_MGV3Q+_P $I_VL;W6_V>/VA=$_;'\&ZA^VA\&?ASXB
M^$/BWXD>./@)HVL?"WXF_##6-;NM=T3PMJOP^M=8LQ8W/@N6_O++1_$$4[:A
MJ-L;6;484O;**X.M\2/^"6_[4'C&3]FKXYZ5^U]X4TO]M[]F_P 6^/-6T?XN
M6WP"T/1/A5XE\%?$2)(=6^&FK?#'0=>M#)H^CP>?#H^KMJDM]/:W]Y#?QR2R
M17,)K?[NWE?KON^W;HA+ENMON>[_ /;5V/QJT[P%\4OB]\'_ /@X7OOC)H?A
MGP-^T!\-OB/\+/C7*OPVUK4=5\.>%?B;\&-#UWQI9Z]X(U_4K:UUDV%_;Z'(
M]K+>6MGJ'V/4Y[2[1)&95_KK_9 ^+EQ\??V6/V=?C9=1K#>?%3X+_#GQUJ,$
M;[TM]5\1^%-,U+5+96R<BWU&>Y@SN;F/J>I_ G]H7]E/QM_P3H_86_X*Q?&C
MXM?'FW^/?Q'_ &UM&T32I+Q/ %MX(NYOB)X[L[OX9Q:/I>DZ?JVH6=Q::EJ/
MC-SH^G6=O#)I.DV445S+>M'=7M?O-^Q1\)=0^ W[(/[,OP9UA576OAE\#?AG
MX-UP(&53KNB>$]+L];90X# /JL=V^& (W8(I15GK>]M?O=O*^]_PZBE:VG?2
MW;E7ETVL?3]%%%60%%%% ",,JPYY4CCKR.WO7\O_ /P6!^"0\2?&J3XM_M'_
M /!/+P[^TO\ LN>"?"_AY=,^.?P:^-T_PD_:6\ 1VL0O_$^G^(=(/B+1%\=>
M'K'4TOKS0]-M@TUM%<QBTNX+N26.7]^/VH?C'XK^ OP9\:?%/P3\&OB#\?\
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MS\\%_P#*3GX[_P#9G'[/_P#ZMKXZT#6TO3]4?H'1110(**** "BBB@ HHHH
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M::_XM\&_9/#LGBWQ!HWQ 3Q#/<Z/97^CZ-'/#<65A=R72ZA;2HPCA;?'YO\
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M>57=NM]7KW[_ '(OVT[^??7S[;%6WM+:VCCC@ACBCC15CCC4(D:  !$1<*J
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M\O\ (]/F\NUO)I6^>WWI?.6BBB@D**** "BBB@ HHHH **** "BBB@ HHHH
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M!+XK_M5_&;]LS]J/PA/XK^&OA[]G']F/XN^'O MKI47@Z]U7XB>/[CQ3\"O
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M/&=XQUSGZG\. 3SVYI5=67<IR.>GMU'X=*9(ZBF"1#D \CJ/0^GUH9U0 L<
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M_P 7>(M;30]*\*R:?JSV]I87EM?Z+'H7V._L]9M1K5K>K<VEZ(OLT:#]5Z_
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M  #\HQZ8/'Y<XZY(S5ZN#^)WC'3/AWX"\8>/]:8IH_@KPOK_ (KU1Q@%-/\
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MQ'^V7^SSX7\%ZOX_U3XBV/\ PCFB_%+6O@E=-IF@>+=?UF]^+/A[4K[2M7\
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MW86N:5N6\N5ZM<S4=UNEHWU^1/LX.7,XQ<]+.ROMI%-W>FB3;T[=_P!S;/\
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M*** "BBB@ HHHH **** "BBB@ HHI"P'!/Z&@!:*B>98P"3\N0"?3/\ G/\
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M:=TF7XM?M$^&?#W[3/QT^#/PJ^&NH?L,_![6O@MJ'[1^B^+=3\%:IXLUJ'Q
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MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_/SP7_ ,I.?CO_ -F<?L__ /JVOCK7Z!U^?G@O_E)S\=_^S./V?_\
MU;7QUH&MI>GZH_0.BBB@04444 %%%% !4;QK)C=GC/0D=01U[=:DHH A,$3
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M3V-O%I(CM&^T1_N2O0?04M<';R_K7^O+9L]J_ITMY65M/Z[/=(_!GP!^Q/\
MM@MX3_9V_8M^(.G_  U7]DS]ESXV>&OB;IOQLT[QE>W_ ,0?BYX#^%OB/4?&
M/P5^&5]\+V\/6D/A?5M#U9O#]OXT\13^)=0T_4;+0;6?2K;[7/<I)6N?V&OV
MM!X!O?V"+;2/ABO[%^H?M%?\+9_X71_PF&H#X@V/P3G^+L/QOG^ Z?"QO##P
M7'BA?%R3>&(/&I\6_P!A-X-DCFGTV345ELS^]^!Z48'I2MT^73;MZ;?<A\S\
MN^W7OZ_AY%>TC$-M!$JE%CC5%0]551A5.2>5  /T[=*L444R0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\_/!?_
M "DY^.__ &9Q^S__ .K:^.M?H'7Y^>"_^4G/QW_[,X_9_P#_ %;7QUH&MI>G
MZH_0.BBB@04444 %%%% !1110 4444 %%%% #70."" <\<C(_'\">.E>(^-/
MV=/@3\0_%-CXR\=?!WX9^+_%>G+$EEXA\1>"/#>M:U;I;R)+;B+4M1TR>Z'D
MR*KQ*TK+$R@QJ#S7N%(1G'L<U49S@[PG.#LU>,I1=G:^S79&=6C2K)1K4J=6
M*::C4A&:36J:4D[-=&MBO:VL-I&L%O#%!#$JQQQ1($CC10 J1JH"JBK@!0 !
M@   "K/2FJH7.!C/:N5\=>.O!WPS\):]X\^('B;1/!W@WPQI\VJ^(?$_B/4K
M72-$T;3K< RWFH:C>216]O"A*J"[AG=ECC5G95,]6^KU;;NV^K;>K;>K;+2L
MDDDDDDDE9::))=%V1UE%?+?P&_;-_9D_:<U'7]+^!'QH\%_$C5/"T,%YK^DZ
M)>7,&K:;I]W/):V>IS:1JMKI^HG2;N>-XK35X;>;3;J10L%P_F)GZA,L8P2Z
M@'.#D<[3@_D>"?7B@8^BH1<0GI*AYQPPZ_Y_3GI3C-$,Y=1CGDX'?N>.Q_(^
MAH DHJ+SX?\ GHF/7<,<^IZ#KTS2F:(=9$'U8 ?>*\$\$A@01G([T 245'YL
M6"?,3 ZG<,#MUZ9..!U-.5E;.T@X.#CL?3Z^HH =1110 444TNBC)8 8)R?0
M=?\ /U]#0 ZH9KB&WCDEGD2*.)2\CR,$1$499V9B%55&2S$@  FOG'XO?M0_
M#?X3"YL;K48]?\2Q*XB\.:-*L]RDNUBB:G=@/:Z4A.TL9GDN-C!TM6!X^1OL
M7[2_[5\RRZ@[_#CX6W$@=(L3VD%]:>8P"K 5_M/7I"AQOF%GI>]-ZN695-<K
MWV]=/Z_JQ2B]WHN[_3N>]_%[]LGP3X/DE\/^ H6\?^+G<VL,6FNS:):W;$JJ
M37\&]M1EW@(+73!,S.P1KB%@V/$]&^!?QW_:,U"W\2?&OQ+?>$_"DA2ZLO"\
M&8KDP,SRQ1V^AL#:Z;A) /M>J>?J3JQ\R.5/),?US\(OV:_AI\)+>.?2M(75
M/$10"X\3:NL=UJ3OSN:T4@P:8I))5+%$<*Q62>3H/H%(HT)*J 2 ,^P& /P'
MX^IIJ;A\"U>\M-%ILVD]'V73S%=+;[^O3;73U/,_AS\(? OPLTT:9X/T"RTU
M2H6ZOV07&K:CSEGOM0EW3S%L#Y R0H JI& J@>GX'H/R%+14-WU8AFT^BX^G
M./\ &@1J.WOC QGUZ=:?10'Z[D;PQ/P\:,!QAE!'!!Z$8Z@'Z@'L*:+:W ($
M,8#<%0BA2#G@J!@]3VJ:B@"(PPDDF)"3W*C/4MUQD?,Q;C^(D]>:8MI:HSNE
MO"CR.'=TC5&=QC#.5 +L,#!;.,#'08L44 5S:6S2K.UO"TR#:DIC4RHN,;5D
M(W*O)RJD DDD9.:?Y,0W$1H,@!BJ@%@ 0 2,$@ D $XY/J:D) ZU4FN5B4NS
MJJ D%F(4#!Q]XX Q[G^1(/Z_JP:=6EYO1)=6_)=240PX"^2  " "HV@,,' .
M0,CCZ<=*;]CM!(9A;0B8J4\T1J)=A_@\P /LYX7=M!Y !KQ)_P!I3X 0^*QX
M%D^-_P *4\9_:/L@\*OX_P#"ZZ]]K+K%]C;23J@O?M?FNJ"V,(G+LJ",L0*]
MKAN4F7S(I5E0A6!0AA@C(Z9Z\].O;UJYTJM.WM*<X*23@YQE%236Z;2O\OT9
ME3K4:KDJ5:E4<7:2IU(S<7VDHMV?D]1XM+4%V%O"&D(,C"- SE0%4N0,L54!
M06R0H '  I_DQ9!\M,J,*=HR!QP#^ SZX&>@I?.BSCS$R<8&X9.<XP.IS@CC
MN".HIRLKC*G(SC//4=1]1WJ#4B%M;+]VWA7YB_$2#YB"I8X7[Q4D9ZXXZ5(D
M<<8(C14!Y.U0N3ZG &3[G)I]% !16'K'B?PWX>ETB'7]?T;1)M?U>#P_H46K
M:G9Z=)K6O75O<W=MHFDI>30MJ.KW-K9W=S;Z;9B:\FM[6YFCA:."5EVP0>0<
M\D?B.#0 M%%% !1110 444$@#)X H **:KJPRI!'7/XD?T-,,\(&3(H'J3QU
M( STR2" .IXQU&0"6BD!# %2"#T(Z&EH **AF8JI(...>,]Q^/?GVK\D?VH_
M^"M/PW_9Y^*FL_!SPI\,_''QM\;>$5M?^$ZC\)7>B:)H/A.6ZMDO(],N=;UJ
M8C4=?%G)%<R:386LHMXIXH[B[BNMULO9@,OQF9U94,!AZN)K1A[24*<;N,$U
M>4FVDDKK6^^F[/.S/-LNR>A#$YEBZ.#HSJ*E"I6ERJ=1QE/EC9-RDHQE)I+1
M)O9'ZZ45\L_LK?M7_#;]KKX5P?%'X:7&H6UM#J5[H/B+PYKMNMEXA\)^)--"
MF_T+7+-7E2"ZA62.>*:*6:VN[26*Z@E979(_A7X'?M1_MJ_M3>/?BAKWPCU[
M]E;P=X'^$'Q\\4_"+Q/\!/B'I7C^_P#C;:^&?!?BC^P=1\5>+/$FC>(K>V\'
MZ]XKTVWO/$7@?2_^$#U/1+JRET^&XU6\#W-U!A6HU</5G0KPE3K4I.%2G--2
MA)6TDNE[Z=]T=.#Q>&Q^%HXW!5Z>)PN(IPJT:]*7-3J4YZQE!]4^O;KTO^R%
M%?(_Q4_;D_9/^!NKZUX<^+'Q]^'G@OQ+X9N=*M/$/AW5=6#^(-+FUG2$U^RE
MN=!TZ"[U1+,Z)+#JMQ?BU-E8:?-#>:A-:PR1E]+PE^V=^R_X^^*L7P4\$?'7
MX=^+/B;=Z?/JMCX5\/Z];ZI=7UK9:9!K5_'I^H6^[2=0OK+2+F#5+W3+*]GU
M*RTV5;VZLX[<-(,CIL^S^X^IJC,J@ G/.> ,GCV&?T^G6OF;PK^U_P#LW>-_
MBI=_!7PM\9/!^N_$JVO]>TD>&K*ZN-]WK/A42_\ "5:'I&JR6ZZ'KFN>%Q!<
M'Q#H^CZG>:IHGV:X_M.QMO)DV_FS\-_VK?CUK>C_ +*5UJOCZ6YG^(__  4O
M_:,^ GC)_P"Q?#R#5_A3X(U/X]V_A?PL?+TI4M(]+A\&^'475;$6VLW7]G*U
MYJ-PUS=&<O\ U]W^:!1;\MM[]=%T/W"4AAD?T_H3CZ'D=P*6N-\<^/\ P5\,
M_".O>.O'WBO0?!O@_P +V$NJ>(/$WB34[/2=%T>PAV^9=7]_?36]M!$&=(UW
MR!I99(X8E>61$;YW\/?MT_LG^*_AOXR^+NB_'7P-+\.OA[?6.F^,?%-Y=WFC
MV6@ZAJJ0R:18W<.M6.G7LUSK:7%LVAPVEK/)K?VB!=*6Z:6/<!9]F?7#.$QG
M/-,\Y/?H3G _+D]?T]Z_,']H?]M#0O%7P:^"?Q,_99^+FA^(=)\2_MD_L]?!
MGQAJ^@6]G?20:1XK\=Z=IGC3P9K.F:]I[7^@ZK=:1>PI<17EAIVLV=M=P75J
M8//@G/KW[)OQ6\>_$7XL_MS^&?&.O/K&B?"3]IJ+P#\/K)K+3K0>'_"<GP=^
M&?B9M*2:QM+:>]4ZUKVJWHN=1EN[Q3=&%;@6\4$,0%G:_K^#2_-GW!YR8S\W
M7!&!D?K4M?G!\-?VF[C0?V@/^"@=K\:OB)I>@_"'X#^//V?]&\'7.N1Z9I6E
M^$;7XB?##1-0U"VEU.WLXKN\.M^+=3@\E]4N;N2*XNTMK:2* I"/M;5OBKX!
MT+Q<G@'5O%VC6'C";P5KGQ&A\/7-T$U:3P/X;O++3]<\3K:["PT?3+_4+*TN
M[LMMAGNH489D6CT_KO\ B#36_9/[TG^31Z317R-X&_;H_9+^)?Q!\,_"SP'\
M?_AUXL\=^,='36_#6@:#KD>HS:O:R:%_PE$<%I>V\3Z8VJ/X;SKPT-[Z/6AH
MR/JC:<+**2=<7QK_ ,%#OV+OAYXWOOAYXT_:.^&GASQ5IVM2>&;O3=0U698E
M\4P",W7A:'5X[9]%NO$]D)%:_P##EOJ#ZU81D27EC"A!)==_ZW_+4+/L_N/M
M.BH;>XBN8HYH7#QRQI*C#HR.-RD<D<@@]3UJ:@04444 %%%% !112%@N,G&?
M\\GM^- "T4PR1CJPZX_$G _6G*RL,J01ZB@!:.M%% "8'H/R%&!Z#\A2T4 '
M2BFLRH-S$*!W/^>OH.I/ YI0RD$@@@9R?3'7\N] "T4T,K9VD''7';-#,J#+
M$ >IH =13!(C' 8$^@]^E*753@L ?3//UQUQ[]!0 ZBH1<0DX$B$Y"XSW/ '
MXDX';-2@@C(Y!H 6BBB@ HIAEC!VEU!YXR,\'!XZ]>/<\#FFF6,\!QDXQCOD
M$C'&#G!_(T 2T57,I7;N8#<0 #CDXSCV^OX9S4X.0#Z@'\Z %HHIK.JD!C@L
M< <DD_@#^?2@!U%,26.3(1U;&<X.>G'\_P"1]*?0 4444 %%%% !1110 444
M4 %%%!&00>AX- !D>OM^/I1D>O\ GK_+FOS2^-UKXQ\$_M__ +'^H>'OBG\4
M(?#GQF@^.FA^-OAE=>--3NOA==Q>!?A5;ZOX:O;'P4Q73=/U2VU3??76H0D7
M%U-(S,PZ#Y#^)&C_ !E_:N^)G_!0KQYX>_:&^,7P>C_8LO8?AC^SKX;^&/C&
MY\+>%8_B3X0^$VB?%OQ1XT^)GAY89M.^(MMK^M^(]*\.MI'B&*?28_"]K<VT
M-M'>SF_B5]_7]$[_ (_\,5RWMKND_O=OP9^]-?GYX+_Y2<_'?_LSC]G_ /\
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M5].^Z6^GK;6^FQ^/_A']KCXE^/?V.OV1/$OC/X]^./!?Q8^)GB/XLZ+KNG_
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M2..>[T+7;3S+BQDGA2X@E@O+.3S3;"XG^=_ASXX_:F_;P\>?'3Q1\,/CY?\
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M_ [Q.^K>&Y+KQ'XML?A3-X8U[1XK?^TGU304BUN"SM;BYU6'3K*Z*13^=-!
MLB?)7A3_ ()T_M2Z-^Q5_P $8/A./A386'Q"_95_;-^'WQA_:%T:#Q+X.0^%
M?"VD_$OQ3KVL>(YM1AU9+#Q%<1:+J%C<26^BW6K:E<9BM88'DBD"'O?CVZ*2
M75]5=_D1:-EKJ_/;2]_OT^>]]%^CGQF_X+5?LC?!7XG?$3X>ZGHOQO\ '&A?
M!;7-*\,_'CXS?#'X5:KXS^"WP0\0:O<+:6^D?$;QK97D+6%Y;7+_ &?4H]*T
MS5_L-PDMK*3>03V\>Y\>_P#@LE^QM^SM\2-(^%'B_6/''BCQKXL^'_PW^)7@
M'3OAKX1D\:Q_$7PU\4M7N-)\,-X*EL=2C75KPQV=SK=^D@M+2UT&,7J7D\\D
M=H_Y,^*_V1?^"A/P!\%?\%$?V+?@U^R]H/QX^&G[=GQ?^(_Q$^'W[2%U\3?"
M>@:/\.-*^,XL[7Q;9?%+P[KTT?B._OO"=C$TFARZ;!*;G45DGMS?QR*@^J_V
M3?\ @F]\4?V??^"B7P;^(OB/PW8^,_A#\&/^":WPW_9NT'XKWUWH\TLWQ<\,
MZXL>NQZ3H-U<2>(M,BGT6?4/L-W]C@MX-)NVTI;DEWBH3;Z6[Z;:ZVUUT^7W
MV1:*UO?R3WT7W:WTW^X^Z/\ @KK\:OB9\!_^";W[2OQG^#7BO4O 'Q)\(>#=
M#U/PGXILK2PGU'0[Z^\6>'=/DN$L]9L=0L7D%I?7$4B75E,%1G*A'"NOPC^R
MC_P51\2Q?\$>_BA^TM\<=4_M3]HW]F+3_'7PF^)=GJT5E;ZIX@^-FEWD>E_#
M@W>EV,-G$Y\93^(O"+S&VLK2WNG.JRV48AA%?H#_ ,%9/@1\3/VE?^">/[2/
MP/\ @YX>7Q5\2?'OA31M.\*: ^I:9I']HWMKXL\/:I+$=2U>ZLM-MFCL[&YE
M5KFZB63REA5_,=,_C=XJ_P""37[26L_M[?#0Z=I5M9_L'_%>[_9N_:%_:HT(
MZ[H'D?\ "]OV<_ VMZ/'X5FT3[8-0U>P\8>((]'N];N;&QOM/NI;O[7->!])
ML7M!WO=;6MY7[_+2_DQT^1P?-[LE)O7=Q2B[6\];;IOT.X_X)5_\%,?BAX%_
MX)R?M*?M4?\ !1+QU\0/'FI_!?\ :LU+X5Z]<6WAGP_=^+/#]KJ$/PG\-:7X
M8MM%T6+PY8RP:7XQ\878NI+EUN;>&2YDDDE\N*$?L#\3OV__ (-?#OXOZ#\
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MM%_"WXZ_"[X]7G[*GC_]K'P;XR_8B_9Z^!'C[X<?";]I[5?V>?'_ ,)_B?\
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M?](M(LC/ZV#W]_Y\?I5&;MT\OR"BBB@04444 %%%% !2'H?H?;^H_F/K2T4
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MN(X9!YAM7GM'6UT*V9&*RV6FAYVY+W,#+M;[Z\&>#?!O@;2(-"\(Z'I>B:=
MJCR=.@1&EE48:6YG"^==7#')>XGDEE<EB7Y(K\*/^"MG[5?QB\-_%'X??LR?
M"?QMKOPNT_7/ T_Q+^('C#PO,;'Q5J>D-KD^@:9X8T'6 ?-TB"2:SN;C6;ZS
M NRL]C%'/"L<R3?'_P"PE^U?\>O@Y^T]\(?AOXF^*WCGXJ?"KXV>)V^'^H^'
M_B'K]WXKUCPUXGU"TNI]!U[P]J^I2R7\%L-11(-;L&NI+3[))*T4,UQ%:LGU
ME#@[,:^2?VRJ^'A!T95Z=%J3J5*4+\TKKW(/1N*E9->ME\#B?$'*\-Q)_J[+
M"8R4X8BGA*N,BH_5HXBK&G*,(7O*:7.E-I.SO;:[_J]G$01X@54%3VPN"0".
M.#G=C'4YY]_Y2OV@/^"<W[6WPK^,?Q#E^#/PM7XV_"KX@>-/$?C?PO?:-XK\
M/Z!K?A:X\7:E=:OJ/AGQ)9>)+RT#II^I3.MAK%D)X[JU>&6YN4G6:&#]/-(O
M_CK^WE\;OVC],T3]H#XC?LX_LW?LY_%&X^ 6DV7P.;PYH_Q,^*?Q,\.>'O#V
MN_$+Q-XF\=^(-#U^\\-^%/#]_K]OX?\ #.A>&+:RNM7:*]U;6]0*QPZ6U/\
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ME]XCTN*6]LU>8B!\G]A?]H;Q#\-_V(?A+JTOP]^,GQ[\:>-?C1^TAX:TC0_
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MOX(\2/?2:I+KVG76EW>L:MX@N)=2O[E]8_MRUDGO+VZO+^&\NYY)CY-\;?\
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MO!GPXLM)EEO+3PEI'ARY\)K9VOAQI?)-XMC]CU2Z2SLK?^T4L[9+:F?\$C?
M?C+5_B/_ ,%#_P!KOQGX:\1>%D_:L_:OU8?#W3O%ND:CH.N3_";X,6^J>#?!
MNL2Z3J\46H65KJDVI:Q]F6=%$RV^^%!:BVDF_;%D5QAE##T--2*./[B*I&>0
M #S@'GW"J#[ #H!2LM/+_*WY#YG9IZWT^6G^2^[S)****9(4444 %%%% !11
M10 4444 %%%% !7Y^>"_^4G/QW_[,X_9_P#_ %;7QUK] Z_'OXY_M$>$/V4O
MVNOVQ?C[XW!N-&^'G["WP$U&UTF.8P7/B/Q%>_&'XW:3X4\+6<PAN#!<^)/$
ME_I>CI=M!+#IZ7DFHW:BSM+ATQQ.(H8/#U\7B:D:.'PU&KB*]6;M"E1HPE4J
M5)/^6$(RD_)'J9)DV:<1YQE?#^1X*OF6<YYF.!RC*<NPT5/$8[,LRQ='!X'!
MT(MI2JXG$UJ5&FFTN::NTKLP_P#@KA_P5(T[]A_P1'\,/A1<Z9K'[3WQ T@W
M6APW<*7^F_"SPI>_;;,?$/7+*:&:RU/69;JUFM?!?AF^S9W=]%/KVO07>B:4
MNA^)?X@M/T_XL_M#_%**QL(/&GQ>^,'Q-\0RLJ!M4\6>-/&/B/46DN+FYGFE
M:[U'4+IU2:[O;RYD9+:UAGN[J:&UMY98]GXH?$CXJ?M2_'#Q+\1/%DFJ^./B
MO\8_&JW!L=,M[_4KW4=;UZ\@TWP_X4\,:6)+Z^%C81-IGACPCX?M6G^PZ7::
M7HU@ACMX(Z_NE_X)8_\ !-+P9^PK\*;'7_%>DZ3KO[37CK2HKCXD^-&2SU&3
MPI:W@@N1\,?!6HI&XL_#>D/#;G7[VRG=_&'B*WEU2[NIM'LO"^F:'_,'+G7C
M'Q-5M5JX#AO*Y>Y=.4,)AIR<86IWY*N:8Z,)2DY-QI0C)<TJ5"$*G^[_ +?P
MP_9J^!>7.>78+BWQLX[HI8A1JQHXGB#.L/0IU<9[3&N$L5@. ^%*F)I4*-*A
M3C6S#$UJ-3V5+'YIBL5@_P V/V*?^#=WPGI%GI'CK]M[Q+-XKUJ>WL[Y?@;\
M/=9N]+\-:2\]NTDVF>.OB!IDEMKFOWT'GQP75CX#NO#VG:?J=A*]EXP\5Z5=
M(Q_H(^$O[*G[-/P'@M8?@[\!_A1\.Y[2"VMUU;PSX'\/V/B.Z2T4)!+JGB@6
M+^(]8NT R;[5M5O;V1R9);AW9F/OU%?O^1<'\.\.4:=+*\LP].K!+FQM:G&O
MCZLEO.IBZD755W>2ITW3HP;:I4H1T/\ '_Q9^DCXT>-698K'<=\=9SB\#B)3
M]CPSEN+KY3PG@*+;Y,/A.'\%5IX"2A#EIO%XR&+S+$PA"6-QV*J+VCCFAAN(
MI(+B*.>"9&CEAF198I8W!5XY(W#(Z,I(96!5@2""*^&_CC_P32_89_:$L+ZW
M^('[-_PWM=6OC-,WC#P)HD'PW\:1WTD+Q1:A+XE\##0M0U>:U9Q/#:>('UC2
M998XQ>Z==PAH6^Z**]K&9?@,QI.AF&"PF.HM-.EB\/2Q%.ST?N583BO5*Y^7
M\,\8<6\%YA#->#^)^(.%LSIRA.&/X>SC,,FQ:E!WA?$9?B,/5DDV_=E)Q:;3
M33:?\0O_  4+_P""&/Q2_9=T#Q'\9/V?]>U3XW?!305DU+Q!H5[8QK\6_A]H
M,4<\MWK6K6FDVL.C^-O#6CQ0)-K?B+0+/1=2TN"Z-]>>#H= TK6/$-K^9W[&
M?[;7QP_8;^**?$CX.ZQ ]GJ<,&F^.? >N++=^#O'V@PW"W"Z=K=C')'+:W]I
M(&FT7Q%I<MIK>C2R7$5O=OIFHZQIFI?Z5=?R/?\ !<W_ ()?>'? .G3_ +9?
M[.?@ZTT'PTU];6?QX^'_ (6TVVL-$T&6^*6NE_%+0=%T^W@M=,TZ]OS#I/CJ
MUL56)=5U#2?$T=B%O/%>IP_@/'/AO4X=;XLX,JU\'_9\EBL3@:-2I*KA(Q;=
M3%X&JY3FZ,(N^(PM1RC&C[249.BG1C_L#]%+Z;6$\9U3^CU])K 91Q,N,:?]
M@Y)Q3F6#P5/ \0UJT8+!\/<58"G2HX2&:8FO3C#)<^P4:%:OF?U*C6HPS.5/
M,ZW](_[(?[5?PS_;,^!?A/XY?"^[QIVMQMIWB7PW<7$<^L^!?&FGP6S^(/!F
MO!$A(U#2I+J":VNC;V\.LZ+>Z3K]C'_9NK6;O]-5_ C_ ,$:_P!NBZ_8_P#V
MG])\+>+=7^S? SX[W^C>!OB)%>7$<6F^&-<GNGM?!7Q&,ES/;6UC'X=U2_;3
M_$EY+,MNG@[5];O9K>\O=*TA(/[[J_4?#_BZ'%^10Q57DAF>#E'"YG2A91]N
MHWAB:<?LT<5!.I!6M"I&M1BY*ES/^!_I@_1SQ/T<?%;%9!@?K.)X&XDHU<^X
M$S'$.52J\JE6=/%Y+C*[NJN9</XJ2P=>HW[3%8*IEN958499A[&F4445]R?R
MF%%1E\$C'3W_ /K51O\ 5;/3+:>\O[FVLK.UB::XN;N>.W@AC3!:22:5DCC1
M0>7=E4=S0!I5R_BGQ?X>\&Z5<ZUXEUK3M$TVU&9+O4+F.!#U(CB5B7FF< ^7
M#$CR.PPJFOC+XI_MJ:+9WS>$_@_I$_CWQ3))-:QW\,$\^C07*C81;06Z&\UB
M6*5T4) L5LV=_GRJ&4\'X8_9C^*7QHUF'Q?^T'XKU&RLRZRVWA.TF O(X,EE
MMU@C#Z;H-O(DCQS0VPGO)QA[AED04!_7]?>:'C3]KCQG\1=7E\%?L[^%-1U*
M^FS"WBBYL?-N(XVPC7=C82C[-8VBY!.H:LX0<%H804=M?X<_L:3ZOJ:^,_CY
MKM[XP\074BW,VA+?74]DD@<2)'J>HN_GW03&QK"S\G3D!*1O+'N0?:?@KX=^
M$/AYI<.C>#M!T_0[&-8Q*MI @GO'C0()[VZ*FXN[@@9:>=VD)RN0F .WJHSE
M"[C)QOH[.UQWTM_P_P#PWD8^CZ#I&@Z=;:5HVGVFF:;:1"*ULK*WAMK>WC ^
MXD4*1IC.225W,Q)9B3FM95VC&2?<G)Y_I[4ZBI;;U;N^[$%%%% !2-G!QZ?_
M *_TI:1ONGG'!Y]/>@#S+XH?"GX<_&7PAJ7@/XI^$]#\:^#M8"C4=!\0V<-]
MIT[QMNAF6*8$PW5M(!+:W<#Q7-K.BS02QR*I'GOP1_9@^ /[->G:MIOP,^&?
MACP!;:W-'=:R=!MC]OU::$RBW;4=4NY;K4;Q;87,RVL5S=/!;+(X@2(LS5\W
M_MV_M ?%[X=:K\#/@O\  J;0=!^)G[07BS7]$T[Q[XITU]:T+P1X>\*:(VN>
M(M8CT9'BCU?7I(Y+6UT;3KN9;2:26X,Z-B(Q>3_LT_&_]HWP'^U'IG[,'[0/
MCKP]\9=-^(WPV\2_$KX<?$;2/"=KX,\0Z7/X.U#3;#Q%X;\5Z+ID[Z5/;31:
MM9WNEZI:(C-*;B!FD5O(LO8IX#'O*Y5XXEK"SC.JL-S5?WD(SM4J-)*DDIIK
MEE.,WTBTCYROF>5T\YI4:N!<L73KX;!/,/8T[TJV*A?#TE.;]O)32UG2A.E'
MF2G--M+ZB_9$_9/M/V<=)^+BZQ=^'O$WB'XC?M&?'KXVV7B2QT&/3]2TG2/C
M#XZO_%UGX7FO;I;B[FET6WO4T^[N(+@6EY)$TL$:0LJG/T+]D"SD\9?MPZIX
MUUJ'7_!O[9MOX6TC4O#ME:7-A>:!X>TKX/)\)]>L+J],SF[N=5MFN[VVN+:&
M%+5)4C8-(K2G[=A<LKYP0&('T"D]L=QCZ>]6:\>VB^[[CZ2[W;=W:[>_3>W7
M3<_(+P)^P]^TC>7G[,OPW^/GQ?\ AIXS_9\_8Z\5^%_&/POB\(>"_$FB_%/X
MG:_\-=&N=!^$=W\5KS4-6NO#&DIX*M9[?5-3'A&S)\5>(M.L[^X&E6RO:OK7
M'[%GQQ\6_MI_#O\ :3\6W?[.7@[2?AAXQ\5ZU!XU^#?@GQUX2^.GQ7\%ZQH.
MM:#H'PP^+EY>Z]>>%-=\,Z6-1L-2U&YN4U.>XOM%LY=&MO#IN;M#^LY /4 _
M6BBW]/7\PN_P:^_?^OEMH?BWKG_!/_\ :8U#X0?M)?!'3/C+\++'P/\ $/\
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M9;4SVS.SJEGHN\7-V7C*L-2UN>+86_T>%X28D^I_@_\ LJ?#CX6_9M2GT_\
MX2OQ2%1I-?UR**5;6;"%SI6FLKVVG@NORS SWVS"2W;!1CZ@$4:XP@&#G R!
MGU(Z'\<X[5-XZ**?YKI;7T[VTMT:;+KIOIK?KY6_6_R/'_A;\"?AW\)+)(/"
M^AVXOS'MNM<ODBNM9NV.-Q>\:(-!$Q&X6UF+>W4G_5'&:]B5%7[J@?0?R]*=
M13$%%%% 'D?QN^.WPG_9P^&/BGXR_&WQEI_P_P#AIX+@LKGQ+XJU2#4+NUTR
M+4-2L](LLV>E6=_J=W+<ZC?V=I!;V%E=7,LLZ*D3$UZ)HVNZ3XDT+2_$6AW]
MOJ6BZYI=CK&DZE:OOMK[3-2M8KRQO8'XW075K-%-$YQF-P2!R*_$3_@J9\2-
M.\9_'?\ 97_92U/X.?%W]H#P!;ZKK7[3G[0/PY^"_@VS\=^(K[P%X#BO/"?P
MNTW6M U#5M"TZ3PSKGQ5UJVU#47OM14E/"#16]M/)/YD/BG[-?[8_P 8_ _[
M"OPY_9[\*6NI_#C]HKP9^U;X5_8#T>_^.OA6.#7/AGX2\0WUQK7PE^(WCCP.
MNLSQR:HOP,.C0Z'X=N==EL]4\7V]II[7^HVLBOJ"OK_7E_FK?,OE]V+OJ^G9
M7LOZMLT?NK9_'#P3?_'+6_V>[>?4C\0O#_PS\/\ Q9U"V-A,-+'@_P 3>(]<
M\*Z7/%J9(AEO6U?P]J*3V*KYD-N()V.V9!7L:SQG: 3R, E2 < 'C/7@Y.,X
M%?SN>+9?CG^S-^TG_P %!O&VJ_'[5/C/\2_AW_P2G3XB^ /''BCP/X!\/:GX
M<UCPYXH^->MZ397^B>$=+L/#VL6MKXATT:M9F]TK>;:[_LV[-Y;V\<LG4^/_
M (]_MT^ /AS^QWX!?XAZW\2OC7^VOK&K^-]=\1?#'X?_  BTV^^%/@?PO\)=
M$\::U\.?A'I_Q%UKP]X,U?5[N^OX)8/%'CW4]8U,6,7B&_L-'GE?3['3R_3^
MMTOQ;0N7:S7S]$W\K.^MF?OV9D SR1C.5!(_^OGMC.:576121G'(((P?R/Z5
M^!VK?'3_ (*6^&_AO^SAX"\32Z-\-/C#\4?VV_$'P2T'Q;\5O#'@#7K[Q7\!
M)OACXJ\8^'?&?CCPO\+M?UCPO:>--/NM/N8;G2?#6MZ/!J^J^&;-9IM-TW5K
MJ>KNL?M=?M.?L]>#OVX/AWK7Q)M/C/\ $'X/_'[]E_X+_"CXJ^/O!OAKPW:Z
M%=?M1>&OANDOB#Q[HO@>ST71[KP]\/O$'B^_U?3T2.SEOK<Z?H-_J%Q*S75/
M^OZ_X <K[K^FEV\U_P .?IY^TY^RWX)_:E\):'X>\37_ (B\*^(/!WB"W\6^
M /B'X+U(:3XP\#^)K>*6W35M$OV@N82EQ:S36>H6%W;7-AJ%K(T=Q"S+#)%Y
MO^S;^PYX5^ ?C[7/BWXA^(WQ$^-_Q>US18?"C?$#XFZGI]]>Z#X5MY8KC_A'
MO#FFZ3INEZ;HME=7<:W6HF"W:YOIUC>:4HDJ/\<>//VG_P!HS]A?QS\3O _Q
M0^)O_#5VCP_L4_&[]JSPKK.H^!_#'@?Q?X9\6_ JXT.TUWPMK5OX#M[72I_
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MH?[O'7 . #DMD*.!DDDX'.YL]3GFT6W37OK>_P">IW\SM;II^%E]S[?\&_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 12E1M)Q^63_G
MK5&158LNP8[D@8/)Z>_/3@=?>KL@.%]?7 (]LY]!WZ^F>:^!?VY_VY?"W[&7
MA#0[B?0+OQY\3/'EY=Z7\.?AYIUW#8W&M75C$DNH:IJVI31SQZ/X;TA9K8:C
MJCV\^R:ZMK6.-GE>2#?"86OC<1#"X6FZE>HU&$$[<S>N_2VK;>B./,,?A<LP
M=;'8VNJ&%H1YJL[.5HW27NI-R;;48Q2;E)I)'V];:9IEI-+/::?;V\\I)EEB
MMHHWDRQ;]Y(J!C\Q+9R222?>M- C=0,;<#&0/3 /7&>@[BOYI?#G_!:#]I?P
M[K,6N?%/X"?#K6?AZ)E;6+'X<>(]93QKHFG@D7%W:KK0N=)UV6T4,\MK&UB)
MMC""['RFOZ"/AY\5?#_Q>^%N@?%;X67MIXIT#QCX:C\1>$IVN/L%MJ7VJU>6
MSLKR?R;N337%XHLM09[:>?3I4N4EMI)H3$?1SC(<UR>4'F-%TU5BE3J>T]JK
MW2Y>9.R=EL[-7OL>1D'$V2Y\JL,JQ/-*C[U6A*A*A/EDDU-0DHWC_-**=F[/
M<]=5$  VXR,],#GJ.,#W/>E\N/CY1@=!V&1C@=!Q7Q-\ OVK_$'Q%\/_ +2-
M]\8OA[I'P7UG]E_XB:KX%^(5KIGCI?B+X>6STKX3^ OB[/XEL_$8\+>$9&M(
MO#OCRVBN;631T>&YT^[VS2QM&]?-WP;_ ."COQ(\:>*_@!J?Q6_9W;X2? 3]
MKR?7+;]FKXHR>/;/7_$.I7=IHFH^,/"&G_%;P6= TV#P+=?$[P/H^I^*/!PT
MW7_$@2.WCTS4S#=2F:/QELM[M*^^]DOO/I+/M_6^G?373H?K4(XQT11^''Y4
M^OQZ^'W_  4Y\;>+=<^$/Q%\0? '_A%OV./VB/B[<?!+X+_'A?'D&H^+[[Q+
M<ZMJ_A_P1XL\9_#-O#%H/#?@+XH:_HMYIGA#4X/$FI7ML)M'O-7L8[?6K<PI
M-_P4]\:1:Y=?%$? "-_V(+#]H,?LVWO[12^/K8>*D\31^-6^&-U\3(OAD= ,
M$_P<M?B<1X,N/$"^+X]:!BDUR'1I=/(0%U_5_O\ 3SV\PY7V^_37MZ^6Y^PU
M%1PN9(D<XRPSD=#R0".2,$#/!(]&88)DIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OX9_^#A?1K?2_V_K6^ACC
M23Q'\"?AWK-TR-*S2W$&M^-O#RR2B0E$D%KH5M$%A B,44;D><\I/]S%?QD?
M\'"7PXUS7_VH+SXEZ9;SW6E?#OX)_ K1_$:V]O--_9]EX\\;_'V+3]8O)(XV
MCM=/AU?PW::,T\\D:-J6OZ7:IOEN4%?FOBU@*F.X(S*5*/// UL)C^5*[=.C
M7C3KR7\OLZ%:K5D_Y*<EU/[A_9W<78/A3Z4O!=+'UEA\-Q9EG$7"*K2J>SIQ
MQF8Y;/&Y71FO^7CQN:Y9@L!0I]<5BJ$M.6Z_0S_@VT\;:=J?[*'QN^'RW(EU
MKPA\?KGQ1=6IE5GM=#\<_#_P9I^C-Y( >.*XU/P-XF9)&)$LB3*H!B;/]%=?
MPL_\$%?VJK7X!_MAGX5>)]233_ O[3FE:?\ #^1YS!%:VWQ-T>[NK_X67EQ,
MT3W+-J%WJ7B+P+86=N\<<^J^.=/N+K]W9*\7]TU/PGS:CF?!>74823Q&5RK9
M=BH:7A*G5E5P\K7ORSPM6BU*R3J*I%7Y&9_M"O#[,>!_I.<:9C7H3CE''M'+
M.,\BQ33<,12QN H8#-Z;FHJFJV%S_+\SA*BI2J0PL\'6J<JQ,+E13.L<<CLP
M541G+'L #D\]/K]:EKQG]H+P]XK\6?!3XO\ AKP->MI_C+Q!\,_&NB^%KU+@
MVKVOB#4_#NI6FD31W*D&W=;^>$I< @P-ME##8"/TRG#VDX0<E!2G"+F]HJ4E
M%R?DD[O<_AZK.5.G4G&//*$)24;VYG&+:2]6K'E6G?MO?LH:K\2V^#^G?'OX
M:WOQ%&H2:0GAB#Q-8/>3:S&_E2Z/;SJWV"XU:.4K$^FP7<EZ'W)Y!<!:^M89
M%ECC=2"'56Z=05R/TP?\BOY*M2UWX0>*_P!D'0OV1?"7P'\8V7[62Z9X<\'6
M/@ ?#+Q%I?BGPK\6=,O+234_B#J/CE]%M[&'3;.^M;GQ'=>)SKSRWMA<2F2-
M5G>.+^JSP3::GIWA+PK9:Y="_P!9L?#NC6>KWJ+M6[U.#3;6&^N57)"K/<K+
M*!D@!N"1BO8SC+*&7J@Z-?VO.Y1DN:$N;D2M5BH+W83;?+=W;B^B9\WP_G6*
MS:>)C7IX>*I4Z%92PZKI4IU92C/"5'6^.I248MR@H7]I:5.%E?KCGMC\:.@Y
MQ[^GZU@^(?$^@^%M-N=8\0ZK9Z/IEFK-<WM_<16T$056;!>5EW.VTK'&F9)&
MPJJ217YN_'C]O6#1?#_C"Z^%UA<MH_A+P]KGB/Q'X^O[&:2UTC0M LKG4-5U
M:STPPLR06EG:RRI>:F8XIG,<-O:S2R1J?"E)0C.I4<:=*G&4YU)R480A%<TI
M3DVE&,8IRDWHDKNR1]AA,)B<=B</@L%AZV*Q>+KT<-A<-AZ<ZU?$8C$5(TJ%
M"C2IJ4ZM:M5G&G2IPC*<YR48Q;:1_+I_P7N\8Q^*/^"B_CO2HKJ2Y'@'X=_"
MWP@RM)#)%:R7'AF/QL]M;>4[LD0;QD9I4G"3+=SW/R>48F;[Z_X(M3?M C]E
M'Q9X"^$NAR6%MXY^,WBKQ5=>-D5[>2'3CX3\%^$OL_\ :EQ*+'3[>UO_  WJ
M)\RVB.J3R7$Z1,4ME4_S9?%[XE^)OC9\5O'_ ,5?%=W>:EXF^(OB_6_%.HRW
M,\EY<"?6=0FN8+&.1]SM!86\D&G6,*@)#:6UO;PHD<:(/]$/_@G1^SYJ?[,G
M[%?[/OP>\168L?%FA>"AK?C2RDBB6ZL/%_CG5M3\=>)-&O)(MRW,_A_5O$EW
MX?\ /\R17BTR/RF,(C _G'PRD\_\1N)>(XTYO"1AF6(I3=TH3S#&QA@J4VTG
M>6#CB)6]UWHO1(_VQ^G-"GX0?0M\$?!;%XC"RXBQ%;@O)\;AHR2E7I<&\-5<
M5Q-F&&C"<E.E1XBKY12DW*<>7,8-RE)QDX?A)^QEX4T"XC\3_$R\?X@>*Y)_
MMCQWYDGT.UNCD[Q'<AKK5I4SC[5J$A#G)-N !G[7M+*VLH8[>VAB@@BC6*&"
M&-(H8HT 54CBC5410   J@#H*MT5_2']?Y'^(PF#ZG]/\*,>Y/Y?T I:* "B
MBB@ HHHH \BT/X'_  [\._%KQS\<=,T1H_B=\1/#7A/P?XH\3W.IZM?37'AC
MP0^K3^'=$T^QOKVYTS1-/M+S7-6U&XAT:SL!J.HWT]]J/VJZ82CR+XE?L-_L
MV?%K4/B_JOC;P!]OU+XZ1_#9_B-?V7B+Q1H]WJ.K_" W9^&OBK29])UBS;PQ
MXR\(F[(TWQ=X:_LGQ$8[:Q@N-1GM[*VAC^NJ*/Z_K]>X7?<^%?"'_!.;]EWP
M=%\6VB\,>,/$VL_'GX7W7P<^,7B[QY\5/B9XX\9_$'P!>P:I:W&BZYXD\3>*
MM2U",BVUB_MK6[TR33[FPMI([>PDM;>&*)?5/BQ^R;\&?C/\//!?PT\8Z+K$
M&B_#2\T'4_AIK7A7Q5XE\'^./A[K/AG2Y-$T?6O"/CCP]JECXDTG4X-(GN-,
MN)XM0:+4]/N;NRU6&^M+NY@E^EJ*!W?=GRWH'['_ ,&]"TGX6Z5-;>,O%,OP
M=^(-[\5/ _B#QS\1_'OC+Q9:^/M2TG6]"O\ Q!JGB/7_ !#>ZEK1N-*\1:O9
M#2]3EN-#M8+E([+2[9;6T$&MKW[)OP$\5Q_'BW\4> =/\06G[2YT%OC/8ZM=
M:C?67B^7POX;L?"?AZX:VGNVBT>YTC1-,L(+&YT%=,GMKJRM=3@DCU2%+P?1
MU% 7?=GQ]\(_V&OV?O@Y/XTU#2-"\0^-M<\?^%8_ 'B?Q/\ &#QKXJ^,'B:^
M^'4*W(@^'D>M_$75/$5[9>"(VO+B27PU920:;?SNMWJ<5[=H)ZQ_AA^P%^S_
M /"7^U=/\-1_$C5/!>I>%=>\#6_PK\<?%WXE>/OA%H?@[Q)$(-8\,:)\,_%O
MB75O"5IHMQ;(EI#92:;<)IMBIT[2#I^GR2VDGVS11MMI_5_SU"[UU>NY\8?!
M7]@G]G;X"^+++QMX(T7Q?J'B#0O#=UX*\$7/C[XC^//B/#\,O!5\\3WOA'X8
MVGCG7]=@\"Z'=BWMH;J#0%L[BZLK2STZ>ZDTVUM[2+K+K]CGX"77[.6M?LH-
MX0F3X&Z[I>O:3>>$UU_Q US';^(_$%_XLU*XM/$,NI2>(;6_'B74KK6;*^BU
M,7.GW?D_9'BBMX8U^HZ*++MY?+L%WW?WGS!X+_9!^"'@?4]&URP\/ZMKNO:)
M\)-1^!L6M^.O%WBSQ_J>K_#36?$#>*-:T'Q-/XQUK61XC?5];=[N_P!0U:.Z
MOIHW>P$ZZ;MLU\H\)_\ !-[]F?P=I?B;PKIME\3+[X;^)O!_BOP _P (O$/Q
MH^*GB'X2Z%X.\:0RV^OZ%X7^'VJ^*[GP]H-K)#-)'I;V-HDOAV,B/PZVE1HB
M+][44!=ZZO7<^&/AO_P3G_9;^%FK^)_$?AKPOXQO?%'C7X5:Y\$_%_B?Q;\5
M_BAXUU_Q)\,]>DL7F\,:KJOBGQ;JEW-:Z7'8I!X;D1XY_#<%Q>QZ-)9B]NO-
M^M/A_P" O#/PP\%^$_AYX*T\:/X/\#^&]&\)>%](%Q=7:Z9H'A_3X-+TFP%U
M>S7%Y<BULK:&'SKJ>>>39NDD9B379T4"NWNPI"N3U8?0TM% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 139V\>A'YX]>.F:_F?_X+1^%=9\._M$? 'XO:Y'<_\*WU7P!XB^%R
MZV\4[:;X;\9'7TUZSAO;E(7@L6U^PN)A:O))&;U],EC7(M!7],I&>M><?%#X
M6^ ?B]X-UGP'\2O".A^-?".NP^1JF@Z]8Q7UC<)D,DGER#=#/ X$MO=6[Q7-
MO*JRP2QR#</8R'-7DN:8?'^S56$'.%:%DY.G6@Z,W3NFN>,9-POU7G<^=XIR
M+_6+)L3ED:WU>K4=&K1JOFY%5P]6%:G&JHM-TIR@HU$G?E?6UC^)[7?$6B^'
M](OM6U.\MH+&UMWF9YY(P+A6!"0VW7[5/-GRT@C#%I#AL)R/Z:/^"5/A+Q+\
M(/V"_A-9_$.UN]#N);'QKXZ.FWZ3BX\/^%_$_BSQ#XMT&SN;:0-<6S6_AS4;
M*9K(!F@WF((DGR5H_#W_ ()/_L+?#CQI:>-]$^#%EJFJZ;?17VD6/BOQ+XK\
M7^'M&N8=A2;3O#OB/6=4T=9(I%\R(S6DJQ2!98@D@5E_2A+:!8UB$4814"!0
M@ 51C"J!T P, 'MFOI.+>+,-G>&HX#!4*L*%.I&M4J8F,55E-77+'E<M.5^\
M^;6732Y\GP3P1CL@QU;-,TQ6%J8B6&GA*-# \_L?9U)TZE2K5E-IRFI4XJ"Y
M5:+=WJHK\*_@EXZ^'_[3=G_P5W^"WPW\9VUUXF_:$\;_ !%N_AU(VF:[IRZO
MX8\0_L=_ [X4Q^+=.N-3TRRMKC3++QM::GI$CK*7:[TZ9%B906KYST?XBZ7^
MV3X$_P"":/[''@O0_&&A_&3]GSQKX"\5_M4:%<^%=?TB\_9Y@_9_^#WB_P !
M:UIWB:^O]/@T^RN_&/CC4M+TOP,(+N[7Q)H-U+J5LCV<@E7^E];2U4[DMX4;
MCE(T4\$$?= Z$ CT(!'(%*MK;*[R+!$KN%#NJ*KN$^YN8 %MO\.2=O;%?!:^
M7W?EKIMKO\G8_4(RLT[:KSZV2OMY)KS\M#^73P%XY/Q'_91_8>_X)G6'AGQ-
M8?M5_!?]H+X#Z#\<?!,GAG7+4_"[P1^S)\2;7QYXA^+NI:[<V,6AIX1\9:)X
M2TJX\#:W;ZG*OB2?Q7!:Z:)+N.[M8,1_$AM?V&]9_P""2+^'O%,O[7=Q^TA<
M?#"S\)/X6U]OMWPTNOVET^*]M^T>-;:S.D1?#T_#6,^(&\62:A&EOXF!TPH+
M]9(H_P"J46EL)#*((A(P ,@0;R!C +8R0,# )P,#&,"C[);>9YWD1>;MV>;L
M7S"F<[2^-Q4GDJ203R1DFBW2_2VW32_5ZZ;_ (="G43WCI?FWM[SZZ):>6^G
MQ$6FQF*PM(20WE01Q;@ ,B,; < G!(49YSG.>:NT@      Z # 'T I:9F%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %?DW\3O@EX-_:0_;/_ &PO@9X_M_.\*_$S]@WX(^&K^=((+BZTFZG^*_QS
MN-%\1Z;'<J]O_;/A;7+?3?$>B2S(\<&KZ593NC",J?UDK\_/!?\ RDY^._\
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M5'JK^&KB2)HT@=M<.BZFNGQI.7F>TD5@AQF]\-/')^)'@;PSXW;PIXO\#_\
M"2Z/9:P?"?C_ $=?#WC/P^;R(2G2_$VB+=7HTK6+3/EWEC]KN!!("!-(I#D
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M0IQ@\SP.*Q'!6=8MJ-I5<;5PF$SG(W5E*TO]AX?R^DE=*EJG'_*8 )( !))
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M 3X3^,K/Q4EOX<US2;KQ2YU&\@BA\-^*+C4?"=C:Q:B\6A->Z_J5W)];>!/
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M+-=\%ZLT]E'<721(VK^';]K4BXD$]IY%T1&TYC3VXRQA=Q8!< Y/3G&/;G-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:KS^Y+[G>_?Y-#;3;?*]97M;N[_DTK;:W/D7XZ^/?VU-&^/G@S]C'X<?$/\
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MF@+KNMT]]UIUOI?:UNJ=]6%UKHVVK+W5\G^*]+VUT/4O^"5?_)LGBW_L[/\
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M3]G3_P /;\-/_FFH_P"&P?V2?^CI/V=/_#V_#3_YIJ+KNOZ_X=?>%GV?]?\
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MOPT_^::BZ[K^O^'7WA9]G_7_  Z^\^BZ*^=/^&P?V2?^CI/V=/\ P]OPT_\
MFFH_X;!_9)_Z.D_9T_\ #V_#3_YIJ+KNOZ_X=?>%GV?]?\.OO/HNBOG3_AL'
M]DG_ *.D_9T_\/;\-/\ YIJ/^&P?V2?^CI/V=/\ P]OPT_\ FFHNNZ_K_AU]
MX6?9_P!?\.OO/HNBOG3_ (;!_9)_Z.C_ &=/_#V_#3_YIJ@_X;&_9,\X1?\
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M=X?\7V6G7<D:S1VE_=>']0U""SNI(6$R6]P\<KQ$2*I3FG==_P"OZ:"S[,]
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M@NULVOG_ %V7W'SK_P ,@?LF8 _X9?\ V>,#U^"OPV_^9JE_X9!_9-_Z-?\
MV>/_  ROPW_^9JOHFBBR[+^O^&7W!=]W]Y\[?\,@_LF_]&O_ +/'_AE?AO\
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M'_AEOAOW_P"Y:KZ)HIV7;R^2V7R"[[O[V?.W_#(/[)O_ $:_^SQ_X97X;_\
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M_P#1K_[/'_AE?AO_ /,U1_PR#^R;_P!&O_L\?^&5^&__ ,S5?1-%%EV7]?\
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M_L\?^&5^&_\ \S5?1-%%EV7]?\,ON"[[O^O^&7W'SM_PR#^R;_T:_P#L\?\
MAE?AO_\ ,U1_PR#^R;_T:_\ L\?^&5^&_P#\S5?1-%%EV7]?\,ON"[[O^O\
MAE]Q\[?\,@_LF_\ 1K_[/'_AE?AO_P#,U1_PR#^R;_T:_P#L\?\ AE?AO_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXJ\#_!7X6^$O$ADD\Z0:[X=\$Z)I.KI)+EO-*7UI,BS$DRJF]N2:].UGX=^
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M6"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,4GV6'&"N1@@\D$@]<D$$Y/)YY/-2XI[]?\ AOO72_?TM:FTK>EOO3_)6O\
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MG\,]"\6_M6?&G_@D+X ^"/[(GQG_ &;O$O[!3:?>_M/_ !%\??"G4?AGX?\
M!NE^&_"NCZ5K_P ,-(\17L-JOC4_$/6-/U.\A2S>8-#K7]I31$RZTUGXGK7[
M#GCJ;_@EK_P5&E_X9<\9S_M"?%']NGQ#?>&D?X6ZQ/\ %#QC\-;'XW^!-3T2
MY\,12://X@OO"R6<_B#5+2[T1CIDD<MY=).=C./[6!:P @A,$9Q@D=>N0.".
MV",8XQBG^3'R"H(/!X _D!1RK\&M?-)7]=-_7N/G?;2Z=OG??S9_,_XL_9G\
M2_"+_@HU^S#X@^"G[,<]U\+O /\ P2U^+O@R31-&\$-I/P\U/QY+%JT^G?#/
MQ1K,>FKI46M>++EXK2[L-4NCJEX=1GNKA+@M<35^<O[+&K_M1_%3]M#_ ()?
M?%;XD_ OXV^&?"?PF^(GQ=^'_C3X5^%/V.HO@C\ ?V8;GQ]X>UKP_I'@_P *
MZCIUBFK^)=,O)[E=;\:>*O%%U_9.G>>(HUBF\Z)_[=S:VYSF-><=NF/3.?QS
MD&C[+ 224!)[Y(/88!7!    '3@<467GO>W32W^0*;LTU>ZM_P .]7]S1_%S
M?Z!\6]3_ &(_^"T?['6B_LE_M ?\+&UW]I/XS?%KPCXPL_A/JH\(^-/"GB3X
MY?"P>'_"?@W5X;<ZAXDUF;2-*U7Q1::;I=A<Z>=$MSJ$,\T;R!/>]/L/$_[$
M/[?'A/\ :I_:1_99^,_QM^#?Q-_8*^ 'PG^&GBCX<_".Y^+&M?!/X@>%/!_@
MO3/%/@+6?"01+GPG?ZS=:7JQ%RWD74S:J+9FN$GUH67]97V2WX_=C([@D'HP
MZCGD,P//(.#3DMH8V+*F&/<LQ_+)/T^G'2ERK3?2W;97\OO[BYO+3JKO71+]
M.M]SQ/X(^--*^(OP.\">,]#^&_BOX3:7K_@ZUN]+^&?C;PDO@KQ=X,L?LA@M
M] UCPC$NW0;VTBB6,:9#NCBA,0@)C=!7\5F@_LP?MT_LT?LN?LQ_M,?LX? W
MXJP_M ZXW[9/[)?Q=\"IX(\2P^*[3X?_ !F\;^-=5^%?Q!U'0H]._M2TT_P=
MKNHWWB:QUVYMEM([@>'V:4:7)*TW]X'V>+.X*02,$!C@]1DC."<$C)'0_3"&
MU@.?W8&1@[2RYZ==I&<8XSQ3:OW^7JG^@D[?A?Y'\Q'[%/[#/C3]EC_@H?XT
M\!:#X \4#X:^&_\ @E'X'^$,/Q,?0M4B\&>+?C!=^,M+UWQC;VWB>2%]*GUG
M4]?NM>UF>P%\]W!#*W[HQA2?S \&:1^U/K7[$7[ W[%=I^Q+^U%:>(/V<OVZ
M/!WCCXU_$+7?AMJVE^%?#B1_%CQCJNGV6@Q-;SZGXIL&T;7IM7U_Q-:P0Z!H
M%M;68NM1?^V;-8_[M_L\6,%<XS@L2S<]>6).,<8Z=?4TGV:$=(U7Z#'T_*BR
M6WG^-O\ )+T&I:WM?;[TK?BK^E_O_F=UKQ'\0?@Q_P %0_\ @IYHNE?L9?$_
MXUP?M$_ 'X;ZE\+]6M/ALNH?!?6;SP'^SOXE@UKPWXU\37*PV,>G^.?$DD/@
M:2TTQKVZU>_U*]T^XBA(EDD^!?V-K_\ :;^*?[>__!-7XP?$_P"#WQNL?"'@
M?1_CE\*O%?A'3?V0K?X$? ;]G/6/%?A3Q38VOPW\'G3;)[[Q!X8MQ/%J/B#Q
M9XINGL3->):V$D-TEUI\7]KQ@C(P5_+@GWR.<_C33;0D@[3E>AR1UXYQU'L<
MC//6BUFG?9WMYW3Z6[/[RE-)6LM59M]K6[76G;LMS^):;PS\8]>_X)>?\%2_
MV.-'_9%_:$A^*6G_ +4GBGQ]HWB.+X1ZK'X<^(.A>(?VN_A[K&F^'_!5U! =
M6\2:AIOARPOO%%U9V&F3V%EH(EU2.Y$#$U]=>(K/Q+^Q;^WY\=_V@/VB?V6/
MC!^T9\*_VEOV/?@O\./A!K7P^^%FH?%2?PKXD\*?#G0?#'BKX%>)-$@MYQX0
M/C'4[*6.2ZOH(;2ZCNX9KP3K<:Z]M_5A]GBP5VX!ZX)4G/J1@_EC/?--:UA8
M ,F0#D>OYCG'J,X/>A*UNMK=NE[:?/\ (%4WT=GTO9].O3;?T/XKOA'_ ,$\
M?CUIG@[_ ((B_#?X^_ [Q'XK\+:!^TW^TG\3OB7\/-2\+WWBSPU\$?A[XYN/
M!/B/P1X/^)'V>*^TK1;19-,FO;K3=:<6<%Y=WFE7T$ES:7=E7TJW[,EB&_X+
MP^'?C?\ LZ_M$WGP,^+_ ,?/@O<^"M*^!OPYOY/&/B71].EGF'C?X1Z0UI8Z
M;XJL/!>III^O:K_9IO+"6QLYK6:+S#M']7PMXAC"XQTVDK@^OR[>>3U]30;>
M(\%>/3)Q^*YP?Q!Q@8P:.5+\OP2_1"YV]TNGX.__  /ZL?@;_P $:/&W[2NO
M>-?V@_"WQ.B\=?$OX%^"=%^&FB? S]ICXR?L]R_L\_&7Q]!#:ZVVM^ _$VCW
MUC8:MXNLO ,K):6GB*\BE)O)KQENIXM0ABM/F[]N_P"-?PX_9]_X+L_!+XG_
M !-^%7Q ^+6@:/\ \$_/$5G:Z-\-/AO=_%+Q/HVLZC\2/&%O9:W'X;LHIKF*
MU>$W6A3ZK"F+&76K9[N2&U9Y5_J"2WAC(9$ ([]_SZ_AFOCC6/V+O!FL_MS>
M%OV[)_%/B.+QUX4^ .I?L_VG@Z(6 \+7.@ZGXJN?%4VM7$AMCJ8U6.ZNI+9%
MCNEMFA2)C&'0[BVEO-?@[_U^+!-7;?5;=WIV74_DCO/V)/VN/"7[+WP)^/5Y
M\)?CKX&^%G_#R7XK_M8>)?V>?A#X;TK7_C1\'?A!XZTW0-)^'_BO1/AUK6GZ
MUIC:_P"#Y='U?4O^$7N-"NDT^RUFRGGL[(27T]EU?[1G[,MO\<OV2/VL?&GP
M ^'7[?\ \5?%GQY_:>_9 U/QYXD^/_PA7P?J_P 2+3PQJ_BNQU3Q=X#\'^#O
M#6BZC/8^%[*]^Q>+O$.H:)9)$UW97L;Q3237I_MW%K   $ QWZGKGG.0?3D=
M,KT)!46T _@!P01GKD# YZ^YYY/S'+<TN5>>UOP2]-O*^NZ#G?;[M%K;IW\_
M,\M^#/P@^&/P)^&^@_#;X1^!/#/PX\$>'[41Z=X:\*Z19Z+I=O(Z(;J[>UM(
MHDEOKV53<7]]<>9=WERTEQ=SRS222'^0#QE^S9^UE\'H?VAOVYO@G\#/B1J?
MQ_\ V=/^"N7QZ^('@7P:G@SQ%_;?Q;_9^^-OA7P7X*\32>'])@T]M5\4^&[^
M_MM-,-_I-M?VL=@->OK<F.*>>'^U;:I4J0"I!&#TP>U1"V@!)$8!..02I&/0
M@@C/?!Y[TVK]UYK?34E.SOO?>_7O]Y_)I^QK^P]\9?V=OV[?^"4OB;Q5\/\
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@* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>nt10016217x4_graphic10x4.jpg
<TEXT>
begin 644 nt10016217x4_graphic10x4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** /"_VF?^2"_%#_L69_\ TIM:_ NOWT_:9_Y(+\4/^Q9G_P#2FUK\"Z_<
MO"W_ )$^8_\ 8R?_ *BX<_D'Z1/_ "4^2?\ 8A7_ *L,:%%%%?IQ_/H4444
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M?"#_ )*E\/O^QNT+_P!.$%?B37[;?"#_ )*E\/O^QNT+_P!.$%?B37U/!O\
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MFXO=7T6UT:PTF_-TMCJ$NM2Z@NF/!=M8WHA6"YEG)LKT/"AL[OR?5?'OQ5\
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M?!__ *D.G4?%7_DJ'Q(_['WQA_ZD.HT?"K_DJ'PW_P"Q]\'_ /J0Z=1\5?\
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MZXBQ^$B\ZR3(U"MA<VX+RREAL^RM87.*^%IYS2Q7$&=99A<'C*M/),-2Q%+
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MXMUM9_V1T[]LO]GBZTKX-_%>T^)O@WP!XT^&'[/Z>"+GP6GP'OO$_P 5=/\
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M $JBKVC]JO\ Y.A_:1_[+W\8?_5A^(J\7T7_ )#.D_\ 83L/_2J*O:/VJ_\
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M1Q.&J9;+#0JX&GA8X"C]4Q.+Q%2CC_:2KX9.G2J0I_&6G_LQ_$C_ (2[X?\
MAWQ!;Z=HNE>/]7_LRP\56NKZ+KVBPM;1W%UJD*W>EZG)9SZM;6=E>FRTE[RV
MDU:]MS8V4[/YDD73^-OV5?%NG_$'Q9X<\)SZ++X8\-V>F:C)XB\0>*=$L+:Q
ML=4GOM/TZ+7+R5[6&UUJ_O-(U&4Z=%;AK>$V[RK#%<VWF6?"OQ:\&Z)\)O@C
MH5YJ\T^O> _CYIOCO6-&2QU1WM/#%C=W%Y)<6]V]HNF2F221BMG;7KW)EG9V
M@7,CCVVV^+/PRTCXA_&#6/#_ ,9=#FTSXBP:3KD6E>*_A[X@U;P%J=X;B\L[
MW0/$5C_9*>(A<6&F+YT5[IEU9V-^=92.]M9WT/[+==&*S+B>CB*DHTG*-&CB
MZ%.$<JQTL-B:E+-L/1CBK47B:M*=3 3]I04IU*#E"<XMTI5.3AR[(?#W%8*A
M2GB53EB<5EF,KU:G$>3T\?@J&)X;Q6)GE_-BHX+#5Z5#.J:H8MTZ5'%1C5I4
MIQA7IT55^"?'7@+Q3\-_$,_AGQ=IIT[5(H(+R'RYX+RSO]/NU9[/4M.OK22:
MUO;&Z56\N:&0E)8YK:X2&[M[B"+CJ]V_:(UCX6ZW\0$O/A-9V-MHBZ#ID.L7
M&D:=?:+H6H^)$:Y;4+S0M%U$)<:7IJ6[V5E';"*W@\VTED@BD1_MEWX37V.7
M5Z^)P&$KXFG.CB*M"G.M3J4'AIPJ./O*5"56M*CKJJ<JLIQ32E:5XK\MSW!X
M3 9SF6"P%>EBL%AL76I8:O0Q<,?2J48R?)*.,IX?"T\3:-HNM3P].G.2;IIP
MY92*_4#_ ()U_P#(/^+/_7YX+_\ 1'B>OR_K]0/^"=?_ "#_ (L_]?G@O_T1
MXGKYKC__ ))3,_\ %@?_ %884^^\%?\ DY&0?]>\W_\ 5+F!^E%%%%?SB?W8
M%%%% !1110 4444 >%_M,_\ )!?BA_V+,_\ Z4VM?@77[Z?M,_\ )!?BA_V+
M,_\ Z4VM?@77[EX6_P#(GS'_ +&3_P#47#G\@_2)_P"2GR3_ +$*_P#5AC0H
MHHK]./Y]"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#TSXE_\R!_V3/PK_P"W]>9UZ9\2_P#F0/\ LF?A7_V_KS.N/+_]TH_]Q/\
MT[,]3.O^1GB?^X/_ *CT@HHHKL/+"NG\*>-?%W@;4'U3P?XCUCPW?RQ"">YT
M>_N+)KFW65)A;7:0NL=W;>;''(;>Y26$NBL8R0*YBBHJ4Z=:$J=6G"K3FK3I
MU(QG"2[2A).,EY--&M"O7PU6G7PU:KAZ]*7-2K4*DZ56G*S7-3J4W&<)6;5X
MR3LWJ=%XH\7>*/&VJ-K7B[7]6\1ZJ85MUO=7O9[V:&U26::.TMC,[+:V<<UQ
M/+%:6RQ6T4DTK1Q*9')YVBBBG3A2A&G2A"G3@E&%.G%0A"*VC&,4HQ2Z)))"
MK5JV(JU*^(JU*]:K)SJUJU256K4F]YU*DW*<Y/K*3;?5A1115F9Z9HG_ "27
MXA_]CI\,/_39\2Z\SKTS1/\ DDOQ#_['3X8?^FSXEUYG7'A?X^8_]AD/_5?@
M3U,P_P!TR/\ [%=;_P!76<!11178>6%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >C?"#_ )*E\/O^QNT+_P!.$%?B37[;?"#_ )*E\/O^
MQNT+_P!.$%?B37U/!O\ OV<_]@F3_P#I[.3\A\:_^1/P;_V,N+?_ %%X2/>O
MV6AX*/[1_P $#\1'LX_!B_$WP@^N-J2V[Z48DUBU>UCUE;R.6S.B2WZVD6M?
M:T^RC2GO#<O'"'D7]H_V^-1\5VOP)_:4M/B9X8\5WN@7GQ7\+:?\(]9^(WB'
MX<)9Z'?PZK!J%K=_!72?#/AJPU^ZT#4?!D;V&J0ZOK%YJ=I!%J7VQI;Z+Q=-
M)_/%4LEQ/,L2S32RK @CA621Y%AC'2.(,Q$:#LB */2NW.^$5G.?Y/GDL;&D
MLJ^KVPU3#3K2;P^84<PC4PF(IXO#/!U:SI?5\2Y4L3"OAW&$Z?)&4*GS7!GB
MI+A'@;BW@V&3U,3+B=XZ^84<QH86FH8_(L5D<\/FN7XC*LPCFN&PD<4\?E\*
M>)RZM@\;[2M2KJI4IU:']2/B/XK>-KC_ (*&>,/@1=ZC9WGPFUS]GW5]6U7P
M9<Z/I#Z;J&M3^'[.:;6=1=;)+K5M1:UTNVTA9=7N+^.'13)IL$,4!0)XU^P/
MX:\=>&/@]^RUK&G^-OB5XM\%^+?%?CN^NM ^'T/PX\'_  M^'T;ZS/I-_9_&
M36-5T>7QM\0-7U759I(?#UC'=PLM^BZ1I4D4.F:'=:E_.=4@EE$1@$D@A9UE
M:$.WE-(JLJR&/.PNJLRJY&X*S '!-?*R\*Z<<J_LK#9KA*-.IA,HPV*E+(J-
M2&)K99@,XP53'."QU.I1Q>)>:4Z_MZ5>-:'U-8>K5Q-#$U(P_3J?TG*\^)GQ
M+F'#&:8JOA\VXJS'+(4^-,50K9?A.(\[X0S>ADOMGDM:AB\JRV'#&*P?U3%8
M*KA:SS?Z[A<-EV+RZA.K_17X3T3X\:;\"_VRM'_9?6VT#XF6/_!0KXP1^&]*
MBM_#5CJ4_AD6/A7[7I_A'_A*VM]&L;Q/#TBZE!*F)I/#-GJ<.F O<PM77_M!
MG2E\ _MWVLDFB3_$:Q_98_9AM_C/=:!:6]E9WGQ+?4/C'=:A=7,5NBAK^XT6
MYT.97+RA-(DT>V$F;=D7^:2.1XG26)WCDC97CDC8HZ.I!5T=2&5E(!5E(((!
M!S2.[R.SNS.[LSN[L6=W8DLS,22S,22S$DDDDG-:?\0QD\6L3/.</>.,PF-=
M2EDRI8VO/#XW(<6\/C,9_:4Y8G!_\(C^K473@\-B,;4Q#G65&-&?-_Q,A3AE
M4LNI<(Y@U/*<RR98?$\7O$9-@J..R?C;*X8_*<H7#U*&79M?C"/]H8N.(JPQ
M^ RBC@(T<)+%5,71_IM^%]U)8WG[/M["EO)-9_\ !);4;J*.[M;:^M'DMY?@
MO,B75E>13V=Y;LR!9K6[@FMKB,M#/%)$[H?EBR^*X^+?[-W[$OQ-_:.O],\6
MO8?MM6VA>)?%7B*WT:R7_A%WGU_4)5U^ZEM(]-C\,6$[64NLZ>+>UTN?0-$M
MK.:%%MHYU_#>MKPWK]_X5\1:%XGTH6C:GX=UC3=<T]+^SM]1L'O-*O(;ZVCO
M]/NTEM-0LI)H$2[L;J*6VN[=I+>XC>&1U.E'PRI4.>LLRC5Q:Q"KT,1' +#8
MFE3]CGE.KA:.+6*K5*$<2\XIN=2,91C+!TYRH57*/L>;$_2,Q.,5'"/AZKA<
MKG@7@L;@9YU+,,OQ-;ZUP97PV98K+)9;A,/C:N7KA2O&CAZLZ<YPS>O2AC,-
M&G4>*_I:^(EK^T9!X-_X*)3?&;7-!U#X:WOPQ\>W_P"SS:03>#9]0'@6[TK6
M_.ET1-"E_P"$AT_0[/28/!VGZ[%K]NL&I^(4AU&Q9IS?7-[_ #%U]S^-_P!N
M'4/$/PZ^(G@'P5\"/@E\'IOB_:Z38?$WQ%\.-#UG2KK6[#0[R"ZT^QT;2Y=9
MGTKP]:21QW%IJ<"6^HI?1:A?W""UU"X-XOPQ7I\ </9CD.&S3^T<-@\'/%XC
M JCA\%0P^&I>RP.5X3!2KRH87%8RC"IB:U*K5J-8B4Z]1SQ-2GAY5_JU'Y[Q
MUX]R#C?,.&O[ S#-LVI95@<[EC,?F^-QV88AXG.N),SS>G@88S,LNRG%UJ&7
M8/$8;"T(2P-.C@Z$:674:^/A@O[1Q?O?[*G_ "=#^S=_V7OX/?\ JP_#M>+Z
MU_R&=6_["=__ .E4M>T?LJ?\G0_LW?\ 9>_@]_ZL/P[7B^M?\AG5O^PG?_\
MI5+7UE/_ )'F,_[%66_^I>:GY=B/^2,RC_LI^(O_ %5<+F91117JGS 4444
M%%%% !1110 4444 =[\*O^2H?#?_ +'WP?\ ^I#IU'Q5_P"2H?$C_L??&'_J
M0ZC1\*O^2H?#?_L??!__ *D.G4?%7_DJ'Q(_['WQA_ZD.HUYG_,Y7_8L?_J5
M$^B_YI+_ +N+_P!YAP5%%%>F?.A1110 4444 %%%% !1110!IZ+_ ,AG2?\
ML)V'_I5%7M'[5?\ R=#^TC_V7OXP_P#JP_$5>+Z+_P AG2?^PG8?^E45>T?M
M5_\ )T/[2/\ V7OXP_\ JP_$5>35_P"1[@O^Q3F?_J9E)]1A_P#DB\V_[*CA
M[_U4\3G@E%%%>L?+A1110 4444 %%%% !1110 5^W/QC_P"2K?$7_L<=?_\
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M?_!#I7_R)1_PA7@W_H4O#/\ X(=*_P#D2NFHH]O7_P"?U7_P9/\ S#ZC@O\
MH#PO_A/2_P#D#F?^$*\&_P#0I>&?_!#I7_R)1_PA7@W_ *%+PS_X(=*_^1*Z
M:BCV]?\ Y_5?_!D_\P^HX+_H#PO_ (3TO_D#F?\ A"O!O_0I>&?_  0Z5_\
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MU'!?] >%_P#">E_\@<S_ ,(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\
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M_F'U'!?] >%_\)Z7_P @<S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\
MP0Z5_P#(E=-11[>O_P _JO\ X,G_ )A]1P7_ $!X7_PGI?\ R!S/_"%>#?\
MH4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E=-11[>O_ ,_JO_@R?^8?4<%_
MT!X7_P )Z7_R!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=
M-11[>O\ \_JO_@R?^8?4<%_T!X7_ ,)Z7_R!S/\ PA7@W_H4O#/_ ((=*_\
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M* "BBB@!P^XW^\O\GIM.'W&_WE_D]-I+>7K^B&]H^GZL****8@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!R??7_>7^8IM.3[Z_[R_P Q
M3:!]%ZO\HA1110(**** "BBB@ HHHH **** ')]]?]Y?YBFTY/OK_O+_ #%-
MH'T7J_RB%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *<_WV_P!YOYFFTY_OM_O-_,TNJ]'^<1]'ZK\I#:***8@HHHH ****
M "BBB@ HHHH *<_WV_WF_F:;3G^^W^\W\S2ZKT?YQ'T?JORD-HHHIB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *]P^#W^JU__ *Z:;_Z#?5X?7N'P>_U6O_\
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M=PZSJ&I0:AJ<5]\%?M"_ OQ<WQ?_ &H8K7]ES]J.&]^*4NM2>&9?@?XX-Y\
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MH **** "BBB@ HHHH **** "BBB@!R??7_>7^8IM.3[Z_P"\O\Q3:!]%ZO\
M*(4444""BBB@ HHHH **** "BBB@!R??7_>7^8IM.3[Z_P"\O\Q3:!]%ZO\
M*(4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IS_ 'V_WF_F:;3G^^W^\W\S2ZKT?YQ'T?JORD-HHHIB"BBB@ HHHH ****
M"BBB@ IS_?;_ 'F_F:;3G^^W^\W\S2ZKT?YQ'T?JORD-HHHIB"BBB@ HHHH
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M * FD?\ @MLO_C-'^L=+_H%J?^#(_P#R(?ZE8C_H.H_^"9__ "9\?45]@_\
M"/Z#_P! 32/_  6V7_QFC_A']!_Z FD?^"VR_P#C-'^L=+_H%J?^#(__ "(?
MZE8C_H.H_P#@F?\ \F?'U%?8/_"/Z#_T!-(_\%ME_P#&:/\ A']!_P"@)I'_
M (+;+_XS1_K'2_Z!:G_@R/\ \B'^I6(_Z#J/_@F?_P F?'U%?8/_  C^@_\
M0$TC_P %ME_\9H_X1_0?^@)I'_@MLO\ XS1_K'2_Z!:G_@R/_P B'^I6(_Z#
MJ/\ X)G_ /)GQ]17V#_PC^@_] 32/_!;9?\ QFC_ (1_0?\ H":1_P""VR_^
M,T?ZQTO^@6I_X,C_ /(A_J5B/^@ZC_X)G_\ )GQ]17V#_P (_H/_ $!-(_\
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MZ#J/_@F?_P F?'U%?8/_  C^@_\ 0$TC_P %ME_\9H_X1_0?^@)I'_@MLO\
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M>#_OS'_\31]EMO\ GW@_[\Q__$T?ZR0_Z!)?^#E_\K#_ %-G_P!#"'_A,_\
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MK$?]!U'_ ,$S_P#DSX^HK[!_X1_0?^@)I'_@MLO_ (S1_P (_H/_ $!-(_\
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MT'4?_!,__DSX^HK[!_X1_0?^@)I'_@MLO_C-'_"/Z#_T!-(_\%ME_P#&:/\
M6.E_T"U/_!D?_D0_U*Q'_0=1_P#!,_\ Y,^/J*^P?^$?T'_H":1_X+;+_P",
MT?\ "/Z#_P! 32/_  6V7_QFC_6.E_T"U/\ P9'_ .1#_4K$?]!U'_P3/_Y,
M^/J*^P?^$?T'_H":1_X+;+_XS1_PC^@_] 32/_!;9?\ QFC_ %CI?] M3_P9
M'_Y$/]2L1_T'4?\ P3/_ .3/CZBOL'_A']!_Z FD?^"VR_\ C-'_  C^@_\
M0$TC_P %ME_\9H_UCI?] M3_ ,&1_P#D0_U*Q'_0=1_\$S_^3/CZBOL'_A']
M!_Z FD?^"VR_^,T?\(_H/_0$TC_P6V7_ ,9H_P!8Z7_0+4_\&1_^1#_4K$?]
M!U'_ ,$S_P#DSX^HK[!_X1_0?^@)I'_@MLO_ (S1_P (_H/_ $!-(_\ !;9?
M_&:/]8Z7_0+4_P#!D?\ Y$/]2L1_T'4?_!,__DSX^HK[!_X1_0?^@)I'_@ML
MO_C-'_"/Z#_T!-(_\%ME_P#&:/\ 6.E_T"U/_!D?_D0_U*Q'_0=1_P#!,_\
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MIW_"ZOB]_P!%,\<?^%+JW_R51_PNKXO?]%,\<?\ A2ZM_P#)5>8T4?V9EO\
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M94ZD8SC**LT445@>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?SO_&7_
M )+'\7?^RI?$+_U+M7KS>O2/C+_R6/XN_P#94OB%_P"I=J]>;U_6F7?\B_ _
M]@>%_P#3$#_-+.O^1SFW_8SQ_P#ZE50HHHKL/,"BBB@ K]+?^"<G^O\ C3]/
MAQ_Z#XZK\TJ_2W_@G)_K_C3]/AQ_Z#XZKY#CW_DDLW],!_ZM,"?I_@S_ ,G+
MX9]<X_\ 6?S8_3NOY^O^#A/]DOX >/OV)OC+^U1XJ\"W%_\ 'OX3^&/A%X-^
M'_Q M?&?CW19_#WAO6OVA/!.GZGIL?A_0_%&F^%-1^UV?C;Q1;M>:OH.H7\:
M:HWDW4;6EBUK_0+7D/QY^ WPH_::^%'BKX(?&_PK_P )M\+_ !M_8?\ PD_A
MC^W/$GAO^T_^$;\2:/XNT7_B=>$=8T#Q#9?8O$.@:3J'_$OU:T^T_9/LEWY]
MC/<VTW\W']XGXD?&7XC:/_P3*^)?@/\ X)__ /!-_P"#VF?#"^^)O@+XF?MA
M^//%/B_X%?MS?MP>&+=M&O?!'PET/PYI?P__ &?+KQU\7(;[QQKFF:%8>,/&
MM[KFF>!OA;X8T:RN$T/7_&?Q!\.V5QR^I_'?]M;]I_\ ::_X)J_%;X$> ?AY
M^S;\=/'W[&?[>?\ PLWX?_M=^$/BZV@^!8O!7QH_9G\)Z_/8?#BVU#X.?$O7
MKGQ#XT\/:)+X#?7AX6U2V^&?BV;QOJ>B32Z>^A7?[/\ [07['WP._:9UKP!X
ML^).G^/=,\=_"N+Q1:_#SXC_  F^,7Q=^!7Q'\*Z;XXATFV\9:+8>.?@SXV\
M"^)9]!\46^AZ1'K&AZAJ-[I-R^GV=TMG'>VT%S'X_P"(O^"87[&.N^'/@!X:
MTOX=^,_AO!^RSX'\2?#CX ZQ\&/CM\>O@OXL^'/@[QF-$3QII=EXM^%_Q+\*
M^(M=N?&4>@60\4ZYXMU'Q!X@UR6?5KV_U6;4-<UB[O0#\6O!_P#P74_:D_:+
MTJ:[_9V^ FB:9XF^"_P?\->-_C3X+N/V;?VSOVI=/^,7Q4U'QY\2O!^J?"OX
M2?$;]E3P7XJ\-_!CP->Z5\)_$6K>"?CA\5[?Q7H_BCQ#X@T;2=.\-7V@^"/'
MNO2?7WQP_P""@'[<>JWWQN\0?LX^$_@!\,O!GP*_X)P_ []OOQ#X*_:@^&7Q
M>U7XP7.K?$K2_CMXEUGX(:Q8^$_B?\/]/\&ZM8:/\)%TG4-6U32;G4O"'B>"
M^TZ\\/\ B&/6?M7@_P"U_'G_  2M_8?^(&E^&]"N?A;XH\$Z'X<^"6G?LU-H
MWP<^-OQT^"&E^*_V?-,;5)+?X.?$6R^$?Q(\&0?$CP.\FN:W)=6'CA->N[MM
M:UDW%\XUC4Q=^_:A^R+^SIJ+?%$R_#+3K6'XR_ +PS^R[\0[#2-9\4:#I.K?
M 7P;8^/=-\+_  [TO1]$US3]*\):=HNG_$[QO966I^#K/0/$"6VL10MJ[II&
MAC30#\>_AY^V3^TQX.T[_@HG\=O%_P 9_@5%HUS\?_V5O"WP/\&_$7P#\<M7
MTOX6S?'7]E?]DGQ_H_ACPCX>\#?$KQ_XZ^,U]H?AKXHSBS^ _P (O '@CQ-\
M?/CO;^,O&^C^(OA;I?Q.;PM\/OB+X_?M,?M3_MSW7PE_96^(OBKX:Z%X<\-?
M\%1/@;^S]\1;N_\ V7?VLOV?U^/W@3XF?LO_ !(^.O@!_B7^SY\1_CW\,/C%
MX%\&Z;)X3UI/&?PUUGQ+<6GQ9O;WX>>+] \4>%?"GA/4=#^)O[V>(/\ @EW^
MQAXDUKX@Z_>> /'5AJ7Q+MO@D?$$GAWX]?'OPO'IWB/]G&Q\!:5\$?B+X+B\
M/?$O35^'_P 5?AYI'PQ\$:/HWQ.\%?V#XXETG2+S3-2UR^LO$WBR#7;/@'_@
MF%^Q7\./%T7Q"T'X8>*M3^(8^+7PZ^/&H>/O''QR^/OQ'\9>(/C%\*/"?Q+\
M#>!/B!XI\0>/?B?XCO\ Q-K6C^%/B_\ $'1)8=<EOM*U6RUBPBU?3KX>%_"7
M]A 'S1IW_!0GXS'X.? 7QS#X.^%$NN?$S_@II\=_V*+_ $-;7Q%H>C?\*R^%
M/Q _:G\)^&;[1+NY\6W9T3QWJ&D_ OPJ^L>(-0.L>%X+B^\27UMX,M+%["RT
MKY+^''_!7#]I]_V?_P!I_P >?%"+X Z;\;_AA^P3XM_:Z\+? KQ/^SM^U9^S
M?X\\#>-_"6EFXO\ PCJ'AKXM>)==\._M0_!.*YO](BN_CK\&/BQX&6"^6TM8
M_",FF^.-'UCPS^I5O_P3"_8NA^*;_%Z;X:>*-2\1Q_&+Q1^T#I?AS5_C3\;]
M4^%/A[XS>.CJK>//B#X>^"U[\19OA+I.N>.'UO56\5BW\&"PU=;^Z@GLQ;7$
M\,GA'Q3_ ."1/P!M?V=/VA_AO^SCIWB?PU\3/B/^R!\5?V1OA%K/Q@^/G[0O
MQ7\"_"#X=_$+2K!;?P)X+T'XA^.?B/8_#OX?1:_X>\*7MY8>!_#D5W;V.@V.
MGV,3:?:PZ=0!O?LN?M3?M@W?[8>H_LD_M>^'/V=+C5_%?[)6C?M<^ /$W[.7
M_":VNG^"=._X67:_#;Q7\)OB /&WB[Q9/XOU2RU+7M(N?!_Q.T.S\"Z!XSL-
M#\37%IX3M[B&[L="_5:OD[]F;]C+X(_LL+J6J?#K2?%]WXQ\0^$?!?@C7?%_
MQ#^+7Q:^-'B.'P;X!&L3>$OA]X8\0_&'QGXTUGPI\-_"U_XC\0WGA[P1X<N=
M(\.V=UJ][?OICZA<27)^L: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K^=2+_@IQ^W)K%[^R-^T%HWAO\ 96T_]D+]L+_@HW!^Q+X/^'GB#PG\7$_:
M9\&^"+/XK_$KX;O\0/%6NS?$71/!47CSQ$?A%XZN[_P/#X*F'PX-SX0BU$>*
M;O\ X2ZTT;^BNOP<LO\ @DWXW\1?M;_#CXF>/A\*-)^$/P<_;&^(_P"VEH>O
M^!_BO^T7?>,?B1XW\1:MXNUWP/X;U/\ 9H\0W5O^S%\#M5TK7_%>G>(/BS\7
M/A;)J_B3XUZMX#TN2\\,>#5\6^*&H Q_"/\ P44_;LM?$_PB^*OQ$\&?LIW_
M .RY\6?^"E7Q$_X)[Z9X2\$6GQ'T_P#:!ALK'XZ_%GX)>!?C(^NZU\1-6\&I
M)I6N>!+<^//AS;^"M3U._P##>C:O\1-)UWP]HFN-HO@SU+]FCPK\:_@;^VC_
M ,%1-7^(/QC\3?M._%.]_93_ &,/BU9M>:#IWP_\):;J9UO]OJP\.?"_X3^
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MPM\4_"OX>VWBSXTZM#X*\#7G@36[[0;71/#J:?'I8CTK4M-DM=7\/^']0TL
M^5_B%_P4D_:Q_9$L_P!K"X_:J\*_L_?%.X^%/[$GPW_;!^%L'P T'XD?#^UB
MU?XB_$OQ1\(K?X3^/;SQ]XR^(#ZMH>E>+M/T&]U#XLZ?;>#H;+PO_;GB#4O!
M5BFW3M'X3XW_ /!1K_@H=^RY\5+W]F/XM>&/V+_&GQO\:^#OV9_BE\)?'?P\
MT[XQ:5\,=$\/_&+]L?X,?LG>/O /Q)\$ZYX[U#QU=ZCX<U?XK7&K> _B?I.M
M^']+\3:9HIO;GX>-JECK_ARP_9[QA^RG^S]\0-:\;Z_XU^'&G^)=1^)'P!_X
M9=\<#5=7\2W&F^(O@0=1\0ZJW@&]T0ZT-%2W>_\ %6O32:[;:?!XID%_Y$FN
M-;VMG%;^#>'/^"8/[%WA^^O-:NOAQXR\<^*;R;X1!/'/Q9^/'Q_^+_Q!TS2/
M@+\2]+^,/PB\'^'_ ![\3?B?XJ\7>&_ '@WXCZ'HOBE? .@ZSIW@_P 2:EI=
MI)XQT7Q%MD$@!^;.H?M__P#!2+X2R_M-^+OC)_PQ=XG^%_[&/[87[-_[.'Q-
M7X<_"OXU:#XV^,WAW]H?Q/\ L_6TFN> AXC^/6M:-\*-?\ ^%?VA/"VH?9_$
M47Q/TSQ1K5MJNE";1[328M8U[L+3_@J#\=!^UE\%?!]EJ'P3^(_P$^-/[7'B
MS]EF6Q^'O[/G[6%OI'@.+2X/B GACQ1HW[>'BB/3OV6OC=X]N[[P-<CQU\*?
MA[X2AF\+7_\ :_A'2/$6OS>"?$7B^[_53QA^QE^S7X]T'XU>&?%GPW_M71/V
MB/BK\.?C;\8K+_A,/'MC_P )A\3OA,WPM?X?^)OM.F^*;.[\/_V WP5^&9_L
M7PM<:)X>U7_A&L:WI.I#6?$ U7Q*S_X)7_L2V7CKPIX^7X=>/+F[^'?QHG_:
M&^%_A"]_:%_:*N_A+\)_C%>^.;SXE:KXS^%WP8F^*K?"GP%-K7C?4=2UO5]&
M\-^#]/\ #M['JFJZ+)I \/:IJ.DW0!^AM%%% !1110!6O?\ CSN_^O:?_P!%
M/7\\?Q=_Y*Q\3_\ LH?C7_U)-3K^AR]_X\[O_KVG_P#13U_/'\7?^2L?$_\
M[*'XU_\ 4DU.OU3PK_Y&&:_]@='_ -/L_G+Z1G_(FX;_ .QGC/\ U%@>>444
M5^V'\F!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;Z+^U;)K+Q);:7'XFTK2;N+0?'&K/>\)X"_8+^(.M77PPGUR^UGX'^)_AO\
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M@3]/\&?^3E\,^N<?^L_FQ^G=%%%?S<?WB%%%% !1110 4444 %%%% !1110
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M'X?>. 02"#X3UX$$<$$&PR"#U%?O78?\?UG_ -?,'_HQ:AG_ -?-_P!=9/\
MT-J/^(J8W_H487_PIJ__ " _^)=LILG_ *RYCNU_N.&Z6_Z>^;_K?\&?^%9_
M$C_HGWC?_P )37O_ ) H_P"%9_$C_HGWC?\ \)37O_D"OWAHH_XBIC?^A1A?
M_"FK_P#("_XEVRG_ **7,?\ PAPW_P M]?Z6OX/?\*S^)'_1/O&__A*:]_\
M(%'_  K/XD?]$^\;_P#A*:]_\@5^\-%'_$5,;_T*,+_X4U?_ ) /^)=LI_Z*
M7,?_  APW_RWU_I:_@]_PK/XD?\ 1/O&_P#X2FO?_(%'_"L_B1_T3[QO_P"$
MIKW_ ,@5^\-%'_$5,;_T*,+_ .%-7_Y /^)=LI_Z*7,?_"'#?_+?7^EK^#W_
M  K/XD?]$^\;_P#A*:]_\@4?\*S^)'_1/O&__A*:]_\ (%?O#11_Q%3&_P#0
MHPO_ (4U?_D _P")=LI_Z*7,?_"'#?\ RWU_I:_@]_PK/XD?]$^\;_\ A*:]
M_P#(%'_"L_B1_P!$^\;_ /A*:]_\@5^\-%'_ !%3&_\ 0HPO_A35_P#D _XE
MVRG_ **7,?\ PAPW_P M]?Z6OX/K\,?B2S!5^'OCAF8A55?">O%F8G   T_)
M)/  Y)X%#?#'XDJQ5OA[XX5E)5E;PGKP96!P00=/R"#P0>0>#7[U6/\ Q^V?
M_7U;_P#HY*+[_C]O/^OJX_\ 1ST?\14QO_0HPO\ X4U?_D!_\2[93:_^LN8[
M_P#0#ANEO^GO6_R\S\%/^%9_$C_HGWC?_P )37O_ ) H_P"%9_$C_HGWC?\
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M ?\ Q+ME/_12YC_X0X;_ .6GX)_\*S^)'_1/O&__ (2FO?\ R!1_PK/XD?\
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MOA7XA:UXDOO"FMZ5=1ZKKHU#1;SP_?@'ZL_\.^OV"?\ HR+]D/\ \1K^#/\
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MYX"_;2^$/[7?[5?[4_[0?QQ\%?&[P]^T7^VMX"TWX@>#?VE/BM\(4_8#\'?
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M (CE\'O_ )CJ^%/^&GOCK_T4"\_\$_AO_P"4U'_#3WQU_P"B@7G_ ()_#?\
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M2,$']G+X/$$%@""#X-P01U%37O[ O[":WETJ_L5_LEJJW$P55_9Q^#H50)&
M  \&@  < #@5]70?Z^'_ *ZQ_P#H:U-?_P#']>?]?,__ *,:@#Y!_P"&!_V%
M?^C+/V3/_$<O@]_\QU'_  P/^PK_ -&6?LF?^(Y?![_YCJ^LZ* /DS_A@?\
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MU>O-Z_K3+O\ D7X'_L#PO_IB!_FEG7_(YS;_ +&>/_\ 4JJ%%%%=AY@4444
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M7\?7[0O[2WQ;_:X^&7_!,7P;K^M:YH/CW]D+XV_LH>/?VY+-?(:\E_:>\/\
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ME[6?V3+#]AZ3X>:AIO[-.CZ=X3TS0O NA_$#XD:+JN@P^!/&^C_$GP;<:/\
M$'3_ !;!\1K+4/#GCC0-&\0Z?J">+&N_M.GPVMS+<:<TUE)^-GC[]N#]JOXW
M_LS_ !<T+PS\?O@IX.^,?PH_:V_X)T:%K.H:;^S%^UM^SK\5M+\"?'O]IWX4
M>"M5\"?%#]F#XT?%+PAX[\$:4_BK48[*\\<:)\9_B)X,^/WP>@^)?PG;P_\
M#?7]1'Q T[IOVD?VE_VKO&?C?X\^&/'NC?LJ>*_V;?V9_P#@H%_P3R_9\MM$
M'@WX_P#AOXL^+OB/X]^(?[%7Q ;XBC7_  M^T)I&A^'])\%:W\5[_6_"V@7$
M/B?3]6N=-T;P_P".-)\2Z!8:U_PEX!^C7B__ ()8?L6>/O%NJ>,O&?@7XC^(
M-1\0S?"74_%^EW?[1O[1L'A3Q[XM^!>C>'/#WPJ^(7Q"\(V'Q5L_#GCWXC^$
MM%\)Z!8P>.?%NFZQXCU,Z>E_K5_J6J237TGN^N_L>_LY^)?^%C_VW\._MO\
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M<GQX_:%^$WB+]D+X;_LW+\&[;QM^TY^T3JGP9U#Q#\;O#?C;Q7X7\)>']/\
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M \\HHHK]L/Y,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$L\=K?I9(G[I_L6_'7]H#QYX^_:W^ _[34WPBUSXH?LQ?%;P/X>M?'/P/\
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MCC\(O$I^'VB+%^S;XQT#QY\1M2^%4%WX8U;P#HOQ'\87FEP^&[/58?#=W?\
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M2&"""%%CAAAAC58XHHHU5(XT541%554* *EHHH **** "BBB@ HHHH ****
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ML_#7[:UY/H'BS0/A3\/?V>OV4=&L_$*_%7PDGB#XB1Z[X/A^.6B?&C]D75/
M'B3Q5J_C?P_H&F?%;Q5?ZEI>O+X3G@B /./V2?\ @D=XC^&_[0GP7^+/QRTC
MX,6WA;]F/X*_%?X/?#CPI\-/BE^T9\5/#_Q-O/C)96/ACQ3XIU+X9_'J\N?
M'[,GP]LO!-OXAL-*_9M^"R>*_ AUKXAZ_J%UXJ.G>'?#>D#ZMLO^".?_  3Z
MB@T"TUSX2>//'UAX.^''C/X.> ],^*7[2?[3GQ0TGX=_"'Q]X!U;X8^(_AC\
M/])\>_&'Q!IO@WP7)X)UF[TK2])T&ULO[!N;;0]<T6:P\0>&/#.J:1^7'B;_
M (+,_M5>!-.\5>(GMO@'\4M"\6_L7_M6?M+_  MU;0_V7_VR?@[\.O"GCO\
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M$7@SQ;#XI\07&L_&OQ!8>,_#^D+HXT^#PY_:"J]UY%\5_P#@J9\4_A?9_$2
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MZQ\9_&GP.\"_%OQ1XFU;7)? .LZE=^*/ FOZOX[^#.C_  _M]9\'^'#ITO\
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MO-"TS6UNKW2]5ATB;5$74DTZ2^TZ>XM+34&GOK"&9+&ZN[R>VDNY@#ZRO?\
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M=1MF96:WO]-OX;BSO("RJQAN(9(RRJ2N0"/(_P#AF+]FO_HWKX'?^&F\!?\
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M-/[.7_1 /@G_ .&J\"?_ "AH ]LHKQ/_ (9I_9R_Z(!\$_\ PU7@3_Y0T?\
M#-/[.7_1 /@G_P"&J\"?_*&@#VRBO$_^&:?V<O\ H@'P3_\ #5>!/_E#1_PS
M3^SE_P!$ ^"?_AJO G_RAH ]LHKQ/_AFG]G+_H@'P3_\-5X$_P#E#1_PS3^S
ME_T0#X)_^&J\"?\ RAH ]WL/^/ZS_P"OF#_T8M0S_P"OF_ZZR?\ H;5XQ8_L
MT?LXF]M ?V?_ ()$&YA!!^%/@0@CS%X(.@X(J*?]FG]G$33 ?L__  3 $L@
M'PJ\"8 WG@?\2&@?1>K_ "B>ST5XG_PS3^SE_P!$ ^"?_AJO G_RAH_X9I_9
MR_Z(!\$__#5>!/\ Y0T"/;**\3_X9I_9R_Z(!\$__#5>!/\ Y0T?\,T_LY?]
M$ ^"?_AJO G_ ,H: /;**\3_ .&:?V<O^B ?!/\ \-5X$_\ E#1_PS3^SE_T
M0#X)_P#AJO G_P H: /;**\3_P"&:?V<O^B ?!/_ ,-5X$_^4-'_  S3^SE_
MT0#X)_\ AJO G_RAH ]LHKQ/_AFG]G+_ *(!\$__  U7@3_Y0T?\,T_LY?\
M1 /@G_X:KP)_\H: /=K'_C]L_P#KZM__ $<E%]_Q^WG_ %]7'_HYZ\2LOV:/
MV<3>6@/[/_P2(-S "#\*O A!!E0$$'0<$$=11>_LT?LXB\NP/V?_ () "YG
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M%/@0 #S&X &@X H ]BHKQ/\ X9I_9R_Z(!\$_P#PU7@3_P"4-'_#-/[.7_1
M/@G_ .&J\"?_ "AH ]LHKQ/_ (9I_9R_Z(!\$_\ PU7@3_Y0T?\ #-/[.7_1
M /@G_P"&J\"?_*&@#VRBO$_^&:?V<O\ H@'P3_\ #5>!/_E#1_PS3^SE_P!$
M ^"?_AJO G_RAH ]LHKQ/_AFG]G+_H@'P3_\-5X$_P#E#1_PS3^SE_T0#X)_
M^&J\"?\ RAH ]LHKQ/\ X9I_9R_Z(!\$_P#PU7@3_P"4-'_#-/[.7_1 /@G_
M .&J\"?_ "AH ]LKT>R_X\[3_KV@_P#125\F?\,T_LY?]$ ^"?\ X:KP)_\
M*&O0[/\ 9C_9L-I:D_L]_ XDVT!)/PG\!$DF)<DG^P.2:"X;OT_5'O-%>'?\
M,Q?LU_\ 1O7P._\ #3> O_E!1_PS%^S7_P!&]? [_P --X"_^4%!J>XT5X=_
MPS%^S7_T;U\#O_#3> O_ )04?\,Q?LU_]&]? [_PTW@+_P"4% 'N-%>'?\,Q
M?LU_]&]? [_PTW@+_P"4%'_#,7[-?_1O7P._\--X"_\ E!0![C17AW_#,7[-
M?_1O7P._\--X"_\ E!1_PS%^S7_T;U\#O_#3> O_ )04 >XT5X=_PS%^S7_T
M;U\#O_#3> O_ )04?\,Q?LU_]&]? [_PTW@+_P"4% 'N-%>'?\,Q?LU_]&]?
M [_PTW@+_P"4%'_#,7[-?_1O7P._\--X"_\ E!0![C17AW_#,7[-?_1O7P._
M\--X"_\ E!1_PS%^S7_T;U\#O_#3> O_ )04 >XT5X=_PS%^S7_T;U\#O_#3
M> O_ )04?\,Q?LU_]&]? [_PTW@+_P"4% 'N-%>'?\,Q?LU_]&]? [_PTW@+
M_P"4%'_#,7[-?_1O7P._\--X"_\ E!0![C17AW_#,7[-?_1O7P._\--X"_\
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M"_\ E!0![C17AW_#,7[-?_1O7P._\--X"_\ E!7=^#/AI\./ARFH1_#WX?\
M@GP)'JS6SZK'X,\*:%X734WLA.MF^H+HEA8K>M:+=7*VS7(E, N)Q$4$LFX
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M#/KG'_K/YL?IW1117\W']XA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M7\F/QQ\+>)?AEXY^/_[7_P ;? ?Q[^+OPTTC]H3XH^,?!/\ P5/_ &(/VP]3
M\2^/?V7_ (3>&_B]%I(^$GBS]D;Q+K]KX27PE\#X_#NM_"OXY:)X0\!>._"6
MM>'_  OKVH^,O"5WXJM;O6Y/LWX^_P#!4']J[P7H'[9/[4_PG\#?LZ:E^Q]^
MP?\ M%Z=^SW\2O 'Q!D^(6E_M%?&5]+L/A?)\2/&7@'Q=::W8> /AV-+U3XK
M>'H/A?X;U_P7X[O_ (H:3;:AJ,4NBW&K>#[+6@#^@&BOYH/%WQKT?X+?MG_&
MSQKXL\'Q^.-&\.?\%:/$FL>9YWCZ]\4>#]-\%_\ !$6W^(>J:C\.M!\(^+_#
MVE:]XHU*Q\.ZEX=M=!\9Z-XU\-W5OXCU&>Q\-0>+5\/^(]$[;X&?&G]K[XY_
MMM_\$H/C+^T2?V=].\ _M%?LK?M7?'7X/>%/@?\ \)]:^(?!.B>-OA]\ _$R
M^"?B=>^+_$VNZ/\ $;4-&\+>)O =S;_$#P99>&-(D\2W?C'2F\,6FEP>%]:\
M0 ']%-%?@UJ?[37[6/P%^+?_  4.\7:K\1?AI\3/"6B?\%)/V$?V=_A_X&UW
MX=?$:R7X?^ _VBO#/[$.C:M;>']5F^/>M:=91:+\/_C5?74FF:5X8T?2M>^.
MP\7_ !DN+2QT#QPWPD\/>G_M&_\ !0#]H+X=ZY^VCX4^&/AWX+WNO_ 7]J3_
M ()Z_L_?"V7QQI'C:XTJ]M/VP;CX'V7B_4/B*_A_QG8WMS?:)<?%+49O#5UX
M=MM'BTVSM],DU/1?$SQ3IJ !^RU%?SMZA^W_ /\ !2+X2R_M-^+OC)_PQ=XG
M^%_[&/[87[-_[.'Q-7X<_"OXU:#XV^,WAW]H?Q/^S];2:YX"'B/X]:UHWPHU
M_P  ^%?VA/"VH?9_$47Q/TSQ1K5MJNE";1[328M8U[1TO_@J3^UW<>'/@#^U
MI=> /V<9/V,_VGOVQM9_8_\ A]\- _Q$TG]J#P<UW\6O'?P6\ ?%GQ=XDU+7
MSX$UN]O?%GP_UW5O'_P7T3P'9ZWX0\,MI\B^-YKRQ\7'0 #^A.BOY[-!_;X_
MX*,#]B?]D3]I?QIIG[.CZG^UYXB\':_<:M\#_P!E+]J+]H&#]GOX,>(_@/XQ
M^)BZYXA^!/@?XVO\6/BSK=YXHT30-(U;6?".MZ+X>^&FG:O=7>K6'C2S2+48
M?T?_ &)_CI\<?VF_ _PP^.6K>,_V7?$_P6\6?!Z^L-:'P4TSXP2^(+O]H3PS
M\3O$7AKQ#K.EZM\2W\,7?A/X>3>$]'MH-6^#_C+X=?\ "SOAM\2CKOA;6/'W
MBS3]#CU75 #[THK^?3]IWXD_MC_"C_@HE^V[\4/V7[C]G&3PS\'O^"</[-WQ
M;^*NB_M!MXUFE\2V/@;X@?MA>(=,\&_#Z;PMXT\'Z=X*OO%>CZ9XOCUSXG^*
M%\1Z!X0N]+\*Q:EX:O[76)KK3\70_P#@KA^T??\ P;_;0_;EO? OP=/[(G[-
M'PX^%FN^!_@W8>$?B4W[2GC;QO\ &W]E_P#9T^.7@S2?%WQ!/C2Z\!^%O"V@
M>)?CQ9:+XK\06'POU*_M_#MIJ-Z^@V4NAMJ&K@']$M%?SN>'?^"I/[7?A+3/
MB=X3^-OA#X>:+K[>"/ASXP^$W[1?BG]C'_@HA^SA\%[3Q/XR^(_@SX<^+O@A
M>_!;XU> 4^,O[07QC\.7/B^3Q)\&O WP(\0IKG[06B:5-H<\7PMU:QUK6K7C
M]._X*M_MI7>G>/\ P)'X1\)7OB;X8?M4^$_@]XP^.=A^PA^VA/K&C_!OQG^S
M5XH^..B_$G6/^">.H>./#_[4&F:I_;ND:/X:U34E\<7/A[3="UB#QQ'HE_X>
MN+.28 _I3HK\,/@M^TM^T7^TI^T__P $T?'FA?';X#2_##XF_LJ_ML>(?BMX
M+^%'A'XSZ_X \:^-O@W\8OV:O OB76]/E\;_ !!^%^M^$?%9MO%FEV?A#PS\
M2/A/KGBK]FS6&^-G@+7M3^,1\=6/B'PE^Y] !1110!6O?^/.[_Z]I_\ T4]?
MBQ\1OVEOC9H/Q"\=Z'I/C7[)I>C>,O%&DZ;:_P#".>$I_LVGZ=K=]9V=OY]S
MH,UQ-Y-O#''YMQ-+-)MWRR/(68_M/>_\>=W_ ->T_P#Z*>OYX_B[_P E8^)_
M_90_&O\ ZDFIU^E>&V P./QV90QV#PF,A3PE&4(XO#T<1&$G6:<H1K0FHR:T
M;23:TV/P/Q[SC-LGRGA^IE.:9CE=2MF.*A6J9=CL3@IU81PT91A4EAJM*4XQ
ME[RC)M)ZI7/0_P#AJSX^?]#Y_P"6OX,_^9VC_AJSX^?]#Y_Y:_@S_P"9VOGF
MBOU[_5[(/^A'D_\ X;,%_P#*#^8O]=N,_P#HKN)__#_FO_S6?0W_  U9\?/^
MA\_\M?P9_P#,[1_PU9\?/^A\_P#+7\&?_,[7SS11_J]D'_0CR?\ \-F"_P#E
M ?Z[<9_]%=Q/_P"'_-?_ )K/H;_AJSX^?]#Y_P"6OX,_^9VC_AJSX^?]#Y_Y
M:_@S_P"9VOGFBC_5[(/^A'D__ALP7_R@/]=N,_\ HKN)_P#P_P":_P#S6?0W
M_#5GQ\_Z'S_RU_!G_P SM'_#5GQ\_P"A\_\ +7\&?_,[7SS11_J]D'_0CR?_
M ,-F"_\ E ?Z[<9_]%=Q/_X?\U_^:SZ&_P"&K/CY_P!#Y_Y:_@S_ .9VC_AJ
MSX^?]#Y_Y:_@S_YG:^>:*/\ 5[(/^A'D_P#X;,%_\H#_ %VXS_Z*[B?_ ,/^
M:_\ S6?1,?[5_P ?HG22/Q]M>-E=&_X1;P6<,I!4X/AP@X(!P00>XIK?M6_'
MUF9F\>Y9B6)_X1;P6,DG).!X< &2>W%?/%%'^KV0?]"/)_\ PV8+_P"4!_KM
MQG_T5W$__A_S7_YK/H;_ (:L^/G_ $/G_EK^#/\ YG:/^&K/CY_T/G_EK^#/
M_F=KYYHH_P!7L@_Z$>3_ /ALP7_R@/\ 7;C/_HKN)_\ P_YK_P#-9]#?\-6?
M'S_H?/\ RU_!G_S.T?\ #5GQ\_Z'S_RU_!G_ ,SM?/-%'^KV0?\ 0CR?_P -
MF"_^4!_KMQG_ -%=Q/\ ^'_-?_FL^AO^&K/CY_T/G_EK^#/_ )G:/^&K/CY_
MT/G_ ):_@S_YG:^>:*/]7L@_Z$>3_P#ALP7_ ,H#_7;C/_HKN)__  _YK_\
M-9]#?\-6?'S_ *'S_P M?P9_\SM*/VK/CX""?'@(!!P?"_@S!]CCP\#@]#@@
M^A!KYXHH_P!7L@_Z$>3_ /ALP7_R@/\ 7;C/_HKN)_\ P_YK_P#-9^S_ ,"_
MCIHGQBT0JP@TOQEI<"'7] $AVLN5B_M?2/-9I;C2+B5E5T9I+C2[B1+.\>19
M+*]U#WFOP#\-^)-;\(:WIWB/PYJ,^EZSI<XN+.\MR-R-@I)%+&X:*XMKB)G@
MNK6=)+>ZMY)+>XCDAD=&_8/X%_'31/C%HA5A!I?C+2X$.OZ )#M9<K%_:^D>
M:S2W&D7$K*KHS27&EW$B6=X\BR65[J'XWQGP9/)ISS++82J954E>I35Y3P$Y
M/2,GJY8:3=J55W<&U2JN_).I_4GA9XITN*:5+(L\JTZ/$5"G:C6?+3I9S2IQ
MNZE-:1ACX13EB,/%*-6*EB<-%05:CA_H.Q_X_;/_ *^K?_T<E%]_Q^WG_7U<
M?^CGHL?^/VS_ .OJW_\ 1R47W_'[>?\ 7U<?^CGK\[/V[HO5_E$JT444""BB
MB@ HHHH **** "BBB@"6#_7P_P#76/\ ]#6IK_\ X_KS_KYG_P#1C5#!_KX?
M^NL?_H:U-?\ _']>?]?,_P#Z,:@"I1110 4444 %%%% !1110 4444 %>CV7
M_'G:?]>T'_HI*\XKT>R_X\[3_KV@_P#124%PW?I^J+-%%%!J%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 ?SO_ !E_Y+'\7?\ LJ7Q"_\ 4NU>O-Z](^,O
M_)8_B[_V5+XA?^I=J]>;U_6F7?\ (OP/_8'A?_3$#_-+.O\ D<YM_P!C/'_^
MI54L6EW=6%U;7UC<W%E>V5Q#=V=Y:326UU:75M(LUO<VUQ"R307$$R)+#-$Z
M212(KHRLH(^S/A/IGP9'PK\0?&#XR:#XK^*WB.Y^($/ABXLM/U;4KG4=(BFT
M;[=9ZGJJ)KFCS21:HT=["^J:E=W\4EQ!IUEI\$,\6H2M\5U^D?[+LWQ)TKX"
M>)-5^"W@?0-7\>3?$5;/4]0\1/8P0ZMX?AT2"5;>QNY-8T:1KG1;R6/%AJ-W
M#80Q:O=WEFUQ=75Q'#X?%E5T,MA5A5EAYSQN#H2JPQRRQRHSJWG2JYBOWF%H
M32O.=-2=TE*+IN;7V'AKAX8S/JV'K8:&-IT\IS/%TL-4RB7$"CBJ.'2HXC#Y
M&VJ&88NGS-4Z5=PBXRFX5%65%/YW^,7BC]GS6?"MM:?"WX4>*?!'B-=:M)Y]
M8UJXNI+272DM+]+FQ59O$VL)Y\UQ)9S(?LJL$MY,3(,I)\R5]W_M+>(/VHM4
M^']E;?&7P/X6\.>$U\3Z=+;W^BW>D3W;ZTNGZNMG;,ECXPUZ8026CW\CL;)(
MP\,8:X0E4E^$*Z>&YJ>6J2JPK?OZJYX9S+/8_9T^ORC%MKK1M^[_ .WCS^/*
M3I9_*$L/4PK^IX9^RJ\+0X/GJI^]_8U.=2,4_P#H)YKUVGHE!!7Z6_\ !.3_
M %_QI^GPX_\ 0?'5?FE7Z6_\$Y/]?\:?I\./_0?'5>?Q[_R26;^F _\ 5I@3
MW/!G_DY?#/KG'_K/YL?IW7XB_P#!0&]O;?\ X*J?\$?K6"[NH+:\^&O_  54
M:[MH;B6*"Z:U_9R^%\EJUQ"CK'.UM(S20&56,+LSQE6))_;JO#OB%^S=\%_B
MI\5_@[\;_'O@S^WOBA\ =,^*^C_"3Q/_ ,)%XKTO_A$]-^-_AO2O"/Q0MO[%
MT;7=.\/:]_PD_A[1=,T_SO$VDZS/HOV;[7X>ETF^FN+F7^;C^\3^1K]B/XE?
M%7P;_P $L]2_X)K/XR\4/\4_VJ-$_97O_P!G/Q;?"VOM6M?V9_\ @H7\+=7^
M)/[1>M^'X%NH+V1/@;;_  @_;FU2/5)ID>UO--\'I+-'<:E:--]>_P#!/7P#
M9?MH?\,I_L[_ +2'C;XA2_ _X*?\$A?V'?BQ\._@'X?^*OCSX9:7\8/&OQBO
MO&6C^//CGXNO?A=XJ\(>+/'=O\-F^%OA7X?Z/H'BW6-4\+>'-6\2WNO66AV^
MM:TFJ3_NQX2_8%_9$\"^)O@9XS\+_!?2-/\ %?[-GP0O?V<?@GX@F\0^--4U
M7P/\&;_31H\_@Z&[U?Q+?RZXT>EM>:?9>(_$QUKQ9IMIK'B.'3M=M4\3>(!J
M?/\ B3_@G1^R=XA\'? GP79^#/'/@.V_9E\"#X8? SQ/\)?CK\=_A'\2? /P
MZ:RT'3KCP3#\4OAQ\2?#/Q$\1^&KZT\,:"-1TCQCXE\16=]=Z9:ZK<Q2:O$E
M^ #Q3X=_M!_L_?L3?#K6OAR_QP_:9_:T\/:%\>OC1X*TV^\+_#OXX_MG>._@
M?J6C:AH?BC5/V>?B'X[^&'A3XH>.A)\+H?&NGZ;X9NOC/K=YXW;P_=66@2:M
MJ%KX;ABLOQ5_96_8T^%7[2OQ]_:K\;_$O_@FAXV_:%L=8_X*D_MB>'=5_:D'
M[69^&6E^#O"EI^TYXDM'ENO@XOQC\(>*;R#X::7/-?76FZ9X/DU+7(K5K#38
MKZ[:.&OZFO@9\"/A1^S7\,]"^#_P5\)IX,^'WAVYUV_T[1SK'B'Q)?3:IXHU
M[4O%'B36M:\3>+=6U[Q5XEU[7_$.L:GK&L:[XCUO5=8U*_O)I[N]F8C$_P )
MO@E\,?@;8>-]+^%OAG_A%['XC?%7XC_&WQG!_;7B'6_[9^)WQ:\2W?B_X@^)
MO-\1:MJ\VG?\)!XBOKK4?[%TJ2Q\/:5YOV31-)TVQ2.V0 _-O0?AS\5/"/\
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M#_P3G_9*^!GQ0\)_&#X<^!_&MCXS^'6@>*_"/PMBU_XY?';QMX+^$G@KQO\
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M(/"WQ3T=KWP+XY\<_$O5]!U[P_)KEYI%_-#XWU2QU**.UDAMK22":>_^9?\
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M="^)WQ.\/VUMXB\5:O!J=MXA\;>&M#U>VGUR/4[WPW!I\>B^%;K1-!EN-,E
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MVDZ9XN\%?$+X8^)?"/C7PUK-MIFNZQISRZ7KMO!>V&HW=CJ-O=V<\D#>^T4
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M'_$N7_59?^:]_P#AP_GGHK^ABBC_ (BO_P!2#_S*?_@X/^)<O^JR_P#->_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#^=_XR_P#)8_B[_P!E2^(7_J7:O7F]>D?&7_DL?Q=_[*E\0O\
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M9$8JW&5![5X)_P ,;?LK_P#1!?AI_P"$W9_X5]+T5_-Q_>)\T?\ #&W[*_\
MT07X:?\ A-V?^%'_  QM^RO_ -$%^&G_ (3=G_A7TO10!\T?\,;?LK_]$%^&
MG_A-V?\ A1_PQM^RO_T07X:?^$W9_P"%?2]% 'S1_P ,;?LK_P#1!?AI_P"$
MW9_X4?\ #&W[*_\ T07X:?\ A-V?^%?2]% 'S1_PQM^RO_T07X:?^$W9_P"%
M'_#&W[*__1!?AI_X3=G_ (5]+T4 ?-'_  QM^RO_ -$%^&G_ (3=G_A1_P ,
M;?LK_P#1!?AI_P"$W9_X5]+T4 ?-'_#&W[*__1!?AI_X3=G_ (4?\,;?LK_]
M$%^&G_A-V?\ A7TO10!\T?\ #&W[*_\ T07X:?\ A-V?^%'_  QM^RO_ -$%
M^&G_ (3=G_A7TO10!\T?\,;?LK_]$%^&G_A-V?\ A1_PQM^RO_T07X:?^$W9
M_P"%?2]% 'S1_P ,;?LK_P#1!?AI_P"$W9_X4?\ #&W[*_\ T07X:?\ A-V?
M^%?2]% 'S1_PQM^RO_T07X:?^$W9_P"%'_#&W[*__1!?AI_X3=G_ (5]+T4
M?-'_  QM^RO_ -$%^&G_ (3=G_A1_P ,;?LK_P#1!?AI_P"$W9_X5]+T4 ?-
M'_#&W[*__1!?AI_X3=G_ (4?\,;?LK_]$%^&G_A-V?\ A7TO10!\T?\ #&W[
M*_\ T07X:?\ A-V?^%'_  QM^RO_ -$%^&G_ (3=G_A7TO10!\T?\,;?LK_]
M$%^&G_A-V?\ A1_PQM^RO_T07X:?^$W9_P"%?2]% 'S1_P ,;?LK_P#1!?AI
M_P"$W9_X4?\ #&W[*_\ T07X:?\ A-V?^%?2]% 'S1_PQM^RO_T07X:?^$W9
M_P"%'_#&W[*__1!?AI_X3=G_ (5]+T4 ?-'_  QM^RO_ -$%^&G_ (3=G_A1
M_P ,;?LK_P#1!?AI_P"$W9_X5]+T4 ?-'_#&W[*__1!?AI_X3=G_ (4?\,;?
MLK_]$%^&G_A-V?\ A7TO10!\T?\ #&W[*_\ T07X:?\ A-V?^%'_  QM^RO_
M -$%^&G_ (3=G_A7TO10!\T?\,;?LK_]$%^&G_A-V?\ A1_PQM^RO_T07X:?
M^$W9_P"%?2]% 'S1_P ,;?LK_P#1!?AI_P"$W9_X4?\ #&W[*_\ T07X:?\
MA-V?^%?2]% 'S1_PQM^RO_T07X:?^$W9_P"%'_#&W[*__1!?AI_X3=G_ (5]
M+T4 ?-'_  QM^RO_ -$%^&G_ (3=G_A1_P ,;?LK_P#1!?AI_P"$W9_X5]+T
M4 ?-'_#&W[*__1!?AI_X3=G_ (4?\,;?LK_]$%^&G_A-V?\ A7TO10!\T?\
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MA7PW_P#"<M/_ (FOS]_X:L^/G_0^?^6OX,_^9VC_ (:L^/G_ $/G_EK^#/\
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M $&9/_X48W_YWB_XF#X,_P"A9Q/_ .$65?\ SZ/T"_X8_P#V7O\ HA7PW_\
M"<M/_B:/^&/_ -E[_HA7PW_\)RT_^)K\_?\ AJSX^?\ 0^?^6OX,_P#F=H_X
M:L^/G_0^?^6OX,_^9VC_ (A?G_\ T&9/_P"%&-_^=X?\3!\&?]"SB?\ \(LJ
M_P#GT?H%_P ,?_LO?]$*^&__ (3EI_\ $T?\,?\ [+W_ $0KX;_^$Y:?_$U^
M?O\ PU9\?/\ H?/_ "U_!G_S.T?\-6?'S_H?/_+7\&?_ #.T?\0OS_\ Z#,G
M_P#"C&__ #O#_B8/@S_H6<3_ /A%E7_SZ/T"_P"&/_V7O^B%?#?_ ,)RT_\
MB:/^&/\ ]E[_ *(5\-__  G+3_XFOS]_X:L^/G_0^?\ EK^#/_F=I1^U9\?
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M]^R\9H@?@3\-R#+&"/\ A'+/D%QG^&I;[]CW]EU;R[5?@3\-@!<3  >'+/
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M&W[*_P#T07X:?^$W9_X4?\,;?LK_ /1!?AI_X3=G_A7TO10!\T?\,;?LK_\
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M2?"?[/C>,?!'@SQ?\2;O5-<L?C3X7U'2+C4?'NM:7X\L-#\0Z;XH\*7.G:)
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MA&K@)XBI2A3QM)5H4*CQ&&PLUB*2?+7C&$Z2G_#JU(^\?MM17\F/Q?\ @O\
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MCSXCW^FZ[\ /VG_VX/BAK2>%_%GV;1])\.? C]DUK#Q=8> -7U?6IM.\4_M
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M%_A(?B7\6O$]S\)W\4^&[>W\,ZEXE^'UQX>\7GPW$= M_$$&DW%W9W'Z,44
M>%^/OV:O@I\3?&'P+^(/C+P7]N\=?LU>(;_Q-\$?&&F>(_%GACQ+X&OM9\/O
MX5\0Z?!K/A;7M%U#6_"OBKPZR:3XQ\#^)I]:\%^,+6UL!XGT#5GTVP>V\Q^
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M11_9VG_\^-G_ . T'_Q%?/?_  Q_^R]_T0KX;_\ A.6G_P 31_PQ_P#LO?\
M1"OAO_X3EI_\31SS_FE_X$_\P]G3_P"?</\ P&/^1]"?V=I__/C9_P#@-!_\
M11_9VG_\^-G_ . T'_Q%?/?_  Q_^R]_T0KX;_\ A.6G_P 31_PQ_P#LO?\
M1"OAO_X3EI_\31SS_FE_X$_\P]G3_P"?</\ P&/^1]"?V=I__/C9_P#@-!_\
M11_9VG_\^-G_ . T'_Q%?/?_  Q_^R]_T0KX;_\ A.6G_P 31_PQ_P#LO?\
M1"OAO_X3EI_\31SS_FE_X$_\P]G3_P"?</\ P&/^1]"?V=I__/C9_P#@-!_\
M11_9VG_\^-G_ . T'_Q%?/?_  Q_^R]_T0KX;_\ A.6G_P 31_PQ_P#LO?\
M1"OAO_X3EI_\31SS_FE_X$_\P]G3_P"?</\ P&/^1]'V&G:?]MM/]!L_^/F'
M_EU@_P">B_[%0SZ=I_GS?Z#9_P"MD_Y=H/[[?[%> 6/['O[+K7EHK? GX;$&
MXA!!\.6>"#(N1]VHIOV/OV7A-*!\"?AN )9 !_PCEGP YQ_#1SS_ )I?^!/_
M #'[.G9?NX;O[,>T?(]__L[3_P#GQL__  &@_P#B*/[.T_\ Y\;/_P !H/\
MXBOGO_AC_P#9>_Z(5\-__"<M/_B:/^&/_P!E[_HA7PW_ /"<M/\ XFCGG_-+
M_P "?^8O9T_^?</_  &/^1]"?V=I_P#SXV?_ (#0?_$4?V=I_P#SXV?_ (#0
M?_$5\]_\,?\ [+W_ $0KX;_^$Y:?_$T?\,?_ ++W_1"OAO\ ^$Y:?_$T<\_Y
MI?\ @3_S#V=/_GW#_P !C_D?0G]G:?\ \^-G_P" T'_Q%']G:?\ \^-G_P"
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M_P"R]_T0KX;_ /A.6G_Q- 'TA17S?_PQ_P#LO?\ 1"OAO_X3EI_\31_PQ_\
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M<M/_ (F@#Z0HKYO_ .&/_P!E[_HA7PW_ /"<M/\ XFC_ (8__9>_Z(5\-_\
MPG+3_P")H ^D*]'LO^/.T_Z]H/\ T4E?%'_#'_[+W_1"OAO_ .$Y:?\ Q->@
MV?[&_P"RP;2U)^ OPT)-O"2?^$;L^28U)/2@N&[]/U1]/T5\T?\ #&W[*_\
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M%^!_[ \+_P"F('^:6=?\CG-O^QGC_P#U*JA11178>8%%%% !7Z6_\$Y/]?\
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MDU?P5J]YHNM>$O%N@>(H?#>M0-HOBN.[\O690#^M2BOY@/VV_P!JG]JCX_\
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M+^(O@S\._BA/\8-$T6T^-GP3^%OB?XC>-?%OQ)\2^)=)\;^.O&UIXI\%>$?
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MS1R(WH:X'_A3WPY_Z%W_ ,J^N_\ RSKTRBOYN/[Q/,_^%/?#G_H7?_*OKO\
M\LZ/^%/?#G_H7?\ RKZ[_P#+.O3** /,_P#A3WPY_P"A=_\ *OKO_P LZ/\
MA3WPY_Z%W_RKZ[_\LZ],HH \S_X4]\.?^A=_\J^N_P#RSH_X4]\.?^A=_P#*
MOKO_ ,LZ],HH \S_ .%/?#G_ *%W_P J^N__ "SH_P"%/?#G_H7?_*OKO_RS
MKTRB@#S/_A3WPY_Z%W_RKZ[_ /+.C_A3WPY_Z%W_ ,J^N_\ RSKTRB@#S/\
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MT+__ )5M<_\ EE7I%%?(GZ6>;_\ "H_AY_T+_P#Y5M<_^65'_"H_AY_T+_\
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M\J^N_P#RSKTRB@#S/_A3WPY_Z%W_ ,J^N_\ RSH_X4]\.?\ H7?_ "KZ[_\
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M[_\ +.O3** /,_\ A3WPY_Z%W_RKZ[_\LZ/^%/?#G_H7?_*OKO\ \LZ],HH
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M\,?%+4OBOXATIO.OM*A\4^'5H _9"BOYYO%/_!4+X[+^T%X!\(V&H_!3XC?
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M\/I^S9XS\$>'KFW^%OB+5H/$,WP%M=)\/ZKI&GZOX;U&3])=$_X*9_M/7WP
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MW]JGPQ8;(K^WT[X?_$#XA^(?"WQL@T^ZOY+GX>>,[3Q+;^&K^[\&/>V?4?\
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M>-<XQ]G3Q+FN3$T6XJ<VJ]!.$ZE/#]-1117PI^OA1110 4444 6[#_C^L_\
MKY@_]&+4,_\ KYO^NLG_ *&U36'_ !_6?_7S!_Z,6H9_]?-_UUD_]#:@?1>K
M_*)%1110(**** "BBB@ HHHH **** +5C_Q^V?\ U]6__HY*+[_C]O/^OJX_
M]'/18_\ '[9_]?5O_P"CDHOO^/V\_P"OJX_]'/0/HO5_E$JT444""BBB@ HH
MHH **** "BBB@"6#_7P_]=8__0UJ:_\ ^/Z\_P"OF?\ ]&-4,'^OA_ZZQ_\
MH:U-?_\ ']>?]?,__HQJ *E%%% !1110 4444 %%%% !1110 5Z/9?\ 'G:?
M]>T'_HI*\XKT>R_X\[3_ *]H/_124%PW?I^J+-%%%!J%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&1ZBB@ HHR/
M449&<9&?3OZ?SXH ***,CU''7VH **3(Z9&?3-&1G&1GTSSZ_P J /R*_P""
ML7Q.^)_PX^$GC7QC\!OC9XD\-_%_X+?!'X@?'*V^$W@GXA?"CP-J=CX-\,3V
M/]O?M-^.-$^(^G:E/\8?A[\$6LH[&?X,0S:#X4^(&H>+Y/#_ (GU";5]1\'7
MOA[]7?#FJIKOA[0M<C2]CCUG1M+U6--2TF]T'4434;&"\5+_ $/4PNHZ->JL
MP%UI.H*M[ITXDL[H">&05YK\5/V=_@%\=+_PCJGQI^"?PH^+>I^ +J\O? ^H
M?$GX?>%/&U[X1N=2N-(O-2?P[<^(]*U&;1UU*\\/>'[W48K%X(;^]T#0KN[C
MFN-'TV6V]CH **** /YW_C+_ ,EC^+O_ &5+XA?^I=J]>;UZ1\9?^2Q_%W_L
MJ7Q"_P#4NU>O-Z_K3+O^1?@?^P/"_P#IB!_FEG7_ ".<V_[&>/\ _4JJ%%%%
M=AY@4444 %?I;_P3D_U_QI^GPX_]!\=5^:5?I;_P3D_U_P :?I\./_0?'5?(
M<>_\DEF_I@/_ %:8$_3_  9_Y.7PSZYQ_P"L_FQ^G=?-?Q[_ &2_@Q^TCJ_@
MCQ)\2+?XCZ=XK^'.G>,-$\(>,?A/\</C5\!O&&F>'/B'+X5E\>^%IO%'P1\?
M_#_6]5\,^+V\$^%'UK0M7OK_ $Z2XT'2]0M8+74K&UO8OI2BOYN/[Q/#!^S5
M\#T_9PN_V1K?P!86/[.U]\']3^ ES\-M,U/7M+LV^$^L^$KGP-JOA:/7M.U:
MU\66\E_X9O;NQN?$-OKT7BF2YN9M8.M_VU(VH'TW1?!_ASP]X.TGP!H^G?8_
M".A^&;#P?I>D_:[^X^R^'-,TN+1;'3OM]U=3ZG/Y&F016WVNYO9K^3;YTUU)
M<,TIZ:B@#Y \6?L'_LP>,/@7\&?V<[WP+KVC?#+]G27P==? <>#?BC\5O!'C
MSX2ZE\/_  Y?>$?!^L^"OBSX4\;:1\4].UG2/#>I:AHSZG+XQN;O5K"]N[?7
M9-3BN9UD]2^ '[._PD_9B\!3?#CX-^';_0O#^H>*_%GC[Q#?:_XJ\6^/O&7C
M/Q]X\UJY\1>-/'?CSX@>/]<\3>./''C#Q-K-W+=ZIXA\4^(-5U)XDM-.AG@T
MO3]/LK7VVB@#X$7_ ()C?L:)X_A^("?#[QL@M_BU#\>[;X:I\>?C\OP!MOC7
M;^*9?&T/Q-MOV=!\3A\#;?Q.GBV:;Q&&A\ )IAUZ:;6SIIU>5[YO6[W]C']F
MO4?']W\4;SX;^=XZOOC1<?M"W6N_\)AX]C\WXP77P)?]FB?Q?_9D7BE-'3?\
M$G;P5_8$>GIX77/_  D::*OBT#7A]044 ?&'B/\ X)Z_L?\ BWX7?#/X+^(?
MA%_:'PT^#OP.\?\ [-WPY\-?\)]\3[3_ (1WX+_%'P?X?\!>.O!G]L6/C6VU
M_5_[<\)^%M!TG_A(M=U74_%>F?8?MVCZ[I^I75Y>7$/B/_@GK^RCXK^+]Q\;
M]9\"^*I/&.I^(?A9XP\2Z/8_&3XT:3\+_'/C+X'0>'[;X.^+_B'\&-)^(-E\
M)/B!XF^&\/A;PZ/"^K^,/!>LW5K-HFC7EPUU?:+H]S8?:M% 'YT'_@E'^P[)
MXM\/^+KKX:^/+_\ X0KXO7WQY^'/@J]_:(_:.G^$OPL^+.K^-+_XB:YXO^%W
MP</Q8'PM^'\VN^,M5U76-7TGPMX2TW0;N/5=5T<Z4F@:IJ&E7/N7B/\ 8L_9
MG\7?LM:+^Q5XB^&O]I?LQ^'_  M\/_!.F?"Y_&7C^WMAX3^%^I^']8\%:!?^
M*+3Q5;^-]8T[3;[PMH;7\.L>);__ (2.UM)=.\3'6-.O]1M;OZEHH ^8_P!J
M?]C;]FW]M;P-H/PW_::^&T?Q*\&^&/$[>,-"TI?%?CCP7/8:])X7\2>"KJ9=
M8^'OB;PGKD^GZAX5\7^(]#U70KK4I]!U:QU)TU/3;M[>T>W\:LO^"8?['UOX
M9^)OAK5/"OQ3\83_ !<O?@_J'C#QOX__ &E/VD?'OQ9BO/V??$=[XN^!]SX0
M^,'BSXKZO\3OAY<?"WQ'J5_J_A*Y\ ^*_#=S:W=[=M=S7HNKA9?T!HH ^!#_
M ,$ROV0'^'-S\-Y_"/Q)NXKKXWK^TJ_Q%O/VAOV@[KX[1?'V/PE:> X?BM9_
M'V;XG/\ &.P\40^"["T\+QBR\:V^D_V#"=*?2WLIKB"9VA?\$R?V-_#-Y\&M
M5T3X>^+;/7?@;XT^+_Q!\+>)9/C3\:[_ ,4>*O%G[0&L:!K_ ,<-4^,WB/4O
MB#>:S\>5^*NK>%?#DWC6R^,M[XXL-7L-&LM :VC\-K+H\OWS10!\5?L\_P#!
M/G]EW]EWQII?C[X1>&?B%;>(?#7PRNO@KX%_X3OX\?';XNZ-\,_A#>ZOX<UV
MY^&WPQ\.?%CXC^-- ^'_ (2DU7PCX9N!IOA;3=,\F#0]-TZ"6+2[6*R7[5HH
MH **** "BBB@ HHHH *_/GP[_P $M_V)O"?C3PWXP\/_  Q\5:;IW@SXHS?&
M_P &_":/XW?'2;]G;PA\89M9NO$"?$;PK^S;<_$B;X%>'O$5AK-Y/JFBKI'P
M_L])\/ZF4U70M+TW5(H[U?T&HH ^:-._8^_9TTG0_!'AO3_AW]GT7X<?M">*
MOVJ?!EE_PEOCJ7^QOCUXV\0?$#Q3XG\=_:)_$TEWJ/\ :>N_%+QW??\ "+ZK
M/?>#;+^W?LNG^';2STS1[?3_ "J]_P"";'['VH_%:P^,5[X \93>)=&^)^N_
M&SP]X<7XY_'FV^$WACXP^*X]6C\8?$SPS\$+/XEV_P ']!\8^,#KNLW'BG5=
M-\$6[:YJ.KZSJ]]'+JVN:U?:C]V44 ?G#XJ_X)-?L+^+?#^@>$+KX9^.]"\'
M:)\&/A_^SOJ'A#P/^T-^T9X!\,^/_@C\*VUEOA[\.OBYHW@[XK:)9_%_1_"W
M_"0:U#I][\2H_$^NR6>IWFFWFKW6FS/:'TCQS_P3S_9/^(WQ=UOXV>+/ ?BF
M[\7^*O$'PX\7>-=%TWXQ_&CP[\+?'_C#X/6^B6OPH\7>/_@MX=^(&E?"/QMX
MD^'<'AO05\*:MXF\%:G<Z=-HNBWA:6]T/1;G3_M:B@#\]/$__!+']B3Q7X:\
M)>#+GX;>.-!\)>$?@?X:_9H'AWP+^T%^T3\/-+\9_L_^#H]6C\,?"/XL1>!O
MBKX?D^,'@W1_[=UK[-9_$^7Q9=21:OK-G=7D]AK>LVE_J_&#_@F9^QI\;[UK
MCQA\-O$VB:;??"WP5\$/$WA#X5?&/XT_!'X>^//@[\-Y]:G\ _#3XA_#OX/?
M$#P/X(\<^$?!X\0ZS9^'].\3:#J3:;H]_-H$$RZ#LTU?O:B@#X3T3_@FS^Q_
MX=^,%A\:]*^'WBN+Q#I'Q=U_]H+1/!ES\9OC3J'P.T+X]>*+37K+6_C-H?[/
M>H?$"Z^".D?$>Z@\3Z_+!XEL/ 4%UIFIZK=Z]I(L=?D_M06?^'<G[(Y^,>B?
M'(^!/&7_  F/A?XL:K\>/">A+\</CK#\)O"?QI\1'5'\4_%#PS\#8/B1%\&M
M%\8^+9M:U>[\4ZE8^!8AKVHZMK.JZC#/JFNZW>ZC]QT4 %%%% !1110 4444
M %%%% ',>-O!OAOXB^#/%WP^\9:;_;'A#QWX8U_P;XJTC[9?Z?\ VKX;\3Z5
M=Z)KFF_;]*NK'5+'[=I=]=6OVS3;VSO[;S?.L[JWN$CE3^:;]D+_ ()P?L+^
M!_\ @I;_ ,%'9E^$-KIGA[]B36?V&?BG^S\-<^,?Q<L-!^%?B'4/@]K'Q8\1
M:]>:KJWQ!N+6_P!.N/&7AS3?$6IR>.O^$CT73X;*2(V2:.;JQE_J KQ+0OV<
MO@KX;^(?QX^*NE^!++_A./VF[#P-I7QUU+4]2UW7=-^(.F?#CPG?>!O!^GZA
MX8US5=1\*Z99:;X3U*^T:[M= T328-<@N9)=?35+K;.H!_/3XF_X+,_M5>!-
M.\5>(GMO@'\4M"\6_L7_ +5G[2_PMU;0_P!E_P#;)^#OPZ\*>._V?/!FC^--
M'\(^&_B]\;M3\+^&OVU?A=J^FZS9I?\ Q1^"MA\,X=2CEMO$UG:>'=$\1^'=
M-?[=U7]I3_@I)=_$[X'_ +(WA;4?V*H?VG_&O[/?Q0_:X^)7Q)\2?#'X]6W[
M/^C?#/PUXS\$>!/ 7PK^'WA^V^*C^,_%7CK5/%OC."#X@>-;[Q3IFG^#O!T$
M/B"+P+<ZOK?A[1]2]F@_X(W_ /!/LV>B:=K?PL^)/C73_"?PT\;?!;P-8_$+
M]J/]JKQ[9_#SX.?$+X?ZO\+?%/PK^'MMXL^-.K0^"O UYX$UN^T&UT3PZFGQ
MZ6(]*U+39+75_#_A_4-+=^WC^QO\2OCQKOP5\6_!WP[\)/$M_P#"SP1\6_A\
MF@?$SXT_M'?LZWNF6'Q-L_ UI!K&B_&#]F+[1\1=<\-00>#7TSXB_!'Q5#/X
M(^+6E7>D->Z[X3U;PU;:E? 'XQ_ C_@N[^VK^TS\-M)U[X8?!3P!_P +#^&/
MP<T?XK?&#POX=_9._;E^/OASXQ^*O&'Q.^*VD>%OA'\+_$W[.&F?%/3O@'I@
M^&/PV%POQE^+VI^,]$\3?%+5Y-+T3PC#X6\%>-;FU^I/C1^V5^W)X6^/WQ*^
M-OP@@M9_!/B;]B3_ ()E_$7P]^R]\0?V>_C;X^^(_P &[3]I_P"/WQO\&>/-
M9O?A9X'^/'AG7/'GQH^'L6C>)]8^(GA/P7X*\*^*_B'X?T'X<?#6"V\/ZG\(
MM2\6?$3ZS^$?_!%']D#P5^SO\&?@GXZL_B#XIUWX>_L_K^SS\1/'?P[^,GQR
M^ "_&_P%K.O>*/&OCKP=\1O#7P>^*'A>P\4?#GQ+XX\=^.-7L_!7BR;Q)%H>
ME^(KO0+;49;&:\%W]&?&K_@F5^QI\??&WA;X@_$#X;>);3Q+X*^&_@#X3^%I
M/AQ\8OC/\'-+T/P3\)?&-_\ $+X266F:%\)?'_@K1K#4_A9XVU2_\2_#[Q#9
MV,&O^&-2FB?3M2CBL=.BM "W_P $^OVGM>_:E^#GBOQ+XN\9_"?QSXM\ ?%G
MQG\,=;UGX5^"?C%\(7==!BTC5-)7XB_ 3X]:;#\3_@/\2!I6N6L>O_#G6O$7
MCVQ-M%IOB[1/&=UIGBF#0] ^[*\!_9Z_9E^$?[+_ (>\7^'OA-IOBN+_ (6'
MX[U#XG?$'Q'X^^)/Q&^+?CGQQX_U30_#WAF]\4>*?'GQ3\4^,/%VK7[^'_"?
MAS1X(9]8^P65AI%K!8V=LOF^9[]0 4444 %%%% !1110!6O?^/.[_P"O:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.S\1Z?J.E6G@_P -?^">O[0\GQE^&_[37Q9\2_""W^*.N_\ !0KQ;^V3\9_
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MF/Q%\5;OX3^ M4^(7Q2^)NMWWC-M&LY?A5H^B>&;;2O!WAE_&5UIE]J>IZ,
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MJ^$=UX9\.^+3XZ^)5OX=\1_&C1OC(=2M_ASI;7/A31].\=WPU?3 #UGX*?\
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MC7?PF\5^--4^!S_LU?'KX#?'[Q9XL\"?#?XF_"O1/%7B/XC?#_Q+X1\;>!O
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M_%_XY>$OA_XE\-^,O^$4_:B^,9D\0^-=#\6V.G^";^:Z\/6O@W4@WB?7-/\
M$^C)+IT7U]X3_P""@O[//C+X:_!?XFZ3<^-HM/\ CK^T)KO[+WA'POJ'A"\L
M_'.D?&'PCK?Q$T?QSH7C?PVT[3>$;+P):_"CQ]XF\6:MJDZV6F>$]!?7$>X@
MO=/2[H?M4?L>6'Q.^"^@?#/X#>%_A1\,+VS_ &E/V4?C1KBPZ)#X*T/4]#^
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MV@?A@OCGP_87OC'X207L@MXM7M+=-87[3ILDVBI!JVDSWWB'Q;_X*Z_"N[^
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MOAZ/B3-9ZIXP_8FA_P""@NBZKJ&BWMGX=D_9IGBFO5\1W.IRX:V\0IHMK?\
MB.?PK);?VK!X?TZ]U*9$CB57^/\ X"?L*?MC7$O_  3P^%?[3L_[-%C\#_\
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M)-*L].BB\-^-;>ZUWQ)?WOZAZA^R[\2_ ?\ P3FU#]DC]FGQMX;^#7QBT/\
M9BOOA/\ "[Q[X=F\9:5X.\%_$MO!4VF6NN>'KO6=3^('Q \)>%D\433RZ)?'
M5/&'BWP/H\]I=Z9-K6KZ+9K< 'EOA/\ X*W_ +,>O:3\<K_Q9X,_:7^">J_
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M4M,NQJVC:-*][J.C6[QM!7R;\3_^"='[</[9'Q8^.?Q#_:EF_9=^%=C\1_\
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M_P +_ 3QQXKM'TOQU_PJN]MM7&O:?9:]<QRV6E:B_A[7/$EMIM_?P>!^ O\
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>nt10016217x4_graphic11x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic11x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M-,DUO4OAUK^F_"B?4?$OCSPO'I7A#P/HVK>&OAEX:U?7/"OB  _JF_X*5?\
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MR\T+6O"=[XBU[6]7\1?%W4[[1XYWG\13^%H= U"[UC2/ ^DZ=<@']90_:!^
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ML6F>%]8%K>6&B6NOZIK>O>(['POH=U?ZJ^H@']P?@[]I+]G;XB>)Y/!'P_\
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MVWT#5-?M_B'I'B+Q)IWC]/B=I^I6GBSQ4Z?$OQ-K6B>&;/PI^@6C:S>>(/\
M@I5_P;)ZOJ&JW.MW]W^P#^RN+W4[R^EU*\N;NVN/B]:W(NKV>6:::Y@F@>VG
M$TK2Q2PM#)M>,J #^_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /D;]JC]A+]E/\ ;9F^%<G[47PK7XL6WP6\4W/C3X>:
M/J/C;XB^'_#6F^);M]):?4=<\*^#O%WAWPUXX4QZ-:6L=CXZTKQ+IT%A/J^F
MP6D=AK^NVVI?1/Q"\ ^#_BMX!\;_  N^(>A6OBCP#\2/"/B3P'XW\-7SW,5E
MXA\(^+]&O?#_ (DT2[ELI[6\BMM5T?4+RQFEM+FWNHXYV>WGAF5)%["B@#\D
M/%G_  0P_P""8'B_]G;P]^RY??LX2V_PF\$^-O%GQ%^'MM'\5_C)JOBOX=>+
M_'>FZ-I?C&]\$^.?$_C[Q!XKT71/$L7A[0[W7? JZK-\/M7US2K'Q'J7A2ZU
M^WCU)>M_9"_X(W?\$]_V)=,^)UE\&O@;;ZE?_&CP-K'PP^*NO_%'Q!K?Q.U3
MQQ\-?$$TTFN^ =4M?%5Y>>'K3PEKJ2Q6_B/1M%T+2[;Q3!8Z6/$XUF33+&6#
MN_\ @II^W?\ \.Z/V9C^T7_PJO\ X7%CXF?#SX=_\(=_PG'_  K[_D?=7DTK
M^V/^$A_X0_QQ_P @K9Y_]G_V'_IV?*^W6>/,/U3^T%\5?^%$_ 3XW_&_^P?^
M$J_X4W\(?B5\5?\ A&/[4_L/_A(_^%>>#-:\7?V#_;7]G:Q_8_\ ;']C_P!G
M_P!J?V3JG]G_ &C[7_9U[Y/V:4 _(/PM_P &VW_!(OPG\2['XD67[/&OZG%I
M.JVNN:/\._$?Q;^)OB#X:V&JV5Y97UM--H&J>);C4->LA/8HEUH/BK6]>\.:
MI:33Z?JVD7]@R6T?Z*?MD?L!?LC_ +?O@KP]X#_:O^#NC_%#2/!^IWFL^#-1
M_M;Q)X3\5>$-2U&S6QU"3P[XP\%ZQX?\2V%CJ<,-D^L:#_:<OAS7;C2M$N-<
MTC49M$TI[/=_8@_::_X;*_9-^!7[47_"$_\ "N/^%U>!K7QG_P (-_PDG_"8
M?\(U]IO;VS_LW_A)O[ \+_VSL^Q^9]L_X1_2MWF;/LJ[-S?5- 'Y_P#[$'_!
M+[]B;_@G?9^)!^RU\'+7P?XC\::?8:7XS\?:_K_B+QOX\\3:?IS^=#I]SXA\
M5:GJ<FCZ/+=+%?7OA[PK!X?\.WVH6]IJ%UI,M[:6L\7Q[JG_  ;G?\$B=6^+
M<GQ<F_9?%M<3ZL_B"Y^'FF_$;XC:=\)IM<DU8:P]VO@2T\316%EI1N,VJ^"M
M-FLOA_'I3'2(_"::<%ME_<*B@#X_^)?[!'[)GQ?_ &DO@[^UU\0_A-'KW[0G
MP!TC3]"^$7CZ+QM\1M#B\'Z3I>HZ]JVGV47@[P[XOTGP'K,=M?\ B;6YD?Q#
MX7U>4K>B!Y&MK6RAM_CGXB?\$&?^"7WQ6_:%\7_M)^._V>KC6?&GQ"UR[\7>
M/?#,?Q&^(NE_#/QEXUO]977[[Q=XA\":1XFL=*O=0U#5E-_J>C@Q^$-6O9;F
M_P!5\-7NH7=W=S?6_P#P4+_:\_X8-_8X^-?[6G_"O?\ A:O_  I[3/"NH_\
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MPSUWX//\,;OQ%XPU2!OAUXDL-1TW6/#Y\5:KX@O?'/F7%IJM\L&M_P#"3?\
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MCZ)IFG?H[10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQIKFO>%-?\+:Q>W6C7<=M>7$NMVQZ7QLW[7-E_P3:_X)C^$OVT?^$NU#XJ^
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M3UI?A?%_;?PQ77_%6N3SVNH6DOC^:"[6V/Q"6*VMA$ ?F_XP_93^#W_!)O\
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M\ /^"<W[17PX_9?_ &)-$'BKXA^"_P!H3Q)_P4'\.?\ !0']MO6?AA\0-/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!=0Q!#:H+D(S%@Z..!XE^R%^T)\0OC?;?%OP_P#%;PEX9\*^/_@W\1;WX?\
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MXX[!2?M\,ZCHU?8RG'V=>-.4Z$ZD$Y$M%%%<I]4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_YM*^RJ*Z?[1S#_ *#L9_X4U_\ Y,^9_P"(>< ?]$-P?_XC.2__ #$?&O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX/\ H;OC+_X(M0_^4U</^K6(_P"@S!_^!S_^0/N/^)D\@_Z)#C#_ ,),%_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT6T>2UTJ._NEDN4L+>1X;59!#&S*@)_4&OSB_86_Y*W^WK_V='XD_P#1^JT
M?H[1110 4444 %%%% !1110 4444 %5KRSMM0L[NPO(A-:7UM/9W4)9U$MM<
MQ/#/$6C9'421.R%D97 .58$ BS10!^&_QH_8@^#7['F@_"O1OV;/ 5O\.?@Q
MH_@Z^^&MGX.L];UK6;'PY>6WQ"^(/Q:L7MKOQ3J^M^)=1N/$VO?%GXDZC?W=
M]JE\EFFG:=I\+6EFFGVJ_P H'_!5'_@L1^U%^S%\7_%?[-G[,GQ]^.'PHU;P
M7<_#W5]5CTH:)'X+A_MSPW9>,;ZW\-SW]]JM^;?48-6T"34X8M&TVPN-4/B&
MVEBE\VZN]2_T&_C_ /"1OC-\/;CPI;7\.F:M::G9:[H=Y=B0V":G9175IY5^
M((Y9Q:W-AJ%];F2!'DMYI8;D17"PM;3?@1_P4:_X)1'X[_L^6G@OXV^+QI_@
MRV^(GA;Q E[\+=8F_P"$C@UC3;/7(+(7!\3^"IM+72+B"^O;6[;RS<B>>S-N
MRMEA_F;XBOCCZ/?TSN,?I*U?#K.N*?"?B[PHRWAWC7BO*J^&J4.$<'A:'#65
M9GG&+R_ZKC<9C*V2Y=P9EM6CEU*G@?K"Q=#&4<TC4PF(P\_W7*<HX=\0_"#(
M?#F'$5/)N)<AXYK\29%E3J8C"RS;'5:V;8VG@O;TJV'I_5,RQF?8Z6)]O+$T
M^=5*53"N$Z,Z?UK_ ,$HO^"S?[.W[?W[,.B?$+QO\0/!OP@^+GASQG?_  B\
M:>$?BEXQ^&O@/6_&GBS0- \+ZXOCGP-X83QG>WMWX4\4Z;XKTP1L+2P^Q^+K
M+Q9X>L;*?3=$L=5U/]K597571E=&4,K*0RLK#*LK#(*D$$$$@@Y'%?Q-_P#!
M0+]E;XP>)OA=\4OVP/A5X4T_X@:-\"/AY;S?$'P#HMS?VWCZ^M+!O$>KQ^)+
M"SBT.]M-4TBSL4^R:S/:W=YKVE65DEZN@WFE6EQ<6GY+_P#!+C_@O]^T5^RU
M^TE\1[7XC?"WXO\ [0GP[^,T'P,^'6@?#'QE^T-XKT_1?V;M/\)B#PXOB#PM
M;>*/ WBO0-/TJ^T74);N]T:WT[X?:9+;V&FB\UY+33TNH_\ 0OPGX]X;\:/!
M+PW\9<BFLOS#Q!P6)QN8\&4/:9E#AW&X;'YGE^8Y?1S6C@\'2Q%/ 9AEM;"T
MHU<)A<17HSIUXX>G3A54/Y<QD^,.#O$_CGPUXFR.5/AW@M8:ADG'>,S##T:W
M$F&='+987%8O+L16EB)5L;AL;]9Q&-PTJN#H8JA7PE:H\36H*?\ IFT5YS\-
M_C#\)_C'IE]K/PE^)?@/XF:3IEY_9^I:CX#\6:'XKL].OB&9+6^GT.^O8[2>
M6-&E@CN&C:>#$\(>%E<^C5]75I5:%25*O2J4:L':=*K"5.I!V3M*$TI1=FG9
MI.S3/I\-B<-C*%/$X3$4,5AJT>:EB,-5IUZ%6-VN:G5I2E3G&Z:O&35TU>Z8
M4445F;A1110 4444 %%%% '\D_\ P4"_X-D/A5^T%^V=\*OCM^SSX0^''A/X
M7>.O$WQJ\<_MF^&_'?Q3^.$6M>-/'7C4KKWASQ+X.DM]2\5S6D=_XQU/7-2U
MG1- U'P%IFC#RX[.+4]+NK?2=(]VO_\ @E1X_P#V5?@A+'X0N/AXWPS^$OAQ
M#8>&?#_B'QUK.NV?A^VN5:\:VD\4: \UY%I<=S<ZE>SZGXC>==.M;F59))(X
MK9_Z8JJ:AI]CJUA>Z7J=G;:AINI6ESI^HV%[!'<V=]8WD+V]W9W=M,KQ7%M<
MV\DD,\$J-'+$[QNK*Q!]+ 9G6P$^:E3H6E*'M'[&FJDJ<53BZ:J)*2C)4TVK
MV=1RJ.\Y-GYGQSX79'QUAI4\RQ><PJT:&*_L^$<WQTLOPN.K2QE6ECI9?4JU
M,/4JTJN,G"+Y%*&"A2P-)T\+1I4H?SA?LJ?MK:U^S)X<\6^%CX,'CO2/$&JV
M.MZ5:S>)W\/0Z!J:6LEEJ]P$70-;:_76+:'1T>-7L!;-I0<-.;IO*^H)?^"M
M&MF*00_ _2HYC&XBDE\?7<T22E2(WDB3PG \L:OAGC6:%G4%5EC)#C[2/_!/
M/]DLSF7_ (5K>;#)O^SCQSX]$&W=GRLCQ+YXCQ\N1/YFW_EINYJZ/^"?O[(J
MD,/A(,@@C/COXF,,@YY5O&95AZA@01P017L5\QX>Q%6=>M@<5.K4:<Y?#=I*
M*;C'&1@M$KV6KNW=MM_D62^'OTA,@RK"9+E/'7"V"RS 0G1PF'E?$RI4JE6I
M6E&-?$<(XC$SBJE6?LU5K2=*'+2I\E*%.$?@'_A[!\0_^B3>#/\ P=:Y_P#$
MUT/PL_X*B>.]=\>>&/#_ ([^'G@T>'_$&NZ1H=U?>&)M>T[4M)75=0M[%M46
M/4;[7H=12Q6<W#:<L5G+=B,PI>P,X<?=O_#"'[)W_1']._\ "E\;_P#S35^"
M/Q1L_#OP\_:?\9V>F6*:3X6\&?&;4DM-/LDDDCT_1-"\6LT=M:QN[R.+>SMM
MD2-(SMM52Q)S75@J>29E[>EA\!4A*%)S;J-IZOECR.->;YKN_3YGS/&>/\;?
M#C^PLTX@X]P&.PN,S6GA8T<!3IU*;4(JM7^N0Q&28&G*@Z4''24Y*\G'V;]X
M_JGHKX"_X>5_LP?]!3QG_P"$A=__ "31_P /*_V8/^@IXS_\)"[_ /DFOFO[
M+S'_ * L3_X*G_D?TG_Q%'PZ_P"BUX;_ /#KA?\ Y8??M%? 7_#RO]F#_H*>
M,_\ PD+O_P"2:N:?_P %(?V6[V\@M9_$GB?2XIG*/?ZAX/UAK.V^5B'G&G1Z
MA>[&8",&"SF*LZLX6,/(I_9>8_\ 0%B?_!,W^2''Q/\ #N<HQ7&O#5Y245S9
MO@X1NW9<TI58QBKO64FHQ6K:2;/O&BJEA?V>J6-EJ>G7,-[I^HVEM?V%Y;.L
MMO=V=Y"EQ:W,$BDK)#/!(DL3J2KHZL#@U;K@::;35FM&GNGV9]U&491C*,E*
M,DI1E%IQE%JZE%JZ:::::=FM4%%%% PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%4GC#Q)INNV^FKHWA?0=)%E9:3I&DP2:9<6FIZG83ZG_ &G<7;VVH:;;P_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV4.HZ3JUG<6&HV-PI:&ZM+J-HIX7VE6 =&(#HR21MAXW1U5A^=^+G E/Q/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=-I7BG1K":XT^2\ /JBOSB_86_Y*W^WK_P!G1^)/_1^JU^CM?G%^PM_R5O\
M;U_[.C\2?^C]5H _1VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1]1UN_CLM7U2:[:RTNTFO;O[/%+H4$<DP@@D9$>:)6(P74<U\WX+?2@^F_\
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M\1_#7QJS_@7/L9P_GO [QN5_V!GD</#(\ZCALZX>QN<8=2P4LTQ=/$TL'F>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P#]K#XIZW\#/V6?VE?C9X9
M71V\1_!WX ?&3XI^'U\0Q23Z VM_#[X=>(_%NE+KD,-[IDLVCF_TBW&IQ1:E
MI\DED9T2]M&(GC_E)_9I_P"":'[9_P#P6O\ A#X"_:=_X*!_\%1_%7CC]F3X
MHH=:\-_ +]F+2]2\'>$M8T_0-8OM.-MK5CXB\&^ ?A_X:\5>"_&6B7>D75S>
M?!KXHZG/<:3.Z>-A?*+ROZS/VDO >M_%/]G;X^?##PU?^&=+\1_$?X+?%/P'
MH&I^-+*VU+P=IVM^+_ VN^'M*O\ Q9IU[I>MV=_X9M+[48+C7K*[T75[:ZTN
M.Z@GTO4(I'M)OY$/V</^"3?_  7;_9'\":1\+_V>_P#@K)^S!\/_ (;^'SK1
M\/\ @0^,?$WBSPEH'_"1:Q/X@UI=#T#QO\!?$NF:.FH:Y=WVKS)IMM;(NHZE
MJMY$L<^JZB]R ?UG?LH_LK?!?]BOX$>"/V</V?\ P]J'AGX7> 4UAM$T[5M?
MUCQ/JDU_XBUO4?$OB'5=1UG7+N\O;F]UGQ!JVI:I<11/;Z;9R79L](T_3=+@
MM+&W^BJ^/?V#O!W[4/@+]F+P'X7_ &R/C9X,_:&_:"L+_P 92>,?BQX @L[?
MPMXALKWQCKEYX6M]/BL?"'@6V630_"T^D:)>E/#-@6O=/N"\EXY:\G^PJ "B
MBB@ HHHH *_.+]A;_DK?[>O_ &='XD_]'ZK7Z.U^<7["W_)6_P!O7_LZ/Q)_
MZ/U6@#]':*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#^"O\ X+??\&Z7QT\1_$GX_P#[8_[+%RGQ*'Q6
M^)MKXRU+X36WB/0O#>LZ?<>,=0FOO%5U>6_B6U\+>$HO#NA:K+/=VNMOXZOM
M:N/M=A92^&9'>]UNU^.O^"3?_!+77M"\(>$?CQ\>=:^(N@/X@L/'&AZ_^S!X
M^\!^)? \VDS6?B34]+T'7+F]O_$.D:]9O<0647B.TA/ABRCO8=40^=<6YCN9
M?])FN(^)/PV\"_%_P-XD^&OQ+\,Z;XP\#>+M/.F>(?#NK)*UGJ%KYT5S$1);
MRP7=G=V=W!;WVG:C8W%KJ.F:A;6NH:?=6U[;03Q_C?C1P3XN>)6#K9;P)XX5
M/!6GC:F7_7.(>&.!I9KQC3H0P68X#.*6!SN'&G#BP/\ :4<3E^.HXO+:&6Y]
M@LQP.)G2X@>&S&.'P'H<)TN".&\%7PV=\ X;Q#P\8XVIA<@XISQ+AR=:=?#X
MK+L/B<+7R#.W+!X.I1JX6-'$TLRP4,'6I*.63J81.O\ SM_\-FV?[%G@SX*_
M"8_%/4/AOX/\:_$71/@M\&_#\F@ZMXV%]X\\>:GJ-]H?A2'5'\/^+-2TRVO[
M^6^-M?\ B/4;'PYH\.RU;4-.LHK:%/IG_AJW]H#_ **+>?\ @D\+_P#RCK^9
M_P#X+C?\$1?B)^RY%X,_:+^#'QR^)_C[X5^,_P!KS2;&P^%6B_"'5=1TC]E'
MP9XLN=?U'PMXKU'XB#QCXKU;6-#\#7,.E^#[;7O&T.B0ZC?ZII@N=3@O[Z.U
MG]D_X)]_\%1OVG?V#?@/H7[/ZCP'\=O#.B>)_$GB./Q'\0M(\3:9XP6/Q/JB
M:E=Z)I][H7C"/1[+2;63[3-9K<:)J-TFH7][=S7,T#PV$'\XX#]FUX_<8X"6
M,X9^G9X\8K'X7$8E9QF>>+B"EA,VQ&(JJO1>$PE/QGGC,MQ5&A-?6EB<PSNG
MCZG/BOK>6OV>"J]'$7TRO"WPNQ>4Y-QMX&^'624,7@(/+\JX8K+-)Y3A,*EA
MJ-O^-:Y9@\1EK=&5*DZ5++,1@W"EAJ&6XZBJV+PW[_+^U?\ M JRL/B)=DJP
M8!M"\*LI(.<,K:$593CE6!!'!!!K]7O@%XZUKXD_"7PEXR\11VR:SJD6JPWK
MV<0M[:YDTK7-3T=;J. 22"%KF.P26>-=D:W+3>1%'!Y2#^>?X7?\%&_"'_!4
M#X3?#S]H[P;X)\0?#FWBT[6?!/B+P5XAOK+4Y=(\7:!XCU4ZG+INI6$GDZAI
M.HZ9=:'>V=U+:V-XIEELKFW9K-9YOUG_ &0OVA;6\/A+X&WGAE;%X-/UA=$U
MVSOY9UO+FVCOO$-Y#J&GSV^;=KB-=5NA=PWS1+(L%FEDBR><O\J_1H\2N(_!
M;Z8G'G@CXO>/?&W'.4O"PX"X4J\78OB;,<#G_'^99OPK5R.IA,OQ>:<58?(J
ME?"ULVR["XN>:0PV,^M895,4_K%&E3_IKCS),KXW\(\BXWX/X)R?)ZTJD\ZS
M..64,OPF(R_)<'A\THYA1Q%2.%RNMBI8?$4L/4Q&'>%]MAIT*T?8ITIR?Z)T
M445_LX?R:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &?JVD:5K^F7VBZ[IFGZSH^IVTMGJ6E:K9V^H:;J%I,I6:UO;&[CFMKJWE4
ME9(9XGC<<,I%?QS_ !N^,?QL_9$^(T_Q _9\_9^MOCI\0OAW\8=4TJS^&&I^
M-++P)9:;INGW7B*TN-0U#5M565KF'2)[.RTV32X;BWO[A[U9UNU6UF63^RBO
M(M?^ 'P-\5:M>:]XC^$/PWUK6]1E:?4-6U'P;H%SJ%_<.Q9[F^NY+ SWERY)
M\RYN'DG<!0TA"J!ZV69C'!0Q=*HJKIXFG&%Z3IN4&N9-J-:,Z;YHR<7S0ETT
M9^3^)?AYB^-<5PMF66XC+,-C^&<QJ8V*S*GCE1Q5.;P]2G2GB,LKX7,*2HXC
M#4ZL%0Q%+WI2DIQDM?X=_P#@DY_P5Y_X*!>$_$W[2/A"[_9JT'Q;X%^*G[<W
M[0WQ,^(GQ0\>_%35/$W_  H+Q;XCT#PQ<:A\%?#WAH^([34];\)>$;[1-(L-
M&FT>[M].23Q3=7<"F.UN$?[8_P""EW_!8#]N73OV9_C-X"^'7[-WP^\9>%?B
M7^S_ /'CPO\ $+XL>$_&.M?#SQ!\#-)U3P!J&C-XWT:TU/Q;J>H:[K.D:;J^
MK>)=*&D/;7-M>^'(HE+SW<!3^E3X>?L$_L9?"B#Q;;?#[]FKX2>&X/'7CC7O
MB3XLC@\)V-X-8\;>)TLH]=UZ4ZF+UK:;4$TZR5[2R-MI\/D VUI"7D+])XK_
M &-_V5/&_A?Q)X+\4_L^_"C5_#'B_0-8\+^(]*E\&Z/;QZGH.OZ=<Z3J^GR7
M%G;VUY E[I]W<6SS6MQ!<Q+*7@FBE575T\3ED<)*C+#5I5Y7<<1RX7FAM:,8
M^SY7#2S<X2G[TN6<;0Y>;&\+>)M;B?#9KA>*<HP^1T/90K9#[;B-T<9%1DJM
M>O4^O/$0Q*<^:C##8K#X.3H4/K&&K*>*6(_EG_X)>_\ !8']NN?]FSX*_#7Q
M[^S9X#\.>!OAW\!_ACHO@;XW>,?&^L_$#Q!\9K?3-!T[2X/$&LZ5I_BO3=5T
M?5M8TZ"+7K^;5)IY'GNI('43!FK]-/\ AZE^T)_T)WP:_P#">\;_ /SPZ_5_
MP=^QA^R?X \*>'/ _A#]GKX3Z+X5\):+IWA[P[I$7@[2;F+3=&TFUBLM/L8[
MB^@NKR=+:UACB66ZN9YW"[I99')8])_PR_\ LY?]$-^%?_A#^'O_ ) KHP^.
MR>E1A"KETZ]2,4I59^Q3D^NE-4XV6T?=YFDG)RE=OP<[X$\8LPS3%XO+?$3!
M9+@:M63PV785YM5I4:2;46YXYXVM[6:M.LHU_81J.2P]*C14*<?P4^.__!8_
M]MGX=>"[;7O@_P#LQ_"+X\^*I=?L=-N/!5MK6N?#R2UT:XL]1GN]?.NZ]XSU
M.RF6QNK6QLSIR6XN+@ZD)TE5+657_%+_ ((Q_P#!6K]OGX?V'Q@^'H_9^TGX
ME?#GXA_M>_&7Q[XY^-?Q(^*>L>)+OX->)-7\%>#/M/PJTCPQ-XCM=7UGPUH-
MSH&BQZ9)I=W!8QW/B^\NHP5M;E'_ +F/^&7_ -G+_HAOPK_\(?P]_P#(%>9?
M"W_@GW^Q1\%=+\0Z+\,/V9/A'X4TSQ7XNU;QYX@M+;PK:7ZZCXMUVWT^TU76
M))-7.H30RWEOI6GQM;6TD%E&+96AMHV>5GQJXK*YXFC5AA*U.C"_M*$8X9QG
M\-DG*$IVE9J=YW2:]DZ<KM^MEO"7BGA.'\URW&\895F.;XITUEV=5JO$,,1@
MU+VJJRE3P^,P^%<Z'-3J8-4\*J=2I&4<QAC:*A2C^4GC/_@K1^U%H/@_Q7KG
MA;X4?!WQIXGT;PUKNJ^'/!T=GXMT*3Q9KVG:7=7FD>&4UN]\>W%GH[Z]J$-O
MI:ZK=V\]MI[70NYX98H71OYYO@M_P65_X*7Z%_P4O_:U^,=C^QKI7BCQW\1_
MAG\%O#WC#]G/5/CM,? ?P9TCP_H/AJQTWQ?X:N)M9_L>\U#Q;:VD.J:I!IJQ
MW"SZA<).QDWFO[P?^&7_ -G+_HAOPK_\(?P]_P#(%>;Z/^P%^Q;H'Q*\8?&#
M2/V9_A'9?$?Q[I6C:)XN\3IX4LY;C6=+\/6]M::/:2V,_FZ5;+96]I;Q))8V
M%M-*(@T\DK,S,\3B\JK2HNCA*V&C"=ZD8+#24X<LUI[6%1\ZDXZ-^SY>:\'/
MEDEP]PCXJ97ALVI9OQAE7$%;%83DR[$8RKQ#1E@\5]8PLK267XO 0^K.A#$-
MRIP6-5>5*,<3'"O$4*OYB?\ #U+]H3_H3O@U_P"$]XW_ /GAUQ'Q)_X*Y?M8
M^%? OB;Q%X$^"OP>^)?B_2=,DN] \!PKXI\+2^)[]9(U33$\0ZEX[O+#26D1
MY)/M5U;31+Y>TH2X(_;K_AE_]G+_ *(;\*__  A_#W_R!5'5/V8OV=8],U&2
M+X'_  M25+&[>-T\$>'PZR+;R,C(18Y#*P!4CD$#'-=3S')))Q65R@Y)I27L
MVXMZ*24G*+:W2DFKK5-:'S%+P]\;:%2G7J>*6'Q5.C.%6IAJL<?&EB(4Y*<J
M%26'I4*\:=:*=.<J%:C649-TZM.:C-?QL?\ !.[_ (*O_P#!0WQ=_P %5?VS
M;JZ_8(UCXI^.OVC;G]E/1?&'P2TG]JK0O"7A']EO1/ ?PMFT^Y\6^'/^$JT3
MQ9HOBL>,O!EM=_$/6])\/S^'KMK_ $V>PFN;O4+VW6'^ZNO\V/4?^"JWP2_8
MJ_X*"_"7XI_!:YT1-9T[XW7'@W]NC4)OA[XBN?$.I>"/ 8L?AI=Z;I>H:E81
MV][J6E>&+CQSI&D7_AJ+4MDD5E=HEP!:F;^Q+X/_ /!;/]E;X[?#KP[\5?AI
MX6^+.N>"?%0U;^Q=4FT#1-(DNCHFN:GX<U,-I^L>(+#4K<0:OI&H6RFYM(?.
M2%;B(-!+%(WGU\N<\75P^7R^N.GSRJ<DZ+M>K)KEC#D]V%.=&%5J"A'$>TA'
MEBHQ7VW#?B-1PW"F79YQY'_52&/EA*& CCL)F\.=0RW#QK/$8C%+&MUL9F6%
MSC%Y;"KBIXK$9&L!BZW/6G7JR_8JBOS*@_X*J? -D)N?!/Q?ADW$!8-&\&7"
M%,##%Y/'5JP8MN!01D  '>2Q5;</_!4_]GB60(_A3XP6ZG.99O#O@YHUP"0"
M+?Q]/+\Q&T;8V&2-Q"Y(EY/F:_Y@ZWR47^4CTX^+_AG*UN,LG5]N:I6COWYJ
M*Y?.]K=3]*J*^0/@Q^W#\"?CCXK@\$>&+[Q)HOBK4!.=&TGQ5H8L&UO[)97>
MHWJZ?>Z9>ZSIR26=G9S3R0:A>6$\Z@"RCNF60)]?UQU\/7PT_9UZ4Z4[*2C.
M+BW%[25]&KIJZNKIK=-'V.2Y]DO$>#_M#(LTP6;8)59X>6(P->%>G3KTU&4Z
M%7D;E2K1A4IU'2J*,_9U*=11Y*D)2****Q/7"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^-/B[^TYH7A+X=_MD? JS^&/CO2OBUH5G??M!6/@[XHZG:Z[>_%J"QL=6O\
M7K.)['3;1+#4K?P_*NF>(]8LHWNQ<S3V_P#HGURXK"SPRI2E3J4U6]M*$:C3
MDX0K3A"5N6#2E!1:;BN?^)%*$HI?6<(<5T.)7FM&GBL#C*V3U,LP^+JY?"I'
M#QQ.+RC!XS$T>:6(Q<)5*&,J8JE.%/$5'A>58.NY8G#UJE0HHHKC/LPHHHH
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M.N_#/6H+:SMG@\/V4NDV=C;)>ZM;:LGBW0KZRMGEN[FTU2VO;2^T[4+'6_\
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M$%W;+_PBEBL<=O:]W^R7_P &Q7[''@#]B+_A6?[17P?^$'B']M_Q1\(OBKX
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M"UGI]A;0!U1GN;^7PU%;PQ"78I:654W[03NP*_*[_@I5?> _@C\*-*UCP?\
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M(7_J(ZO7XD_\$NO^3C=:_P"R5^)O_4A\(5])E?\ R)LX_P ,?_2&?S?XG?\
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MI^N037.HZG=Z;;VG]%U% 'Y/?M!?LJ_'K]O#QA\//%OB_P 2^-_V)KG]C?\
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M+CFJ<-XZE"52=7#.,5=J'UJK/=+W:=/"SG+5_9B[*[=DFU]%E_TDN!\SQE#
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M/]5\P_Y_8/\ \&5__F</^)H> /\ H4<8?^&_)?\ Z(#^EZBOYH?^'@?[7?\
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M$_P:\3>(/&WPZ^&O@KX'_#2/X?>#86\9^)_ OPVU;Q9\0O$OV[6M6^(&N_\
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M<15K\1>_0IS_ -*.BO\ -*_X)K_\%]?V\?V7_P!HKXBR?M36O[4?[</AG5_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=W@NK2Z@D2:">%WCEC=71BI!H _3*BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGP/+J.NZW<:CX<]\_P""?GPG_:.^ OPK7X*?&'X0_L?_  9^&/PUT/PGX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDNP'_L(WNM:GIGB.Y!T>&ZT[79M&TW7?T&T3_@G=^Q-HGQ"^/'Q3'[.?P_\
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ME=&*D$S5FTTVFK-:-/=/LS5--)IIII--.Z:>J::T::V84444#"BBB@ HHHH
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M3"RKN52I&4J$94XTW*ISE%%%<9]<%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?G%^PM_R5O]O7_LZ/Q)_P"C]5K]':_.+]A;_DK?[>O_
M &='XD_]'ZK0!^CM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4A)8;#9%4X2P64_5ZE.,XO$RS6$J;<81P$N=UZ'N7@7]N+Q-\4=$A\2_#/\
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MP[B(48PINT\-3QLN;EC*G'=?O7_PO_\ :#_Z'[QC_P!\C_Y#H_X7_P#M!_\
M0_>,?^^1_P#(=?CC_P $I/\ @YMUK5O@[X&^&'[;'PI_:&^+GQ4LY/&]]K_[
M3'A?P]\.+?PKXMLW\5:SJ&B:<-"LH/AOX?TR]\/Z%<Z=X72.RGE.HW.DRW5U
M+'<RRY_H(\'?\%I/^"?'BFRM[C4OBUK_ ($O9U4G1_&/PT\?&]MV*,[)<7OA
M/0/%7A]&3:59EUIXV<A8GD+#/P6'_9F^/V+P=/'X/Z7GC1C<)5Y>2M@LFXIQ
MBUIPJJ\<+XI59PM"<'+FC'EO:5I)I?M&+^F%X+Y=F=;)LSX.\.LIS/#\WM<)
MF^;Y1E4XN-:I0?+/,.&\-2J7JT9QC[.I/G4>:'-!QD_!?^%__M!_]#]XQ_[Y
M'_R'1_PO_P#:#_Z'[QC_ -\C_P"0Z_1GPS^WM^Q3XOB271?VJ/@2ID8I';:U
M\2O"_A>_D<'&V/3?$^H:/J#D]5"VQW %ER 2/(?V=_\ @JC^Q5^TE?\ QYT_
MPM\7_"W@J7]GSX^>/OV>?$LWQ2\9?#CP?;>+_$OP\FM(-3\8_#:5?'&I_P#"
M5_#36&O$;PSXL*Z<VK1QSL=.MO+PWG5?V<?C;0J1I5OIC>,M&K+F4:57(^+:
M=23@KR483\3U)\J2<K+W4KNQ[V'^DWX:8NC+$X7P^\/L3AX*#G7P^>9!6HP4
MVHTW*K3R&4(J<K1A>2YG91NSY$_X7_\ M!_]#]XQ_P"^1_\ (='_  O_ /:#
M_P"A^\8_]\C_ .0Z_9/P7\4_AC\2(IY_AW\1O ?CV"V8+<S>"_%_A_Q3%;LQ
MD"K/)H>HWR1,3%* )"I)CDQ]QL=Y7)4_9Y^+U&;IU?II^+5*I'XH5,LXGA..
MS5XR\4E):6>J['JT/'[A#%4H5\+X3<)XBA-7A6H8S*ZU*:3M>%2GPW*$DFK:
M-ZKR/XZ_^"K7[5/_  45TC]F3XO>&_A!X7D^)'PG\8?L\_M!Z1\?O%WB#QOI
M_A35/AQX,N?A_=V%]K.@:7<7.G7GB*Z3PU?^*=3%KI\5U<"XT>UMT59;N)9.
M9_X)(?M5_P#!1S4?V;O@UX1^)_A%O 'P,\*?L_?"VR^"/C_0_'6G^)M;\>Z-
M:Z'IUEI5SK6A0W=_J&A/<>'H[74G6^M[>1;B5K=SYBE*_L<\4^%O#'CGPQXC
M\$^-O#F@^,/!GC#0=7\+>+O"/BG2-/\ $'ACQ3X8\0:?<:3KWASQ'H.K6]WI
M6MZ#K>E7=WIFKZ1J=I=:?J6GW5Q97MO-;321M'X0\'^$OA]X6\.^!O 7A;PY
MX(\$^$-&T[P[X3\'>$-$TSPUX6\,>'](M8[+2="\.^'M&M;+2=%T;2[*&&TT
M[2]-M+:RLK6*.WMH(HD5!^L4_HB\?P\)Y>&S^D'G<\YEF[S%>)4\M\1/];E1
M;J35)<OC9'+OK,%.."IU%AEE2RR$85,DJYK_ ,+*^:EXI9&^*5Q$N!<)'"+"
M+#OAV.(R#^RG)*"YM>#GB/9-P]M*/M/K/UEMQQD,+_L;_%+_ (7_ /M!_P#0
M_>,?^^1_\AT?\+__ &@_^A^\8_\ ?(_^0Z_<^BOR/_BGQXM?])K^*_\ X;^)
M?_II^2^X^K_XCMPO_P!&?X8_\'Y=_P#0UY+[C\,/^%__ +0?_0_>,?\ OD?_
M "'1_P +_P#V@_\ H?O&/_?(_P#D.OW/HH_XI\>+7_2:_BO_ .&_B7_Z:?DO
MN#_B.W"__1G^&/\ P?EW_P!#7DON/PP_X7_^T'_T/WC'_OD?_(='_"__ -H/
M_H?O&/\ WR/_ )#K]SZ*/^*?'BU_TFOXK_\ AOXE_P#II^2^X/\ B.W"_P#T
M9_AC_P 'Y=_]#7DON/PP_P"%_P#[0?\ T/WC'_OD?_(='_"__P!H/_H?O&/_
M 'R/_D.OW/HH_P"*?'BU_P!)K^*__AOXE_\ II^2^X/^([<+_P#1G^&/_!^7
M?_0UY+[C\,/^%_\ [0?_ $/WC'_OD?\ R'7\QW_!P'\3/^"B'B[X9Z5:_$CQ
MS\(M9_9$C_:'^$%[\+='>+QT/C5:_$BW^'WB*)+WQ@\^DP^"F\/IK4GCHP#1
M[Z;4?[)N/#X:$W(U!8_]$"J5_ING:I"MOJ=A9:C DJ3I!?VL%W"DT88),L5Q
M'(BRH'<)(%#J&8 @,<_IOA%]#KQ,\,.-\LXLS/Z4/&/B!E^$7LL9PUQ3D>>X
MK XJA*MAZ\IX6IBO$C'T<!CT\-&E2QTL!C/98>MB:7U>2K-Q^;XK\5^'>),E
MQ.58?PWRG(J];WJ68Y;C,%3K4IJ$X*-2-+A^A.O0:GS2HJO1YJD*4N=<B3^(
M?^"=FL_MQ^(OV<[37/\ @H!<? ZZ^-FI>+M=FT6;X":7XVT7PQ+\-XK/1[7P
M]/K^F^.M-TG4K?Q;=ZS!XFO+EM-LH]$N/#]QX<N;/%Q->(GW7117]S9+@\;E
MV3Y5E^99C/.,PP.6X'"8[-IT/JT\SQF&PU*CB<PEAO;8AX=XRM">(=%XC$2I
M>TY)5ZTHNK+\9Q=6C7Q>)KX>@L+0K8BM5HX93]HL/2J5)2IT%4Y*?M/90:AS
MJG34N7F4()\J****],YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH YKQGXHL/!'@_P 5^--5$C:7X0\-:[XHU(0QS2RFPT#2[K5K
MP116\-Q<22&WM) D<%O/,[86*&5RJ-_,K\,O%OQV^#/PJ_X).?\ !0:[_:A_
M:6^*'Q/_ ."@?[4/[/WPY_:*^%/CWXEZYXJ_9RNO '[;VD:WXAD\-_#OX(7L
MTOAGX3P? #7K31+_ .%'B+P&VC:UI^DP^*-)\6W7B?PWXAFT6R_J*N+>"Z@G
MM;F*.XMKF&2WN()D62*:"9&CEBEC8%7CDC9D=&!5E8J00:_'OX.?\$Q?BEX$
MUG]F+X>?$;]IWP]\4/V0_P!BGXLZY\6?V;O@N?@A=:!\2+:]T[0/%_AGX#^&
M_B?\9;CXL^(+;Q=HO[-^C>,;R/P5-HOP]\+W_BO4M,T#5?%LTO\ 8MG8@ _1
M']H_2_VC]=^%^H:%^ROXI^%?@/XKZWJFDZ3%X^^+VA>(/%OA[P)X7O[DV_BC
MQ?HO@WP_/8?\)EXXT'3'>^\&>&=>UC1/">IZY';)XFU(:0ES9W?Y_?\ !![Q
MU\1/B5_P2M_9I\9_%?X@>,/BG\0=5US]I"#Q'X_\?>(-6\4>+?$DVC?M5?&_
M0K&YU;6]<O=1U.[-KI>F6.GV45Q>3)8:=9V>G6OEV=I!$GZ-?"3P?\6_",OQ
M4;XL?&2V^,,7BKXO^+?&'POBM_AMH?PY_P"%3?"35[31(?"?P;N)-$U753\0
M+GP?=V.M7DGQ)UD:9KGB,:ZMM?:5:QZ5;O-X?_P3X_9#_P"&$/V1_AA^RQ_P
ML+_A:G_"M]3^*>H_\)W_ ,(G_P (/_;/_"R_C#X_^+'D_P#",?\ "2^,/[._
ML7_A.?[ \S_A(;[^TO[+_M798?;?[-M #Z#^+7QB^''P+\'S>/OBGXB_X1;P
ME;W]CI<VK?V1KNM[+[4I&CLH/L'AS3-7U)O.=&7S5LVACQF62,$$_!?_  3F
M\7>'O'WC#]M/QOX2U#^UO#'BS]HK4_$/A_4_LE]8?VAH^K)J-[I]Y]BU.VL]
M0M?M%M-'+]GO;2VNHMVR>".0,@_3JXMK:[C,-U;P7,)(8Q7$4<T99>58I(K*
M2#R#C([5^<O["4<</Q7_ &\HH8TBBC_:A\1I''&BI'&BS:J%1$4!551P%4
M< 4 ?I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_#1.@_#F?3_@]\%='^-'@K2?A3XP\3QZY+?VUIXH?XHZ)Y[+):ZC=6\EQ?\
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M.4?\/3?V6?[WQ1_\-OK/_P <H _1VBOSB_X>F_LL_P![XH_^&WUG_P".4?\
M#TW]EG^]\4?_  V^L_\ QR@#]':*_.+_ (>F_LL_WOBC_P"&WUG_ ..4?\/3
M?V6?[WQ1_P##;ZS_ /'* /T=HK\XO^'IO[+/][XH_P#AM]9_^.4?\/3?V6?[
MWQ1_\-OK/_QR@#]':*_.+_AZ;^RS_>^*/_AM]9_^.4?\/3?V6?[WQ1_\-OK/
M_P <H _1VBOSB_X>F_LL_P![XH_^&WUG_P".4?\ #TW]EG^]\4?_  V^L_\
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M>F_LL_WOBC_X;?6?_CE'_#TW]EG^]\4?_#;ZS_\ '* /T=HK\XO^'IO[+/\
M>^*/_AM]9_\ CE'_  ]-_99_O?%'_P -OK/_ ,<H _1VBOSB_P"'IO[+/][X
MH_\ AM]9_P#CE'_#TW]EG^]\4?\ PV^L_P#QR@#]':*_.+_AZ;^RS_>^*/\
MX;?6?_CE'_#TW]EG^]\4?_#;ZS_\<H _1VBOSB_X>F_LL_WOBC_X;?6?_CE'
M_#TW]EG^]\4?_#;ZS_\ '* /T=HK\XO^'IO[+/\ >^*/_AM]9_\ CE'_  ]-
M_99_O?%'_P -OK/_ ,<H _1VBOSB_P"'IO[+/][XH_\ AM]9_P#CE'_#TW]E
MG^]\4?\ PV^L_P#QR@#]':*_.+_AZ;^RS_>^*/\ X;?6?_CE'_#TW]EG^]\4
M?_#;ZS_\<H _1VBOSB_X>F_LL_WOBC_X;?6?_CE'_#TW]EG^]\4?_#;ZS_\
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M_P#'* /T=HK\XO\ AZ;^RS_>^*/_ (;?6?\ XY1_P]-_99_O?%'_ ,-OK/\
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MS<H@E>W'P[U4SK&2 )&B$WF*A) #E0I) SDBIO\ AZ;^RS_>^*/_ (;?6?\
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M_AZ;^RS_ 'OBC_X;?6?_ (Y0!^CM%?G%_P /3?V6?[WQ1_\ #;ZS_P#'*/\
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MA7Q7IRZEI%]Y3P.\8FEM;FWN() '@O+&]M[FPO8&SY-W;31!G"!B =O1110
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)?[;_ (X_:I\
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M*Z'H*Z[=:A#X%OO$.J:%IEYX?M?W,HHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ/AN]T[4;S6/"WP@\*6+0:N]WIEGXB:PTC4M&;Q]K<D8!_:CX%_:#^ ?Q1\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .:\8>+M \!^&=<\7>)[^/3M#\/:5J>LZC<-\\IM-)T^ZU.[2TME
MS->WGV.SN'@LK9)+FY:,QPQNY KX[_X>-_LJ_P#0X:__ .$7XE_^0*^T/$?A
M_2/%OA[7O"OB"T_M#0/$VC:IX?UNP^T75I]MTC6;&?3=2M/M5E-;7MM]ILKF
M:'[1:7%O=0[_ #+>:*54D7Y._P"'?G[(G_1)/_+]^)O_ ,VE=^$>6*,_KT<:
MY\RY/JSH\O+;7F]HT[WVM=6/A.+(>)4L3A7P/6X,IX/V,_KJXFCG/UCZQSKV
M?U9Y;"I3='V=^;VBC-3T2:U,#_AXW^RK_P!#AK__ (1?B7_Y H_X>-_LJ_\
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MZLL6JG(W5]LZ'*N3VC7Y-?'O]H']M#QE_P %5-/_ &"OV=/C)\'?@9X)MO\
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M"?L\>-3XYMO$?A'X#^!O@KX;\:R6<WBZ^\/Z3\0X]#73M9\*7_C>U\&6_A\
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MN?[.\,^$M#L-'T#0[-[70]'C.H76GZ=;WVL:Q=7WIE% !1110 4444 %%%%
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M?^ Q_P @N^[^]FI_;6I_\_/_ )!M_P#XU1_;6I_\_/\ Y!M__C59=%'LZ?\
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M=?$?P-\,M,M-9\>^)=-\+Z7?7RZ9:7NIO(D,]^]O<72VL9BCE8RM;VMQ* 5
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M[:U/_GY_\@V__P :K+HK+V=/_GW#_P !C_D>O=]W][-3^VM3_P"?G_R#;_\
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MK&RC#!NOBZ%%8N<E%QAAG4J1]O*2E%QC2YVU*+2::O[7_;6I_P#/S_Y!M_\
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M9"E&O/"0Q%*6)A0FTH5IT%-U8TI.45&HX*$G)6D[HZW^VM3_ .?G_P @V_\
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M<5.-&A6K2C0=1JE1JU&E"G-KTK^VM3_Y^?\ R#;_ /QJC^VM3_Y^?_(-O_\
M&JYC6=:T;P[IEYK7B#5M-T+1M/C$U_JVL7UKIFF64)=(A+=WU[+#:VT9DD2,
M/-*BF1T0$LR@^:^$?CW\&?'NMR>&_"'Q*\)Z[KJR2Q1:5::I$MY>M#')-,=*
MBN/).L1Q0Q2323:6;R)(4:5G$8W4+#J493C0YHQ^*2IWC'_%)1LOFPQ&:Y=A
M,3AL%BLRP6&QF,:6$PF(QE"CB<4VW%+#4*E2-6NW).*5*$FVFMT>X_VUJ?\
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M:H_MK4_^?G_R#;__ !JLNBI]G3_Y]P_\!C_D=%WW?WLU/[:U/_GY_P#(-O\
M_&J/[:U/_GY_\@V__P :K+HH]G3_ .?</_ 8_P"07?=_>S4_MK4_^?G_ ,@V
M_P#\:H_MK4_^?G_R#;__ !JLNBCV=/\ Y]P_\!C_ )!=]W][-3^VM3_Y^?\
MR#;_ /QJC^VM3_Y^?_(-O_\ &JRZ*/9T_P#GW#_P&/\ D%WW?WLU/[:U/_GY
M_P#(-O\ _&J/[:U/_GY_\@V__P :K+HH]G3_ .?</_ 8_P"07?=_>S4_MK4_
M^?G_ ,@V_P#\:H_MK4_^?G_R#;__ !JLNBCV=/\ Y]P_\!C_ )!=]W][-3^V
MM3_Y^?\ R#;_ /QJC^VM3_Y^?_(-O_\ &JRZ*/9T_P#GW#_P&/\ D%WW?WLU
M/[:U/_GY_P#(-O\ _&J/[:U/_GY_\@V__P :K+HH]G3_ .?</_ 8_P"07?=_
M>S4_MK4_^?G_ ,@V_P#\:JS9ZMJ$MW;Q27&Y))HT=?*@&59@",K&",CN"#Z&
ML*KFG_\ ']:?]?$7_H8J94Z:C*T(?"_LQ[/R&F[K5[KJ^YZ)1117F&P4444
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MMZ3X6MOV:M/E'Q%B\5VENS^%]&\7Z5;7&E/:W@$<<&KVMJ+W56ULZ2NE2:9
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MA+I7BJR=8EEFBOO!^B6/B: 6^X;HY+H:6]A(\1$C6UW/$-RRLC:_['7Q"O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7F+_?;_ 'F_F:].KS%_OM_O-_,UUX3>?I'\V9U.GS_0;1117:9A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5[JTM;ZWFL[ZVM[RTN(VB
MN+6ZACN+>>)QAXYH)E>*6-@2&1U96!P015BBC;832DG&23BTTTTFFFK--/1I
MK1IZ-%>UM+6QMH;.RMK>SM+:-8K>UM88[>V@B082*&"%4BBC4<*B*JJ. !5B
MBB@$E%*,4HQBDHQ22225DDEHDEHDM$@Z]:H6.E:7I?VG^S--L-.^V7#W=Y]A
ML[>T^U74G^LN;G[/''Y]P_\ '-+OD;^)C5^BB[UUWW\_43A!RC-QBY0OR2<4
MY1YE:7*VKQYDDG9JZT84C*KJR.JNC*596 965AAE93D%2"00000<'BEHH**5
MAING:5;+9Z7866FVBO)(MK86L%G;*\K%Y76"WCCB#R.2\C!078EF)))J[111
MON3&,81C"$8PA%*,8Q2C&,5HE&*2226B25D%%%%!11U#3--U>V:RU73['4[-
MV1GM-0M(+VV=HV#QLT%S'+$S(ZAT)0E6 8$$ U<1$C54151$541$4*J(H 55
M4 !54 !5     &*=11=VM?35VZ7=KOYV5_1$J$%)S48J<DHRFHKF<8MN,7*U
MVHN4FDW9.3:W93N-.T^[N+2[NK"RN;JP=Y+&YN+6":XLY)$,;O:321M);N\;
M,CM"R,R,5)*DBKE%%'Z; HQBY.,8IS:E-I).4DE%.32O)J*44W=V26R11NM,
MTV]GM;F\T^QN[FQ=I+*XNK2WN)[.1U*.]K++&\EN[HQ1FB9&925)()%7J**+
MOOMMY HQBY2C&*<VG-I).3244Y-*\FHI13=VDDMD@JE;:;IUG<7=U:6%E:W5
M^ZRWUS;6L$%Q>R*H19+N:*-9+AU0!5>9G8* H(  J[11^NX.,9.+E&+<&W!M
M)N+:<6XMJ\6TVFU9M-K9A5.^T[3]3A%MJ5C9ZC;B2.86]]:P7<(FA8/%*(KA
M)$$D3@/&X7<C ,I! -7**-M@E&,XN,XQE&2M*,DI1:>Z:=TT^S0@ 4!5 "@
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M6-GJ-N)(YA;WUK!=PB:%@\4HBN$D021. \;A=R, RD$ U; "@*H 4
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1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>nt10016217x4_graphic12x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic12x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M>U)+K0=;MWM-36VF6;2=0C*!K28)_-O#\7OA5^SQ_P '+'[3/C?X\?$?P/\
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MB&[@2>(2*K.JR!)%#JKL V0&8#)XSXK_ !&T3X._"WXE?%SQ-:ZK?>&_A9X
M\9?$;Q!9:%!:76N7FB>"/#NH^)M6M=&MM0OM,L+C5;BPTRXATZ"]U+3K26[>
M&.YOK2%GN(U&,I248IN4FHI+=R;LEZMZ%2G"$)5)2480BYRD]E"*<G)^22;?
MD=_17S/^QY^U5\/?VVOV<OAU^T[\*M&\9^'_  %\3?\ A+O[!TCX@Z=H>E>+
M[3_A#/'7B?X?:I_:]AX<\1>*]&@\_6?"FHW5A]CU^_\ -TR:RFN/LMW)/96W
M,^'OVRO!OB/]LCQU^Q5;?"WXY6/C7P#\/[/XB:A\5M4\$:5;? ?6=.O+'P;?
MIHGASQS'XHGU;4/$T4?C6RAGTV?PK9P)<:5KL8OG6QA>[V>&KJI7I.G)5,,J
MCKQ=DZ2I35.IS:_8FU%I7=]KG,L?@Y4<'B(UX.CF#H+!U%S..(>)INM0Y+*_
M[RDG.+DDK+5IZ'U]1116!UGF?C[X+?!SXJZMX)U[XH?";X9_$C7?AIK7_"1_
M#G6O'W@/PMXPU;P!XA^TZ;>_V]X)U'Q#I6HWGA76OMFC:/=_VIH4UA??:=*T
MV?S_ #;&U>(LO@M\'--^*&K_ !OT[X3?#/3_ (T^(-%B\.:]\7K+P'X6M?BA
MK?AZ&'2[>'0=7\?P:5'XKU+188-$T6"+2[W5IK&.'2-+C2 )I]HL7IE%6JE1
M+E52:CRRCRJ4DN63YI1M>W+*23DMFU=ILR="@Y.;HTG-SA4<W3@Y.I3BX0J.
M35^>$&XPE?FC%N*:3L>3>$_@)\"_ 4OQ%G\#?!?X3>"Y_B_>W6I?%J;PG\.?
M!_AV7XHZC?-JSWM_\19-'T:S?QM>WCZ]KCW5UXE;4Y[AM9U9II'.HWAF\)\/
M?\$Y?V _"UGK6FZ+^Q?^S%#IOB#Q'I?BW5-,O/@E\/=7TR3Q'H=MJ=GH>J6F
MG:QH%_9:9/HEKK>MP:,FEP6<&DQZUK T^*V_M2^^T;C_ +8'@)_VUT_89L/#
MOBS4_B3;_L\M^TCKWBNSCT(^!?#/@YO&S> [71M8NI=:CUY/%%[JLEC=V]A;
MZ%/:?V5J=G>O?(K2I%^7OQ6_X.,OV&/A]XJ\;Z1X*\"?M,_M!^"_AK<6MMXY
M^,OP0^&GAS6OA-H\UY<+IT"0^)_%WC[P7+<POK<L&D6^K7.GZ?X=UF>>*?PS
MK>O6T]K+<>AA\+FM:3CAX8J<JE.E6ER3DE*G)\M"4Y<R7O.-J49/F=O<32/$
MQN8<-82$)XZKEM.-&OB<-25:E3E*%:"4\9"C#V<I^XIJ6)E3CR1YU[62<M?U
M>^-G[&G[)_[2/B/PWXP^/?[.WP?^+OBKPC##::!XB\>^!- \0ZS9Z9;3WUW!
MH<VH7]E+<ZCX<BO=3U"_3PUJ<EYH"ZA>7%^-.^V2M.?0O"'P)^"'P^NOB%?>
M O@W\*O!%[\7-1N-7^*UYX0^'GA'PU=?$[5KR359KO4_B%<:-H]E-XTU&ZFU
MW6Y;B]\2/J5S/)K.JO+*S:C=F;X)^,G_  6!_8^^$7[&?@#]NZQN_B%\6_@3
M\1_'=A\.-#?X6^&M'E\96/BNZMO%<U[8>(/#7Q"\3_#TZ,^B7'@W6+#58KF^
M^UF=].O-,M=2T?4+?5&_3[3;Z'5-.L-3MUD2#4;*UOH$F"K,L-W!'<1K*J/(
MBR*DBAPDCJ&!"NPPQYZL,;1I05?ZQ3I*=6C"%24XQC.C*$JU-4Y/W73G*#G'
ME5I-/=';A:F48G$U9X/ZE6Q/LL-BZM:A"E*I.CBZ=186NZT8WJ0KTH553FIR
MYJ:DD^5V?RI\*_V!OV*/@=\1I?BY\(/V6/@7\./B2S736?C#PC\.?#>CZOH7
MV_3KG2-17PI):V*1>#TU+2KV]TW4X_"L6CQZC8WEW:WJSP74Z23:Q^P=^Q5X
M@^*Z_'/6_P!E3X ZK\7!JEQKTOCZ^^%G@^XU^]\1W-S;WC^)]3GDTDQ:KXJC
MO+6&[M/$^I0W>OV-R'GLM1MY9IGD^LJ*S>*Q+DYO$5W-P]FYNK4YG3_Y]N7-
M=P_N7Y?(W679>J<:2P.#5*-7VT::PU%4XUG:]:,%#E571?O$N?1:Z(^>OC_^
MR;^S1^U1I>DZ1^T5\#OAM\8+;P^]R_AZX\;>%].U75_#IO9;.;4$\.Z^T2:[
MH,.IOI]A_:T&DZC9PZK'9VT6HQW,4,:+V/P<^!OP<_9Y\%6WPY^!GPQ\$?";
MP-:W<VHKX8\!^'=,\-Z7/JMS!:VUWK&H0Z;;P-JFMWMO96<-]K.I/=ZI>QVE
MLMW=S""+;ZI14.M6=-475J.C%\RI.<G34OYE"_*GYI7-5A<-&O+%1P]!8J<5
M">)5&FJ\H*R4)5E'VDHI))1<FE9::!117Q1^S)^WA\(?VK?C7^UO\"/AWX<^
M)&C>+OV,_'^D?#GXH:CXTTCPQIWAO7M;UK6/B%HEK=> KS0_&'B+4]4TJ.[^
M&VNR7$_B'1_"UVEO=Z2\=C+)/>16!"E4J0JU(0<H4(QG5DMJ<9SC3BY>4JDX
MQ7FT%7$X>C6PU"K5C"MBYU*>&IR;YJTZ5*=>I&&EFX4:<ZCNU[L6S[7HKY!_
M::_;*\&_LN>-_P!GCP)XH^%OQR^(5_\ M'_$#_A7?AO5_A'X(TKQ9X>\#:C_
M &OX2T?^V_BAJ&H^*/#TWAGPSYWC"SNO[2L+/79_L.F:W-]AWV445U]?42I5
M(0IU)1:A64G3D[6FH2<)-:WTDFG=+78=/$4:M6O0IU%*KAG3C7@D[TW5IJK3
M3;23YJ<E)<K=D];/0****S-@HHHH **** "BBB@ HHHH **** "BBB@#G?&'
MBS0? ?A+Q3XY\57Z:5X7\&>'-;\6>)-4E1WCTW0?#NF76L:Q?R)$KR.EGI]G
M<7#I&C.RQD(K,0#_ )YO[4?[2/Q _:N^-7C#XS?$/4+F:^U^^F@\.Z&]P)].
M\%>#;6YN6\.>#-$1(;:"+3=#LYRDD\=M!/J^J3:EX@U/[1K.KZC=W']X?[9'
MA[6O%G[)'[3OAGPY;7U]K^N? 'XNZ9HVG:9#)<:AJVI77@+7HK31[.WA=))[
MC6)BFF1PH6,C7>SRY0QB?_.XK^B_ G+\'*GGN:2C">/IU<-@J<I).=#"SA.M
M/V>EXK$U(Q4W?WOJT$K6ES?P?],W.\UA7X,X>A5JTLFKX?,<VKTX.4:6-S"E
M6HX6C[97Y:CP%"4Y48V7(\?4E+F<J?)^SGP5_P""2.C^,?AG\$/%OQP_:O\
M ?P \=_M-VT5[\!?A?J7A>/Q3J_B^RU&QT_5- EO-0;QIX9CM+[7+'4M,:/2
M[&RU(V,OB+PSI]S?-XHU-?"H_,#X]?!'QU^SA\7_ !U\$OB5;V%OXS\ :M'I
MFJMI-VU_I%_!>6%GK.C:UI%W+!:7,VDZ]H6I:9K>F&]LK#45L=0MTU'3M/OU
MN+*#]@?V&?V8;CX+_"OPC_P46_:=T[XB^+O#_P /+N*[_97^ 6B:?J6NZ_X^
M\23)=7/A+Q/Y &HR^%O"D&KQ7/B3PZJ6%DMS_8R>.IWN= BTC3?&/Y,_M._%
M7XD_&_X]?$KXK_%S2;G0/'WC77(M5U;0+K3+K2'T"P32]/LO#.A0V%_#!?1V
M6C^%K31=-TZ>]1KR]T^UMKZZFN9[B2XE_2.'<QS;%\0YQAYYQ2SC*<)3K4JM
M2&#PN$I83-XXV\<!ESI7Q&)P^#P$X4\PK8FKB4L:Z<:5>,W7I0_ ..\BX8RO
M@7A7&T>%<5PMQ-F=?"8C#4:N:YAFF)S/AB64+VF=9\L3RX'+\;FN=0J8C(\)
ME^&R^4LHC7J8C"2IK!XFM_5+_P $0_VO/$OQ[^!OBCX.?$76I-<\;_ 2?P_8
M:%JM\\?]I:M\+]:LI[3PS;W4A;S]3O?"E_HFIZ-=:DR[QI-UX7AO&EO3+=W?
M[=U_*+_P;R>%]<N?C-^T)XTA>\3PUHOPQ\.>%]1C7(L)]<\3>*DU;1GES<H'
MO+2P\):\MOMM+@Q0WMSNN;/S4BOOZNJ_FKQ.R_!Y;QKG&'P,84Z,Y8;%2H4T
MHPH5\7A:.(KP44DHJ=2I*LHQ248U5%))6/\ 0+Z.^>9MQ!X1\+8W.)UJ^*HQ
MS#+:6+KRE.KC,'EN8XK!82K*<FY3E2H48X2523<JD\-*<FY2;91117P)^VA1
M7\]5C_P<C_L@ZGHOC#Q;IO[,W[?&I^ OA]JZZ)XY^(^E?!'X=:OX!\(7\MT+
M.TC\2>)]*^-M[8:*;^=X4L(M1:WN;LSP"*W9I%6OV'_98_:S^ 7[:/PHL_C1
M^SGX\M?'W@6XU2Z\/W]RNGZIHVK>'O%&G6FGWVJ>%_$FAZU9V&J:/KFG6NJZ
M=<RV]Q;>1=6-_8:IIES?Z3J%A?W/;B,NQV$A[3$86K2I\W(YRC>"FTI*,I1;
M49.+349--K5)H\C Y]D^9U?88',<-B*WLW55*$[5)TE)QE4IPFHRJ4XR3C*=
M-2C&6DFGH?1U%>%_M+?'O0/V8/@?X\^.WBCP;\1?B!H7P_M-(O-0\'_"7P]9
M>*_B'K2:SXBT?PU#%X;\/ZAK/A^SU&>UN=9AO[Y)]8LA!I5K?72-+) D$O5?
M!OXGZ9\:_A-\-_B]HOA_Q;X4TCXF>"O#GCC3/#/CS2K?0O&N@6/B;2K;5K72
M/%>C6FH:K:Z5X@L(;I+;5;"WU._AM;R.6&.[N%02-S>RJ>R5;E?LG4=)3TM[
M114W'>]U%I[6UW/1^L47B'A/:+ZPJ,<0Z5GS*C*<J<:E[<MG.,HVO>ZVMJ>E
M4445F;!1110 45_/1XR_X.1?V2_A]?0V'C+]E?\ X*">')+S6)]"TJ;6O@=\
M--(MM<U."8P_9=%DU7XZ63:E-,VUX(+9&N)(Y(V\D%P*_23]AS_@H%\/_P!O
M&Q^)%_X#^"_[2/P>C^&5WX6L]3A_:(^'.B?#ZYU]_%D.OS6DOA2/1O&?C!=5
M@TU?#UPFLO</8&SDO=-6);D7+F#OKY7F&&HNO7PM2G15KU)./+K)16TFW[TD
MM%HWJ>+A.(<EQ^)6#PF84:^*ES6HP53G]V$JDK\T$E:$92U:ND[7/O.BOB']
MN/\ X*$_LU?\$]_ 6B^-_P!H+Q%K27_C"[O].^'?PY\%:,/$?Q&^(^I:0VF?
MVQ9^$]%GO-*TL)I$6L:;+J>J^(==T#0;)K_3[*;55U+5-*L;[Y2_9*_X+=_L
ME?M7?':U_9G?PC\>?V>OC=K-O'<>$?!7[1'P_P!,\&R^-'GT>]\2P:?H=YH/
MBGQ9'8:I+X7M(M=M;7Q9'X9BUJWOK*V\+77B&[N(X7BGE^-JX>6*IX6M/#P4
MY2JQ@W'EIM*I-+XI0IMVG.*<8._,U9VUK9WE&'QU/+:^886ECJDJ4(X:51*I
M[2NKT*<OLTZM9:T:=249U4XNG&7-&_[%T45\-_$_]O\ ^#GPG_;8^!'[!WB+
MPU\3+WXO?M"^#=3\<>"_$>BZ-X6N?AOIFDZ5;^/;BXM_%&KWWC/3O$]EJ+I\
M.M;$,.D^#];MF>ZTL/=QB>[:QPI4:M>4HTH2J2A3J59*.\:=*+G4F_*,4V_)
M';B,5A\)&G/$U848U:]'#4Y3;2G7Q%2-*A25D_>J5)1A'I=ZM(^Y**^&_P!F
MC]O_ .#G[5/Q[_:M_9U^'OAKXF:-XV_8^\96_@?XEZIXST;PMI_A;7-6N=?\
M8>'([CP+>Z)XS\1:MJ>G"^\$ZK*\VOZ)X9N1:W&GNMHTTMS!:>5?MP?\%3_A
M-^P=X]\/^ ?B)\ _VL?BE<>(/ B?$$>)_@/\+/#7C?P=HNDMK.NZ+)8:_K6N
M?$/P>^G:S;/H%UJ%U:_8YK:'2[JQNVO<S210[1P.+G76&C0FZ[A&HJ7NJ3A.
MG&K&6K2M*G*,EK>S1RSS?+:>#>83Q=)8*-6=%XCWG!5:=:>'J0?+%RO"M3G3
MEI92B[NRN?IS17X7?LZ_\%^/V9/VG_B+\-?AY\-/V:OVY"GQ0\=Z%\/M)\?:
MO\'/A_\ \*VT/5M=U:UT=;_Q1XIT#XR>(!INC:3/=QSZW=6UEJ%S86J22BRF
M=5B;]T:G%8/$X.:IXJC*C.2;49VNTG9[-VLU:SU+R_-,OS6E*MEV*IXJE"2C
M*=/FY5)Q4DKRC&]XM.ZNO.X445^6/BO_ (*T?!+2_P!M5OV%OA]\&?VF_CQ\
M4M"U_P '>'?B9XJ^"OPRTWQ9\-_A#=^--0TG3H=0^(?B"[\6:/?:-X;\)G6]
M.OO'_BK^QY/#?A:QEN(SJE_K&FZKI%A-##5\2YJA3E4]E3E5J-62A3BTG.<F
MU&*NTM6KMI*[=C3%X_!X"-&6+KPH+$5H8>@I7<JM>:E*-*G&*E*4G&$I62=H
MQE)V2;/U.HK\0/$7_!>']G*T^(WQG\$_#K]FW]MWX_\ AGX"Z]J?A/XA_%[X
M%?!#1?&GPPT[Q-I4UQ:36 UV^^(&@SVEI>:I9W>B:'J.N66CQ^(]7@4:!#J>
MDWFGZO=_KK\&_B?IGQK^$WPW^+VB^'_%OA32/B9X*\.>.-,\,^/-*M]"\:Z!
M8^)M*MM6M=(\5Z-::AJMKI7B"PANDMM5L+?4[^&UO(Y88[NX5!(UU\#B\+"$
M\10G2C.RCS\J=Y04TG&[E%N#4K22:3U1C@\VRW,*E2E@L72Q,Z7,YJES.*4*
MCI2E&;BH3BJB<.:$I1;3LW9GI5%?.G[6G[3?@+]C;]GGXD?M*_$[2/%VN^!?
MA=9:'?\ B#2? =AHVJ>+;R'7_%.A>$;-='L/$&O^%]'N)(M2\06<]R+W7M/5
M+&*ZEB>:=(K:;O\ X*_%7P]\=O@W\)?C?X1L]9T[PI\9/AGX#^*OAC3_ !';
MV-GXAL/#WQ#\+:5XNT6SUZTTS4=8TVUUFUTW6+:#5+?3]6U2Q@ODGBM-1O8%
MCN9<?8U515?DE[%U)454^RZL8QG*%_YE"49/R:.I8G#O$RP:JQ^M1H1Q,J%W
MSK#SJ3I1JM6MRRJ0G!.][Q>AZ917R#\ ?VRO!O[0WQG_ &D/@EX>^%OQR\$Z
MW^S-XJ@\)>)O%GQ,\$:5X;\ ^/KN?6O%&AKJ7PIUZQ\4:W=^*=&2?PI=W<EY
MJ&DZ!*MAJ.CSBV9[N6&V^OJ*M*I1GR58N$^6$N5VORSBIP>C?Q1DI+K9ZCP^
M(HXJG[;#U%5IN=2GSQ32YZ-25*I&TDG>%2$HO3=.UU9A11169L%%%% !1110
M 4444 %%%% !7Q!_P44_:8U+]D[]DOXE_%;PU/:0>/9(M-\&_#EKQ;:5(O&?
MBV\73;358[6\MKRSOY_"^EG5_%\>FWMK<66I?\(^;&\C-K<3$?;]?B1_P7Q\
M,:WKO[%7AK6-+AN)]/\ !?QY\$^(/$@C"&"TTF^\*^/O"5MJ%R2AD 37_$NB
MZ=%MD6,R:H/,1V$31_2<'8'"YEQ3D.!QRA+"8C,\+"O3G9PK0513^KS3WCB'
M%4&MVJEEJT? >*F<9ED'AQQKG&3RJ0S/ \/9C5P=>C=5<)5E1E3^O4FOAG@8
M3EC(R:<8RH*4DXIH_D<\.Z'XY^-OQ/T3P[83WWBWXD_%CQSI^D6MUK&I--J/
MB+QGXWUV*TCN]7UG4IB7N=3UG4A/J.JZA<8#S37EY.%$L@_7+X@?\$<V\-^
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M?\+V_M;[%Y?S_:OLGD;/F\S'-?M=^S3\>] _:?\ @?X#^.WA?P;\1?A_H7Q
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MR^-/C_X@^+OV8/VD_P!E7Q;^TU\#/"'BSQMXGU[1O#GQ+^&7AGQ#XPU?X?\
MA27QC?SZ1X'G\4:]X2^*^C:9X2\.16UJC>,/A+HWV)(X]*M8?R;_ &I/@?\
M''Q7_P $*_!W[8_[2WQY_:#\6_%;XM_M&3?%73_!GB;XC>([OP'/\//B?JUC
MX?\ !EAKG@S7GU.QETVQL_"%Y\2_AHWAR;0=/TBQ^)DZ-;7T"V4-E^C_ /P6
MJ^$7Q8_X*7?M9?LY_L8_"S]DC]H+1;SX/?$N\M_&'[8?B7P5J>E_ C3/AC\1
MO"_@[7?&5[X=\4&(^'/$.GZ3;Z3#<R2ZKK&E:M/XO\(3>!O"6E:SK/B,Q/\
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M?4-6TWP[9>%'^BOVN?VA/^"A?C_PG_P06T#XE?$GXV_LG?M,?'CXR?&'X/\
MQHFTJTU?X7ZEJ>J1?'#]G[X9^"_'WC'X9QQZ7X<UR>Y\*ZS;^-(=(U?PV?#/
M]H>(=871=&LM%U%+5OUZ^.__  0I^ /Q>^,_QD^+O@O]H/\ :I_9VL?VF+^Y
MN?VE?AE\$/B-IOAKX?\ Q?MM334)O$5MK&EW7AV^D?\ X2C5]4U#6-<MO$$O
MBK0);K5]?2R\/V*:S.8_HGQ]_P $FOV5O&]U^P*=/?XA?#G1?^"<GBBU\6_
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M/=P& Q&'SK/L=44%0S#^R_JS4DY/ZIA)T:W/'>%IR7+?XEJ?RU?M_3Z-;_\
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M[CPC+J7Q3\8MX-NHO%FK^'XM;?7O"]Y'I.EC2O$NFZ3JC0W*V9MI?V$^%?\
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MGQ!CU)OA;'9_#ZQGT22 ?$G7#8GQ;<^-UB-II/VA+D07@O\ F/\ AT?^S?\
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M&;<J=.,;2?O-V5BBBBO+/H0HHHH **** "BBB@ HHHH **** /YZ_C3\7/\
M@XPTWXQ_%G3O@A^RY^R9X@^"VG_$SQY9?"'7O$?B#PQ#XAUOX7VOBG58/ &K
MZ]#<?M%:)/%K6I>%(])O=4BGT72)H[Z:=)-+T]PUI%YG_P +I_X.@/\ HT7]
MC/\ \*7PG_\ 1/5_3!17KQS6$8QC_9642Y4ES2PU9RE9)7DUB4FW:[:23;>B
MN?-5.'*LZDYKB3B6"G.4^2GCL(H0YG?D@GE\FH1VBG)M+1MO4_F?_P"%T_\
M!T!_T:+^QG_X4OA/_P"B>H_X73_P= ?]&B_L9_\ A2^$_P#Z)ZOZ8**?]KP_
MZ%&3_P#A-7\O^HKR_%]R/]6:O_13<4?^%^#\O^I=Y?B^Y_,__P +I_X.@/\
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M_P#PI?"?_P!$]1_PNG_@Z _Z-%_8S_\ "E\)_P#T3U?TP44?VO#_ *%&3_\
MA-7\O^HKR_%]P_U9J_\ 13<4?^%^#\O^I=Y?B^Y_,_\ \+I_X.@/^C1?V,__
M  I?"?\ ]$]1_P +I_X.@/\ HT7]C/\ \*7PG_\ 1/5_3!11_:\/^A1D_P#X
M35_+_J*\OQ?</]6:O_13<4?^%^#\O^I=Y?B^Y_,__P +I_X.@/\ HT7]C/\
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MR_%]P_U9J_\ 13<4?^%^#\O^I=Y?B^Y_,_\ \+I_X.@/^C1?V,__  I?"?\
M]$]1_P +I_X.@/\ HT7]C/\ \*7PG_\ 1/5_3!11_:\/^A1D_P#X35_+_J*\
MOQ?</]6:O_13<4?^%^#\O^I=Y?B^Y_,__P +I_X.@/\ HT7]C/\ \*7PG_\
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MAP:-=R>$],UV>YU?0+>+2KW6ELX+Z2;7-)B2W>1GU"T4&9/Y^/\ A=/_  =
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MU?R_ZBO+\7W#_5FK_P!%-Q1_X7X/R_ZEWE^+[G\S_P#PNG_@Z _Z-%_8S_\
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M6:O_ $4W%'_A?@_+_J7>7XON?S/_ /"Z?^#H#_HT7]C/_P *7PG_ /1/4?\
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MZ _Z-%_8S_\ "E\)_P#T3U?TP44?VO#_ *%&3_\ A-7\O^HKR_%]P_U9J_\
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M_P!&B_L9_P#A2^$__HGJ/^%T_P#!T!_T:+^QG_X4OA/_ .B>K^F"BC^UX?\
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M:+^QG_X4OA/_ .B>K^F"BC^UX?\ 0HR?_P )J_E_U%>7XON'^K-7_HIN*/\
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MX?\ 0HR?_P )J_E_U%>7XON'^K-7_HIN*/\ POP?E_U+O+\7W/YG_P#A=/\
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MIHFC_'+_ (*N?\$K_P!FCXLZ5HGB;X Q>$/VO?C_ *S\,O'.EZ+XC^'OQ?\
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M0_9Z_P"R"_%G_P!.=E7WI0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5\!_M&?\%'_@#^S+\1Y?A;XTTOXC^)?$]GH>EZUJO_" :!H.N:?HK:P+B:RT
M?5I]1\5:'<6FN/IL=GK+61M'C&D:QI%VMP_VLQQ>#G_@M#^RS_T(O[01^G@;
MPC_7XB"@#]=**_(K_A]%^RS_ -"'^T'_ .$-X0_^>+1_P^B_99_Z$/\ :#_\
M(;PA_P#/%I77?^M/\T!^NM%?D5_P^B_99_Z$/]H/_P (;PA_\\6C_A]%^RS_
M -"'^T'_ .$-X0_^>+1==_ZT_P T!^NM%?D5_P /HOV6?^A#_:#_ /"&\(?_
M #Q:/^'T7[+/_0A_M!_^$-X0_P#GBT77?^M/\T!^NM%?D5_P^B_99_Z$/]H/
M_P (;PA_\\6C_A]%^RS_ -"'^T'_ .$-X0_^>+1==_ZT_P T!^NM%?D5_P /
MHOV6?^A#_:#_ /"&\(?_ #Q:/^'T7[+/_0A_M!_^$-X0_P#GBT77?^M/\T!^
MNM%?D5_P^B_99_Z$/]H/_P (;PA_\\6C_A]%^RS_ -"'^T'_ .$-X0_^>+1=
M=_ZT_P T!^NM%?D5_P /HOV6?^A#_:#_ /"&\(?_ #Q:/^'T7[+/_0A_M!_^
M$-X0_P#GBT77?^M/\T!^NM%?D5_P^B_99_Z$/]H/_P (;PA_\\6C_A]%^RS_
M -")^T'_ .$-X0_I\1:+KO\ UI_F@/UUHK\H=!_X+%?LNZ_KFC:%!X/^.UE-
MK6JZ=I,-YJ'@CPS'8VLNI7<-G'<WKVWCN[N4M('F$MRT%K<3+"KF*":0+&WZ
M):#\3(?$VBZ5XBT/P=XTO]&UO3[75-+O5M-!A6[L+V%+BUN%AN?$,-Q&LL,B
M.$FACE4-AT5L@=-/"XBK2=:%-^Q514G5E*,*?M7'F5/GG*,7/E][E3;Y=;6U
M.*MF."P^(CA*M=+%2HO$1P\(5*M9T%45)UG3I0G-4O:-4^=I1YWRWN>F45Q/
M_"87_P#T(7C;_OQX:_\ FFH_X3"__P"A"\;?]^/#7_S34_JM;M2_\**'_P M
M\_S[,7]HX7O7_P#"/&>7_3CS1VU%<3_PF%__ -"%XV_[\>&O_FFH_P"$PO\
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M0_\ EOG^?9A_:.%[U_\ PCQGE_TX\T=M17$_\)A?_P#0A>-O^_'AK_YIJ/\
MA,+_ /Z$+QM_WX\-?_--1]5K=J7_ (44/_EOG^?9A_:.%[U__"/&>7_3CS1V
MU%<3_P )A?\ _0A>-O\ OQX:_P#FFH_X3"__ .A"\;?]^/#7_P TU'U6MVI?
M^%%#_P"6^?Y]F']HX7O7_P#"/&>7_3CS1VU%<3_PF%__ -"%XV_[\>&O_FFH
M_P"$PO\ _H0O&W_?CPU_\TU'U6MVI?\ A10_^6^?Y]F']HX7O7_\(\9Y?]./
M-';45Q/_  F%_P#]"%XV_P"_'AK_ .::L1OBQHEMXS\)^ M7T;Q+H7B'QLFN
M2>'(=3L;!K:]3P[ILFJZJSW6G:IJ"6WV>TC!43B,RR21I&&RQ6HX+$SYO9TU
M4<*=6M*-.I2J25*C3E6K5'"$Y2Y*5*$ZE225H0A*4K*+:SJ9OE]+V;K5W0C5
MKX?#4YUZ.(H0GB,77I8;"T54JTH0]IB,16I4*,').I5J0IQ3E)(]1HHHKD/2
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\]OVFO^3UO^">'_85_:4_
M]5[X5K]":_/;]IK_ )/6_P"">'_85_:4_P#5>^%: /T)HHHH **** "BBB@
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M$&O;R#_?<5_V).(O_5#F)\EQI_R*LO\ ^RMX%_\ 6SR$^KZ***\0^M"BBB@
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M;695W;' ]NU#0-+U_P#X*"?MA6^HZN-%>/0?@G]EO7G^SPQM)\+O#(D=Y"R
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M: "BBB@ HHHH **** /@OX@_\I$/V>O^R"_%G_TYV5?>E?!?Q!_Y2(?L]?\
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M/QK\&E7]S9O*(+:WCCUVRU3^QK6UCFANKD7"0(\DKJ*^,S9>"OA!XD^))O\
MQYI7_"T?$L"I)I&@ZKX<U"[U/5+::33WO4T()>I$T<=G$KV<UE]HE,.0/WJ
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M\*T ?H31110 4444 %%%% !1110 4444 ?F'_P %1_V[_$/[#7PE\%:M\/\
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M.EB\'7Y8JMAJU*HHKFLBBBBOH3YL**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\4/$UL8_VY/VW?$#Z
ME!IT'AOPO\$]0E$EC;WDM\Q^%6@>78QFYM[A8DN?*=)A&$DE!0*XVUZ=\5/$
M>I?#?X=V^H_#'2?#7V73(=/MB[--#?3W=U+)/<Z?H-N+R)X=0=9HS'YL,MN9
M9H]T;+E:\T\73^%X?VR/V]_^$LCU:XTQ?!_P1N1::1'(;BXFM?A/I#H%E2)T
MBF0MNMQ.1#(^0ZR*I \^U7XAQ:;"9=6\%:HUIK/B.VCL-#LM:TZ76;?2BEI'
M_:SPZA<W-M9':7-\DL$=Y:Q01S(ML)(Y#U0K5K4Z5U"A&$Y.HE>2FYR?*^FN
MCU=[;(WITJ<Z;G)M\LU%T[)*2=M.:]U>[OH[:/U]XM_ASI/C2+4KCX@>*+_2
MM'\676DZ[I'A'Q3=6\5[:ZQ,D$$5AHDLL4(E4W5K'-;6DQN;M+F=W3 EC%<M
MX._9T\'?"WQ&TEWXR\3>+Y;*TUJZN/A[JNJ>$]6DUVTU2TE@M[?4[;3=/74;
M:VMG5VAN1+;-$H^:?=&<>_>#+VTUCPOH=[=>&+J6;Q#?V?\ 8=NWV?6-2CCM
M)XP-3@O+@7EM92VS$O\ (T0+0Y52.*VH/!NDV&M7.JVR7-S=W]E?B62[DLXM
M9N[:RBEG&DJ72.Y%H\IF4/"%N2TTJK.(Q$J>A3RW#^V4ZD'*\5)3<FG*Z5_=
MV236UW?6^VD/$5%S4XR]G!*RBE%]5N]WI_GIJ=5X9L-#\,VZ>(/!'A_2M!N[
MRP"R'4'U:^M1:D/'!IEGMOFM8H3=^=%<E%$JAW9I%3!&3JWC;P_XLU338]9M
M-8M[J2(^'KBTT^T6/2[R.\EE@GO%N9[62[E@T\74ER2+QHD2 ^;F-7S4L_&V
MGMI&OQ:8PMID*!-'UJ&2UN=.:U6.66!6F6" 6\X5F2YCRKM(X,K2*PKK-2\(
MV^I>$/#^I?:K/3M4,BW5LLKJ/L\=R_ES"U>V=1<I(GF-(6,P5'8Y4#-=\J.&
MI1<9T'>HU3HS@W*=-M:2<>5\W*VW9[V;NNO)-R;O*;E;=]]K[>ENO8^0_C+X
M;\6>"?%6K6=]I.B7GPPUVTAL=$UZ'6F_M>(36\=O=P1Z;'J@M6D7,LF&TTD!
MP^,8I_PR^+'A[QUX=U[P?:>&[F\T[X>W>F0^&M1U2X;3([K5/,LH7=XY9+3,
M]H\KS+ JK]I2%9%CD24,_KS06?B_7-3^$OQ&T^74_#'B*TN(K+Q#;/\ 9VTK
M4'M6A2.RN@T;6]PZ1QF,@[MTHQR:Q?%'AKP?\+-9A\-^&K/3)-'\.Z?;7M[8
M7UPBWUU<V=JFR\N;A)HWGN%ACBG D=I/,19)T:VR"4<'5CC51J<TZ=*A+$QE
M!<WM$N5J$E?W6E:]KM;-6-%5A.FX)+FLE%IMM:+7UMKI:[.G\">);;Q;)JVG
M7OC<VOB"PO1);W%Y<+IUM):F"/39["U:7R+ -!(TJB&4-<2M&9QO1@S=3>V&
MO:+I?B"2[&G?$/P]I5O/>166L10/=,1;EY8;.ZL#9L(2[21K<*[!",^;E17S
MWH.NZ!XLOFATDW>I>'YS=:C<VXTR")I[DF5KBTLM4M;*%U^RS[Y=TET7D,3;
M)&C*@]GX>N-.TO4G?0M1UK3[:]*VD-AJ%P;ZT@B3;->W5TDXG?R&:*>T*LRJ
M'D4X &:]&O@ZDW&<5RT9^SFZ+@K<EH\T>9)22DG*[2;C=VTLCGA*5/E4[N46
MN:^C>J>^_P!ROI?0]:TBS\)_$'X8:$=*BLO"ESJTDSZ)I6IWJ-/INKV<D[7"
M0".<3:C:PFWN)(0QNF 5#.TB+)FAHFJ:GHTM_H\NHZGJB0Z=)9>7;Z66T2\U
M>,H;BY-['9?9(HI9TE:<"X6."=O*8(R[!Y[H'B-)/%5EX8UG^R1HVMW&I1:?
M>V]U8V[>'M2^UW"VEQ*(Y$GLHM110+=1Y0N/ML2$/YF&T%CU?X>^(M2T'6/&
M-EJ7APS727-E81RW%KI]Y>E]0CGU'4D61K>ZWMB2U^UQHS2/_H_R@+R_5U&5
M6DJBM=5*<*EVXPBUI"6[:T7O6?:[;O;ESMM145IL[ZO6S\][[&SHOAOPWK>I
MVOA_Q986][=P1S7UN+61[F!;_4+>74C8-<:5((D2!9) L,\A!>).I&#PMC:^
M$[:P\1:[]F2.?P?>:K::_'K>F>9';6<=U-+I]YID0MHVO;BU%O;VT887AV.P
M9#(0P[_1;[^Q=1>[2^O?$NKZG%;W&F)X=TP&STG2)'BM9+E)WLWBN[MC/&9C
M++</ 7E11$JE5S/C!J.O>&KGP=X*^'7A"'63XQ\1A_B!KVIV5Q?V6B:!Y-W?
MW>I7$UJRP'4);J*WLVLF+[6NG M%,68^7%5U2BW."K<TJ=*-.+<;WDH/E[N7
M,FFVES/>RN]:=.<K-2=KW796L]W9*UO/6^[.(LM87XI:18^*?"WB34M3\92Z
M%<0:#9V4%[HT!CGN+-C>7FE74-O;026RJBDS6\:Y<@C) KVVS\-75WX:\):7
MXJUR"+Q9X?\ [.E\3ZSIMOI#ZK=*+.19K.]NTM)1$FHRXGN%M3 X>!0K1KE3
MT7@O5/ARNI7EAX-T>?[?;Y29_P"PM4T^"!7Y8O,UM D(C; @@5T6XBS-Y<VS
MS%P/$GA:VUKQGI<%QX7U![BUCDU*X\6Z9K$NF:1>7,(1;/3[RQN[V-YKK;+)
MN8Q&#=%)@ $9IU9<\*$J->A"$8U(<T8.2D[*S=^9*W76[LV1)NG*3G972LMV
M]KKI?RUZ[VL?.GC@:_I7Q,BU;P_H^I,EC?V:6-S%!J5SI\]A<13.UO91V7^K
MFTORH8&?4&E^T+(SQEPK,/2;;79O$-OJNFWR-IMP':VU/Q%>Z5J<"(+IRT=I
M"VJ1M'<+*86,DVDJ(@8U.Y=T>>Z\6^/=!TF#3=-\3WAT676_M%@TMLEK=7FF
MW]H8T\M)K"*6U5G0S!G8-MV[6*NRYYC0[C2)-'\13VS-K=HCR6%I]N-Q9V%G
M;7LRS6LTL-^T&I>?%':LK2NYSN/D$*7!]"+7L*<ZF%DG9<M1R;E)\W*FDXV;
M32LKZV6]Q<WOTW&T>9<R=M$X=;7U5UKT]-GU,5RWAJV\W2])M+6[T[P[J%K?
M3+87+KJ5K;6X"/)J%[YMZD\B;WM()+Q4E43&6*4QJ4_%S6_C/\"KGX+_  _\
M;6?C6UDUU=4\,_"^\NVT747NO#O]I0ZD9=$DU71+6WOK.TD6T)N[MKM+&W\F
M$SR1^9%N_;[QIJT<>GV]GHD5KJ.H7&CZIJ8TZWF\R%X;6S*(ES<2RL%""Y(5
M'F4X)/(!(_F>\&ZE\.=-^$'PV^,NJ^$=!\8:7X4\4ZG\//B=H&C7R75II>F:
MJ]D;#6M0T;2+WS+SQ"JV%\+*Y$$]_&#=;L^9SZW#>%I5<5+$.G6YXJ%-1H58
M1J5)3E*U&I&HI*,:TJ<84WHO:.,;N]C[3@;!T<9CIUJ[J1J8:I"I3G3Y6I2G
M>/*X2]Q<RT5]'+ECN[$7CCX/_LA_##1/A%\6/"?B/PYXB7P[K-M\1M/?PEXR
MN;_Q#JL5C+#<?Z1INMZSJB7M^\JJ(=,BL?[6E82)%$<FOI;X"?!K_A,/"]S\
M<[:37-?B^-;:['#X-U.SM](TB6[FBM$N(_%>GRV5C?:?*$N(%E^W2VD[1DO&
M5!+5\^_MT:KX;F\+> Y?!?P-T/PE\'O ]U<7&A^-)=.N9DMM2\/)9RV>BZE8
M>%9HM9M(=3^V'%_KD"Z=:-;G^T)X_,0GZG^"'Q.\&PZ?J7[('QP\0>)X-1\,
M?#GPGXWM?B#H>EZA:>&[>^U?^VO[8^QZWX?T^&*VU:T@L-.-R==O9;253;K'
M#NCN-WUF,Q68++\/64ZM3$U)N%6E74<5C%A%5O4A'V7-!2H5)0E4CSPDE:,;
MM)O[[.)YKBN&%BLNK5*U3$5,3*M4]NY8FG1PU>#]BJ$8^SC"4IPY[232Y=.W
MM'C3X3?"?]FCX.>#?B7?:'XB\4R:#HIMF\&6>NZC>Z;J.L:E++]BM;WQ5K%U
M?Z7HN@2RQ/#JU[K.HPV5G:"-Y+BWB4L>W^(/Q(\7:YJ'@OX0^ -(U:QU?Q98
MS_$1M9\(0+K7@EH]"M+:]/A'7/%-C#?Z5I45XL)M9H9-6L;JZ65OL,JLRM7Q
MM^S)\6? ?B2[U/P[X@U;QVV@:Q\49?!5M\//$6H:1XTFM+[6&L+*."?2=/MM
M0U&'PC;J89X]1U%#%:M<7K7M^8@GE^O?MG^)?CS\%_!_PRU3]G'QLNK>(?"-
M^&UWP38Z3X=MEU'3]3N(8Q?>++.73(-6M]&,-L]M$UM+8D)!=LLH8!E\6G@Z
M\L;0PF(]G/,*TZ]6$\;*5/"KFC?"NM",7!.FVFXU+IW7[R$H19\AE^45_P"T
M\'@\9AI8',:V(K.GBLPG[+"57"%.4'*=-5$I.4G=2O%II.2LDOF/_A$?V8+/
MQUXA^$7B[69--\5VFK:9:^/?#RQS^(M T/2?%%V]I>:5J?Q1UF+6;;1CKR+=
MVS:9:>*;&>-2#!%#+(&;V/Q%^U'X.^'OQR^ OPM@B;X>?!+X0>%=6\9:+\25
MU&:ZN[][LZA:CP1-J5[<7FF0-?/HT<5S'JD)U"YT[4[>/3I89'@DJSH7CB2^
M_9WT'XR^.OA_X)^%?Q8^,5Z/"_CR/7-"AN+*:]L;O;9Z[9Q7ZWK7=^B:BLVF
M13R75Q<W,8@TZ.2=62MR+]ECX4^&?AWH'A_QAXQ\4:C=R_$C3?&$U[8^&(/$
M%UXBUA6T6^_X1_4DU30=4LM)\*WMM!9VUM'%!I]RLMQ?D3XV>7Z=26%@E#&Q
MQ591=;#^QIU/:1^MN@\-C<70Y(.GRPYYTZ*J/$2=.=YS;3DOJ)UJ>)Q-\Y>.
MJ0C5JX"%.A5ISA&=.A&C5Q%.,%RN,9? IN;J1:E/=LEL?@C^R_\ MB6'C:70
M["S\$?$JSGDU%/B?I6EZB]AJ>FSN;J&::_E2ZT^.^0O,JPZ:UJSE8FDA<29?
MS+P!HOCFZT#QAX!\3?M&>-O"U[H%Q'X)^';ZOJ/@>33-?U#3IH]2TGQO:1R:
M(U]<#1KR\BCGO(YVTRVMM'6+4!YEO>;OLO3?!2>&-1\*Z<+Y_ 7@.+5+K2+W
M0/ 6EP3B6UU.WA:WTOQE+>6>IW]L+V>]8QW]E/8C3TN1))<06]NOE_$/[6'Q
M+UK]C#Q'J/@7POX0M?$R:YH^M^(/A)XQL_">I^.[;PGX=?3[J^O/!OB.Y>UU
MG9K>JZ\FMR0R%TG6SUFP4R);)$%\:&'J+%U:>5S3G*G]9P6&JPIUHJE3E&5:
M%.<[0^M*$4U35XN//ROX>;XK*\-*M6<<'5IN;QK<:6,I0E&MAJ=3V4O>FW%5
MKRIRY$I)Q4DGLGT?[/GP4O\ XN? CQ1HWC7Q7H*7>E_%.QL]7U_X<^(-.\6Z
M%;3VFN::]]J]UJMK>Z^;)]9L@+G55@OK9-.NKJ[>"+3XXHXX/LU?%O[/^JP>
M)?#-GXQT+Q3-X$\.#1[+5;>]OM4\-^$-;L;;R9?)-G=27%SJ0LE75I8M4N+U
M8+NX>[\A+4(B?FI^Q:MQX5\.>"'\5ZY->77QSO(M:^)'A2U:+PEI$4^O>-[[
M0[2"PMXTTI#KFEV4-AJM_96SNYL57[3;L6EW?JIX3^$OASP)\<?B'X/TV.VT
MOP=X]L=%\4WB1>"X;FZ.OV=OIVA_V?;:B-&FT2+2]2T'2K5M2N[K=*9;N]DD
MNU;)3AQ->CCL35K<M>G3II8FA@W0^KNG2C*DJL'3]]*=.<9JZYH2MJ[2;-,V
MC)YOF5.5)PA@Z:JTX4*4:5)NG*G"2C%*22T;OKS-7;LS\R/@_P#LAZ3XPT_Q
M]\0/$7[9/BO6(_#FIZF^C^'O$7BCPY#X4UJ!-1D\3PV]];O:6VL06EC-+]GV
MV%[931V%LKADB!<^5_"ZSUCPQK/C>U\<>)SI\FK^.H]3T_1/!&G:Q=>#M5T:
M328[:ULM)UMAJ4]E8:C$T>K:GJ&NZS*@NY+K[)<VUJT$*?<_C"T\7Z7\5?B#
M/KD7@O1_A1I7B&VN#X;^'$WP^N=6?PS'H5CI0NO%.@:@FIZX9;S6E:V?^Q+2
MS6>VE5]C+(\C87CWQII&GZ>=-\<>%O -M>36S2^ O#N@3W"ZQXWL8K%M=T*]
M2TTW43=:4^EV<5O:ZG%J$=K:2W-A<V(@_?);G[?!YM7J2G&M-58XRG3]C1IQ
MPM-X505/W&J,(JHY.SJ.4$XQ:DIQ3NN;/L9F>-IRPB3JJ-&AB:=.4*,I0I2I
MI2J>QI./P-Q3DTTN>U]3O/@%83:+\7?$/BJ]DU^ZTKPIH>G:OX=GU"ZU"X\-
MV^I7VF66G0:-IK:2\-KK=G!#J#Q7,L\FHFVN8WNGGCCMV:/V9/VEO#/Q#6ZT
M?P/JGAV]31-8O9]<U*WG6?5[;7;?5WLM=T^PU&[N)M(L8K+6I+G2&DFB)EM5
M>%)&FFC9OG#PS\0M1\2.FBZ=H^I>([6'P/;3ZEX1\-20VQT_4;F.VU0VCW2;
M'@E6]D6"<2W.^"0NK;+-'0>]Z7\!]3L/">GZWH7A3PUX;MM5U/0/$?A+0'M"
M\.G:Q+I"2^+-+\9:MHTB"ZN=0\3RZC>"2\OC:/=O$ZGS#%CS,UH86GBU6Q\4
MZTZ5*-&$)I)*$5RW3M.4IQO+ELH<O,U4=ES?/8/%.6%G*M-+$4'R8>"IPIQT
M:4KPC)WU;N]?M-MWL^I^*^G^+[/X2:EXYT/3Y+J[U75DE\3KH[S+)'HMB\EM
M:7$<2R.BS6PCM!/<V2):3%9&E5TD)/QI87NM>')]#\?:OK&J^+8;.Z77[?PY
M<2:(-&NK"])@LGUE8;.&8W-K-?VKQVNF7%I>SQH]U*DB0S2K^AWC;XH>-_"_
M@FTOETCP?;75XNJZ'K.DW+M/IRZC9^&]7N(M+TBUANRTUS>:U86O%S]IB%B;
MB9L%1,GQ'\#M UKXJ:!X.\<_%KP_X9\"_$D:WJOVOPG::_;WVFKH^FO>)8VI
MTG2=7NK=;K5K6&#4;6VN$,]O'&862-@4&65XB5/#UY8JE!4'5E'GI24IRIRW
MI;7C[-0<?:1E[L7'2TH\TUL#.G"KBHXB,'2>'IRHN256HJT7-JE#FYI07L[-
MVL]+M7/N'P-K-]X_\"ZC:>#+'0],UP66IZ[KTUMJ%O??V5XAO+Z.5BD-W=WD
M&GPWJW%Y<6T6HQ\Q*,;E4UQWP6^'4]C^T;^SYXHU[Q'J6K^)K3QAXW-Q9_:/
M#(TT17/P/^*MF^I*OAVQLX9]S7*QK 7D:-[E96C'E%EP?@]X/O8_VB/B5XTB
MUU?#7A7Q)X5T*R\&:+YUIIJ+>6D&GCQ&E_I5RL9N;B>[AG^PRW-NYCM&E"-_
M$/5/@IXE\8^*/VEM'M?&/P8O/AKI_@KXF>)]%^'WB)-8TC4=.\<^'KGX6?%'
M=KPCT^]NY+>2>"TM9EMY! 8Q>X\E?*94^9S23H4LRA0;5"K@^=0T]I3]M!.=
M.<IOWXQ;M>#O:+32ER\W;.A'#J<L-7A74L%!U[RY)4_K$8RE#E5^:4'[K2MY
M[-GZOT445^='EA1110 4444 %%%% !7\^/[<GQM_X*8_'+_@HY9?\$Z_V&_C
M9\*_V._#WA?]E2V_:A\8?&SQWX&\/_$/QW\0[34?%NO_  ]3PYX#\/>(],\6
M:6_ANT\3W'AC3]7O;70O#NN^'[FQ\1:Y+XLN(O\ A&O"'BO]@_VPO#ND^+_V
M2?VI/">OZ!\4O%>A>*/V<_C=X=UKPM\#K:RO/C7XETG6_AGXFTW4M ^#]GJ5
MGJ.G77Q2UFSN9M.^']M?Z??64_BRYTB*ZL[J!Y('_AE\ _L8?\&TGCK4+1/$
MW_!2']O[X+_$S1)+NRUOP)\?M9\-_##Q_P##G7;*XCL]5\->(;_6_P!D>3PS
MINNZ;=SFUU"VT;Q=J=NDT5ZB7<HL;XVX!_37_P $D?VE?V[/&WQ2_;9_8]_;
MU\2_"7XQ?%']C#Q%\&-.3]HOX+V%OIGA;XA/\9O"OB3QM<^%=9LM.\-^!]"A
M\5^ +"PT:PU2VT?P-X6N-.FOI].UW3)9[;3O$7B;]NJ_CU_X)\_M*?\ !&3_
M ()=>(OB/\+_ /@GM\=?VW?^"@7Q6^/VJ>%M/3X!^"/ ^H?%6[CU;PB^OVX\
M3^$IM+^"WP1\#6=G+:ZG))XY\16_B#Q5?MX:T#2;^TTV:TTV!;S^PJ@ HHHH
M **** "OSV_::_Y/6_X)X?\ 85_:4_\ 5>^%:_0FOSV_::_Y/6_X)X?]A7]I
M3_U7OA6@#]":*** "BBB@ HHHH **** "BBO-_C)\0[/X1_"/XH_%74(OM%E
M\-?AYXS\>7-MD!KN+PEX=U'7FLX\LNZ6[^P?9H4#!I)941/F85I2I5*]6E1I
M1<ZM:I"E3@MY5*DE"$5YRDTEZF&)Q-'!X;$8O$35+#X6A5Q->H]J=&A3E5JS
M=M;0A&4GY(_BC_:3E_X;&_X*K>,?#2RG^S/B)^TUX=^#4%_IKK<HOA/PKKNA
M_"5/$%HRD1O"_AOPX?$!9>"KR2-N8L3_ &Z^-_ /@OXD^"]?^'?COPUI/BCP
M1XHTF;0]=\-:K:K-IE_IDRJOV=HEV- \#)%/8W5J\%WIUW!;7MA/;7=M!-'_
M !*_\$FKOP7I_P"VEHWQE^+GC+2/#/A/X/\ A+Q]\3->UKQ+-*XU75]2TU_!
M&EV5FD:3WNI^(9=:\<0Z[9:?8P7>I7AT>[DM[:8PR;?[:/ /Q"\$_%+PII/C
MGX>>)M*\6^%-<@%QINM:/<">WE P);>>-@ES8:A:29M]0TN_@M=2TV[26SO[
M6VNHI84_4O%W/,LP7$?#?!.#S;!1S/AKAG"XV&6TL;1AF>'HU:L,+#&K!QJ+
M&4Z"C@,)R8KD5-5)1A&HJBL?S/\ 1<X:S;-^#>/_ !.S7),9/+./N.LQP5?,
ML1@*U7*,9.A0J8ZK@)XR=)X&M5E6SG,HU,&Y>UE3ISG.DZ4HV_C&_;Z_8%^*
MW_!.[XK:+\8/@_K7B>7X0R^)[?5?AI\2]*N)HO$GPY\213->6'A7Q5?V:Q_9
M=6M?+?\ L/7-D5AXHL(I 8XM0BU+38/WP_X)H?\ !43PE^V#HVG_  K^)D^G
M^$_VD]$TEI;JP"P6&A?%2QTV%GOO$?@Q XCAUVVM(FU#Q-X/58Y;6$76M^'X
M[O0;758?#GZH^-_ _A#XD^$M?\">/O#FD^+?!WBC3IM*\0>'=<M(K[3-4L9M
MK-#<6\H(#QRI'<6MQ$8[FSNX8+RTF@NH(9D_C5_X*)_\$[/B)^P5\1-.^-WP
M1U'Q-+\$Y?$UEJW@SQGI-[>Q^*_@YXKCO4N]'T+7=8LW2]MTM[Y(CX.\8B6-
M[QXX=-U*:/7HX)]8]_*<XRGQ.RVCPWQ-4A@^*<+3E')<]Y8Q^N225J%=7BIU
M:EE[;#-J.)LZV'E3Q/NOY+B;A;B;Z/&?XOC[P]H5<U\.,QKTZG%W!W/4E_95
M-S][%X-M5'2PU%2DL)CTIU,OYEAL=#$8"\X_VIT5^.G_  2__P""H&@_M=Z#
M9_"/XN7FF>'?VE/#VF,Q"K;Z;I'Q@TC3;<R77B;PS:QB*ULO%=E:Q/=^+_"%
MHD<0BCN/$_ABW70%U?2/!_[%U^/YWDN8\/YCB,KS2@Z&*H/S=*M2;?L\1AZE
MDJM"JDW":2VE"<85(3A'^IN$.+\AXYR'!<1\.8V.-R[&QMTAB,)B8*+KX''4
M+REA\9AI24:U*3::<*M*=7#U:-:IDZ_KVB>%="UKQ/XEU6PT+P[X<TK4==U[
M6]5NH;'2]'T;2;2:_P!4U34;VX=(+2QL+*WGNKNYF=(H((I)9&5%)'\4'[9G
M[2/Q._X*;_M9>'/!/PITG5]2\)1Z[)X"^ G@8F6)Y;6\FC_MCQUK\<BQP:9?
M>(DT_P#X2'Q#>W,<-MX5\)Z986&HW4T/AZ\U>[^[/^"U7[?R^)M2U']C;X2Z
MO%+X>T*_MI/CKXAL)1*NK^(M-N8;[3_AK9W$9,(L?#5]#;:GXO>)I9I?$MO8
MZ TE@_A[7K/4_L[_ (([_L!-^S_X 3]HCXK:&(/C/\4=$@/A?2-1B/V[X;?#
MK4%2[@MI;9N+'Q7XS3[)J6NK,'U'1=&BTOP^PTJ_F\6:?<_J7#6#PW ?#T^,
MLWI0GG68TI4.'<OJKWX0K0TQ,XW4H^U@U5JS7+*E@K4XU%5QOLE_-_B#FN8>
M-7'-+PFX7Q56EPCD.)IXSC[/,,[TJM7"UE?+J52TH5'AJT7A\-2ESQQ&;<]>
M=%X;*7B)?FY_P4V_X)S^#?V2/V5OV;/%'@>.#4]?\->(-5\#_&CQA':S+?\
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MUEKM],N- GE\.+''HT[K<Z397$>K7-S<Q(_FQK)>6?ERR2.)07,;-AR/XYO
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MA4K8>6LK3P]9U*%17?+.G*-W:X4445YQ[X4444 %%%% !1110 4444 %%%%
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MT^@W/A/7(+>UM]9CO-6$SVVIQW3Z3/#')9W\=S')=$1&$(MS/)Y<@*6ZK(B
M<-XZETOP]XQ^$^KQ17EGXFGBBL[^]GN+&XBO-*N#/ D5[:W$TK>:]HZI<3F
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MG"I3I5XYAA:674ZV%QN(I3=2.(YIX2G2IPA=Q<U)6<Y0Y;VBY-J46_I'X!_
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MJWA>PB_H$^-'Q4\/? KX._%GXW>+K+7-2\)_!SX:>._BIXGT[PQ8P:IXEO\
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MO[2G_JO?"M?H37Y[?M-?\GK?\$\/^PK^TI_ZKWPK0!^A-%%% !1110 4444
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M3N6GU;P7$&:P@A<O-X06*."SC@\+7]W/^T-?Q\_M!_#35?V3/C5X-^*?P/\
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MG\(?!GABQT.+67MIVU_Q;;3>)$\3M)IWDS^%/MEH 5?^#=?XZ?L(-\:?B/\
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M0+_HE_L7_L\:9^R=^RE\ OV=M-CL5?X5?#3PYX>UZYTT2+8ZMXUEM?[5\?\
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MX[75/%E_\4-+_LMU\1:IXKU0/JS1SKJ-O%:Z[INIW=XGV:X%P\*QV_F?O'\
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M)^A=0TWX_P"F06WACP'\-OB)I/@ZQNH_+N=:\'^)]3\1:C$[I)=ZGJ"2:3-
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MVDR_;K;P/KEU(UO'86.J?9Y$2!M0B.F,3IW^D-AP_LQ?\%&]7U'6[OQG\/\
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M%QKSKXZK3I8>@L35P].#E4KSITJ4/W:E*HH7?-K]TT445^;G>%%%% !1110
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MXAZAI]VH/PY\):C$S8\#P:A:O!XGUJV:*3QK/;7.FZ5<#P;9W5QXW^$_'?\
MP5(^.?A7]F/4?V,? .J 17MU>Z!>?$."6>7Q3HO@'5X7BU+X7:!*JX7[5=SW
M$#:UYDU_I&C7USX9TLP".S?1?"?V8O@!XH^)WC;P!\&/!ELD_B_QYK=M9W-T
MZO):Z?YD9N=8UB^:$/)_9'AG1K:[U&^>%6<V.G7,T,3W$HC>^-O%K%X7PCX7
MSO+<MQ^5\=>*&!PV#X8R&O3G3S/+JN.C3HXW-:=*:A5J4Z+K4X9%B'&G+$U<
M?EF/C2]GSPA4^#\/FGC5Q=X=87-\!G/ OA=FF(J<<\4X"M"MEN<?5*LY8#A>
MGB*4ITH5<1*E47%-",IK#T\OS;)O;*HI2J17GA3Q!8>&-$\77NC7=MX6\2ZG
MX@T+0=7FA"6&K:EX6M]!N/$-E9%CF8Z5!XGT(W3A/(#:A'"DCRQ7$<7W3_P1
M$^+LGPB_;:U3X1ZA=S1:!\;O"&N^%H+=KE8K,>*/"D$OCKP?J=\9&5);C^P;
M#Q/H=C&/WK7_ (G2"++2%'_9?_@H/^QUX3T+_@GSI7@SX9Z3)_QC$NE^,M$D
M%G:3ZSK&C0BXL/B5?:G>@6XMVU2UUK4?B+XFDLXXX+K4O#T2PV<<*P1P?R@Z
M?XTU?X.?%[X4_&KP[&DFL> /&OA?Q7:12DK;7.I>$-;L]?L;2Z",CRP:E';3
MV=Y'N ELXGA;Y6(/)]&O*\;X3>,>.\(L[QL:V6^,7A]2I8>LVHX2'&658;$9
MEES52ZA46#S#"Y[E^$4E"K668X"4E&55*I\_]*.M2XH\.N&O&7*,+.&8^"OB
M#A\QQE.G%RQ57@G.L3A<GXAH1A&,IP^M8'$Y3C,4X<].C3P&,=I1IMP_T,]>
MT/2?$^AZSX:U^PM]5T+Q#I6HZ'K6F7:>9:ZCI.K6<UAJ5A<QGB2WO+.XFMYD
M/WHY&7O7\07[,VLZC^PG_P %+O#6@^(KPP:9\/?C;KGP>\6ZGJA?2[.[\$>)
M=1O_  %/XMO4YQIL.C:M9>/+('=#*MG8S*6C*L?[=/"OB;1?&OA?PWXR\-7J
M:EX=\6Z#H_B;0-1B#+'?Z+KVGV^JZ5>QJP#!+JQNX)T# ,%D (!R*_DC_P""
M[OP2_P"$#_:F\,?&"PMWCTGXZ^![6:_G9RPE\;?#B+3_  KK20QA0L4">$YO
M $F-S-+=SWLK ;LG^Y?"O$0J9CG?"^.YHX?/\KQ.'E2DK26)PT*D9Q4)6<9K
M"UL7*334E*C!->ZG#^7OI*X&M1R'A#Q'R?DJ8[@CB+ 8^GB*;O3EE^/K8:=*
MI*I#F52D\SPN5P@FI0<,55<6N>4:G]?5%?+?[$_QK;]H?]E3X'?%NYN_MVM>
M)/ NFV?BRY*+$9O&WAAYO"OC6;R% $$=QXIT75KFVCQ@6DT#(7C=';ZDK\NQ
MF%JX'%XK!5URU\)B*V%K1UTJT*DJ51:I/2<&M4GY']'95F6%SC+,NS?!3]I@
M\TP&$S'"3T]_#8W#T\30EHVKRI58MV;5WN%%%%<YWA1110 4444 %%%% !11
M10 5^)__  4J_9(T'Q1^T[^RU^VMXY_: ^ GP6^!WPM\"?&G]F[]JC3OVCM<
MTKPKX1\7? ;]H7PW=^%M1TWP3XIU>33=*TCQ]J%WJM]H-NFM:[I=I=1ZO87E
MK/='1[_PIXR_;"O\_+_@H)_P6D_X)??MS_MF?L%?%?XI?"S]I7XM?LM?L\I\
M:_\ A;WP*\7^$_!VA6NI>(_%VC>'YOAMXRT?0M*^*;67CRVLO%6A:>OCOPGX
MF\4^'M)O_#^D:;;FV\3:;=^(O">O@'[$?\$2OV8?VBE_:!LOVC/B=^U%^Q;^
MT9\(OV;/V,=(_P"">?P1\7?L?^-M)\=7OCCP3H/CCPA\1/"FJ?%[5-)L2=.U
M[P9X7TG3_"L.@ZS>V.L6SI;W"Z*KMK'BKQM_4+7\6W_!$'XR?\$_OBQ_P6-^
M.'B#_@G9\.?B5^S5\%=1_8BU+3=7^#?B^75);3XH_$FR^-_AC5O$'Q2M=&/C
M;XBZ#X'T/POH-YX>\.>'O#T/B&SG<:Q<7>B:#X=AN?%EA??VDT %%%% !111
M0 4444 ?!?Q!_P"4B'[/7_9!?BS_ .G.RK[TKX+^(/\ RD0_9Z_[(+\6?_3G
M95]Z4 %%%% !1110 5^,O_!:;PK%HGP>^ /[4L$-E!<_LM_M&^"-1\6:U<PM
M+/8?!KXW"?X&?$RWM]@9A&+WQKX*\27.59 /"L4K",Q)<0?LU7S[^UC\$;3]
MI/\ 9D^/OP#NOL<;?%SX2>// NFWE_")[;2?$&O>';^S\,Z\T190TOA[Q$^E
MZY;$L ESI\+_ ,-<.:9)E7$^4YQPOGT74R#BG)LWX7SZG%)RJY%Q'EV*R3.:
M45).+E5RS'8JG&Z:O)-IK0SJ5\9A/9X_+6HYGEF(PN;95)MI0S7*<31S'+*C
M::=J>.PN'F[-.T=UN?"G["WC+^Q?B=J_A&>;9:>-=!D-O%M!,NM>'#-J5G\Q
M(VHFD3>("P )9_*&,#(_6VOY7_V OCMJ.O?"K]G7XR:@=3'B+1;#1+#QS!>J
MUKJTWB?P/?2^#/B+:7D#D36TNIZMHFO1M;W 686UZ@G4%F!_J=BECFCCFAD2
M6&9$EBEC8/')'(H=)$=25='4AE920RD$$@U_GM^SGSG-LEX(\4_ 7B>?+Q1X
M#^*'$'#F+PEYJ.$P&8YAF$)T:<*GO**XIR?BRH^512C6I\T(SDY5/WSQVI8/
M-,RX4X_RI<V4\><+9;FN'J^ZY5:E/"X:I"<W&ZN\KQF5QW>L)6;22B^OQR_X
M*L?L='XF^#Y/VB?A]ID;>//A[I$B^/=/M(MEQXL\!:>CSMJP"D1SZSX)B$]R
MS/&MS?\ AE[RW:ZFDT+0]-E_8VD95965E#*P*LK %64C!5@<@@@D$$8(X-?W
M'X@\"Y-XC\)YKPEGE/\ V7,:-\/BH0C+$9;F%*\\%F6$<FK5\)6M+EYHQKT7
M6PM;FP^(JPE\!X<<?YWX9<8Y/QCD-3_:LMKVQ.$G.4,-FF6UK0QV5XQ1OS8?
M&4+Q4G&4L/7C1Q=%1Q&'HSC^ _\ P26_;%\B6/\ 98^(VK*(9WN[_P"#6JWS
M/F.X;S;[6?A_-=,YC$4^+C6_"JSI$1<G6=&%Y-)=>&]+C_?FOY5?^"B'[*&J
M?LI?&/3?B=\,(]1T7X9>-=<7Q!X+U+1O.L6^'7CJQG&K7'A>TU"R=6TXVEQ
M?$'@J9393KIB7&GV2W4WA:^U&;]TOV$_VL=-_:K^#MIJ^H2VUM\3_!B6.@_$
MS1XC"F[5&AD&G^*K&WB2(1:/XM@M9[ZWB6".+3]4@UC186N8=*COKO\ GSZ/
M/'.<Y%F>9^ WB#/V/%?!_M(<-8JK.3AG?#]&"K4J&&JU+.O]3P<J>,RU^[4J
MY)4C3=&D\KQ#?](?23X R3B#*\I^D)X<4_;<(<:JE4XHPE&$5/(N(Z\_8U<1
MB:-*\</]=QD:F"S1/FITL]IRJ*O6CFV'4?MBBBBOZW/XV"BBB@ K\[?VY/V^
MO"'[*^CS^$O#']G^+?CAJU@D^D>&I2\^D^%+6[7-OK_C-K::"6.)H\W&F:!!
M/#J6K#R99'T_3)DU!O./V^?^"C&C_L^6^I_"GX17%CK_ ,;[B".+4=3DB@U#
M0/AG;W<3,;G48F=X=3\8&%HI=*\/3Q26-B)XM5\0K-;Q6^A:W^3?[&_[$'Q(
M_;,\8WGQ+^(^I^(M,^%<^N:C?^+_ (A7UU]H\3^.]=:Y,^IZ;X;N=46\DO\
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M  J^&GASP]KUSIHD6QU;QK+:_P!J^/\ Q#;K+EU3Q+XXU'Q#X@*M@J^IL
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MFAD>7YAGN:8N. RK"8*O7Q=6JTJ7U6A3E5K5JJ:=J=*G"<DTN9KF::AS<_\
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MHT8R)I]AX&\1>'- MI) !+/HEX$)$9"\O_P6U^"O_"S_ -C#4O&VGVJ3:_\
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M:1SV]AJ-WX,\":'>ZI;Z/8R7++ NM77AK0H-+TV)CNNM6DMX$5I9E4_S(?\
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M.?XJ^+/"<,[_ ! _9L\0>"_VG_ -Y  SZ/JOPEU8W'B?7-I!##2?AGJ_CR\
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M-PE?+\9B\!BH.GBL%B:^$Q--[TZ^&JSHUH.Z3O"I"47HMM@HHHKU3F/YG?\
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M-CL5?X5?#3PYX>UZYTT2+8ZMXUEM?[5\?^(;=9<NJ>)?'&H^(?$!5L%7U-@
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M2:IQ<I:*+4Y))[*^K6FO4^CM%N[*^N;5"J^*I]2U30]8U"RMX1:6FF7\=Q:
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M:?J5E::C87<;0W5C?6\-W9W,+?>BN+:X22&:-L#='(C*<<BO\N\+]#7&>(7
M&0<2<.\>\0>"/&&&S+'<2<&T^"*%++,ARK"8].>!A7RK+:F5YAAN?GKULOEE
M6<8*G@,OS"4*N#QE23I4_P#0?-?&'#Y%GV+R7$Y)@>,<DIX:CEN;RSBI+$XW
M&8FA:->4<3B(XFA5]FXPIXCZSA*TJ^)H2E&M2C:<OS]^&_[>&DWK0:?\4O#K
M:-,[)&WB/PRD][I8+.JF6]T2XEFU.TABCW/+)87>L32M\L5@@X'W-X3\:^$_
M'6F)K'A#Q#I7B'3V"!YM-NHYWMI)(UE6"^MLK=:?=B-E9[.^AM[J,$>9"IXK
MY?\ B3^Q7\,O&!N+_P )27'P^UF5FDVZ;$+_ ,.32.X9S+H,\T+6@*CRX4TB
M_P!.L[<,7-C.0$/PKXL^ _QX^!FH/XBTZ'51:V(<IXR\ ZA?310VY17F-Y]C
M%KK&FVP7;'=-J5C;Z?(X:)9[E,,WAR\9/IL?1AO1\:_#["^/?AS@=)>(G S<
M<\P.!INSQ.:RP.7PG3IX6AR2K5.(N&<OCBL1+V<N*<1-SK&*X2\'O$?W^#\]
MJ\$9_6U60YRKX*M6EK[/#*OB&I2J3NH1P&8UW3IKF_LV$4HGE'_!9+X&?8=9
M\&_'G1[/%MKT:>%/%DL4.U%US2[8?V1=W,H8M-=:MH,26D2>6J6]EX/D<N3+
M@>R_\$:?C6/$?PN\<_ S5;[?J?PXUH>*O"UO/<1[W\(>+YI7U2TT^USYQMM%
M\60WFH:C.5\M;CQE9)NW28&!X\^.>N_';X1>*_@E\6K;3=;B\1Z>R^'/&4-M
M9Z7K&B^*K1FN?#]UJ141:2=*GO$BT76+ZSL[#4;/0=1U6Z#ZE<8MIORW_86^
M+L_[.W[6?@/5=9NFTW0=5UFX^&?CHS2K96J:#XIN8=+-[J4MSY8ATW0=?BT3
MQ1=E]I\G1. 3@'V,C^D1X:\>>+/ 7COX;YCC:>39Z\-X=^*&3YO@UEV<Y!CZ
M^'IT<IQ&>T*=;$X:6'Q&6K XC 8K+\9C\%BGP;F%.EBJE?"XBA3_ %K@/P^X
MAQ7@MXM> O$>'HU<VX:KUO%GPPKX:J\1A<;AL17JXGB/+<FYX0JO$4>(8YI5
MS!8BEAZE*IXC8).E"$X57]F_\%PO@H=-\6_"C]H#2[*06GB;3;KX9^+[F*&*
M.TBUO03<:[X1N+B55$L^I:UHUYXBL]TK,%L/"-I$FT1X.+_P02^+;:-XM_:,
M_9IO[J06NH1Z1\>? ]@(D$$:RRVG@SXASO,""))9IOA_:65J%(%MI5W*IP&
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MV<GBJTT7PCX-\(Q>&;&Z)@G\.Z1>2:Y'J4L.LLCB\U$&UM'>%;*V\K:GSMO
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M1_LK_A*- T_7/[-_M#[+8_;OL/V[[+]L^Q6?VKRO/^RV^_R4 .XK\]OVFO\
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M)#_@CG^T5_P2\_9B^.NA_$7XU?\ !7S0?VDOCFG[/7@;]C3X&6_B?]G[XY_
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MC((/!!!X((ZBNK!8NK@,;A,=1=JV#Q-#%4GM^\P]6%6&O^*".7'82EF&"QF
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M !"\*75K</:I<:QX2UO4= N=6TV;5_"7C[X>>)[;5X(=7NM-^'OB;P]^P/\
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M);CS-!^*,]AI6B-=2W11;.QTCXF6/P_U[5+L/&]OI6DZB,E))$?^U:OXK_\
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MPY\'I88/#_ASQWKWB,:CKNKZ)_=Y^S;X)\8_#3]G7X!_#CXAZC:ZQ\0/A_\
M!7X6>"?'.K6-U+>V6J>,?"G@;0M"\3:C9WL]O:37=K>ZU87MS;W4UK;2W$4J
M2R6\+N8U_&K_ ()@_ 2]^&?[16L^(;C_ (+M:S_P4GCF^%OB72Q^S_?_ !1\
M/^,H-':Y\0>$+@?$T:3I?Q^^)US')X=%H=!6]/AV&*$>*VB;5+9ITM[S]_J
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MB,71IX3-%322E"G3S[),K<E#F3EF523ASSFZW]+=%%%?Z&'Y,%%%% !1110
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MNDM+:YCCFT"_MQ=W$1EG\N3RA&""XSD<4OV@O#/Q%\'_  Z\2^)/"GAWPO\
M$34H/#4\.D>"GT#6&U+5K+76NK+5!>1V^LKOLM0TBY>P0_9%;[2LI21CA%\V
M5%>WI8:=;V-:K6A&FI*%*%3GG%-RJ1G6HI6<9:U$HJ5Y;MKDPN"KSQ&%P5:U
M*%:<.?\ >J,J<79.4ZEDN1)I.]E>TGM8I^!/CO\ "GXMV?BF+]G3Q'X0^(FO
M^$=>TO5[^Q&OVLBQ0W<NGZ?=:P9+>7'DP1B11M"1R3P-",/N->ESZ9IEQI4V
MIC4K;78)_MUQJ']FF-K8^)/+D$5I)=1&01M978A\I&8M(\2# WBOS,_8X_9(
MN_A5?ZKXYBBNO!7B#5]$6^U_P;;6MSI_AK3[^]UN\U.TCTF]O'F8QVHN;:VO
MHI[FZ*207"YA. GZCSVFI^(M(N=$L?"BV!M+JQN;K3M2N1!IVL3BWL[JXU33
M;U8[9/*D)=9<-.I9)0'!^[Z&,H8;!8J4<%BG5I<T82J327O1IP]IS2NN>+DY
M3IR@TE>[EU79Q)A<NR_&0R[+:M/&X:&'6(JUY0E&JZC45.FYJ<HU(QFWR36D
MH]'?3PWQ!#9>,/ ^L^$/&[7FO^'=8ET[3;O2H;R&WE34K?5+74K>&RU22VN8
MM1EM52&[6U@MHWM;B/9,TGDONZ3P]JUCK'@C0+7PC;P1Z?I^H/X92-2?$4-W
M'H5Q+I]S'J46G-I\D>I06UC)%*S2CRI8SNA"J4JAXJ\8Z9X7TO3[CQ]>^#O#
M.EB;4;+3K&XU.V2T;5K(W4VGO%?M<)'*[S1P0JX!\F[($GF"-HS+X1UO2K#2
M(+.WU6#2/$'C2Y6]T"ZO9[8:7JC2#[9<PZ3?JEO:?:7C2X#.OG&9/,8*"^X:
M3BO9.HH6C[7VB2E)TY\RY)O1*-XI1<FE)Q44FV_>7F2I5E@(*I3E*G4FI49J
M[A"R;Y&K6>FO-=6M:VIQ?QX\-Z-XR\,Z);>+M2\5^&_#OA_Q'!XDT&;P+8'[
M9J \.K(;G37E,%W]HEEU&TDW6"J+A8@TC2%8VW?&?@OX]?%32?'HTIM)UKXF
M:5\4O$M[I'AK72[>%]9\)>$DGN;F_P!(UBSO;?5&E>UM[*:.?:MD96C:XC$$
M9,8_1;QCX%\;_$73=9\(:)XATOP]$EEI(@UFSE@U#3=/OK;6--U;74NH4DWQ
M7=_90ZC8R3&YC0O=,1%\P4>>? _X&:A\(?B1XF^)VOWMX\'B&WNK!?MMQ9ZA
MIFEZ39WD=K!)8745K%;Z5;:T;6"Z=)_/N1<78A^T$,5;?"XO"4L+7A6]C7JQ
MC*=+#2FX*]2TX*,X0YX3E92J-3:DZ;C-)35OI<KQV#HY)BZ69PI8Q486PF%J
M^\HRGRMR@XI3C+F:F_?::BXN/O77NMCJ_A_PS=V^HW6LR3Z7I&BK]ES:-=:;
MHMCIUHHW7DZR(HMU2 (]PSH'NVCY!?8?@;Q9\5OAK\0_&VA?&;Q;\4;K2]2^
M'VMZKXH\ 7"K:Z+X3UC1-.O+CPY=QZK]K6YEU."UCU-;=9(-0M8VNA"Y4C$=
M=;^T#X$^+GC*?XDS^%_$=GXD^'WBV#3-&TCPGI#A;3P5<W-WIWVC7=76"9[K
M5\:C&S&WM9M.4?:1O9EC96](\%? KPOI7_"">&/&/AO3?'7B?P_X'B\'3>*4
MMF5)I?+L?[6CCL(W>'3[9M0M,V\=V+B81JHDGEDW2--"GAJ-/ZQ.7M*M2$HS
MIPE2YZ6&C"$J\+S@O?J>TC3EHER7E&,^;FCC@:.59=@(YABL9B)XO&U5"E1P
MDN2=+#SIN4U--5+WFHPE=1M:\;IZ(OPRUG]N?PEXMU[6_B%+X<\*:C>6MIX.
MOO =W!"M]X6$<RS0W]ZYODCGO52VGE,0A!8/&(BS*5^=OV;O$7@3X+?MT?LH
M_L>:/HTFK:UX0\;?&N6Q\77%TT;P^'Q\ ?C%J=F?*9'DU.[\BTATZ\N&N!%;
M/=.!"C,@7[UT3PCJ_P /[>X\-6MG>Z%HT+1)IR:%>V]G:I#;6,\*6FI64MK<
MR:C$V4=X[.6RE,T:2!@BNC>8>'O!O@C5OVO?V+_B%?:=?Z=\0/#OB_X@^';6
MXD,%K!J2:E^S%\;3>[(9+7[3>6]Q:6D]_=[;IFM+^"T620J623SZ^*O@LUPT
MN:66?4<5/+Z%-1IK#55@Y*G.I.*YJRUE"46U%N5TDK)ZX'/L.L%FN#J2Q,L)
M7PV+IX/"R<:<J>,=-QI8BI-4[U8Q3<9T[14DW[RZ?M%1117Y>?+!1110 444
M4 %%%% !7\J'_!;[P'^SO\)OVM/AQ^U;X3_X*L6__!-+]LS6_@D?AUJFDV/@
M_P 8?$0_%[X3V?BF\OO#^I>+?#WPSBO_ !/X;T?^W+&_TK^W/%7A[Q/X6\67
M'@S0[#2=.L]8\"75XW]5]?R%?\%)M$^*7PS_ ."Q/B3]HJ'_ ((X^.?^"F7P
MCU+]DSX;?"Y8M8^'>I>-_!&@?$*Q\:2^*O\ A/? ^J:O\)OBUX1L-;T#PZLG
MA/4/#D7AZUU'[=</K5IXLT4ZCK&G:F >6_L"?\$V_P!B+]O7PKXK\/>&/^"H
MGQ&_;0^(J?M%_!C]H_\ ;]\5+X$^,'A;4_CEH'@K2?'ND_ SX/W6M_$W6=-U
M/1O">FZM=>,=1U;Q&'\;:]K;VMC]DL? TNA>"KG0O[1Z_&3_ ()._&.[^*NJ
M_'&*Y_X) ZI_P2W&B:?\/I$U34?A]HO@<?&DZA<^,5:PB?2?@U\*&U(^ _L8
MN'2>77!:CQ:ICCT\W#M>?LW0 4444 %%%% !7Y[?M-?\GK?\$\/^PK^TI_ZK
MWPK7Z$U^>W[37_)ZW_!/#_L*_M*?^J]\*T ?H31110 4444 %?D9_P %M/B"
M?"/[#6N^#K<$ZG\:?B/\._AGIYCD"20F/6'^(-Y,RX+M;2V?@273)V 55.IQ
M([@R*C_KG7\U_P#P71\=1:W\7_V7O@Y;W$Q/A3PUXY^+_B*QW,+:6+7]0T_P
MIX,O60/L>XLK_P *^*8XF:/=%'=RB-\2R+4U^(*/!^6Y[QIB.1T>"N'<_P"+
M^6JDX5<1PYE&,S7+\,XN4%*>-S+#8/ T:;E%5*V)ITVUSGE9KPWB.-WDWA[A
M'46)\2>*.%?#M2HMQJT<'QKQ#EW#V<8R,HPJ2A#+,DQ^99IB*D82E1PV"K5D
MFZ9^/WAU['P^O]I31C^S/">CW6JO$&"GR=&LF-G"A/'F272VD$2]6D=5 )(!
M_.#XM3>(O&-O;>$M$*W/C;XS>-='\ Z,K;4CN=:\=:PMK<^?G/DVT\,]W#+-
MRMN;B-F.,9^U_B;K']E>"KBPC.VY\3ZC;6 .#EM,TEHM4U)0P/R-]N;0!SP\
M33+T!KQ[]FA?#$?[0^N_&GQYN;X9?L>_"S7_ (F^)6@ET^.XO?&OBVQO-+\*
M^&+1-6E@L9/$&HZ1::I?>#T>:-IO$\.EVD;B:XC%?F'T5,7C?!'Z%_&_C)+!
MRS3C#C#'<09[PY@<4V\7Q%Q3C\?0X&\/L@=6IR3E/BCC/^S\'AN:<U.KG4:R
ME)U7&/E_3XQF"\:?I^\->$^&KTL%P=X3\.<*<,9G/"J,<NR7)\MR^MQ]Q=F4
M*--RI0CDN59J\)C5&%/V<,E6%E!+#*3ZC_@K-\4M%^&WP^_9W_8"^'EV?^$>
M^$GA?PM\1?B8,E+J?Q+/X27PU\'_  _K,?DHDM[X>^&$][\04OX)IXK_ /X7
M<\5P([[2Y17]'G_!NE^Q>?V?/V0;CX^^+=+>T^)'[4-U:>)+:.^LV@O]$^%7
MA^6^LO!-DJW5G#=VQ\33S:IXPF:"YFL-6T;4/"5R$$UIFOY%?V2/@OX^_P""
MGW_!0?PQX5\3SR_:?C%\2-5^('Q8U?38IDLO"W@#3KB;Q'XNCT>.5+Z#2;#2
M_#]M_P (KX(TVY8:;:3R>'- B>.W,"#_ $?_ (U?%CX;_LC_  %U?QOJ=GI^
MC>#_ (<^&K'0_!_A#33'IT>I7EG91Z5X-\"^'H(H)Q;?:W@M--MS#:S6^D:9
M#<:G=1IINFW<L7ZCEG#^6^"?@_PAX>5LSIU8<+\/1S#C#/Z\FGFN<2]MFO$_
M$6-FXQ<JV?<0XC-L]Q=Z<9>UKKEIQ3C!?$\(U<7XJ^*/%'B.\%.&'Q.9RRGA
M/*XQ36"PWLJ6 RC+</%2<8K*,AA@LOBK\LI8AU.9SC*2_-[_ (*\?MB_\*L^
M'P_9Q\!ZC&OCWXJZ-._CF\MI)?M'A;X:W;26<U@'C:..+4_'CQW>E;':Y:W\
M,VVN&YM+>36-#OQYM_P1F_9-71-!U+]JWQIIRG5O$L.H^%OA+:WEM$SZ=X=B
MN&L_%'C& RB22"\UV]MY?#>E3Q+9W4&C6.OG?=Z;XFB*_EO\!_AKX^_X*&?M
M8:OKWQ&UB:WTG6-4N/B!\:?&D<D=CI_A;P9920P)I.F7.HS30::9X(].\&^#
M[25[YM,MO(O9;:\TS0]2=/[#/!-OX0L_!_ABP\ -HA\#Z=H6EZ9X27PW<VMW
MH$7AW3;.&PTFWT>YLI9[6;3K:RMX;>U:":2/RHE"NV,U_*7AKA,=XN>(>8^+
M>=8>I3X:X?K5,IX%R_$1M'VM%NV.<'S0E/#0J3Q5:I[Z>;8I1H5K95&G#^Q.
M*Z^&X)X8PW!. JPEFV9TXXWB'$TVN;DG:]!2TDHU91C1IQ]UK!T7*I3OC'*7
M3T445_5I^-'XD_\ !8C_ ())>%_^"@GPY/Q!^&-CH'A?]K'P!IK#PCXFNE33
MK3XF>'K..YF/PQ\9ZBK1P1B6:4S^#_$FHQW'_".:H7L)YK30-9U:XMO\\+7M
M"\>?"CQ]=Z=J-GXD^'7Q2^&?BM[>ZM+J*_\ #OBWP;XS\):KAH9HV%MJ6BZ_
MH.LV(*-B&[L+ZU5E*21AE_U\Z_GG_P""W'_!'W2OVS?"&K?M*? +1(M/_:N\
M"^'T_M/0M,MK6"V^/_A7180L7A[5L&#'Q(T'3(S#X&\2.\LVKV%K;> -<6?3
M_P#A%-3\&_HW!7&%3*JU+ 8RK_LDI<F&KU'>.&<W9T*R>DL)5;M*[M1;;?[M
MMT_Q'Q/\.7FL:G$O#]+DSG#Q]ICL)1CRO,Z=-)^VHJ+7^WTH1^%+FQ<$H1_V
MB%-5OTD_X)H?MF:3^WA^QQ\)_CY%-8IXUNM-/@[XP:+8B&)/#OQ=\)16UCXR
ML_L,,UQ_9ECK<DEEXS\.:?-/)=0^$?%/AYKHB>211]Z5_G>?\$-?^"FFE_L#
M?'3Q%\./C+>75G^SC\=KK2;'QEJ;M?2_\*K\?:-]HL_#WQ%72HX[GS-'N;:Z
MG\-?$*VLK6WU2;2AH/B#[5>?\(-;>']8_P!!74O'W@K2O!R_$&]\4:(/!,ND
MV>N6GBBVU"WOM&U'2=2@BN=+OM)O;%[B'5X=6@N+=](.F-=MJOVFV73UN6N(
M5?P>*,CJ99G-6CA</4^J8VJZN70A&4[JM)-X2GRIN<\/4E[",=:DX*E4<4ZB
M1]?P%QG@^).&Z>-Q.+HTL?EE!4L[5:I"E["="#OCJKFXJ&'Q-*#Q'MG:E&?M
MJ?,G1FEUU0W%O!=V\]K=0QW%M<PRV]Q;S(LD,\$R-'-#+&X*R1RQLR2(P*LK
M%2""17YHZE_P4&:+QW&FE^"X;GX;13K;7$MS)+#XPO("Z++JMH!=G2;4Q+YD
MEOH]Q%*UVJI'/JU@\S-:_HSX;\2:'XOT/3/$OAK4[;6-#UBV6[T[4;1RT,\+
M%D8%75)8)X)4DM[JUN(XKJSNHIK6ZAAN(98D\_..&\TRFA0EFN"]GA\=3E%*
M;IUJ;YH^_AZZBYQA4=-WE1J?%'F24N2HH^KPWQQPWQ3B,=0R'-(8K$9942K0
M4*M"HX*7+'%X;VL82KX;VBY%B*5XQGR<W*JM&53^>[]I?X.-H>K_ !*^$]R&
M: &Y30+FY=F\RTG$>L>$]0GDB\E99(@=-FO4CQ']J@N;9P0CI7S+_P $P_C7
M)\&/VJ- \/ZQ<O8^&OBO%)\-->AN//$5MKE[<I-X/O'MT(5;R+Q/;VNA_:+A
M3'8V&OZK+(8T+NO[<_MX_#AKW2?#?Q1T^!GFT9U\+^(6178KI=[--=:)>28&
MR*&TU.6\L99&.^6?6;&,#;&2/YHOCMX?N?!/Q2NM5TQY;)-7EMO%>E7-N[I)
M:ZA)<,]X\<P.4N(M8MY[R,1D&".XMMH4;2?^?3+,LQOT3_I9\3\&86G7H\/Y
M=Q%A?$'@>$7R1QG!^;R_VO*</*<E[:2RBMBN&\367LU/$9)CYKE3A;_8#PIQ
MN%\</!CB+@W'U:#Q?$_#F(P<IUV_98/BW*(TU0QU2,(SDG''T<KSRG34*C5"
MC334G[K_ &$_X+B?!N+4?!7PC^/6G6L(O_#.NWOPR\4306<\M[=Z)XDMKKQ#
MX7N;R\CW06NE>'M7T;7[.,3A/-U'QK!'&Y=PA\]_X(6?&P6]]\</V:=4N(U$
MKV7QV\!P&.=I9(KI=*\#_$^T$[.;:&UTZ^M_AUJMI91I'+->^)]?O?WO[]H_
MT7U6X@_;W_X)V:]%91'4/%7C_P"%DZ?V=!=06++\8/ <L&K:993R(TB65C=_
M$#PUIEUY4I0R:#?1&0(EQD?RS_LF?&X?LY_M-?!'XT37?V7P[X<\96FB>/)6
MEN([;_A6OCN-O"/C2[O(K?F[@\/:9JR>,[>UE5HFU3PQITK;&A61/]4\WQ.&
MX0\=>#.,\!7ISX9\6LGAD>*Q5)WH8C'3IX%99BH_#&E2Q-27#=6->K&+G1EF
M$TW^]Y?\[:L*^:^'.>97C*%3#YWX;YK'/7A,0N6OA<OA+&X3B#"5E%S]K7R[
M"RSZ=7#T:DE#&TLOA.-_9>T_K?\ ^"@OP2D_:"_8\^.?PYL;1KWQ"_@ZX\6>
M$((;=+B]G\6^!9X/&&AZ?8;B#%<Z]=:-_P (XTR,K"UUBY0[HY'1OP)_X(%?
M&U?#'QP^*?P)U.]2+3_BIX-M?%GAR&XG?Y_%WP\GG-SI^G6^3&+G5/"FO:UJ
M=]( &>V\)6X<D0H!_5^"" 0000""#D$'D$$<$$=#7\/?C2&7_@GI_P %1+N_
MLXI-%\*_"OX[VOB2RM=*C:X<?!3QY)%JLNB6#3 "YN9/A1XMNO#<[J6":BMU
M%GS(65?[]\/W_;G#?%W"$_>JU\)_:V6P>[Q5'V<9>:7UFCER]U/2532[U_A;
MQQ3X.\0/"SQ3I?N\/A,T_P!6,_KK1++<5[:I!/:+E_9^+S]WFU[U.CK:-X_W
M"T4R*6.:..:&1)89426*6)UDCECD4,DD;J2KHZD,CJ2K*002"#3Z_(C^I=]@
MHHHH **** "BBB@ K^9'_@X"^(/[!O@;Q5\"X?VAO^">GC3_ (*#_M 7_P ,
M_BYXJ\$>$?!WQ%^(/P^M/AY\&?ABNG^)OB-XM\:ZM\/K[4]2TSP_:QW-YK(U
M:3P#KUE:Z=X<\2W>J:SHMIIL:W?]-U?AI_P56\._L3_"[]HO]B[]M#]J?]L*
MR_9:U'X8I\6_A?>>";W0KSQQ%^U!\&?'_AZWT[XA?"VZ\&:3;ZUK]OHFF3:Q
M8/XA\7Z/X6UFSTNP\4KI^K?V=KFH^!_$&@ 'YG?\$,?'W[,NM_MRW?A7X3?\
M$?G_ ."?WCK6_P!C5_CKI?Q8U3]J;XF?&*Y\>? KXA^)_AD_A&?PIX4\:^&O
M#FD:IX1\;7=_I>I)XWT.?5QIMYX>?0+A;.\NKV*#^OROY'_^"&.A?LOI^V7J
M4G@7_@JO/^WIXF^#W[(NK?L]_LT_"Z3X)?$WX6W7PM_9?TSXD^"/%FH2Z_J_
MBG2+#0]:U+0/$4GA[PGI=I'=W]V- >Q,-RND:5H/AWPA_7!0 4444 %%%% !
M1110!\%_$'_E(A^SU_V07XL_^G.RK[TKX+^(/_*1#]GK_L@OQ9_].=E7WI0
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M.CG_ (N9O3RRC&+MB(Y1B+U,4U%:SPM;),MJ47ORRSZ"WFDOZ6/^#6K]F9_
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MSU+1K^'2-%OAI.JJ98KAQ]H@N (1</HL;I&SWAF^S 2OAU"DUGZ3\'I_ _\
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M#);R:G;6$5C<313PKY$<.JZ%<:?<6<D4K/<W-MJ5VI/WS_D3^U%\%<=P_E'
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M!_Y2(?L]?]D%^+/_ *<[*OO2O@OX@_\ *1#]GK_L@OQ9_P#3G95]Z4 %%%%
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MMBL-&TJ5''XNCA,?.E)1M&5-9?A^&\&TU>G.K7@[7E$_J4HHHK^M3R HHHH
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M&]-1KK1-<@M;S5I],L[G4);R^CDM)[+S0;9-L4>X[OL_4?A?;^!--UR3X?\
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M&QCTOQ+\1/&FM>'/$^M1^(M)A\3>&];TGPMK^E#1=,74[&0S0+!^U%?RT?\
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MG[6?Q0U>\G:*ZU+Q)X<UJ#4_#.INZH8[F\O/C1XG\%ZE>V3;5N]-CU;@QQR
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MDBO)HDU2='U>",QI!?Q+;VXC[+0/ ?[*7AS2[/2M/_8W_:!$5KX.U'P&)9O
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M6UO>K!-/9742/!)_ 9^T;_P23_X),?LI_P#!4&U_93_:B^.?[1G[.?[,U_\
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M\6;+3_C#HFF0-/>3SA%TZ/XAZ-;R>+](M9()-2M?&FF:+I?AI/U;(N-LNS'
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M ."G31_*W-+_ ,(SX:_Z .A_^"G3O_D:MP*H &!Q[4NU?0?E0!A?\(SX:_Z
M.A_^"G3O_D:C_A&?#7_0!T/_ ,%.G?\ R-6YA1U 'UQ_6EPI[#\A0!A?\(SX
M:_Z .A_^"G3O_D:C_A&?#7_0 T/_ ,%.G?\ R-6Z0HZA1]<4Q]NT]#QT&,T
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M>/\ @GGIND^%O%$\MWJWBW]F*ZO+;1O!VOF1)+BXNO@UJEX\.F^#=6-T"8_
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M[6#P#XWU28M/K-PKX@\/>(=2FD+2:X9!"-#U2Z+2:U(6T^]N6UDV!U?]!?C
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M_L,']K>&H/#&D07-_-X"U*<?3/QRU7]GCX-_\%._VC?&?_!0WP.WBKX6>/\
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M8.DMH0P$8124=2BBBODS],"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK-/%UKU\7)-;IXFK5<=7[ME=V"BBBO"/?"BBB@ HHHH **** "BBB@ HHHH
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M\%VMPTWC*SMH/$.GW,DQ@T^RGAGFF<Z1>!O.6>S6V6[9$CBMID>-99#ND5?
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M]W'$S%X;6W9;FY%O-)9V\UU#_H\4I@62-?EKL/.\,:[>+8S-X<\,R:C+=O\
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MT?X]^%&D>13ILOPPOO[1\:W\*19,]P?A/>?$.PMX65E>:^0@!U1E_CC_ ."
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M6-K87=EJHN;"66[M[5F,\PCN?WES/ 99)5)&Y<,>5U;1[+P]YOA3PMINB?\
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M_P#HO_@+_P "[[_Y!H_X;Q_8_P#^B_\ @+_P+OO_ )!H ^MZ*^2/^&\?V/\
M_HO_ ("_\"[[_P"0:/\ AO']C_\ Z+_X"_\  N^_^0: /K>BODC_ (;Q_8__
M .B_^ O_  +OO_D&C_AO']C_ /Z+_P" O_ N^_\ D&@#ZWHKY(_X;Q_8_P#^
MB_\ @+_P+OO_ )!H_P"&\?V/_P#HO_@+_P "[[_Y!H ^MZ*^2/\ AO']C_\
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M@QZ#HEQ=V<TSVQM(K2%+:18O#R6T:S"Y,.UD\]VA VC]V-V!D? '7O 7P_\
MV6/AY\3#9Z5I7BCQ;X,L-/T75(]*BTJ[:&2,-I?AZ>[B>>6=84:?[/=LJE\R
M9@3OA:GXWU_Q3>^*M*/@JPC\2Z#'I]GY]MJ[:GH5WJNI6FIMJ\%W9/IUJLQM
M9[&W$EL9<3F4%GB$8$G@OP[\1?&+Q)^S%X*TOQUI7AZT\(Z/X>@C_M?P[,^F
MZIX>M!&!I>LP6B6L@W6T278=A<1<L K\FN6>63Q/U>E44*=%5Z;KPCB:2E.#
MC*453C"4N;GG-/6W-MOH94Y2CS+9NW;79V[:):?<CV^VU/PU+\4?%OBW0_"E
M]XNLO%5AH9U.ZN+^/5O".E:AX>?4WBO9[>:-#9ZC<G5I?,E2&4WJP89E, #<
M+X0BL/A/J/BJY\*>%/#FLZ]J^J/,Z6>J36>EZ;9>)2T-AH@=-(E-M;1R6-R1
M(D3^5YKGRFSEL/X5W_PG\7ZW&GPBU;PC#X?UC5(K'6-5L+DP>*1>>%F+6.F"
MUBMS@1-JUR90UR QD3 X./8[NY\5>'/%GV'4M%&IVFOW=K$U]:W!734&E2.T
MB3PF!OL=_>+>INN 9FQ$#L;8,>JU3A*K0BJCBX4X2I593IU94Z,80@IISY;Q
M49=5HHMJS5L9^TB_>TNUH])=/NT2:ZVVMTYC6=;M8_"%YJ%IH&GZ)>:7X/OM
M"N]*\+Z_*UGH&D7:7/VG3=%O#IEBUI?W!DF,T4=JD<I\C=,,<<U\,_@UK7CO
MPWI9U3[%XDT+PJFHZ9I-AI&NW&GZ.D1BANH-1CL1830:7XD@EG<W%S$UQCRK
M243,1M7F=FO^)M)U^R.EQ3W,6@1WT=CJML/%-OJ&A7\VH0:<-9UV=].:5C/9
MWJ3:7]A=5B*8G<2D+Z_X;U#Q/X?\%0V@U?1TT+3K6\NKCPOHY%KI^N.D$;3Z
M9=W*L?-L+I$2VDC:U81 R<2;L#65+V&%4,$J-+$NO'65U:$H\K3<7SJ34N5.
M,DO?U?NIH3LFMF^O;:^EO+S]-7?D/$/@GQ#8ZRMKX6'ART6'5;33K3[=<OJ!
MU"XM#!/K$.IH;2.*VNA9SVR6VV6Z'FGS"ZEBB\UJ?C?PWX-\7Z/\(DN+#6];
MTCP]_;WBOPSHZOJ:ZC9>+KN^T?4);L30VD$.G-:6!A)#7+J8YOW7W=WN>OW0
MMOA5H6@>%)O#.AZ+ AU.'Q/JR?:+=?WSW&H6MG:HB@/L @9Q<98!"5!P*\]U
MNT\3:'HEIJ?B&S\.7^I-/)!I*6\2R3ZY';P0W?AVYM+YD#VFF6VJSS2WMN(I
M@L?G$-EVPJ&)E7C[/$02=.I4HPIOW)3E&3A&KU;2]Z2B[6;NVFM%2ITHJJZT
MYRC5LH1@TN6222O=6=[7=N_0L> /^$9_X2G4YM#T74;;2M)O-2LK?2M5"6-R
M^K:IHEK;W=MI=RAN FGZ?936UY ,(%N&F;8N2QX#P_H,'@+2;ZU\* VNFZ+-
MJVH3Q^,;MK[5+;5+^^N[N[F:<1R&^TFXAG2UO9Y#"VFZ>LES'#=M$+=^NOO%
ML$FA:)"NEZ'8V>KZLDFHWTVIM+?W9O?(TZ^GT^U^PQB_;$$EH]PUQ 8HX57:
MXB!.?X_AMO".WQ7>7=MIWAV,3Z.+"RTA-1TG7=-O=/CALM-U*U^U6T<%XVIW
M4TOFAKDZD98[!DM@#<5T1]I&O4<O:+VWLX14Y\RFZ5HM:-IRGS>\^6\4VY.R
MLIA#WUS-<ETY)ZW27PWMWVN]#YNTKX,>,'^/.C_$;X:>-KRPL/$_A"^LO$?@
MRS:XT[%F)=6GBUVPMHI'MU"ZP[FR3*M<16\-VTD+W!AB^CK/X'ZMH$]K9^"O
M$D>C6VK7=]XG\?:CX@T6*YOO&$D-@\$^G6MP]^IC+FT6SNWD=Q);I*A!!"UV
M'PYG\7ZVFG7_ (GO--TW2Q:_V/X7L'U-M'?Q#.S27MN+!5MKD6 M;:ZBM9+5
M#<@"U8;P'VKZ1\(?"][\7O&?BE]7\2VM_P"&/"^K3>'-8\-#5WU[3KK2IM&M
M_,TF[M)(+-+>9=1NY9Y,"831MDA3)\O/C\QJ4E5E*K1A3P<(_6)1BISG4;7L
MHRE&,>>4>9)1:ARV2;NO=]*%:M6<E4ESTHT'0T7PISYH\W=).RW;LM3J+3X-
MZQHWPS>\\,:-:66J:I]D6VM=&B7=:Z;-J$-S=E[Q%B:,7,33R;EA86PF")YO
ME*S?!GQ*T:YUKPE\0-%\%:E=>&?&VCV%[#9^(=6M3+87FIMJ862WTLI-YER-
M+5WN9I2L)DNK.:8HA.5_=^STO2]#TNSTNQL[6RTS2K.&UL;6-1#;6]E;1!8X
MHXE5E1(8U_=IG"[% Q7Q'J'PS\/ZGXTD\3> IM2O=-BOM0>=4TM=6LQJ%W<3
MV6JVEC,US;?8':2>ZEN0(I<Q>?(0Q;:/G,FXEJ2KXJ>)5TI^UI5+J[2DE&E5
M<N9<K7+U=[-^\TCF="<97HRC"-K2BUJTFM$TK>>NBL?">A6'BC1_"GABT\5Z
MIIFIZY-X1T72AXBBLVL[_3-<.C6TUQ<6JDRG4DUJ9)M02"2>R6&ZO5=I7:$%
M_3/ACHEEX2\&:Y\1OBSHVE:WKS7$?A;P[J.I>'K6T\8:?I5Q?16MO'>21W6H
M.]OJFM+9W:SBXW+8S[_*8C;75?$]=9UOQ!!I]Q:7NB:;X5BN+8RZ!?G6+?Q'
M:374FG26&L:%+%I<;V-K]I,EP6OI!;W-HH57\M6/RO/I?Q3U3XK^ ?!OP;\7
M0V\'AS7W\3^*_!,VE/H\?B'P^WVG1I+F]FM[V]BN-$TR/4H5L(7A8'5;?3B-
MA563ZQ.6.PMY5:>%B^;$2G*<E[L6Y1BJD/=@I>Y&UN6[U2;DW4,(JUGS."2D
MZLO8U91I.UUS.$9)^TMHXW4;^]:VGN>J6&E>#KAK?6].N]+T[5A>7VIS7NG0
MZM96=U)>?:;B*TBDN;<ZC$9B]QITDBVIM(DB94;RQ5;6]5\6^'M<\/\ @_X;
M6%]J5_XL\-W/B2X\775N]IHC>#KF:VOX;"YE4W)/B P36=Q;*05^SV]ROG+Q
MGTG5-+OM4\1ZS>+8?VJ?#?B :9IUQ+:@W>K'^S[HW=CJ%N[D&WM6CDTV"=99
M,,L+>6"=@Z'4/BGK&LQ6GAS2[W0+2Y?0UM](\,NTEIJ&C:CH-W96U]IT>R"1
M91;6\%[IC,?)WNP.P E:XJE>I!X6=&%&M=+VWMII4W/25-M2U=DV[2:3M9)/
M0XH0;:4E9[I/75V3?HEH].M]SDK/7+70M3\#6U]X:@U77M5U/2K:SUFYTZV\
MV+2=2\/ZA?W&HVTTDYE8M+%!%?Q[4(FN.7;:<^6?LW^ ]4L/VT])^(NHZ?X<
MM-)\4?$/QOHVA#2;9;*_-UX;^%?Q.L$GU&/8/-QIHO8;)UD?=;RRO\HR#H>+
M)GU#X@:1XC^(_@BUGUC1]+N-8T#PI9Z:NIOH-J+RRL-%U>]U&4VILX[C2[WS
MKZWCM),3S*#,RQY;ZP\"Z?HWCCXH_ _QC#IUO9/X#\7^(+."]TRV1=-U?6-4
M^#GQ+TN]>VN RGRK.UGOHYXMC$7#P9;@UQYKBYX3+\6Y1A46/PM6A6J*49QA
M4D[PC2DG\*;BKK1I77,FVNM8:I'V,^6U--OGYDTVFM$EKV3V5S]"J***_,CI
M"BBB@ HHHH **** "BBB@ HHHH *\'_:D^!.C_M0?LV_'G]G/7M1?1=+^.'P
MC^('PNGUZ.T2_G\.S>-/#&I:%9>);6QDE@CO+SPY?7MMK=G:RS113W5A#%*Z
MQLQKWBB@#^=GPI\ /VZ/VH/"_P#P3$_9F_:#_9GU;X!^$/V"/BK\"OCA\?OC
MYXI^*GPG^(NC?&CQQ^R3X7_X1[X7:!\$]%\%>//$OC?5]+^,FN70\8^-=>^)
MGA_P-/X*T>WN=(9-?\0,UE=_T3444 5KRSM-1L[O3[^VAO+&^MI[.]M+F-)K
M>ZM+J)X+BVN(9 R2PSPN\4L;J4=&96!!(K\W_BU^PS\/=5^/O[,.O> O@)\,
M+;X5>&KSXKO\:[.RT'PCI6FW]OJGAC1K;P(-7T&5;:;Q*MOK4.HR6:6]GJ!T
MJ9Y+F06RS"1OTIHH ^</^&/?V5/^C=?@U_X;SPQ_\KJ/^&/?V5/^C=?@U_X;
MSPQ_\KJB_:E_:]_9[_8M\ :'\4/VDO'5YX!\%>)O'>@_#+P_J.G>!OB)\1-0
MU?QWXHL]7OO#_ARQ\-_##PGXS\3SWFJV^A:H;:5='^QF>W2T>Y2[N[.&X\,_
M9X_X*J?L _M3?$^Z^"GP:_:*T34?C#;)(\?PM\>>#?B9\%?B!JI@M+C4+J#P
MYX2^-?@KX>Z[XIN[+3K2ZU._LO#=CJMW8:9;7&I7D$%C!+<* >\?\,>_LJ?]
M&Z_!K_PWGAC_ .5U'_#'O[*G_1NOP:_\-YX8_P#E=7T?10!\X?\ #'O[*G_1
MNOP:_P##>>&/_E=1_P ,>_LJ?]&Z_!K_ ,-YX8_^5U?1]>$_&;]IKX$_L^:Y
M\&O#/QA^(NE>"_$?[0?Q1T+X,_!O0;BRUK5M9\=_$;Q$XCTW1-,TSP_IFK7E
MK9)(]O'JOB?58=/\*>'Y+_3(]?US3'U735N@#&_X8]_94_Z-U^#7_AO/#'_R
MNKYQ_9>_8;^&GAGX>ZWI_P ;?@'\+M0\6S?$?Q[J.FSZOX>\(^)KE/!]]K<D
MWA:"/4+=-02&UATPHEMIQG22QCQ"\$+#97Z.T4 ?.'_#'O[*G_1NOP:_\-YX
M8_\ E=1_PQ[^RI_T;K\&O_#>>&/_ )75\;_$?_@MI_P3/^$GC#XE>!OB#^T'
MX@T'6_@]\0=;^%7Q,NT_9U_:AUGPGX/^('AV_;3=9\-:KX_T'X+ZIX$^U65V
M IN+;Q)<6$\+Q7=K=SV<T,[_ *)?"?XN_"WX[^ /#OQ4^#'Q!\(?%'X;^++:
M2[\.^-O NOZ=XD\.:K';W$MG>16^IZ7<7%NMYIU];W.FZKI\S1W^DZG:W>F:
ME;6M_:W%O$ >:_\ #'O[*G_1NOP:_P##>>&/_E=1_P ,>_LJ?]&Z_!K_ ,-Y
MX8_^5U?1]% 'SA_PQ[^RI_T;K\&O_#>>&/\ Y74?\,>_LJ?]&Z_!K_PWGAC_
M .5U?1]>$_#/]IKX$_&3XH?'/X-?"_XBZ5XS^(_[-6L>$_#OQNT#2++6F@\"
M:_XVTS4M6\/Z+=>(+C3(/#6L:J]IH^J1ZOI_AS6-8NO#.I6%SHWB:+2-7C-C
M0!\F?M.?L,_#WQ+I_P %X_@K\!/AA87>C?M!?#G7_B,VDZ#X1\--=?"?3X-?
M7Q?97\EPM@-9TR>2?2C=:!$;J?42D;1V4_D,4^FO^&/?V5/^C=?@U_X;SPQ_
M\KJ^CZ^:_P!J7]KW]GO]BWP!H?Q0_:2\=7G@'P5XF\=Z#\,O#^HZ=X&^(GQ$
MU#5_'?BBSU>^\/\ ARQ\-_##PGXS\3SWFJV^A:H;:5='^QF>W2T>Y2[N[.&X
M )?^&/?V5/\ HW7X-?\ AO/#'_RNH_X8]_94_P"C=?@U_P"&\\,?_*ZO!_V>
M/^"JG[ /[4WQ/NO@I\&OVBM$U'XPVR2/'\+?'G@WXF?!7X@:J8+2XU"Z@\.>
M$OC7X*^'NN^*;NRTZTNM3O[+PW8ZK=V&F6UQJ5Y!!8P2W"_H/0!\X?\ #'O[
M*G_1NOP:_P##>>&/_E=1_P ,>_LJ?]&Z_!K_ ,-YX8_^5U?1]% 'SA_PQ[^R
MI_T;K\&O_#>>&/\ Y74?\,>_LJ?]&Z_!K_PWGAC_ .5U>/?M3_\ !3C]A']B
MGQ7HO@3]IC]HSPG\./&VO:2VOVWA&'1_&?CGQ+IWA[[3!90>(O$^B?#KPSXN
MU+P9X>O[N<6VE:]XNMM#TG6)[>_BTN\O'TS41:_9G@[QCX2^(?A3P[X[\!>)
M] \:^"?%^C:=XB\*>+O"NKV&O^&O$N@:O:QWNEZUH6MZ5<76FZKI6HV<T5S9
M7]C<SVMS!(DL,KHP) /@;X)_L-_#31?B%^T3J'Q)^ ?PNN_"7B#XCV>H_"."
M_P##WA'6K:R\'IHD,-Q!I>GQ)=OX?M3J8D=M.G@LI'D)F$!4AS]'?\,>_LJ?
M]&Z_!K_PWGAC_P"5U?1]?FY\>O\ @KC^P!^S+\5OB#\$_C/\:/$OASXD_"C3
M?#&L?$C1-#_9_P#VD?B'I_@S2_&6A6GB;PS?Z]XK^&_PA\7>#[*UU;1+ZWO8
M9GUXI$?/M;DP7EI=V\ !]*?\,>_LJ?\ 1NOP:_\ #>>&/_E=1_PQ[^RI_P!&
MZ_!K_P -YX8_^5U:W[.G[4'[/G[7'PYM/BS^S9\7/!?QB\ 75RVGR:[X/U1;
MN32-62VMKR70O$VC7*6NO>$O$<%G>65Y<^'/%&EZ1KEM9WME=3Z?'!=VTDOO
M- 'SA_PQ[^RI_P!&Z_!K_P -YX8_^5U'_#'O[*G_ $;K\&O_  WGAC_Y75]'
MU%<7$%K!-=74T5M;6T4EQ<7%Q(D,$$$*-)----(RQQ111JSR2.RHB*S,P4$T
M ?.O_#'O[*G_ $;K\&O_  WGAC_Y75\X_M;?L-_#7Q7^SY\0- ^ ?P#^%VF_
M%F__ .$4_P"$4O=%\/>$?"FIP_9?&_AN]UW[-K]RFFP6'F>&K;68IM][#]JM
MY);)?,>Y6*39^!'_  55_P"">7[37QFO_P!GWX%?M6?#3XA?%RSEUV*Q\*Z;
M)KVGP^+F\-?:GUL_#;Q+KNBZ5X2^*D5C:6&H:LT_PVUWQ5#-H.GZAXAMI)M#
ML+O4(?T$H **** "BBB@ HHHH **** "BBB@#RWXQ? _X.?M">"Y_AQ\=?A?
MX$^+W@&ZU"PU:X\&_$;PQI'B[PU/JFE2/+INH2Z-K=K>6+WEA*[R6EPT)E@=
MV:-E+'/PCXL_X(R?\$TO%GB71/%L?[,MC\/M:\.^"S\/='/P*^*/QN_9RTFU
M\'MXIUOQK-I#^'/@%\2OAMX=N_M?BGQ%JNLWVH7NE7&J:A<RVJ7M[<6^F:7#
M9_J!10!^37_!*_\ X)D>%/\ @G?I/[1-^-.T1OB!\;OCO\2/$Q\0^'_B3\6O
M'T%Q\$U\=^*=<^!GAC75^)MTD<'C7PIX:\47MGXNUG3]-N]4U_5IY;C7?&?C
M.6"VU-?U=N[2UO[6YL;ZVM[RRO;>:TO+.[ACN+6[M;B-H;BVN;>97BGMYXG>
M*:&5'CEC=D=65B#8HH ^.?$O[+.EZM^TS\-/BWI_ACX9VWP\\)_#KQEX6\0>
M&Y-%MX=1U+7M=NX)M)U"WT>#P])H=Y;V<4;I-=WNI6UY;E@MM;S*21]$_P#"
MJOA?_P!$W\!?^$?X>_\ E=7>T4 <%_PJKX7_ /1-_ 7_ (1_A[_Y74?\*J^%
M_P#T3?P%_P"$?X>_^5U>4?M2_M>_L]_L6^ -#^*'[27CJ\\ ^"O$WCO0?AEX
M?U'3O WQ$^(FH:OX[\46>KWWA_PY8^&_AAX3\9^)Y[S5;?0M4-M*NC_8S/;I
M:/<I=W=G#<>&?L\?\%5/V ?VIOB?=?!3X-?M%:)J/QAMDD>/X6^//!OQ,^"O
MQ U4P6EQJ%U!X<\)?&OP5\/==\4W=EIUI=:G?V7ANQU6[L-,MKC4KR""Q@EN
M% /LK_A57PO_ .B;^ O_  C_  ]_\KJ/^%5?"_\ Z)OX"_\ "/\ #W_RNKO:
M* ."_P"%5?"__HF_@+_PC_#W_P KJ/\ A57PO_Z)OX"_\(_P]_\ *ZN]KPG]
MH[]IKX$_LC_"^_\ C+^T5\1=*^&7PXT_6- \.R:_J5EK6KSWFO\ BC4X=)T+
M1=&\/^&=,UOQ+X@U6^NYC(-/T+1]1NK;3;74=9NXK?2-*U*^M #N?^%5?"__
M *)OX"_\(_P]_P#*ZC_A57PO_P"B;^ O_"/\/?\ RNKO:* /BWX4?LI6'@SX
M\?M,?$?Q-X;^&.J^"OBU>?"R?X>Z%:Z/#?7OAN+P=X:UC2?$B:CIFH>';72=
M'.J:A?6MS;+H=]J2WL<+S7YM9XXXW^E?^%5?"_\ Z)OX"_\ "/\ #W_RNKO:
M* ."_P"%5?"__HF_@+_PC_#W_P KJ/\ A57PO_Z)OX"_\(_P]_\ *ZOD[]IG
M_@I;^QC^Q_\ $O1?@]\?OBCXC\+?$KQ!\/V^*>E^$_#'P1^/GQ8OI?A\FN:G
MX;E\4W-Q\(/AAX\T_3=.@UK1]0L;D:E>6=S;-%%-<01VUY9S7'H'[*?[<G[)
M?[;WAG5_%?[+'QS\&_%[3_#EQ!:^)]-TA]4T7QAX4ENY+N*P/BWP!XLTW0/'
M7A:'5)+"_72+GQ!X<TVVU?[!?'3);L6=R8@#W'_A57PO_P"B;^ O_"/\/?\
MRNH_X55\+_\ HF_@+_PC_#W_ ,KJ[VB@#@O^%5?"_P#Z)OX"_P#"/\/?_*ZC
M_A57PO\ ^B;^ O\ PC_#W_RNKO:_.N/_ (*T_P#!..7]H:']EB+]K/X9R?&N
MY\7GX>V^A1CQ(_A.?X@+%$6\!P_%A=!/PCE\;"\G@T(^$T\<MX@'BJ:+P@=.
M_P"$ID31V /M?_A57PO_ .B;^ O_  C_  ]_\KJ/^%5?"_\ Z)OX"_\ "/\
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MZQDDD[J,E=6NR*L>>"4=)1W=UK>5^J>RM]Q\8Z[X \1>-]#UW0/#O]ERZ_\
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MYD^,OAZ7Q%'8OI>A^(/A)X?M=2BN9IU%[^U'[6C> ?@__P $\/VA+#XZ>/\
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M#P.L^M72:I<N ?8W_!)WXU?%K]K7PS^U#^V;XT\>:YKWP9^/?[2_CW1?V/\
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M'A:SUZPO_&4.D'QEHQUZPN+_ ,!0^*8K0W%SY5I/^?OP7T3]K_P=_P %2?\
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MWA'P_P##'X6?#2RF^(?BWPU8CPSXM\>:Y_:NK>(]%F>&_1KI8[Q0#]):***
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ME1]4D8-))([O\WWV;&!@ MY=%M?R_KU>F@:=+[];;?+^OOLOL;N<A@> 0V<
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M?^"I_P 8?^"COBW3_!W_  4Y\%_M+_%.W_9X^&UOIMO8:U)H7@?3HK[]B?\
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M2IQ!DD,72RYYQ5PT\UP$<12RB-/VKS2I1E752&7*DG4>.E%894_?=7EU-O\
MX97_ &8?^C<?@-_X:#X>_P#S/4?\,K_LP_\ 1N/P&_\ #0?#W_YGJP/!_P"V
M'^SCX^^!GBS]H_PG\3--U3X1> [;Q%-XS\0OIVN:;J'AFZ\*VZW6LZ-K/A;5
MM,L?%-CK\<,MJ^GZ'-HZZEK::CI,VAVVHP:QI<MW[OX2\3Z5XV\*^&O&6A&^
M.A^+= T?Q+HS:GIM_HVHMI6NZ?;ZGIS7^CZK;VFJ:5>-:74+7.G:E:6M_93%
M[:\MH+B*2),L1@<;A/:?6L)B<-[*O+"U57H5:+IXF$5.>'FJD8N-:$)1E.E*
MTXQE%N*35^G YQE&9J@\NS3+\>L3@J698=X+&8?%1KY?6J2I4<=1E0J353"5
M:D)TZ>(@W2J3A.,9N49)>3_\,K_LP_\ 1N/P&_\ #0?#W_YGJ/\ AE?]F'_H
MW'X#?^&@^'O_ ,SU>\T5RGI'@W_#*_[,/_1N/P&_\-!\/?\ YGJ/^&5_V8?^
MC<?@-_X:#X>__,]7O-% '@W_  RO^S#_ -&X_ ;_ ,-!\/?_ )GJ/^&5_P!F
M'_HW'X#?^&@^'O\ \SU>L^+?%.@^!O"OB;QMXIO_ .R_#'@[P_K/BGQ'J?V6
M\OO[.T'P]IUSJVKW_P!BTZWN]0N_LFGVEQ<?9;"TNKRX\ORK6WGG=(FYCX1_
M%OX>_';X=^&OBO\ "KQ!_P )3X \7P7UQX=U_P#LK6]#_M&'3=5O]$O7_LKQ
M'IND:U:>3JFF7UKMOM.MGD\CSH5DMY(99-EAZ[H2Q2H5GAHUHX>6)5.;H1KS
MA.I"A*MR^S5:=.G4J1IN7/*$)R47&,FN5X[!+&PRUXS"K,:F%J8ZG@'B*2QM
M3!4:M*A6QD,*Y^WEA:5>O0HU,1&FZ5.K6I4Y34ZD(OC?^&5_V8?^C<?@-_X:
M#X>__,]1_P ,K_LP_P#1N/P&_P##0?#W_P"9ZO>:*Q.H\&_X97_9A_Z-Q^ W
M_AH/A[_\SU'_  RO^S#_ -&X_ ;_ ,-!\/?_ )GJ]YHH \&_X97_ &8?^C<?
M@-_X:#X>_P#S/4?\,K_LP_\ 1N/P&_\ #0?#W_YGJ]YHH \&_P"&5_V8?^C<
M?@-_X:#X>_\ S/4?\,K_ +,/_1N/P&_\-!\/?_F>KWFB@#P;_AE?]F'_ *-Q
M^ W_ (:#X>__ #/4?\,K_LP_]&X_ ;_PT'P]_P#F>KWFB@#P;_AE?]F'_HW'
MX#?^&@^'O_S/4?\ #*_[,/\ T;C\!O\ PT'P]_\ F>KWFB@#P;_AE?\ 9A_Z
M-Q^ W_AH/A[_ /,]1_PRO^S#_P!&X_ ;_P -!\/?_F>KWFN(^(WQ*\ ?"+P?
MJ_C_ .)WB_0/ O@S0HDEU7Q'XDU&#3=-MC-(L-M;B6=E:YOKVX>.UT_3[5)[
M_4+R6&SL;:XN98XFNG3J5JD*5*G.K5J3C3ITZ<93J5)S:C&$(13E.<I-*,8I
MMMI)-LRKUZ&%H5L3B:U+#8;#TYUJ^(KU(4:%&C3BYU*M:K4E&G3ITX)RG.<H
MQC%.4FDFSSW_ (97_9A_Z-Q^ W_AH/A[_P#,]1_PRO\ LP_]&X_ ;_PT'P]_
M^9ZI/@/^TS\!_P!IO0-4\2_ GXEZ!\0]+T.]BT[7!IBZCI^JZ+=7"S/9KK'A
M_7;'2M?TN'4$MKI]+NK[3(+35%M+QM/GN1:7!BN?'']HKX)?LV>%8?&GQQ^(
MN@?#SP_=W8L-.GU9KRZU#5[["M)::'H.D6FHZ_KEQ;Q.L]W%I&F7KV=KFZNA
M#;*THZ7EV8+&?V<\#C%F'M%2^H/#5EC/:M*2I_5>3V_M'%IJ')S---*QYZSW
M(Y93_;T<YRJ61>Q>)_MI9CA'E/U>,W"5?^T56^I^QC-.#J^VY%-.+E=6,_\
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M8BK[##T*U>O:I+V-&E.K5Y:-.=6M+V<(RG:E2ISJ5':T*<)SE:,6UVXO'X'
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M JC2QAB"Z@@#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,^LSQ-7%U<37RW.YK!0KY>LQSSC)XBO&*RB,ODG_ (*)_%SXBZ+\8_AM\+O
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MN]-UBWTV:6Q,DJ>(++4+K6=*_7_]GO\ 84^"G[.G[/7CS]F3P]=>-?&OPO\
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MU.WT_P %Z?I.;KQ9J>K#2+S3]&TRVM;34]0U406*V,;W5J\_[:_\,7_L\?\
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M_P##K?%7_P";&K_M;P4_Z)CB+_PHQ'_T0F7^K'TNO^CB<"?^$."_^@4_'/\
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MTT[3?$-]IEUK&HZOK7C.26T33M0_6N@ HHHH **** "BBB@ HHHH **^.?\
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M0BX2GRJ<.;_2QHK_ #2?^(@/_@KG_P!':_\ F!OV9?\ YS%'_$0'_P %<_\
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M=)^RCXF\0^+-5\#:^?VA=2L-7N/"?@SPSK>@ZOH>H>('\5KH\\\_PUU.[O\
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M7XV?L/?"O_@JQXU^'_P7_:BT#]H[X@_M&_L:>"8M9^,,=KKLE_\ M+?MA_\
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M[:,NL4%O#&BRW>H:E?W+Q66E:1IMO=ZKJ^H3V^G:99W=]<P6\GX(^%="\/\
MP\_X*D?\$V=.^%&D:1H&C^+?V&-*MO%5KX86"SL?$'AZW^'7Q>N-.U+6Y;)7
M&K-Y^@:%<0:KJ#7%QJESH>D0R7LK6ULT7OW_  6[DGN?@[^S-X=U2&)O 'B3
M]K+X>V'CB6XO7L[.:T70?%9MM*U$IY0;3[VRDUJ]GDDNX%MI-)@G"/(B3VN=
M;A/+I\2\/Y9A,1CJ66YY@Z>._P!IEAZF/PU*&(Q]#$4>>G2H4*E:3RZI+#R]
MC"*=:G"49N$G+?!^)V?4O#[CCB'-,#E&(S_@W-:V36RZGCL/DF/Q-7 Y'C<!
MBO95\3C,;1PM)9]AZ>.A];J3:PM>K"I1C5@J?Z4_ 3]JO]GO]I[P_KWBCX%_
M%#0O'FD^%KJ&T\2^3;ZQH.J>'WN;>6ZLY]9T#Q3INAZ_IMA?PVUXVGZG>:9#
MINH-I^IQ65W/+IFH);<7\*?V\/V1/CA\3=0^#OPJ^.GA'QA\1=/;5U70;*+7
M+.'6O["\QM5/A'7M5TFP\.>-TM;:&XU$2>#M7UU+C1[6\UJV:;2;.ZO8OQ ^
M,+ZK\-_VY?\ @K7X?^$>DVNA:#/_ ,$^M?U_6]#\-^7H.CZ9JJ?#_P"#@G\2
M166F6OV2VUS3](\1>*-7MA'#:W$\VIZKJ(N(IKJYNV\PT[0O#_@GPA_P08\5
M_#72-(TGQCXB^*>JZ?KFK:"L%KJ_B2UUCXK?#FW\7V&N:I:K)>W]F'U_Q%I]
M^EZ]S#HMOJ^JV445I;SSV[>Q#@/**M+V\,7F,89GA,-7R:$JN$E/!U*_#&+X
MBDLVE'#Q6(IIX7ZK!X:G@W*$WB'+]VZ4OE*WC7Q3A<3]2K9;D%2MP[F>8X/B
MNM3PV:4Z6:T,'XC93P'3EPU3ECZCR^O*&9O,JJQ];-E3JTH8)0:K+$1_I4^+
MG[27P1^!.N_#/PO\5O'UAX4\1_&+Q5:^"_AMH;Z;KNLZIXH\0WEYI^G16]O9
M>'M*U:>QL([[5M+M+S7=62PT'3[C4;&*^U.V>ZA#^XU_.'_P4+_9?T+X6_M0
M?LA_'34?'7C[XB_$;XP?MQ>#()+[QCKMU>Z/X$^'\/CW3->\-?#3P+HKS30Z
M3X;\/OJ;*OFS7+SW:375C%I%M>3Z<?Z/*^+SK*,NP&5\/X[ 8O$8R6:8?'3Q
M52K2C0HQK83%*@X86DU[94X7E!U*TY2K2A[6-.C&2IK]=X1XHSW.^(N.<HSK
M+,#E4.&\=D]#+:&&Q$\7BIX3,LL^NJMF.)4_JL\15]VK&CA*4*>%IU%AYUL5
M4IRKR\1^/O[1OP:_9?\ !-K\1?CGXQ_X0?P;>^(+'PM;:Q_PCWBKQ-YNO:E9
M:EJ%E8?V?X/T/Q!JJ>?9Z1J,WVJ2Q2SC^S^7-<1RS0)+!\2OVF/@=\(O!?P]
M^(GC[Q]9:7X(^*WB;PGX0^'GB33=*\0^*M.\4Z]XZTF_USPE;V#^$M(UV1++
M6](TR\O[76KN.VT18(XS/J,+7%LLWYF_\%W;1+_]COP+82LZ17O[2/PYM)'C
MP'1+GPM\1(79-P9=ZJY*[E8;@,@CBOR0^,'CCXD?!;PE\-/^";OQOFO=4\7_
M +/?[;_P6\;_  <\7/!.UEXQ^ ^L:;\0X+6>WN66:-+71M3\1Z+)I=O-J5[<
M6$/B&\\&*EH/ ,UNGU'#G V"SW*,JQZQ>)6*Q&/S"&/P=.I1C-Y5@EAZ<\9@
ME+#S:GA<3B\+'%*HZT71Q"JQC35&;E^;<?>,N<<&<4\2Y(\KR^66X+),BJY)
MFU>CBYTH\2YM/&UZ>4YNZ>.HQ=+,<OR[,:F62H+"S6*P$L-4GB)XJC&G_8M7
MB_QU_:&^#7[-'@^Q\??''QQ9> ?"6I>(;/PI8:Q>Z;KFJI=>(=0T_5-5L],B
MM/#VEZOJ#33:=HFJW>_[(($BLI3)*AV!OY\OVO\ ]J7_ (0W]IGXR>%_^'GO
MQ]^#W]B^,+FR_P"%9>&?V9?^$OT'P9MM+1_['TOQ-_PM71?[9M8]_G+>?V58
M[FF9/(&S)CU'PG\7OVU_@#^S7I?PL_:I\ _M(_\ "._M<>*/%&H:[^U;X>A^
M$5QK^O>$?"/@:X\+^"[/X;'6O'%]X_\ ".DV&L>+[GQ-9:5<3:AJ5KXD-G'I
M8MXKJZ6,'P!&$,KQ^;9D\/E>-5*IB)K+\XP4J-&I@ZF,7+C\?E*R[F?LU2C.
M-2O"I*2E256-VNC-/'"I7J\29+PQP_'&\292\10P-&6><*9Q'%XK#YMALKES
MY+DG$\L_]FGB)8BI2J8?"5*,*<H8F6'J^X?LEH__  4J_8BU_P #^-?B1I'Q
MWTJ\\$_#O4O"&D>,M=7PA\18HM$U'QY)KD7A*VEM)_!\6HW3:Q)X:UM8Y-/L
M[N*V-@YOI+436QFN?"O_ (*-_L6_&WQ]X=^%WPN^..E^*_'GBN:]M_#_ (?M
M_"?Q!TZ;49M.TN^UF]1+W6?"6G:9 8-,TZ]NB;J]@5U@,<9>9XXW^./^"?U_
MIOCGQ=^U)^R#^T1^SW^S#?>.O@5KW@9O%_BWX4_";PE9?#CXGV]X-?N?#D_B
M70HO"MAH:^)/"S3WC:.\]AIUP(-6U:U@T#2M1T77;O4L/_@G3\,/AE\>OVCO
MCU^W9X?^''@;P9X!\-^*-3^!/[+6@>$/">A^%-,L?"WAJUFM?&'Q.?3=&TC3
M8)O$'C>'65M+?5I&DU#3;75/%WA>::YTZWTTP1C>'>'<%3XC=:GG=-Y5A<'7
MP&)CF66XG"8J>;87#5,HIMPRRE4K+%RGB,;*47AI4\OHSC*$<52E&IKE''G'
MF;U^ 5@\1P?B(\2YEFF"SO+ZG#_$&7YIEU'AG,<=1XJKQ5;B+$T<'+*J=+!9
M1&%59A"MGN+H5*=6KE^)A*C^WU%%%?G!^^A1110 4444 %%%% !1110 4444
M %%%% !1110 45C^(KO4[#P_KE]HEBNIZS9:/J=WI&FNQ1-0U.VLIYK"Q=P0
M46[NDB@9@05$A(((S7XVZC^UW^T2+^\5_&2:2ZW,R/ID?A'PHJ6#HY5[0+J.
M@W5^OD,#&5O+F:X4J1+(S@FOYA^D3]+'PY^C-5X8H\>9+QSFU3BRGF57+7PE
MDV68ZA2AE<L+#$K%XO.<]R#!QJ\V,H\F'PV(Q6)4'[6M1I4ITIU/T?@+PPS_
M ,1(YE/),9DV%CE<L/'$?VIB\11G)XE573]E2PF"QU5QM2G>I4A3IMKEA.4E
M)1_:JBOQ)_X:[_:'_P"BA?\ EI^!_P#YFJ/^&N_VA_\ HH7_ ):?@?\ ^9JO
MYH_XJL_1X_Z(WQG_ /$=X'_^F*?H?_$LO'G_ $-N$?\ POSG_P"<!^VU?-?[
M4O[7O[/?[%O@#0_BA^TEXZO/ /@KQ-X[T'X9>']1T[P-\1/B)J&K^._%%GJ]
M]X?\.6/AOX8>$_&?B>>\U6WT+5#;2KH_V,SVZ6CW*7=W9PW'YN_\-=_M#_\
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MAJVFR76G7EO+/IFKZ?8:MILYDL=3L;.^M[BVB[ROP._X(F?%S0/!NJ_M:_\
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MK?F=)_8.^#EK^T'\;_VD/$NL>.?B'XQ_:)_9^\'?LV_%CPWXUN?!L_@'Q)X
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M7XPT?1?&UDVA?&FQ\-/?6T'C'P_X2T31-4>6[75M-N++PSHNM:R0#]QZ***
M"BBB@ HKS?Q#\9/A#X2U:YT'Q7\5?AOX9UVS6!KS1?$/CGPQHNK6BW4$5U;-
M<Z=J6J6UY MQ:S0W,!EA0302Q31[HY%8XO\ PT1^S_\ ]%S^#O\ X<WP5_\
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M#1;WQ!J>C>-;G3;/PWI#:GIWDV7AG2C#*LWZBT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M''?$3P[JWB_X?^.?">@>(KWP?KOBCP=XF\.Z+XMTPXU+POJVMZ+>Z;IWB+3R
M""+W1+RYAU.T((_?VL?-?R ZK_P1"_;Q;4]0>6T^&&MRO>W3RZS'\2 Z:K*\
MSO)J*OJNE6>IN+QRUQOU"TMKQS(6N88YBZC^R^BOK.&>,\XX4CBX97'!2CC)
M4I5OK6'=5J5%34.2<*E*:5IN\7*4;ZJ*;;?YAXA^$O"OB;4RNKQ'/-J<\IAB
M:>%>6XZ.&BX8N5&555:5;#XFE*2="/+4A3IU+-QG.<5!0_C!_P"'('[=W_0
M^&?_ (<;3_\ Y#H_X<@?MW?] #X9_P#AQM/_ /D.O[/J*^I_XC%Q;_S[RC_P
MCK?_ #6?FW_$J/AA_P!!'%7_ (=L'_\ .K^KORM_&#_PY _;N_Z 'PS_ /#C
M:?\ _(=;'[47[&'QU_8Z_P""==CI7QL\8:?>R^-O^"@/[$=[X:^'OA_7+K7_
M  _X-MM&^)\\>I:P+NXM+2TMM;\67.IPKJ-GHZRV8L="TFYNKVZOKB2TTO\
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MUXGUBQL-1_47XN_\%UOV8-=\,?!_PO\ L :OHO[<7[4W[0?BOP-HOPI_9_\
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M^%_C27]K*V_X)0:[X8 _9^_X):?M _M,?MP:%?2V.J7.B:K\+_B'X8L_%_\
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M_:9[_@H-_P"IEX3K]GJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_/\ [J__ ,I.L_X?6?LB_P#0N_&__P ([PI_\W]?!/\ P6%_;#\4?M1?L3?
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M/C!;:1X$^+?@/XE1V]NEIX>AUZ*9=*L;?2]5A3.I7>N3?\$^_P!ACXJ^%?\
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MX([W1EFTA=1U'^AZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>nt10016217x4_graphic13x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic13x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBD) _'\?Y4 +17%P?$/P9=>.M2^&=OKUI+XZTCPYI_BW4O#BB;[=:
M^'-5O;O3M/U60F(0&WNKZQN[:/;*TGF6\@9% R=_6]=T7PWI6H:[XAU73]#T
M32;66]U35]6O(-/TS3K.%=\UW?7UU)%;6MM$OS2SSR)'&H+,P'- &K17B6C_
M +2W[._B'5-/T/0?CI\(]9UG5KJ&QTO2M,^(GA.^U'4;VXD6*WM+*RM]5DN+
MJYGE=(HH((WEDD941"Q KV>YN;>SMYKJ[GAMK6WBDGN+BXD2&""&)#)+--+(
M5CBBC16>21V5$4%F( )H FHKC?!OQ%\ _$2RN]2\ ^-/"WC73["[;3[Z^\*Z
M[INOVEG?(B2/9W-QI=S=107*I(CM#*ZR!6!V\U4TOXJ?#+7/%.H>!]&^(/@O
M5O&>E"1M3\)Z=XFT:]\1Z>(@AE-YHMO>2:C;>4)$,OG6R>6'7=C(H [VBO,]
M0^-/P@TG5K?0-4^*/P_TW7+K69O#MMH]]XPT"TU.XU^W6%Y]%AL9[]+F35(1
M<V_FV*1M<Q^=%NB'F+F]XO\ BM\,?A]/IEMX[^(7@OP9<:RYCTB#Q1XFT?09
M=4D5TB*:?'J=Y:M=N))(X]L D.]U7&Y@" =]17->(_&?A#P?H<WB?Q7XH\/^
M&O#D$<<L^OZ]J]AI.CQ13%!#))J5]<06BI*73RV,VU]PVDY%4;/XB^ =1\,0
M^-;#QIX6OO!USY(M_%-IKVEW/AZ8W%PMI (M8ANGL)#-=/';1A)V+SR)$N7=
M00#LZ*\X7XP_"A_#NK^+T^)7@5O"F@:C-I&N>)1XJT3^P=(U:VD6*XTS4M7^
MV_8++4()'1);.XN([A&95,>2!70:-XU\'>(O#J>+] \4^'M;\*26\MY'XETG
M6-/U#0GM8 S3W*ZM:7$MB8(51C++Y^R,*=[+B@#IZ*^6])_:=\+^*_CUX'^$
MO@2[\,>-_#'C#X:^.?'C>/O#/BNRUFTL+_P9KWAG16\/K;:7%>6<[72>(3<R
MSOJ<,UHUJ(S:/YI>/ZDH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_$*X_9BUNVNM4^$D$&G_  DM-4AMM47P/INNV]C';6+?%(W\LQLWBMYM4M[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$>HBZCW$3,K2JK*!=:;[ZZ]-/\OR['X'>+/AMX#7]C/]H33]-\,Z%H/]M_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^)_@P][\'_"DU[;WO[=/[/7[.X^&,EC;K%'8?$J31/"OPP^)-S!-'%^\O/\
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M4GS##*+Q(M(U36K46D_F-]FWWHF.UA)$N%-=]0 4444 %%%% !1110 4444
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MFZ>OZ[XR_P"20XJ_[)O//_57BC\BR;_D<91_V-,O_P#4RB?E1\!/^2O^#/\
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ML^,7_)8OV6/^RD^./_5-^/:^DZ^;/C%_R6+]EC_LI/CC_P!4WX]H ^DZ***
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M?^JO%'X+DW_(XRC_ +&F7_\ J91/RH^ G_)7_!G_ &&$_DU?LS']Q?I7XS?
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M8_"/_7T__HB:OV4K\:_V;?\ DL?A'_KZ?_T1-7[*5_('T ?^35<5?]E[BO\
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ME\/^+-/\N]>REAUSPQJ4>IZ1+)+;2Q22PP7L*/):RLT,X!CE1E9@?RF^ O\
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M=?\ )$_2)\N/N U\UG_%B?XH_IV/_(]\-O\ L2YU_P"JW)#[S^ ! ^$'@K)
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M\;69?C9XS168*/$EUQN)',X0\$D#ACP !DYQ7[--T/T/\J_&3XW?\EN\9_\
M8R77_I2M=/T^TI< <")J_P#QG"_]4V8+IY-H7@#_ ,E#GG9Y)JNC_P!NPVZZ
MG[%Z;_QZVQ];2W^G$8 Q7R#^VG_R(.A?]C"/_26:OK[3/^/2U_Z](/\ T 5\
M@_MI_P#(@Z%_V,(_])9J_=?I,_\ */\ XC?]D_A__5A@#X7PQ_Y.#PW_ -A]
M3_TQ6*O[%'_(F^)_^PW9_P#I--7V9>_ZJ7_KA-_Z+:OC/]BC_D3?$_\ V&[/
M_P!)IJ^S+W_52_\ 7";_ -%M6/T6_P#E'WPW_P"Q/C/_ %=9F/Q1_P"3@\2_
M]AU'_P!0\*?AGIW_ "/MG_V,,/\ Z7RU^ZL/^JB_ZYI_Z"*_"K3O^1]L_P#L
M88?_ $OEK]U8?]5%_P!<T_\ 017\V?L_O]V\6?\ L:\._P#I?$I^E?2 _B\(
M?]@>9_\ O,)****_T7/YU ]#]/<?RY_+FOG'X_\ P[^.GC"ST/5?@/\ &BT^
M%7B;P^U\T^E>(?".E^,?!'C*WN5MWCL/$=G>(NIZ>T$]OLM]5T:[CN[:"XN2
M(IG:-4^CCT/_ .K]>U?,W[0WQ2^.?PS@T*Z^#WP!'QLMKJ+4YO$\\GQ&\)^
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M]ECV^)/C?KQU^#?CT#&<9)]!S@$] 2 1]*4444 %%%% !1110 4444 %%%%
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M -3L<%%%%?W6?A@4444 %%%% !1110 4444 %%(6"]<],]">!UZ _P">:6@
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MIWQR<>N.I[<#GFJ]M]P_7_&N1\?:5XGUWP[<:?X-\7#P7K;R1R1ZRWA^P\2
MVRH_G6@TS5)K:V8W(9 +CS=\!7*@[B*_I3Y_\$_-5_P_D=G%+',BO&ZR(V=K
MHRNAP2#AE)4\@CKUR.H($E?(?[&OPS^+_P +?A%X:\-_%OQA)K6K6=C=PCP]
M)H^BV\OA^5]:U6[/F:[I%_J"ZT+NWN8)$\QT%J!Y0)(9%^O* "BBB@ HKY]_
M:/\ CI;? /X:>)_&IT'Q%X@U/3/#OB#5M&L='\)>+O$FFS7VC:?)>QQ:_?\
MA?1]6'A_3I75%DO]0-K;JC2.)"(I-GD'C3]I[59/A7X/^(7@[3-7TFXUN:RM
M-3L?%_@_Q-X8=+F?1;34Y3IUEXJTS2;R]T]9+L1P:G!%):72C;'<&57"?*<;
M\8Y1X?\ "N<\8Y\L6\HR+#0Q6-C@:,,1BY4ZF(HX6$:%"I5H1J3E6Q%./*ZL
M%9MN5D>KDF3XS/\ -<'D^ ]E]<QU25*A[>;ITN:-.=5\]11GRKDIRUY7K9=3
M[AHKYR_9N^)_B+XI>&]>U;Q&;7[3I^L1V, M(# @B:U6X.5+ON.90N<@_+TQ
M@GZ-JN">,,HX^X6R;C#(?K2RC/<-/%8'Z[06&Q7LH8BMAG[:@JE54I^TH3]W
MVDGRV;LVTEG648S(<TQF48_V7US U%2K^QFZE+G=.%3W)N,')<LXZ\JUO:ZL
MV4445]2>6%?,'[7G_)'+W_L.Z1_*[KZ?KY@_:\_Y(Y>_]AW2/Y7=?D/C]_R9
M/Q3_ .R'XA_]5]8^MX"_Y+7A;_L>Y;_ZE4SY_P#V,+HV,?Q0O0GF?8]+TN[\
MO.WS!;/J\Q3=@[=X0KG!QG.*]2^'W[4</CSQMI7A%/"BV4FH74MJ;PZD9S;;
M$D)98S:(6#&)<@N.2>,J,^2?L??\@[XN_P#8OVO_ *+UNO'?V>2?^%X^&AV_
MM2[./?$XS^1K^!^ ?$WCC@?@;Z).0<+YW_9F3\9\4\4Y=Q+A/J&6XMYCA%XC
M8;"JDJV-P>)KX5_5\?BZ3G@ZM"I:LY<RG"G*'[YGW#&29[GOBOC\TP?UG%Y-
ME>45\NJ^WQ-+ZO5?#M6KS<E&M3IU?WF'HS2JQFKP2M9R3X;XE?\ )4/%_P#V
M-.J?^G*XKVS]K'_D9/ G_8@:1_*:O$_B5_R5#Q?_ -C3JG_IRN*]L_:Q_P"1
MD\"?]B!I'\IJ_ E_R1/TB?\ LO> O_5]Q8?H,?\ D>^&W_8ESK_U69(>D^(/
MB=XL^&?P0^$=YX4NK:TEU&VU6.[:>TM[PN+:^\R+8MQ&Z(5$LPR!_$OU6MHG
MQ2\8?$_X)_%Z;Q9>6UX=.M-$AM?*L[>TV"YU-_-W"T2 2#]Q'MW8(P<D@UP_
MQA_Y()\%O^N6N?\ I2*I_"#_ )(9\;?^N7AS_P!.5S7[*N-^,/\ B(=/@S_6
M?/?]4O\ B72%3_5O^T\8\DY_^)?%F'/_ &8ZKP3D\<OK3DZ+DZ_[R_,VSXF.
M1Y/_ *MO.?[,P+S;_B(BA_:7U:E]=49<?QP[C]8455M[!NE;FM[/W=C'_95_
MY+-X>_Z]M9_],]]7ZXI]Q?\ =7^0K\COV5?^2S>'O^O;6?\ TSWU?KBGW%_W
M5_D*_I#Z!'_)GL^_[.!FW_JBX;/S?QZ_Y+' ?]D_A?\ U.S =113'D1/O,!Q
MG')./8 $G\!7]O'XF>!?M/\ _)%O%?\ UTT;_P!/%E7RG^Q#_P CEXJ_[%D_
M^G#1Z^JOVGG5O@OXK"G.)-&/0]#K%ESTY_"OE7]B'_D<O%7_ &+)_P#3AH]?
MP'XJZ_3>\$K?]$O0_P#2^-S]ZX6_Y,EQK_V-I_\ I&0GZ5MT/T/\J_&3XW?\
MEN\9_P#8R77_ *4K7[-MT/T/\J_&3XW?\EN\9_\ 8R7/_I2M=7T^O^2!X$_[
M+B/_ *I\P%X _P#)0YY_V)/_ '>PQ^P]A+'#96KRNL:BTMP6=@JY*JH!)( R
M2 .V2!W%?(O[:1SX!T(^OB$'_P E9JA_:Y^&/QB^*7PDN] ^$GC,Z3?R0^'!
M+X8CT+0KJ75YK3Q#H]\U[_;^KZIIITM=/MK:XN&MXI,7JPF#YS*$;F?VH-,\
M2:-\)?#&G^+/%8\9:U'XDG>;71H-EX<%S$\$K01#2M/FGM8?L\?[HLDI,F"S
M@-P/W3Z3.OT?_$9K_HG\/_ZL<O7_  ?^#H?#>&5O^(@\-N^KS"JK?]P*SW[Z
M/3MKW.B_8H_Y$WQ/_P!ANS_])IJ^S+W_ %4O_7";_P!%M7QG^Q1_R)OB?_L-
MV?\ Z335]F7O^JE_ZX3?^BVK'Z+?_*/OAO\ ]B?&?^KK,P\4?^3@\2_]AU'_
M -0\*?AGIW_(^V?_ &,,/_I?+7[JP_ZJ+_KFG_H(K\*M._Y'VS_[&&'_ -+Y
M:_=6'_51?]<T_P#017\V?L_O]V\6?^QKP[_Z7Q*?I7T@/XO"'_8'F?\ [S"2
MBBBO]%S^=0KYH_;&T"T\5?LQ?&SPU?>,M.^'UMKOP_U[2G\8:Q>3:=H^AR7M
MN(8+K5M0MP9K+3'G:.VO[A>(K6XED?"H67Z7)P"?09KY>_:F^,/@GX;_  V\
M5Z5KTGP[U;Q-K7@GQ5JOAWP)\3-1BT[POXML= AMO[>&N23V]U"/#VG0WUO+
MK#-!,RV\J*D3RRQ*0/0_*+]C_P#8I\9^!_VD?A=\4_"'P_\ @Q;?##2K[7O&
MVH?$GP7X\L/&,KVOBSX6V'AF]^&VB6L<\\CVNA>.;?4=5TG7U57.GWUU 959
MY(Q^_0R8SG*D[OO8)!+'KVX]!VX':OP$_8C\+?!5OVE- ^(.F_M2_![P]X[\
M23:N;;]F?]F6Y\0Z7\,O$%R=*UJ>2+7K;6[CR=>NM,LIGO[=].TG1[5)=/\
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M:^Z0, #T&*^;/C%_R6+]EC_LI/CC_P!4WX]H$?2=%%% !1110 4444 %%%%
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M_P!$6E?L@W0_0_RK\;_VAO\ DMOC'_L)Q?\ HBTK\@^G[_R:SA3_ ++O"_\
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M*_\ L14?_4['!1117]UGX8%%%(2!U('U('\Z %HI-RCJP'XBE!!&001ZCD4
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MMM:^]OV</^20>"_^O34?_3G=5\$_M7?\EBUK_KRTG_TVVM?>W[.'_)(/!?\
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M;!ZX8G/)%?SWXB>.2X*\4N#/"R/#M3'5>-LM6*IY]#-8X595*K7S3#1C]0>
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MPVG_ *!)3?B3_P ER\3_ /8]W?\ Z=9:_BK#?\F(R?\ [/?B?_6)RH_89?\
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M91_#KQFVI?9O[/.OA;W[8(C:&VDTF".9+D3@Q-!(CE)$<%74E6# E3Z'\/\
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MR\.?^G*YJY\8?^2"?!;_ *Y:Y_Z4BJ?P@_Y(9\;?^N7AS_TY7-?>K_D]-/\
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MPQ_ZUV1'@>#VGB%D3\LR_P#57C#3T;_DSK7?^PQ;_P#IZTRJ?[$/_(Y>*O\
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M?^1W_P"Y@C_]+%K]RK7_ %$?^ZO_ *"*_#67_D=_^Y@C_P#2Q:_<JU_U$?\
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M\3_^M#F)[/C3_P G!S;_ +!LK_\ 5=A@HI,CU'YBE!!Y!R/45_5I^5!1110
M4R3[A]RH_ L ?S%/IDGW#]5_]"% UNO5?F?B[\<44_%[QM\N?^*CON.3G_2G
M[=R??)/O7ZC>'O%_AGP'\)?"WB+Q=J]KH6B6GA[PK;W.HW8E-O%/J%OI]A9Q
MMY$<K;KB]N8+="J$&25-Q"G(_+OXXX_X6[XWST_X2.^S]/M3U]C_ !3_ &:-
M$_:.^"/A+0KO7-=\/ZPOASP6;*^L?$WC#3-)CMK*\T76;I+W0?#OB#1;'4YI
MX[22WM+J]2>>QD>.:V=#%D?YT_0__P"3U?2%V5LTQ*7SXJSO3TT7J?T3XO\
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MMI7WG^T/_P D@\;_ /8)C_\ 3E8U\&?LI?\ (V>,O^R?>)?_ $;:5_GSX_\
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M9(Y8V4LK)(K!T*L1M9>3U/\ 9^1:Y)D[>K_LK+__ %$HGXIC?]\Q?_837_\
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MU74-T-C?S!@D(\@(\T8@:5<Q$@-&!WQS7CO[6/\ R5F7_L":%_Z0BM?XA_\
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MWUXZ_,.,].]?V.?CI^9O[:[$>-?#>"1_Q3*M@=,_VIJ?..F?P]JQ+/)_9+U
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MS_\ ]>/P*?J.6?\ )->$G_8SRS_UG<Z.Z^!/_)O'QA_ZZ77_ *:;6N(_8_\
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M2&?&W_KEX<_].5S7WJ_Y/33_ .T<8?\ L.!\['_DB7_V<:'_ *\2F8_[*O\
MR6;P]_U[:S_Z9[ZOJ?X\_M/:[\)/'_PI\&Z3\,/B'XCM/%WCJ#P[K6KZ9X/.
MJZ?J&G3>%-<UW[-X0NXM=L3?:Y;W.G6Z7-O-:[8[9;TX9D0GY4_998K\9/#Y
M'7[+K)!QGG^R;T8('J"3GVQU(K[PO?B]\%?$'B'1='OKS3=3\0Z-KBC0Q?Z%
M=W,^DZZR3Z<)].N[BR=+.[9+B:T:YM98W,$TJ"0H_/\ 37T).*>&>&?!_'QX
MBXAR3(IYKXCYQA<LAG&9X/+99AB89'PM&6'P4<96H/%UE*O13IT/:2O5A%I.
M21^9>->5YGF7&.'EE^78W'QPG#N#J8IX3#5L0J%*>/S*U2JZ,)^RA:$WS3LO
M=>Z3,WQ%^T-\)H#)H7B^#5K:Y:*PN+_P[X@\.Q27-K*\-MJ<%OJ%I++/"E[:
M$PR.A\SR+J(>7(S(DA^=OVP=8L?$.E?#76]-D>73]3L]2O;-Y%9':&8VC(61
MB2A]5SQT]:\/_:1'_%Y?&G5<WMJQ'7!.B6>>&W \D]L$]@.*[WX^_P#),O@7
M_P!BU/[?PVOIQ7Y5XJ>-_&7B'PS]);@7/J.20R7@C,L'ALFJ9?@<3AL=.GEW
MBKE>34'CJU;'8BG6F\'2A*JZ="A&59N<8P3Y%]9PKP-D_#N:>&F>X&IC9XW/
M,/4JXR.(K4JE"+Q7"^*QE14(0H4Y1BJSM'FJ3?)9-MJYVNC?\F=:[_V&+?\
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MGV2?\*66X*K@<?AL56\1,QIUL%1>$SJC6J8:JW&A+%+$4>:C4J5'A_<]E/\
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M.CE"\#<J2S#,94X^.E=T9RRG#PJ5*7^K.4T+U*<<WG&E467IX]4XU:R=>4<
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M[K=-U)N-]'",%*7.YP['X$X_X9X^,.#G][=#T_YA%H?Z_I7G_P"R41_PLR]
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M_A*M*TFWFTV"YTJ_O_WWAK6YM!NKC0[O4X4OTGTYH3%:Q7,$<X?3[_T_X/\
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MH?MW<_MH?M*@\C_A=?Q _P#'/$=Z%_(?GWS7]W7[,?\ R;E\ O\ LCGPV_\
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M ^I/ '<U]TY'J.>GO7^C_P!$O_E'KPX_[ \\_P#6HSL_G'Q9_P"3A\2?]?\
M!?\ JKP(C=#]#_*OQO\ VAO^2V^,?^PG%_Z(M*_9!NA^A_E7XW_M#?\ );?&
M/_83B_\ 1%I7Y!]/W_DUG"G_ &7>%_\ 5#GI]E]'_P#Y*K-?^Q%5_P#4[!'M
MG[7O_((^%?\ V!&_]%:;7':O_P FGZ'_ -CU+_Z;9:[']KW_ )!'PK_[ C?^
MBM-KCM7_ .33]#_['J7_ --LM?SWXD?\GK^D?_V9B/\ ZI?#T_0^'/\ DC?#
M?_LM)?\ J=GQV'[$G_(T>+_^P/;_ /IRBK])'^XW^ZW\C7YM_L2?\C1XO_[
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MO [_ +$>'_\ 5CQ.?T+X>_\ )IN-_P#L9_\ NOE1X_\ #K_DIOA/_L:]/_\
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M_)+O G_8O6W_ *%)7J]>4?!3_DE_@3_L7K;_ -"DKU?(Z9Y]*_VO\.O^3?\
M _\ V1_#'_JCP!_%/$/_ "/\\_['&9_^IM<I7_\ Q[2_]<I?_1;5^,OPX_Y+
M;X2_[''3/_2^WK]FK_\ X]I?^N4O_HMJ_&7X<?\ );?"7_8XZ9_Z7V]?QO\
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M(_\ 5AEIU?[57_'W\-O^R=Z%_P"BI:^K/V._^22M_P!C!??^D6G5\I_M5?\
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M"7/PUTG48?%JZ2);J?6?&6CW<#V+:3?7B&.%+&19_/,;AY(MJG+!?CS]N?\
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M5NVMM\S9L+;6VALX.,5Z'\'_ /DV3XM_6_\ _1-M7F'[+G_([^)O^Q!\5_\
MI.E?4</:\>?0G_[)S*__ %L<^/%S+_D0^-'_ &,J_P#ZILN/BCP+_P %_KWQ
MG\0/"G@5OV9;:P_X2?Q5I'AG^T/^%I23M:?VKJ<&G?:OLP\#JLS1";S!!]H0
M.0%,J AQ]H_M. CXWZV2<_/I'&.F=.MAU[CY0.@Y!K^/KX&?\G!?"?\ [*OX
M/_\ 4FT^O[!_VG?^2WZW_O:/_P"F^"OZ5^GI_P FDX<7_5PLG_#)N(?\_P #
M\X\!/^2NS)?]4[C'_P"7V6K]6;/[3O\ J?A7_P!DXT+^5W5ZR_Y-*U'_ +*#
M_P"VEM5']IW_ %/PK_[)QH7\KNKUE_R:5J/_ &4'_P!M+:OY-SO_ )/#X_\
M_9F^(/\ UCN%S]:P7_)'\ _]EKEO_JWS(R_V6_\ D(?$3_LFWB3^4-<Q^SA_
MR7'PM_U_:O\ ^D%_73_LM_\ (0^(G_9-O$G\H:YC]G#_ )+CX6_Z_M7_ /2"
M_KYS@[^%]$G_ +.GG'_KP.$CT,Y_C^+7_9-9?_ZS^9'!^._^2G>)O^QPOO\
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M &5=#_U8GSM^Q[_R#OB[_P!B_:?^B];KQS]GC_DN7AK_ +"=W_*:O8_V/?\
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M -!%?AK+_P CO_W,$?\ Z6+7[E6O^HC_ -U?_017^='T!/\ >?&?_L9\*_\
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M2,_DS^T*<_&SQB1_T%(P.G.(+09X)[YX.#QR!Q7Y!]/U_P#&K>%%WX[PMO\
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M_P#6+X]/G8?\DMXA_P#9QY_^KGAXX/X"?\EB\$?]AM/_ $"2F_$G_DN7B?\
M['N[_P#3K+3O@)_R6+P1_P!AM/\ T"2F_$G_ )+EXG_['N[_ /3K+7X%@_\
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MA6 _Y,3QU_V=K@'_ -9WCX^]J?\ )=9#_P!DGGW_ *L^'#]1/AW_ ,B-X/\
M^Q5\._\ IIM:\4_:\_Y(Y>_]AW2/Y7=?-OQY_P""C7P(_8LT[X2^$OBS8>.K
MK5/%_P .-%\0:8WA/1].U.U2QMK:/3Y%N9;[5=.=)O/MY"JHCJ4VL6!.!G7/
M[6GPR_;&_99\0?$OX5VWB6UT#2?B);>$[N+Q3IUKIM__ &G8V,6H3/'!9W^H
MPO;-!J5N4D,X??YBF-=N3_KIXL+_ (YNXR_[-7B__5!'_,_D7A9/_B(^3?\
M95T/_5BO\T;7['O_ "#OB[_V+]I_Z+UNO'/V>/\ DN7AK_L)W?\ *:O8_P!C
MW_D'?%W_ +%^T_\ 1>MUXY^SQ_R7+PU_V$[O^4U?YT9;_P D[]"'_LM^*?\
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M/^2<^!O^Q5T/_P!-UO7=5POPP_Y)SX&_[%70_P#TW6]=U7^YG"'_ "27"_\
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MY:,Y;*G<:_OS^OZ_$_ UYZ'F7[=O_)Z/[2W_ &6OXA?^I)>U_=U^S'_R;E\
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MP _Y*K-/^Q%7_P#4[+SV[]KW_D$?"O\ [ C?^BM-KCM7_P"33]#_ .QZE_\
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MFXW_ .QG^>'RIGC_ ,.O^2F^$_\ L:]/_P#2]*_;R/[B_2OQ#^'7_)3?"?\
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MV  '&.@K^VK]C4EOV2_V:68DL?@7\+"2>22?!6BDDGJ22223R:_B*_X*.?\
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MRAB">/[TW/P3HO5]O[O<]I_:N_Y+%K7_ %Y:3_Z;;6OS"_X+,_\ )IG['/\
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MO_Z!%7HW[1G_ ")OP2_[$BS_ /18K^/<U_@_2U_['^7_ /KV*1^R8+X_"/\
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MRF6?\DUX2?\ 8SRS_P!9W.CNO@3_ ,F\?&'_ *Z77_IIM:X#]DK_ )*9>?\
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MN>Y_:N))]2?B>I)/J2>3Z]Z_D[Z G_)H^)/^SA9I_P"J'AN_Y+\3]9\?4O\
M6W+WVR#"_CC\QU^X^W/^"]1S^VQHYP0/^%)^"<$X&?\ B:^,\X&=PP,9W*O)
MP,X)KG?V\_\ DP'_ ()=?]B!\3?_ $[>%ZZ/_@O6 /VV-&   'P2\$  < #^
MU?&? ]JYS]O/_DP'_@EU_P!B!\3?_3MX7K^YEM+T_5'X4MY>OZ(^LO\ @C9_
MR:/^U]_V-?@/_P!$3U^A7PH_Y)_^T9_V;Y\3?_4:O*_/7_@C9_R:/^U]_P!C
M7X#_ /1$]?H5\*/^2?\ [1G_ &;Y\3?_ %&KROX%\8?^4T/ C_L083_U.XQ/
MW_A#_DR_'/\ V,*__J)DA_*S^Q#_ ,GA_LT_]EM^&O\ ZEFDU_5C\>/^2Z>)
MO^PY!_Z!'7\IW[$/_)X?[-/_ &6WX:_^I9I-?U8_'C_DNGB;_L.0?^@1UU_3
M]_Y-GP3_ -G"PW_K/YV<W@'_ ,E)G7_8@K?^IF$/S/\ ^#@C_D:_V6?^R;^)
MO_3GHU?-WQ)_Y0D_L]_]G4^+_P#TE\?U](_\'!'_ "-?[+/_ &3?Q-_Z<]&K
MYN^)/_*$G]GO_LZGQ?\ ^DOC^O[DP/\ N6#_ .P7#_\ IF!^(5OXU?\ Z^5/
M_3A7_P""6/\ R2?_ (*-?]FC>*?_ $ENZXS_ ((Q?\G_ 'PV_P"P#\1/_42U
M^NS_ ."6/_))_P#@HU_V:-XI_P#26[KC/^",7_)_WPV_[ /Q$_\ 42U^NB?P
MOY?FB([Q]9?DC]MYCCQJQ_NZ\K8[G;=@X'N<8';)Y(&2/OWXI?M3ZC\.OC+\
M+?AE:?#+XC:SI?BFZ\8VVN:G8>!]2U$WH\/^'[75+%_!US;WT<&JJ)[@_P!J
M$PS>5;H2H4J=WP'+G_A-R "?^)^O Y)_TM<C'?(XQT.>>*^X_C?^W!^Q;\"_
MB/IOA/XW?$'0O#WQ+\(Z?'JVEPWWA#Q)K6J:'9^)+!-UQIVJ:5X?U**S_M6P
M6..X2VNA)-"JQW$87:#_ )T?0$_WGQG_ .QGPK_Z<XK/Z'\>K>SX,NK_ .R9
MIZ+W<IU?KI]VY:_;0N1>>!_!-R(9[;[1J-U/]GNHS#=0>=:V4GE7,)),4\88
M++&6)20,I^[D[?[%O_(A>(/^QB;_ --]E7!?M2>-?#'Q'^$/PM\>>#-236/"
MGBX'Q!X>U6."XMH]1TG4[&QN;*\2"[A@N8EGA=7"3PQRKG#HIR*T/V9/'O@O
MX:_"+Q3XL^('BG0O!OABR\3P07FO>(]2M=)TFUEN[2Q@MHY[Z\DB@B:>9EBB
M#N"[L%7)->[1_P"4^\7_ -D;_P"^?EQPS_Y,#3_['7_O:/MGQ5_R+'B+_L!Z
MM_Z03U_ O_P3U_Y/W_9J_P"RT>%?_3JM?V\Z5^TM^S[\5+;7_"_PU^,WPV\=
M^(Y/"^O:@FB>%?%^BZWJ;6-I82_:KL6=A>33FWM]Z^=,$V(2 6SQ7\0W_!/7
M_D_?]FK_ ++1X5_].JU_?A^!G+?MV_\ )Z/[2W_9:_B%_P"I)>U_=U^S'_R;
ME\ O^R.?#;_U#-%K^$7]NW_D]']I;_LM?Q"_]22]K^[C]F-A_P ,Y? ,>GP<
M^&N?_"-T8=O3'/ID9YI=5Z/\XCZ+U?Y(_-__ (+K?\F-7?\ V5'P/_Z)UVOS
M&_X(=_\ )//VU?\ L4?A_P#^E?B:OTY_X+J$-^PU>$$<?%'P/U.,_N=<Z9ZG
MGIUP">@K\QO^"'?_ "3S]M7_ +%'X?\ _I7XFKY#Q#_Y-_QU_P!D?Q)_ZJ,6
M>MP__P C[)/^QOEO_J;1/U!_9O\ ^2S>"_\ K[O/_3;=UA:S_P EKU/_ +*)
M=_\ I]GK=_9O_P"2S>"_^ON\_P#3;=UA:S_R6O4_^RB7?_I]GK_$S+_^3.\#
M?]GSSK_UF^!S^U\3_P ECG?_ &0^"_\ 5GG)UO[57_)8/$W^YI/_ *8[.NM^
M,O\ R0SX(?\ 7'6O_1MO7)?M5?\ )8/$W^YI/_ICLZZWXR_\D,^"'_7'6O\
MT;;U]QQ%_P E1],?_'F?_KZ.%CQ,N_Y%G@YZX7_UCLP/E_XZ_P#*.#]L/_L$
M^#O_ %(M.K\H?^"+_P#R5C]I?_LT_P"*/_I3H-?J]\=?^4<'[8?_ &"?!W_J
M1:=7Y0_\$7_^2L?M+_\ 9I_Q1_\ 2G0:_P!'_HE_\H]>''_8'GG_ *U&=G\Y
M^+'_ "</B+_L)P7_ *J\O/SZ_9+_ .3M_P!G?_LO/PK_ /4^T2OZPOVA/^2V
M>,_^PNG_ *36-?R>_LE_\G;_ +.__9>?A7_ZGVB5_6%^T)_R6SQG_P!A=/\
MTFL:_(/I^_\ )K.$_P#LN\/_ .J'.C[#P _Y*K-/^Q%7_P#4[+SV[]KW_D$?
M"O\ [ C?^BM-KCM7_P"33]#_ .QZE_\ 3;+78_M>_P#((^%?_8$;_P!%:;7'
M:O\ \FGZ'_V/4O\ Z;9:_GOQ(_Y/7](__LS$?_5+X>GZ'PY_R1OAO_V6DO\
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M>Q2/V3!?'X1_]@$__64@=<__ "9F?^PW:_\ J115PO[.7_(J_''_ +)Y>_\
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MFX@/SCP$_P"2NS+_ +)S&_\ J?EAL_M._P"I^%?_ &3C0OY7=7K+_DTK4?\
MLH/_ +:6U4?VG?\ 4_"O_LG&A?RNZO67_)I6H_\ 90?_ &TMJ_DW._\ D\/C
M_P#]F;X@_P#6.X7/UK!?\D?P#_V6N6_^K?,C+_9;_P"0A\1/^R;>)/Y0US'[
M.'_)<?"W_7]J_P#Z07]=/^RW_P A#XB?]DV\2?RAKF/V</\ DN/A;_K^U?\
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MBYK'_I-)7T.3?\E5]"O_ +%5'_UN<[/-QG_(L\:/^P]_^J/ 'B^A?\E"TO\
M[&NU_P#3HE>J?M3?\ELU_P"FA_\ IGL:\KT+_DH6E_\ 8UVO_IT2O5/VIO\
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M@Y_V!4O_ %C<2=KHW_)G6N_]ABW_ /3UIE?.W@S_ )(M^U;_ -FY?$S_ -,
MKZ)T;_DSK7?^PQ;_ /IZTROG;P9_R1;]JW_LW+XF?^F 5^K\*_\ )\?H??\
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M^(VC?#";QL]G\4+#2].\3?\ "1Z];:G)]FTB2[DM18F#3+%+9BU[/YS-'*9
M5!X4 >!Q;EF)SKA7B;)L%[)8S-N'\YRS".M-TZ*Q..R_$8;#^UFHS<*?M:D/
M:249.,.:23:2??E6)I8/-,MQE;F]CA<?@\35Y(J4_9X?$4JL^6+<5*3C"5ES
M1N]VCYD_9N.[XS>#,<XN[PGV']G78K"U@$_&S4@ 23\1+S  ]-=GS^ P<GI7
MZ4>$?V:/AOX)\0:?XET1-774],E>6U>YO()8U9X9(6#*MI&Q4I*VY0X#$*3]
MT56N/V7?AE<^(9_$\J:RVJ7&K2ZR[&]A,(O9KI[QF6,VA8()W8J#(6 P"Q(S
M7^;N$^B)XM4?#[AKAFH^%?[2RGQ-S#BW%<N=XAX9Y3B\GX:P,%2K/*U*>+5?
M*<5>BZ4(*#IR]JW)I?T?6\7.$Y\0YEF<8YK]6Q7#6'RFC?!T_:_6Z6,S#$2<
MH_6+*ER8JFE+FOS*2Y;*[^#?VJ/F^,/B8#DE-)P._P#R!+(?GD@8Z\BNL^,K
M*?@7\#R&&##K..1SF2#&/7-?:OC3]F[X=^//$-[XFUX:PVIWQ@,[6M[%##_H
M]O#;1A(WM92H\N!-PW'+9(P, 7=>_9_\"^(_#7ASPIJ9U:32O"\=Q%I@2\1)
MPMRRF4S3>22[$*$! 3"]J^ES;Z+7BACL[^D'CZ+X:6'\398U\-\^;UU47M_$
M7(^**7]HP67-83_A,R_$<WLY8EK$.%%73YWY>$\4N&:&"\/</.&9<_#'L?[2
M<<+3<7[/A[%Y8_JUZZ=7_::T/B]G>G>6FQ^/OQU91_P3A_;$!9>-*\'@\C@K
MXCTX-GTQZGCTK\HO^"+X_P"+L?M+>_[)_P 4,<CO<Z%@_0X.#TX//!K^JKQ7
M^R#\*/&'PB^('P4U5O$4?@SXDVVG6OB(6.J1V^J>7IE]#?VQL[TVL@A8RV\:
M2%XI0\09",,V?!OV=?\ @EO^S3^S!KOC+Q#\,YO'XU#QSX%USX>:U_;GB2UU
M"W70?$#VLE\UG##I%FL%\&LX3!<L9#%\^U,.P/\ 8'@1P3G/ASX4<(\%\0O!
MRSC(\/F=+&O 5Y8G".6*SO,L?2]C7G2H3J+ZOBZ7,W2A:?-&VEW^1\=9Y@N(
MN+,WSK+_ &RP>-K8:I15>FJ5:U+!87#SYZ<93C%^THSLE.5XV=]3^,C]DH@_
MM;?L[E?F'_"^?A9R.1\OC[1-V,9SC!SBOZP_VA/^2V>,NO.K(0<'!!MK+!!Z
M8.#^1]*W_ G_  16_8\^'7CSPC\1?#US\5!X@\%>*=$\7Z*MYXOL)[#^UM U
M2VU?3Q=0+H$4LUJ+JUB$T0GC>6+>OFJ6W#[N\4_LR_#?Q?XAO_$VL#66U/49
MEGN6@OHXXBZHL8VQO;2;%VJ/E4J.IQGFOS_Z5/A)Q9XQ<$9#P_PA_92Q^7<4
M4<WQ/]K8ZI@:"P<,JS/"2]G5I87%N=;V^*HVIN$5R<\N>Z2/H/"OB[*>#<[Q
MN89NL5*AB,LJ82FL+1C6G[6>)PM9<T93IVCRT9JZ;ULK6=SY>_:\93I'PL(/
M']B.?P6+3=Q]P,C)]ZX_5R/^&4-#7//_  G,IQWQ_9LHS^8/Y'TK[U\>? _P
M7\1H-$M_$9U-H] M&L[#[)=1P$1,L2YEW02J[!84&X*IK.F_9\\!7'@FW\ 2
M#5/^$?M=2?58E6ZB%U]JDB,+%I_LY#*58_+Y>,^W%?DW&/T<?$;//$?Q?XJP
M+X>_LSC?P[CPODBKYI6IXEYFLMX2PK>,HK 3CAL,JN38W][&KB)./L9>R7M&
MH_691XD<.X'A[@_*Z\<P>)R/B.6:8UPPT)4WA7B<TK+V,G6BYU.7&4O=:BKJ
M:OHF_P \/A%XMUSP#\,?VE/'/AJ>*U\0>$/@SXS\4:#<W%M'=V\&L:%I-WJ>
MGS3VLP,5Q%'<VL+RP2#9*@*-PQK\^/\ @FU_P5!_:Z_:4_:\^'_PA^*OB_PU
MJO@CQ#IWC6YU*RT_P5X?T:]D?1O!>OZQ8&._L;>.YB\O4+"V>14;$B*R/\C%
M:_?RU_9>^&EEX5\?>#[?^VX])^)'A#6O!7B)EOH%O#HVNV,NGWAL[@68$%TD
M$TAMY7CF2*0JQB< J?E?]G3_ ()/_LO?LP?%CP_\9?AM/\0W\7^&[?6;;3QK
MWB2PU#3&BUW1KW0[\7-I;Z)9/,39W\[0GSU\J?9( <%3_07T=?#SB#PN\*,E
MX-XF^HO.,OQN=5Z_]G8J6,PGLL?FN*QM#V=>='#RG+V5=>T3HP49)QU6K_/?
M$7B++^*>*L=G.6*NL)B:."IP6)I1IUD\/A*%"I>"G-)<].3B^:[5FTKV/F+Q
M"<>/M6/( \0W(Z=_M)R.G;(!QT-?C=_P7#(/[<-Z000?AE\-@".1D:*F1GID
M8.1UX/H:_K*NOV4/A9=ZG<:M,NN->7%S)=LW]H1!5FD<R%E"VJL,/@\,"0-I
M."17SC^TM_P2O_9E_:K^)<_Q6^)T_P 08_%-QH^CZ'(?#OB.STVP^PZ%:?8[
M#;;7&C7SK,(CNFD$W[V7$A4,!7YQ]%SP2XS\(,;XC8CBUY0X<4XO(ZV6+*\?
M/&M0R^>=RQ'UE3PN&]C*V84.2,?:J5I^\FDCZ3Q0XVR7B^APY2RE8Q2RK#XJ
MCB?K5"-%-UJ>70A[)QJ5'.SPM7FNHV3C:]S\6O\ @HR1_P .GO\ @G0,\B'P
M>2.^#\*]4 /ORRCCN0.IKYR_9_X_X([_ +:A/&/C/\)L^V-8\*DY^G?TP1U!
MK^FCXN_\$[/@!\:O@3\)/V>/&$OC5/ 'P72P3P?_ &5KMK::PRZ=HLVA0?VK
M?2:7<1WO^ASLS;;:',X63MBN/\*?\$M?V:?!W[/WQ(_9KTB?X@GX=?%+Q%H/
MB?Q*UUXEMIM<74_#DUC/IYT[4%TF.*T@WZ?!Y\/V203$N6.7;/\ 79^1'\WG
M_!#X;?VT7SQM^#/Q)W$]!_H5CU/3'OTKYC_84!'_  4!^ &0>/CSX?S_ , U
M]=Q^@P3GTY'!%?UM_LU?\$L?V9OV5?B,?BA\,+CXAMXF/A[6/#./$/B6RU+3
M_P"S=<BCBOC]E@T6Q8W&V)/)D:8I&1GRV.,<5\,_^".G[)7PH^*GA7XP>%KC
MXG?\)9X.\4VOB_1TO_%=A/I8U:SO5OX/M%I'H,$LML)U&Z(7*,RY!D.2:+Z6
M]7?UM_D-;I]FOS/-OC>P_P"%P>-1GD^)+W'7O=/BO2/VDR#HGP</8?#O1<G_
M +8$_P J^T/$?[,'PT\4:_J/B355UEM2U2]DOKEH;V".$S22&0A4:T=@@)V@
M%R=H"YXK6\6_L]> /&L&@V^MC5FB\.:1;:+IRVUY%$%L[566/S0]M+OEPQ)<
M;3P!C  '^:6,^BCXK5L#XX4(/A?VOB%GF59AP^GG6(Y%A\%QE7SVK_:$O[,3
MPT_J%5*$:<<1SXA.FW"-IO\ I.EXK\+0K<$3E',^7A_ UZ&/MA*=W5J9/3P*
M]BO;^_'V\'=NUH-.S>A^-/\ P4L_Y13(.Y^(_@\X[X/B/4V''7H"?P]:^*/^
M"'W/A+]N#!!Q\+O":D Y(8S^,P 0,G)((QUXK^C/XS?L<?"7XZ? [_AGWQG+
MXFA\ _VSI^NK_8NJPV&L+?:9<SW=H1?/97$8B6>X=W46V7*I\P (;S/]FG_@
MG#^S[^RG8_$RP^%]QXY:'XK:-I^A>)SXB\06NJ,+'3'OGM?L'EZ59I;S;M1N
M?,E=9C(&4' 45_;F1<(YQEW@QEG N)6$>?8/PVP_"M94L1*6!>:TN&XY5+DQ
M,J,9O"O%+2LZ"E[+WW3O[I^*8_.,)B>,L3GU/VJP-;B.>:Q4H)5_JLLQ^M).
MFI.*J^R>L.=KF37-:Q\R_LW,H^,GA$$@'[5)U..D$N?R_GD=0:_F'^,@/_#P
MKX@G'_-TVL].3Q\2YP>!SP>V/TK^XGPG^S1\.?!>OV/B31?[974=.D>2V^T7
MT4L ,@8.)$2UB>12'(VM(5  P 2Q;XE\0?\ !&_]D?Q)\6-4^,FHS?$W_A+M
M7\;S^/[L0>*[*/33K]QJYUMVCMFT-YDM?MQ++#]I++$3$LBBOS/Z*WA)Q9X.
M<$9[P]Q?+*I8_,.*:V<89Y3BZF,H/!U,GRC KVE2IA\,X5O;X&M>FH22I^SE
MSMS<(?2^*7%N4\89Y@,QRA8J-##Y73PE58NC&E/V\<5B:SY(QJ5%*')6A[S<
M6Y<RMHF_YR/^"T'_ "D ^*Y['0?AB1VR%^'?AG<1ZXW#/IGFO0OVS,?\.P_^
M":HR,[/C%QD9/_%67 P.>3EE! Y&1FOZ'/VBO^"3G[+G[3WQ5U_XQ?$F?XBI
MXM\1VFC6>H#P]XFL]+TX1:%I-GHMDT%N^C74T<IL;&!)F-PX=@S*J9Q6Q\1O
M^"7'[-'Q/^"WP;^ _B2;X@IX'^!@\0CP2=.\26EMJ_\ Q4U^VH:B-6O9-'GC
MO@)G*P 6T)B0)RS@NW].-7?I_FGY]O+\;GYDW>VWX]DOT_/R/Q=_X(N_\F_?
MMK>[?#4CW"W7B$G\@0<=:_6']E(C_A+/&7_9/_$HZ'KYEF<?J,^F1GK7N/[.
M/_!.[X!?LN^%OB-X0^&LWC672?BC_8P\3CQ'KUKJDS#0I+V2Q%DT&EV,=N,W
M]P)]\<IE5E!(VC'O7@G]GGP!X O[_4= &K+<:EI5YH]S]KO(YHS9WWE>>%1;
M>+#GRD(;)P1P.M?RCXK>#7&/&/CMX:>(N3/*/]7N$\KHX3-/KF.J4,>ZT,9G
M=>7U7"QPM6%>')F%!<TJ])W4VHOE2?ZQPKQIDV3<"\2<.XQ8MYAFN+5?"NE1
MC.@H*C@(?O:CJ1E!\V&J72A*RY6KW=ORR^';*?B9X4&>OBK3QSQ_R_KW/%?S
M\_\ !5DC_AX3\?22 /\ A)?#7)( &?"_AWJ3TZ]Z_LSTK]E3X7:/J]EK=DNN
M+?6%['?V[/?PM&)XI/-4LHM%)7=U4OR."3UKY,^.7_!(G]E3]H/XL>*OC+X\
MN?B6GB_QC>6=]K"Z+XIL;#2_/LK.TL8?LMI+H=U+ A@LH0R_:7PVYD*@@+G]
M%#P7XR\&LDXNP'&3R=XG.LTRW%8+^R,PJX^G[#"X6O2J^WE5P>$=.I[2LE&*
M512BKW36J\5>,\GXRQN3U\G6+C3P.$Q%&O\ 6Z$:,O:5:U.<>10J5>:/+'6]
MK/1<URG\>O\ DCW[,P[K\,M#)]A_PC7AL<U^>_\ P4V(/_!,[PC@@@_M!:.H
M/8D^&_%H ![\@CZ\=2*_>OQ)^S]X%\5^'_!OAK5VUB73? VB6N@Z*$OD29K.
MSM;2S@>\E\@^?<^190B24*GF-O8J"V:\E^-7["_P4^//P;T[X&^-V\5)X)TS
MQ9;>,K8:-J\%AJ9U>UM+VRC$UTUA/%+:F'4+C= UM@L5;.47';P_X/\ %^6?
M2CXS\7\3_97^J6?<-4\IP2IXZ<LU^LPROA?!OVV!^K*G3I>VR?%-5%BI-PY'
M[-.>F&/XORG$>&&4\(4UBO[6P>9/%5Y2HQ6%]D\3F-;W*RJ.4I\N*HZ>S2OS
MJ^BO_-M_P0N(7XG?M,9(&/V>==4Y_O'7=+PO^]P>.O!XXK]E/V8B!\;/#F2!
MB75"<G^[I>I9_+(_$@5[I^S)_P $SOV<_P!DW6O&&O?"N;QT;_QOX2NO!>M_
M\)#X@M-1@.CW5S;7;FVCMM)T]HKM9K9-EP[RD1LR!0,&OH_P=^S?\._ WB&T
M\3:&-734[)KAH&N+U)8A]I@DMY=\8MTWDQRL Y.\$ [LY)/&GP?XNX]\5_!G
MC+(GE7]C\"9OAL=GJQV.J8;%NC2S[*LQE]1H0PM>.)FL/@ZSY)U*"<^2'.N9
MRB^"^,,HR#A7C/)L<L6\9GV#G0P/L*$:E'GE@L507MZDJM-TU[2M"[4*GN\S
MML?E/X@_Y*'K)'('BB[)(Y 'VZ4Y.,XKW3]KC/\ PL;3< G/A/2@, D$E9R.
M<8Y%?9%W^RA\++W4KG5;@:\UY=W<E[*XU&$ S22F4XS9EMH8X +$@< @<5TG
MCG]GGP!\0M7AUOQ -5:]@L;;3HS:7<4*"VM$=(5(>WE)8!R2<C)P<5_,E+Z(
MWBS'@?Q,X=J/A=8[BWBSA'.LLE'.:SHK!Y-6XJK8[ZS4>7)T:U\YP:HTU"JJ
MG[Y.I'V:E/\ 3)^+G"<L[X9S%1S3V&4Y/F^!Q:>#IJHZ^.AE2I.E'ZPU*GS8
M.MS2<DXKD?*W)I?A+_P6DY_8:_9F'<>/8"?;/A?6L9],Y&/7M7P#^S+_ ,H@
M/V^!T/\ PLGX4<'@\:QX0!XK^H;]H[]AOX+?M1?#/P9\*/B5)XL3POX$U5=8
MT,Z!K%OINHB[2RN;!1<W,NG7<<L0M[J4;5@C.2#N'(/E'@S_ ()<_LU>!?@#
M\5/V;]$G^(+?#SXOZSH.N>+&O/$=G/K8O/#EU87FG#3;]=&BBM8A-IT!E1[6
M;S 7!(! '^D/">6XG)>%>&LGQGL_K>4\/Y-EF*]E/VE+ZS@,NPV%K^SFXQYZ
M?M:4^27+'FC:5E>R_G+-L52QN:9EC*/-[+%X[&8FDIJTU3KXJI6ASJ[2ER35
MTF[.ZOU/YI_^")'_ "?AX4Z?\D_^)G<?]"I>U^Z'PVY^-?A; )QXPTK/!XSJ
M=IC/%>\_LW?\$J/V8_V6?BAI_P 7/AE<?$1_%>F:7K>D6P\0^);+4M,^R:_I
M\NFWYDM(-%L6>7[/,QA<S@1R!6VMC!^H='_9?^&FA^(+'Q+8KK/]IZ??V^I0
MM->020FYMYDG0M']D4E2\8R X^7*C QC^=_I$^#W%_B?Q'X1YKPP\I6&X)XC
MQ.:9S_:6.J8.H\+5QW#F)@L'"GA,3]8J\F5XF\)RHI/V:YGSWC^A>'?&&4<+
MY?Q;ALS6+=3.LMI83!?5J,:L55CA\?2DZSE4I\D%+$T[-*3:YGTL_P"('_@H
MZ0O[<W[3(/&?BKKI&>.#<#!R>,'!YZ<5]<?\%6Q_Q:;_ ()P#C_DT+PGW ^[
M8Z%GGIQ7[Z_%[_@CA^R1\:_B=XR^+/C*X^)W_"4^.=<NO$.MIIGBRQM=,&H7
MD@DE^R6LNA7,L$ (_=Q-<R% <!\  =]\<O\ @EO^S1^T%H/P?\.^/9O'XL/@
MC\/;#X:>#&T?Q':6ERWAW3HK:*W;59KC2+S[9J %K$6O$6!F.[<I#$5_5%K:
M+IH?ER>EK[_A=QW^[IU/B_\ 8%9?^'37@0Y!!\9>,B".01_PF^LC/&>,D<^]
M=KD']DS]L_!''P(\7 \C@_V%J P?3D$<]P17Z)_"C]D'X4_!SX%Z7^SUX2E\
M3/X!TG4M2U2V.JZM%>ZRUQJNI7&JW227R6<$;6_VJYD\J 6RI'&$0 A:U)OV
M6/AG-X#^(?PZ+Z]'X>^)WA?4O"7B7RM1C2^.EZI;RVUPUE=&V86URL,SK%*8
MY%3).PU_+?%/A#Q?G'TG.!?%K"/*?]4N'>'I97F"JXVI3S7ZS+!\3T?W&#6&
MG2JTO:9K@_?>)IOE=7W'R)O]/ROC#*<'X99[PC56*_M7,LPCB<.XT8RPJI*M
MEE1^TK>T4HSY<)52BJ<E=Q]Y79_$Y_P3%P?V]_V9,$'/Q&MP.>N=+U/&#WSV
M]:YK]I7_ )/W^,9[?\--^+.>W'Q$NP>?8@CZ@U_6+\%_^"/'[)GP(^*G@OXO
M^";CXFOXK\":Q#KFAIK'BJPO=+^VPPS0*+NTCT&VDF@\N9_W:W$>"%VL N#3
M\9?\$:_V1?''Q3\0_%_6;CXH+XK\2^--1\=ZBEIXLL(=,_MS4]8DUNX\FU?0
M)98[3[9(P2$W+,(OD\SH1_4BT:?8_+T]O)WU^7;T*7[5QV_%[52<@-I^DD$@
M\XTZV!QQS@]?P]17YB?\%F>?V3?V.5&<CQ?\3F(P<[6MM,*G'7##D'H:_HP\
M<?LY_#WX@:]/XC\0#5FU&XBMX9&M;R**(K;PQP1X1[:7;\D:D[2,N78YW8'B
M7[1'_!/?X#?M.>!/A_\ #SXCR^,XM ^&NHZYJ?AP^'M=M]-O!<:^L27PO9IM
M-O8KB,+!$(%$$?E;3@G<V[^0_"7P2XUX+\??%'Q)SEY-_JYQ>N(UE"P>85<1
MF/\ PJ<28#-<+]:PDL%1IT%]5PU3VO+B:KA5Y8)24G./ZSQ7QIDN=<!<*\-X
M18Q9CDZP"Q;JT(0P[^JY?6PT_95%5E*7[V<+>XN:',_=:2/P;_8?('_!&+]N
M@'@CQ;XG)SQQ_P (=\.N>>WOTKYO_P"")_/[2OQ4 Y)_9Q^)R@>I$.E@C_QU
MO^^3Z&OZ:/AK_P $Z?@!\*_V=OB?^S%X8G\;GX;_ !:U"ZU/Q5)J&OVMUKXN
M+NPT?3I?[.U%=*B@M4\C0[+"M92\^;DD/QR'[-__  2T_9H_9:\8:WXW^&<_
MQ ;6=?\ "6M>"[_^W_$5CJ%K_8NO",7_ )4,.BV>R[_=*8+AF?RB6PC XK^O
M7^B_!'Y-T7J_T_R/XM/V?_\ DYOX,#O_ ,+P^'@QWR?'.D,!CUQS].:_KH_:
M593\<_%)W+@76F#.1C)TZQ('^]STZ^W!J?PI_P $2OV-O!WC7PYX\TFX^*IU
MOPOXFT?Q9IBW/B[37LO[6T/4K;5K)IX(_#L3R6YO+6-YH5FC\Q,H6 QC[^\7
M?LV_#KQKXEO/%6LKJYU2^EAFG-O>Q1P[X((K>/RT>VD,0$<* ^6RD\\@$U_,
MWTIO"?BSQ@X$R7AW@_\ LM9CE_%N"SJO_:V-J8'#_4J&5YO@ZGLZE+"XJ4ZW
MM<=1Y:;A!<O//F;@H3_3/"SB[*N#L^QF8YNL4\-7RJM@X?5*,:]3VU3%X.LN
M:,ZM%*'L\/-<RDVI..C39\2_M4.K7?PV"L#_ ,6\T(=1U\N08]B3T!ZU^?7_
M  4JX_X)F:1D@?\ &1?AKJ?3PKX@4\].H(_ ^E?O;XS_ &?? ?CR71IM?_M:
M1]"TJTTBQ-O>)$!:VA8J9%:"0-,^[YY %;(!7%>3?&?]A?X*?'7X-Q? SQK)
MXLC\$P>+K7QI#_8^LPV6JIJ]GI]WIL(%Y+872-:FWOK@O UNP9WSN& *^.\.
MO KCCA?Z1?$OBCF;R;_5C-LDQ& PL<-CZE;,EB*N7<-X6/M<*\+3IPIJKD]>
M\E7FW&=.7*N9J/J\1<=9'FGASE?"V&6-69X/'T\15E5H0CA7353&SER555E)
MNU>G9.FM>9:VN_Y??^".?_(?_;-/;_AC?XFC/;/VG0SC/K@'\J\:_P""0IQ_
MP4*^!Q/ ^U>,QD\<GP7XBP/J<'CV-?U*?L^?\$N/V:_V:+GXBW?PYN?B$TWQ
M/^'>M_#+Q*=>\266HJ/#>O-:M?&P6'1K,6]_NLXC#<OYPC^8>40QKG?@%_P2
M2_98_9O^*_ACXQ_#RX^))\7>$I=1ETE-:\46-_I0;4]-OM+N1<6<.A6CRJ+6
M_G$:_:%"N$;G!!_LE:._G?[K?Y'X]TWVUZ];?Y>7E<_C+_:'S_PTG\:^#G_A
M='Q XP<_\CIJO;K7Z-?\%MB#^U+X!P0?^,>OAE_Z#J=?NUXL_P"")/[&WC/Q
MEXD\<ZO<?%4:UXI\1ZMXHU-;7Q=IT5G_ &IK.HSZI>F"%O#LCQP&ZN)&2,RN
MRJ0-Y(S7KG[27_!++]F?]J?QQI7C_P")MS\1(]=T?PEHO@NT7P]XELM-L?['
MT'SQ8&2VFT6]S=XG<33)(BR_*3&"* 3MM;\>Z?\ 7S\C\5/VY^/^"-W[!7_8
M;\-^_P#S)GCON.*^=OV4@6_X)4?\%"0!DCQ9\%A@<\_\)%;MCCO@@XK^F?XF
M_P#!.SX _%?]GKX7?LS^*)O&R?#GX17=E>>%&TS7X+373-8V&IZ; =1U%M-F
MCN?]&U:[5REK"6)3)P@%<AX$_P""6W[-'P[^!OQ9_9]T"?XA'P%\9K_PUJ7C
M!KSQ-:RZR+GPK<QW6FG2K^/2(4L%+Q(+@"VE:4 L7#DM0$79_=^:?Z'\TW_!
M$P@_M\>"&!!7_A#OB(V1R &\*W[ GT!!!!.,YK]U_ 3J/CGH+%E"MX\M0#D8
M/_$UC[_XU[K^S?\ \$J/V8?V6OBEI?Q?^&<WQ!?Q;I&GZQIEI_PD'B2RU'3Q
M::W8S:?>I);PZ-92N?(F8P_Z0%CDP^UC7U)I?[,7PWTCQ):^*K0ZT-6L]3BU
M:&1[Z(Q"\CG%QEE6U65HW<8:-I2NWCKS7\L_2.\'^+O%/.?";'<,2RJ.'X,X
MDQ.:YU_:6,J86H\)5QO#F)BL'&&'KJM6<<JQ"<9.FD_9J[]I>'ZCX<\891PM
M@^*Z&:+%RGG66TL+@_JM&%6*JQI8Z#]LYU:?LX\V(I^\E-V4K1=E?\Z_VA65
MOC1XRVL&_P")PQP#DXV1<X')'N..1ZBO1_VBR#X-^"6#G_BB+0X')XC4'CJ.
M2!SWK[.\5?LQ_#;QCX@O_$NL#6CJ6HS^?<F"^ACB+Y0@(KVLKH@$8 42;<$\
M9Q6MXL_9]\!^,[#PYINLG5FMO"^F)I6EF"Z@CE%N@ #32-:OOD(')544_P!W
MKG^?<?\ 14\4\1#QYC3?#7_&QLUPF-X<YLXJJU&CQU3XBJ+,/]@7U:I_9\79
M0]M'V_[KF:7M'^@X?Q7X7I2X"<HYE_QC>%G1S'_9(-N;R*.7+ZO:O^\C]93N
MVX/V?O<M_=/DI_\ DS0CH?[:MFP>#@>((&)Y] RD^QKA?V<P1X5^.&0>?AY>
M@<=?W;GC\!GZ5^@/_"D?!A^'Y^&K?VD_AMKI+LJUU']L\V.X2Y4+.L"J%\R-
M<KY9R.&R*R_"G[/7@'P;8^)-/T;^UA;^*M)ET?5!<W<4Q-I,K*WDE;:+RY!N
MR&(;D#CBOL']''Q(?&_A'Q#_ ,8\L#P3X-X'@7.$\UK>W>>8;AWBC*Y_5*2P
M+C7P;Q&;X1K$RJTI>S]K+V/[M1GY$?$KAY9)Q9E[CC_K&=<7RSS!_P"S0Y%@
MGF.58E*K+VUXUO98*M>"BUS."4G=M?FM\!"#\8O!..<:VF?;Y9!_,@4WXDG_
M (OEXF'.3XYNV'!Y7^U)3D>Q'3UXQU%?HMX9_9B^&GA/7]/\2:2NLKJ6FW*W
M5L9[V&2(2*P;YT6UC9E)&"-_(R#ZTFK_ +,/PTUOQ%>^*+U=9.JWVH2ZE,T=
M]$D(N996F)CC^RED17;*+YAVA5&2!BORZA]$'Q<I>&67<).7"G]K87Q*J\65
M6L[Q#PBRN?#F!RN*C6_LR,YXKZSAZEZ/LHQ5/EFJK<N6/TDO%[A-\38C-E#-
M?JM3AF.417U2G[58I8^KB;N'UA)TW3J)<W,FI)JS6I\.?M9?\E8E/.!HFA9.
M#@?Z #U_KZ\=:U_B)_R;3\(NG_(2U;N.]S/C^GY@]"*^W?''[.OP^^(.N2>(
M/$ U=M0DM[6V8VEY%##Y=I"L$6(VM9<-L7+'=AF))'-6=6_9_P# >L^$]"\%
MWJZF=$\/2W4UA''=1I/ONI?-<RS>0=VPY";54 $Y!/3[;./HP^)V/XK^D!G%
M'_5Q8'Q+R[.<+PXYYQ65=5<QXUX<SZD\QI_V=RX2"P.4XAR<)XF4:SA2Y9<W
M.O(PGBCPU0RCP_P4H9C[?AG$X.MF+6&@X.%#)L?E\UAW[=.K)UL33:4N1<EY
M7]VS^2_A P'[,GQ;YZMJ 'N?(MSQZ\ DX]#Z5YA^RX1_PG'B89&?^$ \5GJ.
MGD(/Y\?7CK7Z(Z!\#_!GASP=KO@;3O[2&B>(3*;\2W2-= S(J/Y$R11K&"%&
M0(SGOD\UD>#?V=/A]X&U&ZU/0QJZ7%YI.H:-.9[V.0&RU-0MRJA;= LF I1P
M.&4,0V6S[F4?1P\1<%Q/]&_.*[X?6%\*\GP."XIC#-*TZKKT.(<TS.HLK7U&
M*QL%AL92M.H\+>:E%0ZKSL7XC\/5\L\1<'".8*KQ1C*U?*[X:"@J<\OPF&C]
M9E[=NC+VE"=U&-16L[H_S^_@80?V@?A/@@_\77\'@X(.#_PDUAP<'KP<CMCF
MO[!_VG?^2W:T><%M'P<'!_T"W'!Z'DX^O'8U1\,_\$1/V-/"GBO0?&6EW?Q:
M.L>'=:T[7]/-QXSL);?[?IEY#>VYG7_A'A++&TT""53,'="P\P,=U?H3XP_9
MR^'GCCQ'<^*=<75FU6Z:!I7M;N&&,_9XXXXU"M:R,%58P0-^ S.R@%C7[']*
M/PIXI\7^ LHX<X1>6+,L#Q9E^=5O[5QE3!8=X+#9;FV%JJ%:GA\5)UE6QE#E
M@Z:4H<[YDXH^1\+N*\KX/S_%YEFRQ,L/7RG$8&/U6E&M456KB<%6CS1E.G:/
M+0J7DG*TN5<MG=?#O[3I_<_"O_LG&A=.>UUW'^\/SS5VR8?\,EZB,\_\+!Z=
M_P#CTM3R.W!'6OMKQA^SQ\/_ !N-$&N+JKGP_HMIH6GM;W<43K8V>_RA(SVT
MI9SO)<C:"0,*,8J:/]G_ ,"1>!Y/A\O]J_\ "/2ZJ=8=3=0F[-V88X>)_LP4
M1[8EPOEYSG)(QC\'S+Z,OB9B^/\ Q3XFI/AQ9=QCX>YMPQE"GF]=8A9EC,@R
M;+*#Q=%9>XT,,\1E]9RK1JUI0IN$O9-R<8_>8?Q.X:I</\+99*.8_6<GXBPF
M:XMK#0]F\/0S#%XF:HR]M><_95X<L6HWFI)V23?P9^RYD:A\1.#_ ,DV\2=C
M_=A/\N?S]#7,_LX GXX>%S@X%]J^3C@9L;X#GW) ^M?HGX,_9X\ >!)]5N-!
M&K)+K&CWVAWC7-W%*39:@$68(4MHB'78#$S%A&S,0,L:J>$OV:_ASX+\1V/B
MG15U<:II\T\\#W-Y#+&'N(I8I"56UC;!25AP_/&<D9KR>'_HK^*.64_ >.)?
M#3EX<<:YAQ#Q"Z6<UI1>"Q/%.0YS16 OEL7BJWU7+L1&I3FL.HU5",9S4[QZ
MLP\5.%\54X[G3CF27$>387 9>I86":Q%#*\;@I^W_?M4Z;JUZ;4DY-QYFXKE
M2E^77CSY?B=XFSQCQA>]?>_X^N<'&.M>R_M8,O\ PF'A7YE^;P%H17D<@1W
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M )%NX'4<G;:G ]< '..F#Z&OM#Q9^S/\./&GB#4?$VM#66U/5)4FNFM[V&*
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M^#Q.8\N&AR.GA\MS#"3]A)UKU)>UQ-*R:A>*D]&DG\F? K_DWWXQ_P#8/O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[OQU_AE_ZR65$T_CRS_'%??CZJ9\Z283_@J!+QD?\-TJ<'W^/2CG'TK^C/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQC_N_P#W'PW_ *8KGN'_  4[_P"46W_!$K_LDGQ__P#4S\%U-^PK_P H0?\
M@K__ -C7^S#_ .K#TFH?^"G?_*+;_@B5_P!DD^/_ /ZF?@NIOV%?^4(/_!7_
M /[&O]F'_P!6'I->13_Y$V'_ .RLH?\ K<1.N/\ &_[DU_ZK8E7_ ((#_P#)
M0O\ @H'_ -HTOVF/_17A.OS;_P""<_\ R?Y^QK_V<[\$?_5B>'Z_23_@@/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'(+%00"<BOV'@U-\!<1V7_,9B_PP>6OYG@8]/^TL,^GLJ2OY^VJ'X^?LT_\
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MR""!BM,9IA^._*$F]>G^J>5(5)-SRVRVJ13]5CZM_6WD?.T__*4"7_L^A/\
MU?8KZ-_X+Z?\I8/VL_\ L+_#C_U4W@>OG-QYG_!4.2-2"W_#=<:$ @D,?CXH
MP5^\.O.0*^CO^"^BX_X*Q?M8KD G5OAP<$@, ?A+X&(^7.2>0.!MS_%7J[YU
M@+?]"#,/PQV37_(PCIA_2OA__3-<]N_X*=_\HMO^")7_ &23X_\ _J9^"ZF_
M85_Y0@_\%?\ _L:_V8?_ %8>DU!_P4[(_P"'6_\ P1) 9"#\(_C]SNXR?&7@
MH[0" 25Y#<  @@$]:F_87(7_ ((@_P#!7\DC \6?LQ G(^4CXA:1][G 'KSQ
MTY/%>13_ .1-AWT_ULHZO3;CA;7WV>W1-['7'^,]'I@UT?\ T+E]^NFG70K?
M\$!_^2A?\% _^T:7[3'_ **\)U^;?_!.?_D_S]C7_LYWX(_^K$\/U^D?_! =
ME_X6%_P4$RW*_P#!-/\ :6&.Y!C\)C=Z*,<@N4SSV!-?FU_P3I>,?M^?L:8=
M3N_:>^"(3) #?\7%\/C@C(XZGM_=+9&>[3Z]Q-JM,OR^^JT_V/';_P!=5W5\
M+-TL/H_CGT\Z'^3/;_\ @L+_ ,I4/VRO^RX:K_Z3:77UW_P<7_\ )Y'P5_[,
MT^ /_I'X@KY#_P""PS*/^"I_[918[/\ B^&J [RHP6M=+('RLPRP.0,[L$94
M-E1]>?\ !Q;@_MC_  6W':!^QG^S^23C[ILM?Y'(( SSN"XP<XX!C#-.OPKJ
MM<BQB6J_Z!LC??R>NVC6XY)\N(=G95Z-_P#RJOS+OQJ_Y5Q/V-O^S^OB7_ZB
MWQAJ#]AG_E![_P %@/\ L=?V4_\ U/(*E^-+ _\ !N+^QP%^?;^WU\2QE<<_
M\4O\7^QP>C9&W=R"IP>*@_89=3_P0]_X+ ;3NQXU_93SC _YGVW7C) (R>1G
M?CG9R*YXM++ZMVO^2TP?5=.+,#>W>W6QI%-5W=/_ ')=/^H*/3=;/U.#_P"#
M=K_E*K\$O^Q2^,7_ *JOQ57QI^QI_P I+_V:/^SR/A;_ .KDT&OLK_@W;=/^
M'JWP17>,GPE\8P02 5Q\*_%6[C.3MQ\W8=<X&:^-/V-2J_\ !3#]F@%@&/[9
M7PO4+QN./C'H709Y)XZ$CD?-776_Y&>?;?\ ).Y9U73$\072[OR6I$$W2PR2
M;;Q%2RL[OW<'MW6F^QW_ /P61_Y2C_ML_P#9=/$?_HFTK[6_X+,_\FE?\$7O
M^S&[3_T#P%7Q/_P62=!_P5$_;9=F"Y^.?B-@&(&?W-J3@YP<8/ R1CD#I7VO
M_P %FB%_9)_X(O%BJY_8;M ,D#D)X!ZDX 'S+R><'(!XSE0:]EP4KZQH2;OI
M:_#F)M>^S\M]NZ*?Q8W_ !6\K_6X]=G_ ,/V8W]GW_E79_;C_P"SU?A#_P"F
MWX;4G_!$W_D@?_!8[_M'?\2O_3?XJIO[/\BI_P &[7[<6XC!_;5^$!W @@?\
M2WX:]3P.021@D?*<XR*/^")K#_A07_!9!L@A?^"=GQ+<[3NX&F^*F/3G &.0
M._3&37/6:^H<0ZK_ )*'!O?IS</:OLM'JS.*=\-H_P#<Y_\ I6*7YGPI_P $
MC1G_ (*9_L0CU_:(^'W8''_$V3!Y!&0>1D'D=*QOV^SL_P""EO[5@PK ?M=?
M$TD$ *V/B;J6=RIM4[L?-QSDYSFMG_@D8R?\/-/V(<.A _:(^'V"&4DXU5.V
M[CWP2<<@'@'#_;]=#_P4O_:N!=!C]KGXG _."0?^%FZD3A>">O'3)XP*]B;:
MS^I9K_D2TNJ_Z#J]GY[;H+/ZLM_]Z;\M:::\DW]^R['W1_P</^(O$&F?\%./
MB/:Z?KFL65LGPQ^!VRWM=2NX($S\,?#SMY<,<HCC#.[,RHJJ79G(+N[-]G>,
MOVV_VIOV/?\ @AO_ ,$RO%O[.?Q?UWX<>(_'/Q+_ &C]$\6:O;:?X?UV\UK2
MM+^(WCJ]TZSN'\3Z1K2QQ6=Q([0_9TA<*5B+^4B(/A?_ (.+"A_X*@?$D;T!
M'PQ^!N0SJ,9^%WAPCJ0>F#R!U'7K7>_ME,O_  X3_P""3QW*,_%_]IXY8[5(
M'CSQR.&(&> #T'##&<''A4:&'Q&3\#T*]&C7HSK9;S4:T(5:<^7AO,Y^]":E
M&24HQDKII22MK8UE*<,1C)0<H24*_O+W6F\5A^NEKIVW6CML?J]^PU_P63_:
M[\'_ /!*/]J_]M#XPZ]9?M&_$?X3?M%_#WP#X7T_QY;Z?X=TN#P]XQM? ]A>
M6SR^"-,T69A:W&O7FH0EHGD^TE8W?R"5'U-_P28_X+V_&7_@H?\ M6']G[Q]
M\#?A;\.O#X^&WC#QRWB3PKKWBJ\U2.Y\,3:,L=J]OK<KV7V2>/49FG<LDB>6
MC(W#(_\ /I^SLX/_  ;N_M^C(P/VPO@:=P(V\W7PN&"QP,COR>J]<U5_X-Q<
M-^WKXXPRL?\ AE'X]?*K9))TW05V@C W8RW)48!^8'%>-F/#F1U<!Q?BO[.P
ML,3AL1BH86K3IN'U;ER?+J\/9TZ4J=)<E:K4J)<B<I3=[['11Q6)C4P456J.
M+UG%R<N=+$U8OF<KMIPLM;V25NA_HKZ?\6_ACJ^H6^DZ5\1_ .IZI=R_9[73
M=.\7^'K[4+FX)8"WM[*VU*2XFE^4_NXT:3*N/+^4UZ,.@K_*5_X)/R$_\%1/
MV-QO)/\ PT7X3(579L@:K./X6<X'.>Q .> :_P!,WQ#^VI^R'X/U_5?"GBS]
MIWX ^&O$^@:A<Z/KOA[7?B[X"TK7-'U:QF>VO=-U/2K_ %VWO;*]M;B-X;BV
MN(8YX94>.6.-U*U^;\4\'U>'\9A<)A*V(S5U\-+$3=/!RC*DHUG1UA2G7;4G
M;WFXKF?*E??V,%COK4)SG"-'D<5K433YHN6[4=DGIKHF^A].T5X!XV_:K_9H
M^&QT ?$/X_?!SP,?%6AV?B?PT/%WQ)\(>'3K_AS4 S6&NZ,-6U:T_M+2+U5)
MM-1M/-M+C_EE,U=IX#^,GPI^*?AZ3Q;\,_B1X%^('A:'4)M)F\1^#/%FA^)=
M#BU6WCBFN--DU71[V\L4OX(IX));1IQ,B31L4VNI/R4L)BHTE7EAL1&C)I1K
M2HU%2DVVDE4<5!MM-))W;3[,[E.#DXJ47);Q4DY+9ZJ]UHU]Z/2Z*HVNHV5[
MO^R75M<[-N_[/<13>6&SMW^6S;"0I*AL%L8ZU=SQGCID<D_7H.WX_A7.4+12
M9^G3U.<]<8QGI^/M1DGL/?DC ]<$ _Y^N !:*0'GL/SS^&0,T9YYP!ZG(_F
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MI,GT/XY_H#^N*">/_P!?] 3^E "T4W)]#_G]?T_*ESQG_'_#/Z4 +13<^Q_
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M.#T_G_0'^= "T4A..V?S_H#2T & >HS7XP_\%:O#?[1>LV/PZO?A98?%K7O
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M9?\ 3JF_OK3V[;+:VQ^=WP6_:)^(OC;]H/X+^'=;LOA7#I^I_'+X817<F@?
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M"N5XKWK8S$VYN]FG+7[3;ZV-JDFJ]9IVY:4VMGO"GHV[MK5[M_@CT;_@EO\
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M%6I6YD^(6G^%+?Q]=.;H*EP]SXFE>XM#]CN#-: 0CXT_8.^+/B[PE^W]\ _
MND6_@N70]>_;'^'ZWUQK/PU^'/B/Q(HU;XJZ%I]V^F^,O$7A75?&&CNENJ&R
M.E:[8?V;=?Z;IYMKHR3M] _\&[7_ "E5^"7_ &*7QB_]57XJKXT_8T_Y27_L
MT?\ 9Y'PM_\ 5R:#777ITWF6?ITX-3X?RR<TXIJ<OK'$"YI)JS>SV^))]"(M
MJGA7_+B*K7;6.">J_7==-W?Z _X*E_$_Q1\+/^"H?[=@\+6W@^X;5_C;JT-Y
M_P )C\._A]\1U1;*.)HA8?\ "P_#'B@Z6=UQ(;A]+%F]WM@%P94MK=8_M?\
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M[_@X3^-_[#?[8_Q@_9D\%_ 'X8^,O#_P^/A2&R\2>)_%7CB+6=27Q'X+\/\
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M\%?A[XF-C9ZF?#WC;XF>#_"VN+I^HPB>QO6TK6]7L;Y;:[A(EMYF@"3)ED)
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M+N4X.,^6TEPSQ'/.5((/>D@TJUMW+Q&Z+$8_>WMY.F#D8"37#J&Y.&QQP<Y
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MRI)W0COM*D$]Z231[624S,UX'9B6V7]VD8).2PB$WEC)Z*J[0. %%:U%%WW
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MF022FZW 8_=7UY"AQCI'%<HN[_:()Z\UIT4[ON_Z_P"&7W 9L^EVUPL:2FY
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MM0U"9ER_V:ULK>:XD949C&A*J3A3]K_\%C-!U[]H#_@I#^TE\6_@WH>K^/\
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M:RETV3:3>R;2ZGK'_!3O_E%M_P $2O\ LDGQ_P#_ %,_!=3?L*_\H0?^"O\
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MWGS?Z@;*X,0F,4(V@/*I:OA+]A_X8_$/X;?ME?LN?$'QSX+\1>&O!W@SX_\
MPF\4>*M>U+3+A+/0] T/QMHNHZMJ=[Y2S2K;V-E;SW$_EQR.(XV*JQP#W?VM
ME3QG$<UF>7N-3!8&G3DL9AVJE2.#QG-"FU4]^4?:03C&[3DD]68^PK>RP_[F
MK_$FO@ENW1LGII>SM?>S:NCL_P#@L+_RE0_;*_[+AJO_ *3:77UW_P '%_\
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MQK]E4LVFGR2LT\5&2UMU3N)^S[_RKL_MQ_\ 9ZOPA_\ 3;\-J3_@B;_R0/\
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MX=SZ?>#7O$'AG0KCX>MJVL6*+ UJUG8KI6H&9I+F.0?99-L;9&:__!#:.?\
M9N_;$\6^/OCE9ZC\-O!U]^SC\8_"EIXA\0Z;?)IT_B+Q!9:-;Z/I"26D%TYN
M[YX9C$IC"!8G+R+QF,7FF6/*^,(K,<"Y5L3BIT8K%X=RK1_L;+J7-2BJC=1>
MTA.G>":YX3CO"254Z%;VN"7L:OPJ;_=RTB\34FF]-%RM/7:ZOJSXO_X)/?\
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MZ?=_\)!-X#@^'=KHLGB9$$)M#IR:G%):NS72SK(N?)*$,?)P^:98LGR&#S'
M*=/,<#.I!XO#J4(+&S;G*+J)Q@E)/F:4;.][&\J%=XBO^YJ^[";E^[G=+EIJ
M[5MKM?\ #$W_  2A_P"4;O\ P7(_[-T^$/\ Z<_BG7SE_P $(_\ E*Y^R/\
M]C=XI_\ 5?\ BROHW_@G*)OA-^PM_P %;_AK\1;/4/"?CKXZ_!#X:>&_A)X:
MU/3KU=1\<Z[HU]\1)]4TW15A@FA>XLH=4T^287,MNNV[CV,YW!?#_P#@D!X8
M\1? ;_@HQ^S5\6/B]H>K^ _AUX1\2^(;SQ+XLUS3KJ/2]'MKKP5XDT^VFNVM
MHKF<)-?7=K:J8X7(DG0D!<D57S3+'2XTMF6 ;KPE[!+&89NM?AG T4J*52]5
MNM3G22AS/VD90MS*P0H5KX#]S5^*F_X<NF,FWT['S?XU_P"4GWB?_L^'5/\
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MVG7L=OKOCGQ1_P (U_8/ARR>W@N";_4OLLY@618X_D^>1<C/C7_!(#PUXD^
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MUC_@AC^SW^S;IUIJ%U\<_"O[9?C/X@^(?AO%I]Z?$&E>#-2T#X@V=CX@N4,
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M+I;#44UEY;2[6%PT-R$D*2*"\<B[E/OG[7G_  <T_M&?LX?M1_'_ . GA_\
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M0PM.+=KMJ-W[2S[98K,%.NE&?)3I+D?L7*TVZ-M;-R;C*;M=JUVT[)K^QO\
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MR%. 3DXHYHNSYHV>SYEK=75M=;I-JVZ3>P77?L_DU=/YK5=UKL?>M%?!B?\
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M ,%-=-FUGXT_LVQ>)](_::UOX6Z1I?CW5->3]FS0-4FU_1O$<LFCVVAZO?\
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M7+J\<NP\L3#&55CHSJ5G552C6A)9EBO<G0Y5S0<4G3BU%7P$\.L1G'$F<XG
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MC)3S,7BL+_JMQ5?$4/W?C#E;G^]IM07^N612U?-9<T*=62UM*$)RORQDUZN
MP&.GQSP#)83$\M7Z/F<0I7H56Y/_ (AQQ)!1C%1<O<G7HTWIRQJ5:5._M*D(
MR\=_X)U:=I\G[67PWC>PL71AXE5D:TMRI7_A&-5."OEXQDYQBO/_  Y8:>?V
MN])0V%D5'QSL05-I;D8'C&W*_P#+/MVKV+_@GIH>HV/[4OA'491:FV\.7'B&
MUU9H]1TV>6.:;PSJWE+:6\5W]IU4%=H:XTNWNK6,99W #-7!^&/#&LO^V):V
MP2S-Q8_%O3M=N5.J:,(QI\GC*!MR3#4FBGN(X\HUC;/-?B48>U#$1U]7CL5@
MGQGQH_K&&M#PYRB<G[2G:,7C^)9<SUT3A5HRYMG&I"5[23/B\JP.._XAUX;_
M .QXEQJ^,6?0I+V4FI2>6\&P<(Z<JDJF&Q$&KKWZ%2-[QLY/V_;"QC_:Q^+$
M*6-FD<6I:4(XUM8%1%.@:40JJ(P%'J *]5_;$T_3Q^SI^Q*XL+(/)\.=?+L+
M2W!<B7PX 6/E\D#CGMQ7&?MW^']3U7]K3QX+1K02>)+[3[G2A-J&DVHN(;;P
M_IHECN6N]0A&ER!HY'QJ0M&>+9Y(D+J]>F?ME:5>P?L]?L96,[6\=U8>#M4T
M24K=V,D8U"]N] 6WCCF2[>UN+5U4)+J-O/+IUJ[*T]TH.*\G+<1@YX;P(A&O
MAW*6$IR<%.#DX_ZB9C2Y^57<HJK"=-N*DE4BX_$FCVLWP680QWTI)U,)B5!X
M_$14YP<(*;\3LIQ,8.51QC"?U:K3K+G<5*C*-2#E!\Q0^"6FZ<W_  3[_:>=
MK"R9AXO\%J&:TMR0K:KH18 F,X!))('!R?4UZ!_P2+T_3Y_B[\15FL+*53X#
MB<B2TMW!<ZQI'S'=&<MR>3R <#BN>^&NB:EX3_8%_:7L=;%M#/=^*_!EQ!]A
MO].UJ(P1ZMH:RM)/HMU?P0L@Y$4\T<CA=R_*W'I/_!*7PUJWASXG>--4U+["
M++5/ D$5I)9:KI.I.[R:OI31K+::;>WUW991.M['"$9MDF'P!\UQ?C,%/@;Q
MJE#$X=K%<31AA7&K!K$2CDO",I1H2BW&HTMU!MKJMS['@++LRI^*'T:X3P6+
MA+ <$SGF"E2G%X6%3B#CI4Y8F+M*G&4I*SFDDYJ[3DK_ +O?V)HV0W]D:9E2
M"I^P6N5((((/E9!! ((Y! -:?3I65-J]I;R-%+)*LB8W!;.[F'/0AXH=IR/3
MCT[UI1L'17!R&4,,@J<$9&5."IQU4@$'((XK^'->M_ZM^EOP/]-1]?DQ_P %
M&H[:X\>? RU^,MW\5;']DB>T\<)\3+KX3_V_]H3QWY6E'P2OC9O"\$^MKX8E
MMSJT,$<$31S:DT89HV5'7]9B<=LYZ?Y__77XB?M%?MCZO?\ [4O@)_V;?&_P
MFOM6^'%O\7_AW\4_AS\;?BC'\+M$U>\T;5?#<=Q<6]EJ3Q64L]E.93H7B"Y>
M9KA6U&WM+&6.*1PAK?MZGU1_P3>NO%MW\*/'[WUU\0+_ .%D?Q;\2V_[/U]\
M4GOI?'-S\)8;72AIK:I+JH759+./6AK":/)J(^U-IJP*X 4 ?HI7RU^RM\6?
MB3\7_!NNZY\3-)^$.E:KIGB/^R=/B^#?Q.T_XI:!+IR:;87?FZCJVF*L.F:H
M+FYG0Z6S.PM4MKHX6=5'T)XG\6>%_!.D7'B#QAXBT3PMH5HT:W6M>(=4LM&T
MJV,KA(Q<:AJ$UO:0[W(5/,E7<Q ')H$=#17P'^T1K-IK>CS?%M/V@M4T;X-6
M/@&^L? .C_!7Q(\?B?QY\7]1OKV#2Y-/U30SJ!\6NB0Z9IGA_P (Z8MU;7FK
MR:A/JEK=VZI%'YCX7O\ XT?%F^\4>$_B7XY\;^ /%'P=_9M^&_B>[@\&:S)X
M;GG^*WBW2/$.KZEKOB4:<@MM;.E?V+86SZ!,)=#\^;4TGLY6D4H#MI>_]:?Y
M_AU/U*KYL^/A/_"9?LO*"0&^/\0)'!Q_PJ?XJ<=Z;\'_ (I>./''[-?PR^*=
MMX3/B[QMXH\#>&=8OO#]OJ5AX9^W:C>6UO'J<T=[JX-I8 R">\2&7Y0I6&-V
M 1V\7^)OCCXM:S\1_P!E^V\3_ ^[\'Z<OQYA?^U9_B3X/UQ?,D^%_P 3;:2/
M[#I.;AS%;3SWHRRJ_P!D,*DS2Q*PMUZK^O\ AM>P6OV^]+\V??>P'&23CN<9
M_0"C;QC)QG/;C\@*<.@[T4"&[!R,G!QQQCC\/SHVXXR<>F%Q]?NYIU% "8Z>
MF,8]?PZ?IGT(HQTY(QZ<?RP/S!I:* $(R,9_'O\ H1_AZBC'OZ?I],?SI:*
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M(#&/:@H#W[]<#IZ< #\<9I]% #2F1C)'IP./T_K]<TFP<\GGZ=L^V>_K3Z*
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MZC!_,G\^:=10 W:/_P!0'\^3^.<T;0?_ -0/ZD$TZB@!NWW[Y]>O7[V>/0#
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M4Z:A*4%"#45"4HI6;1YCHGP8^%7AK4K;6O#GP\\%Z#K-H96MM6TCPQHNGZC
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MEC<6JR(BZIN$(DMX0S*I^<1IG')P#BN/_P""9*JG[3$2JB*#X-\8'*J%;?\
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M:ZW;Z_%XD^(OVZWU)-356U305@,\<RS!&\OPXDQB+* 1YH;;@[BW(_/+]O\
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MKI+;HP5(C8$#Y@"W4A@6->5_%+_D\'Q=_P!EMO?_ %,9Z]6_X*2?\G5^,O\
ML$>"O_43TJNS+_\ DKN /^S=9V_F\5P9?\W]YYV:2;X#\4VWK_Q%GAV[LKO_
M &7Q$BKOJE&,8I.Z2226AU_[1Z*_[#7['Q=0P?\ X3O(*QD@-K]X2.4*GJ>J
MY).YBS<F+]EXD?L>_MG@EBIT#P5P7<G U>\7;EBW!6-5(X4_W0/EJ?\ :-_Y
M,9_8[_[GG_T_7E5_V7_^3/?VSO\ L7_!?_IXOZ^;DE_J%B%T_P"(LR7?1^+4
M+V;U7RVLK;'V=)O_ (BO@7I=^ V&D[))-_\ $"=VDK/XI6NFDFTM&R'_ ()K
M+M^+WQ&"DJO_  H[XA +N<JNR?00H0%B$ +$@*!C.!@5\B_! A?CO\+D5=JO
M\1_"Y(RS*KIKUD4D1&)5)!CYF RV3TS7UY_P37_Y*_\ $;_LA_Q$_P#2GP_7
MR%\$?^2\_"O_ +*/X9_]/ME7U:_Y*;Q-\^&.&V_7ZCQ'K^&G;INSX*>O!/@I
M=M_\9GQDKMMNTLQX+<E=N]FY-VVO;316]Y_;X4+^U[\2. VS7M 7YP&W++H6
MDJRL6!)5<Y12=JG.0V37?_\ !1=,>*O@401N'[/WP^,;L,O$3'K&=CJ4<;E)
M5\,,_*1M*+C@?V^O^3O?B7_V'_#?_ICTBO0?^"B__(U? G_LWWX??^B]8KQ,
MA_C>"FK_ .2,Q[W[Y%D=]=];Z_)=$?3\3?P/I*/_ *N-DZVT27%.?I66RM\2
MM9J=Y_&W(T-2B0?\$RO#C1[H@GQ^=U$9"G>?#U]('9BI8NK_ #!\AR>68Y.8
M_P!E&-'_ &0?VUV*D!_#W@QG"LVYO-U#Q)N#.Q9F&TJO[PN0%PA0'%6-2_Y1
MD>'_ /LOC?\ J-W]1?LG_P#)G_[:O_8N>"/_ $X>(J\S%+_C%N*'U_XC%E>M
MW]KC7AYN_?7OMLM#U<$[<=\#)627T?,YLDE9<OAIQ3%65M%9+1:-I-IN*:\W
M_P""=0+_ +6OPX)>4EV\2EB[[\C_ (1?5>"2H8\G[S,6VY7/.:\[\-KM_:ZT
MF,/( OQSL2 & 4$>,X6R %W#((1OG.4&#SS7HO\ P3G_ .3M?AK_ -S+_P"H
MOJE>>>'/^3OM+_[+G9?^IA!7UN.5N,^,_/PZR>_RS#BE+\SXK*]?#SPZ3VCX
MP9_&*6B2>5<#W5E;^MCJO^"@ Q^UI\6E#R*!J>E$A'VJ^?#^E_>&">#\W!&6
MP3FO5_VPQM_9R_8GVO*HE^&_B$'9*RG#7'A\C).XL5#L%+;L;B1C)!\I_P""
M@/\ R=M\7/\ L):1_P"H_I=>K_MB_P#)N/[$7_9.-?\ _1WARO(R_P#W3P(7
M3ZK3??5< 8__ #_JR/:S)M9C]*1IV<<=BK6V_P"3K98MMF[)*[3=E;8L?!)!
M_P .^/VH I* ^,?!9RI(89U70CM4YP%R3\NW&22,$YKT+_@D47D^+_Q%+22,
MW_"!1L7D<NQ)UO27_P!E0,$+@+RH S7 ?!'_ )1\_M/_ /8X>"O_ $Z:#7??
M\$AO^2O?$7_L08?_ $\:17S?&*7^H_CEY<2P:]7DW"%_O/L/#^4EXG?1@LVN
M?@NJI):*26?<=M76SLVVGNKG]!FT?YY_]"SCZ4ZBBOX1/]01" >HS7Q3\4/V
M$OV._B#\2)/C-\3/A-X,O_$LEE>6&K7FJ-'I^A:U-J4MLRZGK]AYMM9:EKD1
M@$-EJ5PQN(TEF0;FD#5]KU^*?_!73X6?&'Q]#\,M4\!Z?JGC/PYH%EJ[W'@?
M1/&&G>&[VS\7_P#"1>%=1TGQG<Z3?:CIX\46%KHFGZYHAM5^U?8[S4K2?[.P
M9W -;Z?U_7W]C]4/A'\%/A-\#M$OO#OP?\#>'_ 6@:KJ?]LW^F>&K46ME>:F
M]M;V9OYD\QU>5[6VMX?,4@E88P<A<5ZM<6UO=QF&Z@AN86()BGC26,E3D$HX
M920<$9'! (YKX!_X)]:7X\T_P1\5-2\;07GAJP\:?&3Q1XT\ ?#36?&-CXTU
M_P"'G@W5[/2"ND:IJ5C?ZE'$;_6X]5UJ"QCN3#8Q:E'!$L: 1C]!*!?UV_#6
MQ\J?$?\ 9MU7QI\6/#7Q8T/XF7GA6]\'>'9-!\+^&[GP7X3\5^&_#UU=WMQ=
M:IXFT2SU:"*2P\2:K;R0:9<ZDLLDL6G6JVUJ81-<M,>,/V:M2\4:O=>)M/\
MBOXG\)>+/%/@"V^&OQ,UW0-%\-'_ (3GP[:27KVURNGZC87MMX<URT34]3@L
M=5TOY[6"^:)H+CR8G7ZKHH'?^O\ /O\ ,YKP=X3T7P-X5\.^#/#UJ;30?"NB
MZ;H&CVSR&9X--TJSBLK2-Y6^:2188E$DK?/(^YVY:O$/CV /&G[+N !GX_Q
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M."56!D#[<9&\KNXW8Y(!J45F7+ZL'Q:16#)@9,\ERK9P-V!'"ZX!SMR<D8)
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MDGT+CZ=< &I167(^L"4[(=/:#< "9;GS2O<[5B* _5@/4BG7#ZJ)#]EBL6B
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MQ#'$X&A3G6ROPEQ&02Q-; 2QM7&X6C5QV'Y%STYJ#J02G4@O:/XW_P"":_\
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MAYX</ZQA%[3QAX@MS5XPY>7+N#J34^=1]GKAW)<_*G"I0FFU6A>W_P % ?\
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MCGMYXTE@GA=98IHI$5XY8Y$)5XY$8,CJ2K*0RD@@U\X?'S_D=/V7/^S@(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWC5''*O4X*XCP"Y<&Z3<H?6,7AUS*JER.<MTHGY7?\$Y_P#D[7X:_P#<R_\
MJ+ZI7GGAS_D[[2_^RYV7_J805Z'_ ,$Y_P#D[7X:_P#<R_\ J+ZI7GGAS_D[
M[2_^RYV7_J805_3>/_Y+/C+_ +-UD_\ ZL>*3^-<J_Y-[X=_]GAS[_U5<#G5
M_P#!0'_D[;XN?]A+2/\ U']+KU?]L7_DW']B+_LG&O\ _H[PY7E'_!0'_D[;
MXN?]A+2/_4?TNO5_VQ?^3<?V(O\ LG&O_P#H[PY7D9?_ +IX$?\ 8+3_ /6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"RYV7_ *F$%?Z"X_\ Y+/C+_LW63_^K'BD_P I,J_Y-[X=_P#9X<^_]57
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^6?VUP6_9;^,B*"SR>%'1%
M4$EF.H6.%  /)KZFJI>V%GJ5O):7]M!>6LHVRV]S%'/!*N0=LL,JO%(N0#M=
M&&0#C(KT\ES!93G&4YJZ3KK+,SP&8.BI<CK+!8JEB724^67(ZGL^3FY9<M[\
MKM8\;B/*GGW#V>Y'&NL-+.<FS/*EB73=58=YC@J^#5=TE.FZBI>VYW!3AS\O
M+S1O=?R]_P#!.RVN8/VL?AK+-;SQ1_\ %2_/)#(J\^&-4 !)48)/ !QDUYOX
M<5A^UYI3%2JM\<K @L"HPWC*!026QCYN#G&.^!7]65IX-\)Z?/'=:?X;T*PO
M(MQCO;+2-.M;N,LI1BEQ#;)*I96*L0PW*2K9!(/FD?[-GP&MM5'B"U^$G@.#
M7XM0_MB'6(O#FF1ZC'JPN?MJZ@ETEN)5NQ> 7(G!WB8"3.X"OZ0_XF"RS$9U
MGV;XKAS'8=9KPS@LAHT*&-P^)]G4PF(S?$2Q-6K4I86T)_VE"*A&G*2]E)N3
MYDE_'\?HI9U@^'.%\AP?%V68N61<:9AQ5B,5B<MQ6!56GCL+P_A8X2C0I8C,
M+SI_V-6G*I.M",O;TXI+DDY?S@_\% "/^&MOBY@@_P#$QT=N"#PWA_2\'CUP
M??BO5_VQ?^3<?V(O^R<:_P#^CO#E?9G[1?\ P3:\=?&[XQ^,_B;I7C_PIHME
MXENK*:#3[^RUAKR".TTVTL=LSV]M- Y,EM)(C(_W) I VBN0_:]_9#^-VO?#
M']FOX?\ @'PS)X^OOACX4U[1/$&I:/+9V-BDLT^AFTDCCUB]L;@K<QV\Y0!7
M*>4QDVDJ*^^R7Q!X+QG_ !![ TN(<OIXC(\.H9LL7.>"I8&5/@O'8&:K8G%P
MHX9?[8XX>*C6DYU)QC&]S\HXC\*/$7+?^)A<SK\)9K6PG%.,J3X?>7PI9GB,
MSCB/$C+<SI/#X+ 5<1C6GE_-BYN>'BJ=&%251PY6CYM^"/\ RCY_:?\ ^QP\
M%?\ ITT&N^_X)#?\E>^(O_8@P_\ IXTBM#1/@O\ $_X*?L(?M':+\3O"EWX5
MU#5?$?@Z_L+>[N-/N3<VL>MZ)"T\3:==WBJ$<+$RS,A+!BHP16?_ ,$AO^2O
M?$7_ +$&'_T\:16G$V,PF8>'_C=C,!BL/C<)7XCC*ABL)7I8G#UHQRGA*#E2
MK49SIS2G&46XR=I1E%V::,.#\OS#*O%KZ,N7YI@<9EN887@ZK#$X''X:M@\9
MAIO.^.)J%?#8B%.M2DX2C-*<%S1E&4;QDF_Z#J***_AH_P!-PHHHH ***Y?Q
M?X4LO&FBW&@ZCJ'B+3+.Z:)I+OPKXFU[PCK49B<2+]FUSPW?Z;JMJ"1B007<
M8E0LDF5.* /E[]H3]H#QA\./&VE^"O#;^ O"T,OP]\4?$*?QK\4VU*+PMJ\_
MAZZ6VA\!Z#)IMYISGQ/>!UOII);F:6UT_;-::1JTK/%%PFG_ +3OQ=^)UJC?
M##P3X7\-ZEX7^"7A3XQ^.]'^)<.NO=M>^+;34K[2_ >C_P!ERV+:;=R6>BWU
MS+KVHQWRVJW5@DFANS2B/2\=? 'QKH'Q)M/&7A3PMIOQS\)O\*'^'-OX-^+'
MCO5;_4/#.MC7=7UE_%D.N^,H?%(U.'68M2ATO6WD"ZY;6>G6:6$EU!NM%X#P
M9^SG\>?@GIUZ?!T?ACXE:Q\0/@MX?^&OBF76O%%YHD/A/Q/X?N/$JZ1J]I=7
MVFWVH>(?"6FZ3XIDTM+-Y(M9$.A6(C60W#O"%)*R>E^SM9Z]=>U][7TM?4^U
M_ /Q?\*^,OA'X,^+]Y?Z?X8\-^+?#6B>(3<:]J=EI]II?]L6\+_8KK4+N6&S
MWVUS+]C\WS%6:1=R@;@M>%?&3XH_#3Q%X^_9>L?#_P 0O ^NWJ_'V"0V>C>+
M- U.ZV/\+?B?;J1;V>H33'=//#"F$)>:6*)07D13[A\+/A)HW@#X-^ OA'J-
MKI?B#3/!_A/0?#US'>Z=#<:9J-SI-I EQ=C3[Q)XEBGODENX8Y$=HMZ<ED#5
MX]\9_ 7@;1/'G[+UWI/@OPEI=V?C[%&+K3?#FC6-P%'PJ^*,R 36UA'*-D\4
M4J[7!62..0?,BFA;JV_0G3^OE_P?P/L"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XF_X*$?\FF_%3_<
M\,_^I9HU?F5_P2&_Y*]\1?\ L08?_3QI%?IU_P % X)[C]E+XI0V\,MQ,Z>&
M/+B@0R2.?^$MT?A44$DCJ>@ !). 37YJ_P#!);2=2TKXO?$(ZA97-JLG@5(D
M::&2-6=-8T@8#.JCYL,5&=Q"L2!@U_3? \HKZ//B+%RBI2SBNXQ<HJ4DJ'#M
M[1;N_N/XL\3:=27TMO!^I&G.5.EP_052HH2<(.IB.+%!2G;E3ER2LKWTVU1^
M_P!1117\R']IA1110 4444 )M'''3@9Y_GU_&D*J>H!P<^^>>_7N?SI<CKD8
M]<T9'J/S%   !T_SQCGUX &37S9\?/\ D=/V7/\ LX"+_P!5-\5*^E*^:_CY
M_P CI^RY_P!G 1?^JF^*E..Z]5^8'TI1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>nt10016217x4_graphic14x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic14x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( N $1@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M2;B[T^_MRZ,GFVUQ(FY67=D$5V% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_M4Z1\4M?\
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M$4/'O_!*_1/V8OCCJ'QX^'.E_$W2OB-KH\*W$?A+P7X%N_BEK'BOQ#KGB9I
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M2-XZ\3:3)<VNJ:KXL/BJQTBW\-Z1<K]IO+2?2K036R>1)JMGO-W%_/1\>?\
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MWLH$9FO897C4OFES\NUGUZQTV5K==[WL'+&UWI=>NNGZ[]5=WWLM&'_@LO\
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MFN;K1=7,0WRB-@OEG\D/VV/^"F7C3_@LO^SC\$?^"<O[+G[*OQAC^-^K>,_
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M1>,M?;;!IFE6L%I#<3QV[W4L<FH720R_8[%+BY*,(B*_D<_X(,>,/B!\5O\
M@L?_ ,%"/C1\0?ACXE^$^K?%GP;+X\'@WQ-IEWIVIZ'8^(O%<%YI-K?Q7-O
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M);7K31KFSDU_PK:P7,VA3:?J^H:_K'B/3=+TR/4=,LHH[^[O)DL^G_X)<?\
M!5;]I'XU?M/_ !;_ ."??_!0'X3^"OA7^UI\+?#_ /PEVGZG\.;T2^"_'&CE
M8=3N[.RM!K'B.TBNK'0=5TO4=.O](\2:YIVM6-KJ]TTEA);1P3?B+_P6/_9N
MT[]G;_@J%X8_;9_:)^%WQX^(/[&?QQ^%G@WP_P"+/%'P"\0ZSX5\5>"_%^A^
M"M%\+)HLOB#2I81;7TUSX;L]6M-&UB>QT[7--U&6.SN7NM'N?LGVA_P0M\$_
ML/\ QU_:Y^(G[1_[.7[+'[8?@@?"+2;OP]X"_:!^.7Q-U#QAX;\41^(/#/\
M8WBOPIK]IJ**MIXHTZV\0*VE:-IVJ>(XHM-G35KR73&:TBG3DU.UW\5M]&KZ
M:6=M%=.Z[>8[*U]-O.^RVUM\3L]--=3^O:BBBM2 HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW-I:WB".[MK>ZC!W".YACG0-_>"RJR@^X&:EBBCAC2*&-(HHU"1Q1(L<:(.
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M1YEG:/\ 9<?9M]O"WV?&,>1N0^3C:N/+V]!Z"K5% %>2TM)IHKB:UMY9X/\
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MKV]6C[*HHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P#]K'_
M )-9_:6_[(!\9/;_ )IUXC]*K?LA_P#)IW[,/_9O/P6_]5OX:JS^UA_R:S^T
MK_V0#XR?^JZ\1U6_9#Y_9/\ V83Z_L\_!;_U6_ANI^W_ -N_J5]A=^:7Y1_X
M!^8__!7O_@KK\(/V&/A+\4/A]X*^-'AKPM^V1;^$-.U[X;>"];\)ZIXC2X.H
M7L"I<3)-I%SX:<M8_:98H=0O4&54M&Q*JWO7_!,__@IO^S]^WO\ #;PYHO@S
MXO:#X_\ CWX3^&GA+Q)\;/#^B^'M:T&/0=9U6)+/4)8X[[2[+2VMSK*7%N(]
M*N;J&([=N(V1CC_\%0O^"8OPJ_;L^!_Q0L]#^&OPN3]I3Q#X9LM"\$_%SQ;I
M!;5=#%E?03I$VK6RO=Q0"V6>!"L<A02G QQ7M7[!W[!GP5_8K^%?@W2_!_PM
M^'7A3XM/\/?"_A3XI>.?!>CBRN_&>I:);1M=7%Y>N!<75O+J1GNX_,5"7DWL
MN[ ![W-TY;>=V_TMU?733L.UO/\ &^E];[;VT^>]_P XO^"Y'[4_[0OA/5_V
M6OV(OV7/&\GPO^*'[8GC6X\,ZI\2;5RFH>&O!T4L&F:@MC+&%N;26Z>^8S75
MK(MP((S''@N37R[X#_X(;_M]?L@_%[X'?%W]DO\ X**>.?'&J+XPTF/X]:!\
M;9=0'A&^\%@_:]:BL-(M-2U,^([2[D%S8KIMV+*_BEN[34+6\@DM79?L[_@M
M7^PO\??C\?V>?VJ?V38K/5?VA?V2?%=QXK\/^$[^<6\7BS1&E@U&\TVW9V6.
M2\6>R3R[=V3[2DC1(V_:K?$OA']O7_@N[^UA\3O@O\-/ W[%D7[*.GZ'XNTS
M5OBU\2?'FFW-WX<U[PQ9E+/5K.2/5IG"6\JRW-ZMAIA%[=3+:K%,B0OOAKWY
M-J3^'ETV77E?KN]/RN]+1LUUNGW;MK;3SUZ=]4?IC^V+_P %==*_9N^/$?[*
M_P &OV=?'?[77[0NB>#+3Q[\1O!GP^\5>'O!>F> _#=W;1SV]SJ>N>(+75$D
MU.ZBGL[R'1%LXY_[/U"RG6XE>7R1R>H_\%PO@B__  3V\??MY^%OA?XPUUOA
M7XFL/ WQ%^"&HZWI_A[Q;X6\:SZC%INH:+=:])IVI6$UO8S.TD&HQ:9MOXDR
MMM;R;XX_QZ_X*2?\$]/B#X;_ ."FOQ6_:Q^(O[)/Q2_;&^ GQW^'?A6ST[3?
M@;XKU/PQXN\'?$GPYX-T3PZRZJFF3Q7!T1KGP_+<,) ]O)::I;QPNMS;.*KZ
M]_P3=_: \&_\$1OVF_"6@_LU7'A#XQ?'OXE>$_'.D?!'P5>ZYXG\46/A>PU>
M)M+775UC4[UW\0P6$LDNJK;O&^[YIU,H8*7GSR[)2MH^EK=+-O=+>V]MA\L>
M6/=M==]KJW2U_P#@[GZ6Z/\ \%^=.A^)O[*ND?$W]AWX_P#P?^!7[8&M^'?#
M/PE_: \::UX?33=1USQ!8Z(JAO!UKIS7?]DV>O>(-.L)-1GUZTN+C19'\16V
MFN(GTM>^_:?_ ."WEA\(OVGOB+^RC^SY^R3\3/VL_B/\&/#/_"2_%X^%O''A
MGX?VGA*%[:RO8K;3XO$.E:K=>)G%G?VTEPVGQPO%-+%;PP73.67X_P#^"E7[
M+?[07Q#_ &;/^",'AGP)\(O&/B?6_@W\;_@[J?Q/TG1M,6XN? NFZ7X?\+V^
MH7VO1K*HLK2QGLKF.XFRT<30,&(^7/S5_P %:_V/M3^('[8WQ'\5^-?^"?7Q
MM\7:!XS\*>&IO WQ]_8^\5S6?CCQ!J>@0V]OJ$/Q*TZ^$^D0/<(Z60Q:1WK0
M:?;RQ3RH&%.7.KI-OWH^]9ZKKHD]-.W5Z]!)1;=[*R[NU^9+?S6OI9;ZG[Z0
M_P#!5GX >'?V$KK]O/XS^&OB3\$/ ^D9TO6_AYXX\,75G\1E\9F[;3[;P;X>
MTJ]32X_$E_JUXCC1;Z!K.PO+))-1N9;"TM[I[?Y1^$__  7$EO/B;\#O!?[6
M/[$GQN_8T\%_M,FQL_@3\5_B%XBT7Q)X7\7:UJXTVYT73=9MK/1=!N_"2:CI
M>I17HN-0DN)[:0I;SV*Q_:+NU_+K_AU]_P %%_VH/^"(NM_ KXQZWK]]\<O#
MW[0ND?'3X"?#[XE:^;SQ1'\/_#^GZMX?L/A]XNUJZD9+6^GL/$FKZO86]T[Q
M6$UM9V3B)6Q%Z7^TC;_MH_\ !9O7/V._@'K_ .Q9\1_V3_#?P9^(WAOXP?'G
MXH?$@6UOHL%WX<LK/2[_ $CX:;46ZNX[J_O+\V%M*SW4MG';/,RQ).])N24=
MV_=T2=Y;<UWLOG9:[ARJ[[+=W6FNF]FW_5G8^]_&O_!;7Q9%^V;\;/V(O@;^
MP9\7?VA?BC\&-6T^WO;WPA\0_#6C:1J.A22+#K'B74)-3\.3IX<L]*FN+)8+
M>YN;Z74UGG:.2V-HR2-^/7_!='2_A_\ %CXQ_##X!_LA_%/]J2W_ &:$M;7]
MI+QKX-\;>%O"WAWX8^()+6:[U#P_IXU33M5N_&=YH:V&MV>KMIT=@UMJFBWE
MFD$L9BNF\_\ V OV<_C5X _X+3?\%,/C#XP^&?BKP]\+/B%X=\,6?@+QYJNG
MB'0?%+PZNTTJ:/?;R+IU@ DF"*-H WX.!7XK_'3_ ()J_$?X ?M4?MX3?$[]
MA#XP?M<V/[0OQ*\6_%#]F#XD?"+QQKFA>&="N_&6LZYK,^E_%#3]&N[5YK*T
MO/$6G6EU%,8KO?HVHRV\QM+U74O)*^K;:Z6MK9):7=^O3T3*M%NW97W>M[?+
M_/F\C^E7XS?\%J?V5/A?^Q7\+_VT/#MIXK^)6B?&[4(O#?PE^&6A0VECX[\3
M^,VFDL[CPQ>6\TEXFDS:;?1BVU*[BAU-8/.MI8(+I+F$-^+_ ,5OVY?CA^T)
M_P %A_\ @E)I/C;X&_'?]C_5#J.L2^*OA'X[\1+>:-XFT7Q#=&31M6M=1T,Z
M=IGB*VNK2RE2^M[W2+>?3Y=EK,DG#5H?M'_\$F/VCO G_!.C]A_4_AE\)M"U
M/XY_LG_&67X]>,?@;X+U34M1TZ]_MO4-+O-4T/0)]6O;V:\OK*ST+3(IK>"8
MPR74MT]FI ^?HO&>I_MG_MN_\%7/^"9'[2.N_L.?%GX%_"#X2:CJEIKNK^+(
M+.ZU#3;IIC+K^H>)#:B$Z/H\<T-LFAI<HTMQ$\TBY9]I$Y-V::LH=&[O3FN^
MEGTO_F$>56:U^)-W6B7YW6_EKL[']>-?GC^R!_R<W_P45_[+I\//_52Z#7Z'
M5^>/[('_ "<W_P %%?\ LNGP\_\ 52Z#6CWCZ_HR([3_ ,*_]+B?H=1113)"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *1NA^A_E2TC=#]#_*@#\[/%/\ RD ^
M'O\ V0_Q/_ZD]M7Z(Q_ZN/\ W%_]!%?G=XI_Y2 ?#W_LA_B?_P!2>VK]$8_]
M7'_N+_Z"*J6R_K[,11V7HOR'T445(QDD:RQO&W*NI5A[$8/6OSXLM2\6_LI>
M,O%;ZMX>DUCX1>+_ !-=:Y!K.E!Y9_#T]^T:-'>6H(VQ(B1H6&(W$2&)U=VB
MK]"JY/QQX4T_QMX5UOPSJ4:O;:M87%HQ*@E#+&RJZYZ,A(8$<Y''K7XQXQ>'
M&9\98+*>)>$<YQ'#OB-P&\TS3@K-J5.A7PM;%8S!^PQ>19SA,1"=/%Y+G=.E
M2PN-IJ5&M1:IXG#UZ56DF_JN%\]H956Q. S/"0QV19S]6PV;X:3G"K&E2K<]
M+&82K"2E2Q>$E*52BVI0E>5.<'&;-&RN])\6Z!%=0^7?Z-KVF9*MS'<V&H6V
M'C< YVS6\Q5E.#M8@X-?S/\ [0?_  ;:_";QI\>/B=\;?V>/%?@K]G][OP#X
M+'P2\.:7X/U34[7P'\9O#6O/K&K>.]>EFUHKJ^FZ[$(8UL[&.SOK&\2&ZCG:
M.V\BX_:[]F?QI>>';G7?@EXQN5@UWP9=R0Z-)=R>6^IZ*\C_ &-X/,8>:8TP
M"$SA<<X45]FU]'X1>(V'\1.#<HXGP\8X3-HPGE_$64U%'ZSD?$F75)8/.LKQ
M5"3E*E5PF.I5X04U>5/V=2+:E&;\SBSAU95F.,RFO>O@Y\E;!8F,I1CC,OKJ
M-;"8FE5@XMQJTG!R<';FYH2ZH_A>_P""<?[17[;_ .PI_P %"?BU\(OVN?B1
M-:?#SXA_'+5)/BB\OPBMY+KXN^+KVQ3P[X;\=^%O$&I+9:WHWA>_NVLYS<Z4
MLMA.&FW1W#QRB/\ N:MKJWO(8Y[::.>&5%=)(W5U96&0<J3V_+I7Q'^U+_P3
MU_9M_:WU&'Q+\3?"]W%XXM-/@TNP\;^']3NM*\06=E:S/<6L,<T;/;2"WGDD
MDA-Q;3-$9'\HH3FORG_:9^$7[5/_  3%\"6GQU^#7[2_CCXC_"CP[XP\*Z=X
MC^&WQ$5-:AT_PUJ&HBT6./4IVDE6VENGM-+EEA6UF#:C&Z?ZLY_?,)E/#^?X
M?+,)EF.GEW$$XU*>*PV/A6GA<PQ<YN5)83$4W5]@^6U)1JQA&32DVFVW^(YA
MQ#QCP=C.(,RX@RREG7!E&I1Q678W)JM".9Y+EM*A2IXM9E@L1]6>,A"HIXGV
MN%J5:L:;G'V<U&*7]'=%<WX-\3Z;XU\)>&?&&C7$=WH_BG0=)\0Z5=Q$-'=:
M;K%C!J%C<1L."D]M<12J1P0PQ725\3.$J<YTYIQG3E*$XO=2@W&2?FFFF?J=
M*K3KTJ=:E)3I5J<*M.<7>,Z=2*G"2?52BTT^J84445)H%%%% !1110 4444
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M /X)^?\ AH/VC/P_YKA_GWK] Z*+>;Z=7TM_EKZON%_)?=Z?G;\6?GY_9/\
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MX?#]/UK]!**+>;^_T_R_%AS>4?N7]?\ #ORM^?G]D_\ !5/_ *'_ /X)^?\
MAH/VC/\ Y^'/;TH_LG_@JG_T/_\ P3[]_P#BT'[1G_S\.?TK] Z*+>;Z=>UO
M\M>]WW%?R7W>G^7XL_/S^R?^"J?_ $/_ /P3\]_^+0?M&?\ S\/U_2C^R?\
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M!^=GBG_E(!\/?^R'^)__ %)[:OT1C_U<?^XO_H(K\[O%/_*0#X>_]D/\3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%<7\0OB+X%^$_@[7/B!\2O%>A^"?!?AJSDO]<\2^
M(]0@TS2=.M8P27N+JX=$#.?DBB7=+-(5BB1Y&53\[_LQ?MZ_LA?MES^)[/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^)/_  69MHO&<G["'P5\0VTE
M_P##7XN_MD?#S1/B-HKLW]F>)-#TWSM3AT#6(<>5=:?>7<,;S6\V5D$7RC<
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MUS-(\LKP.6Y#A?TKK\,_^"P/Q+_:,_9<\+7G[0?[-?PG^(/CO6[OP!XM\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW4^>$:UY12:;^UJ***^./TL**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I&Z'Z'^5+2-T/T/\J /SL\4_\ *0#X>_\ 9#_$_P#ZD]M7Z(Q_ZN/_
M '%_]!%?G=XI_P"4@'P]_P"R'^)__4GMJ_1&/_5Q_P"XO_H(JI;+^OLQ%'9>
MB_(?1114C"BBB@ HHHH **** "BBB@ HHHH _D*_X*O?\%M7_8=_;?\ #=C\
M-/!M[XCU;P.MSX=^(^C>//">K:+H^NZ9)8O>1'P?XB9XVO(5N;RV6;4+!"J.
MK)\RDEOZ2_V.OVQ/@G^V[\%O#WQF^"'B_3O%.CWMGIMOXEM;*.\AN/"GBN;2
MK/4-5\,:E#>P02+>Z7+=>2SQ^=#*@62*:16S7@7_  43_P""6W[.?_!2;PKX
M8TCXQGQ#X>\4>!9-2F\%>./"4MG'JFCOJ\<4&H1WMC>VTUEK=I-#$!':7WR6
M\Q%Q"R2 [OYQ?C-X%_X*#_L??\%)/V8OA+\!/ /P(TKPA;ZWXA3X#Z7=>(?%
M&@^"/'.D?V);:/=:Q\7K?PY+IEG#XC>"%I)%B0*;HPJA:(J&_-<'EF$\/L=.
MGE65T?[+XMXDS7/.)<YQ.94,+/"YMF$*/)5>'J4E+&2Q3I4\+3C"K!T:6'AS
M<^Z^DJ5JF?T+XG$26*RK+L+@\NP=+#5*OML)AI24TZBF_9^S4Y59-Q:;G)KE
M2U_MAHKF/!4WBRY\(^&KCQY::-8>-)M$TZ7Q59>'9[BZT&UUY[6-M3@T>YN\
M74^G1W9E6TEN/WKPA&D^8FNGK]*5NFV^GGU^9\V%%%% !1110 4444 %%%%
M$4\$-U#+;W$4<\$\;Q30RHKQR1NI5T=&!5E92596!!!(((-?@I^T-\'O'O\
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M/1IZ/9GV5*O1K6]G4C)N$9\NTU&3:BW%VDDVFM5NK;FG1114&H4444 %%%%
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M/[3WP3^,O[.OQ7&O:1HUCXMU>[^-G@#]D_0QX?\ A+H5]J,UC<:;XZ@U._\
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M75)M?>O4^YE.$6E*48M[*4DF_1-W9]&T4 @C(.0>01T(]:*DH**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D+*HRQ"CIDD 9/09-+7PM
M_P %!?V _A=_P4:^">F? KXM>.OBO\/O#.E^-](\=PZU\'M>\/\ A[Q/+J>C
M6&K:=;V-Q>^)/"WBVP?2I8M8N)+B!=,2=IHK=TN8U1TD /YL?!W["V@?\%A/
M^"DW_!0WPS_P42^.?Q0TD?LT?$.+PI\!OV9O"/C"W\&SV?PMN=1U2+P[\5=%
MT[5[+4X+K0;C18=,CU'5-(T&ZDOM4\7PRZQK5E$VAV5[N?LY_LX3_P#!,7_@
ML[\#OV4?V'/C5\1/B5\ _BAX*U?6?C[\&_%'BQ?%UG\,+1%(EU[7!I<%KI.F
MZQ.L%EJ&GW4VEZ1J+JL-LYN;>0"3@OC-_P $*?\ @AC^SAX^E\&?'7_@J!\;
M_A#\2I-'L]3G\/\ CO\ :5_9W\,^+#HE]+/'8W5Q::C\&[?4A8W,MC.+?S0(
MW:W8HI""O3?V'?V!?^"&/P(_;%^ WQ+_ &<_^"EGQ'^.GQ[B\<V-C\/_  !;
M?&[X/_$J#Q/K<UK=BWLO$>E> ?A/9Z\FAK$)6GO;C5]+L+=EC$][%O4/G;6[
M2O=.]]4KIV_%)[)VVV+B[O:[LUM?HNVKO;;HK6T/["Z***T("BBB@ HHHH *
M1NA^A_E2TC=#]#_*@#\[/%/_ "D ^'O_ &0_Q/\ ^I/;5^B,?^KC_P!Q?_01
M7YW>*?\ E(!\/?\ LA_B?_U)[:OT1C_U<?\ N+_Z"*J6R_K[,11V7HOR'T44
M5(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4OVI?@;XB^)G@K5M=^
M$^L:;X-^-^@Z9=7/P^\7:A:2W6G6NM1Q.UE'K=K:E)[_ $TS8\Z#<21GAE+H
M_P!6UQOQ$\ ^%_BIX$\7?#;QK97&H^$?'/A_5/"_B2PM-2U+1[F\T;6;26RU
M"W@U71[JQU33Y9;>:1$N]/O+:[@8B2":.158?-\6\)9%QMD>*X>XBP%',,NQ
M4J-;V=:$9NAB\+5AB,%C*#DG[/$X3$TZ=>A46L:D$]5=/T,LS/&91C:6.P-:
M="O2YH\T6TITJD7"M1J+:=*K3E*%2#TE%O9V:_D>_P""05[_ ,%!/$O_  4D
M_;)M/%GQL^"]K=>'O''AMOVFM'O/A/K.GW_Q"&F03:3:CX<W1OG@\/RV[J&G
M>8;)XW2Y4-&?+K^Q.OYC_@1_P;_Z'^S+^U+\2/VB/AB?#5CIFC>,-$U[]G#P
M_%\5/C)KVL>'-+M;/R]6M?'I\1-#;:I>3W0#6BWFL>+;=H6*27%H!L/Z8Z9_
MP4"M?AS^T1H7[+W[0UMHWA7XC>(/#C>*[&[L&U'^R%T$2O;QZC>:BT5WH=M#
M+-$T;"77(KB)]@>R17)7\YQGBMA>"^(,)P?Q7P]QS3H.&"H87CNEPGB,9P;B
MJE=*DEB\UR2>84LF]G-)5ZV;X?*\+3YG)2C2@ZC]^/#=3.,)4S3*L9E$ZEJM
M6KDO]I0AFM&--*3]EAL7##SQ:<6W&&%GB:EH\NLFHGZ?T55LKVSU*TMK_3[F
M"]LKR&.XM;NUECGM[B"50T<L,T3/'+&ZD%71F5@<@D5:K]I34DI1:::336J:
M:NFGU36J/D&FFTU9K1I[I]F%%%%, HHHH **** "BBB@ HHHH 0@$$'D$$$>
MQX-?QZ_\%>_^#=[Q#^TS^T7:_&[]D;PGX*T*'QM8ZQJ/Q5TC4_%FKZ-=ZQX]
MN7>6+Q$EYJ<FJVL$%\#%'=6ULMM DD6Y($61FK^PNBNC#5_J\^>5&E7BTU*E
M64I4Y=FU%Q;Y7JE>SV:LVCCQV#^NT?8^WKX67,I1KX:485H6?O<DY1FH\T;Q
M;M=)WC:237\GG[!G_! _]J7X4?"BQ\/?&O\ ;0^+/P]&J6,=IK7PP^&/Q(\3
M:YX>T:UM[J<Q6&E7<^IVNE:>LMM(2YT6VCA#RL'27!SXI\=_^#?2#X+_ !H^
M(_Q^\-_%/]I.\^#O@?X,:GXMT;Q5X>^)6K>,_C=>?%VPO&OX-%L/"^EV5IJV
MJ^&IER8]-MKI&+819V8#/]EU%=M;.,96A@J4UAXT,!+FPU"EAJ-*E&3E&4G-
M0@G5<W%<[J2FY6U>YY6&X8RK"U<RQ%-8R>*S6"IXS%XC'XS$8B4(QE&G&C.M
M6FL-&DI2]G##QIQ@WI'16_C*_P""?'_!Q+XV\%77C[X;_MS_  W^-VM>'_!<
M^G:!X'\8^&/@IJ=EXBTB+3;-HGTOXBVNJ7EA.WB'4(XHKA&O+F.\9S*9(W!\
MP?4G[*7_  <9_"OXT?MN?$KX1>*=*^*MM\&_&NL> /#'[.5N?@L-,\2Z!K>K
M 6?B"3XI7L/B*YDT_3[C49(QI]PJW^V(AA&BAZ_=[2_V3?AI\)V^/GCOX#>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPA5K867)BZ>'J-6C7E15)MJ+FI7BOLVBBBOTG^OZ^\^?"BBB@ HHHH ****
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MY(_C_P#$G_!?W]KO3/VU/#7@5/V,_C#:> %\ Z_!JWP5D\'7,OCO7/$<%_\
M9K?QIIFH"T^U?V#I\@2&;R8'M'B,LCR;MK)]K_M#_P#!87]JOX3?"76?%O\
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MB.;T71RNGETJ&(CF3PDHWA6K2J0E3L_>EI*]DD?=U%%%?&'Z<%%%% !1110
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M6GE*QF7X1XG#X;&K-EB>3&3C)?5X.B^>-22<';EOS:']<5%?P.ZK_P %9?\
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M5%;;M0;[K1/;S/VCHK\8/^%Y_P#!7G_HUWX3?^%J!_-AQ_GZ'_"]/^"O.?\
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M:J24D^Z:NOP"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%8>*?$>H^+O$5IX;T^/3X-8\3:LXDU+6[Y(^)K^\<!IYC@L0. !7I=%&O\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\9_$_3=>U'77T_4YK"/08X;YX[Z%+%X6L;2"YN'D<Q 6R;6"5_4*"& 92"I
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M%'/^"NG[+7QN\2^/OV)?A!^P#XJ_X*.?&+1/%'B/P#K?A3Q!\-)QX \.^-_
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MI3PW%$,!FTJ-7%4Z&8X.6$R>*52-L&\QJXBI75>-*3E&3H5(S<7!3E+4^_\
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MC5]MPMP[5O?VF297._?FP5"7ZA1117DGT(4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?%WB0VD-U,=7\1ZL_F:CJURU[=73"XNG^:1(3' #_JXDYS.>\"YYEE?&<3<
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M]UA<5)4VK4U*CAZM*IS5)5E&G_0M\._VBO@;\6O$/B#PG\-?BGX*\:^)?"I
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M!YKQ>#]ECX$6R>7%X!T_9DMB2YOYCD]?FFN9&Q[9P.P&!7T'17QG$?ASX?\
M&&,P^8<5\$\*<2X_"T7A\-C<]X?RO-<5A\/*?M'0HU\=A:]6E2=3WW3A)0<_
M>:OJ>K@,]SO*Z4Z&6YOF>7T:DU4J4L%CL3A:<ZB5E.<*-6$93227,TW96N>+
MP?L\_!JW,9B\ :!^[QMWV<<@XZ;A(&W_ / LUJQ_!+X3QYV> ?"XSC.=&T]N
MG3[UN<=>U>IT5SX;PN\-<%;ZIP!P9AN6SC[#AK)Z5FDHIKDP:M:*2]--BZG$
M&?5?XN=9M4_QYABY=;_:JOJK^;W//[?X5?#FU01V_@OPW$@)(5-'T]%!)R2
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MM!'+\<[FU7(8O:Z9;K)N&/E)*."A.20!G@5Y'"GBSXQ9=P[E65<6^!G'F?\
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MW_U]P!1110 4UT21'CD571U9'1@&5T8%65E.058$@@\$$@TZBEK^7X?C\_)
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MO_9#_$__ *D]M7Z(Q_ZN/_<7_P!!%5+9?U]F(H[+T7Y#Z***D84444 %%%%
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M$ELEV("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_'_+^K/RO]L45\3?\,>Z]_T<]\??_"AL?_D.C_ACW7O^CGOC[_X4-C_\A_\
MZZ-+=>FEE\^O0++O^#\O\W]WF?;-%?$W_#'NO?\ 1SWQ]_\ "AL?P_Y<_P#/
MM1_PQ[KW_1SWQ]_\*&Q_^0Z-+=5MT[V\^GZ= LN_X/R_S?W>9]LT5\3_ /#'
MNO?]'/?'W_PH;'K_ . ?3VI/^&/=>_Z.>^/O_A0V/_R'1IY].G>WGT"WFOQ_
MR_JWI?[9HKXG_P"&/M>_Z.>^/O\ X4-B?_;.D_X8]U[_ *.>^/O_ (4-C_\
M(=&GG]WIY^O];%O-?C_D?;-%?$W_  Q[KW_1SWQ]_P#"AL?_ )#_ %H_X8]U
M[_HY[X^_^%#8_P#R'1IY].GIY^OW?<?-?C_E_5GY7^V:*^)O^&/=>_Z.>^/O
MO_Q4-C_\A\&C_ACW7O\ HY[X^_\ A0V/_P AT::;^>FVJ7>_5OY!9=_P]/\
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M>7GYOYK[BR[_ (/R_P"#]WF?;-%?$Q_8]U[_ *.>^/O_ (4-C_\ (8Q]*/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/W[,O[-7_!5[6?B1\<5^)'AGX"67Q\U[0]4\8^&3\-TU6]\$7&H:E:#3/\
MA#X=8332]Q)%:PR>(6F5FC62XE&0?P \(>*_V@?AE\4/A7_P7&U/6M:/A+Q_
M^W%XH\.^(HY9)DM[?P=/<6[72WJ!O*N;;5/#U[JUM91 -$\NB2,0K1J0N=V3
MY='9Z.[2=M].E_\ @@H_*SL]MENUKK;LC_3TDDCB4O*Z1HN,O(RHHR0!EF(
MR2 ,GDD"G*RNH96#*P!5E(96!Z$$9!![$'%?@9_P</>*;'Q5_P $4_C]XPT"
M]\[3?$<7[/\ K>F7MK*5$UCJOQF^&]W;RQ2QL/EDAG7E6P0<=*^Y_P#@DT[R
M?\$VOV+WD=Y';X!^ RSNS.[8TN,#<S$L2% ')/ J[^]R^3=_1I?J3W\FE]ZN
M?H;4,5Q;SY\F>&;;][RI4DQ]=C''XU^8_P#P62_:Q;]C/_@G)^TM\7]+U/\
MLOQQJ'@JX^&?PQFBN!;WR?$+XFY\):)J&F$D-)>^&;?4-0\8[$RWV;P[<OPJ
M$C^2S_@D/X=^*7_!*/\ X*&_L1>'/BKK>H1?#S_@I+^RYX7U:_CU"6X&GZ=X
MH\=W4^M>$=#$<S&(:SX=OQX'BU.ZD"R6</B74;57$4K^8F[.UF]-7T7_  _X
M)7&EHWLE^?1;WUV/] ]W1%+NRHBC+,[!54>I8D #W)ID4\$X)AFBF"D!C%(D
M@4GH"4)P3VSUK\"/^"S'[(W[??[=OC_]F_\ 9N^!>M7_ (!_8SUG4X]4_:J\
M;^'?'6D^&]=U*TDU@Q2:!>:'+>0:UXBTW2]$LAJ&F:;;Q7.D7>N:K#/JMK<-
MI5H]K^,_P9^!U[_P2;_X+Q_LT_L<_L0?'CXD_$_X3?&[P9H&H?M&_##Q=XDL
M?$B:-%=R>-8]:E\86FA6>EZ)#K?A;PSH5GX\\-ZE)I&GZ_HMC??V?+<7&E:O
M=IJAS.]N72Z2=]V_+?3OU"WFO/RVW^_7_A[?W*45_+#_ ,%MO^"W?PV^%G[.
M]YX>_8)_;(\&V7[3OA?XV:/X6\8Z)X7TRPU[Q!I6@:1<:WIOC.PNK/QAX6U'
M1!'8ZI:6]M>3VP>X22/_ $>8Q,Y;]J/V*?\ @H1^RI^V/H6D>%_@O^T'X(^+
M_P 4O#'PX\*>(_B5HOAQKU-3TFYN[*PL=5O[ZWGTO3K1$;7Y)K:06.^&.=PB
M(D1CR^9-V\KWTMZ;[@TU_EUZK]/Q1][4444Q!1110 4444 %%%% !1110 44
M44 %%%% !1110 4C=#]#_*EI&^ZWT/\ *@#\Y?&4\5K^WSX#N)WV0P? OQ7-
M(Y( 1(_$D#.QSQ@*"3]*Z?5/VC/A=XPUV>T\6^+WTCPII%Z\$/A^WTS6YY-=
MGM)=HNM6N+72Y8VLA)'NALH9660 /.7^5!\V_'+XQWO@']N_PQ>V7PW\9^-Y
M])^$6I:?;Z9X:BTV6]UB'4M7ANY]0T];V]M8WM-,D4V-\97CD%T=L:.GS5]!
MI^UYXA= Q_8V^/KD@986'A$ACW.?[?[DDU^<^(/"O%G%"RK#Y#Q#E>4Y;AJ]
M2MG&6YGE&(S/#YU%QI?5L/B)87,<OJPPU&I%SJ8=5)T\4W&%>,J:E"?N9)F&
M7Y>J\\7@<1B:]2G"&%Q.'QE+"SP;O>I.G[7"XJ$JLTU%3<8SI+6G)2?,NJ^+
M6L^"[[6O 'B7QG8WNK_!"XT.\DAEATR^NM$L]8F,1TR[UJR@MS=Q0RV9DM[%
MI+<A;N54,8.YXNH_9^?0KGQ%XLU#X;:?J%A\+;B.S;3#-9W5CI=UJZ^;'?3Z
M+;WL44_V=56.&Y<1QQFXC8 %D8CSE_VQO%;Q>0_['G[0+0@#]V;'PD4]MJ_V
M]CC\#3HOVRO%\"".']C[]H..,=%2R\)!><]!_;PX]<^O0U\C@?!NOAO$&''%
M7-LJG/Z_'-ZCH<.T:.?/%?V%1R264T^('BIXB'#*5/ZY2RET)<E62I^V<%S/
MTZO$ZGDKRB.&Q"C[!X6*GF#G@O9_798Q8F6 5&,'F'O>QGBU42E!-^RBVSW;
MX9VG]O\ C_XB^-;M-\D&K#PQI,CJ<Q:=I2 2)&&)";[QYG?:%R=N<[17O]?!
MB_MF>,$SL_8__:#7)^;;9>$QD^IQKWOU/..U/_X;/\9_]&A?M"_^ ?A/K_X/
MNGOU]J_4.%>'8\,Y7/ ?6)8W$8C,<SS/&8V=-4ZN+Q69XZMC)SJ).3;I0JT\
M-!N4G[*C35]$EX&8XV688A5N14J<*&'P]&BIJ4:5+#T(4E&+=OB<95):*\IR
M>[/O"BO@_P#X;/\ &G_1H/[0O_@)X3_^7W^?04?\-H>,_P#HT+]H7\;/PG^O
M_$^X]L9S[5])9]G]S\O+S."S?;[U_GYGWA17P?\ \-G^,_\ HT']H7_P$\)_
M_+\_UZ]11_PV?XS_ .C0?VA?_ /PGT_\'_7VZ>]%GV?W/R_S6H6?E]Z_S/O"
MBO@__AM#QG_T:%^T+Z_\>?A/I_X/NOMT]Z/^&S_&?_1H/[0O_@)X3_\ E^/Q
MZ=.IIV?9_<%GY?>O\S[PHKX/_P"&T/&?_1H7[0O'7_0_"?Z9UX?CG&/>C_AL
M_P :?]&@_M"_^ GA/_Y??G_(T6?9_P!?\.OO"S\OO7^9]X5X3\5%)\:?"3:I
M)_X2N?.T<\Z9<C/YFO!?^&S_ !G_ -&A?M"_^ ?A/K_X/NGOU]J8W[9GC!RI
M;]C_ /:#8H<J6LO"1*GU'_$^..._7VKYWBG(%Q+E$LJE7>%4L=E6,]LJ?M&O
M[,S3!YDJ?*W&ZK/"JDW?W5/FL[)/ORW&O+L4L4J<:K5'%4>1S4?]YPU7#N5]
M?@57FM;5JUU<]H^*WBKX?^$/$^FZI\1_""2Z0UA)#9^-)M,NM7M;.Y9QOTNY
M@M;"[:U,ZXDAF<A)BI15RC5YWHGAZ^^)3?$/4_A=<R^#?"/BC2M%L]%U:72+
MFSM-1O[=KAM0U.QTN<:?-):O;O%8M<LMO]HDB?RPZ(LK<Q-^V1XMN%V3_L>_
MM!2KZ/9>$F'8_P#0>R/PZ]P!3HOVRO%\*!(OV/\ ]H.-!T5;+PFH'J<#7N^.
MO.>/P_/<Y\)Y<1<0U\;FV98+^P:N)Q>.CA<KR2EE/$4\1C<HQ&3UL/B>)\%B
M*>*KX)8?%UJD+488MS5"$\3.G147[&#XB>!P<:>%P];Z[&E2H>UQ&,>*P*A1
MQ=+%PG3RVM2E"%7VE&$7>I.BDYN-&,IMK/U'X>_%_P -^/\ X7Z5=_$#1;M(
MIKR/3#:>$K:VBM+>"%&N8FC6]<2M/"#&KN08W/F88C%?H!$'6*-9&#2*BAV
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M46[;X?V.?V@(GQC<ECX2!]>HU[I]/Q S7QN4>'7%N4\09'B7Q7EN:<,9!E^
MR_+LHS3),15S#"K#X54,9C:&/IYG3PZQ^,D_<Q%?!5I83#/ZK0483G*?IXK.
M\OQ6#QE/^S:^&Q^.K5J^(Q.&QM*%"JZE95*5*>'EA)U/844OX5/$TXU9VJU+
MM1Y?ONBO@_\ X;0\9_\ 1H7[0OXV?A/]?^)]Q[8SGVH_X;/\9_\ 1H/[0O\
MX">$_P#Y?G^O7J*_9[/L_N?EY>:/E^5^7WK_ #/O"BO@_P#X;/\ &?\ T:#^
MT+_X!^$^G_@_Z^W3WH_X;0\9_P#1H7[0OK_QY^$^G_@^Z^W3WIV?9_<PL_+[
MU_F?>%%?!_\ PV?XS_Z-!_:%_P# 3PG_ /+\?CTZ=31_PVAXS_Z-"_:%XZ_Z
M'X3_ $SKP_'.,>]%GV?]?\.OO"S\OO7^9]X45\'_ /#9_C/_ *-!_:%_\!/"
M?Z?\3_\ /I[9H_X;/\9_]&A?M"_^ ?A/K_X/NGOU]J+/L_Z_X=?>%GY?>O\
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M%'_#9_C/_HT+]H7\;/PG^O\ Q/ORQG/M19]GKY/_ "#E?E]Z_P S[PHKX/\
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MFX!DD(D!=LD8V23M9)I=[.VGX?\ !?1WZIN^GG?U]-5YKHM;_P">[_P1[O\
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MZGZ^M)_PKNPX_>MQG^-_TXX]_7VKT:BCVD_YF'(N[^__ (!YS_PKRPX_>O\
M]]O^G' ]OI1_PKRP_P">K=,???'\NGJ/I7HU%'M)_P S#D7=_A_D><_\*[L/
M^>K=,???_#I[?Y!_PKRPY_>O_P!]O^O'(]OK7HU%'M)_S,.1=W^'^1YS_P *
M[L.?WK<X_C?]>.?;T]Z7_A7EA_SU?K_??V]NOO\ 3TKT6BCVD_YG^ <B[O[_
M /@'G/\ PKNP_P">K]<_??\ PZ^A_G1_PKRP_P">K]<_??\ PZ^I^OX>C44>
MTG_,PY%W?W_\#R7W'G/_  KRP_YZOW_C?O\ AU]^_/KP?\*[L./WK\9_C?\
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MW\;]O7CD?_7YH_X5Y8<_O6YQ_&^>/PY]O3WKT:BCVD_YG^'^7]?-AR+N_O\
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M1_PKRP_YZMTQ]]\?RZ>H^E>C44>TG_,PY%W?X?Y'G/\ PKNP_P">K=,???\
MPZ>W^0?\*\L.?WK_ /?;_KQR/;ZUZ-11[2?\S#D7=_A_D><_\*[L.?WK<X_C
M?_#GVST]Z7_A7EA_SU?K_??V]NOO]/2O1:*/:3_F?X!R+N_O_P" ><_\*[L/
M^>K]<_??_#\C].O<_P"%>6'_ #U?KG[[_P"'7U/U_#T:BCVD_P"9AR+N_O\
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M=-\3WM[!XK\7Z?9ZK=:7!=:1K^EV41LK2\2(0/;22I,CM(Y#*M?@=^P-<+\
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M&L^'M3OKJVNWUG4-3U*[ABOM+MM4TS^V[[4+BP>Z9HKE=V*;D^9JVBER7O\
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M+P^)A[2DYTIN#;C>="K3K4I7BT[*I3C+?7ELU9LR?VL/V6_C)\??&OP\\2>
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MYUG[1I-YI?V3SMZ_9MHNS+YA60$H%V\Y'D'_  PG\/N/^+O?M-C'I\<_$_\
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M"[_$'POJ?A>77$MOM;6-IJT)M;QA;[XS();22: J'4XE)!!&1X5_PPG\/O\
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M=/\ \,*?#[@?\+=_::X_ZKGXH[]S\OM1_P ,)_#[_HKO[37_ (?/Q1^?W?\
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M-_\ A\_$_P#\12_\,)_#[_HKO[37_A\_%'Y_=_\ K>U 'VU17Q)_PPG\/O\
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M/Q1_\37-^,/V*_ F@>%/$FLVOQ=_:7-WI>A:O?V@E^.'BB2,W5GI]Q<6_F(
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M65K*QU8;#4,'AZ.%PU.-&AAZ4*-&E!6C"G3C&,(KTBK7>KMJW>Y]M45\2?\
M#"?P^_Z*[^TW_P"'S\3_ )?<_P#K^]+_ ,,)_#[_ **[^TU_X?/Q1_\ $UF;
M'VU17Q)_PPG\/O\ HKO[3?\ X?/Q/_\ $4O_  PG\/O^BN_M-?\ A\_%'/\
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MQ+X?U.#<&\G4-&UJTO=.O8MRJWEW-M*FX XR :\W^&O[,_[.'P9U6[U[X/\
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M>VBU?QCXXUB-X;B#3+JX>YTK3%M[B OJ4($LFTK'))^P)^V]\5/VA_$GQD^
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MJLHEA<!HG #(XW*0>:Z.VA%O#'$#G8H&?\^@P*_(O]E_]OKXJ^+O^"1OAO\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@-4RBY:7LO35-;-.^C+C)1UMK=ZWT:=M&K?DUO9GX)? 3]KWX _\$W?VM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3Q:0L=O>VNH^'_&.GZ5KUK>K!#=:;)!#<ZC]T_\ !-W_ (+D7/[2'P)_:O\
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MWN;>5"'BFAD>.12&5B"#5ROYZ_\ @W%_:=\4_&O]B_7?A)X\O[C4O%7[,OQ
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>nt10016217x4_graphic15.jpg
<TEXT>
begin 644 nt10016217x4_graphic15.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^***_SZOVD_CU\<]-
M_:*^/FG:=\9_BQ8:?8?&KXIV5C8V7Q%\86MG96=KXYUV"UM+2U@UB."VMK:"
M-(8((42*&)$CC144 ?<<$<$U^-<1C\/0S"E@'@*-&M*56A.NJBK3G!12A4I\
MKCR-MMN][:;GY!XN^+N!\),!DV.QV38O.8YQB\3A*=/"XJCA94)8:C3K.<W6
MI5%-352R44FFM79Z?Z"M%?YP'_#0_P ?_P#HN7QA_P##F>-?_EW1_P -#_'_
M /Z+E\8?_#F>-?\ Y=U^B_\ $!\?_P!%%@__  @K?_-/K_3T_"?^)S\@_P"B
M&SC_ ,.^"_\ F7U_IZ?Z/]%?YP'_  T/\?\ _HN7QA_\.9XU_P#EW1_PT/\
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M'_\ 118/_P (*W_S3Z_T]#_B<_(/^B&SC_P[X+_YE]?Z>G^C_17^<!_PT/\
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M8 KFC_,OO7]=5]X[/L_N9[]12 @@$$$$ @@Y!!Y!!'!!'0TM,04444 %%%%
M!1110!Z-8_\ 'E9_]>MO_P"B4HHL?^/*S_Z];?\ ]$I17!+=^K_,"U7^<E^U
M!_R<M^T/_P!ES^+7_J?>(*_T;:_SDOVH/^3EOVA_^RY_%K_U/O$%?O7@/_R,
M>(?^P+ _^GZY_%GTS_\ DGN!_P#L<YK_ .H.'/#****_I4_SZ"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /W4_P"#?3_D\SXF?]FQ^,__ %:OP7K^PROX\_\ @WT_Y/,^)G_9
ML?C/_P!6K\%Z_L,K^1/&7_DMJ_\ V+LO_P#3<S_43Z*'_)HL'_V/L[_]/4@H
MHHK\J/Z4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\UN/^/B?_KM+_P"A
MM7I5>:W'_'Q/_P!=I?\ T-JWH;R]%^8$-%%%=(!1110 4444 %?Q>_\ !&;_
M )6$_P#@L/\ ]<?V@O\ UI#P77]H5?Q>_P#!&;_E83_X+#_]<?V@O_6D/!=1
M+XZ/_7U?^DS _FY_X)UZ]<_L_?MK?#W]M>ZNKJP\%_!?]N/P#\/OB+J#7,=M
MI=AX/^,.L>+O#VMW=W)Y9EWVN@1:_?A7D^RRQ6#QRK&2)D_=[_@Z1U#5?VC_
M -I#PY\#O#-_YFD?L??LC>/OVFO'"6\HE^Q7GB;Q=X2\.QVUU&3Y-LM]9WGA
M!HIV)GF$I@B7<\;#\N/V-/@+'\<?^":__!<"X@@%QKWPF\1?#'XP^'PPE!M)
M?A_XN\<:QX@OHVA=6\Z+P6OB>*)7#Q!IQ(P#1HZ?57[/7CWQ?^WE^R=_P6X_
M;N^)&GOJ&O6G[#_P=^ EA=.9WO4U'P5X=\-:]XOU!%@/S6NI:UX0L_$$CSRW
M$L4*B.YEDB^T%^2";IJFUI4O-6_N\U[Z]XP=E?1[7%9:KO>Z]=VO+OMO]_W3
M\ /VX?&?[ W_  ;#>!/B[\,;L:9\5/%GC3Q1\)?AQK9A2=O#OB/QKXQ\1O/X
MBACECEA-YH?A_2=;U'3S,NQ=0@M6!WA*Q_V,?^#8_P"'W[8G[+O@[]J#]M/]
MJ3]HN_\ VB?V@_"*?$[31X-U7P;)H7@BW\9VMSK/ANU\9R>.O"OC7Q#\0M3+
MW]KXA\0KI&O_  _M4EU"^\-Z>=]JOBJ]\XTS]EOQ_P#M3_\ !JO\/M)^&6EW
MVO>+/A#\2]>^.,7AW38&N;[6]%\%^*/&&G^)[>UMXT>6>:Q\.>(=3UA(H1O<
MZ;C.W<*_0;_@G9_P<>_\$\O"W[#'PG\+?M(_$CQ)\+/CC\$_AAI7@/Q-\/I/
MA]XW\37?CO4_ >A+I]E?^ -9\/Z7K6@O'XGM+&RCMH/&FN^$WT_7;JXT^^G7
M3+0:W/HE!N"JM<OL8.*D[1O]IWNES+32^S'JU%/;EBUK:[M&_76VGI?LV?7W
M_!%C]C;]O'_@G9X'_:%^&?[8/QE\'>-?V;?"GB;Q#J7P.NKWQ7?:QXAT+P[H
MM[?7^K>-MUW%<V7A'P1XNTEW\077AC4_$$NIZ%K4-[--IUBEQ=75]\T^'O\
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M/XP:CX@\*ZGXDT'X0:QX2LK& M]CLGT_Q>ES?:M?6\5U9PG^S5E6.=?Z<?\
M@F[\9?CA\<_V3/AUXT_: _9UU7]F'QS:VR>&;3X<ZSXF3Q7=WWA7P]INF67A
MSQHNI)HVAB.W\5V0_M""R-FYMD  N;A65Z_ED_X+R2QI_P $9/\ @C7J;.HT
MZSO_ -FIKN_!S:6X'[+\\A\ZX7,49V6URP#,"5MYB ?*?;_7W^R;\8/A-\;/
M@!\,_%OP;^)WP_\ BOX7L_!_A;P[?>(OAQXQ\/\ C71;#Q%I'AG1EU;P]?ZE
MX<U#4K2QU[26GA35-&NY8=2TZ26..\M8'=5+A?VTVV]80=M+:]M+V3\^KO=V
M'U^[32W^>OK;?Y?R,_\ !T3^TY^U'H?QL_9G^".B_"+QMX?^!^A_$'PEXP\*
M>/\ 3/B!=6'AK]HCQM/#I5U=_#N[\,6VG0V]I<>$KS&GIJ-_>ZO&3JTDHLH$
MEV2>)_\ !QO\;OC/\:/V9?\ @F/\6_VC?V>=9_9<^)E[\5OCS-XC^#&J^(1X
MPU7PY9:+>?#F"PN6U6/1]":[?6-.MHM1@@&F0O&+A(@9>';[:_X.O+ZTT>7_
M ()NZ[JMQ'8:-I/[0NJWVIZG='RK*QL[)O"EY=W%S<,/+BCM[6&:XE9F&V*-
MW/RJ37AG_!U)\5_A-\<_A_\ \$X?'/P=^)7P]^+_ ( U3XN?&'3[7QC\,_&?
MASQ[X1O[BT3X60:A96_B+PKJ6JZ1<7%H[^5>6\5XTUL[!)D1CBLZE[8F\G_R
M[TTU]Z#72^BTT?F]1:W?X=MEKT>]^OD?</Q _P"#C3XE? _XD_"+4?CS_P $
MU_C9\(/V1/C?XB;1OAC\?_&'BN&R\4>)='>TMI=/\0Q?#IO"@TRT-Q%?Z;JT
MVB7OCBWU1=!EN[VS2^N+&>U'Z6_\%(_^"LOP[_8*\,?!C2O"7PZ\0?M'_M _
MM*W$-O\  'X&^";]=.U7QE;SMIJQZYJ>I#3]7N-&T&675K*TM+F+1]0N;^]D
MDBM;5X[+4)K3\K_^#MZQLK3_ ()U?LXQVUK!"NG_ +8OP]LK'RXD!M+,?!7X
MW+]FMVQNB@*VUL&C1@K>1"6!,:$?EA_P6G^&GB/2OVTO^"0GQF\6_&SQY^R_
M\&?&7[('P&^&%I^T[X%GUZVU?X.^+_"6H>(]:\2:]IVI:)J>B76E:I8Z1X_\
M,:CYMGK.FW<VG+>W/VA8-.N)(;G*<.=<W,TH.+:BFN:?*ULEYJ_SN":MI?>-
MK]G:Z_'3\;V/Z'/V/O\ @M5XL^)?[4GAS]C#]N+]C;Q]^PC^T!\2M*?7/@YI
M/BOQ0GC/PO\ $*TBANY3IT&O'PYX6DL-<N/[/U 65JME>VEP]L+5[R"]N+:V
MF_>J;_52_P#7-_\ T$U_%-\"_P!A;]CSQK_P4!_95\1ZW_P<.ZU^VA^T)\'_
M !GX.^)?PM\'^,O&=I\8AXDT[1/%=KK%_P##;PK\2]5^-/CCPYIFL^*QIES:
MW_@K0M7N/& LIVUG_A%IX$BG;^UF;_52_P#7-_\ T$UK1<G\7222=XO2RWY&
MU>]^VEM 7]?U9'^6S^R1^SS_ ,$J?CO^T;^WDW_!3#]JGXG?LT2>&/CCJ"_!
MI?AUJFD:</&2:QXW^*A\?-JXU3X*_%XS'0&TSP<+$PG0 G]L7GF#4]R&P]N\
M >#_ -F/]EG_ (*Y?L,Z)_P1;_:?^,W[1GA[Q=XA\&0_%6;Q6#="#^T?&E[I
M?C'0;[4O#W@'X5V>M^&+CX>M+?:AIM_X-== N+?[?+KVIIJD%EI'UA_P14_X
M)F?L>?\ !1GXU_\ !6?3?VIOAM?>,]5^'?QAT/3_ (8^)]+\;^.O">J^ ;KQ
M]XN_:$CUW5M-L_"WB31]!UR\>?PQX>NH(/%^D>(M/AETM(X[-8+N_BNNR_X)
ML>*=6_X(=?\ !5;5OV!_VJ_AW\)7\ ?&*_ATWX)_M.7?PO\  VC_ !$_L;QQ
MJ<UOX*UNR^,<&@V?C?6/ /BO5[(>$?$WA'Q#KVIZ;X8\7:3)'H\6E_9=0CU7
MCA%\M.34%%R24TI.::GIS.Z2NU9/7332]Q)*][+2>KONG9VMY[.]UKIND1_\
M%EO@/\ /VF?^#A[X-_!+]J+XFW7P<^!?C;X ^$(?'7Q'L?&G@KX>W/AN#1_"
M/Q6U_1Y(O%_Q#T?7O!^C_;_$&EZ5I;/K&DW:727K65J(KVYMIH_@;_@H]^RM
M^Q?_ ,$MOC#^RE\4?^"6O[>7BKXP?%.^\9+>:[HUC\4OA?\ %+6_"JZ1JMA=
M:'KD7C+X-^&/"OAN'3=:OHSH]UX+U[2[_4)I+=-2>66QNXK>+]+/^"JG[*7P
MT_;?_P"#DWX!_LP_%^_\6Z;\.OBA\ _#-MXAOO FJ:9HWBF&/P]X$^+WBVP;
M2M2U?1?$6G6S/J>A627!N-'O!)9O<1(L4CI/'^V'[+?_  ;5_P#!,G]EGXM:
M%\9=-\-_%CXS>)O"=Q::GX1TKXZ>.-%\3^$/#GB*PO;>]L/$T/AKPEX-\"V.
MN:G9F!H;>S\7?\)'X>03O=_V&=3M]/O[/25.4Y3M&*_>?Q&WS1M&#LDNU[KS
M;'97O97OO=WZ=+>O57\NOR+_ ,% _P#@F;^WE_P5H_;$_9KM?C-KFK?"O_@G
M7X>^$7@+4_&,?@7QYX9TSQ6WQ UKPDWBCX@ZA;^ -;&KSQ>+;WQ)?6G@/3-6
MUOPUJ^G:%H^B6=\NDS%M1:^^&?\ @FY\%U_X)X_\'!?C']AO]D#XT_$/XN?L
MV1_#F[G^+FD^*-6TO69/#FLCP+9ZW?:9XVO/"VC^'_"-[XJ\(>)#:)#J>F^'
MM"N+0:E'X:U"V;4]-U$S?H)_P< _\%HM=_9!U7PY^Q'^S9XUTKP!\?/BAH=G
M??$_XVZG%?W-G^SYX \3N;33;S2X-(L-6U-_'6M:>+W5K:ZLM,N[SPQHJV&K
M:=;W.K:IILEARG_! SQ)_P $?OV=]4M_A+\"/VN+#]IK]O/]H&SGO?B;\0K[
MX9_&W0KOQ!+IL4OB#4?"/@B_\<?#G0].T/P=I4T<M_<SZMK":YXPU6 :QJ\H
M$>BZ%H=24'524DI*:E*4I6>EDJ45I>^E^BUU;T3T;NEKMI?[MV[-=/GOJ?CY
M^Q;_ ,$IOV>/^"IG_!4[_@K=X2_:"\9?&?P?IOPH_:2^-7B+P[/\'/$7@?P_
M?7M[K_[07Q#TV\BUJ3QM\.OB%!<6L<%K&]LEC;:=,DI=I9YD*QKTO[7/[(OC
M_P#X-NOVV_V2/CW^R5\=?B;XQ^ 'QK\47OA?Q)X'\?ZKHRZQK&FZ+J/A%?'_
M ,/O'S>&]%T?PKXLT/Q%I.K:7J^AZ];^"]%U+0]3T^WFLH8=9\/Z7KTWIW_!
M+[]OK]D?]@[_ (*N?\%B_$/[6/Q@L_A%H_C_ /:(^,&C>$;R\\)>/_%@UC4M
M*_:'^(U[J%LD'@+PIXJN;0VUK-%*TNH0VD#[PD4KR948O_!9;]NKX3_\%FOV
MJOV"?V-_V +SQ%\9(O#?Q-U/7-7\9V_ACQ9X=T'5=7\5)X6,TMCI/B'2=,\0
M0Z-X \+^'_$6K^*?$FM^'].L]*MFU"Y23^R+2YU&XAJFHMKE]KS^[9^]=S72
M][=]-KV)BE9;7:6M^MU?UVU[*^R6G][.B:M:Z]HVD:[8EFL=:TRPU:S9AAFM
M=1M8KRW+#LQAF0D=CD5_(%_P7F_Y3,?\$0/^RS?#;_UH_P"&]?9/_!0?_@E%
M_P %//VB_CSIOCK]DS_@IY\1/V7OA#I?PL^'7@:T^%GA[XO?M">"M-BUWP?I
M,FF:QXB71/AMK^G^&5GUYA;7$]U':QWL[Q_Z66*(Q_);_@HK\(?BW\!/V]/^
M#=GX/_'CXMZI\=_B]X#\=_#C1_'GQ<UK6O$WB/5/'.M-^U)X)OO[7O-<\975
M[XGU*1+2[M;%;G6;J6[,=HBY6)8T7:4I/1Q:M.G[W1_O(;=2M;/3^76Z_FAY
MW6YX!_P6=^'?[*?Q6_X.$++P)^VU\5O$_P $_P!F?6_@YX/;XB_$OP;=6=EX
MC\.OIOPA\5ZKX173[F_\%?$2UC&K^-K+P[HET)/"&K%[/4;A$-B[+J-I[#\!
M_P#@FQ_P;/>*/C5\*= ^$?\ P4K_ &F/&/Q0U+X@>%(OA_X4?Q3X-2/Q%XNC
MUFTGT+1Y&G_8^TF$17^H106\@?5-/#)(RB\MV(E7CO\ @K!#^Q=/_P ''7AZ
M+_@H2;9?V1V^#?AS_A:9NYOB;;VXD7X(^-6\$;YO@[)%\1$_XN"/"VW^P'4,
M^U=4SHYOP?M[X.>*_P#@T/\ A3\5OAW\2/A'KGA_0/BAX*\8:!XA^'^M+=?\
M%%=4;3/%NGZC!-H5XNG>)&U'0+PPZ@(&%OK%C=:=(>+N!X=PK&R<YW]C_$:?
MM&U.WN[).UNWGS+8E)73:V4-;V:M&#T_'MKY']CT4:Q1QQ*25C1(U+8+%44*
M"2 !G YP ,] *?533[^TU2PLM3L)A<6.HVEM?V5P$D03VEY"EQ;3!)525!+#
M(CA)$210V'56! MUV%!1110 4444 %%%% 'HUC_QY6?_ %ZV_P#Z)2BBQ_X\
MK/\ Z];?_P!$I17!+=^K_,"U7^<E^U!_R<M^T/\ ]ES^+7_J?>(*_P!&VO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:E:76DZM"C1"^T?7-"O])\0:/-+"Q@NSIFJ6BWMOB"\6>$!!\RZW_P $?O\
M@F[XC^%?PN^">M?LN^&+[X7?!;Q'XE\6_##PD_B_XG16OA3Q%XPFTRX\2:G;
M7\'C>+5[^759M'TQY8M7U#4+:'[)&MM# AD5_P!*:*3C%MMQBVU9MI-M=GIJ
MM%IY ?,W[4O['/[-7[:W@+0OAA^U!\+-,^+/@3PUXNL?'FA^'M4UGQ3H=OI_
MBW3-(UK0;'68[KPGKN@:A+-;Z1XBUFR6WN+N6S9+YY)+9YHH)8M7XO?LH?LY
M_'WX,6_[/?QF^$/A#XC?!VRTO1]'TWP5XFM)[VVTBTT"SBT_19=$U47,>OZ)
MJ>FV,*6EKK>DZK9ZS' TL8ORL\XD^A**=EKHM59Z;KL_+5Z>8'P/^S#_ ,$N
MOV ?V-/%M[X^_9L_9@^'WPU\<7UHU@?%\<GB/Q7XDL;.1'CN+?0]:\<Z[XFU
M#P['>Q2-#J T"XTTZC!MAOC<1(B+][D!@5(R"""/4$8(_*EHH24=(I16]DDM
M>^@'RC^S;^P]^RM^R%K_ ,6O%'[./P@TCX7Z]\=-;TWQ'\5]0TO7/%VKOXPU
MK2+SQ)J&FWUU!XF\0:W:Z>]K>>+_ !',D6C0:;;N=3D26)XX+5(,C]JK_@G]
M^QY^VY<>"+W]J/X'>'?BQJ/PXDU"3P1JNH:OXM\.ZQX=.J/:RWT=EK'@SQ#X
M<U-K>>>QM+G[+<W<]M%=6\=U#%'<#S*^Q:*.6-K65NUE;>^VV^OJ'GUWOY]S
MY%O_ -@_]DS5/VDO O[7VI?!_3K_ /:1^&GABT\&^"OBK=^)?&]QK>C>'+'0
M]8\-VU@UC+XF;0-3=-%\0:Q9/?ZQI&H:E/\ ;I+F>[ENXX9X_KJBBG9*]E:[
MN_-Z*[\[)*_D@/S4_:"_X(^?\$W?VJ?BOXD^.'Q__9>\-_$CXJ^+TTF/Q'XO
MU+QG\4=,O-3CT+2++0=)22R\/>.=(TF!;+2-.LK&(6NGP!HK=&DWREW8_9__
M ."/?_!-O]EKXI>'_C5\ _V7/#'PZ^*'A9+^/0/%EAXP^)^K76G+J=G+87PB
ML?$?CC6=)E,]I-+"3<:?,R!]T120*P_2NBIY8WORQO>][*]^][7N!^37Q _X
M(8_\$I/BEX[\:_$WQ]^Q[X2\1>.OB)XL\1>.?&?B"X\=?%^TGUSQ7XLU>\U[
MQ#K$UKIWQ#L]/MI=2U:_N[R2WL;2ULX7F,=M;P0JD2_2_P"RM_P3P_8H_8DG
MUR^_9;_9S^'WPDUGQ)#<6FM>)]*M]3UWQE>Z9=/I<USH1\:>+M2\0>++?PW<
M76B:3?S>&;768- EU+3[;4WTTZA&+FOLZBCEBG=1BGWLK_?8 KY2^-G[#W[*
MW[1GQ:^#?QT^-/P@TCQU\6/V?M7T_7O@]XQOM<\7:;>>"=6TOQ!IWBFPO+.Q
MT+Q!I>D:BUMK^DZ?J*1:WIVIP-);B*2)[>2:&3ZMHJFD]&DUV>NSNON>OJ!^
M='[2?_!)7_@G?^U]\3[WXS_M'?LS^&_B?\3=1TG2=#O?%>I>+?B3HUW<:5H<
M#6VE6CV?A?QIH>E!;.!FC25;!9W4CSI9" 1X=8?\$ _^"06F7UEJ5C^Q5X-M
M[[3[NWOK.X7X@?&AV@NK29+BWF5)/B4\;&*:-'"R(Z,5PRLI(/[$45+A!N[A
M%MZMN*O?OMY("K86-KIEC9Z;8PK;V.GVEO8V=NI9E@M;2%(+>%6=F=EBAC1
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGO\ \%-_ '[3_P"QO^WS\)_^"L?[,/P/\:?M)^$H?A!<? G]J7X,?#N"\O\
MQA>^#M,OM2U70/&.EZ5I.FZEJ=TNFPZ@Z7=ZEAJ=KI3:-87=_!!9))*1ZTX-
MW:]QR23;:TOHM[.S:ZI/1[-?U_7]?>?JO^TS_P $W/V-_P!J7X)>+?@AX\^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVEK"7,5M;Q&12LACAC0R*>2KE5!92>H;(/<4L-K;6Y)@MX("P 8PQ1QE@#D
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MB<DIXF.']ESNLJM&.9SQ'ME!8*I3CR.4]/YZ*^JE_8T^.+_LNS?M@KI6@_\
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M1T/2W2WT%_\ 3+F,7?B'35$L?RE'E<<1-7RU7]$'P/\ ^4"'[2G_ &4Z]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV?QJ^-WB#]C7XL_M,1?M:W']NW'Q6^.4WCOX8>*_#MG:?&&U\2^*?%KQ^)M
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MVNFKM:*_5I@>/>)X_P#@YE_8M\.7O[2'Q(^.?[*O[=WPZ\"6$VM?$K]GK0?
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MPA^)OBJWN[JQCL(;:SM4CTL&W>1D@DD>23U7]DH!?^#@S_@JDJ@!1^S=^RB
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MFV<DZ1Q :/XUL(M;$4DTEQ<?\)/J C3[/;OY?P;^WE^TK\-?VB/^"EF@W?Q
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M/[;A.6,R',<BG4ADU&A4G#'SIU%C<34IXSVF+QE.4'[6I6J-UX\BBZ'(W/\
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M3Z*'_)HL'_V/L[_]/4@HHHK\J/Z4"BBB@ HHHH **** "BBB@ HHHH ****
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M?[2MO"NI:[HOACQ)K6NV6EX^RZAJ2ZM<7QAM;]S8P7+_ .FVM[#')9R_1_\
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M13A&/B"X!9!*C!21QD8.*ZW_ ()N3Z'^V+^P'^T[^Q1XB@L+CQCX.TK4M?\
MAY>WT223V?\ :<\OB#PG=07!C^TPP:-XZT=!/#;N0+*\DB?$=XT;?/9KQQ_9
M>,SJA/*I5<+D.)X<AC\7'&<KA@\^C5Y\8J'U65U@9PIQE1]M^_53F]K1Y+2^
MZX9\'%Q+E'!^-I<2PPN9\;Y9Q[B<DRJ>5>TC6S3@FMA84LH>-_M.G[V<T:U>
MM#%?54L$\,Z;P^+=13A_-U17]*_[,&@Q_L&?\$J/CK\??%VB6.G_ !6^->L7
M?AOPM#JEA;OJD$S_ &[P9X1TK$NV<KI]P_BKQ1/#%(LD,#7LN";?(^J_V//V
M7/B5\#_V%_A/\0/V1?AY\%/&/[2OQMTO1/'7CWX@_&U;D0V?AKQ1:)K4>@V%
MQ80MJ\FG:= FDV,.B6NI:?83:F+WQ%=B>[E\H\68>)&%P,<?4C@(5,/0SV.0
M9?BJN80PV$QV)I8?V^88BM7GAIPP>$P6E-5(O%SQ,Y1]G3BF^7V<C^C]F.;U
M,CP]3.ZN'QV-X.J<:YYEF'R*MF&99+EV)QJPF1X+"X.GF%&KFN9YNN>O/#U5
ME5/ 4Z515:U5J'/_ !^T5_3'_P %=_V8-,L?@/\ !K]JWXC?#'P3X-^/0\5^
M'?"/Q[T7X5WWV7PSX\>^2] N8-4&G17#:A<P:.%LM;N]-O\ 5K"ROH-*O)=3
MCTJT<_;G[-7C[]L3Q;XP^!OA3P3^P5X%_9P_9#M/"FGVWCG2_B+::9IGBJ"(
M*]CJZ^%],CU*#7K.?[3<KJ=K:^,/!/\ :'B6WM-0NM6U&UO-3BN9,ZOB51>2
M87.L)EN&JPJ3S&CBX8O/<!@*-"OEJBZE#"5YTZM3,ZF)YXRP?U;"J-6G*,ZD
MJ+DHG1A?H]8G_7#,N$LRXAQ^'J4*&0XO+*V6<&9SG6*QF!X@J584,;FF"I5\
M+A^'J& =&K3S1X_,ISP]>E4I4(XJ,/:O^7K]A[]EN']L;]H3P[\"Y_&\GP]C
MU[1?$^KGQ-%X=7Q2]J?#NC7.K"W&COK?A]9A=FW$!E.IQ>0&\P1RXV'Q_P"/
M?PO3X)_&SXK_  @CUMO$B?#/Q_XI\$)X@?3AI+:ROAO6+K2AJ3:6M[J0T]KP
M6WGFT&H7H@+^6+F;;O/]&'PI^%W@3X0?\%Y-4\(_#CPWI?A+PO)X#U_Q!!H&
MB6J6.D6%_P"(OA5_:NIKIVGPXMK"UEOKB::.SM(X;2 R,MO!%'A!^$W[>'_)
MZ?[5/_9>_BC_ .I=JE>CD7$F)SGB7V=.I.&4XGA#*<ZPV#J4Z'/1Q&-Q=>,Y
MRJPA[64O9*%-Q=5TO=YHP3;9X'&GA_EW"/AZJM>A1K<39?XI<2<)X_-Z%;&>
MRQ> RG+<-4HTJ>&JU?J].G]8E.LIK#QQ'O\ ).K.,4CY.HHHK[X_#PHHHH *
M*** "BBB@ HHHH **** /W4_X-]/^3S/B9_V;'XS_P#5J_!>O[#*_CS_ .#?
M3_D\SXF?]FQ^,_\ U:OP7K^PROY$\9?^2VK_ /8NR_\ ]-S/]1/HH?\ )HL'
M_P!C[.__ $]2"BBBORH_I0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJ.5_+BDD SY<;OC.,[%+8SVSC&:-PV)**_+/_ (>(Z_\ ]$PT?_PI
M;W_Y4T?\/$=?_P"B8:/_ .%+>_\ RIK[3_B'W%7_ $+Z?_A;@O\ YH/RG_B-
M?AQ_T/*W_AIS?_YB/U,HK\L_^'B.O_\ 1,-'_P#"EO?_ )4T?\/$=?\ ^B8:
M/_X4M[_\J:/^(?<5?]"^G_X6X+_YH#_B-?AQ_P!#RM_X:<W_ /F(_4RBORS_
M .'B.O\ _1,-'_\ "EO?_E31_P /$=?_ .B8:/\ ^%+>_P#RIH_XA]Q5_P!"
M^G_X6X+_ .: _P"(U^''_0\K?^&G-_\ YB/U,HK\L_\ AXCK_P#T3#1__"EO
M?_E31_P\1U__ *)AH_\ X4M[_P#*FC_B'W%7_0OI_P#A;@O_ )H#_B-?AQ_T
M/*W_ (:<W_\ F(_4RBORS_X>(Z__ -$PT?\ \*6]_P#E31_P\1U__HF&C_\
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M^(?<5?\ 0OI_^%N"_P#F@/\ B-?AQ_T/*W_AIS?_ .8C]3**_+/_ (>(Z_\
M]$PT?_PI;W_Y4T?\/$=?_P"B8:/_ .%+>_\ RIH_XA]Q5_T+Z?\ X6X+_P":
M _XC7X<?]#RM_P"&G-__ )B/U,HK\L_^'B.O_P#1,-'_ /"EO?\ Y4T?\/$=
M?_Z)AH__ (4M[_\ *FC_ (A]Q5_T+Z?_ (6X+_YH#_B-?AQ_T/*W_AIS?_YB
M/U,HK\L_^'B.O_\ 1,-'_P#"EO?_ )4T?\/$=?\ ^B8:/_X4M[_\J:/^(?<5
M?]"^G_X6X+_YH#_B-?AQ_P!#RM_X:<W_ /F(_4RBORS_ .'B.O\ _1,-'_\
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M&U\;Z9;^$?A[J?BNP;0;S4=0TN"2>_M+B"**Y:[TRZ#6V&98U1R<.!7YA_\
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MI0-/-V8O*/GB(/&7^V*T335TTT]FG=?>@"BBBF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'HUC_QY6?\ UZV__HE**+'_
M (\K/_KUM_\ T2E%<$MWZO\ ,"U7^=!^T;!9W7[5'QXMM1OETS3[C]H#XH07
MVI/#/<KI]G+\1=<CN;UK>UBFN9UM86><PV\,L\H39%&[LJG_ $7Z_P Y+]J#
M_DY;]H?_ ++G\6O_ %/O$%?O/@0KYAQ$DW%O X))JUU>O7U5TU=;JZ:[IK0_
MB[Z9K4<AX%DXQFHYWF;<)\W+-+!8=N,N24)\LDK/EE&5F^62=FOV5_:]_P""
MG^B?##X7?LT_!'_@G9\;M2M/#_PY\%SZ9X^\5:=X&U+1OM<]E::1IF@Z*EG\
M3O!EE=S,C6VM:O?7ECIY@=KZPC%Z\J7,$6I^SG_P4G^'7QT_92_:0^ '_!0C
MXYW<?B3QQ97MG\//%VK> ?$FNE5O]%QII-O\+O!%_;VI\+>*=/T_686U"WMY
M;L7$T(EFB3RU_GCHK]<_XAWPXLMI8&-*M#%4L9''QSV,,"L^EBXXUX[VT\>\
M$U)NK)P<'1Y/8I044TI+^8/^(\\?//\ $YS4Q.&JY;BLKGDT^"ZE7.7P33RZ
M>50RAX>CD<<XBZ5J$%756.+]M];E.JZCC.5-AX)&0<'J,X/N,@'!]P#Z@5^U
MO_!.#]N3]GKP'\$_BI^QO^V+!K%O\$/B5<:CJ6F>+]+TW5M9B\/2ZI8Q1ZSH
M^JZ?X=L]0\1P075U86FI:'J^AZ7JMU9:S-.MY:QV4JWMC^*5%?1YYDF#X@P$
MLOQLJ].'M:.(HXC"5?8XO"8K#S52AB<-5<9JG6I27NN4)Q:<HRC)-H^!X-XP
MS;@;.Z>>Y/'!5JRPV+P.*P.98=XO+<RR_'4G1Q>7YAAE4I2K87$0:YX0K4IJ
M4(3A4C**9^Z?[<O[:G[)D'[+7@C]A?\ 8CN=>U7X66>LVNL^*?'^O:9XFTNR
M2W.LW'B"6RA@\3:3I7BW5]4N]=O9]0UV]E\/V%E#!#':Z4FIFY/V/]!=+_:M
M_P""0=A^RMH/[)=C^TMXQ\(?#BWT.+3/%7_"!> _CUX6UWQK/>VY'BA_$VM6
MGPGGN]0@\57<MR^NVWF+!?V<@TB7=HZ+8U_)/17RF(\.,IQ&!P6!6:\04%@\
MQQ.<3Q5''89XO'9KB7#FS#'5:^!K1JXFDH6H3I4Z*I\\VHN4KK]+P/T@.*,%
MG&;9P^&^!L9+-,AR_A:EEV*R;'K*\GX;RY5^3),GPN$SC"SP^78F5=RQE'$U
ML6Z[I4(\T:=-0?ZW_&CXA?L)?LO?'+]FWXT?\$]?&OBGQ_?^ O%5[XA^(-CX
MIMO']BCVMK)I\%MI4+^-_!GA-O*US2+K7].N7TT7ICCFW3>2WE;_ -1G_;T_
MX)+V/Q2N/V[+"]\>3_M-W'@IK0_#-/"WCF"[_MF?2ETB6"6XDT%/ANNM&S']
MGW.OIXQGL38&2ZBMYKXB$_RE45OCN ,MS*C@X8S-N(:M?"X7$8"OC_[1IQQV
M9Y?B:[Q%3 9E66%4:^&YVXQC3IT9QA[JJ=3CR?QQX@R'%9K6ROAC@/"X/,<Q
MP.=83)8\/UGDW#^>9?@H8&AG7#^$>9<^!S%TJ<9U:E6OB:4ZR<_8I-Q/4/C9
M\4M8^-WQ=^)'Q=U^)+?5_B+XQUWQ;>6L;F2.R;6+^:ZAL8G*J7BL;=XK2)BH
M+1PJ2 37ZD_MK_M7_ 'XN?\ !/W]B;X(_#WQ[_PD'Q/^$7ASP;8?$/PQ_P (
MMXTTG_A'KO2?AW9:%J$7]M:YX<TWP]JWV?589+7S-#U;4XI=OGPO);%9C^,U
M%?08O(,#BZV1U6ZU!</8CZQ@*-"5.-)M86>#C2K1G2J2E2A1F^6-.=*2DHMS
M:3B_A<NXVSG+L-QCAXQPF+EQS@OJ6=XG&4ZT\2D\SI9M4Q&$E1Q%"E3Q-7%T
M5[25:EB*3ISG&-*,G&<2OU__ ."3?[:'P5_9AU;XY_#K]H.XUG1OAE\>_#.A
MZ-?>+-'TK4=:'AV[T2W\4Z?)_:.G:);7VO/9:EIGBR^B6ZTC3M4NK2\MK4FQ
M>&:6:#\@**VSO)\)G^5XK*<<ZT<-BU34YX>:IUZ<Z-:GB*-6C4E"I&-2G6I4
MYQYH3BW&THRBVGR\'\59IP3Q'EO$^3QPL\PRN>(=*ECJ,J^#KT\7A*^!Q6'Q
M-&%6C4G1KX3$UZ,U3K4JB4^:G4A.,9+^H#]BK]IW_@E'^P_XB^)&A^ /CW\0
M_%@\?Z1;:EJ'Q3\6?#3XA0Z)#';W%Q%I_@#2="TKP.GB4WUFYEU6]U?4?#5M
MIDL-W:P0:U=7$5Q:V_XT?\$[/VI+7]DC]J_P)\4=<N9+?P!J;WG@CXF21V]W
M=O#X%\3RV\=_JJV=C;W=]=OX<U"UTOQ*+.RM+F^OETA["UA::Z45\+45XF%X
M*RVA#/XXC&9IF<N)<)A\)FE7,<1AZM6<,+1Q%"E.E*AA,/&E55/$/51<(RIT
MG3IT^67-]AF?B[Q!CJ_!%7 Y3PWP[#P^S''YEPYA<@P..PN%I5<RQ> QN)HX
MJGBLSQT\10E6P$+KVE.K4A7Q,<16K>T@Z?[9_P#!8']N[X3_ +4%]\)_AA^S
MIXE3Q!\'/ EOJOBS5KVU\->)/"=GJ/CS6I9K.*-=(\4Z'X?U+;H6E->F*Y%@
M()KGQ%J)264J6'7?"[]K[]C3]IW]B_P!^R+^VQXO\9_!G6O@LU@W@/XH^&?#
M&M>+M/U&QT6.72]&C6R\.:'XEU*SUB+0;^?2+VVO]$.DW%K:_;H]5AO)H[(?
M@]14PX&R>CDV5Y-AZV8859/BGC<!F5"O1AF=+&3E5E5Q,JSPTL/5G65:I"K&
MIA94I0:C[-<L7'2KXR\58GBSB/BS'83(LQEQ7EL<GSO(,;@L55X=Q.5TJ6&I
MX? PPD<PACL/2PKPE&KAZE',88BG64YNM+VM12_3?XJ^(O\ @GW\ OC#^SGX
MT_9,USXI?&R3X6>-? 'C3XC:GXQTN30/!_C6/PMKNG:W?6>FZ;XIT'1O$-GJ
M^HG3WMYX'T*V\/V@N5-M)J2AA%^LOQD_;K_X)Q_$7XU_"']J/6/VD?V@O%-Y
MX"U/PEKNB_LQV7AGQYI_@?PYXTTVTU&/3_&^OVNJZ/;>$H=0\,2:@XURZ\):
MWXAU#4-I@TJ'7+*:='_ECHK/'<"X#,?J,\5FN>U,5@L+C,$\;+&8:6+Q>%Q\
MD\11Q,YX&<(IV<83P=/"5*<6XPFDHI=&4>,^=Y$\YIY9PSP5ALOSC,,HS591
M3RG'TLLRW,<DBXX'%9?0HYO2J3FG:I7IYG7S*C7JQ52I2<Y3<OZ*YOVVOV2K
M/_@KU9?M66WQE@OO@?J?PNFTO4/%\7@+XI12Z/XA7P'=>%$T6Y\.7/@:#Q3<
M2S7=K;3I>Z?HM[IH@OX3+>QR174=O^+/[6GCGPM\3?VGOC_\1/!&J?VWX.\;
M?%SQYXG\,:Q]BU'3?[3T/6O$=_?Z9??V?J]I8:I9?:;2>*7[-J%E:7D.[R[B
MWBD5D'SU17H9/PIE^28JCB\+7QM6K0R3!9!!8FIAY0>#P-6=6C4DJ.&HMXEN
M;C4FI*G**5J497D_#XL\3,]XPRW%97F6"R?#8?%\79IQI5EE]#'4ZRS7-\-2
MPV*HPEB<PQ<%@%&DIT:3A*O"I*7-B9PY81****^F/SH**** "BBB@ HHHH *
M*** "BBB@#]U/^#?3_D\SXF?]FQ^,_\ U:OP7K^PROX\_P#@WT_Y/,^)G_9L
M?C/_ -6K\%Z_L,K^1/&7_DMJ_P#V+LO_ /3<S_43Z*'_ ":+!_\ 8^SO_P!/
M4@HHHK\J/Z4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NO\
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MAUXAM=8UKPWI-F;C7?$?B2]M;34O$.ER7VB3:+J>B?VM-I^O6%AZ3^R1X/\
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M0000FXFE,4,<>U%]1JG"\%&]G'EM)6NG&UFKIKIKW3:ZB/Y7O$W_  <FZ/\
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MCAN&00RNA1PR([,I5@0-IQ\0?\%)_P!M?X;?\$]_^"Z?P8_:1^,?@OXL^,/
M%O\ L/ZQX*DM?A'X5TKQ1XB_MCQ'XS\0+8N+37O$OA+2OL<7V20W<C:TMQ&&
MC,5M-N(7^MFBDZ;Y6E*S]ISIVO9\W-:UU?MN';R27W)+]#^0C]IC_@MYXJ_X
M*@?"/QK^Q#_P3$_8\_:H\3?%;X_>&]0^'7C?XB_%/P9X:\'>%/@YX#\676G:
M%KOBC5;KP_XK\=:/:Z?J6A7VO:1+XA\6:_X-TKP]>2V$MO+K5_>06<']*7[$
MW[-UA^R'^RA\!_V;K"ZMM0/PF^'FB>&=2U&S65;34=>2)KSQ!?6@F"S?9+G6
MKJ^DM/.5)?LQA\Q$?<H^I:*<8M-RE+FE:U[<J2T=DDWNTFVV];6LD!^!_P"R
M)97L7_!>S_@J_>R6EU'97'P3_902WNWMY4M9W3X;>!%=(;AD$4K(R.&5'8J4
M8$ J<+^W'_P4W_:"_P""9O[7&J^*?VDO@Y\0OBO_ ,$Z_B5X%\/V/PM\:_ C
MP!H>N>,_AM\9K2.0ZYX5\:W.K>(?#UG?Q>)(+*]U/1EU77-(<VBSMI,.HG3;
MV%/WOHHY6DTI6;DY)VNM7LU?5:]UWT:#I;R2^Y)7_ _FN_8=\<^*_P#@J'_P
M4]T;_@IKX;^!7Q6^"/[*WP$_9D\0? OX/^(?C'H%AX6\8?&CQQXU\175WK6I
M:?H]CJ&M6DWA?POINI>([.ZOM*UO5=,CU8:5;1:C+?MJ]CI_Z-_\%//V._BG
M^V1X+_9J\/?"K4O!6F7WPA_:Q^%/QO\ %#^-M6U;2;:X\'^"HM=35[;1I-(T
M#7Y+O79#J5N;&RNHK&SF"R^;J-N54/\ IM13C&R:;YFW>3VN].BVV6@[ZI]K
M?AL%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ]&L?^/*S_Z];?\ ]$I118_\>5G_ ->MO_Z)2BN"6[]7^8%J
MO\Y+]J#_ ).6_:'_ .RY_%K_ -3[Q!7^C;7^<E^U!_R<M^T/_P!ES^+7_J?>
M(*_>O ?_ )&/$/\ V!8'_P!/US^+/IG_ /)/<#_]CG-?_4'#GH-A^PC^U_JJ
M^ WTS]G_ .(&HQ?$W3KC6/ \]AI]K=V^N:5:VUC=SZBMQ;WDD&GV:0:GIY^T
M:K)8Q/)>00(S3R".H)?V&?VNX?B1%\(I/V?OB./B'-HXU^/PZ-&#LVC'@:B=
M42=M%2V#_N6=]24K<%;=@)V6,_O[_P %"OV@/BO\"_\ @FQ^QS%\(_&_B7X=
MZUXZL_ VCZOXG\'ZO>^'_$D>B:3X#DUEM.T_7M+FM=6TQ+W4;?3WO'L+NW>Y
MMK9[.=I+:>6-M'_@J9^T]\=/ /[$G['_ (F\!?$CQ3X&\7_%C1O!.J>-_&/@
MW5[[PQXJU.7_ (5YIVOW%O%K^BS66JV-I?:O=/>7]M9W<$-YA8;E)8?DK[7!
M<<<4XZIE"I8#(8T\[S/.,HPLJD\>IT:V65)?[77C&<E*BZ<9Q>&IM5*E2GSK
M$4H55"G^39QX.>&F3T>*G7SCC>I7X/X=X5XHS*%&.1RIXO"\0T:<997@YSPU
M.5/%1Q-2E4AF%:,J-"A7=*6!Q53#.MB/YDOBQ\%_BK\"O%+^"OB]X#\1?#_Q
M.EO%=C2O$-D;:2>UF56CN;.XC:6SOK<[@C36=Q/''*&AD9)4=%]G\(?L(?MA
M^/? \'Q(\(_L]?$C6O!=U9W&H6FM0Z.D"WEE;*SR75E87EQ;:I>0.BF2VDMK
M*5;R,H]H9T="W] G_!0_PWH?QM\8?\$CW^(]K:ZI-\5O%_P^TOQU?&**SFU?
M3?%(^'%YKEC)+!Y)@M;ZXU&];R86C6$W+F#RVVD?1'[5_P 3O@_\,_VJ_"6I
M^+/^"CWC;]F[_A6>E>$GM?V;?#_@CQ;/\.+_ $)81=E?$.GZ!"/#OB>+7[:6
M2))=1LM0DT>V6WL[(6_V"*-,Y>)&:UL%DBPF68=YGC\+FN)Q<8X3-LQP\?[,
MQDL"J>&P^6TZN,BL57BY>WKWI82%E4=:<XI[T?H_<,8?.>+GF?$.8+AS)L?P
MW@<KJ3S3AO(L>UQ#E='.)XC,L=GLZ.65'EN$J\GU3!PCB,SJINC]5A"?+_/5
M_P $MOV<?AE^T/\ M>VGPA^/'@Z]U_PQ'X0\;7VI^&KC5?$OA2^MM;T*VB-N
M+FYT#4M$UJUGLKCS$FM'N8U+AH[F%BNT>$_$K]G'Q5XG_:]^.GP%_9X^'/B'
MQ1_PBOQF^*WA;PCX2T!-0UJYTSPQX4\9Z[I>F17FJ:G<W$RVUCIMC;6K:IKF
MI&2XF$8N+R>\N%,O] 'P/\>_LZ?%7_@M%9?$S]FKQ+HWBGPKXW_9\UW5_&.I
M:%I>M:/8GXAV\.I:-K&ZQUK3=*E6]NM%TOPYJ-_/:6:VUY>7TUY+)-J-Q?RO
M\Y?LT>'_ -L6;]M'_@HGXC_9R\8?"SX6?#ZW^,WQSTOXL?%/XK:%I5YI?A*$
M^-?&]_IVM:7JCP6^KP:AX<C@N-6$,^LP>%;2-WU37M,U2.V6)=5Q9F,,RS;,
MYO\ LY+A#)<;3RK/,3C,/@L%F&*QU:A6C4H4Z4ZSK\W[N*HX:&(Q?)2I_NN=
M.',_#'(:N1<*\.4X//'+Q1XRRG%<2<'X#*L9G&;Y'EF4X'%86='&XC$4L+#!
MJ#=:=3%8ZM@,K=7$8BV(5)QJ_CC\7_V,OVIO@'X=A\7?%_X(>.? _A>:Z6S_
M +?U*P@N=*M[F1X8H8[Z\TRYOX=.$\UQ!;VSW[6T=S<RQV\#R3N(S3\*_LA?
MM,^.?AYH?Q7\&_!CQMXG^'OB36%T#0O$NAV$6I6NIZNVK2:%]CM[6UN)-1)C
MU6&:UGF>S2WM_*DGGECMT:8?U#>&[*!/^"8W[:GA/6?VN1^VIK7A;P!\4UU_
MQ[)J^M>+],\/:VG@B36K/0-%\8Z]J&KW'B6PM!]BU:TO+;4[NSL;F:2TMG00
MF-?G;X1_&7QO\!_^"#]M\0?AUK=UX:\8PZQXET#1_$%@$&HZ._BCXS:EH5Q?
MZ;.ZL;/4(+6]G:SOHL3V<^RX@9)8T8%+Q SNM@U&C@<LJYA_K?E_#<)SIYE@
M\'B*&8X:I7HXI8?%*..PLTU"_M554J;<XTVI1*Q/@;P;@\WG+%YOQ'ALA7A7
MGGB!5H4L5P_FN;8#&Y#F.#P>+R^6/R^$\FS.BX5J_*L+]6DJ\(TYXF/+4/Y_
M_C+^R-^TK^SWI6FZ[\9_@WXS\ :+J]P]I8:OK%E!)ILMT@0_9I;W3KF]MK2>
M0.OD17<D#W&'%NLACDVX7P:_9L^//[0MY?V/P6^%7C#XB2Z7$\VI3Z!IC/IU
MB$,.8;K5[M[72H;QEN(I([%[P7LT1::*W>*.1T_>_P"'WQ1\=?M"?\$.?VA]
M9^,WB;6_B1XD\ >-]>T71O%/C/5+OQ+XFF@L-7\ ^)-.GU'7M8DN]6U&[TZX
M\7:E965W?7ES=6^F)::?#.EE:V]O"G[3_P 0_&O['/\ P2F_8UT/]F;5M6^'
M'_"Z]!\(^)/B+\1?!-U<:/XFFUC7_!NF>-M66'Q19F/5])O=:UN]>W^W:=>V
M6H1Z3HJ:);74>E&XM)NZGQKG4F\I>"RM\02XHQ'#D*W/B890H8?"1QTL=*#G
M/%M_5Y*,<+&JI5*FU6"O$\3$>$7!U-1XGCF_$<>!X>'.!X\K8-PRVKQ2ZV,S
M)Y1')Z5>-&EEB7UU.<LQEA'3HT5:6&J-JH?@%\8?@!\:/V?];M?#WQG^&WBK
MX=ZM?P&YT^'Q%IS06^H0JD,DIT_486GTV_:W6X@-U%:7<TMH9X1<I$TL8;U2
MP_82_:_U5? <FE_ #X@:C%\3=-GUCP//8Z?:W=OKFE6MM8W<^HK<6]Y)#I]F
MD&IZ>?M&JR6,3R7<$*,T\@CK]N/AUXS\3_MC_P#!&G]H#6/VE+BY\;^(_@M<
M>)=0^'7Q(\6+%?\ BBXO_!VGZ?K6B:G'X@N(FU"ZU1)+_4?!VH:M-<2ZEJVF
MW=_8ZG>7*W4Y;OO^"A'Q_P#BO\"_^":W[&\?PC\;^)?AWK7CNS\"Z/J_B?P?
MJ][X?\21Z)I/@)]9?3M/U[2YK75M,2^U&#3WO'L+NW>YMK5[.<R6T\L;8OCC
M/IXS Y+2P.4K.)<08[(,=4G/%SR[FP^!AC:.-PKA.->,'"HI5<+5YZEX.C[6
MG*:J4^Q>#G!%'*LXXNQ.<<43X4AP1DG&N2T*5/+*.?1AC\UJY9C,GS-5:%3!
M5:T:M'V>&S'"JAATJ\<5]7Q%.@Z-?\ I?V&OVNX?B1%\(I/V?OB./B'/HXU^
M+PZ-&#LVC'C^T3JB3MHJVP?$+.^I*5N"MNP$[+&?(?BQ\%OBM\#/%+^"?B[X
M"\1> /%"P172:3X@L6MI;BUG56CN+*>-I;2_@.X(TME<3QQRAH9&69'1?Z;/
M^"I?[3WQT\ _L1?L?^)O 7Q(\4^!O%_Q7T?P3JGC?QCX-U>]\,>*M3D_X5YI
M^OW%O%K^BS66JV-I?:O<O>7]M97<$-Y@0W*2P?NZ\T_X*X6WC;XD>%?^":OB
M3POIEGKWQJ\>Q>'QHUQ)HVD:@^L^+M>TCP%J>G6=SIFI6=WH][87/B2^\^72
M]1LKG2'6:6*ZM)+1I8F62\=YWC*^12S'!910P6<UL[P+EAZ^*C5H8K)*4JE7
M%3J5E*E#!UI4ZD%2Y*E6C"*JRK3O[-+B[P8X.RO!\9T^'\VXJQ>;\*X/A#.H
M0QV&RRKAL9EG%V)IT</EU+#X2-+$5LUPE.M1J/$JMA\-BJTWAH82BH^W?XN^
M&_\ @GA^VUXN\+:?XT\/?LW?$C4/#6JZ<-6T_43IUG9O=:<T9F2YCL+^^M=2
M"R1+YD2/9K+,A5HD<.F[YU\*?"3XE>-_B-9?"+PQX+UW4OB;J&JW6A6O@EK0
MV&OMK%E'/+=Z;+9:DUFUK>6R6MP9H+HPNAB=6 8 '^M?P)9_M+>'OVKO@1KG
M[6W_  4"^&_A;QI+9:%X0@_9*^$6H:T+7QAK=_970LT\6_#ZPU5]'\OQ#9/J
M5_-X[U+P]8Z?9:FFD0Z'_9L,.GV<7XM_\%-?B/XR^ __  51^+7Q-^$VK1^$
M?&_A6^^'>MZ#K46DZ-JPL=5U#X0>$([V];2]?T[5='O)+E;Z[,BWVGW,9>9I
M @D5'7HX=XTS?.\TQ>5*GDU6K4R+$YKEN*PD,VIX!8FEBHX2GAJ]?%TH/'X?
MGK4I5,;E\(T^6-2-.,I-*/)Q[X1<)\'\/95Q*Z_%V&PE'C3+N&N(<NS'$<,8
MG.:F78G+IYGB<PP&$RNO5IY-F"HX?$T\/E.=UZE93G0GB)TZ<9>T_,+XE_#+
MQY\'?&VM_#CXF^&=0\'>./#;V2:YX<U7R/M^FOJ6FV>KV*W'V::X@S<Z9J%G
M>1[)G_=7$>[#94<+7I7Q?^+_ ,1?CU\1?$?Q8^+'B+_A*_B!XL?3I/$&OG2=
M#T/^T'TG2+#0=/;^R_#>F:/HMK]GTK2[&UQ9:=;"7R//G$ES+--)YK7Z3A?K
M7U7#?7506,]A1^MK"NH\*L5[./UA89UE&JZ"J\_L752J.GRN:4KH_GO,O[._
MM''_ -CO&O*?KN*_LMYDJ"S%Y=[>I]1>/6%<L,L:\-[+ZTL/)T%7]HJ+=/E8
M4445N<04444 %%%% !1110 4444 %%%% !1110!^ZG_!OI_R>9\3/^S8_&?_
M *M7X+U_897\>?\ P;Z?\GF?$S_LV/QG_P"K5^"]?V&5_(GC+_R6U?\ [%V7
M_P#IN9_J)]%#_DT6#_['V=_^GJ04445^5']*!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %077_ ![7'_7";_T6U3U!=?\ 'M<?]<)O_1;4X[KU
M7YBEL_1_D?S/4445_7Y_F %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110![;^S=_R7;X6_P#8VZ?_ .U*
M_?NOP$_9N_Y+M\+?^QMT_P#]J5^_=?AWBE_R-LN_[%S_ /4FL?U[]';_ ))G
M//\ L>_^\_!A1117Y@?T&%?*G[=O_)C_ .V3_P!FJ?M#?^JB\7U]5U\J?MV_
M\F/_ +9/_9JG[0W_ *J+Q?0..Z]5^9[K\-/^2<?#_P#[$GPI_P"F*PKMJXGX
M:?\ )./A_P#]B3X4_P#3%85VU @HHHH *\\N+:Y,\Q%O.09I""(I"""[8(.W
MD&O0Z*N$W!MI7OW \V^RW/\ S[S_ /?F3_XFC[+<_P#/O/\ ]^9/_B:])HK3
MV[_E7WL#S;[+<_\ /O/_ -^9/_B:/LMS_P ^\_\ WYD_^)KTFBCV[_E7WL#S
M;[+<_P#/O/\ ]^9/_B:/LMS_ ,^\_P#WYD_^)KTFBCV[_E7WL#S;[+<_\^\_
M_?F3_P")H^RW/_/O/_WYD_\ B:])HH]N_P"5?>P/-OLMS_S[S_\ ?F3_ .)H
M^RW/_/O/_P!^9/\ XFO2:*/;O^5?>P/-OLMS_P ^\_\ WYD_^)H^RW/_ #[S
M_P#?F3_XFO2:*/;O^5?>P/-OLMS_ ,^\_P#WYD_^)H^RW/\ S[S_ /?F3_XF
MO2:*/;O^5?>P/-OLMS_S[S_]^9/_ (FC[+<_\^\__?F3_P")KTFBCV[_ )5]
M[ \V^RW/_/O/_P!^9/\ XFC[+<_\^\__ 'YD_P#B:])HH]N_Y5][ \V^RW/_
M #[S_P#?F3_XFC[+<_\ /O/_ -^9/_B:])HH]N_Y5][ \V^RW/\ S[S_ /?F
M3_XFC[+<_P#/O/\ ]^9/_B:])HH]N_Y5][ \V^RW/_/O/_WYD_\ B:/LMS_S
M[S_]^9/_ (FO2:*/;O\ E7WL#S;[+<_\^\__ 'YD_P#B:/LMS_S[S_\ ?F3_
M .)KTFBCV[_E7WL#S;[+<_\ /O/_ -^9/_B:/LMS_P ^\_\ WYD_^)KTFBCV
M[_E7WL#S;[+<_P#/O/\ ]^9/_B:/LMS_ ,^\_P#WYD_^)KTFBCV[_E7WL#S;
M[+<_\^\__?F3_P")H^RW/_/O/_WYD_\ B:])HH]N_P"5?>P/-OLMS_S[S_\
M?F3_ .)H^RW/_/O/_P!^9/\ XFO2:*/;O^5?>P/-OLMS_P ^\_\ WYD_^)H^
MRW/_ #[S_P#?F3_XFO2:*/;O^5?>P/-OLMS_ ,^\_P#WYD_^)H^RW/\ S[S_
M /?F3_XFO2:*/;O^5?>P/-OLMS_S[S_]^9/_ (FC[+<_\^\__?F3_P")KTFB
MCV[_ )5][ \V^RW/_/O/_P!^9/\ XFC[+<_\^\__ 'YD_P#B:])HH]N_Y5][
M \V^RW/_ #[S_P#?F3_XFC[+<_\ /O/_ -^9/_B:])HH]N_Y5][ \V^RW/\
MS[S_ /?F3_XFC[+<_P#/O/\ ]^9/_B:])HH]N_Y5][ \V^RW/_/O/_WYD_\
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M#3O%_P %R4\>^!2XL_"6HPLEP7G%A)<E[DB6RB8$W42X9^,$=*^)OV^QX_\
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M/$R+IMIXG\:ZA!):RZ-X@\,:@+J-[&"!'NKZ[@2U#1);J=CIVO[-/[1/A_\
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M_L;=/_\ :E?OW7X"?LW?\EV^%O\ V-NG_P#M2OW[K\.\4O\ D;9=_P!BY_\
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MVTK5KR"2'7$N?#5AJ7Q/^*=QXG\17=M$D6AVFB#27F2XEDDGN[=CY/\ ,O\
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MNE.T9?RI45_2)^WG^Q!^QW\:OV!/!_\ P5._81\(:U\&?"W_  DVC>%OC9\
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MQ_UPF_\ 1;5/4%U_Q[7'_7";_P!%M7\+QW7JOS/[REL_1_D?S/4445_7Y_F
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M;$4<LS'$9-Q7FN>5<SK5?JM*/#V<QP$H1C0HUI472HR;J<L:BDZ<VKRY8O\
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M_P#51>+Z^JZ^5/V[?^3'_P!LG_LU3]H;_P!5%XOH''=>J_,]U^&G_)./A_\
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MMYXF\5W^J6U["TDUH]K!;AUAE8;HHIY8?J;]C?P'X^^&-Y_P4TT+Q]X0\6>
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M13Q?K\UO%IFN>$-2N$\0_#K5KF\^W:8#/I%K.;#3M)L+?O?^"/VF?LZ?L?\
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M*MC<N=!L#M;!8;AT."1D<$CFNWIDA1110 4444 %%%% !1110 4444 %%%%
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M.H^(;K3/"^BZ#X;633[GQ!K^L7LEK!"]Q:B*&9#<Q?BK7WO^RQXB_;U_:#T
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M'^SM_P G _ K_LL?PQ_]3;1*\<KV/]G;_DX'X%?]EC^&/_J;:)6&*_W;$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQGJNC7<UQ;M>-)+K-O=1O*X8C?M(_/7Q;J7_  32?_@F_P##S3_">@>+XO\
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MZ66T'3C*+EAZ-?$5XRJ\TYJ55SQ-12E%0BXJ*4$TW+ZI^-\X\9_"[X*?$>T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY+[@]E2_Y]T__ (_Y>2^X\=_X9W_ &?_ /HAGP=_\-EX*_\ E)1_PSO^S_\
M]$,^#O\ X;+P5_\ *2O8J*/K6*_Z"<1_X.J?_)>2^X/94O\ GW3_ / (_P"7
MDON/'?\ AG?]G_\ Z(9\'?\ PV7@K_Y24?\ #._[/_\ T0SX._\ ALO!7_RD
MKV*BCZUBO^@G$?\ @ZI_\EY+[@]E2_Y]T_\ P"/^7DON/'?^&=_V?_\ HAGP
M=_\ #9>"O_E)1_PSO^S_ /\ 1#/@[_X;+P5_\I*]BHH^M8K_ *"<1_X.J?\
MR7DON#V5+_GW3_\  (_Y>2^X\=_X9W_9_P#^B&?!W_PV7@K_ .4E'_#._P"S
M_P#]$,^#O_ALO!7_ ,I*]BHH^M8K_H)Q'_@ZI_\ )>2^X/94O^?=/_P"/^7D
MON/'?^&=_P!G_P#Z(9\'?_#9>"O_ )24?\,[_L__ /1#/@[_ .&R\%?_ "DK
MV*BCZUBO^@G$?^#JG_R7DON#V5+_ )]T_P#P"/\ EY+[CQW_ (9W_9__ .B&
M?!W_ ,-EX*_^4E'_  SO^S__ -$,^#O_ (;+P5_\I*]BHH^M8K_H)Q'_ (.J
M?_)>2^X/94O^?=/_ , C_EY+[CQW_AG?]G__ *(9\'?_  V7@K_Y25-;? #X
M#V=Q;WEG\$_A':W=K-%<VMU;?#?P;!<6UQ!(LL%Q;SQ:,DL,T,JK)%+&RR1R
M*KHP8 CURBE]:Q7_ $$U_P#P=4_^2\E]P_94_P#GW#_P"/EY>2^Y!4%U_P >
MUQ_UPF_]%M4]077_ ![7'_7";_T6U8QW7JOS*EL_1_D?S/5](?"G]HS4OA_X
M;N/ 7BCPAH/Q*^'EQ<37B>&=?(MYK"[FWO(VFZDUKJ$4%M/.PN+JUNM-O5:1
M6:SDL7N+IY_F^BOZTQN!PF8T?J^,HJM2YXU(KFG3G3J0OR5:56E*%6E5C=\M
M2E.$XIM*23=_\T\ISC,LCQ:QV58J6$Q/LYT924*5:G6H5;>TH8C#XBG5P^)H
M5.6+G0Q%*I2DXQDX-QBU]6^-?VGDU+PGJ?@KX8_#'PO\)-$\1130^)WT::/4
M=2U>&58XS;17<.E:+#96TL*M#=J;.ZGN(V5([FV02I-@?!KX[:'\,?"WBGPA
MXD^&>G_$;1O%.HV&H75GJFM)IUFC:>L9@CEM)=!UF.Z*3PQW$<C-%Y<B*0A*
MAJ^<:*XED.51P=3 QPTEAZM:GB*K6*Q:Q%2O2E"=*K/&>W^N2G3E3AR2E7;C
M&*BK15CUGQKQ++-*&<2S"#QN&PM; X=/+\L>"H8/$4YTL1AJ65O!_P!F0HUX
M5:GM81P:524Y5)WJ2<CZO\6_'SX2>(/#6N:)I'[,_@WPQJFJ:=<V=CXALM:L
MYKO1[F>,I%?V\2>#K)Y);=B'15NH"2.)4/(\P^(7Q7/CSP7\+/!YT$:4/AGH
ME]HPU :I]N.M?;1IO^DFT_L^T_L[R_[/_P!3]IOM_G?ZU?+^?Q^BKPV2Y=A'
M1E1I5G+#UIXBC*MC<=BI4ZM3#RPLY*6)Q-9V="<H<C;IIR<U%5/>,<?Q9GN9
MT\52Q6)PJI8W"T<%BJ>$RG*,OA6PU#&4<PI0E'+\!A5S0Q="E5]K&U:2A[*5
M1T7*F_I;X'?M*:[\&='\2^'&T4>*/#_B"WE\G3I=7;2CI6H3P/;RWUM-_9VI
MAUFB91/:^3$LC1H_FJV2?FFBBNJA@,)AL1B\70H1I8C'RI3Q=2+G^^E1C*%.
M4H.3A&2C*2<H1BYWO-R:37GXS.<SS# Y9EN,Q<\1@LFAB:>649QI?[+3Q=2%
M2O"-6,%6G"4Z4'&-6I4C24>6BJ<&XOW_ .!GQ\U3X)GQ5';Z%!XBLO$MC:JE
MI<:@VGC2];TUYFTK7('^PZ@LKV8NK@/;"&%YR8&%W#Y #\C\//BSXA^'GBV^
M\4VMO8:VNMQ7MEXET;6DEN--U_3-3D+ZC9WBK(KAI0S&&?,A@EVNT4Z!X9/+
MJ*REE67SJ8ZK/"PE/,H4J>.DW-^WC1A[.DFN:T'"-DI4U"3:C)MRC%KHI\1Y
MY2HY/AZ68UJ='(:N)K91""I1^IU,75]MB7&2I\U6-6I=RA7E5IJ,JE.,53J3
MC+ZAA_:!\)>$K?6[CX0_!S3/AWXFU^QNM)N_$UYXPUKQA<V.F7P;[5%H=E?V
M>G6NE73N8VCN%,\$:Q(OV-RD3Q>1_P#"8^&S\-#X*/@/3/\ A*#KR:M_PL+[
M5%_:WV!1*&T7[)_9GF_9W,B$R?VJ%S&O^CG.1YU14T<IP-"[IPKN;K4:\JM3
M&XVO7J3PZDJ"JUZV(J5JM*DI24,/4J2H+FE^[U9>*XFSC&)1K5L(J4<+BL'3
MPU#*LIPF#HT<;*G+%RP^"PF!HX3#8G$2I4Y5,;0HT\9)P@_;^Z@KZT\ _M(^
M$/#/PU\.?#CQ?\$]$^(MMX;O-8O;._UGQ!#!&)M7U&\OW>+3IO"VJ+;O$EV;
M8R+=R&54WXCW^6OR716F/R[!YG2IT<93G4A2K1Q%/V>(Q&&G"M&%2G&<:N%J
MT:J:A5J1:Y^5J3NG96PR;/<TX?Q%?%957I4:V)PL\'7]O@L#CZ57#3K4*\J4
M\/F&&Q6':=;#4*BE[+GBZ:Y9).2?UEXR_:@MK_P=K/@GX8_"OPO\)M+\41/;
M>)[G1[I=0U'4[1E5&M8)H-)T.&SCFA\RWNFDMKV66"5HX9+8EV?C?!?QRM],
M\&CX<?$7P)I?Q.\#VD\E]H=C=ZM>^'=<\/ZA))&S/I?B*Q@O)H+&2,3I/:+:
M+/(9@J7T5LCVLWS_ $5S4\ARJEAWAH8:4:;KQQ3J?6<6\5]8C%0C76.==XU5
M8P7LXS6(4HT[TTU!N+]&MQGQ)B,;''ULPA.K#!SR]4'@,M66O U)^UJ8.641
MP:RJ>'J5;5JE&>"E"I64:TU*K%37MOQ$^,O_  EGAS3/ 7A+PCIGP[^'>D79
MU.#PWIU]=ZQ?:AJKPQQ2:AKVOWJ07&K3J5<VV;2V\M'5;@WDL,,Z;?B_]HGQ
M#K7Q2\-?%;PSID?A76?#.AZ/HMO9RWYUNUO(],CN89S>,;'2]]KJ,%R\,]H(
MP\:9:*Z$HCDC^=Z*UCD^6PC"/U6,E"GBZ7[V=6LZD<=[/ZY]8=6I-XF>(]E3
M]I4Q#JU'RZ25Y7YZG%.?U9UJCS&I3E6K997_ -GHX;"QH5,F]M_9:P<,-1I0
MP%+!/$5G0H8&.'H1<[NFW&/+]7Q_M'^$M'U2\\:^#_@;X8\._%"^BD+^+9?$
M>L:MHUCJ%ZBQZKJFC>#I;:UL]+N[E3.;62/4I7M6N)#<R:BLEPEQYK\)_C)J
MOPS^)#_$6ZT\>*;B]CU6+6].NKT6']K)JP,D_F7?V*_6%ENQ#=+_ *'*N^%4
M"*,%?&J*B&299"AB</\ 5Y5*>+H+#5_;8G%8BK+#I.,:$:]>O4KTJ,%*3ITJ
M-2G"G)N5.,9:FE7B[B"KB\!C?KM.C7RS%RQ^"^J9?EN"H4\=.4)5,94PF#P=
M#"8G%5G3IJO7Q-"M5Q$(J%:52"Y3Z/\  '[1>K>"?B]XF^*UQH2ZX?%3ZLVH
M^'WU=[*(IJ-PMQ:QC4&T^^++IICB2'=8X=8U $(  \.\4^(;_P 6^)->\4:H
M^_4/$&K7^KW9W%E6:_N9+EHD+<^5#Y@BB& %B1%   %8-%=%#+L%AL1+%4,/
M"GB)X:AA)5$YMO#8:_L:2BY.*4%*W-&*E-*"G*2A#EXL9GV;X_!4\NQF.JU\
M%2Q^,S.%"<:22QV/<7B\0YQA&I.55QNHSG*G3<JCI0@ZM5SZ?P9XPU[P#XGT
MCQ=X9NQ9:UHES]ILYF02Q-NC>&>"XA8A9K:ZMY9;>XA) DAE=<J2"/K5OVM?
M!%U<)X@U3]F[P!?>.O+2>7Q.FHI#"^L1Q;(M073I?#MW>I D@1_LC:Y+.8U,
M?]H!R)A\1T5AC\ERW,JD*V+P\IU84W256EB,3A:DJ3ES>RJ3PM:C*K2YFY*E
M5<Z:;DU%.4K]>3\5Y]D%"KALKQL*6&JUEB98?$8+ 9A0CB8Q4%B:-',<+BZ>
M'Q/)&,'B*$:=9PC&+FXQBEZKK_Q>\4>+_B=IGQ0\6&'5-4TW6=%U*+3K7_B7
M6$-CH=_#>VFBZ>NV[-C9HL;1)(ZW<^^62ZN6N[F2:27Z0UK]J_X4^(]4O-;U
M[]EOPAJ^KZA()K[4M0\36ES>74JQI$KSSR^!F>1A'&B L3A451P!7PU16>)R
M'*L5]653#SIK!T'AL,L+B\9@52H-PE[)+!8C#J4+TX-*2E9Q5K&^!XTXDRYX
M]T,?2K2S/%K'XZ68Y;E>;RQ&,BJD5B92S7!8UPJ\M6I%RIN%U-IW1],Z-\?_
M  _X9^)7B7QWX7^%FF^'=)\0>![_ ,'1^$=+UR.VL].DU!;$3ZNE[%X>C2=V
M>R\Q[0:=!YC2\W0*9?P'P[XBU;PIKNF>(]"NWL=6TB\AOK&YC)RDT+APKJ"/
M,BD&8YHF.V6-F1AAC6)1751R[!8=553HW5>A0PU;VM6M7=6AAX5*=*%1UZE1
MSM"K-2G)N=3F;J2FTFO.QF?9MCI8>5?%)/"8S%YAA?JV'PN"6'QF.J4:V)K4
M(X*AAXTN>IAZ,H0@E3H.FE0A23DG] ?'KXY7/QYUCPSJ<OA=?#]WHVEOI;P6
M^JOJZZC<7,T4C3PI_9FGO:AY5*QVO^EL ZKY[E<MT'QRO%\'^"/AG\$XV3^T
M/"UC+XH\8I$Z,D/BCQ$GG+I\NP<W&F6+B*;<Q*RS.,$$&OF>SO+O3[NVO["Y
MN+*]LIX;JSO+2:2WNK6YMY%E@N+>>)DEAGAE19(I8V5XW561@P!IU[?7NIWE
MUJ&HW=S?W][/+=7E[>3RW-W=W,[F2:XN;B9GFGFED9GDED=G=B69B237-2RC
M#X=Y;1PT(T<!EGMZM##*52;^L5(SITY.=24I<E*%;$-*4I-SJ0:Y522EZ.(X
MIQV-CQ!B\?4GB\ZXBC@\+C,P<*%&*P&'G2K5Z<:6'ITX>VQ-7!X"$I0ITXQH
MT*L9*I+$2E#V/]F[_DNWPM_[&W3_ /VI7[]U^ G[-W_)=OA;_P!C;I__ +4K
M]^Z_)?%+_D;9=_V+G_ZDUC^E/H[?\DSGG_8]_P#>?@PHHHK\P/Z#"OE3]NW_
M ),?_;)_[-4_:&_]5%XOKZKKY4_;M_Y,?_;)_P"S5/VAO_51>+Z!QW7JOS/=
M?AI_R3CX?_\ 8D^%/_3%85VU<3\-/^2<?#__ +$GPI_Z8K"NVH$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY?GW8'1_\)'/_P ^T7_?;T?\)'/_ ,^T7_?;USE%'LH?RK[W_GY?GW8'1_\
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M1_\ "1S_ //M%_WV]'_"1S_\^T7_ 'V]<Y11[*'\J^]_Y^7Y]V!T?_"1S_\
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MFBP?_8^SO_T]2"BBBORH_I0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?^B7_$3_ ,(KQ+_\K*/^%0_%G_HE_P 1/_"*\2__ "LH^OX'_H,PG_A11_\
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MO1/^%0_%G_HE_P 1/_"*\2__ "LH_P"%0_%G_HE_Q$_\(KQ+_P#*RCZ_@?\
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M\*PW/B'XC*V@:S=>']6\.:UH/B:P3PAX<LO$LFCS:->7.J:-+'>9B+VPYO\
MX-U_V=_V=?"WAW_@HC^VIK/PH'BCXS_L0^+O&%]\"M9/B[X@6J^'-&T[X?\
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MBVFA>&91(C =96^X!1110 4444 %%%% !1110 4444 >C6/_ !Y6?_7K;_\
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MXF?]FQ^,_P#U:OP7K^PROX\_^#?3_D\SXF?]FQ^,_P#U:OP7K^PROY$\9?\
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ME)TOR;K9Y\AM$_H7HJN2-DM;*?/O]J[:^2;V^\-G?KK^*L_P1_*YXJ_X(_\
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M7^C;7^<E^U!_R<M^T/\ ]ES^+7_J?>(*_>O ?_D8\0_]@6!_]/US^+/IG_\
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MGF?$S_LV/QG_ .K5^"]?V&5_(GC+_P EM7_[%V7_ /IN9_J)]%#_ )-%@_\
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MO%7C>SC_ +4\!ZEX9U/PX)?%VA3>C^%M7T[X=?\ !R9\2M-\8:I'IMS\?_\
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M\+")-$\%:J^CW]A<,=1L=(U>^T>.9KM)KHRPII]R\B%?I+_@KU#<?#GXU?\
M!*K_ (*"Z7:7.G?\*J_:,\-?"[Q_LAB:>+X=?M$6^FZ7+8ZA<&!I%@T_68(2
MY=HX(A-=M^[:4L(?^"5FF:7^U_\ M>?\%4?V[]>M1XB\"?$?XKR_L@_!ZYU!
M'DTS4O@[\'-+7P_XABL[.<-$^D^)+XV.M&0*PN)-9U*%]I\R%"6O-3NTW.][
MZJ/*I.UNG-=;^7J:[ZW2]++1?/>WW=#[GM_V\-'UK_@E%-^W^+JUM6?]DZ]^
M+6H+I=Q$\&F^/+3P;-'JVCV4SAHR^G>/8;G2;82J&,D,:R1AB5K+_P""-/\
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MBBBBM1!1110!Z-8_\>5G_P!>MO\ ^B4HHL?^/*S_ .O6W_\ 1*45P2W?J_S
MM5_G)?M0?\G+?M#_ /9<_BU_ZGWB"O\ 1MK_ #DOVH/^3EOVA_\ LN?Q:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$_QV\9W4ECXD^/OBW1M?\4QZ38^++#6GGUCP:TND.^CVG@[6-#NM.O;ZTO\
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MYN'W,$$4<LD?Q7_P3L_;B^)W[2.L_'K]GS]IKX<^&_A5^UM^RGXET'PM\7-
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M/$/_ &!8'_T_7/XL^F?_ ,D]P/\ ]CG-?_4'#GAE%%%?TJ?Y]!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '[J?\&^G_)YGQ,_[-C\9_\ JU?@O7]AE?QY_P#!OI_R>9\3/^S8
M_&?_ *M7X+U_897\B>,O_);5_P#L79?_ .FYG^HGT4/^318/_L?9W_Z>I!11
M17Y4?TH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR\+:+XCTN&UMI=(\1G1M/AN]:TBYMXKO3KJ9H+R&"Y6:&/[T_;"M[AOVQ_\
M@WT98)F6#4_'_GLL3E8<_"?X7 >:0N(\D$?/MY!]#7]%]%-0MUZ16O\ =FIW
M^=K>6^HU*R2ML[[]E\S\&OV8()U_X+L?\%3IVAE6"3]G_P#9=6.9HW$4C+\/
MO!P94D(V.RD$$*20001P:P?^""5O/!_P2"M(IH)H93K_ .T01'+&\<A#:SK
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M_P""</A!$G,;B%G'C7X!9192NQF&UOE#$_*W'!Q_1-11R;:[3<]N]]-_/?\
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M7>JV_C#5;NXN[?X41Z7J2^.?& L?"EOI-];Z==?+HK0K(]J+6.2*-^S\*_\
M!>+_ ()*>-O$N@^#_"_[9?@_5O$GB?5]/T'0M,C\!_&*WDU#5M4NH[.PLTGO
M/AS;VD+7%S-'$);FXA@0MNEE1 6"YXZ7E%-J]G*-]=.^NO4&K.W^?ZZGZZ45
MX=X._:2^"/C_ .-7Q:_9V\'^/K#6_C/\"K#P?JGQ8\"PZ=KMO?>#K#Q]I,.N
M>$;B[U&]TJVT._76=*GANXET;5-1DMED6.^2UFS&'Z)^T?\ !/Q'\<_'G[-6
MB>/=/O\ XX?#'P?H'C[QWX CT_7(]0\/>$/%!B70=:N-1GTN+0KJ'4#/#LM]
M/U6[O8?,0W-M"#FKNN_6WS[>NCTWT%_P_P NY[=17Y8^)_\ @MI_P2O\&^'O
M!_BCQ'^V3\.=.TGQY)K$?AG&C^/[W5;H:#J']E:E/J'A_3_!]UX@\/V2WX>W
ML[_Q%IFE66J&&YDTNXO(K6XDB['XQ?\ !7C_ ()I_ 7_ (0'_A9_[8OPAT@_
M$[0(/%/@M=!U#5O'K:EX=NDLI++6;Y/A]I'BEO#UAJ":A VFS^)!I"ZBL=\;
M'[1_9FI?9)YX?S1Z?:77;KUNK=PL^W]/8_1VBO,D^-/P@?X56WQT/Q/\ P_!
M>[\-6?C*#XK7?BS0[/X>MX4OXH9K/Q"_BZ[O8=#ATFX2>'R[V:]CA+RI$6$K
M!*^$O@K_ ,%FO^"8/[0_Q*\/?"#X1_M@_#?Q)\1?%M]%I?A?P[J.G>-O!I\0
M:Q=74%C8:)H^J^./"OAO0]0UW5KZZMK'1=#M=2DU;6[Z>&STFSO;F18B^:*:
M3:3>RNKOT[@?IU17X!?M2?M@_P##-_\ P6K^$UM\7OVA-8^%/[*6B_\ !.OX
MB_$?X@>'?$/CK6M(^$C>*[;XJW>A:-XGU/P@EZ=$UCQG,TMCH'A^:'2+[Q+J
M%U<6.B:,ES=7-M:2?IS^RI_P4"_8S_;>A\0R?LL?M">!/B]=^%)'7Q#H6D3:
MIHOBS2K9%T\G5KCP=XLTS0/%9\/M+JEE9Q>)(M&D\/S:C+)ID6I/J%M<VL*Y
ME=QNKI[75WHG=+>VH=_)V_!/]3[$HKQ/]I#QM\4/AQ\!_BQXX^"?PXG^+WQ=
M\-^"=:U#X;_#6WG@M3XO\9+;F'0=*N)[B\T^..P.H2PW&IE;ZVG;3H+I;:5;
MEHL_R^ZG_P $X_\ @MYJ?P(U7]N/QS_P5M^-OP^_:JTSPG%\>9OV5K5]3T?X
M":#JGAC3K/Q5'\-->T'1_&4'PGMTM-(TR72->\-2?"/6O VLZW%/9>);C5M/
MU76=:<E)II*+E?5VLK)6N]6KO71*[?D%O\OZ^\_KNHKX)_X)A?M0^,OVS/V$
M?V<_VC_B'I-IH_CGXC>"!<^*X=.@%MIM]KFCZGJ&@7^LZ=;*%2UM=:FTQM3%
MI$J06DMU+;6RBVBBKV?XX?M>?LU?LU^)? 'A+X\?%_PK\+-:^*%IXPO_  0O
MBU]0L-,U>Q\ V.GZCXNN[CQ +&7P_HEOHMGJNGRS2Z_JFEI<-=1PV1N9]T:M
M23BI7T:33>FDK6W[W2]78#Z/HK\Y/@S_ ,%=/^":O[0"^-W^%W[8GP@U2/X<
MZ%+XH\9R^)-3U3X=1:-X=MYX[6YUKS?B1I7A*/4--M;F>W@N[O2FOH;6:[LX
M[AHWO+42]G^RM_P4O_84_;:\2:_X-_9=_:0\$?%?Q=X9TL:YJ_A:PM/$WASQ
M#'HOGQ6LNKV6C>,]!\.:CK&F6=S<6MOJ-]H]M?VNF37MC'J$ML]]:"9*<':T
MHN^UI)WMO;76WD!]T45\&_M,_P#!3W]@7]COQMHWPV_:0_:?^'7PT\?:Y%]H
MMO!]RVN^)/$&GV[)ITMO<^)=,\&Z-XBN?"%O?P:K976E7'BM-%AU>S>>\TQ[
MNUL[V:W]>^ O[87[,_[4.O\ Q+\,_L_?&#PM\5]5^$$O@^+XA'PG_:=YI>B?
M\)_H]UK_ (.FMM?FT^WT'Q!::_H]E=7]G?>&M3UBS$41$\\,C(C/FC>W,KWM
M:ZO>U[6WO;7TU ^E**_D/_X*!_M/?M*ZS^S+_P %G?VJ/AA\?_C-\/\ P?\
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M;/Q!XCUC7M8GN-3U6]UC5XKR_EN[V9YG,X!( "CU:M "BBB@ HHHH ]&L?\
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M\/6EIH^B^&M:GO(YY=2T;3M.U/4+:WT^\>:V"7MR7C9II"W[4_L#_L1^!_\
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ME=)TZRB@T_3+&WM+:WCBOWN9>[HJKG>ZU3<GHM[KFL[V[HE*R2[*WX'YJ_\
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M6T$,(=LN[#@[PM:R2C/M[KC).WFTT_\ %?H'_!]7?2W]>9^I-%%%:B"BBB@
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M/]3^$O\ HEN'/_#)EG_S+Y+[CXQ_X=V?L,?]&J_!7_PBM,_^-T?\.[/V&/\
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M/]3^$O\ HEN'/_#)EG_S+Y+[CXQ_X=V?L,?]&J_!7_PBM,_^-T?\.[/V&/\
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MHHHK ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV]E86=O&!'!:VL$4$2 +&BJ *]1_L73/^?;_ ,C7'_QVC^Q=,_Y]O_(UQ_\
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*FBN9ZMONV!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>nt10016217x4_graphic16x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic16x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M9A_:-_9A_94M/VIO"NG?L/VW[-7Q(^%$?[0'A;P]J'PG\=7?C&]\>7MOX/\
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MPFUU6\4>+O"FJ3>-/$-I9:[X[;Q#\7H]4UB_L/AMX;@\7W>CW.H6'ABS\_\
M,C3_ /@A#^UM;^-?V$-"N/#HN?A5\2O#_P ,O$__  4R>[\?^ C,WCOPQ\;/
M'?QB\2Z3XC@C\3S7GCR[D\.>.K7X<:'?^!++Q;HQUCPE9ZS?WG]GO'J4_P"K
M^J?L/?M+ZU^W-_P67^*2> ;6P^&O[7O['_A?X0? 7QG?>,/!AL?%WCF#]G7P
MK\/;[3[S1;#7[[Q;X8M=/\4V%]8W&H^)O#NE6<T-J][82WEI+;33]CP^1X>5
M54Z]+$1G0<OWE6D[*GC<NHNG!M.4*U50QU=2ARU5A9PM[G.Y^9#'\7XV&'>(
MP6(P-2EC(T_W.'Q"YI5\JSS%JO44)QA5PV%=7*,'.%93PT\QIU5*U94HT_SY
MT3_@N9\?-=T7_@E5\7/'^K^)/A!X&^+_ ,7/VKO#O[66EZ9\#;"X\)_%C1O
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M\7>,] U6SO=2\'Z_K=S/<:E)I;:;JGA:XTV.RU*+5M.OS>"H9,JT6W0<:E+
M5?\ :L7AY*A*.;.CB8WJ1A2DWA(0Q$Z52+;IRE'EE3J)&>;8SBJ6&FE'%QG1
MKYQA_P#A/RW'0>,A4X:ABL!-*C4JXFFHYI6JX*EB*-6$8UX4Y.<<10;?[A?%
MC_@JG^S/^RWI'[/7@;XR>)_B+\0OCE\7_A%X'^)%GX&^%/PHUOQGX[U7PMJF
MB2SZU\2M4\->%K4:/H6AQ2Z-XEUB_P!,LKZ348+'1M9DT71K^TTR0K@>'_\
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MJE=X:HH5,-S/^K']L/\ X*Z?LD_L-_&33?@9\<?^%ICQMKOP=T[XT>'&\#^
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M6I.:IY=*G@ZF"G4P]3!PE/$XV'U^I5EAG'"1BZD:BJ<_UC\(O^"KWC[XG_\
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MFO%U'5+_ %&WT'0K#3S?WNN>*1-X3TNWNO$D$NEK^3'A?_@G?^UC;Q?\&_\
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M+_H&X9_\+<U\O^H#U_#S/JC_ (>-?\$]O^C[_P!C3_Q*#X(__-Q1_P /&O\
M@GM_T??^QI_XE!\$?_FXKY7_ .'$'_!)O_HS_P .?^'*^-W_ ,\RC_AQ!_P2
M;_Z,_P##G_AROC=_\\RCER+_ )^YO_X3X/\ ^:?7^GH<_&7_ $#<,_\ A;FO
ME_U >OX>9]4?\/&O^">W_1]_[&G_ (E!\$?_ )N*/^'C7_!/;_H^_P#8T_\
M$H/@C_\ -Q7RO_PX@_X)-_\ 1G_AS_PY7QN_^>91_P .(/\ @DW_ -&?^'/_
M  Y7QN_^>91RY%_S]S?_ ,)\'_\ -/K_ $]#GXR_Z!N&?_"W-?+_ *@/7\/,
M^J/^'C7_  3V_P"C[_V-/_$H/@C_ /-Q1_P\:_X)[?\ 1]_[&G_B4'P1_P#F
MXKY7_P"'$'_!)O\ Z,_\.?\ AROC=_\ /,H_X<0?\$F_^C/_  Y_X<KXW?\
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M1_P\:_X)[?\ 1]_[&G_B4'P1_P#FXKY7_P"'$'_!)O\ Z,_\.?\ AROC=_\
M/,H_X<0?\$F_^C/_  Y_X<KXW?\ SS*.7(O^?N;_ /A/@_\ YI]?Z>AS\9?]
M W#/_A;FOE_U >OX>9]4?\/&O^">W_1]_P"QI_XE!\$?_FXH_P"'C7_!/;_H
M^_\ 8T_\2@^"/_S<5\K_ /#B#_@DW_T9_P"'/_#E?&[_ .>91_PX@_X)-_\
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MB#_@DW_T9_X<_P##E?&[_P">91_PX@_X)-_]&?\ AS_PY7QN_P#GF4<N1?\
M/W-__"?!_P#S3Z_T]#GXR_Z!N&?_  MS7R_Z@/7\/,^J/^'C7_!/;_H^_P#8
MT_\ $H/@C_\ -Q1_P\:_X)[?]'W_ +&G_B4'P1_^;BOE?_AQ!_P2;_Z,_P##
MG_AROC=_\\RC_AQ!_P $F_\ HS_PY_X<KXW?_/,HY<B_Y^YO_P"$^#_^:?7^
MGH<_&7_0-PS_ .%N:^7_ % >OX>9]4?\/&O^">W_ $??^QI_XE!\$?\ YN*/
M^'C7_!/;_H^_]C3_ ,2@^"/_ ,W%?*__  X@_P""3?\ T9_X<_\ #E?&[_YY
ME'_#B#_@DW_T9_X<_P##E?&[_P">91RY%_S]S?\ \)\'_P#-/K_3T.?C+_H&
MX9_\+<U\O^H#U_#S/JC_ (>-?\$]O^C[_P!C3_Q*#X(__-Q1_P /&O\ @GM_
MT??^QI_XE!\$?_FXKY7_ .'$'_!)O_HS_P .?^'*^-W_ ,\RC_AQ!_P2;_Z,
M_P##G_AROC=_\\RCER+_ )^YO_X3X/\ ^:?7^GH<_&7_ $#<,_\ A;FOE_U
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MT^O]/0Y^,O\ H&X9_P#"W-?+_J ]?P\SZH_X>-?\$]O^C[_V-/\ Q*#X(_\
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M!_P2;_Z,_P##G_AROC=_\\RCER+_ )^YO_X3X/\ ^:?7^GH<_&7_ $#<,_\
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M_P )\'_\T^O]/0Y^,O\ H&X9_P#"W-?+_J ]?P\SZH_X>-?\$]O^C[_V-/\
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M]'W_ +&G_B4'P1_^;BOE?_AQ!_P2;_Z,_P##G_AROC=_\\RC_AQ!_P $F_\
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MS_PY7QN_^>91_P .(/\ @DW_ -&?^'/_  Y7QN_^>91RY%_S]S?_ ,)\'_\
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M:?7^GH<_&7_0-PS_ .%N:^7_ % >OX>9]4?\/&O^">W_ $??^QI_XE!\$?\
MYN*/^'C7_!/;_H^_]C3_ ,2@^"/_ ,W%?*__  X@_P""3?\ T9_X<_\ #E?&
M[_YYE'_#B#_@DW_T9_X<_P##E?&[_P">91RY%_S]S?\ \)\'_P#-/K_3T.?C
M+_H&X9_\+<U\O^H#U_#S/JC_ (>-?\$]O^C[_P!C3_Q*#X(__-Q1_P /&O\
M@GM_T??^QI_XE!\$?_FXKY7_ .'$'_!)O_HS_P .?^'*^-W_ ,\RC_AQ!_P2
M;_Z,_P##G_AROC=_\\RCER+_ )^YO_X3X/\ ^:?7^GH<_&7_ $#<,_\ A;FO
ME_U >OX>9]4?\/&O^">W_1]_[&G_ (E!\$?_ )N*/^'C7_!/;_H^_P#8T_\
M$H/@C_\ -Q7RO_PX@_X)-_\ 1G_AS_PY7QN_^>91_P .(/\ @DW_ -&?^'/_
M  Y7QN_^>91RY%_S]S?_ ,)\'_\ -/K_ $]#GXR_Z!N&?_"W-?+_ *@/7\/,
M^J/^'C7_  3V_P"C[_V-/_$H/@C_ /-Q1_P\:_X)[?\ 1]_[&G_B4'P1_P#F
MXKY7_P"'$'_!)O\ Z,_\.?\ AROC=_\ /,H_X<0?\$F_^C/_  Y_X<KXW?\
MSS*.7(O^?N;_ /A/@_\ YI]?Z>AS\9?] W#/_A;FOE_U >OX>9?_ &AOB?\
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MAYGU1_P\:_X)[?\ 1]_[&G_B4'P1_P#FXH_X>-?\$]O^C[_V-/\ Q*#X(_\
MS<5\K_\ #B#_ ()-_P#1G_AS_P .5\;O_GF4?\.(/^"3?_1G_AS_ ,.5\;O_
M )YE'+D7_/W-_P#PGP?_ ,T^O]/0Y^,O^@;AG_PMS7R_Z@/7\/,^J/\ AXU_
MP3V_Z/O_ &-/_$H/@C_\W%'_  \:_P"">W_1]_[&G_B4'P1_^;BOE?\ X<0?
M\$F_^C/_  Y_X<KXW?\ SS*/^'$'_!)O_HS_ ,.?^'*^-W_SS*.7(O\ G[F_
M_A/@_P#YI]?Z>AS\9?\ 0-PS_P"%N:^7_4!Z_AYGU1_P\:_X)[?]'W_L:?\
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M_P .?^'*^-W_ ,\RC_AQ!_P2;_Z,_P##G_AROC=_\\RCER+_ )^YO_X3X/\
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M_A;FOE_U >OX>9]4?\/&O^">W_1]_P"QI_XE!\$?_FXH_P"'C7_!/;_H^_\
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M?_"W-?+_ *@/7\/,^J/^'C7_  3V_P"C[_V-/_$H/@C_ /-Q1_P\:_X)[?\
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M_P##G_AROC=_\\RCER+_ )^YO_X3X/\ ^:?7^GH<_&7_ $#<,_\ A;FOE_U
M>OX>9]4?\/&O^">W_1]_[&G_ (E!\$?_ )N*/^'C7_!/;_H^_P#8T_\ $H/@
MC_\ -Q7RO_PX@_X)-_\ 1G_AS_PY7QN_^>91_P .(/\ @DW_ -&?^'/_  Y7
MQN_^>91RY%_S]S?_ ,)\'_\ -/K_ $]#GXR_Z!N&?_"W-?+_ *@/7\/,^J/^
M'C7_  3V_P"C[_V-/_$H/@C_ /-Q1_P\:_X)[?\ 1]_[&G_B4'P1_P#FXKY7
M_P"'$'_!)O\ Z,_\.?\ AROC=_\ /,H_X<0?\$F_^C/_  Y_X<KXW?\ SS*.
M7(O^?N;_ /A/@_\ YI]?Z>AS\9?] W#/_A;FOE_U >OX>9]4?\/&O^">W_1]
M_P"QI_XE!\$?_FXH_P"'C7_!/;_H^_\ 8T_\2@^"/_S<5\K_ /#B#_@DW_T9
M_P"'/_#E?&[_ .>91_PX@_X)-_\ 1G_AS_PY7QN_^>91RY%_S]S?_P )\'_\
MT^O]/0Y^,O\ H&X9_P#"W-?+_J ]?P\SZH_X>-?\$]O^C[_V-/\ Q*#X(_\
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M+IS:H2C3FU5J580I07Z-4445\V??!1110 4444 %%%% !1110 4444 %%%%
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M-]K+!P]OAZN'P?L%1C!8B+C5GB:M*K7H5*DZDH8CDC0HK[>HHHKP3[,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /\PW]F?1/V-=0_8WU*^TSP]^UA>_\%.]-^+?BF^_9ZU3]F:Q\;7$EM#8
M:%X'N?AW)XGN$@O-"@L=/\3#Q5>[_AU#!\3$:-3+=V]LVCS+^JG[>&C>'+__
M (*(?\$W;/\ X*._!'XP_M$G3O\ @E%\+]3_ &EOAA\)[+Q/KWQ2U3Q]H-I^
MTAJ?BC7;I?AWXN\':J[>$O&-E-XJ\>ZII/BFRT2SL=(UW49I+G0H9(9?Z?\
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M_P"%6_#:+XGK\);?P;_PU7#\,M'C^*Y^)MO:1WO_  MEKO\ M0^(2DWC*/\
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ML/$O_P Q5;__  N7XO\ _15OB3_X7/BC_P"6E'_"Y?B__P!%6^)/_A<^*/\
MY:4?\5<_"G_HQG&/_B59=Y?W?7\/,/\ B4OCW_HZ&6?^(W2_R]?Z6N!_P_:^
M+/\ TB%_X*'?^&P\2_\ S%4?\/VOBS_TB%_X*'?^&P\2_P#S%5O_ /"Y?B__
M -%6^)/_ (7/BC_Y:4?\+E^+_P#T5;XD_P#A<^*/_EI1_P 5<_"G_HQG&/\
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M  4._P##8>)?_F*K^AZBCZYEG_0GA_X7XO\ S]?Z6I_9>?\ _145?_#/EO\
M\CZ_TM?YX?\ A^U\6?\ I$+_ ,%#O_#8>)?_ )BJ/^'[7Q9_Z1"_\%#O_#8>
M)?\ YBJ_H>HH^N99_P!">'_A?B_\_7^EJ?V7G_\ T5%7_P ,^6__ "/K_2U_
MGA_X?M?%G_I$+_P4._\ #8>)?_F*H_X?M?%G_I$+_P %#O\ PV'B7_YBJ_H>
MHH^N99_T)X?^%^+_ ,_7^EJ?V7G_ /T5%7_PSY;_ /(^O]+7^>'_ (?M?%G_
M *1"_P#!0[_PV'B7_P"8JC_A^U\6?^D0O_!0[_PV'B7_ .8JOZ'J*/KF6?\
M0GA_X7XO_/U_I:G]EY__ -%15_\ #/EO_P CZ_TM?YX?^'[7Q9_Z1"_\%#O_
M  V'B7_YBJ/^'[7Q9_Z1"_\ !0[_ ,-AXE_^8JOZ'J*/KF6?]">'_A?B_P#/
MU_I:G]EY_P#]%15_\,^6_P#R/K_2U_GA_P"'[7Q9_P"D0O\ P4._\-AXE_\
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M,^6^7]WU_#S/PG_X?M?%G_I$+_P4._\ #8>)?_F*H_X?M?%G_I$+_P %#O\
MPV'B7_YBJ_=C[=>_\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ.;+O^A33_ /"[
M%^7GZ_AYA_9V??\ 13U?_#/EOE_=]?P\S\)_^'[7Q9_Z1"_\%#O_  V'B7_Y
MBJ/^'[7Q9_Z1"_\ !0[_ ,-AXE_^8JOW8^W7O_/Y=?\ @1+_ /%T?;KW_G\N
MO_ B7_XNCFR[_H4T_P#PNQ?EY^OX>8?V=GW_ $4]7_PSY;Y?W?7\/,_"?_A^
MU\6?^D0O_!0[_P -AXE_^8JC_A^U\6?^D0O_  4._P##8>)?_F*K]V/MU[_S
M^77_ ($2_P#Q='VZ]_Y_+K_P(E_^+HYLN_Z%-/\ \+L7Y>?K^'F']G9]_P!%
M/5_\,^6^7]WU_#S/PG_X?M?%G_I$+_P4._\ #8>)?_F*H_X?M?%G_I$+_P %
M#O\ PV'B7_YBJ_=C[=>_\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ.;+O^A33_
M /"[%^7GZ_AYA_9V??\ 13U?_#/EOE_=]?P\S\)_^'[7Q9_Z1"_\%#O_  V'
MB7_YBJ/^'[7Q9_Z1"_\ !0[_ ,-AXE_^8JOW8^W7O_/Y=?\ @1+_ /%T?;KW
M_G\NO_ B7_XNCFR[_H4T_P#PNQ?EY^OX>8?V=GW_ $4]7_PSY;Y?W?7\/,_"
M?_A^U\6?^D0O_!0[_P -AXE_^8JC_A^U\6?^D0O_  4._P##8>)?_F*K]V/M
MU[_S^77_ ($2_P#Q='VZ]_Y_+K_P(E_^+HYLN_Z%-/\ \+L7Y>?K^'F']G9]
M_P!%/5_\,^6^7]WU_#S/PG_X?M?%G_I$+_P4._\ #8>)?_F*H_X?M?%G_I$+
M_P %#O\ PV'B7_YBJ_=C[=>_\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ.;+O^
MA33_ /"[%^7GZ_AYA_9V??\ 13U?_#/EOE_=]?P\S\)_^'[7Q9_Z1"_\%#O_
M  V'B7_YBJ/^'[7Q9_Z1"_\ !0[_ ,-AXE_^8JOW8^W7O_/Y=?\ @1+_ /%T
M?;KW_G\NO_ B7_XNCFR[_H4T_P#PNQ?EY^OX>8?V=GW_ $4]7_PSY;Y?W?7\
M/,_"?_A^U\6?^D0O_!0[_P -AXE_^8JC_A^U\6?^D0O_  4._P##8>)?_F*K
M^AQ>57/]T?RIU<OUS+/^A/#_ ,+\7_GZ_P!+6_[+S_\ Z*BK_P"&?+?_ )'U
M_I:_SP_\/VOBS_TB%_X*'?\ AL/$O_S%4?\ #]KXL_\ 2(7_ (*'?^&P\2__
M #%5_0]11]<RS_H3P_\ "_%_Y^O]+4_LO/\ _HJ*O_AGRW_Y'U_I:_SP_P##
M]KXL_P#2(7_@H=_X;#Q+_P#,51_P_:^+/_2(7_@H=_X;#Q+_ /,57]#U%'US
M+/\ H3P_\+\7_GZ_TM3^R\__ .BHJ_\ AGRW_P"1]?Z6O\\/_#]KXL_](A?^
M"AW_ (;#Q+_\Q5'_  _:^+/_ $B%_P""AW_AL/$O_P Q5?T/44?7,L_Z$\/_
M  OQ?^?K_2U/[+S_ /Z*BK_X9\M_^1]?Z6O\\/\ P_:^+/\ TB%_X*'?^&P\
M2_\ S%4?\/VOBS_TB%_X*'?^&P\2_P#S%5_0]11]<RS_ *$\/_"_%_Y^O]+4
M_LO/_P#HJ*O_ (9\M_\ D?7^EK_/#_P_:^+/_2(7_@H=_P"&P\2__,51_P /
MVOBS_P!(A?\ @H=_X;#Q+_\ ,57C_P#P6-^/WQW^&'[5N@>'?AK\:_BW\//#
M\WP9\(ZI-H7@;XD>,?"6C2ZG<^)_'5O<ZC)IF@:SI]E)?W$%I:03WC0&XEAM
M;>.21D@B5?RB_P"&Q/VN/^CIOVC?_#W_ !,_^:>OHL+E."Q6'HXB. H1C6@I
MJ+QF-;2?1M.W?\.VO\Z\3^.U7ACB#-N'\15SC%5LIQE3!U,11P61PI5I4^6\
MX1G!SC%WT4M5^?[>_P##]KXL_P#2(7_@H=_X;#Q+_P#,51_P_:^+/_2(7_@H
M=_X;#Q+_ /,57XA?\-B?M<?]'3?M&_\ A[_B9_\ -/1_PV)^UQ_T=-^T;_X>
M_P")G_S3UT?V#A/^@'#?^%>._P _7^EKX/\ Q,G_ '<]_P#"3(/_ )#U_I:_
MM[_P_:^+/_2(7_@H=_X;#Q+_ /,51_P_:^+/_2(7_@H=_P"&P\2__,57XA?\
M-B?M<?\ 1TW[1O\ X>_XF?\ S3T?\-B?M<?]'3?M&_\ A[_B9_\ -/1_8.$_
MZ <-_P"%>._S]?Z6I_Q,G_=SW_PDR#_Y#U_I:_M[_P /VOBS_P!(A?\ @H=_
MX;#Q+_\ ,51_P_:^+/\ TB%_X*'?^&P\2_\ S%5^(7_#8G[7'_1TW[1O_A[_
M (F?_-/1_P -B?M<?]'3?M&_^'O^)G_S3T?V#A/^@'#?^%>._P _7^EJ?\3)
M_P!W/?\ PDR#_P"0]?Z6O[>_\/VOBS_TB%_X*'?^&P\2_P#S%4?\/VOBS_TB
M%_X*'?\ AL/$O_S%5^(7_#8G[7'_ $=-^T;_ .'O^)G_ ,T]'_#8G[7'_1TW
M[1O_ (>_XF?_ #3T?V#A/^@'#?\ A7CO\_7^EJ?\3)_W<]_\),@_^0]?Z6O[
M>_\ #]KXL_\ 2(7_ (*'?^&P\2__ #%4?\/VOBS_ -(A?^"AW_AL/$O_ ,Q5
M?B%_PV)^UQ_T=-^T;_X>_P")G_S3T?\ #8G[7'_1TW[1O_A[_B9_\T]']@X3
M_H!PW_A7CO\ /U_I:G_$R?\ =SW_ ,),@_\ D/7^EK^WO_#]KXL_](A?^"AW
M_AL/$O\ \Q5'_#]KXL_](A?^"AW_ (;#Q+_\Q5?B%_PV)^UQ_P!'3?M&_P#A
M[_B9_P#-/1_PV)^UQ_T=-^T;_P"'O^)G_P T]']@X3_H!PW_ (5X[_/U_I:G
M_$R?]W/?_"3(/_D/7^EK^WO_  _:^+/_ $B%_P""AW_AL/$O_P Q5'_#]KXL
M_P#2(7_@H=_X;#Q+_P#,57XA?\-B?M<?]'3?M&_^'O\ B9_\T]'_  V)^UQ_
MT=-^T;_X>_XF?_-/1_8.$_Z <-_X5X[_ #]?Z6I_Q,G_ '<]_P#"3(/_ )#U
M_I:_M[_P_:^+/_2(7_@H=_X;#Q+_ /,51_P_:^+/_2(7_@H=_P"&P\2__,57
MXA?\-B?M<?\ 1TW[1O\ X>_XF?\ S3T?\-B?M<?]'3?M&_\ A[_B9_\ -/1_
M8.$_Z <-_P"%>._S]?Z6I_Q,G_=SW_PDR#_Y#U_I:_M[_P /VOBS_P!(A?\
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M>[QV+Z6OU]?P^8\LS]*_^M%7I_S)\M[K^[Z_A\_P._X?M?%G_I$+_P %#O\
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M\_EU_P"!$O\ \71]NO?^?RZ_\")?_BZ.;+O^A33_ /"[%^7GZ_AYA_9V??\
M13U?_#/EOE_=]?P\S\)_^'[7Q9_Z1"_\%#O_  V'B7_YBJ/^'[7Q9_Z1"_\
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M)AX>_P""IV@_\+F_L[_AY?IEMIWVO_A7?VO_ (4K]G_9^TCX%>=Y'_"=6O\
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M$\;> /#VM?$CP+ID\2VM[XD^'&G^+-,M[VZTZRDN%N]4TV&ZZ7X#_P#!3?\
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MZ.3_ &'/_$"?CW_],IKW^BCV4/[W_@<__D@_UDSK_H-_\M\)_P#*#P#^W/\
M@I3_ -')_L.?^($_'O\ ^F4T?VY_P4I_Z.3_ &'/_$"?CW_],IKW^BCV4/[W
M_@<__D@_UDSK_H-_\M\)_P#*#P#^W/\ @I3_ -')_L.?^($_'O\ ^F4T?VY_
MP4I_Z.3_ &'/_$"?CW_],IKW^BCV4/[W_@<__D@_UDSK_H-_\M\)_P#*#P#^
MW/\ @I3_ -')_L.?^($_'O\ ^F4T?VY_P4I_Z.3_ &'/_$"?CW_],IKW^BCV
M4/[W_@<__D@_UDSK_H-_\M\)_P#*#P#^W/\ @I3_ -')_L.?^($_'O\ ^F4T
M?VY_P4I_Z.3_ &'/_$"?CW_],IKW^BCV4/[W_@<__D@_UDSK_H-_\M\)_P#*
M#P#^W/\ @I3_ -')_L.?^($_'O\ ^F4T?VY_P4I_Z.3_ &'/_$"?CW_],IKW
M^BCV4/[W_@<__D@_UDSK_H-_\M\)_P#*#P#^W/\ @I3_ -')_L.?^($_'O\
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MM=]#4-O_ ,>\'_7&+_T!:FKPS]:BVXQ;W<4WZM!11104%%%% !1110 4444
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M_-7_ /"G$_\ RWR_/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W_HI?P?\
M_#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+7L%%'U>G_-7_ /"G$_\ RWR_
M/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W_HI?P?\ _#'>-/\ Z(6C^Q/C
M[_T4OX/_ /ACO&G_ -$+7L%%'U>G_-7_ /"G$_\ RWR_/NP_MS&_\^,G_P#$
M>R#_ .=GE^?=GC_]B?'W_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_
M -$+7L%%'U>G_-7_ /"G$_\ RWR_/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]
MB?'W_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+7L%%'U>G_-7_
M /"G$_\ RWR_/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W_HI?P?\ _#'>
M-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+7L%%'U>G_-7_ /"G$_\ RWR_/NP_
MMS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4
MOX/_ /ACO&G_ -$+7L%%'U>G_-7_ /"G$_\ RWR_/NP_MS&_\^,G_P#$>R#_
M .=GE^?=GC_]B?'W_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+
M7L%%'U>G_-7_ /"G$_\ RWR_/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W
M_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+7L%%'U>G_-7_ /"G
M$_\ RWR_/NP_MS&_\^,G_P#$>R#_ .=GE^?=GC_]B?'W_HI?P?\ _#'>-/\
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M\OU3+LOP#?/+.T_:/ X;#NK;E7+[7GY+R<.5SGS;%%%%?(G]<!1110 4444
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M3_T/_P"PY_XB#\>__H^:^=J*/[&RW_H'E_X48K_Y<'_$>?%?_HJO_,'PW_\
M.<^B?^'A?_!2G_H?_P!AS_Q$'X]__1\T?\/"_P#@I3_T/_[#G_B(/Q[_ /H^
M:^=J*/[&RW_H'E_X48K_ .7!_P 1Y\5_^BJ_\P?#?_SG/HG_ (>%_P#!2G_H
M?_V'/_$0?CW_ /1\T?\ #PO_ (*4_P#0_P#[#G_B(/Q[_P#H^:^=J*/[&RW_
M *!Y?^%&*_\ EP?\1Y\5_P#HJO\ S!\-_P#SG/HG_AX7_P %*?\ H?\ ]AS_
M ,1!^/?_ -'S1_P\+_X*4_\ 0_\ [#G_ (B#\>__ */FOG:BC^QLM_Z!Y?\
MA1BO_EP?\1Y\5_\ HJO_ #!\-_\ SG/HG_AX7_P4I_Z'_P#8<_\ $0?CW_\
M1\T?\/"_^"E/_0__ +#G_B(/Q[_^CYKYVHH_L;+?^@>7_A1BO_EP?\1Y\5_^
MBJ_\P?#?_P YSZ)_X>%_\%*?^A__ &'/_$0?CW_]'S1_P\+_ ."E/_0__L.?
M^(@_'O\ ^CYKYVHH_L;+?^@>7_A1BO\ Y<'_ !'GQ7_Z*K_S!\-__.<^B?\
MAX7_ ,%*?^A__8<_\1!^/?\ ]'S1_P /"_\ @I3_ -#_ /L.?^(@_'O_ .CY
MKYVHH_L;+?\ H'E_X48K_P"7!_Q'GQ7_ .BJ_P#,'PW_ /.<^B?^'A?_  4I
M_P"A_P#V'/\ Q$'X]_\ T?-'_#PO_@I3_P!#_P#L.?\ B(/Q[_\ H^:^=J*/
M[&RW_H'E_P"%&*_^7!_Q'GQ7_P"BJ_\ ,'PW_P#.<^B?^'A?_!2G_H?_ -AS
M_P 1!^/?_P!'S1_P\+_X*4_]#_\ L.?^(@_'O_Z/FOG:BC^QLM_Z!Y?^%&*_
M^7!_Q'GQ7_Z*K_S!\-__ #G/HG_AX7_P4I_Z'_\ 8<_\1!^/?_T?-'_#PO\
MX*4_]#_^PY_XB#\>_P#Z/FOG:BC^QLM_Z!Y?^%&*_P#EP?\ $>?%?_HJO_,'
MPW_\YSZ)_P"'A?\ P4I_Z'_]AS_Q$'X]_P#T?-'_  \+_P""E/\ T/\ ^PY_
MXB#\>_\ Z/FOG:BC^QLM_P"@>7_A1BO_ )<'_$>?%?\ Z*K_ ,P?#?\ \YSZ
M)_X>%_\ !2G_ *'_ /8<_P#$0?CW_P#1\T?\/"_^"E/_ $/_ .PY_P"(@_'O
M_P"CYKYVHH_L;+?^@>7_ (48K_Y<'_$>?%?_ **K_P P?#?_ ,YS[@HHHK_A
M[/\ J2"BBB@ HHHH **** /W@^$VC:5XC^ /@/P]KMA;:KH>O?"_1=&UG2[V
M(36>I:5JGAV&QU&PNX6^66VO+2>:WGB;B2*1U/!K\8/A3_P]*_8E_91UO]A7
MX4_L@ZU^T%XU^$NC^*/A1^Q_^V!9?%_]GW0_A/J/PXE34Q\*/&WQK\#^//'N
MB?$#PMXE^#^CZGH&C:]X&TKP1XFT;QN_A.XM/#NMO;7$=Q<_LI\-=7U#P_\
MLY>#]>TGPMKWCG5=$^$FFZOIG@GPM<>&+3Q/XPU#3?"Z7MEX6\.7?C;Q'X/\
M&6NO>(+F&/2=(N/%WB[PMX8AU"[MY->\1Z)I2W>IVO@O_#77[0'_ $BV_;M_
M\.#_ ,$R?_IB]?\ 7YX6?\FQ\./^R#X0_P#6?RX_RIXD_P"2BS[_ +'6:_\
MJ=7/R-^/_P  O^"D&@?#;_@JQ^S=X2_9FN?VE=<_;J\)> =9^'W[1N@>._@?
M\,OAMJ/C'5/V1OA;\"?VA8/'/A'Q=\5=#\8_#_44UCX:7-[\'M*TGPSXF\/Z
M[K'BC3K+Q-XD\,>&],U7Q!:>D:C^S-^VKX/^-7_!:^[^''P(L=8N?VP?V6/@
M!J'[,WC_ ,93? [QI\)_$OQ/^"?[+&E_!75OA'XM\#>-?&=R'\1>(?%.J:BW
MA\_$GP1/\'KJTT&^NO'-_<>'KFRTSQ'^E7_#77[0'_2+;]NW_P .#_P3)_\
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M/\^S/8**\?\ ^%E^-/\ HWKXP?\ @[^ 7_S\:/\ A9?C3_HWKXP?^#OX!?\
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M\OU3,<OQ[7)+.V_:+ XG$.E?F7+[7DY[24.9PGR]G1117R)_7 4444 %%%%
M!1110 5_/K_P5%_Y.-T7_LE?AG_U(?%]?T%5_.U_P4STK]HSQ1^TW<_\*[_8
M]^./Q)\+:%X#\):+9^/O#GCG]DO1?#7BB=_[3UR]N-!T[XA_M->"/',%II5U
MK4GAR]/B7P;X=N9M;T759M+MM1\/2:-KVK^UD%:G0S!5*LN2'L:BYFF]7RV^
M%-_.UC\5\?,GS+/. *F!RK"SQF+><9;55&G*G"7LZ?M^>5ZLZ<+1YE?WKZZ+
M<_/RBH_^$!_;$_Z,'_:(_P##F_L-_P#T85'_  @/[8G_ $8/^T1_X<W]AO\
M^C"K[C^T\#_T$1_\ J?_ "'G^?9G\0_\0VXX_P"B?Q7_ (/P7_S3Y_GV9)14
M?_" _MB?]&#_ +1'_AS?V&__ *,*C_A ?VQ/^C!_VB/_  YO[#?_ -&%1_:>
M!_Z"(_\ @%3_ .0\_P ^S#_B&W''_1/XK_P?@O\ YI\_S[,DHJ/_ (0']L3_
M *,'_:(_\.;^PW_]&%1_P@/[8G_1@_[1'_AS?V&__HPJ/[3P/_01'_P"I_\
M(>?Y]F'_ !#;CC_HG\5_X/P7_P T^?Y]F245'_P@/[8G_1@_[1'_ (<W]AO_
M .C"H_X0']L3_HP?]HC_ ,.;^PW_ /1A4?VG@?\ H(C_ . 5/_D//\^S#_B&
MW''_ $3^*_\ !^"_^:?/\^S)**C_ .$!_;$_Z,'_ &B/_#F_L-__ $85'_"
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M_GV9)14?_" _MB?]&#_M$?\ AS?V&_\ Z,*C_A ?VQ/^C!_VB/\ PYO[#?\
M]&%1_:>!_P"@B/\ X!4_^0\_S[,/^(;<<?\ 1/XK_P 'X+_YI\_S[,DHJ/\
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M6]4O)2L5IIVE:99W5_?7,K"."V@EE<A4)K\W/A3_ ,%;/V:_BCX^^&_A"[\
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MNEMU*6ZW,Z^/Q+.L"$I")781*2J!02*L_P##TG_@F3_TD7_82_\ $NOV?_\
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M (EU^S__ //!H_X>D_\ !,G_ *2+_L)?^)=?L_\ _P \&ONVBC7R^[_@^O\
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M^AQG'W8+_P"9O7^EK_+/_P ->_LF_P#1T'[._P#X>OX:_P#S34?\->_LF_\
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M'+\%_P#R[K]H**]#EQ/_ #]H?^$]3_YI]?Z6OY_[?(/^A9G'_A\P7_T/>O\
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MM\@_Z%F<?^'S!?\ T/>O]+7\7_\ AH7X!?\ 1<?@_P#^'+\%_P#R[H_X:%^
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MW3>EUT37WW^1\UQ6X+*GSQE*/UFCI":@[^_;WG"HK>7+KW1^:7_#QC_@GO\
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MW?L:_P#B3_P2_P#FXH_X>,?\$]_^C[OV-?\ Q)_X)?\ S<5]E446G_-#_P
M?_RSU_I:G-AO^?-?_P **?\ \RGQK_P\8_X)[_\ 1]W[&O\ XD_\$O\ YN*/
M^'C'_!/?_H^[]C7_ ,2?^"7_ ,W%?95%%I_S0_\  '_\L]?Z6IS8;_GS7_\
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M!;+2[K1I] -B_P -/BI\=O&GPZOK:TTNX>#28]0\+70T6:.UOM'^PW]C9W4
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M<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ=9:?:1Q6UM%&I9=E_7_  R^X++LOZ_X9?<:O_#NC]G_ /Z*#^W;_P"+2?\
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M;_Z+JC_AW1^S_P#]%!_;M_\ %I/_  4V_P#HNJ^[:*++LOZ_X9?<%EV7]?\
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M%-O_ *+JONVBBR[+^O\ AE]P679?U_PR^X^$O^'='[/_ /T4']NW_P 6D_\
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M ,D?&O\ PPC\$O\ H>/VRO\ Q8Q_P4(_^B?H_P"&$?@E_P!#Q^V5_P"+&/\
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M'_B4O[2?_P ]>NXHH^K8;_H'H?\ @JG_ /(^2^X/]8<__P"AYG'_ (<\;_\
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MX<\;_P#+_)?<</\ \(-_U4K]HC_Q*7]I/_YZ]'_"#?\ 52OVB/\ Q*7]I/\
M^>O7<44?5L-_T#T/_!5/_P"1\E]P?ZPY_P#]#S./_#GC?_E_DON.'_X0;_JI
M7[1'_B4O[2?_ ,]>C_A!O^JE?M$?^)2_M)__ #UZ[BBCZMAO^@>A_P""J?\
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M?UP%%%% !1110 4444 %?"'QR_8?^!OQC^)&L?$3QIKG[3=OXBU^UTE+ZU\
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M?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P!
M]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D_
M_!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##
M^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]
M=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F
M/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/
M_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\
MHHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C
M?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P!
M]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D_
M_!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##
M^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]
M=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F
M/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/
M_AVC^S'_ -##^V5_XLG_ ."C?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\
MHHY8_P L?N7]=%]P?5<-_P! ]#_P33_^1/@/_AVC^S'_ -##^V5_XLG_ ."C
M?_T5E'_#M']F/_H8?VRO_%D__!1O_P"BLK[\HHY8_P L?N7]=%]P?5<-_P!
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M#[+38O$$,;6&NW'A^WNM0^B?^%??\%-O^CNOV$O_ !71^T!_]-)H_P"%??\
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MT?)_A_G_ %9^5SY/\/\ /^K/RO\ =M%?"7_"OO\ @IM_T=U^PE_XKH_: _\
MII-'_"OO^"FW_1W7["7_ (KH_: _^FDT?)_A_G_5GY7/D_P_S_JS\K_=M%?"
M7_"OO^"FW_1W7["7_BNC]H#_ .FDT?\ "OO^"FW_ $=U^PE_XKH_: _^FDT?
M)_A_G_5GY7/D_P /\_ZL_*_W;17PE_PK[_@IM_T=U^PE_P"*Z/V@/_II-'_"
MOO\ @IM_T=U^PE_XKH_: _\ II-'R?X?Y_U9^5SY/\/\_P"K/RO]VT5\)?\
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MQ^Z5%?A;_P -<?\ !0C_ **7^QK_ .(E?&W_ .CIH_X:X_X*$?\ 12_V-?\
MQ$KXV_\ T=-']F9A_P! D_\ P=AO_E_]6?E<_P"(G^'W_13T/_#3Q%_\YC]T
MJ*_"W_AKC_@H1_T4O]C7_P 1*^-O_P!'31_PUQ_P4(_Z*7^QK_XB5\;?_HZ:
M/[,S#_H$G_X.PW_R_P#JS\KG_$3_  ^_Z*>A_P"&GB+_ .<Q^Z5%?A;_ ,-<
M?\%"/^BE_L:_^(E?&W_Z.FC_ (:X_P""A'_12_V-?_$2OC;_ /1TT?V9F'_0
M)/\ \'8;_P"7_P!6?E<_XB?X??\ 13T/_#3Q%_\ .8_=*BOPM_X:X_X*$?\
M12_V-?\ Q$KXV_\ T=-'_#7'_!0C_HI?[&O_ (B5\;?_ *.FC^S,P_Z!)_\
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M/O\ T4OX/_\ ACO&G_T0M?I655)K+L&EAZLDJ,4I*5"S\US5HRMZQ3TVVO\
MYK>*N PE3Q%XPJ3SO+,/*>=8ERHUJ6<RJTV^3W9NAE%>BY+JZ=6I'M)GL%%>
M/_V)\??^BE_!_P#\,=XT_P#HA:/[$^/O_12_@_\ ^&.\:?\ T0M>A[6I_P!
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MI?P?_P##'>-/_HA:/:U/^@:O_P"!8;_YH_JS\KG]F8+_ **')_\ P1G_ /\
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M7^DK\.8/$=K\/? =KXPU71-=\76W@SPO!XIUOPUH%]X4\.:SXCAT2QCUO5=
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M_P"($_'O_P"F4T6G_P ^Y??#_P"3#_63)?\ H-_\M\7_ /*#]1Z*_+C^W/\
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M_P#TRFC^W/\ @I3_ -')_L.?^($_'O\ ^F4T6G_S[E]\/_DP_P!9,E_Z#?\
MRWQ?_P H/U'HK\N/[<_X*4_]')_L.?\ B!/Q[_\ IE-']N?\%*?^CD_V'/\
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MUG>7$#I*P!]C4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?@-_P52_Y.$\'?]D:\/?\ J;_$.OWYK\!O^"J7_)PG@[_LC7A[_P!3
M?XAU[W#?_(SA_P!>:WY(_!_I'?\ )L\5_P!CC*?_ $]4/S0HHHK]"/\ /<**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _L7T?_ )!.E_\ 8.LO_2:*M&L[1_\ D$Z7_P!@ZR_])HJT:_();OU?YG^O
ME'^%2_Z]P_\ 24%%%%(T"BBB@ HHHH **** /Y)O^"XO_)XOAS_LA7@K_P!2
MWXA5^.%?L?\ \%Q?^3Q?#G_9"O!7_J6_$*OQPK]/RC_D68+_ *\0_4_S#\6O
M^3E<9_\ 8\Q7_M@4445Z)^=A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?Z*'A[_D :'_V!],_](H*_P Z^O\ 10\/?\@#
M0_\ L#Z9_P"D4%?(<5[8#UQ/Y4#^O/HI?Q>.O^O?#?\ Z5GIL4445\<?V(%%
M%% !1110 4444 %?)7QQ_P"1QMO^P%9?^E>H5]:U\E?''_D<;;_L!67_ *5Z
MA77@OXS_ ,$OSB?,<7?\BA_]A-#_ -O/'****]4_+@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\SZ***_P"*<_WH
M"BBB@ HHHH **** /W5^&NKZAX?_ &<O!^O:3X6U[QSJNB?"33=7TSP3X6N/
M#%IXG\8:AIOA=+VR\+>'+OQMXC\'^#+77O$%S#'I.D7'B[Q=X6\,0ZA=V\FO
M>(]$TI;O4[7P7_AKK]H#_I%M^W;_ .'!_P""9/\ ],7KZ8^!G_)&?A9_V(7A
M;_TSVE?E!\,?^"X?PW^-7@70/B?\(OV ?^"IOQ,^'7BJ&\N/#7CCP/\ LEZ=
MXE\+:]!I^I7FCW\NDZYI/Q1NM/OX[/5M.O\ 3KE[:>00WMG<VTA66&15_P"O
MSPL_Y-CX<?\ 9!\(?^L_EQ_E3Q)_R46??]CK-?\ U.KGV/\ \-=?M ?](MOV
M[?\ PX/_  3)_P#IB]'_  UU^T!_TBV_;M_\.#_P3)_^F+U]VUY%\?\ XU>$
M?V;_ ('_ !:^/_C^WUN[\$?!CX>>+/B9XMM?#5G::CXAN/#W@W1;S7=6AT2P
MOK_2K*\U22RLIELK:ZU.PMYK@HDMW C&1?N_F_P_R_J[\K>)\W^'^7]7?E;Y
MO_X:Z_: _P"D6W[=O_AP?^"9/_TQ>C_AKK]H#_I%M^W;_P"'!_X)D_\ TQ>O
MN#3+^#5=-T_5+82+;:E96E_;B50DH@O(([B(2JK.JR".10ZJ[@-D!F R;M'S
M?X?Y?U=^5CYO\/\ +^KORM\)?\-=?M ?](MOV[?_  X/_!,G_P"F+T?\-=?M
M ?\ 2+;]NW_PX/\ P3)_^F+U]VUQ7Q)^(G@WX0_#KQ]\6?B-K<?AKX>_"_P5
MXI^(GCOQ'+9ZCJ$6@>#?!6A7_B7Q/K<MAI%IJ&K7T>E:)IE]?/9Z787NHW*P
M&&RM+FY>*%SYO\/\OZN_*Q\W^'^7]7?E;Y'_ .&NOV@/^D6W[=O_ (<'_@F3
M_P#3%Z/^&NOV@/\ I%M^W;_X<'_@F3_],7KZO\ _$KPM\3OA=X*^,'@B:_UO
MP5\0_ /ASXE>$+A--N[74]7\+>+/#MGXHT"9-(O([>^M[^_TG4+1UTVZB@NX
MKB46L\<<RLJY_P &?B='\9OA;X)^*47@+XG?"^/QMHL6M)\/_C-X.N?A]\4O
M"HEFFA_LOQMX+O+B[NO#NM1^3YLNGS7,SI#+#(7(D !\W^'^7]7?E8^;_#_+
M^KORM\P?\-=?M ?](MOV[?\ PX/_  3)_P#IB]'_  UU^T!_TBV_;M_\.#_P
M3)_^F+U]!:%\>?!7B']H'XC_ +-EC;:^GQ ^%WPO^%OQ;\1W=S8V<?AF;PO\
M7?$/Q-\,^%X-*U%-2EO[G6+?4/A1XF?6+2XTJSMK2UGTB2VO;Z2ZN8;+VNCY
MO\/\OZN_*Q\W^'^7]7?E;X2_X:Z_: _Z1;?MV_\ AP?^"9/_ -,7H_X:Z_:
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M5511_;./_P"?L/\ P53_ /D?ZN_*Q_Q+IX:_] N<?^':K_\ *_ZN_*W\JO\
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M_P#F?^KORL?VG@O^B>R?_P 'Y_\ _/S^KORMX_\ \++\:?\ 1O7Q@_\ !W\
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M#P')3X=YGA)YA-U>:6=V]I]>QV,2Y.5N/LE3OSRY^=*"CL4445\B?UP%%%%
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MVRO_  X__!.3_P"CZK]8**+S_GE]T/\ Y'^KORL?ZK93_)7_ /!\O\C\G_\
MA;_[3G_2-#]LK_PX_P#P3D_^CZH_X6_^TY_TC0_;*_\ #C_\$Y/_ */JOU@H
MHO/^>7W0_P#D?ZN_*Q_JME/\E?\ \'R_R/R?_P"%O_M.?](T/VRO_#C_ /!.
M3_Z/JC_A;_[3G_2-#]LK_P ./_P3D_\ H^J_6"BB\_YY?=#_ .1_J[\K'^JV
M4_R5_P#P?+_(_)__ (6_^TY_TC0_;*_\./\ \$Y/_H^J/^%O_M.?](T/VRO_
M  X__!.3_P"CZK]8**+S_GE]T/\ Y'^KORL?ZK93_)7_ /!\O\C\G_\ A;_[
M3G_2-#]LK_PX_P#P3D_^CZH_X6_^TY_TC0_;*_\ #C_\$Y/_ */JOU@HHO/^
M>7W0_P#D?ZN_*Q_JME/\E?\ \'R_R/R?_P"%O_M.?](T/VRO_#C_ /!.3_Z/
MJC_A;_[3G_2-#]LK_P ./_P3D_\ H^J_6"BB\_YY?=#_ .1_J[\K'^JV4_R5
M_P#P?+_(_)__ (6_^TY_TC0_;*_\./\ \$Y/_H^J/^%O_M.?](T/VRO_  X_
M_!.3_P"CZK]8**+S_GE]T/\ Y'^KORL?ZK93_)7_ /!\O\C\!Z***_XKC_9L
M**** "BBB@ HHHH _?/X&?\ )&?A9_V(7A;_ -,]I7\BO_!'7XW_ +._@7]@
M?]E:W\??\%O[_P#9JUCP_!XKO-?_ &7+GQU^Q/HNB>$88?B_XVU'_A'+RT^(
MOP6UWXJ6=AXNT]HM=O6U/QA+JAB\1S3Z-?:?9/IL=K_69\-?%/ACP-^SEX/\
M;>-O$>@^#_!G@_X2:;XI\7>+O%.KZ?X?\,>%O#'A_P +IJVO>(_$>O:M<6FE
M:)H.B:5:7>IZOJ^IW=KI^FZ?:W%[>W$-M#)(O@O_  ])_P""9/\ TD7_ &$O
M_$NOV?\ _P">#7_7YX6?\FQ\./\ L@^$/_6?RX_RIXD_Y*+/O^QUFO\ ZG5S
M^=+X7_ #X8VOPO\ &W[?&E2^.8_VIO!'_!<JY^%/@#XN67Q:^*$,GA?X/>-?
M^"D?AWX=>+?AAH'ABU\81>!H?AUXU\(?$WX@67BSPNWAN;2O%+>,M:N=;AOY
M)X#!Q?\ P4@U']F[4=*_X+0>)?V[/&6JZ?\ MM_#[7?$7@[]A/P>_P 7OB%X
M-UN+]F3QU\$?">A?"6?X$_#S3?%_AW2_''@GQ/K6L_$J\_::CT/PYXD\/W,5
MKXSB^)'VC3[.95_IA_X>D_\ !,G_ *2+_L)?^)=?L_\ _P \&J\G_!3[_@E_
M-/;W4O\ P4._8*EN;/SOLEQ)^UI^ST\]K]H01S_9YF\?F2#SXP(YO*9?,0!7
MW* *^[NNZ_K_ (=?>>)==U_7_#K[S^=[]HO7O@AXW7_@IO:?MB_$GQKX8_;[
M^$OBC1G_ ."7_P .O#GQL^+>A^/-)T?4_P!GSX9V_P"Q_P")?V-_AIX6\7Z&
MGBGQ_P#$/XUO>7'Q._X5YX=U;4%\6W5YHWC>_ATVR,L'E/[0'P9U;Q/\-O\
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MN"#Q^D2;Y7>1]JC=([.V68DEUW7]?\.OO"Z[K^O^'7WG\[O_  3S_9U_9/\
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M?\.OO"Z[K^O^'7WGW;17PE_P])_X)D_])%_V$O\ Q+K]G_\ ^>#1_P /2?\
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M  )?Y@?<=%?#G_#SO_@FM_TD+_8<_P#$LO@)_P#-_1_P\[_X)K?])"_V'/\
MQ++X"?\ S?T<\/YH_P#@2_S ^XZ*^'/^'G?_  36_P"DA?[#G_B67P$_^;^C
M_AYW_P $UO\ I(7^PY_XEE\!/_F_HYX?S1_\"7^8'W'17PY_P\[_ .":W_20
MO]AS_P 2R^ G_P W]'_#SO\ X)K?])"_V'/_ !++X"?_ #?T<\/YH_\ @2_S
M ^XZ*^'/^'G?_!-;_I(7^PY_XEE\!/\ YOZ/^'G?_!-;_I(7^PY_XEE\!/\
MYOZ.>'\T?_ E_F!]QT5\.?\ #SO_ ()K?])"_P!AS_Q++X"?_-_1_P /._\
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MR[!QE6I1DJ,4XNI!-/LTY73U6C[G^:WBKDF<XCQ%XPK4,HS.O1J9UB94ZM'
M8NI3J1?):4*D*4HSB^CBVGW/8**\?_X:%^ 7_1<?@_\ ^'+\%_\ R[H_X:%^
M 7_1<?@__P"'+\%__+NO0^LX;_H(H?\ @VG_ /)>:^\_/_\ 5[/_ /H1YQ_X
M;,;_ /*/-?>>P45X_P#\-"_ +_HN/P?_ /#E^"__ )=T?\-"_ +_ *+C\'__
M  Y?@O\ ^7='UG#?]!%#_P &T_\ Y+S7WA_J]G__ $(\X_\ #9C?_E'FOO/8
M**\?_P"&A?@%_P!%Q^#_ /X<OP7_ /+NC_AH7X!?]%Q^#_\ X<OP7_\ +NCZ
MSAO^@BA_X-I__)>:^\/]7L__ .A'G'_ALQO_ ,H\U]Y[!17C_P#PT+\ O^BX
M_!__ ,.7X+_^7='_  T+\ O^BX_!_P#\.7X+_P#EW1]9PW_010_\&T__ )+S
M7WA_J]G_ /T(\X_\-F-_^4>:^\]@HKQ__AH7X!?]%Q^#_P#X<OP7_P#+NC_A
MH7X!?]%Q^#__ (<OP7_\NZ/K.&_Z"*'_ (-I_P#R7FOO#_5[/_\ H1YQ_P"&
MS&__ "CS7WGL%%>/_P##0OP"_P"BX_!__P .7X+_ /EW1_PT+\ O^BX_!_\
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MZ+C\'_\ PY?@O_Y=T?\ #0OP"_Z+C\'_ /PY?@O_ .7='UG#?]!%#_P;3_\
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M\/YH_P#@2_S ^XZ*^'/^'G?_  36_P"DA?[#G_B67P$_^;^C_AYW_P $UO\
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M]##^V5_XLG_X*-__ $5E'_#M']F/_H8?VRO_ !9/_P %&_\ Z*RCVDOY(_\
M@;_^0]?Z>A_J=B?^@RA_X+J':45Q?_#M']F/_H8?VRO_ !9/_P %&_\ Z*RC
M_AVC^S'_ -##^V5_XLG_ ."C?_T5E'M)?R1_\#?_ ,AZ_P!/0_U.Q/\ T&4/
M_!=0[2BN+_X=H_LQ_P#0P_ME?^+)_P#@HW_]%91_P[1_9C_Z&']LK_Q9/_P4
M;_\ HK*/:2_DC_X&_P#Y#U_IZ'^IV)_Z#*'_ (+J':45Q?\ P[1_9C_Z&']L
MK_Q9/_P4;_\ HK*/^':/[,?_ $,/[97_ (LG_P""C?\ ]%91[27\D?\ P-__
M "'K_3T/]3L3_P!!E#_P74.THKB_^':/[,?_ $,/[97_ (LG_P""C?\ ]%91
M_P .T?V8_P#H8?VRO_%D_P#P4;_^BLH]I+^2/_@;_P#D/7^GH?ZG8G_H,H?^
M"ZAVE%<7_P .T?V8_P#H8?VRO_%D_P#P4;_^BLH_X=H_LQ_]##^V5_XLG_X*
M-_\ T5E'M)?R1_\  W_\AZ_T]#_4[$_]!E#_ ,%U#M**XO\ X=H_LQ_]##^V
M5_XLG_X*-_\ T5E'_#M']F/_ *&']LK_ ,63_P#!1O\ ^BLH]I+^2/\ X&__
M )#U_IZ'^IV)_P"@RA_X+J':45Q?_#M']F/_ *&']LK_ ,63_P#!1O\ ^BLH
M_P"':/[,?_0P_ME?^+)_^"C?_P!%91[27\D?_ W_ /(>O]/0_P!3L3_T&4/_
M  74.THKB_\ AVC^S'_T,/[97_BR?_@HW_\ 164?\.T?V8_^AA_;*_\ %D__
M  4;_P#HK*/:2_DC_P"!O_Y#U_IZ'^IV)_Z#*'_@NH=I17%_\.T?V8_^AA_;
M*_\ %D__  4;_P#HK*/^':/[,?\ T,/[97_BR?\ X*-__164>TE_)'_P-_\
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M<_\ GP4?\,4? '_GU^,'_B3O[3G_ ,^"CFQ/_/JA_P"%%3_YF]?Z>A[#(/\
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MBOI#_ABCX _\^OQ@_P#$G?VG/_GP4?\ #%'P!_Y]?C!_XD[^TY_\^"CFQ/\
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M3_\ !1O_ .BLH_X=H_LQ_P#0P_ME?^+)_P#@HW_]%91[27\D?_ W_P#(>O\
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M]9F\/^)O@3\5=?\ $T7B1=/T[P]I=YX@U#3[S3O[)?@9_P D9^%G_8A>%O\
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M .FDU\)?\$RO^"K_ ,7OVY/V@/$'PK\;_"GX3^'-!N?@MXK^,[67PU\3^/\
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M.DY1WC)-MOY9_P"'A?\ P4I_Z'_]AS_Q$'X]_P#T?-'_  \+_P""E/\ T/\
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M_$0?CW_]'S1_P\+_ ."E/_0__L.?^(@_'O\ ^CYKYVHH_L;+?^@>7_A1BO\
MY<'_ !'GQ7_Z*K_S!\-__.<^B?\ AX7_ ,%*?^A__8<_\1!^/?\ ]'S1_P /
M"_\ @I3_ -#_ /L.?^(@_'O_ .CYKYVHH_L;+?\ H'E_X48K_P"7!_Q'GQ7_
M .BJ_P#,'PW_ /.<^B?^'A?_  4I_P"A_P#V'/\ Q$'X]_\ T?-'_#PO_@I3
M_P!#_P#L.?\ B(/Q[_\ H^:^=J*/[&RW_H'E_P"%&*_^7!_Q'GQ7_P"BJ_\
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M3_T/_P"PY_XB#\>__H^:^=J*/[&RW_H'E_X48K_Y<'_$>?%?_HJO_,'PW_\
M.<^B?^'A?_!2G_H?_P!AS_Q$'X]__1\T?\/"_P#@I3_T/_[#G_B(/Q[_ /H^
M:^=J*/[&RW_H'E_X48K_ .7!_P 1Y\5_^BJ_\P?#?_SG/HG_ (>%_P#!2G_H
M?_V'/_$0?CW_ /1\T?\ #PO_ (*4_P#0_P#[#G_B(/Q[_P#H^:^=J*/[&RW_
M *!Y?^%&*_\ EP?\1Y\5_P#HJO\ S!\-_P#SG/[ ?!(\3+X,\(KXUU70M=\9
M+X8T >+=;\+>'M0\(^&=8\3#2K0:]JOASPIJWB?QOJOAC0M0U7[7=Z1X>U/Q
MIXNU#1=/FM]-O?$^OW-M)JMWT]9VC_\ ()TO_L'67_I-%6C7YH]&_5G^C]-N
M5.G)N[E"+;[MQ3;TTW[!1112+"BBB@ HHHH **** /YA?^"M&@?M)W7[64EU
MX1^+'P.T/P=<?#7P8_AC0O$?[/?CWQ5XET>QCFUJ#4;?7O%FF?M.>#M+\1W=
MUXCAUO5;*\T_P7X6AL-$U'2O#\]AJ5_HUWXEUW\R?^$9_:R_Z+7^SO\ ^(O_
M !*_^B]K]IO^"HO_ "<;HO\ V2OPS_ZD/B^OSAK]*RJC"678.3E5NZ,6[8BO
M%?*,:BBEILDEY:L_S6\5<WQ=#Q%XPI0I99*-/.L3&+K9)DV(JM+DUG6KX"I6
MJ2[RJ5)R?5L^=_\ A&?VLO\ HM?[._\ XB_\2O\ Z+VC_A&?VLO^BU_L[_\
MB+_Q*_\ HO:^B**]#ZO3_FK_ /A3B?\ Y;Y?GW9^?_VYC?\ GQD__B/9!_\
M.SR_/NSYW_X1G]K+_HM?[.__ (B_\2O_ *+VC_A&?VLO^BU_L[_^(O\ Q*_^
MB]KZ(HH^KT_YJ_\ X4XG_P"6^7Y]V']N8W_GQD__ (CV0?\ SL\OS[L^=_\
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MK_\ A3B?_EOE^?=A_;F-_P"?&3_^(]D'_P [/+\^[/G?_A&?VLO^BU_L[_\
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MV7[#G_BO3X]__3.Z/^$ _P""E/\ T=E^PY_XKT^/?_TSNON.BCE7>7_@<_\
MY(#X<_X0#_@I3_T=E^PY_P"*]/CW_P#3.Z/^$ _X*4_]'9?L.?\ BO3X]_\
MTSNON.BCE7>7_@<__D@/AS_A /\ @I3_ -'9?L.?^*]/CW_],[H_X0#_ (*4
M_P#1V7[#G_BO3X]__3.Z^XZ*.5=Y?^!S_P#D@/AS_A /^"E/_1V7[#G_ (KT
M^/?_ -,[H_X0#_@I3_T=E^PY_P"*]/CW_P#3.Z^XZ*.5=Y?^!S_^2 ^'/^$
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M?'B$ZMIEMXAMO[6\"_\ "/>+F^(D4'A+RM,\_6M%_L63[!^__P -=7U#P_\
MLY>#]>TGPMKWCG5=$^$FFZOIG@GPM<>&+3Q/XPU#3?"Z7MEX6\.7?C;Q'X/\
M&6NO>(+F&/2=(N/%WB[PMX8AU"[MY->\1Z)I2W>IVO@O_#77[0'_ $BV_;M_
M\.#_ ,$R?_IB]?\ 7YX6?\FQ\./^R#X0_P#6?RX_RIXD_P"2BS[_ +'6:_\
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MSHFD:_\ LF?&;]K#0_ASIOQ)\)> ]%U/5TU(_#7Q=XG\":?\3_AKI7@O1I]
M\ ^+-8^(.G7^E^']-FT.\U[YI_9C_P""?7[6%]H7["O[.?QG^"?[3'@*7]D?
MQ'>WGBSX_:G^U)\(]1_9X\#S?#?P/XQ\%_#+QM^R[\.O OBW4/BGXIUKXI:7
MJMFFM:)\0O"G@S0O ]OK?B"U\7:;XEG^R6M?MU_PUU^T!_TBV_;M_P##@_\
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MMHKX2_X:Z_: _P"D6W[=O_AP?^"9/_TQ>C_AKK]H#_I%M^W;_P"'!_X)D_\
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MZ,'_ &B/_#F_L-__ $85'_" _MB?]&#_ +1'_AS?V&__ *,*C^T\#_T$1_\
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M_A ?VQ/^C!_VB/\ PYO[#?\ ]&%1_:>!_P"@B/\ X!4_^0\_S[,/^(;<<?\
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M6BOSJ_X;S^)O_2-O]N/_ ,+#_@G3_P#1_4?\-Y_$W_I&W^W'_P"%A_P3I_\
MH_J+_P!V?_@N?_R(?VGEO_0QP/\ X5X?_P"6'Z*T5^=7_#>?Q-_Z1M_MQ_\
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M (;S^)O_ $C;_;C_ /"P_P""=/\ ]']1_P -Y_$W_I&W^W'_ .%A_P $Z?\
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MLX8P#^Y:BOXN?$&BV=M_P3-_;?\ !GPN^,6@>.?V4H/^"@/[&'@WX+VOP/\
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MR*'_ -A-#_V\\<HHHKU3\N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC<(H0688'"8G RJ1CB'&7PU^QQ\>_P!L_P !_'']DS0_V@=?^&/B[X:?M[^
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M'U?3-32!K*_M9Y=^C7R^[_@^O]+4U\ON_P"#Z_TM?A+_ (>D_P#!,G_I(O\
ML)?^)=?L_P#_ ,\&C_AZ3_P3)_Z2+_L)?^)=?L__ /SP:^J_B5\6_A3\&/#Z
M>+?C#\3OA[\*/"LE];Z7'XF^)7C3PWX%\/OJ=YO^R:<FM>*-2TK36OKKRY/L
M]HMR;B?8_E1MM;'9Z5JNF:YIFGZUHFI6&L:-J]E:ZGI6K:5>6^H:9J>FWT"7
M-EJ&GW]I)-:WME>6TL=Q:W=M++!<02)+#(\;JQ-?+[O^#Z_TM37R^[_@^O\
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M_L)?^)=?L_\ _P \&ONVBC7R^[_@^O\ 2U-?+[O^#Z_TM?A+_AZ3_P $R?\
MI(O^PE_XEU^S_P#_ #P:/^'I/_!,G_I(O^PE_P")=?L__P#SP:^[:*-?+[O^
M#Z_TM37R^[_@^O\ 2U^$O^'I/_!,G_I(O^PE_P")=?L__P#SP:/^'I/_  3)
M_P"DB_["7_B77[/_ /\ /!K[MHHU\ON_X/K_ $M37R^[_@^O]+7X2_X>D_\
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M_P#FGU_I:G_$>L-_T1]?_P 22G_]#I_4-_P\8_X)[_\ 1]W[&O\ XD_\$O\
MYN*/^'C'_!/?_H^[]C7_ ,2?^"7_ ,W%?R\T4?V#/_H,A_X2O_YI]?Z6I_Q'
MK#?]$?7_ /$DI_\ T.G]0W_#QC_@GO\ ]'W?L:_^)/\ P2_^;BC_ (>,?\$]
M_P#H^[]C7_Q)_P""7_S<5_+S11_8,_\ H,A_X2O_ .:?7^EJ?\1ZPW_1'U__
M !)*?_T.G]0W_#QC_@GO_P!'W?L:_P#B3_P2_P#FXH_X>,?\$]_^C[OV-?\
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MZ7K>A:WI=W:ZEI&KZ;=7.GZEI]S;WEG<36TT<C='6/X>_P"0!H?_ &!],_\
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M /FGU_I:G_$>L-_T1]?_ ,22G_\ 0Z?J-_P\8_X)[_\ 1]W[&O\ XD_\$O\
MYN*/^'C'_!/?_H^[]C7_ ,2?^"7_ ,W%?ES11_8,_P#H,A_X2O\ ^:?7^EJ?
M\1ZPW_1'U_\ Q)*?_P!#I^HW_#QC_@GO_P!'W?L:_P#B3_P2_P#FXH_X>,?\
M$]_^C[OV-?\ Q)_X)?\ S<5^7-%']@S_ .@R'_A*_P#YI]?Z6I_Q'K#?]$?7
M_P#$DI__ $.GZC?\/&/^">__ $?=^QK_ .)/_!+_ .;BC_AXQ_P3W_Z/N_8U
M_P#$G_@E_P#-Q7Y<T4?V#/\ Z#(?^$K_ /FGU_I:G_$>L-_T1]?_ ,22G_\
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MW%?95%>I:?\ -#_P!_\ RSU_I:_F?-AO^?-?_P **?\ \RGQK_P\8_X)[_\
M1]W[&O\ XD_\$O\ YN*/^'C'_!/?_H^[]C7_ ,2?^"7_ ,W%?95%%I_S0_\
M '_\L]?Z6IS8;_GS7_\ "BG_ /,I\:_\/&/^">__ $?=^QK_ .)/_!+_ .;B
MC_AXQ_P3W_Z/N_8U_P#$G_@E_P#-Q7V511:?\T/_  !__+/7^EJ<V&_Y\U__
M  HI_P#S*?&O_#QC_@GO_P!'W?L:_P#B3_P2_P#FXH_X>,?\$]_^C[OV-?\
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M$]_^C[OV-?\ Q)_X)?\ S<5]E446G_-#_P  ?_RSU_I:G-AO^?-?_P **?\
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MX>*?C/IW[:/_  4=T7X6?'_]N>Y_:0^'/Q#^%'[//_!1;Q7^RM!^QCH_P2\
MKKGQ(^%$7[7FG? Y+75/BO8ZGI?BWPW\>(M'^(V@1_#FPL+.#P]-X>\(^&-8
M\5Z'XWUKQSJ-XODO[+GB[]M3X#^%/BA^T5\//VC/".C_ +/,/_!;[XE_!#Q?
M^R[-\&O#.L2?$#P7\<OVY=*^$WC;QAJGQAU6>?QIX>\=V.J?$ 2>%M,\*QZ9
MX5T_1?#EG=:O#KNJ:I>VT/ZE_L9?\$C?AM\%?%GQ,^*WQVT^'QU\3_$/[;GQ
MY_:Q\%Z=X<^,GQOU3X,65_XV\<ZYK'PB\;^(_@AK.J^&OA#??&SP!X3U9-,A
M\5W'P[UJ^\-ZI;6-YH/BC4+W0M UJP^[;#]B7]F+3/A[K7PKL?AGY'@+Q#^T
M)%^U3K&@_P#"9_$&3[9\>H/BQI/QQB\=_P!J3>*Y-9M]OQ1T/2_%'_"+VNHP
M>#6^R_V(WAT^'9[G2)@#\(?B3_P48_:QT#]H/PU\0/ 7Q_\ &OQ-^#>M?M^>
M$?V;)? 7@G]B*?2_V)=/^%FM?M%1?LZZIX>D_;"^*>G>!OB7\0?CSI,;7&NZ
MCXF^#&M>-OAB/BAIFKZ'I/AO4OAQ:S:M8^F?M7_M8?\ !076/!O_  5$_:2^
M!O[0_P /?V8_AM_P3M\4^/\ X.^$O@IX_P#@7X5\77OQDUKP;\#?!/Q!UKXD
M>*?'_B[6DU?1-8\2WOQ4T2^_9ZTGPUI$7A;7+S2_"=CXNT7QM8>(M3MKG]%M
M>_X)(_L+^*-;O]6\0?#[XGZE8W'QIOOVC=)\%?\ #3W[4.G_  T\%_'?5?&%
MUX^U3XK_  [^&ND?&+3_  1\/_&E]XLO]2U(ZMX1T/2'LK?5M:T32TL- UO5
M]*O?A;]O/_@E!\5/VN_B7^T5#;?#S]F=O#_[2K_#W0KO]HC4/C9^U#X!\?\
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M=CJUMZIKG[$W[,7B3P7\:/AYK7PS^V^#_P!H7XX^'OVD?C!H_P#PF?Q!M_\
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M8+_KQ#]3_,/Q:_Y.5QG_ -CS%?\ M@4445Z)^=A1110 4444 %%%% !1110
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M_P#!3;_Z+JC_ (=T?L__ /10?V[?_%I/_!3;_P"BZKG_ -BCXE>+?B%\<O\
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MOVF]<_9+MOV1/#_Q2^$WB^.]^)>E?!FU_:)3Q=I_QOFUKPUX0N/@S:?!;5]
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M7_#NC]G_ /Z*#^W;_P"+2?\ @IM_]%U1_P .Z/V?_P#HH/[=O_BTG_@IM_\
M1=5]VT4679?U_P ,ON"R[+^O^&7W'PE_P[H_9_\ ^B@_MV_^+2?^"FW_ -%U
M1_P[H_9__P"B@_MV_P#BTG_@IM_]%U7W;119=E_7_#+[@LNR_K_AE]Q\)?\
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M)JZZ.VA^,7_#G[]@?_HG7Q@_\3%_;/\ _H@J/^'/W[ __1.OC!_XF+^V?_\
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M'6W['?\ T"?VB/\ Q.3]N3_Z(VOT,HHYI?S2^]_UT7W!]2P?_0)A?_">E_\
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M_@ZI_P#)'QK_ ,,(_!+_ *'C]LK_ ,6,?\%"/_HGZ/\ AA'X)?\ 0\?ME?\
MBQC_ (*$?_1/U]E44>SA_)#_ ,!7^7DON#ZUB?\ H(K_ /@ZI_\ )'QK_P ,
M(_!+_H>/VRO_ !8Q_P %"/\ Z)^C_AA'X)?]#Q^V5_XL8_X*$?\ T3]?95%'
MLX?R0_\  5_EY+[@^M8G_H(K_P#@ZI_\D?&O_#"/P2_Z'C]LK_Q8Q_P4(_\
MHGZ/^&$?@E_T/'[97_BQC_@H1_\ 1/U]E44>SA_)#_P%?Y>2^X/K6)_Z"*__
M (.J?_)'QK_PPC\$O^AX_;*_\6,?\%"/_HGZ/^&$?@E_T/'[97_BQC_@H1_]
M$_7V511[.'\D/_ 5_EY+[@^M8G_H(K_^#JG_ ,D?&O\ PPC\$O\ H>/VRO\
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M (L8_P""A'_T3]?95%'LX?R0_P# 5_EY+[@^M8G_ *"*_P#X.J?_ "1\:_\
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MU;6_-UY-+TSF_P#A7W_!3;_H[K]A+_Q71^T!_P#32:/^%??\%-O^CNOV$O\
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MT!_]-)H^3_#_ #_JS\KGR?X?Y_U9^5_NVBOA+_A7W_!3;_H[K]A+_P 5T?M
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M1^-O_P!,8HYG_P ^Y_?#_P"3_JS\KGL:?_050_\  <3_ /,Y]E45\:_\(/\
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MX0?_ (*$?]'/_L:_^((_&W_Z8Q1S/_GW/[X?_)_U9^5SV-/_ *"J'_@.)_\
MF<^RJ*^-?^$'_P""A'_1S_[&O_B"/QM_^F,4?\(/_P %"/\ HY_]C7_Q!'XV
M_P#TQBCF?_/N?WP_^3_JS\KGL:?_ $%4/_ <3_\ ,Y]E45\:_P#"#_\ !0C_
M *.?_8U_\01^-O\ ],8H_P"$'_X*$?\ 1S_[&O\ X@C\;?\ Z8Q1S/\ Y]S^
M^'_R?]6?E<]C3_Z"J'_@.)_^9S[*HKXU_P"$'_X*$?\ 1S_[&O\ X@C\;?\
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M^((_&W_Z8Q1S/_GW/[X?_)_U9^5SV-/_ *"J'_@.)_\ F<^RJ_1*W_X]X/\
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MVOMZ>Y"<KO\ PV[M'<45\:_\(/\ \%"/^CG_ -C7_P 01^-O_P!,8H_X0?\
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M_P#@H1_T<_\ L:_^((_&W_Z8Q1S/_GW/[X?_ "?]6?E<]C3_ .@JA_X#B?\
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M4(_Z.?\ V-?_ !!'XV__ $QBCF?_ #[G]\/_ )/^K/RN>QI_]!5#_P !Q/\
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M4I:7GFV'VK4+#SYOLW_7YX6?\FQ\./\ L@^$/_6?RX_RIXD_Y*+/O^QUFO\
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MKK]H#_I%M^W;_P"'!_X)D_\ TQ>ONVBCYO\ #_+^KORL?-_A_E_5WY6^$O\
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MO\/\OZN_*Q\W^'^7]7?E;X2_X:Z_: _Z1;?MV_\ AP?^"9/_ -,7KP7XI?M
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MX)[_ /T=U?95%'*_^?D_NA_\A_5WY6/;4_\ H%H?^!8G_P":#XU_X:?^-O\
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M'=1_PT_\;?\ I'/^V5_X7'_!/?\ ^CNK[*HHY7_S\G]T/_D/ZN_*Q[:G_P!
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MT'QK_P -/_&W_I'/^V5_X7'_  3W_P#H[J/^&G_C;_TCG_;*_P#"X_X)[_\
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M  +$_P#S0?&O_#3_ ,;?^D<_[97_ (7'_!/?_P"CNH_X:?\ C;_TCG_;*_\
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M=UW7]?\ #K[SQ+KNOZ_X=?>?DC_P4V\0^&/%WQ<LOAA^UUI_[,^H_&[X3?\
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MB[Q5X[\(?\%!+A-,\9VWPVT'1)=/\<A+?7K/QGHJV6B^$Y]'_:^V_P""GO\
MP2^LQ.+3_@H;^P3:BYN9KRY%M^UI^SU +B[N"&GNI_*\?KYMS.P!FGDW2R$
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M_@F3_P!)%_V$O_$NOV?_ /YX-%UW7]?\.OO"Z[K^O^'7WGW;17PE_P /2?\
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M/:0_GA_X$O\ /S7WA]5Q/_0/7_\ !-3_ .1/LJBOC7_AXQ_P3W_Z/N_8U_\
M$G_@E_\ -Q1_P\8_X)[_ /1]W[&O_B3_ ,$O_FXH]I#^>'_@2_S\U]X?5<3_
M - ]?_P34_\ D3[*HKXU_P"'C'_!/?\ Z/N_8U_\2?\ @E_\W%'_  \8_P""
M>_\ T?=^QK_XD_\ !+_YN*/:0_GA_P"!+_/S7WA]5Q/_ $#U_P#P34_^1/LJ
MBOC7_AXQ_P $]_\ H^[]C7_Q)_X)?_-Q1_P\8_X)[_\ 1]W[&O\ XD_\$O\
MYN*/:0_GA_X$O\_-?>'U7$_] ]?_ ,$U/_D3[*HKXU_X>,?\$]_^C[OV-?\
MQ)_X)?\ S<4?\/&/^">__1]W[&O_ (D_\$O_ )N*/:0_GA_X$O\ /S7WA]5Q
M/_0/7_\ !-3_ .1/LJBOC7_AXQ_P3W_Z/N_8U_\ $G_@E_\ -Q1_P\8_X)[_
M /1]W[&O_B3_ ,$O_FXH]I#^>'_@2_S\U]X?5<3_ - ]?_P34_\ D3[*HKXU
M_P"'C'_!/?\ Z/N_8U_\2?\ @E_\W%'_  \8_P"">_\ T?=^QK_XD_\ !+_Y
MN*/:0_GA_P"!+_/S7WA]5Q/_ $#U_P#P34_^1/LJOT2M_P#CW@_ZXQ?^@+7X
M1_\ #QC_ ()[_P#1]W[&O_B3_P $O_FXK]O_  ?XH\,^./"/A;QIX+\1:%XO
M\'>+_#FB>*/"?BSPOJ^G^(/#/BCPSX@TRUU;0?$7AW7M)N+O2];T+6]+N[74
MM(U?3;JYT_4M/N;>\L[B:VFCD;@QLHR]ERR3MSWLT]^2VQ]OP92JTY9C[2G4
MIWCA;<\)0O9XB]N9*]KJ]MKG1T445P'W04444 %%%% !1110 5\E?''_ )'&
MV_[ 5E_Z5ZA7UK7Y7_M7?MK_ +&GPI^,6I_#OXH_M;?LR?#;X@>&-&T*+Q)X
M&\??'KX5^#O&/AZ75[(>(=*CUSPSXB\5Z=K6DR:GX?UC2=<T]+^RMVO='U33
MM3MA+97UM/+U8-I5;MI+D:NVEK=::GS7%<)U,J<80E.7UFB^6$7)V7/=V2;L
MCN**^-?^'C'_  3W_P"C[OV-?_$G_@E_\W%'_#QC_@GO_P!'W?L:_P#B3_P2
M_P#FXKU/:0_GA_X$O\_-?>?F?U7$_P#0/7_\$U/_ )$^RJ*^-?\ AXQ_P3W_
M .C[OV-?_$G_ ()?_-Q1_P /&/\ @GO_ -'W?L:_^)/_  2_^;BCVD/YX?\
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M_P /&/\ @GO_ -'W?L:_^)/_  2_^;BCVD/YX?\ @2_S\U]X?5<3_P! ]?\
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M^)/_  2_^;BCVD/YX?\ @2_S\U]X?5<3_P! ]?\ \$U/_D3[*HKXU_X>,?\
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M:BEC-<BQ35&TS3Y]0M[2WGGL[9B+>( _:ZBOP5T;X"^#?^"D/[>G_!0;PO\
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MT8;^+_VZ_P!"9_"_E^:,&BBBO0,0HHHH **** "BBB@ HHHH **** "BBB@
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M*TM;^6>_F]LU3_@G!\!]2\*?MU>"X]<^)6DZ!_P4"T/3?#OQ;M=)U?PG;_\
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MZ5=:Q<6=C%)J%QIVBZ592W+2/;:?:Q%84^=?^'='[/\ _P!%!_;M_P#%I/\
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MC7R^_P#X'K_3T-?+[_\ @>O]/3[MHKX2_P"'='[/_P#T4']NW_Q:3_P4V_\
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M]#_^W'_XL[_X*4__ $65'_#O3X"?]#_^W'_XL[_X*4__ $65=]Y_RQ_\"?\
M\@9'W'17PY_P[T^ G_0__MQ_^+._^"E/_P!%E1_P[T^ G_0__MQ_^+._^"E/
M_P!%E1>?\L?_  )__( ?<=%?#G_#O3X"?]#_ /MQ_P#BSO\ X*4__194?\.]
M/@)_T/\ ^W'_ .+._P#@I3_]%E1>?\L?_ G_ /( ?<=%?#G_  [T^ G_ $/_
M .W'_P"+._\ @I3_ /194?\ #O3X"?\ 0_\ [<?_ (L[_P""E/\ ]%E1>?\
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M /MQ_P#BSO\ X*4__1947G_+'_P)_P#R 'W'17PY_P .]/@)_P!#_P#MQ_\
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M$/K_ $]/HBBOG?\ X9?^&O\ T,W[1'_B7O[67_SZZ/\ AE_X:_\ 0S?M$?\
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MNR?Y$S^%_+\SZ/HKX<_X=Z? 3_H?_P!N/_Q9W_P4I_\ HLJ/^'>GP$_Z'_\
M;C_\6=_\%*?_ *+*N^\_Y8_^!/\ ^0,3[CHKX<_X=Z? 3_H?_P!N/_Q9W_P4
MI_\ HLJ/^'>GP$_Z'_\ ;C_\6=_\%*?_ *+*B\_Y8_\ @3_^0 ^XZ*^'/^'>
MGP$_Z'_]N/\ \6=_\%*?_HLJ/^'>GP$_Z'_]N/\ \6=_\%*?_HLJ+S_EC_X$
M_P#Y #[CHKX<_P"'>GP$_P"A_P#VX_\ Q9W_ ,%*?_HLJ/\ AWI\!/\ H?\
M]N/_ ,6=_P#!2G_Z+*B\_P"6/_@3_P#D /N.BOAS_AWI\!/^A_\ VX__ !9W
M_P %*?\ Z+*C_AWI\!/^A_\ VX__ !9W_P %*?\ Z+*B\_Y8_P#@3_\ D /N
M.BOAS_AWI\!/^A__ &X__%G?_!2G_P"BRH_X=Z? 3_H?_P!N/_Q9W_P4I_\
MHLJ+S_EC_P"!/_Y #[CHKX<_X=Z? 3_H?_VX_P#Q9W_P4I_^BRH_X=Z? 3_H
M?_VX_P#Q9W_P4I_^BRHO/^6/_@3_ /D /N.BOAS_ (=Z? 3_ *'_ /;C_P#%
MG?\ P4I_^BRH_P"'>GP$_P"A_P#VX_\ Q9W_ ,%*?_HLJ+S_ )8_^!/_ .0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@#\!Z***_XKS_7@**** "BBB@
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M^QK_ .+ _C;_ /2U:/\ AI+_ (*$?]&@?L:_^+ _C;_]+5KV:BO4]DOYY_\
MDG_R/]7?E;X7_6G-OYZ'_@B/^9XS_P -)?\ !0C_ *- _8U_\6!_&W_Z6K1_
MPTE_P4(_Z- _8U_\6!_&W_Z6K7LU%'LE_//_ ,D_^1_J[\K'^M.;?ST/_!$?
M\SQG_AI+_@H1_P!&@?L:_P#BP/XV_P#TM6C_ (:2_P""A'_1H'[&O_BP/XV_
M_2U:]FHH]DOYY_\ DG_R/]7?E8_UIS;^>A_X(C_F>,_\-)?\%"/^C0/V-?\
MQ8'\;?\ Z6K1_P -)?\ !0C_ *- _8U_\6!_&W_Z6K7LU%'LE_//_P D_P#D
M?ZN_*Q_K3FW\]#_P1'_,\9_X:2_X*$?]&@?L:_\ BP/XV_\ TM6C_AI+_@H1
M_P!&@?L:_P#BP/XV_P#TM6O9J*/9+^>?_DG_ ,C_ %=^5C_6G-OYZ'_@B/\
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M]G?_ ,2@^)7_ -"%1_PDW[67_1%/V=__ !*#XE?_ $(5?1%%'LJG_037_P#
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M_9W_ /$H/B5_]"%7T111[*I_T$U__ <-_P#,_P#5WY6/[3P7_1/9/_X/S_\
M^?G]7?E;YW_X2;]K+_HBG[.__B4'Q*_^A"H_X2;]K+_HBG[._P#XE!\2O_H0
MJ^B**/95/^@FO_X#AO\ YG_J[\K']IX+_HGLG_\ !^?_ /S\_J[\K?.__"3?
MM9?]$4_9W_\ $H/B5_\ 0A4?\)-^UE_T13]G?_Q*#XE?_0A5]$44>RJ?]!-?
M_P !PW_S/_5WY6/[3P7_ $3V3_\ @_/_ /Y^?U=^5OG?_A)OVLO^B*?L[_\
MB4'Q*_\ H0J/^$F_:R_Z(I^SO_XE!\2O_H0J^B**/95/^@FO_P" X;_YG_J[
M\K']IX+_ *)[)_\ P?G_ /\ /S^KORM\[_\ "3?M9?\ 1%/V=_\ Q*#XE?\
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MO[#G_BPOX]__ $L2C_A/_P#@I3_T:;^PY_XL+^/?_P!+$K[CHHY7_/+[H?\
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M?\)__P %*?\ HTW]AS_Q87\>_P#Z6)7W'11RO^>7W0_^1 ^'/^$__P""E/\
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M%/VG=>\*:I8? (_LX_$GPQK3OK'C_P 3^ 396:Z?\6H=.U*_OWM)?T(\6_\
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M'[)=_P#LV_%/P5XO\4_$C7O%?C+X;7F@7M\?B1HUM<:K<H3^Y7_#Q?\ 9_\
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M]6T>6\L(M<T35])DN%O]-O+>';_X>+_L_P#_ $3[]NW_ ,5;?\%-O_H1:/\
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M_L__ /1/OV[?_%6W_!3;_P"A%HNNZ_K_ (=?>%UW7]?\.OO/NVBOA+_AXO\
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MOQ@_\0Z_;/\ _H?:.67\LON?]=5]X?7<'_T%X7_PHI?_ "?FOO/TTHK\R_\
MA\#^P/\ ]%%^,'_B'7[9_P#]#[1_P^!_8'_Z*+\8/_$.OVS_ /Z'VCEE_++[
MG_75?>'UW!_]!>%_\**7_P GYK[S]-**_,O_ (? _L#_ /11?C!_XAU^V?\
M_0^T?\/@?V!_^BB_&#_Q#K]L_P#^A]HY9?RR^Y_UU7WA]=P?_07A?_"BE_\
M)^:^\_32BOS+_P"'P/[ _P#T47XP?^(=?MG_ /T/M'_#X']@?_HHOQ@_\0Z_
M;/\ _H?:.67\LON?]=5]X?7<'_T%X7_PHI?_ "?FOO/TTHK\R_\ A\#^P/\
M]%%^,'_B'7[9_P#]#[1_P^!_8'_Z*+\8/_$.OVS_ /Z'VCEE_++[G_75?>'U
MW!_]!>%_\**7_P GYK[S]-**_,O_ (? _L#_ /11?C!_XAU^V?\ _0^T?\/@
M?V!_^BB_&#_Q#K]L_P#^A]HY9?RR^Y_UU7WA]=P?_07A?_"BE_\ )^:^\_32
MBOS+_P"'P/[ _P#T47XP?^(=?MG_ /T/M'_#X']@?_HHOQ@_\0Z_;/\ _H?:
M.67\LON?]=5]X?7<'_T%X7_PHI?_ "?FOO/TTHK\R_\ A\#^P/\ ]%%^,'_B
M'7[9_P#]#[1_P^!_8'_Z*+\8/_$.OVS_ /Z'VCEE_++[G_75?>'UW!_]!>%_
M\**7_P GYK[S]-**_,O_ (? _L#_ /11?C!_XAU^V?\ _0^T?\/@?V!_^BB_
M&#_Q#K]L_P#^A]HY9?RR^Y_UU7WA]=P?_07A?_"BE_\ )^:^\_32BOS+_P"'
MP/[ _P#T47XP?^(=?MG_ /T/M'_#X']@?_HHOQ@_\0Z_;/\ _H?:.67\LON?
M]=5]X?7<'_T%X7_PHI?_ "?FOO/TTHK\R_\ A\#^P/\ ]%%^,'_B'7[9_P#]
M#[1_P^!_8'_Z*+\8/_$.OVS_ /Z'VCEE_++[G_75?>'UW!_]!>%_\**7_P G
MYK[S]-**_,O_ (? _L#_ /11?C!_XAU^V?\ _0^T?\/@?V!_^BB_&#_Q#K]L
M_P#^A]HY9?RR^Y_UU7WA]=P?_07A?_"BE_\ )^:^\_I&M_\ CW@_ZXQ?^@+4
MU<UX,\2Z9XT\'^$_&.BQ:W!H_BSPUH7B728/$OAGQ+X*\1PZ9KNEVNJ6$6O^
M#?&>DZ!XP\):W':W42:KX9\5Z%HOB70;Y9]*UW2=.U2TNK.'I:^=/Z A\$?\
M,?R04444%!1110 4444 %%%% '\^O_!47_DXW1?^R5^&?_4A\7U^<-?2G_!7
MC]JCX0?#_P#:Y?P5XH'Q7MM=\/?#'P5!?MIG[._[0OB30;K^TI]=UVUN- \7
M>&?A=J_A+Q58"SU:WMKO4O"^MZQI^G:Y;:OX9U"YM?$F@:[I.G?EW_PVO\ ?
M^?KXP?\ B,7[3G_SGZ_2LJQ%".78.,JU*,E1BG%U()I]FG*Z>JT?<_S6\5<D
MSG$>(O&%:AE&9UZ-3.L3*G5HX#%U*=2+Y+2A4A2E&<7T<6T^Y]845\G_ /#:
M_P  ?^?KXP?^(Q?M.?\ SGZ/^&U_@#_S]?&#_P 1B_:<_P#G/UZ'UG#?]!%#
M_P &T_\ Y+S7WGY__J]G_P#T(\X_\-F-_P#E'FOO/K"BOD__ (;7^ /_ #]?
M&#_Q&+]IS_YS]'_#:_P!_P"?KXP?^(Q?M.?_ #GZ/K.&_P"@BA_X-I__ "7F
MOO#_ %>S_P#Z$><?^&S&_P#RCS7WGUA17R?_ ,-K_ '_ )^OC!_XC%^TY_\
M.?H_X;7^ /\ S]?&#_Q&+]IS_P"<_1]9PW_010_\&T__ )+S7WA_J]G_ /T(
M\X_\-F-_^4>:^\^L**^3_P#AM?X _P#/U\8/_$8OVG/_ )S]'_#:_P  ?^?K
MXP?^(Q?M.?\ SGZ/K.&_Z"*'_@VG_P#)>:^\/]7L_P#^A'G'_ALQO_RCS7WG
MUA17R?\ \-K_  !_Y^OC!_XC%^TY_P#.?H_X;7^ /_/U\8/_ !&+]IS_ .<_
M1]9PW_010_\ !M/_ .2\U]X?ZO9__P!"/./_  V8W_Y1YK[SZPHKY/\ ^&U_
M@#_S]?&#_P 1B_:<_P#G/T?\-K_ '_GZ^,'_ (C%^TY_\Y^CZSAO^@BA_P"#
M:?\ \EYK[P_U>S__ *$><?\ ALQO_P H\U]Y]845\G_\-K_ '_GZ^,'_ (C%
M^TY_\Y^C_AM?X _\_7Q@_P#$8OVG/_G/T?6<-_T$4/\ P;3_ /DO-?>'^KV?
M_P#0CSC_ ,-F-_\ E'FOO/K"BOD__AM?X _\_7Q@_P#$8OVG/_G/T?\ #:_P
M!_Y^OC!_XC%^TY_\Y^CZSAO^@BA_X-I__)>:^\/]7L__ .A'G'_ALQO_ ,H\
MU]Y]845\G_\ #:_P!_Y^OC!_XC%^TY_\Y^C_ (;7^ /_ #]?&#_Q&+]IS_YS
M]'UG#?\ 010_\&T__DO-?>'^KV?_ /0CSC_PV8W_ .4>:^\^L**^3_\ AM?X
M _\ /U\8/_$8OVG/_G/T?\-K_ '_ )^OC!_XC%^TY_\ .?H^LX;_ *"*'_@V
MG_\ )>:^\/\ 5[/_ /H1YQ_X;,;_ /*/-?>?6%%?)_\ PVO\ ?\ GZ^,'_B,
M7[3G_P Y^C_AM?X _P#/U\8/_$8OVG/_ )S]'UG#?]!%#_P;3_\ DO-?>'^K
MV?\ _0CSC_PV8W_Y1YK[SZPHKY/_ .&U_@#_ ,_7Q@_\1B_:<_\ G/T?\-K_
M  !_Y^OC!_XC%^TY_P#.?H^LX;_H(H?^#:?_ ,EYK[P_U>S_ /Z$><?^&S&_
M_*/-?>?6%?V+Z/\ \@G2_P#L'67_ *315_!Q_P -K_ '_GZ^,'_B,7[3G_SG
MZ_NK\ >(M/\ %_@3P5XLTF#6[;2O%'A+PWXBTRV\2^&?$G@OQ';Z?K6C66I6
M4&O^#O&.E:#XN\)ZW%;7,<>J^&?%6AZ-XDT&^6?2]<TK3M3M;JSA^3XHJTZB
MP/LZD*EGB+\DXRM=4+7Y6[7Z7W/ZQ^B[EV88"KQL\=@<9@U5I\.^R>+PU?#^
MTY)9VY^S]M"'/R*<'+EOR\T;VYE?K:***^1/ZX"BBB@ HHHH **** "N+\0?
M\?R_]>\?_H<E=I7YE_M._P#!3_\ 8T_9A^+6J_"'XV>-/BOX5\=Z+I6B:E<V
M>F?LJ?M9>.M!O-.UVPCU33M0T#QQ\/?@AXJ\#>*;!H;AK*[O/#7B/5K;3-<L
MM7\-ZG+9^(=#UG2['IPJ;JV2;?*]$KOIT1RXO%X7!T76QF)P^$H\T8>UQ-:G
M0I\\G[L?:590CS2L[1O=V=D?<E%?DS_P_!_X)L_]%<^,'_B%?[<7_P!#C1_P
M_!_X)L_]%<^,'_B%?[<7_P!#C7I>SG_)/_P%_P"7FOO/)_UAR#_H>9/_ .'/
M!?\ R_S7WGZS45^3/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?
M^(5_MQ?_ $.-'LY_R3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7WGZS45^3
M/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_ $.-'LY_
MR3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7WGZS45^3/_#\'_@FS_T5SXP?
M^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_ $.-'LY_R3_\!?\ EYK[P_UA
MR#_H>9/_ .'/!?\ R_S7WGZS45^3/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\
M'_@FS_T5SXP?^(5_MQ?_ $.-'LY_R3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\
MR_S7WGZS45^3/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_
MMQ?_ $.-'LY_R3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7WGZS45^3/_#\
M'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_ $.-'LY_R3_\
M!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7WGZS45^3/_#\'_@FS_T5SXP?^(5_
MMQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_ $.-'LY_R3_\!?\ EYK[P_UAR#_H
M>9/_ .'/!?\ R_S7WGZS45^3/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@F
MS_T5SXP?^(5_MQ?_ $.-'LY_R3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7
MWGZS45^3/_#\'_@FS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_
M $.-'LY_R3_\!?\ EYK[P_UAR#_H>9/_ .'/!?\ R_S7WGZS45^3/_#\'_@F
MS_T5SXP?^(5_MQ?_ $.-'_#\'_@FS_T5SXP?^(5_MQ?_ $.-'LY_R3_\!?\
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MFO7,<DUOX?\ "'AC1[74_%/C'Q!+;PSW::%X6T76-6-G;75Y]C^RVMQ-&_\
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M7O!NMZ]XT\)?MP?$;7-1UKPS\*_B=J7B?3]'\/\ B&Q\$>%-'M]5MW6X\_\
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M44 %%%% !1110 4444 ?Z*'A[_D :'_V!],_](H*V*Q_#W_( T/_ + ^F?\
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M3KW18](73;KXA)XZL+'QHGC2>VD\2+XLLK3Q&-2&L6T-XGS/_P *^_X*;?\
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M?\$]?_%:WQT_^F@T?\*P_P""@_\ T=1_P3U_\5K?'3_Z:#7T?^M,O^A;4_\
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M:WQT_P#IH-'_  K#_@H/_P!'4?\ !/7_ ,5K?'3_ .F@T?ZTR_Z%M3_PH_\
MN']6?E<_XE4J?]%U2_\ $<?_ ,_OZL_*_P#%717]JG_"L/\ @H/_ -'4?\$]
M?_%:WQT_^F@T?\*P_P""@_\ T=1_P3U_\5K?'3_Z:#1_K3+_ *%M3_PH_P#N
M']6?E<_XE4J?]%U2_P#$<?\ \_OZL_*_\5=%?VJ?\*P_X*#_ /1U'_!/7_Q6
MM\=/_IH-'_"L/^"@_P#T=1_P3U_\5K?'3_Z:#1_K3+_H6U/_  H_^X?U9^5S
M_B52I_T75+_Q''_\_OZL_*_\5=%?VJ?\*P_X*#_]'4?\$]?_ !6M\=/_ *:#
M1_PK#_@H/_T=1_P3U_\ %:WQT_\ IH-'^M,O^A;4_P#"C_[A_5GY7/\ B52I
M_P!%U2_\1Q__ #^_JS\K_P 5=%?VJ?\ "L/^"@__ $=1_P $]?\ Q6M\=/\
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M_$<?_P _OZL_*_\ %717]JG_  K#_@H/_P!'4?\ !/7_ ,5K?'3_ .F@T?\
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M_P#5GY7^:_XEBPO_ $<? ?\ ADI>7_50^?\ 5U?^-&BO[+O["_;?_P"CPO\
M@G3_ .*V/CQ_],^H_L+]M_\ Z/"_X)T_^*V/CQ_],^H_UHG_ -"RK_X/_P#O
M?^K/RN?\2Q87_HX^ _\ #)2\O^JA\_ZNK_QHT5_9=_87[;__ $>%_P $Z?\
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MP'_ADI>7_50^?]75_P"-&BO[+O["_;?_ .CPO^"=/_BMCX\?_3/J/["_;?\
M^CPO^"=/_BMCX\?_ $SZC_6B?_0LJ_\ @_\ ^]_ZL_*Y_P 2Q87_ *./@/\
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M0>/:<G',<?[3V_UUVNJ7+[&5N?F]W[OHKX2_X5]_P4V_Z.Z_82_\5T?M ?\
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M$^/VGQ^V]WE^&5T?Q.T5_:I_PK#_ (*#_P#1U'_!/7_Q6M\=/_IH-'_"L/\
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MJS\K_P 5=%?VJ?\ "L/^"@__ $=1_P $]?\ Q6M\=/\ Z:#1_P *P_X*#_\
M1U'_  3U_P#%:WQT_P#IH-'^M,O^A;4_\*/_ +A_5GY7/^)5*G_1=4O_ !''
M_P#/[^K/RO\ Q5T5_:I_PK#_ (*#_P#1U'_!/7_Q6M\=/_IH-'_"L/\ @H/_
M -'4?\$]?_%:WQT_^F@T?ZTR_P"A;4_\*/\ [A_5GY7/^)5*G_1=4O\ Q''_
M //[^K/RO_%717]JG_"L/^"@_P#T=1_P3U_\5K?'3_Z:#1_PK#_@H/\ ]'4?
M\$]?_%:WQT_^F@T?ZTR_Z%M3_P */_N']6?E<_XE4J?]%U2_\1Q__/[^K/RO
M_%717]JG_"L/^"@__1U'_!/7_P 5K?'3_P"F@T?\*P_X*#_]'4?\$]?_ !6M
M\=/_ *:#1_K3+_H6U/\ PH_^X?U9^5S_ (E4J?\ 1=4O_$<?_P _OZL_*_\
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M'@G1K^[M?!?Q+M--MO[6UNU;2[&_TKPDNC6/BC06U4:C%Z9_P4]M/@_\$_\
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MZ3XRT:_UG6=6\%6B27?B_3-+TZWN;Z_\+VJ/<>(+6"7284:2[4'^BO\ :>^
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M>NRKC?$7_'[%_P!>J?\ HZ>NC#?Q?^W7^A,_A?R_-&#1117H&(4444 %%%%
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M_P#3%Z+^OW/^NOY]F%_7[G_77\^S/,?@+^P)\5=&_:;G_:W_ &R_VJ(OVO\
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M?_#@_P#!,G_Z8O1?U^Y_UU_/LPOZ_<_ZZ_GV9]VT5\)?\-=?M ?](MOV[?\
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M_P"D8G[<?_A?_P#!-;_Z871_PUE\>_\ I&)^W'_X7_\ P36_^F%T<R[2_P#
M)_\ R('W'17PY_PUE\>_^D8G[<?_ (7_ /P36_\ IA='_#67Q[_Z1B?MQ_\
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M8G[<?_A?_P#!-;_Z871_PUE\>_\ I&)^W'_X7_\ P36_^F%T<R[2_P# )_\
MR('W'17PY_PUE\>_^D8G[<?_ (7_ /P36_\ IA='_#67Q[_Z1B?MQ_\ A?\
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M9?\ 1D7[97_@P_8J_P#HS*/^'I%E_P!&1?ME?^##]BK_ .C,H^KXG_H%Q?\
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M_I&W^W'_ .%A_P $Z?\ Z/ZC_AO/XF_](V_VX_\ PL/^"=/_ -']7??^[/\
M\%S_ /D3@_M/+?\ H8X'_P *\/\ _+#]%:*_.K_AO/XF_P#2-O\ ;C_\+#_@
MG3_]']1_PWG\3?\ I&W^W'_X6'_!.G_Z/ZB_]V?_ (+G_P#(A_:>6_\ 0QP/
M_A7A_P#Y8?HK17YU?\-Y_$W_ *1M_MQ_^%A_P3I_^C^H_P"&\_B;_P!(V_VX
M_P#PL/\ @G3_ /1_47_NS_\ !<__ )$/[3RW_H8X'_PKP_\ \L/T5HK\ZO\
MAO/XF_\ 2-O]N/\ \+#_ ()T_P#T?U'_  WG\3?^D;?[<?\ X6'_  3I_P#H
M_J+_ -V?_@N?_P B']IY;_T,<#_X5X?_ .6'Z*T5^=7_  WG\3?^D;?[<?\
MX6'_  3I_P#H_J/^&\_B;_TC;_;C_P#"P_X)T_\ T?U%_P"[/_P7/_Y$/[3R
MW_H8X'_PKP__ ,L/T5HK\ZO^&\_B;_TC;_;C_P#"P_X)T_\ T?U'_#>?Q-_Z
M1M_MQ_\ A8?\$Z?_ */ZB_\ =G_X+G_\B']IY;_T,<#_ .%>'_\ EA^BM%?G
M5_PWG\3?^D;?[<?_ (6'_!.G_P"C^H_X;S^)O_2-O]N/_P +#_@G3_\ 1_47
M_NS_ /!<_P#Y$/[3RW_H8X'_ ,*\/_\ +#]%:*_.K_AO/XF_](V_VX__  L/
M^"=/_P!']1_PWG\3?^D;?[<?_A8?\$Z?_H_J+_W9_P#@N?\ \B']IY;_ -#'
M _\ A7A__EA^BM%?G5_PWG\3?^D;?[<?_A8?\$Z?_H_J/^&\_B;_ -(V_P!N
M/_PL/^"=/_T?U%_[L_\ P7/_ .1#^T\M_P"AC@?_  KP_P#\L/T5HK\ZO^&\
M_B;_ -(V_P!N/_PL/^"=/_T?U'_#>?Q-_P"D;?[<?_A8?\$Z?_H_J+_W9_\
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M52+?R\@'BL^OTV/PQZ:+31=.RT7RT['Y9+=^K_/SU/\ 5=_X)@?\HYOV'/\
MLUCX(?\ JO\ 0J[;PG^WW^PEX]\5Z?X$\"_MJ_LE>-/'&K:C%I&E>#?"?[1W
MP=\1^*]3U:>[CL(-+T_P[H_C*\U>\U&:^FBLHK*VLY+F2[ECMTB,SJAXG_@F
M!_RCF_8<_P"S6/@A_P"J_P!"K\F?^"0/[#'['7[67_!&_P" NC_M&?LY_!_X
MF?\ "1:K^U=::CXK\0^"M!3Q[IJO^U?\=M*&J>'_ (D6MG:^-_"NLV6EV5I9
MV6O:!X@TS5+&SL[:V@NX[:%8A_$.<?\ (VS3_L8XW_U)JG]V9+_R)LI_[%F
M_P#46D?T,Z]\3OAKX5\:> OAOXG^(?@;PY\1/BK_ ,)3_P *O\!:]XLT#1_&
MGQ(_X0;28=>\;?\ "!>%M0U"WUSQA_PA^AW%OK/BG_A'K'4?^$?TF>'4=6^R
M6<J3-A?%_P".WP0_9\\-6/C/X^?&3X5?!#P?J>N6WAC3?%?Q?^(?A'X:^&M0
M\2WMAJ>JV?AZQUWQGJ^BZ7=ZY=Z7HNLZE;:3;W4E_/8:3J=Y%;O;V%U)%_(S
M^P?\1O'OQ3^(W_!K%XJ^(NMZSXGUFVT;_@LCX.T;Q/XAF\_6=?\  /P[^&VI
M^ OAM>W\C06]Q)+;^ ?#?AW2TN[R/[9J<6GQZM</(]^7;]0_^#@-=4?X=_\
M!,1-#\$:/\3-:;_@LA^Q:ND?#?Q#JEEH>@?$#5&T/XSC3_!&N:WJ>EZYINCZ
M/XKNS#H.IZIJ&BZO9:?97\]W=Z7J$$,EI-YQZ9^S7P@_:#^ G[0FE:EKOP#^
M-_PA^.&AZ-<PV6L:S\(/B5X,^)>E:3>7(F:WM-2U'P9K6M6EC<SK;7#0P74T
M4LHMYBB,(I-O/?$W]K#]EGX*>(]/\'_&7]I7X ?"3Q;JSV46E>%OB;\9/AUX
M"\1ZG)J1VZ='I^B>*O$>E:G>/?GBR2VM9&NCQ )#7X9?#^T\6^"_^"Q'[,7C
M'XU?LC^%?V"[_P >?LP_'7X6_!W3/@3XK\._$KP=^UAX_L9$^(/B#X<_&'QY
MX.\/?#_0/!TGPM\%>&[KQU\.-!\0^ $;Q+KFIW]S!\0KN?1;#PE#Z%_P2*_9
M5_99_:[_ & /"/[3_P"TG\#?@Q^T9\>/VP-=^,'Q%_:%^*/Q8^&WAWQUXQUS
MQ5<_%CQ?X6;P1#K'C+2=0UCPMX9^%FE^$M$\"^%O!_AJ;1O#7A>7PK_:GA[3
M;/4;R[U&[ /W/UOXI?#+PUXQ^'_P[\1_$7P)X?\ B!\65\3O\*_ NM^+O#^E
M>,?B6G@C2(/$'C-_A_X8O]0@UOQDOA'0;FVUOQ.WARQU(:!I%Q!J6JFTLY8Y
MF[NOY@#X"^"/PL_;T_X-N/AO^SA\=-8_:/\ @CX)TS_@K'X>^'GQ7UWXH^&_
MC-J&J:%9?L]:5L\.+\0O"=M::'JVF> ;AY_ FA:;:0)_PBVA>'--\*.JMHFQ
M?Z?Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MC?$7_'[%_P!>J?\ HZ>NRKC?$7_'[%_UZI_Z.GKHPW\7_MU_H3/X7\OS1@T4
M45Z!B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >G)]Q?]U?Y"G4U/N+_NK_(4ZO'.@**** "BBB@ HHHH **** /Y
M]?\ @J+_ ,G&Z+_V2OPS_P"I#XOK\X:_1[_@J+_R<;HO_9*_#/\ ZD/B^OSA
MK]/RC_D68+_KQ#]3_,/Q:_Y.5QG_ -CS%?\ M@4445Z)^=A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?V+Z/_ ,@G2_\
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MZM<_$[QYXAAO;NPB\*QVVG1Q0:1'%IM[<[H;NXD^U?>/_$*%^T)_T=A\&O\
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M>1L\<8PX'X5M0E&%2\G96:OKN[=KDR5TTO+\T<7171_\(Y/_ ,_,7_?#T?\
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MA1110 4444 %%%% !1110!_/K_P5%_Y.-T7_ +)7X9_]2'Q?7YPU_0%^UO\
ML.>*_P!H[XH6/C[1/'/A[PW9VGA#2O#3:?JNG:E=W+SZ?J6MWSW*RVA$0BD3
M58XU0_.&B<GAEKY>_P"'3_Q#_P"BL^#/_!+KG_Q5??9;FV74<#A:57%0A4IT
M8QG%PJ-QDMU=0:^YL_@CQ&\)?$3.N.N*,URSAG%8O+\?FV(Q&$Q,,5ET(UJ,
M^7EG&-7&4ZD4[/2<(R[H_)ZBOUA_X=/_ !#_ .BL^#/_  2ZY_\ %4?\.G_B
M'_T5GP9_X)=<_P#BJ[?[;RK_ *#(?^ 5?_E9\5_Q!+Q2_P"B0QG_ (695_\
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M@_U=SK_H J?^#*/_ ,M/!:*]Z_X4+K'_ $'M-_\  :ZH_P"%"ZQ_T'M-_P#
M:ZH^LT/^?B^Z7^0?ZNYU_P! %3_P91_^6G@M%>]?\*%UC_H/:;_X#75'_"A=
M8_Z#VF_^ UU1]9H?\_%]TO\ (/\ 5W.O^@"I_P"#*/\ \M/!:*]Z_P"%"ZQ_
MT'M-_P# :ZH_X4+K'_0>TW_P&NJ/K-#_ )^+[I?Y!_J[G7_0!4_\&4?_ ):>
M"T5[U_PH76/^@]IO_@-=4?\ "A=8_P"@]IO_ (#75'UFA_S\7W2_R#_5W.O^
M@"I_X,H__+3P6BO>O^%"ZQ_T'M-_\!KJC_A0NL?]![3?_ :ZH^LT/^?B^Z7^
M0?ZNYU_T 5/_  91_P#EIX+17O7_  H76/\ H/:;_P" UU1_PH76/^@]IO\
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MO4Q4J#=E&5[VW>][-;]-;]-'9NS&Y277\%Y/MY^O<_8?_A(X/^?:7_OM*/\
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M$;_PIO#/_P :H_X?V?"/_H@?Q&_\*;PS_P#&J_F%HKL_U>RK_GQ/_P '5?\
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M,LEP&,Q=6%.%*-3$5Z$*E6<:5.,:=-2DVU&$5%;))!1117(?5A1110 4444
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MZUL@HHHKE/J0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>nt10016217x4_graphic17x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic17x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M0CJ?K/\ L#?\%2?@!_P4"LOC+JGP^EM_ 47PK\8ZQH]AX;\>^,?!T'Q#\2>
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M5/!WCOX!?L9_$'Q7\5_AWX@\#_#/]HC_ ()_?%2_TJ>71+?P=J>J7?C'XO\
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M?$JZ_P"#;?\ 96;QZ\[Z+:_\%$]5M?A++<"Z\]OAO!\-_P!H;(\VY_UL-O\
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M\6I.A*@\14<J=6+J2P<<;2H4G&NYU%-TX?V4_$G]J'XO^#_^"@7[//[+&A^
M_A9J7P=^*_PV\5>+_&?C[6?BYX+T3XK>']<T30_BGJ6GZ;X2^$%_XJL_&WC'
M1KJ[\$^'X+[6]#\*:M86%MJFN75S>00Z!J,MC]*Z_P#M%_L^>%/B%I?PC\4_
M';X-^&OBMKEQIEGHOPQU_P")_@G1OB%J]WK4UM;Z-:Z7X+U'7+;Q)J%QJUQ>
MV<&F06FFS2W\UW;16JRO/$K_ ,N^A_$J'XN?\%>O^")?Q.\ > M>^'4'B_\
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M_MW7/@IJWAE=9U:6Z77IM2N[N^U&Z;5Y+F9OOK]E+X"?"7]F/_@X>^-WPS^
MW@S3?AE\/-0_8.MO$,G@OPT]U;>'K?4K[Q)\'8[U[2PDGE2"&ZN-+@U*:W!:
M)M4ENK\*L]P[5RSR>C##5)O$SE7A0QU=*%.$J$HX'&O"RM4]HI_O4E.#4&EN
MV]CT:/%.+K8ZC3CE]*&"JXS)\'*56O4AC:<\XRJ&8TW*@J,J5\-*3I54ZJ<M
M%%1LY'Z\?\%(_P!LW5/V)_V>[3QKX$\+:=\0OCG\3OB/X&^"7[/GPUU4:B]A
MXX^*_C_51;Z;I^HKI$]KJ(TS3M%L];UB<07=A]OO+'3] 34M/N];M+E/B/\
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M=7_:'_9_\/\ Q'L_@YKWQS^#NB?%W4/LOV#X5ZO\3?!6F_$>^^W06]S8_8_
M]YK</B>Y^V6UW:W%KY.EO]H@N;>6'?'-&S?%/[1'_!53]G7]G+]LOX*?L6^,
M;[3K3Q?\3M.NO$7C;XBZ_P"-_!7A/X9_!CPVOAOQAKFDKXWUC5=8:^M?%OB"
MY\-:7;Z3X:U/3]!M)](\6:)KT?B"9KFQTK4?Y1OV1-!_X)3:Y^Q3^T_\0_\
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M?$+6/'G@._\ @I&MA/JMKXSFUOQ'XC:U\;CX::/\1=5\2:!XBEM?$-AKFF^
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M+'Q/#X1U:3Q"MAXDE\.7MU;6>O1Z-<7KZ/=7$%OJ"V\LT:-3O_VM_P!E/2_
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MZ#?^L-O_ )NU1_QT&_\ 6&W_ ,W:H^H?]1N _P#"CT_N>?X/L']M?]2G.O\
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M ,W:H^H?]1N _P#"CT_N>?X/L']M?]2G.O\ P@_^ZG[)45^-O_'0;_UAM_\
M-VJ/^.@W_K#;_P";M4?4/^HW ?\ A1Z?W//\'V#^VO\ J4YU_P"$'_W4_9*O
M./BC\'/A%\</#D/@[XU?"OX<?%_PC;:K;:[;^%OBCX'\,?$#PY;ZW96]Y:6>
MLPZ'XLTO5M,BU6TM-0O[6VU!+5;N"WOKR&*9([F97_+3_CH-_P"L-O\ YNU1
M_P =!O\ UAM_\W:IQP4HR4HX[ QDFFI1Q+C)/35-0335]UV?8F>;0J0E3J9/
MG%2$E:4)Y>IPDNTHRJ-->331]FP_\$[O^"?UO-%<6_[#'['4$\$B303P_LR?
M!2*:&:)@\<L4B>"5>.2-U5T=&#(P#*00#79?%_\ 8W_9,_:!\1VGC'XX_LU_
M [XM^+K'2X=#M/%/Q"^&/@_Q7XBAT6VGN+JUT@:UK&DW>I-IEI<WEY<6=@]R
MUK:3WMY+;Q1/=W#2_ '_ !T&_P#6&W_S=JC_ (Z#?^L-O_F[5;>QQ/-&?]J8
M;FBFHR^O5.:*ERW2=KI/2Z3UY==D<WUK <DJ?^KF/]G-QE.G_9%'DG*%^24H
M<W+)PYI<K:;C=VM=GZ*^+/V4_P!F/QW\,?#'P5\9_L]?!;Q1\(?!,UG<^"_A
MEKGPS\':CX%\'W-A!=VMG=>%?#%SH\FD>';JWM-0U&TCN='M+.?[)J.H6ID-
MO?W<<S]._96_9@T>[UR_TG]G#X#:9?>)_A?#\$/$M]I_P@^'UG>>(O@O;:'H
MWAFW^$.O75OX>CGUCX80>&_#OA_P_%X!U&2Y\*QZ)H6CZ4FDBQTRR@@_.?\
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MNK&V@UC2=/O)+6/4([>[^S"WO(KBUDE@D_,;_CH-_P"L-O\ YNU1_P =!O\
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M;ZQIFFQW$]X-)M-3\1Z+J-]%H[7=S<74NCK/_9DUS-)/-:/*Q>OSL_XZ#?\
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MCN/3%\47/AU)[&RF719M5?35EL[606P>WB9/RP_XZ#?^L-O_ )NU1_QT&_\
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MKO7M,OKG3;?4FLK)]0M[.6&"]DLK*2YCEDM+=H_SC_XZ#?\ K#;_ .;M4?\
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MX=TRSO)6U_PO9^,;O4K.;QY\4?[3N)_$&L:!X8M=.^ZO^"66M?M-_LP^,?\
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MTTTTU=--7336J:;3Z!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M^$]6\0?"?3O%&JW96PA,6J6<'B"T\):C'I(D,TWV^>QLI(R]SO3YK_X+<?\
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MK&R,E/.UOQ!%J6L73J2);J^FER2Y-?BGX9\;^.OV*/V:_A[XY^&^D7TND?\
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ML\JE.,/?G[JDE[T[+WG?[ TS_@F1^P_H_AG]EWP=IWP2^S^'/V,/'>L?$O\
M9JT[_A9/Q=F_X5MXVU[Q[9?$[5M;^V3^/I;_ ,8_:_'&GV>N?V;X^NO%.D0>
M3_9MM80Z1)+I[^R^'OV2?V?/"O[37CK]L70?A_\ 8/VCOB5X$L_AIXV^(O\
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M$3T+QQI7AZQ\33KJ^KW]MK=AI]M?:7KVIW?B729;'Q"8=4A\0_X;,_X+/_\
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M9=_X=,M_^:OZL_*Y_K#@O^@3/?\ Q',__P#G;_5GY7_;.BOQ,_X;,_X+/_\
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M/?\ B>_[/_\ \31_9.*_Y^8#_P .>7?_ #5_5GY7T_UAP7_0)GO_ (CF?_\
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M7-*[LS]0?@5^RG\ _P!FG5OB]KGP3\!_\(5JOQX^(>J?%;XKW7_"4>,_$?\
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MC'5?"FE236E_=PV8AT8IH4<HB\/)I,,4,4?S%_PW-_P6,_Z0V^'O_$]_V?\
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MTWALV?L;XZB_JUOJ]\ZP;]A9)+V/^V?N[))>Y;2*6R0EB^'H_6[9%CE]?O\
M7K<(9NOKG,^:7UJV5?O[RE*353FO)REK*3;_ $K_ &5?V./V</V)_ &H_#/]
MFCX;VOPY\)ZUK\WBG78!KGB;Q1JNN^(KBRL].EU75O$'B_6=>UV[D%G86MO;
MVC:@NG6$:.FGV5HDLJO].5^''_#<W_!8S_I#;X>_\3W_ &?_ /XFC_AN;_@L
M9_TAM\/?^)[_ +/_ /\ $UC4RW'5IRJ5:^#J5)N\ZE3-<!.<GIK*4L4VWYMO
M;T.JAG668:E3P^&R_.,/0I14*5&CPQGE*E3BOLPIPRQ1BE=NT4E>[ZZ_N/17
MX<?\-S?\%C/^D-OA[_Q/?]G_ /\ B:/^&YO^"QG_ $AM\/?^)[_L_P#_ ,34
M?V3BO^?F _\ #GEW_P U?U9^5]?]8<%_T"9[_P"(YG__ ,[?ZL_*_P"X]%?A
MQ_PW-_P6,_Z0V^'O_$]_V?\ _P")H_X;F_X+&?\ 2&WP]_XGO^S_ /\ Q-']
MDXK_ )^8#_PYY=_\U?U9^5S_ %AP7_0)GO\ XCF?_P#SM_JS\K_N/17X<?\
M#<W_  6,_P"D-OA[_P 3W_9__P#B:/\ AN;_ (+&?](;?#W_ (GO^S__ /$T
M?V3BO^?F _\ #GEW_P U?U9^5S_6'!?] F>_^(YG_P#\[?ZL_*_[CT5^''_#
M<W_!8S_I#;X>_P#$]_V?_P#XFC_AN;_@L9_TAM\/?^)[_L__ /Q-']DXK_GY
M@/\ PYY=_P#-7]6?E<_UAP7_ $"9[_XCF?\ _P [?ZL_*_[CT5^''_#<W_!8
MS_I#;X>_\3W_ &?_ /XFC_AN;_@L9_TAM\/?^)[_ +/_ /\ $T?V3BO^?F _
M\.>7?_-7]6?E<_UAP7_0)GO_ (CF?_\ SM_JS\K_ +CT5^''_#<W_!8S_I#;
MX>_\3W_9_P#_ (FC_AN;_@L9_P!(;?#W_B>_[/\ _P#$T?V3BO\ GY@/_#GE
MW_S5_5GY7/\ 6'!?] F>_P#B.9__ /.W^K/RO^X]%?AQ_P -S?\ !8S_ *0V
M^'O_ !/?]G__ .)H_P"&YO\ @L9_TAM\/?\ B>_[/_\ \31_9.*_Y^8#_P .
M>7?_ #5_5GY7/]8<%_T"9[_XCF?_ /SM_JS\K_H?K/["?[*OB#XQ_&OX_P"K
M_"S[7\7/VB?@UJO[/WQC\6_\)O\ $:W_ .$P^$6MZ1X9T+5/"7]@VOB^'PSX
M?^U:5X/\.6O]O>%M&T3Q/#_9WGV^M17-W?377E=U_P $IOV [[P-^SC\-K[]
MGVRO?!/[)7B+Q9XJ_9_T&\^(?Q;NX? NM>.O&UE\1/%LUQ=W'CZ34?&=EK?C
M'3K+5KK1_'MYXHT=5@73+>PATAI+!_D3_AN;_@L9_P!(;?#W_B>_[/\ _P#$
MT?\ #<W_  6,_P"D-OA[_P 3W_9__P#B:Z(X7-8\JCCJ,5#EY$LZP:Y.2G*C
M#EMC/=Y*,YTHVMRTY3@O=DT^&6,X?J.;GD>.FZKFZKGPAF\G4=6O3Q55U&\I
M?.ZF)I4L14<KN=>E3K2O4A"2_1?2/V'OV7="\2?M/^+=*^&'V7Q#^V7HTOA_
M]I/4/^$U^(<__"R-(FT?7]!DM/LESXMFL?!^[2?$^N6GVCP%;>%KH?;O/687
M-M9S6_D=U_P2F_8#OO W[./PVOOV?;*]\$_LE>(O%GBK]G_0;SXA_%N[A\"Z
MUXZ\;67Q$\6S7%W<>/I-1\9V6M^,=.LM6NM'\>WGBC1U6!=,M["'2&DL'^1/
M^&YO^"QG_2&WP]_XGO\ L_\ _P 31_PW-_P6,_Z0V^'O_$]_V?\ _P")H6%S
M6+3CCJ,6G%IK.<&FG"DZ$'=8S>%"4J,7O&DY4U[CLR6,X?FG&>1XZ46IIQEP
MAF\DU5Q,,9533REIJIBX0Q51;3Q-.->5ZL8R/T6TG]AK]E31O$W[3/BZT^$6
MFW&M_MBV$.E_M)/K'B+QGXATSXG:=;V.LZ;%9WOA_7_$FI>'_#\ LO$&KPLG
MA'2_#XD-V)9-\UM:20>5_LJ?\$M/V%?V*?'NL_$_]G#X'P^!_'FM:)?>&9?$
MFH^.?B/XXO;#PWJ-Y9W]WHNC)X\\7>)+;2;>>YL+0W%Y901:O=PQ?9KS4;BV
M9XF^/?\ AN;_ (+&?](;?#W_ (GO^S__ /$T?\-S?\%C/^D-OA[_ ,3W_9__
M /B:/JN:\E2G]=H<E6,(U8?VS@N6I&G&,(1G'ZY:4802A%2348144K)(/KN0
M>THUO[$Q_ML-.K4P]7_5'-_:4*E>HZM:I1G_ &5S4YU:LYU:DX-2G4<IR;E*
M[_5K]H?]G3X-?M6_"?Q%\#OC[X._X3WX6^*[C0[O7_"__"0^*O"WV^X\-ZYI
M_B319/[;\%ZYX<\16OV+6M+L+W99:O;)<>1]GNUGM)9H)/%?VEO^"=O['O[7
M?@+X9_#CX^_!^U\:>&_@U;"S^%LL'BKQMX;\0^"K)M,TK1[BQTOQ5X9\1Z1X
MCN+#4-.T/18=4L-5U/4;+5+C2-*U*_@N-4TO3[VV^#_^&YO^"QG_ $AM\/?^
M)[_L_P#_ ,31_P -S?\ !8S_ *0V^'O_ !/?]G__ .)J:>"S*CR>RQ>&I>SG
M*I3]GF^!A[.I.,83G#EQ:Y9S@E"<HV<HQ46VDD:5\RR7%>V6)RC,L1]8I4Z-
M?VW"F<U?;4:4W5I4JO/E<O:4Z52<ZE.$[QA4<IP2D[O]1?V9_P!E?X _L=_#
M&#X/?LW_  XTKX9?#^+6=1\1W&D6%]K6L7NK>(M62UAU'7M?\0^)=2UGQ'X@
MU>XM;#3M/6_UG5KZ>UTG3-+T>S:WTG2]/LK;Z"K\./\ AN;_ (+&?](;?#W_
M (GO^S__ /$T?\-S?\%C/^D-OA[_ ,3W_9__ /B:SGEN-JSE4J5\'4J3;E.=
M3-<!.<I/>4I2Q3E)OJVVW9^5]J.=Y;AZ5.AA\OSBA1I14*5&EPQGM.E3A%)1
MA"G#+%&$8K11BDE;1;7_ ''HK\./^&YO^"QG_2&WP]_XGO\ L_\ _P 31_PW
M-_P6,_Z0V^'O_$]_V?\ _P")J?[)Q7_/S ?^'/+O_FK^K/ROI_K#@O\ H$SW
M_P 1S/\ _P"=O]6?E?\ <>BOPX_X;F_X+&?](;?#W_B>_P"S_P#_ !-'_#<W
M_!8S_I#;X>_\3W_9_P#_ (FC^R<5_P _,!_X<\N_^:OZL_*Y_K#@O^@3/?\
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MGY7_ *S:*_DR_P"(C;]IK_I''X>_\2HT/_YW5'_$1M^TU_TCC\/?^)4:'_\
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ML:\*D:*H>SC.%=*M&:CS*K%5$^=*1_6;17\F7_$1M^TU_P!(X_#W_B5&A_\
MSNJ/^(C;]IK_ *1Q^'O_ !*C0_\ YW58_P"K>;_] ]+_ ,*\)_\ +_ZL_*_7
M_P 1C\-/^BNRO_P*K_\ *_ZL_*_]9M%?R9?\1&W[37_2./P]_P")4:'_ /.Z
MH_XB-OVFO^D<?A[_ ,2HT/\ ^=U1_JWF_P#T#TO_  KPG_R_^K/RN?\ $8_#
M3_HKLK_\"J__ "O^K/RO_6;17\F7_$1M^TU_TCC\/?\ B5&A_P#SNJ/^(C;]
MIK_I''X>_P#$J-#_ /G=4?ZMYO\ ] ]+_P *\)_\O_JS\KG_ !&/PT_Z*[*_
M_ JO_P K_JS\K_UFT5_)E_Q$;?M-?](X_#W_ (E1H?\ \[JC_B(V_::_Z1Q^
M'O\ Q*C0_P#YW5'^K>;_ /0/2_\ "O"?_+_ZL_*Y_P 1C\-/^BNRO_P*K_\
M*_ZL_*_]9M%?R9?\1&W[37_2./P]_P")4:'_ /.ZHH_U;S?_ *!Z7_A7A/\
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MC_X,I_\ R7]6?E<_XBYP/_T,<3_X;L=_\I/Z#Z*_GP_X3O\ ;"_Z/Y_:)_\
M#9?L-?\ T'M'_"=_MA?]'\_M$_\ ALOV&O\ Z#VC^R<=_P ^H_\ @RG_ /)?
MU9^5S_B+G __ $,<3_X;L=_\I/Z#Z*_GP_X3O]L+_H_G]HG_ ,-E^PU_]![1
M_P )W^V%_P!'\_M$_P#ALOV&O_H/:/[)QW_/J/\ X,I__)?U9^5S_B+G _\
MT,<3_P"&['?_ "D_H/HK^?#_ (3O]L+_ */Y_:)_\-E^PU_]![1_PG?[87_1
M_/[1/_ALOV&O_H/:/[)QW_/J/_@RG_\ )?U9^5S_ (BYP/\ ]#'$_P#ANQW_
M ,I/Z#Z*_GP_X3O]L+_H_G]HG_PV7[#7_P!![1_PG?[87_1_/[1/_ALOV&O_
M *#VC^R<=_SZC_X,I_\ R7]6?E<_XBYP/_T,<3_X;L=_\I/Z#Z*_GP_X3O\
M;"_Z/Y_:)_\ #9?L-?\ T'M'_"=_MA?]'\_M$_\ ALOV&O\ Z#VC^R<=_P ^
MH_\ @RG_ /)?U9^5S_B+G __ $,<3_X;L=_\I/Z#Z*_GP_X3O]L+_H_G]HG_
M ,-E^PU_]![1_P )W^V%_P!'\_M$_P#ALOV&O_H/:/[)QW_/J/\ X,I__)?U
M9^5S_B+G _\ T,<3_P"&['?_ "D_H/HK^?#_ (3O]L+_ */Y_:)_\-E^PU_]
M![1_PG?[87_1_/[1/_ALOV&O_H/:/[)QW_/J/_@RG_\ )?U9^5S_ (BYP/\
M]#'$_P#ANQW_ ,I/Z#Z*_GP_X3O]L+_H_G]HG_PV7[#7_P!![1_PG?[87_1_
M/[1/_ALOV&O_ *#VC^R<=_SZC_X,I_\ R7]6?E<_XBYP/_T,<3_X;L=_\I/Z
M#Z*_GP_X3O\ ;"_Z/Y_:)_\ #9?L-?\ T'M'_"=_MA?]'\_M$_\ ALOV&O\
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M\Q_Y]T__  ;#_/\ JS\KG_$QWAG_ -!6<?\ AIJ__+#^J6BOY6O^%]_MX?\
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M/_P@/^":W_TO2B[_ )9?^2__ "7]6?E</N.BOAS_ (9-^/?_ $D[_;C_ /"
M_P"":W_TO2C_ (9-^/?_ $D[_;C_ /" _P"":W_TO2B[_EE_Y+_\E_5GY7#[
MCHKX<_X9-^/?_23O]N/_ ,(#_@FM_P#2]*/^&3?CW_TD[_;C_P#" _X)K?\
MTO2B[_EE_P"2_P#R7]6?E</N.BOAS_ADWX]_])._VX__  @/^":W_P!+TH_X
M9-^/?_23O]N/_P (#_@FM_\ 2]*+O^67_DO_ ,E_5GY7#[CHKX<_X9-^/?\
MTD[_ &X__" _X)K?_2]*/^&3?CW_ -)._P!N/_P@/^":W_TO2B[_ )9?^2__
M "7]6?E</N.BOAS_ (9-^/?_ $D[_;C_ /" _P"":W_TO2C_ (9-^/?_ $D[
M_;C_ /" _P"":W_TO2B[_EE_Y+_\E_5GY7#[CHKX<_X9-^/?_23O]N/_ ,(#
M_@FM_P#2]*/^&3?CW_TD[_;C_P#" _X)K?\ TO2B[_EE_P"2_P#R7]6?E</N
M.BOAS_ADWX]_])._VX__  @/^":W_P!+TH_X9-^/?_23O]N/_P (#_@FM_\
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M_;=6UKPO%I=[;->P_K=\$?\ @FC:'X-_\%,?@%^U-%X'\=_#/]O#]MG]HO\
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M'?#NEZ5=:78:Y=N-.TT _6KQ+^U?8^&OVU_ 7['$_@F\N;CQQ^S3\2?VC?\
MA84&LL\6EV?PZ\>^"_ \_A1?",&BW-[J=UJK>,%U.'4[;6(V@&GFQ32;R6[2
M:'X8_8T_X*S>/OVP/&GPNU+1/V)?'6E_LQ_&_4/$6D?#_P#:&\!_&7X;_'34
M?!6H:;I.H:[X<;]I[X1_#6VO=:_9OTOQ=9:'K6CVNI^(_$GB!=&\:IH_AC6[
M>T35VU:PW_A!^S'^W5XY_;^\(_MO?M/S?LZ?#+0_#'[)7Q+_ &9M+^$WP.\<
M^.?B1K6AZQXG\=?#7QS:?$N/Q?XZ^$_@O2M7G\2ZAHWBFUO_  U=:-#9>"=,
M\.>!4@NO'=YXE\4R:!\-_"7_ (),_M7V/[3?[+'QL\0?#_\ 8N_9W^(GP(^,
M">*/CM^UU^R7XR^(?PX^(O[87PJTJ7Q#)=_#_P :?LN^$?A#X!^!6@77QHFN
M- NOC)K%YX@UBYCF@U%_"DEK92MHER ?TS4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\;_P#!0#_DT;XM?]R'_P"K-\&5_-/7]+'_  4
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MT5\)?\.MO^"9/_2.C]A+_P 1%_9__P#G?4?\.MO^"9/_ $CH_82_\1%_9_\
M_G?4:^7W_P# ]?Z>@?=M%?"7_#K;_@F3_P!(Z/V$O_$1?V?_ /YWU'_#K;_@
MF3_TCH_82_\ $1?V?_\ YWU&OE]__ ]?Z>@?=M%?"7_#K;_@F3_TCH_82_\
M$1?V?_\ YWU'_#K;_@F3_P!(Z/V$O_$1?V?_ /YWU&OE]_\ P/7^GH'W;17P
ME_PZV_X)D_\ 2.C]A+_Q$7]G_P#^=]1_PZV_X)D_](Z/V$O_ !$7]G__ .=]
M1KY??_P/7^GH'W;17PE_PZV_X)D_](Z/V$O_ !$7]G__ .=]1_PZV_X)D_\
M2.C]A+_Q$7]G_P#^=]1KY??_ ,#U_IZ!]VT5\)?\.MO^"9/_ $CH_82_\1%_
M9_\ _G?4?\.MO^"9/_2.C]A+_P 1%_9__P#G?4:^7W_\#U_IZ!]VT5\)?\.M
MO^"9/_2.C]A+_P 1%_9__P#G?4?\.MO^"9/_ $CH_82_\1%_9_\ _G?4:^7W
M_P# ]?Z>@?=M%?"7_#K;_@F3_P!(Z/V$O_$1?V?_ /YWU'_#K;_@F3_TCH_8
M2_\ $1?V?_\ YWU&OE]__ ]?Z>@?=M%?"7_#K;_@F3_TCH_82_\ $1?V?_\
MYWU'_#K;_@F3_P!(Z/V$O_$1?V?_ /YWU&OE]_\ P/7^GH'W;17PE_PZV_X)
MD_\ 2.C]A+_Q$7]G_P#^=]1_PZV_X)D_](Z/V$O_ !$7]G__ .=]1KY??_P/
M7^GH'W;17PE_PZV_X)D_](Z/V$O_ !$7]G__ .=]1_PZV_X)D_\ 2.C]A+_Q
M$7]G_P#^=]1KY??_ ,#U_IZ!TO\ P4 _Y-&^+7_<A_\ JS?!E?S3U^^WQ/\
M^"87_!-73_ VN7=A_P $\_V&[*[A_LWRKJT_9,^ =M<1>9J^GQ/Y<T/@!)$W
MQN\;[6&Y'9#E6(/R/_P[G_X)[_\ 1B/[&O\ XC!\$O\ YAZ^GR7,Y8/"U*2P
M\:JEB)5.9UG3M>G1CR\OL:E[<M[W5[VLMS^9O&;PSH\9\48#-*F?5<KE0R#"
MX!8>&40S!35+,<TQ'MO;2S; N+E]:</9>QDH^S4O:/VCC#\P:*_3[_AW/_P3
MW_Z,1_8U_P#$8/@E_P#,/1_P[G_X)[_]&(_L:_\ B,'P2_\ F'KV/[>G_P!
M</\ PJ?_ ,S>O]/3\C_X@+A?^BPQ'_B-4_\ Z(O7^GI^8-%?I]_P[G_X)[_]
M&(_L:_\ B,'P2_\ F'H_X=S_ /!/?_HQ']C7_P 1@^"7_P P]']O3_Z X?\
MA4__ )F]?Z>A_P 0%PO_ $6&(_\ $:I__1%Z_P!/3\P:*_3[_AW/_P $]_\
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M8C_Q&J?_ -$7K_3T_,&BOT^_X=S_ /!/?_HQ']C7_P 1@^"7_P P]'_#N?\
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MOV=O_#)_#7_YF:.;$_\ /JA_X45/_F;U_IZ'L,@_Z&><?^&/!?\ T0G[U?\
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M-^ G_P P%>;[W:/_ ($__D?7^GI^N'W'17PY_P .Q/\ @FM_TCT_8<_\1-^
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M1_P[$_X)K?\ 2/3]AS_Q$WX"?_,!1[W:/_@3_P#D?7^GH'W'17PY_P .Q/\
M@FM_TCT_8<_\1-^ G_S 4?\ #L3_ ()K?](]/V'/_$3?@)_\P%'O=H_^!/\
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MT5\.?\.Q/^":W_2/3]AS_P 1-^ G_P P%'_#L3_@FM_TCT_8<_\ $3?@)_\
M,!1[W:/_ ($__D?7^GH'X>_\%IO^3M_#W_9$O!W_ *E7CZOR,K[E_P""N/['
M/[(OPV_:@T+P_P##K]EC]G'P#H,WP@\*:G+HG@KX'_#+PMI$NI7/B7QM!<:A
M)INA>&+"S>^G@M+6&:[:$SRQ6UO&\C)#&J_EU_PSU\ O^B'?!_\ \-IX+_\
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MG_GU0_\ "BI_\S>O]/0]AD'_ $,\X_\ #'@O_HA/8**\?_X9Z^ 7_1#O@_\
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M'_ 6K?M82_MH_#?Q9H_Q0CT7XJ?L\_'2U\/^'?"WA/7/@CXYT/PYIEWI-KX
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M%?A=X2\6ZI\.?V9?#'BS]OW]BOX<?$#X9?%3X-7%]\'_ (PZ?<7WC[X=Z#X
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MO_; HHHKN/SL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXO\ L_\ _1/OV[?_ !5M_P %-O\ Z$6ONVBC7R^[_@^O]+4/A+_AXO\ L_\
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MI_\ S+Z_TM?C7_AN[X)?]"/^V5_XKG_X*$?_ $,%'_#=WP2_Z$?]LK_Q7/\
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M?_S+Z_TM?C7_ (;N^"7_ $(_[97_ (KG_P""A'_T,%'_  W=\$O^A'_;*_\
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MDGBS_HV_]N/_ ,5]?MR?_0]5_7_11_K#C_\ GW@__!5;_P":?7^EJ?\ $KW
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M_P#0FT?\/"_@)_T('[<?_BL3_@I3_P#0FU]QT4>]WC_X"_\ Y+U_I:A\.?\
M#POX"?\ 0@?MQ_\ BL3_ (*4_P#T)M'_  \+^ G_ $('[<?_ (K$_P""E/\
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M/"_@)_T('[<?_BL3_@I3_P#0FU]QT4>]WC_X"_\ Y+U_I:A\.?\ #POX"?\
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M\?!?_0$^,'_B/7Q^_P#G:5[!11RXG_G[0_\ ">I_\T^O]+4]OD'_ $+,X_\
M#Y@O_H>/'_\ A>/@O_H"?&#_ ,1Z^/W_ ,[2C_A>/@O_ * GQ@_\1Z^/W_SM
M*]@HHY<3_P _:'_A/4_^:?7^EJ>WR#_H69Q_X?,%_P#0\>/_ /"\?!?_ $!/
MC!_XCU\?O_G:4?\ "\?!?_0$^,'_ (CU\?O_ )VE>P44<N)_Y^T/_">I_P#-
M/K_2U/;Y!_T+,X_\/F"_^AX\?_X7CX+_ .@)\8/_ !'KX_?_ #M*/^%X^"_^
M@)\8/_$>OC]_\[2O8**.7$_\_:'_ (3U/_FGU_I:GM\@_P"A9G'_ (?,%_\
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M_G:4?\+Q\%_] 3XP?^(]?'[_ .=I7L%%'+B?^?M#_P )ZG_S3Z_TM3V^0?\
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M"CT'68M.NKG4H+W3]7M=0TVXEGU'^F_XM_L1?L:?'WQ7%X\^./[)W[-_Q?\
M'$2V$7_"9?$OX)_#CQMXJFM=+B,&G6%WXA\1>'-0U:]TNSA/EP:5>7<^G(BQ
MJ+7$4>WUH?!SX1#6?AEXB'PK^' \0?!32-:\/_!O71X'\,#6?A+H/B31M/\
M#OB+1/AEJ8TO[;X#TC7_  _I.E:%K6F^%9]*L]4T;3-/TR^AGLK*V@B_)3_6
M@_B:^)'[/_@SX7_\$_/^"M7[2_@OQ'\8-)^-_P#P3@_X*!?$?]F?]AKQ^OQU
M^,DNK_LW_ WP3\7O@=J>@?#SP0DGCAK&_P!(A3XV_$#2KVX\6VGB35=7T?4+
M*PU?4+^/2=-:V^JO^"F_ASP9^TM\9_\ @ICXF?X3:7\2;7]COP'X/T77_C)^
MV7^VEXX^#?PY_94\3-\']-\;VB?LB?LS?!OX=Q^/[O5OB&MUI>LZ=XZ\?^)8
M[3XN_$S3I-"\)ZQ>^#0=-U+^IO4?V;_V>-8\(?$CX?:M\!?@OJG@'XR>+[[X
M@_%_P1J/PN\#WOA#XJ^/=4N=&O=3\;_$CPU<Z%+HOCGQ?J-YX<\/7=]XE\3V
M6J:S=W.@Z-/<7LDNEV+P<OXY_8Z_9*^)WQ.TGXU?$?\ 9C^ /CWXOZ'-IEQI
M7Q/\8?"'P#XC\>V=QHBPIH5Q'XKU?0;O6WG\/BWA/A^:6]DET)XUDTE[-\L0
M#^2>T\<^)_B7H'Q)\>^-?%6K^./&/BG_ (,V]9U;Q5XO\0:M<Z]XA\1^(IO$
M_P 5UUG5O$&N7LUS?ZQK]YJ*7$FM:GJ5S<:G?:H;NYU*XFOI+B5OW[TWP+X]
M^)__  0IT;X;_"R"\O/B5X^_X)1:+X.\!:?IWEC4-5\7>)/V2+31_#^CV,DL
MD26]YK&J7EMI=M=^8C6<UVETC!X5-?=6B?LE?LJ^&=-NM&\.?LS?L^^']'OO
MA3K/P'O=*T3X,_#G2M-O/@=XBUK6/$GB#X,W5C8>&[>UN/A3KOB+Q#K^OZS\
M.Y8G\(:IK6N:QJE[H\]]J=[//[7X>\/:!X2T#0_"GA30]'\,^%_#.CZ9X>\-
M^&_#VF66BZ!X>T#1;*#3='T/0]'TV"VT[2='TG3K:VL-,TRPMK>RL+*W@M;6
M"*"*.-0#\?\ ]ES]NG]B/P3_ ,$C/A)\6_&/C;X=Z3\(?@]^RGX2^'?Q1^%.
MLW^B1^(=$\6_#7X6CPGXV_9XOO /C:]T[4=6^(%QK'A3Q%X*T7P5K$)N?'DT
M<$^EOJ^CZQ:ZG=_DK^T&^C?MH?MS_!SX'>)?V8- N/V:+W_@G7\(/CY^S%^P
M]^T;^UEX]_X)^^!M O?%GB?QQ;^+/B!-X)^ _P +?BKHVJ?'#P%H%U9>$;?P
M9'XBT^Y^&_AJ#4O$.F07E^E]/X1_I#UG_@GU^PEXB^)NH?&?Q#^QM^S!K_Q8
MU;Q ?%NI_$/6_@7\-=6\6ZAXL:Z2^;Q5>:UJ'ANXO+CQ.U_&FH-X@EE;5VU
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MKI>J:/!J6H1:==6T=Y<K)TGP\^&_P[^$7@W1/AU\*/ 7@OX8?#[PU%=0>'/
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M?!.RTGXGZ;\3-5^%WCK]GKP%\2/V9OC18GQ#JGBSQI\,?C/\)&T[3[6;PO\
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M0_#'AC3].EBU+]3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]H#_P"E;4?\+!_X*;?]&B_L)?\ BQ?]H#_Z5M7SOKG_  53_9Z^,TOP2?\
M8Z_:D^!&NV6H_MQ?!#]FSXM7GC_P+\<+VR\3:?\ $O1/B5J1^&WP@U/0?!UM
MITGQ5\6-X)GN?!?C/6;F?X3V5KH.OP^(=>MKNYTF.?V?XL?\%8?^"=WP.^+T
MOP,^*G[4W@/PG\1+#7]*\*>(89M/\8:IX,\$>)]:G>WL?#OQ)^*>A^&M3^%G
MPQUL-')/?Z5\0?&?AJ^TFQ1M1U:"RT\?::/F_P /\OZN_*P=#_PL'_@IM_T:
M+^PE_P"+%_V@/_I6U'_"P?\ @IM_T:+^PE_XL7_: _\ I6U<G\>_^"MG_!.[
M]F'XC^+/A%\<OVF/#G@;XE^!+_1M/\8^#3X1^)?B36/#9\0>$_"GCC2-2U:+
MPCX*U^*U\.W7ACQOX7U$^*7E_P"$:MI-3_LV[U:#5;+4+&T^_/"_BCPUXW\-
M>'O&?@SQ#HGBWP?XMT32O$WA7Q5X9U6QUWPYXE\.:[8P:IHFOZ!K>ESW6FZQ
MHNL:;=6VH:7JFGW-Q97]E<075K/+!+'(Q\W^'^7]7?E8/B__ (6#_P %-O\
MHT7]A+_Q8O\ M ?_ $K:C_A8/_!3;_HT7]A+_P 6+_M ?_2MJ^[:*/F_P_R_
MJ[\K!\)?\+!_X*;?]&B_L)?^+%_V@/\ Z5M1_P +!_X*;?\ 1HO["7_BQ?\
M: _^E;5]VT4?-_A_E_5WY6#X2_X6#_P4V_Z-%_82_P#%B_[0'_TK:C_A8/\
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MZ-L_8<_\3V^/?_TM:OU'HH]I5_Y^2_\  :?_ ,A_5WY6/]6,C_Z ?_+G&?\
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M_BPOX]__ $L2C_A/_P#@I3_T:;^PY_XL+^/?_P!+$K[CHHL_YI?^2_\ R/\
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M_BPOX]__ $L2C_A/_P#@I3_T:;^PY_XL+^/?_P!+$K[CHHL_YI?^2_\ R/\
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M_BPOX]__ $L2C_A/_P#@I3_T:;^PY_XL+^/?_P!+$K[CHHL_YI?^2_\ R/\
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M_P""E/\ T:;^PY_XL+^/?_TL2ON.BBS_ )I?^2__ "/]7?E8/XS/^"N/B?\
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M/ZA_V;?''CO_ ()H?%3]L;X+?';]GW]H/Q=\'OC-^UK\9/VK_P!G?XZ_LW?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_#NC]G_ /Z*#^W;_P"+2?\ @IM_]%U1_P .Z/V?_P#HH/[=O_BTG_@IM_\
M1=5\''_@M_HOC3X-?L;>-?@;^S9>>-/BQ^V,WQRM_#OPL^*?[0/PC^ OA+P?
MJ'[-?BS2? ?Q=T^[^-GB:77O"GB^\'BC6;63X=Z?X-TC5-7\;>%Q)X@OM,\*
M3HVCCSKXI?\ !1']N'Q-^UM_P20\,>!OV8/B)\$]"^/_ (@_:TTKX[_LZ?&/
MQ7X8\ ^(_%'CKX.?#?Q5IVOZ!-XEO_ &NW-[\.OA=:6X^-WPN^(GA#4K?PW\
M?]-U7PY93:/H%_90MI99=E_7_#+[@/TV_P"'='[/_P#T4']NW_Q:3_P4V_\
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M_P .Z/V?_P#HH/[=O_BTG_@IM_\ 1=5]VT4679?U_P ,ON ^$O\ AW1^S_\
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M_P .]/@)_P!#_P#MQ_\ BSO_ (*4_P#T65?<=%'+'^6/W+^NB^X#X<_X=Z?
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M'/\ AWI\!/\ H?\ ]N/_ ,6=_P#!2G_Z+*C_ (=Z? 3_ *'_ /;C_P#%G?\
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M]R_KHON ^'/^'>GP$_Z'_P#;C_\ %G?_  4I_P#HLJ/^'>GP$_Z'_P#;C_\
M%G?_  4I_P#HLJ^XZ*.6/\L?N7]=%]P'PY_P[T^ G_0__MQ_^+._^"E/_P!%
ME1_P[T^ G_0__MQ_^+._^"E/_P!%E7W'11RQ_EC]R_KHON ^'/\ AWI\!/\
MH?\ ]N/_ ,6=_P#!2G_Z+*C_ (=Z? 3_ *'_ /;C_P#%G?\ P4I_^BRK[CHH
MY8_RQ^Y?UT7W ?#G_#O3X"?]#_\ MQ_^+._^"E/_ -%E1_P[T^ G_0__ +<?
M_BSO_@I3_P#195]QT4<L?Y8_<OZZ+[@/AS_AWI\!/^A__;C_ /%G?_!2G_Z+
M*C_AWI\!/^A__;C_ /%G?_!2G_Z+*ON.BCEC_+'[E_71?<!\.?\ #O3X"?\
M0_\ [<?_ (L[_P""E/\ ]%E1_P .]/@)_P!#_P#MQ_\ BSO_ (*4_P#T65?<
M=%'+'^6/W+^NB^X#^>S]NO\ 9VT+X->+/ FF?#;XV?MQ^'+'6?#NI7VI0?\
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M&_%G_1R'[<?_ (L%_;D_^B%KKZ*/[/P'_0#@_P#PFH__ "'DON#_ (B'Q_\
M]%SQA_XDV=?_ #:<A_PC?BS_ *.0_;C_ /%@O[<G_P!$+1_PC?BS_HY#]N/_
M ,6"_MR?_1"UU]%']GX#_H!P?_A-1_\ D/)?<'_$0^/_ /HN>,/_ !)LZ_\
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M_P#^AYG'_ASQO_R\\?\ ^%'>"_\ H-_&#_Q(7X_?_/+H_P"%'>"_^@W\8/\
MQ(7X_?\ SRZ]@HH^K8;_ *!Z'_@JG_\ (^2^X/\ 6'/_ /H>9Q_X<\;_ /+S
MQ_\ X4=X+_Z#?Q@_\2%^/W_SRZ/^%'>"_P#H-_&#_P 2%^/W_P \NO8**/JV
M&_Z!Z'_@JG_\CY+[@_UAS_\ Z'F<?^'/&_\ R\\?_P"%'>"_^@W\8/\ Q(7X
M_?\ SRZ/^%'>"_\ H-_&#_Q(7X_?_/+KV"BCZMAO^@>A_P""J?\ \CY+[@_U
MAS__ *'F<?\ ASQO_P O/'_^%'>"_P#H-_&#_P 2%^/W_P \NBO8**/JV&_Z
M!Z'_ (*I_P#R/DON#_6'/_\ H>9Q_P"'/&__ "\_J8_9P_9;_P""F7['6J_M
MWZ;\(/ _["'Q,\.?M4_MT_M0?M>^ _$GQ/\ VB?C_P"#]5\*V/QQN="@\+^&
MO&?@+PQ^R5XML-5GT.P\,:9?^(K71OB+;PWUS?ZAHVG:S%#:V^N7/.?LK?\
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ML_\ _P \&C_AZ3_P3)_Z2+_L)?\ B77[/_\ \\&BZ[K^O^'7W@?0OQP_9Q^
M7[3'AO2_!W[0WP:^&GQL\*:'KD?B71_#GQ0\&Z%XUT72_$,-A?:7%K=AIVOV
M5]:VNJ1Z;JFHV*7L,:7"VE]=0!Q'/(K>(_#[_@FY_P $_OA-XT\._$?X8_L7
M_LS> /'WA'4$U;PMXR\(_!GP)H'B7P]JD<<D4>H:/K.FZ);WVGWB12RQK<6L
MT<JI(ZA@&-9'_#TG_@F3_P!)%_V$O_$NOV?_ /YX-'_#TG_@F3_TD7_82_\
M$NOV?_\ YX-%UW7]?\.OO ]X_:C^&&O_ !M_9E_:*^#'A2\T?3_%'Q=^!/Q<
M^&'AN_\ $-Q>VF@6.O\ C[X?^(/"FCWFN76FZ?JVHVVCVVHZM;3:G<6&E:E>
MPV23R6NGWDZQVTGYR?M%?\$\_C3\7?\ @B=X?_X)N^&_$_POL?CCI/[+7[+G
MP0N?%6N:UXKMOA0_BOX)'X1_\)7J$&N6'@K4O%[>'M0_X0'6/^$>NY/ L>I7
M?VG3/[2TG2?.NOL?U'_P])_X)D_])%_V$O\ Q+K]G_\ ^>#1_P /2?\ @F3_
M -)%_P!A+_Q+K]G_ /\ G@T77=?U_P .OO ^&/\ @MI_P2.\4?\ !2;X7Z?J
MG[/WCKPE\)/VDM,T>R^&NMZ_XQO-<T3P/\7_ (#3^//#/Q(OOA/\3M5\)>'/
M%/B.73?"GQ'\'^%_BE\/91H.O6>D>*]'U.P&FV:^+;OQ!H_;:#^RY^WM\ _^
M"@O_  4)_:O^!7A']D+XI?#O]M;_ (9._L;1OBU^T#\9OA+XT\%?\,X?!.;X
M;ZC_ &GIW@[]E?XQ:'?_ /"2:YK.KW=E]D\1C[+I.GZ;//\ Z9J5U8Z7]8_\
M/2?^"9/_ $D7_82_\2Z_9_\ _G@T?\/2?^"9/_21?]A+_P 2Z_9__P#G@T77
M=?U_PZ^\#XJ^%7_!)37?%_[&'[='P%_:W\<>$;?XG?\ !0;X[^._VAOB5/\
ML\#7[;X5_!SQUJ.L>$M:^&S_  JL?$=AX6U/79?!>N_#[PCXNUWQ!K^B:%K_
M (ZUB"6P\2W=\EI;ZQ/4\9?!K_@MI^T!\'/"G[,WQ-^)G[*?P"TV\U#PMH?Q
MP_;-_9U^*_QIM?VB_%7@GPUK.@ZAJ>N_!3P%;?"?P1X4^%7Q*\=6^AW=IXCO
M[WQG?>&].M/%&IQ>&]%TA+*UMI/N#_AZ3_P3)_Z2+_L)?^)=?L__ /SP:/\
MAZ3_ ,$R?^DB_P"PE_XEU^S_ /\ SP:+KNOZ_P"'7W@?<.GV4>FV%CIT4UY<
M16%G;645QJ%Y<ZC?SQVL*0)-?:A>RSWE_>2K&'N;R[FFN;J9GGGEDE=W-ROA
M+_AZ3_P3)_Z2+_L)?^)=?L__ /SP:/\ AZ3_ ,$R?^DB_P"PE_XEU^S_ /\
MSP:+KNOZ_P"'7W@?=M%?"7_#TG_@F3_TD7_82_\ $NOV?_\ YX-'_#TG_@F3
M_P!)%_V$O_$NOV?_ /YX-%UW7]?\.OO ^[:*^$O^'I/_  3)_P"DB_["7_B7
M7[/_ /\ /!H_X>D_\$R?^DB_["7_ (EU^S__ //!HNNZ_K_AU]X'W;17PE_P
M])_X)D_])%_V$O\ Q+K]G_\ ^>#1_P /2?\ @F3_ -)%_P!A+_Q+K]G_ /\
MG@T77=?U_P .OO ^[:*^$O\ AZ3_ ,$R?^DB_P"PE_XEU^S_ /\ SP:/^'I/
M_!,G_I(O^PE_XEU^S_\ _/!HNNZ_K_AU]X'W;17PE_P])_X)D_\ 21?]A+_Q
M+K]G_P#^>#1_P])_X)D_])%_V$O_ !+K]G__ .>#1==U_7_#K[P/NVBOA+_A
MZ3_P3)_Z2+_L)?\ B77[/_\ \\&C_AZ3_P $R?\ I(O^PE_XEU^S_P#_ #P:
M+KNOZ_X=?>!]VT5\)?\ #TG_ ()D_P#21?\ 82_\2Z_9_P#_ )X-'_#TG_@F
M3_TD7_82_P#$NOV?_P#YX-%UW7]?\.OO ^[:*^$O^'I/_!,G_I(O^PE_XEU^
MS_\ _/!H_P"'I/\ P3)_Z2+_ +"7_B77[/\ _P#/!HNNZ_K_ (=?>!]VT5\)
M?\/2?^"9/_21?]A+_P 2Z_9__P#G@T?\/2?^"9/_ $D7_82_\2Z_9_\ _G@T
M77=?U_PZ^\#[MHKX2_X>D_\ !,G_ *2+_L)?^)=?L_\ _P \&C_AZ3_P3)_Z
M2+_L)?\ B77[/_\ \\&BZ[K^O^'7W@?;.M?\@RY_[8_^E$5<'7RCJ_\ P5%_
MX)FRZ?<)'_P44_84D=O*VHG[7'P =CB>,G"K\023@ DX' !/05Q7_#SO_@FM
M_P!)"_V'/_$LO@)_\W]=5&45%W:^)]5VC_FOO ^XZ*^'/^'G?_!-;_I(7^PY
M_P")9? 3_P";^C_AYW_P36_Z2%_L.?\ B67P$_\ F_K;FC_-'[U_75?>!]QT
M5\.?\/._^":W_20O]AS_ ,2R^ G_ ,W]'_#SO_@FM_TD+_8<_P#$LO@)_P#-
M_1S1_FC]Z_KJOO ^XZ*^'/\ AYW_ ,$UO^DA?[#G_B67P$_^;^C_ (>=_P#!
M-;_I(7^PY_XEE\!/_F_HYH_S1^]?UU7W@?<=%?#G_#SO_@FM_P!)"_V'/_$L
MO@)_\W]'_#SO_@FM_P!)"_V'/_$LO@)_\W]'-'^:/WK^NJ^\#[CHKX<_X>=_
M\$UO^DA?[#G_ (EE\!/_ )OZ/^'G?_!-;_I(7^PY_P")9? 3_P";^CFC_-'[
MU_75?>!]QT5\.?\ #SO_ ()K?])"_P!AS_Q++X"?_-_1_P /._\ @FM_TD+_
M &'/_$LO@)_\W]'-'^:/WK^NJ^\#[CHKX<_X>=_\$UO^DA?[#G_B67P$_P#F
M_H_X>=_\$UO^DA?[#G_B67P$_P#F_HYH_P T?O7]=5]X'W'17PY_P\[_ .":
MW_20O]AS_P 2R^ G_P W]'_#SO\ X)K?])"_V'/_ !++X"?_ #?T<T?YH_>O
MZZK[P/N.BOAS_AYW_P $UO\ I(7^PY_XEE\!/_F_H_X>=_\ !-;_ *2%_L.?
M^)9? 3_YOZ.:/\T?O7]=5]X'W'17PY_P\[_X)K?])"_V'/\ Q++X"?\ S?T?
M\/._^":W_20O]AS_ ,2R^ G_ ,W]'-'^:/WK^NJ^\#[CHKX<_P"'G?\ P36_
MZ2%_L.?^)9? 3_YOZ/\ AYW_ ,$UO^DA?[#G_B67P$_^;^CFC_-'[U_75?>!
M]QT5\.?\/._^":W_ $D+_8<_\2R^ G_S?T?\/._^":W_ $D+_8<_\2R^ G_S
M?T<T?YH_>OZZK[P/N.BOAS_AYW_P36_Z2%_L.?\ B67P$_\ F_H_X>=_\$UO
M^DA?[#G_ (EE\!/_ )OZ.:/\T?O7]=5]X'W'17PY_P /._\ @FM_TD+_ &'/
M_$LO@)_\W]'_  \[_P"":W_20O\ 8<_\2R^ G_S?T<T?YH_>OZZK[P/N.BOA
MS_AYW_P36_Z2%_L.?^)9? 3_ .;^C_AYW_P36_Z2%_L.?^)9? 3_ .;^CFC_
M #1^]?UU7W@?<=%?#G_#SO\ X)K?])"_V'/_ !++X"?_ #?T?\/._P#@FM_T
MD+_8<_\ $LO@)_\ -_1S1_FC]Z_KJOO ^XZ*^'/^'G?_  36_P"DA?[#G_B6
M7P$_^;^C_AYW_P $UO\ I(7^PY_XEE\!/_F_HYH_S1^]?UU7W@?<=%?#G_#S
MO_@FM_TD+_8<_P#$LO@)_P#-_1_P\[_X)K?])"_V'/\ Q++X"?\ S?T<T?YH
M_>OZZK[P/N.BOAS_ (>=_P#!-;_I(7^PY_XEE\!/_F_H_P"'G?\ P36_Z2%_
ML.?^)9? 3_YOZ.:/\T?O7]=5]X'W'17PY_P\[_X)K?\ 20O]AS_Q++X"?_-_
M1_P\[_X)K?\ 20O]AS_Q++X"?_-_1S1_FC]Z_KJOO ^XZ*^'/^'G?_!-;_I(
M7^PY_P")9? 3_P";^C_AYW_P36_Z2%_L.?\ B67P$_\ F_HYH_S1^]?UU7W@
M?<=%?#G_  \[_P"":W_20O\ 8<_\2R^ G_S?T?\ #SO_ ()K?])"_P!AS_Q+
M+X"?_-_1S1_FC]Z_KJOO ^XZ*^'/^'G?_!-;_I(7^PY_XEE\!/\ YOZ/^'G?
M_!-;_I(7^PY_XEE\!/\ YOZ.:/\ -'[U_75?>!]QT5\.?\/._P#@FM_TD+_8
M<_\ $LO@)_\ -_1_P\[_ .":W_20O]AS_P 2R^ G_P W]'-'^:/WK^NJ^\#[
MCHKX<_X>=_\ !-;_ *2%_L.?^)9? 3_YOZ/^'G?_  36_P"DA?[#G_B67P$_
M^;^CFC_-'[U_75?>!]QT5\.?\/._^":W_20O]AS_ ,2R^ G_ ,W]'_#SO_@F
MM_TD+_8<_P#$LO@)_P#-_1S1_FC]Z_KJOO ^XZ*^'/\ AYW_ ,$UO^DA?[#G
M_B67P$_^;^C_ (>=_P#!-;_I(7^PY_XEE\!/_F_HYH_S1^]?UU7W@?<=%?#G
M_#SO_@FM_P!)"_V'/_$LO@)_\W]'_#SO_@FM_P!)"_V'/_$LO@)_\W]'-'^:
M/WK^NJ^\#[CHKX<_X>=_\$UO^DA?[#G_ (EE\!/_ )OZ/^'G?_!-;_I(7^PY
M_P")9? 3_P";^CFC_-'[U_75?>!]QT5\.?\ #SO_ ()K?])"_P!AS_Q++X"?
M_-_1_P /._\ @FM_TD+_ &'/_$LO@)_\W]'-'^:/WK^NJ^\#[CHKX<_X>=_\
M$UO^DA?[#G_B67P$_P#F_H_X>=_\$UO^DA?[#G_B67P$_P#F_HYH_P T?O7]
M=5]X'W'17PY_P\[_ .":W_20O]AS_P 2R^ G_P W]'_#SO\ X)K?])"_V'/_
M !++X"?_ #?T<T?YH_>OZZK[P/N.BOAS_AYW_P $UO\ I(7^PY_XEE\!/_F_
MH_X>=_\ !-;_ *2%_L.?^)9? 3_YOZ.:/\T?O7]=5]X'W'17PY_P\[_X)K?]
M)"_V'/\ Q++X"?\ S?T?\/._^":W_20O]AS_ ,2R^ G_ ,W]'-'^:/WK^NJ^
M\#[CHKX<_P"'G?\ P36_Z2%_L.?^)9? 3_YOZ/\ AYW_ ,$UO^DA?[#G_B67
MP$_^;^CFC_-'[U_75?>!\F_\%.O^1[^&'_8I:Q_Z>$K\Q*^B_P#@HG^WK^PS
MXV\9_#JZ\&?MG_LG^+K6Q\,:K;WMSX8_:+^#^OP6<\FJK)'!=3:5XQNX[>:2
M/]XD<K([)\RJ5YK\Z_\ AK[]DS_HZ']G;_P]GPU_^::ON\JQ%".7X92KT4U"
M5TZD$U^\ENG*_5?>NY_G-XS9+G.*\3>+*^&RG,\10J8O!NG6H8#%5:4TLKP,
M6X5*=*4))23BW%NS36Z9]$T5\[?\-??LF?\ 1T/[.W_A[/AK_P#--1_PU]^R
M9_T=#^SM_P"'L^&O_P TU>A]9PW_ $$4/_!M/_Y+S7WGYA_J]G__ $(\X_\
M#9C?_E!]$T5\[?\ #7W[)G_1T/[.W_A[/AK_ /--1_PU]^R9_P!'0_L[?^'L
M^&O_ ,TU'UG#?]!%#_P;3_\ DO-?>'^KV?\ _0CSC_PV8W_Y0?1-%?.W_#7W
M[)G_ $=#^SM_X>SX:_\ S34?\-??LF?]'0_L[?\ A[/AK_\ --1]9PW_ $$4
M/_!M/_Y+S7WA_J]G_P#T(\X_\-F-_P#E!]$T5\[?\-??LF?]'0_L[?\ A[/A
MK_\ --1_PU]^R9_T=#^SM_X>SX:__--1]9PW_010_P#!M/\ ^2\U]X?ZO9__
M -"/./\ PV8W_P"4'T317SM_PU]^R9_T=#^SM_X>SX:__--1_P -??LF?]'0
M_L[?^'L^&O\ \TU'UG#?]!%#_P &T_\ Y+S7WA_J]G__ $(\X_\ #9C?_E!]
M$T5\[?\ #7W[)G_1T/[.W_A[/AK_ /--1_PU]^R9_P!'0_L[?^'L^&O_ ,TU
M'UG#?]!%#_P;3_\ DO-?>'^KV?\ _0CSC_PV8W_Y0?1-%?.W_#7W[)G_ $=#
M^SM_X>SX:_\ S34?\-??LF?]'0_L[?\ A[/AK_\ --1]9PW_ $$4/_!M/_Y+
MS7WA_J]G_P#T(\X_\-F-_P#E!]$T5\[?\-??LF?]'0_L[?\ A[/AK_\ --1_
MPU]^R9_T=#^SM_X>SX:__--1]9PW_010_P#!M/\ ^2\U]X?ZO9__ -"/./\
MPV8W_P"4'T317SM_PU]^R9_T=#^SM_X>SX:__--1_P -??LF?]'0_L[?^'L^
M&O\ \TU'UG#?]!%#_P &T_\ Y+S7WA_J]G__ $(\X_\ #9C?_E!]$T5\[?\
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M+\%__+NCZSAO^@BA_P"#:?\ \EYK[P_U>S__ *$><?\ ALQO_P H/8**\?\
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MLP__ ,L/T5HK\ZO^&\_B;_TC;_;C_P#"P_X)T_\ T?U'_#>?Q-_Z1M_MQ_\
MA8?\$Z?_ */ZBTOY*G_@N?\ \CY_GV8?VKE?_0RP'_A9A_\ Y8?HK17YU?\
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MBBOF?_A;_P"TY_TC0_;*_P##C_\ !.3_ .CZH_X6_P#M.?\ 2-#]LK_PX_\
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MR^/?_2,3]N/_ ,+_ /X)K?\ TPNCF7][_P !E_EY_GV8'W'17PY_PUE\>_\
MI&)^W'_X7_\ P36_^F%T?\-9?'O_ *1B?MQ_^%__ ,$UO_IA=',O[W_@,O\
M+S_/LP/N.BOAS_AK+X]_](Q/VX__  O_ /@FM_\ 3"Z/^&LOCW_TC$_;C_\
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MQ/VX_P#PO_\ @FM_],+H_P"&LOCW_P!(Q/VX_P#PO_\ @FM_],+HYE_>_P#
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M *871_PUE\>_^D8G[<?_ (7_ /P36_\ IA=',O[W_@,O\O/\^S ^XZ*^'/\
MAK+X]_\ 2,3]N/\ \+__ ()K?_3"Z/\ AK+X]_\ 2,3]N/\ \+__ ()K?_3"
MZ.9?WO\ P&7^7G^?9@?<=%?#G_#67Q[_ .D8G[<?_A?_ /!-;_Z871_PUE\>
M_P#I&)^W'_X7_P#P36_^F%T<R_O?^ R_R\_S[,#[CHKX<_X:R^/?_2,3]N/_
M ,+_ /X)K?\ TPNC_AK+X]_](Q/VX_\ PO\ _@FM_P#3"Z.9?WO_  &7^7G^
M?9@?<=%?#G_#67Q[_P"D8G[<?_A?_P#!-;_Z871_PUE\>_\ I&)^W'_X7_\
MP36_^F%T<R_O?^ R_P O/\^S ^XZ*^'/^&LOCW_TC$_;C_\ "_\ ^":W_P!,
M+H_X:R^/?_2,3]N/_P +_P#X)K?_ $PNCF7][_P&7^7G^?9@?<=%?#G_  UE
M\>_^D8G[<?\ X7__  36_P#IA='_  UE\>_^D8G[<?\ X7__  36_P#IA=',
MO[W_ (#+_+S_ #[,#[CHKX<_X:R^/?\ TC$_;C_\+_\ X)K?_3"Z/^&LOCW_
M -(Q/VX__"__ .":W_TPNCF7][_P&7^7G^?9@?<=%?#G_#67Q[_Z1B?MQ_\
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M_A-B?_E7G^?9A_8>-_Y_Y/\ ^)#D'_SS/8**\?\ ^%E^-/\ HWKXP?\ @[^
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MUG]H/P[\3_VD?!EKX8T[X?\ A?PG\.O'7[2>D6OQ/\'>/?C#\/=(\83Z9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?RM?\%IO^3M_#W_9$O!W_J5>/J_(ROUS_P""TW_)
MV_A[_LB7@[_U*O'U?D97Z%EG^X83_KS']3_,/Q:_Y.5QG_V/,5_[8%%%%=Q^
M=A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-O\ H[K]A+_Q71^T!_\ 32:/^%??\%-O^CNOV$O_ !71^T!_]-)H^3_#_/\
MJS\KA]VU7>TM9+B&\DMK=[NV26*WNGAC:X@CGV>?'#.RF6))O+C\U$95DV)O
M#;5Q\-?\*^_X*;?]'=?L)?\ BNC]H#_Z:31_PK[_ (*;?]'=?L)?^*Z/V@/_
M *:31\G^'^?]6?E</N6XM+6\6-+NVM[I(IHKF)+B&.=8[BW<203QK*K!)H9
M'BE4!XW 9&5@#5BOA+_A7W_!3;_H[K]A+_Q71^T!_P#32:/^%??\%-O^CNOV
M$O\ Q71^T!_]-)H^3_#_ #_JS\KA]VT5\)?\*^_X*;?]'=?L)?\ BNC]H#_Z
M:31_PK[_ (*;?]'=?L)?^*Z/V@/_ *:31\G^'^?]6?E</NVBOA+_ (5]_P %
M-O\ H[K]A+_Q71^T!_\ 32:/^%??\%-O^CNOV$O_ !71^T!_]-)H^3_#_/\
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MJS\K_2'W'17PY_P@'_!2G_H[+]AS_P 5Z?'O_P"F=T?\(!_P4I_Z.R_8<_\
M%>GQ[_\ IG=%W_++_P E_P#DOZL_*X?<=%?#G_" ?\%*?^CLOV'/_%>GQ[_^
MF=T?\(!_P4I_Z.R_8<_\5Z?'O_Z9W1=_RR_\E_\ DOZL_*X?<=%?#G_" ?\
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M  4I_P"CLOV'/_%>GQ[_ /IG='_" ?\ !2G_ *.R_8<_\5Z?'O\ ^F=T7?\
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MI_Z.R_8<_P#%>GQ[_P#IG='_  @'_!2G_H[+]AS_ ,5Z?'O_ .F=T7?\LO\
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MH]K4_P"@:O\ ^!8;_P":/ZL_*Y_9F"_Z*')__!&?_P#SC/8**\?_ +$^/O\
MT4OX/_\ ACO&G_T0M']B?'W_ **7\'__  QWC3_Z(6CVM3_H&K_^!8;_ .:/
MZL_*Y_9F"_Z*')__  1G_P#\XSV"BO'_ .Q/C[_T4OX/_P#ACO&G_P!$+1_8
MGQ]_Z*7\'_\ PQWC3_Z(6CVM3_H&K_\ @6&_^:/ZL_*Y_9F"_P"BAR?_ ,$9
M_P#_ #C/8**\?_L3X^_]%+^#_P#X8[QI_P#1"T?V)\??^BE_!_\ \,=XT_\
MHA:/:U/^@:O_ .!8;_YH_JS\KG]F8+_HH<G_ /!&?_\ SC/8**\?_L3X^_\
M12_@_P#^&.\:?_1"T?V)\??^BE_!_P#\,=XT_P#HA:/:U/\ H&K_ /@6&_\
MFC^K/RN?V9@O^BAR?_P1G_\ \XSV"BO'_P"Q/C[_ -%+^#__ (8[QI_]$+1_
M8GQ]_P"BE_!__P ,=XT_^B%H]K4_Z!J__@6&_P#FC^K/RN?V9@O^BAR?_P $
M9_\ _.,]@HKQ_P#L3X^_]%+^#_\ X8[QI_\ 1"T?V)\??^BE_!__ ,,=XT_^
MB%H]K4_Z!J__ (%AO_FC^K/RN?V9@O\ HH<G_P#!&?\ _P XSV"BO'_[$^/O
M_12_@_\ ^&.\:?\ T0M']B?'W_HI?P?_ /#'>-/_ *(6CVM3_H&K_P#@6&_^
M:/ZL_*Y_9F"_Z*')_P#P1G__ ,XSV"BO'_[$^/O_ $4OX/\ _ACO&G_T0M%'
MM:G_ $#5_P#P+#?_ #1_5GY7/[,P7_10Y/\ ^",__P#G&?OIX*_:Z^+_ ,2=
M>_X**^(?B1_P7#\.?L,>,_V=_P#@H_\ M8? SX0?##XE^%?V-_$_@P_ GX8:
MQIH\%(_PQ\>^$_#GQ8\837-QK&K^%++7]-\;7EQ>+X8:&SM+_P 2VMY>CZ7\
M(_\ !2W]HRXU[_@BI\5?VDM4TO\ 9Q\#?M(_LZ_\%"_C9^V)X(B\-C3O"5QH
M'P"^#OA3QU\/_&LD?B6T\1>.O#&BV.AS7'Q'L-+TG7!>36?B%=/U"37(8+2.
ML_X ? ?]HWX!VW_!2OX<?&+_ ()->)?VP?"?[2G_  4;_:Y_:B^%\UU\1/V#
MM0^&7C+X;_$Z_P##*?#:U\3V/Q@^/MAXK\-RZA/X5?6;N*^^'=_J/ANRU>TN
M3I,VN07FD0?/FD_\$S?^"F?PM^#W_!,6R^$YT6P^./[-'P#_ ."KAU#7W\:^
M$=<\*_LR^/OVHOAMI4G[-OPA\.77BWQ6/$/B^P\-ZPO_  @>C>*;3_A8^@>#
M-8TL:QK4VH?#_3]&L;_\E/\ 6@_8?X&?\%:O@+\</C1\*/@Q)\'/VM/@U)^T
M/I/B37/V9_B;\=O@/J7P_P#A-^T7IWAG0)_&-S)\,O$Z:UK.I6\NH>!;6Y\<
M:/;?$'P_X%N;_P .+9NL4>J:WX>TS5OC/_@II_P60T/X8?L_?M@Z!^S+X6_:
MA/CGX1:9XC^'^G?MA^#/V?[GQ9^RO\/?CKH%\EEJ'@75?BEK$.JZ'<>(=*UN
MTN? VJ73>#]:\':/XUOM/\/ZUKEA=WEN]?,7PE_8@_:M/[9O_!.']HD_LB_M
M=VUQ^SYXNURP_:K^+?[8/[=?@;]H#XG:YJ/Q+^$?C#P1J.J_"[PX/VA/&7@2
M/X-?"KQ'JEUJ.LZOX4\/>!?'OCFU\0^'HO"OPOO+?0]96U[#X[_L^_\ !1;P
M)^Q9^W+_ ,$V/@G^Q&OQMT;XO_$[]HC7O@3^T5/\9_@KI/PWN/@S^T-X_P#$
M/QHUFS\::'\2?B-I7Q'M/CAX'U;QAJOPZ\,B7P]!X<U3Q)!I7CZ3Q38Z3H4]
MYK0!]_?M3_\ !5GX<_!#2OB;\+_"_@#]IWXL?$WX<_!J#7?BO\5/@-\!]5^*
M/PJ_9G\3>+/ 47B#PGJ?QO\ %=FZ:?X?N+>RU72/'FJ:-HVB>+K_ $CP9*?$
M6KZ+#I$5P4\U^"__  5L\+> /V4_V&-.^)_A3]I/]KK]L/XW?L>?"/\ :&\;
M_"[]EGX'R?%+XI-X.UWPO#%XD^-7BS1-$;P=X(\+^$KSQC:7FAP6\&J66JZI
MX@O;/2O"_A?4#*L<7,:W\.?VZOV4_&G[>'@SX$?L<+^T[X0_;7M_"_Q2^%GC
MD?%GX3^'O"_PO^,VO? SP9\#?B5X(_:"T/XG^.M'U^_^'^BR?#VS^(6C7?P\
MT+Q5::UHVKCX?VT=O=3B;0/A[P1_P3P_;#^ /C/]D?XB:Y^SU^U)\6/!\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _E:_P""TW_)V_A[_LB7@[_U
M*O'U?D97ZY_\%IO^3M_#W_9$O!W_ *E7CZOR,K]"RS_<,)_UYC^I_F'XM?\
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MW_\  ]?Z>@?>-%?"7_#K;_@F3_TCH_82_P#$1?V?_P#YWU'_  ZV_P""9/\
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M]GX  <DDGX?8  Y)/2C7R^__ ('K_3T#[NHKX-M_^"7W_!,*Z@BN;7_@G?\
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MA+_Q$7]G_P#^=]1KY??_ ,#U_IZ!]VT5\)?\.MO^"9/_ $CH_82_\1%_9_\
M_G?4?\.MO^"9/_2.C]A+_P 1%_9__P#G?4:^7W_\#U_IZ!]VT5\)?\.MO^"9
M/_2.C]A+_P 1%_9__P#G?4?\.MO^"9/_ $CH_82_\1%_9_\ _G?4:^7W_P#
M]?Z>@?=M%?"7_#K;_@F3_P!(Z/V$O_$1?V?_ /YWU'_#K;_@F3_TCH_82_\
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MPCUZPAOXO%?@JVBO8;/5/"%U;QW<=O=74$=RD:S)#<W$2N$FD5OV*_X=B?\
M!-;_ *1Z?L.?^(F_ 3_Y@*\',,/4PN)=*;A)J$)7BY6]Y;:Q3TU_IZ?TYX5<
M1X7BKA*CFV#H8C#49X_&T%2Q/L_:J5"<(R;]E.I#E;=U[U^Z1]QT5\.?\.Q/
M^":W_2/3]AS_ ,1-^ G_ ,P%'_#L3_@FM_TCT_8<_P#$3?@)_P#,!7%[W:/_
M ($__D?7^GI^D'W'17PY_P .Q/\ @FM_TCT_8<_\1-^ G_S 4?\ #L3_ ()K
M?](]/V'/_$3?@)_\P%'O=H_^!/\ ^1]?Z>@?<=%?#G_#L3_@FM_TCT_8<_\
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MAS_Q$WX"?_,!1[W:/_@3_P#D?7^GH'W'17PY_P .Q/\ @FM_TCT_8<_\1-^
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M1_P[$_X)K?\ 2/3]AS_Q$WX"?_,!1[W:/_@3_P#D?7^GH'W'17PY_P .Q/\
M@FM_TCT_8<_\1-^ G_S 4?\ #L3_ ()K?](]/V'/_$3?@)_\P%'O=H_^!/\
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MT5\.?\.Q/^":W_2/3]AS_P 1-^ G_P P%'_#L3_@FM_TCT_8<_\ $3?@)_\
M,!1[W:/_ ($__D?7^GH'X>_\%IO^3M_#W_9$O!W_ *E7CZOR,K[E_P""N/['
M/[(OPV_:@T+P_P##K]EC]G'P#H,WP@\*:G+HG@KX'_#+PMI$NI7/B7QM!<:A
M)INA>&+"S>^G@M+6&:[:$SRQ6UO&\C)#&J_EU_PSU\ O^B'?!_\ \-IX+_\
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MG_GU0_\ "BI_\S>O]/0]AD'_ $,\X_\ #'@O_HA/8**\?_X9Z^ 7_1#O@_\
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M;M[WP%\1--T^V\6:%HNLWK^*?"46J/X5\2/=ZKHUQJ5[\?7_ /P3Q^/?@O\
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^WO_AXO^S_ /\
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M $M0^$O^'B_[/_\ T3[]NW_Q5M_P4V_^A%H_X>+_ +/_ /T3[]NW_P 5;?\
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M\ON_X/K_ $M0_'K]L/\ ;:^%7Q._9R^(O@?P1\*OVZ]9\4:W_P (C_9FFO\
M\$Q_^"D.DK<_V;XZ\,:O>YU#6OV4M.TRW\G3]/N[@?:;R'S3$((?,N)(HG_#
M7_A)/%G_ $;?^W'_ .*^OVY/_H>J_L[UK_D&7/\ VQ_]*(JX.O=RS-<5@:$Z
M-&-"495I5&ZL*DI<SA3BTG"M!6M!65F[MZO8_)>//!KACQ#SC#9UG6/S["XK
M"Y;1RNG3RO%9?0P[P]#%8S%PG.&+RO&U'6=3&U8RE&K&#A&FE34E*4_Y /\
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MZ_TM3_B5[@#_ *&_&'_APR7_ .A\_D _X23Q9_T;?^W'_P"*^OVY/_H>J/\
MA)/%G_1M_P"W'_XKZ_;D_P#H>J_K_HH_UAQ__/O!_P#@JM_\T^O]+4_XE>X
M_P"AOQA_X<,E_P#H?/Y /^$D\6?]&W_MQ_\ BOK]N3_Z'JC_ (23Q9_T;?\
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MQ_\ BOK]N3_Z'JC_ (23Q9_T;?\ MQ_^*^OVY/\ Z'JOZ_Z*/]8<?_S[P?\
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M*^OVY/\ Z'JOZ_Z*/]8<?_S[P?\ X*K?_-/K_2U/^)7N /\ H;\8?^'#)?\
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M7_T.-?RFT4?ZN4O^@JI_X+C_ /)>O]+4_P")I\__ .B5R?\ \+<;_D?U9?\
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ME<G_ /"W&_Y']67_  _!_P"";/\ T5SXP?\ B%?[<7_T.-'_  _!_P"";/\
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M,'_B%?[<7_T.-'_#\'_@FS_T5SXP?^(5_MQ?_0XU_*;11_JY2_Z"JG_@N/\
M\EZ_TM3_ (FGS_\ Z)7)_P#PMQO^1_7-X/\ ^"O'[#OQ".H+X!U[]I3QPVD"
MU.JCP?\ L!?M_>)CI@OC<"R.H#1?V8KTV0O#9W8M3<^4+@VMQY._R)=O;?\
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M/7Q^_P#G:5[!11RXG_G[0_\ ">I_\T^O]+4]OD'_ $+,X_\ #Y@O_H>/'_\
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ME9ZA<R:A?237+O>7#2?*W[7_ /P3,^%?[0'PQ_8Y^!GPU\"? [X8_ K]FO\
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M\-)?\%"/^C0/V-?_ !8'\;?_ *6K7LU%'L(_S3^^/_R/]7?E8_ULSC^?#_\
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MV_\ TM6O9J*/81_FG]\?_D?ZN_*Q_K9G'\^'_P#!$?\ /^KORMXS_P -)?\
M!0C_ *- _8U_\6!_&W_Z6K1_PTE_P4(_Z- _8U_\6!_&W_Z6K7LU%'L(_P T
M_OC_ /(_U=^5C_6S./Y\/_X(C_G_ %=^5O&?^&DO^"A'_1H'[&O_ (L#^-O_
M -+5H_X:2_X*$?\ 1H'[&O\ XL#^-O\ ]+5KV:BCV$?YI_?'_P"1_J[\K'^M
MF<?SX?\ \$1_S_J[\K>,_P##27_!0C_HT#]C7_Q8'\;?_I:M'_#27_!0C_HT
M#]C7_P 6!_&W_P"EJU[-11["/\T_OC_\C_5WY6/];,X_GP__ ((C_G_5WY6_
M%W_@K#\9?VU/&7[.O@S2_'7[-G[+O@_2(/C3X=O[?4_"?[9GQ8\>ZC/J,7@;
MXC6\-C/H^L?L)_#JVMK*6VNKRXDU*/6[J>&>UMK5=*GCO);NQ_GQ_MOX^_\
M1-/@_P#^'Q\:?_0]5_3E_P %8_\ DW3P7_V6KPY_Z@WQ'K^>VOK,GHR6"CRU
MZL%[2I[J5%K=7=Y49/7UZZ6TM_('C-G<<5QOB*N.RG+,=7_L[+XNO6EFM*;C
M&G+EBX8/-,+0M'6S5)2=_>DSQ_\ MOX^_P#1-/@__P"'Q\:?_0]4?VW\??\
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M?E;XU_X3C_@H1_T;!^QK_P")W?&W_P"EST?\)Q_P4(_Z-@_8U_\ $[OC;_\
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M#_H+G_X)PW_RC^KORL?\0P\/O^B7P_\ X=N(_P#Y]?U=^5OPQ_X9+_X*$?\
M1,_V-?\ Q+;XV_\ T"U'_#)?_!0C_HF?[&O_ (EM\;?_ *!:OW.HH_M/,/\
MH+G_ ."<-_\ */ZN_*Q_Q##P^_Z)?#_^';B/_P"?7]7?E;^/G]L+PA^U=\+/
MBI8>&_''PS_9Y_MB?P;I.JQ_\(I^T3\2-<TS[#=:GKEO!OO-7_96\+W2W?G6
M=QYL"Z:\*1^2Z74K2/'#\J_VW\??^B:?!_\ \/CXT_\ H>J_8S_@JK_R<IHG
M_9)_"_\ ZD7C*OS3KZ3"JM5P]&I/$UG*<(RE:&&2N]]/J^G_  7Y6_FKBN64
MY1Q'G&68/AW*HX7!8VI0H*IB>(*DU3A:W--YXG)ZZNQX_P#VW\??^B:?!_\
M\/CXT_\ H>J/[;^/O_1-/@__ .'Q\:?_ $/5>P45T>RJ?]!-?_P'#?\ S/\
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M/!?]$]D__@_/_P#Y^'C_ /;?Q]_Z)I\'_P#P^/C3_P"AZH_MOX^_]$T^#_\
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M_P"&^_X)D_\ TNBOE9?^"O,?PL\'_M"67[9/[*_Q(_9H_:*^ 7@_X:^/[?\
M9\T3QSX'^.MS\:_"7QK^(]S\&_A%JGP2\?>#)-)TWQ-_PD_Q:MX? VM0:]H?
MA9O!VH:C876L,UI'JSZ3Z=X+_P""C/CWPOHGQUU/]M7]BKXV_L>GX'? 'Q#^
MT[=ZTVN^%/CS\,?%OPI\,"Z76M'T;XM?#1D\':?\:]+N+46][\&=<N-/\0W,
M5Q!K/AZ]\0>&G_MP%O7[W_73\^[ ];_X9%_: _Z2D_MV_P#AOO\ @F3_ /2Z
M*/\ AD7]H#_I*3^W;_X;[_@F3_\ 2Z*^:_@[_P %0/BOKOQ.^ ^@?M-?L'?%
M']DKX/\ [7'B)/"?[+7QD\7_ !;^%GCNY\5>*]9\-^(/'/@7P7\9?ACX6N8/
M%7P,\;>._!?AR[O](T"ZN/&L5IX@N+?PIJ6IVVH6^KS:7^37_!-SX\?''Q?_
M ,0V_P#PEGQE^*WBC_A;WP[_ ."L]W\6?^$B^(GB_6_^%H77@7R?^$(N?B)_
M:6L7/_":W'@[)_X16;Q+_:<GA[)_LAK/-%O7[W_73\^[ _?G_AD7]H#_ *2D
M_MV_^&^_X)D__2Z*/^&1?V@/^DI/[=O_ (;[_@F3_P#2Z*^<? 7_  5BTGQS
M^P9^R+^W&GP.U'3;']J[X_?"[X$VGPW?X@6UW=^")_B9\>-9^!\7B:X\4CP?
M;P^((='GTAO$DFDQZ!H[WT4XTM=0M'C-^_S=^QO^UU\9_AM\*O\ @H5XDL_A
M;^T+^V9\1G_X+4?MG?L__!OX;>%+_5/$"^&=*3Q-I(\':7XK\?>*+B_\-? 7
M]GWP3!:74.I^,-:-OX,\#0WUK;66E3W6I6UC<%O7[W_73\^[ _1__AD7]H#_
M *2D_MV_^&^_X)D__2Z*/^&1?V@/^DI/[=O_ (;[_@F3_P#2Z*_/;4_^"Y:_
M#OX*_MP^-?CC^RAJO@7XP_L&ZW^SHGQ0^$G@3X^?#KXT^%O%'A#]I#XH:)\-
M/#>N>"/B]X-TB&RF\3>'IKO6]5\1^!/$/@W0-0LWL-%T:34H=0UC5CX5_6S]
ME_XF_'CXM?#(^+?VBOV:+W]E#X@-XAU33X?A7J'Q;\"?&BZ;PY;P6$VD>)9O
M%_P\1- @EU9KJ[MI]!8-?:7<:=+YTL\%Q;3R%O7[W_73\^[ \<_X9%_: _Z2
MD_MV_P#AOO\ @F3_ /2Z*/\ AD7]H#_I*3^W;_X;[_@F3_\ 2Z*^[:*+>OWO
M^NGY]V!\)?\ #(O[0'_24G]NW_PWW_!,G_Z711_PR+^T!_TE)_;M_P##??\
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M _\ S*0?\)W^V%_T?S^T3_X;+]AK_P"@]H_X3O\ ;"_Z/Y_:)_\ #9?L-?\
MT'M3T4?V9@?^@>/_ ('4_P#D_+\^[#_B)7''_108G_P1@?\ YE(/^$[_ &PO
M^C^?VB?_  V7[#7_ -![1_PG?[87_1_/[1/_ (;+]AK_ .@]J>BC^S,#_P!
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M^?VB?_#9?L-?_0>T?\)W^V%_T?S^T3_X;+]AK_Z#VIZ*/[,P/_0/'_P.I_\
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M_P"!U/\ Y/R_/NP_XB5QQ_T4&)_\$8'_ .93U+X-_LQ_$W]O#Q/?_"']H/\
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MMQ_^##]CO_Z#>C_B']^!'_1XO[<?_@P_8[_^@WK]Z:*/KF,_Z#,9_P"%5?\
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M23]N/_PC_P#@G3_] #7Z*T47E_/4_P#!D_\ Y+R_/NP_LK*_^A;@/_"/#_\
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MCP__ ,K/SJ_X8,^)O_223]N/_P (_P#X)T__ $ -'_#!GQ-_Z22?MQ_^$?\
M\$Z?_H :_16BB\OYZG_@R?\ \EY?GW8?V5E?_0MP'_A'A_\ Y6?G5_PP9\3?
M^DDG[<?_ (1__!.G_P"@!H_X8,^)O_223]N/_P (_P#X)T__ $ -?HK11>7\
M]3_P9/\ ^2\OS[L/[*RO_H6X#_PCP_\ \K/SJ_X8,^)O_223]N/_ ,(__@G3
M_P#0 T?\,&?$W_I))^W'_P"$?_P3I_\ H :_16BB\OYZG_@R?_R7E^?=A_96
M5_\ 0MP'_A'A_P#Y6?G5_P ,&?$W_I))^W'_ .$?_P $Z?\ Z &C_A@SXF_]
M))/VX_\ PC_^"=/_ - #7Z*T47E_/4_\&3_^2\OS[L/[*RO_ *%N _\ "/#_
M /RL_.K_ (8,^)O_ $DD_;C_ /"/_P""=/\ ] #1_P ,&?$W_I))^W'_ .$?
M_P $Z?\ Z &OT5HHO+^>I_X,G_\ )>7Y]V']E97_ -"W ?\ A'A__E9^=7_#
M!GQ-_P"DDG[<?_A'_P#!.G_Z &C_ (8,^)O_ $DD_;C_ /"/_P""=/\ ] #7
MZ*T47E_/4_\ !D__ )+R_/NP_LK*_P#H6X#_ ,(\/_\ *S\ZO^&#/B;_ -))
M/VX__"/_ ."=/_T -'_#!GQ-_P"DDG[<?_A'_P#!.G_Z &OT5HHO+^>I_P"#
M)_\ R7E^?=A_965_]"W ?^$>'_\ E9_%U_P5=_9X\>_#S]IC0]"NOVOOVCOB
M!)+\)?"^HC7/&OAW]DRVU>)+CQ'XS@&G1Q^ OV7/ VB&Q@-J9H6ET:74#+<W
M GOYX1;0V_YF?\*T\:?]'"_&#_P2? +_ .<=7[I_\%IO^3M_#W_9$O!W_J5>
M/J_(ROO,NHPE@<+)RK7=&+=L1B$ON55);=%W[L_SC\4<TKX3Q"XNPV'PV4PH
MT,YQ-.G&60Y)5E&*Y;)U*V7U*LW_ 'ISE)]6>/\ _"M/&G_1POQ@_P#!)\ O
M_G'4?\*T\:?]'"_&#_P2? +_ .<=7L%%=OU>G_-7_P#"G$__ "WR_/NSX+^W
M,;_SXR?_ ,1[(/\ YV'C_P#PK3QI_P!'"_&#_P $GP"_^<=1_P *T\:?]'"_
M&#_P2? +_P"<=7L%%'U>G_-7_P#"G$__ "WR_/NP_MS&_P#/C)__ !'L@_\
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M/_\ "M/&G_1POQ@_\$GP"_\ G'45[!11]7I_S5__  IQ/_RWR_/NP_MS&_\
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MAWXTT:#PW>6.D1^!?A9X=U35]&.C:AJ#^*]5U#Q%IEAJ<W[$T4 ?SA_LB_\
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M /D?)?<'^L.?_P#0\SC_ ,.>-_\ EY\[?\,@_LF?]&O?L[?^&3^&O_S,T?\
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MOLJBCV</Y(?^ K_+R7W!]:Q7_03B/_!U3_Y+R7W'QK_P[G_X)[_]&(_L:_\
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M!5)6C%;;12Z+R/UGA^4IY/@93E*<G3G>4FY2=JU1*[;;>B2UZ'PY_P .Q/\
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M_!-;_I'I^PY_XB;\!/\ Y@*/^'8G_!-;_I'I^PY_XB;\!/\ Y@*^XZ*.6/\
M+'[E_71?<!\.?\.Q/^":W_2/3]AS_P 1-^ G_P P%'_#L3_@FM_TCT_8<_\
M$3?@)_\ ,!7W'11RQ_EC]R_KHON ^'/^'8G_  36_P"D>G[#G_B)OP$_^8"C
M_AV)_P $UO\ I'I^PY_XB;\!/_F K[CHHY8_RQ^Y?UT7W ?#G_#L3_@FM_TC
MT_8<_P#$3?@)_P#,!1_P[$_X)K?](]/V'/\ Q$WX"?\ S 5]QT4<L?Y8_<OZ
MZ+[@/XS/^"N/['/[(OPV_:@T+P_\.OV6/V<? .@S?"#PIJ<NB>"O@?\ #+PM
MI$NI7/B7QM!<:A)INA>&+"S>^G@M+6&:[:$SRQ6UO&\C)#&J_EU_PSU\ O\
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M +_HAWP?_P##:>"__E)7L%%'U;#?] ]#_P %4_\ Y'R7W!_K#G__ $/,X_\
M#GC?_EYX_P#\,]? +_HAWP?_ /#:>"__ )24?\,]? +_ *(=\'__  VG@O\
M^4E>P44?5L-_T#T/_!5/_P"1\E]P?ZPY_P#]#S./_#GC?_EYX_\ \,]? +_H
MAWP?_P##:>"__E)1_P ,]? +_HAWP?\ _#:>"_\ Y25[!11]6PW_ $#T/_!5
M/_Y'R7W!_K#G_P#T/,X_\.>-_P#EYX__ ,,]? +_ *(=\'__  VG@O\ ^4E'
M_#/7P"_Z(=\'_P#PVG@O_P"4E>P44?5L-_T#T/\ P53_ /D?)?<'^L.?_P#0
M\SC_ ,.>-_\ EYX__P ,]? +_HAWP?\ _#:>"_\ Y24?\,]? +_HAWP?_P##
M:>"__E)7L%%'U;#?] ]#_P %4_\ Y'R7W!_K#G__ $/,X_\ #GC?_EYX_P#\
M,]? +_HAWP?_ /#:>"__ )24?\,]? +_ *(=\'__  VG@O\ ^4E>P44?5L-_
MT#T/_!5/_P"1\E]P?ZPY_P#]#S./_#GC?_EYX_\ \,]? +_HAWP?_P##:>"_
M_E)1_P ,]? +_HAWP?\ _#:>"_\ Y25[!11]6PW_ $#T/_!5/_Y'R7W!_K#G
M_P#T/,X_\.>-_P#EYX__ ,,]? +_ *(=\'__  VG@O\ ^4E'_#/7P"_Z(=\'
M_P#PVG@O_P"4E>P44?5L-_T#T/\ P53_ /D?)?<'^L.?_P#0\SC_ ,.>-_\
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M]NW_ ,.#_P $R?\ Z8O1_P -=?M ?](MOV[?_#@_\$R?_IB]%_7[G_77\^S
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M"M_P2Z_;KB!\K+O\0?\ @F:57$\9Y$?_  44D?DC VH>2,X&2.*_X:R^/?\
MTC$_;C_\+_\ X)K?_3"ZZJ+7*]_B?V9/I'LO/^K,#[CHKX<_X:R^/?\ TC$_
M;C_\+_\ X)K?_3"Z/^&LOCW_ -(Q/VX__"__ .":W_TPNMN9?WO_  &7^7G^
M?9@?<=%?#G_#67Q[_P"D8G[<?_A?_P#!-;_Z871_PUE\>_\ I&)^W'_X7_\
MP36_^F%T<R_O?^ R_P O/\^S ^XZ*^'/^&LOCW_TC$_;C_\ "_\ ^":W_P!,
M+H_X:R^/?_2,3]N/_P +_P#X)K?_ $PNCF7][_P&7^7G^?9@?<=%?#G_  UE
M\>_^D8G[<?\ X7__  36_P#IA='_  UE\>_^D8G[<?\ X7__  36_P#IA=',
MO[W_ (#+_+S_ #[,#[CHKX<_X:R^/?\ TC$_;C_\+_\ X)K?_3"Z/^&LOCW_
M -(Q/VX__"__ .":W_TPNCF7][_P&7^7G^?9@?<=%?#G_#67Q[_Z1B?MQ_\
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M9A_Q"#Q,_P"B-SC_ ,%TO_EQRE%=7_PH3]O#_I'A^T3_ .'<_8'_ /HSZ/\
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M?9A_K+PQ_P!%3PM_XDF1_P#S?Y_GV9^IE%?EG_P]%M/^C(?VRO\ P8_L4_\
MT9E'_#T6T_Z,A_;*_P#!C^Q3_P#1F4?5\3_T"XO_ ,)<1_\ *_/\^S#_ %EX
M8_Z*GA;_ ,23(_\ YO\ /\^S/U,HK\L_^'HMI_T9#^V5_P"#']BG_P"C,H_X
M>BVG_1D/[97_ (,?V*?_ *,RCZOB?^@7%_\ A+B/_E?G^?9A_K+PQ_T5/"W_
M (DF1_\ S?Y_GV9^IE%?EG_P]%M/^C(?VRO_  8_L4__ $9E'_#T6T_Z,A_;
M*_\ !C^Q3_\ 1F4?5\3_ - N+_\ "7$?_*_/\^S#_67AC_HJ>%O_ !),C_\
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M+PQ_T5/"W_B29'_\W^?Y]F?J917Y9_\ #T6T_P"C(?VRO_!C^Q3_ /1F4?\
M#T6T_P"C(?VRO_!C^Q3_ /1F4?5\3_T"XO\ \)<1_P#*_/\ /LP_UEX8_P"B
MIX6_\23(_P#YO\_S[,_4RBORS_X>BVG_ $9#^V5_X,?V*?\ Z,RC_AZ+:?\
M1D/[97_@Q_8I_P#HS*/J^)_Z!<7_ .$N(_\ E?G^?9A_K+PQ_P!%3PM_XDF1
M_P#S?Y_GV9^IE%?EG_P]%M/^C(?VRO\ P8_L4_\ T9E'_#T6T_Z,A_;*_P#!
MC^Q3_P#1F4?5\3_T"XO_ ,)<1_\ *_/\^S#_ %EX8_Z*GA;_ ,23(_\ YO\
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M_"__ .":W_TPNLN9?WO_  &7^7G^?9GOGW'17PY_PUE\>_\ I&)^W'_X7_\
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MEY_GV8'W'17PY_PUE\>_^D8G[<?_ (7_ /P36_\ IA='_#67Q[_Z1B?MQ_\
MA?\ _!-;_P"F%T<R_O?^ R_R\_S[,#[CHKX<_P"&LOCW_P!(Q/VX_P#PO_\
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M<85,ZQ,HJMG>2X>JD^72=&OF%.M3EWC4IPDNJ1[!17C_ /PLOQI_T;U\8/\
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M $;U\8/_  =_ +_Y^-'_  LOQI_T;U\8/_!W\ O_ )^-'UBG_+7_ /";$_\
MRKS_ #[,/[#QO_/_ "?_ ,2'(/\ YYGL%%>/_P#"R_&G_1O7Q@_\'?P"_P#G
MXT?\++\:?]&]?&#_ ,'?P"_^?C1]8I_RU_\ PFQ/_P J\_S[,/[#QO\ S_R?
M_P 2'(/_ )YGL%%>/_\ "R_&G_1O7Q@_\'?P"_\ GXT?\++\:?\ 1O7Q@_\
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M  4I_P"CLOV'/_%>GQ[_ /IG='_" ?\ !2G_ *.R_8<_\5Z?'O\ ^F=T7?\
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M]AS_ ,0)^/?_ -,IH_MS_@I3_P!')_L.?^($_'O_ .F4T>SJ_P#/N7_@5/\
M^3_JS\KG^L^1_P#0=_Y;8S_YG/U'HK\N/[<_X*4_]')_L.?^($_'O_Z931_;
MG_!2G_HY/]AS_P 0)^/?_P!,IH]G5_Y]R_\  J?_ ,G_ %9^5S_6?(_^@[_R
MVQG_ ,SGZCT5^7']N?\ !2G_ *.3_8<_\0)^/?\ ],IH_MS_ (*4_P#1R?[#
MG_B!/Q[_ /IE-'LZO_/N7_@5/_Y/^K/RN?ZSY'_T'?\ EMC/_F<_4>BORX_M
MS_@I3_T<G^PY_P"($_'O_P"F4T?VY_P4I_Z.3_8<_P#$"?CW_P#3*:/9U?\
MGW+_ ,"I_P#R?]6?E<_UGR/_ *#O_+;&?_,Y^H]%?EQ_;G_!2G_HY/\ 8<_\
M0)^/?_TRFC^W/^"E/_1R?[#G_B!/Q[_^F4T>SJ_\^Y?^!4__ )/^K/RN?ZSY
M'_T'?^6V,_\ F<_4>BORX_MS_@I3_P!')_L.?^($_'O_ .F4T?VY_P %*?\
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M/Q*_^C_H_M_ ?]/_ /P6O_D_ZL_*Y_Q+CXF?] N3_P#AVI?_ "L^(**^W_\
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MB?'W_HI?P?\ _#'>-/\ Z(6C^Q/C[_T4OX/_ /ACO&G_ -$+1[6I_P! U?\
M\"PW_P T?U9^5S^S,%_T4.3_ /@C/_\ YQGL%%>/_P!B?'W_ **7\'__  QW
MC3_Z(6C^Q/C[_P!%+^#_ /X8[QI_]$+1[6I_T#5__ L-_P#-']6?E<_LS!?]
M%#D__@C/_P#YQGL%%>/_ -B?'W_HI?P?_P##'>-/_HA:/[$^/O\ T4OX/_\
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M?] U?_P+#?\ S1_5GY7/[,P7_10Y/_X(S_\ ^<9[!17C_P#8GQ]_Z*7\'_\
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M_!,G]GKXP?L]6'[>4'Q@\(?\(A+\:/\ @IO^V)^T+\-%_M_POK__  DGP?\
MBIXE\/:AX#\7[O"^M:TNC_V[9V-U-_8&OG2O%&E^5Y>LZ+ITKQHX!^FU%%%
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ME]__  /7^GH'W;17PE_P[H_9_P#^B@_MV_\ BTG_ (*;?_1=4?\ #NC]G_\
MZ*#^W;_XM)_X*;?_ $75&OE]_P#P/7^GH'W;17PE_P .Z/V?_P#HH/[=O_BT
MG_@IM_\ 1=4?\.Z/V?\ _HH/[=O_ (M)_P""FW_T75&OE]__  /7^GH'W;17
MPE_P[H_9_P#^B@_MV_\ BTG_ (*;?_1=4?\ #NC]G_\ Z*#^W;_XM)_X*;?_
M $75&OE]_P#P/7^GH'W;17PE_P .Z/V?_P#HH/[=O_BTG_@IM_\ 1=4?\.Z/
MV?\ _HH/[=O_ (M)_P""FW_T75&OE]__  /7^GH'W;17PE_P[H_9_P#^B@_M
MV_\ BTG_ (*;?_1=4?\ #NC]G_\ Z*#^W;_XM)_X*;?_ $75&OE]_P#P/7^G
MH'W;17PE_P .Z/V?_P#HH/[=O_BTG_@IM_\ 1=4?\.Z/V?\ _HH/[=O_ (M)
M_P""FW_T75&OE]__  /7^GH'VSK7_(,N?^V/_I1%7!U^97[8?[$OPJ^&/[.7
MQ%\<>"/BK^W7HWBC1/\ A$?[,U)_^"G'_!2'5EMO[2\=>&-(O<Z?K7[5NHZ9
M<>=I^H7=N/M-G-Y1E$\/EW$<4J?AK_PC?BS_ *.0_;C_ /%@O[<G_P!$+7NY
M9E6*QU"=:C*A&,:TJ;56=2,N90IR;2A1FK6FK.Z=T]%N?DO'GC+PQX>9QALE
MSK 9]BL5BLMHYI3J97A<OKX=8>OBL9A(0G/%YI@JBK*I@JLI1C2E!0E3:J.3
ME&']?]%?R ?\(WXL_P"CD/VX_P#Q8+^W)_\ 1"T?\(WXL_Z.0_;C_P#%@O[<
MG_T0M>C_ *O8_P#Y^8/_ ,&UO_F;U_IZ?$_\30\ ?]"CC#_PWY+_ /1 ?U_T
M5_(!_P (WXL_Z.0_;C_\6"_MR?\ T0M'_"-^+/\ HY#]N/\ \6"_MR?_ $0M
M'^KV/_Y^8/\ \&UO_F;U_IZ'_$T/ '_0HXP_\-^2_P#T0']?]%?R ?\ "-^+
M/^CD/VX__%@O[<G_ -$+1_PC?BS_ *.0_;C_ /%@O[<G_P!$+1_J]C_^?F#_
M /!M;_YF]?Z>A_Q-#P!_T*.,/_#?DO\ ]$!_7_17\@'_  C?BS_HY#]N/_Q8
M+^W)_P#1"T?\(WXL_P"CD/VX_P#Q8+^W)_\ 1"T?ZO8__GY@_P#P;6_^9O7^
MGH?\30\ ?]"CC#_PWY+_ /1 ?U_T5_(!_P (WXL_Z.0_;C_\6"_MR?\ T0M'
M_"-^+/\ HY#]N/\ \6"_MR?_ $0M'^KV/_Y^8/\ \&UO_F;U_IZ'_$T/ '_0
MHXP_\-^2_P#T0']?]%?R ?\ "-^+/^CD/VX__%@O[<G_ -$+1_PC?BS_ *.0
M_;C_ /%@O[<G_P!$+1_J]C_^?F#_ /!M;_YF]?Z>A_Q-#P!_T*.,/_#?DO\
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M $5E'_#M']F/_H8?VRO_ !9/_P %&_\ Z*RCV[_D7_@7_P!KZ_T]#_4O%?\
M0;A__!=3^N_]/3M**XO_ (=H_LQ_]##^V5_XLG_X*-__ $5E'_#M']F/_H8?
MVRO_ !9/_P %&_\ Z*RCV[_D7_@7_P!KZ_T]#_4O%?\ 0;A__!=3^N_]/3M*
M*XO_ (=H_LQ_]##^V5_XLG_X*-__ $5E'_#M']F/_H8?VRO_ !9/_P %&_\
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M@)_T/_[<?_BSO_@I3_\ 194>]VC_ .!/_P"1]?Z>@?<=%?#G_#O3X"?]#_\
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M'17PY_P[T^ G_0__ +<?_BSO_@I3_P#194?\.]/@)_T/_P"W'_XL[_X*4_\
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MQT5\.?\ #O3X"?\ 0_\ [<?_ (L[_P""E/\ ]%E1_P .]/@)_P!#_P#MQ_\
MBSO_ (*4_P#T65'O=H_^!/\ ^1]?Z>@?<=%?#G_#O3X"?]#_ /MQ_P#BSO\
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M_GU0_P#"BI_\S>O]/0]AD'_0SSC_ ,,>"_\ HA/8**\?_P"%'>"_^@W\8/\
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M&/!?_1">P45X_P#\*.\%_P#0;^,'_B0OQ^_^>71_PH[P7_T&_C!_XD+\?O\
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MB1\0/A=K/C7]GE]2T+5+JS\4^(_ T-CI<B6%[I_@VT\3MK<^K:UX?][^'/\
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M7_A5WQ7^('Q._P"$#_X1/_A9=W_P@W]N?\)U_8?_  E'_"3>,/[,_LK^TO\
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MK]PJ^(S[_D82_P"O5+\F?Z$?1Q_Y-GA?^QQFW_IZF%%%%>,?O 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?RM?\%IO^
M3M_#W_9$O!W_ *E7CZOR,K]<_P#@M-_R=OX>_P"R)>#O_4J\?5^1E?H66?[A
MA/\ KS']3_,/Q:_Y.5QG_P!CS%?^V!1117<?G84444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '^C11117X^?[ !1110 4444
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MDJ<6G>32_DR_X49\;?\ HCOQ3_\ #?>+?_E11_PHSXV_]$=^*?\ X;[Q;_\
M*BOZS:*]#_6JO_T"4O\ P9/_ .1/S_\ XE6R7_HK<T_\-V$_^7G\F7_"C/C;
M_P!$=^*?_AOO%O\ \J*/^%&?&W_HCOQ3_P##?>+?_E17]9M%'^M5?_H$I?\
M@R?_ ,B'_$JV2_\ 16YI_P"&["?_ "\_DR_X49\;?^B._%/_ ,-]XM_^5%'_
M  HSXV_]$=^*?_AOO%O_ ,J*_K-HH_UJK_\ 0)2_\&3_ /D0_P")5LE_Z*W-
M/_#=A/\ Y>?R9?\ "C/C;_T1WXI_^&^\6_\ RHH_X49\;?\ HCOQ3_\ #?>+
M?_E17]9M%'^M5?\ Z!*7_@R?_P B'_$JV2_]%;FG_ANPG_R\_DR_X49\;?\
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M4_\ PWWBW_Y44?\ "C/C;_T1WXI_^&^\6_\ RHK^LVBC_6JO_P! E+_P9/\
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MGO\ 1])O+5+N&&YMY9;9I1-''/"[H%E0M^67_#+O[3/_ $;K\=?_  T?C_\
M^9^O[\Z*][#\25L/0I4%A:<E2@H*3J23=NK2CH?SCQ1]'3*>*.(<WX@K<2YC
MA*N;8VIC*F&I8'#5*=&52UX0G.M&4HJVCDD_(_@,_P"&7?VF?^C=?CK_ .&C
M\?\ _P S]'_#+O[3/_1NOQU_\-'X_P#_ )GZ_OSHK;_6JO\ ] E+_P &3_\
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MY_ 9_P ,N_M,_P#1NOQU_P##1^/_ /YGZ/\ AEW]IG_HW7XZ_P#AH_'_ /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX3=/$J,X0MSRC)U+2C&ZYFFU&ZOY_IA_PL;P/_T,FG?]]R__ !JC_A8W@?\
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M<J.*C.KS-1C[.+J7GS.Z7*G=Z;K7]5O^%C>!_P#H9-._[[E_^-4?\+&\#_\
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MN&__  '-/_F\_J*_X;&_9A_Z+1X-_P# F[_^0Z/^&QOV8?\ HM'@W_P)N_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@+X/3X#Z7H_@RP5[Y=*NI;C3HFMOV=J,11"5YQ'&)I(XXI)@BB5XH6E>&-Y
M-[1Q//.T:,2J--*R@&1R9Y?>YKW79JZ6EM.U^N]]5Z!_*W:_!;P[\!/V>_\
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M[QM:^._Q 3['%JWAKPI/);V,GA/1-1CO+A]!MG\6-8::UU87.IT_ NH?&O\
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M?_L1X?\ ]3Z9]34445\0?VX%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_T+>G?]\2__ !VBBCVE3_GY/_P*7^8?V?@/^@'!_P#A-1_^0\E]P?\ "N?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>nt10016217x4_graphic18x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic18x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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ML\5C+ZQC+HFK:]^]]W?^@_\ X:'^"'_15_!O_A06?_R11_PT/\$/^BK^#?\
MPH+/_P"2*_GPVK_='YM_\51M7^Z/S;_XJFO#7+]/^%#&=/\ EU0_N?W?7\?,
M?_$?,Y_Z$.5?^%6-_P#D?+\^[/Z#_P#AH?X(?]%7\&_^%!9__)%'_#0_P0_Z
M*OX-_P#"@L__ )(K^?#:O]T?FW_Q5&U?[H_-O_BJ%X:Y?I_PH8SI_P NJ/\
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MS^[Z_CYA_P 1\SG_ *$.5?\ A5C?_D?+\^[/Z#_^&A_@A_T5?P;_ .%!9_\
MR11_PT/\$/\ HJ_@W_PH+/\ ^2*_GPVK_='YM_\ %4;5_NC\V_\ BJ%X:Y?I
M_P *&,Z?\NJ']S^[Z_CYA_Q'S.?^A#E7_A5C?_D?+\^[/Z#_ /AH;X('_FJ_
M@W_PH;(?SN*4_M#?! <GXK^#,?\ 8PV7L/\ GX]Z_GOVK_= _,_S)%+@ $8
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M#LFM9X;B)CP\,J2+E6!/\\F!SP/NMV_V3Z8_G7:>.@!X@YYQX;\%')52<?\
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M.G_+JC_=O]GU_$7_ !'S.?\ H0Y5_P"%6-_^1\OS[L_H/_X:'^"'_15_!O\
MX4%G_P#)%'_#0_P0_P"BK^#?_"@L_P#Y(K^?#:O]T?FW_P 51M7GY1Q[M^GS
M4+PUR_3_ (4<9T_Y=T/[G]WU_$?_ !'S.O\ H0Y7_P"%6-\O[OI]_F?T'_\
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MD5_/AM7^Z/S;_P"*HVK_ '1^;?\ Q5"\-<OT_P"%#&=/^75#^Y_=]?Q\Q?\
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MIQEA<UK\T,QS!OFR[+L=C(1M*"5JDL%&$VWI&;E%MQU_K<_X;-_95SC_ (:
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MWU_'S'_Q'S.?^A#E7_A5C?+^[Y?GW9_0?_PT/\$/^BK^#?\ PH+/_P"2*/\
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M?XD^$;>UOA.UE<'7+)8KL6TS6]P89!,!(()U:*0J2$D!5L-BJ/\ PT/\$/\
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M .%!9_\ R11_PT/\$/\ HJ_@W_PH+/\ ^2*_GPVK_='YM_\ %4;5_NC\V_\
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M_/HE[X=L+Z74-#MK>?3+VW\11VU]=:?<17MUNL)X+=TC"_9KE4LYL,+F4,>
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M5)0GF[:5'B7+IQ@Z[JJ<E)\E!2G&+565.*E*5./*YR@^526LKJ/.O9RGGB.
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M*C.<4HRFN7WI123>JTL>)+]Q/]U__1BTOW5=N P " I.Q9Y&$<:J((+AP2[
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M::MJMQ8ZIISS,!<QO<"5$LI=NU6A+R. YY^\^ FBZMX9\*:_X \87>LQZ_\
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M>7AO_P D-PS_ -BRC^<C] Z*A:=5+##G;C) &.1GKD=O7&>V:7S1_P \Y?\
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MBMA&HU,3AJN$G)P4K4JT7"HE=>ZW&37,O>3UC:237UQX*_:4T7PQI'PY@O\
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M_P!UO_0379^._P#D8#[^&O!7'_<C>&_\?Y5Q9. W^ZP_,$5VOCU2OB(9P?\
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MB"77+J80Z9-I#W*V:6%G;1W\)DB7= P]<OOVE/V7_"_A'XW>%OAKXK\+^'/
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M.Z7<!N6*!01C)P)"=P"K@@EL#DX .<G%>G>!SN\&_&6,<E_ OA_!XV\_$OP
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MIVLK $9&58,N5.58 @$JP*GH01Q08(6C2,QJ4C140$<A44(HW_?.%55!+$X
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M!^O^-'^MO_4OI?\ @QO^7O'R?X>8?\0LP_\ T-L1_P""_1?\_/+\%WT_(/\
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M_+/N.#2?V!K/_0(U#_P%N?\ XU7]87E1?W%_*CRHO[B_E5?\10K?]"C#=/\
ME[/R\O)_TV3_ ,2U8#3_ (RS,M/^H.AY?]//7^FS^3S^P-<S_P @F_QG_GSN
MLX^NWK[X_"G'0=:/72-0/3DVMSG@8Q_JNG^ K^L'RHO[B_E1Y47]Q?RH_P"(
MH5O^A1ANG_+V?EY>3_IL/^):\!_T5F8_^$6'\O\ IYZ_AYG\GO\ 8&L_] ?4
M/_ 6Y_\ C5!T'7.@TG4 ,=#:71[Y[(!C/.,=>:_K"\J+^XOY4>5%_<7\J/\
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MERQ:4IQBY-*,9-*6MMUYWTMKMIU+';/;U[?GTI"0-N2!N(5<D#<Q. J^I)(
M Y)XZTA7/EJ-RJ_W0ZLK8)09*,%(Y8=0.^,XKX0^+7_!1?X _!?XE>*OA5XO
ML_B!<^)O!;:8FL'0?"D>KV2-J^G66IV!@G358I)!);WT*$FWC83+*JHR*KMI
M1H5<3-TZ$7.23DU9Z17+>3>R2O9MV5VM3DQV/P&5QISS/&4,#3JUXX6G/$3C
M"-7$2IRJ^RI<S3G)TH5*BC&\G"$I6LFU]W"1&SM=#M)!PP.".H.#P1W!IXY
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(EI-_P")/%6H>"=.U1KSQ)K>K3"YUS1K74]/U"'5Q<:<4A??)#)^JNC?LC?
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M;Q1QK!X,_8H_9W^'_BK0_%VA^$+X7_AB^GU+PM8ZMXO\6Z[X>\+:C/(\HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P 51[2'\\/_  )?Y^:^\/9S_DG_ . O_+S7WB44N/\ :3_OXG_Q5&/]I/\
MOXG_ ,51[2'\\/\ P)?Y^:^\/9S_ ))_^ O_ "\U]XE%+C_:3_OXG_Q5&/\
M:3_OXG_Q5'M(?SP_\"7^?FOO#V<_Y)_^ O\ R\U]XE%+C_:3_OXG_P 51C_:
M3_OXG_Q5'M(?SP_\"7^?FOO#V<_Y)_\ @+_R\U]XE%+C_:3_ +^)_P#%48_V
MD_[^)_\ %4>TA_/#_P "7^?FOO#V<_Y)_P#@+_R\U]XE%+C_ &D_[^)_\51C
M_:3_ +^)_P#%4>TA_/#_ ,"7^?FOO#V<_P"2?_@+_P O-?>)12X_VD_[^)_\
M51C_ &D_[^)_\51[2'\\/_ E_GYK[P]G/^2?_@+_ ,O-?>)12X_VD_[^)_\
M%48_VD_[^)_\51[2'\\/_ E_GYK[P]G/^2?_ ("_\O-?>)12X_VD_P"_B?\
MQ5&/]I/^_B?_ !5'M(?SP_\  E_GYK[P]G/^2?\ X"_\O-?>)12X_P!I/^_B
M?_%48_VD_P"_B?\ Q5'M(?SP_P# E_GYK[P]G/\ DG_X"_\ +S7WB44N/]I/
M^_B?_%48_P!I/^_B?_%4>TA_/#_P)?Y^:^\/9S_DG_X"_P#+S7WB44N/]I/^
M_B?_ !5&/]I/^_B?_%4>TA_/#_P)?Y^:^\/9S_DG_P" O_+S7WB44N/]I/\
MOXG_ ,51C_:3_OXG_P 51[2'\\/_  )?Y^:^\/9S_DG_ . O_+S7WB44N/\
M:3_OXG_Q5&/]I/\ OXG_ ,51[2'\\/\ P)?Y^:^\/9S_ ))_^ O_ "\U]XE%
M+C_:3_OXG_Q51%VW,HC<[?XN-I'JIZ$>X-+VE/\ GBWV4DW]RN')-?8E_P"
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M!?\ EYK[Q**7'^TG_?Q/_BJ,?[2?]_$_^*H]I#^>'_@2_P _-?>'LY_R3_\
M 7_EYK[Q**7'^TG_ '\3_P"*HQ_M)_W\3_XJCVD/YX?^!+_/S7WA[.?\D_\
MP%_Y>:^\2BEQ_M)_W\3_ .*HQ_M)_P!_$_\ BJ/:0_GA_P"!+_/S7WA[.?\
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M7_#+[C.\@?\ /.7_ +Y-'D#_ )YR_P#?)K1\L?WI/^_C_P"-'EC^])_W\?\
MQHO+RZ?IY>7X>;"R[+^O^&7W&=Y _P"><O\ WR:/('_/.7_ODUH^6/[TG_?Q
M_P#&CRQ_>D_[^/\ XT7EY=/T\O+\/-A9=E_7_#+[C.\@?\\Y?^^31Y _YYR_
M]\FM'RQ_>D_[^/\ XT>6/[TG_?Q_\:+R\NGZ>7E^'FPLNR_K_AE]QG>0/^><
MO_?)H\@?\\Y?^^36CY8_O2?]_'_QH\L?WI/^_C_XT7EY=/T\O+\/-A9=E_7_
M  R^XSO('_/.7_ODT>0/^><O_?)K1\L?WI/^_C_XT>6/[TG_ '\?_&B\O+I^
MGEY?AYL++LOZ_P"&7W&=Y _YYR_]\FCR!_SSE_[Y-:/EC^])_P!_'_QH\L?W
MI/\ OX_^-%Y>73]/+R_#S8679?U_PR^XSO('_/.7_ODT>0/^><O_ 'R:T?+'
M]Z3_ +^/_C1Y8_O2?]_'_P :+R\NGZ>7E^'FPLNR_K_AE]QG>0/^><O_ 'R:
M/('_ #SE_P"^36CY8_O2?]_'_P :/+']Z3_OX_\ C1>7ET_3R\OP\V%EV7]?
M\,ON,[R!_P \Y?\ ODT>0/\ GG+_ -\FM'RQ_>D_[^/_ (T>6/[TG_?Q_P#&
MB\O+I^GEY?AYL++LOZ_X9?<9WD#_ )YR_P#?)H\@?\\Y?^^36CY8_O2?]_'_
M ,:/+']Z3_OX_P#C1>7ET_3R\OP\V%EV7]?\,ON,[R!_SSE_[Y-'D#_GG+_W
MR:T?+']Z3_OX_P#C1Y8_O2?]_'_QHO+RZ?IY>7X>;"R[+^O^&7W&=Y _YYR_
M]\FCR!_SSE_[Y-:/EC^])_W\?_&CRQ_>D_[^/_C1>7ET_3R\OP\V%EV7]?\
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MR\NGZ>7E^'FPLNR_K_AE]QG>0/\ GG+_ -\FCR!_SSE_[Y-:/EC^])_W\?\
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M_P!./ZMZV_J+V/\ W(?^^'_^/T;'_N0_]\/_ /'Z_ET_X75\8O\ HJ_Q)_\
M"Z\4_P#RUH_X75\8O^BK_$G_ ,+KQ3_\M:/]6:__ $&5.G5_W?Z\K>6I_P 3
M*\/_ /1)XWI_R_R_R_Z<?U;UM_47L?\ N0_]\/\ _'Z-C_W(?^^'_P#C]?RZ
M?\+J^,7_ $5?XD_^%UXI_P#EK1_PNKXQ?]%7^)/_ (77BG_Y:T?ZLU_^@RIT
MZO\ N_UY6\M3_B97A_\ Z)/&]/\ E_E_E_TX_JWK;^HO8_\ <A_[X?\ ^/T;
M'_N0_P#?#_\ Q^OY=/\ A=7QB_Z*O\2?_"Z\4_\ RUH_X75\8O\ HJ_Q)_\
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MO+4_XF5X?_Z)/&]/^7^7^7_3C^K>MOZB]C_W(?\ OA__ (_1L?\ N0_]\/\
M_'Z_ET_X75\8O^BK_$G_ ,+KQ3_\M:/^%U?&+_HJ_P 2?_"Z\4__ "UH_P!6
M:_\ T&5.G5_W?Z\K>6I_Q,KP_P#]$GC>G_+_ "_R_P"G']6];?U%['_N0_\
M?#__ !^@I*1Q AXP&".03GK_ *P_3K]3U%?RZ?\ "ZOC%_T5?XD_^%UXI_\
MEK33\:OC""2WQ5^(Y!QR?''B<D?4G5">>QYQP*/]6JZU^MU.GVI+3W;_ (:?
M\-</^)E<@TMPGC$_^O\ @.R[4/ZM]W]1*G"H#Y.W<%(<B/>V,LBL3NFVG PB
MJ7Y)QBI$7S"5$:H<Y&%9N/H&8@'KD]?I7\RG@O\ :(^,?@KQ'IWB2R^(/C#5
MGLI?,DTW7/$.JZIINH1&17G@O+6^NKB%UE4&/S1&K(#E<$<_OC^SY\??"GQV
M\)Q:SHDRV6KVL<<?B3P[.RKJ&D7^T9WJ&S-82DYM;I%!9& DV/A:X,9E>)P4
M*=>%6=>C*2YIO>#LKWW:6EKJ]VM[Z/\ 1^ _%3(>.JM?!T*=;*,;25XX/%5J
M515X))J5)Q7+.UN:4/=DKJ5N75>^>2<D8)(](7/^?:M&PBQ]L4HC'['(P)BY
M7#!<,.H)+9!)' &> M4/,;(QN"?PL&/S'D]>JKW!)[XYK7TQ [7K,"1_9DIS
MGDLLT:Y)Y/RC(SD$J.*\I5^>Z4I:-;-Z-./GL]^^^O?]1]FHV;<$[I).E!-I
M):IK6U[[OMIVR/(/HW_?AO\ XJCR#Z-_WX;_ .*J[B/^Z_\ W]>C$?\ =?\
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M\-_\55W$?]Q_^_KT8C_NO_W]>J]I+O+I]I^7^3^]A[-?RT__  33\O\ @_\
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M:6:69TCBC5I'95!-<;X;^*_PM\9'6U\(?$KP!XJ;PUIVB:OXC7PWXQ\.ZX=
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M>)_#W[._[.W["?[9_B:-=$\#_!'QG^T)^RQ\?O$VC275WX?N_A]\1?C1X_\
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MO^&7W )@>@_(48'H/R%+119=E_7_  R^X!,#T'Y"C ]!^0I:*++LOZ_X9?<
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M_$WQ5\#_ /!%U?&]UJ7B+0/%_AO]G_\ :*\5?#'5=526/7]%\ :7J/Q&U?\
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M _92_:'7/_%I/%IX.0D,  'H=TG'OQ[DT?7,/I_M>">U[S:[;6F_.WJO0?\
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M@!",JP_O C/IGO2QQ%I[=@PP+F/=\FXJ!AL$$?=8=P20<<'H"K=N!N@;J1<
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MM96V6BTT/F7PE^R=\*?!UUX:U2PM]9U#Q!X:\6^)O':^)]=UK4]8\1Z]XO\
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M'[.__AZ_AK_\TU>C_P#"I_A?_P!$V^'W_A%^'O\ Y H_X5/\+_\ HFWP^_\
M"+\/?_(%&GG]W_!]?Z>AIY_?_P #U_I:^<?\->_LF_\ 1T'[._\ X>OX:_\
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M'[.__AZ_AK_\TU>C_P#"I_A?_P!$V^'W_A%^'O\ Y H_X5/\+_\ HFWP^_\
M"+\/?_(%&GG]W_!]?Z>AIY_?_P #U_I:^<?\->_LF_\ 1T'[._\ X>OX:_\
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M'[.__AZ_AK_\TU>C_P#"I_A?_P!$V^'W_A%^'O\ Y H_X5/\+_\ HFWP^_\
M"+\/?_(%&GG]W_!]?Z>AIY_?_P #U_I:^<?\->_LF_\ 1T'[._\ X>OX:_\
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M'[.__AZ_AK_\TU>C_P#"I_A?_P!$V^'W_A%^'O\ Y H_X5/\+_\ HFWP^_\
M"+\/?_(%&GG]W_!]?Z>AIY_?_P #U_I:^<?\->_LF_\ 1T'[._\ X>OX:_\
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M'[.__AZ_AK_\TU>C_P#"I_A?_P!$V^'W_A%^'O\ Y H_X5/\+_\ HFWP^_\
M"+\/?_(%&GG]W_!]?Z>AIY_?_P #U_I:^<?\->_LF_\ 1T'[._\ X>OX:_\
MS34?\->_LF_]'0?L[_\ AZ_AK_\ --7H_P#PJ?X7_P#1-OA]_P"$7X>_^0*/
M^%3_  O_ .B;?#[_ ,(OP]_\@4:>?W?\'U_IZ&GG]_\ P/7^EKYQ_P ->_LF
M_P#1T'[._P#X>OX:_P#S34?\->_LF_\ 1T'[._\ X>OX:_\ S35Z/_PJ?X7_
M /1-OA]_X1?A[_Y IG_"J_A8#C_A7'P^SG&/^$*\/]>G_/A1IY_=_P 'U_IZ
M&GG]_P#P/7^EKYW_ ,->_LF_]'0?L[_^'K^&O_S34?\ #7O[)O\ T=!^SO\
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M]?PU_P#FFKT?_A4_PO\ ^B;?#[_PB_#W_P @4?\ "I_A?_T3;X??^$7X>_\
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M.,_8,'\,_J*T45JVE=.S?)K?W;]OZ:)3LHI1G9)64972B^5]$]/GLUW/-_\
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MGPX_^:>O1Q\,_A21Q\./ 1;^[_PB&A#KN[G3QS\K<8[>G-/3X7?"MUW'X9^
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M^?F>2_\ #6G[*O\ T<S^S[_X>;X<_P#S24?\-:?LJ_\ 1S/[/O\ X>;X<_\
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MOW&U9)O9NU^VV_WIH]&HJC]HD#$$K@)D<'ENW0]"?PXZ^MB&0R*=V-P/( P
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MIV5HJ[O3DVE>RMW/Z [G58+.&6XN3'!;P#?/<33+#!'&K 22-)*$ 6)=SN6
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M(GLO7]&9M%%%!84444 %%%% !1110 4444 %:6E_\?0_ZXW?_I.]9M:6E_\
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M_P! >BD8@(P)Y;<J^[>7(<>W /)P/>E+X*G^"0UL_1+YN44E\WH?U=?LU_\
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M_"WX1_&S5O#7@R9/$'B;Q]/K^@2V-]H-YJ9UW^PM'2X_>#X@?#?P5\4="O\
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M:6F_>OO^P7<?^CHJS:TM-^]??]@NX_\ 1T5!$]EZ_HS-HHHH+"BBB@ HHHH
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MGB&_LOA]\1-+L;K2+-++Q!I2ZL/#L^H^(] FC\76VAR:'<W>NQZ?8W/P5?\
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M724XUXTFN9M1I)I-V2_&[]J7]C?5_A?_ ,$B]<\!?%'QCJRZY\*Y/&'Q=O?
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MF[*C(4, 0/E7&V'J>RK4ZEF^2<9676S3_K?]5Y^;9='-\LS'*I5?80S+!8K
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MQ\10Z!\A?M&?\$\_V_?$?A3]J3]FSX-:O^S)JO[-_P"T5\:7_:!B\9?$._\
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MC8:]<I<6EW?<]XI_8'^).H_M\^%OCKH_B#P]%^S5-%X/^*OC_P"'=QJ.H?\
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M;J\G_">&ZT33=!TNZT;4+&VU>YO9=*AU7FOV;/V"_CK\,/B_^S[\9/B#XA\
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M?V?_ (T_"CPG\0O _P"T7^V-\4-=\;^*_B5\+_$'PZT[Q'=>$_BSXXOOA_\
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MKNTNXM1T&RUJQL]4O=-]<_85^#OQN^#_ .Q]\%_@?\>M'\ :;X^^%?PV\/\
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M"U&ZET.&QCU"\?4?(6#3KTNMI-^6?[6W_!-C]M+]JSQ-X)^(FN?!+]C;PO\
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MP_KUSJMKHFMZ9'\5=,TE-=\&Q7?BN[UG2M9>_P!/UF]FD^P_@Y^R+\=O!_\
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MSPZ;=ZM#]DOKK5M"TRPGTJ^U#Y?^*'_!(;XV:G\+]?\ AO\ #:3X-Z'877[
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M(:_H=_/H^O>%O%_AJ_DEDT;Q#H6L6=]I>HVD5_=6INX"^GZA=6H2>3\3M/\
M^"27Q5T/]CS5_A)9?LT?L5ZQXF\8?'E?BYXK^#7B/XQ_M;ZYX0MK2S\)Z;X7
MT*^\)?M*^(/'&M_&GPI\2]&FTB&]F\5>&-&T#2]4T"]F\*R:- J7NIZM^G?_
M  3M_9B^*W[+G[-^F_"[XHZCIUQK4?C/Q=XDTGPEH'COQC\2O"OPP\*:_JPN
M]"^&7A?QQ\3I)O''B70?"]L'^SZEX@>._>:YG5?-7YWUC'6JY22=J+II.]E^
MY<X[6?(^>SNG:-GS79E4<$H<B;_B\]]?\">[TV32LWJVDT?EK^S1_P %!OVG
M?CY\4?"?AZ7]O+_@F_X9U'7_ (Q^*/#%Y^S/>^"O%3?M P^'/"WQ)\0>'KCP
MK#)_PNB*$^,]8\*>'GU*PNX]!E@M9+NWNQIMQ"[1/]\W?_!5G]GJV^/Y^" \
M*?M!CPS_ ,+0_P"%(W/[3J?"C4A^RK:?&@RKI2?"R;XM3Z@K?\).?$A7PDRK
MX:N=&B\22+%)K,-F9KU/6/V-/V-K#X$_!OP;X=^(G@+X7WWQ7\.>*_B1XAN?
M&OAW2-,U"_<^+/B7XW\4:1/!XGOM'TO7Y+N#P_XAT^UO)9522&=+BRADN;2&
M&63X5N/V#?VZWO=5_9H@UC]GN#]C/6/VJI_VC)_B4NH>(V_:!3PW=?%P?'>?
MX8GP0/#D7@MKL^,T7P]%XW;Q;+J$>@E;G[&TB&U.5)5.?#4YM*/LX.M/HJGM
M,/S)RV:IT%6JI-_O*R5*-KZZU'2;Q4X)+EKS5**M[]+EK+F7?]XJ,(I;TY2J
M2:2NONV/]NWX3R^ -=^(Z:=\0!HV@_M/2_LGW=M+I^@1WDWQ*@^(UG\,Y=1M
MX'\20Q-X/C\0W\,XU&2[M-6DT0&Z.@'4 +$_.]C_ ,%A/V?;OXVZC\')?A9^
MU78V.E_';6/V:-:^.-_\'X3^SQX?^,^F>);_ ,,V/@[4OB3IWBR\CBOO$^H0
M:=_8(CTJX9;75=+?5TT2XEU..W\*\0?L$_MXMXL\6?"OPY=?LXK^S/J_[<^C
M?MC0>,+_ ,0^,X_C!J.GWGQ6T#XA^)/AS-X=C\-R^&-);3IX+VYT[Q NLZI<
M:H-+MM.DBTQ=5-UI?MI_8(^-,GP5\>_#J:?P"VM>*/\ @HK=?M7VDXUK48=-
M_P"%;W'Q\T_XF+97,\6C-<P>+H_#UM-$NG06[6*ZB(+1==,#2W06';3I2J1D
ME;"JHK/FY5'+(56HZI356OF%22;NX4D[)09E5C:->,90DVI.C9Z*3^O22D[:
MI1C@XJR:YY-7=W;C/CS_ ,%<?"_ASQVWPJ^#GP_^+U_?Z7^T5\./@%>_'CQ9
M\)=7G_9AU[QM+\3-!\)_$_X5>&?BC;>((/-^)^AZ/=^)Y[6/5M*TSP_)>>%M
M8A@U75KR/1M-U7UKQO\ \%8_@)X#_:/TW]G37OA]^TK9)J?Q-'P8M/CX_P '
M;JP_9RE^*BWECI-YX1M?'NLZW9:KJEYIFOW]AH.H7.C>$=7T.#4M2LL:O)82
MF\KYN\4_L&_MZO/>_ +PU=_LUW?[*EG^V/9?M6:'XSU76O'-M\:9](U'X[P?
M&76OAC?>&_['U'PK;S:1>:MK:V/BV'7ICK46D:=9W>D6$VJW.HV7@GQ%_P""
M3/[7?BSX\^)_&4?@+]D7Q)#<_ME:+^TMIW[2GC_QW\6_%W[1EYX#TSXJV/BV
MQ^$V@:#XDT?7?!OPBM=&\(21>%I)? 6J0Z#K^D>#-)TG4/#_ )^JQZWHU4.9
MO#1K77/*G.NXK2FG' 2J04GO:=3%+7F?NR23Y'9U8TU+$NFVTJ*6'2:UES8I
M)V:TERPP[DD_M)O?W?I[X/?\%/\ XA_%W4)$U?X5?$[X+6J?\%$] _97TZW^
M*?PABTRXUCP)KG@WQ=K0T2<I\4('T;QSHE[X5%UXT\1HFO:=X<36O#%A9^&=
M<BUN[N=*]V^&7_!6#]G'XH?&C2OA)H?A7]H#2O"OC3Q;KW@'X2_M(^*OA1J^
MC?LQ_&OQ[X=G>TOO ?PL^*KZ@UQKOB*6?3_$,.EW%]H&C:#K9\+ZQ_9.MW\U
M_P"%SX@\MN?V$OVGM7^)NM0:HOPFB^%EA_P4P\+?MG^$]<LO%VNGQ??_  [U
M'X<>.?#?CGP]K&A3>#FL-+\5Z)JU[X6L_#ZZ?K,]EK^EWFL7E_J.DW6G6<=W
MP_P3_8+_ &Z_#&F?LY_LK?$G7?V>)_V0OV4?B?X;^(7@KXF^&+OQ-+\=?B3H
MWPOU34-4^%?@O7O!$GA_1?!7@BXA.JV]KXQ\5Z-X@U>\U>#PZS)9R7GB&_OP
M4>:,,)"HO?\ JV']K)6:]KR055R:^&4)*4U%M>U;<&XZI5-4Y>VE'E7+4J>S
MCLW'EJN#6C3UY([-;V3:1ZY\ O\ @L?^SW^T/\0OAEX#\/\ PH_:L\#:5\6O
M$_B#P#X#^+OQ.^$%CX<^"OB/XF^&UUU]2^%^G_$/2_&.O:??^.!;>'-5N+6P
MTZWO=*F%LR+K#7P>W3Z[^+/QV\3:%\??V?/V>?A[907_ (L^+2^,_B'XTUC4
M89[S2/!'P3^$\6BV?B?6WMX;^SEEUCQEXS\9> _ OA<03-%;RZWJVOW5M=+H
M$FG:A\9_!C_@GY\;OA]^R[^P%\&]=O?A_=>+?V7OVLW^.7Q#NK76+N]T?4/#
M#:Y\?M2,GA*YN/#%F\OB;R/BAH82!]+T"VCD.LVRW_V:&![GV/XO:!?_  X_
MX*.?LR?'/5;*]N/ _P 2_@3\6_V1]2UN*4/IW@KXAZGXP\$?&KX>C5!'-(;>
M#Q_IW@#Q;X=M+Z6'RO\ A([#PUI,]W!>ZWIT%Y;7L_9<LE/]XG*5EK&*J>]*
M+CISZ-QLK6C:,6U?.7+.IB+748QG&FVVN=J5/E:LU:Z3E:[5[J[2:?Y(VO\
MP5A_:CCFU[Q:/VK/^"?NN:UI'Q_\:?#6S_8FB\->+],_:=\1Z%X;^/.N?"K3
MO#^DWC?%"Y:U\::WX<TZU\46%U?>#H+,13I+=VMI:^;,/TC^'7[=/Q7OO^"F
MWQ6_9'\>:;X9M_@T_ABRLO@SXATS1M6A\2#XJ:1\-O!/Q5\2^%O%>KRZI-I-
M]#K?@CQ'XDUGPREM86DC1> M;*RW;.[Q?%]U_P $[OV_[SX0_$O]F"+X(?\
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MQG^S9^R+\+?@AK>F7-WJ/B'P5\1_V6;O5M>\->*M=TB>.WCN].T_Q/9^%-3
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MKZGJSQ2:OJ[V.CZ/#]LO)OM&GVEO//\ -(_AO@O_ (*B?!C7O@1\6OCEXS\
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MX5_##Q]\ O#7[,OQ@^.7["/QN_:6\$6O@W]L;X+WOPO\+_!RW\>_$GX:>/\
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MYQM7;@<9"\9 +,<EN:L444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^ONZKSLGIMMY$#O*B  $:  $ !0, C! P.,CKCW]34G3I113CMN^GY)_U_F
M44450!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>nt10016217x4_graphic19x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic19x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( ,X$V ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M2UBF_P#A-RU:^[VP?E_5D?IU_P /&(O^B32?^%E_^#%'_#QB+_HDTG_A9?\
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MP)OZL:,#TS_P)OZ,*:X%X:T_X3I=/^8O%_W?^G_D_N] _P"(P>(7_0YH]/\
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M7_X,4?\ #QB+_HDTG_A9?_@Q7YC%?]DCWR_]6IN![_F?\:%P-PS_ -"]]/\
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M0?\ $R7C!_T4F#Z?\R3)O[O_ %+.EOP7<_>+_A]5#_T;O<?^'';_ .=Y0?\
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M&8KMWQ?HO5+Y/_B9'QAZ<281[;9)DSM\/_4LZ6_#S/W@_P"'U4/_ $;O<?\
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MAS1Z?\RW+?+_ *@_+^K(_3O_ (>,1?\ 1)I/_"R__!BC_AXQ%_T2:3_PLO\
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M5#&4:M"6+>!JXJ:IPC3A33G4C3<_:.#JT/$^K0:[XGU[5;6(P6NJ:]K>J00
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M$>&?^QZ\??\ IO\  ]?GZWWO^ G^35^@7P+_ .2$>&?^QZ\??^F_P/6O%O\
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M1E&@Z53!5K\SY*<ZE/V4H0<N:*YFW*\;\]G:+B]7]9P_D-+.<OS#$<F*J8S
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MM/'W&^O^%,' ';]?U[T\?<;Z_P"%>WK>-]^:-_7F1\;ZJSZKMY'[,?\ !/\
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MX\U@ZMLDVM7G68]RDOPISC:<,>F#QTZ]#UQZ4,48$>81DGD AER ,*,'Y<=
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M([,QK##IFGQ1VDEM<"5XKFU)C79(\JRF9%4^:.48!<*H!!.!R1C:RX9F!#@
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MU'QA!#::_)KEE8:M%J-O:1+%:F>UN+=;,[$'EK#':I%%"J1 RF/S'70?C/\
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M26TX22:/6/%_Q8\1>)%\:::C1VOAKQGXXO?&MWI+VUG/<Q7TLLKV^W43 LI
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MNKW4U]J6I7$US>7=RYDFGFD)R[,?3&#@*H"J% 4 #-;:W0 = <$G(&??C/\
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M_AGKXF?] *+Z_P!L:1G\_P"T,Y]^M?I+137%>9+[.&Z?\NWTM_>\OE?R0?\
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MX>TEI>Z^IZ[+?S^7\\?_  PA^TXS,Y^'-CO,4<0D/BSP:[JD4[W*)&S:X6C
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M5_@C_P":&D/["/[39Z^ 8?P\8>"A_+Q$*_H<HH_XB5GW_/O!?^"%Y>?D_O\
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M6-(/_N0I/^&>OB9_T HO_!OH_;_M_K]):*/]:\R_DPW_ (*]/[WD_O\ (?\
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MO]HGKKVW/]1<N=O#KA?_ +$?#B^3P6%YEZ\M[>9^-W[>7B_XN>*?%W@CX _
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M!9YE6,R3#_6LTPV,HSP%"6'EB/:XFZ=.F\/"G4E6YVFE3A3E)J]E%I-?U8?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:=G>W;H?VY_\$?N/^">G[/S'H'^)Q/L!\8OB#G^=?3?Q74CQ3:J1_P PBVP
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M_P# &\_^,4?\(GXC_P"@-J7_ ( WG_QBCZUA_P#G_2_\#C_F'U+&?] F)_\
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M_P $U/\ Y'S_ #[,YVBNB_X1/Q'_ - ;4O\ P!O/_C%'_")^(_\ H#:E_P"
M-Y_\8H^M8?\ Y_TO_ X_YA]2QG_0)B?_  34_P#D?/\ /LSG:*Z+_A$_$?\
MT!M2_P# &\_^,4?\(GXC_P"@-J7_ ( WG_QBCZUA_P#G_2_\#C_F'U+&?] F
M)_\ !-3_ .1\_P ^S.=HKHO^$3\1_P#0&U+_ , ;S_XQ1_PB?B/_ * VI?\
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M4L9_T"8G_P $U/\ Y'S_ #[,YVBNB_X1/Q'_ - ;4O\ P!O/_C%'_")^(_\
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M /CU+ZQ1_P"?L-//^OZ]!O"8I;X:OKM^ZG_\CYF316M_8.M?] J^_P"_<?\
M\>H_L'6O^@5??]^X_P#X]3]O1_Y^0^_^N_Y]F+ZKB?\ H'K_ /@J?_R/G^?9
MF316M_8.M?\ 0*OO^_<?_P >H_L'6O\ H%7W_?N/_P"/4>WH_P#/R'W_ -=_
MS[,/JN)_Z!Z__@J?_P CY_GV9DT5K?V#K7_0*OO^_<?_ ,>H_L'6O^@5??\
M?N/_ ./4>WH_\_(??_7?\^S#ZKB?^@>O_P""I_\ R/G^?9F316M_8.M?] J^
M_P"_<?\ \>H_L'6O^@5??]^X_P#X]1[>C_S\A]_]=_S[,/JN)_Z!Z_\ X*G_
M /(^?Y]F9-%:W]@ZU_T"K[_OW'_\>H_L'6O^@5??]^X__CU'MZ/_ #\A]_\
M7?\ /LP^JXG_ *!Z_P#X*G_\CY_GV9DT5LQ^'=?E8+'I%X2<X#*@)(Y(&'8=
M"#DD=^G&6G0-<4D-I-[D$@X2,C(]S*#^@YI?6*/_ #]A]_\ 7]>C']3Q5D_J
MU>SV?LI__(F116M_8.M?] J^_P"_<?\ \>H_L'6O^@5??]^X_P#X]3]O1_Y^
M0^_^N_Y]F+ZKB?\ H'K_ /@J?_R/G^?9F316M_8.M?\ 0*OO^_<?_P >H_L'
M6O\ H%7W_?N/_P"/4>WH_P#/R'W_ -=_S[,/JN)_Z!Z__@J?_P CY_GV9DT5
MK?V#K7_0*OO^_<?_ ,>H_L'6O^@5??\ ?N/_ ./4>WH_\_(??_7?\^S#ZKB?
M^@>O_P""I_\ R/G^?9F316M_8.M?] J^_P"_<?\ \>H_L'6O^@5??]^X_P#X
M]1[>C_S\A]_]=_S[,/JN)_Z!Z_\ X*G_ /(^?Y]F9-%:W]@ZU_T"K[_OW'_\
M>H_L'6O^@5??]^X__CU'MZ/_ #\A]_\ 7?\ /LP^JXG_ *!Z_P#X*G_\CY_G
MV9DT5K?V!KK$!-(OF)[;(A_[5-/?P[KT3;9-'OE) 8#9&<J<@'_6C'(/Y9[T
MOK%'3][#7;4?U3%6O]6KV_Z]3_\ D?,QJ*UO[!UK_H%7W_?N/_X]1_8.M?\
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M!O/_ (Q1_P (GXC_ .@-J7_@#>?_ !BCZUA_^?\ 2_\  X_YA]2QG_0)B?\
MP34_^1\_S[,YVBNB_P"$3\1_] ;4O_ &\_\ C%'_  B?B/\ Z VI?^ -Y_\
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M^*H\EO[G_D4?_%5>\J+^XOY4>5%_<7\J+ON_Z_X9?<'R7W+R\O)%'R6_N?\
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M_P BC_XJKWE1?W%_*CRHO[B_E1=]W_7_  R^X/DON7EY>2*/DM_<_P#(H_\
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ME_-V^Q'^[_>]?N15\D^C?]]0?_$T>2?1O^^H/_B:M97_ )YQ_P#?)_QHRO\
MSSC_ .^3_C1S2_FETZKIR^7]W\0Y9?S=OL1_N_WO7[D5?)/HW_?4'_Q-'DGT
M;_OJ#_XFK65_YYQ_]\G_ !HRO_/./_OD_P"-'-+^:73JNG+Y?W?Q#EE_-V^Q
M'^[_ 'O7[D36L0^QZBN7 =$!7*G!\LJ60@8#8YP,C(SBL_R3Z-_WU!_\36U
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M3_C1S2_FETZKIR^7]W\0Y9?S=OL1_N_WO7[D/TT%+Z !F!(E^0M'\H,;?."
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M  80%Q!%E0"#W);(X);BF81LYC08 Z+_ +:@]2>U7=1"K>3#8A_U74<X\B/
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M>OW(J^2<CY20""0Q@92 <G*[#D8]O?CK74>'X@UI(RJ&W3,3CRX@O7"C8$W
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MWXE?%GPM\(/C)K/A&+3?%O[$/A+P_KVDO;Z_H7ASQ5XT^)'C2?Q?I]WIEM)
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M.&;(V*<,_)0, <-^WVF2/.7(.W[K\G)&%^7YN01\N<U_,[X&^*'A]_B3//\
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MGV&FVEG)>^?\Y?M>ZIXB^"'QL^*_PJB\5>'_  )\,O!W[//AKQ!^S-JOQ?\
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MD* Q(20C!. 0=N&R3@;<Y(('0X_C0\+^.?%ND:Y\;_B-IGB@_P#">?&+5?\
M@FYXS^.M_P"(_CM\0/A1%K7P)\;_ +,?@G5/B[\0/$/BKPSIGQ%UKX=?##4O
MBK'H_A7QC\7?"7P[NK;X<Z;/>^%])UKP[ID^H0:;^Y?_  3+\4^)_$>@?M!M
M)XK\$^*OA?I'QIBTOX4-\/?C;\2OVEO"N@6,'@GPO>^+?#N@?'GXF?#/X:ZG
M\2-"L_%-S?WMC?Z9;:]IFDW>H:AX:76IY](:23:*YE\2C*-&C.::;7M)4J,J
ML8O32-2HU&^J46G=J[FI#DC":=X3;Y4[*7+S)1;U>MFG:W=Z6L_U@_M&RRZF
M=0T>3("K@H,9W-E1M4X.UC\K$,%)*L \7UH3@3H3C.!DG:20&X'W6((5ONL0
M0I)!%?S:_%V\\5P>+?VVOC!;?$KXL6GC#X/_ +=O[.OA7X;"W^)WCZS\+>$/
M"GB.[^!-MXG\.V_@NT\1P>#M3T;7[37]4^WZ;K.BW\)^UW+6<EM))<3RT#\5
M-:B\3S:PGQ;^)+_MZ'_@H3XE\&ZA\%(?B#XHF:P_9P'QOUO0DM;_ .!C:M_P
MC%E\#(/V;+>R\::;\5KGPQ%;GQ+]@U5/'+:G<0V$F:J1]A0K6D_;4J-7D47S
M1]M4PU)1:?VH3Q%Y1U]R$I77*RE2NI-R2MB*E!;:.E"=64Y*^D)0C%1EI[[<
M==#^EA;^T8@"49*[@I20-C)!^4H#D$$,N-RG&X#(SB1^+]#E\0R^&$?4SJ4.
MC0Z^]R?#_B!?#QT^>[FLXTC\6OI:^%)M4$L#R2Z%#K4FN069BU"?3H[">"YD
M_F/_ &8OASJ'Q!T+]@M?&7Q=_:!U]/CO^R%^T3\2OB])-\??BY;GQWX@\!ZE
M\-)/ #7<UCXMLSX?'@=O%MU#I=QX9ET675(=(TVU\1'5HWO(;OR7XG?'3XW7
MG[,\&M_\+B^)VFZ_??\ !-S]BSQ&OB+3_&FO6>J0^,?$/[:OA#PE?^+!>07\
M"KXEU72W72-6UQQ]OUK2&DM+MY;9YK6:ZC5&FJDWS>\XM0OI)5WAV];WCS)S
MO9)1:;:6KQNG-QBI-*JX)M6O&-%56^NOV?6UDV^5?US&^M1C,R\G .&(SO$>
M"0N ?,(3!P=Q5>K 'C_$7Q,\ ^$M7\':#XD\4Z5H^M?$#7)O#?@S3+R9TO/$
M6NV^DZAKT^F:= L;/)<PZ/I.I:C('"(EK97$C. AK^;7XX^/M4_9Z^,O[7GP
M6T_Q3\1Y?@S!\9?V"4T^T\9_M.>-?AQX$\%-\8/!_P 1O^$]G^)W[1&O>'_B
M_P#$'X5?"CQ?K'@GPW;>*#X0BTR[6^GLK'0[KP]'XAN[B^\E^!.MV7CCXC?L
MU7GQ8^+?AWQSH_P=_P""H/C#P/X)\9^$_B3\7K/X3:5:>+OV0/AYXTT#POX)
M\7?$/XI>(?$OCCPCJOQ?N;_2_ GB/Q=K^J+\0H-1GM/#.CZ?HGB?4/!=*D_:
M3A%;2=F]=+T/;IK1II)Q3[NZT>JU]G;5\UG'FCHKN/-*/?>\6K?-72:/ZM_#
MGC#0_%6B67B'2FU6+3;\S"W77?#OB+PKJ8,%S):.+G0O%&E:/KEB6FB;R1>Z
M=;FXA,=S;^;;313/NB^M6"L)E*N,H<-A@5W@@E>A3Y@>A7D<5_*7\#_BOHOB
M+P;X#F_;/_:!^*_@CX:G]D[Q;XE^#&O2_%_QU\/X_'OQL@_:'^/.F?$"YM?&
M^A:W8W?CSXP>$_"&E_"RW\"_#G4M4\1@Z7JUX^B^%-<L[2>40Z/K_P >OB+\
M"/VHOB5\=_'?QHT/XX?!O_@GQ^QO\6M.TJR\>^-? $O@?XV:U\/_ !YK'BGQ
M+J'@OPUJVAZ6GB+6K_2K-_$^AZ]ITNGW%VMRFHZ%;7D $&=*I[1*\6I-4VWT
M7M8XV4=-7[JP-12][1U:6W-K$XJ"<NGO63T;4948NSVU]O%[:<DUKNOZPD=9
M%5T.58!E.",J>01D X(Y!QR.1Q3JY3P+=W6H>"_"FH7TGFWM]X?TF]NY,YWW
M5W8PSSL",<&61R/;UZUU=;-6;6]FT0G=)]TG]X4444AA1110 4444 9UY!),
MX C#QE '!Y# %_D $D94LS1DL=PV*XVY.1R>G>"O#VAS02Z+X=TS2IK>R;3H
M'L+*RM7BTT7#7:6$+6UO%(MFMW(]Y]F$OEK=2R2!0YWUWM<_XAUV#0](U75)
MK74;J/3-/O;Y[;3+1K_4+I;&"6XEM=/LH2T]Y?310L+6TB1IKAWC1%+.N;A*
M:?+!N\FHV3T;;LKK;>VKVZZ$RC%_$D[:W:NU9WT>Z^7R.:M?"_A6RO%O[;0-
M'AO8[Z^UE;B'3+..\76=4ADL]7U(2QVRR1WNHVT:VES=;FNKM \4SR1!0U/6
M/!O@W7(M<AUKPYHVI6WBBS@TKQ+#JNE65[!XBTNSCN1;:=JL$]NZ:E96R:A=
MI';W7VB!/M4ZA-LP#?@-K/B']LN\UWQSXFT36OVS+;2/'O\ POG4_@+X<LO#
M[_;=%U709/AM8?!+2O&NE:Q96VG>&M%UO7;_ .)NM:S:^,1:P_\ ")66EP->
MVX17&->7'_!4[6O$>DZ6-1^)6E>(/%S7?_"2W*:Y)I/PXN9YOB_H_A,Z+X:N
M+;X?:S=_"&U\*>&=!UWQ.?%H;Q?JFO\ A[QG:W-AX<NI+>==/_28>'6(E[*3
MXLX>PSG"3:Q.+G3J0G3CS2CR25Y*A.,Z=:=/FC3JQBI<M.4ZM+YZ>?X=*2_L
MC,*MG;DI4E+F2<%)IJ+6\E9;R2DUHDW_ $ ^'/A/\-O"^BP:!X5\ ^$O#WAV
MUU6#6+31M!\-Z1I&E6VLPS175OJR:?:6D-FU_;S0QRPW:1+.LJ1R),K*CUT%
M]X(\.:Q<:K<:CX5T6]DUS3(]$UN>]TS3[I]9T6+[6J:1JOGP2KJ6EH;^^:/3
M[Q9;2$W4[10CS'\SS_X#^'O&7@7X3^%M!^(VLW^M>-+:T\SQ%=W'BJ_\;[=0
MGE>5X(/%&J^&?!M_JMG;QNL=M+=>&M)E"#R_LV(UD;W2*Y58D#+*<[@"5!+%
M2^1][MM(R>"?ND@9K\ZKN=+$XBBL4L3["HZ:K4G+EFDVO:1?,VX5>7FC=OW4
MG=[GO4X4Y4J<O9>R<DI*G*,>:*LFE)6:35[>[HM?)GF?@[X0?#SX>Z=?Z1X#
M^'O@_P %:3JD[7.I:7X5\/:1H5AJ,[PK%+-?6FFVUK!=231KY#R2QM(8?W1W
M(% A\*?!3X7>!!JR^"?AAX#\))X@#QZ\GASPIH&BC6K>02@VNJ?V?8P"]A'G
MS$I<B2/]ZX"X>3=[!4<LHB7>P9AD#"XSD]/O%1UXZYYZ5FZM5W;J3=[7]Z6M
MOYM=7YLI4Z:5E"*7915ONMH>+:/\#OA%X/TG7M!\+_"OP!X9T+Q5;F#Q)I6@
M>$_#^DZ?KML%NU:'6;73]/M[74X@M]>(D-Y',H^W7#( 99%?5\1> O /BUKM
M?%7A+PSX@^V:3-X>NUU[0]+U(SZ')>VFK7.ESM?6DXN-+DOK*POIK25I+62^
MLK:X,0N859/1+H/=[%A*KF.3)DR0C,H*[D0G<R@!]C$ @@@XS7YX7^E^-M$_
MX*/>"WU#XK>,_$?A7QQ^RW\?=0L_AK>3Z?8> /"4_@[XG?LS6FC:GI6@:786
M<NI>('3Q5XA.H^)_$>H:WJAAOX=*T^;P[I,<-K>3[:LZM*$9RYI>U;DW)V]E
M0E5NG?2_(E=NR5^Z1<*-.:J<T(6Y6_AO=);/;S_#5'V;X%^$_P .?ALMX?AU
M\.O!O@E-8%D^IGPCX?TCP^NHI9>=]@^V?V39V8O!:)=W1MS.LAB%Q,%8>837
MIVQO,A;'"H0QXX.TC'7/4BGP B"$'!(BC!(Y!(0 X.!D9Z<#Z"I:'*4FY2DY
M-JUY-M[I[O7HEOL*RLDDDD[JRMK_ $@HHHI#/R6_X+-DG]@'XK[0,C7_ (9=
M?0_$;PP2?PP._3-?Q8MGS&QS^[/'KT_KC\*_M0_X+,C_ (P#^*_/#:[\-#^7
MQ'\+*,>_+ 8[GH<"OXKRX$A'L1G'.?O8SZ=NG^-?TKX,\W^KN,Y8W7]H5;^]
MRZ^RH/OK=Z_U8_@GZ4?*^/,IN[-<,X1;-W_X4,RTV=M&_FG9.R&,2"/E)&>H
MQQUZ@]NQ^M;OA_PUK_BJ_&E>&/#^N>)=4\K[4=.\.Z)?:]J L[:2.2Z>2TT_
M%TEN$41M/$2L<DD98,,JV+UP.@'/!QSSSR1GKT)QTXXKU/X/_&KXG_ +QA_P
MGWPB\4W/A#Q:-,O=%.L6VF:%JSMIFH/;R7=JUGX@TW5-/99GM8#YGV7S4V?N
MY$#,K_J>+GC(T:SPD<)+$^RE'#T\35E&TVDO?G&,VH--W:A.5G9*]FOY\RV.
M#>,P;S&IBX8"->$J]3+J.%K8U4TUS.G1QM?"X>4DU'V;G4C'=MW23_5V7]HS
MP-XC\%_#+PQ\5?\ @E/XY^(FH?"_P1I'@G3O$-[XN^)FFW]YIUE"6>.^;3_A
MG%/+ UU-=7$-I?7>II9&XDB@N=AR?SJ_:GU_P'XC\9^';KX??LN:M^RII</A
MLQ7O@_5?$7BOQ&VOZ@FJ:@Y\2PWWBO2='U) MHT6DND=O+ );?RO-* L?<U_
MX*O_ +?\2^4G[0>KXVX'F^ /A$25;ELLWP_9R V0 7([ ;0 /E?XV?M!?&#]
MI#Q'IWBWXS^-9O&OB#2-(&@6&I3:-X;T-X-(CO[O4OL@M_#.BZ)9S#[9>7,H
MGFMY9SYBQ-,88XHT_/\ (>'LXR_,OK>(PV"PE)SG.:I9OGU>%2K4DI2F\-.D
ML+)RDY.[7*F[1M';]:XQXSX9SO(YX#"XC-ZN.4L/2C6S;@OA3!5I4L&H0HPC
MF^48B>81C"-.FH3A)QG&/OQE!N+\8QGG/W>WKGB@]%_ZZ?\ M&>G$CC'..Y_
MECTQCW]\8IA.XH!@$2#. .<QS#!/MG_$YK]*;GRRO&RY'=\[:U79Z[Z;7_)_
MBE11]G6?/S/V-;:*U7LI)OF6]NSWW2;U/[=/^"0'_*/'X ?7XH?^KB^(%?IT
MD*O&<Y!9F.X8R,$K@''0@<_6OS%_X(__ /*/#]G_ #US\4,_^'B\?U^H48 1
M0/0'\3R?S)-?Q)Q!_P C[._^QKCO_4B9_K'P3_R1O"G_ &3F2_\ JMPQEIH\
M*-N61^"Y5=D85?,"JV,("/E4J,$<,<@TBZ+;J"/,E^[L!!"/LP0073:[9W'D
ML2,_+@@&MBBO([:O1<JU>UT]MFTTK-ZK5)I-W^GLM=-&[VZ7]/Z6SZ(Q_P"Q
MK<8Q)(H' ""-,* 5"@HBD* >%SM&,XR2:0:); DAY!EF; 6,##,K!!A 0B%<
M( 0%SQC"XV:*7*K<O3W5:[^Q\-];NW=ZOK<=W=.^JO9]N9).WJDE\C)&CVRR
M"16D0C?@*5QA^JX*G"\L<#DL068X J1-+MT+%2X+<L5(4EN?F; P>3T(]ON@
M :5%/^OQO^;;]1?U^"7Y)+T270R#HUJ2C='2<SAQ'$#YC J[8" !V5GS(N'#
M.S;B2<G]C6V_S"SERFW<0A;/S88,5)4@MG P#@9' (UZ*32:L]DG%*[LHM<K
M25]%;2RT2V#9W5KI\U[*]^_J[ZOKU,G^R(0SL)I5WHR$+Y8(SN (;9GY Q**
M<HC9=5#,Q,;Z%:M UO')+;QLJKB JF A4C VD'D%N<DL26W L&VJ*+)IJVDK
MW7>][_FP\^W_  '^:1XO\*_@3X*^#NE^*M(\(2:W]D\8_$[XF?%K6CJNI-?R
MOXL^+/C#4_'/BTVS^7#]GTMM=U:[;3=."M%96ODQ[IIHA<'TW^PK3:%W/M!8
M[=J;0Q=6#!=N%8 .A*@;EE<-D'%;=%-:6M?2UM7]E67W)6]-.HW)R?,W=]W_
M %^!\_\ Q:^ $'Q6_P"$>GM_BY\;?A7J?AN?49+75/A-XY7PZ=0M]5M(K2[L
M=>T/6=)\2^$]<A0007%A=:EX>N-5TBZ2672=0L?MVI+>]'\)_@EX&^"O@+PY
M\-_ MM>VOAGPREV]H-4O9=9U2]U#4]8O?$6M:UJNJZAYUU?ZQKOB+4]3U[5K
MZ0J]QJFH7-PBQ!D1/7:*%ISVT]I9SMM-Q^%R75J[LWM=]V#;?*GKRWY?*^K_
M .!?;I8RAI%MMVDEOFC8LZJ[DQ$M$"S G$9+LH[.V_[PS2KI-LL?E GRRNTH
M5BV, ,?.@01MNY\SY,2$MN!!(K4HHM_PW3:VJV>FFO305_ZZ].N_0K0VJ01I
M'$2JIG& ._8<?*!D@ 8&#CH!BS111ON"T5ELOZ^[LMET"BBB@ HHHH *SK_3
M+?455)RX"YQM([L&.0058<8PP..HPP!K1HH6C36CC)23ZJ46G%^J:37H)I--
M/523BT]FFK-/R:,@Z/;D8\R4,6#,R[$+8)."$51MY/!!&<$@D# -%LUQM7!&
MS)*HV3'L*$*ZLBLC10LC!04:&(K@HN->BE9)W2UUU_Q6O]]E]UMBFV]WN[_-
M?\,CPWP'^SYX"^'/Q%^-WQ1\.G6?^$I_: \4>$?%WQ >_OTN;!]7\$?#_P -
M_#70CHUDMM"FFVZ>'/"NF&ZC+7$MU?F>Y>81_9X+?UC^Q("<F:7/F&08$:X.
M2P&516VEL&12Q$N-L@9&96VJ*++31:*27DI?$O1K1^6FP-MN[W]W7K[J2B_5
M65GTWW,==%M0V]F=Y#Y>]BL8\P1$% ^$!(!&0 0H+2,%#2R,SHM'M8 BPDQK
M&JH@18U"*BLBK& @$0",4 C"@(%4 *,5K4465[VUVOY:72[)\L;I?RQ[*RV2
M71-/SNMFWNVN[?5]W?$ET&UF!#23@EF8LC*C,K;?W;,J@L@*(5R=R[ JL$+H
MR0Z!:1$'=(YV*K$A!N*@8/"_+R,A5P!EAU)-;E%#BG9-7M9J^MFG=-=G=O5:
MZO4-KI:7M?SM>WW7=O4Q_P"Q;;<[%I&\P1@AMK >4J^7M!& $=%D10-BR .J
MAQNJ_;6L5H@CBR$'13CCN?S//YU9HHLKMVU:2?FHZ17RN[=KONPZ)=KV\N9W
M?WO5][+L@HHHI@%%%% %=K969F+,"V<XQWXX[_CFL>?P]!-%-&EW>6LDT4T2
MW-J\27,!FW?OK>22*54GB+!HY'23YU4N'7<C=!12LKJ5E=)I/JD]TO('JK/5
M7O;ST?Z?U=GR%9_L5_"F+X,?&WX*:IK'CWQ+IO[1FG>.K'XS^.?$/B"VO?B5
MXZN?B#X1C\ ZQK.I>(X=*M;.#5M.\$VFC^%O#3V&CVECH&B^'?#]E8V"Q::@
MD^C?"G@C1/!GAO0/"FAK/%I/AO1M+T'35GD6><:;HUC#8:?'-,R R/#!$<N%
M3<\LQ*X? ["BA12<FOM>S4M6^;V,)PI73=G[.%2I&+W2G)=6#U:;M=.HT[*Z
M]M*$ZO\ X'*G"4N[A%]$8XT6U!3:S*J#:J(L2($"11B,*J "-4A2,1@!/*_=
ME=H7:^72()O+W22_N\;<,.2(S$"V0=^$)'S[LDDG.:U:*>S3N[K;7;;;[E]P
M=_--/T:L_P -"A+I\,T20NS$*,9PIW#:%P05*]E.<9!7(()S5)]"M78EG?:R
M[70+&!)R3F3"_,0I=%8_.J22*K .P.Y14\D;MVU<E/K\:5E+UMIZ:;#4FK6=
MK))6TLEM]W0R8]'MXU"H\@ +$X.T,Q+,A=4VJXC=MZ*X901C&"13O[*B#$B6
M4!LD@;1E]NP2$[<EU0!$9LE%RJD*Q6M2BJ:3W5]WKW;NW\WJ^[U8DVMG;;;2
MUK6M;:UM/NV,DZ/ WF9=\RC#LJQ*VW:RJ@(CYC0.^Q&#!2Q(QG%,;1HRH5+B
M6/;D@JD1^8EF5ON#YD=BZD=#D# )K9HI-)N[UVWU7NV2TVV26VJT=TV";6SM
M_3Z^K;]7<QFT.U>19'9V9(VA0 1JJ0N,21 *@)CD"Q;T)*LT$#E=\2%=6*,0
MQ1Q*25BC2-2<9(10H)Q@9('. !4E%"5E97M=NS;>K=V]6PW:?967HMEZ*P44
M44P"BBBD[VTW _!+_@O:Y'[*OPT3&&D_:$\)2,2.01\-/B^H';/)YSC /%?R
M:[T)PV"0#\P!SDA2!W&/7G X],5_91_P5[^ GQ<_:4^ O@;P9\&/!]QXX\5:
M-\6_#WBF]TJ+6O"OAU8=)MO!WQ&TB>_>Z\6:[H-LX$^L6\1M87,A9Q(@$8D=
M/YX6_P""5G[?BXW_ +/MVA9@J9^)/P5Y&U3L8+\2'P<<@-CY3DD #/\ 1GAG
MG>3X#ANCA\=G.!R^O'%XBK".)J1@G[3V<9.HI2349)*UK6T/X8\?>#.*L\\0
M\3B\JX<SK,,"\IRF,,=E^&G7H.I"I%2ISDHN-XQE)25WHY,_/,@EN5/E!3DI
M^\F,AX4+" ,H,[G<N H&/>OT5_X)Z_L-ZQ^UY\3(;SQ%%>:=\%_!-Y;W7C/6
M8K8I-KVI6YCEM/!NCLP:*:;4&=9-7N3)*FFZ<$#%)KR$IV'PV_X)&?MF^)_'
M/AOP_P#$3X:?\*X\%:G>^7XF\9W'C?X9ZX^D:/&CS7HM=(\->.-8U2\U"^AC
M-EI:1V$D*WTL;7LEK9K/=1?U@_!3X/\ @?X&?#?PQ\-?A_I-MI'ASPS8K;6Z
MQPB*>^E=I);W4-28QQFYU#5)9I;C47D3;.S+"08(+=$[../$+ Y?@EA\GQL,
M;F%;G4,5A)QJ4,/2E3G"56#4G>O=VC=W6LNB3YO"#P.SC-L_69\79=5RK*LM
MQ-.OA\OQ5.=*KF->G[U.C4A.,9+#12YZEKJHTZ?-9S<>U\*^%-&\&:)H_A?P
MOIL.B>'_  [IMGHNE:58H(;2PT^SM_LT%O!"@"1QK$Y$HP3,X624LZ(5[ DC
M(R>HR>YVC:,]OR ]L#BJ$8 )$88;9(E50-JA9&QG@C( (X8D!1QBKY^Z&[EF
MS^ 4_P!37\W1<I2JU*CE*I5J2J5)2DY2<YI2;;D[W=[ONVWUN?W93C3A",*4
M%3IT[TZ=&"M"C"FU!0@MHQT]U+1+:VPVBBBJ- HHHH **** -6V_X\K[_KE'
M_P"A"LJM6V_X\K[_ *Y1_P#H0K*I+>7K^B)A\*^?YL****904444 %%%% !1
M110 4444 :.D?\A*T_WY/_1,M4'^^W^\W\S5_2/^0E:?[\G_ *)EJ@_WV_WF
M_F:75^B_.1*^)_/\H#:***904444 %%%% !1110 4444 /3^+Z#_ -#2KFI_
M\?TWTA_]$1U33^+Z#_T-*N:G_P ?TWTA_P#1$=+JO1_G$2WEZ_HBA1113&%%
M%% !1110 4444 %%%%  5\QQR5)<?=&[EB0./0EN3G@<GI71^'[,2VKB5G(2
MXD)4XP=S'Y<@?=& >#D'J2<U@1#,B ]"P!KKO#X'V20XQ^^D'' P&.!CI^E9
MSC%INRN[)RM:32=TN9:V3L[7MOW=TFTW%/W6KM65KIZ-=GJ[VMYW+3Z1;.6)
MS@D$+MC.W P0&*ECD$Y).>>,8%6%LHU7;N;'X<<8XX]/7/4U<HK"%*G3YG"*
MBY?$UHW[TIZO=VE.4EV<G:UV6Y2=KMOE::OJDUL[;7T1B'0X!C9<7,>4,;[7
MW"1"[R882!\-N<EI$VR.  [, NUZ:-$AD/VB<M(2Q.Y5VDL6!4* %*DL 1AF
M! <L$CV;%%6DDTTM4E%>B=TOE;2^RT6C8FV[WUYFV_-O?[[7?=Z[ZF,VB6K%
MCOEPX =#M*/M"A2RE>=I4'G@Y8$;6(IPT:W  #N#M W;(2WF  &7>8R^_:-@
MRQ"IA%PHQ6O12MI;6VBW?2*BNO2*2]$NR$M+V25[W]U=7=].]WY-NV[OD?V/
M"65S+-N7(!!48&&4;05(0^6PB8Q[2T2[&)!JO+X>MI)?.$]PLFT*#NW8P49<
M _= DBCDV+M0L')7,LI??HH22;:TNV].[BXO397BVM.C#M_=:<?)Q:<6O--)
MWWNK[F6NEHI.)YMI'$>5"*Q)+,%4!?F! ((/W01T #DTN%%*K),N0HR& ("[
MMN#C@+O) ^Z#G &Y@=*BFE;;2^MKNV[>WJVPOMY;:+3;;MLC(_L:VRQ5G7=Z
M!#M +%0I*D@+N; ' !4 !40!3H]LP*NTC+P<%B"KJ?D=&4JT;*"PRI!.XG.0
M,:U%*RNGUBFEY)\MUZ>Y'TLK#N]?[SN_-ZZOUN[]^O0QAHL V?O93L+8.$#
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MYH7CCQ#X*E'BV#X>7\MY967B<>'M?NK/Q%X5LKR^6VU)%CM3&\\#2>A?!/\
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MANZ$:)XNS_X]"1^GMU(S#/\ \$ OV@ "B?&OX6892L@33/%D)P64C;BT+!R
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MPK8? T*-6$G%M-QG"2=FU?5:6'4445YI[X4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** $P.>!SP>.H]#2X Z#';\!T%%% !@>@XZ>W3_ ?D*3
M]!^5+10 F!Z#\A1@>@[]AWZ_GW]:6B@ P!T '^?_ *Y_.BBB@ HHHH ****
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MKM!W[!&&VLS*L8&7DSE5R,$&H(<G9PLGE,=W23*@+PI&[!+$9'RKO3>A#5^
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MLSH%[96MK]U?L._M/?M,_%7QK^TS^S_^UIX3^#?A_P"-_P"S3XH^&]EKFO?
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M.:$;/1WFI-=6OL-O7JOE^BE%,CR40DECL7). 2<#)('&2>3CCTXI]60%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 AZ'UP<?7':L]OF="T(95!8!D[A
M@P/((!)48/8J#U K1HJ7&[O>ST_7S\_P&G;^OZZ77S?=F7(@\S*1$!5"C"8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>nt10016217x4_graphic20x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic20x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( ?0#R@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M.E7GB:YA\.+FTU#3?&,?RY\.?VF_^"QO[:7[;O\ P4Z^"_[._P"WK\#/V>O
MW[&7[06H^ O!GAWXK? WX7:VFL>'_$?C'XO:/X2TJU\0GP#JFMNGA^T^&(MM
M8U74QK&HRKJMI=%+N=)4F^FKG_@JI_P4I_:P^(O[+/P<_8Q_X)W?M%?LV>+]
M3\8V=]^UC\3_ -N']G7Q?H7P)\ >&+31KJU\0Z!HNIP^(?"^I:]:075Q?>)-
M+FDU[X>>.M>O_#/A_P ,:-HT[:_KD-G^?7PC_P""(WA[]O']K?\ X+I']JWX
M)_&#X2:KXA_:(77OV+/VB?$?A/XD>#='M[WQ5XW_ &B[[6O&/@&'4F\/>"_C
M5X*NC9?#>?Q9IZMK=K+H%[IIT76O"^J:UI>OQ@'[(?\ !"K_ (*$_M#_ +>/
MP9^/.F_M*Z;X+U_X@_LT?&B^^#5U\=/A?';0?#3XV26T%U=S:MX?AL8;;3#J
M&D116=U>7VB6.EZ)J_A_Q)X2U:RTC39[V\MQ\R?\%L/B;_P67_8^\/?M!_MJ
M?LZ_M8_ GP5^QS\-K+X/IHOP?U#X8^%O%7Q=M[[Q?KGPZ^%>M3+?^*/@[K6F
M7<5U\0_%=SXA5;WQXXMO#S/';1QW$,&E5[?_ ,$ T^-_P:^ OQ/_ &)?VC/V
M1M8_9U^*'[,_Q(UW36^*?AOX#:A\-O@I^U)H-Q=G0+'XI^&_B#IG@WPQX+^)
M7CFTMO#MAX?UOQ+"9=9\6^"++X?^*)+K5KV;Q&NB>X?\%^_AC\2OC)_P22_:
MR^&_P@^'GCGXJ_$3Q'_PHC_A'O 7PW\)Z_XY\::]_8_[2_P:U[5O[&\+>&-/
MU37-4_LO0]+U/6=1^PV,_P!BTG3K[4;GRK.TN)HP#YC_ &-_VJ/VS?V5?V<3
M^W5_P6-_;>_9_P!;_9=^+/P@^#WBOX.:?X'^')TGQUH7B[XIZ=8^+=*T*^T#
MP)\&O#>L>*_$5YX9OV@ET/PS-XM2R&E:UKDB0:#I&HZW;_6_@;_@N=_P3%^(
MGP)^,'[0_AG]HR.;P-\ H?"=S\7M'OO 'Q&T[XB^#;+QOXU\/?#SPYJC_#B[
M\+1^+O$.AW?C#Q7X?T2Z\0>$M+U_0=*O=2AM]6U*RG66)/A3]OB#]LGX;_\
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M#XW_ , H?_-!]6T5\I?\+"\8_P#0;E_\!;#_ .1:/^%A>,?^@W+_ . MA_\
M(M'^KN,_Y_8;_P "J_\ RH/];\N_Z!\;_P" 4/\ YH/JVBOE+_A87C'_ *#<
MO_@+8?\ R+1_PL+QC_T&Y?\ P%L/_D6C_5W&?\_L-_X%5_\ E0?ZWY=_T#XW
M_P  H?\ S0?5M%?*7_"PO&/_ $&Y?_ 6P_\ D6C_ (6%XQ_Z#<O_ ("V'_R+
M1_J[C/\ G]AO_ JO_P J#_6_+O\ H'QO_@%#_P":#ZMHKY2_X6%XQ_Z#<O\
MX"V'_P BT?\ "PO&/_0;E_\  6P_^1:/]7<9_P _L-_X%5_^5!_K?EW_ $#X
MW_P"A_\ -!]6T5\I?\+"\8_]!N7_ ,!;#_Y%H_X6%XQ_Z#<O_@+8?_(M'^KN
M,_Y_8;_P*K_\J#_6_+O^@?&_^ 4/_F@^K:*^4O\ A87C'_H-R_\ @+8?_(M'
M_"PO&/\ T&Y?_ 6P_P#D6C_5W&?\_L-_X%5_^5!_K?EW_0/C?_ *'_S0?5M%
M?*7_  L+QC_T&Y?_  %L/_D6C_A87C'_ *#<O_@+8?\ R+1_J[C/^?V&_P#
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M .1:/]7<9_S^PW_@57_Y4'^M^7?] ^-_\ H?_-!]6T5\I?\ "PO&/_0;E_\
M 6P_^1:/^%A>,?\ H-R_^ MA_P#(M'^KN,_Y_8;_ ,"J_P#RH/\ 6_+O^@?&
M_P#@%#_YH/JVBOE+_A87C'_H-R_^ MA_\BT?\+"\8_\ 0;E_\!;#_P"1:/\
M5W&?\_L-_P"!5?\ Y4'^M^7?] ^-_P# *'_S0?5M%?*7_"PO&/\ T&Y?_ 6P
M_P#D6C_A87C'_H-R_P#@+8?_ "+1_J[C/^?V&_\  JO_ ,J#_6_+O^@?&_\
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M2ORQE*W>R;L72A[2I3@W;GG"%][<TE&]O*X?\-R?L4_]'@_LM_\ B0/PF_\
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M8=4L]8@O0;.;3+BUCO8KH&W>!9@4KY,_X)(?MT^*O^"A'['^D?''Q]X:\/\
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M['X\_"R[O;Z]NYDM[2SL[2W\523W5U=3R1P6]O!&\TTSI'&C.RJ?IJOXSO\
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M#UK:^$ETOQ'?:-?>/]-\&_#3Q1K&I:UJ+:)H:ZM=:'/-I\6GI/I>I?,VI?\
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M(H;/6_#$&B:Q=V.JVZ7.F:G?7VG9DBM8Y7] _P""\O@[PQ\1/VIO^",/P_\
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M\,?_  J/%7_QNC_B(<^,W_1N_P ,?_"H\5?_ !NH_P"(0\=?]"S#?^'+ ?\
MR_\ JS\K^5_Q-'X-?]%#C_\ Q'\Z_P#F+^K/RO\ U=45_*+_ ,1#GQF_Z-W^
M&/\ X5'BK_XW1_Q$.?&;_HW?X8_^%1XJ_P#C='_$(>.O^A9AO_#E@/\ Y?\
MU9^5S_B:/P:_Z*''_P#B/YU_\Q?U9^5_ZNJ*_E%_XB'/C-_T;O\ #'_PJ/%7
M_P ;H_XB'/C-_P!&[_#'_P *CQ5_\;H_XA#QU_T+,-_X<L!_\O\ ZL_*Y_Q-
M'X-?]%#C_P#Q'\Z_^8OZL_*_]75?E]_P4C_X)KV_[>-Q^SI\2/ _QO\ $'[-
M7[3'[)'Q&F^)?P ^-FB^$=)^(ECX=U34+OPU?ZWI'B?X>:YJ>C:3XMT75;SP
M;X8NOLM]J<,$,NF-;7MKJ^AZGK>AZK^0W_$0Y\9O^C=_AC_X5'BK_P"-T?\
M$0Y\9O\ HW?X8_\ A4>*O_C='_$(>.O^A9AO_#E@/_E_]6?E<_XFC\&O^BAQ
M_P#XC^=?_,7]6?E?[.^%7_!%;Q9!=?\ !0CXP?M,_M<W?[0'[7_[?O[-'C[]
ME?5/CE:_!G2?AQX0^$/PR\:_#VU\!QV7ASX1>&_&W]C^)9;'^P/ VI7<L^L^
M'+B_MO!EAIMO<Z9J6L>*_$WB']'?^">G[(?_  P;^QQ\%/V2_P#A87_"U?\
MA3VF>*M._P"$_P#^$3_X0;_A(O\ A)O'WBOQQYW_  BO_"2^,/[(^Q?\)/\
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M>+?$4'AI[[Q!=6?A.W\1>(;73[:XT^^L['3;_P#Q$.?&;_HW?X8_^%1XJ_\
MC='_ !$.?&;_ *-W^&/_ (5'BK_XW1_Q"'CK_H68;_PY8#_Y?_5GY7/^)H_!
MK_HH<?\ ^(_G7_S%_5GY7_7KX0_\$W?^%5?\%3/VK/\ @I;_ ,+F_M[_ (:<
M^$/@GX5?\*5_X5W_ &7_ ,(1_P (=X;^"GA_^WO^%C_\)UJ/_"2_VC_PI[[7
M_9?_  @>@?9/^$B^S_VC=?V1YVI_FUX7_P"#<K2O#7_!.C3/V'T_:]UAOB!X
M&_:]B_;&^$_[0^C_  5L=$/A#QS;>#M%\%6_A_5OAK>_$[Q'_P )%HRZ;87]
M\US;>/-!G_MJ;0[YK:6VT&XT[7/*O^(ASXS?]&[_  Q_\*CQ5_\ &Z/^(ASX
MS?\ 1N_PQ_\ "H\5?_&Z/^(0\=?]"S#?^'+ ?_+_ .K/RN?\31^#7_10X_\
M\1_.O_F+^K/RO^OG["'[#_[2O[./Q)^,?QA_:C_;C\2_M;^,_BIHO@W0M$\,
MZ?\ "S2?@?\ "7X8VOAFT%EJU[X5^&WAOQ5X@\*P:WXNCT_0+K5M2T#1_!T'
MVVUUF[O-.U;4?$%YJ*>+?\% _P#@DIXO_:F_:J^!O[=/[,7[66O_ +&O[6'P
M1\'WW@&#QY8?#/2_BSH'B_PDT_B"?2=,U7PKK'BGPQI5O/:+XQ\8:9J]QJEM
MXJTWQ)H&L6VC:GH1BTBPG3\[/^(ASXS?]&[_  Q_\*CQ5_\ &Z/^(ASXS?\
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M/'&@W=XVN>']<C'M/_$0Y\9O^C=_AC_X5'BK_P"-T?\ $0Y\9O\ HW?X8_\
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M68;_ ,.6 _\ E_\ 5GY7/^)H_!K_ **''_\ B/YU_P#,7]6?E?Z%\8?\&_\
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MW^V#O^WI^:'_ !$.?&;_ *-W^&/_ (5'BK_XW1_Q$.?&;_HW?X8_^%1XJ_\
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M!7U_XM_Y%CQ!_P!@B_\ _2:2OD"OKN'/]WQ'_7Z/_I"/S_C'_>\'_P!@\_\
MTXPHKY3_ &UOB=\3?@]^SGXU\?\ P?LO[0\?:/?>$X=(M?[!F\2[X=4\5Z-I
M>J'^QX%>2YV:9=W;[@I%OCSS@1DC\+_^'D'_  4;_P"A0_\ ,):G_P#(]?I&
M3<*9CGF%GB\)7P%.E"O/#N.*Q+HU'.$*=1M05*=X.-6*4KJ[4E;2[_!^+O%'
MA_@O,Z64YK@L]Q&)K8*ECXSRW+H8O#JC6K8BA&,JLL31:JJ>&J.4.5I1<'S/
MFLOZ?*\M^.7PU_X7/\%/C!\'O[:_X1O_ (6O\+?B!\-?^$B_LW^V/[ _X3KP
MGJ_A?^VO[(^WZ5_:O]E?VK]N_LW^T].^W>1]E^WV?F_:(_YU?^'D'_!1O_H4
M/_,):G_\CT?\/(/^"C?_ $*'_F$M3_\ D>O5?AUG4DXO%9.U)--?7Y:IJS6E
M"^W8^7C]('@Z$HSCEG%JE&2E%_V)2=G%W3L\<T[-;--=SW3X%_\ !)'_ (*"
M_LT_"OPM\$_@?_P6)UGP'\+_  5_;?\ PC'A2T_8@^%VL6^E?\)'XCU?Q;K7
MEZCXC^*^L:S<?;O$.O:MJ3_;-1N/)>\:"W\FUB@@B^V_@=^P!XL^&/[:\W[;
M7CS]H:3XL^.=:_8U\#_LL^,],F^%ECX-E\5^+/#5]\-M6\1?&:75=,\:ZGIN
ME2>,-8\!7FH/X!T_PNMCHC>(C!:>([F#2HTO?RP_X>0?\%&_^A0_\PEJ?_R/
M1_P\@_X*-_\ 0H?^82U/_P"1ZYJ?A?F=/D4<3E=J;BZ<99MBJD8.":ARQJ0E
M&*BFTDDE;1JR1VU?I(\,5G5<\NXGYJT:D*LX<-8"E.I&K*,JG/.E7A.3E**D
MVY.5]4[MW^T_#7_!&OPK9_L._M>?L5>,/CAJ7B33?VI?VA_%O[1-C\0](^'M
MMX:U#X;>(M8N?AGJOAO2(_#UWXR\30^*K30=:^&EE)J]W_;/AJ;Q)HNKZCI%
MO#X=N!%JP] _8^_X)\_M+_ [XN>'OB3^T+^W=X@_:+\,^!OA"WPA\&?"/1/A
M!H_P<\!FWMY5@TOQGXVT_0?&&N:5XV\66FAW.K:/-JFJ: OB*_\ .TNZU;Q7
MJBZ-;6C?G9_P\@_X*-_]"A_YA+4__D>C_AY!_P %&_\ H4/_ #"6I_\ R/1'
MPOS*$J<HU\HBZ48QA;,ZZ7+&4IQ4HJG:IRRE)Q]HI6YGT"7TD.&)PJTYX#BN
M4:TI3GS</X1R4I0A3G*G-XKFI.<*<(R]DX<RBKZZGK^A_P#!$/XW?#^RU3X&
M_!W_ (*-?%#X2?L3:U\>HOC@WP2\#_#R#1/BCX:C^WV]Q<>"_"?Q]MO'7_"4
M6=D;33],CL;ZYTV71+36K.S\5WW@K6-<@U*?7?K;7/\ @FKXXTG_ (*2P?\
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MK1^T:I>S:<]SJ7YH?\/(/^"C?_0H?^82U/\ ^1Z/^'D'_!1O_H4/_,):G_\
M(]$/"W,:<H2C6RCFIRC*FWF5>7L^55%&,%*FU&"]K.U-)0O*_+=1LJGTD^&J
ML)TYX+BQQJPE"JEP_A8>UYW1<YU7#%1=2K)T*5ZTFZMH6Y[2FI?N[^V7^RMX
M&_;6_9J^*/[-7Q#OM0T?0/B/I%E#;^(=)2.75/#'B30-8T[Q-X3\264$LD*7
MAT;Q)H^F7EYI;W%K%K6FQWNBW%S;VVH32K^-4G_!#S]HKXG^&/@3\#/VJO\
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M!I;>(Y_.^VP?GC_P\@_X*-_]"A_YA+4__D>C_AY!_P %&_\ H4/_ #"6I_\
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M"?%.GZ/H'AJTL=4T/3EUFPO-+EU;2==TR;5M?M]9^'O^'D'_  4;_P"A0_\
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M.&!XLC&C*DX/^P,*YI4*OMZ,)5'BG4G2IUOWD:4Y2I*5GR:*WZ)?%C_@EO\
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MM6NKJQU._P!<N[]?R9_X>0?\%&_^A0_\PEJ?_P CT?\ #R#_ (*-_P#0H?\
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MW-C:VME+XGU&X>34!8^%8?#/P%_P\@_X*-_]"A_YA+4__D>C_AY!_P %&_\
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MW1_PR9^RM_T;/^S]_P"&:^'/_P S=?0-%']IYE_T,<=_X5XC_P"6!_J[P_\
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MV?O_  S7PY_^9NC_ (9,_96_Z-G_ &?O_#-?#G_YFZ^@:*/[3S+_ *&.._\
M"O$?_+ _U=X?_P"A%DW_ (;,%_\ */)?<?/W_#)G[*W_ $;/^S]_X9KX<_\
MS-T?\,F?LK?]&S_L_?\ AFOAS_\ ,W7T#11_:>9?]#''?^%>(_\ E@?ZN\/_
M /0BR;_PV8+_ .4>2^X^?O\ ADS]E;_HV?\ 9^_\,U\.?_F;H_X9,_96_P"C
M9_V?O_#-?#G_ .9NOH&BC^T\R_Z&.._\*\1_\L#_ %=X?_Z$63?^&S!?_*/)
M?<?/W_#)G[*W_1L_[/W_ (9KX<__ #-T?\,F?LK?]&S_ +/W_AFOAS_\S=?0
M-%']IYE_T,<=_P"%>(_^6!_J[P__ -"+)O\ PV8+_P"4>2^X^?O^&3/V5O\
MHV?]G[_PS7PY_P#F;H_X9,_96_Z-G_9^_P##-?#G_P"9NOH&BC^T\R_Z&.._
M\*\1_P#+ _U=X?\ ^A%DW_ALP7_RCR7W'S]_PR9^RM_T;/\ L_?^&:^'/_S-
MT?\ #)G[*W_1L_[/W_AFOAS_ /,W7T#11_:>9?\ 0QQW_A7B/_E@?ZN\/_\
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M **** .>\6?\BUK8['3[@$>H9<$'U!!((Z$$@\5\?CH/H*^P/%G_ "+>M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /N"BBBO
MR\_< HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDC;48\
M\#L,GGC@=_IU]*?37&5/U!_(@T ?SU?\%?/^"D7B3X)73?LW_ _5I-(^(&JZ
M4E]XX\96;Q&^\*Z3?AUM-*TIMSM:ZUJ$:R327)5'L[5E:$&21&7^4G4M1U/6
M=0N]6U?4KW5-3OYWN;[4-0N);V]O+B1BTD]U=7+RSSRNQ)9Y9'8D\FOM3_@I
M1(9?VY?VCC)(\FWQUY:F1V8JJZ/I>%7+-A5).%!PO/ R<_#G[O\ SNK^U> ^
M'\OR+AO+/J=&"Q&/P6%QN-Q3BO;8FKB:%.M[\]9>SI\_+2I)\D$KI*4I,_R,
M\;>-\]XSX^X@6:8JK]1R3-\RRC*<MC4;PF"PN7XNK@U.G2LHO$8ET'6Q%>2=
M2<Y\G-[.G3C%2K'JY_[Y3U!XXXY (QT/2NM\$^.O&7PW\2Z;XQ\!>)-8\)^*
M-'F2YT_6]#O)K&^@EB96"^; Z^9"Y $MO,LD$RY22-U)%<C^[_SNH'E@Y'4?
M6OL90A4C*G5A"I3J1<*D)QC4A*#M>,H33C)-734DTUT[?DU"M6PM:EB,-5JX
M?$4:D*M'$4)RI5J-6#C*%6E4IN,H5(RBI1G%J46DTTTK?VV?\$K_ -OYOVQ?
MAWJ/ASQ\UI;_ !E^',-C#XE-JL4%OXFTJ4"&Q\26EL',T<DS1/#J4(B6*.[!
M*,4=:_7#K7\:/_!"&=A^V9K,,<TR13?";Q$9HEDD2*<IJ^BF,RQJ0DIC+,4+
MAMA)*X).?[+0, #KBOXW\2LBP60<58O"9?!4L+7HT,;3H134,.\1%N=*G=M^
MS52,I06BC&2@DE%(_P!8OH_\8YOQOX:Y5FF>5?K.9X3$XS*<1C).]3&K 3C&
MCB:VB7MYT)TXUI6_>5(2JNSFTEHHHKX$_:@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GO%G_ "+>M?\ 7A/_ "%?
M'Z]!]!_*OL#Q9_R+>M?]>$_\A7Q^O0?0?RKZO(/]VQ'_ %_C_P"FT?GG&O\
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M&Y,+47)&+C'$J,K^ZW=HHHK\3/Z^"BBB@ HHHH **** "BBB@ HHHH ****
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MDUS2G*O4E&*E?V=*%.E%\E.*11117RQ^C!1110 4444 %%%% !1110 4444
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M,""#C!R.,'(P>AIV0>A!XSU'3U^E?G!^\BT444 %%%% !1110 4444 %%%%
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MA<5]?^LX>C7]G]5Y/;4X5.3F^L<W+SIVYN6-[;V5S@O^%9^#O^@;+_X,+_\
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MH^OX[_H,Q/\ X/J?_)!_966?]"_!?^$U'_Y#R_/NS@O^%9^#O^@;+_X,+_\
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MQ7IWB#4].O;W3M3\0>'+>'0X;?PY?)?7R7TL\$\MFB6<PF=XCZ_CO^@S$_\
M@^I_\D']E99_T+\%_P"$U'_Y#R_/NSZ+_P"%9^#O^@;+_P"#"_\ _DBC_A6?
M@[_H&R_^#"__ /DBN]KX=_;Y_P""@/P/_P""<GPH\$?&/X]Z7\0]6\*>/OB]
MX:^"NB6_PVT'1?$.M1>+O%7AOQEXITVXU"SUSQ+X6M8-#33? ^LI=WD-]<W<
M5W+811Z?-'/--;GU_'?]!F)_\'U/_D@_LK+/^A?@O_":C_\ (>7Y]V?4O_"L
M_!W_ $#9?_!A?_\ R11_PK/P=_T#9?\ P87_ /\ )%=[7XJ> O\ @O%^QO\
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ME*A7K3Q%)>QG&*]V7LY0D\/R3E4;4J<IPQ,*L8.G+]W&;E*+C8_K*HK\@/\
M@D59?\%"[+X3:_'^V>?!47A@^,?BTW@NTUC3/C?8_M!1Z[)\9/&4FH3^+Y?B
MM?S:?)\++G3V$WP=CTFSAO$\ R>%_.N+B#$C_K_7?1J>VI0J\DZ?/%2Y)JTE
M=7LU^7==%L>5B:/U>O4HJI3J^SDX^TIN\)6[/\]U?9O<****U, HHHH *^X*
M^'Z^X*^7XD_Y@O\ N9_]P'W'!G_,R_[D_P#W:/Y?_P#@O?\ \G[?\&^?_:0C
M0?\ U<W[*5<S_P %8M=TSQY_P6\_X(A>$OV>M8T36?V@O _Q.\>:M\:8O"5_
MI]QXGT+X%Q>(/A[J^MZ=XNN=,N8]0L]-'PXT#]H*9-'U:X6,6%[K1CL)8M7N
M(;[]SOVRO^"=/[&__!0.S^'^G_M=_!W_ (6W9_"RZ\2WG@.'_A8/Q3\!?V%<
M^+XM#@\12>9\,O&_@N74_P"T8O#FBKLUE]0CM/L>ZQ6V:XNS/R?[(W_!*W_@
MG_\ L*>)]8\;_LL?LV>%OAGXUUW2VT.^\977B+Q]\0O%L.C2S">ZTG2/$OQ0
M\6^--:\/Z;J,J0/JMEH-]IMOJYM+ :G'=KI]D+?Y<^X/Y4_CI^TQ^T?IO[._
M_!T%JVG?M _&[3]5^"_[9?[./A[X.ZG9?%;QW:ZA\)] U?\ ;*UGP]JVA_#2
M\@UZ.Y\":/J>@1QZ'J.F>%Y-*LKW1XTTRY@ELE6 ;W[7%E^U)^Q)_P $POV/
MOB3X'_;8_;=\;^/?^"GWQ(_9.D_:+^(7B+XSZ=KFI?#BQ\;_  <\4^.M?^'G
M[.DOBB]\(6?PJ'C34_$NX:R?$NAW-_I?PTT/0_$/C;0/"HN;"7^HOQ!_P2M_
M8,\4^&?VL_!VO? C[?X<_;F\<^%_B1^U-IW_  L_XRVO_"T?&G@SQQ/\2/#6
ML_:[/XAV]_X)_LWQI<S:S_9WPZNO".DWF_\ LZ_L;K252Q7TSXR?L'?LF?M
M_LT>%_V/_C!\'=)\;_L]^!]&\#Z'X+\#ZEKGBV&\\)VOPVT:+P[X)N_#_C:Q
MU^U\>Z9K>AZ#&^C+XAM_$ZZYJ6E7FJZ=K.H:C9ZSJT%Z ?QQ^/\ ]IW_ (*9
M_P#!.KX1?\%'/AK\,/%_[1\7P/\  /P<^#>J_#>Y_:[^/7[+/QV_:^_9.^(/
MCSXH? ?P/JSZO8?"CXK^.==\.^ O''@'QSXKN_!/VSPE8Z)H&HWG@'Q)H%CH
MNI2>(M;\8_K'^R=^QSX$^#'CK]G71;+_ (+8_M(^+=4_;>_9%\8W/B;X%?$O
MXQ+XZ\2?'<_%CX;1S67QW_9:UC7-3T?4OA%X@\#:A?3>,O!/B2^\%?$GQ;>:
M=H-W;3ZLNG:?XQ\[]5/@!_P2/_X)[_LS> _C7\-_A1^SSI=KX7_:,\)6G@3X
MV0^,/&?Q&^(^H^/O!^GV>JZ?8^';S5_B!XN\2:CHNE6MGK%W'':>%KC08C-%
MIU]*LFH:5IEW:8W[*'_!'/\ X)U_L3?%A?C?^SM^S]%X5^)MEH&K^%_#GB;Q
M'\0?B=\29_!6@Z]+,^LV?@FW^)'C'Q7:>&+K4K>XNM+NM<TR"'Q%)HNH:UHO
M]KC3/$7B*UU4 _%#_@TH^#5GH_[.W[4OQI7XC_%6_O;[]J#Q[\&A\--4\817
M7PG@L_!_@;X,>*U^(]IX-&EQ31_%76YO%AT#Q/XP_M5XM2\-:/X;TH:7:MIY
MN;G])/\ @Y#_ .4+O[9G_=N__K5OP,K[6_9H_P"":7[%_P"Q[\9?BS\>OV<_
MA%+\-?B)\;$U2+Q]-IWCSXBZCX5NX=;\10>+-5AT?P#K7BO4O!'AR*XU^V@N
M[1-"\/V T.U1M&\/?V1H4]SIDWOO[2/[-WP7_:Z^"_C/]GG]H;P9_P +!^#_
M ,0?^$=_X2_PA_PD7BOPG_:__")^*]"\;Z!_Q/\ P1KOAKQ18?8/%'AK1-4_
MXE>MV7VK[%]BO?M.G7-W:3@'FG_!/K_DPG]B+_LT/]FO_P!4SX+K\.O^"AUS
M\4_VP?\ @M#^SY_P31\6?M0?'7]E7]F74?V5=1^/-I8_ ;QQ!\-/'OQV^)UC
MJ_Q&6?3](\8V>E:Y)<VFE:'X7FNF\/\ B6PN=.LK/P!XQU33[&'5M4T;5(_Z
M4OA]X#\*?"OP%X(^&'@/2O["\#?#CPAX:\!^#-#^W:EJG]C>%/"&C67A[P[I
M7]IZS>:CK&H_V=H^G6=G]NU74+[4KOR?M%]>7-U)+._R5^V7_P $WOV-?V_5
M\#2_M3?""/Q_K'PSFU&;P#XGTOQCX[\ >*O"XUB6PFU2WL_$'P_\3>&=1N["
M]DTVSE?3=6FU#3X+F);ZSMK;4%6[4 _F4_;R_:'^,7[,G_!-[X0_ O\ 9K_X
M*=?$?]K_ $3QO_P4-NOV=?'G[4G@'Q!X5A^/OP[^&.JZ/XBUFW_9OUKXI:S\
M2;V34?B+;W5K<:SIOQ)O/%/PYAU3P_IMCI,ESX0^&][:6][\B?M&7?[9'P;_
M &3_ /@K%^R7XTUS]H#Q!^R!X:_9Z^!OC?P9X2_;-_:"_9H^-?[6?P)^*;_'
MO]F.&V\-:_;_  8^+GC+Q'X?^&GCSPSKNO\ B+P_8ZEX9TOPW!;6GA*ZT:ST
MC4=5\0ZMXT_KR3_@DM_P3S7]D6#]AAOV:?"DO[-,'B@^/!X+?6O&*Z]+\0VE
MD=_B)/\ $F+Q'%\2Y?'+6TKZ(/$Y\6_VG%X1\OP-#/%X)@@\/1</\._^"*G_
M  32^%WP@^-OP-\*_LY;?A]^T=IG@G1?C5!JWQ7^-6M>)/&^C_#G7HO$W@O2
MF\;:E\19_&'AC3-$UJVL[L:?X+UOPW9ZD;&RBUB#4(K6)% /PY^#'_*8W_@W
M_P#^T,/@S_U0GQUK[[_X.7/BO\4O@[^PA\)/$_PC^)7C_P"%GB2__;+^#/AZ
M^\0_#GQCXB\$:Y>Z!J'A#XK7%_H=WJWAG4=,O[C1[Z>QLI[S3)KA[*YFL[62
M:!WMXF3]5M%_8"_9(\/?&/\ 9_\ C_H_PF^Q_%S]EOX+V7[/7P)\6_\ "=_$
MRX_X07X/Z?H&N^%[/PA_8-UXRG\,^)_)T+Q+K=C_ &_XQT;Q#XHD^V_:9=:>
M\MK2X@Z_]JG]C[]G3]MCX>:+\*OVG/AW_P +,\ ^'O'.A_$C1]!_X2WQUX,^
MQ^-/#5EK&G:+K/\ :GP^\3>%-:N/L5GK^K0_V==:C/I-S]K\R[L9Y8+9X0#^
M:+Q+\./C;^W!_P %^/\ @I9^QGK/[:W[8'P'_9W\,?L]?!GXB0^%/V?/C)>>
M"[B/7H/A%^R_I]EI6CKK.D^*-,\,^%M3U#XC>*O$?C/3/#%AHDOB_5C9KK=Q
M>0RW1K\8?CO^TI\=/VI?^#<_]F?6_C)\1?$7Q!\??#S_ (*V:)\)/#_C_P ;
M:G<>)_%-WH.D_L[_ !7\4>''\0ZUJOVG4M>N-$N?&ESIL%UK%QJ-Y)I6GV-K
M-<RQ0QQ1_P!^/A#]C+]FOP'^U-\5OVU?"GPW_LK]IGXW>$-$\!_$_P")?_"8
M>/;[_A)_"GAW3?!6D:-I7_"&ZEXIO/A_HOV/3OAWX.M_MWA[PKI.I7']C^;=
M7D\^H:I+??+\/_!&7_@FO!^SGH_[)<7[-^S]GW0/CC%^TCI'@#_A<'Q[;[)\
M:(?"=SX'B\9_\)4WQ2;QM/M\+W=QI?\ PCMSXDF\*-YGVUM".HHEVH!^5'PF
MF^+G["7_  7Z^"O[%VB?M0?M-?M!_"3]K/\ 8ZU[XP_%E?VE_B?'\2=2G^*^
MC:I^T'>V/BWPU!'H&C:+X-@M--^$>D^'K/0O!^E>']/BT>_DL;G[;9:7H]I9
M_P U?AGQ5\7?VH;7_@CUH_Q-_:)^-*^,/%W_  5B_:Y^$VD?&F\\?:]XD^*G
MP\T77]7_ ."<NB:=<^ /%7BR;Q%<Z#J_ARX\07NH>#9#%+IFA>(;F/5!:*!<
M,W^B7XE_8R_9K\7_ +5OP^_;>\1?#?\ M']J#X5_#V]^%7@/XG?\)AX]M/["
M\!:C_P )O]LT'_A"['Q3;?#W5/._X6/XS_XFFL^$]1UF/^V?W6HI_9VE?8?C
M/5O^"%?_  2JUWP)X1^&>L_LIVNI^!_ GC#XL^/_  IH%Y\8OV@IX=(\8?''
M1? V@?$W74O'^+!U&[NM>TWX:^!UL4O[RZMO"M[X?M]6\(0:#JUQ?7UT ?AY
M\-?''QS_ &+OVO\ _@LA_P $Y/ G[4GQY^.WP*^%_P#P30^,O[3_ (/\4_&G
MXB7_ (S^-?P9^,DOPB^'VLQW5E\2H-,\,3Z=<W\WQ+N-;6R\-6L$"RS>$O$,
M,MMXFL?%5WJ7Y@_%KX?^+/VF/@C_ ,&SGCGXH?M#?M)ZAXV_:(^-?BWX$>*/
M&,'Q9U*[\4^$X+/]M32--M/BO\/?$/B&RU[5M!^-=KIWCZ*PMO'6H7>MI!9>
M _AQ:Q:.L'A=8[S^V3]GG_@E?^PI^RU\.OCO\+O@Q\$1X?\ "_[3>@ZIX7^.
M]QJOC_XF>+/%GQ%\.:QH^O:!>:-J7CCQ3XPU?QAI=B-)\3Z]!;1^'-;T9[6[
MU2\UB!TUN>34FYGXC_\ !'__ ()X_%3]FKX/?LC>+_@ EU\"OV?];UCQ!\&O
M#EI\1OBM9^(/ 6I^(M2UC5O$+:9\08_&Y^(%]9:YJ&O:C<ZGI>N>)M5TNYF&
MF2FS670= DTP _$OQ5^TY^T+^S5_P5*_X+$6/@+XD?%+XHZ#^RK_ ,$D])^)
M7P@^'WCOQUK'BWP=:>.O!'PC_9YO[7XBZGX1O]7T[PM=ZNUS)J?BKQM?Z-I^
MF:QXFBN_$D5D'U#6OL\_YV>-?B)^UM^R9_P3=_8^_P""T/@W_@I_^TO\9OVB
M/C=\9M%TKQK\&/B3X_UCQ=^S)XUT_7;KXH#7_@WIWP@N].BM[34/ \O@[Q%H
MFNO'>66B:3-:Z_??"T>#-9TWPEJL_P#9=\+_ /@G]^R+\&_C!XG^/?P_^$::
M;\6/&GP5\(?L[^+/%.L^.?B5XS3Q#\'/ GA_P;X6\,^#=5\/^-O&7B+PO=I:
M:#\/_">GWVNRZ*?$VO#3);C7]:U2[U76+B_^6_ '_!"[_@EC\+_C-X:^._@G
M]E71])\<^"O&+?$/P98S?$'XLZM\/_"?CAKNUOT\2Z!\+]8\=W_P]TZ[M+NQ
MT^XTRQB\-_V+HT^F:1/I&F6,^CZ5)9@'XX:U\/OCE^W/_P %[O\ @I'^QUX@
M_;._;$_9[_9^\/?LY_!/XDGP3\ /C/<>#[RQ\2)\'OV7;*VT'2VU/2_%>C>'
M?#-YJ?Q'\5Z]XVT_PG9Z,?&6KK:?VQ=7UO-<-7WM_P &TW[3'QH_:?\ ^":M
MIX@^.GCWQ+\3/%WPW^.'Q#^%&F^,_&6KW?B'Q9JOA71M#\#^*]%BU[Q!J+3:
MKK5UI;>,[S2;:^U6[OK\Z78V%O)=O';Q)'^LOA#]C+]FOP'^U-\5OVU?"GPW
M_LK]IGXW>$-$\!_$_P")?_"8>/;[_A)_"GAW3?!6D:-I7_"&ZEXIO/A_HOV/
M3OAWX.M_MWA[PKI.I7']C^;=7D\^H:I+?'[)/[&7[-?["WPPOO@U^RO\-_\
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M<9)CX9[FTEAN8'-O/;317,$L+O'+#-#(LL4T3@HRR12('1E(*E000>:_O?\
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M^!/[%_P8A^''A[XB?$#P1X$\<?&'QE.OB+XZ^/\ PSK'B?3+'7;*/6+=DLO
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M492KT*LJ,DY*C*G_ %)_ML_\%F_A3\*=.UCP+^S==6/Q4^*,J36"^)[<-=>
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MF^)=?^&_B+1-?DU?1_%\UI?+I?A;07M+'0/"FBZ#-HOA[0K;1V_::B@#X/\
M&_\ P3S^"WC[_@H)\'?^"D6L>)_BA;?''X)?!S5/@AX4\*Z9K7A2'X4:AX4U
M;_A:?VG4/$.AW7@J\\7W?B%/^%N^)/(N]-\=:3IJ_8=#\S29/LU__:7QII__
M  01_8]T3]D>?]D?0?B#^T;I6FV'[1]Q^U9\/_C99^.O!NF?'CX5?&"X@\+6
MYO\ P'XO\.?#GP_HMCH:Q>$=*/\ 96H^&-2N5NUCUF'5(/$.C^%]8T#]NZ*
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MV['F>'=2=+Q X'G3;A-<7\-I25MI9S@H2771QE)/_+?^_"+.WDY.XY/^0/\
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MQPZZL*$,\,9$=GJ15%.]K;<;:]9RQ:U>&7&ZV+'HPCI\[C4C%\R]UM;--/\
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MI8I7U?PGI5C&]Z/E+_@AC^S%X7T7XO?MF?M*^"O&%C\1?V=_!OQ+^)_['/\
MP3^\0:7'))X;TG]E_0_CGX]^.OQ$M_ 'B"*:YTWQYX!OOC+\1/\ A"M!\>6-
MYJ5MKA^$%R=)U!_#ZZ3;6X!^S/[8/Q[^*7[/WPTT+7O@O^SUXI_:0^)/C/X@
M^&/AWX>\):1K$/A#P7X3'B!=0NM2^)?QF^(ESINMP_#GX2>#].TNYG\1>*ET
M'7;E-1N]$TJ'35CU.?4M-_-?X$_\%D<^/_VK?A+^U;X.^">E>)/V3_V8/$'[
M7/B;XD?LA?'K3?VD/A-XF^&7A759M'\3^%H6N-$\'>)?"7Q7T/5/LNG1^"?$
M%N]WJSS#4)'T33;S0IM;]O\ ^"NG[$'Q9_;B^%7[/_AGX7P?#;QI9_"+]IKP
M%\8_B1\!_C3XP\6>!?A+\>OA]X>TGQ)INK^"/%'B3P)X6\4^)[/4([G5[*[T
M,/9S^&@C:I<ZYI&NW-KHUDOPK\.?^",OQ/\ %GQL_::\4?%KX8_L._LQ? +]
MI7_@GKXR_8UM/@W^QC8^(8[WX6^(=:^)%AXUT#QYJ7]L_"#X>^$OBGXMM2+S
M6]9^(,UCX,OEUC3/"WAJ'PKK.GZ,_BZ\ -OXY?\ !2'_ (*<)^QIXH^,E_\
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M.2(O]3+]QOYS/%'_  2K_;P\?_#O_@F9I7QR^&'[$'[1.E?L!>"?&'P0U_\
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M+^S5^W/^W-^T1^Q_H'[#_B_X*?M;^&OV=?#_ (+^'OQ>^(?Q?^'GB+X5:_\
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MS#^W,I_Z#Z'WR_\ D3U2BO*_^%O>&O\ GQUS_P !K#_Y9T?\+>\-?\^.N?\
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M7?A-K&D:SK%TXDU;7=$\+^*K_2?"]_JD\N;B[GCTJ.*UBO)VDDF@C1?,98U
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M_+]32GU^7ZA1116AH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-@\;0>2<0U,,\ES'$5<+Q+#%5YU<31Q].&,J9;4QN#G!8RIR?>_[2_CKX+>
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M8 8P1SC&,8'&.E35'$K*#N.26/IVXZCJ/3/2I*_AP_V*"BBB@ HHHH ****
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M+%U*D\-"K5K3PV%FE0I59^T]E153FY;)1C*7+:+:BKQC&"2A&$8_R/\ A_\
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M?%_Q=X\\*ZW\:==\6:'XR\*>/8);+7[WP!+X5M+*X\3>%C>WJ7G@S4]2O/\
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M-4TT]%JFKII]'?7II8_$[.+<9)J47RR33BU);III--=4TFMFA-W^RWY4;O\
M98_AT]_\]#SVI>?4?D?\:.0#D\8YP"#_ #II7:7=I?>!UVI>$WTWP+X0\9/N
M8>*]?\;Z1$G[L*(O"<'@^7S5!(?=))XDDC=SE6^SJ@VF-@>0W8XVL,=L#C\C
MC\N*^T_B?X>CC_8<_9*\4!1!=W'Q2_:6T<#RB!=6S7O@*X^TLQ +M%/8O;*V
MXC:N  0<?%QW9.2,Y.>#_C7!E^*^MT*LW:]/,,UPKMM;"9CB</'_ ,DI17?2
MW0]O/\M65XS"4(JT<3D?#N9KNY9KD.6YC5TZ)5\342[QM+5-#=W^RWY4;O\
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M6;=%#)(  Z!QN!!W5^,F6[@9[Y)S^/%?TUPMF"S7AS),>GS2Q&6X5U6O^?\
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ME1E.E2DJE&G2C4J-TZE1PG!0, #T&*6BBOR<_ID**** "BBB@ HHHH ****
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M.&^$^&\@II)91DF6X&5DU>KA\)2A6DTVW>=93G)MMMR;>K84445Y)]*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SWBS_D
M6]:_Z\)_Y"OC]>@^@_E7V!XL_P"1;UK_ *\)_P"0KX_7H/H/Y5]7D'^[8C_K
M_'_TVC\\XU_WG _]>*O_ *<0M%%%>Z?%!1110 4444 %%'K[?YY]/J< ]!D\
M5SNM^+O#/AR)I=<UW3-,"KN\NZNX4F(V[OE@#F9B .56,M[<5<(R<E9-[[)]
MO^":4X3E*-HR=[VLGK9'145\^ZI^TQ\+["7R+.]U36YR=JKI.F2S*Q'?=</:
M/CMA(Y&R#V(K%B_:G\$EF%QH7BR%%94+KIL,A5W V(56ZV[SGE&D1E_B"YR.
MA4JK5U3G;T]//S_#TOV+"8EJZHS^ZWX-W/IRBO#]*_:)^%FILL<NMW.DREPC
M1ZMI]Q:E'Z&-VC%Q&CJ02V^0!5Y; ^:O6M*U[1=<A%QH^JV&IP-@K)974-P,
M$ @,(W8HW/*, P[BIE&4?BC)6MNN_H93I5*?QTYQVU<7;7:SV:\U^9K44?Y_
ME_B/S%%1SKS^[T_S_#TOESKS^[^OZ3\KE%%%'/'S^[^OZ3\KKGCY_=_7])^5
MRBBBFFFKHI--704444QA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?<%%%%?EY^X!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% '(^//#=IXR\&^*O"&H6\=SIWBCPYK6@7L$R[HI;
M?5].N;&5)!ACM*SG.%8@<A20!7^;]X[\-77@OQQXP\'7H5;OPMXHU_P]<*$E
M0";1]4NM/DVI*J2*NZW.U9%5PN-R@@BO]*N3.W(QD$=>!Z=R/7UK^!?_ (*;
M^"T\"?MV?M%Z- TC6UWXV_X2>-GA,.P>+=)TWQ"R ;%1HUEU!TCDC'ER+AE)
MSFOW?P,QTHYEG>67?+B,%0QL8].;"UU0D_6V+C>VZ6NQ_&/TR<GA5X=X/X@2
M7/@<XQF4SDEJZ>9X-8N";[1GED[;ZR:5F]?A+GU'Y'_&E&[IE>>N0>!GKU]<
M?_KJ/*_\]/\ Q\4H*\_O,GC W YY'%?TDD[KIK]VJ_S1_GYT[:>EO\C]N?VE
M%"_\$8/V)!\HS\6-9!P  2P^(A<_[V0"3GGOGC'XCC.!R.@['_&OVX_:6&?^
M",/[$8/WC\6-<(7IDJGQ#Z=SC(Z'J:_$8[<Y+X_X$!CVKY#@O7 9LM6UQ-Q&
M^[;>:UD[V\K/O>_0_5/%W3/N&DU:_AUP U9;)<,X%:]KM?/Y.SN?4?D?\:^Q
M_P#@GY\-%^+?[9?P \&SP075G-X^TO7-3@N!+Y+Z9X7,GB2^5Q$KMS!ICA0P
M$1<HLQ$1?/QKE/\ GI_X^*_;+_@@]X+M_$/[8VN>)YY0?^$"^$WB/4;6,Q+(
M7O==U+2="20R%2(##:7%YRK(\@FVJVT.#V<78YY9PQGN.3<9T<LQ:I25]*U6
ME*C1U_Z^U(?GYGE>%>30S_Q(X(RJI%3I8CB/+*E>,K<LL/A,1#&XB#OI:=##
MU(M=4[6:N?V4*  , #C  [#/ &.,?2G4@Z#Z#OG]>,_E2U_#)_LD%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <]XL
M_P"1;UK_ *\)_P"0KX_7H/H/Y5]@>+/^1;UK_KPG_D*^/UZ#Z#^5?5Y!_NV(
M_P"O\?\ TVC\\XU_WG _]>*O_IQ"T4A]AG\_Z G]* 2>Q'Y]^1R0,Y'/&1[U
M[UG:_P#71;;]4?&<LG%RMHM&]/RW_P"&?9BT444B0KS_ ,?_ !+\+_#G3OMV
MO78-Q,I%CIMN?,OKV09 $4(/RQYP&F<!!V+'Y:W?%WB2T\(^'-6\17I'D:9:
M2S["VWS9 I6&$'LTLK(BGL3^(_+#Q/XLU/Q#JE[XJ\0W#SZE>NQL[?<X%C;/
MN,%G#;R3>4]OY6/-*QAUY;()RW7AJ'M?>?PIV>V^FBWUMK=Z)/OOZ>7X+ZPW
M4D_W<7KIJW>W*KW\G=+31=7;U;QI\?O'_B8RI9WJ>#-"8[3;V4A;5I(VX0SW
M;B)UWCDK:M_> C)''@EUKUD7>1EN-2NF=GDN;MI)7D8DY=;JZ)O%<DL0Q0!2
M20K*_P O,75[<7;$RR.4SN2 ._D0YZK%&S,%7Z?I56O3C",$E&*26G_#O<^E
MI8>G2BHPA&*TV2OHE:[M=OO?5/9ZLVYM?O75DB6&W1L A$#LX'_/0NOEE^ ?
M,6))">=V1FH/[:U+.?M'\.PCRXB&7IB0,A$N1\O[[S" >".",NBJ-E%*VFW]
M?\-V-R/7[U0!*(9U"A LB9;8%VLF[.#'(3N=)%D3@K&J# &UI'BA].N8[JQN
M;_0[M&#I<Z7=2V^UO4(C[-NX9>.1&!4 *ZY(/$T4-)[I/UU)=.+NFKIJS32:
ML]U9I[GVUX"_:4U_2E@MO%P3Q+I.50:M8HD>I0*6 S/ IVSNB\NN$D/SME\U
M]G>&O%.@^+M-BU7P_J$.HVDJ@EHB?-A8@$Q3PG$D,JDX9'4'(K\8+6[GLY1)
M!(4.1N4\HX]'3HPZ]>1D[2"<UZMX!^(&M>%M735O#]RUK> C[;IC,[66IP@Y
M=7BSM8D?*'"^<A<D&0$XY:V%A-7BN62[62EZW_K[V>5B\LI5-::]G-:Z?#+R
MUOR_)6ONK:O]::*\_P#AU\0]'^(NB)J6GMY%_#B/5-+D8&XL;G RI Y:%CDQ
M2XPR\'##GT '->7.#@VFFK/KT\GYGSE2E.E)PG%IIM:_Y[>>@4445<-GZ_HA
MPV?K^B+>GQI+?V44BAHY+NVC=3G#(\R*RG&#@J2#@@\U]<_\(QX:_P"A>T/_
M ,%-A_\ (]?).E_\A+3O^OZT_P#2B.OM*OF^(JE2$L)R3G"\:U^64HWUI[V:
MN?=\(4J52ECG4I4ZC52@DYPC)I<M31<R=OD8?_",>&O^A>T/_P %-A_\CT?\
M(QX:_P"A>T/_ ,%-A_\ (]?BO_P6'_X*.?M1?L.>/OV$/A/^RG\-O@O\1_B#
M^VA\7O$7P;TVS^- \71:/9>)WUKX4^&O!"6NH>%O%OA8:7:ZAK?Q&>+6K[4O
M[1BM[6"WGACA$4_G^9?LX?\ !73]H[X??MB:C^PW_P %7O@7\(?V9/B5K'P9
M\5?M ?#7XO\ PM\=MJ7P3USX:> ?#/C3QCXYU#Q)>>(O$>OW'AJU\/>&?AWX
M\U2ZUR^UVW6U'@[6DU70]+L9M&U74_F_;U_^?U7_ ,&3_P S['ZKAO\ H'H?
M^":?_P B?OK_ ,(QX:_Z%[0__!38?_(]'_",>&O^A>T/_P %-A_\CU\Z_"W]
MN+]C;XW^)=9\&_![]J7X!_$WQ7X=\$K\2==\/>"/BKX,\1ZMI'P_:/3IG\9Z
MA9Z9K%Q-;>&[:'6-&FOM7E5;+3XM9T>6^FMX]5T]KC1^#?[9O[(O[1/BK7O
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M5K6RT:]U72K+5)K.ZU.QBN#V]?\ Y_5?_!D_\P^JX;_H'H?^":?_ ,B?1_\
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M\(QX:_Z%[0__  4V'_R/6Y11[>O_ ,_JO_@R?^8?5<-_T#T/_!-/_P"1,/\
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MWK_\_JO_ (,G_F'U7#?] ]#_ ,$T_P#Y$P_^$8\-?]"]H?\ X*;#_P"1Z/\
MA&/#7_0O:'_X*;#_ .1ZW**/;U_^?U7_ ,&3_P P^JX;_H'H?^":?_R)A_\
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MW1ER3C\",..,@>H*YY'TVXQGIS7Q/ DN;+LZ:UMQ9Q(N96=_^%&4E9]DFO\
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MA52"PL;6:ZN;6RM+:XOG22]N(+:&&:\DC#+')=2QHLEPZ*S!'F9V4,P4@$T
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MJJ:OX3\-:;X@T.Y72Y#^N7[#OPYMOCA\1?\ @K]\0/\ @G-\=O#?B76?$O\
MP3^U[X5_\(K^RO\ L;>+?V1_V6O$7Q:\7^"=.O\ X3ZQ\*-,UW]H#7=9\/\
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M[CWIU?PP?[)!1110 4444 %%%% !1110 4444 !. 3Z5^(G_  6X^(,>K?\
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M,=AO[W_CHK=\+ZA<:1XG\.ZO;2%+O3-<TJ_MI0H+1RV=]#<1NJG(8K(B,%.
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MAR#)'H\E]JTBX!^9&"KD<C@YX/']2&JW M=,O[ECA8+2XD)/8+$Q)[5_,_\
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M*.G':GT'J<=.U%>/#5-]V_T/CX:IONW^A>TO_D):=_U_6G_I1'7VE7Q;I?\
MR$M._P"OZT_]*(Z^TJ^8XD^/"?X:WYTC[_@W^%C_ /KY0_\ 2:H4445\R?:'
MY;0?\$6?^"9]K^S->_L=P?LU[/V<M1^-"?M"WGPZ_P"%Q_'YO.^,">#K3P O
MB_\ X2Y_BHWCN/'A*QM=)_L"+Q.GA<^5]O.BG4WDO'S/V>?^"('_  2]_94^
M,?@GX_\ P#_9B_X0/XN?#JZU6\\'>+?^%T_M"^*/['N=;T#5?"^IR?V#XS^+
M/B+PSJ'VG0M;U2QV:KHU]'#]J^TVZQ7D-O<1?JY7C&N?M#?!SPW\<_ _[-6M
M>-K6Q^-_Q)\%^)OB'X)\!OI6OS7>N^#?!UQ%:>)-;BU>WTJ;P[:1:9<3Q1R6
MNHZQ9W]P7#6EI<(&8 &!^U%^RK\"?VSOA%JWP'_:0\'ZCX_^$VO:KH>LZ[X/
MLO'7Q#\ 6VMWOAK4(]6T--7U+X:^*_!^MZGIVGZO!::O%H][J<^CR:MI^EZG
M/8RWVEZ=<6WQE^S=_P $3?\ @F-^R+\:/!G[0W[//[,W_"OOC!\/O^$B_P"$
M0\7_ /"YOV@O%G]D?\)9X4UWP1K_ /Q(/&_Q6\2^%[_[?X7\2ZWI?_$TT2]^
MR_;?MME]FU&VM+N#]4Z* /(?C-\!OA1^T'H?A/PW\7O"O_"7:+X'^)?@#XP>
M%[+^W/$F@?V7\1OA=X@MO%/@7Q%]H\,:QHMW>_V'KMI;WW]D:C/=Z%J?E_9=
M8TS4+-WMV^1OBO\ \$H/V$?C9\3/&GQ4^(7P>UG4-;^)VO>'_%'Q9\,Z+\7_
M (T^$/A5\7?$?A6&T@\/ZU\5/@WX1^(6A_"SQ[?V*64 NI/$?A&_77LS+XD3
M68[FX23]%Z* /#=._9L^"6D?'J+]IO2O EKIOQK@^!NF?LV6WBVQU?Q%:V5I
M\$M%\9W7Q TKP)9^#(-83P)9VMAXMO;G4[?5[;PS%XB2%TTK^V#H\,&GQ^Y4
M44 >0_"_X#?"CX,:Y\7O$GPU\*_\(WK7QX^)=[\8/BO>_P!N>)-8_P"$J^(V
MH>'] \+7GB+[/K^L:K::'YVA>%]"L?[(\-P:/H4?V'[5%IB7ES>7%QYOX-_8
MH_9=\!?LJC]B3PW\)-)7]EL>%?$W@D_"77-:\5^+=,D\->+]9U?Q#KVGSZ_X
MMU_7/&%Q+<ZYKFI:I9ZE/XADU71[V2WGT:]T]M/T\VOU-10!\&_LY?\ !-/]
MC[]E+QVGQ1^#7P\\2V_Q(T_P#-\*_"_C+XD?%_XS_&O5? WPS?4(]6A\ > Q
M\7OB#XT@\%^%(-1C%Q_9OA>/29;A9+B"ZNYX;B9&_GQ\7?\ !%CX\_M!3Z5\
M*/B?^PQ^R=\!O%7B/XW67Q)^.O[;7P0_:=^,>N_"RX\.S>/]-\:^+]1_9>_8
MN\7S7>C_  H^,WQ T;POX=\#>*/$>N:3:Z"FEIJ*VLMSIOB0:?X&_J9^"G[0
MWP<_:*T_X@:K\&?&UKXWL/A;\5O&OP0\>W%KI6OZ4OA[XI_#J>SMO&?A*9/$
M&E:3+>W&B3:A9I+J.F)>Z+=F8-I^I7:K(R?FC>?\'!?_  1ZT^\NK"\_;1\-
M0W=E<SVEU"?A=\>7,5Q;2M#/$6C^%;QL8Y492R,R-C*LP() /TI_:*_9T^#/
M[6'P=\8_ /\ : \$67Q#^%'CRWT^#Q+X7O+_ %C2#<OI&K6.O:1>V6L^'M1T
MG7M&U/2M9TRPU+3]3T?5+&_M;JUC:.X"%T?YY^!O_!-+]C[]GWQ!\0O&/@KP
M!XK\0^-_BG\,8_@KXW\<_%SXQ?&+XV^,-3^#\2HL?PRLM?\ BSX[\87WA[P4
M/+@:71/#DFDVURUIIWVL3C2=*%EI?!;_ (*0_L4?M$7/P0L_@U\=-*\;7/[1
M^H_&'2?@I%:^$OB'I1\<ZC\ M)T;7?B[;6K:_P"$=)326\&Z3XAT>\N7\0MI
M$6IK>K'H4FJ3Q7$47W!0!\#_  -_X)D?L7_LYZE\$-8^%7POU_3-4_9MU3XN
MZI\"[WQ!\8/C1XW;X<?\+S\(^$_ 7Q)TO2(/&?Q!UZTOM!U;PAX&\+Z+IFAZ
M_;ZOIGAA--DO_#%MI&K:GJ^H7_9>'_V OV2/"WP ^#W[+FA?";[#\"O@'\0O
M"OQ4^$O@;_A//B9=?\(GX]\$^/[WXH>&->_X2:\\97'C'7?[,\=:A>:Y_9?B
M7Q!K.C7OG?V9J&G7>CQQ:>GV-10!\@_'#]@G]DG]I'Q=\0/'7QN^#UAX_P#$
M_P 4OV?[3]EWQU?:EXI\=V-MK?P.T_XAR?%C3O!Z:1HOBG3-%TF]TSXBR#Q7
MIGC71-/TWQ[IVI0V@LO%$%M96=O!YE\&O^"6/[$OP)^*GPS^.G@CX:>+]1^-
M/P>T;Q%X:^'?Q3^(7QR^._Q1\8^'O"?B7PL/!5WX-COOB'\2?$EM?>"M*\,-
M<Z;X2\'ZC9W?AKP1+J>NZMX/TO0];\1:_J6I?H710!^;>L?\$D_V%-1^'?[.
M/PQT?X9>-? 7A[]D<_$1?V==5^&GQZ^/G@#Q[\,;;XM7DM_\2+'2?B9X:^)=
MA\0K^S\6W<S/J46N>)=4,< .GV+VFFR3V<NOX,_X)3?L#?#[P!^T3\+O"?P%
M73O W[67A[PYX;_:&T6Z^)WQDUQ_B;:>%(=9BT;5-6U3Q!\0M4UC3_%XE\0:
MOJ.K>/-!U#2?&WB/6KPZ]XC\0:MK4-O?P_H;10!\9?"#_@GY^R?\#]?TCQ9X
M(^&^HW7BG1_V?;[]EB/7_'7Q%^)GQ,O-2^ NI?$;Q#\6+_X?Z_;?$+QAXETO
MQ#:77CKQ5KNIR:OK.GWOB$:=>)X835T\+6=CHMMYU\$_^"4W["W[/GQ$\%?$
M[X:_"+7(_$?PNCUF+X0:?XU^,7QK^*'@KX,+XB$HUQ_A%\/OB7\0_%G@CX=7
M.H>?<*+[POH&G7VG07-U9Z1<Z=8W5S:R_<VN>/?!'ACQ%X)\(>(_%_AK0O%?
MQ)U+6-'^'OAK5M;T[3]>\;ZKX>\.ZEXNU_3_  II-U<17^OW6B>%]&U7Q!JT
M.F07+Z=H]A<ZA=B&VB:2N,^$'QZ^$GQZB^)4WPD\8VWC&+X0?%_QY\!?B.UM
MIFN:9_PC/Q;^&5Y:V'CGP=.-<TO2S?W.@7=[:PS:GI(O]#O#*&TW5+R-790#
MS[1OV,OV:_#_ ,,/VD_@UI'PW^R?#;]KWQ?\;O'G[1'AO_A,/'MQ_P +"\5_
MM&Z;+I'QFU7^V+KQ3-KWA/\ X3'3II+?[#X'U3PSIOA[=YWA6ST.<+*/<?A]
MX#\*?"OP%X(^&'@/2O["\#?#CPAX:\!^#-#^W:EJG]C>%/"&C67A[P[I7]IZ
MS>:CK&H_V=H^G6=G]NU74+[4KOR?M%]>7-U)+._7UXQKG[0WP<\-_'/P/^S5
MK7C:UL?C?\2?!?B;XA^"? ;Z5K\UWKO@WP=<16GB36XM7M]*F\.VD6F7$\4<
MEKJ.L6=_<%PUI:7"!F ![/117!_%+XG>!?@K\-_'?Q=^)^OP^%?AU\,_"FN^
M./''B6XL]2U"#0?"WAK3KC5M<U:6PT>SU'5KR.PT^UGN7MM-L+R]F$9CMK::
M5EC8 [RBN4\!^./"WQ-\#^#/B3X&U:/7_!/Q!\*>'?''@[78;:]LXM:\+>+-
M(L]>\/ZM%::E;6>HVL>I:3?VEXEM?V=K>P+,(KJV@G62).KH ***\@7X]?"1
M_CY/^R^OC&V/QWMOA!:_'J?X?_V9K@O(_A)>^,[SX>VOC$ZR=+'AIK:7QCI]
MYH@TQ=:;7%EA-T^EK8/'=N >OT444 %%<GIGCWP1K7C#Q7\/='\7^&M5\=^!
M--\+ZQXV\':=K>G7OB;PCI7C?^W#X.U#Q+HEO<2:CHEKXI7PUX@DT";4K>V3
M5HM&U&6R,T=K*R]90 4444 %%%>/_$W]H#X+?!RU\7W'Q+^)7A7PM/X#^#_C
M[]H#Q5HMUJ"WOBK3/@M\+H[1_'_Q*3P?I27_ (JU'PKX8>_L+34-0TO1KU6U
M&^LM+MDGU*[M[60 ]@HKE/ ?CCPM\3? _@SXD^!M6CU_P3\0?"GAWQQX.UV&
MVO;.+6O"WBS2+/7O#^K16FI6UGJ-K'J6DW]I>);7]G:WL"S"*ZMH)UDB3JZ
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MARFP=2>Q]6\!_#G7_%M]_9OA>P><;D%UKUS'&=.LHWVEU:X4M#='8=Z0PJ)
M3N;DD!7C&-[QC%+R2MTMT]$C.I5C"+E)I*UW*6B5^KONKV^;7G;+\$^"]3\0
MZM:>'-&A:?4]0:-;V; :"PLR?WLUPCJ-B(H+1R*QWR$8XK]1_!OA33?!?AW3
MO#VEQ*D%E"%DD P]Q<, 9IY#SEI9,L<\@8%<Y\-OAEHGPZTH6UDHNM3N K:E
MJLJCSKJ4#E4!R8;=&+>7"IPHQGG->EUY>)Q'M7RQ^"+=NMWU?;IH?+8_&_6)
M>SI_PHO_ ,#[2:=[>5GI^"****QAL_7]$<4-GZ_HB]I?_(2T[_K^M/\ THCK
M[2KXMTO_ )"6G?\ 7]:?^E$=?:5?,<2?'A/\-;\Z1]_P;_"Q_P#U\H?^DU0K
M(\0ZS!X<T#7/$-S::G?VV@Z/J>LW%AHNGW&K:S>P:793WTMII.E6BO=:GJ=S
M' T-AI]LCW%[=/%;0JTDB@Z]%?,GVA\5_LM_MR^ ?VLM?\5>'O!_P=_:J^&=
MSX2T>RUF\O\ ]H/]G'XD?!'1M3@OKTV,=IX>U7QOIEA:ZYJ<4BF:ZT^Q>2XM
M[7%S(HC(-?!_QX_Y3\?L$_\ 9CO[4G_J2:/7[B5\K>+?V0OAKXR_:]^$?[:>
MJ:YXY@^*7P8^%7C[X0>%] L-2T"+P!?^&OB+>VU_K=]K^E7'AFZ\176N6LUK
M&NE7.G>*M*L((F=;O3+YBKJ ?R[_  >_:1_X*[7G_!/S]AC_ (*"0_\ !0C3
MO%_B[]I#]H?PK^SOJ'P-^(O[.WPD/PHT_P /?%CXQ>+_ (%>&O%FL:[X,T+P
M]X[USQ9X>\3Z1I'CRZN+'4_#ULUE<'PO:P_V9I5]#XN^Y/B1^T!^VA^QS\2_
M^"B'[,OB?]K3QE^T9?\ @?\ X(T?$[_@H'\*/C#X^^'GP>\*^,?AE\;O"VI_
M%;P)J%MX?T7X?^ M \,7W@R_\1Z#IWC#0O#/BFQ\26WA6'3-.\.6\^HV#ZG-
MJ'Z2>#_^"6G[/W@K]D']FW]BK2O&'QCN/A9^RY\8_A_\;O &OZAX@\$R_$#6
M/%?PX^+VI_&G0]/\8ZK;?#VT\.ZAX>NO%.K7%AJMIHOA7P_J4^@)#:V>K6.H
MK)JLG&?\%"/V)=#\=>#OV[OVJ/ T'Q+\6_M&?$'_ ()1_M#_ +$OA7X:: =,
MU;PUXDT/4=+^)/Q&\,P:!X5LO#$OC'4?B7KGCKQ$N@61MO%$^F7UA-9:;:^&
M!JC'49@#\_\ X??&#_@H3^SE\(/^"8/[7GQI_;>O?VC]%_;0^,'[)?PG^-'[
M/'B/X*_!CP'X6T70OVN_#5G'X1U'X1Z_X%\-VOQ%NO'?P?U75H=0UZ*35=7M
M_BS:VVH:K<Z-X7M=)^Q3?+O[./[4_P#P4[T;_@EW\/O^"B'C7]N1OBIX_P#V
MIM5\&_L[_#+X7>./@/\ "31_A%\!_%OQ#_:NT3X):'\=_&'C'PU8>']:UVY\
M.>&=%\9ZC<VFJII/A"YU_P =>'M,UFPU'3O"-B-5_3?]@7_@E;IW@WX0?L(>
M,/V@?CG^UE\7)?V>?AQ\,_B9\,_V8/V@?$7@J]^&'P"^..I_#+3K2^OHO#5A
M\,_#7C?5==^#5[K'B#PY\'-*^(/BOQ!'\&+.2:R\/6L.J6=IJ-I]<>#?^"8W
M[-7A/_@GQ9_\$T[]O'OCG]GNP\,:WX:M-5\9:YH<GQ,MYM4\?:I\3M+\4VOB
M3PUX7\-:+9>+?!OC?4;?7O!^K6'A:UCTR]T31I;JSU![>Y>\ /A41_MS?L>?
MM8?LN?LR_$K]O7Q;^U3X0_X*#>$OV@OAJ?%?BOX1_"GP-\5/V=?C-\*?@CJO
MQ)M_C7\(+#PE:R:-KW@>_NXIX-1^'GB_0M9T7P$+;P_<W/B/Q!]NGMKSQ/X-
M?\%%?VI?CK\(?V#_ -CV'QJOAS_@H)XI_;#^)?[-W[:_BO0]"T&>Y\ > OV%
MM;3Q/^TQXN@^UZ#J'@RP\3?%/X=W/PKT[0]3@T"/PO=ZY\6-7M_"265]ING6
M]O\ J9\#_P#@G%X4^&/QO\&_M%?%;]HS]IK]KKXL_"CP=X@\!?!#7OVE/%G@
M/6;+X,^'O%MC:Z1XQU'P7HGPY^''PWTJ;QYXYT*QL="\;_$/Q);:[XI\1:39
MQ6DM[;+->F[[;X:_\$^/V?OA5^VU\=/V^?"R>,O^%W_'_P &:/X(\5Z=?ZY8
M2_#O0;&QLO UCKFK>#/"UIHEE<Z3XB\=I\,_ ,_C;5=0UG6&U2[\,VEQ90Z8
M]YJQU$ _GLU7]N_]M_\ :-E_;"_:"^%7QK_;0^'_ (N^"GQL^,7PX_8__9B^
M ?\ P3G^+_Q\_9O\?:3\#=:FT^TT3]H;XH:'\$O%@USQG\;]5TJ7PQX@72/B
M5X4?X)O>KKT"3)._ARQ^_P#3_CI^W+^WA^T%\.?@;X%^,_BK_@F\O@G]@SX$
M?M3?'/PQ#\%O!WBOXTZG\=?C]=^)[33_ (;?V1\?O#-\-,^&OP6UOP.4\6RZ
M;X<M-9\17]_J7@#Q5=:/=ZA$WA_WOXG?\$<?A#X]\1?M&#PC^TI^US\"?@_^
MUYXHU+QK^TI^SG\%O'WP^\/?"#XE>*_$5KIEKXZUN"'7_A9XG\9^#+SXJ1:7
M%;_%B3P=XOT=_'6FSW6C7SVVDS-9U[9\9O\ @F]\+_B#XN^%7Q'^#WQ3^-'[
M'GQ-^$7P<N?V=/#_ (Z_9DU7P'H6HZQ\ 9FM9=/^$WBO2_B)\/\ XD:!K7AK
MPC>03ZWX N!I5IK?@KQ/>W/B+1=5BU!E8 'Q;_P0#TSQ;HGP1_;ST;Q]KFC^
M)_'6D?\ !5K]M#3/&GB7P[I@T7P_XA\6V%[X!M/$>N:%HPU/6AI.CZMK$5Y?
MZ9I@UC5A865Q!:_VG?\ E?:I?:?V_O\ D_G_ ((Q?]G+_M'_ /K(WQ/KZA_8
M/_8/^$O_  3U^%'C+X/_  <\5_%7QEX>\<?%[QE\:M:UGXP^)M&\7^+6\6^.
M;'P]I^LP+KNC^%_"K7FF+'X:LIX)=9MM5U^:\N+^ZU37=2EN%,7I?Q?_ &8?
M /QJ^+W[,GQH\4ZOXOL/%/[*7CGQMX_^'EAX?O\ 1;70-9UGQY\.M>^&6KVW
MC2UU'0-5U'4=,MM!\0WMWIL.AZKX=NH=7BM;BZO;RR26PG /R%_X*I^!OBO\
M2?\ @I]_P1A\$?!CXRW?[/WC?7M'_P""D,*?%W2O!WAOQ[KWA+0K3X.?!;4/
M$G_".>&?&,-SX6NM>U[1K2[\,:?J.N66H6?AY]:;Q&FF:G=Z3;6%S\$_&3_@
MH_\ MZ_LS^/?CE_P3BO_ (]:[\5/BGX8_;&_9@^!?@O]LS2OV:)?B-\;O#WP
M,_:$^ >M_'OQ1?6GP%^%&@:MHGQ/^,OP_P!'TJP\->#DL_"LLOC)[K7]8U33
M[:6R@U'2?Z8OB?\ LI?#OXL?M*_LM_M3>(M9\:67Q!_9'L?COI_PWT?1=1T.
MV\&ZW#^T+X1\.>"_&C>-]/OO#FI:WJ4NF:7X8L+CPNV@^(?#265_->2ZLFMV
M\D-K;_*7QN_X)&_LS_'GQO\ M,?$SQ5XJ^-6A?$;]I3XG?LR?&I/'/@KQ?X9
M\/>*/@+\6_V2_ I^'GPF^(7[/FLIX'N;[PAXDC\/37R:_=>*9_'$5]<:IJ!T
MZ'1[:6*U@ /S"T']KC]MSX-^&O\ @H9X'TCQ5^VE\7_@;X!_X)M_M ?M-_ #
M]KW]KC]B_P"('[.OQ'^#G[1OPS\&ZU OP=UG5O'OP6^&/@+XM6=XD=A\5O">
MKWGA"*^MFMM0\)7NG>(M/TW4-16>_P#B]^VI^SO_ ,$]?@5^T9^T1_P5;L].
MUO\ ;4U/]DK4G\0:Y^ROH.O^,_@YHOQ#\ >)_'_CKX8_LH> _A'\/O&EU\4/
MC'XST^Z\)>&=!U/XI>&+GP=IMKX/\3>+)M/T;7/%<3Z7^G'AG_@E1\*TTW]J
M2]^+OQW_ &D/VB?BK^UM^SGK'[*?C[XW_%KQ)\.)O'_@GX'ZUX<\1^';KP=\
M'=/\(_"_PMX!\"6DC^);OQ3>^?X-UY-:\;0Q>)=>CU2XN=1AO>L^.7_!-+X3
M?&CX"_LE_!*S^)?QA^%VK_L1Z]\)/$O[/7QL\ ZCX$7XN>&M8^#W@O\ X0/1
M9=7OO$?@+7O"6MV/B'0Q#-XRT3_A$K+0M?U2RTV:?34TZS&E2 'X6_"3_@H)
M^UKX/US_ (*7?![3/BI^V1K'@?X3_P#!*#XZ_MF_L]>,?V]_V=_ _P '_P!I
M7PC\3?!(\3>&])\3>'K73_"WAZW\>_";5-6@&O>'=1\?^"8Y9=4T9] @T>VT
MO1]1F\2?2'P^^,'_  4)_9R^$'_!,']KSXT_MO7O[1^B_MH?&#]DOX3_ !H_
M9X\1_!7X,> _"VBZ%^UWX:LX_".H_"/7_ OANU^(MUX[^#^JZM#J&O12:KJ]
MO\6;6VU#5;G1O"]KI/V*;Z"_:&_X)86?@/X1_P#!03]HWP]\:?VMOVIOVL/C
M1_P35_:?_9@>U^)WB#P-XO7QY'XG\&:]XB\)Z'X,\ > _A5X0B\+ZS'XJM+'
M0?"'A'X<+H'A69=8U"6\\*ZUXNUJ^\1W6G^P+_P2MT[P;\(/V$/&'[0/QS_:
MR^+DO[//PX^&?Q,^&?[,'[0/B+P5>_##X!?''4_AEIUI?7T7AJP^&?AKQOJN
MN_!J]UCQ!X<^#FE?$'Q7X@C^#%G)-9>'K6'5+.TU&T /S0U7]N_]M_\ :-E_
M;"_:"^%7QK_;0^'_ (N^"GQL^,7PX_8__9B^ ?\ P3G^+_Q\_9O\?:3\#=:F
MT^TT3]H;XH:'\$O%@USQG\;]5TJ7PQX@72/B5X4?X)O>KKT"3)._ARQ_4_\
M9I_; _:+^,'_  4B^%'PP^(^G>(_A+X+\>?\$:?@_P#M7^-/V;/$GAN#1]2^
M''[1GB_]H75/"/C--2FU[0=/^(-IJ/AW2HSX,ET;6KJRMHH=/CN[SP_9:S)<
M..K^)W_!''X0^/?$7[1@\(_M*?M<_ GX/_M>>*-2\:_M*?LY_!;Q]\/O#WP@
M^)7BOQ%:Z9:^.M;@AU_X6>)_&?@R\^*D6EQ6_P 6)/!WB_1W\=:;/=:-?/;:
M3,UG7IGQ?_X)@?#'QS\9OA#\?O@U\:?CS^R#\3_@Y\ A^RMH>L_LYZE\,K33
MM6_9XBU5M;TWX;:SX?\ BG\,?BAHDUIX=U9FU+PQJ%O907&D:B8=3>.\U/3=
M$O=* /YQ?!'CK]I/]M'_ (*4?L8ZIXV_:X^*OA^^\+_\%)/^"R7[/WPDU[P-
MX:^!RR_"_P"&WP4^ VC>)-$7PB-9^%6NZ=K5WXL\-ZY)X!\17_C.V\5[_"EO
M:7NA?V1XH,WB*?[4/[=/[9?B?PE\5/@9\-/C/9> /C'\=?\ @O9^T_\ L*?#
M/X[:G\*/!_BV#X ? #X<32>+6DT?PE_8&G^#?&GBZQT306\-Z#'\07NM8U^U
MUO6M0N-=&H:-#KFC_='AC_@A;^S7\-O"/PZT#X._'3]J_P"%7BCX3?M+_%_]
MI[X=_%?0?B%X$U?XH^&_$GQW\&:+\//B=X'3Q3XI^%^M2ZKX!U_PAH-AITJZ
M[!JGC:[N$:^U[QKKLDL\<WM^N_\ !)G]G#7/A;\8/AG_ ,)?\;-'OOBK^VWX
MU_X*#:)\4] \7>%]'^*_P/\ VE?&NO6FNS>)?@GXDL_ T>G>'-,T+R+S1M#L
M?$VA>,+XZ#K6LZ?K>JZTUU%/;@'I_P"RQ\+?VLO@I\4?B3X#^-7[5]E^U=\&
M[KP#\.M=^%>L?$'1_ G@_P#:.\">+8+_ ,4Z3X^TKQ5HWPO^&GA#PGXR^&WB
M6.#0M6\)>.-4U1?%FFZS8:]X6OM+U.U@B\02_%?QX_Y3\?L$_P#9CO[4G_J2
M:/7W+^R]^PQX._9M^(_Q8^..L_%OXS_M&?'_ .-6E>#_  WXV^,_QYU;P3J7
MB>V\&^!$OSX;\!>"M(^'O@3X>>#_  1X*MK[5+[6;S1="\.POK&MSKJ>LWE_
M<6UDUMVWBW]D+X:^,OVO?A'^VGJFN>.8/BE\&/A5X^^$'A?0+#4M B\ 7_AK
MXBWMM?ZW?:_I5QX9NO$5UKEK-:QKI5SIWBK2K"")G6[TR^8JZ@'\Q/P^_:?_
M ."G^B_\$G?@#_P5Z\8_M^:MXMN/#/C/P6GCO]FN3X"?!RR\"_$GX7>(_P!K
M2'X :WI?B/Q58Z+:^(I/'^JV^I:7KEOXKT@>';'PYI%G)X;T#1++59K[QCJ?
MM/[3VN?MP?MH_L(?\%2/VJ;3]L:V^&?P3\"C]M[X0>#OV/K;X*_#>^\)7WP0
M^ MEX]^&_C>W^*7B[7[:Q^,ND_&SXB1^%U\9^'+B+Q)H\7P]UA[6RB\*^(_#
M7BR7PY:_L G_  2D_9X3_@G!I7_!+\>,OC0?@%I']@?9O%Y\1>!_^%P/_P (
MY\=[#]H6Q\_7Q\.AX+;S?&FG0:9=>7\/XM_A=Y;*'R-69-:3S;X\?\$:O@S\
M<)?VB/#]C^T9^UI\%/@M^U=XLO\ XC?'K]GKX*>.?AOX=^%/C'XG:KID-GK?
MC^RA\2?";Q=XL\.ZMXNU.WMO%/Q!TC2O%$?A3X@^)K'3[_Q9X?U*VMGL9P#\
MH-*_:_\ C?XFUG]B#]BCP9\6OVH_V>O@E\*?^"77[(_QP^)/C;]CC]D_QY^T
MS\>_B'\0?'7@+0=&\(>$O.\-_"/XR:;\-_A=H6F:5'K6I^))_"H?Q+KD6H^"
MI;BX2[,V@^^1?M9?\%'+?_@FW\7/VEO&?B7QG\+?BS_P3V_:3U_5+O6OCS\"
MKS]EO1_^"C'[(OPSE\,ZP]UXH\ ?&3P1%KGP@\7?&?P;K=_H^BMX$L8[RV^*
M.@6WA30KR"^\37 T/]'_ !I_P2L^%NI:I^S=XW^$?QV_:,_9O^,W[,?[/WA[
M]ESPM\:_@]X@^&\7C7X@_ WPS::'#I7@3XR:7XU^%_C#P)X\TNSU'1%\465N
M/".CVEAXLOKK6+2TC2.QLK/.TW_@C_\ LP6WPA^$OP)UOQ5\;O''PN\ ?M Z
MS^U%\4?#GCKQAX6\2/\ M>_&[5M6F\00^+?VN-7N? ::U\4K32_$$D6MQ^$]
M(U#P;X.UZ^T_1QXTT#Q3:Z+I-M9@%#_@DS^T7\9/VWOA?\3/VXO'WCNT7X4?
M'[XBZQ9?LT?L]Z/)X2O[;X"_"/X9:AJ/@>(>-]=T+3%UC4?C%\2==TS4O%WC
MS3-7\2>(M*\-6K^'K#PTNB0W.I:5!\0?M0_![XZ?'+_@O?;>!O@G^TOXG_95
M5O\ @D1X4U7X@_$3P%X+\'>,/'^L^$;7]L;XDV<7@?PE<>.+;4M%\&W>JZ]J
M&DZY>^,8]%U?4[2Q\-S:+86UNVO2:A9_LM\%/V/OAE^SW\:?VAOC'\*=8\;>
M&K3]IOQ#I/CSXD_!RWU#P^/@M#\5[.R33M>^+_A+PM%X8AUOPS\1/B'9PV@^
M)6HV?BEM'\:7MA8ZUJ^AR:[;1ZF/GW]I#_@F=X4^/7[67A3]MSPI^TU^U%^S
M=^T/X+^"5I^S]H^N_ [Q%\*H?"=]\.8?%WC+QG>Z=XI\'?$?X1_$*S\4R:IJ
MWC:\FN+?5KR71K6\T'PCK6G:19Z[H$>I7 !^5/A3]OO]M#X=_LY^-/C!\5_B
M[:^/M/\ ^"9G_!5G6OV1/VP/B!I_PYT'PM9?M%_LB)+X0^'^N?%G7/!FEV>L
M_P#"-_$WP!K/Q4\,>.Y-.\ ZOH^E6FF^&)YM8FU>VOK]Y?U2_8Y^/7Q2_:<_
M:R_;T\;V_C%I_P!E'X$_$3PM^R1\$O"EEI^EVUEKOQ:^%VBG7_VF_B-J5_)I
M)UW4Y+7QMXKT3X:>&KFTU^3PR^G^#=8EATS^TI;B[KQ/]H;X!^"?V&_^"='Q
M2_9E^"_[-'[3'[:^K?M/7'QE\!^+1X<M_#OCSXJ_%'XV?M&>$/&USKGQQ_:B
M^(EUJ'@5=%T#6M=@T[1/&?QAM-*NG\$6K^$[>PT.*RT[3(;?[,_X)W?LGVG[
M$/[%O[/G[,RW%MJ&O?#KP+;-\0-:M+FXOK;Q!\5/%=[>>,OBGKUI?WD%O?WF
MG:I\0-?\17&C27\27<.B-IUI*J_9E10#\8_AEI?Q%^$G_!4+_@O=\=M-_:CU
M'PI%\$_@_P#LQ?$N>P^+>E>#&^!6LR>)?V9/CGX@^'\7QK?PC\.6^)W_  K7
M]GF:U@/AR#X8ZWX?\;Z_X?MKJV\7:EXYUN>"Y/RK\+?^"AO[2WA7X\_\$_/$
M?@;]JS]MC]J'P5^U%^TG\%_@7\?/&_QP_8TT/X0?L'^.8?BM8ZI%>/\ LI>,
MM6^&?PI^(^@^(/#ESIM[JOA32H[745\3Z%9R:_XIOBFEW>A:W^[GQN_X)5?!
M'XZ_'#]H+XR^(/B9\;_#FF_M7? ^'X&?M&?!_P ):YX&M/A9\4]+T3P)XN\
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M_MH>._VN+/XH?&O]ECXUV?\ P;;?$K]KB^^$\O@SX9R3_##Q?X-\4Z!J>O\
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M"/P_I.K^&[S0+J?PI;ZK!+J=Y^Y^J?\ (-U'_KQN_P#TGDK^=O\ X)7?L?\
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M>&-;41HBX.[2[*[>1F=WDO7+,<@+_:M7\\/_  <%_"7^V_A#\&_C-9PRM=^
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M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\
MX-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+TG_@S7_Y H_X7)%_T+TG
M_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$_P#RD]LHKQ/_ (7)%_T+
MTG_@S7_Y H_X7)%_T+TG_@S7_P"0*/[&S+_H&?\ X-H__+ _UCR;_H-7_@C$
M_P#RD]LJCJG_ "#=1_Z\;O\ ])Y*\A_X7)%_T+TG_@S7_P"0*KW?Q>CN;2ZM
MUT%T:XMYH5=M25E1I8V0,5%DI8*6R5#*2!@$9S50R?,5.#>&:2E%M^UH[)J_
M_+PF?$63.$TL8FW&22]AB=6T[+6BE][L>)T445]V?EA]P4445^7G[@%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%/\ P4)^"7_"_OV1
M_C5\/+> SZS<>$[CQ!X;55.[_A(_"KQZ]I"JRPSL#)=:>D)"1M(RSNJ%2P(^
MUJ@NH8[BWGMY5#Q3Q/%(A&0R2*4=<<9W*Q'XUUX#&5<OQN#Q]!VK8/$T,52?
M:I0JQJQ[:7BD_(\W.<KPN>91FF38V"J8/-LOQF78J#LU*AC</4P]5:IJ_)4=
MKIZVT/\ ,L:-HRT<T4D<J.R2Q2HR21RJ2'1XV >-U8%9$(#*X96&0:^B_P!C
M^Q-[^U7^SI;1;4>7XR> <.RDA?+\06<I)4]01&5 ]2".<5UW[>'P?;X&?M;?
M'#X>P6AMM-MO&=_KNA1%/+B&B^)R->LA;JI?,$!OIK)6)Y-LP/(J+]@](G_;
M+_9G6Y.U1\7O"C#C(\Q;MFB'/JX49XY/'.*_N/%8VEC>&\5F5#WJ6)R*MC*3
M6MXUL!*M&[:6J4U?16:O8_QVRK)<1E7B)EG#V-O#$Y;QG@,HQ3>EZV%SNC@Z
MLE>[Y92@Y)WUB[J333/[XOB?9?;?ACXYL\R W7@OQ# 3$"T@,NC74>8UR"S_
M #$J,Y) Y[U_FV2H@>163YUEE5CM/\,CCD\G.1R#WS7^ECXOV_\ ")^(0QPA
MT+50YQT7^SKC\NW\J_S7M858]5U98/F@35=16)]W+1+>W C8GW7!/OW-?C7@
M.^:EQ-&^BJ95)65W=K'I[=+6T^9_5_TSZ455\/*U[/DXFI-=6N;(9+?32SVZ
MLVOA[X'U;XE>//!OP^\.V[SZSXU\2Z-X8T]8HY7=9M9U&VL/-VQ(\GEP+.T\
MSJC".*)W?:BDC_1I^$W@C2_AI\./!/P^T6WCM=*\&>%M"\-V,,44<,:P:1I\
M-FI5(DC1=YB9V"HHW,6QEJ_C=_X(K?!V'XH?MFZ+XEU*S:YTGX3^'-3\9;FB
M:2!-;N ND:-YC!E6-T%U?7,!8ME[8GR\J"/[9%& ![#L!V]@*\;QNS=U\WRS
M)82_=Y=A98NLEUQ..:Y4]?L8>C3<;ZKVL[:.[^I^A]PLL#PMQ!Q;6@O;9_F4
M,NPDFM5@,GC+GE"715<=B<1":6C>%@Y:Q5G4445^'G]AA1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ#^5?8'BS_D6]:_Z\)_Y"OC]>@^@_E7U>0?[MB/^O\?_ $VC\\XU_P!YP/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W!1117
MY>?N 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGC7Q5X
M=\$>&M9\7>+-7LM!\-^';"?5-:U;4IUM[*QL+6-I)YII'95 "@!54[W<JL8+
MD5_%_P#\%./^"E&J?MB:[;_#?X?6]WX>^!7@[6;B[L5DFDCO_'^JV[M#9Z_K
M=NK(L%A:(&DTC2Y!*R2S?;;ATN42-/["/C[\%_#G[0GPD\<?![Q;=:E9^'_'
M6C2:-J%WI$ZV^HVBO(DT5U:R.'C,D$T4<GERH\4H4HZLK$5_/C>?\&[#&]N/
M[/\ VH'733.YM$O?AO')>I:[SY*7,L/BB*"698S^\:."&*24!UCB7Y!^K>&&
M/X*R?%8C->),5*EF>'FEEL:N%Q%?#4H2A[V(C]7I56\3S.4(\\5[.*4X7G)R
MC_-7TA\D\6^*LMP7#7 .6TL5P]CZ,Y<15*.89?@\?B9PK1=+ 5/K^*PJCETH
M1C4J_5Y3J8F3=*LHTH.%7^9;+XR&C [?*<^G4?X^U!W,#O==I'8/G\\]<9P1
MR#@C/0_U(:=_P;L^#$EB;5_VFO%5Q"'4RQ:=\/\ 1K-WCR-P6:YUV\".1T;R
M'5>H4Y->M:!_P;[_ +,6GW]M=ZW\5/C'K]M#/#++IINO"NFVMY$C!I;:X>VT
M![I89\;7-O/#*BD[7).:_:*OBYP/3;:S#%5FDY6I9=C-9+7E3JTJ:U=TKM+:
M[2U/Y)PWT7/&&NXJIDF68-2<4Y8G/<L<8)VO*2PM;$S:BKW48REI91;:1\0?
MM3Z9J,/_  1*_9$N)?!^G6LL?BSPW<WUVNAQ6\VC:?J"^,FM-9@D7/V.Z\1R
M/IBW>H!FDU4ZA)NW?;& _GS#$*-K*O )SNR3UZ Y'7H>_P!*_P!%?XE?LR?"
M?XJ_ J[_ &=?%/A]&^&=QX=TWPW;:782"RGTFUT:.$:/=:3<1(?L5_IDUM;S
MVMQ&A*R1C<K*2*_(#4O^#>W]G68R'2OC3\9;(LC"'[6O@_4!%*<X9]FA6+2Q
MCY1Y>5=@/FF!8FOB^"O%#AW+\%F6'S;ZU@JN)SS,LRH^SH5,32E1S"O[>*E*
MES2A.DY2IN*ARR2C.]VTOUSQ>^CKQUG^:\/8SAE8#-<-E_!_#_#^*5?&8?+Z
MT,7D>%^ISJPIUN2$Z.)IQIU8-592A+GIRC&$*;E_)2"2/F96]AG]0V0>H'OT
M[U_0E_P2=_X*E6WPIMO#/[+WQ[O63P+)>G3OAW\1+NZE=O"9U"=G@\-^('F+
MM_8!NI#%IM]$T8TI94MYHS:()$]SO_\ @W8\-D2'2_VG]?5MKF$:C\.=,D D
MPWE"9[7Q)"70':9"J*^02A&>%\&_\&\NB:?XFTB_\:?M&:EK7ARRNX[K4=)T
M'P1!HVI7Z1.DGV2'4KK7=1BM$E92CW LY9DC.8PL@$@]WB/C7PTXGR?$9?F.
M9U)1:=2A.. S&.)P^(46J=;#7PJ@JBO:49249P;A)J,G;XS@'PA^D%X=<4X'
M/<AX>H4ZBE'#8^%3/,CGEV-RZK6IRQ&$QU..8NK*BU"-2-2C2E7H5(1JT$YQ
M<9?TE6ES!=V\-S;31SP3PQS031.LD4\$BAXIXI%)5XI48/&RL59"K*<&K-8?
MAS0[3PUHFD>'].#KIVAZ7I^CV"RR&:46>FVL5G;"25OFDD$,*;Y#R[ L>3QN
M5_+,K*4E%MQ4FHMJS<;NS:Z-JS:Z/34_T@@YN$'4BHS<8N<8OFC&;2YHQE9<
MR3ND[*ZULM@HHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 87B>&:X\/ZM!;Q//-+92I'%&I:1V(&%51RQ/8#)/05\K?
M\(UXB& = UK( !_XE=[UQSTA(_(FOL:BO3P.9U,#"=.%*G44YJ;YW---)*RY
M9+2RZ]SP\VR*AFU2C4JUJE-T8.$5!1::E+F;=];]-[?,^.?^$;\1?] #6O\
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M73/CO_A&/$O_ $+VN?\ @IO_ /Y'H_X1CQ+_ -"]KG_@IO\ _P"1Z^Q**/\
M6.O_ - U+_P.8?ZG8;_H,K_^"Z9\=_\ ",>)?^A>US_P4W__ ,CT?\(QXE_Z
M%[7/_!3?_P#R/7V)11_K'7_Z!J7_ (',/]3L-_T&5_\ P73/CO\ X1CQ+_T+
MVN?^"F__ /D>C_A&/$O_ $+VN?\ @IO_ /Y'K[$HH_UCK_\ 0-2_\#F'^IV&
M_P"@RO\ ^"Z9\=_\(QXE_P"A>US_ ,%-_P#_ "/1_P (QXE_Z%[7/_!3?_\
MR/7V)11_K'7_ .@:E_X',/\ 4[#?]!E?_P %TSX[_P"$8\2_]"]KG_@IO_\
MY'H_X1CQ+_T+VN?^"F__ /D>OL2BC_6.O_T#4O\ P.8?ZG8;_H,K_P#@NF?'
M?_",>)?^A>US_P %-_\ _(]'_",>)?\ H7M<_P#!3?\ _P CU]B44?ZQU_\
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M*;__ .1Z/^$8\2_]"]KG_@IO_P#Y'K[$HH_UCK_] U+_ ,#F'^IV&_Z#*_\
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M )'K[$HH_P!8Z_\ T#4O_ YA_J=AO^@RO_X+IGQW_P (QXE_Z%[7/_!3?_\
MR/1_PC'B7_H7M<_\%-__ /(]?8E%'^L=?_H&I?\ @<P_U.PW_097_P#!=,^.
M_P#A&/$O_0O:Y_X*;_\ ^1Z/^$8\2_\ 0O:Y_P""F_\ _D>OL2BC_6.O_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>nt10016217x4_graphic22x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic22x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@G9>M%-LPR_M70;5:3E5=O^&<=H8CH,Y/ICFOX4Q][+$D;AR1\P(^@X7W&
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M*VW[=C_QCEP?:F_\1E&F#_G';?\ ;I^U;;GZ_P#-N7;]:_AS4\$<\D<>F<Y
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MKK2[W5C^Q^?_ (.PGA6R"_\ !/\ NYY[Z01Q10_M0(Z@;@K,91^SQM&W.6!
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MXSC.!V QSSSUY[=J/:U/YOPC_D)PB]H]=$FWT];_ (=3^YH?\'G\1_YQNR#
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MK=[IKTT9_<^O_!YG9$C=_P $Z)U!S@_\-;QGGW'_  S,.O3USVJ9/^#S#32
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MO_/^ON/[FQ_P>=Q'K_P3?D!'4?\ #7JG'X_\,O\ -*O_  ><PL"?^'<,@X)
M/[7J\X.#C_C&"OX9O,VN@YVD<D\'^??/7OC\*7(R=I^4\8)., D=1D#/USG'
ML*AUJR:O.U[?9CY:?#IUMJ]AJ$==+V7=]UKOT/[E?^(SR' S_P $X)!GIG]K
MY.<8_P"K8/4_XXI?^(SN/(7_ (=O3$XSQ^UZF.G(!_X9AP2/R]Z_AJ(P&*D$
MXP$#9QZD9/KP#Z^O%,WE1G&1DA=V0<D_>'&[UQ[=/6G[:K:ZE=ZV3C%:=/L]
M/7775B4(]NOG_FC^YS_B,Y@P2?\ @G%*,8'S?M>1CDYX_P"38SSP>U20_P#!
MYHD\BQ1_\$WYBS$+@?M>1DY)QP/^&8^?S%?PT( [,@4')4L.H)P ",\ @DG<
M.3R<\\^H>#O#L+W%O+>3)$C/&K7,C;8(0TD,>20'DFDC$T<DT%K'/<B$/*L)
M1&(X\5F$\+2E4E*3:3:BH0N].BY;VO\ ?IWL=>&PD:]2--I1N]9.3M:Z7=6O
MTU^Y']QD/_!WK#]C-[>?\$^FM(U16=1^U>LSJSJ&2/'_  S;$"[<\9X SWP*
M-K_P>$:9+.JW7_!/V:SM2RGSC^U7'+/)$9HXW>WM3^SC%YC*C22J9IK:WD,$
ML*W/G (?X[?%MDL7ANWN=/ABG5I-DES+%')(<VSPS[+<-+#&F)7"7$AN)U>&
M"[MGLI@4'B#JSO-.[/)))*99'E;>[R,Q9W=GRSR.[%F=B6)))).<_/9?G>.Q
MM&I6>,M^]G2C&-+#6I.,E%IWH-\U[OWG)6TZ._IXO+\-0JTX1H7]U2E>=7WT
MU=?\O-$[;IK?1H_T%/A__P '/UG\0]"\1ZOIO[%]GI]WX;T.VUR72M3_ &G(
MX9]2AN;I;;R=*F7X!L+N6'=YLH$2N$_Y9UP'B/\ X.KKWPY<VL-Q^P&&BNXV
M:.XE_:F>V59%!(C96_9OD^\1M#*YY(X(YK^,WX%?$BY\)7<<K6\-Z+:)XVM;
ME"Z3VT[8:)274)L;]X#G9D#(X%>Z_%?5+WQMX2U+Q5X?\*ZI<:#X4@M7\3:O
M;V4T]GHK7\QCLWN9K='CMHI'S%&92BR,NTD#-?F.*XNX\RKBAX'%9E#$9-C,
M12IX6M4P>4T%AY5HTZ-*ASQPM*=6=3$2BZ*FW.I.LL/'GE%'UE').',9ECKT
ML'*GBZ5+FJ0AB,94<W'^)-P=:?+"*4G-Q7+%>\W&-C^G"\_X.];NQ9A/_P $
MZB%4@%Q^UM\H+'"J2?V90-S8RJ@DD=*]1^%?_!U<?B9=ZI:R_L,Z/X4%EI<]
M]93:Q^UC/+%JMU$&*Z7;-!^S.NRZF"D1E\J6*KCYLC^07X9^)/!_B#PM/\,-
M6LK2;6_$_BS1-077Y;>U>?2["UMW21;6X=A.IN7DC$\+X3**S= 1U_BSP59_
M"7Q+%=Z7+)?Z#!J$%M!JZVOV?3[W4# D]Q:VMPX2UGGMT9DDBB<R)*P!"L<U
MV9MXC9W"IB\CISJY7G<XU9Y9B)83"UZ6+H48T)>WI1KT)48NK4E6H1I5DYN-
M*=:,7&THXX+AC+W"CCJE*.,P;G"&(I4ZU=3HRDVFDZ-92E"'-2E.>T95(Q;N
M[/\ LIN/^#D[6[7PE'XGF_8=LXY9;J>U72W_ &G+A6+0QVLF1=?\,Z$;G6YW
M;6MU 1 P=M^%^?\ 5?\ @[-DTB\%G<?L HW[UH6GC_:M'D+(IQM+M^S>H )[
MG&,C@YK^>WX@>-O"UKX'\,:WI?B>WUFZUR:\@.E6L,<3V$J6>G1L]W 9'"2J
M\>QE&"P*D'!S7P!XW68ZE?07:G>LS72HL811O 82[>>F=P8;CT )->'P7XA<
M;9M5K/-L;:G*55T83RS"86I#V4XTJM.,'@J,YQI5';VDT^?FNI.-CMSSAO(,
M&J<<'AKR48^TDL3B:BDY>]NZ\DKJ\;16GJ?V+0?\'8M[/)$$_P""?:&*64Q"
MX_X:P01!@I;AF_9O4-TP.1DD55OO^#M.32H;*]U;_@GEK&G:9?W,EK;7]S^T
MP8XYI(LEFA63]G:-98\<K(DI1OX2:_CO2XA:R6U*2KMMY/))SB1_*SE>.1P.
M.HSTI/%7BCQG\3_"VBVO]G3WVA_##P]&L\FF6,TB:>UQ=FVA;56@B9$DD*;8
M'G*N03M;'%?8T^+.)Y8G#\^+P]/ NO['&5ZM+"4)T(5*=6.%G14L/4A6K8C%
M^PPZIR=.,'*ZC.34#R9Y'E3HU'2PU25>-%5*=.-3$5'.2G3=52BIIJG"DYS4
ME\2>ZY;G]?5Y_P '=UC DCVW[ ,]UL*;0?VIXX?,5R1D$?LZRD8 S@@\\9 Y
M- _\'?5JB R?\$^+E&8913^U2@5ACDB0_LXA<=N,G/4"OXIHKQWOXEE4A)!$
M05 *EE&-I;) 9&!79GY3U][5X%8* #L4O&5/WD8,"Q//I@$@GTSVKZ>.;YO#
MDA/&2FY)2<_J^$O9I*UHT(QO=.]HK>UUHEY%3 8!-/ZLHK9I5ZSU6Z?[UV:N
MM+KMYG]XGP)_X.BS\<?$FK^';7]AN/PV^DZ))K+W=[^T_%=1SJE_96(MXD?X
M :>I+&\\TR"9RHBVF(A]ZE?QS?LD7$L/C?7#;3"-6\)78PN]6^76=$!R5&/3
M/.3P:*\7&9]Q+'$3C0S*$*:Y4HRPF$DT[1O=O#-ZMMV;=OE8[J&5Y5*E"4\(
MG)IMOVV*U][3X:ZCM=:(_.#55 U'4QM;<]_>-N')?-S)P#G@CG'3H,].,T*
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MR<74@L4H<T>?DBW'JM7:6ZWU2[6OV1Z>%A4EA^:*]U5))N^E[0T:]# ((.T
ME>2&[@CD9Z=?PII&,9 W9)&<$X"X)S^/YFK$R[&4[3DX)##<$Z< CU[#/X5_
M;Y_P33_83^$'[%7[#?[:ND?'/3H;S_@H?^TC_P $N/VFOVC;SP#JNC:?+J/[
M-G[+>G>$G\/>#/#?B$7K#6/#/C_XL>*_$%GXLUG3FMOM,2^!XO#FJV?AW5O
MTLWBO:%Y[:*U[WO\K>;VMZNQG/W(IO=R22[ZK7KIY][:W:/X=0K8;A=W1"20
M".^XXY^GMC.<$N1F$C!L$(  RX/./F Y/R].,Y'XU^^__!M7\$/#'Q@_X*D>
M"->\=Z5X=UWX>_ ?X._&[XU^.=(\6:-8Z_X:GT*U\%S_  PMKC5-/U2WN[%X
M-(\1_%#0=<@GN+>46][IEK+%MN%B=?MWXD?\%I/^"F7PX\#+\:/%?_!&O]C/
MX?? W6KR*3PK\2OB)_P3^^/6@^#K[2M7G4^&R?'>H_$_1?">IW&J6UQ:QVEY
MI]Q#9ZO<M(=,C*_ND:47%2<G%-M+W6]N5-O9+65OEOO;-)\S44VTDW9VW:5D
MFFWKTWV5GK;^29E )<?*<$[3V(. 3TQQGC'TI54D[NNUL = #QEAV/'&,=C@
MBKVH7DFI:C?7LEO;6[:A=W%[)!;(4MXWNYWG>&&)F=HK>)I"D,;.Y1%52S$9
M/]2W_! O2M,O?^";7_!Q-<W^FV%[<:;^P]8W&G3W5E;W$]A-_P *%_;@D,UE
M+-$\EK*9+>%Q)"4??#&V=T:;2*YG:]M&_N3?Z$OW5=]TK?-7\M+];^G5?RM$
MDD.J[]OW57(X(Y.2 .G/TJ3R]ZJ2@Z<Y.X@Y.-IYP1G\A2!R, D@-@X50/O8
MX R,#L<\CFOZJ?\ @X0T"T7]DC_@@Q:Z)I5A9ZAKO[$UI#)]CM;2RDO]0N_A
MI^R[% ]W-&L0EE:>X;,T[G:99'9P&<EI74G_ "V^=VE;^D.^JOJF[7[.R;=]
M7T\M.JV/Y4(W:,$X(<#<C E=G.1SR"V1V'&<@9QB1I99F>6=FEE.2Q=F9B?4
MLQ9FY[L<D8ZXR?VU\7_\&]'_  56^'WPV^.7Q5\=_ #P[X2\)_L_:1>>(O&L
MVN_&#X461U'PWHWA*P\=>*_$OA&^_P"$N?0==\/^#O"U^=1\0:J-9M+,7FFZ
M[X=TF35O%&AZIHEI4_9__P"#?S_@IK^T9\*O"GQB\+_"7P;X)\(_$CPY8^*/
MA!;?%;XK>!/ GBCXO:;J=A_:^FKX(\*7VK7&MQ2ZCH>[Q!I\OC&T\)V%_H 7
M6;*\GT^XMYYCDE?X)7]'M]UPYVX6YURW7N\VCELGVT3>O1>1^*#C>@^4;@2,
M$X^4YY/N< ^QX-,5?D"DYX.X\$D9/4Y[]._Z&O;OVA/V>/C9^RO\5/%'P2_:
M ^&OB;X7?$_PC=-::OX:\4:>UK<M )9XK76-'O8S+IOB/PSJZP/=:!XI\/WN
MI>'=?L"FH:-J=]92QSOXI&"0%&=V22'/4>N>O)'3W[=UY>?_  -6WI_5]D*V
MMKIWVML_1[;.XG"C<V%QP-O+)G@;O[QYY]N_(RIQ\PD .W\F/7@'M^.>O/J*
M)4=BX1E*Y (!.>H/0D].Q]  >!7J'@_Q?X5TCP;X[\(Z_P"!M#UC6?&4F@KX
M?\=ZB]\^L^ SIU[)-J<NBV]O<+:W,>JVSBVN8[J&5D6-6MS"V2V=24H1YH0=
M27-!<L9)/EE**E+7_GW%N;6\K62N[G5@\/2Q-?V5?$QP4/8UYQK5:<YP=6GA
MYU:%&T-4\36C3PT:C]RG*JJE2T(R/- , 97!8$8_A!//09/;DGH?K2J,GKR-
MP&>0<+G'L.OOUXXJ2YCB@N9H8)VGACD=89_+:)KB($;)FC+-Y9;NA8E3P#@B
MHTR201@=<XP,GT(P.<]C^E7_ %]^IS\LHS<&ES0DXO6ZNG9VE&ZLFK)K3?=,
MDVE21@D84@YS]20>WT_6I85$A P5(;C*]0,9YSP/?MWQQ0$D;C QM]L8_P C
M/X<8K6TVVD<GC(&57*DD D\'J3@]QZ ]1656JJ<')--KS\_ZTW['=A<-*M6A
M"*YDVNCTM9MORT\KWNR[86/F%3T+<K@C'!'!'8$="?;K78V&EQYV%,D,&^ZN
M3EN@.,9SZ]_K4.EV4@Q_>/4@#(' R,\@=N.G0 =^^TO3G"*6!7#Y&5 + <Y.
M,Y&.ASZ]^*^:QV.=.]I6=]-=MK+:W:ZW716U/UWAKAY5?9-X>]U=J4+W6B_/
M75]EJ8R:4CMY0A!4$F,X (Z??;C(!/0@>QP*N)H:R!R\9C<L@7"@J=IPV/ES
MAN,\<8R.]=S9Z4TN=FZ0%BV>@0@9*[B.57(^4X)S\O.171VVA2, 6\K(7:6"
MCY1)P&&[+<8!R.0#Q7SM;-)1D^6IVZM/HWUUZ75M^ZU/UO!<"SKTU.IAZ:AL
MDU%Z[+:^R;:][16^?D3^'%9""@X=OG(!8 '.>5Y!Y&,<G' K+ET*+#[8@W!<
M\!>,\X4]..PSV]P?<#X=8*RLS2,N5'RJ$;)# J">3A>V<=\';7(ZIIP3>AW*
MXW!N A7!XW-D<,<<9QG@UIA<TG.?*ZNMUWZVTW>]O)=3FS3@>GA*,J[PU*T8
MVE=13DK*ZC=6NKO75N_H>%ZC8I&KL-H /4)@=]IP>A'IQ^7%<I-%LR!@#DG;
MR&W=<CCZ XZ\>AKT?4[9E=U<' )!XR'YSU/I_>Y[=JX^[M=I88QD?=QC QV(
M7@YYR?PSFOK<+6NHWEHU?39O2Z7>R>_3RZ?@6>Y:HUJBC2<%!VM9K\+OR5F[
MO976KYEE&[!&!MP<#GKSGOC&<GL<=:O0P(>06V@?*,9(].F<\XSZ<]<5$T3)
M(=V.>F .GN?IWSG/;.*U;5%8*H')' X&3W!X]SC/&.>:]*M4:BG%[VO:W5JZ
MLUKIU7W]_CJ5*U1QG%*S?Q*_1-*Z=^WS*)9PF<G)/"Y! R>O;J 2.F,D5?M5
MCFC=75F=2,+C^$$[R/0#&3QZGMS.NF,Y"#/(7>6;=AB=PP ,[1SUX[<]1KVH
ML["%E<$SR"1"Z*ORD# P3U# #@8R,D\UR5:\.6T%)RNFE'>VBUWLK)WL^ATP
MP[;BVE9M1U=US-/II?7SLWV5CDIC$I\N-5!!+-( 02I/ (('"XZ#DX/3I5<@
MH 2>>0 ?X\_U.?IT'2K,QQ(6*[LYYQR?FYR.AXQU/4\>M4W!;)4$@-C)SC!Y
M(4D$JO/8]/PSUTUI'5NZ5VW=W:U6O5-VVTWT.:=N9\U-7VT245HNE[^;UZ]2
M>UU&]L+J&^L;NZL;NW<-:75E/+;7%O*%VAHI8G21#@\D. <_-GI27MS<:A=2
MW5]<W5[>3LTES>7<TMQ<33-DL\D\C-(Y/3+$] . .&!!M&07VD$,,C:3TP,@
MGZ_X\68K.XD!RI.\8Y!.  0HR?S_ !.!5-PC+FLE)1<5)I)J-[J"?Q<J>O+=
M7EKN<BIQ<_:*FIU.50Y^5<ZIWOR<^LE"+U2NU?5E6":ZAS&EQ<PQM@CR)70Y
MR.2J,$('.>"<DG&0:8+:XDD(0.SNV_>=\C2.6/!+;F+$CD$GC@#&!7HGA;0K
MN74;:)K*WNA>$6J0SQ^8?,G*I&8U'S"0$@J1SGH">*^^_ /[.O@W6_ASX]5#
MJ=O\:/!.S7+CP7J&FBTM1X4B57N=9MKB1?WN0ZE(@N6'W3N.*^8XFX\P7#M#
M#_VG5Q%6@ZV&H4H0<Z]/#+$XBGA%B:U.+DL-@Z-:M1AB,7/EHT%4@YS7-%/V
M<KX>Q&9RE+#4XPY8U9RE*"I^T=."J?5Z<XI<]>I"\Z</BFHRLG9GYN67AZZN
M#&9%DBC8\EHR#D '.2O&/3W]*ZNWT#38T5 I,@Y+N?O,#_%QD#H.>E>@_$.]
MMH[^"PTV$6T5M:0F6,1I&3<LN9?N@97H%)YSDD$YKR^&>=G#$G.?N[CC()/0
M'& >Y&.OKBNFAC,3F&'IXF2^K*I%5(TKIM)OW>=IV;:L^JVUT2.:MAJ&%K2I
MJ7M.248RDU9-M)OE3U:35G>V^QU,/@V*^C$JQ!]JN66!2R@(NX%@%))P.X_,
MD ^L^*_@Y?> -6T71_$>C0/-KGAC2/$VG-9D7*R6>L1O):F5POR2H(\7%NV'
M1B%/)X\]\&^(-5T#7])U?3A#--IU[;WIL[P&>RNOL\B2F"X@W 30RA-LD3?>
M4X(/?["\4>-]8^+'B)?&.KV6E:/YT$4-OI^D(]G:VT8R\<-O;RR2)'#%(=RQ
M)M13PBC''Q/$&;9YEN88-1="632PV-EBZKKRAB(XO]RL'0ITXZ\KM6G.:YE)
M+E:@TI/W<NP> Q6'J*$9+&<]-48\J:=-->VES.R;Y;VBVFGU;;1\XW_PAUG1
MX=/O;[P^+2#6X7GTL2(HDO+8-CSUB +HHP/O#)&?8'W_ ,)?L3?M'>./V?O&
MW[3WAKX:W>I_ GP'J7_"/^+?$UGY1BT^\@^SB6<V3D3RV5NUW;1WE[$K0VKR
M*)V7<-WWU9?$+]CD_P#!/7X@^&M=T#X@:E^V=;>,53POJEO;Q3^'++PLK6C6
MNJKJC9:QTM(!J$.I:;)MGDN#:RQ2!"^.V^*:_M9_L3_LD^!/@?KOQ/T6^_9V
M_:Z\.7OQ,TW0/!]\\^H)+K=EH\\NA:NS/';FT?=8/*B&6-)XWC#-(K$?F.)\
M2N(%5P67SPF!P6;XWB3$Y;E^%S"I4?\ ;65Y?@?[1QV+RI4:E=0JT</5PU:-
M/$SI5:U.ABG2BJDJ=./U7^KF @ISIUJOL(8*E.=5KV$*=>M6=.#<K7JT9RH8
MBE&LDH0G&\THQO+\ [KX97]M%Y\D#!73S"I!+Y<N1@!>%9#'TSV]!7,:AX4N
M((VS&=RAG&588P#D9VGICOU]CQ7ZE_&7]GGXG_ MOA];_%GPR_A^7Q]X3@\8
M>%X7F@N3?^'YE@%K=NT98('BDB(1P&^;/7..,@_9SUKQA\(/B+\;=*U7PYIO
MA[X=7]E8:CHE_<+%K.I27D2LSZ3:;2+HJ)3YB@<%<@$#C[;+O%K**^#P&:5<
MUP%3+,RQN'P&!S+#8B.(P.*QN+S)91A<+0K4/:QJ5*N8WPB<?=C7C*,W%Q;/
M&Q?"=>%6M0HT).MAZ<ZE>C)*-2G"G06*J2ES<JM&A[ZLVYI)V3:1^6KQ2P%E
MDZD$!<XQC/8],^X]O2I+*XCBDD$L:2HZ;!P20<D GG&5/IU&3UKW3Q?X DCB
M>\6$J0D;EVBV[ED&1Y:JN">N2,8 P<'@>'7=L;64( "4;!&-KDD]6 &3D?@?
MR-?KF!S##9C1YZ4XRDU[ZBU[KT>Z6^GD_*^A\5BL+5PT_>BXV>E^KTW]4M.F
MJ[(HO@O@!2<OGMR#^/0$9XZ]O1'&0O0C&1CG;@Y.#_#D?=..:'W)*P=% =?E
M&"3DY)(/!';T)X[T@8?,>AY& & R./7MZ^HY[FO33=E;563NM;[-I=%;5;:6
MT>IP/?MHEKY))_UN&0"<Y!&#WYR.AX[8[\Y)/?%1,#DG@GGG!QM)]/\ /I[U
M)@ CIRI(')P!UR3QGD<X;MZ4F[/R\=1P,C@]N!WSGH/IT%)-)W5W[NOX+37O
MI^6A;3>EUILK[V2ZZ7T?;OL1Q[ANPO.1@@< $_-UYY'3CZU+N;!QU7(YQR?7
M'' ]?S[U$5PV5^4GKD\DX[#C..O3OGN: 1DD,V ",8X8_3@CIS]?2KM=J6G1
M[>F^_1:::7^9#T]='\FKD69-RD*I4, 3U')S@'KDX]. /PJR#A < 'NN,@9[
M<?>P>A]_<5%N0, 5W 9& .,GJ 2."/7W./>Q#'),\4,$;RRRR+'##$C/)+([
M!4C2-0S.[.0BHH+L2% SC)/9*U]5IWW^[U[%0W^7W:K\]M-?3<8Q'S ''W26
M7AL#D*.N.N" >@[]Y88)KJ4K%'\V4#RLT<<$:O*D$;7$LSK#;Q>=-'&T\SQ0
MHTB[W7(JPT%K;@M/+YMQ(H<6]JT3JAEMV9))KK$D*&*1K9FM8%FDD3S[:>;3
M[F,&HYYS,2 B10AV>."$LL47F,6&W>SR.ZJ53S9Y)IVB1$EE<(#23LEINEJW
M_AU:\OTZ+4'%WNEIY:?UZ].MM4K<;VEFORJM[-)'@LWFPVL!DA?.T?N;FXGB
M>1'1R;>WBGMF5H]1M90U:$7B34!)N<*463*J-JQ)&79S'#%$$CAAW.QCBB1(
MDW82-5)%8!()SC)7Y2#T(P0#R?PXQ_2G[%P /E;"E6^;(SDX)*X)Y..:QG"G
M47[R*G?NM%M;[FON=]]"XSG%WBW"R7;;335>MKOR?4]K\)>,X;Q9]*UBZDM1
M.K);)NS:C(X!5GRI/3<!P><U#?Z5-!.)(ANM9V<QMG/F;3@F,CAE!/S'@\<<
M5X\@ 9&&1*O!.3N4$C=AA@X/7CI@>QKT7PWXA$2C3[UFEB,@,!?Y@N1ES&26
M*Y(Y*8!. QQFO"Q.7?5IU,3A(^[4LZV'M[MTDN>G;:6D6[WV;5CU:.,G6A"C
M7<>:#4857HVFT[2OOU6B71;GI_@B$0WTHG#D-#Y:#<W5C\P&1D?4^Y]Z^J/"
M^L>*(_"/BSPOI6K7]CH'B:VBB\5Z;#>M!9Z]8Z>[3V<.I6N[R[@6TV9(&*90
ML#U )^?M)BM8'A8* 7\J196X=U;GDJ"2O( '0].E?0_PB\%:;\1O$]UX=U+Q
MO8>"672+R\AU'5#(;*[:WA:86<N#D>9M\D;5)RZ_0_DW&5?#^PKX_%?N\-@H
MT<95G+"UL;[)X.K"K"K"A0A4JSE3J1C4BX0G4IU(PJ**E!./V&20JQE&C249
MU*SE245*,'*%1)5(N4K*]K)7=FFX[-I^(:9:V?@W43J=_;&.*YN8DTNXB&9(
MT.!,6D7#!2%)4J5()(!XKMK3]H?Q?%X:TKX7ZE=6'B+X?^%_B'>_$3PS8:E8
MF[FM]>OHT2^BN+J1S-+I<\<:HU@S/&& 9-K-FO._&TGG1BV+I)!I]S/!;/&7
M\N<(^SS8@XR(G(+)R1M8 XZ5YV;+#Q_99A,\R1M)L8JT,A8"1) #N(X X..<
M]N/8IY/EV<T:6+S?#T\7B%*%6C*K#FCA:U"%6EA\3AY3YJF&Q$</B*U.4Z<X
MN4<17@OC:?)+'5L%5]EAI>SI0E*F]^:493I.<&D^64.>E%_#S622M:Z^T_C=
MXY^'/CVY\)>*OA[I%MH#ZQHOF^+O#6DVLD%EIOBJQM=*BU5](BC\S%G*L271
MD1L$R-NX&:R_&7PLN_#OPR\'_$>_\8^$]2A\6LKZ%HMAJZ:IKYLG:2&;[=:Q
M@R6K6<L)$\=P1A""@/)K@_A/J\OPXU71_%=QH>G^)+>VC\6V+:/J@S:RG5])
MTNT%RH?A9[;>9HL@%G!#'!(/(Q6;/-(9!((&N)Y;6&)G\JP6:5I6MX(P=D2*
M6V_(%+ $DG=D_,TLHGEE3+\MRW'5J&59,L-)XG%.EF.)S/#S6.ISROVM:<<1
MAIX2,<%+Z[/VTZ^'FZ*_>QE57I5<3#%0JXC$T8U,3BD^2E'GIQPC@Z$GB8\M
MHRC+]XO9Z6JQ<OAEKKW5W"K6ZLC1QNR+*3&4DC9@-I@7&1&>CG(R,@XKVOX<
M>*+?P9K$^A7%UKEMX+\>Z<EKXZLM$:)%UA],62]T3S(Y49&CAO3&9#D$Q[EP
M#BL?Q+\)I;;X1Z1\6+7Q-I=P]UK<NA2Z#'N_M2S%LI/VM\DCRB0"21N);@FL
M;PQ-'JMYINER3/%)%(@MKAAF9!@L?,8[F.[) [ GCMCS,?7R[.,HQ/L)RQ.$
MH5<=@<P@HSA*AC<#*,HUE[6DFZN!Q<*.(P]6$9*-6E3K4FY4XM]F&IU\-C8N
M:C"I*-.KAW/EE&IAIS244XNRO3;A).S:;BU:3M'=?";2;I5UIX4@N[V6YNUL
MH4\NV222=@%6-0P@SD.!R"W(V@\>?^+/AK?>''E>_MKF&UE1KJ*549@495WQ
MY(">9GYAD\\[<\5V/Q0\?WOAW7WT&T5HX[:("X<'#;BH='3#  AAP!_]8YNC
M_%F?Q#"= \0+<7PG;?87L\D;LA2,D1MYC#:FU,*IX!P&XZ>EELN+:>%PV9\R
MQ> J4HUG0E4_VB&#DXRA*E>\?W4/><97G*%FDW?EY\2LHJXFMAI.-'$*M*G?
MDM2=>UDI-6Y54FM](Q=[Z;^N?L>Z3?V_CG7]0L=*?5+&[\'SI&S[1Y4D>LZ.
M6'*NNYQ@L,[@5.0!U*_=S_@F-X9_8P\;? 1+OQ-;Z];_ !4T[5]1MM?M+-=(
MBAMM(N)(FMU5IBL[!Y[:%R6)5F);J**_,\=XOX6699IA\5D.,H5\OS+%Y;4A
MB:DJ5:2P5;V$*TH+$TH\E>E&->E*,%&I1G3JIM33?M4N%Y0HT''&SE&I1IU5
M[&E[2E^\49.,)JG-249/E;4GKS+2VG\@J^!_$>KWVHS6VFS!/MMV5>1642,;
MF3"*6 SN[8X) 'I46F?"_P >:Q?_ &&W\.7ZNKF-W>%HH1C[V^5P%88Y7!.0
M<@8(K]7?$7@FQ-UJ3-:PP/)<7T2)9P^6L06>4[XU"A?E(Z)RN1NP3S\M2Z-K
MR>*8UT_5)K2:"8F&-YW5<>8R@X;,>6VC.XX'&1Q7]%4N.*E6&(J^SPU*$8MP
M<W*?LFHW2J<D]VM=4K6O;J?IO%7T?LBX,R_*<=F^8YMBJ=2ORXZ6!CAZ:J1N
MI.$76A*-"22:5Y5(ZVE--H_;/_@AIX+\3Q?LH_\ !<']FY]+O;KQW\;OV!=<
M\3_#S0-/6T>^\3:K\,?!7QMT/^R;%)YUN&NI==^+'A?3_L\=N\<R:D[2W-H\
M5L9OCS_@VW^&WBKQA_P5[_99\06.A:K)X:\"6WQI\:>*]6BMA'!HVEVGP,^(
MNB:=>WLTV5CM;CQ;KWAG0Y JF0RZO"J%<F6/S3]F[]H3]HK]DOXW>"OVA?A+
MXDL]-^(7@:YOKVP.L6,.NZ)K&E:AI]WHWB'P]XFT>7RXM4T/Q%HM_?Z9?+:3
M6.JV0N(]5T#5=%U^PTK6;#]$_&O_  6A^+>M?#[XF>#/@;^S!^QY^R%\1/C=
MHFJ:+\7OC7^SS\,[OPE\3_$VDZV\0U"#PWJ7]K37'AA]7MUGBU*^FNO$>I1:
ME=7OB+1=1T3Q,PUB+Z_A3/<'Q!1IPGF.6T<5A)N>+G4K\E*&&C>I[6*O*4I2
MDO9Q2OS3:4%*4E$_%N*N!Z']I^TX,HYAC<GQU&G*A3Q;I+&X7$I\E:C5:Y85
M:4(<E53IIR2J<DU%0]I/[N_X)!_&SQ%JR?\ !T1^T]\#?$-Q8>*O$4'C#X^?
M!WQ/I^FV-Y=:=X@U6+]O;XB_#W7++1]2AU?3;FZLM1N]'OH--OX-4L9YHEM;
MN&]@>1)?RU^)G_!;;_@JKX'T^*.Q_;G\97^N-%$DMLWPX_9_>*WNT13=PW$<
M?PL%PDD;;QL:--C?+\P :O3/^"3OQ3\9>!/$GQL_8E^#_P 2OV?O@YIW[=/P
M=OO#/Q6^+GQ]T7Q(TGA5?"OA;XBZ#!I_PSN_#WCSP?I=MXQN-,^)^OWFC7?B
MN'7--?4]/T]VTV2*"YLM2Y'6D_X)H?#G]A3X^?L_^//AU/\ $K]N[P[\6_'&
MG>"/VCM!LY]0T#Q79:;XSB73O%]CXNAU1;)?",6@V=[8S:#+9S37LTRS6GGF
M5)[;YS.>*(K$8*6 S.K# TI8U3DJ-:BLREAZOM(PI.$:J@ZE+D]G"?)SRG*+
MJ047->WE^295PU@\XRK,\EP&>YUF&(RB-#&2<,3'(L#B,%-XB<;RC#ZU#%S<
M:SDZD*=/#QFXIU%$^R_^#@3Q5XI^*GPG_P""'GQ&\=ZG+K_C7QY^S@/&WC'6
MYK>RLIM9\4^*_#7[-&O>(=5EL]/MK/3K634-7O;N[DMK"SM+.!IS%:VT$"I$
MG@?_  <37NM>/?\ @JU\3M)U>7[19^ /AQ\%_!7A2%?-S;Z)>>!--\>W$!,D
MDL8=O$OCKQ#<YA6VAVW*[H6G$T\_SW^V9^V]:_M??LN_\$X- \0>&T\.?%O]
MD_0/''PUUBVTOPYJ&E^"]0\!Z-:^ ]#^'5S:76H^)==U'5?$-]HWP_T>[\2-
M -(L3J-QJ#V%C96LMI:VN-\9?CK\3_V_OVC_ !-^T7\4O#O@S1O'WQ"_X173
M-0TKX=:3KFF>$X%\)^&-*\'Z4EG9>)?$7B[5K>2XTW0[6>^:YUZ[\R_DN6MT
MM;=X[:+S<WXLPN+PF8RPTJR<L;AZ45-)<[P4*^&Q7O7DG'ZQ[-TY:^U@XU%9
M-(_7/!#PSQF<YUD4Z^$I0PV#R_B*G6G52?)5Q&9X"O@YQA%7<(X2&)]I+W71
MDE%I<Z9^T_Q-^*W[*GQVTKX4?"S_ (+%_L3?M!?"[]J?P?\ !OX<^ ;']H?X
M>:Q=V_BB_P# %I+J4N@>-]>\'ZQJ^G6%K)/<WNN7NO6=QX3^*%ROB Z['9Z;
MITL<?AS2/@?_ (*W_L3Z_P# CXF_"GQ;!^T#\1?VH?A5\8?A9IWBGX+>-OBW
MXGUKQ)\1M#\ VOV:ZL?#&N-K;)<0Z7;QZ[:ZEH$UGIGA_3[E-3O8%\/Z9?V&
MHQ-^^W[)WBGXK_%OX;_#7P7^T#^SQ^SE\?M9^%WA72?!_@KQY\3_ (?#7_'6
MG^'=*MY%TNPUW5=4EO8?$%M:P"%)TA72?[0>+[9J[:EJTUSJ<VU^W)^Q/\7/
MVC=>_P"%H?$J33KV_L_#-OX?\+6^EZ/%IVB>&O#]C=7%_;Z'I]K&T\J6,5[J
M.H7"RWUU>WSM=,TET\:0)%MBJ6-S/*J^(PL)8JM-X2IA:LL&\'BZ4*>M>.85
M*3A0QDU%^SI3C1E)S_?2J02<']MD.(X2X0X]R?(<ZQ=#(<#A8Y[A.(,/3SZG
MQ%P_C,7BG2AE=;@[!8S#5\VX<I2KQ^NXRA7QU&A1HJ>"IX2LY0KP_@P\0^"6
MM;=S);&--QPPB8,Q#Y9B #R.AZC /2O#]<T;8[]=A#(&4')YSN (Y)Z'TYK]
MM?VF/V9_$7PYN)DU"R2&":YO!$T<$D,2+;2*C[V=42/=G*JG$@).2< ?F%XO
M\,RVEQ(&1"K,#"-I!!P,J%*J3O4%MQ) W9XP17SN6YE5C6=&O'V5>#?-!Z.R
M:5^5]+):VMT/TGQ#\.L$\%2S#+*M/%Y=BZ+JX;%T>:=.JD[Z5%[LIQ5U."U4
MK\UVFSX\OM,9&<2(=H)P !D]<%?[HZ%AQZ5R-S:#S=Q8HH>-"[#A%<JI*J.6
M"@DD':#@C.,&O<M:L(4,X)$>QVXY W,<%>FX-DX)X'KVJ#PU\*XO&_A_XC:\
MWQ!\!>$I? FC6.K1Z#XOUIM+UCQ='<W0@>R\(6ZVTZ:GJ4#;));4O$XC=64[
M0Q'Z%@,;[1)R>B25[-]5&UDFW=R3>EK:-V/XRXEX5J4L1.CAZ<:M6]>?L_:T
MJ?,J-"MB&W.I.$(J-.E*2A?GDUR4TYNSX'XI^$?"WA3Q&;3P)XJG\=>$_P"S
MM(E7Q/)I,VD0MK%UI\%WJND+!*SG.F74CVPEW%9_+$B#:W/E^[V^7)XY!)S@
M9Z\#@]?KZU:FGE"-:^?,T*2&1;4RR>1YB@IYOE?<#@ #>%WD$9XJJ067'=OO
M '..O0GG)&<]\G..P^CHQG&G&,Y<\DK<]K.6BU?GW:T=M#\>SBMA<3F&)Q&%
MPL<!3K5)U/J5*<ZM##.4_P"#0J59U*SI06E-5JDZO+9SE)ZL!!/7 ],GH>^/
MJ!SZ]L<4A89P5(X., XSCH>0 >.W7^3%"KG#<@;<,6(![ #I_@.F*<QY/^Z,
M@8#$^J^_WNG(YR.2*U_K^OQ/*>VGY7_#^GVU!MIZX)*@9Z@#C *_WO3^5*5&
M1A<'&>OWAC@#T/H>>H'8BF,4#\=_4 ''X=#SR.O/'2FF52!\V-W&%SG(_B('
M(SUQGGG@T:_K_F_P_ 5U=NVO3;R5KNUMU>^NMM;#]Q!R,?*%9A@EL#MG/ P<
M#U/4=A[KIWP8>\^$^L_$V?Q1IEE+IUC#J-GH,J,9M2@>^2R>&*8/M6[C+>;Y
M!4L8U9AG%>$*5&2"<, <G/KC Z%1D @ 8Z'T-6O[2O$MCIPO[T6+,'>S%S,;
M;=G.1$9"F[C(PG4CW-<&/H8ZO'#+ XV.!E3QF&K8B3P\,0\1A*<^;$81*;2I
M/$0]SVR3G!7<+2:DNC#U*%.4WB*+KQG2J0@E-TU"K)6IU&U9OD=I<KLI/=-:
M$)#R*A88+ <H>%Y!YSSQC\.>#2L.2>^<=".#R<],=, GFHDY.T,'"GY=V5XS
MU+8/(&.^3P#TQ3VR1P"3QDC'"@@'J1VZ'U%=_7I_P_KM;K?YF"MRZ[IQ6NK;
M6[TT:?1ZVMV!9"QR58X.,X ]<=20?7N>.GKWOAG3?AY=^&?'%YXL\0:WHOBK
M3]/M;CP'8Z?IJW^G:[?^;BYL-7D#B2RC,7S0WBY$9&65LY7@L@G SQZ\8^O.
M/IU]:-N[#-C.2%/< <KGI@ ]1Z$>M14@ZD5%5:E+WZ<G.GR<[4*D9NG^\A./
M+54?95/=YO9SGR2A/EG'*O2=:"A&K.B^>G/GIN*E:E4C4</>C).-11]G/2_+
M-N+C*TDKD;BBASM Y"\#(!X')YR<YYZ=#3U7@D@!R<CJ-V.[9R1[]>W:H@ =
MH)5G ^=CP >@ )'.<?F ,Y%3%AMY&!GCO@_WO7 [D<CMS5M6LHZ[+H^U[+3=
M]-++S1JFVDVK.RNF[ZV[O\NFW0#\Y('\.X?B,?X_E4H!0# ).. 3P2<$\>G/
M'IC\ S@@/GH& ()QSCKTZ\XX/?'6I.@&WDMQST&,9'KSV.#[XZUE)O2]VNJV
MNU;KVO\ ULREH[VO:SZ_?_6A('C2&2(1 R22(XD))"! V4 ' #;N3GG'2H/X
ML^H! )SM(X&/Z?3J>RJ0.N,G^$<8R2  1USW'/X5(D 8.VX*4*L003Y@'\*\
M9SQZ8].YJ;I<S;U=O.[O%>>EDO+LMRI3E4Y4]HJT59*RW?1:MMO6[Z7'!LC@
M<\\#''U/'7_'TI<CKD#.>I[@8Q^F*;@')' _B&!U&..?3T />D."N!C(&>GT
M)Z=SZ#O4VOZ:/;LU:_S\NI7:]O)W26C3?3JUYZWVT)%&X?+U_P!HDX;GCU_,
M=OIF15R>64@@EBIP"W\/IQV_#--@B>1@JD%F(P2P4#/')..O'7&._K7=Z'\.
MM;U^:.*SDM$# $,]P"1@] (]Q7(/' SUZ<USXG%8?"PE4Q%>%"G%-RG-I:*U
MVVWT6JLKZ/>VFU"C7K34:<)5&VE&,8WNW9;I/1N_EJ[VL<1'#)*RJJC!(7N,
MMQ[<GKTS_4^J^&O#&HWD,;06,[Q&2&$W0@<V\<K@[=\N"H8A,@<D\D=*]2TO
MX/SZ24A^R_VC?,@=KLL!;V[8W%88OF,C$C:'8?=)/ KVRPTNXT#2;.WN%-E%
M)Y<U_'&N^.64.5AF95 5Y%!(!()7.!M4C/P6><:X2-*$,OE1Q4ZDU&'[RUU9
MOF5.//5M*SC!2C&\^5-*,DW]'E^1UW4<L3&I348W:C!M*UF]9)*R7O2:O9+>
MZ/,]!^&=W?W-A8-]G5K^_M[")KF2*")[VYE2)#+-)B."$,PW2.0%&2W&<?1F
M@?LP_$G5?'7BWX;6GAW0!XF\!>$+OQOK5G+J^F30ZAX<T^W2>:30[N.9K;5+
MJ2)DEBBMW+R A%!+8KC;KQ+X;LUCB-G-?KYZ2LX38"ZY 9@3]T$].#@>N*U=
M)^*%_:2V=W$#;7T-]"(-2M998[I;2&02QHUP) [VX*(&A8M&X&UXF7@_F.:Y
MGQ?C:56I@84*+EAZL:2Q6&J2C#$RJ472K<M/%T'.E&C"O2JT91C/FJT:U.I'
MV+IU/J<-A,GISIQK5)J,JL(RG1G"35/V<E*\6I->_P K3TU7*[QDF+-\,8K#
M4+:S\0^'+CPIK<VF6>K6>A:SI<^DZE+:7P9K#4H[2[A28VMXJ-):W*QM#,I)
MCD?:^.*\0^%[:*]CA,^^^$^_[$H4W9CR5D#Q^4H50O(8\ X&.M?<GQ.^*7BK
M]H3Q/X7^(_Q(UT^+_&.E^'M'\)V_B"6TL[06WAG0!*-*TUTL8;9)I+1YILSR
M1EI#(S.['DUOBA\./"OA:'POX^L=3TJ^TKQ-X8DU.:\CU&QO;_1M3M'FBO[#
M5K2 K-I$DK1&6UM[K,LL#QOT*Y^-P/&>.P^)R^EF2Q%/,,72KTOJM"=7%8:G
MCJ2E.>%HXFM1A5E1J4X2G3=6E3KU%"<8Q;BF_;KY)AY0JU**H>QBX3A/G3YJ
M;27M/B24^;1JS2=U9:H^';?PM=ZFJRO;FTL;2653<SJJ2E'0Q"%SG]YDG*C
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MYXQT.?K3SR.?J3ZD<\]NOL*D!4;3M '..^._(QSZCV-(RD\@<G.21C@'H<\
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M^]]"\>W4^CS^+[7R8;S4I=-M9-(M[4165SM8+>7.>8XO+#^K$LQ!..*_/VW
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M,L4\G]*__!M#\2=6^#O[%7_!>+XOZ%I'AGQ#KGPJ_9<^'GQ'T7P_XUTEM?\
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MR<INZL]N9.S5]_=]Y.VUEWN]-6Z<E&.C;6CY;73]U-=GKH][67?3PC_@O/\
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M"7+*$DGJX23/YAO^"G7PA\.P?#[5KQK&47EL+N-%VJTZR&>-XYQ%A=ZHJ[<
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ME? 9(BH"QR9#8!'R\XP:LV^C:39O +33;.2[413-'=EI!L8;MIA?(W=1CL>
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M@N7G@GOK\ACL)[:-6HH-.E.*51)14E*Z5TKV4I7UYM;.VQ\ORIL8XPP7(+=
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MWQU]\=ZLPZ=<S[1L;H"-N2" <YQCA0.P_+O7Z9_\.T_CIX2U(^'_ (G:!=^
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M.$JT:LJ4)0I2:J2:V=.M.%2SM=2JRHT^9NW+3>J^%_Z-]%%%?Z/'\PG\^?\
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MLEJEO9=5H[?\/?5^822222%Y)'FDVI&7D9I&$<:+'''N9F)5(T2-%SA$147
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M!L=./4@D$^OMUI6(X8%< 94?Q#)X)! !(XSC)Z>M1?/DLV",G)'<@G;TZ?7
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M-A8'KG/7 Z8QCL:Y8/(B,J.4,F5D920'4<E& /*-SD'KS3(VX]GP%"@XP#G
M P221D%N.Y.":XX8&A%U.>$*D&X*E"4=*48QBN566J<DY*[TVULC>IBJLHQY
M&X2MS3E=KF=^VU[-+KKW/7'\7Z@=#TR1Y))%?5-4@6'>=H8VVC ;1G (!)YQ
MSDY]8(E\5W\JQP1RQQEEFFC,T0&TXQO)?:< J2IY8'@$UY^T\L6D:4RJKA=7
MU<,7'#+]ET4D8)(#+QM9<$$8R,&NVTKQEIUC"1/;W>^5HTFB7#$I$%V.DAD
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MCM8Q8RJBO"2N[/R5H7CC4?"7B36])C98(['5;J'<$1@8UDWP@"3*[@CH1L4
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M%*,9R@X6?*TSOI9<_9TE&3A&H[.*NU&G":BX*.EN91:2W=^MU?\ 2O\ 9[^
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M=X2E&6K4E9-RTLFVF^:35[-.[V1]":3X0U?5O"W@?Q5;^&[S0O#>M2ZCIO\
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MUNEM%Q)LE6"=_*"CRA* SYPV/U&_X*L_L6WG[%_C%/"$0U:_\ ^-_ ND>/O
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MJ3WJ567E3U)VD@Y.3DY'Y8ZXZYIA4'D$Y'N 1[A<].N>,>]1!6#\9 4DD_\
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M34M6&P_=Q]ET4Y(YP6Z_2LJ1C*ZLV H8_*,KG'3+9SSG!SGKT%:DH!T73R,
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MS-J=@-UD\UZ=\Z*@W'RE95))##I7D_A_Q=871::(7\4MKY3QW-Q.&)GS\N<
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MX?MD\:>*?"F@:_JT6BZ9J6H6>F/K-UN$.FVUQ(H>:8H&;R8PS-D=CT KTO\
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MGK7=>'-"_P"$FNDB2ZMK21IDB0W4ZQ('D( +YP"O.2?3H:\F@U0P.=N#QPI
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M7B"=.IF.6/,JTJ>%>,K4+8?ZQ.,9\M*4^?G]V2C.?O65F?-*O2>9X2>8S?\
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M+T;4M3U2UF2SB74WGU581/'-?*HFFMX_(4P1.Q2,EMJC.:Y@LV<9Z>I^;'N
M!SG'ZTQ 0.>#GKW ]N?TIVX%^O/3.!],>GU[#UJ(PA"ZC%).4INW6<Y.4I>L
MI-MON3S2;W=E9=[15HK6VB22M=6MNWUG28@%2NXM@#G &/4>_MWJ5F)B9P2<
M,NXY!'(P, @\<^_KCH:S7.'P.21STQP3C/;'YXSZ&I1+A<$^@).3@#J1C(]1
MGT/I3<5Y/5/RMHGIZ+_+H*Z;NWKY6=TK-6WMW6Z;OL*A8!D8[MQR)"!N7MM
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M<>GUYQ[=8=^>QZY!([ Y]3CCOZ<8QS5I;W6]FOPNM==&OR[&?]?<22$D[B
MN"&SP 0>#ZGUXI  V "!CGIUQU;'?)_7CN:&QQSD'D+CY58Y.<G!/N.?IW"
MX.3R,<$<X]CDGKVSTXZ$<5L!&R_+CD\C*YZ,2>1V/KCG! %2J%P$#,QY.0,;
M< $YR/<@=,\GFD!'7[JCICJ6XR",\^YZ^N.:E5%E:-#)Y>]U5I#G;%DA?,;
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MR6EE==O*_20EADMCH2>V,8P![8SU_'D4FQP< $;@#U'R@D9 SP,\=,$]N:<
M#G(.WKDXV[1QQUY/8=OQJ6WMKF^G2"VBEFEE95$:#<_\(&>^.XSA0>G.:RND
MFVTDE=MM6233OKVM\RX4YU91ITX2J3DU&,(1<I2<FHI12U;N^FI#'&\DL2*
M79ML:JI)W'@'U/7D<<@'Z?;_ , M,\5Z=):QZ/XCU;PW>7&_2=0DTTE)M4L=
M44&2UE$8R+=U!AFP=VP\$9%?,GA3PVMGK1O-=@DEL=+G@6ZCCF6'9)=/LA9G
M+!]B.P,H&2 #P!R?TS_9P^'_ ,.-<\2S0?$'XY^&OV?? \?AGQOJR>/O$FCZ
MEK\>H^(_#5C;ZC9>&= @TO\ >2ZOJ9GBBL_.<0J=V%>1D5_SCQ"S:,<JJX.E
M#V_MJ4FI?4YXZ%2:CS.E'#4J6)JUJBI-25*.&G*7-&<%S1<E]7P[ELZ.,E7Q
M$94*N'DE[&;]E5=I).R=GK*+2?,KV=[W2/HCP+;ZI8V-_KNE7?AS1I/AMKGA
MF+2[BXU.WC\2W^L7NHF2V;PSH5S'+)J<FC7<"WFHE@88$ ,H*-S]A?MI?\%"
M?&_Q[^ .B_"3XN^'/#WCOXA^#/$=YXCB_:2L],T'1O'>OZ +6:*W\$W&A:+I
M%I;6-O8273Q7EW%>LE_:VMNSV<5PD\TOYK?#,>,/%OA'_A)]:?1=)T?1M1N+
MNVU.>V0>*]9?5[EH8+J]5V49C6)+@101 1Q3 .6?YJZ0W%K!K/GSW6D7T-Q<
M_9&MM0M9)K?5WO81!>/;!"5B:)6W2(S1L[*Q0-M)K\K\)> <?QAXFX?AK!X_
M)*V-HXN.*K99C*\J.%QV(RN>$QD<+#&.C5;QLYQJUE"G4A.-/'8FA&G[C</T
M?B.O+!9$LYK83&NA0I5'#&TZ$\37P$:].K'VDXT:D94\'3AR*LJMZ2]BIU+K
ME3_.*^Q_I;11OM+K<-+-*S-ODR&C_>,=V0NYBO&3@#/%<Z)@P;RU"J_4+@G<
MN0,$].O;!_*OJGXG_"C2M!UZ]LTMM7%BUWF&\ADBFLA#<D310V&61PH+F(K<
M1AD /#* QL>'OV6=4\3>%O&WC'0]0M[?0?AVF@S^*X=1NK:'657Q+>-9Z;_8
M>FSSP7>N()1B\&G0RO9J5DG58R6/])>+^49EP!G>+S+B[!+A_#Y]F5:MET+T
MYX:K+%8I4U#"QH5*UZ;Q,Z=*BE&,DZU",HQG443Y'@7*:7%V4/$9 JN<QRZC
MAZ..JT(5:M58B48M0JI4DE5E!<\TY-WNDVT[>8_!_P /?VIKEMJE_:/=:1I4
MRWDZ,C,LQM]LIA50<L^5&T8QZYZ5]B>'_P"U_$/B&#Q1=6DVF65I<W7V FPE
MMR=-@;RH[>*X9?+NBC8\Z- QB#*&P2:TOAEX,T?PEX7M-,_L2>"X>2X:ZU.]
M9S=WYEVE9FM20MLL9 6-1R1U/!Q]7MJ?PN\+:#H&GZGK^N>/EL=-N;RP\)BX
MCTK3/#>JZDZ2ZE&+F"&6Z=KQXXV8J64LORX!W5_-V9XBIF^:1S"-)O#PISH4
MI5URRH822:=>G0E=NI6JNFZMTY.FHI<J31_>WA/X)4N':7#W$N88BO'&UE];
MJY?4A3C&E)TVJ?M(RBJE*K1<E'62YN:25FSPJ[\(:GXMM[ZXM-&34+<RE5\L
M(;N%69&222(LK*C-M+$ @=,$$YZZ32;73= U#3/&5K?6/B;5$L[>.^N=!-J8
M-*M(DMXXH+:!$C:U9 'EE1/.N @?)=LGS^_\97MOJUUJ/AQIO#L$]SYD%G!<
MM.]JB,3"DD\BEIGCP"'*_,<'KFMW5OB_JWBFU:'Q[)=^(+Y$CMK+79KI8;NP
MAC0(%,:QB*YCVX4K)AMJ@Y#8:N>6$Q#@I)R<TY*$J=H6HRM96=VE>THKX4M+
M+<_HBE#+J6*K8B<*<JTL-5A+$U8P?)>7*^2/+HI)O6;DUHULV>9:I\*/AU>?
M$3PUIH\7:C'\/WO-)C\9>+M&\-3OJ=I;3RNVJ:KI/AN[GBN;B73CY:"T:6-[
MC!DB(SQF:]I4EA<ZC;^'[+[5H5H]YI>FZH;5K.^URWAF=;'7KJUF=YK2^N85
MBG>R8_N96:-<[03Z:NJ:5H2+JC![NYU$JMH)9%^6WF!7[3(N2=J$G!0 Y!)
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M#WX>7ANM6MB]W-9.X:&38 T<ZS#!,S@Y4<#)QG)XQ7]%7[*O_!5CX"_LP?\
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M]LI+VDXKW;2BFU;O97NNZ/SZT/P_J-_JEO"E@994F0I',A$<S!@VQLA0R-@
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MS_ YO/ZA2I3A4FI13BN9J2@K*4G9>\VE>*6^JN<AXNT"RO-#U33-8G"W>IH
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MY(8HS*ZJQ"!OFRQ!5<#E><-D]<#''.0:]/\ !_Q9^)/PK-U:>"/&>K^'K?4
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M&"@D_.03ECD\=2>AZ#'M5)**LMEL-S3=[=OS3:MMWMVTT1,N%,?(W8P8RQ(
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M*9IT?:['F$X<\@Y\T\8:C:6NEQ^&Y;&*/4Q=_:[F^=E>Z2-2^++S58A;>/>
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M9'^<5H6:LTB1 -([MY:!%WL"V B]1\I)SDGCH.*H*GS-G)V/@L .0%S]W&"
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MYXKVCQGX,O/#6@V.O@DI*D>Q1*@,DDA&U50L7(89(! &,\CK7+FM#*J&98+
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MF"**Y<,HD,^[!?"R/D@9W#'KCJ!6I#!)Y-[&\HDN+*4QS74!0PM)!*8Y&C<
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M.-/%#]SFZRW 96JM*M#+,NPD*<85J5.5-5'B*KK8N<G&<N9RG%2;NXJRLXR
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M@:1!X@6RU"V:W\.%<6NLI'DO82I $)1U)&$ . <GO5M;_1OBM\8CJ.C>"/\
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M%],TWS))[718_M$TKP6<+REDBMQ&H=F<5[JUO"8[:\CC2";R)) AD)E%Q*H
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M(KB$>7+]I,[[PTJ-MRJA5V*-N !Z]37WM<+9^(='_P!#M,>0%:['FEXT>X#
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M+]'$C?>9N@'7 & ><UY8"I"@,0.C#&0!W.0?0YZ8]<5[UX@T)[W0YK;:9)+
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M-.@M8XG1%D(W-(?+Z!&!5%PV=S*3N*@X&1@\UZ/K=C?V$%C<ZA97-K%K%O\
M;+!W79]KM$D:V-Q;9.6B\Y&C9P""PXR#7'7L'*Y"(JIN5H^"AZEY V",@8)Q
MDXR/EQGYRA*4U%MV_>>T;6NBLK6OOIOH_4_7\;@L#":G&A2<Z:M!U8J7+:SO
MWBWO?>UM7?5+:X2!U*@* "5/^RW4#D@8/RDCGT /-,C\0:WH6NZ5XET&^EL]
M8TBZ6YL;I527R2IVG*2JZ$,A()=6&,D=.;/AW0K[Q)JEGIUG\L<TRAIP^#:V
MJ2*UW/*'54VQP>9,%++O951<E^/8?B%X-^'NF^*;K3OAEKNIZ_X2M[>VM[;Q
M!K^GG2M1U:X-K&]]/)I;2N]G"-0:6W@3S')AB20X$A ]_A7C"7"7&.0YMAWB
MX8W!5:N.IUZ%%SP\(4%RRH8FHWR)8JE4E3]E)-N,I2=U'7Q<XX7J\7</YED6
M*PL:N79IAJV&K\TFZ$XP=&34&U;VB<HRC?[,)-7Z>AW'Q[^)OQ+U&PNIM*C'
MV)(GN8;5=/M[B\OE.^/4%222$&65F8EAP5'W1UK*\>'Q+XKTF+23X?OT\26T
MZW^C7M_?6BM:VR2+-?Q2W(FD@D,DHS!;$N')"-T&W(\%PV]CJL=[J\DDKH%2
M*"WD6%I&V"* .Z;N 2H14#%L@'FOIK2M'AL(M8F\4>&+RRN['36UFRN+V\ET
MAFM?,QNL[>5%&HRJY1O+4Y8%F*#@K^[9U],'C[$1QV40X=X+Q.48C#UJ<J6/
MR[&XBG4P]>E.G*AB*<,QA2K1O-22=-)RCRS4H-H_-.%_H.>&6'6 SZGF_%.3
M\3TIX:OA<;E.;X3#1PF+P\Z52=3#TY89U(U*L*=2F^:K)>RJ2CRN3N?-VL:=
MXI1=.U+7],FCN!;6\-W?BW$-G<S! 4C2-08#)$B^7(R-\S?,%%<[J4:WR!UC
MV*FW<JLP#*0,\$YW#J5[#MG)KU?6?C'HNIKI_@SQ#<-:V6MZP9[&=W>9XB[K
M&L\><A5CX::-<&505QFL;Q-X3N?#][<6T<@U2U@C2>+4;"WE:PEMY3^YE>;;
MLC=AAC$T@=23%C(7/\K/%.K.IB*E"%#VTZDX4J-!4,+1C4J2J^SPU%<RI4E*
M;M!-JT(IM<MC^P</A</]4^IX''2S*6$A'#8RI4J*KB74II0C4Q;5K5JE-1G)
M65Y3DU>YYQIFBZIJ6V"TADBB /F78C:1+:(@E3*$R,L/E5<9)]"*\X\5^&-2
MO<6,>ZW:*1V-PDA G5GPZRJ=QCWX4,"N1U P*]]TO6]8T*&]M])F6W_M1%BF
M62$21N5.(7C1U)B<$J5.X%3QC/7T:P^!GCN?X?77Q0NM!NAX5?Q1#X4N=;O3
MY=U)XFOM..KPQP64BBYFL)K8-+'>Q@6S./*5W966N[*\YQF58^EF.75I8?&Y
M?.CC,)7@GST,31DO93A+M&3;:=N:]F[;>-G'#F5YWEKR?'65'-.;+L1#$2A3
MH5O;IJ&$AS24I5L4J4O9PC"3ERRNU8^4_ '@?Q5HVK6%[ID]OJ4>HVZP7:VR
M?OX8$=G-C&L\(P6 \R0QE68E2#@U^U/[%W_!.[Q#^W;;^-/%2_%&Q\'^(OAI
M:VMOH UG5!'=QZ9-;*L45QITS1PRV!7?%%)E8HY8]LN!EJ^8?V?M.\#K/X@T
M'X@WE]IVFWSZ3'!=:9:I_:9UC[4&M(;&\)$EA9O#NBO)$(=]X#+@8K]4/ 'A
M+X1:1!>7-E:>+-!U*VTV:.SNE\0^597]E;*)Q93Q68@ED>>X*>4THD3:2P5P
M6)^GRCB_BS-^-_\ 7S-LRK5\[H8U8JEF-',*V'S!5XT'0IM*#E&C1ITW*,*:
MBZ<X2=.:DIMGYMQAPGD?"WAWFOAWD.7T<OP.-P^'P^&AB<CPN<91##SQ%&6,
MI3PN)G1I5_K'*^>4G4G3JSE5@D[)?.'QM_X)T_M7?L]VVA:UX0UGP3\5-(U+
MQ1%X66*76=.BO(-1*I/;FWM(KE95M;M_W1GGD>".1LL0IX^#OBI\1]'L+GQ1
MX'^,WA&71?%?A2>7P[XP\.Z;>?9+B/4K,EK5;:[M0\=W:BX\JY5[=Y([F%'1
MG(-?OOX%\3Z)Y-])XC\5:?I%G'I:ZU'8:AJ"G5;"WT[F,6:2_O)]1D4GR80H
MD9F =../S3^-_P"S%X(_:%^,?B#XH> O&B>(-,^UQ:CJ<'BB-=$\0:E%:Q(\
MMI#'(Q6\EA*-!;")?-ECY5"=N/Z=R/Z3_$V5X7$X3B/!RXDP>(PN*PM'$82M
M3P?$6'Q=:G)1Q$:]'V5+$8>#E:=J%*M12A*$Y2C>?\A/Z+_#>?YKAL=A*6%X
M6S'(L?EV/K8^AE.-I\-X_"4,1"4<OK8"<Z]#"XBK#V;HUJ-6-.M5IU5*#@_=
M^Y/V>->\*^-OAGHL<MR^K:%;^!K2*;3)O"4,?V5)+&WC-U8A[4"<6\;2":17
M5ED&\Y+$U[=XJA^"G@GX6>(1X"MM,L;^Y\(:W9V.I2Z9;2:U#XB&GXTY;FX<
M/-;*\RE4PJQ@/'NS@UXFWQ#O?AQ^SOHEMX \#M-X?FLT\-7/BA[Z&"32+[4+
ML6TNEK L,=]/+;S1F1_M# F, 94$U\Z>+(OC1X&^)$GPLU[PVGB'1/BGI]G%
MHGB":WC\-1QRZE9*EJ]MJ%P5MHEMIY );IID5M@WN@(-?S)B,9'"X>E&=%8B
MM/#QC.O5P\YR@\1S-.51S<TY<[3EJE.[@E[2:?\ 3F#R&OG><8[%K,IY5@,/
MF6)Q.%RW^TX4J698+*9898KGH0<*//0HUXXB.'48J5)SBO@<C\K=:UR'5=6U
MBZU2QBO?%<\)@L]0FT^S\C*SNE\EU;0(J/,WEB5)2<YW8&"0?CKQ+\.-8OO$
MLBZ;81E5=9;M]\:^?,\@)VIO'DHJ$A@.53G/&*^WO%_@/P_X2U/Q!86&HZ@F
MN:7KNH^']3@OKC[5);Z[IT\B7AL;Z)I+>ZMGE)S*C2(ZDRA]KD#QY+"\.K9-
MJ]C)]FFCNI9;I9([F5QN,[2J1& 4^90C#:.& K\[S+,<PP&"Q$J4UB)TX*%/
MGJU*\:,?:)1AR.;Y53DZEW963U2L?KWBCDN%S7AUXE8&FI_6J>,PTL#3IJFZ
M3;<55JJG3DW[.-&M.4G).+:]Y>\_-;WP/9>'/$ME8ZC<VKRZ&J1SW>AR2W%O
M=VTZ),TBO%N61K=96C=?]8#&5Y)X^B?B)X&TKP?XQ\/VGP]^(FE_$+X>^*_"
M&G:F?%46GWMG:VFNW6GJU_X?4WZ+/'J>B7#/;3!<*9E5E 4JQ\I_X7?\*/"&
MI^&;"^\-W-^=&U.,>(KF.<3G5(TE'FS6^$!4YR#%G 50 3FOT ^(OQS_ &-?
M'7A7P?8_"KX:^)KC5)?".JZ=KMM:ZM<6]OH>M7X1AXCMK.15MX[G>J[UAW&0
M*22K N?PWBK.N*\%F?#U6?"G%.-P&8T\TPU7$8;"Y75RJA",8U*.)QU3$U:-
M3!U(3@J^!G&O2C4C5J4:L:E:5"DOX5SRME68XW,91QV78:MAJU&<Z,*L(N,X
M4YTI1A&"3G'EO"HU&5Y-3LES,^X-'_X*Y^!]+_X)=ZU^QKJ?PHURR^+R_##4
MOA#;^(8;?0I_A;<:7J][>1_\)M=1I?3ZF)H-(N(Y+[39]+DN[S7GENH9!;S2
M31_SA^+9[G7]3F\.:5;QRV*Z:L6FRHJ16DIM(UCEEE<A LCNH"H3ECT)ZU]K
MC]FS4C\(=#^(>E^)K>_U/Q)J&H64G@J_:""_;3M*CEG;4[:XED*SSB*W>2XM
M]F]G'EKB3Y6^3_A=I$^HZ+X@\6:Q?I]@BU]K+1]&DL)([FZDC$I=U.T-"B.A
MC>.0@[P67)S7W&6<:8/B#"U<;1Q^&QT>$7#AK#4:>$JX66%Q%#%U,-3H1HQH
MPJ5O9XC#8F,,14E.A7HPQ#IXEQA)Q^ JY%/*YU,/2H3HPS:M4S#$-U'*G5C.
M$)J<:DG+EY(S3GR2C[-2IRY/>43T_P#9VL_AMXH^&'Q7TOX[_&;Q7HFO^!M/
M$WPL^']QXKUR3P]>7444C2R:=H8EGTB622Y C6$QQM""64@# \1\/:3KFJ^+
M)Y_ OA^^UW6[:P>>ZL]*TB\UR>TTY"%O)6M+*VN7BB^;<]RX$"G(>5<$CZ9_
M9/\ V'?&G[6/Q:B^#WPJDT#Q%\1H/#^L_$K5=-U[7K'0DT[PC::G%!J4<-]>
M%DGU-Y+Z*RL;-0>9!-</#!#),GT'_P $T?\ @H'I_P#P3<_:0^-.K77P3?XI
M:'\1]'3P=?Z';:U8:9XH\+ZEX3U:_@VV&K7=O?V=_I][)YB:M:HL*S20VD\,
MC^25?V,'ETWFF?9O+,LZQ&6Y[/"5Z=/'X.G3R/+,/AJ>7X#,J&20I4*%?$8>
M6'Y\YQ.'K5\57J8B<J<*L(UZ$9<&)K.6&P^%CA:'UW+U*E[*-?EQ>(JR;GAG
MBO:R=.G*4H5:5)Q7*_93O&T&X_(?Q@\"VEO\(?!.N^'9K+6-2\26\VHQS131
M+?Z3+I5\8-=LK^V=]UJJ*S>4'+*Q#*A+#:/G.UO-+TC0[W4-8BDDU"2'9IML
M0VUIC\H;H%(0<EB3D]R,"ONC]M#7_A9\7OB*/CC\*OAZWP9\$_%+5]8EM_A?
M+XRM=7U[0M6M+M+C6)-2TZVE*65CKNJS7-U:00PQVD,$HAA=E0 ?"7Q.M]5U
M PI- ;=M-06L-D8OLTI\P(5=58(P 55QQT./XA7)PK-8C"TLKQ&/CBJ-3.LU
MJXC%*+HU(_5LPQ%"."A/F?M:-"5-8?G]GAG/D>)G1HSK>RI_5XG,<?EN65J=
M&-3#O'4L%7C9Q<HU88>FYM2IWBU/VG+)1E.\KQYI.+YO.#\1?$L;RG3]1>S2
M5=DD5M&D'F*!MD60E 64 89> 1P/4]YX4O)]>LYKN6-3<6<:&22) D<B29 8
MJOWB&&& Z9XZ<^2P^'9IIHHYF",T@#M\^X#/W,*<;N>?0]QD5[]X9TK_ (1W
MP_=M"S227DZ6\4;DH%+*& 9CR%)PPS]XG*@GI]UGO]EX3#4J>"I4:>*J5Z$:
M<J%.,)3C[2$9<]2$5SI1OI-KK)->ZC'@''YLN),#*I6K5*%>JXUJ-6I)PES)
M:WG)J+B[.RC=_"M;GGOB[3#(?M!^439*!6(+;%R0P_WQT/7'&22:X5+B:TDA
MEMFV3P2I(DV%QNBE$@1D9621"00492K+E>Y->A>+;M8IHH'97D\@*P7E%F.=
MPW+G+1G(/0<\GFO+)95C,IWYX8NW\1*-@@ 9.",G"]>B@Y%>[@[8C#46TGS1
M2<9:QEKRV>FJ=K-6:=['Z=Q=3RO'XNJJ<Z52O3;IU84G%2I222O*SO'2TF^W
MO+LOO_QA^T;\0OVL/BYX6N?"GP_^'/AC4O#_ ,$='\#7V@V$&A^$])U'0OAM
MHMU)J7BMKN\D@M/^$AEM2\_V=&6ZO942V@5WV)7SI#J%X\K"UA:TU"VG-S'<
M95)X%C.&DCD0D LP&"A)VY(++S7F/@^T35-9T[3UCAEDOKNUMH1<3"&(7,DB
MB+[1(^$BARV9)7PB*<O\I..D\;ZOJ6@:]J&ER:?'9?8[M].G-O=).GVB"4PM
MY%TBB.6V8 $>6&C*L"C$'GY9Y#A<)C:>79;0P].DL%0]G"K*HZ\8TZE1*6(K
M5L34GBU4C55.$94HS@H2C.K4C.$:?Y=GN35L)E<<QISJUJ7-)R=#]Y.C!<OO
M3Y()4X+E3YK\K;LHIIM]AK/B#6M7$-GJNJW>H(8R@!F<H0W+A\$"094,%<,
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MY[CI]17U3^UWX_T/Q[\5-9U3PY:?V;IUU?37CV(18XK<2(JK%$%5(@!C:IC
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M:7_KIIZZ_AN!JS+G1[ ;BQ&IZNV3P3_HNB= ,#CZ=/K5,<88Y9MI *G"D'D
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MR #P3@8_4X'UQ2J_)Q\QP,]^O0Y[]/6ODK6OIYW[[+1]5K?;MJ>ES7:?I?\
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M9T;5[_1[V&ZM9W@,9Y*DD8/!ZY4\'IM('7BOJWPCKIU^*U9XX;ET*,9[@N0
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M=F4&*WGMPK.87/R29C,;*V,$8KY?\(V</BW591KL\DCK:20*9F)\V4R@D[P
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MHS+Z\\.L-22J0H0D^:M##N490I59KW)R@[I22C[O*K62/V ^#/[,7[(7CO\
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MEXG&Y1>!6A=U!^:-<,#QS@UTWQ.M[EM)L[&.$W,TJ1,J@%V52/D=-AW ;>6
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M2B_;*M&#G4J2IJ5Z].G7ASPKQG!*$W&:48TE%Q33M\BF]O&O-/MYY)2RS">
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M6C.!R0<X'?@Y' P/\]J/Q_'_ #ZTN6!SD\_D?SY/ITQP:3&?Z^W^?;)]JO\
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M-/%P-MSL>-/(8$#>CA3N53N;()!49' %<=+HMU;>7>O*\J@B,.2S2=SD@CA
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MPY;$?VMH-];R[4N;5'A(\^SE62.5#$[HPVU\:SZTD4D*6D@DO;52T-QRJM&
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M[MN5Y"KG!&>QR<CT/&1R."*,#KD9.20 0.F>O?V]QZ=6RJ 2%#,IR"K'!';
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M:CJ4XJ+E92:ZVMK9Z7T=W9MWU;>VM7%3JQ5.;NELWV5M$WJTK;:6*@81YXW
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M )^]U!/)QC)P1U)X!QSP0"H1CE2.5'08"8.<'KP1@YR>">AX% &, CH1G .
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MO1;F]2PM]1N-+C:!UGN'P;<R6BAA J@W,OS$LQ(KS?\ :^^'7A7X%:?8>)/
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M7)=]V+Q&$R^<,+AU]9BHQAS1GR\JBU&2;Y7=)WVMJFTW<_8K]A;XP?LM>#/
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M&=*7O24H?:3Z*3M:.]F21:Y--::?8/';0"S<&.41E9IHW< %W(#,RDY5@Q!
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M_L[+:.$AB'B:=&=54J\L/1P]1TI5E.C3E"E;EJ4X-QFXQC&H_>C%1DHG]A\
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MB\Q<'2J5'&"3=KRE*5G&G&.TE=-W>C9\(^*-+CM]/EE#2L9866/+Y,2$,-S
M#&3CC@=\YR,?#UX[175Q .0D\Q#2=<;CZX! Q@8Q[5^B_P <G\/>&/$_BS2O
M#.HIK?AS3=<U&T\.7+KO75-)@N95LYY9. 1*@5B5QGC@]*_/'6&WZA/+C!ED
M=O+P J;G8E$Q_",D 9.,=?3]I\/\34Q>6?6I0J*&*I4<125:$J56,*D54A"I
M2FHRA4A":C4C*W+-233DI)?#\3TO88V5!R4G1J3I.2::FX/DYXR6DHSY>:+6
MC4DUI9O))(<A3C)Y*].F<<\>HZ<<8H23<1C( R6/)QMR!M[X/09!SQ3F.>0<
M#@9(SD_W<#O],<?C3,D 8&.IY&W@G(!';MUQDX_#] 6NG>UM;?UHK+MT1\RO
MZ_X?JOZ]%;,A^3G^]QM.!P.OO^'.<8I$1P>V[&TJ3D*#W]?ICCD'O3U=NXSC
MC XQGN3@C' Z<'C/I1R6SMPPP#GY=_3C!Z=N?0=J>UUILM[/MWTMZ?C:Z!>5
M^]G:5 R<@#&0-WN<=NQ_-AXSC_@1']U00 /8GZ^E.W%2 <LIY&.H/(/KT/(_
MSAI88W$$MSCT/."2/3D\'W YYH2U7G\UT>J\NOWV:W3UV=OQ^\:P ("X!"@A
MCQG.>#TSCMTX]:3:6&XH&QQG/;.3QD$YQD@8]>PHW%FP5RP'4X4'N/3./3TS
M[4\%2"%"[@-V P 4 X)R< CMCGCCD<T[/M>3>^KWMRM/S>SOY,J$=&G+1OT;
M>FR^[;T1$P+QE".&&,*",#'WASC /8YK?US7;WQ#<V][J,=G'-;Z9IVDJMC8
MVUA UOIEK':6TDD5NJJ]RT2*;BX*^;/(6DD8L=U88,@3!PS$\E2N[&1_""2.
M/8'/>C:P))7(R1S@9)R!W]?RHY;N[LE'9W5^E[/2W-9.[\K;L5E'2-U>U]+7
MT5K]_GY"[-BD@X&?E'_U^I ].1US3T1G[;L8W@ Y Z@XZ>F>,GG)IC]N.!C.
M6&#@<]^_KU/7GLJ.02%8JW.=HP&7!X)/IUZX/I2U:OI?>]]5:R5W_P ,T]6]
MP32:OW_4U)PQT>Q4G[VJ:N%[%L6FBYYZ8 X/&2,DUD ."1P,\==QRI'\0QCH
M1TZ9%;4P TBQXP?[1U4]R,_9=#Y!Y .#CKGUZUEH0,CL22#R5R5R0W&5YSUZ
MGTZT7:_\E?X+_)";=TEUO?\ #?\ X=?/8]2^!]U\)[3XN_#^7X[VGBN]^#D?
MB"QD^(]OX#ELH/&,OA8/_P 3%?#D^I*]A'JP3!M/M2^47R& !W5K^(;OP&GQ
M*\8GX52:^?AX?$FK2>!G\61VD/B<>%&N97T8:_'8%[!=86S\E+\6[O$+A6,9
MVD$>- *""<!L<Y!.%P"2-HR3P>.1R<5W'@K3;C4;TI#";AA&VTJIWM@8V[<[
MR0HS@ 9&?:N'&JG&A6JU)-1C2LTY)0TDFY--6OTUE9*^AZ>%Q-65&G@84<.[
M8N6(C6=*^)O.C&DZ7M5-/V2Y>>$>6RJ.3UZ^@^:\[PJX5&G()!9EMRW.&Y8#
M?P.<XR>>,"JOB&P::-)DW231*T<P((7*G:KH[*JR X_ASGC:2 #75:#HJW>K
MV5SJI6+0+'4-/DU%=A>26U@NX#J$2*F6WK;+,2H X! &2H/[4?\ !0;0?V-(
M_P!G#0=<^#%W\.IO&.KZCX=3PG#X-U&*?6#I,4=O_:[:K8)*9K1A'&ZS-=PQ
MR>>'&,DFOQ3BGQ'H<)<7< \,QX?S[-Y<;YCC<MCFF4X)XG*\BJX6.$FGG6(5
MEAZ=>CB9UXW>E'!8JJV_8N#^NRWAZIFN59OF,\;A<+/*:%*K&A7G&-;&*=I6
MP]-R4YR3BZ>BE[SC%I;GY$_LSJH\;ZLI#,X\)W?F##$!CK.C< +C&!@D'/)S
MQTHKW#]E_P /_#F37KJ\U+5=6BURX\,7ZWEII]JAM888M6T5(V+G#&9R,L,D
M8.117Z+'/:-YQ^J9DW"I.$G'!5Y0E*$N63A)64X-I\LUI*.L7:S/#^H2=I*M
MA7&:4XWJ4TU&3BU%QDVXM:QY6[JZ74_.G5O^0KJ7((-[=X&XX7_2).2,9SGH
MW<'%9V,L?FP0!VSE>AYZ<_\ ?0S[5IZHN=4U(YX^W7F3T)(N)>.!T/U_'@53
M6$L<CY1]-HP2>-P))YX'7OTKZNZ5V^B5M.NG_!_X+/+C1E.2:BW=ZQ_'?L_3
M:_;5R@#&TL<=]IX(Z?7CN/P]:NR75[<0V]M<7-S/!:+(EI$[EH[99G\QUBCQ
M\@9L$@#GJ3UI8H6'\)YX+<\8/& 3TY_#OSTW+#2I[ED58V=F(*X4ECGC  ST
MXX')Q[<\57$0A[SY4HZ\S:5K6;=VM+)OKJGYGM87+\37:I454_>\L73A%OFL
MX-)QNN=-I64DTGMLCZ._9GTS[?>7Z"61+B!U$2JHVF*3_7,_<^6%##J,Y&"<
M&OLWQ-XXUKP]I]YX>TBXDMK=9UAEO;.)A/<M,A#6Z$?/&B@AI6*L ,@@D9/G
MG[-'PX31=$OK^XCEBU6]B$TDLD3;;:*)OW,287;B;.Y@V')5<#!-?6,/PCD:
MSO\ QM,1>QV1W36WGQ9DE>/<1]EW;V#H0K,$('S L,@U^=X#B/AW <=4,TSS
M*%Q'DV$JNIB,K=51IXVM",?8WBY1A*,*RC-Q=^>*MI=G^D?A[X?<:1\%L#E6
M0XU\-<0X[#XA3S.<9NIA<OQ-6ISQLN6HJOL*T6N1\T9P5F[,\Y\ 76H7&G*]
M]::?;Z?9P/&%O5.R]$V6=(H&VLK&1BS2R%][9QU&.T\;>._#=CX-FMKAET_5
MA9Q6>G:;I\:-;R0"ZC:16 ?*2S[=Q8(K;RWS8YKY@^(^N:C'J<,<EU]D#0AU
MM@[V\,: LL<:0P@K&R*%"LK,7;EL'(''^%I]*U'Q1IW_  D\@ECCFC@:^GN)
M$D422 ))('XE\F1U(&S)0C/>O]0/#'%\0<9Y/@.)^(9Y32R;-L+A:>3\.X&$
M*,<NPL85/;QKZS=:M*C"G!4W^[@Y\E-*-K_Y[>+./X7\-<VQW"'"&!SJ7$F7
MYI4Q>?\ %V*J2Q%?-<;*HJM)TIS<9T\.JDYSK>R49U>9*4GR.1]">!?@]+K5
MO?ZYXU\27\,-[O\ [/TB!Y,10R+(4N&^SA#YV0@!,K%<L7!&0.JU$Z#X,T6W
MT#6+7Q3JWC&YU/3CX-\8W.KVD'AK1?!EE;W$>H^&M0T00&]U'4)+R1)],U2.
M=38Q":)XYRRM'Z)X@U/1_!\EI;?:%U6TN(S':0Z.)[FXE,0C+M%;1122,&65
M0Q1-JL<# Z\1_P (=J_CVY3QMJ-C/H>EZ ]UI&A6.JQW$.H";B:66ZM[A(Y+
M<W D!@CD1/,4DC(Y/R/TCL/X7\.^%>;4,=EV28?,*-3#8WAO+,-3P=+-<3F[
MQ<'0=HI8^>$J3E4EFE3F2>$]JI5%[M_$^BG5\;^-?&K),?@,;Q-F.40EBJG$
M6+Q6(QDLFI930HQIXBE&K5G]5C74J^%I86E3O4=>I3]U\SDN=\(^'M*O+&?Q
M;JU\FK^([O4I)+22Z5K]ETZ3]S L$\F[R6@"$O'+&9$+E595XKO)[/1-1TY]
M.UG2M/O5>4%+I[?R[F)E&0()X_+>-5R6!5E8-ELG %8'A[X&?%&VGUJ3P-;7
M=U_;4D,-GH-WI=WJK7UW??+/>^&5LT9BUJ,R72M)Y2G[J$+QZ7IWP3^,6CQ:
MS87UT]UJ-KIK0ZMH5QH=L\VFW,@,L)?S09H99HPQF:,B6)AMVA<&O.X/^E!X
M$Y/P3EF"HXFKDW]F8*A@L9PWA,EQE2I@\5"A3>(H0C1H*EB%5O/$*NY-XB$I
M5:K4I22Z^.?HD_2&XF\1N,,RH8:EG$J6<XC%4<]Q&>X;#U)T)XA?5IQ56LL5
M2G0A*E2=)17+-*--N/*=!\$O']IX=U74/ WB:TNM<T74&LM0T7Q$LWG:]X8N
M[:0PV4<4K%A<0^8RQN94.(MH).TYZ_\ :X^+FL>$='\/VMYXFFNHKF6=K6VF
ME3?++*50B[MHM@/"HI^0*%#, <U^?=Q=>*;74M6MK$:I#=()8Y;BPB>*-)[1
M@\ M60(!'Y@VRH&+>8 & XK@;7PE\2?B_K,TGBS4M8>VLW5()[N5IIE*[46-
M!<!O+967&[  XW9)(/X?QWX YMXB\<X/BOPZR&A@.!.+Z6'S1>W57*:=&I2A
M2GC98G"\ML)A\TE3G6PCIPE&JL7.I3@IQBE_2/"OTF,)X5>'-?@_Q%SBKGWB
M=PLL3DJQT)T,PII*:P^%FL34E]8KX[*:&'JTL95;4JM;V,J\G*7,^W^%?AH>
M._%U]>R(EQJNH7UU:V%M L:Q+:J#+=WDLS*S16\!.(PI$CH3LY&:^[/VC_%7
MP7\0Q_#ZX^&OP3^'?P7_ .$.^'EAX,\5Q^&FD>W\=^+-.D:74_&&O2HL32:W
MJ>1'"9"UP8!MFEE8*%\=^"WB[5?A[K-MX/U?P]HA7PM;M97-XF@6]C>W'A[4
M'6)+W4M2AA='U:.2X,:W.]%=2%^8@&OTHU/]F_X9Z'X-M?$&J:GI&I2>)9#J
M$FC@PWQLY)#YMK'*\?FQHTB/G+L3R2RY)6OY0XMPO&?#?''%F"EB,;P=G&29
MC6PE7+\JS&5+"X3 TY4:F5_4\12E1]M#&X54\10G4M.K3JJIS2;27[1X/9/X
M?\9>&^4<52J_VKQ'G>/S#V.;8W!?6Y1S',,-3AB(8C QC5PTO9T71YIXN%2*
MKSG*#@XMO\[_ (=_!W3_ (H^&K35;J'5O#CR7#*FHVTD\D3Q,6"-;1RNK>60
M,C+MM.#C'%?0'P9^(WBW]@;XK6_Q1^'&E^ ?B3/+IU]IVJ^!/BK837^@Z_:7
MT'V:/4RL ,\-[I<\:7%I/"XV2&1'S&[JWZ$_ 3X<> _'WA.?15UFR\)ZS!J@
MTG0-#73VD_M.-5(CELQ;1,B*[?* X3<Q+' Z\+\9_P!F'3[F:TTZ\\5VDLZZ
MH+._N+S2/L]YH-JBMYDWD*/WULSJ8C(V1OPK8+5[4>,_$2K@L%]=XJSO/,NH
MXBCC'@,SSC'XG!U)T94Y0I8FA+%1E5ASQ7,G.*E!M-6DV?H;X;\)*V(S3AG&
M<*9-E&<5LGJ9/B<RP63X;+\RKPKX>5"IBJ.(PE!PY:WM92E."48RY:>LVFOQ
M_P#&WQ.^)WB'5?%'BE[+1=,NM<U_5O%&J?\ "/V'D0:;J&N7MQJ'V/38X?F_
MLZS:X-O:6Z#;%;HD>U0H!Y^_^-GQ*N/#0T#38X-.N]3A73[K6+&"?3;R8,";
MD7&]-WFR_<+C&X?>)ZU](>(/AAH.GS:S9R:BT\NG75U%HK6J9@U:WM93')<D
MG CPWW4)Z?=&,FO&=2LULT6U=FG@@D+(9 'EBDY! *C!X)&.2.<C&<_4P\5.
M"<1A<!0S/PJX1Q.>87&0Q$LPIRQ^'C447)MXJBJ\WB4[Z1JU)136SBTEG6\(
M^,\#B,0LL\6>*\+P]C\###4,OA/ U(T(4W%450K1HTI4JE*"Y92ITX2DTY2U
M;9RG@6?Q5:V=V?$/B"Y6)5\V1KBZFNKB&W2.-I!!-(Q.Z0(4*_,<<*0,9\4_
M: \:Z;XW\;:#'H&B&WT'P9#;V<*1)!LU'473?=:A.8T#//,REKAI69P1@%0,
M5ZEXMU5;.PF\IC;RO&\0CA*X92"OFXQQC^+/;@8()'EVD^%U.@>)M7AT[4KY
M]'L)];U:Z@@N9K2RM9G$$=U?SPPO!9P/(X1)IWC1W.%8MQ7Y_P 2YUD.8YOB
M>)8Y?3RW&8NK*&"RO+Z$,-EV&>*5+!SA3BIPY83AI%OF:J36CDTU^2>->/QF
M1<%9'X?X>K5QV&AB75QF;9A.6+S"KRVQ49SK-I*<Z]U-O1\T8Q2C'EET/A"T
M75;:759[<*FD6T]] 8 ?M3 IEH3PP+;\LJ;=K*"NW/3]LOC/\%_@3\*O^"8?
M[,OC:_\ !/A#0/VC/'GB.;Q+I?CKP9(;RX\2_#KQ'<7>HW5GX\N&ERFNZ7&]
MI:?94A=+22 112QDW$0_!GX2^.[.W\0WNE3!C;7=@?($D@2$2 C:N\_ZP,K9
M'&,8Y.:^PO'?Q&;Q'\/?AY\.;"RT^"S\+V]U86WV%KFXO-1GU?4);EKJZFN;
MAX8WC9X[>.&VBB"1)C;DDG\3XQP6>X/.LOP%*E['!U\70J8WVL+J&4NC+%IT
ME*::K2Q5*E0<E&2E3Q-9R?L^93_FO*:V%JX:=?VKYZ4JE3G34?:58TJU"G"3
MM**HQC552<+/FC"$?C2FOB[]H$:M;IINL:59P7FFZM*^E:@9 -T$I7?;S[N
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M^%FLV.J3Z%J;0:DEOJ$T0CD2&^T^<%K;4+2"81O=Q.=VV6.-HGC^1BV0M4/
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M>Q6SQID2FT<HX;D'>[(P"XX.37PMJUX;F\GE)X9B$!&67!)P.N,#L>?Z_?\
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MM3IKF:[EDEN)9IIY3O>6:1I99&[L\C'<S$8&6P>GI50;MW)Y&,GIM/H.G)P
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MC<-4P'L\10AB(QCB>6+JTXR7[NK#E3A56L$Y.[>IQ^DZ!=ZC<P(^(XVDB"N
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MI9ML*/)-.ZK%!&K.[2R.0D<2*"S.[,JH@#,S, ,D\]GJMO' LKW$HMF*N88
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MM0SDDGA2 ,<@]>N<=.I_3ZTJLO/ZXYR/3'OZ_E3#M(*@ 8P6Z#<.N,]L=?\
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MA3S@<@Y&<\QV=XUI<!S$&*$%@RG&..S8YZ>I'TS6[KFKR:TT,]R8V,4*00C
M0)&H50I!Z@*  >N .<5FW456$5!>RDFW/G;:DK.*Y4K._FTDKM-NR-8PINE.
M3FXU5./+%QC*/*K.3=VGTLDKO5['VA\&?VH_!?P\^%>I> ]<\.R7=[<V5W;0
MSI8Q7-O(L\KR1[1*#MN=LC>9)(WS *5QT;X<OIXI;Z\N;:.2"WN+F::&-PN]
M(F;>H<)\@(!/"X &!MX-0$/*02FS(7)P'4GHI!SC) Z#D #\;5OI^HW+(+2S
MN[QI9EMQ%!;32.\C@I'&JHK$R.>%49)P<>E>=@LJP&6XC,,9AU*%7,JJK8MU
M*TI0E4BG:4.9\L%K)[OLK(^>RGAS*\HQV<8[+Z>(A7SW%+'8_GQ&(KPEB%&,
M%.C1JRE2HIQ2]RBH1N[M7U+UG+'QDX!4<< ^N2>.OMVSGIFM"2:,)\C$<G(!
M4Y.WC '4#IQ^(K6M?AYXR^T-97.@:EIUPB!I8-4L[BPEB0@,I9+I(F7<I!7<
M/F!&,C!.9J.C7>F7+V]VB+)$0KHC*Q4[1UVD]00PZ@@YXQ5_6,'6J6HXBE5D
MXJ:C3J0FW%M<LO<D]&VK23\^JM]+[*O37[RE4@GI[\)1UT=M5T6MO6YT_P -
M-6MM,\9:-/>S2+8_:U2Z*2&-BLH9-I*L.6+#VZ@YR:^Y?&FEP:]8Z?<Z<UNE
M[9Q)#&8]QDFM#MPUS@%F=1D*4PN ,D#D?GI:6S6LUI>.ACA^UPC>2,;@ZMN/
M.0..IP,>HR:_2;P=!:3?8-1N9&9)K2T:%0\9A962-S'D$Y!4_.?X<GGDX_,/
M$.V"Q65YS1G-5:5.O15-+FA5<.1^SE%:7E&K/GEK:*3LO=9]CPLGB*.*P4XM
MZPJQDUK33?+SQNM/>Y;:;RU??P*7P;J;.LLDRVY=G 69FRH3*^:Z@@;<G@X!
MZ<'G/2V_AR!-,%O!*C/&,SNARL[X.XJIR2O;C'(Z\ U]+>*+?P\VERW$7AE;
M:291<B;?*'B2,A945778YF +JI.#QZX&WXB^&OPOL='CO_ _CRRU^YCT"SO=
M3T:7%OJ-I=W:*TL5M$R!9DLI"T<VWYP3GCAC^?U..O:T\)'$4,90E5K2C2]E
MA77P\9TO97^LUZ#JPH1_>QA2>(E!3E=P;DF?0K(71E5]G.DY)-256?+6=[WM
M!N/-K!W<4^6SL?+FF:I=V^G7GA^]CDU"R:.9=(LKN6XN+32[V<_O-0T^W=V@
MM[ME&&9%&\@ D$G/W_\ MF?M$?LX:Y\"?@!HGP2^#%K\*/BAI/@_0?#?QCU;
M3YML'C?5O#VE)9W'B2XCBEPMSJ]VC7<IDCB<"7RF$@B66O@>XB_XF<%DB/#Y
MDIWOCYUVL,2*2 NTA3R3\^,#)X#OBCX3U34_"NE:O$LMT+:9HBD,;/-(H#C>
MR@9+A%!V@9VC@=JZ\7E^6YCG?#U;'59X:C#'RQDZ-*JX4<96E1M2CB8*\)T9
MUZ,*TXIQYZU.$ZDI)M/.AB,30P>,C13J5HT)8>%25W.A&3Y:KBTT[*E+DI\U
MXIN2BDUIRVA_M#_%_P '/I9\!_$CQ9X'?2M1EU:UE\)ZW>Z/<1WDL0@EG6:P
MFBF+/!^[<%]I0 %<"O?/AY\*?B'^UFCQ^!=+U/QO\4?#MAJ_C'59I"9KZ^T*
MR#7&O:KJEY<R@.(F8SS3,Y.3(T@ (:OC_P *^&M36>\O+ZW:QTXV4T<EQJ-L
M8HY$."ZVKS*O[\K]QHSD=SU%?3'P5^*FH^#-8O8?A[XXE\%7"Z5<Z"]W9736
M-_JNF:^GV+5[#[1D_:+>YBE:.XAR5>,D$5[/%N!6"R_$XKA#"Y9AL]PB]O2S
M"6"E4PJ=1N,Z6:?4H1Q>)HU?:RC.@JRE[[J\T'3N_-R>O/$8A4,WJUYX6I)T
MWAY5'&=6;Y7%T9S:C2:<5)345&\5!)N1X)\<O#4.@:C9::RB+6M(BFL=?LED
MAF6RU"-@S".XMWDBN(WR?+E#$$+M"@"M']F?QG:_#+QYIWQ%DTS1->NM%BO8
M;;1]:A6>V-S<6[QV>H11!79;_3KITO+.4#*S1HP [^^?M#? !OA_X)\+^/1J
MD.M:1XONS:W-_;M->"WNY 56.[NQ&T,5R%^<0NXE,9!*XP3\0M%)X3UFYLY@
M9$MK@@LA!&&8%77D9^4_+SC(Y/%>SP_B\MXQX-JX&EC)9AAL70QV78NIR5,/
M+$.G5EA<RPZBY>THQC5G.C&/M)5:=.4/WLIWF89C1K9/G4*TJ+PU2-6A6HPG
M-2=+6-7"3E.R4I.,(S;:2E)2=K:/ZY^/'Q9^+?C;4]23Q[J'B:?5O%9M]3O1
MJR7=C#K4-NAELKVWMI%C0!U8+YMO@2 ?.<U\:7>HWMA>R%9)H9XY%9V#%6Y8
MEE) '&<C P, YK][?^"JWP/TG2OV;?V+_P!I/PO\8?#/Q$;Q'\+_  YX>U*W
M\/V^DVPT&Y;0[2\33;TZ?<SW$FIZ;N>TOVOT@N!/ VY.21_/G-<374LCW#M-
M*Y&Z4<LS==V1\I!8YSG&.,@'-<7A%CLMSCA##8C 97@,GI87$X[*,9E."C:C
M@,=E6+G@)X>"5##0=..&H8:481I05*,HT;6I>Z^*U7H9O9XJOCHU84\50Q=6
M,XNO1K1C*3Y9N4H^SKNK32;:M%37NSBCZ3TNZ37='AO[1[<7T$EN765F4K.0
M-DTIP?W3#EMQQ@,<YYK[P^#O@GXN?'GX3?$C0OAK\/K/Q-X9^$$</B_XE>);
M2>Q$W@_3IXPTVJ/YLD<][:+';SRE+57D2*)RX^7</@7X4Z>%T_4)K_SX=.9;
M:,R/&/+D($F[#-@ J, J#D#MT%=QX-^)WC;X*:IXVT?P1XNU[0O"7Q6TZ/1?
M%5CIM\]M;Z_HP:0R6-ZL3^7/9LS,"K@@;SGCBO.XJR>MFL<9@,H>#EFN68G"
M8[*IYA#$RP49QKX:>+A.6&J4Y3KTL(\3+#4[N/MN3VK]E[1/LRG&QP4Z6*Q:
MJ/"UH5:6(27O\[BXT7&,EI&4G"\KZ7=DVDCH_'<EMHFH:QX=M=8TOQ':V]I:
MSV&NZ7<B6QODN($N UNS!7#0EFAGB.#'(I7WKP9]=(N'D8F1&"*D/50PZN,_
MQ$\YR1ZYQ5SQ3J]C+/*FF0"VLXV6.T9YB\D<*C:5/3/(.#R"FW."*\Z:<JX(
M??@Y5B<'ZD=SQG^E?5Y%E"P^#A&JI2J2ITG4<X0ISG4]G352<XTVZ4*E245.
M<*;C&,G)07+:WD9ACXU:G-3;Y/:223::2Y[QM=<UE&RBWJ]][W^@OA%XNMM)
M^(OAS5=0L8[N#2M1AO4B>0*J7-HXN+>5V8E2H="KJ5(PXXZ$?L?^UK^T-KWQ
MI\ _![3]2\*>'O%<GQ"L+?6O D?AF_M]9U?POK>AZH+:^%WI,0WVMU-%:I%)
M:/O&"K=P3^&OPZTV>[URUDDRLVI7=MI^GARL<4MU>S+!$K2N56-/,=%WDX&X
M;B,&OM'QSX_U_P $:!X-^%$WA_2/#/CCX)^+=9OK'QUH\VSQ"_\ ;)CNI---
MY#,T%U"C2;_G5@A)$;-DFOQSQ*X%RG/>.N"<^IY?AL;GW#?U]X*O6K3I3RS"
MXG+\5&MC,/*&(IUE0_M59-A\>L-3K5*V'J3I2A4INI!_8<.9U7PV19C@JLHK
M!XN2E."@G.I*56C[DIN+M4G3C/V;;22L[Q44R]\5/C!I?CCXX0>,O'WAJS\1
M:-I-[IUGK'A_3+)=$?5['2K"*PN],>(K&L5ZLD,BR28&V9223G%?*GCO6/ G
MBOQ9IMAJTZ^ _ OV[5;CS]/LS?:S8:1F:ZTW2IH8P$GNV BL?M!#+$6$S$@&
MKGC_ %Q]"F:XU:^2]U[5Q-J]SBX66ZBFO99)C/,X.!/,SO*XQU=L =*^3_$>
MN3:E<37$K*6)4(Z<@C'+'!Z_=)..",')K](X'X1PF%H9;4P4:N$PV7Y92RW
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M#^/7K6=M='KH[VMO:VU^ZN^_GO5W:R>GX=-/G_GZ/6N O]B:?A0,:EJW."
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MM2HT\/@.7!T\#BJ#H>UR'"T90H8&G2C4K356JI8B&(DY*=TX2_.<VJI&1(3
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MQ5HS_IV_\'3(8_\ !)?QN%ZGXU?!GU/']MW_ *5_F&;2-_=E)+8_A &3C/\
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M)45U>VFBCRM>ZXO1:I7_ %LT7_@H7+:?\$WO'O[ GB3X7>'_ !+)XE^+EO\
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M2>H(QCT]?0=^N<-)NSON[M;7U76Z[]%H]-Q6O9M:_DUK:_D*J$<8SP, ]<
M9."/3VQW'H[H4P, @D=SD'!'7IC/OQG/6I%_(A<=>"H Y!/7/?O^=1-RV02
M!QC@\X(QZ GK['CK3CK=/ROJ[6LE;1I:KKK\QCG .,9#<Y(!!YXX^N2,]><?
M6+:,$;2-I(Y[$@Y/<]SU.<YR/21EPJGDMZ9W$'U4G.0.N<\>E1YYZ$G@;N.<
MGG\NI. #TH3:6EG[M]==5;?2ZZ[NRMT2 ?QQC(/<Y[^W<4@.3D'![GJ1USTX
M))!'/ YSG%)G) ([9]1]/SYI0I.2 #G]<'.1TRV#GN,_ADMMKJN5N^J6W71=
MNMWL@!CE21@8()9CD>O08Y[_ $HR#DG' &1R/0=.H]?SS2%=QP.@&3GN/3GK
MC\QG(H5!V!S@ <\@<8&>XSCOTX]Z2M9.[3\M'TTO=+3HM+*VG=-V^;LO*_4U
M)0&T>P4Y'_$SU8Y /:VT3@'ID^_^-4\9*=@0OR\\=P6[C..G7WJU*2=%T_J#
M_:FK;LX/_+KHG'' XYST[\52!"E""Q5MI!SZ<_B, <YZ>QIR5[)/5+?JW[OZ
M6=[L+=>MK-]]O\O\K=?1?#D9MW7&WG#8&>OJ.> >W Z5[[H]VSVR !4;RR1'
MN!#\'</8,,YSUSC@'%?--IJK0H%B7GY3USOY'.<\8ZXR.<X[UW&E>+)41TF=
M%V,HC+  ,K#E>#NZ9' ZXYYKY7-LOK8I2?*G9[N[>B6VNN_7I=JS/:P.+A1E
M",7KHDFM+MK5W5FK[IJSUONK_7F@>*_B;X@TG3OAWH_C#Q'_ ,(BD%UI%MH4
MNJ74'AG18=3N)+^ZMKDR.+*TLKR^!F\N8I"\Y7;\QVUY#X\\$:U;1:;%J\-U
M9ZDWG0P_;(&CM+I(7\N1+&X.8KA(U".K1N1AE[D&NH^$?Q&T:VT'Q[X&UC7H
M/#:?$*VTV.+Q%/%%<V=D=(N7NUM+B.3]["MY)LC^TPL'0]<!=U?8OP3^ F@_
M'3PY\3-;\=?&2#4=._9^T6WU^Y\.:+=6_P!KU'1M=G@L!?:'<77FEUM+J>VE
MOS@F*,/MV%,C\CS7.Z/ F)S#,,?A:6795A\;AYU9X+*<7B,5F-7-)8?#4L;&
M6"PLL/4K8K.<?# 8F->I"<?9K&8G$P58^SPN!_UAIX;#8>JZ^(J4E2HJOB84
MX8:-!ZT9>VFYTZ=*G%S4X1E&TE&-+33X]_9HTB]T_P =ZQ]MMI[:*?PE>M;/
M/#-''<*FM:*'>"1U5)54L Q0L 2,XS17](_[:WP&_95_9I^!_P"P'\,/A[XM
ML/BI\2$^$/Q2\0>-O&OAG5?#L\VIZ'KGB3P'JV@IX@@M+B6XAN;&;4[O3=+>
MY"M+:V-W(WS,$C*^TR7BJKFV7T<?/+:L(XB56=%X3$T,50JX1U&\'755NBXU
M:V%]E4Q.'<&\'BI5L(ZE5T?:R\JOE/L*DJ4,5)*'NM5*4J,E.+Y:EH-R?(ZB
M;I3;3J4G"IRPY^1?SU>-=%LY?%.N:E>V1O\ 3DU#4$T>,7,CQZ3$MY*Z<%3%
M'=[5RR8164$C&,'NO ?Q!T;PY9RV%SGRI8VFWJ5=4E18T"J5&X$@98.6W,.,
M#D]H_@J276M>M;RWD71M8N;ZXB1DFDEM#)/*XDG5T#&52=RY4>0"T> &?';^
M#_A?\$E\+_%R;QYXSLO!VN:1\(Y=;^%&DS^%]5UN7XD>.3K5K:Q>'8=0L'1/
M#MY#9K<7/]J76ZV:-S%L8J<_Z6>$O#M;P=\,L-B,\KTU465X+&9O2JX2M3K8
M6M5G[14;1DYRJ4GBHT\94FFW*C.HTU$_,/$"&&\3N,:E+*5B\75KXRO2P4:%
M98J-97C2@O;OF<HQ4(QA=)14K+E29X=XS^,DL]O':Z.S+%N#OY<:RF=C$RE)
M#*"%C4'<V4!.-PS@FO&-*BGF:>2[M;IKF[NX;C3Y'218Y4D;=-Y(=(S,J#Y$
M\DLF.6W'FO2O#D?AK26\21^(_!MUXM75O"^K:?X<BM=>?0I/"OB:Z2!],\3W
MK?9YCK%III$T!TN410W9<;Y4,8#\?HUY=2ZGIEAJ6JS70THQ6EA:/-*+>UB*
MEG^QIN18<NS,ZKG>Y;.1BOY[^DEXD+B; X;)<+53I4<=1QN7U,%7?U;'8)8>
M$JN+C3A4E-KVMJ$HXQ*TKRHIQ4K_ +'X(^'6(X9SF-24)T)5Y4,+C?;4J:K4
ML0ZRG*ASS44Z<%)R?U>4ISY52FE*.GTO\)?!4.MZ]! NBRWUU<"WMH+65%0S
M7,TGEQ!5D7#'GAN,#\J_00? /3O$_@C6O#GBF\L_!FN6JR:=H_C#0];T[4-(
M75HWCDM]$UR"TDEOXY6CC-N?LZ,T$C 2 \BOGG]G[P]'XB\6V&CWMSJ\27L$
MXLKS2X();A]4"M_9EJTEP\<,,<L^U'E)W*#\HSBO8O'OA'Q_X>\/W?B)?!6J
M6'A?3_$J:=K>JA9H(-)\0POL62ZNU"VTC7#'+S,S%F)8,6R:_@/&XU1Q$*U>
M\HU*OU>+J3;3JN/\-<R_B-)M14E+271-G^O7">5Y7E_"U+!5<31PDLPA*C4J
M+#*%6O"51QIPA).+E=TII=W%K=:>;:IX*\9?"ZZET7Q%JWA;Q'IS_9C;ZKI.
MH7%U*J(T<<T-Y!-'%<V<VQAY)E01NQ^\,<^R7'A#P1X<\>V%S'K.O7'@6YMM
M%^UW4)@DU2"XUJTA2"UE*JELT,5_+MDF8I$8$ 5@XK TBWUKXA7+:,JZ)9ZK
MJ.^";4?$$Z2ZA%9VMD]S+- N_8\;QQ%(96) 8A#R>>JM]&L/$]MI3OKEI8KK
M-BWA^TBO[*^%G=3>'U$$5O(]FKQ0S^< \+SQD%R"'4].&GA*,*E6M2@O:5JE
MY*;TER.R5VUS6YU=:N[21]3E60Y;D+JRAB*SE6H\\\34:G5YYVG#V:UG[L<,
MXI-O23WZ>>>)?#/B+PE?:W,;+2=>FL-=^Q+8WMZ#'J^]V^SI!;0,7GD6)HWB
MDCRNY9"68@"O;?$6F>*?#?C[X6R_#]M2U?Q#>^&]/LXFUO3K:>TAO6A:8:78
MQS*;>[CTP2R02SF$N BH=ICX[?PK\(/A_JWQ \"Z9XSU/5-)U#3H9]6\0V]K
M#&;"VM;5!%97=Y<2*9H(;JY6,*S[=Y8#<H850\8_$I_"=]X:U0V][JOB+PM<
M>(-/TGQ1?:4+33K>T2]F>VCTRS%SBZG@A9(KB^E)0YC*C)P.RC1^KJ4JDY0:
MJ1=)7O-6LWIHTGS;N^JLVG8PQ..CB,=ALNP;==K!59S5>DXX:=2K3Q<:=2-2
M46I4IXA3C+EF[X=T9ZJ6O>ZGI>A>(-7E3Q=HVI>.]9T[5!%XAGM)UCO(YELF
M%XFD><[PV^E6]T%5H(T5&,.P,)#D?)?BWP1X9U_4XM+\.3VEDRSW-Q<3^(3%
M8/;[68PV=Q-%M\V4J0@!P&8J,C)SP.N^,?$&JZM<ZHVIW=F]P99"]O<31/(T
MCEFQY3+AG+9,?0=NU<==WK@R7%W-<22'YI,S.TY)'RR3%V+<#!&3R,8.#DVZ
MKK24E34'S*\E9.2]VVMKW:6MW*[?34C!X)X&G5BZ_MZ+PT(.A5:=&$TXN2A"
M3:C:4I<J2B^51U>C(]=\(:IX=U&\BBCGL=1A9H@MQ#B-H9$ R@\M3-')&0X<
M'&TKPW.=[X,_$OQ;X*\8P:?K&EZIKVCW0EMHKC2-/N=133);P&%Q>I;*RV@N
M@65)TA+)M)/7=6)<_%*YL;6>VU=FUV%(6M[625!<7ML4 \A(ICA@F#M(P0!D
M@@5S_P .?BEXI\!Z]!XYT>P@DCL==L-8CTVXA9D>ZTR>.:))U&?.MK@1F.YA
M=65P<$$$Y_6?##QEXR\*L1C'E6'P^;Y9B5B:E7A_&8EX.AF&(^ISCAHSQKA4
MCA:KG3HTUB(P?(G[ZE#F1_,'TDO"OA/Q2R"EA*>#G/B+#3HK 8S#THNK@<)#
M$0>+JRLFZJC3O&G0<H^T@YN[<3]#_P!H[0[CX?\ A?4O#%PFBZ[;^(O!J^)+
MZ/PWJ)UBTT==21[I['6'0J+74DB5?M$4R"6$$@YQFOP&GU&UCO?*Q(D#SR1P
MHP!4)(&557 X2/:J@Y/'S9YR/V1\9?MJ6'QO\9ZI/K'@KPOX97XC"UTK7M/T
M6.32K/3IVA:VOM3>-,)+<RJ6"(%V@N/E.*^%OC)^SM+X5U.76/"=Q_;FARJ[
M)8/LN-7TRT,N(YY!"-LD<@"DR*&*(H!"GK^D\>?2DX1XVX'P/!V=\/X_A[C#
M.L-EV;XM8JGAGA*>91_=XO!T\;0J5J=3ZNH\E*O[3DQ'+3<7=I/_ #\GX5YU
MPEG-6M1K5:F!R^-7+:6%K3JJH\.YK]]4BVH\DY1YTHKEBW9:)GRW=2QQ(65<
M%BK,K"1BH&,#"LO+@<=3SSG-6+#4G>-A#"\1Y,;,KKDC[Q"DL0P&<=?ICBG/
MI<H?RF5XK@$IY4R,I"1MA=V5&UR,\'!]JZ/2O#E_?GRK&$WLP=(X(+<2S3M(
MX7.$C5B I;#@CG'.*_GO$XG!0H?O:D6E[RE4G:*V2D[V7*VK<SER\O-?9GI8
M=8V-92C!\TW&+BHMN;NE&-M=;;))2OY61ZCIL-CJ'PUO/%UUBVO_  NZ6VG)
MY2.M[=.RLD<B,"\K%F+9+IM7\36+XI\4>*K3_A&IOA]JUV]_+8?:[VTO'4W4
MNKR.(9;33X[5O,-OMV&VCE) =F '(KW?Q;X7L/A+\"1HWB412^*?$J2ZO%8,
MB%[1FA_T9&:7;)O Y**"5.5/S BOD/X>?$75/#_B'0?$5G:Z;<ZKI<ADCBU"
MW^TV&!@*+F$L&=U(!4*<J<' [_"9![3-*>:YOE=+ZWA<)F>80P%*O/V>$QT/
M8J-.G";CS+#O%PJR5=7]^?-3NEK^QY#G.;8)+*<!F-; YEB:%"<)T:\J,Z=2
MG5C.U1J4;349VA!I*T6G=:'3:MXXE^(G_%/^+UU#2?'>@21);R,S6MQ;WL&)
M%G.\EI'EDDWR(RD2(&&W*KCV#3_V@]2L/"<F@^*]/NIK^/1[NP@UFSM+I8+[
M41$B6LMQ.@VB*XP!<$OO+[@J*3QX;X@TB;Q9XOO/'-]?2PZKJ>H?VF\&GP>1
M;F9F+F'(#2+$I7"X/"X#=,CTN\TLG3M#BNXYEC\0ZE!;03QR1S@R>:JR*D0;
M>'7)<H!DXSFOZ9\*_'//_""C6CEU##8_+,QIPQ&8Y'CJU>IA<#F$*3K5ZV G
M"I&K&I*4JE.<E!QJ4X4U4C*4;KT..O![!>,&3SSKQ&AB,IXAX=HS5+/\LG0J
M8K,,NC3C]7IYA3UA.345%/G4HMQDN6%XG7?LK?$/Q#\._C-X(^*W@J\U*/Q+
MX1\26FO:GNCW1201WD4EW:1(5$<R75NICV2%68D*QXK] /\ @H'^T9;_ /!0
MOXH'XE+I8TC5_#WABP\':?:W-C#ITQ73VGEE2]E5IC,\D]W(;=WE"JA"*B@8
MKPVV^!>K>%;+2KV6TUOPGX<,ME-K/B0Z-+$$T^1@LMY9QSVT)U": -OEC2=X
MQM&X$# \RUU]1\%QZ]XG6]_M3P!!XF.GC7H+,Q3/>(7^RMJ*,X:S>\MT$[JZ
MHL:N &/!K\0S/+<W\?>(^+/%3@"6(S#B#+E+.N)^'\'C.6M0I3Q6.=''QP:D
MHYW3P]/'8ZG3H8=RQF H8M>UIJ.+I-?'\09IPCPOD/"7#%5U*%/"X1\/87,L
M;AH1I2PU*A1G2P]&:G5>'J2G2BZM6IR8>K4I2J*4*G-;Y)U;X(>*QJ"VT^F2
M0VS-)O8RMY2@DJ)-RQL&/\2^G0 UT.IV?B?P%X7\7^"=.TW2X_#.NZ#;V,>L
M7NG3OX@O7*227D_AB],?DQ6%Q<M):WLD8W2%/*?!^8^_6GQ*\->+FLI]-U"[
MGD\V<2V=K/&([=HQ@"Y97D$A)*$*".&.,X./GKQOXLF-SJEM=:[,;DWT5EH?
MAPP7-\+73G=KB:6UNCNBL8?/:26:'Y&WMD#@FOG\MS?B+-L7A\%F>#I0>!G0
MKSPE;#8A..(H8NE.EB.2U6:JT)T^;VM1>PA2=2<G?DD_E,1@\KPE&K4P]9UG
MB(.G&I2JP494ZT&I4W.Z7+.FVU&'O.2C9I7OXC9ZVK:/=Z%>16Z3QK&LB, '
MVQJ1&4+$,J ,&^7JVT%CT/T3^RS\3=0C\8Z#X(\0ZY?Z!X4U#5(-'UC7-'LY
M[S5=,L2DK6]Q9V<)8W<DLODI(L4;,X>38%9,USNN_"3P[XDO/#>J'6?[,U&X
MLH8=133HH)K=PVXIYL39(D')D+8*]CP178_"+PS>_"3QDNNQ:E::D;'6M.O+
M*ZDMHY90]NSF([7\M(!#YI8E/]80-V, U_1?C-XX<->,/A3ALGSK+Y/CG*,+
M['!S>&C3I5)QY\,IT,;4H5^2<%*.(A&5.O3YX0E.G."E _/^$.#L?PGQ55QN
M G*&4XV<ZU>4*BJ2M:D[.BI)QINI*<>;W4TVU[TM?K6P^/=W8W>K1Z\+&Z.G
M:A<6NBZD\$CS16-I.\-JRM=R+/9RW*K'+<P( 5D=TR,8I^L?%"Q\8ZAH>I7%
MB383M'::XT<BQ7\Z02EEN-/#R@#9(D97>&4#H >:^>/C9XE\)^'M3N]1M[::
M[N[UFOEA>2!H;G4[J4SS3,JMM6$2R,Q3=DC;SFOB.3XE^*SJOV^2\CBDCF9K
M:V0-' @+Y,017!5!PN P)P<5_)?#OAIAL]PZS;!819=+V#C"I5<H*4ITG"<*
M,*;3^-*HZKY80J)2C'G4DOU#'\33P4X8>M5=52E><*?-&<5SQ:4G>Z5KM1TO
M=\VY^[EYXV\4?#B"2;PIJ^N^$H?'OA6XT:\CG-QI<OB31S()%D-P#$UVEO+M
M#-!(R%F"EF!Q7Q!\7_&&J:]Y.FWNOZG?:I)]GM+J\BN;JZ:::VC5(/WB%V>2
MW0>7'N.47Y54$<_-M]\=_'WBRQT2U\4^*M2U.V\+6[VGA^WN[R:X&D6;OYTM
MI9F:0^5:O*=RQ#&2.<D50\,_&:&UUNW%]&T@AODO8;F%PDPN%.!EW.!'D9(X
MZ\\D4LA\+,QR&K6S*I@\%C,SI*4Z];"TX*K75*<XX13Q56BJE=4\/&C"491G
MRNGRPYH4Z9>,XHPN,A3HQK5:5"7(E";:49<L(R5HO3W^9WNKW3M=Z=O8_"CP
MK'*LDMJ\NH._G2B[(>XFN" TGGO)&S%G8ESE@V>#@8!RO&_@[2WM#;QZ?9EQ
M($F=EA>:',>8TB!4%ESPVXD#&.#R?H?6O"7C :#X?^(>O>$/%7AG1?'D-[J'
MAK5];T75+#3M:2VN&AFN]-U"ZMHK2\C#(S;K>60$%B#@"OG_ ,3:Y91PW8>2
M.<!5+2@XN&>-B2JB0C.[@;<$@'FOH\MS'.,3CZ,I8K%5JV'J1A.FZLJBI3YE
M&45*,E%J+3LMGRK>.B\W%8?!4\/.].,(5(.5W%>_%JRE>UW=WU7G8^%O&'AA
MM-OKJ..,+'$_#!%PQZG!4%00>V3WZ<5YW)%.IQL8DX.54G SP0.ASSU'3TKW
MGQSXA@N[J3Y$AC=!BW$84^:V 2[*?O< Y)P,@<=*\FDU"V@W#8"O).2,#T Y
MZ=L \\=>*_I3*<1BZF#HO$4KU7"%TWNTHWULM6][76KLVM#\NQU.A[=JG903
M=FD_*U[O33O:UG?<PFEOE5566X0+V0%.N>O'RYP?K]*I2"0EFFEF=N<EGR>3
MD@9&.3UXZ9Y/:U=ZXCN!%& O&6.=QZ@8/''/(]QG-9$MPSDGYLLY!QTYY8 ]
MP,_7@^]>[2A4M=TXT[VVM>Z^3:]/Z?GN44K)WZ*[NGMJEMTT[VTO;6;[5)!C
M8SC&>">!R.GOZ^G2KVG7YCN!/(AE9<-\[ I@X/S@C&/7GCIBN=D8Y506X).3
MP H'4_B>AY/7'-(LK*K)C:3]YL_> ( '/KQSTY.:UE1C*$HM+WDE)[-IO5)Z
M/OM\S%5)0=U+9Z+TL^FF^E_6U]+>DS>.M1@9OLWE0$J541(BQ*, $I&K!03Q
MS@G(S6>OCK7]Q<:C,K,RLI20J%(/&!NP![<\<#J:X8DDA><@ #@X5>_(XQP>
MA^GK2F-0>K?7UYY(SZCD'WZ#MSQR[!I6="F[I)MTXMNR7==;:J]K.Q<L97;3
M]I)6=U9[/2WW=^B[6/H#PK\??$^@7D%Q=2)?/ 'CAG:,F6!&/S*&,@(5EXW#
MD@[2<8%?5G@;]K[PR),ZY&]E/+F.:>&V3'")RD@DWQOD99@><XP,XK\U I&0
M"3WW-@DD#/4'^'T]^U! /S%\$<D <,>@Z?@>_3VKY?.?#[A?.U+ZU@51J.+C
M[;"R]C.S?-:RC*#7,V[.-KMO1MGK83B7-L'I"O[6#:YH5O>BUHM6];I+1N6Q
M^OW@;X[>"M/UC4?[&U:2]M]=N8Y;P:C<_:X@O\$:">0O$J< HN54#";23GT*
M[^*GA&4W=U>7Z"=+LF-4AA:T%JJY3RV#@LYR.7^@;BOQ)M[^YM65[:Y>%N2&
M#.I!SR.!SC'.<9[5U\'CO6/LGV2XNY64*J!BS$D+\O/)/0#'X#IT^$S#P7RV
MKB%B,/CL5>2IPJNIR.M)048)N?+9VA&,+<J:C%*]E8^AH\=XF--TZN'I<V\7
M%/E3Z^2NVWOIKH?H#\2_C]I4WVB.PU*74#Y$=K!'*1&8XD<EF9TE"%0#\H*Y
MX'O7Q)XJ\8W^NW]U-<7DDL+(RQP*[F",9Y9$#%5=@!N89+'GH<5YG>:@\\CE
M999-W.YN.O)^]QU_3 X[017)",N2Q<  G.1W//3IT_Q-?=\.\$Y7PY1C'"0Y
MZK24JM1)U+>[=)QC&,4K?9BF_><F[G@9GGV)S*I>H[**;23:BVEH[-OOKJ[6
MTMJ;GAS5--TW5S/K&E)JVGS*([BU<%90F2WF03*0(YE.""5(P2,>F5?R6TUW
M>3VD+P6DEQ-);0N0TD4+.?+C=P/FV ]1@$YYQS53>5'.<=&V],'C))X /H3C
M^=!BG<-Y$,LHC!:4QQO(L4(&3*QC!" ?WF( .*^P5.,9RJ:IN,86<GRI1V:C
M?E3Z-K5VU;T/,EB:E7"4\&HTYPI5:E:#5&*K\]2,5*+JQC[2I32AS1@W:+YF
MDKMN,G)W$!0.F."<YQ@\\'';WQUX4,>,#'<$ GD]0 ._)Z'L>/2(L%P>26R!
MW*#L6QTSP 1G'?O3@"$&6)SC[PXP".HQ^ ]<C(-:G#9]O/Y=R3J0<\C(&01S
MCG/K^&,=.: S+[9 /<\9Y_+T'';FF$D$G'IC..?=>ORYZ@'Z'%!&>0> .H'0
M8Z=>IP>,^_<T 3+DYR2,\C!^\.<9)_(].^#4@).#A<L"QQDG/KC@>W'7WYQ7
M5L#DG'7;U&/7@#'H!Q_*GAL%2!D'H#P%XX(';.,G.,>QZ1)-[>OD]M/P[-7Z
ME*W;796?56:]+[73^2W)#SSD=.> 0.N,]3ST ]3U-(,<<_=&<DXR?RR>./IT
M'JU6!SZ'V![XR<X&,@CT^F*<Q8'AP6/)/4' &!]>"/7^D\KVZ_+LKZVVU>S=
MW^-JSM;7J^G5>KOIK?1WOS(=M#9.0#DX'/ICGC@Y_F?Q<N8SP8\XY+'</^^<
MCG!P.?<>H]%\'?#/7?%VF:MKEJUK#INC&V%V;F9()IC/)L5+.)UWSNI&YP@8
MH@#%<8K=T7X1:MXFUR[TC2U!DMHY'ED,4CQQ,L89&:54($4FY5#*,!B<X(.?
M+KYUEF'EB8U\=1@L%&^+?,K8>T:<U&M_*W"I"24E>THNVNO91R[&552=*E)^
MWE^Y2BKS=UI#5<VJ2MU['C",23N(4'.>V 2>1SQ]/8_@N1DG.><A>A8 X4_G
MV_'FNC\5^&+_ ,(:O<Z+J81+ZU5'G6,D@AU+*JN0-QQZ#D\$Y&*YK>>N">IS
M@;@/3KQ]!G!KTJ-2CB:=/$4)QJT:U.$Z=2#3A.$TI1G%V:<90:<7%ZK;>YQ5
M85*-2=.HG"I"3C.+TE&46U*,ET::LUO>X\$\]#GC P<G'\N,'MZ>H /89R?N
M]1@>_'L>QXZDTS=W&>AQD@\GH6QGCW],#L:7?@<G@?D>?H"#WSG.?>J<97O;
M>VBVZ=-59/OOOLF*-K=+WU;ULNG;T_75#B#N!X _VCU/3CD\],?3IQ5VVC\U
MBRX)( "MRNXX' '/?D9]>:H-GA>^ #G'!]0>>2>N?QJWI\\=O=6SW*O):+/&
M;M(6"3/"&&]8I""J.0,(Y!"GG&.*F2ER2MO:R75I/5:]6[6U5V^BL7%)RCS?
M/?1NR3[Z6OUU3UT/I7P#<RZ8MN-1^SV ,<8C%Y 4D:/<&5E0X;#$!D+'!7!!
MP>?M?3O'=AJG@WP9X:'CG7-2T3PS/KNJKX4UC4+7^P]$U[7)(3JM_H%LK-Y0
MOX+: W)(W;@5*OA0OR-J7Q8^%Z_#M-/T'2-0O/&5W/%%/<>((H)HM*T^%=JK
M;SQ;7N+AU5560C: "2,YKQ+0_&,MOJ"17!#6MQ<!G:-M@ARP&5.>!QSSC&!7
MY%F7"^(XI]MB\5A,7E=7!8NLJ$*U.A*5?DHU*$L12A-.I"$X5ZL:=13A.:YN
M5JG.TOM\+FM+*(PHT,10Q/M:<>:5.^G-RMTY332NG:^CLY:ZK3[^T_Q;HM[<
MW*I 6MH7E(O)XUC:8@%$6T)"APH)4;@%. 5/45W^BM:30Q2J%7ST!2.5XEF>
M/);<1U##H"0<CUX-?%6I>.])T&VM7DG34[A3N813 *MNSE@@Q_RT( #$CIP1
MP15>V_:'F_M.*\MM'AM;*":$//<S3>5"I B.5C#&0B,M*8;>.:X,:.T44FU@
M/D\3P#F>+@WE="M[/EE[U:I",7*FE&*7M)TYWJRO+FY(I6LH['KT.(\)1<?K
M=2#E%Q<53BYR<I)-N5KI>S223;=^9^;7U)XQL;O4+MPUI U@EN9F60++ HBD
MR/D<&.2<G!10 254XX&.E^ =[JX^+_PO,TDR1?\ ";>'_(>ZEEC:1!K*1(MK
M'EF\MFCD1Y=I@1H#&760+&WC^C_M$_#V\LT%[((KJ6(>>EW97$R!S$HE$$2K
M)$GE.TR+/,\LDJ>1/##93H0/L;]B#XF_LWZI^T_\(F^*EQ=S>#IO%<1NM31)
MI+]=6FW/I8GM1F:59=3: -* Q!8O(<;C7E5<+G>2X&K#&<-9GBHX.$IPAA<+
M.M4DZ<6Y>PYFH5JU3E48QISM4:C;FDK/KI5L!CJJG0S/#T?;M7YY)-K3E4DO
MA2[M75W>R/\ 5&HHHK^M3\8/YU_^#I!0_P#P29\=@_\ 19/@YCZ_VY>_EQGG
ML<5_F+%.NU5XQD]L<CN<GW]1QSTK_3L_X.C,?\.F_'63C/QD^#8'!/)UV\ Z
M?UXK_,:9=AP^,@#U(QC@$#N<9_+'MY6+NL1JGRN$;+6SLVG;OK;3O8^@RZ">
M$YKK2K--Z75U&R?KNN]GVN8[@(000&+-@, 2PZ!3D=,GCI]<<4CA=H&"."1D
MA@3S@,>WT'_UZDN"I92 ,%@1@8P1R0.X.>>,$\@]*K,VX*"?NDL?PQ[\GU[X
M.?K<=4G?R?3MV]-NS^_&2C"4HI*SU5OE>V_?5?Y#6<@'9M8\ D?= !P20<\_
M@3GVS4!=MW ^7(.&&#SW(XST)! ''H<FI)&*A0K<$[3D<E<'';UZ9JNSE@1N
M.5^0_+TYSG/IS[CMTJUKT_JZW_I;[G%*5M$_^ ]/PUUT>WK:5(Y'. I<G)V@
M#[ON0#C&,CJ?4GM78G+#!."0 ,;0,],]QG()SZ<#'-E)=BD,X!(VY123C/\
MLY_,]SQ55G)9<X5@.JCC R>2>A/?Z4)-O;^KK_/7R%)144XJ2?6Z]/NU_P"
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M*?$-]-\4=028:O=66H:JUZE_>6H,D=UK"IY<,5Z1N4(APS(#7/?#O6?&VF_
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MK7:ZOWML3C%RQC0C5=YM)S47)-:6:C=?$K-ZZ7\CG%\/R"226ZN22SJ#&G+
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M)RE5J5*TF[W_ 'DKZMWN^K=]FM%L/4J<]<D <<9_V1D9.#SWZT[<<8R.F!D
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MGH_@;6+K5-4\'Z%XT\RT>U@TWQ'%-/I\32D>;-Y4,T#22^4-L>'_ '3?/R2
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MG13:)XN^%@30((Y_$YU2]M+KQ#H>@6*R66F6<%K'%<:A80F!!=AF2%"9'?\
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M*;L]&N^J=G\[,5%!#,<YQ^&0"#^H]?2HP02"<%N  ,@ ?R. >?<=C3F(8Y.
MH_@Q@[NH)/ ]AU!Y/I31Q@XY)/0#GCOT[Y)]\YZ<!(Y27!V#)'4<GIW..F,X
M_IS03A2,#DGU[G/7MQG^N>*4.%()_4@=<8S]<\=#WQC-(S#&.F<9 (SQZ?CP
M?7FC^O73U_KL)WOHWOY6MI?_ ('S[H7<<GH-HX(X/([D=?\ /?FJYW;C\N,X
M.0.3D]?R/'YD=14N2#\I+=BI(]1R&Z<9Z9.?05&P#%ADEL@J"VT'&"2"/7H0
M,G'&,9 :]?NU_"Z&_6W]?U_6@Y Q4X/()QU&<>O.#QW[_I3U/<8*G)QR6W=Q
MDGMCZ^E.-RS0BWV* LB.'6,%L]P6ZE0".,$]3@5$QV#^ \<DC'7DDXXQWP/P
M'2C7;37;OK9K^K_=<+6MK?17?F3*V1SM.0#@9R!ZYR>I[^HQTH8_(6R%!'7D
MYZG)'?H<#KGKQ4,;\[3\P[%1C)]\C@^_0\_A,< YQ@8 P", ^I.2#D]?ZYX3
M5MUV_P _Z[ ]G_6O3<8S'YN"2"1EL*2/4'!Z9(X'MWH5NAY (Z9Z] ,'IT/)
MQ@XX%,9R.&_>')PP_0=#^1ST[]VJ<;=RY#%CSGJ,X!Z<#&?;\:?3[_G:SL]?
MZ?X"O9=[+\M;_J7#CH#@J,]MW//MZ$9!]1TJ,DY!QU7=SP,] "!CD\DX[8ZU
M'YF,D#W?VXXP>I . <9]:>C!AN&5!.TEAQSG)[_*/7V[<"E9O97Z?-[(+WV\
MM->NV^NI,%)SA<@ $@G SC/ .3G_ /57K7P<\!6OQ!\8Z'X=N9IX9=2OC;HE
MMM$LB"(RR/%O1SN0(<\'C@9R*XG1]#749;6V9G^TWDL:6-JHW270E95RJ#+
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M<^_&;3[K1+\^7I:S[Z_>[7.=ZZ_*_P!W7[BLS$!R3G!Z_AZ>GY\8&?5V\LH
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MLOV=?&.B>']+\:^+=&DT[P?XAU&VCM-8G0Q6*-<1&>W@^U-(S8B21$<,J%G
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M;<VYL+M!<D@+TV*>JX[#..O;%1R6\8BVD9!!)!(#<?-@-R,#OG.?Y:!4J6&
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M1OO02XFMP@BDE14F@F'ES2)NDMYUN('D"L%=H)55HF=3Y1&Y<$G/;_%_XO\
MQ#^-&LVGB'XD^*]9\7:U8Z?9Z1;:EK%U]JN+;3+"!+:RL(68;5M;:&-4B54
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MP [@5'(&T#DC./3.3G&3SV_)_P NP;@!@#. 05SWY+$8ZC]>*-ZKD ')R<C
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MFFFO;Y=.S9=AE:,ICGYR%QPN,$EB1R00.!DGZ@'']6G_  1R_P""%%]^W/\
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M07_A*?3?$&GVNCZQX<\2WMVFIZUX8^PW$4\VGVRB6UN!(YM2IWC^;N,ZV?\
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MYY'8X&>>_/KFB1EL\'G*D]<=^G!//!]Z;N+$@9R1N([9Z<YX/MQTSQGD(2
M@&=N,@=B>0 ??'3TZ8S51CRI1N]--=TE;5_IWV]<7J[Z7OJ];;)+?7OTON3.
M4R..#C ]3WQD>F>W!ZU"RG:<$C;L!'& ".AXZYX';CZ5#G/)S\I^5^V/[N.O
M'KVS4F\DGC'0@Y'0],?*#D?7(_"G9KY6;TVVT\]U>_F3;S]-/2_6SZV?^9*<
M' 8AB?N@],@<!L=2OMQVP>M-R#GYLC/)/KZ9R.GI[_DS:"6.,YY&#G!'4C.
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MG2C:45&3DV^;E</LV3M=3G=[65C]/+G5M/M=1TXRH_V822?:OLQ\QX5"?*9
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MN_?!IJ*RLK8!4'!8 $8(/3'+'IZ=ZT^S=JUM;6732VO?IMV-VM;+7;YFC9X
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M&DD;WUU/<S/&]W&JL6$=NR[I,\LAXP>1QOBJ^N="L)K>*U,D$]N5DN!O+)D
MD[L!5 4DX())XW<DC],?^"BOC3]@CQ5\7--NO^"?$6H>%_A3JWA/2Y_%OAJW
ML]4TGPK:^+;2WAB6XT?1M1*/:W2VFR/57V.LNHQ3S1O(DH8_FSXE\1Z)>>'-
M8TI[ZV^U& "!"H,SW! C*AQ\W0D@D;L@;@.:^#RW%YQC\SQ&+S-5\?A\1G=:
MIA,+/+ZV EEF6NI0PV&H5(\JJ8I4*U+$8F&,JTJ$\30K4YSH4$HP/9KQPE#"
MTXX-+#U7@(<[E*%65:M:5:324Y0A*I"4*+@JD^1I^\]4?.=UJ21:7IJF4RP'
M5]4"K*?WG-MHQ!8@D@9Q@!O3GDX[+PMJEI:WT<]Q<)81F217O(N9'611L#!L
MG9&>6(QP,]17/Z;\//%7B'PSK>K:%H=_?Z/X+;4=9\3WR0M);Z38O#H5JMS=
MN/\ 512SNB*V&^8X[DUS-Q9W=M;1">WN(H)X5D@4(0P0K\IC5N2K9')Q@'CU
MK]<Q%/ 8V-7!T\53E4A:CB84YTI5:,ZU&G7C"K3NU"JZ-2G5C"I&\J<X5.6T
MH-_)1EB<,U6G2FHRG.5)V<4^2:BY1DM>7F7+H]TTF[-+U9/V@/$]OYFE1W%I
M<6]M?W"QR21M)<W$!^2)6D9OG15Y7>K$ XW$ 8Z#3_BSXML+/4X]+OWTZS\1
M6T=KJMI:RNL.I6\+F9(;N(,2Z13?O(PR_*^",5\QCPGJ^U+LQ';<RE8P),RH
M,;@6 )9<HO4@ ]*]=\":38)J<%AK_GBW:VEDC=-YQ.0-H"JK.V3P  < @MD#
M->7F.0<-87#U*M+ 86JHI5:U*G0IU)5I4FJO,J=W&52%6*G"ZTDDX--(Z\/F
M6:XFK3A4KU4IVI0J57+W4VHI/?=65UTLNY2US5KKQ#)%_:2VX\F3,<HC.]=W
M#,SDDMD\XP ,G&!P._UOXL_ T_L_6OPUTWX13I\<[#QFFIW?QE'B2<65SX51
M)5E\-'PT(_(:5I6CD2]\P2(%*<XKSKQ=977ALZYI5[IU_8ZI$83;I<+%_HUK
M.#,C2;"=TDL#1N%)#J'(8 UX4S$,<\ER69E !)]<C)&>..>U>G@\GP694L%.
M4L12H9?BZ&-P=/!XROA:4ZM.GS1]NL+5A'%824:LO:87$<^'JSBI5*4G"#,,
MQKXS+,1B</5I.GB:D*V&Q4<30?M*=ING.+C4BG1KQ<-U=P3TDW<^Q/V:O%V_
MQ?J=JUE YA\,7S"8_?96U;0\JQ .<'GD$^^.**XS]F'/_"<:SSC_ (I.\/W"
MW_,7T3T__7^=%?30PF&@K*E>\F[J<TFVTV[6=KOM;TO8\!XBL[6GHE%*\4W:
M*2M>ZOM]S9]PZ]\5]>CO[^T\-N=)TN._F;R6^:XD:&Z8QFY=<>;(CJ"L>=A"
MY[#/GVI7^J:YJDNL7UU+/-<M]ID:9B%4RMB641*WEH&8<,H# \9 X%O4EA;4
M[]8X(4BCN[QPP8C=BYD4NX'SN9"P;:.1C@<4R*!!;-''UN/-:0'.TJJAD.>H
M4-V(X'7/6OQ*CAZ%!1=**]I[J<Y6?N^ZW9M63NDU97/]79XS'XF%.GB<75G1
MA"+A1A>%&'*DH\L5915FU:-M_N]P\ ?M&>*?"'@S7_AF76[\,:E)<-!,L:-J
MNDR7T:)>/IM],&:W238/,56VN"0Q+;,3?'S4?"GC'X/?"B#0O!6B^'+OPAY6
MG:OXNTZ9S=>)Y=3N4N%OM<B";"\>%7S)'8 E@IVX"_.<GSI*QDC5Y$>)'&5V
MEHRFT@\E3G&0>GS=!3?!]SJ][HFK:!)=^;;PVCBZT^7S)[9XH)R86^8\$$\%
M2".OO7T_"WL\MS;*>((2A*'#V=Y+F=7 U7#GQF'PN/I5ZE*A?6"INDYRLFK3
MOU.#B/-JN;Y%FG!N.HUL12XER//<MP^.@I2^H8_$Y;.A0J55'^/'D2TFWRNS
MBKI->^S_ +2>D^!?#EAH]II8\821::VGR-:3SB:T6%28[;R8(IXAB=O,$LD3
M?)_$00#\O^*?%7CSXI:'96&IW-E!X?N;S9'IMA9L;J4RSNYCGD+-@JP7S'"C
MYUS&J'.>MT6PTFSC>6Q@C@GGV1ZA;R*7"!&*CRF/S)YHR,'IC'H1]!^'?!>C
M:?X=M;W3[ 1B_1KN1R0T@8L23$PR$&23CG(&0.U?OOBK]*+BGB2OC,KX>C/A
M_A[$4GA*\,/:>/QT*]&<:RQ&-492A2J1;I^SPRC!0J3C6YY69_,_@]]"[A/!
MU*68YW7I<0YEAW+&3C75>-+ U*595,)5PU.$XKFYHOF=6,)1E"/*TFT>/^$=
M&F\#Z5<Q:4[Q2W4*6^H1GA9(5,<IAF5N9%\U%=HRH!(SQ@"O$_B)8SR&Y%JG
M[RYAEEECV,48J5?:I)*JQ)(3G.T$9Z5];ZG8HD4A9!DR LP(;C)"AN^X@DYX
M  /?FO--<\,QZI%(1#&Q5@B;G9<#(WJV#\^[KA<\$#(.:_E["XY4\4L75@N>
MHES7DI\J;3E!RWDM[MVD^MFD?UIQ7PC[7(:F18"4*&&HT94J%*G%0I4(5.7V
MTJ<8N44YRNY2O=MNZ=VCY;\+6UW:6<,,GF7*W F8Q;640@A@H)! <J_&3SS^
M?WU:'4]:^&M[XNUJ2^EL].TSPM:^%IM-@%K9)?FZ%EJ.G:F(ES*Z11Q$SN_!
M((!Q7S_:^'O[-O?MEM:QV\B+(D2$>9;1;E6,N5;(W$Y(')'8\5V&DWNLBQNO
M#1UV\T[1M0=9[ZTBG8:5-/#F19);;YD$A.3'L53N().22=<WK+'MU%9--SO%
M)65K6MRVLFTWYK=O?R_#G+WPC2KY?65>O&M26'I1A*R6(@X0P]6I.I+2FY2E
M)IRLDU:R31]5Z=X8M3HWC?4]1MK98?"=UX1U&3P]>WSB\NKO6D\N%=-NX4+/
M93!@\R[@8R>6/;/U4PMYMO8R/X4\6>&Y!=::@N7MQ>Z7=K'="VF'$S36<KD6
MLQ4L064?=&VYX?\ "DGC+5UGT#QIIUQIGB2PC\+6VCD72ZW+K.FZ0TEC%=+)
M$8&C-U"&259"85VG*XKU?P]\);/Q;9^(M<\8>*-%\/>-_#VD>'= T.TN7DOG
M\3:II_G6U];3W5F'6P>Q18XYKJ]$<,@.\MM.X?+<BFW&"T=TV[6ERIRO>ZLT
MFK+2[Z=#^C74J?5[.E&=-2<.=J=2I/#5:BHTJE%X-3ESTY*-3F248Q;E4<8)
MR7D_B:"7QQX?L]8U;5ICK.K1QSWC1V\;-?W]I-Y+Q7 B4,I'#R229D?<S,3G
MC+T3P3-INS32+>Y:42A#+#NMGCEP1&#(I;EE<,W3!8@>GTG\(_A3'#XZL-&\
M?V,+6<ZM>+!:^)--L[!X)YWANS::G/,;?[1:LHD6, 2$] V3CG/VG'TGX6>(
MM7\/33^'H+;18T.CZOI>L?VD^J6EW$;FS>:2T>6+[=!$Z1SN%53*&R!R:?LL
M3.DZD8Q=.%:-%VCS59J5HN459O9N^FUUULYQ=7(</BHXC,)<M>GE4\74JSDE
MAW3@XT)7E)\D7"HEJ[6=5:ZM'QAXYU?6? ^L:OX9@\4ZI+HNC75EXDTWP?#K
M.J2^&+?6+AR;B[M/#\UR^E->1QB25[V.T6>(JY5P*^>_BC\7K_5&BN&NWNE:
M,_:98X6%NC[\B&XE)8^8N 48X)R !Z=]\+=+O?C;\9-1?4Y?[2&DV[1K 9"M
MI]F*(R7&\#?OCC9R6#*<J4SM+*WT=XZ^#6AVEC>RK91SVJV+&YCM[78D"C?M
MD\TH4"X(5BS;VS[U_;/@U]%;#\9<)X+B[/>*I8*OG,:F(RS+L%@J6(C0ITG/
M"P6/JU*T7K7IU)NA2BN6*4I2YWRK_(?QC^EGB^$N+N,^$>"LL;R"KQ'7QV*K
MU<1*E"I/$T\']8C@H4J,G[\:4*L*TY-7=DE$_-:V\<VMZVGZ<-**W][?@OJ,
MEUF*2*652JM&<  \@LS#Y1QWS^Z7_!(OP=I>N_$_XBZGXFGTJ\GL?#4.@Z<;
ME+6U,=K ]GJ3"T^TH6CN@XCB66T99IE$F3L.T_DY^SI^Q5\2OVEO'YT/P;:I
M'H4FM26XO97CM(+2V61F8M/(X^?Y'\E(XSO('S#)K]K_ /@E1^QAX)_:7_;)
M\?\ P4UOXW>*?A[;?!OP+JUQK=SX?U6QTKQ-KVJ66H0Z'IUEH;7UG+IES!IL
M@FNM7FELI)7M4B2%E#2./N/#OPV_X@YB^(^,>,LSRS)<HK95B.'\*W*IC<RJ
M8[-\YP"RK,,+1BJLL/1QZP=7#T*+K4)N&(4U'V2D?S_QOQE2X]>&RK*EB,5C
MJE;#YQC)3;IX6-'!T9/%8.O.*4)U*4J\9N483NZ7LW&\KGZG_MJ:AX<\9?LQ
M?$S2->\$>%/$.F^#_"=U/:ZG<PH-1\-W4[166G:G8WIB=H[BWNYHI%$+PG8&
M._J:_ ;QE\-/@38?LS:5?65QXRC_ &O)M5T*?0M4TW7 ?!A\,SJTEY;ZW;Q#
MRS; 'S6N&+3I.$7(C)V\1^W#\<_&/P=^/7QU_9IE^-!\?Z3\//&6L_#W4_$&
MB:M++X>\5:/ITZ3:>)H8I%M;G5+2WDBAUF)!)#::Y;W<44CQK&1^:L/QV\90
M73V3:S/JFA+*UJMG<'8[:>2(_+-RI\Y,1_*#&<J.F2#7R?TJ<AH\2>'7AY4X
M0XHP>)J83C6/$BJY?C'"MB<%')ZL*V5XM6JR> QM>I!X_"\]"-:I2I4ZDX33
MJ'H>#V=8WAGB#B*IBJ&+R_%U<#2PV&E2G.E&CB*%9NG7I332C6I\ZE3JQ5XT
MG)<K4>5?<>F7'Q!L[&ZM-?U&UU/3K&S\U[O2&<:A!< &.1?/C8*UL$!<;FRQ
M(SR:]XD_:&EG_9<\*_LK)X!\#Z786OQ%'Q*M/B>UM_Q<75[J2RELI-'O+TJ)
M'LGBN=SVQ<QDPPX4F-*X#PQ\1/@+XI^#/@_P%X#TV2+XEV?B"V\0>-M<N;BY
M66\TVYMA"^A6WG2$WEC:R%5V[%PP+9PV!\E_'KQ=::=K%H/! :3Q'X/NX=2U
M96D+6T=E;3GS8HXA\JNP4.Z@G*H02#7^<N587,>*,[CEF:9;F.6UL#F>)]G#
M,,/]2BZ.#J.CALQJTJ&+G&G@<RE-3PSK5'S4JT.>BIRBH_UW7\1,7BZF28GB
MO,:O$6486M@ISA3Q,YUGAI3@\5A6G&'UFI0I1J<\=9<SN]+R*O[2_B;_ (0+
MP2?"NF/)%>:I>&*[6?<)VMY(IYI9&4D%9)'*)ZE#C&.*_-0#!![-N9N^&8YP
M>XYX/. 0.!7OWQT^+7_"V=2TJ_$4RR6MJHF:0 %KG;M<% 2NV-LJC'DJ!GIS
MX4J[648.&'0@EN_/3G'3Z^M?U?PIEKRG**5"=+V=:4I3J1<5&3M-Q@I:ZN--
M1LWYO6^OYIXW\68#C'CK$U<CQ'MN&LLP>7Y7D,8KDA2PE##4>?EIV2@YUG-5
M&E[S2;;NK36X?&=IY&!CJ/;T/H3CI^-:\0(0 G) QR/_ *_/\ZOW6@WFE1:9
M-=FUV:MIZZC9M;7<%R3;/))$$G$+/]FG#Q.&MY@L@&"5 8$I#:3.1M0D\!5
MSG/X'=NST']:]&O5C)N6G+?XG\+=[/5:;K:]MU>^A\!@\'5HVC*-12LFXN+4
MES*,HMWM:Z:=];JS7=-7[@9@QS_=R,XZ8(/!&>N#UZ<8JU;PEQE@P!/*XR2.
M,'U/X]\5U^@>"M8UB\MH9;"ZM;*5V\W4)('CMXD2-G<!Y  [ *,*I))8#O4<
MFEM:7<UK)NVP2,@9E,;,J$A7"D D%0",=002*\QX[#.I*C3JPJ5H14YQC.,K
M1<G&/PMV?NR5GKIM:Q])@\NJUZD%RV5^6TM)-I1DVUI*R36J33UU;NSG6A(P
M0 <%2NX8( )XZ]QGL*60,RD9' R,Y'7G@9YR.^.>??'2W%BP^959QDX '/RK
MG)_/ '/'7L*SI;9Q$[I$Y?87Z9POW<YZ$9'MCICO6M*M&K.$(I<U2481YFDE
M*;BDV]$E=_%JOO/1KY75PRJ63<53E-VC)^["/->,5S)O16BKN]NFIR3M(\AC
M"Y ;C"\], Y'4G'/!QUXS4<UC/$IE"$C!8@@\IZ9QUSGL 1T-?7>E? _0[KX
M5WOCF+5;+[='"NZU:8^<LBD^8LXW;TW!@Z>7ST&?FROSE=J5LA!,49QOQY9(
M5L8 .2-QW9]1[]:_2N.O#G/_  _H9#BLTG@ZU+/*"K4I82JZJI35.G4E2J\T
M8WFHU(/GA>F[MQF['YYPSG64<6+-XX:IB85<IJ3A/VU-T[S4U&+@W)NTGLFF
M[Z-*Z;\WDR>#@%> /;^>1CG/Y]*SYAAL9ZX/KD YSQCOT/XXXYWY;=MWW003
MD$#GOG)Q].3R>O>LF>$_D2<9Y'X<<$\#MT (&:^0H5(NWO+:WR_X?3\SDQ>'
MJ04FT[W]V7DEMUZ-/TU145=RDY( ((SUPW\(X'(Q^&<X-5Y!&21G>>, >HZ>
MI'/7'/>IYB53.#G(!P.YST.?0''?UQ@5L:-'IK66KS7\#3>3;Q+&5!4PS.Z@
M.S8QT!P.<GC) K>I45.+FU*23C'EBE>\Y1@M';K)/5K3I<\UPYIJ#M%\K;<M
MGRQ<KO?M:_1^AS(4!L-@$ C ;(//(!QVR/IUY[Q,5RV.A P ?F)&.">>!CT[
M'&*?+DR[E&$4D#.00.=I]]WUX_$4PXV\#)VDDL!P1U"]@W?\@"":V5]+W:TN
MNVNSWW27X'&]'H[VZH&7@J#DC!SQ\P[@8[C\L=:16&,X/''.TCMR0#N/7/&/
M<=<,&X[1G+;0,]"1@DGV Q]??I2A=N2<8[C@Y&>I /'//KUII65FUJTTN^W?
M3LUY[Z70B4LHPN_! &6!..>< <^V<\<?F@;!(XZ9."&)'7H,8'? Q@$8SQA,
M@%FX*CC<0,MG/09[8X^F<\&FAP.<G& "O4G'))].F<C/I2WMOV5V[7TTVTOV
MO\UU;OU[7^6EOE_PPNYL_*Q8=\@#U&#W/K[&FDX"H<8ZGZGJ,@],@?UR*%E'
M&2#G(&!V/)S]./<8'K2@H"!G@<';CG(Z-GT[GU/H<!VM=VV6CL][+\GY>;U0
MA0NTD]/]G.3V(YZ'/]::[Y)/&[."!U(!& 1DY.=O3KP!0A7<-HQC([]<GYAZ
M\'ITX[U'@DG+<!V(;N3DX.W@XZ'KC@4XK5ZMVL]M=.CW[;;OIIN$K98;B1G=
MTP.3C!4 YY'7IZD]12%=I5E)X&.>3DC:1P!@9.222._3%*F[& 1@')/0MCJ<
M'C)SGU],=U&&D0]%8G(ZY49'?UZCW%#;7HG>UMUI9/3M?OHM4FAI-V\W97V^
M\>FT<,<$#U&"1T7WR!V/?TY,OF$@ JP!Q@8&00<\\<C [8.?RITWDLWR*05
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M?-'-&KC:5##^?./L@P7$&&HOB#+</B%B*<U]4QM/VM##QGB\#F6#CC,"J]?
M5<7@L;@\)5]K:O*%?#?[-6Y)M3_2<BQE7!U>7!U4^65-RE&<H^TC[*I2J.G)
M\E3EE3E*"NURJ5[<UI']?7@[_@BC\'XK#X0^#OC!\1_B%;>-8=*?PK\1O%'@
M 6$-O?Z_=74\]K/.FKV=W.\8A;[)<WHC<Y6&?8T1./XYOVW/@UH?P-_:+^*'
M@7P?XEOO%W@W1O&WBG2_"VN:I:_9=9OM'TG6KS3K6;5K= $AO7%LWG"-$1W
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M</0PW#+RM9)@IJ.&HY36P\\%AX1J.JH+ZO.I^\JS=6K4J3E*K4DYRG=OF?\
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M\.H=6L5N+J*]UDDNETK2GR99W'RRW7 4%6.Q#@Y.0/E?#W/<5F=>,J$_9XC
MM5,6E2J1P5)5;0Q;C5G54'4K4TH17/5J2;I2Y%JE]1BZ%+!3HR:3IU.6TE+]
MY*SA*-XN,G[KO>U^5<S?1OQE;9-C!(RF#A@PPV1_=)R-ISC..GI67>P;=R#*
MY58SM!97&[.W<.0"203R1].*ZW5-"\2:#&DNJZ5>V\!^5)98B5P^-A!4GY65
M@4)'"D9K@;[52<K\T; GY2#EO0$=5]23P,\YYK]]P&(^M/GH8BG5IMJTZ<XU
M$FFKVE%R3:LEJ[IZN[W]G$XW+?JL$FZ57EM*,XJ%XM)VM*TK-/HM;6\BI_:F
MI65M>Z7!=R0VTX*-'N9O*))9@@RN<@M\Q#9[@8KE3&$0(K,X#-AF)( 8Y*]<
M=^#D=.!S6E-/YC,2/FR<[CDY !X_NY_7TK/ED." 0.N",< ]0>/PSUY'7I7W
MN-S_ #K.:&7X?-,QQ>,HY91E0P5+$UG5C0HMI\D+K17V[)VNTD?F$\MRG U\
M77P&&HX>6,J.IB)T:?)*JTHJ//9\KY8P46TDVUT:TQ;D%2P4#;N !/KCG&/Q
MSCIT-8,J_,_0C)Y!R<$\9^G3@<'UK>NG!)W$JP(RHY4\#YLYR..V"2?IQSMS
M*WWCC:[$$9Z!?EX)_B]!^ XK+#J[OIO^O_ Z?YGRV9RIQNV[V;:5MDWV6JU:
MZ.W?0?I^AZIXAU2PT/1[.6^U/4[N"QL+6%&:2YN+EU6*&-1G<\C$*J]R?K5'
M4[;5_#<VJ>&M4M)K"]M;I[74;.Y5XKBVGMI'#P2QD AHG#*0W1NV3QTOAKQK
MXC\%:G8ZWX<OCI^J:9?VFJ6-ZD<33VM]9/YEM<1O(K;)(GP?EP"#R.!7/^)_
M$FL>+_$&I>(_$5[-J>M:K=S7]_?3%3+<7=T[22S.0 .7=B%"@+G'0"NNF\9/
M%2C.GAGE\:,90?/5EBGBXU$U>G[-4E15/52=1R4U\+BTE\SBEA^2\93]O*<4
MURI04'%)ZJ3;>G9)J^G4YX-T'!&.AY)]\GGV_$?C$Q)RO0 D<]BQY/M@].I
MS5P$J>1U&5[Y]QTP1Q^=5)6)Z*W&20.6(/7+=S[=.E=L=TO\]&M;^?4\]PLK
MWV\O^""GY=HVY7Y&.<$8Z'WZ_A[=:1CG=C&!W[GH ,]QZ8 Q[4P!C]U@,X&>
MV#U'/4GL1T]\T]593P..A!Z<?PGW_P ]*:Y;[[VTWLM'9OU5O+KY39VO;OK\
MU_P?Z6J _*1TQWSR""3POJ>E"X4$=CSE1\V[IAN3C&>3[ #!J3().WJ,[<#;
MM['H<>WXYJ!MP))W8(.,=>>F3STXR.<CJ/5QU[)WO:W?EM;2]G9[;+5@VFUY
M*WG;^NE_F,V[6S\I//.>",Y.!C(('7GI^=/SE@H4#C.1UYY).<9]B/\ '#U9
M<GC:IZ$8*\ <?GG/IGKTP;@2&'!S]T\@=OY >I_*G=WVZ)7?=VM=+;[NVR86
M5KWU[6_K^O-6)5 S@ $\Y)&0V>H7D=/KVZFFL%WY(.T@8'3G&,<9QZ_IQTI
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M)R10955MF?NYP5X5@<[6QSPPP>3QQS@4P YQ@;<\X/ ZD'& >N,@GIGI3 V
MK",('PRJ,-A5&,9&/KC''>IH8Y+AQ&BG=E268K%&JEU7=)+(ZPV\2LRAYIG2
M) P+NJ\CY]_$VEH]59[7>MG=VL[[M^=SZ1VZ;=/3IT73K97W(R QYX";3GG'
M)Y SGO\ J#7UOHVO2:=\%O ^C:1>):WDOCJ^N=2N23Y=M!<0Q16SW!422F0
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M R1SSWZ?4\E2P' .X9R?EP1R3[D8/^<4::7VWT7I==.V_P"MQ/FULDMK._\
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M2>"S72/-F8.\8/\ +1XL\/KKME->VC*TUA#)/"% "RP*JEH@H506 /F9P._
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MYE97OHFFUH^NMM=-+:')4Q+I)1=Y2=_+1V=[M-I/9+_%Z&D\C, "?E48([=
M>/7MU/KZUF7+D%7P>5/1EQP>G;D=SSTSZ4U;C8=C.JD'&W)/4'KGU[<_I5*Z
M<OM97P1@''\.3G'L#UZ>G:O5ITVI:JW1/H[_ (+76^MGH>=B\9&=)M.\MY+2
M\;679-I;;)K5HA;.>A!!SP><=P.."23^!QQFLFXE4L1P&4D%_P"$#ON QDCO
MC'2K;3%ODX &6!^F!@ ^I)/7\*SG)S)A0=V .V&R.N23CD="3UQFNZ$4MWU6
MNG=+K?I=GSM>JW;E>^K;ZO2ZMW6U]G:^]B&1V//WB3P < CH3D\8QS@CCFH&
MZD$C)ST.?R/?Z^U*Y(* [<;@2%'((Y Y/()Z' SSG%-9AD84]3QQG(/)]B.>
MG4_6MXK;?9V]+_==Z;+6S=V<K;;NW^'I_6PY1\K 9R<<@$\YSDX_7VSBC8N[
M<[ ,23C(V\?7D],GIZ$#%(F3TSW^\221@\\$8.3^7?IF0[]IX!(7E?[QQR/8
M$\#\SBE*ZM9VN]=O):=_/_(4G9;7UMO8%"<G&%VD,IP.^5/?U.#WI"5;;N (
M."'X))S]S;Z'OVQWIH(4 E0JL/F[!2.@//4DG\NM1.<%@!R#P",[<<]CR#CU
M'>B/;M9IZ)VLM-/E>]]-^C)C*^G9+7[K]/Z_$GP&9CR#QQE23@'H 3C\>N>W
M--+J 4)Z@Y']T9QG'?'7ZXP.M5R7)'(P!SM!'4="23_^L8YIR@N5 P2Q)SQC
M)QP>@[#OT(I6V?;EZ-6M9/?IUOTL)J[YO1M6=U:U_6RUO8D*\A\E@,%BPQQV
MQD#..?T]13FD."0 PZAL' [[6![\ =1U'%+(SJJ&1&$1;(<@@$G' /(8<'D$
M= .<TBJRY8_IC!'&20.=QZY&?>J:V;LVMM>NFFG71]K=5H4I7;5M%>SZ-:6?
MSUMZ$3!MZLYV[>K,1@@]ATQWSU]A4[8*$D\ <]B<<XR".#TP.>G.:0*-P()
M()5=H !&,L <X]ACW'N]75L\8!P%W<<YYV_WMQY//'''-2W=WZ):Z*ZUMU6]
M[]?RU&K-ROT>GR)[B[6XM[.-+>W@>RA:-I8(V1[K?(TWF7+$E6=0^P8V@(B@
MC/S5510 /F"Y7) VYY/7<<G:.W\^U.;YB, ';DG) QG''J#Z^G>D 4N1M (
M8$'GGJ1].*$WHK<O>]ME;OLKO3?7;8%-R>O2*7W62_ <%'W@H)YZ'.Y>F2?I
MU/O[TYI-S;3C"C .&&T9/R@XZ9..>/Q&::KEB0%8#ID\>N?RQT/X@4AD7.
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M(="G\":GOM;G3- T_P#LY=!M;,Q64.IZGH5\4^T:MJLTKSW4.EEA$Z.Y 1U
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MX;3CYG#<Y.6)QZ\@Y[>XXJE_PU]K^?E_6QC)MK35-.^_EVM]PP*J\9R3C Z
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MQ\7/$NIEM#^)!$<D&AQ/R(8I7<2B0*SI\D;*<IG@,3\$:;\6[3PUXDU30M0
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M#,R7#FVA:YEMC;NV^2=U60HD7F*[ [ :\AL=-AU'5;#3[V[M-+M;JYA>_O\
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M8[D $]1QZ^_6I;F0O<.P^ZY!V=0-PR",=@,\]#R.<$T@"KGC!Z%B-PZ=!_\
M7_&OQ^[DW*7Q3]Y^3:7,OOL?G4G[]DDK.U])7VUNOT=^A/!( V&')Z#J6..Y
M)SSGCZ8]Z]'^&>@OXD\<>%]%6/SCJ&MZ?;" !G\Q9;A$>/: 2QV;OE')X ZX
MKS0$8^49&"<$_=(!/<YXYP<_H:]M_9]UB30?C#\.]0CA29H?$NG;$D("AY9A
M%N.5/3)(&.2 ,<\>+GTZU#)\UKX57Q%++L94HQ<N5.M2P]2=.+D](IR44Y:I
M)Z:'J9;[.IC,-2KOFI>WHJ5E;W74@I+1W^%WLM'U[K]VO%-GIWPN32-&%A!H
M<%W8PHLL:"*&+[+# -CAE+JW(?YF.6QCIBO!;'4]$\9>*=4L-5\3V6E0+I&J
MWT.I2VD][!JCV-L\\>F^1:J\HO+QQY%FX"Q"7F5E7)&E^W-^T)H_B:ZTKP?I
MGADV6N:;:6OVO7Q<[H;H/"$WP6P0>5L""/ECNP#G@U\[_LL:]X,N_CK\(=$^
M*'B>\\'?#7Q+X\\/^$?B5XML&C-_X>\!>)[^'2_$FL6KR6MXEO=65G<F:.Z,
M#BU91,JD+@_QAP5P=GF9<(TN(,QH5LOSG'X6M)4JM;#U9R:DYT<7&NWB8J%=
M*GR1JQ<FK.I2A45E^RYKG&$H9G'+*#HUL+2JQG-T8MRA/DG>DT^6TTF]IRBD
MFTV_=/HGXG^)OBM\0/ASX!^#?CCQ%K#_  Z^$,UWX@^'OPVO-,M;>"SN_%!#
MZCJIN$@2YE>2$IL6YFG2-6<QA&8X\-UJYDT/PG9Z!K^EQV^F:)=/?6JI#YDK
M->N-[RL@,A0@!D$K$9Z8/%?LY_P55_8\^%W[&WQ,^%DGP7^*^J_%CX<_%3P+
M=WFFW>O^*-*\7^(?#FJ^%[FRA>"YUO21%#<:1K-GJ=G=:9YMK"8_LUW#ND"!
MS^6:Z7#J]_'I5]K>G7E_XON8+643H&BM&<100Q%"Q*+""DC#Y6(! '.:].4<
M5DE:&69G3H*CEF(EB94<#/\ =QJN]3$U\+5PRJ4OWL*N(KRQ%7GJ5/:ZR:FG
M&/K-',:3QN#<U''4^6E*JDY+FFKTZD)1IOFC.*C**<5S)NU[M_5O[(&@_L^?
M%/1K[P3XPT;3_$GQ)\19USPMKFL?%G5/A%H/@SP=X/L9-2\0:9XAO\M8:_=>
M+)5AMM+L)A*;:2!F*HSL1\+_ !K\2>&[OQ%XKO?#NA1:/HW]OW4FGZ7;ZW/K
M%O:0QR)&%CUMTC.J0R*DC+< !60[P#D5[7XS^'.G_#F\ATBYNK*ZN-+M3$76
M();W,@C(<6[JS9;D?)DE6)P0<U\K^+=2L+>VD&M0V,&C7%M/(#=3[)86B<A%
M6/<KEG.  JY P0.N/+X5P6'QF?UL]P>/S;,L#CJ=!8+ UL9B)X>A3>(K5ZLL
M%AO:4\*IXBC]7A^ZPE*O+V/[RO5E4E??,\94HX"C@ZM.%*O!\\JO(M6H.%F_
M>:@G*[C=13O)*\CY8^(D N+R+5H8%MHM3B:4@$"(2*(U8A@ I5LY!P/QQ7A6
MJ#R)I(V*%P."C!E)XP-PR,GCV[>U=EXQ\>7?B:41LD-OI]BK6UC;PJ$BB@##
MYC\N6)**2S'(/3K@^:3-YF226Y'S+GD@\,#Z'H>N.]?U_D.!Q&'P="EB4J<J
M<5'V:;J<L4_W495&US.-/EYK73::3E\3_-,RS"%2FXPDZDY2NZCM!)WUM%7T
M>C3NK+1KH))+A=N\DGOR<-W!'<D=">1QQS5)BI (SD'=[#@ <CMTQCO^%*[+
MSG.[)R3U)X).<\Y_KGCO7&0<@?IG ]>PZ>O7K[U]/"*26FW717=DK:7;OUOV
MM;='R]:M>6KNN7E7E_PW7IK:^B+%FMM)=6L-](5MI)XC,R@[BH8X7(/&0<#[
MHZD'BO:O&_A?X2Z3\+]#U+2M?U#_ (6W?>,-235/"HMUDT2U\$)90R:7J<&J
MB1S+?7-Z\L5Q9A5,(123\Q \-((''*G+?3&2<GCKGH.A!JHWS/N )R>"6)*#
MD@*.G)QZ_A@&LJV'J5:V'JQQ5>C"C/GJ4:3BH8A*,DJ=7FC+]W>2G)12FY0A
MRS@E)3\^O#VWLTJE2'LJ].LG3DH^T4(SBZ-2\7S4I<[DXIKWTI7=K"@!<@KC
MG.!QSD=3D\<9&!WJN=I8D #!.>>_.2?7OZ]\594@9R.,98DYWGV';''T]>*K
M$D.<=02.>%Z\<_0XX].V*ZOZWM_7]/H$I)6TT?3M;_+I^8S*@G(#\'G&"#QU
M&< #GH?UH#9QQM., ]V'H,D<=N_7Z5%(X)R<#IU(YP1D\\DCV_#MA%)RA !4
M\MGTQGID<FKLE9/?]?=?=+6]GKK96,F[N]K?\,E^A/C.58G Y &/E)YP,?CN
MSSR#[4P#) )(4\<GC('\L]/ZXQ4@&TD9!)&X ?W><KG'!;.".@QS3=HQNQQR
M2..,C/U],4)VOT3VTUNETMY]WTWO<$K[/^M/\_P8J%2XZ\9Y/4G/'/7IGK_^
MHE#;QAB 0>AQ\P)R><\=?7V[5&\BJN>G.T>N/7V_S^" D@#/ #$9(Z$Y.#[^
M_;KTH6MF[6VU:]-+JWG\F6[13C??6]O1VW_'S\F+\W*@YYSD=P.#UZYZ=N^!
M3@ZJ>2W.  1A,>I/.,\G/'.,8)J:VAFF#F&,A(U9I))&6.")0KMB265DB5Y=
MC+"C,'FEQ%$'E=4,C-:6SLD&V^N8Y25G:/\ T']U-+AH;:XC5[J.:-+>5#?1
M0*$DGM[C3G(24.VMG:UD_.VFKUMLN6Z];69F1"U>2,3NPM[;]X%FG+HDDL2A
MFAMPBO)</EHHW$$<@@,\+W)@@8RB99H;9_\ 0#(&6;S(K^8!+Q5BFE>*6&..
M22.P9T^S,X26ZN(;B)C!?B&5HJHS223R;Y7DD<+'&"Y)"I#&L4,0!^['%%&D
M4<:@)'$B1H%154 4E@6*C.Y@^[(7DY08[DX//X<]*>B2_P"#LK:)O\KZ7ZL"
M8\EM^2['<Q).';DY)ZD\Y)SDDD^]( _0C'.!C &T=6&1V/!SZC\'(VT@L,%3
MDYXR0??@XP.V*DF!+B5,?O >!C W'T[<G\,CG%9[/5?>]+JUVO5+SZ;K0KE5
MKIW>EU:UK^9 <NRJ#D]-[ [".XR.A(/'?CZ"I'0^8L99=I48 !;A?1B>#G&1
MUP3SSDL:/8>"=HSDAA@G(R3R.,Y'Y=ZD);!()8@;0N?N<>HXZ>GKFCM9]+:V
M?;[MW;TWU"R6DEJK.Z?1V;7]/<EVL"<MT]A^'8]>/SI@4ENQS@?-@ =,GMCL
M>IX/KFF;MQP2P&[.01@CCY6!.<?2K]R8W2-E1%"HL1"#J5SRQ)XWX!X''<X-
M3L]?GY;/5=;]KW36MBTHRC)K1QLTGKS7>NKNE9+S^ZY2(.[OPP )X!],<<KW
MX&>>O%.WX^^68G[P"X^<$  '!SQC(&,>XZQA<G:?G(X4Y'?)&1W('Y4[8QPF
M03M).3C;\P  '/('3'T]Z>GX=-&_O[+>RU?>UR6G=JU[6UV[;OKVU?GH*#DG
M_6,0>0=Q(7'&T\;<D<]<C')KT/P?XY31(+S3;T.]E<(#$P4CR7"L3M#';MW-
M\P R6"D,,5YZBX4<$8R,COD]"1[G/MUXJ)LJY!.X\XQC;QGKDX)^O.?J*PQ&
M&HXNE*C6ASPERM:VDI0:E&479V::NO*ZUN72K5*$XU*?NM73WU3MI9_UJ>KM
MXX>WD#Z?>7ENJ$F-PS+@GEBHW$ -T(YX&>YK8;XO^)8X+=(]4N[::TN([FWN
MK9Y8I0R$%M[*PX< JY8 D' (KQ$[R,\J  1G&",D'IZ=NF>><5)N.U&#D@<8
M/+;>GX'UZ'OWKAGDV755#VN&I57#5.K3A4>VMVX-/F3::=UJTTKW.J&98N#E
M*%:=-RUER2E%;Q6BYM&K:=M-3OO$?CG6M<\4MXGDFF%Y,EOYLBRLI=[= BD'
M<<%MJM@'&>>":R/%/B;5?%=]#=ZA,\LD,*P#?U2-!PN01GH3GZG&3QRQ=BI^
M\!R%XSMSVQDXZ@_GZ<61)D$!CT3/O@?,">A]!SUQ^/51P.#P_P!7='#TJ;PM
M'ZO0E&"3I4;17LX.UXQ2C%63M9)6LE?&>)J5?:J=6;C5FJDXRE?FG_,^[3N^
MVJ;+>FWDUC>V]S!<26TUI/'<6\\+M%+#+"R.K)(I4K\R@Y'H#VX_8;]EWXT^
M%?C3I.OO\9OVEM5^#/[07A_7O!A^%/Q0US4->MM*U7PGX?TE=+/PZNK[1I[<
MZ1;W1C"G4I&A1K:>2&6<HVP_C67+'"Y^\N,C@=F!/Z_0\5.K,NXD#"X;/)!"
MY8,X. 2K<@$]LG@\?-\8\(83B[+_ *M/%XC*<PHRI3P&<X&C@JN.P,J=>AB*
ME.$<=A\3AJ^$QDL/3I8_!8BE4P^+P]Z=2*ER5(>EDN=5<FQ+K1I1Q6'DG&O@
MJ\ZD,/B%R.$'4=.<)1E2<G4ISC.$J<[375'^AY^TE\>/V.?VPOV*M&^$&I^
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M5TX6]_=1VV)(H+B:.-F&?E5R%"D8PVT8..#D^]4DC!7;E>GX@?Q _P"UUQT
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MRJ8;OJ4\O<\/6I/GQ4(R=7]W"FJ=2,%*$5"$'[:[C[/FJ.,KRYG)\JC+[_\
MV!O^"BGQH_X)I>!/C5XU\._"G2/'GPW_ &CM&'_"%:,OB:PT1?AQ\3-)M-1T
MJR\720R:9JD^L^'KI]1ADU30&2QDN)+6W2VN8G9V;\,_B7XUN-/TK-]J<^N>
M)=<N-2UO7-8EC$;ZAKNL7MQ?:KJ"A -B/<WDQCB38D01%0*J[1Z;JMIX]O?
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M.#],XYH2U>VLEV2Z.ZU?316[_)4YM\D7*]DTM79+1K2VBWV>KN^H,A#8(8D
M DGU.#QP!S^?;I5L*(HBN27&, C.T'!/.>@Y'X=^]5G'0'YM@5@3D\G<>0<'
MG&#ZYX(P:;N+N%Q\W)'L3Z\G\/<@U3C=)7VMT[>7Z";2NV[65_DMQX!8Y?\
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M^M;A<'DX4XP>N">!C.<=.V<FEW$9'3(P?3TZ>O ]*8,;MP( QC."2<D# !X
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MZOO4[AE&_P!EMI<<XZYXQZG')Z57(V@@ $]> <'/''/.#G@=!QGCAT8WL$!
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M.WMHKB-3+\T>-N=PR*^!K#XO>/+&VU2TL]:ELX=5BCAO8[<B-+B& YBCD55
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MTZV+C7J4*-#"XO'8F='"QC+$8AX; X?$XB.&H*4(UJ\J<:5.52G&4U*I!/\
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MMJET_KIV$50PYW?*<@$CD]>,9Y&/U''%*X#88MR!P5Q\X&> 1T/<]>?0&G'
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M\/WMI=6WAH7RIY5FUSJ $RR2QO(I<1JPR%-?$?Q'_P""<MQ\0;QM2^".C_\
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MCC#D@8ZD @U^<?\ :^KZ#XGA\1VJQ-=V=S-P[R)F191)- SJ=Z;F"*692O\
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MGN.W?\*\U+F25[6O;2^]O)=?/2_S/HWRP>D5T=NEU:[:ZWU].CO=%AOG)5>
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MQ_&Q+8RQV4.H^;!LEN'MQ;K*#.9$0/O:#.\1-PJS$;0^>F,530J1@$C SD'
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MP1T/'KCCT;.ZYMKJ[;6EVEJ]_3\#XZ/*FVKMI-V>E]/+\.[2[W/V'_X)S?\
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MOOK![;/>R/05"2PN'Q#7N5*M:FG_ 'H.DVGW]V6GE<YH1@YSDX/R%CD' ],
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M\'H,_C[]AOHGJ_O6G1>?FU;OL$K]$[OJNFW]7>W<>, $'< W.TG(;'M[9Z'
MJ(D#<=K*P. 20<^F./TX(H)5"1A7."=R _*!@'ZGG\.<YI3V^4# <<'J201U
M'4X)/OZBI3EI>]FXZ_=_3[OYHS3?,KM].O33^G^(;@V2< _W2.".._T'ZYY[
M,8]E'/)'.  >NWU]!^E2*IQGY5S[]?T[5&R,21@'(Z <X)P#GIS^?)Z8.*35
MM+?TEO\ @NK-+I_#9O[O.[V;\_Z0BD]0Q7(/.,$_AWY[GD]J42$MDX.XKGCT
M(_P'Y5(L;* .,8XYY'L<_P"??T7:_!& W7(_B!]3VP.!ZCWH;BUJUMW7X#UM
MOK;?SMN.10#P."78>^2 <Y[>U59""^X\G/O@'_#@?CWJ<AFZC)R.<Y*XSG.1
MQ[9_EFHI5.2>N#CD C/(R>_T]#4QUOK_ "_HW?6^K;N]M[]C."U?HO/JM/GU
M^=Q-V& '3LIZ\_YXZ_SR$@'T/S @>G(&0<8 ['U_5%0E<]3G/)X&>"!GICKC
MT/O2X/)/O]3NR/Y__6J]>K^[Y=]]M]-^A=KK5K3YK1K?N]+/;=CA*W;:<<9P
M"?7K^M2$ Y8!MW1MO7!&X'GKS@<=%/?K3/)?V_/_ .M4H"JOS _*,,0<=00,
M'GH2,\=B#47W22OIJK>6MM797WU[DM-;)Z7U75W71W;^]WWV0U%!!^;.1D@'
M+  D].Q/ /..3ZT9&"689)& 1C ) &0/;@_C1A1M7)YSM+#)9AZGIG& ,X]A
MS2^7GYVP&Z@#Y1@C&&[$]L\<U#W=W?1>5]M.RM^:,S2GPNC61+ !=4U8$?[1
MM-$(_0FL@HA4-NSD\@#/&>PY_KCGT-:\P/\ 8U@<9']J:L,\<?Z+HGJ?Y ]*
MS"J@+M0;W'RMWR03D\<9 .>,9/UJO33:^MM+1TU=TNS\[(/Z_K\2(D8&QL#<
M1CDG ..0>G/8=:5F^4E6!!P,$9&0?3\/3U-'E-A2Q!(R  <Y&?4#\.!2&-CP
M"%)) R>X/\B!P><^AZ52Y79NU].NO2S[ZZ;Z]"_=M>^JV]4[]D]?/:_D6[&Z
MFM)XI[>>>UEMW6>&YMV:.>&>$AX7BDC97CD1\-'(C*\; %"&&:](^(/Q(U#Q
M_;^%4U#1="T^\\-Z(VDW.KZ=#=G5_$UQ+<RWMQK?B:^O+FXGU'6KB20I+=&1
M1Y:JGEJ-H' V^D:E/9W>I6]E//I^GM%'J%[$CM;637#>7;BYE"[(C,WRQ;L;
MSD*">*H!6SAL[1DD GYAG@ X!!]B,GOC-9RI4JE2E5:C*I1<G"6\HN<>65K6
MU<&UJM$[Z;ESI2Y*+G"HE?V]%/FC&3:J4'5BGI)6=:GS*Z^-7332^EOV62?^
M$YUH84*/"5X%V@@G_B<:'R2?7/&.,"BC]E] ?'FM!,X'A&[^]U!_MC0_J?>B
MMH[7[ZV[?UOZLE0?=K\>WFOZ7H?Z#EQX.T#XI_#._P#$4GP'^&$=CI^B-8:I
M8ZMIEMJ>LZCJFD7!>YN-'U&UC@CTY;M6!B210"Y+S;AEAE^/OV0/V;_A_KGP
MV^U?#/X3ZC)XUT/3?$TZVTEW-#!=7"QLOAZ^:WNVT\W4Y8J4W1EG1C$H7 KP
M#XD_'_Q=I=GIGBG2]&U;2O 6NBZ\'^,M/\.VP&A>&7NY+B=/%.L&,-,]O+!(
ML-TL211("H64E0K>,6?[6NNV.B:GX(G\3->^!O$4-KKMOI=IX66YFUJXT)Y+
M71;70-2\@W=@))U"S.DJMY*,[D Y/X5_:-"GB'',:.%K0LHT<3'#1C4C>49*
M,XW]Z,OM2O[K3T;T/]'.$. O&"KC,TQW^L6*I9+CLRJ5<'DL,QQ<:U'!5XS6
M)P]6I&NY0Q.7T:L:D:-FL5[%156E&?/#[<?P[X3^%_BBRU#3_!/@KX1^ I];
MM;G48_!=F&2_@:38C:W=73/<P6$4;*UXDK+;HR(\88XKTOQW^S_X0U/P]XVT
MWPBNLQ>%+GQ1HFO>(=?M]1WS>5/&+VSU/25+_P"D:?)?7<:/:0LT30$C:F,+
M^+GB/]MSP%X=\/>(]!\0Z3XN\6^+O$_B>VTKQ[97-S::=X?A^&[6C'7-)T6\
MG9KN#Q';M)'!;7WD(^ 94;Y,'X5\9_\ !0KX@1Z@KZ!\3O&&@VVF_:=!\/:5
M#JKS1VG@NS4V>@:1>VEO$MA<7%AIZ11R7SJ;F:9&E9R7..F.<4$I4HX.5>F[
MN,:5Z=HRT;;5)P2:=[+9IJZT9]GB?#_.,)6=;&<4T.'\=@:L,-.>9U*F)IYK
M4HRIQHN,95\1B*N*YW4I4:E:7LXQ<*RYK>R/W#^(/[3E_P#L=^)9XXOCGX9^
M$.J^%M"-L\D MO$FI^*)+N[35E\,G0<WEC;6EY96P::?4[<2PWESF*49"U^*
M7Q6_X*+>$_B;X[^)=[XX\.^)_BSX-\<RZSJ?G:SXL?P_J7A3Q'>Z?(-&O?#5
MK9V0LGM-)U<QW<D8BQ=VF;1B@?=7YU_%/XO7/CJ^;5M5-QK]U-<-)K6J:[+C
M^T[MVW1LLMR1)(T49RTC^@5!L&:YW1O%WPHN+3PYINOZ1I^F^)+"XU-];UEK
MUI[:\MFN8KG39+&UB;[/#)I\4:6X"'<^Z1F!;KP8NOC(X:E56"S/$8?VTY+"
M87DK?5_94*M2%>=&<X*I%-1I-4XN?/5IOV<E&37R_$O'&1<&5<1/)I97B,VQ
M6 P^7X[B&6%G0S#%U*$9WHK$4J3JX:C5K\DJ:BZC@XRC"I3A)6_4?]F;]FSQ
MS\0_!7@GXF^+_ASX_P!<\!ZRFI2>,=)T&"ZU&WUBWTEKRYT/Q-XCFT$)J/A;
MPI)'(EM+I=ZT0U&ZMVG8/$JA? _VF/''CWX07.D>'O FIW'@2QU73M0U*\L-
M,MGLI_(U*X:WMH&+LLS0_957=(\IE8%MQ!9Z_??]@?\ X+,^ /@G\/-%^%'C
MC1O 7C.]USPY=KH/C'P[XF\,>$[N2'2GNH+;1/&6BO9HUQ':V$T?V4S[Y[LI
M*I5S(&KY'_;0U/\ 9>_;3\(:/\1-0^*G@'P;\85OE\%:'X-\(^#IM+\)Z1X6
MTHRW$GB37->2:..\OM;GD:"* F9HE5?*2((,_P \\/\ B'Q-P3Q[PMQQB<?G
M6"S>2XCP^:95D^4YS'!<'Y=/'9UEV45LMKUL)]6S"IC<KQ%19C4P]&EF*EA7
M5=&'+#"T/PWCG.L?QY@\URO-W'%8:$<NP^%JXG,:%>./Q-*&'JUEB<'1J16#
MBZD9*4Z\O9*<[RJMWYOYBY=;UVU34+2WO9C!J-RUW>RA%+W-TS%VD>1M\I9F
M+,Q,A)/IQCV/X#? ?QY\;?'6BZ1H6EZF^CG4M/3Q1XAM[.6>R\.:=)(9);R[
ME)^SI.8XF^SI(Z.[#"C.#7W/H7[$_P ,;;54?QA\=_A^ND69D::RTB8O=WZ%
M<A8))IU$<I+ EEW&,G!P<X]\^*G[4W[/_P"SG\$A\/?@!KUC%J,2[-673K7?
M=ZC=I(-^I:KJ32,]Q.&+V]O "T4 +..3FOM.+/&K'YWB(95X;Y#FG$W%?$F,
M=/%9WBLIS+#95E4\:I.KG&:8RM@4\3B(+WZ%%1E2JUG3CB*U*FI*7Y[EG"%+
M"Q^L9]C\+@L#A*494L(L33J5*L:4H3>%IPC/DIPJV?-.G&,H\MHQ=W?YJ_;C
M_;!UCP?K?ASX8?"[72ECX#*:)IOB!S%/K4.EZ=;VUHEQ;O(NW3-7>=)9(KV$
M+<6^Q'CD1BK#Y(\<?MU?M7?$[2;'X<CX^_&[Q+\/].0II'A/7_%NJZY>337J
M$WRSK _VB]$TYD%O%*TPM[4+'$%5"3\7^*?%-]XX\2ZQXGU5C)=:M>37,A))
M.Z0C! P#S@#L/SIWA;Q1K/@KQ#IWB30[NXLM5T6[CNK.[M7$<D5Q%]S!92&!
M4E&5@5(P""#7[+P+X?Y=P+PC@<ARW"T*F-P^#G4QU6JXTXYEFN(3K8K$8N<*
M4HN5?$SJ<]2-)J//*<*3OR'GX[CS/\5B:T*>98O#8+Z_#$X+V,YJME]&*]F_
MJ%3F7L/:4_?J^SY95)1@G-1BT?T,_P#!.NU\5> ?AM\?M4\0_''XF_ /XAV/
M@VW\4?#J^T]X-8\,^-;JSM[R4>#M2TF^$EQ!J=U-,L=K<&6)N)E8'(4_'7Q^
M\2_M*_%4PR?%KXE7WQ"L1J<>M:6VL-%8RZ7/>0+'-%8Z:)7CMXF8J9I ZI+L
M' DR!]7?\$\/VBO"7QKB\8?#7Q]X%^U7MS-_PF&LZ_;0&XU22>TMKF%9H)D5
MY(M,MY9$EU"V39$X 9EQDUX]^TG'"OC6"R\.S:<]MX?NWTV\-LV_[78%VE^T
M,P8QF9E8(N"=A#*26R*_->&_I*^/7#GB7Q#P9C\_S++H9;A\%B\)AL90RO,<
MIIY3B<'&G"&!S&5&OF4H5J^'E35#%XN3PD*M/ZO"E2JNC1[,QX$X,S3),-G_
M -1IXW$8F;]O7?M\-7GB(5JCE.<8^SI2E4YY5:TU3J\\[+F5ES^6>$OA<)]-
MDN;S5[@?VOI5S:W;)"S166569HD4R9^U7*P[,Q@*RMR#R*^[_P!F[]H?X2?
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MC/(8\9QR/4XSQV.>.OZ8J>;1:/[[ZI[;:O9O;1]+E\EUO;M==TG??]>Y""6
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M,VI^$M,\.7*)::@D]M?S70^U0_9[^2>ZLH[.6VU"T%G/.1)CT7]J#X(:_P#
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MY7NW:_F&\,,#)P>2<<G Z_\ ZS[YX-2I]T?7/IT/3/8'O3C^8&< \ DXZX]
M,CKS^=1$!7)Z@#.3C/N.?3.1SU'3/(A2OU:L_+;1:Z+>[].VQGS-M7>ET^A8
M 5E.Y_GSP.< 'CY3[=SSP1TIC.N2IZ$$&0C.#Z>YYZCZ=@::')&6'3@'G@9'
M3U]_H*<5^4\@\=,C//X 9IMJZ5KJZ5T[=MK=K+T9<FKVZ7333MT3=NFE[;^9
M6)()QSVZD<>N#QSCZ_T>@R?N]>&)^@SCGT./KG'>FL&!V\$=3]#@=N>??_\
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M R&8C+=,<''3...#UY_I3!D#[I(W9 XYR3TR?3K_ (T2;@N[@<GG(("DY'_
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MA[1-#U3P[X7T'P)K6M2^!;/3=,TZTO=.TW4Y'C\J\NDB,UTB6^U$,S2%&!;
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MK^]=\UG:]Y:N[>]KWUO>SMKKK.LS22RW-_=7,S,")I+F5G4L-K,N&P 0-IP
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M32L2[8#,V.201DGJ.P_SSDHG1MRYYX8?,#T'(SG/;GCBO[4P&'6$P6%PM_\
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MIXTU[QG<^')-=NM.TW1Y+F*[T.WA-S)K-LCS0JMFD($@>28%E9S&&<!3]\_
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M9/&=_=E*E@01T&>.G!!&3D <X%0[&;[P.WC&0!E1_%GW]N/QQ6C+ RG<5;.
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M&TV]%UU>GEY]+;;/>W8LTU;:^ZVZ/JW_ ,%KKT8W8D8. =W'/MCG_P#4?R:
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MA6ST)R!GYNG&0,G:,\\@']*L0KG&X'.XY!8G( Q[CM_3%&B5D]K>;[[>:O\
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M>L$*(26W!E!V]LY/[M?F#<_C[/X=;3-&T/Q9IFM:OXOT3P_K'AN^>+3?#MO
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M\G'YG\.,4\ABF-H#-@'&.3U;)';@_7\:2T:O:WNOHK;?-V6G;J"35GT33O\
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MFTX9L%5'S8 XR#G /3GGGWQS7HU]X U?3_#4>NW%N8$FB-RJN"C"*.01.V&
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M'"\E5SC/(*C!X[U_?K\#_P#@A-\(O^"=?B#X+?MB?&K^S_B7X+^#VF)XS_:
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MWA/QK_8OQ3LHK5KR.74=4UF'5[+4I(8/*^WFXEN;>XG>%[R!Q%MG E=FP!E
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M<>_< G /L:86!P"-KD$CC=MZ\Y. 2!S@46;T\]ETT7O>::O_ )W9/L_/\/\
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MY1D=)XGZO@J5' 9CB\?2<IO"RK_6(8S,*DZ"]M5IRC)2GA:D:4J=7]>RS/\
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M)(42218($EN98XI#!!*R%1)Y=O;8S_ILIC(V#?':Q>;%&P_>!XKBYFA9YD=
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M4JHR3D8'&/[Q. >N#D YQTXJ4D'<<@$=@#GGN!C! [\U\XM'KYVZ[\NF[?\
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M+,^_:,GAG&W>Q!&0!P!Z'&#7)2L97DWY'.W@X!"G/'L> 3W'':M&=F8X[$C
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MU>E_E;7H_NZW8[2<=;M\W7M;_@_(K2G: 5/?!!)(Z$^OMTJ$.V.@QZ[?Z_\
MUZL29(#C"@\ '/)Y^9CCDG. .GOZ08QDGYEZ\]0PYXX Z]>F#5):*^OZ6:TM
M\O6ZVOH3:2MH_P ?+MMT^[R)/-<=<,1SR 25Z $]>.O''/J<TTDE=H.,$L6
M /)) SC/RD\#IC ]*%8-T7.,$Y] 1Z9Y^H]:=CMGH,\<\=03['I_]>G>32UM
M>]_71ZKNTF_^&'I)+IHU>W:SMIWLWVZ6N)DJ%(R"IW-SDD =?09SC/!P??%.
MWE@ S9!!X(R &SD_[PSP1T)X(H)R!Z]6]/0?D/8=:86 (&2,J22#P1]/7V(Y
M S[TT]+I]4[_ '*_2SLOPVZ%>ZHJVS]>^O;9)]%LOFF<9S@8.!QV[<9[CI1N
M(/ !P5Q^//\ /%&]>F1D=>M)G(.T \@-USM.,].>_%2KWMJDDM>C^'\]5O\
M+>\-[*+>G:ZOHNGK_6[8Y)'W0O('7/KG_#Z&D9F4+CJ<9SSZ9^G?IC%*XVD=
M%8?=R#W'/8XR".Q./T4#Y<DCMG'7@EB<8]#^?%-7OY[V\_=3?R_&[06=U=/H
M^M[:?/3\!Q!"@XR3_#GMQU/'7/:OTX_8L^-7A_P7H%SX=U;3M+U"PN[@2:KI
M.L!I=.U&2!9! ]TD+1S*(BQDB*-N$FTL2.*_,?(P3Z GCO\ KCZ<>O(JS97]
MS83)<6=Q);RHP9#&Y3!!SSM(R>2>AR>F.I^[\/.-:O G$,,ZCA(8^A4PU7 X
MO#2FJ<ZF&KSI3E*C6Y).C6A4I4YPE%6ER\CM&3MY'$&30S[+IX"I4=.\XU85
M8IM1J034'**:YXOF:<;[VDK-*WVG^V!X@T+7]4MY-)6WMQ'=2O L> 6AN74;
M4(^8QPARL6_Y@L?8'%?$_#K\HVD$C@_=/7KZ<C(_GC!TM7UJ_P!<N5O=4NYK
MFY'E1AI&) AA7"J 3C<,]>I&,GIC,9E((7IU'N>V0.U8^('%5+C3BO,N(:&$
ME@J&,>'IT:$Y*=54L+AZ6%I5*TE[KJSI4HN?+HME=*[K(\LEE.5X3 .I[66'
M33G9I.52<JLW%-MJ'M)RY5>Z2&8.2!_>*K^0./S-2I&=I;C.0#[@<-Z_X<'U
MJ/NF!DG.<] !CZ_EU/TQ5D,-FT9XP#CC'/.#UX]:^*N[*VMVM5VZNWX6Z'M*
MS6EOZ_*^^]^^I:@MR^'W''\6>02>0#SG!P?RXZ<[MO$"51%&]&^89W \=N_3
MGL,#H ..I^%7@]/&OBFRTVZ=8]-21#?2-(8R4E+)&$49+,'ZYP!@'/05Z3\:
M?AEIWPRUG2[:PN4DM+^W>6,1N6D'R@QR2YR/GR=JJ6 3#$@L0/KJ/ >?XK@O
M'<<PIT%DN!Q:P<^>;CB:K]I1HRJT*3@HU*4*U>G1DU/F4^9*+Y)N/+2SW+J.
M=4,CESO&UZ*KJR_=J.MHN>O)5M%U&EIR6;;;2/+K*'=( <'>.><< \@'H,>Y
MST)Q7IGARW"S()(@Z;' 'WL!>0V1CN.@Z_I7E4$NTKM8 $@[A\N#CUXZ].#R
M>WKW>C7DUG()'DP"J-$BN7,@;/\ RS&3D;,9(SWVX.3^?+(\QS7"XJKA(J2H
M)*;:O_>;EULDGOI?3>Q^L\-9QEV79A@HXF/-S55+6SCRQ2D^;FBTX[IJ^M]K
MZ/[Q^ /@O3M>\4:#J^M1QWWAK2-3T_4M<T\7 T^XU'1K"ZCN-6TZ"Y>*6.WN
M;JS26TMYVC=8I)A(PVH<_8VNIH&F:GXMD\+^'7T.PU#7+PV&CWE_%KLFC^%;
MZ[DGT6UCU2%(TN[R&TEMX;RZ*1K+(I?: V!\P_!.6+1/AC=Z[=^08[T>?973
M .()2VRX+R(3M=8R5,4P&>"%QAAW?@:YE\7ZU?:1!XONH'UZ6RMVTC08)IR;
M1@/+EO!.G[O86!1HV"1,R[CR,?GG!?AAQ=XN<2YID?#<\NI+*Z<Z^)J9K.KA
MJ.'A2K0IU:D:E*G4K5).4TE1CAZL5&<:CE&]H_WUFGB=P9X'>'N0\6Y_1KUH
M9QA:4/898G7QE2MF*]O03H\SHP=*CA9RIXF5N6%9TY.SDCV:Q\4>&V^'FIZ/
M=>)OLGCCPUKJV>F^&%@8I?:1JZM(^K6U\BRP7$NGW>U)[>X93&I5XP=I"_>/
M[)_A"75(_A[8W6B'55\0^+=-OO'/BW3YHKC6/">A6=Q/#/HQ22<N]CJ\317M
MP5MYC$L>Q%52V/@;QE\)8-&O9-.FTZXLM:LK,7.GR21107BNJ&6QO);BWP;A
MI9%621+AFBE:1TV\YKT_X,?$CXP>$/"K_&?PC$-%M/A?XGLO!.H^-S';326O
MC+Q#8736V@1VK,LEP^HV,%Y+:RS6<UO9-&IRJLH/UWC#X!8_P:_L'.WF7^LF
M1YI)T\7C*%"IA<3A,;AZ5.O5A5IJM6I2I8F%2LL-4I+#P?LU&5*-1W/GO!'Z
M163>/]/B?AVAA?\ 5OB7+G_PAX;&XB$L%B\'BY5*6#=:I3^KOZUAJT*$%"-/
M$2<ZBFH8A+V;^I_CU\,-3TSQ7XGM/ 2:[=^$X?$^M^)Y=/O-,>VM=8L+4RFR
M9+ Q-+>6.H,%MEGE06K@R*BY?%?A3^TA\/VBM[KQ=;7EK(UY+_:.JZ/91&WA
MT6349;H-8+:>5']DDLI8A%+  $BPBKTQ7ZZ_&GXN?&+4_!'@"^\>^*6F\:Z5
M:KIL6KIJ\-MKFN>%]7N#K>A:-K']G21&?2='3SI!--%"X\R-)&VI&@^;?C?+
MKGQV^'/COQ+IOPQTRT\'^$(+:/Q#XM\)Z9=RKI\KVRQ27'B35L>0L=U>R?:L
MS$N\A^0JK8K\'R;'UL+FF&K2A+#N=:G4Q=."DJ,8U*L^94TKI14''EOJDX-\
MI^M\:93_ &SP%B<ASN5&KC,)E,W_ &G2G3=../HTH+#>TEST9U/K$HQ<I*C"
MW/*%2DZB<7^$5WN5P,'(8#;WVAB,'&2<*,]3^0-9DLHSM"Y!]@/X@ /0?C6_
MJT$5M>W-N'$@AED2.5<$2H)'4.#_ +2^Q&<\^N#/'M);'L&R20I/W2" "<]"
M3Q]17]#8:5*5.+DG=I.#VNFDU>^K=M6]U?N?Y<9A3K4JM6FK7A-QFDU)QE"7
M*U?;5IK326ZT:9#\X^Z#D$C)QQZKW!/3/0GTXQ4S+E"N"2>>G(Y&1GMTQD=.
M,@<4Z(J><?-NR%XVD8 Y;)R?PQVZ5:$;<X^89'.=O ' /7/'![4YU5%V22ML
MVM]OOUZ]-5LCGHT>:+=^923371:)?+;7K]IK8S&4C&1MSP >3CIDG'';H!QT
MQ5"X3:S/R01M.0,9R.A(_'H?3Z[KQJ?O $9.<$@CT P/KZ>E9LR@@G!4 [7!
MSCH2!GH<^O0CW-:4JK;6K??735^O]?<<>+P]HVTMVMULNVGRV^2,&=B!M7(8
MYSD8QCT.<'/7TZ5CG!!9\J058<<$EASGOG)/;\ 1C>FC( 91P.&)!SU/3C&?
MT]:S+A #M'!S@MC^$CC'N3@<\%<^G'HP?WO9^MM_+\5T/GZT&G)W=UI9[[)W
M[?/MMI<L2D'2=/&UL'5=7Y'(Q]CT3J.H&?3'.16><@#:NX #!! QVZ$>A[#N
M>E:,T971K# SG5-6/_DIHG)R?3'K6?MX((!P ,$#&><D'D\YZX]<9R:;;NDU
M=*VCO=O2_J]=O6YR1;NT^U];^7YWU&<L1N&T@DXS\S #IP ,9/?WI2> Q3;@
M8*C@[3P7('/ SV'OVPYLE5CV\+\RN,;@QZAF()*@<#CTX[4 ACT#$$@G&,#)
MXYYZ8!P,$U5TK6NUZZ)7W^;Z.[>J\C09T1<@[AELOG8HZJ0PY?.< 8R./2E+
M!^S<,=H&,9'!]\$9# \XIVU0 ",A<D$X(')..N>/IC'?-,*YR01@\@]L=<?E
M[>M*^S2ZZ7TUTVU?7HFKZWOJR92:M;K^A]+_ ++>1XZUL-U_X1*[Z<*/^)QH
MG &!^9S]>P*/V6QCQUK7.?\ BDKW'7_H,:'ZX[YHJXNZ7Z;:=MQIW2;7]7_X
M!\_ZPRC5=4 W#-_>#D@X!N9<!>X..P'8]\8ST 8@DGL  .&Z9VD9/;DGH2:O
MZSC^UM2)3<O]H7AVGN/M$G.,]L<8/';TJLLBJ-IR,G _NKZ<]>.V1GCJ>M1>
M5M%>ZZ-M[+7UN]O^'+BES.[2Y7IYVM_P>OX$X<!N3UQMXR<C.,],=3D8Z<4H
M<9(W#:.@'0]]H],8ZYZY[8J%G3!R0'.2?4E2!S@$?-GMSW[4PN#M'\1R64<E
M?88Y'J0/KP:SL^S_ *=OST]36Z[[_P# _P U\M=BUN!("DC+9^;:0O!^8[>?
M8GU/3I4ZSA<H6(V]&'J>N /7)Y'U/:L\$?=.0#][)R6&.P[#W!ZYXH10SM%O
M*O(!L8X*HJ@CG .[H.W!P,8YII7O?LF^NCM?\'?9E*3BURZMZ-)V?>WX>70Z
M&RMKBZE2&VBDFFE)5(D#,[-GY=BCDD=,<=SZ5Z9I?PP\?ZA*\%OX4UIY(8A<
MRH+*59(H  QF8;01&R'*G)!!&.#S]1_L=_ _X@^*_A[\<OB[X4\3?"73M,\'
M:5H/@W6]"^(]W8-XGUNW\::I$@N?ASI=PAO+C5],%DLUUJ.GQB2PMYBCMMN,
M'];M2\6Z#X7M=+\*W&C^'+G6%\-Z3!J7B33--BCNM8EDM(WCM0"APUNVVWE9
MF/FF-=P(.1^">(7B[+AC-I9)D>687/<;AZU3#YC3CBZU&MEU6GA<OQK=>F\.
MJ<X_5\PP[BJ->I.;G%)6AB/9?HW#/"T<RPL<9BL1/ TYJ$H.I3@X5%*=6FDI
M>UO\5%N_(OBVMRM_@_IWP^\47?E0VNB7T9C/E2230/#'&X5LAW8!5.5P">IX
M'6OL#P/\.KW2?@_:W^FZI/I_B47ET+NTF1X5,'VUX%5I48.,2;I=XVAHV&"!
MAQ^O_B+]G;XF^%_AY82^)+KX/VB>(M0LGT/PA:^)?"&I>+]1?4%B;2[:[%E=
M/-93W#WL.8;SR1#\RS-'L8#\^/VA/ .K_!/QUI'P]\:"T\.^.?"NJ2ZAXNT"
M/5M/U5;N*[BAOK2*232KF;2I88;1Q"H#3MDF/Y&^8?7?1K^EAD64\1\7U\3@
MH5IXKAK-\MRF>1XN./Q,,SP?L,73J595J>&7U6=54J%6OAXUZ="K5HOVE1.?
M+Y_B'X78_,<!DV'IXV-.E2S+#8W'0Q,'[*OE[J1P\XTZ<7-NI&,I349RBY13
M;Y;*_P K>%8/%NL/JY\<:IK<?A;2FA.NRZ1Y^IG[._\ JHIT:XB98F8A68%Q
ML)&W(!K]"?@9X8^ 'QG\%>//AC_PDS>#[/P;H\WB6PEUW09X7U.]2W91IGA\
M*)1-/=%EW*T@WD@[E.%K[NT+X4>"O''[-_QRT7X;O\%?&?P/N]:\)>-]'_:,
MGM]-\-_$F7Q/I_A.UAUGX,Z9X>DN1K"Z5/J4DD%NVH1^1=7%I-?0%O.5X?RW
M\$>()? DWCJXU%'T2RTCP[']@TN33@HNKJ&5MGV6[E53;78!03-N=GC)(7<3
M7\^^(WC'Q;XZ4L=0S3BO/Y\1\)SRJ.64*=:$%D6*Q=3 UY*>7XG*Y4ZV8U6J
MU'$PG%O#TY0^L2I2@E+[KA_A;*.#YTYX+*\OH8#-%B5B:JHJ53%4G1FH1]M"
MHXX>DU-2I1J0YFXMQYN>Z\>U?]E+6[ IJ+^=INE73EK"76TCTMV#$_?BE!:,
MJ,,>N%=3]VO9OAK^SUI]MI]G=3>+O"=G<W45^&M]/NTUO7<6)#3&:PA$8@BN
M%R+9R[%L$XQ7PG\4/CMX_P#B%K4VH>(/$&H74DCNBJ]Q*D*0(0D44<4#QQKY
M<*(A*QC><EB>37):5\3/%.C7=O?:;J]]97-K@Q2Q3R1,X  \MRK9921TSR#C
M/.:^QQ'"'B#F^2T*6/XEP.&QDHJ<Z6'P;JTDU"2A2=>M_%]YQYJTL,KN#DJ,
M%)1CXE'.L@P>.J.CE]=T]8\TJJBFG9M./NR47MRPG&;C[J=KG]?'P=^'_P"P
M'\.?@#8^%_''P\OOC/\ M%^/?#.IWNG>*HF%UX>^%T-Q$7T+4O/%W9);:C I
MBDO+!;*]O(;GS+9W5"H/SA\2K'PYX9\):V=/ABBMI8+=8XYI%TRV%TL8:TU4
M9)DAD@FA\P9902Y4 -P/,_V$O%<?QD_9TUKQQJ?CNVUG]H31_B)I_@;PY\$M
M(T5[K6?$_@*73X[Z]\<R6]G"U[<2Z7(9X9F@*VXBLD^U*K/&3\!_\%&?VIKO
M0K ?"#PGJPGUG46$_B6[C@\BXTN*)W!THMN,L3QN&#@X((( X%?R?#P_XZXA
M\3<AX*Q^,P]>MEM%2QE?!XFG5P\L%'-\;CZ^:YC]6BJM.NY5)4:,<5/#S=.G
MAJ&'I4Z4:<8?IM7.<HR_(,?G%!3IPQK>(HT:SJ.I1K5,/1H4L)@_:P7+0IQC
M%0<%.,I<[E*4U-K\[_VF_CA<>,O$&JZ#I^IW&H6,5Q-!?7\P FU.]$N9G>;[
M\T<4F8X9&8@HH(XZ_'"1.9D2*,W$SLJK!&ID>221]D:(JAF=V;: JJ2Q(51G
M@ZT]K+)(9]0D,!F4S*K#S+N9FBCFAD-N9$>*&X6XAE2XG:*.:W9Y;4W+(8FC
MFN1&C16:BU@<,LFQO,NIT,D[(MQ=%49@(IE@EBMH[2SN!;PRR6?GHTK?Z8\/
MY)@.'<KPF58&FH4:%*$9648RJU%&,9U)\BC%2GJ](I)6BDHQ27\X9ECJV98R
MKBZ[:G4E*25VU".R@K]%=7[VUW/2_B5\%?$7PITOP/X@\3:EX<U32_B1X=_X
M2/PXOA?6(]1DBMRD0:+4G$31V<UO--Y<D"":5Y;:>%UMPT=Q7D%S>23?N!Y<
M%J) Z6T&4BR9)Y(R^YFEN981=3113W<MQ=);E8//,2(BSW%_>7*V\%S=7,\%
ME$8;*&>XEFBM(F8NT5LDCND$3,3(RQ!59CG;D53*YYSUZGC )]<$XSZ]*]3"
MPQ-.C&.+K4\174JKE5IT/J\90E5G*C'V7M*J4Z=%TZ<YJ=JDXRJQC34U"/EM
M)W2O:][.S?1M7ZJ^B\O.XUT (4@9'((;Y@"".0<X/3 [<557AVR0V,@$G)(S
MW]QT_ 8R:LN5;<"<'!X )'3!.<'J#D\?0U'&(V  (8D $;<-Z'GWQQST^E=/
M1_TD[K\TF*7Q:))ZMZ]-NFZOMZ:%61LL?F**" ,]._ ZGG)&<?\ UD&00 @Q
MD=^N3U(Z\]>_7G)J>58QM'"[C@=\$<\_0=?Y"D")CU'3=W!.1GIVP<8'3T)-
M5S65DNWEVOM;?7K?N1RMRN[;KK^'W=[?<(%R3NY/;&?R^GIBGXVK@D?Q$9 )
M'4'_ #S^%(HQC: 2,'C.#R,'.!W[8^AP:KNV"2%&1D9P03NP,'C  .3G/'3%
M)+FTN]/FNBZM=^W^0<Z7V5?U_P" #X#'(!'& >>#@%P?SR/3-*-V5R<<+C(#
M'&>QQGGK_+/%-!ZC(*CH2>5SR?P..N3^'-*Q;)VC"D8W#/R\9^48!W'Z?G6G
M96OIK\K:_<W=;O;8A=/)^G;KT_0E+/N& <AAN). !GE6.,D'&1Z\#G%,8[F^
M56;+D \ <C*KGT&>![Y]:A;.T8RN2,Y_B/?/)([\@9]C1EAGIU&=O!7!P3UR
M1U/0'Z4E&WGTT6][;Z]+;?J-RNMO-[>2[+_/T0]8SL?[V.=QP"HYQSZ<@=?Y
M]#:^=O')X(()8]AQ]WT[]/2@9^9?F.06*LV<XZGJ1[>GTZT@*L 0&7##;NZY
M/ QSR<Y S[4=;O75/3SY5?NUTT6K[.UI=K=?6]OTO^);L["XO[F*SM;::[NK
MF18X+>"-Y997<[5CBBC4N[EL!1CYL\\XK[G^#/[$/C#67L_&'QPN[?X0?"Y$
M_M"ZU7Q1,NGZKJME;^6\L6F6$VV0-(CC$DI0@ E%; %?&'A7Q)K7@_6+3Q%X
M;U&32];TZ4365_$(YFMI58$.J31R1[P5!.Y#@XYKM/B-\</BU\54M(_B!X[\
M0>*H; ,EE;ZA=O\ 9( Y)9HK:(QP*V21N,9P/; KY7B/"<5Y@Z67\/YEEN2X
M3$0J0Q^;U:-;&YQAHRBTEE.$E". A7>CCB<74JPI/WHX2;46_6RVIE&%MB,P
MPV)QM6FU.AA$XT\)6:<>66)KJ3J\D97O1ITXJ22O42NGZO\ M2>+?@;J&H^$
M? _P)\*:9I_ASX?V&I:7?^.X8;J/5_B)J-[?FY&J:K]IE?*64(2TLRB0JT(W
M>6,[F^4N"3R#C([?+GD_GWS_ (T8)1=JG<&(.3D,.-PR,$D=<'CVP:8%X[=<
M#:W)*\@' &%..V3ZU[&3Y53R;+<+EU+$XW&+"PDIXO,<3+%X[$U:M25>O7Q.
M(G9RJ5JM2I4<8J%*FI*G1ITJ,84UQXW%2QF*JXF5.C2=5Q:I4*<:5*G&,(QA
M"$(Z)0C%1UNVTW)MMMN) '89)RW)Y!X'7\L<<'U%2*W*ECMP3@=<]>.G.>34
M7[P$$ 8[KO)SGIC( !7]<XS3G) !'/('T!ZGOT/Z>]>C)-VTW=]^FBZ:=?/3
M[CF4E%-^6W?5:7UW]!TG'.!M+;LCHA&!MP#GGCC..">E)E0I)(Y;KCD8'0D=
ML\_GG.>8A*6R-FW&05SP/7OSCD]1][UX*MC.<\ \GC)SG/3CH.>GOFJ2T2OY
MWZ[W\UKZ[=-P;N[KK;\D+A0#G^)BP[X/&"...,?YX"@D$Y)96Z1CC(QU]<GK
MCC)IJLI9L-G('Y#<>"3TYY]/3T<'7)XQDX!/1CV ZG]*5FE:S?KOTMJMK>=[
M6TTU)=]+*_?7;S&9 (W'&"0N!M';.X\D'H,^YJ4E3M(QP 3CUP<]L_7@?I43
M,K;6RP3D,"."0.AQ[CC@\>AZR*2W4$' XSG@]/;/'3&1TIM[;_TUK96;?:RM
MKV8_Z_S#KCY0,\ACC)'TYZ8]#GGIQ@!  .W( ]AM&.&X]..!ZXP*"/F )!7:
M22>@]N "#T__ %BF8QTQ\VWZX/;D'UX)/('0<BF]UY?/JKK]'IL_4"9RN% (
M)Z[B#R/09QTR>G7\.&J1E?NX50!ZC  &",9R>.W7&>*8-Q))P1QA3P!R<G.#
MD\<?SZU*@*D9.X\$9'0GUR1U'O@4K)*RWUVW^;2Z7_R3*NW)/NUZ=.GR1/G=
MR",E>23C! '*^GH>G6D1R98]G[LI_$KD%I "X8#U)Y &.<Y[5"S ECMQ@G/O
M]/\ .*C8D<@D_P .W;WZ YSR#Z^WKG,PTE=75K-/JGONNMMGT[7LAN5]'9JZ
MO_>MK;;9]>YZ8/BEX[^R6>FQ>*==MK*RC,%K9V^H3I"@8%)<NCJV6!*LA)7'
M&,9KC6>1KB9SN:9P&D9QC)(+9)(R<\DG]3BLF-V#@G<#GKSC([CKD=@#C)QP
M.:OW%W)<2++/)DHGEDJH4E8T)C!P!GG@Y/0\]ZO$UZV*KRKXBI.M6J)<]2I-
MRDVDK+75)6]U:6T25M#' 8' 9?1J4\#A</@U5KJO5AA</2P\*M:6E2O4]DH<
MU9W3=2:F[;_"CJ_!6LS^&O%7A[7[42276F:KI]PD43%6D"SQM(F5(PSH6C.3
MC:W(QS7])GC*UT\Z=X(E@74E@U7PQ8>)K>[O96F?[#KEM;7L6GV\$KO%"+.<
M7$4RQL6VA28UR:_FV\!:]%I/BKP]J\VDVFK+;7]J'T[4%86=QO/EJ)V5HSA2
MPDSN'S*.< Y_JW^'ND6WQ<_9NN-"T*_\-SZ[\*-(;QC?V-O>0-K%U,\<27-A
MH<SDS7%I#93%Y;1I6CS"C1(LAW-^2>(U%5JV70=.,9.CB'"JY*]24)TI.C;[
M/+&\E)_%S.*V9_H7]"[-:66Y;QI*IC82PLLYX>C7PDZ52,<##$X?-*$LUE6<
M9*<*LZE+#U:=-2=-T(3J<L:D6=?^Q-XD^$O@GXB6>L?%RQTGQ!X<NX-9@TS1
M+^":XFM]6L+.:Y@\R 8MH)M0<)#833AHI)OD^4@&N[G_ &K[GXA?&7X-_$".
M-_"OA_3_ !9/X9T[1IM5O-2O=&M-8E^P:->WB.@MK>"RNA"-1L5#0I"=I5LD
MGY5U'X:^/_ DOA_4O$OAZY\,7&KV.GZMH)U&2TD:[M)V5X+TBVFE\@.6#!9M
MC=,J#P*.F_"#6_'_ ,0O#_A/P5%JZZSJ$L4FJZC8K<R6^B727BW']LW A\Q8
MV60YA=_W3, C,IP*_1?HSYQDE/BVGD.>\/U\3B9X;&2RK&X9*^"KU%&5?$9A
M"590:IX>$U2K5(_NHVCR2Y[K])^E;P3C,WX5Q?&_#W&."RZA#+_JF<T\P<L1
M@JF3X55Z=?#97-)PP]?&5ZU&E75.]?$U*2A!P<$W_3?\3/AUJVC^#/AQK]MX
M(\.^,O$VH:=XJLOB!!ID-K%IE_>ZC=RRV>K0V[1!<+ 0(9X51F^Z3P*R?V5_
MVBKCP+X+^(7P@\9Z1?Z;-IVB3'PCJ5I;VDUWH$D_VJ"1[,L@N9)+=Y%W+O8$
MJ20037C?[9WQ:^)/P@^%7[,W@_1=8M+/Q+KS^'_ .M^)I(W-]J5W'I\C37UQ
M'&R(LL\B0M-(=T:,^';)!KX"\4>)OB_X.\70:8WV3QIXG^R->S>)M%>8V.DV
MMS K78UKRV:%=0@W*K6[L$S\WSM\Q_7N-O[#JX7&Y7FN98#!YI]4Q6;Y;6KP
MQ"A.CAL37IJ-*;Y<.^:FW&CA8U%54/9MPLHG\9>&7"F=<6<)X+%O _6<IQN;
M3PT'*NH8BGB<OJ4W5K5G6DHPP]*I6Y:\[2<K\O+)Q:/T^^&OP]\>0>/?$&OZ
MSJGC;Q'X=.DZ#?\ V[6)7E\/RS3M)<C6(;&*3;;Q6KH%FC6-3*S8<,K\>Z^"
M-<\/?"CQ!=:]J]Y!:V%SJ/B;7DDUU6LK"TU"ZC^S0:[86<>6A2"-V,)=!YHD
MPN" 1XI^S!K9U3P/I3?&CQ7X@O##:/-!X)T[6XM,UC5]-TAFOM-U%K9G20V$
MDH^S)8RC-X&50FT@MY'^TE\;_"VH_#3Q5>ZAI.HVOC6]F-KH-GK 5;VVT&XD
M:2$S*OE"WBC@58GB1 \C.2I.U6/\X1Q&&PF!AC,/44DIRE2=52C/DBO:1DX3
M7.G-?#%J]FW?:_ZG+(LWXHXICPO/"KV,WE^3U:F70IT:#I3<\*IT^54H3:4*
MLJE:E%T[2C=W;4?C+_@KO^T?X'N_ /PL\"Z+K%S>B#5-8U>75[&96&NW-QEV
MN;Q(6 $$;2$6[29?)^8Y&*_ET\<^+I->N;F)#,L3S/&%W;F&U@023W<_>.><
M]^<^^?MM?&6X\;_$RST>UC6UT_PGIEM90/'<EVGDE17N P1C& 'X#$!U&%<9
M7<?CG3)8KFZ4.26=@27;=R6SG=TZ]QGJ.]?)QIRQ59YK7AS5*T:<H.[:A%QC
M;ENG;5M*5DVK76I^NYKCZ'#>#H^&^48EK#Y-4KT<PK2Y55Q69SQ$\1BY.<6[
MPIUZM2DH*<DZ<8<KY4B[::-+=LRO%D-P)&SN4<%F/<\G(7(]JY;Q%HAM6+.$
MVA7;?G)==VQ>P^8?Y[U]%>&K*WN-RE5#$ +R-VT8W'I@ #D>I.<#&*Y;Q[HM
MO:02W9=&CFD<0VQ*F51C#.,'H/O'&2<''3%31S*4,;&G%3:D^5*[2U:7:W7^
MMCY'/.':<\IG6482E"$JC?6+BKMWO?5]%KKR[7O\C:K:E"Z%"1O#*0,Y&,@C
M)SC';/48Y-<A<Q*I/&1U ( Y).?Q&3R,\=NU>@:X-MQ*"'(5SM7=N*@9]L!3
MQZX&,#-<+>'>QP2, $>BG)!P,X(([^^>PK]*P<I.E2G+2Z6EW_=V:[NUVO/1
M'\K\0X>E2Q%>,5K&326FGX)::VNM7:_4P)$52<'A2"V ,D$_PYQD\8]CT'K2
M=1@C/RY.-W&<CN#TQQD#Z\UI7"*JMR1W//)!X/'Y\8K(=CM; 9?FSU4\'!(Q
MSU'H3DYY[U[E&7,KM=/Q5M=EWT_ _/,2E!N+CLF_.Z2TMIIV;Z:=RJ003C:W
M(P 0!G//7J.?H,?6A< ],_J!ZD@=:&95&>,+D+N Z,._4?0<GWP.("06 &5!
MR"3@#([8SZ9SZ?C71ZZ>9Y4IV;ZOKK;MY>?0FD&7 )*#[JG. PQG'0\@]_>O
M8?V>W(^.?PD"D@_\+"\*!]PP/^0O;?=ZY]N!]*\7Y)/S=N W3/U'^?;G ]B_
M9[S_ ,+R^$9) _XN%X4&T''36K4<],]R>_/X4_\ @>5KZW[OKT[;Z$7O)-K=
M_CIU\M_PZL_VU:***[SD/YPO^#J<@?\ !(_QSGO\:_@N!]3KE_@U_E[[P,??
M . 2H& 3QGV(/)(XZ5_J$?\ !U. ?^"1_CD$9!^-?P7X]?\ B>7_ -/_ *W6
MO\O'RF)^7&/4D97C.& SR/8'U^F%3XM[?K\/_#?,UA>VC6[W5^WFB<L?XMQ
M(#  ,3Q]\^H'\\\<4H*X92N[.3NP%(X SUX]1_/BFCD <DJVTD8'(QG'M[<
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MOKIYNW3YO5O2\4TCR(-JY" %@."=Q.2,8!_S]3CS D%N2" JD]<@C (&<%2
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MRY6=U6 J6VI&N\-)(R1QAI'1&I>'M-TO1O,N&#74$(9FO)HPEK;R1O,RE8I
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M_6Z]!O4C> N "2.^/ZY(QG)P>@.< 9@67Y0,;L,<9#?=(QQG_/%(RD-NW #
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MM\K7U=EJ[W[;;,:C+FV;:<;WU>MK7W3OLK:]>R/]LZBBBN\XS^<+_@ZG!/\
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MWR.V">YI0-H) ^Z>F?3DGD].#[^E6E;3I?3R78$DMEOV6[&E<LX (4$$LP!
MR,D\\DD^W _'#">25! Z>^#W[8XY_K3P)#(RY7 .23G[O7L.O(//\Q36R&8
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M)H3>(S:Q16>H062C19].N+H^7%()7ED#JHD^T(JH3@X_6?\ X.7M,_9;TO\
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M ?PJ;78]%BT[XG^ ].\8^$KOPYK=KK6FZYHGV>.1IY)K51$M_9R3 7EO)N:
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M!QE>H';#=<G.!],TK=,G)!4!@G)P/XES@'DY/3 Z4U6!RHX+9(((.!Z9&2"
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M&\ 7EAH2^'/#&LW^IZ?=)91IKDJ7KL3%->*#O0 @LHQ\PP3@*!^HX3&X^C'
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MSKT5.-*M.G"56G&:BJD:=1KGIJ:BN?V;BFDKI[EZUN$M)X+EH89OLUPLCQ3
M-%( > Z;T8H_1@K9.>W)J&^G\^[GN5BBA2>9G$,2[8HMV"4C7<VU%_A!)(&.
M35?./QX'\_Z5&Y#  9X)!]><=/\ OD^G:K5M'>[M9O1>>WK96\]39U)*#@FN
M3G4E%)+502O=:Z=5MKKJ!!8=1UX&"..QZ=Z?GICU/Z _U%,SLP""0>FT;F)'
M7(R.,=\^W<4K,N#C))[$8Q@=NHSVZX]_1.]TM?5:ZZ:^77IYKJ1SIZ.]_)K?
M35+H_P K];CUR -V#RW'^]USU'?_  %*2 <\8'/'3 YQT[#CIQZ5$@QRVT9
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M#!PV0?E(P>!R>IZCL,8X]ZK7:S:TW5^D>[7G?SUZ,XVX\U[]5H[7=DO/?O\
M>..0PV@D@<J1P>Q]>1UZ]Z0L.3C"],=3G^1%(DJN-P&T[AG=P3CKD GGI^.>
M:A8_,<$=3QD>O^Z3^M.VZV5UVV5K^M]G?_AWS)+36]O2RMY:WMN_NU=["$=
M.-P!SVSGWZ=S^=&1TR,^G_UOI5=3SMZ94,>/?CU.>YR?Q/6FE""7& H;IDYX
MY]/Y4-;:V2>WW:=/-6UW^0G)Z=+=.G3^MRWC/ )SVQCW[GI_6C'M@_K]*J?>
M[?KU!R#VSV[XS4JR*V1G!4X !SG&>OY?D3TH:OU>ZT_IZ=]+>C=A\UWJ[+31
M7U:Z;Z=7I^++"@G.,>AS_2C<1QU [<<U7+$D$CD9QABO7KG&>U"C<3C@<@9/
MKD#U_$DT[Z7VVW\^_P"OYE<^OEWV[?EJ3@!B3R/EZ$ <CZ<'J>GM0#SGN,8
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MQTL[-6=D[6N^[3WOY;&WY[ X.2,;MH'&XC[OJ-O4'@\9[5GR3.2^"<$G.>"
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M];?YFB", M\I.#@L,#'3'3J.:8YVKE?GQMQR,J"""V>IX.>?7CL*@B8,.I9
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M0ZU5[S?W+_(_AO\ ^(+S3L_\I';_ *8_Y-*M^A(/_1R?J,TA_P"#+K33G/\
MP4=OR2<_\FE6N/R_X:2Z>HSS7]R-%/DA_*M-O(CGEW_+_(_AL_X@N=,&2/\
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M,N=,(Q_P\=U ?3]DRW'/KQ^TD#SWY[FO[DJ*?)'M^+_S*]I.]^9W[Z'\-_\
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M_P##RAACL/V.UQZ=/^&I?3'&>HS7]T%%')%]/Q?^?W]PYI=WK_7R^1_"X/\
M@RR4=/\ @I3)US_R9XO_ -%)[T'_ (,LE((_X>4OSU_XP[4YYSW_ &I/7_ZU
M?W1T4O9P_E_%^7GY??J2?PM_\06*8Q_P\H<<8_Y,[7^O[4IYIG_$%;#D$_\
M!2>0X_ZL]'_T4GT__7S7]T]%/DCV_%_YAOJ]^Y_"S_Q!71 $+_P4GD7/!/\
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M )B<4^GZ=NWHON/X5A_P95PC./\ @I1)R<G_ (P\7J>O_-TE,;_@RJ0G*_\
M!2IUYS_R9PA/Y_\ #4H_.O[K**.2/;\7_F"26WYL_A1/_!E0A _XV5R X )_
MX8Y7MG'_ #=,".OK3Q_P95KM"_\ #RMR/^S.4],?]'2U_=711R1[?B_\QG\*
M8_X,JE!X_P""EDF.>/\ ACE,?A_QE+Q2K_P94Q+D_P##RERQ.2W_  QTOY8_
MX:EX_.O[JZ*.2/;\7_F*RT\M5\C^%C_B"MB_Z23N?^[/!_\ 12]Z:?\ @RLC
MVL%_X*4R*3GG_ACM3C))Z']J7WQUK^ZFBCDCV_%_YC/X5E_X,K0"-W_!2MV
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3 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>nt10016217x4_graphic23x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic23x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MWD(A!,NX!F81K&6&2Q(_@ST/VYX72=WC2Y\DR9VMB3)$FYA(0#G W@@9'3D
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MSJS5&53%2K\$\+5'&4HR<5/%3RB5>C-J*:4Y3A3NIRA[RO\ HMXD_P""]_\
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M97/@69OB'<^)+R,>4\$2VX.<JJ*/D<'D%I.0  NW!QR2>Z>PT]CN-FFX."2
MH)8!N<C&1^\;@GH3TSD?:8WCW-)T<GC0S7,Y5,-EF$AB:M''5Z?UC%<O-6EB
MH^T2K33?)*;7.^7WG+=_RAPK]$#A*GFWBG6S?@K@O!X'.O$#B&IP_EN;\,X+
M&/*.'%7]GEL.'ZWU6I6RO#5*3^L4:-&;PT(5(_5X4E%0I_:7P^_X+G_\%I;[
M6+N+Q5^V5<26*Y:UC'[/'[*L 9%Y(>2V^!L#[B>@#G  &=QW5S_Q:_X+N?\
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MM/2-Y#A!N)Z#U]AGJ3Z"B[[O[V%Y=W][/W7_ .(E_P#X+;?]'J_^:X?LE?\
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M_1ZO_FN'[)7_ ,X:OPEHHN^[^]BN^[^]G[M?\1+_ /P6V_Z/5_\ -</V2O\
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M=]W]["[[O[V?NU_Q$O\ _!;;_H]7_P UP_9*_P#G#4?\1+__  6V_P"CU?\
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MA_/_ !HSC^5%WW?WL+ON_O\ ^"?NU_Q$O_\ !;;_ */5_P#-</V2O_G#4?\
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M/V2O_G#4?\1+_P#P6V_Z/5_\UP_9*_\ G#5^$M%%WW?WL+ON_O9^[7_$2_\
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M)+&8?&>W5"MF&(3C&4\1.@XTZ3H0PU6RJO['U"PL;BWBNHH!<-#D2*9"KP@
M@%D R2>X_GGCC8KT6[&90UM+G<$8N!R<X4X!QG@#C\*Y31?&L@5KB"99EG !
MB:573:0,,,$]<YW=<\_3JH/[/UD-(]W'%.WS;93D;FP6 [X!X!)SGZG/XR\+
M6PG/3Q*FXI[M3YH[<T)0UM9MW;2T6US_ $E_UFROBCZIC\@J86CC)T^:5.#P
MU.A7E&,(4L30QEX.4Y1CS>SE.7+.36D;15ZUU[4#<H[,Q5R-PW,VY2X&#U&,
M#D@@\5Z/J&K0I!#;^4\WGIB41@XC!'L#Z],\8]N>!M],M+,QR2W,%R 1\D;^
MAZ$<X ].<'KSFDO-6,'FS"0*%! (.#@\!01]#P,<#FN*MAZ5>I3=.%E#9)."
M<KQ45_->*5]NUF?9Y/GN9Y!EV8PS#')SQOL>95)T\7.C2C%U*TK-^RM7C+D:
MYG:/-)\K::Y;Q?/"+:2&%P)"[% @)4  _++N&3UQ@X(KY"\<IJ6J/!HMEIUP
MUU-*LZ72+YB[5WC8B0;KA$WA#)*5$<04.^% 8?3GCNY@N/#5S?6")_:5O%)-
M*DSE(96"D@N_\!SC..>*^;_V<?&-CHWQ/M]6\0DW0"2R0M=1+>)#-YF<HD_F
M)'N<JJNL1*@;5>,.Q/ZEP9AZV$RW-,ZHX=XNME=*I.C@KRC7Q&(IT9SC",XM
MJ,)*UN:E44[W4.967^<OTM>*H2S?)N$XU%1AQ#0IXF684N26!HX&5>E!TY0K
MX><WB8U%*G4>'KX:="UI3E2E%R\A\6_#3QEX4MX;[6M$O+*SNB((;B2"=4DF
M$,<QVN\2*R,':)2"1OCEB #QL@\W*LK 9 .,@YX_/_"OVO\ VLOBGX!UWX>3
M*CZ;/J,X\FT#QQ/<1300*66(^3*RB:-)PI*8(<(KB3)'XMN%>Y<*!L"L?NCH
M.<@8/;ICMP"#7W/ /$^9<69&LSS3)YY-BEB:M!X>4IRC4C3M:I3<X0DXZ\DF
MU:4XR:LFD?POQ9D6"R',XX+!9@LPI>QIS=5*,'&3;4HM1;5VTW&S6C6KW+WA
M_5KW2-;TO5+.5UNK&]@N8#N8CS(W#*" >58_*R\ J2,@<U^O)\130#1KJ>,V
M:ZOI=G>D%B"9)(E,H:/ ,9WL6Y'*\]S7YX_ /X7/\0/%]F]S"T>B:1(MWJ%P
M\19)VB*O':J^!'F3!+@!G4;0V/,S7UO\9_B7X+T6^TNPL[Y)=3TN2*&XMH'R
M$LX6561RH8*RH" 6R6^4*.0:^0\0HT\[S[*<CP&%J8S'X;#8NMC9T8.2PM'$
M>Q>&IUY)<L>:=)U/?=H*4;6]JVO[\^B)6Q_A=X1^(OBOQ-Q#@^'.%LVSSAO+
M.%\'F.*A0K<0YKE-7&+.\3E6&G>OB%@\'CJ>&J/"J/UF2J*51K!*$_HV/Q#9
MMY*+.,A(RY)&TD@\D@Y[8Z?3J:J7OC71;1S:R:SI=I=.VU/M-Y#" =I;A9'#
M;L*Q YY![@5\I1_'KP7J$DEKIEOY$GV;>EQ=M)"K2QQ$LJ*\:!W#*RJC$;MQ
M*ANM?#OC#Q%?^(]8OM6O+F61[B[F\E"^%AM2\C11HB85%".%8?><IN<D\U\K
MD7ACBLSQ%>&91Q&54J%.G->VP\*E2K.JWR*,.=0<8^SE[2\E):1Y=;K^@O$_
MZ>^ X(RK+:W!-?*..L;F.+Q.&JSR[,L;@<+@,+@J=*&(<Z\L.\3"M76(IQPL
MJ5%4YKVM:-5JGR2_8[3?%NG7KO$EY;77[S*3VTJ21$8#'+*Y&><XR..<9K<D
MNK2[BD82LACP&<H55L@X"N>&Z8.#QD;NH%?B-HVOZYI<A?3M5O[0J5?]S=3(
MH8' .S?L)/"\J1@@'BOJWX6?M*ZE8/%H7BR*.YLIY$MUU%AAX6?(\VX0\$(=
MH$B@;0&9N.1TYUX38_ TI8K*\3',/9>]+#JFJ%?D5N9THRE5A-V3]R,XM_93
M=D>5X6_M$^'>),;1X?\ $/(JG"M/'RJ4:><?6JF<99"O5=L-'&5*5+ 8O#1C
M4FN;%SIXB,*;:JRA!2D?<FO^ ?#?B[3S;ZQIMK=(PP4DCC?S ,X.XJS(W0A@
M01U/7%?&7Q._9;>R%QJG@L3NREI&TBY"E%4 G;97)5BQSTCD[_*K+D%?MS1O
M%.CW-E;O;3K(LJJ04;>C*0#OW'MSZ  'K76*]M>1E48.CKS@[EP>.F?E.#W^
M@ KX?*N+.(>%L3_L]6O]5C4:GA,0I3P\DFE)3I2?NOIS4W&IVFK6/ZSXZ^CI
MX&?2%R*,\=0RBCQ+6R^C+#<09+*C2S:5>K2YL/.GC:,80KQL[N&*IU\+=ISP
MU1R]JORB^'VHOH6KGP]XML;VQW3")B-,BN-05?)D16C:5X4=(',CNJS2G86$
M2F3&?JF*W?2QM%M'Y1Q<VUVGF2M-:RA_(WB$"-8Y-C%59]Z,-I+[@3[MXF^&
MGA;Q-&B:CI%O<2 ';<JBI<1.,F-TD500T;,Q5AR&)(.>G.W?A/Q9H^CPZ;9W
M<7B#1K,^=!9:E'%)>6K1ABWEWA'G3JZDADED8$9QM)Q7Z<N.N%.*:5*CFW/E
M.-<>159+VN%<I-7M.*]I3O)>[[2"Y4[.<F?P#C?HA?2"\"<RQF:<!X:GX@\.
M4*JQ=:C@(RP>;PP\(.:C5PE;FPV*E&$^1SP57$*=2,I.A3@IH[/X>>+--?2F
M@U]1';66)84.])YI;@QQ1P0K($20*A:23>6/WT\MS&2OOVG:MX<LK-]2L3*T
MEVI6.V8QG[-&3OW/L'DOLD!*&,JQ! ;V^3O"EWX8U:1+0&WT_5+=[A+FS=5C
M:.9E8^7"C?*B$2964*#)M<'ECGZ'TZ+3H=(G;3_*N9EC,<MH%:653$-KO$Y3
MRRI*_(Q.50!0, X^(XAX0HSAB,5D-:6+JT:T/:8:<)PFX5(TY1K4>>HZ=2$X
MRYHN,=;\RLC^G_ WZ0^8X7$93D?BWE^'R;+,QRY_4\]P>/H8M4JN$Q;H5LJS
M7V5*IB\+B*%6$Z56C5C&>'E1493E!Z]'K'B""Z_>P^1)#-&\3JS11SJ V58P
M1,6C5I5$X#1D,YQ\V-PS/#^H6-A>OJ-_*TJVH1+:V$8D>1I/F#&.0;/)0 EF
MDX+X(!4X'S[J?BZZM=>5([::VC+*)!+E4.WAB5;"':I)R@QE2.<\^PVACEC9
MOE+,%*LP) X#$C (^;.,X/  S@D5^;9A@L5ETJ%7$1]ZJE)0DE>$H\C<9Q3:
MTYMVVVOB70_O'@'B[ACC;!Y_@,DG6GA\MK0PU7$47.,<;@<34J1HUZ,Z]*%6
M]6G3G2G4]C3M3DE%N\7'8\8:NFO7BZLL4,1E)#1P6ZP"-4.U-PCQ&6* Y*C
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M@@<8.>*^3SKQ5S?%8J#P=7ZA3BG"-#"2]I=NT7*I.:_>M-OETBH\JY5=W?\
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M4D?R/F?".)QW%N;95PCAZN.PV#Q$I8>5-.*C2]V2:G4Y=%--1EWVVTU/ ?\
MP4B\8>&/ B>&]0A:]>TM@A$0:&2><V&G6T:+*) !&)H[HS#;OVB$K]YQ'\1>
M,?&_C?\ :1^(EN]^C3ZC?SB#3[**.:6&TAED! P%=U5-Z[YV0+DC)&<U]O\
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M&;X&X^S_ #+-\<\P>)6-PT81I_5K*V&KU55HSKS4N:4*BA.-.,N6,G&T:?\
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MUU+&9G\P*#Y4?EC=#&K$/APNY>QSFOJRU@BM@D4:A(@Q^1>'&[D[<],$GGD
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MG32C",+)RY$ZK222;:=W90$'H?[H(Z=O4G!QUZXP3T]6WESLL)@5&V))7R,
MX*(#SV "[N^<Y!Y)JT]O(K[2A9FP0%^8D'!&0N2.G(/IQ]ZH]=L_L>F2F5PL
MTUG<2M&J@M$I4A/, 8D$C[JE0<$Y4?*6Z*4HU*M!--IU:2T5]9.+UMHDU>WF
MNU[?/YM2KY?E6;U:<X1MEF85*>KJ*2IX7$5$XS2B[PE%.SY8/FM)JZ/R!^)7
MCR_\0?$>74S_ *39Z)JS0V%N'_=B&PO-V\'! DN&A+NV"H!4$<&OU:^&/[2'
MA7Q_HOA[PE)I4EG!8W&E0:K=7L#H!/<30K%L=559(9' &_:0=BH #(6KQ?\
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MW1\)FWB?BJ&?K,,EP5+!3H4'A,1&4+>WG2ER\SY9-I4VGR\K4GS2V=F?O?\
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M1XK"9%AJ>88_$)U(X; 5*E5JG*FU&K&$*TE&FZ;7+)*W*[Q=GH?GC!&PD&X
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M$G.#QP?K^/ ';H*X3Q-\4/ ?A(LFM^)=-M;C#".S2X$UY(R@?NDMX'>3>6P
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M[CY<@YP>33%8J<C\0>A'H?:@>EUKII?]?N$P1U&._P"'K2[3M#=B2!]1C/\
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MR 2 ?49X./<>])1@CJ,=_P /6@.EK==_T"BBB@ HI2K#JK#!(.01R.H^H[T
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ML!4^T,DDZLP_=36\; #Y1!(1M"M@?*-IX9TR.WB@DM()([1?+M5,<9=(T^7
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M[.'C>YTK3=1%@D]O>P*(IX'"9$D@\F>220*(DC\Y#,9 %CACP[;R2/V"M?\
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M-#FXOK>WU;4+Y4NIX[>."U,B2[PT4.9JRT>]]TEU26FO7OTW%^!OP&'B?7;
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MQD%1@#GODX(Z YR>#7X]6&L7V@>.HKFSNO-CN[RUA8LRGS;:>:+AI6R4*,R
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M\K^C9Y?,N7MPV(PV8W)QG/0XR..?;G&.,BN#\0PR".>*0*V5;!'S=<'=D$C
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MI7?+*TG%-625KC****^Q/E@HHHH **** "BBB@ HHHH **/7W_3Z44 %%%%
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M%*J06 !8K7Y2_ G4]3U'Q1I6DPS,?M+M'+#"QDEEAVJH@M;<[2]R\LL7DKN
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M212C)"E&!YS@@94\BO@'XI:[!K_C76M1MR6LY;M%A*ON!6*,0DQ')'E,(\H
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M"[UW0(TOM+TS491&)KUY),0LMR+2627-M]H6WE@87"CA6 ,:?FI^R!^P'/\
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MPK;Z6?"KM"UN^GY6:.TS&6DCW%5W*WG*Z+F-FW)(W!_G$=MFUER"#E6S@J>
M&^7&#^(QZ]!5_7_''CZ?PO?Z)I_BW4M.AFLIH /->6+8\;ILEC+JK(0XRA!3
M@%D;)4_EGBQX9YUXL8W@>MA>-,?PN^$\QCB(_5XUYT*\'B:%559PPU6B_K%%
MP:C6G"M+D?(XRBDG_(GCI]%O!U:_$7'?A_@\#]?S++JDLQX9QE>-+#XFK@L)
M45.&3UL3+ZO@E7A&RP<I4,)&NW.FZ+J5)'X[_M%^'=#T;XP^.]/\+A3HEIK+
M6]BBRF6215ABVD,TLDDD;LQ(N&:02NAC'V:4B([=Q^S?XGL_"6E^*187FH+=
MW4(GLXECMBD$UA;7L,2K*QN9);G[2J1S0"95*2((0R-M]1^''P-U;Q%\7-.@
M\1FZU?2;O4M1;Q!J]G'<W3W-K;7 E.H.MO(DOVF5V(8R$(DR^:SRJ/+;]N/^
M$ \%V=E8^(M4T!VN/!=A'<Z/IU_%<10ZU)#,=.TV;5(IVDE@DAM846PAF,ZR
M#8YC$@+C_4K)::AE.64OK<L<Z67X.E]=DVYXMT\/3IRQ,^:\N>LXNI)2][FD
M[N]V?\ZN=X7$8/.<VPN.P4LNQ-#,L;0KX&44G@JU/$S53#65XM49+V:<)2BU
M%.+DK,_)[X,?LX:WJ]PNN>'[?3-(AA33HM3B07FL2>%K^28MI<UC=7%Q8F34
MIY[2YCNY/+O;*VM;@:I<B*"*9K3I?&V@77@/QS=6"Z'?V][ID]E;3ZU?-Y5Q
MJC2O)+=PW\]S*IM["WE)ET^&WMX'NX3*LMPPADGD_;'X7^$OAY_PC_BJ[N-$
MCTS5O$UMJ7C^VAT6":2;4;.PB(-MJ'V=5EMA;VVE2R3K:QE_(G$80A8U'PM^
MVKX*TC3?#MGXULD;0?%R2Z=>76GZC-IM[9:IHTTU[9116%C&6E:\TJ6S6SE,
MRM!%'$I:)24W^FXV3:O=>6^VJ[6[^O3;SHRZ)67^27R7R[K1'S>V@6>G2ZW<
MQF#=?Z)JEA?N5>6WLK;4K>$WUO9V>U;7=.JM<*TQFP'<0F,2QM'\N>)H;#1-
M-MKG1&;74B41Q3VNGVMKME>SN96E=XXI8M/E=+=999887OK:1[BU<EIH8#]!
M^$;?6/BCH&E0Z-INHM=W@FEUL-/'$]]=2K%I\ABLV0-+<R1VS6Q\M4PLL0"X
M#FO-M0L'Q?\ A+6-(N])N+W4[G2+"RMKG*V45C<1K?-;F$*TEQ"C64T<RJ93
M!/<I()U5RL/9.S2\[ZNR[K;[T];-K:M'>V]EK:]MFMU_6OF>B?L%_P#"&V'Q
M%UW4_%<5MKL<MRD?VF2PF>V9GA1'$;7\"7K>5.WV;,HMR1;EX)S"R3'U+]N#
MPS\'_&>J>#Y-$M+--8?4K:RECTJ>SLYTCO1(TGFR?:FYV0QR$W5JEKY=M,DM
MW"[K,OI?@+X::;9^'M1N;:SM[$#3+/R[F,B)KJ!8(5M8B\,L<AO?,CD$IV;M
MFTLQ))KY&_: ^&&HZ]<Z-K/A_7+73]<T*Z^WBPGN9I()(8E)C>2[63>DJ,\4
M48F)4172H&1G(;\ES3PLJ8SC^CX@X/B/,\%C:6$^K/+.:3P4X1H3I1@HPJJT
M).;E43BW)KIN_NL!QG2P_"T^%\3E.$Q=&=;VOUBW+65ZL:DI-M/WXM7@U*Z[
MI:'[K?LM?\$\_P!G_6/@W%KOBS3+;4?$5QIEI>'799$EN+>2*UC-H]K-=/)*
MHMYX&E@+2Y$I,N[+G=_/5^T1^SYH]A^UU??#O3_$:W>FZSK*"75=0N[$W45O
M)O@C\U)@"72*%8G80S@-Y942M(BCZ,\'?\%)_B[X"\ 'P'=V$EMJ5M:W>EO>
MSWJP6E[<V,26\SP7<N"\B2GG82'8.B%=I)_-TZY\2?&7Q$E^(4;F7Q7=7]SJ
M4,1>2.10JEVF02.&6!3((?-60.79@""QK\2\$O"WQSX6X\\4>(N.^-ZF8Y3G
MM*MAN$LMKU(XW#Y?.4I/#XG#PE)_5:-+DI-T*<84JD8PYZ3DFH_>\?\ 'G!>
M<\-\.9+D^7U7*CC\)F.=1BJN'C7K4*4J,Y5E?EQ&*=+$8FE"O-5*E*%6LH37
MM9\W^LS_ ,$8?A9HWP6_X)G_ +,'PUT";[1I?A_3/B9/#.)99A+<>(/C5\2/
M$VH2+),SR%&U'6;LHI8B-"L: (J@?J%7Y(_\$*/%NO\ CG_@E-^R;XG\3B,:
M[?Z;\6[>_$1!C!TGX^?%31K?;@L%_P!$T^#*;FV'*%F*[C^MU?UCPOA\UPG#
M/#N%SW$_7,[PV191A\YQ=U+ZUFM'+\/3S#$\R24O;XN-:K=))\UTD?B6<5,'
M6S?-*N7TU1R^KF..J8&BDXJE@YXFK+#4TGJE"@X12>JM9ZG\)?\ P>M_\XT?
M^[RO_?5*_A3M[F:UD$D,CQNK*P:-BK!E.58,""&4\C&/J*_NL_X/6_\ G&C_
M -WE?^^J5_"77KR^)_+\CR)-J3:W5K?<B>XN);B0RRN\CG.YW)+MEBQ+')R2
M3SSZ5!114DMMN[U?<**** "BBE"ECA02<9X]* 2;V_K6WZB4=L_3]<_X5TFC
M>'[S4W<Q0R2)$B22M'!).L$;L 99@@)6-1DDCDC[H.1FWJWA:\T]HT*,#O9&
M9XS&H/)BW!@KAI5PZAU!56PV&! GGCS<G,N?3W;ZZZK3T:?HUW1K[*?)S\KM
MM>VFCMOLMK^9R%%'2BJ,@HHHH **** "BBB@ HHHH ***,GUH ***4'!!P#C
ML1D?B#P: $HHSW_EQ10 Y5W$#<JY.,MNP.>IPIX Y.,G'0$\4A&"1D'!(R,X
M..XR <'W /J* 2.02#Z@XI* T^?]?U_6A4L@ 6/  ^4YX ;/!.>3D<_*3SCK
M@\4)#)(,J!CGJ0.@R>O?VZTUU93A\YQWSG';KVYXH*LTF[:-+7YKYZ_\'4<[
M(501AAA?G!X!;)Y^^P)P=N=JG& 03EC&#CL#P1R,]>_U':E50023@ CL2.<]
M_P .G4]@<&FT";>C?R731+IMVT_ * 2.0<'U%2LOEC:Z@LP)4@@X&2O;KDJ1
MS]T?,O)IJ,%SD$@CL<8]_K0-)7U=GZ;/3S_KUT3*ECCW$;F"*0?FQN^8Y"J0
M.A8@X[@ L,X +&8,Q)&!Z >W'<=^O/YU9-V[+$C;2L,1@CQ%$I$)>23!*H-[
MAY9&$K R M]["KM!Q4;W;Z^:OYW_ *[E<(=X4\9/)ZX&<=@?P_"G21^7C).2
M6*@C'RABOS>C9'09&.],9LL2,C)./8=AQCH*#N(W$D@$#))."P+#KZX)^N:"
M=+/2[[WZ773^MP3&>2<_PX (W=LY(P/ID^U22(!\P9,<#:."3W( &/KSWJ&G
M$Y X4=1P,>G7U_\ UT FK-:=+::[]_+7SUW$(7 P23SGT'3&._KFD'7IGV]?
M:BC!'48H%UZ=/ZU_$D,IP50; 00V#RV>"">,C':HP2#D$@CH1P1^-/$9*LP(
M(7[W!X'J3C R2%&>K$#O30,D"@JSNNE]OZ6VX,S,2S$LQZDDDGZDU+ Q29'"
MABC!]K*&5MO.'0\,IQAE/!!() S3'7:Q (P IX)(Y ]>_//;TXJ2&5(Y1(T2
MNH&/+.2,E<9/S*2<\]>O!XX("5I:M:/S_K_@^6I:NXYFN&D=88?-_>[8=JHJ
M2L3@)&6" 9/R?PJ ,8QER6\<:F1YE*2 JL896EW*RLSRQ@,%CVJ0I)$C.RE4
M9$FVP--Y\@);R]S!"<*,(1M/0 <+U)Y)QD]Q+90O<7'E)(V'$FX@,6CC# ,Y
M Z97DX(&,@D#-&Y>ETTF[O>^VRT7;H^JZ]#662YM[:.6'5(BD=PR_P!G)--#
M<AF)9I&B,2Q&!U0$NDKB,D*0  :_3W]ECQOJTGAW0=5MH+#4;O0+UFNK]VTV
M74+"RL4"6]E<Z5<2075]86KQPO/>?:[-I;!Y[>*::9Y+>Z_+K3);*'4K;[9Y
MYL5G$=X]LYAF-O(NR0QG#;=H^;HQ*DH03P?T"^$.J6?@B^:Z^'&O7\OA>[N%
MMGN+=#JNJ0->&W:6.QM)].E-M>M:-?1FU,,,<R7<LIF\V..6-IV=]?E:_P"/
MZFT-WHMK6OZ?T_\ AD>/_ME_#_0/!OQCU.Y\$'Q;J_@/Q!H_A_6M \3^+M'D
MTJ_URXO]#L;G6+F.%-3UB%[.#5)+JUL;N*]D@OK*WAO(XE$QQ\A,I&267.,X
M^;.2<%1D#D=3VQT)/%?U'?'[X :=\:_ /@_XC_$7Q_IG@:/6/@G=WW@BSLM&
MO]?MM;?3+/2]"\,2V&EWVHWMAIT^M6^K1#7(89+2'PW,-EGID4OR'^>'X@?L
M[_%'X>RZC/J7AK4;O1+&4H->L+2:YTYHW9A$\LL*,+9I O*3A""0IY(%*ZE=
MQ:DO[NMGI=>5K[.S2M?<*]*=/EYX3@YPIU5&<7"4Z=5)PJ14DG*$UK"23BU?
MMIX=&VU@2S+C)!3DYQ@<$KP>AYY'%/D;,I(=C@\,0,^IXW,.#D?>Y'6K]IHF
MJW[7"6&GWEZUI:SWUTMK:SW#6UE;#-Q>3K%&YBM8.DUPX$4>#N8#&:T5G+,^
MR/#-M9C\P'"C)(R0"<=LY.#0<_+*UK=;[K_/_AK>9]E_L#:R-#_:+T/4[R,O
MX;@\&?$\^-9GU33]#6T\%?\ " ^('\4W2:IJEC?Z?:7K:.+JUTA9TA-UK=QI
M]I;WEK=7$,@Z_P#:>\5>,_A5\0/B%\//#\5]X.\(^.=-T*YO= U6]T/Q)J5S
MX?U>P\/>)]-^W>(--TA8=US?(=3M9[!8[LV%W%;7\R3"ZB/DO[+UMXST[Q5J
MVK^&'U*6/4M#N/ T^@Z=)/&/B!)XSN+72[?P5+;Q,BZM9W-W]DU+4=.E+V\B
M:=")DW/&6Y/XP>*]<U&TL= U33X[)M+N;R7[;?V)7Q7?BZFB+6>NZH+FX6[M
M]+EM1;Z7!(L5Q90I+;"6>U6 AO:SVW2>W;;OIOY>ALKJG=WLTWMNEH[^3U5K
M:[WZGC^J7!D56>1Y0S-Q(T;E7]4PY)'J^T9XX'%8+.[!0SLP4!5#,2%4< *"
M2  .@' [4A9C@%B0.@))Q],TE(YKNR71;(**** '*NXXR!]<^A/8$]O3TIM%
M% =//7]+?J%%%% !1110!^A=SLE:652(C(@EE0@ELYS@C@C=E<<9.<9S5.XT
MF>\4SV5O]J10'<Q@_NE"_,'!XXZ]0?0>D,AWR22*<@'Y5!4#'F,@!R> <[B2
M,C.TKGFM+3M:OM+T^YLS;G[/<>8\CJRI*6^XH+A6 3)R1MY7HN *_G*"K4N6
MI0<75C*$8PG/DYD[*2^*+=HI))/JHW5KG^ME6668VK6P^:TZU'!5Z.)J3Q>'
MH?67&K33E2ER>SJTJ<:M64G.4X6@XN:C*32)?#0A\.K<W5W=6<8;>#Y_E&:%
M#"C2?(KX\T>4R(QQAGW%#M(;QVTU_P 0^+/B=(;25X]*LKNXC2,+F&:UBE$/
MG' "R%W&\#@)TZJ<]A?Z?/J!$#/<1K<,VUXEB8,%E5E#9C?<V!M.T#"E@""V
M0D7@:]\.S-?Z;=2VLMZIB212PE))4OYTCYVJ'!R#M (()X(/TV7ULNPT<?B<
M7B</5S7,L)4PV'=>E?#T&TH.3<8RUMN[*RB[VNV_QWBBEQ+FM3A?(<ERO,<%
MP5PCG>%SC,\/@,PA3S;,;5(XB$(TJU>DYPA.ZH--QG4KTTI5)0A&GZ3K,W]G
MW4=S/Y+Q%UB>9%+-&JJBB/H ,R,.<DD JHY%?('Q>U<ZCXB:$0+'!:01JAY(
ME#N[JXR =H1]I.#\RL#SBOH#5O%6O:'(/#6NQV=Q:7.V[DN5=7:&.-D8$L$9
MF;YU<[7X";>":^?OB%JEEXHU_P"P:5]G-K'Y,27@BE:5I K22NT@),D.6"GD
MH'!?YB(V3T^"LLKX3'PQ%:C&K3G@JKH8ZC54\-*DYTE"22BG&K/]Y'EGKRQY
MDE9L^2^D9QGE^><.5LKP&8UL#B,/Q!@5F7#69X"6&SBEF$</C)8FE.<JM6G4
MP6&C##5OK%%_[S55&KJX)>;:L^C 6QT>+4(R;>-;TWTUM*&NL9E-L(((]L /
M"B4O(1U;!Q6:CR3 H,@(!)QRV00@P !G)8#!.!D^U6+W39K">6WG#B6)MK(4
MVL-P^4X#MC((.T\\X(&0:^D?V;_B#=_#WX@Z9XBA^&>A>/+>WTS4=+N=-OK.
M(PW/VXC-]+<W]OJ4$=W:*WE0&*"$K$[1J<L=WZE.I3IPE5J5(4Z45S3J2E&,
M(QWYG)M1LEKOLO(_B_"X3$XS$T<+A,/6Q&)KSC2I8?#49U\15J3:C&%.E3C*
M<YMM*,(IN4K15[Z=C\(;?X(0^ ]4&J3:SJ/Q0U"WN8&TJ_TZ+_A'X+?8=EQ;
M7RDW!G#D;T\ACE'VN<!:S/"O@V&SOC/"D$+>4%9A$#N622=G2/>H9R,9; !7
MY=WR[5KU_0O CZKXHUSQE=V=MHEQKU]<W$6DV$<%G;Z58O.TD&GVZ0Q0QF.%
M&"NX13(^YRHS7HT/AJVMV\ZRLK-WA789%,>Y?G8@_>RQ8EBV<[L#&*_(>*>.
M*-2KB,!EU15*$:?LG7BURU)R;51>\N64&FH1E=IZM)KE/[[\$OHPYS' Y5Q5
MQ5A*F$QT\4L90RJI"7UFAA:,:=2A-_5Y2JPQ$N:5:O2;C*E%4X2G%^U4?+;+
M3A$\<;Y@C).V4Q!3*"0,LASA?3(4G/( YK9EWQ10Q0S;LR*DFR,J&PX<)L5A
M@8(RQ..O'8='>P2,XCN87W[I LQBVJH923EER&)^4C..<CUK.LH["T:8W!G:
M<JS1 ?P# R%0$ L  ?F*<$>E?GTJ\JB=25Y2NGRQM+FV5VW9V6[V]-K_ -44
M\EIX!_5:;A1I2_=NM5<\/*C&,:=Z;IJ;C>2CRP2;YD[2J-N3/(?BSJD\&O>'
MO[,D%O=V9N=0F*RO#(\=M8L+A08T=LFWE=.<*H<M(P3E?64^(5G=Z996NA6Q
MM+=8A]ON8;F'S+N:0PM%Y8*&X#$;EDFD 6*+)V*0"/G/XEZ?:^(OB!H%G$T[
MVP$;/($:621FN8S<%(^""L$6Y58D?NY",D@'Z$L]$\/PVS0'4;BTM'6TN'<V
MTBNRHHC A6$++&BD*Q%K.$:1B9%2%%4?OO"%#ZOPYEE/WDYT95I*6DKUJLYV
M=V[:.-KO1)7L[H_RY\=\SGFWBYQKB7*E*%/,J>$IRI2C*FX8+!87#)PDHQ3Y
MG!2DXWC*5Y1<HVE+ZE^$EO-K,.FMK<\UWH\MT"TD]HM_;6=E(2JW;^5"L[6T
M4,SAX@6D,@<+"99:^B?B)^SE\.+F\O%TO4],UN)H\PZK:VMQ%:3>;LE3RH;J
M /Y+\;T"+(C[QA3N6N*^!EW:^%=(:1[:YURR9 2+RS6U991L*3.-@BEMHU:1
M$,L!C6"-(HY"&ROMEAXSMKLZ+9:I;:;'#9W$]OY<%WY*-!//)<VYGAC0I!/&
M)&5]K3!=JJI6,*U?51BK*^M]=?E;[EH?D,KMZ+X6OO=K:?\ #[GY)_&S]EG7
M=)^V>(/A]:W21SM*U[I5L'2S$.TO*\4D89"[M$7=78QLSJ Z%6 _.>^AN[&\
MF@OK6YM+N(LCVUQ&\$T3 [2'CD4.,$,!E5SD8 Q7]9<'AA_$/@C7[O3)M"MM
M*M;YK9I-7NA;VUPMPAV6T(,\<=_)%B4RYC5?)P-CY91^!O[4NF>#!XWO]*M]
M'EL/$<.;B[U*RAA73M4>4B*.\+6SAWA"Q+:J)OF4+&T:QE[MGSE",6W&R;W[
MMJW7KH^HI-S@DY2M#X8W;44VFW%-V5VM6MVDWKO\7Z%X=U?Q+?PZ=I%G/>WE
MQ($CA@B>5R68+E@@X&X@9/4\ $\5W_B/X)?$#PIIR:IK>A7]K;2")D8VDS86
M3;\T@ WQA,E6!0L'5QM 5F'U=^Q#%X8\/?&BSM?&J1J0L!MQ)(R17$;[)-K%
M7$8'E'S2DN5<'YU8\U^R?[=.O_!N;X02SZ/!H=I)9Z0+R""WM].BG:2V6 0
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MBMIRSV_VQ7A*O(UI(J21H-T<P3RW 4L*FTFW-QJMM;BZ"3BY$4!@LY96:Z+
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M:;?R*(;22"-(H4!AW1;)%!.X MA6)5>-V6W#!R>"?4M/O+F9; Q.L31RQ\H
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M7$<*!?,BC<L&C:0X(4XST_/[P+XF\*3Z6/#WC2SM[^VOY9H+JS*A2R7TA#S
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M8MT\8BDW9 VJF\LB8888+R0<')-:\K1M-:,A51/C>L,NY@KL2=PP, @'.TL
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MHDZ<*2A*,.5\CYI.Z34B"YM;"Q-_ &D<".+[/)':JKW#;R3([^8ZVZB-R0P
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MMOTOWU/YC?VI=!A:X.IZ597 \BWTVP\4W*(;B2\N(((+1+L,KQSC<;?[1.K
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MH#^OZ^\**!S^OZ#-% !_G\^/ZT4]2!P>AZ@9R>XYP<8/IZ4UL9.WIV_+\.]
MVK)>?E_7]:]4)4D:;R02 JKN8D_=7(!('<@D<<YYJ.ER0,#OP>G(],]: 5KZ
MB_*6/\*DG'4[1G@>IQT]:E41NP 4J  "1N;GH2>> V-W&<9.%.,5!1DCH2*
M32W2?Y_Y?A\Q3C)QTS^E6%>V$4BM"3*VWRY!*XV8SGY=H5MW .X'&,C%5J*
M3MT3]5<<IPRG.,,#DC(&#U(/!^AJ2=E:0[<[>,9!&>,;L'D;L;L=!G J)<[E
MP<'(P3T!SP<^U2212)R^,Y((W LI']X=LYR/4'CO0._NM:[W?;MK_E\^A&,
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M'#X>#G4J2;2LHQ5[)7<I/2*3<FDKGS((9&^ZI/S%< C.1VP3G]*:-W*@<D]
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M^4H5>5.3M"$5EQYG/$?%G"CK>(&28N$X994HU,EX;QU:>-S"C6KWI8FK4S7
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MR\0Z9^T3X-\3ZU)=RZ1;ZS)IEB\<336I@>;<-/=3=G>T;P$NL-HAN-VR1Y7
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M&D10Q;^<.XW>=Y;DE49@-@#$C/4$':W((!SC X.*_L$_X*_?!^W^*'[-]O\
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MSB( YV9(W8_BVCMWYZ 9S@5T;,.&(!Y!' Z_7!)X]<YP.]03*'C*, WF \D
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MW_"1:6+6[N;V/3X(X])U^T$(CLTL+>:*XMBE]-$3(Z1QQ_NHFO+J**)[EX@
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M<+0QF%JPK8;%485:52,DU*G4BI7O!RCS).SU;3O?;3G-0MX4<2/)*&*L$1>
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M.K7AAEA\MIP2HT<-3]Z:E5E.,ZDZLJDY.<G*C&G%WC%M)G]N?1[SOCWP9R'
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M#5-8UL+74.>A7IRG3JP:E"<D[FK)J DA&U/*\IXHXV5!Y2QVQ=TP_/[S!49
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MTKPQJ&H3W45JC3&W9U2&.:20RNJA0H<1,VT-(-Y ]3@>CQ(J@CJ&4Y.<=?\
M ?RJ&V@"-'&1YC,K(1G@;F Y/8GK]/3K6E-#%8@^:Z.=I985()C8K\A8JQ!.
M""5Z]<BOY?Q^,J8W&8C$UN7V^+K5,1-4X*$95*D^><HQC91O)MMM=KROJ_\
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MZCJ$VF^*;6STV6.S?4+F;2;^WA%FUU81QZ?+?K*\+"6:X>]D\V42P75M_HD
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MNJSZ=)!ICS+%;72IB"2-"-C>9C&221AVR"0N =M>5P1R/,L:+N=B552#R6!
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MEF ') ^;C*C/)&01Z9Z#WK[3^'VC^%K?PS#+%XMNI-?E,(E2VU5D2&[O(_\
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M8-TZ4X5&GBYNJI\[E3YJ:7+4;G*U6E-RCS)2:M V-5U73PWV5'A@C\R(V\<
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MON,\< BN+\>>"I/$NBSZ9:W[VL$\\5X(S"94,T<4T2A@-C%,RABH9#O164@
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MW;6ZZ^6U_,E%-*276[\G_P .OZ1\OLI1BIZBFUMZL+1G9[6W,/ WXD9TWD@
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M-\4Z9II\'?%?2_B)>V.M:9JM]J6IQ>(/"&IZ)X6U/P3KFB07=FMC#9M>VVO
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M4-2NKB+0UNWDN; :1HNIVMS']N-II+Z!]JCE9!:7$<]M CQ0ED*_9O ;Z-/
MOA=X5\*\(9SP_EG$.>X3"3QF>YOC<*XUL5F^957C,;",8XF26'PDZRP6&NW.
M5##TY5&ZDI.7QW'?B7GO$_%.:9K@,RQ^6X"=94,!A<+5I2A'"89*E1JSE5H.
M3JUU'VU3:,93Y8W4>9_B71117]+GY&%%%% !1110 5+%)Y;[N>A'&,]O<?H1
M[Y&5,5% )VU/7-*^*,V@>'CH7ARTET6ZNP!J>LQ3K/>7A& -N4B^SIMRH17;
M&1AL@LVYX7\9-I,C2CQ7J%I]IW-<P2VT,@:=!$X99&:=$:5C-YC(5WDQN<E
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MUC*-?EE:JVXSK4Y1E!)SM3LU?E?%^G%85N(%5I0C.W&\H3]Z,M&0"Y !!Y&
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M<D.21,P8$R<LL>(\DBR1/RN68Y^8[LO\W#$G_@/!P1G.<G[8_8M\.?#/QO\
M%F/P-\5D+^&_$6GWB0;BH,>IA5CMY+="I$D@,IVQ*,2[&63Y0".',\?#+,!B
ML?4I5*U/"TU5J4Z7+S^S4XJI./,XQ_=P;J2YFER1DVU8^IX)X6K\;\5Y)PEA
M,=@\NQF>XV&78/%X]UOJD<96IS>%I5EAZ=;$/ZS7C#"TE1HUJLJU:G&%*I*2
M@_C6.-$4;IB-X977:I8,Q4LSJ3M^XV?,X;=\NX%>*MS.654*DA1E78+R",,=
MP4DANFT,R@C."237U)^U5\$1\%?B9)I>EVUQ#X9UVR76=",P=66VD)WVN^0
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M(V*6X0Q*Z"Y8F);H;EA<><#DJX_9;X%ZU\&?C+X0\3>!_B+X3\,>/]1T?3-
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MD2>/:RA26(4E0 N0=Q#$]Q;?%_Q&H@DMIH+=(X6+AT\Z1BAC!D)!BDWF1CM
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M_P I4YP,,#D -&&Z[6/)R#64OB?R_)$U(KEC?32WIKN_6_78JX.-V.,D9]P
M2/R(J58@RABS<DY"H6( XSD$#GWP/4^L;-N.3Z  9Z8  ZY)Z?7WKT+X:V&@
M:EXIT:T\43_9]#EN7%T^\QC<L4KVZ/(/NQSW CA<D[0&)QGKSXBM'#T*V(E"
MI.-"E4K2A2@ZE6<:<'-QIP5G.<DFH13O*32ZG3E67SS;,\ORNE6PN&J9CC<)
M@:>)QU>.&P>'J8NO3P\:^+Q$GR4,-2E4YZ]:5XTJ493::C8Y?2]+N[^[CL[&
MWGN;F8?+#"@>5\9).U68!5_B;=]T'(W?+7Z;_"EM63PUI.E7-I]GGMX8H9(
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M(@\.R_;IH[=VOQ+<VD2HL4DLA>20J@RVPLH:OUW_ &G9OAO'H/QL^'>J^*/
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M40.[#,3P JJI9V))  5<DY/04$W;:6VJ:6_S?7\M/O(7;<[MM"[B3M'1><X
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M_8^&O'OA9QJNJ:A;1:DEM;::9+/1[.>YNK1S=O?13A'C,'F0RI#))&N)T8R
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M:X$=1_G_ !_D:ZG1/".N^(&E&DZ3J5^D!'FRVMM+(D*D$AI2D+A.%9N2"0I
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M,I#G'&Y2S+'OVLV\\4_M*;4VM)NC;N2YVJP8;<D#[C' .0OS$8W 4VX8B!R
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M6%S:LB3E+2-I_P!]&Q!E:,1C)&/,",JQN'!KG/BOXR\*^//">C:A+H=WIWQ
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M)&0<)^\7#,2"&D.,'>6" @MEMC$+@EN1Q%$L2.Q:9&/R$[F5EQ\QD.#M#L@
MVH&!).%)/%1,AD(#L$RN4_=^4OMG:I!)P>0 ">K#(IYM4*NY<IC!VL&/&X*0
M7$:KNRZD#!XW<8&:9#>JTZZ:^G;;?KTOW)I+P@-M>,@J5*!2 X(W,3@@  \*
M,#';FJ2NSR !0BLT:'&< *>,G/)[G/4#-.:&,>80Q*K@J!RS\C(^XNW .<X(
MXQR2*?"L3[4 8[Y5Y+*NP':N68 G:-S9  SE6##:00/>;W2TT6C>MOS>GJOO
M^E_V7O'EQX/^).G6SHS:=X@+Z7=VQD>..0SJ%7 4$%QB1<D]=O)!P?2OC?\
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M1;6TEW;6*3RYZ1F\O+6W)[/.A]JH4!;;SV"BCKTHH ...N>_],4444 %%%%
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M<,R, ""RH<'!7K6A;"=D\U5=3%Y9B=254,V7"+D#<SR!7V[3B*-VWLJ'*O\
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MP2O3OC*Y.#C///!Q6MHUQ:6MW;W%]#//;PSQRO':3QVMT?+8.!'<R6]RL))
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M^%;WTNDG\K6M==4KZM?GT:+$WF!6!4*P#D#=M ;:3QG(![CCWY%3-$D<AR2
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M=[XC^)?CNYL_";>)?%M_KEY#;>'M,M[.2\U.Z$C+!:VUI8:?#*T2I%L"P^3
MS[(WDV2;E'V7UB@J#Q*KT50C"52==UH*C"G&*E*K*;ERJG&-W*HWR12O)I6O
M_/\ B,)B\-B)8+$83$T,9"JJ,\)7H5:6*A5NDJ<L/**KQJ-NR@X*;::M>R<_
MQ-^*FN>//$4[3W5]9:+-(D-KIWF,R6UG-<1RW'RW1,N7E$<DX<C>(SM.T'/(
M^ ?"=IXW\=^'?#0F6S76[Z&V8[Q'!M6)\JW#$22R_,I.8HV<(Q#(VVI\2_A_
MX]^&OB*?PCX_\*^)/"/B>U$5Q=Z1XC@FM-17[0JF&0B=8P8G0Y5_F7DAG!!K
MC]$N=6MM3TV;1C,NHVUPLEFUJLKS13[P$:-@"^]6 8D#@QX/7)Y)5X9AETL1
ME>-P\H8S!2JX#,:,Z6)PK5>@WA\73JTI2I5Z%Y1J1G"<J=2.JDXRN\Z=.=#'
M4Z.+PM=SHXFG#$8.<)TZ[<:D54P\H./M*=26L'%Q4HM['ZN?%#]B,^'?"R:E
MI&K.-1T^R2Z^:1+WRI([=3]F$BNP3=O>6)=H"+N5@>@_)7Q*+N+6;I;R226X
M221'F=W=I0KO&3O<DLI"G;V .!P!7ZWZ'XS^(UI\.SI^OIJ%W)J&GQ7,URRP
MN1*D>9%N'NF$,4;1,0&#A\@%%#88?FAK^E:EX_\ B&-%T+31>:A?7L6DZ=9Z
M?'*VY]XA@7]V"&&XYDG59$(RVX\9_*O"_-N)9PSS!\3YQA<XIY=6E.CFE-4Z
M-.-&%_:2J._\)N,I0E.;5.-.;G)WBU^S>+/ASC.$L-D>.Q?#.:\+8K.52>#R
MS,,-7ISS"E6H4L3&OA^=1;5"G5PT)I0<YU<2H64Z4[^0R!%;"-N7"Y/3G W
M9'8Y'2F5^K&I_P#!)#]I[2OA$WQ6N?"ET(%TQ-6ETDB..ZMK)HA*79!<7$]R
M=C!TEMX3 0I4MO)"?EMJ5E-IUY/8W-N]M<VTC1312;A)')&622-T8 JRN"&5
ME5E8%2JG('VW"O'?!G'$<RGP?Q/DG$L,GQL\NS2639AA\?' XV%W+#XAT)S]
MG.R;C?W9I.4'):GY'G/#>>\//#1SO*\7ECQE'ZQAEBZ,J3K4G;WH<ROHVDXN
MTHO225]:L<SQYVD<^N>.2>,$=SGZ@>E:+:YJCK;K)>W$B6NW[,CS2ND 4Y B
M5I"(P#V0*!VQ5C3=$O+^#[3'87DMFCB.XOH8)Y;>V9F(02R1)(B%MK +)Y9.
M 06R!6CXK\,KX;U:?2ENDOE@ALYQ=)%-;;UNK.*ZVF*?YE,9D\LD##[=RD!@
M!],ZM%U8T7*,JO+4G&-N9Q5/V2J.]FH22KTO=;4I1FFDXIM<D<'F%/!U,<HU
M:6#<L-2G4YW2C4>(>)GAU&#E&5:FY8'$MU(1G2IU*#C.<:C@I?:WPK^*-OIW
MP_TL2^*X)/$C8MX[6X(\\/<7*P16H\QB6XVNSG.[EASDUZO9_%;4=>OU\.0>
M6;J;8;](9D'G1Q1&3?C)\L%2&)'3=CD$9_*Q;JXB($<A3RW5DV@91HS\I4D$
M@J0"#GJ <YYKT/P5XPUW0;^XNM.'VF\O=/EM%ED#M/"TJB,SQL&!)1%QL) 9
M<'&,$_G.;>'.7XJKC\=0GS8G$/$8BC3K0I4Z5+$59J<%STXPMAZ3O+E<93=D
M^=-6?]C< _3)XUX>P'"_"F,C4H</Y52RC*,RJY?B\=7Q>.R; 4Y4<5-4,97Q
M,7F^-IN-)8BG4HX90O2EAG3D^7Z1_:!_M&[TS1M/$4SW,UPTOV>S<O%)! CM
M+))T+L"R9R"%*@@8&*_4G_@AKK7PQ\&?$WQC8_$*WT[1?%^IV*OX8O-=*0B1
M)0B2QVGVG:J2KY#9V#>?-Z;2IKQCX#?L-^,/BMH$?CO5O$=S<WSVD4]E9/"C
M)&LUH7>%86^5F9P+=%C4B0R1EBQVX\?^*?P=\1>"_$MUHC:A>:!XJT"Y\W3M
M8TV=K:='*8C\N:)LLCPR*'0,Z\,A*NH _"..L5P;XE\#<6^!-'BMX+$YAEU;
M!9MG.4.NL3EF(GBXUXSCA)JD\7@H584L/C8<ZC6HSJQ6LHM_38;AW./$3C?,
M_&+*,'7CF^'GA*F1<&YQ]7E4S3+,'EF&P=2=3-(36'P^.J1^L8C#TU!0I5G0
MA4G&#E)?T5?\%7-1^'&M_!SPWHTJZ3?^*=5\16!T/4[%K:XN+.U"R&['F0,W
M[J57"LK'"G:YQD9_%7PCXPT_X&>)_"?BR&U@GMO"MVVIW*2 %H1)(T1OB""/
M]'EN'F&X$J$!!! 8>%?"_4/&-]XDTN/XF^--;\6VEA=0;UU!;N6UA@C011VT
M$;S[%=\*KO\ >4X+.!S7T5^UT?A4?@KJ5WH(NK3Q"+1(+R6S21H(K"\D@B42
M2F5F80LPFE1&F:1 S1;@K(WXYX9>%>$\)\DX=\&J^;9CQGE>;9ACZ.,SBAA*
MU# *.>U51J4X8:O6G/!X>E1FZ?)"7LY5ZDZZ477E?^F<AXCQG"O@_P")/$N>
M<!YA@<]S?+ZWLJ]%4<77R?#8++L3.I2K5\&Z]"3=7 4L9C:\YTUAL+%4FW/#
MV7[E_$S]K3P=\;_@AK7ACX(:9+XWU;Q7X:N+.^TZP42"P%]8 R1R&(L#.GFH
M">%Z+V(K^++XV_";XA_"OQCJVD^/O"FK>&[F[O[J6T&H6DMLEU#YI96MG<*L
MJ1[U+XZ,,'UK^K;_ ((?GX?+\%=>&ERZ=+XDDU)//2:(KJMN(T8W%L8YSEHT
MW0.KQ#;,NZ?=)YN4C_X+I^!OA[JGP&\(>*+^/3K;QGH?BVW:SEBC']J7.ARQ
M.M] (K9A>RP";RV)B23RV7S<;8),?E_T?_$;(?HZ?24SOZ,G#W!^:5^'N)>)
MXX2MQ1F>,Q-3.Y9G'+)XG!8R6"^KK#3RQ*4<!S1E&I&G'ZS.<[.,OXX\1>',
M7XC>&N7>(F.S.A2S++<H^NQP&&A%X%T9U:?UN@ZTY.:Q"Y955NN9*ERVM)?T
M\_\ !MEIM[I/_!%3]BNSO[:6TN/L_P"T#>+#.I60VNI?M4?''4K"?!YV75C=
MVUU$3RT4R,0,XK]RZ_*+_@ASJNAZS_P2D_8TO_#B"/2#X \26<,8_@N=,^)?
MC?3-21CYDH9UU.SO [K(RNX9T.U@!^KM?ZW93C*F895EF/K8>>$JX[+\%C*N
M$J?Q,+4Q.&IUIX>=_MT93=*7]Z+/Y"QV'AA,;C,)3JJO3PN*Q&'A6C91K0H5
M9TXU8VTM445-6TLS^$O_ (/6_P#G&C_W>5_[ZI7\)=?W:?\ !ZW_ ,XT?^[R
MO_?5*_A+KJG\3^7Y(\^?Q/Y?D@HHHJ20HHHH **** "BBOM;X#_L)?'C]HSP
MK)XM^&/AB'6]+A:\A?9<S?:A<V@0B%XDB:.+[3N/V>61UCDVR ?,@5O&SWB+
M(>%\NJ9MQ)G&6Y%E=*<*53,,UQ='!8.G4JMJG">(KRA3C*HTU!.2<FK*[/0R
MS*<RSG$K!Y5@L3F&*<)5%A\+2G6JN$7%2ER03E9.2N[65SXL5V3(4X!QGWQG
M'Z$CZ$TROTW\5?\ !+OXY^$-/M;C5#9IJ,V1=:6UC>P-IK"V:4F\N+J>W)A:
M9)(8I(;9Y)1$2L&\A&_/;Q?X0UGP1K-QH7B+3I-/U&W+;HGDRDL8=XTN;>0&
M1)[:9D8Q2HV&"D?>5A7!PYQKPEQ?"I/AGB'*\[C2CSU/J&)C6<8.3C&IRZ2E
M3E)-1JQ4J<M)1DXM-]N;<,Y]D:I/-\KQ> C5;5-XBFXQ<E:\&X\RC-+5TY-3
MCK>*U.1HJPJP&%RT@25 -B%9#YN6YVLH95900<.$4J&.[>%62O7U!X;5NJ?H
M_P"K?,****!"G'&/3GZY/],4E%36\$UU-%;VZ&2::1(HHP0"\DC!$4%B%&YF
M R2 ,Y) YH#<AHJQ<VTMI/-;3H8Y[>5X)XV9"T<\3-'*AV,RD+(C+D$@XR"0
M:KT 7K"Z2TDDD>".?=!-&BRY*(\L,D:3 #J\+NLL8.5+H%8%2:KO*Y/..1CG
MG@<8S[8 ]L5#4K2"1@60  *"%X)"@ D=MQ R20>>><T%)NUD[-;6ZW?YK]?)
MWM6=TMO+'(Z+((V8E#@"161E9'/&58-M;HVPL%8'!%K4+NSN8+=;73ULFB2;
MSF6:20W'F3,\1(=5"F&(K$=O$I4R87.!DN5)P@(7J 3N.?<[5[=AP.QJ_'':
M-ID\TE^$O8KF*.WTXVT[-/!)&YEN!=J/(B6!E5?)D.]S)N085L!2EHUVCITZ
M;=.NUBM#$DFT?,SLX78O!QC.02""?;'<5Z[X&^$?B;Q5XI\*:')X8U]K;7]9
MT[2LV]G,MQMU&\^SH49XBB2;CD>8(]JA6(V.K'RK3L&X@,F1"LJK-M95<HQ)
M)1F&%8*#@G@8R<CBO["?^"9OAGP-XYT'39])ATW79]!UWRM3206MRVE169BE
MM[>23[)#*'MH(Y4C<JDDKQ1R1!F*Y_#O'[QA_P"()\#8KC">2U,XHT:>*C44
M<0\+3PTX4HO#SJU_8UH0]K6G&G!345.=HQ:DT?H?AOP13XZSE97+'PP,HJA.
M*=.-66(C[1NO!1=2F_<I0E*4HN3@KRY96L?GI\5?^".Y\ >!K/Q#\/\ Q%K^
MJ>+/LMI+-I.M65O]EN[:]\EGDC-NYE@-ODRK(ZL D)(4DJ*\$\/_  &\5>'+
M'5]*2*ZU/Q.@6T-GJ-L@L[:REN9+6XBN8VDD\X7+RS,[! [6T-LF\B,AO[2M
M8\+Z)K-J]M?6$4J>4L(>)%$Z1Q;1&D4@4$*NT*!P"#@\$U_.'XC\;>"3^T%\
M5_#>GZK=:9J7ACXC76A:C;W,T<#1V<*6%E +R**U>.*"(O-=K>R7D5FKWB6\
MHBO7++_*'T&/I4<;>.F;\6<+<9*&,Q.192\^IYLZ6&HRA'$YCAL)1P:CAJ=!
M581]I5E""HNK'V;BI5%.,:?ZUXY^%W#_  3EV69SD<5A%B\9#+?J2G6E"HXX
M2O6=6U6=2:FI44ZCB^5IM6BM5\*?!WX,-X3\6W-MJEMJ%I=:I# (;DPQR6MR
M]O+)!;JYU"2:3R)))8@\EL\DDD(5"K!&KCOVO/V5[N>\M_&$&A7)U+2[JRL_
M$]KI?EP7U]!^\ENY7M9!&1-]G6,6DD:@R)*F\;E+-[K^T1\1W\!_%#1H=5UK
M3+CPEH6G7+75IIBPF\FU;RS'#?B<S):+$MX7+)#<02R1K^^59R57Y_L/VL==
MU>;Q!JGB34KK6-<6[AO-'@O'CO-.O+.&W%D=.U&;5MR(&BCW).9GV2I%;D+)
MN1/]([P3<6FFGY-ZV=]&UKY7T7F?S7))V3<>5J]K:7OT>U^Z3?+YGA'[*7QW
M\2_#CQCX9\%ZRERNDZ#K8N=-T=M*M(#"9KNYO-4NM0FDACNYV'$Z"XFD,?V>
M"*!HXK<1G^@:U_:X\(^((;G]F#Q5X?T>?PE\3_"&F1:[XSU#54.BZ=H=WJL_
MB(R)I=NZ;+V_MI[6V%K/YJI<0+.(OM &/YPO&>J/XN\1P>)9;":&X_M!EOFC
MF,,UA:7,L)ATR[%I"D^ENACFM\&"2Y&J)<F.$1S*9_6+_5?A'!JL=WXRMO%R
MJNG0&._M?$EZ;BRETTK##-;VEV^FRBW$>%6Y*%FE&Y1<1(K5/-)*T;7NFN:]
MMTGMY>=A+KJM+*[NK)VL]KZ6NO71Z')?&G]FO4?AKXKAUO0HX-5^'?B35_%2
M^$]2T^]@N9C;Z1J-I!<I<6<3FZAC2TOK0VLEU! UPOFM&I\J512TNWFLX(PD
M;O&$8 $;B,DHJA<%59<8Y(QD<=,[_CKQ1HU[9-X@^$]UXR\2^ -*$0UNXU&P
M1M2T#7)5WPW>HR6ES-%?Z:8?]&CE*6T2-'>-,D;+A9M#U"74M'BUMK2[;37<
MQ#4E2)[$GS"5$@3<(+B3<)&641R.)0XC *N_Y]QI2QDL+1JQI>TI4YWJPCS2
MBWKK'2,DEITUN[O17_IKZ/./R*CG6*P.+QM/!XW%4.7"XF3A13FY0M1C[:JX
M3E.,;<LG!WBHPYVW%>"_$'P[/J2B5+9V9?E*$NI,SLK%UX95!"1J>0IR>-Q4
MURW@2QNO#VN07=SITD]HLDBLLUS/#:$))(6281,BWC*]N#%#*RQF158@.!7U
MZ-*\':V['4/$B:5<*T4<5K-!#;Q3O)L5&;5KBYCL[.+;D//<PQQ0%XI#(P\P
M+YEJ\NCV5Y/:O+IEG%;)#$#9SSBVD$MM#.92;J6>=+J0W3"\CD"R+?)=PH@\
MH@+*<]QE+*J#^IRJ\JA!1IN52<4[V3C%R::LGRR2DE))KEU=\<^&V18KC?,J
M4<_HT%.=2M+$8KDP="M*FZ?,H3K0HPE%IU(.M2<Z5Z<9*;G4C$^/M9A>*^N)
MV64-+<229E;S<AV; :3)R<>I.<X' R<3.220#GGVY^F*]*^(#6TMV@LWMYH@
M,I)$K(75&9=V7/(8_='&_)*J",#S8J0,G&,XZC.0 3QG/ (R<8!X//%?>4*C
MK4:=5Q<'.*ERNZ<;]&FDTUU36A_,^:X18#'XK!PJPK0P]:5-5J;C*G4L])QG
M3<H24DTXRC*46FFF[D@F;CG: NT8STZ$=^H)'TZ8XIPEEP5C9FC'\))/;!R#
MZY(_,< X,.Q\ [20>F.?T'/YUTVBBZM;N.;3KBUM+O['=LYOWBBMI8VAF26U
M<WJ"V<7ELS1I&TCQ3NRQ^9&7*IJ<<>9JST7?5-]K?KY& ;B7 5^5Q@9 /! !
MP2#G*@#K[]3FMJW.EV*Z?.MP;FXN&62<P^;#/I317,>PH6&R68QHTL;J0JE@
M&P5!J/4]/:"[Q=?9;5[RUBU.WC@GAN8%BO4-U! OV%I4MV,3QJD,@C, ($RH
M,,V-B-9U4LRQB10S*HD95W#<RJ6C#L!DA2T88C!9<[J LT[W35U\3NUZ=N_H
M?H!^S?J&A7&HWLNGWTEQJ-E8R3PV5XRV[PV[7T%SJ$DL(C6:>02"PEMIXIY7
M N;M76-#(\GU#\&-$?XD0Z]>CPU#JM_?1Z_+?0/?1V\ATW3I;F\N;/2[*]\F
MXM]1D,6+L6K27%XO[TH_F[:_-'X5IXETS5K[5/"FE#Q -.M+R1KH7$=E8VXM
MD@N9KAYM4>TBCWV<4?FVCL-06WM[N<K%#$RG]D?V0-?MH[ZV\2&]^'C7.M:#
M#HGAS0]:TI[GQY?>*K]C86%YIJQZ;INC>)#!]I6VNI665FM7EN+L^;;(S5&U
MTO7MUM^>SWTTMN=$7HKZ?)Z[)/\ 0_"SXC:%=>'/''B?2+JQ?3WL]8O46U=6
M'DQ&9FB0%@"RJCJH;D-C@XKB*_7G_@J1^QWXD_9B\;^']6\9V<NDZOXKM9C<
MZ5=ZIHVHS3ZM;E6NIH8-'#I:6D#2-A9YI%DC2)T, ECCD_(F3[[$8P3D8X&#
MSD#L#G('8<<4FK.SZ'-4C9W6S_577WK?S&?C^'/^&/UKL+;4-,%M:KM$4MM#
MF7:&+3.8$0EW*D*J21@[<,,R, "I&.112[!0"Q/9>N!UQ]!S^IXJ5F2,L(]Q
M)^4[P <<%@0"1G<!A@V,9^7GA"B[:Z6>FN^C5[:>>RZ'M/PL\03Z'\0/"M[I
M?VB>XN=9LK.6"UE\AKZ+47CM&B=8U!"H;CE<;B4W1E7VE?K3]H3P;X0\-:W)
MX;B\(SZ#H=MIZZ_J&MVVKS:Y=?:KV^FTVZG$V//TBZAU*6XGOO#]VX:.ULY&
M)D>Y\\?/_P"RM\.O%OQ&^*OA^;PUHNNZE;^#Y;3Q#JQ\-V*WE_#;V,X>V$4<
MF8C=7-P$2%V&!L)'S*N?OK]H2U^%WC#Q9>:Y?>)M3\!WU_I/C#Q/KVE:U83^
M)-/L]3NM,TN+PMX:N8+JRTQ3XBUOQ)!<'4+SSYM.L$FT^""VO!--)32M&Z>M
MTM7^/K?JOR.F.L;66[=^U^6ZO^/1]M=OR)U SWTTM[<W<%Y,GFVJ^6(+=O+M
M1'''*T,<<,21R1D-'LW22,'9AP6;F ?F!XZ@\].O?VKT+Q9IMK;76LW,,5NM
MH^N:DFF76F/9W5A<6PF+0PJ]I?/# (K9XY8Q'%+YCN\9PT,OE>>4CGGHUZO]
M#VS3/%7B'QWJOA[PGX>TW0-%U?4]#\)?#^RDTYAH<.I76GZI ;76M7O)[J.R
MBU>]86\>HZM.T$0AMTES#(KRMW'CGQ]XX\"^"M3^$ECKEQINCZS*UEXTT32[
MY?[)O[SP_J(-KDV<\MM?VZ3"5XKC>PF0AU+1F,GP3PA>#3]<TR_Q@V5['.'>
M))XHBK(R2RPR*T<T<;(-\,C(L@8*' +"NN^+'CG4/&WB"2:ZT>UT.&P\ZVL[
M*VMY8'6S,NZW-RLDTRF7R2A#1G:588>10KD_K^OZ_P"#:;Y;ZIOHNS^_1;O?
MTT/*2<G)_3\JW?#VOZIX8OQK&AZG=Z3JT$,T=K>69"S(+A##*@D()C#PLZ[T
MPXS@$9K"XQG(SG&.<XZYST]L?IWI*#%.SOUZ>3[DL\TMS-+/,[22S2/+(['+
M.[L6=F/=F8EB>Y)-=3X/U.TM=4AM-8O+NUT*\;9?_9<LRNB-]DN?*Z2/:W'E
MSH#@[D&",#') $G &36CJ&D:AI4=D^HVLUFVHVD6H6<5RC133:?<*'M+Y(G
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M554HIR"<MP;DTDC!7#O+$(HS(KN51)'B" ,0H))"J3CA@ &VGY1ELV^3<A/
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M48*,N;_26\=_%3X:^%_ NJ^)-;\1:(?#@TF>4.+RT>WOK:6W?8D"QN!(LD+
MX&"J''RKA:_SZ_VGM4\+>*?V@/B)J_A3RY- U+Q)>RZ?]E*^7Y3W#A401A$
MP>@W$ ?ZQB=U<[K'[0'Q>U7P\WAF]\?>([G06@$ TV;4;AH(T955TC4O\J$
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M[/?P/\$?L[?"KPM\+? -HEMH?AW3XHA.51KG49G7=-=7-R,O<N[,P1VD(5"
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M"T&<Z2]CY=E8ZBUO,UOI^M:/>6DMK=7FL070O)V+7,,S>6A_.GX?_%W0=/\
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M%%#[F#Q;E*/GRPRO@?6VEZSJNC7NE- X6.VOTO8Y("VVZLY&5BJN@/VBWN%
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M20%F<%LXYX;&#D# VJF.H!&3V/-))YB@(^<CYAG.X ]!S@@=P!QSGO3A(JD
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M\(P0:GXA2YN+6RE@LUN-4FM;F9+2UDBLE^T-&2<NT:C&;>(F22/<J'/-=_\
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MAD-Q=03A72437+AD8%"C%B/,Y[R3Q),EKINC;9C@QV=@CSQ*5CCC<VD/D27
M3R;:%<7-U<NFV3;)AP$X<^I//OG..QK]1/\ @E]J_P ,=-^-=Q;?$6STV[34
M])N(]+FU)8/L]I-'%*'P)%+!9TNB)G5MR1H/+5GVJWSW&7$53A+A;/>):668
MK.:F2Y=7Q\<LP<HQQ.,]BE*5*E*:DHR4>:;DHRDHQ?+&3T?I\/Y8L]SK+\IJ
M8NG@8X_$T\/]:KJ].BZE[.4>:*?-)*"U6LE=I'YD7-O+:2!'5XY&#;D(,1Q@
MCE2B$9R<<=CTJD23U)/U/K]:_K@^.?\ P3#^ _QH\-:_K?@C48]!\67=FEWX
M:M=.6R6VDOHPX@@D3 EDM[LEXN&;Y@DC$MEJ_&?Q)_P2'_;=T:>7^S_A1-KM
ME$T9AGL+VS+SI,[+'*8)I$*D%<R(9,J&! (W8_&N _I3>#?&^%K.MQ7EO"&:
M86M##8K)^,<9A^'L7[:4*<I?4Y9G4PU+,*4)3=.=7"SG&,XM2MH?:<1^$/&F
M05H1I99B,[PE6#J4L9D]&KCH*%^5>VIT(SJT)R2C.,*L(\T&FGJ?(?P-^ ?C
M;XEZCX7\1:5X?T[Q#X9D\<6WAV_TZ;7+"RO+Q[2T@UG48FLC=PZC'9#39$#:
M@(TMO/F2W6;SCLK^AOQ)^R3#\*-%^%&E>._@/;_#[Q+X@\&>(;C2?#/B_P"'
MVD6-AXA\*0ZM)=:!KUQJ.F?8KB\;6+*XW21:L)&51''#.8S"B\E^Q3^PE\<_
MV3K2[UWX\_#+1+3PQXD769-3\9^&M;%_XZ\"6MQX>N]..G2:?'OLKBSOKU-.
MOK;RXS-'>0\SB-Z_2[5OVZ_#'Q-\"?#OX(_$V^E\1&UAO?!'A'6O&4$-MJVF
M:=:VD;Z?'K&M)!&MLD%O;[2SW"6@$<<4C>8P8_KW"WB#P)QK3J5N#^+^&N)Z
M-*O5PU2KD>=9?F<:>(H.*K4I?5:]2TH.46G'FC)23BVM3Y+,>&L_R-1CF^2Y
MGELITZ=9/&8.O0?)53<)-U*<8QYK/W7)-I/T/E#]G?X$6GP&\'^-O$D7E^)O
M GC"VT2XTO0=%.G?#B[AU"VLHX_$>FP2:;%XM\5064"O<:6D+:_HT6M6]X]U
M<P1^2UG?]9;Z]*EQI7C+2/[;U31=$U6W\+W/A>]@TT0>"(+MKZ?4;&.U6W6'
M4[6SAGFFM=0O+B,F)4=84SY8]RT/2?!6L:YK%GH\[0)>V>AZ'H&EV-W%_8<V
MN:SJV@6>FZSIT$]VEM%ILFJF..ZDO"JO<M]J\WR"JC\XO^"IWQ]MOA]\+8?
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M=$ (RK@E^5.,G>2!\Q]""?7(&.*S=>U&VU.V%O'Y0"G@ER""1M8'MRLBXQT
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MPWEE?:BNI6<V_3%8WHO4%P-/N#)$/LD@@OI(_B,LQ4+@;>WR]\GD'U/0D=0
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MR-Y@5Q)$<C<I _1F[_DOZ_K74^9DU):.R22ZNRTMI97U]+=#FJ***1B%%%%
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M%\NM72W$[H\VKV5LMM!I>GWQ,<:QS65I$XMUBB?*F0O[KXT_9Q\."*Z@\/\
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MG/GA)J%Y*?[MPGS0BG/D<X36MXM-KEE>RM:7NR7+*Z?NW:E[O+*\5:25TW.
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M6,R79O)-]U<_:)9'D GED\M9, B/&/QY_P""H7_!6;3?@')J/P&^ USI^O\
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M/X;:6]E\3+_Q=#9ZDEA;26VG2:48%+:C,X*QS1B:/8B$DA)FX.P+7S1^VO\
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M 'BD;J!^\4M1EIU\M%^+[=/7OLS@_P!J+P3X=TWQ3]J^&(:\\&R6VGQVNJ)
MJO=:B]HDRVLUM'ON(9--MY)85WLZ7(2=QY;LP?2\:?"?5/ _[+^K?$:Y2)/$
M'B231M%MK.^Q!/:VMUJ=HUU>I#*?.8W5K92Q+ @,8A8R,,;=O8^%]8\.^(?B
M)JND:;K8UO0UU;39+![ZV:*W+6UQ)<HT4.?*5'N_ML"R1131RQR!1.RLK'O?
MVT]2?Q)X/TLM=A[72[RQ,,5M()(&DAAG#((8T5 HRR('"E6\MLJG->1G]>6%
MR7-L3!*4J.78RI&+CS)RCAZEKK72]F[=K?:9]GX>8+"9KQ[P5E>/JRH8/'\5
M\/X/%5HRY)4Z&(S7"4JLE.3?)[DY)S^RGS:6/SMTW,-K;KN^>*.-2XQ]Z,*-
MP(/!R 1_+)!KV'PEXJ\F,V.M37,]O$//B1096\L(1(K;PX'RN&CSN&% "KM-
M>37%C)IAM5DN(9%NE:2,1@GY1Y>W[V#DF3:?E"@H5Y/%:*WLRB-D9D983"&
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MI#!UG0P^']G[T<.I\DW6DY->UJ22B^50@E#FG/\ P.^D_P#3]XJ\6\UK<-\
MX2/#OAM@J]2%-XJGS9WQ+.+45F&8S4K8+!N*YL+E>'ES)-5L97K5'&CA_P
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MJ7A"PM?"YFCGUO4?$Z>*K80VUF]O;:3JE@)]2CEEBLK(7'Q5\4/&FN166O\
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M]G8:3<64PU9)4:#3T=;:T?;&DERKRQR3%MS$K+EV88)"QJP Q7R-\=3<>%_
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M3JJE[6E']W-OV37O#VL+N0T(#*2K,5'4 C!'(!![#CT)'-*;>'&TH-OIM'(
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MQZ8M[M=1,& :XWA$<^7$C2R%@/X\?B3HU_::@UXT3"'RT RN2"7!SM8*8R
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MU,4@/]@-M^W'\$(/@HOBZ?7]/(C\/^0-/$D;VCNEG)'$AF!"^1.JY0A2I0J
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M[.*RLA>F..TMQI5M)$\KW#K"MFL*L?.(9@-KQN"RQL Z#YOMSX*?\$F_C_\
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M\<1@CBF5HA(%'G22AXV=Q/C>H21"DC-G<N ,E59F55!9F(55 R2Q.  .Y).
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M$3DD^O-#=]Q3GS6[Z/3M9[^?=?B2Q0S3.(H(WGD<96.%&E<\;R B L2H!+
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M\Y)+9)JY?S>>97%PCQY1XX0\?[HW49F,<2  !82OE2^4B!&"HR@,HK(PVTD
M[<X)P<9[ GI]*1E)N^CNK:+1V6CN^RZI_P"8X/B0.1GG.,GTP!G.?3O7Z!?L
M>?\ !2']HK]B[6]7USX6>(Y4N=5T*30X!>7^IE-(,BF!=6L(8KN.U?5;>T+6
MUK-?PWD,<0B5H66)$K\^J*$VM4[/NA*<HW??O_7;IL?M?-_P5UU#Q+JVOZIX
M\^&2^*[C6-*DMH[V^U;3Y=8;6)X+Q+W6+F^31(4:>\:<%VCMHY4)$D<J-$H?
MQWQ__P %1?B9XQT[48[3P=X6T?5-3F@:?46$FI-(EN]T4DFCO?-"W0AGCM5F
MMU@8QP(95<K;O#^6:G##IU'7IU[C!R/4$$$9X-*YR[D;<%F(VC"]3]T8&%]!
M@8&!@=*KFEW_ "*]H][+=>OK_F^MU>^M_J35OVOOB_KMG+I>LZG:ZEH[SI<I
MHUQ!MTN.:,R,)/L<31Q3,\DKR,TRN[.<EL8%>':]X]UKQ%;PVE]#I4<%ON$*
MVFFV]LRAB68L\0!=V))>1@7=OF9BP!'%45-V]W<EU)OK_6G^1U&F:X193Z/J
M)4Z1>75K=7;0PV_]IJ;..X$$=E=SQ2F"(M.3)",0R':[HSHI%GPKKVNZ7K&F
M)H=L=6G;5+>>VT62R.JI?W;;K9+86"QRFZDNHIC;M%%$TDVY%"LP0#CJEAGF
MMY(Y8)'BEB=9(Y(W9)(W1@RNCH0R,K*"&4A@0,$4!SO2_P!_6VG]/\N_7'5+
M2PT^[LGMY[K4+M)946X%UIW_  C6K+J++,]A%;Z@8]0:ZTZWBAG:^MHE@:XD
MBAMS<6,5W+R)ED#[R2'(Y/.3GJ3DYR>I/>M+2-<U'1-9T_7[![?^T]+O8=0M
M9+ZQLM5MS=02B:-[NPU2WO+&_C,@S+!?6US!."4GCD4D',ED:9VD?&YB2=JA
M5Y/95 51S@*H"J,!0  */Z_+\^H.5UI?[O35OH[]C<F\3:[<6L5I)?3FVATP
M:0(E)5'TV.Y^V):RA<>9''=8F7?DJX7D!0*P7))Y!'H#G@'D8SSC'3U%317#
MHAA^4PO)'*Z,#AWB#B,E@0R@+(ZD*1D,3@L%(2YECFN)Y8H4MXI)7>.",N8X
M49B4B1I&>1DC4A%:1WD8 %V9B203=TM6^ZT71??KY?\ !A!VG(Z]NO'N,$<C
MWR/:M"34IBLL4*I;03I;+/!$7\J9[8 K*ZNS?,SYD900@=F*J,FL\C&.0<\\
M=OKZ'V_^ME*!)N.B=NO3J3QW$L>=K=6#$9;!(Z="*U[B"RBT73]1AU:SEU"Y
MU35;2ZT)+>\%Y86EG;:5/9:K<7+P+ITMMJLU_?VMM;V]S->6\NCW4EY#!%<6
M;SX;!1C:Q8]^,#H#WP<@Y!XQQD$TV@?,U=/R?3>Z=]-_G?<E:9V"CA0H(&W(
MZXZG))Z9Z]>O& (R2<9YP,#DGC)/<\=>@P/;.:2CKTH%=OY_CV]154L1@$C.
M#@?Y[5]E?"?]C[XA>/?#]YXIE_LC1[(^&)?$>F6'B ZG8WVI:0+AK>XU:QSI
M_D>78I&UR2TC));_ +T,4!*^\_\ !,;]FG0OBW\9+#Q3\7O!>GZU\&= AU-M
M8;Q0VL:;I%[?+I4EU;G3+FQ,$.JZEII-K?1:-/-+%J'F01/:W$,DH7]A?VFO
M@!XY^)7C"TC^#.O^$++X Z/X+UW3O#NE:98W%OJHGCTRV>5$LVM;.XL](O[F
M9Q#HFGS0V\*K-(L85CNI1T;:OY;=NM^J?;YW-Z<$K-WN_P OQZK7:RW:T3_F
MM^(.I/X#O;?P3X7UJUFCTNVM+C6M8TF>WD75];NK87%RZWD2J9+2R%S]BMHV
MY!BE=DC8A:*S/CMX(M/A]\4/%'A6'7[#Q&=/NH3-JNEW<=Y9S7%Q;QSW,8</
M(\<D$SM')!+*\T!4Q3,9%8DJ;OO_ %_20G*5]+6Z*]K:K3^M]'OOXW14[0NA
M96C.4Y8DD'&[:-RDY4[B,C&?PYJ"@Q::W_5>J=TM5U-#2;Z;2]4T[4;<@3V-
M[;7<)897S()DD7([C*C-?JGX*U#PA\6_#EK<SVVF7]R+,1ZE9O$CM;SRQ[9(
MV60%U;=RIQUQC@BOR=4X93Z,#^1KZ$_9^\4W6A_$+2;."[9+76Y&L+F! "C2
M+&TL,ICR I1D9 5'20_6OB>.<A>;97/&X:M4PV9932KXK"UJ<G!RA&*G6HR<
M6IVE&'-!Q:<:D5]ER/Z;^B[XJT. ..L-P]GV5X//N">/,?E>1\195CZ-*O1I
MU:N)5#+\THTL0I8>57"5L3*.(A5C*%;"5*L+*HJ,H_H]X3^%GAKPEIL^GZ';
M/81W=VM[,4DD\TRXV.K/(SDIL^5%Z* H4 #%>E1P) BH@(  SDDDX  +$@'G
M'U]<&IXHRR(Y8E@N#@\,=N=Q'0]L ]#C Z4^:)HW="02&*ED8,C%3CY6X#*"
M& (SD@D$BOY,QF:8G,,34JXO%5<15FVZE2M-RE.=H1NYRUE:,8VOWMOO_P!'
M?"?AQPYP/D.%P'#?#N RC"4*5&E@\)E]"-)87"1<\1-4\/3<J='GQ&+J^UE%
M2D]92DTTAGRDD8_^OP>F#GWR <YZ=ZC,2E2 #C(]L8S@GJ#@@9' QG( .:E4
M$<$CH>..,^OJ?KD=N<\+CY<@_@<9/'7IP.<>@XXP!7%*I.G)<LKJZT;?E_3:
M\O0^WHY=@L=A*OUF@HU(1DE4C3BY4X-J\;)2]HFFDKKF=FK))-_#?[8EU-%H
MWAK34BD\F35IKF6XVDQYBM;A%B+#A6<S;T)(SY;8Y K\])VW%1@ J"..X[$_
MRP.@&>_'Z&?M>^*[6VL-)\)+!'->7LZ:K/.^=UI;V[[5VE<$-<2'R\9 VK)@
M9X/YZ7)!< # &1GUY^I.!TP3P0<=37]=>&D*D>#LL]I1=+FEB:D&Y7=:%2O.
M2K<MERJ;<DEJN6,9+22/^:?Z;];!5OI)>(3P68K,(T*F3X.O&-'V:R_$X/*,
M#A:N6<]Y1K2PJHT_:58/^+.=*;=2E4*]%%&?I^0K[P_DD*4G..G  X&.GKZG
MWI** )D:1%WJ %# $\=3AL$<YR ,\'@#VK[<_9K\5M?%M$GCC1;)4,&P@*8F
MR"Q7@EB8B2QZ[CCH17P]N. N>!R![GO[_CT[5[E\#?$[Z#XKL;8>7Y>IN('8
M@EU:/S7CW;0"5*[E"\C<0Q/.%^;XNR_^TN'\QHQIJ=6G0EB*.MG"I1]]RCH_
M>Y%.-NJDUU/VGZ/W&$N"_%G@[-)XJIA<!6S7#Y=F7+!5(UL)CIQP_LJL&_X:
MQ$J-3F6M.4(U$GRV?ZMIIWVBU*@H@90_F-P@+= #ZG@'T.*W-.LVM8E1@JMC
M  .1A"=K<Y))RI(SWX!QFL_1+LR6$,DJKY2QJ7)!'W]K*2&'3;@YP .V"36_
M"7=W$A5%\PB/!)VH=B@Y[D@;L^^,D 9_C;'5L1'VM&5E34W=WNW\*276^L7)
M26BM;=W_ .G;@?)N'ZD<ISJA[>>-JY?%PBXN$(<RJ3]I);.G%TITJ$XN]6K"
MOS*48+V6I9J[RHGW"(VWS1IO*Q[E!E8 $#9DY8@   X';UC3&NHHK>"X.8;^
M6&*UCG1U;46@MI6#)#_#%%<3*%E\L^7'&[*V%4-YUH=O=->![7>[LNT11[LW
M09AOMP[A0(F106DD*(NWACE2>BU7QE=(1#'::>ES%&\'F&'[0;%1E&2&1R=\
MK*H\UU8H0JC8&!SQ4'&G%U)N46[*"BF^9IKG2DDU\+<+<W7ETNF?1Y_AL7F>
M+IX'!TJ591@Y59SG&$L/-J].:4H.I&]6*O*+LH*I&FOK'LW'VU+"WM+:]T*\
MF@DO[J=8S+#;/(LMC;Q)*QAN&A#1R!0%4L%!^\3EB!\6?MK)%9_"SQ6FE7,L
MMHNBV;+YD;*RR/=6ZS;B5'"@K&.2N![G'I9\:^*VN1='Q!J N55E$@F90490
MAC*)A-I0*@7& H"C"X%8?Q6T\?$_X9WNC7MU&EQ?P7NC3N(T$D,CPQS6UPQ&
MYFMY'C7*$#:ZR>7P.?HLHS?!T,WRC$U(RA0P.;9?BJLY4TY_5</C*56HFX\[
MLH\]1Q^U;37?\8\2_#+BC,/#CQ#R' UZ.89KQ;P!QKP]@</AYN-.>?YUPOF&
M"R])U\/0A0HU\1##8>E.5:E&BZDN>2CRJ7\^O(P>G<'UYZ^_U]J<2\G));:H
M&?11G'X#FO<O%OP#\?\ A*61;K1FOX$9DBN;*9I(Y$WLJN%(5D!R"J_.5R=^
MX?,?,=;\/7_AR00:M82VMQ) DL(WL597QG<P)4%<E67.>.0,\?V3@\TRW,(0
MG@<?A,7&I%RA["O3J.48I.3Y8R<ER\RYDTG&_O)'_,?Q%P-QEPAB<5@^*>%\
M_P"'Z^#JPHXNGFV5XS JC5FY*$93KTH4G[3V<W2E&<H55"3IRE9G,D$'!!!]
M"#G\NM>N?"P%M0N+6;3M)O5O;*Y@M#K%O/)##>F*8VTL7DH6\XR*RQ AMSX
M5OFQY3D22*5!'=FW,2<\$LQ)QSQ[]@V0I^S_ (1^#+N_MM*N[C4M,TN+1-'7
M4WFGT^*:1(+R[=O)FD$;2/*'#E9+O[6D,+,\,EOAMO>?-4X:NVNODU:Z[_\
M!UTL>Z?!NQEO=.T;3?$9N(;5)Y((YH;* '3;?S$O)-1>-H)9A81K9M;;;Z,(
M3&ZH74DK[;J/@/PUH,TUA'8V.L6NMVESIMCJUO=K+J$*VLC7*W<EM"69I&$A
M#R7JP[D)0L)!M%;X(>%](U*[U/QE:^.+[1=&DT^?0KU=2,T=J]I<!HM0EMKJ
M".[M[Q<SRO8O:PRS)''<PM!(Q8'ZM^&7@SX2:9I^K:]+K5EXHO\ 3;K47F@2
M%]4%CIL-T(WU"QTV=K"*68,MY%/93QV\ELJ22R- WEJK=*%2/+.G":DTWSQC
M*ZBU;22=[-:=FD=4:DX**C.:4=N5M:R45=-62;6CUU1^:^M?!>PUC4QID6JQ
M/>VML+B]BB2594LUD;;-<O)NEMYE<%8#N.[:,_*N:[/P]H-]X=G^R.;F<VEP
M]A9,\8BN;B&RLGNI+SSII@EU:2X8V\J1B0"*1G#1HQ'ZD>.X_P!G+X?GP/XL
MT'4M3UQ/%&A0R:OIUGHNF:;.?*N9#/9W.H3/-)</'Y;3?9[9;6(F-V:;;@'D
M?BII7PHU/1_"GC6P^PPZ'K>B3_8M(-G'!>6DBR:E;6U\EK:2PFWNKN'-N)K>
M&2.9K@B6:91.9>',LGP&;X66$QU&%6GRM0E9.=%RWG3DTW&26VMI)<KLFV?5
M<&<<\2\ 9WA\_P"&,QQ&7XVC4INHH3FZ.+I4WSNABJ<9)58-WM&:ER3_ 'D7
M&<;KY@T+54U&TB895_*#;&^\ "5RP.&5@059" RE3E?F&=[@UY5=7,WA^=9I
M=46YM[622))&*Q++8(D":=%+!'YCQ70B<NT]W(JL ^54&+9Z9:3275I%=+#(
ML<J@[R&9 2 >'QL<8.X,IVXYK^1..N"L9POF$I*,JV7UY\V'Q2247?7EG:3Y
M)QU4HVW3:NK'_1K]$;Z4O#OCWPGA\!B*U'+>-\FH0H9KD]2LG4G3I1C"&*P[
MDHRK4)I1E&HDW[W)*U2$HJP1DCVYZ?E\V>QYQCU))X%6;2UN+VZM[2UC:2>X
ME6.)%/S,QZ'V"_>8D@!5)K1T31Y=:O$LXMZM,5"2Y58(LNB&2X=@2(5+C.PA
MR2 "._V)X2^#^E:+%'/I;->:Q9VRS:KJU]':RZ7;PW$85_LB%+E\!7).T2'R
MV+-*C*&'R67997S&=J=O9P<5.3:NE)Z\D;ISG:[MI&T7><?=9_2/&/'N4<(4
M%#%3=3'UH36%PZC)4HRM'EJ8FLKJE2]I4ITVDI5:DIQA2A)N\? /B5I-K!8:
M'-'=->7D<1M=1(99(]Z6ENR.I0,-@*20M(5C9FC^<EN:^Y?V*/A?\%]:^'FO
MW'B_1]'O=7N[N::[N;]HGE33V0!4B5R6C"L'!V\GG!!Q7S+XQTG0[6R6>2U=
M88M1$^HR2M,D.PVM[*##%M*312^3 KJ S,[P*&RXKP+PKKVHZ=JNFVBZY>Z7
MI$^JV*ZBL,DB1-:?:8_/$L<;J2CQY#J&4A3C<,"OA_%CA',N*N'\9D66\18W
MAC$5\1A,7+'Y3/$+$QC@:D:WLHNC.C4G[>*Y)1<FI5%[RDE%O\+XVX5J>)WA
M/C<'A.>68\-2Q.:X26+I14,P@Z>+Q-7+>2C=*-6%G3INW*OJS487A)=!^T/_
M ,$X?B=\9/%_Q!UGX >"[/4_!-F)UTI]3OX]%74KB G-MIL=S%OE9<[4E4!)
MA@AP6-?EEXU_X)X?M)_"CQ3X9L/B7\,]=T/1O$>KV]FNN0H;W2;<3721F*\O
M+03)9%BRF-YB%9"N&\Q@A_NN^$K^'HO!>@P>'YK::R-A RFW;<N94CF!8%Y"
MK$')W/N^\"2.N'^T;X@\'^$O@C\3?%?CMM._X1SPUX2U76+F75(TD@6XL;1Y
M[(1ETDD-R;N.!8#%F82GY/F&:_EWPZ_:!^*/#/$V7>'JX/ROB/)IYOA.&LOA
MBEF='B^O4JSHY/A,14Q*Q%;"5\RK8IT\54PW]FTH5:DY8:,H*4:L/\A./?!G
MASBFA#.L?CZV58W*L!-UJM&E1^ISHT*U7%U5BZ<J<<0U3A4GAE-XA2A2C3:B
MW&49_G?\(?\ @DQ\ _#/PX\+7+6MQ9^/1H]KJ'_"06Y0RVE_/:HXC5BH9XU+
M $Y#<$@>OYT_M&?\%,?CO^ROXK\2? Q7?6#H5W>:59:M-(OF&*"4V\$:2GS'
M_=@;FWL'):-%&$<GW?P=_P %W/AF/AI96VJ^#K__ (3^RTJ&SV-<*EDUTD/E
MPS"/RF%PV$&%695,@4W)A5BH_ O]HGQ'XV_:/^(7BGXG7UM;V]QKVL7-UI\/
M[PN;:60E"Y"@))(K*[X7[RKN;YF<_O7@+X.^+_%?'?&&(^ESD-#/^%<+B*M7
MAFGQAB,OS&G3SJ>/E.-;A^5*K.K1RSZKRMTI2I4W&-*2H1:J.7P_%.=Y54R#
M!83P35>><QH1JYA#AO!SG.&7TZ<%)9A25%J->4VZ<*DX.JZCY(M\R9['\+_%
M7COXH_$+Q+\3_'LTEWJ?B5X9T,H:;;&K32+*-VY8MQFVD@DDJ'."P ^N].,K
MQS11;P2K2.8D+ %$=DW-V/F"-0H^\&8GO7RQ^S_I_B+1_#=C%K((OX-T'E.N
M_P#T99&6,G:HW$J$8D[N1GH2*^I_[2_L^UBCCPCQ227+M&H63S9PJ,)FP79$
MA3;'$#MR[.0K%E/]$<;2I2SVKAL#1P=+!X14LOR^CERC'"TL)@8K#X:G2C%*
M$:4:,*:BHWBWHK15S_7_ .AGP[#A7P*R&G5AFM#&8WVV=YS_ *P4Y4<90QV:
MIXW$RK0:D_:PQ/MZ7LIPIU*=%QG.E.4IG.ZSJ=S9HPV2$Y"R2E-D;R*NP(-H
M 81H@SM/3.1W/,0:W"-.FNS),]_%)-(5@&?,EBC::-5$8+HYC$K #&X*O\0Y
MDU:XM;W4((;^<6EG//''(V]W2(2''GL&#OMCX:1%#,5&0&(%=5HGA?PW?6&L
M+X?FCUZ2"6:V74;6WGELKERP@*QI,J.(I QCQ(A+ERJQG"JWM<*917JRH5*6
M$K5XU<31PU>>'7-4H^W:?M;W]V,$G)SU45':RL?A/TN/&G"\)<N%J8B5>M[/
M$5LJP,YU*5"JJ4E2Y:UO=E1=H^Y44ZTW%RDO>4WS6EZE=_$F'Q$/%!^USW"K
M=L+V\S/=S+;KLDEBYNT*"11<EB(Y#&SH2KK7YE_&;X<:EH.LP,VEQV6F:I=2
M26TUA%/+;1QW-X8X!/=2(A9]_F.%<*!&?W8"*#7]!GPV_96\5VUIX;^*?A7P
M]J<NGZDGV?Q!9C2=5GTW3[>8W-L9M.&KZ;MN;J.)@8I5-I;PQFU$9)"JGYL?
MMX^$-6\&>(-!U6UL;Z#3K#6TL+M L*VJ&VN4N+6-8IG65'EMCETF)1&;F(@-
MG^H\#EE/+J4(8=0C!0C[635ZN(G+652M-ZRFI3E;9)MV2O*_^)_%?%69\7YG
MBLTSBO.M5J59/"8>,FL)EV&O&$,%@L/?DHT*-&G2I1C%<TXTX3F^:]O2OA]X
MKT7]E;3])^%W@RYU>[UR+PG:>(/'US+:FPT[4->U>WMM36*348P;B;3XK>>U
MMH8%,T1VD21F$$C^Y+_@G5\7?!,7[.OPPU>TL+^>Z\.^##JNNZ?KDEM>:C8V
M6CVUDLL&D68G7R[.\U;4=0FMYA$9Q9W'GR[V)V_PXSW6M?'OPOH?Q3\$1:1J
M_B)='T/PIXUT.VDB9-.TNTALM+6:XLWN+:8SA3"R,$#-%--(Y C7S/UJ_9-_
M:$LO@]\//#>A>.X[RY\>:]XKN_#UA_9^I7M@NF:'#HNJ64=SXBLGMK]LD:E!
M9V'V=X[8M9AR%B@'G>M%M/;31Q[6_/U\[]T?,-1LK65DKV6O2SM9-K7RZ;VL
M>S_M6?MA:QXS^.7B;Q-!K][%(GB"[-A;/<21VMA%!=,EA%L=UBSB,#?A1\V$
MW8Y\2\+_ /!0;XD>#'\=^'U\7:AK*>+]%N-$NK2YNI/L.FRW*PDW@16;RYW&
MGVT:L^X2%(D )8A_A#XDZ3XCFUC4]0U&(WIN=5E@MA;RW$3"$.[I,\6!#)]X
M,)9'Q," 5$>4KS-O#MXUZUX\\X6&>1S&UT)62YCF<;C),(KB:*6$1AK=9?L]
MN1(5@B7RE5MM;*_X?C:WXC44[>\^^G3;\O\ +8]5\<^*KGQ1J=[-<-%<7#SR
MRR.RHZ3K*@$A## C^[YF%<Y))# @9YKX<>#]4U;Q;I?A[P_;R23^(]1MK!KC
M[.9)-D\^)$6)/F-M&9QYDBEML D,K(I=JSK@3VZ?9HEOI-0N'3S+>WD:2662
M1,K^[1"^SE(0%522,,&'3T_QG\3])_8\\ VAU -J_P"T'\5[2*'2=$:2?[7X
M'\-7CI;R V-@9I++4]=BNI+3<)K%S8L/W\1G;*;2U\^C]+K?LKVT3]2MDDK7
M>BZ7>UW?_@].Y^OF@1?##11=:S9ZYI%GH'PULHM(T75;^6WF33[OPS:0ZKJ.
MH3W%TZ116>J7LDHAE7S5E0*B[O,Q7,>.?^"V'PTU<>&/ GACQ1K"Z1I<-@?&
MGAV(&XT#7M7LEGL9=6LT\QFM(+ZUD,8TZ!H[>0AI3$^\U^)'[4G[2&JCX"V6
M@Z#:'2[_ ,<QBUU*XTZYM;B3^SXHK?S?,G0I<PHD^TO80AUN"N;JXCCB#'\9
M[/6[O0KX75MJ%RE_:21R0W'EQ22P&)\JUPL\_P!G1YHVED:W6&7>5 1W3RY(
M\:=>%:$*E&7/3GK%N,HMV=GI)1>^CTT^XZ,?@,5E6+KX#'4E1Q>&FH5Z<:M*
MK[.;BI)*K0G4HS]UIWA4DELW?1?WH?!?]I'X'?$<>'-6\.>+=+TNTUWQ/<P7
MOAYYU64PW31.E[''*#$DN9HB#.?)Q;"")O-0J/VB^.WA3P%X2_9@@\2SZ,_B
M/Q];O \<NBZ?;F_!NDFM]/6ZN=-@GMHM.\A;22-GEQ</,=K.S,!_G;_L!_%[
MP;X7^)6F^.OB9</J/AKP&K^*Y/#=Q/+"_B"_TN>6>QT_[1]K=DM_-$EO<):P
M*'9#YDHEV";^S'_@E=_P4W^#O[9'@?\ :0L_&OC?PC\'_%NKZI<ZOX+;QV^@
M)X7T?2;"QN;6T*:7KFL017M];HD.IW<<,=FODB5[:2"9%4;Q::>ENRWM:WEI
MT[/=Z[')R[->OGOY:NU]6DMCX[_X*$:;-X\^''@>[M?#]Q96WP^\'Z)?>+M3
MU?1EL]0TWQ-KOBB+2M8\D?:94N=.L[&YB9%MXP]TPBN)(D;>Y_E&_;*^'E\1
MJ36EQ;:G9^'M8FM=/O+*U\@-!,(YI4:&6."\"S I<*]R@<J%PIW<_P!C7QC\
M86VI_L(>/[WXBV:>/_C+X[^)\^@^"?B#X.ETN+P1'8Z1<6-S>W\(M=8GN?.N
M]%M;N>[2[T_[ 8TWV]U"T&)/YC_B'IMMKQU?2;W2/^$EG\4:<(=/>>^@M=.L
M=0BEBMEN=1+V$U[=2DQRB7?*(B$+?:(HO+\V%!)2M*3YY<RYI2:5[)1BGM'L
MN[UVN;5*SK*G!TZ4%1H4Z*=*G&G*HXMN52MRI<]2\DO:2<IRC%)M))&E_P $
ME/V*OAM\>M.U_P 1?$$07#QBXLX+9E5V5 L>^ JY;#-EQ*NU,H54,1UM_P#!
M5#]BOP!^RS%X*^(G@.Y6SM]0U6*#4-$69(V+PV[A9HH]JI+F3:Q7.X('(+;L
M5\*_#/\ :4^,'[$'CJ_M?#EY8W=N=0N9;G2XO*BMQ*TJN9+>YMTF>145(T*&
M<02A/W:.OESIS/[9'[>OQ*_;"U/3'\401Z=HFBLWV'35*3,Q"N%FFD6U0QL6
MD9R%=P0L,9QY6X_Q[7\-?']_2<H\:PXVHU/!C$X*M#'<.2Q,?W4(X)X:E@8Y
M?*DYNM6Q,X8AXF%2,:;IR5Y<TD?M.&XOX PWAC_9%/*94^-L+6I3P^-6']YX
MN.(=58Q8R.CITH+E=.4DY*3BHNROXK\-_&MT^N3[Y)HVDGFO86@C\P6T]Q*P
M<2L02L"F7)* ; ,G ''J&D_#CXG?M+_%:W\ ?#6SN=2U2*>"53:I+&D5X9(=
MDL\R8",@\QHF#*8Q$\F,J#7S5\.;A(?%NF-<2A8F\Y,AMGF.]O(J1XR <[L
MMQNP<CY37[$?\$M?VAOAW^SG^TQXP/Q*,=K;^,M'M;72-8GL[9K>RFB,QG8W
M 59+>1K60AI 2)/*2)/)!+-^J^*N9YQP7P_QAQ;P=PS'B;BS)>$<3C\AR-0E
M)9AC88B%&45"G#VM7ZO2O7JPIS4YTDZ<;.?,O6X4S?'<2<"Y/PIGG$&(P7#6
M8>(%/#9O7]M)*C1CE4\9AJ-:<J\8TZ>.Q,I4Z/-0E!5,.YN?[J-,^?OV@?\
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MDJ51UJ5W..+YI3C!IR2A[JE&2/\ 5Q_X-O[P7_\ P1@_8UNA@"7_ (:(  Z
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MNZ?X_P#"^D_!/Q.8K;6XYKHZ%<QB)(0T,3M=6LV2F9IA$#;!&"LV?E4L%/\
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MO=VZW=OY2!V$MJ93)&<,&4%26!XSD"OY2_\ @N#\?=!^(WQ3\)_#?0DM)H_
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M>6=S90>$M>:[U4K<S^';VYAM[/34CN9(I9K));>W\N&%)_)BC02B./AO5/\
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MHK1(****Z#QPHI22<9).!@9[#T^G-&X@%03@X)'8D=#^% :?UW_JXF.GO_\
MJKMO /F+XL\..NYE&I0AE&<$;VW D'(RI;D8/7!SS7$UZ9\,39)XGT>2[F$8
M6=_*&W*M<DE8A)@9"E2=I^[NQR"#CDQ\N3 XR?*Y\N%KOEBG*4OW4M%%:N_9
M7=CWN%Z/M^),AH^UAAU4SC+(.O4G&G3I*6-H1=2=2;C"$87YKR:2LC]9M"U
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M[17@IQ]Z#DM[1FHRT][31IV9?\2>";/^RFO'O(9I8DCWP*06_>[3P#P5)8*
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MP,<RS?"95F&)RK+93]G#'9C0PE:K@L&ZFOLUB<1"G1Y_LJ=WI<WR^EA,5F>
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M(2]I&%6C3IRK?O6_>4XRC6IR7NRA44(N3IS.'\9,3&(I$*QLAQ("6R<8.1Z
M9(XZ<U^M7[ '[<'PE\%^ K7X/?$75K?PU/X?EGETK6+L(MIJ5E)'"RPS<;EN
M$*.C.PPQ(!)/3\C?'UVT,4*%0L;(?F7N8^)>2>N"O3OSCFOB#XJ:B+>UG8S&
M(L^47=MD1DFBW3*<AE7@)@$ABW&>0<>)?!OASQSX6H\$<35,=@\)B,52QF%Q
MV6U(QQF7X[#QG"EBZ'M(U*51QA.K"=*M"=*<9R4HIJ$H_P">7TO>)(<+XCB#
M.:<*.+QV45Z=>E/%05*3C4Y.;#73IJ-'$*I3:G&'MFX491ORRYOV[_X*Y_\
M!0SX8^-_AI%\&_A5KD6ORZG>17-_J=F8V@54<(Z;",H(O+_=EN2Y)52"2/QP
M_9?UN]N[;4CJ-U<W*:?>^6EPS%I=L]H&>+S"-S-'O4J<L%4A%P%!/PWJDQFN
M[B3S'DWR;D9BS,5(!8G<3\P);!)]^]??/P$T:7P[X0B6[R+G5KV;49BJC]P-
MEG;VZY /#6T'F'DC>S>N*_7N&_![@[P)\(<-X?\ "_UC$8?Z^\5/'YC*%3,<
M=F&*J1J8S&5I4Z<81DZ-%4E"G"-.G3Y(12]U'\#_ $=.+^)N._I$Y?Q7B:GU
M;"9-EN.K8K#87VG]GT\)1I_5LOPM;WX^T<\?B*->$JC<Y.BY:4Z<VOL2XN(K
M:"69\>6(TE5T&T ,.-P&,D^IY)ZU%^S78:=\:_VH/"W@2]N%M]&TRX@N+_4I
MY)8]/LWGN((W:6:,ADEAM6D=0@;"R%F&TMGQGXE>.H?#?A.^U(R^6!&+6.$L
M#)+<Q08C4*"#^^9<J!SUYXKVG]D&TL/ _P .;/QM<6YU'QY\0=9AEG\M"SVM
ME?:BEFH$I7Y)X;6436T$3#SPCC>=F:^@\+.%U6Q<\\Q5/FIX2:IX3FT3Q%H.
M56R^SAXMMM73G*/8_HCZ>/CM*GE.!\+.',4H3SFE#,.(Y49)N.5.O4EA\&Y*
M2J?[=)0J.-2*J1PU"I":E3J7?Z-_MW_&;5/#FF6WP_\ AQK'A+6[32X!H<-H
MJR07WAC3XY+AD&FQF55DN+S8K73719XHRT9=I,U\,_"7PYKGCS20T=WI$[6N
M@W6G^+6U"-;"V^WRJ)KK5+-;EU@WW%L&6XN;60W2.BO&R[E5?,?'%AXXU#6=
M2UG4[=1=^(-;&DIJ)OHGNKVPFG,MOJ=M9I+))917-NSQPOLB:::1RNY-KR>_
M3BR^'WPHT'PUI,]_=7'B:^N=:\017$!@OK%F22PBT]8GB A6"(FX$0W.ZD22
MX( K]]3=^R2VVZ*W5/OO==+]3_**S22ZNROOLO-]$M/R/4O!]M^S_P"&=&&E
M:+I3"[L4M_M^JZAJ<LEYK6J0VACG:V\I8EBL%D#?9HIF61)))'9I?.*2>F^%
M/VG;+P)<0M!I<MY) T=S/J5L8+.]2-4P+*RN6M!<%$+A8N8HE SY854(^-=$
M'P_TRQUV\\<G7$O)='EC\,6NE2MIT-S>7$WF"]FN&6=+F6S@$<?DX@5C%(_F
M(40-@ZOJ%G%H,4^FPW,*WD1CBU.6X-Y(I5B5CCVA40A#@[E5P[,%)0;@[Z+1
M;;)Z]-+6MU777HN@N76]V_NT=E9_\,O7;7[RU73_ (5?M.W.H>)K*0+K-O<W
M6HZCJ&NV$,NN:=J2>5'!?2ZEO2.>..6,F&\D.Y)< &-7##\FOVEOA!;>(DUF
MZ\/1:IKEAX!TQM6\33V=U!:64.DVJP/>-,K1K>WQM[J6.6W+M)>,]Q&4)CA/
ME_6/[-7B&[\(>)M5LWU1I=+UVQDTS4%O]Z1_9M3C7]Z2_P Q6!VB<-$)<R("
MG+!E\V^-<'BE]"U74;O0K"RLKKQ'K6DZ-K^ER9LM=;2;>U37;V*YER]_;0P/
MIZV\1A9X8KDN\>966-2UC?KUTOJNEUMN]^H):N.KC;OWMV\T_P"M_DCX!?"_
MP7;:];>*-,\2ZHV@3V]H^IZ1K"210SQ><%E@NHA%%#>0PR&8VRMYXWR+-Y"S
M1Q2#ZY^*'[3/[/'@W6;W3-)TN;Q)XBT>VAMA'90S6.FP7UBD&R""\EN LEPP
M$AE%G:-L+N[W18O-7Y__  J\6V=_JGB;PD-3U"YO+JUUAO"CS31P1RZE*OF6
MOE)"%F0+M:.WMA;L_F*CO@-M'RGX@NKYM2O+G4(;AI4O")EN=\4\=Q!NA"R[
M&)60HL1D0[")=Z;%\IZA2:5EWNWOVZ=.F]]=B6U:-EW3_"][=_-[?A]QW_[=
M_P 6CXCDU#PC+9^#](MKI);;2;8MJ]K/%(9$DDN&UE+R:YNI$!1WEN&^5ML0
MC).[]+)?&G[.OBKX>WEY\7_''A_^V-2\/:?X@31K>"ZS82ZG##<2QPVUM=E;
M*2&X<7"(]K);PLNR**.1%+_SOB^(11;[(V)WN%D#(N-RJ#\N%(.!$,EB5!)/
M!&AJ.JZGJ%T!<7=Y=RWP<32,[F60;<1J0H0^7!Y1Q&5"$1D!1'@DYFKWUO;>
M_KU_K9ILE/5>7;1_>C]8_%W[#V@?$S2D^)W[/&O6>J:!=M%I]]HUD'1K74H+
M%I[A'$OVR:[>YD"JZ7?D).0TC*)-YKY+O?V=?'NG6FLZ3>PZ=X1MQ=1MJ%[J
ML<T<U[([2DVS68@W1"TCCDG\NULRDCK&#<%MBGO/V$/'_C'1?C3X)\'6/B+4
M=/T3Q+KVE?;FM9;D2+;QRNC3)'"[0HR"0R,]PH#C?!O:1)%K]6OVT/!I\,^"
MK/XJ27WA<77Q'NM1TSPG#87]O=:[ OA^]?3;R_\ $.G23";0!=,LEQ;7%RK"
MZ C,;1A7(=DXMK1K?M?3^EY]RHV?3?33I:RU[WO=M6>_1GXR6'P>\6^&-%E\
M01^,]"TPK DMM%JT3V$S+?>7#=7(M7<7D16WFE;S5@69HBZKMA2&,<3HZ_$K
M0KR^N?#GC[PS<Q7MA=6.I0Z=XAM=..K64LP:[L)X"\,]PDIQC=N#QR*C%U!6
MO3%\*:IX\\!?%'Q-/XELK&[\#?\ "-7LOV^>YN%\0/K^K2V5Y:V3,%6WBL[+
M44N[B=_G*B>.-"JJH^.;ZP:WN52WD2ZV1!98[8S1N9%RCHC$#S%?8&\R+=N0
MY&0<F+;>?]7_ *[!*R:LM-TT_3UM_P ,SW?6OB=X@T2+4=)UCPG906>L:1:V
M9M7MFBMOLUHZW%O=1SV[!;BZC$9DCE4^67*F:*>,.!X#K/C'5]6DOC)=7$2:
M@46]BCGG,=TD'%NLYEFEDD6%0L:0N[0*B)MC#;BWZ8?L._LU:I^T8?&_P_UR
M*>X\-3>&7N%F:XM[G4- O@UY=17>G-N;R/*6RGNG2-V$UE(1<"..-ROQ#^TI
M\"-=_9X^)^K?#[6;B/4(K94N])U:#8;?4M.F:18IHVC9E,BM&4G4[61Q@J 0
M6=G:]M/Z_/\ KH1-R44T^FMUJM>_SZ]'TTOX7<78GC@0011-"A1I8E*/.I.0
M9L,5=U.0&"KP<$$C)TA9))8/=)=HDL;K'+;R,5ED:0W3P^4N!YBXM\O@NJR2
M)EDD*[L&NBTFRO%GBW6TAA:> ,\T3^3&0X4.ZD#)'F%0F-S%@N,L 49Q;;=]
M=-^W_#^7W=LZ+5M6M8);.#4]1M[67_76L-Y<Q02\8(E@218W]#O4U!;R2-=0
M$R,6:6)&9W;!4NN5=L@[/49Z5K^(M,.G7G$\5PDYDD0QLK.B>8?+,P085I4*
MN!G/)! (.<&,D21D=0ZD?4,,4DDFVDE=W;25V]KON[::B;:E%-MJ-K7>B5[V
M5[I+Y6\C[Q\.>;>:)H=Q*Q^SM%"EQ# !"-QB4-@X!DSC RI++@CIFN'^+OP;
MBB%YXF\+B:YMX[=;[4[38C^4I -Q/"0I#;,EI4(/0R @YRSX7ZKXN\0:=INE
M>%/"&L>+]6L2\3VNEV\MPX@BAR)U*J49HXRBA20S'A22P6O=?%/CV?X9:--;
M^*_!^MZ9J]WITENVE:S;M:,1<PO%O$-PJ!D1F)9T+ %20"1@?B]1YWD7$:CE
MBHXBOB,573RR.*PWM,5A9UW44JE!U56I15/F=+$SIQ49/=I-2_T&R[-?!WQ,
M\-ZN4\:YTLHQ.5\/Y=C*?$.(P.8U,3DV9X3+*>$D\!.E0G2QRJ8ITX8W*Z<Z
MJJPBG!4JDJ=2E_HW_P#!ME;I:_\ !%/]BJ))8I0;;]H&9F@&(UDN?VJ/CC<R
MP@9/S6\LKP29.?,C?(!X'[EU^&?_  ;93+<_\$6/V-;A$6))Y_VDI5B3[L2R
M?M;_ !Y<1+[1@[!Z[>@K]S*_;X7Y(7;;Y8W;M=NRNWR^[>^]M.VA_ -5P=2H
MZ<5&FYS<(Q<G&,')\L8N;<VE&R3FW)I>\[W/X2_^#UO_ )QH_P#=Y7_OJE?P
MEU_=I_P>M_\ .-'_ +O*_P#?5*_A+K.?Q/Y?DCFG\3^7Y(****DD**** "BB
MB@ HHHH **** "BBB@ HHHH **4@C!((!&1[CIQ24 %%%*,=\_AC^M  #VP#
MGU'\JW8-/:9,R1D<Y+%<#@$GE@"!USZ[21P.<V&>*%P_E;SD$%L%25SAL$''
M."<9_.N[T74)+M##(D;/,=D)*QHZLD<@W+(Q7YY%RAWG!! ..,S)\L6^RN.<
MG"+MJHV;?1IVU:\EMKT.=&AS$2.!@",OCRPWR#:&8 J H 92'4@Y8!<MQ4%Q
MH\Z'S'"1J&9#&$*D-&!E3G[K'T;!)SG#$UZU=6]MY5Q+<V;/%;?9AN<06X9&
M=/,*W,D@C8LKJS(JEF!#)\F:X_5YW5'B0JK3S/)*Y527:<1RIN8,^]HPS+F,
MD!LY!&,Y4ZKJ;)*SL_\ P&,GLWTDM6EJS"E7<W9)*S5]GTBW;5M6NEJEKLNI
MQ!M@(F4KM</\N1\W1?E/&1R"!G R1@\U0=2C%3P1C(],@'!]QGFNJ$-S*_E"
M)IV(4%@,L7<80L222<CY1D' R 2#C.N-,NFDG=HI(PD@64LF3$S'&UL').05
MY R?0&MKKNC>\7UBG:]EK?3R=E_P=3%)SCIQZ #\_6DJX]FZ GDXY(QM.,9S
M@]1_ND]#G'%4SU/]>OXTQ#M[;=N3C.<>_09^G./3)IM!&"1Z'%*2,\#CMG&?
MQQ@?IGUH'ON]MEK_ $A,GGGKU]_K1110(**** "C_P"OU]A_7H/>E))"C^Z"
M!T[DGL >I[D^G0 4@_SQF@>B:Z[/_@?T_N"I&="BJJX(P2V%!/R@$9 R1GD;
MB?H#G,9R#R,'TQC]** VNOEKZ_\  "IYYVFV;@N47:"J1QC   &V-57C!/3)
M)))))-044"OOYBY) !)(&2!DX!.,D#H,X&<=<#/2DI2,=#GCGC&#W'X48&TG
M/S9X7'4>N<\?3% [/]?Z_P MQ**53M93C."#@\@X.<$>]*Q#'(&.G Z<#''
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M\_X5R#BC#0PF?9?#,,/3<W&E*OBJ"7M(\DTY86O0G*,XNTH2DX-;Q/U?PO\
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M_P!E,63RHLA>'=$/VD;H@Q*$3)F?=LW?*6(KUFW_ .#8!;<L4_;>&7?S)?\
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M ."E,R98$?\ &'RLA )(WQO^U$P9A\OS(8P2#E3D!=W3?^#,VSL])U'3;O\
MX*'6>HSW[V;IJDW['CQW]C]D>Z<I9RK^U,QB2Y-RJW"@_O$MX48E 5HHHY8]
MOS ^HOV3_P#@U1\)_LU>.KCQ_K7[8Z?%'5TTZ:UT:"Y_9MB\,6.CWSP>1%J$
M<#_';Q,MR8E^8PR".263YWN@<Y['XX?\&RU_\8I7-O\ MR1>$X 9O(AC_9FE
MU=D$LLDV+AO^&AM*BN5CD<%8C;Q6WRC= 3@J44^56M;3YCNU;R\E_E^)\EQ_
M\&>%S ;P6W_!2"ZMUO52&8Q_LG3^9-9"%XWTZZW?M0M!<V6]EE@C:V1X3&B-
M+,@ J*^_X,YX+JSMK6'_ (*#Z;;&UBVQS+^QUN>2=EC$T]R8_P!J*"2ZW&-3
M%'/+(MO\Q1C(S2$HI<D>WXO_ #%?^ON_R1]L_L3_ /!MA<?L?>+M1\6S?MLS
M?$V?4+ 61T^?]GB;PM80Y74HY)E@E^/?BJ%Y)(]3FC):'S"N\O*\DK2#SK]M
MK_@UKM_VP_&.E^*K?]MVW^&$>E"XCM]+@_9>A\4CR)XX1Y NX?C]X3.U9HY)
M]TEM,Y>=QN ')13LK6MI_3!ZJSU_X%NN_1?TV?&^E?\ !E?I5I/YNI?\%'+K
M48U52D$'[(\5C&TB[CFX+_M,WS2PME0T<9@DP&V3HS!E[RW_ .#./0K:RFL8
M_P!OUA%,NF$/_P ,JR>9%-IDBRI-$/\ AI?R5\^0W+3Q&%HY#<LTBO*BR444
MN2/;\7_F"TT5ON3_ #.=\1_\&9MKKJ1B+_@HI'I\H!\^X'[(4ES+<.<@%B?V
MI(%147:L<84HN&."2"O(+_P92[65O^'EN=K!L?\ #&V,X.>O_#59Q]<'%%%'
M)'M^+_S$TG9OIL?J7^PW_P &WG@G]C32]1@N_P!I2T^*^MZI*\EUK5Y\!(?"
MR<EA&L=A+\7_ !6R"./8K 7I$C)N*J&9*J?M\_\ !MMX1_;;T_PHFG?M.:?\
M'==\-7<LLNO6?[/4'C"35+.4-FQEM8_C)X.^SJ&*MYJW4VX(%:(Y!!17Y(O
MKPO7B3'Q>_L#'OQ"ASJ.>OBSC&5%0J86>"E1_L.6?OA[ZN\-4E36'>4^P3Y:
MD::JPA./V3X^XJ?#3X0>8T/]7G"%-Y>LIR:+Y858UHOZ['+UC^=58J;J?6O:
M2E\4W=W_ &/_ .";?[%MM_P3R_8K^"O['EK\1)/BO#\'XO'ZGX@R^%?^$(?Q
M'-X]^*7C?XG7,Q\+?\)+XP_LE;&Y\:2Z4D7_  DFI_:$L5O ]N+C[';_ ''1
M17ZY%*,5%7M%)*[<G9*RO*3<I/NY-MO5ML^0G-U)SG)14IRE-J$(4X)R;;4*
M=.,:=.*;]V$(QA%6C&*BDE^$O_!:[_@BC_P^%_X9H_XR7_X9V_X9V_X7+_S1
MK_A;?_"8?\+;_P"%5?\ 55?AE_PC_P#PC_\ PK+_ *C?]J_VW_S#?[-_T_\
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M[':+'& ?W@:$_M2,\A<8"LL\80\E7SBBBCDCV_%_YC44MEY$'_$%)_UDN_\
M--?_ ,JNC_B"D_ZR7?\ FFO_ .57111R1[?B_P#,7)'M^+_S#_B"D_ZR7?\
MFFO_ .575AO^#*F/RH4C_P""E<J2KO\ -D;]CM623)^3RXU_:EC:(*N0VZ:;
M>3N&SI111R1[?B_\P44ME;YO_,K_ /$%)_UDN_\ --?_ ,JNC_B"D_ZR7?\
MFFO_ .57111R1[?B_P#,.2/;\7_F'_$%)_UDN_\ --?_ ,JNC_B"D_ZR7?\
MFFO_ .57111R1[?B_P#,.2/;\7_F'_$%)_UDN_\ --?_ ,JNC_B"D_ZR7?\
MFFO_ .57111R1[?B_P#,.2/;\7_F'_$%)_UDN_\ --?_ ,JNBBBCDCV_%_YA
)R1[?B_\ ,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>nt10016217x4_graphic24x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic24x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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ML'GD\9#*\=7PD<3.A6RR-&594914W256HH.5W%3DENSY-_X8M^!__/CXD_\
M"AG_ /C-'_#%OP/_ .?'Q)_X4,__ ,9KZRHK]L_U&X._Z)G)?_""A_\ (>7Y
M]V?R)_Q&3Q5_Z.#Q9_X>L9_\M/DW_ABWX'_\^/B3_P *&?\ ^,T?\,6_ _\
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M_P#(>7Y]V'_$9/%7_HX/%G_AZQG_ ,M/DW_ABWX'_P#/CXD_\*&?_P",T?\
M#%OP/_Y\?$G_ (4,_P#\9KZRHH_U&X._Z)G)?_""A_\ (>7Y]V'_ !&3Q5_Z
M.#Q9_P"'K&?_ "T^3?\ ABWX'_\ /CXD_P#"AG_^,T?\,6_ _P#Y\?$G_A0S
M_P#QFOK*BC_4;@[_ *)G)?\ P@H?_(>7Y]V'_$9/%7_HX/%G_AZQG_RT^3?^
M&+?@?_SX^)/_  H9_P#XS1_PQ;\#_P#GQ\2?^%#/_P#&:^LJ*/\ 4;@[_HF<
ME_\ ""A_\AY?GW8?\1D\5?\ HX/%G_AZQG_RT^3?^&+?@?\ \^/B3_PH9_\
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M$G_A0S__ !FOK*BC_4;@[_HF<E_\(*'_ ,AY?GW8?\1D\5?^C@\6?^'K&?\
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MCXD_\*&?_P",T?\ #%OP/_Y\?$G_ (4,_P#\9KZRHH_U&X._Z)G)?_""A_\
M(>7Y]V'_ !&3Q5_Z.#Q9_P"'K&?_ "T^3?\ ABWX'_\ /CXD_P#"AG_^,UY-
M\<_V7?A3X!^%/B[Q=X>M-<CUG1K?39;)[O69KJW5KK6],L9?,@:)5D!M[J4*
M"1M8JPY45^A=?/O[5'_) OB'_P!>>B_^I/HE>)Q)P9PGAN'<_P 1A^'LHHU\
M/DN:5J%:G@J,:E*M2P->I3J0DHIQG"<8RC).ZDKK4^MX \6/$O,..^"<!CN.
MN)\5@L;Q=PWA,9A:^;XNI0Q.%Q.<X*CB,/6IRJ.,Z5:E.=.I"2:E"3BU9GDW
M@?\ 9"^#>O>"O!^N:A9^(&O]:\+>']6OFBUV:*)KS4=)M+RY:.(0D1QF:9RB
M D(I"@X%=3_PQ;\#_P#GQ\2?^%#/_P#&:]W^%O\ R3+X<_\ 8B>$?_4?T^N[
MKOR_@GA"I@,#4J<-Y/.=3!X:<YRP-!RE.5&G*4I-PU<GJV]VW?=GC9YXO>*-
M#.LXH4>/N*J5&CFF84J5.&<8R,*=.GBZT(0A%5+1C"*48I:)))'R;_PQ;\#_
M /GQ\2?^%#/_ /&:/^&+?@?_ ,^/B3_PH9__ (S7UE179_J-P=_T3.2_^$%#
M_P"0\OS[L\O_ (C)XJ_]'!XL_P##UC/_ ):?)O\ PQ;\#_\ GQ\2?^%#/_\
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MC<'?]$SDO_A!0_\ D/+\^[#_ (C)XJ_]'!XL_P##UC/_ ):?)O\ PQ;\#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH _E\_P"#L3_DP7]FC_M(+\&O_5,?M&U_-57]*O\
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M5S&-3ZTLORJA"5"&.S/%UJE+VU-TZ->=:LX?QV45_4'_ ,$\?V$_AOX9U?\
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MAFN.QE3C"DZN5XG&Y)#%87$9+@Z'+*CF6(QV(<,+B85*4/;J'M'_ "%_L;>
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M!XK-)4(Q3>7QKQQGLIT^>M)\BA>B\,IQ4U>#\(L%FN79=PW@,URF<Z_C)G?
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M*_)#1HM+GUC2H-<NKFQT6;4K&+6+VR@6ZO+/2Y+J)-0NK2U=XTN;FWM#--!
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M19[B#542SL]0G?[&532]4)_L^Y_EGK[>^&G[>'Q0^%W[)'Q0_8[T/PKX!OO
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M>$>(\GXFRZCA<1CLDQU+'X:CC859X6I5HWY85X4*V'K2IN[NJ=:G+M)'T/\
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M71? FEZG;,VKZ7XI;3C>^%-%BCTJQM(6#R^7)<?@C17APX"PRRO%Y+6S[/\
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M^S_#I5?$MG!H_B#6[RVU?2]$_/+_ (*Q?MS_  9_:8\?? KX?_ 2YDU'X0_
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M[^A;_P BOC__ +#^'O\ U'S8_P!Q"BBBOY_/[="BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Y:_\ @[2U;3]-_8&_9K%[<K 8_P!O3X5:LX*2OC3]
M*^#'[0?]H7/[N-\K;?;;;<@S*_FCRHWVOM_DY_X:H^ 7_10[/_P2^)__ )25
M_6G_ ,'9$,,O[ O[-/FQ129_X* _!Z$^9&KYAF^#'[1?G1'<#F*7RT\R,_+)
ML3<#M&/YBO\ A#?"'_0J^&__  1Z7_\ (M?OG@Q#/)X7/_[(Q.58>"Q&7^W6
M98'%XR4I.GBN1TGA<QP*II+GYU-5')N-G%)W_BGZ6=;@^EF'!"XHR_B7'3E@
M\]^IO(,XRO*X4X*OE?MUB8YCD6<.M*3=)TI4I4%!*:G&HY1</(?^&J/@%_T4
M.S_\$OB?_P"4E'_#5'P"_P"BAV?_ ()?$_\ \I*]>_X0WPA_T*OAO_P1Z7_\
MBT?\(;X0_P"A5\-_^"/2_P#Y%K]M]CQI_P!#+A?_ ,,F:_\ S_\ 7^GI_(7U
MOPE_Z$'B+_XEW#7_ -!)Y#_PU1\ O^BAV?\ X)?$_P#\I*/^&J/@%_T4.S_\
M$OB?_P"4E>O?\(;X0_Z%7PW_ ."/2_\ Y%H_X0WPA_T*OAO_ ,$>E_\ R+1[
M'C3_ *&7"_\ X9,U_P#G_P"O]/0^M^$O_0@\1?\ Q+N&O_H)/(?^&J/@%_T4
M.S_\$OB?_P"4E'_#5'P"_P"BAV?_ ()?$_\ \I*]>_X0WPA_T*OAO_P1Z7_\
MBT?\(;X0_P"A5\-_^"/2_P#Y%H]CQI_T,N%__#)FO_S_ /7^GH?6_"7_ *$'
MB+_XEW#7_P!!)Y#_ ,-4? +_ **'9_\ @E\3_P#RDH_X:H^ 7_10[/\ \$OB
M?_Y25Z]_PAOA#_H5?#?_ ((]+_\ D6C_ (0WPA_T*OAO_P $>E__ "+1['C3
M_H9<+_\ ADS7_P"?_K_3T/K?A+_T(/$7_P 2[AK_ .@D\A_X:H^ 7_10[/\
M\$OB?_Y24?\ #5'P"_Z*'9_^"7Q/_P#*2O7O^$-\(?\ 0J^&_P#P1Z7_ /(M
M'_"&^$/^A5\-_P#@CTO_ .1:/8\:?]#+A?\ \,F:_P#S_P#7^GH?6_"7_H0>
M(O\ XEW#7_T$GD/_  U1\ O^BAV?_@E\3_\ RDH_X:H^ 7_10[/_ ,$OB?\
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M9,U_^?\ Z_T]#ZWX2_\ 0@\1?_$NX:_^@D\A_P"&J/@%_P!%#L__  2^)_\
MY24?\-4? +_HH=G_ ."7Q/\ _*2O7O\ A#?"'_0J^&__  1Z7_\ (M'_  AO
MA#_H5?#?_@CTO_Y%H]CQI_T,N%__  R9K_\ /_U_IZ'UOPE_Z$'B+_XEW#7_
M -!)Y#_PU1\ O^BAV?\ X)?$_P#\I*/^&J/@%_T4.S_\$OB?_P"4E>O?\(;X
M0_Z%7PW_ ."/2_\ Y%H_X0WPA_T*OAO_ ,$>E_\ R+1['C3_ *&7"_\ X9,U
M_P#G_P"O]/0^M^$O_0@\1?\ Q+N&O_H)/(?^&J/@%_T4.S_\$OB?_P"4E'_#
M5'P"_P"BAV?_ ()?$_\ \I*]>_X0WPA_T*OAO_P1Z7_\BT?\(;X0_P"A5\-_
M^"/2_P#Y%H]CQI_T,N%__#)FO_S_ /7^GH?6_"7_ *$'B+_XEW#7_P!!)Y#_
M ,-4? +_ **'9_\ @E\3_P#RDH_X:H^ 7_10[/\ \$OB?_Y25Z]_PAOA#_H5
M?#?_ ((]+_\ D6C_ (0WPA_T*OAO_P $>E__ "+1['C3_H9<+_\ ADS7_P"?
M_K_3T/K?A+_T(/$7_P 2[AK_ .@D\A_X:H^ 7_10[/\ \$OB?_Y24?\ #5'P
M"_Z*'9_^"7Q/_P#*2O7O^$-\(?\ 0J^&_P#P1Z7_ /(M'_"&^$/^A5\-_P#@
MCTO_ .1:/8\:?]#+A?\ \,F:_P#S_P#7^GH?6_"7_H0>(O\ XEW#7_T$GD/_
M  U1\ O^BAV?_@E\3_\ RDH_X:H^ 7_10[/_ ,$OB?\ ^4E>O?\ "&^$/^A5
M\-_^"/2__D6C_A#?"'_0J^&__!'I?_R+1['C3_H9<+_^&3-?_G_Z_P!/0^M^
M$O\ T(/$7_Q+N&O_ *"3R'_AJCX!?]%#L_\ P2^)_P#Y24?\-4? +_HH=G_X
M)?$__P I*]>_X0WPA_T*OAO_ ,$>E_\ R+1_PAOA#_H5?#?_ ((]+_\ D6CV
M/&G_ $,N%_\ PR9K_P#/_P!?Z>A];\)?^A!XB_\ B7<-?_02>0_\-4? +_HH
M=G_X)?$__P I*/\ AJCX!?\ 10[/_P $OB?_ .4E>O?\(;X0_P"A5\-_^"/2
M_P#Y%H_X0WPA_P!"KX;_ /!'I?\ \BT>QXT_Z&7"_P#X9,U_^?\ Z_T]#ZWX
M2_\ 0@\1?_$NX:_^@D\A_P"&J/@%_P!%#L__  2^)_\ Y24?\-4? +_HH=G_
M ."7Q/\ _*2O7O\ A#?"'_0J^&__  1Z7_\ (M'_  AOA#_H5?#?_@CTO_Y%
MH]CQI_T,N%__  R9K_\ /_U_IZ'UOPE_Z$'B+_XEW#7_ -!)Y#_PU1\ O^BA
MV?\ X)?$_P#\I*/^&J/@%_T4.S_\$OB?_P"4E>O?\(;X0_Z%7PW_ ."/2_\
MY%H_X0WPA_T*OAO_ ,$>E_\ R+1['C3_ *&7"_\ X9,U_P#G_P"O]/0^M^$O
M_0@\1?\ Q+N&O_H)/(?^&J/@%_T4.S_\$OB?_P"4E'_#5'P"_P"BAV?_ ()?
M$_\ \I*]>_X0WPA_T*OAO_P1Z7_\BT?\(;X0_P"A5\-_^"/2_P#Y%H]CQI_T
M,N%__#)FO_S_ /7^GH?6_"7_ *$'B+_XEW#7_P!!)Y#_ ,-4? +_ **'9_\
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M/^A5\-_^"/2__D6CV/&G_0RX7_\ #)FO_P __7^GH?6_"7_H0>(O_B7<-?\
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M4I\&O^B2?#+_ ,(+PK_\JJ/^%*?!K_HDGPR_\(+PK_\ *JO\AO\ BNMB/^C
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M,KNYTZ/4;2U\6:AKGB+3/%VE^(;O3M-U/2[/Q!?>'7TVWO+C2[.!+%[[4.7
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M?L[+^Q7\.?!+Q7+<>5+X=O6NOMT.G;(Y;4Q>>SS+!]N?MN?\%!/VE/V9[#X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '\OG_!V)_R8+^S1_P!I!?@U_P"J8_:-K^:JOZ5?^#L3_DP7]FC_ +2"
M_!K_ -4Q^T;7\U5?TCX#?[GQ)_V$Y;_Z:QA_ OTTO^1EX?\ _8#Q%_ZD90%%
M%%?OY_$)Z7\&?ACK7QI^+7PU^$?AYO+UGXD>-_#/@RRN3#)/%I[>(-7M=-EU
M6ZCA!D^PZ3;SRZE?R 8ALK2>9RJ(S#^QS]LG]E#XX>-/%W[%UE^S1XR^!W@'
MX??L>ZOX?\3:=X3^)7COQ;H-YK&I>%G\*V'A31GL?#_@7Q2C:+I7A'PW<:.E
MY/J%O=7<'BC6();+R8X9Y_Y4_P!AW]I/PO\ LD?M">'?CQXE^'-Y\3YO"&B^
M);?PWH%GXHA\*"S\0>(=*F\/?VU<WT^@^(4NX;/0M2URWCL?L43?;;VTODNX
MVL1%-P/[4GQ\UO\ :A_: ^)_QXU_3(M$O?B%K\=_;:'%=_V@NA:%I6F6'A[P
MQHC:C]FL?[1FTCPWI&E:=<:D+&Q&H7%M+>BRM!/]GC_.N).'\\X@XFRZ5"K2
MR[*<HRK&SI8S$X:AF-+%9EF=\%B,.\!]<PU2U/+^9QQ-5J-.<Y1I1<I<\?WC
M@'C?@[@CP]SZEC,+BL]XFXHXDRFEB<IP&88O(L3EV0<.N.;8#'+.GE./H*6(
MSQ1C4P&&3G7HT:<\14C"G[&7[C_\'!7P)BM?$?P1_:;T*V\RQ\4:9>?"7QC?
MVYM_L)U/2!=>*_ -UOB&^ZOM:T:\\96TERSN@T[PMID*':JBO=/V]/VH?C;^
MS5_P3L_84;X(^,9O 6K?$#X<_"W1M?\ $FF65E/X@31])^#7A^_33=*OK^"[
MCTE+R\GAGO+VRMX]5/V&VAM=0M+>2^AO/R3\8_\ !2&P^(O_  3V\.?L2>-_
M@[/K7B7P7:^';3PE\8'\;P;-)7PEXM.H^'KF#PC)X1>6WFL/ DMS\.WCC\22
M&XT^6?4%N+<W9L+;F/VN_P!OZS_:A_9T_9G^ UM\++GP7+^S]H.@Z1=>*)_&
M,6O1^*)-#\"Z/X-\ZWT>/PSI#:2ETVFR:CMDU/4&@61+7,Q#7 ^;RWA+/)4.
M#LJSG+*>-P7#.?YU1K5L1/!5:&*R=8><LKQTL/+$56Z<ZM2-*EAI0E7HJA#V
MM**7._O<_P#$[@^&,\5>)>%.(<1E.;>(/!7"6)PN%P-'.,-C,MXI^O4(<1Y1
M3Q\,#AXQK4L/1JXFOCX588/%2Q=;ZMB9M^RC^R7_  4I^,/Q'L?^"=7[ ?[4
MFE>)KC1?CQ+K?P2\11_$32+33K'6;+5/BC^S/XYU3QU+IIBM/L^GV_B"[BB>
M\L;2&*R98;=1;@6MKY,'_!<+]H'XY?!G0OV/;GX2?%OXA_#2?Q=I/Q?F\4R^
M!O%FM>&&\03:79_!J33'U<Z/=V@OFT]]7U5K+[1O^S'4+WR=GVB7=^1O[3O_
M  46M/VB?V+OV=_V2H?A)<>$KCX&#X5_:?'4OC>+6X?$I^&/PKU[X9J8/#J>
M%-*?2AKG]MG6F$FM:A_9GV8:<#J'F_;H_HWQW_P5N^&'QG_93TSX0?'']EC2
MOB3\9?"7PTU7P1X,^)6OZIH.KZ-IOBS4_!,G@@_%&*QU+PY)J.CZXD4R>)+G
M1].:XM[CQ!IFGW%EJNDSPZ;?:)PX#@_-\NJ\+XNMPY2QT,KSWBB&+P"J98Y+
M+,WC*GEE2]2K*A+"86K4JXE4.:4Z#G*4:49SDU[&=>*O"^?8;Q&RO#<>XG**
MO$?!WAQ5RW.I4.(8TWQ%PQ*G6XAH6P^%CC(9GF.'HX? /&>SC2QD:,*=3%5*
M5*G$^COV[?%WBGQY_P $5OV3?&'C7Q#K/BOQ7X@^('PZO]<\1^(-1NM6UK5[
MY_#?Q:1[O4=1O9)KJ[N&2-$,L\KN5103@"O8?V\?VHOCE^S/_P $[OV$;CX'
M>,Y_ 6I^._AY\*M'\0^(=.TW3+W63I6D_!K0-1@TS3[O5K._ATM+N\D2XN[J
MRMX=3E6QBMH+Z"REU"VO?QI^,?[?]I\5_P!A#X*_L8I\++G0KSX2Z[X=U>;X
MA/XRBU&VUQ/#VG^,;!8(O#(\,6,NGO>CQ3',SOKMX+8V3Q 7(G62/[-T3_@L
M_P##N]^%GP9^ WQ6_8R\(_%3X3?#_P"&_A/P=XJT_P 8>*M+\1WFL^)?!NA^
M'= T+QAX>TS6/ DVBZ0MC::=X@DETRZ2[U*[FUVQ^Q^)=$CT6\3Q%<N$LZP]
M/*7/AJGFF'R_C#B7-:V5RQ&5QI5,MQ<;8&<85ZSPTN9J,Z.':YE.$(5(T4^>
M.-/Q-X2QN)XEC3X_Q'#F-SOPL\/N&L)Q'3P/$53$8?/\KG!YQ3J5,%A(XZ"I
MIU*6+QL9*$Z56K4P]3%R7LI_?GQ^N#^UQ^P1_P $Y_%_[1=A:VOB7XC_ +3?
M[,%CXH^V6<.GOXIT_P 9ZYKG@GQ!?PC2)=-ATBQ\=>#+N;QU);:=]DM(+9[>
M*UM[)K>T>S^</^"TO[7?[2_P#_:>^#W@GX-?$[Q;\*_"/A_X2Z%X\T_3_"-^
MNFZ9XA\0ZEXT\7Z3=R>(].A1M-\2Z18V7A+1]/M?#'B2SU+2+5%OYAIY@UN8
M2_GQ^WO_ ,%0/$W[75K\,_ _PW\"M\"/A1\(M9M/$OA/1=&U_P _7KGQ3HEO
M+IGA3Q +K1M.T'3_  M#X1T622S\+Z%H,$IT:YO=3NCKE^LFE6^C_547_!9?
MX)?%3PUX1E_:V_88^'OQN^)_@72&M-+\97#^$[_3=6ON&DD71_%G@S6+GPI8
M:E(L=SJ6G6NI>(]-;48S?VVG0J;>SL\<MX2S[*Y9+F>*X9I9KA:6)XEJSX8C
MBLNFLHAG%6D\&J*Q=6."JJ-.G[.JJ<YSIPE&Z;4E3[,]\3N#.(J?%G#N7^(.
M)X<S+$8#P^H4?$2IE^>TGQ17X5PU>&:/$O+<-+-\-*=>O]8PSK4:-+$5J<[.
M*E3G6^N/^"F_A+PI\9O%/_!)OQ3\4O#NDZ1XL^+/Q-^'_A+XB:!+&K&;PIXW
MU'X5:CXQ\.ZA?V\T4UUI/AG4M8O;*VC^UA;?^W]1FM)H6O+B63F/^"NW[=/[
M4'[+O[6WP2\,?!CQ6_AGPAH?PRT+Q^_A;^SH-0T#X@ZOK?C'QEX>U32?%MB%
M2;4]$_LKPU9:5::9;7%CJ.E2W5WK.D7]AJMQI>H6'XR?MO\ _!0/XI_MI_%K
MPE\1K_3X_AEHWPRA:/X6>$_#>MW]_<^$;N?4;75K[Q)-XE>'3)[_ ,77]]I^
MD"?6=.TO0+:*TT#08;72[>YLKB]OOT7UK_@MU\._&6A>"O&?Q$_8?^&OCO\
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MA<+/$<+YMBZ&6QS/'9;F-13PJECH5,!A8TJBIUHTZL3\L:***_<3^.PHHHH
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M"?"W_DF7PY_[$3PC_P"H_I]=W7HY7_R+<N_[ <)_ZCTSP>(?^1_GG_8XS/\
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M=ZUIT^EZ#?Z1#-!]JUS4O"]I<7VJZ!8V>L'5=9T73=5Y[]JCQ/\ LX?L+?\
M!,K5_P!BSX;?&KP?\7OC!\4=40:_>^"=2T>XOII=8\2Z+XG\5>+?$VE:+JNO
MQ^&M%_X1+2M+\$>'[75-334M=@DL+NP2^@L=<FL-,'&M0S]QP%7/Z6?U?$O'
MU%A(1S"&55>'*N/J+,,34C[.. GAYJ$HXBLISKVIP32IPC*.&:SPN-X)4\YP
M_!.)X)PWT?\ )*,LSJU,CK<2X?CW#Y+AWD> HU%7GG='&4I5J<\#AG2I8%>V
MJM2>(JU(SX7X;? #]D;]@K]@_P"%7[9'[0_P3M/VE_BQ\<5\(/X5\#>*;ZT?
MP7IT7CS3=:\7^'K&ST[5-"O],T^"'X=Z>NJ^(-;UOP[XON3XFCATS0Y+'3M0
MBN:K_M0_L\?L@?M6?\$_M5_;Q_9?^%</P*\;?#^:&W\:?#[PZ+2VT*3^R_$F
MF:%XKT#5=%THIX?@NM)T_6X/&.@>)]%T[1KS5M!:TBU_2X9KV*VT+T[P)XF_
M9T_X*5?\$Z/@A^S%XI_:!\!_L_?&OX#3^!M,M['QM>Z1]HU"3X=>&=<\ :#=
M:58ZUJ_A";Q'H?BKP=J$%WJ+>'[VZG\-:^(+74H;Y;2SEU7C_P!ISQ_^S?\
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MGZ#)\1-;\*ZGKR:8_A'3/#]WXAL-,\%:%HDWAG5]3B\N35-?&JV^LZZ_M?\
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M;6ND_P#"4^'="L]5U'4&&G:/I]Y<ZS?/!;Z>]S#]S_\ !1+_ ())?M2?$/\
M:M^(?Q4_9Y\":9X_\ ?%G5;?QE/(GC/P)X7O?#'B35;6 >*[/5K3Q7KOAN2\
MANM=AO\ 7K.^TB'4=]EJD-K<O+J<$[W'KYA@N&L!Q]2PO$.%RC!</TN&I/A_
M#8ZCA,+D-/%SQSGF/)0J1IX".,FZLZDU.'-)2A-WJ.@SY;(\V\0,Z\%,3F7
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M7,$GA[Q5X3\1>&+"VFDGO7\+OIDVH7DTUPTEQ\5_MS_M\:Y^W"WPSDUWX2>
M_AE/\-E\7I#=>#Y;RXN==A\5GPTQ@U*:\AA=8-*?P\TEE$A=?,U.\?"$G?\
MI/#M2MBLIR#*:62PS?A6OD>"ISSK'X[!S=6,<$I>QQ.25*=:<K5X0PTJ7MYP
MHNZO*%&\OY_X[H87+N)>->)\3Q96X7\2<'QAFU:CPEDN3YK2CAZD\WY%B\!Q
M=0Q&$I4U+!5JN8TL1]3I5<5"";5.KBDH_P! WAG]L?\ :0U#_@C-XA_:OO/B
M-YWQ^L6U46OCW_A$/ <?E"V^/]MX)A_XI:+PNG@M]GAB1],_>>''W9^VONU
M"['Y*_L(?ML?M!_&?_@I;^SGX_\ C7\1+WQIK>KZ9K/P3NYX-"\*>&+:Z\&:
M[I7BS4-,T6YTKPAI'AG2)X+/QKJ=EXB:[EM)-1ENM/L1++>16%E9)]G>#/\
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M'*_^1;EW_8#A/_4>F>#Q#_R/\\_['&9_^IM<****[CQPHHHH **** "BBB@
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M&+AC_P"<I7_X71_P4L_Z2H?MD?\ AS_B%_\ /#H_X71_P4L_Z2H?MD?^'/\
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M$/\ PX9M_P#-X?\ $R/C5_T6]7_PQ<,?_.4K_P#"Z/\ @I9_TE0_;(_\.?\
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M?\%+/^DJ'[9'_AS_ (A?_/#H_P"%T?\ !2S_ *2H?MD?^'/^(7_SPZL44?\
M$*^ O^A!#_PX9M_\WA_Q,CXU?]%O5_\ #%PQ_P#.4K_\+H_X*6?])4/VR/\
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M_P N#_4_A+_HEN'/_#)EG_S+Y+[C^/#_ (A1_&7_ $E2^,/_ (9-O_G\4?\
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M_P!#C-/_  X8O_Y<'^I_"7_1+<.?^&3+/_F7R7W'\>'_ !"C^,O^DJ7QA_\
M#)M_\_BC_B%'\9?])4OC#_X9-O\ Y_%?V'T4?VYG7_0XS3_PX8O_ .7!_J?P
ME_T2W#G_ (9,L_\ F7R7W'\>'_$*/XR_Z2I?&'_PR;?_ #^*/^(4?QE_TE2^
M,/\ X9-O_G\5_8?11_;F=?\ 0XS3_P .&+_^7!_J?PE_T2W#G_ADRS_YE\E]
MQ_'A_P 0H_C+_I*E\8?_  R;?_/XH_XA1_&7_25+XP_^&3;_ .?Q7]A]%']N
M9U_T.,T_\.&+_P#EP?ZG\)?]$MPY_P"&3+/_ )E\E]Q_'A_Q"C^,O^DJ7QA_
M\,FW_P _BC_B%'\9?])4OC#_ .&3;_Y_%?V'T4?VYG7_ $.,T_\ #AB__EP?
MZG\)?]$MPY_X9,L_^9?)?<?QX?\ $*/XR_Z2I?&'_P ,FW_S^*/^(4?QE_TE
M2^,/_ADV_P#G\5_8?11_;F=?]#C-/_#AB_\ Y<'^I_"7_1+<.?\ ADRS_P"9
M?)?<?QX?\0H_C+_I*E\8?_#)M_\ /XH_XA1_&7_25+XP_P#ADV_^?Q7]A]%'
M]N9U_P!#C-/_  X8O_Y<'^I_"7_1+<.?^&3+/_F7R7W'\>'_ !"C^,O^DJ7Q
MA_\ #)M_\_BC_B%'\9?])4OC#_X9-O\ Y_%?V'T4?VYG7_0XS3_PX8O_ .7!
M_J?PE_T2W#G_ (9,L_\ F7R7W'\>'_$*/XR_Z2I?&'_PR;?_ #^*/^(4?QE_
MTE2^,/\ X9-O_G\5_8<""2 02IPP!!*G ;!]#M96P><$'H12T?VYG7_0XS3_
M ,.&+_\ EP?ZG\)?]$OPY_X9,LZ?]RODON/X\/\ B%'\9?\ 25+XP_\ ADV_
M^?Q1_P 0H_C+_I*E\8?_  R;?_/XK^P^BC^W,Z_Z'&:?^'#%_P#RX/\ 4_A+
M_HEN'/\ PR99_P#,ODON/X\/^(4?QE_TE2^,/_ADV_\ G\4?\0H_C+_I*E\8
M?_#)M_\ /XK^P^BC^W,Z_P"AQFG_ (<,7_\ +@_U/X2_Z);AS_PR99_\R^2^
MX_CP_P"(4?QE_P!)4OC#_P"&3;_Y_%'_ !"C^,O^DJ7QA_\ #)M_\_BO[#Z*
M/[<SK_H<9I_X<,7_ /+@_P!3^$O^B6X<_P##)EG_ ,R^2^X_CP_XA1_&7_25
M+XP_^&3;_P"?Q7PI_P %+_\ @WF\3?L8_L/?'G]IF_\ ^"@OQ+^,EI\+-*\(
M7\WPUUWX5MX?TKQ0/$'Q&\'>$%@O-8_X6[XC^Q+I[^(5U>-O[%OO-GT^*WV1
M>;]HA_OZK\8?^#A?_E#E^VM_V+/PL_\ 5]_"JIGG.;U(3IU,US*I3J1E"I3G
MCL5.$X33C*$XRJN,HRBVI1:::;333-*/"G"^'JTJ]#AO(*->A4A5HUJ.3Y=3
MJT:M*49TZM*I##1G3J4YQC.$X-2A*,91::3/PC_9K_X-C_%OQD_9S^ /Q?@_
MX*7_ !7\'0?%7X*?"OXD0^$;'X/-J%EX6B\<^!="\3Q^'+.__P"%V:=]MM=#
M35!IEO=_V?8?:8K5)OL=KO\ (3VO_B%'\9?])4OC#_X9-O\ Y_%?TI_\$^O^
M3"?V(O\ LT/]FO\ ]4SX+KZ\IK.LYBE&.;9G&,4E&*Q^*222LDDJMDDM$EHD
M3/A+A2I.4Y\,\/3G.3G.<\ERV4YSD[RE*3PS<I2>KDVVWJW<_CP_XA1_&7_2
M5+XP_P#ADV_^?Q1_Q"C^,O\ I*E\8?\ PR;?_/XK^P^BG_;F=?\ 0XS3_P .
M&+_^7$_ZG\)?]$MPY_X9,L_^9?)?<?QX?\0H_C+_ *2I?&'_ ,,FW_S^*/\
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M8?11_;F=?]#C-/\ PX8O_P"7!_J?PE_T2W#G_ADRS_YE\E]Q_'A_Q"C^,O\
MI*E\8?\ PR;?_/XH_P"(4?QE_P!)4OC#_P"&3;_Y_%?V'T4?VYG7_0XS3_PX
M8O\ ^7!_J?PE_P!$MPY_X9,L_P#F7R7W'\>'_$*/XR_Z2I?&'_PR;?\ S^*B
ME_X-M_C=\&=O_"$?\%<OV@M"_P"$DS_:?]A?#+4="^U?V/C[%]J^Q?'@_:O(
M_M2[\CS?]1YTVS_7/7]BE>+_ !>_YE[_ +BW_N,K\X\7,US#$>'O$%'&XAYI
MA9_V3[7 YQ3I9SEU?ESO+9P^L9;FM/&8#$^RJ1A6H^WPU3V->G2Q%+DK4J=2
M/U'!G#?#^ XERW%Y=DN699C*/USV.-RO!8?+<=0Y\!BJ=3V&-P-/#XJC[2E*
M=&K[*M#VE&=2C/FISG&7\IO_  XH_:K_ .DR7[47_A):_P#_ #]Z/^'%'[5?
M_29+]J+_ ,)+7_\ Y^]?TE45_%'/@/\ HFN!_P#Q >"?_G!Y+[C]XM7_ .AE
MG7_A]SGR_P"H_P D?S:_\.*/VJ_^DR7[47_A):__ //WH_X<4?M5_P#29+]J
M+_PDM?\ _G[U_2511SX#_HFN!_\ Q >"?_G!Y+[@M7_Z&6=?^'W.?+_J/\D?
MS:_\.*/VJ_\ I,E^U%_X26O_ /S]Z/\ AQ1^U7_TF2_:B_\ "2U__P"?O7])
M5%'/@/\ HFN!_P#Q >"?_G!Y+[@M7_Z&6=?^'W.?+_J/\D?S:_\ #BC]JO\
MZ3)?M1?^$EK_ /\ /WH_X<4?M5_])DOVHO\ PDM?_P#G[U_2511SX#_HFN!_
M_$!X)_\ G!Y+[@M7_P"AEG7_ (?<Y\O^H_R1_-K_ ,.*/VJ_^DR7[47_ (26
MO_\ S]Z/^'%'[5?_ $F2_:B_\)+7_P#Y^]?TE44<^ _Z)K@?_P 0'@G_ .<'
MDON"U?\ Z&6=?^'W.?+_ *C_ "1_-K_PXH_:K_Z3)?M1?^$EK_\ \_>C_AQ1
M^U7_ -)DOVHO_"2U_P#^?O7])5)D9*Y&X $C(R 20"1U )5@#T)!QT-'/@/^
MB:X'_P#$!X)_^<'DON"U?_H99U_X?<YZ6_ZC_)?<?S;?\.*/VJ_^DR7[47_A
M):__ //WH_X<4?M5_P#29+]J+_PDM?\ _G[U_2511SX#_HFN!_\ Q >"?_G!
MY+[@M7_Z&6=?^'W.?+_J/\D?S:_\.*/VJ_\ I,E^U%_X26O_ /S]Z/\ AQ1^
MU7_TF2_:B_\ "2U__P"?O7])5%'/@/\ HFN!_P#Q >"?_G!Y+[@M7_Z&6=?^
M'W.?+_J/\D?S:_\ #BC]JO\ Z3)?M1?^$EK_ /\ /WH_X<4?M5_])DOVHO\
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MXYS5X;K8*CC<5B+3P:PD*^%52=*&'^L3J8J5&<X*%.5.4_YJZ*_K+\:>!_\
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M,QQ&:8_)*N4QCA?KF&S/ 8:.)G1FWB%0G1J1J4^3$PJ^RC!RJSY8TYI>Q_Q
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MA^'=1T^/1H],EM+31KG5UMVM]2@;5-1FL;RX7C?^"9WQC^$7@[P[_P %0_\
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ML?\ L9/$/_H^&OK*ODW]BW_DA]C_ -C)XA_]'PU]95_K+P-_R1W#/_8ER_\
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M\Z+_ )ZQ_P#?:_XT>=%_SUC_ .^U_P :^:Z* /I3SHO^>L?_ 'VO^-'G1?\
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M5]<O/#O@/7M$33+VTUC4].;6$OOM*1ZB;G0=-M#H&M&?6_$4&DZ)&NFW;MJ
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M*'M,3BZ$<+/*L=@X8NO64,*ZLZF$CB,.I.=.%:I[)SE\\45ZE\7_ ()?%GX
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MU%S1<J5>%.K3;7V9PC+RM8_-.*>&<XX,XCSKA3B"AA\-G?#^88G*\TP^%Q^
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M_'8;#26)=>I"&!QT\-^@M%%%?6'\]!1110 4444 %%%% !6'K/\ R[?]MO\
MVE6Y6'K/_+M_VV_]I5^=^*__ "0&?_\ =*_]767'T'"W_(^P'_<U_P"H>(,.
MBBBOXS/V **** "BBB@ HHHH ***HV6IZ;J1NQIVH6-^=/O)-.OQ97<%T;+4
M(HH9Y;&[$$DGV:\CAN+>:2VFV3)%/#(R!)4+!+G",H0E.,9U.94XN24IN*YI
M*$6[RY8^]+E3LM7H7J\'^&/[1?PZ^,GC7QIX2^&<NK>,-)\!V]I'KOQ)TBS@
MF^&<GB&ZGD1_!^B^)S>*?$'B"SLEAU:\?1+&_P!"@TZ[M6?6OM4T=J_PAXX^
M,GBS]N_XM^(_V9O@!XIG\.?L]>$$MQ^T!\;_  S(7U3Q?IMT]Q:S?#_X?ZHT
M4MA!I?B26"_TP:R8I[?Q+:Z9K&I6KZIX)L9]+\=?IUX$\!^#_ACX1T+P'X"\
M/Z=X7\)>&K%;#1]%TN$0VUM"'>:::1B6FO+^^NI9[_5-3O);C4=5U*YN]2U*
MZNK^ZN+B7JJ48X>FE63>(J1C*-).WL822DI5M+^TFOAI:.,6IS>L8/\ )>&>
M.\P\1>(:V(X+G@X^''#N/QV79EQ96H_6I<;9Y@Y5L)BLJX.Y:T*,,@R7&1<<
MUXJJQQ5'-,?1GE.14)T:.+S>EUM%%%<I^N!1110 4444 %%%% 'C?[1?_)OG
MQV_[(W\3_P#U"=<K_(CK_7<_:+_Y-\^.W_9&_B?_ .H3KE?Y$=?TCX#?[GQ)
M_P!A.6_^FL8?G?'/\7+O^O>)_P#2J)^PW[%O_)#['_L9/$/_ */AKZRKY-_8
MM_Y(?8_]C)XA_P#1\-?65?ZR\#?\D=PS_P!B7+__ %'@?X:^,G_)U?$'_LK,
MZ_\ 4RJ%?TU?M^_\H3OV)_\ >_9Q_P#5-^-*_F5K]/?VA/\ @HK:_'+]B#X%
M_L>V_P )KCPS<_!Y_AR;OQ[-XSCUB#Q"GP_\%:[X1'V?PZGAG3)-+;59-8CU
M$^9K.H"R2W>S'VMI5NX^;BG*L?F.:<'XC!X=UJ.5Y\L;CI^THP]AAEAJD/:.
M-2I"53WFH\E*-2>M^6VIW^'/$F2Y%P[XJ8'-<:L)BN(N"Y95DU)T,56>-S!X
M_#UEAU/#T*M.@_9PE/VF)G1HV37M.:R/TN_X(F_/^QQ^W)&GS2$:EB-?F?Y_
MA9KBI\HRWSLK*O'S%2!D@UB_\&^?_(M_MRGM_8GP1_\ 2#X[_P"(K\S/^"=7
M_!0S7_V"_%GCNX/@6'XD> OB98:%;>*?#0UO_A'=5M-2\-3ZF=$UW1M5DTS6
MK8/:VNNZW:WVE7%@D6KI<VF_4+%["&1OT)\._P#!<[X=_#<>(/!GPD_8G\(_
M#[X07NDZO_9WAOPEXJT;P?JESXOU:;9<^*-5BT'P#_PC\,-UIJP6T^F0Z=?:
MC]IMUN9/$EW;F"PM/@N*.'>**]?CC Y=D;S#"\48CA_&8;,(9A@</##QRMX:
MIB*-6AB*T*LZTJM!4Z<5RP<).LZBY?9R_:_#GCWPYPN"\'<XS[C"&29CX<8'
MCC*LPR.IDF<XZMCI\21Q]# XJAC<#A:N&IX6&'Q;KUY/VE6%:$<-[%^T]M#U
M'_@G5\3_ !?\&/\ @CE^U-\3_ %[;Z9XT\'^/OBCJ/AK5;FRM]132=7F\&_"
MZPM=6CL;Q);&ZN]+>[_M"PBU"WN]/:^MK?[?8WUF)[.?W;]AO]L/]H#QY_P2
MU_:E^.GC7QQ+XJ^*_P &K[XX6?@KQCKFFZ7>7UN?#_PL\)^.M N=1MQ9QV.J
MSZ/KOBF_:S&H6UQ";*WL=.N(I["V6VK\-O@Y^W]9_"C]@_XT_L8O\++G7;WX
MM:]XCU>'XA)XQBTVUT*/Q!I_@VP,,GAH^&;Z74'LQX6EF#+KEFMR;R.,BW\E
MI'M_LZ_\%"K7X"_L2?M!?LAM\*;CQ1>?'#4?B#>0^/%\9QZ/:^&X_'OP_P#"
M?@.1)?#A\,:G+JKZ4GAJ7549-:L%OFO([)A9B!KN73->!L=CO]8*TLDPV(Q>
M-XXP&886O4E@)5JF1P6'6(DJLZO-"A:6(Y\-.4*E2\OW,FT8\->,639-_J/A
M*?%^.P.6Y1X/9SDF8X2A#.H87#\85GC)X"#P]'#.G5QJE'!.CF-&%2C0Y8+Z
MW3496_8[]D_XU?$W]J?_ ()!_MQ^(OV@/%-Q\3M>\-:;^TII.D:KXALM+-W!
M9^'?@CX9^)/A]9&L[*UCN)="\8:U=ZIHUQ-&\^EI%IUC8R06.E:;;VOG?P&\
M2:_^SC_P0<\6?&+X(74GAGXF^+]9U_4?$7BW2),:UI5]K7QZL_@Y=ZQ;322R
MS6>I6/P_TW3;32;G3Q:3:+<S0>(+1(KR">^F_,/]F/\ X*+6G[._[%O[0_[)
M,OPDN/%ES\<S\5/L_CN/QO%HL'AL?$[X6:!\,W$WAMO"FJ2:H=#&AG6E*:Y8
M?VF;H:<1I_D?;IM/]AW_ (*:W_[+/PT\8? 'XI?"'1?VA/@'XQO;W47\$^(M
M6AMI-"NM6CLXM;M+:#6M%\4:%JWAC5A9)>W/A6ZTNQ@77)KK6[?4H+B]U&*^
M6,X-SB"SSZED]&>!AQSE'$&%R>%;!8?#9ME6#H2AB\+3I>U6&H^TJ3C-TL5&
ME&;HJ\)M1C(RKQ7X4K2X/>:\4XNEG%7P<XGX(S'BJMA,WQN/X8XDS3%TZF69
MA7Q'U>6/Q;P]&E5I+$Y;/$SI1Q3<:U-.I./ZD_\ !/'XS_$W]JO_ ()Z?MO>
M#OVF/$FK?$7PMX,\)^+['1/'_CJ[7Q#KD=IJ/P[USQ%?65[J=[YFJZG<^ ]5
MTO2O%>C:OJUQ=ZI9W.L6T%E?I;Z/IUO8Z'A?]HCXE_LQ?\$,?@U\2OA%J=GH
M?CJ:\O/"VE^(+O3;#6&T*'7OC5X\6_U&RTW5K>\TFYOQ9VTUK;?VE97EK UT
MUR;:26&+'Y]_M#?\%9/"WB'X ^,?V9OV2OV9O"G[,WPZ^(*W=IXUU?2;K2HM
M6UK2M7M+&Q\16MKX?\,:#H6DV&J>(],T^#PWKWB'5]2\57NI>%C)I<<&GSK9
MWME\_>,/V_K/Q1_P3S\ _L+I\++FRO?!FO0ZO-\2W\8Q3VM_'#XT\4>+A#'X
M4'AF*6!W'B"+3RS>(9%0VTET V];<9+@W-<?7ABJW#]' Y=C^.\HS>MD,ZV
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MK%>10S6\LMK)/;(EQ'%/!(\1=4FC8AU^E/\ @C-^TY\;_P!L/2OVN]$_:/\
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M#-'\%:SX:UG6+"RT4WJ:E::4NK65T=+\K1]=CTK4DLKV;2(?.^T_BK_P6!^
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MO5_RB3_;$_[%SX9_^KQ^&-?KW7Y"?\%ZO^42?[8G_8N?#/\ ]7C\,: /L_\
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M7\7992J3S3#\/YW@ZV4\5Y+1=+$8:7L\VRS$-PDZL73Q6&H+GC0JXN%;P?\
M9-_9WT3]F3X)^%OAMIZ6L^OB!-;\?:W:NTR:_P".-2MK?^W+V&XDM;*:73+-
MX8='T$36EO<1Z#INFK=QM??:IYOI.BBN.I4G5G.I4DY3G)RE)[MMW?\ P%T6
MB/V7ASA[*.$\AR?AG(,'2R_)<BR["97EF#HI*%#"8.C&C2BW9.I4E&//6K3O
M4KUI5*U64JDY291114'M!1110 4444 %%%% 'C?[1?\ R;Y\=O\ LC?Q/_\
M4)URO\B.O]=S]HO_ )-\^.W_ &1OXG_^H3KE?Y$=?TCX#?[GQ)_V$Y;_ .FL
M8?G?'/\ %R[_ *]XG_TJB?L-^Q;_ ,D/L?\ L9/$/_H^&OK*ODW]BW_DA]C_
M -C)XA_]'PU]95_K+P-_R1W#/_8ER_\ ]1X'^&OC)_R=7Q!_[*S.O_4RJ%%%
M%?5'YJ%%%% !1110 4444 %%%% !1110 5ZAXT^-OQB^(_AGPGX+\?\ Q1\?
M>,_"/@2U@LO!GACQ-XKUK6M!\+6MKI]OI5K!H6E7]Y/9:;';:9:6^GVXM88S
M#9Q+;1E8LH?+Z*SG1HU)TJE2E2J5*$I2HU)TXRG1E*+A*5*4DY4Y2BW&3@TW
M%M.ZT.BEB\50I8BA0Q.(HT,9"%/%T:5:I3I8JG3FJM.&(IPDH5X4ZB52$:JE
M&,TIQ2DDPHHHK0YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]Y^'_[4W[2WPIT.#PQ\
M-/V@/C-X#\,6K7,EIX9\*?$KQAHGARTEO)A<7<]IH-AJ\.DVUQ<S@RSW$%G'
M/*[.7D;>^[SOQ[\2OB+\5-;'B;XG^/O&OQ'\2+:0Z>OB#QYXIUSQ?K:V%L7:
MWL5U7Q!?:A?+9V[2R&"V$X@B,CF-%+MGBJ*Y:>"P5*O/$TL)A:>)J<WM,13P
M]*%>?,[RYZL8*I+F>LN:3N]6>C6S?-L3@Z67XC-,QKX"AR>QP-;&XFK@Z/LU
MRT_98:=65&GR1]V')!<JTC9!11174><%%%% !1110 4444 %%%% 'B/Q?_Y&
MK]F/_LZ[X+_^G'4Z_P!*ZO\ -4^+4;3>+OV7XDQNE_:R^"D:Y.!N?4]249(!
M(&2,G!X[5_IP?\(%K?\ STL/^_\ +_\ (]?R)XR_\EM7_P"Q=E__ *;F?ZB?
M10_Y-%@_^Q]G?_IZD<517:_\(%K?_/2P_P"_\O\ \CT?\(%K?_/2P_[_ ,O_
M ,CU^5']*'%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%4
M5VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\
M/2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'
M_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\
MO_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%4
M5VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\
M/2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'
M_"!:W_STL/\ O_+_ /(] '%45VO_  @>M_\ /2P_[_R__(]'_"!:W_STL/\
MO_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%4
M5VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\
M/2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'
M_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\
MO_+_ /(] '%45VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%4
M5VO_  @6M_\ /2P_[_R__(]'_"!:W_STL/\ O_+_ /(] '%45VO_  @6M_\
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MG6;2HQE2RG*%7BL%0QV85,/2QN85(9?@?K.,<J,?J2BBBLSZ0**** "BBB@
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ML2&+2-$/B/6;+1QJ^J2@J8].TTWGVR^D# I;0RMD8S7ZQ_\ !4;Q'X/\'_\
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MQ?"+Q[X+ED_LW1K>\OI3%XKUO2M D2&"22/4[Z"V=0[$#A/V-+S4]%_X(?\
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M]\ #P4?BGK:_MA?M=W'B+X1:/XCN_#&N^._"7BC2[C2=!\&VVK:/*-6\/_\
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M5AITUVW[7?MG:QX=T#_@H;_P2FU'Q+<6=G8W/B+]JW0X+B\FBMDDU[Q#\./
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M^3?/CM_V1OXG_P#J$ZY7^1'7](^ W^Y\2?\ 83EO_IK&'YWQS_%R[_KWB?\
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M6?\ WWJ'_P G53HHY5_>_P# I?Y^7Y]V'.^T/_!</_D?+\^[+GVF#_H'6?\
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MF#_H'6?_ 'WJ'_R=1]I@_P"@=9_]]ZA_\G53HHY5_>_\"E_GY?GW8<[[0_\
M!</_ )'R_/NRY]I@_P"@=9_]]ZA_\G4?:8/^@=9_]]ZA_P#)U4Z*.5?WO_ I
M?Y^7Y]V'.^T/_!</_D?+\^[+GVF#_H'6?_?>H?\ R=1]I@_Z!UG_ -]ZA_\
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M9_\ ?>H?_)U'VF#_ *!UG_WWJ'_R=5.BCE7][_P*7^?E^?=ASOM#_P %P_\
MD?+\^[+GVF#_ *!UG_WWJ'_R=1]I@_Z!UG_WWJ'_ ,G53HHY5_>_\"E_GY?G
MW8<[[0_\%P_^1\OS[LN?:8/^@=9_]]ZA_P#)U'VF#_H'6?\ WWJ'_P G53HH
MY5_>_P# I?Y^7Y]V'.^T/_!</_D?+\^[+GVF#_H'6?\ WWJ'_P G4?:8/^@=
M9_\ ?>H?_)U4Z*.5?WO_  *7^?E^?=ASOM#_ ,%P_P#D?+\^[+GVF#_H'6?_
M 'WJ'_R=1]I@_P"@=9_]]ZA_\G53HHY5_>_\"E_GY?GW8<[[0_\ !</_ )'R
M_/NSQSXP72CQ9^R^\-K;P21?M9_!257C:Z8DIJ6ID*PGN9D*EL$X4-E0 P!(
M/^FE_P )QKW_ #UMO_ 9/\:_S(OB_P#\C5^S'_V==\%__3CJ=?Z5U?R+XR*W
M&M??_D79?NV_^7<^]S_4/Z*+;\(\&W;_ )'V=K1)?\OJ71)+Y[G7_P#"<:]_
MSUMO_ 9/\:/^$XU[_GK;?^ R?XUR%%?E1_29U_\ PG&O?\];;_P&3_&C_A.-
M>_YZVW_@,G^-<A10!U__  G&O?\ /6V_\!D_QH_X3C7O^>MM_P" R?XUR%%
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M!U__  G&O?\ /6V_\!D_QH_X3C7O^>MM_P" R?XUR%% '7_\)QKW_/6V_P#
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M;_VE7YWXKNW .?/3_F5[I-?\CK+NCNCZ#A;_ )'V _[F?_4/$&+N']Q?S?\
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MS?\ ^*HW#^XOYO\ _%4VBCF?]W_P&/\ EY?GW8[>OWO^NGY]V.W#^XOYO_\
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M"FG?$6XLM8D\.7OV#Q?8>+/!NIZ?8W-]XBBNM6TC6KZ[%K<W0TBWU'4_(_\
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MPM)48Y;5KK%5JT*,O:4Z<>9QK2I?R@T445^D'X&%%%% !1110 4444 %%%%
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M:XG,:&$E@L%5K<T,)AXO"Y?F4\576%_T!?AU\3OAW\7O"MCXW^%WC;PQX_\
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MIXS!\\<)EV'\/:6'EEL)YBZ]3VM'"XBL\SHYCB(Y;'^NJBBBOUD_SU"BBB@
MHHHH **** "OR$_X+U?\HD_VQ/\ L7/AG_ZO'X8U^O=?D)_P7J_Y1)_MB?\
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M/9:5'<6FAZ5\T_\ !.WX!>)K'1=8_:R^-VHWOBGXZ?'^S@UN+5=8DMYKK0/
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ML372Q.%S%8Q3S&I:%X5Z7UM\M"-Z<N17FKNW]$__  3Q^,'PE\(?\$E?VZ/
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M]8^-$6FV'QKTZ/QMIBZ[XBNKG69_$JSZ=JTHL=2UKRI-9M8?MUUYT$TW._\
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MSQ.-QV+KN]2M7K5&W)[0A!6ITJ<84J4(4H0A$HHHKH/&"BBB@ HHHH ****
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M_%?_ )(#/_\ NE?^KK+CZ#A;_D?8#_N:_P#4/$&'1117\9G[ %%%% !1110
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M.W_9&_B?_P"H3KE?Y$=?Z[G[1?\ R;Y\=O\ LC?Q/_\ 4)URO\B.OZ1\!O\
M<^)/^PG+?_36,/SOCG^+EW_7O$_^E43]AOV+?^2'V/\ V,GB'_T?#7UE7R;^
MQ;_R0^Q_[&3Q#_Z/AKZRK_67@;_DCN&?^Q+E_P#ZCP/\-?&3_DZOB#_V5F=?
M^IE4****^J/S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#YGHKZ8HH ^9Z*^F** /F>BOIBB@#YGHKZ8HH ^9Z*^F** /F>OR$_X+U?\
M*)/]L3_L7/AG_P"KQ^&-?T)U^,/_  <+_P#*'+]M;_L6?A9_ZOOX54 >M?L(
M?\F/?L:_]FI_L\?^JB\'U]65S?\ P3Z_Y,)_8B_[-#_9K_\ 5,^"Z^O* /F>
MBOIBB@#YGHKZ8HH ^9Z*^F** /F>BOIBB@#YGHKZ8HH ^9Z*^F** /F>BOIB
MB@#YGHKZ8HH ^9Z*^F** /F>L/6?^7;_ +;?^TJ^M*\7^+W_ #+W_<6_]QE?
MG?BO_P D!G__ '2O_5UEQ]!PM_R/L!_W-?\ J'B#Q>BBBOXS/V **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \;_:+_P"3?/CM_P!D;^)_
M_J$ZY7^1'7^NY^T7_P F^?';_LC?Q/\ _4)URO\ (CK^D? ;_<^)/^PG+?\
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M>)+6X2"V\4_%'Q-:II^HQ:CJ^F))I(MM-UQK+3-5MO"/AKX7>3C<QE#$PRW
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MA>W%A:66LZU:VLNA:?KLL]K,_P#PC=UJ<7B!;1?MS:8+(_:*^'/C?^T9X_\
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MKX@HX+B3'YKG.+Q^'Q&%A0MEJP.:4ZL98B6:XJ=;+J:4*D*]?EC6_7C]M_\
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M'[?UGXH_X)Y^ ?V%T^%ES97O@S7H=7F^);^,8I[6_CA\:>*/%PAC\*#PS%+
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M(/$>N:@RO?:OK6K74M[J.HW;HJ(UQ=W4TL\I5$4NYVJHP*_6G]B7_@I]X+^
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M0IUZV 48971P>8XC#X=86G"<ZD:$&Z?I?Q;_ .5?KX&?]CK9?^KG^)%>W_\
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M7MO#WAK7=6U6:SU:TTO3M-W^*-(UNTL=/LU2YN7%C:V]S=SW(6YN'MX$A/\
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MM=6TY[2[A@N$9_+D2.925<?./@[_ (*P_LN_ YO&_P 1?V9OV _#?PC^._Q
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M0^/H/$VGL?&-_HOAWQ/;^)=*U<ZG->0FT@?4+W\E?V8_^"BUI^SO^Q;^T/\
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M-QE:2EB<34<>6-6M.G"52$(U)%%%%=I\N%%%% !1110 4444 %%%% !1110
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M /J$ZY7^1'7^NY^T7_R;Y\=O^R-_$_\ ]0G7*_R(Z_I'P&_W/B3_ +"<M_\
M36,/SOCG^+EW_7O$_P#I5$_8;]BW_DA]C_V,GB'_ -'PU]95\F_L6_\ )#['
M_L9/$/\ Z/AKZRK_ %EX&_Y([AG_ +$N7_\ J/ _PU\9/^3J^(/_ &5F=?\
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MX0G-+1N,922?9V3,:BE961F1U*LI*LK JRLIP58'!!!!!! ((P:2J("BBB@
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MLI5L-7Q>'G2Q=<HHHKUS\["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!9>!O^2.X9_P"Q+E__ *CP/\-?&3_DZOB#_P!E9G7_ *F53T[X.?&3XE?
M#XB:!\6/A%XGF\'>/_"_]IC1-?AT[1]8^RIK&DWVAZE'+I7B'3M6T6_AN]+U
M*\M7AU'3;N)3*L\:)<PP31_='_#XW_@H]_T<9_YB+X$?_.PK\R:*]7'9#D>:
M5HXC,LFRK,:\*:I1KX[+L'BZT:492G&E&IB*-2:IQG.<E!245*<I)7DV_FLF
MXSXPX=PU3!</\5\2Y%@ZM>6*JX3)L]S3+,-4Q,Z=.E/$5*&"Q5"E.O.E1HTY
M590=25.E3@Y.,(I?:7P0_P""@W[5W[/GCGXE_$'X>?$E8];^,?B:Y\9?$^VU
MWPYX<UO1?%_BB]U+5-7NM;N=*NM,%OI%_<7^LZG)+/X;_L5I(KD6K9M+>U@@
M[GQ__P %3_VY/B?X9^(O@OQI\9%U7PG\4?#]SX5\4: /!'@*TT]?#E[;7ME=
MZ7HJVGAJ&;1!=VFH7-O>:CI\T.L7J?9VO-1N);.TD@_/2BLJG#?#U;%?7:N1
MY34Q:5!+$SR_"RKKZMR+#VJ.DY)T%2I1I--.$:=.,6HPBETT./\ CG"Y>\IP
MW&/$^'RQO%R> HY[F=/"2>/]L\=S4(8E4Y+%RQ&(GB(RBXU9UZ]2:<ZU24OT
MG^%W_!6S]N?X1?#O0_A?X4^*6CR^%O"?AS1_"?@U-;^'W@;5=1\)^'] LH=-
MTG3M-U"30HYM0CLK"W@M(7\2C79$MX8HE<(BJ/E?2/VJ/VA] ^-VI?M'Z/\
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MG?\ Z>I!1117Y4?TH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MY"?\%ZO^42?[8G_8N?#/_P!7C\,:_7NOR$_X+U?\HD_VQ/\ L7/AG_ZO'X8T
M ?9_["'_ "8]^QK_ -FI_L\?^JB\'U]65\I_L(?\F/?L:_\ 9J?[/'_JHO!]
M?5E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'K/_+M
M_P!MO_:5;E8>L_\ +M_VV_\ :5?G?BO_ ,D!G_\ W2O_ %=9<?0<+?\ (^P'
M_<U_ZAX@PZ***_C,_8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#QO]HO_DWSX[?]D;^)_P#ZA.N5_D1U_KN?M%_\F^?';_LC?Q/_ /4)
MURO\B.OZ1\!O]SXD_P"PG+?_ $UC#\[XY_BY=_U[Q/\ Z51/V._8HGBC^!MB
MK6=O,?\ A)?$1WRM=AN;B'C$-U$F!V^3/J37UM]I@_Z!UG_WWJ'_ ,G5\@_L
M6_\ )#['_L9/$/\ Z/AKZRK_ %DX'BO]3^&=_P#D2Y?]J7_0/#S\OZNS_#?Q
MCFUXJ^(*M'3BS.=X0?\ S&5.KBV]NOGW9<^TP?\ 0.L_^^]0_P#DZC[3!_T#
MK/\ [[U#_P"3JIT5]5RK^]_X%+_/R_/NS\UYWVA_X+A_\CY?GW9<^TP?] ZS
M_P"^]0_^3J/M,'_0.L_^^]0_^3JIT4<J_O?^!2_S\OS[L.=]H?\ @N'_ ,CY
M?GW9<^TP?] ZS_[[U#_Y.H^TP?\ 0.L_^^]0_P#DZJ=%'*O[W_@4O\_+\^[#
MG?:'_@N'_P CY?GW9<^TP?\ 0.L_^^]0_P#DZC[3!_T#K/\ [[U#_P"3JIT4
M<J_O?^!2_P _+\^[#G?:'_@N'_R/E^?=ES[3!_T#K/\ [[U#_P"3J/M,'_0.
ML_\ OO4/_DZJ=%'*O[W_ (%+_/R_/NPYWVA_X+A_\CY?GW9<^TP?] ZS_P"^
M]0_^3J/M,'_0.L_^^]0_^3JIT4<J_O?^!2_S\OS[L.=]H?\ @N'_ ,CY?GW9
M<^TP?] ZS_[[U#_Y.H^TP?\ 0.L_^^]0_P#DZJ=%'*O[W_@4O\_+\^[#G?:'
M_@N'_P CY?GW9<^TP?\ 0.L_^^]0_P#DZC[3!_T#K/\ [[U#_P"3JIT4<J_O
M?^!2_P _+\^[#G?:'_@N'_R/E^?=ES[3!_T#K/\ [[U#_P"3J/M,'_0.L_\
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MP?\ 0.L_^^]0_P#DZJ=%'*O[W_@4O\_+\^[#G?:'_@N'_P CY?GW9<^TP?\
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MDH_X0C0/^>-Q_P"!,E==10!R/_"$:!_SQN/_  )DH_X0C0/^>-Q_X$R5UU%
M'(_\(1H'_/&X_P# F2C_ (0C0/\ GC<?^!,E==10!R/_  A&@?\ /&X_\"9*
M/^$(T#_GC<?^!,E==10!R/\ PA&@?\\;C_P)DH_X0C0/^>-Q_P"!,E==10!R
M/_"$:!_SQN/_  )DH_X0C0/^>-Q_X$R5UU% '(_\(1H'_/&X_P# F2C_ (0C
M0/\ GC<?^!,E==10!R/_  A&@?\ /&X_\"9*/^$(T#_GC<?^!,E==10!R/\
MPA&@?\\;C_P)DH_X0C0/^>-Q_P"!,E==10!R/_"$:!_SQN/_  )DH_X0C0/^
M>-Q_X$R5UU% '(_\(1H'_/&X_P# F2C_ (0C0/\ GC<?^!,E==10!R/_  A&
M@?\ /&X_\"9*/^$(T#_GC<?^!,E==10!R/\ PA&@?\\;C_P)DK\;/^#@GPKH
M^G_\$?/VT;RVBF6>#PU\+C&6G=U!?X\?"R-LJ>#\KMU[\U^X-?C#_P '"_\
MRAR_;6_[%GX6?^K[^%5 'US^P#X.T.X_80_8HN)8IS)/^R1^S?-(1<2 %Y?@
MYX,=R . "S' '0<5];_\(1H'_/&X_P# F2OG'_@GU_R83^Q%_P!FA_LU_P#J
MF?!=?7E '(_\(1H'_/&X_P# F2C_ (0C0/\ GC<?^!,E==10!R/_  A&@?\
M/&X_\"9*/^$(T#_GC<?^!,E==10!R/\ PA&@?\\;C_P)DH_X0C0/^>-Q_P"!
M,E==10!R/_"$:!_SQN/_  )DH_X0C0/^>-Q_X$R5UU% '(_\(1H'_/&X_P#
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MZ?\ ,KW2:_Y'67='='T'"W_(^P'_ ',_^H>(/&=P_N+^;_\ Q5&X?W%_-_\
MXJFT5_&G,_[O_@,?\O+\^[/V"WK][_KI^?=CMP_N+^;_ /Q5&X?W%_-__BJ;
M11S/^[_X#'_+R_/NPMZ_>_ZZ?GW8[</[B_F__P 51N']Q?S?_P"*IM%',_[O
M_@,?\O+\^["WK][_ *Z?GW8[</[B_F__ ,51N']Q?S?_ .*IM%',_P"[_P"
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MPWG@./<D\/\ "\39%G.9YKF& R?&8[*Y8NKEV49OC,WK935R_%5*N'HU:U;
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M?#[PK_8&E:QJ,%L;BW\+'2_#'BF?6O[-U/1M9DGCTQ+&_BMS?O'3_9P\<_\
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M:.$I*&<9AE>$R;'8C 5Z\(9O1P>,JPP"IUW*M4Y(*I_.C17]97[6/@3]F_\
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M /J$ZY7^1'7^NY^T7_R;Y\=O^R-_$_\ ]0G7*_R(Z_I'P&_W/B3_ +"<M_\
M36,/SOCG^+EW_7O$_P#I5$_8;]BW_DA]C_V,GB'_ -'PU]95\F_L6_\ )#['
M_L9/$/\ Z/AKZRK_ %EX&_Y([AG_ +$N7_\ J/ _PU\9/^3J^(/_ &5F=?\
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M?%_[;7[2/B7PGKVB^*/#FK_$?4+G2=?\.ZI8ZWHNIVPLK"(W&GZKIL]S8WL
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M_P )[ZTO?%TXOP/"J/:6-]/)'XA&FSVZV5X+F*%K6=8_CO\ ;;^*?PP\1?\
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MB</6K8;$TJV'K5:4T "@*H 4       8  '  '  X I:**R/K HHHH ****
M"BBB@ HHHH \;_:+_P"3?/CM_P!D;^)__J$ZY7^1'7^NY^T7_P F^?';_LC?
MQ/\ _4)URO\ (CK^D? ;_<^)/^PG+?\ TUC#\[XY_BY=_P!>\3_Z51/U,_9,
M^)WPZ\*_""STGQ+XW\+Z#JB:_KD[Z?JVM6%C=K#/-$T,I@N)HY!'* 2C[=K
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M7]AW_P 1-^ O_P P-'_#L7_@FQ_TCU_8=_\ $3?@+_\ ,#1_Q';.O^A'E?\
MX-Q?_P F'_$F?"7_ $6'$?\ X2Y9_P#*O7^EK_G:_P#"\O@W_P!%0\"_^%-I
M7_R31_PO+X-_]%0\"_\ A3:5_P#)-?Z)7_#L7_@FQ_TCU_8=_P#$3?@+_P#,
M#1_P[%_X)L?](]?V'?\ Q$WX"_\ S T?\1VSK_H1Y7_X-Q?_ ,F'_$F?"7_1
M8<1_^$N6?_*O7^EK_G:_\+R^#?\ T5#P+_X4VE?_ "31_P +R^#?_14/ O\
MX4VE?_)-?Z)7_#L7_@FQ_P!(]?V'?_$3?@+_ /,#1_P[%_X)L?\ 2/7]AW_Q
M$WX"_P#S T?\1VSK_H1Y7_X-Q?\ \F'_ !)GPE_T6'$?_A+EG_RKU_I:_P"=
MK_PO+X-_]%0\"_\ A3:5_P#)-'_"\O@W_P!%0\"_^%-I7_R37^B5_P .Q?\
M@FQ_TCU_8=_\1-^ O_S T?\ #L7_ ()L?](]?V'?_$3?@+_\P-'_ !';.O\
MH1Y7_P"#<7_\F'_$F?"7_18<1_\ A+EG_P J]?Z6O^=K_P +R^#?_14/ O\
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MFQ_TCU_8=_\ $3?@+_\ ,#1_Q';.O^A'E?\ X-Q?_P F'_$F?"7_ $6'$?\
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M-'_"\O@W_P!%0\"_^%-I7_R37^B5_P .Q?\ @FQ_TCU_8=_\1-^ O_S T?\
M#L7_ ()L?](]?V'?_$3?@+_\P-'_ !';.O\ H1Y7_P"#<7_\F'_$F?"7_18<
M1_\ A+EG_P J]?Z6O^=K_P +R^#?_14/ O\ X4VE?_)-'_"\O@W_ -%0\"_^
M%-I7_P DU_HE?\.Q?^";'_2/7]AW_P 1-^ O_P P-'_#L7_@FQ_TCU_8=_\
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M7]AW_P 1-^ O_P P-'_#L7_@FQ_TCU_8=_\ $3?@+_\ ,#1_Q';.O^A'E?\
MX-Q?_P F'_$F?"7_ $6'$?\ X2Y9_P#*O7^EK_G:_P#"\O@W_P!%0\"_^%-I
M7_R31_PO+X-_]%0\"_\ A3:5_P#)-?Z)7_#L7_@FQ_TCU_8=_P#$3?@+_P#,
M#1_P[%_X)L?](]?V'?\ Q$WX"_\ S T?\1VSK_H1Y7_X-Q?_ ,F'_$F?"7_1
M8<1_^$N6?_*O7^EK_G:_\+R^#?\ T5#P+_X4VE?_ "31_P +R^#?_14/ O\
MX4VE?_)-?Z)7_#L7_@FQ_P!(]?V'?_$3?@+_ /,#1_P[%_X)L?\ 2/7]AW_Q
M$WX"_P#S T?\1VSK_H1Y7_X-Q?\ \F'_ !)GPE_T6'$?_A+EG_RKU_I:_P"=
MK_PO+X-_]%0\"_\ A3:5_P#)-'_"\O@W_P!%0\"_^%-I7_R37^B5_P .Q?\
M@FQ_TCU_8=_\1-^ O_S T?\ #L7_ ()L?](]?V'?_$3?@+_\P-'_ !';.O\
MH1Y7_P"#<7_\F'_$F?"7_18<1_\ A+EG_P J]?Z6O^=K_P +R^#?_14/ O\
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M#O\ XB;\!?\ Y@:^;/OSF?\ A[-_P3#_ .C_ /\ 9#_\/[\-O_FAH_X>S?\
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M-_P3#_Z/_P#V0_\ P_OPV_\ FAH_X>S?\$P_^C__ -D/_P /[\-O_FAKIO\
MAV+_ ,$V/^D>O[#O_B)OP%_^8&C_ (=B_P#!-C_I'K^P[_XB;\!?_F!H YG_
M (>S?\$P_P#H_P#_ &0__#^_#;_YH:/^'LW_  3#_P"C_P#]D/\ \/[\-O\
MYH:Z;_AV+_P38_Z1Z_L._P#B)OP%_P#F!H_X=B_\$V/^D>O[#O\ XB;\!?\
MY@: .9_X>S?\$P_^C_\ ]D/_ ,/[\-O_ )H:/^'LW_!,/_H__P#9#_\ #^_#
M;_YH:Z;_ (=B_P#!-C_I'K^P[_XB;\!?_F!H_P"'8O\ P38_Z1Z_L._^(F_
M7_Y@: .9_P"'LW_!,/\ Z/\ _P!D/_P_OPV_^:&C_A[-_P $P_\ H_\ _9#_
M /#^_#;_ .:&NF_X=B_\$V/^D>O[#O\ XB;\!?\ Y@:/^'8O_!-C_I'K^P[_
M .(F_ 7_ .8&@#F?^'LW_!,/_H__ /9#_P##^_#;_P":&C_A[-_P3#_Z/_\
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MOPV_^:&C_A[-_P $P_\ H_\ _9#_ /#^_#;_ .:&NF_X=B_\$V/^D>O[#O\
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MP]F_X)A_]'__ +(?_A_?AM_\T-=-_P .Q?\ @FQ_TCU_8=_\1-^ O_S T?\
M#L7_ ()L?](]?V'?_$3?@+_\P- ',_\ #V;_ ()A_P#1_P#^R'_X?WX;?_-#
M1_P]F_X)A_\ 1_\ ^R'_ .']^&W_ ,T-=-_P[%_X)L?](]?V'?\ Q$WX"_\
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M_$3?@+_\P-'_  [%_P"";'_2/7]AW_Q$WX"__,#0!S/_  ]F_P""8?\ T?\
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M^!U?_DO7^EK\4?\ #SS_ ()T?]'Q?LL?^'O^'W_R]H_X>>?\$Z/^CXOV6/\
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M $!87_P.K_\ )>O]+7XH_P"'GG_!.C_H^+]EC_P]_P /O_E[1_P\\_X)T?\
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M (=B_P#!-C_I'K^P[_XB;\!?_F!H_P"'8O\ P38_Z1Z_L._^(F_ 7_Y@:/\
MB!.2_P#0\S3_ ,$X3_Y#U_I:G^N^,_Z L+_X'5_^2]?Z6OQ1_P ///\ @G1_
MT?%^RQ_X>_X??_+VC_AYY_P3H_Z/B_98_P##W_#[_P"7M?:__#L7_@FQ_P!(
M]?V'?_$3?@+_ /,#1_P[%_X)L?\ 2/7]AW_Q$WX"_P#S T?\0)R7_H>9I_X)
MPG_R'K_2U/\ 7?&?] 6%_P# ZO\ \EZ_TM?S3^.__!2G_@GSK?P/^,NBZ/\
MMJ?LQ:IJ^K_"GXAZ7I6F6'QH\!75]J.HZAX1UBTL;&SMH=;>6XN[NYEBM[>"
M)&DFFD2-%9F /^7[7^P]JW_!,G_@FW'I6IR1_P#!/C]A^.2/3[UXY$_9/^ R
M.CI;2,KHR^ 0RLK %6!!! (((KX%_P"'?7[!/_1D7[(?_B-?P9_^8NOON"^"
M,'P72S"EA,;B<:LPJ8>I-XF%*#IO#QJQ2A[))-2]JV[[65NIX6<9U6SF5"5:
7C2HO#QJ1BJ;D^;VC@VWS-[.&EN^I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>nt10016217x4_graphic25x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic25x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M:/\ AZ3_ ,$R?^DB_P"PE_XEU^S_ /\ SP:_S=_^&-?V:_\ HF<'_A4>-O\
MYI*/^&-?V:_^B9P?^%1XV_\ FDH_X@;Q9_T,>'?_  JS+R_ZE7K^'F'_ !.-
MX;?]"#CC_P -^0__ $1G^D1_P])_X)D_])%_V$O_ !+K]G__ .>#1_P])_X)
MD_\ 21?]A+_Q+K]G_P#^>#7^;O\ \,:_LU_]$S@_\*CQM_\ -)1_PQK^S7_T
M3.#_ ,*CQM_\TE'_ ! WBS_H8\._^%69>7_4J]?P\P_XG&\-O^A!QQ_X;\A_
M^B,_TB/^'I/_  3)_P"DB_["7_B77[/_ /\ /!H_X>D_\$R?^DB_["7_ (EU
M^S__ //!K_-W_P"&-?V:_P#HF<'_ (5'C;_YI*/^&-?V:_\ HF<'_A4>-O\
MYI*/^(&\6?\ 0QX=_P#"K,O+_J5>OX>8?\3C>&W_ $(../\ PWY#_P#1&?Z1
M'_#TG_@F3_TD7_82_P#$NOV?_P#YX-'_  ])_P""9/\ TD7_ &$O_$NOV?\
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MPE_XEU^S_P#_ #P:/^'I/_!,G_I(O^PE_P")=?L__P#SP:_S=_\ AC7]FO\
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M /\ /!K_ #=_^&-?V:_^B9P?^%1XV_\ FDH_X8U_9K_Z)G!_X5'C;_YI*/\
MB!O%G_0QX=_\*LR\O^I5Z_AYA_Q.-X;?]"#CC_PWY#_]$9_I$?\ #TG_ ()D
M_P#21?\ 82_\2Z_9_P#_ )X-'_#TG_@F3_TD7_82_P#$NOV?_P#YX-?YN_\
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M3)_Z2+_L)?\ B77[/_\ \\&O\W?_ (8U_9K_ .B9P?\ A4>-O_FDK])O"/\
MP2^_84U/_@E7\4?VBK[X#VD_QE\/?M8Z?\-]'\:'Q_\ %6.6S\%3^#/AUJLN
MB#1(O'2>&IE>_P!<U2X^W7.C3:F#=F-;T0Q01Q>?F/@_Q-ED<'*OC\BFL;F&
M#RVE[+$9A)QKXVHJ5*=3GRV%J497=24>::C9QA)Z'N9%]*?@'B">:PP>2\7T
MGE&1YIG^(>)P62P53"930^L8BE1]EGU9RQ,X:48S5.E*6DZU->\?VQ?\/2?^
M"9/_ $D7_82_\2Z_9_\ _G@T?\/2?^"9/_21?]A+_P 2Z_9__P#G@U_F[_\
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M])_X)D_])%_V$O\ Q+K]G_\ ^>#1_P /2?\ @F3_ -)%_P!A+_Q+K]G_ /\
MG@U_F[_\,:_LU_\ 1,X/_"H\;?\ S24?\,:_LU_]$S@_\*CQM_\ -)1_Q WB
MS_H8\._^%69>7_4J]?P\P_XG&\-O^A!QQ_X;\A_^B,_TB/\ AZ3_ ,$R?^DB
M_P"PE_XEU^S_ /\ SP:/^'I/_!,G_I(O^PE_XEU^S_\ _/!K_-W_ .&-?V:_
M^B9P?^%1XV_^:2C_ (8U_9K_ .B9P?\ A4>-O_FDH_X@;Q9_T,>'?_"K,O+_
M *E7K^'F'_$XWAM_T(../_#?D/\ ]$9_I$?\/2?^"9/_ $D7_82_\2Z_9_\
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M?Z/?_#TG_@F3_P!)%_V$O_$NOV?_ /YX-'_#TG_@F3_TD7_82_\ $NOV?_\
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MV?\ _P">#1_P])_X)D_])%_V$O\ Q+K]G_\ ^>#7^<S_ ,,N_L_?]$J\+?\
M@/<__)5'_#+O[/W_ $2KPM_X#W/_ ,E4?\0+XC_Z&^2??CO_ )D]?Z6I_P 3
ME<"_]$MQ9_X#D_\ \\S_ $9O^'I/_!,G_I(O^PE_XEU^S_\ _/!H_P"'I/\
MP3)_Z2+_ +"7_B77[/\ _P#/!K_.9_X9=_9^_P"B5>%O_ >Y_P#DJC_AEW]G
M[_HE7A;_ ,![G_Y*H_X@7Q'_ -#?)/OQW_S)Z_TM3_B<K@7_ *);BS_P')__
M )YG^C-_P])_X)D_])%_V$O_ !+K]G__ .>#1_P])_X)D_\ 21?]A+_Q+K]G
M_P#^>#7^<S_PR[^S]_T2KPM_X#W/_P E4?\ #+O[/W_1*O"W_@/<_P#R51_Q
M OB/_H;Y)]^._P#F3U_I:G_$Y7 O_1+<6?\ @.3_ /SS/]&;_AZ3_P $R?\
MI(O^PE_XEU^S_P#_ #P:/^'I/_!,G_I(O^PE_P")=?L__P#SP:_SF?\ AEW]
MG[_HE7A;_P ![G_Y*H_X9=_9^_Z)5X6_\![G_P"2J/\ B!?$?_0WR3[\=_\
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M?Z,W_#TG_@F3_P!)%_V$O_$NOV?_ /YX-'_#TG_@F3_TD7_82_\ $NOV?_\
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M//J,%S9:=8PZOJBVVJ2Z?%IE]^Q'[(%]\"+O]@[_ (*H6WP"\%>,/!/A/0_
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MXHL-.L8/%&N:1KC7MSJ%CJ^G6.A:9!9S7'B?3L;P'^P[\)O#O[->G_M@>*/
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M_A=\/O&4?C_X=P6^BZ_X%\5?VIHNKW=_X?UW38;DVFJ7OA]O[+FU/0]775=
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M@^)[[2VDO;'X?Z)XB76HO$FM7.A^*_#.C)K6I7-QK&HW%Q%)<5ZY^VC^R?\
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MA\.O&'B71I+NUN[=+JV35-%T>]L7N+9F59X5G,D+,!(JD@5]Z_\ #)O[4_\
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ME%N+R?QK_ADW]J?_ *-H_: _\,U\1?\ YG*/^&3?VI_^C:/V@/\ PS7Q%_\
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M,C&AQ#'#Y?AY5J<8Q7^SUHY9@JE7#R<E*I3ERSC3KUZ=7]6/A;_P4/\ V3/
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MG..I<,8RC7S;"9G@J&78[%8V5)0;Q^(P="%)UJ'L:492J8BG0AB:LZS^\?\
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MY+*ZL8[.6/7'=K^'[)LG_-O_ (9-_:G_ .C:/V@/_#-?$7_YG*/^&3?VI_\
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M'&T:2S["2A3IQFZ5>=-5:,E-5:5232J2IJ%./Z(?!3]L[]E?QO\ L'2_L/\
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M+8I:WOY"?\,F_M3_ /1M'[0'_AFOB+_\SE'_  R;^U/_ -&T?M ?^&:^(O\
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MUBQUA[SQ/J\5G#>2>%=9U;3?"5C%+:V%_JFB_:+U['1.^^"__!1W]@7]G_\
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MJ.H^%O"FEZ7$8M)T71]*N]4OKB.WNM<UG6YY]7M]#\.=)_PR;^U/_P!&T?M
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M=?$X_&XW$1A2G3A7S#,\?C,5[*G.HL-0GAL'[?$_5EB*OS_17T!_PR;^U/\
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M3Q%X>\(W7@8ZAIVCZ=XDEM++PQ>>&M;URQU#R-9U3Q#+>QZ=K,$4:1C0K?\
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M0M:^&(;C7X]$2&23P]9ZS-?67AVYU#6KS0[?3[O7M:FO^4_X9-_:G_Z-H_:
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MC"$,36C&,5-V48QFE%*RLDDE9'8_\)_XO_Z#4O\ X#6/_P BT?\ "?\ B_\
MZ#4O_@-8_P#R+7A7Q)^*_@#X1:=X<U7XA>)+'PW9>+O''A/X<>'9;UF']J>,
M/&NIII>A:5 %!PTC_:+Z\N)"EOI^E6&HZG=R16EE/(GHE=OU+"63^J8:SO9_
M5Z5G;>SY.EU?U//_ +2S-)/Z_CDGL_K6(L[6O9^TUMIZ:'8_\)_XO_Z#4O\
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MFGU5FM+'8_\ "?\ B_\ Z#4O_@-8_P#R+1_PG_B__H-2_P#@-8__ "+7Q/\
M$+]LSX!_"KXS>#_@'X]\0>)?#WQ)^(&L^&-!\%6%U\/?';Z'XGU'Q?J&GZ3H
MRZ-XM@\/2^%[ZV_M74[;3-2O(-6>UT>_%Q:ZI+:36TZQ_4]#P.%23>#PZ4E>
M+>'II27=-PU7FAO,<TBHMX['I25XMXK$)26FL7SV:T6VS5NAV/\ PG_B_P#Z
M#4O_ (#6/_R+1_PG_B__ *#4O_@-8_\ R+7'44OJ6#_Z!,-_X(I?_($_VGF7
M_0PQW_A77_\ EGDON.Q_X3_Q?_T&I?\ P&L?_D6C_A/_ !?_ -!J7_P&L?\
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MSR7W'8_\)_XO_P"@U+_X#6/_ ,BT?\)_XO\ ^@U+_P" UC_\BUQU%'U+!_\
M0)AO_!%+_P"0#^T\R_Z&&._\*Z__ ,L\E]QV/_"?^+_^@U+_ . UC_\ (M'_
M  G_ (O_ .@U+_X#6/\ \BUQU%'U+!_] F&_\$4O_D _M/,O^AACO_"NO_\
M+/)?<=C_ ,)_XO\ ^@U+_P" UC_\BT?\)_XO_P"@U+_X#6/_ ,BUQU%'U+!_
M] F&_P#!%+_Y /[3S+_H88[_ ,*Z_P#\L\E]QV/_  G_ (O_ .@U+_X#6/\
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M)_XO_P"@U+_X#6/_ ,BUQU%=?U+!_P#0)AO_  12_P#D#SO[3S+_ *&&._\
M"NO_ /+/)?<=C_PG_B__ *#4O_@-8_\ R+1_PG_B_P#Z#4O_ (#6/_R+7'44
M?4L'_P! F&_\$4O_ ) /[3S+_H88[_PKK_\ RSR7W'8_\)_XO_Z#4O\ X#6/
M_P BT?\ "?\ B_\ Z#4O_@-8_P#R+7'44?4L'_T"8;_P12_^0#^T\R_Z&&._
M\*Z__P L\E]QV/\ PG_B_P#Z#4O_ (#6/_R+1_PG_B__ *#4O_@-8_\ R+7'
M44?4L'_T"8;_ ,$4O_D _M/,O^AACO\ PKK_ /RSR7W'8_\ "?\ B_\ Z#4O
M_@-8_P#R+1_PG_B__H-2_P#@-8__ "+7'44?4L'_ - F&_\ !%+_ .0#^T\R
M_P"AACO_  KK_P#RSR7W'8_\)_XO_P"@U+_X#6/_ ,BT?\)_XO\ ^@U+_P"
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M%VKI?5J=VM[I<EVK:W1?]H9K=1^NYAS22<5]9Q";71I<]VM-]M/(^DO^$_\
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M6/\ \BUQU%'U+!_] F&_\$4O_D _M/,O^AACO_"NO_\ +/)?<=C_ ,)_XO\
M^@U+_P" UC_\BT?\)_XO_P"@U+_X#6/_ ,BUQU%'U+!_] F&_P#!%+_Y /[3
MS+_H88[_ ,*Z_P#\L\E]QV/_  G_ (O_ .@U+_X#6/\ \BT?\)_XO_Z#4O\
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MPG_B_P#Z#4O_ (#6/_R+7'44?4L'_P! F&_\$4O_ ) /[3S+_H88[_PKK_\
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M]*S[V?)K;K;8?]HYFDI/'X]1>S>*Q"3MO9^TUM;6VUE?H>F?\)_XO_Z#4O\
MX#6/_P BT?\ "?\ B_\ Z#4O_@-8_P#R+7P+^T#^WU^RS^R_XUL?A[\9_B'=
M>&O%NH^';+Q5;Z78^$/&'B7&B:AJ&J:99W%Q=^'-#U2SM9IKK1K\"RN)X[Q8
M8X;EX%M[JVEF]U^"WQH^'W[07PYT/XK_  LU6\USP+XDEU:+1-8O=%UC0'U
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M6MG;1+\0_L$?L,?MA?L97OQFT2Z\0? KQ9\,_B9X=U*71_"\7Q'^(TE_X?\
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M[275M4TW38[B:-[Z_L[59;B/]'?V6-<U?]IS5?BQ\1?C1\//$W@3Q?\ !/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&_[(MXW_ /4YAK^[&OX3O^#MS_DXG]D;_LBWC?\ ]3F&O'S[_D65_P#%1_\
M3T#Z+A7_ )'6'_Z]XC_TS,_:C_@V/5?^'6?A4[1D_&OXPDG R3_:VFC)]3@
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M3#ZKAO\ H'H?^":?_P B)@>@_(5_"3_P=O@#]HO]D8@ $_!3QL"0 "0/'4>
M3W R<>F3ZU_=O7\)/_!W!_R<7^R-_P!D5\;_ /J<Q5^C^%&*Q57C?+85,37J
M0>'S&\)UJDXNV!KM7C*33LTFM-'J?.\54*$,EQ$H4:4)*IA[2C3A&2O7@GJD
MGJMS]IO^#8__ )19>%/^RU?&+_T[Z=7]"%?SW_\ !L?_ ,HLO"G_ &6KXQ?^
MG?3J_H0KY?C?_DL.)?\ L<X__P!2)GJY)_R*,M_[ Z'_ *;0445EZU-K4&EW
MDWAW3]+U76DB!T_3]:UB[T#2[J;S$#1WFL6.A^)+NPB$1D<2P:'J+&14C,*J
M[2Q_,1BYRC!.*<I**<I1A%.3LG*<W&$(W>LIRC&*NY-)-GIMI)MWLDV[)R=D
MKZ1BG)OLDFV]$FS^;3X.?M(1_!#]B_\ :+\&7/PYUC7Y/CU^UK^T#\&/#OC?
M6KOPKI7P9\+^)/B!I/AGP\C?%'Q#J>LR:IH6DV6EWFH:](9O"USH^K6>E7=A
M/J^FQ_;;ZP_67X:?"OXQ?L8?L$Z%\-/A!H&E_'+XV_#CPC.VBZ%?ZW#HWAK6
M_&'BWQA<:[XA,.IZO=^'MWA3PE-XEUC4-/M+B]\/ZAKVB:#!IXN=(U74Q-;^
M9_LJ_L1>.O"?[/\ \=OV=/VIM)^$GC#P=\:_B)X[^(%]=?#OQ5XJU1K.7QG;
M^%3;V%OIWBKX>>'6T_4?#>L:%/XAT'Q/;ZM=W>G:E;Z+)!IPN;1KX<OJ/[*'
M[;.J_L9_$S]CS6OB3\+-9CCL4\,?"/XTP^-_'NC>+]8^'&C>*]%O-(\"_%+P
MG;_#>>"TBU?P9IVH>$]<U+P_X[UA5TG4;?0KZR\26=MJ>IZ[^_<19MP[G>85
ML#ALTR7#8-<?99G&=RQU;$8K+L_RV=&E@L+FE.5'$X>LJ638>KF6&S3*,)7P
M>,Q5#&PQ6&K.I"2P?Y]EN#S+ X>%>KA<=4K/A[%8/ JA"G1Q&7XF,W6JX22G
M2J0Y\;4AAJN%QE:%:C2G0E2JTU%IUNK^"7[6'C>Y_;$T_P#9B\0_%[X7_'[P
MUK_P5U3QU'X]\ >%(/#UWX9^)?AK7DT;Q+X%N+S0O%OB;PQJVEVEO8:M?N$2
M'6=(OKJUT/4[N:ZTZXEO\C]FO]K+XO\ [2E[X=U+P=\1OA.OB2R^+.KZ;\>_
MV8M;\('P_P#%?X._#;1-?O\ 0)KS0=:OO'HE\22Z=)%X=?Q)K<_A;4M/U>?Q
M)=VVC/X1US1U\)3V-(_9<_:B?]J[]G_]HR6Q_9J\ :#X"^$M[\&O$7PV\&3^
M-]2TKP;X.2[N+V#_ (0R8Z#X4M-?U/4&U2_M["P?2_!^A^#;>&TM2_C%;4W6
MH<Y9?L8_&OXB>*_V6?&OQ6\+_"3P'\<_@5XX\(>+_BA^U!\,?%.I7GBSXU>&
M_#.BFSNO!NHZ%'X+\(76J:QXVN+73-/\8ZIXOO;G2/#^F0:G-X476+#Q3JWA
M.TX,1#@B4:]15\BH5JV08#VV)I+*L5]3S;#1XDI8RG/*:>%P>%Q-#&JCE<:]
M?A^I2S'"XC^S\7@89AA:^*^L;TY9ZG3BZ>85(0S"OR4I/%TO;8.K_9<Z,EBY
M5:U6E.BYXMTZ>8QEAZE/ZQ1KO#UJ=+V?+^ S^T"W[8'_  4W'P$U3X7>&M3L
M-<^ VM:CX@^)FE>(O%$%S=Z;\%K^31?"NF^&M U#P_\ 9H=<N&GEU?QG>^(+
MAO#5OI]O:6'@KQ3-KDM]X:WO"^M>*?VR='_8(_:R\4?L]Z?\3O#%G\-?VE-,
M^)_@K1H_A_J^GZ7XO\5-X,\'Z1?:/X?^*OBG1(9]%\0:IX!\2QVB'4M6N_#=
MEJMI::[J4UC]NUMO</A-\"?VD?A_\:?VS_BMJVC?!#5+3]H^Z\$7O@S1M.^)
M_CRTN-#?P)X9U3P?96OB>]N?@O<1*FK:5>6FHW5WI5O?'3]0MKBTBLK^VNXK
MFS]5_87^"7Q#_9P_9B^'/P1^)L_@R^\2> !XELCJO@36=<UG0]5L-8\6Z[XE
MLKG=X@\,>%;^RNX8-:6QNK7[)=0M+:-=PW82Y%K;<N=<09=A,-/,L!+),3FV
M!P7!N3X.M0K_ .V5\!BO#7%\.\51J5L%BJ&*J?4<>L#0H3=2,</B*<:F%C4H
M2Q?M-<%EV)K58X;$+'4\'7K9UC:U.I!>QIXBEQ-0S+*7&%:E4I1]OA_;SJ1Y
M6ZE.4HU7"HJ7+M?L9_!K5O@'^SA\//AEKEG;Z1JNFGQ7X@O/#5E>C4]/\%R^
M.O&GB'QT/ NGZF)[H:I:^"D\1KX875ENKB+5I=+EU*"3[/=Q1I]0445^2YEF
M&(S;,<?FF+<98O,L;BL?B914E%XC%UYXBLXJ4IRY74J2:YIRE;XI2=V_K\+A
MZ>$PV'PM%-4<-0I8>DG:ZIT:<:<$[)*ZC%7LDNR2T"BBBN(W"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O0;7_DFFI?]C/'_ .DEA7GU>@VO_)--2_[&>/\ ])+"OJN%/XF?
M_P#9*Y]_ZB'EYK\. _[&F _].GGU%%%?*GJ!1110 4444 %%%% !1110 5^=
M_P#P4@TW7['X8?##XH_#KQGH_A+XV?"7XT^%/$'P5TG6K74]2@^*GC;7M/UK
MPD_P;LM(T>VO=2U/5OB!HNLZG9V$%I:J,V<O]IZKX;\/MK/B72/T0KY._:?^
M!OC'XH:K\!_B+\-K[P]_PL#]G_XKV?Q"TCPYXVU+5-.\$^,M#O\ 2KWP[XN\
M.ZE=Z;HWB<Z'K\VCWQN?"7C'_A%O$%SX:U2W<6UE''JEU=V_TO!^+P^!XDRS
M%XJM2H8>C4KNI]8A3GAL2I83$067XSVL*E*G@LSE*.78VO4A.&'PN*K5Y1DJ
M;3\S.:-3$9;BJ-*$YU)QIJ/LW)5:35:G)XBCR.,I5\*D\31A&2E4JTH4TTY'
MRK^P1\5](_:;^,'QT^-WQ$L+CP%^TOX<\->%_@CXL^!MUHNMZ#?_  B^'NBZ
MSK^MV"R:EK$5KJ'B;4_&/BRXUK5M5U.*'3)/#J6&B^'YM)MFM[?6O$7NO[7]
MGI_@']F6W^ WPHT_3?!NI?'37_!O[+_P]L-'TMDL=%@^)EP-!\4ZFEO8A)85
M\+_"VS\:^)FOR3+$^AK<33;\RC8\ _ 'Q;<?M;^*_P!K'QQI'@[P/J%[\$],
M^"FC>$O!/B/4/$]SXB@3Q>WBG5/&_P 0-8N?!_@N ZU;P:?H'AGP]H]M#XC@
MMM'L7N;O6S*FF:=I7:^,?A=XM\;_ +4GP<\?:I;VD?PL^"G@#XA:UH3QZNWV
M_5?C-\07T_P=!-=Z$(C&VG^$_AO%XKCL]2EE5FO_ !M+%;QL;69T^HS#-,IG
MQ;ALSPM>-#*\!E>79K')Y8NEB\#@LRR;*74R_A[#UXVIYEA(9A"C@Z=?DK8E
M8;%XAXJMB<33Q>+K>5AL+C(Y14PM:$JF*KXK$81XU494L17PN-Q:CB,QJ4W>
M6&K/#RG6E3;A2]K1IJE"E2E1I0^@/#GA[1_"/A[0?"GAVQATOP_X8T72_#VA
M:9;+MM].T?1;&#3=,L8%_AAM+*V@MXE[)&HK\:_V\?B#\/OCY^SQ^TGXMG\<
M^#KSP7\+_"WB?PW\%_"J>*=$EOO&OQ$M;Z+P]XS^+,VB?;#?7-MH6=:\ _"P
M?9HEN+-_'7CJV&M:+XK\!:OIOZE^*;GX[Q_&'X76O@W3_AM/\"[C3?&$GQAU
M'7WUX?$6PU.#3/\ BB(? L=E?0Z(\%[K,D(ULZO87H33+>^\F6TNVLO/^3_V
MD/\ @G5\ ?B/\%?B;X2^$7P)^ ?@GXJ>)_#]S:>$?&EUX(TG0ET379[J"8:E
M-KF@^'-4UJP/EK.K75A87=SNEP(R&9AS<$8[)\FS_*,TSO'UXU\3CLJQE'&X
M)X?&+ 4?[7JPS/\ M7VU>A5PN)K4L-%RG#ZS-9;BZ]3V,JF)H5*6N>4,9C<O
MQF$P.'ING2H8JC.A752B\1/ZI"6%^J<D)PK4H2JRLI>SB\51IQYU&E4C+WG]
MC;Q7X7\6?LM_ *?PMXDT#Q+#HOP>^%_AS69O#^L:=K,6D^(=)^'_ (935-!U
M.33KFY2PUG36EB74-+NC%?6;21K<01EU!^F:\(_9I^"/A_\ 9\^"G@#X9Z+X
M=\(^'M2T?PMX93QN_@JP2QT;Q%X_M?#&BZ/XJ\5&06&F7.I76MWVE">35M1L
M;;4KZ%+>2]ABE!B3W>OD<_JX.OG>;ULOJ5:N"K9CC*N&J5E!5:E*IB*DXSDJ
M;E#WKWCRM^ZTW9W1Z^7PK4\!@Z>(C&%>&&H0JQ@VXQG&G&+2<DGI:SOUOT"B
MBBO).P**** "BBB@ HHHH *]!T?_ ))]XN_Z_=(_]+;*O/J]!T?_ ))]XN_Z
M_=(_]+;*OJ^$/]^S;_LE.+?_ %GLP/+S;^!A?^QIE7_JPPYY]1117RAZ@444
M4 %%%% !1110!A^)XXYO#7B&*6-)8I=#U:.6*15>.2-["X5XY$8%71U)5E8%
M64D$$$BO@[_@E)_RC]_9T_[ WC;_ -6AXWK[A\=1^*9_!_B.W\$Z?X?U3Q3=
M:1?6NBV7BG7-1\.>'Y;VYMY((CJFL:3X>\5:C9VL;2>9(UIH-_,X7RUC0MYB
M?-'["7P4^)_[./[-?@'X'?%+_A [S6/A]'KUG::[X \1^(=<TS6[36O%WB/Q
M+'-<6OB+P9X1NM)N+*#6+6P>*-M5CO9H+B[66R1X[0?686O0CP/G6$EB:$<5
M7XHX;Q='"2K4UB*F&P65<4X?%XB%%RYW3HULRP-.32O)UKP4HT:TJ?D5:=1Y
M[@:RIU'2IY5F=&=90DZ<:M?%Y34HTY3MRJ4X8:O)*]ER6;3G!2^-_BG+^V[^
MP_XQ^*W[2<6O>"?VE?V<_%GCK7/B-\8/AWI_A73?A[\1/ 6A7%AI>@:9K_AO
M63-JEYXBM? WA#PYX7\/RG5-9UC=HNC*)-!L()+[Q3HGZX^&_$.C^+O#N@>*
M_#M[%J7A_P 3Z+I?B'0]1AW"'4-'UJQ@U+3+V(.%<175E<P3Q[E5ML@W '(K
MXKU_P1^V+\;?ASXH^"OQGTK]G_P3X9\=+JOA/QW\2OA7XX\>ZKKVI?#75KN2
MVUO2?"7PT\6?#L6&B:_XG\(R77AI]?UKXFZK!X<O-1F\0VWAW6?LL&BO[[JM
MK\9]!^)WP=\.?#?1/AA;?L[V/A_Q+I_Q.?5SKT7CW0WTG18[7X>:=\/H+*^B
MT3[%)J M8=6&K6-Z(])M+T036ET;(S^GQ#6H9KA,NI8I\.4>(,%#,H8C,,HJ
MX3#8',,ER[+\+/*XXJ&!2RZ6:U)4<7A,"J-+"X[$15"AF-'VLL+4ERY="IA*
MV(G269SRZO+#.GAL9"K5Q&&QN)Q-6.*=)UW]96$BITJV(=2=6A3;J5,//E56
M*Y3X^>*M!_9@_9X^,GQ$\#^'M/T[7+33O$>M:#8:?IQN)O%'Q>^(6MRV?A9=
M12,/>:K?^*OB9XJTV&[FF>>>1]2EV_(JH.V_9W^$MI\"O@;\+/A':R0W$O@7
MP9HVCZOJ$ <)K/B8VXO/%GB!O-9I#-XB\3W6KZY<M(S.]QJ$K.2Q)KC/CW\+
MO%OQ9\<?LXZ3;V]H/A=X(^+2?%_XG73ZNUGJ%W?_  YT+4+WX5^'K72TB?\
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MA_Q'"/\ T3,O_#RO_G7Z_P!/2S15; ]!^0HP/0?D*/\ B6"?_1;0_P#$<?\
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MP/0?D*/^)8)_]%M#_P 1Q_\ S\]?Z>A_Q'"/_1,R_P##RO\ YU^O]/2S15;
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M%5L#T'Y"C ]!^0H_XE@G_P!%M#_Q''_\_/7^GH?\1PC_ -$S+_P\K_YU^O\
M3TLT56P/0?D*,#T'Y"C_ (E@G_T6T/\ Q''_ //SU_IZ'_$<(_\ 1,R_\/*_
M^=?K_3TLT56P/0?D*,#T'Y"C_B6"?_1;0_\ $<?_ ,_/7^GH?\1PC_T3,O\
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MS)7IN3U<4VY0;Y[K97T_0NBBBL#F"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KT.U_Y
M)CJ7_8TQ_P#I'85YY7H=K_R3'4O^QIC_ /2.PKBQOPX;_L-PO_IQ'IY9\6._
M[%F-_P#3://****[3S HHHH **** "BBB@ HHHH **** /+_ (Q_%OPQ\$/
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MBBB@ HHHH **** "O0]&_P"2>>,?^OW1_P#TNLZ\\KT/1O\ DGGC'_K]T?\
M]+K.N/&_PZ/_ &&8+_U+HGIY5_&Q7_8LS3_U!KGGE%%%=AY@4444 %%%% !1
M110 5\>?M$_M@Z5\!/\ A(%TWX-?&GXT'P1I-KX@^(U_\)_#%AK&@?#O1YOL
MMY,OBG6]1U?3((M?A\/W4?BI_#>FPZCJ5CX9FL?$GB(>'_#>IV&LS_8=?,W[
M5]K^T=J'P>\7Z'^S'H7P^U#QYXB\/:]I;ZEXV\6:GX;O-'6]T]+**[\)6-IX
M;U'2=<\42V\MW'I4GB?Q+X3T/1M1@TV]U";6;(7.G"Z=G-*233:6LN5+75M]
M%:__  =G=/E<XJ233:3YI<D5JKMR6J25_GKKL_7/A=\3/!OQD^'OA'XH_#W5
MH]<\&^-]%M==T'441HGDM;@,DMM=V[_O;/4M/NH[C3M4L)PMQI^I6EU97"I/
M!(HX/XK?'O1_AOXG\)_#G1/"7BOXJ?%GQQ9:OK/A_P"&G@23PQ#K47A?01''
MK'C7Q)JWC'Q%X6\,>%_"%AJ%UI^CC4]5UJ.\U36-1M].\/Z9K-U#?QV?EW[
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M.<:E.I&,X3A)2A.$DI1G"46XRC*+3C)-IIIIM,****S*"BBB@ HHHH ****
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M@\(W-CXGGMCJOAB+P_JDSZM=II-Q;+J!M([*YBNH+^X:V\;\1_LM^*+#Q_\
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M1_Q+E_U67_FO?_AP/^(K_P#4@_\ ,I_^#CR>BO6**/\ B7+_ *K+_P U[_\
M#@?\17_ZD'_F4_\ P<>3T5ZQ11_Q+E_U67_FO?\ X<#_ (BO_P!2#_S*?_@X
M\GHKUBBC_B7+_JLO_->__#@?\17_ .I!_P"93_\ !QY/17K%%'_$N7_59?\
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M.!_Q%?\ ZD'_ )E/_P ''D]%>L44?\2Y?]5E_P":]_\ AP/^(K_]2#_S*?\
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MYKW_ .' _P"(K_\ 4@_\RG_X./)Z*]8HH_XER_ZK+_S7O_PX'_$5_P#J0?\
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MJV]G]3HWYN7EO[16O>SM9_MY_P &M_\ RBA\(_\ 9;_C/_Z>=.K^BNOYU/\
M@UO_ .44/A'_ ++?\9__ $\Z=7]%=?N^%_W:A_UZA_Z2C\RQW^^8G_K]4_\
M2F%%%?.G[8'B+Q+X0_9/_:8\5>#;N[T_Q7X;^ GQ;USP_J=A.;;4-*U72_ >
MO7MIJ]A.K*\=]I,L*ZC9F,^:;FVB6)6D*J>F$7.<()I.<HQ3>R<FDF_+4Y3C
M(/VMK?QKXJ\5>&O@%\'_ (A?M :=X!\0S>$_'7Q \':O\-?#?PXT3Q58)!/K
M'A/3/$WC_P <^%Y/&'B;1[:=!J-MX3TW5]&TW4+BRT[6=>TJ6>>2T\Q\3?\
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MLT:5X,ED^&GQ6^,WBSQ[KUWH_ASX;?!3PNGC'Q[=V.EV/VO7?%']AM?6#_\
M"-:!/<Z'IFKZDDK_ &34O$V@0/%MO3)']056-E9M>1ZBUI;-J$5M-917Q@B-
MY%9W$L$]Q:1W13STMIY[:VFF@5Q%++;P2.C/%&5N#A&:<X<\5>\.9QYM'9<R
MNTKV;MK;1-;@?"/P%_;NM_C?\:_^%$ZC^S3^TC\%O%X^'VJ?$UY?C/X1\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "NEA_Y%2Z_["Z_^B+>N:KI8?\ D5+K_L+K
M_P"B+>L:VU/_ *_4O_2T=6%WK_\ 8+7_ /2#FJ***V.4**** "BBB@ HHHH
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M[TFQUOPY=7J-")8T2'6K!DE=)FDD2-H)=_P_KR.4_GL\ _ SXD_!SX.^ /\
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MX]?!>#X4>-]9_:3\0?$KXU']L#P_\,_VAO"7PLT2U\0_LAZ!X(\0^*=;M/\
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M/(:_OGK^!C_@\&_Y.1_8\_[(AXZ_]3R&N+,/]TJ>L/\ TN)Z64_[]2_PU/\
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MQ/2RG_?J7^&I_P"FY'[>?\&M_P#RBA\(_P#9;_C/_P"GG3J_HKK^=3_@UO\
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MJ6C:)-IL/@B+Q-KFAZEJ7B;4;A;;3=3U<>'O#7@C5M6^GO@VOQ#_ &O?@O\
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M!O\ DY']CS_LB'CK_P!3R&O[YZ_@8_X/!O\ DY']CS_LB'CK_P!3R&N+,/\
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MHHH *Z6Q_P"1:UO_ *[V/_I1!7-5TMC_ ,BUK?\ UWL?_2B"L:_PP_Z_4/\
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M?/%RM.TVG<=];7UOU7EKJ_6WZ&+X'^,>K^+_ -F+]K3X[_ S]L&^^,?A#3/
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M2G&%7FC%.,::E62C]G]U*,]90?P6T]'U7X[7^7XJVE^OAO\ P1S\/>*?#O\
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M]X@\1:&=2\+3V-_'-::3JFH(=,\3Z1>:B]C?7!M7_8BO&O@%\!?AU^S7\+]
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M_A'I?QS^$WQH\2_$KP!X4^(6LZ-;:?>Z!\*='U=-"@TV*XNM%T37K0^(-?\
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M9^+X)K_PW!INF:;IEKX NWF^']GIFG6.G6OAB&RM+>"/M/AI_P )/KW[:O\
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M_P#POPG_ ,M\U]X?V=F'_0#C/_":O_\ (%NBJGV^Q_Y_;3_P)A_^+H^WV/\
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M:^\Y_P"SLP_Z <9_X35__D"W153[?8_\_MI_X$P__%T?;['_ )_;3_P)A_\
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MG_@3#_\ %T?;['_G]M/_  )A_P#BZU7$65J3FL[RWF:IQO\ VAA+VIJ"I_\
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M^TW_  ;'_P#*++PI_P!EJ^,7_IWTZOZ$*_GO_P"#8_\ Y19>%/\ LM7QB_\
M3OIU?T(5\]QO_P EAQ+_ -CG'_\ J1,]#)/^11EO_8'0_P#3:"BBLO6M/N]5
MTN\T^QUS5/#=W=1".#7-%AT6?5-.82(YFLX?$6CZ_HKRLJM$1J&CW\/ER.5B
M$HCD3YB*4I1BY1@I22<Y*3C!-V<I*$9S<8K5J$)2LGRQD[)^FVTFTG)I-J*M
M=M+9<S4;O97:5]VEJ?EY_P $C/\ DB/Q[_[/#^.'_I/X.KPKQ1H<WC[_ (+#
M?$1O &KZ_H>F>#/V2KC3/C;K7A'5M0TF\FU'4-,8Z)H[^(M(OH;K0=5/]I^
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MG:/=RZ:X6_FCU" 13ZG'>WT,5VOSV(XBRFKPH\FEC*=6M#@[ Y?3H_4:T?\
MC(<+QQ7S>.)C7>&C_"X:Q%;+UBI5$Y3J2PW*Z+]LO0I9;C(YO]=5&4(2SFOB
M)3^L0=\NJY%3P;I.FJK^/,Z4,0Z2BTHP57F4_<?TM1117YB?4A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>@VO_)--2_[&>/_ -)+"O/J]!M?^2::E_V,\?\ Z26%?5<*?Q,__P"R
M5S[_ -1#R\U^' ?]C3 ?^G3SZBBBOE3U HHHH **** "BBB@ HHHH *YWQ9:
M>*K[P[JMGX)US0_#7BJXMQ'HVO>)/#5[XPT73+@RQE[B^\-:?XG\&W>K*+<3
M)#!%XETL1W+PW$KW$,,EG<=%7B_Q6^%7BGXAZKX+UGPK\<?BG\'+SP?+K<DM
MO\/QX%O=&\6)K5O96WE>+M"\>>#/&.E:LNDQVDQT4BVMS83:E>W:[[U-/N;'
MKP$*4\7157%8?!0BY5%B,5AZF*PT*E*$JE&-?#TL/BIU:56K"%&<?JU>%JEZ
ME*=-33QQ#DJ,^2E4KMI1]G1J1I591G)1FZ=2=2BH2A!RFG[6G*\;1DI-,^(O
MV&YOB[X#^+O[4_[+?QTC\*>,O$&BZGI'QK;XS>%-"U#0+CXK0?&JZU\W^H>,
MK;[1)8:;K&G1:/9>%]"TO3$L+;2-%\-S:#I1U#2?#]EJ<ORQXMT?X[?L!?L&
M_M"_L]>,/!_A+XC?#=H?'O@'X'?$>T\>6^FZGK^A_'V_U;0=*\)W'PZ/AC4_
M$&K_ !'T'6/$NI^,-4T6RBB\,ZII-SJ=C9>)HH]!>_U#]BOA1\$_#'PGN_&^
MOV>I^(/&'CWXFZW9Z_\ $;XD>,I=&G\7^,;S2-/31O#EK?\ _".:)X;\.Z;H
MOA70HH=%\.:#X=\/:-H^FV:3W LI=6U+5]2U#@8?V9;+Q-X_\)_$SXW>//$'
MQHU_X>:Q<>(?AIX<U?2O#OAGX:?#SQ%*0MOXHT'P9X?T^*YUCQ5IUNJQ:1X@
M\>^(?&=[X?EWW_AG^P]0D>Y/Z=1XTRS^W<=C<70P-?):];A?-,QRRG@\7AIY
MKGW#N!=+ZYDL<+/#TLHI8K&ULPI/V]:AA\/E>95*E/*JE>C0RZC\O/),5]0P
M]&C.O3QM.&:87#XF5>C5CA,OS'$*?L,<ZL:D\9.E0AAYKV<*E2IBL-&,L7&G
M.>)J:_[(_P //$7PG_9A^ GPX\7BYC\5>#_A7X-T?Q%:W5W%?2Z;K4.C6KZE
MHRW4"K#);Z+=R2Z39B$R11VEE!%'/<(@N)/Q\_:N_:8T7Q]\!_VKM>\9_"']
MI+1O'WC+P=KWP[^'H\2? 7QYI?@CX8?"_3?$=A+9VMQXQOM+ATBPU'XB7^DV
MOCKX@ZTCPVLET?!_@N2ZUO3_ (<Z%KM_^U7BGX3W_B7XP_"[XK0_%#XD^'=/
M^'&F^,+&^^&&@>(9K'X=?$*;Q1IG]FV=]XZT%/W&LS^&3)/J&B&96:VU-;&[
MBDA^QO'=7_C;\(O#?QZ^%'CGX/>,+[7--\,_$#1)= UF^\-W-A9Z[;6<L\$[
M2Z9<ZIINL:?#<AX$"O=:9>Q!2P,))!7R^'^)\JRSB.AGV:T)YA6S/-<#F^8U
ML%5K8&>3SAGM?&X["4Z53#XF..IUH4L)BW[&=&4J5L#]84:F,A/JS#*\7BLM
MG@,+46'AA<+7P>&A7C#$+&Q>!IT:%:<XU*;H2A*5>C[\9I3OB/9MQHM>'?L%
M?$RS^)_[*GP=O+/PEX]\(+X0\!>!? $\'C_PS+X8NM<NO#'@'PI%-XF\,PRW
M-R=7\&:N;D/H&OH88]3CBG=((Q'S]B5R/P_\&:7\./ ?@GX>:'/?W6B^ _"/
MAOP9I%UJLMO/JESI?A?1K+0]/GU*>SM;&TFOYK2QADO);6RL[>2X:1X+6WB*
MPIUU?'9WBL+CLXS3&X*C+#X3%X_%8C#T9U)59PI5JTYP4IRC&4FU+F=XIQOR
MZVN>U@:-7#X+"4*\U4K4</1IU)QBHJ4X0C%VBFTDFK:/6U^H4445Y9U!1110
M 4444 %%%% !7H.C_P#)/O%W_7[I'_I;95Y]7H.C_P#)/O%W_7[I'_I;95]7
MPA_OV;?]DIQ;_P"L]F!Y>;?P,+_V-,J_]6&'//J***^4/4"BBB@ HHHH ***
M* "OR]_9IM19_P#!2S_@HV==39KVI>'_ -ES4/"LDT<<+7O@^/X<W5CJEQIO
MG1Q7-S96FIV^C:;J%Q8K)8IJUK+!>2O=I"Q_4*O!O'?P!T'Q?\3_  Y\:-$\
M4^*_AQ\4/#W@SQ!\.G\6>#(_"<MQXA\"^(;J#4V\-^)+'Q=X7\4:=JEGH&OV
M\?BCPJQM87T?Q#YL\HO],OM4TF_^EX>S3#8'#\28#%3=&GQ!D$LJABU&<UA:
M]#-\HSNA.I&E&=65'$5<GC@JWLX2E"&*]MR35)PEYF8X6K7J9;B*2YY9?F"Q
M<J-XIU:<\'C,#447*48*=.&,=>',TI2I<EXN?,OA3_@FC%K-Q\6/^"D>MH0O
M@J__ &V/B/8:#'%)YUN_B32]8UR3Q;?0R*YB8ZC9:CX3N6*1KA3&#-.H3R]#
M_@H+X-E^-?Q3_9R^#WP<U74_"7[7&ACQQ\7?AG\4]/U]M$T;X1^"=#M+'3_$
MM]X^BM=&U_5=:\-_$;6$T;P=IFBZ;IJ?:=8MWO=3U Z%INJ^&_%/V%H/[,7@
MSP)^SUK?[/?PKU_QE\-K'6-#UZT;XB^']>N1\3AXK\2>;<:O\1;WQ63%?7_C
M34-4E;4KS4]]L%.S3],CTO3+6PM+.CK?[+FAZQ+\!/$2_$;XE6'Q3_9Z\/2^
M&/#'Q=74= UOQGXMTC5/#=AX;\5V7Q*'BSP[XAT;QC#XP33K;6-8N+G3+?5K
M3Q K:SH&JZ-?37$LWUKXJRJ7&>)XLHXF>&E"GBL!EF&K8.K*%L+PRLGRO'YK
M2I.K3Q&"QU>G3CFN6J6)=2E5Q$<13QV'E4P^)\=93BUDE+*)TE53E2Q&*JPK
M13O5S3ZYBL/A)R4)TZU"G*3PF):IJ,X4W3E0J*-2E\V?\$V?'NIW6@_&CX-?
M%/P3<>"?VG_A1\08+W]H"[O]7N=?U#XH:SXVTQ;WP]\6VUFZB"RV7B;3-+DT
M_2=(TVYN]#T+0-&T-- 73/#VH:-H]A^F=>)_"?X%^'?A5K_Q*\;)KOB/QM\1
M?B_J^@ZM\0O'WBT>'8M;UJ/PGH47ASPEH4%EX2\/>%O#VF>'?"NDI<6^BV%G
MHR77F:AJ5]JNH:KJ5]<WLGME?'\69C@<VS_'9EE]-TJ&,C@ZU2FI5W0ACI8'
M#+,XX)8F4L13RU9BL5_9E&NU5HY?]6I3A3E!TX>SE&&KX3+\/AL3+FJ476A&
M35-5'05>J\,Z[I)4I8GZLZ7UJ=-.$\1[6<7)2YF4445\Z>D%%%% !1110 5_
M"3_P=P?\G%_LC?\ 9%?&_P#ZG,5?W;5_"3_P=P?\G%_LC?\ 9%?&_P#ZG,5?
MI7A)_P ESEG_ &#YE_Z@8@^;XL_Y$>)_Z^8;_P!/TS]IO^#8_P#Y19>%/^RU
M?&+_ -.^G5_0A7\]_P#P;'_\HLO"G_9:OC%_Z=].K^A"OGN-_P#DL.)?^QSC
M_P#U(F>ADG_(HRW_ + Z'_IM!1117RQZ@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7H-K_P DTU+_ +&>/_TDL*\^KT&U_P"2::E_V,\?
M_I)85]5PI_$S_P#[)7/O_40\O-?AP'_8TP'_ *=//J***^5/4"BBB@ HHHH
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M_:;_ (-C_P#E%EX4_P"RU?&+_P!.^G5_0A7\]_\ P;'_ /*++PI_V6KXQ?\
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M*** "BBB@ HHHH **** "O0;7_DFFI?]C/'_ .DEA7GU>@VO_)--2_[&>/\
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M/$$>D0ZMKD6J>'/ 'A36GN;N+1K=7M[O4KK3PTUW.+,7$J317_VG/V5?A_\
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MU-\U5\E6G[3DJI2FX^TBJM2*FUS<DY4VW!\H4445\N>J%%%% !1110 4444
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M_!OA+2M%U[4(]&L[&]U>"!KFXT]KJVD)%W<,^5KO[&WA+43\8=)\/_$CXG^
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M+2<91:>J-J56G7I4Z]&<:E&M3A5I5(/FA4IU(J<)Q:T<9Q:E%K=-,****P-
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MO_"(R2ZB%O/%VB6,T<UN4MHK:ZTV[BM)0;R1+]?]"/H_Q_\ BG\0_@O^RO\
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M3P=J'C'4+"]O;T:M<OX>?4I+V*S\-6+:=HNF0ZKJ$]A:0:C'H][I'T1\(/\
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MH_\ R3[Q=_U^Z1_Z6V5>?5Z#H_\ R3[Q=_U^Z1_Z6V5?5\(?[]FW_9*<6_\
MK/9@>7FW\#"_]C3*O_5AASSZBBBOE#U HHHH **** "BBB@ K\O?V:;46?\
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M_P#ZD3/0R3_D49;_ -@=#_TV@HHHKY8]0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KT&U_P"2::E_V,\?_I)85Y]7H-K_ ,DTU+_L9X__
M $DL*^JX4_B9_P#]DKGW_J(>7FOPX#_L:8#_ -.GGU%%%?*GJ!1110 4444
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M#>FZSXLUK5[?PJWBWPCXEUK6U\+0:C=W-MX>AN-4O9KQ+;28+6VBE$6R'$2
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M3XDV%[\2M:U&XM]+TBR\_P 4>(]-O=9ATS6)K9$U2=--TS2(-+^</!7BZ_\
MAW\>O^"<>J?#:\^.-QX:^+U[XQ\)_$/XK_$?Q;XQTW2OVLVNO!^EW+_$_P#X
M5;XJ\<^*=:TW2UUSQ'?^*O"^J^+]#\-:K>1ZIIPT:&^\.:;H6IB*'AW+%*O+
M#9PIQEDT<YR]U,OJ4(XBC_J]CN()8?%U:N)6'PN*=++Z^%I8;!ULTQ-2I&6*
ME1I8"E6Q5-U.(U1]FJN#<9+&_4L2HXF-1TI_VAA\O52C&%)U*M)2Q-.K.K6A
MA*<8M4E.6(G"E+^@FBOQ<\%_"?6OC'\>?^"F/PP\1?'+]H&ST'P;J/PE_P"$
M(DTGXL^*M/O/#-]XD^&?BGQ-#);7EC>VE_/H.A:OJU_+IO@9KV+P1=1SJ^M:
M!JE_8:-J&EXES\=_VAM:_P""/7PX^,/AW6/%^K^._P"Q]"T_XE>,O"]QJ<OQ
M)M?A?X5^)&I>%?&/BS1=5MDO+]/%(\):!!)X@\67.ZXTVPN?$7BZ:\M;VR74
M((GX>3E5R_#X7.L+6K8W-.$<LJJOAJN$I85\9Y$L]RJNZLZE2-6,*$,30Q-.
M*A.%6C2Y/:>W2ITN(DH8BI5P-:$*.%SC%0]G5A5G562X_P"H8NFH*,>1RJ2I
M3IR;:<)ROR\GO?M]17Y$^!O#.C>*/VV_#&L? /QU\9/%/[->@? 9_B'XSM_"
M7QV^,^H?"E/C+_PG2W7ARSGC/CG4-%\1>./$&BVMPGC+X7ZY!#82Z9+-KOB;
M2[C6M2G-SX[\*_!?[1W[8'[*WAC]H7P)\1+'P9\>_&.LZMXLT[XTS_M(_&32
M=&\'_P!C?$:XM]:\#O\  S2O!%_\-=-\&VGAWP\OA:3P\;F\M]5%EI_BSQ'=
M:QJ<]Z;N?]0\/&-/$8C/88'!MY+1Q5?,,##"U<LQF?+-9X.CF.%>83J4J="A
MDV+Q&-]@\3CH49X:I@\NQT:TG3?]OU&Y4Z> =>NOKLZ5/#UY588JC@/J<:T\
M-66&C&<IU,;1IT>=4\.YQJQK8F@X+F_=BBOP^_:=^(6N>!_C1\2_$?[1^D_%
MZZ_9W\>?#KX<>&?AK^TG^S=XY\>2Z/\ LL^(M2\.:5;^,KOQ%IG@;Q%I#V]G
MK?BKQ!I7C2U\0:GI+:MXG\.#PYX<71/'6DZB- TC]B/AA+I4_P -?A[-H7B6
MW\9Z)+X'\*2:/XPM&WVOBO2VT&P:P\26S_:;S=!KEJ8M3B/VNZ)CNES<3']X
MWB9WPO5R7+,IS.6(EBJ6:TZ<Z=6A0C/ *<L)A\37PM/'TL16A+&X&I7>$Q^"
MQ-+!XNA7INI&C5PM2CB*G=@<UACL5B\*J2I3PDI*4)U&L0XJM4I0JRP\Z<&J
M->,/;4*]*=:C.$E%SA6C.E'N:***^5/6"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *]!M?^2::E_V,\?\ Z26%>?5Z#:_\DTU+_L9X_P#TDL*^
MJX4_B9__ -DKGW_J(>7FOPX#_L:8#_TZ>?4445\J>H%%%% !1110 4444 %%
M%% !7SA\?_C-X^^',GA/PA\'/A'<?&SXM^.(]=U/1O"#^*]*\":!I/A+PI-H
M-KXJ\8^)_%^M0W%E8:?I-]XJ\,Z?:Z5;6]SK.NWVL1Q:;;-%9ZA<6OT?6!XJ
M\4>'_!'AK7_&/BO5+?1/#/A?1]0U[7M7N_,-OIVDZ5:RWM_=RI#'+/*(;>&1
MQ#;Q37$S!8K>&69TC;NRRI2HX[#SK9=#-HJ4HPRZI/%4Z>+K3A*&'IU'@JE'
M%SI^WE3E.CAJU"M7C%T85Z,JBJ1PQ49SH5(PQ,L([)O$QC2E*E",E*I**KQG
M14G34HQG4A.%-M3E":CROX]_9,_:Y\1_'3Q7\5_@W\7?A+??!#X^_!*3P^_C
M;P9+K]AXGT/5-(\3P7%QI'B+PKK=D(S>6$L4,$]U&8KBT@MM6T2>QUG5EO9Q
M997Q>_:6_:@T_P"(_B;PC^S-^R/'^T'X6\"S6'AWQEXWU#XT^!?A;:V'Q N-
M)L?$NH>%M)TSQ6PNM<MM'\.:_P"&)K[7;)C91ZWJ&J>'G5-0T&^6NZ_9J^&G
MB%/&?QK_ &E?'VEZEX=\;?M#ZOX7.D^"=6\M;_X>_"/X=Z5<Z%\-?#VK6T=S
M?QZ?XOUNUO-3\;>.["UO9+73=?\ $?\ PCX$DOA][NZ^+OVJOV*[7]GO3_BG
M^VU^R7\1O&7P@^,O@RT\;?%WX@Z3JGB+5O&7@+XOZ:@U#Q3XUT;Q7H_BG4;V
M4W6HI]KN],Q=7>GQW\-M#9Z39:LVEZ_HOZ3@,/P9BN,,7A/JN6X=8O!97@\K
MRW&QSO,.&*?%&)PN!AF>'KX_*\[P>>4,LI9K]=PN Q=+$YK3BJE.O5=?"4XU
M)?,XBIG5+)J-;VN*J>QKXJMBL31>!P^:2RJG5KO"U(8?%8&M@:F*EA/8UL11
ME3PDVXRIP5.M)Q7Z^:1)JLNDZ7+KMM8V6MR:=92:S9Z9=S:AIMIJKVT3:C;:
M??W-I87%[8P79FBM+NXL;*:YMTCFEM+9W:%/SD^-O[:/[0W@8>/?'OPJ_9'O
M/BA^S[\)M9\1Z9XV^)5W\3=!\,Z_KD7@+4=5T+XE7_@KP&]A?Z]<:/X)U[1M
M4L9M<O(98=:72+^]TRQ;1A_;,7Z">!_$%WXL\%>#_%6H:-=^'+_Q-X7\/^(+
MWP]?LCWV@W>LZ3::C<Z->O'^[>[TN:Y>QN&C^1IH'*_*17@?[4VN^(=:\%7?
MP#^&SNWQ:^/&@>(O"6AWB1N]KX \$745GH?Q#^+VO3)=69M=-\":/XAA;0[>
M.<WOB'QUJ?A/P[9P-%J-_?:;\GPT\%2SR.&S+),OS6%3$JCB*6.QF84,!@,'
M2J2GF>+]KE>,PM?FPV%IU)T\5/%5\-AJ,*U:>%Q51T:E'U\S]O+ .KAL=B,(
MXTN>G.A0P]3$8BM.,8X6CR8JC5IVJU91C*E&E3J59RA!5:,5.,_8/A'\3_#7
MQI^&'@+XL^#FNO\ A&?B'X5T;Q7I$5^D$6HV=MJ]G%=-INJ16MQ=VT.JZ7,\
MNG:G#;7=U;PW]K<10W-Q&BROZ)7$?#/X?Z!\*/AUX%^&/A5)T\-_#WPCX>\&
M:']K=);Q]+\-Z5:Z19S7TT<<2W%]<0VB3WUR(T-Q=R33E0TA%=O7SV.>$>-Q
MCR]58X!XK$/!1KM.LL)[:?U95FDDZJH\BJ-))SNTD>C0]M["C]8<'B/94_;N
MFK0=;DC[5P6MH<_-RJ[TL%%%%<IJ%%%% !1110 4444 %>@Z/_R3[Q=_U^Z1
M_P"EME7GU>@Z/_R3[Q=_U^Z1_P"EME7U?"'^_9M_V2G%O_K/9@>7FW\#"_\
M8TRK_P!6&'//J***^4/4"BBB@ HHHH **** "BBB@#Y?^-/[1%UX"^)GPL^
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MJC^R=2_Y])?_ !W_ .*KY?&9;QUC\-AL'BLEX@J8;"QH1HT8Y'BJ,7]6PE#
MX>=9T<%3EB:M#!4*&%HUL2ZM:G0@J<)J,I)^K1QG#V'JU:]+,,LC5JN;G-YC
M0F[5*LZ]2,.>O)4H5*U2=6<*2A"527-*+:36=16C_9.I?\^DO_CO_P 51_9.
MI?\ /I+_ ..__%5Y?^JO%'_1-Y__ .&?,?\ YG\U]YU?VSD__0URW_PNPO\
M\M,ZBM'^R=2_Y])?_'?_ (JC^R=2_P"?27_QW_XJC_57BC_HF\__ /#/F/\
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M787_ .6F=16C_9.I?\^DO_CO_P 51_9.I?\ /I+_ ..__%4?ZJ\4?]$WG_\
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M])?_ !W_ .*H_LG4O^?27_QW_P"*H_U5XH_Z)O/_ /PSYC_\S^:^\/[9R?\
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ME35-RM:K352%FG>+E*&MF[/FA)-/56U0DT[^3L_6R?ZA11168PHHHH ****
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M %%%% !1110 4444 %%%% !72P_\BI=?]A=?_1%O7-5TL/\ R*EU_P!A=?\
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MP?"_Q''XW^.7[4'Q"TK5/#7CK]I'6?"ATCP+K'EKJ'PX^#OPVTBZ\/\ PO\
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M *&&9??A?_F?U_I:^C?VQIO_ #]Q_D__ ,11_;&F_P#/W'^3_P#Q%><T4?\
M$PO$_P#T)<A_\!S#_P";@_XAAE'_ $,,R^_"_P#S/Z_TM?1O[8TW_G[C_)__
M (BC^V--_P"?N/\ )_\ XBO.:*/^)A>)_P#H2Y#_ . YA_\ -P?\0PRC_H89
ME]^%_P#F?U_I:^C?VQIO_/W'^3__ !%']L:;_P _<?Y/_P#$5YS11_Q,+Q/_
M -"7(?\ P',/_FX/^(891_T,,R^_"_\ S/Z_TM?1O[8TW_G[C_)__B*/[8TW
M_G[C_)__ (BO.:*/^)A>)_\ H2Y#_P" YA_\W!_Q##*/^AAF7WX7_P"9_7^E
MKZ-_;&F_\_<?Y/\ _$4?VQIO_/W'^3__ !%><T4?\3"\3_\ 0ER'_P !S#_Y
MN#_B&&4?]##,OOPO_P S^O\ 2U]&_MC3?^?N/\G_ /B*/[8TW_G[C_)__B*\
MYHH_XF%XG_Z$N0_^ YA_\W!_Q##*/^AAF7WX7_YG]?Z6OHW]L:;_ ,_<?Y/_
M /$4?VQIO_/W'^3_ /Q%><T4?\3"\3_]"7(?_ <P_P#FX/\ B&&4?]##,OOP
MO_S/Z_TM?1O[8TW_ )^X_P G_P#B*/[8TW_G[C_)_P#XBO.:*/\ B87B?_H2
MY#_X#F'_ ,W!_P 0PRC_ *&&9??A?_F?U_I:^C?VQIO_ #]Q_D__ ,11_;&F
M_P#/W'^3_P#Q%><T4?\ $PO$_P#T)<A_\!S#_P";@_XAAE'_ $,,R^_"_P#S
M/Z_TM?1O[8TW_G[C_)__ (BC^V--_P"?N/\ )_\ XBO.:*/^)A>)_P#H2Y#_
M . YA_\ -P?\0PRC_H89E]^%_P#F?U_I:^C?VQIO_/W'^3__ !%']L:;_P _
M<?Y/_P#$5YS11_Q,+Q/_ -"7(?\ P',/_FX/^(891_T,,R^_"_\ S/Z_TM?1
MO[8TW_G[C_)__B*/[8TW_G[C_)__ (BO.:*/^)A>)_\ H2Y#_P" YA_\W!_Q
M##*/^AAF7WX7_P"9_7^EKZ-_;&F_\_<?Y/\ _$4?VQIO_/W'^3__ !%><T4?
M\3"\3_\ 0ER'_P !S#_YN#_B&&4?]##,OOPO_P S^O\ 2U]&_MC3?^?N/\G_
M /B*/[8TW_G[C_)__B*\YHH_XF%XG_Z$N0_^ YA_\W!_Q##*/^AAF7WX7_YG
M]?Z6OHW]L:;_ ,_<?Y/_ /$4?VQIO_/W'^3_ /Q%><T4?\3"\3_]"7(?_ <P
M_P#FX/\ B&&4?]##,OOPO_S/Z_TM?1O[8TW_ )^X_P G_P#B*/[8TW_G[C_)
M_P#XBO.:*/\ B87B?_H2Y#_X#F'_ ,W!_P 0PRC_ *&&9??A?_F?U_I:^C?V
MQIO_ #]Q_D__ ,11_;&F_P#/W'^3_P#Q%><T4?\ $PO$_P#T)<A_\!S#_P";
M@_XAAE'_ $,,R^_"_P#S/Z_TM?1O[8TW_G[C_)__ (BNK@U"S/@V\N1<(8%U
MI8VDPV _V>U.W[N<X93TQS7AU>@VO_)--2_[&>/_ -)+"O7RCQQXAS668QK9
M3DU-8#*,PS2E[*..3G6P%+VU*G/GQ<OW4Y:5%'EG;X91>IS8CP]RS!*BZ>-Q
M\_K.(HX.?.\/[M/$R4)SC:@O?CO&]X]TR7^V--_Y^X_R?_XBC^V--_Y^X_R?
M_P"(KSFBO(_XF%XG_P"A+D/_ (#F'_S<=/\ Q##*/^AAF7WX7_YG]?Z6OHW]
ML:;_ ,_<?Y/_ /$4?VQIO_/W'^3_ /Q%><T4?\3"\3_]"7(?_ <P_P#FX/\
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MP?\ $,,H_P"AAF7WX7_YG]?Z6OHW]L:;_P _<?Y/_P#$4?VQIO\ S]Q_D_\
M\17G-%'_ !,+Q/\ ]"7(?_ <P_\ FX/^(891_P!##,OOPO\ \S^O]+7T;^V-
M-_Y^X_R?_P"(H_MC3?\ G[C_ "?_ .(KSFBC_B87B?\ Z$N0_P#@.8?_ #<'
M_$,,H_Z&&9??A?\ YG]?Z6OHW]L:;_S]Q_D__P 11_;&F_\ /W'^3_\ Q%><
MT4?\3"\3_P#0ER'_ ,!S#_YN#_B&&4?]##,OOPO_ ,S^O]+7T;^V--_Y^X_R
M?_XBOX(?^#OZ[M[K]I#]CXV\HE"?!#QR&*A@ 6\>18&64 G@Y R1QG&1G^YB
MOX2?^#N#_DXO]D;_ +(KXW_]3F*OI^#_ !@SSB[/L-D6.RS*<-A\53Q-2=;"
MQQBKQ>&P]3$04?;8JK3M*5-1E>#?*W:SLS@S+@?+\DP=3,</B\;5JTI4X*%9
MT/9M59QIR;Y*,)72DVK2WM>_7]IO^#8__E%EX4_[+5\8O_3OIU?T(5_/?_P;
M'_\ *++PI_V6KXQ?^G?3J_H0K\#XW_Y+#B7_ +'./_\ 4B9^BY)_R*,M_P"P
M.A_Z;05B^)/$6C>$/#NO^+/$=]%I?A[POHNJ^(M>U.997AT[1M%L9]2U2^E2
M%)9GBM+&VGN)%BCDE98R(T=B%.U6#XJN- M/"_B2Z\5K _A>VT'6+CQ(MS;3
M7MLV@0Z?<2:PMQ9V\4\]W VG+<B6V@@FFGC+11Q2.ZHWS=&,9UJ49PJU(2JT
MXSIT;>VG%S2E"E>,U[62;C3O"2YVKQDM'Z4VU";BXQDHR:E._)%I-ISLXOE3
MUE9IVOJMSX%L/VM?VD?%7P7/[3GPZ_9G\(>-?@[J>B7/BOPWX,7XSS:7\=[[
MP58W-TL_B:YT"W^'VM_#]]5ETVVEUE? 6G>.[S6H;6$:;!J6I>);H:#:]!\:
M/VI?BI\.[G]C6[T+P3\/[GPE^TI\3/@_X \3ZUJWB'Q'<>(O#UY\0K2?5]7L
M]!\)6>BV&F26UKHUK*=.\4:AXWN)8=3DCMKGP3>VL;7LGQ+XF^%O[4?_  3<
M\.ZO\4OV4_%4'[1G[&=JM[XS\1_L^^.KF2ZUWX<^#;[RM<U?6_AYXOA:ZN[G
M0+>R&HWDM]91RP:;;:DVN>(/ WC2>WU?Q3#V'[9OQH\/>-/@W_P3?^.OPO\
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M9)3I25:#:M%_JC1117YJ?3!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Z#:_P#)--2_[&>/_P!)+"O/J]!M?^2::E_V,\?_ *26
M%?5<*?Q,_P#^R5S[_P!1#R\U^' ?]C3 ?^G3SZBBBOE3U HHHH **** "BBB
M@ HHHH *^</C_P#&;Q]\.9/"?A#X.?".X^-GQ;\<1Z[J>C>$'\5Z5X$T#2?"
M7A2;0;7Q5XQ\3^+]:AN+*PT_2;[Q5X9T^UTJVM[G6==OM8CBTVV:*SU"XM?H
M^L#Q5XH\/^"/#6O^,?%>J6^B>&?"^CZAKVO:O=^8;?3M)TJUEO;^[E2&.6>4
M0V\,CB&WBFN)F"Q6\,LSI&W=EE2E1QV'G6RZ&;14I1AEU2>*IT\76G"4,/3J
M/!5*.+G3]O*G*='#5J%:O&+HPKT95%4CABHSG0J1AB981V3>)C&E*5*$9*52
M457C.BI.FI1C.I"<*;:G*$U'E?QW^R=^UWXA^./BGXL_![XP?":\^!WQ[^![
M:!+XX\'3^(-/\2Z#J6C>);>XN=)\1^%]=L_*^U:?)#!!/=HT=Q9P6NK:+/9:
MUJRWLXLO /B5_P %"_CC\,]#L_CSJ_['NNS_ +'EU?::T/Q3MOB/X;E^(EYX
M,\1W.GV_A7XCGX9"!;S0M'U_[=!)IVB>(+VROG6_TU-8U'P]/<Q03_4W[-7P
MT\0IXS^-?[2OC[2]2\.^-OVA]7\+G2?!.K>6M_\ #WX1_#O2KG0OAKX>U:VC
MN;^/3_%^MVMYJ?C;QW86M[):Z;K_ (C_ .$? DE\/O=W6+^UAH<_[0UO;_L@
M^'I;V.V\;R>%?$OQ[\36#-;IX"^"=EXB?5&TZ*_$\0_X3+XMZMX5N/!'A?3(
MX+[R= 7QKXGU*&&UT*R@U;]#PT^$8\7U*,^',OQ&1U*>3RSF+S+-W@LAI4\O
MP[XLJY17P^80KUIT,PGB:>3U<9B\SI5)TJ.'H4<PGC,-)?.5%G#R:-2.8XFG
MCHRQBP5L-@U7Q\IXB:RB.-IU,/*$%/#JG+&PHTL+*,9SJ5)X=4*J?V3IFI6.
MLZ;I^KZ7=17VF:K96FI:=>P-N@O+&^@CNK2ZA8@%HKBWECEC8@91P<#-?'.H
M_M1>-O%GQ*^-'@#X!?"[0/B3;_L[0:1%\3M<\2_$"\\%KK'B[5-)U36F^&WP
MU@L?!7BRQUKQ/IUC901:QJ7B/5_"^CZ1K=W;:)=!DFN-6T_[.AAAMH8K>WBC
M@@@BCA@AB18XH88D"111HH"I'&BJB(H"JH    K\O_\ @FW#%I6N_P#!0*#7
M3':^+X/V\?C9J'B!KE8K68^'KZ+1;[PSJ;),D%Y'H]^KZW?:1<SQ1:?/9.T^
MG_(;@CYO(<#E\\KXHSC$X2./EE&'RM8'!8BKB(4G/,,VH8:IB,2\'6PU:<:.
M%C5H14*M.'UC%4:C3Y(PEZ685\2L5E6"I5GAUC)XIUZ].%-S2PV$G4C3I*O"
MK"+G5<:CYH2?LZ4XIKF<E]V_ WXT>!_VAOA1X*^,GPYN[JZ\(>.=*;4=-74(
M([75+"XMKNYTW5M&U>V@GNX+?5]#U>ROM(U.*VN[RT%[93&SO+RT:&ZE]8K\
MGO\ @B[;:['^P]H-]J:-!HNM?$OXF:GX)M"S.EEX7_MY=/EM(G9R&CC\56'B
M<[ECA4N[DQ;MTDGZPUS<8Y1AN'^*^(\DP=257"95G.88'#3J2C.JJ.'Q-2G3
MIUIQ48RKTHQ5*O*,5%UH3<4E9&N2XRKF&49;CJT5"MB\%AJ]513C'VE2E&4I
M03U4)MN<$VVH2BFV]0HHHKYL],**** "BBB@ HHHH *]!T?_ ))]XN_Z_=(_
M]+;*O/J]!T?_ ))]XN_Z_=(_]+;*OJ^$/]^S;_LE.+?_ %GLP/+S;^!A?^QI
ME7_JPPYY]1117RAZ@4444 %%%% !1110 4444 ?%FH_M1>-O%GQ*^-'@#X!?
M"[0/B3;_ +.T&D1?$[7/$OQ O/!:ZQXNU32=4UIOAM\-8+'P5XLL=:\3Z=8V
M4$6L:EXCU?POH^D:W=VVB709)KC5M/\ >_@;\:/ _P"T-\*/!7QD^'-W=77A
M#QSI3:CIJZA!':ZI87%M=W.FZMHVKVT$]W!;ZOH>KV5]I&IQ6UW>6@O;*8V=
MY>6C0W4OPE_P3;ABTK7?^"@4&NF.U\7P?MX_&S4/$#7*Q6LQ\/7T6BWWAG4V
M29(+R/1[]7UN^TBYGBBT^>R=I]/^0W!&'_P1=MM=C_8>T&^U-&@T76OB7\3-
M3\$VA9G2R\+_ -O+I\MI$[.0T<?BJP\3G<L<*EW<F+=NDD_4.)>&LGP65<0U
M,'16'K<-9AP5@*6*=:O.6;KB#(<SQN85*T*M6I2]H\7ET<7@?JM/#TZ6"J5Z
M=55FJ,X_*Y9F>,KXO+E6J.I3S3#9WB)TN2G&.#>7X_"T</&FX0C/E5'$NC7]
MK.I*5>,)Q</?B_UAHHHK\O/J@HHHH **** "BBB@ K^$G_@[@_Y.+_9&_P"R
M*^-__4YBK^[:OX2?^#N#_DXO]D;_ +(KXW_]3F*OTKPD_P"2YRS_ +!\R_\
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M6_PH\Q?4_P#?+?X4?ZB\;?\ 1'<5?^(]F_\ \Q^:^\/]:>&/^BCR'_P[Y?\
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M7WCZ*9YB^I_[Y;_"CS%]3_WRW^%'^HO&W_1'<5?^(]F__P Q^:^\/]:>&/\
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M?B/X^/B[X@?\$>YM>^*^IW?CK4OA_P#&_3]!^$OQ"U;4;^ZU_7/ ^D?'/1O
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M"BBBH("BBB@ HHHH *_A._X.W/\ DXG]D;_LBWC?_P!3F&O[L:_A._X.W/\
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M\H_^"5_\E_5WY6/]4\G_ ),1_P"#Y?Y?U=^5OX[/^(FW]CK_ *-3_P""AO\
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M+^KORL?ZIY/_ "8C_P 'R_R_J[\K?QV?\1-O['7_ $:G_P %#?\ PQGPM_\
MG^4?\1-O['7_ $:G_P %#?\ PQGPM_\ G^5_8G11_;N8_P#/RC_X)7_R7]7?
ME8_U3R?^3$?^#Y?Y?U=^5OX[/^(FW]CK_HU/_@H;_P"&,^%O_P _RC_B)M_8
MZ_Z-3_X*&_\ AC/A;_\ /\K^Q.BC^W<Q_P"?E'_P2O\ Y+^KORL?ZIY/_)B/
M_!\O\OZN_*W\=G_$3;^QU_T:G_P4-_\ #&?"W_Y_E'_$3;^QU_T:G_P4-_\
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M4^^/_P D']OY/_T'T/\ R?\ ^0\_S[,]6HKRG_A;FA?] [5O^^+/_P"2Z/\
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M6?\ \ET?\+<T+_H':M_WQ9__ "71_968?] M3[X__)!_;^3_ /0?0_\ )_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]E3X7:#X?\9_;=%USXK>#KO3?%5T_@VYT^>1M5U;0M=5/!NF_9M)_3/]I?\
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M?\BAIW_76_\ _2ZXKNZX3X;?\BAIW_76_P#_ $NN*[NOSK'_ ._8S_L)K_\
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MZ#</_P""ZG]=_P"GI\A45]>_\(SX<_Z%_1/_  56'_R/1_PC/AS_ *%_1/\
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M?_%U\<44?\1ZK_\ 1,4O_#O/_P"=H?ZC0_Z&4_\ PD7_ ,T>O]+7['^VV?\
MS]VW_?\ B_\ BZ/MMG_S]VW_ '_B_P#BZ^.**/\ B/5?_HF*7_AWG_\ .T/]
M1H?]#*?_ (2+_P":/7^EK]C_ &VS_P"?NV_[_P 7_P 71]ML_P#G[MO^_P#%
M_P#%U\<44?\ $>J__1,4O_#O/_YVA_J-#_H93_\ "1?_ #1Z_P!+7['^VV?_
M #]VW_?^+_XNC[;9_P#/W;?]_P"+_P"+KXXHH_XCU7_Z)BE_X=Y__.T/]1H?
M]#*?_A(O_FCU_I:_8_VVS_Y^[;_O_%_\71]ML_\ G[MO^_\ %_\ %U\<44?\
M1ZK_ /1,4O\ P[S_ /G:'^HT/^AE/_PD7_S1Z_TM?L?[;9_\_=M_W_B_^+H^
MVV?_ #]VW_?^+_XNOCBBC_B/5?\ Z)BE_P"'>?\ \[0_U&A_T,I_^$B_^:/7
M^EK]C_;;/_G[MO\ O_%_\71]ML_^?NV_[_Q?_%U\<44?\1ZK_P#1,4O_  [S
M_P#G:'^HT/\ H93_ /"1?_-'K_2U^Q_MMG_S]VW_ '_B_P#BZ/MMG_S]VW_?
M^+_XNOCBBC_B/5?_ *)BE_X=Y_\ SM#_ %&A_P!#*?\ X2+_ .:/7^EK]C_;
M;/\ Y^[;_O\ Q?\ Q='VVS_Y^[;_ +_Q?_%U\<44?\1ZK_\ 1,4O_#O/_P"=
MH?ZC0_Z&4_\ PD7_ ,T>O]+7['^VV?\ S]VW_?\ B_\ BZ/MMG_S]VW_ '_B
M_P#BZ^.**/\ B/5?_HF*7_AWG_\ .T/]1H?]#*?_ (2+_P":/7^EK]C_ &VS
M_P"?NV_[_P 7_P 71]ML_P#G[MO^_P#%_P#%U\<44?\ $>J__1,4O_#O/_YV
MA_J-#_H93_\ "1?_ #1Z_P!+7['^VV?_ #]VW_?^+_XNC[;9_P#/W;?]_P"+
M_P"+KXXHH_XCU7_Z)BE_X=Y__.T/]1H?]#*?_A(O_FCU_I:_8_VVS_Y^[;_O
M_%_\71]ML_\ G[MO^_\ %_\ %U\<44?\1ZK_ /1,4O\ P[S_ /G:'^HT/^AE
M/_PD7_S1Z_TM?LR.6*4%HI(Y5!P3&ZN <9P2I(!P0<=<&I*\H^$O_()U3_L(
MK_Z315ZO7[APSG+XAR++<YEAUA'CZ,JKPZJNLJ7+5J4N5573I.=_9\U_9QWM
M;2[^*S+!K+\=B,&JGM50FH^T<>3FO",[\O-.UN:WQ/:_D%%%%>Z<(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!\D^)/\ D8M?_P"PUJO_ *73UBUM>)/^1BU__L-:K_Z7
M3UBU_ &<?\C;-/\ L8XW_P!2:I^\83_=,+_V#T?_ $W$\J^(_P <_@U\'[K0
M[+XJ?%'P)\/+SQ,M\_AVU\8^)])T"XUQ=,:U74&TJ'4KJWDOA9-?6:W1MUD\
MDW4 DV^:F?+#^W+^QLOF;OVHO@0OE.(Y<_$[PD/+<E@$DSJGR.2C@*V"2K#'
MRG'LVJ?##PAK/Q+\*_%G5--2^\8>"O"OBGPCX8NKE(9H-'T_QEJ/AO4=>N[.
M*6)V@U6Z;PKIEFFH0R1SPZ<^H62$0:C=K)_/#_P1^T31?$G[5?[<V@^(M(TO
M7M#U:TUFQU71M:L+35-*U*RN?B9K,5Q9ZAIU]%/9WEK/&S1S6]S#)#*C,CHR
MDBON^&>%N',YX8XGSW$U<Z6(X4R[+,;CJ&'KX*C2Q=7,LWKX%4,,ZN"Q$Z4<
M/A(T*[JU)5'6Q$JM%4Z-.,:LOG\TS7,L%FF5X"E#!.GFV)Q5##SJ0KRG1AAL
M)2K^TJ\E:"FZE:52GR1C'V=.,)\U23<%_1KH?COP5XE\'VOQ!\/^+/#NL>!;
M[2I=<M/&.GZQ87/AFXT6W262?5H];CG.G'3H(X)GFO?M MXDBD>2151B/&=#
M_;&_9.\2ZW-X<T+]I/X'ZGK<-S'9K86_Q.\'F2\NIG,<=OI<CZLD&L3%QL*:
M5+>,C,BN%+H&_"#_ (*/OJ7ACXH?L@?\$Q_AQX@UGPQ\$-3_ .%>MK8&IBWO
MM;?XC?%?6_"FA:1K]XMM;0W>A^![&SDU#38)3)87=]J,-_K-O=ZCH&F75K_0
MN?@1\&W^%,7P.E^&OA"X^$L.B6_AZ/P)<Z-:W&@C3;6W2VM]UO,CR-J$2QQS
MIK+2G6%OT74A?#4 +JISGA+(>'<HR'-\QQ>;8N'%=7,,9D^&P:PF'K8'A_"8
MQ8;"YCF+KTZ\,5C\=3E[:GEN'EA*5.,7[;,(3E[.-8+-\PS+&8_"8>CA*+RF
M.&HXRI6]M4A7S&K1]K6P^&5.4)4L/0DN26)J*M*3:<,/**YGQ6N_M@_LL>&/
M[*'B7]H3X0^'CKNC:;XBT9=<\=^'])?5-!UBUBOM*UBP2_O;=[K3M0M)HKBT
MNX5>">*171R"*ZOP5^T1\ OB/K-OX;\ _&OX4^,O$MW!-=6WAKPWX_\ "VK^
M))[6WCGFGN8_#]EJDVL-;Q0VUQ.\XLO*$$,L^_RD9Q^!?_!9CX6:?\&_V2OV
M+_AA:WPUU?AC?7G@/3_$%Q81V5[>Z?HW@?2M/:8PB>\:S%^-+LI[JUCO)HWF
MMX&=Y##$5R_^"AOC/P_^V?\ &/\ 9D^"W[(%GJGBC]I/X97WB6W\:>);3P[X
MJ^'VM_#9-%_X1;[)9ZSX@\3:/X<N(K#P]K$.JZS/?0RW4'AZ]@\G3)3JNNRV
MES]=E/A7D>>9;PYF.#S#.</E^>RXR^N9[B*>&GE/#^$X7DXX3-,T4L-A?98/
M,VZ:E"OC,)4PU2:H4Y8JK9/Q\7Q9CL#B<RPU?#X*IB, LE]C@*<JBQF8U<T2
M=;"X2U6KSUL+[S3IT:T:L5SR5&-V?TUT55L8[N&RLX;^Z2]OHK6WCO;R.W%I
M'=W<<*+<74=JLDJVR3S!Y5MQ+((5<1B1PNX_FW!^V1^TQXK^-7QW^#?PO_9/
MT'QEJ/P*\5_##1/$.HW/QPTCP_8+H?C^QNM;_MMKO6?"]C]JU1=#^SW3>'-,
MM+R/2ET[6)'UW6;JXT+2M2_(<IR#,,[^OO ?4O9Y9AZ>*QM?&YEE^5X>AAJV
M,PV IUI5\SQ.#I\DL7B\-1^*\95J:DDYQ3^QQF88; _5UB/;\V*J2HT*=#"X
MC%5)U84:F(E!0PM*M*ZHT:L]K-0DTVDVOTNHK\S?B=_P4 N]#'QOUKX::+\&
MM>\/?L^>)/%OA7Q/H/Q$^-/_  @'Q2^(^O\ P]L9I/'&E_"[P1;^#_$1N+?3
MM2/]BZ!K&K7XF\6Z]H^M:/I>@1V[Z9K=UZ?IW[85Q\4KOX2^"_@!X/TS7_B=
M\5O@A8_M"7-A\2=?O_"/A7X;?#:\U*S\.&7Q7JF@:#XLU35O%Y\7W<WAW3O"
M.B:6L-]+HGB&\U'Q)H-G8V<VI>E4X(XFHT*.*K9<J.'J\[G6JXK!TX814\)#
M'S>/<ZZ>"MA)PJKZRJ?-)O#PYL5"="/+'/<KG4G2AB>>K#EY80I5I2K.59T(
MK#I4_P!^W63A^ZYK*U5VHN-1_<=%?!FH?MI>(/!_PHU'Q3\4/@'XO\"?%6?]
MH1?V8?AW\+[W4;T:1\6_B9J]W%:>#-9\#^/M6\*:&)_A=XJC>[U)/'EQX6$-
MM8:+KB:;INOZC:V%CJNO;?M/^/OAY\>OAY\"_P!H[P%X/\)2?'&'6_\ A2_C
MWX;>,-6\7>%-5\0>&K:*^U_P+XMB\2>&/"&L:#KUO:WNF#0M4@L;S2O$\UY'
M%#%I=V9K"UQ_U/S_ ):\OJE&3HPS"I&G3Q^7U:N+I950ABLRK9=3I8J<LQHX
M+#3^L5JV"]O3]E"O.$IK#8GV5_VSE]Z:]K-*;P\7*6'Q$(49XNHZ6&AB93I1
M6&G7JKV<(5_9RYY4U)1]K2Y_MRBO@/Q-^U]X[U?Q#^T[8? _X:^#_'&D_LDP
MVP\?S>+?'FM>%]6\=:[%X4U?Q3X@\(^ M.T3P/XLETZ]T*'3ETV#7/$,9T_7
M?$27&BV5C!IZR>)K;S:X_;^^*$'PZ_9-^)#_ +/'AR?1_P!JOXF>"?!.A1>&
M/C3#XHO="LO&5K9ZEI\,T&M> /A];7/BV:"W\2Z1>:=<ZAIOA[P]JVDV\UWX
MEU.VNG@@ZJ' G$V(C1E3P>%BZSP\?9ULVRG#UJ<\5E4L\P\*U#$8ZE7I3K93
M"6-C"5/FY$Z+2Q,94(Y3S_*Z;FI5JK4/:/FAA,74IR5+%K U)0J4Z$J<HPQ<
ME0<E*UVIJ]-J;_46O._A=\6?AS\:O"4/COX6>+-,\:>$;C4]9T>'7-)^TBU?
M4M U*XTG5;8)=P6UP#;WMK*(I6A$%[:M;ZA8R7.GW=I=3?+WPC_:E^*7BOXZ
M_&;]G/XG_!?0? 7Q/\ ^!-"^)_@2WT#XC7/BWPIX^\%ZU=MH\ER?%%YX*\-W
M.EOINOR66F7%R_AQWFFEU-(],7^QTDU6O\ _VE_&'QC_ &4-"^./PY^"VAV/
MBCQ/\2KCPOIOPQLM?NUT/3;?4/CROP[\0>*=8\1Z5X3>[:TT+2+O5_B+XKU*
MT\)^9/%IVJ3-;1^8]PF=?A+-,'AJSQ6$IJK]=X<P]#&4\XRF>71AQ%@L?C<"
MZDZ=6K&O3QE'#<]/'4L72P>!^JXRCC6ZTH1H7#-\+6JP5*M)P]AF52I1E@L8
ML2Y9=6P]&NHJ4(.G*A.KRRP\Z,JV(]K1G02A%NI]VT5\'Z5^U1\3M8_:MLOV
M7]%^''@+Q5<^'/#4?C+XW^-_#?CW77T3X/Z)?+&WA[2M234O!-F-7\:^)TDA
MFTOPO!/:W"Z?=VVL3S?V7!J]SI7@GBW_ (*=+I/PZD^/_A3PI\*O%WP9A\1#
M3(/!T/QGCM/VEM<\,3>+;7PA#X[T[X4CPE<Z?8P&X%WKUGX4O?$<NK7WA*ZT
MW7M4U#PNT6I:?;[8?@'BG%UL-0PV7TJM3%T,NKX=1Q^ 2E'.'B5E-.;EB8JA
M7S..$KU<%1KNE4KX:,<7&/U6I3K3SJ<0951A5J5<1.$:-3$4ZC>'Q%T\&J3Q
M<DE2;G##.M3A7G#FC"JW1;]M&5-?K717P/XB_:[\9:]\6?C%\*_@/X0^''CS
MQ)\&/AOX2\>2^#_&7C_6O!7C+XL'QQX83QCI2?"Z&S\'>(]/N=)TS1I;"QO=
M6O&N(9_%>M:;H.K?\(C8R6_B&^^T/#FKZSJW@O0=>U#1)-/\0ZGX7TO5[WPY
M<&:PELM9O-)@O+G1)S>Q"XLI+:^D>QD-W")K=D;SX@Z.E>)F&19EE='"5L=2
MI8?Z[2PU:C1EB<.\2J.,PM'&X6K6PRJ.M0HXC"8BC6I5JL(TIJ<J:G[:C7IT
MN[#X_#8N=6&'G.I[&=6$YJE45)SHU94*L(57!4YSIU83A.$).2<5)KDG3E/J
M**_*"W_;_P#C_K7PE_: ^+GA?]E+P_JNC?LW?$CXC^$?B%;W?QP@T^&ZT?X6
MV^GOXKN?!EY_P@%QJ/B+4]-@&K^(-8DUCP_X0TS3]";1[7P_+XUUXZQI^E]'
MJ7[>WQ,T:]_9F^(6N?L]P>'_ -FW]J#QYX"^'?@SQ;J7Q#T^Z^*>FZA\3](M
M]4\$^)O$/@31]+U#P_IOA[5XDU._M+.R\9ZSK3^'K,:AJ\'AS7)(?"UQ]!+P
M[XJC*4'A<O\ :0JXC#NE'/LAJ5GB\+@H9C4P<:5/,IU)XJ6#FJU"A"+GB8QF
MJ"J.$DO/7$>4M)JKB>64*=13>7X^,/95:[P\:SG+#**HJLN2I4;4:;<?:./,
MK_IY7DWQ)^.WP?\ A!J'A#1OB3\0O#?A/7/'^O:5X9\$^'K^\,WB/Q3K.M:O
MI^@V5OHGAZQCN]:U"W75=5TZVU#4H+%],T=;J.YU>\L;3=.OS7\4_P!L*XT7
MXJ?$/X/_  V'P6B\2_"32O"E_P".-1^.OQ>'PGTR_P!8\7Z7'XGT;P;X%MH?
M#7B*[\1:G)X6,%WKFO7<FDZ)X8N=?\.IMU^=]4L;#X[_ &@OVB-)_:G_ &7O
MV&OC1I7AS4/!S^(OV]/V?K+6/".JW27M_P"&]<T/Q1XNTG4=/EO4MK(7MO*U
MK'J.F7C65E+=Z3?V%S/8V4\LMI#T9#P)F6,Q64U<VPF(P^3YE6PM&6(PV)PD
M<52_M/+<5F655)49K$U*5/&X;"SKT9U,-R5*,;.=.56BYYX_/\-1IXNG@ZU.
MIC<-&I-4ZE*LZ4OJV*HX7%Q4TZ<92H5*T:<U&K>,W>TE":7[8T5\%_'#]IWX
MV^!_$7QYC\!_!O08_ G[-WP[T?Q]XI\=?%[6O%'@O1/BM<ZOHUUXFE\)?!W5
M=*\+:SHU]=Z+H^F7FF:IK&I7TXC\:WFF^&Y]$L;4MK<W*^+_ -O/7=.^'G[&
M7Q)\&_!H^*= _:T\5_#KPE*H\<:9:ZKX*U_QI$M[=>'+'3[S3["S\2W\$5CK
MVFVVK7^M>%-'M[^RM[K43'!*]JOF8?@GB'%4L%6P^&PM2GCY1C1?]IY;%4YU
M,J>=TJ>)<\7%8>K5RI/&4Z55QJ2BG0Y5BHRH+IJ9YEU*=>%2K5A+#IN:>%Q+
MYHQQ:P,I4N6DW4A#%M492BG%-JI=TFJC_1ZBOBGX'?M/_$'QI^T/\6/V:_C-
M\)=(^%WCSP/X-\.?$SPG<^%_'%UX_P##GC'P!KE\=&N]1AU>\\)^#KF"YTC6
MY+33G$FD0&\N9-1@6UMETA;G4O-V_;2^*7B[X0>)_P!J+X._!KPOXT_9N\'Z
MEXON3>:KX_U70_BQX_\ A[\/=0N]+\<?$+P7X2?P7+X;TZ'3;K1/$LOA[PSX
MA\6)K7BC3M*6XN3X9U2YAT.2/]3,_P#K+PKP^%B^7*91Q,LSRQ8"K+/L//$Y
M/2H9C];^HUZV/I4J[HTJ6(G-?5L5[14UA,2Z5?VUE_LE552JU?%ITUA<4\1!
M8"I&GC)U,-['V].&'E."J3G3BOWE+E<G5IJ?Z/45\21?MA6GQ1U?X8^"/V9]
M%T3QYXX^*7P;C^/]O=^/M;U+P7X-\%?"J;6;?PO#J?B:]T70?%NLWWBZ[\5W
M,FA:?X(TK3%\VXT;Q'-J_B30+?3;:74O*?BK^VQ^T!\,_P!G_P =?'#4?V3+
MK3+CX0?$_P 1?#[XG^$_$OC;Q!I7VK0-*U'0=,TKXM_"C6)/AG%)\0_AIJTV
MM&676I-'\/\ V6WM;RZM1J5CIVH7L%8;@GB/$XC"X2.#P]#&8O%4<'1P>-S+
M+<!C/;XG$5L)AHU,+C<70KT8XC%4*N'HSJTX0E55-<R6(P[JJIGF6TJ=6LZU
M2I1HTIUIUZ&&Q.(H^SI4X5:KC5H4:D)NE2J0J3C&3<8<SM>G44/TQHKYE\5_
M'#Q-8_$7]G/X>>!M \'>.)_C1H_B?Q=XDUNW\5:I;:5X4^'W@_2?#=_JGCG1
MI[#PWK,6OZ1J.I>*-#\/>'TO)]%.I:KX@T-EG6Q.K7>F?$OP/^/GQZTO]I?]
MOGQ+\<8OAC'X ^!6D_#67QJ?#/BCQA=+\/?AUX>^'GQ%^)&E6G@+3+GP'%+X
M^U2>+6+ZZ\7:GKMQX*GN=6DN7T73FTY=+T6Q,!P?FN/P./QT)86G]3RNEFE'
M"SQ-'ZWCJ57B"CPXJ=##JI[2-5YA.I"$*L83JRITZ=*$Y8K#\YB,YPF'KX>@
MU5G[;%2PDZL:53V-"<<OGF3E4J<O(X_5XQDW%N,%*4IRBJ53E_72BORQ_P"'
MC&H:3J'P.\0^(_"7PBN_AM\=O&7@_P &VFF^ OC?!XQ^,?PH7QQ'>7N@^)/B
MIX)@\)6FD6=A;6?V*W\9V.D>(+J+P7JJ75DFN>)I;C3XI?0H_P!K[XH^-M;^
M.\7P3^&W@#Q_;_ ?XMCX0^)O -YXY\0Z7\9R=,UC3](\2_$BU\(6G@S4["_\
M+127UW>>&-)BU2V/BG1_#NN7MEXHCUV(>$8MJO 7$]"TJ^!H4*+AS/$U<PR^
M&$@_KU/+73JXIXGV%&I'&U(47&M."]Z%6+=&I3J3SAQ!E=32G7J3GS6]E##8
MB59KV$L2I1I*E[2<70BYWA&6SBTIQE%?H91117QQ[1[S\)?^03JG_817_P!)
MHJ]7KRCX2_\ ()U3_L(K_P"DT5>KU_;'AM_R0_#O_8'4_P#4K$'XUQ'_ ,CO
M,/\ K[#_ -,TPHHHK[@\0**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2?$G_(Q:__ -AK
M5?\ TNGK%K:\2?\ (Q:__P!AK5?_ $NGK%K^ ,X_Y&V:?]C'&_\ J35/WC"?
M[IA?^P>C_P"FXE'4KNXL+"ZO+73+[6KBWB,D6EZ;)IL5_>L"!Y-K)K&HZ3IB
M2D$L#>ZC:0X4YE#;0?PU_P""9W[+7[3'[//[2/[0?CWXN_!/7O"OA+XNI>MX
M>U=/&OP?UX::UQXUO-?C37K#PY\2=7U2W;[!>+N.F6.K()HIHPY'E/+^[%%>
MODO%F.R/)>)<BPV$R^OA>*<-@L+F%;%0Q<L51I8#$/%8?ZG*AC,/1IR59\TW
M6H8A224;*-T^+&Y10Q^.RS'U:V(A5RJI6JX:%*5%4IRKTU2J>V4Z-2<ER*R4
M*E.V][GY(_\ !3+]@WQ[^T???#;X]_L_:A8:;^T-\&7LUTBSU&^MM*C\5Z)H
M^L3>*= L]/U:]4Z?I_B/PUXGDN;_ $'^UI[#1;I-:U5-3U&T,5G)7TCH/[2_
M[0>N^&K73U_8@^,>D?%DV]C:ZKIGB+Q?\(]'^$>E:Q=1Q&6_;XG1^.]1U?5?
M"MJ7EGGN?#?@+7?$B);R6@\-O>R6J77V[171+C'$XK),GR+-\KRW.<+P]/%O
M)JV,EF-'%83#XVK3K8G 5*N7X_!_6L ZM-5:5.M%U\--N.'Q-*@Y499K)J=+
M'8S'X/%XG!5<Q5+Z["BL-.E5J4(N%.O&&(P];V5=0;C*4/<J*SJ4Y32FOP]_
MX*J?LW_M9_M2?#KX"^ /AY\(4\?>*O!$]QX@^)'C31/%?PX\%>!;KQ'>>%]&
MTZ]@\'Z-XY^(MOXM&FW.L2:S+!%JUNLNFV=I:0->ZL]R;M$_;5_8H^.GC/Q?
M\$_VS?V2/!^H^#/VHO!<OAVQ\:^!=8U_X?Z/J>OVFC::FEZ9K>H:Q;^,KGP-
M?WNGZ7;R>$_$NF2>*KVU\5^![^TTLRH-&?3M4_<.BO:RSQ3S_*,+P]@L#@<D
MIX;A[^WJ<*,\-C:E'-\)Q+.G/-\OSG#2S%X7$X#$.E1Y</AJ&#]BZ-*5*4*D
M%,XL5PIE^,JYC7KU\=*KF/U"3FJM",\)6RQ..#Q."JK#>UI8BFI33J59UO:*
M<U-2C)H\\^%7B;QMXN\">'];^(WPYU7X4^-[BPMD\3>"M5UKPEXA_LW68[>$
M:DVE:UX,\2>*-)U'0I;TW']C7<]]::M/8+#+JFD:5=N]I'\=?LR^ ?B[X5_:
MR_;5^(?C7X1^)O!_@/XXZ[\)-5\ >)-3\2?"_5%N8OA[X)U'PKK4>JZ1X5\?
M^(=;TM[Z\DMKO1"^GS"XLIG.I?V1<PFV?]"**^0PV>5,)1XAP^'P& IT.(L)
M3P->DOKTE@</2S7 YQ3AE\I8Z4XN.*R["P4L;+'-T(RA*\YNH>Q4P,:T\NJ5
M,1B)5,MK2KTY?N$\14EA*^#E+$I4%%\U+$U9-4%02J--6C%1/R%\(6?[9?['
M7Q5^._@KX<?LQ_\ #2WP@^-7QK\7?&CX<>*]*^*_A;X>2>"-7^(8&J^)/"'B
MV#Q%::Q=6NE:7>VB1VNLS106LGE-<VT^JZGKITG2M3XQ?#K]JGX-_M(_!W]L
M+P+\/T_:-UBX^ 1^!?[17@7P=JNC^#-05_\ A)3XU_X2SP):ZW/,+W3+?7;P
M66DZ"$OM7BTOPYI]KJNI7-UK>J>)+3]9J*^B7'M=XR..J</Y#4Q&)RZKE>?3
M<,TB^(\-5P4< Y8_ES1+!5U3IT\3[7(XY5[3,(1Q=>-:4*<(>=_8$%1=".89
MA&G2Q$,3E\4\(UEM2%=XA*A?"MUX.3E3Y<<\7RX=NC3<+SE+\M/VCO@Q^U%^
MTG\#O"WQ%?PSHW@CXW_"SX\_#[]H;X/_  ,N?$^C7T>DV?PWLWLD\">)?B%8
MQVVB:AXP\7W-UK'BP:FCVWA_0;N?P[X-.IQ6NG:UXLU'TGQ!X%\6?M3_ !Q_
M9H\?^*OA-XU^%7P^_9WU+Q=\2=2L?B;%X+&N^)OB??6-GH'@WP]H5CX5\8^)
MKB"P\&WD&I>+=7\378@T;59[;PS:^&Y-;CO-1OM$_0*BN)<9XZGAJ.'H8#+<
M+]26=4LJJX>GBH5,JPF?8)8#'X/#N6+FJ\%AU-X?$8Y8K'4\17Q&+J8JMBJJ
MJPV>24)59U*F(Q555W@9XN%25)QQ=;+Z_P!8P]>I:C'V<G4455I4/98>=*%.
MC&C3I1Y)?@_XSTSXHZW^TU^VAJWPR_9L^)_C[X5_$'6=+^#7Q:UCX"?'3X7:
M#H'Q#'A7X;Z;'XFT_P 3:#\1M%U?7(O'5HOC&[\(Z]J7POUSP$V@O!?^'8Y;
MCQOI?BS5]8]!\9WOBG]H;PK^QO9_LZ_LP_$G0?#O[)G[4WP_D^*GP^\1:I\-
M_!>L_"NS^$>@6-M=^";*S\9_$#2Y_%5X/#7BO2=9T'5+"XFL-7TTVC7NHVNJ
M7EY;6'UE:?L"> _#?C3QEXL^&/QK_::^#>E?$#Q)K?B_Q=\.?AG\5H-+^'.J
M>)_$OV=O$6NV^B:YX9\0ZCHFKZO+;122ZGX?UK2K^R2."STFYT[3[.QL[7ZS
M^'/PW\(_"GPO#X1\%V%U9Z6NHZQK=[<ZGJ^K>(M=UOQ!XBU2ZUOQ#XB\1^)-
M?O=2U[Q#K^N:O>W5_J>K:OJ%Y>7$TNSS5@B@AB^RS/CK)J%+*Z^58:EC\;EV
M#R_"X3ZS#/<-&4:&0_V%BJN>T:F?5\/B<;#"*G0P$LK=*G1ITX+V\,-2^IXC
MQ<+D.-J2Q4,74GAZ.(K8BK5]E+ 56I3QZQ]*. G' 0J4J$JW-/$+%*<IRDW[
M-U)^VI?$FE^#/C);?\%"_&'Q\E^"/C-/A9=?LK6_PDL->/BCX/&^U+QGHWQ"
M_P"$TBAL]"3XG/JD>F:KISR6%EJ.IP:;Y6K(D>H6]EITC:G%Y+^S'X<_;%_9
MQ_8&U3X=Z#^S=J4_[1OA[7O&\7@GPYJ7Q#^#5QX9NY/'_B_7_$MIXPNM;@^(
MC:<VE>#H-7)U+0;N:RU77-2MK&PL(TT_4;_5]%_6^BODI<;XFKA*.!Q&29%B
M<)2EPRY4:T,V<*\>%:68T,#3K\F;PYJ>+H9IBZ.81CR>U@X/#O"SCSOUUD=*
M-:>(IX['TJTUF:4X2P:<'FLL+.O*G?!RM*E/"49X=N_(U+VGM4[+\VOV</@Y
M\0OV=?AQX9^'^B_"+QGXI^)7Q7^(&F>+/VG/CKXRUOX675IK=_KFKPZA\2M=
MU(V/Q<?QK?AM%EU7PWX"L]$T6^&G75TGB35M/?4+G6QJ_B'[.EO^WM^RWX1M
M?V/='_9OTKXC>'_#&L^*M)^%/[3UU\2_#>E^"M+\#Z[XAN=0TOQ+XW\"-'+X
MBOKKPC)KLVH3^#K35M(UOQ#:V;>'-&,5O9?\)1<_LI16CX[Q6(_M99GDF1YM
M#.<70S'%QQL<U7_"I@UBX8#'4IX;-</4I+!8?&XC!4<OA)95]2G[">!DX4YP
ME9!2I_5/JN.QV$>"HSPU%T'A/]UK>Q>(H253"5(R=>I0I5IXB47BO;1=2-=<
MTD_QR_:T_9V\3?&CQ;\8I=8_9W^(>H_%OP?#X9_X8R_:G^%/B/P3X/\ $QU[
M3_AYX+U2.S^(6IV'C+PU<Z19:#\64\4WS:_XD\.1Z=;^'KS6[+P,^A>([7P\
M^N?J1\-=/\>>&/A/X$TOXC:I%XY^)?A_P!X;L?&^L:(((8_%GC32_#]G!X@O
MM+.I?V+:C^VM9@NIK2:^31;9VN$FN8=*B9X;?T6BO,S7BG&YOE659/7P^%A@
M\HY'A5%XJK.#6$PV$JPI3Q.)KO!X;%2PWU[$X/!?5\)/,<1B<5"C3YZ=.CU8
M3*:&#Q>+QM.I5E6QEU5O[*,6O:U*L'-4J</;5:2J>PI5Z_M*T<-3I4G.7+.4
M_P >OAI\'OVA_#_[*/[?/PPUG]G[QK:>,_V@/B/^U#XB^&>E)XT^!UTM_H_Q
MS\+-H_A>?5[^#XM-IFC3Z/?,Q\36TU[,]M:".?1VUN9WM8J7Q1^"/[17BS]E
M;_@GK\-]+^ ?B]_&O[.'Q:_9C\5?$S1G\:?!.-;70O@AX(U+POXDNM(U*;XJ
MQ:7JT^K7=S!<:!:0W:236YD_M,Z9)&J2?LE17MKQ&S2.,^O1RG(U6_MAYU;V
M>;.FL5+*GE$J?*\W<OJ[P[]IR.7M5B/>594OW1POAO"NBJ#QF/<%@U@D^;!\
MWLEBUC%*_P!3M[15$HWMR>ST<'/WS\G_ !?I'[5W[-'[4_Q@^-_P<_9[O/VA
M_A7^U#H_POO_ !-X,L/B!X5\$>+OA;\1_!?A^V\'1BYDU2;7+'5-+U2Q+76J
M7VF-/I-M-.SW&K:;I_A^VDUO6_:K\ _M4?%KX/?LU72_"!_%OQ.\._M1_#CX
M]^.O _A;QI\-M,T;X<^#?!NH>(-2M_ =KXF\6^)/"T7B[7],TR_T71+O7+*.
MYLO$/B&+Q#KUO_8.ARZ-H5O^I5%<U/CG$4L5DV8K(LAGFF3T<'AGF,Z>:^WS
M'"Y;EW]E9?0QU.GFM.A%8;!1I4I5L#2P6(Q3PV'GBZM>4:KK:RR&G*EC<.\?
MF"PN,G6JK#1EA/9X:KB<3];Q%2A*6$E4DZM?GFH8B5>G256I&C"FG'D_'SXV
M_!C]HSXJ?&S]I5?%GP$NOBQX/\>_!S0/"_[*>O>*_'WP^TSX?_L]ZSJ_PYU3
M2?B)?:_X3E\0:U=VGC^7Q9K<LD/CKPUX5\9^([F+3[?1M%\0:3X.O;F?2/*M
M ^"'[6R? +_@G?X O_V9M<BU3]FKX^^!/B!X\2R^)_P?FNX_!W@FYUBUNKI+
M?5?&FAVS:YJT6NW-_IFB6&H:G EE86XU'5[&_P!1EL--_=BBNZAXE9G0PF"P
M4,ER&5' +!/#QE'.HPC4P61XO(/:JC2SJGAZ=3%87&5L3C?84J,,1F4IXZ</
M;5J[J\]3AC"U*U>N\;CU/$>W]HT\$Y-5L=1S#E<YX*524:5:A"G1]I*<J>&4
M:$9<D*?+^>.A_#OXLW__  42\5_&?5?A!XHTCX.Z[^RS:_!9/%^H^)_A@_F>
M*;#XA#Q:\G]@Z%\0M4\51Z'?:3/-:0:C_9,-_%J<0CFTZ"TD74$\1^!7PU_:
M+_9Q_9J^*G[%T?P>\5^/=1LV^*^@? 3XKZ1JG@0?#+6O!GQ*GO;O1]:\<WFL
M>+=+UOPGJ'A;7/%>JZCXR\/-X8NKV\LK2Z7P3;^+YC&+C]?**\]<<XZ6'A@Z
MV6936P=.AP]3AA91S!4UB>&(XRGE>.<UF'MOK'L,?C<+BX1J0PV(P^)FE0I5
MHTJU/I>14/:2K0Q6+A6E4S"4JJ>'<G2S3V#Q6'2^K\BI\^&H5:,G%U:=2G%N
MI.#G"7XMZA^S!\:/V)/BA^SC\8OV<?AG<_M!>%_ W[-D7[-7QF\#:!K&D>#_
M !-J$%MXHE\<W/Q+\/V^MWEW#>WFO>+=1N]4N/#]DES/;R6"63W"PZS=ZUIO
MZ1?#K3OB'\5_AWXT'[17@G2_"]A\4+?4=&_X4D^J:9XG'A#X?ZAX?B\/7_AW
MQ5XKT:*WL_$OB#Q3(^M:YK,FFLNF:)8:SIWA>QDO;C0[S7M8^@J\)^/7P&TW
MX^Z'X9T2_P#B5\9?A>WA?Q5:^*;?6O@K\0;SX?:[J;6UE?63Z'K-_;6E^E[H
M5T+U;F:%+>WU&"[L[673]3LE-W'=/&<65>(YX"&>1P6%Q])NEB.+:6&QM?.)
M8:&*Q&84(SPT,=3P/M:6*K<BQF$PF&Q_U>%*@\2Z,:]/$*CE$<MCB'@76JX>
M:4J>3SJ4*>#51TJ6&J2565"6(<9487]C6K5,/[1SFJ2FZ<J?QG_P3<^"_B;P
M5IGQ#\2>,O%J?$.Q\!:[XE_9<^ GBR6-9+B3X"?!CXA^,5M;A;H[<7>H^+]4
MU/PMJB6L4>G2:=\,O"<6FSZCI=AIVI76#=?L[_&36/C[_P %"O!&H?#N\A^$
MO[9'A3P5H^@_&Q?$?A(Z+X2M=,^!7B3P;K$]YX4C\0?\)IJ.N6?C/4-*L-*T
MI-&MM/O;.+4]9U+5;&RM].M-<_3SP=X0\-^ /"GAWP1X.TFVT'PKX4T?3] \
M/Z/9^8;?3M*TNVCM+.V1YGEGF9(8U\VYN99KJZF,EQ=337$LDK])5XKCO,)Y
MYQ%G%"CAIO/:%'"1^L472EA*>"S/+,UR_&4*."KT,/2Q]+&91A,35CRUL#5K
MU,5[7"U85;)4LAP\<!EN#G.K%8"<ZS]G-35:=?"XK"8FC.=>%2I*A.CC*U.#
MO"O"$:7+5BX:_E;^S5XS_;ZT70/AI^S3X_\ V9['P:/AYI_A/P=XE_:</Q0\
M)>(/"M]X"\*21V/]N>'/!$=A-J>K>,?$WA?1?["TZWN+R>+0]>U2R\8^*]&A
MT^*7PG<^(_'']F;XJ_%7Q;XH^(/@7X$>,O@C^VIHOQSUZ+X3?M,^!O$WA3P]
M\./%7P9@^)6JZ3HWB?XK1Z/XMU&218O@[/!IOB'0]1\&77Q!\6SVNAP6]MK7
MAR_\3^&M,_<"BMZ'B#B<%FM?-\LR#(\JQ&*;J8NE@7G"PV+JU:LZV-ABZ6)S
M;$K$Y;F,I*EC,DK.63/#PC"A@J-;FQ$LZG#M.OA*>#Q688_%4Z2Y*,JZP3J4
M80C&%"5&=/"4W2Q6&2<J..A;&JI*4IUYPM33(Q(L<:RNLDH1!)(B&)'D"@.Z
M1EY#&K-EE0R2% 0I=L;B^BBOS[^NWY'T1[S\)?\ D$ZI_P!A%?\ TFBKU>O*
M/A+_ ,@G5/\ L(K_ .DT5>KU_;'AM_R0_#O_ &!U/_4K$'XUQ'_R.\P_Z^P_
M],TPHHHK[@\0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^2?$G_(Q:_\ ]AK5?_2Z>L6B
MBOX SC_D;9I_V,<;_P"I-4_>,)_NF%_[!Z/_ *;B%%%%><= 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'O/PE_Y!.J?]A%?_2:*O5Z**_MCPV_Y(?AW_L#J?\
MJ5B#\:XC_P"1WF'_ %]A_P"F:84445]P>(%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>nt10016217x4_graphic26x2.jpg
<TEXT>
begin 644 nt10016217x4_graphic26x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJNUW:HQ5[FW5E +*TT88 X(RI;(R",<<Y&.M %BBJ@O[$X_TRUR> /M,)/Z
M.?K5H$$ @@@@$$'((/(((X((Y!'6@!:*** "BBB@ HHHH **** "BBB@ HHH
MH **"0.IQT'/J3@#\3P/>H6N8$D6)YHUE<96-I$5R,@9",0W<<8R>< X- $U
M%)GDCN/IW[__ *\=#2T %%%% !1110 4444 %%!.!D]OQ_0<TQ9$<LJNI9"
MZ@@LA(! 8 Y!(/>@!]%&?\X/O_A_G(HH **** "BD)QV)]<=N"<XZGTP 3DC
MC&2(!=6YD:$31F5.60.NY1@'<PSP,$')X/(&2"  6***"0 22  ,DG@ #J2>
MP% !144<T,V?*FBEQC/ER(^,],[2<9[9J0L%Y8@  DD\  8SDG@=>YYYQT-
M"T4U'210R,KJ>C(P93]""0?P-.H ***:SJBL[D1HHRSNRJH'?))P,=R<#G@F
M@!U%1Q2Q3+OAD25,E=T;!UR.HRI(_P#K$$<$&I* "BBB@ HHI,C\\8X/?_\
M5D^@Y.!0 M%%1R2Q1+OE=8TSC<Y"+G. ,M@9)^Z.K=LB@"2BF+)&ZAT=70G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_AT_X.U?!ND_!_4_
MV7?BW\+KSQ3X!^('Q8\;>)=+^(FN>%?&GB[1E\666CV6@)ID6JZ=8ZS%I[&S
M5BL+6UO;G:2)!(=I3^XNOXD_^#R&XL9O!?[$5E)/:M*/'WCMKBT:XA$XMWL?
M#PD:2#S!,(BK@&4 1@$@N#T3MRROT5UZW5@N?H^W["G_  3Z^,'PN^ 7[,"^
M']:\$?M-?M _LM7/Q0TGQG\/OBW\0=*\;>%;_1/".@W"^+]0LIO%]TT=IJ>N
MZQF)+NWBM;[[+?0+@CS(OK/Q]_P5"_9X_P""=GB?]F#]B_\ :>3XKV/Q-\8>
M"? WA3PUX[A\+OKW@;Q/>V4&G>&K[4YO%[ZE%,YM;[RIM;NKBS/D&XWEY795
M;SW]@7_@F-^SU\)?B/\ LD_MM?L]>';'PA>ZM^RFO@KXL6NG>+=9UW2?$UYX
MD\/>&-5T75[&TU?4=;^RW\%^=574!I]]:V1AEM56S0H2_P"/'_!R!H^B^)?^
M"I7_  23\/Z[':WNDZIXCM+/4[68J(Y;2;XF^&A-%<NI0F-U W*2J[",A0W*
M=TKI)/33[EY;;%/65KI]-[.]UMOI;IKNGIK;^CCX.?\ !6K]BCXV7W[4=OX?
M^(FH^&[#]CYA+\9]>^('AW4_!>CZ9I;"18];TJ;68X+C4=+N+B,6MI(UM;W%
MY/-;+;6\HNK8RQ_L]?\ !5O]EW]HOXD^!OA;H$/Q,\!^(/B[X9U+QK\#KOXJ
M>!;WP7HOQO\ ".D7,MMJ.O?#/4;FXN%UFUM_+6X\B[33KV2UFBFBM7RRK^7?
M_!R?^SQ;^'/^"9W[1/Q*_9X^&.A:)XP^(?Q"^"NL_M)>*/!^C6MGXD\<?#KP
M7='3;*7Q+<6T)N-8LM%NQX?4A\^5;0"=RQCWU\R_\$_OA#\&/VUO!/\ P2Y_
M:(US_@H7>>,_&G[,+:'%\,OV?/!WPW^'FA>,/#.NZ;;6>C^*O!?BR#1+F3Q5
M=^&[)=':.^UW4K=;":P+7JR-/<(27=U'2^FNRM>W?2R]1*S3[^OE?HM;=W9-
M.^A^^?QN_P""G_[.OP:^,'B3X"Z=I'Q3^-GQ5\ ^$)_'OQ0\*? KP1+\0+GX
M6>$(,-_;/CVXM[ZRM=$25-TD-H9IKYE4;K9"Z!L_X*?\%7?V2OVE/A=^T'\7
M/V>]7\:?&'PO^S7HVFZQ\0(/"'@_4#K-T=0T:[UV;2_#>FZNVER:OJVE6%A?
M?VK:*T(MY[.YBCDF"(\G\^?_  0WU?7="_;>_P""XEA^T)J%MI'QXN?%&OZO
MKD>MW4%DUYX3&N>-Q'?6;WDD'VC2H8FTHF6)/LJV\\+*(@%1O,?^#92WDU+]
ME_\ X*[VVGPMJ%QJ&N^(X+.WM29/MTEWX'^)*6EO:LC?O#=O+&D/EG+[TQUY
M+ZKSOWOIT]>X:6[VMZN[BGTMWOZZ;7/W@\,?\%W?V*_&?['_ (Y_;?\ #&D_
M&_6/@A\-?B#%\.?'%U:_#65O$/A[5I[:TN(]3OM';501H)>]M[1M0CG=ENG$
M1@Y0M];>"_\ @H]^ROXO_8ITC]O^Z\:W/@K]G'6=!OM?MO$/CG3VT+5U@LM8
MO]!2P;1/.N;F;5]0U73Y;33-,M&N;F^DDB$*$,Q7^"+]E3XT_"GX?_\ !N]_
MP4(^$'C#Q[X<T+XH^*OV@[+3M#^'E_JMO'XSU"Z,WA=V:#PZDLFI&U$6EWHD
MOS:I812VTT4TZ2B(2_07[7VG_%6?_@U]_P"";>N^!HM4G\ >%/C$-9^+_P#9
M4271M=(C\7_$G_A%KV]LW#"2Q@\3&S"F91;QW<MJ)V$4@R<V^E[04M.]TM==
MK/\ 4+*R=W>ZOMU5WWZW7R/[.?V>/^"F?[/O[1GCNZ^%>A:+\5/ /Q2E^&UI
M\8/"7P]^*?@>?P?XE^(WPSU&W>XT[Q?X"@FO+JVU[3;U45(D6Z@NE>13+ D8
M:1?B73?^#C;_ ()W7G_"Z;*^D^.6A^*?@1(]OXT\#:E\)=5F\8RWEI?7MAJ]
MKI&C:5>:DUR- DL9YM<O+N6RT[3[?8\EX7<1U\R?L0_![X-?M-?'G]@[]NZ+
M_@H9=_'KXG> /@W_ ,(GX(^%?@?X=_#_ ,,RZ)X/U'PY=6?BOPU\1+#PS,VK
M:-IGAN\GO[&\U/6[>R@ENK2*+3WGGEA,GX^?\$NM"\%:K^UM_P '!VJ>(K#P
M_>ZG:?"WXWV&FZCJ'V::[M=(U7Q-XU_MJ*RNI)1)!97WDZ?'J$MJZB98HDE9
ME(!+NZVUOKZ):Z-^?K^([*Z2>CMM??YI==]/0_L__9B_;U_9F_:V_9J'[67P
ME\>V[_!JTL-8OO$>M^)HO^$?N_!K>'[?[7KEGXLL[F1SI-UI5MBXNU>61/(>
M.6&25)%8_(O@O_@M]^Q3XS^(7PC\#H_Q8\-Z+^T)X@U_PO\  #XJ>*_AY?:-
M\+OC-K?A_5SH$UIX$\1RW<EQJ O];VZ7I<]UIME#=W<B(7C# U_*K_P3HT7X
MJ^+?^#8'_@H3X?\ A++JUQXKA^)WB&[ET_0R\NJ3^$K!_AYJ7C2UM8;=A,8;
MOPU:ZK]I\O[ULD^ Z[L?L7_P1C^/'_!.']J;_@G?^Q!X?^.]O\'->^/'[)&O
M#P?X5\&^.[:VU/Q_X,^)VG^)[F;P]X@\$:"B3ZY>Q:W:2Z-JL-WI]A=64%ZD
MC7:0RV)D1IWMHM5?\O._7_(2\T[63NO-1>ETMKV^:V>A^EG[-?\ P6A_9:_:
MF_:F\2?L=?#SP7\?M*^-_@RW\27?B_0?&WPRD\,6WAFV\*R>1JD^KW-WJ[M#
M&;E[:VM&BAF^T3W=NJA5<.?K']ES]M#P7^U;K_Q@\.>$_AG\:? -_P#!'Q6?
M!'C.3XK^!3X0LI/$\9F-WI6A7?\ :6H1:Q/I\4<4U\UN1%;QW5MND+R%!_,A
M_P %P_AQ\1_^">W_  4E_9#_ ."L?[./A'4?$;_$;Q!;_!KXP>"M%!LAXE\5
M2VJZ?X?M;W[*C^?/XUT"XNM/!NH98H=0\,VTL@,\P-?U8?LO_"_4_A3\&/"V
MA>)KIM2\=ZW]K\<_$G5I&+2:K\1?&MT_B/QC>LY^8H^MWMS'"I8JD,4<:!(D
M2-1/=/=/\'M^MPT_KOI?IYV_$]UU2Z>STW4+R%$EEM;"[N8HY)DMXI)(+>26
M-)+A\I!'(RA6G<%(ER[<+S_GP_!+XV>*?^"EGP-_:_\ #5MK/Q7\2_\ !730
MOVE[C4_@'JGA+QEXPTA_!OP[L_$^FV]L\!L]2L_!OA3X9^#535++53?0R2O.
M+:=%FW*J_IW_ ,'&_P"W]\5_V7?VG_V&/A1KMMXRLOV+O$VJZ!\1OVBSX4N-
M3T@_$S3](^()LM7^'5]K-@]M/<6.EZ#IEMKMWX?LKV"75TU!;>X#I(A7\M?V
M\/\ A$O^">_[:OPQ_P""N7_!*KXM_#SXH_"'XO)%J_Q2^"W@'Q%!J.IZ3I&K
MV5O=^)K'Q/X/T^2;4]/\$>)K&,23W&LV=H_ACQ+%'!.D<QM)"I/YI?$NMM'?
MMZ/6P1]7UVOLK;M:VOJ]M+V=T?W _LU_'SX9:QX5^'7P:UO]I3X+?%?]H?PU
MX'T?2/B)IG@WXC>$-;\1ZEXN\,Z1:6?C'4'\.Z=K%SK,(AU2&Z:]:>RB:*02
M-<)"S;!]&>/O'OA'X7^"?%/Q&\?:[I_A?P3X*T+4O$OBCQ%JLZV^G:/H>D6T
MEW?ZC=3'.V&"WC9^ 79MJ*I9@*_F=_X(B?M-?\$\?VC?C#\6_P!I+X<:?X;3
M]N']K/Q;K_B_QU\+?#GP[EAUGX ^!-#@M[.+1[GQ';Z1::+%H^J.L>JZ]XNM
M[RWNO&.NZDHN+1IH7C7]WOVZK3X+:E^R%^T)H_[15UJNG? _7?AMKOA_XFZG
MHT9EU#1O"VN1KI-[K4 0C;_91O(M1D=RR116QDD0J&5J3NK]_P"OZ_X<.N^F
MB^?6W?71'@WPW_X*I_LW_$9OA;<#P_\ &CP;X?\ CQXRT#P5\!_&'C;X8:SI
M'A+XQ7GB3[8VEZIX+UR![ZU;1IH+)[E;O6CH\LEO)$\-O(694Z_]I/\ X*0?
ML^?LT_%+1O@9JUM\0/BE\:]7\+:QX\G^%'P8\*2>._&N@> ]!L9-1U7QCXDT
MV"[LXM'T2WM(VDC>YN1=W2_/;6DL>'/\F/P=T?\ ;4_X(]_M)?L=? V'XA>
M?V^/^"<7[3GQK\.C]G>2YN++Q=>^#==>YCNM*\2>"EE:]U#P9XET;2=8FUB*
M31)KOPSJ4;SL[6]P=A3Q?XZ\;_"G_@Y0_:LT3XR?M+1_LEV_QR\%Q^%OA5\5
MO%/@SPIXR\-WG@J^\,Z#<^$_"4T_C/[-I6@PZLEK?VMOJ:S_ .BZBJVEW-%#
M<,\4W>ETUJD].]MM;-/:]UN.RNNB>FKNKZ=DW]W?;2Q_2M\>_P#@MC^Q;\ /
MV=/A-^UAK4WQ2\<? /XP7%YINA_$'X;^ ;KQ)I>@:]83RVMUX:\9H][87'AK
M7XKJVN[8Z;?1"7SK2=>@0OZ'XJ_X*F?!;PI^RI\'OVP;CX5?M$ZM\*OC=XB\
M/^'/!MEH'PR.K^,UF\7N\/@_4-4\.6FL/)::7XIN1#::/=1W$_G7%W:I+'")
M2R?!_P #O^"4'P+\1?\ !,7]J_\ 8@^'_P ;M;_:#\%_&#Q;X_\ &?A3XEZ_
MH6BZ?X<T3XKZK:V6J6>H> [K1Y)='U#1['Q5IUA<W>H:9+<V"276H6L<K[ID
MK\Y/^#=;4/VA/VB?"GA_]EGX\Z)JVF?#/_@F)\6?%D^HMJEQ)=6GB[XH:A+J
M>F> O M]9W3 O9?#";_A)/%VF7/EO&FH2:6\2Q"*W+%VFD[:K3R=EIH_GOY7
M%9:ZZ+UVZ[I7>JMIT=S^CSX^?\%)/@%^S]XP^'?PKUK2OB5X[^.7Q*\)7'CS
M2/@/\,/"#^+_ (L:1X/L-$FU_5_$'B?PW!?6R:%8:/8V]PM\UW>"0W$$D-JE
MSMW'F?'_ /P57_96\#_L9VG[>.GW7CKXA?L^M>C3M;U?X?\ A236M>\'WD5X
MVFZE;>+= N+RPN]&GT;5532]4@F+36UY- NQXIDE/\N7QW\>>.O@W_P<V_%U
M_BQ^T4O[*&A?&/X::+X,^$7QD\2>"_#7C3PP/"^I> -$AT;PXW_"5I'HVCV^
ML^(+37--.JR3QQV6JNB:A,(Y9"/IS]JG]D_X4?LA?\$,/^"BG@_X/?M >(?V
MB_"/CKXD0_$2Z\<ZCH^AZ7X3;Q?K^L^%H_$MGX#E\/S3Z/J6F^?;6\M[<:6T
MMC'?8@AG:2*4(7?O-+2-]_*UNM];OIM;7>S26G=M::]6EVM9WNG?OVN?L#X+
M_P""[O[ OC[5?V7]"T'Q%\17U7]K@:C#\*;:X^'^IPQ+J=EJ%UI5MH7B74!,
M^G:/K>KZA:&WT_35O+NX N+&>^2SMKZUFE_,/_@D_P#'WX;Z/^V3_P %7/BG
MX9_:$_:N_:.\0Z??^)/'NN?LW^-?A9>^&O$/P^&A^(]3&I>$]-;5?&NK:)K?
MB+P]=+)X:TF/18?#-@-%M%FGMGG8I#];_P#! G]G3X">.O\ @E3^PEXP\9_#
M#P/XP\6_#74O'7Q%\$>(M>TBRU76/"'CC4O$^O:5?^(='O9XC-8ZA+I<5K:F
M0,RK%;VA \RUMI(_R-_X(A7$4_\ P5+_ ."W42W,$D]WK7[0<MK%'-YLUU'+
M\4?%!2>V$;M++'LD3]Y&6,:N@W84&E?6/FF_P7GZ_>+9M6O;?;IO;[GOW74^
MX?\ @G+_ ,%Y?'/QX\-?ME_M#?&S]GK]HW6OA?X'^+%W8^#]*^#?PTA\>^'?
MA!\-/#GAN"[DTOQ=K%MK%C?7GBQ9!>ZKKD\6G-"RR@VY6&..&+]3OV9_^"Q'
M[,O[7'[._P ;OVG/@=X,^.WBGX<? =HH_%41^'<=KXEUB<0->ZC;^%-$?6VE
MU>XT:P!O]4B>2U,-M\\1F)"G\./^#2_QQ\/K+X1_MD?"O7O$.@1>./$/[2NK
M7]MX OKJVDU^_P!"3PW;VE]?OH$C274ND*T<EG>WLULMG"ZBVFF\V;:?#_@=
M\*/C+^P7_P %F?VFO^"9_P *O#>KR_LY?\% 4M?B)X?O+2YEBT[X8^!8M1O/
M%?B/6[*%8I;=;&PT)?$WPVN?,$$SS76CLLX>*..9INT6W=/1Z=;+]=_78%OM
MII?7T5_)>7=WOT/[)/V;_CUX?_::^#7@KXW^%/"GC[P;X9\?:=-J^@Z-\3/#
M4OA#Q=_9/VJ:"PU*^T":XN9K*TU>")=1TQII ]QI\]O<&-/,*+\J_M%_\%1O
MV:OV<_BU>? 6]MOB5\6?C-H?@C4OB7XR^'/P1\$W?C_Q%X#\ :5;?;+SQ5XO
MAM[BR@TG3UM=US'"TTM^]N$F-HJ3P&3]#=+TRST?3-/TBPB$-AI=E::?90 #
M9#;64*06\:C  $<<:*H "H% 0*!BOXO/V%[#7?@[_P %T?\ @L1??M&7$FF:
M_J7P4\?>,?!USXEO[>S@UCX97%Q)J]I<:9>7T]M%-IUOX973HE^RR2)9Q PS
M-#Y,A5ZJWF[/[F_T!;[-^2^6KTN?OS^T=_P48\!ZS_P33^+'[:7[)&IZS\7=
M-_X5YXA?P9K'@+18];U'PGXCETF[C36/%NAWUUI\^BV?@V],-WXC%XKRZ:(X
MYC:7,>-WX@_\&]/P-O/VR_A_\$/V_/B5\2?VFM'^//PK^)GQJB\>^)9?$NH/
M\,?VEX-?U[48=,L]??5-4U,:I'X)MYTTJ>PTRPT:V@^Q6]LPF=&N'^6O^"/'
MASXB:'_P0L_X*G>*_%7VS3_AMXXG^*NI_#!=2WQV-[#!X9GAUS4M&EN L=U9
MWMRUG;I/;^9'<W%L0A9@P7]>_P#@U0FA?_@D)\.8TEC:6/XQ_&\2QK(AD3=X
MO<QF2)9&:,NBY7<J%U&\*0=Q6_*[=&_FG'\+ZKR&[I;JS3;_ /)+?<W;Y^9^
MU_[4?[5WP>_9!^'EE\1/C!JVH6UEKGB71_!/@_P]H&FRZUXK\;^-?$,XM=#\
M*>%-%A9)-2UG4YSLMX3+#"@R\\\48+CSGX2?MA_!K]IKQ?XQ_9\?PO\ $[P/
M\3=/^&<GC/QQ\+/BEX,U?P3XET?P3KFIMX8M[B\F2:6R9M4FGW6QTC5KJ6.!
M_,DDMYD*+\9?\%MOV9O@+^V)\!OAA^SM\6_C%)\ _B!XX^)9N/V=OB?<M+;>
M'],^+>B:-<WFG:+KVH)/;+91>(+5GMK'9-'?3W4!&FO]JB6*;\U_^"-?QP_;
MM^$_[?GQ;_X)V_MWZ/X9^,WQ ^#_ , _[2\(_M3:5-!K?B:W^&$6L:?J'A[P
M_P")_&HABO\ 7/#&ORSI>:3!K\8UW3-7A-O<.T(8([M/5:='KOV=MO\ @/7L
MNFSV;OMU2M_5O/I?YZ_X-K?'OB71/VE?^"K%IJ.J_$+QKX:^&GB:6'PMX.;7
M=>\77]KIFA^+/%ZVVC^&=-UK5;A&O9+6TALK2,2Q/.XCC>< _+^O/Q[_ ."B
MOP?_ &MO^":'[6_Q9\#VO[6'P/\ AQHV@:Y\/=2^+-M\(I[7Q?H%[+)/I>M^
M)?"NA_\ "16=WKNB^%-0MWTWQ3>Z?J5DUK'/-':7)F*R)_()^QQXY_;J^'9_
MX+*>-OV&8?"FIZGX<^(TFO\ Q8LG2\N?B/?_  LL?B%XK?Q&?AQ#!OM=YTY;
MQ?$%RVW5+31)+B\T=OM<2%?Z<?&O[;7[.O[;/_!OQ^TEX]^ -OX<\%VWA_\
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M>;[+/!"HW?"WXBI:P3"&2-4#$010PRD*RLBK&PV*?D_X<>*O'?PX_P"#A/\
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M"7^LFBE973[7_'34=]_/S?2UONM^)^>VK?\ !*'_ ()P:[KGQ#\2:O\ L:_
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M*U7PY;W%EHNL:WI\L.LV%A>*RW>FQ:QIEQ8:D^EW2NZW&F2W4EA,KN)+=@[
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MA77;YK+4O'&I::D<E[I^@AXC!=7D*S1'[,TT<LF]1$KL0I /:**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^0K_ (*Y_ OX
M5?M._P#!>C_@F!\"OCGX2M?'_P *?&WPP^)%MXG\'ZC>:G9V.J06>G>*M6MT
M>?2KVPOK<QZAIUI<![2Z@D9H0K.5)4[-Q\&/!G_!(G_@L[^R+\,OV2]7\2^
MOV8OVP/!/Q,/Q:^ #^(M9U_P7HVI>"_!_BC6K3Q1X;L=7O-0N=-GCN=&LKMI
M99)9V:._C-V\-SY"?<__  4C_P"":G[8?Q__ &Z?V6_VYOV/?B_\%/A[X_\
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M^*.C>%],EN->NKV;7GOS)I_AN2[TB/3=7L[""TMKBPU"?3XHYVCNTCK]G/\
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M;5(]59UR#+  MSMB)-IOD,O[2VB?M0_ /_@NO^R]X-_8;^'G@+XO?$7X7?\
M!/BS^'UCX,^)OBVW\ ^']6\!^']*A\*ZCJLNN;XE@U+38+?3=4@M+=E:Y99(
M54G  K_^DIW[WUW[KJM^FH:.^JLEHEK;5+6V]E=7UOW=C]2/@U_P6B37H_\
M@JGXI^,WPIT_PO\ #S_@FYXMN-'2\\#ZQJ&M^)/B%I,)UB*(S6&JV]I9V&JW
M5UID$,8@F^R1F]_>92W::3XQ^'O_  6[_P""D_BC]H/]C'X4>*?V!?@AX0\+
M_MS6C^-_@OK%Q\<[B\UFZ^%=L8;_ %+6]56Q^V6.E:_8:!,E^-)OH8'O)B(;
M>#<0E?"GQ5_9H_X*%?\ !/;]G+_@LG\4OVE])^!EE\//VQ/!8\97GQ@\#:ZG
MB Z7\2-=G%E:> -$^&%];3:D;/4;GQ'J&BW'B'5X!#I\ME%K-E<*@W3>"?\
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M (*%_"+]C7]HWXF?LL?M:^#OCE\%+CXMQ_$S]EVVEMH?@_\ 9XM4F@TWQ?\
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M-(OO[-MI]4EMS-<P_:WP ^&G[1GQG_;*U#]LO]H+X.+^SEH?@?X(M\"?A/\
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M4+NRTV76=0GU341:R:G=WMRD4]]<S3K#YYBB+E8D1<*/:J** #K7S]<?LM?
M>Z_:+TW]K*X^'NE2_M!:1X(O?ASIWQ(::_\ [7M?!NH.)+S1$@%V--\B=@ T
MALC<;>!+C-?0-% '#?$GX9^ /C%X)\0?#?XH^$="\=>!?%-C)IOB#POXDT^#
M4](U2SE',=S:7"NA9&Q)%*NV6&55EB=)%5A\,? '_@D7_P $Z/V8/'UO\4?@
ME^RO\./!WCVQ .F>)&M]2UV^T:97,D=SHO\ ;^H:E#I5W&Y(CO+**&Z1/W:2
MHGRU^D%%']?BGIVU2#YGSM\%/V4/V?\ ]G?Q1\6/&GP=^&^C^#?%?QQ\6S^.
M/BKX@M)M0O-6\8^)IY;B9K_4[W4KR\F\N.2[N3;V4!AL[;S6$$$:X4?1-%%
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M[.T4M(T)M;)=92];Z[*VO"Z7UJN[*_L)*]NU2B?5]%%%?EQ]P%%%% !1110
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M2_L[:_JWQ>@^ VI?"[4-9T+XEZWI'QMC^'!\/M?V7Q:MMHU^U\?_ -A@3_\
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MIS4U;&.32:M4<YNI%^<9-QWULS^=/)]3^9I5)R.3T?N?^>;G^=-I5^\/H_\
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M_P!^J?\ 8-4_]/8=?DVOF^Y]FT445^7'WH4444 %%%% !1110 4444 %%%%
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M\D^=/$5W)V:Y9NH^:"OTB]+]=PHHHKRSH"BBB@ HHHH **** "BBB@ HHHH
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M36J\@HHHKQ3J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<D#\R![TG!QTZ<?3C./;I^E']?J)77_ 7??>^^OGK\SXQ^(/[&OA7QW^U9\
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MPM"$K/RE&47YIG!EM.=+!TX5(N$U.LW&6C2E6J2C==+Q:?S"BBBO .\****
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M^PO$?^G9GZQA?]VP_P#UXH_^FXA1117$;A1110 4444 %%%% !1110 4444
M%%%% !1110 UQE2,XZ<\^H].>>G%?G=^SA^UM\0/B[^W-^WE^S'XBT3PG9>"
M_P!ENY^"$/@?6=)M]5B\3:U'\3/AKI/C'5_^$HFN]4NM-N7LM1O9X-/?2]/T
MX):[$N1/*IE/Z)G &3C'OTK\1?V&S_QMT_X+%C/']H?LDX'M_P *'\/=!Z8Q
MT]J]S*</0KX'B.I6I1G/"911KX:<D[TJTLZRJA*<+2BE)TJM2FVU+W*DU9<S
M.3$3E&M@HQDXJ=>49I;3BJ%5\LO).TO5)[I-?3__  4Z_P"3?K'_ +&^Q_\
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M@"*JG<V3CKC&2/US_P""DW['7CC]K'X.?#75/@UKNA>&/VC/V:_BUX)_:$^
M6I^+&O(_"-[X[\$70>Y\*>+9K""YO;'P_P"+M#EU+0KN_MK6]>QFN;:Y:SN(
MHGC-<<3A.66^SJ4ZEHXJ[IS4TM<.[76E]7:^EV_,7"].I3AC%4A.,G5I?Q(R
MBVE#3?>*?G:_3<^<-2^%G[!WP0^)G@KP#XO_ ."B_COP%^UII6O>#M2OI_&'
M[9EZGC3QIKUY=6]W+9WOP0\=^*M6^&WV'QZ9WMU\/Z;\.H8+6RU"%?#\%@4M
M95]I\1_M^_%[5?VT?BC^Q5\#OV8F^(_BCX3^'/ACXW\3?$77_B-:^#?A]IW@
M[QY#?F\DU&_7PWK-W;>)+2YM[6+0O#\%K<R>((#J=TL]E%IC^9\9_MI^&_VD
MO^"@GPW^#?P6M_V$?B3\'/B_I7QT^"WQ#^(OQ.^)J?"J3X->']+^%_B2#Q#X
MKA\._$7P[XO\0>.O$EE?^1+;>%T;P#I,NII<!;Z*PR\8^XO@#\#OBQX0_P""
MEG[<WQL\1^%+K3/A9\5OA9^S;H7@#Q7)?6$]IXDUKP3:>,XO$]I%8PW;ZA;/
MI!U&U!DO+:%)_M>Z-C@ _!IN_1)M=+;J[=K;W2N]W>V]SZGH[V=EHK];K326
MBM?3;\0_:R_;/_:<_9G\*_$+XQVO[(-KXQ^ OP@M!K'Q#\27/QCT/0/'T_A?
M3[RU7Q+XI\$^"%T+5;77=+TC2IYM4M8=0\1:/J>II8W4":?!,T"/8^+W_!06
M^M_'O[/'P:_9<^%=O\??C!^T1\,KCXXZ3H^N>,D^'7A#P7\&K:SM9%\9^+_$
M[Z'X@FM9-3U"\BTG2-*MM+N)[R]AO,R0I!\WY$?M=_LP_M^?'/3?V^?A9\1/
MAS^T]\7?B1\0/$'CZT_96\4_#WXY:3\,_P!D&T^!6I:$E]X6\,^,=&LO$FCZ
MG?>-].M'U#1=4T/7/ &H6OBKQ.ME87WB6VTFYFU6+ZKL_P!G;]HC]F3XX_L+
M_M>:%\%/&GQAM_!W[$>E?LB_M!_"CX:W?AFZ^)7A"[L%M/$WAWQ1X:TOQ'XI
M\,>%=>T^T\1?VCHVOK'XC@N;6 6MY:17R 1@?DNJ_/7J^FW=6ZC26FS>O5ZZ
M)J^N]_36Z1Y[^R5^V#_PJOXS_P#!8[]I7]H3P'XP^%B?#+Q5\"QXE^&VJW\.
MKWUGKMKX!ET.#2?"5^LZ:7JVG^+];DLAX<U>&'3X-2@NK*[NH[5'91]T_#?_
M (* _%VS^,_[/WPG_:B_9RT;X&6_[5%GK"?!;Q'X=^+6G?$I)/%.D^'I?%O_
M  @_CJQM?#^ACPUX@O= AE:S>RO-:L'U**33UN97Q+7YZ:Q^P-^UY^U=X%_X
M*YZ+\9/AKX7^#FO?M>ZQ\$/%7P2L+SQ';^*/#>H6?PYTBSU31_#7BR_T^2"]
MM-2DN-*L] \8NMC#8Z;?W=R]@=3M+>&:7Z6_8K_9^^$NF^/?@WJ]O_P2+C_9
MM^+?@/2%NO&WQC\8Z?\ #>R\/^#O$UIHLFBZI/\ !WQ!X=\3^-/$7BU]6NY;
MN'3KF^T7P8[Z'<O+<RA7VR/M;\=+:^FNE[/TW#35OHEUVLDK[[7ZZ^=G>_ZW
M?',_&D_"KQ?'^STO@8?&*YTT6O@FX^)/]IMX*TW4[J:&W?5M<@T@QZC?6^DV
MTD^H1Z;!+;MJ-Q;Q6CW$$4KNOX\_\$;=6^.MC\7O^"F?PT^/O[0'C/\ :&\2
M?";]IW0O#D?C+Q=+;V=I;O=^ [+5-5M_#/ABP\O1_"'A\ZA<2_8M&TJWM+2"
MVAA>2/S0[G]J/B-XQOO '@W7?%]AX%\:_$F[T6U%Q!X)^'=IH=_XRU\F6.,V
MNB6?B/7O#&C37:AVF"7NNV,1A23]Z'VJ?P\_X)]>'?C'HG[2W[?@^-O[%G[1
M'A+X9_MM?'7_ (3[PKK/C32/A5+X5T;P./ T>@ZCIOQ/CT;XK:MJ>CWU_-!+
M:QV6C:=XCCF%Q$LD\,?F2QIWO'?K?MMU_02^%KM;5Z-ZK\M+^;]3][SJ%E@_
MZ;:#H,_:81PRAP06;!)1E8#E2"#G!S7R%^T3^ROX ^/FI/XQ^*'QB^-6@^"/
M#'A#5(;'PU\._B_XE^$/A/P]>[I+K5/'U[K7P[U#PSK^KZM;6, M3#XFU_5O
M#6GVENLT.BP7)GN9>%?_ ()4?\$YY&W/^QU\$2Y.YF/A5""2 &4@7"ELJ!U7
M!(#,"V<_ ?\ P4&^%/QL@D^#G[$G[.?[*GQAT/\ 8 ET^YU[]HOQ#^S%;_#]
M_%GBO2Y;NX-I\#?!^@^*/'W@B31='UY[<3^.O%#ZH&DTW4H]/L[><QWBRONK
M;V6^][;Z:*^^^GXBW5F]>MK=M5[S?RUOW[_2'_!%+XO?&+XU?L4VGBGXL^,=
M<^)>FZ5\6OBUX*^#GQ3\3I:CQ+\2_@GX*\8W_ASP!XNUV>TM[:'4-1O-/T^2
MUFU0QM-J7V,7<T]Q)*96_7"OF[]EKQ%I.J?"K0_#OAO]G;XF?LS>$?A_:6'@
MOPC\./B7X>\%^&KRQ\/:)8P6FF?V)I7@CQCXTTV#1X;9$MX3-?P7)9':6'<6
M=OI&A;+J)[W_ *_KTMJ%1RE@I*D@@$\#.<*3CM@]QR,XQWJ2F2=/J<?7@\?I
M^E)[?-?BTNEG]S3[- ]3\XO^";7[8?Q$_;&\*?M.Z]\1?#_A'P_<_!7]KWXM
M_L_^&X_"$.K00:EX4\ :;X0O-+U365U;4]3D?7KF77[M+Z6TDM+"2.&V\BQA
M82M+^D%?A9_P0CR?AS^W^QY8_P#!3;]I7<QY8G^P?AB3DGDGG//K7[IU]!Q1
MA,/@L^Q^&PM.%&A2E05.G33C"*GA:%27*G*;2<I2?Q/=VLM%PY=5G6PE.=24
MIR<ZZ<I;M1KU(Q_\!BE%>@4445X!W!1110 4444 %?CE_P %6XM2UGQC^P]X
M:^%^E:/XV_:;?XZ:WXJ^!OPL\;Z1#JGPK\:6OA?PP/\ A9=[\2[BYN88=#T?
MPQX7U*'4-,U^UM]7UC2M6N()],T>[;SGM_V-KYO_ &B/V4O@W^U#8>$+;XJ:
M5KYU3X?:Y/XC\">+_!?B[Q)X!\<^#]6O+5;'4I_#OB_PEJ.E:YID>K621VFK
M6T%V+>_@BA6>-C#&RC_RW]?ZMYC3LT^W]?U^:W/YA=77Q =+U?X5?';PG8?#
MOXL?$;_@K3^RG!^VA\)?"\5CHGP%M_ ?BNRUF]^'T/@2^T[49+/Q-X(\:VWA
MSPS?>(=2U^+2=4\1:Y9B/6-"A#Q+)^R5OX=\)^!/^"R/AC3OAEI6B^&X_&/[
M"6KZA\5-$\*VUKI-AJ$OA[XKVVG^ M;\1:/I$4%K)JMK93ZCI.C7^H0)/'I8
MFM;-S")5'TM8?\$ZOV4;7X3_ ! ^#VJ> ]5\8>'_ (IZWI_B?Q_XB\<^,_%?
MB[XC^)O$NB2I-X9\07WQ(US5;SQ@NK^$VA@7PM?6^JPS:%'!&M@8LR&3T#]G
MW]CSX(?LTZKXN\2_#S2_%&I^-?'2:9;>*OB#\1_''BOXF^/]6TO18?)T?0IO
M&'C;5=9UM-!TP&22RTB&[CL89YYIEAWOD+7R\_T]?P&VO/RT75)7WTM9O3R]
M#LOCM\6O%_PA\.:9KG@WX"_%;]H'4+_5!I\_A?X33?#^#6M,M_)>0ZK?R?$3
MQMX&TD6 <+#BVU*XNS(X(MC&&<?C_P#MG_M.?%+XJS_L:^$?%G[%7[2OP+T>
MX_X*&_L9WLOC_P")]S\$)O"UG-9?%O39[?3ID\!?%WQMXA-UJ<FRW@>+0FMX
M'W-<W$*A2W[X5^:7_!3G_D3/V/?^TD/[#YQD@$+\9--9@2/[R*PZ$9(X[@>G
M];OI_E\Q+=>;6U[K;^MNIZI_P4'_ .38?&O_ %]Z/_Z42U_-/_$WU/\ Z&]?
MTL?\%!_^38?&O_7WH_\ Z42U_-/_ !-]3_Z&]?J7!?\ R*JW_8;5_P#3- ^!
MXF_WVC_V#0_]*F'\:_1__037]07[$'_)L'PN_P"P=J?_ *?-2K^7W^-?H_\
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M:K51MN#:=M=C"I."KX>$H\TYNI[-]8\L+S?_ &\FH_/KL_V;HHHKR3<****
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MO]]H_P#8-#_TJ8?QK]'_ /037]07[$'_ ";!\+O^P=J?_I\U*OY??XU^C_\
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M .AO7]+'_!0?_DV'QK_U]Z/_ .E$M?S3_P 3?4_^AO7ZEP7_ ,BJM_V&U?\
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M_L+Q'_IV9^L87_=L/_UXH_\ IN(4445Q&X4444 %%%% !1110 4444 %%%%
M!1110 4444 ! (P0"/0\BOQ#_8955_X*Z_\ !8TJJ@MJ'[).X@ $_P#%A_#_
M %('/XU^WA(')_SGBOQD_8J\*>*=*_X*L?\ !6[Q/JGAK7],\->*-0_97/AG
MQ!J&CZA9:+XB&E_!#0+/4CH>J7-O%9:LNGW:O:WK6$UPMM<HT,Q212M?09+*
M*R_BA2DDYY)0C!-I.4UGF4S<8)OWI>SA.32N^2,W:R9PXI/ZQ@--L1-OR7L*
MBN_FTO5GT!_P4Z_Y-^L?^QOL?_2"_K^>D=/Q;^9K^A;_ (*=?\F_6/\ V-]C
M_P"D%_7\](Z?BW\S7V_!_P#R)J?_ &$XK\Z1\;Q-_P C*/\ V#P_-BU_3'^P
M'_R;!X%_Z^_$7_IZNZ_F<K^F/]@/_DV#P+_U]^(O_3U=UCQK_P BBE_V'T/_
M $UB"^&?]^J?]@U3_P!/88^S:***_+C[T**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBCI0!^('PN51_P %^/VH6"KN_P"&"_@GS@9Y\;7V>>O/>O=O
M^"K'_)'O '_8^R_^H]J=>4_#/PIXH@_X+I?M+>,YO#FNP^$-0_8>^#.BV/BF
M72;^/P]>ZO;>,M1EN=+M=9> :?<:A!%&\DUI%<//'&I=XPN#7JW_  58_P"2
M/> /^Q]E_P#4>U.ON8-/B'AFS3MDF5IV=[-9>[I]FNQX.+365YG=6_VC$OY?
M6%J?@JG4_1?Y58M?^/JW_P"OF'^:U73J?HO\JL6O_'U;_P#7S#_-:_1S\]/Z
MT?@+_P D2^$W_9/?"7_IDLZ]:KR7X"_\D2^$W_9/?"7_ *9+.O6J_!L5_O.(
M_P"O];_TY(_6Z'\"C_UZI_\ I$0HHHK U"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\)O^",8 ^*?_  5NP ,_\%+OC1G QGYXNN/J?S/K7[LU^)?_
M  2#\'>+?"GQ._X*I7'BCPOX@\.6_B;_ (*+_&#Q!X<GUS1[_2H=>T*[:$VN
MLZ/+?6\":EI=R"#!?6;36TH(V2-FOHLJDED/%,7))RI91RIM)RMF5)OE3U=E
M=NVVK9QUO]]P/;_:;]OX<;7Z;)_B?MI1117SIV!1110 4444 %%%% !1110
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M .BWK]7ZQ_Q1_P#2D?FT=UZK\S^I7]C?_DV?X2?]BRG_ *5W-?35?,O[&_\
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MZW0_@4?^O5/_ -(B%%%%8&H4444 %%%% !1110 4444 %%%% !1110 4444
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M?^G)'ZW0_@4?^O5/_P!(B%%%%8&H4444 %%%% !1110 4444 %%%% !1110
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M( &3C)./? )/Z#.*DJ*0,1M7'(;@D@G@  $$8Z\\].*3V^:_-?U;KL!^&/\
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M2-4M9;+4=.OK:4-'<6EY:32V\\+@K)'(RD8- '\[7_!2C]K+_@CO^VK^PO\
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M5?F>J?\ !0?_ )-A\:_]?>C_ /I1+7\T_P#$WU/_ *&]?TL?\%!_^38?&O\
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MB/[2?_)!/BU_V(^N?^DK5. _W[!?]A>&_P#3T!XC_=Z__7FK_P"D2/Y0I_\
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MD[;JZ3/I_P#X*=?\F_6/_8WV/_I!?U_/2.GXM_,U_0M_P4Z_Y-^L?^QOL?\
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MGU2J_FJM))^MFT?H%1117Y.?>A1110 4444 %%%% !1110 4$9!![C'YT44
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M8H_A_P  ^&M(\ 7.@^&;/[#9V@:PTR?5-0DMFN!-<YNY!)/(HC"?KO7X6?\
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M@[4__3YJ5?R^_P :_1__ $$U_4%^Q!_R;!\+O^P=J?\ Z?-2HXW_ .13A/\
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M:348_$N>I-+$86FZ<92J.LHS=N:GRTTVX]?>TB^7H]7T<O\ P5<_Y*5\/?\
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MP4'_ .38?&O_ %]Z/_Z42U_-/_$WU/\ Z&]?J7!?_(JK?]AM7_TS0/@>)O\
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MX0 [H(Y7E4 L5 5L>T?\%6/^2/> /^Q]E_\ 4>U.OL'1OVC_ (+:U^TMXO\
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MNAWL4VIZ1<:I-IS:I;I-:0VV6B97^7_#V6U_S':U_O6^JT\O[RT/V"K\TO\
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M_P#3<0HHHKE-PHHHH ",\&OQ%_8:X_X*Z?\ !8H=EOOV2%4?W5'P&\/ */0
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M=7T#0O$%NEIKVB:1K=K%)YL=MJ^FV>I6\<N"/,2&\AFC23!(WJH;!(S7Y?\
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M?]R'_P!$I2GJ?]T_^@25^Q'YD?U7?LK?\F]?";_L5XO_ $JNJ^A*^>_V5O\
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M1<=>EF[Z:_(E_P""KG_)2OA[_P!B5!_Z??$%?E%7ZN_\%7/^2E?#W_L2H/\
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MK#'PW%'^^T/^P27_ *?IBU_29_P3N_Y->\)?]ASQ7_Z>;JOYLZ_I,_X)W?\
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M2 %2#R,C/.. P/;^70]#Q7Y:?LH_M%_%_P"(_P#P46_X*4? CQAXL_M?X6_
M*\_9WB^%/AS^Q-%LCX93QS\)=%\2^*5.L6.G6VK:O_:&MW,UVO\ ;%]>M;;S
M';>7" !ZF70QLL+G4L+5A3H4\MI3Q\)I.5;"O,\!3A2IWIRM-8JIAJS?/"T:
M4K2O:,N:NZ*JX55(R<W6DJ+CS6C/V51MRLUIRQ<=4U>7EIV?_!3K_DWZQ_[&
M^Q_](+^OYZ1T_%OYFOZ%O^"G7_)OUC_V-]C_ .D%_7\](Z?BW\S7Z'P?_P B
M:G_V$XK\Z1\1Q-_R,H_]@\/S8M?TQ_L!_P#)L'@7_K[\1?\ IZNZ_F<K^F/]
M@/\ Y-@\"_\ 7WXB_P#3U=UCQK_R**7_ &'T/_36(+X9_P!^J?\ 8-4_]/88
M^S:***_+C[T^!/\ @I-_R;-J?_8V^%__ $JEK^<JOZ-?^"DW_)LVI_\ 8V^%
M_P#TJEK^<JOU+@O_ )%$O^PJI_Z;I'P7$_\ O\/^O$/_ $J0Y/O#_>3_ -&)
M7]%G_!-+_DV;3_\ L;/$7_H=K7\Z:?>'^\G_ *,2OZ+/^":7_)LVG_\ 8V>(
MO_0[6MN,?^1++_L*PO\ [LBX9_Y&3_[ ZW_IZB?H%1117Y.??'YH_P#!43_D
M@GAC_LI%C_ZB_BBOY_:_H"_X*B?\D$\,?]E(L?\ U%_%%?S^U^L\(?\ (DI_
M]A.)_.!^?<2?\C*7_7JE_P"DH0]/Q7^8K^FW]@S_ )-@^'G_ %SU+_TNEK^9
M(]/Q7^8K^FW]@S_DV#X>?]<]2_\ 2Z6N;C3_ )%E'_L,C_Z:9OPO_OM;_L%_
M]S'V)1117Y>?=!1110 4C' )'8$_I2TUB0K$#)"D@=,G'3/;/2@#X9\)_L>S
M^'?^"@'Q2_;>?QLEQ%\1_@+X(^"2> /[&\I],_X0_6[K63XA.N?;G%RM\)X[
M=;'[! T!21VF?<JKX]_P58_Y(]X _P"Q]E_]1[4ZJ_#_ /:*^,.L_P#!7CX\
M?LPZEXM\_P""/@O]DGX7_$[PYX+_ +'T*+^SO&_B+Q3>Z=K&KC78M-7Q%=?:
M[)5C.GW>JRZ?;A5DM[2)R6:U_P %6/\ DCW@#_L?9?\ U'M3KZ[ PQL,_P @
M^NU:=64LNP4\.Z<5%0P<\"Y86E.U.FI5*=)I5)6E>=_?D>+F#IO+,P]G&44J
ME524FW>?MH\\E=OW9/5?YGX*IU/T7^56+7_CZM_^OF'^:U73J?HO\JL6O_'U
M;_\ 7S#_ #6OU(_.3^M'X"_\D2^$W_9/?"7_ *9+.O6J\E^ O_)$OA-_V3WP
ME_Z9+.O6J_!L5_O.(_Z_UO\ TY(_6Z'\"C_UZI_^D1"BBBL#4**** "BBB@
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M1W6_VDW6W[+$(<R?=U?E'_P2=_:4^,O[2O@K]KW5?C/XIC\5ZA\+?VY?C?\
M!WP1)'HFBZ$VC?#SP?I7@>Y\/^'WAT2QL8[YK&;6-0D&IZ@+K5+E;I8[F\FC
M@MUC_5RO9S^&/IYOC*>:5:=?'QE2]O6I14:=1_5Z+IRC%4Z-E[)TU_"A=IMJ
M[N^7!.C+#0>'A*G2<JO+&2:DFJLU-N[;UFI-:[-6TL%%%%>.=04444 %%%%
M!7S-^T]X;U_5?">B:]X%^ 'PN_:,^)/AC6Q<^$/!GQ8\<6GP^T+3H]0@-IKN
MNV7B*\\"_$2*#4;2Q6)8X5\-32RI(WEWEH03)],U\W?M"?LM?#O]I&U\*_\
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M\H4_^ON/^NK?^AR5 W0?[R?^AK4\_P#K[C_KJW_H<E0-T'^\G_H:U^ZO=_\
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M[2H/_@B^&0^AY!''<$=J_=.OG+]F_P#9E^"G[,6D_$W1_@CHUQHNG?%3XO\
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M\MXW3YDFUM)WXL4VJ^ U:3Q$XM*^MZ%1V=EM>*>NB:[L^GO^"G7_ ";]8_\
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M"0"=@S*9"K,&]H_X*L?\D>\ ?]C[+_ZCVIUX5\+0Q_X+Y_M/N58*_P"P7\%
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M6U>7X]Z7X_U7PP^AF"0.NFP_#S5]&U5-5\\QE'NIY+,PAE9-Y##\>/VQ[?\
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MYA1T_%OYFOT_@G_D6XG_ +"ZG_IK#'PW%'^^T/\ L$E_Z?IBU_29_P $[O\
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MU_V(^N?^DK5[=7B/[2?_ "03XM?]B/KG_I*U+ ?[]@O^PO#?^GH#Q'^[U_\
MKS5_](D?RA3_ .ON/^NK?^AR5 W0?[R?^AK4\_\ K[C_ *ZM_P"AR5 W0?[R
M?^AK7[J]W_V[_P"D1/R9[1]/U9_0G_P3#_Y-\U3_ +'_ %/_ -,VA5^CR]!]
M!_*OSA_X)A_\F^:I_P!C_J?_ *9M"K]'EZ#Z#^5?BN?_ /([S'_L(G_Z12/T
M_*O^1;@O^P>G^0M?D?\ \%7/^1-^%/\ V&/%/_HKPY7ZX5^1_P#P5<_Y$WX4
M_P#88\4_^BO#E='#/_(\P/\ BJ_^F*I&<_\ (LQ?^"'_ *=@?AXO4_[D/_HE
M*4]3_NG_ - DI%ZG_<A_]$I2GJ?]T_\ H$E?L1^9']5W[*W_ ";U\)O^Q7B_
M]*KJOH2OGO\ 96_Y-Z^$W_8KQ?\ I5=5]"5^$X__ )&&._["L1_Z?JGZSA?]
MVP__ %XH_P#IN(4445RFX4444 -?!4[AD<<$X[C'.1CG'?\ /I7AG@'XP? C
MQC\7OC)\+O /B+PUJ/QB^%4GA*/XTZ#I>F3VOB#09?$F@VVK>#_^$DOY-/MX
MK][[P]-:7&GE+V],-F4B_=!=@]UK\1?V&O\ E+K_ ,%C/^PA^R3_ .J'\/UZ
MN78*GBL+G=><ZD)9?EE+%4XP<5&K*>:8#".G5O%MP2Q/M4DU[].'JN:O5=.K
MA8*,6JU:4).2;:2I3FG'5).\;7UT;1]'_P#!4O5=*TC]GG3KG6-5TW2;5_&F
MGQ"XU2_MM.MVD;3]2*H+BZDB3>V/N;^0,XX)K^<[_A-?!?\ T._A 9 /'BKP
M\1R,Y!&I'.>N??GFOUF_X.*E#?L3^$LJK?\ %Z?#?W@/^@%XB_7KCTZ^]?Q'
M&-,GY(AR>/3DU^@<(SMD\%:_^TXGK;K2OT?3;;[CX_B&E[3,%K:U&G]F][MK
M^:/_  +WV/Z"_P#A-?!7_0[^$3[?\)5H S[974@PST^4AO3FOZ@?^">6HZ?J
MG[*W@*\TS4++4[.2[\1B.\T^ZBO+61DUN\5PD\,DT;%&!5B')W YYXK_ #<_
M+C[K%CO@<X[X]\5_?K_P0Z4)_P $Y?@XJC:!K/Q R./^ARU?T_#\:QXRES95
M!6M;&4'>]T[4L1ILNKO]W4?#E+DQU3WKVP\OLVTE4I2O\3ZP7_@7=:_KE111
M7Y@?<'P)_P %)O\ DV;4_P#L;?"__I5+7\Y5?T:_\%)O^39M3_[&WPO_ .E4
MM?SE5^I<%_\ (HE_V%5/_3=(^"XG_P!_A_UXA_Z5(<GWA_O)_P"C$K^BS_@F
ME_R;-I__ &-GB+_T.UK^=-/O#_>3_P!&)7]%G_!-+_DV;3_^QL\1?^AVM;<8
M_P#(EE_V%87_ -V1<,_\C)_]@=;_ -/43] J***_)S[X_-'_ (*B?\D$\,?]
ME(L?_47\45_/[7] 7_!43_D@GAC_ +*18_\ J+^**_G]K]9X0_Y$E/\ ["<3
M^<#\^XD_Y&4O^O5+_P!)0AZ?BO\ ,5_3;^P9_P FP?#S_KGJ7_I=+7\R1Z?B
MO\Q7]-O[!G_)L'P\_P"N>I?^ETM<W&G_ "+*/_89'_TTS?A?_?:W_8+_ .YC
M[$HHHK\O/N@HHHH *1NA[<'V[>M+10!X1HWQ@^!.H_'[Q1\$=)\0>&)?VA/#
M7@31/&?BKPU%IDT7BVT^'^L7US::%JEYJLFGI'=Z1/J$=Q%!;1:I</;S,'DM
MH5F5G^+?^"K'_)'O '_8^R_^H]J=>%?"[_E/O^U#_P!F%_!+_P!3:^KW7_@J
MQ_R1[P!_V/LO_J/:G7UV!P5/!9_D$:<ZM18C+L%C).JXMQJ8G!.<X0Y802I1
M>E.+3<8Z.3/%Q]1U,KS!N,8\E2M37*FDU"NDFTV_>:UD[ZN[ZGX*IU/T7^56
M+7_CZM_^OF'^:U73J?HO\JL6O_'U;_\ 7S#_ #6OU(_.3^M'X"_\D2^$W_9/
M?"7_ *9+.O6J\E^ O_)$OA-_V3WPE_Z9+.O6J_!L5_O.(_Z_UO\ TY(_6Z'\
M"C_UZI_^D1"ODG]N/_DV7XE?]>-A_P"G""OK:ODG]N/_ )-E^)7_ %XV'_IP
M@KIRG_D:9=_V'83_ -/P,<?_ +EBO^O%3_TEG\PO9?\ =7_T$4U_N-_NM_(T
M[LO^ZO\ Z"*:_P!QO]UOY&OV^.R]%^1^60^./^*/YH_I:_X)\_\ )L/@S_K^
MUS_TX/7VQ7Q/_P $^?\ DV'P9_U_:Y_Z<'K[8K\3SK_D;YE_V&XG_P!.R/T_
M*_\ D7X/_L&H?^FH!7XB?\%8O^1L^%W_ &+FH?\ I??U^W=?B)_P5B_Y&SX7
M?]BYJ'_I??UZ'"G_ ".\-_@K_P#IF9R<0?\ (JQ'^*A_Z?IGY%58L_\ C]L?
M^ORV_P#1RU7JQ9_\?MC_ -?EM_Z.6OUWK'_%'_TI'YQ+9^C_ "/ZY/A#_P D
MG^&'_9/?!G_J.:;7HE>=_"'_ ))/\,/^R>^#/_4<TVO1*_!<1_O%?_K]5_\
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MB.OXC7^^W^\W\S7WG"7_ "*(?]A.)_\ <)\GG_\ OW_<*'ZC:_OY_P""'O\
MRCH^#_\ V&?B!_ZF6K5_ -7]_/\ P0]_Y1T?!_\ [#/Q _\ 4RU:HXP_Y%4/
M^PRC_P"FZY7#W^_5?^P9_P#IR!^M]%%%?F)]F? G_!2;_DV;4_\ L;?"_P#Z
M52U_.57]&O\ P4F_Y-FU/_L;?"__ *52U_.57ZEP7_R*)?\ 854_]-TCX+B?
M_?X?]>(?^E2')]X?[R?^C$K^BS_@FE_R;-I__8V>(O\ T.UK^=-/O#_>3_T8
ME?T6?\$TO^39M/\ ^QL\1?\ H=K6W&/_ ")9?]A6%_\ =D7#/_(R?_8'6_\
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M&G'*\P5.3G>I6<VU:U1UTYQ6B346[)K1K5,_!5.I^B_RJQ:_\?5O_P!?,/\
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MWAW!<\>9U:_+3E:,[1O*R2;7/45/ZQAI2GRU8^V]C'^=N$5-?]NJSMN^_1_
M_P#P5<_Y*5\/?^Q*@_\ 3[X@K\HJ_5W_ (*N?\E*^'O_ &)4'_I]\05^45?I
MW#G_ "(\N_Z\/_TY,_.LX_Y&6+_Z^Q_],T2[IG_(5TK_ +"-I_Z.6OZ\?AU_
MR3[P)_V)OAC_ -,EC7\AVF?\A72O^PC:?^CEK^O'X=?\D^\"?]B;X8_],EC7
MSO'/\/+?\>*_])H'M\*?'C/\-'\YG94445^>'V04444 %%%% !1110 4444
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MBC_U-O$=?YZ(_B_X#_[/7^A=_P $</\ E')^SA_V!?%'_J;>(Z?&7_(MP_\
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M!XC_ '>O_P!>:O\ Z1(_E"G_ -?<?]=6_P#0Y*@;H/\ >3_T-:GG_P!?<?\
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M1T?!_P#[#/Q _P#4RU:OX!J_OY_X(>_\HZ/@_P#]AGX@?^IEJU1QA_R*H?\
M891_]-URN'O]^J_]@S_].0/UOHHHK\Q/LSX$_P""DW_)LVI_]C;X7_\ 2J6O
MYRJ_HU_X*3?\FS:G_P!C;X7_ /2J6OYRJ_4N"_\ D42_["JG_IND?!<3_P"_
MP_Z\0_\ 2I#D^\/]Y/\ T8E?T6?\$TO^39M/_P"QL\1?^AVM?SII]X?[R?\
MHQ*_HL_X)I?\FS:?_P!C9XB_]#M:VXQ_Y$LO^PK"_P#NR+AG_D9/_L#K?^GJ
M)^@5%%%?DY]\?FC_ ,%1/^2">&/^RD6/_J+^**_G]K^@+_@J)_R03PQ_V4BQ
M_P#47\45_/[7ZSPA_P B2G_V$XG\X'Y]Q)_R,I?]>J7_ *2A#T_%?YBOZ;?V
M#/\ DV#X>?\ 7/4O_2Z6OYDCT_%?YBOZ;?V#/^38/AY_USU+_P!+I:YN-/\
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M$</^4<G[.'_8%\4?^IMXCK_/1'\7_ ?_ &>O]"[_ ((X?\HY/V</^P+XH_\
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MTC_]#6OZM/V:0#\ _A*2<$>"M( XZYBW$9Y R5'."0.F*_E+3_61_P#72/\
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M_P#M=:G^S-J/A&RL/!^F^)T\365W=/)?:A=63VQM9Y(BBK!&P96PC!F)/+C
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MQ'^*A_Z?IGY%58L_^/VQ_P"ORV_]'+5>K%G_ ,?MC_U^6W_HY:_7>L?\4?\
MTI'YQ+9^C_(_KD^$/_))_AA_V3WP9_ZCFFUZ)7G?PA_Y)/\ ##_LGO@S_P!1
MS3:]$K\%Q'^\5_\ K]5_]+D?KM'^%2_Z]P_])04445B:!1110 5^7O\ P3G_
M &L?BW^TYXY_;YT#XH/X9;3_ -G;]LSXB_ WX<#P]HLNDW">!O# A_LM-=FD
MO;P:KJX+,MSJ"1VJSL&86\:E5'Z@Y_SZ_P#ZN]?A-_P1C=3\5/\ @K>H/S+_
M ,%+?C22#D$ / ,Y/'); P>2#VP3[N74*%3)>(ZU6G3E6P]/*WAZLE%U*7M<
M?"G5]G)ZQ]I!N,W&S<5:]F[\E6;6+P5/FM"HZ[E&_P 7)33C==5%MRM9ZI?.
M?_@JY_R4KX>_]B5!_P"GWQ!7Y15^KG_!5L@_$KX?<XV^"83SWQKWB 8'N<'&
M<9K\H-X]#^G^-?I/#B:R3+K_ //A_P#IRHOS/SW./^1EB_\ K['_ -,T30TS
M_D*Z5_V$;3_T<M?UX_#K_DGW@3_L3?#'_IDL:_D-TI@VJZ9CJ-0M&P>I F7.
M,9YY]J_KR^'7_)/O G_8F^&/_3)8U\YQS_#RW_'BO_2:![?"GQXU?W:/YS_R
M.RHHHZ5^>'V045Y)\8/C=\/O@7H>F^(OB)J5UIFEZKJG]CV4MI87&H227WV.
MZOA&T-LK2(IM[.=O,(V;E"$AF4'YX/\ P41_9?\ ^ALUG@D'_BFM4ZC'K$/7
M_/%=M#+<PQ--5</@L36I2;BJE.C.<&T[-*235T]'KHSEJXW!T)NG6Q5"E-)-
MPJ580DD[-.TFG9IZ/;?LS[BHKX;_ .'B?[+W_0V:SU"_\BUJG4_]LN@SR?\
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MZO\ []?^@-7]]'_!<_\ Y1V?$_\ [&CP#_ZD$5?P+C_5_P#?K_T!J_2N#?\
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M_P!LJ/2__/B#OL=7"\6J^)O;^"OQG'_AC*\'?LL_#+P-^TU\8/VK=%F\1/\
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M_E_Z3$_)GM'T_5G]"W_!,/\ Y-\U3_L?]3_],VA5^CR]!]!_*OSA_P""8?\
MR;YJ?4?\5_J?48/_ "!M"ZCM7Z/+T'T'\J_%<_\ ^1WF/_81/_TBD?I^5?\
M(MP7_8/3_(&Z'Z'^5?S#?\','_)./V5/^QP^*?\ Z9O!=?T\MT/T/\J_F&_X
M.8/^2<?LJ?\ 8X?%/_TS>"ZOA[_D=8'_ !S_ /2&+-O^1?B?2G_Z>IG\BC]6
M_P!]_P"8H7JGU3_T:*'ZM_OO_,4+U3ZI_P"C17Z]'9>B_(^!>_RC^2/]'/\
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M?]AE'_TW7*X>_P!^J_\ 8,__ $Y _6^BBBOS$^S/@3_@I-_R;-J?_8V^%_\
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MLNI0/X6A\*^%=2N-8TY['219)<V^JR74^+N[:_FCECC");1'>S?C3_P<E_\
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M&_W6_D:_;X[+T7Y'Y9#XX_XH_FC^EK_@GS_R;#X,_P"O[7/_ $X/7VQ7Q/\
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M6/\ DBW@'_LI"_\ J*>(Z_!!/^6G_767_P!#:OUGA%+^Q:+<8M^VQ&KC%O\
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M[S_;!#+Y(1VCG5&8QR ?M2/VD/V=\#_B_7P7Z#K\4O V?QQKN/RKS[_AA/\
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MT_L)_L0X'_&&_P"RJ=H(4']GKX1X 9BQ _XI X!8EB!U8DGDDT?\,)_L0_\
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M$B]Q=W=S++<7$SDM+-([DDM7NS?L)_L1%3_QAQ^RLQ ;:#^SU\(\#<Q<A?\
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MR]AO];$UI>?$KP9;3Q%[YW4213ZU'(A93N4,HRO(X-?9'_#2'[.__1>O@O\
M^'2\#_\ R]KSUOV%/V(W<R2?L<?LK.YZNW[/GPE<Y_X%X1.">Y'+=_8_X83_
M &(?^C-_V5?_ !'GX1__ #(5\9C,0\7B\1BG'D>(K5*S@G=1=23DXI]4KVO9
M7['TV&H1PV'HT%*4E1IPI\S23DH1C&]M;-I-VN];:GH7_#2'[.__ $7KX+_^
M'2\#_P#R]K^?#_@L[^V[\"/ _P 0/@[IMCXIT/XA?VAX1U2]DN? 'C'P?K<.
MF"'5[N!(;]HM4G2"6<2>:D;,C2( X# <?N;_ ,,)_L0_]&;_ +*O_B//PC_^
M9"@?L*_L2(69/V./V5U) 7*_L]_")2R<G:2/!X.W)/&3SSQDUOE>/EEF-IXR
M%-594XU(J#?*G[2$H.[L[6YK[=+&6.PD,=AI8>4Y04I4Y.22;7).,[6;2=W%
MIWZ/N?Q ?\/"_@R>?[(\3C/_ %%_"7_RYJS8_P#!0_X+1WEI(=&\22K'<VTI
M1M9\) %8YT<Y9=6DP"$89*D8W \9K^Q;]H;]B/\ 8PTKX!_&[4],_9%_9>T_
M4=.^$GQ'OK"_LO@#\*K6\LKRT\'ZQ/:W=K=6_A2.>WN+:>-)H9X'26*1%>-E
M=01PW[%?[&7['?B/]D']F+7=<_9._9HUO6-9^ _PLU+5=7U;X$?"N_U'4K^^
M\&:1/>7U[>W'A6:6ZNKN>22:XF>1WDDD=V9BY)^J7'%96_V"+LT_XSMI9[VO
MI9[:_C?P?]5Z-K_6)*]U=4TVM.B<K?>K?>[_ $1\#/VG/V>M1^"OPBU&3XW?
M"+36U#X8^ KYM/O_ (G>"(KZP:Z\+:7,]E>1'7 8KNTD=[>YC(!CEC:,@%2!
MZG_PTA^SO_T7KX+_ /ATO __ ,O:\]_X83_8AZ_\,;_LJYP!_P F\_"/H!@#
M_D4.@   [ 8'%'_#"?[$/_1F_P"RK_XCS\(__F0KX><G.<YO><Y3:O>SE)RM
M?RO8^HC&,8QCJ^6,8WTUY5%7_!_AYGH7_#2'[.__ $7KX+_^'2\#_P#R]K^2
M[_@N[^V-K\'[2O@/PO\ "GXX^&=0\$:5\-K+45A\+^)/">NZ?::WJ^HW\6J-
M)=V<]Z5N)HK/33+;37&8D6*58\E6']1__#"?[$/_ $9O^RK_ .(\_"/_ .9"
MA?V%/V(U4JO['7[*X7 4*/V>OA&%"KRJ +X07Y >BG(KT,JS!Y7C(XN-*-:4
M(5(*$GRK]Y!PYN9)M.-[JR\KG-C<+#&X:>'E.4%-QO))/X6G:SM=-K75:>9_
MG5?\-;?%X=?B]$.W_'UH/7T^Y6AH_P"UQ\75U?3=_P 7XE4W4(9C<^'BH5I%
M!W[PF$925W!A@D'(.#7^A1XI_8:_8IM_#'B2X@_8^_9:@GAT#69(9H?V?/A+
M%+%(FG7+))'(OA+<CHP#*RD$$ @U\A?\$W?V-_V0?%?["7[+OB+Q+^RK^S9X
MDUW6/A-H-YJFMZY\"OA7J>J:G<RO<F2XOKZY\*2W%U*Y )DFD:0X 8_+7T[X
MUJM-?48KFBU_'=M5%/[-]+Z:6T6JTOX<>&J2:E]8?NM;4U?_ -*_NK_)ZGZ%
M:-^TE^SVVD:4\OQ[^#!D?3;!GS\4? O+FVBW'*Z[M(+9.5^7TXK\5O\ @C[\
M:/@[X;^*'_!5IO$?Q9^&>A+K?_!1OXQZ[HTFL^._"VEIK&B7$D:6^LZ4U[JL
M U#2;AD=8-1M#-9RE6$<S$''Z\#]A/\ 8A_Z,W_95R>3G]GKX1DD^I/_  B!
MR3W)))[TQ_V%?V*)#B3]CO\ 9<E" K%YO[/WPDD5$'"I&K>%"$1%^5%"A5'
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MR:.75JE7V\JO/!0Y>11LN:,[WN[[6V_X'H'_  TA^SO_ -%Z^"__ (=+P/\
M_+VC_AI#]G@]/CU\%S_W5+P/Q_Y7?\YKSW_AA/\ 8A_Z,W_95_\ $>?A'_\
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MN=N593'+'7_?2J^UY$[P4+<E]M7OS?@EO>WH7_#2'[.__1>O@O\ ^'2\#_\
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M8 !9_"3.P )&68L1@-G!I[_L)?L1'G_AC7]E5R022/V>OA$I+ #!!/A'.>,
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ME:%II8W.H-#I=O<W-VT:"&"W&9I8RZ!N+_:L^/:?LP?L\_%?X]/X(\4?$?\
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MI?B*PN+]TL3X@M[H"OIW]B_XEZ3_ ,$Q_P#@GM\%;O\ :V^(7Q-^('QH^/\
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MQI\7P\\>7UK':BY^+?@NV6T@\0:U9V(TSQ7"DVNPSR7'VB6Y^EK;]C3X0?\
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MY"]M=6MQ&>)(9X'>*5<C*,03@\_AC^U/^R[^UQ\/O#/[4/P$_9K^$?@GX_\
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M_6*D.<' R<' SC)[#/;/K0&O]?U\O1L_$K]N:]\(_L]?L>^"OV-Y?&_QD_:
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M?U_75]PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MC>,."K!74X^5T5U!4AAD'J-P5O4%<@@[<?(F@?L:_#VV_:H\3_M>>-=7U[XE
M?%*XT.+PE\,5\7R6]YH7P/\ ",L,8UO1_AGIB1);Z/=>)KN,7.NZ[L;6+Q,V
M?VM+62:*7Z_HH#OY[_U\D(._&,GGW[9_(#\.O-+110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPUI/B_P=XA@M[RTAUGP]K=I%>Z;J$=KJ$%K>VZ7%O*KB*ZMX9DSAT!K^1O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>nt10016217x4_graphic29x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic29x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MYT>+0Y;*\2^LGM;I+YH+A;RU:&1Q<1%_JS_@GW^P)XS_ &YOB5=Z''JU_P"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO@)_PJ7_ (2[_AI[1/&6C_\ "5_\)Y_8'_"$?\);X'UOP9]H_L+_ (0S6O\
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M^+4T,@# $I+#(DL3@;9(W1U)5@3]L?#SQ9^V=X!\/?LLZ7\6_C%^R)_P3_\
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M-0^R00&\U.[TSP]I,-W?W1GO+G[+&9IW545/YAOV]?\ D]C]J_\ [."^*_\
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M?_!/;QM^P?\ \*I^U?\ "8^)[3Q'_P +4_X3KR/[.^R_$3PCX]^Q_P#"#_\
M"'3?;-__  BO]D_:/^$PM=OV_P"W>0WV7['<>F_M1_\ !4WQ9^TS^R+\,OV7
M+[X;3^%[WP;_ ,*X_P"$S^)#?$)_$$OQ'_X0#PI=Z))]M\+GP9HW]C_V]X@D
MT_Q;/N\1ZS]CO=,AM%^TB3[7'\[BN!,_Q&?8C%QPL:>"S7B_,99PWB,&WB.&
M)XGA_,L+4457=1<^+RS$4W147B8\_P"\HQHSDY?>Y?XT<%8'@S Y9/,IXC-^
M&_"S(*?"L8X'-H+ >(E'+>->'LRH.;P<:,G1RSB' UUBI3CE\U1?L<7/%4J:
MI?N)^VG\+?!/QB_X*J?\$_?!/Q#TK3]?\*-X%^*?B:]\/:HD4]AKE[X(TWQ)
MXQT33[VRG22WU33SKFAZ==:KI-U#-9ZII-M?6%[#+9W$Z'TCQ-^T/J>@_M6^
M/O!_Q\_:K_81LOV41INO^ =<_9O\1^)-*3XB:=8OHLL>FW?BFQ\3>&+>&]UC
M5KIK6W\1^&=0UL^$8_#&HSPZ?I][=VL%[J'\_G[3G_!5KQG\<?VC_P!GW]I;
MX??#"U^$?B[]G^WO(=*TN_\ &]SX]TWQ,FH:C)<:G8ZO-9>&/ %Y;Z-K&DW%
M_P"'=9T^UD^TWFEZA=K!J-G(ZLGU#??\%D/V?(/&'BK]H3PS^PEH6G?M4^*O
M"\GA&[\<ZO\ $'^U_#KVG]E6MG:ZEJEO#X9TZ75)8)=/TVRO+:UTK1=<U;P]
M8QZ-)XTL[<JD7DU.!>)EE^0T,3D];&?5^&L3E7U6CBLGE/*\TJYQBL4L2JV+
MKU*.&=;"UJ,EF. CB<30EAXTY0L^4^FH^,GA[//>,\9E_%6%RIXWC_+N(UF.
M+R[BJE1XBX<P_"N5Y;+ 3PN68*CC,P^J9E@\93>0YU++\OQ=/'3KQJ\R<U]/
M?\$C?&EIX2_;5_;'_9M^$?B_P]K_ .S'I]UX]^*WP\M_#<VE^(-+FFN?&O@/
MP[X<O[#QBMLVK:C;6'@NZMM#EMAJ5QIK75K+<XNKI3?2_+'[!GQT_;E_:(_:
MV^-OQ@\$^#/@E\2OB-;^!K3P1XJ^-'QALKCP=X<^#WA2U_X21?#,5B? 26D(
MN?$E[I*+>VT'@_Q#K&LVGAIX6OM!TA=?U4?!G[#W[?.N?LC?M'^./C[X@\$V
M_P 2C\3M \3:'XTT2PU"Q\%N)_%'BK1?%UQK6AM9:'J&F6#V.IZ/LM]#@TRT
MTIK&[ELH&T]8K66W^M/A)_P5=^#7P0^./QCU_P"'/[(.E^'OV?OC?X3\,^&_
M&/PIL_%]@MS)K/A_5?&4MUXSAB?PK)H1A\1:%XWU31]:\"RPM9RBUTS[/XIM
M]/LDTX_1YKPOG%#&<45,'P[A\WKYKD&18;#8^O5P2A5Q&#E"GG$*[>*P6+GB
M<9!0Q"NJ=#%U<+26)<H6I/X#AKQ%X6QF5>'-#->.\=PO@^&N->,<?C\EP>'S
M=U,/@,SIU*_"M7!QAE^;9;2P&5UO:X%VE7QN5X?,<1/+XPJMXB/Z]ZZ-0^,?
M_!._]M/3OC9^TQ\%OVUM=\%?#OXK>*M/\6?#;P9X.M?#OP\\2>&/AGJWB7PQ
MI=EJWAM'T'5M7T74K"+6-/UJTTS3M>TV*^DM[B^NA+:SQ^8?LA?&CX:?&;]C
MC]G/X+?LK_ME>&_V-OC-X"\/Z1X?\9^$M6\ _#/Q!J'C?QW%96I\4W,/ACXD
MQ6;^*CXD\3"X\76^L^ M?N&:#Q*]CXHL9-0;^R=+_-VW_P""MGP4\$?"+XT?
MLW_!S]B/3/A]\#/BKX,\5>$UM-#^,%YIOC:/4O''AS6O"/BKQCKNLZKX$\90
M:OJ-WX?N/#EMH^G3K++HDN@W"W6O:_9:C96>AX?@/_@J/\$_&GP*^%GP)_;1
M_9)T[X\V7P9L=-L?!?C32/%\^B:Q)%HMM9:=IK:IITMO!>?;[O3K&VA\4W\/
MBQ]/\6R6\<FK^'W9I6?P?]2^(5@<9">1XM47Q!1S3 T*3X5DJ-*>62PU2M4X
M=E*>1XI1JVA5P3JX.=*3A5HUL0U6G+[5^+/ TLXRFM2XQRN6+CP1BN',XQF(
M_P"(DTWC,32XBHYA1PM'CR$:/&.7N=!2K8?-UALTI8F$*N&Q6#P$9X6E'[K^
M,?BK]M#X*_\ !3+]D3Q1\4_#O[/?AN?XR^)-/^";_%'X'^%]3CD^+?PYU'QG
M\.T\4Z!X\M_'FJ^(=6TSQ'H,']AKI-Y9VUA-IECJMQ8:)XAUFUM'>Q\O_;^^
M-O[2GCC_ (*C^!/V?? '@WPC\<+7X2^+?!7C7X-?!KQCH>FP^'9O%VI?"/2?
M$VKZQXAUO3[[POK5[IV@RM?^,&_MKQ0-%TW^QTEOK>?2;>XL)_@K]I/_ (*?
M>(?C?\>/V8OB=X2^%6C_  W^'G[)VL^'M9^&GPIBUJ+5;6>XTC7/#NI:BFH:
MU:>']%2TL=5TOPEX>\/6&FV>DO!X<T^QDDT^6>YO+F1_=?BO_P %<OACXD_:
M ^"_[4'PU_9+L?!_QE\#Z^NH_$?Q-J?CRWN[OX@^$[GP/XE^'NH_#^:\T_PA
M:R%(]"UZWN-%\8WENT^G7VDZ9%=^%M4M=.LDB]?!\+Y]A:F2XVOPOE^)QU/A
M'.LJE3HSP5'#X+,YXBM4RN6)D\;&M353!/ZK6J8#$3]A+%5Z.'J4J%FOF,T\
M1>"LRH<5Y1A/$7/,OR?$>*'"/$L:V*HYMB<;FW#]+ 82AQ'# 0642PM:5#-X
M_P!I8:AGF!HO&4\NP>*QV'Q6,YE+]X?@;XK^/NL_M)>,O 7[2'[4_P"S%XHD
MUKPCK,=Q^QA\*="T[Q7>^#;.2'3W.HZUXMU>PT/QVD/]CW,)U6U\9Z3>:3K2
M>(7AL=/L[=M,G/P+_P $G_&6O>"_V\_V]/V7?#,UAI'P2\*?$+X[^,O#_@VR
MT;1[6'3->T'XR^'OAYI,UI?6UA#?VUA9>$K:#2H-&@N(M'A6))HK".95<?*\
M'_!9?X"> OC'J/QV^#_["6AZ5\3/B+$X^,_B_6OB7-:>(?$-I/IJK<:'X8N[
M'PMJ>F:&MSXATOPOKFKZ_P#V*%\1KI%[%J?AA-:U6+Q)IGR'^SG_ ,%(;3]G
MW]M?XW_M7:;\(+O5/#GQXF\=2^(OAQ<^/;>;5- F^('C32/'VIW>E>,4\%V,
M&H'3?$&GW*Z=97/AJP272+T:?=79O+9-7?Q\-P1Q#4RSB:A/(8X99CP]EM+!
M862R+"TGG&!Q*E45+#X'%5%"I&#J/#8[&3GB:\'SXC%1JU/91^HS'Q@X&P_$
M7A[C*7&M3,'D/'.?8C-LQ@^,LPQ,>%LXP'LZ,L3C<WRZC.M1G5C0^OY/E5*C
M@,)6C[+ 9;/#T%B*GZG_ /!'CX]?%#]H[]L#]J?XD?%W7X/$GB]OA?X2\.G4
MK;1M&T*+^R- \7WEII=L+#0K#3K'=;P$JT_V?[1,3NFED;!KG_@+XLN/V*?^
M"1?C+]JSX*>'O#\GQO\ B3\2_$4&M>,]7T33]<FT.V/QLO\ X7V$%\7-I=-H
MND:+X?2^T+1+NXO]+M_%WB,ZO<Z==6VHWMN_Q?\ ";_@JG\(/V>/VDOBE\9O
M@C^QW9>&?!7Q$\":)X//P\L?B?;>&HX=7TKQ1K'B&^\:2W-G\.=<MH)]<BU*
MULI/#EO;RVVE"P4VFL3VCP6-IYE^R#_P4TA^!'PP\=?LZ_&[X)Z-^T+^SOX\
M\1:AKS>#=:UI;:_\*R:U?VFHZK:Z:FJZ5K6CZMI(U&QM_$&G:0+7P]<:?XL:
MZ\1V6N6E[=/M]7'\)YWB<5F.,P_#WL<KJXK@?%/('BLMI?7\NR;"8VEF64JG
M1Q3PL/8U*V'FJ5>=/#UO9*-*51JQ\UDGB9PAE^7Y%E6.XZ>*XBPV7>,.71XV
M67<08G^Q<\XLS+)\1D'$SKXO+HYC66+H83'4I8C"4Z^/PBQ#GB(4.;F&_M;_
M +=7QE_:T_96^$.D_'#]G.WGUK0->U6[T7]K"70]5TBV\47$.IZCINK:5X23
M3O#.C^%M,@N[:"PT?QGI&GZ[K6DZEKWAVTU4:1I&H:=I]MI?RS^P5_R>Q^RA
M_P!G!?"C_P!3/2*^I?VSO^"EMI^T!\&/"?[,/P*^#&F_L\?L]^%;^.]N/"VG
MZQ!JE[XG_LZ]EU'0[6YBL=(TBQT73+;5+BX\0ZGIZR:Y=ZQXE:VUB\UEYK1A
M<_ 'P%^*7_"D/C9\)_C%_87_  D__"L/B#X3\=_\([_:?]B_VY_PC&M6>K_V
M5_:_]GZM_9GV[[+]G^W?V7J'V;S/.^QW&SRF^^RC+<13X7S3!4\BIY#/%_VT
M\%E%/&QQ7LX8R-;V'/+VL\+@ZE><^:6$PU9X/#\RY'34ITZ?XKQ1Q!@:_B-P
MYF]?C/$<:4<K?"<<VXHQ&43R]UZF52PJQOL8+#TLRS2A@Z5+V=/,\PPL<UQ_
M(_:QQ#C2KU_Z0/V[Q_P2GT?]M?Q=XI_:EU#X]:Q\7M*7X?7_ (K\#Z#8Q77P
MPU:VL_!'AYO#MC.ECI5KK5Q:W>A)I4FJV\/B:U$UXUQ!)+':O);GXO\ CM^W
M7XT_;T_;M_9MF_9Q^!>F^/=.^$>HZE'\%OA;\5H8(X_%OB>[LH_$'B/Q?XSM
M-$\3Z9IVBZ=H:>&-*UFRT_\ X2JXTO3[+P3!K&N7-U:7^I:!;_FY^VC^TQ_P
MU[^T1XT^/G_"%?\ "O?^$PLO"EI_PBG_  DG_"6?V=_PC'A31O#'F?V[_8/A
MG[7]N_LG[=L_L:U^S?:/LVZX\K[1+A?LF_M$ZY^RA^T%\.?CWH&B6OB:[\":
MAJ;WGAJ\OI=,MM?T37]"U3PSKVE'48;:].GW-QH^LWIT[47L-1BT[4TLK^33
MK]+8VDWC95P54P.1X+&8A8W,N(L!PQ6P. RW-,Q57+L!C<3EBH8C"85865&G
M1I59KZG.M#$R:P^D,0N6%6/UO$GB[1SGC'-\JP3R?(. \[\1<)G.<Y]P]D,L
M/GN=Y1@.('C,%FF8O,:>*KXO$8:DWFM+"5LOIQ>/;=7 RYZN'G_8]\#?%?Q]
MUG]I+QEX"_:0_:G_ &8O%$FM>$=9CN/V,/A3H6G>*[WP;9R0Z>YU'6O%NKV&
MA^.TA_L>YA.JVOC/2;S2=:3Q"\-CI]G;MIDY^0?V*_B[XZ^'G@;_ (*T_#?P
MAJ&FZ+X,_9"\<_'JX^ &B6?AWP]!:>!V_MW]H+Q(L*Q0Z7''JUE#JWA[29K;
M3]62\L+.WM1I]I;06#M;'X;@_P""R_P$\!?&/4?CM\'_ -A+0]*^)GQ%B<?&
M?Q?K7Q+FM/$/B&TGTU5N-#\,7=CX6U/3-#6Y\0Z7X7US5]?_ +%"^(UTB]BU
M/PPFM:K%XDTSP;]FW_@J3X0^"WQE_:^\8>)_V?;GQA\+?VQ/%=UXK\7^ +OQ
MWIVJ:AX9N-7O?&=_XCTQ=2N?!.F:;XPT'6W\=ZW8OI5_I>A-;Z8EA;O>WDL-
M[-J/Y]3X&XAJ8#-U/AN,(U\!P[5PV":R##0EF&69G1>80H8?"8J<(U)8">,I
MTL7C)SQ.+PU6I#$8EU*_L#]OK>,7 U'.^%I4>/JE6>#SGCK#8_-XRXVS"K3R
M3B#A[$0R2KC,;F>6TJM2C'.J.58C$Y9E=&CE^68_#T*F!P$</@UC7]T_\$Z?
MB=XS^,_[&7_!4WXI?$/5(M:\;>-O#_Q!UKQ)JL.GZ?I45]J,OP+\20O,FG:3
M:V6G6BF.&-1%:6L,0VY";B2?2OV(M$F^ _\ P2?\+?%7X)^/O@)\#?BW\9?$
MOB&X\7_'3XYWBVGAK3'M?B%XM\':5;+J!T;6HKG4=)T?PUI^F>&_#.LP2^&K
M77[[7]7ELY[V^N['4_RR^'G_  4V\"?"'P;^V%\./AE^RU:^&/ G[3]EJ>F^
M'-"LOBIY%M\*+34OAE+\/9A%#_PKFY;Q6&O+BY\3-&]SH,I>=M+ENYY VL2X
MW[)7_!23P]\'_P!GKQ)^R1^T3\![#]HCX Z[K,FJZ=I,GBBY\.:UX8BU'5(-
M:U;3[;?97]O?64>OVZ>*?#YTZZ\*ZMHOB2YU6]_MNZ&H6G]C^]FO"6?8J&<5
M<-D\J&#Q7$?#.9QRB-7*IRQ.58#*/JN*P2P[Q3P$Y8'$2IVP>*J0PN(>%2I.
MI3]G*7QG#GB=P5EU7A3#X[BF&+S3+N _$'AVIQ//"\24H8#B7.>*(YCEV;2Q
MT<N6=489O@:>(4\TRZA6S'!1S%NO&A6]O"'Z(_MK>+O@E\9?A'^R)XR\2_''
M]F#XM_MG_#SXX_"WP]XV\4_!#Q9HM]=^,O!%[XJU*VN$@L+.PT[5;ZRAG/A?
MQ%/8WFF6.E>&-6N/%*^'A:V6IS1:E['_ ,%0_P!O7XT?LE?MA_!#P9\)+OPS
MX?T#Q%X(\"^-/BK)_P (/X9UGQ%\0]$G^(WC#P]:^%=7\0:U9W&IP:+I&FZ%
MK3:';Z#?:!?6%]XCUFY_M4F\A^R?CM^U9_P46T3XWS_ #P7\*?@1H'P<^!G[
M.?B#0M?\*^"K?4[35/$OB&Y\.WD0T]=2\4C0XIM$T]=)A:V72+9-9:75[[4-
M>U[5O$MX-*32O+_V\OVWO^&W/CMX+^-?_"L?^%9?\(?\/O#G@3_A&O\ A-/^
M$T_M'_A'_&/C#Q9_:O\ ;/\ PB?A/[)]K_X2S^S_ +#_ &5=?9_L'VK[9-]J
M^S6W1E7 ^,JXCA]9ME'M,KP]#BB=? X[$9=B:>7O,JV&GE^%^KT7&A&%Z=3$
M4:&&IXBC@*C@G752G"2X>)/&+*\-@.-Y<-<4>PXDQN.\.H8/.,FP6>Y?6SN.
M0X3&TL\S%X_&1GBYU.6M1P.+Q>8UL%BLYH0J2^INC7JTW^YW[7_BW6?@9_P6
M8_9/UOX7G3?#&H_'CP/\+?A[\59H-$T:Y/BSP]XB^,VKZ)K+7C7EA/)'K%[H
MWA_0-*.NV[Q:M;V&BZ=;VEW D+>9Y#^VO^V%:>"O^"L?PU\%_M'7]MK7[+OP
M!\7>$O&>F:!_PA^EZK)X5\0^+_@S8/:^,;I].TUO$VOP>&O&NLZ;XN>R,NKW
M5M#I3?V+I5Y>0VEA-^;7[4'_  4JU']H?]K+X ?M5:3\(K?P!J7P'3P1]C\'
MW?CEO&-KXDF\&?$#5?'0-SK2>#O"TFFP:H-3.CS11:7>36L<;7L-T\LB0P^[
M_&W_ (*V>!?%WQL^$G[2OP=_9;TGX>?'3P?KMKJ7Q \7^(/%T6OQ_$'PPGA7
M6O!UU\/=5@TKP[H<]_8QZ7J5A=Z1XJGN+2^TW4-&TAFT&Z_LC2Y;7EP7!^;X
M=9!+&\/?7*\."\UR+%U*>.RVAB,#F%2I-82H\=*>(E2DL"ZF$P^,PM/&2PRK
M\OLW!3@_0S?Q4X6QTN-*>4\<?V5@JGBWPWQGEM"OD^?XO YSD5"A0>:48Y-&
MC@J>)A+.(4<TQV59EB,KAF$L'SNLJSI58_NSJ>H?M#?%W4?B5\2/V0OVS/V=
M?VE/ 7B'0[_38?V:OB_X$\):QX(\,0ZRB.^F:CXT^%5]HGCR"\C@2_T2W\._
M$'29$N[#4;JP\6W%U>VMMJUC_%G\7="\0^%_BO\ $SPYXN\*Z/X%\4Z%X_\
M&&D^(O!7AU=GA[PEK=AX@U"VU/PWX?7^T-7']A:)>1S:;H[+JVJ*VFVULR:E
M?*PNI?W$T_\ X*^?LH^&/B'KO[1W@[]@2STG]IKQ/:WL&K>+9?B5$VEK<ZA:
MW5M>ZI%=Q>%PG]H:BDP37+W3O"6AZQKUM-<VVHZTXQ))^$_Q"\=>(_BAX]\:
M_$GQA=QWWBOQ_P"*_$'C/Q)>0P):P7&N>)M5N]9U26VM8OW5I;->WDWV:TA
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M +4G[67A33_$GP%^%I\ ?#6PL=?AN_[&OO'_ ,3_ !KX>T>75X9+:ZM5O)_
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MTP^*/[#/[+'A;]BE/B3I/C'XCWEIHEMKWQ]LX%^"OANS_:,_X5_\8]$3P7\
M+7XES2>+8[;3/A5IOCGP/XGU?5/$EE:W%AXAT_53=Z'9>&C<)J<WG8KBS*L+
MA\CQ3^L5:'$#H+ U*.'K5HVQ%*%2BJCHPJ1A4J3JTJ,(2:O5G9R2C)KWLN\,
M^),QQW&.6Q6!PV-X(ABY9S0Q>.PV%FG@<15HXN5".)JT9UJ-"EA\3BJE:G"5
ML/14HPE*I"+_  ,HK]6O@C\(_P!G_P#9]_8WT?\ ;4_:+^%;?'CQ/\5_B9J/
M@#X ?"+4/%.K^%?!8TSPG)?0^*/B%XOO-""W^J1VFM:'K>AQ^'[@7.GRFWT]
M)K2X76IM0\/)^T!^SA^SW\5OA+^S]^UE^S-8I\ ?AK\6?B]I_P"SS\7?A_X[
M\5W_ (A\-?!/XG7$0OE\2Q>-M<N'U&\\!W&@Q7GB#5K_ %%[6#2[-+"=(-).
MHRZ#HPN*<%]=EAI87'1PBQ^(RJ.;.G0> GF>$ISJ5\'&,,1+&J472K4(5I8.
M.'J8JC5PT*KJ^S50?AQFW]D0Q\,QR>IF;R; <25.&57QD,[H\/9G7H4<%FTY
M5<#3RB5.K#$X7&5,)3S2>/H9;BL/CZN&CAW7E0_*:BOVH\8>+O\ @F5\,_B]
MIO[*_AO]EH_M"^ [34_#/@S7_P!J#PY\;_$]UX_\7>)=:AT^*Y\8^ =.\'1S
M>%+^V\.ZAK6HVEMX;TN;^P_%]YIUA&\*PV<)O_F;XW?\$]?BCH'[9/QR_96_
M9^TG4_B]<?"O3(?'MJ\VJ^%]*UJW^&NK:5X/UVPN]>N-4U#P_I=QK&AP>//#
M^B:PUC#8OJNH>9J^FZ)9Z7<QPVQ@^*<'B*BAC<+C,EA5R^>:X6MFSP6'HXC+
MJ=7#T9XARIXRL\)*$\7A?:8?'1PN(@L13O3YU5A2>:^'&:X*A*KE.8Y7Q;4P
M^=TN&LPPO#$<VQV*P.?5\-CL71P$:>(RO"+,X5J669BJ..R:>8X&K/ U^6O[
M.6&JXC\\**_3']CWX#?!2P_9X^/'[;/[2WA+4_B3\-_A+KNA?#;X<_"73/$>
MH^$[?XF?%C7TTZXGL_$7B+1S'J^E:'X8T[7?#^K3BPE#7EO>7\\D=Y_94>B:
MWU?Q@^%_[-W[2O[(_C3]KO\ 9N^%<W[/OCGX#^+?#'AW]H'X/6?B?6?%_@S5
M=$^(6JQZ5X6^('@F_P!<E:]TK?K5S'87'ARUM;*PL;&WU,&T5=&AUKQ%53B;
M"4\PG@WA,=+#4LPP^48C-H0P[R^AFN+A0EAL%4OB5C).I+$X:A*O3PD\+3Q6
M(I8>I6C4]HJ>>'\/,SKY)2S59GD]/,,3D6/XHP/#56KCHYYC>',KJXNGC\VH
MVP$LKA"C3P&/QE/!U\SI9AB,OP.)QM'"SHJBZ_Y1T5^\G_!,'_@GQ\'O%OBW
MX8_$#]K/Q#X&U-?B_HFN:A\ OV=!KIU3Q3\0+33](UK4]1^(7C33= FDFT+P
M7H^E:#K+:-;ZC<VD6J:_##;ZO<:?<0:9H7BC\&ZZ<NS_  .:9CFF78-U:D\I
MA@Y8C$.#CAJL\75Q]'DPM1O]_P#5ZN7UJ5>I!.E&LI48SE4I58P\[/>"LYX<
MR'AO/LU6&H4N)ZN:0P6!593S##4LLP^38I5LQH136">-P^=X3$X/#UI+%3PK
MABJE&G0Q&%G6****]L^1"BBB@ HHHH _J&_X-U/^1=_:Q_[#7P:_](?B97]*
M5?S6_P#!NI_R+O[6/_8:^#7_ *0_$ROZ4J_C#Q4_Y+WB#_'E_P#ZJ< ?ZS_1
MN_Y,KP1_UZSW_P!:?.@HHHK\^/W$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _P \+]M?_D\O]K;_ +.;^/7_ *M3Q77S)7TW^VO_
M ,GE_M;?]G-_'K_U:GBNOF2O[_R?_D4Y7_V+L%_ZC4C_ !$XH_Y*;B+_ +'N
M;_\ JPQ 4445Z)X04444 %?TA?!+XX6OP&^'7_!$CQ#KES%#X)\:1_MB_"?X
MA07D]O;Z1<^$OB3\4O!7AMYM>DNO]&.B:%KMSH7BK44GQ$T6@?.=N:_F]KW[
MXD?M&^-_BC\&?V?O@;K^E^%;/PG^S?;?$>U\#:CHUEJ]OXBU6/XG^(-+\2:^
MWBN[O=<U#3;Y[.^TFVBT<Z1I&A+;VCSI>KJ$S1SQ_,<2Y&\^658::B\)3Q>8
M/'-R2G##8SAW.\KC4I+1RJPQ./H2CRM2C9U%).!^A^'W&,>"Y<1YA3E4CF=?
M+,C63QC!RI5L?E7'?"'$<Z&)DKJGAZN R7&PJ.<90J75"49*K8_5'XG_  5N
M?^"=?[-_[>-K-'<V?BOX[?'2W_90^#EY?/;_ -OCX":9:?\ "S?$_BM;CRU7
M4M'\>>"=8\/^$/$B6J(MEK\=NCLCQ*C>X?'?]G<?M+_\%U-2\%:GIZ7_ ()\
M,0?"GXG?$D7%O#=:<O@GP'\+_ FJW-AJ\,[*C:5XHUQM!\%7; ,8QXF20@*C
M,OY#?M:_MR_'#]M!?A@OQB;PJB_"GP]>Z'H:^%=,U33%U:\U9=*77/%/B(:G
MKFMB[\2ZXNAZ2NH3Z=_96DJME&+'2+(/-YGJVN?\%//CUK7CK]IGXEKX.^#N
MC^.OVIOAQHGPK\9>)M&\.^,;?5?!OA+1_"S^$YH/AG=W7CZ]F\/WFN6*V5]K
M5UJS^(O,UC2-(U#3H]-;3X(Q\E#ASBI45CYRPCX@QN4Y[@L?B85_W>'Q.8U.
M&<OP5>A*2C*<,-EN3UL:X))+%\T+2E6<Y?IU7CWPWEBI9+2IYG'@;*.)^#,X
MR;+JN#7UC'9=D=#Q!SO.,'BX0G.G2JX_/^*<)D\:LI3;RQ0J\U.GA(4J?Z:>
M'/V@OV/XO^"BD_[9R?\ !0V:XU/Q!XFN/#L_PXN?V6_BGIOA>3X>W^CQ>!]+
M\%7?C=O%\5A#9Z3I4&E:G_PED^@Q:5)XFTR/Q?>Z$(WGL3%^S1\(M#_8O_X+
M4^*OA+>V5KH7A'XK>%_B#)\$M0:&"VLM+T3Q_8'QIX;M=#>\DE6.31+CPUXB
M^%MD]PKR:EJNFRV<4,XU"#S?YM*^OOC[^VS\8?VBX?@)=^-;7PGH_C7]GGPQ
MIWA?PE\4_!UMXFTGXE^((-'_ +$GT;5_&7B2^\5:NM_KVD:KHTFOZ=J6BV/A
M\VNN:YKVH1PA[Z-+;IQ7 ^*@Y8'!YCB<3EN8\-XGAO&O&1RZG+ T<+2Y\BQ&
M'I9?@<OCB8X6M/$T*L*_M:LJ6)?[SE3MPY;XQ9=55/-\TR# 8'/\AX^R_C_*
M%E53/L13SG%9CB8T>,L%C<1GF<YW++YYEA*6 QF'JX/ZMAH8G+U^X<YPOQ7@
MZR\)?L__ +06HZ!^U%\%[[XIZ1\/=<\7^%OB!\)SXVUSX?W>H:_8VNJ:-;NG
MC#PT3JEO%I>O?9-9AGL7>VUFUM4C\V6QO=[_ * ?M%?#[]D#QW_P3ST[]JGX
M!_LPWO[/?BE_VG+'X0O'>_%WXE?$QM1\/VW@;6?$&H7,$GBS5_['6"]U%[*W
MW0:(;RUGT>>./4=EQ<VXY2'_ (*N>*?%FGV<W[0O[*O[)7[2GCW2K%+73_BE
M\2_A-I;>-+Z2UB>+3F\53:>(],UNQLT=8FTK3M/\/V=S## 9%%W']L;YK_:=
M_;N^/O[5FF>'_"7CF_\ #'A#X6^$6M)?"7P:^%GAY/!?PP\.W%E9/I]K=6>A
MI=:A?WMQ:VDMQ!IS:UJ^J)HT-W?6^AQZ;;7UW#-WRPG$F8YGE.(Q&#JY3/ U
M\/+,<3AN)<;/*\;AL/[5U:&%R:@X4:[Q52HFZN88;#UJ=&,83G4=.$3Q(9IP
M!D7#W$V!P.:X;B6EG.#QT,AP&/\ #[*:7$>48_&O#1P^+S#BO&*KB\$LMP]"
M45ALCS#'86OBJDZM*EAU6K5#]:?VS/VO-+_9[\(_L0^%+[]E?]E/X[2ZQ^P]
M\"O$*^)OCS\*;?Q[XGTJ.73+[31H6DZG-?VC6F@Q-IS:A%8!&5=0U#4+C?FX
M('Y7?&W]K/PG^TA8^"?!.I_LT_LL?LXZ)8^.]'U?7_'G[/\ \($\'>+6T1H;
MO2=3M-1N;.[U&XU71K:TU.763I$5J\ESJ>F:=)&KO$L;^X6?_!63XGGPC\//
M"'BO]E_]B;XF1?#'P#X7^&WAG7_B=\%/$/C/Q.GACPCID.F:9;W.JZE\1]JO
M(L3WMW%I]MI^GOJ%U>7-O86PG,8\A^./[>^L?'+X;:Y\-;O]EG]B_P"&4&N3
MZ1</XR^#_P $+KP7X_TPZ1JUEJZQ:/XBE\8ZNEE#J#60T_5$-A-]KTRYN[4-
M$9A*GGY!P_C,LE@X5^'%]8I8FLZF;4L^;4(U\36E]:A@97I2=.C5O[%P:E*-
MK79[?&O&^5<00S2K@^/)/ XC 814>&<3P8DZM3!X#"0_LZKG$.3$0AB,5AG%
MXI5HN$)WYE%6/1OC!\"_^"8OAOX9^,M<^#_[<'C_ .(GQ,TS1Y+GP;X(U/X)
M>/\ P]8>)-86:%8].NM;U/P'IMAIL3PM-(;BZO[6)3&%,H+ '[R^/GP@_9Y^
M#/[%O[+7[%/QT_:?G_9E\;76GI^TS\6O#]G\ _%_Q7UOQ7XO\;+JVG:-;:_>
M^$_$&@V6D#P*O]N^#&M;R;4YM;'AK0[_ ,NR71K2:]_G[\$>*&\$>,_"7C--
M#\/^)Y/"7B70_$L?ASQ79W6H>%]>DT+4[74TT?Q'I]E?:9>7VA:D]J+/5K.V
MU&QFNK":>".[@:02KZ=^TI^T3\0?VJOC'XJ^-_Q._L>'Q7XK71X)]-\-V^HV
M7AK1K#0M&L=$T[3- T_5-4UJ]L;".UL$N)8IM3NY+C4;F^OYYI+F\F=O3Q7#
M.:8C&950EG^;5L!@*^)S6IC\2\FJX]9C&C3PF7X:A1641P;PU*G6QV*J3Q&#
MKS5=T94YQJ1A.E\]E_B#PY@LJXEQ=/@KAC"9UG.#R_AJCDN7QXLPV2RR*>*K
M9IG>88S%/BFIFRQ^)Q&$RC+J-+ YIA*4\&L7'$4ZE&I5IXC]J?VW?A+\.?VK
M?V6/V0/C_P##/XWZ)\2;3X2^)_"?[(GQJ^/VM>$-:^'<5MX9U#4=&TWPWX\^
M(FA^+]<N[[P_:>"]3U:WO=?FNM8DCU2[^)+Z[#/9:;<B*Q]T7X*>%-;_ &CO
MV*/!/P+_ &Q/V'U_9@_9=\??#F\^'GPHT[]I+2=:^,/Q+\6GQ'INM>.O&VK^
M&] \,2Z1X@^*?CC67O++1M)L]<DTNUC=8=%_L4Z[J]JWX,_!C]L'XF?!/X*?
M'?\ 9^T?0_ OB_X9_M Z7;V7BC1_'FF:_JQ\-ZG:V-[96_BOP.ND^)]!LM(\
M4Q/-I6H+J6IV.MP_VCX6\+W!L]NEF*X\5^$?Q+UWX,_%'X>_%KPO::1?^(_A
MMXQ\/>-M"LM?@O+K1+O5?#>IVVK6-OJUMIU_I=_/I\MQ:QI=Q6>I6%S)"76&
M[@D*R+Y,>#,XC@\5@%FLOJ^6U,Y_L%5J&#KQQ%+.,/SN>)A&GAZ>&Q>$K8C'
M8&C5I48TJ.#Q$_JU*E&;BOJ)^+'"L\TR[.I<.1^NY_1X3_UT>%QF:X2>!Q/"
MF.5*-+ 5JE?'5\QRS,L-@<GSG%8?%8JIB<5FN!IRQ^)Q%2G&H_K+_@I7\*[;
MX8_MA?&RXM_B7\,OB-_PL;XG?%/XD3P?#?Q/'XDN/ -QXD^*'C)Y/A_\0(T@
M@_X1_P"(/A_R GB'P\YF?3WFA5IGW@U\D?%+XG>,_C/\0O%GQ2^(>J1:UXV\
M;:K)K7B/58=/T_2HK[498XH7F33M)M;+3K13'#&HBM+6&(;<A-Q),?Q1^(.L
M_%KXF?$3XJ^([;3++Q#\3/'7B[X@Z]9Z)#=VVC6FL^,_$&H>(]4MM(M[^]U*
M^@TR"^U*>*PAO-1O[N*T2)+B]NIE>>3A:^[RG U,)@,LIXQT\1CL'@(826)]
ME3A-*4:#K4J;@K1IREAZ"FHM1JNA2G).45;\8XESBCF>=<08C*X5L%D^:YU6
MS.GE_P!8KU*4I0J8M83$5HU7>=>%/&XMTY5$YX=8S$4:;4)RYOT._8(#_#O3
M/VJ_VII%NK:3]GS]GCQ-I7@G6K201S:-\8_CY(/@Y\.[I%.5F\FPU_QEJ+1$
M,?*TR20!1&TL?YXU[MIGQTU+1OV</%7[.VE^'M.LK/QO\6O#7Q/\6>-8+N\3
M7=;L?!WAG5]#\->!KRS4BPE\/:7J>O:IXHB>0/<G6)863RXX/WGA-+ X6M#'
MYOC<1%1EB\1AJ.%]Z,I++\%A8*E&7*Y6YL;7S&O&+LXPKQ4HJ7,W6<9EA*N3
M<+Y1@:CG3RW!8_&9C[DZ<99[FV8598J<%.,'+DRC!Y#@IU$I1G4P4W"I*GR*
M/[F_ WXR2_ W_@D!<^,8?AC\&OBR]S^W->Z#_P (S\<OA_9_$CP= M[\)-.O
M#J]MH%]=6<,.O6ITX6UEJ8E,EO9WNHP*A%VQ7O?^"9G[:EW\6_VW?@G\/I?V
M6OV*_APGB#_A9&[QG\)/V>-$\"_$'1O[*^$?CW6Q_P (_P"*K35KFXTO^T3I
MHTK5?+@?[=HE]J6G/M2\9U_'S_AI?QW_ ,,N_P##)7]D^$O^%<?\+B_X7;_;
M7V#6/^$V_P"$K_X1G_A%/[/_ +2_M[^PO^$>_L[]]]D_X1O^TOMO[S^UO(_T
M:LS]FK]H+QG^RS\;/!?QX^'VF>&-8\7^!?\ A(_[(T[QE9:KJ'ANY_X2?PEK
MW@V__M*ST36O#VIS>3IGB&]GL_LVL6?EW\5K+-]HMTEM9_D,9P;'%Y7Q=&KA
M*-3,\VK9[4RRJ\14C'_;,(Z>!=3EFJ=-JM9S4H2Y5K+F6A^HY5XK5,LXB\+Z
MF'S/%T>'>&<+P;A^(,/' T)SME691KYS&@ITI5ZREADU2=.K!SEI3Y'J?J#\
M+_\ DS+_ (+/_P#93?@U_P"KR\3U^)5?>/[/O_!07XG_ +/*?'2TTCX8? ?X
MD:+^T-XDTGQ/\0/#/Q>\%>(?&'AIKW1=4U_6+"UTW1K7QIHEH=/CU#Q#<7(A
MUM=;E26RTV:&XBGMGEG]3O?^"I&OWULUL_[$7_!.VV5Y()#-8?LXZI8W:^1<
M17&V*[MOB-'<0"4Q>5));R13B)W$4L4A61>S 4,_R?&9Q[')J6/P^88[!XNE
M7CFF'PSC&ED>4Y=5A*E5I2ES1K8"K)/F2E&46K'DYUB^"N*<IX56*XKQ&38[
M(\GS7*\1@Y\.XW'QJ3Q/&'$V?8>M3Q5#$4X<D\)G6'A*/(Y4ZM.HFWH?='Q\
M^$'[//P9_8M_9:_8I^.G[3\_[,OC:ZT]/VF?BUX?L_@'XO\ BOK?BOQ?XV75
MM.T:VU^]\)^(-!LM('@5?[=\&-:WDVIS:V/#6AW_ )=DNC6DU[@_MZ_#[X6_
MM%?L@_LJ_M0> _B]_P +@T7X#ZKH/[+WQX^-%IX!\2>#]?N_!T<^EQ:)XK\2
M>#_$.H:YK=CJ'AF]OXI+FV6YU*;Q!K/Q.BU6RBCLKV.TM/QG_:4_:)^(/[57
MQC\5?&_XG?V/#XK\5KH\$^F^&[?4;+PUHUAH6C6.B:=IF@:?JFJ:U>V-A':V
M"7$L4VIW<EQJ-S?7\\TES>3.W;_!C]L'XF?!/X*?'?\ 9^T?0_ OB_X9_M Z
M7;V7BC1_'FF:_JQ\-ZG:V-[96_BOP.ND^)]!LM(\4Q/-I6H+J6IV.MP_VCX6
M\+W!L]NEF*X\NAPEG6$H9/F<<SKULZPV:3S3,,$_[.A@7+.JDH9]2PV(CE\,
M;-TZ&(F\)]:QE>@Y8/#)48QA0C2^CQGB=PCF6,XIX?J</83!\(X_ARCPYDF;
MQ_M^OG"I\)4:57@O$YC@)YY4RBDJ^-P-)9I_9N5X/&*GFF/E+%3G6QE3$_1O
MQ@^!?_!,7PW\,_&6N?!_]N#Q_P#$3XF:9H\ESX-\$:G\$O'_ (>L/$FL+-"L
M>G76MZGX#TVPTV)X6FD-Q=7]K$IC"F4%@#]Y?'SX0?L\_!G]BW]EK]BGXZ?M
M/S_LR^-KK3T_:9^+7A^S^ ?B_P"*^M^*_%_C9=6T[1K;7[WPGX@T&RT@>!5_
MMWP8UK>3:G-K8\-:'?\ EV2Z-:37O\_?@CQ0W@CQGX2\9IH?A_Q/)X2\2Z'X
MEC\.>*[.ZU#POKTFA:G:ZFFC^(]/LK[3+R^T+4GM19ZM9VVHV,UU833P1W<#
M2"5?3OVE/VB?B#^U5\8_%7QO^)W]CP^*_%:Z/!/IOANWU&R\-:-8:%HUCHFG
M:9H&GZIJFM7MC81VM@EQ+%-J=W)<:C<WU_/-)<WDSMZ>*X9S3$8S*J$L_P V
MK8# 5\3FM3'XEY-5QZS&-&GA,OPU"BLHC@WAJ5.MCL54GB,'7FJ[HRISC4C"
M=+Y[+_$'AS!95Q+BZ?!7#&$SK.<'E_#5')<OCQ9ALEED4\56S3.\PQF*?%-3
M-EC\3B,)E&74:6!S3"4IX-8N.(IU*-2K3Q'[ ?\ !1;P/X%^/W[$7[./[5GP
MA^)L7QXF_9]2T_9F^+GQ2B\%:_X#UG7]&M(;'_A$=:\4^&O%&JZKJNCW>C:U
M>VD5Z)+^];6=7^*<>M6OD:?=);6?X>7/Q'^(=Y!>6MYX\\9W5KJ/A;2? VH6
MUSXHUR>"^\$Z#=6-[H7@Z\AEOFCNO"VBWNF:;=Z3X>G5])TZZT^QN+.TAEM(
M'C]Z^#'[8/Q,^"?P4^._[/VCZ'X%\7_#/]H'2[>R\4:/X\TS7]6/AO4[6QO;
M*W\5^!UTGQ/H-EI'BF)YM*U!=2U.QUN'^T?"WA>X-GMTLQ7'RE7H\-9/BLGP
MV+RS%N.+PF%S'$5<GQ554'7E@<7*GC'3K4Z-&C3HU<-C9XBG%4J5*C[*%#V-
M.G"$81\/C_BK+N*,?EG$.5JIEF9YED6!PO%678=XV&$IYQE<*N4QKX6OBL5B
M\1B\/C\HH8*O4EBL3B,5]9JXSZU7K5:LZD_UC_:!M)M>_P""2W[ 'B+3;DSZ
M9\/_ (K_ +1W@+Q+%;2)<06?B/QEXW\0^--#M]2:&8C3]0;0=+NKNSLKN$7-
MQ87;7T)CM9$-PVZTZ[\/?\$5]*?5TN+7_A/O^"@-SKWA1+F&2(:KI.F?!F?P
M[?WNFELBZL+;6?#.L64]W$!!%J4$]DY%RA#_ #9^SA^VKXO^ '@+QK\&M8^&
M_P +?CC\#OB'K5KXC\3?"WXM:#>ZII=KXBM[*'3)/$_A/4]+U+3-0\->*9]-
MM-/LQK2_V@UF--L+FPMK6^MDNZZ'XI_M^?$3XG?$_P"!GC;_ (5K\'O"O@/]
MFW4[75/@_P# /P[X8U+3_@[HEU;:W;Z_-<ZOH6GZYI^I:S>:OJ-CIDNNR1ZK
MIEGJ(TZ%%L+:.ZU-+_Q_[(SJG6C@88.C/ X7B?,.)J>.^M4HO$4\17QN9TLN
MC0<76IXJ68XSZO4K5%]7IX6FZL:DYRC17U'^M'"-?"5,XJYIBZ.<9CX>9'X?
MXC)_[-Q%18+$8#!Y1P[BL]GC8S^JU\OAD65+&T,+1E]>K9C6CA9T:5*$\7+Z
MB^"OPD\ ?\$Y] \/?M1_M::7:ZK^TG?:0_B;]F/]D[4K>WN->T34I[>X7PK\
M9OC1IKWL-WX3TK2=8M;C^Q-%O8;;Q!INM:=)=6D2^,-#GL_"WYPZI^TQ\?-1
M^*_CWXWVOQ;\?^&?BA\2Y=5_X3+Q=X+\6:]X.U75M-UB[LKRY\.R77AW4-.F
M3PK"VF:1!8^&ED_L:QL]&T>TMK..#2[)(?O_ ,6?\%A/B?X]UV[\4>.?V1/V
M!?&GB6_2VCOO$7BSX!>(?$6NWL=E;16=FEWJVL?$V\U"Y2TLX(+6V6:X=8+:
M&*"()%&B#YP\,_MV>+/"/Q^\??M!:'\!OV7[/5?B#X 'P\O/AM%\+M2M_A#X
M>L-OA,2:[X3\'6?B^VN=)\43/X1MIIM4EUJ]ADFU;79&LLW\?V:\JPF?*>88
M_.LBP^,S7%X50<YYEA98-4J=:$J.48*@Z%1X7!1<ZE>=:LZU7$UZ?M<0Y2E1
MA1SXDS/@QTLCR7A/C+'95PUEF9NM&E3X?S&GFKQ-?"3I8KBG-\7'&8>.99M-
M4J6#H87#+"X?+\'6>'P,80CBJN+^@/ MI-XD_P"",?QML=+N2US\.?VWO"GC
M[Q1:6TB330^'/$_PY\(> M(N-2MHIEFL=.NO$4Z1V=]=1/:W=_9M:6X:X@ED
MMV_LHZ?=:/\ \$QO^"F_BK44N+;0_$NH_LN>$-$NY89%L[_Q%HGQ(O+_ %33
MK&<YCN;ZULO%6B75_;Q+YEG9W-K=7!$$J,OR1^RY^UW\0OV5;[QU#X9\.?#[
MXA^!OBGH5EX<^)GPM^*WAMO%7@'QIINF7%S<:5)JNE0WVFW!O]':_P!3&ESB
M\:UB_M.\%Y8WT;K&O6_M&_ML>)?CK\//"'P3\*?"_P"&/P!^!G@O6YO%.G_#
M'X4:7>V5EKGBV;3ETM?%7C/6-2O+N^\2Z[:6)NK6TOY4M)6AO9FU,ZG=Q6EW
M;NODV;RQ6,RZ&'HRRW'<49;Q"\S^L4XNAA\%7RS,*^"GA&O;RQ53&Y:Z5"I#
MGH/#XA5*DZ<J7LIK!<5\+T\NRO/:V.Q4.(<G\.\_X&CP^L#7G#&8[-L%Q!D6
M#S:EF2E]4IY=0R?/EB<70J^SQ?U[!2HT*5>GB5B:7O/_  1@9F_X*)?!8LQ8
MC1?BHH+$DA4^$_C%$7)SPJJ%4=%4 #  %?E?7OW[,?[1GC?]E#XS>&/CE\.]
M+\*ZSXM\)VWB"TT[3O&ECJ^H^'9H_$GA_4_#=\U[::'KGAS4Y'BL=5N);0P:
MO;+'=I#),L\*O!)X#7T6'P->EQ!FN8R45AL7E61X.BU).;K8#%9]5Q"E#>,5
M#,,-R2?Q-S2^!W^"QV<8+$<$<-Y%3E4>897Q+QCFF+C*FU26$SK+>"\-@90J
MWM.<JN1X]58))TU&E)W]JK%%%%>T?)A1110 4444 ?U#?\&ZG_(N_M8_]AKX
M-?\ I#\3*_I2K^:W_@W4_P"1=_:Q_P"PU\&O_2'XF5_2E7\8>*G_ "7O$'^/
M+_\ U4X _P!9_HW?\F5X(_Z]9[_ZT^=!1117Y\?N(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!_GA?MK_ /)Y?[6W_9S?QZ_]6IXK
MKYDK^FK_ (*%?\%6?VB/V:_VP/B[\%? O@OX%ZMX5\%_\(#_ &5J'C+P)K6L
M^)+C_A(_AAX*\67W]I:E:>,-*M[GRM1UV\@L_+L(/)L(K6W?S7B::3XP_P"'
MYG[6W_1.?V9/_#8>(O\ YX%?V?D><\55\ERBOA^%L!4P];*\OJT*D^)52G.C
M4PE&=*<Z?]C3]G*4)1E*'-+D;<>9VN_\F.+^$_#;!<6\48/'^)&=4,=A.(L[
MPV,HTO#Z>(I4<70S/$TL12IUUQ73]O3IUHSA"LJ=/VD8J?)'F43\9**_9O\
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MW_1.?V9/_#8>(O\ YX%'_#\S]K;_ *)S^S)_X;#Q%_\ / H_M3C#_HD\N_\
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M\*_^CF9]_P"*YG_]%W]6?E?\9**_9O\ X?F?M;?]$Y_9D_\ #8>(O_G@4?\
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M5V^J1W^O:XUU-')IT"VSQO;B)'F5DD+@K^RE?RGXC5<76XSSJICL+3P6+E+
M^VPM+$_7*=)K+,$HJ.)5'#^UYH*,V_8PY7)PL^7F?^E?@+A\LPOA-PEA\FS*
MOF^64Z><K"YCB<O>55\3&7$.;3J.IE[Q>.>'=.M*I12^M5O:1IJK>/M.2)11
M17Q!^OA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB[\/0:OX5\*>(+OX3:MH?C*7P_K>G7.KZ:T'B[3VM3J^I): 06FI\N<YKGF
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M+_PR9E_\S!_Q%+PR_P"CB\"?^)=P_P#_ #P/TVHK\R?^'QO_  3A_P"CC/\
MS$7QW_\ G84?\/C?^"</_1QG_F(OCO\ _.PH_P!4.+/^B7XB_P##)F7_ ,S!
M_P 12\,O^CB\"?\ B7</_P#SP/TVHK\R?^'QO_!.'_HXS_S$7QW_ /G84?\
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M (G_ /SGJ]K_ %_X,_Z*'+__  .I_P#*SY+_ (@5XN_]$%GW_@FA_P#+_/\
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M+3&D: 6.!_PX9_:^_P"BC_LW?^%?\3__ )SU'_#AG]K[_HH_[-W_ (5_Q/\
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M&?VOO^BC_LW?^%?\3_\ YSU'^O\ P9_T4.7_ /@=3_Y6'_$"O%W_ *(+/O\
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M .5A_P 0*\7?^B"S[_P30_\ E_G^?9GXF45^V?\ PX9_:^_Z*/\ LW?^%?\
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M[M=3L^V+[*_X<,_M??\ 11_V;O\ PK_B?_\ .>H_X<,_M??]%'_9N_\ "O\
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M/_\ G/4?Z_\ !G_10Y?_ .!U/_E8?\0*\7?^B"S[_P $T/\ Y?Y_GV9]I_\
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M_%;_ ()J?LJ^/_V:_B?^T;^P;^TGXG^*FE_ VTU[4?B5H/Q(TF>TEN=/\,:
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MG+L7AY3E3<Z.,RZO7IJ4*L)TZE*K[*M"4;RI\DJ<YE%%%>J?-A1110 4444
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M3^T!HG[9?_!5/]H"]T _"GQA=7W[*/[!'@WX<?''QE\(O@FNA:M'=>'?BO\
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M_@NUU.?QOX?TVSMF-UJ%]K?AVPMM-M8YKF_EMH()I(_*O@9^S/\ '']I2_\
M$VE_!'P%=^/+_P ':/'K_B6WM-7\.:0=+TB:9K>.\D?Q%K&CQ3JTR,@BM'N)
MP1DQ!<&O0@^$JF'KXRF^':F$PL_98G%0_LR6'P]3FC'V=>O&]*C/FE&/)4E&
M7-**M=I'B58^)]#'X+*JRX\HYGF-%8C+LMJKB&GC\?A^2515\%@YVQ&*H^SI
M3J*K0IU(<E.4N;E@VNF_X;7_ &R_^CMOVF__  _7Q4_^:NC_ (;7_;+_ .CM
MOVF__#]?%3_YJZV]0_8/_:_TOX01_'F^^ /CR'X62:5'KQ\1"TL9KR'P_+ E
MVOB*[\*P7TOC"R\/"RD74)->N] @TB+3LZA+>I9*TZ^.?"/X'_%[X]>)CX/^
M#7PY\6_$?Q%' MW=V'A;2+G45TNQ>>.V74M;OD5=.T+2_M,L-L=4UF[L=/6X
MFA@:Y$LL:-4(<+5:.(Q%*'#]3#X2<J>+KPCETZ.%J0MSPQ%6*<*,X77-&I*,
MHW5TC*M6\2,-BL#@<15XWP^-S2E3KY9@ZT\^I8K,:%57I5L#AYN-7%TJJ5Z=
M3#PJ0FE[K=CTC_AM?]LO_H[;]IO_ ,/U\5/_ )JZ/^&U_P!LO_H[;]IO_P /
MU\5/_FKKG_CQ^R[\?_V8]9T[0_CM\+O$?P\O-9AEFT:ZU$6&I:%K*V^S[7'H
M_B?0;W5O#>JW-B)8&O[33]6N+JP6YM7O(8%NK<R^"5T8; Y!C*%/$X/!Y/BL
M-53E2Q&&P^"KT*D4VFZ=6E"=.:333<9-736Z.''YSQME6+K9?FF:\4Y;C\-)
M0Q&"Q^.S;!XO#S<8R4:V&Q%6G6I2<7&2C.$6XN+2LTSZ;_X;7_;+_P"CMOVF
M_P#P_7Q4_P#FKH_X;7_;+_Z.V_:;_P##]?%3_P":NOF2BM_['RG_ *%>7?\
MA%AO_E1Q_P"M/$__ $4>??\ AWS#_P":/)?<?3?_  VO^V7_ -';?M-_^'Z^
M*G_S5T?\-K_ME_\ 1VW[3?\ X?KXJ?\ S5U\R44?V/E/_0KR[_PBPW_RH/\
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MRQ^Y?UT7W ?#G_#L3_@FM_TCT_8<_P#$3?@)_P#,!1_P[$_X)K?](]/V'/\
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MTZQT/5K3PZ]MI>INUZFFG4I9H[B]EBCE.-N;V>FFMH]7%+1-OS]$O(#](?\
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M/3]AS_Q$WX"?_,!7W'11RQ_EC]R_KHON ^'/^'8G_!-;_I'I^PY_XB;\!/\
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M[#G_ (B;\!/_ )@*^XZ*.6/\L?N7]=%]P'PY_P .Q/\ @FM_TCT_8<_\1-^
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M?\$UO^D>G[#G_B)OP$_^8"C_ (=B?\$UO^D>G[#G_B)OP$_^8"O3_@-^U_\
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M<E5)3DDK+31?X4!_F3T445_H8?X3A1110 4444 %%%% !1110 4444 %%%%
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M>%'^&VDVPOM'O(?'^C:IXCCU:[F_'SQ'\??VQ_VB/^"??_!"7XC6VKVWCO\
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M2L[:/1]UW?GO?N]>H!1115 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^%/_!:]$C\6?\ !'F.-%CCC_X+%?L<(B(H5$1=2\1*J(J@*JJH 50
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M:Z7>Z5JEYI]TG[I^$O\ @B)\.IO%?PBG_:(_;!_;-_:_^$G[/GBK2_&'P:^
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M2\^L'\IJZ>N8\-]+SZP?RFKIZXZO\27R_P#24!_GA?\ "*?L:?\ 1>OVF_\
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M&O7S)175]2Q/_0XS'_P5E/\ \ZSS?[7R_P#Z);(?_"CB?_Z(_P"KORM]-_\
M"*?L:?\ 1>OVF_\ Q$GX5_\ T:]'_"*?L:?]%Z_:;_\ $2?A7_\ 1KU\R44?
M4L3_ -#C,?\ P5E/_P ZP_M?+_\ HELA_P#"CB?_ .B/^KORM]-_\(I^QI_T
M7K]IO_Q$GX5__1KT?\(I^QI_T7K]IO\ \1)^%?\ ]&O7S)11]2Q/_0XS'_P5
ME/\ \ZP_M?+_ /HELA_\*.)__HC_ *N_*WTW_P (I^QI_P!%Z_:;_P#$2?A7
M_P#1KT?\(I^QI_T7K]IO_P 1)^%?_P!&O7S)11]2Q/\ T.,Q_P#!64__ #K#
M^U\O_P"B6R'_ ,*.)_\ Z(_ZN_*WTW_PBG[&G_1>OVF__$2?A7_]&O1_PBG[
M&G_1>OVF_P#Q$GX5_P#T:]?,E%'U+$_]#C,?_!64_P#SK#^U\O\ ^B6R'_PH
MXG_^B/\ J[\K?3?_  BG[&G_ $7K]IO_ ,1)^%?_ -&O1_PBG[&G_1>OVF__
M !$GX5__ $:]?,E%'U+$_P#0XS'_ ,%93_\ .L/[7R__ *);(?\ PHXG_P#H
MC_J[\K?3?_"*?L:?]%Z_:;_\1)^%?_T:]'_"*?L:?]%Z_:;_ /$2?A7_ /1K
MU\R44?4L3_T.,Q_\%93_ /.L/[7R_P#Z);(?_"CB?_Z(_P"KORM]-_\ "*?L
M:?\ 1>OVF_\ Q$GX5_\ T:]'_"*?L:?]%Z_:;_\ $2?A7_\ 1KU\R44?4L3_
M -#C,?\ P5E/_P ZP_M?+_\ HELA_P#"CB?_ .B/^KORM]-_\(I^QI_T7K]I
MO_Q$GX5__1KT?\(I^QI_T7K]IO\ \1)^%?\ ]&O7S)11]2Q/_0XS'_P5E/\
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M4?4L3_T.,Q_\%93_ /.L/[7R_P#Z);(?_"CB?_Z(_P"KORM]-_\ "*?L:?\
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M_P#Q$GX5_P#T:]?,E%'U+$_]#C,?_!64_P#SK#^U\O\ ^B6R'_PHXG_^B/\
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M_P"C3?V'/_%A?Q[_ /I8E'_"?_\ !2G_ *--_8<_\6%_'O\ ^EB5]QT46?\
M-+_R7_Y'^KORL'PY_P )_P#\%*?^C3?V'/\ Q87\>_\ Z6)1_P )_P#\%*?^
MC3?V'/\ Q87\>_\ Z6)7W'119_S2_P#)?_D?ZN_*P?#G_"?_ /!2G_HTW]AS
M_P 6%_'O_P"EB4?\)_\ \%*?^C3?V'/_ !87\>__ *6)7W'119_S2_\ )?\
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M]_\ TL2C_A/_ /@I3_T:;^PY_P"+"_CW_P#2Q*]&\:_M=?!SP!^U'\%_V/\
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MX6\)7GBY8-?T8>(O$?AB*P\5:=8WUGI=_P"&+KPK=:3J\*7.IZ2=/A-CJ/\
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M2-?P?FW_ "-<S_[&&-_]2:I_MUPK_P DQPY_V(<G_P#5?APHHHKSSW@HHHH
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M\%!?B'\>?^">GBW]A/P5_P $X/VT;+]LKXC?L^V7[->H_![Q!^S7K'@WX2>
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MD_M-_P#AA?BI_P#,I7S)11[+-O\ H-R[_P ->)_^? ?6.&/^A1GW_B1Y?_\
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M_P ,+\5/_F4H_P"&*/VR_P#HTG]IO_PPOQ4_^92OF2BCV6;?]!N7?^&O$_\
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M_AKQ/_SX#ZQPQ_T*,^_\2/+_ /Z%O7^EK]-_\,4?ME_]&D_M-_\ AA?BI_\
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MN.BCWN\?_ 7_ /)>O]+4/AS_ (>=_P#!-;_I(7^PY_XEE\!/_F_H_P"'G?\
MP36_Z2%_L.?^)9? 3_YOZ^XZ*/>[Q_\  7_\EZ_TM0^'/^'G?_!-;_I(7^PY
M_P")9? 3_P";^C_AYW_P36_Z2%_L.?\ B67P$_\ F_K[CHH][O'_ ,!?_P E
MZ_TM0^'/^'G?_!-;_I(7^PY_XEE\!/\ YOZ/^'G?_!-;_I(7^PY_XEE\!/\
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MM0^'/^'G?_!-;_I(7^PY_P")9? 3_P";^C_AYW_P36_Z2%_L.?\ B67P$_\
MF_K[CHH][O'_ ,!?_P EZ_TM0^'/^'G?_!-;_I(7^PY_XEE\!/\ YOZ/^'G?
M_!-;_I(7^PY_XEE\!/\ YOZ^XZ*/>[Q_\!?_ ,EZ_P!+4/AS_AYW_P $UO\
MI(7^PY_XEE\!/_F_H_X>=_\ !-;_ *2%_L.?^)9? 3_YOZ^XZ*/>[Q_\!?\
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M?IO['/\ P4._:)_8DDURP^%>H^'M=\$>)KP:IKOPX\>:;>ZOX2GUW[/;6/\
MPDFGKI6J:'K>BZ^=.M(+">[TO6+>SU2WMM/37M/U==(TA;'Z#_:=_P""QG[2
MO[1WPU\0?!RP\.?#SX/_  Z\46RZ;K]I\/[+71XFU?0Y/FU'PY>^(=2UJ>T@
MT+5GRFJ6NC:%H]UJ%B\^DW][=:5?:C9WGQ?_ ,)7^QI_T07]IO\ \2V^%?\
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M*_V-/^B"_M-_^);?"O\ ^@HH^NXG_H3YC_X-RG_YZ!_9&7_]%3D/_A/Q/_\
M0Y_5GY7^9**^F_\ A*_V-/\ H@O[3?\ XEM\*_\ Z"BC_A*_V-/^B"_M-_\
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MLOV'/_%>GQ[_ /IG=%W_ "R_\E_^2_JS\KA]QT5\.?\ " ?\%*?^CLOV'/\
MQ7I\>_\ Z9W1_P (!_P4I_Z.R_8<_P#%>GQ[_P#IG=%W_++_ ,E_^2_JS\KA
MZ_\ M3_LO_!W]LGX%>.OV=OCOX>F\1?#CQ_9V<.IPV-Z^EZWI.HZ5J%KJ^A>
M(O#NKQ))+I6O:%J]E::CI]UY4]M*T+V.IV>H:3>7^G7?YL>"/^"*7P__ .$J
M^#]_^T=^U]^V-^V-\-_V>?%NF^,/@Q\"_P!H#XBZ#K/PHTK6?#T%TGA'5O'^
MC:/X6TR_^)NN>$IKZ\&D7^M:E9Z?)H\@\(ZGHU_X-FU+0-2^R/\ A /^"E/_
M $=E^PY_XKT^/?\ ],[H_P"$ _X*4_\ 1V7[#G_BO3X]_P#TSNI:3=W!WTZQ
M[WVYK.S_ %^8=-X;_8L^%OA?]MCXA_MXZ?K_ (_F^+WQ+^">A_ ?7?#EYJOA
MV3X;VGA#0-;T/7[/4M)TB'PK;^)X/$DMYX?LX[F\O/&%_ICVTMTD6CPRO%-#
MSW[.?[!'PA_95^/7[27QR^#/BCXF^'=/_:EU^T\:?$3X%S:SX5NO@7I'Q#A$
M1U#XA^!/#H\&0>,/"_BCQ#</J]UXB6/QW>>']3DUVX@?0H['0_!EIX7B_P"$
M _X*4_\ 1V7[#G_BO3X]_P#TSNC_ (0#_@I3_P!'9?L.?^*]/CW_ /3.Z/\
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MI>0>; \-U974:N+C3]3L)[;4M*U"&UU+3+NTU"TMKF+\9Q_P0D^'NI>#M.^
MOC?]N3]O?XA_L;Z/=>'[BP_90\5_&/1)?!%QIWAJ_P!.O=%\!ZUXHT[P;I_B
MV^^%&B#1=$C\-> ["]T=?#4^E6FJZ/K%OK$4=_']Z_\ " ?\%*?^CLOV'/\
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MP^XZ*^'/^$ _X*4_]'9?L.?^*]/CW_\ 3.Z/^$ _X*4_]'9?L.?^*]/CW_\
M3.Z+O^67_DO_ ,E_5GY7#[CHKX<_X0#_ (*4_P#1V7[#G_BO3X]__3.Z/^$
M_P""E/\ T=E^PY_XKT^/?_TSNB[_ )9?^2__ "7]6?E</T,\-]+SZP?RFKIZ
M^9OV=- _:5T,>,/^&AOBS\#?BC]J/A__ (1#_A3'[//C[X#?V'Y']M?\)!_P
MDG_"<?M/?M'_ /"5_P!I^=HG]C_V7_PAO]A?V?JOVW_A(O[8M/["^F:Y*OQR
MTMMH[?RKLVOQ _@6_8V_X)V?M#_MLW-]J'PWTW1_#GP\T34?[*\0?$[QG>3V
M'ABSU...SNKC1-*M["UU#6?$.OQZ?>Q7OV'3M/.GVJR6J:UJ^C#4+&2X^R?C
M;_P0O_:1^'?@O5_''PL\=>!/CW:^'[&:[U3PSX4M]5TCQM<OI]LTFMVOAW1;
MA=3T[Q!=Z;<0W5O!I=OKL'B#5FCB@TW1)M5N$TI?KS]K37M=_9Z_X(E_LG>'
M_@QJ6H>%M+^+=K\)[#XB:KH5U<V5_>6?Q,^'_C'XK^.=+EU"&X&HPP>(?&4)
MT_53%.MK>:&M[X9N(QH^I_V<_DO_  34_8;_ &NK;X:>'OVC_P!F7]KCP%\(
M+[XP^&=<TW4O">J>%H_%]PNG:)XMU+2$?5= UNQUKP]<:C;7F@-?Z7JITEK[
M3K2_N;2"X2UU'48;K^I\5Q;GM7#8WB..?Y/D658?.\5DV699F&5XC%4\P>"J
M24YYCC\-[;&8*K7A1KSC'"X>5.E",8RYI24W_FOEWACP9A\?E' =3@GBKC+B
M7'<'Y;Q7Q#Q#DG$> RW$9''-J5)TJ60Y+F/U3*\VPV#JXO!T:L\PQU.M7J5)
MU(<D(2I+^>B6*6"62&:.2&:&1XI8I4:.6*6-BDD<D;@.DB."KHP#*P*L 013
M*_<[]FCPE\%/"O[27[7.D_M!_ 'XD_MS_M9^$OB=X\C\/>$? OPT@N_A)K>I
M6WB"ZT?Q'XM\16&CS?V+H">*/%&NW4UQ<>+/ $_@SP3IUA9ZCI9FU^]L[*S^
MF_\ @H/^QY\)_$/[!FJ?M<2?LH6/[%_QO\!WWAP:I\+_  GJWA670[_0_$WQ
M*T+P5#'K-EX/TRP\/7<DEKXE@US3[F/0O"?B73YHY-*U5+FPM+2WF^IK<>8/
M#9MEN5XC 8F-/,Z^7X/#YA&O@_8UL7F5*G4P[PV#JUZ.:5\ Y5(TI8_ZC3I0
MJ>[.$=&_S;">"^;9APQG_$6"SG 5*W#^#SS-,;DD\'FKQ6&RSA_$5:./CC\U
MPV#Q/#F#SF,*-3$T\E_MBOB:N'7M*52=IJ'\RU;7ASPYK_C#Q!HOA3PIHNI^
M(_$WB/5+'1- T#1;*XU'5]9U?4KB.TT_3=-L+6.6YO+V\N98X+>W@C>265U5
M5)-?U4?LU?LB?"OP)^Q+\!?BM\$/V*/A!^W?X_\ BKX1TGQ-\4KKXD_$#P5H
MFL:-JNIV"SZSHOA.3QYX8\5>$K1?".K2ZQX(O=/TJY\,:Q8:AH=M?:A#KVLM
M?&S^8?"&K?LG?!;_ (*B_!>#P+^Q_P#%_P"'-[\0]4TKP7J7PP^.WAW0?#.A
M_#;XD^*/'/@X^$_C#\'T?5/'MQ=V&E-:Z[M@L;K2M*MYY(CX+U2RTB<V=KR4
M_$.AC*F<T,NRG%8BKEE'-)4G+%Y9&56KE7-&M'%8-8WZ_E]*I.$OJ]3%8>FL
M1&+4.6;Y5Z=;P+QF64.%,9GO$N78'#<0XOARGB(PRSB&4,/AN)/93PDLMS66
M4?V+GF)H4JU-8_#Y;C:\L#5G%U%4HIU'^'/QR^!OQ%_9S^(FH?"GXKZ5:Z%X
M[T?2?#>JZUHEKJ5GJW]D_P#"4>'].\26.GW5_ITD^G2ZA;Z?JEJE^MA=7EI#
M=>;#%=W C+G@_"'AV;Q?XL\+^$[:XBL[CQ/XBT7P[;W<Z.\-K-K6I6VFQ7$R
M1_.\4$ERLLB)\[(I"\D5_3U^V7XL^!OQ<_X*K? 3]G+7?V=_!-QX@T/XG^#+
MKXF_$C5;71-6F^+?AWQ'\+--O](\+^)=)F\/1W-QIWAV&XL[6V34]:U:W=;"
M$PVMJNQ(_-OVX=<_X)Y_!GXR>+?V2_ _[)'AB?XQ^*/&WP7O]0\>?V)I-KX5
M\%:EXFUCX?WC^'M"T^TOK&]TS29/AE?7-W-IFC6MOX?OO$NJ6L_B#2-?>[U>
M\CRR[CS&8JAD>&KY#CIYIFV14LYJ2P<L'+#8;"SKQP\\?*-7%WIX3WHXJ%.5
M2>(C3J4J%2'MG)1Z\^\%LJR_&<89C@^-,FI<.<,<9XKA.A3S6&:T\PQ^8T<)
M+'4LDIU,/EMJV9ODGEU;$4J%+!2KT,3C*%7ZI&GS?D%^W-^Q3XI_8:^)?A;X
M:^*_&V@>.K[Q3X&MO'-OJ?A[3]1TZUM;2YU_7M 6QFAU(M,]PDV@RW!D0^68
M[B-0-R-GXIK^C[]O7]A_X1^.?^"E_P"R;^S1\+_!GA7X/>#/B=\-;/5_&4'P
M\T#2?# FTS0/$?Q/\0>+]2LX-/TR6Q_X2:Y\'>$[G3M)U"^L+RWAO(M--]%+
M8V[QUVOQ0^*/_!(WX#_&[Q%^Q)\0_P!D?P]8^ O"&FC0O&O[0<UG=:]XJL/$
M\?A>V\06]K9ZOX:L]6^+ERUS=7,.@:AK6E^(M,N+#Q+))!+H2>'[>;4X)RSC
MNH\KR2*P&;<1YMC,GJ9UC(X#"8/#5Z>74\75PLL5+"_6E2E6G5IRI4,'A:E:
MK7G!J/+*44ZXA\&*$.(^+JD\[X9X"X9RKBJAPEE=3.\TS7,,)7SW$99ALRAE
M\,Q66_6(82CAZ\<1C<VS*CA</@Z=6+GSPA.4/YC*ZCPAX(\:?$+68_#G@'PA
MXH\<>(9;>XNXM!\(:!JWB769+6U4/=7,>EZ+:7M\]O;(P:XF6 QPJ0TC*"#6
MK\4K'X=:;\1O&MC\(M<\0>)?AA;>(]33P'KGBS3H=*\37_A<W+MI,FNV5L$M
MTU2.U9(+R>&WL8KV:)KU-,TM;@:=:_TY?\$J/V)?@3\*_B1\+/C]X2_;!\ _
M$OXB>)?@X-0U3X(Z/_PAW_"1Z!<^-?"^DZAKMC<_V9\0M:USS/"-S/)8WWVC
MPU:R>9 WVR+3Y-T:_1<4<5X7AO)I9E5IUI5ZV&JU<#A:F%QG[VO"BJL:&*E1
MH5/J7Q1C.>)]E&$N9-WBTO@_#KPUS+C_ (LI\/X>OA(8+"YAAL/G.8T,RRM?
M5\%5Q<L-4Q>6PQ>,H+-W[DYT:6 ^L3K0Y)0@XSBW_*[J6FZCHNHZAH^L:?>Z
M3J^DWMUINJ:7J5K/8:CINHV,\EK?:?J%C=1Q7-G>V=S%+;W5K<Q1SV\\<D,T
M:2(RCT'X*?#&_P#C7\7OAE\(=+U2ST34OB9XY\,^!K'6-0AFN+'3+OQ-J]KI
M,%]=P6W[^:WM9+I9I8X2)'1"J$,0:_4G_@IQ^QI\$?@[<_$?XZ>"OVL_ WQ5
M\?\ CK]H+Q&-?^#&B?\ "(_\)#X,_P"$PU/QIXEUK^T/[)\?:[K6?"NJ6</A
M^^^V^'-._P!*ND^U_8+C9:/\.?L%?\GL?LH?]G!?"C_U,](K;#\04,UX;Q>=
M9;.:E3P&+J1=7#5Z'L\70PCJRBJ6+HTIU*<*C2C/D=.JE>,I*YRX[@?%\.<?
MY9PEG].C*.(SK+,/..&S#!8Q5\MQN90PT)RQ&68K$TJ%:M0YG.DJT<1AY.TX
M0DD?JM<_\&_WQ,LIFM[S]I_X.VEP@4O!<Z-X@@F0.H=2T4MRCJ&4AE)4;E((
MR"#7YU_MS?L'>(/V'K_X;6.O?%#P;\2V^(]IXJN[67PA;7MLFCCPM-H$,T=^
M+R64NUZ=>C:V,94*+6;=G*X_=']O3]E__@FE\2OVH/'OC#]HK]KSQ+\*/BWJ
M5AX-B\1^!M.UCPU:6FDV]AX-T*PT*6*#4? .N7:'4M"MM.U*0R:G.&DNF:-8
M8RL,?Y6Z9^RE^PYK7_!0O]F_X!?"_P".VJ?%7]GKX@:587WC?Q;J>O:5:WD_
MC>.?X@W%M\,[?6-*T7PHMD/%C^'?!&@0?9(!K?VCQDPTK4!J$NGI;?G_  MQ
M5G&)A0S/-<[S7%86CD^(S;'8#_4SZEAIPHX"6(J4\+G$9QIUW3FU/#RIPBL9
MR*,5&-2\?W#Q(\-^%LOJXWA[AK@_AO+<QQ7%& X9R;.O^(M?VMF%&KBLZHX&
MCB,QX5G1G6P<<124J6.A7JS>4NM.I4E4GATI?D517]@7Q_\ V>O@KX(M_B!X
M%^(/_!)JWU#]GG1/#]W!X2^.W[*6I>!_&7QLN;BU^QG2]2OO"L5EX!^)FE3Q
M644M_JVIZKX@\6Z18ZEISVFLGQ3H>MZE?Q?EO_P3]_8T_9F\6_#K]IO]LW]H
M+3/&OB[]G?X :UXMLO O@#4;FW\.>(O&:>%]&?Q'+_PF-OI&KZ;!+XA73-7\
M':=I7A_2O%MEH.H>,+^^T_5;^[T:W^SWGT>!\1<MQ658O-:F QE*EAZF"I4*
M6'KY;F-3'5LPFJ>$PM!X+&U84L=*<DJV$Q<L/4H)\TVU&;A\%F_@/Q!EW$F6
M<-8?.<JQ6(QU'-<1C,5C<%G^0T,HPN1TG7S/,L9#.,HPM;$9/3HQ<\+F>64\
M=1QK7)1CS3I*K^(M%?TH?#[X1?L8?\%7O@=\9V^!W[-EG^RK^T#\"=*M+GPO
M;^"K_1_^$>\6C7-,\2OX+L/$(TK1=$M?$%KKE_X5N++Q-=W/A:+Q)X:NI=,N
M]-\4:S!>W]C?8'[)/P=_8X@_X)/^)/VA?VD/@SI_C!/!/Q(U"^UK7O"^E:+I
M_P 3O$%O8_$'PII?ASP9;>,YS9:MI^AZ[K&HZ?H&M?8M7L;I/#VH:G%8W$5Q
M)'G2KQ_A</1JQQ.49I1S3"YQEF2XS)O]DJXVCB,WISJX"I2J4L1/"XFEB:<&
MZ+A7CS3]U\J7.\<-X(YECL30J8#BGAW%<.YAPIQ!Q;E7%5LSH93BL'PO7P^%
MSO#XFCB<!2S' 8G+Z]=+$JM@YJG22J14Y2=*/\YU?=OQ=_83\6_"+]COX,?M
MAZEX[\.ZOX:^,_B+0_#NF>#K+3=3@US19M<T+QKKL5S?W\[&PN(H(O!5U!(E
MN [27MNR_+')7ZD^/O@I^R#^WC_P3V^*7[4_[/\ ^S]9_LT_%+]G9/$\.J>'
M/"]SIKZ-JEKX$T?P_P"+_$-MK#Z7I]A%XNTZ]\ :DU]IOB:^T/P[XEM/%=K>
MV]Y/?Z/:7,NM?0OBCQM\ _AK_P $??V-/B!^T#\+Y/C5HGA/6? VH^!_A7+X
M@;PSHGC+XA7&E?$K2;*T\3ZHFE:VPT+2?"FH^+_$<EFVF7<&H:CHNFV5W!-:
M33PR>7F''>*G+*(X#+\=A\9#BG^PLXR6K3P-3&SG]1K8BG0HUW7E@U"O+V,X
M8N.)ITXQ524ZD:<7)_0Y)X,9;2I\3SSO.\GQN4U?#=<9\*<78>KG%#*:-/\
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M?'>8\.X",IU,1+!Y=A\WKX9UZE2K*=6K' X"E/$5ISE.I*%&<GS2>M/]L_\
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M$JA4=6A456C2Q.'KX>JXPE.AB<+7HXBA*4*<W2JP<Z<)W@BBBBO3/GC^_?\
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M21VVL>*/A9XFL;[5/#?C[P]I]VUQ''-#=Z3KNIV>F:YK6F>'KG0M UO4M/\
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M#G@"ZO+F+'Q/\66_ACQCJ-S=VJS^*/#_ (#\/Z]K7@31M3UJ*]\3_#W^O/\
MX),:!^QEHW["'P-O?V$M*33_ (&^(_#R:W)=ZF+*;XB:OX^*QZ=XZN_C#J-H
MB#4OBG9Z]I]QHWB>1,:/8_V99Z3X.AL_ NG^&+*WF$W/E2=M+R=M]=E^KZ=-
M0/TAHHHK4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OA7]M3]
MMG6/V.O^%:_V5^Q[^V-^UA_PL7_A,OM'_#)GP<NOBU_P@/\ PB/_  BOE?\
M"?\ V;4=/_L#_A*?^$GD_P"$5W^=_:O_  CGB3;Y?]FMO^ZJ:[I&CR2.L<<:
ML[N[!41%!9G=F(55502S$@  DD 4G=K1V???\P/P%G_X+[^#]"^)WP=^$OQ$
M_P""='_!2OX1>+_COXSL/ WPQL_BM\ -)\"2>*]8N=4T;2[\Z!:>(/&MEJ&O
MPZ ^OZ5=:^-"M-2N-,M+RVFN(5^TVXE_?ROY^_\ @F;/_P /"_VQ/VF_^"J?
MC56UKX<> O%WB?\ 9%_X)^Z9>V=RNC^'OA%X.E4_$CXV>'K;5--MC_;_ ,8M
M2U2&T'B*V\K6]%MG\??#R_N[S2+2PMK+^@2I@VTVW=7]W1+1:7T[N[] /Q:^
M,7_!:/PA\.OVB_CC^S?\-?V(/V]/VJ?$/[/FN>&O#?Q'\7?LO_!.Q^+'@O2-
M<\3^%K#Q/::;=WVC^*5U'2KN 75_H\MOKFF:9-/JN@:W'9)<V]DUPW2?$7_@
MKKHWPM_8MO\ ]LOXA_L?_M6?"2PL?CAX<^"8^#?Q[\%6OP<^*]Y/XD.CK9>.
M++1M<N]0AF\&R2ZL]K:Z@)0][>Z3J]M$BM9EF_.+]E#]F?\ X+E_"_7/VW/B
M#\'_  1^QS^SM/\ M!?MH_&S]HC^Q?VE]9U[XC_$CQK8^)]4TJ\\)>$;74?@
MQJ'BGP7X>^'.GZ<=7TZSU&]UM_%<FJW>HFTT[1-&:PUJ^^<?^"BO_!0'4OVX
M/^"-/Q)UWXK?#RW^"_Q^_9L_;C^%?P'_ &E?AW9ZK%K6BZ)\1O 'B-'US7_"
MDL-S?:FGA'69'O4L+'4Y+R^TG6=(\0^'8=7\4VFC6OBK7(<Y)-MM.S:3BDM&
MOGHN]GKZ ?V645_.G^QE^TE\3/\ @L7^UEXV_:$^'G[0/C'X.?L#_LB^-X/!
M'@/X%_#CQAJW@#XK?M&^.;C2],UY?B/^T#;Z%J5KX@TOX0ZB/F\$^$KN6WM_
M$EOIVH:->VEG>Z;X\@U/^BRM4^;5;='W\_3MWWVL 4444P"BBB@ HHHH ZGP
MWTO/K!_*:NGKF/#?2\^L'\IJZ>N.K_$E\O\ TE ?R"_L6?MW?LQ>,/V2=7_8
M(_;O/B/2/ATDMPO@+XG:)8ZEJ2Z+I#:ROBK2].U"71+/6?$FC^(O"_BSS;KP
MOK5MH6N:!>Z)=)X;\1V.GZ+I,L?B'Z)^!?C#_@CQ_P $\/&6H_&/X>_M ?%3
MXZ_$L>']6T[0-(L+.X\1R6FD:O(5GL].;2?!?@#P2FLW5K#%974GB[Q1&JG-
MW:6&E^8&3\,_^&*/VR_^C2?VF_\ PPOQ4_\ F4H_X8H_;+_Z-)_:;_\ #"_%
M3_YE*_K_ !W"_#.+JYDJ/%6+R[+\YKU,5FN49?G.7TL!C,1645B*KC5I5JU'
MZURKZU"E5C&LK12A%)'^5N4>(WB%EF&R!XKPVRO/<\X4P6'RWAOBC.N%,\Q&
M=Y7@,(Y/ X=5,/B<+A<5_9WM&\MJ8G#5*F%DW-RJSFV_W _8\_;X_9I\8^!/
MVX?!OC7XMZI^QY\2_P!I3XZ?$OXH^#/B7:66HW^N:+H/CS2M._L:"'QAI6F&
MTAU?P1>:7JBR6MU?^%6FB\1F3P;J%KKUU?ZK9XOQ\_:]_8OOO^"</QH_9%\!
M_M2^./BU\43J&BWFG>._BSX/^*T^K_%_6--^)7@GXIZKJ5AKTOAK6H--L'MK
M&_\ !'AZ+Q;J&ARQ7^@(UY(VA3V?BG5/Q9_X8H_;+_Z-)_:;_P##"_%3_P"9
M2C_ABC]LO_HTG]IO_P ,+\5/_F4K)\(<(K,H9A3XAG1C2S/+<WHX.GF.42HP
MQN5PHT\,W7K86MCJF']G0C!X:IBI4USU)049N$J?0O%+Q0>05,CK<"T<54Q'
M#_$'"^)S2OD/$\,75R?B2IB:V/C#"83,<+E%#&NOBYU8YA1RV.(G[/#TJDIT
M8UJ>(_83]E[XG_L'M\%?A7_PJ']K/XD?\$]?C[H+:7J?QFL[;4_B5XJ\#_$K
M7+*RTS3]=U"\\,^,-<\0_"_5=/U.>SEO?"433B_T.WO)[77/#>J0Q!7B_;B_
MX*)?L]_$?]JW]@C6_ OBS5/B9X'_ &7O'6B>+OB3\7Y?#=YHNH>))-1\4> 9
M/$(T[0'\-^&I9;G2],\$3Z_?C2-#LM$U74M9BT[0+6TM[#,GY ?\,4?ME_\
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M&ME]%8RAEV$PM'%^WQ,YPC4GAY8;V#_@IS\:_AE^T-^V;\3_ (K_  ?\3?\
M"7^ /$6F?#ZWT?7_ .QO$&@?;)M#^'WAK0]43^RO%&E:)K5O]EU33[NUW76G
M0+/Y/GV[36\D4S_9?[#W[9_P#_8H_82^/E_X0^(%K<?MI_%?4+G_ (1OPM#X
M,\83R>';33BOA/P+=:AK^K>#KOX;:@_A :OXN^)Z6$^LWUEJD&H6OAV]MWU!
M[C3T_-3_ (8H_;+_ .C2?VF__#"_%3_YE*/^&*/VR_\ HTG]IO\ \,+\5/\
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M:7XS_1W_ (>=_P#!-;_I(7^PY_XEE\!/_F_H_P"'G?\ P36_Z2%_L.?^)9?
M3_YOZ$H6BN9>[L^97UW7H[J_J@/N.BOAS_AYW_P36_Z2%_L.?^)9? 3_ .;^
MC_AYW_P36_Z2%_L.?^)9? 3_ .;^KYH_S1^]?UU7W@?<=%?#G_#SO_@FM_TD
M+_8<_P#$LO@)_P#-_1_P\[_X)K?])"_V'/\ Q++X"?\ S?T<T?YH_>OZZK[P
M/N.BOAS_ (>=_P#!-;_I(7^PY_XEE\!/_F_H_P"'G?\ P36_Z2%_L.?^)9?
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M_P W]'_#SO\ X)K?])"_V'/_ !++X"?_ #?U'+!JSG=6:7O1T3MY7;VM>^C
M^&/V@/V,_C]^S1_P4 ^%7[??_!/SX:?\)KH'Q971?@S^WI^S/X<\5?#WP#IW
MC;X;:9I\=OX4^-?@RT^(OB'P;X)@\<?#RTTRTL_[/T_7]'U/5;NRT'3].@M]
M(\8?%C5KO]RJ^'/^'G?_  36_P"DA?[#G_B67P$_^;^C_AYW_P $UO\ I(7^
MPY_XEE\!/_F_JDX*]I*S=[75D]-O73KN]-P/N.BOAS_AYW_P36_Z2%_L.?\
MB67P$_\ F_H_X>=_\$UO^DA?[#G_ (EE\!/_ )OZKFC_ #1^]?UU7W@?<=%?
M#G_#SO\ X)K?])"_V'/_ !++X"?_ #?T?\/._P#@FM_TD+_8<_\ $LO@)_\
M-_1S1_FC]Z_KJOO ^XZ*^'/^'G?_  36_P"DA?[#G_B67P$_^;^C_AYW_P $
MUO\ I(7^PY_XEE\!/_F_HYH_S1^]?UU7W@?H9X;Z7GU@_E-73U\S?LZ?M/?L
MU?M'CQA_PSS^T-\#?CS_ ,(:?#__  E__"F/BSX!^*/_  BG_"1?VU_PC_\
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M7/C'Q!#HT.J7T%M+':?;?L%U#H^B:-I^H:M>165[-8Z7)9:;J%Q:>(?M<?\
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M]IA*D:\>5N\.9?%":CY_1117K'S04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_?O^QM_R:#^R
MI_V;=\#?_58>%Z^D:^;OV-O^30?V5/\ LV[X&_\ JL/"]?2-?P?FW_(US/\
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M_8K_ &5O&G[9'CG]L/\ :MTKXDP>#-8^#WP!^#VLWTWP]\$'Q%X%TGQ!X/\
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M%_I/B/PSKMG!>7MK;ZUX>U?3-4CL;_4+ 7?V*_O()U)732L]M):IV=]?ZTW
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M'I_P^\(6_P!N\/\ A?2M1N/[(\VZNYY[_4Y+V8IIMV2YFM$WHDK=M7?I9+S
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M^='E^?=GTW_POKX5_P#1E'[,G_A5_ME__1;4?\+Z^%?_ $91^S)_X5?[9?\
M]%M7S)11_9>&_P"?N8_^'C-O_FT/]8\P_P"@?(?_ !%N&/\ YT>7Y]V?3?\
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MY]V?3?\ POKX5_\ 1E'[,G_A5_ME_P#T6U'_  OKX5_]&4?LR?\ A5_ME_\
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M&/\ YT>7Y]V?3?\ POKX5_\ 1E'[,G_A5_ME_P#T6U'_  OKX5_]&4?LR?\
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MF_'O_I)W^W'_ .$!_P $UO\ Z7I7W'11RK^]_P"!2_S\OS[L#X<_X9-^/?\
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M+O+WMES2N]NE]E;5[??J'UI_PR;\>_\ I)W^W'_X0'_!-;_Z7I1_PR;\>_\
MI)W^W'_X0'_!-;_Z7I7W'15<J_O?^!2_S\OS[L#X<_X9-^/?_23O]N/_ ,(#
M_@FM_P#2]*/^&3?CW_TD[_;C_P#" _X)K?\ TO2ON.BCE7][_P "E_GY?GW8
M'PY_PR;\>_\ I)W^W'_X0'_!-;_Z7I1_PR;\>_\ I)W^W'_X0'_!-;_Z7I7W
M'11RK^]_X%+_ #\OS[L#X<_X9-^/?_23O]N/_P (#_@FM_\ 2]*/^&3?CW_T
MD[_;C_\ " _X)K?_ $O2ON.BCE7][_P*7^?E^?=@?#G_  R;\>_^DG?[<?\
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MWU#[=_X9-^/?_23O]N/_ ,(#_@FM_P#2]*/^&3?CW_TD[_;C_P#" _X)K?\
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M3ETJXU34_"<ETOAKQ44L04M;'Q9I>MZ9:7!34+:RCU&"UNX/RT_X(2 #P?\
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M(!(& :;IYJDV\=EJ23;;RS$I)+5MMYQ9)+5M[$1K<-3E&$<FS^4I-1C&/$6
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MQPL=,L?MVIWUU=?8]-LK.PMO-\FSM;>W2.).8_X9)^*G_0U_LR?^)K_L:?\
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MXJ?]#7^S)_XFO^QI_P#/ZH_X9)^*G_0U_LR?^)K_ +&G_P _JOF2BCV6;?\
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MG*;A",3Z;_X9)^*G_0U_LR?^)K_L:?\ S^J/^&2?BI_T-?[,G_B:_P"QI_\
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M_P!+4/AS_AX7\!/^A _;C_\ %8G_  4I_P#H3:/^'A?P$_Z$#]N/_P 5B?\
M!2G_ .A-K[1T[6=(UC[9_9&JZ;JG]G7CZ=J']G7UK??8=0BBBFDL;S[-++]E
MO(X9X)7MI]DZ1312,@61"U*'Q9X6N/$EWX-M_$OA^?Q?8:;%K-_X5AUG3I?$
MEEH\TL4,.JW>AI<MJEMILLT\,45]-:I:R2S11K*7D0%>]WC_ . OR_O>OX=M
M0^._^'A?P$_Z$#]N/_Q6)_P4I_\ H3:/^'A?P$_Z$#]N/_Q6)_P4I_\ H3:^
MXZ*?O=X_^ O_ .2]?Z6H?#G_  \+^ G_ $('[<?_ (K$_P""E/\ ]";1_P /
M"_@)_P!"!^W'_P"*Q/\ @I3_ /0FU]QT4>]WC_X"_P#Y+U_I:A\.?\/"_@)_
MT('[<?\ XK$_X*4__0FT?\/"_@)_T('[<?\ XK$_X*4__0FU]QT4>]WC_P"
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M#O',<-[\/_ /AW5?BSXWT*5S&?%&C^&-4T'2-/\ #1/E2J]EJOBCQ+X>BUZ
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M5YK=G>Q:M8FQU.XNFN[.S^V]+_X(7_$2/PKX?TWQS^TM\%OA_P#M#>,M(O\
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M65M<7<\,$GS%_P %H6_X)U>+/V<OA[\9OV(Y?@3<_P#!0_XO_'?X9>(/V/\
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M:1^.FC:9X;^+_P ;OB3\0O#ND26D]CH'B7Q3J=]HBWUC%<P6FJW&DF=-/O\
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MJ2V\3IW]%*R6R7W >9Z1\%O@YX?^)WBGXV:#\)OAGHGQE\<Z39Z#XU^+>D>
M_"VF_$[QAH>G0:1:Z?HOBGQ[9Z5#XJ\0:386WA_0;>ST[5M5N[.U@T32(8(4
MCTVR6'TRBBF 4444 %%%% !1110!U/AOI>?6#^4U=/7,>&^EY]8/Y35T]<=7
)^)+Y?^DH#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>nt10016217x4_graphic30x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic30x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M?&&EV5D^HZ1I/AFXOHSK<U]%:163[;>[FMI)%(]C_;K_ &-_$/[&GQEU3X=
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MM>I.GB9.:CAYQA!RC7DZ=1*E)*HW":4?=E;Q^BO<O@3^S]\0/CY\:_"?P/\
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M2G?DJQC5C"4J<[/EFDXRL[-V84445J<X4444 ?U#?\&ZG_(N_M8_]AKX-?\
MI#\3*_I2K^:W_@W4_P"1=_:Q_P"PU\&O_2'XF5_2E7\8>*G_ "7O$'^/+_\
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M"%QX"T^QTFQM;B[\,2:#XDTO3[;3_$4GB"ZBMM*7&IPR/=?VAQO[,WQ/U?\
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MTCQ1K/B&]\:37-A\-]:MHKG78M2M;*70(;>>'3/[/4VVM7%JT%E:>7_L@_\
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M'3+1+^YT#Q%:W5_INB^&+#1_#WAK6K.?PY::YJ'B+6#:OJ-[<VNH?ES\/_\
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MF.+S3+^ O$'AVIQ//"\248X#B3.>*%F.79M+'PRZ.=T(YO@*>(4LTRVA6S'
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M'^/+_P#U4X _UG^C=_R97@C_ *]9[_ZT^=!1117Y\?N(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!_GA?MK_\GE_M;?\ 9S?QZ_\
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M6/Q5=:3JGC+6;G6_AY<Z=%=2QOJ6B^'+?_A 8]&6T$4OB&YT'5Y4AFG6>?\
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M?#W_  E6@V.I>%;G6/#G]OZ<DNH:'_;FGQ7&F?VQ8127NF?:OMMJCSP(IP?
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M8MPK/VC4H2_8'X/? ;X_?M4?\%6W\'_M::?)>>.O"/C1/B%\>[:ZL;!M M?
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MMX%^'VC?V5XR\<:(/^$?\*VD]S;Z7_:(TT:KJOESO]NUN^U+47VO>,B^._\
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MW[''[*OQ9_;C_9]^'W[-/QIU_P#:'^%.CPWOQ7^.>J^*OAYKG@ZT\/Z#\/\
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M_1)Y=_XE$?\ YR!_J[X5_P#1S,^_\5S/_P"B[^K/RO\ C)17[-_\/S/VMO\
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M!_J[X5_]',S[_P 5S/\ ^B[^K/RO^,E%?LW_ ,/S/VMO^B<_LR?^&P\1?_/
MH_X?F?M;?]$Y_9D_\-AXB_\ G@4?VIQA_P!$GEW_ (E$?_G('^KOA7_T<S/O
M_%<S_P#HN_JS\K_C)17[-_\ #\S]K;_HG/[,G_AL/$7_ ,\"C_A^9^UM_P!$
MY_9D_P##8>(O_G@4?VIQA_T2>7?^)1'_ .<@?ZN^%?\ T<S/O_%<S_\ HN_J
MS\K_ (R45^S?_#\S]K;_ *)S^S)_X;#Q%_\ / H_X?F?M;?]$Y_9D_\ #8>(
MO_G@4?VIQA_T2>7?^)1'_P"<@?ZN^%?_ $<S/O\ Q7,__HN_JS\K_C)17[-_
M\/S/VMO^B<_LR?\ AL/$7_SP*/\ A^9^UM_T3G]F3_PV'B+_ .>!1_:G&'_1
M)Y=_XE$?_G('^KOA7_T<S/O_ !7,_P#Z+OZL_*_XR45^S?\ P_,_:V_Z)S^S
M)_X;#Q%_\\"C_A^9^UM_T3G]F3_PV'B+_P">!1_:G&'_ $2>7?\ B41_^<@?
MZN^%?_1S,^_\5S/_ .B[^K/RO^,E%?LW_P /S/VMO^B<_LR?^&P\1?\ SP*/
M^'YG[6W_ $3G]F3_ ,-AXB_^>!1_:G&'_1)Y=_XE$?\ YR!_J[X5_P#1S,^_
M\5S/_P"B[^K/RO\ C)17[-_\/S/VMO\ HG/[,G_AL/$7_P \"C_A^9^UM_T3
MG]F3_P -AXB_^>!1_:G&'_1)Y=_XE$?_ )R!_J[X5_\ 1S,^_P#%<S_^B[^K
M/RO]U_\ !NI_R+O[6/\ V&O@U_Z0_$ROZ4J_&O\ X)%?MJ?%3]LRR^/FK_%'
MP_\ #?0+GP)=?#/3=(C^'7AK4/#EO<P:Y%X]NKM]4CO]>UQKJ:.33H%MGC>W
M$2/,K)(7!7]E*_E/Q&JXNMQGG53'86G@L7*6!]MA:6)^N4Z3668)14<2J.']
MKS049M^QARN3A9\O,_\ 2OP%P^687PFX2P^39E7S?+*=/.5A<QQ.7O*J^)C+
MB'-IU'4R]XO'/#NG6E4HI?6JWM(TU5O'VG)$HHHKX@_7PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#^%W_@L;_P I'_VC/^Z1?^J(
M^&%?F37Z;?\ !8W_ )2/_M&?]TB_]41\,*_,FO[NX0_Y)+A?_LG<D_\ 59A3
M_&+Q2_Y.;XC?]EWQ=_ZT&8!1117T1\(%%%% !1110 4444 %%%% 'ZQ?%K]D
M#X->#O\ @E?^S]^UKHMEXA3XP?$7XDGPQXEO+C7I[C0)=*_MCXN66RST-H1!
M:3"#P=HH\Y)6;='<-C-PV.C_ ."9G[%OP/\ VI?A'^USXR^+%CXDN]:^#GAK
M0M3\%/H?B&?1;:"[O_#/Q$U6X;4;>&&5=00W?AO2RJ2,@6-)D'$S$?3'QLT'
M4==_X(#?LU:GIL?GV?A'XGQZ]K<J)/*MMITWQ)^,WA%9'>"&:*'&N>)=*M&>
M[DMH!)-Y F-Y);6T^W_P1*!LOV:?^"A^K7@-II2^"]"#:G= P:>IT[P#\6[G
M4 ;R79; V-M=6MQ> R9MH+FWEGV1S1LWXSCL[S2/!O%>+IYEBHXW!\;XK+\/
M7C7FJ^'PT>(\%1AA*<T^:%-82JZ:IQT5*;C;E;/ZQR;A#AVIXL^&>68G(,MG
ME&:^$.69YCL'4P=%X/&X^? >;8NKF>(I./LZM>698>->>(FG)XFDIN7/%,^5
M/V'?^"?'P2\??L\>,OVTOVP_B/XF\#?L^>$=4N-(T_1_ UG<W.OZS/8ZUHNA
M3ZUK-W8:#XIU*'0)==U3_A&;;2-%T0:U=WWVC5;C6-"TK3TDU3W;XC_\$]OV
M&_VCOV</BO\ M$?\$^_BIXO36/A!8ZEK'BCX:>-_[6GLYO[.TE/$,OA:W@\1
MZ-I_BW2M:OM'6[7PIK*:CXM\.>)-;M?^$;2\@N8]5U72.*_8._:,_:D_8G_9
M?UWXF^-OV=H/C3^PG\1_$8,M[=>+/"-O-H'B/4=5G\#:S=:?IK3^(=3ET76+
M[0FT36]!\3>%+;1KC7+'1VM=;T&;6+D^(?LJU^ O_!.7_@JE\)/C'XI_9=^%
MU[\ /CO\/=*TJZG,7A=? ^GZ;J%[;ZQ=^'H-7\*^%/$%W\)M6T/QE+X?UO3K
MG5]-:#Q=I[6IU?4DM (+34^7.<USS 9YC\RQF<9O1R;"YW1PV&S3):F79KP[
ME^%57#4JN69]DT)TL91Q<:E5T<5BZF(]O3JU:;PU"34(U/2X5X:X-SK@_).'
M\KX5X8Q7%68<(8O,,PX<XMH9]PWQWG>92PN/Q.&X@X*XKJ4L3E>*RRK1H0Q>
M6Y;0P'U.OA\/7CCL;!.I4H?RST445^X'\>!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'ZK_\ !/#_ ()OVG[6VA>./C5\8?B&?A#^S;\+
M[F\M?%/BN*72++5=<NM*T8:[XA@T[6M?,NA>%-)\*Z1<Z=JNO^*M<T[5+&&.
M\AL;33KF0:E>:-]V^%/V.?\ @C;^U=KS?!7]FGX[?$/PK\9GT[54\*WMVGC2
MXLO%5YI,%QJMYJ7]F_$/PII.E>)%L[%;AI]$\.ZYX4U*ZTS2KC4;.'[/;7FI
M3=)\+[>]^(W_  ;Y^/O#7PQ:2_\ $_@J?Q=)X]LM-E<7<5MX9^/=G\4O%<5R
M[21>2+7X3WECK5W!"95O-)0VIBDDO94KXF_X)K_!S_@G5\<-,T+X<_M#:_\
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MO G_ (EW#_\ \\#]-J*_,G_A\;_P3A_Z.,_\Q%\=_P#YV%'_  ^-_P""</\
MT<9_YB+X[_\ SL*/]4.+/^B7XB_\,F9?_,P?\12\,O\ HXO G_B7</\ _P \
M#]-J*_,G_A\;_P $X?\ HXS_ ,Q%\=__ )V%'_#XW_@G#_T<9_YB+X[_ /SL
M*/\ 5#BS_HE^(O\ PR9E_P#,P?\ $4O#+_HXO G_ (EW#_\ \\#]-J*_,G_A
M\;_P3A_Z.,_\Q%\=_P#YV%'_  ^-_P""</\ T<9_YB+X[_\ SL*/]4.+/^B7
MXB_\,F9?_,P?\12\,O\ HXO G_B7</\ _P \#]-J*_,G_A\;_P $X?\ HXS_
M ,Q%\=__ )V%'_#XW_@G#_T<9_YB+X[_ /SL*/\ 5#BS_HE^(O\ PR9E_P#,
MP?\ $4O#+_HXO G_ (EW#_\ \\#]-J*_,G_A\;_P3A_Z.,_\Q%\=_P#YV%'_
M  ^-_P""</\ T<9_YB+X[_\ SL*/]4.+/^B7XB_\,F9?_,P?\12\,O\ HXO
MG_B7</\ _P \#]-J*_,G_A\;_P $X?\ HXS_ ,Q%\=__ )V%'_#XW_@G#_T<
M9_YB+X[_ /SL*/\ 5#BS_HE^(O\ PR9E_P#,P?\ $4O#+_HXO G_ (EW#_\
M\\#]-J*_,G_A\;_P3A_Z.,_\Q%\=_P#YV%'_  ^-_P""</\ T<9_YB+X[_\
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MS[,_$RBOVS_X<,_M??\ 11_V;O\ PK_B?_\ .>H_X<,_M??]%'_9N_\ "O\
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MFA4KX6&,HNC5=&OA\?@L3@,51J*,9J-2ABJ=.=I0E&<9PYJ<D[*7-&48_/\
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M?$?B#3I;"XM/#&B^$M"NM.MU:]U8VUQ?IHNG?H%5IW2>NO?1@%%%%, HHHH
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MOI-GJ'A<:EI5O=>);NW\'V=MJ.I^#K#3=/\ H_\ X(O1VWQ(_:B_X*A?M6_
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M87-,VPN44IY-6FEA\9&C7Q5*I5J1J^S5+X9RFXQ?YW_\-K_ME_\ 1VW[3?\
MX?KXJ?\ S5T?\-K_ +9?_1VW[3?_ (?KXJ?_ #5UU_BK_@GM^VEX)^%LGQG\
M4_L\>/='^'MOIO\ ;-_J<\.E2ZSH^CK$MQ-JNO\ @NUU.?QOX?TVSMF-UJ%]
MK?AVPMM-M8YKF_EMH()I(_*O@9^S/\<?VE+_ ,3:7\$? 5WX\O\ P=H\>O\
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M'DON/IO_ (;7_;+_ .CMOVF__#]?%3_YJZ/^&U_VR_\ H[;]IO\ \/U\5/\
MYJZ^9**/['RG_H5Y=_X18;_Y4'^M/$__ $4>??\ AWS#_P":/)?<?3?_  VO
M^V7_ -';?M-_^'Z^*G_S5T?\-K_ME_\ 1VW[3?\ X?KXJ?\ S5U\R44?V/E/
M_0KR[_PBPW_RH/\ 6GB?_HH\^_\ #OF'_P T>2^X^F_^&U_VR_\ H[;]IO\
M\/U\5/\ YJZ/^&U_VR_^CMOVF_\ P_7Q4_\ FKKYDHH_L?*?^A7EW_A%AO\
MY4'^M/$__11Y]_X=\P_^:/)?<?3?_#:_[9?_ $=M^TW_ .'Z^*G_ ,U='_#:
M_P"V7_T=M^TW_P"'Z^*G_P U=?,E%']CY3_T*\N_\(L-_P#*@_UIXG_Z*//O
M_#OF'_S1Y+[CZ;_X;7_;+_Z.V_:;_P##]?%3_P":NC_AM?\ ;+_Z.V_:;_\
M#]?%3_YJZ^9**/['RG_H5Y=_X18;_P"5!_K3Q/\ ]%'GW_AWS#_YH\E]Q]-_
M\-K_ +9?_1VW[3?_ (?KXJ?_ #5T?\-K_ME_]';?M-_^'Z^*G_S5U\R44?V/
ME/\ T*\N_P#"+#?_ "H/]:>)_P#HH\^_\.^8?_-'DON/[1/V>/V!OV%?BY\
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M_P"":W_2/3]AS_Q$WX"?_,!7W$2 "20  223@ #DDD\  <DGI7\J'['.H?\
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M^TCIMQ<V7B?QI\1+G5H;;Q'=VWC6:PO+WPO]OA?3_#J6>L_#VQNKC4_ VO\
ME_HQ\0/V+/A;\1_VP_@%^VUKFO\ C^U^*O[.G@GXA> O!/A_2M5\.P?#[5-'
M^)6DZOHVNW/BK2KSPK?>([[4K2UUFZDTF;2/%>AVL$\=NUY9W\:212\]X?\
MV"/A#X+_ &WO%_[>/@#Q1\3? 7Q-^)WP^L?A]\8OA[X8UGPK%\%_C#'I"/'H
MGC'QWX4U3P9JGB$^/=%CAT6+3O$?A;QCX8*1:#;PSVEQ%KWC9/%346I.6^MM
M>W+%779W3NNJ]$!]O4445H 4444 %%%% !1110 4444 %%%% !1110 4444
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MS;Q>)=1U"/3[2.-23=FX*6C5FU=-M==MEVNNG8#\"O$?Q]_;'_:(_P""??\
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ME ?YX7_"*?L:?]%Z_:;_ /$2?A7_ /1KT?\ "*?L:?\ 1>OVF_\ Q$GX5_\
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MG_1>OVF__$2?A7_]&O7S)17K_4L3_P!#C,?_  5E/_SK/EO[7R__ *);(?\
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M4_\ SK#^U\O_ .B6R'_PHXG_ /HC_J[\K?3?_"*?L:?]%Z_:;_\ $2?A7_\
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MK]IO_P 1)^%?_P!&O1_PBG[&G_1>OVF__$2?A7_]&O7S)11]2Q/_ $.,Q_\
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M[7R__HELA_\ "CB?_P"B/^KORM]-_P#"*?L:?]%Z_:;_ /$2?A7_ /1KT?\
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M_L.?^+"_CW_]+$H_X3__ (*4_P#1IO[#G_BPOX]__2Q*^XZ*+/\ FE_Y+_\
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M!JU[Y+_VM</XFTIKC1I[."\M$DF%PJ20.@2:>U2^W\OE_=Z_J_D'*_\ "?\
M_!2G_HTW]AS_ ,6%_'O_ .EB4?\ "?\ _!2G_HTW]AS_ ,6%_'O_ .EB5]QT
M55G_ #2_\E_^1_J[\K!\.?\ "?\ _!2G_HTW]AS_ ,6%_'O_ .EB4?\ "?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?W[_ +&W_)H/[*G_ &;=\#?_ %6'A>OI&OF[]C;_ )-!
M_94_[-N^!O\ ZK#PO7TC7\'YM_R-<S_[&&-_]2:I_MUPK_R3'#G_ &(<G_\
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MZ/\ AM?]LO\ Z.V_:;_\/U\5/_FKH]KFW_0%EW_ATQ/_ ,YP^K\,?]#?/O\
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M;]IO_P /U\5/_FKH_P"&U_VR_P#H[;]IO_P_7Q4_^:NCVN;?] 67?^'3$_\
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M_P#@3_\ D?7^GH'W'17PY_P[$_X)K?\ 2/3]AS_Q$WX"?_,!1_P[$_X)K?\
M2/3]AS_Q$WX"?_,!1[W:/_@3_P#D?7^GH'W'17PY_P .Q/\ @FM_TCT_8<_\
M1-^ G_S 4?\ #L3_ ()K?](]/V'/_$3?@)_\P%'O=H_^!/\ ^1]?Z>@?<=%?
M#G_#L3_@FM_TCT_8<_\ $3?@)_\ ,!1_P[$_X)K?](]/V'/_ !$WX"?_ # 4
M>]VC_P"!/_Y'U_IZ!]QT5\.?\.Q/^":W_2/3]AS_ ,1-^ G_ ,P%'_#L3_@F
MM_TCT_8<_P#$3?@)_P#,!1[W:/\ X$__ )'U_IZ!]QT5\.?\.Q/^":W_ $CT
M_8<_\1-^ G_S 4?\.Q/^":W_ $CT_8<_\1-^ G_S 4>]VC_X$_\ Y'U_IZ!]
MQT5\.?\ #L3_ ()K?](]/V'/_$3?@)_\P%'_  [$_P"":W_2/3]AS_Q$WX"?
M_,!1[W:/_@3_ /D?7^GH'W'17PY_P[$_X)K?](]/V'/_ !$WX"?_ # 4?\.Q
M/^":W_2/3]AS_P 1-^ G_P P%'O=H_\ @3_^1]?Z>@?<=%?#G_#L3_@FM_TC
MT_8<_P#$3?@)_P#,!1_P[$_X)K?](]/V'/\ Q$WX"?\ S 4>]VC_ .!/_P"1
M]?Z>@?<=%?#G_#L3_@FM_P!(]/V'/_$3?@)_\P%'_#L3_@FM_P!(]/V'/_$3
M?@)_\P%'O=H_^!/_ .1]?Z>@?<=%?#G_  [$_P"":W_2/3]AS_Q$WX"?_,!1
M_P .Q/\ @FM_TCT_8<_\1-^ G_S 4>]VC_X$_P#Y'U_IZ!]QT5\.?\.Q/^":
MW_2/3]AS_P 1-^ G_P P%'_#L3_@FM_TCT_8<_\ $3?@)_\ ,!1[W:/_ ($_
M_D?7^GH'W'17PY_P[$_X)K?](]/V'/\ Q$WX"?\ S 4?\.Q/^":W_2/3]AS_
M ,1-^ G_ ,P%'O=H_P#@3_\ D?7^GH'W'17PY_P[$_X)K?\ 2/3]AS_Q$WX"
M?_,!1_P[$_X)K?\ 2/3]AS_Q$WX"?_,!1[W:/_@3_P#D?7^GH'W'17PY_P .
MQ/\ @FM_TCT_8<_\1-^ G_S 4?\ #L3_ ()K?](]/V'/_$3?@)_\P%'O=H_^
M!/\ ^1]?Z>@?H9X;Z7GU@_E-73U\S?LZ?LP_LU?LX#QA_P ,\_L\_ WX#?\
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M;U1?$6G:5:Z#>W]S#%H.LZK/9+;VWB?0I6CU2*QE<:@BQ1N\-RL/@=?T2_\
M!;F!M1^ '_!.#Q!8/%>:./AQXR@2_M7^T6LS:UX*^!5[IKP7,(>VEBN[73+N
M:!UF_?QQ^9 )(P[)ZN;9UB,!G_"V54Z="6&SRMF]+%5:D:CJTOJ&6SQF'6'E
M&I&G&52K%0G[2%3FA=049>\OF^&N$\!G?!7B/Q'7KXR&8<'83A?$Y;A\/.@L
M-B?[9X@I95C7C:<Z%2M4A0PU1U:+P];#\E9*55U8?NW^-OQ._9!_:-^#=O\
M"VZ^)?PSOO"]O\:I8X/AA)/KOA2_'BN69-$DC2W72->U!M/+)XCT5@=873@/
MMR D&&X$/J]M_P $S_VZ+SQYJ?PTM?V>/%,_C#1O#NF>*M5LDUKP6=,T_1-:
MN-6M=(FN_$Y\3#PM!>:E/H6KK9:.^M#6+A;&:2*P:(H[_M-_P5ETZ^TC3?\
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M +./A2+PW+XLU76O$%C%;V6H>,_$NF^*=(C\%W.G^(?#VL6,&NV&DV/B+^H
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MPQ>:;;Z-:ZSI,UEXT\4_TH.B2 *Z*ZAD<!U# /&ZR1N 00&CD571NJNJLI#
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M;EM=/\17NCO%VY-ZV4U&ZDU:]E;ELTTVU?6_;8#^G\D $D@  DDG  ')))X
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MT2WBLO#&KS7UIJ2V5QJ.@:?#!IT>K:3I^@>)-1MK:"XU+Q!<:LU[J=Y\+?\
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M#^R,O_Z*G(?_  GXG_\ H<_JS\K_ #)17TW_ ,)7^QI_T07]IO\ \2V^%?\
M]!11_P )7^QI_P!$%_:;_P#$MOA7_P#044?7<3_T)\Q_\&Y3_P#/0/[(R_\
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M_#$5'AKAZ*G&HHY'E,5."FH32P&'2G%3C":C):Q4X0G9KFC%W2^XZ*^'/^$
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M9W5)VO:#5W=_#OI_>_JWI</N.BOAS_A /^"E/_1V7[#G_BO3X]__ $SNC_A
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M?#G_  @'_!2G_H[+]AS_ ,5Z?'O_ .F=T?\ " ?\%*?^CLOV'/\ Q7I\>_\
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M3Z)<>#;73/WLK6+YE>S2>U^J[_, HHHI@%%%% !1110 4444 %%%% !1110
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MDVE0:M;:_KF@6]["D_?YK+EMHM=U>W2[U^_8#B_&O_!3[X&>%_\ @H]\&O\
M@F;H^G:QXQ^-/Q,\-^+?$?B_7-&O=,3PW\(_["^&/B?XK:!H7BJ.61]0N_$?
MBKPMX6GU*+2K2*%]*TK6_"^KW4DUMK<2P^E^%?VV_"WBG]OSXG?L"V_@C7[3
MQ?\ #'X ^'_C[?\ C^;4=.?PWJFD>(/$'A[P_#X?M-,1?[3AU*WF\0PW$MU,
MQM6BMY50;W2OY]_!/[&D'[$?_!4W_@B_<_%#Q9IWCS]ICXWR?\%&/C)^UO\
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MZK<3_P#1.9]_X:,P_P#F?S7WGS)17TW_ ,,4?ME_]&D_M-_^&%^*G_S*4?\
M#%'[9?\ T:3^TW_X87XJ?_,I1_;&4_\ 0TR[_P +<-_\M#_5;B?_ *)S/O\
MPT9A_P#,_FOO/F2BOIO_ (8H_;+_ .C2?VF__#"_%3_YE*/^&*/VR_\ HTG]
MIO\ \,+\5/\ YE*/[8RG_H:9=_X6X;_Y:'^JW$__ $3F??\ AHS#_P"9_-?>
M?,E%?3?_  Q1^V7_ -&D_M-_^&%^*G_S*4?\,4?ME_\ 1I/[3?\ X87XJ?\
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M .;^C_AYW_P36_Z2%_L.?^)9? 3_ .;^CFC_ #1^]?UU7W@?<=%?#G_#SO\
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MU>MK ?$7P\_9 _:*_8;_ ."F'B+XE?LJ?#^Y\>?L%?MO3:CXE_:>^&NF^,?
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M":W_ $D+_8<_\2R^ G_S?T<T?YH_>OZZK[P/N.BOAS_AYW_P36_Z2%_L.?\
MB67P$_\ F_H_X>=_\$UO^DA?[#G_ (EE\!/_ )OZ.:/\T?O7]=5]X'W'17PY
M_P /._\ @FM_TD+_ &'/_$LO@)_\W]'_  \[_P"":W_20O\ 8<_\2R^ G_S?
MT<T?YH_>OZZK[P/ _P#@J+^S3\;/VB_$?_!-R_\ @WX*_P"$QM/@'_P4I_9K
M^/\ \6I?^$C\)>'O^$3^$?@"_P!:F\7>+?+\5:]H<NN_V3%=V[?V#X:36?$U
M_P"9MTS1KUD<+](?M@_\$]OV0/V^+/P%I_[6?PB_X6O:?#"Y\1WG@:+_ (3[
MXG^!?[#N?%L6BP^()/,^&OC7P=+J?]H1>'='79K#ZA':?8]UDMLUQ=&?+_X>
M=_\ !-;_ *2%_L.?^)9? 3_YOZ/^'G?_  36_P"DA?[#G_B67P$_^;^I]R\M
M8OFM=-IK1)+3[OF!^)'QN_X-U?V2/^&W_P!B+_A37['O_&&/]F_M$?\ #9G_
M !D%\3/^0C_PK9O^%!?\C5\;O^%J_P#)0]O_ "2O]Q_T.G_$CS7V9<?\$[]>
M^)/_  5F_:C^+GQF^!VA^*/V._BY_P $^]#_ &;-(\2:UKOA#4&U/Q!=:UX/
MLO$WA;3]'M_$<OQ-\-W@\*V.L)'XM32-(BC:!7T_Q -1:T+_ '7_ ,/._P#@
MFM_TD+_8<_\ $LO@)_\ -_1_P\[_ .":W_20O]AS_P 2R^ G_P W]*U/HXJ[
M3T<>R5O39V[OS ^7_P#@E5\$/VQOV-X_C)^Q3\<="U?X@?LP_!OQ'+??L4_M
M.7OC'X>ZK>^(?A#KDT6H0_!WQGX6L?$%O\1]*\0_#Z;4C!I.IZIX*B\,NEMX
MG\/:'JVG>#_#_P -[/6/V#KX<_X>=_\ !-;_ *2%_L.?^)9? 3_YOZ/^'G?_
M  36_P"DA?[#G_B67P$_^;^G%Q224DTMKM;:67XJWR ^XZ*^'/\ AYW_ ,$U
MO^DA?[#G_B67P$_^;^C_ (>=_P#!-;_I(7^PY_XEE\!/_F_JN:/\T?O7]=5]
MX'W'17PY_P /._\ @FM_TD+_ &'/_$LO@)_\W]'_  \[_P"":W_20O\ 8<_\
M2R^ G_S?T<T?YH_>OZZK[P/N.BOAS_AYW_P36_Z2%_L.?^)9? 3_ .;^C_AY
MW_P36_Z2%_L.?^)9? 3_ .;^CFC_ #1^]?UU7W@?H9X;Z7GU@_E-73U\S?LZ
M?M/?LU?M'CQA_P ,\_M#? WX\_\ "&GP_P#\)?\ \*8^+/@'XH_\(I_PD7]M
M?\(__P ))_P@^OZY_8?]N_V%K?\ 8_\ :GV7^T_['U7[%Y_]GW?D_3-<E5IS
MDT[K35?X4!_.?X(_9;^+/[77_!&?]E/X7?!K6/#6B>++#QQJ_C&XO/%6N:MH
M&FOHNE>-OC3IEY E]HVD:U=O=O=ZY8/%;M:+!)'',[SH\4:2?0_[(GPF^,_[
M /P>^/GC7_@H/^TGH'C;X8:EX=TJ#0_"&I^/O%?Q!T_3[;2+#7[;6=*TT>/]
M,TJ:;6?%UE=:7H.D^#/"L%^OB#9:VT\<EY'96L/\:%%?UUB_#K&XVCF67U>(
M<,LHS/.\7G%;#QR"D\PH_6\?''5*&&S2IF-1T9)PA36(AA%)J+?L[2<#_+7*
M_'?*,IQ>09YA^!L=/B?A[A'+.%<-C:G&V)CD>*65Y+/)Z&,Q_#M#(:$<7!PJ
MU:[P53,G!2FHJNYPC6/Z(O CC_B'Q^.#P@PJWQ/TT(BNS%(Y/VA_A*IBWG#.
M/+8QL3]]2=PY(KTK_@CCXVTWX@_L4?M-_LS^$K?X6:[\<;+Q7KWQ(\(^ /B[
MI5AKO@GQG8ZSX6\&V6A2Z]X;NKD7.O:+8>+/!IT[Q'?VMJT7AI=5\*WDK?:;
MFS2;^9.I[:YN;.>.YM+B>UN86W17%M+)!/$V"-T<L3+(C8)&58'!(S@FO2QG
M D<7EF>8#^TN6KFW$\N)\/B'@^:&#K_['[/"U:/UI/%TTL+*,ZBJX:4U6NH0
M=.\_!ROQGJ9;Q#P;G2X?53#\,^'5/PZQ^"CFG)5S;!)9HJV8X;%_V<XY7B)2
MS&G.E0EALPA2EA>656K&LU3_ *8?VT-5_:4^ G_!/_7_  [\;H?V,?@G<_'#
M7I=#G_9G^$_P9?2M>U6ZBU;2'N/%>C>)_#'Q,U'PK/KNC:7H>B:YJNLR>%+W
M3]'MX/#^E2Z^VNW6C:>WO_P._9WU;X??L4?LN_$/_@GS\#/V:_B)\6OB5X>\
M*ZY\6_B]\;8;#6M>\,W^I^%[:Z\7WNF:G=7]M=6%OX:\=:=/H=UX8TC5KFW\
M-3Z8$@\):[JEQK&N6?\ )?K>OZ]XFU"35O$FMZOX@U69(HY=3UO4KS5=0ECA
M18H4DO+^:XN72&)5CB5I"L:*J( H #[+Q)XBTW2]3T/3M>UJPT36O)_MG1[+
M5+ZUTO5OL[%[?^T]/@GCM+_R'):'[5#+Y3$LFT\UPU/#_%RRNA@H9O@Z59YQ
M6S7'TX95.GE..C6HK#PP=? X?,*&(Q%+!PC3G1J8O'8BI6J4_P#:'*+@J7KT
M/&[+*?$6,S6MPQFF)PD>%L'PWDN(J\24*_$V3SPF+>.K9IA,XQN18S X+$9I
M5G6I8JCEF3X&AA*-=O QA4C4>(_KU_X*/Z9J?C3XX_\ !,+Q)X:_:'L_@N+G
M4_C'_P (Y^T]I&A:1XL\#6'B[7_"OPIU?PD9EF\0Z/X6O-(^*%OHVLZ7I%A=
MZM>:+X@L[V:PNK/4-!EU*2+Z]\-^'_VF_'7BGQI\'/VSO@O^S?\ %S]G&PTZ
MYO--^.*W-IH:Z_8VUC<O:W6L?![Q!/XZ^P>)@RQ2ZQJ-KK?A'0_#NZ?4= U'
M53!#;#^#.NDF\9^,+C0H?"UQXK\2S^&;9Q);^'9M=U270H'7S,/#I#W3:?$X
M\V7#);J1YDF#\[9\JMX55I9;E>6TL[P;664,70HXJKD:AC,/+$YGB<RAC,%B
M\)F.&Q=&O0>)=&.'K8FO@)*+K1PM.I.?-])A/I)X6&?\19]B.$,TC+B#&Y9C
M<5EN&XOE5RO'4\NX>R[()Y5G&6YID.89;BL%BXX".+GC<+@,%G=-S6&GF.(H
MTJ+A_2O_ ,$Q_#/P^\>VG_!7;X,_L_:EI \-^.)=<\,_!6VO]1O5LIO!>O6?
MQT\*^"=2%W>1W>L3>'K>+4]$CFU&XAO=3MK*YLI=2C>^ND6?^=KXX?!GQM^S
MW\5/%_P<^(T&GVWC3P1=V%EKT&EWAU#3X[C4=(T_6[<6MZ8;<749L=3M29HX
MO)=RQ@DFAV3/YUI.L:OH-_;ZKH6J:CHNJ6C%[74M)OKG3K^V<@J6M[RSEAN(
M6*D@M'(I()&<&J,LLDTDDTTCS32NTDLLKM)))(Y+.\CN2SN[$LS,2S$DDDFO
MNLGX>Q.4YUG&8K,OK6#S:CEW/AJ^&;QD,7E^"PV CB)X[ZPXUHU:5"=2I!X6
M,I5:U_:)4_WOXWQ3QS@.)N$N%<BED#R[-.&,5GOLLPPF/BLKJY9G>;X[.9X*
MED[P2GAIX;$XRG1H55F%2$,/A>7V,GB+X=E%%%?4GYP%%%% !1110 445]0_
ML@_M%Z5^RU\9K'XL:S\*_#WQCLK/P_KVAMX*\3WEM8Z5/)K5O%!'J+W%UH/B
M.$3Z>8S)"ITQV8N0LT)^8\V,JXBAA<16PF%>-Q-.E.=#"*M3P[Q-6*;A15>M
M^ZI.;]WVE3W(WO+0[\JPV!QF98'"YGF,<HR_$8FE2QF:2PE?'1P&'G-*KBG@
M\+_M&)5&+<_8T?WE2W+'5GR]17]E?@_]L'X6>*?^">/CS]N=_P!D3X165_X,
MUR?1T^&JP>'9[34%A\;>&?"(N'\5'P#%-;%D\0-?^6- G :U6VWD3&:/\V?V
M4_VD_!/[<7_!4?\ 9U\33?L^> /A9H&C?#'XD>$K[P-IJZ1XET#7+FP\%_$S
MQ##KU_;OX3\/637JOJL%M&DVFW,D0TVWF2[SLCA_/\'QWFF(P^?XO$<*5L)A
M>'(9I#,:SSG U^3'99A%BYX*-.G3]I-U5*$%B*4:M"+ES7E:27[AFO@QP[@<
M=P3E>#\2\+F69<>5>'*V1X6/"><X3VN3<19F\MI9O.O7K^PI+#RA6JRP.)J8
M;%U%2Y>2FYPD_P"?JBOWL_X+<?L1Z7\(_'NC?M/?"G0['3OAG\3[Y?#/CS1]
M L[*TT?PA\3]-MYHH;RVL]/2"WL=.\::;IMR\\$-LR6GBS0M?GO[M+CQ%IUD
MGUQ_P46\ > ]%_X*5?\ !-O0]'\$^$=)T76_&/A./6M'TWPWHUAI>KQR?%C1
MK>2/5-/M;**TOT>!F@=+N&56A9HV!0E3TT/$' 8O#9#B<)A)UH9UEV?8V<?;
MQA/ 5^'\)2Q&*P5:/LY.=2<ZCI1J?NTHQC74)TZL4<&,\#LZRS'\:9?F>94<
M)6X0SW@O*:<U@ZE2CG.#XWS3$8#+LVPM3V\%2H4J5!8FI1?MI.I*I@Y5*5:A
M4D?RMT5_5/\ MK_MU:3^SQ^U%XH_9STO]@SX)?&'P=I$OP^&9O!5L=:\4KXG
M\/\ ASQ'<Z596UOX1UO2_P"TA>ZF^GZ2_P#9FIA+N*UFDL+J53 _QA_P6I_9
MR^!7PGN/V=OBQ\,?A_%\%/&/QL\/>(+OQQ\'].L=(TO2=&DT*Q\)Z@M^VAZ
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M(U\W?L;?\F@_LJ?]FW? W_U6'A>OI&OX/S;_ )&N9_\ 8PQO_J35/]NN%?\
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MW4\R^ _%7@35?"WBQ+"!KG2;^X5[BW?3;"]N]-_,SP__ ,$LO'>G_L9_$_\
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MHW<.GS:I'I =$N]0?3O#?AS2]/T.SN1I>BPLOS__ ,%6O''[ NL?L?>%M?\
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MJ.O>(=6U37-7NS-J&K:C>W]Q<7,MQ3C=?9WCW5]UMLGMK?H!K44450!1110
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M9**^M_LO#?\ /W,?_#QFW_S:?E_^L>8?] ^0_P#B+<,?_.CR_/NSZ;_X2O\
M8T_Z(+^TW_XEM\*__H**/^$K_8T_Z(+^TW_XEM\*_P#Z"BOF^PM&O[ZRL4=8
MWO;NVM$=P2J-<S)"KL!R54N"0.2 <<U]E_MS?L4^*?V&OB7X6^&OBOQMH'CJ
M^\4^!K;QS;ZGX>T_4=.M;6TN=?U[0%L9H=2+3/<)-H,MP9$/EF.XC4#<C9XZ
MM/*J&-P>75<9CX8W'T\35PE!YMG+E6IX-4Y8F49+%N$525:FVIRBY<RY5*SM
MZV&K\2XS*<TSW#97DM7*<EK9?A\SQBX9X34,)6S65>&7TYPEED:TWB986NHN
ME3J1C[.7M'!27-PG_"5_L:?]$%_:;_\ $MOA7_\ 044?\)7^QI_T07]IO_Q+
M;X5__045\R45V?V7AO\ G[F/_AXS;_YM/)_UCS#_ *!\A_\ $6X8_P#G1Y?G
MW9]-_P#"5_L:?]$%_:;_ /$MOA7_ /044?\ "5_L:?\ 1!?VF_\ Q+;X5_\
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MJ1C-*5I13;1]-_\ "5_L:?\ 1!?VF_\ Q+;X5_\ T%%'_"5_L:?]$%_:;_\
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MVGC_ .L>8?\ 0/D/_B+<,?\ SH\OS[L^F_\ A*_V-/\ H@O[3?\ XEM\*_\
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MW8'PY_P@'_!2G_H[+]AS_P 5Z?'O_P"F=T?\(!_P4I_Z.R_8<_\ %>GQ[_\
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MG='_  @'_!2G_H[+]AS_ ,5Z?'O_ .F=U]QT4^5?WO\ P*7^?E^?=@?#G_"
M?\%*?^CLOV'/_%>GQ[_^F=T?\(!_P4I_Z.R_8<_\5Z?'O_Z9W7W'11RK^]_X
M%+_/R_/NP/AS_A /^"E/_1V7[#G_ (KT^/?_ -,[H_X0#_@I3_T=E^PY_P"*
M]/CW_P#3.Z^XZ*.5?WO_  *7^?E^?=@?#G_" ?\ !2G_ *.R_8<_\5Z?'O\
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MXO%OQ(FTBTEUT?!WX@^%KW3[K0_&2WLZ:<)IEF:VC:\MI;>[M6^;_BC\%/\
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MTBP\5>#O",FB^%M ^(WASQ]K?B":_P#&WB+PUIEW:;O!]EX?NM/M;Z:_>+Q
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MO_\ H6]?Z6OTW_PR3\5/^AK_ &9/_$U_V-/_ )_5'_#)/Q4_Z&O]F3_Q-?\
M8T_^?U7S)11[+-O^@W+O_#7B?_GP'UCAC_H49]_XD>7_ /T+>O\ 2U^F_P#A
MDGXJ?]#7^S)_XFO^QI_\_JC_ (9)^*G_ $-?[,G_ (FO^QI_\_JOF2BCV6;?
M]!N7?^&O$_\ SX#ZQPQ_T*,^_P#$CR__ .A;U_I:_3?_  R3\5/^AK_9D_\
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M^@W+O_#7B?\ Y\!]8X8_Z%&??^)'E_\ ]"WK_2U^F_\ ADGXJ?\ 0U_LR?\
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MG_B:_P"QI_\ /ZH_X9)^*G_0U_LR?^)K_L:?_/ZKYDHH]EFW_0;EW_AKQ/\
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MT('[<?\ XK$_X*4__0FT?\/"_@)_T('[<?\ XK$_X*4__0FU]QT4>]WC_P"
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M6)_P4I_^A-K[CHH][O'_ ,!?_P EZ_TM0^'/^'A?P$_Z$#]N/_Q6)_P4I_\
MH3:/^'A?P$_Z$#]N/_Q6)_P4I_\ H3:^XZ*/>[Q_\!?_ ,EZ_P!+4/AS_AX7
M\!/^A _;C_\ %8G_  4I_P#H3:/^'A?P$_Z$#]N/_P 5B?\ !2G_ .A-K[CK
M);7M#77(_##:UI*^)9M)FUZ+P\VHV8UR70[:\@T^XUJ/23-]O?28+^ZM;&;4
M5MS9Q7ES!;/,LTT:,>]WC_X"_P#Y+U_I:A\9?\/"_@)_T('[<?\ XK$_X*4_
M_0FT?\/"_@)_T('[<?\ XK$_X*4__0FU]O3SP6L,MS<S16]O!&\L\\\B0PPQ
M1J6>2661E2.-%!9W=@JJ"20!5'1M:T;Q%I=CK?A_5M,UW1=3MXKS3=7T:_M=
M3TO4+290\-U8ZA92SVEW;RHP>*>"62*12&1B"#2][O'_ ,!?E_>_JZ^8?%__
M  \+^ G_ $('[<?_ (K$_P""E/\ ]";1_P /"_@)_P!"!^W'_P"*Q/\ @I3_
M /0FU]QU@3>+/"UM-+;W'B7P_!<02R0SP3:SIT4T,T3E)8I8GN5>.6-U9)(W
M561U*L 011[W>/\ X"_+^]Z_>NVH?'?_  \+^ G_ $('[<?_ (K$_P""E/\
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M>>[U P^,?#GA$W"^*AXBBAM@S^(%O_*.@3D+:FWWDS":+]/OV3_!FN?M$_\
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MO#K:[H'CK75NY?$C^(+V+4UME\$/;-"FB6)E;44E$L8M3'/U?C+_ ()L^+]
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M#S7,88K!8#B_(\+F^+Q^,Q66T:N;8NCA:]:679;.,E"E4]_,'C%&[_*/1_\
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MKI@U#XAG29-$M[+4=?UI/AS]I[Q5\+/VB_\ @O7_ ,$RK+]EGQ!X2\9?%/X
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M8KXM^&=M>V%U9>'OB6GB7Q%;ZA!XSN8-3OK&'PYI.EZ9'8:5J'BVR\3?9O\
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M?^!/BU\ ;.Z@9=5\<VNE>,])_P"%*^+CKFB:EH]L_C;5_"NO>"[P7>EZ[IB
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M$6A>*_"WB#XX?%_7/#/CS51KOCCPYK'Q+\9ZGH/C+6U_LH+K'BO1[W6IM/\
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M)'YG_"$?VI_PC/F?\)#_ ,3[?_9F[^V?^)IG[=^_KU'_ (7U\*_^C*/V9/\
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M *7I1=_RR_\ )?\ Y+^K/RN'TE\7?@A\&OC_ .$9? /QS^%7P\^,'@J6[BU
M^%?B7X.T#QKH46I6\<T5MJEMIOB&PU"UM-5M([B86>J6L<.H69E=K6YB9B:X
MS]G_ /9-_9F_94TC5=$_9P^!/PO^"]CKYL#XB?X?^#]'T#4O$K:2+I=*;Q-K
M=K;#6O$;Z8+^^&G/K>H7[6/VZ\^RF+[5/YGD'_#)OQ[_ .DG?[<?_A ?\$UO
M_I>E'_#)OQ[_ .DG?[<?_A ?\$UO_I>E+K?D=^_NWZ=>;^K>EP^I/ ?PH^%O
MPK_X2O\ X5A\-? 'PX_X3SQ;JOC[QQ_P@?@WP[X/_P"$S\=Z[Y/]N>-?%?\
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M4U.(AQ#=1K)('S_^&3?CW_TD[_;C_P#" _X)K?\ TO2C_ADWX]_])._VX_\
MP@/^":W_ -+THW^P_P#R73;^]_5O2X?47C#X2_"KXAZCX&UCQ_\ #/X?>.=7
M^&'B*V\7_#75/&'@SPYXFU'X>>+++ROL?BCP-?:UIM[<^$O$5IY$'V;6] ET
M_4H/)B\JY3RTQ4\;?!;X.?$OQ-\/_&OQ&^$WPS\?^,OA/JT^O?"SQ;XV\!^%
MO%7B;X::Y=7&E7=UK7P_U[7=*O\ 5?!NK7-UH6B7,^H^';O3;R:XT?2II)FD
MT^T:'YH_X9-^/?\ TD[_ &X__" _X)K?_2]*/^&3?CW_ -)._P!N/_P@/^":
MW_TO2B[_ )7_ .2^7][I^GI</N.BOAS_ (9-^/?_ $D[_;C_ /" _P"":W_T
MO2C_ (9-^/?_ $D[_;C_ /" _P"":W_TO2G=_P LO_)?_DOZL_*X?<=%?#G_
M  R;\>_^DG?[<?\ X0'_  36_P#I>E'_  R;\>_^DG?[<?\ X0'_  36_P#I
M>E%W_++_ ,E_^2_JS\KA]QT5\.?\,F_'O_I)W^W'_P"$!_P36_\ I>E'_#)O
MQ[_Z2=_MQ_\ A ?\$UO_ *7I1=_RR_\ )?\ Y+^K/RN'Z&>&^EY]8/Y35T]?
M,W[.GPF\??"X>,/^$X_:>^.7[1_]N'P__9?_  N?0/V:M#_X0W^S/[:^V_\
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M[PEIGB!H-$\4?#.ZUR^NO"6LZ;8/I=E%!+J>O=A^T3^QG\)_&?[&OC[XR?\
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M?/6J_P#!4#XA_'7]N6W_ &,?^"?GPG\*_'+0OA;>$?M>_M/>+]5URU^"7P/
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M2LY-0U*_UBU\1IX1M=1N4\2H/$::C\7/%OB#1/UWHHY(]MFFO+E22_!6??J
M44450!1110 4444 =3X;Z7GU@_E-73US'AOI>?6#^4U=/7'5_B2^7_I* __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>nt10016217x4_graphic31x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic31x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M (><9_\ +/+\^[/UV_X?@?M^_P#0Z> ?_#;>'O\ XBC_ (?@?M^_]#IX!_\
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M/Y8_^ K_ " TO[7U'_GZ;_OB+_XW1_:^H_\ /TW_ 'Q%_P#&ZS:*.2'\L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /\R%_O'\/Y"FTY_O'\/Y"FU_H@?X3G]8?P)^$W[,
M_P#P2M_8>\'_ +77QD^'%I\0OV@/'V@^');1;I;>\U67Q3X^L[SQ/X3^&_A*
M36([W1_!,6B>&X))_&WB>PL[K5+E="\1WUNVO0QZ#X:;XT^.O_!8CX0_M:_
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M=V\-Y'%<VEI,CVT7TO"&=\1YACL9@\XP>(GA(8+#XS"YK4R+'Y%"5>I)0Q&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M *,6J]6+3_C[M?\ KXA_]&+2EL_1_D!Z11117  4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M5R/BGQ_X'\#R:##XR\7>'/"TOBG7++PSX:BU_6;#29-?\0ZBVRPT71X[V>%]
M0U.[?Y;>SM1+/(>%0UUU4X3C&$Y0G&%3F]G-QDHSY&HSY)-6ERMI2LW9NSU
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M;7-'6XDT'7K9K@B.XL;C3C)8:DN5DMFAMYU$BM(!]YPG'A;+O''/,/*GA*.
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MII--6DDT[[I[6[GME%%%8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_,7]7?E8_P")9/!7_HD:O_B1<3__ #X/YH/^(?77O^CIM(_\-!>__/'IR_\
M!OIKA90_[4^E*A8!V7X/7CLJY^8JA^)*!F R0I= QX+*#D?TNT4O^(J<=?\
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MOAN+LIJYQ#-<:Z^"P\\$\)AXU*;JRA-5>:I.HL.ZCC!KGY9*,FXZM1/Z3_\
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MAXPN?&FA:K?:=XFD\5:YJ$E[<7EE?Z?+%=PS37DYCAB@D"JI2!%V )7^G?\
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M"=W[%VG_ +$OP$LO %UJ5MX@^(/B>_;Q9\3/$5G$T=E?>);N%(AIVEB4>?\
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MQ"^,376C75QX;N-*>/4+#Q'H?@>W\8>(/#.HP21-!XHTO0[>.5;J[M@_R?\
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M?[,_QK^"/[0OQ#^&'@K]I"Y^*/[.>C:3?_$;]E_4/@M?6W[4&A0^*=3T_0]
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MZ+U=1D C+ 9!. >3T)X'J>*_@K\9_$;XT3_L<_!#X<>-X_VG=4^#/C/]I/\
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M&G@J]33_ !%I#1ZE;VLLC6-U(B"XB1K>=75X))$(->[5_GQ>-[?]H_P+\$O
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MQ#Y<W]F_V]#I-EIGB3PS=7!'D0ZG!<V']H06\LBFZL+I6A#^7($_87_@@/\
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M'J]XD0CMO%5C8^((64_*]P\8M=05>/X;F$.PX.Y\GJ<?-DN3'(!C.UL<]."
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
MOKX@\4>,/A3:_'BYT6_\,7$WBX:K;12:H+N58VNI+32'BE$*P-&/W4ENHRX/
M[D\X:OM^O*[_ ."WPYU/Q=_PG-YH1D\2F\@OS?C4-0C5KJWCMXHG:VCN5MF
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M\5M&UK_@GU\:/V*/!GP(G\ Z"+O3OCU8>.=3\8WOCE]3UZXU?5].N_"OPO\
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MRJ7_ !0_[)O^T9_ZT?XKKZ1U?_DY+_@U-_[-P^/?_K%'P$K]0_AK_P $9?\
M@G%\(M"^/OA/X>_L_P!SX<\'_M-^%(/ _P 8_"-I\6_C6?#WB/PM;ZQ_;T.E
M6-C)\1&;PTL&JYN+*]\.3:7J.E6\EQI>CWFGZ1>7EA<?44W[&'[-5QXE_93\
M7R_#;?XB_8B\-Z_X1_9@U#_A,?'R_P#"L?#WB?P3H'PZUS3_ +(OBE;'QI]N
M\&^%]"T?[7\0K;Q9?6WV'^T+.YM]5N;R^N$HRM&]M%%;M_#)/LMTOO\ O _
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M;.Z_X1^VN&5SMN&TWSIG=U=]GO;\5K:WFW\@Y?-;>G;3\7]WW?M;^WQ^U?\
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M?WUC80>=J%Q%;PR,(8UD),MR\GR^3:P(&GNYI,A4@MXY978KM1B17UY^R/\
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M/$F,:F6*/0O#=U!J>HVZ3 F!M3U:0F,!9(3D@?ONJJBA45450%55 5551@*
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M-]U:7"%D;^TO]@K_ (+3_LI_MK1Z3X.U/6(_@C\=+E(XI_AAX\O;>VM]:O
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MZ;=O]F\+:OHP60S^(]*6V-^S-#=Q7&#(GYK%<AE<8SD,N2,J<CG'/*]\'!Y
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M3;.:?P)\(? OAVT&@Z+;Z#I]\L<VKOIX^T6VDMJ$2+J>KR7E]=P_9+9(G_I
M^(7Q#^'GP$\ R:]XBN;+P]X;T*TCLM*TJRB1)KN2*(1V6CZ+I\(#3W,VU8H8
MHD*IDRRE$5W'\R7[2'[,OQV_X*C_ +1P^)'PX.@>%++2O#UIX3U-O$HOFT+P
MEH&GWE_?:6\U_913-J>OWK7\TMYI5H,HS1MO2!1*WH<+\5UN,\=B,1Q5A,KR
MO@3!SEB,=7K4I0695<+*E4R_ 9AB*E2<,33AB(4<7BZ>%P]&GBL12H4L0JGM
M84Y\V:913R.C2HY57Q>+XAKQ5.A"$T_JT*MXXK$X>E%)TY2IRJ4J$JU2I*A3
MJ5)TG!1G-97_  21_:^_:]^*?[:VE^#/''Q?\<_%#P9XI\(^+M8\<:-XKO(]
M1TO2(],ABFTO6]+B2W2+09DU&5+".WL1;6EU#*86B)BC9?ZUZ_F4_P"$S_9U
M_P""'WAN[\#^'X)_VB_VR?B?I5GJOBW4&>+0]*\/>'83)'I-M>W 6Y'AKPM'
M=K<S:?H]JMUKFLW'G7MULB$<B?H+_P $PO\ @H[XB_;KMOBCHOCCX=Z7X%\8
M?#270KUYO#FHW6I^'M8T/Q&+Y;)HS>QI>6FIVEQIUS%=P2[HY(V@G@8AG0?,
M>*&1XKB">)XYX>R"C@.#<%A,'@J6.A2PV73S**KRI+-*66WI8EX6I5Q%+"T*
MTL/&=2A3I5>50;5/U^%<PHY>J>0YCF,\1G5>M6KSH2G6Q2PS=*,_JD\6U.G[
M:-.FZM2FJK4:DY16K3G^LU%%%?AA]Z%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y?1117H %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6+3_C[M?\
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MDZ99"3,FC>!=+N,1W^H/'\EWKURD\22$EI'=/)3^<N,^$\;1S2679WC\#DG
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MH'B_P_XVU+5AK>IP2R/KL\L^AZ<]M=2K&88UD5 PE)'ZN5_.-_P1,^!G@O\
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MF5\U]1?#/XU>/?A9/$?"^J)<Z('!G\,ZF6O/#\T:]$@M]ZR6+*% 22REC"#
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MC:Q97.FZII>HV\5U8ZAI][$]O=V=W;3*\4]O<02/%+%(K(Z,000:^(_V+_\
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M?%K2M,T7XD):^#O#/CH6AEL=-U#5+""W\2RQ0#1YA>S V]RD\P4JZU\Q7/\
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M76B>*?@%#8>'Y;#2M6\8:)=6.GQ0>(OBK 9/%&H7VCPSZ'?O;I+97D[+(D/
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M.DH0IQE&2YE4WE*[246Y)IRNERHYG_@LM\%_$7CG]E*T^.WPULYI_C3^Q?\
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M;;_X92_XNA_PK+_AF/\ :T^%7[4?_(D_\)G_ ,)O_P *R_M;_BAO^1M\)_\
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MAL:3\+[/Q/::;H_@_1WT>^TBV\-V'BVW>&+Q7XIFTW4M+T^\TS0]']'^)_\
MP2\^,G[1?[*WPA^''[1?[9=QXH_; _9S^+D'QA_9Z_;2\!_ CP3\/-?^&^M:
M1<VY\/Z+>_#?1-9BT/Q-X?BLK:VBUZQL]6\)KXDN=(\)WNKBZO?#37>L?LO1
M2Y(]NEMWWOWWOK?>X'X7^'_^"67[4?QT^/GP%^,/_!2C]M30_P!J'P;^ROXJ
ME\;_  ;^"/P[^!^C?!OP5K_Q%LAI7_"/_%7XJ76C:RSZ_K5K=:/::O)X*72[
MOPY97Z3:;I.J6WA/6?%OAKQ/W_QC_P""</[2/A;]I7XM?M-?\$\OVN]"_91U
MG]I6S\/Q?M&?#;QG\%-$^,'P_P#%OC/1+'6-&L_C9X7MM5UBS_X1CXAZ5INJ
MK?RZ/;:<N@^-/$EJVI>,+VYM]0U.SN_V1HI\D?.][WN^:]K;WOMIH[ ?E#_P
M32_X)DZO_P $^?%W[5OCGQ)^TEKO[2/BK]K#QAX%^(7C+Q%XF^'MGX'UNW\;
MZ#;^,[OQIKM]=:?XP\2V6M'QQXI\<ZOKUO:V^FZ#'X:M5@T</K94ZD?U>HHI
MI)*RV^;W=^NH!1113 **** "K%I_Q]VO_7Q#_P"C%JO5BT_X^[7_ *^(?_1B
MTI;/T?Y >D4445P %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9'B#7]'\*Z%K'B7Q#J%KI.A:!IM[J^L:G>RK!::?INGV\EU>7=S,Y"Q
MPP01/)(Y. JFM>N6\<>#= ^(G@_Q/X$\568U#PUXPT'5/#>NV)9D^U:7K%I+
M97L(D0AHV>"9PCKRC88=*UHJBZU%8B52-!U::KRI*,JL:+FO:NG&34744.9P
M4FHN5DW:Y%3G4)^S474Y)>S4VU!SL^52:NU%RMS-)M*]M3\(/''_  <%_ K2
M/%%SIG@+X,?$;Q]X5MKJ6W7Q<^H:-X;CU."*5HS?Z5I&H>=>RV4R+YMJ]Y]C
M>=&5O+16#5]^_LB?M>?L<_M<7.K_ !2^%UEX9\-_%:WL(/#GC/3O%6AZ'X>^
M)UAIMQ+]IM=.U"[(^U:QH5S/&9;2>TO;O3I9HVV[95=1^(7Q3_X-^_CAHWB:
M[A^"/Q<\!^)? DD\K:-%\0+?5-%\3Z/8^8QM=/O[G2H[ZQU=K2(K']NBCLGN
M FZ2W1CS]1?L]_\ !$?QA\)/#>I^(M<^-.B:C\5M<MXK6XL;#P[=1^$-*TZV
M9KB&RL;\WT>L37DER09]1>.) H416RC<3_0^>9+X'RR.G+(^)J^69A7C2ITZ
M]*MFF,KUHRE!U(9K@*M-0I0<8N51QC@X0JJ/+S1]R7YQE^8<>QQTUCLKCB,/
M'G=2DXX6A2C:.GU7$0J.4_>MRQE[=RC=.S=X_K[\=/V>_P!G'Q)X6\2^-_B)
MX3T?1[3P[H>J^(-7\6Z,5T+4;+3=*LI[Z]O)+ZR$:2+#!#),S3QR [<DX)K^
M.SP[^V_X*\2W6LC7_A_?Z?X(U77-9E\*SQS0:[=2^#FU"XC\-7/B2PNH8UN-
M4N=&6WNK^:T(C#S,L<*XQ7ZK_M4Z-\4OV;O S?"']H'XMKI?PR^.D&J_#^UT
MI?&UY<67BNV%D+[5]/M5N8FU714CL(E-U?QRI#$L@MWE_P!(17_+;5?V,_A[
MK]F+SX<>-[K3K<1J+2$O9^*-&2)%"PPQ3VDT-U'&D>U0S"3"@=<BOJ?"_)L/
ME]+'U\TXEJ9[D]=4,/D]3"5,54PF&JTY.IB:D_>JJAB(WH0C1ISJ0A"4W5BI
M2AR^-Q7CI8F>&IX;*EEV-@ZE7&1K0HQKU8RC&-&,&N55*3_>.4W&,W)14&E>
M^M>?#G]EKXP6&H:QX9UC3- OX;.ZU&[E\.WT>D7T$=O \\[7?AS4#Y3[0AWB
M%$W,>&.<C\X[;2=:\1:[I'A+P-I]QX@\4^,/$UAX.\":2(P;K6M>UW45TW1(
MI(4X1<R+>WV"5@M8+ARVU":]2^+/P3\3_!ZYTD^(+_0[^WUN2ZBTB\T>XF6>
M46>#<-/:S)'<6Z!7 9F9XV8LF3D5^K7_  0D_9@A^+?[1_BW]I#Q-8"Y\(?L
M[6+>'?!(GAWVE[\6/%]A_P 3#4HRWR/+X5\)SR6R[2SV][K"$A)4S7Z9Q5Q#
M2X*X1S;/J.8U,?>G##9-3Q,E47]H5G.CAX*7NNK&%2]:M3M!1HX>JE%-2/FL
MGRV>=9QA<!+#J@N9U<;.FN5K"P49U96U4)3C^ZA)73JU:;VU7]'O[#?[+/A/
M]B7]F#P1\)+*6T?5-&TF;Q/\3?%;I'#)XD\=:LC:KXNU^^N"JN;>.[>6VL?.
M9OLFDV5G!G;#S^#W[>?_  <?>%O!]QXC^&7[$7A>V\<^)+*XOM&N_C;XUMYX
M? VEWMK*]K=3>$/#*F'4/%\EO,DJP:C>W&FZ,9426--1MV^;^FSXLOY?PK^)
M<AZ)X \8O_WSX>U%O?TK_)NNCF[O3SS?Z@W))ZWUQSSG^=?YZ9GCL54K.M4J
MNIB,94KU\17J>]6J5IU(3J5')WBZE2=64IRDG=NZMJSW_&3C;-^!<CRFGP_'
M#8>OFE?$8*.)J4E5E@:&$P]*47A:4FZ'M&IQA&5:%6%.,=*;=G'TW]H'XV?%
M;]JKQ5J'C3]HGQSKWQ>\0ZB9HS<^,+IKZRTRWF<2&P\.Z2-FG>'-.C8@Q66D
MV]K&K*'<R/ES\Q#PKXF\*GS? >LB^TU 6;P=XHEFN;0*.L6DZR"UUI[$$K"D
MXFA#;00H!->DU].?LL?L>?M"?MF^/V^'7[/O@.X\7ZO9+9W'B/5KFYCTOPKX
M/TR^F>"#5?%&MS!X["UD,4Q@@ABN+V\$,BVMO(PKR%*;DTN:<I2^%WJ.3]W6
MVNK5[ST:2UE%)G\FY/G/&.>YK+ 8>6*XHQ6<5W5Q.59E!YKA<=4C#WZU2AB9
M\N$E2HQ?^WX:K@J^$HP7L\51A%6^*]*\?:3=WBZ-KEO<^$/$9X_LC7=L,5RV
M!EM-U/Y;.^C)Y4*ZR[<%T4D"OTT_8[_X)G?M=_MNZM;+\(?AM>Z;X%,\4>I?
M%SQU!>^'?AUI\+.!)+9:E+;M<^)[B-<N+'P]#>,P WS1*=X_I_\ V1_^#;']
MF3P1X=34_P!LN[B_:2\:W^GRQ2>$H8[SP_\ ##PI->0&*4Z3!;7,>O:WJ5J&
M(M]9O[RRC20>=!I<3A9![+'^PW^W]_P3LC34O^"<7QJA_:%_9^T?,G_#$/[3
MVJRO-H6D0GS6T?X*_&>'??\ AT+'YD.FZ+K^GS:7%(R-++<2%W;NI8%NTJMX
M+5.DI)NU]%SK9/>T92DEISZV/Z*X=\ ,HJU,)FG$<*V#<J:J8GAC!9A/%X*G
M7YDU'^U94Z6-6'<?CPBJ8BK3E[JS;$0U?3?L-_\ !!?]E#]E<Z1XU^*=NO[2
M'QCLFANT\0>-M,@B\#>'M0CP^_PIX"9[JQC:*3F._P!=N-9O2562-K8_*/W(
M)LM+LBS&UT_3[&W+,Q,5K9V=K;H2S$GRX;>"&-223LCC123A17X9S?\ !=[]
MGGPU\*_C*WQW\(>,/V2/VH/A#\//$GBNY_9V_:)L+CPW=>*=:T739)K+3O /
MB^"#^Q/'6G:OJ1M[*SN]&9+Z2*X6[&F^0I>OC3]E[X@?&+_@XG\.W?Q,\=_$
MW_AG#]@?PCK,7ACQ!^R_\'O&[W7QD^,'BNRM;6XU*+XT>-[&'3KGPOX!GG,K
M:-X>TRT$^N6&Z266.6(7<??3A3IQY:48Q6]HV5V^LGNWKJW=G]!Y;E>79/A*
M. RO!87+L%15J6&PE&%&E%:7ERP2<YO1SJ2<JDWK.3=V?H1\9/\ @LI\,?\
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M9:M[=/Q\S[!_;N_X(Z?LF?MQPZAXGU306^$_QJE@E^Q_%WX?6EG9:G>W6TM
M/&6B&--*\6V:RA3+]L2WU/R]T=OJD (Q_%K^W'_P2F_:R_82U"_U3Q]X3D\=
M_"-+F5=-^-'@"QO=1\*FV+GR?^$JL%2;4?!=](A4O%J8FT]Y/,6TU&X6-C7^
MBE\#/CI\*?VD_A9X1^-'P4\9Z1X]^''C?3(M4T#Q%HUPLT$T;_+/:7<61-8:
MG83A[74=-NTBN[&ZBD@N(D="*].U'3M/U>QN]+U6RM-2TV_@DM;ZPO[>&[L[
MRVF4I-;W-M.DD,\,J$I)%*C(ZDA@0:YJV%I5KR7N3>O/'KI;WX_#-6[Z]I(_
M/.,_#+A;C:G.IF&$6$S3EM2SG 1A1QT6E[JQ'NNEC::T7)B8SE&/NTJM)^\?
MY&HVE596#JP!5T(9&![JP)# CH0>?PHZ<8Z^HYX_SS]*_N8_;V_X-X_@9\<?
M[:^(O[)^H:=^S]\4+EKC4+GP8UG)<_"#Q7>/F0QMI5NZ7?@N\GDSB_T,3V"L
M^9='/,@_CF_:1_9<^.W[)/Q#N/A?\?\ P!J?@3Q4L<MUIIG>.^T/Q-I<4P@.
MN>%M<MLVFLZ2\CHAFBV36\CK!=00S;E'E5:%:@TI1;@K6G&\H/;?2\)-]))*
M_P ,I-G\?\<>%'$W!'M<76IQS3)%.*CF^#C+DI\\HPIQQV&;E5P<Y2<8*3=3
M#SFU&%=R?(O(?"7B[Q5X"\2Z/XR\#^)-<\'^+O#]U'>Z'XG\,ZG=:-KNDW4;
M I-8ZE920SPY8#S(V9X9ES'-&Z,17]1W[ /_  <;^)_"@T/X9?MV:5+XL\/H
M+?3[3X_>%+)8_$6FQ+MB2?XA>$K=?)U>!!@WGB'P^UO=1A#-<Z/<L[S+_*?4
M%W_QZW'7/DRCMT*$?YXJ:52I1]^$N75-Q=G":T^*/>WVDU+S>QYW!/B#Q-P9
MBZ,,JQKJ9?6KTUB<IQ?-6P%;GFE*4:7-&6&K--_O\-*E-NWM/:07*?ZX7ACQ
M-H/C3PUH'B_POJ=KK7AKQ3HNF>(?#^L63B6SU71=9LH=0TS4+63H]O>6=Q#/
M"Q W)(IQS7XV_P#!;3]C$_M ?L\'XY> ])-U\9_V<;74?%.F0VD.Z\\7?#IP
MDOCSP=-L&^;&F1RZ_I*[)7CU/342% URS#]%_P!B\ ?L@_LN@=!^S]\( /\
MP@=!]*^DKFV@O+>XM+J*.>VNH9;:X@E4/%-!/&T4T4B,"KQR1LR.K AE8@C!
MK[#*<SQF39C@,VP%1T<9@,31Q5":V4Z<E+DDOM4ZD>:G5@])TISA*ZDS_0G$
MX:CC\'5PN)@IT<51=.K'^[..\;[2@[2A+>,XQDFFDS_/O^!/[2/A3X:_#/6;
M.'PI%?\ B2_FCU+0=2M$$"^(K>_CWQ)XEOB3-#'HSEMD,(VSQYA"QS!F'@'C
M7QSXJ^(6OS^)/%FJ2ZAJ$A*6\2DI8Z9;!RT=EIMMDQVUK'D\+\\A^9V9V.?I
M;_@H!^S,_P"R+^U]\5?A)86;6_@/7[G_ (6M\)I-FV >"O&=W/<:AH<)!*_\
M4MXG75-+CC#%EL39L45=H,7P;_9:L_B=X-T[QS?^-YM,T^]NKZWDTS3])BDN
M+6:PN#!-'-J%U<I;!B%2;*Q$HD@)&0<_Z$9#G61YADV"XMI?NX9U0I593E[2
MO.C7E#EKX-<JFX.C7I5:51*R<Z;3?*H17\ZX_!8W"XW$934?-/!5)PBO=@IT
MU*,H5FKQYE4A4A.-]>6:T5W?]2O^" /[34OA+XF?$S]D/Q#?8T#Q[;7GQC^%
M4<\I$=IXBLDM[#XB>'K)78@)=6\.F^(XH(514D>_?:SNSU_5R2%!+$ #DDD
M >I)X%?Q'>!O!7P,_9C\:^&/C#I_Q*;0?'GPUO+K7?#_ (EU+Q1:M+I4\FGS
MV&H-/HMBC1WMG<V4LL=S9W"RPR ([@F(5^T6B_ W]M[X\Z5IGB'4_'UZOACQ
M%86FLZ5J.H^.7ATZ^TO4H$NK.\M+'PZB*T%S;3)-"OF?<<#CK7\S^(G ^5XC
MBG'YY'/,OR#*<XG'%J&80G3KSQO+&.8O"4+TU7IRJN.(DXU%*-7$2@X12@Y?
MI_#?$.*AE.'P/]GXG,,7@TZ#EAG!THT+WPRK5/>]E*,'[)*4?AI)IO6WU_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M '^A_P#CE']BZE_S[C_O]#_\<KNZ*/;S[1^Y_P"8'"?V+J7_ #[C_O\ 0_\
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M +_0_P#QRC^Q=2_Y]Q_W^A_^.5W=%'MY]H_<_P#,#A/[%U+_ )]Q_P!_H?\
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MDR^,/$]K<M^Q?^SYKR&[T/\ 9I^#6I2>=HWB>YTJZ0VO_"VO'.G"SU/5M8$
MO-,MGCBBF6298;*;:I_:[]-.ZVMTMU^]CTO=I;6ZJ^VFC^?S\SG?!7["G[2/
M_!2_6M+^.W_!4;5-5\"_ V6\A\1?"/\ X)W>"==OK#PKHFF,3+HNJ_M&:_82
M6=QX\\8O92*]]X:5(M)TNXFF@+1XELA^Z7@+X>>!/A9X5T?P-\-O!_AOP)X.
MT"TAL-%\,^%-'L-"T33;2!!'%#::?IT%O;1*J@981[W.6=F8DGL:*:26O7J^
MO]>6POZ_KUMJ%%%%, K,UC1='\1:9>Z+K^E:=K>CZE;RVFH:5JUE;:CIU]:S
MHT<UM=V5W'-;7$$L;,DD4L;HZL592"16G10!^(?QF_X)(W/PH\9ZK^T?_P $
MM_B*?V/OCUYS:QKWPMM4N;O]F#XW2PEYY-!^('PVBE&G:!/JI)M5\3>';:.X
MTYI?M*632KYH]_\ V$O^"AUG^T]JWC#]G7]H#X=77[.W[:OPGM!%\6?@%XGG
M2XM=;TEP8(_B%\+M6F5(?&OPZUWYI(+RU22;3_,^S7RO&T%W<_I[7Y>?\%*O
MV%-7_:7\+>%_CE^S[K47PO\ VXOV;Y;CQG^SM\5[!%MKG4+VP5KV]^%/C2:(
M*^L_#[QTL;Z3J6EWYN+.TEO&NT@*27<<ZM;;U:[_ /!_#OW3_KM]_P#7S/A?
MX[?#OQ%_P1@^.6H_MD? '3=1OO\ @GM\9O%]G_PV;^S[HT$T]C\"_$>N7<=G
M#^T=\+-)AWPZ;H@N)U3X@>'K*&WM_(2&:$&-[?\ LW^@OPGXK\.>._#'A_QI
MX/UG3_$7A7Q5H^G>(/#NO:5<QW>FZOHVK6L5[IVHV-S$S1SVUW:S1S12(2&5
MAWR*^%/V&?VI_ O_  4?_9(DU_QGX-M=-\1S)XE^"W[2WP7\26<<S^#_ (D:
M+;G0_B#X+UG2[L2F32[SSVO--:Y0BZTB_MRX$R3)'\/_ /!,[7O$/[$7[3GQ
MH_X)*_$O6=1U+P=X:L+GX\?L,>)M<N6N)];^ 'B#4[F/7_ABMY<.'N-1^%.M
ME;:"W1&)TRZEE3;!#&BB\MGMTM_P_P"?JK%F[Z:I:^FB_#\OQ_>NOXL_^#HW
M)^/G[*7/"_"?XA\=AGQ5H@X^N!GI7]IE?Q9_\'1G_)?/V5/^R3_$+]/%6B?X
MURXW_=I_XZ/XUJ:?X-^FY^:^+_\ R;?BGI_LF$_]66"_/8_ET]>^1P?Q'KSZ
M_P#ZJK7?_'K<>T,I_P#'#_G^=6>,]<#/7GI_.JUW_P >MQ_UPE_+8V?TKQE\
M#UTL];[6MIZ>7^>G^?V&TQ.'_P"O]'5[7]I'?^O0_P!4G]B__DT+]E[_ +-^
M^$/Z> M!%?2]?-'[%^/^&0OV7L?]&_?"'\_^$"T'/ZU]+U]''9>B_(_U'I_P
MZ?\ @C_Z2C^?+_@X'^ ">)_@-\.OVE]'L=^N? GQ?;Z/XGN(8\O+\-_B%=6N
MAZ@;EP1BWT?Q!+I&I("K[1)<$%,DG^6C3KSQ/?+9^%-'U'7KB"^N_*L/#^G7
M]VL-U?W9"[;>QAECADNKEE4,?O.< FO]"[]I_P"$NG?';]G?XT?"#5(4FMOB
M#\-_%GAN+S(5N/(U"^T>Z72KN.)^#/9:D+2[MV&&CFAC="&45_G?^"]2UOPI
MJ_AW4)K24^)?!NN+!>6$N]I_[<\+:G-IU[:7"Q#S@\EW82B81J7 8@#C _K7
MZ/&>2Q.3YYP[4<:D\LQ-/,\!&H]%2QL)4ZT(WNU"GBJ$:LI):3Q<G>[U_)/$
M; 1I8S 9C%.,<52GA:[@K>_AW&<)2LTY.I2J\B6S5"*/6[/]F7XRZY'+!)\.
M;^*&ZBFM[AM6NK*S9H)T:&9)//N#+M:-F#J06()XY%?U%_L'_ML6'P,_9"^$
M'PG^.^E^)=0^*'PVT6Y\&WRZ#%;:O9WF@Z)>SV_A6]&J--;V^Z30OL5NUMEY
M+=K8K(Q)&/YRM7_;(^,%T\IMO#_AS1M[N5']A:C>2IO)(^>\R&(!Z[0<FOU,
M_P""-/B_P]^TU\7_ ([_  Z_:(TG0O&>H:%X2\%^.OAY#J&E&Q%GILU]JFB^
M*K9(X%A@FMX]0BTN8&X,DH:Y95"KNKZ'Q9RZCC>'J&<<69>ZV!R3%0G&&3UK
M8R+Q\Z>$:G*K-0EAY598=U%"<)J<:<U>,9)^9PCB:U#,:F"RC$1IU\;1:D\9
M!NB_JZ=9.$8JZJ*/M%%M234Y)K6Y^L&L?\%2?"<<JQZ%\+M>NE=MJ2ZOKFDZ
M;DDX&Z.'[8ZD]0#G'>OY;/VU/VXOCU^T[\5O&#?$/QEX@\'>$-+U>_T[PU\(
M=*UO4-$\.^'M)M9GCMWU&VMY+"3Q!J=Y'&MS-J]ZKPR%PEI&D2@5_<3H?P#^
M!WAU5&C?##P):8^ZZZ!IDLG/_32:&1CZ9SGWKP[X]VO[ WA;6-(OOVB[#]G/
M2=?\A$TB7X@Z?X/36#:P8$:PI>P->M:QY 3>AA' 7IQ^0<$\;\&\.YNZV3\!
M9GC\94H2IT:T<2\=F-)Q:G*6'P]2&(C!S22JU*,J=2,%92<)3C+[+.\ASS,L
M(H8WB'"T*,:BE.FZ7L,-.ZM%5*L72<N5N\(5(2A-O5*7+*/\\_\ P0FT#]HW
M4OVA=3\4>&-0\90?LYZ9X4UBT\?RZQ>ZK-X)UWQ#=-;#P[9^'[?4I9+:Z\16
MLR37-Q?:6 EIIZ2PW4I:YABK^NRO)O@_XY^"OC/PM;O\#O$?@'7?"&G!;6WA
M^'UYH\VD:>%&%@%II!$5GP.$:&,D#."!7K-?!>(G%%;B[B7$9I7RB.23A1HX
M-8)QDL2H4.>2J8Z<J5&57%3]HTY.E34:4:5))JFI2^AX;RJ&3Y73PE/&/'*5
M2=9UTU[*]113A0BIU%"E'ETCSRO)SDVN;E11117PQ[P4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!=[C_THEK\CS!>_AWVC7_.C^?Z>9^%?26?_"=PBN^/S9_=AL$OU&5_5_\
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MX5*BG451N=[QB^BBBOQL^U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME!YKX3\5>.O&/CB\:^\7>)-7U^Y9G;=J5[-<QIYC%F6*!V,,29/$<:*BC(4
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M_!^N2WGA_3+YM7U%?#=G'JTE[?1RM!,T=]"H@CB5 ,''[S_#[_@A=_P2_P#
M5VFJW7[-&F?$O7E*N^O?&3QAXZ^*FI3S!@YGG'C#Q'J5E+*[C+L]F<\C 7BO
MXFXXJ5JO&7$]6OAYX6M4SW,IU,-5G2G4H.6*J/V4Y4)U:,I05HMTJLZ;:O&<
MD[G[ID,:<,ERF%.HJL(Y?A(QJ04XQFE1IKGBJL85$I:M*<(26BE%.Z7\^/\
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MDGTH _$+_@@?$=(_9=_:$\%H[/:> _V[?VK?#.G]?+2R@\?-=11Q _=C0W3
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MA:M;NL]AJ.J^']!BM9KFZMI426TBUH/;I,HD^SNZJ5_>P         #  '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1)9;$W,4;76FS6MRJXD(46EUWNU^%_Q?X@]=?1/RMHOZ[W['VU1113$%%%%
M!1110 4444 %?#7_  4L^/UK^S%^PE^T]\99;K[-J/AOX3^)['PPJ2".XN_%
M_B2R?PYX5LK,$AI+NYUS5+)((8\R2,-J#/(^Y:_!'_@I7=O^V?\ MJ_L<_\
M!,_PO+_:?A'1/$]A^UU^UZMJ1-;:5\+OAM?PO\.O!^M,A:.!_'GBTR[;.X"R
MRVUC;W"(8R&(_P"OZ_,:W]-7Z+OH]]OF??G_  3!^ UW^S1^P%^RK\&]5@EM
MM?\ #'PA\,77BF*= EROBKQ':_\ "2>(UNAC)N4U?5KN.9FRQ=#N)-?S2?\
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M,(RDTC]JK\5Y!AZ$J\\PIN,6ER0IU9592>T8TN13;T;>B44G*3239_0F !P
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MP:S?V]^XG=(WCN9CIBWBP1RQI*RRMY=?-G[/_@+6O"GQM_:H\0Q_#3XG^!O
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MU_LF:"C"7XBZ)IJG;\</A;I]NNR'XH^&;4W,FL64<,I\16DDLK1O*]V6Y/\
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MULHQE2<K6IT:&:4L'/$3NTN7#>V=_4[J.8X+$.U/$0<OY9/DEVT4[7UTTO\
MBCZ)HIJLK*K*058!E(((((R"",@@CD$<&G5^HG:%%%% !111UZ4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?(/]=*&0Y;G6;<4X#,<3G/"W#U3'5<?BJF$RC)J\\?BX9O'!^THQIPK4\;#
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M$?!&FH2L&EZ5^U#XCO+6VA (CMX?[2L;EUBB4[4&XD*,9[TR,?\ !P;\*V>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+]I]'U*WUG2=+UBT$HM-6T^SU*U$Z".<6][ EQ")D#2*DHCD4.JR.JL"H8@
MG0SQGVSV_P ?_K>]?FOXT^(GQ(\8_&'X"_LN>!/&FJ_##2-8^#VF^/O&WC/0
M(+5O%-W86VG>5:Z1X;O+R.:+3Y";)WGG2,N#-DY2/8V1HOQ=^+'P\\;_ +3W
M[.WB;Q[K'CN;P%\'-5^)7PZ^(VHP6D'BW3()-)WBQUR_L8HX;V_LKF>">SNI
M(5ES#*<>6XC3XK_B7[.L5A8U\'GV0T\SQ&24N,\/PM7EFSS:CP)B^*X\)8;/
MJV-CEDLGG5AC9PQ=7*X8]Y@\L?UI4W7OA#H7$M"$7*IAZ\J-.H\)4Q<?9*E+
M,(818J6'C3=155%J\%6Y/9>T]V_)[Y^H&?PST]^,_P"<9]:0^G&"#DD_YSU]
MJ_$W0_%?[2EK^QKH_P"UI<?M%^,;[Q/X;V:G#X,O$TR?PAK7ARQU\://8^)$
M-NMYJVM7Q,DTM]-<DQ1E;:*)3&LH['XM_M7^)O&7Q6^%WP^;QA\2/A)X'U/X
M.^'OBEXKU#X1^%]0\3^/]3U?Q181W5GHUL-/L-2N=,TG3RX,]RMLT3G=%.VZ
M6''TL?HH\58K.,;EV3<4\.9]A,CS?C?(>)\RRO"<25'D>;<!4LOKYQ@5EE3)
MJ6:9S6Q%/-<!2RV6387%4,3BJM6C4K4*5!XB>7^M>&C2I2KX/$4*F)A@ZN$I
M3J8=K$4L;.<*51UH594J,8^SE.?M91E&FX/EYYN$?ZUO^"</CJY+^-_A_<SN
M]I&EGXDTZ)R"EO)(YL=0\L8R!-NLV*@\%"3R:_5ROY:_^"#'Q5^)WQ#\9?&O
M1_B"OB[6;?X?SV>C^$_'GB[PEJ'A'5?&7A;6[UI]+GU+3[ZTM=^JVO\ 8D_V
MV0 2'SXC,JN1O_J4K^XO"/A7B#@?@G \(\28C#8S'9!BL?@\/C<'4K5<+C,K
MJXF>.RRO0EB:5#$PA]4Q=.FL-B:%#$X)TW@L10HU\/4IQ_6>%,PAFF18/&TX
MU(0J^VC&%5)3A[*M.E*#LY)\LX22DFU))-:,****_33Z(**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI-UHNLV<D;,C/]ENT07-LY&8;VT>XLYXRLL$\D;!ZX[!SCO_ )/^?2O]2/\
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M=Y=W=K86MQ>WUS!9V=I#+<W5W=2QP6UM;PH9)IYYY66.&&*-6>221E1$4LQ
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M:/M7#VLHJSJ+<_'[]E[]DV7XM?LM_"S3/$7Q6^(NA?#?69I];\8?"2W@T_\
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M44?\0MX#_P"B?I?^%V:?_-WE^?=A_P 3(^-7_1;UO_#'PS_\Y?+\^[/Z1_\
MB(J\;?\ 1K/A;_PZNK?_ ##T?\1%7C;_ *-9\+?^'5U;_P"8>OYN**/^(6\!
M_P#1/TO_  NS3_YN\OS[L/\ B9'QJ_Z+>M_X8^&?_G+Y?GW9_2/_ ,1%7C;_
M *-9\+?^'5U;_P"8>C_B(J\;?]&L^%O_  ZNK?\ S#U_-Q11_P 0MX#_ .B?
MI?\ A=FG_P W>7Y]V'_$R/C5_P!%O6_\,?#/_P Y?+\^[/Z1_P#B(J\;?]&L
M^%O_  ZNK?\ S#T?\1%7C;_HUGPM_P"'5U;_ .8>OYN**/\ B%O ?_1/TO\
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M^?:+_OMZ/^$CG_Y]HO\ OMZYRBN#V4/Y5][_ ,_+\^[/<.C_ .$CG_Y]HO\
MOMZ/^$CG_P"?:+_OMZYRBCV4/Y5][_S\OS[L#H_^$CG_ .?:+_OMZ/\ A(Y_
M^?:+_OMZYRBCV4/Y5][_ ,_+\^[ Z/\ X2.?_GVB_P"^WH_X2.?_ )]HO^^W
MKG**/90_E7WO_/R_/NP.C_X2.?\ Y]HO^^WH_P"$CG_Y]HO^^WKG**/90_E7
MWO\ S\OS[L#H_P#A(Y_^?:+_ +[>C_A(Y_\ GVB_[[>N<HH]E#^5?>_\_+\^
M[ Z/_A(Y_P#GVB_[[>C_ (2.?_GVB_[[>N<HH]E#^5?>_P#/R_/NP.C_ .$C
MG_Y]HO\ OMZ/^$CG_P"?:+_OMZYRBCV4/Y5][_S\OS[L#H_^$CG_ .?:+_OM
MZ/\ A(Y_^?:+_OMZYRBCV4/Y5][_ ,_+\^[ Z/\ X2.?_GVB_P"^WH_X2.?_
M )]HO^^WKG**/90_E7WO_/R_/NP.C_X2.?\ Y]HO^^WH_P"$CG_Y]HO^^WKG
M**/90_E7WO\ S\OS[L#H_P#A(Y_^?:+_ +[>C_A(Y_\ GVB_[[>N<HH]E#^5
M?>_\_+\^[ Z0>(IR0/LT7)Q]]ZZRO,%ZCZC^=>GUA6C&/+RJU[WWZ6[@%%%%
M8@%%%% !1110 4444 %%%% !1110 4444 %%%% !]*_D/^)]L/B'^U;^U9JW
MQBL;7Q+\4_#WQ=USPO8:1XQ@MKU_"WPJL @\ V_AC0]55K:U\/:MI3IJ#:E9
M6VW4;R::2>=I!NK^O"OD/]H+]A+]EO\ :>US3_%7Q?\ A?8:UXLTVV%C#XKT
MG4M7\,>(YM.7=MTV_P!7\.WVFW>I6$;,6BM;Z2XCA8DPA-S9_1/#KB[+^$LP
MS&KF-#%2H9A@HX58O 4Z57&X5TZ\*_+"G5K895*&(Y%"O".(I3O"C-.:A*G/
MYKB;)<1G.&PT,-4HJIAL0ZWL<1*<:%92IRIMRE"G5<*E-2<J<O9333G#W7-3
MC^#'_!/_ /9C\._'']H3XV^$]&U34-*^"7@#2?">H:]8^')FGT;3_B/K<D\V
MJ^$_#%[*UQ9:&LMA'_:&OV.E$&VN)XPL<#ON'[\^//&/[+'[!7P3UWQ[X]UC
MP9\&_A7X6LF?5M9U:2)+O5[AD81:?"'\[5_%'B#59!Y-EI=HE]J-_<.(K>W8
MD@?)OQ^_:C_9*_X)5_#CPQ\%_A%\-U\4?&+QO-]D^#/[*7P;M1K'Q4^)WB2]
MS$NKZG:P_;]4L=&,JF77?''B0M:PPQ2[9[B<+"?$_@#_ ,$[OC'^TQ\4?#W[
M8_\ P58U32/'?Q%T2[&M_!#]D+0+I[S]G_\ 9O@F)EL9M3TUGEMOB-\3;>$Q
M?VAXAUA[[3[.^606,<ZPVCVW-QUQMBN+,SK2H5<91R>G&A2PN"Q%1*51T*-.
ME+&8V%*4J<\5B)QE6:E4K.BIJE&M4Y959Z</9!1R?"056%">-DZDJU>G#2*J
M3<U0H.:4HTJ4'&":C351QYW"/,HQ_G-_:_\ V$_CY^VKIOQ7_;L^!?[-GC+]
MGO\ 8DU76[?Q4OP4CGGT[XU_&303YA\1_&:P\!) UQX+\':K*(M=G\%V3P:A
MJ5B)]:LK&7SY6D^0?A7X 7Q0WAWP-\*=%LVLKB%$TJSTR+[/I>GV$?%SJ&HR
M#!M(;;#&_GO"+HSJ\,F;C$8_OU^+7[=G[(?P0UR\\!>//C9\/M)\96-H4_X0
M6'5[.[UGS3$%M-)?3[,S1V=W=EHX+:SO#;LV]1L"$5^$4GP<U?XG>,OV@_BI
M^RI^S9H]KK6KQWOC75?!7AV]CT33M:U2VMU:UTI=2NV.DZ?XD\1 ?VE<Z/I1
MM+*\OG>21(Y9C<M^N^%'$V=Y%@,?B.(<KE#+J>7X=9=Q+G$JV'J4,+3]G3P^
M7T:N+O[?*H)NM1IX-TZ5&JU&3G+$TW#X_B_+,#CL1AJ668E2Q4\14^L97@HT
MZL:E:7O5,54C1M[/&/2$YU^9U*:O%05&:G\0P)\//V0OA]YI:/7/'.MI\K#8
MFJ>*=5C 'E(,>9IOA33Y"59L(DJJVXRW,@ _-#Q%JDOBK5]8UC4;/3UG\07E
MS=7NGV-E'#IA:]<E[.WT]5,7D/N\OR=K":1V8JSN*U/'/C#Q9XT\9^([_P ?
M1ZMIOC;3;^;2O$?A?7K"YT76/!EW:,4/AR[T"]6*XT>.Q*LL8>(1704W2S3"
M3>?K+]ESX&Q:K);_ !8\<6\4/A[2VDN_"NGZB/)M[^>RR\OBC41*5"Z-IK(Q
MLO-417%Q$\Q,D<8%?T7A9X3+<!/-Z^*ACZV.ITZKQ-&I&K#%*I'FHT<)*#=.
M=%IWC."Y7"\[1I1C&'YK5C5K5E@XTG05"4H>RG'DG2<?=G.M&23C-:IQGKS6
M@US-FO\ L9?\%&_VE_V&K^'P[X4O9?B7\&8KS_B;_ KQY?W$?]B*64W9^'7B
M.[$NH>#K[:"R:)?_ &KPV\K;EL[1Y'D']9/[(/\ P4S_ &5_VR+2#3? _C2+
MPA\3HH8VUCX0?$!X?#?CS3YRH\T:?8WDB6WB6Q5]PCU+P]<:C;2*%+F)FV#^
M+;]H3X@>&_B/\1;[6/"^D65GIEE&=-.M6\7DW7BNXMY'$FMWJ(%B*'(M[%Q&
MLDEM&KRL[L#7EWA?P#XB^(>O6FF>$=(O=1\2Z;!/K.G7FE7LVD:OHZZ?F9KW
M3]<M9[6\TNX5U46SV]U"TTY6+$A*H?S#C'P:R#BBA+., H<*YS5INOB%",99
M96JS2G-XS#1]FJ,V[N5?"NE)RE*=>C5JN27UF2\:YCE4XX3$MYK@HR]G3YYM
M8JG%.T50K-2=2*2]VE54TDE&G.G!)'^E#17\0G[.O_!7C]N+]F"6W\*>+M4@
M_:!\%:1(EE/X0^,2SZ/\1])A@W!K/3O'MI%%//,H*I'_ ,)-IVH?)&NZYRQ<
M_NA\!O\ @NU^QC\4!9:5\5+WQ+^SCXLG"1267Q,TZ0^%);D[%<:?XZTE+K0)
MH&D8K"]Y+8RLHW/&F2!_-7$?ACQIPPYSQN3UL7@HW:S'*^;'X.4.E2<J,/;8
M>-K.^*HT%9Z-GZ=EO%.29HHQH8V%&N]/JV+:PU=2ZQC&<N2JUVHSJ-=;/0_:
MNBN!\#?%3X9_$[3(=9^'/Q \&^.=*G ,5_X4\2:1KUL^5#;?-TV[N KA6!9&
MPZYPR@UWU? /1M/1IM-=FG9I]FGHT];I]CZ']=5Z/9_,_-#]MW_@E!^R+^W-
M87VH^/\ P3'X,^*C0,NE?&+X?QV^@^,[6X"@0G63#%_9WBNR5E7S;/Q!:7I,
M89;>>U<B5?XW_P!MG_@B5^V1^R'J5YK/A[PK?_M!_"4WBQ:;X[^%^D76IZ_8
MQ7$BQVL7BSP';?:-;TZZ+ND4M[ID.H:09,-]HA5@H_T3Z0JK##*"/0@$?K7-
M6PE*M>33A4?_ "\A92>VDDTXRNDE[R;LDDU8^%XO\.>%>-*<GFV C3QRCRTL
MVP7+ALQIV5H*591E#$TXZ6I8JG6A%*T%!^\OX;?V!_\ @WB^-OQN_L/XC?M=
M7^I? CX8W2P7]O\ #O3I+63XN^)[&3;)'%J;E;NP\"6MU%_K4N$NO$$:':UI
M9RG?'_87^S?^RC^S]^R3X&M/A[\ ?AGX=^'^@P(GVR?3K8SZ]KMRJJ'O_$7B
M&\:XUG7+Z4KN:?4+R?8,1PK'$B(OT1@>@XZ>U%51P]*@O<5Y-6E.5G.7J[))
M:+W8I15E9:'H\+\&<.<'83ZKD674L-*48QQ&,J6K8_%N.O-B<7)>UFFUS*E%
MPH0?\.E!:!12$@=3CZ]/SZ?YSTKP[XL?M,_L^? O39M6^+WQF^''P^M((7N&
M7Q+XMT;3[V6*,[7-MITEW_:%VP;Y0EM;2N6^4*3Q71&,IRC"$7*<W:,(IRE)
M]HQ5VWY)-GU#:2;;223;;T22W;>R2ZMGN51RRQ01O--)'##$K/)+*ZQQQHHR
MSN[D*BJ 2S,0 .2<5^ 'Q]_X.!?V?/"B7ND_LW^ /&'Q\UR/S88?$5U!-X#^
M'$4RML$IU[7+=-2U6'K*O]DZ9*)D "3*6!'XI?$S]L_]M_\ X*#>*IOA_P",
M/C#I_P .O!]_:7=\?AG\-;G4/!7A*;3+;8+FVUC7(;B7Q?XKG6)U=K%]2LK:
M=!*&M_+<BOTCA[PHXSS]+$2RZ6398H^TJYEG2G@Z4:2LY3IX9PEC:_NMN#AA
M_92>CJQ5VOFLRXNR3+KP6*6.Q-^2.%P+C7FYW2M.HI1H4[-VDI5?:+6U-VL?
MT0_MF_\ !9_]FW]FMM5\#_"VX@_:(^-=J)K9O"?@?4H)?"/A>]7<@?QUX[B$
M^BZ4L$@;SM+L9K[6G\MX_L<3%6/\IG[2_P"U7\?_ -L7QA'XR_: \:G7H=/N
MI+KPI\.=#2?3/AAX%W95!HOAYF+:IJD<9\N3Q%XA:^U23)-N;6,B,>?>*OAK
M9?"?Q\_P]UV=+?1--O\ 31>ZIH=DMMYVC:@(GFU:RM9@^^=8W=RURTKL\3F1
MF:OH7]HWX"^&? 'A?PKXQ^'D=U/X=58=-UZYGNVOI+I[^,7&D>()9N(XX[U=
MT,JQ*D",T.T+NY_IC@KPRX1X,K9;BJO/G>=8R+GA<UQ="*PU":C":^HX9N4,
M).7,E"I4=?%WE;VU.,G3/R[/.*LWSN->C&V!P-.2C4PE&3]I4C??$5=Z\4T^
M>G%4Z-E?V<Y1YSF/V4M0\$P_$Q=*\8:)I>I7^L6?D>$M3U5#<0:9K,.9'LS:
M39M';5;7S(H+B>)GBG18XBI? YO]HGX7'X8?$.[2PC>/PQXG:XUOP^Q#%+8S
M3$ZEHY9@</IUU(XC0G<;5H3AEY'AMM<7-I<VUW93/;WMG/#=6=S$VV6VN[=U
MEMYXRN3OCE56&,AAN7G.*_3J"+1?VP?@MI]C9Z]HOA[QGI^LZ?I.H^(M0AN+
MS2O!/B^":WLM7O=3@L\376G3:?,]_<V5M)YH#QK-L*/7Z'F>(>48ZEF<YU9X
M+$4_JV+IKGJ.G*G&52E4HT8J4I2:4OW=-7DU.T93JH^;P\%BZ<L-'D5:$E.D
MY<L5).48SA.4VHQZ6<VHK2[BHW?BW[&/Q%\5W/CVS^!.E>'O$/C=?%$&IZWI
M6D^']-N-8N_"T6G6LUUK&L:K#"C1Z?X1N;>)X[VXN2EN;QHHX%EFF=#_ $<?
M\$E/ O[.7PT;XH6'@_PM:Z-\;/&>LW7B/Q'XCU&<7>H>(?##S!]/T?PR\Z[M
M(\/>'';R)/#]F$2*XS?70EDD#K]<_L%_L#_ []BCX:16'@!%\9^._&5C9:A\
M0?C%K26]UXC\=7<UNDH%M-&OE:1X5AWD:+X>TX1V5I:>69OM5T9+J3Y"_:[^
M"FO_ +-GQ+TW]H?X3L^B^&9]:_M:]>$LMCX0\13@M?QWH!6./PKXE7SH[R.4
MBWM[FXD4; \13^8,ZXTRWQ.QV<</1HU<DIXN=.OD56I5G!XW'X)55%9I1A)T
MO:8E3DZ=%*?LUS<KJ8M4W/\ 4L'DF)X5HX+-7...G2C*GF,(0A+V&&Q$H.3P
ME245/DI.,>>=X\UDWRT7/E_;*6*.>-X9HTEBE1HY8I$62.1'!5TD1P5=&!(9
M6!##@C!(K\V/VC_^"?WASQL]_P",O@X;/P?XP=WO;KPX6-KX9UV[4F02VQBP
M_A_5)' V7EF4M_-P\D*LSR'K/V;?^"D_[*?[1EUHO@_0?BMX7T_XJ7D(M[OP
M+J=V^F7EQJ\"E+RW\/SZBEM;:]$TB/):G3IIY9H"K+&<G/W_ %^1TJO%' N:
MM3HXW)\;&SJ8;%T*M.CBZ*DTG.C5C&GBL/-I^SJPNOMT:D9)27V4X93Q!@[J
M6'QM!_#5I3A.I1FUTG%N5&K&_O0E9I^[.+5T?@#IW_!07XR?L@W-K\)?C!\/
M_%GQ/\3ZA)<:9X'\&/)#9^-OM%G%N-Q)XAO2NEZCX,MT"M/KMS-+);QEPLUP
M5\M?H7]G+_@J<?B'\4O"OPA^/GP7O?@AKWQ%OI-*^'7B>Q\4Z?XU\#Z]KRQM
M+#X6U'5[&.";0O$%W&K?8(;ZW6UOY%,-O.9=J-SO_!4K]G'XM>*?%WPA_:5^
M$7@K4?BA+\,M"\6>"?B!\/= :'_A+KKP=XH:VO/^$D\(6TQ1-4U;1;NT)N-*
M$@N+VRE*6H:4;3^??P!_9[^-_P"TS\9_A':0?!KXF_"SX7?#7XE>&/BAX_\
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M><XF>;XAY8J.4TL?5PF"GB84Z%2I/&XE1A!+D@XITZN(<IRK3CIQMX;^%_\
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MA4Z5%>U_&4? CXX-X-;XC+\&OBL?AZE@NJOX['P[\7GP:FELGF+J3>*!H_\
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MR4)5:3C*7L_S>HHHK](/P,_O6_8%_P"3*OV7O^R*^!/_ $R6U?75?(O[ O\
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MFW4K-75*%KKSG)Z03Z7NWTB[,_7CXC_M7?!#X92RV>M>,+/4]6B+*VC^'?\
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M]G7PKJRJD7B_Q?XD>V@M/%/B(1RK+H?A#1[B:2ZNE(N_,,$UC)^<_P#G_/\
M7UKK/!GCKQ=\/-8CU[P5K^H>'=40IOGT^8Q)<QQG*07UN0;>]MP23Y-S'*F2
M2 #R/W[@WZ7_ !3E]:CA^-<HP.?X%N,:V.RRG'+,VIQ^U4]CS2RW%M=*,:6
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M@_.FA:/^U'\19%T.X>WNO#_Q+TG0/&TD-Q"^'L[ZXU:P@U8;2-DD;7>\+G#
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MC_@I1XUFETKP]K'P@\/7%_F*WA\$_"K6=>UF#S,HK6K:QKM]#O0GY9)K1E+
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MUKXC^$[VTU'1[6VU6/3]*\:2>&KN2SO9["^M"4M4NI+0R%U>91&*_;SX-_\
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MOALYP6%Q3P6(Q&%590I8J-&E7=&7MJ=*7.J5>E-VBU::UOH=317*_P#"2/\
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M8FUBSA^UV.H:?;'&V[N-/U6VL;U+,E@!=>0;?<0ID#$ \IIO[6_[.&K^+H/
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MNC@\UI\"2RBM.MC53Y,R6,IQI0>+I_6US89X?G:IJ]-VK+F?O:;/RX\+U*^
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M0G545.45964FUHNRL4445P'0%%%% !1110 5_#C_ ,%I/^4B7QI_[ _PI_\
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M'$?^J3)0HHHK\8/Z["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK.ICJRE)5HP<(TTJ<91E*?\ %9_PYU_X* ?]$>T;_P .C\,/_FMH_P"'.O\
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M_P ),;_\\@_XD]\+_P#H;<;?^'7)O_H>/XK/^'.O_!0#_HCVC?\ AT?AA_\
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M\11PN$P6 PTZ]&2YZ-3$4J[HU+5:7)5A3G HHHK\[/WT**** "BBB@ HHHH
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MVB+?XXZ5=L@DMD^'YTJ37YM/*LY585OH;BS+%1&+E6X+OM/LFCZ7I=U\?_\
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MPO5J4ZLZDIX>/]I8J>&HXF*J5(Y?#"XC"8*G*,:CC3<'B*M51YI/EY4[/4_
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M+/V,?V?95U*S\1W^F06EO;1QQV-I%;16UM86RE2L%M#%''#$N ,K$BJHPJ
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MVF\2#5(O''Q$U[2&M[C0H[ZUM_(TJZU!=2FL&A,%N+JXB_3C_@DMXET/P/\
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MX>\.V"3I<:Y?7/A2[M/C'\(UB$AE>UL-0OXA\/+#:(=^F:#?V*8C5WD^1?\
M@B=^U[^SI^RI_P --?\ "_OB3;?#W_A.D^#DGA3[3X=\8:__ &POA3_A:O\
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M_P #?@MX@TNUL9OBMX]\=QZ-:ZSXEUG3?#VCVE_J]K%=>"/&&A>(-=\6:O\
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MZ;J5SI%\]A8>-8M/N;$IH-W8ZI;:8D%I<WTUSD_\%5?^41'[#/\ V&?V9?\
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M_H[]#?\ Y-_Q+_V6.(_]4F2A1117XP?UV%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >H4445YX&3K?_(-F_WH?_1J
M5PM=UK?_ "#9O]Z'_P!&I7G.HW]MI6GWVJ7C,EIIUG<W]TZ(TKI;6D+W$[+&
M@+NRQ1L0B@LQ& ,FM?;T<-AJ^)Q%6G0P^'A5KUZU6<:=*C1I4_:5:M2I)J,*
M=.$93G.348Q3;:29=.$ZLX4J<93J5)QA3A%.4ISFU&,8Q6KE*3226K;21<HK
MQO1OCU\-=>\/Z[XGTW5;Z32?#IB&IR2Z/J4$Z&:3RHQ!:RVZSW.9,J?)1\$'
M/ S6]\/OBKX+^)\%_<>#[^YOHM,:!+LW%A=V!C-RK/#M6[BB,@948Y0$ @@D
M'BOA\F\6_"WB/,,CRG(/$3@O.LTXFP6*S+AW+\LXDRG'8W/,OP53%TL9C<IP
MV'Q52MC\+A:N QU/$5\-"I3HSP>)C4E&5"HH^[C.$^)\OP^.Q>.X?SG!X7+*
MU+#YCB,3EV*HT<#7KQHRHT<54J4HQH5:D<10E"%1QE)5:;2]^-_1J***_0SY
M\**^4?VQ_P!K7PS^Q9\)['XU>./AG\9/B3X%A\9:1X;\:2?!3P1)X^UWX>>'
MM5TW6[RY^)?BG18KW3Y;?P#X=N=*M+/Q+JT4[W%A_:]DUK9ZA=R06%R?LN?M
MR?LD_MI>'3XD_9C^/7@#XL1068O]4T#1]4?3?'GART:Y>SCG\6?#GQ!!I'CW
MPI#/=1O%:3>(?#FFPWP"S6,ES!)'*ZNKVNK]NH'U=17X_?M\>/O^"AOCS]I_
M]GK]C3]BS_A(/V?_  %\1/!OBGXD_'?]NJ[^"4OQ9\*_#+3M$FU2'P[\.?##
MZ^(/AS#XXUZZT"XAU/1M?NCKMU9>*_"NH:'/HUI9:M=7GSQ\)_BK^VA^PQ_P
M4?\ V8_V&/C[^U?%^W-\)?VRO!/QDUKP/KWBWX>>&_A]\;O@/K7P>\*W_C"*
M]UZ[\(R:A#X\\(>*[#2+W1#?ZZ;2YGU--0U73WT.#PGJ6G>*TY6=K.UU&^EK
MNUEO?KO:WZ!_0117\\1^,/[;W_!3#]M/]K_X,_LO_M47'[%'[,'[#'BW3?A!
MJ?COP?\ ##P;\2_B1\:?VA;2XOCXCMM1_P"$U(MM"\$_#_Q'X:U33-2T;3+J
MTC\2:2EC::H-5C\67J>#/K3_ ()A?M;_ !P^+/B+]K#]D']K"\T;Q%^U%^PM
M\2]!\"^-/B7X=T;3_#&C?&SX<^/[#6-;^$GQ;7PKI2QZ1X7U[Q3H&B7EWXD\
M.:(BZ7I9FTBXCM]-EU5]*LA33:5GJVDWLVM[:W[[I+0#]::*_(/_ (+L_'3X
MN?LW_P#!,OX[?%[X&>/==^&?Q+\-Z[\';;0_&/AN6"#6-,@U[XP>"-"UB*VE
MN(+F)5U#2-1O;"XW0L3;W,BJ5)##])/@+K>J^)?@9\&/$>O7T^IZYK_PG^'6
MMZSJ5R5:YU'5=5\'Z/?ZC?7#*JJT]W>3S7$I554R2,0H'%/F7,XZW23\M0/6
M**_E"^"G[:O[57B#P1_P<N:CK7QP\;:C>_LC^._CSIO[-ES<75FTGP>L/#6K
M?M/P:%;>$"MDHMH],B\'^&8[870NRJZ-9[BQ1R_[X?\ !.GQ]XR^*O[!7['/
MQ+^(GB'4/%GCSQY^S;\'?%GC#Q/JKQR:GX@\1Z[X&T74=8U>_>*.*-[O4+ZX
MFN;ADBC5I9&*HH.*2FI-))ZIO7RER_F!]FT5SWB[Q7X<\!^%/$_CGQAK%CX>
M\)>#/#VM>*_%.OZG,MMINA^'/#NFW.L:WK&H7#_)!8Z9IEG=7MW,WRQ002.W
M"FOY0/\ @F?_ ,%(OVP_%'[:/P<^)'[5?C_59OV1O^"JDG[3D7[('@36WT5+
M/X-^,/@Q\5;FU\)^$&N5T_3KFUM[[PK$_@K33#->2>-=;\1^$]0E:YNH9;A2
M4E%I.^OX:I7?97:5^X']<%%%<]XN\5^'/ ?A3Q/XY\8:Q8^'O"7@SP]K7BOQ
M3K^IS+;:;H?ASP[IMSK&MZQJ%P_R06.F:99W5[=S-\L4$$CMPIJ@.AHK^1__
M ()G_P#!2+]L/Q1^VC\'/B1^U7X_U6;]D;_@JI)^TY%^R!X$UM]%2S^#?C#X
M,?%6YM?"?A!KE=/TZYM;>^\*Q/X*TTPS7DGC76_$?A/4)6N;J&6X7]E_^"FO
MQ?\ VX/"EM^SA\#/V$O NLI\0_VE_BP_@;QQ^T@_PPU7XG>!?V6?AMI\.F#7
M_B)XHL8;>7PSIFM2MKEO>^%YO'#2^']2M?#?B?2XM/N]8NM,N+"%---I/1I6
MMKK:VG9W33[ ?J317\W_ ,0?&G[?O_!+K]HC]BM/BY^W2W[=WP9_;&_:5\$?
MLS>+_A;\1?@]X+^&?Q&\(>)_B3(ML?BM\+]<\%76K7EQX?\ #>O7:7=YX+NH
M3H>FZ3=:1X,@66\UO3O%?AW^D"G&5[JS36C3MU5]TVNH!17YS_%?_@K;_P $
MY_@=KOQ/\+?%C]J?P/X)\4_!WQAIO@+X@>%]4T?QQ+XETSQ5JMG<ZA;Z=I&@
M6'A6\U?QA#;6=JT^KZKX,L_$&CZ L]@-<O\ 3GU/3ENOKCX)?M _!+]I+X?6
MGQ6^ WQ2\%?%?X=WEQ<V2>+/!>NV>L:7;:C90V]Q?Z3J;02>=H^LZ?!=VLNH
M:/JT-EJEA'<P->6D(FCW---V33?9--]OST ]@HK\W]"_X*]_\$TO$WQM/[/&
MB?MA_":]^*S:Z?"]OI1NM<MO#&H^)/MHTV/0M(^)=YHMO\,=9U:ZU$KI]A8:
M3XPO+G4+YX[.QCN+B1(V^E/V@/VM_P!G']E:7X<1_M#?%CP[\*(?BUXKD\%>
M!-1\4Q:M#HFJ>(8;9+VYM]1UZTTV[T7POI]E9.+R_P!>\5W^B:!I]HLMS>ZG
M!!#,Z'-'75::/5:/LP/HRBOA7]G+_@II^P5^UMXXU#X9_L\_M/?#;XC_ !!T
M^34E'@VTN=7T#Q'J\6CV\EWJE[X6TKQ9I6@W?C+2["SBEO+K5_"<>M:7#9Q2
M73W@MT:0?G1^Q9_P6N^%G[4__!2/]I7]E\?%CP)=?"Q5^&OAS]BR#P_X#\?Z
M9KWQ:UNQ\%>*O&'QTU'Q%K&MZ7,UMJ/AJ\TJ73;2/5H/!&BMI6D0+I5AJ^I7
M%SJ=^G..FJ?,[*SOJ!_0#17Y@_\ !/[XP^%;#]GK]HCXE>/OVZM-_:C\%_#_
M /:(^-UQXI^-?C+PSJGPDT'X+>'_  QI_AR^U/X3ZM)XTFMXWT?X7V9EO;CQ
M:)XM%O(M8D:!U%K*:_-#_@J%_P %D_@/XX_8Y\6:E_P3T_;-T*Y^-/@OXX?!
MS1]>'@6?4]!\8)X/U?Q:-'\176D:?XPT'2[CQ+X2N'N++3]0\2>&K75]"AEO
M;"&35(I+ZT$Z<XJ*DW:ZO:ZN_374#^FVBO$_V@/VCO@7^RO\.-2^+?[0WQ/\
M*_"CX>:5/;6<_B+Q3>O EUJ-XS"TTG1M-M(KO6/$&M70262VT70=/U+59X(+
MFXBLV@MIY(_-/V5?V[_V0_VW-*US5_V6OCMX-^+<?AEH/^$DTK2AK&A>*] B
MNY)8K*\UKP5XNTOP_P",-+TV_E@GBT_5+W0X-.OY;>>.SNIW@E5*NKVNK]KJ
M_P!VX'UO17YL_%3_ (+ _P#!-'X)_&*^^ GQ-_:]^&/AOXHZ1J$VD:_HJ1^*
M=<T;PQK5K>?V??Z'XM\<^'/#NK^ O"6NZ5?![76=$\2^)]+U719H;E-5L[,V
MUQY7Z*:-K.C^(]'TKQ#X>U73==T#7=-L=9T/7-&OK75-'UG1]4M8K[3-5TK4
M[&6>RU'3=1LIX+RQOK.>:UN[6:*XMY9(I$<B:>S3MO9IV TJ*_.3XP>,&T__
M (*2?LB>#A^V+=_#Q?$'PN^,=\W[&<?@3Q#JEI^T$=.\/>(IAXYG\>VG_%.^
M&'^'7D_VNFG:M_I.J'1U@L_WEQ'73?&/_@J'_P $_/V?OC+9?L_?&/\ :L^%
M7@/XNW5W8V%WX2U;4[^8>&KS4[6TO]/M_'>OZ;IU]X8^'<EY87]CJ%O_ ,)W
MK7AP2:?>6M\I^R7$4SG,E>[22=KMKLG^H'WK17XP_P#!$+]H3XN?M$_LZ?M(
M^,OC3\2-:^).K>%?VY/VA? 'AG7O$%U:W#Z5\/\ PQ:>!9_#N@65Q;0P0C1]
M+74KV6S+;R%NI':9U((]^T+_ (*]_P#!-+Q-\;3^SQHG[8?PFO?BLVNGPO;Z
M4;K7+;PQJ/B3[:--CT+2/B7>:+;_  QUG5KK42NGV%AI/C"\N=0OGCL[&.XN
M)$C9*2:3;2OM=I?(#](**^2_CY^W9^R-^RWXV\-_#S]H;XZ>#_A'XK\7^#O$
M_C[P]:>,DUG3M-O_  IX/BGEU[43XD72I?#-E/"]NUGIVDW^KVNLZ]JDMGI&
M@Z?J>J7]C9W'/_LJ?\%%OV)_VW+[Q%I/[+O[0O@SXJ:]X5MS>Z[X8M;?Q%X6
M\76>F+<I9/K47A'QSHGACQ+?^'X[R6WM)?$&G:5=Z)#<W=C!+?I+?6:3NZO:
MZOVNK_<!]J45_.#\ /\ @MS\+/VF/VU/VW/V;%_:"\#>#_A;8^ -$T;]BSQA
MX<^&WQ&'B'Q1KFD_"GQWXV^.GCO7[C4=+FO)M4^'-YH\DMEI]]!X(TR\TOPY
M;VVB6&KZM=SZG?\ '_M-_P#!3ZR_8J_X(Q_#[QEX+_;=L/VE?VJ?C5X,\=:9
M^S5^T#K_ ,+?%NAWGQGU#0OCIHOA7XE^,;#PIXBT74]+\/:K\&O!7CEO[)M/
MB#<6^F:UJ7A;3IH-.U^SGFTJ6?:1LW?1)OITMTOUOI_P4!_3=17\L_[)_P 1
MX-2\(?L8>/['_@N1\4_C*/BC^V9X.\&^)+7Q?\(_'D_A[XR^/M+TG0=<\9_L
MM>#8KK2-(U+P3X=U>Y\;6#CQ1XDBD\/0V-SI5K8)8V^FR:?:_N-^U9_P42_8
MK_8AN?#FG_M1_M ^#_A5K'BR&2Z\/^'+JT\2>*?%5_I\4PMGU8^$_ VA^)_$
MEGHAN=]LFN7VEVND2W,-S;Q7KS6MPD0IIIMV25MVK:J^]P/M*BO*?A%\<_@[
M\?/AMI'QA^#'Q*\'?$GX8:Y;W5SIWC?PIK=GJ>@NM@SIJ4%W=QR#^S;[298Y
M8-8TW4DM-1TBYBFMM2M;6>*2-?Q;_;Q_X+(_L?>(?V3/VPO"W['_ .VIX O/
MVG/A]\)=;UWP0_@G5;N#49M5TN[L)[J[^'/B;5=)A\(^/KRPTQ;Z]N8O!6K>
M))+?3(+W4)8EL[6XGBIRBE=M:JZU6OIW _?JBOF[]C7Q9XC\>_L@_LJ>.O&.
MKW?B#Q=XT_9M^!OBSQ5KVH,KW^M^(_$?PP\+ZQKFKWKHD:/=ZEJ=Y=7MRR(B
MM-,Y5%! 'TC36J3[@*O4?4?SKT^O,%ZCZC^=>GUSU_L?]O?^V@%%%%<X!111
M0 4UT61&1P&5U*L" 001@\'BG44 ?'OQX_9LT;Q]975Y96D NW1F*B-<LX!/
M9<Y) (/4'HV0*_(?XB? CQ;X(O;A#8SRV\;L%#*<*OHDG0CY>C>G)SR/Z.B
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MP>%/"FF>$M,@T[3H(XEBC5&9%"Y*@#C 'I_3W._:6=K8Q+#:PQP1HH4*B@<
M8%6:_LKAWAK(>$<JH9)PWE>%RG+,.O<P^%I\KG-J*G6KU9.5;$XBIRKVN(Q%
M2K7JM)U*DM+?14:%*A"-.E"-.$=5&*TYK*\I-MN4G;63;?W!1117N&P4444
M%%%% !1110 4'G_/^-%% #54+G 49.3M&T$GJ<>I[FG444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?PX_\%I/^4B7QI_[ _PI_P#5
M4>"Z_N.K^37_ (*D_L!?M=_'7]M?XI_$SX4_!O4?%W@?7=,^'<&DZ];^*/ N
MFQ7DNC_#KPMH^I(MGK?BC3=2B-KJ5C=6K&>SB61H3)"9(621OUCP<Q^!R[BG
M%U\PQN$P-"61XNE&MC,31PM*566-RZ4:<:E><(.I*,)R4$^9QC)I6B[?S/\
M2LR3.L_\.,LP6191FF=8RGQAEN)GA,IR_%YEB88>&49]3G7G0P=&M5C1A4JT
MJ<JK@H1G5IQ<E*<4_P">FBOT-_X=2?\ !0#_ *-VU?\ \+;X8?\ S;4?\.I/
M^"@'_1NVK_\ A;?##_YMJ_IO_6GAC_HH\A_\.^7_ /S1YK[S_/7_ (AIXC_]
M&_XV_P#$5SW_ .8#\\J*_0W_ (=2?\% /^C=M7_\+;X8?_-M1_PZD_X* ?\
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M_P""@'_1NVK_ /A;?##_ .;:O0_UIX8_Z*/(?_#OE_\ \T>:^\\3_B&GB/\
M]&_XV_\ $5SW_P"8#\\J*_0W_AU)_P % /\ HW;5_P#PMOAA_P#-M1_PZD_X
M* ?]&[:O_P"%M\,/_FVH_P!:>&/^BCR'_P .^7__ #1YK[P_XAIXC_\ 1O\
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MUI9)V4FM+[+17Z@?SW?\%%O@7^WW=?\ !/KX1^%?!W[ GP[_ &>[/_@FQ'X
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M2NC^A^BOYX/^(AWX-?\ 1NWQ-_\ "I\*_P#QJC_B(=^#7_1NWQ-_\*GPK_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]0HHHKSP,G6_^0;-_
MO0_^C4KA:[K6_P#D&S?[T/\ Z-2N%KJH? _\3_) %%%%; %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 J]1]1_.O3Z\
MP7J/J/YUZ?7/7^Q_V]_[: 4445S@%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?@I_P<'?\FK?!_\ [.!TO_U7/Q#K
M^1*OZ[?^#@[_ )-6^#__ &<#I?\ ZKGXAU_(E7]?>#O_ "1&$_[#LQ_]2&?Y
M:_2J_P"3P9I_V)\B_P#4&(4445^I'\XA1110 4444 %?J7_P1A_Y2)_!#_L%
M?%C_ -5)XVK\M*_4O_@C#_RD3^"'_8*^+'_JI/&U?-<9_P#)(\3_ /8@S?\
M]0*Y]_X4?\G/\._^RWX6_P#5W@C^XVBBBOX4/]F0HHHH **** "BBB@ HHHH
M **** "BBB@ KA-;_P"0E<?2'_T3'7=UPFM_\A*X^D/_ *)CK:A\;_PO\T!X
M]\0?B[X(^&#Z:GB_4+JR;5EF:R6UTZ\OS(L$D,4A86D4ACQ)/$HWXR6XZ'&-
MXG^/?PV\(6^A76MZI?0Q>([..^TLP:3?W326\K.J&98(7:WD)1LQ2A9  3MP
M#CSS]H[PM\/?$=WX0/CC6I=*DM6NAIJ1P2S+<>9=V#2[C$Z[/WL<"9(. ^1R
M*X/XK>!OA#JVE>#(O$GBF?3;.RL[*WTVY2V>5FMU:]\LX4[8P<R</G C4DD;
MJ_AKQ:\</';A;B7QLR_A+$^!\,KX+P_ ]3@U<4\18'!YE3GG4<HEGBXRHUN+
M\LEET)K%8W^Q)8BCE,<1?".$L7&HI5/W#A;@W@7,LMX.Q&:TN-98K-ZF<1SA
MY9E]:MAG'"O$1P3RF4,LK_6'%TZ?UQ0J5W!JJFJ=FX_:FDZG9ZUIFGZQI\AE
ML-3L[>_LY61HVDMKJ)9H7:-P'0M&ZDHP#*>" 0:T*YSP?;:=9^%/#EII%T;[
M2[;1=-@TZ\9=AN;**TB2WG*_PF2(*Y'O71U_;F2XG$XS)\IQ>->&>,Q668#$
MXMX.2GA'B:^%I5:[PLU.JIX9U93="2J5%*ERM3G?F?XSCJ=*CC<91H*JJ-+%
M8BG15=.-94J=6<::K1<8.-7D2]HG"#4[IQCLBOCB\_X*!_L<:/\ M)^)_P!D
M/Q1\?/ W@?\ :(\+'PB)?AUX]O9O!-UXA/CK0])\0>%H/ ^N>)H-,\,^.=2U
M.RUFUB&@>%=9U7Q%:W:317FD6Z>1+/\ 8]?AS_P5A_:3_P""06FQI\"?VY/
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MAC5@C8_EI_X+J_\ !,7]BC]GK]A'PG\5_P!GGX.>!_@)XS^$7Q,^"/@JVOO
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M#2-(N[+PK!IF@ZE<^!VNDT:UU&/4;W4_Z>JJ+?O7W4K:;6Y8[>N_JP"BBBJ
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M.-&M]:TJS\3Z#]J72=;MK>X!$-]:P7U_9F1"!<:=J&H:;=+-87]Y;3?S"?\
M!7SXN_M3^+OC/\!="_;Q_9AN/V=_^"5?P>_;C\&^.;_]H_X>ZIH7QT\>>,[;
MP)K_ (K\*_#[7O&.F>!OB1I/B7X,> ?B/X?UV>[U:6#PK?>/_"]MK]K'H<7B
M?QEIK> -5B;E'5/316M=;ZN3^RO/U>NR#^M^BHX9H;F&*XMY8I[>>*.:">&1
M989H95#Q2Q2H622*1&5XY$9E=6#*2"#7\ZOPWE_:M_X*S?M(_MQQG]K;X\?L
M@?L=_LE_M">)OV7/A-H'[*6M^%O!'Q*^)?Q8^&/V6'XA>-O&_P 5KSP_KVM3
M^&()CHVKZ7X/L;6+3-4TCQM8:>]SI]UX:U*^\54W:R2;;=DOQ;;>R0']%U%?
MSW_LI?M6?M+>"/%O_!2S_@G-^TM\8XOC+\:/V,O@B/B?\'/VDK#2H?!/CKXE
M?#'QO\+G\4:?J/BK1M/O)(K?QA\-K[Q'X+TR?Q)I<MQ-?:AJ4JZE?W=_IUOK
MOB#Y(_X)M?LU?\%$_P!N3_@GM\+?VJ=>_P""J'[4_P .OC-J=G\1(_V?-"TO
M5M)U/X:0:?X2\>^+/#%M=?M$Z/XAT'5/$7QIU+Q1XIT37+N+5-:UZY@\.>#+
MSPU9:587UMI,.CK//M:+;=[JZT<6DT[NV[Z?D!_1Q^T?^U=\%OV4['X5WGQC
MU_4=(F^-GQD\"? 3X8:;I.@:MKM]XH^)WQ$OWL_#^B*=/MI+#1[58+>_U34-
M9\07VE:3:V&G7"+>3:E-I^GWN/XY_:2USP;^U;\$/V:+;X%?%3Q1H7QA\'^.
M_%6I?'G0]&O+CX4?#&X\%Z7JFHVOAWQQK4>GS6>GZQXI?3H['0H+C4;1[FZO
M[5(XIBZJW\>W[5GQ9\9_\%*_V3_^"0O[4?C/XZ_%WP%\5==_;L^#W[&WQA\
M?#7Q79:'X$\%_%[P]XM\>?:?VA_"OA]-%,7AKX\W_AN^\->)M)U>W:32/#>G
MZ_;:'9Z9<VFGPW,O[B>//%?QB^"'_!7'_@E-^RIIWQ^^-/C/X87?[*WQYL_B
M);^-?'&H:C<_&3Q!X!^'?BR/1?'GQ5M;+^S]%\6>-3>Z9;:Q/K-SI:.NJK]J
MMHX"J!94VV[;)PL]+^\XW35_/?IZ@?O917\IGPM\!_MN?MZ?\%$?^"L'P)M/
M^"@G[2G[.O[.GP'^*/@>WT>P^%'B.:'QC:^)?%NB^*$\'Z!X%\4ZI)-=> ?
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MTU#4K/PMJFA_$*N??W7H^5;:OLOU;T0']"%%?R_66B?MJ?L;_P#!9'_@G/\
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M -5S\0Z_D2K^NW_@X._Y-6^#_P#V<#I?_JN?B'7\B5?U]X._\D1A/^P[,?\
MU(9_EK]*K_D\&:?]B?(O_4&(4445^I'\XA1110 4444 %?J7_P $8?\ E(G\
M$/\ L%?%C_U4GC:ORTK]2_\ @C#_ ,I$_@A_V"OBQ_ZJ3QM7S7&?_)(\3_\
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MFFU:_HT!^45U_P $WOB7\<?V*OCE^Q]^WU^V!X@_; G^+NO0ZOX?^+UG\%O
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M8W?B"YTZVOKRY*16UI+-*\L(3S4^IJ*NRLUWO?Y@?R3_ !:_90_X*7_M)?\
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MCGQOI'@GS;RT3QUXWN3-:Z5X3\)-J-H;)[R>>]U2%98]3DT8:,)-11-I:MV
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M_GUE_(?XT<T?YH_>OZZK[P*%%7_[+U#_ )]9?R'^-']EZA_SZR_D/\:.:/\
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MMBW_ ,1=:_:/^-0_;M_X*K6/_!-[]G'PG_9=Q^R=\)OV7?VB_ GPV^-OQ/\
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M_;"^'/[+?A.2T^!O[1GBOPE)X2\:>/?AW\3?AU\9A%'XE@O[2R\0:E<:;?\
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MWJM]HGB/6O#ZZ9KVJ?6W["_[(VK_  K_ ."*^@_L>_MJ6MG\%&C_ &??VB?
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M/]A3X+_"2_\ C!\,?$]Q\0=-\8?M;^ M6\%>"=7\8^-/AQ\5;C3O"VDZ4_\
MPDUEITY\*R>*==C\2)>6=A''X8TBVU&_BB]A_P""BC_\%!O _P ;OA;\2_@9
M\%- _;H_8JU7X=>)/ 7[2?[#NJ67P?T36'\0B[O]6T7XO>'?%'CW1-0UCQ7/
M<17&D:3-X$5-:TZ-/"LUG;:%'<^.KGQ/X5^!?V,_^";'Q ^+O[5/[9WQR\?_
M +$WA_\ X)L?LI_M+_L2^-?V1+;]GWP7XV\$WWC+QE=_%#5-%N-7^+]SX0\"
MV5UX'^&^KV/A:RO+!M!73/#\^@ZZVDI::7KTC^*]:U!/FYW:^^FDMK+KK!QO
MT=FGU3 ^2OAA^T3XH_:A^!4W[7_Q;_X+Y^&OV6?VRO&VG:GXX^%O[+O@;XS?
M"7PG^S-\';>SN[H>#?AK\3_@YXAUS6;OQM>Z_H]A83ZYJ?BF]M];\*7GB%K;
MQ'I?C/4?#U\=<Z/]N']M?Q!_P4 _X-\/A%^T;XVTK1=$^(VK?M*_"?P?\2--
M\.17<&@KXP\#_%#5] N-3TF"\:66TM/$NDVVD>*?[.6XO(M'FUN71X[V[6P^
MT2>M?!WP'_P4;_8\_9R7]BZ3_@D-\)_VGOC%X"T;Q9\//@'^V%I/C#]GP_"[
MQAHL,VLKX*\??$W1_&VFV_B/06\$V5[H,=OX<\8:EH&J?$"RTB329KGP[>)+
MJUY]%?ME?\$^/VUOB%_P1^^%O[+L7_"+?M#?M8V?Q8^$_P 1/B9)X(T?X*?
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MHXG#5*6(I-MTZD6V?YY/[4G['7QZ_8^\9GPC\9O!\^GV=Y/<IX7\<:0+C4O
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M4444 %%%% !1110 4444 %%%% !7":W_ ,A*X^D/_HF.N[KA-;_Y"5Q](?\
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M*[NW6T4E%+96Z?+L 4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /4****\\ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"_,G_Q->D44>W?\J^]@>;_ &2[_P"?:X_[\R?_ !-'V2[_ .?:X_[\R?\
MQ->D44>W?\J^]@>;_9+O_GVN/^_,G_Q-'V2[_P"?:X_[\R?_ !->D44>W?\
M*OO8'F_V2[_Y]KC_ +\R?_$T?9+O_GVN/^_,G_Q->D44>W?\J^]@>;_9+O\
MY]KC_OS)_P#$T?9+O_GVN/\ OS)_\37I%%'MW_*OO8'F_P!DN_\ GVN/^_,G
M_P 31]DN_P#GVN/^_,G_ ,37I%%'MW_*OO8'F_V2[_Y]KC_OS)_\31]DN_\
MGVN/^_,G_P 37I%%'MW_ "K[V!YO]DN_^?:X_P"_,G_Q-'V2[_Y]KC_OS)_\
M37I%%'MW_*OO8'F_V2[_ .?:X_[\R?\ Q-'V2[_Y]KC_ +\R?_$UZ111[=_R
MK[V!YO\ 9+O_ )]KC_OS)_\ $T?9+O\ Y]KC_OS)_P#$UZ111[=_RK[V!YO]
MDN_^?:X_[\R?_$T5Z111[=_RK[V 4445@ 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5'3=+TS1K2/3](TZPTJPB:1HK+3;2WL;2)I7:25H[:UCBA1
MI)&:20J@+NS,V6)-7J*=W9J[LVFU?1M7LVMFU=V[7?<3C%R4G%.45*,9-+F4
M9.+DD]TI.,7))V;C&^RL4444AA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>O\ 3T/^)S>%/^B.XA_\*\M_^3/]#"BO\\__ (;P_;5_Z.O_ &A/_#M^-_\
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M",5_EZ_T]#_B<WA3_HCN(?\ PKRW_P"3/]#"BO\ //\ ^&\/VU?^CK_VA/\
MP[?C?_Y<T?\ #>'[:O\ T=?^T)_X=OQO_P#+FC_B!.<?]#W+/_!&*_R]?Z>A
M_P 3F\*?]$=Q#_X5Y;_\F?Z&%%?YY_\ PWA^VK_T=?\ M"?^';\;_P#RYH_X
M;P_;5_Z.O_:$_P##M^-__ES1_P 0)SC_ *'N6?\ @C%?Y>O]/0_XG-X4_P"B
M.XA_\*\M_P#DS_0PHK_//_X;P_;5_P"CK_VA/_#M^-__ )<T?\-X?MJ_]'7_
M +0G_AV_&_\ \N:/^($YQ_T/<L_\$8K_ "]?Z>A_Q.;PI_T1W$/_ (5Y;_\
M)G^AA17^>?\ \-X?MJ_]'7_M"?\ AV_&_P#\N:/^&\/VU?\ HZ_]H3_P[?C?
M_P"7-'_$"<X_Z'N6?^",5_EZ_P!/0_XG-X4_Z([B'_PKRW_Y,_T,**_SS_\
MAO#]M7_HZ_\ :$_\.WXW_P#ES1_PWA^VK_T=?^T)_P"';\;_ /RYH_X@3G'_
M $/<L_\ !&*_R]?Z>A_Q.;PI_P!$=Q#_ .%>6_\ R9_H845_GG_\-X?MJ_\
M1U_[0G_AV_&__P N:/\ AO#]M7_HZ_\ :$_\.WXW_P#ES1_Q G./^A[EG_@C
M%?Y>O]/0_P")S>%/^B.XA_\ "O+?_DS_ $,**_SS_P#AO#]M7_HZ_P#:$_\
M#M^-_P#Y<T?\-X?MJ_\ 1U_[0G_AV_&__P N:/\ B!.<?]#W+/\ P1BO\O7^
MGH?\3F\*?]$=Q#_X5Y;_ /)G^AA17^>?_P -X?MJ_P#1U_[0G_AV_&__ ,N:
M/^&\/VU?^CK_ -H3_P .WXW_ /ES1_Q G./^A[EG_@C%?Y>O]/0_XG-X4_Z(
M[B'_ ,*\M_\ DS_0PHK_ #S_ /AO#]M7_HZ_]H3_ ,.WXW_^7-'_  WA^VK_
M -'7_M"?^';\;_\ RYH_X@3G'_0]RS_P1BO\O7^GH?\ $YO"G_1'<0_^%>6_
M_)G^AA17^>?_ ,-X?MJ_]'7_ +0G_AV_&_\ \N:/^&\/VU?^CK_VA/\ P[?C
M?_Y<T?\ $"<X_P"A[EG_ ((Q7^7K_3T/^)S>%/\ HCN(?_"O+?\ Y,_T,**_
MSS_^&\/VU?\ HZ_]H3_P[?C?_P"7-'_#>'[:O_1U_P"T)_X=OQO_ /+FC_B!
M.<?]#W+/_!&*_P O7^GH?\3F\*?]$=Q#_P"%>6__ "9_H845_GG_ /#>'[:O
M_1U_[0G_ (=OQO\ _+FC_AO#]M7_ *.O_:$_\.WXW_\ ES1_Q G./^A[EG_@
MC%?Y>O\ 3T/^)S>%/^B.XA_\*\M_^3/]#"BO\\__ (;P_;5_Z.O_ &A/_#M^
M-_\ Y<T?\-X?MJ_]'7_M"?\ AV_&_P#\N:/^($YQ_P!#W+/_  1BO\O7^GH?
M\3F\*?\ 1'<0_P#A7EO_ ,F?Z&%%?YY__#>'[:O_ $=?^T)_X=OQO_\ +FC_
M (;P_;5_Z.O_ &A/_#M^-_\ Y<T?\0)SC_H>Y9_X(Q7^7K_3T/\ B<WA3_HC
MN(?_  KRW_Y,_P!#"BO\\_\ X;P_;5_Z.O\ VA/_  [?C?\ ^7-'_#>'[:O_
M $=?^T)_X=OQO_\ +FC_ (@3G'_0]RS_ ,$8K_+U_IZ'_$YO"G_1'<0_^%>6
M_P#R9_H845_GG_\ #>'[:O\ T=?^T)_X=OQO_P#+FC_AO#]M7_HZ_P#:$_\
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M%>6__)G^AA17^>?_ ,-X?MJ_]'7_ +0G_AV_&_\ \N:/^&\/VU?^CK_VA/\
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M^GH?\3F\*?\ 1'<0_P#A7EO_ ,F?Z&%%?YY__#>'[:O_ $=?^T)_X=OQO_\
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M>'[:O_1U_P"T)_X=OQO_ /+FC_AO#]M7_HZ_]H3_ ,.WXW_^7-'_ ! G./\
MH>Y9_P"",5_EZ_T]#_B<WA3_ *([B'_PKRW_ .3/]#"BO\\__AO#]M7_ *.O
M_:$_\.WXW_\ ES1_PWA^VK_T=?\ M"?^';\;_P#RYH_X@3G'_0]RS_P1BO\
M+U_IZ'_$YO"G_1'<0_\ A7EO_P F?Z&%%?YY_P#PWA^VK_T=?^T)_P"';\;_
M /RYH_X;P_;5_P"CK_VA/_#M^-__ )<T?\0)SC_H>Y9_X(Q7^7K_ $]#_B<W
MA3_HCN(?_"O+?_DS_0PHK_//_P"&\/VU?^CK_P!H3_P[?C?_ .7-'_#>'[:O
M_1U_[0G_ (=OQO\ _+FC_B!.<?\ 0]RS_P $8K_+U_IZ'_$YO"G_ $1W$/\
MX5Y;_P#)G^AA17^>?_PWA^VK_P!'7_M"?^';\;__ "YH_P"&\/VU?^CK_P!H
M3_P[?C?_ .7-'_$"<X_Z'N6?^",5_EZ_T]#_ (G-X4_Z([B'_P *\M_^3/\
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MZ9INJJDTD/S+^R/_ ,$_?CM^V'9>)?%'@E_"/@?X7^#&N8/%/Q;^)NM3>'O
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MOEF"HX['8#"QJRH>WQ<ZE:NH*GA_9*TJRG#^'"BOMSXG?L(_%GX7_LG?"_\
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MA\4:@WC>^UZQ@U&.[O3I]EI^FG0?#OB*9[N>X5M[7$$$,48#!Y781U]HW_\
MP0J_;2LOAG=^-X+WX2ZIXNL--BU*]^#^E^,+^Y\=0/);0W<F@KJ!T&/P/-XF
MMX9TD:QB\6'2KF,$Z=KE]++:0W7E8_BWAO+,9++\PSG X/&0E0A/#XBK[.<'
MB8J=&4KKEC3E%QE*JVJ5-2C[2<.:-_H\E\,>/^(LKIYWD7"><9KE56GC*E+&
MX+#>VI55@*GLL5"GRRYZE>%12A##0B\17<*GL*554YN/XQ45_1=_P1/\':=J
MGP/_ ."A=MK'A6RU'7K;P;X<T2.WU+0X+O5[>2;PE\71<Z0D5U:R7D3RW]K;
MB?3U56DN[>$20F:%-OQO_P $E_@[X]L?^"@O[/MYXT^%GBZS\-VLOQ/N+ZZ\
M4>!]9M]$MIXO@S\17TN:ZGU;2TL(98]6%B]A),ZNFHBT:W87(A->?7XPP]"I
MQC3GAHJ7">%IXE*6+A%YG[3*I9FJ=).E>@URK#\W^T7E)3Y5\#]W!^%>-QE#
MPJKT\PFX>)N98C+I.&65:D>'OJ_$M/AUU\3..)2QB;J/&.#^I<L82HN;_C+\
MF:*_I3\&^&?#;?\ !PEXET9O#^AMI$%]KVH0:4=)L#IL-^/V8H=4%]%8FW^R
MQW@U-WU$7*1+,+YWNP_VAC(?RZ_X*O:5IFC?\%!OVD=/T?3K#2;!/$/A&X2R
MTVSM[&T2XO\ X;>#+^^G6VM8XH5FO;ZZN;V[E"![B[N)[F9GFED=KRGBR&:Y
MM@<J6!E0>-X2P/%2KO$*HJ<,;7IT%@G35&#E*G[12^L<\5.S7L8[F7$WAE5X
M;X9SGB26<4\7#)_$W./#>6$C@9495ZN4X.MBWFZK/%553IUU1E36"=*<J3:E
M]:J:Q/SQHK]R/^"'GPC\*7GQ5^-G[47Q+M=.;X>?LT_"[4-2>^U>U\^VTSQ%
MXCM-3N[G7X%FC>UN1X>\!^&/&BWT9#2VDFMZ5=*8W,+-ZO\ \%I_A]X7^*WP
MC_9,_;P^'&AP:5H'Q,\%:)X4\56]K]DS8Q^)]$?XA?#^WO8M/MXH6U/3#/X\
MT'7K^8JRW5GHVF%(FACB&%;C7#T>+Z7"KP51TYJE0J9JZRC0I9G7P=7'T,O=
M%TGS3JX6G&<:BKIJI5A3=+52?9A?"/'8KPNQ/B1'-Z$:U)XC&4.&EA)SQF)X
M?P>:87)<9GD<6L0E3I8?,L14ISHRPCC*CAZM:.);C*G#^>"BBOV@\/\ _!#'
M]KCQ$G@#4[3Q?\$8?"OCCP=I_BZX\5W?BKQ-;Z?X7DU6/2)M)\-ZI92^#4U:
M_P!>U>/5@-.&AV.I:2)=.OX=4U72GFT4:Q[^:Y]D^1JA+-\PPV7QQ/MO8/$2
M<%5=",9U8P:3O**G"T/BG*4804I247\1PUP7Q5QC/%PX8R/'YW/ ?57C(X&G
M&H\-'&59T</.JG*/+3G.G4YJC_=TH4YU:LH4X2FOQ?HK[L_:B_X)X?M!_LF?
M$KP%\/?B-;^&=1L?BEK%KH?@'X@>&=3OK[P5K>I7%YIME<6-S/>:58:YH^H:
M3+J]BVIV>HZ)$[1227&COK%I"US7V5?_ /!![]K/1;CQA+KGC_X#Z9X?\+>%
M1X@M/$\OBKQ2NE^(M133M8U&^T#3X;KP99ZA92:)!HXGUK5M8M+#28;+5-.N
M-,N-6EM_$%KH7#6XQX8P^'P>+K9W@88?,:<ZN"J^U<HXF%*K3HU?9<D9.4Z5
M6I&%2E95:<N=3A'V=3E]G">%7B+CL=FN687A#.:N/R.O1PV;X;ZNJ=3+ZN)P
M];%X9XGVLX1A2Q&&H5*U#$<SP]:FZ3IU9>WH^T_$FBOU4^ '_!(G]HSXW?#C
MPS\4]?\ %GPG^!GA;Q_)8Q?#6#XO>);_ $?Q!\0%UBRBO- OM!T;2M'U9UT_
M75E TI+^XM=;U&W7^TM/T.\TNXL;R\^?/BC^P!^T]\)_VC?"O[+FM^!X-:^)
M_C^:$_#UO"VJ6^I^&O&^DS7>HVI\1Z/K5TNG&PT2S&D:G>ZQ)XFM- O_  ]I
MEC/J7B#3]+L@DS[T>*.'L1B\3@:.<8">*P=.O5Q%/V\8JG3PJ;Q4_:RY:,XX
M9)O$NG4G[#EE[7DY96X\5X<\=8++,OSG%<*YU2R[-:V#P^ Q'U*I.5>OF+BL
MNI.A34\32EF#G!8!5Z-/ZZYP^K>UYX7^+J*_67XK_P#!(SXJ_"[P/\4/$L?[
M0'[,?C?Q9\$? ]WX^^+/PH\(_$#5+WXB>%-#L;>6^NG;0I?#D4XVZ:L=W;R:
MZGAR*^;S[>Q:YE6T^W>9?LM_\$R?CS^TY\/[CXQ?V]\.?@Q\&DNOL6F?$CXP
M^(9_#ND>)[N/4;G2+V+PQ;V>GZE<7D6G:I;-IUSJ&J'1M*N-09M.TN_U&_M-
M1MK+*/%W#<L#4S%9OA5@Z5:EAY5I>U@W7KP52A2I4ITXUJTZU-JI15&G4]K3
M4JD.:$9271/PPX^IYOA\A?"^8RS7%83$XZEA::H5E'!X.K*AC,1B,12K3PN$
MI83$1^KXJ6*KT?J^(<*%;DJSA"7YST5]U?M._P#!/']H7]E#XB?#[P)\1K?P
MIJ.G_%;6;70OA]\0O"NLW6I^"->U&>YTBVN+2::ZTS3_ !!H]UI<FN:>;^#5
M?#]J;B-KBXT)]:L[:2Z'VOI__! []L.Z\9ZKX:O/%_P4T_0=-T/3=2M_'3^(
M?%LV@ZSJNHC4%?PUI5A_PA<7B*34=)>R@GUB]N](L]&CT_5+&73=1U34X]3T
M?3YQ'&/"^%PN%QM?/,!3PN.HU:^$K.K>&(IT*D*-;V7*I.52E5J1IU*-O;0G
MS1E!.$U'7!>%/B-F.8YEE.#X/SNOF.48K#8+,\(L+R5<#7QE"KBL)]8]I*$:
M='$X>C.O0Q3E]5JTG3G"LXUJ+J?A]17ZR?!S_@EC\;!^W3X:_9:^+UGX(L5T
M#3=*^,/B:>X\1:V_A;XC_!?1O&FE:-K[>"M6T/3(]>:[\1HVI:3IUOJ=IX4U
M2RFM[U]0DT:>WB+_ &7_ ,%5_P#@E/;^ YM6_:&_9VT?X9> ?A+H^C?#3PKJ
M/PPLM6\1VGB;6_B!XK\?6_@6#4- L]2L[SPS;6]VWB;PJ+J*3Q'H]ND&FZQJ
MLML+LS2W_%5X\X;I9QE>3_7J=2IF^%AB<+BZ4H3P;]O4A2P=&512YO:8N4I>
MRM%PC[-JK*#>GJX;P7X^Q/"W$?%/]CUJ%'AC,:N7YGEF(IUJ6:Q^IX>KB,SQ
M-/#RI<CH99"%-XCFJQJS5:,L/3JI>]_.A17[6Z!_P0X_:#U*Y7PGK7QT_9B\
M,?&"Y\/6_BFS^#=YX_UG4?&L.AR&2*XOM8L]*\,74UK:VUVBV7]IZ-:^(M"F
MN/-5-7'ECS,[_@G9_P $VO%?Q#_;*\9> /C[X7\*KX<_9BUG3G^-7PX\3ZKK
M"WGB;_A)M'\2KX-7PX_AV![/6M)DU*QTOQ)+<76LZ=IFIZ#)9;1JEIJ4MF^E
M7CKA>&!S/'4<UP^+AE6$^N8BE0;]K4I2G&E1>'554XUXXC$3I8:E6IRE0]M5
MIQG5BI)F.&\&_$6KF_#V3XKAO&Y95XES-95@<3C8Q6&H8F%*>)Q<<=*A*O4P
M=3 X&EB,?B<+6IQQJPN&KU*6&J.FXGXRQQO*Z11(\DDCK'''&I=Y'<A41$4%
MF=F(554$L2  2:M7^G:AI5U)8ZI8WFFWL) FL[^UGL[J(GH)+>X2.5">P9!7
M]/?Q$_X(Y_$SPQ^V(GQR_9?\9_LT_#WPAX3^)G@3XA_##X8>-]:\?79TK6/"
MY\.:T=+UC2;30-3G.G:GXMT^^NXM/TSQ DD&F7\%MI-QI1BM8K/X)_X*9?"_
M]L/XV?MX>"OA;\0?"WPN\7_'/Q;\,/"FG>!?#WP"77[?PWJ/A>WO_&VII-?7
MGC^2RU"#4K"YM?%=_KNJ:S=PZ7IFA65O,]Y!IUB7BX\KX]R?.<;A*. Q&#>%
MJY36S/'5,3B_J^*RYT84JDJ-;#SHNA*-*$Y/$XB.+]E1=.3O*"4GZO$?@KQ5
MPGE&9XO.<!FRS##\3X7A[**& ROZ]EN>QQ-3$4*>+PN/I8M8NG4Q-:E3C@,%
M4RMXC%*O335*JW3C^-U%?M[JO_!!C]K&S\/ZC/I7Q&_9_P#$OCW2=)EUJ\^&
M6D^,O$4&O2VTD!DTFSLM0UCPAI>D)J6KW,%]I]O+K=QH7AQ+NV4GQ&]J]Q<V
MGQ9^S'_P3V^.W[47Q*^,'PE\-7'A#P)XY^"%GJ+^-]&^(E[KMC-!K&F:U=>'
M;GP[:#PUX>\4//J<.L6=Q:SEDCM46,R03W):.-_5P_&/"^*PN,QF'SO U<-E
M\:<\;4522^KTZLXTZ56<)151TJE2484ZL82IS;7+)GS6.\*O$3+<QRG*L=PC
MF^'Q^>3K4LIH3HP:QM;#495\1AZ5:%25!8FA1A.I7PU2K"O2C%NI3C8^%:*_
M9R^_X(5?MKV?PI'Q!C?X87WBR/21K%W\'+3Q3J$GCR&-H8)O[%@OSH0\#WGB
M> 23&YTZ+Q8-,9;?9IVN:E>3P6C_ )+_  [\ ^(?B?\ $/P1\,?"]NDWBGQ]
MXP\.^"-!M[AFAB.M^)M8M-$T];J0J3;VZ7EY$;J9EQ!"LDK@*C5V9=Q%D>;T
M\96RS-,'C:67R:QDZ%52CATE.7/4V_=2C3J.G65Z514YNG.7)*WEY]P)QCPO
M7RK"\0<.9KE.(SN,9931QF%G3GCFYTH.E16M\13G7H0K867+B:$JU%5J5-U8
M<WLVJ_L>_M!Z)^SEHW[5^K>"+?3_ (&^(+Z+3]'\57GBKPC;W^H33ZY?>&[=
M[;PG-KB>+9HKC5M.O(X&BT1WEL86UI$;0P=2'S+7]+?_  5ST[6_$.N_L7_\
M$P?V<]'N_$EYX7\-Z!J]OX:M9K$RW=Y8:)>> OAX=5OGEA@TNXT+PMI'CKQ)
MXIO]4DMK2WT?78/$.H30V:/<GX)^*_\ P2,^*OPN\#_%#Q+'^T!^S'XW\6?!
M'P/=^/OBS\*/"/Q U2]^(GA30[&WEOKIVT*7PY%.-NFK'=V\FNIX<BOF\^WL
M6N95M/MWS>0\:X7%Y?@\7GF*P67XC.<1BJ^48*$*RK+*'C7@\NK8M<]?EG7D
MHWQ,_J^&J2JQA3A"49Q7WO&OA'F.6YYFN5\'9?F^>X+A3 Y=@^)\VJ5<)/"2
MXGCE$<TSW"Y6U3P;J4L%"4[9=3^O8_#T\/5JUJM2G*G,_)JBOZO]*_X(I:'J
MG[!VF_#E=)^$4/[7.HZI9^*%^-1UKQ[+H,5G=^+8]2&F&Z33/M<EJGP\D'A\
MZ>GA/^R7UD?VJL'VXC6J_(3X9?\ !*+XV^/(_BAXC\2?%'X!?";X7?"7XM>+
MO@[XB^*GQ%\?RZ/X8U?Q-X)\3S>$];E\+@:0\\ME)JL<2:3)XK/A ZL+NU2T
MW3.\<>N6^(G"V8PS&I',(8>.78Z6"E]87O8I.:AA\3A(4O:3K4<7+G6'@HK$
M2]G-RH02N^?/O GQ(R&MD-">1U<?4S[)Z>;T_J+O#+FJ3K8W 9I5Q*P]+"8K
M+*;I2QU:4W@*;Q%&-/&5)3LOR[KO_&/PG^*?P\TOPUK?Q ^&GC_P-HOC.T>_
M\'ZOXQ\&^(O#.E^++"*&TN)+WPUJ&M:;96FNVD<%_8SO<Z7-=0I#>6DC.$N(
M6?ZX_;._X)U_'3]B6V\*>(?'U[X/\9_#[QQ=2:?X<^('@#4K_4-"?55M)-1A
MT;5(=5TS2;[3=4O=+AGU33PD-YIFHV5O=O8:G<RV-]%;?T&_M]?L.?&']MSX
M1?L,>'OA=?>#/#^F>"/AYJ5]XN\6^.];N-)T/2/^$A\*?"2QT'3HK?2].UK7
M-2U;6YK'4ETZ"STE[$/821:CJ6G/<6/VK/,N/,IP5;AJO2Q>!K9)GE7-85\T
ME6E&GA5EV%]K%1CRW=6IB''#RHSC&HIR4(P=221KP_X+\39OA>/\'B<LSC"\
M7<(8;ANM@N'(82%2OF4L]S*.&G*<W/ECAJ&!Y\?#$T9SH2I0E5G5C1A*1_'V
M 2< 9)X '4GTKJ++P/XTU+Q%I'A#3O"'BC4/%GB!]/CT'PO9:!JUUXBUM]6B
MCGTM-(T6"TDU+4GU*":*;3UL[:8WD4L<EN)$=6/W!\>?V%?VD/V'/CI\'=&\
M8V_@K5+OQ9XTT"Y^%GCG2[B?7OAWXAU_2->T*06&K6>K:39:K;G2;_4=(&OZ
M1K&@+%=6EQ*=-;6;'?.WZU_&N]_:8D_X*X_L&:?^TV?@</$MMI^CWOAN/X$P
M^-?[ 30[_7/'$%P=9NO'T*:Y/K#:MIUXJ0P2-I,&FI926T,-_=:FTW3CN+\-
M3CA*V62R_,<'C,FSO-:.(CCG&=1Y3A_:JG1P\:$_:QE43I8ENM2GAI*2E3<X
MN#X<F\+<?7J9CA.(J>>9#FF5\5\(<-8O!3R95*-!<3XWZNZ^+QU3&TOJM2&'
M<,5@(QPN)HYA"=.5.M&E456/\X/B#X:_$7PEXPE^'GBKP#XU\,^/X9K.WF\#
M^(/"NNZ+XPBGU&WAN]/@E\,ZE86VM1S7UK<V]S9QM9![JWGAF@5XY49N-EBE
M@DDAFCDAFB=HY8I4:.2.1"5=)$<!D=6!#*P#*000"*_I\\>O\=D_X+K?$L?L
M[CX3'X@R?"[P^C_\+GM_$4W@W_A'_P#A3'@9]6(F\)6\_B.SU@,EJ=.N-+>U
M:3$]E>W']F7=]!/ZS^R?_P $XK?XZ?$/]KWX\_MH>$_@K\2?$'Q,^(_Q#\%^
M'-,\%WWCNSTGP;XL\%^-_&G@_P >ZCI=K-#H=S8:?J&IZ7I)\+:O/?:MXMCT
MRP-_>7=AJ>I:@+OQ*OB3A,OP&%S#-</1ITL1D&2YLJ.$Q:JX^IBLVE9X6GA*
MM.E!4:5.-6LL14Q:<H49I0<[(^NPW@#F>>9WF.1\-8[%U\3@>->+N&IXO-,L
M>&R:AEO#$(M9EB,TPM?%598O$UJN%PDL#1RQJG6Q=&3K*DI2/Y)Z*_8*/_@C
M!^T%/\>_$/[.<'Q;^ !^(6A?![0_C3##+K_CZ.SU;PQKOBOQ!X,6"T9/AW-<
MPWFD:UH4(ULW=M##;6GB/PW/9/J+7E]%IOR'^R9^Q!\7_P!KWXR>*_@CX+N/
M#G@SQ5X&\/:]XA\77'Q"EUK3+#1$\/:]I7AB]TFX71]$UR^_MPZWK%M:II[V
M<8$=OJ,\DR?8F1_KJ7%7#U?#8O&4LUPTL-@,+A\;BZMZD8T<+BU*6'KR4H*4
MH55"2BX*3YER-*6A^88GPVXYPF/RS*\1PUF-/'YSF..RG+,-:C.>+S++94X8
M[!P<*LH0K89U:<JBJRII4Y*JFZ=YKXYHKK_B#X.O/AUX]\;_  ^U#5-$UR_\
M"^+_ !+X.OM:\-7<^H>'-7O/#&LWNB7.J:!?W-K87-[HFH36+W>E7=Q8V<]S
M8S032VMO([0IU/P+^#WB7]H#XO> /@QX/OM$TWQ-\1?$%OX=T?4/$=Q>VFAV
M=U<1S3?:-3N--T_5;^.UCB@D9C::=>3$A52%BV1[,\5AZ>%GC9U8PPL*$L5.
MM*ZC'#QINK*J]+J*IIS>ETEM?0^5I9=C:^8TLIHX>I4S&MC89=2PD.5U:F-J
M5UAH8>.O*ZDJ[5*/O<KDUK;4\GHK]O="_P"""/[8NK:CXUL;_P 6_!3P_!X<
MOS8>&]3U/Q)XKDL_'P%EI]X^J:+#8^"[K4],T6WDO9M(N+K7]/TV^.LZ?<K9
M:9?:)-9:[=<]\-_^"%/[:_CC3O$%YXBF^%?PJN]*U75-(TC2O'/BS4KJ]\3'
M2KL6<FMZ?_PA/A[Q;#9^&[R193IU_J,MMJ-Y&+>[BT;^SKVUOI?EWQ_P8HU)
MOB3*^6E['G_?^\_;QYH*$.7GJM+^*J<9N@TXUO9RBTOT1>"GBPZE"DN N(N?
M$?6?9_[%:"^J3Y*SJU7-4\.G*WU=UYTEBU*$L(ZT9Q;_ !STW2-5UJ>2UT?3
M-0U:YBMKJ]EMM-LKF^GCL[&"2ZO;N2&UBED2VL[:*6XNIV416\$<DTKI&C,,
M\@@D$8(X(/4'T-?O3_P2P^%O[<7P/_:7_:6^$OPN\/\ P*\,?%'P9X/T;3?B
M9HO[02^++K3[2+^UH;SPY/X8U;X:)=ZA<Q:BE]'J(F@U$>']:T.]L=37[;/!
MI,L'Q#^S]_P3^_:'_;5\.?'3XK?#.]\ 7FJ?#WQ/>0ZOX3OM0U'1-;\8>*-6
M^UZS)IG@ZVMO#\OANSCN6\R&R?7=8\.Z7;3RV\5U/I^G)<7UKJN+,NIXS-88
MO%9;A\LR^CDU6GF,<>JOM5G,)2P\J]*-%4\/1J/D^KUEB*L*U.7M6Z<=N=^&
MF>XC*^&ZF5Y;G^.X@SS%<68:OD<\E>&^K/A2I2ACJ>$Q$\7.OCL51C*K]=PL
ML#A:V%K4WAHQK5+.7YZ45^SGQ"_X(5_MK>#/".D^(_#TGPO^)^L7EUIECJG@
MOP3XJOH-?TBXU.^2Q$OVOQ=HGACP]?:=I;S1'7+V/683IRBZN4@NM-LY]17C
M?VA?^",_[6/[//P=U;XSZIJ/PS\?:'X4TZ36/'>B?#_7=?OO$/A/1K:.XGU3
M79+;7?#&@6>KZ-H$,"G7IM)O;B_L \MXFF7.C6&HZM:%#CCA'$SPU*AQ#EE2
MIBZ[PV'IK$)3G73C%0<9).GSRG&-*=10A5<DJ4IL,9X/>*& HX_$8S@;B&A0
MRS!1S'&UY8*4J5+!RC4FZT:D'*%=TH4JD\12P[JUL+&#EB:=):GY*T5]Q?LC
M_P#!/WX[?MAV7B7Q1X)?PCX'^%_@QKF#Q3\6_B;K4WA[P-INI6EM97UQHD-U
M9V.JZC?ZM#IM]!J5T(-.&E:79O#)K6JZ8U]IB7OT=XQ_X(S_ +4?A;XB?"'P
ME8^)?A)XM\%_&K66T+PG\8?#7B;5[[P'8:D?#?B+Q;:6GB1%\/'Q%9R:KH7A
MC4KK2+_2=&USP[?3RZ?8+K\=]=^1'U8KBOAS!8RME^*SC T<90IU*E:A.K[U
M-4:+KU(3DDX*M&BG5^K\WMY0]Z--IH\[+O#3CW-LJPN=Y;PKG&+RO&UZ%#"8
MNEAO<Q$L3BH8*C5I0E*-66$GBYQPWUY4_J<:S<)UXN,K?D?5^YTO4[.UL[V[
MTZ_M;+4$:2PN[FSN(+6^C5F1I+.XEC6*Y175E9X7=0RLI.00/ZL?VV_^"*_A
M+Q^?A"/V6U^"?P(/ASPWJ^C_ ! 'BWQ%XXMCXPNH_P"PAH&H6H6P\5&]NK Q
MZ]_:>J77V/4[[^T;/[?/?^3!]D^1?^"HW@']L?X6_L:_LP_"SXWW_P"S1KOP
MG^'_ (C\(>!_!FK_  ;M_'Q\;:EJGA7X9ZUH/A6?7I/%-G::-_9UUX5M-5DU
M ^&[>R@O]9%E<?8+>WCM88?F\K\1\FSNMDE#+)476S3$UZ.)PF.Q#PN-P5.D
MJ_+4A2IT<10Q4ZKI*4:4,3!JG4C*4E+FC'[WB+P%XKX/PO%V+XBIXJ.$X=R_
M!XO 9IE&!_M'*,VKXF>#]K1JXBMB<!C,NHX:.*E3J8FK@*JEB*-2G"$H<E2I
M_/S17[0^!_\ @A7^V)XJ\&:/XC\1>(O@O\,/$GB*.631OASX\\7ZXGBUC")Y
MS;:B?"_A3Q-HMI?S:; =3CT^SU35+NTMW$.MQZ->07UO:?D)XU\'^(OAYXR\
M6^ /%UA_97BSP-XFU[P?XGTL7-I>C3?$7AG5;O1=:L/MEA/=6-W]CU*RN;?[
M397-Q:3^7YMM/-"Z2-]7EG$.29S6Q-#*LSPF/JX.WUB&&JJIR1E*4%.,E[M6
MDYPE%5:4IT^96Y[M7_->(>!>+^$\+E^-XDX=S3)<-FBE]1JX_#RH>UE&G3K2
MHU(-^TPV(C2JPJ/#8F%'$*#<O9VC*W,UHV6D:MJ5OJ%WIVEZC?VNDVRWNJW-
ME97-U;Z99O/%:I=ZA-!%)'96S7,\%NL]RT433S10AS)(BM^K/P:_X(V?M0_'
M'X7_  @^+_A#Q1\'X/!GQ9L[G6'N-8\2>)+*]\"^'H+74KB/6/%5O_PB$D,R
MW<^FC2X+'PY=:Y>)J.IZ9)<QV^C+K>L:)]@_LP?"']M3]E_X1_\ !1[X.?#3
M6_V6-?\ "7PKM?$%M\4]=\6Q>.M1\07<G_"HM0UF_E^'TVB:3!87=S%X0N!$
MNB^/$FTS2?%\,MC)9_99];FN_%S'C?)J%/$PRW'9;C\?A*]&EB,)5QD\+&C&
M>8T<MK.K66&KJ%2G7JJ,*3AS59.'+[DHR?UN1>$/%>,KY?6S_)L_R7),TP6+
MQ. S3#933S.>+E3R'$Y_A%A\)+'X)UJ&(PF'=2IB(U>2A!55)>UI3IQ_G4KJ
M_!7@/QQ\2?$%KX3^'7@SQ7X^\57T=Q-9>&?!7AW5_%/B"\BM(FGNI;71M#L[
M_4;B.V@5IKAXK9UAB5I)"J D?<7[-'_!.#XK?M#?"C6/CWK7Q ^$GP!^!^FW
M]UHUC\2_CAXJ;PEH/B'6+:5["6'1I3:3P_V9:ZR(M%O=:U*YT^R.I&ZL-(_M
MG4]+U/3[3]$/^";W[+7CG]D7_@J%X2^&?COQ#X'\676L? 'Q7X]\/^)OAWK%
M[KGA;7/"WB2SE@TK4+*^U#2M&NBTDNE7B2(UEY+"-)[.YO+.:WNI=,YXQRK+
M\+G:P>*PV,S3)\%C<3+ \U11E5P5*-2K0G6A!T_:4O:4U7I0G*M1YK3A%WMS
M\*>%?$F=YEPB\TRW,,JX<XISC)\NIYPZ=%SAALXQ,J&&QE/"U*L:ZHXE4JSP
M6(K4887%.FW1J5([_P ^VN:'K?AG6=4\.^)-'U3P_P"(-#O[O2M:T+7-/N])
MUG1]4L)GMK[3=4TR_AM[W3[^SN(Y+>[L[N"&XMYHWBFC1U91WI^"/Q?7X5CX
MX-\-/&B_!]M6CT-/B2WA_45\'R:I+=W6GK:Q:V8!92[=2LY],EFCD:W@U01:
M;/-'?7%O;R_J;XZ_X)^_&;]L7]KW]O7QIX/USP#\._AQ\+?CU\6)O%GQ'^*V
MK:SX=\'PW$?B37]6OK"SU33?#^N137&B:1"NL^));DV=CH&D75C>ZC=Q'4+"
M&Z^D/^"6V@1?M%?L0_\ !07]B_5+C3?$>F:/]G\8^ -;M)M5&GW?BKQ'I&L'
MP[JFG+J=OI%[;Z%I7C3X1>#_ !19VE_;:3<71U:]74;&UDFO(UX\QXUP^$RF
MGF6'>&Q%3!5>'Y\08:,JDI9=@LZG0A*491Y8/$4UB(U*=*<FW3BW4C%/F7JY
M#X28[,^)JV08V&88&CF^&XWI<$8^=.C3AGV;<)4<96ITZE.7/56!KO!5*%?$
M4J<4J\X0H5*DER2_G1HHHK[L_&@HHHH **** "BBB@#HO"'_ "-OA?\ [&+1
M/_3G:U_I<6__ ![P?]<8O_0%K_-'\(?\C;X7_P"QBT3_ -.=K7^EQ;_\>\'_
M %QB_P#0%K^=/'K^)PQ_@S?_ -*RT_O/Z%G^[>(G_7_A?_TWGQ-1117\]']R
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S)^VO\ \F:?
MM;?]FR?'K_U5?BNO\\*O]#W]M?\ Y,T_:V_[-D^/7_JJ_%=?YX5?TSX$?\BG
M/O\ L8X;_P!1F?Y[?3._Y*;@O_L19A_ZL(B-T/T/\J@J=NA^A_E4%?NY_&!^
MJ/\ P1;_ .4B?P5_[ WQ7_\ 54>,J_2C]J;_ (*N>#OV5OVE_P!H+PK\)?V*
M?A!9?&W1_$&I>&-4^/VJ:O9-K7BV:2VTRZDO/$FFZ'X"T#Q3?6$TT5E)<:*?
MB2L,TEE#*;L2JCI_/!\#_CA\2_V<_B5H7Q<^$6O0^&O'OAN'5[?2-7GT?1M>
MBMX==TB^T+5(WTS7[#4M,G%QIFHW=N&FM'>%I!- T<T:2+A_%+XG>-/C-\0O
M%GQ2^(NK1ZYXW\;ZM-K?B35HM.TW28[W49DCB:6/3M(M+'3;1!%%%&L5I:0Q
M@(&*EV=V^!S3@K#9YQ7/-LVI4L5E/]@8?+H858S'8>K+&T<QK8IRKTL-*A2K
MX1T:MO9UJU6$JGQ8?W8S7[5PWXNX_@_PUH\,<,XG$Y;Q,N-L=GU7,997D^-P
MM/*<5D6#RZ-/!XG,*>,Q.#S-8K#.?ML)A</4A0M[/&WG.D?T(_\ !!SQSXH^
M)O[3G[6OQ$\;:K/KGB[QMX1TSQ/XCU:XVK)?:QK7C>ZO[Z98T"Q6\/G3,EM:
MP)';6ENL5M;1Q011QKV__!'*Q\::I^RA_P %!M,^&[7R?$34=6\56/@)]+OX
M=*U-/&EW\-O$5OX6;3M4N+FSM]-OEUR2Q-I?SWEK#9W CN);F!(VE7\"_P!F
MS]K;X\_LD:]XD\2? ?QA;>$-5\6Z1;:'K\UWX8\+^)H[W3[.\%_:Q+!XFT?5
MH[5X;G<PEM%@=U=DE,BA GZ^_P#!*O\ :-^'_P (/V./V[6\0_&?P'\-OBMJ
MNF>)_$/PZLO$'C;PSX5\6ZUXFA^%OB$Z+>>#=(U6_LKW6M23Q(MI#8P:-9W<
MG]IO:VL<)EF@B?Y7C7AO'X>AQ7F&&I8:KA\WK\$T,NPM*%:K*DLIQ4*%58G#
MTZ,8PPT?:0Y51J5/W,9\RIV2?Z7X0\?Y+C<9X;Y)F&)S##X[AC!>+N-SW,L5
M6PN'AB7Q-E\L7AI9?CJV*G4JX^?L*JG+%4:-L7.GR.NI-KZE_P""*_P]^,OP
M0\#?MK>,/VF/"OCOX=^![B3PSK&I2?%;3M;\-3:AJ'A;2?B/J/Q1\1;_ !*U
MC<-#!I5[HW_"0>(G1K?49!!G5&DTFY6-G[+MS\)-5_X(@6 \:_"WQ/\ '3P;
MX.\1^,;KXP?#7X<>*K_P_P"*;NYTSXW:EXFM[R]N- OH=12/PSX?U#P;XQU3
M3KJ2SV^'+"+6Y8GLH8)KC\5OC+_P5)_;<^/'PUNOA/\ $#XOF3PAK%@VF^*H
MO#?A7PIX1U+QC9.[&6T\0ZIX<T?3KIK"ZB8VFH:3I+Z5H^JV9:UU73[V*257
M\?\ V;/VU?VEOV29M8_X43\2[[PII?B*>"Z\0>&KW2]$\2^%]6NK=%BCO9="
M\2:=JEE9:F84BMI-8TE-.U>:TAALY;][6)(1KBN!.(<REFN:XNME>%S?&9_P
M_F]'!8#&YA0P*H\/X/$8&-)9A3PU/&X7$8JGBJE:.(HT)SHU:=&2:=_9<N6>
M,_ W#\.&^&\MP?$69<+Y5P5QQPOB\VSO*<CQN<2Q7'&:X#.:N)>1U\=7RG,,
M%EU?+J&%G@L7C*=/%X:OBZ<E.*B\1^FWQY_;1^&FM_\ !.KQG^S5\!_V._CM
M\,O@W=>)_#EKI?Q \9ZEK7BGP-X/UL?$G2?B1J.F#Q5JD&HD:KKEYINHPVND
M2:S$Z'5[RXBBV!HI/U'_ &CO^2X?\$3O^PSKG_JMOA=7\W?[2/\ P48_:W_:
MN\+-X"^,/Q(M-2\!'6K'Q O@[0?"'A+PUI?]JZ:EU'8337VE:-!XBOX;87DS
MQV6IZW>V/VA8+MK9KNVMYXJGB;_@H9^UGXPUSX$>)-?^)-E>:U^S7-+<?"&]
M3P-X"M?^$>FGTW1]'N'N[>U\-0VFN^=IVA:=;LNMP7RIY<DT*QSRO*=:G 69
MU88"=&EE^!J0Q/%>+QU.><9GFLZV(S_(8Y70KSQV,P4:U>O*O",\8_9TX1@O
M:4_;5934N>AXT\/X>OG%+%8G/,XP]3 >&>5Y-7I<+</<-T<+@.">,WQ%B\'3
MR?*LVJ87"82.#J5:>5I5L15J5I*AB/JF'A2</Z ?"O\ RL$_$K_LC%A_ZI?P
M#7S!^R_\0_'.I_\ !>;XJ6^I>*]<U&#4/'G[1O@&[AOM0GNXY/!?A+1/%EWX
M9\,(MPT@@T;0[CPQH,NFV5OY45JVF6_E@ RB3\B;7]O/]J&R_:.U+]K"U^(-
ME%\<M8T6/P]J/BO_ (0SP4]G<:/%H&G^&DL_^$;D\/OX<AVZ3I=C%]H@TN*Z
M,L'GF<R2S&3A_"/[5OQS\"_M"ZE^U+X8\76VG_&W5]>\7^)=0\5/X:\,WEK/
MJ_CNVU2T\3SCP[>Z1<>'(H[^WUG4(XX(=+CBL_.5[-8)(HF72EP'FD<+C:52
M>6SJ5_#O!\*49.I6DH9GAZ-2$ZKE+"<T<&ZCISC5BG6?(I.@I12.;$>,_#T\
MRRK%8>CQ!2P^#\=LV\3,73C1PE.5;A['8G#U*6%C"&9\E3-50CB*=3#5)1PB
M564%C90J39_4K^PN_AJW_P""A7_!6/PU;PV4?BW6/$/@C5M"TNRU&'0M5OM+
MC/C@>+[JPGMY([VU,WB#Q%X6DU/7+6VE-EJ>I6-W=7$5W=6XNOC/]FO]L[]G
M7]EK7_C!H'[.'_!.;]J/2O%UYI4]E\5/#4GB;Q9XV^PP>!)=95Y?%.EZJ?$+
M:#:>'[G4-8AU/4FM;?['!<WJ7$A3Y*_#G3?VMOVA]$^/FL_M.Z!\3-5T#XV>
M(=4O]6UGQAHUCHMA'J<NI+$E[8ZAX<BTW_A%M0T6X2WM5ET&_P!%N='E-K:R
MS64DT$<B_5GCO_@L'^WU\0?".H^"M5^+VEZ9H^N:%J?ASQ#-X?\ AYX!TS5=
M;TS6+2XL=06;4_\ A'I[K2;F:TNI(4O/#3Z'=6V$FM98+A?./)7\/<TEB*_M
M(X/,L%FF6<.X3'X>IGV<951HXG),#0P<Y3H8'"U:>:8><J$<1A?;^PJT:[E)
M>SYG)^I@O'/AVG@,%[">:9!F_#O$/'>9Y+CJ'!?"G$N*Q6 XOSC%YI2ITL;G
M&8X>OP[CJ<,94P68/!+&8?$X.,(R==TZ=./YC5_2K_P42_Y0L_L!_P#8;_9W
M_P#6>?BE7\U5?3OQ(_;%_:%^+?P/^'7[.?C[QQ;ZU\(OA3/H%SX(\-1^%?".
MESZ7+X6\/ZKX5\/M-KNDZ'8Z]J0TS0-:U+3D&HZC=?:A<?:K_P"UWT45TGWG
M$&28O-<QX7Q>&GAX4LESAX_%QK3J1G.B\+5H\M!0I5(SJ<\T^6I*E'EN^>^A
M^,<$<799PWD/B+E>/HXVIB.+>%H9+EL\+2H5*-+%QS'#8MSQLJN)H3I4/94I
MI3HT\1/GLO96=S]S?CCX \;_ !N_X(:_LIVOPC\)>(OB+J'AGQ+X.U36-(\(
MZ-J.MZW#8^'[KXG^!];N+;1;*WEU74$TOQ+J-M97G]GV=UY,'G:DW_$KMKB\
MCYK]M3X7>.?@S_P1)_97^'/Q)T&X\+^-="^+^A76M^'[UXFOM)/B,_''Q1I]
MGJ"0O(MMJ,>E:U8_VA82,+G3KPSV%VD5U;S1I^4/[./_  4>_:X_95\$WOPX
M^$/Q&M+#P/<7&J:A9>'?$'A7PWXGM-!U?5Q&;S5="GUC3;B_L97FC%W_ &:U
MW-X?DO9+B]N-'GN;NZEFY'XQ_MU_M4?M _#6+X2_&3XJWWCWP9#XXG^(D=MK
M&B>&EU1?$\[:ZRRIKMEH]KJ\6E6:^(]5M]+\/PWD>A:18/::9I>GV>FZ=I]I
M:_'X;@[B2AF.%I.KDSR3 \:8KBFE5]MC/[2K4L6L0E0G3^K?5H5,/&O-2M/E
MK2E%QG35-JI^HX_Q4X!QF09CB(X?BN/%V;^$N6^'&(P[PN5_V!AL1E;R]O'4
M\1]?^OU*.-E@:<H-T5/"PA4C.E7E7BZ'[0?\%M/%/B33/V7/V"?#&G:[JMAX
M>\1>&+_4]>T6SOKBVTW6-0\-^!OA>- N]2M(I$BO)M'_ +:U5M.:=7^RO?W$
MD061]P[[_@HYJ5[XH_9W_P""2?B_Q!-_:WB?6/$_P;U+4M=O(XI-2N[WQ!X'
M^'NJ:W,]R$5U_M34(H;R]CC*13SP02.A,$6S\ /CQ^U]\?\ ]I;PS\-/"/QD
M\9VWBG0OA%I]WIG@6U@\+^%?#\FEVE]I^AZ9=+<7/AW1M*N-2>6S\.Z5'OU"
M2X*- \D>QYY6?2^(W[:O[2/Q7\(_!?P/XX\>V^J>&_V?7T.7X56,'A+P=IK^
M'I_#6FZ7I&ASW-SIV@VUSKDFGZ?H]C @UR34([C9))=QW$LTKM67<"9G@\)P
ME2G4RU5\CS#B/%XZI3J5OWM+-XXR.'5"?U6,ZDU&KAXXA55248T[1E45."<Y
M[XR\/9IF?B9BJ=#/W@^+\CX!RW)Z%>AA/]FK\*U,HJXV6,I+,ITJ%*53"8Z>
M"EAY8B4YXARJ0H2K56OV._X+J?$/QSX<_;"_9AL="\5ZYI=AX3\!^&/'WAS3
M[34)TT_2/&C?$_Q/;MXGM+$L;1=9:WT#1[9KUX7E:WT^W@),*LC??/[6]SX5
MT?\ X*^?\$Y=6\2C3+2"\\&_$_0UOKUK2U:XUF_T/QSIG@>P:[GDMS-,?&&M
MV,6C61F=Y-4U 06-O-=WH@G_ )6?VAOVK?CG^U/XW\/?$7XV^+;;Q3XM\+:#
M:>&]#U&T\-^&O#L=GI%CJ^I:Y;6[6/AW2=,L;ETU/5KV<SW5O-,ZR+"[F&-$
M72^/_P"V-^T5^T[XO\&>/?C#\09=;\6_#VS2S\&ZUHFB>'_!=YH/EZH-9CO+
M&3P=I>AM'J46II#=P:B2;NVEMX&M983&*RH>'V8++^&<#4KX"A_9G#_%.3YG
M6P\JSG*KGN%="A5PR>'I.O&C.<ZM5UI4)*3;@IRDV=6-\<<BEGGB'G.'P6=8
MQ<0\<>''%?#^$QU/#0I4\/P9F,,9C<+F#6.Q"P=3%4:-'#8?ZI#&0E"*C5E2
MA"*?]#7[3/QK_9M_9K_X*&:KXZUC]BG]H/QQ^TO#J>AZYX4^)?A+Q_XJO=+\
M=VVN^"K?PKIT_A;PK]METN_L$T)[KP1<:/;:3/;V]_I6I:6L3S6K.?1O@?\
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M<!PG3JK$T*^7Y-F5>A@*=.K."RRC0GC'*E2I2Q%:C4@HQ_H*_P""NQTW3O\
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MG(<+C\+6X8Q-:MC*\\OHYK3RZC@JRE1IQP>#E[.KA7B,)3IX2'LF?LC_ ,%
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M. 9KZ_6S.4<?&,<SQD5*>&I4G6HRO"%;$TN5S/Z%?"O_ "L$_$K_ +(Q8?\
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MP_!O"^8PS?!TL/5PBE_K=B\=2SS+LLQE%TZN-P%+ UG1QG-7PG[UO$/]B/\
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M -$8T;_PZWPJ_P#FPH_X<M?\%#_^B,:-_P"'6^%7_P V%'^N?"/_ $4^0?\
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M8SG_ .8S\JJ*_57_ (<M?\%#_P#HC&C?^'6^%7_S84?\.6O^"A__ $1C1O\
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M^55%?JK_ ,.6O^"A_P#T1C1O_#K?"K_YL*/^'+7_  4/_P"B,:-_X=;X5?\
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M -$8T;_PZWPJ_P#FPH_X<M?\%#_^B,:-_P"'6^%7_P V%'^N?"/_ $4^0?\
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M._\  _3O_E;7T7_$"^(?^AODOWX[_P"9/7^GI\+_ ,3E<"_]$OQ;_P" Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\
M_P!O[]MC_@IK^QOXVU_7+7X8?!+7_P!GO4=;N5\"_$?3_!WC7Q#;Z;I<]XL.
MD:)\0KRW\;Z:?#OBLQS6L4C7NFV6AZU>RRIX:OM2-M>06?YM?\/\_P!MG_H6
M/V?O_"%\9?\ SR:_2,K\+>)<ZP-#,<MK9-BL+B(J4*E+,HRY963E2JJ-)^SK
M4V^6K2E:=.5U)(_ ^(_I'^'_  GG&,R+B#"\5Y;F6"J2IU:.(R"I352"DXT\
M3AY3Q$57PE=+VF'Q-.]*M3:G"331_9#17\;W_#_/]MG_ *%C]G[_ ,(7QE_\
M\FC_ (?Y_ML_]"Q^S]_X0OC+_P">37H?\08XT_DRO_PO_P#N)X7_ !-EX2_\
M_>(__#+_ /??]6?E?]-O^#@[_DU;X/\ _9P.E_\ JN?B'7\B5?H3^UU_P4M_
M:#_;4\!^'?AW\7-'^&.G:#X8\70>--.E\$>'->T?4GU>WT;6-#CCNKC5?%FO
MP2V1L];O&:&.UAE,ZP.+@(CQR?GM7] ^'F09APUPUA\JS-45BZ>*Q=62H5?:
MT^2M5<X6GRQN^7=6T9_$'CGQMDGB!X@XWB3AZ6*EEN(R_*\-3>-P_P!6K^UP
MF&5*LI4N>I:*FO=?,^9:Z!1117VY^/A1110 4444 %?J7_P1A_Y2)_!#_L%?
M%C_U4GC:ORTKW7]FW]H7QU^RS\8?#'QO^&]KX=O?&'A*#7[?3+;Q787NIZ%)
M'XC\/ZGX:OS>66G:GH]W*R:?JUR]L8M0@$=TL,D@EC1HG\;B+ U\SR#.\NPO
M(\3C\JQ^#PZJ2Y(>VQ.%JT:?/.SY8\\US2L[*[LSZO@3.,'P]QMPCGV8NJL!
MDO$N1YKC71I^UK+"8#,L-BL0Z5.\?:5/94I\D.:/-*T;J]S_ $8Z*_C>_P"'
M^?[;/_0L?L_?^$+XR_\ GDT?\/\ /]MG_H6/V?O_  A?&7_SR:_F#_B#'&G\
MF5_^%_\ ]Q/]%/\ B;+PE_Y^\1_^&7_[[_JS\K_V0T5_&]_P_P _VV?^A8_9
M^_\ "%\9?_/)KVSX"?\ !6G_ (*>_M->.[3X=?!7X0?!/QGXCG47%\]KX#\7
MVVB^'M-W%9-9\3Z]=_$N'2?#^DQD>6MWJ5U!]KNVAT[3TO-3NK2RGQQ'A!Q;
MA*%7$XJIDV&P]"#J5J]?,XTJ-*G'64ZE2=*,(1764FDCKP/TI/#',\9ALORZ
MCQ7C\=C*L*&%P>#X?J8G%8FM4:4*5"A1Q,ZE6I)NRA",I.SLC^K6BN6\#)XS
MC\%>$8_B/+X<G^(4?AG0H_'5QX/74$\)W'C!-+M5\27'AB/5T358O#\^L"\E
MT>+4E^WQ:>]O'=EIUD9NIK\OG'DG.'-&?)*4>>#O"7*VN:#:5XRM>+LKIIV1
M_15*I[6E2J\E2E[2G"I[*K%0JT^>*ER58IR4:D+\LXJ349)J[M<****DT"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIA<,^:I&-/ZW7Q=2G&JBBBBOBC];"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%S_HJ7Q&_P#"W\3?_+.C_A</Q<_Z*E\1O_"W\3?_ "SH_P"(#8O_ **7#?\
MALJ__-OK_3T/^)T<I_Z(+,?_  ^X;R_ZEOK^'F?Z35%?YLO_  N'XN?]%2^(
MW_A;^)O_ )9T?\+A^+G_ $5+XC?^%OXF_P#EG1_Q ;%_]%+AO_#95_\ FWU_
MIZ'_ !.CE/\ T068_P#A]PWE_P!2WU_#S/\ 2:HK_-E_X7#\7/\ HJ7Q&_\
M"W\3?_+.C_A</Q<_Z*E\1O\ PM_$W_RSH_X@-B_^BEPW_ALJ_P#S;Z_T]#_B
M='*?^B"S'_P^X;R_ZEOK^'F?Z35%?YLO_"X?BY_T5+XC?^%OXF_^6='_  N'
MXN?]%2^(W_A;^)O_ )9T?\0&Q?\ T4N&_P##95_^;?7^GH?\3HY3_P!$%F/_
M (?<-Y?]2WU_#S/])JBO\V7_ (7#\7/^BI?$;_PM_$W_ ,LZ/^%P_%S_ **E
M\1O_  M_$W_RSH_X@-B_^BEPW_ALJ_\ S;Z_T]#_ (G1RG_H@LQ_\/N&\O\
MJ6^OX>9_I-45_FR_\+A^+G_14OB-_P"%OXF_^6='_"X?BY_T5+XC?^%OXF_^
M6='_ ! ;%_\ 12X;_P -E7_YM]?Z>A_Q.CE/_1!9C_X?<-Y?]2WU_#S/])JB
MO\V7_A</Q<_Z*E\1O_"W\3?_ "SH_P"%P_%S_HJ7Q&_\+?Q-_P#+.C_B V+_
M .BEPW_ALJ__ #;Z_P!/0_XG1RG_ *(+,?\ P^X;R_ZEOK^'F?Z35%?YLO\
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M $5+XC?^%OXF_P#EG1_PN'XN?]%2^(W_ (6_B;_Y9T?\0&Q?_12X;_PV5?\
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M3PV']G[)X"3;?/SJI&W+RN_44445^>G[B%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?Q?_\ !>+_
M )/HC_[(O\/O_3CXKK^T"OXO_P#@O%_R?1'_ -D7^'W_ *<?%=?K7@M_R6?_
M '2<=_Z7AC^9/I:?\FFE_P!E+DW_ *1CC\9K6UN;VYM[*RMY[N\NYXK6TM+6
M*2XN;JYN)%B@M[>")7EFGFE=(XHHT:221E1%9F /W5'_ ,$P_P!OB7P$GQ(C
M_9A^(C>')+:*Z2Q T'_A.&AFD6*/'PP.LCXEF4LP=K?_ (1+[1'#FXDB6 &0
M<M_P3X\?_#KX7_MI?L[>.OBNNG+X%T+X@VAU74-7DM8-*\/WVI:?J&C^&_%V
MI75Z\=M8V'@SQ/J&C>*[O4)70:=!HTE\&#6ZFOZ,/^"@GP[_ ."G_A?XO:M^
MU-^Q[\:/$7C#X0)X<T*^TWX0^#]8MM<;P]86'A:SM]<U"U^%VM:??>#_ (D6
M&NW=M<>(+*]TJ+Q!XR>ZUM[;3=)2TTZRO*_=.*.*\RRG/<MR7!O),#''8&IB
MX9EQ#/%T\#B<1#$*@LKH5<*XJABG%QK.O6=2G&$X15*=1QA4_C3PY\-<AXGX
M-S_BW-8\79S5R?.*&5U<@X'HY97SG+\#6P+Q<N),;ALRC4EC<NA44\+'!X-4
M*\ZM&K*>)HT(U*U'^0VXM[BTN)[2[@FM;JUFEM[FVN(GAN+>XA=HYH)X9%62
M*:&16CEBD57C=61U# @0U^IO[$'[#FD_M6:;\;_VF/VD?B1JWPX_9]^#ESKF
MM_%+Q'HMG;7'C;Q3KR:5>^*O$6G:%')8ZI%I,^EV]Q8:EJ4\GAS6KO49]6T_
M0/#VB7E_?3W6C^]?$W_@GY^R'\9OV2OB5^U9^P5\3OBGJB?!&/6)_B-\/?BS
M9Z>UU<:?X:T_3=:UV:RN8]'\.7&C7MAX3N;OQ<EU%/XLT?7X83H5DNAZM:WT
M,/KXGC+)L'F']FXB>*=2EB<)@<9C:&#Q%7*\#C\:HO#8/%8Y0]G3JUN>G;1P
MI^T@J\Z3;4?F,O\ "CBS-LC_ +>P-/+E1Q&7YIG.5Y3B\TP6&XBSC)<GG.&8
M9IEV33JNOB,/AO95KI2C5Q'U>L\%2Q,5"4_PXHK]=OVXOV#_ (-?!S]D[]F'
M]K/]GO6_B'J_@_XP6>A6GC73_'>N^'/$<^B:SXL\'IXGT&*TG\.>%O#*6<^G
MW>C^+] \2BX2[M3JEMI5O:)ITHFCOOJ?QG_P1C\$'3/V/?A3X.\8>/-#_:-^
M-7AV\\=?&34_%5]X>USX>_#SP9X,\':%>?$^[T[PQINA>'_$-UJ-CX^\:^#/
M"G@JSD\2,NI)=:A_;$\4<<^KZ3A+CSAV&&P6*K8BO1IXW$9KAE&KAY*KAIY+
M"I4S*6*I1<ITX8>%-2;@JDIJI24(RE42.N'@OQW6S#-LMPN!PF,Q&4X'AK'R
MGA\;"6'QU'BZKAZ&00R[$5(TZ=>ICJV(]FO:NA3I.AB95:D(4)2/YXJ*_HM\
M'_\ !.G_ ()F?'_Q[\3?V7O@'^T#\<[/]HWX86NNB3Q'XLT_2=6\#ZWJ7A35
M[30?%;VMC!X0\.6VO:5HFKR_8C;Z5XA\/WUPETNLZ+?^)]$T^[G;PW]AC_@E
MM\/_ -HOP'^UI:_&GQQXF^%_Q-^ /CO5?AO%JVGZOX<_X0/PIK/ARTU/_A(M
M:\7VVI:/+/K>DZ+J.EW+7BVGB7PU!/I=M<*NIZ=),FJ6F?\ Q$#A^&%QF*Q*
MS+!+ ?V?/$8?&9=B*&+6&S2K&C@L93H23E6PU6<G>5-RJ4^5JI3C)PC+I7@A
MQO6S+*LMR]Y!F[SE9W3P6.RK/L#C<M>/X=P\L5FV58C&4YJGA<PPU*,6J>(5
M.C6YXRHUYTXU:E/\1**_H?\ $'_!,#]AGXT?LQ?%KXK_ +$O[0GQ'^(7C3X%
M:1XDN/$+Z_:+?:)XLUCPGX>O/$]]H$?AZ?P+X+UNSN?$5K%';^$O$6A7FJ^'
MFQ]G,&NW"WEY;?SP5[&1\1Y=Q!'&?4HXRC6R^O'#XS"8_!UL%B\/.I#VE)U*
M%>,9QC6I^_3;U<;\RB]#Y/C'@//>")Y4\VGE>*PF=X*>.RK,LES3"9OEF-HT
M:KH8E4,9@YSISJ86NO8UTO=4[<DJD?>"BOV[^ G_  3N_9E\ ?LL^$OVQ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *_B__P""\7_)]$?_ &1?X??^G'Q77]H%?Q?_ /!>+_D^B/\
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M\230W'B+7]:U^>VACMK>?6M4OM5F@MXD6.*"&2^GG>*&.-$2.)&5$1%55"J
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M>9W8(&=V" [0SL0,L22ZO;R]E$]Y=W-W,JJ@FNIY;B4(I+*@DE=W"J68JH.
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ME7,IYE4XBRBIDV:8/VJRO#2P26#KSH8.O35;V%.EAYU:.(KJM4J_UMZS=_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Q7_ /'*/^(>#XR?]'#_  Q_\)?Q7_\ '*/^(@\(?]#?_P L,T\O^H+S0?\
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M *&__EAFGE_U!>:#_B!OBE_T2_\ YF^'?+_J;^:/YVZ*_HD_XAX/C)_T</\
M#'_PE_%?_P <H_XAX/C)_P!'#_#'_P )?Q7_ /'*/^(@\(?]#?\ \L,T\O\
MJ"\T'_$#?%+_ *)?_P S?#OE_P!3?S1_.W17]$G_ !#P?&3_ *.'^&/_ (2_
MBO\ ^.4?\0\'QD_Z.'^&/_A+^*__ (Y1_P 1!X0_Z&__ )89IY?]07F@_P"(
M&^*7_1+_ /F;X=\O^IOYH_G;HK^B3_B'@^,G_1P_PQ_\)?Q7_P#'*/\ B'@^
M,G_1P_PQ_P#"7\5__'*/^(@\(?\ 0W_\L,T\O^H+S0?\0-\4O^B7_P#,WP[Y
M?]3?S1_.W17]$G_$/!\9/^CA_AC_ .$OXK_^.4?\0\'QD_Z.'^&/_A+^*_\
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MT\O^H+S0?\0-\4O^B7_\S?#OE_U-_-'\[=%?T2?\0\'QD_Z.'^&/_A+^*_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>70
<FILENAME>nt10016217x4_graphic32x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic32x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M_K3Q/_T4>??^'?,/_FCR7W'TW_PVO^V7_P!';?M-_P#A^OBI_P#-71_PVO\
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M_:;_ /#]?%3_ .:NOF2BC^Q\I_Z%>7?^$6&_^5!_K3Q/_P!%'GW_ (=\P_\
MFCR7W'TW_P -K_ME_P#1VW[3?_A^OBI_\U='_#:_[9?_ $=M^TW_ .'Z^*G_
M ,U=?,E%']CY3_T*\N_\(L-_\J#_ %IXG_Z*//O_  [YA_\ -'DON/IO_AM?
M]LO_ *.V_:;_ /#]?%3_ .:NC_AM?]LO_H[;]IO_ ,/U\5/_ )JZ^9**/['R
MG_H5Y=_X18;_ .5!_K3Q/_T4>??^'?,/_FCR7W'TW_PVO^V7_P!';?M-_P#A
M^OBI_P#-71_PVO\ ME_]';?M-_\ A^OBI_\ -77S)11_8^4_]"O+O_"+#?\
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MW[3?_A^OBI_\U='_  VO^V7_ -';?M-_^'Z^*G_S5U\R44?V/E/_ $*\N_\
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MC+\LQ$N)506.Q^%BIU\#AH5\TI5*F,A'EDL-&'MIJ4'"$N>%_&O^&U_VR_\
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MNOF2BC^Q\I_Z%>7?^$6&_P#E0?ZT\3_]%'GW_AWS#_YH\E]Q]-_\-K_ME_\
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M/_FKKYDHH_L?*?\ H5Y=_P"$6&_^5!_K3Q/_ -%'GW_AWS#_ .:/)?<?3?\
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MHH_L?*?^A7EW_A%AO_E0?ZT\3_\ 11Y]_P"'?,/_ )H\E]Q]-_\ #:_[9?\
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M_FKKYDHH_L?*?^A7EW_A%AO_ )4'^M/$_P#T4>??^'?,/_FCR7W'TW_PVO\
MME_]';?M-_\ A^OBI_\ -71_PVO^V7_T=M^TW_X?KXJ?_-77S)11_8^4_P#0
MKR[_ ,(L-_\ *@_UIXG_ .BCS[_P[YA_\T>2^X^F_P#AM?\ ;+_Z.V_:;_\
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M7T_XU_8P_:6^'G@W5/'/B_X:2:3I/A[0_#?B?Q9I2^*O ^I>._ _ASQ>(O\
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MM[J76H?AOH/BB33Y+2[M;E8[RWEMUU/A)^Q+^T[\>/ ?BOXD?!_X9_\ "?\
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M:'X0\3Z#\&]+USPSX]2TD\(>)-%^,?P+U;0-<CU"W-SI\EKK.G_$RYTU4U!
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MZ<L5%R;A^DG_  2KM?@[^U#\.?C5^RA\3/@]\%-.^.W@/PN^M_#?XP6?[/\
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M^KZ?J$BZ<)A,UQ:75V(#Y4DP_B<HKCQ7AQ5Q,<PC_;=&'U^'$D)/^R92=/\
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M%N@6'BS0]1\/W^K>&+[4-3TNQU^SL=4M[6[DTJ^OM&U."RO?)$%X+.26V>6
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M@OCM_P!$5^+7_AN/&/\ \IJ/KV"_Z#,+_P"%%+_Y,/['S?\ Z%69?^$.*_\
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MO_E7FOO/):*]:_X4%\=O^B*_%K_PW'C'_P"4U'_"@OCM_P!$5^+7_AN/&/\
M\IJ/KV"_Z#,+_P"%%+_Y,/['S?\ Z%69?^$.*_\ E7FOO/):*]:_X4%\=O\
MHBOQ:_\ #<>,?_E-1_PH+X[?]$5^+7_AN/&/_P IJ/KV"_Z#,+_X44O_ ),/
M['S?_H59E_X0XK_Y5YK[SR6BO6O^%!?';_HBOQ:_\-QXQ_\ E-1_PH+X[?\
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M@OCM_P!$5^+7_AN/&/\ \IJ/KV"_Z#,+_P"%%+_Y,/['S?\ Z%69?^$.*_\
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M662SP^4XRG"FL'G%?/</&O"3J*LH9CB\15NVI2A6=)MPC34/;_\ @H)X&NO
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M,+_X44O_ ),/['S?_H59E_X0XK_Y5YK[SR6BO6O^%!?';_HBOQ:_\-QXQ_\
ME-1_PH+X[?\ 1%?BU_X;CQC_ /*:CZ]@O^@S"_\ A12_^3#^Q\W_ .A5F7_A
M#BO_ )5YK[SR6BO6O^%!?';_ *(K\6O_  W'C'_Y34?\*"^.W_1%?BU_X;CQ
MC_\ *:CZ]@O^@S"_^%%+_P"3#^Q\W_Z%69?^$.*_^5>:^\\EHKUK_A07QV_Z
M(K\6O_#<>,?_ )34?\*"^.W_ $17XM?^&X\8_P#RFH^O8+_H,PO_ (44O_DP
M_L?-_P#H59E_X0XK_P"5>:^\\EHKUK_A07QV_P"B*_%K_P -QXQ_^4U'_"@O
MCM_T17XM?^&X\8__ "FH^O8+_H,PO_A12_\ DP_L?-_^A5F7_A#BO_E7FOO/
M):*]:_X4%\=O^B*_%K_PW'C'_P"4U'_"@OCM_P!$5^+7_AN/&/\ \IJ/KV"_
MZ#,+_P"%%+_Y,/['S?\ Z%69?^$.*_\ E7FOO/):*]:_X4%\=O\ HBOQ:_\
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MW'C'_P"4U'_"@OCM_P!$5^+7_AN/&/\ \IJ/KV"_Z#,+_P"%%+_Y,/['S?\
MZ%69?^$.*_\ E7FOO/):*]:_X4%\=O\ HBOQ:_\ #<>,?_E-1_PH+X[?]$5^
M+7_AN/&/_P IJ/KV"_Z#,+_X44O_ ),/['S?_H59E_X0XK_Y5YK[SR6BO6O^
M%!?';_HBOQ:_\-QXQ_\ E-1_PH+X[?\ 1%?BU_X;CQC_ /*:CZ]@O^@S"_\
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M,+_X44O_ ),/['S?_H59E_X0XK_Y5YK[SR6BO6O^%!?';_HBOQ:_\-QXQ_\
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MZ#,+_P"%%+_Y,/['S?\ Z%69?^$.*_\ E7FOO/):*]:_X4%\=O\ HBOQ:_\
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M_&UUXK\,?%WPT=5\+:GJ_P 7?#MG?6L?A*VNO"J)-JMWJUYI,EU/HOL6D_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]HB8P74EN3'-<?LO_#V/1YC%*<I+-J=L$TV0J'DO[<+:EKB(!?[6OBU^R/\
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MA^^'O_"S?&?_  :.?M)^(_C;#?\ B>V\'_'7P?I?[,_B#Q@@UO4?#WP?T_\
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M(IM#\/7GB*3PM\+_ (?^#;7Q-KDNE6-MK_Q#N?''BFQM88/$),GUQ0 4444
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M71K7XI?$#X.>&_ /B/4(&A>VTO1K+6/ GCC4WUF9FMX+70M:N]0$%EI1E?\
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M)XBTWQ3>^(V?Q%XJ\,7EM^0_@'XJ>+/B9_P1Q_;L_P""J'C[5XE_X*1>"_\
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MVLGAGQ8MYT/_  5-_P""7L>MV7_!,KX1_LU:+^TY\%_V>?V8_&'QF75_C?\
ML[>,OB?\;/BA^S9X5UGP5X;?P]I?A_X87NO^(?C=XR@\6ZIX8MM!T+Q5X%\1
MZU=?"JPL]7LT\#^(8O%MAIQ]$_X)G?LN_MN_ /\ ;=\:W5G^U'^VU\>?^">&
MJ? ^YN+.3]NVRUK3O&T7QDN?$.CGP[X=\">&OB5K]O\ %?2X]+T*37M>\1^*
MI_A9\)_#MV;U/"M]H7B+6K2VUC2@#X,_X.ZO WA6_P# O["/C.]TE;KQ'/\
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MVU1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_#?@[5#K&CZ-J$FH>'=(TV[EN-&T=I9G&E:>+< _GT_X*G_"NX_: _X../\
M@FQ\%?B7X]^)GP\^$OB']F;Q'>^"?%?PM\9ZUX$\5^%OB'86W[4&OG6? OBV
MRCDD\*_$&Y\5>%?AG:7&M:(GVZ'3K?PD[S13Q6[P_0'_  0^_;+^-OA/4O\
M@J+\"/VU?VDF\<? ;_@GC\?Q\+O!'[3G[0_C'1].UJSTT_$GXQ^"M9TWX@_%
MCQ/J-NGB*TFN?!?A?4M#N_$FK7E_H-QXD_X1RUU:?0KOPEHNC?N1^T7^PO\
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MA5X-\,ZYXSM?B[JVL^'=-TS4=.U?2/A_X %_J8\2^(/ ?[ T %%%% !1110
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MCV,//[P.P_X2*T_YX7'Y1_\ QRC_ (2*T_YX7'Y1_P#QRN/HH]C#S^\#L/\
MA(K3_GA<?E'_ /'*/^$BM/\ GA<?E'_\<KR36?'G@;P[XF\'^"_$'C/PGH7C
M'XA2ZY#X!\)ZSXBT?3/$WCB;PQIG]M>)8O!^@WMY!JGB:7P]HW_$VUR/1;6]
M;2=,_P!/OQ;VO[VNKH]C#S^\#L/^$BM/^>%Q^4?_ ,<H_P"$BM/^>%Q^4?\
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MCV,//[P.P_X2*T_YX7'Y1_\ QRC_ (2*T_YX7'Y1_P#QRN/HH]C#S^\#L/\
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M4D#R;CGVC_\ CE<?2KU'U'\Z/8P\_O ]/HHHKD **** "BBB@ HHHH ****
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MCV,//[P.P_X2*T_YX7'Y1_\ QRC_ (2*T_YX7'Y1_P#QRN/HH]C#S^\#L/\
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M@^(?[37PT^/7Q[^(?[5?[*'CKPAXI^'KZ?K/C3XS:1I<7C'X,_&W4_B)\1-
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M **** "BBB@ HHHH _G^_;$_:L^'_P"SQ_P4#\4>#_\ @H=KGQ<T+]DWXG?
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M[OOWZ@%%%%6 4J]1]1_.DI5ZCZC^= 'I]%%%>> 4444 %%%% !1110 4444
M<YXC_P!1;?\ 75__ $"N2KK?$?\ J+;_ *ZO_P"@5R5=='X%ZL#^.+4I_&.J
M_P#!S-K_ .R%=?&3]HN']FKQ'X,U77+SX1:3^TK\??#_ (:L-3UG]D&3QW=W
M/AV7P_\ $?2]8\+-!XSFE\2:/_PCFIZ7_P (]J1B;P__ &9;VEE;VWJ?PZ_;
M>_:B_P"";/\ P5XG_P"";_QD^*GQ5_:[_9F^-6D66O\ [.VH?%/6M%USX_\
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MUV?2]"U+^;CXH_&/Q7^TQ_P7"_X)C?M=?#3]EC]K[_A1_@WX :#HOC/Q%?\
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M^?8?]_9O_CE'MX]I?A_GZ_T] X*BN]_L;3?^?8?]_9O_ (Y1_8VF_P#/L/\
MO[-_\<H]O'M+\/\ /U_IZ!P5%=[_ &-IO_/L/^_LW_QRC^QM-_Y]A_W]F_\
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MW_QRC^QM-_Y]A_W]F_\ CE'MX]I?A_GZ_P!/0."HKO?[&TW_ )]A_P!_9O\
MXY1_8VF_\^P_[^S?_'*/;Q[2_#_/U_IZ!P5%=[_8VF_\^P_[^S?_ !RC^QM-
M_P"?8?\ ?V;_ ..4>WCVE^'^?K_3T#@JY[Q=X1\+>/O"WB+P/XX\.Z+XO\&^
M+M%U/PWXI\+>)-,M-9\/^(O#^LVDNGZMHNM:3J$4]EJ6F:E93S6E[97<,MO<
M6\KQ2HR,17KW]C:;_P ^P_[^S?\ QRC^QM-_Y]A_W]F_^.4O;Q_E?X?Y^O\
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M^?8?]_9O_CE']CZ:/^78?]_9O_CE'MX]I?A_GZ_T] TZ***Y0"BBB@ HHHH
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M*/[&TW_GV'_?V;_XY1[>/:7X?Y^O]/0."HKO?[&TW_GV'_?V;_XY1_8VF_\
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M_P"_LW_QRC^QM-_Y]A_W]F_^.4>WCVE^'^?K_3T#@J*[W^QM-_Y]A_W]F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >:_&3XP?#C]G_X5^/OC5\7O%.G>"OAI\,O#&J>+O&7B?4V?[-IFC:5
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M444 %%%% !1110 4444 %%%% !1110 5\U?M6?M9_!K]BWX3ZE\<?C]?>+M
M^%>A7=A9^)/%_ACX?^-/B#9^%VU6^M-+TR[\26?@;1-?U31M*OM4OK33(=8O
M+&/2DU&ZM+*XO(;F\LX[CZ5K\8?^#A?_ )0Y?MK?]BS\+/\ U??PJH ]^/\
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M17\LGA#]O'_@HSHG[-7_  2._;@\=?'[X8^)O /[6?[17P'_ &<_C7^S[8?
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M:)XN*6IE,$,ATKX<^"1+<1P1RW*B&.:69+2!( #^CO\ :8_;%_9<_8X\'_\
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M9;2RMH(%EN9YKB01AYI9)&9VT/MUE_S^6O\ X$1?_%T?;K+_ )_+7_P(B_\
MBZ+/L_N8'QC^V=^P[X,_;:B^ 47C?XL_&?X8C]G#X]^"/VF/AY)\(+GX56<K
M_&#X:KJ*^ _$6OR?$GX3_$TW]KX:_MG6&M]$M/[.T?4FU*5M>L]6-MIWV+$N
M/V!_#4_[:$7[=J_'_P#:"MOC3%^SA#^RN-/MV^ P\!R?"F+Q-_PG<D$N@S?
M>;4Y->N?B$7\<3:L=?VIJ\ATNVM+?PC%;^&H?NG[=9?\_EK_ .!$7_Q='VZR
M_P"?RU_\"(O_ (NBS[/[F!^/-E_P15^"%G^QC\:/V$)?VD_VN-2^!OQW^)%Q
M\4/&\FIZ]^SW=>-XM>U+Q7I'CC7['0O$O_#.,<>GZ-XB\6:%I.MZG!-IE[?Q
M75M+'I&HZ7:ZAJ<%[WO[2/\ P2K\&_'[4OV>/B5HO[2?[1WP9_:@_9J\*S>
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MO=5?MUE_S^6O_@1%_P#%T?;K+_G\M?\ P(B_^+HL^S^Y@6J*J_;K+_G\M?\
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M?MUE_P _EK_X$1?_ !='VZR_Y_+7_P "(O\ XNBS[/[F!\K?M$_L:?!#X_\
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M>$+?P^\[:3:WFD^%XKVV@\->%]<T']Z?MUE_S^6O_@1%_P#%T?;K+_G\M?\
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M8V*3SF25;.RM+4.(+:%$L_;K+_G\M?\ P(B_^+HL^S^Y@6J*J_;K+_G\M?\
MP(B_^+H^W67_ #^6O_@1%_\ %T6?9_<P+5%5?MUE_P _EK_X$1?_ !='VZR_
MY_+7_P "(O\ XNBS[/[F!:HIJ.DBAXW61&SM=&#*<$@X920<$$'!X((HI <-
MK?\ R$KCZ0_^B8ZRJ_,/]O?P;^UAHMW^US^T7X1_:K^)/P>^$OP8_8\U?Q;\
M(/A?\.-(^#5Y:>)?C5X)\&?&+Q9XN\3_ !&O/B!\)?'7B23PY'##\+[/1M&\
M.>(_#S7MSINNM>/%:[%U+\2O^"8WQ3_X*D_\%'/^"</QD_:"\'?MV_$W2OVI
M/AC^T;XP\$>!?#<O@G]F^W^&?Q&\*^&?AS\$/&__  A/B.SU+X/07FC>(-7F
M\5^*=-\/^+;3Q5HNF:??:I9-XDM;S3+5;BQZXSLHKE;?(FMM4DO^#;O;S _K
MQHK^67P'_P %4-9_97_X*Y_\%#/@I^VG^V!JR_LB? [X8:7XB^%^C>.O"?A+
M4->L/%OB^?X)>)X=&\-6?PG^&EC\0?&T^@:3XV\6VEEI]M8:_>6/@W3;C7O$
MCW*Z+J?B*+]^M&_;4_95UW]F2#]LNP^.7@6/]F*XT&Y\1I\8-5O[C0?#2V%I
MJT_AZ>UG@UVUTW6;7Q"/$MO+X7B\)7.EP^*KCQ5Y?AFWT:77IX=/DN,XROK9
MJ]TVKJV[]/,#Z@HKY&^&W[=/[,?Q;\-?%[Q'X#\<^(M4N?@)ID>M?%[X?ZA\
M)?C%X;^-W@C1KSPXOB_1-6U+]G[Q-X!TCXY7&G^+/##KK7@BYTSX>WT?C>TW
MKX3.L7$,\$7S%\/?^"W/_!+?XJ:E\,=%\!_M8^'M<USXQ_%2/X+?#W0I/A[\
M8]&UW5_B'.?"26>FW^B:]\.]+U7PSHFHW/CCPW8:5XU\4V>B^"-5U.XU+3-.
M\175_P"'?$EOI#YH_P RUVU6NMOST]0/U6HKX(\7?\%/?V&? GC;3O _BOXZ
MV>E?VI\1V^#MK\1&\#_$RZ^ W_"VX[:.\N/AA/\ M&V/@RY^ MMX\T^!KD:W
MX8G^(T>J^'+K3=6T_P 16^E:CIMW:14?VB_^"IG["W[)7Q>TKX%?M&?&;5?A
M5\2M?L=-U/P_IFO_  :^.]QX?\0:;JJ@6FH:!X_T;X8ZG\/=;LDN"^G7]UI7
MBF[@TG68+O1-5DLM8L[JQA.:/\RTWU6@'Z"T5\ > ?\ @J-^PM\4_@K\9?V@
M?AS\<'\:?#7]GEH3\;F\._##XQ:IX_\ AE:SW]S8)JOBSX.6OP^D^,.G:%&V
MGZO>W>O-X#;1M/T7P]XIU^_OK71/"GB34-*RO"/_  5;_87\?_L_ZY^U-X)^
M*/CSQ7\!/#GC_1OA?J_Q"T']FO\ :AU.S@\;Z_)9VVEZ3!HMK\&9/$VH6T^H
MZEI&B3Z[INB7?AZP\1:YH'AO4-5M=>U[1].O3FC_ #1VONMN_H!^BE%>>^.O
MBCX,^&OPI\8_&KQK?WF@_#WP!\/?$/Q1\6ZIJ.CZO9W^B^#/"OAN\\6:]?WV
M@7EE;Z]:7FG:'875Q=:/=:=!J\$T+V4]E%>(T"_SX_\ !-']J/\ ;$_X+,:K
M\;?VA]:^-WC']D+]DWX7?%&T^&WPE^$O[/.E?#E/'GCKQ#H\>C>/=3NOB_\
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M.PN8[*_A\V":XL+47$:4KINR>MK_ "O;\P/:**^"_B[^TOXOUK]KGP'^PO\
M XVVE>/-2^%&H?M _'CXL:CI/]M6GP9^"*^(G\#^&K3PAIEW$?#>M?&CXF>,
M5O=/\&6OBB34- \%Z)H6L>/_ !)X+\?:5:6GA'6Y_P#@I)^U-XD_9!_9"^)_
MQ5^'6A3>+_C7J5M:_#WX ^";/37UN_\ %?QD\;-+IOA2&WT*-DDURS\+6ZZK
M\0_$FEQRPO<>$/!OB$K-$8]X'))-]([_ )V\_P#/3>X'W;17RE^Q?^TYX?\
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M5N[\@/\ ,,_:\^-'P]^+_P"P7\7O"_[/OPUU3]F+X0?#W_@I!;^+Y?V.]*\
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M:?@Y\2OA;_:DRN\>DS>//!VL>&;;5F6-7D/]EW.I1:@H1'?=;#:CG"G^7/\
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MWN)- ^*7BO1+>SCNO%R>!;C7-)\,/J-CI>H:J-;@UW3-$_!#2OVBO@9\*O\
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MUSQ%!XT_:YUCQ(;RZ@MUTOXF>(KC5/C'X^-Q'<R7.E^&=0\/Q1I:ZI/M]/\
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M\.Y1I.DZ#9ZUITGBGQGXYTQO#F@^&?&GU3\,/AMX+^#?PX\!_"7X<Z)!X;\
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M )+?_;Z/^$;_ .GW_P EO_M]=111[6I_-^$?\@.7_P"$;_Z??_);_P"WT?\
M"-_]/O\ Y+?_ &^NHHH]K4_F_"/^0'+_ /"-_P#3[_Y+?_;Z/^$;_P"GW_R6
M_P#M]=111[6I_-^$?\@.7_X1O_I]_P#);_[?1_PC?_3[_P"2W_V^NHHH]K4_
MF_"/^0'+_P#"-_\ 3[_Y+?\ V^C_ (1O_I]_\EO_ +?7444>UJ?S?A'_ " Y
M?_A&_P#I]_\ );_[?1_PC?\ T^_^2W_V^NHHH]K4_F_"/^0'+_\ "-_]/O\
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M )+?_;Z/^$;_ .GW_P EO_M]=111[6I_-^$?\@.7_P"$;_Z??_);_P"WT?\
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M /+C\*_XG?X3_P"D/OHR_P#B"Y;_ /.\_B1_X7?_ ,'!O_0K?M5?^(R>'?\
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M #O/XD?^%W_\'!O_ $*W[57_ (C)X=_^=31_PN__ (.#?^A6_:J_\1D\._\
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M3_Z0^^C+_P"(+EO_ ,[S^)'_ (7?_P '!O\ T*W[57_B,GAW_P"=31_PN_\
MX.#?^A6_:J_\1D\._P#SJ:_MNHH_XAOF/_1PN-?_  ZU_P#Y<'_$[_"?_2'W
MT9?_ !!<M_\ G>?Q(_\ "[_^#@W_ *%;]JK_ ,1D\.__ #J:/^%W_P#!P;_T
M*W[57_B,GAW_ .=37]MU%'_$-\Q_Z.%QK_X=:_\ \N#_ (G?X3_Z0^^C+_X@
MN6__ #O/XD?^%W_\'!O_ $*W[57_ (C)X=_^=31_PN__ (.#?^A6_:J_\1D\
M._\ SJ:_MNHH_P"(;YC_ -'"XU_\.M?_ .7!_P 3O\)_](??1E_\07+?_G>?
MQ(_\+O\ ^#@W_H5OVJO_ !&3P[_\ZFC_ (7?_P '!O\ T*W[57_B,GAW_P"=
M37]MU%'_ !#?,?\ HX7&O_AUK_\ RX/^)W^$_P#I#[Z,O_B"Y;_\[S^)'_A=
M_P#P<&_]"M^U5_XC)X=_^=31_P +O_X.#?\ H5OVJO\ Q&3P[_\ .IK^VZBC
M_B&^8_\ 1PN-?_#K7_\ EP?\3O\ "?\ TA]]&7_Q!<M_^=Y_$C_PN_\ X.#?
M^A6_:J_\1D\._P#SJ:/^%W_\'!O_ $*W[57_ (C)X=_^=37]MU%'_$-\Q_Z.
M%QK_ .'6O_\ +@_XG?X3_P"D/OHR_P#B"Y;_ /.\_B1_X7?_ ,'!O_0K?M5?
M^(R>'?\ YU-'_"[_ /@X-_Z%;]JK_P 1D\.__.IK^VZBC_B&^8_]'"XU_P##
MK7_^7!_Q._PG_P!(??1E_P#$%RW_ .=Y_$C_ ,+O_P"#@W_H5OVJO_$9/#O_
M ,ZFC_A=_P#P<&_]"M^U5_XC)X=_^=37]MU%'_$-\Q_Z.%QK_P"'6O\ _+@_
MXG?X3_Z0^^C+_P"(+EO_ ,[S^)'_ (7?_P '!O\ T*W[57_B,GAW_P"=31_P
MN_\ X.#?^A6_:J_\1D\._P#SJ:_MNHH_XAOF/_1PN-?_  ZU_P#Y<'_$[_"?
M_2'WT9?_ !!<M_\ G>?Q(_\ "[_^#@W_ *%;]JK_ ,1D\.__ #J:/^%W_P#!
MP;_T*W[57_B,GAW_ .=37]MU%'_$-\Q_Z.%QK_X=:_\ \N#_ (G?X3_Z0^^C
M+_X@N6__ #O/XD?^%W_\'!O_ $*W[57_ (C)X=_^=31_PN__ (.#?^A6_:J_
M\1D\._\ SJ:_MNHH_P"(;YC_ -'"XU_\.M?_ .7!_P 3O\)_](??1E_\07+?
M_G>?Q(_\+O\ ^#@W_H5OVJO_ !&3P[_\ZFC_ (7?_P '!O\ T*W[57_B,GAW
M_P"=37]MU%'_ !#?,?\ HX7&O_AUK_\ RX/^)W^$_P#I#[Z,O_B"Y;_\[S^)
M'_A=_P#P<&_]"M^U5_XC)X=_^=31_P +O_X.#?\ H5OVJO\ Q&3P[_\ .IK^
MVZBC_B&^8_\ 1PN-?_#K7_\ EP?\3O\ "?\ TA]]&7_Q!<M_^=Y_$C_PN_\
MX.#?^A6_:J_\1D\._P#SJ:/^%W_\'!O_ $*W[57_ (C)X=_^=37]MU%'_$-\
MQ_Z.%QK_ .'6O_\ +@_XG?X3_P"D/OHR_P#B"Y;_ /.\_B1_X7?_ ,'!O_0K
M?M5?^(R>'?\ YU-'_"[_ /@X-_Z%;]JK_P 1D\.__.IK^VZBC_B&^8_]'"XU
M_P##K7_^7!_Q._PG_P!(??1E_P#$%RW_ .=Y_$C_ ,+O_P"#@W_H5OVJO_$9
M/#O_ ,ZFC_A=_P#P<&_]"M^U5_XC)X=_^=37]MU%'_$-\Q_Z.%QK_P"'6O\
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M[S^)'_A=_P#P<&_]"M^U5_XC)X=_^=31_P +O_X.#?\ H5OVJO\ Q&3P[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^'WB[P7\#O@G>>%/!'C;Q1X+N;/PU\1;;QY\3/C39_#:\U?POX!6UF\):_\
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MKPA\7?#VBGQ=87'AH>&=:A\7>$M0D\*R?I1\'_BGX1^.7PF^&'QJ^']W/?\
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MY-Y]"W_M&;@K_P!4>0!1117ZJ?P %%%% !1110 4444 %%%% !1110 4444
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M(?C'P3$GQ$\=:/<:'+:_\)(VCZ+H/A:37Y+O6=,\4RZ!$OP)\,;/XB6^C?\
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M(:W^BGP_^"_QK\9_$O\ X+X?LD7/P:^-/@?QC^W!;^)O$GP=^)OB+P#K>E?
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MT=QKG_AEK#_YYU'_ !#=^&O^CN-<_P##+6'_ ,\ZC^U_%O\ Z(?*/_#U@O\
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M_/.H_M?Q;_Z(?*/_  ]8+_YY!_Q"K]GU_P!)1>(O_BL^(O\ Z#?7^EK^^?\
MP\1_8/\ ^CPOV</_  [_ ((_^7-'_#Q']@__ */"_9P_\._X(_\ ES7X&?\
M$-WX:_Z.XUS_ ,,M8?\ SSJ/^(;OPU_T=QKG_AEK#_YYU']K^+?_ $0^4?\
MAZP7_P \@_XA5^SZ_P"DHO$7_P 5GQ%_]!OK_2U_?/\ X>(_L'_]'A?LX?\
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M6'_SSJ/[7\6_^B'RC_P]8+_YY!_Q"K]GU_TE%XB_^*SXB_\ H-]?Z6O[Y_\
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M&^O]+7]\_P#AXC^P?_T>%^SA_P"'?\$?_+FC_AXC^P?_ -'A?LX?^'?\$?\
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ML^(O_H-]?Z6O[Y_\/$?V#_\ H\+]G#_P[_@C_P"7-'_#Q']@_P#Z/"_9P_\
M#O\ @C_Y<U^!G_$-WX:_Z.XUS_PRUA_\\ZC_ (AN_#7_ $=QKG_AEK#_ .>=
M1_:_BW_T0^4?^'K!?_/(/^(5?L^O^DHO$7_Q6?$7_P!!OK_2U_5G]H'XR_\
M!,3]H+7?A-\0M7_; _9\\)?&S]G_ ,5W'C;X%?&KPO\ %OX=1>.?AUK.I6,F
MC^)]'BFO;^ZL]?\ A_\ $+P[/=>%?B1X!UJ"XT/Q3H-T)4&E^)M*\->)=!^F
MO^'B/[!__1X7[.'_ (=_P1_\N:_ S_B&[\-?]'<:Y_X9:P_^>=1_Q#=^&O\
MH[C7/_#+6'_SSJ/[7\6_^B'RC_P]8+_YY!_Q"K]GU_TE%XB_^*SXB_\ H-]?
MZ6O[Y_\ #Q']@_\ Z/"_9P_\._X(_P#ES1_P\1_8/_Z/"_9P_P##O^"/_ES7
MX&?\0W?AK_H[C7/_  RUA_\ /.H_XAN_#7_1W&N?^&6L/_GG4?VOXM_]$/E'
M_AZP7_SR#_B%7[/K_I*+Q%_\5GQ%_P#0;Z_TM?WS_P"'B/[!_P#T>%^SA_X=
M_P $?_+FC_AXC^P?_P!'A?LX?^'?\$?_ "YK\#/^(;OPU_T=QKG_ (9:P_\
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M$4<'"K75*$*2JSDJ<8QLD4445ZA\(%%%% !1110 4444 ?Q%?MV^(M!\(?\
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M&^O]+7]\_P#AXC^P?_T>%^SA_P"'?\$?_+FC_AXC^P?_ -'A?LX?^'?\$?\
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ML^(O_H-]?Z6O[Y_\/$?V#_\ H\+]G#_P[_@C_P"7-'_#Q']@_P#Z/"_9P_\
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M ((_^7-'_#Q']@__ */"_9P_\._X(_\ ES7X&?\ $-WX:_Z.XUS_ ,,M8?\
MSSJ/^(;OPU_T=QKG_AEK#_YYU']K^+?_ $0^4?\ AZP7_P \@_XA5^SZ_P"D
MHO$7_P 5GQ%_]!OK_2U_?/\ X>(_L'_]'A?LX?\ AW_!'_RYH_X>(_L'_P#1
MX7[.'_AW_!'_ ,N:_ S_ (AN_#7_ $=QKG_AEK#_ .>=1_Q#=^&O^CN-<_\
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MTM?WS_X>(_L'_P#1X7[.'_AW_!'_ ,N:/^'B/[!__1X7[.'_ (=_P1_\N:_
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MCN-<_P##+6'_ ,\ZC_B&[\-?]'<:Y_X9:P_^>=1_:_BW_P!$/E'_ (>L%_\
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M-?@9_P 0W?AK_H[C7/\ PRUA_P#/.H_XAN_#7_1W&N?^&6L/_GG4?VOXM_\
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MO"OQ(\ ZU!<:'XIT&Z$J#2_$VE>&O$N@_37_  \1_8/_ .CPOV</_#O^"/\
MY<U^!G_$-WX:_P"CN-<_\,M8?_/.H_XAN_#7_1W&N?\ AEK#_P">=1_:_BW_
M -$/E'_AZP7_ ,\@_P"(5?L^O^DHO$7_ ,5GQ%_]!OK_ $M?WS_X>(_L'_\
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MXCU6]^'-KX=T;Q+XCUB]T'P=X0\)>&/!.B64]IX<TWPU;>%]'T31-.^!M?\
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MOC;3]+MIO"/BOQ#\&I=*U<ZU:6[)>?U(U49<RO;MUOT3?16LW;OIL@"BBBJ
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^2_C7^VK\$_@9XPO/A]KT7Q/\=>.]&\'1_$3Q;X2^"OP?^)7QHUOP#X
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M6NW=YK.C6%CJ=Y=74OY ?\1)?_5F/_FQ7_XBJ/\ B)+_ .K,?_-BO_Q%5/\
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M /Q$E_\ 5F/_ )L5_P#B*H_XB2_^K,?_ #8K_P#$52_XBUX=?]#^/_AHSO\
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M[0_XI]?2]_Z-'_YOOAC_ /1H?U$45_+O_P 1)?\ U9C_ .;%?_B*H_XB2_\
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ML/\ \<H_L;4O^?8_]_8?_CE-.FG=22T2^/31)+2]M$K ?CA_P4(_X)Y_'/\
M;0U/XN>&M(^,?P>B^ OQA^!_PX^&>I?"#XW_  M\<?$V'P!\4/"'BSXKZG_P
MTC\'-8\-_%/P%%\.?B?X?T+QUX?M+"*'2M:T_P ?/X=BT;QK+;:):68?P7XJ
M_P#!##1-3T__ ()H:C\!_P!H _"_XB_\$W(=#M?#?BKQ]\--1^+.@_%1-(\2
M>'O'#7/B?PE:_%+X?SZ)O\;Z7K>M)I^A>)H85TSQ3>>&X+NSM-*T&\TW^@G^
MQM2_Y]C_ -_8?_CE']C:E_S['_O[#_\ '*'[)WNXZ[OFUWOO?NK@?AG^T/\
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ME_S['_O[#_\ '*.>'\T?_ E_F!F45I_V-J7_ #['_O[#_P#'*/[&U+_GV/\
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M_P#QRA^S::<HZMN_,KW:MW[:>GH!_-Q_P4T_8W3]J7P)^P#_ ,$@?@&UY>>
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MS7]E/_Q'CX1?_,?1_P ,(?L/?]&:_LI_^(\?"+_YCZ^K**/['RG_ *%>7?\
MA%AO_E0?\1'\0_\ HO.,_P#Q*,\_^;CY3_X80_8>_P"C-?V4_P#Q'CX1?_,?
M1_PPA^P]_P!&:_LI_P#B/'PB_P#F/KZLHH_L?*?^A7EW_A%AO_E0?\1'\0_^
MB\XS_P#$HSS_ .;CY3_X80_8>_Z,U_93_P#$>/A%_P#,?1_PPA^P]_T9K^RG
M_P"(\?"+_P"8^OJRBC^Q\I_Z%>7?^$6&_P#E0?\ $1_$/_HO.,__ !*,\_\
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M,_\ Q*,\_P#FX^4_^&$/V'O^C-?V4_\ Q'CX1?\ S'T?\,(?L/?]&:_LI_\
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M(_B'_P!%YQG_ .)1GG_S<?MW_P ,(?L/?]&:_LI_^(\?"+_YCZ/^&$/V'O\
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M  BPW_RH/^(C^(?_ $7G&?\ XE&>?_-Q\I_\,(?L/?\ 1FO[*?\ XCQ\(O\
MYCZ/^&$/V'O^C-?V4_\ Q'CX1?\ S'U]644?V/E/_0KR[_PBPW_RH/\ B(_B
M'_T7G&?_ (E&>?\ S<?*?_#"'[#W_1FO[*?_ (CQ\(O_ )CZ/^&$/V'O^C-?
MV4__ !'CX1?_ #'U]644?V/E/_0KR[_PBPW_ ,J#_B(_B'_T7G&?_B49Y_\
M-Q\I_P##"'[#W_1FO[*?_B/'PB_^8^C_ (80_8>_Z,U_93_\1X^$7_S'U]64
M4?V/E/\ T*\N_P#"+#?_ "H/^(C^(?\ T7G&?_B49Y_\W'RG_P ,(?L/?]&:
M_LI_^(\?"+_YCZ/^&$/V'O\ HS7]E/\ \1X^$7_S'U]644?V/E/_ $*\N_\
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M5_XEM?!JZEX[@/['RG_H5Y=_X18;_P"5!_Q$?Q#_ .B\XS_\2C//_FX^C?\
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M<9_^)1GG_P W';?\,(?L/?\ 1FO[*?\ XCQ\(O\ YCZ/^&$/V'O^C-?V4_\
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MJE2I*4YR<FVRBBBJ,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***_#GX^_M5?MPZ7_ ,%9_A?^P%\(OBM\
M ?!_PX^+?[->N_M%V/B[QY^SIXK^(_BWPG_PC?B7Q1X=OO!;C1/VAOAGIFOP
MZD_ALWECK[VNDS:5'>K:76EZT]J;VY /W&HK\8/%W[?G[2O[%'[3OP2^!_\
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MB)XA\;:EIUAHL>@:C<W#6DVA65CJ)\6>)O$=N+VRT#P5INK>(Y([J&TBM[D
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M[B.VLOQ_^RE^S#\5?A;X;^!_Q)_9X^"GCGX-^#+G2KSP9\+/$_PP\&:O\/\
MP==Z%8WNE:+=>$O"5YHTNA^&;G2M)U/4])T^?0[*PEM-)U/4M,A9+#4+RWF
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M-^R@'Y7_ +6W@CX#?'C_ (*Q_P#!,?P/XFTSP#\2_ATGP-_;]>;P;]NT[6O
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M9JB?L[^ ([[X[?M1:A I20W6GZG\&_AGKOPSO8F1HGO/B;I-K+_Q]H#^G8
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M/90_E7WO_/R_/NP.C_X2.?\ Y]HO^^WH_P"$CG_Y]HO^^WKG**/90_E7WO\
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M<_\ S[1?]]O7.44>RA_*OO?^?E^?=@='_P )'/\ \^T7_?;T?\)'/_S[1?\
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M_B#;:K?->ZG;RR>!/$T^IW?B+4[6[_63XH_'7XVVWC7XL?!__AW_ /%[XO\
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MOC_\#OB]_P $R_&_P3_94_X5%\)?'GQ-T?X:_'K4]<\,:AIGA6^3P3H^L_\
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M+?X>RP:B'T?Q-J4-O/>1)WYNMUS)6C=+16ULUKZV^X#]7O%O[?VM^#_VA_\
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MX8?\%6/V _CK<?LRP7_[2OQ4_9D_;%\-^,/AK\"]<T?Q=<>,M<\)3?"K3/
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MGP3)HL&@^'(?%OB+1KCQE'XLUWQ+K>AZ8/#GA:TO^E_X)-_#'XR_ [_@G_\
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MQG^!?Q7^%^C:AJ4L\.GZ;KGCCP-KGAS1-3OI;6"ZN$M-.U74;.]N&BM;IQ%
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M+_XBC[%9_P#/I;?]^(O_ (BCVZ_E?WH#SBBO1_L5G_SZ6W_?B+_XBC[%9_\
M/I;?]^(O_B*/;K^5_>@/.**]'^Q6?_/I;?\ ?B+_ .(H^Q6?_/I;?]^(O_B*
M/;K^5_>@/.**]'^Q6?\ SZ6W_?B+_P"(H^Q6?_/I;?\ ?B+_ .(H]NOY7]Z
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M)?\ F'OCY_\ .LH_X?/_ /!-3_HY+_S#WQ\_^=97SE_Q#;_LB?\ 1:_VC_\
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M_@FI_P!')?\ F'OCY_\ .LH_X?/_ /!-3_HY+_S#WQ\_^=97SE_Q#;_LB?\
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M+_S#WQ\_^=97SE_Q#;_LB?\ 1:_VC_\ P;?#+_YVM'_$-O\ LB?]%K_:/_\
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M^?(?ZH?LU/\ HZ?TD?\ PW\/?_2Y_JS\K_1O_#Y__@FI_P!')?\ F'OCY_\
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M-_\ !N,_^?(?ZH?LU/\ HZ?TD?\ PW\/?_2Y_JS\K_1O_#Y__@FI_P!')?\
MF'OCY_\ .LH_X?/_ /!-3_HY+_S#WQ\_^=97SE_Q#;_LB?\ 1:_VC_\ P;?#
M+_YVM'_$-O\ LB?]%K_:/_\ !M\,O_G:T?VMXS?]"+@W_P &XS_Y\A_JA^S4
M_P"CI_21_P##?P]_]+G^K/RO]&_\/G_^":G_ $<E_P"8>^/G_P ZRC_A\_\
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MH^J>-O#ND1R>&]/\9M9Q^))_"TMOX;U74=2T?0_#5GHG%?\ $-O^R)_T6O\
M:/\ _!M\,O\ YVM'_$-O^R)_T6O]H_\ \&WPR_\ G:T?VMXS?]"+@W3;][C/
M_GR'^J'[-3_HZ?TD?_#?P]_]+G^K/RO]&_\ #Y__ ()J?]')?^8>^/G_ ,ZR
MC_A\_P#\$U/^CDO_ ##WQ\_^=97SE_Q#;_LB?]%K_:/_ /!M\,O_ )VM'_$-
MO^R)_P!%K_:/_P#!M\,O_G:T?VMXS?\ 0BX-_P#!N,_^?(?ZH?LU/^CI_21_
M\-_#W_TN?ZL_*_T;_P /G_\ @FI_T<E_YA[X^?\ SK*/^'S_ /P34_Z.2_\
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M:";&Z5V'*_"AE.5(/!/7!YHK^ 6BORU^.?%K;;R[AW5M_P"Z9GU_[JY_<_\
MQ2I^CU_T67C-_P")#P1_]+L_U8****_JD_P!"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM2OG^$7A#0]*TCPW\=?A%\(++X=^)/$7A#Q9J&K_ !D\>^*;M8' /ZN#X_\
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MDU?XHWOB7PWK?Q&?XB:?J&OVUSH_WV2!_P ')Q)( '_!#HDDG  '[>F223P
M!R2>E '[BUQ^C^/_  7XA\7>,_ >A^)-+U7Q?\.X_#<GCG0;&?[1>^%6\86-
MUJOAJVUKRU,-E?ZMI-H^K6^G2RB_32KC3M3GMHK'5M+N+S^4>\_:O_:6^'7C
MK_@GG\7]#^.GQW^.'B3XV?\ !3GP9^R9^TK\?/#OB+5[3_@F]\9/"GQF^(?Q
M&\/+\+_V:O@[\0O%EEJ5\_PB\(:'I6D>&_CK\(OA!9?#OQ)XB\(>+-0U?XR>
M/?%-VL#]]^S#<Q_LS?$W_@X/_:WT?6OBYXV\9_LH?%'XF^/?"/A3Q)\:?BUJ
M7@CQG?>'/V;-4\2:?:?$SPBGBU= \96=E<P0V6G:GK^EZC>^!M M;6'PD^D6
MVAZ5;V@!_557B?[1_P 9T_9U^!'Q8^.UQX%\5?$?3_A)X#\3?$'6?"7@N[\)
MV/B&^T+PGI-UK>N7-I<^-?$GA70DATO2;*[U.^5M5DU.2QM+B/1-*US6&LM'
MO?PN_9T^&W_!1._O/^"?7[8'P\_:4DUSX=?%"'P-XM_;(N?C_P#M4^+O'7PX
M_: \ _M&MX U2QNO@K\#KOX8Z9\.O@!XM\-ZMKMW#\%O!7PR3P8YFU7PY\.]
M?U[Q#;G4QKOGOB3Q[XN_X*2?LH?\%BOVDM6^//QY^&OAG]G77OVS_P!FGX$?
M"+X8>/+CP5\/]/\ !?P&^".G:E?>)OBQX$;0XXOB-XI^,]]KOB$>+M%^)<&O
M6GA/P9K>GZ1X(A\+^*M(T_Q;9 '[^_LG_'=/VH?V9/@%^T='X7;P3'\<_A'X
M"^*L?@]]9'B)_#*>./#FG^(4T-]>72M#76&TU;\6C:BNCZ8+LQ&86-L'\I?:
MO$.IWNBZ%K&KZ;X=UCQ=J&F:;>7UEX7\/3^'[;7?$-U:P/-!HVCW'BO7/#'A
MF#4M1D1;6SEU_P 1:'I"3RHVH:K8VHDN8_@__@DS_P HP_V /^S0_@%_ZK;P
M]7R9X2^(?BG_ (*"?\%!?V\/@')\</CM\#_A1^P%8? 7P+X/T'X#^/[OX5^(
M?&_Q7^,/A7QQXL\6_%;Q_J$&BOJ_B+3/!5_X?T;PW\.?!&L7&L?"O7ET36=<
M\6^%O%^E>(CI@ /N;_@GU^V7I?[?7[,'A7]IS1?A_JGPQTCQ?XN^*7AS3?"&
MN:]8^(M9M++X<_$OQ5\/K;4-5O\ 3+*RTZ'4-;B\-KK%WI5@VI6FC3WKZ7;Z
MYKD5HFK7?VK7\4W_  3K^,?Q9'[&W_!)/]A?P#XL\4>%]/\ VI_BG_P48\8?
M$'Q%X,^)>J? KXB_$"P_9L^+?B;Q9I_PJ\(?&/PYX<\2:Q\.8O%VH^(;CQ7X
M^U7PC8Z/XMO/#/@T>"] \2Z!#XSO[H?J=;:?_P %#_V5?V2_^"B^@_&+]LOX
M(?#"S\/:EH7CW]CWXQ?&#XC>+OVA/B9^SG\'OB7XX\06.N>&_BSK&J^ HO'?
MQ2UW2[+3;OPQ^S=>ZKIOQ'\8?$#XCO+X5+:U%I>E>&;< _H+K\Y_VN_^"C/@
MG]F?X$_#G]H+P3\.?$G[17P[^)GQ5\*?"?2O&7P_\2^#M)\":#JWBOXB:?\
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M;7?A/;Z#I=GX"^&?C*]^+%EX)^']_P"&O&GC?4M-U#PL]EXG\+^&;:6^ET$
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MSA_X*?B;_P#/*H_XB2/VN_\ HBG[.'_@I^)O_P \JC_B,7!'_07CO_#=B/\
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MA8>"OA!X%UGP^-&\+1VGA>"T_M^]L[K1M.TQ-3M[^^TZTOHOYG?^(DC]KO\
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M2/VN_P#HBG[.'_@I^)O_ ,\JC_B,7!'_ $%X[_PW8C_(/^*;/TIO^B=X5_\
M$RRC_P"3/WH\'_\ !*#P'HW[3EE^UIX]_:@_:S^-GQ6O/@'K/[./Q$'Q,\9?
M#?\ X1CXH_#+5O$A\6Q>%_$'AWP5\*_!UEX8\+:9XACL-5C\(_#0>"- U^]T
MM9O&]IXL/B7XB#QOP5A_P1<^%=I^Q]X<_8DF_:U_;4N?@_X0\8>$/$WAB=O&
M_P %I/$FB:3\.?&DOQ%^'/@K3WU#X#:CX;L]"\)^.9[CQ.-5L_#=MXU\0W3:
M;H/B;Q5JW@7P?\/O"'@_\5/^(DC]KO\ Z(I^SA_X*?B;_P#/*H_XB2/VN_\
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MOXP/^(DC]KO_ *(I^SA_X*?B;_\ /*H_XB2/VN_^B*?LX?\ @I^)O_SRJ/\
MB,7!'_07CO\ PW8C_(/^*;/TIO\ HG>%?_$RRC_Y,_L_K\U_VJO^":/P]_:0
M^-1_:*\,?%+XB_L__&;7OV?/B'^RC\3/&7PRM_"MY)\3?V?_ (EKG5/#&N6/
MBO1-9M],\6>$[U[C6_AUX]T0V6JZ#K36;^(+3Q?HVC:+H=A_/1_Q$D?M=_\
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M "/1_P (OX9_Z%W0O_!1I_\ \CT44 NGR_\ <8?\(OX9_P"A=T+_ ,%&G_\
MR/1_PB_AG_H7="_\%&G_ /R/110"Z?+_ -QA_P (OX9_Z%W0O_!1I_\ \CT?
M\(OX9_Z%W0O_  4:?_\ (]%% +I\O_<8?\(OX9_Z%W0O_!1I_P#\CT?\(OX9
M_P"A=T+_ ,%&G_\ R/110"Z?+_W&'_"+^&?^A=T+_P %&G__ "/1_P (OX9_
MZ%W0O_!1I_\ \CT44 NGR_\ <8?\(OX9_P"A=T+_ ,%&G_\ R/1_PB_AG_H7
M="_\%&G_ /R/110"Z?+_ -QA_P (OX9_Z%W0O_!1I_\ \CT?\(OX9_Z%W0O_
M  4:?_\ (]%% +I\O_<8?\(OX9_Z%W0O_!1I_P#\CT?\(OX9_P"A=T+_ ,%&
MG_\ R/110"Z?+_W&'_"+^&?^A=T+_P %&G__ "/1_P (OX9_Z%W0O_!1I_\
M\CT44 NGR_\ <8?\(OX9_P"A=T+_ ,%&G_\ R/1_PB_AG_H7="_\%&G_ /R/
M110"Z?+_ -QA_P (OX9_Z%W0O_!1I_\ \CT?\(OX9_Z%W0O_  4:?_\ (]%%
M +I\O_<8?\(OX9_Z%W0O_!1I_P#\CT?\(OX9_P"A=T+_ ,%&G_\ R/110"Z?
M+_W&'_"+^&?^A=T+_P %&G__ "/1_P (OX9_Z%W0O_!1I_\ \CT44 NGR_\
M<8?\(OX9_P"A=T+_ ,%&G_\ R/1_PB_AG_H7="_\%&G_ /R/110"Z?+_ -QA
M_P (OX9_Z%W0O_!1I_\ \CT?\(OX9_Z%W0O_  4:?_\ (]%% +I\O_<8?\(O
MX9_Z%W0O_!1I_P#\CT?\(OX9_P"A=T+_ ,%&G_\ R/110"Z?+_W&'_"+^&?^
MA=T+_P %&G__ "/1_P (OX9_Z%W0O_!1I_\ \CT44 NGR_\ <8?\(OX9_P"A
M=T+_ ,%&G_\ R/1_PB_AG_H7="_\%&G_ /R/110"Z?+_ -QA_P (OX9_Z%W0
MO_!1I_\ \CT?\(OX9_Z%W0O_  4:?_\ (]%% +I\O_<8?\(OX9_Z%W0O_!1I
M_P#\CT?\(OX9_P"A=T+_ ,%&G_\ R/110"Z?+_W&'_"+^&?^A=T+_P %&G__
M "/1_P (OX9_Z%W0O_!1I_\ \CT44 NGR_\ <8?\(OX9_P"A=T+_ ,%&G_\
MR/1_PB_AG_H7="_\%&G_ /R/110"Z?+_ -QA_P (OX9_Z%W0O_!1I_\ \CT?
M\(OX9_Z%W0O_  4:?_\ (]%% +I\O_<8?\(OX9_Z%W0O_!1I_P#\CT?\(OX9
M_P"A=T+_ ,%&G_\ R/110"Z?+_W&'_"+^&?^A=T+_P %&G__ "/1_P (OX9_
MZ%W0O_!1I_\ \CT44 NGR_\ <8?\(OX9_P"A=T+_ ,%&G_\ R/1_PB_AG_H7
M="_\%&G_ /R/110"Z?+_ -QA_P (OX9_Z%W0O_!1I_\ \CT?\(OX9_Z%W0O_
M  4:?_\ (]%% +I\O_<8?\(OX9_Z%W0O_!1I_P#\CT?\(OX9_P"A=T+_ ,%&
MG_\ R/110"Z?+_W&'_"+^&?^A=T+_P %&G__ "/1_P (OX9_Z%W0O_!1I_\
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67_X2VA__ "#1117 ?:KI\O\ W&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>71
<FILENAME>nt10016217x4_graphic33x1.jpg
<TEXT>
begin 644 nt10016217x4_graphic33x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M)T'3)OC!8W$WB?QAKVMV>G:3\0I?$O@O3TT77+2*70M!LM1MKDW]Y-?R?O\
MZ9_P3J_85\:?M*>!_@-9_![QGX7'Q4_8JM/CS;Z]IGQ>\57MIX(\17/BZ'1$
MGTC2=:CU*]UG52NIJK2ZYKL_AJ.STNVC7PI+?7MWJ*?R\M>S3W[:C?DZG<37
M9O;TW\US*VH323&>Y-[<1SPWDANW+_:9H[F*Y<R.Z3I*1(/U2TW_ (*^_'W1
M_B]X1^-NF_"3]G:U\:^"?@O-\!-#VZ!\6I-(C^'S:]I/B&UMKBPF^,LCSZII
MU[I1BL]1^THS6FHZA'>Q7DAL9K'Z/B?)N)*^%RVCD6.QL:V%R[,J-?$1S3$8
M5UL=.CAOJ->OS8CFKJ.(IUIOVGM53A-TVI4Y2@_@O#OBS@'!9EG^,XSR;**F
M$S+/<AQ6#P,^&\#F,<)E%'%YA_;.#P?+@>3!\^ KX:BO8/#RKU*4:ZE#$4H5
M5@_L'_LY_!'XS>';36O%OAW7_B/X]A_:#^&?@;Q-X(U@>+?!OPH\/_ SQ==:
M5I7B#QS?_%S1M4\(:'HGQ'EUO5#I/@3PUJWC2:^UW5K6PT71OAYXXU#Q);KI
M'VYX;_8*_9+\+?M$?\%)/@SXU\!^*?&_A']FKX0Z7\8?AQK\/CW7_#WC?1K;
M5?A9:>.[_P -)<6$Q\+:J;"XUB"VT'5/$/AC57A?3(Y=:M=;@O)[5?S2^"_[
M?_Q,^!7P?\4?!;P?\-_@O?\ A?6_C!IOQPT"Z\4>%_$&OZKX!\>:+-X=N-#O
M?"\]WXM\J[AT"7PIHAT;_A+(?$MRD<5Y;ZI=:M;7\T(]0O\ _@JE\7KWXF_M
M!_%0_!OX MXA_:9^'FC?#'XH17.E_%>6SO/"^D^&'\(.FEI:?%NPDTZ^U'1/
MLEI>7:.[(FF:>]FMK<+?3W_#FN5<:8K,<WJ87$8NC@,11]G@:=+-_93IU(9A
MDE>G5BJ4\/'#)X.EFU!PA&51NJZ>(K8F%2E.G['#?$GA+EV0\,4,RP.6XK.<
M#BU7SFMB.%UBJ5?#U<CXNP5?#5)8FEC9X^:S3$\-8R-6K.-&*P\:V"PF K4,
M12J_=&B_LB?L+Z_XC_X)Y^-C\!?'&F^'?VV-,\4>'=1^&-O\</$ESX:\#ZQH
M%GI\J>+QXAN=%'C;Q#J$LVIQC^QX==\.Z)MC60VV(G@O?F+P?^PC\-;+7?\
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MTW^VO_R>7^UM_P!G-_'K_P!6IXKKSJO_ "-L%_V+LT_]2<G/=P__ "3.;_\
M8]X=_P#5?Q0?,E%%%>B>$?H-_P $]_C9K_[.7B']H;XW>&A-+J7PZ^"7@/7)
M["&=;5M:T-OVS/V3+#Q1X;>Y:*86]OXF\,WFK^'[J<1.\5MJ<TB#>JD?J9^V
M1\+/!?PE_:U\%_MV?#O4-*N?!W[4VE_"I_@W]A?3+>6;XI?%R6RT'Q]XPM]
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M/CC\3M)^,6N_ WX ^'?B$FJ^#-4\::[X4T7XCZ=+\3H_ =]IVI>'M#\:)/\
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M'K=AK;Z#+J6H+INI?$&_UNQU"_E\-:8-1AL_$$.D7UNU]%-I8DN_/B[/3O\
M@JW\8+"[_9VU27X*?LX:KJ_[+>G^,=(^#MUJGA7X@I9^&-+\7Z?INB?9(-'T
M7XG:+IDYT'P]H^EZ-HMW?07E_$FGVNK75U<^(5FU>?S7E7&%"ID\<-&J\#@,
MCP^!Q6"AG'U:&(Q,,BQN%<(^P=%T(0S/ZC.6*C.MBHPBJ^%J4N6I0?O+B7PL
MQN&XIGCZF'CG.<\88S.,OS>KPL\?6P.7U.,LGS*-2JL9#%QQM2MP\\XH1RV=
M'"Y=.K)X3,:&)56CC8?5/[2?[*_[!WPC^,?[*G[*_BG0-7\*_%/Q3_9GB?\
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M?&G5;V]\>^'+?QG;^$]4T.]U/PII%V?![Z(_A]0^JV5Q;WFFZD]E%\\^%?\
M@FY\';?Q;^QS^S5XJBUK4/B7^US\$/'?Q<UWXSV&L7DW_"I_$&G?#V\\8^#_
M  ]X7\)Z?J$/A/Q!X.T^YTZ73?%]QX@_M+6O%US>6\_AGQ)X(MS';M\@V/\
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M#CQIHD^@:-XJT'7M>G\2>%]5MYCI03POI]GJ&H7^DZSX@\0>*_!7X#?L=_\
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M0+F'7] U;PSJ,%S#9ZAIVI1M_9>LWGV.ZL]3MKFVNA!,TDT:S03_ $-\:?\
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MIXX+ZCI-IH'BV.Y\-W>JZ/-\.XO#&FC2KFS\+_\ "/S:Q>P>*H-;]N#X(_\
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MC?B+_H :U_X*[[_XQ7^E]11_Q'JI_P!$M#_P\R_^=8?\254/^CCU?_$3A_\
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M/^)*J'_1QZO_ (B</_HD/\T'_A&_$7_0 UK_ ,%=]_\ &*/^$;\1?] #6O\
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M]''J_P#B)P_^B0_S0?\ A&_$7_0 UK_P5WW_ ,8H_P"$;\1?] #6O_!7??\
MQBO]+ZBC_B/53_HEH?\ AYE_\ZP_XDJH?]''J_\ B)P_^B0_S0?^$;\1?] #
M6O\ P5WW_P 8H_X1OQ%_T -:_P#!7??_ !BO]+ZBC_B/53_HEH?^'F7_ ,ZP
M_P")*J'_ $<>K_XB</\ Z)#_ #0?^$;\1?\ 0 UK_P %=]_\8H_X1OQ%_P!
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M5_\ #D;_ ()@_P#1LG_F9_VA/_GL4?\ #D;_ ()@_P#1LG_F9_VA/_GL4?\
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M'\*G_"9Z)_?N?_ <_P#Q5'_"9Z)_?N?_  '/_P 57]U?_#D;_@F#_P!&R?\
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M6OE>#I\N H49QA"OA\96K1DJ%-QJ5'2DO>3@[W/S;Z9?[/7P!X:R_P  N(?
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MU_X*[[_XQ7^E]11_Q'JI_P!$M#_P\R_^=8?\254/^CCU?_$3A_\ 1(?YH/\
MPC?B+_H :U_X*[[_ .,4?\(WXB_Z &M?^"N^_P#C%?Z7U%'_ !'JI_T2T/\
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M_P!$A_F@_P#"-^(O^@!K7_@KOO\ XQ1_PC?B+_H :U_X*[[_ .,5_I?44?\
M$>JG_1+0_P##S+_YUA_Q)50_Z./5_P#$3A_]$A_F@_\ "-^(O^@!K7_@KOO_
M (Q1_P (WXB_Z &M?^"N^_\ C%?Z7U%'_$>JG_1+0_\ #S+_ .=8?\254/\
MHX]7_P 1.'_T2'^:#_PC?B+_ * &M?\ @KOO_C%'_"-^(O\ H :U_P""N^_^
M,5_I?44?\1ZJ?]$M#_P\R_\ G6'_ !)50_Z./5_\1.'_ -$A_F@_\(WXB_Z
M&M?^"N^_^,4?\(WXB_Z &M?^"N^_^,5_I?44?\1ZJ?\ 1+0_\/,O_G6'_$E5
M#_HX]7_Q$X?_ $2'^:#_ ,(WXB_Z &M?^"N^_P#C%'_"-^(O^@!K7_@KOO\
MXQ7^E]11_P 1ZJ?]$M#_ ,/,O_G6'_$E5#_HX]7_ ,1.'_T2'^:#_P (WXB_
MZ &M?^"N^_\ C%'_  C?B+_H :U_X*[[_P",5_I?44?\1ZJ?]$M#_P /,O\
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M ,%=]_\ &*_TOJ*/^(]5/^B6A_X>9?\ SK#_ (DJH?\ 1QZO_B)P_P#HD/\
M-!_X1OQ%_P! #6O_  5WW_QBC_A&_$7_ $ -:_\ !7??_&*_TOJ*/^(]5/\
MHEH?^'F7_P ZP_XDJH?]''J_^(G#_P"B0_S0?^$;\1?] #6O_!7??_&*/^$;
M\1?] #6O_!7??_&*_P!+ZBC_ (CU4_Z):'_AYE_\ZP_XDJH?]''J_P#B)P_^
MB0_S0?\ A&_$7_0 UK_P5WW_ ,8H_P"$;\1?] #6O_!7??\ QBO]+ZBC_B/5
M3_HEH?\ AYE_\ZP_XDJH?]''J_\ B)P_^B0_S0?^$;\1?] #6O\ P5WW_P 8
MH_X1OQ%_T -:_P#!7??_ !BO]+ZBC_B/53_HEH?^'F7_ ,ZP_P")*J'_ $<>
MK_XB</\ Z)#_ #0?^$;\1?\ 0 UK_P %=]_\8H_X1OQ%_P! #6O_  5WW_QB
MO]+ZBC_B/53_ *):'_AYE_\ .L/^)*J'_1QZO_B)P_\ HD/\T'_A&_$7_0 U
MK_P5WW_QBBO]+ZBC_B/53_HEH?\ AYE_\ZP_XDJH?]''J_\ B)P_^B0****_
MGH_N<**** "OS8^*/_!4CX!_"/\ :^\)?L*>*? GQTG_ &E/B)HTWB?X;>#-
M&\$^'[[3OB!X3C@\7W<7BCPWXKE\:VOAI=)N;;P'XN=(]:U/1]4MY]#O=-O]
M-L]506!_2>OXX_\ @J1%\9Y_^#E__@GK%^SO>_#33_C:_P"Q+J0^&UY\8[#Q
M/J7PPA\2AOVZ#:_\)I9^#+[3O%,FC21":*631;K[9;2O#="WO8X9+*X /Z5?
M@Y^W'\&_B]XA_:3\*W>E_$3X,:Y^R5%H-[\=8/C]X43X6:?X1T/Q'I/BG7].
M\6KX@U;5)_#FJ>"#H7@[7=;?QMI^KS^%'T6"+5[;5[G3)ENQX-=?\%<_V3HO
M VH_&VQTSX^^(/V7=&UK5="U?]K;PS\ _B)X@_9ZLY]$UJ^\-ZMK5MXETS2[
MCQ3K_@73_$.F7^BWGQ.\+^#=<^&MMJ%LT4_BZ-7BDD_'7_@I1H?Q#\.?\$#'
M^#E[97UM^VG_ ,,3_LO>)_VF=%;1-<NOBW>_!?X&_%+P)%\1[OQCK^G60EL-
M&\-^,_'GBS5_LOBS4+>#7/#4_P 9K[P_I^IV&D^.;G2OMO\ 9?\ %/PNUW_@
MV\T'6IQ!)\-['_@F!\4/#_C:/1AHR--/X1^"OC7PE\4K> (]QI;:Q-XET;Q1
M!<B^W33:R\XUFWCOWO;= #]#/VCO^"A?[.?[-/[,^F_MC>(]5U[XC_LS:A#H
M=W+\7_@G::)\3/"NG:=XHUO2O#/A?5KJ72?$,-W=Z3K_ (CUBRT&SU+1;75K
M.TU9Q8ZQ-ID\UHMSY7H'_!6W]D:[\5?LV>%_'UW\2O@=%^V'X*\/^//V8_&G
MQG\!77A3X9?&#1O%.EV6M:#8:%\2=/O]=\%Z-XJU#3-5T.=/!WC'6?#7BB&;
MQ+X4L+C28=2\5^'+/5/Y+_@Y8_%2S_X- _VLY/B''J4?A74/C_X8OO@>+^4O
M WPK;]J[]F6UU*328C(YMM-D^,MK\7',6R$2ZB=0O%C9;H3S0_'NX\??M%ZO
M_P $"_V&/VXKKPW\ OV"O%_[-G[)7C;X,_'/X?:+JNL>)?BEXHNOV=_A5X>O
M_A_XU\7ZWK6FV/PUUF#Q!>6G@2?4/#NGZG9>$8OB)X2^(7B2UUG2KRQ'A@ _
MJ>^._P#P6C_9'_9TO?C>WQ&\*?M)1^$?V>?B/#\(_B?\5-%^!?B/4OA-I?Q(
MN(M#N(O!FF?$![FUT+7O$QM/$FB7\N@:3/=:U:Z9?PZM=Z?!I9-X/HWX#_M]
M_"+]H'XI>"_A%X<\&?&;PCXG^)'[-T'[67P\O_B#X"CT/PIXV^"-UKO@KP]!
MXC\/^*-.UO7-)N-5%]\0?"DM[X5N)[7Q+H]EJMK=:WI>FI=V(NOR5_X.A/#V
M@>'O^"3'Q CT#0]'T--8_:)^$_B'5DT?3++3$U37]8\0:E<ZMKFHK900"]UC
M5+C]_J.IW(EO;V;][<SRO\U?7,WA7QCJ7_!$'PIXG^#7ANVU#]HC2_\ @D=#
MX4^$7B+2].+?$/2I_&/[,'@F_P!5T#P%KFGVD_B&PU3Q'K'A#PAJ5CH^F7$%
MGKOC+PIX'FU-6DT;3KJR /:3_P %6/V8/$/Q2\??"+X(Z+\??VI/$WP@UN_\
M._&C5?V:/@+\0OBIX&^$^LZ=I]_?S:5XG\?V6EV'A#6=;G;3;O3;'PU\/]7\
M:^)[_6K>\TBST6:^TS5H;#ZK_9R_:8^%?[5/@WQ%X]^$-QXKN?#GA?X@^*OA
M?JY\:>!?%WPU\0V7C;P+)9V/C/0]2\$>/](\.^-_#VH^&->N+OPQK.F^*?#F
MA:K::]H^JV[6!M8K:\N_P\_X-6[GX>2_\$I= M_!LEJ?%-K\=?C#_P +9BAE
MTM[E/&\VHZ5)H[WD5A(U[$9?AF/ "P?VVD=_)%%NMU;21ISM_0=X1T7P+H][
MXXE\%PZ)!>:UXTN=:\>QZ+=Q7!/CJ?0/#UI?3:O:PW$T>F:W<Z%9>'KF]M/*
MLY;E9H-7N;>2ZU2:\NP#Y)^%_P#P4G_8R^.'[4&J_L?_  7^,^C?%;XU>'?
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MXES6OC#X2>!]8\6_"O0=%L1:_#CX$Z9XF3PYKNK^%_A5I?@+Q-H>IZU]!_\
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MI3X>G\#ZQ\2/''BSP[HEM\2O!FO>*_B?90_$6YN/%;6FH^(]"_LF.[T/0M&
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MXDL((O$6G:?XNU32;;^PIKN:ZO;:_P##7C+3_#?R5_P<A_\ *%W]LS_NW?\
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M:TU;5+#5$MI[9K5Y+;7+&\MM;LM06)RT.K6>H0:I;7(6\M[R*[1)U^(O@?\
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M#=PO;RO8ZKI5S9:IIEXB2,UMJ&FWEI?V4P2YL[F"XBCE2Y10!\-? 3_@F_\
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MX>TC0_".E_%'X^^-OC7IWPW\+^+?&GCSPY\+M%U[P[X+\%^&_ UGXU\>S?\
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MKJH751\%;SQQ<_"076FMKFK2>&M_@R2'P6]]/_PA<7AY7*U^A]% 'Y!^'/\
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M5INKZ78^()=2LM.U6RM]1LK>"\C$]?2U% &!X7\-Z=X0T#3/#6DW.OW>G:3
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ML;V :MJS?:2^JZ@USR&C?L*_LS^'_P!J/Q+^VAH_A+QK9?M)>,=#A\+>*/B
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M8FA>"M7UG6M'U"R\)> OA=XM77&NM=CBO4NKJ]\>WUFT C6%;73[20 2RS*
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M "GQ_:E_[*O^VO\ ^K)\1U_8/7YEX5_\B3.O^RKSO\\,?W+]/O\ Y.CX:_\
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M<?\ K2GB&OZS:_DR_P""G?\ RG1_8)_[#O[''_K2GB&OZS:_.."/^1]XA?\
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M+0Q1PM>WK37)BC2,RE$4  _D<_X);?%#X5?L3?\ !87_ (+A>#?VL?BC\/\
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M1O?VB8].U?P9J5MHVC7GQFTFP\"^$-%^)$VIWFH0^-?CI\1KNP5IXIV/E_\
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M:U?27N]/TK3+B"_OKB"UECE;^KKX?> _"GPL\!>"/ACX$TF+0/ _PY\(>&O
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M4M$C\7^/OAOJWPUCT>\MDN]<EOS9+;FQU."YD_K1_8P_X* _L\?MV_ 7Q/\
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M+YD%Q%%/"^-T4T<<J%716$M !1110 4444 ?R9?\%._^4Z/[!/\ V'?V./\
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MVJZ38:#8ZA-?V=O+^&/[$$/['_Q ^'7_  ;[^'/'Z_!7Q#XUTO\ :#_X*1>
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MP-^(V@_'+]EK6/@SX&A\%V/[._Q)\=?LS?';XE:3X[\+_%?PIXOGN/#?P_\
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ME:"1E+PM)$S12&,J7C9D8E214U '\7/QJL?V,_A[XD_X.;?@[X*MOV;/!O@
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M7Q!XYL/#FJ>&]*\5>%_;=!\1_P#!,WPY^W]_P2[T/]GB_P#V<-&_9U'[*O\
MP41_9WDNAJ'P^N/#_CSPQ\-O$GAKX8P6WC+Q+<WE]#\0_#7C35?!?Q;U;P]X
MI\7:IJ]K\3;?4O%'BB"\U6Z\2ZM-=_U,6]O!:P16UK!#;6UO&D,%O;QI#!#%
M&H6.***-5CCC10%1$5550 H &*EH _@R^%'AO]BWX9_L2_\ !+KXO>%9?@;H
M'Q-T+_@N]X)TO5/B>NO^%Y/B+HWP-\,?M3?&R1M!N?%UWJ,WB;1_A%I_@"3P
MUXGU+PTE[9^!FCU>W\=7^FOJGB";6[_[5_:JU_\ 9%\<?M=?\%&/V>?^"G7[
M1WQ/^#0^*=_\,O&G[-$?A3X9?!#QMI7Q?_9?O_A9X/MO!.C_ +/7CWQY^S)\
M<OB5H?CCPI\4_"GBRX/AKX>>.?"-IK/Q4\27^M_#_P /:CXNNO&FJR?U\56F
MLK.XGM;J>TMI[FQ:5K*YF@BEGLVG3RYFM9G1I+=IHP(Y3$R&1!L<E>* /-?@
M9X=U+PA\$_@[X3UBX\>7>K^%_A9\/O#NJW7Q3U_0_%?Q.N=2T7PEI&FWUQ\1
MO%'AB"U\->)/'DUU;2R>+]?\/6MMH>L>(&U'4=)@AL+FWC7U.BB@ HHHH **
M** "BBB@ HHHH **** "J>H:A8:187VJZK?6>F:7IEG<ZAJ6I:A<PV5AI]A9
M0O<WE]?7ER\5O:6=I;Q27%S<W$D<,$,;RRNB(S"Y10!_,I_P26_;C_8V^"6D
M?\%9]:^+'[4?P&\!VVM_\%C/VY?B5X;L=?\ BCX0MO$7B_P)XAC^',GAKQ/X
M(\)IJLOBGQMIGBDZ-JUOX5?PGH^LR>)[W3;VPT"+4;ZWEMU^"?#EIH'@"3Q_
M^W?\?O",/PB\&_\ !1O_ (*]?#[XC?L@WG[0<_C_ .%OP'^$>D_";PW\;-0^
M"?[2O[4'@;2M5T+6-7T[XC0^(=5\8Z=\.M<U/P-H_C/Q#X<\)>,_$OQ&\(_#
MX2>)=/\ [8:@N;6VO(3;W=O!=0,\4C07,,<\+/!*D\+F.560O#/''-$Q7,<L
M:2(0Z*0 ?Q'Z1\4-0T3_ ()?_P#!8_P_\%O$-O\ %'1_!O\ P5>\<?%7XE>#
M_A5]O\,W7B3]B;Q?XO\ V<=>\9WO@;3O#,E_;?#WX8?&30O^$WFT%?-D\-^(
M_AA!\5G\._\ "1:5X?\ $ES:?>_[8/QX_P""5.O_ +-'[5/QO^ _P^M/B]\+
M/B-\/_V+?!'[0WQ ^#'C+QS\+?V?-,L=&^,N@Z+^SMX)^+%SX$LKI]"M_"%C
MKNLM\8O#?@?P#J7Q'\,?"ZRTKX=>*=(TK4_&O@:PE_IZBMK>!YY(8(89+J43
MW4D421O<S+%' LT[HH::40PQ0B20LXBBCC!V(H$*:=I\5DVF1V%E'IKQ30/I
MZ6L"63PW&\W$+6BQB!HIS+(9HS&4E\Q]X;>V0#^#C]IOXE_LZ:AX2_X.$=.\
M??%S]F?XK7_Q,^%W_!/[XC_!76_AMH.AZ3\*?&_QFTSX<^/_  ;XY^(_[.?A
MB3Q)\01:1Z-XFDMO!&J>/]&\7>(;PZ_J%IH_B'QE=>(?$J6U_P#K'_P4J^"?
M[''@G]CG_@GAJOPO\'?!;PO^SEXZ_P""HW[ _C?X\^/?!%QH&D^ O%'A!_\
MA(/"'CKXG?%+XHZ)>P0:DLNDAK+QA\4?$_B:34IKV6XU'7/$CZO<W%Y+_31%
M9VD$K3PVMM#,T$%JTT4$4<K6UL9#;6[2(H<P6YFE,$)/EQ&60QJN]LR2Q17$
M4L$\4<T$T;Q30RHLD4L4BE)(I8W#))'(C%'1P59258$$B@#^.#]J#P3^Q_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ%X:T/QI9:5J/BKP:=>T$?$SQ-=W?@*?2O'7BJ/P=<^'=&\4>%99C<:MM_\
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M2_A?:6.M>!_#U]XJ_P"$4OM.UBS\0^(]0UKX@>'])\)Z?K&DZCH1D76]3O\
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M?#/XS^(=3_;U^/\ I'A/P);:[\/_  ^FN6'PX^%_[0VG?#3XV:/;V%QXFO\
MPEJWQ0\;+INH>#OAUX9LO$TPM(?%-GXP\1:OX5EM]#L]9^W/C=_P60_98^ .
MD>.;WQQX5^-\^O?!7P3\&/B#^TS\/]#\(^$+GX@?LO>&?CW=:-8_#RX^+_AS
M4?B#I3WM]->^(-&M_$6D_"6Y^*.I^$H]5TG4?$5KIVD:UHNH:C^!%K_P2B_;
M_P!'_83_ ."*.DW'[.NKW'Q@_P""=/[8GQ&\;?&GX):?\2/@1=^*M?\ AU\0
MOVE;3XVV7C7P#XJ'Q:3X8ZG:Z=HVBZ?X?O-%UCQMH>O+KFL&XET^W\/:7>ZW
M7L/_  5 _8Q_X*?_ +8OQ9_;<\->&OV/O#>D_"OXI_LU_!5_A3XM^&'Q;^"'
MP]G\:_%/P(WPO\9^(/#_ .T;XLL9_#7Q>_:&O_#=QI7Q-^&OP>\'>.VM_@MX
M2U=_"WBX>'K:X;2/B1H !^WG[2__  5H_9?_ &7++]D3Q-XQT3XQ^-?AK^VY
M)X33X&_%7X5>!+'QAX/OU\;0^&-0\-MK>FR^)=)^(-I+JF@>+M&\1Z?IVE>!
M]:U;5-+:\M]'T_4=;L;G2(\_X0_\%C/V)OBI\//VN/B9K'B3X@?!#0OV'/$]
MIX7_ &DM-^.WPZUWP1XL\!W&L:UK7ASPM=R>$[$>(-<O'\7^(/#VKZ%X>\-0
MV8\>2Z[:KH.H^$=.UJZL]/N/R;_::_8G_;D^)?[+O_! _P &^#/V4/&6L>,/
MV&?$G[,_BO\ :-\.GXH?LZ:1=^#[+X%>'/AAX3UG3[*Z\1?&71=,\1ZQXD'A
M#5-<T"V\/7NIVL&FO:6WB"^T76I)M+@^:_&O_!(G]NKXN^'?^#@7PQJ7P-UK
MP+/^VO\ &_X9?'G]DO5M0^*_P4ET7XF'X+_'OXN?$$>"_$MGX7^*FLW_ (:U
M'QYX6\;Z:WA:+QY8:+X9TS7&M[_Q1K.@7>APQR@']"/@#_@K;^QQXIT+X^ZS
M\0/$WB?]G2[_ &:O!'@'XK?%/PM\?=#L?"_BRQ^#_P 5O#7AGQ1\,?BAHND>
M%M;\:C7M#\;0>+M"T.P\,Z?<R?$W1O&>H:=X(\7> O#GBO6O#^D:MZA\ /\
M@H!\%OVA_$.J?#[P]H?Q%\#?&2V^$/AG]H#P_P# [XIZ1X9\'_%#Q[\$?'"W
MO_"$?$WP1IP\7ZGX>U7P]XBN+,:;=V]YXDTS7O 6LWVF:)\5-&\!ZMJ%M9/^
M#'QU_P"":?[1?[>/_!/OXH0>)?V,KS]FK]O6Y_9_^&/@;Q1XW^)GQTT'XC^*
M/VC/&?PP\?\ P[\8OX.\->+M,^,_CO3O#7P=UF'X>:C?Z;H/Q2_X1[^PO'VN
M>!%TAX/"W@?4_$_B7Z/_ &6/V+/VM/'/_!3W]E_]M/XV?"W7_@7X _9A_P""
M97PK_9HU'3=;\6?#Z\N_''QY;2O$2^.O#&@:)\/O'?C.[O\ X<>$;GX@^)+D
M>)_%TUG!J?B/0]%D\-6^N6"6^M6 !Z-=?\'&'[$EK^S)=_M<-\+?VJY?@YI/
M[0%_^S/X@U"#P!\+WUOP[\4[7P/I_P 0+&QU71C\:%D;1]=T"ZU%=*UK39]0
MM4U'P_JMCJXTJ2Y\/MKGVCXV_P""I7[.OA']H+XF_LXZ7X:^,7Q(\7_!3Q1\
M / _QB\1?#;P?HFO^#/AGXS_ &E?%^@^$OAEH'BB[O?%VD>(DA8^(+;6_%/B
MS2O#.I^ O"5G;7.@:WXLM?'\NF^#-0_D;\=_\$>_^"HNE?L$?M _L ^"_P!C
MO6_'NL7O_!2*\_:5\,_&.V^-?[.'AKX?^+OA7I/PRU7X:Z%?:#8>*_BUH_BO
M^UO$4QM_$+:7K>BZ%/HFD74-MJBPZZESH]O^J7[7O[ ?[9GQ"_X*1:5^W5^Q
M_P#!GXE_LX?M'67QJ^ _A75?B9>>+?@UK_P ^,G[.&M?!_P"GQ,\0?&OPK_P
MN*]\8:+XU^$-Y#K?PD\>>&_">B^(O"GQ5T?PKX.U7X6VMUXMAU3QK; ']6U?
MSA?\%F_VMOVS?V8OVL_^"8_P^^%'QVT;P=\$OVJOVKO!?@'QOX)\,?#'3K'Q
MO>>&/#GQ!^!-IKND>(/BGKWB'Q3>WNG^*)?&FMQ21>!_#7PSN;;0WAT+4[WQ
M!$]_=7_Z"_L-_MA?M,_'K]HC]N?X ?M*?L[>%?@C?_LO^// T?P[USP=\0]/
M\>6?CGX:_$^7X@S>"KKQ&MG=7+Z/XIG\-^"-*\:-#/'HM_<^'_'>AMJG@SPF
MT5C-XC^!?^"T_P"RA^UU^U-^U#_P3(\:?L]?LT^-?B=X*_8__:,A^,'Q4\4V
M?Q"_9X\)6-]X;D\8_!#Q(^G^#M,^(GQJ\'>)=7UZWL_ ?B"WFMM2T+1-.:\2
MT2WU6>WN5N5 ,?\ X.:OV@OC[^R/^Q[\'/CU^S3\;/B=\&?B-J?[2GA'X0ZS
M>>#/%-Y;:'K/@G7OA?\ &KQG=6VH>%[T7WA]M5@UWP9H\MMK]MIUMK/V03Z=
M=7MU9"T@M/Z"OA3HB^'?AMX)TE=7\2:^\'AS39[C6O%_B+5_%?B35+S4(%U&
M^O=5U[7+N]U&\FGO+N=XXFF6SL+<PZ=I=K8Z7:6=E;_@M_P<3?LD_M:_\% /
MV-_@M\#_ -EK]G7Q;X]\<Z;\?? OQL\2IJ7C_P" G@O2?"FAZ5\+/C'X1U/P
MUJVH>,?C!H?V[Q;9ZOX[T0/%X7@\0^&IK9;Z>T\37'V>-)_O?X@?$W]M3Q5:
M_LP_#/X1_LA?&KX7VFI_%7]G_5OCY\7O'OQ-_9.L='^&/P=\">.-"\4_%+PM
M!H_@7]H'XG>+/&7B7QUH/A27X?7FG>&O"][HW_",>-]1O;3Q3#JMH([0 _3*
MBBB@ HHHH **** "BBB@ HHHH _CX_X)Y?\ *?']J7_LJ_[:_P#ZLGQ'7]@]
M?Q\?\$\O^4^/[4O_ &5?]M?_ -63XCK^P>OS+PK_ .1)G7_95YW^>&/[E^GW
M_P G1\-?^S >%W_IG-PHHHK]-/X:"BBB@ HHHH **** "BBB@ K^5#]K+_@H
M#^U9X[_:[_X*[^!?@]\=M6^#?PY_X)C_ +%"?$[X367@#3? ^JR^*OVA+'0/
M#'CW5_%OQ';Q+X;\4VGBW1[6VOO&?PFU#X;ZY)=>#+2Q33O$X\,67Q(TJVU[
M2OZKZ_EL_;1_8$_:>\&_M7?\%4?B'\!_@3K_ ,</!W_!4']B/3O@]X.NO"&O
M^!O#\/PT_:"32O#GPRU;1O'W_"7^)]&;2O"&H^%;'6/B[<>/[GRM#;4([KP.
MCQZ_J&BQ7H!^X?[!?[46I_M@_L-?L\?M2OHFE_\ "5_%7X0:3XG\1>&_#MW!
M;Z+_ ,+$TZWN=%\::'H5Q>:EJ8T[2QXWT?6K#3(=7U.YOM)M/(M=;G^WVM[M
M_G7^,G[,?_!7CX!>,OV)_#7Q*_X*]_%/XB_&#]KO]K7P=\*]>^"WPC\):5X=
M\.^%/A='I&O_ !$^._C[POXPUZ]BUC5M#^%G@;PW?/\ +\/M#$;ZSH2&VMU!
M67];/V./AQ^V?^Q9KW[#'["/A;]G[X>>*OV,OAY^R3;Q?'K]J*U\<V6G>(-"
M_:+BA\3ZGKNB^%_ LNH6NJZCHVM^-8[2[R_AJ^_M#3O'K:Y+XIT^\\(ZKHNK
M^CZG\&?B9\7_ /@KCX9^-GC3P3>VGP"_8U_9-UKPW\$O$NM6AM8->_:1_::\
M41P_%'Q%X,N5<MJEAX7^"W@31/!>NRR1I%8ZGXKFMH6FEDF%L ?DC_P5.\6?
M\%@/V.?C5^S;^TI\+_VS] ^(B?'_ /;!T;]GCX=_L':'\']-M/A=I?A[QS+X
MAU3P7X=U;QJ5?Q5\3IKW0_"EMI_CSQQJ>B>$O%NA^(?$EU>>!+O2- @@LK#^
MK.OYH_COXK_X+'ZK^VKX\^/'@7_@DUHGQ7TCX6Z'XN^&'[$'B/XF?MA_LU:#
MX:^$=EXEL9]&\8?'?5/AG8>.K[6=8^(7Q4:.RAUF2+Q3X;UK0/A#:P?"O0I-
M$O\ 7/B!XC\7_P!)FD6E[8:3IECJ6J3ZYJ%GIUE:7^M75M96=SK%[;VT4-UJ
MEQ9Z;!:Z=:SZA.DEW-;6%M;64$DS16L$,"1QJ :%%%% !1110 4444 %%%%
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M$'Q#^!G_  5S^%'[3]O?>%OCA^S;I_P*U;]E+X7_ !<U;Q#H5M\!OA&OQO\
M#&EZ+\7O%FB>)SXA^(_B'XD:%:^+_%6KZ;>ZAXW^,TGFZ1X!\(??.@?#[]JW
M]G[]NK_@I[\>[#]DSQ1\;-$_:\^#_P"R!_PI-? WQ ^# \$7WQ"^!7PD\:^
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ME0>';:'QQK!T^+2?1/ 'P<_:@\/?$K_@M-X@U7]EGXAG0OVK'\,ZS^SS,GQ
M_9PFG^)<^F?LY:'\#=1T1[(?&XGP?<_V_IS:_;7'CF3P_IUSX5,\DMS;:]%!
MX?O #Z)^ O\ P5P_9(_:+^)?[/?PN\#)\:=)U?\ :F^'_B3Q]\#/$OCOX+>-
M_!WP[^(1\$>$XO&_Q \'>%OB%JMBOA3Q1XP^'OAN4W/C>#PKJ>N^'_#VHP7/
MAR\\1#Q+;RZ.O=:9_P %+?V9-0^+_P +?A3=W'Q(\/:1\?-2F\._L\?'/Q+\
M./$.C_L]?'[QA!;I>?\ "(?"OXI3Q-I^L:IJED9+WP9JNJV6B>$?B?:1K/\
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MV)OB=I8!^ROPW_X*)?LO?$#]GCXL_M-:CXKUGX7_  ]^ /C_ ,:_";X\:?\
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MRZE)?^+[7Q'!I7A;5OUH_P""A'P6^/WQW^ '[!?B;X:_ WQAK7C/]F_]NO\
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M_LA?#/4?V?O#'[,'QJ\51Z_\+OB_\9?VA_VH?B)XR_9N/Q#_ &F_VQ/&VN^
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MS+PK_P"1)G7_ &5>=_GAC^Y?I]_\G1\-?^S >%W_ *9S<****_33^&@HHHH
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MT5J;Z75IM3DE6RCTR.R5KR2_>=;5+53<-*(07K\4?^"YO[(.E?MS_";]D_\
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M"Z;J>I:>LT4BR"QU"^M WV>[GCD^NO\ @IC\(_!/[*O_  2&_P"".W_!1O\
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M,_$>G^%_C'K?Q3^(7Q!^'/A/P[I^L>/],O\ 6K";0M4^'U_JWB/Q?_8*M?\
MA9[S6[#X?Z==Z8VAW8!_3;17X1_!W_@KKXL\,:M^UUHG[7O@?P7-H_[-O[,.
M@?M>:)\:/V;H]3U3X0>-?"%UX+\(7GCKX%V.K^(?%OB?2K[XS_#_ .)7B0>
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M7A_Q5X=T6/P5#X4N/"7@>7P8VG>*M9UKQ+;>(O&_B:'5'T+X>^#O"S:5KUZ
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M2IY;P12-]$^)O^"+>O?'KX3?L5?LT_M@_M1:/\7/V6_V(M$^'UKX4^$?PH^
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MTU?B:GC+2?#6F-9^/+G4)O[$N?"^KZ[X6U;]U:* /Y^OCM_P0[;XJ^*/VO\
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MBA\8?@=_P2Z^$DW[6O@WPSJ7_!-+4?A5X@TKQ$/V:]5\0VGQ5USX-6'@[1?
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MR_'GX_\ Q*_: _9^U#XP^&[O]FO7_B;\.8?AX^A:A<W/CZ_^*/A+X=P2W/\
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M\2KNSM["YU"S^',>C^$]1A\>WFEQZIIRZO:>$IM8N-(N+R&TU.*UNF\D?3]
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M$M;'QMXSG\.36T&D:GH>L^(9]2:]OX;6VT] #S__ ((]?\%'G_X*A?L=:?\
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MGC/2(OAE%\-M8\&_$3PK+::-XQTG1? GAF\N[?2-,ETK5='N4O)[WS#XI_\
M!+GX2_%WX$>/O@=XC^,G[0&F7'Q?^.>C?M&?&3XP>'-4^$5M\7?B?\4/"WB/
MPKXB\%7VN:KK7P=U_P ):'H7@.+P%X#\,>#?#O@CP;X6T[2/"/@W1=%D2\WZ
MO=:H 6/!_P"T'\?-5_X*9_M!?LI:SXA\!7GPO\&_L?\ PY^.GPSM-(\$7WA_
M6M/\2_$+XF>-O!9MO''B"_\ %7BV7Q1)I4?@D2P7^A:?X.TR6UU>:&?PM->6
M,.HS_(/A'XS_ +=7Q0_:V\$?L:_"O]IBT\7:Y\ /!ND>*?\ @I=^T1:?!_X8
MK\(?A]XO\6Z/_:'@7X _L\^&+CPE!KFH_%3Q%MEUC6-7\7^*?$7A[P/X-6/5
M=6T[4O%RWOP^LOT"TS]AK2])_:E\8?M>VO[1?[0Y^*WC;]G[3/V<M7M9/^%
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M!7A_Q%J&B^)/"&K)X9/B2XUD^.O"&B:=IEI\+?$WP]?3=*FT\ _&#]A3X_\
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MAX3M$US5-4U'1-8\3ZAJ?B#4 #\K?A=X\_;Y^!_PO_X+6?M,?LF?$']GK1?
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M?VZ_V>?^">WP/U+X\?M%>([[3O#\5]!H?A;PEX9M+/6/B'\2?%EXDDMEX/\
MA]X<O=2TB#6M>N((9[N5KW5-*T;2M/M[G4]<U?2]-MYKM/FO6O\ @H;^T/X%
M^%S?&SXI_P#!-3]HKP-\,]2N]!31IXOB9\ _$OCSPOI7B[4O"^B>%_$GQL^&
MFE^/$\3_  YT>;5_$\?_  E5OX1B^+'B/X=Z+INJ:YXYT#1+?3=5AT[\;/\
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M_P"#9KXM>,?%&OZA\5_BKXU_8UT+XA_%;3/%6JZ)\0]?M_'7@OX&Z_XWGO\
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M'T*Z,GXP?%?]D?PQ_P %2?V1_P#@F-;?\%$?VQ_$_P"R5^WIJ7P9U?Q)\)O
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M^'O%-[-IVJZ;/J=IJ4?Z#_\ !);PEXJ^$'Q*_P""C'[./ASX@>/_ (H?LG_
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M$6]T6\\)Z/-X=\/R^*?B WARQC\0#4H/#B^%]!UK6M4U2PN9_P E?V%_B/\
M'CQM\=/^"%/C;X_^-?B+<_$;XU_L%?M6^(?'>E>*/B-XXU;0_',O@W2OAA:_
M"+XBWG@G6M?N/"D7Q!\1?"O7QXF\1>*]+T&S\2^))O$6IWWB'4=4:-)H?#_$
MM_+I'_!+7]K/Q?H_C'Q9X5U;PE_P6Y^*&G7%WX4^(7BWP=82:3XP_P""A/@K
MPWXJT3QMI?AKQ!I.C>*]!U3PCKUY#=:%XWL=9TB&WOH]4@LH+M;:]0 _K^HK
M^93XJ?L^^%/BY^W)_P %J_!_C#XE_M":CX<\*?LA?LV?%/PKX?TK]I7XV:)8
M_#[X@:CX/^/7C"SG\/0:%XZL7L]!T#Q3HMAXY\+_  XU9M2^'.B:WJ+W=CX/
M738M#L=,\L_9M\/W?A;QM_P;W?M2+\8_C=XD^,/[6_@OQ%X0_:1\6>-?CG\0
MO%^C_%O3)_V.=8\2Z+X=\2>$==\1WG@>#_A$_%>A:9%H@T7P_I6J7NNVXUWQ
M7<^)?';-XC(!_5]17\7/[1&O+X$_X)1_\%Y="?Q5JGA3Q1\&_P#@K!\1+3X&
M6L_BS5M)\2?#K0-1UW]F*T\#Z;\-IYM4AU;0=(O/ ]]XYM_#^E>'YH+.;PQ=
M^)8[2V;3)M0#?:OQ,^ O@WXS_MO?\%I?#'B;XI?'[6O"?AS]C[]FKXL>#M'T
M/]IKXTZ5I7@7QWJG@WX\^,M/O/#*^'O'EG]G\.Z'XGT;3_'?A3X=ZG)J?PWT
M;6=2:\L/""Z9%H=EI@!_3C378HCLJ-(RJS"-"@>0@$A$,CQQAG(VJ9)$0$C<
MZKDC^4/]FWP_=^%O&W_!O=^U(OQC^-WB3XP_M;^"_$7A#]I'Q9XU^.?Q"\7Z
M/\6],G_8YUCQ+HOAWQ)X1UWQ'>>!X/\ A$_%>A:9%H@T7P_I6J7NNVXUWQ7<
M^)?';-XC/!?&'XH7>M?&G]F3]H;X0?$_Q[XJLY?^"^?@3]GQ?CQ\0OC#CXM:
MMX3\?^/M9\#?&W]DWPG\&O#5G'IWP\_9/\$:!I7AVQT+2?&^LQ>+/&NHW4OC
MX_#SPKH7B73=?\7@']#7[$/[8]W^V+;_ +5$][\*[_X2W/[-/[8'Q2_90GT7
M5O%.E>*M5UVZ^%OA7X<ZWJ'BG49M"MET31[F_P!3\;WNGC0])U;Q/8VEOI4%
MS%XDU$WK+;_<-?Q@3? 7P%\0/V4_^"Z'[6-I\=/CG\-?B?\ L_\ _!3;]M+X
MB_LT^*_A#\>/'7@OPI8?%;0?!'PDUCX;G1_!OA;7+?P7XR\2?&;Q9X@\+_#<
MZMJVD:]XBOM-NO#VC>!-0T&ZN[R35_Z\O@IJ/Q UCX-_"75_BS86^E?%35/A
MEX#U'XEZ7:0M;VNF_$"^\*Z5<^,K"VMWAMG@M[/Q'+J5O#"]O T4<:HT,14H
MH!Z;1110 4444 %%%% !1110 4444 %%%% !17Q)_P -Z_"#_H6_B3_X)_"_
M_P V-'_#>OP@_P"A;^)/_@G\+_\ S8U_,G_$Y?T7/^CU\%_^%6,_^8_/\^S/
MT7_B$GB3_P!$?F__ (+I?_+3[;HKXD_X;U^$'_0M_$G_ ,$_A?\ ^;&C_AO7
MX0?]"W\2?_!/X7_^;&C_ (G+^BY_T>O@O_PJQG_S'Y_GV8?\0D\2?^B/S?\
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MCHVK>%KK7-.M](UEO!<]KI:#P3#JVFVT=EJ-KX271;6]@>Y6XAD^VWAGQ/\
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M_P!"W\2?_!/X7_\ FQH_X;U^$'_0M_$G_P $_A?_ .;&C_B<OZ+G_1Z^"_\
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MQG_S'Y_GV8?\0D\2?^B/S?\ \%TO_EI]MT5\2?\ #>OP@_Z%OXD_^"?PO_\
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M-IT7V?PL^DK))O\ .O\ AO7X0?\ 0M_$G_P3^%__ )L:/^&]?A!_T+?Q)_\
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MA!_T+?Q)_P#!/X7_ /FQH_XG+^BY_P!'KX+_ /"K&?\ S'Y_GV8?\0D\2?\
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M7_\ FQKZ'_B<OZ+G_1Z^"_\ PJQG_P Q^?Y]F?Q;_P 0D\2?^B/S?_P72_\
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MG_P3^%__ )L:/^)R_HN?]'KX+_\ "K&?_,?G^?9A_P 0D\2?^B/S?_P72_\
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M .%6,_\ F/S_ #[,/^(2>)/_ $1^;_\ @NE_\M/MNBOB3_AO7X0?]"W\2?\
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M^"__  JQG_S'Y_GV8?\ $)/$G_HC\W_\%TO_ ):=YXZ_8F_8Z^*'B[QSX_\
MB/\ LL?L^>._'/Q.T72/#GQ'\8>+OA!X#\0>)?'F@Z#)H<FC:/XPUO5-"N=1
M\1Z=IP\,^&X;:UU:XNXDM?#VAV>TVNDV$-O8L?V+?V.=+?Q;)IG[)O[-&G/X
M^T"S\*>.GL?@1\+;1_&GA?3K./3M/\-^+6M_"L9\1Z!8Z?#%86>CZP;S3K6S
MBCM8+9($5!YW_P -Z_"#_H6_B3_X)_"__P V-'_#>OP@_P"A;^)/_@G\+_\
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M ()_"_\ \V-'_#>OP@_Z%OXD_P#@G\+_ /S8T?\ $Y?T7/\ H]?!?_A5C/\
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M#]E2E-_5]%? 6F?\%+?V7-2T+P)XP.H?$O3O ?Q"\::QX T3XAZK\(_B!9>
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MYU<+6A6IQKT9<E6E*5.4E&I!VO%V?*XR5XRBV4445X9VA1110 4444 %%%%
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M\\3:D+&]U.ZEL](@F@^S:+H^G6%SJ&O:W<R+:Z;;)%$JW6I7NFZ=??)OP?\
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MEMH&MK'=R-+K&GCQ#IOAR.266'Y>^$>E:AXQ_P""I_[-_B;PKJ$%YX>\&?\
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MX,^)O$WC_P#9$^-O[??@3X>:)X)^+-U^Q]8_#3X9?V)X?TG09DN_@UX#UO\
MX3WXA:%INFVLT$2ZAX_>\\-^$/#L]M=I-X0^"WP\M;9[2TU5M-LO#OV6+6^G
M^#W@/]K'PY^TO:?"WP[XA_9<^,?@G]I&^M=<\2?%'XH>,_B9X4\+_$KQ?>_&
MKQ7IEYH]DT'Q'^&?B6[?6=#O/$FI:M=W7A$>&_!^C^(TL?%&CZ?JWQS^C'6I
M8/C*OB^-J&$Q/!O$V$X#QF%?#N,S*4^/GP[C.(,RX<K4\AQ^<9C0C0E@,9D.
M68VAEN.J9GG^$QN&Q.!RG X+$YC3]9>(L)ULHA2R>=6GF^75<[HU/K]+#J.1
M_P!H4,!A\PC+&T,+0FYK$4L;B*,\11CA\%4HU*5;%5JT*#_HCO9+N*RNY=/M
MH;R_CM;B2RM+FZ:QM[J[2)VMK:XO4MKU[.&>8)%+=)9W;6\;-*MM.4$3_(_[
M%'[7_A_]M/X8^*?B9X=\%:YX#MO"GQ*UOX:7NC:_J.G:I>3:EH7A[PIK]S?Q
M7.E@6WV62/Q5!:QIEG\VSFDW&.2.OPS_ &1_BC<S_P#!0G]AB3P=XKO7\*_$
M_P#9X\::3XY\2W'B'3;?Q9\>6\*:%\=8].^('QS\(:!J.MZ/H7C_ %3Q+X4T
MVYM]+U3Q?X^\5BPT7P[?>)O%;^(KK4-&TKZ5_P""//Q?^&?P._8C^/7Q&^+'
MC'2/ _@K2OVN/'%O>Z]J\DQMTN-3\"?!VST^V@@M(;J]O;F[N) D-M96UQ.R
MK+-Y8AAFD3[WC;Z*E/P]X X[C66,XTXW4?!S'\&5<KRW-<%F5!\:\9^*O!>=
M</RX=PV89E#,,=BL?P#1J8*G5HRS.E3Q%"C5P>7YA/%X"CXN3^)DL]SS)7#V
M649.WQ90S>.)Q&&K8>?]D91PSG&#QRQ]2AAW0HTJ&>3C6E&:P\I0G.-6O05*
MO/\ >S4M0@TG3M0U2ZCO9;;3;*ZU"YBTW3=1UK49(+."2XFCT_1]'M;[5]6O
M7CC9;73=+L;S4;Z<QVMC:W%S+%"_QU^S[^VUX&_:9^)GQ]^%_P -O!OC;2]8
M^ !TG3-?NOB/IK>"5U;Q1JFH>*]-.DP:.Z:KXDT>PL;KPPT=[?Z[HUEJ\3W4
MBCPVWV5&N_KW0==T7Q1H>C>)O#>JZ?KOAWQ%I6G:[H.N:3=P7^E:SHNKV<.H
M:7JNF7UL\EM>Z?J-C<07EE=V\DD%S;31S1.T;JQ_$G_@F=_R?Q_P5;_[++I_
M_J?_ !@K\0\.N!>',\\-/I \09[EV/EQ'X<<,<(YKD#EC:V$PN$QF:>(_#/#
M&94L?EU.E2K8BK]0S+&44JV*A"A.7-]7]O3A5A]AG^=8_!<0\#8'!8B@LOX@
MS+-,+CDJ,*M2K2PV09CF.'G0Q$I2A3C[?#TIWA3;FE;VG))Q?VA^S#^W(_[3
M/QH^.'P:TSX27_@W4/V=O$M]X2^)FM:QXST[4;5=;M-;\4^&HH/"UIIFBM)K
MD4^M>$]15[B]GT.*'3=MZ&FN3%ITWWW7X-?\$L/^3ZO^"L7_ &7_ %7_ -7#
M\=:_9#X8?%WPS\6;WXI0^%'2\T_X7?$Z_P#A9>:U;WEI>Z=K6NZ-X2\'>(M>
METV2TDD\N+1-6\577A&_AN-L\>M^'-5(4V[6[OZGTC/#G*.#/$O/LGX(R"IE
MO#&0<'>&.=8]0Q>8XZGA<5QAP5PMG6*JU\9FV-QE=SQ6=9]7HX/"TZMXX2E'
MDHRCA<7B'S< 9_B\WX=P6+SG'1Q&8X[-N(L'1O2P]&52EE6;YEA*484L+1I0
M2IX3!0G5JRCK5F[S3J4J9ZK1117\ZGWP4444 %%%% !1110 4444 %%%% 'X
M@_LR?\I'OB__ -CE\?/_ %*M4K]OJ_$']F3_ )2/?%__ +'+X^?^I5JE?M]7
M]-_2I_Y+;@S_ +-1P1_Z;S _?OI%?\E9PM_V;GA/_P!(QH4445_,A^ A1110
M 4444 %%%% !1110 5\S_M"_M0^"_P!GW5OA!X-U+2]5\4_$CX^>.H?AY\*O
M!>CO:6C:IK#M8Q7VN:_J]](D&A>#/#L^K:*GB76+:UUK5[&/6+.73?#FLD3Q
MP_3%?CC^WUH&L6O[>W_!+[QY<R2CP='\3O&G@N6YD@CCTW2O%>L+X9N=&M)]
M1,*$:CXMA2:WTJPFN9#<-X<NS96Z2?:FG_7? [A#A_CCQ!H9'Q-*<LJH\*^(
M7$/U.EB*F$J9IC^$N .)>*,IRE8FBG5I4\PS/)\)A\2J,Z.(K86=?#X.O1QE
M7#S7RW&6:X[)LBGC,N45B9YGD. ]K*G&K'#4,TSW+LMQ6*=.3492H8;%U:E-
MS4Z<*JA.K"=*,XO]#OV=/VCO _[2WA'Q%XE\(66O:#J?@?Q[XI^%_P 0/!OB
MJWL+?Q'X,\>^#KM+76M$U%M)U'5]'OH6CGM-1TW5-'U6_L;S3[V 226NIPZC
MIEAX;^T[^VWJWP \?Z9\./ _[,GQZ_:2\0-X5L/%WBD_!?PEJWB2Q\$:=KNJ
M:SI7ABW\0W6EZ1JR6NH>()?#7B*XM+.X%M*+/3!<J)8KE&3X@_X)U^-O"WP/
MT[_@I'^T/\5O&6G>$O@I<_MA^.;:P\27\#S:6;C3/%.L6]YJ6F7&FV]YJ.NI
MK5SXP\,Z1I]OIL%\LU]:-!IZ27,MVH@_:*_9!\ ?M*_%'XE?M-_L@?MU:KH?
M[3UOX6\*>.FT70_B?X5F\,:=X5M_!>G'PCI\UOX030_%7@7PQXBT*/1KV+6O
M$-QXBTR5=0N[O5--OXM9DD@_?\#X->%O#GCMQ?E7&D<SI>$^5X2A0R;.<?E?
M&>.X3H\8YME'!^8RX9XEXCX5C0S3*\#PW5XJJ83'YC'%5<5@:U'*)YE1QU+&
MS^L_#5N+>),?P5E6*RAX>?$^)JSJ8O"4,3E%'-)Y3A<7FN'_ +1R[+\S<\-B
M:V81RV-2A0=.-*M">*6'G0G1C[/]$_B3^V/X=^"'[.&@_M$_&CX7?%OPE!JO
MAG3O$NJ_#[1/!VJ>*O%/A!=6N=*MK+1_&.HK;:/X6\'ZV)-=TBTN['QCK?AP
MQ:M-?:3;/>76DW_E>[?!/XG67QJ^$/PT^+VFZ5=:'IWQ+\$>&_&]CH]]/#=7
MNF6?B32[;5;:RN[BW5();FWAN4CG>%?*,BMY99<,?RH_:M\3_%CQI_P16\0>
M+/CE9+8_%;Q!\(?A1JGC"(VATZZN+NZ^)?@9[#4M5TS[+8II.O:QHYT[5O$6
MCPV5E;:3KM[J.G6MI;6]K% GWG^P9_R93^RE_P!D ^%?_J':37YOQSX;<,9%
MX-X_C##X&C0XLP7TB>-O#+&U\JSW%9QPT\DX?X=P&;86ED$L13C5KX)8G,73
MH9EC:^-QN/PV&P^)EB*?UBI1/H,FXAS+&\6T,JJ5I3RRMP%D_$5*&)P5/"9C
M]<QV/K86I+'*$G&G6=.AS3P]&%&E0J5)TU"7)&9]9T445_-9^A!1110 4444
M %%%% !1110 4444 ?C%^UK_ ,I#/V<O^PC\#/\ U:NIU^SM?C%^UK_RD,_9
MR_["/P,_]6KJ=?L[7](>-_\ R0/T>?\ LVM7_P!6;/W7Q;_Y([P2_P"R"G_Z
MGL****_F\_"@HHHH **** "L+Q1K?_"->&?$7B/[#=:I_P (_H6KZW_9MD-U
MYJ/]E:?<7_V&T7:V;J[^S_9X!M;,LB#:>AW:*UH3I4Z]&I6I?6*,*M.=6A[2
M5+VU*,TZE+VL$YT_:03A[2*<H<W-%72)FI2A)0ER2<9*,^52Y)--1ERO27*[
M/E>CM9GP?K/[7WQ&\/?$;X%_";6OV<[K3OB!^T!X2\;^+?"'AZY^*.BK-HP^
M'_ABR\4>(?#_ (ONQX:-AI?B!+>^BTVVAL+K5]*?58YHI]6M[-!?-]1?![Q[
MKOQ+\ :9XN\3_#[7OA9XAN-7\8:)K'@/Q+>Z;J>K:%?>#_&?B#P?.9-3T:2?
M2-3LM5;0?[:TC4M+N+G3]0TC4;&\L[FYMYHYY/A;]H>>$?\ !33_ ()UP&:(
M3_\ "$_M:MY)D3S=LOPZTHQMY>=^V06UP4.,/Y$VW/E/M\Z_:>U!OBU^UMXK
M_9L^*/Q4\ _"CP._P'\&>,?@]8_$BQ\:2Z-XK\1W_B'QKI?CKQ=X5U/PE\;/
M@E:Q?$?PK,GABWT.TUB[\7:OI%AIEWX@\)V7A^*7Q/=ZM_4M7PVX5XJROP\I
M9;DF X,>?>&&+\5>*^(,LI\9\59I@LOROQ0\1N!L9E^1<+UL]QSS7#/ 8'AK
M,<5"*IXW!87)<TS:>8PP;QU*7YM'B#,\LQ6?2Q&,KYNL%Q'1X9RS XAY1EN&
MK5\5PWP_G5*OC<RA@J/U6HJ]?,</2;YJ5:KC,-A5AY5O837W%\2_VB+CX>?M
M%_LV? ,^!+S4;?\ :%N/BC'%X[DUW3[/3_#_ /PK+X>ZKXXO+6VT2*.]U75K
MZ\>UTVRE-V-#L+6WU W5K>:I<03V4/TU7X:^*/ 5SXR^)G_!)+X?^-_C=XW^
M-$-Y)^V-I=[\;M'E\0_"GQ9\2O#&E_"S4)='U:TUC1/%&J>)H--\2^%['3])
M/C32/%\FJ>.O#-TWBZPURVF\2174/D6H>*?&_P !-=\=? /3OBUJFG?L9V_[
M:_ASX00?%KXIZSXP\<:7X2L_$GP(U'Q#XH^$/B+Q#I7C/X?>([?X:Z+\7[C1
M/#^M7MK\2/#UOHLVGZYI_C6^OM+U/Q1IFN^S5^CKD7$> X4P'#/$E# \2X+@
MC/,]XAC+(>)98/B[!Y)XV^)W %7/LCI9KB*>=4^*<7E?#^14\J\/GP[E6.S2
M&$Q-3DP.:0QV&EQPX]QN KYG6S'+YULOK9Q@L%@+8W+U5RJMC.#^&\\C@L;+
M#0E@Y9;2Q./QLL5GOU_%4,-*K3C>MAG1J+^B>H+JZMK*VN+V]N(+2SM();J[
MN[J6.WMK6VMXVEGN+B>5DBA@AB1Y)99'6..-6=V55)'\]_Q5^$-YX"\$V/AW
MPG^UGXD\<>#F_;1_91M_#?AWX.W/C7PA\.OA%#\2?%C#Q9\/_#^HZM\7OBYI
MOBFWN(/^$1^(>E>#-;N;R+X7W3Z/K6CV5MIOCZZM[OWWX>>!?#_AWXH_\%:_
M@0ESXCU_X5Z'\,/@?XCT7P9X[\9^+/B);V>K>-?@O\0=:\9:@-0\=ZUXAUR^
ME\1ZUINFZEK4FHZG>FZN(;>*1A:Q6UM%\YC?H]Y#0R7'YY@/$;%9MAL%0PN:
MJG'@/-,FJU\CJ<8>%W"F)JRI9]FN7X["YOAY>*N48JG@9Y?5RW%SRG.(8;/*
MF >4YIFOHT>.L=/%T,'7R"GA:E:I4PKD\ZPV+C#&QRGB3,Z<5+!8:O1J86HN
M&L52E6C7CB*2Q6$=3!1K+%8;#?KGX*\9^&OB)X1\-^//!FJQ:YX3\7Z-I_B'
MPWK-O'<0P:KHNJVZ7>G:A!'=107"0W=K+'/$)H8I#&ZED4G%<9\9?B[H?P:\
M-:%K6K0?VAJ7C#XA?#WX5>#-%^UK8#6_'/Q.\6:9X0\-6,]\T%T;'3;>[U-M
M7UV_BL]0NM/\/Z9JM[9:9JEY;P:;=?C_ /!T_#C5_@U_P3P^#_AZ_37-;\=?
M '7/$/C#X,?\)O8>!/@]XX5_AAX%TOQEXS^,^J6=MJ6O>(]>^'^CS2ZOX4\!
M:!IM_K5_K4L.OW\GA32/#]UXJL/ -.M-$^*G[#'_  2]U_XFZS<>-_&<G[<?
MPM^%^I:UKGB?5+C6KSX>?\-!?&;PS8Z9=R+JD<S6TGA_P?!8:?JKJ-0BL]#F
M6QOXUM+@K]7EGT9LEH\18?%9KG^<RX6I^(SX6JY54R*E3SS$955Q/BU'*L7.
MK'.L$Y4,8_"7,,-C<=1H8+"R6;4)91BL5B\'F6%R_P O$>(F+E@)T\-@L(LR
MED"S*.)CC92P5/$QI\+/$TE%X2M:=+_6FA4HT93K5$\+-8NG2I5L/5K_ +]?
M!OQW\1O'6D^*7^)_PAOO@[XD\,>-=8\*1Z7)XKTWQKH7BO2M/MM.N].\;^#_
M !)8Z?HEQ?\ AG7(=0*6HU?P_H6KVEW9WMCJ&FVUU;31)Z_7Y>GP_P"%_ W_
M  4IL?!91-#^%_B#_@G=XEM;S0]4U2^/A36;[PW\7_"FBWDVH1ZK>RV5_J>E
M_#ZR@L+_ %*\:6_C\.P(EY=&U&3\.? /7?C%XI_9)_8XO/AU%IW[1.IZ#IW[
M67B7XB?LR^)_'NJ^'O$/Q9\$Z;^T0VAZ3XZ\*^-;Q;K2H/&7P:U"^\.7'AI-
M<U!=2M[?Q+;W7A2,ZK!8Y^6?@-A.)Z.'XFRC/<LX;R?.?]2\1A<#7R_$8'*,
MNAQ?PIXHY_3PZSCB#B[,J.#CA<;X6XS*9XKB'B&CE6'KY]A,7F^?Y3E^ QM:
MGZ2XVJY=.IEV*P6)S#%83^UX5:\*].MBJ\LJS/AK N;PF RO#SJNI1XEI8I4
M\!@9XJ<,%5I83 XJO7HPE_1+17X,?"KPO\+_ -H[]I[X'^#;+Q7^T,_P-\7_
M /!,.RURQ\,>*_BU\4/!WBG5;O0_BQX/^'8E\00:)XLL%LK^^TOPW97_ (CA
M\(367A?QIJ>E1>(YUU_2M1N+C4_N_P#X)Q:AXSN/@#XBT7Q-XIUKQ[X9\#?'
M7XX?#OX/^/\ Q'J\OB'6_&WP?\#^/M3\.^$=<OM>F59-85+BQU?1["] \DZ7
MI5C#:K%:PP0Q_,^(/@E2X%X<Q>;RXGQ6)S?*ZO#G]KY!FG#;R*KA:/$N)XJP
M.&I8?&/.LR^M9M@<;PCF$<RRJIA,)*CA:D,5AL3BWALQHX/T<BXPEG6/I859
M=2IX7$QS#ZKCL-F'UV-6674\LK5)3I?4\/[/"UJ.:4'A\3&K54JD73J4Z7M*
M$ZOWQ1117X&?;A1110 4444 %%%% !1110 4444 ?FCK_P %?'?B[_@I,OQK
M\5_ "X\2? VV_9/C^!5OXF\17_P?UJP7QS'\:)/'$?B2W\*7_C>[\21:'%X=
MN[J%-0/A^+6U:2YMDTK,WE2K^VA\$_'^H?&#X"_';P+^S[X0_:H\,>!O#GCO
MX7_$/X#^*I_ MH(O#7C&70-9T;QWX%_X6&C>%;/7_#NM^&+6SU-1%)J>I:/<
MVVD6:V=E-J.K:7^EM%?LV!\;N)<#G_"&>0RG(IPX0X)K< 8?*/:\34<MS+(,
M7E&8Y+C9XVKAN)*.:X+-<5@\SKS>9\/9GD=?#XNEA<5A%AZF'C?Y*MP=E];
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M/H.HVUA!:VUS+/\ VL7BGB@LT^V']N:*Y\+](//<!/*?J/!G ^'PV25^"JV
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MZ2NF^(+OQ1XA%X+OQ<+7PKI^CZ2;.]\9:;X]\/\ ]I_XD? C]BGX #PSX/\
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M/_Z(W!_^'JM_\[O7^EK_ #M_\(;XO_Z%7Q)_X(]4_P#D6C_A#?%__0J^)/\
MP1ZI_P#(M?T244?\4D>'?^CWYU_X@V!_^B8/^)I,?_T1N#_\/5;_ .=WK_2U
M_G;_ .$-\7_]"KXD_P#!'JG_ ,BT?\(;XO\ ^A5\2?\ @CU3_P"1:_HDHH_X
MI(\._P#1[\Z_\0; _P#T3!_Q-)C_ /HC<'_X>JW_ ,[O7^EK_.W_ ,(;XO\
M^A5\2?\ @CU3_P"1:/\ A#?%_P#T*OB3_P $>J?_ "+7]$E%'_%)'AW_ */?
MG7_B#8'_ .B8/^)I,?\ ]$;@_P#P]5O_ )W>O]+7^=O_ (0WQ?\ ]"KXD_\
M!'JG_P BT?\ "&^+_P#H5?$G_@CU3_Y%K^B2BC_BDCP[_P!'OSK_ ,0; _\
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M3_P1ZI_\BT?\(;XO_P"A5\2?^"/5/_D6OZ)**/\ BDCP[_T>_.O_ !!L#_\
M1,'_ !-)C_\ HC<'_P"'JM_\[O7^EK_.W_PAOB__ *%7Q)_X(]4_^1:/^$-\
M7_\ 0J^)/_!'JG_R+7]$E%'_ !21X=_Z/?G7_B#8'_Z)@_XFDQ__ $1N#_\
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M_P""/5/_ )%K^B2BC_BDCP[_ -'OSK_Q!L#_ /1,'_$TF/\ ^B-P?_AZK?\
MSN]?Z6O\[?\ PAOB_P#Z%7Q)_P""/5/_ )%H_P"$-\7_ /0J^)/_  1ZI_\
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MB_\ Z%7Q)_X(]4_^1:/^$-\7_P#0J^)/_!'JG_R+7]$E%'_%)'AW_H]^=?\
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MG_R+1_PAOB__ *%7Q)_X(]4_^1:_HDHH_P"*2/#O_1[\Z_\ $&P/_P!$P?\
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M?C"T;59M*2_U66T\7>$OAGXOTBVNK;2)FT6[T@6UL]SJ'B>SLI/Z?_%GQO\
M@#:_"'2_BEXN^(OPZN_@M\0]/\/6GA_Q3>ZOI.M>#OB'9_$5;>R\)Z/X;\IK
MZV\;W'CO^TK6P\.:#HL&K7OBF6^AL=,L;^6Y2%P#\MK'_@M3X!T'_@I79?\
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M7[2?[$/Q+^/'[(GPJO/B5\,-5UN^^-7[$7Q@^&%E\+OBWX)^#UMH5C]C;3/
M?CSQ+<>&_B-XL^',OAG6_ _QN\)>*]!U[0-;O/C=H5QM /[1*_,']L[_ (*K
M?!']BWXU?L]?L^^,_AU\;_%7Q'_:4^+/@OX2^ M0T?X>:MH'PNM]4\5>(O V
MC7^J7GQ2\7QZ)X;\0VGANQ\>Z1?:G:?#8>/=0M-19= UF#0[T7TNG?6WP+_:
MT_9L_:9UKXL>'?@'\9O _P 5-=^!OB\^!/BSI7A/5/MM]X)\3F74K>WM-4@D
MBA>2QU"YT77+32==L!>:!K%WH6NVFE:I>7.BZI%:?SP_\'$G_)XG_!"#_L^+
M_P!ZC^R[0!^K7_!4[_@IMIW_  2S^%G@;XW>//@GK7Q7^&GC;X@:;\*TN_!W
MC?2M%\4:/XYU?P[XR\7:?;7GA[7=$-G<:!<Z!X(UB6/6K/Q!-<QZC']ANM'M
MHGM;V[_1KX>:]XC\4>"?#/B3Q9X<T_PCK^NZ5!JM]X:TSQ$_BNUT=+[=<6-H
M=?;1/#RW]V-/DM7U'R-*BM+74'NK*RN]4M+:'5+S^8O_ (.]?^4;'P1_[/B^
M&O\ ZH7]I>OWU^+_ .TY\-OV7?A3\%/$/Q$U33[5OB3\0/@/\%O"FF76M:3H
MMUJ6M?$_Q/X9\+ZCJUO+J]Q;6\NF?#[PM?Z_\3/%@5_-A\(>#M<EAS<BW1P#
MZQK\,M5_X+%?$D_MH?M$_L%^ OV!_B-\6OV@OV:?AVGQ7\;:/X$^-OPO@TC7
M? 5QIWPSU>RU7P5J/C:W\'RZYJ%[IWQ<\%36WAN6SL/$,T][=V,6FR7MD\#?
MJE^SC^U%^SY^UW\/9?BM^S5\6/"7QA^'UOXCU?PA>>)/"-Y-<6^G>*-"6TFU
M30=4M+RWL]2TK5(+/4=+U2.TU&RM9;S1=7T?7+);C2-7TV]NOY/3\*_&OQI_
MX.6/^"M'@SX=_M.^./V3M=F_8/\ #-RWQ>\!:/\ ##Q!)8VMO\+/V%-/NM-\
M4V?Q.\*^)+-?!]O=7<.O:_)X2U;X>^.(Y/#EM;Z7\1/#EA+K,5^ ?MQ\&?\
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M5-+\)WUK>Z9XINO&O@2ZM-8UMM"2U\-^++/Q ;2Z%K=Z?'T/_!.__@JS8_\
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M!N+B*Y6U:[6TN]3US5_L5^GAWPQI>MZ_)I^H#35L+K\#/^"/WQ_^#7['M_\
M\%8OVE/VF?C/X3^$_P !OC?_ ,%7/B1\)_A'XD\3YCT'Q)X]L/$WCO5=3O-#
MUC3+2^N=4TG5-)\2Z,]WK+Y\*^'[#PIK&K7FIV%I;:W=0?/'_!?KQ/\ M8>(
MO@/^WAX@^./[&'Q*TOX=6GC#X;?![]GK]H!OB?\ !S4/A+\./@1H/QP^&.OW
M.O6'@6Q\53_$Z?QW^TKX^\-Z/J7C/5[CP];-IF@:/\)/!S:=8VW@3Q!XA\4
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M_P C[Q"_[*6/_J,C^U?I2_\ )IOH<_\ 9D*O_J[D%%%%?HY_%04444 %%%%
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M\-?VB?A1XQ\#:EX5\2>'H_B/X?A6_P!:'AR?PO=:)XNLM>LDT?P;,;KP+X8
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M_:?^(OAZRCT^W:R^- \9^.?B9\$YO&=OY=WI/@/X(?#GXB^!O$.EVNF6-W.
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M?PX\3?%OQ1IOC_0_$5_IMU!$WA+6=4T;PY8^)=+U1I-,NK[3M-M[Z!IX(E4
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M5[:;PQ"]H\\FERJ@!_:-17X=_L0_"C4OV9?^"H/[9/[.GP4^('Q5\<?LG?\
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M]UC4;K6-:U)[2PAA2YU;7=9OK_6M=U:Z\[4];UF_OM6U6ZN]1O+FYE[NBB@
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M\*/_  K/%_\ \11_Q$K_ !R_Z-H^%'_A6>+_ /XBC_B+W O_ $,\3_X;<?\
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MPH_\*SQ?_P#$4?\ $2O\<O\ HVCX4?\ A6>+_P#XBC_B+W O_0SQ/_AMQ_\
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M$K_'+_HVCX4?^%9XO_\ B*/^(O<"_P#0SQ/_ (;<?_\ */ZL_*Y_Q3E^E?\
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M-2TO5/%/A:WT"/1]?U32-1T_3K_1]3U6TNK_ $F]TW3;K3;BUFT^S>#ZAHH
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
